Rsid Chr Position Ref P_value Gwas_trait Gene_symbol Variant_type Pubmedid rs568632519 chr1 565596 G A 7.28E-05 Cognitive impairment induced by topiramate / / 22091778 rs10751454 chr1 807512 A G 2.20E-13 Health and aging,CVD and cancer age of onset FAM41C intron 22174011 rs10751454 chr1 807512 A G 5.40E-21 Health and aging,CVD and cancer age of onset FAM41C intron 22174011 rs10751454 chr1 807512 A G 7.70E-09 Health and aging,CVD and cancer age of onset FAM41C intron 22174011 rs3748592 chr1 880238 A G 1.09E-04 Smoking initiation NOC2L intron 24665060 rs7526076 chr1 998395 A G 2.84E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3934834 chr1 1005806 C T 6.00E-07 Body mass index / / 19851299 rs6689308 chr1 1029805 A G 5.62E-04 Eating disorders C1orf159 intron 23568457 rs6687776 chr1 1030565 C T 9.40E-05 Post-operative nausea and vomiting C1orf159 intron 21694509 rs7545952 chr1 1031060 A G 1.68E-04 Eating disorders (purging via substances) C1orf159 intron 23568457 rs12145826 chr1 1066029 G A 6.14E-05 Celiac disease / / 23936387 rs11260603 chr1 1079198 T C 4.00E-07 IgG glycosylation / / 23382691 rs4442317 chr1 1106784 T C 5.26E-04 Smoking initiation / / 24665060 rs11260542 chr1 1110019 A G 8.24E-04 Alcohol dependence TTLL10 intron 20201924 rs3819001 chr1 1138913 T C 5.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) TNFRSF18 UTR-3 23648065 rs11260562 chr1 1165310 G A 6.12E-04 Multiple complex diseases SDF4 intron 17554300 rs715643 chr1 1172907 C T 2.61E-04 Celiac disease / / 23936387 rs6697886 chr1 1173611 G A 9.70E-05 Alcohol dependence / / 21703634 rs11804831 chr1 1194804 T C 2.46E-05 Waist Circumference UBE2J2 intron pha003023 rs12103 chr1 1247494 T C 8.00E-13 Inflammatory bowel disease CPSF3L cds-synon 23128233 rs151152085 chr1 1322654 C T 0.000061 Breast cancer(er negative) CCNL2 missense 23555315 rs1695824 chr1 1365570 A C 4.23E-04 Multiple complex diseases / / 17554300 rs819976 chr1 1421531 C A 1.30E-05 Odorant perception ATAD3B cds-synon 23910658 rs9439462 chr1 1462766 C T 7.57E-05 Cognitive impairment induced by topiramate ATAD3A intron 22091778 rs3766178 chr1 1478180 T C 3.26E-05 Glucose levels SSU72 intron pha003058 rs880051 chr1 1493727 G A 1.89E-05 Glucose levels SSU72 intron pha003058 rs880051 chr1 1493727 G A 6.44E-05 Glucose levels SSU72 intron pha003061 rs2296716 chr1 1497824 C T 8.76E-07 Glucose levels SSU72 intron pha003058 rs2296716 chr1 1497824 C T 2.54E-05 Glucose levels SSU72 intron pha003061 rs4648782 chr1 1542186 G A 5.44E-04 Smoking initiation / / 24665060 rs28464684 chr1 1566160 T C 1.64E-04 Intracranial aneurysm / / 22286173 rs7531583 chr1 1706160 A G 9.21E-04 Acute lung injury /DK intron 22295056 rs9786963 chr1 1759026 T C 3.01E-04 Alzheimer's disease GNB1 intron 17998437 rs10907192 chr1 1793111 A G 7.59E-05 Cognitive performance GNB1 intron 19734545 rs7511905 chr1 1793786 A C 1.64E-04 Alzheimer's disease GNB1 intron 17998437 rs3855951 chr1 1804302 C T 1.55E-04 Alzheimer's disease GNB1 intron 17998437 rs7525092 chr1 1810090 C T 9.86E-05 Lung function (forced expiratory volume in 1 second) GNB1 intron pha003103 rs6688000 chr1 1823922 A G 3.16E-04 Alzheimer's disease / / 17998437 rs3820011 chr1 1888193 C A 4.91E-04 Smoking initiation KIAA1751 missense 24665060 rs2803291 chr1 1892325 T C 7.55E-04 Acute lung injury KIAA1751 intron 22295056 rs3795277 chr1 1981118 A C 1.11E-05 Celiac disease PRKCZ nearGene-5 23936387 rs884080 chr1 2026749 A G 4.53E-04 Urate levels PRKCZ intron 23263486 rs3128296 chr1 2068906 G T 2.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) PRKCZ intron 23648065 rs425277 chr1 2069172 C T 2.00E-08 Height PRKCZ intron 20881960 rs3753242 chr1 2069681 C T 8.80E-05 Response to lithium treatment in bipolar disorder PRKCZ intron 19448189 rs3753242 chr1 2069681 C T 1.00E-06 Response to antipsychotic treatment in schizophrenia (reasoning) PRKCZ intron 21107309 rs424079 chr1 2071340 C A 8.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PRKCZ intron 20877124 rs262669 chr1 2082489 G A 8.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PRKCZ intron 20877124 rs262683 chr1 2155869 C T 1.33E-05 Cognitive test performance / / 20125193 rs2460000 chr1 2156362 A G 1.36E-04 HIV-1 progression to AIDS and death / / 21811574 rs2460000 chr1 2156362 A G 1.51E-04 HIV-1 progression to AIDS and death / / 21811574 rs2460000 chr1 2156362 A G 3.14E-05 HIV-1 progression to AIDS and death / / 21811574 rs10797416 chr1 2182342 T C 0.0000837 Coronary artery disease SKI intron 23202125 rs6673129 chr1 2202774 C T 1.37E-05 Cognitive test performance SKI intron 20125193 rs12045693 chr1 2205581 C A 3.00E-06 IgG glycosylation SKI intron 23382691 rs2843163 chr1 2227422 C T 7.45E-04 Response to cytidine analogues (gemcitabine) SKI intron 24483146 rs12562937 chr1 2229478 C T 3.50E-06 Urinary metabolites SKI intron 21572414 rs2173049 chr1 2240006 T C 8.49E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SKI UTR-3 20877124 rs2643902 chr1 2245439 T C 3.77E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2645077 chr1 2249236 G A 1.68E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs12080256 chr1 2251357 C A 1.98E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2055204 chr1 2280661 G A 4.19E-04 Smoking initiation MORN1 intron 24665060 rs7527871 chr1 2281726 A C 8.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) MORN1 intron 23648065 rs2843130 chr1 2283313 C G 4.06E-04 Body mass index MORN1 intron 21701565 rs2840528 chr1 2283896 A G 1.22E-04 Body mass index MORN1 intron 21701565 rs2840528 chr1 2283896 A G 9.85E-05 Blood Pressure MORN1 intron pha003039 rs2840531 chr1 2286408 C T 3.69E-04 Body mass index MORN1 intron 21701565 rs2494428 chr1 2339074 C T 9.97E-04 HIV-1 viral setpoint PEX10 intron 17641165 rs7556447 chr1 2346099 C G 7.90E-06 Parkinson's disease (age of onset) / / 19772629 rs4648843 chr1 2366316 C T 1.20E-05 Monocyte chemoattractant protein-1 / / pha003071 rs10910078 chr1 2390588 T C 3.13E-07 Non-obstructive azoospermia / / 22197933 rs10910078 chr1 2390588 T C 0.00000663 Autism spectrum disorders / / 22412387 rs2477686 chr1 2392648 G C 6.00E-12 Non-obstructive azoospermia / / 22197933 rs11588930 chr1 2408834 G A 0.000055 Coronary artery calcification PLCH2 intron 23727086 rs2477703 chr1 2425992 C T 9.99E-04 Amyotrophic lateral sclerosis (sporadic) PLCH2 intron 24529757 rs2236395 chr1 2446880 A G 6.30E-05 Rheumatoid arthritis PANK4 intron 22446963 rs12073504 chr1 2452979 C G 5.00E-06 Obesity-related traits PANK4 intron 23251661 rs10797431 chr1 2501222 G T 0.0000144 Primary biliary cirrhosis / / 22961000 rs10797432 chr1 2501338 C T 3.00E-12 Ulcerative colitis / / 23128233 rs734999 chr1 2513216 C T 3.00E-09 Ulcerative colitis / / 21297633 rs10910097 chr1 2521430 C T 1.29E-04 Multiple complex diseases FAM213B UTR-3 17554300 rs10752747 chr1 2524915 G T 6.31E-10 Celiac disease and Rheumatoid arthritis MMEL1 intron 21383967 rs3748816 chr1 2526746 A G 3.00E-09 Celiac disease MMEL1 missense 20190752 rs3748816 chr1 2526746 A G 3.00E-09 Asthma MMEL1 missense 21150878 rs3748816 chr1 2526746 A G 3.28E-09 Celiac disease and Rheumatoid arthritis MMEL1 missense 21383967 rs3748816 chr1 2526746 A G 1.60E-12 Multiple sclerosis MMEL1 missense 21833088 rs3748816 chr1 2526746 A G 3.28E-09 Multiple sclerosis MMEL1 missense 22190364 rs3748816 chr1 2526746 A G 0.000000021 Primary sclerosing cholangitis MMEL1 missense 22521342 rs3748816 chr1 2526746 A G 7.41E-12 Primary sclerosing cholangitis MMEL1 missense 23603763 rs2843401 chr1 2528133 T C 6.60E-09 Rheumatoid arthritis MMEL1 intron 23143596 rs2843401 chr1 2528133 T C 7.24E-10 Rheumatoid arthritis (CCP positive) MMEL1 intron 23143596 rs2843403 chr1 2529097 T C 0.000000794 Graves' disease MMEL1 intron 22922229 rs2843403 chr1 2529097 T C 0.00000563 Graves' disease and Hashimoto's thyroiditis MMEL1 intron 22922229 rs10910099 chr1 2533552 A C 5.40E-07 Multiple complex diseases MMEL1 intron 17554300 rs12138909 chr1 2538738 C T 5.61E-08 Celiac disease and Rheumatoid arthritis MMEL1 intron 21383967 rs12138909 chr1 2538738 C T 9.18E-05 Cognitive impairment induced by topiramate MMEL1 intron 22091778 rs4445406 chr1 2539400 T C 5.40E-12 Celiac disease MMEL1 intron 22057235 rs4445406 chr1 2539400 T C 5.40E-12 Celiac disease MMEL1 intron 23143596 rs10910108 chr1 2539532 A G 0.000331 Primary biliary cirrhosis (anti-mitochondrial antibody positive) MMEL1 intron 22936693 rs6684865 chr1 2546229 G A 5.37E-06 Multiple complex diseases MMEL1 intron 17554300 rs4648654 chr1 2553083 G A 0.00067 Primary biliary cirrhosis MMEL1 intron 22936693 rs3890745 chr1 2553624 T C 5.73E-06 Multiple complex diseases MMEL1 intron 17554300 rs3890745 chr1 2553624 T C 1.00E-07 Rheumatoid arthritis MMEL1 intron 18794853 rs3890745 chr1 2553624 T C 4.00E-06 Rheumatoid arthritis MMEL1 intron 20453842 rs3890745 chr1 2553624 T C 1.00E-07 Celiac disease and Rheumatoid arthritis MMEL1 intron 21383967 rs3890745 chr1 2553624 T C 5.60E-06 Rheumatoid arthritis MMEL1 intron 22446963 rs3890745 chr1 2553624 T C 1.00E-06 Rheumatoid arthritis MMEL1 intron 24449572 rs4474198 chr1 2553758 C T 4.75E-06 Multiple complex diseases MMEL1 intron 17554300 rs4648356 chr1 2709164 C A 4.28E-10 Celiac disease and Rheumatoid arthritis / / 21383967 rs4648356 chr1 2709164 C A 1.00E-14 Multiple sclerosis / / 21833088 rs2377041 chr1 2713327 C T 8.89E-05 Serum metabolites / / 19043545 rs4648482 chr1 2749921 T C 7.74E-05 Aortic root size / / 21223598 rs11580768 chr1 2799480 C T 3.85E-06 Ankle-brachial index / / 22199011 rs2842909 chr1 2859724 C T 7.79E-04 Taste perception / / 22132133 rs7548727 chr1 2865778 T C 4.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2485944 chr1 2883858 C T 7.27E-05 Major depressive disorder / / 22472876 rs12044030 chr1 2889577 C T 3.62E-05 ldl cholesterol / / pha003076 rs7533362 chr1 2896735 A G 1.91E-06 ldl cholesterol / / pha003076 rs7533362 chr1 2896735 A G 5.97E-05 Cholesterol / / pha003078 rs1572657 chr1 2902128 C T 3.33E-05 Fibrinogen / / pha003068 rs7534897 chr1 2928421 C T 0.0000755 Salmonella-induced pyroptosis / / 22837397 rs2142569 chr1 2944527 G A 4.00E-06 Substance dependence phenotypes / / 24832863 rs12409277 chr1 2957600 T C 1.00E-06 Body mass (lean) / / 24863034 rs2297829 chr1 2984087 C A 6.38E-04 White matter integrity / / 22425255 rs6695131 chr1 3000924 T C 0.00069 Salmonella-induced pyroptosis PRDM16 intron 22837397 rs2981884 chr1 3002072 A G 9.40E-06 Panic disorder PRDM16 intron 19165232 rs7538096 chr1 3057661 T C 1.92E-05 Hemoglobin PRDM16 intron pha003098 rs7538096 chr1 3057661 T C 1.71E-05 Erythrocyte counts PRDM16 intron pha003099 rs2651899 chr1 3083712 T C 4.00E-09 Migraine PRDM16 intron 21666692 rs2651899 chr1 3083712 T C 4.20E-04 Migraine PRDM16 intron 22683712 rs2651899 chr1 3083712 T C 1.56E-05 Migraine without aura PRDM16 intron 23793025 rs2651899 chr1 3083712 T C 2.54E-04 Migraine with aura PRDM16 intron 23793025 rs2651899 chr1 3083712 T C 3.06E-04 Migraine - clinic-based PRDM16 intron 23793025 rs2651899 chr1 3083712 T C 4.00E-14 Migraine PRDM16 intron 23793025 rs2651899 chr1 3083712 T C 4.34E-14 Migraine PRDM16 intron 23793025 rs17390062 chr1 3089849 T C 5.26E-05 Coronary heart disease PRDM16 intron 21606135 rs12737500 chr1 3094708 C T 7.67E-04 Suicide attempts in bipolar disorder PRDM16 intron 21423239 rs12737500 chr1 3094708 C T 1.90E-05 White matter hyperintensity burden PRDM16 intron 21681796 rs17390167 chr1 3094831 C G 1.70E-05 White matter hyperintensity burden PRDM16 intron 21681796 rs12750165 chr1 3095491 A G 1.80E-05 White matter hyperintensity burden PRDM16 intron 21681796 rs12733843 chr1 3097073 G A 1.80E-05 White matter hyperintensity burden PRDM16 intron 21681796 rs12072073 chr1 3130016 T C 6.49E-04 Alzheimer's disease PRDM16 intron 22005930 rs10909901 chr1 3131235 C T 4.80E-04 Alzheimer's disease PRDM16 intron 22005930 rs2817145 chr1 3133422 T A 7.54E-04 Alzheimer's disease PRDM16 intron 22005930 rs10492940 chr1 3197747 C A 4.12E-04 Suicide attempts in bipolar disorder PRDM16 intron 21423239 rs16823802 chr1 3199217 C T 3.43E-05 Tunica Media PRDM16 intron pha003036 rs12565013 chr1 3203137 A C 3.43E-05 Tunica Media PRDM16 intron pha003036 rs4648377 chr1 3211458 A C 9.21E-04 Tourette syndrome PRDM16 intron 22889924 rs2455136 chr1 3218329 A T 9.75E-05 Self-reported allergy PRDM16 intron 23817569 rs2500283 chr1 3218923 G C 1.49E-04 Self-reported allergy PRDM16 intron 23817569 rs2500282 chr1 3219497 A G 1.18E-04 Self-reported allergy PRDM16 intron 23817569 rs4233025 chr1 3223280 C T 9.54E-05 Self-reported allergy PRDM16 intron 23817569 rs4648473 chr1 3223764 A G 9.91E-05 Self-reported allergy PRDM16 intron 23817569 rs4145901 chr1 3223955 A G 9.18E-05 Self-reported allergy PRDM16 intron 23817569 rs2500278 chr1 3225940 C T 8.60E-04 Amyotrophic Lateral Sclerosis PRDM16 intron 17362836 rs2483261 chr1 3227416 C G 1.48E-04 Self-reported allergy PRDM16 intron 23817569 rs2483262 chr1 3229134 G T 1.49E-04 Self-reported allergy PRDM16 intron 23817569 rs12409315 chr1 3229258 A G 5.57E-05 Multiple complex diseases PRDM16 intron 17554300 rs16824089 chr1 3230544 T C 3.61E-06 Tunica Media PRDM16 intron pha003036 rs4648477 chr1 3251975 G A 1.29E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs4648477 chr1 3251975 G A 1.29E-08 Facial morphology PRDM16 intron 23028347 rs4648478 chr1 3252007 C T 1.12E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs4648478 chr1 3252007 C T 1.12E-08 Facial morphology PRDM16 intron 23028347 rs7516150 chr1 3253889 C T 2.52E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs7516150 chr1 3253889 C T 2.52E-08 Facial morphology PRDM16 intron 23028347 rs7552331 chr1 3253941 G A 3.97E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs7552331 chr1 3253941 G A 3.97E-08 Facial morphology PRDM16 intron 23028347 rs1572037 chr1 3254369 T C 2.45E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs1572037 chr1 3254369 T C 2.45E-08 Facial morphology PRDM16 intron 23028347 rs1999527 chr1 3256108 C A 1.72E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs1999527 chr1 3256108 C A 1.72E-08 Facial morphology PRDM16 intron 23028347 rs4648379 chr1 3261516 C T 1.13E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs4648379 chr1 3261516 C T 1.13E-08 Facial morphology PRDM16 intron 23028347 rs12748963 chr1 3275149 C T 1.74E-04 Epilepsy PRDM16 intron 22116939 rs17399569 chr1 3278959 C T 4.00E-05 Response to statin therapy PRDM16 intron 20339536 rs11807862 chr1 3279268 T A 2.20E-06 Response to statin therapy PRDM16 intron 20339536 rs6658356 chr1 3280253 G A 2.00E-06 Response to statin therapy PRDM16 intron 20339536 rs6424073 chr1 3285628 G A 3.21E-04 Cognitive decline PRDM16 intron 23732972 rs12135987 chr1 3289524 G A 5.22E-05 Cognitive performance PRDM16 intron 19734545 rs868688 chr1 3300807 C T 8.70E-04 Response to cytadine analogues (cytosine arabinoside) PRDM16 intron 24483146 rs10492939 chr1 3302871 G A 9.12E-06 Bilirubin levels,in serum PRDM16 intron 19389676 rs2493278 chr1 3307746 T C 7.17E-04 Parkinson's disease PRDM16 intron 17052657 rs11578011 chr1 3318532 T C 5.41E-05 Elbow pain PRDM16 intron pha003008 rs2493285 chr1 3333595 G A 4.01E-04 Sudden cardiac arrest PRDM16 intron 21658281 rs3806164 chr1 3380057 G A 2.66E-04 Smoking quantity ARHGEF16 missense 24665060 rs2185639 chr1 3389727 C T 9.17E-05 Relative hand skill in reading disability ARHGEF16 missense 24068947 rs2821041 chr1 3404227 C T 9.71E-05 Relative hand skill in reading disability / / 24068947 rs4648505 chr1 3405296 T C 4.13E-05 Relative hand skill in reading disability MEGF6 UTR-3 24068947 rs10909969 chr1 3480149 C T 8.03E-05 Bipolar disorder MEGF6 intron 17486107 rs2821017 chr1 3520871 G A 5.18E-05 Caffeine consumption MEGF6 intron 21490707 rs4276857 chr1 3544346 T C 1.22E-04 Bipolar disorder TPRG1L intron 18317468 rs2208993 chr1 3575833 C G,T 4.05E-04 Response to cytadine analogues (cytosine arabinoside) TP73 intron 24483146 rs2224718 chr1 3576060 T C 6.86E-04 Response to cytadine analogues (cytosine arabinoside) TP73 intron 24483146 rs3765696 chr1 3587505 T C 2.50E-04 Body mass index TP73 intron 17255346 rs12027041 chr1 3591448 G C 1.08E-05 Multiple complex diseases TP73 intron 17554300 rs12027041 chr1 3591448 G C 3.50E-09 Progranulin levels TP73 intron 21087763 rs12027041 chr1 3591448 G C 3.50E-09 Myocardial infarction TP73 intron 21211798 rs3765736 chr1 3616601 C T 2.10E-05 Heart Rate TP73 intron pha003054 rs6424090 chr1 3628677 A G 4.33E-04 Sarcoidosis TP73 intron 19165924 rs9662633 chr1 3649562 G A 6.00E-06 Visceral adipose tissue adjusted for BMI TP73 cds-synon 22589738 rs12562437 chr1 3651031 C T 2.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio TP73 UTR-3 22589738 rs10910018 chr1 3651409 G A 2.00E-06 Visceral fat TP73 UTR-3 22589738 rs3737589 chr1 3662845 A G 4.33E-04 Lung function (forced expiratory volume in 1 second) TP73-AS1 intron 24023788 rs12120656 chr1 3665867 G T 1.06E-04 Type 2 diabetes / / 17463246 rs12120656 chr1 3665867 G T 9.39E-04 Lymphocyte counts / / 22286170 rs76597070 chr1 3669356 G A 3.00E-06 Obesity-related traits CCDC27 missense 23251661 rs1181889 chr1 3671027 T C 3.29E-04 Type 2 diabetes CCDC27 intron 17463246 rs2275837 chr1 3686318 G A 9.72E-04 Multiple complex diseases CCDC27 intron 17554300 rs1175550 chr1 3691528 A G 8.62E-15 Red blood cell traits LOC388588 intron 23222517 rs1175550 chr1 3691528 A G 5.00E-10 Blood trace element (Cu levels) LOC388588 intron 23720494 rs1175549 chr1 3691727 A C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC388588 intron 22628534 rs1175549 chr1 3691727 A C 0.0000265 Otitis media (children 3 years old or younger) LOC388588 intron 23133572 rs1175549 chr1 3691727 A C 1.35E-14 Red blood cell traits LOC388588 intron 23222517 rs2799182 chr1 3696000 T C 1.06E-07 Red blood cell traits / / 23222517 rs8379 chr1 3696890 A C 1.76E-08 Red blood cell traits LRRC47 UTR-3 23222517 rs9424283 chr1 3705226 C G 3.14E-04 Lymphocyte counts LRRC47 intron 22286170 rs7513053 chr1 3709487 A G 4.26E-13 Red blood cell traits LRRC47 intron 23222517 rs6667255 chr1 3711689 T C 1.74E-13 Red blood cell traits LRRC47 intron 23222517 rs7535775 chr1 3719057 G A 3.90E-07 Red blood cell traits / / 23222517 rs2154068 chr1 3720965 A G 9.34E-08 Red blood cell traits / / 23222517 rs12135894 chr1 3728061 C T 1.93E-09 Red blood cell traits / / 23222517 rs2027548 chr1 3739512 G A 7.99E-04 Amyotrophic Lateral Sclerosis CEP104 intron 17362836 rs6688969 chr1 3743391 C T 4.48E-09 Red blood cell traits CEP104 intron 23222517 rs7511793 chr1 3744249 A G 2.21E-12 Red blood cell traits CEP104 intron 23222517 rs7545274 chr1 3744261 C A 8.86E-04 Alcohol dependence CEP104 intron 21314694 rs7545274 chr1 3744261 C A 3.25E-13 Red blood cell traits CEP104 intron 23222517 rs2275833 chr1 3745721 C T 3.34E-11 Red blood cell traits CEP104 intron 23222517 rs2298224 chr1 3756155 T C 4.91E-04 Multiple complex diseases CEP104 intron 17554300 rs17412654 chr1 3758493 T C 6.42E-09 Red blood cell traits CEP104 intron 23222517 rs7538067 chr1 3761772 C T 3.69E-08 Red blood cell traits CEP104 intron 23222517 rs10492942 chr1 3764216 C T 8.34E-12 Red blood cell traits CEP104 intron 23222517 rs16824230 chr1 3766240 A G 6.22E-13 Red blood cell traits CEP104 intron 23222517 rs10909804 chr1 3770929 C T 8.20E-13 Red blood cell traits CEP104 intron 23222517 rs10797348 chr1 3781096 C A 4.39E-10 Red blood cell traits DFFB intron 23222517 rs4074709 chr1 3796948 G T 1.00E-04 Information processing speed DFFB intron 21130836 rs4073324 chr1 3797995 C T 2.17E-04 Cholesterol DFFB intron 17255346 rs4131373 chr1 3807388 G A 9.14E-06 HIV-1 viral setpoint C1orf174 cds-synon 17641165 rs4131373 chr1 3807388 G A 1.29E-05 AIDS progression C1orf174 cds-synon 19115949 rs6701422 chr1 3808171 T C 6.03E-05 Epilepsy (remission after treatment) C1orf174 intron 23962720 rs12082157 chr1 3811810 T C 1.01E-05 HIV-1 viral setpoint C1orf174 intron 17641165 rs6687869 chr1 3821216 G A 1.81E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100133612 intron 20877124 rs6687869 chr1 3821216 G A 4.24E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100133612 intron 20877124 rs35583447 chr1 3829614 A G 5.48E-05 Epilepsy (remission after treatment) LOC100133612 intron 23962720 rs35241263 chr1 3831232 A G 8.64E-05 Epilepsy (remission after treatment) / / 23962720 rs10737395 chr1 4007558 C A 3.62E-04 Blood pressure LOC728716 intron 17255346 rs10737395 chr1 4007558 C A 2.69E-05 Common variable immunodeficiency LOC728716 intron 21497890 rs4654479 chr1 4009694 G A 3.36E-04 Blood pressure LOC728716 intron 17255346 rs12031275 chr1 4026068 G A,T 9.20E-06 Serum metabolites / / 19043545 rs4654521 chr1 4028282 C T 1.49E-05 Serum metabolites / / 19043545 rs3935162 chr1 4031327 G A 9.20E-05 Serum metabolites / / 19043545 rs12722968 chr1 4065348 C T 1.48E-04 Birth weight / / 17255346 rs79004239 chr1 4080348 C T 0.00006336 Sarcoidosis / / 22952805 rs7514530 chr1 4120311 C T 9.16E-05 Coronary heart disease / / pha003030 rs7524800 chr1 4121584 A G 5.17E-05 Coronary heart disease / / pha003030 rs6669278 chr1 4123099 C T 0.00004214 Sarcoidosis / / 22952805 rs6673959 chr1 4123117 A G 7.97E-06 Hearing function / / 21493956 rs4391636 chr1 4130684 T C 7.17E-04 Multiple complex diseases / / 17554300 rs12021796 chr1 4133241 T G 6.22E-04 Multiple complex diseases / / 17554300 rs10915417 chr1 4137042 C G 2.54E-04 Multiple complex diseases / / 17554300 rs10915421 chr1 4145615 T C 2.94E-05 Coronary heart disease / / pha003030 rs10915424 chr1 4146369 G A 3.59E-05 Coronary heart disease / / pha003030 rs4600014 chr1 4157198 A G 6.61E-05 Alzheimer's disease / / 17998437 rs10915428 chr1 4158955 G T 3.67E-05 Kawasaki disease / / 22446961 rs4400585 chr1 4182785 G T 7.00E-04 Alzheimer's disease / / 17998437 rs4400585 chr1 4182785 G T 1.58E-04 Alzheimer's disease / / pha002879 rs10915437 chr1 4183006 A G 1.56E-04 Migraine with aura / / 23793025 rs10915437 chr1 4183006 A G 3.00E-08 Migraine - clinic-based / / 23793025 rs10915437 chr1 4183006 A G 6.13E-04 Migraine / / 23793025 rs12409803 chr1 4193426 G A 0.00000354 HDL cholesterol particle diameter / / 23263444 rs6663939 chr1 4197256 C T 0.00000387 HDL cholesterol particle diameter / / 23263444 rs10915445 chr1 4197642 G A 0.00000389 HDL cholesterol particle diameter / / 23263444 rs10915445 chr1 4197642 G A 2.86E-05 Waist Circumference / / pha003024 rs16840838 chr1 4201349 G A 1.54E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4654492 chr1 4201815 C T 2.79E-04 Multiple complex diseases / / 17554300 rs12143662 chr1 4202993 C T 0.00000395 HDL cholesterol particle diameter / / 23263444 rs4654497 chr1 4224558 T C 1.09E-04 Type 2 diabetes / / 17463246 rs4654497 chr1 4224558 T C 9.22E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3890729 chr1 4230712 A T 2.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs16840958 chr1 4285991 T C 5.45E-04 Multiple complex diseases / / 17554300 rs12132422 chr1 4295304 A G 4.32E-04 Alcohol dependence / / 20201924 rs1908490 chr1 4312205 C T 7.20E-06 Coronary heart disease / / pha003035 rs966321 chr1 4315204 G T 8.00E-06 Factor VII / / 17903294 rs966321 chr1 4315204 G T 2.20E-08 Tanning / / 19340012 rs966321 chr1 4315204 G T 8.84E-04 Common variable immunodeficiency / / 21497890 rs966321 chr1 4315204 G T 1.05E-05 Coronary heart disease / / pha003035 rs964715 chr1 4316784 T C 4.10E-05 Bladder cancer / / 24163127 rs2411738 chr1 4326368 G A 6.22E-06 Coronary heart disease / / pha003035 rs6677984 chr1 4330287 A G 2.84E-05 Coronary heart disease / / pha003035 rs16838549 chr1 4343581 G A 7.23E-05 Multiple complex diseases / / 17554300 rs351615 chr1 4370385 G A 2.68E-05 Alzheimer's disease / / 17998437 rs351596 chr1 4377911 C T 9.71E-04 Multiple complex diseases / / 17554300 rs351596 chr1 4377911 C T 6.11E-05 Suicide attempts in bipolar disorder / / 21423239 rs7418164 chr1 4380518 G A 2.78E-04 Multiple complex diseases / / 17554300 rs2171985 chr1 4381253 G T 3.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs496925 chr1 4396552 C T 2.12E-04 Multiple complex diseases / / 17554300 rs528291 chr1 4414045 A G 3.53E-04 Taste perception / / 22132133 rs349390 chr1 4423896 T C 8.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16838812 chr1 4424115 A G 4.02E-04 Multiple complex diseases / / 17554300 rs16838813 chr1 4424145 G A 2.17E-04 Multiple complex diseases / / 17554300 rs16838813 chr1 4424145 G A 7.10E-07 Glioma (high-grade) / / 19578366 rs75411 chr1 4425414 C T 3.63E-06 Obesity-related traits / / 23251661 rs589870 chr1 4440749 C T 6.09E-06 Obesity-related traits / / 23251661 rs12037374 chr1 4443108 C T 1.50E-05 Urinary metabolites / / 21572414 rs239339 chr1 4444539 G T 3.00E-06 Obesity-related traits / / 23251661 rs6679220 chr1 4459689 T C 1.00E-04 Diabetic nephropathy / / pha002866 rs12116790 chr1 4464933 A G 7.14E-04 Type 2 diabetes / / 17463246 rs349403 chr1 4474002 A G 9.50E-05 Body mass index LOC284661 intron 20818722 rs4654432 chr1 4481215 C T 7.84E-04 Multiple complex diseases LOC284661 intron 17554300 rs4654432 chr1 4481215 C T 7.20E-05 Diabetic nephropathy LOC284661 intron pha002866 rs4654433 chr1 4481632 G A 9.90E-05 Diabetic nephropathy LOC284661 intron pha002866 rs1762814 chr1 4496256 C T 1.70E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10737409 chr1 4522466 G A 7.03E-04 Type 2 diabetes / / 17463246 rs4654438 chr1 4559901 T C 2.00E-06 Smooth-surface caries / / 24556642 rs9660574 chr1 4560405 G A 3.22E-06 Smooth-surface caries / / 24556642 rs4654548 chr1 4562476 G A 4.09E-06 Smooth-surface caries / / 24556642 rs10753381 chr1 4565906 C T 1.76E-06 Smooth-surface caries / / 24556642 rs1762826 chr1 4572778 C T 7.89E-05 Waist Circumference / / pha003023 rs608203 chr1 4581585 T C 5.94E-04 Stroke / / pha002886 rs608492 chr1 4598001 G C 2.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs592726 chr1 4599243 C T 2.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs542688 chr1 4600621 C G 2.37E-04 Suicide attempts in bipolar disorder / / 21041247 rs694935 chr1 4603324 T A 2.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs241215 chr1 4604104 T A 2.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs17348839 chr1 4605403 C A 3.22E-08 Multiple complex diseases / / 17554300 rs241220 chr1 4608204 G A 2.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs241221 chr1 4609050 T C 5.79E-04 Suicide attempts in bipolar disorder / / 21041247 rs241278 chr1 4629408 T C 9.31E-04 Type 2 diabetes / / 17463246 rs7526879 chr1 4630483 C T 6.15E-04 Type 2 diabetes / / 17463246 rs1541318 chr1 4634978 A G 1.79E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1541318 chr1 4634978 A G 4.33E-04 Smoking initiation / / 24665060 rs1157688 chr1 4636767 T C 4.79E-05 Obesity (extreme) / / 21935397 rs515279 chr1 4643688 T A,C,G 9.32E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs504274 chr1 4648573 C T 2.18E-05 Suicide attempts in bipolar disorder / / 21041247 rs504274 chr1 4648573 C T 5.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs589176 chr1 4660552 A G 5.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs11590266 chr1 4668423 A G 2.50E-05 Urinary metabolites / / 21572414 rs3896439 chr1 4668670 G A 2.00E-08 Dental caries / / 23064961 rs6668002 chr1 4682104 T C 9.98E-05 Asthma / / pha003127 rs12403290 chr1 4682532 C A 2.50E-05 Urinary metabolites / / 21572414 rs875807 chr1 4685672 A G 4.20E-05 Triglycerides / / pha003080 rs7553610 chr1 4687874 G A 5.72E-04 Smoking initiation / / 24665060 rs2101195 chr1 4697300 C T 4.27E-04 Type 2 diabetes / / 17463246 rs7533451 chr1 4705931 G A 5.59E-04 Alzheimer's disease / / 17998437 rs3947662 chr1 4718551 G T 1.10E-04 Primary sclerosing cholangitis AJAP1 intron 19944697 rs12409187 chr1 4733793 G A 6.54E-05 Aging (time to event) AJAP1 intron 21782286 rs11588881 chr1 4737383 C T 3.47E-04 Type 2 diabetes AJAP1 intron 17463246 rs11588881 chr1 4737383 C T 1.30E-04 Primary sclerosing cholangitis AJAP1 intron 19944697 rs11588881 chr1 4737383 C T 3.84E-05 Homeostasis model assessment of beta-cell function (interaction) AJAP1 intron 24204828 rs2071995 chr1 4738678 C T 3.79E-05 QT interval AJAP1 intron 22726844 rs1076944 chr1 4748305 G T 2.04E-04 Epilepsy AJAP1 intron 22116939 rs7525374 chr1 4754057 A G 4.43E-04 Myopia (pathological) AJAP1 intron 21095009 rs7518469 chr1 4756276 G T 2.44E-04 Alzheimer's disease (late onset) AJAP1 intron 21379329 rs3766964 chr1 4792184 T C 1.10E-05 Urinary metabolites AJAP1 intron 21572414 rs16839536 chr1 4793580 C G 6.27E-04 Multiple complex diseases AJAP1 intron 17554300 rs414176 chr1 4805106 A C 1.60E-06 Urinary metabolites AJAP1 intron 21572414 rs422988 chr1 4819117 A C 5.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) AJAP1 intron 20877124 rs397559 chr1 4820799 C T 9.92E-04 Multiple complex diseases AJAP1 intron 17554300 rs397559 chr1 4820799 C T 5.24E-04 Alzheimer's disease AJAP1 intron 17998437 rs397559 chr1 4820799 C T 4.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) AJAP1 intron 20877124 rs424723 chr1 4824742 C T 7.60E-05 Intelligence AJAP1 intron 21826061 rs2743979 chr1 4825152 G A 6.44E-05 Intelligence AJAP1 intron 21826061 rs7518471 chr1 4828606 C T 7.27E-05 Hepatocellular carcinoma AJAP1 intron 22807686 rs423285 chr1 4831076 C T 0.0000586 Follicular lymphoma AJAP1 intron 23025665 rs11805709 chr1 4847594 C T 1.21E-06 Serum metabolites / / 19043545 rs12028290 chr1 4889912 C A 3.99E-06 Multiple complex diseases / / 17554300 rs12094945 chr1 4933154 T G 1.17E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2031246 chr1 4959786 A G 1.48E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2031246 chr1 4959786 A G 3.45E-05 Waist-Hip Ratio / / pha003013 rs2031246 chr1 4959786 A G 7.70E-05 Waist-Hip Ratio / / pha003028 rs41524347 chr1 4972186 T G 9.00E-04 Multiple complex diseases / / 17554300 rs10915670 chr1 4975417 G A 1.60E-05 Diabetes Mellitus / / pha003060 rs10915671 chr1 4983217 G A 6.25E-05 Type 1 diabetes / / 18978792 rs12045266 chr1 4996275 G T 3.30E-06 Urinary metabolites / / 21572414 rs12048035 chr1 4996307 C G 2.20E-06 Urinary metabolites / / 21572414 rs17349719 chr1 5001809 A G 4.47E-04 Multiple complex diseases / / 17554300 rs12754637 chr1 5023321 G A 5.33E-05 Colorectal cancer / / 19723657 rs7525837 chr1 5030660 G A 9.29E-26 Narcolepsy / / 19629137 rs7518523 chr1 5031561 A G 5.44E-05 Serum metabolites / / 19043545 rs12757902 chr1 5036234 G A 3.86E-05 Cardiovascular disease / / pha003064 rs10915307 chr1 5063293 G A 3.13E-04 Type 2 diabetes / / 17463246 rs10915310 chr1 5068210 A G 1.06E-04 Type 2 diabetes / / 17463246 rs10799151 chr1 5068245 A G 2.44E-04 Type 2 diabetes / / 17463246 rs12047764 chr1 5077552 T C 8.99E-04 Type 2 diabetes / / 17463246 rs9439507 chr1 5090997 A G 4.35E-04 Alzheimer's disease (late onset) / / 21379329 rs10915329 chr1 5114102 C T 9.18E-05 Glucose levels / / pha003058 rs6603832 chr1 5127543 A G 4.72E-05 Personality dimensions / / 18957941 rs10915336 chr1 5137666 G A 3.70E-05 Parkinson's disease (familial) / / 18985386 rs12047111 chr1 5142784 A G 6.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs2334263 chr1 5142818 T C 4.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs6680801 chr1 5145066 G A 6.20E-04 Aortic root size / / 21223598 rs3101225 chr1 5156245 A C 7.66E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7513590 chr1 5170712 A G 5.00E-06 Anthropometric traits / / 19260139 rs12743573 chr1 5204164 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10753353 chr1 5211134 T C 0.000505473 Hypertension (early onset hypertension) / / 22479346 rs12026977 chr1 5231170 T C 5.97E-04 Smoking initiation / / 24665060 rs12041491 chr1 5253436 G A 4.03E-04 Multiple complex diseases / / 17554300 rs16840183 chr1 5280502 T G 1.15E-05 Alcohol consumption / / 23953852 rs677735 chr1 5295176 A G 5.84E-05 Alcohol consumption / / 23953852 rs2353169 chr1 5296844 T C 9.98E-05 stroke (ischemic) / / 17434096 rs12135834 chr1 5309667 C T 7.50E-04 Coronary heart disease / / 21606135 rs4465222 chr1 5310258 T C 4.93E-06 Alcohol consumption / / 23953852 rs6686714 chr1 5310609 G T 8.90E-04 Coronary heart disease / / 21606135 rs12732868 chr1 5334637 T G 4.55E-07 Schizophrenia / / 21926974 rs17423547 chr1 5341464 T C 4.98E-05 Orofacial clefts / / 22419666 rs604664 chr1 5343032 T C 1.73E-04 Cholesterol / / 17255346 rs557477 chr1 5346474 T G 1.90E-06 Urinary metabolites / / 21572414 rs7530063 chr1 5352492 T C 3.10E-05 Cognitive function / / 24684796 rs912988 chr1 5354844 C T 6.00E-06 Major depressive disorder / / 23377640 rs9439521 chr1 5368589 G A 3.37E-04 Multiple complex diseases / / 17554300 rs9439522 chr1 5368747 T G 2.09E-04 Multiple complex diseases / / 17554300 rs9439523 chr1 5368769 A G 3.14E-04 Multiple complex diseases / / 17554300 rs9439525 chr1 5369177 G A 4.52E-04 Multiple complex diseases / / 17554300 rs12040942 chr1 5371159 C A 3.33E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10915413 chr1 5371579 C T 2.13E-04 Multiple complex diseases / / 17554300 rs4478820 chr1 5371934 A G 2.40E-04 Multiple complex diseases / / 17554300 rs874995 chr1 5386597 A T 9.96E-04 Type 2 diabetes / / 17463246 rs16840538 chr1 5390209 A G 7.97E-04 Multiple complex diseases / / 17554300 rs1326005 chr1 5403585 A G 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7364349 chr1 5421533 G A 5.89E-04 Smoking initiation / / 24665060 rs11801594 chr1 5426110 T C 7.56E-05 Platelet counts / / pha003100 rs6603835 chr1 5475663 C A 1.00E-04 Prostate cancer / / 21743057 rs6688540 chr1 5478901 C T 5.33E-04 Multiple complex diseases / / 17554300 rs6688540 chr1 5478901 C T 8.00E-05 Prostate cancer / / 21743057 rs6603839 chr1 5480101 C T 5.02E-04 Multiple complex diseases / / 17554300 rs10907211 chr1 5492043 C A 5.52E-04 Rheumatoid arthritis / / 21452313 rs9787315 chr1 5544659 G C 5.31E-04 Multiple complex diseases / / 17554300 rs9787315 chr1 5544659 G C 0.000192 Salmonella-induced pyroptosis / / 22837397 rs9729637 chr1 5545452 G T 0.0000295 Uterine leiomyomata / / 23040493 rs9786944 chr1 5548512 G A 0.0000824 Uterine leiomyomata / / 23040493 rs9786944 chr1 5548512 G A 4.20E-04 Myasthenia gravis / / 23055271 rs12128558 chr1 5569491 C A 2.61E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17028213 chr1 5615931 C T 4.75E-04 Multiple complex diseases / / 17554300 rs7523214 chr1 5625929 C G 2.30E-07 Urinary metabolites / / 21572414 rs7528859 chr1 5661009 T A 2.34E-05 Migraine - clinic-based / / 23793025 rs7528859 chr1 5661009 T A 5.00E-06 Migraine with aura / / 23793025 rs11260661 chr1 5671493 G C 9.34E-04 Type 2 diabetes / / 17463246 rs17426290 chr1 5683697 C T 4.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs1775401 chr1 5686132 C T 4.82E-04 Multiple complex diseases / / 17554300 rs770683 chr1 5689702 A G 7.54E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs17028416 chr1 5689921 G C 4.94E-04 Multiple complex diseases / / 17554300 rs17426695 chr1 5696425 G A 3.87E-05 Cognitive test performance / / 20125193 rs6670965 chr1 5696677 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10492947 chr1 5699475 C A 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs11260666 chr1 5699634 G A 2.67E-04 Multiple complex diseases / / 17554300 rs4845812 chr1 5707816 C T 5.00E-06 Metabolite levels (MHPG) / / 23319000 rs1775408 chr1 5717138 A G 7.59E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12038771 chr1 5723643 G A 1.60E-05 Multiple complex diseases / / 17554300 rs707580 chr1 5724940 T C 3.18E-04 Multiple complex diseases / / 17554300 rs2649071 chr1 5753350 G A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs796396 chr1 5764879 A G 1.40E-05 Urinary metabolites / / 21572414 rs2649086 chr1 5782769 T C 8.96E-05 Diabetes (gestational) / / 22233651 rs2842258 chr1 5790498 A G 8.72E-04 Type 2 diabetes / / 17463246 rs17028719 chr1 5795008 A G 8.90E-07 Alcohol dependence / / 22096494 rs17028719 chr1 5795008 A G 3.20E-06 Alcohol and nictotine co-dependence / / 22488850 rs17429690 chr1 5814135 G A 4.58E-04 Multiple complex diseases / / 17554300 rs9661578 chr1 5881752 C T 4.53E-05 Cocaine dependence / / 23958962 rs9661578 chr1 5881752 C T 6.10E-05 Cocaine dependence / / 23958962 rs548726 chr1 5913621 T C 5.00E-07 Response to taxane treatment (placlitaxel) / / 23006423 rs4908559 chr1 5944138 A G 1.77E-04 Smoking cessation NPHP4 intron 18519826 rs4908559 chr1 5944138 A G 6.32E-04 Smoking cessation NPHP4 intron 18519826 rs2282281 chr1 5948677 G A 3.19E-07 Smoking cessation NPHP4 intron 18519826 rs3747987 chr1 5966119 T C 5.74E-05 Smoking cessation NPHP4 intron 18519826 rs551207 chr1 6007446 C T 9.65E-05 Height NPHP4 intron pha003011 rs4908458 chr1 6033973 C T 0.000085 Panic disorder NPHP4 intron 23149450 rs4908458 chr1 6033973 C T 8.50E-05 Serum tamsulosin hydrochloride concentration NPHP4 intron 23151678 rs4908639 chr1 6038583 G C 1.32E-06 Smoking cessation NPHP4 intron 18519826 rs806104 chr1 6042934 G A 2.40E-04 Bipolar disorder NPHP4 intron 19259986 rs4908728 chr1 6102419 C T 9.28E-05 Femoral neck bone geometry KC/B2 intron 22087292 rs6685332 chr1 6109173 G A 3.40E-04 Response to cytadine analogues (cytosine arabinoside) KC/B2 intron 24483146 rs3789541 chr1 6141325 G A 1.54E-05 Bone mineral density KC/B2 intron 19181680 rs3789541 chr1 6141325 G A 1.69E-04 Alzheimer's disease (late onset) KC/B2 intron 21379329 rs7531562 chr1 6177202 G T 5.66E-04 Multiple complex diseases CHD5 intron 17554300 rs731975 chr1 6222501 C A 4.80E-05 Cognitive function CHD5 intron 24684796 rs709209 chr1 6278414 A G 1.07E-07 QT interval RNF207 missense 19305409 rs846111 chr1 6279370 G C 1.00E-16 QT interval RNF207 missense 19305408 rs846111 chr1 6279370 G C 4.00E-16 QT interval RNF207 missense 19305409 rs4908541 chr1 6291810 A G 8.58E-05 Cognitive test performance ICMT intron 20125193 rs114389068 chr1 6314183 C T 0.0000607 Menopause (age at onset) GPR153 cds-synon 23424626 rs10489535 chr1 6343825 G A 6.69E-04 Multiple complex diseases ACOT7 intron 17554300 rs17029376 chr1 6409979 A G 4.80E-04 Multiple complex diseases ACOT7 intron 17554300 rs4582826 chr1 6461530 T C 6.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs373598296 chr1 6511582 AG A 6.32E-04 Smoking quantity ESPN intron 24665060 rs9434774 chr1 6511582 A G 6.32E-04 Smoking quantity ESPN intron 24665060 rs3007421 chr1 6530189 G A 7.70E-05 Alzheimer's disease PLEKHG5 intron 19136949 rs3007421 chr1 6530189 G A 7.79E-05 Waist Circumference PLEKHG5 intron pha003025 rs3935435 chr1 6572175 G A 1.10E-04 Myasthenia gravis PLEKHG5 intron 23055271 rs7540913 chr1 6581877 G A 7.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 UTR-3 20877124 rs13513 chr1 6585804 C T 5.21E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 UTR-3 20877124 rs7548042 chr1 6586070 C T 4.27E-04 Multiple complex diseases NOL9 intron 17554300 rs11122083 chr1 6593532 G A 1.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 intron 20877124 rs6679649 chr1 6606608 C T 3.42E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 intron 20877124 rs6679649 chr1 6606608 C T 4.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 intron 20877124 rs10746502 chr1 6607199 T C 2.61E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 intron 20877124 rs10864625 chr1 6614230 G A 3.42E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 cds-synon 20877124 rs10864625 chr1 6614230 G A 4.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 cds-synon 20877124 rs925745 chr1 6615690 A G 0.00008794 Sarcoidosis TAS1R1 intron 22952805 rs11587438 chr1 6631431 C T 4.00E-06 White blood cell types TAS1R1 intron 21738478 rs11122100 chr1 6638064 T C 3.94E-05 Cognitive performance TAS1R1 intron 19734545 rs4908932 chr1 6639847 G T 1.37E-04 Tourette syndrome / / 22889924 rs731024 chr1 6644723 G A 4.58E-04 Alcohol dependence ZBTB48 intron 24277619 rs731024 chr1 6644723 G A 7.96E-04 Response to alcohol consumption (flushing response) ZBTB48 intron 24277619 rs1556036 chr1 6651728 C T 1.06E-04 Multiple complex diseases KLHL21 UTR-3 17554300 rs1556036 chr1 6651728 C T 4.54E-05 Heart Rate KLHL21 UTR-3 pha003051 rs4587589 chr1 6657355 C T 1.07E-04 Multiple complex diseases KLHL21 intron 17554300 rs11583755 chr1 6672729 A C 2.30E-05 Crohn's disease (time to surgery) / / 23665963 rs10779795 chr1 6677064 A G 8.53E-04 Alcohol dependence PHF13 intron 24277619 rs2072948 chr1 6679848 C T 6.73E-05 Blood Pressure PHF13 intron pha003049 rs2235564 chr1 6713114 C T 5.97E-05 Multiple complex diseases D/JC11 intron 17554300 rs2235564 chr1 6713114 C T 1.81E-05 Blood Pressure D/JC11 intron pha003049 rs6577584 chr1 6715390 T G 1.86E-05 Blood Pressure D/JC11 intron pha003049 rs2281190 chr1 6720990 C A 2.23E-05 Blood Pressure D/JC11 intron pha003049 rs6659873 chr1 6723806 T G 2.23E-05 Blood Pressure D/JC11 intron pha003049 rs277686 chr1 6747897 C G 9.43E-05 Multiple complex diseases D/JC11 intron 17554300 rs278020 chr1 6764643 C T 9.62E-04 Alcohol dependence / / 24277619 rs278021 chr1 6764663 T C 2.90E-05 Kidney function and endocine traits / / 17903292 rs277672 chr1 6771607 G T 5.32E-04 Multiple complex diseases / / 17554300 rs202577 chr1 6784053 A G 5.59E-04 Multiple complex diseases / / 17554300 rs449250 chr1 6797684 G A 5.90E-05 Coronary restenosis / / 21878436 rs422111 chr1 6823923 A G 2.50E-05 Urinary metabolites / / 21572414 rs448886 chr1 6829582 C A 2.50E-05 Malaria / / 19465909 rs12088027 chr1 6884248 T C 4.20E-04 Heart Failure CAMTA1 intron pha002884 rs10864244 chr1 6908448 G A 5.40E-05 Coffee consumption CAMTA1 intron 21357676 rs17029988 chr1 6938689 C T 1.03E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CAMTA1 intron 20031582 rs12751613 chr1 6978622 A C 6.74E-04 Heart Failure CAMTA1 intron pha002884 rs11586158 chr1 7002266 A G 7.97E-04 Smoking quantity CAMTA1 intron 24665060 rs7538627 chr1 7006698 T A 4.45E-04 Smoking quantity CAMTA1 intron 24665060 rs7554752 chr1 7014444 G A 3.15E-04 Smoking quantity CAMTA1 intron 24665060 rs884736 chr1 7015105 T C 0.0001 Gains in maximal O2 uptake response CAMTA1 intron 21183627 rs884736 chr1 7015105 T C 7.45E-05 Coronary restenosis CAMTA1 intron 21878436 rs1013248 chr1 7019816 T G 4.96E-04 Alzheimer's disease CAMTA1 intron 17998437 rs17030082 chr1 7029262 G A 4.28E-04 Alzheimer's disease CAMTA1 intron 17998437 rs6679134 chr1 7035830 A G 2.02E-04 Alzheimer's disease CAMTA1 intron 17998437 rs1317016 chr1 7048043 C G 5.01E-05 Blood pressure CAMTA1 intron 24001895 rs12043302 chr1 7055024 C T 6.95E-05 Waist Circumference CAMTA1 intron pha003023 rs17030152 chr1 7083719 T C 3.46E-04 Barrett's esophagus CAMTA1 intron 24121790 rs6686587 chr1 7099660 G A 1.68E-04 Heart Failure CAMTA1 intron pha002884 rs4908591 chr1 7110510 G A 2.71E-04 Alzheimer's disease (late onset) CAMTA1 intron 21379329 rs11120822 chr1 7113112 G C 1.00E-06 Stearic acid (18:0) plasma levels CAMTA1 intron 23362303 rs7553100 chr1 7117542 A G 5.80E-06 Urinary metabolites CAMTA1 intron 21572414 rs10779671 chr1 7119489 A G 4.60E-06 Urinary metabolites CAMTA1 intron 21572414 rs9434833 chr1 7144893 C T 2.30E-06 Urinary metabolites CAMTA1 intron 21572414 rs4908443 chr1 7179721 T C 1.08E-04 Parkinson's disease CAMTA1 intron 17052657 rs4908443 chr1 7179721 T C 6.68E-06 Coronary heart disease CAMTA1 intron pha003030 rs7527889 chr1 7213619 C T 4.33E-05 Multiple complex diseases CAMTA1 intron 17554300 rs6680365 chr1 7236810 A G 0.0000538 Migraine CAMTA1 intron 22678113 rs6680365 chr1 7236810 A G 5.38E-05 Migraine CAMTA1 intron 22683712 rs1304711 chr1 7270320 A C 9.95E-04 Type 2 diabetes CAMTA1 intron 17463246 rs17030589 chr1 7278776 C G 5.86E-04 Multiple complex diseases CAMTA1 intron 17554300 rs4908449 chr1 7292700 T C 2.00E-05 Episodic memory CAMTA1 intron 17470457 rs6577427 chr1 7314231 T C 6.86E-04 Multiple complex diseases CAMTA1 intron 17554300 rs7547519 chr1 7316136 A G 7.00E-09 Episodic memory CAMTA1 intron 17470457 rs7549382 chr1 7320903 C G 1.00E-04 Episodic memory CAMTA1 intron 17470457 rs2071924 chr1 7352974 G A 4.84E-04 Lung function (forced vital capacity) CAMTA1 intron 24023788 rs10489142 chr1 7363310 A G 7.16E-04 Alcohol dependence CAMTA1 intron 21314694 rs6668927 chr1 7377498 C T 8.98E-04 Alzheimer's disease CAMTA1 intron 22005930 rs12563394 chr1 7380747 A G 4.56E-04 Alzheimer's disease CAMTA1 intron 22005930 rs12739426 chr1 7386456 C A 4.91E-04 Alzheimer's disease CAMTA1 intron 22005930 rs2301460 chr1 7389944 A C 3.25E-04 Alzheimer's disease CAMTA1 intron 22005930 rs2301461 chr1 7389977 T C 1.50E-04 Type 2 diabetes and 6 quantitative traits CAMTA1 intron 17848626 rs705680 chr1 7402502 T C 6.68E-04 Multiple complex diseases CAMTA1 intron 17554300 rs845244 chr1 7406114 A G 7.96E-04 Multiple complex diseases CAMTA1 intron 17554300 rs705677 chr1 7409910 A C 2.00E-04 Episodic memory CAMTA1 intron 17470457 rs845237 chr1 7412051 A G 7.94E-04 Smoking cessation CAMTA1 intron 24665060 rs1894655 chr1 7417290 T C 8.38E-04 Alzheimer's disease CAMTA1 intron 22005930 rs4908626 chr1 7422216 G T 5.54E-04 Alzheimer's disease CAMTA1 intron 22005930 rs6677597 chr1 7422919 G T 5.45E-04 Alzheimer's disease CAMTA1 intron 22005930 rs1418489 chr1 7425064 A G 2.52E-06 Asthma (childhood onset) CAMTA1 intron 23829686 rs845222 chr1 7429092 T G 7.74E-04 Type 2 diabetes CAMTA1 intron 17463246 rs3752543 chr1 7430394 T C 5.39E-04 Alzheimer's disease CAMTA1 intron 22005930 rs11579620 chr1 7432615 G A 4.71E-04 Alzheimer's disease CAMTA1 intron 22005930 rs845218 chr1 7433862 T C 4.04E-04 Smoking cessation CAMTA1 intron 24665060 rs6677949 chr1 7445435 C A 2.30E-04 Smoking cessation CAMTA1 intron 24665060 rs845233 chr1 7446240 T C 2.26E-04 Smoking cessation CAMTA1 intron 24665060 rs7524314 chr1 7449971 G A 6.85E-05 Body Mass Index CAMTA1 intron pha003020 rs2097518 chr1 7460433 G A 3.67E-04 Alzheimer's disease CAMTA1 intron 17998437 rs11120917 chr1 7478076 C T 1.45E-05 Anxiety in major depressive disorder CAMTA1 intron 24047446 rs11120917 chr1 7478076 C T 9.19E-04 Heart Failure CAMTA1 intron pha002884 rs11120921 chr1 7485306 C T 4.90E-04 Response to taxane treatment (placlitaxel) CAMTA1 intron 23006423 rs17030828 chr1 7491320 C T 3.81E-04 Type 2 diabetes CAMTA1 intron 17463246 rs947678 chr1 7492616 A C 6.00E-04 Episodic memory CAMTA1 intron 17470457 rs1193221 chr1 7492991 T G 4.72E-04 Suicide attempts in bipolar disorder CAMTA1 intron 21423239 rs1307984 chr1 7497547 C T 9.31E-04 Suicide attempts in bipolar disorder CAMTA1 intron 21423239 rs2185789 chr1 7500182 G A 7.26E-04 Suicide attempts in bipolar disorder CAMTA1 intron 21423239 rs17030881 chr1 7502288 A C,G 5.13E-05 Type 2 diabetes CAMTA1 intron 17463246 rs17030881 chr1 7502288 A C,G 2.06E-04 Multiple complex diseases CAMTA1 intron 17554300 rs12119558 chr1 7504737 G A 5.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAMTA1 intron 20877124 rs1616122 chr1 7521585 C T 5.00E-06 Periodontal microbiota CAMTA1 intron 22699663 rs1149332 chr1 7528846 C T 5.00E-06 Puberty onset CAMTA1 intron 24770850 rs1149336 chr1 7532290 C T 5.79E-06 Puberty onset CAMTA1 intron 24770850 rs1149336 chr1 7532290 C T 9.00E-07 Puberty onset (breast development) CAMTA1 intron 24770850 rs2796483 chr1 7541345 C T 9.70E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) CAMTA1 intron 24236485 rs17030993 chr1 7549488 T C 7.91E-05 Coronary heart disease CAMTA1 intron pha003056 rs1750849 chr1 7552326 G C 4.30E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) CAMTA1 intron 24236485 rs12033734 chr1 7566789 C G 9.48E-04 Insulin resistance CAMTA1 intron 21901158 rs12063665 chr1 7568588 T G 1.70E-05 Non-word repetition CAMTA1 intron 23738518 rs1193179 chr1 7569602 C T 6.30E-07 Type 2 diabetes CAMTA1 intron 17293876 rs1193179 chr1 7569602 C T 6.30E-07 Type 2 diabetes CAMTA1 intron 19184112 rs7536730 chr1 7635253 G T 4.99E-04 Multiple complex diseases CAMTA1 intron 17554300 rs941017 chr1 7655998 T C 4.87E-05 Cognitive impairment induced by topiramate CAMTA1 intron 22091778 rs6691275 chr1 7670013 T C 3.10E-04 Cisplatin and carboplatin cytotoxicity,in blood cell lines CAMTA1 intron 21844884 rs2056674 chr1 7670217 T A 5.40E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CAMTA1 intron 21844884 rs4908663 chr1 7712132 G A 1.90E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CAMTA1 intron 24023788 rs17376559 chr1 7718093 G A 9.40E-05 Serum metabolites CAMTA1 intron 19043545 rs3011925 chr1 7721360 G A 3.00E-06 PR interval in Tripanosoma cruzi seropositivity CAMTA1 intron 24324551 rs1891215 chr1 7727854 T C 7.64E-05 Brain derived neurotrophic factor levels,in serum CAMTA1 intron 22047184 rs1891216 chr1 7728391 T G 9.66E-06 Brain derived neurotrophic factor levels,in serum CAMTA1 intron 22047184 rs6661392 chr1 7735950 C T 1.37E-05 Brain derived neurotrophic factor levels,in serum CAMTA1 intron 22047184 rs6673977 chr1 7736097 A G 1.37E-05 Brain derived neurotrophic factor levels,in serum CAMTA1 intron 22047184 rs2995032 chr1 7753132 T C 4.39E-06 Multiple complex diseases CAMTA1 intron 17554300 rs2995034 chr1 7770901 C T 4.43E-06 Multiple complex diseases CAMTA1 intron 17554300 rs12563101 chr1 7777673 G A 1.15E-11 Metabolite levels CAMTA1 intron 22286219 rs2032563 chr1 7801288 G A 4.02E-04 Longevity CAMTA1 intron 22279548 rs9919223 chr1 7812398 A G 9.18E-04 Multiple complex diseases CAMTA1 intron 17554300 rs12093175 chr1 7818318 G T 2.53E-04 Multiple complex diseases CAMTA1 intron 17554300 rs41402249 chr1 7822723 G C 3.37E-04 Multiple complex diseases CAMTA1 intron 17554300 rs11587479 chr1 7823085 A C 5.40E-05 Stroke CAMTA1 intron pha002886 rs707458 chr1 7832212 C T 6.82E-05 Crohn's disease VAMP3 intron 18587394 rs697673 chr1 7837842 T C 2.64E-05 Stroke VAMP3 intron pha002886 rs228641 chr1 7862899 T C 6.93E-04 Smoking initiation PER3 intron 24665060 rs35426314 chr1 7869968 G A 4.28E-16 HDL cholesterol PER3 missense 23063622 rs4908482 chr1 7877488 A G 8.48E-04 Suicide attempts in bipolar disorder PER3 intron 21423239 rs2797685 chr1 7879063 C T 7.00E-09 Crohn's disease PER3 intron 21102463 rs228688 chr1 7879130 T G 7.40E-04 Suicide attempts in bipolar disorder PER3 intron 21423239 rs228691 chr1 7880469 A G 9.71E-04 Suicide attempts in bipolar disorder PER3 intron 21423239 rs10462020 chr1 7880683 T G 8.39E-06 Type 2 diabetes PER3 missense 21647700 rs228694 chr1 7883834 A G 9.73E-04 Suicide attempts in bipolar disorder PER3 intron 21423239 rs707472 chr1 7906008 G T 3.63E-06 Crohn's disease / / 18587394 rs12566535 chr1 7924094 G A 7.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs504560 chr1 7926542 A G 9.16E-05 Asthma / / pha003127 rs228725 chr1 7929819 T C 0.000130044 Primary sclerosing cholangitis / / 23603763 rs228703 chr1 7944264 A G 4.96E-04 Aortic root size / / 21223598 rs227163 chr1 7961206 C T 3.00E-09 Rheumatoid arthritis / / 24390342 rs227163 chr1 7961206 C T 3.90E-04 Rheumatoid arthritis / / 24390342 rs664673 chr1 7970075 C T 7.70E-05 Endometriosis / / 21151130 rs679563 chr1 7971078 G A 6.40E-04 Endometriosis / / 23104006 rs161811 chr1 7999602 C T 5.65E-04 Multiple complex diseases TNFRSF9 intron 17554300 rs9657955 chr1 8001358 G A 0.000000484 Triglycerides TNFRSF9 intron 23063622 rs226473 chr1 8008968 T C 9.52E-05 Atrial fibrillation / / 21846873 rs35675666 chr1 8021973 G T 5.00E-09 Ulcerative colitis PARK7 intron 21297633 rs35675666 chr1 8021973 G T 1.00E-15 Inflammatory bowel disease PARK7 intron 23128233 rs161802 chr1 8042826 G T 2.00E-07 Stroke (ischemic) PARK7 intron 24262325 rs12727642 chr1 8046672 C A 9.00E-08 Celiac disease / / 20190752 rs12727642 chr1 8046672 C A 5.94E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs225132 chr1 8095500 T G 6.00E-08 Stroke (ischemic) / / 24262325 rs12748993 chr1 8129507 A G 9.00E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7539255 chr1 8133352 T C 6.76E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10864330 chr1 8168564 C T 8.00E-05 Lung adenocarcinoma / / 22797724 rs7527904 chr1 8189854 T C 0.0000861 Primary sclerosing cholangitis / / 23603763 rs7542367 chr1 8199263 T C 2.66E-04 Alzheimer's disease (late onset) / / 21379329 rs9434617 chr1 8200328 T C 3.67E-04 Alzheimer's disease (late onset) / / 21379329 rs1455701 chr1 8213010 T C 6.99E-05 HDL cholesterol / / pha003075 rs11121129 chr1 8268095 G A 2.16E-04 Scoliosis / / 21216876 rs11121129 chr1 8268095 G A 0.000000017 Psoriasis / / 23143594 rs411654 chr1 8274807 A G 5.64E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs385137 chr1 8274963 T C 4.35E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs421490 chr1 8275284 A G 3.00E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7513908 chr1 8302619 G A 1.90E-05 Major depressive disorder / / 21042317 rs438895 chr1 8338355 G A 7.00E-06 Economic and political preferences / / 22566634 rs11121152 chr1 8357221 C T 8.04E-04 Multiple complex diseases / / 17554300 rs12727604 chr1 8365102 G A 4.37E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9628987 chr1 8386730 A C 5.00E-06 Breast cancer SLC45A1 intron 23468962 rs2305016 chr1 8395441 T C 9.43E-05 Non-alcoholic fatty liver disease histology (other) SLC45A1 intron 20708005 rs202161082 chr1 8397995 G A 0.00015 Breast cancer SLC45A1 missense 23555315 rs2252865 chr1 8422676 T C 3.00E-06 Schizophrenia RERE intron 21926974 rs2252865 chr1 8422676 T C 1.78E-08 Glaucoma-related traits RERE intron 22058429 rs2252865 chr1 8422676 T C 2.38E-09 Glaucoma-related traits RERE intron 22058429 rs2252865 chr1 8422676 T C 3.54E-09 Glaucoma-related traits RERE intron 22058429 rs2252865 chr1 8422676 T C 5.26E-08 Glaucoma-related traits RERE intron 22058429 rs2252865 chr1 8422676 T C 8.16E-09 Glaucoma-related traits RERE intron 22058429 rs2252865 chr1 8422676 T C 9.41E-09 Glaucoma-related traits RERE intron 22058429 rs2252865 chr1 8422676 T C 5.00E-07 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) RERE intron 23453885 rs2252865 chr1 8422676 T C 0.000219 Bipolar disorder RERE intron 23637625 rs2252865 chr1 8422676 T C 0.000476 Schizophrenia RERE intron 23637625 rs10779702 chr1 8423510 A G 4.75E-04 Prostate cancer mortality RERE intron 20978177 rs894875 chr1 8432136 C T 3.85E-04 Self-reported allergy RERE intron 23817569 rs6678140 chr1 8436802 C T 2.81E-04 Self-reported allergy RERE intron 23817569 rs2708633 chr1 8439625 C A 2.68E-04 Self-reported allergy RERE intron 23817569 rs3765971 chr1 8445360 C T 2.61E-04 Self-reported allergy RERE intron 23817569 rs2120461 chr1 8447722 C T 3.00E-06 Bone mineral density RERE intron 22504420 rs2120461 chr1 8447722 C T 2.15E-04 Self-reported allergy RERE intron 23817569 rs2661863 chr1 8452725 T C 2.55E-04 Self-reported allergy RERE intron 23817569 rs301791 chr1 8468372 A T 8.20E-05 Prostate cancer mortality RERE intron 20978177 rs301791 chr1 8468372 A T 2.59E-04 Self-reported allergy RERE intron 23817569 rs301790 chr1 8469284 G C 1.93E-04 Self-reported allergy RERE intron 23817569 rs301789 chr1 8469337 A G 2.59E-04 Self-reported allergy RERE intron 23817569 rs1763839 chr1 8473336 G A 3.35E-04 Self-reported allergy RERE intron 23817569 rs302714 chr1 8486131 A C 1.74E-04 Self-reported allergy RERE intron 23817569 rs301797 chr1 8487323 C A 2.66E-04 Self-reported allergy RERE intron 23817569 rs301798 chr1 8488565 A G 8.07E-07 Glaucoma-related traits RERE intron 22058429 rs301798 chr1 8488565 A G 2.53E-04 Self-reported allergy RERE intron 23817569 rs301799 chr1 8489302 C T 3.00E-06 Thyroid peroxidase antibody positivity RERE intron 24586183 rs302719 chr1 8490320 T G 5.03E-05 Prostate cancer mortality RERE intron 20978177 rs172531 chr1 8495590 A G 4.03E-05 Schizophrenia RERE intron 19571811 rs172531 chr1 8495590 A G 4.11E-05 Prostate cancer mortality RERE intron 20978177 rs172531 chr1 8495590 A G 2.32E-04 Self-reported allergy RERE intron 23817569 rs301801 chr1 8495945 T C 4.11E-05 Prostate cancer mortality RERE intron 20978177 rs301801 chr1 8495945 T C 2.33E-04 Self-reported allergy RERE intron 23817569 rs2784739 chr1 8497558 T G 6.76E-04 Self-reported allergy RERE intron 23817569 rs301803 chr1 8498680 A T 2.08E-04 Self-reported allergy RERE intron 23817569 rs2784740 chr1 8501057 T A 6.11E-04 Self-reported allergy RERE intron 23817569 rs301819 chr1 8501786 A G 5.84E-05 Vitiligo RERE intron 20410501 rs301819 chr1 8501786 A G 8.85E-09 Vitiligo RERE intron 21326295 rs301818 chr1 8503242 G A 2.78E-04 Self-reported allergy RERE intron 23817569 rs11121182 chr1 8522553 C A 1.70E-05 Urinary metabolites RERE intron 21572414 rs4908760 chr1 8526142 G A 7.00E-15 Vitiligo RERE intron 20410501 rs4908760 chr1 8526142 G A 3.54E-14 Vitiligo RERE intron 22561518 rs11806357 chr1 8526642 T C 1.85E-05 Multiple complex diseases RERE intron 17554300 rs11121194 chr1 8569906 C T 5.77E-04 Vitiligo RERE intron 20410501 rs17386406 chr1 8643497 G A 9.71E-04 Type 2 diabetes RERE intron 17463246 rs6679128 chr1 8702530 C T 9.07E-05 Multiple complex diseases RERE intron 17554300 rs7547833 chr1 8742451 C T 8.18E-05 Alzheimer's disease RERE intron 22005930 rs11121220 chr1 8755282 A G 1.61E-05 Multiple complex diseases RERE intron 17554300 rs12025126 chr1 8759554 T C 6.00E-08 Vertical cup-disc ratio RERE intron 20548946 rs12025126 chr1 8759554 T C 2.66E-04 Glaucoma-related traits RERE intron 22058429 rs12025126 chr1 8759554 T C 3.18E-04 Glaucoma-related traits RERE intron 22058429 rs4908773 chr1 8769728 T C 4.95E-04 Type 2 diabetes RERE intron 17463246 rs4908778 chr1 8804888 C G 5.85E-04 Smoking initiation RERE intron 24665060 rs12024032 chr1 8808185 C T 4.82E-04 Type 2 diabetes RERE intron 17463246 rs4908511 chr1 8812390 G C 5.28E-04 Type 2 diabetes RERE intron 17463246 rs12410886 chr1 8878809 A C 7.90E-05 Birth weight / / 17255346 rs11582339 chr1 8898807 G T 1.43E-04 Birth weight / / 17255346 rs10864368 chr1 8918313 T C 2.50E-05 Urinary metabolites / / 21572414 rs4418632 chr1 8994112 T C 1.23E-06 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs12091891 chr1 9000220 A G 8.56E-04 Alcohol dependence / / 20201924 rs1475734 chr1 9000628 G T 0.000695441 Hypertension (early onset hypertension) / / 22479346 rs11809994 chr1 9005269 A C 0.000013 Mean arterial pressure / / 22510845 rs1409147 chr1 9005320 A G 0.0000063 Panic disorder / / 23149450 rs1409147 chr1 9005320 A G 6.30E-06 Serum tamsulosin hydrochloride concentration / / 23151678 rs2274327 chr1 9009406 C T 7.10E-04 Multiple complex diseases CA6 missense 17554300 rs2274327 chr1 9009406 C T 3.74E-04 Smoking initiation CA6 missense 24665060 rs2274328 chr1 9009444 A C 1.96E-04 Body mass index CA6 missense 17255346 rs7513804 chr1 9045124 C T 1.10E-04 Multiple complex diseases / / 17554300 rs9803645 chr1 9049872 C T 4.90E-05 Cognitive test performance / / 20125193 rs12031065 chr1 9079154 C T 2.73E-05 Non-small cell lung cancer SLC2A7 intron 21866343 rs12145292 chr1 9118596 C A 7.96E-05 Orofacial clefts SLC2A5 intron 22419666 rs6694527 chr1 9119028 G A 1.32E-11 HDL cholesterol SLC2A5 intron 23063622 rs3820034 chr1 9129867 G A 1.24E-05 Follicle stimulating hormone SLC2A5 UTR-5 24049095 rs12080794 chr1 9151325 C T 9.00E-06 Response to antidepressant treatment (citalopram) / / 23726668 rs1001567 chr1 9194614 G T 3.08E-05 Atopy / / 21625490 rs11802925 chr1 9228624 T C 9.09E-05 Schizophrenia / / 19571809 rs4908527 chr1 9234143 C T 1.80E-05 Urinary metabolites / / 21572414 rs10489436 chr1 9285721 A G 8.83E-04 Longevity / / 22279548 rs6662509 chr1 9317604 C T 3.00E-10 Height H6PD intron 23563607 rs9435168 chr1 9331952 A G 7.64E-06 Fibrinogen / / pha003068 rs7517538 chr1 9332703 T C 1.06E-07 Lymphocyte counts / / 22286170 rs1294028 chr1 9364634 A G 2.00E-04 Schizophrenia SPSB1 intron 19197363 rs630075 chr1 9370911 A G 7.00E-05 Triglycerides SPSB1 intron 19074352 rs9660159 chr1 9382469 G A 5.27E-04 Amyotrophic lateral sclerosis (sporadic) SPSB1 intron 24529757 rs4908842 chr1 9387311 T C 5.90E-05 Triglycerides SPSB1 intron 19074352 rs926247 chr1 9394008 T C 2.97E-04 Type 2 diabetes SPSB1 intron 17463246 rs478103 chr1 9402403 T C 2.02E-05 Sudden cardiac arrest SPSB1 intron 21658281 rs11121380 chr1 9408959 A C 5.00E-08 Response to tocilizumab in rheumatoid arthritis SPSB1 intron 22491018 rs11121382 chr1 9411469 G C 4.09E-06 Parkinson's disease (motor and cognition) SPSB1 intron 22658654 rs11121382 chr1 9411469 G C 4.00E-06 Immune response to anthrax vaccine SPSB1 intron 22658931 rs9435244 chr1 9417946 G A 1.90E-05 Urinary metabolites SPSB1 intron 21572414 rs9435245 chr1 9419290 T C 2.80E-06 Urinary metabolites SPSB1 intron 21572414 rs9308447 chr1 9432390 C T 5.00E-07 Dental caries / / 23064961 rs17393334 chr1 9432911 G A 1.45E-05 Major depressive disorder / / 19107115 rs17393468 chr1 9438540 T C 1.49E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs9787285 chr1 9499246 G A 7.24E-05 Myopia (pathological) / / 23049088 rs9787285 chr1 9499246 G A 4.57E-05 Hodgkin's lymphoma / / 24149102 rs10735516 chr1 9507004 T G 0.000098 Salmonella-induced pyroptosis / / 22837397 rs12034064 chr1 9508955 T C 5.23E-04 Hodgkin's lymphoma / / 24149102 rs10864424 chr1 9510088 G T 5.14E-05 Glucose levels / / pha003057 rs10746490 chr1 9525697 G A 2.57E-04 Common variable immunodeficiency / / 21497890 rs6679380 chr1 9533238 C T 8.33E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs12023288 chr1 9602962 C A 2.77E-04 Alzheimer's disease SLC25A33 intron 24755620 rs11121441 chr1 9610125 C T 9.12E-05 Multiple complex diseases SLC25A33 intron 17554300 rs6660810 chr1 9615158 G A 7.02E-04 Alzheimer's disease SLC25A33 intron 24755620 rs4423053 chr1 9621407 A G 3.75E-04 Alzheimer's disease SLC25A33 intron 24755620 rs9430273 chr1 9624113 C A 3.84E-04 Alzheimer's disease SLC25A33 intron 24755620 rs9430274 chr1 9624285 A G 4.22E-04 Alzheimer's disease SLC25A33 intron 24755620 rs12124860 chr1 9627103 G A 7.74E-04 Alzheimer's disease SLC25A33 intron 24755620 rs9430152 chr1 9632396 T G 3.29E-04 Alzheimer's disease SLC25A33 intron 24755620 rs9430153 chr1 9637227 A G 3.18E-04 Alzheimer's disease SLC25A33 intron 24755620 rs9430332 chr1 9645372 C T 3.18E-04 Alzheimer's disease / / 24755620 rs9430174 chr1 9647137 G A 3.28E-04 Alzheimer's disease / / 24755620 rs6669846 chr1 9650571 C T 1.91E-04 Multiple complex diseases TMEM201 intron 17554300 rs6540961 chr1 9650729 A G 4.60E-04 Alzheimer's disease TMEM201 intron 24755620 rs3923984 chr1 9653835 A G 7.57E-04 Alzheimer's disease TMEM201 intron 24755620 rs7544083 chr1 9654197 T C 5.89E-04 Alzheimer's disease TMEM201 intron 24755620 rs4073710 chr1 9655795 G A 1.71E-04 Glycosylated haemoglobin levels TMEM201 intron 17255346 rs11121464 chr1 9695888 T C 4.60E-05 Intracerebral hemorrhage / / 24656865 rs12568084 chr1 9734287 G A 1.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIK3CD intron 20877124 rs12568084 chr1 9734287 G A 3.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIK3CD intron 20877124 rs9430635 chr1 9738786 C G 3.63E-04 Multiple complex diseases PIK3CD intron 17554300 rs4240910 chr1 9750457 T C 9.15E-04 Multiple complex diseases PIK3CD intron 17554300 rs11121482 chr1 9777529 A G 0.00000146 Cholesterol,total PIK3CD intron 23063622 rs12032209 chr1 9897001 A C 1.10E-05 Urinary metabolites / / 21572414 rs1933734 chr1 9902128 T C 9.36E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs1220421 chr1 10008221 G A 2.80E-04 Response to statin treatment (atorvastatin),change in cholesterol levels NM/T1 intron 20031582 rs7516611 chr1 10013014 A C,G,T 8.80E-06 Urinary metabolites NM/T1 intron 21572414 rs2890358 chr1 10027540 G A 3.00E-06 Lymphocyte counts NM/T1 intron 22286170 rs12082318 chr1 10036009 G A 9.07E-05 Cognitive impairment induced by topiramate NM/T1 intron 22091778 rs12136213 chr1 10046460 A G 4.05E-04 Alzheimer's disease (late onset) / / 21379329 rs12140058 chr1 10049177 T G 0.000858 Antisocial behavior / / 23077488 rs2295294 chr1 10190884 A T 0.0000086 Lumbar spine bone mineral density UBE4B intron 22692763 rs2295294 chr1 10190884 A T 0.000377 Lumbar spine bone mineral density (males) UBE4B intron 22692763 rs12092513 chr1 10231463 C T 1.18E-05 Coronary heart disease UBE4B intron pha003032 rs11121524 chr1 10232534 C G 5.45E-04 Alcohol dependence UBE4B intron 21314694 rs2180184 chr1 10235946 T C 5.36E-04 Self-reported allergy UBE4B intron 23817569 rs6541080 chr1 10236039 G A 2.50E-05 Urinary metabolites UBE4B intron 21572414 rs7418410 chr1 10236402 C T 4.34E-04 Alzheimer's disease (late onset) UBE4B intron 21379329 rs7418410 chr1 10236402 C T 1.10E-05 Urinary metabolites UBE4B intron 21572414 rs2180185 chr1 10246129 G C 1.40E-05 Urinary metabolites / / 21572414 rs4348727 chr1 10265606 G A 1.51E-04 Self-reported allergy / / 23817569 rs17396340 chr1 10286176 G A 3.00E-08 Mean platelet volume KIF1B intron 22139419 rs10492969 chr1 10286358 T C 8.90E-04 Type 2 diabetes and 6 quantitative traits KIF1B intron 17848626 rs12751375 chr1 10291874 C G 1.25E-04 Self-reported allergy KIF1B intron 23817569 rs374529040 chr1 10291874 C CAG 1.25E-04 Self-reported allergy KIF1B intron 23817569 rs12136376 chr1 10296452 C T 1.22E-04 Self-reported allergy KIF1B intron 23817569 rs12755094 chr1 10305711 T C 1.21E-04 Self-reported allergy KIF1B intron 23817569 rs6700866 chr1 10306038 A G 1.21E-04 Self-reported allergy KIF1B intron 23817569 rs946501 chr1 10309580 G C 4.52E-04 Self-reported allergy KIF1B intron 23817569 rs4846207 chr1 10313811 T C 4.50E-04 Self-reported allergy KIF1B intron 23817569 rs4846208 chr1 10313839 T C 1.39E-04 Self-reported allergy KIF1B intron 23817569 rs12402052 chr1 10318652 C G 1.24E-04 Self-reported allergy KIF1B cds-synon 23817569 rs4846210 chr1 10322153 A G 1.27E-04 Self-reported allergy KIF1B intron 23817569 rs12757288 chr1 10323921 T C 4.14E-04 Self-reported allergy KIF1B intron 23817569 rs12064209 chr1 10326184 C G 1.02E-04 Multiple complex diseases KIF1B intron 17554300 rs1339458 chr1 10328338 C T 1.31E-04 Self-reported allergy KIF1B intron 23817569 rs12131785 chr1 10341516 C T 1.50E-05 Bulimia nervosa KIF1B intron 23568457 rs912962 chr1 10348712 A C 9.60E-05 Triglycerides KIF1B intron 19074352 rs10492972 chr1 10353112 T C 3.00E-10 Multiple sclerosis KIF1B intron 18997785 rs7520935 chr1 10354271 G T 1.48E-04 Self-reported allergy KIF1B intron 23817569 rs3753037 chr1 10355834 C T 1.48E-04 Self-reported allergy KIF1B intron 23817569 rs2275424 chr1 10356562 C A 1.44E-04 Self-reported allergy KIF1B intron 23817569 rs1536263 chr1 10378914 T C 1.23E-04 Self-reported allergy KIF1B intron 23817569 rs17401924 chr1 10384439 A G 1.26E-04 Self-reported allergy KIF1B intron 23817569 rs17401966 chr1 10385471 A G 2.00E-18 Hepatocellular carcinoma KIF1B intron 20676096 rs17401966 chr1 10385471 A G 1.70E-18 Hepatitis B KIF1B intron 21750111 rs17401966 chr1 10385471 A G 1.70E-18 Hepatocellular carcinoma (hepatitis B virus related) KIF1B intron 23242368 rs17401966 chr1 10385471 A G 1.26E-04 Self-reported allergy KIF1B intron 23817569 rs12734551 chr1 10391536 T G 1.10E-04 Self-reported allergy KIF1B intron 23817569 rs1556916 chr1 10403482 G A 3.80E-04 Self-reported allergy KIF1B intron 23817569 rs11576866 chr1 10414432 A G 1.01E-04 Self-reported allergy KIF1B intron 23817569 rs7546364 chr1 10418815 G A 3.67E-04 Self-reported allergy KIF1B intron 23817569 rs3748578 chr1 10420918 G A 1.12E-04 Self-reported allergy KIF1B intron 23817569 rs12403443 chr1 10423988 A G 5.81E-06 Self-reported allergy KIF1B intron 23817569 rs17411502 chr1 10431158 T C 9.65E-05 Self-reported allergy KIF1B intron 23817569 rs11121551 chr1 10435170 T C 3.89E-04 Self-reported allergy KIF1B intron 23817569 rs11121552 chr1 10435324 C A 1.15E-04 Self-reported allergy KIF1B cds-synon 23817569 rs4846216 chr1 10447792 T A 5.16E-04 Lymphocyte counts LOC100287506 intron 22286170 rs6679596 chr1 10454502 A T 6.43E-04 Type 2 diabetes LOC100287506 intron 17463246 rs3737155 chr1 10459779 G A 5.70E-04 Type 2 diabetes and 6 quantitative traits PGD intron 17848626 rs3737155 chr1 10459779 G A 2.39E-04 Self-reported allergy PGD intron 23817569 rs1889309 chr1 10479678 G A 1.23E-04 Self-reported allergy PGD intron 23817569 rs544289 chr1 10499236 A G 2.19E-04 Alzheimer's disease APITD1 intron 24755620 rs2847337 chr1 10502710 A G 4.80E-05 Alzheimer's disease APITD1 UTR-3 24755620 rs1307489 chr1 10507236 A G 4.80E-05 Alzheimer's disease APITD1-CORT intron 24755620 rs1307490 chr1 10508679 T C 5.17E-05 Alzheimer's disease APITD1-CORT intron 24755620 rs1307494 chr1 10509703 C T 5.27E-05 Alzheimer's disease APITD1-CORT intron 24755620 rs666103 chr1 10511589 T C 1.01E-04 Alzheimer's disease CORT cds-synon 24755620 rs1307497 chr1 10512056 T C 8.91E-06 Alzheimer's disease CORT UTR-3 21627779 rs1307497 chr1 10512056 T C 9.03E-04 Self-reported allergy CORT UTR-3 23817569 rs1307497 chr1 10512056 T C 1.78E-04 Alzheimer's disease CORT UTR-3 24755620 rs6540931 chr1 10512509 T C 9.11E-04 Self-reported allergy / / 23817569 rs2483686 chr1 10515414 T C 1.03E-04 Alzheimer's disease / / 24755620 rs944973 chr1 10516393 C G 3.35E-06 Alzheimer's disease / / 21627779 rs685746 chr1 10537437 C G 2.33E-06 Self-reported allergy PEX14 intron 23817569 rs607941 chr1 10539543 C T 1.01E-05 Self-reported allergy PEX14 intron 23817569 rs668805 chr1 10544547 G A 7.24E-07 Self-reported allergy PEX14 intron 23817569 rs669701 chr1 10544725 A G 1.53E-06 Self-reported allergy PEX14 intron 23817569 rs596537 chr1 10554709 G T 2.49E-06 Self-reported allergy PEX14 intron 23817569 rs620405 chr1 10554794 T C 2.41E-06 Self-reported allergy PEX14 intron 23817569 rs622623 chr1 10555257 C T 1.76E-06 Self-reported allergy PEX14 intron 23817569 rs636291 chr1 10556097 G A 3.21E-06 Self-reported allergy PEX14 intron 23817569 rs648324 chr1 10556447 G T 1.55E-06 Self-reported allergy PEX14 intron 23817569 rs648399 chr1 10556485 T C 1.66E-06 Self-reported allergy PEX14 intron 23817569 rs662064 chr1 10557251 T C 1.59E-06 Self-reported allergy PEX14 intron 23817569 rs660725 chr1 10557544 A G 1.84E-06 Self-reported allergy PEX14 intron 23817569 rs647281 chr1 10558210 G A 9.25E-05 Alzheimer's disease PEX14 intron 24755620 rs589400 chr1 10561282 A G 1.06E-06 Self-reported allergy PEX14 intron 23817569 rs2506901 chr1 10563492 A G 1.76E-06 Self-reported allergy PEX14 intron 23817569 rs10864459 chr1 10563609 A G 2.01E-06 Self-reported allergy PEX14 intron 23817569 rs10864460 chr1 10563671 G C 4.48E-06 Self-reported allergy PEX14 intron 23817569 rs2506902 chr1 10563681 C T 2.10E-04 Primary sclerosing cholangitis PEX14 intron 19944697 rs2506902 chr1 10563681 C T 1.62E-06 Self-reported allergy PEX14 intron 23817569 rs2781230 chr1 10563717 G A 2.94E-06 Self-reported allergy PEX14 intron 23817569 rs2847344 chr1 10564675 G A 7.47E-07 Self-reported allergy PEX14 intron 23817569 rs616488 chr1 10566215 A G 2.00E-10 Breast cancer PEX14 intron 23535729 rs616488 chr1 10566215 A G 1.00E-08 Breast cancer PEX14 intron 23535733 rs616488 chr1 10566215 A G 3.79E-06 Self-reported allergy PEX14 intron 23817569 rs616402 chr1 10566272 C T 5.50E-07 Self-reported allergy PEX14 intron 23817569 rs12129512 chr1 10572967 G T 1.40E-04 Self-reported allergy PEX14 intron 23817569 rs1411402 chr1 10579545 G T 4.64E-07 Self-reported allergy PEX14 intron 23817569 rs2483677 chr1 10580891 C T 3.99E-07 Self-reported allergy PEX14 intron 23817569 rs2056417 chr1 10581658 G A 4.00E-07 Self-reported allergy PEX14 intron 23817569 rs2480782 chr1 10593296 G T 6.77E-04 Alzheimer's disease PEX14 intron 24755620 rs2026792 chr1 10594790 A G 7.02E-06 Self-reported allergy PEX14 intron 23817569 rs12375 chr1 10596341 C T 8.28E-06 Self-reported allergy PEX14 cds-synon 23817569 rs2480777 chr1 10597551 C T 9.76E-06 Self-reported allergy PEX14 intron 23817569 rs2506892 chr1 10598216 G A 1.27E-05 Self-reported allergy PEX14 intron 23817569 rs2480775 chr1 10606996 G T 3.09E-05 Neuroblastoma PEX14 intron pha002895 rs12120962 chr1 10609505 G A 5.26E-05 Hearing function PEX14 intron 17255346 rs10864463 chr1 10613560 A G 9.93E-05 Neuroblastoma PEX14 intron pha002895 rs12127400 chr1 10613660 C T 4.55E-05 Hearing function PEX14 intron 17255346 rs17035305 chr1 10616505 C A 1.53E-05 Self-reported allergy PEX14 intron 23817569 rs12028449 chr1 10617034 G A 1.62E-05 Self-reported allergy PEX14 intron 23817569 rs11121587 chr1 10618109 A G 1.38E-05 Self-reported allergy PEX14 intron 23817569 rs11121594 chr1 10626922 G C 4.04E-04 Alzheimer's disease PEX14 intron 17998437 rs6687502 chr1 10633273 G A 4.10E-04 Alzheimer's disease PEX14 intron 17998437 rs12741973 chr1 10638604 C T 7.00E-06 optic disc size (rim) PEX14 intron 20395239 rs284272 chr1 10653628 G T 5.48E-04 Smoking cessation PEX14 intron 24665060 rs10864468 chr1 10655709 G A 3.76E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs284267 chr1 10656351 C A 1.20E-04 Multiple complex diseases PEX14 intron 17554300 rs11121598 chr1 10658202 G A 3.76E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs11121599 chr1 10666735 A G 3.08E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs12722934 chr1 10668379 A T 3.08E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs6666075 chr1 10669098 C G 3.08E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs3790630 chr1 10673094 C T 6.83E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs284238 chr1 10678488 A T 1.61E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs284237 chr1 10678610 G A 2.08E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs284235 chr1 10678843 C T 7.11E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs190775 chr1 10683683 G T 2.39E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs185864 chr1 10687726 G C 9.06E-07 Alcohol dependence (age at onset) PEX14 intron 24962325 rs284303 chr1 10690883 C T 9.06E-07 Alcohol dependence (age at onset) PEX14 nearGene-3 24962325 rs284301 chr1 10694125 G A 1.12E-06 Alcohol dependence (age at onset) / / 24962325 rs61776290 chr1 10694907 C T 2.00E-07 Alcohol dependence (age at onset) / / 24962325 rs284243 chr1 10705880 A G 2.90E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs778228 chr1 10708142 A G 1.64E-06 Alcohol dependence (age at onset) CASZ1 cds-synon 24962325 rs284300 chr1 10709309 C G 8.55E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs284298 chr1 10710255 G A 8.55E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs284296 chr1 10712089 A G 1.37E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs284295 chr1 10712097 A G 1.37E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs2242287 chr1 10714911 T C 6.42E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs476164 chr1 10719566 T C 7.42E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs284322 chr1 10725498 G A 5.54E-06 Alcohol dependence (age at onset) CASZ1 cds-synon 24962325 rs284320 chr1 10727020 T C 4.30E-04 Obesity,menopause CASZ1 intron 21424828 rs284320 chr1 10727020 T C 2.02E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs11121604 chr1 10730002 A G 3.11E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs61776326 chr1 10742120 G A 7.20E-07 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs284261 chr1 10743749 G A 2.80E-04 Multiple complex diseases CASZ1 intron 17554300 rs516243 chr1 10750432 A G 9.00E-06 Migraine - clinic-based CASZ1 intron 23793025 rs11805515 chr1 10767785 T C 7.44E-05 Cognitive test performance CASZ1 intron 20125193 rs710133 chr1 10771488 C T 1.86E-04 Type 2 diabetes CASZ1 intron 17463246 rs284233 chr1 10777260 G A 9.38E-05 Cognitive impairment induced by topiramate CASZ1 intron 22091778 rs284254 chr1 10786314 A G 6.14E-05 Cognitive impairment induced by topiramate CASZ1 intron 22091778 rs880315 chr1 10796866 T C 3.00E-10 Blood pressure CASZ1 intron 21572416 rs880315 chr1 10796866 T C 7.00E-07 Blood pressure CASZ1 intron 21572416 rs880315 chr1 10796866 T C 1.52E-04 Blood pressure (age interaction) CASZ1 intron 24954895 rs880315 chr1 10796866 T C 5.45E-05 Blood pressure (age interaction) CASZ1 intron 24954895 rs12046278 chr1 10799577 T C 5.00E-06 Systolic blood pressure CASZ1 intron 19430479 rs12046278 chr1 10799577 T C 5.00E-06 Coronary heart disease CASZ1 intron 21347282 rs4845843 chr1 10801585 G A 3.63E-05 Multiple complex diseases CASZ1 intron 17554300 rs205483 chr1 10814938 C T 0.0000725 Nonsyndromic striae distensae (stretch marks) CASZ1 intron 23633020 rs205484 chr1 10815421 T C 4.49E-05 Blood pressure CASZ1 intron 17255346 rs205472 chr1 10832322 G A 7.73E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CASZ1 intron 21844884 rs205474 chr1 10832861 C T 3.87E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CASZ1 intron 21844884 rs1613696 chr1 10838798 C T 2.41E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CASZ1 intron 21844884 rs1776219 chr1 10874152 T G 3.62E-04 Multiple complex diseases / / 17554300 rs527676 chr1 10891777 G A 3.71E-04 Lymphocyte counts / / 22286170 rs4845960 chr1 10947580 G A 9.25E-05 ldl cholesterol / / pha003076 rs10864479 chr1 10968730 T G 9.01E-04 Type 2 diabetes / / 17463246 rs1280985 chr1 10984406 T A 1.90E-05 Coffee consumption / / 21357676 rs1281014 chr1 11009543 G A 4.47E-04 Multiple complex diseases C1orf127 intron 17554300 rs138476809 chr1 11009844 G A 0.00044 Breast cancer C1orf127 missense 23555315 rs2003046 chr1 11032827 C A 9.60E-07 Ewing sarcoma C1orf127 intron 22327514 rs2003046 chr1 11032827 C A 1.99E-10 Male-pattern baldness C1orf127 intron 22693459 rs12565727 chr1 11033082 A G 9.00E-11 Male-pattern baldness C1orf127 intron 22693459 rs9659356 chr1 11034817 A G 1.29E-09 Male-pattern baldness C1orf127 intron 22693459 rs11576658 chr1 11037736 C T 9.20E-08 Ewing sarcoma C1orf127 intron 22327514 rs11576658 chr1 11037736 C T 1.06E-09 Male-pattern baldness C1orf127 intron 22693459 rs11121667 chr1 11038476 C T 1.17E-09 Male-pattern baldness C1orf127 intron 22693459 rs7542158 chr1 11040193 G A 1.20E-09 Male-pattern baldness C1orf127 intron 22693459 rs11121671 chr1 11043780 C A,T 4.48E-04 Alcohol dependence / / 24277619 rs9430158 chr1 11043861 G C 2.43E-08 Male-pattern baldness / / 22693459 rs7547568 chr1 11044829 T A 2.20E-08 Male-pattern baldness / / 22693459 rs9430161 chr1 11046855 G T 5.80E-05 Glioma (high-grade) / / 19578366 rs9430161 chr1 11046855 G T 1.00E-20 Ewing sarcoma / / 22327514 rs12085877 chr1 11087687 C T 0.00000166 Triglycerides MASP2 missense 23063622 rs12072993 chr1 11094362 A G 0.000000013 Cholesterol,total MASP2 intron 23063622 rs12142107 chr1 11097867 C T 0.00031 Prostate cancer (non-advanced prostate cancer) MASP2 cds-synon 23555315 rs12139042 chr1 11167146 G A 1.00E-11 Corneal curvature MTOR UTR-3 24963161 rs17036350 chr1 11171226 C T 4.00E-13 Corneal curvature MTOR intron 21665993 rs2300095 chr1 11265717 A G 3.69E-06 Obesity MTOR intron 22484627 rs74225573 chr1 11280994 T C 6.00E-18 Corneal curvature MTOR intron 24963161 rs12124983 chr1 11286178 T C 8.11E-04 Type 2 diabetes MTOR intron 17463246 rs17036631 chr1 11347492 C T 5.41E-06 Job-related exhaustion UBIAD1 UTR-3 23620144 rs11121720 chr1 11364920 T C 2.00E-04 Job-related exhaustion / / 23620144 rs4845992 chr1 11383839 A T 9.32E-05 Type 2 diabetes / / 17463246 rs4845992 chr1 11383839 A T 4.90E-04 Multiple complex diseases / / 17554300 rs2982384 chr1 11401745 G A 6.00E-04 Multiple complex diseases / / 17554300 rs2744854 chr1 11419868 C T 1.64E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs6661145 chr1 11485666 T C 9.60E-05 White matter hyperintensity burden / / 21681796 rs3123602 chr1 11489175 G A 7.90E-05 White matter hyperintensity burden / / 21681796 rs877309 chr1 11489678 A G 7.80E-05 White matter hyperintensity burden / / 21681796 rs3099624 chr1 11496994 C T 2.08E-07 Alopecia areata / / 22027810 rs3099627 chr1 11499388 A G 3.80E-28 Narcolepsy / / 19629137 rs11577773 chr1 11516521 C T 1.08E-04 Smoking initiation / / 24665060 rs12026602 chr1 11518397 C T 5.25E-04 Smoking initiation / / 24665060 rs12046038 chr1 11525533 A G 1.68E-04 Heart Failure / / pha002885 rs6674692 chr1 11533011 C T 7.40E-04 Multiple complex diseases / / 17554300 rs10159458 chr1 11534053 A C 5.59E-04 Multiple complex diseases / / 17554300 rs6674713 chr1 11550632 G C 6.32E-05 Multiple complex diseases PTCHD2 intron 17554300 rs2745276 chr1 11641283 G A 2.40E-05 Triglycerides / / 19074352 rs2817644 chr1 11647669 C T 7.80E-06 Triglycerides / / 19074352 rs1810483 chr1 11671329 C A 9.15E-04 Aortic root size / / 21223598 rs7550768 chr1 11680283 C T 1.96E-07 Schizophrenia / / 21926974 rs17037122 chr1 11689663 A G 5.20E-04 Schizophrenia / / 19197363 rs2336030 chr1 11736600 C T 1.00E-06 Visceral adipose tissue adjusted for BMI MAD2L2 intron 22589738 rs4846033 chr1 11788564 A G 4.00E-06 Schizophrenia / / 18347602 rs4075033 chr1 11811234 A G 4.94E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11121822 chr1 11814216 G A 4.10E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1133398 chr1 11814631 A G 6.43E-04 Schizophrenia / / 19197363 rs12132479 chr1 11836450 A G 2.90E-07 Natriuretic peptide levels C1orf167 intron 21273288 rs7538516 chr1 11836682 C T 8.70E-10 Natriuretic peptide levels C1orf167 missense 21273288 rs140362679 chr1 11836811 G A 6.87E-05 Acne (severe) C1orf167 intron 24927181 rs6541001 chr1 11837367 C T 8.60E-07 Natriuretic peptide levels C1orf167 UTR-3 21273288 rs10864540 chr1 11838099 A G 1.72E-05 Alcohol and nictotine co-dependence C1orf167 UTR-3 20158304 rs12134663 chr1 11838646 A C 2.70E-07 Natriuretic peptide levels LOC100506310 intron 21273288 rs12134663 chr1 11838646 A C 3.00E-21 Homocysteine levels LOC100506310 intron 23824729 rs6697244 chr1 11838848 G T 7.40E-10 Natriuretic peptide levels LOC100506310 missense 21273288 rs4845882 chr1 11843167 A G 7.20E-10 Natriuretic peptide levels LOC100506310 intron 21273288 rs4846047 chr1 11843632 C G 6.10E-04 Natriuretic peptide levels LOC100506310 intron 21273288 rs4846048 chr1 11846252 G A 6.10E-04 Natriuretic peptide levels MTHFR UTR-3 21273288 rs3737967 chr1 11847449 G A 2.00E-04 Natriuretic peptide levels LOC100506310 missense 21273288 rs1537516 chr1 11847861 G A 1.10E-06 Natriuretic peptide levels MTHFR UTR-3 21273288 rs1537514 chr1 11848068 G C 1.90E-07 Natriuretic peptide levels LOC100506310 missense 21273288 rs1537514 chr1 11848068 G C 1.36E-04 Blood pressure LOC100506310 missense 22100073 rs4846049 chr1 11850365 T G 9.70E-12 Natriuretic peptide levels MTHFR UTR-3 21273288 rs4846049 chr1 11850365 T G 1.48E-08 Blood pressure MTHFR UTR-3 22100073 rs4846049 chr1 11850365 T G 1.60E-08 Blood pressure MTHFR UTR-3 22100073 rs4846049 chr1 11850365 T G 1.90E-82 Blood pressure MTHFR UTR-3 22100073 rs4846049 chr1 11850365 T G 2.90E-19 Blood pressure MTHFR UTR-3 22100073 rs4846049 chr1 11850365 T G 2.96E-10 Blood pressure MTHFR UTR-3 22100073 rs4846049 chr1 11850365 T G 3.71E-10 Blood pressure MTHFR UTR-3 22100073 rs4846049 chr1 11850365 T G 5.20E-07 Blood pressure MTHFR UTR-3 22100073 rs2274976 chr1 11850927 C T 2.30E-06 Natriuretic peptide levels MTHFR missense 21273288 rs3818762 chr1 11851003 G C 3.10E-14 Natriuretic peptide levels MTHFR intron 21273288 rs3818762 chr1 11851003 G C 1.30E-25 Blood pressure MTHFR intron 22100073 rs3818762 chr1 11851003 G C 1.60E-05 Blood pressure MTHFR intron 22100073 rs3818762 chr1 11851003 G C 3.20E-99 Blood pressure MTHFR intron 22100073 rs3818762 chr1 11851003 G C 8.80E-15 Blood pressure MTHFR intron 22100073 rs576853093 chr1 11851003 G GCACACACACACAC 3.10E-14 Natriuretic peptide levels MTHFR intron 21273288 rs576853093 chr1 11851003 G GCACACACACACAC 1.30E-25 Blood pressure MTHFR intron 22100073 rs576853093 chr1 11851003 G GCACACACACACAC 1.60E-05 Blood pressure MTHFR intron 22100073 rs576853093 chr1 11851003 G GCACACACACACAC 3.20E-99 Blood pressure MTHFR intron 22100073 rs576853093 chr1 11851003 G GCACACACACACAC 8.80E-15 Blood pressure MTHFR intron 22100073 rs13306556 chr1 11852110 C T 1.70E-06 Natriuretic peptide levels MTHFR intron 21273288 rs13306556 chr1 11852110 C T 2.90E-04 Atrial fibrillation MTHFR intron 21846873 rs13306556 chr1 11852110 C T 1.27E-04 Blood pressure MTHFR intron 22100073 rs1476413 chr1 11852300 C T 7.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MTHFR intron 20877124 rs1476413 chr1 11852300 C T 2.90E-12 Natriuretic peptide levels MTHFR intron 21273288 rs1476413 chr1 11852300 C T 1.20E-04 Blood pressure MTHFR intron 22100073 rs1476413 chr1 11852300 C T 1.70E-45 Blood pressure MTHFR intron 22100073 rs1476413 chr1 11852300 C T 2.28E-05 Coronary heart disease MTHFR intron pha003030 rs17375901 chr1 11852516 C T 6.00E-07 Atrial fibrillation MTHFR intron 19597492 rs4846051 chr1 11854457 G A 1 Drug response to Methotrexate MTHFR cds-synon 16439441 rs1801131 chr1 11854476 T G 1 Drug response to Folic Acid MTHFR missense 16572443 rs1801131 chr1 11854476 T G 1 Drug response to Methotrexate MTHFR missense 16572443 rs1801131 chr1 11854476 T G 1 Drug response to Nitrous Oxide MTHFR missense 18580170 rs1801131 chr1 11854476 T G 1 Drug response to Folic Acid MTHFR missense 19016697 rs1801131 chr1 11854476 T G 1 Drug response to Methotrexate MTHFR missense 19016697 rs1801131 chr1 11854476 T G 8.30E-12 Natriuretic peptide levels MTHFR missense 21273288 rs1801131 chr1 11854476 T G 3.10E-36 Blood pressure MTHFR missense 22100073 rs1801131 chr1 11854476 T G 8.40E-06 Blood pressure MTHFR missense 22100073 rs12121543 chr1 11854671 C A 1.80E-15 Natriuretic peptide levels MTHFR intron 21273288 rs12121543 chr1 11854671 C A 3.20E-05 Blood pressure MTHFR intron 22100073 rs1994798 chr1 11854755 G A 2.40E-09 Natriuretic peptide levels MTHFR intron 21273288 rs1994798 chr1 11854755 G A 5.60E-04 Blood pressure MTHFR intron 22100073 rs2066462 chr1 11854896 G A 1.50E-07 Natriuretic peptide levels MTHFR cds-synon 21273288 rs6541003 chr1 11855867 G A 2.20E-09 Natriuretic peptide levels MTHFR intron 21273288 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 11418485 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 11710708 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 12453860 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 12915598 rs1801133 chr1 11856378 G A 1 Drug response to Folic Acid MTHFR missense 16572443 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 16572443 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 17488658 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 18381794 rs1801133 chr1 11856378 G A 1 Drug response to Nitrous Oxide MTHFR missense 18580170 rs1801133 chr1 11856378 G A 1 Drug response to Folic Acid MTHFR missense 19016697 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 19016697 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 19208607 rs1801133 chr1 11856378 G A 4.36E-13 Folate pathway vitamin levels MTHFR missense 19303062 rs1801133 chr1 11856378 G A 9.30E-05 Homocysteine levels,in plasma MTHFR missense 19525478 rs1801133 chr1 11856378 G A 8.00E-35 Homocysteine levels MTHFR missense 20031578 rs1801133 chr1 11856378 G A 2.36E-07 Schizophrenia MTHFR missense 22037552 rs1801133 chr1 11856378 G A 1.75E-11 homocysteine levels MTHFR missense 23696881 rs1801133 chr1 11856378 G A 4.00E-104 Homocysteine levels MTHFR missense 23824729 rs1801133 chr1 11856378 G A 5.42E-04 Schizophrenia MTHFR missense 24043878 rs17421511 chr1 11857788 G A 2.90E-07 Natriuretic peptide levels MTHFR intron 21273288 rs4846052 chr1 11857951 T C 2.20E-09 Natriuretic peptide levels MTHFR intron 21273288 rs4846052 chr1 11857951 T C 9.38E-05 Response to mTOR inhibitor (rapamycin) MTHFR intron 24009623 rs17037388 chr1 11858036 A G 3.00E-06 Blood pressure MTHFR intron 21060006 rs17037388 chr1 11858036 A G 4.00E-04 Blood pressure MTHFR intron 21060006 rs17037388 chr1 11858036 A G 6.20E-05 Blood pressure MTHFR intron 21060006 rs17037388 chr1 11858036 A G 8.80E-06 Blood pressure MTHFR intron 21060006 rs17037388 chr1 11858036 A G 1.00E-04 Blood pressure MTHFR intron 22100073 rs17421560 chr1 11858324 G A 1.60E-06 Natriuretic peptide levels MTHFR intron 21273288 rs13306553 chr1 11860117 A G 2.40E-04 Atrial fibrillation MTHFR intron 21846873 rs11121832 chr1 11860120 T C 3.00E-05 Natriuretic peptide levels MTHFR intron 21273288 rs2066471 chr1 11860458 C T 2.80E-07 Natriuretic peptide levels MTHFR intron 21273288 rs7533315 chr1 11860683 T C 1.90E-04 Natriuretic peptide levels MTHFR intron 21273288 rs17037390 chr1 11860843 G A 3.10E-06 Blood pressure MTHFR intron 21060006 rs17037390 chr1 11860843 G A 6.00E-04 Blood pressure MTHFR intron 21060006 rs17037390 chr1 11860843 G A 6.70E-05 Blood pressure MTHFR intron 21060006 rs17037390 chr1 11860843 G A 9.60E-06 Blood pressure MTHFR intron 21060006 rs17037390 chr1 11860843 G A 2.30E-04 Natriuretic peptide levels MTHFR intron 21273288 rs17037390 chr1 11860843 G A 8.00E-04 Atrial fibrillation MTHFR intron 21846873 rs17037390 chr1 11860843 G A 3.71E-06 Blood pressure MTHFR intron 22100073 rs17037396 chr1 11862047 C T 1.00E-07 Natriuretic peptide levels MTHFR intron 21273288 rs17037396 chr1 11862047 C T 2.80E-04 Atrial fibrillation MTHFR intron 21846873 rs17037396 chr1 11862047 C T 1.81E-04 Blood pressure MTHFR intron 22100073 rs17037397 chr1 11862163 C A 1.80E-06 Natriuretic peptide levels MTHFR intron 21273288 rs9651118 chr1 11862214 T C 2.30E-04 Natriuretic peptide levels MTHFR intron 21273288 rs9651118 chr1 11862214 T C 2.48E-05 Esophageal cancer (squamous cell) MTHFR intron 22960999 rs17367504 chr1 11862778 A G 2.00E-13 Systolic blood pressure MTHFR intron 19430483 rs17367504 chr1 11862778 A G 6.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MTHFR intron 20877124 rs17367504 chr1 11862778 A G 1.10E-04 Blood pressure MTHFR intron 21060006 rs17367504 chr1 11862778 A G 1.80E-05 Blood pressure MTHFR intron 21060006 rs17367504 chr1 11862778 A G 3.00E-04 Blood pressure MTHFR intron 21060006 rs17367504 chr1 11862778 A G 3.60E-06 Blood pressure MTHFR intron 21060006 rs17367504 chr1 11862778 A G 2.10E-04 Natriuretic peptide levels MTHFR intron 21273288 rs17367504 chr1 11862778 A G 2.00E-13 Coronary heart disease MTHFR intron 21347282 rs17367504 chr1 11862778 A G 2.00E-13 Blood pressure MTHFR intron 21378095 rs17367504 chr1 11862778 A G 3.80E-04 Atrial fibrillation MTHFR intron 21846873 rs17367504 chr1 11862778 A G 2.00E-16 Blood pressure MTHFR intron 21909110 rs17367504 chr1 11862778 A G 8.72E-22 Systolic blood pressure MTHFR intron 21909115 rs17367504 chr1 11862778 A G 1.20E-06 Blood pressure MTHFR intron 22100073 rs2066470 chr1 11863057 G A 4.20E-07 Natriuretic peptide levels MTHFR cds-synon 21273288 rs2066470 chr1 11863057 G A 1.40E-04 Atrial fibrillation MTHFR cds-synon 21846873 rs2066470 chr1 11863057 G A 7.74E-05 Blood pressure MTHFR cds-synon 22100073 rs7553194 chr1 11864149 G A 5.80E-08 Natriuretic peptide levels MTHFR intron 21273288 rs3753582 chr1 11865542 A C 1.30E-08 Natriuretic peptide levels MTHFR intron 21273288 rs13306561 chr1 11865804 A G 1.70E-04 Blood pressure MTHFR intron 21060006 rs13306561 chr1 11865804 A G 3.00E-05 Blood pressure MTHFR intron 21060006 rs13306561 chr1 11865804 A G 6.00E-04 Blood pressure MTHFR intron 21060006 rs13306561 chr1 11865804 A G 7.90E-06 Blood pressure MTHFR intron 21060006 rs13306561 chr1 11865804 A G 1.70E-05 Natriuretic peptide levels MTHFR intron 21273288 rs13306561 chr1 11865804 A G 3.00E-04 Atrial fibrillation MTHFR intron 21846873 rs13306561 chr1 11865804 A G 3.24E-06 Blood pressure MTHFR intron 22100073 rs13306560 chr1 11866183 C T 1.20E-08 Blood pressure CLCN6 UTR-5 21060006 rs13306560 chr1 11866183 C T 2.90E-11 Blood pressure CLCN6 UTR-5 21060006 rs13306560 chr1 11866183 C T 3.40E-05 Blood pressure CLCN6 UTR-5 21060006 rs13306560 chr1 11866183 C T 5.40E-06 Blood pressure CLCN6 UTR-5 21060006 rs13306560 chr1 11866183 C T 6.10E-06 Blood pressure CLCN6 UTR-5 21060006 rs3737965 chr1 11866451 G A 1.30E-07 Natriuretic peptide levels CLCN6 intron 21273288 rs3737964 chr1 11867044 T A,C,G 4.00E-05 Natriuretic peptide levels CLCN6 intron 21273288 rs4846054 chr1 11869230 C T 6.70E-11 Natriuretic peptide levels CLCN6 intron 21273288 rs4846056 chr1 11869578 T C 4.00E-05 Natriuretic peptide levels CLCN6 intron 21273288 rs17037425 chr1 11870383 G A 1.70E-05 Natriuretic peptide levels CLCN6 intron 21273288 rs17037425 chr1 11870383 G A 4.30E-04 Atrial fibrillation CLCN6 intron 21846873 rs17037425 chr1 11870383 G A 1.22E-05 Blood pressure CLCN6 intron 22100073 rs6687229 chr1 11872656 C T 8.70E-09 Natriuretic peptide levels CLCN6 intron 21273288 rs12123964 chr1 11872714 A C 2.00E-07 Natriuretic peptide levels CLCN6 intron 21273288 rs12404124 chr1 11873869 G T 3.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CLCN6 intron 20877124 rs12404124 chr1 11873869 G T 1.80E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs198391 chr1 11876417 C T 1.30E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs2076001 chr1 11879267 A G 9.00E-09 Natriuretic peptide levels CLCN6 intron 21273288 rs2076002 chr1 11879360 G A 9.00E-09 Natriuretic peptide levels CLCN6 intron 21273288 rs198393 chr1 11879685 C T 4.30E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs2050265 chr1 11879699 A G 6.30E-05 Natriuretic peptide levels CLCN6 intron 21273288 rs198399 chr1 11883629 T A 4.30E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs12567136 chr1 11883731 C T 6.30E-05 Natriuretic peptide levels CLCN6 intron 21273288 rs2076003 chr1 11884147 T C 1.10E-07 Natriuretic peptide levels CLCN6 intron 21273288 rs2076004 chr1 11886813 G A 8.90E-09 Natriuretic peptide levels CLCN6 intron 21273288 rs7537765 chr1 11887303 A G 6.50E-05 Natriuretic peptide levels CLCN6 intron 21273288 rs535107 chr1 11889468 A G 1.80E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs503040 chr1 11890695 C T 1.70E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs2236797 chr1 11892650 C T 1.40E-08 Natriuretic peptide levels CLCN6 intron 21273288 rs17037452 chr1 11895675 A G 1.40E-08 Natriuretic peptide levels CLCN6 intron 21273288 rs2075538 chr1 11896602 T C 9.00E-09 Natriuretic peptide levels CLCN6 intron 21273288 rs198406 chr1 11897592 A G 3.00E-08 Natriuretic peptide levels CLCN6 intron 21273288 rs2075539 chr1 11897758 G A 1.10E-07 Natriuretic peptide levels CLCN6 intron 21273288 rs198408 chr1 11898130 T A 5.50E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs2272803 chr1 11898789 G T 1.10E-07 Natriuretic peptide levels CLCN6 intron 21273288 rs1023252 chr1 11899033 G T 4.00E-16 Natriuretic peptide levels CLCN6 intron 21273288 rs198413 chr1 11900802 T C 1.68E-04 Multiple complex diseases CLCN6 UTR-3 17554300 rs17350396 chr1 11900838 A G 1.80E-07 Natriuretic peptide levels CLCN6 UTR-3 21273288 rs14078 chr1 11903010 G A 4.28E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CLCN6 UTR-3 21844884 rs198358 chr1 11904076 T C 3.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs198358 chr1 11904076 T C 1.15E-05 Atrial fibrillation / / 21846873 rs7552330 chr1 11904092 G A 8.20E-08 Natriuretic peptide levels / / 21273288 rs5068 chr1 11905974 A G 2.10E-04 Atrial fibrillation NPPA UTR-3 21846873 rs5068 chr1 11905974 A G 3.18E-05 Blood pressure NPPA UTR-3 22100073 rs5065 chr1 11906068 A G 1 Drug response to Amlodipine NPPA-AS1 intron 18212314 rs5065 chr1 11906068 A G 1 Drug response to Chlorthalidone NPPA-AS1 intron 18212314 rs5065 chr1 11906068 A G 1 Drug response to Doxazosin NPPA-AS1 intron 18212314 rs5065 chr1 11906068 A G 1 Drug response to Lisinopril NPPA-AS1 intron 18212314 rs5063 chr1 11907648 C T 8.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NPPA missense 20877124 rs5063 chr1 11907648 C T 5.00E-08 Natriuretic peptide levels NPPA missense 21273288 rs198372 chr1 11909514 G A 3.00E-04 Blood pressure NPPA nearGene-5 21060006 rs632793 chr1 11910677 A G 2.14E-15 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs632793 chr1 11910677 A G 3.60E-11 Natriuretic peptide levels / / 21273288 rs198375 chr1 11913757 T C 4.00E-11 Natriuretic peptide levels / / 21273288 rs198375 chr1 11913757 T C 1.10E-04 Blood pressure / / 22100073 rs6668352 chr1 11914829 G A 1.70E-18 Natriuretic peptide levels / / 21273288 rs198388 chr1 11917340 C T 1.95E-13 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs198388 chr1 11917340 C T 3.90E-10 Natriuretic peptide levels / / 21273288 rs198388 chr1 11917340 C T 7.10E-04 Blood pressure / / 22100073 rs198389 chr1 11919271 A G 1.70E-12 Natriuretic peptide levels / / 21273288 rs12406089 chr1 11921181 C G 3.50E-16 Natriuretic peptide levels / / 21273288 rs12406383 chr1 11921993 C A 3.70E-18 Natriuretic peptide levels / / 21273288 rs6668659 chr1 11922298 T G 5.30E-16 Natriuretic peptide levels / / 21273288 rs6668659 chr1 11922298 T G 2.00E-05 Blood pressure / / 22100073 rs6676300 chr1 11925300 A G 5.75E-14 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6676300 chr1 11925300 A G 9.30E-14 Natriuretic peptide levels / / 21273288 rs116228357 chr1 11925732 C T 6.00E-04 Polycystic ovary syndrome / / 22178785 rs1318408 chr1 11925781 A G 8.60E-05 Natriuretic peptide levels / / 21273288 rs12562952 chr1 11927056 T C 3.39E-11 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12562952 chr1 11927056 T C 3.60E-04 Natriuretic peptide levels / / 21273288 rs1009592 chr1 11928714 C G 4.00E-11 Natriuretic peptide levels / / 21273288 rs11801879 chr1 11928819 T C 1.80E-05 Blood pressure / / 21060006 rs11801879 chr1 11928819 T C 4.00E-04 Blood pressure / / 21060006 rs11801879 chr1 11928819 T C 6.00E-06 Blood pressure / / 21060006 rs1009591 chr1 11928830 T C 2.60E-08 Natriuretic peptide levels / / 21273288 rs1009591 chr1 11928830 T C 9.95E-05 Monocyte chemoattractant protein-1 / / pha003071 rs11803049 chr1 11928895 G A 1.07E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11803049 chr1 11928895 G A 5.90E-06 Natriuretic peptide levels / / 21273288 rs11804222 chr1 11936514 G A 3.23E-05 Alcohol withdrawal symptoms / / 22072270 rs12724129 chr1 11957639 C T 6.83E-06 Asthma / / 20698975 rs12085006 chr1 11958723 A G 6.00E-10 Folate pathway vitamin levels / / 19744961 rs11800086 chr1 11971749 G A 2.53E-04 Glycosylated haemoglobin levels / / 17255346 rs7554547 chr1 11973888 A G 3.47E-04 Tourette syndrome / / 22889924 rs6682554 chr1 11986621 T C 7.16E-05 Neuroblastoma / / pha002895 rs2273289 chr1 12018290 T C 0.000000129 Major depressive disorder age at onset<15 PLOD1 intron 22915352 rs2273289 chr1 12018290 T C 0.000000448 Major depressive disorder age at onset<20 PLOD1 intron 22915352 rs2273289 chr1 12018290 T C 0.00000134 Major depressive disorder age at onset<35 PLOD1 intron 22915352 rs2273289 chr1 12018290 T C 0.00000392 Major depressive disorder age at onset<25 PLOD1 intron 22915352 rs2273289 chr1 12018290 T C 0.00000436 Major depressive disorder age at onset<30 PLOD1 intron 22915352 rs2273289 chr1 12018290 T C 3.19E-05 Anxiety and major depressive disorder PLOD1 intron 24047446 rs1540923 chr1 12032030 A G 4.09E-04 Myocardial Infarction PLOD1 intron pha002873 rs1474868 chr1 12044164 C T 8.97E-04 Myocardial Infarction MFN2 intron pha002873 rs2336384 chr1 12046063 G T 1.00E-08 Platelet counts MFN2 intron 22139419 rs2878677 chr1 12053264 T C 1.61E-05 Schizophrenia MFN2 intron 19571811 rs2295283 chr1 12082926 A G 0.0002 Migraine MIIP missense 22678113 rs17037598 chr1 12153413 G T 1.13E-04 Response to cytidine analogues (gemcitabine) TNFRSF8 intron 24483146 rs11569837 chr1 12157740 C T 7.64E-04 Smoking quantity TNFRSF8 intron 24665060 rs11121868 chr1 12170974 C T 9.52E-04 Type 2 diabetes TNFRSF8 intron 17463246 rs2230624 chr1 12175658 G A,T 0.00026 Breast cancer TNFRSF8 missense 23555315 rs646249 chr1 12180124 G A 2.60E-05 Urinary metabolites TNFRSF8 intron 21572414 rs2230625 chr1 12186058 A G 3.47E-04 Taste perception TNFRSF8 missense 22132133 rs535068 chr1 12189561 G A 5.32E-06 Carotenoid and tocopherol levels TNFRSF8 intron 19185284 rs1148472 chr1 12194451 T C 0.0000922 post-traumatic stress disorder TNFRSF8 intron 22869035 rs1148472 chr1 12194451 T C 9.22E-05 Schizophrenia TNFRSF8 intron 22883433 rs686190 chr1 12223839 T C 8.58E-04 Multiple complex diseases / / 17554300 rs1061622 chr1 12252955 T G 1 Drug response to Infliximab TNFRSF1B missense 18565259 rs1061622 chr1 12252955 T G 0.0003 Stroke TNFRSF1B missense 23422753 rs5746059 chr1 12262792 A G 4.42E-04 Response to TNF antagonist treatment TNFRSF1B intron 21061259 rs235219 chr1 12264355 A G 1.26E-05 Type 1 diabetes TNFRSF1B intron 21980299 rs5746068 chr1 12267555 C G 0.00000154 HDL cholesterol TNFRSF1B UTR-3 23063622 rs1061628 chr1 12267999 C T 1.30E-05 Urinary metabolites TNFRSF1B UTR-3 21572414 rs235216 chr1 12269624 C T 1.25E-11 HDL cholesterol TNFRSF1B nearGene-3 23063622 rs235216 chr1 12269624 C T 4.12E-10 Cholesterol,total TNFRSF1B nearGene-3 23063622 rs374450 chr1 12305286 G A 9.50E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VPS13D intron 20877124 rs374450 chr1 12305286 G A 8.75E-05 Myopia (pathological) VPS13D intron 21095009 rs235243 chr1 12319994 G T 9.55E-05 Major depressive disorder VPS13D intron 21621269 rs148728975 chr1 12419883 G A 7.00E-07 Asthma VPS13D intron 24406073 rs11121906 chr1 12488475 C A 7.95E-05 Acute lymphoblastic leukemia (childhood) VPS13D intron 19684603 rs6683371 chr1 12492582 A G 8.69E-05 Acute lymphoblastic leukemia (childhood) VPS13D intron 19684603 rs12406819 chr1 12577209 G A 5.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12406819 chr1 12577209 G A 6.34E-05 Myopia (pathological) / / 21095009 rs760943 chr1 12598434 T C 6.20E-05 Alcoholism (heaviness of drinking) / / 21529783 rs6659122 chr1 12615069 G T 8.43E-05 Smoking initiation / / 24665060 rs3128451 chr1 12641488 G T 2.80E-04 Amyotrophic Lateral Sclerosis DHRS3 intron 17827064 rs12045736 chr1 12654035 C T 9.86E-05 Glycosylated haemoglobin levels DHRS3 intron 17255346 rs13376289 chr1 12661179 G T 2.04E-04 Celiac disease DHRS3 intron 23936387 rs6689733 chr1 12680180 G A 3.40E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs3000896 chr1 12682574 T C 6.42E-05 Monocyte chemoattractant protein-1 / / pha003071 rs3010931 chr1 12684324 C T 3.90E-04 Alcohol dependence / / 20201924 rs12070206 chr1 12689692 G A 4.52E-05 Cognitive test performance / / 20125193 rs4845911 chr1 12693125 G A 1.33E-05 Non-obstructive azoospermia / / 22541561 rs2489258 chr1 12700815 T C 7.45E-04 Obesity (extreme) / / 21935397 rs7512542 chr1 12702393 C T 6.38E-06 Multiple complex diseases / / 17554300 rs7512542 chr1 12702393 C T 1.36E-28 Narcolepsy / / 19629137 rs17458785 chr1 12709554 G A 1.29E-05 Waist-Hip Ratio AADACL4 intron pha003013 rs17458785 chr1 12709554 G A 2.09E-05 Waist-Hip Ratio AADACL4 intron pha003028 rs11121955 chr1 12723184 G A 9.09E-05 Blood Pressure AADACL4 intron pha003047 rs2489260 chr1 12741240 G A 8.00E-06 Obesity-related traits / / 23251661 rs3010948 chr1 12754569 C T 5.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17038464 chr1 12786444 G A 8.56E-05 Response to mTOR inhibitor (rapamycin) AADACL3 UTR-3 24009623 rs3010903 chr1 12796044 G T 4.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17038489 chr1 12805936 T C 4.26E-04 Multiple complex diseases / / 17554300 rs1812242 chr1 12835868 T C 8.68E-05 Glycosylated haemoglobin levels PRAMEF12 missense 17255346 rs111797423 chr1 12836235 C T 2.20E-11 Metabolite levels PRAMEF12 cds-synon 22286219 rs1856638 chr1 12910136 A G 6.59E-06 Multiple complex diseases / / 17554300 rs41468748 chr1 12911096 G T 4.22E-06 Multiple complex diseases / / 17554300 rs11580598 chr1 13783354 C T 2.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2940310 chr1 13805706 C T 0.000690619 Hypertension (early onset hypertension) LRRC38 intron 22479346 rs3845607 chr1 13806039 T C 2.25E-04 Alzheimer's disease (late onset) LRRC38 intron 21379329 rs2990683 chr1 13841055 T C 9.87E-04 Alzheimer's disease / / 17998437 rs3856278 chr1 13859570 A G 5.06E-04 Multiple complex diseases / / 17554300 rs11805703 chr1 13861990 G C 5.87E-04 Multiple complex diseases / / 17554300 rs11805703 chr1 13861990 G C 8.61E-04 Response to TNF antagonist treatment / / 21061259 rs10927872 chr1 13885203 C T 5.07E-04 Obesity (extreme) / / 21935397 rs12735797 chr1 13905218 G A 1.36E-04 White matter integrity / / 22425255 rs2885135 chr1 13906527 G C 9.00E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2361030 chr1 13906554 C T 7.98E-04 Coronary Artery Disease / / 17634449 rs2361030 chr1 13906554 C T 9.37E-05 White matter integrity / / 22425255 rs2361030 chr1 13906554 C T 7.72E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10927903 chr1 13912887 G A 3.11E-05 Response to cytadine analogues (cytosine arabinoside) PDPN intron 24483146 rs10927905 chr1 13916997 T C 2.53E-04 Celiac disease PDPN intron 23936387 rs16852000 chr1 13920167 T G 5.12E-04 Multiple complex diseases PDPN intron 17554300 rs11587701 chr1 13946497 A G 8.61E-04 Bipolar disorder,schizoaffective / / 19567891 rs11587701 chr1 13946497 A G 1.50E-05 Urinary metabolites / / 21572414 rs11587701 chr1 13946497 A G 0.0000267 Coronary artery calcification / / 23394302 rs10927910 chr1 13948765 G A 9.37E-04 Multiple complex diseases / / 17554300 rs17390405 chr1 13949087 G A 6.99E-04 Depression (quantitative trait) / / 20800221 rs12143609 chr1 13957405 C T 5.83E-04 Type 2 diabetes / / 17463246 rs16852640 chr1 13971360 G A 9.91E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2495057 chr1 14035513 T C 8.15E-04 Suicide attempts in bipolar disorder PRDM2 intron 21423239 rs2495053 chr1 14040030 T C 3.80E-04 Type 2 diabetes PRDM2 intron 17463246 rs2495053 chr1 14040030 T C 2.60E-05 Anger PRDM2 intron 24489884 rs6429794 chr1 14045394 T G 1.41E-04 Multiple complex diseases PRDM2 intron 17554300 rs1203631 chr1 14067208 A G 3.20E-04 Multiple complex diseases PRDM2 intron 17554300 rs2359756 chr1 14096420 A G 4.17E-04 Response to alcohol consumption (flushing response) PRDM2 intron 24277619 rs1203651 chr1 14109114 A G 9.46E-04 Multiple complex diseases PRDM2 cds-synon 17554300 rs1980471 chr1 14118119 C G 9.94E-04 Multiple complex diseases PRDM2 intron 17554300 rs1203639 chr1 14120432 C T 8.44E-04 Multiple complex diseases PRDM2 intron 17554300 rs1203638 chr1 14121892 G T 1.29E-04 Parkinson's disease PRDM2 intron 17052657 rs2744692 chr1 14125227 T C 5.11E-05 Vaspin levels PRDM2 intron 22907691 rs2697992 chr1 14125496 G C 4.97E-05 Vaspin levels PRDM2 intron 22907691 rs2245218 chr1 14139826 C T 4.61E-05 Parkinson's disease PRDM2 intron 16252231 rs1203690 chr1 14162023 T G 6.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2744671 chr1 14195122 T C 6.64E-05 Suicide attempts in bipolar disorder / / 21423239 rs16853069 chr1 14196212 T C 4.89E-04 Insulin resistance / / 21901158 rs17350970 chr1 14216150 C T 6.50E-06 Urinary metabolites / / 21572414 rs2697979 chr1 14221528 G A 4.61E-05 Atopic dermatitis / / 23042114 rs6429800 chr1 14228077 G A 1.40E-06 Urinary metabolites / / 21572414 rs7536590 chr1 14232891 C T 7.17E-04 Insulin resistance / / 21901158 rs7543809 chr1 14232929 T C 4.40E-04 Insulin resistance / / 21901158 rs12745720 chr1 14240110 C T 1.10E-05 HIV-1 viral setpoint / / 17641165 rs12122426 chr1 14240350 A C 9.28E-05 Elbow pain / / pha003008 rs10489150 chr1 14253566 A G 4.00E-05 Body Mass Index / / pha003019 rs6661262 chr1 14254750 G A 1.30E-04 Schizophrenia / / 19197363 rs7538374 chr1 14255978 T G 1.72E-04 Multiple complex diseases / / 17554300 rs16853208 chr1 14257199 T C 3.11E-04 Multiple complex diseases / / 17554300 rs2206585 chr1 14261909 G T 7.12E-05 Body Mass Index / / pha003019 rs4662054 chr1 14268523 A G 2.87E-05 Body Mass Index / / pha003019 rs4662054 chr1 14268523 A G 6.73E-05 Body Mass Index / / pha003022 rs4661455 chr1 14277864 T C 4.54E-04 Type 2 diabetes / / 17463246 rs2359896 chr1 14280562 G A 8.82E-06 Body Mass Index / / pha003019 rs2359896 chr1 14280562 G A 2.44E-05 Body Mass Index / / pha003022 rs12024045 chr1 14297220 A G 9.77E-04 Multiple complex diseases / / 17554300 rs10489148 chr1 14313480 G T 2.00E-05 Multiple complex diseases / / 17554300 rs6691183 chr1 14320651 C A 1.44E-04 Multiple complex diseases / / 17554300 rs12129723 chr1 14331940 G A 8.66E-04 Alzheimer's disease / / 22005930 rs6429822 chr1 14342347 G A 2.89E-05 Rheumatoid arthritis / / 17804836 rs4661465 chr1 14345544 G A 9.62E-05 Hypertension / / 19609347 rs3929673 chr1 14353071 T G 3.94E-04 Alzheimer's disease / / 22005930 rs4662075 chr1 14353195 C G 9.77E-04 Alzheimer's disease / / 22005930 rs4662076 chr1 14357851 T G 5.90E-06 Alzheimer's disease (late onset) / / 21460841 rs7527934 chr1 14358424 G T 5.87E-06 Alzheimer's disease (late onset) / / 21460841 rs10754905 chr1 14361699 C T 6.89E-06 Alzheimer's disease (late onset) / / 21460841 rs7551069 chr1 14361749 A G 6.65E-06 Alzheimer's disease (late onset) / / 21460841 rs2359909 chr1 14364585 G T 7.53E-06 Alzheimer's disease (late onset) / / 21460841 rs2359910 chr1 14364963 A G 9.67E-06 Alzheimer's disease (late onset) / / 21460841 rs10733140 chr1 14365171 C A 7.70E-06 Alzheimer's disease (late onset) / / 21460841 rs7514368 chr1 14368784 T C 8.25E-06 Alzheimer's disease (late onset) / / 21460841 rs6662320 chr1 14370368 A G 7.80E-05 Major depressive disorder / / 21042317 rs6671878 chr1 14372093 T A 9.67E-06 Alzheimer's disease (late onset) / / 21460841 rs10737917 chr1 14372776 T A 9.71E-06 Alzheimer's disease (late onset) / / 21460841 rs10737918 chr1 14385135 A G 8.10E-05 Major depressive disorder / / 21042317 rs16853528 chr1 14388300 T C 2.23E-04 Multiple complex diseases / / 17554300 rs10733143 chr1 14390137 A G 7.60E-05 Major depressive disorder / / 21042317 rs7515917 chr1 14439042 T C 6.83E-04 Type 2 diabetes / / 17463246 rs10429936 chr1 14450545 T C 9.58E-04 Type 2 diabetes / / 17463246 rs16853613 chr1 14455748 A G 4.38E-04 Multiple complex diseases / / 17554300 rs929125 chr1 14477944 G A 8.92E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs568434 chr1 14523180 C A 3.85E-04 Aortic root size / / 21223598 rs4478803 chr1 14559081 C T 3.97E-04 Insulin resistance / / 21901158 rs4478803 chr1 14559081 C T 7.70E-04 Intelligence (childhood) / / 23358156 rs10928056 chr1 14585648 G A 8.20E-04 Alcohol dependence / / 20201924 rs12406699 chr1 14598055 C T 2.58E-04 IgE levels / / 17255346 rs1416623 chr1 14649876 T C 0.000566716 Hypertension (early onset hypertension) / / 22479346 rs12121975 chr1 14673385 G T 7.25E-04 Substance dependence / / 21818250 rs12134023 chr1 14677729 C A 3.75E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4113453 chr1 14680899 G A 9.33E-05 Major depressive disorder / / 21621269 rs820671 chr1 14692271 A G 1.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs10803270 chr1 14700804 A G 4.89E-06 Alzheimer's disease (late onset) / / 21460841 rs10927416 chr1 14708719 A C 2.59E-04 Multiple complex diseases / / 17554300 rs12085004 chr1 14773232 G A 1.16E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4450012 chr1 14775550 C T 9.80E-06 Urinary metabolites / / 21572414 rs16850285 chr1 14787410 C T 5.87E-04 Obesity (extreme) / / 21935397 rs2480054 chr1 14792535 A G 4.00E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs16850320 chr1 14795469 G C 3.36E-04 Type 2 diabetes / / 17463246 rs16850332 chr1 14796547 T A 4.44E-05 Type 2 diabetes / / 17463246 rs16850384 chr1 14822916 T C 5.88E-05 Multiple complex diseases / / 17554300 rs11807837 chr1 14841189 A C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12733185 chr1 14842486 G A 5.37E-05 Fibrinogen / / pha003068 rs2105239 chr1 14857643 A G 3.00E-04 Chronic fatigue syndrome / / 21912186 rs4661292 chr1 14915147 G A 7.72E-04 Multiple complex diseases / / 17554300 rs10803289 chr1 14934220 G A 8.92E-04 Multiple complex diseases KAZN intron 17554300 rs11579756 chr1 14947920 T C 0.000117 Schizophrenia KAZN intron 23637625 rs4661295 chr1 14999190 C T 2.41E-04 Multiple complex diseases KAZN intron 17554300 rs6429673 chr1 15025974 A G 1.51E-05 Response to tocilizumab in rheumatoid arthritis KAZN intron 22491018 rs4661300 chr1 15038771 T G 5.58E-04 Multiple complex diseases KAZN intron 17554300 rs4661515 chr1 15038791 A T 7.03E-04 Multiple complex diseases KAZN intron 17554300 rs12136961 chr1 15039673 G A 8.30E-04 Multiple complex diseases KAZN intron 17554300 rs6698433 chr1 15065915 G C 8.86E-04 Alzheimer's disease KAZN intron 22005930 rs6690550 chr1 15066365 T C 8.93E-04 Alzheimer's disease KAZN intron 22005930 rs10803311 chr1 15066944 T C 9.91E-04 Alzheimer's disease KAZN intron 22005930 rs4661302 chr1 15092813 G A 1.30E-05 Urinary metabolites KAZN intron 21572414 rs4661303 chr1 15101472 C T 5.33E-04 Multiple complex diseases KAZN intron 17554300 rs804125 chr1 15111927 G T 7.91E-05 Coronary heart disease KAZN intron pha003055 rs1721831 chr1 15115510 T C 3.11E-05 Birth weight KAZN intron 17255346 rs1630519 chr1 15116208 G T 6.49E-05 Coronary heart disease KAZN intron pha003055 rs1721829 chr1 15117060 A G 2.26E-05 Coronary heart disease KAZN intron pha003055 rs10489353 chr1 15140362 G A 9.54E-06 Serum metabolites KAZN intron 19043545 rs17368807 chr1 15153369 G A 1.80E-05 Urinary metabolites KAZN intron 21572414 rs3845593 chr1 15162350 A G 8.77E-05 Non-alcoholic fatty liver disease histology (other) KAZN intron 20708005 rs7416912 chr1 15194562 G T 3.78E-04 Response to cytadine analogues (cytosine arabinoside) KAZN intron 24483146 rs2803396 chr1 15197909 T C 4.80E-06 Glioma (high-grade) KAZN intron 19578366 rs12029721 chr1 15216489 A G 7.91E-06 Retinopathy in non-diabetics KAZN intron 23393555 rs12410007 chr1 15264270 A G 0.00000003 Brain microstructure and intellectual performance KAZN intron 22723713 rs10927602 chr1 15295333 A G 5.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KAZN intron 20877124 rs7544674 chr1 15297249 T A 1.61E-04 Multiple complex diseases KAZN intron 17554300 rs4661553 chr1 15304859 C T 2.23E-04 Multiple complex diseases KAZN intron 17554300 rs7529561 chr1 15328151 A C 3.53E-04 Alcohol consumption (maxi-drinks) KAZN intron 24277619 rs7539545 chr1 15331603 A T 8.30E-06 Urinary metabolites KAZN intron 21572414 rs6681053 chr1 15334782 T C 6.26E-05 Fibrinogen KAZN intron pha003068 rs11578349 chr1 15338903 G T 9.20E-04 Response to cytadine analogues (cytosine arabinoside) KAZN intron 24483146 rs6429702 chr1 15339902 T G 7.39E-04 Response to statin treatment (atorvastatin),change in cholesterol levels KAZN intron 20031582 rs6429703 chr1 15339960 T C 8.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) KAZN intron 23648065 rs10927631 chr1 15346330 T C 4.70E-06 Urinary metabolites KAZN intron 21572414 rs6657768 chr1 15346891 T A 3.00E-07 Urinary metabolites KAZN intron 21572414 rs6667220 chr1 15347640 G A 8.00E-06 Chronic obstructive pulmonary disease-related biomarkers KAZN intron 23144326 rs4520412 chr1 15359967 C T 4.01E-04 Multiple complex diseases KAZN intron 17554300 rs6674129 chr1 15363223 A C 1.83E-05 Blood Pressure KAZN intron pha003046 rs12138732 chr1 15377554 G A 8.70E-06 Urinary metabolites KAZN intron 21572414 rs1513548 chr1 15379185 T C 8.66E-05 Aortic root size KAZN intron 21223598 rs476859 chr1 15428508 C T 8.25E-05 Aortic root size KAZN intron 21223598 rs496567 chr1 15435257 A G 3.84E-04 Type 2 diabetes KAZN intron 17463246 rs6659639 chr1 15440156 G A 5.17E-05 Crohn's disease KAZN intron 17684544 rs761301 chr1 15471992 T G 9.70E-05 Psoriasis C1orf126 intron 19169255 rs10927689 chr1 15484465 A G 1.33E-04 Type 2 diabetes TMEM51 intron 17463246 rs16851354 chr1 15495620 T C 4.84E-05 Tuberculosis TMEM51 intron 24057671 rs7539166 chr1 15495905 T G 4.57E-98 Multiple complex diseases TMEM51 intron 17554300 rs16851358 chr1 15500332 C T 1.43E-04 Type 2 diabetes TMEM51 intron 17463246 rs16851358 chr1 15500332 C T 2.50E-05 Urinary metabolites TMEM51 intron 21572414 rs10754886 chr1 15502481 C T 2.30E-05 Urinary metabolites TMEM51 intron 21572414 rs10754887 chr1 15502539 A G 2.30E-05 Urinary metabolites TMEM51 intron 21572414 rs4661326 chr1 15527323 C T 4.65E-05 Bipolar disorder and schizophrenia TMEM51 intron 20889312 rs3820064 chr1 15542073 G A 4.05E-04 Multiple complex diseases TMEM51 intron 17554300 rs10927733 chr1 15543268 C G 3.90E-04 Smoking initiation TMEM51 intron 24665060 rs549 chr1 15546825 A G 1.60E-04 Osteoarthritis TMEM51 UTR-3 19508968 rs12124285 chr1 15548397 G A 9.72E-04 Multiple complex diseases / / 17554300 rs10737909 chr1 15548636 G T 2.00E-07 Migraine / / 23793025 rs10737909 chr1 15548636 G T 8.91E-05 Migraine without aura / / 23793025 rs11585832 chr1 15569822 G A 3.13E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1752020 chr1 15572133 A G 1.00E-05 Urinary metabolites / / 21572414 rs12144738 chr1 15591641 T C 7.25E-04 Tourette syndrome FHAD1 intron 22889924 rs12725686 chr1 15608418 C T 2.00E-11 Brain microstructure and intellectual performance FHAD1 intron 22723713 rs10803378 chr1 15626718 G A 6.91E-05 Socioeconomic Factors FHAD1 intron pha003066 rs10127456 chr1 15653872 G A 3.18E-05 Serum metabolites FHAD1 intron 19043545 rs7532826 chr1 15677932 A G 5.23E-05 Gallstones FHAD1 intron 17632509 rs16851617 chr1 15699117 G A 3.78E-04 Insulin resistance FHAD1 intron 21901158 rs2249097 chr1 15699327 G C 5.25E-06 Multiple complex diseases FHAD1 intron 17554300 rs2496330 chr1 15718470 T G 6.66E-05 Multiple complex diseases FHAD1 intron 17554300 rs1883426 chr1 15726116 A T 6.20E-05 Primary sclerosing cholangitis / / 19944697 rs742361 chr1 15726566 G A 6.11E-05 Cardiovascular disease / / pha003065 rs742362 chr1 15726791 A G 2.34E-04 Multiple complex diseases / / 17554300 rs2473344 chr1 15728289 T C 4.10E-05 Primary sclerosing cholangitis / / 19944697 rs2092324 chr1 15733394 G A 9.19E-05 Serum metabolites / / 19043545 rs2092324 chr1 15733394 G A 7.56E-05 Insulin resistance / / 21901158 rs2496321 chr1 15743884 A C 2.75E-04 Alcohol dependence EFHD2 intron 20201924 rs2496320 chr1 15744271 T C 5.26E-04 Alcohol dependence EFHD2 intron 20201924 rs11579489 chr1 15790639 G A 3.00E-06 Stroke (ischemic) CELA2A intron 22384361 rs2901964 chr1 15792426 C G 5.00E-06 Erectile dysfunction and prostate cancer treatment CELA2A intron 20932654 rs6675825 chr1 15811346 C T 7.95E-05 Serum metabolites CELA2B intron 19043545 rs4233533 chr1 15829187 G A 0.0000734 Cholesterol,total CASP9 intron 23063622 rs4646043 chr1 15832110 T G 1.10E-04 Coronary heart disease CASP9 intron 21966275 rs2308939 chr1 15833450 G A,C,T 3.36E-11 Cholesterol,total CASP9 missense 23063622 rs2308939 chr1 15833450 G A,C,T 4.29E-09 HDL cholesterol CASP9 missense 23063622 rs2308941 chr1 15844718 G A 2.14E-04 Acute lung injury CASP9 missense 22295056 rs12124078 chr1 15869899 A G 9.49E-22 Chronic kidney disease D/JC16 intron 22479191 rs78309148 chr1 15871023 G A 0.00067 Prostate cancer D/JC16 missense 23555315 rs59905655 chr1 16071010 C T 2.00E-06 Obesity-related traits TMEM82 missense 23251661 rs12725198 chr1 16080171 G A 3.00E-06 Cardiac Troponin-T levels / / 23247143 rs938295 chr1 16087260 C T 6.30E-04 Endometriosis FBLIM1 intron 23104006 rs10737910 chr1 16109669 C T 2.99E-04 Type 2 diabetes FBLIM1 intron 17463246 rs4661661 chr1 16161836 T C 3.20E-04 Smoking cessation / / 24665060 rs4661663 chr1 16161958 G T 1.23E-04 Smoking cessation / / 24665060 rs10737911 chr1 16167855 T C 1.90E-05 Type 2 diabetes FLJ37453 intron 17463246 rs6668183 chr1 16173814 G C 2.06E-04 Heart rate FLJ37453 intron 23583979 rs7552077 chr1 16196759 A G 3.30E-05 Type 2 diabetes SPEN intron 17463246 rs4661670 chr1 16212219 G T 4.63E-04 Smoking cessation SPEN intron 24665060 rs10927873 chr1 16251900 C T 4.90E-04 Heart Failure SPEN intron pha002885 rs848210 chr1 16259813 A G 4.41E-05 Type 2 diabetes SPEN missense 17463246 rs926619 chr1 16279386 C G 3.40E-04 Smoking cessation ZBTB17 intron 24665060 rs4661346 chr1 16282776 G C 8.81E-05 Serum metabolites ZBTB17 intron 19043545 rs10927875 chr1 16299312 C T 1.00E-09 Dilated cardiomyopathy ZBTB17 intron 21459883 rs4661681 chr1 16321523 T C 2.34E-04 Smoking cessation / / 24665060 rs1739843 chr1 16343254 T C 5.28E-13 Dilated cardiomyopathy HSPB7 intron 20975947 rs1056207 chr1 16344827 G A 6.97E-05 Smoking cessation HSPB7 UTR-5 24665060 rs1889785 chr1 16348729 G A 4.45E-06 Heart rate CLCNKA intron 23583979 rs1972359 chr1 16356187 C T 4.12E-04 Smoking cessation CLCNKA intron 24665060 rs1805152 chr1 16356501 G A 5.96E-05 Cholesterol CLCNKA missense pha003078 rs883867 chr1 16358085 C A 1.11E-04 Smoking cessation CLCNKA intron 24665060 rs9442193 chr1 16367339 G A 1.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs9442235 chr1 16393357 T G 6.00E-06 Cognitive performance FAM131C intron 19734545 rs17416878 chr1 16446980 A G 3.70E-07 Kawasaki disease / / 22446962 rs17416878 chr1 16446980 A G 0.000486 Salmonella-induced pyroptosis / / 22837397 rs1497406 chr1 16505320 A G 3.00E-19 Liver enzyme levels (gamma-glutamyl transferase) / / 22001757 rs1497406 chr1 16505320 A G 4.00E-08 Gamma gluatamyl transferase levels / / 22010049 rs6677710 chr1 16507618 T C 1.30E-04 Multiple complex diseases / / 17554300 rs4537547 chr1 16510798 A G 1.12E-04 Multiple complex diseases / / 17554300 rs12740413 chr1 16515879 C T 0.000013 Aging / / 22445811 rs6697459 chr1 16518866 T G 1.23E-04 Multiple complex diseases / / 17554300 rs221032 chr1 16525549 C T 5.73E-05 Multiple complex diseases ARHGEF19 intron 17554300 rs221035 chr1 16526529 G A 3.20E-12 Lymphocyte counts ARHGEF19 intron 22286170 rs221049 chr1 16530850 T G 4.75E-05 Multiple complex diseases ARHGEF19 intron 17554300 rs10489599 chr1 16585818 A G 6.00E-04 Chronic fatigue syndrome FBXO42 intron 21912186 rs6603859 chr1 16706075 G T 1 Drug response to Daunorubicin C1orf144 intron 18451141 rs12138174 chr1 16715466 T C 9.36E-04 Acute lung injury C1orf144 intron 22295056 rs11543230 chr1 16785564 C T 4.96E-04 Multiple complex diseases NECAP2 UTR-3 17554300 rs156851 chr1 16814994 C T 2.80E-04 Height CROCCP3 intron 17255346 rs156869 chr1 16830508 G A 3.19E-04 Height / / 17255346 rs4316363 chr1 16924151 T C 5.73E-04 Multiple complex diseases / / 17554300 rs3851919 chr1 16924335 A G 9.69E-05 Multiple complex diseases / / 17554300 rs1977269 chr1 17004850 C A,G,T 4.06E-05 Platelet counts / / pha003100 rs12563353 chr1 17037560 A G 3.00E-05 Psoriasis ESPNP intron 20953190 rs3915536 chr1 17045646 C T 1.05E-04 Type 2 diabetes ESPNP intron 17463246 rs6586513 chr1 17216331 C A 4.00E-06 Allergic rhinitis / / 22036096 rs9435730 chr1 17305903 G A 3.97E-04 Response to taxane treatment (placlitaxel) MFAP2 intron 23006423 rs2284746 chr1 17306675 C G 4.00E-29 Height MFAP2 intron 20881960 rs2284746 chr1 17306675 C G 1.10E-19 Height MFAP2 intron 21194676 rs2284746 chr1 17306675 C G 1.90E-08 Height MFAP2 intron 21194676 rs2284746 chr1 17306675 C G 4.10E-13 Height MFAP2 intron 21194676 rs2284746 chr1 17306675 C G 8.00E-16 Pulmonary function MFAP2 intron 21946350 rs2284746 chr1 17306675 C G 6.40E-04 Coronary heart disease MFAP2 intron 21966275 rs2284746 chr1 17306675 C G 2.00E-11 Pulmonary function (interaction) MFAP2 intron 23284291 rs2284746 chr1 17306675 C G 5.00E-15 Height MFAP2 intron 23563607 rs3754511 chr1 17310019 G A 1.72E-04 Response to taxane treatment (placlitaxel) MFAP2 nearGene-5 23006423 rs9435736 chr1 17323449 T C 7.78E-04 Response to taxane treatment (placlitaxel) ATP13A2 intron 23006423 rs6684770 chr1 17325955 G A 2.54E-04 Multiple complex diseases ATP13A2 intron 17554300 rs3738814 chr1 17331676 A G 2.00E-07 Height ATP13A2 intron 20189936 rs2647168 chr1 17340878 C T 1.96E-04 Lymphocyte counts / / 22286170 rs34916635 chr1 17371298 C T 1.20E-04 Atrial fibrillation SDHB missense 21846873 rs2746533 chr1 17394046 A G 8.23E-05 Menopause (age at onset) PADI2 UTR-3 22267201 rs2235927 chr1 17394775 G A 1.21E-06 Asthma PADI2 UTR-3 23181788 rs3818042 chr1 17398849 G A 5.31E-04 Pulmonary function PADI2 intron 20010834 rs730387 chr1 17410557 G A 9.52E-06 Rheumatoid arthritis PADI2 intron 19503088 rs2977272 chr1 17536952 C T 7.66E-04 Obesity (extreme) PADI1 intron 21935397 rs2977235 chr1 17557178 C T 1.90E-05 Urinary metabolites PADI1 intron 21572414 rs4268393 chr1 17559196 T C 4.60E-06 Urinary metabolites PADI1 intron 21572414 rs3003412 chr1 17564847 C T 3.85E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) PADI1 intron 24192120 rs2977310 chr1 17564990 T C 5.28E-05 Age-related macular degeneration PADI1 intron pha002890 rs2977225 chr1 17573439 T C 2.13E-04 Vaspin levels / / 22907691 rs2977225 chr1 17573439 T C 0.000213 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs3003419 chr1 17573988 G A 3.59E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs12562867 chr1 17576638 A C 1.00E-04 Prostate cancer PADI3 intron 21743057 rs4363467 chr1 17586653 C T 9.70E-04 Type 2 diabetes and 6 quantitative traits PADI3 intron 17848626 rs3003426 chr1 17588162 G A 1.39E-05 Serum metabolites PADI3 intron 19043545 rs3003429 chr1 17591679 T C 4.00E-07 Pulmonary function (interaction) PADI3 intron 23284291 rs2977293 chr1 17599444 C T 8.79E-05 Cognitive test performance PADI3 intron 20125193 rs2977293 chr1 17599444 C T 5.77E-05 Heart Rate PADI3 intron pha003053 rs2977293 chr1 17599444 C T 1.14E-06 Heart Rate PADI3 intron pha003054 rs11585118 chr1 17605774 C A 2.24E-08 Common traits (Other) PADI3 intron 20585627 rs12568771 chr1 17613809 A G 1.94E-04 Age-related macular degeneration / / 22125219 rs7548900 chr1 17622654 C A 3.83E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1886302 chr1 17635396 A G 1.63E-04 Age-related macular degeneration PADI4 intron 22125219 rs10788664 chr1 17647475 C T 0.00076 fMRI brain tests in schizophrenia PADI4 intron 22440650 rs10888024 chr1 17649796 A G 0.000224 fMRI brain tests in schizophrenia PADI4 intron 22440650 rs1748041 chr1 17655407 C T 0.000268 Schizophrenia PADI4 intron 22440650 rs11203366 chr1 17657534 G A 1.57E-07 Rheumatoid arthritis PADI4 missense 21452313 rs11203366 chr1 17657534 G A 0.000436 fMRI brain tests in schizophrenia PADI4 missense 22440650 rs11203367 chr1 17657616 T C 0.000285 fMRI brain tests in schizophrenia PADI4 missense 22440650 rs1635597 chr1 17659556 A G 9.19E-04 Multiple complex diseases PADI4 intron 17554300 rs874881 chr1 17660499 G C 8.18E-04 Response to taxane treatment (placlitaxel) PADI4 missense 23006423 rs1635594 chr1 17661805 A G 7.30E-05 Rheumatoid arthritis PADI4 intron 24782177 rs1748035 chr1 17661996 T C 7.05E-04 Multiple complex diseases PADI4 intron 17554300 rs1748035 chr1 17661996 T C 0.000313 fMRI brain tests in schizophrenia PADI4 intron 22440650 rs1748033 chr1 17662662 T C 0.000313 fMRI brain tests in schizophrenia PADI4 cds-synon 22440650 rs1635586 chr1 17664770 A G 5.23E-05 Rheumatoid arthritis PADI4 intron 21452313 rs11203368 chr1 17666508 C T 6.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PADI4 intron 20877124 rs11203368 chr1 17666508 C T 2.61E-08 Rheumatoid arthritis PADI4 intron 21452313 rs2301888 chr1 17672730 G A 1.00E-18 Rheumatoid arthritis PADI4 intron 24390342 rs2301888 chr1 17672730 G A 6.00E-09 Rheumatoid arthritis PADI4 intron 24390342 rs2301888 chr1 17672730 G A 8.00E-13 Rheumatoid arthritis PADI4 intron 24390342 rs2240339 chr1 17674108 C T 1.46E-10 Rheumatoid arthritis (CCP positive) PADI4 intron 23143596 rs2240339 chr1 17674108 C T 2.57E-10 Rheumatoid arthritis PADI4 intron 23143596 rs2240336 chr1 17674402 C T 5.90E-09 Rheumatoid arthritis PADI4 intron 23143596 rs2240336 chr1 17674402 C T 5.91E-09 Rheumatoid arthritis (CCP positive) PADI4 intron 23143596 rs2240335 chr1 17674537 C A 8.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PADI4 cds-synon 20877124 rs2240335 chr1 17674537 C A 2.00E-08 Rheumatoid arthritis PADI4 cds-synon 21452313 rs2240335 chr1 17674537 C A 2.00E-08 Rheumatoid arthritis PADI4 cds-synon 21505073 rs2240335 chr1 17674537 C A 2.30E-05 Rheumatoid arthritis PADI4 cds-synon 21673997 rs7538876 chr1 17722363 G A 4.00E-12 Basal cell carcinoma PADI6 intron 18849993 rs7538876 chr1 17722363 G A 4.00E-12 Nasopharyngeal carcinoma PADI6 intron 20512145 rs7538876 chr1 17722363 G A 7.00E-14 Basal cell carcinoma PADI6 intron 24403052 rs6586542 chr1 17763566 G C 8.56E-05 Lymphocyte counts RCC2 intron 22286170 rs2883272 chr1 17773159 G A 1.41E-05 Intelligence / / 21826061 rs2883272 chr1 17773159 G A 9.42E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6659366 chr1 17800419 A G 2.69E-05 Body mass index / / 17255346 rs2254135 chr1 17834742 C T 3.00E-06 Response to hepatitis C treatment / / 22095909 rs2248129 chr1 17855824 C T 8.09E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs2244300 chr1 17857601 G A 4.73E-05 Aging (time to event) / / 21782286 rs2477735 chr1 17869179 T C 2.70E-04 Alcohol dependence ARHGEF10L intron 20201924 rs10788679 chr1 17916962 A G 5.11E-06 Esophageal cancer (squamous cell) ARHGEF10L intron 22960999 rs6693036 chr1 17919817 T C 3.00E-06 Obesity-related traits ARHGEF10L intron 23251661 rs17469160 chr1 17998920 G C 6.95E-04 Type 2 diabetes ARHGEF10L intron 17463246 rs7522419 chr1 18033499 A G 3.58E-05 Cognitive impairment induced by topiramate / / 22091778 rs7522419 chr1 18033499 A G 6.46E-06 Height / / pha003010 rs7522419 chr1 18033499 A G 9.95E-07 Height / / pha003011 rs2185324 chr1 18040004 C T 2.18E-06 Height / / pha003011 rs1553400 chr1 18042035 A G 4.64E-06 Height / / pha003010 rs1553400 chr1 18042035 A G 6.10E-07 Height / / pha003011 rs260514 chr1 18052645 G A 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer / / 21245432 rs7512028 chr1 18059244 T C 5.76E-04 Multiple complex diseases / / 17554300 rs7534822 chr1 18086999 T G 2.15E-04 Alzheimer's disease (late onset) ACTL8 intron 21379329 rs7547331 chr1 18090929 T C 5.86E-05 Multiple complex diseases ACTL8 intron 17554300 rs10888060 chr1 18099283 G A 3.07E-04 Alzheimer's disease (late onset) ACTL8 intron 21379329 rs11577496 chr1 18105498 G A 2.60E-04 Alzheimer's disease (late onset) ACTL8 intron 21379329 rs16830757 chr1 18124527 C T 0.0000596 Primary sclerosing cholangitis ACTL8 intron 23603763 rs500035 chr1 18132269 G A 4.29E-04 Multiple complex diseases ACTL8 intron 17554300 rs1890788 chr1 18156864 A G 5.50E-06 Urinary metabolites / / 21572414 rs7545559 chr1 18158156 C T 5.50E-06 Urinary metabolites / / 21572414 rs12097284 chr1 18159342 C T 2.46E-05 Intelligence / / 21826061 rs12097284 chr1 18159342 C T 0.0002 Migraine / / 22678113 rs495347 chr1 18163922 C T 6.06E-05 Sarcoidosis / / 19165924 rs807455 chr1 18171347 C T 6.91E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs697760 chr1 18179816 G T 6.54E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs647619 chr1 18183424 G A 3.00E-04 Personality dimensions / / 23903073 rs587276 chr1 18193604 C T 2.10E-06 Urinary metabolites / / 21572414 rs11203223 chr1 18196800 T G 6.90E-07 Urinary metabolites / / 21572414 rs11203224 chr1 18201633 G A 2.30E-06 Urinary metabolites / / 21572414 rs7538231 chr1 18202181 G A 1.30E-06 Urinary metabolites / / 21572414 rs578987 chr1 18203380 C G 3.13E-04 Type 2 diabetes / / 17463246 rs1339934 chr1 18236459 A G 6.78E-06 Obesity-related traits / / 23251661 rs1339934 chr1 18236459 A G 9.18E-04 Alcohol dependence / / 24277619 rs12087706 chr1 18241309 C T 9.12E-04 Alzheimer's disease / / 17998437 rs6686929 chr1 18244707 C T 3.00E-06 Obesity-related traits / / 23251661 rs673567 chr1 18278257 G A 2.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs673567 chr1 18278257 G A 4.89E-05 Osteoarthritis (knee and hip) / / 21177295 rs673567 chr1 18278257 G A 8.00E-04 Osteoarthritis (knee and hip) / / 21177295 rs1192573 chr1 18286068 G A 0.00008906 Sarcoidosis / / 22952805 rs794229 chr1 18289233 G T 1.98E-04 Type 2 diabetes / / 17463246 rs4920402 chr1 18289481 G A 8.20E-04 Multiple complex diseases / / 17554300 rs4920402 chr1 18289481 G A 2.71E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs16861326 chr1 18294487 G A 2.00E-06 Erectile dysfunction and prostate cancer treatment / / 20932654 rs2095842 chr1 18297407 A G 2.56E-04 Multiple complex diseases / / 17554300 rs2095842 chr1 18297407 A G 8.25E-05 Alzheimer's disease / / 17998437 rs2095842 chr1 18297407 A G 8.95E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs871644 chr1 18297688 G A 2.40E-04 Multiple complex diseases / / 17554300 rs871644 chr1 18297688 G A 8.56E-05 Alzheimer's disease / / 17998437 rs871644 chr1 18297688 G A 8.95E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1192633 chr1 18304543 G A 9.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs11588830 chr1 18314621 C T 1.87E-04 Multiple complex diseases / / 17554300 rs11588830 chr1 18314621 C T 5.83E-04 Alzheimer's disease / / 17998437 rs16861410 chr1 18335597 C G 0.0001988 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16861410 chr1 18335597 C G 1.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1192621 chr1 18337250 T A 8.20E-05 Thyroid peroxidase antibody levels / / 24586183 rs1192622 chr1 18337268 A G 6.93E-04 Type 2 diabetes / / 17463246 rs1192625 chr1 18339791 T C 7.52E-06 Carotenoid and tocopherol levels / / 19185284 rs1108624 chr1 18342807 G A 0.0002527 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1108624 chr1 18342807 G A 2.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs794237 chr1 18342964 A G 3.99E-04 Alzheimer's disease / / 24755620 rs16861446 chr1 18348784 C T 0.0002954 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16861446 chr1 18348784 C T 2.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs16861481 chr1 18360161 G A 0.0001653 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16861481 chr1 18360161 G A 1.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs16861517 chr1 18374542 G A 0.0004773 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16861517 chr1 18374542 G A 4.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9659407 chr1 18387310 G A 8.58E-04 Heart Failure / / pha002884 rs9286088 chr1 18391974 A C 1.30E-05 stroke (ischemic) / / 17434096 rs4920421 chr1 18392608 C T 5.50E-05 Endometriosis / / 21151130 rs4920422 chr1 18392752 C A 2.52E-04 Alcohol dependence / / 21314694 rs4920425 chr1 18408139 C T 8.06E-06 Heart Failure / / pha002884 rs9804128 chr1 18425011 A G 2.00E-09 Venous thromboembolism (gene x gene interaction) / / 23509962 rs12739708 chr1 18426428 C T 3.27E-04 Myopia (pathological) / / 21095009 rs12724674 chr1 18431501 G A 5.96E-13 Multiple complex diseases / / 17554300 rs1342569 chr1 18438351 T C 4.17E-04 Myopia (pathological) IGSF21 intron 21095009 rs10443386 chr1 18444514 C A 4.10E-05 White matter hyperintensity burden IGSF21 intron 21681796 rs16861578 chr1 18447490 C A 2.99E-04 Response to taxane treatment (placlitaxel) IGSF21 intron 23006423 rs12735521 chr1 18450321 C T 4.70E-05 White matter hyperintensity burden IGSF21 intron 21681796 rs987293 chr1 18451900 A G 2.20E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) IGSF21 intron 24023788 rs9726285 chr1 18484945 G C 2.50E-05 Urinary metabolites IGSF21 intron 21572414 rs17435018 chr1 18487906 C T 2.01E-05 Response to citalopram treatment IGSF21 intron 19846067 rs4920300 chr1 18490061 C T 1.34E-04 Vaspin levels IGSF21 intron 22907691 rs4920300 chr1 18490061 C T 0.0001343 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit IGSF21 intron 22907730 rs9728569 chr1 18510033 T G 9.75E-05 Cholesterol IGSF21 intron pha003083 rs1033190 chr1 18528848 G T 6.15E-04 Alcohol dependence IGSF21 intron 20201924 rs4920311 chr1 18563991 G C 6.60E-04 Atrial fibrillation IGSF21 intron 21846873 rs371505 chr1 18586420 C A 8.88E-04 Alzheimer's disease IGSF21 intron 17998437 rs516656 chr1 18589743 C G 5.37E-04 Alzheimer's disease IGSF21 intron 17998437 rs1555219 chr1 18630150 T C 8.84E-04 Coronary Artery Disease IGSF21 intron 17634449 rs11260978 chr1 18632801 A G 3.91E-04 Atopy IGSF21 intron 21625490 rs761585 chr1 18633940 G A 7.70E-04 Coronary Artery Disease IGSF21 intron 17634449 rs4920475 chr1 18643335 C T 9.09E-04 Multiple complex diseases IGSF21 intron 17554300 rs4920478 chr1 18655339 G A 5.00E-06 Urinary metabolites IGSF21 intron 21572414 rs33947700 chr1 18665124 C T 9.55E-04 Multiple complex diseases IGSF21 intron 17554300 rs542634 chr1 18672774 G A 4.08E-05 Height IGSF21 intron pha003011 rs16861827 chr1 18678170 C T 2.00E-04 Pancreatic cancer IGSF21 intron 23180869 rs16861827 chr1 18678170 C T 5.91E-05 Tuberculosis IGSF21 intron 24057671 rs12125819 chr1 18696135 G A 3.94E-04 Suicide attempts in bipolar disorder IGSF21 intron 21423239 rs12566510 chr1 18705694 A G 9.18E-04 Multiple complex diseases / / 17554300 rs10492995 chr1 18707373 A C 2.71E-04 Fibrinogen / / 17255346 rs10492995 chr1 18707373 A C 4.67E-04 HIV-1 viral setpoint / / 17641165 rs7538442 chr1 18716278 A G 7.04E-05 Orofacial clefts / / 20023658 rs1336131 chr1 18722737 G T 5.74E-05 Diabetes (gestational) / / 22233651 rs1336122 chr1 18761124 A G 8.66E-05 Bipolar disorder and schizophrenia / / 20889312 rs1336128 chr1 18765308 A G 5.35E-04 Multiple complex diseases / / 17554300 rs1568339 chr1 18766761 C A 2.48E-05 Bipolar disorder and schizophrenia / / 20889312 rs7535812 chr1 18786779 C G 1.12E-04 Coronary heart disease / / 21606135 rs1414642 chr1 18787446 C T 2.88E-06 Phospholipid levels (plasma) / / 21829377 rs3007728 chr1 18794241 C T 1.67E-06 Phospholipid levels (plasma) / / 21829377 rs3007729 chr1 18795255 T C 8.46E-06 Lung adenocarcinoma / / 19836008 rs3007729 chr1 18795255 T C 5.00E-06 Diabetic retinopathy / / 21441570 rs16862008 chr1 18801486 G A 3.33E-06 Phospholipid levels (plasma) / / 21829377 rs7528206 chr1 18807117 T C 5.06E-04 Response to alcohol consumption (flushing response) / / 24277619 rs2992745 chr1 18809896 A T 8.60E-05 Response to statin therapy KLHDC7A UTR-3 20339536 rs3007719 chr1 18811668 T C 8.70E-05 Response to statin therapy KLHDC7A UTR-3 20339536 rs72646406 chr1 18815045 A G 0.0000556 Sarcoidosis / / 22952805 rs909950 chr1 18824363 G A 3.12E-04 Type 2 diabetes / / 17463246 rs17351871 chr1 18838322 G C 8.75E-04 Obesity (extreme) / / 21935397 rs12401403 chr1 18863502 A G 2.34E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs114799364 chr1 18900554 C T 2.72E-06 Prostate cancer / / 24185611 rs4920334 chr1 18913558 T C 7.68E-04 Multiple complex diseases / / 17554300 rs4920516 chr1 18913618 G C 7.63E-04 Multiple complex diseases / / 17554300 rs6684839 chr1 18920685 G A 8.60E-06 Urinary metabolites / / 21572414 rs4920520 chr1 18929842 G A 8.22E-05 Cleft lip / / 20436469 rs4920520 chr1 18929842 G A 6.45E-06 Orofacial clefts / / 22863734 rs4920522 chr1 18940380 C T 4.61E-06 Cleft lip / / 20436469 rs4920522 chr1 18940380 C T 9.41E-07 Orofacial clefts / / 22863734 rs7541797 chr1 18951985 G C 8.70E-06 Urinary metabolites / / 21572414 rs17352100 chr1 18952112 C T 6.55E-07 Cleft lip / / 20436469 rs17352100 chr1 18952112 C T 8.70E-06 Urinary metabolites / / 21572414 rs17352100 chr1 18952112 C T 3.25E-07 Orofacial clefts / / 22863734 rs766325 chr1 18956458 G A 2.21E-06 Cleft lip PAX7 nearGene-5 20436469 rs766325 chr1 18956458 G A 7.39E-07 Orofacial clefts PAX7 nearGene-5 22863734 rs10907325 chr1 18964021 A T 2.54E-04 Body mass index PAX7 intron 21701565 rs10907325 chr1 18964021 A T 5.31E-04 Body mass index PAX7 intron 21701565 rs7364475 chr1 18965061 C T 2.77E-04 Orofacial clefts PAX7 intron 22863734 rs10907326 chr1 18965360 T G 2.90E-04 Body mass index PAX7 intron 21701565 rs10907326 chr1 18965360 T G 6.00E-04 Body mass index PAX7 intron 21701565 rs11583072 chr1 18966007 G T 1.42E-06 Orofacial clefts PAX7 intron 22863734 rs56675509 chr1 18971634 G C 1.03E-05 Orofacial clefts PAX7 intron 22863734 rs9439713 chr1 18972776 G A 2.87E-06 Orofacial clefts PAX7 intron 22863734 rs9439714 chr1 18976489 T C 7.02E-08 Orofacial clefts PAX7 intron 22863734 rs4920524 chr1 18978372 T G 4.94E-08 Orofacial clefts PAX7 intron 22863734 rs6695765 chr1 18979320 T C 2.43E-06 Cleft lip PAX7 intron 20436469 rs6695765 chr1 18979320 T C 1.12E-06 Orofacial clefts PAX7 intron 22863734 rs742071 chr1 18979874 G T 1.57E-07 Cleft lip PAX7 intron 20436469 rs742071 chr1 18979874 G T 7.00E-09 Orofacial clefts PAX7 intron 22863734 rs6659735 chr1 18983697 G A,C,T 8.13E-06 Cleft lip PAX7 intron 20436469 rs6659735 chr1 18983697 G A,C,T 1.36E-06 Orofacial clefts PAX7 intron 22863734 rs56075776 chr1 18986508 G A 2.16E-06 Orofacial clefts PAX7 intron 22863734 rs1339063 chr1 18989575 A T 5.84E-06 Orofacial clefts PAX7 intron 22863734 rs2236835 chr1 18990251 G A 8.00E-06 Body mass index PAX7 intron 23669352 rs4920338 chr1 18990793 C T 2.36E-05 Cleft lip PAX7 intron 20436469 rs4920338 chr1 18990793 C T 8.39E-07 Orofacial clefts PAX7 intron 22863734 rs4920339 chr1 18991005 C T 1.29E-06 Orofacial clefts PAX7 intron 22863734 rs12141588 chr1 18995326 C T 2.84E-04 Suicide attempts in bipolar disorder PAX7 intron 21423239 rs16862125 chr1 18999794 C A 5.00E-04 Smoking initiation PAX7 intron 24665060 rs2236832 chr1 18999831 A G 9.70E-05 Waist Circumference PAX7 intron pha003025 rs545793 chr1 19016522 G C 3.05E-04 Smoking initiation PAX7 intron 24665060 rs2236826 chr1 19019980 T C 5.34E-04 Smoking initiation PAX7 intron 24665060 rs2236824 chr1 19032272 G C 2.00E-06 Response to amphetamines PAX7 intron 22952603 rs624761 chr1 19044877 C T 7.65E-05 Amyotrophic Lateral Sclerosis PAX7 intron 17827064 rs2743189 chr1 19056382 C T 6.91E-04 Alcohol dependence PAX7 intron 21314694 rs2236805 chr1 19057730 G A 2.98E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) PAX7 intron 24023788 rs1160680 chr1 19080506 A G 8.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7414734 chr1 19094738 G A 5.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4920344 chr1 19104381 A G 6.19E-04 Multiple complex diseases / / 17554300 rs6669544 chr1 19109036 C G 4.40E-06 Urinary metabolites / / 21572414 rs4920537 chr1 19109183 C T 4.87E-05 Cognitive impairment induced by topiramate / / 22091778 rs12566799 chr1 19123033 G A 2.26E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7411058 chr1 19134260 A G 2.51E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7411577 chr1 19134834 A C 8.12E-05 Alzheimer's disease (age of onset) / / 22005931 rs7417542 chr1 19135214 G A 8.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12063142 chr1 19139517 C T 5.00E-07 Parkinson's disease / / 20070850 rs72651812 chr1 19141142 C G 1.88E-05 Acne (severe) / / 24927181 rs6662718 chr1 19169613 G A 2.37E-05 Alzheimer's disease (age of onset) TAS1R2 intron 22005931 rs28441017 chr1 19206334 G A 9.00E-06 Anorexia nervosa ALDH4A1 intron 23568457 rs4911977 chr1 19239515 T C 3.55E-05 Multiple complex diseases IFFO2 intron 17554300 rs6698642 chr1 19255671 C T 2.32E-07 Facial morphology IFFO2 intron 22341974 rs4912013 chr1 19284564 T C 1.45E-04 Alcohol dependence / / 21314694 rs16862426 chr1 19321495 C T 9.00E-08 Methotrexate phramacokinetics (acute lymphoblastic leukemia) / / 19901119 rs6690097 chr1 19323050 G C 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs7523455 chr1 19332076 A G 2.00E-07 Methotrexate phramacokinetics (acute lymphoblastic leukemia) / / 19901119 rs28829049 chr1 19349281 C T 6.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs7527580 chr1 19378508 G A 7.67E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs7527580 chr1 19378508 G A 8.72E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs7527580 chr1 19378508 G A 7.13E-04 Stroke / / pha002887 rs12123383 chr1 19386585 A C 4.00E-06 Response to amphetamines / / 22952603 rs3748761 chr1 19400691 C G 8.54E-04 Alzheimer's disease UBR4 nearGene-3 17998437 rs10158468 chr1 19402390 T C 9.95E-04 Response to cytidine analogues (gemcitabine) UBR4 intron 24483146 rs2146866 chr1 19405237 A G 8.46E-04 Response to cytidine analogues (gemcitabine) UBR4 intron 24483146 rs12740975 chr1 19437923 G A 6.43E-04 Schizophrenia UBR4 intron 19197363 rs2274001 chr1 19464773 C T 5.94E-04 Response to cytidine analogues (gemcitabine) UBR4 intron 24483146 rs1009806 chr1 19500551 T C 8.07E-04 Schizophrenia UBR4 intron 19197363 rs710880 chr1 19564049 G A 4.84E-04 Multiple complex diseases KIAA0090 intron 17554300 rs710865 chr1 19568972 A G 1.00E-07 Brain structure KIAA0090 intron 20171287 rs10917275 chr1 19576035 T C 6.83E-06 Serum metabolites KIAA0090 intron 19043545 rs2073102 chr1 19583330 G C 9.98E-04 Alzheimer's disease MRTO4 intron 24755620 rs1042380 chr1 19584004 G A 1.54E-05 Serum metabolites MRTO4 cds-synon 19043545 rs7527253 chr1 19593199 T C 7.79E-04 Alzheimer's disease / / 24755620 rs10917331 chr1 19604101 G A 6.88E-04 Alzheimer's disease / / 24755620 rs1738025 chr1 19609254 T C 1.42E-04 Height AKR7A3 missense 17255346 rs1738023 chr1 19611241 T C 1.26E-04 Height AKR7A3 missense 17255346 rs859217 chr1 19640698 G A 9.37E-04 Multiple complex diseases PQLC2 intron 17554300 rs2064378 chr1 19644855 G A 3.70E-04 Suicide attempts in bipolar disorder PQLC2 intron 21041247 rs4912069 chr1 19645673 G A 3.98E-04 Suicide attempts in bipolar disorder PQLC2 intron 21041247 rs2268809 chr1 19667552 C T 3.83E-04 Multiple complex diseases CAPZB intron 17554300 rs72651465 chr1 19671766 T A 4.06E-04 Acne (severe) CAPZB intron 24927181 rs191942 chr1 19691754 G A 8.33E-04 Multiple complex diseases CAPZB intron 17554300 rs214321 chr1 19693128 C A 5.71E-05 Multiple complex diseases CAPZB intron 17554300 rs10917434 chr1 19707302 G A 8.72E-04 Type 2 diabetes CAPZB intron 17463246 rs7667 chr1 19718824 G A 8.00E-06 Crohn's disease and psoriasis CAPZB intron 22482804 rs12403041 chr1 19730927 A G 8.03E-04 Multiple complex diseases CAPZB intron 17554300 rs4244002 chr1 19738190 C T 5.80E-04 Multiple complex diseases CAPZB intron 17554300 rs1472565 chr1 19755030 T C 6.30E-05 Hypothyroidism CAPZB intron 22493691 rs2088828 chr1 19757646 C A 2.59E-04 Alzheimer's disease (late onset) CAPZB intron 21379329 rs12137160 chr1 19763379 C T 8.47E-04 Multiple complex diseases CAPZB intron 17554300 rs12137162 chr1 19763396 C A 8.25E-04 Multiple complex diseases CAPZB intron 17554300 rs10799810 chr1 19764032 G A 2.43E-04 Alzheimer's disease (late onset) CAPZB intron 21379329 rs4911995 chr1 19765004 G C 1.70E-04 Multiple complex diseases CAPZB intron 17554300 rs4911996 chr1 19765205 G C 8.24E-04 Multiple complex diseases CAPZB intron 17554300 rs12045440 chr1 19765518 T G 5.48E-04 Type 2 diabetes CAPZB intron 17463246 rs12045440 chr1 19765518 T G 2.00E-11 Thyroid volume CAPZB intron 21565293 rs12045440 chr1 19765518 T G 3.00E-14 Thyroid volume CAPZB intron 21565293 rs4911997 chr1 19765669 G A 3.22E-04 Multiple complex diseases CAPZB intron 17554300 rs10492997 chr1 19769371 C T 3.49E-04 Multiple complex diseases CAPZB intron 17554300 rs1002365 chr1 19797248 T C 9.90E-05 Hypothyroidism CAPZB intron 22493691 rs3813986 chr1 19801268 C T 2.76E-04 Multiple complex diseases CAPZB intron 17554300 rs10799817 chr1 19805997 C G 8.22E-04 Type 2 diabetes CAPZB intron 17463246 rs924519 chr1 19806259 C T 7.67E-04 Type 2 diabetes CAPZB intron 17463246 rs6664461 chr1 19809171 C T 9.57E-06 Insulin Resistance CAPZB intron pha003062 rs6664461 chr1 19809171 C T 1.27E-05 Insulin-related traits CAPZB intron pha003063 rs1995311 chr1 19820119 T G 1.87E-04 Tuberculosis / / 22306650 rs873095 chr1 19823329 G A 4.70E-08 Thyroid function / / 20826269 rs2314146 chr1 19824008 A G 5.80E-06 Thyroid stimulating hormone / / 24852370 rs6683419 chr1 19827780 G A 3.00E-07 Thyroid stimulating hormone / / 24852370 rs16822442 chr1 19827970 A G 3.30E-08 Thyroid function / / 20826269 rs11807599 chr1 19831939 C T 6.00E-08 Thyroid function / / 20826269 rs11806434 chr1 19832437 G A 5.70E-08 Thyroid function / / 20826269 rs12136721 chr1 19832987 C G 5.70E-08 Thyroid function / / 20826269 rs4394682 chr1 19837537 A G 4.00E-08 Thyroid function / / 20826269 rs12138950 chr1 19839115 A C 3.50E-08 Thyroid function / / 20826269 rs12138950 chr1 19839115 A C 3.00E-18 Thyroid volume / / 21565293 rs568931048 chr1 19839115 A AC 3.50E-08 Thyroid function / / 20826269 rs568931048 chr1 19839115 A AC 3.00E-18 Thyroid volume / / 21565293 rs10799824 chr1 19841174 G A 3.50E-08 Thyroid function / / 20826269 rs10799824 chr1 19841174 G A 1.00E-08 Thyroid hormone levels / / 23408906 rs10799824 chr1 19841174 G A 3.00E-14 Thyroid hormone levels / / 23408906 rs10799824 chr1 19841174 G A 4.00E-21 Thyroid hormone levels / / 23408906 rs10917468 chr1 19843354 T C 1.00E-14 Thyroid volume / / 21565293 rs10917468 chr1 19843354 T C 0.00025 Prostate cancer / / 23555315 rs10917469 chr1 19843576 A G 9.95E-04 Multiple complex diseases / / 17554300 rs10917469 chr1 19843576 A G 3.20E-08 Thyroid function / / 20826269 rs6426809 chr1 19858271 C T 4.51E-04 Alzheimer's disease / / 17998437 rs10917477 chr1 19861106 A G 2.00E-08 Thyroid function / / 22494929 rs10917477 chr1 19861106 A G 6.80E-05 Blood Pressure / / pha003048 rs4912122 chr1 19876438 A G 8.79E-04 Multiple complex diseases / / 17554300 rs10917493 chr1 19882170 T G 2.42E-05 Insulin Resistance / / pha003062 rs717536 chr1 19905646 G C 4.42E-04 Multiple complex diseases / / 17554300 rs1770480 chr1 19916784 C T 4.41E-08 Thyroid function / / 22494929 rs2745217 chr1 19921747 C T 1.46E-08 Thyroid function / / 22494929 rs2792043 chr1 19924662 A C 2.77E-08 Thyroid function MINOS1 intron 22494929 rs860847 chr1 19927553 C A 7.04E-05 Adipocyte fatty acid-binding protein concentration,in serum MINOS1 intron 21863005 rs1770483 chr1 19930252 T A 7.03E-04 Multiple complex diseases MINOS1 intron 17554300 rs1770483 chr1 19930252 T A 9.34E-05 Adipocyte fatty acid-binding protein concentration,in serum MINOS1 intron 21863005 rs1320978 chr1 19947973 A G 2.25E-08 Thyroid function MINOS1 intron 22494929 rs10917504 chr1 19965927 C A 1.00E-04 Prostate cancer C1orf151-NBL1 intron 21743057 rs6693503 chr1 19987294 A G 0.0000161 Uterine leiomyomata / / 23040493 rs16822732 chr1 20015300 G A 5.30E-05 Asthma TMCO4 intron 11022011 rs2050121 chr1 20016849 G A 6.76E-05 Blood pressure (response to calcium channel blocker) TMCO4 intron 24192120 rs3748748 chr1 20018195 G A 6.63E-05 Asthma TMCO4 intron 11022011 rs3748748 chr1 20018195 G A 4.78E-04 Orofacial clefts TMCO4 intron 22863734 rs3934191 chr1 20026572 A G 3.51E-04 Response to cytidine analogues (gemcitabine) TMCO4 intron 24483146 rs3929668 chr1 20052373 C T 6.97E-04 Lymphocyte counts TMCO4 intron 22286170 rs10917526 chr1 20056933 G A 2.30E-05 Urinary metabolites TMCO4 intron 21572414 rs3850533 chr1 20061456 T C 2.40E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) TMCO4 intron 23648065 rs12140071 chr1 20110436 T C 9.81E-05 Parent of origin effect on language impairment (paternal) TMCO4 intron 24571439 rs10799837 chr1 20135612 G A 8.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1317209 chr1 20140036 G A 2.00E-10 Ulcerative colitis / / 20228799 rs1317209 chr1 20140036 G A 2.00E-10 Asthma / / 21907864 rs3767216 chr1 20140340 A G 2.77E-05 Sudden cardiac arrest / / 21658281 rs3806308 chr1 20142866 C T 7.00E-09 Ulcerative colitis / / 19122664 rs10799839 chr1 20148249 C T 4.43E-05 Blood Pressure / / pha003045 rs10799839 chr1 20148249 C T 4.51E-05 Blood Pressure / / pha003047 rs10917552 chr1 20158334 T C 0.0005392 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10917552 chr1 20158334 T C 5.39E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2314762 chr1 20158604 T G 6.46E-05 Blood pressure / / 24001895 rs4271183 chr1 20163290 T G 2.48E-05 Pulmonary function / / 19300500 rs12137940 chr1 20165383 C A 2.72E-05 Pulmonary function / / 19300500 rs6426833 chr1 20171860 G A 5.00E-13 Ulcerative colitis / / 19122664 rs6426833 chr1 20171860 G A 2.00E-11 Ulcerative colitis / / 19915572 rs6426833 chr1 20171860 G A 2.00E-21 Ulcerative colitis / / 20228799 rs6426833 chr1 20171860 G A 4.00E-35 Ulcerative colitis / / 21297633 rs6426833 chr1 20171860 G A 2.00E-68 Ulcerative colitis / / 23128233 rs6426833 chr1 20171860 G A 7.22E-08 Ulcerative colitis / / 23511034 rs10917558 chr1 20173972 C T 2.99E-05 Pulmonary function / / 19300500 rs6690967 chr1 20183342 C T 4.42E-04 Blood pressure / / 17255346 rs12117495 chr1 20183445 A G 6.54E-05 Pulmonary function / / 19300500 rs16823043 chr1 20184603 G A 2.88E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7531128 chr1 20187321 G A 2.00E-05 Urinary metabolites / / 21572414 rs6686814 chr1 20187511 C T 7.44E-05 Longevity / / 20304771 rs16823061 chr1 20190672 G A 7.05E-05 Longevity / / 20304771 rs7517912 chr1 20192876 A T 6.64E-05 Longevity / / 20304771 rs12064952 chr1 20197978 G C 5.00E-05 Longevity / / 20304771 rs4654903 chr1 20200990 A G 7.00E-09 Ulcerative colitis / / 23511034 rs12124726 chr1 20209469 A C 2.55E-08 Sickle cell anemia (severity) OTUD3 intron 20029952 rs4654910 chr1 20213087 C A 4.70E-05 Longevity OTUD3 intron 20304771 rs1339717 chr1 20222500 G A 8.52E-04 Alzheimer's disease OTUD3 intron 22005930 rs4654925 chr1 20227723 G C,T 9.00E-22 Ulcerative colitis OTUD3 intron 20228798 rs4654925 chr1 20227723 G C,T 9.00E-22 Multiple sclerosis OTUD3 intron 22190364 rs10916668 chr1 20233086 G A 7.82E-05 Pulmonary function OTUD3 missense 19300500 rs10492999 chr1 20237760 A G 7.83E-05 Pulmonary function OTUD3 UTR-3 19300500 rs1046548 chr1 20238343 A G 9.66E-04 Suicide attempts in bipolar disorder OTUD3 UTR-3 21423239 rs17401847 chr1 20238466 A G 1.35E-05 Longevity OTUD3 UTR-3 20304771 rs12028511 chr1 20247674 C A 1.97E-04 Alzheimer's disease (late onset) PLA2G2E intron 21379329 rs2233687 chr1 20250799 C T 3.89E-05 Waist-Hip Ratio / / pha003029 rs1093733 chr1 20258473 T C 6.72E-04 Alzheimer's disease / / 22005930 rs818968 chr1 20279405 C T 4.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs4655010 chr1 20287919 C A 1.14E-05 Post-operative nausea and vomiting / / 21694509 rs12568139 chr1 20311676 A G 3.33E-04 Smoking quantity / / 24665060 rs3767225 chr1 20399643 T C 6.64E-04 Type 2 diabetes PLA2G5 intron 17463246 rs10916704 chr1 20400991 G T 1.47E-10 Cholesterol,total PLA2G5 intron 23063622 rs10916704 chr1 20400991 G T 4.52E-08 LDL cholesterol PLA2G5 intron 23063622 rs11573213 chr1 20402010 A C 0.000000331 Cholesterol,total PLA2G5 intron 23063622 rs576634 chr1 20406545 C T 0.000000425 Triglycerides PLA2G5 intron 23063622 rs576634 chr1 20406545 C T 1.60E-10 Cholesterol,total PLA2G5 intron 23063622 rs11573244 chr1 20407582 C T 1.39E-08 LDL cholesterol PLA2G5 intron 23063622 rs11573244 chr1 20407582 C T 1.45E-08 Cholesterol,total PLA2G5 intron 23063622 rs10916705 chr1 20413887 C G 8.65E-04 Depression (quantitative trait) PLA2G5 intron 20800221 rs11573288 chr1 20416794 C T 9.05E-04 Depression (quantitative trait) PLA2G5 intron 20800221 rs11573288 chr1 20416794 C T 2.18E-04 Smoking quantity PLA2G5 intron 24665060 rs11573291 chr1 20417765 G A 2.55E-04 Multiple complex diseases PLA2G5 UTR-3 17554300 rs6699362 chr1 20423099 T G 7.55E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4655155 chr1 20427541 C T 1.08E-04 Alzheimer's disease (late onset) / / 21379329 rs492738 chr1 20429861 C A 4.17E-04 Alzheimer's disease (late onset) / / 21379329 rs1567102 chr1 20444473 C T 0.00079897 Hypertension (early onset hypertension) PLA2G2D intron 22479346 rs623784 chr1 20452434 A C,G,T 8.67E-06 Obesity-related traits / / 23251661 rs12722987 chr1 20455220 C A 7.00E-06 Obesity-related traits / / 23251661 rs12745152 chr1 20469854 G A 3.58E-05 Cardiovascular disease PLA2G2F intron pha003064 rs12025316 chr1 20494741 C G 4.32E-04 Response to cytidine analogues (gemcitabine) PLA2G2C intron 24483146 rs2301472 chr1 20498914 C T 4.41E-04 Response to cytidine analogues (gemcitabine) PLA2G2C intron 24483146 rs2301475 chr1 20499168 T C 1.06E-05 Response to cytidine analogues (gemcitabine) PLA2G2C intron 24483146 rs2301475 chr1 20499168 T C 8.65E-04 Response to cytadine analogues (cytosine arabinoside) PLA2G2C intron 24483146 rs10916718 chr1 20501442 T C 1.57E-05 Platelet counts PLA2G2C intron 21507922 rs2301478 chr1 20501974 G A 1.87E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10799612 chr1 20502761 C G 3.30E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs3179690 chr1 20518226 G A 3.11E-08 Secreted IFN-gamma response to smallpox vaccine UBXN10 UTR-3 22661280 rs7517797 chr1 20532401 T C 7.11E-04 Multiple complex diseases / / 17554300 rs10799615 chr1 20541370 A G 0.0002 Migraine / / 22678113 rs7533370 chr1 20542980 A G 9.51E-04 Multiple complex diseases / / 17554300 rs6692412 chr1 20561095 C T 8.85E-04 Multiple complex diseases / / 17554300 rs4655165 chr1 20562389 G A 2.74E-05 Cleft lip / / 20436469 rs2157508 chr1 20572621 T C 4.65E-05 Serum metabolites / / 19043545 rs2157508 chr1 20572621 T C 1.11E-04 Smoking cessation / / 24665060 rs6426624 chr1 20572638 A G 8.55E-05 Serum metabolites / / 19043545 rs2157510 chr1 20572894 A G 4.65E-05 Serum metabolites / / 19043545 rs743983 chr1 20583322 T G 4.10E-05 Serum metabolites / / 19043545 rs17354986 chr1 20585773 C T 6.84E-04 Acute lung injury / / 22295056 rs966366 chr1 20592340 T C 8.54E-07 Type 2 diabetes / / 17463246 rs966366 chr1 20592340 T C 1.62E-04 Acute lung injury / / 22295056 rs2017456 chr1 20598351 C T 8.14E-04 Type 2 diabetes / / 17463246 rs4655183 chr1 20604014 A C 1.24E-04 Type 2 diabetes / / 17463246 rs12116793 chr1 20625777 C A 1.76E-04 Suicide attempts in bipolar disorder VWA5B1 intron 21423239 rs12134413 chr1 20630594 A C 1.42E-04 Suicide attempts in bipolar disorder VWA5B1 intron 21423239 rs16823838 chr1 20631012 C G 8.65E-04 Multiple complex diseases VWA5B1 intron 17554300 rs12140623 chr1 20632815 G A 3.06E-04 Suicide attempts in bipolar disorder VWA5B1 intron 21423239 rs11809335 chr1 20635722 A G 6.67E-05 Height VWA5B1 intron pha003011 rs12124623 chr1 20667464 G T 5.67E-04 Suicide attempts in bipolar disorder VWA5B1 intron 21423239 rs10916782 chr1 20726556 G A 7.79E-04 Response to cytidine analogues (gemcitabine) LOC339505 intron 24483146 rs912813 chr1 20728889 T A 1.50E-05 Urinary metabolites LOC339505 intron 21572414 rs879484 chr1 20729212 T C 4.85E-04 Response to cytidine analogues (gemcitabine) LOC339505 intron 24483146 rs10753498 chr1 20733376 T C 1.10E-05 Urinary metabolites LOC339505 intron 21572414 rs7514144 chr1 20735869 C T 9.09E-05 Common variable immunodeficiency LOC339505 intron 21497890 rs10799633 chr1 20740016 C A 2.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC339505 intron 20877124 rs1886737 chr1 20745074 C A 2.00E-04 Type 2 diabetes LOC339505 intron 17463246 rs974332 chr1 20745485 T C 3.47E-04 Multiple complex diseases LOC339505 intron 17554300 rs10916799 chr1 20767524 C T 4.90E-06 Blood Pressure / / pha003040 rs750070 chr1 20769184 A C 4.81E-05 Blood Pressure / / pha003040 rs10799636 chr1 20770887 T C 6.06E-05 Body Mass Index / / pha003006 rs97922 chr1 20804065 T G 1.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs609210 chr1 20849079 C T 4.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6698887 chr1 20857064 G A 7.91E-04 Multiple complex diseases / / 17554300 rs660423 chr1 20865703 T C 6.17E-04 Aortic root size / / 21223598 rs561411 chr1 20866328 C T 8.50E-04 Aortic root size / / 21223598 rs667357 chr1 20872694 C T 2.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12072199 chr1 20877812 T C 4.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs675397 chr1 20883422 T C 3.47E-05 Bladder cancer / / 19648920 rs677214 chr1 20883816 C T 4.19E-04 Iron levels / / pha002876 rs639400 chr1 20900123 C T 2.10E-05 Urinary metabolites / / 21572414 rs532545 chr1 20915172 C T 1 Drug response to Cytarabine / / 19458626 rs532545 chr1 20915172 C T 1 Drug response to Daunorubicin / / 19458626 rs2072671 chr1 20915701 A C 1 Drug response to Gemcitabine CDA missense 15224082 rs2072671 chr1 20915701 A C 1 Drug response to Carboplatin CDA missense 17194903 rs2072671 chr1 20915701 A C 1 Drug response to Cisplatin CDA missense 17194903 rs2072671 chr1 20915701 A C 1 Drug response to Fluorouracil CDA missense 17194903 rs2072671 chr1 20915701 A C 1 Drug response to Gemcitabine CDA missense 17194903 rs2072671 chr1 20915701 A C 1 Drug response to Cytarabine CDA missense 19458626 rs2072671 chr1 20915701 A C 1 Drug response to Daunorubicin CDA missense 19458626 rs517483 chr1 20930035 C T 2.69E-05 Leukocyte Counts CDA intron pha003091 rs60369023 chr1 20931474 G A 1 Drug response to Gemcitabine CDA missense 15224082 rs60369023 chr1 20931474 G A 1 Drug response to Carboplatin CDA missense 17194903 rs60369023 chr1 20931474 G A 1 Drug response to Cisplatin CDA missense 17194903 rs60369023 chr1 20931474 G A 1 Drug response to Fluorouracil CDA missense 17194903 rs60369023 chr1 20931474 G A 1 Drug response to Gemcitabine CDA missense 17194903 rs527912 chr1 20934283 G A 9.40E-05 Type 2 diabetes CDA intron 17463248 rs527912 chr1 20934283 G A 7.42E-05 Adipocyte fatty acid-binding protein concentration,in serum CDA intron 21863005 rs573337 chr1 20936233 C G 1.00E-05 Urinary metabolites CDA intron 21572414 rs12404655 chr1 20943195 A G 2.70E-05 Urinary metabolites CDA intron 21572414 rs12404655 chr1 20943195 A G 1.17E-04 Acute lung injury CDA intron 22295056 rs1048977 chr1 20945055 C T 1 Drug response to Gemcitabine CDA cds-synon 15224082 rs3820321 chr1 20962827 G A 4.00E-05 Type 2 diabetes PINK1 intron 17463248 rs2298298 chr1 20964328 A G 9.00E-05 Personality dimensions PINK1 intron 18957941 rs3102071 chr1 20968011 A G 8.90E-05 Personality dimensions PINK1 intron 18957941 rs2298299 chr1 20974802 A G 2.00E-04 Acute lung injury PINK1 intron 22295056 rs1573132 chr1 20978024 C A 3.20E-04 Schizophrenia(treatment response to risperidone) DDOST nearGene-3 19850283 rs622525 chr1 20979818 A T 8.90E-05 Personality dimensions DDOST intron 18957941 rs607254 chr1 20980880 G A 3.40E-05 Type 2 diabetes DDOST intron 17463248 rs589709 chr1 20983987 G A 2.90E-05 Type 2 diabetes DDOST intron 17463248 rs640742 chr1 20984554 A C 2.90E-05 Type 2 diabetes DDOST intron 17463248 rs623817 chr1 20986078 G A 3.10E-05 Type 2 diabetes DDOST intron 17463248 rs674114 chr1 20989672 G A 6.80E-05 Type 2 diabetes DDOST nearGene-5 17463248 rs630484 chr1 20992606 G T 4.80E-05 Type 2 diabetes KIF17 intron 17463248 rs12118760 chr1 20999804 T C 2.20E-05 Type 2 diabetes KIF17 intron 17463248 rs12025912 chr1 21002699 T C 2.35E-04 Acute lung injury KIF17 intron 22295056 rs12025916 chr1 21002726 T C 2.17E-04 Acute lung injury KIF17 intron 22295056 rs2296223 chr1 21011182 G A 0.0005775 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KIF17 intron 23233654 rs2296223 chr1 21011182 G A 5.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIF17 intron 23233662 rs17407280 chr1 21020405 C T 3.60E-04 Type 2 diabetes KIF17 intron 17463246 rs149579175 chr1 21051116 G A 0.00022 Breast cancer SH2D5 missense 23555315 rs10916852 chr1 21052693 G T 3.26E-04 Coronary heart disease SH2D5 intron 21971053 rs35472344 chr1 21052693 GC G 3.26E-04 Coronary heart disease SH2D5 intron 21971053 rs951805 chr1 21060356 G A 2.90E-05 Urinary metabolites / / 21572414 rs1021077 chr1 21106016 T C 1.20E-05 Urinary metabolites HP1BP3 intron 21572414 rs10916891 chr1 21199974 T G 1.51E-04 Multiple complex diseases EIF4G3 intron 17554300 rs10916891 chr1 21199974 T G 2.02E-04 Lymphocyte counts EIF4G3 intron 22286170 rs4654885 chr1 21220491 T C 4.21E-09 Multiple complex diseases EIF4G3 intron 17554300 rs10157616 chr1 21244582 T C 1.88E-04 Multiple complex diseases EIF4G3 intron 17554300 rs10916901 chr1 21245001 A G 0.000041 Mean arterial pressure EIF4G3 intron 22510845 rs3767248 chr1 21276854 A G 4.14E-04 Coronary heart disease EIF4G3 intron 21971053 rs12021529 chr1 21306161 T C 7.25E-05 Multiple complex diseases EIF4G3 intron 17554300 rs10916930 chr1 21395357 T C 2.70E-04 Multiple complex diseases EIF4G3 intron 17554300 rs2282714 chr1 21587849 G A 1.53E-04 Myopia (pathological) ECE1 intron 21095009 rs3026862 chr1 21604387 C G 3.18E-10 LDL cholesterol ECE1 intron 23063622 rs213010 chr1 21639167 A G 3.89E-04 Alzheimer's disease (late onset) ECE1 intron 21379329 rs213032 chr1 21654735 T C 6.00E-06 Obesity-related traits ECE1 intron 23251661 rs3026815 chr1 21664475 C T 3.08E-06 Personality dimensions ECE1 intron 18957941 rs3026815 chr1 21664475 C T 1.77E-05 Depression (quantitative trait) ECE1 intron 20800221 rs213006 chr1 21678600 T G 2.00E-05 Depression (quantitative trait) / / 20800221 rs12736884 chr1 21725505 G C 3.90E-04 Alcohol dependence / / 20201924 rs12750103 chr1 21736327 A G 9.00E-11 Brain activation patterns in response to human facial expressions-for the negative faces task / / 22828495 rs12750103 chr1 21736327 A G 9.00E-11 Airflow obstruction / / 22837378 rs1566524 chr1 21737466 C A,G,T 4.01E-04 Insulin resistance / / 21901158 rs10916983 chr1 21742737 T C 3.19E-04 Bipolar disorder,schizoaffective / / 19567891 rs10916983 chr1 21742737 T C 9.15E-06 Creutzfeldt-Jakob disease (variant) / / 22137330 rs1976403 chr1 21766453 A C 2.00E-50 Liver enzyme levels (alkaline phosphatase) / / 22001757 rs4654748 chr1 21786068 C T 8.00E-18 Folate pathway vitamin levels NBPF3 intron 19303062 rs4654748 chr1 21786068 C T 4.00E-11 Folate pathway vitamin levels NBPF3 intron 19744961 rs4654748 chr1 21786068 C T 6.73E-09 Vitamin B6 NBPF3 intron 23696881 rs10799701 chr1 21820990 A G 3.00E-20 Metabolic traits / / 21886157 rs1780324 chr1 21821757 A G 7.00E-15 Liver enzyme levels / / 18940312 rs1780324 chr1 21821757 A G 7.14E-05 Blood cell counts and other traits / / 20139978 rs1697421 chr1 21823292 C T 1.00E-27 Phosphorus levels / / 20558539 rs1697421 chr1 21823292 C T 0.00082 Prostate cancer / / 23555315 rs1697421 chr1 21823292 C T 2.00E-20 Blood metabolite ratios / / 24816252 rs1697421 chr1 21823292 C T 3.00E-14 Blood metabolite ratios / / 24816252 rs6667242 chr1 21826566 A G 1.11E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs16825455 chr1 21837755 A G 9.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) ALPL intron 23648065 rs7535497 chr1 21840709 T G 6.43E-04 Type 2 diabetes ALPL intron 17463246 rs7523855 chr1 21840886 C T 6.04E-04 Type 2 diabetes ALPL intron 17463246 rs1890431 chr1 21852078 C T 6.48E-05 Tunica Media ALPL intron pha003036 rs1697414 chr1 21874996 T A 6.98E-04 Multiple complex diseases ALPL intron 17554300 rs885814 chr1 21875916 C T 6.00E-06 Response to TNF-alpha inhibitors in rheumatoid arthritis ALPL intron 22569225 rs885813 chr1 21877074 C T 3.49E-05 Lactate dehydrogenase levels ALPL intron 20981236 rs3767155 chr1 21885195 C T 3.09E-04 Alzheimer's disease ALPL intron 24755620 rs1767429 chr1 21889340 A G 1.93E-04 Alzheimer's disease ALPL intron 24755620 rs1256335 chr1 21890386 G A 1.00E-15 Folate pathway vitamin levels ALPL intron 19744961 rs3738097 chr1 21894816 T C 9.86E-04 Type 2 diabetes ALPL intron 17463246 rs3767142 chr1 21901558 G A 3.27E-04 Alzheimer's disease ALPL intron 24755620 rs2242420 chr1 21904529 C T 5.00E-13 Blood cell counts and other traits ALPL UTR-3 20139978 rs2242420 chr1 21904529 C T 5.08E-13 Blood cell counts and other traits ALPL UTR-3 20139978 rs7515386 chr1 21921736 G A 7.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4654973 chr1 21927820 C G 7.22E-04 Obesity (extreme) RAP1GAP intron 21935397 rs829370 chr1 21933193 C T 3.99E-05 Socioeconomic Factors RAP1GAP intron pha003066 rs861212 chr1 21935433 G T 8.91E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RAP1GAP intron 20877124 rs829417 chr1 21943136 C T 1 Drug response to Etoposide RAP1GAP intron 17537913 rs829418 chr1 21943504 A G 7.54E-05 Socioeconomic Factors RAP1GAP intron pha003066 rs829406 chr1 21949462 A G 1.36E-04 Fibrinogen RAP1GAP intron 17255346 rs829406 chr1 21949462 A G 9.04E-04 Coronary heart disease RAP1GAP intron 21606135 rs829411 chr1 21953138 A G 6.91E-04 Acute lung injury RAP1GAP intron 22295056 rs1531829 chr1 21953304 G A 7.69E-04 Multiple complex diseases RAP1GAP intron 17554300 rs829412 chr1 21953436 A G 2.71E-04 Type 2 diabetes RAP1GAP intron 17463246 rs829412 chr1 21953436 A G 7.03E-04 Multiple complex diseases RAP1GAP intron 17554300 rs4654974 chr1 21954294 T C 7.64E-05 Cognitive test performance RAP1GAP intron 20125193 rs4654974 chr1 21954294 T C 2.59E-04 Suicide attempts in bipolar disorder RAP1GAP intron 21041247 rs9426770 chr1 21955744 G C 2.61E-04 Suicide attempts in bipolar disorder RAP1GAP intron 21041247 rs9426674 chr1 21957239 G C 2.69E-04 Suicide attempts in bipolar disorder RAP1GAP intron 21041247 rs11591167 chr1 21958536 C T 2.14E-05 Mammographic density RAP1GAP intron 22532574 rs9426771 chr1 21958739 G A,C,T 3.87E-04 Suicide attempts in bipolar disorder RAP1GAP intron 21041247 rs9426772 chr1 21959590 T C 8.84E-04 Suicide attempts in bipolar disorder RAP1GAP intron 21041247 rs6679565 chr1 21962551 G A 2.13E-04 Coronary heart disease RAP1GAP intron 21606135 rs12142081 chr1 21966833 G T 4.92E-05 Cognitive test performance RAP1GAP intron 20125193 rs6426721 chr1 21972480 G A 2.23E-04 Multiple complex diseases RAP1GAP intron 17554300 rs12128325 chr1 22002867 G A 3.50E-06 Urinary metabolites / / 21572414 rs333188 chr1 22040294 T C 9.43E-05 Non-alcoholic fatty liver disease histology (other) USP48 intron 20708005 rs7554400 chr1 22052387 T C 1.58E-05 Cognitive performance USP48 intron 19734545 rs6664218 chr1 22055917 A G 1.29E-05 Cognitive performance USP48 intron 19734545 rs333204 chr1 22080775 A G 3.00E-05 Cognitive performance USP48 intron 19734545 rs541552 chr1 22081011 T C 3.00E-05 Cognitive performance USP48 intron 19734545 rs6667223 chr1 22088841 G A 3.74E-05 Lymphocyte counts USP48 intron 22286170 rs884726 chr1 22110418 T C 1.21E-05 Cognitive performance / / 19734545 rs10917047 chr1 22124166 C T 4.34E-05 Cognitive performance / / 19734545 rs12737091 chr1 22174518 G T 3.78E-05 Aortic root size HSPG2 cds-synon 21223598 rs142149919 chr1 22188296 G A 0.00000049 Breast cancer HSPG2 missense 23555315 rs1869780 chr1 22222455 G T 1.42E-04 Multiple complex diseases HSPG2 missense 17554300 rs3820285 chr1 22336277 C G 7.30E-04 Iris characteristics CELA3A missense 21835309 rs3117048 chr1 22345093 A G 7.25E-04 Kawasaki disease / / 21326860 rs3117048 chr1 22345093 A G 8.28E-05 Major depressive disorder / / 22472876 rs2501299 chr1 22345647 C T 5.47E-05 Major depressive disorder / / 22472876 rs760923 chr1 22357217 G T 2.30E-04 Endometriosis / / 23104006 rs2473277 chr1 22361845 G A 5.88E-04 Schizophrenia / / 19197363 rs2473277 chr1 22361845 G A 3.75E-06 Schizophrenia / / 19571811 rs2473277 chr1 22361845 G A 1.00E-04 Endometriosis / / 21151130 rs2501279 chr1 22368342 C T 1.90E-05 Endometriosis / / 21151130 rs2501276 chr1 22373624 C T 2.00E-07 Immune response to smallpox vaccine (IL-6) / / 22610502 rs2056975 chr1 22408527 A G 5.53E-04 Multiple complex diseases CDC42 intron 17554300 rs2268179 chr1 22414785 G T 0.00000134 Uterine leiomyomata CDC42 intron 23040493 rs2268177 chr1 22415410 A T 1.50E-08 Bone mineral density (paediatric,total body less head) CDC42 intron 24945404 rs2268177 chr1 22415410 A T 9.70E-11 Bone mineral density (paediatric,skull) CDC42 intron 24945404 rs10917151 chr1 22422721 G A 7.00E-09 Endometriosis / / 23472165 rs7412010 chr1 22436446 G C 2.30E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs7412010 chr1 22436446 G C 2.50E-12 Bone mineral density (paediatric,skull) / / 24945404 rs7412010 chr1 22436446 G C 2.60E-09 Bone mineral density (paediatric,total body less head) / / 24945404 rs4654783 chr1 22439520 T C 2.00E-04 Endometriosis / / 23104006 rs3765350 chr1 22447316 A G 3.00E-08 Bone mineral density (paediatric,lower limb) WNT4 intron 24945404 rs3765350 chr1 22447316 A G 3.60E-11 Bone mineral density (paediatric,skull) WNT4 intron 24945404 rs3765350 chr1 22447316 A G 4.00E-09 Bone mineral density (paediatric,total body less head) WNT4 intron 24945404 rs3765350 chr1 22447316 A G 6.00E-08 Bone mineral density (paediatric,lower limb) WNT4 intron 24945404 rs3765350 chr1 22447316 A G 7.00E-10 Bone mineral density (paediatric,total body less head) WNT4 intron 24945404 rs2235529 chr1 22450487 C T 3.00E-09 Endometriosis WNT4 intron 23472165 rs2235529 chr1 22450487 C T 1.00E-08 Bone mineral density (paediatric,upper limb) WNT4 intron 24945404 rs2235529 chr1 22450487 C T 1.20E-09 Bone mineral density (paediatric,total body less head) WNT4 intron 24945404 rs2235529 chr1 22450487 C T 3.00E-07 Bone mineral density (paediatric,upper limb) WNT4 intron 24945404 rs2235529 chr1 22450487 C T 3.00E-12 Bone mineral density (paediatric,skull) WNT4 intron 24945404 rs3820282 chr1 22468215 C T 2.00E-09 Bone mineral density (paediatric,total body less head) WNT4 intron 24945404 rs3820282 chr1 22468215 C T 2.10E-08 Bone mineral density (paediatric,upper limb) WNT4 intron 24945404 rs3820282 chr1 22468215 C T 9.70E-12 Bone mineral density (paediatric,skull) WNT4 intron 24945404 rs12042083 chr1 22472732 G A 1.10E-08 Bone mineral density (paediatric,total body less head) / / 24945404 rs12042083 chr1 22472732 G A 3.30E-10 Bone mineral density (paediatric,skull) / / 24945404 rs7515106 chr1 22473410 T C 3.60E-05 Endometriosis / / 21151130 rs7515106 chr1 22473410 T C 2.10E-06 Endometriosis / / 23104006 rs7515106 chr1 22473410 T C 1.50E-09 Bone mineral density (paediatric,skull) / / 24945404 rs7515106 chr1 22473410 T C 7.80E-09 Bone mineral density (paediatric,total body less head) / / 24945404 rs7542242 chr1 22477493 C T 2.90E-06 Endometriosis / / 21151130 rs7517829 chr1 22480159 A G 2.30E-05 Coffee consumption / / 21357676 rs16826658 chr1 22485871 T G 2.00E-06 Endometriosis / / 20601957 rs16826658 chr1 22485871 T G 3.50E-05 Endometriosis / / 21151130 rs16826658 chr1 22485871 T G 4.61E-05 Calcium levels / / pha003085 rs7521902 chr1 22490724 C A 5.00E-06 Ovarian cancer / / 20852632 rs7521902 chr1 22490724 C A 4.20E-05 Endometriosis / / 21151130 rs7521902 chr1 22490724 C A 1.00E-10 Bone mineral density / / 22504420 rs7521902 chr1 22490724 C A 3.00E-11 Endometriosis / / 23104006 rs7521902 chr1 22490724 C A 1.58E-05 Bone mineral density (paediatric,total body less head) / / 24945404 rs7521902 chr1 22490724 C A 3.30E-12 Bone mineral density (paediatric,skull) / / 24945404 rs7521902 chr1 22490724 C A 3.32E-12 Bone mineral density (paediatric,skull) / / 24945404 rs7521902 chr1 22490724 C A 3.81E-07 Bone mineral density (paediatric,upper limb) / / 24945404 rs2807357 chr1 22491984 A G 5.42E-04 Multiple complex diseases / / 17554300 rs3920498 chr1 22492887 G C 1.00E-10 Bone mineral density (paediatric,skull) / / 24945404 rs3920498 chr1 22492887 G C 2.00E-12 Bone mineral density (paediatric,skull) / / 24945404 rs2807356 chr1 22493672 T C 3.59E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs909813 chr1 22496703 G A 8.82E-04 Multiple complex diseases / / 17554300 rs17360053 chr1 22499530 T C 9.00E-06 Obesity-related traits / / 23251661 rs12568557 chr1 22500228 T C 5.35E-04 Smoking cessation / / 24665060 rs16826705 chr1 22501716 C T 3.83E-04 Multiple complex diseases / / 17554300 rs742356 chr1 22501846 A G 3.10E-06 Endometriosis / / 23104006 rs2744704 chr1 22503550 A T 7.16E-05 Aging (time to event) / / 21782286 rs2744718 chr1 22523727 T C 2.88E-04 Osteoarthritis (knee and hip) / / 21177295 rs2744718 chr1 22523727 T C 3.66E-05 Osteoarthritis (knee and hip) / / 21177295 rs2473249 chr1 22537071 C T 1.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs2473250 chr1 22537649 A G 7.77E-04 Alcohol dependence / / 24277619 rs2473256 chr1 22539529 G A 1.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs1883418 chr1 22540161 G A 1.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs760917 chr1 22545088 T A 1.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs1569583 chr1 22547352 T C 4.26E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2505709 chr1 22547479 C T 1.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs2473268 chr1 22549172 G A 1.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs2491213 chr1 22549397 G A 1.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs732266 chr1 22550624 C T 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs2505711 chr1 22551925 G A 1.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs3856181 chr1 22552969 C G 6.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs2744747 chr1 22571462 T C 7.60E-04 Testosterone levels / / 22675492 rs909814 chr1 22573942 T C 9.00E-07 Testosterone levels / / 22675492 rs909814 chr1 22573942 T C 7.00E-06 IgG glycosylation / / 23382691 rs2744757 chr1 22577937 C G 5.20E-04 Testosterone levels / / 22675492 rs2807339 chr1 22578063 T C 7.82E-04 Bipolar disorder,schizoaffective / / 19567891 rs2807339 chr1 22578063 T C 3.10E-04 Testosterone levels / / 22675492 rs2143101 chr1 22578436 G A 5.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2744759 chr1 22579798 T G 6.47E-05 Cleft lip / / 20436469 rs12737805 chr1 22612690 A G 7.37E-04 HIV-1 viral setpoint / / 17641165 rs6690148 chr1 22648411 C T 2.12E-04 Type 2 diabetes / / 17463246 rs1934477 chr1 22664774 T C 9.62E-04 Acute lung injury / / 22295056 rs1934478 chr1 22665210 G A 9.99E-04 Acute lung injury / / 22295056 rs10493012 chr1 22672846 A G 2.65E-04 Multiple complex diseases / / 17554300 rs12742784 chr1 22682366 C T 1.10E-09 Bone mineral density (spine) / / 19801982 rs12756978 chr1 22684755 G C 1.50E-08 Bone mineral density (spine) / / 19801982 rs10753536 chr1 22685251 G A 8.90E-05 Endometriosis / / 21151130 rs11810369 chr1 22687651 G A 1.50E-08 Bone mineral density (spine) / / 19801982 rs12750721 chr1 22689273 G A 1.20E-08 Bone mineral density (spine) / / 19801982 rs12723796 chr1 22691606 G A 4.50E-10 Bone mineral density (spine) / / 19801982 rs12723796 chr1 22691606 G A 9.00E-06 Endometriosis / / 21151130 rs7537281 chr1 22692078 A T 4.90E-10 Bone mineral density (spine) / / 19801982 rs7524102 chr1 22698447 A G 5.00E-16 Bone mineral density (hip) / / 18445777 rs7524102 chr1 22698447 A G 9.00E-09 Bone mineral density (spine) / / 18445777 rs7524102 chr1 22698447 A G 1.00E-16 Bone mineral density (hip) / / 19079262 rs7524102 chr1 22698447 A G 3.00E-10 Bone mineral density (spine) / / 19801982 rs7524102 chr1 22698447 A G 3.00E-07 Ulcerative colitis / / 19915572 rs7524102 chr1 22698447 A G 3.80E-06 Endometriosis / / 21151130 rs7524102 chr1 22698447 A G 2.00E-13 Ulcerative colitis / / 21297633 rs7524102 chr1 22698447 A G 1.00E-06 Bone mineral density / / 21533022 rs7524102 chr1 22698447 A G 9.00E-07 Bone mineral density / / 21533022 rs7524102 chr1 22698447 A G 3.00E-09 Dupuytren's disease / / 21732829 rs7524102 chr1 22698447 A G 0.00038 Prostate cancer / / 23555315 rs34920465 chr1 22700351 A G 3.00E-08 Bone mineral density / / 24249740 rs34920465 chr1 22700351 A G 3.00E-13 Bone mineral density / / 24249740 rs34920465 chr1 22700351 A G 6.01E-10 Bone mineral density / / 24249740 rs12568930 chr1 22702231 T C 4.60E-10 Bone mineral density (spine) / / 19801982 rs12568930 chr1 22702231 T C 1.40E-07 Ulcerative colitis / / 19915572 rs12568930 chr1 22702231 T C 2.80E-06 Endometriosis / / 21151130 rs12568930 chr1 22702231 T C 1.00E-17 Inflammatory bowel disease / / 23128233 rs12561997 chr1 22702280 G A 6.30E-10 Bone mineral density (spine) / / 19801982 rs6696981 chr1 22702858 G T 2.00E-08 Bone mineral density (spine) / / 19079262 rs6696981 chr1 22702858 G T 6.40E-10 Bone mineral density (spine) / / 19801982 rs6696981 chr1 22702858 G T 3.70E-06 Endometriosis / / 21151130 rs6696981 chr1 22702858 G T 7.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs6696981 chr1 22702858 G T 0.00063 Prostate cancer / / 23555315 rs10493013 chr1 22703035 T C 4.80E-10 Bone mineral density (spine) / / 19801982 rs11803476 chr1 22703325 C T 6.40E-10 Bone mineral density (spine) / / 19801982 rs6684375 chr1 22706434 C T 4.80E-10 Bone mineral density (spine) / / 19801982 rs6684479 chr1 22706534 C T 7.60E-10 Bone mineral density (spine) / / 19801982 rs6426748 chr1 22707565 C T 7.60E-10 Bone mineral density (spine) / / 19801982 rs10917221 chr1 22709136 T C 4.83E-04 Aortic root size / / 21223598 rs7550872 chr1 22711378 T C 2.00E-09 Bone mineral density (spine) / / 19801982 rs7550872 chr1 22711378 T C 2.70E-06 Endometriosis / / 21151130 rs6426749 chr1 22711473 G C 9.00E-08 Bone mineral density (hip) / / 19801982 rs6426749 chr1 22711473 G C 3.98E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6426749 chr1 22711473 G C 7.00E-57 Bone mineral density / / 22504420 rs6426749 chr1 22711473 G C 0.00018 Prostate cancer / / 23555315 rs6426749 chr1 22711473 G C 1.06E-07 Bone mineral density / / 24249740 rs6426749 chr1 22711473 G C 7.58E-07 Bone mineral density / / 24249740 rs6426749 chr1 22711473 G C 9.79E-09 Bone mineral density / / 24249740 rs6426749 chr1 22711473 G C 2.27E-04 Bone mineral density (paediatric,total body less head) / / 24945404 rs2185341 chr1 22725825 C T 2.10E-05 Caffeine consumption / / 21490707 rs2185341 chr1 22725825 C T 9.63E-04 Tourette syndrome / / 22889924 rs7543680 chr1 22731269 G A 1.00E-10 Bone mineral density (spine) / / 19079262 rs10917225 chr1 22733144 T C 4.50E-05 Cognitive impairment induced by topiramate / / 22091778 rs4655059 chr1 22735906 A C 1.29E-05 Cognitive impairment induced by topiramate / / 22091778 rs111724808 chr1 22737946 T G 4.00E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs113487266 chr1 22737951 T C 4.03E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs111245681 chr1 22737964 T C 8.71E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs76652604 chr1 22738033 G T 4.33E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs4515757 chr1 22744686 T C 7.29E-05 Body Mass Index / / pha003020 rs10917234 chr1 22782602 A G 4.78E-04 Type 2 diabetes ZBTB40 intron 17463246 rs4233289 chr1 22790455 A C 6.40E-04 Type 2 diabetes ZBTB40 intron 17463246 rs4655067 chr1 22814289 T C 3.98E-04 Type 2 diabetes ZBTB40 intron 17463246 rs4655068 chr1 22814354 C T 4.13E-04 Type 2 diabetes ZBTB40 intron 17463246 rs209753 chr1 22821968 T C 9.94E-04 Lymphocyte counts ZBTB40 intron 22286170 rs209722 chr1 22843428 G A 4.72E-04 Type 2 diabetes ZBTB40 intron 17463246 rs7551801 chr1 22846452 C G 4.51E-04 Type 2 diabetes ZBTB40 intron 17463246 rs209709 chr1 22877813 G A 1.56E-04 Heart Failure / / pha002885 rs606002 chr1 22915753 T C 7.40E-05 Lipoproteins EPHA8 missense pha003079 rs209693 chr1 22922026 T G 4.32E-04 Type 2 diabetes EPHA8 intron 17463246 rs209705 chr1 22934644 A G 4.42E-04 Type 2 diabetes / / 17463246 rs158761 chr1 22954372 C A 8.58E-04 Alcohol dependence / / 24277619 rs12033074 chr1 22966609 C G 1.05E-04 Type 2 diabetes C1QA nearGene-3 17463246 rs6690827 chr1 22967496 G A 1.05E-04 Type 2 diabetes / / 17463246 rs2935537 chr1 22970514 G A 0.000000125 Triglycerides C1QC UTR-5 23063622 rs294189 chr1 22983464 G T 0.00008678 Sarcoidosis C1QB intron 22952805 rs631090 chr1 22986403 T C 8.80E-05 Systemic sclerosis C1QB intron 21750679 rs631090 chr1 22986403 T C 5.91E-04 Response to cytidine analogues (gemcitabine) C1QB intron 24483146 rs201673207 chr1 22991643 C CAG 1 Drug response to Etoposide / / 17537913 rs647955 chr1 22991643 C G 1 Drug response to Etoposide / / 17537913 rs1010011 chr1 23056136 C A 2.08E-04 Taste perception EPHB2 intron 22132133 rs12732926 chr1 23057190 G A 3.83E-05 Cognitive test performance EPHB2 intron 20125193 rs10753541 chr1 23061992 T C 8.71E-05 Serum metabolites EPHB2 intron 19043545 rs7516175 chr1 23096818 A C 5.27E-04 Schizophrenia EPHB2 intron 19197363 rs6692683 chr1 23102856 G A 3.95E-04 Suicide attempts in bipolar disorder EPHB2 intron 21423239 rs893961 chr1 23118173 T C 3.85E-04 Multiple complex diseases EPHB2 intron 17554300 rs4506436 chr1 23127876 T C 3.71E-04 Gallstones EPHB2 intron 17632509 rs12723359 chr1 23137761 G A 5.67E-05 Testicular dysgenesis syndrome EPHB2 intron 22140272 rs7536195 chr1 23142496 C T 3.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EPHB2 intron 20877124 rs893966 chr1 23144006 C T 3.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EPHB2 intron 20877124 rs4654821 chr1 23160272 T A,C,G 4.40E-05 Crohn's disease EPHB2 intron 20570966 rs4654824 chr1 23183130 C T 5.49E-04 Schizophrenia EPHB2 intron 19197363 rs10799771 chr1 23206684 A G 8.35E-05 Insulin Resistance EPHB2 intron pha003062 rs10799771 chr1 23206684 A G 6.63E-05 Insulin-related traits EPHB2 intron pha003063 rs309543 chr1 23225322 A G 4.35E-04 Suicide attempts in bipolar disorder EPHB2 intron 21041247 rs1832047 chr1 23266939 G A 7.20E-04 Alcohol dependence / / 20201924 rs587168 chr1 23371608 A C 1.42E-04 Oral cancers (chewing tobacco related) KDM1A intron 22503698 rs5027299 chr1 23375693 A G 1.19E-18 Multiple complex diseases KDM1A intron 17554300 rs5027299 chr1 23375693 A G 2.88E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers KDM1A intron 21775533 rs11587694 chr1 23477511 T C 3.31E-04 Myocardial Infarction LUZP1 intron pha002873 rs2806561 chr1 23504795 A G 6.89E-05 Panic disorder / / 19165232 rs674386 chr1 23521835 G A 0.0000442 LDL cholesterol / / 23063622 rs1738475 chr1 23536891 C G 3.00E-12 Height / / 20881960 rs10917360 chr1 23539010 G A 7.19E-06 Myocardial Infarction / / pha002873 rs1047694 chr1 23628436 C T 8.89E-06 Height / / 22021425 rs2849021 chr1 23631714 T G 6.15E-06 Height / / 22021425 rs665977 chr1 23696152 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ZNF436 UTR-5 22628534 rs649458 chr1 23712528 T A 1.64E-04 QT interval TCEA3 intron 22726844 rs2275355 chr1 23724183 C T 3.51E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer TCEA3 intron 21483023 rs6682786 chr1 23743296 A G 7.30E-05 Schizophrenia(treatment response to risperidone) TCEA3 intron 19850283 rs1077514 chr1 23766233 C T 7.39E-04 Multiple complex diseases ASAP3 intron 17554300 rs1077514 chr1 23766233 C T 6.00E-09 Cholesterol,total ASAP3 intron 24097068 rs7522616 chr1 23794914 A G 6.30E-05 Alcohol dependence ASAP3 intron 21703634 rs12142232 chr1 23816120 T G 2.19E-05 Blood Pressure / / pha003044 rs2282720 chr1 23839769 A G 1.68E-04 Schizophrenia(treatment response to risperidone) E2F2 intron 19850283 rs3218148 chr1 23851787 G A 1.97E-04 Bulimia nervosa E2F2 intron 23568457 rs11574 chr1 23885498 T C 1.24E-04 Height ID3 missense 17255346 rs4514282 chr1 23912167 C T 2.66E-04 Alzheimer's disease / / 17998437 rs6677615 chr1 23942802 G A 2.60E-04 Alcohol dependence / / 20201924 rs6677615 chr1 23942802 G A 7.20E-04 Alcohol dependence / / 20201924 rs6677615 chr1 23942802 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1317329 chr1 23966837 C T 5.69E-04 Intracranial aneurysm MDS2 intron 20613766 rs12084240 chr1 23980452 C G 3.66E-05 Parkinson's disease (motor and cognition) / / 22658654 rs11577033 chr1 24038231 T C 4.10E-04 Alcohol dependence / / 20201924 rs11577033 chr1 24038231 T C 5.70E-04 Alcohol dependence / / 20201924 rs10917420 chr1 24062987 C T 0.00000183 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs10917420 chr1 24062987 C T 3.25E-05 Tuberculosis / / 24057671 rs11591202 chr1 24102080 A C 6.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100506963 intron 20877124 rs7521571 chr1 24281021 G A 1.09E-04 Vaspin levels / / 22907691 rs7521571 chr1 24281021 G A 0.0001089 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs17338135 chr1 24286897 C T 9.49E-06 Obesity-related traits PNRC2 intron 23251661 rs114176962 chr1 24290676 G A 1.10E-04 Obesity-related traits / / 17903300 rs6667686 chr1 24300849 T C 2.00E-06 Obesity-related traits SRSF10 intron 23251661 rs7553231 chr1 24347103 T C 2.30E-04 Alcohol dependence / / 20201924 rs7553231 chr1 24347103 T C 5.00E-04 Alcohol dependence / / 20201924 rs11586125 chr1 24377326 T C 4.20E-04 Alcohol dependence / / 20201924 rs11586125 chr1 24377326 T C 7.90E-04 Alcohol dependence / / 20201924 rs7540557 chr1 24377944 T C 2.50E-04 Alcohol dependence / / 20201924 rs7540557 chr1 24377944 T C 5.90E-04 Alcohol dependence / / 20201924 rs4649163 chr1 24379601 T C 4.70E-05 Vaspin levels / / 22907691 rs4649163 chr1 24379601 T C 0.000047 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs4649163 chr1 24379601 T C 0.0002016 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs4649171 chr1 24395575 A G 1.25E-04 Vaspin levels MYOM3 intron 22907691 rs4649171 chr1 24395575 A G 0.0001247 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit MYOM3 intron 22907730 rs4276861 chr1 24412447 T C 1.41E-04 Vaspin levels MYOM3 intron 22907691 rs4276861 chr1 24412447 T C 0.000141 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks MYOM3 intron 22907730 rs11249132 chr1 24413907 C A 2.35E-04 Alzheimer's disease MYOM3 intron 22005930 rs4276859 chr1 24416133 C T 4.20E-04 Alcohol dependence MYOM3 cds-synon 20201924 rs4276859 chr1 24416133 C T 4.90E-04 Alcohol dependence MYOM3 cds-synon 20201924 rs4276859 chr1 24416133 C T 2.80E-04 Alzheimer's disease MYOM3 cds-synon 22005930 rs12568789 chr1 24422626 C T 1.78E-04 Suicide attempts in bipolar disorder MYOM3 intron 21423239 rs3934861 chr1 24431956 G A 4.00E-06 Bipolar disorder (mood-incongruent) MYOM3 intron 23092984 rs3934861 chr1 24431956 G A 7.41E-05 Body Mass Index MYOM3 intron pha003009 rs12062136 chr1 24433006 C A 6.69E-04 Parkinson's disease MYOM3 intron 17052657 rs12062136 chr1 24433006 C A 2.55E-05 AIDS progression MYOM3 intron 19115949 rs12062136 chr1 24433006 C A 4.48E-06 Height MYOM3 intron pha003011 rs7534564 chr1 24437063 A G 9.83E-05 Non-alcoholic fatty liver disease histology (other) MYOM3 intron 20708005 rs7534564 chr1 24437063 A G 1.36E-06 Body Mass Index MYOM3 intron pha003009 rs7534564 chr1 24437063 A G 2.58E-07 Height MYOM3 intron pha003010 rs7534564 chr1 24437063 A G 7.83E-10 Height MYOM3 intron pha003011 rs11249175 chr1 24440043 C T 9.96E-04 Acute lung injury / / 22295056 rs6686007 chr1 24442907 T C 8.12E-04 Acute lung injury / / 22295056 rs11249201 chr1 24452399 T C 1.21E-04 Multiple complex diseases IL22RA1 intron 17554300 rs7513249 chr1 24472083 C T 1.25E-04 Hearing function / / 17255346 rs4648940 chr1 24475177 C T 3.50E-05 Alcohol dependence / / 24277619 rs4330872 chr1 24476370 C T 4.55E-05 Height / / pha003011 rs10903032 chr1 24480864 G A 1.90E-04 Suicidal ideation with citalopram treatment IL28RA UTR-3 19724244 rs10903034 chr1 24480905 C T 3.02E-06 Suicidal ideation with citalopram treatment IL28RA UTR-3 19724244 rs12028945 chr1 24482004 G A 1.60E-04 Endometriosis IL28RA UTR-3 21151130 rs11249006 chr1 24482474 G A 4.20E-05 Suicidal ideation with citalopram treatment IL28RA UTR-3 19724244 rs4649195 chr1 24485941 T C 3.20E-04 Suicidal ideation with citalopram treatment IL28RA intron 19724244 rs1416834 chr1 24486660 G A 3.60E-06 Suicidal ideation with citalopram treatment IL28RA intron 19724244 rs6698365 chr1 24497823 G T 1.18E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines IL28RA intron 21844884 rs6698365 chr1 24497823 G T 6.50E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines IL28RA intron 21844884 rs3893318 chr1 24505944 G T 2.52E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines IL28RA intron 21844884 rs3893319 chr1 24506049 A G 1.63E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines IL28RA intron 21844884 rs3893319 chr1 24506049 A G 9.84E-07 Cisplatin and carboplatin cytotoxicity,in blood cell lines IL28RA intron 21844884 rs7552167 chr1 24518643 A G 8.50E-12 Psoriasis / / 23143594 rs7552167 chr1 24518643 A G 6.00E-05 Erythrocyte counts / / pha003099 rs4649203 chr1 24519920 G A 7.00E-08 Psoriasis / / 20953190 rs12046369 chr1 24526135 G T 5.60E-05 Blood Pressure / / pha003048 rs16860738 chr1 24532144 T C 9.67E-04 Alcohol dependence LOC284632 intron 21314694 rs11249039 chr1 24552835 A G 8.30E-05 Creatinine levels / / 20222955 rs10903062 chr1 24556756 G A 2.60E-05 Creatinine levels / / 20222955 rs7517309 chr1 24572806 A G 2.80E-05 Creatinine levels / / 20222955 rs12407356 chr1 24578011 G A 3.36E-05 Bipolar disorder and schizophrenia / / 20889312 rs6670533 chr1 24584490 G A 6.00E-06 Fasting insulin-related traits (interaction with BMI) / / 22581228 rs7535789 chr1 24607419 T C 1.88E-04 Multiple complex diseases / / 17554300 rs10794657 chr1 24626174 A G 2.00E-07 Adiponectin levels / / 22479202 rs2248219 chr1 24645356 A G 7.72E-05 Orofacial clefts GRHL3 nearGene-5 22419666 rs16829445 chr1 24659047 G C 5.76E-04 Multiple complex diseases GRHL3 intron 17554300 rs9424363 chr1 24773803 T A 7.68E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) NIPAL3 intron 24192120 rs11249117 chr1 24780356 C A 1.00E-04 Information processing speed NIPAL3 intron 21130836 rs195717 chr1 24826104 G A 5.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RCAN3AS intron 20877124 rs196402 chr1 24838493 A G 1.50E-05 Reading and spelling RCAN3 intron 23738518 rs11801912 chr1 24861373 T C 1.47E-04 Suicide attempts in bipolar disorder RCAN3 intron 21423239 rs11801547 chr1 24861399 A G 1.40E-04 Suicide attempts in bipolar disorder RCAN3 intron 21423239 rs11799673 chr1 24861471 G A 2.57E-04 Suicide attempts in bipolar disorder RCAN3 intron 21423239 rs6669881 chr1 24862749 A G 1.30E-04 Suicide attempts in bipolar disorder RCAN3 UTR-3 21423239 rs10489444 chr1 24863530 C T 9.06E-05 Suicide attempts in bipolar disorder LOC100506985 intron 21423239 rs7540973 chr1 24864576 G T 1.32E-04 Suicide attempts in bipolar disorder LOC100506985 intron 21423239 rs6697800 chr1 24867540 G A 1.30E-04 Suicide attempts in bipolar disorder LOC100506985 intron 21423239 rs2809964 chr1 24875490 C T 3.88E-05 Lung adenocarcinoma LOC100506985 intron 19836008 rs6424099 chr1 24881126 C T 6.00E-05 Asthma LOC100506985 intron 20698975 rs2809963 chr1 24889450 A T 3.12E-04 Suicide attempts in bipolar disorder C1orf130 intron 21423239 rs2809963 chr1 24889450 A T 0.0000137 HDL cholesterol particle diameter C1orf130 intron 23263444 rs9729036 chr1 24917543 A G 4.43E-04 Multiple complex diseases C1orf130 intron 17554300 rs12072370 chr1 24967165 G A 1.30E-04 Insulin resistance / / 21901158 rs4601530 chr1 25044111 C T 2.00E-12 Height / / 20881960 rs3131499 chr1 25076296 A T 9.20E-04 Multiple complex diseases CLIC4 intron 17554300 rs10732912 chr1 25128123 A C 3.39E-04 Multiple complex diseases CLIC4 intron 17554300 rs3131513 chr1 25193155 G A 2.00E-06 Alcohol dependence / / 23942779 rs3131513 chr1 25193155 G A 3.20E-04 Nicotine use / / 23942779 rs3131513 chr1 25193155 G A 3.50E-04 Illicit drug use / / 23942779 rs4648881 chr1 25197155 G A 0.000000466 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs4648881 chr1 25197155 G A 0.000084 Oligoarticular juvenile idiopathic arthritis / / 23603761 rs4648881 chr1 25197155 G A 0.000213 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis / / 23603761 rs11249196 chr1 25216152 T A 7.52E-04 Multiple complex diseases / / 17554300 rs2236851 chr1 25243554 C T 4.30E-05 Taste perception RUNX3 intron 22132133 rs7551188 chr1 25273200 T C 9.00E-06 Crohn's disease RUNX3 intron 23266558 rs876109 chr1 25273288 T C 9.49E-04 Alzheimer's disease RUNX3 intron 22005930 rs72657048 chr1 25289734 C G 3.80E-06 Celiac disease RUNX3 intron 22057235 rs7536201 chr1 25293084 T C 2.30E-12 Psoriasis / / 23143594 rs10903118 chr1 25294878 T C 7.00E-04 Ankylosing spondylitis / / 21743469 rs10751776 chr1 25296743 A C 7.00E-06 IgG glycosylation / / 23382691 rs11249215 chr1 25297184 G A 9.23E-04 Type 2 diabetes / / 17463246 rs11249215 chr1 25297184 G A 9.00E-11 Ankylosing spondylitis / / 21743469 rs11581762 chr1 25298408 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10903122 chr1 25303576 A G 2.00E-10 Celiac disease / / 20190752 rs10903122 chr1 25303576 A G 2.00E-10 Asthma / / 21150878 rs10903122 chr1 25303576 A G 1.73E-10 Celiac disease and Rheumatoid arthritis / / 21383967 rs10903122 chr1 25303576 A G 2.00E-10 Asthma / / 21907864 rs10903122 chr1 25303576 A G 1.73E-10 Multiple sclerosis / / 22190364 rs12567208 chr1 25308531 T G 1.31E-04 Prion diseases / / 22210626 rs9438880 chr1 25322574 A G 1.14E-04 Prion diseases / / 22210626 rs11249232 chr1 25331585 A G 3.09E-04 Aortic root size / / 21223598 rs755394 chr1 25333899 T C 7.75E-04 Aortic root size / / 21223598 rs10903126 chr1 25344155 A G 9.76E-05 Cognitive test performance / / 20125193 rs387240 chr1 25359929 T C 1.00E-05 Urinary metabolites / / 21572414 rs4649057 chr1 25375177 T C 1.70E-05 Urinary metabolites / / 21572414 rs11248971 chr1 25375583 G A 1.19E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs369427 chr1 25378444 A G 5.60E-06 Urinary metabolites / / 21572414 rs10489162 chr1 25379395 C G 2.00E-05 Urinary metabolites / / 21572414 rs10903024 chr1 25397349 T C 2.25E-04 Body mass index / / 17255346 rs16830335 chr1 25400812 T C 0.0005013 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16830335 chr1 25400812 T C 5.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs427614 chr1 25401437 G A 3.25E-09 HDL cholesterol particle diameter / / 23263444 rs380337 chr1 25401850 A G 3.08E-09 HDL cholesterol particle diameter / / 23263444 rs10903027 chr1 25402624 C T 5.00E-06 IgG glycosylation / / 23382691 rs12076534 chr1 25405012 G A 0.0004577 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12076534 chr1 25405012 G A 4.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7514299 chr1 25405809 T A 0.0004568 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7514299 chr1 25405809 T A 4.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10493026 chr1 25407854 G T 7.31E-05 Waist-Hip Ratio / / pha003028 rs12091321 chr1 25407933 C G 0.0004562 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12091321 chr1 25407933 C G 4.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12081177 chr1 25408685 G T 0.0004574 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12081177 chr1 25408685 G T 4.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7533661 chr1 25413466 G A 0.0004311 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7533661 chr1 25413466 G A 4.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11588172 chr1 25421990 T C 9.02E-06 Chronic obstructive pulmonary disease / / 19300482 rs803313 chr1 25434242 T C 8.23E-05 Major depressive disorder / / 21621269 rs7530932 chr1 25467161 G A 8.20E-04 Alcohol dependence / / 20201924 rs2064251 chr1 25469913 G A 9.72E-06 Anorexia nervosa / / 21079607 rs6600257 chr1 25472465 G A 0.0000344 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12736858 chr1 25521090 C T 1.20E-05 Hypothyroidism / / 22493691 rs11248998 chr1 25529362 C T 5.60E-05 Hypothyroidism / / 22493691 rs77353590 chr1 25535051 C T 0.0000542 Menopause (age at onset) / / 23424626 rs1043879 chr1 25570081 T C 2.00E-09 Erythrocyte sedimentation rate C1orf63 missense 21700265 rs1043879 chr1 25570081 T C 1.34E-04 Myocardial Infarction C1orf63 missense pha002883 rs1830962 chr1 25623967 A G 4.20E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines RHD intron 21844884 rs3091242 chr1 25674785 C T 2.00E-13 Erythrocyte sedimentation rate TMEM50A intron 21700265 rs1293259 chr1 25695835 G A 2.90E-71 Rhesus system E antigen RHCE intron 22611595 rs926438 chr1 25753638 C T 5.57E-04 Multiple complex diseases / / 17554300 rs926438 chr1 25753638 C T 8.77E-05 Smoking behavior / / 20418889 rs873308 chr1 25758655 G A 4.64E-09 Triglycerides TMEM57 intron 19060911 rs873308 chr1 25758655 G A 0.00000113 LDL cholesterol TMEM57 intron 23063622 rs11802413 chr1 25760920 C T 3.03E-04 Multiple complex diseases TMEM57 intron 17554300 rs11802413 chr1 25760920 C T 4.11E-05 Smoking behavior TMEM57 intron 20418889 rs7541095 chr1 25761291 T C 4.73E-05 Smoking behavior TMEM57 intron 20418889 rs10903129 chr1 25768937 A G 3.95E-04 Multiple complex diseases TMEM57 intron 17554300 rs10903129 chr1 25768937 A G 5.00E-10 Cholesterol,total TMEM57 intron 19060911 rs10903129 chr1 25768937 A G 2.30E-04 Lipid levels TMEM57 intron 19936222 rs10903129 chr1 25768937 A G 3.87E-05 Smoking behavior TMEM57 intron 20418889 rs10903129 chr1 25768937 A G 5.00E-13 Erythrocyte sedimentation rate TMEM57 intron 21700265 rs12027135 chr1 25775733 A T 3.98E-05 Smoking behavior TMEM57 intron 20418889 rs12027135 chr1 25775733 A T 1.00E-10 LDL cholesterol TMEM57 intron 20686565 rs12027135 chr1 25775733 A T 4.00E-11 Cholesterol,total TMEM57 intron 20686565 rs12027135 chr1 25775733 A T 2.00E-14 LDL cholesterol TMEM57 intron 24097068 rs12027135 chr1 25775733 A T 5.00E-12 Cholesterol,total TMEM57 intron 24097068 rs61776821 chr1 25885528 G A 0.0000781 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs61776822 chr1 25885592 G A 0.0000664 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs61776823 chr1 25887525 G A 0.0000744 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs12096438 chr1 25889422 C T 0.0000417 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs6687605 chr1 25889632 T C 0.0000396 Nonsyndromic striae distensae (stretch marks) LDLRAP1 missense 23633020 rs6701596 chr1 25889917 T C 0.0000365 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs6661159 chr1 25890050 A G 0.0000392 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs28969504 chr1 25890189 A G 0.0000387 Nonsyndromic striae distensae (stretch marks) LDLRAP1 cds-synon 23633020 rs4075184 chr1 25890835 G A 0.0000348 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs3856239 chr1 25891174 G A 0.000038 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs56214942 chr1 25891959 G A 0.0000417 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs11799800 chr1 25891971 C T 0.0000386 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs4400597 chr1 25892298 G T 0.0000381 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs3856240 chr1 25892525 T C 0.0000424 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs4523506 chr1 25893221 G T 0.0000382 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs4603124 chr1 25893243 G A 0.0000652 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs11563 chr1 25894853 G T 0.00005 Nonsyndromic striae distensae (stretch marks) LDLRAP1 UTR-3 23633020 rs7491 chr1 25895238 C T 0.0000527 Nonsyndromic striae distensae (stretch marks) LDLRAP1 UTR-3 23633020 rs3924236 chr1 25895406 C T 0.0000714 Nonsyndromic striae distensae (stretch marks) LDLRAP1 nearGene-3 23633020 rs3924235 chr1 25895526 G A 0.0000637 Nonsyndromic striae distensae (stretch marks) LDLRAP1 nearGene-3 23633020 rs4659357 chr1 25900240 G A 5.69E-05 Cognitive impairment induced by topiramate / / 22091778 rs2065970 chr1 26051523 A G 8.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAN1C1 intron 20877124 rs2065970 chr1 26051523 A G 6.02E-08 Common variable immunodeficiency MAN1C1 intron 21497890 rs2744768 chr1 26057309 T G 9.90E-05 Hypothyroidism MAN1C1 intron 22493691 rs2786876 chr1 26073443 T C 7.97E-04 Smoking quantity MAN1C1 intron 24665060 rs12130495 chr1 26085398 G T 1.10E-04 Pulmonary emphysema MAN1C1 intron 24383474 rs17163225 chr1 26087669 T G 1.50E-04 Multiple complex diseases MAN1C1 intron 17554300 rs17163225 chr1 26087669 T G 0.0000029 Mean arterial pressure MAN1C1 intron 22510845 rs3820514 chr1 26110065 A G 7.14E-04 Smoking quantity MAN1C1 intron 24665060 rs11247740 chr1 26137025 T A 1.34E-04 Multiple complex diseases SEPN1 intron 17554300 rs6872 chr1 26144674 G A 2.98E-06 Phospholipid levels (plasma) SEPN1 UTR-3 21829377 rs7552868 chr1 26155201 G T 4.48E-05 HDL cholesterol FAM54B intron pha003075 rs213627 chr1 26172111 A G 3.38E-05 HDL cholesterol C1orf135 intron pha003075 rs11247815 chr1 26176728 C T 4.95E-04 Multiple complex diseases C1orf135 intron 17554300 rs1257163 chr1 26250059 C T 0.000162905 Hypertension (early onset hypertension) / / 22479346 rs2275101 chr1 26310213 T C 3.19E-04 Intracranial aneurysm PAFAH2 intron 20613766 rs12743484 chr1 26335929 G A 1.50E-04 Intracranial aneurysm / / 20613766 rs17163470 chr1 26351382 T C 2.10E-04 Multiple complex diseases EXTL1 intron 17554300 rs12072473 chr1 26353367 G A 7.87E-05 Cognitive impairment induced by topiramate EXTL1 intron 22091778 rs1938404 chr1 26358202 G A 7.17E-04 Bipolar disorder EXTL1 intron 19259986 rs1317709 chr1 26384690 T G 5.18E-04 Alzheimer's disease TRIM63 intron 17998437 rs1317709 chr1 26384690 T G 8.27E-04 Bipolar disorder TRIM63 intron 19259986 rs2275949 chr1 26385150 G C 2.39E-04 Alzheimer's disease TRIM63 intron 17998437 rs2997447 chr1 26387423 G A 2.91E-06 Waist-hip ratio TRIM63 intron 20935629 rs2783681 chr1 26441207 A C 5.76E-04 Multiple complex diseases PDIK1L intron 17554300 rs868551 chr1 26475521 A G 6.90E-05 Malaria / / 19465909 rs11247864 chr1 26517667 T C 0.00000311 Lumbar spine bone mineral density (premenopausal) CATSPER4 intron 23074152 rs11247864 chr1 26517667 T C 0.000805 Femoral neck bone mineral density (premenopausal) CATSPER4 intron 23074152 rs11809207 chr1 26521140 G A 6.00E-08 Height CATSPER4 intron 19343178 rs17257155 chr1 26526439 A G 4.53E-04 Alzheimer's disease CATSPER4 missense 17998437 rs17257155 chr1 26526439 A G 7.68E-32 Narcolepsy CATSPER4 missense 19629137 rs4585968 chr1 26535146 G A 2.25E-04 Heart Failure / / pha002884 rs11579247 chr1 26549637 G A 6.93E-05 Cognitive performance / / 19734545 rs10493028 chr1 26552921 T C 3.73E-05 Cognitive performance / / 19734545 rs2050473 chr1 26554096 C G 5.01E-06 Statin-induced myopathy / / 21826682 rs2050475 chr1 26565665 G A 6.89E-04 Multiple complex diseases CEP85 intron 17554300 rs17163749 chr1 26568165 A G 3.80E-04 Primary sclerosing cholangitis CEP85 intron 19944697 rs10902723 chr1 26568542 T C 9.00E-06 Obesity-related traits CEP85 intron 23251661 rs3795686 chr1 26582091 G A 0.00076 Breast cancer CEP85 missense 23555315 rs12757113 chr1 26597144 G A 2.88E-04 Alzheimer's disease CEP85 intron 17998437 rs3795685 chr1 26601385 G A 9.99E-04 Alzheimer's disease CEP85 intron 17998437 rs6598955 chr1 26619649 C T 4.00E-06 Obesity-related traits UBXN11 intron 23251661 rs6598955 chr1 26619649 C T 7.00E-06 Obesity-related traits UBXN11 intron 23251661 rs12068388 chr1 26621596 G A 1 Drug response to Etoposide UBXN11 intron 17537913 rs7541416 chr1 26622911 G A 2.40E-05 Tuberculosis UBXN11 intron 24057671 rs4290051 chr1 26624327 G A 2.72E-04 Multiple complex diseases UBXN11 intron 17554300 rs12726972 chr1 26639634 G A 1.08E-04 Alzheimer's disease UBXN11 intron 17998437 rs11247915 chr1 26650550 C A 5.00E-06 Obesity-related traits AIM1L intron 23251661 rs7544018 chr1 26651132 C G 6.86E-04 Lymphocyte counts AIM1L intron 22286170 rs12563321 chr1 26666502 C T 0.0000287 Uterine leiomyomata AIM1L intron 23040493 rs10902742 chr1 26676257 G T 0.0000591 Uterine leiomyomata AIM1L intron 23040493 rs4233461 chr1 26681306 G A 6.24E-05 Elbow pain / / pha003008 rs9438620 chr1 26716136 C T 8.21E-04 Schizophrenia / / 19197363 rs11587947 chr1 26719264 C T 9.69E-06 Obesity-related traits / / 23251661 rs12722898 chr1 26721287 G A 1.13E-04 Vaspin levels / / 22907691 rs12722898 chr1 26721287 G A 0.0000728 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs12722898 chr1 26721287 G A 0.0001126 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs7532866 chr1 26741544 A G 3.00E-08 Height LIN28A intron 20881960 rs12728900 chr1 26746807 G A 0.0000228 Otitis media (children 3 years old or younger) LIN28A intron 23133572 rs6656196 chr1 26758773 G A 2.93E-08 Red blood cell traits DHDDS UTR-5 23222517 rs3811461 chr1 26759149 A G 1.06E-07 Red blood cell traits DHDDS intron 23222517 rs11247958 chr1 26767367 C T 6.01E-08 Red blood cell traits DHDDS intron 23222517 rs4659374 chr1 26779270 C T 4.95E-06 Leprosy DHDDS intron 22019778 rs3816539 chr1 26786627 G A 1.33E-07 Red blood cell traits DHDDS missense 23222517 rs6690458 chr1 26789787 T C 1.25E-07 Red blood cell traits DHDDS intron 23222517 rs6675469 chr1 26789813 G A 1.44E-07 Red blood cell traits DHDDS intron 23222517 rs2290588 chr1 26797508 C T 8.13E-08 Red blood cell traits DHDDS UTR-3 23222517 rs4659375 chr1 26804090 G A 7.92E-08 Red blood cell traits / / 23222517 rs7530096 chr1 26820218 G A 2.35E-07 Red blood cell traits / / 23222517 rs4970498 chr1 26844195 G A 1.69E-07 Red blood cell traits / / 23222517 rs12046497 chr1 26847640 C T 2.01E-07 Red blood cell traits / / 23222517 rs12094989 chr1 26848386 C T 2.96E-07 Red blood cell traits / / 23222517 rs4970466 chr1 26849312 G A 2.17E-07 Red blood cell traits / / 23222517 rs7539320 chr1 26850665 C T 1.97E-07 Red blood cell traits / / 23222517 rs6670311 chr1 26865485 C G 0.000000201 Triglycerides RPS6KA1 intron 23063622 rs282177 chr1 26899125 C T 6.39E-05 Multiple sclerosis RPS6KA1 intron 17660530 rs190737 chr1 26899444 C A 4.40E-04 Nonalcoholic fatty liver disease RPS6KA1 intron 21423719 rs2229714 chr1 26900708 G A 1.51E-06 Dilated cardiomyopathy RPS6KA1 UTR-3 20975947 rs6699237 chr1 26925843 C T 2.69E-05 Multiple complex diseases / / 17554300 rs17162257 chr1 26929002 T G 1.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6598860 chr1 27021684 G A 7.73E-04 Alzheimer's disease ARID1A nearGene-5 24755620 rs4589135 chr1 27041714 T C 9.58E-04 Alzheimer's disease ARID1A intron 24755620 rs12742115 chr1 27079931 T C 8.94E-05 Response to mTOR inhibitor (rapamycin) ARID1A intron 24009623 rs12748152 chr1 27138393 C T 1.00E-09 Triglycerides / / 24097068 rs12748152 chr1 27138393 C T 1.00E-15 HDL cholesterol / / 24097068 rs12748152 chr1 27138393 C T 3.00E-12 LDL cholesterol / / 24097068 rs17162339 chr1 27252823 C A 3.36E-04 Multiple complex diseases NUDC intron 17554300 rs12239134 chr1 27272864 C T 5.66E-05 Multiple complex diseases NUDC UTR-3 17554300 rs6669265 chr1 27361219 G A 5.97E-07 Hearing function / / 21493956 rs2256674 chr1 27375717 A G 4.30E-04 Blood pressure / / 17255346 rs5810 chr1 27426219 A G 9.25E-04 Suicide attempts in bipolar disorder SLC9A1 UTR-3 21423239 rs6598870 chr1 27428321 T C 9.25E-04 Suicide attempts in bipolar disorder SLC9A1 intron 21423239 rs12118026 chr1 27432745 A G 9.25E-04 Suicide attempts in bipolar disorder SLC9A1 intron 21423239 rs12123077 chr1 27437217 A G 9.51E-04 Suicide attempts in bipolar disorder SLC9A1 intron 21423239 rs11806219 chr1 27448048 G A 5.57E-11 Triglycerides SLC9A1 intron 23063622 rs11807614 chr1 27464917 A G 1.15E-13 Triglycerides SLC9A1 intron 23063622 rs11247611 chr1 27467984 C T 8.73E-06 Post-operative nausea and vomiting SLC9A1 intron 21694509 rs12751422 chr1 27493679 T C 5.50E-04 Type 2 diabetes / / 17463246 rs12117956 chr1 27497582 A G 0.0000397 Uterine leiomyomata / / 23040493 rs6687674 chr1 27537101 G A 0.0000467 Uterine leiomyomata / / 23040493 rs12565684 chr1 27661037 T C 7.81E-05 Response to mTOR inhibitor (rapamycin) TMEM222 intron 24009623 rs187197622 chr1 27677375 G A 0.000038 Breast cancer(er negative) SYTL1 missense 23555315 rs1138294 chr1 27688633 G A 6.79E-04 Premature ovarian failure MAP3K6 missense 19508998 rs11548323 chr1 27731651 C T 2.00E-06 Estradiol plasma levels (breast cancer) WASF2 UTR-3 23518928 rs2474293 chr1 27755669 A C 7.08E-04 Multiple complex diseases WASF2 intron 17554300 rs6598886 chr1 27849300 T C 8.20E-05 Multiple complex diseases / / 17554300 rs6598886 chr1 27849300 T C 2.04E-05 Myocardial Infarction / / pha002873 rs7512595 chr1 27857171 A G 9.40E-05 Myocardial Infarction / / pha002873 rs17357586 chr1 27873001 G C 1.10E-04 Multiple complex diseases AHDC1 intron 17554300 rs17162040 chr1 27883227 T C 3.18E-04 Response to taxane treatment (placlitaxel) AHDC1 intron 23006423 rs4908343 chr1 27931698 G A 1.21E-07 Esophageal cancer (squamous cell) / / 20729853 rs6658795 chr1 27960011 C T 3.92E-04 Multiple complex diseases FGR intron 17554300 rs73494 chr1 27975384 A G 3.86E-06 Bipolar disorder / / 17486107 rs17162722 chr1 27997568 C T 5.95E-04 Multiple complex diseases IFI6 intron 17554300 rs10902662 chr1 27998394 C T 6.86E-04 Type 2 diabetes IFI6 intron 17463246 rs2788686 chr1 28012280 G C 1.37E-04 Type 2 diabetes / / 17463246 rs6598902 chr1 28105709 T C 6.57E-08 Gallstones STX12 intron 17632509 rs1467464 chr1 28211650 T C 3.99E-04 Smoking initiation C1orf38 intron 24665060 rs6564 chr1 28212975 C T 5.78E-04 Smoking initiation C1orf38 UTR-3 24665060 rs3766396 chr1 28221554 A G 2.09E-04 Lymphocyte counts RPA2 intron 22286170 rs2295367 chr1 28224312 C T 2.04E-07 Lymphocyte counts RPA2 intron 22286170 rs6679432 chr1 28227665 T C 6.36E-04 Smoking initiation RPA2 intron 24665060 rs2474470 chr1 28234999 C T 5.36E-04 Smoking initiation RPA2 intron 24665060 rs6700473 chr1 28236682 G A 2.20E-04 Smoking initiation RPA2 intron 24665060 rs4409675 chr1 28262409 A T 2.00E-06 Corneal astigmatism SMPDL3B intron 23322567 rs12565238 chr1 28299346 C T 3.39E-04 Type 2 diabetes EYA3 UTR-3 17463246 rs7529792 chr1 28306250 C T 8.12E-04 Schizophrenia EYA3 intron 19197363 rs2492958 chr1 28314423 A G 5.51E-07 Multiple complex diseases EYA3 intron 17554300 rs10493035 chr1 28315461 C T 1.98E-04 Type 2 diabetes EYA3 intron 17463246 rs17162928 chr1 28343518 G T 3.40E-04 Type 2 diabetes EYA3 intron 17463246 rs2311587 chr1 28416898 G A 3.40E-04 Type 2 diabetes / / 17463246 rs2486674 chr1 28420384 A G 4.65E-05 Post-operative nausea and vomiting / / 21694509 rs11247752 chr1 28426001 T G 2.10E-05 Urinary metabolites / / 21572414 rs1769711 chr1 28455037 A G 8.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10751727 chr1 28461661 T C 4.08E-04 Alzheimer's disease (late onset) / / 21379329 rs6679420 chr1 28500834 G A 0.000000146 LDL cholesterol PTAFR intron 23063622 rs17162987 chr1 28521479 T C 2.59E-04 Multiple complex diseases PTAFR nearGene-5 17554300 rs12129745 chr1 28572317 G C 1.96E-05 Lymphocyte counts / / 22286170 rs4252976 chr1 28962633 G A 6.97E-04 Smoking initiation TAF12 intron 24665060 rs9426394 chr1 29007729 G T 2.09E-05 Smoking initiation GMEB1 intron 24665060 rs2236861 chr1 29139756 G A 0.0005 Coronary artery calcification OPRD1 intron 23727086 rs2236861 chr1 29139756 G A 7.31E-05 Height OPRD1 intron pha003011 rs678849 chr1 29145188 C T 9.36E-06 Amyotrophic Lateral Sclerosis OPRD1 intron 17827064 rs797397 chr1 29151183 G A 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes OPRD1 intron 22628534 rs419335 chr1 29151844 A G 6.81E-04 Response to statin treatment (atorvastatin),change in cholesterol levels OPRD1 intron 20031582 rs538485 chr1 29164561 T G 8.30E-06 Urinary metabolites OPRD1 intron 21572414 rs4654323 chr1 29168957 G T 6.61E-04 Response to statin treatment (atorvastatin),change in cholesterol levels OPRD1 intron 20031582 rs595725 chr1 29172715 C A 5.30E-04 Breast cancer and prostate cancer OPRD1 intron 17903305 rs16837730 chr1 29180014 C T 4.00E-04 Upper aerodigestive tract cancers OPRD1 intron 21437268 rs6690810 chr1 29186859 A G 3.18E-12 Multiple complex diseases OPRD1 intron 17554300 rs157217 chr1 29208997 A G 1.81E-04 Multiple complex diseases / / 17554300 rs203279 chr1 29242454 T A 2.41E-04 Multiple complex diseases EPB41 intron 17554300 rs157208 chr1 29245406 T C 3.14E-04 Birth weight EPB41 intron 17255346 rs150088 chr1 29262533 A G 8.32E-05 Serum metabolites EPB41 intron 19043545 rs204057 chr1 29272057 C A 1.82E-04 Birth weight EPB41 intron 17255346 rs1038493 chr1 29288078 A G 4.55E-05 Response to statin treatment (atorvastatin),change in cholesterol levels EPB41 intron 20031582 rs2985334 chr1 29345027 T G 3.50E-05 Sleep and circadian phenotypes EPB41 intron 17903308 rs2985334 chr1 29345027 T G 6.00E-06 Amyotrophic lateral sclerosis (sporadic) EPB41 intron 24529757 rs2788890 chr1 29352653 G C 6.05E-04 Response to statin treatment (atorvastatin),change in cholesterol levels EPB41 intron 20031582 rs4654388 chr1 29397790 A G 5.75E-04 Multiple complex diseases EPB41 intron 17554300 rs2503015 chr1 29407230 T A 7.33E-04 Response to statin treatment (atorvastatin),change in cholesterol levels EPB41 intron 20031582 rs2254241 chr1 29418033 A G 2.19E-04 Response to statin treatment (atorvastatin),change in cholesterol levels EPB41 intron 20031582 rs12039988 chr1 29425833 G A 8.63E-04 Tourette syndrome EPB41 intron 22889924 rs12045777 chr1 29429004 C T 2.43E-04 Sleep time EPB41 intron 23728906 rs578800 chr1 29437106 G A 1.68E-04 Multiple complex diseases EPB41 intron 17554300 rs1994859 chr1 29497820 C T 1.05E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SRSF4 intron 20031582 rs3094740 chr1 29507647 G C 9.25E-04 Multiple complex diseases SRSF4 intron 17554300 rs1128400 chr1 29542637 A G 8.80E-05 Response to statin treatment (atorvastatin),change in cholesterol levels MECR missense 20031582 rs2640467 chr1 29556158 T C 4.72E-05 Amyotrophic lateral sclerosis (sporadic) MECR intron 24529757 rs12057666 chr1 29571758 T G 2.13E-04 Multiple complex diseases PTPRU intron 17554300 rs1032425 chr1 29575605 C A 3.79E-04 Amyotrophic lateral sclerosis (sporadic) PTPRU intron 24529757 rs7550930 chr1 29594563 T C 8.03E-06 Asthma PTPRU intron 21790008 rs7518159 chr1 29621460 C T 1.72E-07 Multiple complex diseases PTPRU intron 17554300 rs9426315 chr1 29625375 G A 2.32E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PTPRU intron 20031582 rs3737606 chr1 29630956 A G 5.24E-05 Bipolar disorder and schizophrenia PTPRU intron 20889312 rs12735793 chr1 29636976 G A 1.60E-06 Primary sclerosing cholangitis PTPRU intron 21151127 rs1997865 chr1 29643881 T A 2.50E-05 Urinary metabolites PTPRU intron 21572414 rs761429 chr1 29678592 G A 7.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs761430 chr1 29678774 C A 3.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4654339 chr1 29742743 T C 0.00004661 Sarcoidosis / / 22952805 rs6426360 chr1 29743391 T C 0.00002399 Sarcoidosis / / 22952805 rs6657309 chr1 29743408 A G 0.0000793 Sarcoidosis / / 22952805 rs1408857 chr1 29743630 C T 0.000007098 Sarcoidosis / / 22952805 rs10799133 chr1 29745602 A G 0.00002337 Sarcoidosis / / 22952805 rs4431811 chr1 29746380 A G 0.00006519 Sarcoidosis / / 22952805 rs6686991 chr1 29747162 G T 0.00006337 Sarcoidosis / / 22952805 rs10753338 chr1 29747573 A C 0.00003257 Sarcoidosis / / 22952805 rs9426341 chr1 29747979 G T 0.00001326 Sarcoidosis / / 22952805 rs6700562 chr1 29748777 C T 0.00006355 Sarcoidosis / / 22952805 rs2182112 chr1 29749659 T C 0.00001413 Sarcoidosis / / 22952805 rs2147782 chr1 29749776 T C 0.0000468 Sarcoidosis / / 22952805 rs1408863 chr1 29750255 A G 0.00008708 Sarcoidosis / / 22952805 rs1408862 chr1 29750448 T C 0.00008833 Sarcoidosis / / 22952805 rs9426445 chr1 29752947 A G 0.00005496 Sarcoidosis / / 22952805 rs10915268 chr1 29753610 G A 3.10E-06 Urinary metabolites / / 21572414 rs977497 chr1 29754433 A G 0.00004048 Sarcoidosis / / 22952805 rs10915272 chr1 29754708 G A 2.40E-06 Urinary metabolites / / 21572414 rs1359465 chr1 29756066 C T 0.00002194 Sarcoidosis / / 22952805 rs10915275 chr1 29761294 G T 0.00007444 Sarcoidosis / / 22952805 rs2182111 chr1 29764800 A T 0.00006852 Sarcoidosis / / 22952805 rs4654355 chr1 29794279 G A 4.95E-05 Serum metabolites / / 19043545 rs6426365 chr1 29806634 A G 3.53E-04 Schizophrenia / / 19197363 rs6664690 chr1 29827798 C T 6.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12069708 chr1 29854675 A C 3.88E-04 Alzheimer's disease / / 17998437 rs12071830 chr1 29854740 T G 6.67E-04 Alzheimer's disease / / 17998437 rs7547083 chr1 29859057 G A 4.27E-04 Alzheimer's disease / / 17998437 rs6426342 chr1 29859764 G C 6.06E-04 Alzheimer's disease / / 17998437 rs10914282 chr1 30062973 G A 8.99E-04 Multiple complex diseases / / 17554300 rs1932397 chr1 30063197 C T 7.10E-05 Type 2 diabetes / / 17463248 rs1932397 chr1 30063197 C T 5.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs6603927 chr1 30064009 A G 2.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs6603926 chr1 30066155 A G 7.00E-05 Type 2 diabetes / / 17463248 rs6603926 chr1 30066155 A G 6.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs9660251 chr1 30068857 T C 1.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs9662524 chr1 30070403 G C 7.30E-05 Type 2 diabetes / / 17463248 rs9662524 chr1 30070403 G C 4.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs915409 chr1 30071270 T C 7.30E-05 Type 2 diabetes / / 17463248 rs915409 chr1 30071270 T C 3.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs4949306 chr1 30072549 A G 6.06E-05 Suicide attempts in bipolar disorder / / 21423239 rs1932392 chr1 30074983 T C 3.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs9286938 chr1 30077101 T C 9.10E-05 Type 2 diabetes / / 17463248 rs9286938 chr1 30077101 T C 4.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs9659523 chr1 30077600 A C 1.00E-04 Type 2 diabetes / / 17463248 rs9659523 chr1 30077600 A C 1.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs4949293 chr1 30078801 T C 3.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs436400 chr1 30079888 T A 3.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs4949178 chr1 30081323 G A 2.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs4949291 chr1 30081359 C T 2.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs271306 chr1 30082664 G C 1.00E-04 Type 2 diabetes / / 17463248 rs271306 chr1 30082664 G C 2.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs10798895 chr1 30086662 G A 3.30E-05 Type 2 diabetes / / 17460697 rs10798895 chr1 30086662 G A 2.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs4949283 chr1 30090260 A G 8.54E-05 Suicide attempts in bipolar disorder / / 21423239 rs2044073 chr1 30093697 G T 2.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs2044072 chr1 30093908 G A 3.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs16832700 chr1 30094324 C T 8.44E-04 Multiple complex diseases / / 17554300 rs4949611 chr1 30103858 G A 4.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs502545 chr1 30109482 G A 5.56E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs9442466 chr1 30111858 C T 6.60E-04 Myopia (pathological) / / 21095009 rs271327 chr1 30115843 A G 4.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs175249 chr1 30116035 C G 4.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs692787 chr1 30117517 A G 6.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs271385 chr1 30119005 T C 7.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs271383 chr1 30120287 A C 3.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs271372 chr1 30126979 A G 6.50E-04 Type 2 diabetes / / 17463246 rs271372 chr1 30126979 A G 7.40E-06 Urinary metabolites / / 21572414 rs187954 chr1 30134604 C A 8.65E-06 Alcohol and nictotine co-dependence / / 20158304 rs175250 chr1 30134671 T C 5.14E-04 Type 2 diabetes / / 17463246 rs271364 chr1 30136721 C T 3.83E-04 Type 2 diabetes / / 17463246 rs271364 chr1 30136721 C T 9.80E-06 Urinary metabolites / / 21572414 rs166604 chr1 30148652 T C 2.60E-04 Type 2 diabetes / / 17463246 rs520527 chr1 30149566 T C 2.73E-04 Type 2 diabetes / / 17463246 rs271351 chr1 30152120 G A,C,T 9.17E-04 Multiple complex diseases / / 17554300 rs4259710 chr1 30184426 A G 5.03E-04 Multiple complex diseases / / 17554300 rs1866967 chr1 30185662 A G 3.49E-05 Pulmonary function / / 19300500 rs1866967 chr1 30185662 A G 5.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs4949268 chr1 30186956 T C 8.03E-05 Pulmonary function / / 19300500 rs6673417 chr1 30188608 T C 7.94E-05 Pulmonary function / / 19300500 rs17262657 chr1 30191649 T C 3.39E-05 Pulmonary function / / 19300500 rs10914271 chr1 30213840 T C 8.05E-05 Height / / pha003010 rs10914271 chr1 30213840 T C 4.99E-05 Height / / pha003011 rs920600 chr1 30222525 A G 5.31E-05 Height / / pha003010 rs920600 chr1 30222525 A G 3.03E-05 Height / / pha003011 rs12045312 chr1 30234753 A G 5.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12145316 chr1 30245413 C T 6.30E-05 Height / / pha003011 rs6691847 chr1 30265652 T C 7.00E-06 Non-alcoholic fatty liver disease / / 23535911 rs10914475 chr1 30278550 C T 4.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs2166884 chr1 30288207 G A 1.53E-04 Schizophrenia / / 19197363 rs12748731 chr1 30301308 T C 8.61E-06 IgE levels / / 17255346 rs12145293 chr1 30314005 A G 3.89E-04 Smoking initiation / / 24665060 rs12145156 chr1 30318156 G T 4.43E-04 Smoking initiation / / 24665060 rs921197 chr1 30319889 G A 8.03E-04 Schizophrenia / / 19197363 rs7512834 chr1 30322046 C T 3.69E-04 Schizophrenia / / 19197363 rs12134222 chr1 30348925 C A 3.77E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2197783 chr1 30359165 T C 3.65E-04 Type 2 diabetes / / 17463246 rs1001709 chr1 30359862 G A 5.50E-07 Urinary metabolites / / 21572414 rs12090063 chr1 30360122 C T 9.45E-04 Alzheimer's disease / / 22005930 rs10798921 chr1 30399109 A G 7.45E-04 Multiple complex diseases / / 17554300 rs4949232 chr1 30410502 A C 1.98E-06 Major depressive disorder / / 22472876 rs16833076 chr1 30414182 T G 1.70E-05 Urinary metabolites / / 21572414 rs16833076 chr1 30414182 T G 3.02E-05 Major depressive disorder / / 22472876 rs1498243 chr1 30415026 G A 3.89E-05 Major depressive disorder / / 22472876 rs1354366 chr1 30415774 G C 2.15E-04 Type 2 diabetes / / 17463246 rs10798928 chr1 30417560 C T 2.00E-04 Type 2 diabetes / / 17463246 rs11583644 chr1 30419370 G A 4.41E-04 Type 2 diabetes / / 17463246 rs4949522 chr1 30420739 A G 6.52E-04 Type 2 diabetes / / 17463246 rs4949237 chr1 30420873 T C 2.45E-04 Type 2 diabetes / / 17463246 rs4949238 chr1 30422596 A G 3.20E-05 Major depressive disorder / / 22472876 rs10914667 chr1 30423829 T A 2.22E-04 Type 2 diabetes / / 17463246 rs12407717 chr1 30426014 C T 4.00E-05 Major depressive disorder / / 21042317 rs12407717 chr1 30426014 C T 1.20E-06 Major depressive disorder / / 22472876 rs267700 chr1 30430366 T G 3.11E-06 Bipolar disorder and schizophrenia / / 20889312 rs1009080 chr1 30431560 G A 8.50E-07 Bipolar disorder and schizophrenia / / 20889312 rs1009080 chr1 30431560 G A 3.00E-06 Schizophrenia / / 21926974 rs4949526 chr1 30432219 T C 4.00E-07 Bipolar disorder and schizophrenia / / 20889312 rs4949526 chr1 30432219 T C 0.000111 Schizophrenia / / 23637625 rs6694545 chr1 30437268 A G 1.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs6694545 chr1 30437268 A G 3.91E-04 Smoking cessation / / 24665060 rs12401298 chr1 30439760 A G 3.95E-05 Major depressive disorder / / 22472876 rs10753284 chr1 30445050 T C 3.25E-04 Smoking cessation / / 24665060 rs904300 chr1 30459412 T C 7.64E-04 Smoking cessation / / 24665060 rs4949241 chr1 30459797 G A 9.93E-05 Major depressive disorder / / 22472876 rs409226 chr1 30472960 A G 5.46E-05 Heart Rate / / pha003053 rs452132 chr1 30478996 A G 3.35E-05 Heart Rate / / pha003053 rs404170 chr1 30485741 A G 6.23E-05 Suicide attempts in bipolar disorder / / 21423239 rs397310 chr1 30486849 C A 5.33E-05 Suicide attempts in bipolar disorder / / 21423239 rs387055 chr1 30486853 A G 7.31E-05 Suicide attempts in bipolar disorder / / 21423239 rs373073 chr1 30491129 G A 5.77E-05 Suicide attempts in bipolar disorder / / 21423239 rs267721 chr1 30496978 A G 6.69E-05 Suicide attempts in bipolar disorder / / 21423239 rs267720 chr1 30497242 G T 6.68E-05 Suicide attempts in bipolar disorder / / 21423239 rs12732511 chr1 30501138 C T 6.43E-05 Suicide attempts in bipolar disorder / / 21423239 rs12140391 chr1 30506347 C T 1.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs17341620 chr1 30508461 G A 5.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs12145453 chr1 30513725 T C 8.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs2860031 chr1 30525714 A G 3.00E-06 Bipolar disorder (mood-incongruent) / / 23092984 rs11580589 chr1 30529289 A G 9.29E-06 Bipolar disorder / / 19488044 rs11580589 chr1 30529289 A G 1.35E-05 Bipolar disorder and schizophrenia / / 20889312 rs11580589 chr1 30529289 A G 2.48E-05 Bipolar Disorder / / pha002858 rs11580622 chr1 30529446 A C 7.24E-05 Bipolar disorder and schizophrenia / / 20889312 rs391479 chr1 30530885 T C 2.35E-05 Bipolar disorder and schizophrenia / / 20889312 rs433112 chr1 30531039 T C 1.10E-05 Bipolar disorder and schizophrenia / / 20889312 rs391725 chr1 30532738 C A 1.33E-05 Bipolar disorder and schizophrenia / / 20889312 rs419527 chr1 30532849 T G 1.33E-05 Bipolar disorder and schizophrenia / / 20889312 rs16833203 chr1 30533883 C T 5.53E-04 Nicotine dependence / / 17158188 rs746758 chr1 30536711 T C 3.19E-05 Bipolar disorder and schizophrenia / / 20889312 rs369715 chr1 30554684 G A 5.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs12755901 chr1 30561353 G A 0.000094 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6670744 chr1 30561697 C G 0.0000991 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11584193 chr1 30565805 G C 0.0000872 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs61759065 chr1 30565900 A T 0.0000943 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs910696 chr1 30567596 G A 3.00E-06 Smoking behavior / / 19247474 rs2076977 chr1 30574158 T C 1.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs2376909 chr1 30574667 T G 1.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs12088570 chr1 30575319 C T 9.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs12742458 chr1 30576573 T C 5.40E-05 Endometriosis / / 21151130 rs10915026 chr1 30578274 C T 0.0000786 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10915029 chr1 30578922 C T 5.26E-04 Multiple complex diseases / / 17554300 rs12122307 chr1 30606563 G A 0.0007337 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12122307 chr1 30606563 G A 7.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2180233 chr1 30627712 C T 9.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs6425881 chr1 30659586 G A 2.02E-05 Cognitive impairment induced by topiramate / / 22091778 rs7523165 chr1 30660403 A G 7.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs12072928 chr1 30660839 T G 3.99E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs10915040 chr1 30663554 A G 4.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs16833396 chr1 30687128 C A 4.13E-05 Body Mass Index / / pha003007 rs13375139 chr1 30691713 C T 6.94E-05 Alcohol consumption / / 23743675 rs59765152 chr1 30691817 C T 6.03E-05 Alcohol consumption / / 23743675 rs2142714 chr1 30692598 G A 6.69E-04 Smoking cessation / / 24665060 rs2142713 chr1 30692648 T C 6.54E-04 Smoking cessation / / 24665060 rs11806668 chr1 30694698 C T 3.76E-05 Body Mass Index / / pha003007 rs11806668 chr1 30694698 C T 8.44E-05 Body Mass Index / / pha003015 rs2179163 chr1 30709045 C T 6.72E-04 Smoking cessation / / 24665060 rs58267302 chr1 30731997 T C 5.75E-05 Alcohol consumption / / 23743675 rs459233 chr1 30750679 A G 3.86E-04 Aortic root size / / 21223598 rs376299 chr1 30754821 T G 5.29E-06 Intelligence / / 21826061 rs58245 chr1 30755532 G A 1.34E-06 Intelligence / / 21826061 rs463128 chr1 30759956 T C 2.65E-05 Intelligence / / 21826061 rs463128 chr1 30759956 T C 7.23E-04 Heart Failure / / pha002884 rs460911 chr1 30761304 G A 2.29E-05 Intelligence / / 21826061 rs411238 chr1 30787227 G A 5.87E-05 Intelligence / / 21826061 rs411238 chr1 30787227 G A 8.52E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs411238 chr1 30787227 G A 9.70E-05 Heart Failure / / pha002884 rs117311 chr1 30789341 C A 3.27E-04 Alzheimer's disease / / 17998437 rs437709 chr1 30792212 G A 4.19E-05 Triglycerides / / pha002904 rs6688031 chr1 30802598 C T 7.97E-04 Multiple complex diseases / / 17554300 rs10799104 chr1 30883503 C T 3.77E-04 Multiple complex diseases / / 17554300 rs11577262 chr1 30918166 T C 4.01E-04 Endometrial cancer / / 24096698 rs11577262 chr1 30918166 T C 7.90E-05 Endometrial cancer / / 24096698 rs454774 chr1 30923203 G T 2.10E-05 Malaria / / 19465909 rs262603 chr1 30941636 A C 2.74E-04 Multiple complex diseases / / 17554300 rs262584 chr1 30946775 C A 2.42E-04 Taste perception / / 22132133 rs12408702 chr1 30975928 C T 3.40E-06 Urinary metabolites / / 21572414 rs16833790 chr1 30980131 A G 4.20E-06 Urinary metabolites / / 21572414 rs3104429 chr1 30985076 T C 1.50E-05 Urinary metabolites / / 21572414 rs72650565 chr1 30993931 T C 9.07E-06 Stroke (ischemic) / / 21957438 rs6692098 chr1 30998096 A C 2.19E-04 Multiple complex diseases / / 17554300 rs4949613 chr1 31006103 A G 2.47E-04 Multiple complex diseases / / 17554300 rs51397 chr1 31013775 T C 8.97E-04 Body mass index / / 21701565 rs1484837 chr1 31017683 C T 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs904257 chr1 31022237 A G 2.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs3104434 chr1 31023291 G T 4.97E-04 Smoking initiation / / 24665060 rs2377368 chr1 31024967 G A 7.94E-04 Type 2 diabetes / / 17463246 rs3104425 chr1 31034663 C T 2.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs530973 chr1 31062295 C T 8.93E-05 Dengue shock syndrome / / 22001756 rs609015 chr1 31070154 A G 7.19E-04 Multiple complex diseases / / 17554300 rs6426041 chr1 31074793 T G 6.14E-06 Serum metabolites / / 19043545 rs633832 chr1 31081441 G A 5.13E-04 Multiple complex diseases / / 17554300 rs544789 chr1 31083478 A G 3.01E-04 Multiple complex diseases / / 17554300 rs1188446 chr1 31163456 A G 3.76E-04 Body mass index / / 21701565 rs1188445 chr1 31163876 G A 1.10E-05 Obesity-related traits / / 17658951 rs1188444 chr1 31164624 T C 8.27E-04 White matter integrity / / 22425255 rs716486 chr1 31167561 G A 1.90E-06 Urinary metabolites / / 21572414 rs1033867 chr1 31167998 T C 3.97E-05 Longevity / / 20304771 rs1149023 chr1 31176942 G T 9.93E-04 Multiple complex diseases / / 17554300 rs912218 chr1 31180714 G A 7.03E-04 Type 2 diabetes / / 17463246 rs4949290 chr1 31203860 G A 2.36E-05 Colorectal cancer / / 21242260 rs3795437 chr1 31206806 T C 8.09E-05 Longevity LAPTM5 intron 20304771 rs12404920 chr1 31206957 T C 7.88E-05 Longevity LAPTM5 intron 20304771 rs10914189 chr1 31207781 C T 6.26E-04 Smoking initiation LAPTM5 intron 24665060 rs1188349 chr1 31223657 G A 5.00E-04 Acute lymphoblastic leukemia (childhood) LAPTM5 intron 20189245 rs12063364 chr1 31272051 A G 2.37E-04 Osteoarthritis / / 19508968 rs2377570 chr1 31298769 A G 0.000063 Primary sclerosing cholangitis / / 22521342 rs4949316 chr1 31315593 G C 9.00E-06 Metabolite levels (5-HIAA) / / 23319000 rs2488230 chr1 31320651 G A 3.63E-05 Prostate cancer / / 22923026 rs3935266 chr1 31330844 G A 9.68E-05 Prostate cancer / / 22923026 rs947643 chr1 31461438 G A 2.17E-04 Type 2 diabetes PUM1 intron 17463246 rs7536851 chr1 31471702 A C 2.29E-05 Systemic lupus erythematosus PUM1 intron pha002867 rs10753241 chr1 31490614 A G 2.20E-05 Systemic lupus erythematosus PUM1 intron pha002867 rs10753242 chr1 31494475 T G 2.16E-05 Systemic lupus erythematosus PUM1 intron pha002867 rs6694709 chr1 31520472 A C 7.75E-04 Tourette syndrome PUM1 intron 22889924 rs7526662 chr1 31539051 A G 1.86E-05 Systemic lupus erythematosus / / pha002867 rs11577241 chr1 31647583 G C 2.95E-04 Depression (quantitative trait) / / 20800221 rs2066163 chr1 31650749 A G 2.92E-04 Depression (quantitative trait) / / 20800221 rs4949356 chr1 31653988 A G 2.91E-04 Depression (quantitative trait) NKAIN1 UTR-3 20800221 rs6425715 chr1 31658678 A G 2.89E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs6693735 chr1 31659496 C G 5.26E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs2377717 chr1 31673263 C T 7.79E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs4949197 chr1 31676938 A G 9.22E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs10798827 chr1 31682312 T G 8.72E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs2889710 chr1 31682380 G A 5.03E-04 Response to cytidine analogues (gemcitabine) NKAIN1 intron 24483146 rs10753244 chr1 31683500 A G 6.74E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs10798828 chr1 31683890 C T 7.23E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs12033154 chr1 31686085 A G 6.69E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs6699372 chr1 31704333 G A 9.47E-04 Coronary Artery Disease NKAIN1 intron 17634449 rs17440445 chr1 31722562 A G 7.84E-05 Multiple complex diseases / / 17554300 rs17440445 chr1 31722562 A G 6.19E-04 Taste perception / / 22132133 rs7515867 chr1 31724744 T C 5.83E-05 Multiple complex diseases / / 17554300 rs7515988 chr1 31731061 A G 2.59E-06 Multiple complex diseases / / 17554300 rs10753245 chr1 31731208 T C 1.16E-04 Multiple complex diseases / / 17554300 rs12725881 chr1 31736123 T C 9.55E-05 Multiple complex diseases SNRNP40 intron 17554300 rs41412349 chr1 31769752 T G 1.41E-04 Multiple complex diseases / / 17554300 rs6696341 chr1 31782052 A G 7.82E-04 Taste perception ZCCHC17 intron 22132133 rs6679365 chr1 31787866 G T 6.34E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs7523438 chr1 31788313 A G 6.26E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs7556340 chr1 31788453 T A 2.94E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs10914355 chr1 31796985 G A 3.82E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs10798845 chr1 31822636 G A 4.29E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs4949389 chr1 31824023 G A 2.74E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs3795432 chr1 31829873 C T 9.66E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs4949391 chr1 31833706 G T 2.88E-04 Multiple complex diseases ZCCHC17 intron 17554300 rs17495262 chr1 31837632 C T 2.63E-04 Multiple complex diseases ZCCHC17 UTR-3 17554300 rs7523777 chr1 31839136 A G 0.0000017 Cholesterol,total FABP3 intron 23063622 rs11578034 chr1 31842153 C T 3.36E-04 Iron levels FABP3 intron pha002876 rs951545 chr1 31844665 G A 4.86E-04 Multiple complex diseases FABP3 intron 17554300 rs951545 chr1 31844665 G A 1.70E-05 Urinary metabolites FABP3 intron 21572414 rs6425744 chr1 31850657 A G 2.50E-05 Urinary metabolites / / 21572414 rs1995585 chr1 31855474 A G 2.84E-04 Multiple complex diseases / / 17554300 rs10914372 chr1 31857998 A G 4.83E-04 Iron levels / / pha002876 rs12122236 chr1 31858901 T C 2.84E-04 Multiple complex diseases / / 17554300 rs905929 chr1 31862917 G C 4.50E-06 Urinary metabolites / / 21572414 rs7534378 chr1 31863558 G A 5.21E-04 Multiple complex diseases / / 17554300 rs7534465 chr1 31863663 G A 3.85E-04 Multiple complex diseases / / 17554300 rs6659255 chr1 31869669 C T 0.000072 Carotid intima media thickness / / 23152477 rs1039630 chr1 31881472 T C 8.72E-05 Alcohol dependence SERINC2 nearGene-5 21703634 rs2839939 chr1 31881637 T C 7.80E-05 Multiple complex diseases SERINC2 nearGene-5 17554300 rs4478858 chr1 31883925 T C 8.96E-05 Alcohol dependence SERINC2 intron 21703634 rs4478858 chr1 31883925 T C 3.00E-08 Alcohol dependence SERINC2 intron 23455491 rs1934290 chr1 31884180 T C 1.40E-04 Multiple complex diseases SERINC2 intron 17554300 rs12037108 chr1 31895394 T C 5.93E-04 Multiple complex diseases SERINC2 intron 17554300 rs4949402 chr1 31898234 T C 9.44E-05 Alcohol dependence SERINC2 cds-synon 21703634 rs2275435 chr1 31898536 C T 9.53E-05 Alcohol dependence SERINC2 intron 21703634 rs7548985 chr1 31915981 C T 3.08E-04 Multiple complex diseases / / 17554300 rs4261154 chr1 31921862 G A 7.25E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10798854 chr1 31934343 G A 3.63E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4949419 chr1 31977336 A G 1.40E-05 Multiple complex diseases / / 17554300 rs10914424 chr1 31980298 C T 5.89E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10914427 chr1 31982584 G A 8.91E-04 Response to cytidine analogues (gemcitabine) LOC284551 nearGene-5 24483146 rs6667261 chr1 31992493 T C 6.18E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6669615 chr1 31997793 C T 9.57E-04 Multiple complex diseases / / 17554300 rs12125499 chr1 32000490 G T 1.20E-05 Cognitive performance / / 19734545 rs12125499 chr1 32000490 G T 8.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs4949437 chr1 32012283 T C 8.25E-04 Coronary Artery Disease / / 17634449 rs6425775 chr1 32034245 A C 0.00063 Salmonella-induced pyroptosis / / 22837397 rs10914446 chr1 32054094 A C 2.65E-04 Type 2 diabetes / / 17463246 rs4949448 chr1 32062066 G T 2.36E-04 Type 2 diabetes / / 17463246 rs6681414 chr1 32070234 G A 2.47E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2271933 chr1 32092525 A G 8.29E-04 Type 2 diabetes HCRTR1 missense 17463246 rs2271933 chr1 32092525 A G 9.80E-05 Speech perception in dyslexia HCRTR1 missense 19786962 rs10798882 chr1 32108547 C G 6.99E-04 Type 2 diabetes PEF1 intron 17463246 rs7524405 chr1 32108579 C A 6.62E-04 Type 2 diabetes PEF1 intron 17463246 rs4949455 chr1 32114793 G A 4.32E-04 Type 2 diabetes / / 17463246 rs909002 chr1 32139635 C T 9.30E-04 Type 2 diabetes COL16A1 intron 17463246 rs4949458 chr1 32142332 T G 4.67E-05 Pulmonary function COL16A1 intron 20010835 rs4949459 chr1 32142354 G T 2.22E-05 Pulmonary function COL16A1 intron 20010835 rs2297679 chr1 32157009 G T 3.00E-05 Educational attainment COL16A1 intron 21694764 rs12040661 chr1 32209650 G A 8.13E-04 Taste perception BAI2 intron 22132133 rs10914477 chr1 32240262 G A 3.68E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs8179509 chr1 32273434 A G 5.69E-04 Smoking initiation SPOCD1 intron 24665060 rs16834735 chr1 32276442 C T 6.26E-05 Orofacial clefts SPOCD1 intron 20023658 rs11589992 chr1 32300130 T C 3.65E-05 Serum metabolites / / 19043545 rs16834744 chr1 32312698 T G 5.80E-04 Multiple complex diseases / / 17554300 rs7521293 chr1 32315551 C A 2.20E-06 Urinary metabolites / / 21572414 rs671101 chr1 32336098 A G 1.70E-04 Myasthenia gravis / / 23055271 rs671101 chr1 32336098 A G 7.83E-05 Alcohol consumption / / 23953852 rs682654 chr1 32371523 C A 2.36E-06 Alcohol consumption / / 23953852 rs639233 chr1 32372881 C T 2.06E-06 Alcohol consumption PTP4A2 UTR-3 23953852 rs563978 chr1 32390324 C T 2.08E-05 Tunica Media PTP4A2 intron pha003037 rs591833 chr1 32397890 G A 1.98E-06 Alcohol consumption PTP4A2 intron 23953852 rs646370 chr1 32401166 A G 4.06E-05 Alcohol consumption PTP4A2 intron 23953852 rs680327 chr1 32438231 A G 0.000622 Height (Pygmy height) / / 22570615 rs680328 chr1 32438234 A G 0.000622 Height (Pygmy height) / / 22570615 rs16834895 chr1 32602531 A C 6.95E-04 Multiple complex diseases KP/6 intron 17554300 rs6425793 chr1 32668428 A G 9.63E-06 Anorexia nervosa CCDC28B intron 23568457 rs12032332 chr1 32672932 G A 1.60E-05 Schizophrenia IQCC missense 19571808 rs747020 chr1 32697934 G A 6.98E-04 Coronary Artery Disease MTMR9LP intron 17634449 rs747020 chr1 32697934 G A 7.54E-04 Schizophrenia MTMR9LP intron 19197363 rs747020 chr1 32697934 G A 8.20E-06 Schizophrenia MTMR9LP intron 19571808 rs747020 chr1 32697934 G A 1.40E-05 Urinary metabolites MTMR9LP intron 21572414 rs587707 chr1 32699227 T C 4.15E-04 Multiple complex diseases MTMR9LP intron 17554300 rs669538 chr1 32711360 C T 0.00042 Endometrial cancer / / 22426144 rs16834954 chr1 32784954 T C 1.27E-04 Multiple complex diseases HDAC1 intron 17554300 rs7532909 chr1 32826793 T C 8.22E-04 Multiple complex diseases / / 17554300 rs2270537 chr1 32829281 G A 4.00E-05 HIV-1 control TSSK3 cds-synon 20041166 rs11588497 chr1 33030461 A G 2.21E-05 Height ZBTB8A intron pha003010 rs11588497 chr1 33030461 A G 9.53E-06 Height ZBTB8A intron pha003011 rs359955 chr1 33134774 A C 2.27E-05 Coronary heart disease RBBP4 intron pha003056 rs696626 chr1 33195429 G A 7.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs699006 chr1 33199367 C G 7.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs4951771 chr1 33233223 C T 9.32E-04 Multiple complex diseases KIAA1522 intron 17554300 rs881393 chr1 33256645 G C 2.73E-04 Multiple complex diseases YARS intron 17554300 rs10914621 chr1 33277080 C T 1.59E-04 Multiple complex diseases YARS intron 17554300 rs12760548 chr1 33280648 T G 2.73E-04 Multiple complex diseases YARS intron 17554300 rs61739743 chr1 33292008 G A 0.00025 Prostate cancer S100PBP missense 23555315 rs16835198 chr1 33326681 G T 2.19E-04 Multiple complex diseases / / 17554300 rs11811702 chr1 33350183 G A 5.82E-06 Multiple sclerosis / / 19525953 rs1284373 chr1 33355923 C T 6.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HPCA intron 20877124 rs7527330 chr1 33380108 T G 7.64E-04 HIV-1 viral setpoint / / 17641165 rs194655 chr1 33421461 T C 4.17E-04 Multiple complex diseases RNF19B intron 17554300 rs10914658 chr1 33530750 G A 6.06E-15 Gender / / 22362730 rs638130 chr1 33585070 A G 1.97E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) ADC intron 24192120 rs654947 chr1 33599915 T C 1.90E-05 Urinary metabolites / / 21572414 rs689187 chr1 33611890 C A,G,T 8.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRIM62 UTR-3 20877124 rs3912145 chr1 33614162 T C 1.40E-04 Iris characteristics TRIM62 intron 21835309 rs676069 chr1 33622077 T C 7.10E-04 Alcohol dependence TRIM62 intron 21314694 rs587042 chr1 33638736 C T 8.81E-05 Hypertension (early onset hypertension) TRIM62 intron 22479346 rs587910 chr1 33643361 A G 2.40E-05 Urinary metabolites TRIM62 intron 21572414 rs636561 chr1 33645971 C T 9.80E-06 Urinary metabolites TRIM62 intron 21572414 rs9729837 chr1 33673559 T G 6.51E-05 Coronary Artery Disease / / 17634449 rs6425809 chr1 33702965 G C 4.38E-04 Multiple complex diseases / / 17554300 rs4653002 chr1 33770526 T C 0.000689932 Hypertension (early onset hypertension) / / 22479346 rs10914692 chr1 33832933 G A 0.000525414 Hypertension (early onset hypertension) PHC2 missense 22479346 rs12127097 chr1 33850890 T C 6.68E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs6661037 chr1 33872593 T C 2.21E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs1998623 chr1 33893290 G A 6.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4653135 chr1 33893830 C T 5.92E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs12032996 chr1 33920586 G A 7.10E-06 Urinary metabolites / / 21572414 rs12565140 chr1 33928758 T C 3.00E-07 Estradiol plasma levels (breast cancer) / / 23518928 rs4653152 chr1 33931116 G A 3.88E-05 Prostate cancer / / pha002878 rs10798953 chr1 33937135 T C 2.04E-05 Alcohol dependence / / 19581569 rs16835496 chr1 33938845 A G 9.09E-04 Response to cytidine analogues (gemcitabine) ZSCAN20 intron 24483146 rs10798959 chr1 33983019 C T 8.00E-06 Metabolite levels (HVA/MHPG ratio) CSMD2 intron 23319000 rs12751162 chr1 34014134 C A 1.26E-05 Common variable immunodeficiency CSMD2 intron 21497890 rs915108 chr1 34023749 T C 5.88E-05 Lung cancer CSMD2 intron 18978787 rs6701268 chr1 34041191 T G 2.20E-04 Alcohol dependence CSMD2 intron 20201924 rs6701268 chr1 34041191 T G 1.43E-04 Schizophrenia CSMD2 intron 21747397 rs6425830 chr1 34044616 A G 6.40E-06 Urinary metabolites CSMD2 intron 21572414 rs416391 chr1 34048268 C T 3.40E-04 Alcohol dependence CSMD2 intron 20201924 rs416391 chr1 34048268 C T 4.00E-05 Alcohol dependence CSMD2 intron 20201924 rs416391 chr1 34048268 C T 3.99E-05 Alcoholism CSMD2 intron pha002892 rs1493988 chr1 34068364 G T 8.80E-04 Alzheimer's disease CSMD2 intron 22005930 rs564148 chr1 34173820 C T 9.00E-06 Response to amphetamines CSMD2 intron 22952603 rs612279 chr1 34173973 A G 8.91E-06 Response to amphetamines CSMD2 intron 22952603 rs570408 chr1 34174424 G A 8.03E-06 Response to amphetamines CSMD2 intron 22952603 rs16835742 chr1 34180842 G T 8.00E-08 Intelligence CSMD2 intron 22449649 rs7533254 chr1 34181830 G A 9.45E-04 Alcohol dependence CSMD2 intron 21314694 rs667892 chr1 34189552 C T 6.03E-06 Prion diseases CSMD2 intron 22210626 rs555733 chr1 34194736 T C 4.34E-05 Prion diseases CSMD2 intron 22210626 rs508796 chr1 34197058 T C 1.36E-05 Prion diseases CSMD2 intron 22210626 rs554862814 chr1 34203689 TACTC T 8.69E-06 Prion diseases CSMD2 intron 22210626 rs6661190 chr1 34203689 T C 8.69E-06 Prion diseases CSMD2 intron 22210626 rs512332 chr1 34206933 A G 2.02E-04 Response to cytadine analogues (cytosine arabinoside) CSMD2 intron 24483146 rs513049 chr1 34206979 G C 8.44E-04 Multiple complex diseases CSMD2 intron 17554300 rs475622 chr1 34207470 G A 1.12E-05 Prion diseases CSMD2 intron 22210626 rs1550545 chr1 34210087 G A 9.91E-06 Prion diseases CSMD2 intron 22210626 rs4578181 chr1 34210532 G A 9.47E-06 Prion diseases CSMD2 intron 22210626 rs9943159 chr1 34213077 A G 3.05E-06 Prion diseases CSMD2 intron 22210626 rs989661 chr1 34217931 C T 3.08E-04 Multiple complex diseases CSMD2 intron 17554300 rs474474 chr1 34238283 T C 0.00087 Prostate cancer CSMD2 missense 23555315 rs476463 chr1 34248064 G A 1.00E-06 Brain structure CSMD2 intron 20171287 rs717030 chr1 34249330 T C 5.37E-05 Lipoproteins CSMD2 intron pha003079 rs6425838 chr1 34254416 C T 6.04E-05 Cognitive test performance CSMD2 intron 20125193 rs545170 chr1 34256734 T C 3.32E-05 Body mass (lean) CSMD2 intron 19268274 rs10914782 chr1 34267945 T C 9.19E-05 Serum metabolites CSMD2 intron 19043545 rs12567192 chr1 34270994 T C 6.06E-04 Smoking quantity CSMD2 intron 24665060 rs10914783 chr1 34271055 G A 2.71E-06 Multiple complex diseases CSMD2 intron 17554300 rs10798993 chr1 34276880 A G 6.06E-04 Smoking quantity CSMD2 intron 24665060 rs10798994 chr1 34277174 T C 2.16E-04 Smoking quantity CSMD2 intron 24665060 rs11587451 chr1 34277979 A G 4.66E-04 Smoking quantity CSMD2 intron 24665060 rs3845473 chr1 34282691 G A 5.18E-05 Smoking quantity CSMD2 intron 24665060 rs3845476 chr1 34283894 A G 1.57E-04 Smoking quantity CSMD2 intron 24665060 rs3842834 chr1 34284118 G A 5.19E-04 Premature ovarian failure CSMD2 intron 19508998 rs3842834 chr1 34284118 G A 2.30E-04 Smoking quantity CSMD2 intron 24665060 rs12067054 chr1 34291676 C T 7.60E-05 Smoking quantity CSMD2 intron 24665060 rs3845477 chr1 34291836 A G 1.29E-04 Smoking quantity CSMD2 intron 24665060 rs10914789 chr1 34294874 T C 8.40E-04 Primary sclerosing cholangitis CSMD2 intron 19944697 rs6425850 chr1 34308585 T G 7.28E-04 Smoking initiation CSMD2 intron 24665060 rs746667 chr1 34312179 C G 7.78E-04 Alzheimer's disease CSMD2 intron 17998437 rs11542686 chr1 34329968 A G 1.40E-36 Health and aging,CVD and cancer age of onset HMGB4 missense 22174011 rs11542686 chr1 34329968 A G 3.00E-20 Health and aging,CVD and cancer age of onset HMGB4 missense 22174011 rs11542686 chr1 34329968 A G 4.00E-14 Health and aging,CVD and cancer age of onset HMGB4 missense 22174011 rs11542686 chr1 34329968 A G 6.80E-08 Health and aging,CVD and cancer age of onset HMGB4 missense 22174011 rs1321627 chr1 34331390 C G 6.43E-04 Alzheimer's disease CSMD2 intron 17998437 rs1108927 chr1 34333267 T G 7.79E-05 Cognitive impairment induced by topiramate CSMD2 intron 22091778 rs12122958 chr1 34340819 C G 7.76E-04 Multiple complex diseases CSMD2 intron 17554300 rs6425855 chr1 34346361 G T 3.99E-04 Smoking cessation CSMD2 intron 24665060 rs4653358 chr1 34349815 C A 4.67E-04 Smoking cessation CSMD2 intron 24665060 rs2281597 chr1 34359858 G C 5.00E-07 Attention deficit hyperactivity disorder CSMD2 intron 18839057 rs911216 chr1 34375199 A C 7.30E-04 Alcohol dependence CSMD2 intron 20201924 rs7536114 chr1 34379375 T G 1.20E-04 Alcohol dependence CSMD2 intron 20201924 rs12029535 chr1 34383662 T C 7.71E-04 Multiple complex diseases CSMD2 intron 17554300 rs12031839 chr1 34386710 A G 3.10E-06 Urinary metabolites CSMD2 intron 21572414 rs7555410 chr1 34394682 C A 4.13E-05 Lung function (forced expiratory volume in 1 second) CSMD2 intron 17255346 rs7555410 chr1 34394682 C A 5.56E-04 Suicide attempts in bipolar disorder CSMD2 intron 21423239 rs504471 chr1 34418942 A G 2.93E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) CSMD2 intron 23648065 rs7529498 chr1 34472274 T C 0.000802662 Hypertension (early onset hypertension) CSMD2 intron 22479346 rs504527 chr1 34473608 A C 3.20E-05 Lipid traits CSMD2 intron 17903299 rs2358756 chr1 34479922 T C 2.73E-05 Alcoholism CSMD2 intron pha002893 rs12563211 chr1 34486225 C T 6.55E-07 Post-operative nausea and vomiting CSMD2 intron 21694509 rs16836204 chr1 34486486 C T 4.30E-04 Type 2 diabetes CSMD2 intron 17463246 rs2118109 chr1 34490918 C T 6.41E-07 Post-operative nausea and vomiting CSMD2 intron 21694509 rs2164581 chr1 34491558 A G 6.82E-05 Alcoholism CSMD2 intron pha002893 rs10914850 chr1 34496094 T C 3.57E-04 Alzheimer's disease (late onset) CSMD2 intron 21379329 rs10914851 chr1 34496126 T C 3.57E-04 Alzheimer's disease (late onset) CSMD2 intron 21379329 rs12035502 chr1 34499772 C T 4.28E-04 Alzheimer's disease (late onset) CSMD2 intron 21379329 rs2625684 chr1 34505115 T C 7.65E-04 Alcohol consumption (maxi-drinks) CSMD2 intron 24277619 rs9426003 chr1 34602870 G A 4.93E-04 Amyotrophic lateral sclerosis (sporadic) CSMD2 intron 24529757 rs1335855 chr1 34648046 T C 5.80E-04 Type 2 diabetes C1orf94 intron 17463246 rs11584467 chr1 34665219 G A 8.00E-07 Urinary metabolites C1orf94 intron 21572414 rs12128858 chr1 34723928 T C 2.01E-05 Response to metformin / / 21186350 rs771404 chr1 34726167 G A,C,T 6.21E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12039643 chr1 34727726 G T 1.20E-05 Urinary metabolites / / 21572414 rs10914894 chr1 34734066 G A 3.42E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1414470 chr1 34736287 G A 3.00E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs880017 chr1 34741605 A G 2.07E-04 Kawasaki disease / / 21326860 rs771392 chr1 34748815 C G 1.64E-08 Corneal structure / / 22003120 rs771390 chr1 34750936 T C 6.00E-07 Epilepsy (generalized) / / 22949513 rs6704508 chr1 34756509 T G 2.17E-04 White matter integrity / / 22425255 rs11588801 chr1 34761911 T C 2.59E-04 White matter integrity / / 22425255 rs1404350 chr1 34764974 A C 4.66E-04 Heart Failure / / pha002884 rs7523842 chr1 34765880 T G 4.49E-04 Heart Failure / / pha002884 rs10732274 chr1 34790295 A G 5.84E-04 Heart Failure / / pha002884 rs1917247 chr1 34805625 C A 1.87E-04 Type 2 diabetes / / 17463246 rs6695784 chr1 34815393 A G 2.98E-04 Acute lung injury / / 22295056 rs2294193 chr1 34866656 C T 7.40E-04 White matter integrity / / 22425255 rs2092028 chr1 34872737 A G 2.35E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2092028 chr1 34872737 A G 7.00E-05 Lung function (forced vital capacity) / / 24023788 rs1883109 chr1 34892913 C A 8.92E-05 Potassium levels / / pha003086 rs17385253 chr1 34895009 T C 3.30E-05 Neuroticism / / 17667963 rs2142534 chr1 34900172 A G 9.16E-05 Myopia (pathological) / / 21095009 rs4653032 chr1 34902910 C A 1.82E-05 Asthma / / 23181788 rs10753308 chr1 34907148 A G 7.61E-04 Nicotine dependence / / 17158188 rs10489377 chr1 34915676 G A 0.0000836 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs67211730 chr1 34917267 T A 0.0000837 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10914952 chr1 34919213 G A 1.64E-04 Attention deficit hyperactivity disorder / / pha002875 rs2075933 chr1 34921075 C T 8.35E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1016091 chr1 34924596 C T 7.41E-04 Taste perception / / 22132133 rs4653040 chr1 34930403 G A 0.0000792 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs798076 chr1 34936568 G A 3.00E-04 Smoking quantity / / 24665060 rs10914956 chr1 34938132 C A 0.0000659 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs3845485 chr1 34985459 A G 1.63E-28 Narcolepsy / / 19629137 rs7556065 chr1 34988276 A T 7.78E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10914967 chr1 34989237 G A 6.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs4587532 chr1 34994991 C G 1.80E-05 Urinary metabolites / / 21572414 rs4653054 chr1 35009882 C T 2.10E-05 Urinary metabolites / / 21572414 rs6665029 chr1 35040991 T C 2.51E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs1886340 chr1 35069285 G A 1.11E-05 Coronary heart disease / / pha003030 rs12048230 chr1 35070977 G A 1.88E-04 Alzheimer's disease (late onset) / / 21460841 rs4653061 chr1 35072298 G A 4.77E-05 Coronary heart disease / / pha003030 rs10914991 chr1 35074860 A T 8.76E-05 Schizophrenia(age at onset) / / 21688384 rs12117895 chr1 35079250 G A 4.01E-05 Schizophrenia(age at onset) / / 21688384 rs2147384 chr1 35082968 A C 3.62E-05 Schizophrenia(age at onset) / / 21688384 rs7544557 chr1 35084074 T C 3.06E-05 Coronary heart disease / / pha003030 rs10799074 chr1 35087725 G A 1.57E-04 Alzheimer's disease (late onset) / / 21460841 rs4653067 chr1 35088484 C A 2.97E-05 Schizophrenia(age at onset) / / 21688384 rs2359631 chr1 35090073 T C 6.37E-05 Pancreatic cancer / / pha002889 rs7547341 chr1 35090895 A C 2.74E-04 Alzheimer's disease (late onset) / / 21460841 rs6667879 chr1 35094437 G A 5.14E-04 Acute lung injury / / 22295056 rs7548924 chr1 35095368 C T 5.56E-04 Acute lung injury / / 22295056 rs868501 chr1 35097520 C T 5.56E-04 Acute lung injury / / 22295056 rs612353 chr1 35113184 A G 9.05E-05 Attention deficit hyperactivity disorder / / pha002875 rs12048853 chr1 35119247 C T 8.14E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs725790 chr1 35148448 A C 0.00000693 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs41495144 chr1 35149756 G C 9.00E-04 Multiple complex diseases / / 17554300 rs10915020 chr1 35157716 T A 0.00000054 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs16836898 chr1 35159859 C T 0.000000728 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs16836900 chr1 35159912 T C 9.63E-04 Multiple complex diseases / / 17554300 rs12030047 chr1 35160305 A C 3.47E-04 Multiple complex diseases / / 17554300 rs1932768 chr1 35165972 G A 0.00000136 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs2145390 chr1 35283939 T C 1.85E-05 Formal thought disorder in schizophrenia / / 22648509 rs7526035 chr1 35289039 G A 9.00E-06 Formal thought disorder in schizophrenia / / 22648509 rs11264139 chr1 35303369 A G 8.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6703979 chr1 35315737 C T 3.00E-05 Lung cancer / / 18978790 rs7525948 chr1 35353904 G A 4.12E-04 Iron levels DLGAP3 intron pha002876 rs10493064 chr1 35369014 T A 1.00E-04 Information processing speed DLGAP3 intron 21130836 rs11263872 chr1 35446830 G A 1.50E-05 HIV-1 control / / 20041166 rs12407202 chr1 35462487 C T 1.50E-05 HIV-1 control ZMYM6 intron 20041166 rs2335466 chr1 35617631 A C 8.32E-04 Multiple complex diseases / / 17554300 rs1498111 chr1 35641608 A G 9.97E-04 Multiple complex diseases / / 17554300 rs11264112 chr1 35645343 A C 2.39E-04 Hearing function / / 17255346 rs11264112 chr1 35645343 A C 2.58E-04 Multiple complex diseases / / 17554300 rs3738694 chr1 35648316 C T 2.38E-04 Hearing function / / 17255346 rs10908385 chr1 35654725 G A 7.55E-05 Multiple complex diseases SFPQ intron 17554300 rs11264114 chr1 35656064 T A 5.07E-04 Multiple complex diseases SFPQ intron 17554300 rs11264115 chr1 35656664 G A 7.04E-04 Multiple complex diseases SFPQ intron 17554300 rs7543044 chr1 35674311 A G 1.23E-04 Type 2 diabetes / / 17463246 rs673604 chr1 35687815 T C 6.00E-06 Endometrial cancer / / 21499250 rs593461 chr1 35709777 G A 5.54E-06 Rheumatoid arthritis / / 17804836 rs659215 chr1 35843029 C T 7.45E-05 Multiple complex diseases ZMYM4 intron 17554300 rs10908393 chr1 35854157 G C 5.52E-04 Multiple complex diseases ZMYM4 intron 17554300 rs10157137 chr1 35901222 A G 1.27E-06 Multiple complex diseases KIAA0319L intron 17554300 rs2275247 chr1 35908451 T C 1.00E-10 Systemic lupus erythematosus and Systemic sclerosis KIAA0319L intron 23740937 rs1203137 chr1 35951038 A G 2.42E-04 Type 2 diabetes KIAA0319L intron 17463246 rs1635718 chr1 35974469 C G 5.87E-04 Type 2 diabetes KIAA0319L intron 17463246 rs2074676 chr1 36027711 G A 8.76E-04 Multiple complex diseases NCDN intron 17554300 rs11264179 chr1 36056721 T C 2.70E-05 Coffee consumption TFAP2E intron 21357676 rs953035 chr1 36079508 G A 2.00E-05 Rheumatoid arthritis PSMB2 intron 17804836 rs676614 chr1 36107510 C A 6.34E-04 Multiple complex diseases / / 17554300 rs11264186 chr1 36149745 A G 5.70E-04 Multiple complex diseases / / 17554300 rs636658 chr1 36151125 C G 4.26E-04 Multiple complex diseases / / 17554300 rs2095247 chr1 36153830 C T 9.26E-04 Multiple complex diseases / / 17554300 rs12048483 chr1 36159594 A C 6.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) / / 21239504 rs1333647 chr1 36161383 C A,G,T 5.15E-04 Lymphocyte counts / / 22286170 rs6688464 chr1 36172195 G A 4.40E-05 Bipolar disorder / / 19488044 rs6688464 chr1 36172195 G A 6.00E-05 Bipolar Disorder / / pha002858 rs6696354 chr1 36176509 T C 0.000006 Mean arterial pressure / / 22510845 rs577483 chr1 36205166 A G 9.16E-04 Multiple complex diseases CLSPN intron 17554300 rs577483 chr1 36205166 A G 2.37E-05 Bipolar disorder CLSPN intron 19488044 rs577483 chr1 36205166 A G 3.31E-05 Bipolar Disorder CLSPN intron pha002858 rs535638 chr1 36216835 C T 5.87E-04 Multiple complex diseases CLSPN intron 17554300 rs535638 chr1 36216835 C T 2.80E-05 Bipolar disorder CLSPN intron 19488044 rs535638 chr1 36216835 C T 3.92E-05 Bipolar Disorder CLSPN intron pha002858 rs16822339 chr1 36220558 C A 7.50E-04 Multiple complex diseases CLSPN intron 17554300 rs11263830 chr1 36345798 G A 9.82E-04 Multiple complex diseases / / 17554300 rs645383 chr1 36373823 C G 7.06E-04 Multiple complex diseases EIF2C1 intron 17554300 rs581459 chr1 36375110 C T 1.96E-04 Multiple complex diseases EIF2C1 intron 17554300 rs12031138 chr1 36407806 A G 8.51E-04 Multiple complex diseases EIF2C3 intron 17554300 rs12041193 chr1 36412760 C T 5.31E-04 Multiple complex diseases EIF2C3 intron 17554300 rs683622 chr1 36443569 A G 4.52E-04 Multiple complex diseases EIF2C3 intron 17554300 rs7542179 chr1 36461122 G A 3.23E-04 Multiple complex diseases EIF2C3 intron 17554300 rs491603 chr1 36532316 T C 8.45E-10 Central corneal thickness / / 21098505 rs3767703 chr1 36555758 C T 5.94E-09 Central corneal thickness ADPRHL2 intron 21098505 rs7550047 chr1 36567343 A G 2.26E-09 Central corneal thickness COL8A2 nearGene-5 21098505 rs7553155 chr1 36568236 A T 2.90E-05 Urinary metabolites / / 21572414 rs96067 chr1 36571920 G A 5.40E-13 Central corneal thickness / / 21098505 rs96067 chr1 36571920 G A 3.00E-11 Corneal structure / / 23291589 rs274137 chr1 36577945 T C 1.30E-05 Urinary metabolites / / 21572414 rs12074848 chr1 36585077 C T 9.98E-09 Central corneal thickness / / 21098505 rs4653160 chr1 36599547 C T 1.24E-06 Central corneal thickness / / 21098505 rs7522400 chr1 36613380 A G 6.68E-07 Central corneal thickness TRAPPC3 intron 21098505 rs522468 chr1 36653677 T G 3.80E-04 Alcohol dependence / / 20201924 rs200307550 chr1 36786521 A G 0.00014 Breast cancer (ER positive) SH3D21 missense 23555315 rs200307550 chr1 36786521 A G 0.00026 Breast cancer SH3D21 missense 23555315 rs12116935 chr1 36789546 A G 0.00000698 Alcohol dependence / / 23691058 rs3795498 chr1 36807481 C T 8.47E-04 Glycosylated haemoglobin levels STK40 missense 17255346 rs10796882 chr1 36818066 G A 2.26E-04 Glycosylated haemoglobin levels STK40 intron 17255346 rs11583322 chr1 36822312 T C 3.20E-04 Alcohol dependence STK40 intron 20201924 rs11583322 chr1 36822312 T C 0.000000011 Alcohol dependence STK40 intron 23691058 rs4451521 chr1 36831264 C G 1.56E-04 Alcohol dependence STK40 intron 21314694 rs11577980 chr1 36836476 C T 7.05E-04 Suicide attempts in bipolar disorder STK40 intron 21423239 rs1339767 chr1 36855957 G C 2.14E-04 Glycosylated haemoglobin levels / / 17255346 rs884925 chr1 36861993 A G 4.51E-04 Alzheimer's disease LSM10 intron 22005930 rs884925 chr1 36861993 A G 7.27E-04 Smoking initiation LSM10 intron 24665060 rs4653186 chr1 36862929 T G 2.55E-04 Alzheimer's disease LSM10 intron 22005930 rs16822823 chr1 36874242 A G 7.44E-04 Alcohol dependence / / 21314694 rs6702784 chr1 36904720 A C 4.00E-06 Diabetic retinopathy OSCP1 intron 21441570 rs953517 chr1 36910277 C T 5.51E-04 Alzheimer's disease OSCP1 intron 22005930 rs11263898 chr1 36912531 G A 7.51E-04 Alzheimer's disease OSCP1 intron 22005930 rs6425987 chr1 36924676 A G 6.00E-04 Alzheimer's disease MRPS15 intron 22005930 rs3917991 chr1 36934805 C G 6.30E-04 Atrial fibrillation CSF3R missense 21846873 rs3917989 chr1 36935128 G A 2.53E-04 Lymphocyte counts CSF3R intron 22286170 rs3917924 chr1 36945653 G A 2.33E-05 Hemoglobin CSF3R intron pha003096 rs3917924 chr1 36945653 G A 3.60E-05 Hematocrit CSF3R intron pha003097 rs11263901 chr1 36960626 G A 2.04E-06 Hearing function / / 21493956 rs4481816 chr1 36977811 G C 5.34E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11263915 chr1 37019556 G A 5.54E-05 Waist Circumference / / pha003023 rs7540413 chr1 37040374 T C 9.59E-04 Heart Failure / / pha002884 rs4653197 chr1 37041069 C T 9.10E-04 Multiple complex diseases / / 17554300 rs12567252 chr1 37041357 A C 1.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs4653210 chr1 37074351 T G 2.60E-05 Systemic sclerosis / / 21750679 rs12090333 chr1 37077776 C T 6.64E-04 Alzheimer's disease / / 17998437 rs6685372 chr1 37126710 G A 4.43E-04 Multiple complex diseases / / 17554300 rs1076773 chr1 37136423 C T 4.37E-04 Type 2 diabetes / / 17463246 rs743012 chr1 37136670 G A 5.01E-04 Multiple complex diseases / / 17554300 rs7528341 chr1 37141174 C T 4.91E-04 Multiple complex diseases / / 17554300 rs34305923 chr1 37144140 C T 4.86E-04 Multiple complex diseases / / 17554300 rs589249 chr1 37162352 A G 3.00E-07 Schizophrenia / / 23894747 rs7515535 chr1 37182396 T A 8.19E-04 Multiple complex diseases / / 17554300 rs1395455 chr1 37185190 A G 3.99E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1002655 chr1 37192677 C G 3.20E-05 Schizophrenia / / 19571811 rs1002656 chr1 37192741 C T 8.65E-04 Multiple complex diseases / / 17554300 rs6425998 chr1 37197720 T C 6.29E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7549591 chr1 37198352 T C 5.81E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs502808 chr1 37212617 G A 5.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1472823 chr1 37220721 G A 2.30E-05 Urinary metabolites / / 21572414 rs1472823 chr1 37220721 G A 6.06E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12083196 chr1 37233430 T C 2.70E-05 Urinary metabolites / / 21572414 rs12083196 chr1 37233430 T C 4.76E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs525798 chr1 37240886 G T 1.60E-05 Urinary metabolites / / 21572414 rs11801494 chr1 37250088 C T 0.0002 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs528137 chr1 37280785 C T 2.75E-05 Amyotrophic lateral sclerosis (sporadic) GRIK3 intron 24529757 rs484017 chr1 37303737 T C 4.95E-04 Multiple complex diseases GRIK3 intron 17554300 rs547390 chr1 37317442 G A 8.95E-04 Multiple complex diseases GRIK3 intron 17554300 rs1587526 chr1 37362476 T C 6.90E-04 Cognitive impairment induced by topiramate GRIK3 intron 22091778 rs41344852 chr1 37398177 G C 8.34E-05 Multiple complex diseases GRIK3 intron 17554300 rs613720 chr1 37525676 C A 4.00E-05 Serum metabolites / / 19043545 rs218422 chr1 37537709 T C 1.37E-04 Cholesterol / / 17255346 rs760964 chr1 37574864 G A 6.94E-04 Multiple complex diseases / / 17554300 rs215773 chr1 37596240 G T 6.01E-04 Multiple complex diseases / / 17554300 rs215792 chr1 37605441 T C 3.30E-04 Multiple complex diseases / / 17554300 rs215792 chr1 37605441 T C 1.72E-04 Arthritis (juvenile idiopathic) / / 22354554 rs215791 chr1 37606291 T C 2.80E-04 Multiple complex diseases / / 17554300 rs41387646 chr1 37612620 A G 1.00E-04 Multiple complex diseases / / 17554300 rs4653252 chr1 37622070 C A 2.22E-05 Serum metabolites / / 19043545 rs998176 chr1 37636117 G A 3.84E-05 Serum metabolites / / 19043545 rs4653254 chr1 37644737 T C 1.06E-05 Serum metabolites / / 19043545 rs1501540 chr1 37723078 A G 2.24E-04 Multiple complex diseases / / 17554300 rs905108 chr1 37724364 A T 5.63E-04 Multiple complex diseases / / 17554300 rs6426015 chr1 37770623 A G 6.96E-06 Common variable immunodeficiency / / 21497890 rs6426016 chr1 37773586 T C 9.57E-05 Femoral neck bone geometry / / 22087292 rs3898790 chr1 37774697 T G 6.70E-05 Femoral neck bone geometry / / 22087292 rs11264024 chr1 37777759 G A 8.84E-05 Femoral neck bone geometry / / 22087292 rs1411931 chr1 37782874 A G 5.80E-05 Lipid traits / / 17903299 rs761158 chr1 37787733 A G 7.70E-06 Urinary metabolites / / 21572414 rs6659871 chr1 37794345 G A 4.77E-04 Type 2 diabetes / / 17463246 rs2811615 chr1 37861304 G C 7.01E-04 Type 2 diabetes / / 17463246 rs875361 chr1 37865954 G A 1.96E-04 Myopia (pathological) / / 21095009 rs2811626 chr1 37880752 T C 1.60E-05 Myopia (pathological) / / 21095009 rs16824119 chr1 37888656 G A 9.31E-05 Myopia (pathological) / / 21095009 rs4428850 chr1 37889172 G T 7.85E-05 Myopia (pathological) / / 21095009 rs10796907 chr1 37900173 A G 2.81E-05 Lymphocyte counts / / pha003094 rs10796907 chr1 37900173 A G 6.75E-06 Neutrophil count / / pha003095 rs11264049 chr1 37902135 T C 1.49E-04 Multiple complex diseases / / 17554300 rs6700586 chr1 37957376 G A 4.80E-06 Alopecia areata / / 22027810 rs9253 chr1 37958813 C G 4.00E-06 Hemostatic factors and hematological phenotypes MEAF6 UTR-3 17903294 rs215864 chr1 37967774 C A 3.30E-05 Chronic obstructive pulmonary disease MEAF6 intron 19300482 rs116251390 chr1 38032607 C T 0.00026 Breast cancer (ER positive) GNL2 missense 23555315 rs10908355 chr1 38035286 G T 1.58E-04 Lymphocyte counts GNL2 intron 22286170 rs4074961 chr1 38092723 C T 4.00E-13 Axial length RSPO1 intron 24144296 rs4653314 chr1 38117562 T C 1.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs573381957 chr1 38117562 TC T 1.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs615530 chr1 38161694 A G 8.41E-04 Alcohol dependence CDCA8 intron 20201924 rs3790623 chr1 38169578 G A 3.42E-05 HIV-1 progression to AIDS and death CDCA8 intron 21811574 rs3790623 chr1 38169578 G A 6.54E-04 HIV-1 progression to AIDS and death CDCA8 intron 21811574 rs531454 chr1 38173597 A G 5.22E-04 Alcohol dependence CDCA8 intron 20201924 rs7822 chr1 38174987 T C 4.84E-04 Suicide attempts in bipolar disorder CDCA8 UTR-3 21423239 rs7541350 chr1 38191538 T C 7.58E-06 Prostate cancer EPHA10 intron pha002878 rs17464981 chr1 38192537 T C 8.93E-06 Prostate cancer EPHA10 intron pha002878 rs731174 chr1 38196841 T C 5.00E-06 Prostate cancer (gene x gene interaction) EPHA10 intron 22219177 rs482818 chr1 38233399 C G 9.59E-04 Multiple complex diseases / / 17554300 rs12117544 chr1 38247153 T A 8.00E-06 Cognitive performance / / 20125193 rs579689 chr1 38256166 G A 6.54E-04 Multiple complex diseases / / 17554300 rs12563037 chr1 38258644 G C 2.29E-04 Multiple complex diseases / / 17554300 rs2291297 chr1 38272660 G A 6.90E-05 Hypothyroidism YRDC intron 22493691 rs28411352 chr1 38278579 C T 3.00E-12 Rheumatoid arthritis MTF1 UTR-3 24390342 rs28411352 chr1 38278579 C T 6.00E-09 Rheumatoid arthritis MTF1 UTR-3 24390342 rs28411352 chr1 38278579 C T 7.80E-05 Rheumatoid arthritis MTF1 UTR-3 24390342 rs3748682 chr1 38279987 T C 9.00E-06 Hypothyroidism MTF1 UTR-3 22493691 rs12751325 chr1 38289383 T C 8.40E-05 Hypothyroidism MTF1 cds-synon 22493691 rs12742756 chr1 38347417 A G 1.50E-05 Hypothyroidism INPP5B intron 22493691 rs12728438 chr1 38349400 G A 6.00E-05 Hypothyroidism INPP5B intron 22493691 rs4634868 chr1 38465315 G A 4.70E-05 Inflammatory demyelinating disease FHL3 intron 19850125 rs11211383 chr1 38482356 T G 1.12E-05 Alcohol consumption UTP11L intron 23953852 rs535056 chr1 38522092 T C 1.85E-05 Cognitive test performance / / 20125193 rs1108183 chr1 38559394 C G 7.69E-04 Multiple complex diseases / / 17554300 rs11206585 chr1 38568328 T C 5.29E-05 Erythrocyte counts / / pha003099 rs7547921 chr1 38602073 C A 6.13E-05 Type 2 diabetes / / 17463246 rs7547921 chr1 38602073 C A 8.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs883220 chr1 38616871 C A 2.83E-05 Rheumatoid arthritis / / 17804836 rs883220 chr1 38616871 C A 9.63E-07 Rheumatoid arthritis / / 19503088 rs883220 chr1 38616871 C A 0.000000021 Rheumatoid arthritis / / 23143596 rs883220 chr1 38616871 C A 2.09E-08 Rheumatoid arthritis (CCP positive) / / 23143596 rs12131057 chr1 38624129 G A 4.00E-07 Rheumatoid arthritis / / 20453842 rs6693777 chr1 38630862 A G 3.72E-06 Panic disorder / / 19165232 rs12140275 chr1 38633879 A T 2.00E-09 Rheumatoid arthritis / / 24390342 rs12140275 chr1 38633879 A T 4.00E-09 Rheumatoid arthritis / / 24390342 rs7544568 chr1 38639208 G A 3.21E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs17534243 chr1 38650917 A G 8.45E-04 Multiple complex diseases / / 17554300 rs898978 chr1 38667704 T G 2.86E-04 Multiple complex diseases / / 17554300 rs7537377 chr1 38682207 A G 4.24E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6685558 chr1 38687060 T C 8.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1755302 chr1 38704189 A G 9.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs12095190 chr1 38711632 G A 9.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs11802770 chr1 38721663 T C 3.00E-06 Waist-to-hip circumference ratio (interaction) / / 23192594 rs12075234 chr1 38738214 A G 1.95E-05 Cognitive impairment induced by topiramate / / 22091778 rs12075234 chr1 38738214 A G 3.27E-05 Coronary heart disease / / pha003032 rs1543632 chr1 38747960 C T 6.97E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2798809 chr1 38792565 A G 3.33E-16 Triglycerides / / 23063622 rs11210569 chr1 38805929 T C 4.40E-05 Chronic obstructive pulmonary disease / / 19300482 rs6679637 chr1 38806630 G A 6.29E-05 Systemic sclerosis / / 21750679 rs6701668 chr1 38845585 C A 9.87E-04 Type 2 diabetes / / 17463246 rs17478958 chr1 38851959 A C 6.29E-04 Tourette syndrome / / 22889924 rs12132779 chr1 38876635 A G 5.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs11806392 chr1 38876866 A G 6.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs6678251 chr1 38880715 T C 7.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs6600426 chr1 38884018 A G 6.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs6600426 chr1 38884018 A G 7.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs4290027 chr1 38884529 G A 9.42E-06 Cognitive decline / / 23207651 rs1932362 chr1 38910848 G A 5.20E-04 Tourette syndrome / / 22889924 rs2252153 chr1 38919423 G A 3.00E-05 Prostate cancer / / 21743057 rs2252059 chr1 38919983 G A 3.00E-05 Prostate cancer / / 21743057 rs11590421 chr1 38994115 G A 2.00E-07 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4970603 chr1 39041667 T C 4.05E-05 Coronary heart disease / / pha003030 rs4970605 chr1 39047119 G A 1.92E-19 Multiple complex diseases / / 17554300 rs12026014 chr1 39060495 G A 5.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2985763 chr1 39065974 G A 1.64E-06 Schizophrenia / / 20185149 rs2985763 chr1 39065974 G A 2.83E-05 Bipolar disorder / / 20451256 rs1925382 chr1 39077100 G A 4.44E-04 HIV-1 viral setpoint / / 17641165 rs3011197 chr1 39079046 A G 1.83E-04 Glycosylated haemoglobin levels / / 17255346 rs3011199 chr1 39079150 A C 4.15E-04 Multiple complex diseases / / 17554300 rs12077396 chr1 39080101 G C 1.46E-05 Glycosylated haemoglobin levels / / 17255346 rs4970606 chr1 39081829 A G 5.32E-05 Glycosylated haemoglobin levels / / 17255346 rs11211081 chr1 39115477 A G 8.00E-05 Coronary heart disease / / pha003030 rs724321 chr1 39123603 G A 1.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17484092 chr1 39147240 T C 2.46E-04 Multiple complex diseases / / 17554300 rs17484306 chr1 39159100 T C 6.12E-04 Type 2 diabetes / / 17463246 rs17484306 chr1 39159100 T C 5.11E-04 Multiple complex diseases / / 17554300 rs10493084 chr1 39164153 G A 1.40E-04 Crohn's disease / / 17684544 rs4970620 chr1 39165402 G C 5.14E-04 Multiple complex diseases / / 17554300 rs10890338 chr1 39166659 G A 1.05E-04 Multiple complex diseases / / 17554300 rs12409323 chr1 39169671 G A 9.74E-05 Type 2 diabetes and other traits / / 19734900 rs17556883 chr1 39197064 T C 0.000065 Endometrial cancer / / 22426144 rs12065672 chr1 39199381 C A 3.78E-04 Multiple complex diseases / / 17554300 rs4246510 chr1 39217894 G C 2.19E-04 Multiple complex diseases / / 17554300 rs4970625 chr1 39221925 C A 4.06E-05 Duodenal ulcer / / 22387998 rs4970625 chr1 39221925 C A 4.96E-05 Monocyte counts / / pha003089 rs12043383 chr1 39229313 T C 3.91E-04 Alzheimer's disease / / 17998437 rs4970627 chr1 39238597 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1320454 chr1 39291144 C A 5.11E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs16825583 chr1 39302499 A G 4.95E-04 Multiple complex diseases / / 17554300 rs7541734 chr1 39302880 C T 4.36E-05 Bipolar disorder / / 17486107 rs4494114 chr1 39339682 T C 6.07E-05 Type 2 diabetes GJA9-MYCBP intron 17463246 rs4491033 chr1 39352083 T G 8.83E-05 Type 2 diabetes RHBDL2 UTR-3 17463246 rs9438980 chr1 39355371 A G 2.50E-04 Type 2 diabetes RHBDL2 intron 17463246 rs6674910 chr1 39357157 A G 1.02E-04 Type 2 diabetes RHBDL2 intron 17463246 rs7539067 chr1 39359694 T C 1.08E-04 Type 2 diabetes RHBDL2 intron 17463246 rs4246511 chr1 39380385 T C 9.00E-17 Menopause (age at onset) RHBDL2 intron 22267201 rs6422258 chr1 39406644 T C 9.16E-04 Suicide attempts in bipolar disorder RHBDL2 intron 21423239 rs6600281 chr1 39412766 C G 1.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs4475740 chr1 39425489 A G 1.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs7550511 chr1 39427374 A C 8.00E-05 Suicide attempts in bipolar disorder / / 21423239 rs12127660 chr1 39434565 C T 1.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs7537437 chr1 39439538 G A 8.20E-07 Menopause (age at onset) / / 22267201 rs7537437 chr1 39439538 G A 2.38E-10 Lymphocyte counts / / 22286170 rs7538228 chr1 39477635 T G 4.81E-04 Schizophrenia / / 19197363 rs6663155 chr1 39498491 G A 4.81E-04 Schizophrenia NDUFS5 intron 19197363 rs10465799 chr1 39518006 G A 3.03E-04 Schizophrenia / / 19197363 rs260970 chr1 39551242 G A 0.000680168 Hypertension (early onset hypertension) MACF1 intron 22479346 rs11580989 chr1 39583686 T C 4.17E-05 Birth weight MACF1 intron 17255346 rs628523 chr1 39624761 A G 8.49E-04 Type 2 diabetes MACF1 intron 17463246 rs7538300 chr1 39652764 C A 8.33E-05 HDL particle features MACF1 intron pha002900 rs663978 chr1 39679685 A G 1.15E-04 Multiple complex diseases MACF1 intron 17554300 rs16826012 chr1 39719519 T C 8.57E-04 Multiple complex diseases MACF1 intron 17554300 rs16826012 chr1 39719519 T C 4.24E-04 Aortic root size MACF1 intron 21223598 rs3120282 chr1 39772180 T C 8.07E-04 Response to cytadine analogues (cytosine arabinoside) MACF1 intron 24483146 rs2296172 chr1 39835817 A G 7.80E-05 HDL particle features MACF1 missense pha002900 rs587404 chr1 39908506 G A 7.10E-05 Rheumatoid arthritis MACF1 missense 21673997 rs587404 chr1 39908506 G A 6.18E-05 HDL particle features MACF1 missense pha002900 rs2296173 chr1 39913351 A G 8.82E-05 HDL particle features MACF1 intron pha002900 rs1180379 chr1 39915035 G A 3.04E-04 Coronary Artery Disease MACF1 intron 17634449 rs687848 chr1 39919234 A G 5.10E-05 Rheumatoid arthritis MACF1 intron 21673997 rs4660762 chr1 39926824 G A 7.53E-05 Response to hepatitis C treatment MACF1 intron 19684573 rs3738676 chr1 39991588 G T 8.03E-04 Stroke BMP8A UTR-3 pha002886 rs17264866 chr1 40022777 C G 1.56E-07 Multiple complex diseases / / 17554300 rs4660293 chr1 40028180 A G 1.37E-04 Multiple complex diseases PABPC4 intron 17554300 rs4660293 chr1 40028180 A G 4.00E-10 HDL cholesterol PABPC4 intron 20686565 rs4660293 chr1 40028180 A G 3.00E-18 HDL cholesterol PABPC4 intron 24097068 rs4660293 chr1 40028180 A G 2.65E-05 HDL particle features PABPC4 intron pha002900 rs11577939 chr1 40036669 G C 4.54E-05 Longevity PABPC4 intron 20304771 rs2293476 chr1 40036847 G C 1.94E-04 Multiple complex diseases PABPC4 intron 17554300 rs11206377 chr1 40049104 A G 3.00E-04 Behcet's disease / / 19442274 rs11206377 chr1 40049104 A G 7.00E-04 Behcet's disease / / 19442274 rs11206377 chr1 40049104 A G 7.00E-04 Behcet's disease / / 19442274 rs7539261 chr1 40050503 A T 1.28E-04 Multiple complex diseases / / 17554300 rs12037222 chr1 40064961 G A 6.00E-11 C-reactive protein / / 21300955 rs3916164 chr1 40069939 G A 3.00E-10 Red blood cell traits / / 23222517 rs6600293 chr1 40083819 C A 3.87E-05 Lymphocyte counts / / 22286170 rs1148945 chr1 40096053 T C 5.50E-04 Body mass index HEYL intron 21701565 rs784611 chr1 40125988 T A 9.30E-05 Response to lithium treatment in bipolar disorder NT5C1A intron 19448189 rs873917 chr1 40132795 T G 8.00E-06 Amyotrophic lateral sclerosis NT5C1A intron 19451621 rs784600 chr1 40139553 C T 3.22E-04 Multiple complex diseases / / 17554300 rs784600 chr1 40139553 C T 7.97E-05 Caffeine consumption / / 21490707 rs785108 chr1 40152676 T C 9.64E-04 Multiple complex diseases HPCAL4 intron 17554300 rs538302 chr1 40153748 T C 5.49E-04 Coronary Artery Disease HPCAL4 intron 17634449 rs538758 chr1 40155188 A G 1.70E-04 Multiple complex diseases HPCAL4 intron 17554300 rs546422 chr1 40158828 C T 5.20E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs7553968 chr1 40222660 G C 0.0000882 post-traumatic stress disorder PPIE intron 22869035 rs7553968 chr1 40222660 G C 8.82E-05 Schizophrenia PPIE intron 22883433 rs12123153 chr1 40248931 A G 2.03E-04 Smoking initiation BMP8B intron 24665060 rs7531010 chr1 40275071 G A 7.03E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1999574 chr1 40288051 G A 2.60E-04 Intelligence (childhood) / / 23358156 rs11206937 chr1 40290011 A G 7.30E-06 Osteoarthritis / / 22566624 rs17569868 chr1 40292911 A C 5.74E-04 Multiple complex diseases / / 17554300 rs230275 chr1 40301897 G C 1.00E-04 Response to interferon beta in multiple sclerosis / / 18195134 rs12123609 chr1 40303627 C T 9.76E-04 Multiple complex diseases / / 17554300 rs230310 chr1 40307719 A G 6.00E-05 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) TRIT1 intron 24325915 rs3134615 chr1 40362066 C A 5.56E-04 Response to taxane treatment (placlitaxel) MYCL1 UTR-3 23006423 rs3134613 chr1 40364803 C A 8.76E-04 Schizophrenia MYCL1 intron 19197363 rs3117088 chr1 40369232 T C 7.53E-04 Schizophrenia / / 19197363 rs3117096 chr1 40389966 A G 3.70E-04 Smoking initiation / / 24665060 rs3131706 chr1 40413098 T C 2.37E-04 Nicotine dependence / / 17158188 rs3131703 chr1 40419681 A G 4.34E-04 Smoking initiation / / 24665060 rs3103778 chr1 40433771 A G 3.29E-04 Schizophrenia(treatment response to risperidone) MFSD2A intron 19850283 rs3103778 chr1 40433771 A G 2.40E-05 Urinary metabolites MFSD2A intron 21572414 rs3103778 chr1 40433771 A G 9.00E-06 PR interval MFSD2A intron 23534349 rs12402428 chr1 40503725 T C 6.52E-04 Alcohol dependence / / 21314694 rs16826852 chr1 40531094 A G 6.47E-04 Alcohol dependence CAP1 intron 21314694 rs16826856 chr1 40534842 T A 8.52E-04 Type 2 diabetes CAP1 intron 17463246 rs6688203 chr1 40549930 C A 6.60E-04 Alcohol dependence PPT1 intron 21314694 rs7513553 chr1 40553333 G T 6.43E-04 Rheumatoid arthritis PPT1 intron 21452313 rs12118846 chr1 40553444 A G 6.98E-04 Smoking cessation PPT1 intron 24665060 rs3131651 chr1 40555321 C T 1.44E-05 Osteoarthritis (knee and hip) PPT1 intron 21177295 rs3131651 chr1 40555321 C T 3.33E-04 Osteoarthritis (knee and hip) PPT1 intron 21177295 rs3131651 chr1 40555321 C T 3.50E-04 Osteoarthritis (knee and hip) PPT1 intron 21177295 rs3122438 chr1 40555802 G A 3.48E-04 Rheumatoid arthritis PPT1 intron 21452313 rs4660390 chr1 40560399 C T 9.30E-04 HIV-1 viral setpoint PPT1 intron 17641165 rs10889147 chr1 40561471 C T 2.88E-04 Rheumatoid arthritis PPT1 intron 21452313 rs6700346 chr1 40588548 C T 4.30E-05 Glioma (high-grade) / / 19578366 rs6600318 chr1 40601636 T C 5.52E-04 Alcohol dependence / / 20201924 rs12074893 chr1 40628119 C T 4.43E-04 Alcohol dependence RLF intron 20201924 rs4600036 chr1 40636387 G T 1.10E-05 Glioma (high-grade) RLF intron 19578366 rs6600320 chr1 40647407 A G 4.20E-05 Glioma (high-grade) RLF intron 19578366 rs12144950 chr1 40680128 A G 4.80E-04 Iris characteristics RLF intron 21835309 rs16827120 chr1 40765561 G A 0.00000194 HDL cholesterol / / 23063622 rs41480445 chr1 40766618 C T 8.20E-04 Multiple complex diseases COL9A2 UTR-3 17554300 rs407752 chr1 40803855 G A 7.30E-04 Bipolar disorder / / 19259986 rs2235701 chr1 40883095 C T 7.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity SMAP2 intron 24324551 rs427371 chr1 40883266 A G 6.80E-04 Multiple complex diseases SMAP2 intron 17554300 rs427371 chr1 40883266 A G 1.87E-04 Orofacial clefts SMAP2 intron 22863734 rs10489434 chr1 40922062 T C 9.10E-04 Alzheimer's disease ZNF643 intron 24755620 rs10489435 chr1 40922377 C T 5.12E-04 Body mass index ZNF643 intron 21701565 rs736861 chr1 40931003 A G 3.78E-04 Multiple complex diseases / / 17554300 rs736861 chr1 40931003 A G 5.21E-04 Schizophrenia / / 19197363 rs10789144 chr1 40955156 A T 6.64E-05 Multiple sclerosis ZNF642 intron 17660530 rs4604685 chr1 40976258 T C 7.24E-05 Cognitive test performance DEM1 intron 20125193 rs2184878 chr1 40994050 T C 8.67E-05 Cognitive test performance / / 20125193 rs1999822 chr1 41026749 G A 3.00E-05 Response to antidepressants / / 19736353 rs6677621 chr1 41053260 C T 9.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs16827403 chr1 41057570 A C 8.32E-05 Cognitive test performance / / 20125193 rs16827403 chr1 41057570 A C 1.99E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16827403 chr1 41057570 A C 2.05E-05 Lipoproteins / / pha003079 rs590775 chr1 41065744 A G 7.85E-04 Type 2 diabetes / / 17463246 rs3767955 chr1 41104475 G A 3.60E-04 Response to taxane treatment (placlitaxel) RIMS3 intron 23006423 rs12562229 chr1 41105238 A G 8.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RIMS3 intron 20877124 rs1534955 chr1 41107699 C G 8.97E-04 Depression (quantitative trait) RIMS3 intron 20800221 rs11208590 chr1 41108149 T C 1.80E-05 Age-related macular degeneration RIMS3 intron 20861866 rs11208590 chr1 41108149 T C 5.49E-05 Age-related macular degeneration RIMS3 intron 21197116 rs11208590 chr1 41108149 T C 1.97E-05 Age-related macular degeneration RIMS3 intron pha000001 rs11208590 chr1 41108149 T C 6.28E-06 Age-related macular degeneration RIMS3 intron pha002856 rs2780944 chr1 41115608 C T 4.60E-04 Depression (quantitative trait) RIMS3 intron 20800221 rs12728027 chr1 41115671 T C 4.35E-04 Depression (quantitative trait) RIMS3 intron 20800221 rs200548994 chr1 41115671 TG T 4.35E-04 Depression (quantitative trait) RIMS3 intron 20800221 rs10458576 chr1 41117899 G A 4.20E-04 Depression (quantitative trait) RIMS3 intron 20800221 rs4332353 chr1 41130424 G A 4.42E-04 Depression (quantitative trait) RIMS3 intron 20800221 rs965949 chr1 41154407 G A 9.17E-04 Major depressive disorder / / 22472876 rs2274956 chr1 41212950 G A 5.51E-04 Schizophrenia NFYC intron 19197363 rs2361651 chr1 41230214 G A 3.37E-04 Body mass index NFYC intron 17255346 rs823682 chr1 41231057 C T 6.34E-04 Schizophrenia NFYC intron 19197363 rs4660456 chr1 41239511 A G 4.00E-06 Platelet counts / / 21507922 rs823673 chr1 41240519 C T 3.94E-05 Pulmonary function in asthmatics / / 23541324 rs2769255 chr1 41245354 C T 5.17E-06 Aging (time to event) / / 21782286 rs2251413 chr1 41245859 C A 3.53E-04 Birth weight / / 17255346 rs11806175 chr1 41292969 C T 0.000007 HDL cholesterol particle diameter KCNQ4 intron 23263444 rs3767943 chr1 41293419 G A 9.18E-05 Chronic obstructive pulmonary disease KCNQ4 intron 19300482 rs11801911 chr1 41293857 C A 0.000007 HDL cholesterol particle diameter KCNQ4 intron 23263444 rs3754175 chr1 41294897 G A 8.49E-04 Multiple complex diseases KCNQ4 intron 17554300 rs913378 chr1 41298652 T C 8.60E-04 Amyotrophic lateral sclerosis (sporadic) KCNQ4 intron 24529757 rs12402583 chr1 41306571 T C 0.000059 Prostate cancer (advanced) / / 23555315 rs12564411 chr1 41319052 A G 1.35E-04 Type 2 diabetes / / 17463246 rs6600354 chr1 41348072 C A 3.68E-05 HDL cholesterol / / pha003074 rs11209104 chr1 41349252 A T 4.80E-04 Type 2 diabetes / / 17463246 rs1576100 chr1 41367298 T A 2.68E-04 IgE levels / / 17255346 rs12407657 chr1 41396308 A T 9.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs11580126 chr1 41421336 G A 3.87E-05 Serum albumin level / / pha003084 rs12067645 chr1 41425864 G A 2.54E-04 Response to alcohol consumption (flushing response) / / 24277619 rs12408576 chr1 41464437 A G 9.51E-04 Response to taxane treatment (placlitaxel) CTPS intron 23006423 rs17357905 chr1 41484317 T C 4.85E-04 Alcohol dependence SLFNL1 intron 21314694 rs6678816 chr1 41485589 G T 4.95E-04 Response to taxane treatment (placlitaxel) SLFNL1 intron 23006423 rs1138293 chr1 41486245 C T 4.43E-04 Fibrinogen SLFNL1 missense 17255346 rs17357954 chr1 41487337 G T 5.45E-04 Response to taxane treatment (placlitaxel) SLFNL1 UTR-5 23006423 rs6686842 chr1 41530871 T C 2.00E-08 Height SCMH1 intron 18391952 rs2268677 chr1 41542504 A C 2.45E-04 Type 2 diabetes SCMH1 intron 17463246 rs2024860 chr1 41562243 C T 6.92E-04 Response to taxane treatment (placlitaxel) SCMH1 intron 23006423 rs721651 chr1 41563329 A C 7.54E-04 Response to taxane treatment (placlitaxel) SCMH1 intron 23006423 rs213753 chr1 41607331 A G 5.45E-04 Response to taxane treatment (placlitaxel) SCMH1 intron 23006423 rs12127030 chr1 41638398 A C 8.06E-04 Response to taxane treatment (placlitaxel) SCMH1 intron 23006423 rs6672508 chr1 41666571 C G 9.53E-04 Alcohol dependence SCMH1 intron 21314694 rs6672914 chr1 41666929 C T 6.34E-04 Response to taxane treatment (placlitaxel) SCMH1 intron 23006423 rs11209718 chr1 41688938 C T 3.00E-09 Height SCMH1 intron 23563607 rs3845571 chr1 41716039 A C 5.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2154319 chr1 41745770 T C 2.00E-12 Height / / 20881960 rs12035913 chr1 41757057 C T 1.62E-04 Type 2 diabetes / / 17463246 rs2364535 chr1 41766236 G A 2.76E-05 Type 2 diabetes / / 17463246 rs4233488 chr1 41781013 T C 0.000000976 Triglycerides / / 23063622 rs2363810 chr1 41783873 G A 5.04E-04 Type 2 diabetes / / 17463246 rs2363810 chr1 41783873 G A 1.02E-05 Lipid levels / / 19016617 rs2363810 chr1 41783873 G A 2.35E-05 Lipid levels / / 19016617 rs12042464 chr1 41786854 G A 8.05E-04 Type 2 diabetes / / 17463246 rs12042464 chr1 41786854 G A 5.79E-04 Bipolar disorder,schizoaffective / / 19567891 rs12043581 chr1 41788265 G A 7.11E-04 Type 2 diabetes / / 17463246 rs12043581 chr1 41788265 G A 5.43E-04 Bipolar disorder,schizoaffective / / 19567891 rs17362424 chr1 41794403 G T 8.56E-04 Type 2 diabetes / / 17463246 rs4660187 chr1 41799160 G A 8.52E-04 Alzheimer's disease / / 24755620 rs12757611 chr1 41808972 G A 6.52E-04 Type 2 diabetes / / 17463246 rs12757611 chr1 41808972 G A 5.43E-04 Bipolar disorder,schizoaffective / / 19567891 rs12047439 chr1 41809640 T A 9.06E-04 Type 2 diabetes / / 17463246 rs12047439 chr1 41809640 T A 4.95E-04 Bipolar disorder,schizoaffective / / 19567891 rs6660265 chr1 41818676 T C 6.75E-04 Bipolar disorder,schizoaffective / / 19567891 rs4660527 chr1 41821779 G A 2.09E-05 Recombination rate / / 21698098 rs7547654 chr1 41831361 G C 5.15E-05 Obesity (extreme) FOXO6 intron 21935397 rs1317558 chr1 41839083 C T 6.17E-04 Suicide attempts in bipolar disorder FOXO6 intron 21423239 rs4660531 chr1 41839822 G T 3.00E-06 Bipolar disorder FOXO6 intron 21926972 rs2810583 chr1 41880343 C T 9.68E-05 IgE levels / / 17255346 rs10493095 chr1 41881922 A G 3.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs114174493 chr1 41892201 G A 0.00035944 Sarcoidosis / / 22952805 rs12142181 chr1 41912985 C T 1.92E-06 Prion diseases / / 22210626 rs11590973 chr1 41926652 C T 9.45E-06 Bipolar disorder / / 18317468 rs2492074 chr1 41933422 C T 1.25E-04 Self-reported allergy / / 23817569 rs10789371 chr1 41938428 A G 6.20E-06 Dietary macronutrient intake / / 23372041 rs734359 chr1 41945902 C T 1.98E-14 Cholesterol,total EDN2 intron 23063622 rs734359 chr1 41945902 C T 2.44E-15 LDL cholesterol EDN2 intron 23063622 rs734359 chr1 41945902 C T 8.42E-12 Triglycerides EDN2 intron 23063622 rs11210344 chr1 41972880 G T 4.19E-04 Multiple complex diseases HIVEP3 UTR-3 17554300 rs3738577 chr1 41973349 G A 2.92E-04 Multiple complex diseases HIVEP3 UTR-3 17554300 rs11809423 chr1 41976529 C T 0.0003424 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) HIVEP3 missense 23233654 rs11809423 chr1 41976529 C T 3.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) HIVEP3 missense 23233662 rs633297 chr1 41985453 C A,T 1.36E-04 Alzheimer's disease HIVEP3 intron 17998437 rs646228 chr1 41986066 C A 7.82E-04 Alzheimer's disease HIVEP3 intron 17998437 rs679449 chr1 41988634 C A 9.16E-04 Alzheimer's disease HIVEP3 intron 17998437 rs687766 chr1 41998849 C G 3.21E-04 Alzheimer's disease HIVEP3 intron 17998437 rs12121881 chr1 42002738 C T 5.65E-04 Type 2 diabetes HIVEP3 intron 17463246 rs182676510 chr1 42003977 C T 0.00037173 Sarcoidosis HIVEP3 intron 22952805 rs114060246 chr1 42004054 C A 0.00038402 Sarcoidosis HIVEP3 intron 22952805 rs10493102 chr1 42008521 G T 7.95E-04 Type 2 diabetes HIVEP3 intron 17463246 rs10789394 chr1 42026023 G A 8.10E-05 Malaria HIVEP3 intron 19465909 rs4509569 chr1 42037875 T C 4.16E-04 Type 2 diabetes HIVEP3 intron 17463246 rs1815257 chr1 42041479 A C 3.83E-04 Intracranial aneurysm HIVEP3 intron 22286173 rs1570355 chr1 42042317 C T 2.35E-04 Alzheimer's disease HIVEP3 intron 17998437 rs6600380 chr1 42054814 A G 3.92E-04 Alzheimer's disease HIVEP3 intron 17998437 rs943374 chr1 42056194 A G 4.78E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs6700352 chr1 42071438 T G 6.76E-04 Rheumatoid arthritis HIVEP3 intron 21452313 rs12045563 chr1 42073905 T C 5.86E-04 Rheumatoid arthritis HIVEP3 intron 21452313 rs17363834 chr1 42076607 C T 9.59E-04 Rheumatoid arthritis HIVEP3 intron 21452313 rs11210498 chr1 42077958 T G 7.58E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs2148635 chr1 42082452 T C 1.10E-05 Urinary metabolites HIVEP3 intron 21572414 rs7519983 chr1 42083369 G A 6.75E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs6600384 chr1 42085141 G A 6.50E-06 Urinary metabolites HIVEP3 intron 21572414 rs16828495 chr1 42085437 A G 9.00E-05 Multiple complex diseases HIVEP3 intron 17554300 rs6658500 chr1 42088344 C T 8.70E-06 Urinary metabolites HIVEP3 intron 21572414 rs11210499 chr1 42089703 T C 5.80E-06 Urinary metabolites HIVEP3 intron 21572414 rs11210501 chr1 42091634 T C 7.28E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs1109255 chr1 42091708 C T 5.45E-04 Disc degeneration (lumbar) HIVEP3 intron 24216480 rs752010 chr1 42093015 C T 2.00E-06 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs2077172 chr1 42093340 A G 2.31E-06 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs6664724 chr1 42093821 G A 4.27E-06 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs2038978 chr1 42094719 A G 2.65E-06 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs6681441 chr1 42098321 G A 1.90E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs4083593 chr1 42099583 A G 6.77E-06 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs11210503 chr1 42101134 A G 2.26E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs10890151 chr1 42101843 C A 6.92E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs10789405 chr1 42101962 C T 2.13E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs11210509 chr1 42109311 T C 4.96E-04 Alzheimer's disease HIVEP3 intron 17998437 rs1123483 chr1 42114198 A G 6.33E-04 Alzheimer's disease HIVEP3 intron 17998437 rs1123483 chr1 42114198 A G 5.40E-05 Cognitive function HIVEP3 intron 24684796 rs2148636 chr1 42119844 T C 9.10E-06 Urinary metabolites HIVEP3 intron 21572414 rs12077598 chr1 42172773 T A 5.22E-05 Self-reported allergy HIVEP3 intron 23817569 rs2036962 chr1 42177347 C T 1.00E-04 Self-reported allergy HIVEP3 intron 23817569 rs2036961 chr1 42178084 G A 5.05E-05 Multiple complex diseases HIVEP3 intron 17554300 rs4526604 chr1 42182144 T C 1.04E-04 Self-reported allergy HIVEP3 intron 23817569 rs6600388 chr1 42189456 A G 1.22E-04 Self-reported allergy HIVEP3 intron 23817569 rs11210517 chr1 42198081 C T 8.34E-04 Multiple complex diseases HIVEP3 intron 17554300 rs710235 chr1 42202714 T C 1.78E-05 Asthma HIVEP3 intron 20920776 rs4284254 chr1 42213076 G A 1.98E-06 Asthma HIVEP3 intron 20920776 rs12126740 chr1 42223909 C T 7.38E-04 Alzheimer's disease HIVEP3 intron 17998437 rs2165303 chr1 42228019 A G 8.78E-05 Self-reported allergy HIVEP3 intron 23817569 rs732554 chr1 42230644 C G 1.08E-04 Self-reported allergy HIVEP3 intron 23817569 rs4660206 chr1 42234757 A G 2.09E-04 Self-reported allergy HIVEP3 intron 23817569 rs7517484 chr1 42250456 T C 3.16E-06 Asthma HIVEP3 intron 20920776 rs12137296 chr1 42251918 G A 7.25E-06 Type 2 diabetes HIVEP3 intron 21573907 rs349439 chr1 42259008 G T 6.08E-04 Lymphocyte counts HIVEP3 intron 22286170 rs17373758 chr1 42259133 C A 8.29E-04 Multiple complex diseases HIVEP3 intron 17554300 rs10493098 chr1 42261889 T C 6.91E-04 Schizophrenia HIVEP3 intron 19197363 rs10493097 chr1 42262138 C A 1.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HIVEP3 intron 20877124 rs16828722 chr1 42270666 C T 5.63E-05 Major depressive disorder HIVEP3 intron 22472876 rs349423 chr1 42297124 C T 9.00E-06 Bronchopulmonary dysplasia HIVEP3 intron 23897914 rs972352 chr1 42297604 A C 6.73E-04 Insulin resistance HIVEP3 intron 21901158 rs655198 chr1 42326017 A G 8.87E-05 Asthma HIVEP3 intron 20159242 rs525382 chr1 42329120 T G 2.76E-04 Type 2 diabetes HIVEP3 intron 17463246 rs609572 chr1 42329303 C T 2.42E-04 Type 2 diabetes HIVEP3 intron 17463246 rs12734651 chr1 42330585 C A 3.75E-04 Schizophrenia HIVEP3 intron 19197363 rs12734651 chr1 42330585 C A 9.46E-05 Orofacial clefts HIVEP3 intron 22419666 rs11210537 chr1 42345723 G A 6.39E-05 IgE levels in asthmatics (D.p. specific) HIVEP3 intron 23967269 rs11210537 chr1 42345723 G A 6.99E-05 IgE levels in asthmatics (D.f. specific) HIVEP3 intron 23967269 rs2993120 chr1 42350837 A C 5.17E-05 IgE levels in asthmatics (D.p. specific) HIVEP3 intron 23967269 rs2993120 chr1 42350837 A C 6.00E-05 IgE levels in asthmatics (D.f. specific) HIVEP3 intron 23967269 rs12024772 chr1 42353344 A G 4.55E-05 IgE levels in asthmatics (D.p. specific) HIVEP3 intron 23967269 rs12024772 chr1 42353344 A G 5.73E-05 IgE levels in asthmatics (D.f. specific) HIVEP3 intron 23967269 rs1408946 chr1 42364249 G C 1.08E-05 Personality dimensions HIVEP3 intron 18957941 rs6600391 chr1 42371447 C T 2.73E-06 Asthma (childhood onset) HIVEP3 intron 23829686 rs661428 chr1 42451518 A C 4.52E-04 Smoking initiation HIVEP3 intron 24665060 rs642112 chr1 42453317 C A,G,T 7.88E-04 Multiple complex diseases HIVEP3 intron 17554300 rs7546128 chr1 42473659 C A 1.88E-04 Smoking initiation HIVEP3 intron 24665060 rs10736422 chr1 42480320 C T 2.27E-04 Smoking initiation HIVEP3 intron 24665060 rs6689536 chr1 42487523 T C 2.24E-04 Smoking initiation HIVEP3 intron 24665060 rs4660212 chr1 42496399 A G 2.27E-04 Smoking initiation HIVEP3 intron 24665060 rs12042133 chr1 42499365 C A 3.54E-04 Smoking initiation HIVEP3 intron 24665060 rs6696291 chr1 42500421 A G 5.62E-04 Smoking initiation HIVEP3 intron 24665060 rs12758407 chr1 42507013 T G 4.29E-05 Self-reported allergy / / 23817569 rs10437061 chr1 42515695 C T 1.94E-04 Multiple complex diseases / / 17554300 rs2042065 chr1 42516770 A C 6.30E-04 Smoking initiation / / 24665060 rs11210581 chr1 42556915 T C 5.33E-04 Smoking initiation / / 24665060 rs6672120 chr1 42577444 T C 5.13E-04 Multiple complex diseases / / 17554300 rs4660218 chr1 42597873 A G 7.78E-04 Smoking initiation / / 24665060 rs7542228 chr1 42598964 A G 7.76E-04 Smoking initiation / / 24665060 rs7539864 chr1 42601648 C G,T 7.76E-05 Self-reported allergy / / 23817569 rs12119339 chr1 42608400 G A 6.04E-04 Smoking initiation / / 24665060 rs11210601 chr1 42613302 T C 1.21E-04 Smoking initiation / / 24665060 rs4660610 chr1 42616910 G A 1.49E-04 Smoking initiation / / 24665060 rs3754283 chr1 42617032 A G 1.35E-04 Smoking initiation / / 24665060 rs11210604 chr1 42623672 T G 3.01E-07 Panic disorder / / 19165232 rs11210604 chr1 42623672 T G 3.64E-23 Narcolepsy / / 19629137 rs624614 chr1 42647914 A G 4.66E-05 Erythrocyte counts FOXJ3 intron pha003101 rs12402117 chr1 42738366 G A 2.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) FOXJ3 intron 23648065 rs12402117 chr1 42738366 G A 2.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) FOXJ3 intron 23648065 rs2494366 chr1 42798204 C T 1.80E-04 Type 2 diabetes and 6 quantitative traits FOXJ3 intron 17848626 rs2494366 chr1 42798204 C T 4.66E-05 Erythrocyte counts FOXJ3 intron pha003101 rs913426 chr1 42806191 A G 2.73E-04 Taste perception / / 22132133 rs6679533 chr1 42835396 C T 5.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9803864 chr1 42879737 T G 8.36E-04 Response to taxane treatment (placlitaxel) RIMKLA intron 23006423 rs1055055 chr1 42880516 T C 5.97E-04 Type 2 diabetes RIMKLA cds-synon 17463246 rs16829473 chr1 42885523 C A,G,T 2.84E-04 Multiple complex diseases RIMKLA UTR-3 17554300 rs11210643 chr1 42893164 G A 8.28E-04 Multiple complex diseases / / 17554300 rs3748845 chr1 42901082 A C 5.11E-04 Multiple complex diseases ZMYND12 intron 17554300 rs4660634 chr1 42901173 C T 4.92E-04 Multiple complex diseases ZMYND12 intron 17554300 rs10890197 chr1 42902906 C T 7.07E-04 Multiple complex diseases ZMYND12 intron 17554300 rs10493108 chr1 42908102 A C 6.15E-04 Multiple complex diseases ZMYND12 intron 17554300 rs4622104 chr1 42978242 C T 3.64E-04 Multiple complex diseases / / 17554300 rs4607934 chr1 42983413 G A 2.10E-04 Multiple complex diseases / / 17554300 rs7411957 chr1 43008018 G A 5.33E-04 Multiple complex diseases CCDC30 intron 17554300 rs16829623 chr1 43009319 T C 7.70E-04 Multiple complex diseases CCDC30 intron 17554300 rs12408987 chr1 43052471 T G 5.32E-04 Multiple complex diseases CCDC30 intron 17554300 rs16829846 chr1 43133657 C T 3.60E-04 Smoking initiation PPIH intron 24665060 rs12046563 chr1 43137280 A G 9.42E-05 Oral cancers (chewing tobacco related) PPIH intron 22503698 rs3895305 chr1 43154492 G T 6.19E-04 Lymphocyte counts YBX1 intron 22286170 rs4660656 chr1 43197508 G A,C,T 7.55E-04 Parkinson's disease / / 17052657 rs323716 chr1 43277312 T C 9.80E-06 Glioma (high-grade) CCDC23 intron 19578366 rs17381767 chr1 43281728 C T 7.01E-04 Insulin resistance CCDC23 intron 21901158 rs7540604 chr1 43299835 T C 6.56E-05 Bipolar disorder ERMAP intron 19488044 rs7520697 chr1 43315966 G A 4.96E-05 Cognitive test performance ZNF691 intron 20125193 rs4660234 chr1 43319272 C T 2.66E-06 Gallstones / / 17632509 rs12070405 chr1 43357369 G T 5.93E-06 Asthma (childhood onset) / / 23829686 rs16830039 chr1 43366503 T G 1.52E-04 Cholesterol / / 17255346 rs3820548 chr1 43398396 A G 3.78E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SLC2A1 intron 24023788 rs5031048 chr1 43406154 C G 4.74E-04 Multiple complex diseases SLC2A1 intron 17554300 rs11808361 chr1 43419215 C T 0.00029 Coronary artery calcification SLC2A1 intron 23727086 rs841839 chr1 43430084 C A 5.64E-04 Type 2 diabetes FLJ32224 intron 17463246 rs2367159 chr1 43432589 T C 5.64E-04 Type 2 diabetes FLJ32224 intron 17463246 rs841572 chr1 43436051 G A 1.58E-05 Cardiovascular disease / / pha003065 rs11210774 chr1 43450729 C T 3.84E-05 Serum metabolites / / 19043545 rs1754154 chr1 43470766 G T 5.95E-05 Blood Pressure / / pha002903 rs634669 chr1 43505440 T C 4.17E-04 Insulin resistance / / 21901158 rs588662 chr1 43530154 A G 8.35E-04 Multiple complex diseases / / 17554300 rs1198394 chr1 43540338 G A 9.07E-04 Alcohol dependence / / 21314694 rs519789 chr1 43580261 G A 0.00039631 Sarcoidosis / / 22952805 rs16830359 chr1 43596384 G A 8.59E-31 Narcolepsy / / 19629137 rs16830359 chr1 43596384 G A 1.00E-07 Cardiac hypertrophy / / 21348951 rs585655 chr1 43597014 G A 1.36E-04 Insulin resistance / / 21901158 rs490876 chr1 43600931 T C 1.32E-04 Insulin resistance / / 21901158 rs601504 chr1 43603715 G C 5.77E-04 Type 2 diabetes / / 17463246 rs601504 chr1 43603715 G C 4.64E-04 Insulin resistance / / 21901158 rs545220 chr1 43605870 G A 7.84E-04 Insulin resistance / / 21901158 rs16830399 chr1 43610139 C G 8.61E-05 Multiple complex diseases / / 17554300 rs16830399 chr1 43610139 C G 9.36E-04 Insulin resistance / / 21901158 rs475093 chr1 43616337 G C 9.80E-05 Gallstones FAM183A intron 17632509 rs12033506 chr1 43618969 G T 7.43E-05 Insulin resistance FAM183A intron 21901158 rs76382232 chr1 43628307 T C 0.0004086 Sarcoidosis / / 22952805 rs621559 chr1 43645411 G A 2.00E-06 Telomere length WDR65 intron 21460395 rs663824 chr1 43649508 A G 0.0000819 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity WDR65 missense 22945461 rs513009 chr1 43663376 A G 9.69E-04 Insulin resistance WDR65 intron 21901158 rs150404479 chr1 43688550 T C 1.00E-06 Bipolar disorder (body mass index interaction) WDR65 missense 24322204 rs2484714 chr1 43699970 G A 2.56E-05 Alzheimer's disease WDR65 cds-synon 17998437 rs3862227 chr1 43720994 A G 5.53E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs11210819 chr1 43721710 G A 9.26E-04 Alzheimer's disease / / 17998437 rs2151673 chr1 43741224 G A 8.51E-04 Aortic root size / / 21223598 rs6697017 chr1 43751701 C T 2.18E-04 Celiac disease / / 23936387 rs34783763 chr1 43757762 T C 2.52E-05 Celiac disease / / 23936387 rs1098182 chr1 43785768 G C 4.51E-05 Response to taxane treatment (placlitaxel) TIE1 intron 23006423 rs11210834 chr1 43787437 A G 5.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TIE1 intron 20877124 rs17292650 chr1 43803807 G T 1.64E-05 Platelet counts MPL missense 21507922 rs12731981 chr1 43804340 G A 3.66E-04 Smoking initiation MPL missense 24665060 rs2069387 chr1 43828080 T G 1.64E-05 Platelet counts CDC20 intron 21507922 rs1999674 chr1 43881941 A G 8.41E-05 Serum metabolites SZT2 intron 19043545 rs2782651 chr1 43920686 C G 4.98E-05 Serum metabolites HYI nearGene-5 19043545 rs12069733 chr1 43941508 G A 1.37E-07 Parkinson's disease / / 17052657 rs6429604 chr1 43955148 A G 1.52E-04 Depression (quantitative trait) / / 20800221 rs6687571 chr1 43957515 G A 3.56E-05 Personality dimensions / / 18957941 rs6687571 chr1 43957515 G A 1.60E-04 Depression (quantitative trait) / / 20800221 rs7417538 chr1 43959942 G A 1.61E-04 Depression (quantitative trait) / / 20800221 rs2039529 chr1 43960479 A G 7.57E-05 Depression (quantitative trait) / / 20800221 rs2039528 chr1 43960530 A G 1.60E-05 Personality dimensions / / 18957941 rs2039528 chr1 43960530 A G 7.25E-05 Depression (quantitative trait) / / 20800221 rs2039528 chr1 43960530 A G 1.60E-05 Personality dimensions / / 21173776 rs6675341 chr1 43970956 C T 1.18E-04 Depression (quantitative trait) / / 20800221 rs10749849 chr1 43974489 G A 1.87E-04 Depression (quantitative trait) / / 20800221 rs1413937 chr1 43975238 G A 1.63E-04 Depression (quantitative trait) / / 20800221 rs10890251 chr1 43976266 A C 2.24E-05 Personality dimensions / / 18957941 rs10890251 chr1 43976266 A C 3.10E-04 Depression (quantitative trait) / / 20800221 rs11210858 chr1 43978837 T C 3.05E-04 Depression (quantitative trait) / / 20800221 rs11210859 chr1 43979782 G A 3.04E-04 Depression (quantitative trait) / / 20800221 rs1413938 chr1 43981265 C T 3.08E-04 Depression (quantitative trait) / / 20800221 rs2367617 chr1 43981961 A G 3.08E-04 Depression (quantitative trait) / / 20800221 rs11210862 chr1 43984142 C T 3.18E-04 Depression (quantitative trait) / / 20800221 rs1413939 chr1 43984627 G C 1.66E-04 Depression (quantitative trait) / / 20800221 rs11210863 chr1 43985678 C T 3.21E-04 Depression (quantitative trait) / / 20800221 rs11210864 chr1 43991832 G A 2.23E-05 Personality dimensions / / 18957941 rs11210864 chr1 43991832 G A 4.91E-04 Depression (quantitative trait) / / 20800221 rs11577317 chr1 43992893 A G 4.07E-04 Depression (quantitative trait) / / 20800221 rs11590627 chr1 43999120 T C 2.12E-04 Depression (quantitative trait) PTPRF intron 20800221 rs2819332 chr1 44005280 G A 5.00E-06 Amyotrophic lateral sclerosis (age of onset) PTPRF intron 22959728 rs2782640 chr1 44009033 C T 5.04E-04 Smoking initiation PTPRF intron 24665060 rs2782641 chr1 44013355 G A 1.56E-04 Smoking initiation PTPRF intron 24665060 rs2819333 chr1 44014573 A T 5.34E-04 Smoking initiation PTPRF intron 24665060 rs11582876 chr1 44062827 C T 6.75E-04 Alcohol dependence PTPRF intron 21314694 rs11210886 chr1 44071546 G A 8.15E-04 Multiple complex diseases PTPRF intron 17554300 rs11210886 chr1 44071546 G A 6.48E-04 Obesity (extreme) PTPRF intron 21935397 rs11210888 chr1 44076630 C T 5.55E-04 Obesity (extreme) PTPRF intron 21935397 rs11804031 chr1 44081912 A G 5.40E-04 Obesity (extreme) PTPRF intron 21935397 rs16831024 chr1 44084620 G T 5.36E-04 Obesity (extreme) PTPRF intron 21935397 rs11210893 chr1 44101767 T G 4.61E-04 Obesity (extreme) / / 21935397 rs11210894 chr1 44102587 C T 4.60E-04 Obesity (extreme) / / 21935397 rs11210896 chr1 44103275 G A 4.59E-04 Obesity (extreme) / / 21935397 rs660899 chr1 44117006 G T 4.00E-06 Hypertension risk in short sleep duration KDM4A intron 22322875 rs4336891 chr1 44126440 G A 5.47E-04 Obesity (extreme) KDM4A intron 21935397 rs669446 chr1 44129779 A G 7.08E-04 Parkinson's disease KDM4A intron 17052657 rs669446 chr1 44129779 A G 5.00E-06 Amyotrophic lateral sclerosis (age of onset) KDM4A intron 22959728 rs10789441 chr1 44130564 A G 5.98E-04 Obesity (extreme) KDM4A intron 21935397 rs304303 chr1 44178070 T G 1.29E-05 Alopecia areata ST3GAL3 intron 22027810 rs12410155 chr1 44188465 A C 2.00E-04 Information processing speed ST3GAL3 intron 21130836 rs4660260 chr1 44195353 T C 2.55E-06 Alopecia areata ST3GAL3 intron 22027810 rs12733500 chr1 44208306 T G 6.11E-05 Pulmonary function ST3GAL3 intron 20010835 rs2367725 chr1 44215828 C A,G,T 9.00E-06 Aging (time to event) ST3GAL3 intron 21782286 rs7520053 chr1 44226657 A G 8.93E-04 Schizophrenia (cytomegalovirus infection interaction) ST3GAL3 intron 23358160 rs12760274 chr1 44249344 A G 8.33E-05 Alcohol consumption ST3GAL3 intron 23953852 rs6701645 chr1 44254514 C T 6.84E-07 Red blood cell traits ST3GAL3 intron 23222517 rs12741964 chr1 44254586 G A 1.12E-04 Schizophrenia (cytomegalovirus infection interaction) ST3GAL3 intron 23358160 rs16831192 chr1 44255687 G A 3.42E-05 Cognitive impairment induced by topiramate ST3GAL3 intron 22091778 rs12122504 chr1 44256819 C G 7.70E-07 Red blood cell traits ST3GAL3 intron 23222517 rs11210927 chr1 44266420 A G 7.27E-07 Red blood cell traits ST3GAL3 intron 23222517 rs12133508 chr1 44277746 C T 6.06E-07 Red blood cell traits ST3GAL3 intron 23222517 rs37458 chr1 44290530 A G 0.00014 Breast cancer ST3GAL3 missense 23555315 rs3791073 chr1 44297673 T C 3.58E-04 Insulin resistance ST3GAL3 intron 21901158 rs3011217 chr1 44303266 A G 7.64E-05 Receptive language ability ST3GAL3 intron 24687471 rs3011225 chr1 44319373 G A 7.00E-08 Amyotrophic lateral sclerosis (age of onset) ST3GAL3 intron 22959728 rs2906466 chr1 44322220 A G 3.90E-05 Brain structure ST3GAL3 intron 22504417 rs2906457 chr1 44338575 A C 5.59E-05 Cognitive performance ST3GAL3 intron 19734545 rs2906457 chr1 44338575 A C 9.84E-06 Brain structure ST3GAL3 intron 22504417 rs2428853 chr1 44343173 C G 3.20E-05 Response to statin therapy ST3GAL3 intron 20339536 rs2788371 chr1 44343962 A G 9.20E-05 Response to statin therapy ST3GAL3 intron 20339536 rs2527776 chr1 44345292 G A 1.17E-05 Brain structure ST3GAL3 intron 22504417 rs803676 chr1 44352458 A G 7.60E-05 Response to statin therapy ST3GAL3 intron 20339536 rs2428854 chr1 44356185 C A 7.90E-05 Response to statin therapy ST3GAL3 intron 20339536 rs803683 chr1 44358148 G T 8.00E-05 Response to statin therapy ST3GAL3 intron 20339536 rs16831389 chr1 44363143 C T 1.47E-04 Alzheimer's disease ST3GAL3 intron 24755620 rs783304 chr1 44365457 A G 5.85E-04 Alzheimer's disease ST3GAL3 intron 24755620 rs16831424 chr1 44387353 C T 3.42E-05 Cognitive impairment induced by topiramate ST3GAL3 intron 22091778 rs12569336 chr1 44391288 T A 2.31E-04 Alzheimer's disease ST3GAL3 intron 24755620 rs12561948 chr1 44396196 A G 2.54E-04 Alzheimer's disease ST3GAL3 UTR-3 24755620 rs4448553 chr1 44411589 A G 3.90E-05 Brain structure / / 22504417 rs7556565 chr1 44416090 C T 3.46E-05 Brain structure IPO13 intron 22504417 rs6675620 chr1 44417630 C T 3.60E-05 Brain structure IPO13 intron 22504417 rs2301993 chr1 44426025 G A 4.10E-05 Brain structure IPO13 intron 22504417 rs7161 chr1 44438974 C T 2.75E-06 Systemic lupus erythematosus and Systemic sclerosis DPH2 UTR-3 23740937 rs1362153 chr1 44469031 T C 7.00E-06 Alcohol dependence (age at onset) SLC6A9 intron 24962325 rs2485993 chr1 44503040 A G 8.60E-05 Schizophrenia / / 24253340 rs751442 chr1 44509551 A C 5.44E-04 Nicotine dependence / / 17158188 rs751442 chr1 44509551 A C 8.78E-05 Schizophrenia / / 24253340 rs2158822 chr1 44519447 G C 4.50E-06 Urinary metabolites / / 21572414 rs11210949 chr1 44535401 T C 0.0000629 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs942755 chr1 44537401 G A 0.0000803 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6662888 chr1 44602159 G A 2.68E-04 Type 2 diabetes / / 17463246 rs2799480 chr1 44684995 T C 9.11E-04 Alzheimer's disease DMAP1 intron 22005930 rs4660781 chr1 44700764 A G 8.86E-05 Stroke ERI3 intron pha002887 rs1778905 chr1 44724788 A G 7.40E-04 Alzheimer's disease ERI3 intron 22005930 rs2799475 chr1 44727612 T C 8.48E-04 Alzheimer's disease ERI3 intron 22005930 rs325168 chr1 44731068 T G 7.03E-04 Type 2 diabetes ERI3 intron 17463246 rs10890295 chr1 44745450 T A 3.72E-04 Type 2 diabetes ERI3 intron 17463246 rs459358 chr1 44745624 C T 5.82E-04 Alzheimer's disease ERI3 intron 22005930 rs325163 chr1 44751710 T C 5.87E-04 Alzheimer's disease ERI3 intron 22005930 rs325160 chr1 44759392 C G 1.70E-04 Type 2 diabetes ERI3 intron 17463246 rs325160 chr1 44759392 C G 1.30E-05 Lipid levels ERI3 intron 18193043 rs325154 chr1 44764677 C T 9.33E-04 Alzheimer's disease ERI3 intron 22005930 rs12058010 chr1 44765646 C T 1.50E-05 Urinary metabolites ERI3 intron 21572414 rs6429535 chr1 44766071 C T 2.22E-04 Type 2 diabetes ERI3 intron 17463246 rs11210982 chr1 44793760 G A 1.97E-04 Alzheimer's disease ERI3 intron 22005930 rs2524353 chr1 44807164 C T 8.52E-04 Type 2 diabetes ERI3 intron 17463246 rs172853 chr1 44809445 T G 6.35E-04 Alzheimer's disease ERI3 intron 22005930 rs226065 chr1 44819375 A G 5.69E-04 Alzheimer's disease ERI3 intron 22005930 rs226069 chr1 44822097 G A 4.05E-04 Alzheimer's disease / / 22005930 rs4660790 chr1 44828525 G T 8.60E-05 Stroke / / pha002887 rs3888585 chr1 44856052 C A 9.06E-05 Cognitive test performance / / 20125193 rs7555873 chr1 44912147 T C 4.95E-04 Multiple complex diseases RNF220 intron 17554300 rs12071805 chr1 44921331 C G 1.29E-04 Multiple complex diseases RNF220 intron 17554300 rs9804150 chr1 44951245 A G 8.67E-05 Lung function (forced expiratory volume in 1 second) RNF220 intron pha003102 rs781775 chr1 44972309 G A 3.82E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) RNF220 intron 23648065 rs781774 chr1 44972337 G A 5.00E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma RNF220 intron 22205395 rs781771 chr1 44974082 T C 1.40E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma RNF220 intron 22205395 rs781770 chr1 44974119 C T 2.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) RNF220 intron 23648065 rs12138940 chr1 44974796 A G 2.50E-05 Anxiety in major depressive disorder RNF220 intron 24047446 rs781790 chr1 44976806 A G 5.91E-05 Cognitive impairment induced by topiramate RNF220 intron 22091778 rs781790 chr1 44976806 A G 2.85E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) RNF220 intron 23648065 rs272531 chr1 44988433 G A 3.66E-04 Schizophrenia RNF220 intron 19197363 rs272531 chr1 44988433 G A 6.68E-05 Insulin resistance RNF220 intron 21901158 rs272537 chr1 44992714 A T 5.40E-06 Urinary metabolites RNF220 intron 21572414 rs746733 chr1 44999614 G A 3.55E-05 F-cell distribution RNF220 intron 21326311 rs7525212 chr1 45029679 G A,T 3.92E-04 Schizophrenia RNF220 intron 19197363 rs270716 chr1 45054866 A G 1.20E-05 Urinary metabolites RNF220 intron 21572414 rs459160 chr1 45080932 T C 1.73E-04 Body mass index RNF220 intron 17255346 rs459160 chr1 45080932 T C 8.20E-04 Multiple complex diseases RNF220 intron 17554300 rs461043 chr1 45081101 T C 1.56E-11 Multiple complex diseases RNF220 intron 17554300 rs1051648 chr1 45116935 C T 6.82E-05 Cognitive test performance RNF220 UTR-3 20125193 rs17391430 chr1 45234389 G A 2.24E-04 Multiple complex diseases / / 17554300 rs12072767 chr1 45258232 C T 0.00042089 Sarcoidosis / / 22952805 rs6676749 chr1 45264545 T G 3.01E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11584440 chr1 45268356 C A 3.73E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PLK3 intron 21844884 rs11211036 chr1 45270024 G C 2.32E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PLK3 cds-synon 21844884 rs11211037 chr1 45275551 A C 1.75E-04 Longevity BTBD19 intron 22279548 rs11211040 chr1 45291908 G A 5.98E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PTCH2 intron 21844884 rs3795720 chr1 45307506 G A 0.00004 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer PTCH2 intron 21245432 rs6429550 chr1 45311749 G A 1.89E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6429550 chr1 45311749 G A 9.73E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7517439 chr1 45312867 G A 2.16E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7517639 chr1 45313150 G A 3.91E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6692487 chr1 45317392 G A 4.79E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines EIF2B3 intron 21844884 rs11579580 chr1 45318718 C G 5.92E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines EIF2B3 intron 21844884 rs11211044 chr1 45318752 C T 0.00002 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer EIF2B3 intron 21245432 rs12733586 chr1 45327230 G A 7.88E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines EIF2B3 intron 21844884 rs7528461 chr1 45331753 G A 5.74E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines EIF2B3 intron 21844884 rs263975 chr1 45358527 T C 0.00002 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer EIF2B3 intron 21245432 rs263977 chr1 45360287 T G 0.00002 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer EIF2B3 intron 21245432 rs3767490 chr1 45360658 A C 4.40E-04 Multiple complex diseases EIF2B3 intron 17554300 rs608649 chr1 45363887 T C 2.69E-04 Multiple complex diseases EIF2B3 intron 17554300 rs1572379 chr1 45369086 A G 6.38E-04 Response to cytadine analogues (cytosine arabinoside) EIF2B3 intron 24483146 rs12093313 chr1 45371160 G A 9.53E-04 Response to cytadine analogues (cytosine arabinoside) EIF2B3 intron 24483146 rs11211053 chr1 45373666 G A 5.51E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines EIF2B3 intron 21844884 rs263966 chr1 45376737 G A 0.00004 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer EIF2B3 intron 21245432 rs452989 chr1 45417184 T C 0.00004 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer EIF2B3 intron 21245432 rs11211059 chr1 45430218 C T 7.16E-05 Multiple complex diseases EIF2B3 intron 17554300 rs489676 chr1 45452227 G C 0.00003 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer EIF2B3 UTR-5 21245432 rs264011 chr1 45460832 A G 0.00003 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer / / 21245432 rs7528534 chr1 45470130 T C 1.98E-05 Type 2 diabetes HECTD3 intron 17463246 rs7528534 chr1 45470130 T C 9.52E-04 Multiple complex diseases HECTD3 intron 17554300 rs2050869 chr1 45503639 G A 9.85E-05 Serum metabolites ZSWIM5 intron 19043545 rs3850855 chr1 45523893 T C 5.45E-04 Cocaine dependence ZSWIM5 intron 23958962 rs3850855 chr1 45523893 T C 6.09E-06 Cocaine dependence ZSWIM5 intron 23958962 rs11211074 chr1 45530509 T C 2.39E-04 Cocaine dependence ZSWIM5 intron 23958962 rs11211074 chr1 45530509 T C 3.43E-06 Cocaine dependence ZSWIM5 intron 23958962 rs346733 chr1 45585207 C T 1.57E-04 HIV-1 viral setpoint ZSWIM5 intron 17641165 rs1226757 chr1 45592886 G A 1.57E-04 Smoking quantity ZSWIM5 intron 24665060 rs346718 chr1 45610429 G T 4.07E-04 Multiple complex diseases ZSWIM5 intron 17554300 rs1938300 chr1 45672783 T C 1.38E-05 Cocaine dependence / / 23958962 rs1938300 chr1 45672783 T C 1.71E-04 Cocaine dependence / / 23958962 rs2997460 chr1 45694796 C T 1.55E-04 HIV-1 viral setpoint / / 17641165 rs2997460 chr1 45694796 C T 4.18E-06 Cocaine dependence / / 23958962 rs2997460 chr1 45694796 C T 7.66E-05 Cocaine dependence / / 23958962 rs1938407 chr1 45722622 A G 1.49E-05 Cocaine dependence / / 23958962 rs1938407 chr1 45722622 A G 2.66E-04 Cocaine dependence / / 23958962 rs1938297 chr1 45740469 T C 2.55E-05 Smoking quantity / / 24665060 rs4233497 chr1 45763753 T C 3.00E-04 HIV-1 viral setpoint / / 17641165 rs3219487 chr1 45798555 T C 4.19E-04 Insulin resistance MUTYH intron 21901158 rs3219487 chr1 45798555 T C 2.78E-05 Lymphocyte counts MUTYH intron 22286170 rs9429157 chr1 45808863 G A 0.00079 Prostate cancer TOE1 missense 23555315 rs9429072 chr1 45810091 A G 6.26E-05 Femoral neck bone geometry TESK2 UTR-3 22087292 rs2153608 chr1 45813941 A G 5.72E-05 Femoral neck bone geometry TESK2 intron 22087292 rs9429076 chr1 45819489 T C 6.88E-04 Insulin resistance TESK2 intron 21901158 rs7543428 chr1 45839643 A G 3.70E-05 Femoral neck bone geometry TESK2 intron 22087292 rs11211101 chr1 45849311 G C 3.16E-07 Lymphocyte counts TESK2 intron 22286170 rs2487442 chr1 45857176 G C 2.26E-04 Insulin resistance TESK2 intron 21901158 rs2487442 chr1 45857176 G C 8.78E-05 Femoral neck bone geometry TESK2 intron 22087292 rs1771551 chr1 45883643 C G 9.06E-04 Insulin resistance TESK2 intron 21901158 rs1771551 chr1 45883643 C G 5.95E-05 Femoral neck bone geometry TESK2 intron 22087292 rs4660306 chr1 45978675 T C 2.00E-09 Homocysteine levels PRDX1 intron 23824729 rs16832557 chr1 45978923 T C 6.62E-06 Multiple complex diseases PRDX1 intron 17554300 rs10736426 chr1 45984353 G A 9.85E-04 Amyotrophic lateral sclerosis (sporadic) PRDX1 intron 24529757 rs487174 chr1 46009536 A G 1.70E-05 Urinary metabolites / / 21572414 rs3748645 chr1 46035470 G A 4.97E-05 Amyotrophic lateral sclerosis (sporadic) AKR1A1 intron 24529757 rs1053941 chr1 46084383 G T 5.00E-11 Blood metabolite levels /SP UTR-3 24816252 rs11211176 chr1 46223086 G A 6.48E-06 Multiple sclerosis / / 17660530 rs6680211 chr1 46315007 C G 7.11E-04 Nicotine dependence MAST2 intron 17158188 rs6429582 chr1 46321843 T C 3.76E-04 Multiple complex diseases MAST2 intron 17554300 rs6429582 chr1 46321843 T C 6.00E-05 Malaria MAST2 intron 19465909 rs12732188 chr1 46333358 G A 2.00E-04 Cognitive impairment induced by topiramate MAST2 intron 22091778 rs10890361 chr1 46346234 T A 6.46E-04 Multiple complex diseases MAST2 intron 17554300 rs10890361 chr1 46346234 T A 9.40E-06 Malaria MAST2 intron 19465909 rs10890363 chr1 46356148 A G 6.28E-04 Multiple complex diseases MAST2 intron 17554300 rs10890363 chr1 46356148 A G 9.10E-05 Malaria MAST2 intron 19465909 rs4545281 chr1 46360054 C T 5.82E-04 Multiple complex diseases MAST2 intron 17554300 rs7556436 chr1 46363880 A G 6.63E-04 Multiple complex diseases MAST2 intron 17554300 rs7556436 chr1 46363880 A G 5.20E-05 Malaria MAST2 intron 19465909 rs4660905 chr1 46461587 A G 3.83E-04 Hearing function MAST2 intron 17255346 rs4073846 chr1 46462881 A G 7.46E-04 Multiple complex diseases MAST2 intron 17554300 rs11579634 chr1 46466391 C T 6.98E-04 Multiple complex diseases MAST2 intron 17554300 rs2236560 chr1 46495434 G A 8.02E-04 Type 2 diabetes MAST2 intron 17463246 rs1622208 chr1 46498375 A G 9.69E-04 Hearing function MAST2 cds-synon 17255346 rs1052607 chr1 46499526 A G 9.34E-05 Calcium levels MAST2 missense pha003085 rs1768809 chr1 46502836 A C 1.15E-04 Multiple complex diseases / / 17554300 rs1768808 chr1 46503217 C T 1.18E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs7538978 chr1 46505054 G A 2.86E-04 Hearing function / / 17255346 rs1707322 chr1 46505147 A G 3.78E-04 Hearing function / / 17255346 rs1707321 chr1 46505309 A G 2.08E-04 Multiple complex diseases / / 17554300 rs785467 chr1 46521559 A T 8.02E-04 Hearing function PIK3R3 missense 17255346 rs785465 chr1 46522577 A C 3.78E-04 Hearing function PIK3R3 intron 17255346 rs1613296 chr1 46546852 T G 3.73E-04 Hearing function PIK3R3 intron 17255346 rs785495 chr1 46587887 T C 5.14E-04 Multiple complex diseases PIK3R3 intron 17554300 rs1983261 chr1 46617981 G A 4.95E-04 Multiple complex diseases / / 17554300 rs17102048 chr1 46622385 G A 0.000749 Height (Pygmy height) / / 22570615 rs3855959 chr1 46633874 T C 3.00E-05 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) / / 24325915 rs7538871 chr1 46671997 A G 6.20E-05 Multiple complex diseases POMGNT1 intron 17554300 rs9793263 chr1 46722389 A G 5.33E-04 Coronary heart disease RAD54L intron 21606135 rs2295465 chr1 46726057 A C 3.87E-05 Multiple complex diseases RAD54L intron 17554300 rs12410307 chr1 46730398 G A 1.94E-04 Coronary heart disease RAD54L intron 21606135 rs17102098 chr1 46741211 A G 0.0000116 Cholesterol,total RAD54L intron 23696881 rs12142240 chr1 46747301 T C 4.70E-05 Menopause (age at onset) LRRC41 intron 22267201 rs4660344 chr1 46805222 A G 2.24E-05 Osteoarthritis (knee and hip) / / 21177295 rs4660344 chr1 46805222 A G 2.25E-05 Osteoarthritis (knee and hip) / / 21177295 rs4660344 chr1 46805222 A G 6.80E-04 Osteoarthritis (knee and hip) / / 21177295 rs2145408 chr1 46861907 A G 7.42E-04 Type 2 diabetes FAAH intron 17463246 rs2145408 chr1 46861907 A G 7.96E-04 Suicide attempts in bipolar disorder FAAH intron 21041247 rs6429600 chr1 46864511 G A 8.06E-04 Suicide attempts in bipolar disorder FAAH intron 21041247 rs324423 chr1 46885104 A G 7.92E-04 Multiple complex diseases / / 17554300 rs116435220 chr1 46890686 C T 2.18E-08 Cholesterol,total / / 23696881 rs1571138 chr1 46895641 A G 2.53E-04 Multiple complex diseases / / 17554300 rs10890398 chr1 46925594 T C 3.93E-04 Smoking quantity / / 24665060 rs11211287 chr1 46939999 G C 8.10E-05 Immunoglobulin A / / 20694011 rs7542172 chr1 46990681 G A 2.00E-12 Blood metabolite levels / / 24816252 rs1267301 chr1 46992853 C G 3.45E-04 Multiple complex diseases / / 17554300 rs12564756 chr1 47018447 C T 6.60E-04 Smoking quantity LOC100507423 intron 24665060 rs1054743 chr1 47035643 T C 8.45E-04 Type 2 diabetes MKNK1 intron 17463246 rs744096 chr1 47107390 A G 5.04E-04 Multiple complex diseases ATPAF1 intron 17554300 rs744096 chr1 47107390 A G 9.25E-05 Serum metabolites ATPAF1 intron 19043545 rs1933932 chr1 47109328 C T 8.90E-04 Alcohol dependence ATPAF1 intron 21314694 rs2289447 chr1 47118168 C T 2.20E-08 Asthma (childhood onset) ATPAF1 intron 21696813 rs620431 chr1 47118189 G T 4.00E-04 Asthma (childhood onset) ATPAF1 intron 21696813 rs1150068 chr1 47118918 A G 2.00E-04 Asthma (childhood onset) ATPAF1 intron 21696813 rs11211334 chr1 47121419 T C 1.69E-04 Multiple complex diseases ATPAF1 intron 17554300 rs11211334 chr1 47121419 T C 1.76E-05 Serum metabolites ATPAF1 intron 19043545 rs611468 chr1 47124479 A G 5.11E-04 Multiple complex diseases ATPAF1 intron 17554300 rs611468 chr1 47124479 A G 6.63E-05 Serum metabolites ATPAF1 intron 19043545 rs7354865 chr1 47124999 C T 4.68E-04 Multiple complex diseases ATPAF1 intron 17554300 rs12094663 chr1 47134321 T G 3.42E-04 Multiple complex diseases / / 17554300 rs1025806 chr1 47139103 C T 5.24E-04 Multiple complex diseases ATPAF1-AS1 missense 17554300 rs1025806 chr1 47139103 C T 3.59E-05 Alzheimer's disease (late onset) ATPAF1-AS1 missense 23565137 rs1025806 chr1 47139103 C T 9.73E-04 Alzheimer's disease (late onset) ATPAF1-AS1 missense 23565137 rs625590 chr1 47139675 C T 4.55E-04 Multiple complex diseases / / 17554300 rs1048380 chr1 47142538 G A 1.00E-04 Asthma (childhood onset) KIAA0494 UTR-3 21696813 rs1048351 chr1 47143480 C T 3.08E-05 Alzheimer's disease (late onset) KIAA0494 UTR-3 23565137 rs1048351 chr1 47143480 C T 8.72E-04 Alzheimer's disease (late onset) KIAA0494 UTR-3 23565137 rs7412469 chr1 47146533 T C 5.46E-04 Multiple complex diseases KIAA0494 intron 17554300 rs7412469 chr1 47146533 T C 3.59E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs7412469 chr1 47146533 T C 9.73E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs2275380 chr1 47147728 C T 1.25E-04 Multiple complex diseases KIAA0494 intron 17554300 rs2275380 chr1 47147728 C T 4.99E-05 Serum metabolites KIAA0494 intron 19043545 rs1150064 chr1 47148044 T A 8.79E-05 Asthma (childhood onset) KIAA0494 intron 21696813 rs2119301 chr1 47153547 C A,G,T 6.54E-04 Multiple complex diseases KIAA0494 intron 17554300 rs2304745 chr1 47154272 C T 3.60E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs2304745 chr1 47154272 C T 9.76E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs61782563 chr1 47158266 A G 3.59E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs61782563 chr1 47158266 A G 9.68E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs61782564 chr1 47158649 C T 3.62E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs61782564 chr1 47158649 C T 9.78E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs3766217 chr1 47159109 G T 3.97E-04 Multiple complex diseases KIAA0494 intron 17554300 rs3766217 chr1 47159109 G T 3.59E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs3766217 chr1 47159109 G T 9.73E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs34932727 chr1 47161275 G A 4.38E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs2405026 chr1 47162648 T C 3.44E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs2405026 chr1 47162648 T C 9.26E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs4274009 chr1 47165879 G A 3.26E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs4274009 chr1 47165879 G A 8.75E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs55914029 chr1 47166848 G A 3.10E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs55914029 chr1 47166848 G A 8.29E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs1440486 chr1 47167238 C T 2.26E-05 Asthma (childhood onset) KIAA0494 intron 21696813 rs1440486 chr1 47167238 C T 3.11E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs1440486 chr1 47167238 C T 8.20E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs60675294 chr1 47169845 C G 3.07E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs60675294 chr1 47169845 C G 8.04E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs61782568 chr1 47171101 T C 3.06E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs61782568 chr1 47171101 T C 8.01E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs10158678 chr1 47176606 C T 1.81E-04 Multiple complex diseases KIAA0494 intron 17554300 rs2218189 chr1 47176818 T C 1.00E-04 Asthma (childhood onset) KIAA0494 intron 21696813 rs12071983 chr1 47178065 T C 1.52E-04 Multiple complex diseases KIAA0494 intron 17554300 rs6688195 chr1 47178195 C T 2.98E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs6688195 chr1 47178195 C T 7.82E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs10789491 chr1 47179310 A G 1.00E-06 Response to hepatitis C treatment KIAA0494 intron 22095909 rs3766215 chr1 47181022 C T 2.94E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs3766215 chr1 47181022 C T 7.60E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs3737731 chr1 47182206 C T 2.92E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs3737731 chr1 47182206 C T 7.36E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs3766212 chr1 47184181 C T 3.04E-04 Multiple complex diseases KIAA0494 UTR-5 17554300 rs3766212 chr1 47184181 C T 9.27E-05 Serum metabolites KIAA0494 UTR-5 19043545 rs3766211 chr1 47184196 A G 4.54E-04 Multiple complex diseases KIAA0494 UTR-5 17554300 rs8851 chr1 47184569 G C 3.33E-05 Alzheimer's disease (late onset) KIAA0494 UTR-5 23565137 rs8851 chr1 47184569 G C 7.96E-04 Alzheimer's disease (late onset) KIAA0494 UTR-5 23565137 rs17102473 chr1 47185155 G A 2.65E-05 Alzheimer's disease (late onset) / / 23565137 rs17102473 chr1 47185155 G A 6.41E-04 Alzheimer's disease (late onset) / / 23565137 rs6429608 chr1 47187036 A G 3.26E-04 Alzheimer's disease (late onset) / / 23565137 rs6429608 chr1 47187036 A G 9.80E-06 Alzheimer's disease (late onset) / / 23565137 rs7519866 chr1 47187255 A G 2.89E-04 Alzheimer's disease (late onset) / / 23565137 rs7519866 chr1 47187255 A G 9.66E-06 Alzheimer's disease (late onset) / / 23565137 rs6670495 chr1 47187908 T A 7.93E-06 Asthma (childhood onset) / / 21696813 rs4660957 chr1 47188150 G T 1.48E-05 Multiple complex diseases / / 17554300 rs6662321 chr1 47220059 C T 9.00E-04 Asthma (childhood onset) / / 21696813 rs201934421 chr1 47226827 TC T 2.21E-05 HDL cholesterol / / pha003075 rs986034 chr1 47226827 T G 2.21E-05 HDL cholesterol / / pha003075 rs11583588 chr1 47234335 G A 6.44E-05 Schizophrenia / / pha002859 rs1572603 chr1 47272403 G A 3.19E-04 White matter integrity CYP4B1 intron 22425255 rs4646486 chr1 47278997 T C 5.76E-05 White matter integrity CYP4B1 intron 22425255 rs4646487 chr1 47279175 C T 1 Drug response to Docetaxel CYP4B1 missense 20038957 rs4646487 chr1 47279175 C T 1 Drug response to Thalidomide CYP4B1 missense 20038957 rs4646487 chr1 47279175 C T 6.68E-05 White matter integrity CYP4B1 missense 22425255 rs4646492 chr1 47281183 C T 2.91E-05 White matter integrity CYP4B1 intron 22425255 rs4646493 chr1 47281302 A G 3.22E-05 White matter integrity CYP4B1 intron 22425255 rs17102599 chr1 47283344 G T 0.000000147 Triglycerides CYP4B1 intron 23063622 rs17102599 chr1 47283344 G T 0.000000176 Cholesterol,total CYP4B1 intron 23063622 rs4646495 chr1 47283505 G A,T 5.03E-05 White matter integrity CYP4B1 intron 22425255 rs12059860 chr1 47284923 T C 8.00E-06 Testosterone levels CYP4B1 UTR-3 22675492 rs17102644 chr1 47318400 G A 1.51E-05 White matter integrity CYP4Z2P intron 22425255 rs6665009 chr1 47321982 T C 1.78E-05 White matter integrity CYP4Z2P intron 22425255 rs6678639 chr1 47331966 A G 8.00E-86 Blood metabolite ratios CYP4Z2P intron 24816252 rs6663731 chr1 47347427 A T 1.00E-14 Blood metabolite levels CYP4Z2P intron 24816252 rs6663731 chr1 47347427 A T 5.00E-11 Blood metabolite levels CYP4Z2P intron 24816252 rs6687264 chr1 47374039 T C 1.51E-05 White matter integrity / / 22425255 rs11587251 chr1 47392596 G A 1.70E-04 White matter integrity / / 22425255 rs9333029 chr1 47396162 A G 2.00E-61 Blood metabolite levels CYP4A11 intron 24816252 rs9333016 chr1 47399034 C T 2.62E-05 Diabetes Mellitus CYP4A11 intron pha003059 rs9332998 chr1 47404186 T C 5.00E-32 Metabolic traits CYP4A11 intron 21886157 rs10789496 chr1 47416441 T C 9.30E-05 HIV-1 control / / 20041166 rs10789496 chr1 47416441 T C 4.32E-05 Diabetes Mellitus / / pha003059 rs150968551 chr1 47428558 T G 4.00E-07 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs9727862 chr1 47481616 G A 5.82E-04 Alcohol dependence / / 20201924 rs9727862 chr1 47481616 G A 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12140581 chr1 47517960 G C 8.07E-04 Smoking quantity / / 24665060 rs4926805 chr1 47572046 C T 4.01E-05 Orofacial clefts CYP4Z1 intron 22419666 rs7531972 chr1 47661620 A C 5.53E-05 Prion diseases / / 22210626 rs741959 chr1 47676233 A G 4.36E-07 Red blood cell traits / / 23222517 rs2070930 chr1 47683464 G A 6.03E-04 Insulin resistance TAL1 UTR-3 21901158 rs977747 chr1 47684677 T G 6.32E-07 Red blood cell traits TAL1 UTR-3 23222517 rs2984618 chr1 47690438 G T 8.50E-07 Red blood cell traits TAL1 intron 23222517 rs11211480 chr1 47693220 A G 3.22E-08 Red blood cell traits TAL1 intron 23222517 rs7534271 chr1 47693981 C G 8.61E-09 Red blood cell traits TAL1 intron 23222517 rs11211481 chr1 47694167 A G 5.30E-09 Red blood cell traits TAL1 intron 23222517 rs2798349 chr1 47698703 G A 2.50E-04 Multiple complex diseases / / 17554300 rs6700838 chr1 47700027 C T 1.01E-08 Red blood cell traits / / 23222517 rs1015890 chr1 47702229 G A 8.55E-07 Red blood cell traits / / 23222517 rs911910 chr1 47706970 G A 2.15E-08 Red blood cell traits / / 23222517 rs11211483 chr1 47707435 G C 1.04E-04 Insulin resistance / / 21901158 rs10890472 chr1 47708112 G T 4.96E-08 Red blood cell traits / / 23222517 rs13376679 chr1 47726087 T C 0.00013 Prostate cancer STIL missense 23555315 rs9436412 chr1 47766604 A G 6.58E-04 Multiple complex diseases STIL intron 17554300 rs17103186 chr1 47854514 C T 3.00E-12 Corneal curvature / / 24963161 rs60078183 chr1 47857307 G A 8.20E-12 Corneal curvature / / 24963161 rs6673934 chr1 47870564 G C 1.75E-05 Intracerebral hemorrhage / / 24656865 rs4926854 chr1 47870661 C T 4.31E-05 Intracerebral hemorrhage / / 24656865 rs55718554 chr1 47871581 C G 2.35E-05 Intracerebral hemorrhage / / 24656865 rs17103227 chr1 47889417 T C 9.78E-04 Coronary heart disease / / 21971053 rs2820972 chr1 47891585 T C 1.00E-33 Metabolite levels / / 22286219 rs527430 chr1 47918821 G A 4.00E-07 Response to antidepressant treatment / / 22041458 rs6588397 chr1 47943032 C T 1.49E-04 Response to alcohol consumption (flushing response) / / 24277619 rs11582540 chr1 48009997 C A 3.00E-06 Response to amphetamines / / 22952603 rs502392 chr1 48017067 T C 2.21E-05 stroke (ischemic) / / 17434096 rs17420782 chr1 48019222 A G 9.00E-06 Anxiety in major depressive disorder / / 24047446 rs685001 chr1 48025063 C A 9.00E-06 Obesity-related traits / / 23251661 rs2507007 chr1 48046320 G T 2.40E-04 Major depressive disorder / / 21042317 rs12402772 chr1 48062278 C T 1.81E-05 Type 2 diabetes / / 17463246 rs10890492 chr1 48063350 G A 1.41E-04 Renal cell carcinoma / / 22010048 rs12742768 chr1 48065019 A G 3.37E-04 Stroke / / pha002886 rs11211579 chr1 48095100 A G 4.24E-04 Insulin resistance / / 21901158 rs2506991 chr1 48098406 A G 2.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs2506987 chr1 48100829 A G 3.94E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs1876598 chr1 48102145 A C 2.69E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2457058 chr1 48102692 A G 3.39E-05 Follicular lymphoma / / 21533074 rs12133618 chr1 48215337 C T 8.00E-06 Urinary metabolites / / 21572414 rs1561572 chr1 48216886 G A 8.95E-04 Taste perception / / 22132133 rs11584807 chr1 48220454 C T 3.95E-05 Bilirubin levels,in serum / / 19389676 rs12085966 chr1 48229395 C T 2.92E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) LOC388630 UTR-3 24023788 rs12038866 chr1 48234217 G C 8.36E-04 Suicide attempts in bipolar disorder LOC388630 intron 21041247 rs6588505 chr1 48254782 C T 1.51E-04 White matter integrity LOC388630 intron 22425255 rs6588505 chr1 48254782 C T 9.00E-06 Obesity-related traits LOC388630 intron 23251661 rs4927069 chr1 48262619 A C 8.29E-04 White matter integrity LOC388630 intron 22425255 rs10890501 chr1 48270907 T G 5.35E-04 White matter integrity LOC388630 intron 22425255 rs6698119 chr1 48274987 A G 7.00E-06 Bone mineral density (BMD),in women LOC388630 intron 20164292 rs875398 chr1 48275263 G A 7.45E-05 White matter integrity LOC388630 intron 22425255 rs6667893 chr1 48287014 C T 1.58E-05 White matter integrity LOC388630 intron 22425255 rs11211611 chr1 48288016 C A 7.45E-05 White matter integrity LOC388630 intron 22425255 rs10890506 chr1 48295033 A G 1.72E-05 White matter integrity LOC388630 intron 22425255 rs12031340 chr1 48299660 T C 7.73E-06 Testosterone levels LOC388630 intron 22675492 rs10890507 chr1 48309587 T C 2.81E-04 White matter integrity LOC388630 intron 22425255 rs11211621 chr1 48319515 C T 9.94E-05 White matter integrity LOC388630 intron 22425255 rs946836 chr1 48321221 C T 5.00E-06 White matter integrity LOC388630 intron 22425255 rs367993311 chr1 48331522 CA CCA,CTG 5.64E-04 Taste perception LOC388630 intron 22132133 rs7536189 chr1 48331522 C T 5.64E-04 Taste perception LOC388630 intron 22132133 rs10890510 chr1 48334490 A C 1.58E-04 White matter integrity LOC388630 intron 22425255 rs884133 chr1 48335405 T C 7.26E-04 Insulin resistance LOC388630 intron 21901158 rs7556536 chr1 48335976 T A 7.32E-05 Serum metabolites LOC388630 intron 19043545 rs10493130 chr1 48341005 G A 1.92E-04 White matter integrity LOC388630 intron 22425255 rs12048888 chr1 48343224 T C 1.54E-05 White matter integrity LOC388630 intron 22425255 rs1497095 chr1 48386888 C T 3.79E-04 White matter integrity LOC388630 intron 22425255 rs10493131 chr1 48387427 C T 4.68E-04 Intracranial aneurysm LOC388630 intron 20613766 rs11211632 chr1 48406460 A G 1.44E-05 White matter integrity LOC388630 intron 22425255 rs11584659 chr1 48444398 C T 7.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC388630 intron 20877124 rs17103980 chr1 48445208 C A 7.25E-04 Insulin resistance LOC388630 intron 21901158 rs6695419 chr1 48479075 G A 9.69E-06 Multiple complex diseases / / 17554300 rs303925 chr1 48503280 C T 5.00E-04 Type 2 diabetes / / 17463246 rs6588642 chr1 48507037 C G 4.27E-04 Type 2 diabetes / / 17463246 rs7549671 chr1 48512119 C T 4.59E-04 Type 2 diabetes / / 17463246 rs560004 chr1 48549673 T C 8.91E-04 Bone mass and geometry / / 17903296 rs555774 chr1 48556111 G A 5.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs17428691 chr1 48567117 G A 7.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs12741362 chr1 48606878 G A 4.47E-04 Smoking initiation SKINTL intron 24665060 rs17104225 chr1 48630940 C T 2.36E-05 Multiple complex diseases SKINTL intron 17554300 rs11205449 chr1 48647124 T G 5.92E-05 Serum metabolites SKINTL intron 19043545 rs11205449 chr1 48647124 T G 3.57E-05 Orofacial clefts SKINTL intron 22419666 rs1740109 chr1 48672113 C A,G 8.93E-04 Obesity (extreme) / / 21935397 rs533598 chr1 48673521 C A 4.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs537303 chr1 48673936 T C 6.45E-04 Obesity (extreme) / / 21935397 rs490631 chr1 48683405 A T 5.96E-04 Obesity (extreme) / / 21935397 rs960722 chr1 48683611 C T 1.28E-05 Orofacial clefts / / 22419666 rs212989 chr1 48695081 G A 9.84E-04 Obesity (extreme) SLC5A9 missense 21935397 rs540944 chr1 48705879 T C 5.78E-04 Obesity (extreme) SLC5A9 intron 21935397 rs850763 chr1 48708228 G T 8.96E-04 Obesity (extreme) SLC5A9 STOP-GAIN 21935397 rs986027 chr1 48713394 C T 9.10E-06 Stroke (ischemic) SLC5A9 UTR-3 22384361 rs498502 chr1 48725096 G C 6.36E-04 Multiple complex diseases / / 17554300 rs12085605 chr1 48784409 C G 6.31E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs1418105 chr1 48785665 C T 6.35E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2067692 chr1 48796120 C A 6.30E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs11205475 chr1 48802740 C A 6.64E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs3767614 chr1 48804443 G C 5.86E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs968183 chr1 48818458 T C 6.66E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs17429004 chr1 48823047 A G 8.92E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs932087 chr1 48824156 A T 7.30E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs11205480 chr1 48839282 A T 5.70E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs11205481 chr1 48843171 C G 6.02E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2252984 chr1 48867985 C T 2.32E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2803280 chr1 48880280 G A 1.89E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs1416048 chr1 48882926 A G 2.07E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2255264 chr1 48911430 C T 3.16E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2255525 chr1 48925577 T G 2.01E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2803282 chr1 48932772 C G 3.07E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2245681 chr1 48937351 G C 1.91E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2798127 chr1 48951377 T A 7.87E-05 Suicide attempts in bipolar disorder / / 21423239 rs17470284 chr1 48959577 G A 3.78E-06 Gallstones / / 17632509 rs12032082 chr1 48965583 C T 6.64E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs12722731 chr1 48988124 T C 4.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs12078199 chr1 48992153 A C 4.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs2798119 chr1 48996065 T C 7.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs2246557 chr1 49001780 C T 5.34E-04 Acute lung injury AGBL4 intron 22295056 rs2803270 chr1 49031238 C T 9.16E-07 Esophageal cancer (squamous cell) AGBL4 intron 22960999 rs11802042 chr1 49033734 A C 9.73E-04 Acute lung injury AGBL4 intron 22295056 rs2798095 chr1 49036512 G A 5.40E-06 Urinary metabolites AGBL4 intron 21572414 rs17373183 chr1 49037217 C T 3.04E-04 Type 2 diabetes AGBL4 intron 17463246 rs17104522 chr1 49040423 C T 1.21E-04 Suicide attempts in bipolar disorder AGBL4 intron 21423239 rs10493134 chr1 49042952 A G 4.92E-05 Suicide attempts in bipolar disorder AGBL4 intron 21423239 rs6665839 chr1 49043877 C T 1.80E-06 Urinary metabolites AGBL4 intron 21572414 rs319960 chr1 49059615 C T 1.91E-04 Response to taxane treatment (placlitaxel) AGBL4 intron 23006423 rs11583036 chr1 49064097 T C 2.67E-04 Osteoarthritis (knee and hip) AGBL4 intron 21177295 rs11583036 chr1 49064097 T C 2.70E-05 Osteoarthritis (knee and hip) AGBL4 intron 21177295 rs11583036 chr1 49064097 T C 3.11E-04 Osteoarthritis (knee and hip) AGBL4 intron 21177295 rs319978 chr1 49067379 C T 1.45E-06 Osteoarthritis (knee and hip) AGBL4 intron 21177295 rs319978 chr1 49067379 C T 1.70E-06 Osteoarthritis (knee and hip) AGBL4 intron 21177295 rs319978 chr1 49067379 C T 7.74E-05 Osteoarthritis (knee and hip) AGBL4 intron 21177295 rs320027 chr1 49082023 C T 2.20E-05 Urinary metabolites AGBL4 intron 21572414 rs12566140 chr1 49087404 G A 7.85E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs11205517 chr1 49092039 T C 2.82E-04 Type 2 diabetes AGBL4 intron 17463246 rs7516699 chr1 49098326 A G 1.50E-05 Urinary metabolites AGBL4 intron 21572414 rs12562662 chr1 49104486 T C 7.33E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs7535727 chr1 49106290 G T 8.74E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs7535727 chr1 49106290 G T 9.10E-06 Urinary metabolites AGBL4 intron 21572414 rs12058997 chr1 49107826 T C 8.69E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs973886 chr1 49120520 T G 2.57E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs6674328 chr1 49122201 C T 2.70E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs7556311 chr1 49123567 G A 3.06E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs7556329 chr1 49123618 G C 3.07E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs444167 chr1 49138646 A G 9.44E-04 Myopia (pathological) AGBL4 intron 21095009 rs319959 chr1 49145514 G T 0.000268 Salmonella-induced pyroptosis AGBL4 intron 22837397 rs319981 chr1 49151886 A G 0.000494 Salmonella-induced pyroptosis AGBL4 intron 22837397 rs6695778 chr1 49164688 A C 3.12E-05 Multiple complex diseases AGBL4 intron 17554300 rs4926747 chr1 49165860 C T 4.60E-05 Lung adenocarcinoma AGBL4 intron 22797724 rs320062 chr1 49179307 T C 1.83E-04 Amyotrophic lateral sclerosis (sporadic) AGBL4 intron 24529757 rs17104710 chr1 49179498 G A 8.94E-05 Cognitive impairment induced by topiramate AGBL4 intron 22091778 rs1385152 chr1 49193394 G T 5.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) AGBL4 intron 20877124 rs6661901 chr1 49196060 G A 5.30E-05 Asthma (bronchodilator response) BEND5 intron 22792082 rs4926749 chr1 49203349 C A 5.80E-05 Creatinine levels BEND5 intron 20222955 rs11588373 chr1 49215159 T A 1.79E-04 Insulin resistance BEND5 intron 21901158 rs12407980 chr1 49220637 G A 4.23E-04 Insulin resistance BEND5 intron 21901158 rs12086219 chr1 49221303 G A 6.95E-05 Multiple complex diseases BEND5 intron 17554300 rs1934377 chr1 49237975 C A 7.38E-04 Multiple complex diseases BEND5 intron 17554300 rs7514802 chr1 49268066 T C 7.43E-04 Multiple complex diseases AGBL4 intron 17554300 rs4457622 chr1 49346828 C T 3.96E-04 Body mass index AGBL4 intron 17255346 rs4457622 chr1 49346828 C T 1.02E-04 Type 2 diabetes AGBL4 intron 17463246 rs2032022 chr1 49388622 T G 9.34E-05 Alzheimer's disease AGBL4 intron 22832961 rs1343432 chr1 49396989 G C 1.82E-04 Major depressive disorder AGBL4 intron 22472876 rs17105335 chr1 49436107 T C 5.42E-05 Amyotrophic Lateral Sclerosis AGBL4 intron 18057069 rs3121514 chr1 49451272 T C 6.41E-05 Bipolar disorder and schizophrenia AGBL4 intron 20889312 rs3118223 chr1 49463801 G A 8.20E-04 Crohn's disease AGBL4 intron 17684544 rs3127556 chr1 49468025 G A 9.12E-04 Multiple complex diseases AGBL4 intron 17554300 rs6669433 chr1 49482703 A C 7.67E-04 Multiple complex diseases AGBL4 intron 17554300 rs7536787 chr1 49525465 C T 9.39E-04 Multiple complex diseases AGBL4 intron 17554300 rs11205596 chr1 49541827 G T 7.84E-04 Type 2 diabetes AGBL4 intron 17463246 rs11205596 chr1 49541827 G T 9.20E-05 Personality dimensions AGBL4 intron 18957941 rs6588238 chr1 49552036 C T 3.95E-05 Multiple complex diseases AGBL4 intron 17554300 rs7527364 chr1 49566557 A G 5.64E-05 Bipolar disorder and schizophrenia AGBL4 intron 20889312 rs590503 chr1 49581006 C T 8.42E-04 Alzheimer's disease AGBL4 intron 22005930 rs483330 chr1 49591977 G A 5.11E-05 Bipolar disorder and schizophrenia AGBL4 intron 20889312 rs11591141 chr1 49664304 C T 2.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) AGBL4 intron 23648065 rs925043 chr1 49695123 G A,C,T 4.99E-12 Gout AGBL4 intron pha001406 rs1431638 chr1 49762418 C T 2.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) AGBL4 intron 23648065 rs17105629 chr1 49799321 T C 2.89E-04 Multiple complex diseases AGBL4 intron 17554300 rs6659225 chr1 49822433 T C 2.50E-04 Primary sclerosing cholangitis AGBL4 intron 19944697 rs1415985 chr1 49930749 T C 1.20E-05 Alzheimer's disease (late onset) AGBL4 intron 21460841 rs1933271 chr1 49949006 C T 2.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) AGBL4 intron 23648065 rs1949995 chr1 49975795 G C 0.0004159 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) AGBL4 intron 23233654 rs1949995 chr1 49975795 G C 4.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) AGBL4 intron 23233662 rs2178085 chr1 50023956 C T 2.70E-05 Response to lithium treatment in bipolar disorder AGBL4 intron 19448189 rs17105712 chr1 50052684 T C 3.45E-04 Multiple complex diseases AGBL4 intron 17554300 rs10888663 chr1 50081573 A C 7.91E-04 Alzheimer's disease AGBL4 intron 24755620 rs2211459 chr1 50104642 G A 6.40E-04 Alzheimer's disease AGBL4 intron 24755620 rs2051086 chr1 50105201 T A,C 9.08E-04 Response to taxane treatment (placlitaxel) AGBL4 intron 23006423 rs2051086 chr1 50105201 T A,C 0.0005304 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) AGBL4 intron 23233654 rs2051086 chr1 50105201 T A,C 5.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) AGBL4 intron 23233662 rs2051086 chr1 50105201 T A,C 5.30E-04 Response to antipsychotic treatment AGBL4 intron 23241943 rs1343161 chr1 50110850 G A 3.30E-04 Primary sclerosing cholangitis AGBL4 intron 19944697 rs4408195 chr1 50128198 G A 2.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) AGBL4 intron 23648065 rs12135410 chr1 50141741 T C 6.96E-04 Alzheimer's disease AGBL4 intron 24755620 rs11205641 chr1 50185075 A G 8.40E-06 Alzheimer's disease (late onset) AGBL4 intron 20885792 rs11205641 chr1 50185075 A G 8.40E-06 Alzheimer's disease (late onset) AGBL4 intron 21460841 rs4926829 chr1 50220117 C T 7.32E-04 Alzheimer's disease AGBL4 intron 24755620 rs12144042 chr1 50229397 G A 7.74E-04 Alzheimer's disease AGBL4 intron 24755620 rs4926831 chr1 50290101 C T 1.20E-05 Alzheimer's disease (late onset) AGBL4 intron 20885792 rs4926831 chr1 50290101 C T 1.20E-05 Alzheimer's disease (late onset) AGBL4 intron 21460841 rs6675647 chr1 50308556 C T 6.08E-04 Multiple complex diseases AGBL4 intron 17554300 rs4926833 chr1 50311454 G A 0.0008306 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) AGBL4 intron 23233654 rs4926833 chr1 50311454 G A 8.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) AGBL4 intron 23233662 rs12067197 chr1 50366482 A G 6.50E-04 Alzheimer's disease AGBL4 intron 24755620 rs7518987 chr1 50426542 A G 6.34E-04 Alzheimer's disease AGBL4 intron 24755620 rs9659092 chr1 50443589 A G 4.50E-06 Alzheimer's disease (late onset) AGBL4 intron 20885792 rs9659092 chr1 50443589 A G 4.50E-06 Alzheimer's disease (late onset) AGBL4 intron 21460841 rs12758298 chr1 50484613 C A 1.80E-05 Response to lithium treatment in bipolar disorder AGBL4 intron 19448189 rs10888678 chr1 50509729 G A 9.07E-04 Alzheimer's disease / / 24755620 rs4525085 chr1 50534526 A G 6.40E-04 Alzheimer's disease ELAVL4 intron 24755620 rs4926548 chr1 50547166 T A 6.54E-04 Alzheimer's disease ELAVL4 intron 24755620 rs6673246 chr1 50554373 G A 6.54E-04 Alzheimer's disease ELAVL4 intron 24755620 rs11583200 chr1 50559820 C T 1.80E-05 Alzheimer's disease (late onset) ELAVL4 intron 20885792 rs11583200 chr1 50559820 C T 1.80E-05 Alzheimer's disease (late onset) ELAVL4 intron 21460841 rs11205682 chr1 50567676 T C 6.94E-04 Alzheimer's disease ELAVL4 intron 24755620 rs11205683 chr1 50570665 G A 7.92E-04 Alzheimer's disease ELAVL4 intron 24755620 rs2480693 chr1 50588665 C T 7.58E-04 Multiple complex diseases ELAVL4 intron 17554300 rs9436447 chr1 50590732 G A 7.90E-04 Alcohol dependence ELAVL4 intron 20201924 rs9436447 chr1 50590732 G A 8.10E-04 Alcohol dependence ELAVL4 intron 20201924 rs2494884 chr1 50591405 G T 2.43E-04 Multiple complex diseases ELAVL4 intron 17554300 rs2494884 chr1 50591405 G T 7.70E-05 Creatinine levels ELAVL4 intron pha003069 rs12092053 chr1 50607029 T G 6.00E-06 Obesity-related traits ELAVL4 intron 23251661 rs12081193 chr1 50698759 C A 8.70E-05 Coffee consumption / / 21357676 rs4926853 chr1 50709222 A G 8.56E-04 Type 2 diabetes / / 17463246 rs4926853 chr1 50709222 A G 0.0003 Migraine / / 22678113 rs1393637 chr1 50753599 C T 5.13E-04 Bipolar disorder / / 19259986 rs1875635 chr1 50765982 G A 8.60E-05 Body Mass Index / / pha003009 rs12566635 chr1 50791465 T C 4.81E-04 Smoking cessation / / 24665060 rs6689749 chr1 50800516 G T 4.58E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs6657279 chr1 50808295 A G 5.90E-05 Panic disorder / / 19165232 rs1110220 chr1 50815397 A G 7.30E-05 Lung adenocarcinoma / / 22797724 rs11205712 chr1 50817701 G A 5.24E-05 Multiple complex diseases / / 17554300 rs7517924 chr1 50844929 T G 8.34E-04 Multiple complex diseases / / 17554300 rs2055491 chr1 50852769 T C 4.77E-04 Multiple complex diseases / / 17554300 rs2484676 chr1 50872673 A T 1.88E-04 Multiple complex diseases / / 17554300 rs2484676 chr1 50872673 A T 8.88E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs1278537 chr1 50882159 G T 7.10E-04 Alcohol dependence / / 20201924 rs1278530 chr1 50889255 G A 1.40E-04 Alcohol dependence / / 20201924 rs1278530 chr1 50889255 G A 1.60E-04 Alcohol dependence / / 20201924 rs7550594 chr1 50891093 C T 9.64E-07 Schizophrenia / / 21926974 rs7550594 chr1 50891093 C T 1.33E-04 Self-reported allergy / / 23817569 rs4381241 chr1 50907438 T C 1.50E-04 Alcohol dependence FAF1 intron 20201924 rs4381241 chr1 50907438 T C 1.70E-04 Alcohol dependence FAF1 intron 20201924 rs17106184 chr1 50909985 G A 4.00E-09 Type 2 diabetes FAF1 intron 24509480 rs956084 chr1 50911347 C T 1.50E-10 HDL cholesterol FAF1 intron 23063622 rs12134715 chr1 50912441 A C 2.38E-05 Personality dimensions FAF1 intron 22628180 rs12134715 chr1 50912441 A C 1.37E-05 Self-reported allergy FAF1 intron 23817569 rs12565493 chr1 50917596 T C 2.47E-05 Personality dimensions FAF1 intron 22628180 rs12565493 chr1 50917596 T C 1.57E-05 Self-reported allergy FAF1 intron 23817569 rs12142848 chr1 50918388 C T 2.41E-05 Personality dimensions FAF1 intron 22628180 rs12142848 chr1 50918388 C T 1.60E-05 Self-reported allergy FAF1 intron 23817569 rs12133928 chr1 50919942 T C 2.66E-05 Personality dimensions FAF1 intron 22628180 rs12133928 chr1 50919942 T C 1.48E-05 Self-reported allergy FAF1 intron 23817569 rs12063722 chr1 50931102 C T 5.85E-04 Multiple complex diseases FAF1 intron 17554300 rs12562938 chr1 50931160 C T 3.25E-05 Personality dimensions FAF1 intron 22628180 rs3827730 chr1 50937848 T C 1.40E-06 Alcohol dependence FAF1 intron 20201924 rs3827730 chr1 50937848 T C 4.10E-05 Alcohol dependence FAF1 intron 20201924 rs3827730 chr1 50937848 T C 4.00E-06 Depression and alcohol dependence FAF1 intron 22064162 rs3827730 chr1 50937848 T C 1.42E-06 Alcoholism FAF1 intron pha002892 rs3827730 chr1 50937848 T C 4.08E-05 Alcoholism FAF1 intron pha002893 rs3789576 chr1 50945526 G T 9.78E-04 Response to cytidine analogues (gemcitabine) FAF1 intron 24483146 rs12116432 chr1 50949724 A T 3.65E-05 Personality dimensions FAF1 intron 22628180 rs12116432 chr1 50949724 A T 2.14E-05 Self-reported allergy FAF1 intron 23817569 rs9645408 chr1 50983135 T C 3.28E-05 Self-reported allergy FAF1 intron 23817569 rs11205726 chr1 50986057 C T 4.30E-05 Self-reported allergy FAF1 intron 23817569 rs10888691 chr1 50991426 G C 4.37E-05 Self-reported allergy FAF1 intron 23817569 rs12135541 chr1 50997461 T C 4.82E-05 Self-reported allergy FAF1 intron 23817569 rs12137729 chr1 50999860 T C 4.44E-05 Self-reported allergy FAF1 intron 23817569 rs3789584 chr1 51029387 T C 2.22E-04 Multiple complex diseases FAF1 intron 17554300 rs12118892 chr1 51029609 G T 2.00E-05 Urinary metabolites FAF1 intron 21572414 rs12118892 chr1 51029609 G T 4.88E-05 Self-reported allergy FAF1 intron 23817569 rs12073534 chr1 51034926 T C 6.90E-05 Self-reported allergy FAF1 intron 23817569 rs12122697 chr1 51043243 G T 6.04E-05 Self-reported allergy FAF1 intron 23817569 rs3789585 chr1 51051105 G C 6.13E-05 Self-reported allergy FAF1 intron 23817569 rs11205738 chr1 51060054 G A 6.10E-05 Self-reported allergy FAF1 intron 23817569 rs12568008 chr1 51076822 G A 2.00E-05 Urinary metabolites FAF1 intron 21572414 rs12568008 chr1 51076822 G A 5.47E-05 Self-reported allergy FAF1 intron 23817569 rs17106336 chr1 51078564 T C 2.78E-04 Multiple complex diseases FAF1 intron 17554300 rs17106336 chr1 51078564 T C 1.20E-05 Urinary metabolites FAF1 intron 21572414 rs17106336 chr1 51078564 T C 5.65E-05 Self-reported allergy FAF1 intron 23817569 rs11205741 chr1 51079296 C A 6.93E-05 Self-reported allergy FAF1 intron 23817569 rs10888700 chr1 51086337 T C 1.22E-04 Multiple complex diseases FAF1 intron 17554300 rs11577903 chr1 51086847 T C 4.45E-05 Self-reported allergy FAF1 intron 23817569 rs11205743 chr1 51087465 C G 9.30E-06 Multiple complex diseases FAF1 intron 17554300 rs11205743 chr1 51087465 C G 4.72E-05 Self-reported allergy FAF1 intron 23817569 rs10788929 chr1 51090942 T C 8.81E-05 Self-reported allergy FAF1 intron 23817569 rs12120719 chr1 51092829 T C 1.95E-05 Self-reported allergy FAF1 intron 23817569 rs11577260 chr1 51094117 G A 6.61E-05 Self-reported allergy FAF1 intron 23817569 rs11205748 chr1 51100042 A G 7.42E-05 Self-reported allergy FAF1 intron 23817569 rs12567589 chr1 51110167 C T 7.73E-05 Self-reported allergy FAF1 intron 23817569 rs11205750 chr1 51113531 A G 7.60E-05 Self-reported allergy FAF1 intron 23817569 rs11205752 chr1 51116645 T C 7.12E-05 Self-reported allergy FAF1 intron 23817569 rs10888703 chr1 51118706 C A 6.58E-05 Self-reported allergy FAF1 intron 23817569 rs12117653 chr1 51123315 C A 7.42E-05 Self-reported allergy FAF1 intron 23817569 rs11205760 chr1 51174330 C T 1.67E-05 Multiple complex diseases FAF1 intron 17554300 rs11205760 chr1 51174330 C T 3.40E-05 Alcohol dependence FAF1 intron 20201924 rs11205760 chr1 51174330 C T 6.90E-04 Alcohol dependence FAF1 intron 20201924 rs11205760 chr1 51174330 C T 3.37E-05 Alcoholism FAF1 intron pha002892 rs6680846 chr1 51188674 G C 3.16E-04 Multiple complex diseases FAF1 intron 17554300 rs12239279 chr1 51304834 G A 1.48E-05 Height FAF1 intron 22021425 rs12092977 chr1 51410517 T C 6.40E-15 HDL cholesterol FAF1 intron 23063622 rs3813634 chr1 51475488 G A 7.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs3813634 chr1 51475488 G A 4.50E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs12092511 chr1 51477088 G A 6.85E-04 Multiple complex diseases / / 17554300 rs12092511 chr1 51477088 G A 7.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs7555006 chr1 51480258 A G 3.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs17391905 chr1 51546140 T G 3.00E-10 Ventricular conduction / / 21076409 rs11807353 chr1 51615023 C A 1.40E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11205821 chr1 51631884 C T 5.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17106443 chr1 51644702 A G 5.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17106443 chr1 51644702 A G 8.91E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12728955 chr1 51709522 T C 8.27E-05 Schizophrenia (cytomegalovirus infection interaction) RNF11 intron 23358160 rs6701572 chr1 51719315 G A 6.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RNF11 intron 20877124 rs3748615 chr1 51753722 G A 1.91E-04 Response to cytidine analogues (gemcitabine) TTC39A UTR-3 24483146 rs17392930 chr1 51753904 G A,C,T 0.0000104 LDL cholesterol particle diameter TTC39A missense 23263444 rs11205836 chr1 51804731 C T 3.40E-05 Diabetes Mellitus TTC39A intron pha003060 rs6659736 chr1 51814274 C T 1.30E-07 Lymphocyte counts / / 22286170 rs6673480 chr1 51859242 C T 2.00E-06 IgE grass sensitization EPS15 intron 22036096 rs7411629 chr1 52005824 T C 0.0000684 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10399893 chr1 52010157 G A 2.50E-05 Urinary metabolites / / 21572414 rs10399889 chr1 52010203 C T 1.60E-05 Urinary metabolites / / 21572414 rs12732738 chr1 52032789 A G 2.80E-05 Urinary metabolites / / 21572414 rs13375698 chr1 52059408 T A 2.26E-04 Multiple complex diseases / / 17554300 rs856614 chr1 52252006 A G 2.32E-05 Body Mass Index OSBPL9 intron pha003006 rs856614 chr1 52252006 A G 2.26E-05 Body Mass Index OSBPL9 intron pha003019 rs856614 chr1 52252006 A G 2.42E-05 Body Mass Index OSBPL9 intron pha003020 rs1004815 chr1 52258725 T A,C,G 3.00E-05 Alcohol dependence NRD1 intron 21703634 rs1417364 chr1 52263082 G A 9.18E-06 Alcohol dependence NRD1 intron 21703634 rs8375 chr1 52266242 G A,C,T 2.00E-05 Smoking behavior NRD1 cds-synon 20418888 rs7551758 chr1 52274078 T G 1.30E-05 Smoking behavior NRD1 intron 20418888 rs2747525 chr1 52284018 A C 4.80E-06 Smoking behavior NRD1 intron 20418888 rs11205896 chr1 52290984 T G 1.70E-05 Smoking behavior NRD1 cds-synon 20418888 rs2077725 chr1 52293570 G A 1.60E-05 Smoking behavior NRD1 intron 20418888 rs2077725 chr1 52293570 G A 8.92E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) NRD1 intron 23648065 rs11205897 chr1 52298151 C T 2.50E-05 Smoking behavior NRD1 intron 20418888 rs6702037 chr1 52310756 A G 6.30E-06 Smoking behavior NRD1 intron 20418888 rs4422953 chr1 52310882 C T 8.70E-06 Smoking behavior NRD1 intron 20418888 rs6676789 chr1 52316785 T C 6.40E-06 Smoking behavior NRD1 intron 20418888 rs6676789 chr1 52316785 T C 8.92E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) NRD1 intron 23648065 rs883058 chr1 52317231 T A 1.10E-05 Smoking behavior NRD1 intron 20418888 rs7526552 chr1 52320559 T C 1.90E-05 Smoking behavior NRD1 intron 20418888 rs6691091 chr1 52323772 G C 4.60E-05 Smoking behavior NRD1 intron 20418888 rs2842576 chr1 52324228 C T 6.07E-06 Alcohol dependence NRD1 intron 20202923 rs2842576 chr1 52324228 C T 7.90E-06 Alcohol dependence NRD1 intron 21703634 rs2842576 chr1 52324228 C T 2.50E-04 Alcohol dependence NRD1 intron 21956439 rs6588415 chr1 52334047 A G 1.10E-05 Smoking behavior NRD1 intron 20418888 rs1538881 chr1 52337039 T C 6.30E-06 Smoking behavior NRD1 intron 20418888 rs1538881 chr1 52337039 T C 5.42E-05 Prostate cancer NRD1 intron pha002878 rs1890946 chr1 52342427 T C 6.00E-06 Smoking behavior NRD1 intron 20418888 rs6663305 chr1 52343297 A G 8.40E-06 Smoking behavior NRD1 intron 20418888 rs6663305 chr1 52343297 A G 8.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) NRD1 intron 23648065 rs138608728 chr1 52344157 G A 0.000012 Breast cancer (ER positive) NRD1 missense 23555315 rs736756 chr1 52344414 A C 2.90E-05 Smoking behavior NRD1 UTR-5 20418888 rs11205902 chr1 52348769 G T 2.91E-04 Alzheimer's disease / / 17998437 rs11205902 chr1 52348769 G T 5.00E-05 Smoking behavior / / 20418888 rs6588416 chr1 52375424 T C 2.94E-04 Alzheimer's disease RAB3B UTR-3 17998437 rs6588416 chr1 52375424 T C 7.80E-05 Serum metabolites RAB3B UTR-3 19043545 rs1954260 chr1 52391032 C T 4.70E-06 Smoking behavior RAB3B intron 20418888 rs11205911 chr1 52396312 A G 6.30E-07 Smoking behavior RAB3B intron 20418888 rs12566236 chr1 52396943 G T 7.10E-07 Smoking behavior RAB3B intron 20418888 rs10888740 chr1 52400097 A G 2.60E-06 Smoking behavior RAB3B intron 20418888 rs6698110 chr1 52404141 T C 2.10E-07 Smoking behavior RAB3B intron 20418888 rs1935289 chr1 52406872 T C 4.60E-06 Smoking behavior RAB3B intron 20418888 rs2809943 chr1 52416140 C T 4.18E-04 Alzheimer's disease RAB3B intron 17998437 rs2809943 chr1 52416140 C T 5.15E-05 Serum metabolites RAB3B intron 19043545 rs2809944 chr1 52417538 T C 6.91E-05 Multiple sclerosis RAB3B intron 20598377 rs7541308 chr1 52418121 G T 1.70E-06 Smoking behavior RAB3B intron 20418888 rs6686975 chr1 52423134 G A 6.70E-06 Smoking behavior RAB3B intron 20418888 rs10888743 chr1 52423167 C T 4.20E-06 Smoking behavior RAB3B intron 20418888 rs12039206 chr1 52569002 A G 7.09E-04 Multiple complex diseases / / 17554300 rs1288706 chr1 52754871 G A 7.59E-05 Erythrocyte counts ZFYVE9 intron pha003099 rs2753399 chr1 52774357 T C 0.0000116 Menopause (age at onset) ZFYVE9 intron 23424626 rs2762819 chr1 52798033 G A 9.21E-04 Insulin resistance ZFYVE9 intron 21901158 rs9633423 chr1 52836139 G A 1.70E-05 Smoking behavior / / 20418888 rs9633423 chr1 52836139 G A 4.71E-11 Lymphocyte counts / / 22286170 rs3087476 chr1 52854961 G A 2.57E-04 Insulin resistance ORC1 missense 21901158 rs835036 chr1 52997240 T C 1.40E-05 Smoking behavior ZCCHC11 intron 20418888 rs12138419 chr1 53056187 G A 3.98E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs17374258 chr1 53110002 C T 2.46E-05 Menopause (age at onset) FAM159A intron 22267201 rs706497 chr1 53114736 T C 4.70E-05 Myasthenia gravis FAM159A intron 23055271 rs856721 chr1 53162156 C A 0.00056 Salmonella-induced pyroptosis SELRC1 intron 22837397 rs374662 chr1 53164549 C A 0.00022 Salmonella-induced pyroptosis / / 22837397 rs440871 chr1 53173052 C T 0.000303 Salmonella-induced pyroptosis / / 22837397 rs425520 chr1 53179805 C G 0.000312 Salmonella-induced pyroptosis / / 22837397 rs6703127 chr1 53180565 C T 0.000235 Salmonella-induced pyroptosis / / 22837397 rs146750 chr1 53183447 C G 0.000403 Salmonella-induced pyroptosis / / 22837397 rs374849 chr1 53185631 G A 0.000378 Salmonella-induced pyroptosis / / 22837397 rs269293 chr1 53187767 A C 0.000454 Salmonella-induced pyroptosis / / 22837397 rs4926930 chr1 53217335 A G 0.000789 Salmonella-induced pyroptosis ZYG11B intron 22837397 rs505444 chr1 53251860 T C 4.68E-30 Narcolepsy ZYG11B intron 19629137 rs12731800 chr1 53286967 A G 2.10E-06 Urinary metabolites ZYG11B intron 21572414 rs551591 chr1 53301876 A G 0.0000573 Salmonella-induced pyroptosis / / 22837397 rs504816 chr1 53307957 T G 0.000035 Salmonella-induced pyroptosis / / 22837397 rs514406 chr1 53330458 A G 5.73E-04 Multiple complex diseases ZYG11A intron 17554300 rs514881 chr1 53336737 C T 0.000561 Salmonella-induced pyroptosis ZYG11A intron 22837397 rs481440 chr1 53344976 C T 8.08E-04 Alcohol dependence ZYG11A intron 21314694 rs139969883 chr1 53377291 C T 0.000069 Breast cancer ECHDC2 missense 23555315 rs11206061 chr1 53455899 T C 7.43E-04 Suicide attempts in bipolar disorder SCP2 intron 21423239 rs11581638 chr1 53459690 C T 6.00E-04 Multiple complex diseases SCP2 UTR-3 17554300 rs11588200 chr1 53512519 G T 5.07E-04 Multiple complex diseases SCP2 intron 17554300 rs6664845 chr1 53514497 C G 8.84E-04 Multiple complex diseases SCP2 intron 17554300 rs4926946 chr1 53515101 C A 5.51E-04 Multiple complex diseases SCP2 intron 17554300 rs17107767 chr1 53517997 T C 7.30E-04 Multiple complex diseases / / 17554300 rs12096165 chr1 53518049 T G 9.29E-04 Multiple complex diseases / / 17554300 rs11584649 chr1 53530487 C T 3.75E-04 Multiple complex diseases PODN intron 17554300 rs17107812 chr1 53532920 C A 5.08E-04 Insulin resistance PODN intron 21901158 rs6697308 chr1 53534687 C G 8.47E-04 Multiple complex diseases PODN intron 17554300 rs2275456 chr1 53536025 T C 0.0000031 Chronic obstructive pulmonary disease (moderate to severe) PODN intron 22986903 rs11583585 chr1 53554406 T C 2.98E-04 Type 2 diabetes SLC1A7 intron 17463246 rs4926953 chr1 53569492 T C 2.57E-04 Type 2 diabetes SLC1A7 intron 17463246 rs17108032 chr1 53580585 G A 0.000000667 Triglycerides SLC1A7 cds-synon 23063622 rs17108032 chr1 53580585 G A 5.41E-10 Cholesterol,total SLC1A7 cds-synon 23063622 rs3820201 chr1 53581670 A G 1.00E-06 Hippocampal atrophy SLC1A7 intron 22745009 rs3753600 chr1 53591287 G A 1.37E-11 Triglycerides SLC1A7 intron 23063622 rs3753600 chr1 53591287 G A 2.85E-11 HDL cholesterol SLC1A7 intron 23063622 rs34418279 chr1 53608425 C A 3.33E-04 Multiple complex diseases / / 17554300 rs7556421 chr1 53619482 C T 8.42E-05 Height / / pha003011 rs6695567 chr1 53629585 G A 3.62E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6695567 chr1 53629585 G A 4.00E-06 Systemic lupus erythematosus / / 21408207 rs1288331 chr1 53631049 T C 2.93E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7531337 chr1 53641911 C A 6.66E-04 Type 2 diabetes / / 17463246 rs12058755 chr1 53670451 G A 2.46E-08 Cholesterol,total CPT2 intron 23063622 rs11578832 chr1 53674542 G A 5.20E-04 Coronary heart disease CPT2 intron 21966275 rs13375749 chr1 53695882 T C 8.30E-04 Myocardial infarction MAGOH intron 21107343 rs13375749 chr1 53695882 T C 3.00E-28 Blood metabolite levels MAGOH intron 24816252 rs2297656 chr1 53701581 A G 5.28E-05 Bipolar disorder and schizophrenia MAGOH intron 20889312 rs17785382 chr1 53707953 A G 2.73E-05 Bipolar disorder and schizophrenia LOC100507564 intron 20889312 rs17785382 chr1 53707953 A G 5.59E-07 Bipolar disorder LOC100507564 intron 22182935 rs17785382 chr1 53707953 A G 1.74E-05 Schizophrenia LOC100507564 intron pha002857 rs5177 chr1 53711735 G C 8.10E-05 Bipolar disorder and schizophrenia LRP8 UTR-3 20889312 rs5177 chr1 53711735 G C 5.00E-05 Schizophrenia LRP8 UTR-3 pha002857 rs5176 chr1 53711809 T G 3.44E-37 LDL cholesterol LRP8 UTR-3 23063622 rs5176 chr1 53711809 T G 5.12E-52 HDL cholesterol LRP8 UTR-3 23063622 rs5176 chr1 53711809 T G 6.51E-78 Cholesterol,total LRP8 UTR-3 23063622 rs5176 chr1 53711809 T G 8.86E-21 Triglycerides LRP8 UTR-3 23063622 rs5174 chr1 53712727 C T 3.40E-05 Schizophrenia LRP8 missense 21791550 rs5174 chr1 53712727 C T 0.000000094 Psychosis LRP8 missense 23164818 rs10788950 chr1 53713336 A G 5.50E-04 Response to taxane treatment (placlitaxel) LRP8 intron 23006423 rs11206127 chr1 53713549 G A 4.25E-05 Bipolar disorder and schizophrenia LRP8 intron 20889312 rs11206127 chr1 53713549 G A 3.16E-05 Schizophrenia LRP8 intron pha002857 rs869987 chr1 53723190 G T 3.86E-05 Bipolar disorder and schizophrenia LRP8 intron 20889312 rs869987 chr1 53723190 G T 4.54E-05 Schizophrenia LRP8 intron pha002857 rs869988 chr1 53723349 T C 5.85E-05 Bipolar disorder and schizophrenia LRP8 intron 20889312 rs2297661 chr1 53723965 C G 0.00000038 Cholesterol,total LRP8 intron 23063622 rs1288489 chr1 53772544 C G 1.60E-04 Type 2 diabetes LRP8 intron 17463246 rs2788032 chr1 53777631 A C 6.00E-06 Body mass index (interaction) LRP8 intron 23192594 rs2788032 chr1 53777631 A C 1.18E-04 Amyotrophic lateral sclerosis (sporadic) LRP8 intron 24529757 rs872314 chr1 53787483 A G 5.92E-06 Multiple complex diseases LRP8 intron 17554300 rs3820198 chr1 53792651 A C 2.70E-05 Alcohol dependence LRP8 missense 22096494 rs12354192 chr1 53796783 C T 2.39E-04 Multiple complex diseases / / 17554300 rs1416095 chr1 53808693 A G 1.20E-05 Alcohol dependence / / 22096494 rs10888780 chr1 53813684 A G 3.72E-05 Cognitive test performance / / 20125193 rs12041966 chr1 53832697 T C 9.88E-05 Type 2 diabetes / / 17463246 rs17108398 chr1 53845985 G A 2.50E-05 Urinary metabolites / / 21572414 rs6660818 chr1 53857444 T A 7.30E-06 Urinary metabolites / / 21572414 rs114216682 chr1 53871085 G C 7.00E-08 Chronic obstructive pulmonary disease / / 21685187 rs1776421 chr1 53884457 C T 6.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs9436924 chr1 53913080 C T 7.30E-06 Nicotine use / / 23942779 rs41366756 chr1 53917443 C T 5.48E-04 Multiple complex diseases / / 17554300 rs41443646 chr1 53921571 T C 8.18E-04 Multiple complex diseases / / 17554300 rs1108989 chr1 53929463 T A 6.69E-05 Arthritis (juvenile idiopathic) DMRTB1 intron 22354554 rs1288632 chr1 53929536 C G 5.71E-05 Arthritis (juvenile idiopathic) DMRTB1 intron 22354554 rs11579575 chr1 53936718 G T 9.24E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1296438 chr1 53937177 A G 7.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1296438 chr1 53937177 A G 1.00E-04 Illicit drug use / / 23942779 rs1296438 chr1 53937177 A G 6.20E-04 Non-substance related behavioral disinhibition / / 23942779 rs1296438 chr1 53937177 A G 7.90E-06 Nicotine use / / 23942779 rs17108559 chr1 53947868 C T 1.48E-04 Multiple complex diseases / / 17554300 rs1298637 chr1 53958603 C T 1.60E-04 Illicit drug use / / 23942779 rs1298637 chr1 53958603 C T 3.80E-04 Non-substance related behavioral disinhibition / / 23942779 rs1298637 chr1 53958603 C T 5.00E-06 Nicotine use / / 23942779 rs943519 chr1 53965546 C T 5.17E-05 Cognitive test performance / / 20125193 rs10749691 chr1 53974987 G T 1.30E-05 Response to statin therapy GLIS1 intron 20339536 rs10749691 chr1 53974987 G T 2.85E-05 Smoking initiation GLIS1 intron 24665060 rs475322 chr1 53975436 C A 5.19E-04 Smoking initiation GLIS1 intron 24665060 rs2280511 chr1 53976188 C T 2.60E-05 Response to statin therapy GLIS1 intron 20339536 rs6588480 chr1 53978119 A G 8.00E-06 Response to statin therapy GLIS1 intron 20339536 rs11206169 chr1 54005060 C T 8.02E-04 Type 2 diabetes GLIS1 intron 17463246 rs3889128 chr1 54009233 G C 3.10E-05 Anger GLIS1 intron 24489884 rs2986655 chr1 54011192 A G 2.96E-05 stroke (ischemic) GLIS1 intron 17434096 rs41488848 chr1 54011503 G C 2.83E-04 Multiple complex diseases GLIS1 intron 17554300 rs12141264 chr1 54020542 C T 2.75E-05 Myopia (pathological) GLIS1 intron 23049088 rs2873096 chr1 54029856 C A 3.83E-04 Lung function (forced vital capacity) GLIS1 intron 24023788 rs2091407 chr1 54032698 G A 2.50E-05 Urinary metabolites GLIS1 intron 21572414 rs11206174 chr1 54038523 G C 2.40E-05 Urinary metabolites GLIS1 intron 21572414 rs10788958 chr1 54040670 C G 2.50E-06 Digit length ratio GLIS1 intron 20303062 rs4926603 chr1 54041558 G A 6.00E-06 Digit length ratio GLIS1 intron 20303062 rs2950250 chr1 54042714 T G 9.50E-07 Digit length ratio GLIS1 intron 20303062 rs3108391 chr1 54042889 C T 6.40E-06 Digit length ratio GLIS1 intron 20303062 rs4634849 chr1 54043110 C T 8.40E-06 Digit length ratio GLIS1 intron 20303062 rs11585273 chr1 54043386 G A 6.80E-06 Digit length ratio GLIS1 intron 20303062 rs11585344 chr1 54043786 G A 6.70E-06 Digit length ratio GLIS1 intron 20303062 rs12089978 chr1 54045180 T C 6.80E-06 Digit length ratio GLIS1 intron 20303062 rs12084713 chr1 54045226 G A 7.10E-06 Digit length ratio GLIS1 intron 20303062 rs17386087 chr1 54045624 T C 4.90E-04 Alzheimer's disease GLIS1 intron 17998437 rs17386087 chr1 54045624 T C 7.00E-06 Digit length ratio GLIS1 intron 20303062 rs17386108 chr1 54045718 T A 4.93E-04 Alzheimer's disease GLIS1 intron 17998437 rs17386108 chr1 54045718 T A 7.10E-06 Digit length ratio GLIS1 intron 20303062 rs12137291 chr1 54046217 G T 8.50E-06 Digit length ratio GLIS1 intron 20303062 rs941129 chr1 54046556 T C 7.89E-05 Cognitive test performance GLIS1 intron 20125193 rs3006884 chr1 54047225 G A 7.00E-06 Digit length ratio GLIS1 intron 20303062 rs12140369 chr1 54047882 A T 8.20E-06 Digit length ratio GLIS1 intron 20303062 rs2950252 chr1 54048719 C G 8.20E-06 Digit length ratio GLIS1 intron 20303062 rs2948045 chr1 54051898 T C 1.20E-06 Digit length ratio GLIS1 intron 20303062 rs4926604 chr1 54051924 T C 1.30E-06 Digit length ratio GLIS1 intron 20303062 rs6588482 chr1 54054618 T A 1.30E-06 Digit length ratio GLIS1 intron 20303062 rs1879735 chr1 54055693 A G 1.40E-06 Digit length ratio GLIS1 intron 20303062 rs4927011 chr1 54058231 C T 1.30E-06 Digit length ratio GLIS1 intron 20303062 rs7551844 chr1 54061333 T C 2.90E-06 Digit length ratio GLIS1 intron 20303062 rs7551844 chr1 54061333 T C 2.14E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy GLIS1 intron 23834954 rs10888795 chr1 54061446 G A 8.70E-06 Digit length ratio GLIS1 intron 20303062 rs6588483 chr1 54061779 G A 6.80E-06 Digit length ratio GLIS1 intron 20303062 rs3013754 chr1 54061978 A C 2.80E-06 Digit length ratio GLIS1 intron 20303062 rs2948053 chr1 54062273 A G 2.80E-06 Digit length ratio GLIS1 intron 20303062 rs10159298 chr1 54064240 C T 3.19E-05 Body Composition GLIS1 intron pha003012 rs10159298 chr1 54064240 C T 9.02E-05 Body Mass Index GLIS1 intron pha003021 rs17382220 chr1 54066599 A T 6.20E-06 Digit length ratio GLIS1 intron 20303062 rs4927012 chr1 54068016 C T 6.20E-06 Digit length ratio GLIS1 intron 20303062 rs6663966 chr1 54070013 C T 0.000052 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 GLIS1 intron 21873659 rs17382457 chr1 54071428 G A 4.50E-06 Digit length ratio GLIS1 intron 20303062 rs12563871 chr1 54071610 A G 4.50E-06 Digit length ratio GLIS1 intron 20303062 rs3013749 chr1 54072759 A T 5.00E-05 Height GLIS1 intron 19396169 rs2948048 chr1 54074729 G A 6.35E-05 Body Composition GLIS1 intron pha003012 rs7542387 chr1 54078923 A G 5.80E-06 Digit length ratio GLIS1 intron 20303062 rs11801290 chr1 54079964 G A 6.80E-06 Digit length ratio GLIS1 intron 20303062 rs3006898 chr1 54083312 T C 9.79E-05 Body Composition GLIS1 intron pha003012 rs2141079 chr1 54120873 C T 5.37E-04 Parkinson's disease GLIS1 intron 17052657 rs17109076 chr1 54129705 A G 7.00E-04 Multiple complex diseases GLIS1 intron 17554300 rs2950243 chr1 54135651 A G 5.80E-04 Multiple complex diseases GLIS1 intron 17554300 rs797913 chr1 54198562 C T 9.28E-04 Alcohol dependence GLIS1 intron 21314694 rs12075528 chr1 54199484 C T 4.88E-04 Alcohol dependence GLIS1 intron 21314694 rs761490 chr1 54216654 C G 3.00E-05 Social communication problems / / 24047820 rs4354491 chr1 54314043 C T 3.27E-06 Body Mass Index / / pha003019 rs4354491 chr1 54314043 C T 4.20E-05 Body Mass Index / / pha003020 rs4354491 chr1 54314043 C T 5.98E-05 Body Mass Index / / pha003022 rs11206226 chr1 54320337 A G 5.00E-06 Nonalcoholic fatty liver disease YIPF1 intron 22719876 rs6588492 chr1 54328025 G A 4.23E-05 Blood pressure (response to angiotensin II receptor blocker) YIPF1 intron 24192120 rs6681549 chr1 54328814 G A 8.83E-04 Type 2 diabetes YIPF1 intron 17463246 rs6588493 chr1 54328988 C A 8.41E-04 Type 2 diabetes YIPF1 intron 17463246 rs7541049 chr1 54343294 T C 7.11E-04 Type 2 diabetes YIPF1 intron 17463246 rs7541170 chr1 54343462 T C 6.46E-04 Type 2 diabetes YIPF1 intron 17463246 rs6680026 chr1 54345792 C T 4.23E-05 Blood pressure (response to angiotensin II receptor blocker) YIPF1 intron 24192120 rs12131461 chr1 54366364 G A 1.27E-05 Body Mass Index DIO1 intron pha003019 rs12131461 chr1 54366364 G A 6.05E-05 Body Mass Index DIO1 intron pha003020 rs3766467 chr1 54373185 G A,C,T 7.76E-05 Obesity (extreme) DIO1 intron 21935397 rs2235544 chr1 54375570 C A 3.00E-18 Thyroid hormone levels DIO1 intron 23408906 rs2235544 chr1 54375570 C A 5.00E-15 Thyroid hormone levels DIO1 intron 23408906 rs2235544 chr1 54375570 C A 8.00E-32 Thyroid hormone levels DIO1 intron 23408906 rs2235544 chr1 54375570 C A 6.00E-07 Multiple myeloma (hyperdiploidy) DIO1 intron 23502783 rs12073655 chr1 54393492 C A 6.11E-05 Obesity (extreme) HSPB11 intron 21935397 rs11206252 chr1 54397240 G A 6.14E-05 Obesity (extreme) HSPB11 intron 21935397 rs12092723 chr1 54422901 C G 2.77E-04 Multiple complex diseases LRRC42 intron 17554300 rs12092723 chr1 54422901 C G 7.00E-05 Obesity (extreme) LRRC42 intron 21935397 rs10888828 chr1 54441756 A G 2.20E-04 Obesity (extreme) / / 21935397 rs114147144 chr1 54443865 T C 3.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs11206266 chr1 54443867 C T 2.21E-04 Obesity (extreme) / / 21935397 rs638749 chr1 54450490 A G 9.82E-04 Myopia (pathological) / / 21095009 rs7515322 chr1 54450901 A G 7.26E-05 Multiple complex diseases / / 17554300 rs7515322 chr1 54450901 A G 1.91E-04 Obesity (extreme) / / 21935397 rs7525809 chr1 54451080 G A 3.62E-04 Multiple complex diseases / / 17554300 rs7525809 chr1 54451080 G A 1.91E-04 Obesity (extreme) / / 21935397 rs145889899 chr1 54476084 C T 0.00000014 Breast cancer(er negative) LDLRAD1 splice-5 23555315 rs145889899 chr1 54476084 C T 0.00000025 Breast cancer LDLRAD1 splice-5 23555315 rs17109656 chr1 54476147 G A 9.03E-05 Multiple complex diseases LDLRAD1 intron 17554300 rs17109656 chr1 54476147 G A 1.68E-04 Obesity (extreme) LDLRAD1 intron 21935397 rs11805505 chr1 54480410 T A 6.49E-04 Obesity (extreme) LDLRAD1 intron 21935397 rs12047169 chr1 54487417 C T 6.61E-04 Myopia (pathological) / / 21095009 rs6694292 chr1 54566190 G A 4.75E-04 Coronary Artery Disease / / 17634449 rs6694397 chr1 54566310 G A 5.03E-04 Coronary Artery Disease / / 17634449 rs12063422 chr1 54585415 T C 1.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs581554 chr1 54614409 C T 7.91E-04 Coronary heart disease CDCP2 intron 21606135 rs11587789 chr1 54615599 A C 4.50E-04 Alzheimer's disease CDCP2 intron 22005930 rs7519887 chr1 54619404 C T 7.27E-05 Cognitive test performance CDCP2 UTR-5 20125193 rs10493175 chr1 54636977 T C 8.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs625643 chr1 54637167 T C 8.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs625643 chr1 54637167 T C 3.23E-04 Coronary heart disease / / 21606135 rs682705 chr1 54637417 G A 9.07E-06 Parkinson's disease / / 16252231 rs7520966 chr1 54645262 T C 2.96E-05 Parkinson's disease CYB5RL intron 16252231 rs1890566 chr1 54668278 A G 8.00E-07 Migraine MRPL37 intron 23793025 rs17392549 chr1 54677786 G A 8.16E-04 Telomere length MRPL37 intron 23900074 rs4061073 chr1 54696743 A G 0.0000131 Carotid intima media thickness SSBP3 intron 23152477 rs4061073 chr1 54696743 A G 3.29E-04 Stroke SSBP3 intron pha002887 rs688383 chr1 54718489 T C 3.34E-04 Amyotrophic Lateral Sclerosis SSBP3 intron 17362836 rs655274 chr1 54721930 C T 2.61E-04 Amyotrophic Lateral Sclerosis SSBP3 intron 17362836 rs3766432 chr1 54729952 G C 6.98E-13 Metabolite levels SSBP3 intron 22286219 rs3766431 chr1 54730036 G A 1.60E-05 Smoking behavior SSBP3 intron 20418888 rs679200 chr1 54732940 A G 1.65E-04 Amyotrophic Lateral Sclerosis SSBP3 intron 17362836 rs603901 chr1 54741767 C T 4.21E-04 Amyotrophic Lateral Sclerosis SSBP3 intron 17362836 rs11206315 chr1 54743408 G A 0.00000625 Child behavior checklist/1.5-5 pervasive developmental problems SSBP3 intron 23049896 rs9326028 chr1 54750625 T C 9.68E-04 Aortic root size SSBP3 intron 21223598 rs4927081 chr1 54756342 T C 5.81E-04 Alcohol dependence SSBP3 intron 20201924 rs6678619 chr1 54762350 G A 6.85E-04 HIV-1 viral setpoint SSBP3 intron 17641165 rs4927086 chr1 54766101 T C 3.89E-04 Taste perception SSBP3 intron 22132133 rs7523947 chr1 54766816 C T 2.21E-04 Parkinson's disease SSBP3 intron 17052657 rs17390642 chr1 54768377 A G 2.00E-04 Taste perception SSBP3 intron 22132133 rs11206329 chr1 54777562 A G 6.31E-05 Major depressive disorder (broad) SSBP3 intron 20038947 rs7524749 chr1 54779243 G A 6.34E-05 Major depressive disorder (broad) SSBP3 intron 20038947 rs12021758 chr1 54787049 T C 5.96E-04 Multiple complex diseases SSBP3 intron 17554300 rs12021758 chr1 54787049 T C 1.62E-04 Gallstones SSBP3 intron 17632509 rs17110393 chr1 54790576 G A 1.10E-05 Urinary metabolites SSBP3 intron 21572414 rs12404565 chr1 54796148 T C 4.32E-04 Multiple complex diseases SSBP3 intron 17554300 rs2317387 chr1 54830569 A C 4.00E-04 Acute lymphoblastic leukemia (childhood) SSBP3 intron 20189245 rs11206344 chr1 54852994 C A 7.49E-05 Longevity SSBP3 intron 20304771 rs6690450 chr1 54854079 C A 9.09E-05 Longevity SSBP3 intron 20304771 rs213490 chr1 54854984 G A 8.02E-05 Longevity SSBP3 intron 20304771 rs213496 chr1 54869816 T C 2.68E-04 Body mass index SSBP3 intron 21701565 rs213496 chr1 54869816 T C 3.16E-04 Body mass index SSBP3 intron 21701565 rs4244644 chr1 54883163 C T 9.65E-05 Response to citalopram treatment / / 19846067 rs4927107 chr1 54888245 A C 3.85E-05 Response to citalopram treatment / / 19846067 rs7550485 chr1 54928493 G A 9.63E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs190963 chr1 54946847 G A 1.70E-06 Glioma (high-grade) / / 19578366 rs4927133 chr1 54953523 T C 4.98E-05 Cognitive test performance / / 20125193 rs299895 chr1 54962448 C T 7.60E-04 Multiple complex diseases / / 17554300 rs1888182 chr1 54967890 C T 8.64E-04 Taste perception / / 22132133 rs299881 chr1 54968494 T C 3.17E-04 Taste perception / / 22132133 rs4927134 chr1 54984107 A C 0.000000041 Dependent (behavior influenced) stressful life events / / 23237013 rs4927134 chr1 54984107 A C 0.000000058 Stressful life events / / 23237013 rs11809810 chr1 55023706 A G 5.07E-09 Triglycerides ACOT11 intron 23063622 rs449484 chr1 55030530 A G 1.51E-04 Body mass index ACOT11 intron 21701565 rs449484 chr1 55030530 A G 4.97E-05 Body mass index ACOT11 intron 21701565 rs537696 chr1 55031313 C A 3.26E-04 Blood pressure ACOT11 intron 17255346 rs300280 chr1 55033869 T C 4.74E-06 Waist Circumference ACOT11 intron pha003023 rs300271 chr1 55046039 G T 5.23E-05 Waist Circumference ACOT11 intron pha003023 rs17110757 chr1 55049806 G A 7.90E-07 Glioma (high-grade) ACOT11 intron 19578366 rs1702002 chr1 55060548 C T 1.32E-04 Body mass index ACOT11 intron 21701565 rs1702002 chr1 55060548 C T 3.74E-04 Body mass index ACOT11 intron 21701565 rs4927139 chr1 55061254 T G 1.91E-04 Body mass index ACOT11 intron 21701565 rs4927139 chr1 55061254 T G 4.11E-04 Body mass index ACOT11 intron 21701565 rs732509 chr1 55067992 A G 1.20E-04 Body mass index ACOT11 intron 21701565 rs732509 chr1 55067992 A G 2.45E-04 Body mass index ACOT11 intron 21701565 rs17398958 chr1 55071769 G T 4.47E-05 Coronary heart disease ACOT11 intron pha003031 rs2289015 chr1 55075062 C T 1.74E-05 Response to treatment for acute lymphoblastic leukemia FAM151A missense 19176441 rs2117262 chr1 55089880 A G 8.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ACOT11 intron 20877124 rs10736390 chr1 55103945 A G 1.88E-05 Pancreatic cancer / / 23180869 rs1368882 chr1 55107019 G A 2.00E-06 Non-substance related behavioral disinhibition / / 23942779 rs1368882 chr1 55107019 G A 2.10E-04 Nicotine use / / 23942779 rs1368882 chr1 55107019 G A 2.90E-04 Alcohol dependence / / 23942779 rs10888859 chr1 55117520 G A 2.00E-04 Cognitive impairment induced by topiramate HEATR8 intron 22091778 rs558184 chr1 55123936 C T 3.50E-07 Urinary metabolites HEATR8 intron 21572414 rs1529783 chr1 55129564 T C 4.62E-04 Multiple complex diseases HEATR8 intron 17554300 rs1180937 chr1 55191644 T C 8.38E-05 Prostate cancer TTC4 intron pha002878 rs61768793 chr1 55193477 A G 7.40E-11 Metabolite levels TTC4 intron 22286219 rs2873551 chr1 55217907 T C 2.60E-05 Type 2 diabetes / / 19184112 rs2108035 chr1 55218155 C T 2.41E-04 Blood pressure / / 17255346 rs2108035 chr1 55218155 C T 7.47E-04 Schizophrenia / / 19197363 rs2240396 chr1 55223190 C T 2.98E-06 Blood pressure PARS2 UTR-3 17255346 rs1180955 chr1 55225846 T C 1.22E-05 Serum metabolites PARS2 intron 19043545 rs1180948 chr1 55228159 C G 1.11E-05 Serum metabolites PARS2 intron 19043545 rs10430114 chr1 55234711 G T 1.76E-06 Blood pressure / / 17255346 rs10888879 chr1 55243590 G T 1.35E-05 Multiple complex diseases / / 17554300 rs12740946 chr1 55244197 T C 7.52E-05 Stroke / / pha002887 rs619476 chr1 55263551 T C 5.39E-04 Response to cytidine analogues (gemcitabine) TTC22 intron 24483146 rs671108 chr1 55266797 G C 5.72E-04 Response to cytidine analogues (gemcitabine) TTC22 missense 24483146 rs689322 chr1 55267509 G A 6.94E-04 Schizophrenia TTC22 nearGene-5 21674006 rs616315 chr1 55278841 G A 3.26E-04 Response to cytidine analogues (gemcitabine) C1orf177 intron 24483146 rs7549251 chr1 55304970 G A 1.80E-06 Stroke (ischemic) C1orf177 intron 22384361 rs17111100 chr1 55307693 C A 2.73E-04 Response to cytadine analogues (cytosine arabinoside) C1orf177 UTR-3 24483146 rs11206451 chr1 55311452 C T 2.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs687912 chr1 55312440 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs683737 chr1 55314142 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1138030 chr1 55317685 G A 2.16E-04 Response to cytadine analogues (cytosine arabinoside) DHCR24 UTR-3 24483146 rs642737 chr1 55333453 A G 5.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DHCR24 intron 20877124 rs1469344 chr1 55386167 C T 1.30E-05 Urinary metabolites / / 21572414 rs677321 chr1 55387362 C T 5.67E-04 Type 2 diabetes / / 17463246 rs678358 chr1 55387637 G T 7.04E-04 Type 2 diabetes / / 17463246 rs41517445 chr1 55389569 A G 4.47E-04 Type 2 diabetes / / 17463246 rs7522847 chr1 55394678 A G 3.42E-04 Cocaine dependence / / 23958962 rs7522847 chr1 55394678 A G 4.22E-04 Cocaine dependence / / 23958962 rs604778 chr1 55397406 T C 9.21E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6588538 chr1 55398277 C T 1.10E-06 Urinary metabolites / / 21572414 rs11206473 chr1 55398932 G A 9.20E-07 Urinary metabolites / / 21572414 rs1889209 chr1 55404022 A G 1.30E-05 Urinary metabolites / / 21572414 rs1889209 chr1 55404022 A G 2.11E-06 LDL cholesterol / / 23726366 rs11206476 chr1 55405850 G T 9.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs11206480 chr1 55416827 G T 1.92E-04 Cholesterol / / 17255346 rs11206482 chr1 55419855 C T 2.97E-04 Cholesterol / / 17255346 rs10218716 chr1 55425286 A G,T 7.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs7523658 chr1 55428397 C T 2.35E-04 Cholesterol / / 17255346 rs7551937 chr1 55430634 G A 7.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs2317948 chr1 55434443 T G 5.50E-06 Type 2 diabetes / / 17293876 rs2317948 chr1 55434443 T G 5.50E-06 Type 2 diabetes / / 19184112 rs2317948 chr1 55434443 T G 9.78E-05 Lactate dehydrogenase levels / / 20981236 rs1015979 chr1 55449273 C T 6.43E-04 Alzheimer's disease TMEM61 intron 17998437 rs13374752 chr1 55453391 A G 6.11E-06 Asthma (childhood onset) TMEM61 intron 23829686 rs2495513 chr1 55457815 C T 3.98E-05 Longevity / / 21612516 rs34561376 chr1 55464986 G A 0.0008 Prostate cancer BSND missense 23555315 rs759914 chr1 55465594 G T 6.16E-05 Atopy BSND intron 21625490 rs6682884 chr1 55474325 A C 1.00E-05 Urinary metabolites BSND UTR-3 21572414 rs4339899 chr1 55474476 C G 1.10E-05 Urinary metabolites BSND nearGene-3 21572414 rs2495505 chr1 55484810 C T 4.23E-05 Cognitive test performance / / 20125193 rs2479418 chr1 55494877 A G 5.28E-05 LDL lipoproteins / / pha002902 rs11206510 chr1 55496039 T C 4.00E-11 LDL cholesterol / / 18193043 rs11206510 chr1 55496039 T C 7.50E-06 Lipid levels / / 18193044 rs11206510 chr1 55496039 T C 4.00E-08 LDL cholesterol / / 19060906 rs11206510 chr1 55496039 T C 1.00E-08 Myocardial infarction (early onset) / / 19198609 rs11206510 chr1 55496039 T C 1.00E-10 LDL cholesterol / / 20864672 rs11206510 chr1 55496039 T C 1.00E-08 Coronary heart disease / / 21347282 rs11206510 chr1 55496039 T C 9.00E-08 Coronary heart disease / / 21378990 rs11206510 chr1 55496039 T C 2.44E-11 Metabolite levels / / 22286219 rs11206510 chr1 55496039 T C 9.10E-08 Pericardial fat / / 22589742 rs11206510 chr1 55496039 T C 1.66E-14 Cholesterol,total / / 23063622 rs11206510 chr1 55496039 T C 1.89E-15 LDL cholesterol / / 23063622 rs11206510 chr1 55496039 T C 0.00000015 LDL cholesterol / / 23100282 rs11206510 chr1 55496039 T C 0.0000076 Apolipoprotein B levels / / 23100282 rs11206510 chr1 55496039 T C 1.50E-07 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) / / 23103227 rs11206510 chr1 55496039 T C 0.0000703 Coronary artery disease with myocardial infarction / / 23202125 rs11206510 chr1 55496039 T C 0.000207 Triglycerides / / 23202125 rs11206510 chr1 55496039 T C 1.55E-21 Coronary artery disease (CAD) (males) / / 23202125 rs11206510 chr1 55496039 T C 2.04E-21 Coronary artery disease (CAD) age <=50 / / 23202125 rs11206510 chr1 55496039 T C 3.54E-20 Cholesterol,total / / 23202125 rs11206510 chr1 55496039 T C 4.07E-11 Coronary artery disease (CAD) (females) / / 23202125 rs11206510 chr1 55496039 T C 5.23E-20 LDL cholesterol / / 23202125 rs11206510 chr1 55496039 T C 7.12E-41 Coronary artery disease (CAD) age >50 / / 23202125 rs11206510 chr1 55496039 T C 2.03E-04 Coronary artery disease / / 24262325 rs2479415 chr1 55498745 C T 0.0000206 Circulating PCSK9 levels / / 22460556 rs2182833 chr1 55500429 A G 2.19E-09 Cholesterol,total / / 23063622 rs2182833 chr1 55500429 A G 2.76E-09 LDL cholesterol / / 23063622 rs10788994 chr1 55500976 C T 1.06E-09 Cholesterol,total / / 23063622 rs10788994 chr1 55500976 C T 5.40E-10 LDL cholesterol / / 23063622 rs2149041 chr1 55502137 C G 1.11E-09 LDL cholesterol / / 23063622 rs2149041 chr1 55502137 C G 1.68E-09 Cholesterol,total / / 23063622 rs17111503 chr1 55503448 A G 1.86E-11 Cholesterol,total PCSK9 nearGene-5 23063622 rs17111503 chr1 55503448 A G 6.29E-11 LDL cholesterol PCSK9 nearGene-5 23063622 rs2479409 chr1 55504650 G A 2.00E-28 LDL cholesterol PCSK9 nearGene-5 20686565 rs2479409 chr1 55504650 G A 4.00E-24 Cholesterol,total PCSK9 nearGene-5 20686565 rs2479409 chr1 55504650 G A 0.000179 Circulating PCSK9 levels PCSK9 nearGene-5 22460556 rs2479409 chr1 55504650 G A 1.03E-09 LDL cholesterol PCSK9 nearGene-5 23063622 rs2479409 chr1 55504650 G A 3.64E-09 Cholesterol,total PCSK9 nearGene-5 23063622 rs2479409 chr1 55504650 G A 2.00E-39 Cholesterol,total PCSK9 nearGene-5 24097068 rs2479409 chr1 55504650 G A 3.00E-50 LDL cholesterol PCSK9 nearGene-5 24097068 rs11591147 chr1 55505647 G T 2.00E-44 LDL cholesterol PCSK9 missense 18193044 rs11591147 chr1 55505647 G T 1.60E-07 Lipid levels PCSK9 missense 19802338 rs11591147 chr1 55505647 G T 1.80E-10 Lipid levels PCSK9 missense 19802338 rs11591147 chr1 55505647 G T 1.08E-10 Lipid levels PCSK9 missense 19913121 rs11591147 chr1 55505647 G T 4.95E-12 Lipid levels PCSK9 missense 19913121 rs11591147 chr1 55505647 G T 1.10E-09 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 1.15E-10 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 1.29E-28 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 1.30E-23 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 2.20E-13 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 2.30E-13 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 3.00E-08 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 3.57E-08 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 4.59E-12 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 5.30E-23 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 7.00E-22 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 7.75E-28 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 8.20E-18 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 2.86E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PCSK9 missense 20031582 rs11591147 chr1 55505647 G T 2.00E-44 Coronary heart disease PCSK9 missense 21347282 rs11591147 chr1 55505647 G T 5.00E-09 Response to statin therapy (LDL-C) PCSK9 missense 22331829 rs11591147 chr1 55505647 G T 2.05E-14 LDL cholesterol PCSK9 missense 22460556 rs11591147 chr1 55505647 G T 2.20E-15 Circulating PCSK9 levels PCSK9 missense 22460556 rs11591147 chr1 55505647 G T 1.73E-28 LDL cholesterol PCSK9 missense 22629316 rs11591147 chr1 55505647 G T 2.74E-14 LDL cholesterol (female) PCSK9 missense 22629316 rs11591147 chr1 55505647 G T 8.15E-18 LDL cholesterol (male) PCSK9 missense 22629316 rs11591147 chr1 55505647 G T 2.46E-52 Cholesterol,total PCSK9 missense 23063622 rs11591147 chr1 55505647 G T 3.11E-59 LDL cholesterol PCSK9 missense 23063622 rs11591147 chr1 55505647 G T 0.000836 LDL cholesterol PCSK9 missense 23236364 rs2479410 chr1 55505861 G A 1.38E-10 Cholesterol,total PCSK9 intron 23063622 rs2479410 chr1 55505861 G A 3.92E-11 LDL cholesterol PCSK9 intron 23063622 rs644000 chr1 55511995 A G 1.58E-10 LDL cholesterol PCSK9 intron 23063622 rs644000 chr1 55511995 A G 6.41E-09 Cholesterol,total PCSK9 intron 23063622 rs499718 chr1 55512549 T C 0.000165996 Primary sclerosing cholangitis PCSK9 intron 23603763 rs2495478 chr1 55512995 G A 1.00E-07 Wilms tumor PCSK9 intron 22544364 rs28362225 chr1 55513358 C A 5.81E-09 Triglycerides PCSK9 intron 23063622 rs11206514 chr1 55516004 C A 0.000000198 Cholesterol,total PCSK9 intron 23063622 rs11206514 chr1 55516004 C A 0.000000253 LDL cholesterol PCSK9 intron 23063622 rs10888898 chr1 55516508 A G 3.63E-08 Cholesterol,total PCSK9 intron 23063622 rs10888898 chr1 55516508 A G 5.85E-08 LDL cholesterol PCSK9 intron 23063622 rs11800231 chr1 55517940 G A,T 1.02E-10 LDL cholesterol PCSK9 intron 23236364 rs11806638 chr1 55518160 C A 0.000000108 LDL cholesterol (female) PCSK9 intron 22629316 rs11806638 chr1 55518160 C A 0.0000308 LDL cholesterol (male) PCSK9 intron 22629316 rs11806638 chr1 55518160 C A 4.65E-11 LDL cholesterol PCSK9 intron 22629316 rs11806638 chr1 55518160 C A 2.38E-14 Cholesterol,total PCSK9 intron 23236364 rs11806638 chr1 55518160 C A 6.85E-08 LDL cholesterol PCSK9 intron 23236364 rs2483205 chr1 55518316 C T 0.00000119 LDL cholesterol PCSK9 intron 23063622 rs2495477 chr1 55518467 A G 0.000000166 LDL cholesterol PCSK9 intron 23063622 rs2495477 chr1 55518467 A G 3.51E-09 Cholesterol,total PCSK9 intron 23063622 rs2479413 chr1 55518682 C T 1.09E-13 LDL cholesterol PCSK9 intron 23063622 rs2479413 chr1 55518682 C T 2.83E-13 Cholesterol,total PCSK9 intron 23063622 rs7552841 chr1 55518752 C T 7.90E-05 Coronary heart disease PCSK9 intron 21966275 rs499883 chr1 55519174 G A 1.45E-11 LDL cholesterol PCSK9 intron 22629316 rs499883 chr1 55519174 G A 1.29E-18 LDL cholesterol PCSK9 intron 23063622 rs499883 chr1 55519174 G A 7.16E-17 Cholesterol,total PCSK9 intron 23063622 rs1165287 chr1 55520212 G A 1.44E-09 LDL cholesterol PCSK9 intron 23063622 rs1165287 chr1 55520212 G A 3.03E-12 Cholesterol,total PCSK9 intron 23063622 rs1165287 chr1 55520212 G A 0.00000742 LDL cholesterol PCSK9 intron 23236364 rs634272 chr1 55520265 T C 3.57E-10 LDL cholesterol PCSK9 intron 23063622 rs634272 chr1 55520265 T C 4.16E-11 Cholesterol,total PCSK9 intron 23063622 rs557435 chr1 55520864 A G 0.000000133 LDL cholesterol PCSK9 intron 23063622 rs557435 chr1 55520864 A G 0.000000247 LDL cholesterol (male) PCSK9 intron 23063622 rs557435 chr1 55520864 A G 0.000000369 Total cholesterol in males PCSK9 intron 23063622 rs557435 chr1 55520864 A G 5.92E-08 Cholesterol,total PCSK9 intron 23063622 rs557435 chr1 55520864 A G 4.34E-05 LDL lipoproteins PCSK9 intron pha002902 rs471705 chr1 55521242 T G 3.23E-14 LDL cholesterol PCSK9 intron 23063622 rs471705 chr1 55521242 T G 7.84E-16 Cholesterol,total PCSK9 intron 23063622 rs7525407 chr1 55522425 G A 0.00000124 Cholesterol,total PCSK9 intron 23063622 rs7525407 chr1 55522425 G A 2.18E-08 LDL cholesterol PCSK9 intron 23063622 rs533375 chr1 55523361 A G 0.00000111 Cholesterol,total PCSK9 intron 23063622 rs533375 chr1 55523361 A G 1.16E-08 LDL cholesterol PCSK9 intron 23063622 rs562556 chr1 55524237 G A 0.00000029 LDL cholesterol PCSK9 missense 23063622 rs565436 chr1 55524601 G A 1.17E-09 LDL cholesterol PCSK9 intron 23063622 rs565436 chr1 55524601 G A 1.32E-09 Cholesterol,total PCSK9 intron 23063622 rs483462 chr1 55525400 G A 7.99E-04 Substance dependence PCSK9 intron 21818250 rs11206517 chr1 55526428 T G 1.34E-08 LDL cholesterol PCSK9 intron 23063622 rs631220 chr1 55527479 A G 0.000000207 LDL cholesterol PCSK9 intron 23063622 rs643257 chr1 55527918 C T 0.000000359 LDL cholesterol PCSK9 intron 23063622 rs505151 chr1 55529187 G A 9.88E-10 LDL cholesterol PCSK9 missense 22629316 rs505151 chr1 55529187 G A 1.91E-10 LDL cholesterol PCSK9 missense 23236364 rs505151 chr1 55529187 G A 3.09E-09 Cholesterol,total PCSK9 missense 23236364 rs17111568 chr1 55537198 G A 1.74E-04 Multiple complex diseases USP24 intron 17554300 rs17111584 chr1 55546696 T C 5.80E-04 Response to statin therapy (LDL-C) USP24 intron 22331829 rs683880 chr1 55546895 T C 5.67E-04 Substance dependence USP24 intron 21818250 rs17111652 chr1 55590465 C T 9.36E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) USP24 intron 22566498 rs17111657 chr1 55591283 C A 8.89E-04 Suicide attempts in bipolar disorder USP24 intron 21423239 rs17111684 chr1 55625548 C T 2.00E-17 LDL cholesterol USP24 intron 23726366 rs17111689 chr1 55627525 C G 5.07E-04 Suicide attempts in bipolar disorder USP24 intron 21423239 rs1115058 chr1 55653588 C T 8.79E-04 Suicide attempts in bipolar disorder USP24 intron 21423239 rs4926670 chr1 55662680 C T 3.07E-05 LDL lipoproteins USP24 intron pha002902 rs6671533 chr1 55670896 G C 3.94E-04 Suicide attempts in bipolar disorder USP24 intron 21041247 rs6703366 chr1 55673420 T G 6.08E-04 Suicide attempts in bipolar disorder USP24 intron 21041247 rs6668777 chr1 55683807 A C 6.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs7529366 chr1 55685344 A G 6.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs17111725 chr1 55686616 A G 8.95E-05 Serum metabolites / / 19043545 rs17111725 chr1 55686616 A G 5.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs7512894 chr1 55696547 G A 1.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs10788998 chr1 55699023 G A 8.57E-04 Suicide attempts in bipolar disorder / / 21041247 rs11206538 chr1 55715412 C T 1.13E-05 Esophageal cancer (squamous cell) / / 22960999 rs12409228 chr1 55725176 C T 0.0000692 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1018101 chr1 55725288 A G 0.0000641 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10888908 chr1 55726519 T C 1.42E-14 Metabolite levels / / 22286219 rs6662286 chr1 55730327 T C 1.46E-11 Metabolite levels / / 22286219 rs2088487 chr1 55739925 T C 1.97E-11 Metabolite levels / / 22286219 rs4927214 chr1 55742322 T C 6.59E-04 Type 2 diabetes / / 17463246 rs12239436 chr1 55742837 G A 5.00E-06 Coronary heart disease / / 21347282 rs1874774 chr1 55743297 T G 2.90E-04 Type 2 diabetes / / 17463246 rs12071742 chr1 55747825 G A 6.03E-04 Alzheimer's disease / / 22005930 rs17111834 chr1 55748606 G A 6.07E-04 Alzheimer's disease / / 22005930 rs17111847 chr1 55749478 T C 6.10E-04 Alzheimer's disease / / 22005930 rs10493202 chr1 55764106 A C 2.96E-04 Type 2 diabetes / / 17846124 rs207154 chr1 55781281 T C 1.18E-04 Blood pressure / / 17255346 rs207154 chr1 55781281 T C 1.79E-11 Metabolite levels / / 22286219 rs6676932 chr1 55785672 T C 3.20E-04 Blood pressure / / 17255346 rs17111925 chr1 55789351 G A 2.46E-05 Diabetic nephropathy / / pha002852 rs17111925 chr1 55789351 G A 6.56E-05 Diabetic nephropathy / / pha002864 rs726815 chr1 55790861 C T 3.88E-04 Blood pressure / / 17255346 rs10489488 chr1 55792722 G A 2.90E-04 Blood pressure / / 17255346 rs964219 chr1 55793244 A G 6.78E-05 Blood pressure / / 17255346 rs207167 chr1 55798859 T C 3.63E-12 Metabolite levels / / 22286219 rs207160 chr1 55803411 C T 8.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs207155 chr1 55804902 T C 2.40E-05 Blood pressure / / 17255346 rs207155 chr1 55804902 T C 1.28E-10 Metabolite levels / / 22286219 rs207150 chr1 55806465 T C 1.38E-05 Blood pressure / / 17255346 rs207150 chr1 55806465 T C 1.10E-06 LDL lipoproteins / / pha002902 rs207145 chr1 55808143 C T 4.68E-05 Blood pressure / / 17255346 rs207138 chr1 55811215 C T 1.84E-04 Vaspin levels / / 22907691 rs207138 chr1 55811215 C T 0.0001842 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs207136 chr1 55814164 C T 2.06E-05 Blood pressure / / 17255346 rs207136 chr1 55814164 C T 3.39E-04 Type 2 diabetes / / 17463246 rs207135 chr1 55814244 C T 2.06E-05 Blood pressure / / 17255346 rs207135 chr1 55814244 C T 4.76E-04 Type 2 diabetes / / 17463246 rs207129 chr1 55814908 A G 1.48E-10 Metabolite levels / / 22286219 rs207127 chr1 55815584 G A 2.26E-05 Blood pressure / / 17255346 rs207127 chr1 55815584 G A 3.92E-06 LDL lipoproteins / / pha002902 rs880385 chr1 55820099 T G 7.69E-04 Multiple complex diseases / / 17554300 rs2179853 chr1 55820713 A C 1.06E-05 Blood pressure / / 17255346 rs2802881 chr1 55831918 T C 6.60E-06 Blood pressure / / 17255346 rs7520205 chr1 55834309 G A 1.80E-06 Urinary metabolites / / 21572414 rs2746685 chr1 55837603 A G 6.60E-06 Blood pressure / / 17255346 rs3946077 chr1 55838572 G A 2.50E-05 Urinary metabolites / / 21572414 rs2746683 chr1 55841735 A C 3.76E-05 Blood pressure / / 17255346 rs2802877 chr1 55843810 C T 3.76E-05 Blood pressure / / 17255346 rs2802857 chr1 55863658 A G 3.00E-04 Blood pressure / / 17255346 rs761483 chr1 55874284 C T 1.42E-04 Blood pressure / / 17255346 rs6673648 chr1 55894893 C A 7.39E-05 Blood pressure / / 17255346 rs17406602 chr1 55909030 A G 3.84E-04 Sarcoidosis / / 19165924 rs12068336 chr1 55929930 G A 6.51E-05 Multiple complex diseases / / 17554300 rs11206601 chr1 55931747 T C 1.08E-04 Multiple complex diseases / / 17554300 rs874664 chr1 55933344 A G 1.58E-04 Multiple complex diseases / / 17554300 rs12568687 chr1 55934389 C T 1.58E-04 Multiple complex diseases / / 17554300 rs7532502 chr1 55938887 G A 3.22E-04 Multiple complex diseases / / 17554300 rs2649629 chr1 55953290 G A 5.48E-05 Blood pressure / / 17255346 rs1998013 chr1 55958030 C T 5.00E-13 Metabolite levels (atherosclerosis) / / 22916037 rs1780542 chr1 55963519 A G 2.09E-04 Blood pressure / / 17255346 rs1740125 chr1 55965199 C T 3.30E-04 Blood pressure / / 17255346 rs1740123 chr1 55969501 C T 3.25E-04 Blood pressure / / 17255346 rs1740118 chr1 55981250 G A 1.45E-04 Blood pressure / / 17255346 rs1695960 chr1 55983525 G A 3.27E-04 Blood pressure / / 17255346 rs356086 chr1 55994302 A G 2.85E-07 Common variable immunodeficiency / / 21497890 rs2649627 chr1 55998405 C T 4.21E-04 Blood pressure / / 17255346 rs6658576 chr1 56035952 T C 0.00039 Prostate cancer / / 23555315 rs17416739 chr1 56055848 C T 4.17E-08 Multiple complex diseases / / 17554300 rs17416739 chr1 56055848 C T 3.78E-07 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs4926690 chr1 56056400 G A 6.88E-05 Lymphocyte counts / / pha003094 rs4926690 chr1 56056400 G A 8.54E-05 Neutrophil count / / pha003095 rs10888935 chr1 56060951 T A 7.00E-07 Inflammatory biomarkers / / 22228203 rs6704127 chr1 56070382 A C 2.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1587432 chr1 56074120 A G 2.42E-04 Acute lung injury / / 22295056 rs1392132 chr1 56079739 T G 1.84E-04 Schizophrenia / / 20832056 rs17418151 chr1 56102010 C G 6.84E-05 Multiple sclerosis / / 17660530 rs1165472 chr1 56108604 A G 4.00E-06 Paclitaxel-induced neuropathy / / 23776197 rs10443215 chr1 56112774 C T 9.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel) / / 24025145 rs72669744 chr1 56116505 C T 1.00E-19 Lipid metabolism phenotypes / / 22286219 rs17112596 chr1 56120296 C T 5.02E-20 Metabolite levels / / 22286219 rs9436520 chr1 56137245 A G 8.73E-05 Hemoglobin concentration / / 20534544 rs2767503 chr1 56152725 T G 7.09E-05 Hemoglobin concentration / / 20534544 rs12565309 chr1 56157154 G A 1.82E-04 Alzheimer's disease (late onset) / / 21379329 rs9326037 chr1 56163458 G A 1.63E-04 Alzheimer's disease (late onset) / / 21379329 rs1183736 chr1 56183163 A C 3.76E-04 Hemoglobin concentration / / 20534544 rs11206661 chr1 56191097 C G 7.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs76831627 chr1 56198190 G T 6.66E-05 Acne (severe) / / 24927181 rs1165500 chr1 56219293 A C 3.59E-05 Telomere length / / 23900074 rs12061007 chr1 56233601 A G 7.54E-04 Multiple complex diseases / / 17554300 rs12061007 chr1 56233601 A G 2.84E-05 Lymphocyte counts / / 22286170 rs12092608 chr1 56240702 T C 4.81E-05 Telomere length / / 23900074 rs3122555 chr1 56263555 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6588574 chr1 56287724 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6659096 chr1 56292073 C A 4.24E-04 Multiple complex diseases / / 17554300 rs4497258 chr1 56317834 G A 9.72E-05 Bipolar disorder / / 19259986 rs9326038 chr1 56326293 G A 5.56E-06 Serum metabolites / / 19043545 rs6656739 chr1 56351783 T G 4.91E-04 Multiple complex diseases / / 17554300 rs6684428 chr1 56359813 T A 5.00E-07 Airflow obstruction / / 22837378 rs6699599 chr1 56405040 T C 7.31E-04 Smoking quantity LOC100507652 intron 24665060 rs7534660 chr1 56421196 G C 7.00E-04 Multiple complex diseases / / 17554300 rs7512875 chr1 56421399 C T 7.54E-04 Multiple complex diseases / / 17554300 rs6694316 chr1 56425121 G T 1.06E-05 Tuberculosis / / 24057671 rs2192102 chr1 56429031 C A 4.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs12409063 chr1 56432184 G A 4.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs11206704 chr1 56444449 C T 6.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11206709 chr1 56448410 T C 5.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11206729 chr1 56516424 T C 1.31E-04 Aortic root size / / 21223598 rs7512228 chr1 56574395 C T 5.67E-04 Aortic root size / / 21223598 rs778126 chr1 56605334 T G 6.54E-04 Aortic root size / / 21223598 rs1537226 chr1 56615004 G T 2.49E-04 Multiple complex diseases / / 17554300 rs2792788 chr1 56740723 T C 9.08E-04 Insulin resistance / / 21901158 rs1581995 chr1 56745004 C T 1.44E-05 Leprosy / / 22019778 rs10888965 chr1 56750081 T C 5.28E-04 Insulin resistance / / 21901158 rs12118755 chr1 56750366 C T 4.62E-05 Cognitive test performance / / 20125193 rs1341347 chr1 56763781 A G 5.81E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs3005884 chr1 56771709 C T 6.41E-04 Eye color / / 23118974 rs3005885 chr1 56776172 T A 6.00E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2994553 chr1 56785889 T G 2.42E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs3005897 chr1 56786595 C T 3.78E-04 Barrett's esophagus / / 24121790 rs12138574 chr1 56790773 C T 9.64E-06 Biliary atresia / / 20460270 rs3005907 chr1 56790785 T A 1.76E-04 Type 2 diabetes / / 17463246 rs3005914 chr1 56797754 T C 7.17E-05 Erythrocyte counts / / pha003101 rs3121168 chr1 56798123 G T 9.62E-05 Erythrocyte counts / / pha003101 rs2994565 chr1 56798308 A G 7.29E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2994565 chr1 56798308 A G 2.25E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs6670695 chr1 56799648 T A,C 0.00043318 Sarcoidosis / / 22952805 rs11206793 chr1 56802112 A T 8.66E-04 Depression (quantitative trait) / / 20800221 rs12079898 chr1 56804358 G A 7.34E-05 Depression (quantitative trait) / / 20800221 rs17113792 chr1 56829396 A G 7.88E-04 Depression (quantitative trait) / / 20800221 rs17113795 chr1 56840459 T A 7.85E-04 Depression (quantitative trait) / / 20800221 rs17113799 chr1 56844652 T C 5.47E-04 Depression (quantitative trait) / / 20800221 rs7539724 chr1 56845274 A G 5.42E-04 Depression (quantitative trait) / / 20800221 rs7538333 chr1 56848954 C T 1.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11206801 chr1 56850686 C A 6.00E-08 AB1-42 levels / / 20932310 rs11206802 chr1 56851200 G A 4.72E-04 Depression (quantitative trait) / / 20800221 rs4373790 chr1 56852348 C T 4.53E-04 Depression (quantitative trait) / / 20800221 rs7521622 chr1 56869084 T A 1.48E-04 Spine bone size / / 23207799 rs1931077 chr1 56870735 T C 5.64E-04 Spine bone size / / 23207799 rs3005922 chr1 56873524 G A 5.97E-04 Smoking quantity / / 24665060 rs11206803 chr1 56877509 C T 3.12E-04 Type 2 diabetes / / 17463246 rs884277 chr1 56881763 A G 1.43E-04 Type 2 diabetes / / 17463246 rs4363444 chr1 56898998 C T 2.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs875153 chr1 56900270 C T 4.30E-05 Celiac disease / / 17558408 rs7550882 chr1 56903392 C T 8.33E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2780293 chr1 56905072 A G 9.71E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2780293 chr1 56905072 A G 1.61E-10 Tumor biomarkers / / 23300138 rs2780293 chr1 56905072 A G 1.61E-10 Type 2 diabetes / / 23300278 rs6588628 chr1 56905211 A G 4.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6421495 chr1 56905445 T A 4.09E-04 Alcohol dependence / / 21314694 rs4319365 chr1 56907720 G A 5.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6694114 chr1 56909550 G A 9.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11206814 chr1 56918048 C T 0.0000267 Aging / / 22445811 rs7525717 chr1 56927638 G A 0.00000576 Aging / / 22445811 rs17114036 chr1 56962821 A G 4.00E-19 Coronary heart disease PPAP2B intron 21378990 rs17114036 chr1 56962821 A G 3.81E-19 Pericardial fat PPAP2B intron 22589742 rs17114036 chr1 56962821 A G 0.000266 Coronary artery disease (CAD) (females) PPAP2B intron 23202125 rs17114036 chr1 56962821 A G 0.000823 Coronary artery disease (CAD) age <=50 PPAP2B intron 23202125 rs17114036 chr1 56962821 A G 1.43E-09 Coronary artery disease (CAD) age >50 PPAP2B intron 23202125 rs17114036 chr1 56962821 A G 2.16E-08 Coronary artery disease with myocardial infarction PPAP2B intron 23202125 rs17114036 chr1 56962821 A G 5.80E-12 Coronary artery disease PPAP2B intron 23202125 rs17114036 chr1 56962821 A G 8.07E-08 Coronary artery disease (CAD) (males) PPAP2B intron 23202125 rs17114036 chr1 56962821 A G 1.00E-08 Coronary artery disease PPAP2B intron 24262325 rs17114036 chr1 56962821 A G 2.00E-08 Coronary artery disease or large artery stroke PPAP2B intron 24262325 rs17114036 chr1 56962821 A G 3.00E-08 Coronary artery disease or ischemic stroke PPAP2B intron 24262325 rs17114046 chr1 56966350 A G 2.00E-07 Coronary heart disease PPAP2B intron 21378988 rs17114046 chr1 56966350 A G 3.00E-07 Coronary heart disease PPAP2B intron 21846871 rs17114046 chr1 56966350 A G 4.04E-06 Coronary heart disease PPAP2B intron 22319020 rs4912314 chr1 56968477 C T 2.02E-05 Sickle cell anemia (severity) PPAP2B intron 20029952 rs4912314 chr1 56968477 C T 2.90E-05 Urinary metabolites PPAP2B intron 21572414 rs1361823 chr1 56990399 G A 7.52E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PPAP2B intron 21844884 rs2404715 chr1 57008778 C T 3.75E-15 Coronary heart disease PPAP2B intron 21378990 rs1041602 chr1 57013198 C T 4.06E-04 Schizophrenia PPAP2B intron 19197363 rs1261411 chr1 57017739 C T 2.10E-05 Urinary metabolites PPAP2B intron 21572414 rs1777275 chr1 57032468 A C 1.10E-05 Lymphocyte counts PPAP2B intron 22286170 rs12038246 chr1 57069614 A T 3.26E-04 Multiple complex diseases / / 17554300 rs12038246 chr1 57069614 A T 5.10E-04 Coronary heart disease / / 21966275 rs2404986 chr1 57084155 T C 7.86E-04 Multiple complex diseases / / 17554300 rs2404987 chr1 57088605 T C 8.61E-05 Blood Pressure / / pha003045 rs2404987 chr1 57088605 T C 6.21E-05 Blood Pressure / / pha003047 rs10888995 chr1 57094025 T A 6.98E-04 Multiple complex diseases / / 17554300 rs10888995 chr1 57094025 T A 2.60E-05 Urinary metabolites / / 21572414 rs10889000 chr1 57100380 G A 9.96E-06 Lymphocyte counts / / 22286170 rs2746349 chr1 57126650 C T 7.80E-06 Urinary metabolites PRKAA2 intron 21572414 rs2746347 chr1 57126919 C T 4.00E-07 Lymphocyte counts PRKAA2 intron 22286170 rs2179761 chr1 57157544 G A 2.20E-05 Urinary metabolites PRKAA2 intron 21572414 rs1342382 chr1 57177388 T A 0.00007 Asthma PRKAA2 UTR-3 18401594 rs1342382 chr1 57177388 T A 2.10E-05 Urinary metabolites PRKAA2 UTR-3 21572414 rs6656021 chr1 57202872 A T 4.48E-04 Multiple complex diseases C1orf168 intron 17554300 rs6658790 chr1 57203011 T C 3.20E-04 Multiple complex diseases C1orf168 intron 17554300 rs12137718 chr1 57203226 A G 1.70E-05 Urinary metabolites C1orf168 intron 21572414 rs1156845 chr1 57209695 T C 1.99E-04 Schizophrenia C1orf168 intron 21674006 rs11206912 chr1 57211204 C G 1.70E-04 Multiple complex diseases C1orf168 intron 17554300 rs7555378 chr1 57218159 G A 6.55E-04 Multiple complex diseases C1orf168 intron 17554300 rs857107 chr1 57222599 T C 2.74E-05 Lymphocyte counts C1orf168 intron 22286170 rs17372114 chr1 57243454 T C 1.20E-05 Urinary metabolites C1orf168 intron 21572414 rs17372114 chr1 57243454 T C 5.00E-07 Resistin levels C1orf168 intron 22843503 rs1738403 chr1 57246559 G A 3.79E-04 Multiple complex diseases C1orf168 intron 17554300 rs1774825 chr1 57249558 A C 1.99E-05 Response to cholinesterase inhibitors in Alzheimer's disease C1orf168 intron 23374588 rs10889017 chr1 57259632 C G 2.70E-05 Urinary metabolites C1orf168 intron 21572414 rs6662617 chr1 57269521 A G 9.00E-06 Obesity-related traits C1orf168 intron 23251661 rs10489622 chr1 57275653 T C 8.18E-04 Alzheimer's disease C1orf168 intron 17998437 rs10489622 chr1 57275653 T C 2.45E-04 Alzheimer's disease C1orf168 intron pha002879 rs12048846 chr1 57291520 A G 4.49E-04 Type 2 diabetes / / 17463246 rs10489623 chr1 57317559 A G 7.14E-05 Major depressive disorder (broad) / / 20038947 rs1329449 chr1 57319629 G A 8.14E-05 Major depressive disorder (broad) C8A nearGene-5 20038947 rs6697767 chr1 57326073 A G 3.88E-11 LDL cholesterol C8A intron 23063622 rs7339932 chr1 57333483 G T 0.000000109 LDL cholesterol C8A intron 23063622 rs2269119 chr1 57336775 G C 9.78E-05 Major depressive disorder (broad) C8A intron 20038947 rs1885002 chr1 57340381 A G 1.71E-05 Major depressive disorder (broad) C8A intron 20038947 rs6588657 chr1 57348436 C T 5.32E-05 Lymphocyte counts C8A intron 22286170 rs6694643 chr1 57349407 A T 6.23E-05 Major depressive disorder (broad) C8A intron 20038947 rs6697228 chr1 57349464 T C 9.14E-05 Major depressive disorder (broad) C8A intron 20038947 rs6683663 chr1 57356476 A G 5.69E-05 Major depressive disorder (broad) C8A intron 20038947 rs11206932 chr1 57362007 T A 6.27E-05 Major depressive disorder (broad) C8A intron 20038947 rs3768215 chr1 57362787 C T 6.89E-05 Major depressive disorder (broad) C8A intron 20038947 rs6697608 chr1 57363037 G A 1.02E-15 LDL cholesterol C8A intron 23063622 rs17114548 chr1 57367041 T A 2.26E-04 Insulin resistance C8A intron 21901158 rs17114555 chr1 57373778 G A 0.00000179 LDL cholesterol C8A missense 23063622 rs17373091 chr1 57391310 C T 1.50E-05 Urinary metabolites / / 21572414 rs17301090 chr1 57391429 G C 1.50E-05 Urinary metabolites / / 21572414 rs605648 chr1 57395251 T C 8.94E-04 Alcohol dependence C8B intron 24277619 rs2025006 chr1 57396276 C T 2.10E-05 Urinary metabolites C8B intron 21572414 rs9661996 chr1 57401110 C A 4.16E-04 Alzheimer's disease (late onset) C8B intron 21379329 rs1013579 chr1 57422484 C T 5.15E-05 Glycosylated haemoglobin levels C8B missense 17255346 rs856843 chr1 57427251 C A 9.96E-04 Alcohol dependence C8B intron 21314694 rs1774909 chr1 57447740 T C 9.61E-04 Coronary Artery Disease / / 17634449 rs1774908 chr1 57447820 T C 4.50E-04 Coronary Artery Disease / / 17634449 rs11206948 chr1 57450486 T C 2.06E-22 Narcolepsy / / 19629137 rs11206955 chr1 57467935 A G 5.79E-05 Alzheimer's disease DAB1 intron 17998437 rs11206955 chr1 57467935 A G 2.19E-04 Alzheimer's disease DAB1 intron pha002879 rs12035887 chr1 57468791 G T 8.06E-05 Alzheimer's disease DAB1 intron 17998437 rs697580 chr1 57477034 G C 3.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs1854508 chr1 57478856 A G 8.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs11810899 chr1 57481284 T C 7.02E-04 Alzheimer's disease DAB1 intron 17998437 rs11810899 chr1 57481284 T C 3.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs11810899 chr1 57481284 T C 2.01E-04 Alzheimer's disease DAB1 intron pha002879 rs6668269 chr1 57481828 T C 6.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs17114816 chr1 57481883 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs3754268 chr1 57484663 A G 3.75E-04 Alzheimer's disease DAB1 intron 17998437 rs3754268 chr1 57484663 A G 1.70E-05 Urinary metabolites DAB1 intron 21572414 rs706360 chr1 57490074 C T 1.30E-05 Urinary metabolites DAB1 intron 21572414 rs706361 chr1 57490333 T C 3.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs3768206 chr1 57498094 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs4912233 chr1 57498643 C T 7.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs12118564 chr1 57500176 G C 6.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs11206964 chr1 57524101 T C 9.79E-04 Multiple complex diseases DAB1 intron 17554300 rs476744 chr1 57535630 G A 1.36E-05 Epilepsy (remission after treatment) DAB1 intron 23962720 rs534080 chr1 57584721 G A 4.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DAB1 intron 20877124 rs17541203 chr1 57625932 T C 2.00E-06 Pubertal anthropometrics DAB1 intron 23449627 rs4124453 chr1 57633048 C G 0.0008539 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DAB1 intron 23233654 rs4124453 chr1 57633048 C G 8.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) DAB1 intron 23233662 rs7533282 chr1 57633496 T G 4.19E-05 Cognitive performance DAB1 intron 19734545 rs7533282 chr1 57633496 T G 0.0008524 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DAB1 intron 23233654 rs7533282 chr1 57633496 T G 8.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) DAB1 intron 23233662 rs17115233 chr1 57636071 G A 0.0008644 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DAB1 intron 23233654 rs17115233 chr1 57636071 G A 8.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) DAB1 intron 23233662 rs6680429 chr1 57637497 G A 6.60E-09 Vitamin D concentrations DAB1 intron 20600896 rs6680429 chr1 57637497 G A 6.60E-09 Vitamin D concentrations DAB1 intron 20600896 rs17115240 chr1 57640066 T C 0.000584 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DAB1 intron 23233654 rs17115240 chr1 57640066 T C 5.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) DAB1 intron 23233662 rs17541479 chr1 57640721 C T 2.06E-04 Hearing function DAB1 intron 17255346 rs11810300 chr1 57654660 C T 9.01E-06 PR interval in Tripanosoma cruzi seropositivity DAB1 intron 24324551 rs1394397 chr1 57656611 A G 3.00E-06 PR interval in Tripanosoma cruzi seropositivity DAB1 intron 24324551 rs480836 chr1 57662361 G A 2.00E-04 Cognitive impairment induced by topiramate DAB1 intron 22091778 rs17115341 chr1 57665932 C T 7.39E-04 Alcohol dependence DAB1 intron 21314694 rs197597 chr1 57683417 C T 3.00E-04 Cognitive impairment induced by topiramate DAB1 intron 22091778 rs1504584 chr1 57690336 T C 4.00E-04 Multiple complex diseases DAB1 intron 17554300 rs1504584 chr1 57690336 T C 7.52E-04 Response to cytadine analogues (cytosine arabinoside) DAB1 intron 24483146 rs1604885 chr1 57690668 C A 1.36E-04 Multiple complex diseases DAB1 intron 17554300 rs1604885 chr1 57690668 C A 7.52E-04 Response to cytadine analogues (cytosine arabinoside) DAB1 intron 24483146 rs12130571 chr1 57698001 C A 8.78E-04 Alcohol dependence DAB1 intron 21314694 rs2764664 chr1 57741163 T C 1.56E-04 Taste perception DAB1 intron 22132133 rs12057381 chr1 57769516 G A 8.44E-06 Prostate cancer DAB1 intron 24185611 rs736109 chr1 57783651 C T 3.93E-06 Non-small cell lung cancer DAB1 intron 21866343 rs12401342 chr1 57793948 C A 4.32E-04 Response to cytadine analogues (cytosine arabinoside) DAB1 intron 24483146 rs90940 chr1 57795436 T C 1.30E-06 Non-small cell lung cancer DAB1 intron 21866343 rs267650 chr1 57795780 T C 4.94E-07 Non-small cell lung cancer DAB1 intron 21866343 rs6587767 chr1 57800285 C T 8.24E-06 Non-small cell lung cancer DAB1 intron 21866343 rs12061812 chr1 57802603 C A 7.19E-07 Non-small cell lung cancer DAB1 intron 21866343 rs12087888 chr1 57802759 T C 4.61E-07 Non-small cell lung cancer DAB1 intron 21866343 rs12087888 chr1 57802759 T C 1.64E-05 Blood Pressure DAB1 intron pha003039 rs12087888 chr1 57802759 T C 1.14E-05 Blood Pressure DAB1 intron pha003045 rs12087888 chr1 57802759 T C 6.72E-05 Blood Pressure DAB1 intron pha003047 rs11207010 chr1 57802886 G C 3.54E-07 Non-small cell lung cancer DAB1 intron 21866343 rs11207011 chr1 57803349 G A 1.57E-05 Blood Pressure DAB1 intron pha003039 rs11207011 chr1 57803349 G A 1.11E-05 Blood Pressure DAB1 intron pha003045 rs11207011 chr1 57803349 G A 6.50E-05 Blood Pressure DAB1 intron pha003047 rs10159302 chr1 57805550 A C 9.00E-06 HIV-1 control DAB1 intron 20041166 rs1077424 chr1 57810304 G C 6.50E-07 Non-small cell lung cancer DAB1 intron 21866343 rs6687842 chr1 57815932 C A 2.66E-05 Non-small cell lung cancer DAB1 intron 21866343 rs11207016 chr1 57816224 C A 5.88E-06 Non-small cell lung cancer DAB1 intron 21866343 rs1424467 chr1 57816489 G A 9.47E-06 Non-small cell lung cancer DAB1 intron 21866343 rs1862925 chr1 57822311 C T 1.01E-05 Non-small cell lung cancer DAB1 intron 21866343 rs10889038 chr1 57826766 T C 8.18E-06 Non-small cell lung cancer DAB1 intron 21866343 rs10889038 chr1 57826766 T C 6.60E-05 Blood Pressure DAB1 intron pha003039 rs10889039 chr1 57828545 C T 1.65E-05 Non-small cell lung cancer DAB1 intron 21866343 rs2216808 chr1 57837089 G A 1.90E-06 Non-small cell lung cancer DAB1 intron 21866343 rs10047073 chr1 57841631 G C 1.90E-06 Non-small cell lung cancer DAB1 intron 21866343 rs10047071 chr1 57841662 C T 3.66E-05 Blood Pressure DAB1 intron pha003039 rs2405697 chr1 57843007 G A 1.76E-05 Non-small cell lung cancer DAB1 intron 21866343 rs3909556 chr1 57846985 C T 6.55E-07 Non-small cell lung cancer DAB1 intron 21866343 rs3738552 chr1 57852513 C A,G,T 1.11E-04 Multiple complex diseases DAB1 intron 17554300 rs3861834 chr1 57854103 G A 2.83E-05 Non-small cell lung cancer DAB1 intron 21866343 rs17115722 chr1 57855219 T C 4.04E-04 Multiple complex diseases DAB1 intron 17554300 rs507466 chr1 57855425 A G 5.14E-04 Multiple complex diseases DAB1 intron 17554300 rs532926 chr1 57855876 T C 7.66E-05 Serum metabolites DAB1 intron 19043545 rs566847 chr1 57857310 T G 9.02E-04 Multiple complex diseases DAB1 intron 17554300 rs566847 chr1 57857310 T G 6.66E-05 Serum metabolites DAB1 intron 19043545 rs567773 chr1 57857390 C A 2.23E-05 Non-small cell lung cancer DAB1 intron 21866343 rs540431 chr1 57859521 G A 1.25E-05 Non-small cell lung cancer DAB1 intron 21866343 rs11207026 chr1 57860215 A T 9.61E-05 Serum metabolites DAB1 intron 19043545 rs17425189 chr1 57862949 T C 5.99E-07 Non-small cell lung cancer DAB1 intron 21866343 rs2405994 chr1 57871016 G A 8.95E-06 Non-small cell lung cancer DAB1 intron 21866343 rs11585751 chr1 57872987 G A 9.67E-06 Non-small cell lung cancer DAB1 intron 21866343 rs269042 chr1 57874048 T A 2.27E-05 Non-small cell lung cancer DAB1 intron 21866343 rs17115765 chr1 57874866 C T 2.00E-04 Cognitive impairment induced by topiramate DAB1 intron 22091778 rs269060 chr1 57881463 T C 0.0000865 Salmonella-induced pyroptosis DAB1 intron 22837397 rs11207036 chr1 57904853 A G 4.12E-04 Rheumatoid arthritis DAB1 intron 21452313 rs12045017 chr1 57914548 C G 6.92E-04 Response to statin treatment (atorvastatin),change in cholesterol levels DAB1 intron 20031582 rs17426429 chr1 57920416 G A 9.11E-05 Bipolar disorder and schizophrenia DAB1 intron 20889312 rs17115807 chr1 57921505 T C 1.76E-04 Height DAB1 intron 17255346 rs10493223 chr1 57934034 C T 3.03E-04 Lung function (forced vital capacity) DAB1 intron 24023788 rs10493223 chr1 57934034 C T 5.92E-05 Eosinophil counts DAB1 intron pha003088 rs2691462 chr1 57954416 C T 3.42E-04 Response to taxane treatment (placlitaxel) DAB1 intron 23006423 rs1341320 chr1 57966528 G A 7.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DAB1 intron 20877124 rs1341320 chr1 57966528 G A 5.00E-06 Plasma amyloid beta peptide concentrations (ABx-40) DAB1 intron 24535457 rs1524715 chr1 58003409 A T 6.15E-04 Coronary Artery Disease DAB1 intron 17634449 rs11207058 chr1 58003804 C A 6.73E-04 Coronary Artery Disease DAB1 intron 17634449 rs1524716 chr1 58005178 A C 2.82E-04 Coronary Artery Disease DAB1 intron 17634449 rs1880443 chr1 58015312 G A 9.88E-04 Coronary Artery Disease DAB1 intron 17634449 rs12083422 chr1 58049270 C T 1.97E-21 Multiple complex diseases DAB1 intron 17554300 rs1572945 chr1 58069523 C T 7.85E-06 Blood pressure DAB1 intron 17255346 rs1935046 chr1 58075285 C T 1.39E-05 Blood pressure DAB1 intron 17255346 rs10493231 chr1 58075542 C A 1.77E-04 Blood pressure DAB1 intron 17255346 rs1524721 chr1 58079584 G A 4.56E-05 Blood pressure DAB1 intron 17255346 rs1341316 chr1 58087789 A G 8.24E-05 Type 2 diabetes and other traits DAB1 intron 19734900 rs17116134 chr1 58093163 C T 3.40E-04 Multiple complex diseases DAB1 intron 17554300 rs1539053 chr1 58099707 A G 7.09E-06 Type 2 diabetes and other traits DAB1 intron 19734900 rs1539053 chr1 58099707 A G 7.10E-06 Alzheimer's disease (late onset) DAB1 intron 21460841 rs7522826 chr1 58126517 T C 8.33E-05 Response to mTOR inhibitor (rapamycin) DAB1 intron 24009623 rs3131729 chr1 58198767 C T 9.87E-06 Kawasaki disease DAB1 intron 21221998 rs10493232 chr1 58229635 C G 7.30E-04 Type 2 diabetes DAB1 intron 17463246 rs1886140 chr1 58231158 A G 0.0000065 Asthma (exacerbation) DAB1 intron 23706709 rs2406282 chr1 58232329 T G 7.58E-04 Type 2 diabetes DAB1 intron 17463246 rs1323827 chr1 58232720 A G 8.72E-04 Type 2 diabetes DAB1 intron 17463246 rs1408141 chr1 58245641 A C 6.24E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs1924268 chr1 58249119 A C 3.61E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs1581762 chr1 58251060 A G 5.86E-05 Intelligence DAB1 intron 21826061 rs1581763 chr1 58251248 T C 3.59E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs1323835 chr1 58253042 G A 3.58E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs12565523 chr1 58256148 T G 4.04E-06 Alcohol dependence (age at onset) DAB1 intron 24962325 rs12568292 chr1 58256191 C A 4.04E-06 Alcohol dependence (age at onset) DAB1 intron 24962325 rs1408146 chr1 58256479 T C 6.61E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs35738462 chr1 58256544 T C 2.00E-06 Alcohol dependence (age at onset) DAB1 intron 24962325 rs1323836 chr1 58256909 T G 6.59E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs1323838 chr1 58257250 T C 2.41E-06 Alcohol dependence (age at onset) DAB1 intron 24962325 rs7554147 chr1 58257587 T C 2.41E-06 Alcohol dependence (age at onset) DAB1 intron 24962325 rs1886143 chr1 58258134 G T 6.57E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs7544843 chr1 58263767 G A 3.53E-06 Alcohol dependence (age at onset) DAB1 intron 24962325 rs2406284 chr1 58269042 T C 6.96E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs706412 chr1 58317833 A G 4.41E-04 Parkinson's disease DAB1 intron 17052657 rs706412 chr1 58317833 A G 1.26E-04 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs985795 chr1 58319828 T G 2.00E-06 Bulimia nervosa DAB1 intron 23568457 rs852801 chr1 58321909 G A 4.00E-06 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs852802 chr1 58323943 T C 4.00E-06 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs852806 chr1 58324779 A G 6.48E-04 Parkinson's disease DAB1 intron 17052657 rs852806 chr1 58324779 A G 1.01E-04 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs764742 chr1 58326194 G A 6.95E-05 Obesity (extreme) DAB1 intron 21935397 rs852807 chr1 58329157 A G 9.39E-04 Parkinson's disease DAB1 intron 17052657 rs852807 chr1 58329157 A G 2.77E-04 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs2038379 chr1 58336058 C T 1.06E-04 Mammographic density DAB1 intron 22532574 rs722187 chr1 58339643 C T 5.35E-04 Parkinson's disease DAB1 intron 17052657 rs722187 chr1 58339643 C T 1.50E-04 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs1202824 chr1 58349005 T C 1.50E-05 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs1202834 chr1 58360111 T C 4.82E-04 Multiple complex diseases DAB1 intron 17554300 rs1022636 chr1 58360565 C G 1.50E-04 Multiple complex diseases DAB1 intron 17554300 rs1202835 chr1 58362123 C T 3.04E-04 Multiple complex diseases DAB1 intron 17554300 rs1202837 chr1 58365396 G A 4.83E-04 Multiple complex diseases DAB1 intron 17554300 rs6679454 chr1 58367236 A G 3.00E-07 Immune reponse to smallpox (secreted IL-10) DAB1 intron 22610502 rs1202849 chr1 58370098 T C 4.48E-04 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs12118826 chr1 58373450 G A 2.49E-06 Mammographic density DAB1 intron 22532574 rs1884487 chr1 58375966 T C 7.78E-04 Smoking quantity DAB1 intron 24665060 rs12125894 chr1 58376445 T C 3.26E-06 Mammographic density DAB1 intron 22532574 rs4412616 chr1 58422760 A C 7.39E-05 Serum metabolites DAB1 intron 19043545 rs1343635 chr1 58431135 T C 8.66E-04 Schizophrenia DAB1 intron 19197363 rs1343635 chr1 58431135 T C 6.49E-05 Cognitive performance DAB1 intron 19734545 rs1343635 chr1 58431135 T C 7.70E-04 Response to taxane treatment (placlitaxel) DAB1 intron 23006423 rs1187981 chr1 58441667 T C 5.05E-05 Cognitive performance DAB1 intron 19734545 rs1187984 chr1 58443065 T A,G 1.73E-05 Multiple complex diseases DAB1 intron 17554300 rs4912290 chr1 58452314 G A 5.77E-05 Antineutrophil cytoplasmic antibody-associated vasculitis DAB1 intron 22808956 rs1187995 chr1 58454436 C G 4.13E-05 Multiple complex diseases DAB1 intron 17554300 rs17434789 chr1 58457604 T C 1.72E-04 Multiple complex diseases DAB1 intron 17554300 rs17131774 chr1 58514090 A G 6.98E-05 Major depressive disorder DAB1 intron 21621269 rs2764675 chr1 58522420 T G 2.66E-05 Bipolar disorder and schizophrenia DAB1 intron 20889312 rs17116805 chr1 58531206 C T 1.32E-04 Multiple complex diseases DAB1 intron 17554300 rs17116836 chr1 58537102 G A 1.00E-04 Prostate cancer DAB1 intron 21743057 rs3121907 chr1 58540836 T C 9.13E-04 Type 2 diabetes DAB1 intron 17463246 rs873989 chr1 58556598 T C 1.30E-04 Neuroticism DAB1 intron 17667963 rs1776184 chr1 58563007 C T 7.15E-04 Multiple complex diseases DAB1 intron 17554300 rs1213770 chr1 58571279 T C 3.12E-05 QT interval DAB1 intron 22726844 rs1342876 chr1 58578612 T C 6.56E-04 Multiple complex diseases DAB1 intron 17554300 rs558475 chr1 58601866 C A 2.28E-04 Glycosylated haemoglobin levels DAB1 intron 17255346 rs6667829 chr1 58610928 T G 2.60E-05 Urinary metabolites DAB1 intron 21572414 rs637081 chr1 58631192 G A 0.00044547 Sarcoidosis DAB1 intron 22952805 rs3905539 chr1 58651750 C T 5.33E-04 Multiple complex diseases DAB1 intron 17554300 rs1953811 chr1 58654363 C T 7.41E-04 Multiple complex diseases DAB1 intron 17554300 rs507981 chr1 58656147 T G 8.49E-05 Body Fat Distribution DAB1 intron pha003016 rs507981 chr1 58656147 T G 2.43E-05 Body Fat Distribution DAB1 intron pha003017 rs507981 chr1 58656147 T G 1.46E-05 Body Fat Distribution DAB1 intron pha003018 rs17117101 chr1 58671217 G T 2.60E-04 Multiple complex diseases DAB1 intron 17554300 rs1832489 chr1 58673515 G C 2.32E-04 Multiple complex diseases DAB1 intron 17554300 rs10889086 chr1 58673708 T C 4.14E-05 Body Fat Distribution DAB1 intron pha003017 rs10889086 chr1 58673708 T C 2.53E-05 Body Fat Distribution DAB1 intron pha003018 rs946311 chr1 58676997 G A 2.30E-05 Body Fat Distribution DAB1 intron pha003017 rs946311 chr1 58676997 G A 2.08E-05 Body Fat Distribution DAB1 intron pha003018 rs2185166 chr1 58684088 T C 2.85E-05 Body Fat Distribution DAB1 intron pha003017 rs2185166 chr1 58684088 T C 2.38E-05 Body Fat Distribution DAB1 intron pha003018 rs17117148 chr1 58693743 G C 1.05E-06 Retinopathy in non-diabetics DAB1 intron 23393555 rs574802 chr1 58730127 T C 8.11E-04 HIV-1 viral setpoint / / 17641165 rs17117233 chr1 58743154 C T 1.70E-06 Thyroid function / / 20826269 rs6668411 chr1 58746316 T C 1.42E-04 Multiple complex diseases / / 17554300 rs11576201 chr1 58756648 G A 9.00E-07 Thyroid function / / 20826269 rs527409 chr1 58757915 T C 1.00E-06 Kawasaki disease / / 21221998 rs10493251 chr1 58764081 C T 5.80E-07 Thyroid function / / 20826269 rs1924565 chr1 58779442 T G 3.55E-04 Alzheimer's disease / / 24755620 rs10493240 chr1 58784150 G T 5.62E-04 Alzheimer's disease / / 24755620 rs1213640 chr1 58794017 A C 8.20E-04 Alzheimer's disease / / 24755620 rs3861824 chr1 58807217 G A 6.29E-05 HIV(mother-to-child transmission) / / 20487506 rs6587811 chr1 58826916 G A 7.35E-04 Multiple complex diseases / / 17554300 rs4912335 chr1 58834962 C T 9.38E-04 Multiple complex diseases / / 17554300 rs6699998 chr1 58845645 G A 9.50E-04 Multiple complex diseases / / 17554300 rs17496683 chr1 58848671 G A 2.76E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs849492 chr1 58857598 C A 9.44E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs338934 chr1 58857666 A G 7.20E-04 Tourette syndrome / / 22889924 rs338934 chr1 58857666 A G 3.32E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs849481 chr1 58866940 G A 2.29E-04 Multiple complex diseases / / 17554300 rs3850540 chr1 58872823 G C 6.27E-04 Multiple complex diseases / / 17554300 rs849469 chr1 58894050 T C 3.30E-06 Urinary metabolites / / 21572414 rs706430 chr1 58903338 A G 8.02E-06 Cardiovascular disease / / 18179892 rs12086988 chr1 58903733 C G 6.17E-07 Lymphocyte counts / / 22286170 rs706457 chr1 58920920 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1000476 chr1 58921516 T C 7.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs12407003 chr1 58939634 G A 8.46E-05 Height / / pha003011 rs338228 chr1 58943030 G C 1.36E-04 Multiple complex diseases / / 17554300 rs2271004 chr1 58996203 T C 5.74E-04 Lymphocyte counts OMA1 intron 22286170 rs12139475 chr1 59005187 G A 4.01E-04 Multiple complex diseases OMA1 intron 17554300 rs638065 chr1 59036625 C T 8.00E-06 Word reading / / 23738518 rs6683669 chr1 59041092 G A 2.90E-05 Rheumatoid arthritis (ACPA-negative) TACSTD2 nearGene-3 24532677 rs201254365 chr1 59042425 C A 0.000000163 Prostate-specific antigen TACSTD2 missense 23555315 rs17117889 chr1 59055724 A G 2.78E-04 Depression (quantitative trait) / / 20800221 rs11579447 chr1 59100106 T G 6.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs232907 chr1 59102834 C A 2.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs232905 chr1 59104500 G A 3.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs232904 chr1 59105260 C T 6.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs232902 chr1 59106153 A G 4.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs232899 chr1 59107652 G A 2.23E-04 Depression (quantitative trait) / / 20800221 rs232895 chr1 59108799 C T 2.47E-04 Depression (quantitative trait) / / 20800221 rs232894 chr1 59109001 T C 2.56E-04 Depression (quantitative trait) / / 20800221 rs232892 chr1 59110018 C T 2.56E-04 Depression (quantitative trait) / / 20800221 rs7527235 chr1 59110167 A C 9.57E-04 Multiple complex diseases / / 17554300 rs232891 chr1 59110502 C T 4.41E-04 Depression (quantitative trait) / / 20800221 rs232885 chr1 59112057 C A 8.53E-04 Multiple complex diseases / / 17554300 rs232885 chr1 59112057 C A 5.70E-04 Lipid traits / / 17903299 rs232885 chr1 59112057 C A 2.58E-04 Depression (quantitative trait) / / 20800221 rs232882 chr1 59113033 G A 2.60E-04 Depression (quantitative trait) / / 20800221 rs17117956 chr1 59114347 T C,G 2.58E-04 Depression (quantitative trait) / / 20800221 rs232877 chr1 59115293 A T 3.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs232876 chr1 59115781 C T 2.52E-04 Depression (quantitative trait) / / 20800221 rs232874 chr1 59118656 T G 2.50E-04 Depression (quantitative trait) / / 20800221 rs232871 chr1 59119072 A G 2.50E-04 Depression (quantitative trait) / / 20800221 rs232867 chr1 59119180 A T 3.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs232863 chr1 59119701 C A 3.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs232862 chr1 59119881 T C 1.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs232860 chr1 59120563 A G 2.93E-04 Depression (quantitative trait) MYSM1 UTR-3 20800221 rs232857 chr1 59120650 C T 3.97E-04 Suicide attempts in bipolar disorder MYSM1 UTR-3 21423239 rs232777 chr1 59125683 C T 2.80E-04 Depression (quantitative trait) MYSM1 missense 20800221 rs232778 chr1 59126616 A G 1.97E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs232779 chr1 59126676 A C 5.01E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs232780 chr1 59127207 T C 2.80E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs6587835 chr1 59127936 G A 2.80E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs10430103 chr1 59128193 A C 8.66E-04 Multiple complex diseases MYSM1 intron 17554300 rs232782 chr1 59128237 G A 2.80E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs232783 chr1 59129516 G T 5.18E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs232784 chr1 59129644 A C 9.18E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs232786 chr1 59130229 A C 2.83E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs232787 chr1 59130407 C T 2.83E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs232788 chr1 59130614 C T 5.14E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs232790 chr1 59131311 G T 5.13E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs232794 chr1 59133024 T G 2.82E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs232795 chr1 59133268 A G 2.82E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs675871 chr1 59136875 C T 5.05E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs513436 chr1 59137273 C T 5.46E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs542750 chr1 59138172 C T 5.46E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs17118097 chr1 59141365 G A 1.44E-04 Multiple complex diseases MYSM1 intron 17554300 rs4912369 chr1 59145958 C A 6.72E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs4912372 chr1 59146221 A G 5.98E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs2746083 chr1 59161678 C A 5.19E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs2811893 chr1 59162148 T C 3.00E-07 Diabetic retinopathy MYSM1 intron 21310492 rs2811893 chr1 59162148 T C 2.50E-05 Urinary metabolites MYSM1 intron 21572414 rs6677560 chr1 59162793 A G 1.50E-05 Urinary metabolites MYSM1 intron 21572414 rs11207296 chr1 59165042 A C 5.67E-04 Multiple complex diseases MYSM1 intron 17554300 rs4912202 chr1 59174026 G A 2.96E-04 Depression (quantitative trait) / / 20800221 rs11582157 chr1 59177924 A G 6.17E-05 Suicide attempts in bipolar disorder / / 21423239 rs17264915 chr1 59180394 C A 4.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs2811856 chr1 59184738 T C 1.00E-04 Prostate cancer / / 21743057 rs11583201 chr1 59186777 G A 6.04E-04 Depression (quantitative trait) / / 20800221 rs12747063 chr1 59190140 C A 7.22E-04 Depression (quantitative trait) / / 20800221 rs12405774 chr1 59191545 G A 8.91E-04 Depression (quantitative trait) / / 20800221 rs7524931 chr1 59197556 G C 8.86E-04 Depression (quantitative trait) / / 20800221 rs1323281 chr1 59201820 A T 8.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs2760480 chr1 59203121 T C 4.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs2760482 chr1 59204825 T C 7.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs1969772 chr1 59205102 G A 1.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12137541 chr1 59209416 G A 1.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs6677589 chr1 59230033 G A 1.90E-04 Lipid traits / / 17903299 rs17356414 chr1 59319508 C T 1.70E-05 Type 2 diabetes LOC100131060 intron 17463248 rs4601609 chr1 59325626 T C 5.00E-06 Cognitive performance LOC100131060 intron 19734545 rs6676059 chr1 59329756 G A 1.70E-05 Type 2 diabetes LOC100131060 intron 17463248 rs12133457 chr1 59330763 G A 1.70E-05 Type 2 diabetes LOC100131060 intron 17463248 rs17118349 chr1 59351143 C T 8.07E-04 Alcohol dependence LOC100131060 intron 20201924 rs927743 chr1 59368947 G T 1.00E-04 Schizophrenia / / 19197363 rs6699576 chr1 59422826 G T 1.19E-04 Multiple complex diseases / / 17554300 rs3949912 chr1 59423103 G A 9.17E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs7543260 chr1 59435688 T C 2.35E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs7543260 chr1 59435688 T C 9.78E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs7537319 chr1 59443050 G A 4.03E-04 Taste perception / / 22132133 rs2985883 chr1 59464838 G A 9.89E-05 Type 2 diabetes / / 17463246 rs2716139 chr1 59471986 A C 1.57E-04 Type 2 diabetes / / 17463246 rs12031587 chr1 59472053 C T 2.66E-04 Type 2 diabetes / / 17463246 rs2716140 chr1 59472397 A C 1.37E-04 Type 2 diabetes / / 17463246 rs2716121 chr1 59474554 C T 1.63E-04 Type 2 diabetes / / 17463246 rs17464532 chr1 59483091 G C 8.17E-04 Multiple complex diseases / / 17554300 rs2716133 chr1 59483255 T A 1.28E-04 Type 2 diabetes / / 17463246 rs12030196 chr1 59483320 A C 1.98E-04 Type 2 diabetes / / 17463246 rs17118549 chr1 59484327 C T 1.40E-05 Amyotrophic lateral sclerosis / / 17671248 rs2764924 chr1 59484502 G A 9.95E-05 Type 2 diabetes / / 17463246 rs11207369 chr1 59485091 G T 2.28E-04 Type 2 diabetes / / 17463246 rs2764922 chr1 59485277 G A 1.26E-04 Type 2 diabetes / / 17463246 rs3010334 chr1 59485823 C T 1.58E-04 Type 2 diabetes / / 17463246 rs12748496 chr1 59486551 G A 2.23E-04 Type 2 diabetes / / 17463246 rs9436591 chr1 59489803 A G 2.57E-05 Fibrinogen / / 17255346 rs6587843 chr1 59540811 C T 3.21E-05 Fibrinogen / / 17255346 rs4424536 chr1 59544435 G A 1.80E-05 Fibrinogen / / 17255346 rs2989868 chr1 59553662 G A 3.72E-05 Fibrinogen / / 17255346 rs3010322 chr1 59567199 G A 5.61E-05 Prion diseases / / 22210626 rs1114505 chr1 59572316 T C 6.75E-04 Depression (quantitative trait) / / 20800221 rs6704170 chr1 59582235 G A 8.69E-05 Height / / pha003011 rs3861829 chr1 59590817 G A 2.29E-05 Cognitive test performance / / 20125193 rs11207409 chr1 59606640 G A 7.30E-04 Type 2 diabetes HSD52 intron 17463246 rs17118876 chr1 59616910 C G 0.0000149 Polycystic ovary syndrome / / 22951595 rs17118876 chr1 59616910 C G 1.49E-05 Intracranial aneurysm / / 22961961 rs474103 chr1 59619571 T G 6.42E-05 Response to hepatitis C treatment / / 19684573 rs331645 chr1 59637387 G A 3.06E-05 Response to hepatitis C treatment / / 19684573 rs17119055 chr1 59658543 G A 1.78E-04 Bipolar disorder / / 18317468 rs17119087 chr1 59669115 T C 2.47E-04 Bipolar disorder / / 18317468 rs331633 chr1 59680579 A G 2.94E-04 Insulin resistance / / 21901158 rs12402265 chr1 59690602 G A 6.67E-04 Heart Failure / / pha002884 rs6700125 chr1 59702797 T C 1.80E-05 Amyotrophic lateral sclerosis / / 17671248 rs6690993 chr1 59703982 G A 2.00E-04 Amyotrophic lateral sclerosis / / 17671248 rs12142820 chr1 59716043 A T 5.10E-04 Alcohol dependence / / 21314694 rs835367 chr1 59762468 A G 2.00E-06 Obesity-related traits FGGY nearGene-5 23251661 rs9787234 chr1 59796808 C T 7.79E-06 Obesity-related traits FGGY intron 23251661 rs17119280 chr1 59799161 G A 7.00E-06 Response to antipsychotic therapy (extrapyramidal side effects) FGGY intron 19875103 rs835382 chr1 59799511 A T 9.66E-04 Multiple complex diseases FGGY intron 17554300 rs835441 chr1 59823244 C T 2.38E-04 IgE levels FGGY intron 17255346 rs17119329 chr1 59830402 G A 8.54E-05 IgE levels FGGY intron 17255346 rs17119329 chr1 59830402 G A 2.94E-04 Multiple complex diseases FGGY intron 17554300 rs7539697 chr1 59832762 G A 6.40E-06 Obesity-related traits FGGY intron 23251661 rs835435 chr1 59844471 G A 6.88E-06 Obesity-related traits FGGY cds-synon 23251661 rs7534016 chr1 59853319 A G 5.00E-06 Obesity-related traits FGGY intron 23251661 rs11583924 chr1 59858582 G A 0.00047 Salmonella-induced pyroptosis FGGY intron 22837397 rs835425 chr1 59860544 G A 2.02E-04 IgE levels FGGY intron 17255346 rs1390694 chr1 59865755 A G 1.30E-13 Health and aging,CVD and cancer age of onset FGGY intron 22174011 rs1390694 chr1 59865755 A G 2.00E-14 Health and aging,CVD and cancer age of onset FGGY intron 22174011 rs1390694 chr1 59865755 A G 3.20E-23 Health and aging,CVD and cancer age of onset FGGY intron 22174011 rs1390694 chr1 59865755 A G 5.60E-18 Health and aging,CVD and cancer age of onset FGGY intron 22174011 rs17096906 chr1 59868942 A G 5.82E-04 Multiple complex diseases FGGY intron 17554300 rs17119472 chr1 59919752 A G 5.70E-04 Multiple complex diseases FGGY intron 17554300 rs648883 chr1 59979255 C A 6.28E-04 Response to statin treatment (atorvastatin),change in cholesterol levels FGGY intron 20031582 rs2798652 chr1 60007275 T C 1.54E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FGGY intron 20877124 rs11583338 chr1 60033913 T C 7.63E-06 Platelet counts FGGY intron 21507922 rs11583825 chr1 60034402 T C 7.63E-06 Platelet counts FGGY intron 21507922 rs4497239 chr1 60045220 A G 7.10E-04 Bipolar disorder,schizoaffective FGGY intron 19567891 rs2407603 chr1 60045290 G A 5.59E-04 Bipolar disorder,schizoaffective FGGY intron 19567891 rs10493267 chr1 60058706 A G 3.53E-04 Bipolar disorder,schizoaffective FGGY intron 19567891 rs12745808 chr1 60068731 A G 7.63E-06 Platelet counts FGGY intron 21507922 rs12727131 chr1 60084516 G A 3.00E-06 Neutrophil count FGGY intron 21507922 rs4522023 chr1 60111987 G A 6.09E-04 Smoking quantity FGGY intron 24665060 rs10889148 chr1 60119961 T C 3.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FGGY intron 20877124 rs10889148 chr1 60119961 T C 1.12E-05 Smoking quantity FGGY intron 24665060 rs6587867 chr1 60134050 A G 1.22E-05 Smoking quantity FGGY intron 24665060 rs4072736 chr1 60142112 G C 1.99E-05 Multiple complex diseases FGGY intron 17554300 rs4357555 chr1 60161256 G A 9.52E-05 Blood pressure (response to angiotensin II receptor blocker) FGGY intron 24192120 rs11207507 chr1 60166147 G C 7.36E-04 Multiple complex diseases FGGY intron 17554300 rs6661666 chr1 60168554 A C 4.37E-05 Hodgkin's lymphoma FGGY intron 24149102 rs1933213 chr1 60183673 G T 5.00E-04 Obesity (extreme) FGGY intron 21935397 rs9436182 chr1 60185680 C A 5.37E-04 Obesity (extreme) FGGY intron 21935397 rs1890211 chr1 60198238 A T 9.05E-05 Multiple complex diseases FGGY intron 17554300 rs1890212 chr1 60198430 G A 6.28E-04 Coronary heart disease FGGY intron 21971053 rs674949 chr1 60240601 G A 2.30E-05 Urinary metabolites / / 21572414 rs9436605 chr1 60243182 T G 0.00000409 Common carotid artery thickness (average of near and far wall measures) / / 23487405 rs9436605 chr1 60243182 T G 9.65E-04 Self-reported allergy / / 23817569 rs9436188 chr1 60257931 A G 5.61E-05 Parkinson's disease / / 17052657 rs9436188 chr1 60257931 A G 1.04E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12057866 chr1 60272522 A G 4.68E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11207520 chr1 60275095 T G 2.93E-04 Parkinson's disease / / 17052657 rs11207520 chr1 60275095 T G 6.85E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11207520 chr1 60275095 T G 1.52E-04 Common variable immunodeficiency / / 21497890 rs3767996 chr1 60281712 A G 5.08E-04 Response to cytidine analogues (gemcitabine) HOOK1 intron 24483146 rs3767999 chr1 60289241 T G 2.48E-04 Schizophrenia HOOK1 intron 19197363 rs1155002 chr1 60373775 T C 1.11E-04 Dental caries CYP2J2 intron 21940522 rs11572245 chr1 60381437 C G 9.73E-04 Type 2 diabetes CYP2J2 intron 17463246 rs890291 chr1 60437812 C T 1.50E-05 Urinary metabolites / / 21572414 rs7411728 chr1 60446789 G A 6.30E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs642307 chr1 60460733 C A 1.87E-04 IgE levels C1orf87 intron 17255346 rs12041866 chr1 60484531 C T 7.93E-04 Suicide attempts in bipolar disorder C1orf87 intron 21423239 rs17120013 chr1 60494107 G A 9.12E-04 Type 2 diabetes C1orf87 intron 17463246 rs17120017 chr1 60495735 G A 3.86E-04 Multiple complex diseases C1orf87 intron 17554300 rs677129 chr1 60499928 A G 6.49E-04 Suicide attempts in bipolar disorder C1orf87 intron 21423239 rs680390 chr1 60505578 A G 4.19E-04 Suicide attempts in bipolar disorder C1orf87 intron 21423239 rs7543186 chr1 60531017 C A 1.45E-04 Alzheimer's disease (late onset) C1orf87 intron 21379329 rs17120082 chr1 60534428 C G 1.04E-04 Hearing function C1orf87 intron 17255346 rs17120143 chr1 60559382 A G 8.66E-04 Multiple complex diseases / / 17554300 rs583848 chr1 60568038 T A 1.90E-06 Urinary metabolites / / 21572414 rs686119 chr1 60579899 A T 4.62E-04 Weight loss (gastric bypass surgery) / / 23643386 rs6677345 chr1 60581154 T C 1.45E-04 Alzheimer's disease (late onset) / / 21379329 rs684867 chr1 60586930 C A 2.70E-05 Urinary metabolites / / 21572414 rs688026 chr1 60587677 C T 1.90E-05 Urinary metabolites / / 21572414 rs634161 chr1 60589775 T C 2.17E-04 Alzheimer's disease / / 17998437 rs616637 chr1 60593303 G A 2.40E-05 Urinary metabolites / / 21572414 rs87061 chr1 60594980 G T 5.80E-05 Glioma (high-grade) / / 19578366 rs646860 chr1 60598301 G A 6.50E-04 Volumetric brain MRI / / 17903297 rs601344 chr1 60600945 A G 2.90E-05 Glioma (high-grade) / / 19578366 rs656464 chr1 60601856 T C 5.97E-04 Multiple complex diseases / / 17554300 rs619806 chr1 60602824 A C 7.06E-04 Alzheimer's disease / / 22005930 rs671094 chr1 60602865 G C 7.04E-04 Alzheimer's disease / / 22005930 rs582695 chr1 60607442 A G 6.77E-04 Alzheimer's disease / / 22005930 rs609462 chr1 60609043 C T 9.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs609462 chr1 60609043 C T 8.68E-04 Alzheimer's disease / / 22005930 rs655146 chr1 60611029 G T 3.20E-05 Glioma (high-grade) / / 19578366 rs656416 chr1 60611269 A G 7.54E-04 Alzheimer's disease / / 22005930 rs618570 chr1 60615397 G C 4.98E-06 Periodontitis (PAL4Q3) / / 24024966 rs620794 chr1 60615839 G C 4.99E-06 Periodontitis (PAL4Q3) / / 24024966 rs11207574 chr1 60626168 A G 8.74E-04 Multiple complex diseases / / 17554300 rs922356 chr1 60631000 G A 4.68E-06 Periodontitis (PAL4Q3) / / 24024966 rs17120284 chr1 60634158 G T 4.54E-06 Periodontitis (PAL4Q3) / / 24024966 rs12072323 chr1 60639683 G T 4.65E-06 Periodontitis (PAL4Q3) / / 24024966 rs7534167 chr1 60661493 G T 4.35E-06 Periodontitis (PAL4Q3) / / 24024966 rs12125049 chr1 60667702 C T 4.20E-07 Glioma (high-grade) / / 19578366 rs7530841 chr1 60667936 A C 4.35E-06 Periodontitis (PAL4Q3) / / 24024966 rs1381890 chr1 60669529 T C 4.55E-06 Periodontitis (PAL4Q3) / / 24024966 rs17120349 chr1 60671732 G T 3.83E-06 Periodontitis (PAL4Q3) / / 24024966 rs12122772 chr1 60672543 A C 7.54E-04 Multiple complex diseases / / 17554300 rs12081932 chr1 60681873 C T 4.32E-06 Periodontitis (PAL4Q3) / / 24024966 rs11207580 chr1 60691150 G T 4.31E-06 Periodontitis (PAL4Q3) / / 24024966 rs17120400 chr1 60691588 G A 4.00E-06 Periodontitis (PAL4Q3) / / 24024966 rs4529739 chr1 60704783 T C 2.69E-06 Breast cancer (survival) / / 20332263 rs12741643 chr1 60752854 A G 0.000247 Salmonella-induced pyroptosis / / 22837397 rs298171 chr1 60785950 A T 4.60E-05 Response to statin therapy / / 20339536 rs298170 chr1 60787155 A G 4.30E-05 Response to statin therapy / / 20339536 rs454776 chr1 60794707 C T 4.00E-05 Response to statin therapy / / 20339536 rs2992354 chr1 60795185 T C 4.00E-05 Response to statin therapy / / 20339536 rs390331 chr1 60800662 T C 1.60E-05 Response to statin therapy / / 20339536 rs298166 chr1 60806703 T G 1.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs427970 chr1 60815042 C T 2.20E-05 Response to statin therapy / / 20339536 rs12137879 chr1 60815316 C T 5.41E-05 LDL lipoproteins / / pha002902 rs11585396 chr1 60817360 C A 6.19E-06 Diabetes Mellitus / / pha003059 rs17120557 chr1 60817919 T A 9.73E-04 Multiple complex diseases / / 17554300 rs298128 chr1 60848538 A G 6.50E-05 Information processing speed / / 21130836 rs298137 chr1 60855214 C T 4.82E-05 Eosinophil counts / / pha003088 rs403304 chr1 60869362 G T 6.27E-04 Smoking initiation / / 24665060 rs298157 chr1 60872291 C T 9.55E-04 Stroke / / pha002887 rs298154 chr1 60874869 C G 2.23E-04 Multiple complex diseases / / 17554300 rs298152 chr1 60875777 G A 2.79E-04 Multiple complex diseases / / 17554300 rs298151 chr1 60875812 T C 2.98E-04 Multiple complex diseases / / 17554300 rs298149 chr1 60875939 C T 2.47E-04 Multiple complex diseases / / 17554300 rs626286 chr1 60876100 C G 6.59E-04 Multiple complex diseases / / 17554300 rs7529292 chr1 60876146 T C 1.52E-04 Multiple complex diseases / / 17554300 rs7529292 chr1 60876146 T C 8.76E-05 Leukocyte Counts / / pha003091 rs298160 chr1 60879175 G A 1.63E-05 Basophils / / pha003087 rs7551363 chr1 60888999 T G 6.94E-04 Obesity (extreme) / / 21935397 rs1501227 chr1 60907394 G A 7.10E-05 Response to statin therapy / / 20339536 rs12760685 chr1 60909142 C T 5.37E-04 Smoking initiation / / 24665060 rs4915695 chr1 60962168 A G 6.10E-05 Cognitive test performance / / 20125193 rs4915695 chr1 60962168 A G 1.70E-05 Cortisol secretion,in saliva / / 21316860 rs4636500 chr1 60975806 T C 1.08E-04 Multiple complex diseases / / 17554300 rs4915697 chr1 60983285 T C 1.47E-04 Multiple complex diseases / / 17554300 rs12138423 chr1 60986573 G A 7.53E-05 Major depressive disorder / / 22472876 rs4515823 chr1 60993142 T G 3.09E-04 Multiple complex diseases / / 17554300 rs10889182 chr1 60998195 T G 1.62E-07 Bipolar disorder / / 22182935 rs10889182 chr1 60998195 T G 6.94E-05 Major depressive disorder / / 22472876 rs10889184 chr1 61006050 G A 7.33E-05 Major depressive disorder / / 22472876 rs11207633 chr1 61007182 A G 1.54E-07 Bipolar disorder / / 22182935 rs11207633 chr1 61007182 A G 4.65E-05 Major depressive disorder / / 22472876 rs10889187 chr1 61010758 G A 1.30E-07 Bipolar disorder / / 22182935 rs10889187 chr1 61010758 G A 4.44E-05 Major depressive disorder / / 22472876 rs10889189 chr1 61025026 C G 5.51E-05 Multiple complex diseases / / 17554300 rs10889189 chr1 61025026 C G 7.56E-07 Bipolar disorder / / 22182935 rs4564178 chr1 61030369 C T 6.73E-05 Body mass (lean) / / 19268274 rs1461356 chr1 61037015 G A 4.42E-07 Multiple complex diseases / / 17554300 rs12565755 chr1 61041875 T C 5.00E-08 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs12565755 chr1 61041875 T C 0.000153 Salmonella-induced pyroptosis / / 22837397 rs1381171 chr1 61042598 T C 1.79E-05 Major depressive disorder / / 22472876 rs1572358 chr1 61056625 T C 1.86E-05 Major depressive disorder / / 22472876 rs2989476 chr1 61059259 G C 1.71E-07 Multiple complex diseases / / 17554300 rs2989476 chr1 61059259 G C 2.00E-06 Bipolar disorder / / 21254220 rs2989476 chr1 61059259 G C 3.00E-06 Bipolar disorder / / 21738484 rs3896178 chr1 61061996 G A 1.30E-05 Multiple complex diseases / / 17554300 rs3896178 chr1 61061996 G A 4.62E-05 Serum metabolites / / 19043545 rs3896178 chr1 61061996 G A 2.03E-04 Bipolar disorder,schizoaffective / / 19567891 rs484743 chr1 61062474 G A 3.70E-07 Multiple complex diseases / / 17554300 rs537110 chr1 61084790 T C 7.35E-04 Schizophrenia / / 19197363 rs2987775 chr1 61087726 A G 4.89E-05 Multiple complex diseases / / 17554300 rs2447043 chr1 61087920 A G 7.36E-05 Multiple complex diseases / / 17554300 rs472913 chr1 61095558 G C 2.00E-07 Bipolar disorder / / 19416921 rs555070 chr1 61099680 G A 1.09E-05 Multiple complex diseases / / 17554300 rs1399162 chr1 61169395 A G 8.79E-04 Type 2 diabetes / / 17463246 rs10493294 chr1 61170724 G A 2.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1514178 chr1 61205469 T C 3.01E-04 Type 2 diabetes / / 17463246 rs1514178 chr1 61205469 T C 2.00E-07 Phospholipid levels (plasma) / / 21829377 rs6650097 chr1 61264342 A G 4.66E-04 Smoking cessation / / 24665060 rs17302852 chr1 61274799 T C 9.87E-04 Coronary heart disease / / 21606135 rs1877734 chr1 61282089 G A 0.000636172 Hypertension (early onset hypertension) / / 22479346 rs648787 chr1 61296240 G A 1.11E-05 Body Mass Index / / pha003006 rs643397 chr1 61300983 A G 7.73E-04 Acute lung injury / / 22295056 rs574095 chr1 61327635 G A 2.90E-05 Urinary metabolites / / 21572414 rs12138640 chr1 61338655 G A 7.94E-04 Multiple complex diseases / / 17554300 rs12028543 chr1 61368719 G A 8.80E-04 Obesity (extreme) / / 21935397 rs575726 chr1 61369313 G A 2.70E-05 Urinary metabolites / / 21572414 rs12035256 chr1 61463825 C T 3.38E-05 Coronary heart disease / / pha003031 rs12035256 chr1 61463825 C T 9.78E-05 Coronary heart disease / / pha003056 rs1779865 chr1 61483042 T G 1.86E-05 Myopia (severe) / / 23933737 rs2173345 chr1 61485568 A C 9.59E-05 Myopia (severe) / / 23933737 rs11207695 chr1 61554927 C T 1.86E-04 Type 2 diabetes NFIA intron 17463246 rs964091 chr1 61567939 G A 1.52E-04 Type 2 diabetes NFIA intron 17463246 rs10493302 chr1 61571392 T C 2.27E-05 Type 2 diabetes NFIA intron 17463246 rs6693597 chr1 61582546 T G 7.01E-05 Parkinson's disease NFIA intron 21248740 rs12403502 chr1 61606969 T A 8.97E-05 Type 2 diabetes NFIA intron 17463246 rs2008968 chr1 61607034 C T 1.01E-04 Response to taxane treatment (placlitaxel) NFIA intron 23006423 rs334728 chr1 61609007 C T 8.60E-04 Coronary Artery Disease NFIA intron 17634449 rs334699 chr1 61620496 A G 2.00E-07 Thyroid hormone levels NFIA intron 23408906 rs334699 chr1 61620496 A G 5.00E-12 Thyroid hormone levels NFIA intron 23408906 rs334699 chr1 61620496 A G 6.00E-07 Thyroid hormone levels NFIA intron 23408906 rs168022 chr1 61629453 G A 8.63E-04 Rheumatoid arthritis NFIA intron 21452313 rs334716 chr1 61639503 G A 7.09E-04 Coronary Artery Disease NFIA intron 17634449 rs12086591 chr1 61647156 T G 2.53E-04 Type 2 diabetes NFIA intron 17463246 rs7552300 chr1 61688282 C T 5.82E-06 Asthma (childhood onset) NFIA intron 23829686 rs17121853 chr1 61708978 C G 5.07E-04 Prostate cancer mortality NFIA intron 20978177 rs17377428 chr1 61729721 G A 9.70E-06 Urinary metabolites NFIA intron 21572414 rs17121875 chr1 61731652 A C 7.10E-07 Urinary metabolites NFIA intron 21572414 rs437021 chr1 61738270 C T 1.00E-06 Biomarkers NFIA intron 17903293 rs41492448 chr1 61769989 T C 4.40E-04 Multiple complex diseases NFIA intron 17554300 rs2363876 chr1 61776742 C T 3.61E-04 Smoking initiation NFIA intron 24665060 rs41423747 chr1 61781106 C T 3.80E-06 Urinary metabolites NFIA intron 21572414 rs6691768 chr1 61791863 G A 1.00E-07 Celiac disease NFIA intron 20190752 rs6691941 chr1 61792008 G A 3.43E-04 Smoking initiation NFIA intron 24665060 rs11801720 chr1 61798624 A G 0.000287 Salmonella-induced pyroptosis NFIA intron 22837397 rs9436636 chr1 61812773 G A 5.30E-05 Breast cancer NFIA intron 22452962 rs41350144 chr1 61815799 A T 3.00E-07 Bipolar disorder NFIA intron 22925353 rs2364467 chr1 61816354 C G 8.99E-07 Bipolar disorder NFIA intron 22925353 rs2364467 chr1 61816354 C G 1.61E-04 Response to cytadine analogues (cytosine arabinoside) NFIA intron 24483146 rs2024789 chr1 61817001 G C 2.00E-06 Bipolar disorder NFIA intron 22925353 rs7528918 chr1 61818422 A G 1.57E-04 Response to cytadine analogues (cytosine arabinoside) NFIA intron 24483146 rs17121983 chr1 61820072 C G 4.00E-07 Bipolar disorder NFIA intron 22925353 rs7556462 chr1 61821819 T C 4.00E-07 Bipolar disorder NFIA intron 22925353 rs4915737 chr1 61822283 G C 4.00E-07 Bipolar disorder NFIA intron 22925353 rs4915737 chr1 61822283 G C 1.57E-04 Response to cytadine analogues (cytosine arabinoside) NFIA intron 24483146 rs7553582 chr1 61824375 C T 4.00E-06 Bipolar disorder NFIA intron 22925353 rs41453448 chr1 61824389 G A 2.00E-07 Bipolar disorder NFIA intron 22925353 rs1125777 chr1 61831890 C T 2.00E-07 Bipolar disorder NFIA intron 22925353 rs12568010 chr1 61831938 A G 2.00E-07 Bipolar disorder NFIA intron 22925353 rs10489911 chr1 61838509 C T 8.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NFIA intron 20877124 rs17356748 chr1 61843343 C G 5.69E-04 Multiple complex diseases NFIA intron 17554300 rs2474388 chr1 61859802 G T 1.89E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs10889219 chr1 61861554 T C 8.36E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs2180201 chr1 61864119 G C 2.18E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs1474872 chr1 61864231 C A 2.29E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs2474384 chr1 61868766 C T 5.15E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs7535730 chr1 61871356 A G 8.06E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs9436640 chr1 61873677 T G 5.00E-18 Ventricular conduction NFIA intron 21076409 rs9436640 chr1 61873677 T G 7.44E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs6587924 chr1 61895257 C A 8.05E-05 Major depressive disorder (broad) NFIA intron 20038947 rs2207790 chr1 61897967 G A 9.49E-05 Major depressive disorder (broad) NFIA intron 20038947 rs2207790 chr1 61897967 G A 6.00E-18 Electrocardiographic conduction measures NFIA intron 23463857 rs12404081 chr1 61941846 A G 9.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs4281350 chr1 61949463 T G 6.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4915748 chr1 61954169 C T 2.70E-05 Methamphetamine dependence / / 23594818 rs10889228 chr1 61958583 C T 9.94E-04 Multiple complex diseases / / 17554300 rs3890764 chr1 61961953 G A 7.61E-04 Parkinson's disease / / 16252231 rs3890764 chr1 61961953 G A 1.08E-05 Body Mass Index / / pha003009 rs3890764 chr1 61961953 G A 9.39E-05 Weight / / pha003027 rs35231142 chr1 61964427 C T 4.47E-04 Multiple complex diseases / / 17554300 rs12036419 chr1 61971449 G A 5.92E-04 Multiple complex diseases / / 17554300 rs2499516 chr1 61977297 G T 5.42E-04 Multiple complex diseases / / 17554300 rs7512200 chr1 61978694 A G 5.82E-04 Multiple complex diseases / / 17554300 rs1933299 chr1 62000281 T G 6.05E-05 Taste perception / / 22132133 rs2365269 chr1 62060213 A G 6.47E-05 Lactate dehydrogenase levels / / 20981236 rs12036661 chr1 62077191 C T 7.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs7545391 chr1 62078347 T C 3.23E-05 Body Mass Index / / pha003014 rs12137416 chr1 62087783 C T 2.71E-04 Alzheimer's disease / / 17998437 rs1933293 chr1 62089261 T C 7.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12118986 chr1 62103814 C A 4.43E-05 Height / / pha003010 rs12118986 chr1 62103814 C A 7.23E-05 Height / / pha003011 rs2886326 chr1 62111054 A G 0.0005946 Hypertension (early onset hypertension) / / 22479346 rs6681890 chr1 62114181 G A 3.94E-06 Psoriasis / / 20953190 rs10889249 chr1 62119809 T C 1.63E-04 Stroke / / pha002886 rs11207801 chr1 62126262 G A 6.91E-05 Hypertension (early onset hypertension) / / 22479346 rs6694023 chr1 62130167 A G 7.90E-05 Major depressive disorder / / 21621269 rs9783018 chr1 62135356 T C 2.52E-22 Narcolepsy / / 19629137 rs12117475 chr1 62142097 G A 9.59E-04 Alzheimer's disease / / 17998437 rs17122715 chr1 62190897 A G 5.49E-04 Multiple complex diseases TM2D1 UTR-5 17554300 rs2365498 chr1 62312654 G A 6.90E-04 Myocardial Infarction I/DL intron pha002883 rs4598521 chr1 62341157 T C 7.05E-04 Coronary Artery Disease I/DL intron 17634449 rs6685516 chr1 62342230 T C 4.80E-04 Myasthenia gravis I/DL intron 23055271 rs9326052 chr1 62356590 G A 3.00E-04 Acute lymphoblastic leukemia (childhood) I/DL intron 20189245 rs4915788 chr1 62357407 T G 1.62E-04 Type 2 diabetes I/DL intron 17463246 rs1056513 chr1 62380298 G A 1.00E-07 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 2.00E-07 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 2.00E-07 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 3.00E-06 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 3.00E-07 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 3.00E-07 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 6.00E-06 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 7.00E-06 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 7.00E-06 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 7.00E-06 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 8.00E-06 Obesity-related traits I/DL missense 23251661 rs11207864 chr1 62380658 C T 6.34E-04 Iron levels I/DL intron pha002876 rs2482863 chr1 62387598 T C 9.34E-05 Response to taxane treatment (placlitaxel) I/DL intron 23006423 rs11207865 chr1 62387652 A G 3.99E-04 Myocardial Infarction I/DL intron pha002883 rs10889271 chr1 62400487 C T 1.39E-04 Type 2 diabetes I/DL intron 17463246 rs10889272 chr1 62402549 C T 1.00E-04 Alcoholism (heaviness of drinking) I/DL intron 21529783 rs11207877 chr1 62426771 C T 3.45E-04 Type 2 diabetes I/DL intron 17463246 rs7512525 chr1 62427888 C T 2.60E-04 Type 2 diabetes I/DL intron 17463246 rs1123777 chr1 62488522 T C 2.10E-05 Urinary metabolites I/DL intron 21572414 rs2499818 chr1 62489450 A G 9.32E-05 Smoking initiation I/DL intron 24665060 rs11585888 chr1 62499673 G A 3.38E-04 Alzheimer's disease I/DL intron 22005930 rs6673889 chr1 62504123 T C 3.40E-04 Alzheimer's disease I/DL intron 22005930 rs6685442 chr1 62504194 A G 7.78E-04 Alzheimer's disease I/DL intron 22005930 rs6661849 chr1 62504715 G C 4.01E-04 Alzheimer's disease I/DL intron 22005930 rs17378995 chr1 62504841 T C 6.34E-04 Alzheimer's disease I/DL intron 22005930 rs7539653 chr1 62504958 A G 4.72E-04 Alzheimer's disease I/DL intron 22005930 rs7519802 chr1 62505280 G A 4.69E-04 Alzheimer's disease I/DL intron 22005930 rs10493313 chr1 62511018 T A 5.46E-04 Alzheimer's disease I/DL intron 22005930 rs11576777 chr1 62512735 T G 5.49E-04 Alzheimer's disease I/DL intron 22005930 rs11579010 chr1 62513239 A G 8.21E-04 Alzheimer's disease I/DL intron 22005930 rs2498982 chr1 62516683 G C 8.72E-04 Response to taxane treatment (placlitaxel) I/DL missense 23006423 rs12072096 chr1 62523223 A G 8.82E-04 Alzheimer's disease I/DL intron 17998437 rs6682776 chr1 62556579 A T 6.99E-04 Alzheimer's disease I/DL intron 22005930 rs10127438 chr1 62560928 C T 9.32E-04 Multiple complex diseases I/DL intron 17554300 rs6700644 chr1 62575981 T C 7.77E-04 Alzheimer's disease I/DL intron 17998437 rs12044746 chr1 62580201 G A 1.44E-04 Multiple complex diseases I/DL intron 17554300 rs2476194 chr1 62594593 C T 5.93E-04 Myopia (pathological) I/DL cds-synon 21095009 rs11207909 chr1 62607786 G A 1.00E-04 Multiple complex diseases I/DL intron 17554300 rs17123151 chr1 62623177 G A 0.0002 Migraine I/DL intron 22678113 rs10889294 chr1 62630362 A C 2.41E-04 Multiple complex diseases / / 17554300 rs6684324 chr1 62635058 C T 8.14E-04 Multiple complex diseases / / 17554300 rs6684324 chr1 62635058 C T 9.86E-04 Alzheimer's disease / / 22005930 rs2457832 chr1 62635116 C T 6.87E-04 Multiple complex diseases / / 17554300 rs6687095 chr1 62635246 G T 8.57E-04 Alzheimer's disease / / 22005930 rs2481703 chr1 62644118 A G 7.60E-05 Cognitive test performance / / 20125193 rs2481703 chr1 62644118 A G 3.68E-04 Acute lung injury / / 22295056 rs4019803 chr1 62687104 A G 3.20E-05 Cognitive test performance / / 20125193 rs2067994 chr1 62708339 A G 8.39E-05 Cognitive performance KANK4 intron 19734545 rs958802 chr1 62723566 C T 1.45E-04 Celiac disease KANK4 intron 23936387 rs17123303 chr1 62733826 T C 8.27E-04 Body mass index KANK4 intron 21701565 rs12038843 chr1 62736841 A G 4.90E-04 Alzheimer's disease (late onset) KANK4 intron 21379329 rs17123324 chr1 62741296 G A 4.07E-04 Suicide attempts in bipolar disorder KANK4 intron 21041247 rs765691 chr1 62759848 T A 8.25E-05 Serum metabolites KANK4 intron 19043545 rs2765265 chr1 62761379 C T 5.82E-04 Multiple complex diseases KANK4 intron 17554300 rs201504584 chr1 62761907 CAGAGT C 1.72E-05 Waist Circumference KANK4 intron pha003023 rs6704270 chr1 62761907 C A 1.72E-05 Waist Circumference KANK4 intron pha003023 rs2182241 chr1 62805139 G C 2.10E-04 Multiple complex diseases / / 17554300 rs6675459 chr1 62818217 T C 7.82E-04 Insulin resistance / / 21901158 rs997532 chr1 62842677 G A 5.57E-04 White matter integrity / / 22425255 rs3949904 chr1 62848090 G A 8.50E-05 Celiac disease / / 17558408 rs3949904 chr1 62848090 G A 1.20E-05 Urinary metabolites / / 21572414 rs3949904 chr1 62848090 G A 7.22E-05 Tunica Media / / pha003036 rs7523497 chr1 62853146 A G 6.76E-08 Non-obstructive azoospermia / / 22197933 rs7523622 chr1 62890510 C A 8.62E-04 Alcohol dependence / / 21314694 rs10493324 chr1 62898142 C T 0.00045776 Sarcoidosis / / 22952805 rs626787 chr1 62901243 C G 4.41E-05 Multiple complex diseases / / 17554300 rs626787 chr1 62901243 C G 6.01E-12 Metabolite levels / / 22286219 rs631106 chr1 62901807 C A 4.67E-12 Metabolite levels / / 22286219 rs9436221 chr1 62903359 T C 1.47E-11 Metabolite levels USP1 intron 22286219 rs9436222 chr1 62903363 C G 1.48E-11 Metabolite levels USP1 intron 22286219 rs9436223 chr1 62903547 C T 1.60E-11 Metabolite levels USP1 intron 22286219 rs12029068 chr1 62904295 C T 5.69E-12 Metabolite levels USP1 intron 22286219 rs9436661 chr1 62904575 T G 9.09E-11 Metabolite levels USP1 intron 22286219 rs10493322 chr1 62905893 C T 8.40E-12 Metabolite levels USP1 intron 22286219 rs638714 chr1 62906489 G T 8.44E-12 Metabolite levels USP1 intron 22286219 rs638305 chr1 62906537 G T 8.46E-12 Metabolite levels USP1 intron 22286219 rs637723 chr1 62906728 C T 6.25E-12 Metabolite levels USP1 intron 22286219 rs656297 chr1 62907595 A G 5.90E-12 Metabolite levels USP1 intron 22286219 rs642845 chr1 62908235 T C 8.35E-12 Metabolite levels USP1 intron 22286219 rs641540 chr1 62908538 A G 8.35E-12 Metabolite levels USP1 intron 22286219 rs598253 chr1 62911341 T C 8.45E-12 Metabolite levels USP1 intron 22286219 rs11207969 chr1 62911751 A G 5.65E-12 Metabolite levels USP1 intron 22286219 rs659656 chr1 62912120 C G 8.46E-12 Metabolite levels USP1 intron 22286219 rs10158897 chr1 62912919 C T 4.91E-12 Metabolite levels USP1 intron 22286219 rs10158897 chr1 62912919 C T 9.00E-06 Lipid traits USP1 intron 24386095 rs783291 chr1 62914978 G A 2.97E-11 Metabolite levels USP1 intron 22286219 rs11207970 chr1 62915473 C T 8.34E-12 Metabolite levels USP1 intron 22286219 rs583609 chr1 62916796 T C 5.80E-12 Metabolite levels USP1 UTR-3 22286219 rs583609 chr1 62916796 T C 3.23E-08 Cholesterol,total USP1 UTR-3 23063622 rs597470 chr1 62917796 T G 1.46E-11 Metabolite levels / / 22286219 rs597078 chr1 62917857 G A,C,T 8.35E-12 Metabolite levels / / 22286219 rs597078 chr1 62917857 G A,C,T 4.25E-08 Cholesterol,total / / 23063622 rs597076 chr1 62917865 T A 1.44E-11 Metabolite levels / / 22286219 rs630144 chr1 62918864 A G 8.36E-12 Metabolite levels / / 22286219 rs636523 chr1 62920008 A G 7.74E-12 Metabolite levels / / 22286219 rs636523 chr1 62920008 A G 5.00E-07 Lipid traits / / 24386095 rs636497 chr1 62920029 A G 8.36E-12 Metabolite levels / / 22286219 rs624660 chr1 62920388 C A 5.64E-12 Metabolite levels / / 22286219 rs634341 chr1 62921422 T C 8.46E-12 Metabolite levels DOCK7 intron 22286219 rs3913007 chr1 62921586 T C 4.16E-12 Metabolite levels DOCK7 intron 22286219 rs4350231 chr1 62922660 G A 1.40E-12 Metabolite levels DOCK7 intron 22286219 rs12023489 chr1 62923858 G A 1.63E-12 Metabolite levels DOCK7 intron 22286219 rs12037659 chr1 62923863 C T 8.47E-12 Metabolite levels DOCK7 intron 22286219 rs1305520 chr1 62926057 A T 2.08E-12 Metabolite levels DOCK7 intron 22286219 rs1167996 chr1 62927797 T G 1.58E-11 Metabolite levels DOCK7 intron 22286219 rs998403 chr1 62928549 G A 3.96E-12 Metabolite levels DOCK7 intron 22286219 rs1167998 chr1 62931632 C A 1.30E-06 Lipid levels DOCK7 intron 18193043 rs1167998 chr1 62931632 C A 2.00E-12 Triglycerides DOCK7 intron 19060911 rs1167998 chr1 62931632 C A 4.10E-09 Lipid levels DOCK7 intron 19936222 rs1167998 chr1 62931632 C A 2.21E-12 Metabolite levels DOCK7 intron 22286219 rs1167998 chr1 62931632 C A 1.20E-27 Cholesterol,total DOCK7 intron 23063622 rs1167998 chr1 62931632 C A 5.49E-27 Triglycerides DOCK7 intron 23063622 rs1167998 chr1 62931632 C A 5.78E-16 Triglycerides in males DOCK7 intron 23063622 rs1167998 chr1 62931632 C A 6.86E-09 LDL cholesterol DOCK7 intron 23063622 rs1167998 chr1 62931632 C A 8.48E-10 Triglycerides in females DOCK7 intron 23063622 rs1167998 chr1 62931632 C A 5.71E-06 Triglycerides DOCK7 intron pha003081 rs1167998 chr1 62931632 C A 8.52E-06 Lipid levels DOCK7 intron pha003082 rs1168002 chr1 62934308 A G 3.72E-12 Metabolite levels DOCK7 intron 22286219 rs1007205 chr1 62936912 T C 1.13E-10 Metabolite levels DOCK7 intron 22286219 rs10889330 chr1 62939466 G C 8.38E-12 Metabolite levels DOCK7 intron 22286219 rs1979722 chr1 62940097 G A 3.65E-12 Metabolite levels DOCK7 intron 22286219 rs10889331 chr1 62943007 G T 1.57E-11 Metabolite levels DOCK7 intron 22286219 rs1168009 chr1 62943954 G A 1.57E-11 Metabolite levels DOCK7 intron 22286219 rs1168010 chr1 62943979 G A 9.31E-11 Metabolite levels DOCK7 intron 22286219 rs1183260 chr1 62945418 A G 3.25E-11 Metabolite levels DOCK7 intron 22286219 rs6587976 chr1 62945631 C T 8.30E-12 Metabolite levels DOCK7 intron 22286219 rs1305521 chr1 62949034 A G 1.99E-11 Metabolite levels DOCK7 intron 22286219 rs11207974 chr1 62949960 T C 1.95E-11 Metabolite levels DOCK7 intron 22286219 rs10889332 chr1 62950858 C T 6.05E-12 Metabolite levels DOCK7 intron 22286219 rs10889332 chr1 62950858 C T 8.00E-15 Metabolite levels (atherosclerosis) DOCK7 intron 22916037 rs10493326 chr1 62953373 G A 5.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DOCK7 intron 20877124 rs1690761 chr1 62955862 C T 1.28E-11 Metabolite levels DOCK7 intron 22286219 rs10889333 chr1 62957030 G A 4.55E-12 Metabolite levels DOCK7 intron 22286219 rs10889333 chr1 62957030 G A 4.85E-06 Triglycerides DOCK7 intron pha003081 rs10889333 chr1 62957030 G A 9.52E-06 Lipid levels DOCK7 intron pha003082 rs10889334 chr1 62957199 C G 5.73E-12 Metabolite levels DOCK7 intron 22286219 rs10789112 chr1 62957758 T C 5.80E-12 Metabolite levels DOCK7 intron 22286219 rs10889335 chr1 62960101 A G 3.45E-13 Metabolite levels DOCK7 cds-synon 22286219 rs1168041 chr1 62960250 T C 1.08E-12 Metabolite levels DOCK7 intron 22286219 rs1168040 chr1 62960575 T C 1.96E-12 Metabolite levels DOCK7 intron 22286219 rs1168036 chr1 62962734 A G 5.78E-12 Metabolite levels DOCK7 intron 22286219 rs1002687 chr1 62963737 G A 6.11E-13 Metabolite levels DOCK7 intron 22286219 rs1168034 chr1 62963914 G C 6.42E-11 Metabolite levels DOCK7 intron 22286219 rs35529421 chr1 62965621 T A,G 6.11E-13 Metabolite levels DOCK7 intron 22286219 rs1168032 chr1 62967747 A G 1.84E-12 Metabolite levels DOCK7 intron 22286219 rs1168031 chr1 62967987 C T 6.11E-13 Metabolite levels DOCK7 intron 22286219 rs1168030 chr1 62968491 C T 6.11E-13 Metabolite levels DOCK7 intron 22286219 rs1168029 chr1 62969402 G A 3.00E-13 Lipid metabolism phenotypes DOCK7 intron 22286219 rs1168028 chr1 62969431 G A 7.37E-12 Metabolite levels DOCK7 intron 22286219 rs1168027 chr1 62970184 T C 6.11E-13 Metabolite levels DOCK7 intron 22286219 rs1168026 chr1 62970996 T C 8.47E-13 Metabolite levels DOCK7 intron 22286219 rs1184865 chr1 62973795 A G 6.12E-13 Metabolite levels DOCK7 intron 22286219 rs1168042 chr1 62974150 A T 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs11207976 chr1 62976751 G A 7.36E-12 Metabolite levels DOCK7 intron 22286219 rs11207977 chr1 62977307 C T 3.95E-12 Metabolite levels DOCK7 intron 22286219 rs1781212 chr1 62977419 G A 1.30E-12 Metabolite levels DOCK7 intron 22286219 rs1168044 chr1 62977558 A C 5.78E-12 Metabolite levels DOCK7 intron 22286219 rs10889336 chr1 62980410 T C 5.73E-13 Metabolite levels DOCK7 intron 22286219 rs10889337 chr1 62980607 G A 2.24E-12 Metabolite levels DOCK7 intron 22286219 rs10889337 chr1 62980607 G A 5.31E-06 Triglycerides DOCK7 intron pha003081 rs10889337 chr1 62980607 G A 8.43E-06 Lipid levels DOCK7 intron pha003082 rs12090886 chr1 62981440 G A 3.97E-11 Metabolite levels DOCK7 intron 22286219 rs12090886 chr1 62981440 G A 2.42E-08 Cholesterol,total DOCK7 intron 23063622 rs1168045 chr1 62982891 C A,T 7.62E-12 Metabolite levels DOCK7 intron 22286219 rs1168045 chr1 62982891 C A,T 2.64E-08 Cholesterol,total DOCK7 intron 23063622 rs11207979 chr1 62982994 G A 4.01E-12 Metabolite levels DOCK7 intron 22286219 rs1168046 chr1 62983693 A C 5.46E-12 Metabolite levels DOCK7 intron 22286219 rs1168046 chr1 62983693 A C 1.86E-08 Cholesterol,total DOCK7 intron 23063622 rs1168047 chr1 62983751 C T 5.52E-12 Metabolite levels DOCK7 intron 22286219 rs1168047 chr1 62983751 C T 2.15E-08 Cholesterol,total DOCK7 intron 23063622 rs10889338 chr1 62984897 C T 3.95E-12 Metabolite levels DOCK7 intron 22286219 rs10889338 chr1 62984897 C T 1.45E-08 Cholesterol,total DOCK7 intron 23063622 rs1168050 chr1 62986955 C T 5.52E-12 Metabolite levels DOCK7 intron 22286219 rs1168050 chr1 62986955 C T 2.66E-08 Cholesterol,total DOCK7 intron 23063622 rs1690766 chr1 62987289 T C 5.52E-12 Metabolite levels DOCK7 intron 22286219 rs1781195 chr1 62988972 T C 5.94E-12 Metabolite levels DOCK7 intron 22286219 rs1627591 chr1 62989807 C T 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs11577840 chr1 62991369 T C 2.68E-12 Metabolite levels DOCK7 intron 22286219 rs12062275 chr1 62991905 T C 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs11207980 chr1 62992749 T C 3.95E-12 Metabolite levels DOCK7 intron 22286219 rs12403207 chr1 62993620 T C 2.18E-12 Metabolite levels DOCK7 intron 22286219 rs1168015 chr1 62996046 C G 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs1168013 chr1 62996838 C G 5.27E-04 Type 2 diabetes DOCK7 intron 17463246 rs1168013 chr1 62996838 C G 6.00E-08 Triglycerides DOCK7 intron 20864672 rs1168013 chr1 62996838 C G 5.87E-12 Metabolite levels DOCK7 intron 22286219 rs4915840 chr1 62999595 C G 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs11327850 chr1 62999675 CT C 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs7534572 chr1 62999675 C G 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs1168018 chr1 63001120 A C 2.04E-11 Metabolite levels DOCK7 intron 22286219 rs1168017 chr1 63002551 A G 2.18E-12 Metabolite levels DOCK7 intron 22286219 rs7548877 chr1 63005950 T C 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs11207981 chr1 63006087 C A 5.46E-12 Metabolite levels DOCK7 intron 22286219 rs1168023 chr1 63006595 A T 5.62E-12 Metabolite levels DOCK7 intron 22286219 rs1781221 chr1 63006842 A C 5.96E-12 Metabolite levels DOCK7 intron 22286219 rs11207982 chr1 63007182 C T 3.90E-12 Metabolite levels DOCK7 intron 22286219 rs1184547 chr1 63007228 G A 5.91E-12 Metabolite levels DOCK7 intron 22286219 rs1168022 chr1 63007721 A T 5.63E-12 Metabolite levels DOCK7 intron 22286219 rs1168021 chr1 63009900 A G 5.95E-12 Metabolite levels DOCK7 intron 22286219 rs1168020 chr1 63009956 C T 5.95E-12 Metabolite levels DOCK7 intron 22286219 rs1179765 chr1 63010110 G C 5.65E-12 Metabolite levels DOCK7 intron 22286219 rs12074528 chr1 63010871 T C 5.95E-12 Metabolite levels DOCK7 intron 22286219 rs10889339 chr1 63012056 A G 5.95E-12 Metabolite levels DOCK7 intron 22286219 rs10889340 chr1 63012071 A C 4.07E-12 Metabolite levels DOCK7 intron 22286219 rs11207983 chr1 63012107 C T 5.95E-12 Metabolite levels DOCK7 intron 22286219 rs2029763 chr1 63013134 A G 5.38E-12 Metabolite levels DOCK7 intron 22286219 rs11207984 chr1 63013396 C T 5.98E-12 Metabolite levels DOCK7 intron 22286219 rs11207985 chr1 63013786 A G 6.01E-12 Metabolite levels DOCK7 intron 22286219 rs10789113 chr1 63015199 A T 3.92E-12 Metabolite levels DOCK7 intron 22286219 rs11207986 chr1 63018170 T C 6.01E-12 Metabolite levels DOCK7 intron 22286219 rs10159255 chr1 63020816 C A 5.27E-12 Metabolite levels DOCK7 intron 22286219 rs2131925 chr1 63025942 G T 3.00E-18 LDL cholesterol DOCK7 intron 20686565 rs2131925 chr1 63025942 G T 5.00E-41 Cholesterol,total DOCK7 intron 20686565 rs2131925 chr1 63025942 G T 9.00E-43 Triglycerides DOCK7 intron 20686565 rs2131925 chr1 63025942 G T 4.01E-12 Metabolite levels DOCK7 intron 22286219 rs2131925 chr1 63025942 G T 3.00E-32 LDL cholesterol DOCK7 intron 24097068 rs2131925 chr1 63025942 G T 3.00E-74 Triglycerides DOCK7 intron 24097068 rs2131925 chr1 63025942 G T 4.00E-80 Cholesterol,total DOCK7 intron 24097068 rs2131926 chr1 63026011 C T 4.01E-12 Metabolite levels DOCK7 intron 22286219 rs10889343 chr1 63026429 T G 4.01E-12 Metabolite levels DOCK7 intron 22286219 rs4329540 chr1 63027024 C T 3.29E-12 Metabolite levels DOCK7 intron 22286219 rs10889344 chr1 63033941 T C 6.14E-12 Metabolite levels DOCK7 intron 22286219 rs10789114 chr1 63034222 T C 4.13E-12 Metabolite levels DOCK7 intron 22286219 rs7555577 chr1 63034363 A C 6.27E-12 Metabolite levels DOCK7 intron 22286219 rs12116574 chr1 63037837 C T 3.95E-12 Metabolite levels DOCK7 intron 22286219 rs6696502 chr1 63039533 C T 2.42E-12 Metabolite levels DOCK7 intron 22286219 rs12038768 chr1 63040728 G T 4.21E-12 Metabolite levels DOCK7 intron 22286219 rs11207990 chr1 63041086 T C 6.21E-12 Metabolite levels DOCK7 intron 22286219 rs11207992 chr1 63041800 T G 4.15E-12 Metabolite levels DOCK7 intron 22286219 rs1472257 chr1 63042126 A G 5.17E-12 Metabolite levels DOCK7 intron 22286219 rs10789116 chr1 63042738 A G 4.00E-12 Metabolite levels DOCK7 intron 22286219 rs11207993 chr1 63044464 C T 5.70E-04 Lipid levels DOCK7 intron 19802338 rs11207993 chr1 63044464 C T 6.10E-05 Cognitive test performance DOCK7 intron 20125193 rs1748201 chr1 63045506 A C 2.56E-11 Metabolite levels DOCK7 intron 22286219 rs1748200 chr1 63046039 T C 6.24E-12 Metabolite levels DOCK7 intron 22286219 rs1629122 chr1 63046578 C A 6.26E-12 Metabolite levels DOCK7 intron 22286219 rs9436224 chr1 63048275 A C 4.26E-11 Metabolite levels DOCK7 intron 22286219 rs34465969 chr1 63048276 A C 8.93E-12 Metabolite levels DOCK7 intron 22286219 rs35194512 chr1 63048277 A C 4.14E-12 Metabolite levels DOCK7 intron 22286219 rs11207995 chr1 63049551 A C 5.02E-04 Type 2 diabetes DOCK7 intron 17463246 rs11207995 chr1 63049551 A C 3.86E-12 Metabolite levels DOCK7 intron 22286219 rs11207995 chr1 63049551 A C 6.00E-10 Lipid traits DOCK7 intron 24386095 rs1748195 chr1 63049593 C G 9.24E-04 Type 2 diabetes DOCK7 intron 17463246 rs1748195 chr1 63049593 C G 2.00E-10 Triglycerides DOCK7 intron 18193043 rs1748195 chr1 63049593 C G 6.16E-12 Metabolite levels DOCK7 intron 22286219 rs1748195 chr1 63049593 C G 1.27E-13 Cholesterol,total DOCK7 intron 23063622 rs1748195 chr1 63049593 C G 3.08E-13 Triglycerides DOCK7 intron 23063622 rs12042319 chr1 63049819 G A 5.15E-04 Type 2 diabetes DOCK7 intron 17463246 rs12042319 chr1 63049819 G A 3.24E-07 Cardiovascular disease DOCK7 intron 18179892 rs12042319 chr1 63049819 G A 5.85E-12 Metabolite levels DOCK7 intron 22286219 rs3850634 chr1 63050598 T G 3.93E-12 Metabolite levels DOCK7 intron 22286219 rs12048208 chr1 63055280 G A 0.00000003 Triglycerides DOCK7 intron 23063622 rs12048208 chr1 63055280 G A 2.05E-09 Cholesterol,total DOCK7 intron 23063622 rs12048208 chr1 63055280 G A 9.52E-05 LDL lipoproteins DOCK7 intron pha002902 rs11207996 chr1 63055470 G A 4.13E-12 Metabolite levels DOCK7 intron 22286219 rs1748197 chr1 63056112 G A 4.19E-12 Metabolite levels DOCK7 intron 22286219 rs1748197 chr1 63056112 G A 0.000000623 Triglycerides DOCK7 intron 22629316 rs1748197 chr1 63056112 G A 0.0000821 Triglycerides (males) DOCK7 intron 22629316 rs1748197 chr1 63056112 G A 0.000551 Triglycerides (females) DOCK7 intron 22629316 rs1748197 chr1 63056112 G A 1.10E-09 LDL cholesterol DOCK7 intron 23063622 rs1748197 chr1 63056112 G A 1.79E-28 Triglycerides DOCK7 intron 23063622 rs1748197 chr1 63056112 G A 5.47E-23 Triglycerides DOCK7 intron 23063622 rs1748197 chr1 63056112 G A 6.75E-29 Cholesterol,total DOCK7 intron 23063622 rs2366636 chr1 63056670 G A 4.19E-12 Metabolite levels DOCK7 intron 22286219 rs1748199 chr1 63057136 T C 3.36E-12 Metabolite levels DOCK7 intron 22286219 rs6690733 chr1 63060311 A C 5.66E-12 Metabolite levels DOCK7 intron 22286219 rs11207997 chr1 63061906 C T 8.91E-12 Metabolite levels DOCK7 intron 22286219 rs11207997 chr1 63061906 C T 1.03E-10 LDL cholesterol DOCK7 intron 23063622 rs11207997 chr1 63061906 C T 4.27E-24 Triglycerides DOCK7 intron 23063622 rs11207997 chr1 63061906 C T 6.33E-29 Cholesterol,total DOCK7 intron 23063622 rs17123725 chr1 63063830 T C 0.00000118 Triglycerides ANGPTL3 intron 23063622 rs17123725 chr1 63063830 T C 4.04E-08 LDL cholesterol ANGPTL3 intron 23063622 rs10789117 chr1 63072265 A C 6.37E-12 Metabolite levels DOCK7 intron 22286219 rs10789117 chr1 63072265 A C 0.00000021 LDL cholesterol (female) DOCK7 intron 23063622 rs10789117 chr1 63072265 A C 1.04E-09 LDL cholesterol DOCK7 intron 23063622 rs10789117 chr1 63072265 A C 1.87E-23 Triglycerides DOCK7 intron 23063622 rs10789117 chr1 63072265 A C 8.71E-29 Cholesterol,total DOCK7 intron 23063622 rs6675401 chr1 63073975 C T 6.41E-12 Metabolite levels DOCK7 intron 22286219 rs6678483 chr1 63074442 C A 6.42E-12 Metabolite levels DOCK7 intron 22286219 rs10889347 chr1 63075826 G A 6.41E-12 Metabolite levels DOCK7 intron 22286219 rs10889348 chr1 63078222 A T 8.08E-13 Metabolite levels DOCK7 intron 22286219 rs10889349 chr1 63081919 A G 4.29E-12 Metabolite levels DOCK7 intron 22286219 rs61471917 chr1 63084030 G A 4.28E-12 Metabolite levels DOCK7 intron 22286219 rs10889350 chr1 63085266 C T 4.29E-12 Metabolite levels DOCK7 intron 22286219 rs12239736 chr1 63085997 T A 3.74E-11 Metabolite levels DOCK7 intron 22286219 rs6587980 chr1 63090858 C T 6.91E-12 Metabolite levels DOCK7 intron 22286219 rs10157265 chr1 63093617 C T 4.34E-12 Metabolite levels DOCK7 intron 22286219 rs11485618 chr1 63094207 A G 4.18E-12 Metabolite levels DOCK7 intron 22286219 rs10789118 chr1 63094692 A G 4.19E-12 Metabolite levels DOCK7 intron 22286219 rs7520810 chr1 63095711 C T 4.18E-12 Metabolite levels DOCK7 intron 22286219 rs10789119 chr1 63098235 G A 4.16E-12 Metabolite levels DOCK7 intron 22286219 rs10889352 chr1 63099023 T C 4.18E-12 Metabolite levels DOCK7 intron 22286219 rs2366638 chr1 63099577 G A 4.33E-12 Metabolite levels DOCK7 intron 22286219 rs1570694 chr1 63103217 A G 4.12E-12 Metabolite levels DOCK7 intron 22286219 rs12047226 chr1 63105538 T C 4.17E-12 Metabolite levels DOCK7 intron 22286219 rs7539035 chr1 63106767 C A 5.47E-04 Type 2 diabetes DOCK7 intron 17463246 rs7539035 chr1 63106767 C A 4.54E-06 Lymphocyte counts DOCK7 intron 22286170 rs7539035 chr1 63106767 C A 6.69E-12 Metabolite levels DOCK7 intron 22286219 rs995000 chr1 63107526 C T 5.40E-04 Type 2 diabetes DOCK7 intron 17463246 rs995000 chr1 63107526 C T 1.91E-11 Metabolite levels DOCK7 intron 22286219 rs11208000 chr1 63108374 A G 5.01E-12 Metabolite levels DOCK7 intron 22286219 rs993013 chr1 63111069 G T 1.27E-11 Metabolite levels DOCK7 intron 22286219 rs1168085 chr1 63112320 C G 5.94E-12 Metabolite levels DOCK7 intron 22286219 rs1168086 chr1 63112389 A G 5.94E-12 Metabolite levels DOCK7 intron 22286219 rs746735 chr1 63113511 C A 5.91E-12 Metabolite levels DOCK7 intron 22286219 rs1168089 chr1 63113719 T C 2.34E-11 Metabolite levels DOCK7 intron 22286219 rs10889353 chr1 63118196 A C 4.36E-04 Type 2 diabetes DOCK7 intron 17463246 rs10889353 chr1 63118196 A C 3.00E-07 Triglycerides DOCK7 intron 19060906 rs10889353 chr1 63118196 A C 4.00E-12 Cholesterol,total DOCK7 intron 19060911 rs10889353 chr1 63118196 A C 8.00E-06 LDL cholesterol DOCK7 intron 19060911 rs10889353 chr1 63118196 A C 1.40E-04 Lipid levels DOCK7 intron 19802338 rs10889353 chr1 63118196 A C 1.19E-13 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 1.30E-14 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 1.40E-12 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 1.60E-11 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 2.77E-12 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 3.00E-10 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 7.30E-10 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 1.96E-09 Blood cell counts and other traits DOCK7 intron 20139978 rs10889353 chr1 63118196 A C 2.00E-09 Blood cell counts and other traits DOCK7 intron 20139978 rs10889353 chr1 63118196 A C 8.00E-06 Coronary heart disease DOCK7 intron 21347282 rs10889353 chr1 63118196 A C 4.41E-12 Metabolite levels DOCK7 intron 22286219 rs10889353 chr1 63118196 A C 1.41E-08 Cholesterol,total DOCK7 intron 23063622 rs10889353 chr1 63118196 A C 9.39E-10 Lipid traits DOCK7 intron 24386095 rs10889353 chr1 63118196 A C 4.07E-05 LDL lipoproteins DOCK7 intron pha002902 rs10889353 chr1 63118196 A C 4.05E-06 Triglycerides DOCK7 intron pha003081 rs10889353 chr1 63118196 A C 8.46E-06 Lipid levels DOCK7 intron pha003082 rs1168097 chr1 63120371 C T 4.27E-12 Metabolite levels DOCK7 intron 22286219 rs1168097 chr1 63120371 C T 2.34E-08 Cholesterol,total DOCK7 intron 23063622 rs1168098 chr1 63121294 G A 4.25E-12 Metabolite levels DOCK7 intron 22286219 rs1168099 chr1 63122859 C A 2.11E-11 Metabolite levels DOCK7 intron 22286219 rs4495740 chr1 63124465 T G 4.22E-12 Metabolite levels DOCK7 intron 22286219 rs1168102 chr1 63127705 C T 5.08E-12 Metabolite levels DOCK7 intron 22286219 rs1168103 chr1 63128081 C T 4.21E-12 Metabolite levels DOCK7 intron 22286219 rs10889354 chr1 63129082 T C 4.22E-12 Metabolite levels DOCK7 intron 22286219 rs11208001 chr1 63130431 C T 4.46E-12 Metabolite levels DOCK7 intron 22286219 rs2479464 chr1 63130991 G A 4.21E-12 Metabolite levels DOCK7 intron 22286219 rs1168132 chr1 63133468 T A 6.16E-12 Metabolite levels DOCK7 intron 22286219 rs4587594 chr1 63133930 G A 3.50E-12 Metabolite levels DOCK7 intron 22286219 rs4587594 chr1 63133930 G A 4.77E-06 Triglycerides DOCK7 intron pha003081 rs4587594 chr1 63133930 G A 9.92E-06 Lipid levels DOCK7 intron pha003082 rs1168124 chr1 63139730 C T 4.61E-12 Metabolite levels DOCK7 intron 22286219 rs11208004 chr1 63145439 G A 3.43E-12 Metabolite levels DOCK7 intron 22286219 rs10889356 chr1 63155349 G A 1.00E-10 Metabolite levels / / 22286219 rs1168114 chr1 63156043 A G 2.26E-11 Metabolite levels / / 22286219 rs12136083 chr1 63163073 T C 1.33E-11 Metabolite levels / / 22286219 rs2182866 chr1 63163591 G A,C,T 4.94E-04 Multiple complex diseases / / 17554300 rs880694 chr1 63173284 C T 3.29E-06 Triglycerides / / pha003081 rs880694 chr1 63173284 C T 1.07E-05 Lipid levels / / pha003082 rs4409689 chr1 63177365 C T 3.29E-06 Triglycerides / / pha003081 rs4409689 chr1 63177365 C T 1.07E-05 Lipid levels / / pha003082 rs7518497 chr1 63177696 A C 1.42E-11 Metabolite levels / / 22286219 rs9787151 chr1 63179138 C T 3.29E-06 Triglycerides / / pha003081 rs9787151 chr1 63179138 C T 1.07E-05 Lipid levels / / pha003082 rs4915849 chr1 63180740 G A 4.95E-04 Multiple complex diseases / / 17554300 rs12130333 chr1 63191777 C T 6.34E-04 Type 2 diabetes / / 17463246 rs12130333 chr1 63191777 C T 2.00E-08 Triglycerides / / 18193044 rs12130333 chr1 63191777 C T 2.25E-11 Triglycerides / / 23063622 rs12130333 chr1 63191777 C T 4.78E-16 Cholesterol,total / / 23063622 rs6679002 chr1 63199936 G T 2.00E-15 Blood metabolite levels / / 24816252 rs17316337 chr1 63268989 A G 0.000668 fMRI brain tests in schizophrenia ATG4C intron 22440650 rs6683832 chr1 63276904 G A 5.60E-05 Blood Phenotypes ATG4C intron 17903294 rs11582138 chr1 63277459 A G 4.12E-04 Lung function (forced expiratory volume in 1 second) ATG4C intron 17255346 rs12042640 chr1 63366796 T C 1.71E-06 Aging (time to event) / / 21782286 rs56337244 chr1 63368615 C T 7.99E-11 Metabolite levels / / 22286219 rs200589189 chr1 63384292 T TG 1.43E-04 Alcohol dependence / / 21314694 rs7556152 chr1 63384292 T G 1.43E-04 Alcohol dependence / / 21314694 rs13376351 chr1 63389782 G A 8.00E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2780882 chr1 63405427 C A 8.57E-05 Information processing speed / / 21130836 rs2780883 chr1 63410619 A G 2.00E-04 Information processing speed / / 21130836 rs4915858 chr1 63411308 A G 9.10E-06 Urinary metabolites / / 21572414 rs1931080 chr1 63414144 G T 9.10E-06 Urinary metabolites / / 21572414 rs1931080 chr1 63414144 G T 9.10E-04 Breast cancer (survival) / / 22232737 rs2065585 chr1 63414401 G A 9.10E-06 Urinary metabolites / / 21572414 rs12121455 chr1 63433037 C T 8.79E-04 Response to alcohol consumption (flushing response) / / 24277619 rs2150031 chr1 63441761 A G 6.43E-05 Elbow pain / / pha003008 rs6696619 chr1 63452789 T C 1.89E-04 Premature ovarian failure / / 19508998 rs17124192 chr1 63456797 A G 5.76E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17124200 chr1 63459814 G A 1.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3818637 chr1 63466655 A G 6.14E-06 Hemoglobin concentration / / 20534544 rs17124237 chr1 63470187 A C 4.31E-05 Suicide attempts in bipolar disorder / / 21423239 rs7541201 chr1 63478358 G A 1.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs12143251 chr1 63478914 C G 2.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs12038327 chr1 63480004 T C 4.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs2026786 chr1 63480641 T A,G 4.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs17124318 chr1 63480730 C G,T 4.00E-06 Weight / / 20966902 rs17124318 chr1 63480730 C G,T 6.00E-07 Body mass index / / 20966902 rs17124399 chr1 63489983 C T 1.18E-05 Hemoglobin concentration / / 20534544 rs944188 chr1 63492959 C A 2.02E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs944188 chr1 63492959 C A 5.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1330221 chr1 63495975 T C 3.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1330221 chr1 63495975 T C 6.51E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6664042 chr1 63501851 C T 4.58E-05 Waist Circumference / / pha003023 rs7519367 chr1 63502030 G A 3.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs6694848 chr1 63503606 A G 7.95E-04 Multiple complex diseases / / 17554300 rs6694848 chr1 63503606 A G 7.19E-06 Waist Circumference / / pha003023 rs1874930 chr1 63507395 A C 3.10E-04 Hemoglobin concentration / / 20534544 rs881939 chr1 63517230 T C 4.60E-05 Response to TNF antagonist treatment / / 21061259 rs11208115 chr1 63521755 T C 3.10E-04 Hemoglobin concentration / / 20534544 rs17124480 chr1 63529093 A G 2.52E-05 Response to TNF antagonist treatment / / 21061259 rs12039756 chr1 63536774 T C 7.11E-04 Response to TNF antagonist treatment / / 21061259 rs11808494 chr1 63545178 A G 4.55E-04 Alzheimer's disease (late onset) / / 21379329 rs953654 chr1 63549282 C T 5.91E-06 Kawasaki disease / / 21221998 rs6673535 chr1 63562762 C T 6.58E-05 Multiple complex diseases / / 17554300 rs1498942 chr1 63566915 C T 2.43E-04 Gallstones / / 17632509 rs10493340 chr1 63591129 A G 2.00E-06 Blood pressure / / 17903302 rs6692500 chr1 63603161 C T 3.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs1887808 chr1 63614961 G A 4.62E-06 Stroke (ischemic) / / 22941190 rs6588016 chr1 63638791 G A 0.0000126 Tuberculosis with late age of onset LINC00466 intron 22551897 rs7554824 chr1 63641989 C A 6.44E-05 Obesity (extreme) LINC00466 intron 21935397 rs7515372 chr1 63643251 C A 6.39E-05 Obesity (extreme) LINC00466 intron 21935397 rs11208148 chr1 63645215 A C 3.60E-04 Alzheimer's disease (late onset) LINC00466 intron 21379329 rs4253945 chr1 63655914 C T 6.11E-04 Obesity (extreme) LINC00466 intron 21935397 rs12724092 chr1 63657649 C G 6.05E-04 Obesity (extreme) LINC00466 intron 21935397 rs1328589 chr1 63674914 T G 6.50E-05 Asthma LINC00466 intron 20159242 rs997791 chr1 63694517 G A 5.79E-05 Smoking initiation LINC00466 intron 24665060 rs12240186 chr1 63697711 A G 5.19E-05 Smoking initiation LINC00466 intron 24665060 rs1328586 chr1 63698424 T C 1.00E-04 Smoking initiation LINC00466 intron 24665060 rs1854335 chr1 63703330 C A 4.16E-04 Multiple complex diseases LINC00466 intron 17554300 rs10493343 chr1 63713524 C A 1.37E-05 Asthma LINC00466 intron 20159242 rs10493343 chr1 63713524 C A 5.12E-05 Smoking initiation LINC00466 intron 24665060 rs4915889 chr1 63719825 A G 2.61E-05 Smoking initiation LINC00466 intron 24665060 rs538071 chr1 63720224 T C 6.19E-04 Multiple complex diseases LINC00466 intron 17554300 rs952998 chr1 63743891 C G 1.41E-04 Multiple complex diseases LINC00466 intron 17554300 rs2031402 chr1 63744393 T C 1.45E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LINC00466 intron 20031582 rs12747934 chr1 63767597 G A 1.87E-05 Celiac disease LINC00466 intron 23936387 rs2367270 chr1 63775056 C A 3.82E-04 Alzheimer's disease (late onset) LINC00466 intron 21379329 rs6588025 chr1 63790503 T C 3.96E-05 Celiac disease FOXD3 UTR-3 23936387 rs10749738 chr1 63793155 A G 1.99E-04 Celiac disease / / 23936387 rs12021563 chr1 63812269 C T 3.40E-05 Personality dimensions / / 18957941 rs12021563 chr1 63812269 C T 4.69E-05 Lymphocyte counts / / 22286170 rs7522426 chr1 63821329 G A 3.18E-04 Alzheimer's disease (late onset) / / 21379329 rs12135006 chr1 63861211 C A 3.33E-04 Aortic root size ALG6 intron 21223598 rs4630153 chr1 63881552 C T 5.68E-04 Glycosylated haemoglobin levels ALG6 missense 17255346 rs3009577 chr1 63914117 A G 2.54E-04 Alzheimer's disease (late onset) ITGB3BP intron 21379329 rs6588044 chr1 63958304 G A 2.25E-04 Alzheimer's disease (late onset) ITGB3BP intron 21379329 rs17391823 chr1 63986865 T C 4.89E-04 Lymphocyte counts ITGB3BP intron 22286170 rs217478 chr1 63991267 T C 3.43E-04 Alzheimer's disease (late onset) EFCAB7 cds-synon 21379329 rs17125177 chr1 64075768 T C 1.38E-04 Amyotrophic lateral sclerosis (sporadic) PGM1 intron 24529757 rs855314 chr1 64095111 A G 5.94E-05 Celiac disease PGM1 missense 23936387 rs2269252 chr1 64098065 T C 2.64E-05 Multiple complex diseases PGM1 intron 17554300 rs34922283 chr1 64100478 A AT 8.74E-04 Obesity (extreme) PGM1 intron 21935397 rs6588052 chr1 64100478 A T 8.74E-04 Obesity (extreme) PGM1 intron 21935397 rs2269248 chr1 64102114 A G 6.91E-04 Obesity (extreme) PGM1 intron 21935397 rs2301054 chr1 64107028 A G 6.81E-08 Alcohol consumption PGM1 intron 21665994 rs2269247 chr1 64107284 C T 2.98E-07 Alcohol consumption PGM1 intron 21665994 rs2269246 chr1 64107491 T C 7.45E-08 Alcohol consumption PGM1 intron 21665994 rs2269245 chr1 64107893 G A 7.43E-08 Alcohol consumption PGM1 intron 21665994 rs2269245 chr1 64107893 G A 4.47E-06 Type 1 diabetes PGM1 intron 21980299 rs2269241 chr1 64108771 T C 1.23E-05 Multiple complex diseases PGM1 intron 17554300 rs2269241 chr1 64108771 T C 4.00E-07 Type 1 diabetes PGM1 intron 19430480 rs2269241 chr1 64108771 T C 3.57E-08 Alcohol consumption PGM1 intron 21665994 rs2269240 chr1 64109264 T C 8.21E-08 Alcohol consumption PGM1 intron 21665994 rs2269239 chr1 64109359 C G 7.43E-07 Multiple complex diseases PGM1 intron 17554300 rs3790857 chr1 64111866 C T 3.37E-09 Multiple complex diseases PGM1 intron 17554300 rs3790857 chr1 64111866 C T 1.37E-07 Alcohol consumption PGM1 intron 21665994 rs11576729 chr1 64114429 G T 9.15E-08 Alcohol consumption PGM1 intron 21665994 rs2269238 chr1 64117537 G T 1.98E-06 Multiple complex diseases PGM1 intron 17554300 rs2269238 chr1 64117537 G T 7.19E-08 Alcohol consumption PGM1 intron 21665994 rs2269235 chr1 64118915 A G 3.45E-08 Alcohol consumption PGM1 intron 21665994 rs2269234 chr1 64118976 A G 4.47E-08 Alcohol consumption PGM1 intron 21665994 rs2269233 chr1 64119346 T C 3.15E-08 Alcohol consumption PGM1 intron 21665994 rs12027168 chr1 64120613 T C 6.25E-08 Alcohol consumption PGM1 intron 21665994 rs2749100 chr1 64124979 G T 4.44E-05 Multiple complex diseases PGM1 intron 17554300 rs2749100 chr1 64124979 G T 7.63E-07 Alcohol consumption PGM1 intron 21665994 rs11208264 chr1 64125072 T C 3.38E-05 Multiple complex diseases PGM1 intron 17554300 rs11208264 chr1 64125072 T C 9.37E-07 Alcohol consumption PGM1 intron 21665994 rs11208265 chr1 64125234 G T 7.24E-05 Multiple complex diseases PGM1 intron 17554300 rs8294 chr1 64125368 C T 2.32E-09 Alcohol consumption PGM1 UTR-3 21665994 rs4643 chr1 64125439 A C 2.17E-06 Multiple complex diseases PGM1 UTR-3 17554300 rs4643 chr1 64125439 A C 2.31E-09 Alcohol consumption PGM1 UTR-3 21665994 rs855350 chr1 64127004 C T 9.58E-07 Alcohol consumption / / 21665994 rs2749097 chr1 64127468 C G 2.00E-09 Alcohol consumption (transferrin glycosylation) / / 21665994 rs2013012 chr1 64128209 C T 1.99E-04 Multiple complex diseases / / 17554300 rs1506397 chr1 64145283 C G 6.01E-08 Alcohol consumption / / 21665994 rs1395246 chr1 64147162 G C 4.61E-32 Narcolepsy / / 19629137 rs1395246 chr1 64147162 G C 7.71E-06 Height / / 20400458 rs1354718 chr1 64147950 A G 7.97E-05 HIV-1 viral setpoint / / 21490045 rs7548548 chr1 64151369 G C 9.81E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7548548 chr1 64151369 G C 1.04E-07 Alcohol consumption / / 21665994 rs2819157 chr1 64166213 C T 6.98E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12087869 chr1 64166968 T C 4.83E-05 Lung adenocarcinoma / / 19836008 rs2658407 chr1 64172809 A C 2.67E-04 Hearing function / / 17255346 rs4915914 chr1 64177299 G A 1.65E-04 Hearing function / / 17255346 rs2819172 chr1 64192575 G A 7.50E-05 Height / / pha003011 rs4915919 chr1 64195043 A C 2.09E-06 Diabetes Mellitus / / pha003059 rs11208281 chr1 64199752 C T 1.63E-04 Multiple complex diseases / / 17554300 rs1754546 chr1 64216658 A G 4.97E-05 Cognitive performance / / 19734545 rs11208285 chr1 64221643 T A 6.23E-05 Bipolar disorder / / 19488044 rs11208285 chr1 64221643 T A 9.59E-05 Bipolar Disorder / / pha002863 rs2819130 chr1 64231541 G A 2.10E-04 Crohn's disease / / 17435756 rs2819130 chr1 64231541 G A 8.84E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs7552384 chr1 64237404 G C 5.30E-07 Fetal hemoglobin levels / / 18245381 rs620019 chr1 64240929 T C 8.84E-04 Alcohol consumption (maxi-drinks) ROR1 intron 24277619 rs659406 chr1 64256018 C T 1.00E-04 Serum metabolites ROR1 intron 19043545 rs659406 chr1 64256018 C T 2.01E-05 Diabetes Mellitus ROR1 intron pha003059 rs602227 chr1 64256988 A G 4.52E-05 Diabetes Mellitus ROR1 intron pha003059 rs596985 chr1 64277035 A G 4.13E-05 Crohn's disease ROR1 intron 23850713 rs631029 chr1 64312152 G A 7.97E-04 Multiple complex diseases ROR1 intron 17554300 rs675893 chr1 64317180 G T 8.59E-04 Multiple complex diseases ROR1 intron 17554300 rs7513180 chr1 64339801 G A 7.85E-05 Cognitive test performance ROR1 intron 20125193 rs11208308 chr1 64340452 T C 4.38E-05 Body Mass Index ROR1 intron pha003014 rs687578 chr1 64346361 C G,T 8.35E-04 Alzheimer's disease ROR1 intron 17998437 rs662986 chr1 64348148 A G 4.43E-04 Alzheimer's disease ROR1 intron 17998437 rs662437 chr1 64348338 T C 5.19E-04 Alzheimer's disease ROR1 intron 17998437 rs855851 chr1 64351518 T C 1.06E-04 Multiple complex diseases ROR1 intron 17554300 rs3861946 chr1 64383389 C A 6.69E-04 Heart Failure ROR1 intron pha002884 rs285339 chr1 64442169 G A 8.80E-05 Lung adenocarcinoma ROR1 intron 22797724 rs285385 chr1 64469469 G A,T 8.33E-04 Multiple complex diseases ROR1 intron 17554300 rs834485 chr1 64484485 C T 5.01E-04 Myocardial Infarction ROR1 intron pha002883 rs834487 chr1 64486207 A G 4.57E-04 Multiple complex diseases ROR1 intron 17554300 rs834487 chr1 64486207 A G 3.31E-04 Alzheimer's disease ROR1 intron 17998437 rs1260836 chr1 64488856 G A 9.31E-04 Alzheimer's disease ROR1 intron 22005930 rs1260836 chr1 64488856 G A 7.01E-04 Myocardial Infarction ROR1 intron pha002883 rs1260817 chr1 64502933 T G 3.52E-04 Type 2 diabetes ROR1 intron 17463246 rs1260773 chr1 64534922 G A 2.00E-04 Myasthenia gravis ROR1 intron 23055271 rs10493354 chr1 64541533 G A 7.68E-04 Type 2 diabetes ROR1 intron 17463246 rs10493354 chr1 64541533 G A 7.00E-06 Urinary metabolites ROR1 intron 21572414 rs12409562 chr1 64550053 A G 1.42E-04 Alzheimer's disease (late onset) ROR1 intron 21379329 rs3933251 chr1 64560848 T G 4.73E-05 Bladder cancer ROR1 intron 19648920 rs2806541 chr1 64566396 G A 6.83E-05 Bladder cancer ROR1 intron 19648920 rs2762849 chr1 64596766 T C 2.32E-05 Bipolar disorder and schizophrenia ROR1 intron 20889312 rs10489902 chr1 64607328 T G 5.55E-04 Type 2 diabetes ROR1 intron 17846124 rs12025819 chr1 64612395 C A 1.16E-05 Hearing function ROR1 intron 17255346 rs6588083 chr1 64614011 T C 9.49E-05 Schizophrenia ROR1 intron 19197363 rs3884549 chr1 64628407 T A 0.0002287 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ROR1 intron 23233654 rs3884549 chr1 64628407 T A 2.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) ROR1 intron 23233662 rs4915657 chr1 64630026 G C 8.48E-05 Femoral neck bone geometry ROR1 intron 22087292 rs4915657 chr1 64630026 G C 0.0002301 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ROR1 intron 23233654 rs4915657 chr1 64630026 G C 2.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) ROR1 intron 23233662 rs4915658 chr1 64630237 A G 0.0006204 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ROR1 intron 23233654 rs4915658 chr1 64630237 A G 6.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) ROR1 intron 23233662 rs6676128 chr1 64635283 T C 0.0002429 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ROR1 intron 23233654 rs6676128 chr1 64635283 T C 2.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) ROR1 intron 23233662 rs7534614 chr1 64640415 C G 0.000237 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ROR1 intron 23233654 rs7534614 chr1 64640415 C G 2.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) ROR1 intron 23233662 rs11208376 chr1 64640898 T G 0.0001836 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ROR1 intron 23233654 rs11208376 chr1 64640898 T G 1.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) ROR1 intron 23233662 rs10489900 chr1 64646624 A G 2.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs11208377 chr1 64647608 C T 0.0001924 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11208377 chr1 64647608 C T 1.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4333885 chr1 64649858 A G 0.0001938 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4333885 chr1 64649858 A G 1.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7546930 chr1 64649955 G A 0.0002012 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7546930 chr1 64649955 G A 2.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6681495 chr1 64652405 T C 0.0002016 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6681495 chr1 64652405 T C 2.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11208380 chr1 64656971 A G 4.35E-04 Alzheimer's disease (late onset) / / 21379329 rs11208383 chr1 64659070 G A 9.14E-04 Multiple complex diseases / / 17554300 rs825175 chr1 64679749 C T 2.70E-05 Urinary metabolites UBE2U intron 21572414 rs41529245 chr1 64707668 G A 7.88E-04 Aortic root size UBE2U intron 21223598 rs4915956 chr1 64712355 T A 3.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4915962 chr1 64751610 G A 2.85E-05 Body Mass Index / / pha003014 rs11583668 chr1 64785839 A T 9.75E-04 Type 2 diabetes / / 17463246 rs4915972 chr1 64791688 T C 3.49E-05 Body Mass Index / / pha003014 rs1390473 chr1 64804379 A G 1.60E-04 Renal cell carcinoma / / 24220910 rs17126437 chr1 64811160 G T 3.42E-05 Body Mass Index / / pha003014 rs10493358 chr1 64812821 A G 4.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1390484 chr1 64831392 T C 7.91E-05 Post-operative nausea and vomiting / / 21694509 rs1514966 chr1 64834710 A G 3.33E-04 Smoking initiation / / 24665060 rs10493359 chr1 64837281 T C 2.44E-04 Smoking initiation / / 24665060 rs6588092 chr1 64855419 A G 1.16E-04 Smoking initiation / / 24665060 rs11208446 chr1 64868352 G A 9.00E-06 Bilirubin levels / / 22085899 rs305535 chr1 64914437 A C 7.77E-06 Sodium levels / / pha003093 rs305544 chr1 64918776 C T 7.69E-06 Sodium levels / / pha003093 rs12128329 chr1 64925891 G A 1.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs764457 chr1 64981488 C T 5.19E-04 Premature ovarian failure CACHD1 intron 19508998 rs9326061 chr1 64986799 G C 1.60E-05 Urinary metabolites CACHD1 intron 21572414 rs893075 chr1 64998367 T C 1.85E-04 Multiple complex diseases CACHD1 intron 17554300 rs17126643 chr1 65010606 T G 6.43E-05 Alcohol consumption CACHD1 intron 23953852 rs6681578 chr1 65013586 T C 5.06E-08 Schizophrenia CACHD1 intron 21926974 rs1436751 chr1 65064340 A G 2.71E-04 Aortic root size CACHD1 intron 21223598 rs2375268 chr1 65069961 A G 1.28E-04 Aortic root size CACHD1 intron 21223598 rs12407953 chr1 65084275 G C 9.65E-05 Schizophrenia(age at onset) CACHD1 intron 21688384 rs12097652 chr1 65085942 A G 8.86E-04 Aortic root size CACHD1 intron 21223598 rs2118102 chr1 65099978 G A 1.15E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers CACHD1 intron 21775533 rs751666 chr1 65100865 T C 8.07E-04 Smoking quantity CACHD1 intron 24665060 rs111303300 chr1 65109273 A C 0.00005063 Sarcoidosis CACHD1 intron 22952805 rs111631599 chr1 65109276 T C 0.0000501 Sarcoidosis CACHD1 intron 22952805 rs1561168 chr1 65115319 G A 3.05E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) CACHD1 intron 17982456 rs1561168 chr1 65115319 G A 1.10E-05 Urinary metabolites CACHD1 intron 21572414 rs1561167 chr1 65115513 T A 9.70E-06 Urinary metabolites CACHD1 intron 21572414 rs7552864 chr1 65119146 T C 7.10E-06 Urinary metabolites CACHD1 intron 21572414 rs7517300 chr1 65128071 T C 7.50E-06 Urinary metabolites CACHD1 intron 21572414 rs11208492 chr1 65128375 G A 1.10E-05 Urinary metabolites CACHD1 intron 21572414 rs11208493 chr1 65128395 C T 5.40E-06 Urinary metabolites CACHD1 intron 21572414 rs7513574 chr1 65135341 G T 1.75E-06 Diabetes (gestational) CACHD1 intron 22233651 rs2478156 chr1 65144191 G C 2.10E-05 Iron levels CACHD1 intron 21208937 rs17126889 chr1 65156862 T C 2.75E-04 Response to cytadine analogues (cytosine arabinoside) CACHD1 intron 24483146 rs1926304 chr1 65161230 T G 8.51E-04 Iron levels / / pha002876 rs2148323 chr1 65161633 T C 8.53E-04 Iron levels / / pha002876 rs11208510 chr1 65167537 T A 4.85E-04 Nonalcoholic fatty liver disease / / 21423719 rs11208512 chr1 65170405 T C 1.44E-04 Alzheimer's disease / / 24755620 rs7530486 chr1 65182826 T C 9.57E-05 Bipolar disorder and schizophrenia / / 20889312 rs7530486 chr1 65182826 T C 3.00E-04 Alzheimer's disease (late onset) / / 21379329 rs7530486 chr1 65182826 T C 6.92E-04 Alzheimer's disease / / 24755620 rs1926310 chr1 65188498 G C 3.70E-04 Type 2 diabetes / / 17463246 rs1926312 chr1 65193698 A T 2.91E-04 Alzheimer's disease / / 22005930 rs10493367 chr1 65206148 A G 3.50E-04 Alzheimer's disease / / 22005930 rs998125 chr1 65211521 A G 3.17E-04 Alzheimer's disease RAVER2 intron 22005930 rs12038159 chr1 65212345 G A 3.79E-04 Alzheimer's disease RAVER2 intron 22005930 rs12043554 chr1 65214034 T C 4.13E-04 Alzheimer's disease RAVER2 intron 22005930 rs12040026 chr1 65214219 G A 4.05E-04 Alzheimer's disease RAVER2 intron 22005930 rs10493368 chr1 65220035 T A 4.84E-04 Alzheimer's disease RAVER2 intron 22005930 rs10493369 chr1 65221656 G A 4.60E-04 Alzheimer's disease RAVER2 intron 22005930 rs17126970 chr1 65221766 T C 5.26E-04 Alzheimer's disease RAVER2 intron 22005930 rs12049564 chr1 65221984 A G 5.36E-04 Alzheimer's disease RAVER2 intron 22005930 rs11208518 chr1 65223510 C T 4.50E-04 Alzheimer's disease RAVER2 intron 22005930 rs11208519 chr1 65223552 T C 5.70E-04 Alzheimer's disease RAVER2 intron 22005930 rs11208520 chr1 65227239 G A 9.16E-04 Alzheimer's disease RAVER2 intron 22005930 rs11208521 chr1 65228129 G A 6.49E-04 Alzheimer's disease RAVER2 intron 22005930 rs6671355 chr1 65231009 T A 9.30E-04 Alzheimer's disease RAVER2 intron 22005930 rs12029333 chr1 65235586 A G 9.85E-04 Alzheimer's disease RAVER2 intron 22005930 rs3790529 chr1 65280620 G A 9.50E-05 HIV-1 control RAVER2 intron 20041166 rs12353950 chr1 65299088 A C 6.81E-05 Type 2 diabetes JAK1 UTR-3 17463246 rs17390055 chr1 65304953 T C 7.83E-05 Type 2 diabetes JAK1 intron 17463246 rs4916005 chr1 65309387 T C 2.98E-04 Suicide attempts in bipolar disorder JAK1 intron 21041247 rs10789166 chr1 65312813 A G 3.21E-04 Suicide attempts in bipolar disorder JAK1 intron 21041247 rs12093269 chr1 65331786 C T 3.00E-04 Suicide attempts in bipolar disorder JAK1 intron 21041247 rs3818753 chr1 65339232 A G 1.62E-08 LDL cholesterol JAK1 intron 23063622 rs10889504 chr1 65390503 G C 6.44E-04 Multiple complex diseases JAK1 intron 17554300 rs17127168 chr1 65408513 A G 8.35E-04 Suicide attempts in bipolar disorder JAK1 intron 21423239 rs11579758 chr1 65445542 G A 1.50E-05 Urinary metabolites / / 21572414 rs3014983 chr1 65460691 C T 2.30E-05 Urinary metabolites / / 21572414 rs519282 chr1 65487083 T G 5.95E-06 Glaucoma (primary open-angle) / / 22605921 rs11208575 chr1 65509848 G A 7.61E-04 Multiple complex diseases / / 17554300 rs478665 chr1 65515533 A G 1.00E-06 Estradiol plasma levels (breast cancer) / / 23518928 rs2375675 chr1 65553193 A C 4.33E-05 Varicose Veins / / pha001411 rs1572664 chr1 65580328 C A 2.25E-05 Leukocyte Counts / / pha003091 rs11208589 chr1 65580573 T C 6.06E-05 Leukocyte Counts / / pha003091 rs6588114 chr1 65585503 C T 0.0000983 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6588115 chr1 65585799 T A 0.0000983 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6695432 chr1 65586115 C T 0.000091 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6695445 chr1 65586154 C A 0.0000636 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6696301 chr1 65586815 G A 0.0000893 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7515954 chr1 65587028 T C 0.0000704 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7551568 chr1 65587239 G C 0.0000266 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7551569 chr1 65587240 G A 0.0000401 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs36003337 chr1 65587853 T C 0.0000645 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35192521 chr1 65587857 A T 0.0000632 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12044147 chr1 65588329 C A,T 0.0000633 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12037302 chr1 65588420 A G 0.0000673 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12044210 chr1 65588500 C T 0.0000845 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7513657 chr1 65589947 G A 0.0000789 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6588117 chr1 65590511 A G 0.0000828 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6588118 chr1 65590762 A G 0.0000663 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6588119 chr1 65590965 C T 0.0000805 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4375305 chr1 65591114 C T 0.000078 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7548217 chr1 65591956 G A 0.00008 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7548059 chr1 65591966 C T 0.0000798 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7548222 chr1 65591969 G C 0.0000827 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17127361 chr1 65594282 A G 6.30E-04 Type 2 diabetes / / 17463246 rs1109374 chr1 65633497 T C 7.97E-05 Nicotine smoking AK4 intron 19268276 rs4916031 chr1 65681543 T C 9.80E-05 Multiple complex diseases AK4 intron 17554300 rs4916032 chr1 65681622 G T 8.81E-05 Multiple complex diseases AK4 intron 17554300 rs1889925 chr1 65687556 G A 8.23E-04 Alcohol consumption (maxi-drinks) AK4 intron 24277619 rs1336472 chr1 65695930 G A 4.00E-10 Venous thromboembolism (gene x gene interaction) AK4 UTR-3 23509962 rs1889928 chr1 65710802 A G 1.50E-06 Urinary metabolites / / 21572414 rs10889531 chr1 65714118 G T 9.10E-07 Urinary metabolites / / 21572414 rs1613638 chr1 65716872 T C 9.36E-04 Type 2 diabetes / / 17463246 rs1613638 chr1 65716872 T C 3.40E-06 Urinary metabolites / / 21572414 rs550075 chr1 65723174 C A 3.10E-06 Urinary metabolites / / 21572414 rs2477786 chr1 65732242 C T 2.10E-24 Progranulin levels D/JC6 intron 21087763 rs2477786 chr1 65732242 C T 2.10E-24 Myocardial infarction D/JC6 intron 21211798 rs2477786 chr1 65732242 C T 4.70E-06 Urinary metabolites D/JC6 intron 21572414 rs4916041 chr1 65782658 T A 1 Drug response to Etoposide D/JC6 intron 17537913 rs2281855 chr1 65785372 G A 5.25E-05 Attention deficit hyperactivity disorder D/JC6 intron 22420046 rs6588131 chr1 65801562 C A 1 Drug response to Etoposide D/JC6 intron 17537913 rs2375699 chr1 65808281 G A 1 Drug response to Etoposide D/JC6 intron 17537913 rs1413885 chr1 65815659 C T 3.00E-07 Anticoagulant levels D/JC6 intron 22216198 rs7541003 chr1 65832352 A T 5.96E-04 Multiple complex diseases D/JC6 intron 17554300 rs6588144 chr1 65858088 T C 6.85E-04 Smoking initiation D/JC6 intron 24665060 rs4332387 chr1 65859108 G C 4.37E-04 Smoking initiation D/JC6 intron 24665060 rs11208645 chr1 65861798 A G 2.76E-05 Cognitive impairment induced by topiramate D/JC6 intron 22091778 rs4655762 chr1 65869274 C T 1.90E-04 Alzheimer's disease D/JC6 intron 22005930 rs2148682 chr1 65869489 T C 3.03E-04 Alzheimer's disease D/JC6 intron 22005930 rs11208646 chr1 65873605 A T 2.47E-04 Alzheimer's disease D/JC6 intron 22005930 rs10493377 chr1 65879252 A G 7.81E-05 Atopy D/JC6 UTR-3 21625490 rs9436735 chr1 65885061 C G 1.65E-13 LDL cholesterol LEPR nearGene-5 23063622 rs9436735 chr1 65885061 C G 3.01E-13 Cholesterol,total LEPR nearGene-5 23063622 rs9436735 chr1 65885061 C G 5.33E-08 HDL cholesterol LEPR nearGene-5 23063622 rs9436297 chr1 65888854 T C 5.90E-05 Glioma (high-grade) LEPR intron 19578366 rs9436299 chr1 65892888 C A 0.00000721 C-reactive protein LEPR intron 23505291 rs17127608 chr1 65893941 C T 3.13E-14 LDL cholesterol LEPR intron 23063622 rs3790433 chr1 65894342 C T 3.40E-06 Soluble leptin receptor levels LEPR intron 20167575 rs7534511 chr1 65895130 A G 7.23E-09 Soluble leptin receptor levels LEPR intron 20167575 rs9436300 chr1 65895264 A G 6.74E-09 Soluble leptin receptor levels LEPR intron 20167575 rs9436301 chr1 65895927 T C 1.44E-08 Soluble leptin receptor levels LEPR intron 20167575 rs9436302 chr1 65896561 G A 4.40E-10 Soluble leptin receptor levels LEPR intron 20167575 rs9436303 chr1 65896674 A G 1.19E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1887285 chr1 65897747 A G 2.90E-05 Schizophrenia LEPROT UTR-3 19571809 rs7602 chr1 65897951 G A 6.04E-10 Soluble leptin receptor levels LEPROT UTR-3 20167575 rs1045895 chr1 65897981 G A 5.10E-05 Coffee consumption LEPROT UTR-3 21357676 rs9436742 chr1 65898331 C T 2.49E-09 LDL cholesterol LEPROT UTR-3 23063622 rs1046011 chr1 65898996 C T 7.34E-09 Soluble leptin receptor levels LEPROT UTR-3 20167575 rs1046011 chr1 65898996 C T 0.00000889 C-reactive protein LEPROT UTR-3 23505291 rs11804091 chr1 65903879 A G 2.40E-06 Soluble leptin receptor levels LEPR intron 20167575 rs970468 chr1 65906490 C A 2.30E-06 Soluble leptin receptor levels LEPR intron 20167575 rs9436747 chr1 65911607 T C 2.60E-06 Soluble leptin receptor levels LEPR intron 20167575 rs6657868 chr1 65913707 A G 2.30E-06 Soluble leptin receptor levels LEPR intron 20167575 rs4655811 chr1 65923157 C G 3.40E-07 Soluble leptin receptor levels LEPR intron 20167575 rs6669354 chr1 65925349 T G 2.80E-06 Soluble leptin receptor levels LEPR intron 20167575 rs7555955 chr1 65937479 A G 0.00000894 C-reactive protein LEPR intron 23505291 rs12409877 chr1 65943872 A G 0.0000444 C-reactive protein LEPR intron 23505291 rs2025804 chr1 65946121 G A 3.10E-06 Soluble leptin receptor levels LEPR intron 20167575 rs2025804 chr1 65946121 G A 0.00000636 C-reactive protein LEPR intron 23505291 rs2025803 chr1 65946506 A G 2.61E-06 Lymphocyte counts LEPR intron 22286170 rs10158579 chr1 65950056 T C 2.81E-10 Soluble leptin receptor levels LEPR intron 20167575 rs11808888 chr1 65952781 G A 2.86E-10 Soluble leptin receptor levels LEPR intron 20167575 rs17127673 chr1 65955725 A G 3.94E-10 Soluble leptin receptor levels LEPR intron 20167575 rs10128072 chr1 65957096 A C 3.48E-10 Soluble leptin receptor levels LEPR intron 20167575 rs1327121 chr1 65957337 G A 3.10E-06 Soluble leptin receptor levels LEPR intron 20167575 rs17127677 chr1 65958274 G T 3.90E-10 Soluble leptin receptor levels LEPR intron 20167575 rs6702545 chr1 65960036 G T 0.0000615 C-reactive protein LEPR intron 23505291 rs11800909 chr1 65961780 A G 7.10E-07 Soluble leptin receptor levels LEPR intron 20167575 rs17127690 chr1 65962949 A G 4.33E-10 Soluble leptin receptor levels LEPR intron 20167575 rs6694528 chr1 65963016 C T 4.31E-10 Soluble leptin receptor levels LEPR intron 20167575 rs11800275 chr1 65963704 T A 4.31E-10 Soluble leptin receptor levels LEPR intron 20167575 rs11208654 chr1 65965566 C T 3.10E-06 Soluble leptin receptor levels LEPR intron 20167575 rs11208654 chr1 65965566 C T 0.0000046 C-reactive protein LEPR intron 23505291 rs10157275 chr1 65966503 C T 2.39E-10 Soluble leptin receptor levels LEPR intron 20167575 rs1327115 chr1 65966839 T G 6.80E-06 Soluble leptin receptor levels LEPR intron 20167575 rs2104564 chr1 65969430 C T 9.87E-13 Soluble leptin receptor levels LEPR intron 20167575 rs10889556 chr1 65969552 G A 6.02E-13 Soluble leptin receptor levels LEPR intron 20167575 rs10889556 chr1 65969552 G A 0.0000796 C-reactive protein LEPR intron 23505291 rs12062820 chr1 65970495 T C 8.09E-04 Multiple complex diseases LEPR intron 17554300 rs12062820 chr1 65970495 T C 6.17E-10 Soluble leptin receptor levels LEPR intron 20167575 rs10889557 chr1 65970704 A G,T 7.67E-13 Soluble leptin receptor levels LEPR intron 20167575 rs11208656 chr1 65970787 A G 7.72E-04 Multiple complex diseases LEPR intron 17554300 rs11208656 chr1 65970787 A G 6.17E-10 Soluble leptin receptor levels LEPR intron 20167575 rs12079231 chr1 65971155 C G 6.13E-10 Soluble leptin receptor levels LEPR intron 20167575 rs7516840 chr1 65972595 C G 5.93E-13 Soluble leptin receptor levels LEPR intron 20167575 rs11208657 chr1 65973353 G A 1.35E-12 Soluble leptin receptor levels LEPR intron 20167575 rs12068561 chr1 65973953 T C 6.21E-13 Soluble leptin receptor levels LEPR intron 20167575 rs6672331 chr1 65975847 G C 2.74E-04 Menarche (age at onset) LEPR intron 21102462 rs1327116 chr1 65976051 A C 6.30E-13 Soluble leptin receptor levels LEPR intron 20167575 rs10889558 chr1 65976966 A G 6.29E-13 Soluble leptin receptor levels LEPR intron 20167575 rs7533108 chr1 65977844 C G 6.38E-13 Soluble leptin receptor levels LEPR intron 20167575 rs2767485 chr1 65978917 T C 5.97E-10 Soluble leptin receptor levels LEPR intron 20167575 rs11208659 chr1 65979280 T C 2.00E-09 Obesity (early onset extreme) LEPR intron 23563609 rs1171274 chr1 65980838 C T 6.07E-13 Soluble leptin receptor levels LEPR intron 20167575 rs1171275 chr1 65982633 C T 1.20E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1180445 chr1 65982919 T C 1.20E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1475397 chr1 65983158 C T 3.76E-10 Soluble leptin receptor levels LEPR intron 20167575 rs1475398 chr1 65983257 C G 1.41E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1627238 chr1 65986079 G A 1.20E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1782755 chr1 65986804 C A 3.10E-04 Multiple complex diseases LEPR intron 17554300 rs1782755 chr1 65986804 C A 1.20E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1171276 chr1 65987449 A G 2.75E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1171278 chr1 65988146 C T 2.45E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1171279 chr1 65988493 C T 4.09E-09 Soluble leptin receptor levels LEPR intron 20167575 rs12135802 chr1 65992140 A G 4.87E-05 Diabetes Mellitus LEPR intron pha003060 rs1751492 chr1 65992625 C T 6.00E-13 Soluble leptin receptor levels LEPR intron 20167575 rs1782754 chr1 65993348 G A 9.66E-13 Soluble leptin receptor levels LEPR intron 20167575 rs6697315 chr1 65993556 C T 3.50E-13 Soluble leptin receptor levels LEPR intron 20167575 rs2154381 chr1 65995701 G A 7.27E-14 Soluble leptin receptor levels LEPR intron 20167575 rs1171269 chr1 65996802 T C 1.28E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171270 chr1 65997841 G A 1.28E-12 Soluble leptin receptor levels LEPR intron 20167575 rs10749753 chr1 65998467 A G 6.21E-05 Cognitive test performance LEPR intron 20125193 rs1171271 chr1 65998790 C T 1.29E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1177681 chr1 65999119 G A 1.29E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171272 chr1 65999811 G T 1.29E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1022981 chr1 66000034 G A 1.29E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1186403 chr1 66000533 C T 7.45E-14 Soluble leptin receptor levels LEPR intron 20167575 rs1171261 chr1 66001402 T C 3.79E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171262 chr1 66001746 A T 1.57E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171263 chr1 66001933 T C 1.75E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171264 chr1 66003014 C G 2.41E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171265 chr1 66003252 A G 3.54E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171266 chr1 66003824 T C 2.42E-13 Soluble leptin receptor levels LEPR intron 20167575 rs1171267 chr1 66003854 T G 1.43E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1782763 chr1 66007900 C T 5.62E-11 Soluble leptin receptor levels LEPR intron 20167575 rs1409802 chr1 66021351 A G 5.29E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1409802 chr1 66021351 A G 0.0000249 C-reactive protein LEPR intron 23505291 rs6673324 chr1 66031063 G A 6.85E-12 Soluble leptin receptor levels LEPR intron 20167575 rs7519977 chr1 66033496 G A 1.38E-11 Soluble leptin receptor levels LEPR intron 20167575 rs10158279 chr1 66033696 T G 1.18E-11 Soluble leptin receptor levels LEPR intron 20167575 rs1137100 chr1 66036441 A G 1.87E-11 Soluble leptin receptor levels LEPR missense 20167575 rs10789184 chr1 66036962 G A 1.87E-11 Soluble leptin receptor levels LEPR intron 20167575 rs12033452 chr1 66038435 C A 1.16E-12 Soluble leptin receptor levels LEPR intron 20167575 rs6657632 chr1 66038666 A G 1.16E-12 Soluble leptin receptor levels LEPR intron 20167575 rs11208674 chr1 66039317 T C 1.16E-12 Soluble leptin receptor levels LEPR intron 20167575 rs11208674 chr1 66039317 T C 0.0000734 C-reactive protein LEPR intron 23505291 rs35919106 chr1 66039425 C CG 1.14E-11 Soluble leptin receptor levels LEPR intron 20167575 rs4655517 chr1 66039425 C T 1.14E-11 Soluble leptin receptor levels LEPR intron 20167575 rs4655518 chr1 66039858 T G 1.16E-12 Soluble leptin receptor levels LEPR intron 20167575 rs4655680 chr1 66041469 G T 7.76E-13 Soluble leptin receptor levels LEPR intron 20167575 rs3790427 chr1 66042750 T C 1.91E-11 Soluble leptin receptor levels LEPR intron 20167575 rs3790427 chr1 66042750 T C 0.0000095 C-reactive protein LEPR intron 23505291 rs3790425 chr1 66043112 A G 4.30E-12 Soluble leptin receptor levels LEPR intron 20167575 rs3790425 chr1 66043112 A G 0.0000202 C-reactive protein LEPR intron 23505291 rs3790424 chr1 66044013 A G 4.03E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1343982 chr1 66045251 C T 4.03E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1343981 chr1 66045328 A G 4.03E-12 Soluble leptin receptor levels LEPR intron 20167575 rs11208675 chr1 66045424 T A,G 4.03E-12 Soluble leptin receptor levels LEPR intron 20167575 rs10789185 chr1 66045864 G C 2.87E-11 Soluble leptin receptor levels LEPR intron 20167575 rs10493379 chr1 66045927 G A 4.02E-12 Soluble leptin receptor levels LEPR intron 20167575 rs6691346 chr1 66046397 G A 4.02E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1938487 chr1 66047267 T C 4.03E-12 Soluble leptin receptor levels LEPR intron 20167575 rs11208676 chr1 66048123 A G 3.48E-12 Soluble leptin receptor levels LEPR intron 20167575 rs6673591 chr1 66048389 A G 2.10E-11 Soluble leptin receptor levels LEPR intron 20167575 rs11208677 chr1 66048417 A G 3.52E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1938489 chr1 66048622 A G 9.45E-05 Body Mass Index LEPR intron pha003009 rs12038998 chr1 66049128 C A 3.27E-12 Soluble leptin receptor levels LEPR intron 20167575 rs12038998 chr1 66049128 C A 0.0000326 C-reactive protein LEPR intron 23505291 rs10889563 chr1 66049167 A G 1.93E-11 Soluble leptin receptor levels LEPR intron 20167575 rs4655528 chr1 66049489 A G 3.31E-12 Soluble leptin receptor levels LEPR intron 20167575 rs11208679 chr1 66049738 G A 4.02E-12 Soluble leptin receptor levels LEPR intron 20167575 rs10789186 chr1 66050477 G A 2.07E-11 Soluble leptin receptor levels LEPR intron 20167575 rs6676495 chr1 66052117 G A 1.99E-12 Soluble leptin receptor levels LEPR intron 20167575 rs6676419 chr1 66052209 C T 9.15E-12 Soluble leptin receptor levels LEPR intron 20167575 rs4370791 chr1 66052228 A G 1.68E-12 Soluble leptin receptor levels LEPR intron 20167575 rs12028951 chr1 66053081 G A 1.65E-12 Soluble leptin receptor levels LEPR intron 20167575 rs12042877 chr1 66053148 C T 1.58E-12 Soluble leptin receptor levels LEPR intron 20167575 rs12042877 chr1 66053148 C T 0.0000369 C-reactive protein LEPR intron 23505291 rs12042884 chr1 66053192 C G 1.35E-12 Soluble leptin receptor levels LEPR intron 20167575 rs3828039 chr1 66053556 A G 1.31E-12 Soluble leptin receptor levels LEPR intron 20167575 rs10749754 chr1 66054640 G A 5.65E-11 Soluble leptin receptor levels LEPR intron 20167575 rs6696954 chr1 66054995 T G 2.81E-12 Soluble leptin receptor levels LEPR intron 20167575 rs6696954 chr1 66054995 T G 1.56E-08 Amyloid A Levels LEPR intron 21124955 rs12564626 chr1 66056542 G A 5.00E-11 Soluble leptin receptor levels LEPR intron 20167575 rs11208682 chr1 66056596 G A 4.91E-11 Soluble leptin receptor levels LEPR intron 20167575 rs10889567 chr1 66057050 T C 7.49E-11 Soluble leptin receptor levels LEPR intron 20167575 rs10449758 chr1 66057117 A G 4.88E-11 Soluble leptin receptor levels LEPR intron 20167575 rs2154380 chr1 66057441 T C 4.83E-11 Soluble leptin receptor levels LEPR intron 20167575 rs10736402 chr1 66058000 C T 4.86E-11 Soluble leptin receptor levels LEPR intron 20167575 rs1137101 chr1 66058513 A G 4.45E-11 Soluble leptin receptor levels LEPR missense 20167575 rs4655537 chr1 66058801 A G 3.04E-11 Soluble leptin receptor levels LEPR intron 20167575 rs4655537 chr1 66058801 A G 6.64E-10 C-reactive protein LEPR intron 23505291 rs10889568 chr1 66059445 T C 2.98E-11 Soluble leptin receptor levels LEPR intron 20167575 rs10889568 chr1 66059445 T C 0.0000198 C-reactive protein LEPR intron 23505291 rs10732836 chr1 66059460 C T 4.29E-11 Soluble leptin receptor levels LEPR intron 20167575 rs4655539 chr1 66059663 A T 4.23E-11 Soluble leptin receptor levels LEPR intron 20167575 rs6669117 chr1 66061072 T C 4.25E-11 Soluble leptin receptor levels LEPR intron 20167575 rs12405556 chr1 66063117 G T 2.96E-11 Soluble leptin receptor levels LEPR intron 20167575 rs12405556 chr1 66063117 G T 0.0000168 C-reactive protein LEPR intron 23505291 rs3762274 chr1 66064113 T C 1.28E-08 Soluble leptin receptor levels LEPR intron 20167575 rs3828033 chr1 66064710 C T 1.27E-08 Soluble leptin receptor levels LEPR intron 20167575 rs11801408 chr1 66075136 C T 0.0000753 C-reactive protein LEPR intron 23505291 rs6690625 chr1 66077590 T G 9.49E-10 Soluble leptin receptor levels LEPR intron 20167575 rs6690625 chr1 66077590 T G 2.42E-08 C-reactive protein LEPR intron 23505291 rs6678033 chr1 66077624 G A 7.70E-06 Soluble leptin receptor levels LEPR intron 20167575 rs6678033 chr1 66077624 G A 1.21E-09 Amyloid A Levels LEPR intron 21124955 rs6678033 chr1 66077624 G A 1.19E-08 C-reactive protein LEPR intron 23844046 rs12040007 chr1 66080160 G A 1.08E-09 Soluble leptin receptor levels LEPR intron 20167575 rs4655555 chr1 66080269 T A 4.76E-09 Soluble leptin receptor levels LEPR intron 20167575 rs4655555 chr1 66080269 T A 9.34E-08 C-reactive protein LEPR intron 23505291 rs4655556 chr1 66080563 G A 1.22E-09 Soluble leptin receptor levels LEPR intron 20167575 rs201721079 chr1 66080787 T TC 8.70E-06 Soluble leptin receptor levels LEPR intron 20167575 rs201721079 chr1 66080787 T TC 1.58E-08 C-reactive protein LEPR intron 23844046 rs35308591 chr1 66080787 T TC 8.70E-06 Soluble leptin receptor levels LEPR intron 20167575 rs35308591 chr1 66080787 T TC 1.58E-08 C-reactive protein LEPR intron 23844046 rs4655557 chr1 66080787 T C 8.70E-06 Soluble leptin receptor levels LEPR intron 20167575 rs4655557 chr1 66080787 T C 1.58E-08 C-reactive protein LEPR intron 23844046 rs1938484 chr1 66081282 C A 1.26E-09 Soluble leptin receptor levels LEPR intron 20167575 rs34499590 chr1 66081791 C T 5.80E-15 LDL cholesterol LEPR missense 23063622 rs34499590 chr1 66081791 C T 7.22E-09 Triglycerides LEPR missense 23063622 rs10889569 chr1 66086194 A T 4.71E-10 Amyloid A Levels LEPR intron 21124955 rs10889569 chr1 66086194 A T 9.00E-09 C-reactive protein LEPR intron 23844046 rs7516341 chr1 66088143 T C 4.27E-10 Amyloid A Levels LEPR intron 21124955 rs7516341 chr1 66088143 T C 1.57E-08 C-reactive protein LEPR intron 23844046 rs6700896 chr1 66089782 C T 3.00E-14 C-reactive protein LEPR intron 19567438 rs6700896 chr1 66089782 C T 5.93E-10 Amyloid A Levels LEPR intron 21124955 rs6700896 chr1 66089782 C T 2.71E-08 C-reactive protein LEPR intron 23844046 rs6588153 chr1 66092017 T A 4.87E-10 Amyloid A Levels LEPR intron 21124955 rs6588153 chr1 66092017 T A 8.74E-09 C-reactive protein LEPR intron 23844046 rs1892535 chr1 66097181 G A 6.24E-09 Soluble leptin receptor levels LEPR intron 20167575 rs12025906 chr1 66101384 T C 6.90E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1805096 chr1 66102257 G A 1.92E-10 Amyloid A Levels LEPR cds-synon 21124955 rs1805096 chr1 66102257 G A 2.00E-09 C-reactive protein LEPR cds-synon 22939635 rs1805096 chr1 66102257 G A 2.20E-14 C-reactive protein LEPR cds-synon 23505291 rs1805096 chr1 66102257 G A 2.25E-08 C-reactive protein LEPR cds-synon 23844046 rs7518632 chr1 66103350 C A,G,T 5.03E-09 Soluble leptin receptor levels LEPR nearGene-3 20167575 rs1892534 chr1 66105944 C T 7.00E-21 C-reactive protein / / 18439548 rs1892534 chr1 66105944 C T 1.33E-09 Amyloid A Levels / / 21124955 rs1892534 chr1 66105944 C T 1.23E-07 C-reactive protein / / 23844046 rs1892534 chr1 66105944 C T 4.77E-07 Inflammation / / pha002897 rs7531867 chr1 66107546 G A 4.44E-10 Amyloid A Levels / / 21124955 rs7531867 chr1 66107546 G A 1.19E-08 C-reactive protein / / 23844046 rs1938492 chr1 66117829 A C 2.33E-10 Amyloid A Levels / / 21124955 rs1938492 chr1 66117829 A C 5.00E-14 Fibrinogen / / 23969696 rs2186245 chr1 66118064 C T 4.74E-09 Soluble leptin receptor levels / / 20167575 rs12130476 chr1 66124850 G C 4.57E-09 Soluble leptin receptor levels / / 20167575 rs12145237 chr1 66124882 C T 6.03E-09 Soluble leptin receptor levels / / 20167575 rs10789192 chr1 66125770 G A 3.27E-10 Amyloid A Levels / / 21124955 rs10789192 chr1 66125770 G A 1.78E-08 C-reactive protein / / 23844046 rs4655772 chr1 66130398 A G 0.0000336 Height (Pygmy height) / / 22570615 rs11208700 chr1 66133443 A T 2.20E-06 Soluble leptin receptor levels / / 20167575 rs11208700 chr1 66133443 A T 9.84E-09 Amyloid A Levels / / 21124955 rs12042779 chr1 66133950 T C 3.65E-10 Amyloid A Levels / / 21124955 rs12042779 chr1 66133950 T C 1.78E-08 C-reactive protein / / 23844046 rs12042807 chr1 66134052 T C 3.65E-10 Amyloid A Levels / / 21124955 rs12042807 chr1 66134052 T C 1.78E-08 C-reactive protein / / 23844046 rs12043772 chr1 66135034 T A 6.03E-09 Soluble leptin receptor levels / / 20167575 rs11807752 chr1 66138575 A G 5.08E-04 Alzheimer's disease / / 17998437 rs11208707 chr1 66139513 C T 7.24E-09 Soluble leptin receptor levels / / 20167575 rs10736403 chr1 66140396 A G 7.30E-09 Soluble leptin receptor levels / / 20167575 rs10749756 chr1 66140511 C T 7.58E-09 Soluble leptin receptor levels / / 20167575 rs12567606 chr1 66141884 A G 1.30E-09 Soluble leptin receptor levels / / 20167575 rs12117858 chr1 66142094 C T 7.61E-09 Soluble leptin receptor levels / / 20167575 rs4655778 chr1 66142336 G A 7.87E-09 Soluble leptin receptor levels / / 20167575 rs4655779 chr1 66142530 A G 7.69E-09 Soluble leptin receptor levels / / 20167575 rs4655780 chr1 66142777 C A 7.84E-09 Soluble leptin receptor levels / / 20167575 rs34796214 chr1 66142972 A AG 7.76E-09 Soluble leptin receptor levels / / 20167575 rs4655782 chr1 66142972 A G 7.76E-09 Soluble leptin receptor levels / / 20167575 rs4655783 chr1 66143044 T C 2.40E-06 Soluble leptin receptor levels / / 20167575 rs4655783 chr1 66143044 T C 9.57E-09 Amyloid A Levels / / 21124955 rs10158937 chr1 66144876 A C 1.45E-08 Soluble leptin receptor levels / / 20167575 rs11208709 chr1 66146017 G A 7.85E-09 Soluble leptin receptor levels / / 20167575 rs11208710 chr1 66146039 A G 7.32E-09 Soluble leptin receptor levels / / 20167575 rs12026918 chr1 66146246 C G 7.62E-09 Soluble leptin receptor levels / / 20167575 rs11208711 chr1 66147846 G T 3.12E-10 Amyloid A Levels / / 21124955 rs11208711 chr1 66147846 G T 3.23E-08 C-reactive protein / / 23844046 rs2375803 chr1 66152889 T C 5.74E-04 Alzheimer's disease / / 17998437 rs4655582 chr1 66153363 C G 3.20E-10 Amyloid A Levels / / 21124955 rs12022410 chr1 66153933 A G 2.60E-06 Soluble leptin receptor levels / / 20167575 rs12022410 chr1 66153933 A G 9.51E-09 Amyloid A Levels / / 21124955 rs12022410 chr1 66153933 A G 0.0000336 Height (Pygmy height) / / 22570615 rs4655583 chr1 66155407 C A 3.40E-09 Soluble leptin receptor levels / / 20167575 rs4655584 chr1 66155515 T G 2.29E-10 Amyloid A Levels / / 21124955 rs4655584 chr1 66155515 T G 3.33E-08 C-reactive protein / / 23844046 rs4655585 chr1 66155627 T C 2.30E-10 Amyloid A Levels / / 21124955 rs4655585 chr1 66155627 T C 3.53E-08 C-reactive protein / / 23844046 rs2211651 chr1 66156021 G T 1.66E-10 Amyloid A Levels / / 21124955 rs2211651 chr1 66156021 G T 1.02E-06 Inflammation / / pha002897 rs2889195 chr1 66156730 C T 6.60E-04 Lipid traits / / 17903299 rs2889195 chr1 66156730 C T 3.00E-10 Amyloid A Levels / / 21124955 rs2889195 chr1 66156730 C T 5.95E-07 Inflammation / / pha002897 rs12042379 chr1 66158464 G T 8.21E-09 Soluble leptin receptor levels / / 20167575 rs11208720 chr1 66159055 A G 7.08E-09 Soluble leptin receptor levels / / 20167575 rs4655792 chr1 66159264 T G 4.70E-09 Soluble leptin receptor levels / / 20167575 rs4655793 chr1 66159278 C A 5.07E-09 Soluble leptin receptor levels / / 20167575 rs4655794 chr1 66159301 T C 3.60E-06 Soluble leptin receptor levels / / 20167575 rs4655794 chr1 66159301 T C 5.29E-09 Amyloid A Levels / / 21124955 rs4655794 chr1 66159301 T C 0.0000336 Height (Pygmy height) / / 22570615 rs4655795 chr1 66159368 G T 4.02E-09 Soluble leptin receptor levels / / 20167575 rs6664534 chr1 66160075 T A 3.80E-09 Soluble leptin receptor levels / / 20167575 rs6588156 chr1 66160433 A G 3.13E-09 Soluble leptin receptor levels / / 20167575 rs6588158 chr1 66160621 T C 1.99E-10 Amyloid A Levels / / 21124955 rs4420065 chr1 66161461 T C 2.23E-10 Amyloid A Levels / / 21124955 rs4420065 chr1 66161461 T C 4.00E-62 C-reactive protein / / 21300955 rs4420065 chr1 66161461 T C 6.67E-07 Inflammation / / pha002897 rs6667615 chr1 66162630 A G 3.07E-09 Soluble leptin receptor levels / / 20167575 rs67564250 chr1 66162630 AA AAA,AGC 3.07E-09 Soluble leptin receptor levels / / 20167575 rs6667616 chr1 66162631 A C 3.03E-09 Soluble leptin receptor levels / / 20167575 rs4394621 chr1 66165836 G A 3.84E-09 Soluble leptin receptor levels / / 20167575 rs7524581 chr1 66166499 T C 5.10E-06 Soluble leptin receptor levels / / 20167575 rs7524581 chr1 66166499 T C 2.82E-11 Amyloid A Levels / / 21124955 rs7524581 chr1 66166499 T C 0.000301 Height (Pygmy height) / / 22570615 rs4425959 chr1 66167819 G A 5.88E-09 Soluble leptin receptor levels / / 20167575 rs4425959 chr1 66167819 G A 2.02E-08 Amyloid A Levels / / 21124955 rs7541434 chr1 66168499 A C 6.50E-06 Soluble leptin receptor levels / / 20167575 rs7541434 chr1 66168499 A C 1.35E-11 Amyloid A Levels / / 21124955 rs10889576 chr1 66168566 T C 7.26E-09 Soluble leptin receptor levels / / 20167575 rs10889576 chr1 66168566 T C 1.31E-08 Amyloid A Levels / / 21124955 rs12753193 chr1 66169679 G A 4.00E-07 Metabolic traits / / 19060910 rs12753193 chr1 66169679 G A 5.50E-06 Soluble leptin receptor levels / / 20167575 rs12753193 chr1 66169679 G A 1.22E-11 Amyloid A Levels / / 21124955 rs12753193 chr1 66169679 G A 0.000537 Height (Pygmy height) / / 22570615 rs12753193 chr1 66169679 G A 3.76E-07 Inflammation / / pha002897 rs17416194 chr1 66171192 G A 2.50E-08 Amyloid A Levels / / 21124955 rs12121677 chr1 66171970 T C 5.57E-04 Alcohol dependence / / 20201924 rs17407727 chr1 66172006 C A 1.80E-08 Amyloid A Levels / / 21124955 rs10493383 chr1 66174932 C G 9.94E-08 Pure-tone audiometry / / pha001966 rs4278348 chr1 66175395 T C 3.54E-08 Amyloid A Levels / / 21124955 rs7532805 chr1 66183130 G A 4.64E-08 Amyloid A Levels / / 21124955 rs17127955 chr1 66193548 A G 2.73E-04 Multiple complex diseases / / 17554300 rs4338330 chr1 66195239 C T 7.30E-04 Type 2 diabetes / / 17463246 rs4288572 chr1 66201022 G A 1.33E-08 Amyloid A Levels / / 21124955 rs10789198 chr1 66202755 G A 1.20E-08 Amyloid A Levels / / 21124955 rs4655800 chr1 66211691 A G 1.54E-08 Amyloid A Levels / / 21124955 rs11208728 chr1 66213043 A G 1.48E-08 Amyloid A Levels / / 21124955 rs12131840 chr1 66231771 C T 1.30E-06 Soluble leptin receptor levels / / 20167575 rs12046844 chr1 66238379 G A 5.84E-04 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs6659197 chr1 66239897 A C 8.25E-05 Coronary heart disease / / 21606135 rs4384209 chr1 66279125 A G 2.00E-06 Economic and political preferences (feminism/equality) PDE4B intron 22566634 rs10493389 chr1 66310865 T C 7.00E-06 Echocardiographic traits PDE4B intron 17903301 rs4353064 chr1 66357675 A C 3.91E-04 Stroke PDE4B intron pha002887 rs17128103 chr1 66368865 C T 4.34E-04 Alcohol dependence PDE4B intron 21314694 rs11809491 chr1 66420658 G T 8.03E-11 LDL cholesterol PDE4B intron 23063622 rs2503209 chr1 66484652 T C 2.85E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs2503215 chr1 66490013 A T 2.32E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs7553522 chr1 66492484 T A 1.36E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs2455031 chr1 66492628 C T 3.26E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs7553844 chr1 66492784 T A 2.75E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs7525758 chr1 66494755 A G 8.78E-05 Cognitive test performance PDE4B intron 20125193 rs2455033 chr1 66500466 T C 8.99E-04 Type 2 diabetes PDE4B intron 17463246 rs2455033 chr1 66500466 T C 4.48E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs2489905 chr1 66501072 A T 4.39E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs2455013 chr1 66516557 A G 5.77E-05 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs12040042 chr1 66517050 A G 3.46E-06 Systemic lupus erythematosus and Systemic sclerosis PDE4B intron 23740937 rs2503222 chr1 66518697 C T 2.58E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) PDE4B intron 24236485 rs2455012 chr1 66520998 A G 3.06E-05 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs2455012 chr1 66520998 A G 7.00E-07 Staphylococcus aureus infection PDE4B intron 24847357 rs4492586 chr1 66528569 T C 3.06E-05 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs9436757 chr1 66528892 G A 6.72E-04 Multiple complex diseases PDE4B intron 17554300 rs9436757 chr1 66528892 G A 3.07E-05 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs1500963 chr1 66529821 G A 2.58E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) PDE4B intron 24236485 rs2503228 chr1 66547142 A G 2.71E-05 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs17455267 chr1 66549751 G A 3.63E-05 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs4655595 chr1 66558759 A G 2.70E-06 Type 2 diabetes PDE4B intron 17463249 rs4655595 chr1 66558759 A G 2.68E-06 Multiple complex diseases PDE4B intron 17554300 rs1566527 chr1 66569098 T A 8.82E-05 Serum metabolites PDE4B intron 19043545 rs596662 chr1 66603875 A C 3.30E-05 Diabetic retinopathy PDE4B intron 21441570 rs17128445 chr1 66610968 G A 5.70E-05 Diabetic retinopathy PDE4B intron 21441570 rs673143 chr1 66620119 G A 3.70E-05 Diabetic retinopathy PDE4B intron 21441570 rs582237 chr1 66621527 A G 3.70E-05 Diabetic retinopathy PDE4B intron 21441570 rs2485381 chr1 66627732 G A 8.44E-04 Alcohol dependence PDE4B intron 24277619 rs11208807 chr1 66634921 C T 3.63E-05 Amyotrophic Lateral Sclerosis PDE4B intron 18057069 rs556303 chr1 66635795 T A 7.40E-05 Diabetic retinopathy PDE4B intron 21441570 rs6656638 chr1 66645924 G A 1.26E-04 Self-reported allergy PDE4B intron 23817569 rs490094 chr1 66647385 A G 2.08E-26 Narcolepsy PDE4B intron 19629137 rs486438 chr1 66674663 A C 0.00000182 Triglycerides PDE4B intron 23063622 rs486438 chr1 66674663 A C 3.45E-11 LDL cholesterol PDE4B intron 23063622 rs10493398 chr1 66674738 G A 6.07E-04 Schizophrenia PDE4B intron 21674006 rs567279 chr1 66688029 G T 0.00000031 Cholesterol,total PDE4B intron 23063622 rs567279 chr1 66688029 G T 1.28E-09 Triglycerides PDE4B intron 23063622 rs567279 chr1 66688029 G T 4.13E-21 LDL cholesterol PDE4B intron 23063622 rs17423910 chr1 66689109 A G 4.67E-05 Acute lymphoblastic leukemia (childhood) PDE4B intron 22076464 rs952635 chr1 66691885 C T 2.80E-04 Type 2 diabetes and 6 quantitative traits PDE4B intron 17848626 rs1358751 chr1 66725267 A G 0.00019 Coronary artery calcification PDE4B intron 23727086 rs6700403 chr1 66735601 T C 1.49E-04 Nicotine smoking PDE4B intron 19268276 rs12728294 chr1 66740467 T C 5.42E-05 Nicotine smoking PDE4B intron 19268276 rs499320 chr1 66745060 G A 3.77E-05 Lung function (forced expiratory volume in 1 second) PDE4B intron 24023788 rs499320 chr1 66745060 G A 3.79E-04 Lung function (forced vital capacity) PDE4B intron 24023788 rs12060491 chr1 66745352 A G 9.92E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) PDE4B intron 24023788 rs519044 chr1 66756717 C T 1.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE4B intron 20877124 rs546784 chr1 66762466 T C 1.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE4B intron 20877124 rs546784 chr1 66762466 T C 9.00E-06 Acute lymphoblastic leukemia (childhood) PDE4B intron 23007406 rs2312065 chr1 66762737 C T 7.00E-04 Acute lymphoblastic leukemia (childhood) PDE4B intron 20189245 rs12030788 chr1 66768129 A G 4.09E-04 Multiple complex diseases PDE4B intron 17554300 rs6683977 chr1 66769100 G C 5.00E-06 Acute lymphoblastic leukemia (childhood) PDE4B intron 23007406 rs17427907 chr1 66805270 T C 6.20E-04 Multiple complex diseases PDE4B intron 17554300 rs2788646 chr1 66806953 T C 3.30E-04 Volumetric brain MRI PDE4B intron 17903297 rs17128817 chr1 66812100 C T 3.75E-08 LDL cholesterol PDE4B intron 23063622 rs4655835 chr1 66814826 T C 5.40E-04 Taste perception PDE4B intron 22132133 rs2275644 chr1 66831099 G A 8.13E-04 Suicide attempts in bipolar disorder PDE4B intron 21041247 rs7538869 chr1 66831322 T G 8.14E-04 Suicide attempts in bipolar disorder PDE4B intron 21041247 rs783036 chr1 66831370 G A 5.91E-04 Smoking initiation PDE4B cds-synon 24665060 rs2311985 chr1 66834815 A G 8.19E-04 Suicide attempts in bipolar disorder PDE4B intron 21041247 rs783051 chr1 66849410 C A 2.00E-05 Urinary metabolites / / 21572414 rs783050 chr1 66849448 T G 2.00E-05 Urinary metabolites / / 21572414 rs783048 chr1 66849905 C T 2.00E-05 Urinary metabolites / / 21572414 rs6701234 chr1 66851897 T G 8.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs6703929 chr1 66852161 T C 8.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs6691740 chr1 66852802 C A 8.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs12239708 chr1 66854570 T A 8.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs12406429 chr1 66856026 G A 8.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs1341246 chr1 66879613 C G 9.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10493405 chr1 66920877 G A 3.03E-04 Hearing function / / 17255346 rs1832420 chr1 66939920 A G 4.47E-05 Suicide attempts in bipolar disorder / / 21423239 rs10749760 chr1 66946306 G C 2.88E-04 Multiple complex diseases / / 17554300 rs4393126 chr1 66952788 G A 5.21E-04 Multiple complex diseases / / 17554300 rs4567260 chr1 66953482 G A 1.54E-05 Blood pressure / / 17255346 rs11208877 chr1 66954924 C A 5.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11208878 chr1 66955878 C T 6.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1338209 chr1 66957094 T C 6.91E-04 Multiple complex diseases / / 17554300 rs1025994 chr1 66957148 G A 7.15E-04 Multiple complex diseases / / 17554300 rs1025991 chr1 66958183 T G 8.43E-04 Multiple complex diseases / / 17554300 rs1020381 chr1 66960715 A G 6.35E-05 Blood pressure / / 17255346 rs1415975 chr1 66962193 C T 1.72E-04 Blood pressure / / 17255346 rs6588201 chr1 66963631 G T 7.86E-04 Multiple complex diseases / / 17554300 rs7544886 chr1 66968939 T C 5.90E-04 Multiple complex diseases / / 17554300 rs7555470 chr1 66969013 A C 8.14E-04 Multiple complex diseases / / 17554300 rs7533097 chr1 66969084 C T 2.11E-04 Blood pressure / / 17255346 rs7533097 chr1 66969084 C T 6.06E-04 Multiple complex diseases / / 17554300 rs7533097 chr1 66969084 C T 0.000216 Colorectal cancer vs. adenoma controls / / 22532847 rs7533837 chr1 66986781 A G 6.18E-05 Multiple complex diseases / / 17554300 rs10493408 chr1 66992054 C A 7.19E-05 Multiple complex diseases / / 17554300 rs10493408 chr1 66992054 C A 9.21E-04 Alzheimer's disease / / 17998437 rs12040232 chr1 66992277 T C 8.61E-05 Multiple complex diseases / / 17554300 rs1338203 chr1 66992613 A G 7.86E-05 Multiple complex diseases / / 17554300 rs6689313 chr1 66994889 A C 5.31E-05 Multiple complex diseases / / 17554300 rs12750223 chr1 67019819 A G 3.60E-07 Urinary metabolites SGIP1 intron 21572414 rs10889627 chr1 67023343 T C,G 9.12E-04 Suicide attempts in bipolar disorder SGIP1 intron 21423239 rs7537440 chr1 67031907 T G 9.16E-04 Type 2 diabetes SGIP1 intron 22158537 rs10889630 chr1 67034789 C T 3.74E-05 Tuberculosis SGIP1 intron 20694014 rs12125455 chr1 67034992 G A 5.70E-07 Urinary metabolites SGIP1 intron 21572414 rs12131909 chr1 67037898 C G 6.10E-07 Urinary metabolites SGIP1 intron 21572414 rs4655625 chr1 67039730 C T 5.70E-07 Urinary metabolites SGIP1 intron 21572414 rs1373909 chr1 67040875 A G 9.75E-04 Type 2 diabetes SGIP1 intron 22158537 rs6699200 chr1 67041309 T C 3.28E-05 Tuberculosis SGIP1 intron 20694014 rs1867631 chr1 67046126 C A 5.00E-06 Menopause (age at onset) SGIP1 intron 23307926 rs4147266 chr1 67048743 T G 5.58E-05 Tuberculosis SGIP1 intron 20694014 rs2166307 chr1 67052736 T C 7.16E-04 Suicide attempts in bipolar disorder SGIP1 intron 21041247 rs12049347 chr1 67061496 C T 2.50E-07 Urinary metabolites SGIP1 intron 21572414 rs12117202 chr1 67062569 C G,T 5.54E-05 Tuberculosis SGIP1 intron 20694014 rs6588207 chr1 67066555 A G 4.24E-08 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs10443224 chr1 67074053 T C 9.66E-04 Multiple complex diseases SGIP1 intron 17554300 rs10889635 chr1 67075575 G A 2.52E-08 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs11208921 chr1 67076054 C G 6.81E-05 Tuberculosis SGIP1 intron 20694014 rs12141816 chr1 67082018 G A 5.73E-05 Tuberculosis SGIP1 intron 20694014 rs11208923 chr1 67082442 A G 1.60E-06 Urinary metabolites SGIP1 intron 21572414 rs10493412 chr1 67082759 G C 5.58E-05 Tuberculosis SGIP1 intron 20694014 rs6656912 chr1 67083671 T C 4.24E-07 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs17436311 chr1 67083792 A G 5.17E-05 Tuberculosis SGIP1 intron 20694014 rs6588210 chr1 67084419 G C 9.18E-04 Multiple complex diseases SGIP1 intron 17554300 rs12129319 chr1 67084783 C G 1.20E-06 Urinary metabolites SGIP1 intron 21572414 rs12131306 chr1 67086547 C T 1.20E-06 Urinary metabolites SGIP1 intron 21572414 rs4655641 chr1 67089764 C T 1.00E-06 Urinary metabolites SGIP1 intron 21572414 rs1536112 chr1 67107225 A G 1.73E-04 Suicide attempts in bipolar disorder SGIP1 intron 21423239 rs2147776 chr1 67107403 T C 3.86E-04 Suicide attempts in bipolar disorder SGIP1 intron 21423239 rs6588213 chr1 67107894 C T 6.90E-04 Multiple complex diseases SGIP1 intron 17554300 rs17490057 chr1 67109277 G C 0.0006 Prostate cancer SGIP1 missense 23555315 rs6689755 chr1 67113050 G A 2.27E-04 Suicide attempts in bipolar disorder SGIP1 intron 21423239 rs12726588 chr1 67113648 T C 1.40E-06 Urinary metabolites SGIP1 intron 21572414 rs1925341 chr1 67115084 A G 8.23E-04 Taste perception SGIP1 intron 22132133 rs1998716 chr1 67117106 T A 1.31E-04 Suicide attempts in bipolar disorder SGIP1 intron 21423239 rs6681460 chr1 67123057 A G 7.30E-08 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs6681460 chr1 67123057 A G 7.00E-06 Presence of antiphospholipid antibodies SGIP1 intron 23509613 rs1570814 chr1 67124943 C T 2.80E-06 Urinary metabolites SGIP1 intron 21572414 rs6689451 chr1 67142852 G A 2.12E-04 Multiple complex diseases SGIP1 intron 17554300 rs11811699 chr1 67143760 A G 2.59E-04 Multiple complex diseases SGIP1 intron 17554300 rs10789215 chr1 67151185 T C 8.51E-08 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs2146904 chr1 67160336 A G 4.37E-07 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs10493414 chr1 67161716 T A 6.41E-04 Multiple complex diseases SGIP1 intron 17554300 rs4143025 chr1 67167548 C T 6.46E-04 Multiple complex diseases SGIP1 intron 17554300 rs3738167 chr1 67171266 G T 7.55E-05 Fibrinogen SGIP1 intron pha003068 rs17129365 chr1 67174554 A G 6.84E-04 Type 2 diabetes SGIP1 intron 17463246 rs10889649 chr1 67178005 G A 8.73E-04 Suicide attempts in bipolar disorder SGIP1 intron 21041247 rs1498354 chr1 67180489 T A 8.58E-04 Suicide attempts in bipolar disorder SGIP1 intron 21041247 rs11208951 chr1 67188107 C T 8.24E-04 Suicide attempts in bipolar disorder SGIP1 intron 21041247 rs536410 chr1 67191084 T C 1.69E-07 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs2483704 chr1 67195353 G A 3.63E-07 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs2916 chr1 67216697 G A 1.87E-07 Electroencephalogram traits,in brain / / 20421487 rs6695554 chr1 67230205 T G 9.40E-05 Response to statin therapy TCTEX1D1 intron 20339536 rs12727422 chr1 67235320 C A 8.60E-05 Response to statin therapy TCTEX1D1 intron 20339536 rs7535868 chr1 67235541 C T 9.90E-05 Response to statin therapy TCTEX1D1 intron 20339536 rs55899951 chr1 67260378 A C 0.00009391 Sarcoidosis / / 22952805 rs56107937 chr1 67260398 G A 0.00008219 Sarcoidosis / / 22952805 rs7543667 chr1 67260854 A T 0.0000963 Sarcoidosis / / 22952805 rs17129478 chr1 67288443 T G 1.20E-05 Urinary metabolites WDR78 intron 21572414 rs1925399 chr1 67349271 G C 9.44E-04 Type 2 diabetes WDR78 intron 17463246 rs1925408 chr1 67365034 C T 9.47E-04 Multiple complex diseases WDR78 intron 17554300 rs1925411 chr1 67370292 C T 4.20E-06 Crohn's disease WDR78 intron 17804789 rs1983860 chr1 67372061 G T 3.58E-06 Crohn's disease WDR78 intron 17804789 rs12083687 chr1 67406962 G A 9.07E-04 Multiple complex diseases MIER1 intron 17554300 rs2985824 chr1 67410171 A G 8.09E-04 Multiple complex diseases MIER1 intron 17554300 rs12090955 chr1 67412261 G T 6.35E-04 Multiple complex diseases MIER1 intron 17554300 rs4655662 chr1 67416432 T C 3.57E-04 Celiac disease MIER1 intron 23936387 rs3008871 chr1 67419089 G A 7.69E-04 Multiple complex diseases MIER1 intron 17554300 rs4655663 chr1 67430103 G A 8.17E-04 Multiple complex diseases MIER1 intron 17554300 rs2985797 chr1 67431499 T C 8.12E-04 Multiple complex diseases MIER1 intron 17554300 rs12137403 chr1 67437043 C A,T 4.97E-04 Multiple complex diseases MIER1 intron 17554300 rs4620509 chr1 67449941 A G 6.13E-06 Crohn's disease MIER1 intron 17804789 rs4486425 chr1 67460791 T C 5.47E-05 Crohn's disease / / 17804789 rs2815351 chr1 67477980 A G 4.47E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2755242 chr1 67479598 T C 3.58E-04 Celiac disease SLC35D1 intron 23936387 rs2755244 chr1 67484470 T C 7.98E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2065002 chr1 67487119 C A 3.58E-04 Celiac disease SLC35D1 intron 23936387 rs2755245 chr1 67487964 C G 7.82E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2755246 chr1 67488984 A G 6.12E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2815361 chr1 67494591 G T 5.53E-05 Amyotrophic lateral sclerosis (sporadic) SLC35D1 intron 24529757 rs12091194 chr1 67495728 C T 3.30E-05 Odorant perception SLC35D1 intron 23910658 rs17129627 chr1 67503666 C G 9.17E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2815371 chr1 67504313 A G 5.43E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2815380 chr1 67510857 G A 9.25E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2815380 chr1 67510857 G A 8.04E-05 Crohn's disease SLC35D1 intron 17804789 rs1024228 chr1 67512695 A G 1.23E-05 Crohn's disease SLC35D1 intron 17804789 rs1024229 chr1 67512903 G T 1.53E-04 Celiac disease SLC35D1 intron 23936387 rs1024230 chr1 67512920 A C 1.53E-04 Celiac disease SLC35D1 intron 23936387 rs2208577 chr1 67513574 A C 8.91E-05 Crohn's disease SLC35D1 intron 17804789 rs2208577 chr1 67513574 A C 3.00E-04 Celiac disease SLC35D1 intron 23936387 rs2755259 chr1 67517022 T C 1.87E-06 Crohn's disease SLC35D1 intron 17804789 rs2755262 chr1 67521736 T C 2.01E-06 Crohn's disease SLC35D1 nearGene-5 17804789 rs11208994 chr1 67525043 A G 1.51E-08 Crohn's disease / / 17804789 rs12097741 chr1 67528006 A C 8.51E-05 Rheumatoid arthritis / / 17804836 rs2755263 chr1 67529243 A G 5.13E-05 Crohn's disease / / 17804789 rs17129659 chr1 67579395 C T 8.32E-07 Crohn's disease C1orf141 intron 17804789 rs11209002 chr1 67590461 T C 2.00E-07 Crohn's disease C1orf141 intron 17804789 rs7515029 chr1 67596372 A G 1.82E-09 Multiple complex diseases / / 17554300 rs3762318 chr1 67597119 G A 4.19E-05 Psoriasis / / 20953187 rs3762318 chr1 67597119 G A 3.00E-11 Leprosy / / 22019778 rs3762318 chr1 67597119 G A 1.24E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs2024825 chr1 67597977 T C 1.86E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs4655679 chr1 67599657 C T 3.16E-12 Multiple complex diseases / / 17554300 rs4655679 chr1 67599657 C T 2.00E-07 Crohn's disease / / 17804789 rs12069782 chr1 67600101 C T 3.00E-07 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs12095536 chr1 67600142 T C 1.41E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs12090164 chr1 67600163 G A 8.76E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs11209003 chr1 67601132 G T 1.00E-08 Crohn's disease / / 17804789 rs1321156 chr1 67604702 G C 9.99E-04 Coronary Artery Disease / / 17634449 rs10789224 chr1 67605134 T C 2.47E-12 Multiple complex diseases / / 17554300 rs9729046 chr1 67607082 C G 5.87E-05 Crohn's disease / / 17804789 rs7539795 chr1 67609446 A G 4.18E-07 Multiple complex diseases / / 17554300 rs4655683 chr1 67611613 G A 2.95E-04 Crohn's disease / / 17068223 rs4655683 chr1 67611613 G A 4.76E-05 Crohn's disease / / 17804789 rs4655684 chr1 67611772 C T 1.29E-11 Multiple complex diseases / / 17554300 rs6588245 chr1 67611799 C T 3.01E-07 Multiple complex diseases / / 17554300 rs10889657 chr1 67615487 T C 2.31E-05 Crohn's disease / / 17804789 rs11209008 chr1 67623298 G A 8.79E-09 Crohn's disease / / 17804789 rs10889661 chr1 67625309 T A 3.56E-05 Crohn's disease / / 17804789 rs11465759 chr1 67632404 T G 0.000000299 Triglycerides IL23R intron 23063622 rs11465759 chr1 67632404 T G 1.02E-11 LDL cholesterol IL23R intron 23063622 rs11465759 chr1 67632404 T G 5.52E-12 Cholesterol,total IL23R intron 23063622 rs10889664 chr1 67635475 C T 4.15E-05 Crohn's disease IL23R intron 17804789 rs76418789 chr1 67648596 G A 2.00E-10 Crohn's disease IL23R missense 23850713 rs6588248 chr1 67652984 T G 8.81E-06 Leprosy IL23R intron 22019778 rs2064689 chr1 67653010 G A 8.52E-05 Crohn's disease IL23R intron 17068223 rs2064689 chr1 67653010 G A 1.00E-07 Crohn's disease IL23R intron 17804789 rs17375018 chr1 67655147 G A 1.13E-08 Multiple complex diseases IL23R intron 17554300 rs17375018 chr1 67655147 G A 8.71E-05 Crohn's disease IL23R intron 17804789 rs6664119 chr1 67655895 C T 9.51E-08 Multiple complex diseases IL23R intron 17554300 rs12401432 chr1 67656931 C G 6.44E-05 Crohn's disease IL23R intron 17804789 rs10489630 chr1 67662622 A C 7.07E-05 Crohn's disease IL23R intron 17068223 rs10489630 chr1 67662622 A C 1.26E-05 Crohn's disease IL23R intron 17804789 rs714512 chr1 67664154 T G 1.60E-05 Crohn's disease IL23R intron 17804789 rs7556198 chr1 67665543 A G 1.48E-06 Crohn's disease IL23R intron 17804789 rs11209018 chr1 67667291 G A 3.17E-12 Multiple complex diseases IL23R intron 17554300 rs1004820 chr1 67670133 T G 4.58E-05 Crohn's disease IL23R intron 17804789 rs1004819 chr1 67670213 G A 1.78E-14 Crohn's disease IL23R intron 17068223 rs1004819 chr1 67670213 G A 6.25E-06 Crohn's disease IL23R intron 17804789 rs2902440 chr1 67670916 G A 8.81E-09 Crohn's disease IL23R intron 17804789 rs7539625 chr1 67672765 G A 2.15E-08 Crohn's disease IL23R intron 17804789 rs11805303 chr1 67675516 C T 6.00E-12 Crohn's disease IL23R intron 17554300 rs11805303 chr1 67675516 C T 1.82E-39 Crohn's disease IL23R intron 18587394 rs10889669 chr1 67675728 T G 6.53E-06 Crohn's disease IL23R intron 17804789 rs790632 chr1 67678922 C A 1.86E-05 Serum metabolites IL23R intron 19043545 rs2019262 chr1 67679990 G A 9.20E-05 Crohn's disease IL23R intron 17804789 rs7517847 chr1 67681669 T G 4.00E-13 Inflammatory bowel disease IL23R intron 17068223 rs7517847 chr1 67681669 T G 3.00E-12 Crohn's disease IL23R intron 17435756 rs7517847 chr1 67681669 T G 7.80E-06 Crohn's disease IL23R intron 17804789 rs7517847 chr1 67681669 T G 4.00E-06 Plasma omega-6 polyunsaturated fatty acid levels IL23R intron 24823311 rs7518660 chr1 67685443 G A 6.18E-08 Crohn's disease IL23R intron 17804789 rs11465802 chr1 67685598 A C 5.04E-07 Crohn's disease IL23R intron 17804789 rs10789228 chr1 67687064 C T 1.00E-04 Crohn's disease IL23R intron 17804789 rs10489629 chr1 67688349 T C 1.62E-11 Crohn's disease IL23R intron 17068223 rs10489629 chr1 67688349 T C 5.04E-12 Multiple complex diseases IL23R intron 17554300 rs41396545 chr1 67689608 A G 7.93E-10 Multiple complex diseases IL23R intron 17554300 rs41396545 chr1 67689608 A G 9.37E-05 Smoking quantity IL23R intron 24665060 rs2201841 chr1 67694202 A G 1.10E-14 Crohn's disease IL23R intron 17068223 rs2201841 chr1 67694202 A G 5.36E-12 Multiple complex diseases IL23R intron 17554300 rs2201841 chr1 67694202 A G 3.16E-08 Crohn's disease IL23R intron 17804789 rs2201841 chr1 67694202 A G 3.00E-08 Psoriasis IL23R intron 19169254 rs2201841 chr1 67694202 A G 1.00E-13 Ulcerative colitis IL23R intron 20228799 rs2201841 chr1 67694202 A G 3.00E-08 Psoriasis IL23R intron 20953187 rs2201841 chr1 67694202 A G 1.30E-13 Multiple sclerosis IL23R intron 22190364 rs12031203 chr1 67696547 G A 1.33E-06 Crohn's disease IL23R intron 17804789 rs11804284 chr1 67699254 T C 2.64E-17 Crohn's disease IL23R intron 17804789 rs12030948 chr1 67701765 G T 3.33E-05 Crohn's disease IL23R intron 17068223 rs11465804 chr1 67702526 T G 3.33E-16 Crohn's disease IL23R intron 17068223 rs11465804 chr1 67702526 T G 3.50E-15 Crohn's disease IL23R intron 17447842 rs11465804 chr1 67702526 T G 9.00E-04 Psoriasis IL23R intron 17587057 rs11465804 chr1 67702526 T G 2.08E-05 Crohn's disease IL23R intron 17804789 rs11465804 chr1 67702526 T G 7.00E-63 Crohn's disease IL23R intron 18587394 rs11465804 chr1 67702526 T G 1.00E-06 Crohn's disease IL23R intron 20570966 rs11465804 chr1 67702526 T G 7.00E-63 Asthma IL23R intron 21150878 rs11465804 chr1 67702526 T G 6.20E-06 Ankylosing spondylitis IL23R intron 21743469 rs11465804 chr1 67702526 T G 6.66E-63 Multiple sclerosis IL23R intron 22190364 rs10489628 chr1 67704107 G A 1.96E-04 Crohn's disease IL23R intron 17068223 rs10489628 chr1 67704107 G A 7.63E-07 Multiple complex diseases IL23R intron 17554300 rs10489628 chr1 67704107 G A 6.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) IL23R intron 17982456 rs11209026 chr1 67705958 G A 4.00E-11 Inflammatory bowel disease IL23R missense 17068223 rs11209026 chr1 67705958 G A 2.00E-18 Crohn's disease IL23R missense 17447842 rs11209026 chr1 67705958 G A 4.76E-04 Multiple complex diseases IL23R missense 17554300 rs11209026 chr1 67705958 G A 1.40E-04 Psoriasis IL23R missense 17587057 rs11209026 chr1 67705958 G A 2.17E-07 Crohn's disease IL23R missense 17684544 rs11209026 chr1 67705958 G A 1.32E-08 Crohn's disease IL23R missense 17804789 rs11209026 chr1 67705958 G A 2.15E-68 Crohn's disease IL23R missense 18587394 rs11209026 chr1 67705958 G A 7.00E-11 Inflammatory bowel disease IL23R missense 18758464 rs11209026 chr1 67705958 G A 1.00E-08 Ulcerative colitis IL23R missense 19122664 rs11209026 chr1 67705958 G A 3.00E-10 Ulcerative colitis IL23R missense 19915572 rs11209026 chr1 67705958 G A 9.00E-14 Ankylosing spondylitis IL23R missense 20062062 rs11209026 chr1 67705958 G A 7.00E-07 Psoriasis IL23R missense 20953190 rs11209026 chr1 67705958 G A 1.00E-64 Crohn's disease IL23R missense 21102463 rs11209026 chr1 67705958 G A 5.00E-28 Ulcerative colitis IL23R missense 21297633 rs11209026 chr1 67705958 G A 2.00E-17 Ankylosing spondylitis IL23R missense 21743469 rs11209026 chr1 67705958 G A 4.00E-21 Crohn's disease IL23R missense 22293688 rs11209026 chr1 67705958 G A 1.00E-18 Crohn's disease IL23R missense 22412388 rs11209026 chr1 67705958 G A 4.00E-14 Crohn's disease IL23R missense 22936669 rs11209026 chr1 67705958 G A 8.00E-161 Inflammatory bowel disease IL23R missense 23128233 rs6682033 chr1 67708670 A G 4.10E-04 Crohn's disease IL23R intron 17068223 rs6682033 chr1 67708670 A G 4.33E-05 Smoking quantity IL23R intron 24665060 rs1343151 chr1 67719129 G A 2.74E-12 Crohn's disease IL23R intron 17068223 rs1343151 chr1 67719129 G A 2.30E-09 Crohn's disease IL23R intron 17447842 rs1343151 chr1 67719129 G A 3.16E-08 Crohn's disease IL23R intron 17804789 rs1343151 chr1 67719129 G A 1.91E-05 Response to acetaminophen (hepatotoxicity) IL23R intron 21177773 rs1343151 chr1 67719129 G A 2.24E-04 Smoking quantity IL23R intron 24665060 rs1008193 chr1 67719911 C G 8.52E-05 Smoking quantity IL23R intron 24665060 rs6693831 chr1 67720867 T C 9.44E-05 HIV-1 viral setpoint IL23R intron 22174851 rs6693831 chr1 67720867 T C 0.0008156 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) IL23R intron 23233654 rs6693831 chr1 67720867 T C 8.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) IL23R intron 23233662 rs10889675 chr1 67722216 C A 1.36E-05 Multiple complex diseases IL23R intron 17554300 rs10889676 chr1 67722567 C A 3.36E-07 Crohn's disease IL23R intron 17804789 rs4655694 chr1 67723552 G A 0.0005315 Sarcoidosis IL23R intron 22952805 rs10889677 chr1 67725120 C A 3.40E-14 Crohn's disease IL23R UTR-3 17068223 rs10889677 chr1 67725120 C A 2.40E-06 Crohn's disease IL23R UTR-3 17447842 rs10889677 chr1 67725120 C A 2.00E-07 Crohn's disease IL23R UTR-3 17804789 rs10889677 chr1 67725120 C A 1.00E-08 Ulcerative colitis IL23R UTR-3 19122664 rs9988642 chr1 67726104 T C 3.16E-08 Crohn's disease IL23R nearGene-3 17804789 rs9988642 chr1 67726104 T C 1.10E-26 Psoriasis IL23R nearGene-3 23143594 rs2000252 chr1 67727555 C T 2.63E-04 Smoking quantity / / 24665060 rs12567232 chr1 67728018 G A 2.00E-07 Crohn's disease / / 17804789 rs6669582 chr1 67730055 A G 1.38E-07 Crohn's disease / / 17804789 rs10789230 chr1 67730628 G T 2.37E-08 Crohn's disease / / 17804789 rs7547569 chr1 67731368 T C 2.99E-05 Crohn's disease / / 17804789 rs7539328 chr1 67732603 G A 8.44E-07 Crohn's disease / / 17068223 rs11583760 chr1 67735948 C T 3.95E-05 Crohn's disease / / 17804789 rs11209032 chr1 67740092 G A 5.50E-13 Crohn's disease / / 17068223 rs11209032 chr1 67740092 G A 8.00E-05 Ankylosing spondylitis / / 21743469 rs11209033 chr1 67744500 C G 1.47E-10 Multiple complex diseases / / 17554300 rs11209033 chr1 67744500 C G 1.44E-06 Crohn's disease / / 17804789 rs6660226 chr1 67744601 G A 5.98E-08 Multiple complex diseases / / 17554300 rs6660226 chr1 67744601 G A 1.08E-05 Behcet's disease / / 23291587 rs12141431 chr1 67747023 G C 5.00E-13 Multiple complex diseases / / 17554300 rs12119179 chr1 67747415 A C 5.38E-11 Multiple complex diseases / / 17554300 rs12119179 chr1 67747415 A C 8.36E-05 Crohn's disease / / 17804789 rs7546245 chr1 67750474 T C 5.89E-11 Multiple complex diseases / / 17554300 rs7546245 chr1 67750474 T C 4.71E-06 Crohn's disease / / 17804789 rs7546245 chr1 67750474 T C 2.80E-04 Ankylosing spondylitis / / 21743469 rs11209039 chr1 67751193 A G 1.34E-07 Multiple complex diseases / / 17554300 rs11209040 chr1 67752671 G A,C 8.43E-05 Crohn's disease / / 17804789 rs1495966 chr1 67753353 T C 6.09E-05 Behcet's disease / / pha002888 rs1495965 chr1 67753508 C T 3.55E-09 Crohn's disease / / 17068223 rs1495965 chr1 67753508 C T 2.00E-11 Behcet's disease / / 20622879 rs1495965 chr1 67753508 C T 6.99E-05 Behcet's disease / / pha002888 rs924080 chr1 67760140 T C 3.83E-06 Crohn's disease / / 17068223 rs924080 chr1 67760140 T C 7.00E-09 Behcet's disease / / 20622878 rs924080 chr1 67760140 T C 5.36E-06 Behcet's disease / / 23291587 rs924080 chr1 67760140 T C 5.35E-06 Behcet's disease / / pha002888 rs3762317 chr1 67772582 A G 8.40E-04 Alcohol dependence / / 20201924 rs56194793 chr1 67790598 T C 2.24E-37 Primary biliary cirrhosis IL12RB2 intron 22961000 rs11209050 chr1 67791736 A C 9.60E-19 Primary biliary cirrhosis IL12RB2 intron 21399635 rs10489626 chr1 67793171 C G 0.0000048 Triglycerides IL12RB2 intron 23063622 rs191377276 chr1 67793935 T A 0.000033 Prostate cancer (advanced) IL12RB2 missense 23555315 rs72678531 chr1 67798445 T C 1.00E-23 Primary biliary cirrhosis (anti-mitochondrial antibody positive) IL12RB2 intron 22936693 rs72678531 chr1 67798445 T C 2.66E-23 Primary biliary cirrhosis IL12RB2 intron 22936693 rs72678531 chr1 67798445 T C 4.13E-19 Primary biliary cirrhosis in females IL12RB2 intron 22936693 rs72678531 chr1 67798445 T C 2.47E-38 Primary biliary cirrhosis IL12RB2 intron 22961000 rs11209051 chr1 67798895 C T 1.93E-36 Primary biliary cirrhosis IL12RB2 intron 22961000 rs10889681 chr1 67799170 T C 1.67E-36 Primary biliary cirrhosis IL12RB2 intron 22961000 rs6659932 chr1 67802371 A C 4.97E-19 Primary biliary cirrhosis IL12RB2 intron 22936693 rs3790566 chr1 67814440 T C 8.24E-08 Systemic lupus erythematosus and Systemic sclerosis IL12RB2 intron 23740937 rs3790567 chr1 67822377 A G 1.77E-05 Multiple complex diseases IL12RB2 intron 17554300 rs3790567 chr1 67822377 A G 3.00E-11 Primary biliary cirrhosis IL12RB2 intron 19458352 rs3790567 chr1 67822377 A G 8.00E-12 Primary biliary cirrhosis IL12RB2 intron 20639880 rs3790567 chr1 67822377 A G 1.97E-04 Systemic sclerosis IL12RB2 intron 21779181 rs3790567 chr1 67822377 A G 2.45E-05 Systemic lupus erythematosus and Systemic sclerosis IL12RB2 intron 23740937 rs3790568 chr1 67836060 G A 5.27E-04 Diabetic retinopathy IL12RB2 intron 20871662 rs12759271 chr1 67906853 G T 6.84E-04 Stroke / / 22306652 rs12116575 chr1 67912259 C T 7.82E-04 Stroke / / 22306652 rs1954118 chr1 67914487 T A 1.48E-04 Multiple complex diseases / / 17554300 rs6657603 chr1 67935310 T G 2.22E-04 Gallstones / / 17632509 rs12037907 chr1 67972435 A C 8.14E-05 Colorectal cancer / / 19723657 rs11209101 chr1 67989691 C A 5.60E-06 Hemoglobin / / pha003098 rs6686812 chr1 67991360 A G 6.13E-05 Hemoglobin / / pha003098 rs7524558 chr1 67993782 C T 4.33E-04 Multiple complex diseases / / 17554300 rs1340592 chr1 68021103 G A 8.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6693292 chr1 68023168 A C 8.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4081356 chr1 68032769 G T 1.58E-04 Rheumatoid arthritis / / 21452313 rs11209119 chr1 68038390 G A 1.20E-04 Rheumatoid arthritis / / 21452313 rs12083789 chr1 68044856 A T 9.92E-04 Multiple complex diseases / / 17554300 rs9919329 chr1 68046274 C T 8.90E-04 Rheumatoid arthritis / / 21452313 rs787538 chr1 68050630 T C 6.00E-05 Asthma and hay fever / / 24388013 rs787539 chr1 68051023 C T 6.00E-04 Lymphocyte counts / / 22286170 rs787520 chr1 68055306 A G 3.77E-04 Multiple complex diseases / / 17554300 rs2105262 chr1 68058216 G A 9.45E-04 Type 2 diabetes / / 17463246 rs787498 chr1 68071100 C T 2.36E-04 Body mass index / / 21701565 rs787498 chr1 68071100 C T 3.61E-04 Body mass index / / 21701565 rs787499 chr1 68071382 C T 3.45E-04 Body mass index / / 21701565 rs787499 chr1 68071382 C T 4.16E-04 Body mass index / / 21701565 rs10789239 chr1 68101467 T C 6.79E-04 Type 2 diabetes / / 17463246 rs12129053 chr1 68105186 G A 3.29E-06 Schizophrenia / / 24253340 rs12129053 chr1 68105186 G A 1.53E-05 Hypertension / / pha003041 rs344924 chr1 68105453 A G 3.00E-07 non-small cell lung cancer / / 23478653 rs12076129 chr1 68106197 G T 9.97E-05 Waist Circumference / / pha003024 rs12076129 chr1 68106197 G T 5.89E-05 Waist Circumference / / pha003025 rs12076129 chr1 68106197 G T 7.87E-05 Weight / / pha003027 rs11209133 chr1 68106505 T C 1.88E-05 Waist Circumference / / pha003024 rs11209133 chr1 68106505 T C 1.27E-05 Waist Circumference / / pha003025 rs11209133 chr1 68106505 T C 3.72E-05 Weight / / pha003026 rs11209133 chr1 68106505 T C 5.20E-05 Weight / / pha003027 rs12134425 chr1 68117203 T G 6.60E-05 Insulin-related traits / / pha003063 rs344938 chr1 68126437 G A 7.71E-04 Obesity (extreme) / / 21935397 rs12748843 chr1 68128130 A C 4.20E-04 Multiple complex diseases / / 17554300 rs11209138 chr1 68128639 G A 4.68E-04 Multiple complex diseases / / 17554300 rs344931 chr1 68135838 T C 8.67E-04 Obesity (extreme) / / 21935397 rs3783468 chr1 68152363 G A 5.29E-04 Parkinson's disease GADD45A intron 17052657 rs598602 chr1 68161837 A G 9.39E-04 Obesity (extreme) / / 21935397 rs41335250 chr1 68162655 A G 2.57E-04 Multiple complex diseases / / 17554300 rs7419 chr1 68167491 C T 3.26E-04 Multiple complex diseases GNG12 UTR-3 17554300 rs12036629 chr1 68189166 G A 2.10E-04 Multiple complex diseases GNG12 intron 17554300 rs11209143 chr1 68189965 G A 2.46E-04 Multiple complex diseases GNG12 intron 17554300 rs604256 chr1 68191951 T C 2.05E-04 Type 2 diabetes GNG12 intron 17463246 rs2803461 chr1 68194025 A G 2.79E-04 Type 2 diabetes GNG12 intron 17463246 rs2803462 chr1 68194151 G A 2.09E-04 Type 2 diabetes GNG12 intron 17463246 rs632959 chr1 68197671 A G 2.07E-04 Type 2 diabetes GNG12 intron 17463246 rs3766272 chr1 68221471 A G 4.08E-04 Multiple complex diseases GNG12 intron 17554300 rs12121525 chr1 68223227 G A 7.10E-05 HIV-1 control GNG12 intron 20041166 rs12061806 chr1 68256929 C T 7.00E-04 Multiple complex diseases GNG12 intron 17554300 rs1276300 chr1 68258818 G A 5.20E-05 White matter hyperintensity burden GNG12 intron 21681796 rs1276301 chr1 68259402 T C 5.40E-05 White matter hyperintensity burden GNG12 intron 21681796 rs1276303 chr1 68260778 C T 6.30E-05 White matter hyperintensity burden GNG12 intron 21681796 rs1276304 chr1 68260901 G C 6.20E-05 White matter hyperintensity burden GNG12 intron 21681796 rs1276305 chr1 68262269 T C 6.00E-05 White matter hyperintensity burden GNG12 intron 21681796 rs1276309 chr1 68262903 A G 6.90E-05 White matter hyperintensity burden GNG12 intron 21681796 rs1276311 chr1 68264927 A G 6.60E-05 White matter hyperintensity burden GNG12 intron 21681796 rs11209156 chr1 68273407 C T 5.90E-05 White matter hyperintensity burden GNG12 intron 21681796 rs6671283 chr1 68282901 A G 1.31E-05 Response to tamoxifen in breast cancer GNG12 intron 22180457 rs12239301 chr1 68283171 A G 0.00038 Coronary artery calcification GNG12 intron 23727086 rs2492874 chr1 68283492 C A 6.80E-05 White matter hyperintensity burden GNG12 intron 21681796 rs12132247 chr1 68284145 C T 0.00005 Coronary artery calcification GNG12 intron 23727086 rs2154376 chr1 68327576 T C 8.50E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs1938446 chr1 68335624 G A 8.70E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs10157622 chr1 68337493 G A 8.60E-04 Multiple complex diseases LOC100289178 intron 17554300 rs10157622 chr1 68337493 G A 8.30E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs12143705 chr1 68342367 T G 1.10E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs7554886 chr1 68345009 G C 1.10E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs12095487 chr1 68346631 G A 2.60E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs12095488 chr1 68346632 G A 1.10E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs8179318 chr1 68352002 A G 1.20E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs1344148 chr1 68354321 G A 2.20E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs12132081 chr1 68354648 C T 1.20E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs1892525 chr1 68355614 G C 4.45E-04 Multiple complex diseases LOC100289178 intron 17554300 rs1892525 chr1 68355614 G C 7.20E-07 White matter hyperintensity burden LOC100289178 intron 21681796 rs1892525 chr1 68355614 G C 0.0000579 white matter hyperintensity burden LOC100289178 intron 23674528 rs11209171 chr1 68356836 A T 2.90E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs11209171 chr1 68356836 A T 0.000142 white matter hyperintensity burden LOC100289178 intron 23674528 rs11590313 chr1 68357032 G A 1.60E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs11590313 chr1 68357032 G A 0.0000737 white matter hyperintensity burden LOC100289178 intron 23674528 rs7520899 chr1 68358177 C T 1.70E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs7520899 chr1 68358177 C T 0.0000634 white matter hyperintensity burden LOC100289178 intron 23674528 rs7521135 chr1 68358247 G T 1.60E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs7521135 chr1 68358247 G T 0.0000625 white matter hyperintensity burden LOC100289178 intron 23674528 rs7521244 chr1 68358336 G C 1.20E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs7521244 chr1 68358336 G C 0.0000668 white matter hyperintensity burden LOC100289178 intron 23674528 rs12025677 chr1 68359887 T C 5.50E-04 Multiple complex diseases LOC100289178 intron 17554300 rs12025677 chr1 68359887 T C 1.90E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs12025677 chr1 68359887 T C 0.0000609 white matter hyperintensity burden LOC100289178 intron 23674528 rs10789247 chr1 68360980 A C 1.20E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs10789247 chr1 68360980 A C 0.0000621 white matter hyperintensity burden LOC100289178 intron 23674528 rs10889722 chr1 68361428 G A 1.20E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs10889722 chr1 68361428 G A 0.0000628 white matter hyperintensity burden LOC100289178 intron 23674528 rs12073947 chr1 68363490 A C 3.80E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs12073947 chr1 68363490 A C 0.0000233 white matter hyperintensity burden LOC100289178 intron 23674528 rs1317272 chr1 68363580 A G 3.80E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs1317272 chr1 68363580 A G 0.000032 white matter hyperintensity burden LOC100289178 intron 23674528 rs12405649 chr1 68386944 G C 7.08E-04 Smoking initiation LOC100289178 intron 24665060 rs17130402 chr1 68424715 C A 1.59E-04 Multiple complex diseases LOC100289178 intron 17554300 rs1926283 chr1 68448661 A G 2.29E-10 Common variable immunodeficiency LOC100289178 intron 21497890 rs1926278 chr1 68453859 C T 2.99E-05 Tuberculosis LOC100289178 intron 24057671 rs12141436 chr1 68463212 G A 7.23E-04 Alzheimer's disease LOC100289178 intron 22005930 rs1926289 chr1 68465932 T C 7.39E-04 Alzheimer's disease LOC100289178 intron 22005930 rs7553612 chr1 68479872 C T 4.33E-06 Liver disease in chronic hepatitis B virus infection LOC100289178 intron 24065354 rs12069862 chr1 68491995 G A 5.42E-04 Anorexia nervosa LOC100289178 intron 23568457 rs4433365 chr1 68500883 G C 3.79E-04 Multiple complex diseases LOC100289178 intron 17554300 rs269340 chr1 68561012 T C 2.28E-04 Major depressive disorder LOC100289178 intron 22472876 rs9436797 chr1 68567418 G A 4.81E-05 Vaspin levels WLS intron 22907691 rs9436797 chr1 68567418 G A 0.0000481 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks WLS intron 22907730 rs11805150 chr1 68568921 T C 8.01E-05 Height WLS intron pha003010 rs6671127 chr1 68571220 A C 6.72E-05 Height WLS intron pha003010 rs6671127 chr1 68571220 A C 4.50E-05 Height WLS intron pha003011 rs1337406 chr1 68573853 G A 3.20E-05 Cognitive performance WLS intron 19734545 rs269352 chr1 68579397 G A 3.92E-05 Height WLS intron pha003010 rs269352 chr1 68579397 G A 5.41E-05 Height WLS intron pha003011 rs14130 chr1 68584745 A G 7.98E-07 Height WLS intron pha003010 rs14130 chr1 68584745 A G 1.74E-05 Height WLS intron pha003011 rs12046920 chr1 68586620 T G 7.43E-06 Height WLS intron pha003010 rs12046920 chr1 68586620 T G 1.70E-05 Weight WLS intron pha003027 rs10158352 chr1 68587777 T C 9.59E-05 Insulin-related traits WLS intron pha003063 rs2566784 chr1 68602735 G T 3.30E-08 Bone mineral density (spine) WLS intron 19801982 rs1864570 chr1 68604773 G A 7.32E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) WLS intron 23648065 rs9970306 chr1 68613579 C T 1.40E-08 Bone mineral density (spine) WLS intron 19801982 rs3762371 chr1 68620762 G A 2.20E-08 Bone mineral density (spine) WLS intron 19801982 rs12733835 chr1 68622994 C A 2.70E-09 Bone mineral density (spine) WLS intron 19801982 rs2566759 chr1 68631792 G A 1.40E-11 Bone mineral density (spine) WLS intron 19801982 rs2566758 chr1 68632483 C T 4.10E-09 Bone mineral density (spine) WLS intron 19801982 rs1367448 chr1 68633924 G A 5.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) WLS intron 23648065 rs1367447 chr1 68634030 C T 1.70E-12 Bone mineral density (spine) WLS intron 19801982 rs1864569 chr1 68634257 G A 6.43E-04 Alzheimer's disease WLS intron 24755620 rs1430742 chr1 68635075 T C 3.00E-13 Bone mineral density (spine) WLS intron 19801982 rs2566755 chr1 68635390 T C 2.00E-12 Bone mineral density (hip) WLS intron 19801982 rs2195682 chr1 68635743 C T 1.20E-12 Bone mineral density (spine) WLS intron 19801982 rs2772304 chr1 68636580 C A 2.10E-08 Bone mineral density (spine) WLS intron 19801982 rs4233320 chr1 68638451 G T 1.50E-12 Bone mineral density (spine) WLS intron 19801982 rs17482952 chr1 68639385 A G 3.66E-04 Bone mineral density (paediatric,total body less head) WLS intron 24945404 rs17482952 chr1 68639385 A G 3.92E-04 Bone mineral density (paediatric,skull) WLS intron 24945404 rs6677666 chr1 68640101 C T 3.80E-13 Bone mineral density (spine) WLS intron 19801982 rs878548 chr1 68640286 A G 4.30E-13 Bone mineral density (spine) WLS intron 19801982 rs891528 chr1 68640353 A G 3.50E-09 Bone mineral density (spine) WLS intron 19801982 rs891527 chr1 68641160 A T 4.10E-08 Bone mineral density (spine) WLS intron 19801982 rs2566754 chr1 68641238 T G 4.10E-08 Bone mineral density (spine) WLS intron 19801982 rs944082 chr1 68643091 T C 1.10E-11 Bone mineral density (spine) WLS intron 19801982 rs12407028 chr1 68647716 T C 3.60E-13 Bone mineral density (spine) WLS intron 19801982 rs12407028 chr1 68647716 T C 3.00E-45 Bone mineral density WLS intron 22504420 rs12407028 chr1 68647716 T C 0.000313 Lumbar spine bone mineral density (premenopausal) WLS intron 23074152 rs2772300 chr1 68648026 G A 5.70E-13 Bone mineral density (spine) WLS intron 19801982 rs1430740 chr1 68657510 T C 1.20E-08 Bone mineral density (spine) WLS intron 19801982 rs1430740 chr1 68657510 T C 1.00E-11 Bone mineral density WLS intron 24249740 rs2820500 chr1 68658961 T C 3.20E-10 Bone mineral density (spine) WLS intron 19801982 rs2820500 chr1 68658961 T C 4.66E-04 Obesity (extreme) WLS intron 21935397 rs1036066 chr1 68660205 A C 8.20E-10 Bone mineral density (spine) WLS intron 19801982 rs1036066 chr1 68660205 A C 4.53E-04 Obesity (extreme) WLS intron 21935397 rs12568456 chr1 68661486 T G 1.50E-12 Bone mineral density (spine) WLS intron 19801982 rs2116047 chr1 68661751 A G 1.10E-09 Bone mineral density (spine) WLS intron 19801982 rs2116047 chr1 68661751 A G 4.21E-04 Obesity (extreme) WLS intron 21935397 rs2116046 chr1 68662252 G A 1.20E-08 Bone mineral density (spine) WLS intron 19801982 rs2039154 chr1 68662813 G A 9.90E-10 Bone mineral density (spine) WLS intron 19801982 rs2039154 chr1 68662813 G A 4.36E-04 Obesity (extreme) WLS intron 21935397 rs919540 chr1 68663143 C T 9.30E-10 Bone mineral density (spine) WLS intron 19801982 rs919540 chr1 68663143 C T 4.48E-04 Obesity (extreme) WLS intron 21935397 rs17130567 chr1 68663847 A G 1.60E-12 Bone mineral density (spine) WLS intron 19801982 rs7554551 chr1 68665023 T C 4.30E-13 Bone mineral density (spine) WLS intron 19801982 rs2149823 chr1 68668292 C T 5.02E-04 Multiple complex diseases WLS intron 17554300 rs2772286 chr1 68685389 T C 4.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WLS intron 20877124 rs12563946 chr1 68692744 G A 3.49E-04 Multiple complex diseases WLS intron 17554300 rs12097456 chr1 68703087 C T 9.88E-04 Alcohol dependence / / 24277619 rs2772294 chr1 68703843 G A 1.91E-05 Psoriasis / / 18364390 rs3001033 chr1 68708808 G A 4.72E-04 Multiple complex diseases / / 17554300 rs1360181 chr1 68714135 T C 4.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12730489 chr1 68735304 C T 5.47E-05 Intelligence / / 21826061 rs1360182 chr1 68738278 T C 6.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs3923451 chr1 68757334 C T 4.40E-05 Osteoarthritis (knee and hip) / / 21177295 rs3923451 chr1 68757334 C T 4.91E-05 Osteoarthritis (knee and hip) / / 21177295 rs11209261 chr1 68785213 T A 3.00E-06 Airflow obstruction / / 22837378 rs4926354 chr1 68803646 T C 2.88E-04 Gallstones / / 17632509 rs4926381 chr1 68816800 C T 9.79E-05 ldl cholesterol / / pha003076 rs11209290 chr1 68871027 G A 9.41E-05 Cognitive test performance / / 20125193 rs11209290 chr1 68871027 G A 8.87E-10 Parkinson's disease / / 21812969 rs10518295 chr1 68884158 G A 6.30E-05 Endometriosis / / 21151130 rs10493443 chr1 68884722 T C 1.62E-04 Statin-induced myopathy / / 21826682 rs12030710 chr1 68899762 G A 6.50E-05 Endometriosis RPE65 intron 21151130 rs114379164 chr1 68905294 G A,C 0.00021 Prostate cancer RPE65 missense 23555315 rs17130691 chr1 68905981 T A 9.35E-05 Smoking cessation RPE65 intron 24665060 rs17130694 chr1 68909113 C T 6.82E-04 Smoking cessation RPE65 intron 24665060 rs2012235 chr1 68912755 T C 0.0000209 Uterine leiomyomata RPE65 intron 23040493 rs435066 chr1 68927513 T C 4.00E-06 IgG glycosylation / / 23382691 rs435066 chr1 68927513 T C 5.00E-06 IgG glycosylation / / 23382691 rs435066 chr1 68927513 T C 7.00E-06 IgG glycosylation / / 23382691 rs435066 chr1 68927513 T C 7.00E-06 IgG glycosylation / / 23382691 rs435066 chr1 68927513 T C 8.00E-06 IgG glycosylation / / 23382691 rs10889769 chr1 68931366 A G 2.96E-04 Multiple complex diseases / / 17554300 rs10789263 chr1 68949139 T C 5.06E-04 Multiple complex diseases DEPDC1 intron 17554300 rs1041046 chr1 69002658 C T 8.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1924529 chr1 69022171 G A 4.81E-04 Multiple complex diseases / / 17554300 rs12132065 chr1 69047142 T G 7.18E-06 Personality dimensions / / 22628180 rs10518303 chr1 69050472 A G 3.02E-04 Multiple complex diseases / / 17554300 rs7547034 chr1 69063771 T C 8.47E-06 Personality dimensions / / 22628180 rs2507205 chr1 69068554 T C 2.38E-04 Smoking cessation / / 24665060 rs11209332 chr1 69088662 G A 6.27E-04 Multiple complex diseases / / 17554300 rs12136070 chr1 69089971 C T 8.84E-04 Multiple complex diseases / / 17554300 rs1492075 chr1 69156133 A G 1.24E-04 Alzheimer's disease (late onset) / / 21379329 rs854285 chr1 69158190 T G 8.04E-05 Post-operative nausea and vomiting / / 21694509 rs12405430 chr1 69168941 T G 8.00E-05 Endometriosis / / 21151130 rs9988609 chr1 69315228 A G 5.78E-05 Telomere length / / 24795349 rs17435919 chr1 69439156 G A 3.44E-04 Multiple complex diseases / / 17554300 rs4650310 chr1 69445925 A G 9.64E-04 Prostate cancer / / 23023329 rs6588344 chr1 69446281 T G 3.05E-05 Duodenal ulcer / / 22387998 rs2842040 chr1 69516639 G A 9.79E-04 Alcohol dependence / / 24277619 rs1507860 chr1 69520596 G A 4.80E-05 Malaria / / 19465909 rs1507860 chr1 69520596 G A 9.00E-06 Soluble leptin receptor levels / / 20167575 rs906474 chr1 69526551 G C 9.63E-04 Response to TNF antagonist treatment / / 21061259 rs1567214 chr1 69526682 G C 1.20E-06 Soluble leptin receptor levels / / 20167575 rs12131089 chr1 69529365 C A 6.10E-06 Soluble leptin receptor levels / / 20167575 rs2456910 chr1 69554417 A G 9.21E-04 Multiple complex diseases / / 17554300 rs1281556 chr1 69568991 G A 2.76E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1281556 chr1 69568991 G A 4.19E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs17436927 chr1 69577933 C G 6.38E-04 Type 2 diabetes / / 17463246 rs4147141 chr1 69579252 G A 6.00E-06 Attention deficit hyperactivity disorder / / 18821565 rs4147141 chr1 69579252 G A 8.00E-06 Inattentive symptoms / / 18821565 rs12086324 chr1 69681190 C T 1.04E-04 Alcohol dependence / / 24277619 rs4650135 chr1 69684997 T C 5.00E-06 Inattentive symptoms / / 18821565 rs4650135 chr1 69684997 T C 3.71E-04 Smoking quantity / / 24665060 rs2901175 chr1 69688646 C G 2.30E-05 Urinary metabolites / / 21572414 rs5010843 chr1 69694205 G A 4.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12404688 chr1 69815440 G A 1.18E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11209440 chr1 69851078 G A 1.18E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1926256 chr1 69879074 C T 4.12E-05 HDL cholesterol / / pha003074 rs4388647 chr1 69886702 T C 1.40E-05 Urinary metabolites / / 21572414 rs11209457 chr1 69894849 G A 0.000000485 Secreted IFN-gamma response to smallpox vaccine / / 22661280 rs12135013 chr1 69895080 T G 5.50E-05 HDL cholesterol / / pha003074 rs9326089 chr1 69909410 A C 1.01E-04 Hearing function / / 17255346 rs17495923 chr1 69915596 C A 2.30E-05 Urinary metabolites / / 21572414 rs10789294 chr1 69939539 G C 6.72E-05 Progressive supranuclear palsy / / 21685912 rs1952142 chr1 69948854 C G 7.92E-05 Progressive supranuclear palsy / / 21685912 rs1341795 chr1 69960136 T G 3.94E-05 Progressive supranuclear palsy / / 21685912 rs12048011 chr1 69969838 C T 8.38E-04 Type 2 diabetes / / 17463246 rs10889833 chr1 69975660 G A 2.54E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs4589058 chr1 69993512 A G 3.33E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1935244 chr1 70003853 C A 9.41E-04 Alzheimer's disease / / 22005930 rs1341784 chr1 70007663 T C 8.63E-05 Lymphocyte counts / / pha003094 rs10889836 chr1 70010325 C T 7.32E-04 Alzheimer's disease / / 22005930 rs947420 chr1 70014986 C T 2.56E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4650295 chr1 70029922 C T 9.44E-05 Lymphocyte counts / / pha003094 rs4650295 chr1 70029922 C T 7.95E-05 Neutrophil count / / pha003095 rs1245058 chr1 70048064 C T 4.10E-05 Lipid traits / / 17903299 rs1749517 chr1 70064870 G C 6.00E-05 Triglycerides / / 19074352 rs11809230 chr1 70084797 C T 1.20E-05 Urinary metabolites / / 21572414 rs12030270 chr1 70085637 G C 7.50E-04 Alzheimer's disease / / 22005930 rs11209505 chr1 70097194 A G 4.80E-05 Lymphocyte counts / / pha003094 rs2066296 chr1 70097708 T G 9.92E-05 Orofacial clefts / / 22419666 rs2066296 chr1 70097708 T G 4.80E-05 Lymphocyte counts / / pha003094 rs1245072 chr1 70115756 A T 1.80E-05 Blood Phenotypes / / 17903294 rs7515290 chr1 70116825 A G 5.15E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs12044761 chr1 70121115 G A 3.44E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs12023616 chr1 70121268 A G 2.93E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs800930 chr1 70126607 G A 1.10E-05 Urinary metabolites / / 21572414 rs800930 chr1 70126607 G A 2.77E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs800930 chr1 70126607 G A 4.70E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1417437 chr1 70154441 T C 4.00E-06 Orofacial clefts / / 22419666 rs1417437 chr1 70154441 T C 9.00E-06 Orofacial clefts / / 22419666 rs11209521 chr1 70157066 T C 5.81E-04 Multiple complex diseases / / 17554300 rs1417436 chr1 70160178 T C 1.16E-05 Orofacial clefts / / 22419666 rs10889850 chr1 70207079 T G 2.00E-06 Body mass index / / 24348519 rs17131023 chr1 70219191 T C 3.70E-27 Narcolepsy / / 19629137 rs17397812 chr1 70225832 G A 2.51E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs75115510 chr1 70243630 C T 2.79E-04 Acne (severe) LRRC7 intron 24927181 rs2175743 chr1 70295901 C T 3.58E-05 Parkinson's disease (motor and cognition) LRRC7 intron 22658654 rs2175743 chr1 70295901 C T 3.58E-05 Immune response to anthrax vaccine LRRC7 intron 22658931 rs12734666 chr1 70297051 A G 2.60E-05 Urinary metabolites LRRC7 intron 21572414 rs6686752 chr1 70302082 C T 1.61E-04 Multiple complex diseases LRRC7 intron 17554300 rs6691577 chr1 70302201 A G 9.23E-05 Multiple complex diseases LRRC7 intron 17554300 rs12086732 chr1 70313699 G A,T 7.59E-04 Multiple complex diseases LRRC7 intron 17554300 rs6703428 chr1 70316302 A G 1.22E-04 Multiple complex diseases LRRC7 intron 17554300 rs11209557 chr1 70319359 G C 1.09E-04 Multiple complex diseases LRRC7 intron 17554300 rs11209557 chr1 70319359 G C 2.40E-05 Urinary metabolites LRRC7 intron 21572414 rs2226284 chr1 70335682 T C 4.58E-04 Multiple complex diseases LRRC7 intron 17554300 rs2226284 chr1 70335682 T C 3.00E-08 Hypertension risk in short sleep duration LRRC7 intron 22322875 rs12037173 chr1 70355981 A G 4.00E-06 Attention deficit hyperactivity disorder LRRC7 intron 21784300 rs17131083 chr1 70359726 C T 0.000313 Salmonella-induced pyroptosis LRRC7 intron 22837397 rs1023008 chr1 70404540 A T 6.00E-06 Obesity-related traits LRRC7 intron 23251661 rs17131089 chr1 70415779 T C 0.000657 Salmonella-induced pyroptosis LRRC7 intron 22837397 rs12035355 chr1 70460238 C T 1.41E-04 Multiple complex diseases LRRC7 intron 17554300 rs721242 chr1 70492561 C T 3.95E-05 Bipolar disorder (mania) LRRC7 intron 23326512 rs17097485 chr1 70492884 T G 9.09E-06 Bipolar disorder (mania) LRRC7 intron 23326512 rs10493463 chr1 70493703 C T 1.72E-05 Bipolar disorder (mania) LRRC7 intron 23326512 rs17131142 chr1 70499912 G T 2.82E-04 Multiple complex diseases LRRC7 intron 17554300 rs10493467 chr1 70500691 G A 7.46E-05 Bipolar disorder (mania) LRRC7 intron 23326512 rs7547666 chr1 70594571 T G 2.00E-05 Urinary metabolites / / 21572414 rs654025 chr1 70602342 C T 2.60E-06 Urinary metabolites / / 21572414 rs2274913 chr1 70689215 T C 5.72E-05 Cognitive decline SRSF11 intron 22054870 rs3767207 chr1 70709759 G A 8.84E-05 Cognitive decline SRSF11 intron 22054870 rs3767206 chr1 70715093 G A 4.52E-04 Suicide,with and without major depression SRSF11 intron 22059935 rs664051 chr1 70869116 G A 2.94E-04 Alcohol dependence / / 24277619 rs672203 chr1 70887099 A G 2.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) CTH intron 24025145 rs17131304 chr1 70892915 A T 2.61E-11 HDL cholesterol CTH intron 23063622 rs145785987 chr1 70896038 T C 0.000031 Prostate cancer CTH missense 23555315 rs145785987 chr1 70896038 T C 0.000063 Prostate cancer (non-advanced prostate cancer) CTH missense 23555315 rs12561944 chr1 70910065 A G 4.60E-05 Alcohol dependence / / 20201924 rs12561944 chr1 70910065 A G 8.90E-05 Alcohol dependence / / 20201924 rs12561944 chr1 70910065 A G 4.65E-05 Alcoholism / / pha002892 rs12561944 chr1 70910065 A G 8.87E-05 Alcoholism / / pha002893 rs555671 chr1 70913726 G A 1.50E-05 Urinary metabolites / / 21572414 rs10458561 chr1 70921173 G A 4.00E-07 Antipsychotic-induced QTc interval prolongation / / 20921969 rs8179319 chr1 70934259 G A 6.32E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) / / 24025145 rs17131317 chr1 70947746 A G 1.99E-05 Suicide attempts in bipolar disorder / / 21423239 rs17131318 chr1 70947851 A T 1.43E-05 Suicide attempts in bipolar disorder / / 21423239 rs12094445 chr1 70953934 C T 1.29E-05 Suicide attempts in bipolar disorder / / 21423239 rs2651248 chr1 70957413 G T 6.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs1333680 chr1 70963368 T C 8.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs1333680 chr1 70963368 T C 7.97E-05 Body Mass Index / / pha003006 rs1333680 chr1 70963368 T C 2.67E-05 Waist Circumference / / pha003024 rs2807907 chr1 70986488 A G 5.51E-05 Body Mass Index / / pha003020 rs2651244 chr1 70995562 G A 2.00E-08 Inflammatory bowel disease / / 23128233 rs2651244 chr1 70995562 G A 7.49E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs17131783 chr1 70997811 G A 6.51E-05 Cognitive impairment induced by topiramate / / 22091778 rs2780747 chr1 71002192 A G 7.30E-04 Multiple complex diseases / / 17554300 rs2780748 chr1 71002220 A T 5.34E-04 Multiple complex diseases / / 17554300 rs582435 chr1 71010207 C T 7.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9425029 chr1 71011845 C T 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9424946 chr1 71011982 C T 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6700601 chr1 71012395 C A 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4650061 chr1 71013233 A G 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4515743 chr1 71014024 T G 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4546874 chr1 71014538 C T 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs3121981 chr1 71014641 T C 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4649923 chr1 71028151 G A 1.70E-05 Urinary metabolites / / 21572414 rs4649923 chr1 71028151 G A 4.98E-05 Post-operative nausea and vomiting / / 21694509 rs3121983 chr1 71028815 A G 2.10E-05 Urinary metabolites / / 21572414 rs11209658 chr1 71103816 T C 1.60E-04 Myopia (pathological) / / 21095009 rs10889884 chr1 71120020 C T 9.38E-05 Cognitive test performance / / 20125193 rs1334995 chr1 71127061 A G 2.29E-04 Osteoarthritis / / 19508968 rs1334995 chr1 71127061 A G 9.29E-04 Myopia (pathological) / / 21095009 rs6683555 chr1 71132536 C T 2.24E-04 Myopia (pathological) / / 21095009 rs2820529 chr1 71134588 T C 7.03E-04 Myopia (pathological) / / 21095009 rs2782763 chr1 71142202 T C 2.38E-04 Osteoarthritis / / 19508968 rs2820526 chr1 71153714 C A 2.86E-05 Heart Rate / / pha003053 rs1334997 chr1 71154117 T C 1.42E-05 Glucose levels / / pha003058 rs3001038 chr1 71163715 G A 2.59E-04 Myopia (pathological) / / 21095009 rs2820551 chr1 71163908 G A 5.41E-06 Glucose levels / / pha003058 rs2820551 chr1 71163908 G A 8.38E-05 Glucose levels / / pha003061 rs2421787 chr1 71195538 G A 6.84E-04 Myopia (pathological) / / 21095009 rs2421787 chr1 71195538 G A 3.19E-05 Glucose levels / / pha003058 rs11209689 chr1 71229637 G T 6.85E-05 Myopia (pathological) / / 21095009 rs7547597 chr1 71241232 C A 6.85E-05 Myopia (pathological) / / 21095009 rs10889889 chr1 71250352 A C 9.08E-05 Receptive language ability / / 24687471 rs10493479 chr1 71251704 T C 1.13E-04 Myopia (pathological) / / 21095009 rs2260454 chr1 71255441 G A 3.31E-04 Premature ovarian failure / / 19508998 rs1409982 chr1 71267891 C T 9.33E-05 Receptive language ability / / 24687471 rs1327455 chr1 71273323 T A 5.67E-05 Multiple complex diseases / / 17554300 rs2257772 chr1 71275174 G A 1.11E-04 Myopia (pathological) / / 21095009 rs4603079 chr1 71286947 C T 1.39E-05 Glucose levels / / pha003058 rs4603079 chr1 71286947 C T 9.87E-05 Glucose levels / / pha003061 rs1409988 chr1 71291825 G A 1.39E-05 Glucose levels / / pha003058 rs1409988 chr1 71291825 G A 9.87E-05 Glucose levels / / pha003061 rs2182707 chr1 71294542 G T 1.94E-04 Myopia (pathological) / / 21095009 rs17131450 chr1 71296002 G A 1.70E-06 Stevens-Johnson syndrome / / 20947153 rs959 chr1 71318261 T C 7.95E-05 Myopia (pathological) PTGER3 UTR-3 21095009 rs6664305 chr1 71321740 C T 2.94E-04 Myopia (pathological) PTGER3 intron 21095009 rs1409986 chr1 71331498 A G 0.00000101 Obstructive sleep apnea PTGER3 intron 23155414 rs1325949 chr1 71337193 T C 2.00E-04 Stevens-Johnson syndrome PTGER3 intron 20947153 rs7543182 chr1 71339973 C A 2.50E-04 Stevens-Johnson syndrome PTGER3 intron 20947153 rs7555874 chr1 71343960 C T 4.60E-04 Stevens-Johnson syndrome PTGER3 intron 20947153 rs1409978 chr1 71353104 T C 4.39E-04 Myopia (pathological) PTGER3 intron 21095009 rs4998697 chr1 71358190 T C 4.96E-05 Basophils PTGER3 intron pha003087 rs1327464 chr1 71366238 G A 1.00E-04 Response to interferon beta in multiple sclerosis PTGER3 intron 18195134 rs875727 chr1 71373738 T C 7.15E-19 Glaucoma (primary open-angle) PTGER3 intron 22419738 rs578096 chr1 71394683 T C 5.04E-04 Psoriasis PTGER3 intron 20953187 rs12097924 chr1 71398902 G T 4.70E-05 Orofacial clefts PTGER3 intron 22419666 rs13374231 chr1 71403260 G C 3.75E-05 Orofacial clefts PTGER3 intron 22419666 rs651265 chr1 71415135 A G 6.18E-04 Psoriasis PTGER3 intron 20953187 rs5697 chr1 71436747 C A 4.23E-04 Type 2 diabetes PTGER3 UTR-3 17463246 rs909848 chr1 71443150 T C 7.00E-06 IgG glycosylation PTGER3 intron 23382691 rs11209733 chr1 71471750 C G 9.30E-04 Type 2 diabetes PTGER3 UTR-3 17463246 rs12130153 chr1 71471875 T C 9.32E-04 Type 2 diabetes PTGER3 UTR-3 17463246 rs2268062 chr1 71485299 T C 3.97E-04 Type 2 diabetes PTGER3 intron 17463246 rs2817864 chr1 71503105 T G 1.07E-05 Platelet counts PTGER3 intron 21507922 rs2817866 chr1 71503447 G A 6.43E-05 Post-operative nausea and vomiting PTGER3 intron 21694509 rs12402425 chr1 71520017 G A 7.88E-04 Response to taxane treatment (placlitaxel) ZRANB2-AS1 intron 23006423 rs2796200 chr1 71658888 A G 2.45E-04 Menarche (age at onset) ZRANB2-AS2 intron 23599027 rs2796200 chr1 71658888 A G 4.23E-04 Menarche (age at onset) ZRANB2-AS2 intron 23599027 rs12131265 chr1 71712223 C T 1.34E-05 Alcohol dependence / / 23089632 rs11209757 chr1 71728900 T G 1.29E-05 Alcohol dependence / / 23089632 rs12405821 chr1 71876406 G T 2.33E-04 Type 2 diabetes NEGR1 intron 17463246 rs11209780 chr1 71876652 G A 1.78E-04 Multiple complex diseases NEGR1 intron 17554300 rs2056206 chr1 71936910 T C 2.42E-05 Blood pressure NEGR1 intron 24001895 rs6662613 chr1 71964277 G T 2.50E-05 Urinary metabolites NEGR1 intron 21572414 rs6675439 chr1 71986552 T C 9.10E-06 Urinary metabolites NEGR1 intron 21572414 rs12754625 chr1 71987496 C T 4.20E-06 Urinary metabolites NEGR1 intron 21572414 rs12754625 chr1 71987496 C T 8.18E-04 Alzheimer's disease NEGR1 intron 24755620 rs7535916 chr1 72018365 T C 1.69E-06 Multiple complex diseases NEGR1 intron 17554300 rs10889921 chr1 72045626 T C 7.25E-05 Progressive supranuclear palsy NEGR1 intron 21685912 rs1334992 chr1 72051206 C A 1.00E-04 Cognitive impairment induced by topiramate NEGR1 intron 22091778 rs10493485 chr1 72071129 A T 2.00E-06 Hemostatic factors and hematological phenotypes NEGR1 intron 17903294 rs10493486 chr1 72079898 G A 2.06E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NEGR1 intron 20877124 rs12136092 chr1 72093635 G A 4.03E-04 Multiple complex diseases NEGR1 intron 17554300 rs10889923 chr1 72099161 G C 1.91E-05 Multiple complex diseases NEGR1 intron 17554300 rs1577396 chr1 72101417 T C 5.11E-06 Multiple complex diseases NEGR1 intron 17554300 rs1041676 chr1 72104447 C T 4.73E-05 Cognitive decline NEGR1 intron 22054870 rs17091720 chr1 72222002 T C 1.95E-04 Multiple complex diseases NEGR1 intron 17554300 rs12024388 chr1 72253577 T C 7.62E-05 Diabetic nephropathy NEGR1 intron pha002852 rs12141391 chr1 72274473 C A 7.00E-06 Systemic lupus erythematosus NEGR1 intron 18204098 rs1350648 chr1 72287866 G T 9.28E-04 Multiple complex diseases NEGR1 intron 17554300 rs546741 chr1 72289671 G A 8.25E-04 Multiple complex diseases NEGR1 intron 17554300 rs554161 chr1 72343350 T A 8.67E-04 Multiple complex diseases NEGR1 intron 17554300 rs2114213 chr1 72404727 C A 6.44E-04 Multiple complex diseases NEGR1 intron 17554300 rs11209875 chr1 72413527 T G 4.60E-04 Smoking initiation NEGR1 intron 24665060 rs6703903 chr1 72415949 C A 3.03E-04 Smoking initiation NEGR1 intron 24665060 rs6677919 chr1 72455832 G A 4.92E-04 Smoking initiation NEGR1 intron 24665060 rs6661979 chr1 72458685 C T 3.82E-04 Smoking initiation NEGR1 intron 24665060 rs111868476 chr1 72459050 G C 1.90E-11 Metabolite levels NEGR1 intron 22286219 rs1937186 chr1 72461042 A G 1.97E-04 Lung function (forced expiratory volume in 1 second) NEGR1 intron 17255346 rs147218787 chr1 72461269 T C 0.00054379 Sarcoidosis NEGR1 intron 22952805 rs12139692 chr1 72461382 C T 3.46E-05 Vascular dementia NEGR1 intron 22116812 rs12042679 chr1 72481896 T C 5.64E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines NEGR1 intron 21844884 rs1486087 chr1 72509490 T C 4.75E-04 Alzheimer's disease (late onset) NEGR1 intron 21379329 rs988421 chr1 72549836 C T 4.30E-05 Parkinson's disease NEGR1 intron 17052657 rs10493493 chr1 72569309 G T 3.14E-05 Lymphocyte counts NEGR1 intron pha003094 rs1486096 chr1 72584184 G A 1.92E-05 HDL cholesterol NEGR1 intron pha003075 rs1486096 chr1 72584184 G A 6.52E-05 Lymphocyte counts NEGR1 intron pha003094 rs1545932 chr1 72622312 T G 1.04E-04 Multiple complex diseases NEGR1 intron 17554300 rs1157072 chr1 72634912 A G 6.43E-04 Nicotine smoking NEGR1 intron 19268276 rs2298152 chr1 72654730 A G 9.31E-05 Erythrocyte counts NEGR1 intron pha003099 rs1675356 chr1 72683226 C T 6.31E-05 HDL cholesterol NEGR1 intron pha003075 rs1194269 chr1 72703860 G A 8.43E-05 HDL cholesterol NEGR1 intron pha003075 rs1776012 chr1 72717743 A G 8.90E-06 Smoking behavior NEGR1 intron 20418888 rs9424977 chr1 72725344 T C 4.60E-06 Smoking behavior NEGR1 intron 20418888 rs9424977 chr1 72725344 T C 9.32E-05 HDL cholesterol NEGR1 intron pha003075 rs1620977 chr1 72729142 A G 3.49E-04 Taste perception NEGR1 intron 22132133 rs1380995 chr1 72733841 A T 1.60E-04 Self-reported allergy NEGR1 intron 23817569 rs12137231 chr1 72735458 T C 1.80E-04 Self-reported allergy NEGR1 intron 23817569 rs9326098 chr1 72740734 C G 5.19E-04 Multiple complex diseases NEGR1 intron 17554300 rs3101336 chr1 72751185 T C 1.10E-07 Smoking behavior / / 20418888 rs3101336 chr1 72751185 T C 1.00E-13 Obesity / / 23563607 rs3101336 chr1 72751185 T C 2.00E-08 Obesity (early onset extreme) / / 23563609 rs2568958 chr1 72765116 G A 1.00E-11 Body mass index / / 19079260 rs2568958 chr1 72765116 G A 2.00E-08 Weight / / 19079260 rs2568958 chr1 72765116 G A 9.90E-08 Smoking behavior / / 20418888 rs2568958 chr1 72765116 G A 2.00E-14 Body mass index / / 23563607 rs2568958 chr1 72765116 G A 4.00E-16 Obesity / / 23563607 rs2815752 chr1 72812440 G A 6.00E-08 Body mass index / / 19079261 rs2815752 chr1 72812440 G A 6.00E-08 Smoking behavior / / 20418888 rs2815752 chr1 72812440 G A 2.00E-22 Body mass index / / 20935630 rs2815752 chr1 72812440 G A 5.90E-07 Menarche (age at onset) / / 21102462 rs2815752 chr1 72812440 G A 1.61E-22 Body mass index / / 23001569 rs990871 chr1 72823713 C T 4.00E-06 Subcutaneous adipose tissue / / 22589738 rs7531118 chr1 72837239 T C 2.00E-17 Obesity / / 23563607 rs10789336 chr1 72838406 G A 1.00E-06 Body mass index / / 23669352 rs1993709 chr1 72838529 A G 5.00E-13 Obesity (early onset extreme) / / 23563609 rs17092613 chr1 72871597 A G 1.36E-04 Multiple complex diseases / / 17554300 rs12406365 chr1 72874258 G A 4.36E-05 Major depressive disorder (broad) / / 20038947 rs17092663 chr1 72879614 G A 5.73E-04 Alzheimer's disease / / 22005930 rs10789340 chr1 72940273 A G 5.43E-04 Type 2 diabetes / / 17463246 rs1775368 chr1 72992580 A T 6.70E-05 Type 2 diabetes / / 17846125 rs17092900 chr1 73003410 A G 8.39E-04 Multiple complex diseases / / 17554300 rs2245438 chr1 73042360 G A 7.48E-04 Multiple complex diseases / / 17554300 rs4649963 chr1 73109325 A C 8.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs7524643 chr1 73135952 T A 1.17E-04 Body mass index / / 23669352 rs10127441 chr1 73150180 G T 4.98E-04 Multiple complex diseases / / 17554300 rs2841187 chr1 73236826 C T 4.70E-05 Iron levels / / 21208937 rs10889990 chr1 73245168 G A 5.10E-05 Malaria / / 19465909 rs10889991 chr1 73245256 G A 7.70E-05 Malaria / / 19465909 rs7546928 chr1 73311542 G A 3.94E-04 Multiple complex diseases / / 17554300 rs1405051 chr1 73348484 G A 1.40E-04 Longevity and age-related phenotypes / / 17903295 rs6689491 chr1 73352029 C A 2.00E-05 Longevity and age-related phenotypes / / 17903295 rs6657082 chr1 73353328 A T 5.50E-05 Longevity and age-related phenotypes / / 17903295 rs10789351 chr1 73373796 C A 7.77E-04 Alzheimer's disease / / 17998437 rs10493513 chr1 73379589 G A 1.50E-06 Longevity and age-related phenotypes / / 17903295 rs10493514 chr1 73380512 T C 2.80E-06 Longevity and age-related phenotypes / / 17903295 rs17093667 chr1 73394093 T A 8.75E-05 Alzheimer's disease / / 17998437 rs4274011 chr1 73482160 G A 6.89E-04 Alzheimer's disease / / 17998437 rs4650199 chr1 73652122 T C 0.000000598 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs11210177 chr1 73655821 A G 0.000000759 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs12069039 chr1 73658085 G C 0.00000119 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs7514832 chr1 73658507 A T 0.00000111 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs10890018 chr1 73662169 A G 0.00000114 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs7522520 chr1 73664563 C T 0.00000124 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs4650201 chr1 73665844 A G 0.00000103 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs6684841 chr1 73706449 A G 0.000000251 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs6684841 chr1 73706449 A G 0.00000154 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs11210187 chr1 73715233 T C 0.000000597 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs4650206 chr1 73720577 T C 0.00000062 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs4571923 chr1 73736562 G A 0.00000113 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs11210193 chr1 73743873 A G 0.000000897 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs11210193 chr1 73743873 A G 0.00000184 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs7549372 chr1 73755529 A G 0.000000459 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs7549372 chr1 73755529 A G 0.000000833 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs10789368 chr1 73814159 A G 0.00000282 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs10493515 chr1 73815631 T G 2.30E-05 Longevity and age-related phenotypes / / 17903295 rs2340400 chr1 73821281 T C 6.87E-05 Blood Pressure / / pha003039 rs10789369 chr1 73824909 A G 4.00E-10 Schizophrenia / / 23974872 rs11210220 chr1 73849655 T G 6.55E-05 Major depressive disorder / / 22472876 rs11210222 chr1 73849687 T C 8.57E-05 Major depressive disorder / / 22472876 rs1923236 chr1 73853826 T C 5.38E-04 Insulin resistance / / 21901158 rs11210226 chr1 73854284 A G 2.74E-04 Insulin resistance / / 21901158 rs10493517 chr1 73858351 G A 4.20E-05 Longevity and age-related phenotypes / / 17903295 rs10493518 chr1 73860631 G A 3.60E-05 Longevity and age-related phenotypes / / 17903295 rs1885251 chr1 73866020 G T 0.000000233 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs7543202 chr1 73872885 A G,T 6.36E-04 Insulin resistance / / 21901158 rs11210235 chr1 73878194 T C 0.000000257 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs10465868 chr1 73880654 A G 0.000000243 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs7521446 chr1 73890390 T C 0.000000188 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs11210242 chr1 73897809 C T 0.000000393 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs11210243 chr1 73898030 C G 1.24E-04 Multiple complex diseases / / 17554300 rs4113050 chr1 73910055 T C 0.000000611 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs4350155 chr1 73911420 C G 5.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11210251 chr1 73912799 C G 0.00000041 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs505725 chr1 73930405 C A 0.00000328 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs622421 chr1 73930493 A G 0.00000498 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs11210255 chr1 73931737 G A 0.0000022 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs17570390 chr1 73938246 T C 5.29E-05 Major depressive disorder / / 21621269 rs12754690 chr1 73939898 C T 0.00000188 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs482063 chr1 73942338 G A 1.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1578022 chr1 73944277 C G 0.0000593 Major depressive disorder / / 23149448 rs17511652 chr1 73962827 C G 5.41E-04 Type 2 diabetes / / 17463246 rs17511652 chr1 73962827 C G 7.70E-04 Multiple complex diseases / / 17554300 rs11210266 chr1 73964312 G T 0.00000404 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs2341260 chr1 74054060 C T 4.00E-06 Cardiac Troponin-T levels / / 23247143 rs1566585 chr1 74069017 A C 2.93E-05 Creatinine levels / / pha003069 rs11210304 chr1 74074098 A G 2.99E-05 Creatinine levels / / pha003069 rs2341263 chr1 74083035 C T 3.00E-06 Metabolite levels (X-11787) / / 23934736 rs11210308 chr1 74084868 C A 4.49E-04 Aortic root size / / 21223598 rs11210317 chr1 74087657 T G 2.79E-05 Creatinine levels / / pha003069 rs7553862 chr1 74109213 G A 9.10E-06 Urinary metabolites / / 21572414 rs4606267 chr1 74112883 G A 2.23E-06 Common variable immunodeficiency / / 21497890 rs1909068 chr1 74116666 G A 7.70E-04 Multiple complex diseases / / 17554300 rs4584347 chr1 74141838 C T 4.66E-04 Sudden cardiac arrest / / 21658281 rs4478768 chr1 74151090 T G 2.65E-05 Hypertension / / pha003042 rs4326578 chr1 74157945 A G 4.49E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2342207 chr1 74158592 T C 4.21E-05 Hypertension / / pha003042 rs9425128 chr1 74169283 C T 6.27E-04 Alcohol dependence / / 20201924 rs1497840 chr1 74174778 G A 7.91E-04 Heart Failure / / pha002884 rs2132999 chr1 74236657 G A 7.95E-04 Multiple complex diseases / / 17554300 rs7544208 chr1 74255352 A T 4.18E-04 Multiple complex diseases / / 17554300 rs1497842 chr1 74259955 G C 1.62E-04 Multiple complex diseases / / 17554300 rs1340430 chr1 74264128 A G 2.04E-05 Multiple complex diseases / / 17554300 rs1340429 chr1 74264228 A G 2.31E-04 Multiple complex diseases / / 17554300 rs1340428 chr1 74265781 A G 3.18E-04 Multiple complex diseases / / 17554300 rs7516730 chr1 74265891 A T 1.55E-04 Multiple complex diseases / / 17554300 rs72683874 chr1 74317594 T C 3.76E-11 Metabolite levels / / 22286219 rs6672527 chr1 74338530 C T 3.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs6672527 chr1 74338530 C T 6.15E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6672527 chr1 74338530 C T 6.02E-04 Myocardial Infarction / / pha002883 rs11210359 chr1 74339167 G A 8.00E-06 Bipolar disorder and schizophrenia / / 21057379 rs11210361 chr1 74339944 T C 3.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs967881 chr1 74343741 G A 3.35E-04 Suicide attempts in bipolar disorder / / 21041247 rs17520168 chr1 74344519 T C 3.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs17579506 chr1 74344710 T C 3.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs11210363 chr1 74349846 G A 3.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs2789708 chr1 74357210 T A 1.37E-05 Suicide attempts in bipolar disorder / / 21041247 rs2792075 chr1 74357362 C T 1.39E-05 Suicide attempts in bipolar disorder / / 21041247 rs10890086 chr1 74361786 C A 1.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs1770494 chr1 74363716 A G 5.84E-04 Multiple complex diseases / / 17554300 rs12747535 chr1 74363988 A G 2.48E-04 Multiple complex diseases / / 17554300 rs17094575 chr1 74364041 G T 8.50E-06 Urinary metabolites / / 21572414 rs1340434 chr1 74365646 C T 2.85E-04 Multiple complex diseases / / 17554300 rs1340434 chr1 74365646 C T 4.97E-06 Suicide attempts in bipolar disorder / / 21041247 rs11210366 chr1 74367555 C T 7.11E-05 Suicide attempts in bipolar disorder / / 21041247 rs4650235 chr1 74370640 A G 9.50E-05 Suicide attempts in bipolar disorder / / 21041247 rs7544252 chr1 74376862 G C 4.69E-06 Suicide attempts in bipolar disorder / / 21041247 rs12062996 chr1 74377795 T C 4.66E-06 Suicide attempts in bipolar disorder / / 21041247 rs7550937 chr1 74379312 G A 4.63E-06 Suicide attempts in bipolar disorder / / 21041247 rs1768649 chr1 74379949 A G 4.62E-06 Suicide attempts in bipolar disorder / / 21041247 rs11210368 chr1 74380471 G A 4.60E-06 Suicide attempts in bipolar disorder / / 21041247 rs10493526 chr1 74385680 T C 5.38E-06 Suicide attempts in bipolar disorder / / 21041247 rs2733260 chr1 74387277 T C 4.53E-06 Suicide attempts in bipolar disorder / / 21041247 rs1340424 chr1 74387876 C G 1.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs12076161 chr1 74388884 A C 5.11E-06 Suicide attempts in bipolar disorder / / 21041247 rs12077198 chr1 74388935 A G 5.09E-06 Suicide attempts in bipolar disorder / / 21041247 rs7533599 chr1 74393112 G A 4.21E-06 Suicide attempts in bipolar disorder / / 21041247 rs12081389 chr1 74395561 T A 4.19E-06 Suicide attempts in bipolar disorder / / 21041247 rs2733262 chr1 74396896 T C 1.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs12082647 chr1 74398127 A C 4.29E-04 Multiple complex diseases / / 17554300 rs12082647 chr1 74398127 A C 3.52E-06 Suicide attempts in bipolar disorder / / 21041247 rs10890092 chr1 74402318 C T 1.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs10890093 chr1 74402825 G T 3.51E-06 Suicide attempts in bipolar disorder / / 21041247 rs10890094 chr1 74402888 A G 3.51E-06 Suicide attempts in bipolar disorder / / 21041247 rs2733265 chr1 74403128 G C 1.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs1340447 chr1 74403780 C A 4.31E-04 Multiple complex diseases / / 17554300 rs1340447 chr1 74403780 C A 1.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs2733267 chr1 74405054 G A 1.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs10493528 chr1 74412652 T A 3.52E-06 Suicide attempts in bipolar disorder / / 21041247 rs2789706 chr1 74413924 T C 9.38E-05 Suicide attempts in bipolar disorder / / 21041247 rs1417259 chr1 74418437 T G 3.17E-06 Suicide attempts in bipolar disorder / / 21041247 rs7544238 chr1 74419407 C A 3.18E-06 Suicide attempts in bipolar disorder / / 21041247 rs1361463 chr1 74422211 T A 8.21E-05 Multiple complex diseases / / 17554300 rs1361463 chr1 74422211 T A 3.41E-06 Suicide attempts in bipolar disorder / / 21041247 rs11210377 chr1 74423383 G T 3.43E-06 Suicide attempts in bipolar disorder / / 21041247 rs12116914 chr1 74423618 T G 3.44E-06 Suicide attempts in bipolar disorder / / 21041247 rs12064944 chr1 74429944 A G 3.48E-06 Suicide attempts in bipolar disorder / / 21041247 rs12064998 chr1 74430102 A G 3.51E-06 Suicide attempts in bipolar disorder / / 21041247 rs11210383 chr1 74435508 C A 2.51E-04 Multiple complex diseases / / 17554300 rs11210383 chr1 74435508 C A 3.58E-06 Suicide attempts in bipolar disorder / / 21041247 rs6424568 chr1 74440382 G A 6.52E-05 Suicide attempts in bipolar disorder / / 21041247 rs12138557 chr1 74442523 C A 3.29E-04 Multiple complex diseases / / 17554300 rs12138557 chr1 74442523 C A 3.71E-06 Suicide attempts in bipolar disorder / / 21041247 rs10890101 chr1 74445584 C T 1.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs9662322 chr1 74452323 G T 4.84E-06 Suicide attempts in bipolar disorder / / 21041247 rs11210389 chr1 74454701 A C 2.64E-05 Suicide attempts in bipolar disorder / / 21041247 rs11210390 chr1 74454776 C T 2.63E-05 Suicide attempts in bipolar disorder / / 21041247 rs2343194 chr1 74457400 G A 4.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs4650237 chr1 74459849 T G 2.62E-05 Suicide attempts in bipolar disorder / / 21041247 rs6663201 chr1 74460997 T C 7.90E-06 Suicide attempts in bipolar disorder / / 21041247 rs6660710 chr1 74461136 A G 7.88E-06 Suicide attempts in bipolar disorder / / 21041247 rs4556311 chr1 74461828 G A 3.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs2343196 chr1 74462422 T C 7.91E-06 Suicide attempts in bipolar disorder / / 21041247 rs1384883 chr1 74501477 C T 9.28E-05 Orofacial clefts LRRIQ3 intron 22419666 rs7535929 chr1 74560002 T G 8.72E-05 Orofacial clefts LRRIQ3 intron 22419666 rs10493529 chr1 74623448 A T 2.18E-04 Multiple complex diseases LRRIQ3 intron 17554300 rs10493529 chr1 74623448 A T 1.90E-05 Subclinical atherosclerosis LRRIQ3 intron 17903303 rs1483790 chr1 74627358 T C 2.74E-04 Multiple complex diseases LRRIQ3 intron 17554300 rs17591292 chr1 74646058 C T 5.38E-04 Alcohol dependence LRRIQ3 intron 21314694 rs518769 chr1 74699912 G A 1.96E-04 Suicide attempts in bipolar disorder FPGT-TNNI3K intron 21423239 rs12118620 chr1 74727955 C G 5.00E-16 Health and aging,CVD and cancer age of onset TNNI3K intron 22174011 rs12118620 chr1 74727955 C G 8.00E-12 Health and aging,CVD and cancer age of onset TNNI3K intron 22174011 rs516569 chr1 74782279 A G 5.87E-04 Myopia (pathological) TNNI3K intron 21095009 rs1527683 chr1 74822937 T C 8.71E-04 Suicide attempts in bipolar disorder TNNI3K intron 21423239 rs699842 chr1 74874431 T C 7.52E-04 Acute lung injury TNNI3K intron 22295056 rs7517677 chr1 74880189 T G 9.71E-05 Body Fat Distribution TNNI3K intron pha003018 rs17095295 chr1 74895901 G A 3.43E-04 Multiple complex diseases TNNI3K intron 17554300 rs17095295 chr1 74895901 G A 9.71E-05 Body Fat Distribution TNNI3K intron pha003018 rs477159 chr1 74898117 G A 0.0000338 post-traumatic stress disorder TNNI3K intron 22869035 rs477159 chr1 74898117 G A 3.38E-05 Schizophrenia TNNI3K intron 22883433 rs792884 chr1 74899573 T G 0.0000157 post-traumatic stress disorder TNNI3K intron 22869035 rs792884 chr1 74899573 T G 1.57E-05 Schizophrenia TNNI3K intron 22883433 rs643371 chr1 74900897 A C 0.0000987 post-traumatic stress disorder TNNI3K intron 22869035 rs643371 chr1 74900897 A C 9.87E-05 Schizophrenia TNNI3K intron 22883433 rs1325604 chr1 74907316 G A 0.000085 post-traumatic stress disorder TNNI3K intron 22869035 rs1325604 chr1 74907316 G A 8.50E-05 Schizophrenia TNNI3K intron 22883433 rs6690871 chr1 74977277 A G 9.69E-04 Obesity (extreme) TNNI3K intron 21935397 rs1040070 chr1 74977870 G C 9.94E-04 Obesity (extreme) TNNI3K intron 21935397 rs1040070 chr1 74977870 G C 1.07E-08 Obesity TNNI3K intron 22484627 rs984167 chr1 74981547 A T 8.20E-05 HDL particle features TNNI3K intron 21283740 rs1514177 chr1 74991402 C G 5.00E-09 Obesity TNNI3K intron 23563607 rs1514175 chr1 74991644 A G 8.00E-14 Body mass index TNNI3K intron 20935630 rs1514175 chr1 74991644 A G 6.38E-05 Body mass index TNNI3K intron 22344219 rs1514175 chr1 74991644 A G 8.16E-14 Body mass index TNNI3K intron 23001569 rs1514175 chr1 74991644 A G 3.00E-11 Body mass index TNNI3K intron 23669352 rs1514174 chr1 74993063 C T 6.00E-06 Pubertal anthropometrics TNNI3K intron 23449627 rs1514174 chr1 74993063 C T 1.00E-08 Obesity TNNI3K intron 23563607 rs113313252 chr1 75000011 A AT 4.32E-11 Body mass index TNNI3K intron 23669352 rs12142020 chr1 75000011 A T 4.32E-11 Body mass index TNNI3K intron 23669352 rs201167096 chr1 75000011 A AT 4.32E-11 Body mass index TNNI3K intron 23669352 rs3894212 chr1 75001683 T G 1.80E-04 Type 2 diabetes and 6 quantitative traits TNNI3K intron 17848626 rs7541513 chr1 75014195 G A 2.30E-04 Iris characteristics / / 21835309 rs10789396 chr1 75014362 T C 7.82E-04 Obesity (extreme) / / 21935397 rs4287129 chr1 75016147 T G 5.46E-05 Type 2 diabetes / / 17463246 rs3931879 chr1 75030642 A T 4.70E-04 Type 2 diabetes / / 17463246 rs2305549 chr1 75055419 T C 5.48E-04 Heart Failure C1orf173 missense pha002885 rs41337449 chr1 75099977 T C 9.08E-05 Multiple complex diseases C1orf173 intron 17554300 rs17095690 chr1 75106741 G A 1.65E-05 Attention deficit hyperactivity disorder C1orf173 intron 20732627 rs696666 chr1 75146093 T C 4.15E-04 Type 2 diabetes / / 17463246 rs696667 chr1 75149512 A G 3.07E-04 Type 2 diabetes / / 17463246 rs696668 chr1 75149922 G T 3.07E-04 Type 2 diabetes / / 17463246 rs575533 chr1 75155657 T C 8.76E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12061533 chr1 75158118 A G 5.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1340985 chr1 75160724 A G 3.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6662846 chr1 75170143 A C 4.20E-05 Glioma (high-grade) / / 19578366 rs17552114 chr1 75172652 T C 9.54E-04 Coronary Artery Disease CRYZ cds-synon 17634449 rs11485264 chr1 75197533 A G 1.00E-04 Cognitive impairment induced by topiramate CRYZ intron 22091778 rs3931020 chr1 75235317 T C 6.00E-12 Resistin levels / / 22843503 rs17095902 chr1 75240211 A G 9.70E-04 Major depressive disorder / / 22472876 rs1409785 chr1 75248122 G A 6.50E-07 Glioma (high-grade) / / 19578366 rs7547190 chr1 75252764 C T 4.98E-05 Cognitive impairment induced by topiramate / / 22091778 rs1575983 chr1 75262196 A C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11161851 chr1 75298782 T C 7.00E-06 Visceral fat / / 22589738 rs12747472 chr1 75311462 T C 5.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs12120668 chr1 75321017 G C 8.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs12033503 chr1 75326398 C T 9.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs12743570 chr1 75333502 G C 3.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs7552148 chr1 75340175 C T 3.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs6664850 chr1 75352327 G A 2.04E-04 Height / / 17255346 rs6664850 chr1 75352327 G A 6.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs1327098 chr1 75361993 G A 7.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs17562236 chr1 75374025 A G 6.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs12755578 chr1 75374854 C G 6.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs12121720 chr1 75386937 G A 5.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs12127639 chr1 75395198 C G 6.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs12129191 chr1 75395327 A G 6.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs12732265 chr1 75398270 T C 6.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs10782637 chr1 75403587 C A 6.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs17096151 chr1 75425129 C T 8.45E-05 Aging (time to event) / / 21782286 rs11162286 chr1 75427397 A G 3.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs7522882 chr1 75442994 T A 4.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs2346344 chr1 75446663 T G 4.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs3845358 chr1 75449592 A C 2.41E-04 Height / / 17255346 rs3845358 chr1 75449592 A C 4.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs12743802 chr1 75458806 G A 3.85E-05 Paclitaxel-induced neuropathy / / 23776197 rs10493550 chr1 75460333 G A 5.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs3912426 chr1 75462461 A G 4.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs6693646 chr1 75466410 G T 4.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs12750340 chr1 75469124 C T 5.21E-04 Suicide attempts in bipolar disorder / / 21041247 rs696676 chr1 75479163 A G 9.69E-04 Type 2 diabetes / / 17463246 rs12089365 chr1 75486214 A G 4.77E-04 Multiple complex diseases / / 17554300 rs12089365 chr1 75486214 A G 6.28E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6703099 chr1 75534319 T C 8.69E-04 Type 2 diabetes / / 17463246 rs2077678 chr1 75534827 A G 4.40E-05 Kidney function and endocine traits / / 17903292 rs7541725 chr1 75549806 T C 7.21E-04 Multiple complex diseases / / 17554300 rs11162495 chr1 75555722 T G 8.83E-04 Type 2 diabetes / / 17463246 rs12138223 chr1 75615026 A G,T 6.82E-05 Serum metabolites LHX8 intron 19043545 rs7545324 chr1 75662563 A G 8.88E-05 Body Mass Index / / pha003015 rs1405311 chr1 75675047 T G 8.88E-05 Body Mass Index SLC44A5 intron pha003015 rs149696907 chr1 75693501 G A 0.000037 Breast cancer SLC44A5 missense 23555315 rs41385949 chr1 75702129 C T 7.43E-04 Multiple complex diseases SLC44A5 intron 17554300 rs616827 chr1 75703209 G T 1.61E-05 Body Mass Index SLC44A5 intron pha003015 rs596098 chr1 75722892 G A 8.73E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs1249675 chr1 75770625 C T 7.00E-06 Capecitabine sensitivity SLC44A5 intron 22864933 rs11163089 chr1 75778546 C T 7.71E-04 Type 2 diabetes SLC44A5 intron 17463246 rs1249667 chr1 75779988 G A 5.13E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs1262045 chr1 75781308 T G 3.09E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs1249666 chr1 75781855 T C 2.57E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs1249664 chr1 75785042 T C 3.31E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs17097953 chr1 75801795 A G 8.35E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs10493574 chr1 75803142 C T 6.74E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs17096776 chr1 75808190 C T 6.93E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs17097955 chr1 75811152 T C 6.89E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs17096782 chr1 75812191 T C 5.11E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs1249811 chr1 75863089 G A 1.50E-06 Urinary metabolites SLC44A5 intron 21572414 rs4540592 chr1 75883281 T C 3.33E-06 Total ventricular volume SLC44A5 intron 21116278 rs12410333 chr1 75895626 T C 5.12E-06 Total ventricular volume SLC44A5 intron 21116278 rs10493575 chr1 75903516 G A 3.42E-06 Total ventricular volume SLC44A5 intron 21116278 rs2040079 chr1 75906421 G T 3.29E-06 Total ventricular volume SLC44A5 intron 21116278 rs2040082 chr1 75906874 A G 3.23E-06 Total ventricular volume SLC44A5 intron 21116278 rs2347218 chr1 75911113 A G 1.40E-06 Urinary metabolites SLC44A5 intron 21572414 rs2587031 chr1 75911769 G A 1.60E-06 Urinary metabolites SLC44A5 intron 21572414 rs1857353 chr1 75913826 C T 2.00E-06 MRI atrophy measures SLC44A5 intron 21116278 rs4598448 chr1 75963934 G A 8.85E-04 Alzheimer's disease SLC44A5 intron 17998437 rs12401888 chr1 75967778 C T 8.68E-04 Glycemic traits (pregnancy) SLC44A5 intron 23903356 rs13373826 chr1 75970795 A G 2.93E-09 Multiple complex diseases SLC44A5 intron 17554300 rs211786 chr1 75992019 A G 6.81E-04 Multiple complex diseases SLC44A5 intron 17554300 rs7553832 chr1 76091427 G A 2.47E-04 Hemoglobin concentration / / 20534544 rs211718 chr1 76106675 T C 4.63E-06 Serum metabolites / / 19043545 rs211718 chr1 76106675 T C 1.00E-63 Metabolite levels / / 20037589 rs211718 chr1 76106675 T C 2.00E-71 Metabolic traits / / 21886157 rs2347540 chr1 76119468 G A 2.50E-05 Esophageal cancer (squamous cell) / / 22960999 rs1535740 chr1 76134765 C A 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7552404 chr1 76135946 A G 1.00E-77 Blood metabolite levels / / 24816252 rs7552404 chr1 76135946 A G 3.00E-43 Blood metabolite levels / / 24816252 rs12045299 chr1 76154750 T C 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12045299 chr1 76154750 T C 8.40E-04 Myopia (pathological) / / 21095009 rs4949874 chr1 76161889 T C 2.00E-172 Blood metabolite ratios / / 24816252 rs1391520 chr1 76174752 A C 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1391520 chr1 76174752 A C 8.40E-04 Myopia (pathological) / / 21095009 rs1251079 chr1 76189445 T C 4.90E-04 Type 2 diabetes ACADM nearGene-5 17463246 rs12744608 chr1 76206490 G T 3.58E-04 Alzheimer's disease (late onset) ACADM intron 21379329 rs1146579 chr1 76209792 T A,C,G 1.80E-05 Serum metabolites ACADM intron 19043545 rs11161510 chr1 76210289 C T 1.72E-06 Serum metabolites ACADM intron 19043545 rs11161511 chr1 76210477 C T 3.33E-06 Serum metabolites ACADM intron 19043545 rs1146581 chr1 76213024 T G 7.96E-05 Attention deficit hyperactivity disorder ACADM intron 22420046 rs9660848 chr1 76214508 G A 3.58E-04 Alzheimer's disease (late onset) ACADM intron 21379329 rs11161521 chr1 76216330 T C 1.00E-63 Blood metabolite levels ACADM intron 24816252 rs11161521 chr1 76216330 T C 6.00E-100 Blood metabolite levels ACADM intron 24816252 rs1694419 chr1 76219801 G A 2.49E-05 Serum metabolites ACADM intron 19043545 rs1146586 chr1 76227974 C T 2.91E-10 LDL cholesterol ACADM intron 23063622 rs1146634 chr1 76252011 G A 1.70E-05 Urinary metabolites RABGGTB intron 21572414 rs5745309 chr1 76261914 T G 4.84E-04 Response to cytadine analogues (cytosine arabinoside) MSH4 nearGene-5 24483146 rs1146644 chr1 76264788 T C 2.50E-05 Urinary metabolites MSH4 intron 21572414 rs5745331 chr1 76273313 A G 3.47E-04 Alcohol dependence MSH4 intron 20201924 rs5745354 chr1 76275178 G A 9.22E-04 Myopia (pathological) MSH4 intron 21095009 rs1144337 chr1 76278877 T A,C,G 9.22E-04 Myopia (pathological) MSH4 intron 21095009 rs12024645 chr1 76284395 A G 5.71E-04 Myopia (pathological) MSH4 intron 21095009 rs1251272 chr1 76289004 C T 0.0003488 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs1251272 chr1 76289004 C T 3.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs12076093 chr1 76301656 G A 0.0003491 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs12076093 chr1 76301656 G A 3.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs10873738 chr1 76302233 A G 0.0003494 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs10873738 chr1 76302233 A G 3.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs9970840 chr1 76303720 A G 4.84E-04 Response to cytadine analogues (cytosine arabinoside) MSH4 intron 24483146 rs12090712 chr1 76304215 C T 0.0003494 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs12090712 chr1 76304215 C T 3.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs7514912 chr1 76307558 A G 0.0003499 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs7514912 chr1 76307558 A G 3.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs7548391 chr1 76307595 C T 0.0003502 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs7548391 chr1 76307595 C T 3.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs1603734 chr1 76311632 T C 0.0003512 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs1603734 chr1 76311632 T C 3.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs2047435 chr1 76313874 C A,T 0.0003518 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs2047435 chr1 76313874 C A,T 3.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs12409592 chr1 76317549 G A 6.86E-04 Myopia (pathological) MSH4 intron 21095009 rs11161887 chr1 76386305 A G 4.50E-04 Myopia (pathological) ASB17 intron 21095009 rs10873804 chr1 76394150 C A 2.62E-04 Myopia (pathological) ASB17 intron 21095009 rs3795251 chr1 76397972 C T 2.62E-04 Myopia (pathological) ASB17 missense 21095009 rs1251594 chr1 76415210 A C 0.0003271 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1251594 chr1 76415210 A C 3.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6685657 chr1 76417440 G A 9.74E-04 Alzheimer's disease / / 17998437 rs1251588 chr1 76420745 C T 7.06E-04 Myocardial Infarction / / pha002883 rs12405994 chr1 76435420 A T 3.80E-07 Malaria / / 19465909 rs1251539 chr1 76436260 C A 0.0003236 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1251539 chr1 76436260 C A 3.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1417402 chr1 76437196 G A 5.00E-07 Malaria / / 19465909 rs12566984 chr1 76438011 G T 4.20E-04 Myopia (pathological) / / 21095009 rs1251560 chr1 76451190 T C 0.0003173 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1251560 chr1 76451190 T C 3.17E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1417403 chr1 76454816 C T 0.0003162 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1417403 chr1 76454816 C T 3.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1340686 chr1 76455075 G A 0.0003152 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1340686 chr1 76455075 G A 3.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1361488 chr1 76455765 A C 0.0003164 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1361488 chr1 76455765 A C 3.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1770878 chr1 76456329 C T 0.0003182 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1770878 chr1 76456329 C T 3.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1770879 chr1 76456512 C G 0.0003197 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1770879 chr1 76456512 C G 3.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12731410 chr1 76464725 C A 9.49E-04 Depression (quantitative trait) / / 20800221 rs12122440 chr1 76477207 A C 2.00E-06 Pubertal anthropometrics / / 23449627 rs12753569 chr1 76484014 G T 8.00E-06 Personality dimensions / / 20691247 rs3179693 chr1 76484827 G A 8.73E-05 Type 2 diabetes / / 17463246 rs6672844 chr1 76486884 A G 1.10E-04 Type 2 diabetes / / 17463246 rs17598972 chr1 76487108 T C 6.84E-04 Type 2 diabetes / / 17463246 rs10493577 chr1 76489223 A T 2.84E-04 Type 2 diabetes / / 17463246 rs11162069 chr1 76489779 A T 1.22E-04 Type 2 diabetes / / 17463246 rs17097922 chr1 76490425 C G 1.07E-04 Type 2 diabetes / / 17463246 rs17097929 chr1 76491041 G T 1.27E-04 Type 2 diabetes / / 17463246 rs1866254 chr1 76492334 T C 2.81E-05 Type 2 diabetes / / 17463246 rs946161 chr1 76510513 A G 3.04E-05 Multiple complex diseases / / 17554300 rs17097997 chr1 76510789 T A 3.25E-04 Type 2 diabetes / / 17463246 rs1251493 chr1 76518108 T A 1.35E-04 Type 2 diabetes / / 17463246 rs1340688 chr1 76520630 T G 1.45E-04 Type 2 diabetes / / 17463246 rs17098034 chr1 76532801 A C 7.12E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1251465 chr1 76538396 G A 7.41E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1251575 chr1 76557784 A G 6.05E-05 stroke (ischemic) ST6GAL/C3 intron 17434096 rs915404 chr1 76602662 A G 2.80E-09 Adiponectin levels ST6GAL/C3 intron 20887962 rs7548049 chr1 76608072 C T 0.00005091 Sarcoidosis ST6GAL/C3 intron 22952805 rs2706183 chr1 76617830 G A 7.80E-05 Adverse response to radiation therapy ST6GAL/C3 intron 23719583 rs2783658 chr1 76620313 C T 2.40E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs425110 chr1 76625747 A G 1.63E-04 Multiple complex diseases ST6GAL/C3 intron 17554300 rs3011997 chr1 76627054 C T 2.60E-04 Multiple complex diseases ST6GAL/C3 intron 17554300 rs1414403 chr1 76627868 G A 5.36E-04 Multiple complex diseases ST6GAL/C3 intron 17554300 rs517036 chr1 76680525 T C 3.25E-06 F-cell distribution ST6GAL/C3 intron 21326311 rs547342 chr1 76687275 A G 5.47E-04 Multiple complex diseases ST6GAL/C3 intron 17554300 rs547342 chr1 76687275 A G 1.09E-05 F-cell distribution ST6GAL/C3 intron 21326311 rs17098442 chr1 76700296 C G 5.26E-04 Response to cytadine analogues (cytosine arabinoside) ST6GAL/C3 intron 24483146 rs17098450 chr1 76700697 G A 5.26E-04 Response to cytadine analogues (cytosine arabinoside) ST6GAL/C3 intron 24483146 rs544858 chr1 76725259 A G 4.87E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ST6GAL/C3 intron 24023788 rs6696780 chr1 76731907 G A 8.47E-08 Electroencephalogram traits,in brain ST6GAL/C3 intron 20421487 rs12079387 chr1 76746838 C A,T 3.99E-05 Orofacial clefts ST6GAL/C3 intron 22419666 rs10873876 chr1 76772328 T C 4.00E-06 Acute lymphoblastic leukemia (childhood) ST6GAL/C3 intron 19684603 rs10873876 chr1 76772328 T C 4.00E-06 Nasopharyngeal carcinoma ST6GAL/C3 intron 20512145 rs3884182 chr1 76774201 G A 8.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ST6GAL/C3 intron 20877124 rs2392030 chr1 76784636 T C 8.37E-05 ldl cholesterol ST6GAL/C3 intron pha003076 rs4421636 chr1 76785393 C T 8.46E-04 Myocardial Infarction ST6GAL/C3 intron pha002883 rs11585239 chr1 76785765 A G 0.0004475 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs11585239 chr1 76785765 A G 4.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs17098734 chr1 76787267 A G 0.000402 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs17098734 chr1 76787267 A G 4.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs17098736 chr1 76787466 G T 0.0003996 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs17098736 chr1 76787466 G T 4.00E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs4628548 chr1 76791163 G A 9.30E-04 Alzheimer's disease ST6GAL/C3 intron 24755620 rs10493590 chr1 76794327 C G 0.0001976 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs10493590 chr1 76794327 C G 1.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs10493591 chr1 76796785 A G 0.0001976 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs10493591 chr1 76796785 A G 1.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs4408196 chr1 76798359 A C 0.0001976 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs4408196 chr1 76798359 A C 1.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs17672606 chr1 76799446 G A 0.0001976 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs17672606 chr1 76799446 G A 1.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs1325290 chr1 76801781 C G 1.30E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs752819 chr1 76803522 G A 5.63E-04 Type 2 diabetes ST6GAL/C3 intron 17463246 rs752819 chr1 76803522 G A 0.0001976 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs752819 chr1 76803522 G A 1.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs7539896 chr1 76806274 C G 0.0007443 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs7539896 chr1 76806274 C G 7.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs7516680 chr1 76806409 G A 0.0007424 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs7516680 chr1 76806409 G A 7.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs17098793 chr1 76809752 A G 0.0007408 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs17098793 chr1 76809752 A G 7.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs12562911 chr1 76822600 A G 7.62E-04 Alcohol dependence ST6GAL/C3 intron 21314694 rs7524886 chr1 76826279 C T 6.00E-05 Immunoglobulin A ST6GAL/C3 intron 20694011 rs12239582 chr1 76837237 A C 2.70E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs12144344 chr1 76839536 C T 5.86E-04 Type 2 diabetes ST6GAL/C3 intron 17463246 rs12144344 chr1 76839536 C T 2.20E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs12144344 chr1 76839536 C T 6.00E-07 Serum vitamin D-binding protein levels ST6GAL/C3 intron 24740207 rs12144344 chr1 76839536 C T 3.52E-05 ldl cholesterol ST6GAL/C3 intron pha003076 rs1540964 chr1 76840728 A C 7.65E-04 Type 2 diabetes ST6GAL/C3 intron 17463246 rs1540964 chr1 76840728 A C 2.80E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs1359468 chr1 76851135 A G 7.18E-04 Type 2 diabetes ST6GAL/C3 intron 17463246 rs1359468 chr1 76851135 A G 2.80E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs6667721 chr1 76867853 G A 1.30E-05 Bone mineral density (BMD),in women ST6GAL/C3 intron 20164292 rs11577449 chr1 76869325 T A 0.000167 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs11577449 chr1 76869325 T A 1.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs7515898 chr1 76871716 G A 0.000709798 Hypertension (early onset hypertension) ST6GAL/C3 intron 22479346 rs4949631 chr1 76898955 G A 7.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ST6GAL/C3 intron 20877124 rs4949718 chr1 76899464 T C 2.23E-05 Type 2 diabetes ST6GAL/C3 intron 17463246 rs4949718 chr1 76899464 T C 1.00E-06 Liver enzyme levels (aspartate transaminase) ST6GAL/C3 intron 24124411 rs4949718 chr1 76899464 T C 2.00E-07 Liver enzyme levels (alanine transaminase) ST6GAL/C3 intron 24124411 rs1436086 chr1 76973245 G T 1.10E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs315087 chr1 76989264 T C 1.67E-05 Tuberculosis ST6GAL/C3 intron 24057671 rs410076 chr1 77001631 G A 1.03E-07 Electroencephalogram traits,in brain ST6GAL/C3 intron 20421487 rs172714 chr1 77015113 T C 7.34E-08 Electroencephalogram traits,in brain ST6GAL/C3 intron 20421487 rs172714 chr1 77015113 T C 5.24E-04 Depression (quantitative trait) ST6GAL/C3 intron 20800221 rs6675095 chr1 77016065 G A 3.57E-04 Depression (quantitative trait) ST6GAL/C3 intron 20800221 rs315049 chr1 77023273 G A 2.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315049 chr1 77023273 G A 3.85E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315049 chr1 77023273 G A 4.32E-06 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315049 chr1 77023273 G A 8.14E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315014 chr1 77033959 C A 2.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315014 chr1 77033959 C A 2.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315014 chr1 77033959 C A 4.63E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315014 chr1 77033959 C A 6.85E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs417415 chr1 77035168 T C 2.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs417415 chr1 77035168 T C 4.63E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs7513970 chr1 77041694 G A 5.95E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs369258 chr1 77042204 G A 1.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs369258 chr1 77042204 G A 2.81E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315029 chr1 77042405 G A 1.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315029 chr1 77042405 G A 2.81E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs2117905 chr1 77052596 A G 1.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315039 chr1 77054590 T C 6.75E-05 Serum albumin level ST6GAL/C3 intron pha003084 rs56012468 chr1 77055776 C T 2.00E-05 Serum albumin level ST6GAL/C3 intron pha003084 rs2574775 chr1 77069228 G A 2.71E-04 Smoking initiation ST6GAL/C3 intron 24665060 rs2647389 chr1 77072458 T C 3.60E-05 Multiple sclerosis ST6GAL/C3 intron 17660530 rs665178 chr1 77075591 C T 0.000175 Salmonella-induced pyroptosis ST6GAL/C3 intron 22837397 rs485141 chr1 77083864 C A 7.38E-05 Coronary restenosis ST6GAL/C3 intron 21878436 rs3748712 chr1 77098483 A T 9.38E-04 Multiple complex diseases / / 17554300 rs12134580 chr1 77121319 T C 7.52E-05 Depression (quantitative trait) / / 23290196 rs551585 chr1 77126373 C A 3.00E-07 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs664576 chr1 77179690 T C 8.58E-05 Neuroblastoma / / pha002895 rs7534158 chr1 77188392 C T 6.40E-05 Blood pressure / / 19114657 rs619463 chr1 77196032 C A 9.43E-05 Cardiovascular disease / / pha003064 rs2221083 chr1 77221362 A G 4.28E-05 LDL lipoproteins / / pha002902 rs4506508 chr1 77256336 C A 1.15E-04 Multiple complex diseases / / 17554300 rs11162212 chr1 77256966 C A 6.42E-04 Body mass index / / 21701565 rs4586020 chr1 77265640 C A 4.85E-05 Odorant perception / / 23910658 rs17099699 chr1 77372136 C G 5.46E-04 Multiple complex diseases ST6GAL/C5 intron 17554300 rs12567699 chr1 77437423 G A 4.85E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ST6GAL/C5 intron 20877124 rs4949764 chr1 77462662 T C 1.45E-05 Response to Vitamin E supplementation ST6GAL/C5 intron 22437554 rs199698 chr1 77506217 C T 6.71E-04 Multiple complex diseases ST6GAL/C5 intron 17554300 rs199699 chr1 77507030 T C 2.49E-04 Multiple complex diseases ST6GAL/C5 intron 17554300 rs12084236 chr1 77507127 A G 1.68E-04 Multiple complex diseases ST6GAL/C5 intron 17554300 rs41515647 chr1 77517009 C A 6.67E-06 Multiple complex diseases ST6GAL/C5 intron 17554300 rs191827 chr1 77548518 T C 1.70E-05 Urinary metabolites / / 21572414 rs1048575 chr1 77558057 G C 9.89E-04 Obesity (extreme) PIGK UTR-3 21935397 rs2069224 chr1 77560216 C T 4.62E-04 Obesity (extreme) PIGK intron 21935397 rs11162271 chr1 77563988 G A 5.10E-04 Obesity (extreme) PIGK intron 21935397 rs11806823 chr1 77565415 A G 5.18E-04 Obesity (extreme) PIGK intron 21935397 rs4949766 chr1 77569489 C T 5.32E-04 Obesity (extreme) PIGK intron 21935397 rs7538430 chr1 77590961 A G 5.29E-04 Obesity (extreme) PIGK intron 21935397 rs1146675 chr1 77630053 G A 5.22E-04 Obesity (extreme) PIGK intron 21935397 rs1779174 chr1 77694640 C T 8.98E-04 Type 2 diabetes / / 17463246 rs12091579 chr1 77697013 C T 4.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs12407610 chr1 77707310 A T 5.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs1592340 chr1 77719729 G A 4.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs10518441 chr1 77726980 A G 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10518441 chr1 77726980 A G 6.12E-05 Prostate cancer / / pha002878 rs2799549 chr1 77727898 T C 5.03E-05 Cognitive test performance / / 20125193 rs1167220 chr1 77729805 G A 6.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs1988302 chr1 77731287 C A 4.80E-06 Urinary metabolites / / 21572414 rs940283 chr1 77737217 C T 4.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs10518446 chr1 77740836 G C 2.00E-04 Coronary Artery Disease / / 17634449 rs1851736 chr1 77747248 G T 2.40E-06 Urinary metabolites / / 21572414 rs7517698 chr1 77749363 G A,C 5.75E-07 Multiple sclerosis AK5 intron 17660530 rs10747353 chr1 77751193 A C 3.49E-04 Epilepsy AK5 intron 22116939 rs10782645 chr1 77754853 G A 2.67E-05 Cognitive impairment induced by topiramate AK5 intron 22091778 rs2689683 chr1 77755686 C T 4.60E-06 Urinary metabolites AK5 intron 21572414 rs2689676 chr1 77764869 G A 7.90E-06 Urinary metabolites AK5 intron 21572414 rs10493603 chr1 77768778 A G 8.78E-05 Cognitive impairment induced by topiramate AK5 intron 22091778 rs10493603 chr1 77768778 A G 3.26E-04 Epilepsy AK5 intron 22116939 rs2815319 chr1 77775066 A G 1.40E-05 Urinary metabolites AK5 intron 21572414 rs12751884 chr1 77784762 A G 3.11E-04 Epilepsy AK5 intron 22116939 rs2602951 chr1 77791025 T G 1.10E-05 Urinary metabolites AK5 intron 21572414 rs2815326 chr1 77798945 C T 8.90E-06 Urinary metabolites AK5 intron 21572414 rs17378915 chr1 77804242 A G 2.10E-05 Urinary metabolites AK5 intron 21572414 rs1463324 chr1 77806954 G A 7.40E-06 Urinary metabolites AK5 intron 21572414 rs1010196 chr1 77815566 C T 4.34E-04 Epilepsy AK5 intron 22116939 rs12073962 chr1 77817304 G C 5.20E-04 Suicide attempts in bipolar disorder AK5 intron 21423239 rs6672375 chr1 77818143 A G 4.20E-05 Leukocyte Counts AK5 intron pha003091 rs1377733 chr1 77819743 A G 6.20E-04 Heart Failure AK5 intron pha002885 rs10493604 chr1 77826732 T G 6.85E-05 Odorant perception AK5 intron 23910658 rs10493604 chr1 77826732 T G 2.37E-04 Stroke AK5 intron pha002887 rs7546131 chr1 77844602 G A 6.47E-06 Sodium levels AK5 intron pha003093 rs6663047 chr1 77865140 G A 3.24E-06 Sodium levels AK5 intron pha003093 rs4949802 chr1 77876353 T C 4.20E-05 Response to alcohol consumption (flushing response) AK5 intron 24277619 rs10873937 chr1 77879827 C T 1.31E-04 Nicotine smoking AK5 intron 19268276 rs12131772 chr1 77883671 C G 2.55E-04 Nicotine smoking AK5 intron 19268276 rs6658302 chr1 77908985 A G 5.18E-04 Multiple complex diseases AK5 intron 17554300 rs1498405 chr1 77927948 A G 8.73E-04 Obesity (extreme) AK5 intron 21935397 rs11162351 chr1 77944732 C G 5.65E-04 Multiple complex diseases AK5 intron 17554300 rs6695572 chr1 77945635 G A 2.63E-09 Narcolepsy AK5 intron 19629137 rs6695572 chr1 77945635 G A 2.76E-04 Obesity (extreme) AK5 intron 21935397 rs6698295 chr1 77945965 G A 2.76E-04 Obesity (extreme) AK5 intron 21935397 rs4949803 chr1 77951083 C T 1.52E-04 Response to statin treatment (atorvastatin),change in cholesterol levels AK5 intron 20031582 rs2088518 chr1 77951330 A T 2.80E-04 Obesity (extreme) AK5 intron 21935397 rs9324162 chr1 77954804 A G 1.46E-04 Obesity (extreme) AK5 intron 21935397 rs17380544 chr1 77958712 G A 4.79E-04 Obesity (extreme) AK5 intron 21935397 rs2803155 chr1 77958837 A C 6.27E-04 Obesity (extreme) AK5 intron 21935397 rs11162355 chr1 77961074 G T 6.70E-04 Obesity (extreme) AK5 intron 21935397 rs7514041 chr1 77964269 G A 6.44E-04 Obesity (extreme) AK5 intron 21935397 rs11806197 chr1 77964855 A G 3.33E-04 Obesity (extreme) AK5 intron 21935397 rs11806197 chr1 77964855 A G 2.56E-05 Brain structure AK5 intron 22504417 rs3112830 chr1 77966494 A T 5.68E-05 Multiple complex diseases AK5 intron 17554300 rs2803152 chr1 77966756 T C 6.44E-04 Obesity (extreme) AK5 intron 21935397 rs12049202 chr1 77967523 C T 2.95E-05 Brain structure AK5 intron 22504417 rs12040471 chr1 77968401 T A 3.42E-04 Obesity (extreme) AK5 intron 21935397 rs12042881 chr1 77968443 G A 3.45E-04 Obesity (extreme) AK5 intron 21935397 rs12042881 chr1 77968443 G A 2.66E-05 Brain structure AK5 intron 22504417 rs17380796 chr1 77976117 A G 7.04E-05 Obesity (extreme) AK5 intron 21935397 rs12729914 chr1 77980235 T C 4.00E-04 Obesity (extreme) AK5 intron 21935397 rs11811611 chr1 77982017 C T 3.99E-04 Obesity (extreme) AK5 intron 21935397 rs12042177 chr1 77986638 A G 3.63E-04 Obesity (extreme) AK5 intron 21935397 rs3509 chr1 78025551 C T 7.98E-04 Multiple complex diseases AK5 UTR-3 17554300 rs3509 chr1 78025551 C T 3.41E-04 Lymphocyte counts AK5 UTR-3 22286170 rs3509 chr1 78025551 C T 7.21E-04 Response to taxane treatment (placlitaxel) AK5 UTR-3 23006423 rs728741 chr1 78029365 A G 4.80E-05 Cognitive function / / 24684796 rs17381664 chr1 78048331 T C 3.00E-08 Obesity ZZZ3 intron 23563607 rs1389790 chr1 78089399 T C 5.90E-05 Cognitive function ZZZ3 intron 24684796 rs17100965 chr1 78206733 A G 6.71E-04 Multiple complex diseases USP33 intron 17554300 rs12085547 chr1 78295506 G A 9.69E-04 Suicide attempts in bipolar disorder FAM73A intron 21423239 rs9729667 chr1 78349214 C T 6.84E-05 Recombination rate NEXN-AS1 intron 21698098 rs1166706 chr1 78359029 T C 5.60E-05 Cognitive function NEXN intron 24684796 rs1166706 chr1 78359029 T C 8.70E-05 Cognitive function NEXN intron 24684796 rs11807240 chr1 78418776 G A 9.39E-04 Amyotrophic lateral sclerosis (sporadic) FUBP1 intron 24529757 rs17383213 chr1 78433531 T C 1.99E-04 Smoking initiation FUBP1 intron 24665060 rs11162405 chr1 78469660 A G 2.54E-05 Bipolar disorder / / 21926972 rs7524504 chr1 78494732 G T 3.75E-04 Multiple complex diseases / / 17554300 rs6424659 chr1 78501215 T C 7.55E-05 Cognitive impairment induced by topiramate / / 22091778 rs631045 chr1 78557514 G A 1.44E-06 Lymphocyte counts GIPC2 intron 22286170 rs718294 chr1 78564196 G A 3.35E-04 Alzheimer's disease GIPC2 intron 17998437 rs1022103 chr1 78589598 T C 2.43E-05 Personality dimensions GIPC2 intron 22628180 rs554298 chr1 78604614 G A 0.00000231 Sasang constitution (Soeum) / / 22394158 rs17101358 chr1 78605081 A G 3.74E-05 Multiple complex diseases / / 17554300 rs17391694 chr1 78623626 C T 6.82E-07 Lung adenocarcinoma / / 19836008 rs17391694 chr1 78623626 C T 2.00E-11 Height / / 20881960 rs17391694 chr1 78623626 C T 3.00E-09 Crohn's disease / / 23128233 rs1890850 chr1 78641967 G A 3.32E-05 Personality dimensions / / 22628180 rs17101475 chr1 78643674 C T 2.47E-04 Multiple complex diseases / / 17554300 rs4385660 chr1 78655779 G A 1.61E-05 Personality dimensions / / 22628180 rs11162429 chr1 78665643 A G 3.30E-05 Personality dimensions / / 22628180 rs12406019 chr1 78678130 A G 6.87E-04 Multiple complex diseases / / 17554300 rs2882801 chr1 78717850 G A 1.78E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) MGC27382 intron 24023788 rs10489948 chr1 78747540 T C 6.42E-04 Multiple complex diseases MGC27382 intron 17554300 rs6424762 chr1 78749908 C A 8.92E-04 Multiple complex diseases MGC27382 intron 17554300 rs6424762 chr1 78749908 C A 1.70E-05 Asthma MGC27382 intron 22561531 rs2882802 chr1 78762998 A G 2.45E-04 Birth weight MGC27382 intron 17255346 rs2104621 chr1 78772009 G C 2.15E-06 Serum metabolites MGC27382 intron 19043545 rs7545762 chr1 78772285 T A 8.88E-04 Type 2 diabetes MGC27382 intron 17463246 rs12064888 chr1 78805511 A G 5.30E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) MGC27382 intron 24236485 rs648425 chr1 78887208 T C 8.00E-07 Systolic blood pressure (alcohol consumption interaction) / / 24376456 rs674345 chr1 78894934 C T 6.87E-04 Alzheimer's disease / / 22005930 rs3753380 chr1 78956432 T C 1 Drug response to Latanoprost / / 17467803 rs3766354 chr1 78957550 G A 5.00E-04 Myocardial infarction PTGFR intron 21107343 rs1575397 chr1 78977962 G C 3.23E-04 Smoking initiation PTGFR intron 24665060 rs672561 chr1 78987302 T C 9.00E-06 IgG glycosylation PTGFR intron 23382691 rs3766345 chr1 78990275 C G 7.19E-05 Orofacial clefts PTGFR intron 22419666 rs473027 chr1 78992202 A G 8.44E-04 Multiple complex diseases PTGFR intron 17554300 rs473027 chr1 78992202 A G 7.12E-05 Serum metabolites PTGFR intron 19043545 rs1265663 chr1 78997913 C T 0.000000744 Triglycerides PTGFR intron 23063622 rs12060353 chr1 79001920 T G 7.28E-04 Coronary heart disease PTGFR intron 21606135 rs3766332 chr1 79001994 A T 2.90E-04 Multiple complex diseases PTGFR intron 17554300 rs3766332 chr1 79001994 A T 0.00028 Coronary artery calcification PTGFR intron 23727086 rs12074883 chr1 79002544 C T 2.94E-04 Coronary heart disease PTGFR UTR-3 21606135 rs12737480 chr1 79036992 C T 4.00E-05 Lung cancer / / 18978790 rs6424779 chr1 79041520 C T 8.00E-05 Lung cancer / / 18978790 rs3820093 chr1 79095526 G A 1.07E-05 Amyotrophic Lateral Sclerosis IFI44L missense 17827064 rs1981071 chr1 79102726 C T 2.50E-04 Amyotrophic Lateral Sclerosis IFI44L missense 17827064 rs273252 chr1 79106899 T C 8.93E-06 Serum metabolites IFI44L intron 19043545 rs4650590 chr1 79110518 A G 5.21E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) IFI44L UTR-3 23648065 rs1333971 chr1 79133774 C T 3.49E-04 Multiple complex diseases / / 17554300 rs4650376 chr1 79176868 C T 2.00E-06 IgG glycosylation / / 23382691 rs1033999 chr1 79211929 C T 9.86E-05 Waist-Hip Ratio / / pha003013 rs1033999 chr1 79211929 C T 3.58E-05 Waist-Hip Ratio / / pha003028 rs1751529 chr1 79214489 G A 9.12E-05 Waist-Hip Ratio / / pha003013 rs1751529 chr1 79214489 G A 3.30E-05 Waist-Hip Ratio / / pha003028 rs12133510 chr1 79221675 A G 2.31E-04 Coronary heart disease / / 21606135 rs10493613 chr1 79223199 T C 8.88E-05 Waist-Hip Ratio / / pha003028 rs1937023 chr1 79225626 C T 8.18E-05 Waist-Hip Ratio / / pha003028 rs1937020 chr1 79227956 C T 4.00E-06 Anorexia nervosa / / 23568457 rs4650608 chr1 79238015 T C 5.42E-04 Multiple complex diseases / / 17554300 rs4650608 chr1 79238015 T C 8.00E-09 Bipolar disorder / / 22182935 rs4650608 chr1 79238015 T C 8.49E-07 Major depressive disorder / / 22472876 rs4650608 chr1 79238015 T C 1.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs4650608 chr1 79238015 T C 0.000206 Schizophrenia / / 23637625 rs4650608 chr1 79238015 T C 1.22E-05 Bipolar disorder and schizophrenia / / 24280982 rs4650608 chr1 79238015 T C 1.77E-04 Bipolar disorder and schizophrenia / / 24280982 rs4650608 chr1 79238015 T C 8.00E-09 Bipolar disorder and schizophrenia / / 24280982 rs10873996 chr1 79246505 G A 8.11E-05 Waist-Hip Ratio / / pha003013 rs10873996 chr1 79246505 G A 9.80E-05 Waist-Hip Ratio / / pha003028 rs12730292 chr1 79254762 C G 5.00E-06 Bipolar disorder / / 21926972 rs10873998 chr1 79263805 T C 4.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs12034709 chr1 79272660 T C 9.31E-04 Myocardial Infarction / / pha002883 rs1937028 chr1 79277854 T C 7.00E-04 Parkinson's disease / / 17052657 rs12136365 chr1 79288819 T C 7.64E-05 Serum metabolites / / 19043545 rs12044353 chr1 79295415 G A 7.09E-05 Serum metabolites / / 19043545 rs2352513 chr1 79295552 A G,T 6.22E-05 Serum metabolites / / 19043545 rs6694893 chr1 79299115 T A 9.50E-05 Serum metabolites / / 19043545 rs6694893 chr1 79299115 T A 6.30E-04 Coronary heart disease / / 21606135 rs6680564 chr1 79300939 A C 7.80E-05 Serum metabolites / / 19043545 rs6680564 chr1 79300939 A C 5.40E-04 Coronary heart disease / / 21606135 rs12026347 chr1 79303750 C T 8.83E-04 Coronary heart disease / / 21606135 rs1248482 chr1 79319633 T A 4.25E-05 Serum metabolites / / 19043545 rs1248482 chr1 79319633 T A 6.67E-06 Recombination rate / / 21698098 rs1780731 chr1 79336024 C T 6.34E-05 Serum metabolites / / 19043545 rs2996691 chr1 79336607 T G 9.84E-05 Body Mass Index / / pha003020 rs2882958 chr1 79353290 A G 2.80E-05 Urinary metabolites / / 21572414 rs10518589 chr1 79353515 A T 2.40E-05 Self-reported allergy / / 23817569 rs17411879 chr1 79358211 A C 3.75E-05 Serum metabolites ELTD1 intron 19043545 rs17411879 chr1 79358211 A C 3.52E-04 Coronary heart disease ELTD1 intron 21606135 rs3811438 chr1 79403450 T C 1.68E-04 Arthritis (juvenile idiopathic) ELTD1 intron 22354554 rs12029928 chr1 79437368 C T 1.20E-04 Arthritis (juvenile idiopathic) ELTD1 intron 22354554 rs1352556 chr1 79460634 C G 1.10E-05 Urinary metabolites ELTD1 intron 21572414 rs1352556 chr1 79460634 C G 9.26E-04 Coronary heart disease ELTD1 intron 21606135 rs17406957 chr1 79500085 T C 4.81E-04 Type 2 diabetes / / 17463246 rs6687262 chr1 79509109 T C 2.00E-06 IgG glycosylation / / 23382691 rs6687262 chr1 79509109 T C 4.00E-07 IgG glycosylation / / 23382691 rs6687262 chr1 79509109 T C 5.00E-07 IgG glycosylation / / 23382691 rs17131734 chr1 79520923 T C 8.83E-04 Multiple complex diseases / / 17554300 rs1332829 chr1 79543571 C A 8.71E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17408443 chr1 79583385 T C 5.24E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs11162635 chr1 79587564 A G 8.66E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs228465 chr1 79613934 T C 3.93E-04 Multiple complex diseases / / 17554300 rs228563 chr1 79646219 C A 7.50E-04 Type 2 diabetes / / 17463246 rs228563 chr1 79646219 C A 2.73E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs41416051 chr1 79646680 A T 1.72E-04 Multiple complex diseases / / 17554300 rs7529406 chr1 79682535 A C 6.13E-05 Chronic obstructive pulmonary disease / / 19300482 rs12027718 chr1 79836598 C T 2.40E-05 Major depressive disorder (broad) / / 20038947 rs11811462 chr1 79839129 A G 2.36E-05 Major depressive disorder (broad) / / 20038947 rs3015033 chr1 79847236 G A 2.27E-05 Major depressive disorder (broad) / / 20038947 rs3015042 chr1 79851769 C T 2.20E-05 Major depressive disorder (broad) / / 20038947 rs3015046 chr1 79853343 G A 2.13E-05 Major depressive disorder (broad) / / 20038947 rs3015049 chr1 79853708 G A 2.10E-05 Major depressive disorder (broad) / / 20038947 rs3015063 chr1 79856108 A G 1.98E-05 Major depressive disorder (broad) / / 20038947 rs3015065 chr1 79856314 A G 1.96E-05 Major depressive disorder (broad) / / 20038947 rs3000157 chr1 79858023 T A 4.91E-05 Major depressive disorder (broad) / / 20038947 rs12030324 chr1 79861842 G A 2.10E-05 Major depressive disorder (broad) / / 20038947 rs3000162 chr1 79864610 C T 2.26E-05 Major depressive disorder (broad) / / 20038947 rs3000165 chr1 79870833 G A 2.81E-05 Major depressive disorder (broad) / / 20038947 rs3000166 chr1 79873161 C T 2.92E-05 Major depressive disorder (broad) / / 20038947 rs12046087 chr1 79886246 C A 3.34E-05 Major depressive disorder (broad) / / 20038947 rs12039488 chr1 79892025 G A 3.45E-05 Major depressive disorder (broad) / / 20038947 rs12041009 chr1 79896125 T C 3.49E-05 Major depressive disorder (broad) / / 20038947 rs3000140 chr1 80000648 G T 2.00E-06 Obesity-related traits / / 23251661 rs11162772 chr1 80116138 A G 6.89E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6698618 chr1 80129920 C T 1.35E-05 Bipolar disorder and schizophrenia / / 20889312 rs7533906 chr1 80134123 C T 4.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs6681417 chr1 80147123 G A 3.78E-05 Bipolar disorder and schizophrenia / / 20889312 rs11162785 chr1 80148857 T G 9.31E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1479739 chr1 80150038 A T 3.97E-05 Bipolar disorder and schizophrenia / / 20889312 rs12076080 chr1 80150181 T C 1.41E-05 Bipolar disorder and schizophrenia / / 20889312 rs10874059 chr1 80150246 G A 2.77E-05 Bipolar disorder and schizophrenia / / 20889312 rs1524174 chr1 80159221 A C 2.47E-05 Attention deficit hyperactivity disorder / / 20732627 rs722589 chr1 80174338 C G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs12569151 chr1 80176139 A G 3.30E-05 Monocyte chemoattractant protein-1 / / pha003071 rs1317042 chr1 80177985 C T 3.03E-04 Hearing function / / 17255346 rs1524183 chr1 80179889 G A,C 8.63E-05 Schizophrenia / / 19571809 rs1524183 chr1 80179889 G A,C 1.09E-05 Bipolar disorder and schizophrenia / / 20889312 rs1524183 chr1 80179889 G A,C 4.82E-05 Schizophrenia / / pha002857 rs6424669 chr1 80190866 G C 1.60E-05 Attention deficit hyperactivity disorder / / 20732627 rs6424669 chr1 80190866 G C 2.55E-05 Bipolar disorder and schizophrenia / / 20889312 rs7539380 chr1 80192565 A T 6.02E-05 Personality dimensions / / 18957941 rs6672282 chr1 80199565 G A 5.93E-05 Schizophrenia / / 19571809 rs6672282 chr1 80199565 G A 5.49E-06 Attention deficit hyperactivity disorder / / 20732627 rs6672282 chr1 80199565 G A 3.44E-05 Bipolar disorder and schizophrenia / / 20889312 rs10874067 chr1 80207766 A T 2.90E-05 Bipolar disorder and schizophrenia / / 20889312 rs7543390 chr1 80218574 A C 1.06E-05 Attention deficit hyperactivity disorder / / 20732627 rs7543390 chr1 80218574 A C 7.31E-06 Bipolar disorder and schizophrenia / / 20889312 rs1464732 chr1 80220979 A C 4.90E-05 Schizophrenia / / 19571809 rs1464732 chr1 80220979 A C 5.47E-05 Bipolar disorder and schizophrenia / / 20889312 rs7517325 chr1 80226910 G T 8.25E-05 Hearing function / / 17255346 rs3927739 chr1 80233281 C T 9.89E-05 Schizophrenia / / 19571809 rs3927739 chr1 80233281 C T 5.97E-05 Bipolar disorder and schizophrenia / / 20889312 rs12024204 chr1 80243001 A G 6.00E-06 Endometriosis / / 21151130 rs1568764 chr1 80258075 G A 5.63E-04 Smoking quantity / / 24665060 rs1916849 chr1 80267607 G A 6.01E-05 Glucose levels / / pha003058 rs1880268 chr1 80269886 A G 0.000705 Height (Pygmy height) / / 22570615 rs12046936 chr1 80271579 C T 9.02E-05 Personality dimensions / / 18957941 rs11162826 chr1 80276868 C T 5.94E-04 Smoking quantity / / 24665060 rs11577790 chr1 80277272 C A 4.63E-04 Premature ovarian failure / / 19508998 rs12744944 chr1 80278733 G A 2.67E-06 Post-operative nausea and vomiting / / 21694509 rs12744944 chr1 80278733 G A 9.60E-06 Endometriosis / / 23104006 rs7523939 chr1 80285992 C T 4.01E-05 Schizophrenia / / 20832056 rs12024531 chr1 80287742 C T 4.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs11162830 chr1 80289838 G T 3.29E-04 Schizophrenia / / 20832056 rs6424675 chr1 80324850 A G 9.98E-05 Schizophrenia / / 19571809 rs6424675 chr1 80324850 A G 1.31E-05 Bipolar disorder and schizophrenia / / 20889312 rs1830893 chr1 80361955 G T 2.65E-04 Multiple complex diseases / / 17554300 rs10493640 chr1 80365091 A T 1.95E-04 Multiple complex diseases / / 17554300 rs1325203 chr1 80369991 A G 7.44E-05 Multiple complex diseases / / 17554300 rs12123414 chr1 80384756 G A 8.67E-29 Narcolepsy / / 19629137 rs7518019 chr1 80388657 A G 0.00013 Cognitive impairment (no dementia) / / 23042215 rs12085600 chr1 80416562 A G 5.61E-04 Multiple complex diseases / / 17554300 rs7524563 chr1 80416987 G T 1.20E-04 Scoliosis / / 21216876 rs12031699 chr1 80435627 C T 2.98E-06 Scoliosis / / 21216876 rs17104170 chr1 80441636 A T 9.83E-04 Multiple complex diseases / / 17554300 rs2050470 chr1 80452405 T C 1.40E-06 Urinary metabolites / / 21572414 rs12085038 chr1 80460168 C T 6.33E-06 Obesity-related traits / / 23251661 rs1041705 chr1 80463537 T G 1.20E-05 Urinary metabolites / / 21572414 rs10493631 chr1 80477880 T C 5.00E-06 Obesity-related traits / / 23251661 rs1340682 chr1 80483406 A G 7.82E-05 Lactate dehydrogenase levels / / 20981236 rs4650447 chr1 80484171 A G 5.21E-04 Multiple complex diseases / / 17554300 rs10493658 chr1 80513706 A C 4.41E-04 Multiple complex diseases / / 17554300 rs10518631 chr1 80513790 A G 3.29E-06 Multiple complex diseases / / 17554300 rs12120142 chr1 80513847 T C 2.14E-04 Multiple complex diseases / / 17554300 rs7549131 chr1 80514496 A G 2.12E-04 Multiple complex diseases / / 17554300 rs6424682 chr1 80514544 G T 2.57E-04 Multiple complex diseases / / 17554300 rs6424683 chr1 80514574 T C 3.66E-04 Multiple complex diseases / / 17554300 rs6699236 chr1 80514706 T C 2.70E-06 Multiple complex diseases / / 17554300 rs6699329 chr1 80514773 T C 2.83E-04 Multiple complex diseases / / 17554300 rs12123981 chr1 80515241 G A 1.75E-04 Multiple complex diseases / / 17554300 rs10493660 chr1 80531263 A G 3.06E-04 Multiple complex diseases / / 17554300 rs981126 chr1 80531794 T A 2.09E-06 Multiple complex diseases / / 17554300 rs1572349 chr1 80537217 A G 2.48E-06 Multiple complex diseases / / 17554300 rs1572349 chr1 80537217 A G 8.93E-04 Premature ovarian failure / / 19508998 rs1414411 chr1 80538189 T C 5.20E-05 Malaria / / 19465909 rs6424687 chr1 80542078 G A 0.0000686 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10782716 chr1 80544581 A G 1.13E-04 Multiple complex diseases / / 17554300 rs12087239 chr1 80552566 T G 1.60E-05 Urinary metabolites / / 21572414 rs6658821 chr1 80562482 T A 6.50E-04 Multiple complex diseases / / 17554300 rs6658821 chr1 80562482 T A 1.60E-07 Urinary metabolites / / 21572414 rs11162922 chr1 80572058 A G 1.80E-06 Multiple complex diseases / / 17554300 rs12401477 chr1 80582021 A C 1.30E-07 Urinary metabolites / / 21572414 rs4384179 chr1 80586993 G A 1.09E-05 Premature ovarian failure / / 19508998 rs4384179 chr1 80586993 G A 1.09E-05 Other erythrocyte phenotypes / / 19862010 rs11162928 chr1 80588364 C T 3.70E-06 Urinary metabolites / / 21572414 rs12119851 chr1 80589958 A C 6.40E-06 Urinary metabolites / / 21572414 rs7512762 chr1 80596275 C A 1.09E-04 Multiple complex diseases / / 17554300 rs4471217 chr1 80596899 A G 4.20E-06 Urinary metabolites / / 21572414 rs6673937 chr1 80606877 C T 7.75E-04 Multiple complex diseases / / 17554300 rs6686600 chr1 80606901 A G 7.20E-06 Urinary metabolites / / 21572414 rs12144259 chr1 80608086 C T 4.60E-06 Urinary metabolites / / 21572414 rs7544729 chr1 80613215 A G 7.56E-04 Premature ovarian failure / / 19508998 rs12407162 chr1 80613801 T C 2.80E-06 Urinary metabolites / / 21572414 rs11162943 chr1 80619109 C T 6.22E-05 Multiple complex diseases / / 17554300 rs10874118 chr1 80638947 G A 8.25E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4503307 chr1 80641525 C T 1.30E-05 Lung adenocarcinoma / / 22797724 rs7521092 chr1 80644813 C A 1.48E-04 Multiple complex diseases / / 17554300 rs17104471 chr1 80653552 A G 2.70E-06 Lung adenocarcinoma / / 22797724 rs10493661 chr1 80659055 G A 2.80E-05 Lung adenocarcinoma / / 22797724 rs12044546 chr1 80670378 C T 2.00E-05 Urinary metabolites / / 21572414 rs3014989 chr1 80710753 A T 3.10E-06 Urinary metabolites / / 21572414 rs1418818 chr1 80711659 T C 2.80E-06 Urinary metabolites / / 21572414 rs1687816 chr1 80734553 T A 1.30E-05 Urinary metabolites / / 21572414 rs11162963 chr1 80734581 C T 4.00E-06 Aging (time to event) / / 21782286 rs1954338 chr1 80741675 A G 5.09E-04 Parkinson's disease / / 17052657 rs1776286 chr1 80741898 C A 2.80E-05 Urinary metabolites / / 21572414 rs41338944 chr1 80793418 T C 1.95E-05 Multiple complex diseases / / 17554300 rs35020936 chr1 80804503 A G 2.12E-05 Multiple complex diseases / / 17554300 rs2389026 chr1 80811353 C G 2.52E-05 Multiple complex diseases / / 17554300 rs1781780 chr1 80825325 T C 8.37E-04 Multiple complex diseases / / 17554300 rs2997195 chr1 80838880 C T 3.85E-05 Cognitive impairment induced by topiramate / / 22091778 rs1896250 chr1 80857194 G A 7.89E-10 Multiple complex diseases / / 17554300 rs1549556 chr1 80858494 C T 6.11E-04 Multiple complex diseases / / 17554300 rs6424701 chr1 80867299 A T 9.99E-05 Multiple complex diseases / / 17554300 rs6677470 chr1 80869792 A G 5.81E-04 Smoking initiation / / 24665060 rs17390593 chr1 80876340 C A 2.59E-04 Multiple complex diseases / / 17554300 rs3909721 chr1 80877080 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1896251 chr1 80888808 C T 7.62E-05 Cognitive performance / / 19734545 rs12118390 chr1 80911114 G A 3.00E-07 Estradiol plasma levels (breast cancer) / / 23518928 rs718003 chr1 80956319 T C 5.05E-04 Alzheimer's disease / / 24755620 rs12022941 chr1 80984672 A G 2.90E-04 Multiple complex diseases / / 17554300 rs12026235 chr1 80992047 T C 5.27E-04 Multiple complex diseases / / 17554300 rs11163043 chr1 81002200 A G 6.50E-05 Multiple complex diseases / / 17554300 rs12080797 chr1 81014137 T C 1.50E-05 Urinary metabolites / / 21572414 rs10493664 chr1 81024403 T C 2.50E-04 Sarcoidosis / / 19165924 rs11163056 chr1 81039056 G A 1.82E-04 Alzheimer's disease / / 17998437 rs10874143 chr1 81042755 A C 1.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10493672 chr1 81111793 G T 1.99E-04 Multiple complex diseases / / 17554300 rs7542755 chr1 81130780 G A 9.20E-05 Body Mass Index / / pha002896 rs17105337 chr1 81143088 T C 0.000843 Salmonella-induced pyroptosis / / 22837397 rs952756 chr1 81150622 A G 3.20E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs841671 chr1 81156849 C T 4.22E-04 Self-reported allergy / / 23817569 rs5020501 chr1 81208897 G A,T 7.23E-05 Cognitive test performance / / 20125193 rs2389062 chr1 81212060 A C 8.59E-04 Body mass index / / 21701565 rs41340345 chr1 81305845 G A 4.78E-04 Coronary Artery Disease / / 17634449 rs1953745 chr1 81355884 T C 7.83E-04 Smoking quantity / / 24665060 rs4650355 chr1 81376282 C T 4.99E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12739375 chr1 81377308 A G 4.99E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10493682 chr1 81377571 G A 8.08E-04 Alzheimer's disease / / 17998437 rs10493682 chr1 81377571 G A 5.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1338129 chr1 81378256 C A 4.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1338128 chr1 81378292 A G 6.12E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10493683 chr1 81378769 G A 5.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10493684 chr1 81378929 C T 5.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2185044 chr1 81379082 T C 6.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2152988 chr1 81379238 C T 7.28E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2152988 chr1 81379238 C T 5.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1415929 chr1 81380131 T C 7.28E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1415929 chr1 81380131 T C 5.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1338127 chr1 81384148 C T 6.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1339118 chr1 81391273 T C,G 2.27E-04 Smoking initiation / / 24665060 rs1415936 chr1 81398439 C A 2.40E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1415935 chr1 81398711 A G 2.13E-04 Smoking initiation / / 24665060 rs10874182 chr1 81401098 C T 4.92E-04 Alcohol dependence / / 24277619 rs10874184 chr1 81401550 A G 1.27E-04 Smoking initiation / / 24665060 rs12751933 chr1 81404227 G A 1.34E-04 Smoking initiation / / 24665060 rs7515605 chr1 81430056 G A 3.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs6684037 chr1 81432941 G A 7.04E-04 Rheumatoid arthritis (ACPA-negative) / / 24532677 rs7537835 chr1 81433165 G A 4.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs7537835 chr1 81433165 G A 1.41E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6694777 chr1 81436522 G T 9.19E-05 Body Composition / / pha003012 rs1863618 chr1 81450244 G A 7.37E-04 Suicide attempts in bipolar disorder / / 21041247 rs1863618 chr1 81450244 G A 5.23E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs919139 chr1 81450754 C T 6.69E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10874192 chr1 81452990 G A 4.64E-04 Myopia (pathological) / / 21095009 rs11163177 chr1 81453334 T G 1.60E-05 Urinary metabolites / / 21572414 rs1426787 chr1 81453585 G T 3.07E-05 Body Composition / / pha003012 rs1426787 chr1 81453585 G T 4.34E-05 Body Mass Index / / pha003021 rs6424732 chr1 81455333 G C 4.72E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1030414 chr1 81468442 A G 4.94E-04 Stroke / / pha002886 rs17105836 chr1 81526130 A G 3.77E-04 Tourette syndrome / / 22889924 rs11583080 chr1 81530739 T C 3.86E-04 Aortic root size / / 21223598 rs672797 chr1 81560554 C A 4.20E-08 Type 1 diabetes / / 17632545 rs11163194 chr1 81578784 A G 8.34E-04 Alzheimer's disease / / 22005930 rs1195693 chr1 81579076 A G 1.50E-05 Urinary metabolites / / 21572414 rs1146408 chr1 81581873 C T 2.70E-05 Urinary metabolites / / 21572414 rs1195699 chr1 81583172 A G 2.10E-05 Urinary metabolites / / 21572414 rs12128534 chr1 81586357 G A 9.19E-04 Alzheimer's disease / / 22005930 rs1648692 chr1 81588340 G C 8.98E-04 Alzheimer's disease / / 22005930 rs1648690 chr1 81589935 G C 7.72E-04 Alzheimer's disease / / 22005930 rs1768400 chr1 81591135 A G 7.58E-04 Alzheimer's disease / / 22005930 rs1426788 chr1 81592062 T C 7.62E-04 Alzheimer's disease / / 22005930 rs1648689 chr1 81592929 C T 7.67E-04 Alzheimer's disease / / 22005930 rs1768395 chr1 81594126 T G 2.60E-05 Urinary metabolites / / 21572414 rs1752219 chr1 81597906 C T 7.33E-04 Alzheimer's disease / / 22005930 rs1768389 chr1 81598101 T C 2.60E-05 Urinary metabolites / / 21572414 rs1768388 chr1 81598364 A G 6.98E-04 Alzheimer's disease / / 22005930 rs1146414 chr1 81601170 G C 7.30E-04 Body mass index / / 21701565 rs1146414 chr1 81601170 G C 8.75E-04 Body mass index / / 21701565 rs1146416 chr1 81601541 C T 9.33E-04 Alzheimer's disease / / 22005930 rs17106034 chr1 81609864 C T 2.63E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1327712 chr1 81614826 A C 4.47E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1327712 chr1 81614826 A C 4.49E-05 Scoliosis / / 21216876 rs10493685 chr1 81622201 G A 1.60E-04 Type 2 diabetes / / 17846125 rs3898651 chr1 81622580 T G 4.13E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17106106 chr1 81624781 C T 3.96E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4120877 chr1 81656725 G T 3.66E-05 Cognitive performance / / 19734545 rs10874202 chr1 81688359 A G 4.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs4650518 chr1 81699270 C T 4.10E-07 Urinary metabolites / / 21572414 rs9645301 chr1 81704582 A T 1.00E-04 Type 2 diabetes / / 17463246 rs4650519 chr1 81720233 C A 7.46E-04 Multiple complex diseases / / 17554300 rs1547674 chr1 81745893 C T 8.79E-05 Multiple complex diseases / / 17554300 rs10782752 chr1 81755537 G A 3.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs10782752 chr1 81755537 G A 7.00E-04 Smoking initiation / / 24665060 rs1327613 chr1 81764583 T A 9.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12027847 chr1 81766037 G A 7.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs10158280 chr1 81768971 T C 9.39E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2182766 chr1 81796468 A G 9.14E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs111722172 chr1 81811786 G T 2.80E-11 Metabolite levels / / 22286219 rs11163267 chr1 81843506 T A,C 7.76E-04 Smoking initiation / / 24665060 rs10874238 chr1 81872593 G A 8.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs6681688 chr1 81881212 C T 8.74E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs4336893 chr1 81887417 T C 9.46E-04 Multiple complex diseases / / 17554300 rs4362026 chr1 81890814 T G 8.74E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs10782760 chr1 81896746 A G 6.93E-05 Serum metabolites / / 19043545 rs11163298 chr1 81924594 C T 2.15E-05 Type 2 diabetes / / 17463246 rs3924703 chr1 81944199 A G 0.000000068 Mean arterial pressure / / 22510845 rs12142040 chr1 81949079 A G 2.50E-05 Urinary metabolites / / 21572414 rs11163323 chr1 81986458 C T 0.000017 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 / / 21873659 rs11586072 chr1 81987161 C A 1.66E-04 Type 2 diabetes / / 17463246 rs17420488 chr1 81992020 G A 2.30E-05 Urinary metabolites / / 21572414 rs17454529 chr1 81995750 G A 3.74E-04 Multiple complex diseases / / 17554300 rs17454592 chr1 81996353 G A 5.60E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs17106650 chr1 81999759 G A 3.42E-05 Response to TNF antagonist treatment / / 21061259 rs12022306 chr1 82026353 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7532624 chr1 82029505 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1924558 chr1 82061064 T G 9.75E-05 Height / / 17255346 rs6671683 chr1 82068875 G C 1.54E-04 Multiple complex diseases / / 17554300 rs17456217 chr1 82073276 G C 4.44E-04 Multiple complex diseases / / 17554300 rs11809789 chr1 82074852 G A 6.00E-06 Bilirubin levels / / 22085899 rs17456431 chr1 82086743 G C 4.24E-04 Multiple complex diseases / / 17554300 rs17423111 chr1 82103535 G A 9.23E-04 Multiple complex diseases / / 17554300 rs12117862 chr1 82110055 T C 1.11E-04 Coronary heart disease / / 21606135 rs480304 chr1 82123485 C A 5.92E-04 Smoking quantity / / 24665060 rs561278 chr1 82132298 A C 3.13E-04 Smoking quantity / / 24665060 rs11578678 chr1 82168757 T C 7.18E-04 Body mass index / / 21701565 rs11163350 chr1 82170329 C T 2.85E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11163350 chr1 82170329 C T 3.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12732009 chr1 82175317 G T 4.33E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12732009 chr1 82175317 G T 4.87E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12129647 chr1 82182566 G A 4.83E-05 Intracerebral hemorrhage / / 24656865 rs9285611 chr1 82183055 C T 1.70E-05 Pulmonary function / / 17903307 rs9285611 chr1 82183055 C T 1.88E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs9324183 chr1 82195760 G T 6.10E-06 Height / / 17255346 rs9324183 chr1 82195760 G T 2.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12139644 chr1 82197327 G A 6.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1391475 chr1 82210952 T C 1.27E-04 IgE levels / / 17255346 rs1391475 chr1 82210952 T C 1.70E-05 Crohn's disease / / 20570966 rs9782905 chr1 82219539 A G 3.99E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs9324187 chr1 82225803 G T 1.77E-04 Response to TNF antagonist treatment / / 21061259 rs11163372 chr1 82247248 C T 3.00E-06 Temperament / / 22832960 rs1391478 chr1 82248794 A G 2.97E-04 Response to TNF antagonist treatment / / 21061259 rs1391478 chr1 82248794 A G 8.78E-04 Body mass index / / 21701565 rs371363 chr1 82349354 C T 2.80E-04 Type 2 diabetes and 6 quantitative traits LPHN2 intron 17848626 rs371363 chr1 82349354 C T 2.58E-06 Paclitaxel sensitivity in NCI60 cancer cell lines LPHN2 intron 21314952 rs12401346 chr1 82352612 T C 5.54E-04 Response to TNF antagonist treatment LPHN2 intron 21061259 rs1341260 chr1 82364661 T C 6.61E-04 Nicotine dependence LPHN2 intron 17158188 rs284227 chr1 82379446 C T 7.55E-05 Celiac disease LPHN2 intron 23936387 rs626085 chr1 82384574 C T 3.95E-04 Alzheimer's disease LPHN2 intron 22005930 rs993906 chr1 82390698 T C 1.89E-04 Alzheimer's disease LPHN2 intron 22005930 rs6681544 chr1 82398544 C T 6.00E-06 Metabolite levels (X-11787) LPHN2 intron 23934736 rs1475394 chr1 82412099 C T 9.31E-05 Triglycerides LPHN2 intron pha003080 rs385367 chr1 82415199 A G 7.65E-05 Celiac disease LPHN2 intron 23936387 rs1327022 chr1 82436281 G A 8.58E-04 Major depressive disorder LPHN2 intron 22472876 rs9438724 chr1 82438148 A C 7.56E-05 Celiac disease LPHN2 intron 23936387 rs10518658 chr1 82461630 T C 9.93E-05 Triglycerides / / pha003080 rs4970642 chr1 82465731 A G 2.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17472507 chr1 82479448 G A 4.27E-05 Triglycerides / / pha003080 rs4291539 chr1 82503816 C T 2.37E-05 Longevity / / 21612516 rs11163417 chr1 82517645 T C 3.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4486485 chr1 82526505 G C 2.60E-05 Urinary metabolites / / 21572414 rs11163422 chr1 82566070 A T 7.80E-04 Multiple complex diseases / / 17554300 rs10493708 chr1 82571186 A G 4.80E-04 Multiple complex diseases / / 17554300 rs17436254 chr1 82762033 A G 8.68E-06 Obesity-related traits / / 23251661 rs785584 chr1 82762700 T C 7.43E-06 Obesity-related traits / / 23251661 rs1770678 chr1 82765052 T C 7.00E-06 Obesity-related traits / / 23251661 rs11579674 chr1 82836557 A G 2.13E-04 Insulin resistance / / 21901158 rs11163467 chr1 82848122 C T 5.77E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs1290281 chr1 82857453 G A 3.95E-04 Multiple complex diseases / / 17554300 rs10437023 chr1 82901026 G A 9.60E-05 Parkinson's disease (familial) / / 18985386 rs10437024 chr1 82901264 A C 9.60E-05 Parkinson's disease (familial) / / 18985386 rs10437024 chr1 82901264 A C 2.02E-05 Parkinson's disease / / pha002868 rs2225083 chr1 82960385 G A 9.58E-04 Eye color / / 23118974 rs7523716 chr1 82964864 G T 4.52E-04 Alzheimer's disease / / 17998437 rs7537124 chr1 82964897 A T 4.89E-04 Alzheimer's disease / / 17998437 rs10747397 chr1 82965159 T C 5.18E-04 Alzheimer's disease / / 17998437 rs12745149 chr1 82991633 T C 7.89E-04 Body mass index / / 21701565 rs318422 chr1 83019476 A G 1.61E-04 Multiple complex diseases / / 17554300 rs11579295 chr1 83036341 A G 8.18E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs9729834 chr1 83039338 G A 4.73E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17108556 chr1 83052706 G A 1.91E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10874322 chr1 83054799 C T 2.00E-06 Response to taxane treatment (docetaxel) / / 23006423 rs1281400 chr1 83055625 C G 7.14E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2011057 chr1 83058155 C T 3.61E-05 Post-operative nausea and vomiting / / 21694509 rs2011057 chr1 83058155 C T 5.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11163526 chr1 83096605 A G 5.75E-04 Smoking initiation / / 24665060 rs1361196 chr1 83097024 T C 7.36E-05 Bipolar disorder / / 19488044 rs1416079 chr1 83097138 A G 1.09E-05 Bipolar disorder / / 19488044 rs1416078 chr1 83097228 T C 7.20E-05 Bipolar disorder / / 19488044 rs6604921 chr1 83098959 T C 1.57E-04 Alzheimer's disease (late onset) / / 21379329 rs17493817 chr1 83101655 A G 3.90E-05 Parkinson's disease (age of onset) / / 19772629 rs373905 chr1 83112722 C T 2.06E-05 Alcohol dependence / / 21703634 rs428943 chr1 83115057 A G 3.48E-04 Alzheimer's disease (late onset) / / 21379329 rs453456 chr1 83117369 G A 2.04E-05 Alcohol dependence / / 21703634 rs2787985 chr1 83118044 T G 4.62E-04 Alzheimer's disease (late onset) / / 21379329 rs2787985 chr1 83118044 T G 1.20E-05 Alcohol dependence / / 21703634 rs10874325 chr1 83118256 G C 5.37E-05 Serum metabolites / / 19043545 rs1433761 chr1 83132400 A C 9.33E-05 Alcohol dependence / / 21703634 rs3845616 chr1 83135055 A G 7.02E-04 Smoking cessation / / 24665060 rs12239057 chr1 83136159 C T 2.94E-04 Lung function (forced vital capacity) / / 24023788 rs10493722 chr1 83171994 C T 7.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs9324200 chr1 83172488 A G 4.10E-06 Erythrocyte counts / / pha003090 rs1469744 chr1 83173469 T C 2.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1469744 chr1 83173469 T C 3.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1469743 chr1 83178180 G T 5.92E-05 Alcohol dependence / / 21703634 rs12744723 chr1 83184129 C T 7.16E-05 Alcohol dependence / / 21703634 rs10493727 chr1 83188821 C T 4.51E-05 Alcohol dependence / / 21703634 rs1338361 chr1 83196421 T C 5.74E-05 Alcohol dependence / / 21703634 rs11588508 chr1 83202936 A G 5.61E-05 Alcohol dependence / / 21703634 rs11588936 chr1 83203139 T A 5.43E-05 Alcohol dependence / / 21703634 rs2060361 chr1 83204106 C T 7.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs17109039 chr1 83221252 G T 2.53E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11807023 chr1 83225779 C T 3.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs320909 chr1 83227702 T G 7.97E-04 Type 2 diabetes / / 17463246 rs11163566 chr1 83230397 C A 4.08E-04 Alzheimer's disease (late onset) / / 21379329 rs6429835 chr1 83231866 C T 3.79E-05 Alcohol dependence / / 21703634 rs17505362 chr1 83233401 G A 1.24E-04 Multiple complex diseases / / 17554300 rs6429839 chr1 83266863 G A 0.0000829 Tuberculosis with late age of onset / / 22551897 rs17109259 chr1 83291401 C A 1.37E-04 Multiple complex diseases / / 17554300 rs11163585 chr1 83311835 C T 9.00E-07 Response to antipsychotic treatment / / 20195266 rs1146366 chr1 83358442 G A 4.97E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1440447 chr1 83412781 T C 9.77E-04 Type 2 diabetes / / 17463246 rs4146730 chr1 83444431 G A 2.10E-05 Urinary metabolites / / 21572414 rs2289445 chr1 83451691 C T 3.57E-05 Smoking initiation / / 24665060 rs7556305 chr1 83464725 A G 3.58E-04 Stroke / / pha002886 rs6702898 chr1 83465825 C T 2.66E-04 Stroke / / pha002886 rs6668833 chr1 83473598 T C 1.05E-05 Bipolar disorder,affective / / 20528957 rs1930278 chr1 83486078 A G 4.47E-04 Celiac disease / / 23936387 rs12742923 chr1 83489844 C T 8.00E-07 HIV-associated dementia / / 22628157 rs10487981 chr1 83530267 T C 3.32E-04 Parkinson's disease / / 16252231 rs323973 chr1 83535877 C A 5.91E-04 Type 2 diabetes / / 17463246 rs323973 chr1 83535877 C A 9.10E-04 Multiple complex diseases / / 17554300 rs17344386 chr1 83541990 T C 4.71E-05 Parkinson's disease / / 16252231 rs323932 chr1 83553972 A C 6.14E-04 Type 2 diabetes / / 17463246 rs6684000 chr1 83554149 A G 6.14E-04 Type 2 diabetes / / 17463246 rs6684000 chr1 83554149 A G 9.97E-04 Multiple complex diseases / / 17554300 rs6684000 chr1 83554149 A G 5.99E-04 Sarcoidosis / / 19165924 rs537877 chr1 83572881 G T 4.97E-05 Cognitive test performance / / 20125193 rs11163687 chr1 83665119 A G 3.60E-08 Glioma (high-grade) / / 19578366 rs11163695 chr1 83701382 A C 2.66E-04 Alzheimer's disease (late onset) / / 21379329 rs12403322 chr1 83701728 A G 8.36E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2077053 chr1 83716959 C T 1.10E-05 Iron levels / / 21208937 rs11163719 chr1 83792651 G A 4.27E-04 Multiple complex diseases / / 17554300 rs4907021 chr1 83857369 G A 9.77E-06 Bipolar disorder and schizophrenia / / 20889312 rs2260390 chr1 83871950 G A 3.22E-05 Bipolar disorder and schizophrenia / / 20889312 rs17130039 chr1 83964564 T A,G 9.73E-05 Multiple complex diseases / / 17554300 rs3861696 chr1 83975531 G A 7.38E-05 Coronary heart disease / / pha003032 rs10493740 chr1 83989898 G T 3.55E-04 Heart Failure / / pha002884 rs4142781 chr1 84024341 C T 8.85E-04 Multiple complex diseases / / 17554300 rs12097883 chr1 84059930 C T 5.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs4363435 chr1 84067452 G A 5.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11163783 chr1 84086070 T C 3.91E-04 Acute lung injury / / 22295056 rs10874398 chr1 84088645 G C 6.56E-04 Acute lung injury / / 22295056 rs6695005 chr1 84091702 G C 6.01E-04 Acute lung injury / / 22295056 rs11163786 chr1 84093452 A G 6.25E-04 Acute lung injury / / 22295056 rs10874400 chr1 84094265 G A 9.91E-04 Acute lung injury / / 22295056 rs12563303 chr1 84094411 G A 9.91E-04 Acute lung injury / / 22295056 rs12562642 chr1 84094604 T C 9.91E-04 Acute lung injury / / 22295056 rs12562651 chr1 84094868 A G 9.91E-04 Acute lung injury / / 22295056 rs11163788 chr1 84095392 C A 9.73E-04 Acute lung injury / / 22295056 rs11163794 chr1 84111016 T C 6.16E-04 Acute lung injury / / 22295056 rs11163795 chr1 84111208 C G 6.16E-04 Acute lung injury / / 22295056 rs8179422 chr1 84111398 C G 6.29E-04 Acute lung injury / / 22295056 rs8179462 chr1 84111468 T C 6.74E-04 Acute lung injury / / 22295056 rs4907033 chr1 84111799 T A 3.81E-04 Acute lung injury / / 22295056 rs4457599 chr1 84112891 G A 1.77E-05 Alzheimer's disease / / 21098978 rs4457599 chr1 84112891 G A 6.44E-04 Acute lung injury / / 22295056 rs4539154 chr1 84113159 G A 1.76E-05 Alzheimer's disease / / 21098978 rs2068611 chr1 84113646 C T 1.75E-05 Alzheimer's disease / / 21098978 rs4907035 chr1 84114899 A T 2.74E-07 Alzheimer's disease / / 21098978 rs4907035 chr1 84114899 A T 9.23E-04 Acute lung injury / / 22295056 rs12035245 chr1 84115574 T C 8.85E-04 Acute lung injury / / 22295056 rs12566397 chr1 84116576 G A 9.46E-04 Acute lung injury / / 22295056 rs10218575 chr1 84123370 G C 6.90E-04 Multiple complex diseases / / 17554300 rs17577039 chr1 84204198 A G 2.90E-05 HIV-1 control / / 20041166 rs6683294 chr1 84218373 G A 2.90E-05 HIV-1 control / / 20041166 rs17129137 chr1 84219787 C T 8.60E-05 Tunica Media / / pha003038 rs17129251 chr1 84228589 G A 3.49E-04 Alzheimer's disease / / 24755620 rs17129289 chr1 84232748 T C 7.00E-06 Obesity-related traits / / 23251661 rs11163843 chr1 84252434 C A 9.36E-04 Multiple complex diseases / / 17554300 rs7552393 chr1 84254551 A G 5.00E-07 Select biomarker traits / / 17903293 rs7539409 chr1 84254735 G A 1.00E-06 Alzheimer's Disease / / 20061627 rs6676587 chr1 84276429 T C 6.81E-04 Multiple complex diseases / / 17554300 rs2179763 chr1 84295861 A G 9.54E-04 Tourette syndrome / / 22889924 rs970457 chr1 84296540 C T 5.41E-04 Depression (quantitative trait) / / 20800221 rs3738575 chr1 84296983 A G 5.35E-04 Tourette syndrome / / 22889924 rs932448 chr1 84308491 C T 8.02E-04 Alzheimer's disease / / 24755620 rs6576951 chr1 84312493 T C 2.80E-05 Urinary metabolites / / 21572414 rs6692233 chr1 84327214 G A 1.02E-04 Multiple complex diseases / / 17554300 rs12118434 chr1 84328629 G A 5.58E-05 Multiple complex diseases / / 17554300 rs2024591 chr1 84329235 C T 1.95E-05 Multiple complex diseases / / 17554300 rs11163862 chr1 84355418 T A 2.39E-04 Multiple complex diseases TTLL7 intron 17554300 rs12142944 chr1 84380880 C T 9.72E-04 Suicide attempts in bipolar disorder TTLL7 intron 21423239 rs10465746 chr1 84387632 T G 8.00E-06 Obesity-related traits TTLL7 intron 23251661 rs481354 chr1 84409393 G C 2.60E-04 Multiple complex diseases TTLL7 intron 17554300 rs7551787 chr1 84419297 T C 2.47E-04 Multiple complex diseases TTLL7 intron 17554300 rs4907191 chr1 84444165 G A 6.37E-05 Multiple complex diseases TTLL7 intron 17554300 rs10493743 chr1 84444412 T C 8.53E-04 Suicide attempts in bipolar disorder TTLL7 intron 21423239 rs10493744 chr1 84444752 T C 7.32E-05 Multiple complex diseases TTLL7 intron 17554300 rs12042443 chr1 84444766 G A 4.67E-04 Multiple complex diseases TTLL7 intron 17554300 rs1886769 chr1 84471134 C A 0.00003 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer / / 21245432 rs11163887 chr1 84474718 G A 6.01E-04 Multiple complex diseases / / 17554300 rs955524 chr1 84490456 G A 2.42E-04 Multiple complex diseases / / 17554300 rs669110 chr1 84498812 G A 2.40E-04 Multiple complex diseases / / 17554300 rs626376 chr1 84516043 T C 5.23E-04 Multiple complex diseases / / 17554300 rs810915 chr1 84516349 A C 6.50E-04 Multiple complex diseases / / 17554300 rs1811643 chr1 84527291 G A 3.61E-04 Multiple complex diseases / / 17554300 rs2892811 chr1 84527394 T C 9.18E-04 Multiple complex diseases / / 17554300 rs663521 chr1 84530053 T G 4.03E-04 Multiple complex diseases / / 17554300 rs12031680 chr1 84535297 C A 6.81E-04 Multiple complex diseases / / 17554300 rs1565823 chr1 84576620 G A 1.00E-04 Cognitive impairment induced by topiramate PRKACB intron 22091778 rs1016379 chr1 84590129 A G 2.21E-04 Multiple complex diseases PRKACB intron 17554300 rs12723299 chr1 84590315 C T 3.33E-04 Multiple complex diseases PRKACB intron 17554300 rs2139931 chr1 84590527 A G 2.01E-04 Multiple complex diseases PRKACB intron 17554300 rs11163905 chr1 84594399 G A 6.49E-04 Multiple complex diseases PRKACB intron 17554300 rs903263 chr1 84622513 G T 1.00E-06 Breast cancer (male) PRKACB intron 23001122 rs1057738 chr1 84670816 A C 3.88E-05 Cognitive impairment induced by topiramate PRKACB UTR-3 22091778 rs12088543 chr1 84717983 T C 3.31E-05 Male fertility / / 22633400 rs606816 chr1 84720376 C A 1.01E-06 Monocyte counts / / pha003089 rs621750 chr1 84721408 G A 1.01E-06 Monocyte counts / / pha003089 rs11163933 chr1 84728627 C T 9.04E-05 Male fertility / / 22633400 rs11163934 chr1 84728697 C A 3.49E-05 Male fertility / / 22633400 rs12047850 chr1 84729134 A C 3.46E-05 Type 2 diabetes / / 17463246 rs316672 chr1 84743949 T G 1.00E-05 Cognitive impairment induced by topiramate / / 22091778 rs316672 chr1 84743949 T G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs316672 chr1 84743949 T G 6.76E-05 Cognitive impairment induced by topiramate / / 22091778 rs316669 chr1 84745099 A G 1.52E-06 Cognitive impairment induced by topiramate / / 22091778 rs316669 chr1 84745099 A G 1.74E-06 Cognitive impairment induced by topiramate / / 22091778 rs316669 chr1 84745099 A G 2.34E-05 Cognitive impairment induced by topiramate / / 22091778 rs316669 chr1 84745099 A G 2.47E-06 Cognitive impairment induced by topiramate / / 22091778 rs1983077 chr1 84745373 G A 2.40E-05 Cognitive impairment induced by topiramate / / 22091778 rs1983077 chr1 84745373 G A 2.42E-06 Cognitive impairment induced by topiramate / / 22091778 rs1983077 chr1 84745373 G A 3.57E-06 Cognitive impairment induced by topiramate / / 22091778 rs1983077 chr1 84745373 G A 6.14E-06 Cognitive impairment induced by topiramate / / 22091778 rs17373911 chr1 84745603 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6697296 chr1 84759975 C A 2.42E-04 Multiple complex diseases / / 17554300 rs1085093 chr1 84761348 T C 3.00E-06 Metabolic syndrome / / 20694148 rs316662 chr1 84787312 A C 4.46E-07 Obesity-related traits SAMD13 intron 23251661 rs315553 chr1 84792973 G T 4.00E-06 Obesity-related traits SAMD13 intron 23251661 rs315540 chr1 84816587 A C 6.96E-06 Obesity-related traits / / 23251661 rs315535 chr1 84820409 C T 6.62E-05 Major depressive disorder (broad) / / 20038947 rs315535 chr1 84820409 C T 7.38E-06 Obesity-related traits / / 23251661 rs17478556 chr1 84852123 G C 1.02E-05 Bipolar disorder UOX intron 19488044 rs17478556 chr1 84852123 G C 2.93E-05 Bipolar Disorder UOX intron pha002863 rs12752696 chr1 84856633 C T 8.23E-05 Brain derived neurotrophic factor levels,in serum UOX intron 22047184 rs621869 chr1 84856784 T C 5.85E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) UOX intron 24192120 rs10082174 chr1 84859152 C G 6.92E-05 Brain derived neurotrophic factor levels,in serum UOX intron 22047184 rs12144715 chr1 84865230 A T 7.00E-06 Response to hepatitis C treatment D/SE2B intron 22095909 rs634531 chr1 84866855 T C 2.33E-04 Obesity (extreme) D/SE2B intron 21935397 rs604708 chr1 84868961 T C 8.00E-06 IgG glycosylation D/SE2B intron 23382691 rs3116406 chr1 84874242 C G 7.83E-05 Obesity (extreme) D/SE2B intron 21935397 rs3768250 chr1 84880380 T C 9.21E-05 Obesity (extreme) D/SE2B cds-synon 21935397 rs1506702 chr1 84894055 T C 9.51E-05 Obesity (extreme) / / 21935397 rs1340596 chr1 84896033 C A 8.30E-05 Diabetic retinopathy / / 21441570 rs7514800 chr1 84896441 G A 1.04E-04 Obesity (extreme) / / 21935397 rs959363 chr1 84898321 A C 1.27E-04 Obesity (extreme) / / 21935397 rs10874441 chr1 84899304 G A 1.32E-04 Obesity (extreme) / / 21935397 rs1340598 chr1 84904099 T C 2.72E-04 Obesity (extreme) / / 21935397 rs10493746 chr1 84904279 G A 4.14E-04 Obesity (extreme) / / 21935397 rs4345821 chr1 84907970 T C 2.64E-04 Obesity (extreme) / / 21935397 rs12755232 chr1 84918056 A C 2.38E-04 Obesity (extreme) / / 21935397 rs12729133 chr1 84922553 C T 1.28E-04 Obesity (extreme) / / 21935397 rs7540794 chr1 84924179 A T 1.29E-04 Obesity (extreme) / / 21935397 rs2794217 chr1 84962577 T C 4.30E-05 Intracerebral hemorrhage RPF1 intron 24656865 rs2659173 chr1 84981405 T A 4.78E-05 Intracerebral hemorrhage SPATA1 intron 24656865 rs17113057 chr1 85101762 C G 1.19E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17113057 chr1 85101762 C G 8.03E-04 Smoking quantity / / 24665060 rs2911613 chr1 85111124 C A 2.59E-05 Progressive supranuclear palsy SSX2IP UTR-3 21685912 rs818526 chr1 85198264 T C 8.16E-05 Monocyte counts / / pha003089 rs12744552 chr1 85216685 T C 5.17E-05 Orofacial clefts / / 20023658 rs1750491 chr1 85226299 T C 2.00E-06 Dental caries / / 23064961 rs1770566 chr1 85227586 A G 1.40E-06 Glioma (high-grade) / / 19578366 rs9661368 chr1 85234868 A G 3.15E-05 Personality dimensions / / 18957941 rs1620453 chr1 85234978 C A 7.58E-04 Body mass index / / 21701565 rs1417296 chr1 85236777 G T 1.17E-05 Personality dimensions / / 18957941 rs11576745 chr1 85240246 C T 9.13E-04 Alcohol dependence / / 21314694 rs11576745 chr1 85240246 C T 7.70E-05 Coronary heart disease / / pha003055 rs10782529 chr1 85268243 C T 4.00E-06 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy / / 23118302 rs10873658 chr1 85271091 C T 9.54E-04 Alzheimer's disease / / 22005930 rs4243771 chr1 85276032 A T 6.44E-04 Alzheimer's disease / / 22005930 rs9728717 chr1 85290409 T C 9.00E-06 Economic and political preferences (time) LPAR3 intron 22566634 rs11161467 chr1 85305197 A T 5.73E-04 Multiple complex diseases LPAR3 intron 17554300 rs1983853 chr1 85311192 C T 2.00E-06 Type 1 diabetes LPAR3 intron 18840781 rs12062882 chr1 85313108 C T 6.34E-04 Alzheimer's disease LPAR3 intron 24755620 rs4907103 chr1 85316840 G T 0.0000977 Schizophrenia LPAR3 intron 23637625 rs942683 chr1 85319741 C T 8.45E-04 Alzheimer's disease LPAR3 intron 22005930 rs942684 chr1 85319822 T C 8.50E-04 Alzheimer's disease LPAR3 intron 22005930 rs10873661 chr1 85328096 G A 6.11E-06 Coronary heart disease LPAR3 intron pha003055 rs1325273 chr1 85332120 T C 1.55E-05 Coronary heart disease LPAR3 intron pha003055 rs4243774 chr1 85356878 T C 2.00E-06 Smoking cessation LPAR3 intron 24665060 rs4579776 chr1 85357025 A G 8.64E-04 Type 2 diabetes LPAR3 intron 17463246 rs12057637 chr1 85392616 A C 1.94E-05 Personality dimensions MCOLN2 intron 18957941 rs12145073 chr1 85394258 T G 7.14E-06 Serum dimethylarginine levels (asymmetric) MCOLN2 intron 24159190 rs17117593 chr1 85398979 C T 7.77E-04 Type 2 diabetes MCOLN2 intron 17463246 rs1325277 chr1 85400114 C A 5.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) MCOLN2 intron 23648065 rs597630 chr1 85419947 T C 5.47E-05 Lymphocyte counts MCOLN2 intron 22286170 rs41383647 chr1 85426256 T C 2.60E-05 Urinary metabolites MCOLN2 intron 21572414 rs6576739 chr1 85468319 T G 3.22E-04 Lymphocyte counts / / 22286170 rs17119333 chr1 85485170 C G 5.30E-06 Urinary metabolites MCOLN3 intron 21572414 rs41461649 chr1 85509512 C T 2.60E-05 Urinary metabolites MCOLN3 intron 21572414 rs6576745 chr1 85529628 T C 1.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WDR63 intron 20877124 rs6695223 chr1 85531711 C T 3.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WDR63 intron 20877124 rs6695223 chr1 85531711 C T 5.00E-09 Venous thromboembolism (gene x gene interaction) WDR63 intron 23509962 rs17099213 chr1 85537706 T C 1.70E-05 Urinary metabolites WDR63 intron 21572414 rs17120570 chr1 85539127 G A 2.88E-04 Smoking initiation WDR63 intron 24665060 rs709764 chr1 85560264 G A 3.79E-05 Cognitive impairment induced by topiramate WDR63 intron 22091778 rs2050842 chr1 85582549 G A 4.60E-05 Diabetic retinopathy WDR63 intron 21441570 rs6576749 chr1 85583162 C G 4.60E-05 Diabetic retinopathy WDR63 intron 21441570 rs10873688 chr1 85605433 C T 3.26E-12 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10873688 chr1 85605433 C T 3.69E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs7532792 chr1 85609928 G A 1.44E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs930912 chr1 85617482 T A 4.43E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs11161535 chr1 85621174 A T 4.34E-10 Serum dimethylarginine levels (asymmetric) / / 24159190 rs7511739 chr1 85622457 G A 1.10E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs17122364 chr1 85627099 A G 7.13E-07 Serum dimethylarginine levels (asymmetric) SYDE2 intron 24159190 rs4907138 chr1 85628953 C T 8.17E-07 Serum dimethylarginine levels (asymmetric) SYDE2 intron 24159190 rs145522533 chr1 85646380 A G 2.99E-06 Serum dimethylarginine levels (asymmetric) SYDE2 intron 24159190 rs11161543 chr1 85653831 G A 1.63E-04 Alzheimer's disease SYDE2 intron 22005930 rs12144280 chr1 85654216 T C 1.85E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) SYDE2 intron 24159190 rs12144280 chr1 85654216 T C 3.58E-10 Serum dimethylarginine levels (asymmetric) SYDE2 intron 24159190 rs72722607 chr1 85654397 G A 1.00E-09 Serum dimethylarginine levels (asymmetric) SYDE2 intron 24159190 rs112356857 chr1 85657385 G A 6.77E-10 Serum dimethylarginine levels (asymmetric) SYDE2 intron 24159190 rs709788 chr1 85676959 A G 1.10E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs709788 chr1 85676959 A G 3.70E-11 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12028498 chr1 85677283 G C 6.88E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12732108 chr1 85678877 G A 6.16E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs7540356 chr1 85679100 A G 1.02E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs72722624 chr1 85681964 G A 9.27E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs72722628 chr1 85682652 G A 3.93E-09 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10782542 chr1 85683583 G T 1.30E-04 Alzheimer's disease / / 22005930 rs12125292 chr1 85685189 T C 2.55E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs10782543 chr1 85689134 G A 1.04E-04 Alzheimer's disease / / 22005930 rs72722632 chr1 85689491 G A 4.12E-09 Serum dimethylarginine levels (asymmetric) / / 24159190 rs72722638 chr1 85693127 G A 1.94E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs17123650 chr1 85694671 C T 1.34E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs11583836 chr1 85696534 T A 1.35E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs11161556 chr1 85701014 A T 1.28E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs6671589 chr1 85702868 C T 1.29E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs72722643 chr1 85703134 C T 1.29E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs72722644 chr1 85703544 A C 2.31E-09 Serum dimethylarginine levels (asymmetric) / / 24159190 rs7515154 chr1 85704435 C T 1.99E-05 Anxiety and major depressive disorder / / 24047446 rs10747317 chr1 85705346 G A 3.28E-04 Alzheimer's disease / / 22005930 rs6663690 chr1 85705801 C T 1.20E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs60156243 chr1 85706839 C T 1.09E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10782544 chr1 85707253 T C 1.98E-07 Serum dimethylarginine levels (symmetric) / / 24159190 rs4949892 chr1 85707822 C T 1.03E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs11577656 chr1 85708279 C T 1.66E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12065422 chr1 85715978 C G 5.70E-04 Lymphocyte counts C1orf52 UTR-3 22286170 rs10158486 chr1 85720007 T C 2.59E-06 Serum dimethylarginine levels (asymmetric) C1orf52 intron 24159190 rs10158486 chr1 85720007 T C 4.32E-08 Serum dimethylarginine levels (symmetric) C1orf52 intron 24159190 rs10158486 chr1 85720007 T C 6.18E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) C1orf52 intron 24159190 rs11161570 chr1 85721911 T C 2.42E-06 Serum dimethylarginine levels (symmetric) C1orf52 intron 24159190 rs11161570 chr1 85721911 T C 4.37E-06 Serum dimethylarginine levels (asymmetric) C1orf52 intron 24159190 rs17382844 chr1 85723318 A G 1.73E-07 Serum dimethylarginine levels (asymmetric) C1orf52 intron 24159190 rs17382844 chr1 85723318 A G 4.28E-08 Serum dimethylarginine levels (symmetric) C1orf52 intron 24159190 rs17382844 chr1 85723318 A G 8.89E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) C1orf52 intron 24159190 rs4949926 chr1 85724328 C T 6.45E-07 Serum dimethylarginine levels (asymmetric) C1orf52 cds-synon 24159190 rs71652692 chr1 85725426 G T 1.00E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs71652692 chr1 85725426 G T 1.17E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs71652692 chr1 85725426 G T 3.02E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161574 chr1 85727044 T C 2.73E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10493763 chr1 85727218 T C 1.73E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10493763 chr1 85727218 T C 4.66E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs10493763 chr1 85727218 T C 9.55E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs2647395 chr1 85728664 C G 8.92E-07 Serum dimethylarginine levels (symmetric) / / 24159190 rs2647394 chr1 85729987 A G 4.87E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs10873697 chr1 85730575 G A 1.29E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs10873697 chr1 85730575 G A 5.86E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12126112 chr1 85730595 C T 1.78E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs12126112 chr1 85730595 C T 6.29E-08 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12126112 chr1 85730595 C T 8.54E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs113428154 chr1 85730627 T C 2.63E-10 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12126141 chr1 85730696 C T 2.04E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs12126141 chr1 85730696 C T 4.53E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs12126141 chr1 85730696 C T 6.37E-08 Serum dimethylarginine levels (asymmetric) / / 24159190 rs2735590 chr1 85731310 T C 2.32E-06 Serum dimethylarginine levels (symmetric) BCL10 nearGene-3 24159190 rs1060846 chr1 85732065 A G 3.23E-06 Serum dimethylarginine levels (symmetric) BCL10 UTR-3 24159190 rs962409 chr1 85732941 A C 3.43E-06 Serum dimethylarginine levels (symmetric) BCL10 UTR-3 24159190 rs2252408 chr1 85733929 C T 2.20E-07 Serum dimethylarginine levels (asymmetric) BCL10 intron 24159190 rs12134420 chr1 85738308 C T 4.80E-08 Serum dimethylarginine levels (symmetric) BCL10 intron 24159190 rs144541104 chr1 85739751 T C 1.24E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) BCL10 intron 24159190 rs144541104 chr1 85739751 T C 5.91E-10 Serum dimethylarginine levels (asymmetric) BCL10 intron 24159190 rs2735594 chr1 85741921 G C 1.62E-07 Serum dimethylarginine levels (asymmetric) BCL10 intron 24159190 rs78416998 chr1 85742155 G A 1.86E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) BCL10 UTR-5 24159190 rs78416998 chr1 85742155 G A 1.93E-08 Serum dimethylarginine levels (asymmetric) BCL10 UTR-5 24159190 rs2735593 chr1 85742338 G C 1.61E-07 Serum dimethylarginine levels (asymmetric) LOC646626 missense 24159190 rs11555520 chr1 85743452 G A 6.79E-05 Body Mass Index LOC646626 UTR-3 pha003009 rs12136214 chr1 85745566 C T 3.51E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs116057745 chr1 85746632 A G 1.63E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs6698331 chr1 85746929 T C 3.28E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs6693365 chr1 85749715 C G 2.22E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs2133183 chr1 85750598 C T 1.01E-10 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12729231 chr1 85754207 C T 2.62E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161584 chr1 85755127 A G 6.04E-08 Serum dimethylarginine levels (asymmetric) / / 24159190 rs6668948 chr1 85757406 T C 1.30E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs12757160 chr1 85759668 A G 3.33E-09 Serum dimethylarginine levels (symmetric) / / 24159190 rs12757160 chr1 85759668 A G 6.25E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs34743622 chr1 85760353 A G 1.43E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs12754032 chr1 85760508 T C 2.50E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs35654640 chr1 85760543 T TG 3.79E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs57483398 chr1 85760543 T C 3.79E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs141922542 chr1 85761234 G A 2.38E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs141922542 chr1 85761234 G A 2.81E-11 Serum dimethylarginine levels (asymmetric) / / 24159190 rs11161585 chr1 85761663 G C 9.53E-04 Alzheimer's disease / / 22005930 rs11161585 chr1 85761663 G C 1.49E-07 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161586 chr1 85761786 T C 1.31E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11590047 chr1 85763154 C T 1.22E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161588 chr1 85763861 G A 1.19E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs2030075 chr1 85763899 C T 5.28E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs34983308 chr1 85764134 G A 1.35E-09 Serum dimethylarginine levels (asymmetric) / / 24159190 rs34983308 chr1 85764134 G A 6.37E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs11161589 chr1 85764886 A G 5.28E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161590 chr1 85764998 A G 5.30E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs10782547 chr1 85765293 C G 5.28E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11583827 chr1 85765682 G C 1.23E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11587512 chr1 85765798 A G 6.43E-05 Serum metabolites / / 19043545 rs11587512 chr1 85765798 A G 1.24E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161591 chr1 85765990 C T 1.46E-11 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161592 chr1 85766230 C A 1.18E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs7554249 chr1 85767794 C T 2.98E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs7554249 chr1 85767794 C T 6.37E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs186590599 chr1 85768633 G C 2.33E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs186590599 chr1 85768633 G C 2.80E-11 Serum dimethylarginine levels (asymmetric) / / 24159190 rs61771982 chr1 85768644 G A 5.29E-07 Serum dimethylarginine levels (symmetric) / / 24159190 rs12093484 chr1 85768860 A G 1.02E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs17125445 chr1 85769032 C T 1.01E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11585614 chr1 85770620 T C 9.69E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs2012099 chr1 85771452 C T 8.21E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs2012099 chr1 85771452 C T 9.22E-07 Serum dimethylarginine levels (symmetric) / / 24159190 rs233100 chr1 85772009 G A 1.00E-06 Multiple sclerosis / / 21833088 rs233101 chr1 85772334 A G 2.01E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs233101 chr1 85772334 A G 6.21E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs233102 chr1 85772701 C A 2.08E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs233102 chr1 85772701 C A 6.19E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs138851971 chr1 85774687 G A 1.70E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs138851971 chr1 85774687 G A 3.62E-11 Serum dimethylarginine levels (asymmetric) / / 24159190 rs35240561 chr1 85775217 C G 1.00E-13 Serum dimethylarginine levels (symmetric) / / 24159190 rs35240561 chr1 85775217 C G 2.21E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs35240561 chr1 85775217 C G 5.65E-10 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12047189 chr1 85775448 A C 4.26E-11 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12122154 chr1 85775865 C T 8.53E-04 Alzheimer's disease / / 22005930 rs4949897 chr1 85776121 G C 9.33E-11 Serum dimethylarginine levels (asymmetric) / / 24159190 rs34561661 chr1 85777250 C T 1.48E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs34561661 chr1 85777250 C T 2.30E-13 Serum dimethylarginine levels (symmetric) / / 24159190 rs34561661 chr1 85777250 C T 8.80E-12 Serum dimethylarginine levels (asymmetric) / / 24159190 rs72722663 chr1 85777534 T G 7.90E-12 Serum dimethylarginine levels (asymmetric) / / 24159190 rs4949889 chr1 85778344 G A 5.18E-12 Serum dimethylarginine levels (asymmetric) / / 24159190 rs1874807 chr1 85779393 G A 1.62E-04 Alzheimer's disease / / 22005930 rs1874807 chr1 85779393 G A 4.60E-10 Serum dimethylarginine levels (symmetric) / / 24159190 rs72722665 chr1 85780781 T C 1.46E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs72722665 chr1 85780781 T C 2.96E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12042780 chr1 85780903 A G 2.41E-15 Serum dimethylarginine levels (asymmetric) / / 24159190 rs233108 chr1 85781720 C T 2.54E-18 Serum dimethylarginine levels (symmetric) / / 24159190 rs233108 chr1 85781720 C T 3.12E-08 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10489510 chr1 85782571 C G 8.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10489510 chr1 85782571 C G 6.42E-04 Menopause (age at onset) / / 22267201 rs10489510 chr1 85782571 C G 1.17E-15 Serum dimethylarginine levels (asymmetric) / / 24159190 rs233109 chr1 85783101 T C 2.38E-18 Serum dimethylarginine levels (symmetric) / / 24159190 rs233109 chr1 85783101 T C 4.30E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12138621 chr1 85783970 T C 1.08E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs12138621 chr1 85783970 T C 4.52E-13 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12138621 chr1 85783970 T C 6.12E-14 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161597 chr1 85784936 G A 1.12E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 UTR-3 24159190 rs11161597 chr1 85784936 G A 4.21E-13 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs11161597 chr1 85784936 G A 6.25E-14 Serum dimethylarginine levels (symmetric) DDAH1 UTR-3 24159190 rs233111 chr1 85785655 T C 1.20E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 UTR-3 24159190 rs233111 chr1 85785655 T C 3.65E-06 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs233112 chr1 85785751 T C 1.54E-06 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs233112 chr1 85785751 T C 4.39E-18 Serum dimethylarginine levels (symmetric) DDAH1 UTR-3 24159190 rs3813600 chr1 85786166 G A 3.33E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 UTR-3 24159190 rs3813600 chr1 85786166 G A 8.88E-08 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs233113 chr1 85786299 T A 3.22E-08 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs233113 chr1 85786299 T A 3.52E-18 Serum dimethylarginine levels (symmetric) DDAH1 UTR-3 24159190 rs233114 chr1 85786957 T G 3.18E-08 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs233114 chr1 85786957 T G 3.50E-18 Serum dimethylarginine levels (symmetric) DDAH1 UTR-3 24159190 rs233115 chr1 85786977 G A 3.13E-08 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs233115 chr1 85786977 G A 3.46E-18 Serum dimethylarginine levels (symmetric) DDAH1 UTR-3 24159190 rs3087894 chr1 85787118 G C 3.10E-08 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs3087894 chr1 85787118 G C 3.44E-18 Serum dimethylarginine levels (symmetric) DDAH1 UTR-3 24159190 rs1498375 chr1 85787323 T A 3.09E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1498375 chr1 85787323 T A 3.43E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1498374 chr1 85787334 C T 3.11E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1498374 chr1 85787334 C T 4.11E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1498374 chr1 85787334 C T 6.76E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233118 chr1 85787967 T C 2.99E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233118 chr1 85787967 T C 4.46E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233119 chr1 85788052 T C 3.15E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233119 chr1 85788052 T C 3.44E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233120 chr1 85788490 A C 1.03E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233120 chr1 85788490 A C 8.32E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2300633 chr1 85788826 A G 2.31E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140272 chr1 85789757 G A 3.50E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12140272 chr1 85789757 G A 6.59E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140272 chr1 85789757 G A 7.09E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233121 chr1 85789913 G A 3.47E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233121 chr1 85789913 G A 3.56E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1498373 chr1 85790633 G A 3.58E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1498373 chr1 85790633 G A 3.63E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72722671 chr1 85791003 T C 1.50E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2300634 chr1 85791257 T C 3.57E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2300634 chr1 85791257 T C 3.82E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233124 chr1 85791658 T C 3.18E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233124 chr1 85791658 T C 5.21E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2284797 chr1 85792383 C T 1.11E-11 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2284797 chr1 85792383 C T 1.25E-16 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2284797 chr1 85792383 C T 1.72E-17 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12122816 chr1 85792384 C T 1.11E-11 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12122816 chr1 85792384 C T 1.26E-16 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12122816 chr1 85792384 C T 1.76E-17 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2268667 chr1 85793746 G A 3.68E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2268667 chr1 85793746 G A 3.90E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233127 chr1 85793801 A G 3.69E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233127 chr1 85793801 A G 3.71E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233128 chr1 85794413 G C 4.06E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233128 chr1 85794413 G C 8.04E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs18582 chr1 85794819 A G 2.39E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs18582 chr1 85794819 A G 3.30E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233130 chr1 85795112 T C 2.39E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233130 chr1 85795112 T C 3.30E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233131 chr1 85795259 G A 2.38E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233131 chr1 85795259 G A 3.30E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs731194 chr1 85795951 G A 3.06E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161599 chr1 85795965 G A 1.07E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11161599 chr1 85795965 G A 1.20E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161599 chr1 85795965 G A 6.34E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs423105 chr1 85796427 A G 2.33E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs423105 chr1 85796427 A G 3.35E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233132 chr1 85796545 A G 2.32E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233132 chr1 85796545 A G 3.37E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233133 chr1 85796557 G T 2.12E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233133 chr1 85796557 G T 3.16E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs28489187 chr1 85797110 A G 1.00E-20 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs28489187 chr1 85797110 A G 1.00E-40 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs761601 chr1 85797298 A G 2.19E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs761601 chr1 85797298 A G 3.57E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2474121 chr1 85798038 G A 2.46E-23 Narcolepsy DDAH1 intron 19629137 rs2389913 chr1 85798075 T C 3.96E-04 Multiple complex diseases DDAH1 intron 17554300 rs12121675 chr1 85798484 A G 3.40E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12121675 chr1 85798484 A G 7.82E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12121675 chr1 85798484 A G 9.04E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs233055 chr1 85798486 A C 7.21E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs233055 chr1 85798486 A C 8.58E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233055 chr1 85798486 A C 9.67E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233057 chr1 85798855 T C 2.03E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233057 chr1 85798855 T C 3.83E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233058 chr1 85798865 G T 2.02E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233058 chr1 85798865 G T 3.86E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233059 chr1 85798936 G A 2.01E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233059 chr1 85798936 G A 3.88E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233060 chr1 85798943 C T 2.00E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233060 chr1 85798943 C T 3.91E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233061 chr1 85799282 G A 2.41E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233061 chr1 85799282 G A 2.85E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72722677 chr1 85800179 G A 5.47E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72722677 chr1 85800179 G A 8.94E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs233062 chr1 85800385 T G 2.62E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233062 chr1 85800385 T G 6.30E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs3768227 chr1 85804087 A G 1.77E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs3768227 chr1 85804087 A G 4.44E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs173026 chr1 85804249 G A 1.76E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs173026 chr1 85804249 G A 4.47E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs190804399 chr1 85804743 A T 2.76E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs190804399 chr1 85804743 A T 3.02E-20 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12754297 chr1 85804745 A T 1.93E-19 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12754297 chr1 85804745 A T 4.28E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12754297 chr1 85804745 A T 4.54E-06 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs566641032 chr1 85804745 A AT 1.93E-19 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs566641032 chr1 85804745 A AT 4.28E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs566641032 chr1 85804745 A AT 4.54E-06 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs74599242 chr1 85804747 T A 4.42E-08 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12035116 chr1 85804837 C T 1.03E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233066 chr1 85804930 T C 1.51E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233066 chr1 85804930 T C 4.95E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233067 chr1 85804978 C G 1.49E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233067 chr1 85804978 C G 4.92E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233068 chr1 85805355 G A 2.21E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233068 chr1 85805355 G A 3.27E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233069 chr1 85805466 C T 1.40E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233069 chr1 85805466 C T 5.71E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233071 chr1 85806005 C T 1.39E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233071 chr1 85806005 C T 5.78E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233072 chr1 85807695 A G 2.18E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233072 chr1 85807695 A G 3.58E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233072 chr1 85807695 A G 2.50E-04 Renal cell carcinoma DDAH1 intron 24220910 rs12717763 chr1 85808164 T A 1.25E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12717763 chr1 85808164 T A 2.61E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12717763 chr1 85808164 T A 4.61E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233074 chr1 85809065 T C 1.36E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233074 chr1 85809065 T C 6.33E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs3768223 chr1 85809183 T C 1.24E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs3768223 chr1 85809183 T C 2.67E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs3768223 chr1 85809183 T C 4.73E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12120551 chr1 85810903 T C 1.26E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12120551 chr1 85810903 T C 2.51E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12120551 chr1 85810903 T C 4.56E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12124170 chr1 85811182 A G 1.34E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12124170 chr1 85811182 A G 6.48E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs4949898 chr1 85811652 A G 5.29E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233080 chr1 85814552 A G 5.59E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs233080 chr1 85814552 A G 5.81E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2284800 chr1 85815610 T C 1.66E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2284800 chr1 85815610 T C 2.74E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2230820 chr1 85816134 T C 1.33E-13 Serum dimethylarginine levels (symmetric) DDAH1 cds-synon 24159190 rs2230820 chr1 85816134 T C 2.12E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 cds-synon 24159190 rs2230820 chr1 85816134 T C 3.75E-14 Serum dimethylarginine levels (asymmetric) DDAH1 cds-synon 24159190 rs41301261 chr1 85816224 G A 1.48E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs41301261 chr1 85816224 G A 2.33E-06 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs41301261 chr1 85816224 G A 6.89E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2076699 chr1 85817295 G A 4.45E-05 Cognitive performance DDAH1 intron 19734545 rs2076699 chr1 85817295 G A 1.38E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2076699 chr1 85817295 G A 2.13E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2076699 chr1 85817295 G A 4.42E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs180841827 chr1 85817542 A G 1.60E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233087 chr1 85821000 T C 1.68E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233087 chr1 85821000 T C 6.99E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2300637 chr1 85822772 T C 1.27E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2300637 chr1 85822772 T C 6.74E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233091 chr1 85823044 G C 1.24E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233091 chr1 85823044 G C 6.69E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233093 chr1 85823120 G A 1.24E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233093 chr1 85823120 G A 6.74E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2300639 chr1 85823676 T A 1.39E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2300639 chr1 85823676 T A 2.19E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2300639 chr1 85823676 T A 3.89E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2300640 chr1 85823795 C G 1.40E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2300640 chr1 85823795 C G 2.27E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2300640 chr1 85823795 C G 4.13E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233095 chr1 85824816 T C 1.23E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233095 chr1 85824816 T C 6.86E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233097 chr1 85825473 G C 2.12E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233097 chr1 85825473 G C 4.33E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233099 chr1 85826194 T C 1.17E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233099 chr1 85826194 T C 6.88E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2474123 chr1 85827452 G A 1.08E-16 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs7520993 chr1 85828090 A C 2.08E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7520993 chr1 85828090 A C 2.29E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12130145 chr1 85828970 G C 1.42E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12130145 chr1 85828970 G C 2.03E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12130145 chr1 85828970 G C 3.60E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233046 chr1 85829405 A G 2.37E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233046 chr1 85829405 A G 2.53E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs111820059 chr1 85830429 G A 4.53E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs111820059 chr1 85830429 G A 8.21E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs233047 chr1 85830570 G A 1.22E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233047 chr1 85830570 G A 6.88E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs4949890 chr1 85830632 T C 2.31E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs4949890 chr1 85830632 T C 9.38E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs66811655 chr1 85831544 T G 4.71E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs66811655 chr1 85831544 T G 6.67E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12038426 chr1 85831790 A C 1.03E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs71652696 chr1 85831792 A C 1.39E-15 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs71652696 chr1 85831792 A C 1.99E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs71652696 chr1 85831792 A C 9.80E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs75481609 chr1 85834202 G C 3.02E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs141923044 chr1 85835078 G A 4.94E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs141923044 chr1 85835078 G A 6.26E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12758768 chr1 85835206 C T 4.60E-15 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12758768 chr1 85835206 C T 7.08E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12758768 chr1 85835206 C T 8.19E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72722691 chr1 85835439 T C 1.33E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs79695640 chr1 85836073 T C 3.94E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs79695640 chr1 85836073 T C 5.06E-15 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs79695640 chr1 85836073 T C 9.99E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs986639 chr1 85836392 G C 2.07E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs986639 chr1 85836392 G C 3.52E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs986639 chr1 85836392 G C 4.53E-08 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1498377 chr1 85836436 G A 1.54E-07 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72722692 chr1 85837169 G C 8.05E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233050 chr1 85837793 T C 3.69E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233050 chr1 85837793 T C 7.25E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs4949899 chr1 85838237 G A,T 2.46E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233051 chr1 85838413 G A 1.04E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs233051 chr1 85838413 G A 2.86E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs140056707 chr1 85838505 T G 2.93E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233053 chr1 85839507 G A 1.44E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233053 chr1 85839507 G A 2.67E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233054 chr1 85840191 T G 3.61E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233054 chr1 85840191 T G 7.05E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1391556 chr1 85841056 C G 2.02E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2012683 chr1 85841485 C T 3.54E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2012683 chr1 85841485 C T 6.87E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12139958 chr1 85842112 A G 2.39E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12139958 chr1 85842112 A G 3.78E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12139958 chr1 85842112 A G 5.73E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72722697 chr1 85843863 G C 2.56E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2064510 chr1 85844330 G C 1.60E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs729655 chr1 85844617 A C 1.88E-16 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs729655 chr1 85844617 A C 4.43E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs729655 chr1 85844617 A C 6.72E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2011825 chr1 85844671 T C 2.26E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2011825 chr1 85844671 T C 4.31E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs4512701 chr1 85844835 G A 1.51E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs4631749 chr1 85844852 T C 1.49E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs997251 chr1 85845367 T C 3.42E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs997251 chr1 85845367 T C 6.28E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs41289749 chr1 85845872 A G 2.35E-17 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs41289749 chr1 85845872 A G 3.31E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs41289749 chr1 85845872 A G 7.51E-07 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1884139 chr1 85845998 G T 1.00E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1884139 chr1 85845998 G T 2.22E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12044537 chr1 85846385 T A 1.43E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12044537 chr1 85846385 T A 3.04E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs67611930 chr1 85846592 A G 3.29E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs67611930 chr1 85846592 A G 6.00E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2207368 chr1 85847683 A G 3.29E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2207368 chr1 85847683 A G 5.51E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12568573 chr1 85848821 T C 1.05E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12568573 chr1 85848821 T C 2.31E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12047422 chr1 85848830 T G 3.23E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12047422 chr1 85848830 T G 5.58E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs3920521 chr1 85848866 A C 1.49E-16 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs3920521 chr1 85848866 A C 1.65E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11588128 chr1 85848998 G A 1.05E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11588128 chr1 85848998 G A 2.32E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140103 chr1 85849489 G A 8.46E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12140103 chr1 85849489 G A 9.50E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140170 chr1 85849723 G A 1.28E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12140170 chr1 85849723 G A 3.58E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140170 chr1 85849723 G A 5.21E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72724606 chr1 85850246 T C 3.20E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72724606 chr1 85850246 T C 5.45E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72724608 chr1 85852755 A G 1.25E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72724608 chr1 85852755 A G 4.29E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs36110608 chr1 85852936 A C 1.00E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs36110608 chr1 85852936 A C 4.37E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs36110608 chr1 85852936 A C 7.49E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161606 chr1 85853902 T C 3.84E-04 Alzheimer's disease DDAH1 intron 22005930 rs11161606 chr1 85853902 T C 1.59E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161606 chr1 85853902 T C 8.93E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10782548 chr1 85855098 T A 1.48E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10782548 chr1 85855098 T A 7.70E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs10489513 chr1 85855622 A G 3.75E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10489513 chr1 85855622 A G 7.28E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140935 chr1 85855716 G A 1.09E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12140935 chr1 85855716 G A 4.97E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12140935 chr1 85855716 G A 6.68E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161607 chr1 85855855 T C 1.92E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161607 chr1 85855855 T C 3.03E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72724610 chr1 85856396 G C 1.72E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1342323 chr1 85857574 A T 9.59E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs77529889 chr1 85857838 A G 3.29E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12033483 chr1 85858123 C T 9.67E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6576761 chr1 85858274 G A 1.10E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6576761 chr1 85858274 G A 5.03E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6671599 chr1 85858857 T C 2.82E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6671599 chr1 85858857 T C 5.45E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs35193119 chr1 85859265 T C 4.73E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs35193119 chr1 85859265 T C 4.78E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs35193119 chr1 85859265 T C 7.72E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs6576763 chr1 85859376 T C 1.13E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6576763 chr1 85859376 T C 2.09E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs7515261 chr1 85859804 C T 1.20E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10747318 chr1 85859910 A G 1.27E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140457 chr1 85860170 G A 3.78E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12140457 chr1 85860170 G A 4.28E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12140457 chr1 85860170 G A 4.52E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10873701 chr1 85860374 C T 1.31E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs4949900 chr1 85861034 T G 2.72E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs4949900 chr1 85861034 T G 5.25E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs4428939 chr1 85861564 A G 1.42E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2177461 chr1 85861976 C G 2.60E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2177461 chr1 85861976 C G 5.16E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12564698 chr1 85862711 C A 1.09E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12564698 chr1 85862711 C A 1.97E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161609 chr1 85862736 G T 2.09E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs3949301 chr1 85863383 G A 2.56E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs3949301 chr1 85863383 G A 5.37E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12034249 chr1 85864391 C T 2.47E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12118950 chr1 85864519 T C 2.41E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12118950 chr1 85864519 T C 3.74E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12118950 chr1 85864519 T C 3.88E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161610 chr1 85865896 C T 1.08E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161610 chr1 85865896 C T 1.24E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161610 chr1 85865896 C T 3.62E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2892888 chr1 85866147 A G 3.80E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2892888 chr1 85866147 A G 7.11E-10 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2892888 chr1 85866147 A G 7.85E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs6576764 chr1 85866411 A T 2.48E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6576764 chr1 85866411 A T 5.28E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12125557 chr1 85867406 A G 1.99E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12125557 chr1 85867406 A G 2.32E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6704103 chr1 85868657 C A 2.50E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6704103 chr1 85868657 C A 4.00E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161611 chr1 85868679 C A 2.38E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161611 chr1 85868679 C A 5.39E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1357635 chr1 85868798 A G 9.48E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1357636 chr1 85869042 A C 5.63E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12758237 chr1 85870783 G A 1.57E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12758237 chr1 85870783 G A 2.29E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12758237 chr1 85870783 G A 3.30E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6576765 chr1 85871012 A T 1.13E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6576765 chr1 85871012 A T 1.66E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12133722 chr1 85873237 C T 1.52E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12133722 chr1 85873237 C T 1.63E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12133722 chr1 85873237 C T 4.52E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12564550 chr1 85874205 A C 1.16E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12564550 chr1 85874205 A C 2.51E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6657732 chr1 85874495 C T 3.11E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6657732 chr1 85874495 C T 3.16E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6657817 chr1 85874614 C T 1.66E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6657817 chr1 85874614 C T 3.66E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6576766 chr1 85876218 A G 1.11E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6576766 chr1 85876218 A G 7.53E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6576767 chr1 85876316 G A 1.68E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6576767 chr1 85876316 G A 3.72E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs6576767 chr1 85876316 G A 4.79E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs17127199 chr1 85876355 T C 1.08E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs17127199 chr1 85876355 T C 2.36E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1554597 chr1 85877098 C T 1.40E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1554597 chr1 85877098 C T 3.22E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12138852 chr1 85878208 C T 2.93E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12138852 chr1 85878208 C T 4.37E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12138852 chr1 85878208 C T 4.98E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1001604 chr1 85879524 C G 2.13E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1001604 chr1 85879524 C G 3.05E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12132677 chr1 85879613 A C 3.08E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12132677 chr1 85879613 A C 3.84E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12132677 chr1 85879613 A C 4.91E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs7532508 chr1 85880468 C G 3.33E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7532508 chr1 85880468 C G 7.51E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs7546931 chr1 85880976 T C 6.88E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10782549 chr1 85881278 T G 6.39E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs56215900 chr1 85881759 T G 1.06E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs56215900 chr1 85881759 T G 2.28E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2016104 chr1 85882871 G A 7.83E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1975755 chr1 85882905 A G 2.09E-04 Alzheimer's disease DDAH1 intron 22005930 rs1975755 chr1 85882905 A G 6.90E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1006988 chr1 85883320 C G 2.05E-04 Alzheimer's disease DDAH1 intron 22005930 rs7525786 chr1 85884076 C T 8.87E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs7547571 chr1 85884091 G T 1.84E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7547571 chr1 85884091 G T 5.10E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10873702 chr1 85884101 T C 7.81E-05 Alzheimer's disease DDAH1 intron 22005930 rs10873702 chr1 85884101 T C 6.85E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs61783046 chr1 85884365 G A 5.31E-08 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2124139 chr1 85884370 T C 7.50E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs17384213 chr1 85884621 G A 7.49E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12123745 chr1 85884772 T C 2.71E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12123745 chr1 85884772 T C 3.49E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12123745 chr1 85884772 T C 4.15E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1965876 chr1 85885178 A G 7.45E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1608537 chr1 85885731 C G 7.42E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1608536 chr1 85885836 C T 2.40E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1608536 chr1 85885836 C T 2.54E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1608536 chr1 85885836 C T 2.93E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2840319 chr1 85886224 C T 1.93E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2840319 chr1 85886224 C T 3.84E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6697083 chr1 85887775 A T 1.99E-04 Alzheimer's disease DDAH1 intron 22005930 rs6697083 chr1 85887775 A T 1.59E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6697083 chr1 85887775 A T 1.72E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6420965 chr1 85888480 C T 3.63E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1523995 chr1 85888986 A C 1.74E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7521189 chr1 85889596 G A 5.43E-04 Alzheimer's disease DDAH1 intron 22005930 rs7521189 chr1 85889596 G A 7.71E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12135333 chr1 85890494 C A 2.41E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12135333 chr1 85890494 C A 2.94E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12135333 chr1 85890494 C A 2.98E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1523994 chr1 85890726 G A 2.17E-04 Alzheimer's disease DDAH1 intron 22005930 rs1523994 chr1 85890726 G A 7.10E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12128907 chr1 85891385 A G 3.36E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12128907 chr1 85891385 A G 5.45E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12128907 chr1 85891385 A G 6.12E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6672870 chr1 85891457 G T 7.10E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12129013 chr1 85891709 A C 5.27E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12129013 chr1 85891709 A C 7.00E-12 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2389948 chr1 85892383 C G 8.16E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72724632 chr1 85892717 C T 1.03E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs72724632 chr1 85892717 C T 2.29E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7540393 chr1 85893728 C T 7.67E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12131926 chr1 85893955 A G 1.19E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12131926 chr1 85893955 A G 1.29E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12131926 chr1 85893955 A G 4.79E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12029221 chr1 85893977 G C 1.92E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146374 chr1 85894027 G A 1.45E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs561614 chr1 85894864 G A 2.32E-17 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs561422 chr1 85894932 T A 4.65E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146377 chr1 85895609 C T 5.27E-17 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs146482999 chr1 85895652 G A 1.24E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs146482999 chr1 85895652 G A 2.28E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12125900 chr1 85895781 G A 3.15E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12125900 chr1 85895781 G A 3.23E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12125900 chr1 85895781 G A 5.18E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146378 chr1 85895820 G A 1.72E-20 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146379 chr1 85896551 T C 1.31E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1146379 chr1 85896551 T C 6.21E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12743049 chr1 85897386 G A 1.24E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12743049 chr1 85897386 G A 2.47E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12743049 chr1 85897386 G A 2.67E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs17384381 chr1 85897570 C G 1.23E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs17384381 chr1 85897570 C G 2.46E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs17384381 chr1 85897570 C G 2.66E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11582061 chr1 85897781 G C 2.20E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11582061 chr1 85897781 G C 9.72E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs17388521 chr1 85897904 G A 2.21E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs17388521 chr1 85897904 G A 7.87E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs17388521 chr1 85897904 G A 8.02E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161614 chr1 85898160 T G 8.58E-04 Alcohol dependence DDAH1 intron 21314694 rs11161614 chr1 85898160 T G 3.34E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161614 chr1 85898160 T G 4.89E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11161614 chr1 85898160 T G 6.50E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs35956189 chr1 85898461 G A,T 8.46E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs990916 chr1 85898508 A G 1.42E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1523993 chr1 85899128 C T 6.44E-06 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1523993 chr1 85899128 C T 6.03E-05 Neuroblastoma DDAH1 intron pha002895 rs506082 chr1 85899215 A C 1.90E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs506082 chr1 85899215 A C 8.32E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs669173 chr1 85899428 T C 1.14E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs669173 chr1 85899428 T C 2.60E-08 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12129502 chr1 85900727 T C 2.55E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12129502 chr1 85900727 T C 2.88E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12129502 chr1 85900727 T C 6.24E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs34749578 chr1 85900964 A G 1.16E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs34749578 chr1 85900964 A G 7.78E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12130380 chr1 85901309 T C 1.15E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12130380 chr1 85901309 T C 1.67E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12130380 chr1 85901309 T C 4.06E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12736004 chr1 85901367 G A 2.69E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12736004 chr1 85901367 G A 3.50E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12736004 chr1 85901367 G A 6.92E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs570121 chr1 85901598 C T 7.99E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs3851268 chr1 85901887 T A 7.97E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs483530 chr1 85901919 A T 9.05E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs71582955 chr1 85901919 AT A 9.05E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs539714 chr1 85904338 C T 2.15E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12130591 chr1 85904985 G A 6.99E-05 Cognitive performance DDAH1 intron 19734545 rs12130591 chr1 85904985 G A 3.68E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12130591 chr1 85904985 G A 3.90E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12130591 chr1 85904985 G A 5.24E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs591917 chr1 85905136 A G 3.68E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs591917 chr1 85905136 A G 6.15E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs17388696 chr1 85905427 G A 1.66E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs604974 chr1 85905705 A G 1.20E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12724823 chr1 85906385 G T 2.18E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12724823 chr1 85906385 G T 3.65E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12724823 chr1 85906385 G T 4.12E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs75778210 chr1 85906730 T C 2.18E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs75778210 chr1 85906730 T C 3.88E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11161615 chr1 85906816 G A 1.99E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11161615 chr1 85906816 G A 3.21E-11 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161616 chr1 85907625 C T 1.27E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11161616 chr1 85907625 C T 3.40E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161616 chr1 85907625 C T 3.77E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs499869 chr1 85907851 A T 1.36E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1261681 chr1 85908282 A G 9.07E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1240939 chr1 85908649 T G 1.01E-15 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10782550 chr1 85908784 T C 1.35E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs10782550 chr1 85908784 T C 2.04E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10782550 chr1 85908784 T C 8.71E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs661686 chr1 85909210 T C 5.13E-16 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs4949904 chr1 85909275 C T 3.18E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs4949904 chr1 85909275 C T 9.03E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs34278923 chr1 85909708 G A 3.14E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs34278923 chr1 85909708 G A 9.70E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12034839 chr1 85910777 G A 8.57E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12034839 chr1 85910777 G A 9.00E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12049529 chr1 85910893 C A 2.72E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12049529 chr1 85910893 C A 4.06E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12049529 chr1 85910893 C A 6.53E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs28529751 chr1 85910951 G A 1.83E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs28529751 chr1 85910951 G A 5.80E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs28529751 chr1 85910951 G A 8.23E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1146381 chr1 85911290 A G 2.43E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1146381 chr1 85911290 A G 8.81E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2124140 chr1 85912143 G T 1.36E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs600098 chr1 85912584 T C 2.38E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs530006 chr1 85913508 G T 6.85E-04 Alzheimer's disease DDAH1 intron 22005930 rs530006 chr1 85913508 G T 8.13E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161617 chr1 85913538 T C 3.25E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11161617 chr1 85913538 T C 4.69E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161617 chr1 85913538 T C 4.77E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72724639 chr1 85913632 C G 8.72E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs631817 chr1 85913740 T C 2.67E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs648216 chr1 85915057 C A 1.16E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs648216 chr1 85915057 C A 5.79E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs648310 chr1 85915134 T C 1.24E-06 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs648310 chr1 85915134 T C 3.84E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs659070 chr1 85915149 A G 2.66E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11587876 chr1 85915183 T C 4.15E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12726532 chr1 85915373 T C 2.73E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12726532 chr1 85915373 T C 3.36E-12 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12726532 chr1 85915373 T C 4.23E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11801146 chr1 85915374 C T 2.61E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11801146 chr1 85915374 C T 3.33E-12 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11801146 chr1 85915374 C T 4.13E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs35755993 chr1 85915374 C CT 2.61E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs35755993 chr1 85915374 C CT 3.33E-12 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs35755993 chr1 85915374 C CT 4.13E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2935 chr1 85917563 G A 7.11E-04 Myopia (pathological) DDAH1 intron 21095009 rs2935 chr1 85917563 G A 2.61E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2935 chr1 85917563 G A 3.16E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs17127710 chr1 85918009 C T 4.36E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146382 chr1 85918101 C T 3.46E-04 Alzheimer's disease DDAH1 intron 22005930 rs1146382 chr1 85918101 C T 2.09E-15 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs35761966 chr1 85918357 G A 1.30E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs35761966 chr1 85918357 G A 2.13E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs35761966 chr1 85918357 G A 2.97E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs56216312 chr1 85918454 C T 1.21E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs56216312 chr1 85918454 C T 5.84E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1146384 chr1 85919710 G A,C 1.79E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1146384 chr1 85919710 G A,C 6.00E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12717764 chr1 85920219 G C 5.78E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs67644506 chr1 85920734 G C 2.80E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs67644506 chr1 85920734 G C 2.92E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs191306675 chr1 85921067 G A 1.62E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs191306675 chr1 85921067 G A 3.10E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs506733 chr1 85922661 C T 2.21E-06 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs506733 chr1 85922661 C T 4.83E-19 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs506733 chr1 85922661 C T 6.31E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs36104818 chr1 85923472 G A 2.38E-10 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs877041 chr1 85923920 G A 1.69E-10 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs877041 chr1 85923920 G A 2.92E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs582145 chr1 85923999 T C 5.09E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs582145 chr1 85923999 T C 7.49E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs560090 chr1 85924255 A G 1.42E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs560090 chr1 85924255 A G 2.67E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12568675 chr1 85924464 T C 1.92E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12568675 chr1 85924464 T C 5.77E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs597168 chr1 85925028 T C 3.66E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs974874 chr1 85925108 T G 1.18E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs974874 chr1 85925108 T G 4.89E-31 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs974874 chr1 85925108 T G 5.46E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs17389112 chr1 85925235 C T 4.87E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1523991 chr1 85925978 T G 3.37E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1523991 chr1 85925978 T G 3.55E-08 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6658151 chr1 85926281 A T 4.71E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs61783057 chr1 85926726 G A 9.89E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs56154783 chr1 85926818 G C 2.13E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs56154783 chr1 85926818 G C 6.49E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12032315 chr1 85927407 C T 7.00E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146386 chr1 85927482 C T 1.23E-15 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146386 chr1 85927482 C T 5.11E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1146386 chr1 85927482 C T 6.20E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1241320 chr1 85928237 A C 1.11E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs4949905 chr1 85928564 T C 3.46E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161619 chr1 85928811 C T 9.69E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs529582 chr1 85929008 T C 7.89E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs527762 chr1 85929214 C A 5.42E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12044882 chr1 85931014 G T 2.67E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs61223539 chr1 85931843 T C 1.25E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs55639236 chr1 85932800 G A 3.39E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs55639236 chr1 85932800 G A 6.18E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs149635670 chr1 85934276 C T 1.34E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs665091 chr1 85935422 T G 1.67E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs535723 chr1 85936622 T G 4.18E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs7539880 chr1 85938435 T C 4.89E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7539880 chr1 85938435 T C 9.92E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs7547650 chr1 85938436 G A 4.87E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7547650 chr1 85938436 G A 9.93E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12060713 chr1 85938487 G A 5.04E-10 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2210073 chr1 85938561 T C 4.26E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2210073 chr1 85938561 T C 9.69E-05 Height DDAH1 intron pha003011 rs7540169 chr1 85938736 T C 6.31E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12134668 chr1 85938882 C T 1.00E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12134668 chr1 85938882 C T 2.25E-32 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12134668 chr1 85938882 C T 9.32E-17 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12134672 chr1 85938901 C A 1.06E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12134672 chr1 85938901 C A 2.88E-32 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12134672 chr1 85938901 C A 3.48E-16 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs10157640 chr1 85939177 C T 2.03E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10157640 chr1 85939177 C T 3.77E-08 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10157643 chr1 85939250 C T 1.95E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10157643 chr1 85939250 C T 2.57E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs10157643 chr1 85939250 C T 3.37E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7538364 chr1 85939350 A G 1.53E-15 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7538364 chr1 85939350 A G 2.29E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs7538364 chr1 85939350 A G 2.56E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10158333 chr1 85939476 T C 1.07E-31 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10158333 chr1 85939476 T C 1.57E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10158333 chr1 85939476 T C 2.23E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs10157511 chr1 85939854 T G 1.13E-31 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10157511 chr1 85939854 T G 1.25E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10157511 chr1 85939854 T G 6.34E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs975880 chr1 85939935 C A 6.10E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1403955 chr1 85940105 T G 1.24E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1403955 chr1 85940105 T G 3.13E-31 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1403955 chr1 85940105 T G 4.62E-11 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1403954 chr1 85940157 C T 1.27E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1403954 chr1 85940157 C T 2.03E-30 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1403954 chr1 85940157 C T 5.44E-11 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1403951 chr1 85940249 C A 1.68E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1403951 chr1 85940249 C A 3.66E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1403951 chr1 85940249 C A 9.43E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72724655 chr1 85940875 C G 1.13E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146395 chr1 85951597 T C 0.000713015 Hypertension (early onset hypertension) DDAH1 intron 22479346 rs2066357 chr1 85971357 G A 3.00E-04 Psoriasis DDAH1 intron 20953189 rs677691 chr1 85974030 A C 4.85E-04 Suicide attempts in bipolar disorder DDAH1 intron 21423239 rs577177 chr1 85995113 A G 3.00E-04 Response to statin treatment (atorvastatin),change in cholesterol levels DDAH1 intron 20031582 rs17099678 chr1 86006208 C T 7.94E-04 Alzheimer's disease DDAH1 intron 17998437 rs17099679 chr1 86008398 A G 6.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) DDAH1 intron 23648065 rs12734233 chr1 86008536 G A 6.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) DDAH1 intron 23648065 rs17127884 chr1 86021696 G A 4.93E-04 Multiple complex diseases DDAH1 intron 17554300 rs7543409 chr1 86049823 C T 2.20E-06 Urinary metabolites / / 21572414 rs6576779 chr1 86061662 C T 3.20E-06 Urinary metabolites / / 21572414 rs11578464 chr1 86072408 T G 1.40E-05 Urinary metabolites / / 21572414 rs12566306 chr1 86074635 C A 1.47E-05 Cognitive impairment induced by topiramate / / 22091778 rs1999186 chr1 86085545 G A 6.51E-04 Alcohol dependence / / 24277619 rs143554335 chr1 86105750 C T 6.48E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs2970548 chr1 86118447 A G 9.64E-04 Multiple complex diseases ZNHIT6 UTR-3 17554300 rs3753786 chr1 86175554 A G 2.00E-05 Urinary metabolites / / 21572414 rs6672312 chr1 86176188 C T 2.80E-05 Urinary metabolites / / 21572414 rs2389972 chr1 86190666 A G 0.000107 Oxaliplatin induced nausea/vomiting in response to colorectal cancer treatment / / 22310351 rs6682235 chr1 86208801 C T 2.26E-04 Multiple complex diseases COL24A1 intron 17554300 rs147783303 chr1 86210343 A G 7.29E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) COL24A1 intron 24159190 rs392038 chr1 86233871 G A 1.68E-04 Smoking initiation COL24A1 intron 24665060 rs313728 chr1 86245155 C T 1.10E-04 Smoking initiation COL24A1 intron 24665060 rs10158651 chr1 86274325 G T 2.39E-06 Lipid levels COL24A1 intron 19913121 rs11161691 chr1 86319439 A G 8.51E-04 Type 2 diabetes COL24A1 intron 17463246 rs2046159 chr1 86330589 A G 1.20E-05 Height COL24A1 intron 21194676 rs2046159 chr1 86330589 A G 7.10E-07 Height COL24A1 intron 21194676 rs7554796 chr1 86331245 C T 7.47E-04 Type 2 diabetes COL24A1 intron 17463246 rs7542433 chr1 86351624 C A 9.84E-04 Self-reported allergy COL24A1 intron 23817569 rs1858556 chr1 86371149 T C 0.00007 Asthma COL24A1 intron 18401594 rs10493777 chr1 86377028 C T 0.00007 Asthma COL24A1 intron 18401594 rs12723176 chr1 86413022 C T 9.56E-04 Type 2 diabetes COL24A1 intron 17463246 rs2134411 chr1 86463640 G A 2.37E-05 Multiple complex diseases COL24A1 intron 17554300 rs10873740 chr1 86464262 T C 8.52E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) COL24A1 intron 24236485 rs11161717 chr1 86464981 A G 8.52E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) COL24A1 intron 24236485 rs17128651 chr1 86465736 G A 1.10E-04 Alcohol dependence COL24A1 intron 20201924 rs17128651 chr1 86465736 G A 7.70E-04 Alcohol dependence COL24A1 intron 20201924 rs12143304 chr1 86505755 A G 4.78E-05 Major depressive disorder COL24A1 intron 20516156 rs583315 chr1 86526618 C T 3.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL24A1 intron 20877124 rs17415692 chr1 86533142 C T 5.81E-05 Platelet counts COL24A1 intron pha003100 rs10873744 chr1 86549569 G A 9.76E-04 Lymphocyte counts COL24A1 intron 22286170 rs10493786 chr1 86553669 A C 9.90E-04 Type 2 diabetes and 6 quantitative traits COL24A1 intron 17848626 rs1605417 chr1 86563632 C G 8.37E-05 Acute lymphoblastic leukemia (childhood) COL24A1 intron 19684603 rs12044349 chr1 86566278 T C 3.79E-04 Multiple complex diseases COL24A1 intron 17554300 rs7540048 chr1 86622285 C T 0.000000285 LDL cholesterol / / 23063622 rs1507294 chr1 86637089 T G 1.90E-04 Multiple complex diseases / / 17554300 rs6687339 chr1 86638265 A G 8.42E-04 Type 2 diabetes / / 17463246 rs6576808 chr1 86638748 G A 7.33E-05 Parkinson's disease / / 21738487 rs12083520 chr1 86693196 A C 4.14E-04 Alzheimer's disease / / 17998437 rs11587664 chr1 86714346 G A 2.71E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1323035 chr1 86784804 C A 5.47E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs272500 chr1 86827633 A T 5.18E-13 Lymphocyte counts ODF2L intron 22286170 rs421105 chr1 86838158 C T 5.20E-04 Smoking initiation ODF2L cds-synon 24665060 rs272514 chr1 86845563 T C 6.45E-04 Multiple complex diseases ODF2L intron 17554300 rs1407719 chr1 86851420 A G 8.76E-05 Lung function (forced expiratory volume in 1 second) ODF2L intron pha003102 rs5026277 chr1 86885620 C T 1.89E-04 Smoking initiation / / 24665060 rs1334149 chr1 86899021 A G 8.58E-05 Socioeconomic Factors CLCA2 intron pha003067 rs17409304 chr1 86900372 C G 5.09E-04 Multiple complex diseases CLCA2 missense 17554300 rs11161828 chr1 86902967 A G 9.51E-04 Coronary heart disease CLCA2 intron 21971053 rs2390059 chr1 86909493 C T 9.77E-04 Coronary heart disease CLCA2 cds-synon 21971053 rs2791519 chr1 86934176 T G 3.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs2791516 chr1 86938706 C T 1.05E-06 Systemic lupus erythematosus and Systemic sclerosis CLCA1 intron 23740937 rs5744329 chr1 86940715 G A 1.27E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CLCA1 intron 20031582 rs926064 chr1 86941348 G A 6.46E-04 Type 2 diabetes CLCA1 intron 17463246 rs1321695 chr1 86947747 C A 4.37E-04 Type 2 diabetes CLCA1 intron 17463246 rs2791508 chr1 86954398 T C 1.84E-05 Multiple complex diseases CLCA1 intron 17554300 rs1321689 chr1 86959796 C T 2.78E-04 Smoking initiation CLCA1 intron 24665060 rs1028575 chr1 86966851 T C 2.34E-04 Nicotine dependence / / 17158188 rs2791480 chr1 86968584 C G 4.38E-05 Nicotine dependence / / 17158188 rs17129266 chr1 86969110 G C 6.15E-04 Multiple complex diseases / / 17554300 rs7538979 chr1 86971778 A G 9.15E-04 Multiple complex diseases / / 17554300 rs1321687 chr1 86974034 C A 9.59E-04 Nicotine dependence / / 17158188 rs1321686 chr1 86974115 C T 9.72E-04 Nicotine dependence / / 17158188 rs12734135 chr1 86992633 C T 9.89E-04 Multiple complex diseases / / 17554300 rs12750427 chr1 86995816 A G 1.38E-04 Type 2 diabetes / / 17463246 rs1575177 chr1 87000484 T C 3.79E-05 Waist Circumference / / pha003023 rs11161841 chr1 87003472 T A 7.00E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10782575 chr1 87020617 G T 0.0003651 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CLCA4 intron 23233654 rs10782575 chr1 87020617 G T 3.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) CLCA4 intron 23233662 rs10782575 chr1 87020617 G T 7.44E-05 Amyotrophic lateral sclerosis (sporadic) CLCA4 intron 24529757 rs772605 chr1 87028669 A G 9.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) CLCA4 intron 23233662 rs772601 chr1 87032324 A G 7.45E-04 Multiple complex diseases CLCA4 intron 17554300 rs772598 chr1 87039945 A G 7.57E-04 Type 2 diabetes CLCA4 intron 17463246 rs1953652 chr1 87051201 C T 4.00E-06 IgG glycosylation / / 23382691 rs1953652 chr1 87051201 C T 5.00E-06 IgG glycosylation / / 23382691 rs1953652 chr1 87051201 C T 9.00E-06 IgG glycosylation / / 23382691 rs539145 chr1 87122714 G T 3.83E-04 Multiple complex diseases / / 17554300 rs11161871 chr1 87140602 C A 8.92E-04 Type 2 diabetes / / 17463246 rs3766008 chr1 87184393 C T 6.48E-04 Depression (quantitative trait) SH3GLB1 intron 20800221 rs3766008 chr1 87184393 C T 2.13E-04 Suicide attempts in bipolar disorder SH3GLB1 intron 21423239 rs263462 chr1 87188921 G A 6.44E-04 Depression (quantitative trait) SH3GLB1 intron 20800221 rs263462 chr1 87188921 G A 1.02E-04 Suicide attempts in bipolar disorder SH3GLB1 intron 21423239 rs263482 chr1 87201299 T C 6.36E-04 Depression (quantitative trait) SH3GLB1 intron 20800221 rs263482 chr1 87201299 T C 1.01E-04 Suicide attempts in bipolar disorder SH3GLB1 intron 21423239 rs263480 chr1 87203757 C G 4.90E-04 Depression (quantitative trait) SH3GLB1 intron 20800221 rs263480 chr1 87203757 C G 9.19E-05 Suicide attempts in bipolar disorder SH3GLB1 intron 21423239 rs376906 chr1 87212934 G A 4.94E-04 Depression (quantitative trait) SH3GLB1 UTR-3 20800221 rs376906 chr1 87212934 G A 1.99E-04 Suicide attempts in bipolar disorder SH3GLB1 UTR-3 21423239 rs263491 chr1 87223804 T G 4.95E-04 Depression (quantitative trait) / / 20800221 rs263491 chr1 87223804 T G 4.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs263489 chr1 87227431 A T 4.97E-04 Depression (quantitative trait) / / 20800221 rs263489 chr1 87227431 A T 3.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs263485 chr1 87234742 A G 5.05E-04 Depression (quantitative trait) / / 20800221 rs263485 chr1 87234742 A G 2.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs166412 chr1 87242062 T G 1.43E-04 Multiple complex diseases / / 17554300 rs691531 chr1 87245278 C T 9.90E-07 Multiple complex diseases / / 17554300 rs691481 chr1 87246014 A G 2.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs691241 chr1 87246327 A G 2.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs692441 chr1 87255790 T C 7.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs525467 chr1 87256056 G A 9.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs797979 chr1 87258974 G T 8.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs12074463 chr1 87259306 T C 9.52E-04 Parkinson's disease / / 17052657 rs12074463 chr1 87259306 T C 0.0003261 Sarcoidosis / / 22952805 rs492895 chr1 87260215 A G 0.00058066 Sarcoidosis / / 22952805 rs797978 chr1 87263948 A G 0.00059295 Sarcoidosis / / 22952805 rs691396 chr1 87265806 T C 5.03E-05 C-Reactive Protein / / pha003070 rs691369 chr1 87266144 G A 8.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs691135 chr1 87266383 T A 4.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs691155 chr1 87269292 C T 3.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs6698706 chr1 87276009 T A 3.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs1335853 chr1 87288314 C T 3.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs17129524 chr1 87288755 A G 3.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs10782586 chr1 87292548 C G 6.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs7539403 chr1 87297001 T C 8.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs12142266 chr1 87297849 T C 9.89E-04 Obesity (extreme) / / 21935397 rs12142266 chr1 87297849 T C 1.20E-04 Suicidal ideation / / 22030708 rs17418454 chr1 87482713 G A 6.05E-04 HIV-1 viral setpoint HS2ST1 intron 17641165 rs6576860 chr1 87485257 C T 4.80E-04 Insulin resistance HS2ST1 intron 21901158 rs17452535 chr1 87488653 A G 5.49E-05 Stroke HS2ST1 intron pha002886 rs17452535 chr1 87488653 A G 4.14E-05 Glucose levels HS2ST1 intron pha003061 rs12120670 chr1 87577135 T A 3.71E-04 Depression (quantitative trait) / / 20800221 rs7553864 chr1 87613358 T C 3.00E-06 Smoking behavior LOC339524 intron 19247474 rs10873823 chr1 87660268 A T 2.79E-05 Bipolar disorder / / 19488044 rs6576874 chr1 87675036 G A 8.57E-05 Erythrocyte counts / / pha003101 rs7542364 chr1 87687466 A G 5.03E-05 Erythrocyte counts / / pha003101 rs10873824 chr1 87688394 A G 1.42E-05 Mathematical ability / / 24801482 rs7546843 chr1 87699558 A G 5.79E-04 Multiple complex diseases / / 17554300 rs6576878 chr1 87705031 A G 6.00E-06 White blood cell types / / 21738478 rs1109790 chr1 87710779 G A 3.31E-05 Multiple complex diseases / / 17554300 rs882573 chr1 87711640 A T 9.19E-04 Multiple complex diseases / / 17554300 rs4655937 chr1 87712256 C T 7.87E-04 Type 2 diabetes / / 17463246 rs4655937 chr1 87712256 C T 5.28E-04 Multiple complex diseases / / 17554300 rs10493797 chr1 87720928 G C 1.79E-04 Multiple complex diseases / / 17554300 rs1411705 chr1 87728263 G C 1.49E-04 Multiple complex diseases / / 17554300 rs11583437 chr1 87729323 A G 1.75E-04 Multiple complex diseases / / 17554300 rs1888340 chr1 87731239 G A 2.52E-04 Multiple complex diseases / / 17554300 rs12035326 chr1 87739930 A G 0.000138 Salmonella-induced pyroptosis / / 22837397 rs6576888 chr1 87746317 T G 4.72E-05 Serum metabolites / / 19043545 rs6576888 chr1 87746317 T G 5.87E-06 Post-operative nausea and vomiting / / 21694509 rs6576888 chr1 87746317 T G 4.30E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs10127691 chr1 87748856 T C 4.00E-05 Prostate cancer / / 21743057 rs6675584 chr1 87752776 C A 7.01E-06 Blood pressure (response to calcium channel blocker) / / 24192120 rs6688319 chr1 87752886 A C 6.02E-04 Type 2 diabetes / / 17463246 rs6688319 chr1 87752886 A C 3.52E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs6576889 chr1 87762304 C T 1.40E-05 Urinary metabolites / / 21572414 rs11161973 chr1 87769531 T C 2.50E-05 Urinary metabolites / / 21572414 rs879988 chr1 87774197 G T 2.50E-05 Urinary metabolites / / 21572414 rs4655952 chr1 87776842 G A 2.50E-05 Urinary metabolites / / 21572414 rs17422436 chr1 87834794 G A 8.60E-04 Type 2 diabetes LOC100505768 intron 23209189 rs11161992 chr1 87835674 C T 5.55E-04 Taste perception LOC100505768 intron 22132133 rs12094766 chr1 87836555 T C 8.62E-04 Multiple complex diseases LOC100505768 intron 17554300 rs11161993 chr1 87838608 A G 1.61E-04 Taste perception / / 22132133 rs11582903 chr1 87846054 C A 3.94E-06 Aging (time to event) / / 21782286 rs11162001 chr1 87862587 C T 9.59E-04 Alzheimer's disease / / 24755620 rs4655956 chr1 87868540 A G 8.56E-04 Alzheimer's disease / / 24755620 rs12758097 chr1 87877226 G A 2.26E-04 Tourette syndrome / / 22889924 rs12758097 chr1 87877226 G A 8.61E-04 Alzheimer's disease / / 24755620 rs1006625 chr1 87877540 A G 8.55E-04 Alzheimer's disease / / 24755620 rs10873844 chr1 87882213 C T 9.67E-04 Alzheimer's disease / / 24755620 rs12565028 chr1 87921397 C T 1.00E-05 Urinary metabolites / / 21572414 rs17131727 chr1 87950279 T C 2.64E-04 Tourette syndrome / / 22889924 rs12410191 chr1 88036573 T G 6.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs902296 chr1 88039284 C A 5.13E-04 Multiple complex diseases / / 17554300 rs902296 chr1 88039284 C A 4.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9433138 chr1 88055578 G A 6.42E-04 Depression (quantitative trait) / / 20800221 rs60417255 chr1 88055640 G T 0.0000469 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6696952 chr1 88071963 A G 2.51E-04 Schizophrenia / / 20832056 rs11162051 chr1 88078503 C T 4.79E-04 Smoking quantity / / 24665060 rs923545 chr1 88083782 G A 4.11E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs4655977 chr1 88086152 T C 3.73E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4655978 chr1 88087990 C G 5.30E-06 Urinary metabolites / / 21572414 rs1490166 chr1 88119200 C T 1.40E-05 Urinary metabolites / / 21572414 rs1414648 chr1 88128663 T C 3.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs12132154 chr1 88129038 C A 8.72E-05 Cognitive impairment induced by topiramate / / 22091778 rs6678935 chr1 88131531 G T 3.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs983332 chr1 88132380 G T 5.00E-06 Response to TNF antagonist treatment / / 18615156 rs983332 chr1 88132380 G T 1.50E-04 Endometriosis / / 21151130 rs10922746 chr1 88149030 A C 7.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs17130103 chr1 88150542 T C 1.89E-10 Multiple complex diseases / / 17554300 rs17130108 chr1 88154873 A C 8.71E-04 Multiple complex diseases / / 17554300 rs12568911 chr1 88166163 A G 3.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs305467 chr1 88168623 T A 6.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs10801871 chr1 88176320 A G 3.70E-05 Primary sclerosing cholangitis / / 19944697 rs305445 chr1 88208135 G A 1.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs35214987 chr1 88226329 G C 2.40E-05 Urinary metabolites / / 21572414 rs35214987 chr1 88226329 G C 9.00E-07 Cognitive function / / 24684796 rs2436974 chr1 88240066 G A 5.63E-04 Iron levels / / pha002876 rs1369036 chr1 88261805 A G 3.42E-06 Multiple complex diseases / / 17554300 rs2491281 chr1 88287371 C T 8.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs6673871 chr1 88301277 A G 3.92E-04 Smoking initiation / / 24665060 rs2491302 chr1 88313724 T C 4.91E-04 Alzheimer's disease (late onset) / / 21379329 rs10218533 chr1 88335474 T C 0.000517 Salmonella-induced pyroptosis / / 22837397 rs41341750 chr1 88338185 A C 9.36E-05 Multiple complex diseases / / 17554300 rs3008440 chr1 88343418 A G 1.90E-04 Alzheimer's disease (late onset) / / 21379329 rs2503248 chr1 88358924 T C 1.45E-04 IgE levels / / 17255346 rs2503251 chr1 88363167 C A 3.50E-04 Multiple complex diseases / / 17554300 rs2503253 chr1 88363289 T C 3.78E-05 IgE levels / / 17255346 rs2503256 chr1 88364454 A G 1.24E-04 IgE levels / / 17255346 rs17130220 chr1 88399387 T C 2.98E-05 Multiple complex diseases / / 17554300 rs10489945 chr1 88413589 C T 8.39E-04 Schizophrenia / / 19197363 rs6691335 chr1 88416590 T C 6.58E-05 Cognitive impairment induced by topiramate / / 22091778 rs1413536 chr1 88423397 C T 1.64E-04 Coronary heart disease / / 21606135 rs2991716 chr1 88423966 T C 2.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1413527 chr1 88430037 T C 6.12E-05 Serum metabolites / / 19043545 rs1334331 chr1 88441066 C A 1.18E-04 Coronary heart disease / / 21606135 rs3008465 chr1 88453303 A C 8.07E-04 HIV-1 viral setpoint / / 17641165 rs12133568 chr1 88495250 A G 3.37E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4265406 chr1 88497975 A G 7.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs12133500 chr1 88499703 G C 6.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs12567534 chr1 88500903 A G 6.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs12143926 chr1 88504370 T C 2.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs12566596 chr1 88506791 G C 2.69E-04 Suicide attempts in bipolar disorder / / 21041247 rs12117077 chr1 88512371 T C 2.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs10923014 chr1 88513365 C T 2.19E-04 Suicide attempts in bipolar disorder / / 21041247 rs4655998 chr1 88514186 A C 2.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs4656000 chr1 88514400 G A 2.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs4656001 chr1 88514430 A G 2.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs4656002 chr1 88514728 C T 1.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs10923015 chr1 88514979 T A 1.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs4656003 chr1 88515494 C T 1.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs12568661 chr1 88519718 G A 5.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs12118601 chr1 88521377 C T 1.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs4655864 chr1 88521416 T A 5.08E-04 Multiple complex diseases / / 17554300 rs4656008 chr1 88524540 G T 5.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs10754315 chr1 88529368 T C 5.20E-04 Suicide attempts in bipolar disorder / / 21041247 rs4656013 chr1 88604157 C T 6.57E-04 Obesity (extreme) / / 21935397 rs1336578 chr1 88610289 C T 6.58E-06 Serum metabolites / / 19043545 rs1336578 chr1 88610289 C T 6.44E-06 Stroke (ischemic) / / 22941190 rs17130276 chr1 88621694 A C 8.77E-04 Multiple complex diseases / / 17554300 rs12032672 chr1 88625636 A C 1.00E-06 Periodontal microbiota / / 22699663 rs1932754 chr1 88634245 G A 9.50E-05 Serum metabolites / / 19043545 rs1932754 chr1 88634245 G A 9.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs12041762 chr1 88641601 C T 3.30E-05 Diabetic retinopathy / / 21441570 rs12041762 chr1 88641601 C T 8.19E-05 Heart Rate / / pha003054 rs12567486 chr1 88645313 T C 7.70E-05 Diabetic retinopathy / / 21441570 rs4656020 chr1 88646891 G A 7.80E-05 Diabetic retinopathy / / 21441570 rs10923035 chr1 88647092 C T 2.01E-04 Taste perception / / 22132133 rs10923038 chr1 88651771 C A 4.00E-07 Serum protein levels (sST2) / / 23999434 rs12755168 chr1 88657007 T G 5.73E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1932757 chr1 88665329 T C 7.08E-05 Coronary heart disease / / 21606135 rs6698308 chr1 88666005 A G 2.74E-04 Multiple complex diseases / / 17554300 rs12032086 chr1 88673612 T C 6.70E-04 Type 2 diabetes / / 17463246 rs10493803 chr1 88673676 G T 1.85E-04 Coronary heart disease / / 21606135 rs12403601 chr1 88674545 G T 2.14E-04 Coronary heart disease / / 21606135 rs10923044 chr1 88681580 T C 7.72E-05 Coronary heart disease / / 21606135 rs6684410 chr1 88682190 C T 9.66E-05 Multiple complex diseases / / 17554300 rs4300194 chr1 88699950 T C 1.16E-04 Coronary heart disease / / 21606135 rs12730130 chr1 88701591 T A 1.21E-04 Coronary heart disease / / 21606135 rs673212 chr1 88728999 C G 3.40E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs472473 chr1 88738404 G A 4.37E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1295491 chr1 88740865 T C 1.69E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1288671 chr1 88741916 G C 7.31E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs569619 chr1 88742010 T G 1.36E-04 Coronary heart disease / / 21606135 rs10923053 chr1 88743657 A G 1.33E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6679982 chr1 88757128 C T 3.24E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6692873 chr1 88760420 C T 3.10E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs608410 chr1 88770663 T C 7.44E-04 Coronary heart disease / / 21606135 rs591604 chr1 88779226 A C,G,T 1.90E-04 Coronary heart disease / / 21606135 rs589824 chr1 88779625 C T 6.17E-05 Coronary heart disease / / 21606135 rs555994 chr1 88780562 C T 1.11E-05 Coronary heart disease / / 21606135 rs473821 chr1 88781342 C T 3.09E-06 Coronary heart disease / / 21606135 rs687790 chr1 88786051 C T 5.57E-05 Orofacial clefts / / 22419666 rs127382 chr1 88788948 T C 4.21E-04 Coronary heart disease / / 21606135 rs127384 chr1 88790960 T C 1.43E-04 Coronary heart disease / / 21606135 rs127384 chr1 88790960 T C 6.04E-05 Orofacial clefts / / 22419666 rs480054 chr1 88791432 G A 1.97E-04 Coronary heart disease / / 21606135 rs2179965 chr1 88802012 A G 1.00E-06 Cognitive test performance / / 17903297 rs766353 chr1 88821516 A G 2.18E-04 Coronary heart disease / / 21606135 rs6682490 chr1 88825290 T A 6.25E-04 Coronary heart disease / / 21606135 rs9428070 chr1 88838394 G T 1.35E-04 Aortic root size / / 21223598 rs9287153 chr1 88840027 T A 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs400666 chr1 88855885 T C 4.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs507241 chr1 88855999 A G 7.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10801891 chr1 88906024 G A 7.33E-05 Monocyte chemoattractant protein-1 / / pha003071 rs12723729 chr1 88919469 A G 6.96E-05 Monocyte chemoattractant protein-1 / / pha003071 rs2044264 chr1 88965798 A G 0.000097 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs306336 chr1 88972879 A G 0.00000194 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs12409611 chr1 88973472 T C 0.0000102 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs6671025 chr1 88979447 C A 0.0000122 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs10493815 chr1 89016499 G A 4.77E-05 Neutrophil count / / pha003095 rs306298 chr1 89020534 G A 7.70E-05 Parkinson's disease (age of onset) / / 19772629 rs642773 chr1 89040252 C T 0.000057 Tuberculosis with late age of onset / / 22551897 rs642773 chr1 89040252 C T 4.65E-04 Myocardial Infarction / / pha002883 rs12024611 chr1 89072924 G A 3.94E-05 Celiac disease / / 23936387 rs17130538 chr1 89079544 C T 1.79E-06 Retinopathy in non-diabetics / / 23393555 rs1373259 chr1 89081648 A G 4.40E-06 Urinary metabolites / / 21572414 rs662452 chr1 89104124 T C 7.67E-04 Multiple complex diseases / / 17554300 rs7534720 chr1 89116300 T C 5.44E-05 Celiac disease / / 23936387 rs6699417 chr1 89123443 C T 5.00E-09 Height / / 20881960 rs6699417 chr1 89123443 C T 3.33E-05 Monocyte counts / / pha003089 rs10493817 chr1 89126887 T G 1.54E-04 Celiac disease / / 23936387 rs10493817 chr1 89126887 T G 7.68E-05 Monocyte counts / / pha003089 rs10754252 chr1 89133812 G A 3.33E-05 Monocyte counts / / pha003089 rs1490738 chr1 89137605 A C 0.000148 Coronary artery disease / / 23202125 rs6698181 chr1 89143305 C T 5.30E-05 Type 2 diabetes / / 17463246 rs12145922 chr1 89146234 C A 2.40E-05 Height / / 21194676 rs12145922 chr1 89146234 C A 2.70E-08 Height / / 21194676 rs12145922 chr1 89146234 C A 3.30E-04 Height / / 21194676 rs12145922 chr1 89146234 C A 4.00E-11 Liver enzyme levels (gamma-glutamyl transferase) / / 22001757 rs3806340 chr1 89148793 G T 5.63E-05 Monocyte counts / / pha003089 rs430600 chr1 89225976 T C 1.72E-04 Celiac disease PKN2 cds-synon 23936387 rs12744822 chr1 89247191 A T 0.00018 Coronary artery calcification PKN2 intron 23727086 rs786911 chr1 89265248 T C 1.92E-04 Celiac disease PKN2 intron 23936387 rs786911 chr1 89265248 T C 7.53E-05 Monocyte counts PKN2 intron pha003089 rs786921 chr1 89286673 G A 2.87E-04 Celiac disease PKN2 intron 23936387 rs10801687 chr1 89307261 G A 2.38E-04 Celiac disease / / 23936387 rs10801687 chr1 89307261 G A 7.53E-05 Monocyte counts / / pha003089 rs17130643 chr1 89341408 C T 4.00E-06 Obesity-related traits GTF2B intron 23251661 rs7524919 chr1 89372589 G A 0.000678964 Hypertension (early onset hypertension) / / 22479346 rs10922510 chr1 89373702 C T 7.84E-05 Bipolar disorder / / 20451256 rs11805182 chr1 89375410 C T 7.78E-05 Bipolar disorder / / 20451256 rs13375223 chr1 89376633 C T 2.63E-05 Bipolar disorder / / 20451256 rs7538497 chr1 89384717 T G 0.000712901 Hypertension (early onset hypertension) / / 22479346 rs7524728 chr1 89384950 C T 0.000712901 Hypertension (early onset hypertension) / / 22479346 rs17472003 chr1 89409488 A G 6.44E-05 Bipolar disorder CCBL2 intron 20451256 rs10922530 chr1 89427252 G A 8.70E-07 Pulmonary function CCBL2 intron 17903307 rs3753683 chr1 89427571 G C 1.87E-06 Pulmonary function CCBL2 intron 17903307 rs1409149 chr1 89429149 T C 9.12E-06 Pulmonary function CCBL2 intron 17903307 rs10518418 chr1 89437113 G T 7.49E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CCBL2 intron 20031582 rs1409150 chr1 89473175 T C 4.28E-04 Prostate cancer mortality GBP3 UTR-3 20978177 rs4656078 chr1 89479074 C T 9.86E-04 Alzheimer's disease GBP3 missense 24755620 rs10801705 chr1 89500382 G A 2.07E-04 Parkinson's disease / / 17052657 rs2149186 chr1 89505043 G T 3.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs6675866 chr1 89517810 T C 9.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs12408132 chr1 89517918 C T 8.71E-04 Suicide attempts in bipolar disorder / / 21041247 rs12740160 chr1 89551004 G A 8.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs12725861 chr1 89566096 G A 9.50E-04 Alzheimer's disease (late onset) / / 21460841 rs2209957 chr1 89583573 A G 8.52E-05 ldl cholesterol GBP2 intron pha003077 rs6428503 chr1 89584069 T C 6.70E-04 Alzheimer's disease (late onset) GBP2 intron 20885792 rs6428503 chr1 89584069 T C 6.70E-04 Alzheimer's disease (late onset) GBP2 intron 21460841 rs10922573 chr1 89588380 A G 8.30E-04 Alzheimer's disease (late onset) GBP2 intron 21460841 rs10922574 chr1 89589383 T C 6.53E-04 Suicide attempts in bipolar disorder GBP2 intron 21041247 rs2893089 chr1 89630721 G T 6.54E-04 Suicide attempts in bipolar disorder GBP7 intron 21041247 rs615739 chr1 89643644 A G 3.35E-05 Cholesterol / / pha003083 rs6703905 chr1 89656749 C T 1.43E-04 Bipolar disorder GBP4 intron 18317468 rs7547610 chr1 89696603 G A 6.99E-04 Myocardial Infarction / / pha002873 rs2209307 chr1 89723344 G A 7.62E-05 Multiple complex diseases / / 17554300 rs148301962 chr1 89726438 G A 0.000029 Breast cancer (ER positive) GBP5 cds-synon 23555315 rs1117177 chr1 89787286 A G 4.88E-05 Hypertension / / pha003041 rs6669828 chr1 89804195 G A 1.50E-05 Urinary metabolites / / 21572414 rs7511795 chr1 89842459 T C 9.70E-05 Iron levels GBP6 intron 21208937 rs928652 chr1 89849201 C G 7.80E-05 Parkinson's disease (familial) GBP6 intron 18985386 rs1984129 chr1 89857106 G A 5.20E-05 Parkinson's disease (familial) / / 18985386 rs1984129 chr1 89857106 G A 6.86E-05 Alzheimer's disease (late onset) / / 21379329 rs928656 chr1 89859768 C T 9.73E-05 Alzheimer's disease (late onset) / / 21379329 rs12098051 chr1 89890973 G T 3.60E-05 Intracerebral hemorrhage / / 24656865 rs12753970 chr1 89893138 A G 1.90E-05 Personality dimensions / / 22628180 rs7545722 chr1 89894471 A G 6.40E-05 Parkinson's disease (familial) / / 18985386 rs72953868 chr1 89896790 G A 1.43E-05 Intracerebral hemorrhage / / 24656865 rs72953868 chr1 89896790 G A 3.57E-05 Intracerebral hemorrhage / / 24656865 rs11577456 chr1 89899019 G A 2.43E-05 Intracerebral hemorrhage / / 24656865 rs11577456 chr1 89899019 G A 4.46E-05 Intracerebral hemorrhage / / 24656865 rs4259628 chr1 89927234 G A 1.43E-04 Coronary Artery Disease / / 17634449 rs3929231 chr1 89927727 C T 1.49E-04 Coronary Artery Disease / / 17634449 rs6692501 chr1 89935101 A G 1.50E-05 Urinary metabolites / / 21572414 rs1585364 chr1 89972062 G T 5.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2125724 chr1 90000410 C G 1.46E-05 Personality dimensions LRRC8B intron 22628180 rs9428043 chr1 90005132 T C 4.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) LRRC8B intron 23648065 rs9428043 chr1 90005132 T C 9.25E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) LRRC8B intron 23648065 rs922107 chr1 90022796 A G 3.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) LRRC8B intron 23648065 rs6699344 chr1 90023768 G A 2.02E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LRRC8B intron 23648065 rs6699344 chr1 90023768 G A 2.73E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) LRRC8B intron 23648065 rs6699344 chr1 90023768 G A 4.13E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) LRRC8B intron 23648065 rs922106 chr1 90025519 C A 9.00E-07 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) LRRC8B intron 23648065 rs17099922 chr1 90027582 C T 0.000871 Salmonella-induced pyroptosis LRRC8B intron 22837397 rs10922664 chr1 90032940 A G 3.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LRRC8B intron 23648065 rs10922664 chr1 90032940 A G 5.80E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) LRRC8B intron 23648065 rs10922664 chr1 90032940 A G 9.28E-07 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) LRRC8B intron 23648065 rs7516314 chr1 90050831 A G 3.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LRRC8B intron 23648065 rs7516314 chr1 90050831 A G 3.77E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) LRRC8B intron 23648065 rs7516314 chr1 90050831 A G 5.80E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) LRRC8B intron 23648065 rs12135419 chr1 90053245 C T 3.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LRRC8B intron 23648065 rs12135419 chr1 90053245 C T 3.77E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) LRRC8B intron 23648065 rs12135419 chr1 90053245 C T 5.80E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) LRRC8B intron 23648065 rs6428557 chr1 90066090 T G 3.53E-04 Multiple complex diseases / / 17554300 rs6428558 chr1 90066415 T C 2.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1215494 chr1 90066806 G A 1.60E-05 Bone mineral density (BMD),in women / / 20164292 rs1215547 chr1 90072888 C T 3.67E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6428561 chr1 90102619 G A 1.34E-04 Nicotine smoking LRRC8C intron 19268276 rs10754283 chr1 90112431 G T 5.00E-06 Amyotrophic lateral sclerosis (sporadic) LRRC8C intron 24529757 rs2390794 chr1 90125566 G A 1.23E-04 Nicotine smoking LRRC8C intron 19268276 rs2390794 chr1 90125566 G A 1.13E-08 Metabolite levels LRRC8C intron 23281178 rs10801766 chr1 90125934 C T 7.86E-09 Metabolite levels LRRC8C intron 23281178 rs17494625 chr1 90126393 G A 7.88E-04 Body mass index LRRC8C intron 21701565 rs10737709 chr1 90126813 A T 2.27E-08 Metabolite levels LRRC8C intron 23281178 rs2146338 chr1 90221128 C T 2.87E-07 Lymphocyte counts / / 22286170 rs1215582 chr1 90239551 A G 4.46E-05 Bipolar disorder / / 19488044 rs1215582 chr1 90239551 A G 8.52E-05 Bipolar Disorder / / pha002863 rs7549625 chr1 90251996 G A 9.57E-04 Multiple complex diseases / / 17554300 rs10754295 chr1 90322384 C T 6.56E-05 Serum metabolites LRRC8D intron 19043545 rs2802031 chr1 90339669 A G 4.68E-04 Coronary Artery Disease LRRC8D intron 17634449 rs4658342 chr1 90356770 T G 6.71E-04 Taste perception LRRC8D intron 22132133 rs1938032 chr1 90357651 G A 7.05E-04 Type 2 diabetes LRRC8D intron 17463246 rs2703986 chr1 90447918 G T 5.45E-05 Personality dimensions / / 18957941 rs2490113 chr1 90456097 C G 2.24E-05 Personality dimensions / / 18957941 rs10922743 chr1 90492517 A G 7.97E-05 Blood Pressure ZNF326 intron pha003046 rs2816855 chr1 90501669 A G 8.90E-05 Serum metabolites / / 19043545 rs17130950 chr1 90511157 C T 7.46E-04 Type 2 diabetes / / 17463246 rs2813746 chr1 90539764 C A 1.72E-06 Temporal lobe volumes / / 20197096 rs2813747 chr1 90539813 T G 8.91E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2390866 chr1 90546731 A G 8.70E-05 Coronary heart disease / / pha003032 rs2390866 chr1 90546731 A G 8.56E-05 Fibrinogen / / pha003068 rs17130969 chr1 90556150 G T 3.77E-05 Height / / pha003011 rs2813760 chr1 90569361 A G 4.59E-05 Hypertension / / 19609347 rs2813760 chr1 90569361 A G 4.21E-05 Fibrinogen / / pha003068 rs1329644 chr1 90575147 T C 7.41E-05 Height / / pha003010 rs12409406 chr1 90582562 C T 2.58E-05 Fibrinogen / / pha003068 rs4456078 chr1 90594990 C T 1.38E-04 Body mass index / / 17255346 rs6428571 chr1 90600934 C T 1.19E-05 Colorectal cancer / / 21242260 rs6428572 chr1 90601121 T C 2.22E-05 Cognitive test performance / / 20125193 rs3922967 chr1 90626396 C T 3.15E-05 Gaucher disease severity / / 22388998 rs17130996 chr1 90660195 G C 5.08E-04 Type 2 diabetes / / 17463246 rs17130996 chr1 90660195 G C 5.80E-06 Urinary metabolites / / 21572414 rs17130997 chr1 90664986 A G 8.15E-05 Hearing function / / 17255346 rs10922809 chr1 90668256 G T 2.32E-04 Hearing function / / 17255346 rs7553296 chr1 90671625 C A 1.98E-04 Cholesterol / / 17255346 rs10754299 chr1 90674002 G A 2.28E-04 Cholesterol / / 17255346 rs4233435 chr1 90738800 C T 2.36E-04 Type 2 diabetes / / 17463246 rs3923534 chr1 90739291 C A 6.50E-04 Type 2 diabetes / / 17463246 rs12060187 chr1 90753594 G A 2.01E-04 Type 2 diabetes / / 17463246 rs4578202 chr1 90799813 C T 6.18E-05 Multiple complex diseases / / 17554300 rs10801805 chr1 90820257 G A 3.00E-06 Upper aerodigestive tract cancers / / 21437268 rs17131014 chr1 90830678 C G 7.10E-04 Multiple complex diseases / / 17554300 rs4658158 chr1 90849539 C T 8.92E-04 Bipolar disorder,schizoaffective / / 19567891 rs10218464 chr1 90866978 A T 9.47E-07 Response to antidepressants / / 20360315 rs6701608 chr1 90869227 A C 4.66E-07 Response to antidepressants / / 20360315 rs17131041 chr1 90873828 C T 9.89E-04 Multiple complex diseases / / 17554300 rs2136093 chr1 90875888 T C 4.00E-07 Response to antidepressants / / 20360315 rs1472887 chr1 90879608 T C 5.85E-07 Response to antidepressants / / 20360315 rs7522605 chr1 90894538 G C 7.72E-07 Response to antidepressants / / 20360315 rs1027854 chr1 90915627 A G 7.55E-07 Response to antidepressants / / 20360315 rs1337576 chr1 90916072 A G 2.35E-06 Response to antidepressants / / 20360315 rs506368 chr1 90920022 G A 7.49E-07 Response to antidepressants / / 20360315 rs2136094 chr1 90925982 C A 5.86E-07 Response to antidepressants / / 20360315 rs10801814 chr1 90931765 T C 9.17E-04 Coronary Artery Disease / / 17634449 rs2390582 chr1 90943907 A G 2.00E-05 Biomarkers / / 17903293 rs2390582 chr1 90943907 A G 1.00E-06 Coronary artery calcification / / 17903303 rs699526 chr1 90952184 G A 7.58E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10159226 chr1 91010959 G A 4.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10922885 chr1 91091083 G A 3.53E-04 Multiple complex diseases / / 17554300 rs4233429 chr1 91099903 T G 9.23E-06 Personality dimensions / / 23658558 rs10754306 chr1 91132104 C T 5.62E-06 Lipid traits / / 21777205 rs12046571 chr1 91137786 G T 6.41E-04 Alzheimer's disease / / 24755620 rs12116456 chr1 91141196 G A 8.28E-05 Alcoholism / / pha002893 rs12116456 chr1 91141196 G A 4.99E-05 Soluble levels of adhesion molecules / / pha003072 rs17131133 chr1 91155931 A G 5.10E-05 Alcohol dependence / / 20201924 rs17131133 chr1 91155931 A G 5.10E-05 Alcoholism / / pha002893 rs17131133 chr1 91155931 A G 4.99E-05 Soluble levels of adhesion molecules / / pha003072 rs10922903 chr1 91159586 T C 2.80E-05 Urinary metabolites / / 21572414 rs12133004 chr1 91175419 T C 2.70E-05 Alcohol dependence / / 20201924 rs12133004 chr1 91175419 T C 8.80E-04 Alcohol dependence / / 20201924 rs12133004 chr1 91175419 T C 2.75E-05 Alcoholism / / pha002893 rs4101233 chr1 91238773 C T 4.66E-05 Serum metabolites / / 19043545 rs6676886 chr1 91244343 C G 5.90E-05 Serum metabolites / / 19043545 rs3845561 chr1 91246342 G A 5.15E-05 Serum metabolites / / 19043545 rs10922924 chr1 91252863 G A 9.46E-05 Serum metabolites LOC100505821 intron 19043545 rs3843306 chr1 91288130 T A 5.00E-06 Pulmonary function decline LOC100505821 intron 22424883 rs17131213 chr1 91291013 A T 1.76E-05 Serum metabolites LOC100505821 intron 19043545 rs2390647 chr1 91358183 T C 9.65E-14 Gender / / 22362730 rs165284 chr1 91523553 A T 8.60E-05 Longevity and age-related phenotypes / / 17903295 rs469846 chr1 91529589 G A 3.43E-05 Systemic lupus erythematosus / / pha002867 rs164898 chr1 91569689 G A 6.00E-06 Metabolic syndrome / / 20694148 rs458190 chr1 91600305 G A 2.99E-04 Smoking cessation / / 24665060 rs609256 chr1 91602617 A T 4.26E-05 Smoking cessation / / 24665060 rs17482259 chr1 91619499 G T 7.45E-06 Serum metabolites / / 19043545 rs613217 chr1 91620228 G A 5.38E-04 Smoking cessation / / 24665060 rs599513 chr1 91622835 T C 3.74E-04 Smoking cessation / / 24665060 rs616710 chr1 91626325 T C 4.56E-04 Smoking cessation / / 24665060 rs17542509 chr1 91636192 C A 9.85E-04 Type 2 diabetes / / 17463246 rs665484 chr1 91663930 C A 2.30E-04 Primary sclerosing cholangitis / / 19944697 rs635894 chr1 91667917 A G 2.43E-04 Smoking cessation / / 24665060 rs635894 chr1 91667917 A G 5.41E-06 Height / / pha003010 rs635894 chr1 91667917 A G 6.90E-05 Height / / pha003011 rs12563349 chr1 91683648 G A 2.22E-04 Type 2 diabetes / / 17463246 rs11487636 chr1 91695097 A C 4.58E-04 Alzheimer's disease (late onset) / / 21379329 rs12403887 chr1 91699151 A C 1.49E-04 Type 2 diabetes / / 17463246 rs281966 chr1 91738762 T C 3.75E-04 Alzheimer's disease (late onset) HFM1 intron 21379329 rs12567930 chr1 91800946 A G 4.65E-04 Type 2 diabetes HFM1 intron 17463246 rs11166001 chr1 91872374 C T 5.71E-04 Multiple complex diseases / / 17554300 rs383730 chr1 91881997 C G 5.40E-07 Intracranial aneurysm / / 20364137 rs17485896 chr1 91887372 T C 3.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs12744237 chr1 91901342 T A 3.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs6683496 chr1 91917977 T G 9.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs7540260 chr1 91919533 A G 9.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs505892 chr1 91937695 A G 6.25E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs497379 chr1 91938724 C T 3.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs522712 chr1 91943207 T G 7.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs10493847 chr1 91944713 C T 4.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs6604023 chr1 91944897 G C 4.29E-06 Coronary artery calcification / / 22144573 rs546872 chr1 91970335 C T 5.15E-04 Multiple complex diseases CDC7 intron 17554300 rs483532 chr1 91980447 A G 2.07E-05 Body Mass Index CDC7 cds-synon pha003007 rs483532 chr1 91980447 A G 1.33E-05 Weight CDC7 cds-synon pha003027 rs1983170 chr1 91986482 G A 5.21E-05 Body Mass Index CDC7 intron pha003007 rs1983170 chr1 91986482 G A 2.15E-05 Weight CDC7 intron pha003027 rs6688261 chr1 91987034 C T 9.09E-04 Multiple complex diseases CDC7 intron 17554300 rs12127718 chr1 91997490 T A 9.40E-06 Digit length ratio / / 20303062 rs595801 chr1 91999640 A G 2.51E-04 Multiple complex diseases / / 17554300 rs17501381 chr1 92003919 T C 3.77E-05 Cognitive decline / / 23732972 rs17501512 chr1 92012481 G C 2.13E-04 Cognitive decline / / 23732972 rs963911 chr1 92014051 G T 2.01E-04 Glycosylated haemoglobin levels / / 17255346 rs963911 chr1 92014051 G T 1.22E-39 Narcolepsy / / 19629137 rs11164935 chr1 92015389 C A 1.48E-05 Glycosylated haemoglobin levels / / 17255346 rs1949009 chr1 92016653 T C 2.62E-05 Body Mass Index / / pha003007 rs1949009 chr1 92016653 T C 4.17E-06 Weight / / pha003027 rs17131491 chr1 92017649 A C 7.24E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12134245 chr1 92021464 C T 6.24E-05 Weight / / pha003027 rs6687904 chr1 92025262 A G 6.89E-05 Blood Pressure / / pha003043 rs4658231 chr1 92041502 A G 4.38E-04 Obesity (extreme) / / 21935397 rs4658232 chr1 92042039 G A 4.27E-04 Obesity (extreme) / / 21935397 rs17131499 chr1 92061160 C T 8.96E-04 Obesity (extreme) / / 21935397 rs12031250 chr1 92061445 T C 8.45E-04 Obesity (extreme) / / 21935397 rs12029135 chr1 92062074 C T 8.42E-04 Obesity (extreme) / / 21935397 rs4658238 chr1 92064082 C T 1.10E-05 Urinary metabolites / / 21572414 rs12028899 chr1 92064350 T C 8.41E-04 Obesity (extreme) / / 21935397 rs12024768 chr1 92065464 G T 7.62E-04 Obesity (extreme) / / 21935397 rs1192415 chr1 92077097 G A 3.00E-07 optic disc size (disc) / / 20395239 rs1192415 chr1 92077097 G A 3.00E-28 Optic disc parameters / / 20548946 rs1192415 chr1 92077097 G A 8.00E-17 Optic disc parameters / / 21307088 rs1192415 chr1 92077097 G A 9.31E-12 Glaucoma-related traits / / 22058429 rs1192419 chr1 92080059 A G 1.02E-11 Glaucoma-related traits / / 22058429 rs1192419 chr1 92080059 A G 8.22E-09 Glaucoma-related traits / / 22058429 rs1192419 chr1 92080059 A G 8.95E-12 Glaucoma-related traits / / 22058429 rs4658104 chr1 92087522 G A 9.53E-04 Alzheimer's disease / / 24755620 rs1887054 chr1 92099741 G A 6.93E-05 Asthma / / 23181788 rs2478168 chr1 92100560 A G 4.90E-04 Multiple complex diseases / / 17554300 rs12410523 chr1 92120137 G A 8.92E-05 Alcohol consumption / / 23743675 rs11165262 chr1 92153974 T C 2.39E-04 Response to taxane treatment (placlitaxel) TGFBR3 intron 23006423 rs12082710 chr1 92155337 T C 2.45E-04 Testicular dysgenesis syndrome TGFBR3 intron 22140272 rs12133463 chr1 92156208 C T 7.99E-04 Response to taxane treatment (placlitaxel) TGFBR3 intron 23006423 rs7549755 chr1 92157808 T C 9.95E-05 Postoperative ventricular dysfunction TGFBR3 intron 21980348 rs3754021 chr1 92158751 T C 8.65E-05 Postoperative ventricular dysfunction TGFBR3 intron 21980348 rs1926261 chr1 92162920 C T 8.25E-06 Celiac disease and Rheumatoid arthritis TGFBR3 intron 21383967 rs3767569 chr1 92173371 C T 3.25E-04 Type 2 diabetes TGFBR3 intron 17463246 rs2046736 chr1 92175008 C T 2.68E-04 Response to taxane treatment (placlitaxel) TGFBR3 intron 23006423 rs17512269 chr1 92177062 C T 5.82E-05 Diabetes (gestational) TGFBR3 intron 22233651 rs17512269 chr1 92177062 C T 3.27E-04 Response to taxane treatment (placlitaxel) TGFBR3 intron 23006423 rs17512269 chr1 92177062 C T 1.06E-04 Cognitive function TGFBR3 intron 24684796 rs11165354 chr1 92194322 C A 4.00E-06 Type 2 diabetes TGFBR3 intron 23209189 rs11165354 chr1 92194322 C A 3.34E-04 Heart Failure TGFBR3 intron pha002884 rs10783003 chr1 92195746 C T 2.60E-06 Type 2 diabetes TGFBR3 intron 23209189 rs7517044 chr1 92198162 A G 1.90E-06 Type 2 diabetes TGFBR3 intron 23209189 rs12403389 chr1 92208764 G C 9.63E-06 Bone mineral density TGFBR3 intron 19249006 rs2029356 chr1 92209311 T C 4.00E-04 Atrial fibrillation TGFBR3 intron 21846873 rs17131547 chr1 92211020 G A 9.98E-04 Multiple complex diseases TGFBR3 intron 17554300 rs17131547 chr1 92211020 G A 1.00E-06 Bone mineral density TGFBR3 intron 19249006 rs17131547 chr1 92211020 G A 3.60E-04 Atrial fibrillation TGFBR3 intron 21846873 rs284170 chr1 92214628 T C 5.72E-04 Suicide attempts in bipolar disorder TGFBR3 intron 21041247 rs284172 chr1 92214851 A T 5.16E-04 Suicide attempts in bipolar disorder TGFBR3 intron 21041247 rs11165441 chr1 92224347 G A 3.01E-05 Multiple sclerosis TGFBR3 intron 19525953 rs284198 chr1 92238167 G T 5.95E-04 White matter integrity TGFBR3 intron 22425255 rs12751910 chr1 92243307 G A 7.30E-06 Urinary metabolites TGFBR3 intron 21572414 rs17443164 chr1 92246048 C G 1.00E-05 Urinary metabolites TGFBR3 intron 21572414 rs6683840 chr1 92249817 A G 5.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TGFBR3 intron 20877124 rs1329980 chr1 92254946 T C 0.00000109 HDL cholesterol TGFBR3 intron 23063622 rs1329980 chr1 92254946 T C 4.78E-08 LDL cholesterol TGFBR3 intron 23063622 rs2489188 chr1 92332489 C T 9.09E-04 Alcohol dependence TGFBR3 intron 21314694 rs6680614 chr1 92358371 G T 5.12E-04 Type 2 diabetes TGFBR3 intron 17463246 rs7550034 chr1 92364576 A G 8.81E-04 Alzheimer's disease TGFBR3 intron 17998437 rs34856868 chr1 92554283 G A 2.00E-06 Obesity-related traits BTBD8 missense 23251661 rs11166141 chr1 92561392 A G 9.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs6684317 chr1 92563120 C G 9.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs11166144 chr1 92563373 G A 9.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs2128646 chr1 92564147 A T 9.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs2128645 chr1 92564644 C T 9.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs981583 chr1 92571295 T A 0.000658 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs981583 chr1 92571295 T A 6.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs4658290 chr1 92572296 C G 0.0006583 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs4658290 chr1 92572296 C G 6.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs10875204 chr1 92579675 G A 0.0005029 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs10875204 chr1 92579675 G A 5.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs7533077 chr1 92584519 A G 0.0005404 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs7533077 chr1 92584519 A G 5.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs7542358 chr1 92587233 A G 0.0002718 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs7542358 chr1 92587233 A G 2.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs7542373 chr1 92587270 A G 0.0004574 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs7542373 chr1 92587270 A G 4.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs2391114 chr1 92587687 G A 0.000419 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs2391114 chr1 92587687 G A 4.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs6604080 chr1 92588993 T A 0.0004021 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs6604080 chr1 92588993 T A 4.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs3851273 chr1 92589511 G A 0.0003817 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs3851273 chr1 92589511 G A 3.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs10875209 chr1 92590826 A G 0.0003662 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs10875209 chr1 92590826 A G 3.66E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs3851272 chr1 92591916 G A 0.0003492 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs3851272 chr1 92591916 G A 3.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs3851271 chr1 92592222 T C 0.0003508 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs3851271 chr1 92592222 T C 3.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs10875214 chr1 92597344 G C 0.0003533 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs10875214 chr1 92597344 G C 3.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs1157469 chr1 92598705 T C 0.0003681 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs1157469 chr1 92598705 T C 3.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs1157470 chr1 92598807 T A 0.0003574 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs1157470 chr1 92598807 T A 3.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs1982720 chr1 92600183 C G 0.0003529 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs1982720 chr1 92600183 C G 3.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs12119246 chr1 92602477 A G 0.0002028 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs12119246 chr1 92602477 A G 2.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs2839877 chr1 92604320 G T 0.0003596 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs2839877 chr1 92604320 G T 3.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs2893200 chr1 92608029 G A 0.00038 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs2893200 chr1 92608029 G A 3.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs6604082 chr1 92641607 C A 9.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIAA1107 intron 23233662 rs1483022 chr1 92646021 G A 9.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIAA1107 cds-synon 23233662 rs565156 chr1 92647532 C A 6.95E-04 IgE levels KIAA1107 missense 17255346 rs12069690 chr1 92667250 T C 0.00060524 Sarcoidosis / / 22952805 rs191562237 chr1 92668558 T G 0.00061753 Sarcoidosis / / 22952805 rs77814661 chr1 92676992 G A 0.00062982 Sarcoidosis / / 22952805 rs146182052 chr1 92678371 A G 0.00064211 Sarcoidosis / / 22952805 rs3131824 chr1 92689936 G A 3.01E-05 Alcohol consumption C1orf146 intron 23953852 rs3122320 chr1 92705638 C T 4.76E-05 Alcohol consumption C1orf146 intron 23953852 rs61732740 chr1 92709824 G C 0.0006544 Sarcoidosis C1orf146 missense 22952805 rs149037808 chr1 92710088 A G 0.00066669 Sarcoidosis C1orf146 intron 22952805 rs1487539 chr1 92739699 C T 2.75E-05 Alcohol consumption GLMN intron 23953852 rs3103177 chr1 92756507 A G 2.54E-05 Alcohol consumption GLMN intron 23953852 rs116334257 chr1 92767507 C T 0.00067898 Sarcoidosis RPAP2 intron 22952805 rs146695390 chr1 92769759 T C 0.00069127 Sarcoidosis RPAP2 intron 22952805 rs147871470 chr1 92775941 G A 0.00070356 Sarcoidosis RPAP2 intron 22952805 rs145384375 chr1 92787153 T C 0.00071585 Sarcoidosis RPAP2 intron 22952805 rs6668685 chr1 92791812 G T 3.17E-05 Alcohol consumption RPAP2 intron 23953852 rs138848285 chr1 92797991 T C 0.00072814 Sarcoidosis RPAP2 intron 22952805 rs1906279 chr1 92816148 T C 2.41E-05 Alcohol consumption RPAP2 intron 23953852 rs2046616 chr1 92831569 G A 0.0005366 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RPAP2 intron 23233654 rs2046616 chr1 92831569 G A 5.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) RPAP2 intron 23233662 rs79703486 chr1 92846017 T C 0.00074043 Sarcoidosis RPAP2 intron 22952805 rs114670042 chr1 92863966 G A 0.00075272 Sarcoidosis / / 22952805 rs2025607 chr1 92890344 C T 2.89E-05 Alcohol consumption / / 23953852 rs11164607 chr1 92947138 A C 7.72E-05 Multiple sclerosis GFI1 intron 17660530 rs7540564 chr1 92957826 C A 3.09E-05 Schizophrenia / / 19571809 rs2031494 chr1 92965969 T C 4.08E-05 Alcohol consumption / / 23953852 rs4970698 chr1 92972933 T C 3.47E-05 Alcohol consumption / / 23953852 rs10782922 chr1 92974595 G A 3.03E-05 Alcohol consumption EVI5 UTR-3 23953852 rs4970700 chr1 92975493 A G 2.31E-04 Multiple sclerosis EVI5 UTR-3 17660530 rs4970700 chr1 92975493 A G 7.81E-05 Schizophrenia EVI5 UTR-3 19571809 rs1886682 chr1 92977275 A G 3.09E-05 Alcohol consumption EVI5 UTR-3 23953852 rs6603979 chr1 92979354 A G 4.00E-05 Alcohol consumption EVI5 cds-synon 23953852 rs1408916 chr1 92992627 G A 5.20E-05 Alcohol consumption EVI5 intron 23953852 rs4970712 chr1 92993547 A C 4.90E-05 Alcohol consumption EVI5 intron 23953852 rs6603981 chr1 92993807 C T 5.20E-05 Alcohol consumption EVI5 intron 23953852 rs7515577 chr1 93009438 C A 3.00E-08 Cholesterol,total EVI5 intron 20686565 rs7515577 chr1 93009438 C A 2.00E-08 Cholesterol,total EVI5 intron 24097068 rs4847377 chr1 93023150 A C 5.43E-05 Alcohol consumption EVI5 intron 23953852 rs1556562 chr1 93034023 G T 4.78E-05 Alcohol consumption EVI5 intron 23953852 rs12743520 chr1 93037112 C A 4.78E-05 Multiple sclerosis EVI5 intron 17660530 rs10782936 chr1 93041906 A G 8.11E-05 Schizophrenia EVI5 intron 19571809 rs11808092 chr1 93073228 C A 1.50E-05 Multiple sclerosis EVI5 missense 19525955 rs6682801 chr1 93074541 G A 6.61E-05 Schizophrenia EVI5 intron 19571809 rs1415296 chr1 93090476 G C 7.17E-05 Multiple sclerosis EVI5 intron 17660530 rs10735781 chr1 93121107 G C 1.68E-04 Multiple sclerosis EVI5 intron 17660530 rs10735781 chr1 93121107 G C 7.55E-06 Multiple sclerosis EVI5 intron 19525953 rs10735781 chr1 93121107 G C 6.97E-05 Schizophrenia EVI5 intron 19571809 rs10735781 chr1 93121107 G C 4.50E-09 Multiple sclerosis EVI5 intron 21833088 rs11800848 chr1 93127927 A C 2.88E-05 Multiple sclerosis EVI5 intron 17660530 rs77382266 chr1 93144726 G A 2.30E-09 Joint damage severity in rheumatoid arthritis EVI5 intron 23696630 rs11810217 chr1 93148377 C T 6.00E-15 Multiple sclerosis EVI5 intron 21833088 rs11810217 chr1 93148377 C T 3.20E-04 Multiple sclerosis EVI5 intron 24234648 rs4847267 chr1 93155347 C T 3.61E-04 Multiple sclerosis EVI5 intron 17660530 rs34202284 chr1 93160002 G A 4.49E-05 Multiple sclerosis EVI5 intron 17660530 rs6680578 chr1 93176878 T A 2.08E-04 Multiple sclerosis EVI5 intron 17660530 rs11164814 chr1 93261373 A G 1.99E-05 Multiple sclerosis / / 19525953 rs6604026 chr1 93303603 T C 8.00E-06 Multiple sclerosis RPL5 intron 17660530 rs6604026 chr1 93303603 T C 3.00E-06 Multiple sclerosis RPL5 intron 19525955 rs6604026 chr1 93303603 T C 3.61E-06 Bipolar disorder and schizophrenia RPL5 intron 20889312 rs6604026 chr1 93303603 T C 1.01E-05 Schizophrenia RPL5 intron pha002857 rs10782945 chr1 93304272 C T 9.52E-05 Schizophrenia RPL5 intron 19571809 rs10782945 chr1 93304272 C T 5.88E-06 Bipolar disorder and schizophrenia RPL5 intron 20889312 rs10782945 chr1 93304272 C T 7.36E-06 Schizophrenia RPL5 intron pha002857 rs10874744 chr1 93306317 G A 7.39E-05 Alcohol consumption RPL5 intron 23953852 rs7514280 chr1 93320869 C T 7.08E-05 Multiple sclerosis FAM69A intron 17660530 rs7514280 chr1 93320869 C T 1.36E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs7514280 chr1 93320869 C T 9.85E-06 Schizophrenia FAM69A intron pha002857 rs10874746 chr1 93323971 T C 1.09E-05 Multiple sclerosis FAM69A intron 17660530 rs10874746 chr1 93323971 T C 3.51E-05 Schizophrenia FAM69A intron 19571809 rs10874746 chr1 93323971 T C 7.00E-11 Height FAM69A intron 20881960 rs10874746 chr1 93323971 T C 6.38E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs10874746 chr1 93323971 T C 3.17E-05 Schizophrenia FAM69A intron pha002857 rs111536942 chr1 93332055 C T 0.00076501 Sarcoidosis FAM69A intron 22952805 rs2811600 chr1 93334138 C T 1.71E-05 Multiple sclerosis FAM69A intron 17660530 rs2811600 chr1 93334138 C T 8.28E-05 Schizophrenia FAM69A intron 19571809 rs2811600 chr1 93334138 C T 1.18E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs2811600 chr1 93334138 C T 1.59E-06 Schizophrenia FAM69A intron pha002857 rs77039154 chr1 93338642 G C 0.0007773 Sarcoidosis FAM69A intron 22952805 rs2811593 chr1 93343891 T C 2.24E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs2811593 chr1 93343891 T C 2.91E-06 Schizophrenia FAM69A intron pha002857 rs35183060 chr1 93346928 A T 4.91E-05 Multiple sclerosis FAM69A intron 17660530 rs35183060 chr1 93346928 A T 1.52E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs35183060 chr1 93346928 A T 5.50E-06 Schizophrenia FAM69A intron pha002857 rs7536563 chr1 93349046 A G 2.27E-05 Multiple sclerosis FAM69A intron 17660530 rs7536563 chr1 93349046 A G 5.09E-05 Schizophrenia FAM69A intron 19571809 rs7536563 chr1 93349046 A G 1.16E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs7536563 chr1 93349046 A G 2.24E-06 Schizophrenia FAM69A intron pha002857 rs10782946 chr1 93352669 G A 8.52E-05 Alcohol consumption FAM69A intron 23953852 rs2391177 chr1 93353943 G A 7.81E-05 Alcohol consumption FAM69A intron 23953852 rs2481713 chr1 93354889 G T 6.86E-05 Alcohol consumption FAM69A intron 23953852 rs2263247 chr1 93364067 T C 7.68E-05 Alcohol consumption FAM69A intron 23953852 rs2255723 chr1 93368309 G T 1.11E-05 Multiple sclerosis FAM69A intron 17660530 rs2255723 chr1 93368309 G T 1.39E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs2255723 chr1 93368309 G T 7.20E-05 Alcohol consumption FAM69A intron 23953852 rs2255723 chr1 93368309 G T 1.94E-06 Schizophrenia FAM69A intron pha002857 rs12066638 chr1 93375391 C G 7.38E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs12066638 chr1 93375391 C G 3.64E-06 Schizophrenia FAM69A intron pha002857 rs11164835 chr1 93379093 G A 5.36E-05 Multiple sclerosis FAM69A intron 17660530 rs11164835 chr1 93379093 G A 9.84E-07 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs11164835 chr1 93379093 G A 1.46E-06 Schizophrenia FAM69A intron pha002857 rs9651257 chr1 93385136 T C 3.40E-05 Multiple sclerosis FAM69A intron 17660530 rs9651257 chr1 93385136 T C 2.02E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs9651257 chr1 93385136 T C 4.49E-06 Schizophrenia FAM69A intron pha002857 rs7515257 chr1 93393718 G A 7.86E-05 Alcohol consumption FAM69A intron 23953852 rs11164838 chr1 93395378 C T 6.01E-05 Multiple sclerosis FAM69A intron 17660530 rs11164838 chr1 93395378 C T 6.81E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs6698233 chr1 93397300 C T 7.62E-05 Alcohol consumption FAM69A intron 23953852 rs10493863 chr1 93399694 T C 7.95E-05 Alcohol consumption FAM69A intron 23953852 rs7542608 chr1 93401194 A G 7.18E-05 Alcohol consumption FAM69A intron 23953852 rs12745968 chr1 93401837 A G 8.01E-05 Multiple sclerosis FAM69A intron 17660530 rs12745968 chr1 93401837 A G 8.97E-05 Schizophrenia FAM69A intron 19571809 rs12745968 chr1 93401837 A G 8.00E-07 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs12745968 chr1 93401837 A G 1.04E-06 Schizophrenia FAM69A intron pha002857 rs17380908 chr1 93402551 C T 5.74E-05 Multiple sclerosis FAM69A intron 17660530 rs4847386 chr1 93420907 G A 1.18E-04 Parkinson's disease FAM69A intron 17052657 rs10874753 chr1 93429087 C A 1.85E-06 Bipolar disorder and schizophrenia / / 20889312 rs10874753 chr1 93429087 C A 4.57E-06 Schizophrenia / / pha002857 rs514235 chr1 93438456 T C 6.81E-06 Bipolar disorder and schizophrenia / / 20889312 rs6671268 chr1 93439821 T C 1.97E-04 Parkinson's disease / / 17052657 rs660870 chr1 93445417 C A 4.81E-05 Schizophrenia / / 19571809 rs660870 chr1 93445417 C A 2.60E-06 Bipolar disorder and schizophrenia / / 20889312 rs660870 chr1 93445417 C A 3.16E-05 Schizophrenia / / pha002857 rs521428 chr1 93445497 G A 2.12E-05 Multiple sclerosis / / 17660530 rs521428 chr1 93445497 G A 5.65E-05 Schizophrenia / / 19571809 rs521428 chr1 93445497 G A 2.52E-06 Bipolar disorder and schizophrenia / / 20889312 rs521428 chr1 93445497 G A 4.57E-05 Schizophrenia / / pha002857 rs532834 chr1 93468062 A T 1.82E-07 Multiple sclerosis / / 17660530 rs496465 chr1 93474165 A G 9.75E-05 Multiple sclerosis / / 17660530 rs12067005 chr1 93543119 A G 3.97E-05 Intelligence / / 21826061 rs1856027 chr1 93544131 T C 4.36E-04 Type 2 diabetes / / 22158537 rs12128131 chr1 93546299 T G 4.60E-04 Type 2 diabetes MTF2 intron 22158537 rs2295423 chr1 93581024 T C 7.67E-04 Type 2 diabetes MTF2 intron 22158537 rs2391228 chr1 93606940 G A 4.19E-05 Intelligence / / 21826061 rs1572343 chr1 93616202 T C 4.74E-04 Type 2 diabetes TMED5 UTR-3 22158537 rs1060622 chr1 93620393 G A 6.46E-04 Type 2 diabetes TMED5 missense 22158537 rs2783489 chr1 93626984 C T 2.85E-04 Type 2 diabetes TMED5 intron 22158537 rs4847235 chr1 93627727 T C 4.09E-04 Type 2 diabetes TMED5 intron 22158537 rs2152358 chr1 93634009 G A 8.16E-04 Type 2 diabetes TMED5 intron 22158537 rs10874762 chr1 93639101 T G 6.04E-04 Type 2 diabetes TMED5 intron 22158537 rs1335679 chr1 93645182 C T 6.26E-04 Type 2 diabetes TMED5 intron 22158537 rs7535628 chr1 93648728 T C 3.32E-04 Type 2 diabetes CCDC18 intron 22158537 rs6682670 chr1 93649732 A G 6.09E-04 Type 2 diabetes CCDC18 intron 22158537 rs7517363 chr1 93652785 C T 5.04E-04 Type 2 diabetes CCDC18 intron 22158537 rs11164879 chr1 93655522 G A 6.66E-04 Type 2 diabetes CCDC18 intron 22158537 rs7513705 chr1 93666349 T C 3.14E-04 Type 2 diabetes CCDC18 intron 22158537 rs12030549 chr1 93669218 T C 6.01E-04 Type 2 diabetes CCDC18 intron 22158537 rs531358 chr1 93676011 C T 5.62E-04 Type 2 diabetes CCDC18 intron 22158537 rs2765545 chr1 93677269 G A 3.64E-04 Type 2 diabetes CCDC18 intron 22158537 rs661126 chr1 93678968 T G 5.83E-04 Type 2 diabetes CCDC18 intron 22158537 rs612037 chr1 93682878 G A 4.47E-04 Type 2 diabetes CCDC18 intron 22158537 rs797668 chr1 93694789 C G 5.83E-04 Type 2 diabetes CCDC18 intron 22158537 rs3754186 chr1 93711782 T A 7.77E-04 Type 2 diabetes CCDC18 intron 22158537 rs622608 chr1 93715219 G A 4.32E-04 Type 2 diabetes CCDC18 intron 22158537 rs693737 chr1 93724924 G A 5.29E-04 Type 2 diabetes CCDC18 intron 22158537 rs2296558 chr1 93736555 C T 7.59E-04 Type 2 diabetes CCDC18 intron 22158537 rs6541401 chr1 93738948 G A 7.98E-04 Type 2 diabetes CCDC18 intron 22158537 rs9432681 chr1 93761896 A G 7.49E-04 Type 2 diabetes / / 22158537 rs6680107 chr1 93770880 G A 7.78E-04 Type 2 diabetes / / 22158537 rs9432453 chr1 93771629 G A 6.64E-04 Type 2 diabetes / / 22158537 rs1000607 chr1 93772001 T C 7.37E-04 Type 2 diabetes / / 22158537 rs4240966 chr1 93774812 C A 7.02E-04 Type 2 diabetes / / 22158537 rs4000699 chr1 93779805 C T 5.53E-04 Type 2 diabetes LOC100131564 intron 22158537 rs2031226 chr1 93786764 G T 5.97E-04 Type 2 diabetes LOC100131564 intron 22158537 rs6703310 chr1 93788740 T G 6.01E-04 Type 2 diabetes LOC100131564 intron 22158537 rs2391254 chr1 93795166 A T 2.38E-04 Type 2 diabetes LOC100131564 intron 22158537 rs942196 chr1 93802264 T A 5.04E-04 Type 2 diabetes LOC100131564 intron 22158537 rs3767964 chr1 93815490 T C 2.86E-04 Type 2 diabetes DR1 intron 22158537 rs4847240 chr1 93817946 A G 2.59E-04 Type 2 diabetes DR1 intron 22158537 rs12044883 chr1 93820575 G A 3.09E-04 Type 2 diabetes DR1 intron 22158537 rs11164938 chr1 93939870 A G 5.49E-04 Alcohol dependence FNBP1L intron 21314694 rs4847428 chr1 93942442 A G 7.55E-05 Serum metabolites FNBP1L intron 19043545 rs4847431 chr1 93984804 G C 3.92E-05 Nicotine dependence FNBP1L intron 17158188 rs237425 chr1 94012287 G A 9.56E-05 Pancreatic cancer FNBP1L intron pha002874 rs2295330 chr1 94037329 C T 6.09E-04 Coronary heart disease BCAR3 cds-synon 21971053 rs6667494 chr1 94038847 G A 0.00007483 Sarcoidosis BCAR3 intron 22952805 rs17110111 chr1 94042207 C T 5.81E-05 Insulin resistance BCAR3 intron 21901158 rs236316 chr1 94044597 C T 1.27E-07 Intelligence BCAR3 intron 21826061 rs3950119 chr1 94049237 T C 3.04E-05 Intelligence BCAR3 intron 21826061 rs236322 chr1 94056279 G T 7.48E-05 Intelligence BCAR3 intron 21826061 rs236330 chr1 94059554 C T 5.40E-04 Intelligence (childhood) BCAR3 intron 23358156 rs6677770 chr1 94066635 T C 5.96E-05 Intelligence BCAR3 intron 21826061 rs12739747 chr1 94077247 T A 1.81E-04 Insulin resistance BCAR3 intron 21901158 rs236313 chr1 94089708 A C 2.24E-05 Asthma BCAR3 intron 23181788 rs236301 chr1 94113981 C T 8.72E-05 Intelligence BCAR3 intron 21826061 rs236292 chr1 94120564 T C 5.28E-04 Type 2 diabetes BCAR3 intron 17463246 rs11580965 chr1 94129664 A T 4.47E-05 Insulin resistance BCAR3 intron 21901158 rs236285 chr1 94132788 G A 5.92E-05 Intelligence BCAR3 intron 21826061 rs2102629 chr1 94172121 A G 2.62E-04 Smoking cessation / / 24665060 rs12132625 chr1 94213931 G C 1.28E-04 Multiple complex diseases / / 17554300 rs4240956 chr1 94223769 A T 3.90E-06 Urinary metabolites / / 21572414 rs2818164 chr1 94237195 G T 4.20E-06 Urinary metabolites / / 21572414 rs2143990 chr1 94249517 T C 4.20E-06 Urinary metabolites / / 21572414 rs17100392 chr1 94281597 A G 7.74E-05 Parkinson's disease (motor and cognition) / / 22658654 rs17100392 chr1 94281597 A G 7.74E-05 Immune response to anthrax vaccine / / 22658931 rs6664719 chr1 94334724 A C 9.50E-06 Urinary metabolites / / 21572414 rs11165029 chr1 94348081 C A 8.91E-04 Multiple complex diseases / / 17554300 rs11165029 chr1 94348081 C A 7.06E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11165047 chr1 94440105 G A 4.60E-05 Multiple complex diseases / / 17554300 rs11165048 chr1 94440182 G A 4.13E-05 Multiple complex diseases / / 17554300 rs12404808 chr1 94440302 C T 2.80E-05 Multiple complex diseases / / 17554300 rs12404811 chr1 94440332 C T 5.64E-05 Multiple complex diseases / / 17554300 rs12410905 chr1 94444197 T C 3.12E-05 Multiple complex diseases / / 17554300 rs1413899 chr1 94444481 G A 2.53E-05 Multiple complex diseases / / 17554300 rs35550403 chr1 94445595 G A 2.75E-05 Multiple complex diseases / / 17554300 rs41351346 chr1 94445793 T C 3.14E-05 Multiple complex diseases / / 17554300 rs41353346 chr1 94445839 T C 3.35E-05 Multiple complex diseases / / 17554300 rs17110714 chr1 94457555 A G 1.99E-04 Multiple complex diseases / / 17554300 rs17110736 chr1 94462769 G A 5.00E-06 Dialysis-related mortality ABCA4 intron 21546767 rs1800555 chr1 94463617 C T 2.57E-04 Insulin resistance ABCA4 missense 21901158 rs12070273 chr1 94466088 A G 4.66E-05 Height ABCA4 intron pha003011 rs4147864 chr1 94467238 G A 4.66E-05 Height ABCA4 intron pha003011 rs4147863 chr1 94471154 C T 8.89E-04 Response to alcohol consumption (flushing response) ABCA4 intron 24277619 rs11165063 chr1 94477649 C G 9.70E-06 Urinary metabolites ABCA4 intron 21572414 rs567370 chr1 94478573 C T 7.30E-06 Urinary metabolites ABCA4 intron 21572414 rs915200 chr1 94481904 C T 3.30E-04 Type 2 diabetes ABCA4 intron 17463246 rs11806129 chr1 94482377 A G 1.17E-11 LDL cholesterol ABCA4 intron 23063622 rs11806129 chr1 94482377 A G 7.08E-08 Cholesterol,total ABCA4 intron 23063622 rs61754056 chr1 94486905 C T 0.000000163 Prostate-specific antigen ABCA4 missense 23555315 rs472908 chr1 94487354 G A 3.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ABCA4 intron 20877124 rs1320502 chr1 94501799 C T 1.51E-04 Multiple complex diseases ABCA4 intron 17554300 rs12087003 chr1 94503183 A G 1.83E-09 LDL cholesterol ABCA4 intron 23063622 rs12087003 chr1 94503183 A G 1.86E-08 Cholesterol,total ABCA4 intron 23063622 rs17110922 chr1 94509045 A T 0.00000191 Cholesterol,total ABCA4 intron 23063622 rs17110922 chr1 94509045 A T 6.65E-10 LDL cholesterol ABCA4 intron 23063622 rs3789399 chr1 94511717 G C 8.67E-05 Meningococcal disease ABCA4 intron 20694013 rs544830 chr1 94512893 C T 3.60E-05 Meningococcal disease ABCA4 intron 20694013 rs4147836 chr1 94516474 C T 2.40E-04 Obesity (extreme) ABCA4 intron 21935397 rs1191231 chr1 94516985 A C 6.89E-05 Meningococcal disease ABCA4 intron 20694013 rs497511 chr1 94523113 G A 1.76E-05 Meningococcal disease ABCA4 intron 20694013 rs550060 chr1 94524784 A G 1.84E-05 Meningococcal disease ABCA4 intron 20694013 rs521538 chr1 94525623 A G 1.25E-05 Orofacial clefts ABCA4 intron 22863734 rs4147833 chr1 94528363 C T 1.50E-04 Obesity (extreme) ABCA4 intron 21935397 rs4847273 chr1 94529743 A G 1.82E-05 Obesity (extreme) ABCA4 intron 21935397 rs6661519 chr1 94530163 C A 1.87E-05 Obesity (extreme) ABCA4 intron 21935397 rs1007347 chr1 94530518 T C 2.06E-05 Obesity (extreme) ABCA4 intron 21935397 rs1191232 chr1 94531192 A G 8.67E-06 Orofacial clefts ABCA4 intron 22863734 rs3789405 chr1 94531324 T C 2.10E-05 Obesity (extreme) ABCA4 intron 21935397 rs3789407 chr1 94531606 G C 8.77E-05 Obesity (extreme) ABCA4 intron 21935397 rs4140392 chr1 94532013 C T 9.45E-05 Obesity (extreme) ABCA4 intron 21935397 rs1931575 chr1 94533014 T C 3.93E-05 Obesity (extreme) ABCA4 intron 21935397 rs1931575 chr1 94533014 T C 2.00E-06 Palmitoleic acid (16:1n-7) plasma levels ABCA4 intron 23362303 rs2151849 chr1 94535174 A G 3.62E-04 Obesity (extreme) ABCA4 intron 21935397 rs3789412 chr1 94536067 C T 3.95E-04 Obesity (extreme) ABCA4 intron 21935397 rs12759306 chr1 94537642 C A 2.68E-05 Tunica Media ABCA4 intron pha003034 rs1761375 chr1 94538011 G A 3.94E-04 Amyotrophic lateral sclerosis (sporadic) ABCA4 intron 24529757 rs4847274 chr1 94540069 G C 0.00084 Salmonella-induced pyroptosis ABCA4 intron 22837397 rs2275035 chr1 94545160 C T 3.74E-05 Cleft lip ABCA4 intron 20436469 rs2275035 chr1 94545160 C T 4.06E-05 Obesity (extreme) ABCA4 intron 21935397 rs4147827 chr1 94548080 C G 2.58E-05 Cleft lip ABCA4 intron 20436469 rs560426 chr1 94553438 C T 5.70E-12 Cleft lip ABCA4 intron 20436469 rs560426 chr1 94553438 C T 3.00E-12 Orofacial clefts ABCA4 intron 22863734 rs560426 chr1 94553438 C T 5.00E-10 Orofacial clefts ABCA4 intron 22863734 rs563429 chr1 94553866 A G 6.33E-05 Orofacial clefts ABCA4 intron 22863734 rs4847196 chr1 94554453 G A 2.27E-05 Cleft lip ABCA4 intron 20436469 rs4847196 chr1 94554453 G A 7.55E-04 Obesity (extreme) ABCA4 intron 21935397 rs4847196 chr1 94554453 G A 8.08E-05 Coronary heart disease ABCA4 intron pha003030 rs952499 chr1 94558425 T C 7.19E-07 Cleft lip ABCA4 intron 20436469 rs952499 chr1 94558425 T C 7.18E-08 Orofacial clefts ABCA4 intron 22863734 rs2068334 chr1 94559715 G A 6.13E-04 Obesity (extreme) ABCA4 intron 21935397 rs4147823 chr1 94561272 A C 7.51E-04 Obesity (extreme) ABCA4 intron 21935397 rs4147822 chr1 94561489 A G 2.68E-04 Obesity (extreme) ABCA4 intron 21935397 rs3789422 chr1 94566311 C T 0.000027 Coronary artery calcification ABCA4 intron 23727086 rs2297636 chr1 94568822 T C 5.83E-06 Cleft lip ABCA4 intron 20436469 rs481931 chr1 94570016 G T 8.57E-08 Cleft lip ABCA4 intron 20436469 rs570926 chr1 94570218 T C 3.24E-07 Cleft lip ABCA4 intron 20436469 rs1211213 chr1 94571420 A G 5.50E-05 Cleft lip ABCA4 intron 20436469 rs4147816 chr1 94574780 C T 3.01E-04 Type 2 diabetes ABCA4 intron 17463246 rs4147816 chr1 94574780 C T 6.51E-08 Cleft lip ABCA4 intron 20436469 rs4147812 chr1 94575043 A C 9.12E-08 Cleft lip ABCA4 intron 20436469 rs4147812 chr1 94575043 A C 9.90E-10 Orofacial clefts ABCA4 intron 22863734 rs4147811 chr1 94575056 C T 4.02E-08 Cleft lip ABCA4 intron 20436469 rs3827712 chr1 94575171 T C 8.57E-08 Cleft lip ABCA4 intron 20436469 rs3789432 chr1 94575308 T C 1.39E-07 Cleft lip ABCA4 intron 20436469 rs2297634 chr1 94576968 T C 2.50E-05 Age-related macular degeneration ABCA4 intron 20861866 rs2297634 chr1 94576968 T C 2.27E-05 Age-related macular degeneration ABCA4 intron 21197116 rs2297634 chr1 94576968 T C 4.39E-05 Orofacial clefts ABCA4 intron 22863734 rs2297634 chr1 94576968 T C 3.18E-05 Age-related macular degeneration ABCA4 intron pha002856 rs10782976 chr1 94581125 G A 4.77E-05 Cleft lip ABCA4 intron 20436469 rs4147804 chr1 94582227 G A 7.25E-06 Cleft lip ABCA4 intron 20436469 rs4147803 chr1 94582293 G C 4.67E-06 Cleft lip ABCA4 intron 20436469 rs4147799 chr1 94584459 A G 7.70E-05 HDL particle features ABCA4 intron 21283740 rs3789451 chr1 94586328 C T 8.45E-06 Cleft lip ABCA4 intron 20436469 rs3789451 chr1 94586328 C T 3.56E-07 Orofacial clefts ABCA4 intron 22863734 rs3789452 chr1 94587501 T A 7.30E-07 Cleft lip ABCA4 nearGene-5 20436469 rs2151846 chr1 94587687 T G 1.61E-07 Cleft lip ABCA4 nearGene-5 20436469 rs11802196 chr1 94594043 A C 9.98E-06 Cleft lip / / 20436469 rs11802196 chr1 94594043 A C 1.55E-06 Orofacial clefts / / 22863734 rs6686599 chr1 94596831 G A 3.73E-06 Cleft lip / / 20436469 rs6686599 chr1 94596831 G A 1.96E-06 Orofacial clefts / / 22863734 rs1931565 chr1 94596867 A G 1.02E-05 Orofacial clefts / / 22863734 rs2774920 chr1 94611300 A G 1.00E-06 D-dimer levels / / 21502573 rs1411701 chr1 94635028 G A 5.88E-07 Orofacial clefts ARHGAP29 UTR-3 22863734 rs2274788 chr1 94674726 T C 6.26E-05 Cognitive test performance ARHGAP29 intron 20125193 rs2274788 chr1 94674726 T C 1.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients ARHGAP29 intron 23400010 rs6541340 chr1 94678512 T C 1.45E-05 Orofacial clefts ARHGAP29 intron 22863734 rs3789688 chr1 94691240 T C 2.46E-06 Orofacial clefts ARHGAP29 intron 22863734 rs12750249 chr1 94721660 T C 4.00E-06 IgG glycosylation LOC100505940 intron 23382691 rs11165110 chr1 94752469 G A 1.02E-04 Orofacial clefts LOC100505940 intron 22863734 rs11584317 chr1 94792449 C T 7.63E-04 Smoking initiation LOC100505940 intron 24665060 rs2172133 chr1 94803032 A G 1.61E-05 Orofacial clefts / / 22863734 rs12057415 chr1 94829769 T C 3.52E-05 Cleft lip / / 20436469 rs12057415 chr1 94829769 T C 2.05E-06 Orofacial clefts / / 22863734 rs2391467 chr1 94850443 A G 2.11E-05 Cleft lip / / 20436469 rs2391467 chr1 94850443 A G 1.10E-06 Orofacial clefts / / 22863734 rs598962 chr1 94916649 A C,G,T 2.28E-10 Cholesterol,total ABCD3 intron 23063622 rs598962 chr1 94916649 A C,G,T 2.56E-13 LDL cholesterol ABCD3 intron 23063622 rs529642 chr1 94979573 G C 4.97E-04 Multiple complex diseases ABCD3 intron 17554300 rs1144302 chr1 95000114 C T 0.000000962 LDL cholesterol F3 intron 23063622 rs1144302 chr1 95000114 C T 0.00000227 Cholesterol,total F3 intron 23063622 rs3917608 chr1 95004486 T G 3.49E-06 Lipid levels F3 intron 19913121 rs3789685 chr1 95004938 T C 3.47E-06 Lipid levels F3 intron 19913121 rs3789685 chr1 95004938 T C 0.00000169 Cholesterol,total F3 intron 23063622 rs698945 chr1 95011785 A G 5.60E-04 Multiple complex diseases / / 17554300 rs1146509 chr1 95029581 G T 6.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs2022309 chr1 95052476 G T 4.00E-08 End-stage coagulation / / 23381943 rs12029080 chr1 95053353 T G 6.00E-52 D-dimer levels / / 21502573 rs698941 chr1 95055219 C T 1.90E-06 Urinary metabolites / / 21572414 rs12079330 chr1 95058953 G A 9.01E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1778214 chr1 95061355 G A 8.04E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1747649 chr1 95062032 G A 8.92E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7542900 chr1 95070041 T C 6.00E-06 Type 2 diabetes / / 22238593 rs11807669 chr1 95070114 T C 2.30E-04 Lipopolysaccharide induced cytokine levels / / 23823136 rs4474258 chr1 95081445 C T 5.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU) / / 24025145 rs12725598 chr1 95093341 G C 5.84E-04 Insulin resistance / / 21901158 rs2971940 chr1 95111759 A G 4.95E-04 Multiple complex diseases / / 17554300 rs947386 chr1 95117157 C T 5.68E-05 Alcohol and nictotine co-dependence / / 20158304 rs841361 chr1 95151813 C T 9.36E-07 Autism / / 22843504 rs841329 chr1 95169762 G A 8.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs2391423 chr1 95240361 C T 4.62E-05 Major depressive disorder (broad) / / 20038947 rs12743267 chr1 95249306 C T 3.40E-04 Alcohol dependence / / 20201924 rs11165257 chr1 95302135 G T 2.74E-04 Alcohol dependence SLC44A3 intron 20201924 rs3849303 chr1 95320536 G A 8.43E-04 Amyotrophic lateral sclerosis (sporadic) SLC44A3 intron 24529757 rs859101 chr1 95324784 G T 7.00E-06 Type 2 diabetes SLC44A3 intron 17293876 rs859101 chr1 95324784 G T 7.00E-06 Type 2 diabetes SLC44A3 intron 19184112 rs859098 chr1 95330372 G A 6.04E-04 Premature ovarian failure SLC44A3 missense 19508998 rs859098 chr1 95330372 G A 8.21E-05 Cognitive impairment induced by topiramate SLC44A3 missense 22091778 rs859098 chr1 95330372 G A 4.58E-05 Blood Pressure SLC44A3 missense pha002903 rs859096 chr1 95333068 G T 3.60E-05 Response to Vitamin E supplementation SLC44A3 intron 22437554 rs859096 chr1 95333068 G T 9.47E-04 Iron levels SLC44A3 intron pha002876 rs859096 chr1 95333068 G T 3.28E-05 Blood Pressure SLC44A3 intron pha002903 rs17520351 chr1 95334187 C T 4.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) SLC44A3 intron 23934736 rs735937 chr1 95335769 T C 1.95E-05 Iron levels SLC44A3 intron 19880490 rs735937 chr1 95335769 T C 1.95E-05 Iron levels SLC44A3 intron pha002876 rs10493878 chr1 95337418 T C 2.96E-05 Lipoproteins SLC44A3 intron pha003079 rs7531174 chr1 95338091 A G 1.60E-04 Type 2 diabetes and 6 quantitative traits SLC44A3 intron 17848626 rs6700314 chr1 95346659 G A 3.91E-04 Multiple complex diseases SLC44A3 intron 17554300 rs12067920 chr1 95379758 A G 3.55E-04 Response to taxane treatment (placlitaxel) CNN3 intron 23006423 rs860873 chr1 95387208 G A 2.00E-14 Stearic acid (18:0) plasma levels CNN3 intron 23362303 rs11165281 chr1 95429780 G T 6.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6698046 chr1 95449282 A G 4.59E-04 Multiple complex diseases ALG14 intron 17554300 rs2391388 chr1 95485825 A C 3.00E-11 Palmitic acid (16:0) plasma levels ALG14 intron 23362303 rs6675668 chr1 95515637 T G 2.00E-18 Stearic acid (18:0) plasma levels ALG14 intron 23362303 rs6674604 chr1 95517539 C A 1.67E-05 Cleft lip ALG14 intron 20436469 rs12037609 chr1 95518483 C T 5.56E-04 Multiple complex diseases ALG14 intron 17554300 rs4630159 chr1 95543678 G T 8.03E-04 Multiple complex diseases / / 17554300 rs4950058 chr1 95548151 T C 8.65E-04 Multiple complex diseases / / 17554300 rs9437689 chr1 95549536 C T 5.00E-08 Phospholipid levels (plasma) / / 22359512 rs4950059 chr1 95551129 C T 2.01E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7512953 chr1 95554294 T G 2.30E-05 Malaria / / 19465909 rs7512953 chr1 95554294 T G 2.55E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12562498 chr1 95555165 C T 2.58E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12563154 chr1 95562187 C T 2.24E-04 Response to cytidine analogues (gemcitabine) TMEM56 intron 24483146 rs4950076 chr1 95577297 T C 7.04E-04 Response to cytidine analogues (gemcitabine) TMEM56 intron 24483146 rs11165315 chr1 95592609 A G 4.93E-04 Smoking initiation TMEM56 intron 24665060 rs7366121 chr1 95596496 G T 0.000253322 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs10874905 chr1 95598593 A C 1.82E-04 Smoking initiation TMEM56 intron 24665060 rs12039183 chr1 95611650 A G 0.00039702 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs10157405 chr1 95614838 T C 8.89E-05 Fibrinogen TMEM56 intron pha003068 rs997370 chr1 95619368 T G 0.000217114 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs11165321 chr1 95619743 G A 0.000208004 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs2148796 chr1 95622341 C T 0.000125941 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs10874906 chr1 95630658 T C 0.000291725 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs965314 chr1 95633722 A G 8.35E-05 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs11165334 chr1 95638667 A G 9.78E-05 Non-alcoholic fatty liver disease histology (other) TMEM56 intron 20708005 rs11165334 chr1 95638667 A G 0.00061292 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs10458508 chr1 95643224 T C 0.00061292 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs6703408 chr1 95656546 T C 0.00061292 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs1556742 chr1 95674341 C A 7.43E-05 Hypertension (early onset hypertension) TMEM56-RWDD3 intron 22479346 rs1414896 chr1 95692310 G A 2.00E-06 Non-alcoholic fatty liver disease histology (AST) TMEM56-RWDD3 intron 20708005 rs6671200 chr1 95697529 A C 2.00E-15 Stearic acid (18:0) plasma levels TMEM56-RWDD3 intron 23362303 rs6671200 chr1 95697529 A C 6.72E-05 Fibrinogen TMEM56-RWDD3 intron pha003068 rs2182021 chr1 95769863 C T 3.52E-05 Fibrinogen / / pha003068 rs12118116 chr1 95774330 T C 2.75E-06 Fibrinogen / / pha003068 rs2236390 chr1 95776788 C T 7.89E-05 Stroke / / pha002886 rs17113360 chr1 95782459 T C 3.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs17113368 chr1 95786229 C T 1.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs17113374 chr1 95789364 C T 1.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs2391635 chr1 95794306 C T 5.36E-04 Type 2 diabetes / / 17463246 rs11165389 chr1 95815863 T G 3.47E-11 Schizophrenia / / 22037555 rs11590181 chr1 95818596 T G 3.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs11165396 chr1 95823682 C T 2.50E-05 Urinary metabolites / / 21572414 rs11165403 chr1 95829158 T G 6.92E-04 Type 2 diabetes / / 17463246 rs11165406 chr1 95832611 G A 2.50E-05 Urinary metabolites / / 21572414 rs7531902 chr1 95835124 A G 2.82E-04 Alzheimer's disease (late onset) / / 21379329 rs11586346 chr1 95861202 A C 1.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs17113478 chr1 95861722 C G 1.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs4950054 chr1 95890977 C T 2.10E-05 Urinary metabolites / / 21572414 rs4949963 chr1 95906877 T A 2.10E-05 Urinary metabolites / / 21572414 rs12032935 chr1 95915727 G T 2.30E-05 Urinary metabolites / / 21572414 rs12040149 chr1 95915823 C A 2.40E-05 Urinary metabolites / / 21572414 rs979015 chr1 95920476 A G 1.08E-05 C-Reactive Protein / / pha003070 rs12409850 chr1 95947820 A G 4.54E-05 Body Mass Index / / pha003019 rs12409850 chr1 95947820 A G 1.26E-05 Body Mass Index / / pha003020 rs1577863 chr1 95967757 G A 2.94E-04 HIV-1 viral setpoint / / 17641165 rs11165433 chr1 95976798 A G 8.79E-05 Obesity (extreme) / / 21935397 rs1582123 chr1 95977445 A G 1.00E-04 Obesity (extreme) / / 21935397 rs945827 chr1 95981576 G A 9.56E-05 Obesity (extreme) / / 21935397 rs876394 chr1 95982340 T C 8.36E-05 Body Mass Index / / pha003020 rs945826 chr1 95984156 G A 9.24E-04 Type 2 diabetes / / 17463246 rs945826 chr1 95984156 G A 9.45E-05 Obesity (extreme) / / 21935397 rs881713 chr1 95985066 G A 6.34E-04 Multiple complex diseases / / 17554300 rs881713 chr1 95985066 G A 4.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs881713 chr1 95985066 G A 8.44E-04 Stroke / / pha002886 rs11165434 chr1 95986339 G T 4.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs491043 chr1 95987974 A G 1.04E-04 Obesity (extreme) / / 21935397 rs12135050 chr1 95992463 G A 4.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs7522301 chr1 95993281 C T 1.06E-04 Obesity (extreme) / / 21935397 rs611087 chr1 95995427 A G 1.07E-04 Obesity (extreme) / / 21935397 rs12136757 chr1 95997068 T C 4.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs12141480 chr1 95998883 G C 4.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs1509178 chr1 96001525 T C 4.43E-04 Suicide attempts in bipolar disorder / / 21041247 rs563232 chr1 96008701 C T 9.95E-05 Obesity (extreme) / / 21935397 rs678378 chr1 96008944 A G 4.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs1355136 chr1 96019439 C T 5.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs519693 chr1 96023412 C T 5.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs1396626 chr1 96025546 G A 3.36E-05 Partial epilepsies / / 20522523 rs1396626 chr1 96025546 G A 3.32E-05 Epilepsy / / 22116939 rs12145270 chr1 96025590 T A 7.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs12125877 chr1 96025725 C G 7.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs12125905 chr1 96025809 C G 8.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs592158 chr1 96102889 G C 9.11E-04 Type 2 diabetes / / 17463246 rs6693882 chr1 96145968 A G 2.00E-06 Pain / / 19207018 rs12142219 chr1 96148182 A G 8.79E-05 Orofacial clefts / / 22419666 rs7554994 chr1 96152973 T C 4.26E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1931260 chr1 96173170 T C 7.64E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1931255 chr1 96187319 G A 5.05E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2051029 chr1 96309286 G A 5.92E-05 Platelet counts / / pha003100 rs12564173 chr1 96311796 T G 6.14E-05 Platelet counts / / pha003100 rs4949973 chr1 96316274 T C 9.70E-04 Multiple complex diseases / / 17554300 rs11165503 chr1 96317398 A G 6.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs1342397 chr1 96343511 C T 8.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs10874963 chr1 96343561 C G 9.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs1539359 chr1 96347574 C T 9.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs12122872 chr1 96348379 C T 4.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs1418454 chr1 96357521 G A 8.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs11165509 chr1 96359485 A G 6.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs11165510 chr1 96365162 C T 7.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs11165512 chr1 96366519 G A 3.51E-04 Gallstones / / 17632509 rs17420083 chr1 96422669 G A 9.78E-04 Type 2 diabetes / / 17463246 rs1889060 chr1 96425796 A T 3.40E-06 Urinary metabolites / / 21572414 rs619758 chr1 96481173 T C 2.90E-05 Urinary metabolites / / 21572414 rs10518593 chr1 96501069 C A 9.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs161110 chr1 96504076 G T 2.20E-05 Urinary metabolites / / 21572414 rs184412 chr1 96505335 G A 2.20E-05 Urinary metabolites / / 21572414 rs150892 chr1 96516252 C T 2.50E-05 Urinary metabolites / / 21572414 rs222887 chr1 96526728 G T 9.04E-05 Eosinophil counts / / pha003088 rs1144326 chr1 96541099 A G 2.20E-05 Urinary metabolites / / 21572414 rs223246 chr1 96551837 A C 1.40E-05 Urinary metabolites / / 21572414 rs223245 chr1 96552025 G A 1.40E-05 Urinary metabolites / / 21572414 rs12089599 chr1 96586426 C T 1.00E-05 Urinary metabolites / / 21572414 rs1222069 chr1 96595179 A C 1.60E-05 Cognitive function / / 24684796 rs2391735 chr1 96604969 A G 1.31E-04 Multiple complex diseases / / 17554300 rs321580 chr1 96647642 A G 2.43E-05 Smoking initiation / / 24665060 rs321564 chr1 96655156 C A,G,T 3.42E-05 Smoking initiation / / 24665060 rs321566 chr1 96656104 C T 4.13E-04 Type 2 diabetes / / 17463246 rs321567 chr1 96656207 C T 3.17E-04 Smoking initiation / / 24665060 rs17114704 chr1 96666138 T G 5.94E-05 Cognitive test performance / / 20125193 rs17374320 chr1 96673887 G T 3.49E-04 Alzheimer's disease / / 17998437 rs17365931 chr1 96679692 C T 8.05E-04 Alzheimer's disease / / 17998437 rs321588 chr1 96688818 G A 6.81E-05 Blood Pressure / / pha003040 rs901469 chr1 96723560 A G 5.71E-05 Cognitive test performance / / 20125193 rs324867 chr1 96755467 C T 8.78E-04 Multiple complex diseases / / 17554300 rs10874992 chr1 96775958 G A 8.80E-06 Urinary metabolites / / 21572414 rs11165585 chr1 96780748 A G 7.20E-06 Urinary metabolites / / 21572414 rs11165590 chr1 96791584 T G 8.50E-06 Urinary metabolites / / 21572414 rs17114928 chr1 96793488 C T 2.50E-05 Urinary metabolites / / 21572414 rs4000377 chr1 96802619 A T 2.10E-06 Urinary metabolites / / 21572414 rs324870 chr1 96803851 T C 1.00E-04 Tuberculosis / / 20694014 rs162018 chr1 96817319 C T 5.76E-04 Multiple complex diseases / / 17554300 rs12737060 chr1 96819473 T C 1.00E-05 Urinary metabolites / / 21572414 rs6593598 chr1 96908637 T C 6.06E-04 Insulin resistance / / 21901158 rs927512 chr1 96932939 A G 4.15E-04 Insulin resistance / / 21901158 rs1973993 chr1 96943994 T C 1.00E-06 Weight / / 19079260 rs1973993 chr1 96943994 T C 1.30E-05 Smoking behavior / / 20418888 rs1555543 chr1 96944797 A C 4.00E-10 Body mass index / / 20935630 rs1555543 chr1 96944797 A C 3.68E-10 Body mass index / / 23001569 rs1967769 chr1 96993449 T C 2.05E-04 Multiple complex diseases / / 17554300 rs3912027 chr1 96993603 G T 2.09E-04 Multiple complex diseases / / 17554300 rs12120893 chr1 97007132 C T 2.30E-05 Urinary metabolites / / 21572414 rs17426562 chr1 97036113 G A 9.25E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10783050 chr1 97037083 T C 4.00E-06 Body mass index / / 19079260 rs10783050 chr1 97037083 T C 2.80E-06 Smoking behavior / / 20418888 rs11165690 chr1 97113731 T C 1.78E-06 Schizophrenia / / 19571811 rs12071951 chr1 97113915 T G 5.00E-07 Schizophrenia / / 22688191 rs6673531 chr1 97115049 G A 1.41E-05 Bipolar disorder / / 21771265 rs1496116 chr1 97152559 T C 1.78E-09 Narcolepsy / / 19629137 rs7544736 chr1 97164343 A G 6.00E-07 Schizophrenia / / 19571811 rs10875032 chr1 97198331 G T 8.99E-06 Bipolar disorder PTBP2 intron 21771265 rs10489798 chr1 97245046 A G 6.20E-05 Electrocardiographic traits and heart rate variability PTBP2 intron 17903306 rs12725199 chr1 97293792 C A 2.00E-04 Systolic blood pressure / / 19430483 rs12740489 chr1 97296935 G A 6.73E-05 Blood Pressure / / pha002903 rs635578 chr1 97304571 C A 5.72E-04 Type 2 diabetes / / 17463246 rs559734 chr1 97304868 G C 8.48E-04 Lymphocyte counts / / 22286170 rs11584143 chr1 97316690 G A 1.22E-04 Epilepsy / / 22116939 rs1401836 chr1 97332684 C T 1.82E-05 Type 2 diabetes / / 17463246 rs11165731 chr1 97340388 A G 1.02E-04 Type 2 diabetes / / 17463246 rs12069698 chr1 97352212 C G 9.96E-05 Type 2 diabetes / / 17463246 rs6675133 chr1 97353641 T C 1.50E-05 Type 2 diabetes / / 17463246 rs2681194 chr1 97365977 C T 9.67E-05 Blood Pressure / / pha002903 rs2681194 chr1 97365977 C T 2.42E-05 Height / / pha003011 rs950390 chr1 97374535 A T 9.55E-05 Type 2 diabetes / / 17463246 rs950390 chr1 97374535 A T 5.07E-04 Multiple complex diseases / / 17554300 rs4433451 chr1 97378162 C T 3.23E-05 Type 2 diabetes / / 17463246 rs2030342 chr1 97388226 C T 9.42E-05 Height / / pha003010 rs2030342 chr1 97388226 C T 1.27E-05 Height / / pha003011 rs6659733 chr1 97404744 A G 5.23E-05 Type 2 diabetes / / 17463246 rs10493887 chr1 97410506 T C 6.02E-05 Type 2 diabetes / / 17463246 rs10493887 chr1 97410506 T C 5.34E-04 Multiple complex diseases / / 17554300 rs11165745 chr1 97428382 T G 8.09E-05 Epilepsy (remission after treatment) / / 23962720 rs10493888 chr1 97434827 G C 3.29E-04 Type 2 diabetes / / 17463246 rs10493888 chr1 97434827 G C 9.06E-05 Epilepsy (remission after treatment) / / 23962720 rs3002273 chr1 97439491 G T 7.51E-05 Height / / pha003011 rs10493889 chr1 97447183 T C 8.00E-04 Colorectal cancer / / 17618283 rs182358 chr1 97463150 C T 8.90E-06 Major depressive disorder / / 21042317 rs290822 chr1 97469304 C G 3.38E-08 Pure-tone audiometry / / pha001964 rs290825 chr1 97477667 A G 8.99E-04 Multiple complex diseases / / 17554300 rs11165765 chr1 97490921 C T 9.87E-04 Multiple complex diseases / / 17554300 rs6656001 chr1 97498401 T A 3.35E-04 Multiple complex diseases / / 17554300 rs6664634 chr1 97498499 G A 2.91E-04 Multiple complex diseases / / 17554300 rs11165783 chr1 97569544 T C 7.50E-05 Tooth agenesis (third molar) DPYD intron 24172245 rs1399291 chr1 97576922 C T 2.55E-05 Hypertension DPYD intron 21082022 rs9437663 chr1 97585937 A G 6.49E-04 Suicide attempts in bipolar disorder DPYD intron 21423239 rs10493890 chr1 97588830 C T 6.33E-04 Cognition,early reading ability DPYD intron 17684495 rs6593634 chr1 97635212 A C 4.39E-04 HIV-1 viral setpoint DPYD intron 17641165 rs10875053 chr1 97636966 C G 3.74E-04 Coronary Artery Disease DPYD intron 17634449 rs7529372 chr1 97647338 C T 3.45E-08 Metabolite levels DPYD intron 23281178 rs6656660 chr1 97649209 G T 3.45E-08 Metabolite levels DPYD intron 23281178 rs4128473 chr1 97672838 T C 5.16E-08 Metabolite levels DPYD intron 23281178 rs17116566 chr1 97686367 A G 2.57E-04 Multiple complex diseases DPYD intron 17554300 rs17116594 chr1 97701403 C T 6.96E-04 Response to taxane treatment (placlitaxel) DPYD intron 23006423 rs12758854 chr1 97711561 G A 0.0000572 Tuberculosis with late age of onset DPYD intron 22551897 rs493517 chr1 97721227 A G 5.13E-05 Partial epilepsies DPYD intron 20522523 rs495257 chr1 97721392 A G 6.06E-05 Partial epilepsies DPYD intron 20522523 rs644428 chr1 97737704 C T 7.31E-04 Multiple complex diseases DPYD intron 17554300 rs7512040 chr1 97781640 G A,C,T 7.35E-04 Response to cytidine analogues (gemcitabine) DPYD intron 24483146 rs10875069 chr1 97793775 T G 3.48E-04 Response to cytidine analogues (gemcitabine) DPYD intron 24483146 rs1607779 chr1 97794265 C A 3.51E-05 Cognitive impairment induced by topiramate DPYD intron 22091778 rs11165846 chr1 97819667 C G 9.00E-06 Platelet counts DPYD intron 21507922 rs12403997 chr1 97832736 G A 2.24E-04 Vaspin levels DPYD intron 22907691 rs12403997 chr1 97832736 G A 0.0002237 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks DPYD intron 22907730 rs11165851 chr1 97845577 T A 4.63E-24 Narcolepsy DPYD intron 19629137 rs6665429 chr1 97853619 C T 3.25E-04 Amyotrophic Lateral Sclerosis DPYD intron 17362836 rs4950031 chr1 97854245 T G 1.16E-04 Vaspin levels DPYD intron 22907691 rs4950031 chr1 97854245 T G 0.0001162 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks DPYD intron 22907730 rs7538155 chr1 97855144 T C 1.16E-04 Vaspin levels DPYD intron 22907691 rs7538155 chr1 97855144 T C 0.0001162 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks DPYD intron 22907730 rs7530072 chr1 97856731 C T 7.57E-04 Myopia (pathological) DPYD intron 21095009 rs7530072 chr1 97856731 C T 1.16E-04 Vaspin levels DPYD intron 22907691 rs7530072 chr1 97856731 C T 0.0001162 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks DPYD intron 22907730 rs955850 chr1 97857761 T C 6.01E-04 Amyotrophic Lateral Sclerosis DPYD intron 17362836 rs11165870 chr1 97895762 T C 4.34E-05 Serum metabolites DPYD intron 19043545 rs11165870 chr1 97895762 T C 7.16E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs2225882 chr1 97896277 T G 4.94E-04 Multiple complex diseases DPYD intron 17554300 rs7517433 chr1 97898232 T C 3.50E-05 Left ventricular hypertrophy DPYD intron pha003052 rs12129397 chr1 97900552 A T 7.07E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs11165873 chr1 97902790 A T 7.05E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs4949953 chr1 97904780 T C 7.03E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs7517899 chr1 97907753 C T 6.48E-04 Alzheimer's disease DPYD intron 22005930 rs1415681 chr1 97908878 T G 4.08E-05 Left ventricular hypertrophy DPYD intron pha003052 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 12668918 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 15093568 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 17000684 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 17121937 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 17350823 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 18299612 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 19147868 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 9817272 rs3897854 chr1 97918306 C T 6.33E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs12354219 chr1 97920956 T C 6.32E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs7531138 chr1 97923499 T A 1.52E-04 Suicide attempts in bipolar disorder DPYD intron 21041247 rs7550959 chr1 97926839 G A 9.59E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs4451581 chr1 97949431 A C 2.10E-05 Inflammatory demyelinating disease DPYD intron 19850125 rs2811182 chr1 97971440 G A 2.74E-05 Amyotrophic lateral sclerosis (sporadic) DPYD intron 24529757 rs11165887 chr1 97974659 G A 1.50E-05 Urinary metabolites DPYD intron 21572414 rs1801159 chr1 97981395 T C 1 Drug response to Fluorouracil DPYD missense 17848752 rs1801159 chr1 97981395 T C 1 Drug response to Fluorouracil DPYD missense 9918128 rs7519652 chr1 97984103 C A 2.70E-05 Urinary metabolites DPYD intron 21572414 rs2811173 chr1 97992257 C T 9.01E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) DPYD intron 23648065 rs2786785 chr1 97997645 A T 2.00E-04 Cognitive impairment induced by topiramate DPYD intron 22091778 rs4950041 chr1 98003908 A G 4.34E-04 Alzheimer's disease (late onset) DPYD intron 21379329 rs6663357 chr1 98044939 A C 7.94E-04 Response to cytadine analogues (cytosine arabinoside) DPYD intron 24483146 rs7533902 chr1 98079228 T C 1.20E-04 Obesity-related traits DPYD intron 17903300 rs17117003 chr1 98082388 A C 1.34E-04 Multiple complex diseases DPYD intron 17554300 rs2786508 chr1 98141828 C T 4.42E-06 Sleep duration DPYD intron 22105623 rs2297595 chr1 98165091 T C 1 Drug response to Capecitabine DPYD missense 19104657 rs2297595 chr1 98165091 T C 1 Drug response to Fluorouracil DPYD missense 19104657 rs10493895 chr1 98271226 A C 1.60E-05 Blood Phenotypes DPYD intron 17903294 rs4246514 chr1 98297731 C G 4.21E-04 Multiple complex diseases DPYD intron 17554300 rs4421623 chr1 98316285 T G 9.57E-04 Multiple complex diseases DPYD intron 17554300 rs4372296 chr1 98320492 C A 9.17E-04 Multiple complex diseases DPYD intron 17554300 rs4379706 chr1 98322379 C T 9.29E-04 Multiple complex diseases DPYD intron 17554300 rs1801265 chr1 98348885 G A 1 Drug response to Fluorouracil / / 17848752 rs1801265 chr1 98348885 G A 1 Drug response to Fluorouracil / / 9918128 rs9324380 chr1 98461132 G C 2.20E-05 Urinary metabolites MIR137HG intron 21572414 rs77177281 chr1 98471702 A G 2.00E-06 PR interval in Tripanosoma cruzi seropositivity MIR137HG intron 24324551 rs1198572 chr1 98497176 A C 3.14E-05 Aging (time to event) MIR137HG intron 21782286 rs1625579 chr1 98502934 G T 2.00E-11 Schizophrenia MIR137HG intron 21926974 rs1625579 chr1 98502934 G T 2.00E-11 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) MIR137HG intron 23453885 rs1625579 chr1 98502934 G T 0.00000376 Schizophrenia MIR137HG intron 23637625 rs12410326 chr1 98546248 T C 1.64E-05 Multiple complex diseases / / 17554300 rs1198588 chr1 98552832 A T 5.00E-07 Schizophrenia / / 22688191 rs1198588 chr1 98552832 A T 2.00E-12 Schizophrenia / / 23974872 rs1507061 chr1 98569656 G A 1.61E-05 Major depressive disorder / / 21621269 rs6679864 chr1 98579211 A G 6.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs355374 chr1 98588753 A G 0.000317882 Hypertension (early onset hypertension) / / 22479346 rs17117765 chr1 98601247 T C 5.26E-04 Multiple complex diseases / / 17554300 rs2632303 chr1 98617672 T C 5.85E-04 Multiple complex diseases / / 17554300 rs2660309 chr1 98622407 C T 4.35E-05 Hypertension (early onset hypertension) / / 22479346 rs12734505 chr1 98627901 A G 2.34E-05 Major depressive disorder / / 21621269 rs10493900 chr1 98645213 A G 7.10E-05 Cardiovascular disease / / 17903304 rs698997 chr1 98659529 C T 5.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs11577139 chr1 98666125 C A 8.00E-07 Prostate cancer / / 21743057 rs11165973 chr1 98719851 G A 4.03E-07 Multiple complex diseases LOC729987 intron 17554300 rs6664206 chr1 98840567 A T 1.13E-04 Alzheimer's disease (late onset) / / 21460841 rs17118281 chr1 98848697 A G 5.96E-05 Alzheimer's disease (late onset) / / 21460841 rs1328306 chr1 98882770 T C 2.40E-05 Urinary metabolites / / 21572414 rs17118459 chr1 98925555 T C 5.55E-05 Multiple complex diseases / / 17554300 rs4950128 chr1 98927114 C A,G 4.78E-04 Type 2 diabetes / / 17463246 rs1434364 chr1 98927742 C T 3.78E-04 Type 2 diabetes / / 17463246 rs770918 chr1 98928937 A G 9.10E-04 Crohn's disease / / 17684544 rs648124 chr1 98937092 C T 1.56E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs591520 chr1 98964498 A G 6.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs591545 chr1 98964518 T C 6.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs3867319 chr1 98964760 G A 8.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs12064487 chr1 99021875 G A 0.00080188 Sarcoidosis / / 22952805 rs12129212 chr1 99096771 T C 1.00E-04 Prostate cancer / / 21743057 rs4402170 chr1 99129503 C G 6.98E-04 Multiple complex diseases SNX7 intron 17554300 rs6577322 chr1 99164434 G A 5.71E-04 Multiple complex diseases SNX7 cds-synon 17554300 rs9727115 chr1 99177253 G A 2.00E-07 Proinsulin levels SNX7 intron 21873549 rs12725220 chr1 99184798 G A 3.08E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) SNX7 intron 23648065 rs17118895 chr1 99209996 A G 9.15E-05 Multiple complex diseases SNX7 intron 17554300 rs6674890 chr1 99231152 A T 8.50E-04 Multiple complex diseases / / 17554300 rs4908035 chr1 99236025 T C 1.01E-04 Multiple complex diseases / / 17554300 rs1384168 chr1 99242320 C T 6.07E-05 Multiple complex diseases / / 17554300 rs7524208 chr1 99290670 C T 4.40E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11166132 chr1 99317472 A C 4.36E-04 Fibrinogen / / 17255346 rs11166132 chr1 99317472 A C 6.22E-04 Type 2 diabetes / / 17463246 rs1358432 chr1 99318760 G A 4.36E-04 Fibrinogen / / 17255346 rs1358431 chr1 99318835 A G 4.36E-04 Fibrinogen / / 17255346 rs10493905 chr1 99334877 A G 4.44E-04 Multiple complex diseases / / 17554300 rs11166135 chr1 99348836 A G 1.00E-06 Dental caries / / 23064961 rs984271 chr1 99358358 G T 4.63E-04 Alzheimer's disease LPPR5 UTR-3 22005930 rs1481501 chr1 99359944 A G 3.18E-04 Alzheimer's disease LPPR5 intron 22005930 rs10875195 chr1 99365922 C T 1.84E-04 Alzheimer's disease LPPR5 intron 22005930 rs1871786 chr1 99366163 T C 5.01E-04 Alzheimer's disease LPPR5 intron 22005930 rs6679030 chr1 99366837 T C 6.49E-04 Alzheimer's disease LPPR5 intron 22005930 rs6675949 chr1 99366952 A G 1.09E-04 Taste perception LPPR5 intron 22132133 rs1383832 chr1 99367844 G A 4.86E-04 Alzheimer's disease LPPR5 intron 22005930 rs10875196 chr1 99378914 G A 9.57E-05 Rheumatoid arthritis LPPR5 intron 17804836 rs1471581 chr1 99382491 A G 8.93E-04 Coronary Artery Disease LPPR5 intron 17634449 rs1571500 chr1 99386293 T C 2.00E-06 Dental caries LPPR5 intron 23259602 rs2497750 chr1 99407351 A G 3.07E-04 Height LPPR5 intron 17255346 rs382051 chr1 99426616 C T 6.19E-04 Suicide attempts in bipolar disorder LPPR5 intron 21423239 rs6682665 chr1 99433123 T G 4.94E-04 Multiple complex diseases LPPR5 intron 17554300 rs1360152 chr1 99440212 A T 4.90E-04 Multiple complex diseases LPPR5 intron 17554300 rs309061 chr1 99443077 T G 7.57E-04 Suicide attempts in bipolar disorder LPPR5 intron 21423239 rs12084355 chr1 99449969 T C 6.38E-04 Multiple complex diseases LPPR5 intron 17554300 rs10443196 chr1 99453287 T C 9.00E-06 Obesity-related traits LPPR5 intron 23251661 rs10489924 chr1 99458974 T C 7.00E-04 Crohn's disease LPPR5 intron 17684544 rs10489925 chr1 99461323 T C 4.90E-04 Multiple complex diseases LPPR5 intron 17554300 rs7413228 chr1 99484386 A C 6.83E-04 Heart Failure LOC100129620 intron pha002885 rs12030123 chr1 99486885 G A 1.38E-04 Heart Failure LOC100129620 intron pha002885 rs1350176 chr1 99495135 G T 5.78E-04 Heart Failure LOC100129620 intron pha002885 rs7530449 chr1 99515902 T G 7.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) LOC100129620 intron 23648065 rs10493907 chr1 99516241 C G 4.90E-04 Multiple complex diseases LOC100129620 intron 17554300 rs897603 chr1 99518345 A G 5.16E-06 Obesity-related traits LOC100129620 intron 23251661 rs10747502 chr1 99524047 A G 1.00E-09 Myopia (pathological) LOC100129620 intron 23049088 rs10747502 chr1 99524047 A G 5.00E-07 Obesity-related traits LOC100129620 intron 23251661 rs12409665 chr1 99530067 T G 3.18E-05 Parkinson's disease (motor and cognition) LOC100129620 intron 22658654 rs12409665 chr1 99530067 T G 3.18E-05 Immune response to anthrax vaccine LOC100129620 intron 22658931 rs17119481 chr1 99533944 A C 2.39E-04 Alzheimer's disease (late onset) LOC100129620 intron 21379329 rs17119481 chr1 99533944 A C 7.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) LOC100129620 intron 23648065 rs12411241 chr1 99551140 A G 2.44E-05 Blood Pressure LOC100129620 intron pha003050 rs17119565 chr1 99583493 C A 6.03E-04 Multiple complex diseases LOC100129620 intron 17554300 rs303386 chr1 99589379 C T 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) LOC100129620 intron 23648065 rs303386 chr1 99589379 C T 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) LOC100129620 intron 23648065 rs302748 chr1 99597328 A G 7.57E-04 Myopia (pathological) LOC100129620 intron 21095009 rs302748 chr1 99597328 A G 7.47E-05 Blood Pressure LOC100129620 intron pha003044 rs863686 chr1 99610153 A G 9.73E-06 Hearing function LOC100129620 intron 21493956 rs587509 chr1 99615714 C T 4.86E-06 Hearing function / / 21493956 rs621215 chr1 99619424 G A 3.73E-06 Hearing function / / 21493956 rs687101 chr1 99637572 G A 6.25E-07 Hearing function / / 21493956 rs604876 chr1 99641020 T C 1.91E-06 Hearing function / / 21493956 rs638723 chr1 99641669 A G 6.59E-07 Hearing function / / 21493956 rs668206 chr1 99643963 G T 9.64E-07 Hearing function / / 21493956 rs6577368 chr1 99644223 A G 4.72E-04 Insulin resistance / / 21901158 rs712937 chr1 99645446 A G 3.15E-07 Hearing function / / 21493956 rs712936 chr1 99647039 T C 2.84E-07 Hearing function / / 21493956 rs712934 chr1 99648976 T A 2.33E-07 Hearing function / / 21493956 rs712932 chr1 99651500 G C 2.32E-07 Hearing function / / 21493956 rs12080341 chr1 99653855 A G 3.30E-04 Insulin resistance / / 21901158 rs712931 chr1 99654168 G T 2.38E-07 Hearing function / / 21493956 rs819786 chr1 99654527 G A 2.39E-07 Hearing function / / 21493956 rs819785 chr1 99655620 G A 2.41E-07 Hearing function / / 21493956 rs3911410 chr1 99660145 G A 2.44E-06 Hearing function / / 21493956 rs664835 chr1 99663968 T A 4.74E-07 Hearing function / / 21493956 rs819778 chr1 99665186 A G 5.00E-07 Hearing function / / 21493956 rs645441 chr1 99670057 T G 5.65E-07 Hearing function / / 21493956 rs685267 chr1 99671349 A C 8.37E-07 Hearing function / / 21493956 rs819797 chr1 99687402 G A 5.74E-06 Ankle-brachial index / / 22199011 rs7530667 chr1 99691732 T C 8.43E-06 Ankle-brachial index / / 22199011 rs819746 chr1 99693744 C A 5.04E-06 Ankle-brachial index / / 22199011 rs819748 chr1 99695168 C A 4.19E-06 Ankle-brachial index / / 22199011 rs819750 chr1 99697063 G T 5.11E-04 Ankle-brachial index / / 22199011 rs819756 chr1 99701930 C T 9.71E-06 Ankle-brachial index / / 22199011 rs6577370 chr1 99711864 C A 8.71E-71 Multiple complex diseases / / 17554300 rs6577370 chr1 99711864 C A 4.29E-04 Smoking initiation / / 24665060 rs819910 chr1 99764226 C T 1.14E-05 Lung function (forced vital capacity) LPPR4 intron pha003104 rs819914 chr1 99765872 G A 2.15E-05 Lung function (forced vital capacity) LPPR4 intron pha003104 rs712878 chr1 99780284 T C 1.91E-05 Lung function (forced vital capacity) / / pha003104 rs12135248 chr1 99780891 A G 8.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs12743824 chr1 99782957 C A 5.00E-06 Non-alcoholic fatty liver disease histology (other) / / 23213074 rs12140879 chr1 99793111 G A 6.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs1325957 chr1 99794023 T C 6.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs1419059 chr1 99911058 T C 0.0007631 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1419059 chr1 99911058 T C 7.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs713265 chr1 99937037 A G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs17120530 chr1 99952060 A G 0.000141 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17120530 chr1 99952060 A G 1.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12032219 chr1 99953165 G A 0.00006866 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12032219 chr1 99953165 G A 6.87E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4623724 chr1 99954032 C G 0.0004875 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4623724 chr1 99954032 C G 4.88E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4908327 chr1 99993077 C T 5.89E-04 Multiple complex diseases / / 17554300 rs11166266 chr1 99999237 C T 1.87E-14 Gender / / 22362730 rs12135239 chr1 100041459 G A 3.24E-04 Lymphocyte counts / / 22286170 rs6702619 chr1 100046246 T G 0.000000577 Colorectal cancer / / 22532847 rs6702619 chr1 100046246 T G 3.29E-08 Colorectal cancer vs. adenoma controls / / 22532847 rs7543130 chr1 100049785 C A 1.00E-07 Aortic root size / / 19584346 rs1361378 chr1 100071637 T C 7.87E-04 Multiple complex diseases / / 17554300 rs11166284 chr1 100087539 A T 2.80E-05 Urinary metabolites / / 21572414 rs12077588 chr1 100089604 T G 5.61E-05 Multiple complex diseases / / 17554300 rs4908005 chr1 100161691 G T 1.00E-05 Urinary metabolites / / 21572414 rs6679943 chr1 100163271 T C 2.74E-04 Alzheimer's disease / / 24755620 rs12024467 chr1 100190830 G A 0.000242 Salmonella-induced pyroptosis FRRS1 intron 22837397 rs17121183 chr1 100248380 T C 9.68E-04 Alzheimer's disease / / 22005930 rs12023333 chr1 100267478 T C 3.93E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs6689305 chr1 100268991 G A 9.00E-06 White matter integrity (interaction) / / 23218918 rs1493617 chr1 100270735 C A 3.07E-05 Personality dimensions / / 22628180 rs11166344 chr1 100272171 G C 3.93E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs9887771 chr1 100276744 C G 1.04E-04 Alzheimer's disease / / 24755620 rs11166358 chr1 100305320 T C 7.37E-05 Hearing impairment / / 19047183 rs17121403 chr1 100335977 A G 7.00E-06 Pulmonary function decline AGL missense 22424883 rs903125 chr1 100352470 C A 3.64E-04 Alzheimer's disease AGL intron 24755620 rs3753494 chr1 100358103 C T 3.30E-04 Alzheimer's disease AGL missense 24755620 rs3818568 chr1 100377789 C T 9.50E-06 Urinary metabolites AGL intron 21572414 rs17121644 chr1 100385430 C T 4.78E-05 Age-related macular degeneration AGL intron pha002890 rs2149194 chr1 100401929 G T 1.00E-05 Urinary metabolites / / 21572414 rs1541044 chr1 100411287 T C 6.59E-04 Alzheimer's disease / / 24755620 rs6701658 chr1 100426978 A G 4.60E-05 Glioma (high-grade) / / 19578366 rs7530361 chr1 100462860 T C 5.40E-05 Glioma (high-grade) SLC35A3 intron 19578366 rs7518943 chr1 100463422 C A 1.27E-04 Alzheimer's disease SLC35A3 intron 17998437 rs7518943 chr1 100463422 C A 1.96E-04 Alzheimer's disease SLC35A3 intron pha002879 rs11166389 chr1 100466279 G A 6.10E-08 Glioma (high-grade) SLC35A3 intron 19578366 rs495871 chr1 100474456 C T 3.21E-05 Age-related macular degeneration SLC35A3 intron pha002890 rs575323 chr1 100482396 G A 3.32E-05 Age-related macular degeneration SLC35A3 intron pha002890 rs501700 chr1 100520311 G A 2.40E-05 Glioma (high-grade) HIAT1 intron 19578366 rs560659 chr1 100523536 G A 1.92E-04 Alzheimer's disease HIAT1 intron 17998437 rs560659 chr1 100523536 G A 1.01E-04 Alzheimer's disease HIAT1 intron pha002879 rs644835 chr1 100543962 A G 3.10E-05 Glioma (high-grade) HIAT1 intron 19578366 rs640030 chr1 100574992 C T 3.10E-05 Glioma (high-grade) SASS6 intron 19578366 rs663519 chr1 100592653 A G 5.59E-05 Vascular dementia SASS6 intron 22116812 rs687513 chr1 100598867 C T 5.10E-05 Glioma (high-grade) CCDC76 missense 19578366 rs6681721 chr1 100609639 C T 2.47E-05 Age-related macular degeneration CCDC76 cds-synon pha002890 rs12733952 chr1 100611571 C T 4.78E-05 Alzheimer's disease CCDC76 intron pha002879 rs506044 chr1 100611931 A G 2.60E-05 Glioma (high-grade) CCDC76 intron 19578366 rs6677080 chr1 100633469 T A 1.44E-04 Alzheimer's disease LRRC39 intron pha002879 rs11166407 chr1 100637708 G A 2.00E-05 Alzheimer's disease LRRC39 intron 17998437 rs11166407 chr1 100637708 G A 2.01E-05 Alzheimer's disease LRRC39 intron pha002879 rs11166412 chr1 100656265 C T 2.16E-04 Alzheimer's disease DBT UTR-3 pha002879 rs2810424 chr1 100663679 T C 6.30E-06 Glioma (high-grade) DBT intron 19578366 rs12021720 chr1 100672060 T C 1.50E-07 Glioma (high-grade) DBT missense 19578366 rs4143055 chr1 100690122 T C 1.42E-04 Alzheimer's disease DBT intron 17998437 rs4143055 chr1 100690122 T C 2.54E-05 Alzheimer's disease DBT intron pha002879 rs3806237 chr1 100715782 T C 2.00E-04 Cognitive impairment induced by topiramate DBT nearGene-5 22091778 rs17454070 chr1 100732855 T C 1.00E-04 Information processing speed RTCD1 intron 21130836 rs3119186 chr1 100781537 T C 7.42E-04 Multiple complex diseases / / 17554300 rs478859 chr1 100796120 T C 0.00000573 Colorectal adenoma / / 23677573 rs478859 chr1 100796120 T C 0.00000573 Colorectal adenoma (including hyperplasic) / / 23677573 rs478859 chr1 100796120 T C 0.0000274 Colorectal adenoma (excluding hyperplasic) / / 23677573 rs7534479 chr1 100798137 G A 6.30E-04 Depression (quantitative trait) / / 20800221 rs4907906 chr1 100802399 T C 3.70E-06 Urinary metabolites / / 21572414 rs10783130 chr1 100806897 C G 3.41E-08 Metabolite levels / / 23281178 rs11166439 chr1 100808286 G C 3.20E-08 Metabolite levels / / 23281178 rs529224 chr1 100818178 G C 1.57E-05 Response to statin treatment (atorvastatin),change in cholesterol levels CDC14A UTR-5 20031582 rs17420882 chr1 100818728 T G 6.98E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CDC14A intron 20031582 rs630646 chr1 100822776 G A 3.40E-06 Urinary metabolites CDC14A intron 21572414 rs17122341 chr1 100843757 C A 1.30E-05 Urinary metabolites CDC14A intron 21572414 rs7512321 chr1 100862989 C G 3.38E-04 Multiple complex diseases CDC14A intron 17554300 rs584350 chr1 100908324 A G 5.20E-06 Urinary metabolites CDC14A intron 21572414 rs10493923 chr1 100930254 C T 1.20E-05 Urinary metabolites CDC14A intron 21572414 rs17122625 chr1 100944262 G A 1.38E-04 Multiple complex diseases CDC14A intron 17554300 rs2809823 chr1 101003762 C A 1.80E-05 Post-operative nausea and vomiting GPR88 UTR-5 21694509 rs2030048 chr1 101006577 A G 3.99E-05 Response to statin treatment (atorvastatin),change in cholesterol levels GPR88 UTR-3 20031582 rs1874779 chr1 101012512 G A 3.40E-06 Urinary metabolites / / 21572414 rs12038174 chr1 101013455 C T 1.60E-06 Urinary metabolites / / 21572414 rs11166474 chr1 101015181 C T 1.70E-06 Urinary metabolites / / 21572414 rs10875308 chr1 101024423 T C 8.76E-05 Kawasaki disease / / 22081228 rs1335751 chr1 101027524 T C 2.00E-06 Urinary metabolites / / 21572414 rs10875310 chr1 101027566 C T 9.90E-06 Urinary metabolites / / 21572414 rs1542837 chr1 101029768 T C 3.15E-05 Kawasaki disease / / 22081228 rs2809791 chr1 101039059 C T 5.30E-04 Multiple complex diseases / / 17554300 rs2647327 chr1 101041766 G A 1.80E-05 Urinary metabolites / / 21572414 rs10493929 chr1 101043928 A C 1.60E-05 Urinary metabolites / / 21572414 rs10875317 chr1 101045438 G T 1.80E-05 Urinary metabolites / / 21572414 rs7524322 chr1 101047730 C G 7.60E-06 Urinary metabolites / / 21572414 rs12728424 chr1 101055002 G A 7.27E-05 Kawasaki disease / / 22081228 rs11583008 chr1 101085094 A G 1.11E-06 Kawasaki disease / / 22081228 rs17412243 chr1 101094662 G A 6.91E-05 Tardive dyskinesia LOC100128787 intron 20939080 rs2484535 chr1 101107748 C T 5.24E-06 Kawasaki disease LOC100128787 intron 22081228 rs955336 chr1 101108982 G A 4.00E-04 Type 2 diabetes LOC100128787 intron 17463246 rs17412577 chr1 101109431 C T 4.00E-05 Tardive dyskinesia LOC100128787 intron 20939080 rs10493934 chr1 101124201 T A 2.75E-05 Tardive dyskinesia / / 20939080 rs1932351 chr1 101142049 C T 1.79E-06 Kawasaki disease / / 22081228 rs2050471 chr1 101175651 C T 9.08E-06 Kawasaki disease / / 22081228 rs3783599 chr1 101183887 C T 0.00000017 Triglycerides VCAM1 nearGene-5 23063622 rs3176860 chr1 101187219 A G 6.24E-04 Depression (quantitative trait) VCAM1 intron 20800221 rs3917056 chr1 101195902 G C 2.61E-09 Triglycerides VCAM1 intron 23063622 rs3181088 chr1 101198708 C T 3.61E-04 Suicide attempts in bipolar disorder VCAM1 intron 21423239 rs3176874 chr1 101199886 A G 2.18E-05 Alcohol dependence VCAM1 intron 21703634 rs3783621 chr1 101204495 C A 9.03E-04 Multiple complex diseases VCAM1 UTR-3 17554300 rs11586136 chr1 101236137 T C 8.35E-06 Primary biliary cirrhosis / / 21399635 rs17123397 chr1 101276999 A G 8.17E-05 Smoking cessation / / 24665060 rs7541397 chr1 101322866 A G 4.61E-05 Smoking cessation / / 24665060 rs11812031 chr1 101327772 A G 5.72E-04 Smoking cessation / / 24665060 rs12048904 chr1 101331536 T C 4.00E-08 Multiple sclerosis / / 21833088 rs7543296 chr1 101348100 C A 4.42E-04 Smoking cessation EXTL2 intron 24665060 rs2893468 chr1 101355549 A G 5.62E-04 Smoking cessation EXTL2 intron 24665060 rs3737580 chr1 101360215 C T 1.53E-04 Depression (quantitative trait) EXTL2 UTR-5 20800221 rs11579723 chr1 101396743 G T 3.03E-04 Smoking cessation SLC30A7 intron 24665060 rs11581062 chr1 101407519 A G 3.00E-10 Multiple sclerosis SLC30A7 intron 21833088 rs12023712 chr1 101462232 G A 1.82E-04 Depression (quantitative trait) DPH5 intron 20800221 rs12119832 chr1 101463138 G A 1.82E-04 Depression (quantitative trait) DPH5 intron 20800221 rs11166536 chr1 101476712 G C 1.82E-04 Depression (quantitative trait) DPH5 intron 20800221 rs17409729 chr1 101535778 T G 7.00E-05 Response to lithium treatment in bipolar disorder LOC100506051 intron 19448189 rs17450029 chr1 101540999 T C 3.00E-06 QT interval (interaction) LOC100506051 intron 23459443 rs950038 chr1 101549316 A G 4.80E-04 Type 2 diabetes and 6 quantitative traits LOC100506029 intron 17848626 rs17410015 chr1 101551926 T C 2.00E-06 Response to antipsychotic treatment LOC100506029 intron 20195266 rs12756986 chr1 101604753 T C 2.00E-04 Blood pressure / / 17255346 rs17417367 chr1 101620729 A G 6.70E-05 Alcohol dependence / / 22096494 rs17123757 chr1 101622960 T C 7.57E-05 Blood pressure / / 17255346 rs1999134 chr1 101681468 A C 4.50E-05 Heart Rate / / pha003053 rs12404070 chr1 101682050 T C 4.95E-04 Multiple complex diseases / / 17554300 rs12404070 chr1 101682050 T C 1.13E-05 Personality dimensions / / 22628180 rs33967958 chr1 101701481 T C 1.00E-04 Cognitive impairment induced by topiramate S1PR1 nearGene-5 22091778 rs17100954 chr1 101704029 G A 0.000026 Coronary artery calcification S1PR1 intron 23727086 rs12090529 chr1 101707126 T C 1.20E-05 HIV-1 control S1PR1 nearGene-3 20041166 rs12097137 chr1 101709445 G T 1.87E-13 HDL cholesterol / / 23063622 rs12097137 chr1 101709445 G T 2.64E-11 Cholesterol,total / / 23063622 rs2031959 chr1 101711783 T G 8.70E-04 Atrial fibrillation / / 21846873 rs765344 chr1 101716688 C T 8.46E-05 Cognitive test performance / / 20125193 rs7532171 chr1 101724951 C T 3.81E-05 Alcohol and nictotine co-dependence / / 20158304 rs7520706 chr1 101751884 T G 1.69E-04 Amyotrophic lateral sclerosis / / 20801718 rs13376006 chr1 101768580 G C 1.15E-04 Type 2 diabetes / / 17463246 rs17124135 chr1 101770101 A G 8.44E-04 Multiple complex diseases / / 17554300 rs9433784 chr1 101784340 G T 7.19E-04 Alcohol dependence / / 21314694 rs12564407 chr1 101809218 A G 4.00E-05 Bipolar disorder / / 24387768 rs12564407 chr1 101809218 A G 4.00E-05 Bipolar disorder / / 24387768 rs11802191 chr1 101834723 C A 7.86E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1491643 chr1 101849423 G A 2.86E-05 Cholesterol / / pha003083 rs6577245 chr1 101849830 G A 1.03E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12403551 chr1 101864215 G A 3.28E-06 Alopecia areata / / 22027810 rs10493947 chr1 101868793 G A 5.83E-04 Multiple complex diseases / / 17554300 rs10493947 chr1 101868793 G A 8.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1826316 chr1 101872865 C T 1.50E-06 Parkinson's disease / / 20711177 rs2338971 chr1 101880005 T C 4.00E-10 Parkinson's disease / / 24511991 rs2338971 chr1 101880005 T C 5.00E-10 Parkinson's disease / / 24511991 rs4908144 chr1 101889855 T C 0.0000153 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6662461 chr1 101891186 C G 0.0000121 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11581429 chr1 101913527 C T 9.34E-04 Multiple complex diseases / / 17554300 rs12118351 chr1 101919802 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10493955 chr1 101922436 A T 6.79E-04 Multiple complex diseases / / 17554300 rs10493955 chr1 101922436 A T 1.30E-05 Urinary metabolites / / 21572414 rs1777877 chr1 101930897 G T 7.70E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1777867 chr1 101937782 C T 1.52E-04 Multiple complex diseases / / 17554300 rs1777867 chr1 101937782 C T 5.40E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1948368 chr1 101938477 G A 6.00E-06 Bipolar disorder / / 18711365 rs1948368 chr1 101938477 G A 5.40E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs726646 chr1 101938663 T G 5.40E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1361812 chr1 101939689 T G 1.26E-05 Cognitive impairment induced by topiramate / / 22091778 rs1419103 chr1 101940656 A T 5.60E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1777894 chr1 101940809 C T 5.60E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1777894 chr1 101940809 C T 9.73E-06 Cognitive impairment induced by topiramate / / 22091778 rs1776911 chr1 101941385 A T 5.70E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1776907 chr1 101945977 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1776905 chr1 101947657 T A 5.70E-05 Multiple complex diseases / / 17554300 rs387176 chr1 101963766 G A 7.32E-05 Multiple complex diseases / / 17554300 rs396954 chr1 101964376 T A 2.76E-05 Multiple complex diseases / / 17554300 rs374982 chr1 101973050 G A 4.53E-04 Insulin resistance / / 21901158 rs263908 chr1 101973613 C A 9.03E-05 Cognitive impairment induced by topiramate / / 22091778 rs263912 chr1 101975151 T G 2.20E-06 Parkinson's disease / / 20711177 rs263906 chr1 101978334 T C 2.42E-05 Bipolar disorder / / 21926972 rs263906 chr1 101978334 T C 0.000483 Bipolar disorder / / 23070075 rs263918 chr1 101984932 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs263918 chr1 101984932 C T 8.97E-04 Major depressive disorder / / 22472876 rs1688582 chr1 101992222 A G 2.33E-05 Cognitive impairment induced by topiramate / / 22091778 rs12137486 chr1 101994207 C T 5.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1199575 chr1 101996097 G A 3.65E-05 Cognitive impairment induced by topiramate / / 22091778 rs12748695 chr1 102000069 C A 6.96E-04 Type 2 diabetes / / 17463246 rs721021 chr1 102016643 T A 9.37E-04 Multiple complex diseases / / 17554300 rs721018 chr1 102016712 G A 5.98E-04 Multiple complex diseases / / 17554300 rs4626910 chr1 102017100 T C 9.03E-04 Multiple complex diseases / / 17554300 rs6665373 chr1 102017438 T G 8.78E-04 Multiple complex diseases / / 17554300 rs984132 chr1 102030001 C T 2.47E-04 Multiple complex diseases / / 17554300 rs11164278 chr1 102184478 T C 0.0000468 Polycystic ovary syndrome / / 22951595 rs11164278 chr1 102184478 T C 4.68E-05 Intracranial aneurysm / / 22961961 rs2225904 chr1 102193896 G A 8.68E-04 Alzheimer's disease / / 24755620 rs1445227 chr1 102199014 A G 3.50E-05 Squamous cell carcinoma / / 23341777 rs1445227 chr1 102199014 A G 8.95E-04 Alzheimer's disease / / 24755620 rs12565816 chr1 102200090 T G 8.95E-04 Alzheimer's disease / / 24755620 rs10493963 chr1 102222083 T C 3.30E-05 Relative hand skill in reading disability / / 24068947 rs12022918 chr1 102225750 C T 2.36E-05 Relative hand skill in reading disability / / 24068947 rs7536591 chr1 102226863 T C 5.24E-05 Relative hand skill in reading disability / / 24068947 rs959163 chr1 102228731 G A 2.88E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs12026998 chr1 102229779 C A 7.27E-04 Multiple complex diseases / / 17554300 rs4908181 chr1 102233475 T C 3.39E-04 Coronary heart disease / / 21971053 rs10874514 chr1 102234964 C T 2.00E-09 Lipid levels / / 18193044 rs1470438 chr1 102239205 G A 5.78E-05 Relative hand skill in reading disability / / 24068947 rs1020368 chr1 102241441 C T 4.35E-05 Relative hand skill in reading disability / / 24068947 rs11164301 chr1 102243101 G A 4.49E-04 Lung function (forced vital capacity) / / 24023788 rs10782852 chr1 102249785 C T 2.48E-05 Relative hand skill in reading disability / / 24068947 rs559183695 chr1 102249785 C CTTCTTTCTAAAGAAAGAGTTTGATGGTTTATCAT 2.48E-05 Relative hand skill in reading disability / / 24068947 rs11164304 chr1 102256943 T C 2.39E-05 Relative hand skill in reading disability / / 24068947 rs10493976 chr1 102263909 C T 8.16E-04 Schizophrenia / / 19197363 rs1854169 chr1 102274276 C T 6.53E-06 Osteoarthritis OLFM3 intron 22763110 rs4907956 chr1 102312703 G T 5.83E-06 Alcohol dependence OLFM3 intron 20202923 rs4907956 chr1 102312703 G T 2.40E-05 Alcohol dependence OLFM3 intron 21703634 rs4907956 chr1 102312703 G T 0.0000507 Nicotine dependence (smoking) OLFM3 intron 22377092 rs1336798 chr1 102351870 T C 0.0000374 Nicotine dependence (smoking) D/JA1P5 intron 22377092 rs12731963 chr1 102382404 T C 0.000047 Nicotine dependence (smoking) OLFM3 intron 22377092 rs755181 chr1 102404247 T C 7.67E-04 Amyotrophic Lateral Sclerosis OLFM3 intron 17362836 rs1415088 chr1 102413524 C A 4.92E-04 Amyotrophic Lateral Sclerosis OLFM3 intron 17362836 rs4907957 chr1 102423144 T C 2.70E-07 Urinary metabolites OLFM3 intron 21572414 rs4907957 chr1 102423144 T C 0.00000068 Common carotid artery thickness (far walls) OLFM3 intron 23487405 rs4907957 chr1 102423144 T C 0.00000114 Common carotid artery thickness (average of near and far wall measures) OLFM3 intron 23487405 rs10782865 chr1 102453599 A T 8.84E-04 Type 2 diabetes OLFM3 intron 17463246 rs10493964 chr1 102484211 A G 2.91E-06 Varicose Veins / / pha001413 rs6675297 chr1 102548118 G C 3.54E-04 Multiple complex diseases / / 17554300 rs11578152 chr1 102577021 A G 2.30E-05 Urinary metabolites / / 21572414 rs11164386 chr1 102578097 T G 8.57E-05 Multiple complex diseases / / 17554300 rs10493978 chr1 102579307 C T 7.16E-04 Multiple complex diseases / / 17554300 rs2022858 chr1 102608577 G A 6.11E-04 Multiple complex diseases / / 17554300 rs2022858 chr1 102608577 G A 2.20E-05 Urinary metabolites / / 21572414 rs1938355 chr1 102677845 T C 1.18E-04 Bipolar disorder / / 19259986 rs10874555 chr1 102687572 G A 1.80E-05 Urinary metabolites / / 21572414 rs12731867 chr1 102699430 G A 4.26E-04 Type 2 diabetes / / 17463246 rs11164428 chr1 102706193 C G 2.50E-06 Stroke (ischemic) / / 21957438 rs10782879 chr1 102708517 A G 1.12E-04 Multiple complex diseases / / 17554300 rs11804344 chr1 102722923 C G 3.37E-04 Gallstones / / 17632509 rs17126268 chr1 102726399 T C 1.58E-05 Glomerular filtration rate / / 24351856 rs17126268 chr1 102726399 T C 9.64E-05 Chronic kidney disease / / 24351856 rs7539242 chr1 102726802 G A 1.58E-05 Glomerular filtration rate / / 24351856 rs7539242 chr1 102726802 G A 1.58E-05 Glomerular filtration rate / / 24351856 rs7539242 chr1 102726802 G A 9.64E-05 Chronic kidney disease / / 24351856 rs7539242 chr1 102726802 G A 9.64E-05 Chronic kidney disease / / 24351856 rs12120258 chr1 102734951 G T 1.58E-05 Glomerular filtration rate / / 24351856 rs12120258 chr1 102734951 G T 9.64E-05 Chronic kidney disease / / 24351856 rs12140211 chr1 102739517 C T 1.48E-05 Glomerular filtration rate / / 24351856 rs12140211 chr1 102739517 C T 7.59E-04 Chronic kidney disease / / 24351856 rs2889234 chr1 102742475 T C 6.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12407943 chr1 102760382 G T 9.31E-04 Heart Failure / / pha002884 rs1261698 chr1 102794417 C A 3.31E-05 Vitiligo / / 19890347 rs1272970 chr1 102829724 T G 6.43E-04 Multiple complex diseases / / 17554300 rs1572999 chr1 102830435 A G 8.28E-04 Multiple complex diseases / / 17554300 rs1573002 chr1 102830754 G A 8.74E-04 Multiple complex diseases / / 17554300 rs200979159 chr1 102830754 GTC G 8.74E-04 Multiple complex diseases / / 17554300 rs1418096 chr1 102830849 T C 5.70E-04 Multiple complex diseases / / 17554300 rs1361461 chr1 102925321 C T 9.16E-04 Multiple complex diseases / / 17554300 rs12752401 chr1 102967150 C T 1.90E-04 Cholesterol / / 17255346 rs12035823 chr1 102995218 T C 5.81E-04 Tourette syndrome / / 22889924 rs1517426 chr1 103040474 G T 5.75E-04 Type 2 diabetes / / 17463246 rs11164556 chr1 103080187 G A 6.17E-05 Blood Pressure / / pha003050 rs11164559 chr1 103088742 G T 7.74E-05 Bone mineral density / / 19181680 rs7533876 chr1 103110933 G A 5.17E-06 Response to metformin / / 21186350 rs7533876 chr1 103110933 G A 1.60E-06 Urinary metabolites / / 21572414 rs10874639 chr1 103133909 A G 3.00E-06 Protein quantitative trait loci / / 18464913 rs10493982 chr1 103171983 G A 2.42E-05 Bilirubin levels,in serum / / 19389676 rs720315 chr1 103175049 T A 2.89E-05 Bilirubin levels,in serum / / 19389676 rs1376359 chr1 103203107 T C 8.78E-05 Coronary restenosis / / 21878436 rs1376359 chr1 103203107 T C 9.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs478830 chr1 103230040 A C 8.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs514077 chr1 103231606 T C 5.09E-06 Bilirubin levels,in serum / / 19389676 rs606756 chr1 103238392 C T 3.90E-04 Multiple complex diseases / / 17554300 rs11164597 chr1 103238444 T C 3.72E-04 Schizophrenia / / 20832056 rs2598461 chr1 103298338 C A 2.11E-04 Lung function (forced vital capacity) / / 24023788 rs1241181 chr1 103347865 G A 1.18E-04 Multiple complex diseases COL11A1 intron 17554300 rs1241182 chr1 103348100 A C 2.00E-04 Alcohol dependence COL11A1 intron 20201924 rs1241182 chr1 103348100 A C 4.30E-04 Alcohol dependence COL11A1 intron 20201924 rs17446095 chr1 103372775 C A 3.09E-05 Bipolar disorder,affective COL11A1 intron 20528957 rs3753841 chr1 103379918 G A 9.00E-10 Glaucoma (primary open-angle) COL11A1 missense 22922875 rs4908274 chr1 103389914 A T 1.09E-04 Schizophrenia COL11A1 intron 20832056 rs12138977 chr1 103393457 C T 8.30E-05 Information processing speed COL11A1 intron 21130836 rs3102053 chr1 103422730 T C 3.00E-04 Pseudoexfoliation syndrome COL11A1 intron 20808326 rs1012281 chr1 103427407 T C 2.60E-05 Urinary metabolites COL11A1 intron 21572414 rs2615977 chr1 103452392 A C 3.88E-06 Osteoarthritis (knee and hip) COL11A1 intron 21177295 rs2615977 chr1 103452392 A C 9.91E-05 Osteoarthritis (knee and hip) COL11A1 intron 21177295 rs12756627 chr1 103457229 A G 7.20E-04 Depression (quantitative trait) COL11A1 intron 20800221 rs12724152 chr1 103458395 C A 7.20E-04 Depression (quantitative trait) COL11A1 intron 20800221 rs11809524 chr1 103459537 C T 9.00E-06 Bone mineral density COL11A1 intron 22504420 rs12723167 chr1 103463624 G A 7.26E-04 Depression (quantitative trait) COL11A1 intron 20800221 rs12733933 chr1 103465596 G A 7.29E-04 Depression (quantitative trait) COL11A1 intron 20800221 rs11164661 chr1 103541331 G A 2.76E-05 Schizophrenia COL11A1 intron 19571811 rs1415363 chr1 103552935 A G 6.73E-04 Smoking initiation COL11A1 intron 24665060 rs1572521 chr1 103562868 T G 1.42E-11 Triglycerides COL11A1 intron 23063622 rs4338381 chr1 103572927 A G 1.60E-10 Height COL11A1 intron 21194676 rs4338381 chr1 103572927 A G 3.40E-05 Height COL11A1 intron 21194676 rs4338381 chr1 103572927 A G 9.00E-07 Height COL11A1 intron 21194676 rs6577357 chr1 103589265 T A 1.13E-04 Aortic root size / / 21223598 rs1572516 chr1 103591909 A C 5.94E-04 Multiple complex diseases / / 17554300 rs1572516 chr1 103591909 A C 4.60E-06 Urinary metabolites / / 21572414 rs10874684 chr1 103596035 C T 9.86E-04 Multiple complex diseases / / 17554300 rs10874684 chr1 103596035 C T 3.60E-06 Urinary metabolites / / 21572414 rs17127531 chr1 103601156 G A 7.40E-04 Multiple complex diseases / / 17554300 rs17127531 chr1 103601156 G A 2.90E-06 Urinary metabolites / / 21572414 rs872317 chr1 103609693 T C 1.22E-05 Bilirubin levels,in serum / / 19389676 rs1337199 chr1 103611252 G A 1.73E-05 Bilirubin levels,in serum / / 19389676 rs12131191 chr1 103621727 G A 3.00E-06 Urinary metabolites / / 21572414 rs3861744 chr1 103622234 A G 2.77E-05 Bilirubin levels,in serum / / 19389676 rs1358459 chr1 103636607 C T 2.60E-05 Urinary metabolites / / 21572414 rs1528202 chr1 103662258 C T 2.70E-05 Urinary metabolites / / 21572414 rs6683683 chr1 103671460 G A 9.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs1406139 chr1 103683335 G A 1.84E-05 Bilirubin levels,in serum / / 19389676 rs10493998 chr1 103728254 C T 2.40E-05 Urinary metabolites / / 21572414 rs4907992 chr1 103763252 A G 4.85E-04 Alcohol dependence / / 20201924 rs7524694 chr1 104019631 T C 7.00E-06 Obesity-related traits / / 23251661 rs1930212 chr1 104324819 A G 6.69E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10881490 chr1 104381824 C T 3.17E-04 Tourette syndrome / / 22889924 rs1930206 chr1 104393357 C G 3.78E-04 Blood pressure / / 17255346 rs1579026 chr1 104405855 G A 8.50E-04 HIV-1 viral setpoint / / 17641165 rs1930192 chr1 104408821 A C 9.57E-04 HIV-1 viral setpoint / / 17641165 rs1999480 chr1 104419830 T C 8.55E-04 HIV-1 viral setpoint / / 17641165 rs12143917 chr1 104433984 G A 4.68E-04 Iron levels / / pha002876 rs6683918 chr1 104446681 G A 1.62E-06 Iron levels / / 19880490 rs6683918 chr1 104446681 G A 1.62E-06 Iron levels / / pha002876 rs1182580 chr1 104446782 C T 2.37E-05 Multiple sclerosis / / 19525953 rs41419745 chr1 104452958 T A 4.41E-06 Multiple sclerosis / / 17660530 rs11185337 chr1 104476678 C A 3.49E-05 Multiple sclerosis / / 17660530 rs551284 chr1 104484407 A G 1.02E-05 Iron levels / / 19880490 rs551284 chr1 104484407 A G 1.02E-05 Iron levels / / pha002876 rs619879 chr1 104487148 G A 1.23E-05 Iron levels / / 19880490 rs619879 chr1 104487148 G A 1.23E-05 Iron levels / / pha002876 rs144192269 chr1 104488097 G A 0.00000196 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs41445945 chr1 104489522 G C 3.64E-04 Multiple complex diseases / / 17554300 rs1330388 chr1 104492281 T C 6.77E-04 Iron levels / / pha002876 rs12725332 chr1 104509012 G A 3.84E-05 Iron levels / / 19880490 rs12725332 chr1 104509012 G A 3.84E-05 Iron levels / / pha002876 rs12126657 chr1 104511450 G A,C 9.28E-04 Obesity (extreme) / / 21935397 rs517139 chr1 104522097 T C 6.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs6586440 chr1 104534262 C T 7.09E-04 Multiple complex diseases / / 17554300 rs1330408 chr1 104546820 C T 7.32E-04 Iron levels / / pha002876 rs4141899 chr1 104547617 T C 2.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12026645 chr1 104562381 A G 9.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12031508 chr1 104572622 A T 8.75E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1330402 chr1 104580557 A G 1.49E-05 Iron levels / / 19880490 rs1330402 chr1 104580557 A G 1.49E-05 Iron levels / / pha002876 rs3934285 chr1 104598941 G A 2.00E-06 Obesity-related traits / / 23251661 rs10494003 chr1 104621168 G C 1.60E-04 Multiple complex diseases / / 17554300 rs11185373 chr1 104621467 A T 2.57E-04 Multiple complex diseases / / 17554300 rs1999228 chr1 104629019 A G 1.85E-04 Multiple complex diseases / / 17554300 rs11800756 chr1 104637412 C T 2.83E-04 Multiple complex diseases / / 17554300 rs10494007 chr1 104638728 A G 2.43E-04 Type 2 diabetes / / 17846124 rs12144936 chr1 104682747 C G 9.59E-04 Obesity (extreme) / / 21935397 rs1932466 chr1 104706300 G A 0.000041 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1932465 chr1 104706506 G C 5.61E-06 Type 2 diabetes / / 17846124 rs1932465 chr1 104706506 G C 5.60E-06 Type 2 diabetes / / 21647700 rs10494009 chr1 104710766 G C 1.06E-04 Type 2 diabetes / / 17846124 rs200895163 chr1 104719055 C CT 0.0000505 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7523109 chr1 104719055 C T 0.0000505 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12407548 chr1 104731827 A G 2.10E-04 Multiple complex diseases / / 17554300 rs7527726 chr1 104736011 C A 5.16E-05 Post-operative nausea and vomiting / / 21694509 rs11185389 chr1 104747846 A G 7.56E-04 Alzheimer's disease / / 17998437 rs59602554 chr1 104748342 C A 0.0000321 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1928327 chr1 104770475 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1928327 chr1 104770475 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1928327 chr1 104770475 G A 3.25E-05 Cognitive impairment induced by topiramate / / 22091778 rs3866247 chr1 104778806 C T 6.83E-05 Cognitive impairment induced by topiramate / / 22091778 rs12067058 chr1 104779012 G A 1.82E-04 Multiple complex diseases / / 17554300 rs4633297 chr1 104798629 G A 6.17E-04 Multiple complex diseases / / 17554300 rs12407649 chr1 104798853 C A 5.10E-05 Cortisol secretion,in saliva / / 21316860 rs12086216 chr1 104800294 C T 9.30E-05 HIV-1 control / / 20041166 rs7555154 chr1 104818279 G C 5.69E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1497676 chr1 104820635 C T 6.93E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6586471 chr1 104846498 T C 7.61E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11185422 chr1 104849763 G A 1.20E-05 Telomere length / / 23001564 rs10881542 chr1 104852738 T C 2.00E-06 Glaucoma (primary open-angle) / / 22922875 rs10785866 chr1 104887259 G A 7.53E-05 Cortisol secretion,in saliva / / 21316860 rs9662111 chr1 104894847 G A 4.85E-05 Telomere length / / 23001564 rs2646709 chr1 104954647 C T 6.37E-04 Alzheimer's disease / / 17998437 rs1448395 chr1 104966942 T C 9.44E-04 HIV-1 viral setpoint / / 17641165 rs11184169 chr1 104978179 C T 3.43E-04 Type 2 diabetes / / 17463246 rs11184173 chr1 104986052 C T 2.50E-04 IgE levels / / 17255346 rs11184173 chr1 104986052 C T 2.99E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs12744616 chr1 104987296 G T 8.12E-04 Type 2 diabetes / / 17463246 rs7411648 chr1 104997471 C T 6.97E-05 Heart Rate / / pha003053 rs12090634 chr1 104997692 G T 6.90E-05 Heart Rate / / pha003053 rs12035511 chr1 105051438 A C 4.66E-04 Acute lung injury / / 22295056 rs12752353 chr1 105054589 T G 4.66E-04 Acute lung injury / / 22295056 rs381728 chr1 105055075 T A 3.33E-04 Insulin resistance / / 21901158 rs12042136 chr1 105063644 A G 7.33E-04 Acute lung injury / / 22295056 rs316951 chr1 105076810 C T 2.48E-05 Celiac disease / / 23936387 rs11184197 chr1 105081773 G A 3.22E-05 Cortisol secretion,in saliva / / 21316860 rs12022925 chr1 105081913 T G 8.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6695172 chr1 105086051 T C 2.61E-05 Cortisol secretion,in saliva / / 21316860 rs12026360 chr1 105088785 G A 5.19E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2121956 chr1 105089396 A G 2.03E-05 Cortisol secretion,in saliva / / 21316860 rs2121956 chr1 105089396 A G 1.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs316942 chr1 105090738 A G 2.36E-04 Insulin resistance / / 21901158 rs316942 chr1 105090738 A G 2.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1448378 chr1 105091696 T C 2.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11578246 chr1 105095501 T G 5.16E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2084447 chr1 105102314 A G 3.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7553985 chr1 105106498 T C 2.70E-05 Type 2 diabetes / / 17460697 rs7553985 chr1 105106498 T C 2.77E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7553985 chr1 105106498 T C 7.75E-04 Iron levels / / pha002876 rs12172730 chr1 105111535 G A 4.87E-05 Parkinson's disease / / 19915575 rs2166890 chr1 105112356 C T 2.40E-05 Type 2 diabetes / / 17460697 rs7552405 chr1 105113849 C T 3.00E-05 Type 2 diabetes / / 17460697 rs7552405 chr1 105113849 C T 1.21E-05 Cortisol secretion,in saliva / / 21316860 rs11184211 chr1 105115188 A G 3.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1448394 chr1 105118613 G A 4.30E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11184213 chr1 105119392 C T 8.32E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs114152980 chr1 105119612 C T 0.000074 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12568560 chr1 105140299 G A 6.81E-05 Cortisol secretion,in saliva / / 21316860 rs4847178 chr1 105144179 T C 3.10E-05 Personality dimensions / / 18957941 rs10494020 chr1 105189711 A G 3.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7532749 chr1 105219763 T G 8.81E-04 Type 2 diabetes / / 17463246 rs7532749 chr1 105219763 T G 9.25E-04 Multiple complex diseases / / 17554300 rs7532749 chr1 105219763 T G 7.46E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12725071 chr1 105220965 C T 4.52E-06 Asthma / / 20698975 rs7543757 chr1 105227914 T C 5.37E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7543757 chr1 105227914 T C 4.60E-06 Adiposity / / 19461586 rs7543757 chr1 105227914 T C 1.64E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6702883 chr1 105243080 A G 3.24E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12117597 chr1 105282847 T C 1.26E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11578700 chr1 105292119 A C 5.07E-05 Paget's disease / / 20436471 rs11578700 chr1 105292119 A C 5.26E-05 Paget's disease / / 21623375 rs1481397 chr1 105303590 C T 2.60E-05 Urinary metabolites / / 21572414 rs1871782 chr1 105304918 C A 1.80E-05 Urinary metabolites / / 21572414 rs11184300 chr1 105312623 A G 9.64E-05 Waist Circumference / / pha003023 rs7523359 chr1 105324488 C T 1.70E-05 Urinary metabolites / / 21572414 rs12036613 chr1 105325538 G A 9.50E-06 Urinary metabolites / / 21572414 rs12043310 chr1 105332372 G A 1.20E-05 Urinary metabolites / / 21572414 rs12042214 chr1 105344196 T C 1.50E-05 Urinary metabolites / / 21572414 rs12038712 chr1 105395417 T C 7.20E-06 Urinary metabolites / / 21572414 rs11811929 chr1 105396240 C T 5.12E-04 Prostate cancer mortality / / 20978177 rs11811929 chr1 105396240 C T 2.30E-05 Urinary metabolites / / 21572414 rs12029384 chr1 105425455 C G 1.80E-06 Urinary metabolites / / 21572414 rs1376368 chr1 105449139 C T 4.25E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7526166 chr1 105453412 T G 2.64E-04 Multiple complex diseases / / 17554300 rs2084670 chr1 105469987 C T 3.53E-05 Suicide attempts in bipolar disorder / / 21423239 rs6702908 chr1 105475361 C T 8.39E-04 Multiple complex diseases / / 17554300 rs1466154 chr1 105476957 A C 4.06E-05 Suicide attempts in bipolar disorder / / 21423239 rs1466153 chr1 105476963 C A 4.84E-05 Suicide attempts in bipolar disorder / / 21423239 rs11184372 chr1 105489615 T C 1.82E-04 Multiple complex diseases / / 17554300 rs4548451 chr1 105502327 T A 1.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs994239 chr1 105505952 T G 5.31E-05 Multiple complex diseases / / 17554300 rs12136584 chr1 105507435 C A 3.29E-04 Multiple complex diseases / / 17554300 rs7550524 chr1 105507848 A G 1.99E-04 Multiple complex diseases / / 17554300 rs991024 chr1 105508155 T C 9.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9729540 chr1 105509351 T C 9.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6657473 chr1 105511033 C A,T 4.34E-05 Multiple complex diseases / / 17554300 rs4466665 chr1 105525087 T A 4.21E-04 Multiple complex diseases / / 17554300 rs12039264 chr1 105537204 A G 6.95E-04 Multiple complex diseases / / 17554300 rs11184409 chr1 105541666 A T 8.49E-06 Personality dimensions / / 22628180 rs1158909 chr1 105552128 T A 5.04E-04 Multiple complex diseases / / 17554300 rs11184413 chr1 105552936 A C 4.25E-04 Multiple complex diseases / / 17554300 rs2923300 chr1 105561345 A G 3.24E-04 Multiple complex diseases / / 17554300 rs2122691 chr1 105568426 G T 3.24E-04 Multiple complex diseases / / 17554300 rs2923297 chr1 105569484 T C 6.00E-04 Multiple complex diseases / / 17554300 rs2034525 chr1 105574256 T C 0.0000038 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) / / 23080225 rs12410176 chr1 105593913 C T 2.32E-04 White matter integrity / / 22425255 rs1584633 chr1 105612342 C T 7.58E-04 Prostate cancer mortality / / 20978177 rs11184448 chr1 105688179 A G 7.78E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs17015466 chr1 105688537 G A 7.78E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs4601631 chr1 105720963 A C 8.93E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs6667576 chr1 105725458 C T 7.86E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs11184469 chr1 105735780 A G 4.31E-05 Substance dependence / / 21818250 rs6583163 chr1 105993658 T C 8.92E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12118827 chr1 106001235 G A 9.47E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12735409 chr1 106001606 G A 9.39E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7512514 chr1 106002632 C T 8.90E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12144596 chr1 106005296 T A 8.99E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2501603 chr1 106007141 A G 8.25E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12740181 chr1 106007454 C T 8.53E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1516156 chr1 106032070 A G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1516155 chr1 106034597 G A 7.11E-04 Obesity (extreme) / / 21935397 rs11184596 chr1 106057617 T C 1.83E-05 Duodenal ulcer / / 22387998 rs12120660 chr1 106086980 A G 6.40E-06 Urinary metabolites / / 21572414 rs12120660 chr1 106086980 A G 6.50E-04 Smoking initiation / / 24665060 rs777080 chr1 106099097 A C 2.25E-04 Coronary Artery Disease / / 17634449 rs10785759 chr1 106124761 C T 5.52E-04 Smoking initiation / / 24665060 rs11807640 chr1 106161451 C T 1.99E-05 Coronary heart disease / / pha003030 rs2842597 chr1 106172488 G A 1.92E-05 Coronary heart disease / / pha003030 rs12743318 chr1 106195966 C T 0.000446678 Hypertension (early onset hypertension) / / 22479346 rs1163495 chr1 106242233 G A 8.62E-04 Multiple complex diseases / / 17554300 rs1163499 chr1 106243931 G C 8.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs790966 chr1 106244640 A G 7.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs1163521 chr1 106328719 T C 3.45E-22 Narcolepsy / / 19629137 rs11184708 chr1 106430287 A T 2.00E-06 Waist-to-hip circumference ratio (interaction) / / 23192594 rs17016501 chr1 106438336 C T 3.77E-05 Coronary heart disease / / pha003056 rs17016501 chr1 106438336 C T 6.03E-06 Diabetes Mellitus / / pha003060 rs7515037 chr1 106446157 T G 2.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs940426 chr1 106449970 C T 2.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1380289 chr1 106453318 C T 2.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11184717 chr1 106477681 A C 9.30E-06 Urinary metabolites / / 21572414 rs498428 chr1 106570045 G T 3.51E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11184734 chr1 106590173 C T 1.95E-04 Multiple complex diseases / / 17554300 rs11184738 chr1 106599395 G A 1.72E-04 Multiple complex diseases / / 17554300 rs11184738 chr1 106599395 G A 5.94E-13 Esophageal cancer / / 21642993 rs12408810 chr1 106640943 C T 9.00E-06 Obesity (early onset extreme) / / 23563609 rs1889463 chr1 106653622 T C 7.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1031339 chr1 106701386 T A 9.81E-04 Multiple complex diseases / / 17554300 rs11184786 chr1 106726037 C T 1.55E-06 Common variable immunodeficiency / / 21497890 rs10881372 chr1 106753277 C T 7.88E-05 Blood Pressure / / pha003043 rs12724740 chr1 106780771 A G 0.0007921 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12724740 chr1 106780771 A G 7.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12733837 chr1 106781522 T A 9.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4431871 chr1 106810236 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2150037 chr1 106832596 C G 9.27E-05 Tuberculosis / / 20694014 rs7517409 chr1 106833140 C A 1.50E-05 Urinary metabolites / / 21572414 rs2210094 chr1 106833610 C G 7.77E-05 Tuberculosis / / 20694014 rs1330225 chr1 106835943 T C 1.00E-08 Blood pressure measurement (low sodium intervention) / / 24165912 rs1330225 chr1 106835943 T C 1.22E-04 Blood pressure measurement (low sodium intervention) / / 24165912 rs1330225 chr1 106835943 T C 7.00E-09 Blood pressure measurement (low sodium intervention) / / 24165912 rs1330226 chr1 106843175 C T 2.70E-05 Bone mineral traits,in men / / 21427758 rs1330226 chr1 106843175 C T 4.64E-05 Bone mineral traits,in men / / 21427758 rs1330226 chr1 106843175 C T 8.56E-05 Bone mineral traits,in men / / 21427758 rs12117640 chr1 106878317 G T 2.11E-04 Alzheimer's disease (late onset) / / 21379329 rs7538613 chr1 106882826 G A 3.19E-04 Alzheimer's disease (late onset) / / 21379329 rs11184870 chr1 106887181 C T 3.39E-04 Alzheimer's disease (late onset) / / 21379329 rs11184871 chr1 106887450 G A 2.73E-06 Left ventricular mass / / 21212386 rs11184871 chr1 106887450 G A 2.87E-04 Alzheimer's disease (late onset) / / 21379329 rs12565323 chr1 106906072 G A 2.35E-04 Alzheimer's disease (late onset) / / 21379329 rs2026790 chr1 106914392 A C 8.76E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs17433090 chr1 106933198 G A 0.0004882 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17433090 chr1 106933198 G A 4.88E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6582965 chr1 106937705 C G 4.76E-05 Odorant perception / / 23910658 rs2988394 chr1 106963817 T A 5.51E-05 Multiple complex diseases / / 17554300 rs10881403 chr1 106990083 T A 4.24E-05 Glaucoma (primary open-angle) / / 22605921 rs1575738 chr1 107031734 C T 2.70E-05 Urinary metabolites / / 21572414 rs12045753 chr1 107056847 G A 1.62E-06 Glaucoma (primary open-angle) / / 22605921 rs12025734 chr1 107075244 G A 6.17E-05 Glaucoma (primary open-angle) / / 22605921 rs11184922 chr1 107106193 C T 7.29E-04 Taste perception / / 22132133 rs4440890 chr1 107110129 G A 5.79E-05 Personality dimensions / / 18957941 rs10494045 chr1 107112572 C A 6.61E-05 AIDS progression / / 19115949 rs4915129 chr1 107113504 C T 9.40E-05 Personality dimensions / / 18957941 rs4915129 chr1 107113504 C T 6.60E-05 AIDS progression / / 19115949 rs12121466 chr1 107149412 A C 2.52E-04 Longevity / / 22279548 rs10785799 chr1 107191485 A G 6.11E-05 Cervical cancer / / 24700089 rs10494048 chr1 107195059 G T 9.66E-05 Prostate cancer / / pha002878 rs10881442 chr1 107219644 C T 8.91E-05 Intelligence / / 21826061 rs10881442 chr1 107219644 C T 5.65E-05 Lipoproteins / / pha003079 rs6703591 chr1 107222150 G A 6.68E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4342878 chr1 107227063 T A 2.65E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4462181 chr1 107230730 A G 1.30E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4336881 chr1 107232816 A C 1.30E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs10785805 chr1 107233800 G A 5.15E-05 Intelligence / / 21826061 rs10785805 chr1 107233800 G A 5.32E-05 Lipoproteins / / pha003079 rs4914986 chr1 107255899 T A 1.38E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4436418 chr1 107264055 T C 2.17E-04 Multiple complex diseases / / 17554300 rs9887893 chr1 107279889 G A 7.26E-05 Intelligence / / 21826061 rs2176758 chr1 107281362 C T 1.37E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6686425 chr1 107289810 C T 9.96E-04 Type 2 diabetes / / 17463246 rs1519883 chr1 107291768 C T 3.51E-05 Intelligence / / 21826061 rs12097821 chr1 107336301 G T 6.00E-10 Non-obstructive azoospermia / / 22197933 rs12119184 chr1 107338996 G A 6.02E-05 Intelligence / / 21826061 rs12024651 chr1 107404931 G A 6.36E-06 Glaucoma (primary open-angle) / / 22605921 rs3968588 chr1 107425864 G A 3.42E-04 Multiple complex diseases / / 17554300 rs1519881 chr1 107432265 A G 7.00E-06 Urinary metabolites / / 21572414 rs12726652 chr1 107432576 G A 5.00E-07 Response to antipsychotic treatment in schizophrenia (working memory) / / 21107309 rs12726652 chr1 107432576 G A 0.000248 Salmonella-induced pyroptosis / / 22837397 rs10494055 chr1 107449940 T C 8.17E-04 Multiple complex diseases / / 17554300 rs12125971 chr1 107463643 C T 7.00E-06 Intelligence / / 22449649 rs17495607 chr1 107501181 T C 4.08E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17496332 chr1 107546375 A G 1.00E-11 Sex hormone-binding globulin levels / / 22829776 rs17496332 chr1 107546375 A G 2.00E-07 Sex hormone-binding globulin levels / / 22829776 rs10494056 chr1 107547919 C A 4.29E-06 AIDS / / 19754311 rs6675948 chr1 107557477 C G 3.80E-04 Iris characteristics / / 21835309 rs10047147 chr1 107561147 C T 6.70E-05 Height / / pha003010 rs10881455 chr1 107561546 G A 6.70E-05 Height / / pha003010 rs4118325 chr1 107577832 G A 6.00E-07 AIDS / / 19754311 rs4118325 chr1 107577832 G A 5.82E-05 Height / / pha003010 rs11185057 chr1 107596964 T C 6.23E-05 Height / / pha003010 rs17018290 chr1 107609774 C G 5.85E-04 Multiple complex diseases / / 17554300 rs1762495 chr1 107634116 T C 3.40E-05 AIDS / / 19754311 rs1762495 chr1 107634116 T C 1.94E-04 Scoliosis / / 21216876 rs6583007 chr1 107676684 C T 2.49E-04 Fibrinogen / / 17255346 rs4481881 chr1 107686418 T C 3.08E-05 Orofacial clefts NTNG1 intron 20023658 rs4307594 chr1 107693167 T C 2.00E-05 Orofacial clefts NTNG1 intron 20023658 rs6681613 chr1 107717689 G A 5.39E-07 Lymphocyte counts NTNG1 intron 22286170 rs6694986 chr1 107829678 T C 4.00E-04 Pulmonary function NTNG1 intron 23932459 rs10494067 chr1 107830858 A C 6.00E-06 Anorexia nervosa NTNG1 intron 21079607 rs4604720 chr1 107837159 G A 3.15E-05 Asthma NTNG1 intron 23181788 rs17509160 chr1 107855013 C T 6.70E-05 Pulmonary function NTNG1 intron 23932459 rs7411507 chr1 107865978 G A 1.91E-05 Prostate cancer NTNG1 intron 18264096 rs6672549 chr1 107874959 G A 2.07E-04 Celiac disease NTNG1 intron 23936387 rs12747408 chr1 107920219 C T 1.95E-05 Parkinson's disease (motor and cognition) NTNG1 intron 22658654 rs12747408 chr1 107920219 C T 1.95E-05 Immune response to anthrax vaccine NTNG1 intron 22658931 rs7544259 chr1 107929543 A G 1.51E-05 Parkinson's disease (motor and cognition) NTNG1 intron 22658654 rs7544259 chr1 107929543 A G 1.51E-05 Immune response to anthrax vaccine NTNG1 intron 22658931 rs2587899 chr1 107946650 G T 9.87E-04 Multiple complex diseases NTNG1 intron 17554300 rs17018944 chr1 107955428 A G 4.20E-04 Multiple complex diseases NTNG1 intron 17554300 rs12731224 chr1 107961159 A G 3.49E-06 Body Mass Index NTNG1 intron pha003007 rs12731224 chr1 107961159 A G 5.07E-05 Body Mass Index NTNG1 intron pha003015 rs480392 chr1 107979396 A C 1.38E-08 Triglycerides NTNG1 cds-synon 23063622 rs480392 chr1 107979396 A C 1.77E-08 HDL cholesterol NTNG1 cds-synon 23063622 rs1373337 chr1 107980407 G A 2.04E-05 Body Mass Index NTNG1 intron pha003007 rs1444038 chr1 107981316 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) NTNG1 intron 20189245 rs1444038 chr1 107981316 G A 1.82E-05 Body Mass Index NTNG1 intron pha003007 rs12735678 chr1 107984135 T C 1.76E-05 Body Mass Index NTNG1 intron pha003007 rs17019069 chr1 107985632 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) NTNG1 intron 20189245 rs590987 chr1 107986409 G A 4.08E-04 Multiple complex diseases NTNG1 intron 17554300 rs17531774 chr1 107987328 C T 9.00E-04 Acute lymphoblastic leukemia (childhood) NTNG1 intron 20189245 rs17531997 chr1 107992327 C G 6.55E-04 Smoking quantity NTNG1 intron 24665060 rs17466589 chr1 107992571 A G 5.00E-04 Acute lymphoblastic leukemia (childhood) NTNG1 intron 20189245 rs521721 chr1 108001448 G A 1.99E-04 Multiple complex diseases NTNG1 intron 17554300 rs96501 chr1 108018847 C T 2.90E-05 Urinary metabolites NTNG1 intron 21572414 rs96501 chr1 108018847 C T 1.79E-04 Celiac disease NTNG1 intron 23936387 rs653383 chr1 108021506 C T 2.00E-04 Cognitive impairment induced by topiramate NTNG1 intron 22091778 rs650251 chr1 108026510 T G 1.16E-04 Multiple complex diseases / / 17554300 rs11808800 chr1 108040994 T C 9.41E-06 Mathematical ability / / 24801482 rs533165 chr1 108070545 C T 8.89E-04 Multiple complex diseases / / 17554300 rs521420 chr1 108074669 C G 2.60E-05 Urinary metabolites / / 21572414 rs17535067 chr1 108074954 G A 9.90E-06 Urinary metabolites / / 21572414 rs608827 chr1 108076343 C T 5.13E-04 Aortic root size / / 21223598 rs12565052 chr1 108079880 G C 6.70E-05 Response to statin therapy / / 20339536 rs12564555 chr1 108085686 T C 3.30E-05 Response to statin therapy / / 20339536 rs12566146 chr1 108091675 T C 5.80E-05 Response to statin therapy / / 20339536 rs2769668 chr1 108115145 T C 1.30E-05 Urinary metabolites VAV3 UTR-3 21572414 rs1410403 chr1 108123685 C T 3.33E-04 Schizophrenia VAV3 intron 20832056 rs1328199 chr1 108127895 C T 1.76E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) VAV3 intron 24023788 rs11803410 chr1 108141478 G A 5.68E-04 Multiple complex diseases VAV3 intron 17554300 rs1410406 chr1 108156360 G A 0.000650658 Hypertension (early onset hypertension) VAV3 intron 22479346 rs11185151 chr1 108173844 C T 9.50E-06 Digit length ratio VAV3 intron 20303062 rs4915061 chr1 108176019 G A 2.17E-04 Multiple complex diseases VAV3 intron 17554300 rs12752530 chr1 108176582 A C 2.50E-04 Multiple complex diseases VAV3 intron 17554300 rs6693140 chr1 108181947 C T 2.83E-04 Suicide attempts in bipolar disorder VAV3 intron 21041247 rs4914952 chr1 108184270 C A 9.60E-06 Digit length ratio VAV3 intron 20303062 rs12410676 chr1 108185309 G A 1.52E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) VAV3 missense 24023788 rs4557997 chr1 108192390 C T 9.16E-05 Heart rate VAV3 intron 23583979 rs12077977 chr1 108199479 C T 1.35E-04 Multiple complex diseases VAV3 intron 17554300 rs17479604 chr1 108203647 C A 6.98E-04 Suicide attempts in bipolar disorder VAV3 intron 21041247 rs2494047 chr1 108212860 T C 7.00E-04 Multiple complex diseases VAV3 intron 17554300 rs12140510 chr1 108213416 C T 8.74E-04 Suicide attempts in bipolar disorder VAV3 intron 21423239 rs2494052 chr1 108218925 G T 1.40E-04 Multiple complex diseases VAV3 intron 17554300 rs6677871 chr1 108238325 T C 5.14E-04 Parkinson's disease VAV3 intron 16252231 rs17019729 chr1 108245664 T C 4.10E-05 Hypothyroidism VAV3 intron 22493691 rs6583042 chr1 108246246 A G 5.60E-06 Hypothyroidism VAV3 intron 22493691 rs2494069 chr1 108246853 C T 4.52E-04 Multiple complex diseases VAV3 intron 17554300 rs4503375 chr1 108250282 A G 1.37E-04 Multiple complex diseases VAV3 intron 17554300 rs4503375 chr1 108250282 A G 1.80E-05 Hypothyroidism VAV3 intron 22493691 rs17019810 chr1 108268801 C T 8.41E-04 Myopia (pathological) VAV3 intron 21095009 rs17019810 chr1 108268801 C T 2.00E-06 Hypothyroidism VAV3 intron 22493691 rs17019823 chr1 108269953 A C 6.46E-04 Multiple complex diseases VAV3 intron 17554300 rs17019823 chr1 108269953 A C 8.41E-04 Myopia (pathological) VAV3 intron 21095009 rs17019823 chr1 108269953 A C 8.00E-09 Hypothyroidism VAV3 intron 22493691 rs17019828 chr1 108270130 T C 3.40E-04 Multiple complex diseases VAV3 intron 17554300 rs6674340 chr1 108273631 A G 5.00E-05 Hypothyroidism VAV3 intron 22493691 rs7519428 chr1 108281720 G A 3.60E-05 Cognitive function VAV3 intron 24684796 rs12031375 chr1 108286368 A G 3.20E-05 Cognitive function VAV3 intron 24684796 rs6583045 chr1 108286971 A G 2.57E-05 Major depression (suicidal thoughts and behavior) VAV3 intron 21750702 rs41486546 chr1 108298979 T A 1.60E-05 Urinary metabolites VAV3 intron 21572414 rs12142335 chr1 108302922 G A 8.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) VAV3 intron 23648065 rs7417283 chr1 108303686 C T 4.51E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs7417283 chr1 108303686 C T 5.59E-06 Glycemic traits (pregnancy) VAV3 intron 23903356 rs7514025 chr1 108307642 C T 6.52E-04 Glycemic traits (pregnancy) VAV3 intron 23903356 rs6690837 chr1 108312656 T C 8.31E-04 Glycemic traits (pregnancy) VAV3 intron 23903356 rs6583048 chr1 108313258 C T 5.44E-04 Glycemic traits (pregnancy) VAV3 cds-synon 23903356 rs4462178 chr1 108315137 C T 8.45E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) VAV3 intron 23648065 rs4914959 chr1 108319079 G A 3.76E-04 Glycemic traits (pregnancy) VAV3 intron 23903356 rs4914960 chr1 108321313 A G 5.31E-04 Glycemic traits (pregnancy) VAV3 intron 23903356 rs7521681 chr1 108322535 G A 7.00E-07 Asthma and hay fever VAV3 intron 24388013 rs4514263 chr1 108325510 G A 3.87E-04 Glycemic traits (pregnancy) VAV3 intron 23903356 rs11185177 chr1 108325738 G A 3.04E-04 Glycemic traits (pregnancy) VAV3 intron 23903356 rs11185178 chr1 108329926 T G 8.14E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs11185178 chr1 108329926 T G 8.95E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs4914961 chr1 108333763 T C 7.31E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs4914961 chr1 108333763 T C 9.14E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs4244133 chr1 108334622 T C 5.89E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs4244133 chr1 108334622 T C 7.01E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs17020055 chr1 108336533 A C 6.50E-09 Hypothyroidism VAV3 intron 22493691 rs10494076 chr1 108338327 A G 3.10E-05 Blood Phenotypes VAV3 intron 17903294 rs17020088 chr1 108351812 T C 5.40E-09 Hypothyroidism VAV3 intron 22493691 rs4612651 chr1 108356293 C T 1.21E-04 Celiac disease VAV3 intron 23936387 rs12126655 chr1 108356820 A G 2.00E-08 Thyroid stimulating hormone VAV3 intron 24722205 rs4915076 chr1 108359505 T C 8.00E-10 Hypothyroidism VAV3 intron 22493691 rs4915077 chr1 108366016 T C 8.00E-10 Hypothyroidism VAV3 intron 22493691 rs7537000 chr1 108376302 A G 3.00E-04 Cognitive impairment induced by topiramate VAV3 intron 22091778 rs7537000 chr1 108376302 A G 2.11E-04 Celiac disease VAV3 intron 23936387 rs9787296 chr1 108382827 A G 4.66E-04 Thyroid stimulating hormone VAV3 intron 24852370 rs10494080 chr1 108402075 C A 7.37E-04 Multiple complex diseases VAV3 intron 17554300 rs10494080 chr1 108402075 C A 9.72E-05 Celiac disease VAV3 intron 23936387 rs10494081 chr1 108402103 C T 9.76E-04 Type 2 diabetes VAV3 intron 17463246 rs1360564 chr1 108411794 T C 7.58E-05 Waist-Hip Ratio VAV3 intron pha003028 rs11185191 chr1 108418552 T A 6.95E-04 Multiple complex diseases VAV3 intron 17554300 rs11185215 chr1 108450627 A G 3.96E-04 Alzheimer's disease (late onset) VAV3 intron 21379329 rs345314 chr1 108462844 C T 2.14E-04 Alzheimer's disease (late onset) VAV3 intron 21379329 rs1571965 chr1 108519529 C T 0.00001 HDL cholesterol particle diameter / / 23263444 rs12121990 chr1 108523670 G T 0.00035 Prostate cancer / / 23555315 rs2336645 chr1 108524174 T G 7.67E-05 AIDS progression / / 19115949 rs1219765 chr1 108541909 A G 9.77E-05 Sodium levels / / pha003093 rs12071280 chr1 108555998 T C 5.37E-04 Multiple complex diseases / / 17554300 rs1781070 chr1 108569698 G A 1.62E-04 Alzheimer's disease (late onset) / / 21379329 rs12569350 chr1 108588372 G A 7.82E-04 Substance dependence / / 21818250 rs1777454 chr1 108596968 T G 8.55E-04 Substance dependence / / 21818250 rs1777478 chr1 108612220 C T 9.23E-04 Multiple complex diseases / / 17554300 rs1781064 chr1 108615524 G A 4.25E-04 Taste perception / / 22132133 rs2996918 chr1 108621812 A G 1.52E-05 Cognitive performance / / 19734545 rs10881502 chr1 108641819 T C 8.12E-04 Coronary Artery Disease / / 17634449 rs11185272 chr1 108662219 C T 5.01E-05 Information processing speed / / 21130836 rs1777450 chr1 108663295 T C 4.41E-05 Cognitive performance / / 19734545 rs665659 chr1 108663841 C G 8.26E-05 Serum metabolites / / 19043545 rs17513833 chr1 108680234 C T 6.50E-04 Amyotrophic lateral sclerosis (sporadic) SLC25A24 intron 24529757 rs10494090 chr1 108693336 A G 5.30E-13 Glioma (high-grade) SLC25A24 intron 19578366 rs559761 chr1 108700637 C A 4.58E-04 Alzheimer's disease (late onset) SLC25A24 intron 21379329 rs662590 chr1 108719572 G A 7.93E-05 Multiple complex diseases SLC25A24 intron 17554300 rs490680 chr1 108724518 A G 9.46E-05 Blood Pressure SLC25A24 intron pha003045 rs490680 chr1 108724518 A G 2.18E-05 Blood Pressure SLC25A24 intron pha003047 rs491785 chr1 108724693 G A 9.46E-05 Blood Pressure SLC25A24 intron pha003045 rs491785 chr1 108724693 G A 2.18E-05 Blood Pressure SLC25A24 intron pha003047 rs828999 chr1 108744934 G A 5.70E-05 Glioma (high-grade) / / 19578366 rs7418288 chr1 108754099 G A 1.63E-04 Alzheimer's disease (late onset) / / 21379329 rs6694641 chr1 108755582 T C 1.99E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6583070 chr1 108756690 G A 1.18E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2152560 chr1 108762012 G A 5.86E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11185305 chr1 108763904 C T 5.75E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4970822 chr1 108859231 C A 1.60E-05 White matter hyperintensity burden / / 21681796 rs4970821 chr1 108859314 T C 3.06E-07 Esophageal cancer (squamous cell) / / 22960999 rs12117427 chr1 108863863 A G 1.80E-05 White matter hyperintensity burden / / 21681796 rs949905 chr1 108870158 T C 1.90E-05 White matter hyperintensity burden / / 21681796 rs2275563 chr1 108877608 G T 1.40E-05 White matter hyperintensity burden / / 21681796 rs12404827 chr1 108888654 A G 4.60E-05 Major depressive disorder / / 21042317 rs7512836 chr1 109052161 C T 6.08E-05 Multiple complex diseases / / 17554300 rs7515114 chr1 109052264 C A 8.93E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6666724 chr1 109084300 C T 6.07E-04 Alzheimer's disease / / 24755620 rs1353722 chr1 109098737 A C 6.51E-04 Alzheimer's disease / / 24755620 rs1353725 chr1 109098932 A G 6.51E-04 Alzheimer's disease / / 24755620 rs11102031 chr1 109101851 C T 7.97E-04 Alzheimer's disease / / 24755620 rs943806 chr1 109156284 C T 1.62E-06 Asthma (childhood onset) FAM102B intron 23829686 rs17026815 chr1 109271037 T C 0.0007494 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FNDC7 intron 23233654 rs17026815 chr1 109271037 T C 7.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) FNDC7 intron 23233662 rs4970810 chr1 109273610 G A 6.14E-04 Response to cytidine analogues (gemcitabine) FNDC7 intron 24483146 rs1690726 chr1 109330016 G A 6.73E-04 Multiple complex diseases STXBP3 intron 17554300 rs1149160 chr1 109336794 G C 9.90E-04 Multiple complex diseases STXBP3 intron 17554300 rs17555669 chr1 109356394 T A 0.0006625 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17555669 chr1 109356394 T A 6.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1277216 chr1 109359231 A C 4.70E-04 Pulmonary function AK/D1 intron 23932459 rs1277213 chr1 109359502 A G 3.27E-04 Response to cytidine analogues (gemcitabine) AK/D1 intron 24483146 rs6683747 chr1 109376539 C A 6.44E-04 Amyotrophic lateral sclerosis (sporadic) AK/D1 intron 24529757 rs1277014 chr1 109386466 A G 2.76E-04 Multiple complex diseases AK/D1 intron 17554300 rs1277203 chr1 109392837 C T 9.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) AK/D1 intron 23648065 rs11583007 chr1 109392853 C T 8.00E-05 Prostate cancer AK/D1 intron 21743057 rs9440631 chr1 109394524 G A 1.45E-05 Tuberculosis AK/D1 missense 22306650 rs6667820 chr1 109400568 A G 5.44E-04 Multiple complex diseases SRG7 intron 17554300 rs12752417 chr1 109400639 G T 4.47E-04 Aortic root size SRG7 intron 21223598 rs11587109 chr1 109405971 C T 9.68E-04 Acute lung injury / / 22295056 rs7523050 chr1 109417679 C A 3.70E-06 Subcutaneous adipose tissue volume in HIV-infected men GPSM2 nearGene-5 21897333 rs7523050 chr1 109417679 C A 4.80E-06 Subcutaneous adipose tissue volume in HIV-infected men GPSM2 nearGene-5 21897333 rs7523050 chr1 109417679 C A 9.90E-07 Subcutaneous adipose tissue volume in HIV-infected men GPSM2 nearGene-5 21897333 rs839854 chr1 109471634 T G 1.59E-04 Response to taxane treatment (placlitaxel) GPSM2 intron 23006423 rs12030 chr1 109472813 T C 1.90E-05 Urinary metabolites CLCC1 UTR-3 21572414 rs10607 chr1 109473017 C T 3.67E-05 Smoking quantity CLCC1 UTR-3 24665060 rs193139 chr1 109483975 T C 3.20E-06 Subcutaneous adipose tissue volume in HIV-infected men CLCC1 intron 21897333 rs193139 chr1 109483975 T C 3.90E-06 Subcutaneous adipose tissue volume in HIV-infected men CLCC1 intron 21897333 rs193139 chr1 109483975 T C 9.50E-06 Subcutaneous adipose tissue volume in HIV-infected men CLCC1 intron 21897333 rs338466 chr1 109486196 A G 4.62E-05 Response to taxane treatment (placlitaxel) CLCC1 cds-synon 23006423 rs839547 chr1 109494147 A G 1.42E-04 Response to taxane treatment (placlitaxel) CLCC1 intron 23006423 rs28634276 chr1 109611326 T G 7.45E-04 Response to taxane treatment (placlitaxel) TAF13 intron 23006423 rs531842 chr1 109689314 C T 1.08E-04 Multiple complex diseases KIAA1324 intron 17554300 rs609031 chr1 109692890 C T 8.94E-04 Multiple complex diseases KIAA1324 intron 17554300 rs609031 chr1 109692890 C T 2.36E-04 Lymphocyte counts KIAA1324 intron 22286170 rs648673 chr1 109727284 C G 4.26E-04 Multiple complex diseases KIAA1324 intron 17554300 rs4268379 chr1 109778237 C T 0.000000732 Coronary artery disease SARS intron 23202125 rs611060 chr1 109782190 C T 2.55E-04 Obesity (extreme) / / 21935397 rs4246519 chr1 109783555 A G 1.60E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs586254 chr1 109784781 A G 4.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs585362 chr1 109789795 C T 7.97E-09 Triglycerides / / 19060911 rs585362 chr1 109789795 C T 1.29E-20 Cholesterol,total / / 23063622 rs585362 chr1 109789795 C T 3.76E-25 LDL cholesterol / / 23063622 rs10858082 chr1 109798721 G A 7.00E-05 Response to statin therapy CELSR2 intron 20339536 rs10858082 chr1 109798721 G A 1.80E-08 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 intron 22003152 rs10858082 chr1 109798721 G A 1.28E-20 LDL cholesterol CELSR2 intron 23063622 rs10858082 chr1 109798721 G A 2.64E-23 Cholesterol,total CELSR2 intron 23063622 rs4970833 chr1 109804646 G A 1.06E-14 Cholesterol,total CELSR2 intron 23063622 rs4970833 chr1 109804646 G A 1.23E-14 LDL cholesterol CELSR2 intron 23063622 rs4970833 chr1 109804646 G A 9.17E-07 Non-small cell lung cancer (survival) CELSR2 intron 23704207 rs6698843 chr1 109806834 C T 2.91E-14 LDL cholesterol CELSR2 cds-synon 23063622 rs6698843 chr1 109806834 C T 7.82E-15 Cholesterol,total CELSR2 cds-synon 23063622 rs6689614 chr1 109807099 G A 1.15E-14 Cholesterol,total CELSR2 cds-synon 23063622 rs6689614 chr1 109807099 G A 3.71E-14 LDL cholesterol CELSR2 cds-synon 23063622 rs6657811 chr1 109807283 A T 2.00E-08 LDL cholesterol CELSR2 intron 18262040 rs6657811 chr1 109807283 A T 6.60E-07 Response to statin therapy CELSR2 intron 20339536 rs6657811 chr1 109807283 A T 2.40E-08 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 intron 22003152 rs6657811 chr1 109807283 A T 3.02E-30 LDL cholesterol CELSR2 intron 23063622 rs6657811 chr1 109807283 A T 8.92E-31 Cholesterol,total CELSR2 intron 23063622 rs41279714 chr1 109813485 C T 7.08E-12 Metabolite levels CELSR2 intron 22286219 rs17035665 chr1 109813719 C T 0.000000283 Cholesterol,total CELSR2 intron 23063622 rs17035665 chr1 109813719 C T 4.19E-08 LDL cholesterol CELSR2 intron 23063622 rs4970834 chr1 109814880 C T 1.19E-04 Type 2 diabetes CELSR2 intron 17463246 rs4970834 chr1 109814880 C T 1.44E-05 Multiple complex diseases CELSR2 intron 17554300 rs4970834 chr1 109814880 C T 3.43E-04 Coronary Artery Disease CELSR2 intron 17634449 rs4970834 chr1 109814880 C T 1.70E-06 Cardiovascular disease CELSR2 intron 18179892 rs4970834 chr1 109814880 C T 3.00E-11 LDL cholesterol CELSR2 intron 18262040 rs4970834 chr1 109814880 C T 9.53E-09 Triglycerides CELSR2 intron 19060911 rs4970834 chr1 109814880 C T 2.00E-14 Lipid levels CELSR2 intron 19802338 rs4970834 chr1 109814880 C T 4.60E-17 Lipid levels CELSR2 intron 19802338 rs4970834 chr1 109814880 C T 2.00E-08 Lipid levels CELSR2 intron 19913121 rs4970834 chr1 109814880 C T 5.18E-09 Lipid levels CELSR2 intron 19913121 rs4970834 chr1 109814880 C T 4.00E-08 Lipoprotein A [Lp(a)] levels and coronary artery disease CELSR2 intron 20032323 rs4970834 chr1 109814880 C T 4.10E-07 Response to statin therapy CELSR2 intron 20339536 rs4970834 chr1 109814880 C T 1.29E-10 Lipid levels CELSR2 intron 20370913 rs4970834 chr1 109814880 C T 6.85E-13 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 intron 20442857 rs4970834 chr1 109814880 C T 4.41E-13 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 intron 22003152 rs4970834 chr1 109814880 C T 0.000000175 HDL cholesterol CELSR2 intron 23063622 rs4970834 chr1 109814880 C T 1.78E-64 LDL cholesterol CELSR2 intron 23063622 rs4970834 chr1 109814880 C T 4.70E-59 Cholesterol,total CELSR2 intron 23063622 rs4970834 chr1 109814880 C T 0.000157 LDL cholesterol CELSR2 intron 23236364 rs611917 chr1 109815252 A G 1.50E-10 LDL cholesterol CELSR2 intron 18262040 rs611917 chr1 109815252 A G 9.63E-13 Triglycerides CELSR2 intron 19060911 rs611917 chr1 109815252 A G 2.20E-09 Lipid levels CELSR2 intron 19802338 rs611917 chr1 109815252 A G 2.90E-12 Lipid levels CELSR2 intron 19802338 rs611917 chr1 109815252 A G 1.97E-06 Lipid levels CELSR2 intron 19913121 rs611917 chr1 109815252 A G 6.69E-07 Lipid levels CELSR2 intron 19913121 rs611917 chr1 109815252 A G 2.50E-05 Response to statin therapy CELSR2 intron 20339536 rs611917 chr1 109815252 A G 4.71E-13 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 intron 22003152 rs611917 chr1 109815252 A G 1.19E-39 Cholesterol,total CELSR2 intron 23063622 rs611917 chr1 109815252 A G 4.78E-40 LDL cholesterol CELSR2 intron 23063622 rs611917 chr1 109815252 A G 2.49E-07 LDL lipoproteins CELSR2 intron pha002902 rs7528419 chr1 109817192 A G 2.41E-09 Lipid levels CELSR2 UTR-3 19913121 rs7528419 chr1 109817192 A G 8.09E-09 Lipid levels CELSR2 UTR-3 19913121 rs7528419 chr1 109817192 A G 3.00E-07 Lipoprotein A [Lp(a)] levels and coronary artery disease CELSR2 UTR-3 20032323 rs7528419 chr1 109817192 A G 6.10E-08 Response to statin therapy CELSR2 UTR-3 20339536 rs7528419 chr1 109817192 A G 1.65E-08 Cardiovascular disease risk factors CELSR2 UTR-3 21943158 rs7528419 chr1 109817192 A G 1.00E-17 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 UTR-3 22003152 rs7528419 chr1 109817192 A G 1.12E-11 Metabolite levels CELSR2 UTR-3 22286219 rs7528419 chr1 109817192 A G 1.69E-51 LDL cholesterol CELSR2 UTR-3 22629316 rs7528419 chr1 109817192 A G 3.44E-31 LDL cholesterol (female) CELSR2 UTR-3 22629316 rs7528419 chr1 109817192 A G 6.28E-25 LDL cholesterol (male) CELSR2 UTR-3 22629316 rs7528419 chr1 109817192 A G 1.48E-68 LDL cholesterol CELSR2 UTR-3 23063622 rs7528419 chr1 109817192 A G 8.70E-67 Cholesterol,total CELSR2 UTR-3 23063622 rs7528419 chr1 109817192 A G 9.02E-09 HDL cholesterol CELSR2 UTR-3 23063622 rs11102967 chr1 109817245 C A,G,T 0.000000411 Cholesterol,total CELSR2 UTR-3 23063622 rs12740374 chr1 109817590 G T 3.20E-14 LDL cholesterol CELSR2 UTR-3 18262040 rs12740374 chr1 109817590 G T 2.00E-42 LDL cholesterol CELSR2 UTR-3 19060906 rs12740374 chr1 109817590 G T 1.82E-09 Lipid levels CELSR2 UTR-3 19913121 rs12740374 chr1 109817590 G T 4.70E-09 Lipid levels CELSR2 UTR-3 19913121 rs12740374 chr1 109817590 G T 2.00E-07 Lipoprotein A [Lp(a)] levels and coronary artery disease CELSR2 UTR-3 20032323 rs12740374 chr1 109817590 G T 5.50E-08 Response to statin therapy CELSR2 UTR-3 20339536 rs12740374 chr1 109817590 G T 9.00E-29 Coronary heart disease CELSR2 UTR-3 21347282 rs12740374 chr1 109817590 G T 6.61E-14 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) CELSR2 UTR-3 21541012 rs12740374 chr1 109817590 G T 8.70E-09 Cardiovascular disease risk factors CELSR2 UTR-3 21943158 rs12740374 chr1 109817590 G T 1.46E-17 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 UTR-3 22003152 rs12740374 chr1 109817590 G T 3.60E-13 Metabolic syndrome phenotype CELSR2 UTR-3 22022282 rs12740374 chr1 109817590 G T 8.00E-16 Metabolic syndrome phenotype CELSR2 UTR-3 22022282 rs12740374 chr1 109817590 G T 1.24E-11 Metabolite levels CELSR2 UTR-3 22286219 rs12740374 chr1 109817590 G T 2.89E-51 LDL cholesterol CELSR2 UTR-3 22629316 rs12740374 chr1 109817590 G T 5.06E-31 LDL cholesterol (female) CELSR2 UTR-3 22629316 rs12740374 chr1 109817590 G T 7.47E-25 LDL cholesterol (male) CELSR2 UTR-3 22629316 rs12740374 chr1 109817590 G T 1.35E-08 HDL cholesterol CELSR2 UTR-3 23063622 rs12740374 chr1 109817590 G T 3.00E-66 Cholesterol,total CELSR2 UTR-3 23063622 rs12740374 chr1 109817590 G T 3.75E-69 LDL cholesterol CELSR2 UTR-3 23063622 rs12740374 chr1 109817590 G T 2.00E-22 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 UTR-3 23118302 rs12740374 chr1 109817590 G T 1.63E-17 LDL cholesterol CELSR2 UTR-3 23236364 rs12740374 chr1 109817590 G T 4.43E-13 Cholesterol,total CELSR2 UTR-3 23236364 rs660240 chr1 109817838 T C 3.80E-14 LDL cholesterol CELSR2 UTR-3 18262040 rs660240 chr1 109817838 T C 8.10E-08 Response to statin therapy CELSR2 UTR-3 20339536 rs660240 chr1 109817838 T C 1.00E-26 LDL cholesterol CELSR2 UTR-3 20864672 rs660240 chr1 109817838 T C 2.00E-22 Cardiovascular disease risk factors CELSR2 UTR-3 21943158 rs660240 chr1 109817838 T C 7.39E-17 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 UTR-3 22003152 rs660240 chr1 109817838 T C 2.38E-12 Metabolite levels CELSR2 UTR-3 22286219 rs660240 chr1 109817838 T C 4.09E-11 LDL cholesterol CELSR2 UTR-3 23063622 rs660240 chr1 109817838 T C 6.59E-12 Cholesterol,total CELSR2 UTR-3 23063622 rs3832016 chr1 109818158 C CT 1.67E-13 Cholesterol,total CELSR2 UTR-3 23063622 rs3832016 chr1 109818158 C CT 6.18E-13 LDL cholesterol CELSR2 UTR-3 23063622 rs57677983 chr1 109818158 C A,G,T 1.67E-13 Cholesterol,total CELSR2 UTR-3 23063622 rs57677983 chr1 109818158 C A,G,T 6.18E-13 LDL cholesterol CELSR2 UTR-3 23063622 rs629301 chr1 109818306 G T 3.10E-14 LDL cholesterol CELSR2 UTR-3 18262040 rs629301 chr1 109818306 G T 2.01E-08 Triglycerides CELSR2 UTR-3 19060911 rs629301 chr1 109818306 G T 1.76E-08 Lipid levels CELSR2 UTR-3 19913121 rs629301 chr1 109818306 G T 6.50E-09 Lipid levels CELSR2 UTR-3 19913121 rs629301 chr1 109818306 G T 5.40E-08 Response to statin therapy CELSR2 UTR-3 20339536 rs629301 chr1 109818306 G T 1.00E-170 LDL cholesterol CELSR2 UTR-3 20686565 rs629301 chr1 109818306 G T 6.00E-131 Cholesterol,total CELSR2 UTR-3 20686565 rs629301 chr1 109818306 G T 1.17E-11 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) CELSR2 UTR-3 21541012 rs629301 chr1 109818306 G T 1.78E-17 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 UTR-3 22003152 rs629301 chr1 109818306 G T 2.62E-12 Metabolite levels CELSR2 UTR-3 22286219 rs629301 chr1 109818306 G T 1.19E-07 Coronary heart disease CELSR2 UTR-3 22319020 rs629301 chr1 109818306 G T 1.44E-43 LDL cholesterol CELSR2 UTR-3 23063622 rs629301 chr1 109818306 G T 1.57E-08 HDL cholesterol CELSR2 UTR-3 23063622 rs629301 chr1 109818306 G T 5.68E-38 Cholesterol,total CELSR2 UTR-3 23063622 rs629301 chr1 109818306 G T 0.00016 Coronary artery calcification CELSR2 UTR-3 23727086 rs629301 chr1 109818306 G T 2.00E-170 Cholesterol,total CELSR2 UTR-3 24097068 rs629301 chr1 109818306 G T 5.00E-241 LDL cholesterol CELSR2 UTR-3 24097068 rs646776 chr1 109818530 C T 3.00E-29 LDL cholesterol / / 18193044 rs646776 chr1 109818530 C T 4.80E-20 LDL cholesterol / / 18262040 rs646776 chr1 109818530 C T 2.00E-12 LDL cholesterol / / 19060910 rs646776 chr1 109818530 C T 8.00E-23 LDL cholesterol / / 19060911 rs646776 chr1 109818530 C T 9.00E-22 Cholesterol,total / / 19060911 rs646776 chr1 109818530 C T 8.00E-12 Myocardial infarction (early onset) / / 19198609 rs646776 chr1 109818530 C T 3.50E-24 Lipid levels / / 19802338 rs646776 chr1 109818530 C T 4.90E-19 Lipid levels / / 19802338 rs646776 chr1 109818530 C T 1.03E-08 Lipid levels / / 19913121 rs646776 chr1 109818530 C T 2.40E-08 Lipid levels / / 19913121 rs646776 chr1 109818530 C T 1.20E-32 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 1.60E-13 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 1.77E-53 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 2.20E-20 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 2.40E-27 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 3.70E-39 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 4.97E-46 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 5.00E-09 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 6.00E-09 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 6.29E-19 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 7.10E-11 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 9.20E-12 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 2.00E-07 Lipoprotein A [Lp(a)] levels and coronary artery disease / / 20032323 rs646776 chr1 109818530 C T 4.00E-06 Response to statin therapy / / 20339536 rs646776 chr1 109818530 C T 2.00E-30 Progranulin levels / / 21087763 rs646776 chr1 109818530 C T 2.41E-06 Cardiovascular disease risk factors / / 21239051 rs646776 chr1 109818530 C T 8.00E-12 Coronary heart disease / / 21347282 rs646776 chr1 109818530 C T 6.00E-10 Coronary heart disease / / 21378988 rs646776 chr1 109818530 C T 9.37E-09 Cardiovascular disease risk factors / / 21943158 rs646776 chr1 109818530 C T 3.10E-17 Coronary heart disease / / 21966275 rs646776 chr1 109818530 C T 2.15E-17 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs646776 chr1 109818530 C T 2.65E-12 Metabolite levels / / 22286219 rs646776 chr1 109818530 C T 1.20E-68 Cholesterol,total / / 23063622 rs646776 chr1 109818530 C T 6.19E-09 HDL cholesterol / / 23063622 rs646776 chr1 109818530 C T 7.90E-74 LDL cholesterol / / 23063622 rs646776 chr1 109818530 C T 0.00000024 Apolipoprotein B levels response after 40mg daily simvastatin treatment / / 23100282 rs646776 chr1 109818530 C T 0.000095 LDL cholesterol response after 40mg daily simvastatin treatment / / 23100282 rs646776 chr1 109818530 C T 3.90E-41 Apolipoprotein B levels / / 23100282 rs646776 chr1 109818530 C T 6.10E-28 LDL cholesterol / / 23100282 rs646776 chr1 109818530 C T 6.10E-28 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) / / 23103227 rs646776 chr1 109818530 C T 3.96E-08 Cholesterol,total / / 23236364 rs646776 chr1 109818530 C T 0.00021 Coronary artery calcification / / 23727086 rs646776 chr1 109818530 C T 2.19E-12 LDL lipoproteins / / pha002902 rs646776 chr1 109818530 C T 7.39E-05 Cholesterol / / pha003073 rs646776 chr1 109818530 C T 2.68E-05 Cholesterol / / pha003078 rs3902354 chr1 109819296 C A 1.00E-08 Cholesterol,total / / 24886709 rs55882046 chr1 109819981 C T 2.27E-10 Cholesterol,total / / 23063622 rs55882046 chr1 109819981 C T 6.94E-10 LDL cholesterol / / 23063622 rs11577931 chr1 109820884 A G 1.02E-08 LDL cholesterol / / 23063622 rs11577931 chr1 109820884 A G 1.96E-09 Cholesterol,total / / 23063622 rs583104 chr1 109821307 G T 1.15E-08 Lipid levels / / 19913121 rs583104 chr1 109821307 G T 2.18E-08 Lipid levels / / 19913121 rs583104 chr1 109821307 G T 3.00E-07 Lipoprotein A [Lp(a)] levels and coronary artery disease / / 20032323 rs583104 chr1 109821307 G T 5.37E-12 Metabolite levels / / 22286219 rs583104 chr1 109821307 G T 0.000000141 HDL cholesterol / / 23063622 rs583104 chr1 109821307 G T 3.58E-67 LDL cholesterol / / 23063622 rs583104 chr1 109821307 G T 6.01E-65 Cholesterol,total / / 23063622 rs602633 chr1 109821511 T G 4.80E-14 Lipid levels / / 18193043 rs602633 chr1 109821511 T G 5.70E-14 LDL cholesterol / / 18262040 rs602633 chr1 109821511 T G 2.21E-07 Lipid levels / / 19913121 rs602633 chr1 109821511 T G 3.15E-08 Lipid levels / / 19913121 rs602633 chr1 109821511 T G 9.00E-08 Lipoprotein A [Lp(a)] levels and coronary artery disease / / 20032323 rs602633 chr1 109821511 T G 8.40E-08 Response to statin therapy / / 20339536 rs602633 chr1 109821511 T G 5.00E-08 LDL cholesterol / / 21977987 rs602633 chr1 109821511 T G 1.38E-16 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs602633 chr1 109821511 T G 5.44E-12 Metabolite levels / / 22286219 rs602633 chr1 109821511 T G 0.000000128 HDL cholesterol / / 23063622 rs602633 chr1 109821511 T G 5.86E-65 Cholesterol,total / / 23063622 rs602633 chr1 109821511 T G 6.92E-65 LDL cholesterol / / 23063622 rs602633 chr1 109821511 T G 0.0000342 Coronary artery disease (CAD) (females) / / 23202125 rs602633 chr1 109821511 T G 1.32E-18 Coronary artery disease (CAD) (males) / / 23202125 rs602633 chr1 109821511 T G 2.23E-16 Coronary artery disease with myocardial infarction / / 23202125 rs602633 chr1 109821511 T G 2.77E-20 Coronary artery disease (CAD) age <=50 / / 23202125 rs602633 chr1 109821511 T G 4.97E-08 Coronary artery disease (CAD) age >50 / / 23202125 rs602633 chr1 109821511 T G 1.00E-08 Coronary artery disease / / 24262325 rs1277930 chr1 109822143 G A 5.75E-12 Metabolite levels / / 22286219 rs1277930 chr1 109822143 G A 2.64E-12 LDL cholesterol / / 23063622 rs1277930 chr1 109822143 G A 9.43E-14 Cholesterol,total / / 23063622 rs599839 chr1 109822166 G A 9.00E-08 Type 2 diabetes / / 17463246 rs599839 chr1 109822166 G A 2.19E-05 Multiple complex diseases / / 17554300 rs599839 chr1 109822166 G A 4.00E-09 Coronary heart disease / / 17634449 rs599839 chr1 109822166 G A 1.00E-07 LDL cholesterol / / 18179892 rs599839 chr1 109822166 G A 6.00E-33 LDL cholesterol / / 18193043 rs599839 chr1 109822166 G A 3.00E-21 Lipid levels / / 18193044 rs599839 chr1 109822166 G A 1.00E-33 LDL cholesterol / / 18262040 rs599839 chr1 109822166 G A 4.31E-08 Lipid levels / / 19913121 rs599839 chr1 109822166 G A 4.79E-08 Lipid levels / / 19913121 rs599839 chr1 109822166 G A 6.00E-08 Response to statin therapy / / 20339536 rs599839 chr1 109822166 G A 3.70E-16 Lipid levels / / 20370913 rs599839 chr1 109822166 G A 3.00E-15 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs599839 chr1 109822166 G A 2.82E-04 Cardiovascular disease risk factors / / 21239051 rs599839 chr1 109822166 G A 4.00E-09 Coronary heart disease / / 21347282 rs599839 chr1 109822166 G A 3.00E-10 Coronary heart disease / / 21378990 rs599839 chr1 109822166 G A 2.00E-19 Metabolite levels / / 21909109 rs599839 chr1 109822166 G A 1.12E-08 Cardiovascular disease risk factors / / 21943158 rs599839 chr1 109822166 G A 2.63E-17 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs599839 chr1 109822166 G A 4.13E-12 Metabolite levels / / 22286219 rs599839 chr1 109822166 G A 2.89E-10 Pericardial fat / / 22589742 rs599839 chr1 109822166 G A 0.000000153 HDL cholesterol / / 23063622 rs599839 chr1 109822166 G A 1.21E-57 Cholesterol,total / / 23063622 rs599839 chr1 109822166 G A 1.43E-59 LDL cholesterol / / 23063622 rs599839 chr1 109822166 G A 0.000000556 HDL cholesterol / / 23202125 rs599839 chr1 109822166 G A 2.94E-168 LDL cholesterol / / 23202125 rs599839 chr1 109822166 G A 4.12E-130 Cholesterol,total / / 23202125 rs599839 chr1 109822166 G A 1.00E-08 Coronary artery disease or ischemic stroke / / 24262325 rs599839 chr1 109822166 G A 8.00E-17 Coronary artery disease or large artery stroke / / 24262325 rs35358959 chr1 109824250 G A 6.63E-11 Metabolite levels PSRC1 cds-synon 22286219 rs657420 chr1 109826136 C T 3.94E-16 LDL cholesterol / / 23063622 rs657420 chr1 109826136 C T 8.38E-15 Cholesterol,total / / 23063622 rs655246 chr1 109832283 A G 2.07E-12 Cholesterol,total / / 23063622 rs655246 chr1 109832283 A G 4.11E-16 LDL cholesterol / / 23063622 rs17645031 chr1 109834938 C T 7.05E-19 LDL cholesterol / / 23063622 rs17645031 chr1 109834938 C T 7.81E-21 Cholesterol,total / / 23063622 rs41306199 chr1 109835163 C T 1.43E-20 Cholesterol,total MYBPHL UTR-3 23063622 rs41306199 chr1 109835163 C T 8.49E-18 LDL cholesterol MYBPHL UTR-3 23063622 rs12127701 chr1 109838264 A G 7.31E-11 Cholesterol,total MYBPHL intron 23063622 rs12127701 chr1 109838264 A G 8.07E-12 LDL cholesterol MYBPHL intron 23063622 rs12127701 chr1 109838264 A G 0.000271 Coronary artery disease MYBPHL intron 23202125 rs629001 chr1 109838918 C T 2.87E-12 Cholesterol,total MYBPHL missense 23063622 rs629001 chr1 109838918 C T 6.36E-13 LDL cholesterol MYBPHL missense 23063622 rs7515901 chr1 109839896 C T 0.0000073 Coronary artery disease MYBPHL intron 23202125 rs592107 chr1 109848726 A T 8.16E-05 Cognitive test performance MYBPHL intron 20125193 rs413582 chr1 109851126 C T 1.02E-09 Cholesterol,total / / 23063622 rs413582 chr1 109851126 C T 3.67E-11 LDL cholesterol / / 23063622 rs2228604 chr1 109884775 T G 4.67E-04 Multiple complex diseases SORT1 cds-synon 17554300 rs4970843 chr1 109887191 T C 0.00032 LDL cholesterol (female) SORT1 intron 23063622 rs4970843 chr1 109887191 T C 1.47E-11 LDL cholesterol SORT1 intron 23063622 rs4970843 chr1 109887191 T C 1.47E-11 LDL cholesterol (male) SORT1 intron 23063622 rs4970843 chr1 109887191 T C 1.83E-09 Cholesterol,total SORT1 intron 23063622 rs17646665 chr1 109912051 A G 1.52E-11 Cholesterol,total SORT1 intron 23063622 rs17646665 chr1 109912051 A G 4.71E-13 LDL cholesterol SORT1 intron 23063622 rs17646731 chr1 109919525 G A 1.97E-11 LDL cholesterol SORT1 intron 23063622 rs17646731 chr1 109919525 G A 1.98E-09 Cholesterol,total SORT1 intron 23063622 rs1149175 chr1 109922377 G A 4.48E-04 Multiple complex diseases SORT1 intron 17554300 rs10858092 chr1 109943893 C T 2.69E-04 Multiple complex diseases PSMA5 UTR-3 17554300 rs7518013 chr1 109944078 T C 2.91E-04 Multiple complex diseases PSMA5 UTR-3 17554300 rs17586966 chr1 109955569 T C 1.61E-04 Type 2 diabetes PSMA5 intron 17463246 rs17586966 chr1 109955569 T C 4.17E-25 Narcolepsy PSMA5 intron 19629137 rs10776807 chr1 109956156 G A,C 2.42E-04 Multiple complex diseases PSMA5 intron 17554300 rs4970760 chr1 109985439 A G 2.97E-04 Multiple complex diseases / / 17554300 rs1933182 chr1 109999838 A C 1.00E-07 Chronic kidney disease / / 20383146 rs1933182 chr1 109999838 A C 3.18E-07 Chronic kidney disease / / 22479191 rs10857787 chr1 110010289 C T 9.44E-04 Multiple complex diseases SYPL2 intron 17554300 rs12049330 chr1 110031188 T G 6.00E-06 Major depressive disorder ATXN7L2 intron 20125088 rs1043274 chr1 110042444 C T 9.00E-06 Obesity-related traits CYB561D1 UTR-3 23251661 rs6677291 chr1 110056126 C T 9.35E-05 Alcohol withdrawal symptoms / / 22072270 rs528815 chr1 110061479 C T 1.50E-05 Multiple complex diseases / / 17554300 rs534135 chr1 110061625 T C 1.24E-04 Multiple complex diseases / / 17554300 rs534135 chr1 110061625 T C 9.00E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs475381 chr1 110062040 A T 1.16E-05 Multiple complex diseases / / 17554300 rs2692705 chr1 110063313 G C 1.41E-05 Multiple complex diseases / / 17554300 rs6537803 chr1 110063540 G A 7.54E-05 Alcohol withdrawal symptoms / / 22072270 rs528077 chr1 110065752 C A 1.43E-04 Multiple complex diseases / / 17554300 rs529773 chr1 110065906 A G 1.03E-04 Multiple complex diseases / / 17554300 rs474234 chr1 110070814 A C 2.30E-04 Multiple complex diseases / / 17554300 rs474234 chr1 110070814 A C 4.03E-04 Lymphocyte counts / / 22286170 rs558370 chr1 110071113 A G 2.76E-04 Multiple complex diseases / / 17554300 rs7536291 chr1 110075608 G A 4.29E-05 Multiple complex diseases / / 17554300 rs1434285 chr1 110080809 G T 2.26E-09 Lymphocyte counts / / 22286170 rs7550711 chr1 110082886 C T 5.00E-06 Stearic acid (18:0) plasma levels GPR61 intron 23362303 rs6537837 chr1 110119732 C T 1.00E-06 Major depressive disorder G/I3 intron 20125088 rs17024258 chr1 110147321 C T 9.00E-12 Obesity G/T2 intron 23563607 rs510619 chr1 110157364 C T 2.03E-04 Amyotrophic Lateral Sclerosis G/T2 nearGene-5 17362836 rs2071487 chr1 110233081 T C 2.00E-05 Urinary metabolites GSTM1 cds-synon 21572414 rs10857796 chr1 110235032 A G 6.68E-05 Femoral neck bone geometry GSTM1 intron 22087292 rs11101992 chr1 110266754 A C 0.00048 Coronary artery calcification / / 23727086 rs3814309 chr1 110277403 T C 4.01E-09 Lymphocyte counts GSTM3 UTR-3 22286170 rs146952826 chr1 110280921 C T 0.0000044 Breast cancer(er negative) GSTM3 missense 23555315 rs11591171 chr1 110298107 A C 3.14E-05 Cognitive test performance EPS8L3 intron 20125193 rs11581614 chr1 110329003 T C 2.00E-04 Systolic blood pressure / / 19430483 rs11581614 chr1 110329003 T C 0.00081417 Sarcoidosis / / 22952805 rs17024863 chr1 110331262 C T 8.45E-04 Multiple complex diseases / / 17554300 rs10494112 chr1 110352477 A G 1.67E-14 Paget's disease / / 20436471 rs10494112 chr1 110352477 A G 7.00E-35 Paget's disease / / 21623375 rs3887891 chr1 110358890 C T 2.10E-05 Lipid levels / / 18193043 rs499345 chr1 110361682 C A 3.02E-16 Paget's disease / / 20436471 rs484959 chr1 110366083 T C 5.00E-24 Paget's disease / / 20436471 rs525566 chr1 110375695 G A 7.41E-05 Parkinson's disease / / 17052657 rs6537883 chr1 110405271 T C 3.00E-06 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs6695237 chr1 110415626 G A 4.00E-05 Coronary Artery Disease / / 17634449 rs453577 chr1 110426778 G A 6.17E-04 Multiple complex diseases / / 17554300 rs333960 chr1 110439480 C T 2.00E-07 Obesity-related traits / / 23251661 rs185460835 chr1 110447555 A T 0.00082646 Sarcoidosis / / 22952805 rs333949 chr1 110451043 C T 7.63E-06 Obesity-related traits / / 23251661 rs333951 chr1 110451690 T C 7.71E-05 Serum metabolites CSF1 nearGene-5 19043545 rs333970 chr1 110466338 C A 0.000740986 Hypertension (early onset hypertension) CSF1 cds-synon 22479346 rs333947 chr1 110470764 G A 9.55E-04 Multiple complex diseases CSF1 intron 17554300 rs7540934 chr1 110483773 G A 3.43E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs390923 chr1 110499669 A G 5.90E-04 Endometriosis / / 23104006 rs11577194 chr1 110500175 T C 6.54E-04 Type 2 diabetes / / 17463246 rs1466788 chr1 110618730 A G 3.00E-16 Blood metabolite levels / / 24816252 rs17025426 chr1 110645327 C T 2.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs493039 chr1 110646246 A T 4.72E-04 Smoking cessation / / 24665060 rs11576956 chr1 110646858 A G 3.00E-04 Endometriosis / / 23104006 rs514341 chr1 110652880 C T 6.00E-06 Alcohol dependence (age at onset) / / 24962325 rs4641310 chr1 110654498 G A 2.01E-05 Type 2 diabetes / / 17463246 rs2168144 chr1 110657532 G A 1.42E-05 Type 2 diabetes / / 17463246 rs11102055 chr1 110662374 A G 1.29E-04 Type 2 diabetes / / 17463246 rs11102058 chr1 110666410 A G 1.70E-05 Type 2 diabetes / / 17463246 rs7518801 chr1 110677921 A C 3.58E-04 Alzheimer's disease (late onset) / / 21379329 rs924181 chr1 110680114 G A 4.91E-04 Alzheimer's disease (late onset) / / 21379329 rs4839165 chr1 110681542 T G 4.59E-04 Alzheimer's disease (late onset) / / 21379329 rs10494113 chr1 110684287 T C 4.10E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1123250 chr1 110686356 A G 9.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs975512 chr1 110690577 G A 6.16E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2002384 chr1 110698651 A G 3.59E-04 Alzheimer's disease (late onset) SLC6A17 intron 21379329 rs4838931 chr1 110701071 T C 2.26E-04 Alzheimer's disease (late onset) SLC6A17 intron 21379329 rs1010891 chr1 110712154 G A 2.08E-04 Alzheimer's disease (late onset) SLC6A17 intron 21379329 rs6689641 chr1 110720400 A G 7.10E-04 Pulmonary function SLC6A17 intron 23932459 rs12128502 chr1 110723699 G A 1.50E-05 Urinary metabolites SLC6A17 intron 21572414 rs11802526 chr1 110724507 G A 4.03E-04 Alzheimer's disease (late onset) SLC6A17 intron 21379329 rs4839223 chr1 110728459 A G 9.69E-04 HIV-1 viral setpoint SLC6A17 intron 17641165 rs4839225 chr1 110729248 C T 9.69E-04 HIV-1 viral setpoint SLC6A17 intron 17641165 rs2011688 chr1 110729404 C T 0.00000442 VLDL cholesterol particle diameter SLC6A17 intron 23263444 rs495959 chr1 110732133 C T 1.26E-05 Alzheimer's disease (late onset) SLC6A17 intron 21379329 rs17025524 chr1 110733674 C T 2.20E-06 Urinary metabolites SLC6A17 intron 21572414 rs2784140 chr1 110738296 G A 6.12E-05 Cytomegalovirus antibody response SLC6A17 cds-synon 21993531 rs2784140 chr1 110738296 G A 4.26E-06 Acute lymphoblastic leukemia (B-cell precursor) SLC6A17 cds-synon 23996088 rs642655 chr1 110738990 A C 4.43E-04 HIV-1 viral setpoint SLC6A17 intron 17641165 rs2761442 chr1 110739864 A G 4.86E-05 Cytomegalovirus antibody response SLC6A17 intron 21993531 rs958798 chr1 110770223 G T 6.27E-04 Parkinson's disease KCNC4 intron 17052657 rs958798 chr1 110770223 G T 4.00E-07 Self-rated health KCNC4 intron 20707712 rs12138917 chr1 110791822 C T 8.71E-04 Multiple complex diseases / / 17554300 rs2209158 chr1 110795018 A C 1.10E-05 Urinary metabolites / / 21572414 rs4839282 chr1 110814129 T A 3.00E-04 Pseudoexfoliation syndrome / / 20808326 rs6682717 chr1 110815623 G C 3.00E-04 Pseudoexfoliation syndrome / / 20808326 rs3904626 chr1 110816491 T C 1.75E-04 Cholesterol / / 17255346 rs3904626 chr1 110816491 T C 7.46E-04 Multiple complex diseases / / 17554300 rs2885145 chr1 110817219 A G 1.75E-04 Cholesterol / / 17255346 rs2885145 chr1 110817219 A G 6.03E-04 Multiple complex diseases / / 17554300 rs2361047 chr1 110819387 A G 1.75E-04 Cholesterol / / 17255346 rs2361047 chr1 110819387 A G 6.08E-04 Multiple complex diseases / / 17554300 rs11102076 chr1 110819974 C T 1.75E-04 Cholesterol / / 17255346 rs11102076 chr1 110819974 C T 9.39E-04 Multiple complex diseases / / 17554300 rs3849178 chr1 110820295 A G 1.75E-04 Cholesterol / / 17255346 rs3849178 chr1 110820295 A G 5.60E-04 Multiple complex diseases / / 17554300 rs3820662 chr1 110821383 G A 8.20E-05 Cholesterol / / 17255346 rs3820662 chr1 110821383 G A 7.76E-04 Multiple complex diseases / / 17554300 rs4838977 chr1 110823116 G A 1.75E-04 Cholesterol / / 17255346 rs4838977 chr1 110823116 G A 5.49E-04 Multiple complex diseases / / 17554300 rs638531 chr1 110829417 G A 9.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs638531 chr1 110829417 G A 2.42E-05 Alzheimer's disease / / 22832961 rs626971 chr1 110831331 T C 4.25E-04 Insulin resistance LOC440600 intron 21901158 rs637686 chr1 110839445 A T 3.70E-05 Immunoglobulin A LOC440600 intron 20694011 rs4112315 chr1 110842415 C T 6.51E-04 Multiple complex diseases LOC440600 intron 17554300 rs532121 chr1 110844894 T C 2.12E-04 Suicide attempts in bipolar disorder LOC440600 intron 21423239 rs650290 chr1 110846510 T A 6.15E-04 Suicide attempts in bipolar disorder LOC440600 intron 21423239 rs473411 chr1 110846616 C T 6.15E-04 Suicide attempts in bipolar disorder LOC440600 intron 21423239 rs17358933 chr1 110849205 G A 1.62E-04 Multiple complex diseases LOC440600 intron 17554300 rs17358933 chr1 110849205 G A 8.37E-04 Alcohol dependence LOC440600 intron 21314694 rs9645348 chr1 110854963 G A 5.50E-06 Urinary metabolites LOC440600 intron 21572414 rs1466806 chr1 110861927 C T 8.40E-06 Urinary metabolites LOC440600 intron 21572414 rs1160505 chr1 110863039 G C 2.64E-04 Response to platinum-based chemotherapy in small-cell lung cancer LOC440600 intron 20463552 rs4838992 chr1 110864149 A G 6.17E-04 Multiple sclerosis LOC440600 intron 17660530 rs12568839 chr1 110877085 C T 1.54E-04 Response to platinum-based chemotherapy in small-cell lung cancer LOC440600 intron 20463552 rs12022711 chr1 110880586 C T 6.92E-05 Response to platinum-based chemotherapy in small-cell lung cancer LOC440600 intron 20463552 rs1572263 chr1 110885736 G A 7.81E-04 Suicide attempts in bipolar disorder RBM15 intron 21423239 rs4501839 chr1 110895987 T G 6.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs6669004 chr1 110906780 G A 5.22E-04 Suicide attempts in bipolar disorder SLC16A4 intron 21423239 rs12028977 chr1 110907716 C T 5.96E-04 Suicide attempts in bipolar disorder SLC16A4 intron 21423239 rs6673423 chr1 110916018 T C 6.50E-04 Suicide attempts in bipolar disorder SLC16A4 intron 21423239 rs12126890 chr1 110922814 G A 3.08E-04 Suicide attempts in bipolar disorder SLC16A4 intron 21423239 rs814759 chr1 110930882 C G 5.17E-04 Suicide attempts in bipolar disorder SLC16A4 intron 21423239 rs7556440 chr1 110931112 A G 4.56E-04 Suicide attempts in bipolar disorder SLC16A4 intron 21423239 rs6657333 chr1 110960311 T G 3.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs6537657 chr1 110961722 T C 4.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs11102104 chr1 110966784 T G 3.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs2132989 chr1 110967354 A T 3.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs6687382 chr1 110969946 C T 7.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs12048154 chr1 110974489 A G 2.10E-05 Urinary metabolites / / 21572414 rs7534322 chr1 110989088 A C 3.38E-04 Alzheimer's disease / / 17998437 rs62623571 chr1 110996652 C T 0.00028 Breast cancer PROK1 missense 23555315 rs11102110 chr1 111003201 C T 9.47E-05 Alzheimer's disease / / 22832961 rs12407530 chr1 111003777 T C 2.40E-05 Urinary metabolites / / 21572414 rs12407530 chr1 111003777 T C 8.34E-05 Alzheimer's disease / / 22832961 rs4839431 chr1 111033809 T C 2.00E-07 Immune reponse to smallpox (secreted IFN-alpha) / / 22610502 rs6537663 chr1 111034818 T C 2.21E-04 Fibrinogen / / 17255346 rs12031009 chr1 111040235 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7543509 chr1 111051999 A G 5.34E-05 Parkinson's disease / / 17052657 rs1281179 chr1 111056389 T C 3.11E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17025957 chr1 111062049 C T 3.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17025978 chr1 111069611 G A 6.60E-06 Type 2 diabetes / / 17463248 rs17025982 chr1 111070294 T C 7.80E-06 Type 2 diabetes / / 17463248 rs7522150 chr1 111077162 G T 4.75E-04 Myopia (pathological) / / 21095009 rs7553144 chr1 111084462 C T 6.53E-04 Myopia (pathological) / / 21095009 rs2790372 chr1 111087124 C A 7.50E-05 Type 2 diabetes / / 17463248 rs2790372 chr1 111087124 C A 7.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs2799765 chr1 111088151 T C 8.50E-05 Type 2 diabetes / / 17463248 rs1626078 chr1 111089239 C T 8.90E-05 Type 2 diabetes / / 17463248 rs1625029 chr1 111089405 C T 7.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs1622675 chr1 111089642 A T 8.30E-05 Type 2 diabetes / / 17463248 rs1627572 chr1 111089670 G A 8.90E-05 Type 2 diabetes / / 17463248 rs1281173 chr1 111094802 C T 8.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs903050 chr1 111098766 T C 1.74E-04 Multiple complex diseases / / 17554300 rs903050 chr1 111098766 T C 8.01E-05 Suicide attempts in bipolar disorder / / 21041247 rs903050 chr1 111098766 T C 8.56E-05 Suicide attempts in bipolar disorder / / 21041247 rs6537668 chr1 111100562 T C 4.12E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs12407862 chr1 111102214 C T 3.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs6656346 chr1 111103688 G A 4.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs1105101 chr1 111104913 C G 5.70E-04 Suicide attempts in bipolar disorder / / 21041247 rs6537671 chr1 111106530 T C 5.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs7526907 chr1 111111368 A G 7.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs923826 chr1 111114154 A G 0.000706 Salmonella-induced pyroptosis / / 22837397 rs17684735 chr1 111131424 T C 2.87E-05 Birth weight / / 17255346 rs4839069 chr1 111137811 A G 6.05E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) KC/2 intron 24023788 rs41404544 chr1 111142811 T C 5.58E-05 Response to metformin KC/2 intron 21186350 rs12047887 chr1 111144007 G A 2.81E-05 Cognitive test performance KC/2 intron 20125193 rs4839542 chr1 111155595 C T 1.25E-05 Cognitive test performance KC/2 intron 20125193 rs2172514 chr1 111166960 G A 9.19E-04 Response to TNF antagonist treatment KC/2 intron 21061259 rs41451648 chr1 111176693 T C 3.69E-04 Type 2 diabetes / / 17463246 rs41451648 chr1 111176693 T C 1.24E-04 Multiple complex diseases / / 17554300 rs7513434 chr1 111186329 C T 2.95E-04 Bipolar disorder,schizoaffective / / 19567891 rs2797533 chr1 111186784 C T 4.60E-04 Alcohol dependence / / 20201924 rs12084550 chr1 111198184 T C 2.20E-05 Urinary metabolites / / 21572414 rs2640487 chr1 111206885 C T 3.20E-04 Alcohol dependence / / 20201924 rs1319782 chr1 111211533 C T 8.60E-04 Alcohol dependence / / 20201924 rs2640480 chr1 111213248 C A 4.30E-04 Alcohol dependence / / 20201924 rs12061304 chr1 111237685 A G 1.00E-06 Panic disorder / / 19165232 rs12061304 chr1 111237685 A G 0.0000613 Panic disorder / / 23149450 rs12061304 chr1 111237685 A G 6.13E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs11102149 chr1 111240982 G C 3.14E-06 Panic disorder / / 19165232 rs11102149 chr1 111240982 G C 0.0000615 Panic disorder / / 23149450 rs11102149 chr1 111240982 G C 6.15E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs12085135 chr1 111243375 C G 4.69E-04 Fibrinogen / / 17255346 rs12085135 chr1 111243375 C G 5.04E-04 Multiple complex diseases / / 17554300 rs343602 chr1 111257724 A G 2.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs343602 chr1 111257724 A G 5.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs343604 chr1 111258770 T C 4.32E-05 Acute lymphoblastic leukemia (childhood) / / 22076464 rs4839556 chr1 111262340 G A 3.60E-04 Myasthenia gravis / / 23055271 rs343614 chr1 111276629 G A 1.69E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs343778 chr1 111281285 A G 0.00002168 Sarcoidosis / / 22952805 rs41453452 chr1 111295050 G C 3.09E-04 Alcohol dependence / / 21314694 rs420033 chr1 111295674 G A 6.17E-05 Alcohol dependence / / 19581569 rs440156 chr1 111295948 G A 4.23E-04 Type 2 diabetes / / 17463246 rs508446 chr1 111309830 C T 4.38E-04 Type 2 diabetes / / 17463246 rs574508 chr1 111311541 C T 3.49E-04 Type 2 diabetes / / 17463246 rs528752 chr1 111312272 A G 3.58E-04 Type 2 diabetes / / 17463246 rs526874 chr1 111312489 T C 6.31E-04 Type 2 diabetes / / 17463246 rs488147 chr1 111319892 A G 9.17E-04 Type 2 diabetes / / 17463246 rs1999511 chr1 111322419 C A 6.60E-05 Myasthenia gravis / / 23055271 rs343810 chr1 111330896 C T 8.49E-05 Bipolar disorder and schizophrenia / / 20889312 rs343819 chr1 111342490 C T 1.50E-04 Alcohol dependence / / 20201924 rs343819 chr1 111342490 C T 8.00E-06 Alcohol dependence / / 20201924 rs343819 chr1 111342490 C T 7.98E-06 Alcoholism / / pha002893 rs518785 chr1 111359802 G A 1.57E-11 Lymphocyte counts / / 22286170 rs6685538 chr1 111393622 G A 4.00E-04 Alcohol dependence / / 20201924 rs6677149 chr1 111393713 T A 8.64E-04 Type 2 diabetes / / 17846124 rs6677149 chr1 111393713 T A 4.89E-05 Bipolar disorder and schizophrenia / / 20889312 rs17688638 chr1 111394866 T C 3.93E-05 Bipolar disorder and schizophrenia / / 20889312 rs17688644 chr1 111395110 T C 4.31E-05 Bipolar disorder and schizophrenia / / 20889312 rs12566518 chr1 111395388 G T 4.45E-05 Bipolar disorder and schizophrenia / / 20889312 rs4631693 chr1 111396088 C T 3.10E-04 Alcohol dependence / / 20201924 rs4631693 chr1 111396088 C T 7.50E-05 Alcohol dependence / / 20201924 rs4631693 chr1 111396088 C T 7.53E-05 Alcoholism / / pha002892 rs718463 chr1 111396606 G A 2.30E-04 Alcohol dependence / / 20201924 rs718463 chr1 111396606 G A 5.30E-05 Alcohol dependence / / 20201924 rs718463 chr1 111396606 G A 5.28E-05 Alcoholism / / pha002892 rs12730405 chr1 111396915 A G 2.80E-04 Alcohol dependence / / 20201924 rs12730405 chr1 111396915 A G 6.40E-05 Alcohol dependence / / 20201924 rs12730405 chr1 111396915 A G 6.44E-05 Alcoholism / / pha002892 rs6672672 chr1 111397090 C T 3.10E-04 Alcohol dependence / / 20201924 rs6672672 chr1 111397090 C T 7.20E-05 Alcohol dependence / / 20201924 rs6672672 chr1 111397090 C T 7.22E-05 Alcoholism / / pha002892 rs6687919 chr1 111397176 T G 1.50E-04 Alcohol dependence / / 20201924 rs6687919 chr1 111397176 T G 4.40E-04 Alcohol dependence / / 20201924 rs6687898 chr1 111397316 A G 1.50E-04 Alcohol dependence / / 20201924 rs6687898 chr1 111397316 A G 4.40E-04 Alcohol dependence / / 20201924 rs6690536 chr1 111397451 T C 1.70E-04 Alcohol dependence / / 20201924 rs6690536 chr1 111397451 T C 4.80E-04 Alcohol dependence / / 20201924 rs11102170 chr1 111401239 T C 5.24E-05 Bipolar disorder and schizophrenia / / 20889312 rs17637944 chr1 111401704 T C 2.54E-05 Bipolar disorder and schizophrenia / / 20889312 rs6696248 chr1 111404291 T C 4.24E-05 Bipolar disorder and schizophrenia / / 20889312 rs6701134 chr1 111406899 A G 2.90E-04 Alcohol dependence / / 20201924 rs6701134 chr1 111406899 A G 6.60E-05 Alcohol dependence / / 20201924 rs6701134 chr1 111406899 A G 6.65E-05 Alcoholism / / pha002892 rs7513168 chr1 111412912 T C 1.50E-05 Alcohol dependence / / 20201924 rs7513168 chr1 111412912 T C 1.90E-04 Alcohol dependence / / 20201924 rs7513168 chr1 111412912 T C 1.49E-05 Alcoholism / / pha002893 rs2885805 chr1 111417915 C A 5.00E-06 Cytomegalovirus antibody response CD53 intron 21993531 rs2885805 chr1 111417915 C A 0.000000215 Tuberculosis with late age of onset CD53 intron 22551897 rs1494320 chr1 111422188 T C 0.00000279 Tuberculosis with late age of onset CD53 intron 22551897 rs4839583 chr1 111433622 C T 1.33E-04 Multiple complex diseases CD53 intron 17554300 rs2070748 chr1 111434711 C T 2.35E-05 Multiple complex diseases CD53 intron 17554300 rs1712675 chr1 111463053 G C 3.16E-04 Multiple complex diseases / / 17554300 rs12567355 chr1 111463624 G A 9.00E-06 Obesity-related traits / / 23251661 rs1774766 chr1 111466602 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1774766 chr1 111466602 T C 1.38E-05 Body Mass Index / / pha003021 rs1418425 chr1 111468886 T C 0.00000964 Aging / / 22445811 rs1418425 chr1 111468886 T C 0.0000535 Tuberculosis with late age of onset / / 22551897 rs12724986 chr1 111595360 T A 7.08E-04 Alzheimer's disease / / 22005930 rs12087782 chr1 111602976 A T 8.11E-04 Alzheimer's disease / / 22005930 rs12752511 chr1 111641712 A G 8.93E-04 Alzheimer's disease / / 22005930 rs11102212 chr1 111642031 A G 6.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17026872 chr1 111646770 G A 8.98E-04 Alzheimer's disease / / 22005930 rs325894 chr1 111652548 T C 2.87E-05 Bipolar disorder / / 21771265 rs325921 chr1 111664343 A G 2.74E-05 Bipolar disorder DRAM2 intron 21771265 rs1335645 chr1 111684276 A G 7.00E-09 Liver enzyme levels (gamma-glutamyl transferase) CEPT1 intron 22001757 rs17026995 chr1 111706368 A G 5.85E-04 Multiple complex diseases CEPT1 intron 17554300 rs608881 chr1 111730901 C T 4.90E-04 Type 2 diabetes DENND2D cds-synon 17463246 rs2764546 chr1 111762482 G A 2.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2182114 chr1 111784227 C T 9.00E-04 Type 2 diabetes and 6 quantitative traits CHI3L2 intron 17848626 rs2182114 chr1 111784227 C T 8.20E-05 Lipid traits CHI3L2 intron 17903299 rs942697 chr1 111791503 G C 5.02E-15 Lymphocyte counts / / 22286170 rs6691256 chr1 111796627 C A 7.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17654531 chr1 111799685 A G 1.16E-05 Parkinson's disease / / pha002868 rs4838896 chr1 111821777 T C 5.87E-06 Nephrolithiasis / / 22396660 rs12027550 chr1 111821946 C G 8.84E-05 Longevity / / 20304771 rs4323713 chr1 111823220 G T 4.70E-04 Crohn's disease RP11-165H20.1 intron 17684544 rs4240529 chr1 111824744 A G 8.32E-06 Paget's disease / / 20436471 rs12401767 chr1 111829797 G A 3.36E-05 Nephrolithiasis / / 22396660 rs3806448 chr1 111832205 G A 1.88E-05 Cognitive impairment induced by topiramate / / 22091778 rs3806446 chr1 111832291 T C 4.96E-05 Cognitive impairment induced by topiramate / / 22091778 rs3806446 chr1 111832291 T C 2.35E-05 Nephrolithiasis / / 22396660 rs4240530 chr1 111853581 C T 8.40E-04 Alcohol dependence CHIA intron 20201924 rs4839122 chr1 111854207 T C 5.05E-04 Alcohol dependence CHIA intron 21314694 rs11590452 chr1 111863942 C T 7.06E-04 Multiple complex diseases / / 17554300 rs11102249 chr1 111864700 G A 7.17E-08 Metabolite levels / / 23281178 rs12029516 chr1 111884013 C T 8.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9645351 chr1 111894870 G A 2.49E-04 Response to cytadine analogues (cytosine arabinoside) C1orf88 UTR-3 24483146 rs2050605 chr1 111903304 T C 3.89E-05 Vitiligo / / 19890347 rs17027501 chr1 111905989 C A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1764807 chr1 111956206 C T 6.75E-04 Type 2 diabetes / / 17463246 rs1419093 chr1 111962152 T C 0.000294 Salmonella-induced pyroptosis OVGP1 intron 22837397 rs1264913 chr1 111974935 A G 2.08E-04 Type 2 diabetes / / 17463246 rs6692745 chr1 112019159 A G 1.66E-04 Lymphocyte counts C1orf162 intron 22286170 rs7737 chr1 112026152 C T 1.63E-04 Heart rate ADORA3 UTR-3 23583979 rs1361133 chr1 112027033 G T 4.39E-06 Corneal structure ADORA3 intron 22003120 rs3767602 chr1 112029763 G A 9.76E-05 Cognitive performance ADORA3 intron 19734545 rs41320847 chr1 112049950 A G 2.16E-04 Multiple complex diseases ADORA3 intron 17554300 rs6537704 chr1 112052105 C T 2.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADORA3 intron 20877124 rs6537704 chr1 112052105 C T 4.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADORA3 intron 20877124 rs1539582 chr1 112095646 A G 5.83E-04 Multiple complex diseases ADORA3 intron 17554300 rs9988442 chr1 112096662 C T 0.00000062 Triglycerides ADORA3 intron 23063622 rs13376212 chr1 112103480 C A 8.30E-04 Coronary heart disease ADORA3 intron 21966275 rs10776733 chr1 112107669 A G 7.00E-06 Obesity-related traits ADORA3 nearGene-5 23251661 rs17663802 chr1 112108667 A C 5.86E-05 Cognitive impairment induced by topiramate / / 22091778 rs1415797 chr1 112125404 G C 2.65E-04 Type 2 diabetes / / 17463246 rs10494137 chr1 112127299 G A 9.89E-04 Type 2 diabetes / / 17463246 rs10857899 chr1 112127718 G A 3.06E-06 Parkinson's disease / / pha002868 rs2800880 chr1 112130624 T C 9.34E-05 Monocyte counts / / pha003089 rs1890548 chr1 112135958 T C 9.47E-05 Tunica Media / / pha003038 rs6677933 chr1 112139008 T C 5.10E-06 Urinary metabolites / / 21572414 rs2786991 chr1 112147569 T C 4.09E-05 Tunica Media LOC100129269 intron pha003038 rs2477425 chr1 112152602 T C 1.88E-05 Serum metabolites / / 19043545 rs508594 chr1 112165171 T G 1.94E-05 Tunica Media RAP1A intron pha003038 rs1324889 chr1 112183640 A G 2.11E-05 Tunica Media RAP1A intron pha003038 rs494453 chr1 112192122 T C 4.00E-08 Osteoporosis RAP1A intron 20548944 rs11576942 chr1 112203185 G T 4.85E-05 Serum metabolites RAP1A intron 19043545 rs575208 chr1 112206391 T C 1.56E-05 Tunica Media RAP1A intron pha003038 rs10489469 chr1 112234084 G T 8.04E-04 Schizophrenia RAP1A intron 19197363 rs17028287 chr1 112244798 A T 3.20E-06 Urinary metabolites RAP1A intron 21572414 rs197437 chr1 112274653 A G 6.28E-04 Obesity (extreme) FAM212B intron 21935397 rs11102329 chr1 112276608 T C 5.61E-04 Obesity (extreme) FAM212B intron 21935397 rs11102329 chr1 112276608 T C 4.83E-05 Coronary heart disease FAM212B intron pha003032 rs11102329 chr1 112276608 T C 2.27E-05 Monocyte chemoattractant protein-1 FAM212B intron pha003071 rs17568965 chr1 112279555 T A 1.80E-04 Lymphocyte counts FAM212B intron 22286170 rs3754026 chr1 112283838 T C 9.65E-04 Suicide attempts in bipolar disorder FAM212B intron 21423239 rs197394 chr1 112286309 T C 4.71E-04 Multiple complex diseases FAM212B intron 17554300 rs197394 chr1 112286309 T C 5.95E-04 Obesity (extreme) FAM212B intron 21935397 rs881249 chr1 112286948 G C 2.19E-04 Suicide attempts in bipolar disorder FAM212B intron 21423239 rs2076589 chr1 112292547 C T 3.85E-04 Suicide attempts in bipolar disorder FAM212B intron 21423239 rs197380 chr1 112292706 A T 9.62E-04 Obesity (extreme) FAM212B intron 21935397 rs197381 chr1 112292778 T G 9.65E-04 Obesity (extreme) FAM212B intron 21935397 rs191803 chr1 112300120 G C 9.78E-04 Obesity (extreme) DDX20 intron 21935397 rs197404 chr1 112302886 G A 9.94E-04 Obesity (extreme) DDX20 intron 21935397 rs499842 chr1 112304184 C G 4.78E-04 Suicide attempts in bipolar disorder DDX20 intron 21423239 rs197409 chr1 112307615 A G 8.95E-04 Obesity (extreme) DDX20 intron 21935397 rs197410 chr1 112307875 T C 9.19E-04 Obesity (extreme) DDX20 intron 21935397 rs197411 chr1 112308178 G A 9.26E-04 Obesity (extreme) DDX20 intron 21935397 rs197414 chr1 112309123 C A 9.45E-04 Obesity (extreme) DDX20 missense 21935397 rs197414 chr1 112309123 C A 2.22E-05 Coronary heart disease DDX20 missense pha003032 rs197414 chr1 112309123 C A 1.04E-05 Monocyte chemoattractant protein-1 DDX20 missense pha003071 rs85276 chr1 112309331 T C 9.45E-04 Obesity (extreme) DDX20 missense 21935397 rs85276 chr1 112309331 T C 2.22E-05 Coronary heart disease DDX20 missense pha003032 rs85276 chr1 112309331 T C 1.04E-05 Monocyte chemoattractant protein-1 DDX20 missense pha003071 rs7522845 chr1 112312305 A G 9.42E-04 Obesity (extreme) / / 21935397 rs544941 chr1 112312334 A T 3.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs11803207 chr1 112314565 T C 9.40E-04 Obesity (extreme) / / 21935397 rs499817 chr1 112314822 A G 9.39E-04 Obesity (extreme) / / 21935397 rs12138774 chr1 112317692 C G 9.43E-04 Obesity (extreme) / / 21935397 rs535317 chr1 112320800 C T 5.71E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs17722309 chr1 112339880 T C 8.06E-05 Waist Circumference KCND3 intron pha003024 rs12096089 chr1 112349066 A C 2.79E-04 Type 2 diabetes KCND3 intron 17463246 rs12096089 chr1 112349066 A C 1.90E-04 Multiple complex diseases KCND3 intron 17554300 rs12059906 chr1 112349596 G A 2.24E-04 Multiple complex diseases KCND3 intron 17554300 rs17028612 chr1 112349657 G A 5.09E-04 Type 2 diabetes KCND3 intron 17463246 rs17028612 chr1 112349657 G A 2.49E-04 Multiple complex diseases KCND3 intron 17554300 rs17028627 chr1 112351440 G C 5.83E-04 Type 2 diabetes KCND3 intron 17463246 rs17028627 chr1 112351440 G C 1.54E-04 Multiple complex diseases KCND3 intron 17554300 rs626737 chr1 112385812 T C 9.24E-04 HIV-1 viral setpoint KCND3 intron 17641165 rs12044963 chr1 112392360 G T 9.00E-10 Immune reponse to smallpox (secreted IFN-alpha) KCND3 intron 22610502 rs2788612 chr1 112416363 T C 1.05E-12 Response to radiotherapy in cancer (late toxicity) KCND3 intron 24785509 rs2788612 chr1 112416363 T C 6.00E-16 Response to radiotherapy in cancer (late toxicity) KCND3 intron 24785509 rs7415980 chr1 112421677 C T 5.28E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs528779 chr1 112424077 C T 4.19E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs11102353 chr1 112426519 T G 8.27E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs612790 chr1 112426577 C G 3.70E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs2813862 chr1 112427918 C G 2.70E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs1767283 chr1 112428953 T C 2.57E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs1767283 chr1 112428953 T C 2.80E-10 P wave duration KCND3 intron 24850809 rs605604 chr1 112433863 C A 2.96E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs605604 chr1 112433863 C A 2.17E-10 P wave duration KCND3 intron 24850809 rs2798334 chr1 112437344 T C 9.21E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs2798334 chr1 112437344 T C 1.00E-06 Visceral adipose tissue adjusted for BMI KCND3 intron 22589738 rs2798334 chr1 112437344 T C 8.00E-11 P wave duration KCND3 intron 24850809 rs2813865 chr1 112437956 A G 7.92E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs894848 chr1 112438818 A G 4.47E-04 Multiple complex diseases KCND3 intron 17554300 rs2995807 chr1 112450636 T C 6.15E-05 Depression (quantitative trait) KCND3 intron 23290196 rs2120436 chr1 112451447 C T 4.38E-09 P wave duration KCND3 intron 24850809 rs2034124 chr1 112451681 A G 3.70E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs12090194 chr1 112454822 C T 3.08E-09 P wave duration KCND3 intron 24850809 rs4839182 chr1 112456538 A G 1.69E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs4839183 chr1 112456882 A G 7.19E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs1443926 chr1 112461902 A G 5.12E-09 P wave duration KCND3 intron 24850809 rs1545300 chr1 112464004 C T 5.06E-09 P wave duration KCND3 intron 24850809 rs17029069 chr1 112464376 C T 8.00E-06 Cardiac repolarization KCND3 intron 22683750 rs12408551 chr1 112467932 T C 1.60E-04 Body mass index KCND3 intron 17255346 rs11102355 chr1 112470093 T C 1.26E-04 Body mass index KCND3 intron 17255346 rs2010749 chr1 112470581 T C 8.08E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs1443927 chr1 112471029 C G 8.24E-04 Suicide attempts in bipolar disorder KCND3 intron 21423239 rs1443927 chr1 112471029 C G 5.35E-09 P wave duration KCND3 intron 24850809 rs12025303 chr1 112474929 C T 4.60E-06 Response to radiotherapy in cancer (late toxicity) KCND3 intron 24785509 rs12025303 chr1 112474929 C T 7.40E-05 Response to radiotherapy in cancer (late toxicity) KCND3 intron 24785509 rs12145374 chr1 112480536 A C 2.78E-10 P wave duration KCND3 intron 24850809 rs1373290 chr1 112501812 T C 5.07E-05 Information processing speed KCND3 intron 21130836 rs11102365 chr1 112507906 G C 7.84E-04 Response to cytadine analogues (cytosine arabinoside) KCND3 intron 24483146 rs3000747 chr1 112538477 T C 2.10E-04 Multiple complex diseases LOC643355 intron 17554300 rs3000752 chr1 112547125 T G 8.34E-04 White matter integrity / / 22425255 rs7548711 chr1 112550542 T C 2.32E-04 White matter integrity / / 22425255 rs12562249 chr1 112555423 G A 9.34E-04 White matter integrity / / 22425255 rs17739527 chr1 112570739 T C 8.63E-04 Type 2 diabetes / / 17463246 rs4839202 chr1 112586954 G A 8.31E-04 Bipolar disorder,schizoaffective / / 19567891 rs4839202 chr1 112586954 G A 8.94E-04 Alzheimer's disease / / 22005930 rs655856 chr1 112594445 G A 6.17E-04 Alzheimer's disease / / 22005930 rs1838300 chr1 112595728 T G 4.56E-04 Alzheimer's disease / / 22005930 rs269079 chr1 112597532 A G 6.00E-04 Alzheimer's disease / / 22005930 rs269131 chr1 112613028 A G 1.63E-04 Multiple complex diseases / / 17554300 rs6691573 chr1 112613106 T C 1.66E-04 Colorectal cancer / / 24836286 rs1440176 chr1 112643780 T A 1.31E-04 Coronary Artery Disease / / 17634449 rs2788424 chr1 112731802 C T 5.52E-04 Type 2 diabetes / / 17463246 rs1440169 chr1 112732217 C T 3.98E-04 Type 2 diabetes / / 17463246 rs6670755 chr1 112732305 A G 4.46E-04 Type 2 diabetes / / 17463246 rs1416203 chr1 112762293 A G 4.46E-04 Type 2 diabetes / / 17463246 rs17029953 chr1 112822460 A G 9.74E-04 Multiple complex diseases / / 17554300 rs7555668 chr1 112856570 C T 3.00E-06 Cognitive performance / / 20125193 rs1105182 chr1 112888147 T A 8.10E-04 Insulin resistance / / 21901158 rs1343275 chr1 112897590 G A 2.25E-05 Information processing speed / / 21130836 rs2492506 chr1 112940944 G A 6.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CTTNBP2NL intron 20877124 rs2492510 chr1 112951159 A G 7.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CTTNBP2NL intron 20877124 rs1175645 chr1 112981412 A G 2.40E-04 Type 2 diabetes and 6 quantitative traits CTTNBP2NL intron 17848626 rs2256883 chr1 112991698 T C 2.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CTTNBP2NL cds-synon 20877124 rs1759692 chr1 112993998 A G 2.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CTTNBP2NL intron 20877124 rs2488787 chr1 113005808 T A 8.73E-04 Parkinson's disease / / 16252231 rs11102479 chr1 113006804 G A 7.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12097320 chr1 113009795 T C 7.28E-04 Multiple complex diseases / / 17554300 rs6692731 chr1 113019182 C T 0.000000304 Triglycerides WNT2B intron 23063622 rs2780266 chr1 113025285 G C 7.33E-04 Multiple complex diseases WNT2B intron 17554300 rs3790606 chr1 113052186 G C 5.80E-05 Parkinson's disease (age of onset) WNT2B intron 19772629 rs7516521 chr1 113054936 T G 4.36E-11 HDL cholesterol WNT2B intron 23063622 rs17030475 chr1 113086626 T C 3.63E-04 Multiple complex diseases ST7L intron 17554300 rs17030613 chr1 113190807 A C 3.42E-04 Amyotrophic Lateral Sclerosis CAPZA1 intron 17362836 rs17030613 chr1 113190807 A C 1.00E-08 Blood pressure CAPZA1 intron 21572416 rs17030613 chr1 113190807 A C 8.00E-06 Blood pressure CAPZA1 intron 21572416 rs2932529 chr1 113193364 G A 5.70E-05 Electrocardiographic traits and heart rate variability CAPZA1 intron 17903306 rs3790598 chr1 113196896 G A 1.91E-04 Alcohol dependence CAPZA1 intron 20201924 rs2932538 chr1 113216543 A G 8.00E-06 Blood pressure / / 21909110 rs2932538 chr1 113216543 A G 1.00E-09 Systolic blood pressure / / 21909115 rs2932538 chr1 113216543 A G 3.00E-07 Hypertension / / 21909115 rs4839257 chr1 113219388 A T 9.70E-04 Multiple complex diseases MOV10 intron 17554300 rs2306936 chr1 113246630 G A 6.65E-04 Multiple complex diseases RHOC intron 17554300 rs12144044 chr1 113248791 C A 5.70E-04 Multiple complex diseases RHOC intron 17554300 rs11590090 chr1 113313563 C A 3.00E-06 Hyperactive-impulsive symptoms / / 18821565 rs4378202 chr1 113331134 C T 5.43E-04 Multiple complex diseases / / 17554300 rs10857978 chr1 113338649 T C 3.49E-05 Hypertension / / 21082022 rs11804649 chr1 113348570 C T 5.60E-05 Lipoproteins / / pha003079 rs4838968 chr1 113360437 G C 1.38E-11 Corneal structure / / 22003120 rs7550843 chr1 113452233 T G 2.47E-05 Smoking initiation / / 24665060 rs7551223 chr1 113452613 T A 6.13E-04 Smoking initiation / / 24665060 rs11585690 chr1 113456368 A C 4.87E-04 Celiac disease SLC16A1 UTR-3 23936387 rs11804107 chr1 113472147 C A 0.000000167 HDL cholesterol SLC16A1 intron 23063622 rs6691781 chr1 113710616 C T 3.61E-04 Multiple complex diseases / / 17554300 rs7555991 chr1 113755018 C T 0.000470398 Hypertension (early onset hypertension) / / 22479346 rs773602 chr1 113781358 C T 3.93E-04 Parkinson's disease / / 17052657 rs773564 chr1 113824297 C T 4.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs773564 chr1 113824297 C T 0.00075 Endometrial cancer / / 22426144 rs773563 chr1 113824805 A C 2.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12047722 chr1 113868398 G A 8.71E-04 Multiple complex diseases / / 17554300 rs7546431 chr1 113869497 G A 5.20E-08 Metabolite levels / / 23281178 rs1342652 chr1 113874491 T A 5.41E-04 Multiple complex diseases / / 17554300 rs4839312 chr1 113876419 T C 9.92E-04 Multiple complex diseases / / 17554300 rs2153894 chr1 113878311 C T 7.69E-04 Multiple complex diseases / / 17554300 rs1578712 chr1 113880299 T G 5.50E-04 Self-reported allergy / / 23817569 rs12026077 chr1 113883467 A G 5.15E-04 Multiple complex diseases / / 17554300 rs10494157 chr1 113891038 G A 5.32E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs12723859 chr1 113891396 A G 2.98E-05 Multiple complex diseases / / 17554300 rs4839315 chr1 113896837 A G 7.98E-04 Multiple complex diseases / / 17554300 rs10494161 chr1 113919454 C G 4.07E-04 Coronary heart disease / / 21606135 rs12049447 chr1 113922845 C T 1.17E-06 Multiple complex diseases / / 17554300 rs12049447 chr1 113922845 C T 4.11E-06 Type 1 diabetes / / 18978792 rs10458459 chr1 113967405 C T 9.26E-07 Multiple complex diseases MAGI3 intron 17554300 rs10458459 chr1 113967405 C T 3.28E-06 Type 1 diabetes MAGI3 intron 18978792 rs12030900 chr1 113974263 A G 1.20E-06 Multiple complex diseases MAGI3 intron 17554300 rs12030900 chr1 113974263 A G 4.62E-06 Type 1 diabetes MAGI3 intron 18978792 rs1573996 chr1 113985456 A G 1.86E-06 Multiple complex diseases MAGI3 intron 17554300 rs1573996 chr1 113985456 A G 2.44E-06 Type 1 diabetes MAGI3 intron 18978792 rs12045559 chr1 113996866 G T 1.50E-06 Multiple complex diseases MAGI3 intron 17554300 rs12739961 chr1 113996947 C T 3.98E-04 Multiple complex diseases MAGI3 intron 17554300 rs4839321 chr1 114047464 G A 9.07E-04 Coronary heart disease MAGI3 intron 21606135 rs12022849 chr1 114063523 A G 8.25E-07 Multiple complex diseases MAGI3 intron 17554300 rs12022849 chr1 114063523 A G 3.36E-06 Type 1 diabetes MAGI3 intron 18978792 rs6694861 chr1 114063592 A G 8.00E-04 Chronic fatigue syndrome MAGI3 intron 21912186 rs10858000 chr1 114075796 C T 4.00E-06 Rheumatoid arthritis MAGI3 intron 17159887 rs2153977 chr1 114080071 C T 4.70E-06 Fasting plasma glucose MAGI3 intron 19060907 rs2153977 chr1 114080071 C T 5.56E-06 Rheumatoid arthritis MAGI3 intron 19503088 rs2153977 chr1 114080071 C T 2.72E-06 Glucose levels MAGI3 intron pha002899 rs10858002 chr1 114082932 A G 3.66E-08 Multiple complex diseases MAGI3 intron 17554300 rs10858002 chr1 114082932 A G 1.64E-04 Coronary Artery Disease MAGI3 intron 17634449 rs17031648 chr1 114084105 T A 6.37E-04 Coronary Artery Disease MAGI3 intron 17634449 rs4456089 chr1 114084544 C T 1.07E-11 Multiple complex diseases MAGI3 intron 17554300 rs17013326 chr1 114089316 G A 1.87E-10 Multiple complex diseases MAGI3 intron 17554300 rs12035317 chr1 114096097 T G 3.12E-07 Rheumatoid arthritis MAGI3 intron 19503088 rs12035317 chr1 114096097 T G 8.74E-05 Glucose levels MAGI3 intron pha002899 rs1343128 chr1 114108252 G A 4.00E-06 Rheumatoid arthritis MAGI3 intron 17159887 rs1418958 chr1 114110836 A T 2.00E-04 Rheumatoid arthritis MAGI3 intron 17159887 rs1343125 chr1 114111036 A G 1.80E-04 Rheumatoid arthritis MAGI3 intron 17159887 rs1343125 chr1 114111036 A G 1.55E-10 Multiple complex diseases MAGI3 intron 17554300 rs1217201 chr1 114123773 G A 4.00E-06 Rheumatoid arthritis MAGI3 intron 17159887 rs1113523 chr1 114129474 A G 4.64E-11 Multiple complex diseases MAGI3 intron 17554300 rs1217236 chr1 114132712 G A 4.00E-06 Rheumatoid arthritis MAGI3 intron 17159887 rs1217228 chr1 114139359 T G 4.00E-06 Rheumatoid arthritis MAGI3 intron 17159887 rs1217227 chr1 114139616 C T 5.94E-11 Multiple complex diseases MAGI3 intron 17554300 rs1217226 chr1 114139922 C T 4.00E-06 Rheumatoid arthritis MAGI3 intron 17159887 rs1217226 chr1 114139922 C T 9.93E-11 Multiple complex diseases MAGI3 intron 17554300 rs1217225 chr1 114139991 G A 6.82E-04 Multiple complex diseases MAGI3 intron 17554300 rs1217225 chr1 114139991 G A 2.13E-05 Type 1 diabetes MAGI3 intron 18978792 rs79925084 chr1 114148011 A G 3.04E-06 Obesity-related traits MAGI3 intron 23251661 rs78563144 chr1 114156217 G A 3.04E-06 Obesity-related traits MAGI3 intron 23251661 rs3761931 chr1 114157023 G A 2.40E-05 Urinary metabolites MAGI3 intron 21572414 rs1217200 chr1 114161116 C A 7.23E-13 Multiple complex diseases MAGI3 intron 17554300 rs77911012 chr1 114161807 A G 3.04E-06 Obesity-related traits MAGI3 intron 23251661 rs1217192 chr1 114162194 G A 4.00E-04 Rheumatoid arthritis MAGI3 intron 17159887 rs1217193 chr1 114162619 C G 1.00E-05 Rheumatoid arthritis MAGI3 intron 17159887 rs1230666 chr1 114173410 A G 3.62E-10 Multiple complex diseases MAGI3 intron 17554300 rs1230666 chr1 114173410 A G 1.95E-06 Arthritis (juvenile idiopathic) MAGI3 intron 22354554 rs1230666 chr1 114173410 A G 2.00E-08 Thyroid peroxidase antibody levels MAGI3 intron 24586183 rs3747998 chr1 114186138 G C 6.40E-06 Urinary metabolites MAGI3 intron 21572414 rs1777237 chr1 114187371 G A 1.00E-05 Rheumatoid arthritis MAGI3 intron 17159887 rs1146182 chr1 114196883 C A 1.00E-05 Rheumatoid arthritis MAGI3 intron 17159887 rs79247801 chr1 114203971 A G 3.04E-06 Obesity-related traits MAGI3 intron 23251661 rs76231474 chr1 114206036 C T 3.04E-06 Obesity-related traits MAGI3 intron 23251661 rs1146187 chr1 114212571 A G 1.00E-05 Rheumatoid arthritis MAGI3 intron 17159887 rs77600616 chr1 114213935 G C 3.04E-06 Obesity-related traits MAGI3 intron 23251661 rs17274634 chr1 114217527 T C 6.50E-06 Urinary metabolites MAGI3 intron 21572414 rs1230658 chr1 114218451 C G 1.05E-12 Multiple complex diseases MAGI3 intron 17554300 rs61742849 chr1 114226143 G A 6.00E-06 Bulimia nervosa MAGI3 missense 23568457 rs4839335 chr1 114233871 G A 1.37E-05 Rheumatoid arthritis / / 17804836 rs4839335 chr1 114233871 G A 5.66E-09 Rheumatoid arthritis / / 19503088 rs4839335 chr1 114233871 G A 3.20E-04 Myasthenia gravis / / 23055271 rs1111695 chr1 114243899 C A 2.91E-07 Rheumatoid arthritis PHTF1 intron 19503088 rs1230649 chr1 114244177 G T 6.95E-13 Multiple complex diseases PHTF1 intron 17554300 rs74901666 chr1 114248264 G A 3.04E-06 Obesity-related traits PHTF1 intron 23251661 rs6698586 chr1 114249382 C T 1.00E-05 Rheumatoid arthritis PHTF1 intron 17159887 rs1230647 chr1 114253639 C T 1.52E-05 Rheumatoid arthritis PHTF1 intron 17804836 rs1230647 chr1 114253639 C T 6.42E-09 Rheumatoid arthritis PHTF1 intron 19503088 rs1230647 chr1 114253639 C T 3.80E-04 Myasthenia gravis PHTF1 intron 23055271 rs1981319 chr1 114267645 C A 1.00E-05 Rheumatoid arthritis PHTF1 intron 17159887 rs2273758 chr1 114280717 A C 2.00E-05 Rheumatoid arthritis PHTF1 intron 17159887 rs2273758 chr1 114280717 A C 1.28E-07 Multiple complex diseases PHTF1 intron 17554300 rs78089789 chr1 114282370 C G 3.04E-06 Obesity-related traits PHTF1 intron 23251661 rs6679677 chr1 114303808 C A 8.00E-24 Type 1 diabetes / / 17554260 rs6679677 chr1 114303808 C A 5.00E-26 Type 1 diabetes / / 17554300 rs6679677 chr1 114303808 C A 6.00E-25 Rheumatoid arthritis / / 17554300 rs6679677 chr1 114303808 C A 4.95E-09 Crohn's disease / / 18587394 rs6679677 chr1 114303808 C A 6.00E-42 Rheumatoid arthritis / / 18794853 rs6679677 chr1 114303808 C A 1.00E-40 Type 1 diabetes / / 18978792 rs6679677 chr1 114303808 C A 8.00E-24 Multiple sclerosis / / 22190364 rs6679677 chr1 114303808 C A 1.07E-06 Arthritis (juvenile idiopathic) / / 22354554 rs6679677 chr1 114303808 C A 3.00E-13 Hypothyroidism / / 22493691 rs6679677 chr1 114303808 C A 2.00E-15 Crohn's disease / / 23128233 rs6679677 chr1 114303808 C A 1.11E-18 Oligoarticular juvenile idiopathic arthritis / / 23603761 rs6679677 chr1 114303808 C A 3.19E-25 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs6679677 chr1 114303808 C A 3.45E-11 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis / / 23603761 rs3789598 chr1 114318727 C A 2.00E-05 Rheumatoid arthritis RSBN1 intron 17159887 rs2797409 chr1 114330202 T C 9.69E-06 Rheumatoid arthritis RSBN1 intron 17804836 rs2797409 chr1 114330202 T C 6.90E-11 Rheumatoid arthritis RSBN1 intron 19503088 rs2797409 chr1 114330202 T C 2.60E-04 Myasthenia gravis RSBN1 intron 23055271 rs2797409 chr1 114330202 T C 2.81E-04 Systemic lupus erythematosus and Systemic sclerosis RSBN1 intron 23740937 rs2040040 chr1 114331645 T A 6.90E-06 Urinary metabolites RSBN1 intron 21572414 rs1217396 chr1 114338236 C T 2.60E-13 Multiple complex diseases RSBN1 intron 17554300 rs1217380 chr1 114343336 G A 3.00E-05 Rheumatoid arthritis RSBN1 intron 17159887 rs78399433 chr1 114346137 T C 3.04E-06 Obesity-related traits RSBN1 intron 23251661 rs75453168 chr1 114348204 T C 3.04E-06 Obesity-related traits RSBN1 intron 23251661 rs6537798 chr1 114351706 C A 7.95E-07 Multiple complex diseases RSBN1 intron 17554300 rs3811021 chr1 114356663 A G 4.46E-04 Cognition,early reading ability PTPN22 UTR-3 17684495 rs1217413 chr1 114357750 G A 4.00E-08 Rheumatoid arthritis PTPN22 intron 17159887 rs1217395 chr1 114374435 C T 1.00E-05 Rheumatoid arthritis PTPN22 intron 17159887 rs2476601 chr1 114377568 A G 2.00E-80 Type 1 diabetes / / 17554260 rs2476601 chr1 114377568 A G 1.00E-07 Type 1 diabetes / / 17632545 rs2476601 chr1 114377568 A G 2.00E-11 Rheumatoid arthritis / / 17804836 rs2476601 chr1 114377568 A G 5.20E-06 Systemic lupus erythematosus / / 18204446 rs2476601 chr1 114377568 A G 1.00E-08 Crohn's disease / / 18587394 rs2476601 chr1 114377568 A G 9.00E-85 Type 1 diabetes / / 19430480 rs2476601 chr1 114377568 A G 2.00E-21 Rheumatoid arthritis / / 19503088 rs2476601 chr1 114377568 A G 1.00E-07 Vitiligo / / 20410501 rs2476601 chr1 114377568 A G 9.00E-74 Rheumatoid arthritis / / 20453842 rs2476601 chr1 114377568 A G 4.00E-09 Crohn's disease / / 21102463 rs2476601 chr1 114377568 A G 1.00E-08 Asthma / / 21150878 rs2476601 chr1 114377568 A G 1.00E-08 Rheumatoid arthritis / / 21156761 rs2476601 chr1 114377568 A G 9.82E-09 Vitiligo / / 21326295 rs2476601 chr1 114377568 A G 9.10E-74 Celiac disease and Rheumatoid arthritis / / 21383967 rs2476601 chr1 114377568 A G 2.00E-111 Type 1 diabetes autoantibodies / / 21829393 rs2476601 chr1 114377568 A G 5.93E-80 Type 1 diabetes / / 21980299 rs2476601 chr1 114377568 A G 3.40E-12 Multiple sclerosis / / 22190364 rs2476601 chr1 114377568 A G 6.20E-71 Rheumatoid arthritis / / 22446963 rs2476601 chr1 114377568 A G 3.90E-13 Hypothyroidism / / 22493691 rs2476601 chr1 114377568 A G 6.10E-13 Vitiligo / / 22561518 rs2476601 chr1 114377568 A G 3.74E-15 Hashimoto's thyroiditis / / 22922229 rs2476601 chr1 114377568 A G 4.03E-16 Graves' disease / / 22922229 rs2476601 chr1 114377568 A G 9.69E-23 Graves' disease and Hashimoto's thyroiditis / / 22922229 rs2476601 chr1 114377568 A G 8.00E-10 Myasthenia gravis / / 23055271 rs2476601 chr1 114377568 A G 0.000175 Rheumatoid arthritis (CCP negative) / / 23143596 rs2476601 chr1 114377568 A G 7.50E-77 Rheumatoid arthritis / / 23143596 rs2476601 chr1 114377568 A G 9.23E-78 Rheumatoid arthritis (CCP positive) / / 23143596 rs2476601 chr1 114377568 A G 6.60E-170 Rheumatoid arthritis / / 24390342 rs2476601 chr1 114377568 A G 9.00E-170 Rheumatoid arthritis / / 24390342 rs2476601 chr1 114377568 A G 5.00E-33 Rheumatoid arthritis / / 24449572 rs138092829 chr1 114380886 T C 0.0000016 Breast cancer (ER positive) PTPN22 missense 23555315 rs1217407 chr1 114393748 A G 9.00E-06 Rheumatoid arthritis PTPN22 intron 17159887 rs1217407 chr1 114393748 A G 1.50E-05 Rheumatoid arthritis PTPN22 intron 17804836 rs1217407 chr1 114393748 A G 5.29E-09 Rheumatoid arthritis PTPN22 intron 19503088 rs1217407 chr1 114393748 A G 2.40E-04 Myasthenia gravis PTPN22 intron 23055271 rs1217410 chr1 114396816 C T 1.00E-05 Rheumatoid arthritis PTPN22 intron 17159887 rs3789609 chr1 114397799 C T 6.50E-06 Urinary metabolites PTPN22 intron 21572414 rs1217418 chr1 114401231 A G 1.63E-07 Rheumatoid arthritis PTPN22 intron 19503088 rs1217418 chr1 114401231 A G 4.47E-04 Lung function (forced expiratory volume in 1 second) PTPN22 intron 24023788 rs79241487 chr1 114401782 G A 3.04E-06 Obesity-related traits PTPN22 intron 23251661 rs2488457 chr1 114415368 G A,C 1.95E-13 Multiple complex diseases LOC100287722 intron 17554300 rs1235005 chr1 114417437 C G 5.11E-08 Multiple complex diseases LOC100287722 intron 17554300 rs6665194 chr1 114417843 G A 4.18E-07 Rheumatoid arthritis LOC100287722 intron 19503088 rs1217384 chr1 114419760 G C 6.00E-07 Urinary metabolites BCL2L15 UTR-3 21572414 rs12566340 chr1 114420328 C T 9.64E-05 Rheumatoid arthritis BCL2L15 UTR-3 17804836 rs12566340 chr1 114420328 C T 3.99E-09 Rheumatoid arthritis BCL2L15 UTR-3 19503088 rs7529353 chr1 114420462 G A 7.69E-05 Rheumatoid arthritis BCL2L15 UTR-3 17804836 rs7529353 chr1 114420462 G A 4.81E-10 Rheumatoid arthritis BCL2L15 UTR-3 19503088 rs7529353 chr1 114420462 G A 4.80E-04 Myasthenia gravis BCL2L15 UTR-3 23055271 rs2358994 chr1 114429461 G A 4.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BCL2L15 intron 20877124 rs10776775 chr1 114436482 G A 4.70E-10 Multiple complex diseases LOC100287722 intron 17554300 rs10776775 chr1 114436482 G A 2.73E-05 Arthritis (juvenile idiopathic) LOC100287722 intron 22354554 rs1217401 chr1 114438951 A G 2.33E-05 Multiple complex diseases AP4B1 missense 17554300 rs1217401 chr1 114438951 A G 2.67E-05 Type 1 diabetes AP4B1 missense 18978792 rs141417436 chr1 114442885 A G 0.000041 Breast cancer(er negative) AP4B1 missense 23555315 rs12079716 chr1 114444594 T G 2.00E-06 Obesity-related traits AP4B1 intron 23251661 rs6661817 chr1 114447034 G C 6.02E-10 Multiple complex diseases AP4B1 intron 17554300 rs11552449 chr1 114448389 C A,G,T 2.00E-08 Breast cancer DCLRE1B missense 23535729 rs3811019 chr1 114471583 C G 9.24E-12 Multiple complex diseases / / 17554300 rs12127377 chr1 114489973 A G 8.89E-05 Alzheimer's disease HIPK1 intron 21098978 rs1553450 chr1 114490780 A G 8.03E-05 Alzheimer's disease HIPK1 intron 21098978 rs11102707 chr1 114493583 G A 7.90E-05 Alzheimer's disease HIPK1 intron 21098978 rs12129050 chr1 114496607 A G 8.06E-05 Alzheimer's disease HIPK1 intron 21098978 rs11102709 chr1 114512083 G C 7.36E-05 Alzheimer's disease HIPK1 intron 21098978 rs10108 chr1 114516330 C T 7.23E-05 Alzheimer's disease HIPK1 UTR-3 21098978 rs6537801 chr1 114525552 C T 3.93E-04 Aortic root size / / 21223598 rs11810241 chr1 114529760 A G 1.60E-05 Bipolar disorder / / 19488044 rs11810241 chr1 114529760 A G 3.55E-05 Bipolar Disorder / / pha002863 rs12029840 chr1 114531480 C T 1.46E-06 Multiple complex diseases / / 17554300 rs12029840 chr1 114531480 C T 4.30E-06 Stroke (ischemic) / / 22384361 rs7520320 chr1 114535293 C T 7.42E-06 Multiple complex diseases / / 17554300 rs3006971 chr1 114536207 G A 6.57E-06 Rheumatoid arthritis / / 19503088 rs1503836 chr1 114541498 G T 9.76E-06 Rheumatoid arthritis / / 19503088 rs12402202 chr1 114541955 A C 5.90E-04 Type 2 diabetes / / 17463246 rs10494164 chr1 114546528 A G 9.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10494164 chr1 114546528 A G 7.25E-06 Rheumatoid arthritis / / 19503088 rs2938323 chr1 114546804 G A 3.88E-06 Rheumatoid arthritis / / 19503088 rs77730918 chr1 114548091 G A 2.47E-06 Obesity-related traits / / 23251661 rs2938330 chr1 114555118 T C 7.81E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4274061 chr1 114555337 C A 2.63E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2938345 chr1 114568164 A T 4.40E-07 Urinary metabolites / / 21572414 rs2938340 chr1 114577595 C G 8.50E-07 Urinary metabolites / / 21572414 rs3006995 chr1 114578864 A G 9.50E-08 Urinary metabolites / / 21572414 rs10776776 chr1 114583160 T G 9.10E-08 Urinary metabolites / / 21572414 rs12092195 chr1 114583472 T C 1.74E-06 Obesity-related traits / / 23251661 rs2938317 chr1 114586587 T C 6.40E-08 Urinary metabolites / / 21572414 rs78972990 chr1 114587196 A G 6.96E-06 Obesity-related traits / / 23251661 rs2938334 chr1 114591798 T C 2.60E-04 Iris characteristics / / 21835309 rs3007005 chr1 114592265 G T 1.90E-08 Urinary metabolites / / 21572414 rs3007007 chr1 114594412 C A 9.20E-09 Urinary metabolites / / 21572414 rs2938351 chr1 114594919 G A 2.30E-08 Urinary metabolites / / 21572414 rs3007012 chr1 114606156 T C 1.10E-07 Urinary metabolites / / 21572414 rs79079833 chr1 114607364 T C 2.00E-06 Obesity-related traits / / 23251661 rs1330700 chr1 114618054 C T 2.40E-05 Urinary metabolites / / 21572414 rs58491015 chr1 114622458 T C 4.56E-06 Obesity-related traits / / 23251661 rs2774291 chr1 114631167 A G 1.50E-05 Urinary metabolites / / 21572414 rs9659122 chr1 114639504 T C 3.99E-05 Multiple complex diseases SYT6 intron 17554300 rs9659122 chr1 114639504 T C 7.43E-04 Response to TNF antagonist treatment SYT6 intron 21061259 rs9659029 chr1 114643892 C A 9.96E-05 Multiple complex diseases SYT6 intron 17554300 rs9659029 chr1 114643892 C A 6.36E-04 Response to TNF antagonist treatment SYT6 intron 21061259 rs519553 chr1 114655222 A G 2.00E-04 Type 2 diabetes SYT6 intron 17463246 rs519553 chr1 114655222 A G 9.30E-06 Urinary metabolites SYT6 intron 21572414 rs2774307 chr1 114670969 A G 8.33E-04 Type 2 diabetes SYT6 intron 17463246 rs2774307 chr1 114670969 A G 8.00E-06 Breast cancer (prognosis) SYT6 intron 23319801 rs500739 chr1 114677029 G T 6.99E-04 Alzheimer's disease SYT6 intron 17998437 rs529989 chr1 114677948 C A 4.70E-05 Nicotine use SYT6 intron 23942779 rs529989 chr1 114677948 C A 6.00E-06 Illicit drug use SYT6 intron 23942779 rs529989 chr1 114677948 C A 5.22E-05 Inflammation SYT6 intron pha002897 rs11102738 chr1 114677997 T C 9.87E-06 Calcium levels SYT6 intron pha003085 rs12038780 chr1 114681240 C T 4.55E-05 Lung function (forced expiratory volume in 1 second) SYT6 intron pha003103 rs2774298 chr1 114687012 T C 5.74E-04 Suicide attempts in bipolar disorder SYT6 intron 21423239 rs2291369 chr1 114688434 G A 6.99E-04 Suicide attempts in bipolar disorder SYT6 intron 21423239 rs11576155 chr1 114713151 C T 9.25E-04 Multiple complex diseases / / 17554300 rs17535387 chr1 114713359 G T 6.86E-05 Potassium levels / / pha003086 rs2774292 chr1 114715584 G A 3.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs2629817 chr1 114716196 C T 3.77E-05 Anxiety and major depressive disorder / / 24047446 rs6695728 chr1 114720926 G A 1.27E-04 Multiple complex diseases / / 17554300 rs1158366 chr1 114735242 C A 4.19E-05 Amyotrophic lateral sclerosis / / 23624525 rs1158366 chr1 114735242 C A 2.89E-05 Odorant perception / / 23910658 rs6537816 chr1 114750905 A G 7.67E-04 Alzheimer's disease / / 17998437 rs209897 chr1 114752415 G A 8.41E-04 Alzheimer's disease / / 17998437 rs6670053 chr1 114780835 T C 9.83E-04 Multiple complex diseases / / 17554300 rs6671139 chr1 114782179 A G 8.48E-04 Type 2 diabetes / / 17463246 rs6666714 chr1 114794857 C T 2.82E-07 Facial morphology / / 22341974 rs12146102 chr1 114799870 A G 2.74E-07 Facial morphology / / 22341974 rs41470845 chr1 114856929 T A 6.86E-04 Multiple complex diseases / / 17554300 rs10858044 chr1 114869468 C T 4.51E-04 Type 2 diabetes / / 17463246 rs9429542 chr1 114928743 C T 2.55E-04 Multiple complex diseases / / 17554300 rs6537825 chr1 114948281 A G 3.00E-08 Autism TRIM33 missense 24189344 rs11582563 chr1 114959540 G A 1.98E-07 Autism TRIM33 intron 24189344 rs11582563 chr1 114959540 G A 1.28E-05 Heart Failure TRIM33 intron pha002885 rs11585926 chr1 114973690 T C 1.98E-07 Autism TRIM33 intron 24189344 rs11589568 chr1 114996324 T C 1.98E-07 Autism TRIM33 intron 24189344 rs11589568 chr1 114996324 T C 1.28E-05 Heart Failure TRIM33 intron pha002885 rs7511633 chr1 114999277 G A 1.65E-04 Alzheimer's disease (late onset) TRIM33 intron 21379329 rs7511633 chr1 114999277 G A 1.98E-07 Autism TRIM33 intron 24189344 rs6661053 chr1 115039119 T C 1.65E-04 Alzheimer's disease (late onset) TRIM33 intron 21379329 rs6661053 chr1 115039119 T C 1.98E-07 Autism TRIM33 intron 24189344 rs11102800 chr1 115040932 C T 5.82E-08 Autism TRIM33 intron 24189344 rs3827735 chr1 115052708 C A 3.22E-05 Autism TRIM33 intron 24189344 rs3827735 chr1 115052708 C A 6.39E-08 Autism TRIM33 intron 24189344 rs11102807 chr1 115061584 A G 3.67E-04 Alzheimer's disease (late onset) / / 21379329 rs11102807 chr1 115061584 A G 4.06E-08 Autism / / 24189344 rs10858047 chr1 115073876 T C 2.23E-05 Autism / / 24189344 rs11587400 chr1 115079658 C T 8.36E-08 Autism / / 24189344 rs1877455 chr1 115099092 C T 6.72E-08 Autism / / 24189344 rs1877455 chr1 115099092 C T 8.70E-08 Autism / / 24189344 rs7539721 chr1 115171649 C T 2.39E-05 Autism DENND2C intron 24189344 rs10858049 chr1 115196166 A G 9.54E-05 Periodontitis (Chronic) DENND2C intron 25008200 rs6537841 chr1 115200808 A G 2.04E-05 Autism DENND2C intron 24189344 rs761755 chr1 115222434 G A 2.55E-05 Autism AMPD1 intron 24189344 rs12407408 chr1 115234275 G A 4.70E-04 Smoking initiation AMPD1 intron 24665060 rs926938 chr1 115239816 A G 4.00E-08 Autism AMPD1 nearGene-5 24189344 rs11558867 chr1 115259599 G GG,GT 2.77E-08 Autism CSDE1 UTR-3 24189344 rs8453 chr1 115259599 G T 2.77E-08 Autism CSDE1 UTR-3 24189344 rs1065634 chr1 115259768 T C 2.30E-05 Urinary metabolites CSDE1 UTR-3 21572414 rs10489525 chr1 115263685 G A 1.20E-05 Urinary metabolites CSDE1 intron 21572414 rs10489525 chr1 115263685 G A 5.51E-06 Autism CSDE1 intron 24189344 rs10489525 chr1 115263685 G A 9.33E-08 Autism CSDE1 intron 24189344 rs2798657 chr1 115355281 C T 2.96E-05 F-cell distribution / / 21326311 rs360603 chr1 115389709 A G 5.48E-04 Fibrinogen / / 17255346 rs360614 chr1 115399940 T G 3.40E-04 Fibrinogen SYCP1 intron 17255346 rs12741053 chr1 115407873 T C 7.68E-04 Suicide attempts in bipolar disorder SYCP1 intron 21041247 rs12741053 chr1 115407873 T C 9.07E-04 Heart Failure SYCP1 intron pha002885 rs360589 chr1 115470852 T C 1.15E-05 Body Composition SYCP1 intron pha003012 rs360589 chr1 115470852 T C 1.66E-05 Body Mass Index SYCP1 intron pha003021 rs360595 chr1 115473206 G A 9.11E-05 Alcohol consumption SYCP1 intron 23953852 rs360668 chr1 115481598 G A 5.63E-04 Fibrinogen SYCP1 intron 17255346 rs2008873 chr1 115497162 T A 6.43E-04 Suicide attempts in bipolar disorder SYCP1 intron 21041247 rs7526486 chr1 115528289 C T 9.63E-04 Alzheimer's disease SYCP1 intron 24755620 rs1321108 chr1 115572365 A G 2.09E-05 Alcohol consumption TSHB nearGene-5 23953852 rs1998008 chr1 115580540 A C 1.94E-05 Alcohol consumption / / 23953852 rs12046203 chr1 115580731 T C 4.09E-04 Multiple complex diseases / / 17554300 rs11102878 chr1 115590998 T C 6.89E-05 Alcohol consumption TSPAN2 UTR-3 23953852 rs6537850 chr1 115602119 T C 3.87E-04 Multiple complex diseases TSPAN2 intron 17554300 rs1321106 chr1 115609203 C T 2.36E-04 Alzheimer's disease (late onset) TSPAN2 intron 21379329 rs717275 chr1 115610091 T C 6.90E-05 Personality dimensions TSPAN2 intron 18957941 rs1286366 chr1 115617856 T C 1.55E-05 Body Composition TSPAN2 intron pha003012 rs1286366 chr1 115617856 T C 7.57E-06 Body Mass Index TSPAN2 intron pha003021 rs17479252 chr1 115621860 C T 9.95E-04 Alcohol dependence TSPAN2 intron 21314694 rs910623 chr1 115624404 A G 5.80E-04 Obesity-related traits TSPAN2 intron 17903300 rs2144549 chr1 115625348 C T 2.50E-04 Type 2 diabetes and 6 quantitative traits TSPAN2 intron 17848626 rs1966175 chr1 115633281 A G 2.11E-04 Multiple complex diseases / / 17554300 rs10218480 chr1 115666678 T C 7.64E-04 Type 2 diabetes / / 17463246 rs11581510 chr1 115672145 G A 5.70E-04 Alcohol dependence / / 20201924 rs11581510 chr1 115672145 G A 8.40E-04 Alcohol dependence / / 20201924 rs2078371 chr1 115677183 T C 1.10E-05 Migraine / / 21666692 rs2078371 chr1 115677183 T C 1.80E-04 Myasthenia gravis / / 23055271 rs12134493 chr1 115677946 C A 1.19E-05 Migraine - clinic-based / / 23793025 rs12134493 chr1 115677946 C A 5.00E-08 Migraine without aura / / 23793025 rs12134493 chr1 115677946 C A 5.00E-14 Migraine / / 23793025 rs12134493 chr1 115677946 C A 6.19E-04 Migraine with aura / / 23793025 rs6691441 chr1 115722813 C T 5.13E-04 Multiple complex diseases / / 17554300 rs9803637 chr1 115722917 G A 6.98E-04 Multiple complex diseases / / 17554300 rs742872 chr1 115726190 C T 2.60E-04 Multiple complex diseases / / 17554300 rs742871 chr1 115726316 T C 3.86E-04 Multiple complex diseases / / 17554300 rs195207 chr1 115727948 C A 8.50E-05 Alcoholism (heaviness of drinking) / / 21529783 rs9429549 chr1 115733494 C T 2.57E-05 Multiple complex diseases / / 17554300 rs195204 chr1 115734091 T C 9.00E-06 Alcoholism (heaviness of drinking) / / 21529783 rs10489532 chr1 115735049 C T 9.73E-05 Multiple complex diseases / / 17554300 rs10489532 chr1 115735049 C T 2.20E-05 Urinary metabolites / / 21572414 rs973836 chr1 115735898 T A 5.95E-04 Multiple complex diseases / / 17554300 rs12035380 chr1 115739084 C T 0.000706 Asthma / / 22502797 rs11806316 chr1 115753482 G A 0.00000151 Coronary artery disease / / 23202125 rs1040605 chr1 115759830 A G 8.14E-04 Multiple complex diseases / / 17554300 rs971723 chr1 115774074 A C 9.08E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs1294378 chr1 115777538 G A 5.00E-06 Personality dimensions / / 18957941 rs1777719 chr1 115782068 A G 0.000336 Asthma / / 22502797 rs7542599 chr1 115782754 T C 8.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs10489531 chr1 115783002 G A 9.70E-04 Volumetric brain MRI / / 17903297 rs2268793 chr1 115831783 C T 6.78E-04 Suicide attempts in bipolar disorder NGF intron 21423239 rs10489530 chr1 115839680 G A 8.65E-04 Alcohol dependence NGF intron 21314694 rs4573519 chr1 115843087 T C 2.91E-04 Multiple complex diseases NGF intron 17554300 rs4839435 chr1 115858104 G A 8.40E-04 Body mass index NGF intron 21701565 rs7523654 chr1 115861265 T C 7.14E-06 Bipolar disorder and schizophrenia NGF intron 20889312 rs12060354 chr1 115868382 A G 3.29E-04 Multiple complex diseases NGF intron 17554300 rs4839436 chr1 115869089 G C 1.49E-05 Bipolar disorder and schizophrenia NGF intron 20889312 rs10776799 chr1 115873047 G T 6.31E-06 Bipolar disorder and schizophrenia NGF intron 20889312 rs10776799 chr1 115873047 G T 4.84E-05 Bipolar disorder NGF intron 21926972 rs10776799 chr1 115873047 G T 2.52E-05 Major depressive disorder NGF intron 22472876 rs10776799 chr1 115873047 G T 0.00000968 Bipolar disorder NGF intron 23637625 rs4332358 chr1 115875645 C T 5.00E-06 Bipolar disorder and schizophrenia NGF intron 20889312 rs10858075 chr1 115877522 C T 3.37E-04 Epilepsy NGF intron 22116939 rs17033706 chr1 115877624 G A 8.60E-05 Bipolar disorder and schizophrenia NGF intron 20889312 rs17033706 chr1 115877624 G A 8.27E-05 Major depressive disorder NGF intron 22472876 rs10776801 chr1 115882541 A G 4.76E-06 Arthritis (juvenile idiopathic) NGF nearGene-5 22354554 rs12405977 chr1 115895377 A G 8.29E-05 Femoral neck bone geometry / / 22087292 rs12136101 chr1 115910335 T C 1.78E-04 Parkinson's disease / / 17052657 rs7552722 chr1 115921355 T C 7.00E-06 Non-alcoholic fatty liver disease / / 23535911 rs990267 chr1 115941974 T C 5.72E-04 Insulin resistance / / 21901158 rs484395 chr1 115945738 A T 7.94E-05 Insulin resistance / / 21901158 rs1327126 chr1 115973920 C T 8.46E-05 Type 2 diabetes / / 17463246 rs9429756 chr1 116017908 A G 9.66E-05 Post-operative nausea and vomiting / / 21694509 rs9429756 chr1 116017908 A G 8.85E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs17033862 chr1 116033426 C T 3.86E-04 Multiple complex diseases / / 17554300 rs538254 chr1 116072652 C T 4.77E-20 Metabolite levels / / 22286219 rs1409807 chr1 116074080 G A 6.95E-04 Type 2 diabetes / / 17463246 rs3860222 chr1 116136810 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs3860222 chr1 116136810 C T 4.93E-05 Cognitive impairment induced by topiramate / / 22091778 rs10494177 chr1 116155498 T C 7.46E-04 Type 2 diabetes / / 17846124 rs4240548 chr1 116170427 T C 5.53E-05 Cognitive impairment induced by topiramate / / 22091778 rs4839464 chr1 116174524 T C 4.51E-05 Cognitive impairment induced by topiramate / / 22091778 rs17034114 chr1 116200790 C T 1.00E-04 Cognitive impairment induced by topiramate VANGL1 intron 22091778 rs10923133 chr1 116201064 T C 6.80E-05 Personality dimensions VANGL1 intron 18957941 rs10801911 chr1 116203864 A G 4.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VANGL1 intron 20877124 rs10801911 chr1 116203864 A G 4.01E-04 Smoking initiation VANGL1 intron 24665060 rs10923142 chr1 116204661 C T 9.33E-05 Soluble levels of adhesion molecules VANGL1 intron pha003072 rs10801913 chr1 116214279 A G 5.53E-05 Myocardial Infarction VANGL1 intron pha002873 rs12137412 chr1 116214846 C T 2.64E-04 Alzheimer's disease (late onset) VANGL1 intron 21379329 rs6699583 chr1 116223306 T G 4.66E-05 Myocardial Infarction VANGL1 intron pha002873 rs17034230 chr1 116239266 C T 5.79E-04 Depression (quantitative trait) VANGL1 UTR-3 20800221 rs3811006 chr1 116240212 C T 5.85E-04 Depression (quantitative trait) VANGL1 UTR-3 20800221 rs17034260 chr1 116245150 C T 7.01E-04 HIV-1 viral setpoint CASQ2 intron 17641165 rs4423004 chr1 116253342 C A 3.42E-04 Myocardial Infarction CASQ2 intron pha002873 rs3010396 chr1 116273788 A G 3.64E-04 Myocardial Infarction CASQ2 intron pha002873 rs10754356 chr1 116292469 A G 2.50E-05 Urinary metabolites CASQ2 intron 21572414 rs4564143 chr1 116293963 T C 2.50E-05 Urinary metabolites CASQ2 intron 21572414 rs4839478 chr1 116295007 G A 1.38E-04 Lung function (forced expiratory volume in 1 second) CASQ2 intron 17255346 rs4074536 chr1 116310967 T C 2.00E-08 Ventricular conduction CASQ2 missense 21076409 rs12039739 chr1 116333111 C T 3.91E-06 Multiple complex diseases / / 17554300 rs12040622 chr1 116333773 C A 3.06E-05 Cholesterol / / 17255346 rs12040622 chr1 116333773 C A 6.87E-04 Heart Failure / / pha002885 rs10494185 chr1 116337217 T G 1.88E-04 Lung function (forced vital capacity) / / 24023788 rs10494185 chr1 116337217 T G 1.92E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs4272626 chr1 116348427 T C 7.69E-05 Multiple complex diseases / / 17554300 rs2811586 chr1 116368612 C T 1.38E-04 Bipolar disorder / / 18317468 rs10399824 chr1 116371836 A G 3.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs2797198 chr1 116373246 A G 6.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs2811570 chr1 116385122 T C 3.01E-04 Alzheimer's disease (late onset) / / 21379329 rs10923616 chr1 116387058 G A 7.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs10923633 chr1 116391331 A C 9.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs1342723 chr1 116433092 C G 1.22E-04 Insulin resistance / / 21901158 rs1155342 chr1 116453761 A G 5.84E-04 Multiple complex diseases / / 17554300 rs7538141 chr1 116465009 G A 3.27E-04 Multiple complex diseases / / 17554300 rs10923806 chr1 116469435 G A 7.24E-06 Longevity / / 21612516 rs7520415 chr1 116478617 G A 5.55E-04 Multiple complex diseases / / 17554300 rs10923885 chr1 116499503 G C 5.84E-04 Multiple complex diseases / / 17554300 rs10923924 chr1 116521362 C A 1.80E-06 Multiple complex diseases SLC22A15 intron 17554300 rs12071340 chr1 116524839 C T 5.84E-04 Multiple complex diseases SLC22A15 intron 17554300 rs12726299 chr1 116525672 G A 1.50E-07 Autism SLC22A15 intron 22843504 rs1775698 chr1 116537950 G A 1.00E-04 Cognitive impairment induced by topiramate SLC22A15 intron 22091778 rs17035172 chr1 116579016 T G 7.88E-05 Bipolar disorder SLC22A15 intron 19488044 rs12093582 chr1 116704771 G A 5.19E-04 Myocardial Infarction / / pha002873 rs12079216 chr1 116733698 G A 7.58E-06 Multiple complex diseases / / 17554300 rs1884989 chr1 116740195 T C 7.22E-06 Multiple complex diseases / / 17554300 rs4839516 chr1 116740450 C A 4.00E-07 Word reading / / 23738518 rs10923995 chr1 116751013 G A 2.30E-05 Urinary metabolites / / 21572414 rs12125273 chr1 116776537 T C 9.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12121082 chr1 116778098 G A 9.23E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12131904 chr1 116784149 A C 9.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11583110 chr1 116793745 C A 5.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs2184484 chr1 116801420 A G 4.13E-04 Suicide attempts in bipolar disorder / / 21041247 rs12746213 chr1 116810249 C T 2.53E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12091470 chr1 116812681 T G 9.94E-05 Multiple complex diseases / / 17554300 rs12089467 chr1 116819325 C T 2.87E-04 Hearing function / / 17255346 rs6665077 chr1 116880188 G A 6.55E-04 Multiple complex diseases / / 17554300 rs6660918 chr1 116889275 G T 3.77E-06 Multiple complex diseases / / 17554300 rs6660918 chr1 116889275 G T 9.11E-05 Insulin resistance / / 21901158 rs1407717 chr1 116913613 T C 1.39E-08 LDL cholesterol / / 23063622 rs12070283 chr1 116922853 G A 8.97E-04 Insulin resistance ATP1A1 intron 21901158 rs41464748 chr1 116932771 G A 1.63E-04 Type 2 diabetes ATP1A1 intron 17463246 rs12130872 chr1 116933372 G A,C,T 5.57E-04 Smoking cessation ATP1A1 intron 24665060 rs12092869 chr1 116959495 G C 5.00E-04 Insulin resistance ATP1A1OS intron 21901158 rs7544671 chr1 116965558 C T 2.90E-04 Multiple complex diseases / / 17554300 rs17035635 chr1 116965829 T C 1.54E-04 Multiple complex diseases / / 17554300 rs17035658 chr1 116988030 C T 6.87E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs12128828 chr1 116991956 A G 9.31E-04 Multiple complex diseases / / 17554300 rs12067801 chr1 116996509 G A 1.73E-04 Insulin resistance / / 21901158 rs12067801 chr1 116996509 G A 3.03E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs6669460 chr1 117019315 C G 8.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs6671978 chr1 117019614 C T 6.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs12085912 chr1 117019988 G C 8.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs12090008 chr1 117020344 C G 7.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs17035862 chr1 117032885 G C 3.90E-04 Self-reported allergy / / 23817569 rs12025416 chr1 117038287 T C 1.16E-09 Multiple sclerosis LOC100506459 intron 19525953 rs12025416 chr1 117038287 T C 1.00E-07 Multiple sclerosis LOC100506459 intron 21244703 rs10802189 chr1 117056730 C T 7.28E-05 Diabetes Mellitus / / pha003060 rs758518 chr1 117081810 A G 7.63E-05 Diabetes Mellitus CD58 intron pha003059 rs12044852 chr1 117087779 C A 1.90E-05 Multiple sclerosis CD58 intron 17660530 rs1335532 chr1 117100957 A G 1.00E-07 Multiple sclerosis CD58 intron 19525955 rs1335532 chr1 117100957 A G 3.00E-16 Multiple sclerosis CD58 intron 21833088 rs1335532 chr1 117100957 A G 1.51E-09 Multiple sclerosis CD58 intron 22190364 rs1335532 chr1 117100957 A G 1.20E-08 Multiple sclerosis CD58 intron 24234648 rs1335532 chr1 117100957 A G 7.83E-06 Diabetes Mellitus CD58 intron pha003059 rs2300747 chr1 117104215 A G 3.00E-10 Multiple sclerosis CD58 intron 19525953 rs2300747 chr1 117104215 A G 4.40E-10 Multiple sclerosis CD58 intron 21833088 rs2300747 chr1 117104215 A G 6.00E-09 Multiple sclerosis CD58 intron 22190364 rs17036023 chr1 117129711 A G 5.00E-06 Asthma (childhood onset) IGSF3 intron 23829686 rs517857 chr1 117207065 C T 4.34E-04 Response to cytadine analogues (cytosine arabinoside) IGSF3 intron 24483146 rs17400882 chr1 117227332 G C 6.88E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs699710 chr1 117228773 A G 3.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs699710 chr1 117228773 A G 6.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs568359 chr1 117231902 T C 1.69E-04 Schizophrenia / / 20832056 rs2050655 chr1 117235278 T C 4.93E-04 Multiple complex diseases / / 17554300 rs41359245 chr1 117250252 C T 1.36E-04 Multiple complex diseases / / 17554300 rs11586238 chr1 117263138 C G 3.74E-04 Type 2 diabetes / / 17463246 rs11586238 chr1 117263138 C G 4.85E-04 Multiple complex diseases / / 17554300 rs11586238 chr1 117263138 C G 1.30E-09 Celiac disease and Rheumatoid arthritis / / 21383967 rs11586238 chr1 117263138 C G 1.00E-09 Multiple sclerosis / / 22190364 rs11586238 chr1 117263138 C G 1.50E-05 Rheumatoid arthritis / / 22446963 rs11586238 chr1 117263138 C G 3.69E-10 Rheumatoid arthritis / / 23143596 rs624988 chr1 117263790 T C 1.20E-05 Rheumatoid arthritis / / 24390342 rs624988 chr1 117263790 T C 8.00E-10 Rheumatoid arthritis / / 24390342 rs519264 chr1 117271568 T C 6.32E-06 Serum metabolites / / 19043545 rs497573 chr1 117271612 A G 5.66E-06 Serum metabolites / / 19043545 rs11582506 chr1 117277321 A G 8.60E-04 Type 2 diabetes / / 17463246 rs11582506 chr1 117277321 A G 8.16E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs798000 chr1 117280696 C T 0.00000431 Rheumatoid arthritis (CCP positive) / / 23143596 rs798000 chr1 117280696 C T 0.0000062 Rheumatoid arthritis / / 23143596 rs798037 chr1 117308238 A C 0.000442935 Hypertension (early onset hypertension) CD2 intron 22479346 rs699738 chr1 117311147 C A 0.000501718 Hypertension (early onset hypertension) CD2 missense 22479346 rs798023 chr1 117339802 G A 3.55E-04 Multiple complex diseases / / 17554300 rs6428670 chr1 117367190 T C 2.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs7555532 chr1 117398643 A T 7.31E-04 Type 2 diabetes / / 17463246 rs12037202 chr1 117426406 T C 1.21E-04 Body mass index / / 17255346 rs1122726 chr1 117431253 A G 1.17E-04 Multiple complex diseases / / 17554300 rs10923158 chr1 117442421 C T 6.06E-06 Waist-Hip Ratio / / pha003013 rs10923158 chr1 117442421 C T 1.38E-06 Waist-Hip Ratio / / pha003028 rs2182605 chr1 117463537 T C 9.12E-04 Suicide attempts in bipolar disorder PTGFRN intron 21423239 rs2806864 chr1 117469781 C G 6.00E-07 Erectile dysfunction and prostate cancer treatment PTGFRN intron 20932654 rs12078461 chr1 117472049 G A 2.02E-179 Multiple complex diseases PTGFRN intron 17554300 rs2246315 chr1 117477572 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes PTGFRN intron 22628534 rs2806880 chr1 117479245 C T 1.61E-04 Multiple complex diseases PTGFRN intron 17554300 rs6692981 chr1 117479752 T C 3.93E-04 Suicide attempts in bipolar disorder PTGFRN intron 21423239 rs4641299 chr1 117483361 G A 4.27E-04 Schizophrenia(treatment response to risperidone) PTGFRN intron 19850283 rs4433378 chr1 117491123 A G 4.84E-06 Type 2 diabetes PTGFRN intron 17463246 rs12566708 chr1 117499648 A G 5.53E-04 Suicide attempts in bipolar disorder PTGFRN intron 21423239 rs17036665 chr1 117514048 A G 2.94E-04 Body mass index PTGFRN intron 17255346 rs17036665 chr1 117514048 A G 2.48E-04 Type 2 diabetes PTGFRN intron 17463246 rs10801922 chr1 117529458 G A 0.00085104 Sarcoidosis PTGFRN missense 22952805 rs3829881 chr1 117531813 T C 1.05E-04 Acne (severe) PTGFRN UTR-3 24927181 rs3829881 chr1 117531813 T C 5.47E-05 Serum albumin level PTGFRN UTR-3 pha003084 rs10801925 chr1 117541054 C T 9.14E-04 Multiple complex diseases / / 17554300 rs2764851 chr1 117548322 C G 2.17E-04 Alzheimer's disease CD101 intron 17998437 rs2764850 chr1 117550623 A G 7.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CD101 intron 20877124 rs2764850 chr1 117550623 A G 1.83E-04 Acne (severe) CD101 intron 24927181 rs7551890 chr1 117552321 T G 3.23E-05 Multiple complex diseases CD101 intron 17554300 rs6686551 chr1 117573173 T C 1.57E-04 Lung function (forced vital capacity) CD101 intron 24023788 rs6686551 chr1 117573173 T C 4.69E-04 Lung function (forced expiratory volume in 1 second) CD101 intron 24023788 rs1289666 chr1 117638270 C T 4.70E-04 Weight loss (gastric bypass surgery) TTF2 intron 23643386 rs2477719 chr1 117651363 T G 7.53E-04 Lymphocyte counts / / 22286170 rs907661 chr1 117747094 T A 2.10E-05 Urinary metabolites VTCN1 intron 21572414 rs12046117 chr1 117751365 C T 1.00E-06 Arthritis (juvenile idiopathic) VTCN1 intron 19116933 rs41490749 chr1 117751736 G A 6.91E-05 Type 2 diabetes VTCN1 intron 17463246 rs3806373 chr1 117754059 T C 4.38E-04 Alcohol dependence / / 20201924 rs4659229 chr1 117755800 T C 3.98E-04 Type 2 diabetes / / 17463246 rs7537801 chr1 117757911 C G 3.35E-04 Type 2 diabetes / / 17463246 rs1892409 chr1 117759325 C T 5.59E-04 Alcohol dependence / / 20201924 rs12098035 chr1 117759451 C T 5.95E-04 Alcohol dependence / / 20201924 rs10801944 chr1 117761373 G C 1.38E-04 Type 2 diabetes / / 17463246 rs6692758 chr1 117773202 G A 1.72E-04 Type 2 diabetes / / 17463246 rs1146284 chr1 117809327 A G 6.47E-04 Amyotrophic lateral sclerosis / / 23624525 rs10801954 chr1 117809849 A G 6.05E-04 Smoking cessation / / 24665060 rs6683482 chr1 117813173 T A 1.15E-04 Multiple complex diseases / / 17554300 rs12125871 chr1 117816368 A G 7.39E-05 Lung adenocarcinoma / / 19836008 rs7521942 chr1 117817937 C T 1.15E-04 Alzheimer's disease / / 24755620 rs1289817 chr1 117829295 C A 1.39E-04 Alzheimer's disease / / 24755620 rs12142453 chr1 117833996 G T 2.70E-05 Urinary metabolites / / 21572414 rs12122172 chr1 117841156 C T 1.70E-05 Urinary metabolites / / 21572414 rs11577581 chr1 117850886 G A 3.51E-04 Alzheimer's disease / / 24755620 rs12410934 chr1 117854559 T C 1.90E-05 Urinary metabolites / / 21572414 rs12403240 chr1 117862312 A G 6.80E-04 Alzheimer's disease / / 24755620 rs12088312 chr1 117878314 C T 6.93E-04 Alzheimer's disease / / 24755620 rs7514323 chr1 118002719 A G 3.20E-06 Prostate cancer (early onset) MAN1A2 intron 24740154 rs1290539 chr1 118029601 T G 4.11E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) MAN1A2 intron 24023788 rs10923323 chr1 118048968 G A 9.39E-04 Alzheimer's disease MAN1A2 intron 24755620 rs2622366 chr1 118078875 C T 1.40E-05 Prostate cancer / / 18264096 rs10923347 chr1 118118765 G A 6.79E-04 Multiple complex diseases / / 17554300 rs12730116 chr1 118133230 G C 5.04E-04 Type 2 diabetes / / 17463246 rs1808806 chr1 118174222 A G 5.91E-04 Multiple complex diseases / / 17554300 rs319506 chr1 118185332 T C 3.86E-04 Type 2 diabetes / / 17463246 rs319498 chr1 118194657 A G 6.10E-04 Type 2 diabetes / / 17463246 rs377875 chr1 118201128 T C 5.35E-04 Multiple complex diseases / / 17554300 rs377875 chr1 118201128 T C 6.11E-04 Smoking cessation / / 24665060 rs7549770 chr1 118209904 G A 1.90E-04 Multiple complex diseases / / 17554300 rs963264 chr1 118225110 A G 6.25E-04 Type 2 diabetes / / 17463246 rs965574 chr1 118225308 C G 6.70E-04 Type 2 diabetes / / 17463246 rs965574 chr1 118225308 C G 1.46E-04 Multiple complex diseases / / 17554300 rs731017 chr1 118225681 T C 5.22E-04 Type 2 diabetes / / 17463246 rs731017 chr1 118225681 T C 1.21E-04 Multiple complex diseases / / 17554300 rs10754358 chr1 118233846 C T 1.96E-05 Reading and spelling / / 23738518 rs319490 chr1 118281894 G A 6.06E-04 Type 2 diabetes / / 17463246 rs11586992 chr1 118288903 G A 2.16E-04 Alzheimer's disease / / 22005930 rs12740113 chr1 118292742 C T 1.37E-04 Alzheimer's disease / / 22005930 rs319464 chr1 118293093 A G 3.16E-05 Fibrinogen / / 17255346 rs12731636 chr1 118296638 G T 1.17E-04 Alzheimer's disease / / 22005930 rs12408188 chr1 118296695 A G 1.41E-04 Alzheimer's disease / / 22005930 rs319471 chr1 118297105 T C 2.96E-04 Fibrinogen / / 17255346 rs12725531 chr1 118298914 A T 3.85E-04 Alzheimer's disease / / 22005930 rs379058 chr1 118301575 T A 1.15E-04 Alzheimer's disease / / 22005930 rs1371 chr1 118406208 A C 5.08E-04 Suicide attempts in bipolar disorder GDAP2 UTR-3 21423239 rs77073478 chr1 118441771 G A 0.000015 Breast cancer(er negative) GDAP2 missense 23555315 rs749003 chr1 118531980 C T 4.81E-04 Premature ovarian failure SPAG17 intron 19508998 rs4144543 chr1 118536585 G A 6.99E-04 Alzheimer's disease SPAG17 intron 24755620 rs6428727 chr1 118575757 T C 6.14E-04 Alzheimer's disease SPAG17 intron 24755620 rs10733099 chr1 118577067 G T 4.37E-04 Alzheimer's disease SPAG17 intron 24755620 rs7551906 chr1 118689892 T C 4.12E-05 Multiple complex diseases SPAG17 intron 17554300 rs6700302 chr1 118699633 C G 2.61E-04 Alzheimer's disease SPAG17 intron 24755620 rs10923505 chr1 118730945 G A 9.83E-04 Alzheimer's disease / / 24755620 rs10923507 chr1 118731761 C T 3.72E-04 Alzheimer's disease / / 24755620 rs6685352 chr1 118732429 G A 3.73E-04 Alzheimer's disease / / 24755620 rs1777268 chr1 118739713 T G 1.18E-04 Multiple complex diseases / / 17554300 rs1782411 chr1 118740017 A G 1.18E-04 Multiple complex diseases / / 17554300 rs9661113 chr1 118799439 T C 2.94E-04 Coronary heart disease / / 21606135 rs7551954 chr1 118799927 C T 3.21E-04 Coronary heart disease / / 21606135 rs10802017 chr1 118810834 T C 2.41E-04 Coronary heart disease / / 21606135 rs7527203 chr1 118816729 C T 2.00E-06 Obesity-related traits / / 23251661 rs7515420 chr1 118823147 A G 3.25E-04 Coronary heart disease / / 21606135 rs1938283 chr1 118831937 C A 3.31E-04 Coronary heart disease / / 21606135 rs1938275 chr1 118841141 T C 7.59E-06 Lipoproteins / / pha003079 rs11576263 chr1 118842089 T C 3.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs10923537 chr1 118846667 A G 5.58E-05 Lipoproteins / / pha003079 rs7513580 chr1 118849909 G A 2.65E-05 Multiple complex diseases / / 17554300 rs9428104 chr1 118855587 A G 6.00E-23 Height / / 20881960 rs7534091 chr1 118864616 A G 2.00E-16 Height / / 23563607 rs4375253 chr1 118864968 C T 8.11E-05 Alcohol dependence / / 21703634 rs17038182 chr1 118868405 G C 1.47E-04 Multiple complex diseases / / 17554300 rs17038182 chr1 118868405 G C 5.00E-07 Height / / 19396169 rs10802023 chr1 118878656 T C 2.18E-05 Alcohol dependence / / 21703634 rs12083887 chr1 118881689 A G 1.85E-04 Alzheimer's disease (late onset) / / 20885792 rs12735613 chr1 118883973 G A 4.00E-11 Height / / 18391952 rs12735613 chr1 118883973 G A 1.70E-05 Height / / 19396169 rs12735613 chr1 118883973 G A 1.94E-05 Height / / 19893584 rs2474937 chr1 118902978 A G 8.00E-10 Congenital heart malformation / / 23708190 rs10923556 chr1 118903196 C T 8.77E-05 Alcohol dependence / / 21703634 rs12135821 chr1 118943449 G A 9.13E-05 Alzheimer's disease (late onset) / / 20885792 rs1146338 chr1 118987451 T C 1.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs1146337 chr1 118987765 A G 1.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs1213994 chr1 118989522 A G 1.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs2798449 chr1 118992961 G A 9.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs1146335 chr1 119002799 C T 6.17E-04 Schizophrenia / / 19197363 rs1146333 chr1 119005483 C A 2.94E-04 Multiple complex diseases / / 17554300 rs1146324 chr1 119013403 T C 4.32E-04 Schizophrenia / / 19197363 rs1146320 chr1 119016240 A C 3.79E-04 Schizophrenia / / 19197363 rs1229119 chr1 119023640 C T 2.91E-05 Schizophrenia / / 19197363 rs1146313 chr1 119026090 C T 2.16E-05 Schizophrenia / / 19197363 rs12408596 chr1 119034534 T C 2.78E-04 Schizophrenia / / 19197363 rs12145150 chr1 119042243 A C 1.49E-05 Alzheimer's disease (late onset) / / 21379329 rs4659090 chr1 119068372 C T 8.62E-04 Type 2 diabetes / / 17463246 rs4659090 chr1 119068372 C T 4.79E-04 Alzheimer's disease / / 24755620 rs4659091 chr1 119068639 G T 4.79E-04 Alzheimer's disease / / 24755620 rs6660988 chr1 119068677 C T 7.98E-04 Multiple complex diseases / / 17554300 rs1830853 chr1 119069110 T C 7.33E-05 Alzheimer's disease / / 24755620 rs10923586 chr1 119069342 T C 5.11E-04 Alzheimer's disease / / 24755620 rs942584 chr1 119076921 C A 2.05E-04 Alzheimer's disease / / 24755620 rs6428751 chr1 119079566 A G 4.08E-04 Multiple complex diseases / / 17554300 rs6428751 chr1 119079566 A G 8.39E-04 Alzheimer's disease / / 24755620 rs12134541 chr1 119084491 A C 3.52E-04 Multiple complex diseases / / 17554300 rs4590660 chr1 119085082 G A 5.57E-04 Multiple complex diseases / / 17554300 rs11590971 chr1 119099887 T C 4.44E-04 Multiple complex diseases / / 17554300 rs11590559 chr1 119099981 A G 8.69E-04 Alzheimer's disease / / 24755620 rs12022971 chr1 119101922 T C 3.65E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17185776 chr1 119102839 T C 5.95E-06 Asthma / / 21790008 rs17257972 chr1 119106612 G A 1.00E-04 Schizophrenia / / 19197363 rs1936068 chr1 119108658 T C 5.05E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10754383 chr1 119117474 C A 4.97E-06 Relative hand skill in reading disability / / 24068947 rs10802044 chr1 119117589 G C 1.00E-04 Prostate cancer / / 21743057 rs10802044 chr1 119117589 G C 9.47E-05 Relative hand skill in reading disability / / 24068947 rs1343298 chr1 119123811 T C 7.45E-06 Relative hand skill in reading disability / / 24068947 rs1911166 chr1 119126331 T C 7.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1911166 chr1 119126331 T C 4.38E-06 Relative hand skill in reading disability / / 24068947 rs4329498 chr1 119133609 T C 1.76E-04 Schizophrenia / / 19197363 rs4659105 chr1 119138227 A G 8.01E-06 Relative hand skill in reading disability / / 24068947 rs12138163 chr1 119139697 G A 4.21E-06 Relative hand skill in reading disability / / 24068947 rs4658990 chr1 119140388 G A 4.20E-06 Relative hand skill in reading disability / / 24068947 rs4659109 chr1 119142879 C A 4.08E-06 Relative hand skill in reading disability / / 24068947 rs4463652 chr1 119143773 A G 4.17E-06 Relative hand skill in reading disability / / 24068947 rs10802047 chr1 119144432 A T 2.00E-06 Relative hand skill in reading disability / / 24068947 rs10802047 chr1 119144432 A T 2.37E-06 Relative hand skill in reading disability / / 24068947 rs12137431 chr1 119146884 T C 4.16E-06 Relative hand skill in reading disability / / 24068947 rs12120076 chr1 119148939 C G 4.22E-06 Relative hand skill in reading disability / / 24068947 rs10802049 chr1 119149428 C T 4.15E-06 Relative hand skill in reading disability / / 24068947 rs4659111 chr1 119150184 G T 4.24E-06 Relative hand skill in reading disability / / 24068947 rs10923630 chr1 119152617 A G 4.17E-06 Relative hand skill in reading disability / / 24068947 rs10157240 chr1 119153953 G T 5.02E-06 Relative hand skill in reading disability / / 24068947 rs1742854 chr1 119157211 G T 4.19E-06 Relative hand skill in reading disability / / 24068947 rs6685605 chr1 119159490 T G 2.82E-05 Relative hand skill in reading disability / / 24068947 rs10923636 chr1 119185080 C T 2.04E-04 Multiple complex diseases / / 17554300 rs10923636 chr1 119185080 C T 1.10E-05 Urinary metabolites / / 21572414 rs2360627 chr1 119188329 C T 2.50E-05 Urinary metabolites / / 21572414 rs12143914 chr1 119203300 C T 2.90E-05 Parkinson's disease (age of onset) / / 19772629 rs7521782 chr1 119253471 C T 3.28E-04 Alzheimer's disease (late onset) / / 21379329 rs4144542 chr1 119259807 G T 2.88E-04 Alzheimer's disease (late onset) / / 21379329 rs4144542 chr1 119259807 G T 8.90E-06 Urinary metabolites / / 21572414 rs6688928 chr1 119261698 A G 9.55E-05 Relative hand skill in reading disability / / 24068947 rs10923658 chr1 119272779 G A 4.34E-04 Schizophrenia / / 19197363 rs17022367 chr1 119282172 G A 5.06E-05 Relative hand skill in reading disability / / 24068947 rs369417542 chr1 119282172 G GA 5.06E-05 Relative hand skill in reading disability / / 24068947 rs12039075 chr1 119285701 A G 5.41E-05 Relative hand skill in reading disability / / 24068947 rs1570816 chr1 119291382 A G 1.62E-04 Alzheimer's disease (late onset) / / 21379329 rs17185832 chr1 119293640 A G 1.02E-04 Premature ovarian failure / / 19508998 rs12063988 chr1 119295915 C T 1.68E-04 Alzheimer's disease (late onset) / / 21379329 rs10923668 chr1 119296728 C T 1.00E-05 Urinary metabolites / / 21572414 rs9787117 chr1 119296803 C G 8.40E-06 Urinary metabolites / / 21572414 rs2764473 chr1 119300747 T C 2.00E-05 Urinary metabolites / / 21572414 rs10923673 chr1 119316263 T G 3.06E-04 Longevity / / 22279548 rs1853774 chr1 119318683 C T 4.89E-04 Schizophrenia / / 19197363 rs4659120 chr1 119319805 A G 1.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2485961 chr1 119344903 T C 7.81E-04 Schizophrenia / / 19197363 rs1766799 chr1 119367975 T C 8.15E-05 Relative hand skill in reading disability / / 24068947 rs1766803 chr1 119383818 T C 1.67E-04 Schizophrenia / / 19197363 rs868157 chr1 119392083 T G 1.59E-04 Multiple complex diseases / / 17554300 rs1766807 chr1 119406760 A G 6.56E-04 Schizophrenia / / 19197363 rs7552120 chr1 119419556 C T 4.81E-05 Multiple complex diseases / / 17554300 rs1014098 chr1 119458215 C T 4.28E-04 Multiple complex diseases TBX15 intron 17554300 rs10923702 chr1 119485466 C T 9.76E-04 Alzheimer's disease TBX15 intron 22005930 rs6701231 chr1 119495661 C G 4.13E-09 Waist-hip ratio TBX15 intron 20935629 rs1155949 chr1 119496579 C T 6.07E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TBX15 intron 24023788 rs78411379 chr1 119496772 A G 0.0000962 Menopause (age at onset) TBX15 intron 23424626 rs12143789 chr1 119497154 G C 3.70E-04 Multiple complex diseases TBX15 intron 17554300 rs984222 chr1 119503843 C G 9.00E-25 Waist-hip ratio TBX15 intron 20935629 rs10923714 chr1 119512913 G A 7.49E-04 Alcohol dependence TBX15 intron 21314694 rs10923714 chr1 119512913 G A 6.80E-05 Waist-hip ratio TBX15 intron 23966867 rs10923714 chr1 119512913 G A 4.04E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TBX15 intron 24023788 rs12742627 chr1 119525788 G A 2.14E-04 Height TBX15 intron 17255346 rs7545737 chr1 119533823 A G 4.64E-05 Brain structure TBX15 nearGene-5 22504417 rs7545737 chr1 119533823 A G 2.58E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TBX15 nearGene-5 24023788 rs1409158 chr1 119538890 C T 8.99E-04 Multiple complex diseases / / 17554300 rs1409158 chr1 119538890 C T 6.86E-09 Lymphocyte counts / / 22286170 rs7522839 chr1 119542855 G T 6.82E-06 Waist-hip ratio / / 20935629 rs2765542 chr1 119560326 T A 5.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17185996 chr1 119608732 T C 2.43E-06 Waist-hip ratio WARS2 intron 20935629 rs17023211 chr1 119624967 C T 1.41E-04 Multiple complex diseases WARS2 intron 17554300 rs10494221 chr1 119634224 C T 3.65E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) WARS2 intron 17982456 rs1341580 chr1 119657057 T G 4.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WARS2 intron 20877124 rs6677940 chr1 119659849 A G 1.77E-04 Cholesterol WARS2 intron 17255346 rs4387216 chr1 119680296 C T 5.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WARS2 intron 20877124 rs116411856 chr1 119701541 G A 0.0000816 Menopause (age at onset) / / 23424626 rs868675 chr1 119773596 T C 6.28E-04 Heart Failure / / pha002884 rs12730226 chr1 119789289 C T 4.92E-05 Post-operative nausea and vomiting / / 21694509 rs1341797 chr1 119795133 G A 7.00E-05 Alcohol dependence / / 20201924 rs1341797 chr1 119795133 G A 6.95E-05 Alcoholism / / pha002892 rs35171095 chr1 119797210 C G 5.25E-04 Type 2 diabetes / / 17463246 rs11580295 chr1 119836236 C T 7.07E-05 Lung adenocarcinoma / / 19836008 rs11580295 chr1 119836236 C T 4.36E-05 Partial epilepsies / / 20522523 rs12040905 chr1 119853231 C G 7.36E-05 Aging (time to event) / / 21782286 rs1891224 chr1 119854742 G A 1.90E-06 Alcohol dependence / / 22096494 rs699770 chr1 119860975 A G 1.04E-04 Alzheimer's disease / / 17998437 rs699771 chr1 119871977 C A,G,T 8.87E-06 Alcohol dependence / / 20202923 rs699771 chr1 119871977 C A,G,T 2.80E-05 Alcohol dependence / / 21956439 rs699771 chr1 119871977 C A,G,T 1.70E-06 Alcohol dependence / / 22096494 rs699771 chr1 119871977 C A,G,T 3.40E-06 Alcohol and nictotine co-dependence / / 22488850 rs838528 chr1 119899035 G T 9.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3753264 chr1 119909514 A G 5.25E-05 HIV-1 progression to AIDS and death HAO2 nearGene-5 21811574 rs2005390 chr1 119940381 T G 8.90E-04 Stroke / / pha002887 rs12141041 chr1 119952776 T C 2.00E-12 Blood metabolite levels / / 24816252 rs17023793 chr1 120019818 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs41415744 chr1 120021211 G T 8.82E-04 Multiple complex diseases / / 17554300 rs2011191 chr1 120023888 G A 9.50E-04 Multiple complex diseases / / 17554300 rs911244 chr1 120023971 C T 9.52E-04 Multiple complex diseases / / 17554300 rs911244 chr1 120023971 C T 7.36E-05 Bipolar disorder and schizophrenia / / 20889312 rs4567318 chr1 120030539 G C 4.75E-04 Multiple complex diseases / / 17554300 rs10802112 chr1 120091434 T C 2.25E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4659200 chr1 120099980 C T 7.00E-04 Obesity-related traits / / 17903300 rs41427946 chr1 120109260 C T 4.22E-26 Narcolepsy / / 19629137 rs4659203 chr1 120110104 T C 1.11E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10923875 chr1 120150949 T C 1.29E-04 Type 2 diabetes / / 17463246 rs10923875 chr1 120150949 T C 2.43E-04 Multiple complex diseases / / 17554300 rs347905 chr1 120180034 A G 2.09E-04 Birth weight ZNF697 intron 17255346 rs347905 chr1 120180034 A G 8.11E-05 Chronic Hepatitis C infection ZNF697 intron 21725309 rs481357 chr1 120200843 T C 7.19E-05 Aging (time to event) / / 21782286 rs541503 chr1 120208297 T C 3.00E-12 Serum metabolites / / 20037589 rs1163251 chr1 120209755 T C 7.00E-27 Blood metabolite levels / / 24816252 rs12025390 chr1 120216287 C T 5.40E-05 Cognitive performance / / 19734545 rs478093 chr1 120255126 A G 2.00E-14 Metabolite levels (Glycine metabolism) PHGDH intron 23378610 rs477992 chr1 120257576 A G 5.99E-05 Serum metabolites PHGDH intron 19043545 rs477992 chr1 120257576 A G 3.00E-14 Metabolic traits PHGDH intron 21886157 rs942835 chr1 120263018 T C 4.50E-04 Coronary heart disease PHGDH intron 21606135 rs894079 chr1 120263657 A G 7.55E-05 Coronary heart disease PHGDH intron 21606135 rs920513 chr1 120272606 C A 6.94E-04 Multiple complex diseases PHGDH intron 17554300 rs17024167 chr1 120282232 T C 1.46E-05 Tunica Media PHGDH intron pha003034 rs17258425 chr1 120286863 A G 5.51E-05 Multiple complex diseases PHGDH nearGene-3 17554300 rs608358 chr1 120289407 C A 8.83E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs532208 chr1 120292279 G T 5.65E-05 Serum metabolites HMGCS2 intron 19043545 rs4659233 chr1 120303332 G A 5.99E-04 Smoking initiation HMGCS2 intron 24665060 rs12562383 chr1 120305525 A T 1.82E-05 Serum metabolites HMGCS2 intron 19043545 rs3790692 chr1 120309868 A G 3.15E-05 Serum metabolites HMGCS2 intron 19043545 rs935059 chr1 120333201 A T 4.86E-05 Serum metabolites / / 19043545 rs947268 chr1 120376477 C G 7.90E-04 Type 2 diabetes / / 17846126 rs140014891 chr1 120384066 C T 0.00048 Breast cancer NBPF7 missense 23555315 rs10923915 chr1 120404592 G A 9.96E-05 Multiple complex diseases / / 17554300 rs2843027 chr1 120425577 A C 4.73E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7547168 chr1 120435163 A G 7.36E-05 Magnesium levels / / pha003092 rs2793823 chr1 120437718 G A 1.05E-04 Type 2 diabetes ADAM30 cds-synon 17463246 rs2641352 chr1 120446063 T C 0.000031 Type 2 diabetes (females) / / 22885922 rs3897478 chr1 120451190 T C 2.00E-11 Crohn's disease / / 23128233 rs835575 chr1 120456563 G A,C,T 9.25E-06 Type 2 diabetes NOTCH2 UTR-3 17463246 rs10127888 chr1 120498250 C G 1.00E-05 Type 2 diabetes NOTCH2 intron 17463246 rs17186372 chr1 120500951 C G 0.0002 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 NOTCH2 intron 21873659 rs2934381 chr1 120506108 G A 8.43E-06 Type 2 diabetes NOTCH2 intron 17463246 rs2453044 chr1 120508524 A G 1.37E-05 Type 2 diabetes NOTCH2 intron 17463246 rs10923931 chr1 120517959 G T 8.70E-08 Type 2 diabetes NOTCH2 intron 17463246 rs10923931 chr1 120517959 G T 4.26E-05 Multiple complex diseases NOTCH2 intron 17554300 rs10923931 chr1 120517959 G T 4.00E-08 Type 2 diabetes NOTCH2 intron 18372903 rs10923931 chr1 120517959 G T 4.00E-08 Coronary heart disease NOTCH2 intron 21347282 rs10923931 chr1 120517959 G T 4.00E-08 Type 2 diabetes NOTCH2 intron 21647700 rs10923931 chr1 120517959 G T 0.000013 Type 2 diabetes NOTCH2 intron 22885922 rs10923931 chr1 120517959 G T 4.00E-08 Type 2 diabetes NOTCH2 intron 23300278 rs2793831 chr1 120523902 T C 3.68E-06 Type 2 diabetes NOTCH2 intron 17463246 rs6683357 chr1 121164607 G A 2.56E-05 Alzheimer's disease (late onset) / / 21379329 rs6600671 chr1 121200490 T G 6.00E-07 Hip geometry / / 17903296 rs6600671 chr1 121200490 T G 6.64E-04 Alzheimer's disease / / 24755620 rs2319969 chr1 121207335 C T 8.21E-04 Alzheimer's disease / / 24755620 rs2319971 chr1 121226982 G T 4.09E-04 Alzheimer's disease / / 24755620 rs4147001 chr1 121236110 T C 4.67E-05 Cognitive test performance / / 20125193 rs41500448 chr1 121238279 A G 4.38E-04 Multiple complex diseases / / 17554300 rs11249433 chr1 121280613 A G 2.30E-05 Type 2 diabetes EMBP1 intron 17293876 rs11249433 chr1 121280613 A G 2.30E-05 Type 2 diabetes EMBP1 intron 19184112 rs11249433 chr1 121280613 A G 7.00E-10 Breast cancer EMBP1 intron 19330030 rs11249433 chr1 121280613 A G 7.00E-10 Nasopharyngeal carcinoma EMBP1 intron 20512145 rs11249433 chr1 121280613 A G 2.00E-26 Breast cancer EMBP1 intron 23535729 rs11249431 chr1 121286203 A C,G,T 4.70E-05 Type 2 diabetes EMBP1 intron 17293876 rs11249431 chr1 121286203 A C,G,T 4.70E-05 Type 2 diabetes EMBP1 intron 19184112 rs11249431 chr1 121286203 A C,G,T 4.64E-04 Alzheimer's disease (late onset) EMBP1 intron 21379329 rs11249395 chr1 121311799 G A 3.02E-04 Alzheimer's disease (late onset) / / 21379329 rs141066291 chr1 144922638 T A 0.000079 Breast cancer(er negative) PDE4DIP missense 23555315 rs61805374 chr1 144931387 T G 0.00031 Prostate cancer PDE4DIP missense 23555315 rs1778596 chr1 144991278 T A 8.66E-15 Gender PDE4DIP intron 22362730 rs587667473 chr1 144992181 A C 2.00E-06 Capecitabine sensitivity PDE4DIP intron 22864933 rs12136740 chr1 145104261 T G 3.84E-04 Coronary heart disease SEC22B intron 21971053 rs10797649 chr1 145394955 C A 4.28E-05 Taste perception / / 22132133 rs12091564 chr1 145395604 T C 2.00E-07 Coronary heart disease / / 21626137 rs10218795 chr1 145416056 C T 2.00E-07 Coronary heart disease HFE2 intron 21626137 rs6661602 chr1 145428296 C T 2.76E-04 Alcohol dependence / / 21314694 rs2031370 chr1 145471860 T C 2.63E-04 Amyotrophic lateral sclerosis (sporadic) ANKRD34A intron 24529757 rs16827018 chr1 145545225 T G 1.27E-04 Celiac disease / / 23936387 rs720899 chr1 145550922 A C,G,T 3.58E-05 Cognitive test performance ANKRD35 intron 20125193 rs10494240 chr1 145551515 A G 9.70E-04 Multiple complex diseases ANKRD35 intron 17554300 rs12125340 chr1 145554450 T C 3.36E-04 Multiple complex diseases ANKRD35 intron 17554300 rs143087712 chr1 145562149 C A 0.000093 Breast cancer(er negative) ANKRD35 missense 23555315 rs6424380 chr1 145571398 T C 1.25E-04 Alcohol dependence / / 21314694 rs17352344 chr1 145586048 T C 5.60E-06 Contrast sensitivity PIAS3 UTR-3 24152035 rs2004659 chr1 145588184 T A,C,G 3.35E-08 Urate levels NUDT17 intron 23263486 rs2004659 chr1 145588184 T A,C,G 3.90E-05 Epilepsy (remission after treatment) NUDT17 intron 23962720 rs9286836 chr1 145588536 C T 3.39E-05 Epilepsy (remission after treatment) NUDT17 intron 23962720 rs9729027 chr1 145592073 A T 2.58E-05 Epilepsy (remission after treatment) / / 23962720 rs1887806 chr1 145594799 C T 2.69E-05 Epilepsy (remission after treatment) POLR3C intron 23962720 rs913513 chr1 145595423 G A 2.70E-05 Epilepsy (remission after treatment) POLR3C intron 23962720 rs2018027 chr1 145595820 A G 2.70E-05 Epilepsy (remission after treatment) POLR3C intron 23962720 rs9728345 chr1 145597417 C A 3.15E-08 Urate levels POLR3C intron 23263486 rs9728345 chr1 145597417 C A 2.72E-05 Epilepsy (remission after treatment) POLR3C intron 23962720 rs11587821 chr1 145599038 G T 2.01E-08 Urate levels POLR3C intron 23263486 rs11587821 chr1 145599038 G T 2.74E-05 Epilepsy (remission after treatment) POLR3C intron 23962720 rs10752826 chr1 145602791 C G 1.89E-08 Urate levels POLR3C intron 23263486 rs10752826 chr1 145602791 C G 2.78E-05 Epilepsy (remission after treatment) POLR3C intron 23962720 rs4970859 chr1 145605318 C T 3.57E-08 Urate levels POLR3C intron 23263486 rs4970859 chr1 145605318 C T 2.80E-05 Epilepsy (remission after treatment) POLR3C intron 23962720 rs12402787 chr1 145609971 T C 1.69E-05 Epilepsy (remission after treatment) POLR3C intron 23962720 rs61816194 chr1 145614468 C T 2.65E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs12732381 chr1 145630536 T A 2.52E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs17354594 chr1 145632500 A G 3.63E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs12402867 chr1 145636226 G A 1.96E-08 Urate levels RNF115 intron 23263486 rs12402867 chr1 145636226 G A 2.62E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs12724816 chr1 145639324 G T 1.87E-08 Urate levels RNF115 intron 23263486 rs12724816 chr1 145639324 G T 2.67E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs11583404 chr1 145640157 T C 2.63E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs12405132 chr1 145644984 C T 3.01E-08 Urate levels RNF115 intron 23263486 rs12405132 chr1 145644984 C T 2.45E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs12744221 chr1 145645606 C T 6.00E-06 Epilepsy (remission after treatment) RNF115 intron 23962720 rs12729321 chr1 145645820 G T 2.44E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs2040085 chr1 145651861 G A 2.26E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs2040086 chr1 145651876 C A 2.56E-08 Urate levels RNF115 intron 23263486 rs2040086 chr1 145651876 C A 2.26E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs2799107 chr1 145660663 G A 2.12E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs12725120 chr1 145661313 C T 2.12E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs2318299 chr1 145662666 T C 1.56E-08 Urate levels RNF115 intron 23263486 rs2318299 chr1 145662666 T C 2.12E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs718942 chr1 145662853 T A 2.12E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs34958017 chr1 145666719 G A 1.27E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs12728500 chr1 145667088 C A 2.12E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs1680663 chr1 145671455 C G 2.12E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs35687015 chr1 145674149 T A 2.12E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs112745056 chr1 145674825 T A 3.49E-06 Osteoarthritis RNF115 intron 21871595 rs11591191 chr1 145675931 T C 2.09E-08 Urate levels RNF115 intron 23263486 rs11591191 chr1 145675931 T C 2.12E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs12750384 chr1 145681484 T C 1.36E-08 Urate levels RNF115 intron 23263486 rs12750384 chr1 145681484 T C 2.03E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs34695381 chr1 145683334 G C 2.09E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs2624756 chr1 145687529 G A 9.08E-05 Epilepsy (remission after treatment) RNF115 intron 23962720 rs17354678 chr1 145689271 A G 1.70E-09 Urate levels / / 23263486 rs17354678 chr1 145689271 A G 9.37E-05 Epilepsy (remission after treatment) / / 23962720 rs12123298 chr1 145690472 C A,G,T 1.55E-09 Urate levels / / 23263486 rs17352469 chr1 145693383 A G 4.51E-09 Urate levels / / 23263486 rs17352469 chr1 145693383 A G 2.90E-05 Epilepsy (remission after treatment) / / 23962720 rs2231375 chr1 145696694 G A 3.06E-09 Urate levels CD160 intron 23263486 rs2231375 chr1 145696694 G A 2.86E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs1778523 chr1 145698023 C G 2.86E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs1471634 chr1 145702115 C T 2.84E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs1023945 chr1 145703115 T C 2.51E-08 Urate levels CD160 intron 23263486 rs1970612 chr1 145703590 G T 2.81E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs1552172 chr1 145704759 T A 3.91E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs12755149 chr1 145704918 T A 2.80E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs1471628 chr1 145707057 A T 9.51E-09 Urate levels CD160 intron 23263486 rs1471629 chr1 145707240 C A 2.72E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs1471630 chr1 145707297 A G 2.38E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs2449411 chr1 145708698 T C 3.17E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs4970874 chr1 145709394 T C 1.81E-10 Urate levels CD160 intron 23263486 rs4970874 chr1 145709394 T C 2.34E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs35880546 chr1 145713071 T C 2.18E-05 Epilepsy (remission after treatment) CD160 intron 23962720 rs744877 chr1 145714376 G T 6.82E-09 Urate levels CD160 intron 23263486 rs9728526 chr1 145716763 G A 3.68E-08 Urate levels / / 23263486 rs3753436 chr1 145718113 A G 2.36E-08 Urate levels / / 23263486 rs10910845 chr1 145723120 A C 1.57E-08 Uric acid levels / / 19503597 rs10910845 chr1 145723120 A C 3.90E-08 Urate levels / / 20884846 rs10910845 chr1 145723120 A C 4.87E-25 Urate levels / / 23263486 rs1967017 chr1 145723645 T C 5.00E-09 Uric acid levels / / 19503597 rs1967017 chr1 145723645 T C 4.00E-08 Urate levels / / 20884846 rs1967017 chr1 145723645 T C 3.16E-26 Urate levels / / 23263486 rs1471633 chr1 145723739 A C 3.77E-09 Uric acid levels / / 19503597 rs1471633 chr1 145723739 A C 3.60E-08 Urate levels / / 20884846 rs1471633 chr1 145723739 A C 1.00E-29 Urate levels / / 23263486 rs12129861 chr1 145725689 G A 3.00E-09 Uric acid levels / / 19503597 rs12129861 chr1 145725689 G A 5.38E-20 Urate levels / / 23263486 rs900347 chr1 145726727 A G 2.14E-18 Urate levels / / 23263486 rs1797052 chr1 145727683 C T 8.00E-09 Contrast sensitivity PDZK1 UTR-5 24152035 rs1298954 chr1 145730160 A G 7.16E-19 Urate levels PDZK1 intron 23263486 rs9659930 chr1 145730701 G C 7.32E-14 Urate levels PDZK1 intron 23263486 rs882210 chr1 145732946 G C 1.72E-08 Urate levels PDZK1 intron 23263486 rs9728619 chr1 145736438 T C 3.99E-08 Uric acid levels PDZK1 intron 19503597 rs9728619 chr1 145736438 T C 3.11E-21 Urate levels PDZK1 intron 23263486 rs2355388 chr1 146499296 C T 3.40E-05 Serum metabolites LOC728989 intron 19043545 rs1853782 chr1 146508774 C T 0.0000451 Salmonella-induced pyroptosis LOC728989 intron 22837397 rs12122100 chr1 146508934 C T 1.00E-06 HIV-1 control LOC728989 intron 20041166 rs6665411 chr1 146547095 G A 5.10E-06 HIV-1 control / / 20041166 rs11239930 chr1 146560564 G A 2.00E-06 AIDS progression / / 21502085 rs6593732 chr1 146566324 T C 7.63E-04 Type 2 diabetes / / 17463246 rs17359526 chr1 146580479 T C 9.82E-04 Type 2 diabetes / / 17463246 rs6693631 chr1 146580724 T C 9.82E-04 Type 2 diabetes / / 17463246 rs75365816 chr1 146593915 G A 0.00086333 Sarcoidosis / / 22952805 rs79365757 chr1 146593944 G C 0.00087562 Sarcoidosis / / 22952805 rs111666024 chr1 146594841 G T 0.00088791 Sarcoidosis / / 22952805 rs12065005 chr1 146600482 A G 4.71E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11239934 chr1 146604423 G C 3.57E-05 Multiple complex diseases / / 17554300 rs1348316 chr1 146643555 A G 1.23E-05 Waist-Hip Ratio PRKAB2 intron pha003029 rs2077749 chr1 146652637 A G 3.75E-05 Multiple complex diseases LOC100505794 intron 17554300 rs7532458 chr1 146676901 A G 5.39E-06 Multiple complex diseases FMO5 intron 17554300 rs10900325 chr1 146692174 T C 2.95E-04 Body mass index FMO5 intron 21701565 rs2354432 chr1 146693229 C T 2.37E-04 Body mass index FMO5 intron 21701565 rs2354432 chr1 146693229 C T 8.76E-04 Body mass index FMO5 intron 21701565 rs2354432 chr1 146693229 C T 9.34E-05 Orofacial clefts FMO5 intron 22419666 rs7537483 chr1 146709877 C G 5.99E-04 Multiple complex diseases / / 17554300 rs7537483 chr1 146709877 C G 2.93E-04 Body mass index / / 21701565 rs3820130 chr1 146724003 A G 2.92E-04 Body mass index CHD1L intron 21701565 rs3737845 chr1 146724408 G A 3.04E-04 Body mass index CHD1L intron 21701565 rs17160062 chr1 146731367 T C 6.38E-04 Body mass index CHD1L intron 21701565 rs4950392 chr1 146736548 G A,C,T 8.51E-05 Body Mass Index CHD1L intron pha003019 rs10793656 chr1 146751272 T A,C,G 4.96E-04 Lung function (forced expiratory volume in 1 second) CHD1L intron 24023788 rs7516430 chr1 146767062 A G 7.66E-06 Orofacial clefts CHD1L intron 22419666 rs6538 chr1 146767353 G A 4.83E-04 Lung function (forced expiratory volume in 1 second) CHD1L UTR-3 24023788 rs945742 chr1 146785157 A G 9.80E-05 Body Mass Index / / pha003019 rs11239984 chr1 146791729 G A 3.96E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2353983 chr1 146813137 C T 9.66E-05 Serum metabolites / / 19043545 rs2353983 chr1 146813137 C T 9.53E-05 Orofacial clefts / / 22419666 rs4626937 chr1 146826675 T C 4.40E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2353987 chr1 146827556 G T 4.26E-05 Body Mass Index / / pha003019 rs11240009 chr1 146842342 A G 8.24E-05 Post-operative nausea and vomiting / / 21694509 rs4950322 chr1 146854836 G A 2.00E-07 Protein quantitative trait loci / / 18464913 rs4950322 chr1 146854836 G A 7.00E-07 Protein quantitative trait loci / / 18464913 rs12408395 chr1 146906368 G A 4.20E-05 Post-operative nausea and vomiting LOC100289211 intron 21694509 rs6678706 chr1 146917617 G A 9.34E-04 Type 2 diabetes LOC100289211 intron 17463246 rs11240053 chr1 146923557 G A 1.30E-05 HIV-1 control LOC100289211 intron 20041166 rs11240065 chr1 146940196 T C 9.57E-07 Stroke (ischemic) LOC100289211 intron 21957438 rs148158062 chr1 146940196 T TGTTCCTTC 9.57E-07 Stroke (ischemic) LOC100289211 intron 21957438 rs56352300 chr1 146940196 T TGTTCCTTC 9.57E-07 Stroke (ischemic) LOC100289211 intron 21957438 rs2803533 chr1 146954674 G A 1.51E-06 Esophageal cancer (squamous cell) LOC100289211 intron 22960999 rs12406844 chr1 146969411 C T 2.98E-04 Epilepsy LOC100289211 intron 22116939 rs2000072 chr1 146970568 G A,C,T 3.69E-05 Personality dimensions LOC100289211 intron 18957941 rs2000072 chr1 146970568 G A,C,T 9.44E-05 Bipolar disorder LOC100289211 intron 19488044 rs2000072 chr1 146970568 G A,C,T 5.54E-05 Bipolar Disorder LOC100289211 intron pha002863 rs10900374 chr1 146970946 G A 6.32E-06 Stroke (ischemic) LOC100289211 intron 21957438 rs1845807 chr1 146973797 G A 6.22E-06 Stroke (ischemic) LOC100289211 intron 21957438 rs586000 chr1 146976138 T C 6.67E-04 Coronary Artery Disease LOC100289211 intron 17634449 rs631288 chr1 146979516 C T 4.06E-05 Type 2 diabetes LOC100289211 intron 17463246 rs631288 chr1 146979516 C T 3.00E-06 PR interval in Tripanosoma cruzi seropositivity LOC100289211 intron 24324551 rs17160321 chr1 146984463 G A 9.65E-06 Stroke (ischemic) LOC100289211 intron 21957438 rs17160322 chr1 146984515 A G 9.65E-06 Stroke (ischemic) LOC100289211 intron 21957438 rs17160327 chr1 146985525 G T 9.58E-06 Stroke (ischemic) LOC100289211 intron 21957438 rs1013587 chr1 146986473 A G 9.63E-06 Stroke (ischemic) LOC100289211 intron 21957438 rs12046574 chr1 146989520 C T 9.60E-06 Stroke (ischemic) / / 21957438 rs4950328 chr1 147004811 T C 5.14E-04 Parkinson's disease / / 16252231 rs3806218 chr1 147011783 T C 3.74E-04 Parkinson's disease / / 16252231 rs12072533 chr1 147017524 A C 4.69E-04 Nicotine dependence BCL9 intron 17158188 rs594206 chr1 147020456 A C,G,T 6.00E-07 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) BCL9 intron 24025145 rs716703 chr1 147021148 C T 5.39E-04 Nicotine dependence BCL9 intron 17158188 rs10494251 chr1 147023894 C T 9.83E-05 Crohn's disease BCL9 intron 17684544 rs4950461 chr1 147033573 G A 4.57E-05 Alzheimer's disease (late onset) BCL9 intron 21379329 rs7526407 chr1 147070609 T C 2.20E-04 Multiple complex diseases BCL9 intron 17554300 rs583583 chr1 147083114 C T 6.00E-07 Schizophrenia (negative symptoms) BCL9 intron 23382809 rs12129752 chr1 147099287 G T 5.77E-04 Smoking initiation / / 24665060 rs10157759 chr1 147107123 C T 9.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs6663082 chr1 147107966 G A 7.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs10494248 chr1 147108260 G A 7.90E-04 Crohn's disease / / 17684544 rs11579007 chr1 147136284 G A 4.40E-05 Lymphocyte counts ACP6 intron 22286170 rs13374159 chr1 147142457 C T 6.26E-04 Alcohol dependence ACP6 UTR-5 20201924 rs1001193 chr1 147166377 A G 4.12E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6593803 chr1 147205770 T C 6.34E-05 Cognitive test performance / / 20125193 rs6593807 chr1 147213954 G A 6.86E-04 Insulin resistance / / 21901158 rs2353 chr1 147222372 A G 1.02E-05 Cognitive test performance / / 20125193 rs1891498 chr1 147226791 A G 9.00E-06 Cognitive performance / / 20125193 rs2232190 chr1 147231373 A G 2.20E-04 Atrial fibrillation GJA5 UTR-5 21846873 rs10793704 chr1 147239987 T A 5.07E-04 Insulin resistance GJA5 intron 21901158 rs10793705 chr1 147240307 C A,G,T 6.16E-04 Multiple complex diseases GJA5 intron 17554300 rs6670327 chr1 147241723 A C 5.65E-05 Insulin resistance GJA5 intron 21901158 rs10900396 chr1 147242596 G A 8.13E-04 Insulin resistance GJA5 intron 21901158 rs1342705 chr1 147254256 C T 2.70E-04 Crohn's disease / / 17684544 rs10494257 chr1 147254569 T C 5.00E-04 Crohn's disease / / 17684544 rs12061877 chr1 147264252 T C 3.39E-04 Type 2 diabetes / / 17463246 rs11240124 chr1 147268211 A C 1.37E-04 Multiple complex diseases / / 17554300 rs11240129 chr1 147282508 C T 0.000751746 Hypertension (early onset hypertension) / / 22479346 rs12069680 chr1 147284943 G A 2.38E-04 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs12069680 chr1 147284943 G A 3.10E-04 Fasting insulin (interaction) / / 24204828 rs12076930 chr1 147285007 T C 0.000751746 Hypertension (early onset hypertension) / / 22479346 rs10458586 chr1 147288094 G C 8.54E-04 Multiple complex diseases / / 17554300 rs1086603 chr1 147288276 G A 1.12E-25 Narcolepsy / / 19629137 rs1353428 chr1 147326222 C A 6.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1353428 chr1 147326222 C A 1.00E-04 Tetralogy of Fallot / / 23297363 rs1353428 chr1 147326222 C A 1.44E-05 Basophils / / pha003087 rs10900403 chr1 147340734 T G 4.64E-05 Basophils / / pha003087 rs1495962 chr1 147342037 C A 3.15E-04 Heart rate / / 23583979 rs903786 chr1 147364001 G A,C,T 6.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs903786 chr1 147364001 G A,C,T 1.10E-04 Major depressive disorder / / 21042317 rs903785 chr1 147364076 A C 1.30E-04 Major depressive disorder / / 21042317 rs903784 chr1 147364099 C A,G,T 1.40E-04 Major depressive disorder / / 21042317 rs2352834 chr1 147365020 G A,C,T 4.70E-04 Major depressive disorder / / 21042317 rs7512708 chr1 147369425 C G 6.02E-04 Multiple complex diseases / / 17554300 rs17160783 chr1 147379941 A G 2.46E-05 Hirschsprung's disease GJA8 intron 19196962 rs2132397 chr1 147381558 G A,C,T 1.28E-05 Age-related macular degeneration GJA8 nearGene-3 pha000002 rs1763457 chr1 147795678 T C 2.87E-04 Tourette syndrome / / 22889924 rs12561867 chr1 147801691 G A 1.29E-04 IgE levels / / 17255346 rs2932433 chr1 147806677 C T 8.97E-04 Multiple complex diseases / / 17554300 rs11579261 chr1 149039120 C T 2.38E-11 Neuroblastoma / / 19536264 rs17162082 chr1 149040066 C T 7.16E-04 Multiple complex diseases / / 17554300 rs17162082 chr1 149040066 C T 2.38E-11 Neuroblastoma / / 19536264 rs17161949 chr1 149045105 T C 2.38E-11 Neuroblastoma / / 19536264 rs6673776 chr1 149060682 T C 2.38E-11 Neuroblastoma / / 19536264 rs17162074 chr1 149064521 G A 2.38E-11 Neuroblastoma / / 19536264 rs11587304 chr1 149147738 C A 3.62E-11 Neuroblastoma / / 19536264 rs3853524 chr1 149160437 C T 7.83E-11 Neuroblastoma / / 19536264 rs3738319 chr1 149815323 G A 6.23E-04 Taste perception / / 22132133 rs16835135 chr1 149880483 A G 1.36E-06 White blood cell count SV2A intron 21738479 rs11205277 chr1 149892872 A G 1.00E-10 Height / / 18391951 rs11205277 chr1 149892872 A G 5.00E-32 Height / / 20881960 rs7544531 chr1 149897217 C A,T 6.49E-06 White blood cell count SF3B4 intron 21738479 rs11205303 chr1 149906413 T C 4.00E-23 Height MTMR11 missense 23563607 rs1061955 chr1 149914357 G A 4.00E-06 Obesity-related traits OTUD7B UTR-3 23251661 rs16833178 chr1 149996352 G A 7.19E-04 Multiple complex diseases / / 17554300 rs12063329 chr1 150002436 T C 6.92E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs11205321 chr1 150026207 T C 1.72E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs12058524 chr1 150066384 C T 2.03E-06 Uric acid levels VPS45 intron 21294900 rs7517537 chr1 150114083 C T 1.80E-06 Uric acid levels VPS45 intron 21294900 rs7521783 chr1 150143193 T C 7.97E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs7521783 chr1 150143193 T C 0.000558 Bipolar disorder / / 23637625 rs11205347 chr1 150210120 C T 1.36E-06 White blood cell count / / 21738479 rs12138787 chr1 150246070 T C 3.06E-04 Schizophrenia C1orf54 intron 19197363 rs942453 chr1 150257262 A G 1.84E-04 Schizophrenia C1orf51 intron 19197363 rs12139286 chr1 150262455 G A 6.53E-06 Schizophrenia / / 19571811 rs12403795 chr1 150278389 C T 5.00E-06 Illicit drug use MRPS21 intron 23942779 rs11806171 chr1 150310827 A C 2.87E-04 Heart rate PRPF3 intron 23583979 rs11587682 chr1 150324284 C T 7.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) PRPF3 intron 23453885 rs834234 chr1 150352494 C G 4.87E-04 Type 2 diabetes RPRD2 intron 17463246 rs834234 chr1 150352494 C G 2.61E-04 Multiple complex diseases RPRD2 intron 17554300 rs834238 chr1 150366469 C A 3.56E-04 Type 2 diabetes RPRD2 intron 17463246 rs834238 chr1 150366469 C A 1.71E-04 Multiple complex diseases RPRD2 intron 17554300 rs698915 chr1 150388318 A G 5.07E-06 Post-operative nausea and vomiting RPRD2 intron 21694509 rs12738490 chr1 150402419 T C 8.87E-04 Multiple complex diseases RPRD2 intron 17554300 rs12738490 chr1 150402419 T C 1.99E-07 Major depressive disorder RPRD2 intron 22472876 rs12726415 chr1 150402613 C G 3.84E-04 Lung function (forced expiratory volume in 1 second) RPRD2 intron 17255346 rs11581051 chr1 150426409 C G 1.05E-04 Lung function (forced expiratory volume in 1 second) RPRD2 intron 17255346 rs10888582 chr1 150428819 G A 3.88E-04 Lung function (forced expiratory volume in 1 second) RPRD2 intron 17255346 rs12029359 chr1 150432802 G A 3.23E-05 Neuroblastoma RPRD2 intron pha002895 rs4451552 chr1 150455854 G C 2.77E-04 Type 2 diabetes / / 17463246 rs4451552 chr1 150455854 G C 9.80E-05 Multiple complex diseases / / 17554300 rs4446975 chr1 150456169 C T 3.93E-04 Type 2 diabetes / / 17463246 rs7542068 chr1 150463772 C G 4.03E-04 Lung function (forced expiratory volume in 1 second) TARS2 intron 17255346 rs7542068 chr1 150463772 C G 9.14E-06 Panic disorder TARS2 intron 19165232 rs9661040 chr1 150483236 A C 7.95E-04 Type 2 diabetes ECM1 intron 17463246 rs9661040 chr1 150483236 A C 2.43E-04 Multiple complex diseases ECM1 intron 17554300 rs12132918 chr1 150498138 C T 1.38E-04 Schizophrenia / / 19197363 rs12119250 chr1 150528885 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) ADAMTSL4 intron 20708005 rs6655975 chr1 150542128 A G 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11204666 chr1 150543128 C T 3.60E-04 Coronary heart disease / / 21966275 rs11204666 chr1 150543128 C T 0.0000212 Coronary artery disease / / 23202125 rs1913117 chr1 150552534 G A 0.000000135 Triglycerides MCL1 nearGene-5 23063622 rs1355637 chr1 150582438 C A,G,T 5.10E-06 Parkinson's disease (age of onset) / / 19772629 rs2055975 chr1 150618632 A C 3.46E-04 Tourette syndrome / / 22889924 rs4970926 chr1 150673684 T C 2.00E-04 Cognitive impairment induced by topiramate HORMAD1 intron 22091778 rs2230061 chr1 150727539 G A 4.00E-08 Fat body mass CTSS missense 24064335 rs12568757 chr1 150729793 G A 7.44E-06 Lymphocyte counts CTSS intron 22286170 rs7518440 chr1 150790762 A G 0.000000172 Cholesterol,total ARNT intron 23063622 rs7518440 chr1 150790762 A G 4.06E-08 HDL cholesterol ARNT intron 23063622 rs10305685 chr1 150811005 T C 3.47E-08 HDL cholesterol ARNT intron 23063622 rs10305650 chr1 150848977 G A 2.01E-08 HDL cholesterol ARNT intron 23063622 rs7412746 chr1 150860471 C T 9.00E-11 Melanoma / / 21983785 rs7412746 chr1 150860471 C T 1.90E-04 Melanoma / / 24980573 rs2272214 chr1 150931462 G A 2.80E-05 Urinary metabolites SETDB1 intron 21572414 rs4451553 chr1 150937329 C T 1.18E-05 Sphingolipid levels / / 19798445 rs267738 chr1 150940625 T G 2.36E-04 Tourette syndrome CERS2 missense 22889924 rs267738 chr1 150940625 T G 1.00E-07 Rhegmatogenous retinal detachment CERS2 missense 23585552 rs4970988 chr1 150950062 G A 1.00E-07 Urate levels / / 23263486 rs267734 chr1 150951477 T C 1.00E-12 Chronic kidney disease / / 20383146 rs267734 chr1 150951477 T C 1.03E-04 Lymphocyte counts / / 22286170 rs267734 chr1 150951477 T C 3.66E-09 Chronic kidney disease / / 22479191 rs267734 chr1 150951477 T C 2.00E-05 Glomerular filtration rate / / 23535967 rs267733 chr1 150958836 A C,G,T 6.71E-04 Tourette syndrome ANXA9 missense 22889924 rs267733 chr1 150958836 A C,G,T 5.00E-09 LDL cholesterol ANXA9 missense 24097068 rs11204754 chr1 150961254 T C 6.44E-05 Melanoma ANXA9 intron 21926416 rs1722784 chr1 150961869 A G 2.00E-06 Melanoma ANXA9 intron 21926416 rs771204 chr1 150974162 G A 2.87E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FAM63A intron 24023788 rs771205 chr1 150975108 T C 6.75E-04 Alzheimer's disease FAM63A missense 24755620 rs3738479 chr1 150997842 T A 9.00E-04 Chronic kidney disease PRUNE intron 21931561 rs4970989 chr1 151003600 T A 5.00E-04 Acute lung injury PRUNE intron 22295056 rs4970991 chr1 151004003 T C 6.46E-04 Acute lung injury PRUNE intron 22295056 rs7550434 chr1 151008928 G A 6.51E-04 Acute lung injury BNIPL nearGene-5 22295056 rs955955 chr1 151011543 G A 4.95E-05 Cognitive impairment induced by topiramate BNIPL intron 22091778 rs2091219 chr1 151012060 A G 8.51E-04 Acute lung injury BNIPL intron 22295056 rs6694158 chr1 151014134 C G 7.02E-04 Type 2 diabetes BNIPL intron 17463246 rs12068365 chr1 151015868 G A 4.95E-05 Cognitive impairment induced by topiramate BNIPL missense 22091778 rs6587552 chr1 151018861 A G 5.34E-04 Type 2 diabetes BNIPL intron 17463246 rs6587553 chr1 151019180 A G 3.86E-04 Type 2 diabetes BNIPL UTR-3 17463246 rs2902810 chr1 151026815 C T 4.90E-04 Endometriosis CDC42SE1 intron 23104006 rs2140709 chr1 151036816 A G 1.95E-04 Type 2 diabetes MLLT11 intron 17463246 rs11204774 chr1 151062957 G A 1.72E-04 Multiple complex diseases GABPB2 missense 17554300 rs11204774 chr1 151062957 G A 6.13E-05 Cognitive impairment induced by topiramate GABPB2 missense 22091778 rs11807526 chr1 151115997 A C 9.81E-04 Obesity (extreme) SEMA6C intron 21935397 rs6689566 chr1 151143166 C T 2.39E-04 Suicide attempts in bipolar disorder TMOD4 intron 21423239 rs11204785 chr1 151150857 T C 3.35E-05 Magnesium levels VPS72 intron pha003092 rs10749660 chr1 151174772 A G 9.52E-05 Magnesium levels PIP5K1A intron pha003092 rs4520422 chr1 151179943 C T 9.52E-05 Magnesium levels PIP5K1A intron pha003092 rs7532935 chr1 151210789 C T 9.52E-05 Magnesium levels PIP5K1A intron pha003092 rs4971030 chr1 151280995 T C 8.81E-05 Magnesium levels PI4KB intron pha003092 rs1056847 chr1 151288172 G A 8.81E-05 Magnesium levels PI4KB cds-synon pha003092 rs5022636 chr1 151295061 A G 5.56E-05 Magnesium levels PI4KB intron pha003092 rs2025900 chr1 151331304 A T 1.39E-04 Multiple complex diseases / / 17554300 rs2800953 chr1 151338570 G A 9.47E-05 Multiple complex diseases SELENBP1 intron 17554300 rs2769265 chr1 151344150 C A 4.83E-05 Brain structure SELENBP1 intron 22504417 rs2769264 chr1 151344741 T G 2.71E-05 Brain structure SELENBP1 intron 22504417 rs2769264 chr1 151344741 T G 3.00E-20 Blood trace element (Cu levels) SELENBP1 intron 23720494 rs4971036 chr1 151351060 G A 2.68E-04 IgE levels / / 17255346 rs2769270 chr1 151355858 G A 1.20E-05 Urinary metabolites / / 21572414 rs2296840 chr1 151372047 C T 1 Drug response to Desipramine PSMB4 UTR-5 18504423 rs2296840 chr1 151372047 C T 1 Drug response to Fluoxetine PSMB4 UTR-5 18504423 rs7172 chr1 151372138 G A 3.90E-22 Progranulin levels PSMB4 cds-synon 21087763 rs7172 chr1 151372138 G A 3.90E-22 Myocardial infarction PSMB4 cds-synon 21211798 rs16833263 chr1 151433133 T C 5.26E-04 Smoking cessation / / 24665060 rs10888419 chr1 151484219 A C 0.000587 Salmonella-induced pyroptosis CGN intron 22837397 rs7552458 chr1 151488782 T G 7.33E-04 Cervical cancer CGN intron 21716314 rs11204838 chr1 151493814 C T 4.00E-04 Cervical cancer CGN intron 21716314 rs2337359 chr1 151495796 T C 7.98E-04 Cervical cancer CGN intron 21716314 rs1573130 chr1 151497140 T C 7.77E-04 Cervical cancer CGN intron 21716314 rs1573129 chr1 151497376 G A 8.79E-04 Multiple complex diseases CGN intron 17554300 rs6678068 chr1 151501737 T C 6.22E-05 Asthma CGN intron pha003128 rs1891593 chr1 151535916 C T 2.57E-04 Alzheimer's disease TUFT1 intron 17998437 rs12751350 chr1 151550673 G A 1.85E-04 Gallstones TUFT1 intron 17632509 rs12122920 chr1 151588735 G A 5.90E-04 Endometriosis SNX27 intron 23104006 rs6690942 chr1 151629958 A G 9.95E-04 Response to cytidine analogues (gemcitabine) SNX27 intron 24483146 rs1211981 chr1 151632646 T C 4.70E-04 Endometriosis SNX27 intron 23104006 rs1048694 chr1 151669997 C A 7.63E-04 Aortic root size SNX27 UTR-3 21223598 rs1308145 chr1 151673350 T C 9.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) CELF3 UTR-3 23648065 rs1308152 chr1 151679441 T C 1.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) CELF3 intron 23648065 rs1308152 chr1 151679441 T C 3.79E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) CELF3 intron 23648065 rs2280474 chr1 151681567 G A 5.10E-04 Coronary heart disease CELF3 intron 21966275 rs3762302 chr1 151684262 T C 3.34E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) CELF3 intron 23648065 rs939592 chr1 151686983 T A 1.10E-05 Serum metabolites CELF3 intron 19043545 rs868360 chr1 151691148 C T 6.96E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs6696250 chr1 151695271 T C 1.50E-04 Endometriosis RIIAD1 intron 23104006 rs2298294 chr1 151701345 A G 5.39E-04 Response to cytidine analogues (gemcitabine) RIIAD1 UTR-3 24483146 rs11204885 chr1 151747970 A G 8.71E-12 Non-obstructive azoospermia TDRKH cds-synon 22197933 rs11204885 chr1 151747970 A G 1.45E-04 Lung function (forced vital capacity) TDRKH cds-synon 24023788 rs4845579 chr1 151770138 T C 8.50E-04 Multiple complex diseases / / 17554300 rs9017 chr1 151778683 C T 7.80E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) RORC UTR-3 23648065 rs11588634 chr1 151780686 T A 2.64E-04 Suicide attempts in bipolar disorder RORC intron 21041247 rs11588258 chr1 151780728 A T 2.66E-04 Suicide attempts in bipolar disorder RORC intron 21041247 rs1521177 chr1 151782130 G T 3.91E-05 Soluble levels of adhesion molecules RORC intron pha003072 rs7540530 chr1 151790858 G A 1.89E-04 Type 2 diabetes RORC intron 22158537 rs4845604 chr1 151801680 G A 4.00E-16 Inflammatory bowel disease RORC intron 23128233 rs3811418 chr1 151805049 A G 4.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RORC nearGene-5 20877124 rs11204897 chr1 151809066 A G 1.09E-07 Hair morphology / / 19896111 rs7536659 chr1 151816718 T C 2.58E-05 Serum metabolites / / 19043545 rs6587625 chr1 151820324 T C 7.12E-05 Orofacial clefts THEM5 missense 22419666 rs2279503 chr1 151824089 T C 9.40E-07 Urinary metabolites THEM5 intron 21572414 rs4845624 chr1 151827813 G A 1.35E-06 White blood cell count / / 21738479 rs2879130 chr1 151830098 C T 5.81E-05 Orofacial clefts / / 22419666 rs12566232 chr1 151839838 A C 6.00E-19 Blood metabolite levels / / 24816252 rs6685187 chr1 151858888 A G 3.00E-26 Blood metabolite levels THEM4 intron 24816252 rs10788817 chr1 151882856 C G 3.00E-13 Metabolite levels / / 24625756 rs10788819 chr1 151895093 C T 2.00E-08 Hair morphology / / 19896111 rs10788819 chr1 151895093 C T 1.32E-07 Common traits (Other) / / 20585627 rs3007711 chr1 151897377 G T 4.35E-04 Alzheimer's disease (late onset) / / 21379329 rs3007685 chr1 151898037 T G 4.26E-04 Alzheimer's disease (late onset) / / 21379329 rs6686874 chr1 151915740 G A 5.51E-05 Gallstones / / 17632509 rs6693388 chr1 151930645 T C 4.00E-38 Blood metabolite ratios / / 24816252 rs7541099 chr1 151938763 C T 9.84E-04 Type 2 diabetes / / 17463246 rs2999531 chr1 151971497 C T 1.16E-07 Lymphocyte counts / / 22286170 rs3007671 chr1 151999347 G T 3.46E-17 Hair morphology / / 19896111 rs3007671 chr1 151999347 G T 6.03E-28 Common traits (Other) / / 20585627 rs3007671 chr1 151999347 G T 1.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs3007671 chr1 151999347 G T 2.45E-04 Tourette syndrome / / 22889924 rs2999547 chr1 152002663 A C 3.43E-17 Hair morphology / / 19896111 rs2999547 chr1 152002663 A C 1.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs12123975 chr1 152004804 A G 1.14E-18 Hair morphology / / 19896111 rs12130862 chr1 152027015 A T 3.12E-28 Hair morphology / / 19896111 rs3007684 chr1 152034430 G T 1.29E-10 Common traits (Other) / / 20585627 rs3124314 chr1 152037515 T C 4.00E-06 Hair morphology / / 19896111 rs16833835 chr1 152059580 G C 8.58E-05 Multiple complex diseases TCHHL1 missense 17554300 rs17646946 chr1 152062767 G A 1.50E-31 Hair morphology / / 19896111 rs17646946 chr1 152062767 G A 2.00E-42 Common traits (Other) / / 20585627 rs11204925 chr1 152073120 A G 1.01E-06 White blood cell count / / 21738479 rs9050 chr1 152079314 C A 3.91E-10 Atopic dermatitis TCHH UTR-3 23886662 rs9050 chr1 152079314 C A 4.00E-06 Atopic dermatitis TCHH UTR-3 23886662 rs9050 chr1 152079314 C A 4.30E-07 Atopic dermatitis TCHH UTR-3 23886662 rs11803731 chr1 152083325 A T 3.00E-31 Hair morphology TCHH missense 19896111 rs4845418 chr1 152136230 G C 4.43E-29 Hair morphology / / 19896111 rs1496036 chr1 152140016 G A 6.67E-06 Hair morphology / / 19896111 rs969359 chr1 152144260 C T 5.88E-04 Multiple complex diseases / / 17554300 rs7527318 chr1 152224948 C T 6.04E-04 Insulin resistance / / 21901158 rs7541297 chr1 152225041 A T 4.78E-04 Insulin resistance / / 21901158 rs11204971 chr1 152259078 A G 5.02E-09 Atopic dermatitis / / 21666691 rs3126085 chr1 152300817 G A 6.00E-12 Atopic dermatitis / / 21666691 rs1858483 chr1 152310086 T C 2.63E-10 Hair morphology FLG-AS1 intron 19896111 rs3120665 chr1 152316590 A G 4.00E-06 Personality dimensions FLG-AS1 intron 20691247 rs3120667 chr1 152318161 A G 2.00E-06 Eating disorders FLG-AS1 intron 23568457 rs1923504 chr1 152360184 T C 1.92E-06 White blood cell count / / 21738479 rs10888485 chr1 152363581 A G 5.16E-06 White blood cell count / / 21738479 rs2146117 chr1 152416909 A T 1.60E-05 Urinary metabolites / / 21572414 rs6587673 chr1 152430152 G A 2.82E-08 Common traits (Other) / / 20585627 rs6700998 chr1 152434009 T G 3.31E-08 Common traits (Other) / / 20585627 rs6661961 chr1 152442289 T C 9.00E-11 Atopic dermatitis / / 23886662 rs908922 chr1 152454591 G A 4.00E-06 Hair morphology / / 19896111 rs1199156 chr1 152459747 T C 7.18E-05 Hematocrit / / pha003097 rs6669608 chr1 152475233 A G 8.22E-06 Hair morphology / / 19896111 rs499913 chr1 152476743 T A 0.00000072 Asthma / / 23040885 rs4845779 chr1 152479176 T C 9.33E-11 Common traits (Other) / / 20585627 rs1885531 chr1 152480233 T G 0.0000037 Asthma / / 23040885 rs6658925 chr1 152482801 A G 3.59E-04 Coronary heart disease / / 21606135 rs2105117 chr1 152484129 G A 9.77E-08 Common traits (Other) LCE5A missense 20585627 rs3753451 chr1 152485227 T G 7.41E-08 Common traits (Other) / / 20585627 rs73004856 chr1 152487917 G A 3.00E-06 Obesity-related traits CRCT1 missense 23251661 rs1053590 chr1 152488428 T C 8.13E-08 Common traits (Other) CRCT1 UTR-3 20585627 rs548252 chr1 152489742 C T 8.11E-04 Multiple complex diseases / / 17554300 rs548252 chr1 152489742 C T 7.96E-04 Coronary heart disease / / 21606135 rs4845783 chr1 152492559 G A 6.00E-06 Asthma / / 21804549 rs499697 chr1 152493154 G A 1.00E-10 Common traits (Other) / / 20585627 rs1538084 chr1 152496012 A C 5.01E-07 Asthma / / 21804549 rs12116609 chr1 152497685 C T 4.17E-08 Common traits (Other) / / 20585627 rs4845443 chr1 152507156 G A 9.82E-04 Coronary heart disease / / 21606135 rs1001149 chr1 152508562 C T 2.22E-06 Monocyte chemoattractant protein-1 / / pha003071 rs549044 chr1 152514332 C T 3.11E-05 F-cell distribution / / 21326311 rs6587688 chr1 152529622 T C 1.47E-07 Asthma / / 21804549 rs4240887 chr1 152530510 A G 3.16E-08 Common traits (Other) / / 20585627 rs4240889 chr1 152534954 C A 6.87E-04 Endometrial cancer / / 24096698 rs4845790 chr1 152536760 C T 2.87E-05 Glucose levels / / pha003058 rs4845791 chr1 152536784 G A 3.76E-05 Glucose levels / / pha003058 rs10888501 chr1 152537954 G A 1.00E-06 Response to antipsychotic treatment / / 19721433 rs17659359 chr1 152538358 G C 2.48E-05 Schizophrenia LCE3E UTR-3 20185149 rs7516108 chr1 152542229 T C 2.30E-05 Psoriasis / / 19169255 rs7516108 chr1 152542229 T C 1.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7516108 chr1 152542229 T C 3.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4085613 chr1 152550018 T G 7.00E-30 Psoriasis / / 19169255 rs4085613 chr1 152550018 T G 7.00E-30 Multiple sclerosis / / 22190364 rs4085613 chr1 152550018 T G 1.54E-05 Personality dimensions / / 22628180 rs4112788 chr1 152551276 A G 6.30E-09 Psoriasis / / 19169255 rs4112788 chr1 152551276 A G 3.00E-10 Psoriasis / / 20953190 rs4112788 chr1 152551276 A G 1.57E-05 Personality dimensions / / 22628180 rs477392 chr1 152555176 C G 1.36E-05 Personality dimensions / / 22628180 rs12067374 chr1 152568230 C G 2.72E-06 Personality dimensions / / 22628180 rs6677595 chr1 152590187 C T 1.34E-05 Personality dimensions / / 22628180 rs6677595 chr1 152590187 C T 2.10E-33 Psoriasis / / 23143594 rs6701307 chr1 152590444 G A 1.34E-05 Personality dimensions / / 22628180 rs6693105 chr1 152590663 T C 1.39E-05 Personality dimensions / / 22628180 rs4845446 chr1 152590750 T C 1.39E-05 Personality dimensions / / 22628180 rs4845449 chr1 152591024 T A 1.32E-05 Personality dimensions / / 22628180 rs1886734 chr1 152591142 A C 1.70E-08 Psoriasis / / 19169255 rs1886734 chr1 152591142 A C 1.37E-05 Personality dimensions / / 22628180 rs4845450 chr1 152591200 T C 1.70E-05 Personality dimensions / / 22628180 rs4845454 chr1 152592184 C T 9.80E-09 Psoriasis / / 19169255 rs4845454 chr1 152592184 C T 1.36E-05 Personality dimensions / / 22628180 rs1581803 chr1 152592281 G T 1.35E-05 Personality dimensions / / 22628180 rs6700158 chr1 152592828 T G 1.34E-05 Personality dimensions / / 22628180 rs10888503 chr1 152593549 C T 1.39E-05 Personality dimensions / / 22628180 rs6702463 chr1 152598711 T A 1.43E-05 Personality dimensions / / 22628180 rs4845459 chr1 152603842 C A 1.48E-05 Personality dimensions / / 22628180 rs16834273 chr1 152609951 C G 3.87E-05 Multiple complex diseases / / 17554300 rs16834276 chr1 152610224 T G 1.76E-04 Multiple complex diseases / / 17554300 rs11205051 chr1 152610256 A C 1.29E-04 Multiple complex diseases / / 17554300 rs1325508 chr1 152612910 T C 4.30E-05 Multiple complex diseases / / 17554300 rs1325508 chr1 152612910 T C 5.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs989834 chr1 152618544 A T 1.27E-04 Multiple complex diseases / / 17554300 rs1325507 chr1 152619264 G A 8.48E-05 Multiple complex diseases / / 17554300 rs1325507 chr1 152619264 G A 5.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11205060 chr1 152624426 C T 5.40E-05 Multiple complex diseases / / 17554300 rs908929 chr1 152624922 A G 5.05E-05 Multiple complex diseases / / 17554300 rs908929 chr1 152624922 A G 6.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10888505 chr1 152625148 A G 1.59E-04 Multiple complex diseases / / 17554300 rs10888505 chr1 152625148 A G 8.56E-04 Alcohol dependence / / 20201924 rs11205061 chr1 152626061 A G 9.71E-05 Multiple complex diseases / / 17554300 rs10888507 chr1 152626270 C G 1.29E-04 Multiple complex diseases / / 17554300 rs12096806 chr1 152643160 G A 3.22E-04 Alcohol dependence / / 20201924 rs12060809 chr1 152648950 T C 4.80E-04 Alcohol dependence LCE2C UTR-3 20201924 rs3904415 chr1 152672756 C T 2.85E-05 Multiple complex diseases / / 17554300 rs11205084 chr1 152684306 A G 3.77E-05 Multiple complex diseases / / 17554300 rs2224986 chr1 152684866 C T 2.74E-05 Multiple complex diseases / / 17554300 rs1332498 chr1 152690448 T C 3.30E-05 Bone mineral density / / 21927923 rs16834421 chr1 152712747 G A 7.96E-06 Multiple complex diseases / / 17554300 rs16834421 chr1 152712747 G A 6.36E-04 Insulin resistance / / 21901158 rs11205096 chr1 152715824 C A 1.56E-04 Multiple complex diseases / / 17554300 rs12023710 chr1 152719318 T C 8.44E-06 Multiple complex diseases / / 17554300 rs12023710 chr1 152719318 T C 2.02E-04 Insulin resistance / / 21901158 rs11578927 chr1 152728472 A C 2.75E-04 HIV-1 viral setpoint / / 17641165 rs2297487 chr1 152734390 C T 1.87E-04 Multiple complex diseases KPRP UTR-3 17554300 rs1591077 chr1 152734796 G A 2.36E-04 HIV-1 viral setpoint / / 17641165 rs913998 chr1 152749891 G T 7.14E-05 Multiple complex diseases / / 17554300 rs16834495 chr1 152750800 G A 5.82E-05 Multiple complex diseases / / 17554300 rs950337 chr1 152756774 T C 6.06E-04 Multiple complex diseases / / 17554300 rs6694602 chr1 152773905 G A 7.65E-05 Insulin resistance / / 21901158 rs7411365 chr1 152780139 C T 2.75E-04 Multiple complex diseases / / 17554300 rs7411365 chr1 152780139 C T 1.80E-05 Malaria / / 19465909 rs7517755 chr1 152796449 T C 2.60E-05 Urinary metabolites / / 21572414 rs7517755 chr1 152796449 T C 8.89E-08 White blood cell count / / 21738479 rs2339392 chr1 152820248 C T 8.99E-04 Multiple complex diseases / / 17554300 rs7519200 chr1 152824413 G T 7.75E-04 Multiple complex diseases / / 17554300 rs16834715 chr1 152844585 C T 8.03E-04 Multiple complex diseases / / 17554300 rs3737861 chr1 152850938 A C 6.63E-06 White blood cell count SMCP intron 21738479 rs3737861 chr1 152850938 A C 2.10E-05 Body Mass Index SMCP intron pha002896 rs3856026 chr1 152869763 T C 3.72E-05 Cognitive test performance / / 20125193 rs11809092 chr1 152874742 C T 2.50E-04 Multiple complex diseases / / 17554300 rs1854779 chr1 152880672 T C 5.56E-05 Cortisol secretion,in saliva / / 21316860 rs34599045 chr1 152886874 G C 4.00E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs4240864 chr1 152901477 G A 5.74E-04 Multiple complex diseases / / 17554300 rs1999885 chr1 152907785 G C 4.33E-07 Breast cancer / / 20852631 rs16834788 chr1 152944937 C T 1.68E-04 Amyotrophic lateral sclerosis (sporadic) SPRR4 UTR-3 24529757 rs2879490 chr1 152947163 A G 8.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4041402 chr1 152947397 T C 7.30E-05 Pericardial fat / / 22589742 rs1415972 chr1 152953552 G A 7.17E-06 White blood cell count / / 21738479 rs1611753 chr1 152956381 C T 8.81E-05 Cognitive test performance / / 20125193 rs1611760 chr1 152957573 T C 7.39E-05 Cognitive test performance SPRR1A intron 20125193 rs4845503 chr1 152959939 A G 7.70E-05 Pericardial fat / / 22589742 rs1415961 chr1 152973464 G A 7.39E-05 Cognitive test performance / / 20125193 rs6683514 chr1 152984397 A G 6.20E-05 Pericardial fat / / 22589742 rs2339491 chr1 152985322 T C 8.81E-05 Cognitive test performance / / 20125193 rs4041401 chr1 152985629 A G 8.20E-05 Pericardial fat / / 22589742 rs7548977 chr1 152987365 T C,G 1.10E-05 Pericardial fat / / 22589742 rs4845513 chr1 152998066 T C 7.80E-06 Pericardial fat / / 22589742 rs10888524 chr1 153000125 A G 7.60E-05 Pericardial fat / / 22589742 rs10888525 chr1 153000215 G A 7.60E-05 Pericardial fat / / 22589742 rs10888526 chr1 153000311 G T 6.10E-05 Pericardial fat / / 22589742 rs11205174 chr1 153001230 A G 6.00E-05 Pericardial fat / / 22589742 rs11205175 chr1 153001296 A C 6.00E-05 Pericardial fat / / 22589742 rs10788853 chr1 153002231 C T 7.70E-05 Pericardial fat / / 22589742 rs10788855 chr1 153002359 A T 6.00E-05 Pericardial fat / / 22589742 rs11205177 chr1 153002502 G A 7.30E-05 Pericardial fat / / 22589742 rs1415965 chr1 153002750 G A 5.90E-05 Pericardial fat / / 22589742 rs1415966 chr1 153002864 A G 5.80E-05 Pericardial fat / / 22589742 rs1933382 chr1 153003295 T G 5.80E-05 Pericardial fat / / 22589742 rs4845336 chr1 153003853 C T 5.20E-05 Pericardial fat SPRR1B intron 22589742 rs4845515 chr1 153003871 G T 5.20E-05 Pericardial fat SPRR1B intron 22589742 rs4845518 chr1 153003903 A G 5.20E-05 Pericardial fat SPRR1B intron 22589742 rs4845519 chr1 153003916 A C 5.20E-05 Pericardial fat SPRR1B intron 22589742 rs2070964 chr1 153004213 C T 5.20E-05 Pericardial fat SPRR1B intron 22589742 rs1334850 chr1 153004519 G T 5.10E-05 Pericardial fat SPRR1B intron 22589742 rs1334848 chr1 153004721 A T 5.10E-05 Pericardial fat SPRR1B intron 22589742 rs1108410 chr1 153005662 T C 6.50E-06 Pericardial fat / / 22589742 rs423692 chr1 153005681 T G 5.00E-05 Pericardial fat / / 22589742 rs489323 chr1 153006047 G A 4.90E-05 Pericardial fat / / 22589742 rs1415969 chr1 153006448 G T 5.40E-05 Pericardial fat / / 22589742 rs373740781 chr1 153006641 G GA 4.90E-05 Pericardial fat / / 22589742 rs382292 chr1 153006641 G A 4.90E-05 Pericardial fat / / 22589742 rs451939 chr1 153006877 C T 4.80E-05 Pericardial fat / / 22589742 rs406350 chr1 153007492 C T 4.80E-05 Pericardial fat / / 22589742 rs407448 chr1 153007504 C T 4.00E-05 Pericardial fat / / 22589742 rs557553 chr1 153010370 T G 4.80E-05 Pericardial fat / / 22589742 rs561143 chr1 153010734 C T 4.70E-05 Pericardial fat / / 22589742 rs10788856 chr1 153011517 G C 4.70E-05 Pericardial fat / / 22589742 rs1048296 chr1 153012240 A C 4.70E-05 Pericardial fat SPRR2D UTR-3 22589742 rs1750309 chr1 153013630 G A,C 4.70E-05 Pericardial fat / / 22589742 rs1995308 chr1 153014082 T A 3.50E-06 Pericardial fat / / 22589742 rs409986 chr1 153014741 C A 4.80E-05 Pericardial fat / / 22589742 rs441229 chr1 153015059 A C 5.40E-05 Pericardial fat / / 22589742 rs1890285 chr1 153015396 T C 8.70E-05 Pericardial fat / / 22589742 rs368912 chr1 153016204 C G 5.50E-05 Pericardial fat / / 22589742 rs310126 chr1 153019416 A C 4.50E-05 Pericardial fat / / 22589742 rs310105 chr1 153022253 A G 5.10E-05 Pericardial fat / / 22589742 rs12079087 chr1 153023888 T C 6.90E-06 Pericardial fat / / 22589742 rs6664380 chr1 153030365 G T 6.80E-06 Pericardial fat / / 22589742 rs12083211 chr1 153032131 T A 6.70E-06 Pericardial fat / / 22589742 rs582345 chr1 153033406 G A 4.40E-05 Pericardial fat / / 22589742 rs6675009 chr1 153033783 G A 7.00E-06 Pericardial fat / / 22589742 rs6587724 chr1 153034501 T A 7.00E-06 Pericardial fat / / 22589742 rs608509 chr1 153034650 G C 4.30E-05 Pericardial fat / / 22589742 rs821755 chr1 153036245 G C 4.30E-05 Pericardial fat / / 22589742 rs7531076 chr1 153039167 G T 7.90E-06 Pericardial fat / / 22589742 rs6673356 chr1 153041903 A G 9.20E-06 Pericardial fat / / 22589742 rs6693927 chr1 153044009 G A 9.10E-06 Pericardial fat SPRR2B intron 22589742 rs440598 chr1 153044733 T C 4.60E-05 Pericardial fat / / 22589742 rs6686526 chr1 153044996 T C 9.20E-06 Pericardial fat / / 22589742 rs1500937 chr1 153045483 G C 9.20E-06 Pericardial fat / / 22589742 rs11812015 chr1 153045584 G T 9.20E-06 Pericardial fat / / 22589742 rs11205181 chr1 153045728 C T 9.20E-06 Pericardial fat / / 22589742 rs11205182 chr1 153045748 C T 9.20E-06 Pericardial fat / / 22589742 rs7543689 chr1 153046803 A T 9.30E-06 Pericardial fat / / 22589742 rs11590835 chr1 153047166 T C 9.30E-06 Pericardial fat / / 22589742 rs662506 chr1 153048386 C A 3.80E-05 Pericardial fat / / 22589742 rs11576797 chr1 153049417 T C 9.20E-06 Pericardial fat / / 22589742 rs399550 chr1 153049917 T C 4.40E-05 Pericardial fat / / 22589742 rs201057762 chr1 153050058 A AG 4.40E-05 Pericardial fat / / 22589742 rs387930 chr1 153050058 A G 4.40E-05 Pericardial fat / / 22589742 rs10888529 chr1 153050654 G T 9.40E-06 Pericardial fat / / 22589742 rs6692062 chr1 153051729 T C 1.00E-05 Pericardial fat / / 22589742 rs383582 chr1 153084246 C T 1.89E-05 Rheumatoid arthritis (ACPA-negative) / / 24532677 rs1119266 chr1 153097240 G A 2.30E-05 Urinary metabolites / / 21572414 rs11205209 chr1 153104182 A G 2.80E-05 Urinary metabolites / / 21572414 rs11577955 chr1 153119519 G A 5.60E-05 Pericardial fat / / 22589742 rs11578865 chr1 153126302 G A 5.00E-05 Pericardial fat / / 22589742 rs499893 chr1 153127880 T C 2.70E-05 Urinary metabolites / / 21572414 rs12068238 chr1 153136355 T C 3.25E-04 Lung function (forced vital capacity) / / 24023788 rs11585767 chr1 153142328 C T 4.40E-05 Pericardial fat / / 22589742 rs498131 chr1 153143504 C G 5.56E-06 White blood cell count / / 21738479 rs943139 chr1 153163377 A G 0.000396 Salmonella-induced pyroptosis / / 22837397 rs1831238 chr1 153169522 G A 1.43E-06 White blood cell count / / 21738479 rs1410869 chr1 153169596 A C 7.33E-07 White blood cell count / / 21738479 rs10888535 chr1 153171148 G C 2.73E-06 White blood cell count / / 21738479 rs1410858 chr1 153182116 C A 3.64E-06 White blood cell count / / 21738479 rs11205222 chr1 153182979 A G 7.27E-05 Personality dimensions / / 18957941 rs1980908 chr1 153183088 G A 5.04E-04 Smoking quantity / / 24665060 rs1980909 chr1 153183327 A C 1.85E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10788860 chr1 153184789 A G 8.99E-04 Coronary Artery Disease / / 17634449 rs10788860 chr1 153184789 A G 9.94E-05 Serum metabolites / / 19043545 rs10494294 chr1 153185017 G A 6.70E-05 Personality dimensions / / 18957941 rs11205224 chr1 153185549 C T 7.23E-05 Personality dimensions / / 18957941 rs34345817 chr1 153185549 CA C 7.23E-05 Personality dimensions / / 18957941 rs11583156 chr1 153192077 C T 4.83E-05 Personality dimensions / / 18957941 rs16835081 chr1 153197544 C T 4.98E-05 Personality dimensions / / 18957941 rs16835083 chr1 153197618 C T 3.09E-05 Personality dimensions / / 18957941 rs16835086 chr1 153206051 T A 1.72E-04 Coronary Artery Disease / / 17634449 rs4517302 chr1 153207416 G T 8.45E-05 Coronary Artery Disease / / 17634449 rs1329097 chr1 153224122 T A 3.61E-04 Type 2 diabetes / / 17463246 rs821431 chr1 153271524 C T 6.67E-06 White blood cell count PGLYRP3 intron 21738479 rs821426 chr1 153282072 C A 7.10E-05 Endometriosis PGLYRP3 intron 21151130 rs2771122 chr1 153312644 A G 5.62E-05 HIV-1 viral setpoint PGLYRP4 intron 22174851 rs2288990 chr1 153318008 C G 5.81E-05 Type 2 diabetes PGLYRP4 intron 17463246 rs12027903 chr1 153327756 G T 4.27E-04 Alcohol dependence / / 20201924 rs3006412 chr1 153390542 G C 3.12E-04 Fibrinogen S100A7A UTR-5 17255346 rs16835308 chr1 153404808 T C 4.31E-04 Fibrinogen / / 17255346 rs12047494 chr1 153446797 T C 5.39E-08 Metabolite levels / / 23281178 rs12022550 chr1 153452931 G A 5.39E-08 Metabolite levels / / 23281178 rs12025638 chr1 153456349 G A 5.39E-08 Metabolite levels / / 23281178 rs16835332 chr1 153456926 G C 5.39E-08 Metabolite levels / / 23281178 rs3014848 chr1 153457385 G A 5.39E-08 Metabolite levels / / 23281178 rs2986209 chr1 153459457 T G 5.39E-08 Metabolite levels / / 23281178 rs4845552 chr1 153479998 G A 6.00E-06 Hippocampal atrophy / / 19668339 rs138355706 chr1 153520235 G A 0.00035 Breast cancer (ER positive) S100A3 missense 23555315 rs8401 chr1 153533898 A G 1.47E-06 White blood cell count S100A2 UTR-3 21738479 rs1046379 chr1 153604029 C T 1.47E-06 White blood cell count S100A1 intron 21738479 rs10797056 chr1 153613783 A G 6.03E-04 Type 2 diabetes CHTOP intron 17463246 rs10797056 chr1 153613783 A G 1.00E-05 Lymphocyte counts CHTOP intron 22286170 rs7934 chr1 153618766 C T 7.96E-04 Type 2 diabetes CHTOP UTR-3 17463246 rs913859 chr1 153620086 A G 5.60E-04 Myocardial Infarction / / pha002883 rs913860 chr1 153620127 T A 7.28E-04 Type 2 diabetes / / 17463246 rs6427671 chr1 153637404 A G 1.81E-06 White blood cell count ILF2 intron 21738479 rs7536700 chr1 153640827 C T 4.00E-06 Multiple myeloma (IgH translocation) ILF2 intron 23502783 rs10082235 chr1 153656650 C T 5.40E-05 Carotid intima media thickness NPR1 intron 19679847 rs11264236 chr1 153658480 G A 1.93E-06 White blood cell count NPR1 intron 21738479 rs6698058 chr1 153703013 C T 2.31E-04 Type 2 diabetes INTS3 intron 17463246 rs6427183 chr1 153706699 T G 3.76E-04 Multiple complex diseases INTS3 intron 17554300 rs11264336 chr1 153708633 A G 2.57E-05 Monocyte counts INTS3 intron pha003089 rs7515716 chr1 153708906 G A 2.50E-05 Monocyte counts INTS3 intron pha003089 rs12097583 chr1 153723037 T C 2.50E-05 Monocyte counts INTS3 intron pha003089 rs10752613 chr1 153760104 T A 1.94E-04 Multiple complex diseases / / 17554300 rs9427228 chr1 153768451 C T 1.30E-05 Lipoproteins LOC343052 intron pha003079 rs12738361 chr1 153768740 C T 4.75E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9426935 chr1 153769400 C T 5.00E-06 Lentiform nucleus volume LOC343052 intron 22903471 rs16835600 chr1 153773429 T C 6.14E-05 Multiple complex diseases LOC343052 intron 17554300 rs4434872 chr1 153774276 T C 8.00E-06 Conduct disorder (symptom count) / / 20585324 rs4434872 chr1 153774276 T C 3.82E-04 Insulin resistance / / 21901158 rs4451582 chr1 153777669 G T 9.23E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines GATAD2B UTR-3 21844884 rs1139620 chr1 153777848 C T 9.87E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines GATAD2B UTR-3 21844884 rs6668066 chr1 153786182 G A 7.34E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines GATAD2B intron 21844884 rs4363451 chr1 153790501 C T 8.23E-04 Multiple complex diseases GATAD2B intron 17554300 rs4596938 chr1 153794697 T C 8.60E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines GATAD2B intron 21844884 rs6690242 chr1 153801098 C T 3.20E-05 Lipoproteins GATAD2B intron pha003079 rs6427306 chr1 153812119 C T 7.31E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines GATAD2B intron 21844884 rs4845576 chr1 153825404 C T 8.09E-04 Multiple complex diseases GATAD2B intron 17554300 rs4520447 chr1 153829389 T C 4.15E-04 Multiple complex diseases GATAD2B intron 17554300 rs7414227 chr1 153848996 G A 3.00E-06 Lentiform nucleus volume GATAD2B intron 22903471 rs4845584 chr1 153885261 C A 9.39E-05 Multiple complex diseases GATAD2B intron 17554300 rs2252508 chr1 153913770 A G 5.70E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines DENND4B intron 21844884 rs2252508 chr1 153913770 A G 5.00E-06 Lentiform nucleus volume DENND4B intron 22903471 rs10908557 chr1 153927052 C G 7.14E-04 Multiple complex diseases CRTC2 intron 17554300 rs61755890 chr1 153934820 C T 0.0008 Prostate cancer SLC39A1 missense 23555315 rs2072704 chr1 153935543 G A 2.07E-05 Lipoproteins SLC39A1 intron pha003079 rs11264736 chr1 153939130 C T 7.47E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SLC39A1 intron 21844884 rs11264736 chr1 153939130 C T 4.00E-06 Lentiform nucleus volume SLC39A1 intron 22903471 rs2494663 chr1 154092056 C A 1.12E-04 Acute lymphoblastic leukemia (childhood) NUP210L intron 22076464 rs4521985 chr1 154123523 G A 0.000722799 Hypertension (early onset hypertension) NUP210L intron 22479346 rs11265251 chr1 154157090 T C 9.84E-05 Suicide attempts in bipolar disorder TPM3 intron 21041247 rs4074015 chr1 154167626 G C 0.000000442 HDL cholesterol / / 23063622 rs6719 chr1 154179679 T C 3.95E-05 Suicide attempts in bipolar disorder C1orf43 UTR-3 21041247 rs9803857 chr1 154191791 G A 4.30E-05 Suicide attempts in bipolar disorder C1orf43 intron 21041247 rs2879788 chr1 154204310 A T 4.19E-05 Suicide attempts in bipolar disorder UBAP2L intron 21041247 rs12062977 chr1 154211516 C T 4.06E-05 Suicide attempts in bipolar disorder UBAP2L intron 21041247 rs10158820 chr1 154217763 C T 4.05E-05 Suicide attempts in bipolar disorder UBAP2L intron 21041247 rs6427509 chr1 154219718 C T 4.03E-05 Suicide attempts in bipolar disorder UBAP2L intron 21041247 rs2340473 chr1 154225344 T C 4.03E-05 Suicide attempts in bipolar disorder UBAP2L intron 21041247 rs1194596 chr1 154238383 A G 8.16E-04 Suicide attempts in bipolar disorder UBAP2L intron 21041247 rs1194596 chr1 154238383 A G 1.39E-05 Lymphocyte counts UBAP2L intron 22286170 rs1212352 chr1 154239283 T A 1.55E-04 Acute lymphoblastic leukemia (childhood) UBAP2L intron 22076464 rs1044013 chr1 154243115 C T 7.78E-04 Suicide attempts in bipolar disorder UBAP2L UTR-3 21041247 rs1194593 chr1 154245512 A G 7.68E-04 Suicide attempts in bipolar disorder HAX1 intron 21041247 rs1760802 chr1 154259275 C G 7.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs3103309 chr1 154270877 C T 2.88E-05 HIV-1 viral setpoint / / 17641165 rs4103781 chr1 154280622 C T 3.15E-05 Self-reported allergy / / 23817569 rs3916566 chr1 154282146 C T 7.80E-05 Self-reported allergy / / 23817569 rs6427560 chr1 154287687 A G 9.06E-05 Self-reported allergy / / 23817569 rs1194610 chr1 154296076 T C 2.20E-04 Coronary heart disease AQP10 cds-synon 21966275 rs1194610 chr1 154296076 T C 7.41E-05 Soluble levels of adhesion molecules AQP10 cds-synon pha003072 rs1194588 chr1 154313232 T C 6.22E-04 Response to cytidine analogues (gemcitabine) ATP8B2 intron 24483146 rs1194587 chr1 154317153 C T 1.03E-04 Self-reported allergy ATP8B2 cds-synon 23817569 rs1194586 chr1 154317418 T C 1.03E-04 Self-reported allergy ATP8B2 intron 23817569 rs1194585 chr1 154318564 G A 1.02E-04 Self-reported allergy ATP8B2 intron 23817569 rs1194584 chr1 154319756 G T 8.70E-05 Self-reported allergy ATP8B2 intron 23817569 rs1194592 chr1 154324384 C G 7.01E-05 Self-reported allergy / / 23817569 rs2483712 chr1 154325149 A C 3.78E-05 Self-reported allergy / / 23817569 rs6688376 chr1 154326366 C T 7.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs12025518 chr1 154340789 A C 6.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs11582424 chr1 154363985 A C 6.04E-04 Alcohol dependence / / 24277619 rs11265608 chr1 154364140 G A 0.0000574 Oligoarticular juvenile idiopathic arthritis / / 23603761 rs11265608 chr1 154364140 G A 0.000112 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis / / 23603761 rs11265608 chr1 154364140 G A 2.75E-08 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs17654071 chr1 154369252 A G 3.53E-04 Alcohol dependence / / 24277619 rs2054855 chr1 154370938 C T 8.84E-04 Multiple complex diseases / / 17554300 rs1552481 chr1 154376353 C T 5.17E-14 HDL cholesterol IL6R nearGene-5 23063622 rs12089132 chr1 154378336 T C 1.71E-31 HDL cholesterol IL6R intron 23063622 rs72698115 chr1 154379369 A C 1.26E-08 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) IL6R intron 23603761 rs4845618 chr1 154400015 G T 0.00000059 C-reactive protein IL6R intron 23505291 rs4845618 chr1 154400015 G T 2.76E-10 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs2228144 chr1 154401679 G A 5.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy) IL6R cds-synon 24554482 rs7553796 chr1 154404406 A C 0.0000024 C-reactive protein IL6R intron 23505291 rs7553796 chr1 154404406 A C 5.10E-12 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs7518199 chr1 154407419 A C 3.89E-07 Fibrinogen IL6R intron 20978265 rs7518199 chr1 154407419 A C 1.06E-20 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs7518199 chr1 154407419 A C 1.67E-10 C-reactive protein IL6R intron 23505291 rs4845371 chr1 154408340 T C 0.00000245 C-reactive protein IL6R intron 23505291 rs4845371 chr1 154408340 T C 2.71E-12 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs6667434 chr1 154409100 A G 0.0000025 C-reactive protein IL6R intron 23505291 rs6667434 chr1 154409100 A G 3.36E-12 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs4553185 chr1 154410955 C T 1.98E-04 Alzheimer's disease (late onset) IL6R intron 21379329 rs4553185 chr1 154410955 C T 0.00000206 C-reactive protein IL6R intron 23505291 rs4553185 chr1 154410955 C T 4.40E-12 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs4537545 chr1 154418879 C T 2.00E-14 C-reactive protein IL6R intron 19567438 rs4537545 chr1 154418879 C T 1.98E-07 Fibrinogen IL6R intron 20978265 rs4537545 chr1 154418879 C T 6.40E-04 Atrial fibrillation IL6R intron 21846873 rs4537545 chr1 154418879 C T 2.20E-11 C-reactive protein IL6R intron 23505291 rs4537545 chr1 154418879 C T 9.63E-22 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs4537545 chr1 154418879 C T 5.09E-05 C-reactive protein IL6R intron 23844046 rs12730935 chr1 154419892 G A 4.87E-60 Interleukin-6R IL6R intron 23696881 rs7529229 chr1 154420778 T C 8.28E-08 Fibrinogen IL6R intron 20978265 rs7529229 chr1 154420778 T C 8.30E-04 Atrial fibrillation IL6R intron 21846873 rs7529229 chr1 154420778 T C 1.77E-21 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs7529229 chr1 154420778 T C 2.28E-11 C-reactive protein IL6R intron 23505291 rs28638007 chr1 154421354 T C 4.90E-04 Atrial fibrillation IL6R intron 21846873 rs28638007 chr1 154421354 T C 0.000000369 C-reactive protein IL6R intron 23505291 rs28638007 chr1 154421354 T C 1.77E-12 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs4845625 chr1 154422067 T C 4.80E-04 Atrial fibrillation IL6R intron 21846873 rs4845625 chr1 154422067 T C 3.10E-04 Coronary heart disease IL6R intron 21966275 rs4845625 chr1 154422067 T C 0.00000043 Coronary artery disease with myocardial infarction IL6R intron 23202125 rs4845625 chr1 154422067 T C 0.0000367 Coronary artery disease (CAD) age >50 IL6R intron 23202125 rs4845625 chr1 154422067 T C 0.0000655 Coronary artery disease (CAD) (males) IL6R intron 23202125 rs4845625 chr1 154422067 T C 0.000201 Coronary artery disease (CAD) age <=50 IL6R intron 23202125 rs4845625 chr1 154422067 T C 0.000374 Coronary artery disease (CAD) (females) IL6R intron 23202125 rs4845625 chr1 154422067 T C 3.64E-10 Coronary artery disease IL6R intron 23202125 rs4845625 chr1 154422067 T C 0.00000042 C-reactive protein IL6R intron 23505291 rs4845625 chr1 154422067 T C 1.18E-12 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs4845625 chr1 154422067 T C 1.93E-05 Coronary artery disease IL6R intron 24262325 rs4845626 chr1 154423485 G T 6.13E-04 Multiple complex diseases IL6R intron 17554300 rs4845626 chr1 154423485 G T 4.96E-04 Response to taxane treatment (placlitaxel) IL6R intron 23006423 rs4129267 chr1 154426264 C T 7.00E-06 Pulmonary function IL6R intron 17903307 rs4129267 chr1 154426264 C T 2.00E-57 Protein quantitative trait loci IL6R intron 18464913 rs4129267 chr1 154426264 C T 8.41E-07 Fibrinogen IL6R intron 20978265 rs4129267 chr1 154426264 C T 2.00E-48 C-reactive protein IL6R intron 21300955 rs4129267 chr1 154426264 C T 2.00E-08 Asthma IL6R intron 21907864 rs4129267 chr1 154426264 C T 1.63E-21 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs4129267 chr1 154426264 C T 8.80E-12 C-reactive protein IL6R intron 23505291 rs4129267 chr1 154426264 C T 6.00E-27 Fibrinogen IL6R intron 23969696 rs2228145 chr1 154426970 A C,G,T 2.00E-08 C-reactive protein IL6R missense 18439548 rs2228145 chr1 154426970 A C,G,T 2.00E-11 Fibrinogen IL6R missense 20031577 rs2228145 chr1 154426970 A C,G,T 0.000000013 Rheumatoid arthritis IL6R missense 23143596 rs2228145 chr1 154426970 A C,G,T 0.00000002 Circulating C-reactive protein IL6R missense 23505291 rs2228145 chr1 154426970 A C,G,T 0.0000153 Coronary heart disease IL6R missense 23505291 rs2228145 chr1 154426970 A C,G,T 1.02E-21 Interleukin-6 (IL-6) levels IL6R missense 23505291 rs2228145 chr1 154426970 A C,G,T 1.80E-11 Fibrinogen IL6R missense 23505291 rs2228145 chr1 154426970 A C,G,T 2.00E-57 Circulating soluble interleukin-6 (sIL-6) IL6R missense 23505291 rs2228145 chr1 154426970 A C,G,T 2.36E-08 Circulating interleukin-6 (IL-6) IL6R missense 23505291 rs2228145 chr1 154426970 A C,G,T 4.00E-09 Rheumatoid arthritis IL6R missense 24390342 rs2228145 chr1 154426970 A C,G,T 5.00E-06 Rheumatoid arthritis IL6R missense 24390342 rs2228145 chr1 154426970 A C,G,T 9.20E-05 Rheumatoid arthritis IL6R missense 24390342 rs2228145 chr1 154426970 A C,G,T 2.00E-08 C-reactive protein IL6R missense 18439548 rs2228145 chr1 154426970 A C,G,T 2.00E-11 Fibrinogen IL6R missense 20031577 rs2228145 chr1 154426970 A C,G,T 0.000000157 Rheumatoid arthritis (CCP positive) IL6R missense 23143596 rs2228145 chr1 154426970 A C,G,T 1.08E-11 C-reactive protein IL6R missense 23505291 rs2228145 chr1 154426970 A C,G,T 8.84E-60 Interleukin-6R IL6R missense 23696881 rs11265618 chr1 154430092 C T 8.34E-04 Multiple complex diseases IL6R intron 17554300 rs11265618 chr1 154430092 C T 1.16E-06 Rheumatoid arthritis IL6R intron 19503088 rs11265618 chr1 154430092 C T 5.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IL6R intron 20877124 rs11265618 chr1 154430092 C T 8.10E-04 Response to taxane treatment (placlitaxel) IL6R intron 23006423 rs4240872 chr1 154436195 C T 4.51E-04 Alcohol dependence IL6R intron 20201924 rs4240872 chr1 154436195 C T 7.73E-05 Alzheimer's disease (late onset) IL6R intron 21379329 rs4240872 chr1 154436195 C T 7.21E-05 Abdominal aortic aneurysm IL6R intron 24046328 rs4240872 chr1 154436195 C T 4.26E-04 Myocardial infarction IL6R intron 24916648 rs4509570 chr1 154436384 G C 8.10E-04 Coronary heart disease IL6R intron 21966275 rs4509570 chr1 154436384 G C 3.08E-08 Interleukin-6 (IL-6) levels IL6R intron 23505291 rs2229238 chr1 154437896 T C 7.00E-07 Coronary heart disease IL6R UTR-3 22319020 rs7514452 chr1 154438084 C T 3.47E-06 Alzheimer's disease (late onset) IL6R UTR-3 21379329 rs7514452 chr1 154438084 C T 6.83E-05 Abdominal aortic aneurysm IL6R UTR-3 24046328 rs6700296 chr1 154473660 T C 6.26E-04 Multiple complex diseases SHE intron 17554300 rs12740969 chr1 154487060 T G 0.00000495 C-reactive protein TDRD10 intron 23505291 rs12740969 chr1 154487060 T G 1.20E-11 Interleukin-6 (IL-6) levels TDRD10 intron 23505291 rs6674171 chr1 154491683 A G 1.15E-05 Abdominal aortic aneurysm TDRD10 intron 22055160 rs7556449 chr1 154505886 A G 3.05E-06 Alzheimer's disease (late onset) TDRD10 intron 21379329 rs12136771 chr1 154511502 T C 9.00E-04 Multiple complex diseases TDRD10 intron 17554300 rs75323106 chr1 154511502 T TC 9.00E-04 Multiple complex diseases TDRD10 intron 17554300 rs3811448 chr1 154516578 G A 1.69E-06 Alzheimer's disease (late onset) TDRD10 missense 21379329 rs7543174 chr1 154527672 C T 9.51E-05 IgE levels UBE2Q1 intron 22075330 rs4074436 chr1 154531910 G A 3.54E-08 White blood cell count / / 21738479 rs9427089 chr1 154534766 G A 9.63E-07 White blood cell count / / 21738479 rs4845652 chr1 154538205 C T 0.0000479 Sarcoidosis / / 22952805 rs2072661 chr1 154548880 G A 1 Drug response to Nicotine CHRNB2 UTR-3 18593715 rs11264221 chr1 154551717 C T 1.13E-04 Multiple complex diseases CHRNB2 UTR-3 17554300 rs884618 chr1 154601157 A G 5.20E-07 White blood cell count ADAR nearGene-5 21738479 rs9427108 chr1 154607914 G A 5.15E-07 White blood cell count / / 21738479 rs12092890 chr1 154608570 C T 1.34E-04 Multiple complex diseases / / 17554300 rs9426831 chr1 154609657 A T 3.16E-06 White blood cell count / / 21738479 rs11264233 chr1 154625632 G A 2.69E-07 White blood cell count / / 21738479 rs9427113 chr1 154626477 A G 1.51E-08 White blood cell count / / 21738479 rs9427114 chr1 154626705 T C 1.27E-08 White blood cell count / / 21738479 rs1876304 chr1 154633513 G T 8.50E-06 Asthma / / pha003128 rs9427118 chr1 154637584 C T 4.73E-06 White blood cell count / / 21738479 rs6698385 chr1 154652572 A G 2.83E-05 Asthma / / pha003128 rs2036627 chr1 154669577 C T 7.24E-06 Smoking behavior KCNN3 nearGene-3 19188921 rs1995662 chr1 154679567 C T 8.77E-06 Smoking behavior KCNN3 UTR-3 19188921 rs1995662 chr1 154679567 C T 1.87E-04 Parkinson's disease KCNN3 UTR-3 21248740 rs4845663 chr1 154692088 T C 1.09E-06 White blood cell count KCNN3 intron 21738479 rs3738028 chr1 154698817 C A 4.60E-05 Type 2 diabetes KCNN3 intron 17460697 rs10494301 chr1 154701218 T C 5.68E-04 Obesity (extreme) KCNN3 intron 21935397 rs12402320 chr1 154701406 C T 0.000436065 Hypertension (early onset hypertension) KCNN3 intron 22479346 rs6682000 chr1 154711226 C A 1.02E-04 Amyotrophic lateral sclerosis (sporadic) KCNN3 intron 24529757 rs1506985 chr1 154713341 T C 0.0000466 post-traumatic stress disorder KCNN3 intron 22869035 rs1506985 chr1 154713341 T C 4.66E-05 Schizophrenia KCNN3 intron 22883433 rs4999127 chr1 154714006 G A 0.0000206 post-traumatic stress disorder KCNN3 intron 22869035 rs4999127 chr1 154714006 G A 2.06E-05 Schizophrenia KCNN3 intron 22883433 rs4845390 chr1 154726374 T C 5.29E-04 Multiple complex diseases KCNN3 intron 17554300 rs10494300 chr1 154726546 G C 4.16E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy KCNN3 intron 24578207 rs10494300 chr1 154726546 G C 4.16E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy KCNN3 intron 24578207 rs6682291 chr1 154732776 A C 4.40E-04 Alzheimer's disease KCNN3 intron 24755620 rs1131820 chr1 154744852 A G 3.55E-04 Multiple complex diseases KCNN3 cds-synon 17554300 rs6691316 chr1 154754194 C T 7.00E-06 Obesity-related traits KCNN3 intron 23251661 rs6691316 chr1 154754194 C T 9.00E-06 Obesity-related traits KCNN3 intron 23251661 rs4079531 chr1 154761265 G A 2.00E-04 Cognitive impairment induced by topiramate KCNN3 intron 22091778 rs954785 chr1 154770139 G T 3.60E-06 Non-small cell lung cancer (survival) KCNN3 intron 23704207 rs1702176 chr1 154777157 G A 1 Drug response to Etoposide KCNN3 intron 17537913 rs2798601 chr1 154779685 A G 7.96E-05 Postoperative ventricular dysfunction KCNN3 intron 21980348 rs7512194 chr1 154781889 G A 6.07E-04 Amyotrophic Lateral Sclerosis KCNN3 intron 17362836 rs1106236 chr1 154787136 T C 7.29E-05 Blood Pressure KCNN3 intron pha003048 rs1218598 chr1 154795389 G A 9.10E-05 Endometriosis KCNN3 intron 21151130 rs6681392 chr1 154796712 T C 4.73E-06 White blood cell count KCNN3 intron 21738479 rs12128882 chr1 154811435 T C 9.71E-05 Sodium levels KCNN3 intron pha003093 rs12740456 chr1 154814197 C A 9.71E-05 Coronary heart disease KCNN3 intron pha003030 rs6666258 chr1 154814268 G C 2.00E-14 Atrial fibrillation KCNN3 intron 22544366 rs13376333 chr1 154814353 C T 2.00E-21 Atrial fibrillation KCNN3 intron 20173747 rs883905 chr1 154815366 G A 4.77E-06 White blood cell count KCNN3 intron 21738479 rs4845396 chr1 154828409 G A 6.50E-05 Endometriosis KCNN3 intron 21151130 rs1218582 chr1 154834183 G A 2.00E-08 Prostate cancer KCNN3 intron 23535732 rs10796934 chr1 154849479 G C 4.53E-04 Multiple complex diseases / / 17554300 rs10908445 chr1 154849590 G A 2.81E-04 Multiple complex diseases / / 17554300 rs4845678 chr1 154853295 T C 4.84E-04 Multiple complex diseases / / 17554300 rs1630500 chr1 154855055 G A 2.00E-08 Parkinson's disease / / 24842889 rs4845679 chr1 154861187 G T 9.67E-05 Serum metabolites / / 19043545 rs4845681 chr1 154868055 G T 9.30E-04 Multiple complex diseases / / 17554300 rs4845681 chr1 154868055 G T 9.78E-05 Serum metabolites / / 19043545 rs12130132 chr1 154880386 G A 7.71E-04 Multiple complex diseases / / 17554300 rs10908448 chr1 154882544 C T 2.75E-04 Multiple complex diseases / / 17554300 rs4845690 chr1 154886817 T C 2.77E-04 Multiple complex diseases / / 17554300 rs12143679 chr1 154891287 C G 0.0000762 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs16836525 chr1 154898899 C T 0.0003 Prostate cancer PMVK missense 23555315 rs16836525 chr1 154898899 C T 0.00061 Prostate cancer (non-advanced prostate cancer) PMVK missense 23555315 rs4578216 chr1 154900721 T C 4.90E-04 Atrial fibrillation PMVK intron 21846873 rs11264286 chr1 154903047 G A 5.93E-06 White blood cell count PMVK intron 21738479 rs877343 chr1 154910012 A G 5.50E-05 Coronary heart disease / / 21966275 rs4845693 chr1 154911257 C T 2.21E-04 Multiple complex diseases / / 17554300 rs3766921 chr1 154935253 G C 1.47E-06 White blood cell count SHC1 UTR-3 21738479 rs4845401 chr1 154941593 C G 3.00E-10 White blood cell count SHC1 intron 21738479 rs12075984 chr1 154943881 A G 1.02E-06 White blood cell count SHC1 intron 21738479 rs12076073 chr1 154944156 A G 3.17E-06 White blood cell count SHC1 intron 21738479 rs11585145 chr1 154947496 A T 1.94E-06 White blood cell count CKS1B intron 21738479 rs10908449 chr1 154955724 C T 9.42E-04 Multiple complex diseases / / 17554300 rs10908449 chr1 154955724 C T 2.88E-06 White blood cell count / / 21738479 rs4845700 chr1 154981708 C T 9.13E-08 White blood cell count ZBTB7B intron 21738479 rs4845405 chr1 155007302 C A 4.88E-04 Myocardial Infarction DCST1 intron pha002873 rs11264300 chr1 155019710 A C 1.36E-04 Myocardial Infarction DCST1 missense pha002873 rs7367207 chr1 155079477 C T 8.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11264329 chr1 155095158 A G 1.22E-06 Lung cancer / / 19654303 rs11264329 chr1 155095158 A G 4.40E-06 Digit length ratio / / 20303062 rs11264329 chr1 155095158 A G 9.46E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11264330 chr1 155098905 G A 5.00E-06 Obesity-related traits / / 23251661 rs4971066 chr1 155105882 T G 2.47E-05 Cervical cancer EF/1 intron 24700089 rs9297 chr1 155106550 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) EF/1 UTR-3 20708005 rs12726330 chr1 155108167 G A 5.00E-08 Parkinson's disease / / 22451204 rs4246529 chr1 155115260 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12025371 chr1 155119327 A T 5.54E-06 White blood cell count / / 21738479 rs35304908 chr1 155119327 A AT 5.54E-06 White blood cell count / / 21738479 rs63172161 chr1 155119327 A AT 5.54E-06 White blood cell count / / 21738479 rs10157801 chr1 155120012 A G 1.20E-05 Urinary metabolites / / 21572414 rs10908458 chr1 155126948 T C 2.00E-15 Liver enzyme levels (gamma-glutamyl transferase) / / 22001757 rs4971079 chr1 155130391 G A 5.60E-06 Urinary metabolites / / 21572414 rs4276913 chr1 155131673 A G 2.40E-05 Urinary metabolites / / 21572414 rs4971092 chr1 155143946 C T 1.14E-06 White blood cell count KRTCAP2 intron 21738479 rs4971059 chr1 155148781 G A 3.02E-09 Urate levels TRIM46 intron 23263486 rs3814316 chr1 155149718 G A 6.48E-11 Urate levels TRIM46 cds-synon 23263486 rs11264341 chr1 155151493 C T 6.00E-19 Urate levels TRIM46 intron 23263486 rs9426886 chr1 155151754 A T 1.12E-14 Urate levels TRIM46 intron 23263486 rs4971100 chr1 155155731 G A 1.82E-14 Urate levels TRIM46 intron 23263486 rs2070803 chr1 155157715 A G 1.20E-06 Gastric cancer (diffuse-type gastric cancer) TRIM46 nearGene-3 18488030 rs4072037 chr1 155162067 C T 2.00E-36 magnesium levels MUC1 cds-synon 20700443 rs4072037 chr1 155162067 C T 4.00E-07 Esophageal cancer and gastric cancer MUC1 cds-synon 20729852 rs4072037 chr1 155162067 C T 3.91E-09 Urate levels MUC1 cds-synon 23263486 rs2075570 chr1 155182164 C T 9.20E-07 Gastric cancer (diffuse-type gastric cancer) MTX1 intron 18488030 rs2049805 chr1 155194980 T C 2.00E-12 Renal function-related traits (BUN) GBAP1 intron 22797727 rs2990245 chr1 155197462 C T 2.63E-08 Urate levels GBAP1 nearGene-5 23263486 rs1142287 chr1 155230131 C T 2.00E-13 Crohn's disease SCAMP3 cds-synon 21102463 rs1142287 chr1 155230131 C T 2.00E-13 Crohn's disease SCAMP3 cds-synon 21102463 rs4971072 chr1 155273869 G A 3.14E-14 White blood cell count / / 21738479 rs2297480 chr1 155279482 T G 1 Drug response to Alendronate FDPS intron 18687167 rs2297480 chr1 155279482 T G 1 Drug response to Ibandronate FDPS intron 18687167 rs2297480 chr1 155279482 T G 1 Drug response to Pamidronate FDPS intron 18687167 rs2297480 chr1 155279482 T G 1 Drug response to Risedronate FDPS intron 18687167 rs2297480 chr1 155279482 T G 1 Drug response to Zoledronate FDPS intron 18687167 rs11264359 chr1 155282829 A G 3.80E-05 Crohn's disease FDPS intron 20570966 rs11264363 chr1 155318308 G C 5.16E-04 Type 2 diabetes ASH1L intron 17463246 rs1886905 chr1 155372672 T C 6.62E-06 White blood cell count ASH1L intron 21738479 rs570246343 chr1 155372672 T TC 6.62E-06 White blood cell count ASH1L intron 21738479 rs1325908 chr1 155413304 C A 9.65E-04 Type 2 diabetes ASH1L intron 17463246 rs1325908 chr1 155413304 C A 4.10E-06 White blood cell count ASH1L intron 21738479 rs6688636 chr1 155478897 T C 4.30E-05 Crohn's disease ASH1L intron 20570966 rs6688636 chr1 155478897 T C 2.82E-06 White blood cell count ASH1L intron 21738479 rs6696888 chr1 155508882 G A 1.30E-13 White blood cell count ASH1L intron 21738479 rs602905 chr1 155628628 C G 4.67E-06 Age-related macular degeneration / / pha000001 rs651905 chr1 155641975 A G 4.67E-06 Age-related macular degeneration YY1AP1 intron pha000001 rs821551 chr1 155688580 C A 5.07E-11 White blood cell count DAP3 intron 21738479 rs348184 chr1 155697810 A G 4.92E-04 Multiple complex diseases DAP3 intron 17554300 rs348184 chr1 155697810 A G 1.05E-22 Narcolepsy DAP3 intron 19629137 rs372780 chr1 155698028 A C 7.52E-07 White blood cell count DAP3 intron 21738479 rs394851 chr1 155719467 G T 1.63E-10 White blood cell count MSTO2P intron 21738479 rs822485 chr1 155763032 G A 2.20E-04 Multiple complex diseases GON4L intron 17554300 rs822519 chr1 155840706 C T 9.02E-04 Insulin resistance SYT11 intron 21901158 rs729022 chr1 155852123 C T 4.57E-06 White blood cell count SYT11 UTR-3 21738479 rs2282301 chr1 155868625 G A 7.00E-06 Conduct disorder (interaction) RIT1 UTR-3 18846501 rs3856261 chr1 155876613 G A 2.49E-07 White blood cell count RIT1 intron 21738479 rs670523 chr1 155878732 A G 6.00E-11 Inflammatory bowel disease RIT1 intron 23128233 rs572609 chr1 155897716 T C 3.05E-04 Multiple complex diseases KIAA0907 intron 17554300 rs11264422 chr1 155907823 T A 1.69E-08 White blood cell count / / 21738479 rs142470296 chr1 155912426 A G 0.000058 Prostate cancer (advanced) RXFP4 missense 23555315 rs2364403 chr1 155927752 G A 1.00E-06 Amyotrophic lateral sclerosis (age of onset) ARHGEF2 intron 22959728 rs6670493 chr1 155956903 C G 9.89E-06 White blood cell count / / 21738479 rs11589188 chr1 155971887 T C 6.00E-05 Alcohol dependence / / 21703634 rs34372695 chr1 156030037 C T 4.00E-12 Parkinson's disease / / 21292315 rs34372695 chr1 156030037 C T 3.60E-12 Parkinson's disease / / 22438815 rs2275075 chr1 156040310 A G 8.00E-05 Waist circumference and related phenotypes / / 18454146 rs11264432 chr1 156042915 G A 1.99E-04 Suicide attempts in bipolar disorder MEX3A UTR-3 21041247 rs12035615 chr1 156055344 C T 7.91E-04 Multiple complex diseases LM/ intron 17554300 rs10737170 chr1 156063880 C A 2.47E-04 Response to taxane treatment (placlitaxel) LM/ intron 23006423 rs10737170 chr1 156063880 C A 8.62E-08 Parkinson's disease LM/ intron 24842889 rs6661281 chr1 156074845 T C 6.12E-04 Suicide attempts in bipolar disorder LM/ intron 21041247 rs915179 chr1 156078249 A G 5.97E-04 Suicide attempts in bipolar disorder LM/ intron 21041247 rs915179 chr1 156078249 A G 2.37E-05 Longevity LM/ intron 22279548 rs915180 chr1 156079083 C T 4.82E-04 Suicide attempts in bipolar disorder LM/ intron 21041247 rs505058 chr1 156106185 T C 2.00E-04 Alzheimer's disease (late onset) LM/ cds-synon 21460841 rs12128066 chr1 156127368 T C 2.10E-05 Bipolar disorder and schizophrenia SEMA4A intron 20889312 rs112223391 chr1 156156094 G A 3.61E-05 Intracerebral hemorrhage / / 24656865 rs7534339 chr1 156156219 T C 3.14E-05 Intracerebral hemorrhage / / 24656865 rs6427304 chr1 156156789 A G 6.80E-05 White matter hyperintensity burden / / 21681796 rs6427304 chr1 156156789 A G 4.02E-07 Intracerebral hemorrhage / / 24656865 rs11587860 chr1 156156951 G C 3.10E-07 Intracerebral hemorrhage / / 24656865 rs2758615 chr1 156158367 T C 5.08E-07 Intracerebral hemorrhage / / 24656865 rs57056972 chr1 156159064 C A 3.61E-05 Intracerebral hemorrhage / / 24656865 rs2842864 chr1 156159217 G A 5.09E-07 Intracerebral hemorrhage / / 24656865 rs2842865 chr1 156159532 G A 5.64E-07 Intracerebral hemorrhage / / 24656865 rs55910626 chr1 156159909 C G 3.57E-05 Intracerebral hemorrhage / / 24656865 rs2758616 chr1 156160358 T C 7.73E-07 Intracerebral hemorrhage / / 24656865 rs2842869 chr1 156160696 A G 5.16E-07 Intracerebral hemorrhage / / 24656865 rs10159384 chr1 156160822 C T 3.61E-05 Intracerebral hemorrhage / / 24656865 rs2758618 chr1 156160892 T C 5.16E-07 Intracerebral hemorrhage / / 24656865 rs61462713 chr1 156161682 C T 3.78E-05 Intracerebral hemorrhage / / 24656865 rs2758619 chr1 156162559 A G 5.27E-07 Intracerebral hemorrhage / / 24656865 rs41265025 chr1 156163906 C T 3.64E-05 Intracerebral hemorrhage SLC25A44 UTR-5 24656865 rs2540183 chr1 156164885 C G 8.65E-08 Intracerebral hemorrhage SLC25A44 intron 24656865 rs3001790 chr1 156165290 T G 4.71E-07 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2984615 chr1 156165317 G C 4.71E-07 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2842882 chr1 156165342 T G 4.70E-07 Intracerebral hemorrhage SLC25A44 intron 24656865 rs55675376 chr1 156165881 C T 3.62E-05 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2842857 chr1 156168736 T C 6.30E-05 White matter hyperintensity burden SLC25A44 intron 21681796 rs2842857 chr1 156168736 T C 5.01E-07 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2072499 chr1 156169610 A G 3.00E-08 Testicular germ cell tumor SLC25A44 intron 23666240 rs2072499 chr1 156169610 A G 4.37E-07 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2253677 chr1 156171296 C G 3.13E-04 Multiple complex diseases SLC25A44 intron 17554300 rs2253677 chr1 156171296 C G 6.20E-05 White matter hyperintensity burden SLC25A44 intron 21681796 rs2253677 chr1 156171296 C G 5.02E-07 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2253809 chr1 156172125 T C 4.14E-07 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2241109 chr1 156173082 C T 6.74E-04 Alcohol dependence SLC25A44 intron 20201924 rs2241109 chr1 156173082 C T 3.80E-05 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2266514 chr1 156173685 T C 3.86E-07 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2736605 chr1 156174475 T C 5.46E-07 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2736607 chr1 156174930 G T 3.71E-05 Intracerebral hemorrhage SLC25A44 intron 24656865 rs72708291 chr1 156177285 A T 3.70E-05 Intracerebral hemorrhage SLC25A44 intron 24656865 rs2241108 chr1 156181007 C G 5.20E-05 White matter hyperintensity burden SLC25A44 UTR-3 21681796 rs2241108 chr1 156181007 C G 4.20E-07 Intracerebral hemorrhage SLC25A44 UTR-3 24656865 rs2853641 chr1 156181770 A G 5.30E-05 White matter hyperintensity burden SLC25A44 UTR-3 21681796 rs2853641 chr1 156181770 A G 4.20E-07 Intracerebral hemorrhage SLC25A44 UTR-3 24656865 rs2075163 chr1 156181833 T G 0.00007648 Sarcoidosis SLC25A44 UTR-3 22952805 rs2241107 chr1 156182710 T C 5.40E-05 White matter hyperintensity burden / / 21681796 rs2241107 chr1 156182710 T C 4.27E-07 Intracerebral hemorrhage / / 24656865 rs1060604 chr1 156184268 T C 8.29E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs1137703 chr1 156184458 T C 4.47E-07 Intracerebral hemorrhage PMF1 intron 24656865 rs2244144 chr1 156184598 G A 8.20E-05 White matter hyperintensity burden PMF1 intron 21681796 rs2244144 chr1 156184598 G A 8.22E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2540175 chr1 156184747 T C 5.08E-07 Intracerebral hemorrhage PMF1 intron 24656865 rs2853643 chr1 156184831 G A 8.29E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs7534434 chr1 156186615 A G 4.62E-07 Intracerebral hemorrhage PMF1 intron 24656865 rs2540173 chr1 156188214 A G 1.90E-05 White matter hyperintensity burden PMF1 intron 21681796 rs2540173 chr1 156188214 A G 4.85E-07 Intracerebral hemorrhage PMF1 intron 24656865 rs116902958 chr1 156188624 T A 0.0000329 Sarcoidosis PMF1 intron 22952805 rs2853646 chr1 156189626 C T 7.44E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs6427307 chr1 156190083 A G 5.34E-07 Intracerebral hemorrhage PMF1 intron 24656865 rs2247476 chr1 156190280 C A 3.86E-05 Intracerebral hemorrhage PMF1 intron 24656865 rs887953 chr1 156191149 T C 8.20E-05 White matter hyperintensity burden PMF1 intron 21681796 rs887953 chr1 156191149 T C 7.55E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs909269 chr1 156192028 C T 4.16E-05 Intracerebral hemorrhage PMF1 intron 24656865 rs2758598 chr1 156194339 G A 1.20E-07 Intracerebral hemorrhage PMF1 intron 24656865 rs2758600 chr1 156195205 C T 8.32E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2540171 chr1 156195682 G A 3.54E-05 Intracerebral hemorrhage PMF1 intron 24656865 rs2248074 chr1 156195888 C T 5.44E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2736613 chr1 156196016 T C 5.43E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2842868 chr1 156196407 T G 3.55E-05 Intracerebral hemorrhage PMF1 intron 24656865 rs2984613 chr1 156197380 C T 1.44E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2984613 chr1 156197380 C T 2.00E-10 Intracerebral hemorrhage PMF1 intron 24656865 rs3001789 chr1 156197614 T G 1.59E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2758603 chr1 156198994 T C 1.56E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2758605 chr1 156200445 G C 9.40E-06 White matter hyperintensity burden PMF1 intron 21681796 rs2758605 chr1 156200445 G C 0.0000979 white matter hyperintensity burden PMF1 intron 23674528 rs2758605 chr1 156200445 G C 1.55E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2842870 chr1 156200671 T C 1.65E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs1052053 chr1 156202173 A C,G,T 9.55E-04 Multiple complex diseases PMF1 missense 17554300 rs1052053 chr1 156202173 A C,G,T 5.00E-06 White matter hyperintensity burden PMF1 missense 21681796 rs1052053 chr1 156202173 A C,G,T 0.0000605 white matter hyperintensity burden PMF1 missense 23674528 rs1052053 chr1 156202173 A C,G,T 9.24E-08 Intracerebral hemorrhage PMF1 missense 24656865 rs2736609 chr1 156202640 C T 1.82E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2758607 chr1 156202759 G A 1.80E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2251636 chr1 156202809 G C 1.21E-07 Intracerebral hemorrhage PMF1 intron 24656865 rs2758608 chr1 156202860 A T 1.80E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2758609 chr1 156202868 G A 1.80E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2251847 chr1 156204047 G A 1.00E-05 White matter hyperintensity burden PMF1 intron 21681796 rs2251847 chr1 156204047 G A 1.62E-08 Intracerebral hemorrhage PMF1 intron 24656865 rs2842873 chr1 156204653 C T 6.40E-06 White matter hyperintensity burden PMF1 intron 21681796 rs2842873 chr1 156204653 C T 0.00000751 white matter hyperintensity burden PMF1 intron 23674528 rs2842873 chr1 156204653 C T 1.40E-07 Intracerebral hemorrhage PMF1 intron 24656865 rs1052067 chr1 156206121 G A 5.12E-05 Alcohol dependence PMF1 missense 20201924 rs1052067 chr1 156206121 G A 5.12E-05 Alcoholism PMF1 missense pha002891 rs182363024 chr1 156208217 G A 0.00007925 Sarcoidosis PMF1 intron 22952805 rs2842880 chr1 156232358 T C 3.00E-04 Cognitive impairment induced by topiramate SMG5 intron 22091778 rs6684514 chr1 156255456 G A 3.00E-09 Blood cell counts and other traits TMEM79 missense 20139978 rs6684514 chr1 156255456 G A 3.39E-09 Blood cell counts and other traits TMEM79 missense 20139978 rs6684514 chr1 156255456 G A 1.00E-23 Glycated hemoglobin levels TMEM79 missense 24647736 rs11264467 chr1 156273061 C T 1.07E-04 Lymphocyte counts / / 22286170 rs2249790 chr1 156287360 C T 2.00E-04 Cognitive impairment induced by topiramate CCT3 intron 22091778 rs7525133 chr1 156341494 G A 5.00E-06 Visceral adipose tissue adjusted for BMI RHBG intron 22589738 rs2245623 chr1 156347131 G A 1.61E-04 IgE levels RHBG missense 17255346 rs872120 chr1 156352396 C T 0.00000998 Polycystic ovary syndrome RHBG intron 22951595 rs872120 chr1 156352396 C T 9.98E-06 Intracranial aneurysm RHBG intron 22961961 rs6686886 chr1 156356480 G A 6.58E-04 Lymphocyte counts / / 22286170 rs6686886 chr1 156356480 G A 9.00E-06 Subcutaneous adipose tissue / / 22589738 rs16837376 chr1 156392455 A T 2.94E-04 Type 2 diabetes C1orf61 intron 17463246 rs10494305 chr1 156400060 C T 4.70E-05 Kawasaki disease / / 22446962 rs11264483 chr1 156406381 G C 1.67E-10 White blood cell count / / 21738479 rs4414033 chr1 156406853 G A 1.78E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1171663 chr1 156413502 A C 4.81E-04 Smoking cessation / / 24665060 rs1050316 chr1 156434703 G T 3.20E-10 Migraine / / 22683712 rs2274316 chr1 156446242 C A 3.60E-08 Migraine MEF2D intron 22683712 rs2274316 chr1 156446242 C A 1.00E-07 Migraine - clinic-based MEF2D intron 23793025 rs2274316 chr1 156446242 C A 1.00E-08 Migraine MEF2D intron 23793025 rs2274316 chr1 156446242 C A 2.31E-05 Migraine without aura MEF2D intron 23793025 rs1925950 chr1 156450740 G A 2.97E-08 Migraine / / 22683712 rs202206511 chr1 156456301 C CT 7.00E-11 Migraine MEF2D intron 22683712 rs202206511 chr1 156456301 C CT 1.35E-07 Migraine - clinic-based MEF2D intron 23793025 rs202206511 chr1 156456301 C CT 1.42E-05 Migraine without aura MEF2D intron 23793025 rs202206511 chr1 156456301 C CT 1.91E-08 Migraine MEF2D intron 23793025 rs3790455 chr1 156456301 C T 7.00E-11 Migraine MEF2D intron 22683712 rs3790455 chr1 156456301 C T 1.35E-07 Migraine - clinic-based MEF2D intron 23793025 rs3790455 chr1 156456301 C T 1.42E-05 Migraine without aura MEF2D intron 23793025 rs3790455 chr1 156456301 C T 1.91E-08 Migraine MEF2D intron 23793025 rs3790459 chr1 156461707 A T 2.85E-08 Migraine MEF2D intron 22683712 rs10908505 chr1 156468243 T A 5.70E-11 White blood cell count MEF2D intron 21738479 rs12136856 chr1 156473114 C G 3.90E-08 Migraine / / 22683712 rs11264489 chr1 156480831 A G 6.00E-04 Obesity (extreme) / / 21935397 rs6685228 chr1 156486009 G A 7.53E-04 Smoking initiation / / 24665060 rs6674079 chr1 156486061 A G 5.07E-04 Obesity (extreme) / / 21935397 rs1750307 chr1 156488420 T A 6.22E-04 Obesity (extreme) / / 21935397 rs1171564 chr1 156498673 T A 5.43E-04 Type 2 diabetes IQGAP3 intron 17463246 rs1609666 chr1 156502991 A G 1.34E-04 Type 2 diabetes IQGAP3 intron 17463246 rs1609666 chr1 156502991 A G 4.83E-05 Serum metabolites IQGAP3 intron 19043545 rs1609666 chr1 156502991 A G 7.14E-04 Suicide attempts in bipolar disorder IQGAP3 intron 21423239 rs744224 chr1 156518379 G A 4.30E-05 Type 2 diabetes IQGAP3 missense 17463246 rs12760461 chr1 156525023 T C 9.80E-04 Suicide attempts in bipolar disorder IQGAP3 intron 21423239 rs6682716 chr1 156551848 A G 2.98E-08 White blood cell count TTC24 missense 21738479 rs12090808 chr1 156555819 A G 3.68E-10 Triglycerides TTC24 missense 23063622 rs10796961 chr1 156556321 G A 3.05E-07 White blood cell count TTC24 cds-synon 21738479 rs879461 chr1 156567496 C T 6.28E-05 Serum metabolites GPATCH4 intron 19043545 rs879461 chr1 156567496 C T 7.70E-33 Lymphocyte counts GPATCH4 intron 22286170 rs41434645 chr1 156570715 T G 5.82E-04 Multiple complex diseases GPATCH4 intron 17554300 rs11576266 chr1 156572159 A G 1.03E-07 White blood cell count / / 21738479 rs7536235 chr1 156581534 T C 5.44E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1056695 chr1 156622252 G A 9.37E-05 Coronary heart disease BCAN missense pha003035 rs11360 chr1 156629037 A G 3.57E-05 stroke (ischemic) BCAN UTR-3 17434096 rs147070824 chr1 156641200 T A 0.00009 Prostate cancer (advanced) NES missense 23555315 rs12145743 chr1 156700651 T G 0.00054 Breast cancer RR/D1 intron 23555315 rs12145743 chr1 156700651 T G 2.00E-08 HDL cholesterol RR/D1 intron 24097068 rs6670122 chr1 156707775 T G 2.25E-41 Narcolepsy MRPL24 intron 19629137 rs4399146 chr1 156713558 G A 0.0006 Breast cancer HDGF missense 23555315 rs1412310 chr1 156746608 G A 1.79E-04 HIV-1 viral setpoint PRCC intron 17641165 rs2644615 chr1 156761618 C T 1.80E-05 Urinary metabolites PRCC intron 21572414 rs928392 chr1 156770816 T C 2.20E-05 Urinary metabolites PRCC nearGene-3 21572414 rs7531222 chr1 156789781 C T 8.58E-06 White blood cell count NTRK1 intron 21738479 rs12756019 chr1 156799912 G A 4.89E-08 White blood cell count NTRK1 intron 21738479 rs6337 chr1 156848995 C T 1.27E-08 White blood cell count NTRK1 cds-synon 21738479 rs2768759 chr1 156852463 A C 1 Drug response to Aspirin / / 18511696 rs2768762 chr1 156860462 G T 5.01E-14 White blood cell count / / 21738479 rs12566888 chr1 156869047 G T 4.00E-16 Platelet aggregation PEAR1 intron 20526338 rs12566888 chr1 156869047 G T 5.00E-19 Platelet aggregation PEAR1 intron 20526338 rs12041331 chr1 156869714 G A 7.70E-09 Platelet response with aspirin and clopidogrel PEAR1 intron 23392654 rs2768744 chr1 156872149 G A 1.96E-09 White blood cell count PEAR1 intron 21738479 rs749256 chr1 156884365 T C 2.12E-04 Alzheimer's disease PEAR1 intron 24755620 rs822436 chr1 156892394 T C 1.06E-06 White blood cell count LRRC71 intron 21738479 rs865239 chr1 156896164 A G 4.37E-06 White blood cell count LRRC71 intron 21738479 rs822430 chr1 156902259 G A 2.76E-05 Lipid levels LRRC71 cds-synon 19913121 rs822431 chr1 156902281 T G 0.000553649 Primary sclerosing cholangitis LRRC71 missense 23603763 rs12402294 chr1 156910488 A G 9.38E-04 Multiple complex diseases ARHGEF11 intron 17554300 rs2275201 chr1 156915038 C T 1.37E-06 White blood cell count ARHGEF11 intron 21738479 rs12138039 chr1 156918137 C T 2.23E-06 White blood cell count ARHGEF11 cds-synon 21738479 rs6655972 chr1 156929865 A G 2.17E-06 White blood cell count ARHGEF11 intron 21738479 rs6680271 chr1 156945708 C G 2.95E-06 White blood cell count ARHGEF11 intron 21738479 rs1572407 chr1 156946099 T C 2.30E-06 White blood cell count ARHGEF11 intron 21738479 rs6427339 chr1 156954267 C T 1.50E-07 White blood cell count ARHGEF11 intron 21738479 rs6427340 chr1 156954384 T C 9.72E-07 White blood cell count ARHGEF11 intron 21738479 rs1572411 chr1 156969896 G T 1.31E-06 White blood cell count ARHGEF11 intron 21738479 rs822577 chr1 156972467 T C 1.44E-06 White blood cell count ARHGEF11 intron 21738479 rs7550260 chr1 157001661 C A 4.93E-05 Intracranial aneurysm ARHGEF11 intron 20613766 rs16838014 chr1 157049635 A T 5.55E-04 Smoking initiation / / 24665060 rs7551464 chr1 157055398 G A 2.16E-07 White blood cell count / / 21738479 rs7534239 chr1 157058424 A G 9.97E-04 Multiple complex diseases / / 17554300 rs7534239 chr1 157058424 A G 0.000000233 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment / / 23392654 rs7534239 chr1 157058424 A G 2.33E-07 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1176535 chr1 157061550 G A 5.46E-06 White blood cell count / / 21738479 rs1176535 chr1 157061550 G A 0.000000913 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment / / 23392654 rs1176535 chr1 157061550 G A 9.13E-07 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1176536 chr1 157062364 G A,C,T 1.81E-10 White blood cell count ETV3L UTR-3 21738479 rs7544345 chr1 157064929 C T 1.00E-10 White blood cell count ETV3L intron 21738479 rs1571045 chr1 157066129 C T 1.10E-04 Alcohol dependence ETV3L intron 20201924 rs17404670 chr1 157066893 G A 1.28E-11 White blood cell count ETV3L intron 21738479 rs6427351 chr1 157066950 T C 7.07E-04 Type 2 diabetes ETV3L intron 17463246 rs16838099 chr1 157083542 C T 6.57E-04 Multiple complex diseases / / 17554300 rs1183449 chr1 157083817 A G 2.07E-07 White blood cell count / / 21738479 rs11264618 chr1 157090760 C G 5.72E-04 Type 2 diabetes / / 17463246 rs2231856 chr1 157095470 A G 2.52E-05 Smoking cessation ETV3 cds-synon 24665060 rs6704373 chr1 157104470 C G 6.66E-04 Type 2 diabetes ETV3 intron 17463246 rs6704373 chr1 157104470 C G 5.29E-06 White blood cell count ETV3 intron 21738479 rs6427353 chr1 157109624 G A 5.61E-06 Post-operative nausea and vomiting / / 21694509 rs10494309 chr1 157118421 T C 6.37E-05 Post-operative nausea and vomiting / / 21694509 rs11264624 chr1 157127118 G A 6.18E-05 Suicide attempts in bipolar disorder / / 21423239 rs11264625 chr1 157128705 T C 2.46E-05 Suicide attempts in bipolar disorder / / 21423239 rs6427356 chr1 157130566 A G 8.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs6427356 chr1 157130566 A G 2.39E-05 Suicide attempts in bipolar disorder / / 21423239 rs6657122 chr1 157130597 T A 1.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs6657097 chr1 157130719 A G 1.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs2148397 chr1 157131744 C T 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs6661210 chr1 157132388 A G 3.48E-05 Suicide attempts in bipolar disorder / / 21423239 rs6675005 chr1 157132732 G A 2.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs10796971 chr1 157133121 G A 1.96E-05 Suicide attempts in bipolar disorder / / 21423239 rs10796972 chr1 157133137 G A 1.91E-05 Suicide attempts in bipolar disorder / / 21423239 rs6700498 chr1 157133150 C T 1.34E-05 Suicide attempts in bipolar disorder / / 21423239 rs1176542 chr1 157133476 G A 1.49E-05 Suicide attempts in bipolar disorder / / 21423239 rs1176543 chr1 157133595 C A 1.37E-05 Suicide attempts in bipolar disorder / / 21423239 rs1176551 chr1 157135656 T C 1.39E-05 Suicide attempts in bipolar disorder / / 21423239 rs1176555 chr1 157136541 G C 9.47E-04 Multiple complex diseases / / 17554300 rs1176555 chr1 157136541 G C 1.38E-05 Suicide attempts in bipolar disorder / / 21423239 rs1538386 chr1 157140456 A T 1.31E-05 Suicide attempts in bipolar disorder / / 21423239 rs16838195 chr1 157145225 T G 5.76E-67 Multiple complex diseases / / 17554300 rs2316825 chr1 157168984 C G 3.15E-04 Multiple complex diseases / / 17554300 rs7511847 chr1 157187436 G A 2.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7511847 chr1 157187436 G A 4.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1338672 chr1 157187711 T C 3.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12070704 chr1 157262482 T C 3.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs6427368 chr1 157275152 T C 2.53E-08 White blood cell count / / 21738479 rs11264673 chr1 157279122 A C 1.91E-07 White blood cell count / / 21738479 rs4661028 chr1 157322310 A C 8.16E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs4661129 chr1 157322796 C T 2.03E-07 Inflammatory biomarkers / / 22291609 rs1408554 chr1 157323211 T C 4.46E-10 White blood cell count / / 21738479 rs12239592 chr1 157327571 T C 1.61E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs11264696 chr1 157328953 T C 1.32E-06 White blood cell count / / 21738479 rs2224901 chr1 157331407 G A 1.98E-08 White blood cell count / / 21738479 rs9427266 chr1 157332482 G A 1.24E-06 White blood cell count / / 21738479 rs12134519 chr1 157333244 G A 2.89E-08 White blood cell count / / 21738479 rs2317049 chr1 157334428 A G 5.55E-08 White blood cell count / / 21738479 rs2317050 chr1 157334724 A G 1.96E-08 White blood cell count / / 21738479 rs2147445 chr1 157335891 C T 2.60E-05 Hypertension / / 22384028 rs1967788 chr1 157336988 C G 1.18E-07 White blood cell count / / 21738479 rs1967792 chr1 157337305 A T 3.54E-08 White blood cell count / / 21738479 rs2151157 chr1 157337663 T C 2.30E-08 White blood cell count / / 21738479 rs11264700 chr1 157338094 C T 7.66E-09 White blood cell count / / 21738479 rs12138542 chr1 157342962 G A 8.36E-06 White blood cell count / / 21738479 rs2873343 chr1 157356480 C G 9.11E-06 White blood cell count / / 21738479 rs11264714 chr1 157360752 C A 6.86E-04 Tourette syndrome / / 22889924 rs12043295 chr1 157361577 T C 3.99E-04 Multiple complex diseases / / 17554300 rs10465957 chr1 157365378 C T 6.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs12734925 chr1 157367179 C T 2.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10908564 chr1 157369433 T G 4.20E-05 Cognitive performance / / 19734545 rs4246530 chr1 157378637 C A 7.84E-04 Multiple complex diseases / / 17554300 rs4246534 chr1 157383740 T C 9.40E-04 Multiple complex diseases / / 17554300 rs16838537 chr1 157385496 T C 1.32E-05 Socioeconomic Factors / / pha003066 rs12748574 chr1 157387799 C T 2.01E-05 Femoral neck bone geometry / / 22087292 rs12076935 chr1 157389398 G T 3.56E-05 Femoral neck bone geometry / / 22087292 rs4971147 chr1 157389741 T C 3.60E-05 Parkinson's disease (age of onset) / / 19772629 rs7523656 chr1 157402121 G A 7.82E-04 Type 2 diabetes / / 17463246 rs4399149 chr1 157403585 A T 5.40E-08 White blood cell count / / 21738479 rs4060884 chr1 157430425 A G 3.28E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4060884 chr1 157430425 A G 1.64E-06 White blood cell count / / 21738479 rs6686423 chr1 157437510 G A 8.00E-06 Renal sinus fat / / 22044751 rs12132012 chr1 157443532 C T 3.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12132012 chr1 157443532 C T 3.23E-08 White blood cell count / / 21738479 rs6427381 chr1 157453883 G A 7.30E-10 White blood cell count / / 21738479 rs3845582 chr1 157456260 A G 2.42E-07 White blood cell count / / 21738479 rs3845586 chr1 157484453 G A 1.19E-10 White blood cell count FCRL5 UTR-3 21738479 rs3811035 chr1 157485561 G A 5.56E-14 White blood cell count FCRL5 intron 21738479 rs6696309 chr1 157490710 G A 2.00E-10 White blood cell count FCRL5 intron 21738479 rs17416676 chr1 157503805 G A 3.79E-07 White blood cell count FCRL5 intron 21738479 rs2012199 chr1 157509025 C T 1.00E-04 Upper aerodigestive tract cancers FCRL5 missense 21437268 rs2244798 chr1 157527963 G A 1.45E-06 White blood cell count / / 21738479 rs849832 chr1 157531532 G C 1.06E-13 White blood cell count / / 21738479 rs16838818 chr1 157535159 C A 9.31E-04 Coronary heart disease / / 21606135 rs2758684 chr1 157537530 T G 7.47E-13 White blood cell count / / 21738479 rs12566695 chr1 157538363 A G 1.16E-06 White blood cell count / / 21738479 rs11264764 chr1 157538612 G A 9.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs11264764 chr1 157538612 G A 2.69E-05 Orofacial clefts / / 22419666 rs6669223 chr1 157540981 A T 1.23E-06 White blood cell count / / 21738479 rs14335 chr1 157544850 C T 9.72E-07 White blood cell count FCRL4 UTR-3 21738479 rs10489673 chr1 157550066 T C 3.82E-07 White blood cell count FCRL4 intron 21738479 rs4246533 chr1 157552944 G C 6.26E-07 White blood cell count FCRL4 intron 21738479 rs2778003 chr1 157569194 G A 4.82E-04 Stroke / / pha002887 rs9427302 chr1 157612420 C T 9.05E-08 White blood cell count / / 21738479 rs12145148 chr1 157615261 T A 1.60E-05 Urinary metabolites / / 21572414 rs2785663 chr1 157620758 T G 3.52E-07 White blood cell count / / 21738479 rs2778010 chr1 157621513 T C 3.88E-04 Alcohol dependence / / 21314694 rs2785666 chr1 157625122 G A 4.55E-08 White blood cell count / / 21738479 rs2785657 chr1 157631311 T C 1.50E-07 White blood cell count / / 21738479 rs12082327 chr1 157634415 C T 1.85E-05 Body mass index / / 17255346 rs10908581 chr1 157638275 A G 8.98E-07 White blood cell count / / 21738479 rs6679422 chr1 157641266 C A 3.50E-07 White blood cell count / / 21738479 rs10908583 chr1 157641683 C T 1.02E-08 Graves' disease / / 21841780 rs10908584 chr1 157641758 T A 3.47E-08 White blood cell count / / 21738479 rs2210911 chr1 157643867 A G 6.28E-08 Graves' disease / / 21841780 rs11264794 chr1 157647789 C A 1.83E-07 White blood cell count FCRL3 nearGene-3 21738479 rs2282284 chr1 157648543 T C 6.82E-04 Body mass index FCRL3 missense 17255346 rs7549100 chr1 157657842 A G 2.90E-05 Urinary metabolites FCRL3 intron 21572414 rs11264798 chr1 157661848 C G 4.86E-14 Positivity for ZnT8A in Type 1 diabetes FCRL3 intron 22526605 rs12080623 chr1 157665064 A G 7.56E-05 HIV-1 control FCRL3 intron 20041166 rs7522061 chr1 157668390 T C 1.65E-08 Graves' disease FCRL3 missense 21841780 rs7522061 chr1 157668390 T C 1.13E-16 Positivity for ZnT8A in Type 1 diabetes FCRL3 missense 22526605 rs7522061 chr1 157668390 T C 1.74E-11 Positivity for ZnT8RA in Type 1 diabetes FCRL3 missense 22526605 rs7522061 chr1 157668390 T C 8.13E-12 Positivity for ZnT8WA in Type 1 diabetes FCRL3 missense 22526605 rs7522061 chr1 157668390 T C 0.0000108 Graves' disease FCRL3 missense 22922229 rs7522061 chr1 157668390 T C 0.0000236 Graves' disease and Hashimoto's thyroiditis FCRL3 missense 22922229 rs2210913 chr1 157668993 C T 9.95E-06 White blood cell count FCRL3 intron 21738479 rs3761959 chr1 157669278 C T 3.00E-06 Multiple sclerosis FCRL3 intron 21833088 rs3761959 chr1 157669278 C T 2.00E-13 Graves' disease FCRL3 intron 21841780 rs7528684 chr1 157670816 A G 1.06E-06 White blood cell count FCRL3 nearGene-5 21738479 rs7528684 chr1 157670816 A G 1.00E-11 Type 1 diabetes autoantibodies FCRL3 nearGene-5 21829393 rs7528684 chr1 157670816 A G 0.000314 Positivity for ZnT8A in Type 1 diabetes FCRL3 nearGene-5 22526605 rs2210914 chr1 157673628 T C 1.25E-08 White blood cell count / / 21738479 rs2317230 chr1 157674997 G T 1.90E-04 Rheumatoid arthritis / / 24390342 rs2317230 chr1 157674997 G T 2.00E-07 Rheumatoid arthritis / / 24390342 rs2317230 chr1 157674997 G T 8.30E-05 Rheumatoid arthritis / / 24390342 rs17676303 chr1 157679691 C T 6.53E-04 Multiple complex diseases / / 17554300 rs17727339 chr1 157680114 T C 5.10E-04 Multiple complex diseases / / 17554300 rs2873407 chr1 157693368 G A 4.85E-04 Fibrinogen / / 17255346 rs1537948 chr1 157694094 T C 2.01E-04 Fibrinogen / / 17255346 rs1537949 chr1 157701249 T C 2.17E-06 White blood cell count / / 21738479 rs10430455 chr1 157703238 T A 9.00E-04 Rheumatoid arthritis / / 22446963 rs7517644 chr1 157717028 A G 5.59E-06 Graves' disease FCRL2 intron 21841780 rs6696643 chr1 157718283 A T 5.06E-08 White blood cell count FCRL2 intron 21738479 rs7529060 chr1 157725264 T G 8.40E-07 White blood cell count FCRL2 intron 21738479 rs12408952 chr1 157730028 T C 0.00000563 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment FCRL2 intron 23392654 rs12408952 chr1 157730028 T C 5.63E-06 Thiazide-induced adverse metabolic effects in hypertensive patients FCRL2 intron 23400010 rs12568320 chr1 157744004 A G 2.00E-04 Cognitive impairment induced by topiramate FCRL2 intron 22091778 rs6427402 chr1 157749544 C T 1.67E-06 White blood cell count / / 21738479 rs12743184 chr1 157754359 A G 1.16E-07 Graves' disease / / 21841780 rs12132140 chr1 157767362 C T 4.32E-05 Panic disorder FCRL1 intron 19165232 rs12132140 chr1 157767362 C T 8.47E-05 Body Mass Index FCRL1 intron pha003020 rs3811024 chr1 157768000 G C 6.96E-05 Lymphocyte counts FCRL1 cds-synon 22286170 rs2050568 chr1 157770241 C T 3.70E-08 Graves' disease FCRL1 intron 21841780 rs4971154 chr1 157771880 C T 3.60E-06 White blood cell count FCRL1 cds-synon 21738479 rs6689427 chr1 157780892 A G 1.13E-08 Graves' disease FCRL1 intron 21841780 rs6696137 chr1 157782581 T C 0.000000111 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment FCRL1 intron 23392654 rs6696137 chr1 157782581 T C 1.11E-07 Thiazide-induced adverse metabolic effects in hypertensive patients FCRL1 intron 23400010 rs2148135 chr1 157783485 C T 4.84E-08 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment FCRL1 intron 23392654 rs2148135 chr1 157783485 C T 4.84E-08 Thiazide-induced adverse metabolic effects in hypertensive patients FCRL1 intron 23400010 rs11264825 chr1 157788270 A G 0.000000081 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment FCRL1 intron 23392654 rs11264825 chr1 157788270 A G 8.10E-08 Thiazide-induced adverse metabolic effects in hypertensive patients FCRL1 intron 23400010 rs2765493 chr1 157798000 G A 6.73E-08 Graves' disease / / 21841780 rs2765501 chr1 157804648 G A 7.62E-06 White blood cell count CD5L intron 21738479 rs2765502 chr1 157805107 G A 1.66E-06 Graves' disease CD5L intron 21841780 rs2260040 chr1 157811392 G A 9.13E-05 Graves' disease CD5L intron 21841780 rs2281870 chr1 157811585 G T 5.14E-05 Leukocyte Counts CD5L UTR-5 pha003091 rs4971115 chr1 157829702 G A 8.85E-04 Obesity (extreme) / / 21935397 rs17690088 chr1 157834858 C T 8.75E-04 Obesity (extreme) / / 21935397 rs11264835 chr1 157836891 T C 2.28E-08 White blood cell count / / 21738479 rs6427405 chr1 157840353 T C 3.37E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7537631 chr1 157848670 T C 1.56E-06 White blood cell count / / 21738479 rs7537631 chr1 157848670 T C 9.00E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7537631 chr1 157848670 T C 2.36E-06 Lymphocyte counts / / pha003094 rs4272616 chr1 157865663 T C 5.45E-09 White blood cell count / / 21738479 rs11264845 chr1 157871097 A G 4.19E-07 White blood cell count / / 21738479 rs7545514 chr1 157878897 G A 2.45E-06 White blood cell count / / 21738479 rs7524095 chr1 157879294 C T 9.20E-05 Premature ovarian failure / / 19508998 rs7524095 chr1 157879294 C T 9.20E-05 Other erythrocyte phenotypes / / 19862010 rs4971165 chr1 157891524 A C,G,T 5.71E-05 Blood Pressure / / pha003039 rs4971166 chr1 157891597 A G 1.70E-05 Urinary metabolites / / 21572414 rs4971166 chr1 157891597 A G 2.86E-07 White blood cell count / / 21738479 rs12022838 chr1 157891609 G A 2.19E-06 White blood cell count / / 21738479 rs7524979 chr1 157891709 G A 3.53E-09 White blood cell count / / 21738479 rs12123550 chr1 157905094 T A 5.22E-04 Multiple complex diseases / / 17554300 rs12123554 chr1 157905143 T C 5.50E-05 Alcohol dependence / / 20201924 rs12123554 chr1 157905143 T C 5.48E-05 Alcoholism / / pha002892 rs12124798 chr1 157906955 A T 5.00E-04 Multiple complex diseases / / 17554300 rs11264863 chr1 157907065 G C 5.42E-04 Multiple complex diseases / / 17554300 rs10494321 chr1 157908444 A G 2.00E-05 Type 2 diabetes / / 17903298 rs1925035 chr1 157909525 C T 1.49E-05 Neuroblastoma / / pha002895 rs6684686 chr1 157909708 A G 6.03E-04 Multiple complex diseases / / 17554300 rs6701170 chr1 157913954 T C 5.03E-04 Multiple complex diseases / / 17554300 rs4971168 chr1 157914172 C T 4.03E-04 Multiple complex diseases / / 17554300 rs927698 chr1 157926455 G A 9.85E-07 White blood cell count / / 21738479 rs720773 chr1 157934242 A G 6.61E-07 White blood cell count / / 21738479 rs12403172 chr1 157937856 C A 7.00E-05 Response to statin therapy / / 20339536 rs11580979 chr1 157969306 G T 6.76E-05 Coronary heart disease KIRREL intron pha003030 rs11585913 chr1 157976896 C T 9.30E-04 Type 2 diabetes KIRREL intron 17463246 rs3892165 chr1 157977049 A G 9.81E-04 Type 2 diabetes KIRREL intron 17463246 rs6680584 chr1 157978956 A G 2.31E-06 White blood cell count KIRREL intron 21738479 rs7519243 chr1 157992818 T C 9.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIRREL intron 23233662 rs7548850 chr1 158005274 G C 8.71E-04 Multiple complex diseases KIRREL intron 17554300 rs12045704 chr1 158008229 T C 5.55E-06 Personality dimensions KIRREL intron 23658558 rs7540377 chr1 158040767 A G 1.60E-05 Urinary metabolites KIRREL intron 21572414 rs10908615 chr1 158042153 C T 2.30E-06 Iron levels KIRREL intron 21208937 rs7364493 chr1 158056651 A G 4.43E-06 White blood cell count KIRREL intron 21738479 rs7514301 chr1 158057420 A T 7.89E-08 White blood cell count KIRREL intron 21738479 rs3820676 chr1 158057691 A C 6.96E-04 Type 2 diabetes KIRREL intron 17463246 rs3820676 chr1 158057691 A C 4.14E-07 White blood cell count KIRREL intron 21738479 rs6427419 chr1 158058109 C A 2.41E-11 White blood cell count KIRREL intron 21738479 rs6427419 chr1 158058109 C A 8.00E-06 Obesity-related traits KIRREL intron 23251661 rs3768540 chr1 158060515 C T 3.20E-11 White blood cell count KIRREL intron 21738479 rs912572 chr1 158061626 G T 2.34E-05 Post-operative nausea and vomiting KIRREL intron 21694509 rs3768538 chr1 158066042 A G 5.82E-07 White blood cell count / / 21738479 rs6427420 chr1 158066834 A G 3.80E-06 White blood cell count / / 21738479 rs874844 chr1 158067047 A C 5.00E-11 White blood cell count / / 21738479 rs3820677 chr1 158068344 A G 4.75E-11 White blood cell count / / 21738479 rs567631262 chr1 158071131 G GT 7.29E-04 Type 2 diabetes / / 17463246 rs942540 chr1 158071131 G A 7.29E-04 Type 2 diabetes / / 17463246 rs17421546 chr1 158074220 G A 6.95E-05 Left ventricular hypertrophy / / pha003052 rs17455763 chr1 158134119 T A 8.54E-08 White blood cell count / / 21738479 rs1570699 chr1 158145229 T C 2.44E-04 Heart Failure / / pha002885 rs3087210 chr1 158146028 G A 2.36E-04 Heart Failure / / pha002885 rs1690769 chr1 158158597 C T 1.60E-05 Urinary metabolites / / 21572414 rs1690778 chr1 158167760 A T 9.91E-04 Multiple complex diseases / / 17554300 rs401904 chr1 158170546 T C 3.64E-06 White blood cell count LOC100505799 intron 21738479 rs400214 chr1 158171078 T C 3.29E-04 Hearing function LOC100505799 intron 17255346 rs400214 chr1 158171078 T C 2.20E-05 Esophageal cancer (squamous cell) LOC100505799 intron 22960999 rs1748383 chr1 158173706 T C 3.89E-06 White blood cell count / / 21738479 rs440862 chr1 158175824 A G 3.96E-06 White blood cell count / / 21738479 rs384414 chr1 158179236 C T 2.51E-06 White blood cell count / / 21738479 rs402699 chr1 158179483 G A 2.32E-06 White blood cell count / / 21738479 rs449838 chr1 158182363 C T 2.30E-06 White blood cell count / / 21738479 rs594364 chr1 158182407 C T 1.60E-06 White blood cell count / / 21738479 rs607948 chr1 158183129 T C 1.25E-06 White blood cell count / / 21738479 rs12040592 chr1 158183743 C A 1.11E-06 White blood cell count / / 21738479 rs691314 chr1 158183942 G A 2.30E-06 White blood cell count / / 21738479 rs623215 chr1 158184244 T A 1.01E-06 White blood cell count / / 21738479 rs691551 chr1 158184353 T A 1.30E-06 White blood cell count / / 21738479 rs448556 chr1 158184570 C T 1.14E-06 White blood cell count / / 21738479 rs377795 chr1 158184769 A T 9.89E-06 White blood cell count / / 21738479 rs393304 chr1 158184815 G A 4.20E-06 White blood cell count / / 21738479 rs448005 chr1 158185165 G A 1.42E-06 White blood cell count / / 21738479 rs1633149 chr1 158192745 A G 9.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1633149 chr1 158192745 A G 3.30E-06 White blood cell count / / 21738479 rs429201 chr1 158194899 C T 3.46E-08 White blood cell count / / 21738479 rs374513 chr1 158195465 C T 3.40E-06 White blood cell count / / 21738479 rs411089 chr1 158224825 C T 8.28E-04 Parkinson's disease CD1A intron 17052657 rs411089 chr1 158224825 C T 6.30E-04 Amyotrophic Lateral Sclerosis CD1A intron 17362836 rs1230716 chr1 158232763 C G 4.17E-12 White blood cell count / / 21738479 rs12077177 chr1 158256016 G A 5.30E-05 Hearing function / / 17255346 rs7544532 chr1 158292236 C T 1.86E-06 White blood cell count / / 21738479 rs10797007 chr1 158295629 A G 2.02E-04 Parkinson's disease / / 17052657 rs10797007 chr1 158295629 A G 1.20E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10797007 chr1 158295629 A G 9.25E-07 White blood cell count / / 21738479 rs10158210 chr1 158311985 A G 3.02E-09 White blood cell count / / 21738479 rs2317955 chr1 158315924 G T 8.97E-05 Rheumatoid arthritis / / 19503088 rs11264960 chr1 158319787 A G 4.95E-09 White blood cell count / / 21738479 rs2873587 chr1 158324413 A G 1.49E-04 Multiple complex diseases CD1E missense 17554300 rs1065457 chr1 158324425 A G 1.94E-04 Parkinson's disease CD1E missense 17052657 rs1065457 chr1 158324425 A G 3.40E-05 Amyotrophic Lateral Sclerosis CD1E missense 17362836 rs1065457 chr1 158324425 A G 8.92E-05 Serum metabolites CD1E missense 19043545 rs1065457 chr1 158324425 A G 3.19E-09 White blood cell count CD1E missense 21738479 rs11264963 chr1 158335533 A G 5.16E-08 White blood cell count / / 21738479 rs13376124 chr1 158338434 A G 5.94E-04 Acute lung injury / / 22295056 rs7547997 chr1 158341273 G A 6.74E-08 White blood cell count / / 21738479 rs2157685 chr1 158346251 G A,T 5.94E-04 Acute lung injury / / 22295056 rs6701609 chr1 158346590 A G 5.94E-04 Acute lung injury / / 22295056 rs6704215 chr1 158346717 A G 8.65E-04 Acute lung injury / / 22295056 rs7511778 chr1 158347220 A G 8.65E-04 Acute lung injury / / 22295056 rs7545457 chr1 158347399 C T 8.65E-04 Acute lung injury / / 22295056 rs11807992 chr1 158350654 A C 8.65E-04 Acute lung injury / / 22295056 rs11808003 chr1 158350707 A T 8.65E-04 Acute lung injury / / 22295056 rs11809920 chr1 158351914 G C 8.65E-04 Acute lung injury / / 22295056 rs11808876 chr1 158351980 T C 9.78E-04 Acute lung injury / / 22295056 rs11808874 chr1 158352170 A C 9.78E-04 Acute lung injury / / 22295056 rs7553679 chr1 158353356 G A 9.78E-04 Acute lung injury / / 22295056 rs12239158 chr1 158353465 C T 9.78E-04 Acute lung injury / / 22295056 rs4656284 chr1 158381815 G A 3.44E-04 Smoking initiation / / 24665060 rs17628151 chr1 158394230 T C 7.49E-04 Smoking initiation / / 24665060 rs6427437 chr1 158414877 T A 5.84E-04 Smoking initiation / / 24665060 rs12127971 chr1 158425271 C A 1.12E-04 Smoking initiation / / 24665060 rs12728815 chr1 158431310 A C 1.77E-04 Smoking initiation / / 24665060 rs1002309 chr1 158433074 A T 1.56E-05 Smoking initiation / / 24665060 rs12403683 chr1 158441462 T C 7.77E-12 Red blood cell traits / / 23222517 rs11264980 chr1 158453439 G T 5.57E-04 Multiple complex diseases / / 17554300 rs11264980 chr1 158453439 G T 2.25E-12 Red blood cell traits / / 23222517 rs10489832 chr1 158454356 G A 2.80E-05 Sleep and circadian phenotypes / / 17903308 rs950488 chr1 158459975 C A 0.000000004 Mean corpuscular hemoglobin concentration / / 22560525 rs950488 chr1 158459975 C A 1.87E-11 Red blood cell traits / / 23222517 rs879636 chr1 158462797 C T 3.97E-09 Red blood cell traits / / 23222517 rs12041363 chr1 158475894 T C 1.82E-08 Red blood cell traits / / 23222517 rs12041363 chr1 158475894 T C 5.10E-05 Glycated hemoglobin levels / / 24405752 rs12044799 chr1 158490295 A G 1.25E-12 Red blood cell traits / / 23222517 rs11265005 chr1 158493055 C G 2.86E-11 Red blood cell traits / / 23222517 rs11265022 chr1 158512619 T A 5.63E-04 Multiple complex diseases / / 17554300 rs11265022 chr1 158512619 T A 8.12E-14 Red blood cell traits / / 23222517 rs16840314 chr1 158517353 G A 4.91E-04 Multiple complex diseases OR6Y1 cds-synon 17554300 rs16840314 chr1 158517353 G A 7.93E-13 Red blood cell traits OR6Y1 cds-synon 23222517 rs9804152 chr1 158518939 T C 5.74E-05 Longevity / / 20304771 rs12042917 chr1 158529661 G T 7.50E-13 Red blood cell traits / / 23222517 rs863343 chr1 158534385 A G 9.82E-12 Red blood cell traits / / 23222517 rs863344 chr1 158534831 G A 3.54E-04 Multiple complex diseases / / 17554300 rs863344 chr1 158534831 G A 3.07E-14 Red blood cell traits / / 23222517 rs863366 chr1 158553168 G C 7.65E-08 Red blood cell traits / / 23222517 rs863368 chr1 158553332 A G 8.18E-08 Red blood cell traits / / 23222517 rs2479861 chr1 158554142 G A 3.17E-07 Red blood cell traits / / 23222517 rs2479862 chr1 158554257 G T 7.68E-08 Red blood cell traits / / 23222517 rs2482959 chr1 158554702 C T 7.18E-08 Red blood cell traits / / 23222517 rs12119726 chr1 158556839 A G 4.30E-06 Carotenoid and tocopherol levels / / 19185284 rs857695 chr1 158558142 T A 5.10E-08 Red blood cell traits / / 23222517 rs2157690 chr1 158569486 A T 1.79E-08 Red blood cell traits / / 23222517 rs1103852 chr1 158570890 C A 1.30E-07 Red blood cell traits / / 23222517 rs857719 chr1 158573336 T A 2.76E-08 Red blood cell traits / / 23222517 rs857684 chr1 158575729 C T 8.21E-09 Other erythrocyte phenotypes / / 19862010 rs857684 chr1 158575729 C T 4.00E-16 Red blood cell traits / / 23222517 rs860772 chr1 158576100 G C 2.74E-10 Red blood cell traits / / 23222517 rs857685 chr1 158577109 A C 5.63E-16 Red blood cell traits OR10Z1 missense 23222517 rs857686 chr1 158577788 C A 2.02E-08 Red blood cell traits / / 23222517 rs857688 chr1 158578018 T C 1.25E-08 Red blood cell traits / / 23222517 rs12724903 chr1 158578865 A C 1.30E-04 Alcohol dependence / / 20201924 rs2479868 chr1 158580069 C T 1.12E-08 Other erythrocyte phenotypes SPTA1 nearGene-3 19862010 rs2479868 chr1 158580069 C T 3.60E-15 Red blood cell traits SPTA1 nearGene-3 23222517 rs12128171 chr1 158580477 A G 6.02E-08 Red blood cell traits SPTA1 nearGene-3 23222517 rs12601 chr1 158580759 G A 3.10E-04 Iris characteristics SPTA1 UTR-3 21835309 rs2157691 chr1 158582838 G C 6.05E-09 Other erythrocyte phenotypes SPTA1 intron 19862010 rs2157691 chr1 158582838 G C 2.73E-15 Red blood cell traits SPTA1 intron 23222517 rs2518491 chr1 158585230 C T 5.72E-09 Other erythrocyte phenotypes SPTA1 intron 19862010 rs2518491 chr1 158585230 C T 5.06E-15 Red blood cell traits SPTA1 intron 23222517 rs2779116 chr1 158585415 C A,G,T 5.74E-09 Other erythrocyte phenotypes SPTA1 intron 19862010 rs2779116 chr1 158585415 C A,G,T 3.00E-09 Glycated hemoglobin levels SPTA1 intron 20858683 rs2779116 chr1 158585415 C A,G,T 1.71E-11 Red blood cell traits SPTA1 intron 23222517 rs2022003 chr1 158586966 A T 3.68E-10 Red blood cell traits SPTA1 intron 23222517 rs7553252 chr1 158588916 C G 1.16E-07 Red blood cell traits SPTA1 intron 23222517 rs1616 chr1 158592455 G T 6.93E-04 Smoking initiation SPTA1 intron 24665060 rs12088990 chr1 158596524 A G 3.47E-08 Red blood cell traits SPTA1 intron 23222517 rs3737515 chr1 158597507 G C 8.30E-09 Red blood cell traits SPTA1 missense 23222517 rs4511106 chr1 158598499 G A 7.48E-08 Red blood cell traits SPTA1 intron 23222517 rs12138682 chr1 158600194 T C 8.48E-09 Red blood cell traits SPTA1 intron 23222517 rs6682458 chr1 158603013 C G 1.84E-07 Red blood cell traits SPTA1 intron 23222517 rs11811522 chr1 158604143 G A 6.29E-06 Serum metabolites SPTA1 intron 19043545 rs11811522 chr1 158604143 G A 7.58E-08 Red blood cell traits SPTA1 intron 23222517 rs16830483 chr1 158604391 T C 6.16E-04 Alzheimer's disease SPTA1 missense 24755620 rs3738791 chr1 158606449 G T 1.79E-07 Red blood cell traits SPTA1 cds-synon 23222517 rs857725 chr1 158607935 T G 6.97E-09 Other erythrocyte phenotypes SPTA1 missense 19862010 rs857725 chr1 158607935 T G 0.00000002 Mean corpuscular hemoglobin concentration SPTA1 missense 22560525 rs857725 chr1 158607935 T G 1.60E-13 Red blood cell traits SPTA1 missense 23222517 rs857721 chr1 158612548 T A 1.00E-10 Other erythrocyte phenotypes SPTA1 intron 19862010 rs857721 chr1 158612548 T A 7.03E-04 Blood cell counts and other traits SPTA1 intron 20139978 rs857721 chr1 158612548 T A 1.60E-15 Red blood cell traits SPTA1 intron 23222517 rs6702040 chr1 158614198 C T 2.19E-07 Red blood cell traits SPTA1 intron 23222517 rs10443907 chr1 158614667 C T 8.92E-08 Red blood cell traits SPTA1 intron 23222517 rs17635940 chr1 158615988 G T 1.99E-08 Red blood cell traits SPTA1 intron 23222517 rs12076831 chr1 158616398 C T 1.98E-08 Red blood cell traits SPTA1 intron 23222517 rs10443899 chr1 158616614 T A 1.22E-08 Red blood cell traits SPTA1 intron 23222517 rs2246434 chr1 158618455 G A 4.18E-08 Other erythrocyte phenotypes SPTA1 intron 19862010 rs2246434 chr1 158618455 G A 6.04E-09 Glycated hemoglobin levels SPTA1 intron 22885924 rs2246434 chr1 158618455 G A 2.65E-14 Red blood cell traits SPTA1 intron 23222517 rs861409 chr1 158620477 C G 2.38E-13 Red blood cell traits SPTA1 intron 23222517 rs863327 chr1 158620647 G A 8.73E-14 Red blood cell traits SPTA1 intron 23222517 rs16840439 chr1 158622819 G T 3.92E-04 Lung function (forced expiratory volume in 1 second) SPTA1 intron 24023788 rs2276401 chr1 158624779 T C 1.64E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SPTA1 intron 24023788 rs857691 chr1 158626378 C T 5.22E-13 Red blood cell traits SPTA1 cds-synon 23222517 rs2518493 chr1 158631171 A C,G 2.04E-12 Red blood cell traits SPTA1 cds-synon 23222517 rs7519423 chr1 158635308 G T 1.49E-04 Multiple complex diseases SPTA1 intron 17554300 rs71579625 chr1 158635852 A AG 5.34E-08 White blood cell count SPTA1 intron 21738479 rs857680 chr1 158635852 A G 5.34E-08 White blood cell count SPTA1 intron 21738479 rs703115 chr1 158643037 T C 4.33E-04 Sudden cardiac arrest SPTA1 intron 21658281 rs378557 chr1 158643513 G A 1.61E-07 White blood cell count SPTA1 intron 21738479 rs703116 chr1 158644105 T A 1.92E-07 White blood cell count SPTA1 intron 21738479 rs325998 chr1 158646833 C T 2.71E-07 White blood cell count SPTA1 intron 21738479 rs325993 chr1 158648490 T C 2.19E-08 White blood cell count SPTA1 intron 21738479 rs703124 chr1 158649464 T C 3.45E-08 White blood cell count SPTA1 intron 21738479 rs413514 chr1 158649921 A G 8.36E-09 White blood cell count SPTA1 intron 21738479 rs390718 chr1 158655840 C T 5.44E-08 White blood cell count SPTA1 intron 21738479 rs7534057 chr1 158662730 T G 5.41E-08 White blood cell count / / 21738479 rs2494033 chr1 158668042 A C 2.71E-09 White blood cell count / / 21738479 rs703131 chr1 158670763 G T 2.90E-07 White blood cell count / / 21738479 rs16840675 chr1 158687031 C T 2.98E-06 White blood cell count OR6K3 missense 21738479 rs857924 chr1 158696300 G A 8.14E-09 White blood cell count / / 21738479 rs167821 chr1 158702189 A G 1.07E-04 Sudden cardiac arrest / / 21658281 rs183447 chr1 158707235 G A 4.25E-06 White blood cell count / / 21738479 rs381510 chr1 158708549 A G 6.16E-06 White blood cell count / / 21738479 rs2564856 chr1 158712627 T G 4.78E-04 Sudden cardiac arrest / / 21658281 rs425539 chr1 158719221 G C 5.84E-06 White blood cell count / / 21738479 rs454127 chr1 158720188 A G 1.45E-07 White blood cell count / / 21738479 rs10489844 chr1 158728389 C T 6.47E-04 Multiple complex diseases / / 17554300 rs10489844 chr1 158728389 C T 4.14E-09 White blood cell count / / 21738479 rs11802305 chr1 158729323 C T 4.75E-04 Sarcoidosis / / 19165924 rs1864346 chr1 158736445 C T 2.63E-04 Multiple complex diseases OR6N1 missense 17554300 rs1864346 chr1 158736445 C T 5.54E-09 White blood cell count OR6N1 missense 21738479 rs1864347 chr1 158736517 A T 2.98E-04 Multiple complex diseases / / 17554300 rs1864347 chr1 158736517 A T 6.58E-09 White blood cell count / / 21738479 rs7513257 chr1 158741903 A T 6.43E-05 Schizophrenia(age at onset) / / 21688384 rs11265070 chr1 158743995 A G 6.96E-04 Depression (quantitative trait) / / 20800221 rs2325694 chr1 158744060 G A 2.85E-04 Multiple complex diseases / / 17554300 rs857835 chr1 158747492 A G 5.25E-04 Coronary heart disease / / 21971053 rs857847 chr1 158754813 G A 9.38E-05 Waist Circumference / / pha003025 rs857849 chr1 158756914 G T 8.45E-04 Multiple complex diseases / / 17554300 rs857850 chr1 158756976 C T 5.71E-06 Multiple complex diseases / / 17554300 rs857854 chr1 158763983 T C 1.15E-08 White blood cell count / / 21738479 rs857859 chr1 158771450 T A 8.01E-11 White blood cell count / / 21738479 rs919477 chr1 158772845 C T 1.41E-04 Parkinson's disease / / 17052657 rs7550055 chr1 158778764 T G 1.34E-04 Parkinson's disease / / 17052657 rs857782 chr1 158780584 A T 5.48E-06 White blood cell count / / 21738479 rs13376489 chr1 158785647 C A 9.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs13376489 chr1 158785647 C A 1.34E-06 Obesity-related traits / / 23251661 rs11265075 chr1 158787438 G C 2.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs2875712 chr1 158788542 A G 2.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs12090080 chr1 158789208 G C 3.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs11265079 chr1 158793852 G T 7.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs11265081 chr1 158796545 G A 2.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs12089272 chr1 158796905 T A 2.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs7545956 chr1 158803370 A T 3.31E-04 Suicide attempts in bipolar disorder MNDA intron 21423239 rs7513873 chr1 158803873 G A 5.75E-04 Suicide attempts in bipolar disorder MNDA intron 21423239 rs12092047 chr1 158804755 A G 4.72E-04 Suicide attempts in bipolar disorder MNDA intron 21423239 rs11265085 chr1 158807011 A G 4.60E-04 Suicide attempts in bipolar disorder MNDA intron 21423239 rs11805139 chr1 158816738 C G 6.76E-04 Suicide attempts in bipolar disorder MNDA intron 21423239 rs2106091 chr1 158821200 T C 5.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs2106091 chr1 158821200 T C 5.24E-06 Obesity-related traits / / 23251661 rs12568794 chr1 158846099 C T 5.67E-04 Lymphocyte counts / / 22286170 rs12088342 chr1 158871453 T G 8.86E-04 Alzheimer's disease / / 22005930 rs861319 chr1 158915917 A G 4.24E-06 White blood cell count PYHIN1 intron 21738479 rs1101999 chr1 158932555 C T 4.00E-09 Asthma PYHIN1 intron 21804549 rs10908697 chr1 158941634 A G 8.56E-05 Glucose levels PYHIN1 intron pha003058 rs856146 chr1 158959450 T C 7.22E-06 White blood cell count / / 21738479 rs4657616 chr1 158971086 A G 4.64E-11 White blood cell count / / 21738479 rs4657616 chr1 158971086 A G 5.00E-47 Hematology traits / / 23263863 rs4657618 chr1 158972490 T C 5.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs856064 chr1 158983285 T C 7.25E-08 White blood cell count IFI16 intron 21738479 rs1057024 chr1 158990247 A G 1.28E-08 White blood cell count IFI16 cds-synon 21738479 rs856049 chr1 158990412 A G 2.18E-11 White blood cell count IFI16 intron 21738479 rs1101993 chr1 158996895 G A 7.06E-07 White blood cell count IFI16 intron 21738479 rs1101993 chr1 158996895 G A 2.53E-06 Obesity-related traits IFI16 intron 23251661 rs12094741 chr1 158998665 G A 2.80E-06 Obesity-related traits IFI16 intron 23251661 rs856054 chr1 159001521 C T 3.31E-17 White blood cell count IFI16 intron 21738479 rs861318 chr1 159002222 A G 1.00E-06 Obesity-related traits IFI16 intron 23251661 rs1057027 chr1 159002377 C A 1.05E-06 Obesity-related traits IFI16 missense 23251661 rs1057028 chr1 159002389 T A 2.68E-04 Insulin resistance IFI16 missense 21901158 rs1772415 chr1 159002778 A G 6.49E-04 Insulin resistance IFI16 intron 21901158 rs1772413 chr1 159003409 A G 2.52E-06 White blood cell count IFI16 intron 21738479 rs1772408 chr1 159005649 A G 8.00E-07 Celiac disease and Rheumatoid arthritis IFI16 intron 21383967 rs2570916 chr1 159012646 C A,G,T 4.31E-19 White blood cell count IFI16 intron 21738479 rs2793845 chr1 159032255 G T 6.82E-06 Obesity-related traits / / 23251661 rs855871 chr1 159044651 G A 7.40E-08 White blood cell count AIM2 intron 21738479 rs855866 chr1 159052720 A G 1.43E-17 White blood cell count / / 21738479 rs855867 chr1 159052847 G A 1.33E-08 White blood cell count / / 21738479 rs2852720 chr1 159060560 T C 9.32E-08 White blood cell count / / 21738479 rs2518564 chr1 159062436 G A 4.47E-22 White blood cell count / / 21738479 rs2814764 chr1 159064568 A T 5.98E-09 White blood cell count / / 21738479 rs1894043 chr1 159069211 T C 6.81E-23 White blood cell count / / 21738479 rs2518565 chr1 159070113 A G 6.65E-06 White blood cell count / / 21738479 rs2852723 chr1 159073725 G A 4.08E-06 White blood cell count / / 21738479 rs2852727 chr1 159086986 G A 1.20E-12 White blood cell count / / 21738479 rs1894044 chr1 159088334 G C 2.45E-12 White blood cell count / / 21738479 rs2518569 chr1 159095575 T G 4.62E-09 Inflammatory biomarkers / / 22291609 rs2518570 chr1 159096902 C G 3.10E-08 White blood cell count / / 21738479 rs2814779 chr1 159098713 A G 3.07E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2814779 chr1 159098713 A G 4.13E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11265142 chr1 159099908 A G 1.28E-09 Inflammatory biomarkers / / 22291609 rs1103577 chr1 159100315 T C 5.05E-12 White blood cell count / / 21738479 rs863030 chr1 159108794 G A 1.27E-06 White blood cell count / / 21738479 rs863036 chr1 159117109 T A 1.31E-06 White blood cell count / / 21738479 rs3026935 chr1 159117690 T C 2.05E-04 Height / / 17255346 rs3026943 chr1 159131926 A C 8.15E-08 Inflammatory biomarkers / / 22291609 rs3026946 chr1 159135282 C T 4.19E-08 Inflammatory biomarkers / / 22291609 rs965358 chr1 159140349 T A 1.59E-09 Inflammatory biomarkers / / 22291609 rs3026968 chr1 159147452 C T 9.00E-14 Inflammatory biomarkers CADM3 intron 22291609 rs1474747 chr1 159148513 C T 3.00E-06 Select biomarker traits CADM3 intron 17903293 rs1474747 chr1 159148513 C T 5.74E-10 Inflammatory biomarkers CADM3 intron 22291609 rs16841832 chr1 159154312 G A 1.11E-08 Inflammatory biomarkers CADM3 intron 22291609 rs2281300 chr1 159156285 C T 3.20E-09 Inflammatory biomarkers CADM3 intron 22291609 rs3027001 chr1 159169463 C T 1.08E-07 White blood cell count CADM3 intron 21738479 rs3027001 chr1 159169463 C T 8.44E-05 IgE levels CADM3 intron 22075330 rs3027009 chr1 159173887 A G 7.00E-07 Lean body mass and age at menarche (combined) DARC UTR-5 22744181 rs3027012 chr1 159174123 C T 1.52E-09 White blood cell count DARC UTR-5 21738479 rs3027012 chr1 159174123 C T 8.92E-15 Inflammatory biomarkers DARC UTR-5 22291609 rs3027012 chr1 159174123 C T 1.74E-07 Obesity-related traits DARC UTR-5 23251661 rs2814778 chr1 159174683 T C 1.10E-13 Blood cell counts and traits,in red and white blood cells DARC UTR-5 21153663 rs2814778 chr1 159174683 T C 1.40E-103 Blood cell counts and traits,in red and white blood cells DARC UTR-5 21153663 rs2814778 chr1 159174683 T C 4.10E-82 Blood cell counts and traits,in red and white blood cells DARC UTR-5 21153663 rs2814778 chr1 159174683 T C 5.50E-85 Blood cell counts and traits,in red and white blood cells DARC UTR-5 21153663 rs2814778 chr1 159174683 T C 1.00E-08 Neutrophil count DARC UTR-5 21507922 rs2814778 chr1 159174683 T C 7.00E-55 White blood cell count DARC UTR-5 22037903 rs2814778 chr1 159174683 T C 6.48E-08 Circulating myeloperoxidase levels (serum) DARC UTR-5 23620142 rs863002 chr1 159174920 C T 8.20E-10 White blood cell count DARC intron 21738479 rs863002 chr1 159174920 C T 3.59E-13 Obesity-related traits DARC intron 23251661 rs3027016 chr1 159175193 A G 3.06E-06 Obesity-related traits DARC UTR-5 23251661 rs12075 chr1 159175354 G A 1.14E-09 White blood cell count DARC missense 21738479 rs12075 chr1 159175354 G A 5.00E-24 White blood cell count DARC missense 22037903 rs12075 chr1 159175354 G A 4.00E-51 Inflammatory biomarkers DARC missense 22291609 rs12075 chr1 159175354 G A 1.30E-29 Duffy system Fya antigen DARC missense 22611595 rs12075 chr1 159175354 G A 1.00E-21 Monocyte chemoattractant protein-1 DARC missense 23017229 rs12075 chr1 159175354 G A 4.10E-04 Type 2 diabetes DARC missense 23209189 rs12075 chr1 159175354 G A 1.00E-21 Obesity-related traits DARC missense 23251661 rs13962 chr1 159175527 G A 2.00E-11 IgE levels DARC frameshift 22075330 rs863006 chr1 159177748 G A 1.03E-16 Obesity-related traits / / 23251661 rs3027031 chr1 159178273 C G 3.97E-09 Inflammatory biomarkers / / 22291609 rs3027040 chr1 159181492 C A 9.31E-07 White blood cell count / / 21738479 rs3027041 chr1 159181560 T C 6.02E-08 White blood cell count / / 21738479 rs3027044 chr1 159181869 T C 9.14E-04 Alzheimer's disease / / 17998437 rs3027048 chr1 159183713 C T 1.99E-10 White blood cell count / / 21738479 rs12034864 chr1 159184980 A G 1.46E-10 White blood cell count / / 21738479 rs12034864 chr1 159184980 A G 6.95E-07 Inflammatory biomarkers / / 22291609 rs3027056 chr1 159186231 G A 9.45E-07 Inflammatory biomarkers / / 22291609 rs3027061 chr1 159186600 A G 2.00E-07 White blood cell count / / 21738479 rs3027063 chr1 159186781 C T 4.24E-10 White blood cell count / / 21738479 rs3027063 chr1 159186781 C T 7.42E-07 Inflammatory biomarkers / / 22291609 rs17666424 chr1 159187530 G A 3.22E-11 Inflammatory biomarkers / / 22291609 rs3027077 chr1 159191648 C T 2.71E-07 White blood cell count / / 21738479 rs863011 chr1 159194172 C T 8.26E-17 Inflammatory biomarkers / / 22291609 rs4083420 chr1 159194838 A G 3.60E-07 Inflammatory biomarkers / / 22291609 rs10489849 chr1 159196765 C T 1.00E-06 Select biomarker traits / / 17903293 rs10489849 chr1 159196765 C T 2.48E-08 Inflammatory biomarkers / / 22291609 rs863013 chr1 159200020 G T 3.32E-07 White blood cell count / / 21738479 rs863013 chr1 159200020 G T 2.43E-07 IgE levels / / 22075330 rs863013 chr1 159200020 G T 1.54E-07 Inflammatory biomarkers / / 22291609 rs863013 chr1 159200020 G T 2.92E-05 Inflammation / / pha002897 rs6660102 chr1 159211064 G T 5.14E-08 White blood cell count / / 21738479 rs6660102 chr1 159211064 G T 5.72E-13 Inflammatory biomarkers / / 22291609 rs863017 chr1 159214544 A T 1.20E-17 Inflammatory biomarkers / / 22291609 rs12072644 chr1 159215287 C T 5.70E-08 White blood cell count / / 21738479 rs12072644 chr1 159215287 C T 6.70E-13 Inflammatory biomarkers / / 22291609 rs863018 chr1 159215326 C T 2.05E-06 White blood cell count / / 21738479 rs863018 chr1 159215326 C T 5.25E-07 IgE levels / / 22075330 rs3845624 chr1 159218266 A C 2.37E-10 White blood cell count / / 21738479 rs3845624 chr1 159218266 A C 2.00E-11 Inflammatory biomarkers / / 22291609 rs11265158 chr1 159224030 T C 6.96E-15 White blood cell count / / 21738479 rs10908702 chr1 159228378 C T 5.82E-15 White blood cell count / / 21738479 rs10908702 chr1 159228378 C T 2.28E-04 Age-related macular degeneration / / 22125219 rs113854958 chr1 159230098 TA T 2.63E-08 IgE levels / / 22075330 rs2494257 chr1 159230098 T A 2.63E-08 IgE levels / / 22075330 rs2511211 chr1 159230471 T G 3.80E-09 IgE levels / / 22075330 rs2427832 chr1 159233075 A G 1.49E-04 Myopia (pathological) / / 21095009 rs2427832 chr1 159233075 A G 2.81E-18 Inflammatory biomarkers / / 22291609 rs2494258 chr1 159234579 T C 5.74E-18 Inflammatory biomarkers / / 22291609 rs12405354 chr1 159237652 A G 1.97E-12 Inflammatory biomarkers / / 22291609 rs2511212 chr1 159244893 C T 4.71E-17 Inflammatory biomarkers / / 22291609 rs2494260 chr1 159246185 T C 2.59E-16 Inflammatory biomarkers / / 22291609 rs2427834 chr1 159246523 A G 6.78E-09 Inflammatory biomarkers / / 22291609 rs2494261 chr1 159251294 G A 4.04E-19 Inflammatory biomarkers / / 22291609 rs2494262 chr1 159253672 C A 7.88E-11 White blood cell count / / 21738479 rs2494262 chr1 159253672 C A 1.51E-07 IgE levels / / 22075330 rs2427836 chr1 159254764 T C 4.30E-04 Parkinson's disease FCER1A intron 17052657 rs2427836 chr1 159254764 T C 8.72E-10 White blood cell count FCER1A intron 21738479 rs2427836 chr1 159254764 T C 6.07E-09 IgE levels FCER1A intron 22075330 rs2511214 chr1 159254866 G T 1.07E-10 White blood cell count FCER1A intron 21738479 rs2511214 chr1 159254866 G T 8.99E-08 IgE levels FCER1A intron 22075330 rs2494263 chr1 159255794 G A 1.87E-11 Inflammatory biomarkers FCER1A intron 22291609 rs2427837 chr1 159258545 G A 1.79E-04 IgE levels FCER1A intron 17255346 rs2427837 chr1 159258545 G A 9.82E-12 IgE levels FCER1A intron 22075330 rs2427837 chr1 159258545 G A 1.28E-07 Obesity-related traits FCER1A intron 23251661 rs2247584 chr1 159259680 T G 1.39E-09 White blood cell count FCER1A intron 21738479 rs2247584 chr1 159259680 T G 3.34E-09 IgE levels FCER1A intron 22075330 rs2427824 chr1 159265062 T C 1.33E-11 Inflammatory biomarkers FCER1A intron 22291609 rs16841987 chr1 159265266 G A 1.20E-09 Inflammatory biomarkers FCER1A intron 22291609 rs3845625 chr1 159265876 C T 6.31E-09 Inflammatory biomarkers FCER1A intron 22291609 rs2427825 chr1 159266066 T C 9.46E-04 Myopia (pathological) FCER1A intron 21095009 rs2427825 chr1 159266066 T C 3.19E-12 Inflammatory biomarkers FCER1A intron 22291609 rs2494264 chr1 159266838 T A 2.20E-10 White blood cell count FCER1A intron 21738479 rs2494264 chr1 159266838 T A 1.37E-09 IgE levels FCER1A intron 22075330 rs2251746 chr1 159272060 T C 5.41E-05 IgE levels FCER1A intron 17255346 rs2251746 chr1 159272060 T C 2.00E-20 IgE levels FCER1A intron 18846228 rs2251746 chr1 159272060 T C 5.00E-26 IgE levels FCER1A intron 22075330 rs2427828 chr1 159273041 G A 7.07E-11 Inflammatory biomarkers FCER1A intron 22291609 rs2494265 chr1 159275274 A T 7.28E-11 Inflammatory biomarkers FCER1A intron 22291609 rs2252226 chr1 159276153 C T 6.12E-07 White blood cell count FCER1A intron 21738479 rs2252226 chr1 159276153 C T 2.49E-07 IgE levels FCER1A intron 22075330 rs7549785 chr1 159277868 G A 5.94E-09 Inflammatory biomarkers FCER1A UTR-3 22291609 rs2494250 chr1 159278251 G C 1.00E-14 Select biomarker traits / / 17903293 rs2494250 chr1 159278251 G C 5.23E-11 Inflammatory biomarkers / / 22291609 rs2494251 chr1 159281151 G A 7.24E-04 Parkinson's disease / / 17052657 rs2494251 chr1 159281151 G A 2.17E-09 White blood cell count / / 21738479 rs2494251 chr1 159281151 G A 3.12E-08 IgE levels / / 22075330 rs2427829 chr1 159282011 A G 8.36E-05 IgE levels / / 22075330 rs7522607 chr1 159285991 T C 5.78E-09 Inflammatory biomarkers / / 22291609 rs4269772 chr1 159290661 T C 8.85E-04 Myopia (pathological) / / 21095009 rs4269772 chr1 159290661 T C 1.30E-08 Inflammatory biomarkers / / 22291609 rs12724895 chr1 159291045 T A 1.57E-08 White blood cell count / / 21738479 rs12724895 chr1 159291045 T A 3.38E-08 IgE levels / / 22075330 rs4282816 chr1 159292850 G A 8.57E-05 IgE levels / / 22075330 rs4498803 chr1 159305157 C T 8.58E-05 IgE levels / / 22075330 rs12074934 chr1 159308071 T G 8.68E-12 White blood cell count / / 21738479 rs16842041 chr1 159308539 G A 9.54E-12 White blood cell count / / 21738479 rs12128960 chr1 159313447 A T 3.88E-09 White blood cell count / / 21738479 rs12128960 chr1 159313447 A T 1.22E-05 IgE levels / / 22075330 rs12132451 chr1 159313842 G A 3.75E-10 White blood cell count / / 21738479 rs12132451 chr1 159313842 G A 1.21E-05 IgE levels / / 22075330 rs10218647 chr1 159319803 G A 2.15E-04 Celiac disease / / 23936387 rs10908709 chr1 159320180 C A 3.33E-09 White blood cell count / / 21738479 rs10908709 chr1 159320180 C A 1.22E-05 IgE levels / / 22075330 rs11265174 chr1 159320359 T A 3.53E-08 White blood cell count / / 21738479 rs11265174 chr1 159320359 T A 1.15E-08 Inflammatory biomarkers / / 22291609 rs10908710 chr1 159320979 G A 8.65E-04 Parkinson's disease / / 17052657 rs10908710 chr1 159320979 G A 1.18E-10 White blood cell count / / 21738479 rs10908710 chr1 159320979 G A 1.22E-05 IgE levels / / 22075330 rs10908711 chr1 159321259 G A 1.92E-11 White blood cell count / / 21738479 rs4443888 chr1 159321675 G T 3.05E-04 Myopia (pathological) / / 21095009 rs4443888 chr1 159321675 G T 1.15E-11 White blood cell count / / 21738479 rs9782926 chr1 159323392 T A 1.42E-07 White blood cell count / / 21738479 rs9782926 chr1 159323392 T A 2.55E-09 Inflammatory biomarkers / / 22291609 rs11265177 chr1 159325834 A G 2.27E-09 Inflammatory biomarkers / / 22291609 rs4656784 chr1 159326880 A G 2.00E-16 IgE levels / / 22075330 rs4656784 chr1 159326880 A G 2.69E-07 Inflammatory biomarkers / / 22291609 rs11265178 chr1 159329046 C A 2.24E-10 White blood cell count / / 21738479 rs11265178 chr1 159329046 C A 1.23E-05 IgE levels / / 22075330 rs10494322 chr1 159336948 T C 1.73E-07 White blood cell count / / 21738479 rs4399156 chr1 159338072 G A 1.21E-13 Inflammatory biomarkers / / 22291609 rs4517343 chr1 159339006 A G 2.82E-12 White blood cell count / / 21738479 rs4517343 chr1 159339006 A G 1.25E-07 Inflammatory biomarkers / / 22291609 rs4537549 chr1 159339036 C G 2.88E-13 White blood cell count / / 21738479 rs4537549 chr1 159339036 C G 1.25E-07 Inflammatory biomarkers / / 22291609 rs6692378 chr1 159339241 T C 7.27E-14 White blood cell count / / 21738479 rs6692378 chr1 159339241 T C 8.10E-05 IgE levels / / 22075330 rs6692378 chr1 159339241 T C 4.52E-07 Inflammatory biomarkers / / 22291609 rs6677678 chr1 159339520 C T 3.73E-13 White blood cell count / / 21738479 rs6677678 chr1 159339520 C T 1.25E-07 Inflammatory biomarkers / / 22291609 rs10908713 chr1 159339559 T C 2.97E-13 White blood cell count / / 21738479 rs10908713 chr1 159339559 T C 1.82E-07 Inflammatory biomarkers / / 22291609 rs12141365 chr1 159340299 T C 7.52E-08 IgE levels / / 22075330 rs10908714 chr1 159340353 T A 4.86E-12 White blood cell count / / 21738479 rs10908714 chr1 159340353 T A 6.07E-07 IgE levels / / 22075330 rs4400605 chr1 159340416 T C 3.44E-13 White blood cell count / / 21738479 rs4400605 chr1 159340416 T C 1.78E-07 Inflammatory biomarkers / / 22291609 rs7548833 chr1 159340591 T C 3.55E-06 White blood cell count / / 21738479 rs7548736 chr1 159340686 A G 1.36E-12 White blood cell count / / 21738479 rs12142553 chr1 159341672 T C 1.12E-13 Inflammatory biomarkers / / 22291609 rs4130236 chr1 159341851 C T 1.95E-07 Inflammatory biomarkers / / 22291609 rs6687734 chr1 159342302 C T 5.78E-06 White blood cell count / / 21738479 rs6702853 chr1 159342410 T A 9.39E-08 White blood cell count / / 21738479 rs6702853 chr1 159342410 T A 3.54E-07 Inflammatory biomarkers / / 22291609 rs6687840 chr1 159342439 C T 7.00E-06 Chemerin levels / / 20237162 rs6687840 chr1 159342439 C T 3.13E-13 White blood cell count / / 21738479 rs6687840 chr1 159342439 C T 2.69E-07 Inflammatory biomarkers / / 22291609 rs11265180 chr1 159343648 G C 1.53E-09 Inflammatory biomarkers / / 22291609 rs6701545 chr1 159351967 T C 1.89E-07 Inflammatory biomarkers / / 22291609 rs4446959 chr1 159357684 T C 8.00E-06 Chemerin levels / / 20237162 rs4446959 chr1 159357684 T C 2.74E-12 White blood cell count / / 21738479 rs4446959 chr1 159357684 T C 2.69E-08 Inflammatory biomarkers / / 22291609 rs11265186 chr1 159375903 C T 3.31E-14 Inflammatory biomarkers / / 22291609 rs10908716 chr1 159376343 A G 3.31E-14 Inflammatory biomarkers / / 22291609 rs10908717 chr1 159376352 C A 3.31E-14 Inflammatory biomarkers / / 22291609 rs3122633 chr1 159377458 T C 1.94E-07 Inflammatory biomarkers / / 22291609 rs11265187 chr1 159378594 C T 2.00E-04 Myopia (pathological) / / 21095009 rs11265187 chr1 159378594 C T 3.87E-14 Inflammatory biomarkers / / 22291609 rs12034969 chr1 159384944 T C 1.13E-13 White blood cell count / / 21738479 rs12034969 chr1 159384944 T C 6.53E-05 IgE levels / / 22075330 rs12034969 chr1 159384944 T C 4.32E-07 Inflammatory biomarkers / / 22291609 rs11265190 chr1 159391401 G A 6.54E-12 White blood cell count / / 21738479 rs11265190 chr1 159391401 G A 6.45E-05 IgE levels / / 22075330 rs11265190 chr1 159391401 G A 4.13E-07 Inflammatory biomarkers / / 22291609 rs4492615 chr1 159391863 T C 3.95E-14 Inflammatory biomarkers / / 22291609 rs12118201 chr1 159396941 C T 4.69E-07 IgE levels / / 22075330 rs12118201 chr1 159396941 C T 8.76E-08 Inflammatory biomarkers / / 22291609 rs12043437 chr1 159398715 T C 2.38E-05 Suicide attempts in bipolar disorder / / 21423239 rs11265191 chr1 159400359 C T 6.05E-05 IgE levels / / 22075330 rs11265191 chr1 159400359 C T 2.09E-07 Inflammatory biomarkers / / 22291609 rs11265193 chr1 159401656 G T 5.39E-14 Inflammatory biomarkers / / 22291609 rs11265194 chr1 159403689 G T 3.87E-08 Inflammatory biomarkers / / 22291609 rs4128725 chr1 159405959 T C 4.00E-12 Select biomarker traits / / 17903293 rs4128725 chr1 159405959 T C 5.46E-14 Inflammatory biomarkers / / 22291609 rs12145079 chr1 159406538 G A 3.28E-12 White blood cell count / / 21738479 rs12145616 chr1 159409479 T G 6.58E-07 Inflammatory biomarkers / / 22291609 rs10908721 chr1 159409533 G A 8.10E-04 Multiple complex diseases OR10J1 UTR-5 17554300 rs12048482 chr1 159409857 A G 5.64E-05 IgE levels OR10J1 missense 22075330 rs12048482 chr1 159409857 A G 1.44E-07 Inflammatory biomarkers OR10J1 missense 22291609 rs12118628 chr1 159409884 G A 1.36E-04 Myopia (pathological) OR10J1 missense 21095009 rs12118628 chr1 159409884 G A 5.64E-14 Inflammatory biomarkers OR10J1 missense 22291609 rs4656236 chr1 159410975 G A 1.44E-04 IgE levels / / 17255346 rs4656236 chr1 159410975 G A 3.58E-07 White blood cell count / / 21738479 rs4656236 chr1 159410975 G A 1.77E-07 IgE levels / / 22075330 rs4656236 chr1 159410975 G A 2.80E-07 Inflammatory biomarkers / / 22291609 rs4656236 chr1 159410975 G A 8.74E-06 Obesity-related traits / / 23251661 rs4656237 chr1 159413824 T C 5.72E-04 Myopia (pathological) / / 21095009 rs4656237 chr1 159413824 T C 4.08E-14 Inflammatory biomarkers / / 22291609 rs12410729 chr1 159414034 T C 5.07E-14 Inflammatory biomarkers / / 22291609 rs11265196 chr1 159418212 G A 1.30E-07 White blood cell count / / 21738479 rs11265196 chr1 159418212 G A 3.72E-05 IgE levels / / 22075330 rs11265196 chr1 159418212 G A 1.80E-07 Inflammatory biomarkers / / 22291609 rs11265198 chr1 159420307 G A 2.10E-07 White blood cell count / / 21738479 rs4562618 chr1 159429748 T A 6.88E-05 Alzheimer's disease / / 22832961 rs7540542 chr1 159430327 G T 1.87E-07 IgE levels / / 22075330 rs7540542 chr1 159430327 G T 1.91E-07 Inflammatory biomarkers / / 22291609 rs12565926 chr1 159431839 C T 1.59E-05 Alzheimer's disease / / 22832961 rs12133577 chr1 159432278 C T 4.47E-11 White blood cell count / / 21738479 rs12133577 chr1 159432278 C T 3.33E-07 IgE levels / / 22075330 rs11265204 chr1 159439913 A G 6.66E-04 Parkinson's disease / / 17052657 rs11265204 chr1 159439913 A G 2.06E-06 White blood cell count / / 21738479 rs11265204 chr1 159439913 A G 3.39E-07 IgE levels / / 22075330 rs12566875 chr1 159440210 C G 5.69E-05 Alzheimer's disease / / 22832961 rs12034243 chr1 159441441 G A 9.89E-12 White blood cell count / / 21738479 rs12034243 chr1 159441441 G A 3.55E-07 IgE levels / / 22075330 rs4339862 chr1 159441628 C A 1.13E-11 White blood cell count / / 21738479 rs7519020 chr1 159446104 A G 8.07E-06 White blood cell count / / 21738479 rs4233351 chr1 159446370 G A 9.12E-06 White blood cell count / / 21738479 rs6678321 chr1 159446883 G A 9.99E-06 White blood cell count / / 21738479 rs11265206 chr1 159449083 T C 5.53E-13 Inflammatory biomarkers / / 22291609 rs7541480 chr1 159449464 A G 9.26E-06 White blood cell count / / 21738479 rs10908724 chr1 159450168 G T 9.79E-13 Inflammatory biomarkers / / 22291609 rs4133289 chr1 159453937 C T 2.00E-07 Hemostatic factors and hematological phenotypes / / 17903294 rs4133289 chr1 159453937 C T 2.13E-06 White blood cell count / / 21738479 rs12132709 chr1 159454237 G A 1.20E-06 White blood cell count / / 21738479 rs12756262 chr1 159455330 A G 1.20E-06 White blood cell count / / 21738479 rs12135090 chr1 159457072 G A 1.01E-06 White blood cell count / / 21738479 rs7555008 chr1 159457808 T C 2.32E-07 White blood cell count / / 21738479 rs12141291 chr1 159460871 C T 5.68E-06 White blood cell count / / 21738479 rs4325129 chr1 159462381 A G 6.21E-06 White blood cell count / / 21738479 rs4325129 chr1 159462381 A G 6.00E-06 Obesity-related traits / / 23251661 rs12567624 chr1 159468713 T A 4.63E-07 White blood cell count / / 21738479 rs12726858 chr1 159469428 A G 4.99E-08 White blood cell count / / 21738479 rs6689654 chr1 159471321 G T 4.11E-06 White blood cell count / / 21738479 rs6699279 chr1 159473788 G C 5.91E-08 White blood cell count / / 21738479 rs12142583 chr1 159477947 A G 1.49E-12 Inflammatory biomarkers / / 22291609 rs11811256 chr1 159478230 T C 3.30E-07 Inflammatory biomarkers / / 22291609 rs6687017 chr1 159478262 T C 7.08E-06 White blood cell count / / 21738479 rs12047230 chr1 159479005 A G 1.36E-08 White blood cell count / / 21738479 rs12047230 chr1 159479005 A G 1.03E-10 Inflammatory biomarkers / / 22291609 rs12124964 chr1 159479032 C T 6.36E-07 White blood cell count / / 21738479 rs12143656 chr1 159479148 A G 1.17E-12 Inflammatory biomarkers / / 22291609 rs6689142 chr1 159483350 C A 9.63E-05 Alzheimer's disease / / 22832961 rs12564423 chr1 159486149 C T 8.29E-05 Alzheimer's disease / / 22832961 rs11265218 chr1 159486640 T C 7.67E-13 Inflammatory biomarkers / / 22291609 rs6427482 chr1 159499258 G A 7.37E-08 Inflammatory biomarkers / / 22291609 rs10908733 chr1 159504054 T A 9.86E-12 Inflammatory biomarkers / / 22291609 rs1584250 chr1 159507674 C T 2.20E-10 Inflammatory biomarkers / / 22291609 rs11265230 chr1 159515295 A G 8.98E-11 Inflammatory biomarkers / / 22291609 rs6659792 chr1 159515398 A T 2.23E-07 White blood cell count / / 21738479 rs2084257 chr1 159523486 C A 6.32E-16 White blood cell count / / 21738479 rs1584252 chr1 159523628 A T 4.09E-08 White blood cell count / / 21738479 rs1584252 chr1 159523628 A T 9.38E-05 IgE levels / / 22075330 rs1584252 chr1 159523628 A T 4.10E-10 Inflammatory biomarkers / / 22291609 rs2166587 chr1 159549993 A C,T 8.80E-04 Coronary heart disease / / 21966275 rs17457976 chr1 159580873 A G 9.68E-06 White blood cell count / / 21738479 rs2794502 chr1 159582055 T G 8.83E-05 Socioeconomic Factors / / pha003066 rs10494331 chr1 159582103 C T 1.90E-05 Type 2 diabetes / / 17903298 rs10494331 chr1 159582103 C T 2.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs4233355 chr1 159582218 G A 1.73E-06 White blood cell count / / 21738479 rs4233355 chr1 159582218 G A 3.53E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs2592889 chr1 159584265 C T 3.28E-04 Multiple complex diseases / / 17554300 rs2794505 chr1 159584337 C G 3.43E-04 Multiple complex diseases / / 17554300 rs1446971 chr1 159585164 G A 1.04E-08 Inflammatory biomarkers / / 22291609 rs1446970 chr1 159585193 G C 5.52E-06 White blood cell count / / 21738479 rs1374485 chr1 159585282 A G 7.40E-06 White blood cell count / / 21738479 rs2794506 chr1 159585560 A G 8.28E-07 White blood cell count / / 21738479 rs2794506 chr1 159585560 A G 3.02E-07 Inflammatory biomarkers / / 22291609 rs2592879 chr1 159589734 C G 4.00E-04 Multiple complex diseases / / 17554300 rs2794509 chr1 159592810 G T 4.11E-06 White blood cell count / / 21738479 rs2794510 chr1 159592915 T C 4.58E-04 Multiple complex diseases / / 17554300 rs2794510 chr1 159592915 T C 6.30E-06 White blood cell count / / 21738479 rs983788 chr1 159595417 A G,T 1.23E-06 White blood cell count / / 21738479 rs983788 chr1 159595417 A G,T 4.76E-07 Inflammatory biomarkers / / 22291609 rs983789 chr1 159595682 G T 6.24E-11 Inflammatory biomarkers / / 22291609 rs983790 chr1 159595717 A G 5.58E-06 White blood cell count / / 21738479 rs1446954 chr1 159596129 G C 7.40E-16 Inflammatory biomarkers / / 22291609 rs1446955 chr1 159596156 G A 9.28E-11 Inflammatory biomarkers / / 22291609 rs1446956 chr1 159596721 T C 5.87E-09 Inflammatory biomarkers / / 22291609 rs1446957 chr1 159596766 C G 7.99E-13 Inflammatory biomarkers / / 22291609 rs2794514 chr1 159598303 A G 3.73E-11 Inflammatory biomarkers / / 22291609 rs12060842 chr1 159598747 G A 5.09E-13 Inflammatory biomarkers / / 22291609 rs984553 chr1 159599414 A G 2.41E-06 White blood cell count / / 21738479 rs984553 chr1 159599414 A G 2.98E-11 Inflammatory biomarkers / / 22291609 rs1446958 chr1 159599807 A G 4.76E-06 White blood cell count / / 21738479 rs1446958 chr1 159599807 A G 2.48E-11 Inflammatory biomarkers / / 22291609 rs2794525 chr1 159602515 G A 3.64E-11 White blood cell count / / 21738479 rs2794525 chr1 159602515 G A 1.73E-12 Inflammatory biomarkers / / 22291609 rs6427488 chr1 159602870 C T 6.72E-09 White blood cell count / / 21738479 rs2592881 chr1 159605100 T C 1.19E-13 Inflammatory biomarkers / / 22291609 rs1867939 chr1 159605894 A C 2.81E-11 Inflammatory biomarkers / / 22291609 rs2808651 chr1 159606226 T C 2.45E-09 White blood cell count / / 21738479 rs2808651 chr1 159606226 T C 5.65E-11 Inflammatory biomarkers / / 22291609 rs2808652 chr1 159606256 T C 3.60E-12 Inflammatory biomarkers / / 22291609 rs2808653 chr1 159606420 C T 5.64E-11 Inflammatory biomarkers / / 22291609 rs1446959 chr1 159606804 T A 2.01E-08 White blood cell count / / 21738479 rs7529729 chr1 159607351 T A 5.66E-09 White blood cell count / / 21738479 rs985472 chr1 159608945 T A 5.75E-11 Inflammatory biomarkers / / 22291609 rs4656241 chr1 159613986 T C 3.06E-07 Inflammation / / pha002897 rs2808660 chr1 159616159 G A 4.00E-08 Inflammatory biomarkers / / 22291609 rs2592900 chr1 159616629 A G 5.44E-08 Inflammatory biomarkers / / 22291609 rs2592901 chr1 159617163 C T 7.57E-08 Inflammatory biomarkers / / 22291609 rs1446977 chr1 159619356 A T 6.92E-08 Inflammatory biomarkers / / 22291609 rs41497649 chr1 159624757 G A 8.68E-04 Type 2 diabetes / / 17463246 rs41497649 chr1 159624757 G A 7.83E-11 Inflammatory biomarkers / / 22291609 rs12087465 chr1 159625299 C A 8.05E-14 Inflammatory biomarkers / / 22291609 rs2794526 chr1 159625478 G A 5.61E-07 Inflammatory biomarkers / / 22291609 rs2794526 chr1 159625478 G A 1.56E-08 C-reactive protein / / 23844046 rs16827462 chr1 159627891 G A 9.75E-08 C-reactive protein / / 22492993 rs1891186 chr1 159629021 A G 8.34E-05 Premature ovarian failure / / 19508998 rs1891186 chr1 159629021 A G 8.34E-05 Other erythrocyte phenotypes / / 19862010 rs1891186 chr1 159629021 A G 1.42E-07 Inflammatory biomarkers / / 22291609 rs1891186 chr1 159629021 A G 1.31E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1891186 chr1 159629021 A G 2.83E-05 Inflammation / / pha002897 rs1891187 chr1 159629053 T A 3.75E-07 Inflammatory biomarkers / / 22291609 rs1891187 chr1 159629053 T A 7.32E-09 C-reactive protein / / 23844046 rs1446976 chr1 159629194 A G 1.52E-07 Inflammatory biomarkers / / 22291609 rs1446976 chr1 159629194 A G 5.84E-09 C-reactive protein / / 23844046 rs1446975 chr1 159629342 T C 1.03E-07 Inflammatory biomarkers / / 22291609 rs1446975 chr1 159629342 T C 7.67E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1446974 chr1 159629384 T C 6.37E-08 Inflammatory biomarkers / / 22291609 rs2794500 chr1 159635021 C T 8.34E-05 Premature ovarian failure / / 19508998 rs2794500 chr1 159635021 C T 8.34E-05 Other erythrocyte phenotypes / / 19862010 rs2794500 chr1 159635021 C T 1.05E-07 Inflammatory biomarkers / / 22291609 rs2794500 chr1 159635021 C T 7.67E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2794500 chr1 159635021 C T 4.11E-05 Inflammation / / pha002897 rs2794498 chr1 159636116 G T 3.38E-08 Inflammatory biomarkers / / 22291609 rs2794498 chr1 159636116 G T 1.58E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs895582 chr1 159637919 G A 3.23E-08 Inflammatory biomarkers / / 22291609 rs895581 chr1 159637987 A G 2.36E-08 Inflammatory biomarkers / / 22291609 rs895581 chr1 159637987 A G 2.71E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11585798 chr1 159638015 T A 5.95E-06 White blood cell count / / 21738479 rs1971863 chr1 159638931 T C 6.39E-08 Inflammatory biomarkers / / 22291609 rs1971863 chr1 159638931 T C 2.78E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1811472 chr1 159642349 G C 1.21E-11 C-reactive protein / / 23844046 rs1811472 chr1 159642349 G C 2.27E-15 Inflammation / / pha002897 rs12567054 chr1 159644968 T G 2.22E-16 C-reactive protein / / 23844046 rs2794515 chr1 159646544 T C 6.51E-05 Glucose levels / / pha003061 rs16842484 chr1 159646924 T C 7.71E-08 Inflammatory biomarkers / / 22291609 rs12744244 chr1 159647656 C A 7.73E-06 White blood cell count / / 21738479 rs12744244 chr1 159647656 C A 8.78E-08 Inflammatory biomarkers / / 22291609 rs12744244 chr1 159647656 C A 2.50E-06 Inflammation / / pha002897 rs12093699 chr1 159647988 G A 6.00E-06 Protein quantitative trait loci / / 18464913 rs12093699 chr1 159647988 G A 1.62E-13 Inflammation / / pha002897 rs10494326 chr1 159649700 C T 4.31E-11 C-reactive protein / / 22492993 rs10494326 chr1 159649700 C T 4.00E-73 C-reactive protein / / 22939635 rs10494326 chr1 159649700 C T 4.00E-73 C-reactive protein / / 22939635 rs2592887 chr1 159652939 C T 2.80E-09 C-reactive protein / / 21647738 rs2592887 chr1 159652939 C T 2.80E-07 Metabolic syndrome phenotype / / 22022282 rs2592887 chr1 159652939 C T 8.40E-08 Metabolic syndrome phenotype / / 22022282 rs2592887 chr1 159652939 C T 7.16E-13 Inflammatory biomarkers / / 22291609 rs2592887 chr1 159652939 C T 1.38E-14 C-reactive protein / / 23844046 rs2592887 chr1 159652939 C T 1.51E-16 Inflammation / / pha002897 rs2592887 chr1 159652939 C T 8.96E-05 Weight / / pha003026 rs1470515 chr1 159653599 C T 2.10E-09 C-reactive protein / / 21647738 rs1470515 chr1 159653599 C T 6.31E-13 Inflammatory biomarkers / / 22291609 rs1470515 chr1 159653599 C T 4.33E-19 C-reactive protein / / 23844046 rs16842502 chr1 159653863 C A 4.42E-07 Inflammatory biomarkers / / 22291609 rs16842502 chr1 159653863 C A 5.56E-21 C-reactive protein / / 23844046 rs16842502 chr1 159653863 C A 9.62E-11 C-reactive protein / / 24763700 rs7531832 chr1 159654216 A G 5.94E-11 C-reactive protein / / 22492993 rs726640 chr1 159655518 G A 2.00E-13 C-reactive protein / / 22492993 rs16842520 chr1 159657850 C G 1.79E-09 C-reactive protein / / 22492993 rs12749227 chr1 159659109 C T 1.67E-06 White blood cell count / / 21738479 rs12749227 chr1 159659109 C T 1.96E-07 Inflammatory biomarkers / / 22291609 rs12739022 chr1 159659431 T C 3.58E-11 White blood cell count / / 21738479 rs12739022 chr1 159659431 T C 1.97E-07 Inflammatory biomarkers / / 22291609 rs12754915 chr1 159660869 T C 5.29E-07 White blood cell count / / 21738479 rs12754915 chr1 159660869 T C 2.24E-07 Inflammatory biomarkers / / 22291609 rs1935193 chr1 159664090 T A 1.07E-12 C-reactive protein / / 23844046 rs16842525 chr1 159664624 T C 6.79E-10 C-reactive protein / / 22492993 rs2808624 chr1 159665921 C G 2.00E-09 C-reactive protein / / 21647738 rs2808624 chr1 159665921 C G 3.17E-13 Inflammatory biomarkers / / 22291609 rs2808624 chr1 159665921 C G 2.96E-19 C-reactive protein / / 23844046 rs1341666 chr1 159667059 C G 6.84E-10 C-reactive protein / / 22492993 rs2027469 chr1 159667190 G A 1.23E-06 Inflammation / / pha002897 rs2369146 chr1 159668195 A G 3.90E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs11265257 chr1 159668984 C T 1.90E-09 C-reactive protein / / 21647738 rs11265257 chr1 159668984 C T 3.80E-13 Inflammatory biomarkers / / 22291609 rs11265257 chr1 159668984 C T 2.75E-19 C-reactive protein / / 23844046 rs12741825 chr1 159670145 C T 7.51E-12 White blood cell count / / 21738479 rs12741825 chr1 159670145 C T 1.34E-07 Inflammatory biomarkers / / 22291609 rs12741825 chr1 159670145 C T 1.08E-08 C-reactive protein / / 23696881 rs12755606 chr1 159670336 C G 9.99E-08 Inflammatory biomarkers / / 22291609 rs12239267 chr1 159670928 C T 2.43E-09 C-reactive protein / / 22492993 rs1572970 chr1 159673585 G A 8.45E-07 Inflammatory biomarkers / / 22291609 rs1572970 chr1 159673585 G A 3.17E-10 C-reactive protein / / 23844046 rs876537 chr1 159674933 C T 1.00E-09 C-reactive protein / / 21647738 rs876537 chr1 159674933 C T 1.80E-19 C-reactive protein / / 23844046 rs876537 chr1 159674933 C T 1.49E-15 C-reactive protein / / 24763700 rs2808628 chr1 159676011 G A 7.30E-09 C-reactive protein / / 21647738 rs2808628 chr1 159676011 G A 4.40E-15 Inflammatory biomarkers / / 22291609 rs2808628 chr1 159676011 G A 1.07E-19 C-reactive protein / / 23844046 rs2808628 chr1 159676011 G A 7.50E-16 C-reactive protein / / 24763700 rs16842559 chr1 159676171 T C 4.05E-07 Inflammatory biomarkers / / 22291609 rs16842559 chr1 159676171 T C 4.00E-21 C-reactive protein / / 23844046 rs16842559 chr1 159676171 T C 1.99E-12 C-reactive protein / / 24763700 rs16842568 chr1 159676220 A G 4.04E-07 Inflammatory biomarkers / / 22291609 rs16842568 chr1 159676220 A G 4.15E-21 C-reactive protein / / 23844046 rs16842568 chr1 159676220 A G 1.99E-12 C-reactive protein / / 24763700 rs2808629 chr1 159676796 G A 3.20E-08 Biomarkers / / 17903293 rs2808629 chr1 159676796 G A 1.00E-08 C-reactive protein / / 21647738 rs2808629 chr1 159676796 G A 5.05E-15 Inflammatory biomarkers / / 22291609 rs2808629 chr1 159676796 G A 4.97E-20 C-reactive protein / / 23844046 rs2808629 chr1 159676796 G A 6.64E-16 C-reactive protein / / 24763700 rs6667499 chr1 159677654 G A 9.35E-10 C-reactive protein / / 22492993 rs2794520 chr1 159678816 C T 3.00E-08 Select biomarker traits / / 17903293 rs2794520 chr1 159678816 C T 3.00E-22 Metabolic traits / / 19060910 rs2794520 chr1 159678816 C T 2.00E-186 C-reactive protein / / 21300955 rs2794520 chr1 159678816 C T 1.10E-08 C-reactive protein / / 21647738 rs2794520 chr1 159678816 C T 0.00064 Rosuvastatin induced percent change in C-reactive protein (CRP) / / 22230323 rs2794520 chr1 159678816 C T 1.82E-15 Inflammatory biomarkers / / 22291609 rs2794520 chr1 159678816 C T 8.88E-16 C-reactive protein / / 23844046 rs2794520 chr1 159678816 C T 7.39E-16 C-reactive protein / / 24763700 rs2794520 chr1 159678816 C T 2.92E-22 Inflammation / / pha002897 rs3093077 chr1 159679636 A C 3.65E-07 Inflammatory biomarkers / / 22291609 rs3093077 chr1 159679636 A C 5.14E-17 C-reactive protein / / 23844046 rs3093077 chr1 159679636 A C 1.18E-11 C-reactive protein / / 24763700 rs3093075 chr1 159679913 G T 3.62E-07 Inflammatory biomarkers / / 22291609 rs3093075 chr1 159679913 G T 1.45E-20 C-reactive protein / / 23844046 rs3093075 chr1 159679913 G T 1.15E-11 C-reactive protein / / 24763700 rs2808630 chr1 159680868 C T 7.00E-06 Lung cancer / / 18385676 rs2808630 chr1 159680868 C T 7.00E-06 Nasopharyngeal carcinoma / / 20512145 rs3093068 chr1 159681364 G C 0.000712 Interleukin-6 (IL-6) levels / / 23505291 rs3093068 chr1 159681364 G C 2.73E-17 C-reactive protein / / 23505291 rs1205 chr1 159682233 C T 1.10E-08 C-reactive protein CRP UTR-3 21647738 rs1205 chr1 159682233 C T 5.42E-16 Inflammatory biomarkers CRP UTR-3 22291609 rs1205 chr1 159682233 C T 1.29E-18 C-reactive protein CRP UTR-3 23505291 rs1205 chr1 159682233 C T 2.61E-20 C-reactive protein CRP UTR-3 23844046 rs1205 chr1 159682233 C T 5.09E-16 C-reactive protein CRP UTR-3 24763700 rs1130864 chr1 159683091 G A 4.59E-17 C-reactive protein CRP UTR-3 23505291 rs1800947 chr1 159683438 C G 3.02E-14 C-reactive protein CRP cds-synon 23505291 rs3091244 chr1 159684665 G A,T 6.00E-28 C-reactive protein CRP nearGene-5 18439548 rs3091244 chr1 159684665 G A,T 3.00E-07 C-reactive protein CRP nearGene-5 21647738 rs3091244 chr1 159684665 G A,T 4.19E-35 C-reactive protein CRP nearGene-5 23505291 rs3093059 chr1 159685136 A G 4.00E-21 C-reactive protein CRP nearGene-5 21196492 rs3093059 chr1 159685136 A G 4.00E-21 Asthma CRP nearGene-5 21907864 rs3093059 chr1 159685136 A G 0.000175 Interleukin-6 (IL-6) levels CRP nearGene-5 23505291 rs3093059 chr1 159685136 A G 1.37E-18 C-reactive protein CRP nearGene-5 23505291 rs3093058 chr1 159685315 T A 7.55E-10 C-reactive protein CRP nearGene-5 22492993 rs9628671 chr1 159687972 C T 1.34E-09 C-reactive protein / / 22492993 rs2027471 chr1 159689388 T A 1.30E-07 C-reactive protein / / 21647738 rs2027471 chr1 159689388 T A 0.00011 Rosuvastatin induced percent change in C-reactive protein (CRP) / / 22230323 rs2027471 chr1 159689388 T A 2.97E-16 Inflammatory biomarkers / / 22291609 rs2027471 chr1 159689388 T A 2.30E-05 C-reactive protein / / 22492993 rs2027471 chr1 159689388 T A 3.95E-19 C-reactive protein / / 23844046 rs2027471 chr1 159689388 T A 3.92E-14 C-reactive protein / / 24763700 rs1341665 chr1 159691559 G A 1.20E-07 C-reactive protein / / 21647738 rs1341665 chr1 159691559 G A 2.00E-20 Inflammatory biomarkers / / 22291609 rs1341665 chr1 159691559 G A 2.30E-05 C-reactive protein / / 22492993 rs1341665 chr1 159691559 G A 8.84E-19 C-reactive protein / / 23505291 rs1341665 chr1 159691559 G A 3.75E-19 C-reactive protein / / 23844046 rs1341665 chr1 159691559 G A 3.76E-14 C-reactive protein / / 24763700 rs3116656 chr1 159692372 A G 1.06E-06 White blood cell count / / 21738479 rs3116656 chr1 159692372 A G 4.08E-07 Inflammatory biomarkers / / 22291609 rs12068753 chr1 159692537 T A 7.09E-07 Inflammatory biomarkers / / 22291609 rs12068753 chr1 159692537 T A 0.000261 Interleukin-6 (IL-6) levels / / 23505291 rs12068753 chr1 159692537 T A 8.02E-19 C-reactive protein / / 23505291 rs12068753 chr1 159692537 T A 4.19E-20 C-reactive protein / / 23844046 rs12068753 chr1 159692537 T A 2.18E-12 C-reactive protein / / 24763700 rs2808634 chr1 159692573 T C 3.00E-10 C-reactive protein / / 22939635 rs3116653 chr1 159696910 G C 4.63E-06 White blood cell count / / 21738479 rs3116653 chr1 159696910 G C 7.66E-07 Inflammatory biomarkers / / 22291609 rs16842599 chr1 159697475 T C 3.02E-07 Inflammatory biomarkers / / 22291609 rs16842599 chr1 159697475 T C 1.15E-20 C-reactive protein / / 23844046 rs16842599 chr1 159697475 T C 1.55E-12 C-reactive protein / / 24763700 rs3116651 chr1 159698485 C T 6.48E-06 White blood cell count / / 21738479 rs7553007 chr1 159698549 G A 8.00E-44 C-reactive protein / / 19567438 rs7553007 chr1 159698549 G A 1.20E-08 C-reactive protein / / 21647738 rs7553007 chr1 159698549 G A 1.41E-15 Inflammatory biomarkers / / 22291609 rs7553007 chr1 159698549 G A 2.90E-05 C-reactive protein / / 22492993 rs7553007 chr1 159698549 G A 1.00E-09 C-reactive protein / / 22939635 rs7553007 chr1 159698549 G A 1.00E-37 C-reactive protein / / 22939635 rs7553007 chr1 159698549 G A 5.09E-20 C-reactive protein / / 23844046 rs7553007 chr1 159698549 G A 2.00E-16 C-reactive protein / / 24763700 rs11265260 chr1 159700039 A G 7.00E-06 C-reactive protein / / 18439552 rs11265260 chr1 159700039 A G 1.50E-07 Inflammatory biomarkers / / 22291609 rs11265260 chr1 159700039 A G 1.12E-17 C-reactive protein / / 23844046 rs11265260 chr1 159700039 A G 4.45E-09 Inflammation / / pha002897 rs12727021 chr1 159702487 G A,C,T 3.57E-06 White blood cell count / / 21738479 rs12081252 chr1 159706513 T C 9.84E-08 Inflammatory biomarkers / / 22291609 rs12081252 chr1 159706513 T C 1.47E-20 C-reactive protein / / 23844046 rs12081252 chr1 159706513 T C 2.10E-12 C-reactive protein / / 24763700 rs12081264 chr1 159706560 T C 9.86E-08 Inflammatory biomarkers / / 22291609 rs12081264 chr1 159706560 T C 4.94E-20 C-reactive protein / / 23844046 rs12081264 chr1 159706560 T C 2.42E-12 C-reactive protein / / 24763700 rs12081480 chr1 159706990 T G 1.98E-20 C-reactive protein / / 23844046 rs12081480 chr1 159706990 T G 1.90E-12 C-reactive protein / / 24763700 rs4275453 chr1 159708047 C T 8.88E-13 C-reactive protein / / 23844046 rs4275453 chr1 159708047 C T 5.26E-09 C-reactive protein / / 24763700 rs12728740 chr1 159710093 C A 1.93E-10 White blood cell count / / 21738479 rs10437339 chr1 159710385 C G 3.43E-11 C-reactive protein / / 23844046 rs11265263 chr1 159710517 C A,T 3.00E-06 Vaccine-related adverse events / / 21396408 rs10437340 chr1 159710809 G C 2.64E-07 Inflammatory biomarkers / / 22291609 rs12083620 chr1 159713225 T A 2.64E-07 Inflammatory biomarkers / / 22291609 rs11265265 chr1 159713556 T C 4.74E-08 C-reactive protein / / 23844046 rs12049404 chr1 159713844 C T 1.40E-07 C-reactive protein / / 21647738 rs12049404 chr1 159713844 C T 3.68E-12 C-reactive protein / / 23844046 rs12760041 chr1 159714035 C T 5.16E-09 White blood cell count / / 21738479 rs4285692 chr1 159714149 T C 7.28E-10 C-reactive protein / / 23844046 rs11588887 chr1 159717162 G A 1.90E-07 C-reactive protein / / 21647738 rs11588887 chr1 159717162 G A 5.35E-09 C-reactive protein / / 23844046 rs12734907 chr1 159719594 A T 7.44E-10 White blood cell count / / 21738479 rs4131568 chr1 159722056 C T 3.48E-10 White blood cell count / / 21738479 rs4131568 chr1 159722056 C T 4.39E-05 Inflammation / / pha002897 rs4656849 chr1 159723521 A G 1.80E-05 Inflammation / / pha002897 rs4512645 chr1 159729047 G A 6.39E-10 White blood cell count / / 21738479 rs4364879 chr1 159736755 A G 2.91E-07 Inflammation / / pha002897 rs4406626 chr1 159743181 C A 2.06E-04 Cholesterol / / 17255346 rs3806185 chr1 159748886 C T 3.99E-08 Inflammatory biomarkers / / 22291609 rs3806185 chr1 159748886 C T 4.83E-07 Type 2 diabetes / / 23300278 rs3820099 chr1 159749188 C A 7.48E-05 Cholesterol / / 17255346 rs1129923 chr1 159752066 G A 3.90E-05 Height DUSP23 missense 21194676 rs1129923 chr1 159752066 G A 7.40E-07 Height DUSP23 missense 21194676 rs4233356 chr1 159753183 A G 9.00E-06 Interstitial lung disease / / 21787189 rs16842662 chr1 159762120 A G 2.90E-05 Monocyte counts / / pha003089 rs11265282 chr1 159774408 T C 6.71E-14 Esophageal cancer FCRL6 intron 21642993 rs2501343 chr1 159794576 G T 2.30E-05 Urinary metabolites / / 21572414 rs2501354 chr1 159815642 G A 8.10E-05 Type 2 diabetes C1orf204 intron 17463248 rs2501353 chr1 159815940 G T 2.14E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) C1orf204 intron 24023788 rs2501351 chr1 159816313 T G 2.10E-05 Urinary metabolites C1orf204 intron 21572414 rs2501350 chr1 159817004 G C 7.00E-05 Type 2 diabetes C1orf204 intron 17463248 rs6659742 chr1 159818513 C T 7.00E-07 Multiple sclerosis (OCB status) C1orf204 intron 23472185 rs11587021 chr1 159825916 C T 2.93E-12 White blood cell count VSIG8 intron 21738479 rs2501335 chr1 159831370 A G 8.28E-14 White blood cell count VSIG8 intron 21738479 rs4074846 chr1 159831406 G A 2.24E-13 White blood cell count VSIG8 intron 21738479 rs2501334 chr1 159832915 G A 1.04E-10 White blood cell count / / 21738479 rs12409375 chr1 159833733 C T 3.85E-06 White blood cell count / / 21738479 rs3795332 chr1 159834428 T G 2.85E-06 White blood cell count / / 21738479 rs11265287 chr1 159838965 C G 2.63E-14 White blood cell count / / 21738479 rs6673451 chr1 159840131 G C 7.21E-09 White blood cell count / / 21738479 rs11265289 chr1 159842103 C T 3.51E-14 White blood cell count / / 21738479 rs4545332 chr1 159842566 T A 2.15E-08 White blood cell count CCDC19 intron 21738479 rs4460634 chr1 159842691 C G 5.34E-08 White blood cell count CCDC19 intron 21738479 rs145923860 chr1 159842779 C T 0.00011 Prostate cancer (advanced) CCDC19 missense 23555315 rs11265290 chr1 159843606 T C 5.28E-08 White blood cell count CCDC19 intron 21738479 rs6682796 chr1 159852822 G A 8.55E-08 White blood cell count CCDC19 intron 21738479 rs6671929 chr1 159853139 A G 6.84E-08 White blood cell count CCDC19 intron 21738479 rs11265291 chr1 159853321 G A 8.87E-15 White blood cell count CCDC19 intron 21738479 rs2501324 chr1 159856429 C T 2.33E-12 Bilirubin levels,in serum CCDC19 cds-synon 20639394 rs145722573 chr1 159858278 G T 0.000067 Prostate cancer (advanced) CCDC19 missense 23555315 rs4656855 chr1 159859260 T C 2.79E-13 White blood cell count CCDC19 intron 21738479 rs2501321 chr1 159859279 A G 4.29E-06 Alzheimer's disease CCDC19 intron 17998437 rs2501321 chr1 159859279 A G 2.80E-05 Urinary metabolites CCDC19 intron 21572414 rs4656856 chr1 159859392 C T 2.01E-15 White blood cell count CCDC19 intron 21738479 rs10752631 chr1 159862153 T C 2.31E-15 White blood cell count CCDC19 intron 21738479 rs2494487 chr1 159866460 A G 3.59E-10 White blood cell count CCDC19 intron 21738479 rs3806192 chr1 159871184 C G 2.61E-15 White blood cell count / / 21738479 rs11265294 chr1 159875153 C T 7.08E-15 White blood cell count / / 21738479 rs10752632 chr1 159875455 G A 2.00E-14 White blood cell count / / 21738479 rs2494481 chr1 159878126 C A 9.60E-09 White blood cell count / / 21738479 rs1320566 chr1 159903634 C T 6.73E-06 Myopia (severe) IGSF9 intron 23933737 rs4262538 chr1 159908045 C T 5.70E-04 Type 2 diabetes IGSF9 intron 17463246 rs1316275 chr1 159913388 G A 6.29E-06 White blood cell count IGSF9 UTR-5 21738479 rs2840582 chr1 159916937 A G 7.13E-07 White blood cell count / / 21738479 rs16831153 chr1 159920719 G A 3.40E-04 Response to antidepressants / / 19736353 rs2789419 chr1 159920826 T A 3.96E-06 White blood cell count / / 21738479 rs2249707 chr1 159922959 C T 3.60E-06 White blood cell count SLAMF9 intron 21738479 rs2840584 chr1 159925431 C T 1.82E-09 Multiple complex diseases / / 17554300 rs2840584 chr1 159925431 C T 2.30E-06 White blood cell count / / 21738479 rs1316963 chr1 159928711 G A 5.41E-06 White blood cell count / / 21738479 rs2840588 chr1 159931395 C A 6.47E-04 Multiple complex diseases LOC100505633 intron 17554300 rs7541727 chr1 159932319 C T 1.97E-04 Taste perception LOC100505633 intron 22132133 rs7541727 chr1 159932319 C T 3.98E-04 Response to cytadine analogues (cytosine arabinoside) LOC100505633 intron 24483146 rs2840591 chr1 159940000 G A 4.79E-04 Tourette syndrome LOC100505633 intron 22889924 rs2789424 chr1 159942456 C T 1.13E-10 White blood cell count LOC100505633 intron 21738479 rs2789425 chr1 159949651 T C 1.14E-06 White blood cell count / / 21738479 rs1317712 chr1 159954369 C T 1.10E-04 Multiple complex diseases / / 17554300 rs2494208 chr1 159973615 G A 3.17E-04 Multiple complex diseases / / 17554300 rs2185214 chr1 159976751 A G 2.50E-04 HIV-1 viral setpoint / / 17641165 rs1934078 chr1 159977049 C T 3.91E-04 Multiple complex diseases / / 17554300 rs16831234 chr1 159977732 T A 0.0000433 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12086013 chr1 159983651 G A 0.0000453 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7531304 chr1 159984431 T C 0.0000128 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12058277 chr1 159985517 C T 0.0000202 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2211108 chr1 159988685 G A 6.31E-04 Type 2 diabetes / / 17463246 rs6427502 chr1 159989928 C G 0.00000518 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12726002 chr1 159991096 C A 0.00000574 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12403242 chr1 159995482 C G 8.65E-06 White blood cell count / / 21738479 rs12409352 chr1 160000435 A T 9.40E-06 White blood cell count PIGM missense 21738479 rs12409352 chr1 160000435 A T 0.000071 Breast cancer PIGM missense 23555315 rs17367150 chr1 160006809 A G 0.0000139 Nonsyndromic striae distensae (stretch marks) KCNJ10 nearGene-3 23633020 rs1053074 chr1 160009121 A C 0.000083 Nonsyndromic striae distensae (stretch marks) KCNJ10 UTR-3 23633020 rs12729701 chr1 160012406 A G 0.0000146 Nonsyndromic striae distensae (stretch marks) KCNJ10 intron 23633020 rs12133079 chr1 160016464 C A 8.68E-07 White blood cell count KCNJ10 intron 21738479 rs11265313 chr1 160029456 G A 1.50E-05 Height KCNJ10 intron 21998595 rs2737703 chr1 160055932 C T 6.52E-05 Waist Circumference KCNJ9 intron pha003025 rs2753268 chr1 160058252 G A 9.43E-05 Body Mass Index KCNJ9 UTR-3 pha003015 rs2753268 chr1 160058252 G A 2.33E-05 Weight KCNJ9 UTR-3 pha003026 rs6688363 chr1 160077854 C T 2.00E-07 Response to antipsychotic treatment / / 23241943 rs3761685 chr1 160084643 T C 0.0000963 HDL cholesterol ATP1A2 nearGene-5 23063622 rs1023420 chr1 160094343 T C 8.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ATP1A2 intron 20877124 rs1321655 chr1 160094458 A G,T 1.49E-11 HDL cholesterol ATP1A2 intron 23063622 rs1321655 chr1 160094458 A G,T 2.29E-08 LDL cholesterol ATP1A2 intron 23063622 rs1321655 chr1 160094458 A G,T 4.15E-10 Cholesterol,total ATP1A2 intron 23063622 rs11265329 chr1 160095446 C T 1.52E-08 White blood cell count ATP1A2 intron 21738479 rs16831388 chr1 160095625 A G 1.19E-04 Heart rate ATP1A2 intron 23583979 rs11265332 chr1 160117195 C G 7.64E-06 White blood cell count / / 21738479 rs12138430 chr1 160123781 A G 9.22E-04 Amyotrophic Lateral Sclerosis ATP1A4 intron 17362836 rs12144820 chr1 160126188 G A 6.08E-07 White blood cell count ATP1A4 intron 21738479 rs953104 chr1 160131429 G A 9.58E-05 Potassium levels ATP1A4 intron pha003086 rs1935306 chr1 160152057 C T 8.04E-04 Tourette syndrome ATP1A4 intron 22889924 rs659235 chr1 160159156 G A 3.11E-04 Birth weight / / 17255346 rs3827532 chr1 160170731 C T 2.69E-05 Alzheimer's disease (age of onset) CASQ1 intron 22005931 rs680083 chr1 160180906 G A 1.14E-04 Fibrinogen PEA15 intron 17255346 rs1061511 chr1 160189500 C A 2.40E-04 Fibrinogen DCAF8 intron 17255346 rs16831628 chr1 160193057 G A 5.72E-04 Alzheimer's disease DCAF8 intron 17998437 rs4596880 chr1 160224700 T A 1.54E-04 Fibrinogen DCAF8 intron 17255346 rs6661197 chr1 160234691 T G 5.12E-05 Fibrinogen / / 17255346 rs2795067 chr1 160251792 A G 4.06E-05 Fibrinogen PEX19 intron 17255346 rs2820421 chr1 160256004 C A 5.63E-05 Fibrinogen PEX19 nearGene-5 17255346 rs3789042 chr1 160265515 T C 8.72E-05 Fibrinogen COPA intron 17255346 rs6699059 chr1 160278311 A G 3.62E-04 Fibrinogen COPA intron 17255346 rs4656896 chr1 160295829 C T 5.58E-05 Alzheimer's disease (age of onset) COPA intron 22005931 rs16831810 chr1 160296841 G A 4.80E-05 Alzheimer's disease (age of onset) COPA intron 22005931 rs1802778 chr1 160303416 G A 3.72E-04 Fibrinogen COPA cds-synon 17255346 rs7512872 chr1 160310363 A G 4.13E-05 Fibrinogen COPA intron 17255346 rs2147471 chr1 160311845 C A 1.01E-04 Fibrinogen COPA intron 17255346 rs10752637 chr1 160312265 T G 9.02E-05 Fibrinogen COPA intron 17255346 rs1324738 chr1 160312625 C T 1.93E-04 Multiple complex diseases COPA intron 17554300 rs6669689 chr1 160318940 A G 4.47E-04 Fibrinogen NCSTN intron 17255346 rs6664438 chr1 160321359 C T 2.18E-04 Bipolar disorder NCSTN intron 18317468 rs6664438 chr1 160321359 C T 2.50E-05 Urinary metabolites NCSTN intron 21572414 rs6664438 chr1 160321359 C T 5.32E-08 Glucose levels NCSTN intron pha003061 rs1041066 chr1 160321656 G A 6.48E-05 Alzheimer's disease (age of onset) NCSTN intron 22005931 rs6677637 chr1 160324771 C T 5.32E-08 Glucose levels NCSTN intron pha003061 rs12724113 chr1 160328804 G A 8.80E-05 Parkinson's disease (age of onset) NCSTN nearGene-3 19772629 rs12724113 chr1 160328804 G A 1.58E-07 White blood cell count NCSTN nearGene-3 21738479 rs4656256 chr1 160331019 A G 8.52E-10 White blood cell count / / 21738479 rs4656256 chr1 160331019 A G 4.48E-06 Type 2 diabetes / / 22961080 rs4656902 chr1 160333742 T G 3.77E-04 Multiple complex diseases / / 17554300 rs4656902 chr1 160333742 T G 3.64E-05 Glucose levels / / pha003061 rs10908776 chr1 160334362 C T 8.86E-06 White blood cell count / / 21738479 rs12407581 chr1 160349641 C T 8.28E-04 Lymphocyte counts / / 22286170 rs12404657 chr1 160351229 C A 6.90E-05 Menopause (age at onset) / / 22267201 rs7513382 chr1 160372109 G T 1.20E-06 White blood cell count VANGL2 intron 21738479 rs6688100 chr1 160399586 T C 7.49E-06 White blood cell count / / 21738479 rs12757461 chr1 160415924 G A 4.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11585691 chr1 160420036 C T 5.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16832015 chr1 160421916 C T 2.00E-06 Cognitive performance / / 19734545 rs1149392 chr1 160428188 A G 7.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1149386 chr1 160441241 G C 1.50E-08 Graves' disease / / 21900946 rs3795327 chr1 160458782 A G 1.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLAMF6 intron 20877124 rs1265883 chr1 160464911 C A 2.25E-04 Type 2 diabetes SLAMF6 intron 17463246 rs1265883 chr1 160464911 C A 8.06E-05 Rheumatoid arthritis SLAMF6 intron 21452313 rs1265883 chr1 160464911 C A 2.00E-18 Graves' disease SLAMF6 intron 23612905 rs1268524 chr1 160470258 C T 0.000023 Salmonella-induced pyroptosis SLAMF6 intron 22837397 rs6660233 chr1 160473163 G T 7.90E-06 Urinary metabolites SLAMF6 intron 21572414 rs6689237 chr1 160492270 G A 1.80E-05 Urinary metabolites SLAMF6 intron 21572414 rs6689237 chr1 160492270 G A 5.35E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) SLAMF6 intron 24192120 rs2147466 chr1 160504157 G A 8.97E-07 White blood cell count / / 21738479 rs1408595 chr1 160506277 T A 7.13E-07 White blood cell count / / 21738479 rs11265432 chr1 160507016 T C 5.35E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs12134393 chr1 160512224 G A 2.80E-07 White blood cell count CD84 UTR-3 21738479 rs10737176 chr1 160512616 G A 6.44E-07 White blood cell count CD84 UTR-3 21738479 rs1503860 chr1 160513456 G A 1.38E-07 Response to anti-TNF treatment in rheumatoid arthritis CD84 UTR-3 23555300 rs6427528 chr1 160516308 A G 2.00E-06 Response to anti-TNF treatment in rheumatoid arthritis CD84 UTR-3 23555300 rs6427528 chr1 160516308 A G 7.78E-08 Response to anti-TNF treatment in rheumatoid arthritis CD84 UTR-3 23555300 rs3733266 chr1 160516659 C G 8.20E-06 Urinary metabolites CD84 UTR-3 21572414 rs3766389 chr1 160517214 A G 8.20E-06 Urinary metabolites CD84 UTR-3 21572414 rs10908788 chr1 160548263 A G 8.00E-06 Urinary metabolites CD84 intron 21572414 rs349250 chr1 160556144 A G 2.50E-05 Urinary metabolites / / 21572414 rs6668881 chr1 160569131 G A 2.70E-05 Urinary metabolites / / 21572414 rs111643709 chr1 160591741 C T 3.60E-11 Metabolite levels SLAMF1 intron 22286219 rs6672302 chr1 160600319 G T 6.85E-06 Telomere length SLAMF1 intron 23900074 rs2295612 chr1 160616703 G T 2.16E-04 Alzheimer's disease (late onset) SLAMF1 missense 21379329 rs10218843 chr1 160626061 A G 3.84E-06 Schizophrenia (treatment refractory) / / 22479419 rs11265461 chr1 160630143 T C 2.00E-07 Schizophrenia (treatment refractory) / / 22479419 rs11265464 chr1 160660312 T C 4.69E-04 Multiple complex diseases CD48 intron 17554300 rs11265472 chr1 160674460 T C 9.59E-05 Non-alcoholic fatty liver disease histology (other) CD48 intron 20708005 rs10489639 chr1 160679527 G A 4.90E-05 Kidney function and endocine traits CD48 intron 17903292 rs10489639 chr1 160679527 G A 9.33E-05 Sudden cardiac arrest CD48 intron 21658281 rs10908805 chr1 160679733 C T 3.41E-04 Multiple complex diseases CD48 intron 17554300 rs1503849 chr1 160680764 A G 5.56E-04 Multiple complex diseases CD48 intron 17554300 rs17313034 chr1 160713848 T C 5.93E-05 Cervical cancer SLAMF7 intron 24700089 rs489286 chr1 160722550 A G 3.39E-04 Response to cytadine analogues (cytosine arabinoside) SLAMF7 intron 24483146 rs495706 chr1 160723256 A G 6.78E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs518721 chr1 160723517 A G 6.78E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11582702 chr1 160727986 C T 1.10E-05 Cervical cancer / / 24700089 rs574491 chr1 160735814 A G 4.78E-04 Schizophrenia / / 20832056 rs574491 chr1 160735814 A G 1.20E-05 Urinary metabolites / / 21572414 rs528095 chr1 160738146 T C 3.59E-04 Schizophrenia / / 20832056 rs528095 chr1 160738146 T C 1.40E-05 Urinary metabolites / / 21572414 rs12068654 chr1 160743749 T G 5.00E-06 Cervical cancer / / 24700089 rs493644 chr1 160745399 C T 7.97E-06 White blood cell count / / 21738479 rs16832364 chr1 160746013 A C 2.54E-05 Type 2 diabetes / / 17463246 rs576523 chr1 160746076 G A 2.00E-07 Capecitabine sensitivity / / 22864933 rs7556098 chr1 160747615 C T 8.78E-05 Kawasaki disease / / 22081228 rs6427545 chr1 160770515 G A 3.97E-04 Type 2 diabetes LY9 intron 17463246 rs6656939 chr1 160773346 C G 5.30E-04 Type 2 diabetes LY9 intron 17463246 rs4656932 chr1 160779495 G A 1.80E-04 Primary sclerosing cholangitis LY9 intron 19944697 rs560681 chr1 160786670 A G 2.96E-04 Insulin resistance LY9 intron 21901158 rs3766377 chr1 160800559 A G 1.25E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses CD244 UTR-3 17903301 rs3766377 chr1 160800559 A G 2.50E-05 Psoriasis CD244 UTR-3 20953189 rs4656940 chr1 160830268 A G 6.00E-07 Crohn's disease CD244 intron 21102463 rs2274910 chr1 160852046 T C 1.00E-09 Crohn's disease ITLN1 intron 18587394 rs2274910 chr1 160852046 T C 1.00E-09 Asthma ITLN1 intron 21150878 rs2274910 chr1 160852046 T C 1.46E-09 Multiple sclerosis ITLN1 intron 22190364 rs4656958 chr1 160856964 A G 7.00E-09 Inflammatory bowel disease / / 23128233 rs11265510 chr1 160859559 A G 1.61E-04 Multiple complex diseases / / 17554300 rs11265519 chr1 160878913 C A 2.20E-04 Multiple complex diseases / / 17554300 rs11265519 chr1 160878913 C A 3.82E-07 Crohn's disease / / 18587394 rs6691672 chr1 160885530 A G 3.95E-04 Multiple complex diseases / / 17554300 rs2252389 chr1 160922195 A G 4.87E-04 Response to taxane treatment (placlitaxel) ITLN2 intron 23006423 rs4596920 chr1 160922751 C T 5.20E-06 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) ITLN2 intron 21221126 rs12126313 chr1 160925455 C A 3.80E-05 Suicidal ideation / / 20877300 rs1556260 chr1 161014446 C T 4.08E-09 Lymphocyte counts USF1 intron 22286170 rs2774279 chr1 161017556 C T 2.39E-04 Alzheimer's disease ARHGAP30 cds-synon 22005930 rs61733353 chr1 161018422 C G 0.00028 Breast cancer ARHGAP30 missense 23555315 rs11588189 chr1 161019621 C T 4.01E-04 Alzheimer's disease ARHGAP30 intron 22005930 rs12130871 chr1 161026490 A G 7.74E-04 Alzheimer's disease ARHGAP30 intron 22005930 rs10797092 chr1 161037042 A C 1.45E-04 IgE levels ARHGAP30 intron 17255346 rs3892375 chr1 161054054 T C 3.41E-04 Schizophrenia PVRL4 intron 20832056 rs1556258 chr1 161056455 T C 0.0000377 Nonsyndromic striae distensae (stretch marks) PVRL4 intron 23633020 rs4078017 chr1 161074092 G A 1.80E-05 Urinary metabolites PFDN2 intron 21572414 rs17389237 chr1 161092761 A G 1.60E-05 Urinary metabolites NIT1 intron 21572414 rs10797093 chr1 161103445 T G 3.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs3813620 chr1 161145005 C T 1.60E-05 Urinary metabolites B4GALT3 cds-synon 21572414 rs3813624 chr1 161170977 C T 3.92E-04 Lung function (forced expiratory volume in 1 second) NDUFS2 intron 17255346 rs10908826 chr1 161172525 C T 1.67E-04 Lung function (forced expiratory volume in 1 second) NDUFS2 intron 17255346 rs3924264 chr1 161178684 T C 2.73E-04 Type 2 diabetes NDUFS2 intron 17463246 rs3557 chr1 161188893 T G 8.96E-04 Type 2 diabetes FCER1G UTR-3 17463246 rs6413453 chr1 161192316 G A 4.46E-05 Atrial fibrillation APOA2 intron 21846873 rs4073054 chr1 161200487 C A 1.40E-06 Type 2 diabetes NR1I3 intron 17463246 rs4073054 chr1 161200487 C A 2.00E-08 Lipid levels NR1I3 intron 19936222 rs4073054 chr1 161200487 C A 5.70E-11 Lipid levels NR1I3 intron 19936222 rs4073054 chr1 161200487 C A 9.01E-05 Telomere length NR1I3 intron 21573004 rs4073054 chr1 161200487 C A 4.00E-19 Blood metabolite levels NR1I3 intron 24816252 rs11265572 chr1 161213063 G T 5.25E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2502807 chr1 161217693 C A 9.22E-05 Cognitive test performance / / 20125193 rs10494349 chr1 161259741 T C 7.31E-05 Common variable immunodeficiency / / 21497890 rs4436408 chr1 161260215 G A 5.67E-05 Cognitive impairment induced by topiramate / / 22091778 rs12750393 chr1 161262428 C T 8.67E-05 Smoking initiation / / 24665060 rs4657015 chr1 161272441 A G 8.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs16832790 chr1 161275943 C T 2.13E-04 Coronary heart disease MPZ cds-synon 21606135 rs17394957 chr1 161313437 C T 0.00004 Endoxifen sentivity (5 uM) SDHC intron 23508821 rs4474277 chr1 161329401 G A 0.00000119 Primary sclerosing cholangitis SDHC intron 23603763 rs16832872 chr1 161335902 G A 9.20E-04 Coronary heart disease C1orf192 intron 21606135 rs12744234 chr1 161361979 C T 3.02E-04 Lymphocyte counts / / 22286170 rs72717009 chr1 161405053 C T 1.00E-07 Rheumatoid arthritis / / 24390342 rs72717009 chr1 161405053 C T 5.00E-07 Rheumatoid arthritis / / 24390342 rs4657039 chr1 161462728 A G 2.20E-05 Ulcerative colitis / / 19915573 rs7511868 chr1 161463331 G A 5.42E-05 Ulcerative colitis / / 19915573 rs6427595 chr1 161463498 G A 8.48E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs7535475 chr1 161463587 C A 3.00E-06 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia / / 24039173 rs6696854 chr1 161463814 T C 3.65E-05 Ulcerative colitis / / 19915573 rs6696854 chr1 161463814 T C 8.48E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs6684851 chr1 161464412 C T 3.67E-05 Ulcerative colitis / / 19915573 rs12746613 chr1 161467042 C T 5.70E-04 Rheumatoid arthritis / / 22446963 rs12746613 chr1 161467042 C T 0.00000433 Rheumatoid arthritis / / 23143596 rs12139150 chr1 161470505 G C 2.81E-06 Ulcerative colitis / / 19915573 rs10800309 chr1 161472158 A G 7.00E-04 Systemic lupus erythematosus / / 18204446 rs10800309 chr1 161472158 A G 2.22E-05 Ulcerative colitis / / 19915573 rs10800309 chr1 161472158 A G 3.00E-09 Ulcerative colitis / / 20228799 rs10800309 chr1 161472158 A G 2.80E-09 Multiple sclerosis / / 22190364 rs10494360 chr1 161475750 G A 0.00003 Rheumatoid arthritis FCGR2A intron 23143596 rs6671847 chr1 161478810 G A 8.50E-09 Ulcerative colitis FCGR2A intron 19915573 rs1801274 chr1 161479745 A G 6.78E-07 Systemic lupus erythematosus FCGR2A missense 18204446 rs1801274 chr1 161479745 A G 2.00E-12 Ulcerative colitis FCGR2A missense 19915573 rs1801274 chr1 161479745 A G 2.00E-20 Ulcerative colitis FCGR2A missense 21297633 rs1801274 chr1 161479745 A G 7.00E-11 Kawasaki disease FCGR2A missense 22081228 rs1801274 chr1 161479745 A G 3.67E-08 Cholesterol,total FCGR2A missense 23063622 rs1801274 chr1 161479745 A G 2.00E-38 Inflammatory bowel disease FCGR2A missense 23128233 rs1801274 chr1 161479745 A G 2.12E-04 Ulcerative colitis FCGR2A missense 23511034 rs1801274 chr1 161479745 A G 5.02E-04 Systemic lupus erythematosus and Systemic sclerosis FCGR2A missense 23740937 rs1801274 chr1 161479745 A G 9.00E-06 Systemic lupus erythematosus FCGR2A missense 24871463 rs12142755 chr1 161481743 A G 5.87E-04 Response to cytadine analogues (cytosine arabinoside) FCGR2A intron 24483146 rs368433 chr1 161484210 T C 2.00E-08 Helicobacter pylori serologic status FCGR2A intron 23652523 rs17400517 chr1 161485259 G T 4.95E-08 Helicobacter pylori serologic status FCGR2A intron 23652523 rs9427401 chr1 161492175 C G 4.57E-08 Helicobacter pylori serologic status / / 23652523 rs396991 chr1 161514542 A C 1 Drug response to Rituximab FCGR3A missense 12975461 rs396991 chr1 161514542 A C 1 Drug response to Rituximab FCGR3A missense 16609067 rs396991 chr1 161514542 A C 1 Drug response to Cetuximab FCGR3A missense 17704420 rs396991 chr1 161514542 A C 1 Drug response to Infliximab FCGR3A missense 19005160 rs396991 chr1 161514542 A C 1 Drug response to Rituximab FCGR3A missense 19018870 rs67418890 chr1 161540857 T A 1.00E-10 Lipid metabolism phenotypes / / 22286219 rs10917688 chr1 161658780 C T 1.06E-04 Multiple complex diseases / / 17554300 rs1538972 chr1 161676557 G A 7.81E-05 Neuroblastoma / / pha002895 rs1954173 chr1 161677784 G A 6.24E-04 Rheumatoid arthritis FCRLA intron 21452313 rs1954174 chr1 161677807 C T 5.00E-06 Alcohol dependence FCRLA intron 21956439 rs1954174 chr1 161677807 C T 0.000247946 Hypertension (early onset hypertension) FCRLA intron 22479346 rs12135523 chr1 161678254 A G 6.52E-07 White blood cell count FCRLA intron 21738479 rs12134087 chr1 161678311 C T 1.06E-06 White blood cell count FCRLA intron 21738479 rs12136407 chr1 161678377 T C 1.52E-06 White blood cell count FCRLA intron 21738479 rs1934908 chr1 161680868 T C 4.20E-06 White blood cell count FCRLA intron 21738479 rs71634903 chr1 161681869 A G 0.000019 Prostate cancer (advanced) FCRLA missense 23555315 rs11746 chr1 161683136 G A 2.31E-06 White blood cell count FCRLA missense 21738479 rs1891020 chr1 161694454 A G 3.19E-06 Lymphocyte counts FCRLB intron 22286170 rs16858733 chr1 161697977 G C 8.89E-04 Alzheimer's disease / / 22005930 rs1503814 chr1 161709119 C T 4.96E-04 Multiple complex diseases / / 17554300 rs1027702 chr1 161712857 C T 5.74E-08 Neuroblastoma (low-risk) / / 21436895 rs1027702 chr1 161712857 C T 2.71E-07 Neuroblastoma / / pha002895 rs10917835 chr1 161717293 T A 3.50E-04 Type 2 diabetes / / 22158537 rs1063178 chr1 161721707 C T 2.42E-05 Neuroblastoma / / pha002895 rs3820449 chr1 161727172 G A 3.23E-06 Neuroblastoma / / pha002895 rs12745240 chr1 161728001 G A 8.04E-05 Neuroblastoma / / pha002895 rs7519514 chr1 161739190 A G 3.06E-08 White blood cell count ATF6 intron 21738479 rs7519514 chr1 161739190 A G 6.37E-06 Type 2 diabetes ATF6 intron 22158537 rs905594 chr1 161741274 T C 5.32E-08 White blood cell count ATF6 intron 21738479 rs905594 chr1 161741274 T C 3.52E-05 Type 2 diabetes ATF6 intron 22158537 rs905594 chr1 161741274 T C 3.81E-06 Diabetes Mellitus ATF6 intron pha003059 rs1027700 chr1 161757036 A T 1.15E-07 Type 2 diabetes ATF6 intron 22158537 rs6698956 chr1 161758744 T C 0.0004616 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ATF6 intron 23233654 rs6698956 chr1 161758744 T C 4.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) ATF6 intron 23233662 rs11576878 chr1 161775577 A G 2.06E-07 Type 2 diabetes ATF6 intron 22158537 rs2134697 chr1 161780979 G A 1.02E-05 Type 2 diabetes ATF6 intron 22158537 rs16849542 chr1 161786495 A G 1.77E-25 Narcolepsy ATF6 intron 19629137 rs11581556 chr1 161793612 G A 8.59E-07 Type 2 diabetes ATF6 intron 22158537 rs10918029 chr1 161795896 G A 0.0004025 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ATF6 intron 23233654 rs10918029 chr1 161795896 G A 4.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) ATF6 intron 23233662 rs12691498 chr1 161809706 T A 0.000373 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ATF6 intron 23233654 rs12691498 chr1 161809706 T A 3.73E-04 Methotrexate clearance (acute lymphoblastic leukemia) ATF6 intron 23233662 rs1006310 chr1 161811555 T C 2.61E-07 White blood cell count ATF6 intron 21738479 rs1006310 chr1 161811555 T C 5.86E-04 Type 2 diabetes ATF6 intron 22158537 rs3767635 chr1 161820904 A G 1.80E-05 Urinary metabolites ATF6 intron 21572414 rs931778 chr1 161823618 A G 1.98E-07 White blood cell count ATF6 intron 21738479 rs931778 chr1 161823618 A G 8.73E-04 Type 2 diabetes ATF6 intron 22158537 rs3767633 chr1 161826615 T A 8.00E-06 IgG glycosylation ATF6 intron 23382691 rs2340721 chr1 161849385 A C 3.46E-07 White blood cell count ATF6 intron 21738479 rs2340721 chr1 161849385 A C 7.96E-04 Type 2 diabetes ATF6 intron 22158537 rs10918137 chr1 161862555 G A 3.36E-07 White blood cell count ATF6 intron 21738479 rs12124509 chr1 161867489 G A 1.14E-07 White blood cell count ATF6 intron 21738479 rs2341475 chr1 161878608 A G 8.85E-05 Type 2 diabetes ATF6 intron 22158537 rs12079579 chr1 161880482 G A 0.00056 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ATF6 intron 23233654 rs12079579 chr1 161880482 G A 5.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) ATF6 intron 23233662 rs4657121 chr1 161883083 G A 7.90E-07 Type 2 diabetes ATF6 intron 22158537 rs4657121 chr1 161883083 G A 4.49E-05 Neuroblastoma ATF6 intron pha002895 rs7554023 chr1 161896364 A G 1.00E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ATF6 intron 24023788 rs10918270 chr1 161915501 G A 8.00E-06 Parkinson's disease (age of onset) ATF6 intron 19772629 rs3795649 chr1 161931562 G A 9.69E-05 Heart Failure ATF6 UTR-3 pha002885 rs2499844 chr1 161935361 G A,C 8.82E-07 Type 2 diabetes / / 22158537 rs2490439 chr1 161935854 G T 1.18E-06 Type 2 diabetes / / 22158537 rs2490438 chr1 161936788 G A 1.19E-06 Type 2 diabetes / / 22158537 rs2490431 chr1 161941219 T C 1.50E-08 White blood cell count / / 21738479 rs4656342 chr1 161942491 C G 1.34E-07 White blood cell count / / 21738479 rs12076482 chr1 161942885 G A 0.0007398 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12076482 chr1 161942885 G A 7.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6693833 chr1 161943058 C T 1.81E-06 White blood cell count / / 21738479 rs2340725 chr1 161943634 T C 1.28E-07 White blood cell count / / 21738479 rs2340726 chr1 161943780 G A 3.66E-07 White blood cell count / / 21738479 rs6427642 chr1 161944753 C G 1.16E-07 White blood cell count / / 21738479 rs1962508 chr1 161945419 C A 2.51E-07 White blood cell count / / 21738479 rs1962509 chr1 161945467 C G 3.33E-07 White blood cell count / / 21738479 rs2340727 chr1 161946727 A G 8.87E-07 White blood cell count / / 21738479 rs2340727 chr1 161946727 A G 2.00E-23 Hematology traits / / 23263863 rs10918341 chr1 161950399 A G 3.24E-10 White blood cell count / / 21738479 rs10918341 chr1 161950399 A G 8.21E-05 Type 2 diabetes / / 22158537 rs10918342 chr1 161950451 G A 4.59E-11 White blood cell count / / 21738479 rs12039519 chr1 161953400 G A 7.00E-06 Parasitemia in Tripanosoma cruzi seropositivity OLFML2B UTR-3 24324551 rs16835120 chr1 161955633 C T 3.39E-04 Multiple complex diseases OLFML2B intron 17554300 rs12217099 chr1 161956109 C T 8.68E-04 Response to taxane treatment (placlitaxel) OLFML2B intron 23006423 rs2499836 chr1 161967681 A G 8.58E-05 Schizophrenia OLFML2B missense 24253340 rs2499834 chr1 161969636 T G 0.000779 Ovarian cancer OLFML2B intron 22794196 rs7523246 chr1 161972767 G A 4.79E-08 White blood cell count OLFML2B intron 21738479 rs11812028 chr1 161974641 A T 7.93E-11 White blood cell count OLFML2B intron 21738479 rs16838789 chr1 161981845 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes OLFML2B intron 22628534 rs12119861 chr1 161985004 C T 7.83E-05 HIV-1 control OLFML2B intron 20041166 rs16839677 chr1 161987385 G A 3.91E-05 Odorant perception OLFML2B intron 23910658 rs12072417 chr1 162000045 T G 7.62E-04 Multiple complex diseases / / 17554300 rs7551221 chr1 162000398 T C 5.80E-06 Major depressive disorder / / 21042317 rs1415268 chr1 162006451 A T 1.00E-06 QT interval / / 16648850 rs2880058 chr1 162014632 A G 2.00E-10 QT interval / / 20031603 rs2880058 chr1 162014632 A G 6.70E-09 Electrocardiographic traits / / 20062061 rs12036340 chr1 162015740 A G 4.12E-08 QT interval / / 23166209 rs4657139 chr1 162029907 A T 1.00E-10 QT interval / / 16648850 rs10918594 chr1 162030688 C G 1 Drug response to Isradipine / / 19247217 rs10918594 chr1 162030688 C G 1 Drug response to Verapamil / / 19247217 rs12143842 chr1 162033890 C T 2.00E-78 QT interval / / 19305408 rs12143842 chr1 162033890 C T 2.00E-78 QT interval / / 19305409 rs12143842 chr1 162033890 C T 1.00E-83 QT interval / / 19587794 rs12143842 chr1 162033890 C T 1.20E-08 Electrocardiographic traits / / 20062061 rs12143842 chr1 162033890 C T 2.00E-15 QT interval / / 23166209 rs12143842 chr1 162033890 C T 4.58E-05 Heart Rate / / pha003053 rs16847548 chr1 162035274 T C 2.34E-07 QT interval / / 19587794 rs16847548 chr1 162035274 T C 1.84E-10 QT interval / / 23166209 rs10918602 chr1 162037700 T C 4.97E-08 QT interval NOS1AP nearGene-5 23166209 rs12090585 chr1 162038776 G A 7.80E-10 Electrocardiographic traits NOS1AP nearGene-5 20062061 rs16849413 chr1 162043629 C T 3.03E-04 Multiple complex diseases NOS1AP intron 17554300 rs4656349 chr1 162049824 G A 4.10E-09 Electrocardiographic traits NOS1AP intron 20062061 rs6670339 chr1 162055806 C T 3.70E-10 Electrocardiographic traits NOS1AP intron 20062061 rs4657140 chr1 162061265 T C 1.60E-09 Electrocardiographic traits NOS1AP intron 20062061 rs4657140 chr1 162061265 T C 8.79E-05 Neutrophil count NOS1AP intron pha003095 rs1415257 chr1 162062044 C T 9.45E-05 Neutrophil count NOS1AP intron pha003095 rs12036529 chr1 162070706 A T 6.12E-06 White blood cell count NOS1AP intron 21738479 rs12757771 chr1 162076521 C T 4.89E-04 Coronary heart disease NOS1AP intron 21971053 rs76078015 chr1 162079688 G A 0.0000217 Menopause (age at onset) NOS1AP intron 23424626 rs1415259 chr1 162085309 C T 7.00E-10 Electrocardiographic traits NOS1AP intron 20062061 rs1415259 chr1 162085309 C T 8.38E-05 Neutrophil count NOS1AP intron pha003095 rs10494366 chr1 162085685 G T 1.00E-10 QT interval NOS1AP intron 16648850 rs10494366 chr1 162085685 G T 9.00E-04 Electrocardiographic traits and heart rate variability NOS1AP intron 17903306 rs10494366 chr1 162085685 G T 1 Drug response to Isradipine NOS1AP intron 19247217 rs10494366 chr1 162085685 G T 1 Drug response to Verapamil NOS1AP intron 19247217 rs10494366 chr1 162085685 G T 5.00E-22 Electrocardiographic traits NOS1AP intron 20062063 rs10494366 chr1 162085685 G T 8.38E-05 Neutrophil count NOS1AP intron pha003095 rs76662883 chr1 162089318 G A,C,T 9.00E-06 Obesity-related traits NOS1AP intron 23251661 rs10753758 chr1 162089331 A G 7.98E-04 Type 2 diabetes NOS1AP intron 17463246 rs12140791 chr1 162091284 C T 0.0000638 Major depressive disorder NOS1AP intron 23149448 rs12140791 chr1 162091284 C T 5.12E-05 Schizophrenia NOS1AP intron pha002857 rs10458392 chr1 162092110 T G 3.30E-08 Electrocardiographic traits NOS1AP intron 20062061 rs1572495 chr1 162099301 G A 4.43E-06 White blood cell count NOS1AP intron 21738479 rs12084985 chr1 162099951 G A 6.71E-06 White blood cell count NOS1AP intron 21738479 rs16856782 chr1 162100112 C T 6.62E-06 White blood cell count NOS1AP intron 21738479 rs16856785 chr1 162100287 G C 6.73E-06 White blood cell count NOS1AP intron 21738479 rs12093845 chr1 162101829 A G 8.22E-06 White blood cell count NOS1AP intron 21738479 rs10494367 chr1 162103178 G A 8.88E-06 White blood cell count NOS1AP intron 21738479 rs4657154 chr1 162108119 A G 6.30E-09 Electrocardiographic traits NOS1AP intron 20062061 rs4657155 chr1 162108265 C A 3.38E-05 Bipolar disorder and schizophrenia NOS1AP intron 20889312 rs16857031 chr1 162112910 C G 1.00E-34 QT interval NOS1AP intron 19305408 rs1932933 chr1 162118046 T C 4.30E-04 Electrocardiographic traits and heart rate variability NOS1AP intron 17903306 rs1932933 chr1 162118046 T C 1.30E-09 Electrocardiographic traits NOS1AP intron 20062061 rs1932933 chr1 162118046 T C 8.40E-04 Alcohol dependence NOS1AP intron 20201924 rs1932933 chr1 162118046 T C 0.00000582 Alcohol dependence NOS1AP intron 23691058 rs1932932 chr1 162120579 C G 7.45E-07 White blood cell count NOS1AP intron 21738479 rs4656355 chr1 162123797 A G 4.62E-07 White blood cell count NOS1AP intron 21738479 rs10918790 chr1 162128822 G A 1.09E-06 White blood cell count NOS1AP intron 21738479 rs12029454 chr1 162133117 G A 3.00E-45 QT interval NOS1AP intron 19305408 rs12029454 chr1 162133117 G A 1.10E-05 Electrocardiographic traits NOS1AP intron 20062061 rs12029454 chr1 162133117 G A 4.37E-09 QT interval NOS1AP intron 23166209 rs1337068 chr1 162133146 G A 8.31E-08 Triglycerides NOS1AP intron 23063622 rs10918796 chr1 162133343 C A 3.50E-07 White blood cell count NOS1AP intron 21738479 rs6427656 chr1 162134638 G A 7.75E-07 White blood cell count NOS1AP intron 21738479 rs945713 chr1 162135670 G A 2.82E-05 QT interval NOS1AP intron 16648850 rs945713 chr1 162135670 G A 2.40E-04 Electrocardiographic traits and heart rate variability NOS1AP intron 17903306 rs945713 chr1 162135670 G A 2.45E-07 White blood cell count NOS1AP intron 21738479 rs11805598 chr1 162140336 A G 5.10E-07 White blood cell count NOS1AP intron 21738479 rs7549718 chr1 162140862 A G 2.12E-07 White blood cell count NOS1AP intron 21738479 rs7534004 chr1 162146709 G A 3.11E-09 QT interval NOS1AP intron 23166209 rs12135795 chr1 162149765 A G 1.57E-07 White blood cell count NOS1AP intron 21738479 rs12724220 chr1 162152998 A G 2.98E-08 White blood cell count NOS1AP intron 21738479 rs6671817 chr1 162153226 A G 1.17E-08 White blood cell count NOS1AP intron 21738479 rs10127719 chr1 162156170 T C 1.75E-08 QT interval NOS1AP intron 23166209 rs7546234 chr1 162156304 G A 7.30E-06 Coffee consumption NOS1AP intron 21357676 rs12087800 chr1 162161940 G A 7.03E-06 QT interval NOS1AP intron 23166209 rs1415263 chr1 162166043 C T 1.48E-05 QT interval NOS1AP intron 16648850 rs12567315 chr1 162166646 G A 1.82E-09 QT interval NOS1AP intron 23166209 rs6663969 chr1 162166919 G C 5.38E-06 White blood cell count NOS1AP intron 21738479 rs6692381 chr1 162167884 C T 1.23E-09 QT interval NOS1AP intron 23166209 rs6667431 chr1 162167921 G A 1.85E-09 QT interval NOS1AP intron 23166209 rs4306106 chr1 162171994 G A 5.07E-09 QT interval NOS1AP intron 23166209 rs10800352 chr1 162172689 A G 4.69E-09 QT interval NOS1AP intron 23166209 rs4480335 chr1 162173377 A C 4.32E-09 QT interval NOS1AP intron 23166209 rs12116744 chr1 162180456 G A 3.56E-09 QT interval NOS1AP intron 23166209 rs12027785 chr1 162181145 T A 3.45E-09 QT interval NOS1AP intron 23166209 rs3934467 chr1 162182677 C T 2.58E-09 QT interval NOS1AP intron 23166209 rs4657173 chr1 162185546 G T 4.60E-07 QT interval NOS1AP intron 23166209 rs4391647 chr1 162186931 A G 7.73E-10 QT interval NOS1AP intron 23166209 rs16858527 chr1 162187715 A G 5.84E-05 Nephrolithiasis NOS1AP intron 22396660 rs6683968 chr1 162191412 T G 1.00E-04 QT interval NOS1AP intron 16648850 rs6683968 chr1 162191412 T G 1.00E-04 Electrocardiographic traits and heart rate variability NOS1AP intron 17903306 rs16858695 chr1 162193738 C T 5.45E-05 Nephrolithiasis NOS1AP intron 22396660 rs12734991 chr1 162194576 C T 9.99E-07 White blood cell count NOS1AP intron 21738479 rs4657175 chr1 162195738 T G 1.00E-09 QT interval NOS1AP intron 22726844 rs4657175 chr1 162195738 T G 7.24E-10 QT interval NOS1AP intron 23166209 rs4657175 chr1 162195738 T G 7.24E-10 Schizophrenia NOS1AP intron 23212062 rs12123267 chr1 162199351 C T 1.67E-09 QT interval NOS1AP intron 23166209 rs4424487 chr1 162199362 T A 5.58E-07 White blood cell count NOS1AP intron 21738479 rs6664702 chr1 162204907 T C 5.46E-08 QT interval NOS1AP intron 23166209 rs4431825 chr1 162210471 A G 6.03E-06 White blood cell count NOS1AP intron 21738479 rs4657178 chr1 162210610 C T 7.00E-33 QT interval NOS1AP intron 19305409 rs10919021 chr1 162235390 C T 2.33E-10 Triglycerides NOS1AP intron 23063622 rs4497188 chr1 162235513 T C 5.83E-04 Multiple complex diseases NOS1AP intron 17554300 rs6427667 chr1 162244026 G C 4.97E-04 Suicide attempts in bipolar disorder NOS1AP intron 21041247 rs7511679 chr1 162247404 C T 4.91E-04 Suicide attempts in bipolar disorder NOS1AP intron 21041247 rs7525777 chr1 162247439 T C 4.71E-04 Suicide attempts in bipolar disorder NOS1AP intron 21041247 rs7528328 chr1 162247779 T C 4.71E-04 Suicide attempts in bipolar disorder NOS1AP intron 21041247 rs7528328 chr1 162247779 T C 1.10E-06 Urinary metabolites NOS1AP intron 21572414 rs7525955 chr1 162247832 A G 4.71E-04 Suicide attempts in bipolar disorder NOS1AP intron 21041247 rs7525955 chr1 162247832 A G 1.30E-06 Urinary metabolites NOS1AP intron 21572414 rs11800645 chr1 162248078 T G 4.89E-04 Suicide attempts in bipolar disorder NOS1AP intron 21041247 rs6670958 chr1 162249715 G A 8.26E-05 Cognitive impairment induced by topiramate NOS1AP intron 22091778 rs2819325 chr1 162283511 G A 3.36E-08 Cholesterol,total NOS1AP intron 23063622 rs2819325 chr1 162283511 G A 5.76E-13 HDL cholesterol NOS1AP intron 23063622 rs370911 chr1 162293305 A G 1.55E-16 Cholesterol,total NOS1AP intron 23063622 rs370911 chr1 162293305 A G 1.61E-14 LDL cholesterol NOS1AP intron 23063622 rs370911 chr1 162293305 A G 2.60E-14 HDL cholesterol NOS1AP intron 23063622 rs370911 chr1 162293305 A G 2.81E-08 Triglycerides NOS1AP intron 23063622 rs425820 chr1 162293664 G A 0.000000527 HDL cholesterol NOS1AP intron 23063622 rs12048222 chr1 162294094 A G 1.20E-05 Urinary metabolites NOS1AP intron 21572414 rs1912439 chr1 162294145 A G 2.63E-08 HDL cholesterol NOS1AP intron 23063622 rs1858232 chr1 162303838 A G 7.88E-04 Type 2 diabetes NOS1AP intron 17463246 rs347311 chr1 162303907 G C 7.62E-06 Cognitive decline NOS1AP intron 22054870 rs1858233 chr1 162303999 C T 6.22E-04 Response to cytadine analogues (cytosine arabinoside) NOS1AP intron 24483146 rs347313 chr1 162304276 A G 8.23E-04 Rheumatoid arthritis NOS1AP intron 21452313 rs10919200 chr1 162305160 G A 5.07E-04 Type 2 diabetes NOS1AP intron 17463246 rs347273 chr1 162317513 G A 1.75E-05 Word reading NOS1AP intron 23738518 rs347272 chr1 162318498 A G 1.57E-05 Word reading NOS1AP intron 23738518 rs11577628 chr1 162319524 A G 5.00E-06 Word reading NOS1AP intron 23738518 rs2661814 chr1 162320006 G A 1.05E-09 LDL cholesterol NOS1AP intron 23063622 rs12745104 chr1 162327313 C T 8.52E-05 Lipid levels NOS1AP intron pha003082 rs1510291 chr1 162328061 C T 0.000000473 HDL cholesterol NOS1AP intron 23063622 rs6681981 chr1 162331621 A G 5.70E-04 Alcohol dependence NOS1AP intron 20201924 rs16860953 chr1 162333917 G A 3.86E-08 LDL cholesterol NOS1AP UTR-5 23063622 rs10919293 chr1 162347618 A G 2.54E-04 Smoking quantity / / 24665060 rs4657188 chr1 162347877 G C 7.69E-07 White blood cell count / / 21738479 rs10494369 chr1 162357035 A G 8.48E-05 Taste perception / / 22132133 rs164420 chr1 162359746 T C 9.42E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs164423 chr1 162360279 A G 1.43E-04 Lung function (forced vital capacity) / / 24023788 rs2655732 chr1 162363732 A G 1.13E-04 Heart Failure / / pha002884 rs11804223 chr1 162412492 G C 8.67E-04 Multiple complex diseases / / 17554300 rs469726 chr1 162417107 G A 2.38E-04 Multiple complex diseases / / 17554300 rs6673387 chr1 162458412 C T 7.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17471292 chr1 162509510 T A 7.90E-07 Red blood cell traits / / 23222517 rs7545344 chr1 162540329 T C 0.000641 Salmonella-induced pyroptosis UAP1 intron 22837397 rs11585602 chr1 162551783 T C 1.02E-08 Metabolite levels UAP1 intron 23281178 rs10917570 chr1 162556810 C T 1.02E-08 Metabolite levels UAP1 intron 23281178 rs6672561 chr1 162559479 A G 2.27E-04 Type 2 diabetes UAP1 intron 17463246 rs10494372 chr1 162571578 G A 1.73E-04 Type 2 diabetes / / 17463246 rs7528465 chr1 162578873 T C 9.41E-05 Glucose levels / / pha003061 rs6668320 chr1 162580337 G C 2.06E-04 Type 2 diabetes / / 17463246 rs6702652 chr1 162597545 T G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7544972 chr1 162600119 T C 3.25E-04 Type 2 diabetes / / 17463246 rs10494373 chr1 162619362 A C 1.74E-05 Brain structure DDR2 intron 22504417 rs4233391 chr1 162639552 T C 2.20E-04 Multiple complex diseases DDR2 intron 17554300 rs4657219 chr1 162639774 G T 1.55E-04 Multiple complex diseases DDR2 intron 17554300 rs4657222 chr1 162644317 G C 8.88E-04 Multiple complex diseases DDR2 intron 17554300 rs10799862 chr1 162644411 T C 6.78E-04 Multiple complex diseases DDR2 intron 17554300 rs10917587 chr1 162661463 A G 1.29E-07 White blood cell count DDR2 intron 21738479 rs17433759 chr1 162673705 C T 5.95E-04 Type 2 diabetes DDR2 intron 17463246 rs16843850 chr1 162685018 C T 6.24E-04 Smoking initiation DDR2 intron 24665060 rs16843853 chr1 162685303 G A 6.24E-04 Smoking initiation DDR2 intron 24665060 rs10047103 chr1 162702302 C G 1.44E-04 Smoking initiation DDR2 intron 24665060 rs2684866 chr1 162726281 A C 4.55E-07 White blood cell count DDR2 intron 21738479 rs2805025 chr1 162732491 G A 5.68E-07 White blood cell count DDR2 intron 21738479 rs1779991 chr1 162733409 C T 1.52E-04 Smoking initiation DDR2 intron 24665060 rs1780007 chr1 162748025 A C 4.35E-07 White blood cell count DDR2 intron 21738479 rs1779999 chr1 162753092 C T 2.47E-06 White blood cell count / / 21738479 rs4656381 chr1 162776137 G A 3.93E-04 Colorectal cancer HSD17B7 intron 23266556 rs2684879 chr1 162802615 C A 4.11E-04 Colorectal cancer / / 23266556 rs2805042 chr1 162803754 G A 3.43E-04 Colorectal cancer / / 23266556 rs2684880 chr1 162810754 C T 3.23E-04 Colorectal cancer / / 23266556 rs6699770 chr1 162813432 G A 2.40E-04 Colorectal cancer / / 23266556 rs6691351 chr1 162813583 A G 1.71E-04 Colorectal cancer / / 23266556 rs6679069 chr1 162813651 C T 5.78E-04 Colorectal cancer / / 23266556 rs10737489 chr1 162813950 T C 1.24E-04 Colorectal cancer / / 23266556 rs1892124 chr1 162816583 A G 2.56E-06 Colorectal cancer / / 23266556 rs10753591 chr1 162817400 C T 8.17E-06 Colorectal cancer / / 23266556 rs1858236 chr1 162818421 A G 2.61E-04 Colorectal cancer / / 23266556 rs1912453 chr1 162821291 A G 9.00E-06 Colorectal cancer / / 23266556 rs11800473 chr1 162836981 C T 4.37E-05 HDL cholesterol C1orf110 intron pha003074 rs7555990 chr1 162841904 C T 1.73E-05 Cognitive test performance / / 20125193 rs12047510 chr1 162842202 T C 5.54E-05 Cleft lip / / 20436469 rs12047510 chr1 162842202 T C 5.36E-05 Orofacial clefts / / 22863734 rs7541250 chr1 162862158 C G 6.90E-05 Insulin resistance / / 21901158 rs12124253 chr1 162862846 A C 7.72E-04 Depression (quantitative trait) / / 20800221 rs12124253 chr1 162862846 A C 2.39E-06 White blood cell count / / 21738479 rs4657236 chr1 162864403 A T 1.76E-04 Depression (quantitative trait) / / 20800221 rs10917632 chr1 162864476 C T 2.41E-04 Depression (quantitative trait) / / 20800221 rs2343485 chr1 162864623 C T 9.79E-04 Insulin resistance / / 21901158 rs10917633 chr1 162865197 T C 3.40E-04 Depression (quantitative trait) / / 20800221 rs12730805 chr1 162873220 C A 7.90E-04 Alcohol dependence / / 20201924 rs16846622 chr1 162875195 G A 3.85E-04 Multiple complex diseases / / 17554300 rs17489752 chr1 162877069 G T 2.70E-05 Urinary metabolites / / 21572414 rs4657238 chr1 162880984 T C 2.00E-05 Urinary metabolites / / 21572414 rs10917638 chr1 162881137 T C 5.56E-05 Cervical cancer / / 24700089 rs6681091 chr1 162905434 T G 2.40E-06 Creutzfeldt-Jakob disease (variant) / / 22137330 rs1961879 chr1 162914749 C T 2.61E-04 Heart Failure / / pha002885 rs12021880 chr1 162920421 T C 8.22E-07 Glaucoma-related traits / / 22058429 rs2343331 chr1 162930820 C T 2.49E-05 Crohn's disease / / 17435756 rs2880605 chr1 162932038 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12403644 chr1 162936636 T A 1.30E-05 Urinary metabolites / / 21572414 rs17438400 chr1 162938179 C T 5.57E-08 Metabolite levels / / 23281178 rs12126781 chr1 162940693 A G 1.30E-08 Metabolite levels / / 23281178 rs16847292 chr1 162944464 T C 4.65E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11580679 chr1 162944573 A G 8.30E-06 Urinary metabolites / / 21572414 rs7340068 chr1 162946949 G A 4.65E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2661322 chr1 162961560 G C,T 7.22E-08 Metabolite levels / / 23281178 rs2842006 chr1 163009498 T C 7.71E-06 Schizophrenia / / 19197363 rs2661339 chr1 163018934 T G 1.31E-04 Age-related macular degeneration / / 22125219 rs2661275 chr1 163031580 T C 6.66E-05 Type 2 diabetes / / 17463246 rs2661275 chr1 163031580 T C 3.72E-05 Schizophrenia / / 20832056 rs2661274 chr1 163031621 C T 6.98E-05 Type 2 diabetes / / 17463246 rs2661274 chr1 163031621 C T 2.83E-05 Schizophrenia / / 20832056 rs10917670 chr1 163032842 C T 1 Drug response to Risperidone / / 18204343 rs951439 chr1 163033691 C T 1 Drug response to Perphenazine / / 16604300 rs951439 chr1 163033691 C T 1 Drug response to Quetiapine / / 16604300 rs951439 chr1 163033691 C T 1 Drug response to Risperidone / / 16604300 rs951439 chr1 163033691 C T 1 Drug response to Ziprasidone / / 16604300 rs951439 chr1 163033691 C T 1 Drug response to Perphenazine / / 17588543 rs951439 chr1 163033691 C T 1 Drug response to Quetiapine / / 17588543 rs951439 chr1 163033691 C T 1 Drug response to Risperidone / / 17588543 rs951439 chr1 163033691 C T 1 Drug response to Ziprasidone / / 17588543 rs951439 chr1 163033691 C T 1 Drug response to Perphenazine / / 18204343 rs951439 chr1 163033691 C T 1 Drug response to Quetiapine / / 18204343 rs951439 chr1 163033691 C T 1 Drug response to Risperidone / / 18204343 rs951439 chr1 163033691 C T 1 Drug response to Ziprasidone / / 18204343 rs2661319 chr1 163039777 T C 1 Drug response to Perphenazine RGS4 intron 17588543 rs2661319 chr1 163039777 T C 1 Drug response to Quetiapine RGS4 intron 17588543 rs2661319 chr1 163039777 T C 1 Drug response to Risperidone RGS4 intron 17588543 rs2661319 chr1 163039777 T C 1 Drug response to Ziprasidone RGS4 intron 17588543 rs2661319 chr1 163039777 T C 1 Drug response to Perphenazine RGS4 intron 18204343 rs2661319 chr1 163039777 T C 1 Drug response to Quetiapine RGS4 intron 18204343 rs2661319 chr1 163039777 T C 1 Drug response to Risperidone RGS4 intron 18204343 rs2661319 chr1 163039777 T C 1 Drug response to Ziprasidone RGS4 intron 18204343 rs2842030 chr1 163040495 G T 1 Drug response to Perphenazine RGS4 intron 16904822 rs2842030 chr1 163040495 G T 1 Drug response to Quetiapine RGS4 intron 16904822 rs2842030 chr1 163040495 G T 1 Drug response to Risperidone RGS4 intron 16904822 rs2842030 chr1 163040495 G T 1 Drug response to Ziprasidone RGS4 intron 16904822 rs2842030 chr1 163040495 G T 1 Drug response to Perphenazine RGS4 intron 17588543 rs2842030 chr1 163040495 G T 1 Drug response to Quetiapine RGS4 intron 17588543 rs2842030 chr1 163040495 G T 1 Drug response to Risperidone RGS4 intron 17588543 rs2842030 chr1 163040495 G T 1 Drug response to Ziprasidone RGS4 intron 17588543 rs10759 chr1 163046351 G T 2.67E-04 Smoking initiation RGS4 UTR-3 24665060 rs2841957 chr1 163053018 C T 4.45E-06 Response to mTOR inhibitor (rapamycin) / / 24009623 rs2063142 chr1 163053289 A G 4.00E-06 Response to mTOR inhibitor (rapamycin) / / 24009623 rs2841959 chr1 163058194 T C 5.70E-05 Telomere length / / 23900074 rs1507740 chr1 163075021 C T 8.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1507740 chr1 163075021 C T 0.00000464 Platelet thrombus as measured by PFA-100ColA closure time upon shear stress / / 22550155 rs2841984 chr1 163086196 G C 1.32E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs1507739 chr1 163087085 G A 1.31E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs6691456 chr1 163090421 A G 0.0008 Alpha-2-adrenoceptor-mediated vasoconstriction / / 23337848 rs6691456 chr1 163090421 A G 2.33E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2841993 chr1 163111066 C T 2.36E-05 Monocyte counts / / pha003089 rs3806368 chr1 163113878 G A 5.39E-04 Multiple complex diseases RGS5 UTR-3 17554300 rs1054943 chr1 163114096 G C 6.69E-06 Multiple complex diseases RGS5 UTR-3 17554300 rs7540909 chr1 163132634 C T 7.07E-04 Heart Failure RGS5 intron pha002884 rs12035879 chr1 163142555 G A 4.00E-06 Liver enzyme levels (alanine transaminase) RGS5 intron 24124411 rs10917693 chr1 163145664 T C 5.72E-04 Smoking initiation RGS5 intron 24665060 rs4657247 chr1 163151897 C T 2.96E-05 Bipolar disorder RGS5 intron 19488044 rs4657247 chr1 163151897 C T 1.05E-05 Bipolar Disorder RGS5 intron pha002863 rs12566267 chr1 163153168 T G 2.48E-05 Bipolar disorder RGS5 intron 19488044 rs12566267 chr1 163153168 T G 8.82E-06 Bipolar Disorder RGS5 intron pha002863 rs4132246 chr1 163154369 A C,G 4.90E-05 Bipolar Disorder RGS5 intron pha002863 rs7513108 chr1 163163777 T G 4.54E-05 Erythrocyte counts RGS5 intron pha003101 rs937925 chr1 163228151 T C 9.41E-06 Tunica Media RGS5 intron pha003034 rs937925 chr1 163228151 T C 2.39E-05 Tunica Media RGS5 intron pha003036 rs3010367 chr1 163258354 T C 4.58E-05 Serum metabolites RGS5 intron 19043545 rs16852030 chr1 163260844 A G 1.02E-05 Tunica Media RGS5 intron pha003034 rs16852030 chr1 163260844 A G 4.71E-05 Tunica Media RGS5 intron pha003036 rs3010370 chr1 163282358 G A 6.82E-05 Serum metabolites RGS5 intron 19043545 rs2136241 chr1 163289571 C T 7.76E-05 Cognitive test performance RGS5 intron 20125193 rs2136241 chr1 163289571 C T 6.90E-04 Cisplatin and carboplatin cytotoxicity,in blood cell lines RGS5 intron 21844884 rs12408485 chr1 163289988 G A 2.80E-05 Urinary metabolites RGS5 intron 21572414 rs3806364 chr1 163290473 G C 2.20E-05 Urinary metabolites RGS5 intron 21572414 rs2292275 chr1 163292217 T C 1.60E-05 Urinary metabolites NUF2 intron 21572414 rs2292275 chr1 163292217 T C 4.81E-04 Body mass index NUF2 intron 21701565 rs2292275 chr1 163292217 T C 5.11E-06 White blood cell count NUF2 intron 21738479 rs12735996 chr1 163296293 C G 2.40E-05 Urinary metabolites NUF2 intron 21572414 rs2136243 chr1 163302789 T C 3.74E-04 Body mass index NUF2 intron 21701565 rs2136243 chr1 163302789 T C 6.72E-07 White blood cell count NUF2 intron 21738479 rs11802875 chr1 163313539 C T 9.09E-04 Multiple complex diseases NUF2 missense 17554300 rs17362993 chr1 163313880 G A 1.70E-04 Myasthenia gravis NUF2 intron 23055271 rs1396544 chr1 163330805 G A 6.57E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1995785 chr1 163332621 G A 2.10E-04 Interstitial lung disease / / 23583980 rs1995785 chr1 163332621 G A 7.84E-04 Smoking initiation / / 24665060 rs12735960 chr1 163341499 T C 9.59E-05 Bipolar disorder / / 18317468 rs3013493 chr1 163355061 A G 3.52E-05 Multiple complex diseases / / 17554300 rs6689760 chr1 163358704 C T 1.08E-04 Multiple complex diseases / / 17554300 rs17363368 chr1 163358833 A G 2.38E-04 Type 2 diabetes / / 17463246 rs6704467 chr1 163364512 A G 5.80E-05 Multiple complex diseases / / 17554300 rs6704467 chr1 163364512 A G 8.03E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4638099 chr1 163365521 C T 7.54E-05 Multiple complex diseases / / 17554300 rs17359359 chr1 163372030 G A 1.78E-04 Type 2 diabetes / / 17463246 rs17359359 chr1 163372030 G A 1.10E-04 Plasma trimethylamine N-oxide levels / / 24675659 rs4657270 chr1 163378647 G A 8.88E-05 Iron status biomarkers / / 19084217 rs4265409 chr1 163414559 C T 5.12E-04 Multiple complex diseases / / 17554300 rs12734758 chr1 163420695 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10917759 chr1 163435598 A G 9.65E-04 Type 2 diabetes / / 17463246 rs12139998 chr1 163441103 A C 9.22E-04 Type 2 diabetes / / 17463246 rs10917773 chr1 163449989 C T 9.32E-04 Intraocular pressure / / 23836780 rs12119063 chr1 163453573 T G 8.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs10917775 chr1 163454111 G A 7.45E-04 Type 2 diabetes / / 17463246 rs10917775 chr1 163454111 G A 9.69E-06 Personality dimensions / / 22628180 rs1890798 chr1 163457348 T C 2.19E-05 Lung adenocarcinoma / / 19836008 rs16854856 chr1 163460730 C T 4.39E-04 Multiple complex diseases / / 17554300 rs2791136 chr1 163470515 T C 5.12E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2791138 chr1 163470851 T C 8.91E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6427740 chr1 163478748 G C 4.26E-04 Body mass index / / 21701565 rs16855237 chr1 163480472 C A 1.97E-04 Multiple complex diseases / / 17554300 rs12565565 chr1 163482240 A G 7.82E-04 Body mass index / / 21701565 rs12038132 chr1 163483608 T C 7.12E-04 Body mass index / / 21701565 rs3001089 chr1 163500711 T G 5.00E-07 Chronic obstructive pulmonary disease (moderate to severe) / / 24621683 rs2791131 chr1 163507977 G A 9.58E-06 Prion diseases / / 22210626 rs6679806 chr1 163528747 G A 6.31E-04 Iron levels / / pha002876 rs12034856 chr1 163544574 A G 9.33E-06 White blood cell count / / 21738479 rs16858747 chr1 163698330 C A 7.27E-04 Multiple complex diseases / / 17554300 rs1932355 chr1 163714719 A G 0.00000229 Fasting blood glucose / / 22216000 rs10494397 chr1 163735376 C T 9.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs4657305 chr1 163762232 T C 1.16E-05 Osteoarthritis (knee and hip) / / 21177295 rs4657305 chr1 163762232 T C 7.16E-05 Osteoarthritis (knee and hip) / / 21177295 rs6671893 chr1 163775335 A G 2.20E-05 Urinary metabolites / / 21572414 rs1016610 chr1 163781066 T C 5.30E-05 Serum metabolites / / 19043545 rs7553942 chr1 163781591 G A 8.03E-05 Serum metabolites / / 19043545 rs12031632 chr1 163801544 A G 4.86E-05 Serum metabolites / / 19043545 rs10917866 chr1 163810259 C G 9.22E-05 Serum metabolites / / 19043545 rs796694 chr1 163829349 C A 1.00E-05 Prostate cancer / / 21743057 rs10494400 chr1 163830144 T C 1.07E-04 Type 2 diabetes / / 17463246 rs781934 chr1 163838187 C T 1.00E-05 Prostate cancer / / 21743057 rs16861608 chr1 163855085 C T 1.90E-06 Urinary metabolites / / 21572414 rs6669526 chr1 163857031 C T 9.52E-04 Obesity (extreme) / / 21935397 rs2346102 chr1 163857585 G T 2.06E-09 LDL cholesterol / / 23063622 rs6661534 chr1 163859805 G A 6.60E-06 Urinary metabolites / / 21572414 rs1441178 chr1 163864334 C T 7.53E-05 Stroke / / pha002887 rs1441178 chr1 163864334 C T 6.76E-05 Cholesterol / / pha003083 rs1816756 chr1 163866023 C T 2.93E-05 Cholesterol / / pha003083 rs2881310 chr1 163887606 G A 5.80E-05 Personality dimensions / / 18957941 rs2881310 chr1 163887606 G A 3.30E-06 Urinary metabolites / / 21572414 rs1961041 chr1 163906277 T C 1.27E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs16823121 chr1 163912475 T C 9.20E-06 Urinary metabolites / / 21572414 rs4657319 chr1 163912523 G C,T 7.14E-04 Bipolar disorder / / 19259986 rs4657319 chr1 163912523 G C,T 1.96E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs12033122 chr1 163917950 C A 9.44E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs12027802 chr1 163919788 G A 3.38E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1444439 chr1 163950439 A G 8.39E-04 Myocardial Infarction / / pha002873 rs424950 chr1 163956503 G C 5.00E-06 Sex hormone-binding globulin levels / / 22675492 rs260913 chr1 163968414 T C 3.26E-04 Smoking quantity / / 24665060 rs7551501 chr1 164011540 C T 4.92E-04 Multiple complex diseases / / 17554300 rs3929860 chr1 164085202 T A 4.39E-04 Multiple complex diseases / / 17554300 rs10800006 chr1 164120948 A T 2.79E-05 Body mass (lean) / / 19268274 rs7539840 chr1 164127511 G A 3.27E-05 Body mass (lean) / / 19268274 rs7551656 chr1 164127702 T C 2.75E-05 Body mass (lean) / / 19268274 rs6686539 chr1 164131343 A T 4.18E-05 Body mass (lean) / / 19268274 rs803441 chr1 164183831 G A 2.87E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs6697445 chr1 164211914 G C 1.63E-04 Lipid levels / / 19016617 rs6697445 chr1 164211914 G C 5.02E-04 Lipid levels / / 19016617 rs16826875 chr1 164212053 G A 7.42E-04 Multiple complex diseases / / 17554300 rs10494412 chr1 164212480 T C 1.63E-04 Lipid levels / / 19016617 rs10494412 chr1 164212480 T C 7.00E-04 Lipid levels / / 19016617 rs10494413 chr1 164213652 G A 1.45E-04 Lipid levels / / 19016617 rs10494413 chr1 164213652 G A 6.56E-04 Lipid levels / / 19016617 rs4142895 chr1 164226999 T A 2.40E-05 Urinary metabolites / / 21572414 rs6682660 chr1 164227437 C A 3.96E-04 Type 2 diabetes / / 17463246 rs11809129 chr1 164229645 T C 6.58E-04 Type 2 diabetes / / 17463246 rs10917967 chr1 164230383 A G 4.97E-04 Type 2 diabetes / / 17463246 rs10917967 chr1 164230383 A G 1.80E-05 Urinary metabolites / / 21572414 rs1934038 chr1 164242726 T C 7.29E-06 White blood cell count / / 21738479 rs1578087 chr1 164244096 T A,G 7.71E-06 White blood cell count / / 21738479 rs16828112 chr1 164284812 G A 4.40E-04 Multiple complex diseases / / 17554300 rs9287061 chr1 164328387 T C 2.03E-06 Statin-induced myopathy / / 21826682 rs769305 chr1 164331903 A C 4.68E-04 Multiple complex diseases / / 17554300 rs16829156 chr1 164332201 G A 1.99E-05 Multiple complex diseases / / 17554300 rs12566285 chr1 164400183 C A 7.52E-04 Type 2 diabetes / / 17463246 rs1289726 chr1 164412847 G T 1.74E-04 Schizophrenia / / 19197363 rs10918010 chr1 164426985 C T 6.96E-04 Alzheimer's disease / / 17998437 rs12723400 chr1 164440415 G A 7.02E-05 stroke (ischemic) / / 17434096 rs1538370 chr1 164447212 A G 2.69E-05 Multiple sclerosis (age of onset) / / 19010793 rs10494417 chr1 164447438 A G 9.44E-05 Post-operative nausea and vomiting / / 21694509 rs7550193 chr1 164452742 G C 1.47E-04 Nicotine dependence / / 17158188 rs7517505 chr1 164453373 T C 1.58E-04 Nicotine dependence / / 17158188 rs2027290 chr1 164454550 A C 1.42E-04 Nicotine dependence / / 17158188 rs10800021 chr1 164454649 C G 1.86E-04 Nicotine dependence / / 17158188 rs10800030 chr1 164491497 A G 8.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12038282 chr1 164534207 A G 5.70E-05 Diabetic retinopathy PBX1 intron 21441570 rs12039194 chr1 164537228 G A 5.40E-05 Diabetic retinopathy PBX1 intron 21441570 rs2800791 chr1 164563425 A G 1.03E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PBX1 intron 20031582 rs16833167 chr1 164580108 T C 1.57E-04 Multiple complex diseases PBX1 intron 17554300 rs2800785 chr1 164583573 G C 3.18E-04 Coronary Artery Disease PBX1 intron 17634449 rs16833488 chr1 164609582 C T 7.25E-04 Amyotrophic Lateral Sclerosis PBX1 intron 17362836 rs16833488 chr1 164609582 C T 1.22E-05 Orofacial clefts PBX1 intron 22419666 rs2800780 chr1 164611689 A G 6.00E-07 Urinary metabolites PBX1 intron 21572414 rs10494419 chr1 164611901 T G 2.12E-04 Alcohol dependence PBX1 intron 21314694 rs2800779 chr1 164612150 T G 4.79E-04 Multiple complex diseases PBX1 intron 17554300 rs10800040 chr1 164618913 T C 3.49E-04 Body mass index PBX1 intron 21701565 rs1387390 chr1 164628310 C T 3.78E-04 Body mass index PBX1 intron 21701565 rs41515147 chr1 164636953 G A 1.06E-04 Multiple complex diseases PBX1 intron 17554300 rs1552560 chr1 164656976 T C 1.09E-04 Acute lung injury PBX1 intron 22295056 rs1780352 chr1 164663211 C T 4.24E-05 Monocyte chemoattractant protein-1 PBX1 intron pha003071 rs2800798 chr1 164666253 G A 4.83E-05 Monocyte chemoattractant protein-1 PBX1 intron pha003071 rs10494420 chr1 164683116 G A 1.04E-05 Varicose Veins PBX1 intron pha001411 rs1489333 chr1 164683738 A G 9.73E-05 Aging (time to event) PBX1 intron 21782286 rs1387389 chr1 164689762 G A 4.00E-06 Breast cancer (prognosis) PBX1 intron 23319801 rs1489331 chr1 164690183 A G 7.20E-04 Multiple complex diseases PBX1 intron 17554300 rs10494421 chr1 164738727 C T 1.50E-05 Urinary metabolites PBX1 intron 21572414 rs6670655 chr1 164739171 T C 3.00E-06 Height PBX1 intron 20966902 rs12736383 chr1 164739573 A G 1.50E-05 Urinary metabolites PBX1 intron 21572414 rs10494422 chr1 164781015 A C 5.09E-04 Nicotine smoking PBX1 intron 19268276 rs3767367 chr1 164782006 A G 4.82E-04 Parkinson's disease PBX1 intron 17052657 rs956409 chr1 164786799 G A 1.03E-05 Taste perception PBX1 intron 22132133 rs3767364 chr1 164790534 A G 1.84E-04 Response to platinum-based chemotherapy in non-small-cell lung cancer PBX1 intron 21483023 rs9887944 chr1 164800483 A G 6.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PBX1 intron 20877124 rs1107533 chr1 164807125 A G 9.29E-05 Body mass (lean) PBX1 intron 19268274 rs12081132 chr1 164809687 A G 5.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PBX1 intron 20877124 rs10918081 chr1 164825891 T C 9.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs4345787 chr1 164828928 T C 9.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs1890535 chr1 164829035 A G 8.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs1890535 chr1 164829035 A G 3.32E-05 Coronary restenosis / / 21878436 rs10918083 chr1 164837493 T C 9.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs11580794 chr1 164856772 A G 3.53E-04 Hearing function / / 17255346 rs1936078 chr1 164879202 G A 3.51E-04 Fibrinogen / / 17255346 rs1936078 chr1 164879202 G A 3.29E-04 White matter integrity / / 22425255 rs1419067 chr1 164922847 G A 7.74E-05 Chronic Hepatitis C infection / / 21725309 rs1891737 chr1 164928753 A C 5.03E-04 White matter integrity / / 22425255 rs1936085 chr1 164931749 A G 1.10E-04 Type 2 diabetes / / 17463246 rs4275431 chr1 164934462 G A 1.50E-05 Schizophrenia / / 19571808 rs1954402 chr1 164935156 A T 8.51E-05 Multiple complex diseases / / 17554300 rs7516582 chr1 164936976 T C 1.18E-04 Multiple complex diseases / / 17554300 rs7516582 chr1 164936976 T C 7.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs10800062 chr1 164940608 A C 9.10E-05 Type 2 diabetes / / 23209189 rs1573182 chr1 164958641 A G 3.20E-05 Schizophrenia / / 19571808 rs1419070 chr1 164968421 A C 9.30E-05 Schizophrenia / / 19571808 rs6702388 chr1 164970360 T C 8.49E-05 Neuroticism / / 23229837 rs723821 chr1 165016712 C A 9.83E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs723821 chr1 165016712 C A 7.80E-04 Coronary heart disease / / 21606135 rs723821 chr1 165016712 C A 2.60E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs723822 chr1 165016732 A T 7.44E-04 Coronary heart disease / / 21606135 rs12049436 chr1 165032101 T C 1.80E-05 Urinary metabolites / / 21572414 rs12049436 chr1 165032101 T C 7.89E-05 Cognitive decline / / 23732972 rs10494430 chr1 165036995 T C 5.99E-05 Schizophrenia / / 19571809 rs12119600 chr1 165038271 G A 4.01E-05 Cognitive impairment induced by topiramate / / 22091778 rs6426897 chr1 165102499 G A 7.86E-04 Tourette syndrome / / 22889924 rs60624478 chr1 165107979 G A 6.00E-06 Response to methotrexate in juvenile idiopathic arthritis / / 24709693 rs60950492 chr1 165110832 A G 4.05E-05 Response to methotrexate in juvenile idiopathic arthritis / / 24709693 rs1394443 chr1 165128583 A G 7.20E-06 Urinary metabolites / / 21572414 rs1343546 chr1 165137227 A G 2.00E-05 Urinary metabolites / / 21572414 rs903339 chr1 165137560 G A 1.50E-05 Urinary metabolites / / 21572414 rs1891927 chr1 165138246 G A 5.83E-05 Myopia (pathological) / / 21640322 rs968853 chr1 165146572 G A 2.60E-05 Urinary metabolites / / 21572414 rs1891931 chr1 165160578 G T 9.70E-07 Urinary metabolites / / 21572414 rs1891931 chr1 165160578 G T 9.70E-06 Obesity-related traits / / 23251661 rs989335 chr1 165161763 A G 7.44E-05 Heart Rate / / pha003053 rs7416223 chr1 165170050 C T 0.00000781 Inter-adventitial common carotid artery diameter / / 23246012 rs4656435 chr1 165175374 G A 5.05E-04 Response to cytidine analogues (gemcitabine) LMX1A intron 24483146 rs1354510 chr1 165175515 A G 7.78E-05 Response to acetaminophen (hepatotoxicity) LMX1A intron 21177773 rs1532815 chr1 165180089 T A 6.00E-07 Response to acetaminophen (hepatotoxicity) LMX1A intron 21177773 rs10494436 chr1 165196400 A G 1.90E-05 Urinary metabolites LMX1A intron 21572414 rs10494438 chr1 165199023 G A 6.92E-05 Body Fat Distribution LMX1A intron pha003017 rs1394439 chr1 165213822 G A 8.48E-04 Response to TNF antagonist treatment LMX1A intron 21061259 rs10918143 chr1 165222368 C T 3.11E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LMX1A intron 20877124 rs10918143 chr1 165222368 C T 8.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LMX1A intron 20877124 rs6656615 chr1 165241580 T A 1.25E-04 Insulin resistance LMX1A intron 21901158 rs6662186 chr1 165264733 A C 1.20E-04 Pulmonary function LMX1A intron 23932459 rs875822 chr1 165286563 T G 2.80E-05 Urinary metabolites LMX1A intron 21572414 rs1395548 chr1 165313427 A C 1.22E-06 Bone mass and geometry LMX1A intron 17903296 rs10918148 chr1 165317732 C T 1.90E-05 Urinary metabolites LMX1A intron 21572414 rs12081765 chr1 165341849 A G 7.52E-04 Response to TNF antagonist treatment / / 21061259 rs1506942 chr1 165341896 G C 1.08E-12 Multiple complex diseases / / 17554300 rs17469292 chr1 165365379 A G 7.30E-05 Response to ximelagatran treatment / / 17505501 rs2134095 chr1 165377552 G A 5.10E-04 Major depressive disorder RXRG cds-synon 22472876 rs3767339 chr1 165378064 A C 6.42E-04 Major depressive disorder RXRG intron 22472876 rs10489744 chr1 165380623 G A 6.86E-04 Major depressive disorder RXRG intron 22472876 rs466639 chr1 165394882 T C 1.00E-13 Menarche (age at onset) RXRG intron 21102462 rs466639 chr1 165394882 T C 4.80E-06 Urinary metabolites RXRG intron 21572414 rs157879 chr1 165398844 T G 9.30E-06 Urinary metabolites RXRG intron 21572414 rs285480 chr1 165403903 G A 4.00E-07 Personality dimensions RXRG intron 21368711 rs10800098 chr1 165409095 G A 4.00E-06 AIDS RXRG intron 19754311 rs285482 chr1 165410723 G T 3.03E-04 Multiple complex diseases RXRG intron 17554300 rs752739 chr1 165412959 G A 6.72E-04 Suicide attempts in bipolar disorder RXRG intron 21423239 rs285428 chr1 165422559 T C 0.00089 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines / / 23204130 rs12402931 chr1 165423287 C A 2.60E-05 Urinary metabolites / / 21572414 rs7519141 chr1 165425536 A G 3.98E-04 Multiple complex diseases / / 17554300 rs7519629 chr1 165425966 A G 2.46E-04 Multiple complex diseases / / 17554300 rs2859731 chr1 165436058 T G 3.72E-05 Psoriasis / / 18364390 rs4657443 chr1 165436331 G A 8.30E-05 Personality dimensions / / 18957941 rs10800102 chr1 165438912 T C 8.90E-05 Personality dimensions / / 18957941 rs962979 chr1 165440058 G A 8.90E-05 Personality dimensions / / 18957941 rs10918196 chr1 165448157 T C 9.00E-06 Lentiform nucleus volume LOC400794 intron 22903471 rs285483 chr1 165454213 G A 5.30E-04 Alzheimer's disease LOC400794 intron 24755620 rs184041 chr1 165462091 G C 5.29E-04 Response to taxane treatment (placlitaxel) LOC400794 intron 23006423 rs184043 chr1 165464051 G A 8.01E-04 Type 2 diabetes LOC400794 intron 17463246 rs184043 chr1 165464051 G A 3.82E-04 Coronary heart disease LOC400794 intron 21971053 rs285477 chr1 165483326 T G 9.55E-04 Multiple complex diseases LOC400794 intron 17554300 rs285463 chr1 165486905 T C 3.40E-04 Taste perception LOC400794 intron 22132133 rs285461 chr1 165497692 T C 9.56E-05 Pulmonary function in asthmatics LOC400794 intron 23541324 rs2254782 chr1 165505504 A G 5.55E-04 Multiple complex diseases LOC400794 intron 17554300 rs285439 chr1 165517729 C T 3.50E-08 Lymphocyte counts LOC400794 intron 22286170 rs952375 chr1 165559225 A G 3.17E-04 Tourette syndrome / / 22889924 rs1337441 chr1 165573850 A G 3.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1337446 chr1 165576753 C T 7.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs6690679 chr1 165597321 C T 8.38E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6657788 chr1 165599804 A G 1.13E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4147592 chr1 165600146 G A 3.20E-06 Fasting plasma glucose MGST3 UTR-5 19060907 rs6686643 chr1 165616588 T C 7.00E-06 Total ventricular volume MGST3 intron 21116278 rs2297765 chr1 165622207 C T 6.84E-05 Meningococcal disease MGST3 intron 20694013 rs11506 chr1 165631506 A G 8.48E-05 Melanoma ALDH9A1 UTR-3 21926416 rs12080699 chr1 165639043 C G 9.90E-05 Response to statin therapy ALDH9A1 intron 20339536 rs2882006 chr1 165651153 T A 6.10E-07 Lymphocyte counts ALDH9A1 intron 22286170 rs1913844 chr1 165651502 G C 0.0000699 Panic disorder ALDH9A1 intron 23149450 rs1913844 chr1 165651502 G C 6.99E-05 Serum tamsulosin hydrochloride concentration ALDH9A1 intron 23151678 rs17452017 chr1 165684677 C T 3.00E-04 Bipolar disorder / / 24387768 rs4656461 chr1 165687205 G A 6.00E-14 Glaucoma / / 21532571 rs4656461 chr1 165687205 G A 9.60E-06 Intraocular pressure / / 22570627 rs4656461 chr1 165687205 G A 8.30E-07 Intraocular pressure / / 24002674 rs7524755 chr1 165694897 T C 7.80E-06 Intraocular pressure TMCO1 UTR-3 22570627 rs1913845 chr1 165695579 C T 1.16E-05 Serum metabolites TMCO1 UTR-3 19043545 rs6660601 chr1 165695855 C T 7.50E-06 Intraocular pressure TMCO1 UTR-3 22570627 rs10918271 chr1 165704732 C T 8.89E-06 Blood Pressure TMCO1 intron pha003043 rs6696454 chr1 165707923 T C 6.40E-06 Intraocular pressure TMCO1 intron 22570627 rs7555523 chr1 165718979 C A 2.00E-08 Intraocular pressure TMCO1 intron 22570627 rs7555523 chr1 165718979 C A 1.88E-04 Intraocular pressure TMCO1 intron 23836780 rs17418864 chr1 165732482 T C 7.25E-04 Multiple complex diseases TMCO1 intron 17554300 rs17418864 chr1 165732482 T C 1.40E-05 Urinary metabolites TMCO1 intron 21572414 rs4657476 chr1 165732661 C T 6.40E-06 Intraocular pressure TMCO1 intron 22570627 rs7518099 chr1 165736880 C T 2.14E-05 Glaucoma TMCO1 intron 21532571 rs7518099 chr1 165736880 C T 7.80E-06 Intraocular pressure TMCO1 intron 22570627 rs7518099 chr1 165736880 C T 1.04E-04 Intraocular pressure TMCO1 intron 23836780 rs7518099 chr1 165736880 C T 8.00E-08 Intraocular pressure TMCO1 intron 24002674 rs2790053 chr1 165737704 C G 7.70E-06 Intraocular pressure TMCO1 intron 22570627 rs2251768 chr1 165738311 A T 7.70E-06 Intraocular pressure / / 22570627 rs2790052 chr1 165738463 G C 7.60E-06 Intraocular pressure / / 22570627 rs2814471 chr1 165739598 C T 7.40E-06 Intraocular pressure LOC100147773 intron 22570627 rs12562047 chr1 165829156 T G 0.000027 Aging UCK2 intron 22445811 rs4657482 chr1 165831649 A G 2.00E-06 Testicular germ cell tumor UCK2 intron 19483681 rs4657482 chr1 165831649 A G 2.00E-06 Nasopharyngeal carcinoma UCK2 intron 20512145 rs4657482 chr1 165831649 A G 4.67E-06 Statin-induced myopathy UCK2 intron 21826682 rs4657482 chr1 165831649 A G 6.00E-06 Testicular germ cell tumor UCK2 intron 23666239 rs3790672 chr1 165873392 T C 2.00E-08 Testicular germ cell tumor UCK2 intron 23666240 rs3790674 chr1 165873619 A G 6.37E-04 Multiple complex diseases UCK2 intron 17554300 rs12118019 chr1 165887138 G C 1.50E-05 Urinary metabolites / / 21572414 rs561315 chr1 165887397 C G 7.00E-06 Urinary metabolites / / 21572414 rs530717 chr1 165887761 C T 2.10E-05 Urinary metabolites / / 21572414 rs505877 chr1 165893530 C T 5.40E-06 Urinary metabolites / / 21572414 rs4657493 chr1 165917109 G T 6.98E-04 Stroke / / pha002887 rs16853832 chr1 165919309 G A 9.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs4540635 chr1 165924619 T G 4.42E-04 White matter integrity / / 22425255 rs7524799 chr1 165935581 T C 6.74E-06 Chronic obstructive pulmonary disease / / 19300482 rs7522756 chr1 165961938 A G 1.44E-05 Chronic obstructive pulmonary disease / / 19300482 rs732285 chr1 165967420 G A 4.86E-05 Chronic obstructive pulmonary disease / / 19300482 rs732285 chr1 165967420 G A 8.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6426962 chr1 165996331 A C 1.94E-05 Chronic obstructive pulmonary disease / / 19300482 rs12139648 chr1 166004371 G T 8.38E-05 Sudden cardiac arrest / / 21658281 rs1319898 chr1 166007024 C T 5.99E-05 Lung adenocarcinoma / / 19836008 rs6426968 chr1 166083488 T G 4.62E-05 Serum metabolites FAM78B intron 19043545 rs7513325 chr1 166084296 A G 4.11E-05 Serum metabolites FAM78B intron 19043545 rs4074897 chr1 166086171 G A 0.000012 Chronic kidney disease FAM78B intron 23539754 rs4656479 chr1 166107783 A G 9.57E-04 Multiple complex diseases FAM78B intron 17554300 rs9787101 chr1 166118896 C T 9.99E-05 Serum metabolites FAM78B intron 19043545 rs9651038 chr1 166128406 A G 8.74E-10 Multiple complex diseases FAM78B intron 17554300 rs2116519 chr1 166130218 G A 0.0000011 Chronic kidney disease FAM78B intron 23539754 rs12144426 chr1 166152034 T A 0.000035 Primary sclerosing cholangitis / / 22521342 rs6658513 chr1 166166695 G A 7.50E-06 Primary sclerosing cholangitis / / 19944697 rs7552225 chr1 166170361 C G 1.10E-05 Primary sclerosing cholangitis / / 19944697 rs1451606 chr1 166174572 G A 8.42E-06 Serum metabolites / / 19043545 rs1451606 chr1 166174572 G A 1.70E-05 Primary sclerosing cholangitis / / 19944697 rs10753713 chr1 166174854 C T 3.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10753714 chr1 166174940 C G 8.30E-06 Primary sclerosing cholangitis / / 19944697 rs896403 chr1 166176043 T C 1.50E-06 Primary sclerosing cholangitis / / 21151127 rs4391646 chr1 166177384 T C 8.80E-07 Primary sclerosing cholangitis / / 21151127 rs6678400 chr1 166177760 G T 9.50E-07 Primary sclerosing cholangitis / / 21151127 rs1432122 chr1 166226118 A G 9.18E-05 Cognitive impairment induced by topiramate / / 22091778 rs2599513 chr1 166235714 T C 2.03E-04 Vaspin levels / / 22907691 rs2599513 chr1 166235714 T C 0.0002028 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs16856830 chr1 166251769 C T 5.76E-04 Multiple complex diseases / / 17554300 rs16856830 chr1 166251769 C T 5.20E-05 Primary sclerosing cholangitis / / 19944697 rs2568106 chr1 166264243 C T 1.12E-04 Vaspin levels / / 22907691 rs2568106 chr1 166264243 C T 0.0001063 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs2568106 chr1 166264243 C T 0.0001122 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs4575063 chr1 166271612 T C 8.85E-04 Multiple complex diseases / / 17554300 rs10800212 chr1 166302712 A G 1.30E-05 Urinary metabolites / / 21572414 rs7523538 chr1 166317814 A G 6.70E-05 Femoral neck bone geometry / / 22087292 rs7523538 chr1 166317814 A G 0.00029 Fasting blood glucose / / 22216000 rs16857044 chr1 166348632 G A 9.67E-04 Myopia (pathological) / / 21095009 rs16857044 chr1 166348632 G A 3.90E-04 Insulin resistance / / 21901158 rs12746568 chr1 166356784 T C 2.06E-04 Celiac disease / / 23936387 rs16857179 chr1 166448963 A C 2.02E-05 Coronary heart disease / / pha003032 rs7552571 chr1 166456476 T G 3.75E-04 Multiple complex diseases / / 17554300 rs4002 chr1 166540210 G A 4.04E-04 Tourette syndrome / / 22889924 rs10918532 chr1 166545275 C T 6.98E-04 Tourette syndrome / / 22889924 rs17431003 chr1 166545748 A G 2.28E-04 Tourette syndrome / / 22889924 rs10494467 chr1 166550436 G A 8.68E-04 Sarcoidosis / / 21540310 rs7539202 chr1 166552723 T C 5.48E-05 Serum metabolites / / 19043545 rs472652 chr1 166564305 C T 3.17E-04 Alzheimer's disease (late onset) / / 21379329 rs12741275 chr1 166593754 T C 9.85E-06 Obesity-related traits FMO9P intron 23251661 rs714339 chr1 166595209 C T 8.91E-05 Stroke / / pha002886 rs12120439 chr1 166601757 C T 3.01E-04 Tourette syndrome / / 22889924 rs491814 chr1 166607463 C T 1.76E-04 Vaspin levels / / 22907691 rs491814 chr1 166607463 C T 0.0001761 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs3125821 chr1 166610608 G A 1.76E-04 Vaspin levels / / 22907691 rs3125821 chr1 166610608 G A 0.0001761 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs3845541 chr1 166618118 T G 6.25E-04 Bipolar disorder,schizoaffective / / 19567891 rs565064 chr1 166628260 C T 1.76E-04 Vaspin levels / / 22907691 rs565064 chr1 166628260 C T 0.0001761 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs577317 chr1 166631034 A G 2.28E-04 Substance dependence / / 21818250 rs579089 chr1 166631859 T C 1.76E-04 Vaspin levels / / 22907691 rs579089 chr1 166631859 T C 0.0001761 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs3904701 chr1 166634268 G C 6.03E-04 Bipolar disorder,schizoaffective / / 19567891 rs190191518 chr1 166656404 C T 9.71E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs11807188 chr1 166656798 T C 5.88E-04 Stroke / / pha002886 rs7517690 chr1 166662705 C T 8.78E-04 Bipolar disorder,schizoaffective / / 19567891 rs540656 chr1 166669237 G A 2.73E-05 Stroke / / pha002886 rs579100 chr1 166674289 A C 2.63E-04 Insulin resistance / / 21901158 rs1856091 chr1 166686630 G A 7.14E-04 Insulin resistance / / 21901158 rs4657594 chr1 166706135 C T 1.04E-04 Insulin resistance / / 21901158 rs1815531 chr1 166717206 T C 2.12E-05 Cognitive test performance / / 20125193 rs563244 chr1 166730775 A C 2.85E-04 Stroke / / pha002886 rs480820 chr1 166758542 A C 4.03E-04 Alzheimer's disease (late onset) / / 21379329 rs858796 chr1 166765794 T C 6.47E-04 Smoking initiation / / 24665060 rs858798 chr1 166766242 T C 4.68E-04 Smoking initiation / / 24665060 rs858814 chr1 166772579 T C 7.41E-04 Smoking initiation / / 24665060 rs6667673 chr1 166777148 A G 1.13E-05 Bilirubin levels,in serum / / 19389676 rs16858093 chr1 166777544 T C 5.58E-04 Multiple complex diseases / / 17554300 rs2205647 chr1 166778754 C A 1.12E-05 Bilirubin levels,in serum / / 19389676 rs10157620 chr1 166794977 G T 4.42E-04 Smoking initiation / / 24665060 rs4656517 chr1 166856059 G A 5.12E-05 Major depressive disorder / / 21621269 rs4656517 chr1 166856059 G A 8.80E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs17331190 chr1 166857963 C G 2.10E-05 Pericardial fat / / 22589742 rs6427044 chr1 166870475 A C 4.10E-07 Urinary metabolites / / 21572414 rs1053407 chr1 166882737 C T 6.24E-04 Alcohol consumption (maxi-drinks) ILDR2 UTR-3 24277619 rs10489574 chr1 166910831 A G 3.90E-05 Pericardial fat ILDR2 intron 22589742 rs393025 chr1 166944928 C A 1.32E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs7545911 chr1 166947681 G A 7.52E-06 Hemoglobin / / pha003098 rs7545911 chr1 166947681 G A 1.55E-05 Erythrocyte counts / / pha003099 rs402031 chr1 166950458 A G 1.18E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs7528849 chr1 166954870 A G 6.53E-04 Lymphocyte counts / / 22286170 rs10918607 chr1 166957803 T C 5.86E-05 Hemoglobin / / pha003098 rs10918607 chr1 166957803 T C 7.04E-05 Erythrocyte counts / / pha003099 rs11578336 chr1 166958710 T G 5.86E-06 Hemoglobin MAEL missense pha003098 rs11578336 chr1 166958710 T G 1.37E-05 Erythrocyte counts MAEL missense pha003099 rs1041238 chr1 166974420 T C 6.08E-05 Atopy MAEL intron 21625490 rs12133327 chr1 166982285 A G 5.63E-05 Atopy MAEL intron 21625490 rs6661553 chr1 167005881 A G 4.85E-04 Smoking initiation / / 24665060 rs12410568 chr1 167015496 G A 1.02E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4233414 chr1 167021041 T C 5.31E-04 Multiple complex diseases / / 17554300 rs10918613 chr1 167037025 G A 2.75E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) GPA33 intron 24023788 rs12133648 chr1 167044527 G T 6.62E-05 Response to mTOR inhibitor (rapamycin) GPA33 intron 24009623 rs10918616 chr1 167045333 A G 7.23E-05 Response to mTOR inhibitor (rapamycin) GPA33 intron 24009623 rs10918618 chr1 167045512 G A 4.91E-05 Response to mTOR inhibitor (rapamycin) GPA33 intron 24009623 rs73028893 chr1 167046455 A G 6.00E-06 QRS duration in Tripanosoma cruzi seropositivity GPA33 intron 24324551 rs10918619 chr1 167048067 C G 7.23E-05 Response to mTOR inhibitor (rapamycin) GPA33 intron 24009623 rs10918620 chr1 167048120 A G 4.18E-05 Response to mTOR inhibitor (rapamycin) GPA33 intron 24009623 rs10918621 chr1 167051092 C A 8.09E-05 Response to mTOR inhibitor (rapamycin) GPA33 intron 24009623 rs2281964 chr1 167059336 C T 0.00000639 Panic disorder GPA33 intron 23149450 rs2281964 chr1 167059336 C T 6.39E-06 Serum tamsulosin hydrochloride concentration GPA33 intron 23151678 rs2281962 chr1 167059760 A G 3.78E-05 Insulin Resistance GPA33 UTR-5 pha003062 rs2281962 chr1 167059760 A G 1.26E-05 Insulin-related traits GPA33 UTR-5 pha003063 rs10918625 chr1 167063520 A G 1.90E-05 Pericardial fat / / 22589742 rs12042641 chr1 167065025 G A 2.10E-05 Pericardial fat DUSP27 intron 22589742 rs12042641 chr1 167065025 G A 3.46E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) DUSP27 intron 24023788 rs10918626 chr1 167065837 T G 2.00E-05 Pericardial fat DUSP27 intron 22589742 rs10127714 chr1 167066609 A C 2.20E-05 Pericardial fat DUSP27 intron 22589742 rs10127745 chr1 167066742 T G 2.00E-05 Pericardial fat DUSP27 intron 22589742 rs12044569 chr1 167066796 G A 1.90E-05 Pericardial fat DUSP27 intron 22589742 rs11590638 chr1 167070558 G C 2.40E-05 Pericardial fat DUSP27 intron 22589742 rs267746 chr1 167096931 A C 4.61E-04 Type 2 diabetes DUSP27 missense 17463246 rs11806848 chr1 167102492 C A 5.54E-04 Multiple complex diseases / / 17554300 rs4656525 chr1 167121665 G A 5.98E-04 Stroke / / pha002887 rs1532482 chr1 167124465 A T 8.10E-05 Personality dimensions / / 18957941 rs869714 chr1 167126250 C T 1.54E-05 Parkinson's disease / / pha002868 rs7527143 chr1 167127354 G A 2.65E-05 Parkinson's disease / / pha002868 rs12021649 chr1 167135333 C T 6.86E-04 Multiple complex diseases / / 17554300 rs2861445 chr1 167136353 G C 6.55E-04 Multiple complex diseases / / 17554300 rs6691080 chr1 167140959 A G 8.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10918653 chr1 167143896 G A 1.18E-05 Parkinson's disease (motor and cognition) / / 22658654 rs1391295 chr1 167151280 C A 3.48E-04 Smoking quantity / / 24665060 rs9803659 chr1 167156500 T C 4.00E-06 Liver enzyme levels / / 18940312 rs10494472 chr1 167159608 C G 3.36E-05 Type 2 diabetes / / 17463246 rs10494472 chr1 167159608 C G 1.09E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs6675659 chr1 167169509 T A 5.95E-04 Obesity (extreme) / / 21935397 rs10800292 chr1 167172438 G A 5.57E-04 Obesity (extreme) / / 21935397 rs1021621 chr1 167198536 A G 3.60E-05 Celiac disease POU2F1 intron 17558408 rs10494474 chr1 167199180 C G 2.60E-04 Statin-induced myopathy POU2F1 intron 21826682 rs1391294 chr1 167211472 A G 2.47E-05 Multiple complex diseases POU2F1 intron 17554300 rs2814036 chr1 167228298 G A 3.11E-05 Multiple complex diseases POU2F1 intron 17554300 rs1359059 chr1 167234166 G A 9.31E-04 Alzheimer's disease POU2F1 intron 17998437 rs4656538 chr1 167259755 A G 9.11E-04 Alzheimer's disease POU2F1 intron 17998437 rs1028703 chr1 167270716 A C 5.33E-04 Fibrinogen POU2F1 intron 17255346 rs2177692 chr1 167317798 G A 1.43E-05 Multiple complex diseases POU2F1 intron 17554300 rs12742052 chr1 167334349 G A 1.03E-04 Multiple complex diseases POU2F1 intron 17554300 rs2949666 chr1 167392702 A G 5.70E-05 Celiac disease POU2F1 UTR-3 17558408 rs1917534 chr1 167397271 G A 1.81E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs1917534 chr1 167397271 G A 5.02E-05 Erythrocyte counts / / pha003099 rs953809 chr1 167403625 A G 6.90E-05 Cognitive test performance CD247 intron 20125193 rs2480679 chr1 167407517 A G 6.92E-05 Cognitive test performance CD247 intron 20125193 rs840016 chr1 167408670 C T 2.00E-06 Rheumatoid arthritis CD247 intron 20453842 rs1404567 chr1 167408874 A G 6.09E-05 Cognitive test performance CD247 intron 20125193 rs864537 chr1 167411384 A G 4.00E-07 Celiac disease CD247 intron 20190752 rs864537 chr1 167411384 A G 2.00E-11 Celiac disease and Rheumatoid arthritis CD247 intron 21383967 rs864537 chr1 167411384 A G 2.20E-11 Rheumatoid arthritis CD247 intron 23143596 rs2056626 chr1 167420425 T G 3.00E-09 Systemic sclerosis CD247 intron 20383147 rs2056626 chr1 167420425 T G 1.66E-07 Celiac disease and Rheumatoid arthritis CD247 intron 21383967 rs2056626 chr1 167420425 T G 1.00E-06 Systemic sclerosis CD247 intron 21750679 rs2056626 chr1 167420425 T G 3.00E-06 Systemic sclerosis CD247 intron 21779181 rs2056626 chr1 167420425 T G 0.000239004 Primary sclerosing cholangitis CD247 intron 23603763 rs7523907 chr1 167427247 C T 4.06E-07 Celiac disease and Rheumatoid arthritis CD247 intron 21383967 rs12737372 chr1 167451115 C T 1.84E-05 Orofacial clefts CD247 intron 22419666 rs2949655 chr1 167451850 G A 3.55E-05 Orofacial clefts CD247 intron 22419666 rs863455 chr1 167457824 C T 8.41E-04 Coronary heart disease CD247 intron 21971053 rs858543 chr1 167467298 A G 8.37E-04 Systemic lupus erythematosus CD247 intron 22004975 rs858543 chr1 167467298 A G 4.00E-04 Systemic lupus erythematosus CD247 intron 23273568 rs704853 chr1 167468864 G T 2.47E-07 Systemic lupus erythematosus CD247 intron 22004975 rs704853 chr1 167468864 G T 1.79E-04 Systemic lupus erythematosus CD247 intron 23273568 rs10918708 chr1 167499290 G A 3.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs858492 chr1 167502112 T C 3.76E-05 Hearing function / / 17255346 rs10918710 chr1 167503235 G A 8.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs12038219 chr1 167503917 G C 5.05E-04 Multiple complex diseases / / 17554300 rs10489191 chr1 167505895 T C 3.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs932398 chr1 167506663 T C 9.81E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs16859159 chr1 167507857 A G 9.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs16859165 chr1 167508118 T C 9.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs2064294 chr1 167510182 G A 9.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs2860662 chr1 167510837 T C 6.00E-04 Response to taxane treatment (placlitaxel) CREG1 UTR-3 23006423 rs2143300 chr1 167510996 G A 6.00E-04 Response to taxane treatment (placlitaxel) CREG1 UTR-3 23006423 rs2031131 chr1 167511256 T C 6.41E-06 Suicide attempts in bipolar disorder CREG1 UTR-3 21423239 rs3820392 chr1 167512531 C T 8.73E-04 Suicide attempts in bipolar disorder CREG1 intron 21423239 rs1229430 chr1 167513418 C T 8.00E-05 Alcoholism (heaviness of drinking) CREG1 intron 21529783 rs12042693 chr1 167513723 G A 6.91E-04 Suicide attempts in bipolar disorder CREG1 intron 21423239 rs12022039 chr1 167514197 C G 7.99E-04 Suicide attempts in bipolar disorder CREG1 intron 21423239 rs2982475 chr1 167514919 G C 1.51E-05 Suicide attempts in bipolar disorder CREG1 intron 21423239 rs4657669 chr1 167521425 C T 6.90E-05 Suicide attempts in bipolar disorder CREG1 intron 21423239 rs1737487 chr1 167523387 T C 6.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs1737487 chr1 167523387 T C 6.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2984801 chr1 167526473 G A 1.10E-06 Urinary metabolites / / 21572414 rs11577169 chr1 167526508 C G 7.57E-05 Suicide attempts in bipolar disorder / / 21423239 rs2902346 chr1 167526823 G A 3.70E-07 Urinary metabolites / / 21572414 rs2902347 chr1 167526972 C T 5.00E-07 Urinary metabolites / / 21572414 rs1737480 chr1 167528912 C T 3.60E-06 Urinary metabolites / / 21572414 rs1773548 chr1 167529639 G A 5.18E-04 Myopia (pathological) / / 21095009 rs1773548 chr1 167529639 G A 8.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs909935 chr1 167533014 C T 4.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs4657670 chr1 167534270 T C 6.70E-05 Type 2 diabetes / / 17463246 rs7543683 chr1 167542337 A G 4.10E-05 Personality dimensions / / 18957941 rs7554445 chr1 167554337 T G 3.80E-05 Personality dimensions / / 18957941 rs12124252 chr1 167557852 A C 4.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs6666091 chr1 167563012 T C 1.94E-04 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs4657679 chr1 167572558 C T 5.40E-05 Personality dimensions / / 18957941 rs1013057 chr1 167580349 T C 7.00E-06 Personality dimensions / / 18957941 rs11809621 chr1 167585884 G T 6.00E-04 Tourette syndrome / / 22889924 rs1229403 chr1 167589943 T C 4.78E-05 Osteoarthritis (knee and hip) / / 21177295 rs1890131 chr1 167597473 C T 5.10E-07 Coronary spasm / / 18075462 rs3738222 chr1 167600220 T C 4.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RCSD1 intron 20877124 rs3738222 chr1 167600220 T C 9.79E-04 Tourette syndrome RCSD1 intron 22889924 rs12760768 chr1 167619333 C T 9.67E-05 Non-alcoholic fatty liver disease histology (other) RCSD1 intron 20708005 rs1022538 chr1 167625652 C T 8.76E-05 Non-alcoholic fatty liver disease histology (other) RCSD1 intron 20708005 rs12131752 chr1 167632361 G T 5.00E-04 Coronary heart disease RCSD1 intron 21971053 rs1229358 chr1 167640711 T A 4.50E-06 Urinary metabolites RCSD1 intron 21572414 rs12066500 chr1 167666218 C T 1.60E-05 Urinary metabolites RCSD1 intron 21572414 rs4657699 chr1 167679477 T C 6.17E-05 Bladder cancer / / 19648920 rs4657699 chr1 167679477 T C 4.00E-06 Urinary metabolites / / 21572414 rs1933077 chr1 167680498 C G 7.19E-06 Personality dimensions / / 18957941 rs16859491 chr1 167699295 C T 3.08E-04 Type 2 diabetes MPZL1 intron 17463246 rs16859491 chr1 167699295 C T 4.00E-06 Urinary metabolites MPZL1 intron 21572414 rs4145462 chr1 167718499 A G 1.00E-06 Alzheimer's disease (late onset) MPZL1 intron 22881374 rs12757250 chr1 167739355 T C 2.28E-04 Amyotrophic Lateral Sclerosis MPZL1 intron 17362836 rs4472738 chr1 167739821 C A 6.87E-05 Left ventricular hypertrophy MPZL1 intron pha003052 rs3752606 chr1 167758784 A G 6.35E-05 Myopia (pathological) MPZL1 UTR-3 21640322 rs10918774 chr1 167777775 G A 8.37E-04 Acute lung injury / / 22295056 rs10918774 chr1 167777775 G A 6.32E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12060498 chr1 167787265 C T 3.24E-04 Fibrinogen ADCY10 intron 17255346 rs4656560 chr1 167790618 T C 1.00E-04 Information processing speed ADCY10 intron 21130836 rs1476075 chr1 167794406 G A 9.95E-05 Information processing speed ADCY10 intron 21130836 rs17482924 chr1 167801355 G A 2.66E-04 Lymphocyte counts ADCY10 intron 22286170 rs16859735 chr1 167803349 T A 1.68E-04 Multiple complex diseases ADCY10 intron 17554300 rs3752608 chr1 167803823 G T 7.27E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) ADCY10 intron 23648065 rs204262 chr1 167814468 A G 4.46E-04 Fibrinogen ADCY10 intron 17255346 rs204262 chr1 167814468 A G 8.34E-04 Suicide attempts in bipolar disorder ADCY10 intron 21041247 rs7512378 chr1 167825134 A G 9.60E-05 Attention deficit hyperactivity disorder ADCY10 intron 22420046 rs7512378 chr1 167825134 A G 6.21E-05 Hepatocellular carcinoma ADCY10 intron 22807686 rs203812 chr1 167837285 A C 8.40E-04 Taste perception ADCY10 intron 22132133 rs203849 chr1 167849414 A G 1.18E-05 Breast cancer ADCY10 cds-synon 24143190 rs10489202 chr1 167903079 G T 7.39E-04 Type 2 diabetes BRP44 intron 17463246 rs10489202 chr1 167903079 G T 1.70E-04 Type 2 diabetes and 6 quantitative traits BRP44 intron 17848626 rs10489202 chr1 167903079 G T 1.00E-08 Schizophrenia BRP44 intron 22037555 rs16828104 chr1 168090899 C T 7.10E-04 Multiple complex diseases GPR161 intron 17554300 rs10489208 chr1 168094709 C T 7.08E-04 Multiple complex diseases GPR161 intron 17554300 rs10489208 chr1 168094709 C T 2.29E-15 Lymphocyte counts GPR161 intron 22286170 rs4657739 chr1 168142489 C T 2.98E-04 Celiac disease / / 23936387 rs4657741 chr1 168149142 G A 1.97E-04 Celiac disease TIPRL intron 23936387 rs2294253 chr1 168156627 C T 4.87E-05 Celiac disease TIPRL intron 23936387 rs2235207 chr1 168159262 C T 2.94E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) TIPRL intron 22566498 rs2235207 chr1 168159262 C T 1.26E-04 Celiac disease TIPRL intron 23936387 rs1040404 chr1 168159890 G A 9.59E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) TIPRL intron 22566498 rs1040404 chr1 168159890 G A 8.24E-05 Celiac disease TIPRL intron 23936387 rs1040403 chr1 168164197 T G 6.21E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) TIPRL intron 22566498 rs2072778 chr1 168168750 A G 1.30E-05 Urinary metabolites TIPRL intron 21572414 rs2072776 chr1 168169452 G A 3.90E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) TIPRL UTR-3 22566498 rs10157201 chr1 168172624 A G 3.78E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2075976 chr1 168269338 A C 6.03E-04 Breast cancer TBX19 intron 21060860 rs6427122 chr1 168274691 C T 7.75E-05 Multiple complex diseases TBX19 intron 17554300 rs2239613 chr1 168284327 A G 7.61E-06 Glycemic traits (pregnancy) / / 23903356 rs10753772 chr1 168295144 A G 2.38E-06 Glycemic traits (pregnancy) / / 23903356 rs10800353 chr1 168295203 T C 2.16E-06 Glycemic traits (pregnancy) / / 23903356 rs982702 chr1 168296436 T C 1.85E-06 Glycemic traits (pregnancy) / / 23903356 rs982702 chr1 168296436 T C 5.61E-04 Smoking cessation / / 24665060 rs1005423 chr1 168297451 C T 4.38E-06 Glycemic traits (pregnancy) / / 23903356 rs6674077 chr1 168299478 C T 3.36E-07 Glycemic traits (pregnancy) / / 23903356 rs2179184 chr1 168300075 A G 1.83E-06 Glycemic traits (pregnancy) / / 23903356 rs1040412 chr1 168300722 C A 2.88E-07 Glycemic traits (pregnancy) / / 23903356 rs2103570 chr1 168302975 C G 5.65E-07 Glycemic traits (pregnancy) / / 23903356 rs6685637 chr1 168303347 G A 2.75E-06 Glycemic traits (pregnancy) / / 23903356 rs6688030 chr1 168303543 C T 1.98E-06 Glycemic traits (pregnancy) / / 23903356 rs7512951 chr1 168309388 C T 6.23E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1886004 chr1 168332753 A G 8.80E-04 Type 2 diabetes / / 17846125 rs16860520 chr1 168380748 A G 6.42E-04 Type 2 diabetes LOC100505918 intron 17463246 rs12740293 chr1 168381150 A G 0.000264 Salmonella-induced pyroptosis LOC100505918 intron 22837397 rs2300564 chr1 168391067 T C 8.67E-04 Alzheimer's disease LOC100505918 intron 17998437 rs7417366 chr1 168463587 A G 0.000122 Lumbar spine bone mineral density (females) / / 22692763 rs7417366 chr1 168463587 A G 0.000575 Lumbar spine bone mineral density (males) / / 22692763 rs7417366 chr1 168463587 A G 7.42E-08 Lumbar spine bone mineral density / / 22692763 rs16860688 chr1 168463868 T G 1.34E-04 Progressive supranuclear palsy / / 21685912 rs10918916 chr1 168490420 A C 2.48E-04 Multiple complex diseases / / 17554300 rs12759385 chr1 168494126 G A 3.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs1323532 chr1 168496272 G T 6.19E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs1040508 chr1 168500750 C T 7.66E-05 Serum metabolites / / 19043545 rs1040509 chr1 168500984 G T 8.45E-04 Multiple complex diseases / / 17554300 rs1040509 chr1 168500984 G T 2.04E-05 Serum metabolites / / 19043545 rs12049040 chr1 168521615 G A 2.73E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs1933107 chr1 168524895 A G 2.23E-04 Premature ovarian failure / / 19508998 rs1933105 chr1 168526394 T G 1.82E-05 Serum metabolites / / 19043545 rs6427130 chr1 168549422 C T 2.09E-04 Multiple complex diseases XCL1 intron 17554300 rs6700487 chr1 168549885 T C 6.82E-04 Suicide attempts in bipolar disorder XCL1 intron 21423239 rs2143312 chr1 168556301 T A 2.60E-05 Urinary metabolites / / 21572414 rs7556321 chr1 168560132 G A 3.80E-05 Malaria / / 19465909 rs10918931 chr1 168562091 T C 9.29E-10 Narcolepsy / / 19629137 rs7533545 chr1 168566976 G A 1.79E-05 Smoking cessation / / 24665060 rs2419117 chr1 168589182 T G 1.73E-05 Alzheimer's disease (late onset) / / 21379329 rs11580561 chr1 168599216 C T 1.03E-04 Alzheimer's disease (late onset) / / 21379329 rs11580561 chr1 168599216 C T 4.48E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7551639 chr1 168608152 G A 5.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7551639 chr1 168608152 G A 2.20E-04 Dental caries / / 21940522 rs1412337 chr1 168618641 G A 2.00E-09 Morbidity-free survival / / 17903295 rs16861246 chr1 168623309 G A 6.73E-04 Multiple complex diseases / / 17554300 rs16861250 chr1 168623998 C T 9.67E-05 Multiple complex diseases / / 17554300 rs1538173 chr1 168642062 T C 2.80E-06 Bone mass and geometry / / 17903296 rs12116794 chr1 168666850 A C 3.12E-05 Amyotrophic lateral sclerosis (sporadic) DPT intron 24529757 rs545833 chr1 168689940 C T 5.19E-07 QT interval DPT intron 19305409 rs545833 chr1 168689940 C T 7.09E-05 Lactate dehydrogenase levels DPT intron 20981236 rs545833 chr1 168689940 C T 2.19E-04 Vaspin levels DPT intron 22907691 rs545833 chr1 168689940 C T 0.0002193 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks DPT intron 22907730 rs11590043 chr1 168692615 C A 7.71E-06 Waist Circumference DPT intron pha003023 rs6427150 chr1 168725876 A G 5.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs926431 chr1 168734730 G A 3.00E-06 Urinary metabolites / / 21572414 rs2744666 chr1 168737147 A G 1.40E-06 Urinary metabolites / / 21572414 rs2786765 chr1 168741270 C T 1.80E-06 Urinary metabolites / / 21572414 rs2786767 chr1 168742357 C T 6.70E-06 Urinary metabolites / / 21572414 rs6659944 chr1 168779469 G A 9.47E-05 Height / / pha003011 rs41370344 chr1 168787307 T C 8.83E-04 Type 2 diabetes / / 17463246 rs41370344 chr1 168787307 T C 1.29E-04 Body mass index / / 21701565 rs41370344 chr1 168787307 T C 4.32E-04 Body mass index / / 21701565 rs857633 chr1 168833962 C T 6.97E-04 Smoking cessation / / 24665060 rs1322496 chr1 168842658 C G 7.93E-05 Hypertension / / 19609347 rs2419391 chr1 168849228 C G 5.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs2146204 chr1 168874099 A C 2.97E-06 Hypertension / / 19609347 rs17514217 chr1 168889407 T A 4.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs17514217 chr1 168889407 T A 6.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs17514245 chr1 168889557 A G 4.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs17514245 chr1 168889557 A G 5.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs7530207 chr1 168890420 G C 4.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs7530207 chr1 168890420 G C 6.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs6427160 chr1 168892181 T C 4.80E-04 Intelligence (childhood) / / 23358156 rs2010667 chr1 168902339 C G 4.29E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs34429748 chr1 168927684 C CA 9.10E-06 Urinary metabolites / / 21572414 rs6702394 chr1 168927684 C T 9.10E-06 Urinary metabolites / / 21572414 rs41351446 chr1 168933987 C T 4.44E-04 Multiple complex diseases / / 17554300 rs10489373 chr1 168939789 G A 5.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10489376 chr1 168961407 G A 9.20E-04 Multiple complex diseases / / 17554300 rs16861846 chr1 168961568 A C 5.08E-04 Multiple complex diseases / / 17554300 rs16861846 chr1 168961568 A C 8.80E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6665379 chr1 168982164 G A 1.26E-05 Schizophrenia(age at onset) / / 21688384 rs12095831 chr1 168989553 T C 4.80E-04 Multiple complex diseases / / 17554300 rs4656640 chr1 168996958 T G 4.09E-05 Cholesterol / / 17255346 rs1320975 chr1 169022734 C T 4.58E-04 Alzheimer's disease / / 24755620 rs114101204 chr1 169026054 G A 2.86E-10 Venous thrombosis / / 22675575 rs114964168 chr1 169032877 C T 2.26E-10 Venous thrombosis / / 22675575 rs12061601 chr1 169070450 T C 5.03E-07 Venous thromboembolism / / 22672568 rs12061601 chr1 169070450 T C 5.88E-10 QT interval / / 23166209 rs12061601 chr1 169070450 T C 5.88E-10 Schizophrenia / / 23212062 rs1320976 chr1 169073346 G A 2.00E-10 QT interval / / 23166209 rs2032045 chr1 169078076 G A 3.51E-04 Multiple complex diseases ATP1B1 intron 17554300 rs1200131 chr1 169078859 G A 9.29E-04 Multiple complex diseases ATP1B1 intron 17554300 rs77977611 chr1 169081792 T G 5.13E-13 Venous thrombosis ATP1B1 intron 22675575 rs75112989 chr1 169099137 G A 3.59E-20 Venous thrombosis ATP1B1 intron 22675575 rs10919071 chr1 169099483 A G 1.00E-15 QT interval ATP1B1 intron 19305409 rs1138486 chr1 169101935 C T 4.23E-06 QT interval ATP1B1 UTR-3 23166209 rs77979353 chr1 169115022 T C 2.66E-22 Venous thrombosis NME7 intron 22675575 rs3766053 chr1 169126401 A C 2.70E-05 Urinary metabolites NME7 intron 21572414 rs1200164 chr1 169126895 G C 9.84E-06 QT interval NME7 intron 23166209 rs16861990 chr1 169135127 A C 2.00E-06 D-dimer levels NME7 intron 21502573 rs16861990 chr1 169135127 A C 4.90E-20 Venous thromboembolism NME7 intron 21980494 rs16861990 chr1 169135127 A C 2.00E-12 Venous thromboembolism NME7 intron 22672568 rs16861990 chr1 169135127 A C 4.71E-20 Venous thrombosis NME7 intron 22675575 rs12029857 chr1 169151228 T C 9.39E-06 Venous thromboembolism NME7 intron 22672568 rs144737447 chr1 169160458 C T 2.10E-28 Venous thrombosis NME7 intron 22675575 rs3766074 chr1 169163017 G A 3.59E-04 Stroke NME7 intron pha002886 rs10800418 chr1 169183385 A C,T 8.90E-06 Urinary metabolites NME7 intron 21572414 rs2227246 chr1 169208179 C T 2.77E-27 Venous thrombosis NME7 intron 22675575 rs10800427 chr1 169272451 A T 4.01E-23 Venous thrombosis NME7 intron 22675575 rs10800428 chr1 169272453 G A 2.33E-23 Venous thrombosis NME7 intron 22675575 rs12125501 chr1 169273808 G A 0.000149 Coronary artery disease NME7 intron 23202125 rs1208327 chr1 169296864 C T 1.45E-22 Venous thromboembolism NME7 intron 21980494 rs1208327 chr1 169296864 C T 7.96E-13 Venous thromboembolism NME7 intron 22672568 rs1208327 chr1 169296864 C T 8.44E-21 Venous thrombosis NME7 intron 22675575 rs1200063 chr1 169314430 T C 5.21E-22 Venous thrombosis NME7 intron 22675575 rs10919147 chr1 169315527 A G 5.82E-04 Stroke NME7 intron pha002886 rs1209731 chr1 169324793 T C 4.68E-27 Venous thrombosis NME7 intron 22675575 rs7538157 chr1 169351544 A C 9.03E-25 Venous thromboembolism BLZF1 intron 21980494 rs7538157 chr1 169351544 A C 1.04E-14 Venous thromboembolism BLZF1 intron 22672568 rs10919158 chr1 169357144 C T 4.51E-04 Stroke BLZF1 intron pha002886 rs10919164 chr1 169384437 T C 2.26E-04 Amyotrophic lateral sclerosis (sporadic) C1orf114 intron 24529757 rs16862153 chr1 169393888 C T 6.51E-04 Type 2 diabetes C1orf114 intron 17463246 rs10919168 chr1 169394226 A G 7.66E-06 Venous thromboembolism C1orf114 intron 22672568 rs12092506 chr1 169405517 A G 2.13E-04 Epilepsy / / 22116939 rs1208135 chr1 169424098 A G 2.12E-20 Venous thromboembolism / / 21980494 rs1208135 chr1 169424098 A G 4.26E-11 Venous thromboembolism / / 22672568 rs1208135 chr1 169424098 A G 1.39E-20 Venous thrombosis / / 22675575 rs1208134 chr1 169428944 C T 2.12E-20 Venous thromboembolism / / 21980494 rs1208134 chr1 169428944 C T 4.46E-11 Venous thromboembolism / / 22672568 rs1208134 chr1 169428944 C T 7.13E-21 Venous thrombosis / / 22675575 rs2678166 chr1 169435027 C T 1.46E-32 Venous thrombosis SLC19A2 UTR-3 22675575 rs1983546 chr1 169446183 A G 1.00E-06 Urinary metabolites SLC19A2 intron 21572414 rs2038024 chr1 169455982 C A 1.12E-08 Venous thromboembolism / / 22672568 rs2038024 chr1 169455982 C A 1.75E-09 Activated protein C resistance / / 23188048 rs2901092 chr1 169456393 A G 7.81E-07 Venous thromboembolism / / 22672568 rs10800448 chr1 169460406 A G 4.95E-09 Venous thrombosis / / 22675575 rs6696217 chr1 169460726 A G 1.38E-13 Venous thromboembolism / / 21980494 rs6696217 chr1 169460726 A G 6.33E-14 Venous thromboembolism / / 22672568 rs6696217 chr1 169460726 A G 3.02E-17 Venous thrombosis / / 22675575 rs4656682 chr1 169463518 A G 9.98E-11 Venous thrombosis / / 22675575 rs67150165 chr1 169463518 AT AAT,AGC 9.98E-11 Venous thrombosis / / 22675575 rs4656683 chr1 169463519 T C 9.01E-11 Venous thrombosis / / 22675575 rs1894692 chr1 169467654 G A 1.79E-13 Venous thromboembolism / / 21980494 rs1894692 chr1 169467654 G A 2.85E-21 Venous thromboembolism / / 22672568 rs1894692 chr1 169467654 G A 2.72E-34 Venous thrombosis / / 22675575 rs4264045 chr1 169470748 T G 4.02E-26 Venous thrombosis / / 22675575 rs6670848 chr1 169472899 A G 7.25E-25 Venous thrombosis / / 22675575 rs10737547 chr1 169476052 A G 1.49E-22 Venous thromboembolism / / 21980494 rs10737547 chr1 169476052 A G 6.25E-17 Venous thromboembolism / / 22672568 rs10737547 chr1 169476052 A G 7.31E-25 Venous thrombosis / / 22675575 rs6687813 chr1 169477574 A C 2.00E-14 D-dimer levels / / 21502573 rs6687813 chr1 169477574 A C 8.61E-23 Venous thromboembolism / / 21980494 rs6687813 chr1 169477574 A C 6.24E-17 Venous thromboembolism / / 22672568 rs6687813 chr1 169477574 A C 2.24E-25 Venous thrombosis / / 22675575 rs970740 chr1 169479974 C T 4.47E-26 Venous thromboembolism / / 21980494 rs970740 chr1 169479974 C T 4.35E-17 Venous thromboembolism / / 22672568 rs970740 chr1 169479974 C T 5.01E-26 Venous thrombosis / / 22675575 rs6427194 chr1 169481121 T A 5.06E-26 Venous thromboembolism F5 nearGene-3 21980494 rs6427194 chr1 169481121 T A 4.30E-17 Venous thromboembolism F5 nearGene-3 22672568 rs6427194 chr1 169481121 T A 5.02E-25 Venous thrombosis F5 nearGene-3 22675575 rs6427195 chr1 169481176 A T 5.06E-26 Venous thromboembolism F5 nearGene-3 21980494 rs6427195 chr1 169481176 A T 4.28E-17 Venous thromboembolism F5 nearGene-3 22672568 rs6427195 chr1 169481176 A T 5.24E-25 Venous thrombosis F5 nearGene-3 22675575 rs6427196 chr1 169481223 C G 5.29E-26 Venous thromboembolism F5 UTR-3 21980494 rs6427196 chr1 169481223 C G 4.24E-17 Venous thromboembolism F5 UTR-3 22672568 rs6427196 chr1 169481223 C G 6.04E-25 Venous thrombosis F5 UTR-3 22675575 rs6427196 chr1 169481223 C G 2.11E-28 Activated protein C resistance F5 UTR-3 23188048 rs6427196 chr1 169481223 C G 4.00E-51 Venous thromboembolism F5 UTR-3 23650146 rs2213865 chr1 169486128 G A 5.58E-05 Cognitive impairment induced by topiramate F5 intron 22091778 rs2420370 chr1 169490392 G C 4.15E-26 Venous thromboembolism F5 intron 21980494 rs2420370 chr1 169490392 G C 8.47E-17 Venous thromboembolism F5 intron 22672568 rs6682179 chr1 169490401 T C 5.63E-25 Venous thrombosis F5 intron 22675575 rs6682179 chr1 169490401 T C 1.43E-28 Activated protein C resistance F5 intron 23188048 rs2420371 chr1 169491555 G A 1.20E-12 Venous thromboembolism F5 intron 19278955 rs2420371 chr1 169491555 G A 4.02E-26 Venous thromboembolism F5 intron 21980494 rs2420371 chr1 169491555 G A 4.00E-80 Hemostatic factors and hematological phenotypes F5 intron 22443383 rs2420371 chr1 169491555 G A 9.61E-17 Venous thromboembolism F5 intron 22672568 rs2420371 chr1 169491555 G A 6.09E-26 Venous thrombosis F5 intron 22675575 rs9332637 chr1 169494996 G A 3.06E-08 HDL cholesterol F5 intron 23063622 rs2420372 chr1 169498056 A G 3.39E-26 Venous thromboembolism F5 intron 21980494 rs2420372 chr1 169498056 A G 7.47E-17 Venous thromboembolism F5 intron 22672568 rs2420372 chr1 169498056 A G 2.19E-25 Venous thrombosis F5 intron 22675575 rs6009 chr1 169498834 T C 3.96E-26 Venous thromboembolism F5 intron 21980494 rs6009 chr1 169498834 T C 7.26E-17 Venous thromboembolism F5 intron 22672568 rs6009 chr1 169498834 T C 1.93E-25 Venous thrombosis F5 intron 22675575 rs6009 chr1 169498834 T C 1.24E-27 Activated protein C resistance F5 intron 23188048 rs6030 chr1 169498975 T C 3.00E-06 Uric acid levels F5 missense 23703922 rs6427197 chr1 169500590 C A 3.75E-26 Venous thromboembolism F5 intron 21980494 rs6427197 chr1 169500590 C A 6.92E-17 Venous thromboembolism F5 intron 22672568 rs6427197 chr1 169500590 C A 2.08E-25 Venous thrombosis F5 intron 22675575 rs1557570 chr1 169507844 G T 9.51E-06 Venous thromboembolism F5 intron 22672568 rs6031 chr1 169511903 G A 0.00000152 HDL cholesterol F5 missense 23063622 rs1018827 chr1 169514006 A G 2.00E-26 Venous thromboembolism F5 intron 21980494 rs1018827 chr1 169514006 A G 4.24E-17 Venous thromboembolism F5 intron 22672568 rs1018827 chr1 169514006 A G 1.36E-25 Venous thrombosis F5 intron 22675575 rs6025 chr1 169519049 T C 1 Drug response to Oral Contraceptives and Venous Thrombosis / / 10225605 rs6025 chr1 169519049 T C 1 Drug response to Oral Contraceptives and Venous Thrombosis / / 11583312 rs6025 chr1 169519049 T C 1 Drug response to Oral Contraceptives and Venous Thrombosis / / 15799206 rs6025 chr1 169519049 T C 1 Drug response to Oral Contraceptives and Venous Thrombosis / / 16113779 rs6025 chr1 169519049 T C 3.73E-15 Venous thromboembolism / / 21980494 rs6025 chr1 169519049 T C 2.00E-22 Venous thromboembolism / / 22672568 rs6025 chr1 169519049 T C 4.23E-35 Venous thrombosis / / 22675575 rs6025 chr1 169519049 T C 4.20E-104 Activated protein C resistance / / 23188048 rs6020 chr1 169519112 C T 1.88E-04 Type 2 diabetes F5 missense 17463246 rs6020 chr1 169519112 C T 0.000047 Prostate cancer F5 missense 23555315 rs2213868 chr1 169521553 G A 3.35E-27 Venous thrombosis F5 intron 22675575 rs6035 chr1 169521849 T C 9.15E-05 Cognitive impairment induced by topiramate F5 cds-synon 22091778 rs9332579 chr1 169525312 C T 0.000013 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 F5 intron 21873659 rs9332570 chr1 169528075 C G 0.0000011 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 F5 intron 21873659 rs9332569 chr1 169528180 C A 1.40E-09 Cholesterol,total F5 intron 23063622 rs6427203 chr1 169529031 A C 0.0000018 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 F5 intron 21873659 rs7545236 chr1 169530070 A C 0.0000012 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 F5 intron 21873659 rs1894701 chr1 169530586 T C 0.0000013 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 F5 intron 21873659 rs9332552 chr1 169537036 G A 0.00000125 Triglycerides F5 intron 23063622 rs2298908 chr1 169538544 C T 0.0000013 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 F5 intron 21873659 rs6663533 chr1 169539348 T G 4.21E-04 Multiple complex diseases F5 intron 17554300 rs6663533 chr1 169539348 T G 0.00026 Coronary artery calcification F5 intron 23727086 rs6019 chr1 169541513 C G 0.00026 Coronary artery calcification F5 missense 23727086 rs6703865 chr1 169550963 G A 1.00E-09 Hippocampal atrophy F5 intron 22745009 rs6028 chr1 169551682 T C 3.00E-09 Activated partial thromboplastin time F5 cds-synon 22703881 rs9332492 chr1 169553110 A C 1.41E-08 Cholesterol,total F5 intron 23063622 rs9332682 chr1 169553860 G A 1.35E-10 HDL cholesterol F5 intron 23063622 rs6128 chr1 169562904 C T 0.0000031 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 SELP cds-synon 21873659 rs6128 chr1 169562904 C T 0.00056 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 SELP cds-synon 21873659 rs6128 chr1 169562904 C T 0.00043 Coronary artery calcification SELP cds-synon 23727086 rs3917831 chr1 169562949 A G 2.43E-11 Cholesterol,total SELP cds-synon 23063622 rs6136 chr1 169563951 T G 4.00E-61 Soluble levels of adhesion molecules SELP missense 20167578 rs3917820 chr1 169564745 G A 2.71E-04 Type 2 diabetes SELP intron 17463246 rs3917820 chr1 169564745 G A 5.47E-06 Cardiovascular disease SELP intron 18179892 rs6133 chr1 169565346 C A,G 0.000011 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 SELP missense 21873659 rs6133 chr1 169565346 C A,G 0.00023 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 SELP missense 21873659 rs6127 chr1 169566313 C T 3.91E-04 Smoking quantity SELP missense 24665060 rs3917793 chr1 169567545 C A 4.70E-04 Coronary heart disease SELP intron 21966275 rs3917781 chr1 169569733 A G 9.25E-04 Multiple complex diseases SELP intron 17554300 rs3917781 chr1 169569733 A G 1.03E-08 HDL cholesterol SELP intron 23063622 rs3917779 chr1 169570848 G A 0.000016 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 SELP intron 21873659 rs3917779 chr1 169570848 G A 0.00029 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 SELP intron 21873659 rs3917770 chr1 169572179 G A 5.99E-04 Multiple complex diseases SELP intron 17554300 rs2235302 chr1 169580290 C T 4.00E-16 Soluble levels of adhesion molecules SELP intron 20167578 rs3917693 chr1 169589370 C T 8.04E-10 Venous thrombosis SELP intron 22675575 rs3917683 chr1 169591373 T C 4.18E-06 Total ventricular volume SELP intron 21116278 rs3917862 chr1 169593113 A G 4.35E-06 Venous thromboembolism SELP intron 22672568 rs732314 chr1 169599254 T C 5.49E-06 Total ventricular volume SELP intron 21116278 rs1569476 chr1 169608917 C T 3.00E-07 Total ventricular volume / / 21116278 rs7531806 chr1 169651044 G A 1.00E-08 Acne (severe) / / 24399259 rs4987381 chr1 169661180 C A 7.72E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987345 chr1 169668608 A G 8.59E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987343 chr1 169668856 T C 7.44E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987340 chr1 169669143 C T 7.16E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs964555 chr1 169671088 A C 2.34E-05 Alcohol dependence SELL intron 20201924 rs964555 chr1 169671088 A C 2.34E-05 Alcoholism SELL intron pha002891 rs4987325 chr1 169671217 T G 6.43E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987324 chr1 169671237 A C 1.74E-04 Type 2 diabetes SELL intron 17463246 rs4987324 chr1 169671237 A C 9.99E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987323 chr1 169671277 G C 1.85E-04 Type 2 diabetes SELL intron 17463246 rs4987323 chr1 169671277 G C 9.99E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987395 chr1 169671386 T A 7.35E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987314 chr1 169672343 C T 1.23E-05 Alcohol dependence SELL intron 20201924 rs4987314 chr1 169672343 C T 1.23E-05 Alcoholism SELL intron pha002891 rs12137905 chr1 169672867 C T 9.32E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs2229569 chr1 169673838 G A 9.88E-06 Alcoholism SELL missense pha002891 rs4987308 chr1 169674116 C G 6.82E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987307 chr1 169674403 G T 5.25E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987304 chr1 169674561 A C 6.42E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987302 chr1 169674983 G A 6.92E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs4987299 chr1 169675349 T C 1.64E-04 Type 2 diabetes SELL intron 17463246 rs2205847 chr1 169676223 G T 1.94E-04 Alcohol dependence SELL intron 20201924 rs1131498 chr1 169676486 A G 4.00E-06 Amyotrophic lateral sclerosis SELL missense 19451621 rs1131498 chr1 169676486 A G 4.00E-06 Amyotrophic lateral sclerosis SELL missense 19451621 rs1051091 chr1 169677709 A G 2.11E-04 Alcohol dependence SELL cds-synon 20201924 rs4987285 chr1 169678024 T C 6.00E-05 Alcohol dependence SELL intron 20201924 rs4987285 chr1 169678024 T C 6.00E-05 Alcoholism SELL intron pha002891 rs1569457 chr1 169680074 G A 6.01E-04 Suicide attempts in bipolar disorder SELL intron 21423239 rs2205849 chr1 169681357 T C 1.40E-05 Alcohol dependence SELL nearGene-5 20201924 rs2205849 chr1 169681357 T C 1.40E-05 Alcoholism SELL nearGene-5 pha002891 rs4656703 chr1 169688135 A C 4.48E-05 Alcohol dependence / / 20201924 rs4656703 chr1 169688135 A C 4.48E-05 Alcoholism / / pha002891 rs12133642 chr1 169689800 A G 1.87E-04 Type 2 diabetes / / 17463246 rs12133642 chr1 169689800 A G 9.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs12133666 chr1 169689832 A T 7.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs3917449 chr1 169691219 G A 5.35E-05 Alcohol dependence / / 20201924 rs3917449 chr1 169691219 G A 5.35E-05 Alcoholism / / pha002891 rs3917462 chr1 169691667 T C 0.000093 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 SELE nearGene-3 21873659 rs3917441 chr1 169692121 G C 3.00E-04 Suicide attempts in bipolar disorder SELE UTR-3 21423239 rs4786 chr1 169692132 T C 1.21E-04 Alcohol dependence SELE UTR-3 20201924 rs5359 chr1 169692522 T C 6.98E-06 Alcohol dependence SELE UTR-3 20201924 rs5359 chr1 169692522 T C 6.98E-06 Alcoholism SELE UTR-3 pha002891 rs5357 chr1 169692713 A G 4.25E-04 Suicide attempts in bipolar disorder SELE UTR-3 21423239 rs3917427 chr1 169696033 A G 9.73E-04 Suicide attempts in bipolar disorder SELE intron 21423239 rs3917425 chr1 169696754 A T 2.72E-04 Type 2 diabetes SELE intron 17463246 rs3917425 chr1 169696754 A T 9.99E-04 Suicide attempts in bipolar disorder SELE intron 21423239 rs5367 chr1 169697076 A G 9.55E-04 Suicide attempts in bipolar disorder SELE intron 21423239 rs1076637 chr1 169697444 C T 1.89E-05 Alcohol dependence SELE intron 20201924 rs1076637 chr1 169697444 C T 1.89E-05 Alcoholism SELE intron pha002891 rs5364 chr1 169698647 C T 5.27E-09 Lipid levels SELE missense 19913121 rs5363 chr1 169698789 A G 9.53E-04 Suicide attempts in bipolar disorder SELE cds-synon 21423239 rs3917419 chr1 169699819 G A 2.43E-05 Alcohol dependence SELE intron 20201924 rs3917419 chr1 169699819 G A 2.43E-05 Alcoholism SELE intron pha002891 rs3917411 chr1 169700756 A T 1.74E-04 Type 2 diabetes SELE intron 17463246 rs3917411 chr1 169700756 A T 9.73E-04 Suicide attempts in bipolar disorder SELE intron 21423239 rs3917410 chr1 169701108 A G 1.48E-04 Type 2 diabetes SELE intron 17463246 rs932307 chr1 169702705 G A 3.96E-04 Alcohol dependence SELE intron 20201924 rs1805193 chr1 169702772 C A 9.95E-04 Suicide attempts in bipolar disorder SELE UTR-5 21423239 rs3917400 chr1 169702899 G A 9.94E-04 Suicide attempts in bipolar disorder SELE intron 21423239 rs5353 chr1 169702974 T C 5.11E-05 Alcohol dependence SELE intron 20201924 rs5353 chr1 169702974 T C 5.11E-05 Alcoholism SELE intron pha002891 rs3917392 chr1 169704335 T C 1.05E-04 Type 2 diabetes SELE nearGene-5 17463246 rs10489181 chr1 169712597 T C 7.70E-05 Malaria / / 19465909 rs17527744 chr1 169721968 A C 5.03E-05 Type 2 diabetes / / 17463246 rs12145504 chr1 169722279 A G 9.63E-04 Type 2 diabetes / / 17463246 rs4537624 chr1 169725425 G T 5.03E-05 Type 2 diabetes / / 17463246 rs2420505 chr1 169728137 A G 1.16E-04 Type 2 diabetes / / 17463246 rs12128695 chr1 169729450 C T 5.39E-04 Type 2 diabetes / / 17463246 rs17593568 chr1 169734937 T A 4.40E-04 Type 2 diabetes / / 17463246 rs12121606 chr1 169735197 G A 9.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs12121681 chr1 169735399 G C 7.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs12122781 chr1 169736514 G A 1.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs12027035 chr1 169738202 T G 0.000691631 Hypertension (early onset hypertension) / / 22479346 rs2205851 chr1 169739650 C T 1.86E-04 Attention deficit hyperactivity disorder / / 22420046 rs12125023 chr1 169746015 T A 9.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs17593862 chr1 169748286 C T 5.03E-05 Type 2 diabetes / / 17463246 rs17593862 chr1 169748286 C T 9.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs12132633 chr1 169756215 G A 7.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs12130372 chr1 169757316 A G 3.80E-04 Type 2 diabetes / / 17463246 rs12132222 chr1 169758564 A G 3.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs12145417 chr1 169760895 C T 5.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs12145574 chr1 169761370 C T 6.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs12135361 chr1 169761591 A G 4.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs10489177 chr1 169762807 T G 2.67E-04 Celiac disease METTL18 missense 23936387 rs3766135 chr1 169768500 C T 4.28E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs12141572 chr1 169769566 G C 4.04E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs10489176 chr1 169770637 C T 4.27E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs3766138 chr1 169773160 T C 8.60E-04 Type 2 diabetes C1orf112 intron 17463246 rs12143161 chr1 169779664 A G 4.64E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs17529304 chr1 169781291 A G 4.24E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs2420510 chr1 169788584 T C 0.000404 Breast cancer early age of onset C1orf112 intron 18463975 rs12122767 chr1 169790668 G A 3.60E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs12121443 chr1 169792642 A T 3.72E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs3766141 chr1 169792692 T C 3.54E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs2272920 chr1 169799880 G T 8.81E-04 Suicide attempts in bipolar disorder C1orf112 missense 21423239 rs10489174 chr1 169800090 C T 8.82E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs17601631 chr1 169800690 A G 8.79E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs17529791 chr1 169803690 A C 8.82E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs3766143 chr1 169803717 C T 8.84E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs9645329 chr1 169804720 T A 7.73E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs12119635 chr1 169805549 T C 7.67E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs12123432 chr1 169807095 G A 7.50E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs12133074 chr1 169808651 C T 7.49E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs12126591 chr1 169809974 G C 7.48E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs17602051 chr1 169811877 C T 7.49E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs2272919 chr1 169811966 T G 7.49E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs17602072 chr1 169812534 C A 7.32E-04 Suicide attempts in bipolar disorder C1orf112 intron 21423239 rs1046058 chr1 169822543 A G 7.49E-04 Suicide attempts in bipolar disorder SCYL3 UTR-3 21423239 rs12143301 chr1 169823790 C G 7.09E-04 Suicide attempts in bipolar disorder SCYL3 missense 21423239 rs12132384 chr1 169824068 A G 7.10E-04 Suicide attempts in bipolar disorder SCYL3 cds-synon 21423239 rs12135726 chr1 169824104 G A 7.04E-04 Suicide attempts in bipolar disorder SCYL3 cds-synon 21423239 rs12128929 chr1 169826080 A G 8.77E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs17602701 chr1 169828327 G A 7.49E-04 Suicide attempts in bipolar disorder SCYL3 cds-synon 21423239 rs12136425 chr1 169830104 G C 7.49E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs17543611 chr1 169836175 T C 7.49E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12134837 chr1 169836765 A G 7.48E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12135642 chr1 169836946 T C 7.46E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs17543730 chr1 169838715 C T 7.44E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12119368 chr1 169840213 C T 7.47E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12122419 chr1 169843017 C T 7.45E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12141317 chr1 169843436 A G 9.69E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12142093 chr1 169843609 A G 7.49E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12145458 chr1 169843623 G A 7.48E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12143057 chr1 169844093 T C 7.46E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12127500 chr1 169853190 C T 6.11E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs17603570 chr1 169854113 T C 6.11E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12124032 chr1 169855107 C T 5.87E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs17603666 chr1 169856028 T C 5.86E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12144624 chr1 169856622 A T 4.41E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12144683 chr1 169856743 A G 3.65E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs17544586 chr1 169857490 C T 4.40E-04 Suicide attempts in bipolar disorder SCYL3 intron 21423239 rs12131357 chr1 169862064 C G 2.40E-05 Urinary metabolites SCYL3 intron 21572414 rs12124561 chr1 169875679 T C 7.00E-04 Type 2 diabetes / / 17463246 rs12125595 chr1 169876537 T C 7.93E-04 Smoking cessation / / 24665060 rs12125679 chr1 169876817 T A 2.30E-05 Urinary metabolites / / 21572414 rs10919271 chr1 169905053 G A 2.39E-04 Celiac disease KIFAP3 intron 23936387 rs673789 chr1 169908455 G C 5.37E-04 Multiple complex diseases KIFAP3 intron 17554300 rs2806385 chr1 169909254 T G 9.31E-04 Type 2 diabetes KIFAP3 intron 17463246 rs545963 chr1 169937418 C T 2.30E-06 Urinary metabolites KIFAP3 intron 21572414 rs41496844 chr1 169945664 A G 6.61E-04 Multiple complex diseases KIFAP3 intron 17554300 rs654664 chr1 169946436 C T 1.80E-05 Urinary metabolites KIFAP3 intron 21572414 rs12124907 chr1 169980811 C A 2.30E-05 Urinary metabolites KIFAP3 intron 21572414 rs12123693 chr1 169985324 C T 9.46E-05 Celiac disease KIFAP3 intron 23936387 rs1541160 chr1 169995802 C T 2.00E-08 Amyotrophic lateral sclerosis KIFAP3 intron 19451621 rs10800495 chr1 169998200 C T 7.18E-05 Celiac disease KIFAP3 intron 23936387 rs1415551 chr1 170002212 T C 1.77E-04 Celiac disease KIFAP3 intron 23936387 rs16862968 chr1 170002561 T C 1.30E-05 Urinary metabolites KIFAP3 intron 21572414 rs4656732 chr1 170004722 G A 1.46E-04 Multiple complex diseases KIFAP3 intron 17554300 rs1928887 chr1 170007869 A C 6.75E-04 Type 2 diabetes KIFAP3 intron 17463246 rs1928887 chr1 170007869 A C 6.39E-05 Multiple complex diseases KIFAP3 intron 17554300 rs10494479 chr1 170027498 G A 1.50E-05 Urinary metabolites KIFAP3 intron 21572414 rs12146137 chr1 170037624 C T 9.64E-05 Celiac disease KIFAP3 UTR-5 23936387 rs12141613 chr1 170044163 A G 2.40E-05 Urinary metabolites KIFAP3 nearGene-5 21572414 rs10919298 chr1 170064344 T C 9.24E-06 Waist-hip ratio / / 20935629 rs16863031 chr1 170070827 G A 1.89E-06 Waist-hip ratio / / 20935629 rs12042109 chr1 170085453 C A 6.15E-04 Alzheimer's disease / / 17998437 rs16863069 chr1 170126741 A C 2.80E-05 Cognitive function METTL11B intron 24684796 rs495524 chr1 170128608 A T 2.00E-06 Methotrexate phramacokinetics (acute lymphoblastic leukemia) METTL11B intron 19901119 rs551042 chr1 170132339 C T 8.49E-06 C-reactive protein METTL11B intron 22492993 rs10158534 chr1 170172417 T G 4.61E-04 Alcohol dependence / / 20201924 rs10919328 chr1 170177483 G C 5.70E-06 Urinary metabolites / / 21572414 rs12116424 chr1 170186354 G A 2.50E-05 Urinary metabolites / / 21572414 rs3936027 chr1 170187033 G T 1.04E-11 Multiple complex diseases / / 17554300 rs1412787 chr1 170208724 C T 4.10E-04 Alcohol dependence / / 20201924 rs12122745 chr1 170210475 T C 2.96E-04 Multiple complex diseases / / 17554300 rs10919335 chr1 170213020 C G 1.90E-07 Urinary metabolites / / 21572414 rs6701383 chr1 170312674 A G 8.06E-04 Multiple complex diseases / / 17554300 rs1412795 chr1 170319649 G A 7.05E-05 Blood Pressure / / pha003040 rs1930538 chr1 170330773 C T 9.88E-06 Waist-hip ratio / / 20935629 rs6427247 chr1 170380480 A G 4.92E-04 Diabetic retinopathy / / 20871662 rs6427260 chr1 170517184 A G 6.36E-04 Multiple complex diseases GORAB intron 17554300 rs3903239 chr1 170569317 A G 8.00E-14 Atrial fibrillation / / 22544366 rs17549441 chr1 170592126 C A 8.02E-04 Smoking quantity / / 24665060 rs659580 chr1 170633896 T C 1.00E-06 Response to angiotensin II receptor blocker therapy PRRX1 intron 22566498 rs489090 chr1 170661764 C A 7.59E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) PRRX1 intron 22566498 rs2187895 chr1 170684431 G C 7.01E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) PRRX1 intron 22566498 rs6701640 chr1 170696474 A C 5.32E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) PRRX1 intron 22566498 rs12409048 chr1 170699149 G A 7.10E-05 HIV-1 control PRRX1 intron 20041166 rs3820416 chr1 170707675 T C 6.02E-05 HIV-1 control PRRX1 UTR-3 20041166 rs4656797 chr1 170708637 C G 5.50E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) PRRX1 nearGene-3 22566498 rs16863548 chr1 170709358 T C 5.71E-04 Multiple complex diseases / / 17554300 rs6679313 chr1 170715110 A G 1.68E-04 Body mass index / / 17255346 rs2421494 chr1 170715531 G A 8.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs991230 chr1 170719187 G A 7.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10800542 chr1 170764915 T G 1.48E-04 Body mass index / / 17255346 rs2143109 chr1 170773031 A G 2.48E-04 Body mass index / / 17255346 rs10737555 chr1 170795855 A C 9.79E-04 Multiple complex diseases / / 17554300 rs6677161 chr1 170797204 C T 6.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10489239 chr1 170856852 C T 3.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs10489241 chr1 170858095 T C 3.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs12038181 chr1 170860531 C T 3.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs6681815 chr1 170894922 T C 6.06E-04 Type 2 diabetes / / 17463246 rs139086068 chr1 170965700 G A 0.00067 Prostate cancer C1orf129 missense 23555315 rs16863938 chr1 170984413 T C 0.000619 Salmonella-induced pyroptosis C1orf129 intron 22837397 rs2204792 chr1 170987278 T C 6.14E-05 HIV-1 viral setpoint C1orf129 intron 22174851 rs16864042 chr1 171079005 G T 8.71E-06 Schizophrenia FMO3 intron 20185149 rs7051320 chr1 171079700 C T 4.98E-04 Alcohol dependence FMO3 intron 21314694 rs7061710 chr1 171080615 G C 8.00E-14 Blood metabolite levels FMO3 intron 24816252 rs2266780 chr1 171083242 A G 1.13E-05 Schizophrenia FMO3 missense 20185149 rs12089338 chr1 171088560 T C 1.21E-05 Prion diseases / / 22210626 rs1795240 chr1 171091875 A G 5.00E-08 Lentiform nucleus volume / / 22903471 rs2281006 chr1 171110869 G T 2.10E-05 Schizophrenia FMO6P intron 20185149 rs7063044 chr1 171116760 C T 9.00E-06 Schizophrenia FMO6P intron 20185149 rs6608452 chr1 171117113 C T 9.73E-06 Schizophrenia FMO6P intron 20185149 rs7879557 chr1 171117341 A T 5.51E-06 Schizophrenia FMO6P intron 20185149 rs16864136 chr1 171133889 C A 4.86E-04 Lymphocyte counts / / 22286170 rs7545752 chr1 171148521 G A 9.02E-04 Alzheimer's disease / / 22005930 rs12752688 chr1 171151638 C T 3.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7512785 chr1 171179287 C T 4.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FMO2 UTR-3 20877124 rs10912593 chr1 171188057 C T 3.00E-05 Anger / / 24489884 rs7551531 chr1 171214880 G A 5.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7551531 chr1 171214880 G A 8.88E-05 Potassium levels / / pha003086 rs16864314 chr1 171251196 A G 1.55E-04 Multiple complex diseases FMO1 missense 17554300 rs10798304 chr1 171258642 C T 6.73E-05 Bipolar Disorder / / pha002863 rs6660565 chr1 171261193 G A 2.00E-06 Sudden cardiac arrest / / 21658281 rs11576306 chr1 171312508 A G 2.66E-04 Alzheimer's disease (late onset) / / 21379329 rs1018391 chr1 171340430 T C 2.16E-05 Sudden cardiac arrest / / 21658281 rs10912887 chr1 171364141 C T 7.31E-05 Lipoproteins / / pha003079 rs10737306 chr1 171366426 A T 1.80E-06 Urinary metabolites / / 21572414 rs7523796 chr1 171391273 C A 4.63E-04 Myopia (pathological) / / 21095009 rs17644596 chr1 171393826 G C 1.20E-05 Urinary metabolites / / 21572414 rs12122751 chr1 171394149 A G 3.54E-04 Coronary heart disease / / 21606135 rs10912988 chr1 171400498 C T 5.53E-04 Multiple complex diseases / / 17554300 rs960845 chr1 171413250 A G 3.13E-04 Alzheimer's disease / / 17998437 rs4916386 chr1 171449207 T C 7.96E-05 Myopia (severe) / / 23933737 rs10913149 chr1 171472188 A G 2.17E-05 Lung function (forced expiratory volume in 1 second) PRRC2C intron pha003102 rs4384265 chr1 171478523 G A 5.43E-06 Myopia (severe) PRRC2C intron 23933737 rs2038042 chr1 171481592 G A 6.13E-06 Myopia (severe) PRRC2C intron 23933737 rs10913157 chr1 171486912 G A 0.00073 Prostate cancer PRRC2C missense 23555315 rs10913157 chr1 171486912 G A 2.17E-05 Lung function (forced expiratory volume in 1 second) PRRC2C missense pha003102 rs2272810 chr1 171511442 A G 2.47E-04 Multiple complex diseases PRRC2C intron 17554300 rs2421847 chr1 171557600 A G 9.00E-07 Alzheimer's disease (cognitive decline) PRRC2C missense 23535033 rs929115 chr1 171591189 T G 6.88E-04 Type 2 diabetes / / 20818381 rs12035960 chr1 171615206 C T 8.11E-05 Height MYOC intron pha003011 rs235913 chr1 171618656 T G 6.71E-04 White matter integrity MYOC intron 22425255 rs11800109 chr1 171639099 T C 1.46E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs11576221 chr1 171653696 A G 9.22E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12081515 chr1 171680631 A G 8.70E-05 Bipolar disorder and schizophrenia VAMP4 intron 20889312 rs1001373 chr1 171684506 G A 9.77E-05 Erythrocyte counts VAMP4 intron pha003099 rs10913582 chr1 171715585 G A 6.50E-04 Smoking initiation / / 24665060 rs17649250 chr1 171720586 G C 5.93E-07 Lymphocyte counts / / 22286170 rs17650204 chr1 171755071 A G 7.76E-04 Iron levels METTL13 cds-synon pha002876 rs6668165 chr1 171794638 G C 5.13E-04 Multiple complex diseases / / 17554300 rs10753196 chr1 171797810 A G 3.12E-06 Cognitive test performance / / 20125193 rs6683945 chr1 171840264 G A 1.45E-05 Insulin-related traits DNM3 intron 19902172 rs12121064 chr1 171863472 T G 7.03E-05 Body Mass Index DNM3 intron pha003015 rs10798751 chr1 171889347 T G 9.72E-04 Multiple complex diseases DNM3 intron 17554300 rs2093184 chr1 171892085 G A 9.61E-04 Alzheimer's disease DNM3 intron 17998437 rs6673413 chr1 171896950 T C 7.01E-06 Lipid traits DNM3 intron 21777205 rs2038479 chr1 171939290 C A 1.34E-09 Metabolite levels DNM3 intron 23281178 rs6425521 chr1 171942783 C A 1.32E-06 Kawasaki disease DNM3 intron 21221998 rs10914127 chr1 171943948 A G 1.07E-09 Metabolite levels DNM3 intron 23281178 rs2180748 chr1 171947018 T G 2.00E-08 Mean platelet volume DNM3 intron 24026423 rs10914141 chr1 171947316 G T 1.05E-05 Multiple complex diseases DNM3 intron 17554300 rs10914144 chr1 171949750 T C 2.00E-14 Mean platelet volume DNM3 intron 19820697 rs10914144 chr1 171949750 T C 1.00E-24 Mean platelet volume DNM3 intron 22139419 rs10914144 chr1 171949750 T C 2.00E-12 Platelet counts DNM3 intron 22139419 rs10914144 chr1 171949750 T C 2.10E-14 Mean platelet volume DNM3 intron 22423221 rs10914144 chr1 171949750 T C 1.49E-08 Metabolite levels DNM3 intron 23281178 rs10914144 chr1 171949750 T C 2.00E-08 Mean platelet volume DNM3 intron 24026423 rs2208370 chr1 171955331 G A 2.00E-04 Cognitive impairment induced by topiramate DNM3 intron 22091778 rs17346452 chr1 172053287 T C 1.00E-23 Height DNM3 intron 20881960 rs4244192 chr1 172072635 A G 6.37E-04 Alzheimer's disease DNM3 intron 17998437 rs4604727 chr1 172090738 C G 1 Drug response to Etoposide DNM3 intron 17537913 rs2421987 chr1 172100831 G A 3.50E-05 Endometriosis DNM3 intron 21151130 rs2421987 chr1 172100831 G A 9.10E-05 Monocyte chemoattractant protein-1 DNM3 intron pha003071 rs10911111 chr1 172117680 A G 3.90E-04 Alzheimer's disease DNM3 intron 17998437 rs10911112 chr1 172118780 G A 6.59E-05 Monocyte chemoattractant protein-1 DNM3 intron pha003071 rs2146901 chr1 172119559 T C 1.60E-04 Endometriosis DNM3 intron 21151130 rs2146901 chr1 172119559 T C 3.78E-05 Monocyte chemoattractant protein-1 DNM3 intron pha003071 rs2181624 chr1 172119582 C G 1.43E-04 Alzheimer's disease DNM3 intron 17998437 rs10797791 chr1 172121859 G A 6.16E-04 Alzheimer's disease DNM3 intron 17998437 rs10797791 chr1 172121859 G A 6.78E-05 Monocyte chemoattractant protein-1 DNM3 intron pha003071 rs650169 chr1 172188062 C T 7.12E-04 Type 2 diabetes DNM3 intron 17463246 rs678962 chr1 172189889 T G 3.00E-08 Height DNM3 intron 18391951 rs678962 chr1 172189889 T G 6.97E-05 Cognitive test performance DNM3 intron 20125193 rs479336 chr1 172199573 T G 9.00E-15 Bone mineral density DNM3 intron 22504420 rs12075079 chr1 172219995 A G 8.24E-05 Cognitive test performance DNM3 intron 20125193 rs12075079 chr1 172219995 A G 7.00E-12 Height DNM3 intron 23563607 rs10489290 chr1 172223403 C A 4.86E-05 Cognitive test performance DNM3 intron 20125193 rs2421992 chr1 172241251 C T 5.00E-08 Height DNM3 intron 20881960 rs12139001 chr1 172241820 G C 1.14E-05 Smoking behavior DNM3 intron 20418889 rs4619005 chr1 172257261 C A 1.38E-05 Smoking behavior DNM3 intron 20418889 rs2757490 chr1 172264401 C T 7.08E-04 Depression (quantitative trait) DNM3 intron 20800221 rs2757493 chr1 172267419 T C 1.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DNM3 intron 20877124 rs16844255 chr1 172271050 C T 5.16E-05 Cognitive test performance DNM3 intron 20125193 rs17368984 chr1 172318558 T C 2.20E-05 Urinary metabolites DNM3 intron 21572414 rs6676665 chr1 172346174 C A 6.29E-04 Type 2 diabetes DNM3 intron 17463246 rs6676665 chr1 172346174 C A 0.00000016 Inter-adventitial common carotid artery diameter DNM3 intron 23246012 rs4916251 chr1 172346396 T A 4.10E-04 Type 2 diabetes DNM3 intron 17463246 rs4916251 chr1 172346396 T A 0.000000188 Inter-adventitial common carotid artery diameter DNM3 intron 23246012 rs4916251 chr1 172346396 T A 0.00065 Abdominal aortic aneurysm DNM3 intron 23246012 rs1011731 chr1 172346548 G A 9.58E-05 Multiple sclerosis DNM3 intron 17660530 rs1011731 chr1 172346548 G A 1.00E-17 Waist-hip ratio DNM3 intron 20935629 rs3213564 chr1 172349921 G A 0.000000327 Inter-adventitial common carotid artery diameter DNM3 intron 23246012 rs9425586 chr1 172351052 T C 6.40E-04 Type 2 diabetes DNM3 intron 17463246 rs9425586 chr1 172351052 T C 0.000000158 Inter-adventitial common carotid artery diameter DNM3 intron 23246012 rs1023479 chr1 172355132 G A 7.02E-04 Type 2 diabetes DNM3 intron 17463246 rs1023479 chr1 172355132 G A 0.000000159 Inter-adventitial common carotid artery diameter DNM3 intron 23246012 rs2213731 chr1 172359815 C A 0.000000208 Inter-adventitial common carotid artery diameter DNM3 intron 23246012 rs2227198 chr1 172360164 A G 2.21E-04 Substance dependence DNM3 intron 21818250 rs3768445 chr1 172362949 G T 8.15E-08 Inter-adventitial common carotid artery diameter DNM3 intron 23246012 rs10489284 chr1 172367062 A G 6.19E-04 Suicide attempts in bipolar disorder DNM3 intron 21041247 rs4471302 chr1 172367137 T C 6.13E-04 Suicide attempts in bipolar disorder DNM3 intron 21041247 rs6698987 chr1 172368967 T C 5.41E-04 Type 2 diabetes DNM3 intron 17463246 rs6698987 chr1 172368967 T C 1.76E-04 Alcohol dependence DNM3 intron 21314694 rs1063412 chr1 172410967 G A 0.000000014 Soluble CD14 PIGC missense 23162014 rs4916266 chr1 172450795 C A 1.66E-04 Multiple complex diseases / / 17554300 rs16844585 chr1 172453197 T G 0.00000855 Inter-adventitial common carotid artery diameter / / 23246012 rs2213736 chr1 172464497 C T 6.97E-04 Multiple complex diseases / / 17554300 rs10489279 chr1 172498216 G A 0.000789097 Hypertension (early onset hypertension) / / 22479346 rs7518180 chr1 172583137 C T 0.000000176 Triglycerides / / 23063622 rs2859242 chr1 172624864 C T 6.73E-05 Alcohol dependence / / 20201924 rs2859242 chr1 172624864 C T 6.73E-05 Alcoholism / / pha002891 rs10458360 chr1 172633975 G C 4.27E-04 Type 2 diabetes FASLG intron 17463246 rs6673027 chr1 172645898 C T 7.09E-05 Blood Pressure / / pha003049 rs859670 chr1 172673322 C A 6.08E-04 Multiple complex diseases / / 17554300 rs12068671 chr1 172681031 T C 1.40E-10 Celiac disease / / 22057235 rs859637 chr1 172711000 T C 2.00E-06 Celiac disease / / 20190752 rs859624 chr1 172730829 T C 2.70E-05 Allergic sensitization / / 23817571 rs11810332 chr1 172789765 A G 1.58E-05 Asthma / / pha003128 rs10912477 chr1 172795995 A C 1.49E-04 Type 2 diabetes / / 17463246 rs10912477 chr1 172795995 A C 7.78E-04 Tourette syndrome / / 22889924 rs10912477 chr1 172795995 A C 1.57E-05 Asthma / / pha003128 rs12037853 chr1 172852403 A G 9.46E-05 Multiple complex diseases / / 17554300 rs7517810 chr1 172853460 C T 2.00E-15 Crohn's disease / / 21102463 rs9286879 chr1 172862234 A G 2.00E-09 Crohn's disease / / 18587394 rs9286879 chr1 172862234 A G 2.00E-09 Asthma / / 21150878 rs9286879 chr1 172862234 A G 1.53E-09 Multiple sclerosis / / 22190364 rs9286879 chr1 172862234 A G 6.00E-22 Crohn's disease / / 23128233 rs9286879 chr1 172862234 A G 8.25E-07 Celiac disease / / 24999842 rs10489276 chr1 172862939 C T 3.98E-05 Multiple complex diseases / / 17554300 rs10489276 chr1 172862939 C T 9.01E-08 Crohn's disease / / 18587394 rs2157453 chr1 172863948 G A 8.00E-07 Celiac disease / / 24999842 rs12142280 chr1 172864652 T A 8.30E-09 Celiac disease / / 22057235 rs4145469 chr1 172874991 C G 1.60E-06 Multiple complex diseases / / 17554300 rs6688532 chr1 172892952 A C 8.16E-07 Multiple complex diseases / / 17554300 rs12035082 chr1 172898377 T C 2.00E-07 Crohn's disease / / 17554261 rs12035082 chr1 172898377 T C 3.97E-07 Multiple complex diseases / / 17554300 rs12037606 chr1 172898402 G A 3.37E-07 Multiple complex diseases / / 17554300 rs7517726 chr1 172913577 C G 1.99E-06 Multiple complex diseases / / 17554300 rs4916290 chr1 172914284 G C 2.14E-05 Multiple complex diseases / / 17554300 rs16845215 chr1 172942014 G A 1.90E-05 Multiple complex diseases / / 17554300 rs6693531 chr1 172948860 C T 3.02E-04 Multiple complex diseases / / 17554300 rs6697964 chr1 172962496 G A 5.82E-04 Multiple complex diseases / / 17554300 rs2092357 chr1 172973645 G A 9.45E-05 Panic disorder / / 19165232 rs6425196 chr1 172981545 A G 8.19E-04 Diabetic retinopathy / / 20871662 rs12122495 chr1 172982715 C G 1.54E-04 Multiple complex diseases / / 17554300 rs12117214 chr1 172985389 G A 1.34E-04 Multiple complex diseases / / 17554300 rs1033465 chr1 172987730 T A 1.56E-04 Multiple complex diseases / / 17554300 rs16845306 chr1 173008568 T C 7.14E-04 Multiple complex diseases / / 17554300 rs9286880 chr1 173018680 T G 2.62E-08 Metabolite levels TNFSF18 intron 23281178 rs7537126 chr1 173021349 T C 5.66E-04 Diabetic retinopathy / / 20871662 rs4916297 chr1 173037763 C T 9.83E-09 Metabolite levels / / 23281178 rs2422272 chr1 173049073 G A 1.41E-08 Metabolite levels / / 23281178 rs202148845 chr1 173050272 G GA 2.91E-08 Metabolite levels / / 23281178 rs2223833 chr1 173050272 G A 2.91E-08 Metabolite levels / / 23281178 rs2207060 chr1 173055263 A C 6.17E-09 Metabolite levels / / 23281178 rs6425203 chr1 173064279 C T 1.25E-08 Metabolite levels / / 23281178 rs974363 chr1 173071389 G T 8.11E-09 Metabolite levels / / 23281178 rs6674831 chr1 173075630 G A 9.43E-09 Metabolite levels / / 23281178 rs10912533 chr1 173079943 C T 7.93E-09 Metabolite levels / / 23281178 rs4916306 chr1 173085211 T G 9.41E-09 Metabolite levels / / 23281178 rs12034497 chr1 173092191 A G 7.99E-09 Metabolite levels / / 23281178 rs6663179 chr1 173110953 A G 4.20E-04 Multiple complex diseases / / 17554300 rs10912551 chr1 173119967 G T 9.91E-04 Acute lung injury / / 22295056 rs7553711 chr1 173131908 T C 4.08E-08 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs10157163 chr1 173132965 C T 9.67E-08 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs6665456 chr1 173140765 T C 0.000000074 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs16845506 chr1 173141800 T A,G 0.0000049 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs6676785 chr1 173145017 A G 8.08E-08 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs4916312 chr1 173146357 G A 0.000000099 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs4090391 chr1 173147090 C T 7.73E-08 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs10127495 chr1 173148671 A C 8.49E-08 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs11811788 chr1 173150727 C G 4.23E-04 Acute lung injury / / 22295056 rs11811788 chr1 173150727 C G 0.00003 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs10127727 chr1 173150964 G A 0.00000561 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs6691738 chr1 173152036 T G 9.88E-08 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs7514229 chr1 173154304 G T 1.92E-04 Acute lung injury TNFSF4 UTR-3 22295056 rs3861950 chr1 173156292 T C 2.71E-04 Acute lung injury TNFSF4 intron 22295056 rs3861950 chr1 173156292 T C 5.42E-08 Narcolepsy (non-HLA narcolepsy) TNFSF4 intron 23459209 rs4081545 chr1 173159516 T C 2.94E-04 Acute lung injury TNFSF4 intron 22295056 rs4081545 chr1 173159516 T C 0.000000073 Narcolepsy (non-HLA narcolepsy) TNFSF4 intron 23459209 rs10465507 chr1 173162439 C A 0.00000633 Narcolepsy (non-HLA narcolepsy) TNFSF4 intron 23459209 rs10798264 chr1 173163357 G A 0.00000726 Narcolepsy (non-HLA narcolepsy) TNFSF4 intron 23459209 rs10912560 chr1 173164457 A G 0.0000139 Narcolepsy (non-HLA narcolepsy) TNFSF4 intron 23459209 rs10912561 chr1 173164565 C T 0.00000657 Narcolepsy (non-HLA narcolepsy) TNFSF4 intron 23459209 rs4916313 chr1 173164787 T C 0.000000157 Narcolepsy (non-HLA narcolepsy) TNFSF4 intron 23459209 rs13343108 chr1 173168230 T C 0.0000171 Narcolepsy (non-HLA narcolepsy) TNFSF4 intron 23459209 rs7525284 chr1 173168397 G A 4.69E-04 Acute lung injury TNFSF4 intron 22295056 rs7525284 chr1 173168397 G A 0.0000119 Narcolepsy (non-HLA narcolepsy) TNFSF4 intron 23459209 rs10912564 chr1 173170618 C T 3.76E-04 Acute lung injury TNFSF4 intron 22295056 rs11811856 chr1 173171673 C G 7.02E-04 Acute lung injury TNFSF4 intron 22295056 rs11811856 chr1 173171673 C G 0.0000287 Narcolepsy (non-HLA narcolepsy) TNFSF4 intron 23459209 rs2205960 chr1 173191475 G T 3.00E-32 Systemic lupus erythematosus / / 19838193 rs2205960 chr1 173191475 G T 6.30E-09 Multiple sclerosis / / 22190364 rs2205960 chr1 173191475 G T 3.00E-12 Systemic lupus erythematosus / / 23273568 rs2205960 chr1 173191475 G T 7.82E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1012507 chr1 173219471 G T 1.60E-10 Systemic lupus erythematosus LOC100506023 intron 23273568 rs844648 chr1 173223863 G A 7.90E-08 Systemic lupus erythematosus LOC100506023 intron 23273568 rs704840 chr1 173226195 T G 1.90E-10 Systemic lupus erythematosus LOC100506023 intron 23273568 rs704840 chr1 173226195 T G 4.00E-07 Systemic lupus erythematosus and Systemic sclerosis LOC100506023 intron 23740937 rs844656 chr1 173235835 T G 7.90E-05 Alcoholism (heaviness of drinking) LOC100506023 intron 21529783 rs10489265 chr1 173236065 A C 7.60E-12 Systemic lupus erythematosus LOC100506023 intron 23273568 rs10798267 chr1 173266444 T C 3.77E-05 Diabetes Mellitus LOC100506023 intron pha003059 rs6685520 chr1 173278169 G A 4.30E-05 Personality dimensions LOC100506023 intron 18957941 rs6685520 chr1 173278169 G A 9.91E-05 Blood pressure (response to calcium channel blocker) LOC100506023 intron 24192120 rs4916321 chr1 173284199 G T 7.00E-06 Multiple sclerosis LOC100506023 intron 23412934 rs61828284 chr1 173299743 C T 0.00000547 Rheumatoid arthritis (CCP positive) LOC100506023 intron 23143596 rs61828284 chr1 173299743 C T 0.0000568 Rheumatoid arthritis LOC100506023 intron 23143596 rs17346536 chr1 173300840 A G 4.10E-06 Diabetic retinopathy LOC100506023 intron 21441570 rs1342038 chr1 173301516 G A 4.00E-06 Diabetic retinopathy LOC100506023 intron 21441570 rs10798269 chr1 173309713 A G 1.00E-07 Systemic lupus erythematosus LOC100506023 intron 18204446 rs1539259 chr1 173312501 T G 8.58E-04 Amyotrophic Lateral Sclerosis LOC100506023 intron 17362836 rs1857066 chr1 173332629 A C 2.32E-09 Systemic lupus erythematosus and Systemic sclerosis LOC100506023 intron 23740937 rs17350697 chr1 173333916 C T 1.90E-04 Attention deficit hyperactivity disorder LOC100506023 intron pha002875 rs2105325 chr1 173349725 A C 3.00E-11 Rheumatoid arthritis LOC100506023 intron 24390342 rs2105325 chr1 173349725 A C 7.00E-13 Rheumatoid arthritis LOC100506023 intron 24390342 rs6701588 chr1 173353159 G A 4.21E-05 Asthma LOC100506023 intron 22561531 rs1557121 chr1 173353881 T C 7.70E-06 Myasthenia gravis LOC100506023 intron 23055271 rs4294450 chr1 173389640 C T 1.66E-04 Response to taxane treatment (placlitaxel) LOC100506023 intron 23006423 rs3934576 chr1 173398436 T C 1.66E-04 Response to taxane treatment (placlitaxel) LOC100506023 intron 23006423 rs3934575 chr1 173398533 T C 1.66E-04 Response to taxane treatment (placlitaxel) LOC100506023 intron 23006423 rs6660804 chr1 173438399 C A 7.89E-04 Response to taxane treatment (placlitaxel) LOC100506023 intron 23006423 rs912767 chr1 173456445 A G 6.59E-04 Response to taxane treatment (placlitaxel) PRDX6 intron 23006423 rs7521536 chr1 173465265 T C 3.46E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12065426 chr1 173470105 A G 3.61E-04 Response to taxane treatment (placlitaxel) SLC9A11 UTR-3 23006423 rs12037210 chr1 173474773 C T 7.85E-04 Smoking quantity SLC9A11 intron 24665060 rs16846125 chr1 173497712 A G 3.85E-04 Multiple complex diseases SLC9A11 intron 17554300 rs6425246 chr1 173516245 A G 9.16E-04 Multiple complex diseases SLC9A11 intron 17554300 rs12027862 chr1 173532805 G A 5.01E-04 Multiple complex diseases SLC9A11 intron 17554300 rs898658 chr1 173541768 T C 7.69E-04 Multiple complex diseases SLC9A11 intron 17554300 rs898657 chr1 173542017 G T 6.60E-04 Multiple complex diseases SLC9A11 intron 17554300 rs6691482 chr1 173542864 T C 2.17E-06 Cognition,early reading ability SLC9A11 intron 17684495 rs6691482 chr1 173542864 T C 4.00E-05 Breast cancer and prostate cancer SLC9A11 intron 17903305 rs6684491 chr1 173551720 A T 1.38E-05 Age-related macular degeneration SLC9A11 intron pha000001 rs6678784 chr1 173574871 A G 4.80E-06 Age-related macular degeneration / / pha000001 rs12065033 chr1 173579034 C T 3.39E-06 Age-related macular degeneration ANKRD45 UTR-3 pha000001 rs7550036 chr1 173682365 G A 1.44E-05 Age-related macular degeneration / / pha000001 rs10912671 chr1 173689891 A G 1.87E-04 Type 2 diabetes KLHL20 intron 17463246 rs6425256 chr1 173722545 A G 5.62E-04 Multiple complex diseases KLHL20 intron 17554300 rs16846395 chr1 173725101 G A 1.28E-05 Multiple complex diseases KLHL20 cds-synon 17554300 rs16846398 chr1 173725376 C G 5.65E-04 Multiple complex diseases KLHL20 intron 17554300 rs7536773 chr1 173735378 T C 1.44E-05 Age-related macular degeneration KLHL20 cds-synon pha000001 rs6692452 chr1 173754505 A G 1.44E-05 Age-related macular degeneration KLHL20 UTR-3 pha000001 rs2144708 chr1 173780119 A G 7.02E-05 Type 2 diabetes CENPL intron 17463246 rs3791020 chr1 173813197 G A 5.71E-07 Type 2 diabetes DARS2 intron 17463246 rs6691327 chr1 173813448 T G 4.10E-04 Multiple complex diseases DARS2 intron 17554300 rs6691327 chr1 173813448 T G 1.44E-05 Age-related macular degeneration DARS2 intron pha000001 rs2295366 chr1 173825692 T G 1.17E-06 Type 2 diabetes DARS2 intron 17463246 rs2065170 chr1 173845232 T C 9.26E-05 Cholesterol ZBTB37 intron 17255346 rs35571466 chr1 173852874 A G 3.92E-04 Type 2 diabetes ZBTB37 intron 17463246 rs9425766 chr1 173853127 T C 4.62E-04 Type 2 diabetes ZBTB37 intron 17463246 rs16846526 chr1 173856237 G A 9.10E-05 Cholesterol / / 17255346 rs9425430 chr1 173857283 A G 4.85E-04 Type 2 diabetes / / 17463246 rs16846546 chr1 173860182 T C 8.55E-05 Cholesterol / / 17255346 rs10489894 chr1 173866024 A G 2.81E-04 Type 2 diabetes / / 17463246 rs6691053 chr1 173868955 C T 2.37E-05 Educational attainment / / 21694764 rs9425436 chr1 173870364 G A 3.30E-04 Type 2 diabetes / / 17463246 rs2227611 chr1 173875467 A G 4.06E-08 LDL cholesterol SERPINC1 intron 23063622 rs2759328 chr1 173876705 C T 1.44E-04 Cholesterol SERPINC1 intron 17255346 rs5878 chr1 173878832 T C 6.24E-04 Type 2 diabetes SERPINC1 cds-synon 17463246 rs5878 chr1 173878832 T C 4.05E-04 Multiple complex diseases SERPINC1 cds-synon 17554300 rs941989 chr1 173881871 C T 7.39E-04 Type 2 diabetes SERPINC1 intron 17463246 rs941988 chr1 173881893 C T 7.77E-05 Cholesterol SERPINC1 intron 17255346 rs2227589 chr1 173886216 C T 7.11E-05 Cholesterol SERPINC1 intron 17255346 rs1951627 chr1 173891817 G A 5.44E-05 Lymphocyte counts / / 22286170 rs10912711 chr1 173961992 T C 8.37E-04 Multiple complex diseases RC3H1 cds-synon 17554300 rs10912742 chr1 174160343 C T 1.89E-07 Multiple complex diseases RABGAP1L intron 17554300 rs16846809 chr1 174219398 A G 6.70E-04 Asthma RABGAP1L intron 20698975 rs6670617 chr1 174246712 C A 8.65E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) RABGAP1L intron 23648065 rs4650989 chr1 174258877 G A 3.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) RABGAP1L intron 23648065 rs7555067 chr1 174266642 C T 8.61E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) RABGAP1L intron 23648065 rs17301013 chr1 174312813 C T 5.19E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) RABGAP1L intron 23648065 rs12094364 chr1 174356463 C A 1.38E-04 Multiple complex diseases RABGAP1L intron 17554300 rs10489257 chr1 174359128 G A 1.40E-04 Multiple complex diseases RABGAP1L intron 17554300 rs17373189 chr1 174369767 A G 3.90E-05 Anger RABGAP1L intron 24489884 rs10489261 chr1 174440683 C T 1.10E-04 Asthma RABGAP1L intron 20698975 rs12088073 chr1 174497642 A C 5.18E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) RABGAP1L intron 23648065 rs6425284 chr1 174499977 G A 3.62E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) RABGAP1L intron 23648065 rs6425284 chr1 174499977 G A 7.79E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) RABGAP1L intron 23648065 rs17301853 chr1 174552811 C T 1.00E-06 Migraine without aura RABGAP1L intron 23793025 rs17301853 chr1 174552811 C T 7.00E-06 Migraine - clinic-based RABGAP1L intron 23793025 rs6664864 chr1 174592050 A G 2.56E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) RABGAP1L intron 23648065 rs6692753 chr1 174737457 G T 4.20E-04 Asthma RABGAP1L intron 20698975 rs3018410 chr1 174818547 A G 3.61E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) RABGAP1L intron 23648065 rs3753563 chr1 174923346 T C 7.70E-05 Alcoholism (heaviness of drinking) RABGAP1L intron 21529783 rs6686962 chr1 174953569 C A 2.63E-04 Birth weight RABGAP1L intron 17255346 rs10912870 chr1 174988016 C T 7.25E-04 Response to taxane treatment (placlitaxel) MRPS14 intron 23006423 rs12409660 chr1 175022207 G C 1.79E-05 Suicide attempts in bipolar disorder / / 21041247 rs1009418 chr1 175029547 A T 7.12E-05 Birth weight / / 17255346 rs10798331 chr1 175034437 A G 4.63E-05 Suicide attempts in bipolar disorder / / 21041247 rs10912878 chr1 175034643 A T 1.77E-05 Suicide attempts in bipolar disorder / / 21041247 rs16847812 chr1 175049379 G A 8.16E-04 Fibrinogen TNN missense 17255346 rs7521981 chr1 175091151 G A 2.60E-05 Urinary metabolites TNN intron 21572414 rs2072041 chr1 175092840 T C 8.34E-04 Rheumatoid arthritis TNN intron 21452313 rs12094153 chr1 175094025 G A 5.49E-05 Alcohol dependence TNN intron 21703634 rs4651322 chr1 175104719 T C 7.98E-04 Rheumatoid arthritis TNN intron 21452313 rs2072038 chr1 175105778 T C 3.40E-05 HIV-1 control TNN intron 20041166 rs2157588 chr1 175107826 C T 7.16E-05 Alcohol dependence TNN intron 21703634 rs12135071 chr1 175117548 C T 7.44E-05 Epilepsy (remission after treatment) / / 23962720 rs6701037 chr1 175120079 A C 1.75E-06 Alcohol dependence / / 20202923 rs6701037 chr1 175120079 A C 2.00E-07 Alcohol dependence / / 21703634 rs6701037 chr1 175120079 A C 2.30E-04 Alcohol dependence / / 21956439 rs6701037 chr1 175120079 A C 0.0000331 Central corneal thickness in patients with an IOP <= 21mmHg and no history of IOP>= 21mmHg / / 22661486 rs73032636 chr1 175122587 C T 7.30E-05 Epilepsy (remission after treatment) / / 23962720 rs56237830 chr1 175124377 C T 8.70E-05 Epilepsy (remission after treatment) / / 23962720 rs6425323 chr1 175125036 C T 2.27E-06 Alcohol dependence / / 20202923 rs6425323 chr1 175125036 C T 3.13E-07 Alcohol dependence / / 21703634 rs6425323 chr1 175125036 C T 2.80E-04 Alcohol dependence / / 21956439 rs1057302 chr1 175126423 A G 1.94E-06 Alcohol dependence KIAA0040 UTR-3 20202923 rs1057302 chr1 175126423 A G 5.12E-07 Alcohol dependence KIAA0040 UTR-3 21703634 rs1057302 chr1 175126423 A G 6.20E-04 Alcohol dependence KIAA0040 UTR-3 21956439 rs1057285 chr1 175126845 T C 2.86E-05 Epilepsy (remission after treatment) KIAA0040 UTR-3 23962720 rs4650716 chr1 175128711 C A 2.57E-05 Alcohol dependence KIAA0040 UTR-3 21703634 rs1057239 chr1 175130204 G A 2.01E-06 Alcohol dependence KIAA0040 UTR-5 20202923 rs1057239 chr1 175130204 G A 1.93E-06 Alcohol dependence KIAA0040 UTR-5 21703634 rs1057239 chr1 175130204 G A 3.10E-04 Alcohol dependence KIAA0040 UTR-5 21956439 rs1057239 chr1 175130204 G A 1.20E-06 Alcohol and nictotine co-dependence KIAA0040 UTR-5 22488850 rs1894709 chr1 175132371 G T 2.78E-06 Alcohol dependence KIAA0040 intron 20202923 rs1894709 chr1 175132371 G T 2.12E-06 Alcohol dependence KIAA0040 intron 21703634 rs1894709 chr1 175132371 G T 4.30E-04 Alcohol dependence KIAA0040 intron 21956439 rs1894709 chr1 175132371 G T 1.60E-06 Alcohol and nictotine co-dependence KIAA0040 intron 22488850 rs10489327 chr1 175134314 C T 2.70E-05 Urinary metabolites KIAA0040 intron 21572414 rs10489326 chr1 175134677 A G 4.90E-05 Alcohol dependence KIAA0040 intron 21703634 rs760486 chr1 175137376 G T 2.48E-04 Alzheimer's disease KIAA0040 intron 17998437 rs12136973 chr1 175140319 T C 3.50E-07 Amyotrophic Lateral Sclerosis KIAA0040 intron 17362836 rs1008459 chr1 175151183 T C 1.00E-07 Amyotrophic Lateral Sclerosis KIAA0040 intron 17362836 rs3766685 chr1 175156428 G C 3.10E-04 Alzheimer's disease KIAA0040 intron 17998437 rs3766682 chr1 175157838 A G 6.10E-05 Response to antidepressants KIAA0040 intron 19736353 rs760489 chr1 175172539 G A 8.84E-05 Glycosylated haemoglobin levels / / 17255346 rs760489 chr1 175172539 G A 1.05E-04 Heart Failure / / pha002884 rs875326 chr1 175289399 C T 2.10E-05 Effectiveness of iloperidone treatment in schizophrenia / / 18521090 rs875326 chr1 175289399 C T 2.51E-05 Bipolar disorder / / 21926972 rs875326 chr1 175289399 C T 0.000500808 Hypertension (early onset hypertension) / / 22479346 rs7551235 chr1 175294275 G A 0.000146117 Hypertension (early onset hypertension) TNR intron 22479346 rs3766680 chr1 175296448 T C 4.00E-06 Tonometry TNR intron 17903302 rs10489319 chr1 175320746 T C 8.46E-06 Stroke (ischemic) TNR intron 22941190 rs2236886 chr1 175321636 C G,T 8.29E-06 Stroke (ischemic) TNR intron 22941190 rs16848281 chr1 175322842 T C 9.95E-04 Obesity (extreme) TNR intron 21935397 rs10912966 chr1 175323386 G A 7.90E-04 Obesity (extreme) TNR intron 21935397 rs10798390 chr1 175326303 A G 5.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TNR intron 20877124 rs16848304 chr1 175336185 G C 9.39E-04 Obesity (extreme) TNR intron 21935397 rs16848329 chr1 175339089 A G 7.85E-06 Stroke (ischemic) TNR intron 22941190 rs16848353 chr1 175341548 G A 8.01E-06 Stroke (ischemic) TNR intron 22941190 rs12730963 chr1 175342485 T C 8.15E-06 Stroke (ischemic) TNR intron 22941190 rs7534171 chr1 175358778 G T 1.68E-04 Multiple complex diseases TNR intron 17554300 rs859468 chr1 175381926 C T 8.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TNR intron 20877124 rs6666777 chr1 175391741 C T 7.53E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) TNR intron 23648065 rs2105913 chr1 175410119 G A 2.19E-05 Hypertension TNR intron 19609347 rs873525 chr1 175419201 G A 7.35E-04 Coronary heart disease TNR intron 21606135 rs7548041 chr1 175440469 C T 6.12E-05 Bipolar disorder and schizophrenia TNR intron 20889312 rs12081663 chr1 175476197 G T 4.90E-04 Type 2 diabetes TNR intron 17463246 rs7515041 chr1 175505966 A G 9.82E-07 Obesity and osteoporosis TNR intron 19714249 rs7515041 chr1 175505966 A G 1.30E-05 Urinary metabolites TNR intron 21572414 rs1534901 chr1 175511784 G A 4.80E-06 Urinary metabolites TNR intron 21572414 rs7540211 chr1 175528957 T G 2.88E-04 Age-related macular degeneration TNR intron 22125219 rs10913008 chr1 175531634 G A 2.99E-04 Schizophrenia TNR intron 19197363 rs7539708 chr1 175569473 A G 1.42E-05 HIV-1 viral setpoint TNR intron 17641165 rs1323127 chr1 175579354 A C 5.34E-04 Type 2 diabetes TNR intron 17463246 rs1359047 chr1 175582788 T C 6.67E-06 Rheumatoid arthritis TNR intron 19503088 rs1359047 chr1 175582788 T C 8.12E-05 Attention deficit hyperactivity disorder TNR intron 22420046 rs10798406 chr1 175586033 A C 4.79E-04 Aortic root size TNR intron 21223598 rs12030347 chr1 175587531 G C 5.97E-04 Aortic root size TNR intron 21223598 rs12037583 chr1 175593305 C T 8.26E-05 HIV-1 viral setpoint TNR intron 17641165 rs998677 chr1 175642887 G A 4.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TNR intron 20877124 rs7544659 chr1 175647041 A G 2.47E-04 Coronary Artery Disease TNR intron 17634449 rs12401659 chr1 175652529 T C 7.15E-04 Multiple complex diseases TNR intron 17554300 rs12404663 chr1 175658531 G A 9.80E-06 Urinary metabolites TNR intron 21572414 rs12404663 chr1 175658531 G A 7.80E-04 Alzheimer's disease TNR intron 22005930 rs1535578 chr1 175664240 G C 3.11E-04 Alzheimer's disease TNR intron 22005930 rs1155910 chr1 175664892 C T 3.21E-04 Alzheimer's disease TNR intron 22005930 rs12034759 chr1 175667600 G A 2.83E-05 Alzheimer's disease TNR intron 22005930 rs7539097 chr1 175669902 A G 2.93E-05 Alzheimer's disease TNR intron 22005930 rs7527642 chr1 175670134 C A 2.91E-05 Alzheimer's disease TNR intron 22005930 rs4652109 chr1 175670201 T C 3.70E-04 Response to cytadine analogues (cytosine arabinoside) TNR intron 24483146 rs16848982 chr1 175671241 T A 2.65E-05 Alzheimer's disease TNR intron 22005930 rs12408049 chr1 175671536 C T 3.70E-06 Urinary metabolites TNR intron 21572414 rs12408049 chr1 175671536 C T 2.59E-05 Alzheimer's disease TNR intron 22005930 rs12404438 chr1 175671940 A G 2.56E-05 Alzheimer's disease TNR intron 22005930 rs10913061 chr1 175672947 G C 3.51E-05 Alzheimer's disease TNR intron 22005930 rs12034220 chr1 175675281 T G 2.55E-05 Alzheimer's disease TNR intron 22005930 rs10913063 chr1 175675596 G A 6.52E-04 Multiple complex diseases TNR intron 17554300 rs12038088 chr1 175678789 T G 2.13E-05 Alzheimer's disease TNR intron 22005930 rs12038088 chr1 175678789 T G 2.97E-04 Smoking initiation TNR intron 24665060 rs12049604 chr1 175680596 C A 5.40E-06 Urinary metabolites TNR intron 21572414 rs12049604 chr1 175680596 C A 2.29E-05 Alzheimer's disease TNR intron 22005930 rs12042335 chr1 175680758 G C 4.12E-05 Alzheimer's disease TNR intron 22005930 rs17377915 chr1 175712027 G A 7.30E-04 Obesity (extreme) TNR intron 21935397 rs17312292 chr1 175715606 G C 7.00E-06 Corneal astigmatism / / 23322567 rs12127628 chr1 175719996 G A 8.05E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs535335 chr1 175728110 T C 3.10E-06 Personality dimensions / / 23658558 rs16849103 chr1 175729733 G T 1.55E-04 Multiple complex diseases / / 17554300 rs671000 chr1 175731846 T C 4.21E-06 Personality dimensions / / 23658558 rs501915 chr1 175732289 C T 5.71E-06 Personality dimensions / / 23658558 rs6425361 chr1 175756706 T C 5.65E-06 Personality dimensions / / 23658558 rs491132 chr1 175832906 A G 4.10E-06 Iron levels / / 21208937 rs6656281 chr1 175886511 A G 6.28E-04 Tourette syndrome / / 22889924 rs6687849 chr1 175904809 C T 6.22E-05 Bipolar disorder and schizophrenia / / 20889312 rs1357338 chr1 175930886 A G 9.15E-05 Bipolar disorder and schizophrenia RFWD2 intron 20889312 rs1357337 chr1 175930937 C T 6.91E-05 Elbow pain RFWD2 intron pha003008 rs6704250 chr1 175932662 G C 3.00E-05 Bipolar disorder and schizophrenia RFWD2 intron 20889312 rs4622022 chr1 176014340 C A 5.61E-04 Type 2 diabetes RFWD2 intron 17846125 rs12033847 chr1 176027978 C T 2.68E-05 HIV-1 control RFWD2 intron 20041166 rs2502826 chr1 176043797 C T 6.91E-05 Elbow pain RFWD2 intron pha003008 rs2481653 chr1 176044121 A C 5.65E-05 Bipolar disorder and schizophrenia RFWD2 intron 20889312 rs2481627 chr1 176092167 T G 5.71E-05 Elbow pain RFWD2 intron pha003008 rs10913150 chr1 176172795 G T 6.91E-05 Elbow pain RFWD2 intron pha003008 rs191606 chr1 176241018 A G 2.19E-05 Serum metabolites / / 19043545 rs2455738 chr1 176291703 C T 3.10E-04 Lung function (forced vital capacity) / / 24023788 rs4471226 chr1 176423140 C T 2.96E-04 Fractional exhaled nitric oxide (childhood) / / 24315451 rs4471226 chr1 176423140 C T 3.00E-06 Fractional exhaled nitric oxide (childhood) / / 24315451 rs7553073 chr1 176429600 A G 5.59E-06 Stroke (ischemic) / / 22941190 rs7531549 chr1 176434044 G A 3.91E-07 Stroke (ischemic) PAPPA2 intron 22941190 rs7515586 chr1 176435567 C T 4.36E-07 Stroke (ischemic) PAPPA2 intron 22941190 rs7536647 chr1 176440645 G T 1.48E-04 Smoking initiation PAPPA2 intron 24665060 rs6671694 chr1 176520317 C T 9.65E-04 Response to taxane treatment (placlitaxel) PAPPA2 intron 23006423 rs1506780 chr1 176550847 T C 1.16E-04 Multiple complex diseases PAPPA2 intron 17554300 rs10913209 chr1 176554443 G A 3.78E-04 Age-related macular degeneration PAPPA2 intron 22125219 rs10798473 chr1 176646383 A G 9.45E-05 Serum metabolites PAPPA2 intron 19043545 rs4507975 chr1 176684432 A G 4.00E-09 Venous thromboembolism (gene x gene interaction) PAPPA2 intron 23509962 rs1555070 chr1 176772958 T C 1.71E-04 Multiple complex diseases PAPPA2 intron 17554300 rs1555070 chr1 176772958 T C 0.000244 Oxaliplatin induced neuropathy in response to colorectal cancer treatment PAPPA2 intron 22310351 rs6656137 chr1 176775678 C T 4.55E-04 Type 2 diabetes PAPPA2 intron 17463246 rs10913257 chr1 176778610 G T 3.70E-04 Type 2 diabetes PAPPA2 intron 17463246 rs1022523 chr1 176788394 G A 8.40E-05 Coronary heart disease PAPPA2 intron pha003032 rs1325598 chr1 176792249 A G 1.00E-09 Height PAPPA2 intron 20881960 rs12118034 chr1 176809368 C T 7.33E-04 Type 2 diabetes PAPPA2 cds-synon 17463246 rs2294494 chr1 176812620 T C 7.79E-04 Multiple complex diseases / / 17554300 rs1883431 chr1 176812896 C T 2.39E-04 Type 2 diabetes / / 17463246 rs16850248 chr1 176813430 C T 9.69E-05 Multiple complex diseases / / 17554300 rs16850255 chr1 176818541 T C 1.18E-05 Longevity / / 20304771 rs12094387 chr1 176819875 T C 1.23E-05 Longevity / / 20304771 rs1534957 chr1 176821057 G A 1.26E-05 Longevity / / 20304771 rs10913265 chr1 176832273 C T 5.09E-04 Multiple complex diseases ASTN1 UTR-3 17554300 rs17313104 chr1 176852976 G C 8.13E-04 Type 2 diabetes ASTN1 intron 17463246 rs6664879 chr1 176871637 G T 8.47E-04 Type 2 diabetes ASTN1 intron 17463246 rs10913275 chr1 176878265 G A 8.12E-04 Type 2 diabetes ASTN1 intron 17463246 rs10913281 chr1 176942706 C T 4.94E-04 Multiple complex diseases ASTN1 intron 17554300 rs12135256 chr1 176975445 C G 9.76E-04 Alcohol dependence ASTN1 intron 21314694 rs12135256 chr1 176975445 C G 5.50E-04 QT interval ASTN1 intron 22726844 rs2861887 chr1 177041997 C T 1.10E-25 Narcolepsy ASTN1 intron 19629137 rs6425412 chr1 177073727 A G 0.0002 Migraine ASTN1 intron 22678113 rs227519 chr1 177089904 A G 6.99E-04 Type 2 diabetes ASTN1 intron 17463246 rs12090000 chr1 177152360 A G 4.12E-04 Type 2 diabetes FAM5B intron 17463246 rs12090000 chr1 177152360 A G 0.0002 Migraine FAM5B intron 22678113 rs1521442 chr1 177164539 C T 8.05E-04 Response to statin treatment (atorvastatin),change in cholesterol levels FAM5B intron 20031582 rs760689 chr1 177194569 C G 1.80E-05 Urinary metabolites FAM5B intron 21572414 rs6683060 chr1 177196068 G T 9.64E-05 Multiple complex diseases FAM5B intron 17554300 rs6674725 chr1 177198818 G T 6.67E-05 Postoperative ventricular dysfunction FAM5B intron 21980348 rs926319 chr1 177204137 C A 7.25E-04 Multiple complex diseases FAM5B intron 17554300 rs6699955 chr1 177214110 T C 4.60E-04 Multiple complex diseases FAM5B intron 17554300 rs12744134 chr1 177223673 G A 8.85E-05 Postoperative ventricular dysfunction FAM5B intron 21980348 rs12083865 chr1 177230782 C T 1.32E-05 Telomere length FAM5B intron 20139977 rs10798508 chr1 177232064 C T 7.21E-04 Multiple complex diseases FAM5B intron 17554300 rs2139876 chr1 177237394 C T 8.03E-04 Multiple complex diseases FAM5B intron 17554300 rs2139876 chr1 177237394 C T 3.22E-05 Serum metabolites FAM5B intron 19043545 rs11587000 chr1 177261108 G A 5.52E-05 Cholesterol / / pha003073 rs16851037 chr1 177271313 G A 7.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs2861972 chr1 177274018 A G 7.92E-04 Type 2 diabetes / / 17463246 rs1123317 chr1 177300379 C T 4.05E-06 Cholesterol / / pha003073 rs1123317 chr1 177300379 C T 2.86E-05 ldl cholesterol / / pha003076 rs1123317 chr1 177300379 C T 1.82E-05 Cholesterol / / pha003078 rs4652245 chr1 177302972 G T 5.50E-04 Type 2 diabetes / / 17463246 rs4140633 chr1 177304940 A G 4.38E-04 Type 2 diabetes / / 17463246 rs3946142 chr1 177305858 C T 4.96E-04 Type 2 diabetes / / 17463246 rs6425419 chr1 177309473 G A 3.75E-04 Multiple complex diseases / / 17554300 rs4650963 chr1 177309490 G T 1.14E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6658794 chr1 177314198 G A 1.19E-04 Type 2 diabetes / / 17463246 rs1107923 chr1 177332967 C A 2.13E-04 Multiple complex diseases / / 17554300 rs2902103 chr1 177341802 T G 1.80E-04 Multiple complex diseases / / 17554300 rs2902103 chr1 177341802 T G 1.70E-04 Insulin resistance / / 21901158 rs7513623 chr1 177346429 C A 2.41E-04 Multiple complex diseases / / 17554300 rs10429832 chr1 177355133 C T 1.93E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs10913317 chr1 177355420 G A 3.76E-04 Multiple complex diseases / / 17554300 rs12117677 chr1 177358514 T C 2.58E-04 Multiple complex diseases / / 17554300 rs16851156 chr1 177360312 A G 4.80E-04 Multiple complex diseases / / 17554300 rs736840 chr1 177363013 A G 9.55E-05 Type 2 diabetes LOC100506128 intron 17463246 rs736840 chr1 177363013 A G 0.000649 Salmonella-induced pyroptosis LOC100506128 intron 22837397 rs6657693 chr1 177367162 T C 4.16E-04 Multiple complex diseases LOC100506128 intron 17554300 rs10913331 chr1 177380428 G A 1.87E-04 Multiple complex diseases LOC100506128 intron 17554300 rs10913334 chr1 177383617 G A 2.30E-04 Multiple complex diseases LOC100506128 intron 17554300 rs17609581 chr1 177384135 C T 1.57E-04 Multiple complex diseases LOC100506128 intron 17554300 rs12141778 chr1 177387794 C T 4.98E-04 Multiple complex diseases LOC100506128 intron 17554300 rs12026256 chr1 177433576 A G 1.67E-11 Alcohol consumption LOC100506128 intron pha001398 rs7521346 chr1 177434054 C T 7.74E-05 Smoking initiation LOC100506128 intron 24665060 rs12140698 chr1 177446916 C T 4.98E-06 Cardiovascular disease LOC100506128 intron 18179892 rs1885020 chr1 177451209 C T 1.01E-04 Celiac disease LOC100506128 intron 23936387 rs10913355 chr1 177455532 G A 9.79E-04 Multiple complex diseases LOC100506128 intron 17554300 rs16851585 chr1 177568799 C G 5.00E-06 Age-related macular degeneration / / 23326517 rs2862033 chr1 177583180 G C 9.57E-05 Serum metabolites / / 19043545 rs1252070 chr1 177600210 A C 2.85E-04 Type 2 diabetes / / 17463246 rs1252068 chr1 177602068 C T 3.02E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs1252077 chr1 177615594 C T 4.53E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs1252076 chr1 177617650 T C 6.13E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs1572511 chr1 177621201 T C 3.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7529907 chr1 177639015 A G 4.08E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs12035381 chr1 177648733 A G 8.29E-04 Type 2 diabetes / / 17463246 rs16851688 chr1 177648870 C T 1.73E-07 Type 2 diabetes / / 17463246 rs2104212 chr1 177651210 G A 4.91E-04 Insulin resistance / / 21901158 rs1885646 chr1 177652462 A G 1.01E-04 Schizophrenia / / 21674006 rs12140439 chr1 177722907 C A 1.00E-06 Schizophrenia / / 23894747 rs12046610 chr1 177755681 T C 5.68E-04 Coronary heart disease / / 21971053 rs4618929 chr1 177772715 T C 5.16E-04 Obesity (extreme) / / 21935397 rs4442331 chr1 177772815 G A 7.28E-04 Obesity (extreme) / / 21935397 rs4532784 chr1 177773099 G C 7.11E-04 Obesity (extreme) / / 21935397 rs4650976 chr1 177777450 C G 1.03E-04 Obesity (extreme) / / 21935397 rs4650977 chr1 177777608 G C 1.02E-04 Obesity (extreme) / / 21935397 rs6668375 chr1 177781284 C T 8.11E-04 Obesity (extreme) / / 21935397 rs76020919 chr1 177781293 C A 0.0000397 Menopause (age at onset) / / 23424626 rs6674700 chr1 177782904 C T 1.11E-04 Multiple complex diseases / / 17554300 rs4081366 chr1 177784137 C T 1.37E-06 Body mass index / / 23669352 rs74703854 chr1 177784203 A G 0.0000397 Menopause (age at onset) / / 23424626 rs116881786 chr1 177787323 A G 0.0000397 Menopause (age at onset) / / 23424626 rs10798570 chr1 177788008 T G 7.26E-04 Obesity (extreme) / / 21935397 rs10798571 chr1 177788180 T C 7.22E-04 Obesity (extreme) / / 21935397 rs78937547 chr1 177788728 T G 0.00000189 Menopause (age at onset) / / 23424626 rs4081367 chr1 177790062 T C 6.87E-04 Obesity (extreme) / / 21935397 rs10913435 chr1 177790711 T A 6.75E-04 Obesity (extreme) / / 21935397 rs79775735 chr1 177792041 C A 0.0000397 Menopause (age at onset) / / 23424626 rs117217277 chr1 177792712 A G 0.0000397 Menopause (age at onset) / / 23424626 rs12039449 chr1 177798421 T C 5.45E-04 Alzheimer's disease / / 22005930 rs4132288 chr1 177802710 G A 7.14E-04 Telomere length / / 23900074 rs7525646 chr1 177802872 A G 6.94E-04 Alzheimer's disease / / 22005930 rs76571116 chr1 177805878 T C 0.0000157 Menopause (age at onset) / / 23424626 rs76471454 chr1 177806598 G A 0.0000397 Menopause (age at onset) / / 23424626 rs2902200 chr1 177806838 A G 6.83E-04 Telomere length / / 23900074 rs12043001 chr1 177807335 T C 5.68E-04 Alzheimer's disease / / 22005930 rs7537762 chr1 177808463 G A 3.77E-04 Multiple complex diseases / / 17554300 rs10913445 chr1 177809560 G C 3.64E-04 Telomere length / / 23900074 rs10913446 chr1 177809861 T C 7.83E-05 Lung function (forced vital capacity) / / pha003104 rs117674205 chr1 177810653 G C 0.0000397 Menopause (age at onset) / / 23424626 rs12143390 chr1 177811306 T G 2.20E-05 Urinary metabolites / / 21572414 rs12143390 chr1 177811306 T G 6.28E-04 Alzheimer's disease / / 22005930 rs3886720 chr1 177812017 G A 6.94E-04 Alzheimer's disease / / 22005930 rs117260315 chr1 177815766 C T 0.0000397 Menopause (age at onset) / / 23424626 rs12757638 chr1 177815769 G A 6.82E-04 Obesity (extreme) / / 21935397 rs6689521 chr1 177818786 A G 7.96E-05 Lung function (forced vital capacity) / / pha003104 rs3131312 chr1 177820480 C T 4.86E-04 Obesity (extreme) / / 21935397 rs3131313 chr1 177821366 T C 6.62E-05 Multiple complex diseases / / 17554300 rs3131315 chr1 177823179 T A 4.90E-04 Obesity (extreme) / / 21935397 rs3131318 chr1 177825403 A C 4.77E-04 Obesity (extreme) / / 21935397 rs3131319 chr1 177825832 T G 9.89E-04 Obesity (extreme) / / 21935397 rs79468804 chr1 177827154 C T 0.0000397 Menopause (age at onset) / / 23424626 rs1571347 chr1 177827338 C T 9.75E-04 Obesity (extreme) / / 21935397 rs1410410 chr1 177828736 A G 4.74E-04 Obesity (extreme) / / 21935397 rs3131321 chr1 177829458 A G 4.70E-04 Obesity (extreme) / / 21935397 rs3131322 chr1 177830530 T C 8.95E-04 Obesity (extreme) / / 21935397 rs116923068 chr1 177831176 C G 0.0000397 Menopause (age at onset) / / 23424626 rs4142027 chr1 177833576 C T 9.04E-04 Obesity (extreme) / / 21935397 rs1536669 chr1 177834077 T C 4.91E-04 Obesity (extreme) / / 21935397 rs943763 chr1 177836264 A C 4.57E-04 Obesity (extreme) / / 21935397 rs633715 chr1 177852580 T C 2.00E-08 Menarche (age at onset) / / 21102462 rs633715 chr1 177852580 T C 5.70E-05 Obesity (extreme) / / 21935397 rs633715 chr1 177852580 T C 4.00E-19 Obesity / / 23563607 rs633715 chr1 177852580 T C 5.00E-12 Body mass index / / 23563607 rs633715 chr1 177852580 T C 7.00E-20 Obesity / / 23563607 rs633715 chr1 177852580 T C 9.00E-23 Obesity / / 23563607 rs10913454 chr1 177852789 C A 6.03E-06 Type 2 diabetes / / 17463246 rs10913454 chr1 177852789 C A 1.80E-04 Obesity (extreme) / / 21935397 rs10798577 chr1 177853220 C G 7.57E-06 Type 2 diabetes / / 17463246 rs10798577 chr1 177853220 C G 1.81E-04 Obesity (extreme) / / 21935397 rs516636 chr1 177855517 C A 3.00E-09 Body mass index / / 22344221 rs10798578 chr1 177856925 C T 1.96E-05 Type 2 diabetes / / 17463246 rs10798578 chr1 177856925 C T 3.93E-04 Obesity (extreme) / / 21935397 rs1336785 chr1 177859642 G C 3.96E-04 Obesity (extreme) / / 21935397 rs527065 chr1 177868882 G T 2.04E-06 Obesity (extreme) / / 21935397 rs685233 chr1 177869941 A G 4.99E-04 Type 2 diabetes / / 17463246 rs685233 chr1 177869941 A G 2.07E-06 Obesity (extreme) / / 21935397 rs623130 chr1 177871886 T C 2.12E-06 Obesity (extreme) / / 21935397 rs574367 chr1 177873210 G T 6.76E-05 Obesity (extreme) / / 21935397 rs574367 chr1 177873210 G T 9.47E-20 Body mass index / / 22344219 rs574367 chr1 177873210 G T 2.00E-19 Body mass index / / 24861553 rs10157480 chr1 177873333 A G 1.92E-04 Obesity (extreme) / / 21935397 rs576101 chr1 177873383 T A 2.20E-06 Obesity (extreme) / / 21935397 rs527248 chr1 177875514 A G 6.97E-05 Obesity (extreme) / / 21935397 rs589500 chr1 177876946 C T 7.04E-05 Obesity (extreme) / / 21935397 rs604388 chr1 177877979 T C 2.21E-06 Obesity (extreme) / / 21935397 rs693232 chr1 177881651 C G 7.22E-05 Obesity (extreme) / / 21935397 rs617763 chr1 177885238 C T 2.35E-06 Obesity (extreme) / / 21935397 rs618759 chr1 177885488 A G 2.61E-06 Obesity (extreme) / / 21935397 rs630372 chr1 177885762 G A 4.52E-05 Obesity (extreme) / / 21935397 rs10913461 chr1 177887117 C G 2.51E-04 Obesity (extreme) / / 21935397 rs512898 chr1 177888429 T C 3.64E-06 Obesity (extreme) / / 21935397 rs543874 chr1 177889480 A G 4.00E-23 Body mass index / / 20935630 rs543874 chr1 177889480 A G 6.51E-05 Obesity (extreme) / / 21935397 rs543874 chr1 177889480 A G 3.56E-23 Body mass index / / 23001569 rs543874 chr1 177889480 A G 2.00E-13 Body mass index / / 23583978 rs543874 chr1 177889480 A G 4.90E-04 Menarche (age at onset) / / 23599027 rs543874 chr1 177889480 A G 4.00E-11 Body mass index / / 23669352 rs506589 chr1 177894287 T C 6.57E-05 Obesity (extreme) / / 21935397 rs8030 chr1 177897975 C T 6.34E-06 Obesity (extreme) / / 21935397 rs545608 chr1 177899121 G C 6.61E-05 Obesity (extreme) SEC16B intron 21935397 rs575908 chr1 177900098 T C 6.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SEC16B intron 20877124 rs575908 chr1 177900098 T C 7.31E-06 Obesity (extreme) SEC16B intron 21935397 rs591120 chr1 177902753 G C 1.11E-08 Body mass index SEC16B missense 23669352 rs10489882 chr1 177904495 T C 8.85E-04 Obesity (extreme) SEC16B intron 21935397 rs2902210 chr1 177905174 T C 1.13E-04 Type 2 diabetes SEC16B intron 17463246 rs2902210 chr1 177905174 T C 4.20E-04 Obesity (extreme) SEC16B intron 21935397 rs10913469 chr1 177913519 T C 1.00E-08 Weight SEC16B intron 19079260 rs10913469 chr1 177913519 T C 6.00E-08 Body mass index SEC16B intron 19079260 rs10913469 chr1 177913519 T C 4.20E-06 Smoking behavior SEC16B intron 20418888 rs10913469 chr1 177913519 T C 2.40E-08 Menarche (age at onset) SEC16B intron 21102462 rs10913469 chr1 177913519 T C 3.92E-04 Obesity (extreme) SEC16B intron 21935397 rs10913469 chr1 177913519 T C 3.18E-08 Obesity SEC16B intron 22484627 rs116071515 chr1 177929074 G T 0.0000306 Menopause (age at onset) SEC16B intron 23424626 rs12137761 chr1 177936525 A G 5.24E-05 Cytomegalovirus antibody response SEC16B intron 21993531 rs2152716 chr1 177962184 G A 6.48E-04 Insulin resistance / / 21901158 rs12409266 chr1 177970998 C T 3.13E-05 Telomere length / / 23001564 rs7340104 chr1 177971866 C T 7.24E-05 HDL cholesterol / / pha003074 rs17360705 chr1 177989198 A C 3.15E-04 Amyotrophic lateral sclerosis (sporadic) LOC730102 intron 24529757 rs946817 chr1 177997709 A G 6.39E-04 Rheumatoid arthritis LOC730102 intron 21452313 rs16852409 chr1 178041772 A G 6.75E-04 Multiple complex diseases / / 17554300 rs316274 chr1 178142208 G A 8.00E-07 Immune response to smallpox vaccine (IL-6) RASAL2 intron 22542470 rs12036491 chr1 178163651 C A 7.35E-05 Amyotrophic lateral sclerosis (sporadic) RASAL2 intron 24529757 rs608656 chr1 178201147 A G 3.12E-05 Cognitive test performance RASAL2 intron 20125193 rs2225586 chr1 178204132 G A 0.000082 Sarcoidosis RASAL2 intron 22952805 rs1412784 chr1 178206664 A G 0.00002185 Sarcoidosis RASAL2 intron 22952805 rs116375667 chr1 178387833 T C 0.000072 Nonsyndromic striae distensae (stretch marks) RASAL2 intron 23633020 rs2017349 chr1 178419417 A G 7.52E-05 Cognitive test performance RASAL2 intron 20125193 rs6672334 chr1 178454768 G A 9.92E-05 Cognitive test performance / / 20125193 rs74441626 chr1 178460785 C A 0.0000961 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2746325 chr1 178463591 C T 2.65E-05 Cognitive test performance / / 20125193 rs2746325 chr1 178463591 C T 1.70E-05 Urinary metabolites / / 21572414 rs10158298 chr1 178470865 C A 9.90E-06 Urinary metabolites / / 21572414 rs12760731 chr1 178471222 C T 5.00E-06 Obesity-related traits / / 23251661 rs12754916 chr1 178484065 A G 1.83E-05 Brain derived neurotrophic factor levels,in serum C1orf49 intron 22047184 rs12023718 chr1 178491879 T C 6.00E-06 Obesity-related traits C1orf49 intron 23251661 rs12033565 chr1 178491966 C T 7.64E-06 Obesity-related traits C1orf49 intron 23251661 rs4457535 chr1 178497186 A G 8.50E-04 Type 2 diabetes / / 17463246 rs4650994 chr1 178515312 G A 7.00E-09 HDL cholesterol C1orf220 intron 24097068 rs4233175 chr1 178517591 A G 3.78E-06 Alcohol dependence / / 20202923 rs10913569 chr1 178518008 A G 9.22E-07 Alcohol dependence / / 20202923 rs10798618 chr1 178519124 A C 7.41E-04 Type 2 diabetes / / 17463246 rs2811297 chr1 178551472 C T 5.50E-04 Type 2 diabetes / / 17463246 rs2811302 chr1 178552875 C T 6.65E-04 Type 2 diabetes / / 17463246 rs3922812 chr1 178659933 G A 8.80E-04 Type 2 diabetes / / 17846124 rs16853243 chr1 178661341 C T 4.32E-05 Meningococcal disease / / 20694013 rs7543277 chr1 178679194 T C 1.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs2811280 chr1 178686247 A G 7.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs2811280 chr1 178686247 A G 8.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs16853302 chr1 178686331 A C 4.03E-04 Schizophrenia / / 19197363 rs16853302 chr1 178686331 A C 4.39E-05 Meningococcal disease / / 20694013 rs10913619 chr1 178691366 T C 1.45E-05 Serum metabolites / / 19043545 rs2773080 chr1 178696750 T C 8.00E-04 Type 2 diabetes RALGPS2 intron 17846124 rs4651005 chr1 178719306 C T 8.94E-04 Response to taxane treatment (placlitaxel) RALGPS2 intron 23006423 rs16853350 chr1 178765148 T G 7.50E-04 Suicide attempts in bipolar disorder RALGPS2 intron 21423239 rs965558 chr1 178782625 A G 9.40E-04 Suicide attempts in bipolar disorder RALGPS2 intron 21423239 rs3766642 chr1 178813531 G A 9.57E-04 Suicide attempts in bipolar disorder RALGPS2 intron 21423239 rs2297687 chr1 178820327 G A 1.93E-10 Triglycerides ANGPTL1 cds-synon 23063622 rs12565332 chr1 178824416 C G 9.05E-04 Suicide attempts in bipolar disorder ANGPTL1 intron 21423239 rs6696204 chr1 178841980 A G 9.92E-05 Insulin-related traits RALGPS2 intron pha003063 rs2184464 chr1 178849489 G A 2.67E-04 Suicide attempts in bipolar disorder RALGPS2 intron 21423239 rs4652341 chr1 178956553 C T 1.86E-04 Body mass index / / 21701565 rs10913672 chr1 178981416 G A 8.30E-06 Urinary metabolites / / 21572414 rs3813638 chr1 178994644 C T 2.01E-05 Body Mass Index / / pha002896 rs6425512 chr1 179000143 G A 1.27E-05 Body Mass Index FAM20B intron pha002896 rs6425513 chr1 179006462 G A 6.98E-05 Body Mass Index FAM20B intron pha002896 rs3766635 chr1 179016483 T C 8.79E-04 Acute lung injury FAM20B intron 22295056 rs16853590 chr1 179020377 C G 8.79E-04 Acute lung injury FAM20B intron 22295056 rs12131503 chr1 179034229 T A 3.26E-04 Body mass index FAM20B intron 21701565 rs10798652 chr1 179061427 C T 4.98E-04 Lymphocyte counts TOR3A intron 22286170 rs1128952 chr1 179065125 C T 8.84E-05 Erythrocyte counts TOR3A UTR-3 pha003101 rs1325195 chr1 179071756 G A 5.00E-06 IgE grass sensitization ABL2 UTR-3 22036096 rs17277288 chr1 179077613 T C 2.70E-04 Atrial fibrillation ABL2 missense 21846873 rs3818433 chr1 179079190 T C 3.92E-05 Body Mass Index ABL2 intron pha002896 rs2274230 chr1 179084080 T G 4.11E-04 Response to taxane treatment (placlitaxel) ABL2 cds-synon 23006423 rs9724754 chr1 179084408 C A 4.11E-04 Response to taxane treatment (placlitaxel) ABL2 intron 23006423 rs17277358 chr1 179100710 C T 4.11E-04 Response to taxane treatment (placlitaxel) ABL2 intron 23006423 rs9650996 chr1 179124290 G A 3.76E-06 Left ventricular mass ABL2 intron 21212386 rs12080991 chr1 179242140 T C 4.63E-05 Smoking initiation / / 24665060 rs1004959 chr1 179251673 G C 7.39E-04 Smoking initiation / / 24665060 rs12143460 chr1 179273031 A G 7.91E-04 Suicide attempts in bipolar disorder SOAT1 intron 21423239 rs17277834 chr1 179293079 C A 8.49E-04 Suicide attempts in bipolar disorder SOAT1 intron 21423239 rs4651024 chr1 179312102 T C 3.30E-05 Bone mineral density (BMD),in women SOAT1 intron 20164292 rs2152319 chr1 179315357 C A 2.30E-05 Bone mineral density (BMD),in women SOAT1 intron 20164292 rs13306729 chr1 179316687 A G 7.18E-04 Smoking initiation SOAT1 intron 24665060 rs1044925 chr1 179323738 C A 2.26E-04 Sudden cardiac arrest SOAT1 UTR-3 21658281 rs10913753 chr1 179400260 A G 8.61E-04 Multiple complex diseases AXDND1 intron 17554300 rs4651028 chr1 179407523 A G 9.46E-04 Multiple complex diseases AXDND1 intron 17554300 rs4130266 chr1 179415532 T G 8.81E-04 Multiple complex diseases AXDND1 intron 17554300 rs10494520 chr1 179452275 G A 6.74E-04 Schizophrenia AXDND1 cds-synon 21674006 rs12047808 chr1 179469314 A G 6.00E-06 Multiple sclerosis (age of onset) AXDND1 intron 19010793 rs10913801 chr1 179471750 T G 2.22E-06 Esophageal cancer (squamous cell) AXDND1 intron 22960999 rs1410587 chr1 179516072 C T 6.00E-04 Alcohol dependence AXDND1 intron 20201924 rs16854304 chr1 179518459 G T 7.48E-04 Body mass index AXDND1 intron 21701565 rs2274626 chr1 179521932 G T 1.40E-04 Breast cancer and prostate cancer NPHS2 intron 17903305 rs2274626 chr1 179521932 G T 7.80E-04 Alcohol dependence NPHS2 intron 20201924 rs745317 chr1 179525311 C T 2.88E-05 Multiple sclerosis (age of onset) NPHS2 intron 19010793 rs7517766 chr1 179547750 A G 5.11E-04 Multiple complex diseases / / 17554300 rs12403885 chr1 179548291 T G 1.10E-05 Urinary metabolites / / 21572414 rs4652420 chr1 179562143 G A 2.60E-05 Urinary metabolites TDRD5 intron 21572414 rs4652421 chr1 179563717 G A 4.60E-05 Biliary atresia TDRD5 intron 20460270 rs10753200 chr1 179564144 G A 4.02E-04 Body mass index TDRD5 intron 21701565 rs10753200 chr1 179564144 G A 5.82E-04 Body mass index TDRD5 intron 21701565 rs4652424 chr1 179569088 C G 9.31E-04 Alzheimer's disease TDRD5 intron 17998437 rs4652424 chr1 179569088 C G 5.01E-04 Body mass index TDRD5 intron 21701565 rs4652424 chr1 179569088 C G 6.63E-04 Body mass index TDRD5 intron 21701565 rs10913839 chr1 179593166 G A 5.63E-04 Multiple complex diseases TDRD5 intron 17554300 rs16854429 chr1 179609589 G T 7.29E-05 Alcohol dependence TDRD5 intron 21703634 rs1498122 chr1 179682093 A T 7.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504057 chr1 179687259 A G 7.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs1052447 chr1 179711649 T G 1.00E-04 Prostate cancer / / 21743057 rs10913876 chr1 179721771 G T 1.00E-04 Prostate cancer FAM163A intron 21743057 rs2454199 chr1 179729554 A G 3.70E-04 Insulin resistance FAM163A intron 21901158 rs17370180 chr1 179742819 A C 1.30E-05 Urinary metabolites FAM163A intron 21572414 rs4448484 chr1 179748514 T C 3.80E-04 Type 2 diabetes FAM163A intron 17463246 rs12756748 chr1 179757855 T G 4.78E-05 ldl cholesterol FAM163A intron pha003077 rs12756748 chr1 179757855 T G 3.72E-05 Cholesterol FAM163A intron pha003083 rs10798724 chr1 179766086 C T 8.55E-05 Information processing speed FAM163A intron 21130836 rs10913892 chr1 179786385 T C 1.40E-05 Urinary metabolites / / 21572414 rs10913893 chr1 179790518 G A 2.00E-05 Urinary metabolites / / 21572414 rs16854795 chr1 179790833 A G 8.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs1048418 chr1 179831248 G A 3.44E-05 Cognitive test performance TOR1AIP2 UTR-3 20125193 rs1300068 chr1 179858333 C T 3.86E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TOR1AIP1 intron 24023788 rs3845388 chr1 179882095 G A 2.27E-05 Cognitive test performance TOR1AIP1 intron 20125193 rs6689160 chr1 179891565 A G 5.80E-08 Glaucoma (primary open-angle) / / 22428042 rs474258 chr1 179895764 A G 4.75E-05 Height / / 22021425 rs475233 chr1 179895861 T C 4.26E-05 Height / / 22021425 rs585355 chr1 179900644 T C 1.50E-05 Urinary metabolites / / 21572414 rs2281805 chr1 179909076 T C 8.87E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs2501618 chr1 179958809 T C 1.30E-07 Atopy CEP350 intron 19961619 rs2501618 chr1 179958809 T C 1.49E-05 Malignant pleural mesothelioma CEP350 intron 23626673 rs2501618 chr1 179958809 T C 1.52E-04 Malignant pleural mesothelioma CEP350 intron 23626673 rs4076449 chr1 179997018 T C 1.00E-04 Cognitive impairment induced by topiramate CEP350 intron 22091778 rs12125245 chr1 180000542 G T 2.71E-05 Cognitive test performance CEP350 missense 20125193 rs6425603 chr1 180018254 C T 6.49E-04 Lymphocyte counts CEP350 intron 22286170 rs10913927 chr1 180039137 C T 1.05E-04 Lymphocyte counts CEP350 intron 22286170 rs111829180 chr1 180053531 G A 1.98E-11 Metabolite levels CEP350 intron 22286219 rs6685965 chr1 180110092 C A,G,T 5.36E-08 Metabolite levels / / 23281178 rs3845391 chr1 180119544 T G 8.72E-06 Cognitive test performance / / 20125193 rs55946907 chr1 180130723 C T 9.00E-06 Anorexia nervosa QSOX1 intron 23568457 rs16855395 chr1 180150719 T G 9.46E-05 Multiple complex diseases QSOX1 intron 17554300 rs10913943 chr1 180162364 C T 1.00E-04 Information processing speed QSOX1 intron 21130836 rs3767165 chr1 180165091 A G 1.37E-05 Triglycerides QSOX1 intron 19074352 rs3767165 chr1 180165091 A G 1.37E-05 Polyunsaturated fatty acid levels,in plasma QSOX1 intron 19148276 rs12145255 chr1 180169367 C T 8.78E-04 Body mass index / / 21701565 rs7521602 chr1 180177266 G T 0.00031 Salmonella-induced pyroptosis / / 22837397 rs10913949 chr1 180178695 T G 3.47E-04 White matter integrity / / 22425255 rs355623 chr1 180194443 A G 2.77E-04 Type 2 diabetes / / 17463246 rs355621 chr1 180194672 C G 5.55E-04 Type 2 diabetes / / 17463246 rs357050 chr1 180234729 T C 3.56E-04 Smoking initiation LHX4 intron 24665060 rs2290478 chr1 180238495 A G 5.62E-04 Smoking quantity LHX4 intron 24665060 rs1925339 chr1 180261070 G T 2.34E-05 Personality dimensions ACBD6 intron 22628180 rs10798745 chr1 180291777 T C 2.34E-05 Personality dimensions ACBD6 intron 22628180 rs4642852 chr1 180356025 C A 2.37E-05 Personality dimensions ACBD6 intron 22628180 rs6661208 chr1 180361630 T C 2.37E-05 Personality dimensions ACBD6 intron 22628180 rs7542223 chr1 180420271 T C,G 1.46E-05 Tuberculosis ACBD6 intron 22306650 rs1538620 chr1 180489737 G A 8.70E-05 Personality dimensions / / 18957941 rs4651067 chr1 180494062 G A 4.84E-05 Odorant perception / / 23910658 rs12039331 chr1 180501196 A G 2.18E-05 Personality dimensions / / 22628180 rs4652519 chr1 180549164 G A 6.73E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs6661325 chr1 180597577 T C 9.89E-05 Serum metabolites / / 19043545 rs7527074 chr1 180645441 C T 9.00E-06 Asthma (childhood onset) XPR1 intron 23829686 rs6681878 chr1 180674565 A T 3.27E-04 Multiple complex diseases XPR1 intron 17554300 rs16856409 chr1 180699554 A G 4.82E-04 Response to cytidine analogues (gemcitabine) XPR1 intron 24483146 rs12401315 chr1 180706924 C A 9.60E-06 Urinary metabolites XPR1 intron 21572414 rs6700926 chr1 180722353 G A 2.34E-04 Alzheimer's disease XPR1 intron 22005930 rs7556592 chr1 180753483 G T 2.60E-05 Urinary metabolites XPR1 intron 21572414 rs7544774 chr1 180757628 T C 3.34E-04 Bone mass and geometry XPR1 intron 17903296 rs12080611 chr1 180766896 G A 2.31E-04 Multiple complex diseases XPR1 intron 17554300 rs12075809 chr1 180772435 A G 3.25E-04 Multiple complex diseases XPR1 intron 17554300 rs3789373 chr1 180774130 C T 9.52E-04 Alcohol dependence XPR1 intron 21314694 rs2271668 chr1 180849081 A G 8.82E-04 Response to cytidine analogues (gemcitabine) XPR1 intron 24483146 rs10914123 chr1 180849494 T C 2.90E-04 Alzheimer's disease XPR1 intron 22005930 rs10494535 chr1 180858459 C T 7.40E-04 Response to cytidine analogues (gemcitabine) XPR1 UTR-3 24483146 rs10914134 chr1 180891542 A C 9.89E-05 Waist Circumference KIAA1614 intron pha003023 rs10753229 chr1 180920226 G T 3.23E-04 Multiple complex diseases LOC100509205 intron 17554300 rs1411478 chr1 180962282 A G 4.00E-11 Progressive supranuclear palsy STX6 intron 21685912 rs1411479 chr1 181006930 A G 5.46E-04 Premature ovarian failure MR1 intron 19508998 rs1411479 chr1 181006930 A G 4.65E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) MR1 intron 24023788 rs10797666 chr1 181018799 A C 2.00E-04 Cognitive impairment induced by topiramate MR1 intron 22091778 rs2282348 chr1 181027925 G T 6.91E-05 Body Mass Index MR1 UTR-3 pha003022 rs10797668 chr1 181035754 A G 9.09E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs6682093 chr1 181042889 G A 9.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6682093 chr1 181042889 G A 1.03E-05 Serum alpha1-antitrypsin levels / / 23990791 rs3856068 chr1 181046368 A C 9.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3856068 chr1 181046368 A C 1.67E-05 Serum alpha1-antitrypsin levels / / 23990791 rs4651082 chr1 181050713 T C 9.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3892275 chr1 181054522 G A 9.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6662507 chr1 181056160 G A 0.0006803 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6662507 chr1 181056160 G A 6.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6662507 chr1 181056160 G A 1.42E-05 Serum alpha1-antitrypsin levels / / 23990791 rs2275470 chr1 181065807 G A 0.0007103 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2275470 chr1 181065807 G A 7.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2275470 chr1 181065807 G A 1.79E-05 Serum alpha1-antitrypsin levels / / 23990791 rs4652563 chr1 181088058 T C 1.83E-05 Multiple complex diseases / / 17554300 rs6700566 chr1 181095552 C A 5.05E-04 Alzheimer's disease / / 17998437 rs4652564 chr1 181104869 C G 3.44E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4652565 chr1 181109008 C G 5.99E-04 Alzheimer's disease / / 17998437 rs881964 chr1 181109478 C T 2.51E-05 Osteoarthritis (knee and hip) / / 21177295 rs881964 chr1 181109478 C T 4.79E-04 Osteoarthritis (knee and hip) / / 21177295 rs3856075 chr1 181110097 T G 7.10E-04 Alzheimer's disease / / 17998437 rs12127075 chr1 181127902 T A 9.08E-04 Multiple complex diseases / / 17554300 rs4652572 chr1 181128206 T C 3.84E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs946645 chr1 181154177 A G 8.46E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4048562 chr1 181261712 G A 3.76E-06 Phospholipid levels (plasma) / / 21829377 rs3911590 chr1 181262158 A G 3.52E-06 Phospholipid levels (plasma) / / 21829377 rs3845427 chr1 181262438 T A 9.51E-07 Phospholipid levels (plasma) / / 21829377 rs10910917 chr1 181265245 A G 3.54E-06 Phospholipid levels (plasma) / / 21829377 rs2332203 chr1 181266420 G A 1.61E-06 Phospholipid levels (plasma) / / 21829377 rs2332206 chr1 181273842 A G 4.10E-06 Phospholipid levels (plasma) / / 21829377 rs7523745 chr1 181274415 T C 3.90E-06 Phospholipid levels (plasma) / / 21829377 rs6658112 chr1 181280106 C G 1.82E-06 Phospholipid levels (plasma) / / 21829377 rs3894266 chr1 181289937 C G 2.25E-06 Phospholipid levels (plasma) / / 21829377 rs7525299 chr1 181296112 A G 9.00E-05 Height / / pha003011 rs12119916 chr1 181307883 A G 6.07E-05 Cognitive test performance / / 20125193 rs12408625 chr1 181329186 C T 4.78E-04 Type 2 diabetes / / 17463246 rs4517314 chr1 181339616 C T 1.25E-06 Type 2 diabetes / / 21799836 rs16857239 chr1 181377529 A C 5.15E-04 Type 2 diabetes / / 17463246 rs16857248 chr1 181378036 C A 8.45E-04 Type 2 diabetes / / 17463246 rs591650 chr1 181384078 T G 2.05E-05 Blood Pressure / / pha003044 rs4287138 chr1 181399618 G T 5.52E-04 Sarcoidosis / / 19165924 rs12566751 chr1 181417812 T C 1.30E-05 Blood Pressure / / pha003046 rs3856086 chr1 181422435 T G 4.44E-07 Lymphocyte counts / / 22286170 rs3856087 chr1 181424533 G A 2.00E-05 Blood Pressure / / pha003046 rs2332267 chr1 181426910 C T 8.00E-06 Coronary artery calcification / / 23870195 rs12066616 chr1 181428761 C T 3.44E-05 Blood Pressure / / pha003046 rs6424813 chr1 181433468 G A 8.61E-05 Schizophrenia / / 24253340 rs644796 chr1 181436054 T C 1.01E-05 C-reactive protein / / 22492993 rs16857380 chr1 181443599 A G 1.70E-05 Urinary metabolites / / 21572414 rs146609419 chr1 181453509 T TC 9.76E-05 Lung function (forced expiratory volume in 1 second) CAC/1E intron pha003103 rs556321 chr1 181453509 T C 9.76E-05 Lung function (forced expiratory volume in 1 second) CAC/1E intron pha003103 rs517209 chr1 181488212 T G 4.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/1E intron 20877124 rs16857512 chr1 181494835 A G 2.14E-08 Multiple complex diseases CAC/1E intron 17554300 rs7512415 chr1 181508622 A G 6.94E-04 Type 2 diabetes CAC/1E intron 17463246 rs6682262 chr1 181524561 T A 9.87E-04 Obesity (extreme) CAC/1E intron 21935397 rs17495655 chr1 181526354 G A 2.60E-06 Urinary metabolites CAC/1E intron 21572414 rs10910960 chr1 181532332 G A 1.15E-04 Progressive supranuclear palsy CAC/1E intron 21685912 rs1953690 chr1 181534435 G A 1.30E-05 Urinary metabolites CAC/1E intron 21572414 rs10494540 chr1 181549547 T G 3.58E-05 Cognitive impairment induced by topiramate CAC/1E intron 22091778 rs2877652 chr1 181553797 T C 1.07E-04 HIV-1 viral setpoint CAC/1E intron 21490045 rs3856094 chr1 181561783 C T 4.73E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CAC/1E intron 24023788 rs199960 chr1 181579231 G A 2.42E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CAC/1E intron 24023788 rs199960 chr1 181579231 G A 3.36E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CAC/1E intron 24023788 rs4271174 chr1 181582350 G T 4.28E-06 HIV-1 viral setpoint CAC/1E intron 21490045 rs175338 chr1 181605165 A G 1.82E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CAC/1E intron 24023788 rs17742601 chr1 181618101 C G 6.53E-05 Alzheimer's disease CAC/1E intron 17998437 rs4083386 chr1 181622824 T C 1.36E-04 Prion diseases CAC/1E intron 22210626 rs3820260 chr1 181638511 C T 3.90E-05 Breast cancer CAC/1E intron 17529974 rs3753737 chr1 181645227 G A 7.00E-05 Iris characteristics CAC/1E intron 21835309 rs3845441 chr1 181655752 C A,G,T 7.00E-06 IgG glycosylation CAC/1E intron 23382691 rs576602 chr1 181754059 A C 2.56E-04 Multiple complex diseases CAC/1E intron 17554300 rs638132 chr1 181768985 G A 0.0000492 Polycystic ovary syndrome CAC/1E UTR-3 22951595 rs638132 chr1 181768985 G A 4.92E-05 Intracranial aneurysm CAC/1E UTR-3 22961961 rs695072 chr1 181816509 T C 0.000735988 Hypertension (early onset hypertension) / / 22479346 rs4465155 chr1 181821407 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs525867 chr1 181828097 A G 2.40E-05 Urinary metabolites / / 21572414 rs6691114 chr1 181842049 G C 2.94E-04 Multiple complex diseases / / 17554300 rs535607 chr1 181848014 A G 1.18E-05 Serum metabolites / / 19043545 rs79066418 chr1 181887010 G A 0.00007204 Sarcoidosis / / 22952805 rs74560931 chr1 181902708 A G 0.00007557 Sarcoidosis / / 22952805 rs78555787 chr1 181939630 G A 0.0000871 Sarcoidosis / / 22952805 rs115469509 chr1 181948224 G A 0.00006038 Sarcoidosis / / 22952805 rs145761963 chr1 182012460 G A 0.00009604 Sarcoidosis / / 22952805 rs12565808 chr1 182013486 G A 7.53E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2452905 chr1 182018765 A G 4.53E-04 Body mass index / / 21701565 rs7554182 chr1 182021283 C T 6.00E-08 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) / / 24554482 rs8179259 chr1 182052276 C G 1.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs3856106 chr1 182054977 C T 1.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs10797754 chr1 182055497 G C 1.38E-04 Multiple complex diseases / / 17554300 rs3856108 chr1 182056046 A T 1.04E-04 Multiple complex diseases / / 17554300 rs7537211 chr1 182058556 A G 2.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs7537211 chr1 182058556 A G 9.73E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7545241 chr1 182063963 T G 2.32E-04 Multiple complex diseases / / 17554300 rs10911019 chr1 182064484 C T 3.16E-04 Multiple complex diseases / / 17554300 rs10911021 chr1 182081960 C T 2.00E-08 Cardiovascular heart disease in diabetics / / 23982368 rs3856111 chr1 182084976 A G 6.62E-04 Type 2 diabetes / / 17463246 rs12409614 chr1 182085441 A G 9.69E-04 Coronary Artery Disease / / 17634449 rs12409614 chr1 182085441 A G 8.66E-05 Serum metabolites / / 19043545 rs12407822 chr1 182087214 G A 4.50E-04 Multiple complex diseases / / 17554300 rs10911024 chr1 182114569 G A 5.11E-04 Coronary Artery Disease / / 17634449 rs12564594 chr1 182116368 A G 3.92E-04 Alcohol dependence / / 20201924 rs4121149 chr1 182118604 G A 5.62E-07 Blood pressure / / 21996601 rs1779826 chr1 182131540 A G 1.64E-04 Multiple complex diseases / / 17554300 rs1689800 chr1 182168885 A G 3.00E-10 HDL cholesterol / / 20686565 rs1689800 chr1 182168885 A G 5.00E-20 HDL cholesterol / / 24097068 rs1779819 chr1 182178482 A G 1.53E-04 Multiple complex diseases / / 17554300 rs4113814 chr1 182178847 C T 1.00E-04 Multiple complex diseases / / 17554300 rs1419326 chr1 182182651 A C 2.30E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10911032 chr1 182185360 T C 8.51E-05 Coronary Artery Disease / / 17634449 rs113154036 chr1 182191448 G A 0.00009703 Sarcoidosis / / 22952805 rs10911042 chr1 182205415 T C 1.27E-04 Coronary Artery Disease / / 17634449 rs1018611 chr1 182224790 G A 5.12E-04 Type 2 diabetes / / 17463246 rs11802583 chr1 182237758 A G 5.05E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2256917 chr1 182249873 A G 4.64E-04 Multiple complex diseases / / 17554300 rs12031309 chr1 182255948 A G 9.63E-04 Coronary Artery Disease / / 17634449 rs12024291 chr1 182280599 C T 1.20E-04 Major depressive disorder / / 21042317 rs16858833 chr1 182283571 G C 8.00E-04 Major depressive disorder / / 21042317 rs6703548 chr1 182291435 T G 7.40E-04 Major depressive disorder / / 21042317 rs10797766 chr1 182291545 G A 4.20E-04 Major depressive disorder / / 21042317 rs2985441 chr1 182305147 T C 9.52E-05 Type 2 diabetes / / 17463246 rs2985441 chr1 182305147 T C 7.40E-06 Glioma (high-grade) / / 19578366 rs2246475 chr1 182312757 C T 2.77E-04 Alzheimer's disease / / 17998437 rs2256956 chr1 182319935 G A 1.56E-07 Iris color / / 18252221 rs17509621 chr1 182366278 T C 2.34E-06 Type 2 diabetes / / 17463246 rs3818458 chr1 182376260 C T 2.68E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12568218 chr1 182404479 C G 8.90E-04 Type 2 diabetes / / 17463246 rs497915 chr1 182406654 A G 2.60E-05 Urinary metabolites / / 21572414 rs677739 chr1 182407610 A G 2.60E-05 Urinary metabolites / / 21572414 rs267866 chr1 182420448 G A 6.03E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) RGSL1 intron 23648065 rs16859058 chr1 182456423 T A 2.70E-04 Blood pressure RGSL1 intron 17255346 rs12024567 chr1 182457029 G A,C,T 2.59E-04 Blood pressure RGSL1 intron 17255346 rs17568993 chr1 182537494 C T 2.63E-07 Lymphocyte counts / / 22286170 rs12034992 chr1 182538063 G A 1.49E-05 Blood pressure / / 17255346 rs12723593 chr1 182538582 C G 2.40E-05 Urinary metabolites / / 21572414 rs627839 chr1 182542081 G T 3.21E-04 Fasting insulin (interaction) / / 24204828 rs627839 chr1 182542081 G T 4.93E-04 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs11072 chr1 182543331 A G 5.00E-05 Iris characteristics R/SEL UTR-3 21835309 rs11072 chr1 182543331 A G 6.29E-04 Smoking cessation R/SEL UTR-3 24665060 rs533259 chr1 182549019 A G 6.00E-09 Multiple sclerosis R/SEL intron 23412934 rs682585 chr1 182559510 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes R/SEL nearGene-5 22628534 rs12041623 chr1 182561633 T C 3.90E-04 Alzheimer's disease / / 17998437 rs10489966 chr1 182575376 T G 2.73E-04 Alzheimer's disease / / 17998437 rs10752878 chr1 182582375 T G 3.62E-06 Postoperative ventricular dysfunction / / 21980348 rs602988 chr1 182586203 C T 1.05E-04 Multiple complex diseases / / 17554300 rs1287820 chr1 182589331 C G 5.08E-05 Postoperative ventricular dysfunction / / 21980348 rs528846 chr1 182592336 C T 4.98E-04 Multiple complex diseases / / 17554300 rs528846 chr1 182592336 C T 7.79E-05 Lung adenocarcinoma / / 19836008 rs488735 chr1 182609461 A G 2.60E-05 Multiple complex diseases / / 17554300 rs529502 chr1 182614303 A G 5.64E-04 Multiple complex diseases / / 17554300 rs12409524 chr1 182625258 T C 7.41E-04 Type 2 diabetes RGS8 intron 17463246 rs4652741 chr1 182626738 C A 6.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RGS8 intron 20877124 rs567397 chr1 182640638 A G 2.40E-04 Smoking initiation RGS8 intron 24665060 rs680277 chr1 182640864 T C 1.81E-04 Smoking initiation RGS8 missense 24665060 rs7512765 chr1 182672104 G A 2.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs1287968 chr1 182672251 T C 6.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs621071 chr1 182682811 T C 7.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs2482806 chr1 182684087 A C 2.49E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2482806 chr1 182684087 A C 8.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs542324 chr1 182684489 T A 9.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs595289 chr1 182696117 C G 7.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs2482808 chr1 182700570 T C 4.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs1287982 chr1 182701073 T G 3.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs6663553 chr1 182714585 C T 3.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs10797792 chr1 182717434 A G 4.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs12031590 chr1 182722554 A G 3.50E-05 Suicide attempts in bipolar disorder / / 21423239 rs9787058 chr1 182724185 C G 5.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs9787061 chr1 182724241 C A 5.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs7540658 chr1 182744205 A C 3.23E-04 Schizophrenia / / 21926974 rs6692387 chr1 182754545 T C 4.28E-05 Multiple complex diseases / / 17554300 rs6677418 chr1 182820248 T A 1.24E-04 Multiple complex diseases DHX9 intron 17554300 rs10797794 chr1 182858008 G A 1.19E-04 Cocaine dependence / / 23958962 rs78487548 chr1 182922215 G T 0.00042 Breast cancer SHCBP1L missense 23555315 rs16859878 chr1 182938992 C T 2.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs10911180 chr1 182959364 C A 1.40E-04 IgE levels in asthmatics / / 23967269 rs12753817 chr1 182970337 T A 4.12E-04 Type 2 diabetes / / 17463246 rs4233192 chr1 182970837 G T 8.74E-04 Type 2 diabetes / / 17463246 rs4233192 chr1 182970837 G T 4.42E-04 Lymphocyte counts / / 22286170 rs10752881 chr1 182973491 A G 5.00E-06 Colorectal cancer / / 24836286 rs4487994 chr1 182982173 T A 8.92E-05 Colorectal cancer / / 23266556 rs4454510 chr1 182982303 G A 9.94E-05 Colorectal cancer / / 23266556 rs10752885 chr1 182982878 G C 1.57E-04 Colorectal cancer / / 23266556 rs10911191 chr1 182984524 T C 9.45E-04 Type 2 diabetes / / 17463246 rs10911191 chr1 182984524 T C 9.32E-05 Colorectal cancer / / 23266556 rs10797812 chr1 182984597 G A 2.40E-04 Neuroticism / / 17667963 rs12126434 chr1 182988414 G A 8.96E-05 Colorectal cancer / / 23266556 rs10737236 chr1 182988608 T C 9.01E-04 Type 2 diabetes / / 17463246 rs10737236 chr1 182988608 T C 8.99E-05 Colorectal cancer / / 23266556 rs10737237 chr1 182989269 A G 8.99E-05 Colorectal cancer / / 23266556 rs10797813 chr1 182989366 C T 8.82E-05 Colorectal cancer / / 23266556 rs10797814 chr1 182990929 C A 8.48E-05 Colorectal cancer LAMC1 nearGene-5 23266556 rs6695746 chr1 182991355 T C 8.77E-05 Colorectal cancer LAMC1 nearGene-5 23266556 rs6695837 chr1 182991462 T C 7.01E-05 Colorectal cancer LAMC1 nearGene-5 23266556 rs4652763 chr1 182994084 A G 8.74E-05 Colorectal cancer LAMC1 intron 23266556 rs4652764 chr1 182994115 G A 4.34E-04 Colorectal cancer LAMC1 intron 23266556 rs4642853 chr1 182996242 C T 8.92E-05 Colorectal cancer LAMC1 intron 23266556 rs4651138 chr1 183001312 C A 8.29E-05 Colorectal cancer LAMC1 intron 23266556 rs6678517 chr1 183002639 A G 2.82E-06 Colorectal cancer LAMC1 intron 23266556 rs10911203 chr1 183004076 G A 6.53E-05 IgE levels in asthmatics LAMC1 intron 23967269 rs10797819 chr1 183006911 A G 1.03E-04 Colorectal cancer LAMC1 intron 23266556 rs12043805 chr1 183008150 T A 2.34E-06 Colorectal cancer LAMC1 intron 23266556 rs4652769 chr1 183009196 T C 1.05E-04 Colorectal cancer LAMC1 intron 23266556 rs10911205 chr1 183009277 C A 2.57E-06 Colorectal cancer LAMC1 intron 23266556 rs10911206 chr1 183012423 A G 1.12E-04 Colorectal cancer LAMC1 intron 23266556 rs4366285 chr1 183013672 T G 2.13E-05 Colorectal cancer LAMC1 intron 23266556 rs10911209 chr1 183013988 T G 1.10E-04 Colorectal cancer LAMC1 intron 23266556 rs6660111 chr1 183014289 G A 1.10E-04 Colorectal cancer LAMC1 intron 23266556 rs6664995 chr1 183017345 T C 1.10E-04 Colorectal cancer LAMC1 intron 23266556 rs10797822 chr1 183017769 A G 1.09E-04 Colorectal cancer LAMC1 intron 23266556 rs4422969 chr1 183020762 G A 9.14E-05 Colorectal cancer LAMC1 intron 23266556 rs10752890 chr1 183021910 A G 1.45E-04 Colorectal cancer LAMC1 intron 23266556 rs10911211 chr1 183022299 A T 2.56E-06 Colorectal cancer LAMC1 intron 23266556 rs4652772 chr1 183023696 G C 1.08E-04 Colorectal cancer LAMC1 intron 23266556 rs10911212 chr1 183024469 C T 1.08E-04 Colorectal cancer LAMC1 intron 23266556 rs4546885 chr1 183025555 G C 1.61E-05 Colorectal cancer LAMC1 intron 23266556 rs3934579 chr1 183027432 G A 1.08E-04 Colorectal cancer LAMC1 intron 23266556 rs3934697 chr1 183027512 A G 1.08E-04 Colorectal cancer LAMC1 intron 23266556 rs10797828 chr1 183028430 G A 9.41E-06 Colorectal cancer LAMC1 intron 23266556 rs3935384 chr1 183028970 C T 2.58E-04 Smoking cessation LAMC1 intron 18519826 rs3935384 chr1 183028970 C T 1.08E-04 Colorectal cancer LAMC1 intron 23266556 rs4266836 chr1 183029070 T G 1.02E-04 Colorectal cancer LAMC1 intron 23266556 rs10797829 chr1 183033228 A G 1.25E-04 Colorectal cancer LAMC1 intron 23266556 rs6424883 chr1 183037695 T C 8.71E-05 Non-alcoholic fatty liver disease histology (other) LAMC1 intron 20708005 rs6424883 chr1 183037695 T C 2.20E-06 Colorectal cancer LAMC1 intron 23266556 rs12120747 chr1 183042531 G A 2.58E-06 Colorectal cancer LAMC1 intron 23266556 rs10797832 chr1 183044034 A G 1.23E-04 Colorectal cancer LAMC1 intron 23266556 rs10911222 chr1 183047363 G A 1.25E-04 Colorectal cancer LAMC1 intron 23266556 rs10911229 chr1 183050368 C G 1.26E-04 Colorectal cancer LAMC1 intron 23266556 rs10911232 chr1 183052533 C T 2.16E-04 Type 2 diabetes LAMC1 intron 17463246 rs10911232 chr1 183052533 C T 3.35E-06 Colorectal cancer LAMC1 intron 23266556 rs10911233 chr1 183052585 G A 2.84E-06 Colorectal cancer LAMC1 intron 23266556 rs4397624 chr1 183053131 C T 2.43E-04 Colorectal cancer LAMC1 intron 23266556 rs10911235 chr1 183053746 G A 1.34E-04 Colorectal cancer LAMC1 intron 23266556 rs4652773 chr1 183054827 A C,G 1.33E-04 Colorectal cancer LAMC1 intron 23266556 rs2151669 chr1 183055398 T G 1.33E-04 Colorectal cancer LAMC1 intron 23266556 rs6672306 chr1 183058898 G A 6.54E-04 Colorectal cancer LAMC1 intron 23266556 rs4233194 chr1 183060917 G C 7.87E-05 Colorectal cancer LAMC1 intron 23266556 rs7525917 chr1 183065406 A G 6.25E-05 Colorectal cancer LAMC1 intron 23266556 rs6424885 chr1 183066254 T G 6.37E-05 Colorectal cancer LAMC1 intron 23266556 rs10752897 chr1 183071024 C T 9.67E-05 Colorectal cancer LAMC1 intron 23266556 rs2296288 chr1 183072590 T C 7.79E-05 Colorectal cancer LAMC1 cds-synon 23266556 rs10797835 chr1 183072908 T C 5.79E-05 Colorectal cancer LAMC1 intron 23266556 rs2027075 chr1 183073266 A G 6.61E-05 Colorectal cancer LAMC1 intron 23266556 rs2027078 chr1 183073478 G A 6.43E-05 Colorectal cancer LAMC1 intron 23266556 rs2027080 chr1 183074415 C T 6.46E-05 Colorectal cancer LAMC1 intron 23266556 rs10797837 chr1 183075121 C G 6.65E-05 Colorectal cancer LAMC1 intron 23266556 rs2333622 chr1 183075456 T C 6.70E-05 Colorectal cancer LAMC1 intron 23266556 rs12091137 chr1 183075732 A G 9.35E-04 Type 2 diabetes LAMC1 intron 17463246 rs12091137 chr1 183075732 A G 4.76E-05 Smoking cessation LAMC1 intron 18519826 rs12091137 chr1 183075732 A G 6.51E-05 Colorectal cancer LAMC1 intron 23266556 rs12086466 chr1 183075778 T C 9.66E-04 Type 2 diabetes LAMC1 intron 17463246 rs12086466 chr1 183075778 T C 5.79E-05 Smoking cessation LAMC1 intron 18519826 rs12086466 chr1 183075778 T C 7.42E-05 Colorectal cancer LAMC1 intron 23266556 rs723015 chr1 183076581 C T 6.93E-05 Smoking cessation LAMC1 intron 18519826 rs10911247 chr1 183076993 A G 6.43E-05 Colorectal cancer LAMC1 intron 23266556 rs10797838 chr1 183077020 A G 1.01E-04 Smoking cessation LAMC1 intron 18519826 rs10797838 chr1 183077020 A G 6.22E-05 Colorectal cancer LAMC1 intron 23266556 rs10797839 chr1 183077797 T C 2.05E-05 Smoking cessation LAMC1 intron 18519826 rs10797839 chr1 183077797 T C 6.35E-05 Colorectal cancer LAMC1 intron 23266556 rs10752898 chr1 183077896 T C 9.66E-05 Smoking cessation LAMC1 intron 18519826 rs10752898 chr1 183077896 T C 7.67E-05 Colorectal cancer LAMC1 intron 23266556 rs3768625 chr1 183078712 G T 8.58E-05 Colorectal cancer LAMC1 intron 23266556 rs3768624 chr1 183079252 C T 6.44E-05 Colorectal cancer LAMC1 intron 23266556 rs2296290 chr1 183079412 C T 6.31E-05 Colorectal cancer LAMC1 intron 23266556 rs2296291 chr1 183079509 C T 6.58E-05 Colorectal cancer LAMC1 intron 23266556 rs6672093 chr1 183079853 T C 6.30E-05 Colorectal cancer LAMC1 intron 23266556 rs10911249 chr1 183080690 G A 6.77E-05 Colorectal cancer LAMC1 intron 23266556 rs10911251 chr1 183081194 A C 9.00E-08 Colorectal cancer LAMC1 intron 23266556 rs10797842 chr1 183081867 G A 4.49E-04 Type 2 diabetes LAMC1 intron 17463246 rs10797842 chr1 183081867 G A 1.15E-04 Colorectal cancer LAMC1 intron 23266556 rs1537520 chr1 183084229 C T 8.84E-05 Colorectal cancer LAMC1 intron 23266556 rs6692207 chr1 183085304 T C 7.84E-05 Colorectal cancer LAMC1 intron 23266556 rs6424888 chr1 183085696 A G 8.07E-05 Colorectal cancer LAMC1 intron 23266556 rs20563 chr1 183085755 A G 6.08E-04 Colorectal cancer LAMC1 missense 23266556 rs2296292 chr1 183086757 A C 7.92E-05 Colorectal cancer LAMC1 cds-synon 23266556 rs10797848 chr1 183087727 A G 8.60E-05 Colorectal cancer LAMC1 intron 23266556 rs10797849 chr1 183088988 A G 8.53E-05 Colorectal cancer LAMC1 intron 23266556 rs3768622 chr1 183090011 G A 7.98E-05 Colorectal cancer LAMC1 intron 23266556 rs10752902 chr1 183090265 T A 8.50E-05 Colorectal cancer LAMC1 intron 23266556 rs6424889 chr1 183091796 G C 8.54E-05 Colorectal cancer LAMC1 intron 23266556 rs4652776 chr1 183091920 G A 8.51E-05 Colorectal cancer LAMC1 intron 23266556 rs4651139 chr1 183091963 C T 8.52E-05 Colorectal cancer LAMC1 intron 23266556 rs4652777 chr1 183091992 T G 8.59E-05 Colorectal cancer LAMC1 intron 23266556 rs3768620 chr1 183092237 G A 8.55E-05 Colorectal cancer LAMC1 intron 23266556 rs3768619 chr1 183092404 C G 8.55E-05 Colorectal cancer LAMC1 intron 23266556 rs3768617 chr1 183092500 C T 2.86E-06 Colorectal cancer LAMC1 intron 23266556 rs7518957 chr1 183093028 A T 8.59E-05 Colorectal cancer LAMC1 intron 23266556 rs2093982 chr1 183094191 T C 4.40E-05 Colorectal cancer LAMC1 intron 23266556 rs2093983 chr1 183094210 T C 8.68E-05 Colorectal cancer LAMC1 intron 23266556 rs2093985 chr1 183094322 C T 3.55E-04 Colorectal cancer LAMC1 intron 23266556 rs20558 chr1 183094547 T C 6.33E-04 Colorectal cancer LAMC1 missense 23266556 rs1886499 chr1 183095024 C T 3.08E-05 Colorectal cancer LAMC1 intron 23266556 rs2296293 chr1 183095477 G A 8.26E-05 Colorectal cancer LAMC1 intron 23266556 rs2296294 chr1 183095596 T C 1.94E-04 Colorectal cancer LAMC1 intron 23266556 rs2224933 chr1 183095765 A G 1.13E-04 Colorectal cancer LAMC1 intron 23266556 rs1413390 chr1 183096634 G A 9.26E-05 Colorectal cancer LAMC1 intron 23266556 rs1413389 chr1 183096668 C T 9.84E-05 Colorectal cancer LAMC1 intron 23266556 rs1413387 chr1 183096774 G A 9.89E-05 Colorectal cancer LAMC1 intron 23266556 rs7529465 chr1 183096880 A G 9.86E-05 Colorectal cancer LAMC1 intron 23266556 rs4651140 chr1 183096952 G T 9.90E-05 Colorectal cancer LAMC1 intron 23266556 rs4651141 chr1 183096969 A G 9.89E-05 Colorectal cancer LAMC1 intron 23266556 rs4651143 chr1 183097398 A G 9.82E-05 Colorectal cancer LAMC1 intron 23266556 rs1360704 chr1 183099380 T C 2.76E-06 Colorectal cancer LAMC1 intron 23266556 rs2296300 chr1 183099701 G A 8.18E-05 Colorectal cancer LAMC1 intron 23266556 rs6691755 chr1 183099821 G A 9.08E-05 Colorectal cancer LAMC1 intron 23266556 rs2333620 chr1 183100555 T C 9.01E-05 Colorectal cancer LAMC1 intron 23266556 rs10752903 chr1 183100863 A G 9.23E-05 Colorectal cancer LAMC1 intron 23266556 rs10737245 chr1 183100884 G A 9.22E-05 Colorectal cancer LAMC1 intron 23266556 rs10752904 chr1 183101038 A G 9.19E-05 Colorectal cancer LAMC1 intron 23266556 rs10797852 chr1 183101302 C T 9.35E-05 Colorectal cancer LAMC1 intron 23266556 rs12061219 chr1 183101471 G A 9.05E-05 Colorectal cancer LAMC1 intron 23266556 rs12095664 chr1 183101686 G A 7.29E-05 Colorectal cancer LAMC1 intron 23266556 rs3768616 chr1 183103551 T C 8.88E-05 Colorectal cancer LAMC1 intron 23266556 rs3768615 chr1 183103604 A G 8.72E-05 Colorectal cancer LAMC1 intron 23266556 rs10911260 chr1 183106230 C A 6.53E-04 Colorectal cancer LAMC1 intron 23266556 rs2274984 chr1 183107446 G T 8.75E-04 Type 2 diabetes LAMC1 intron 17463246 rs2274984 chr1 183107446 G T 1.29E-04 Colorectal cancer LAMC1 intron 23266556 rs2027085 chr1 183108611 T G 7.23E-05 Smoking cessation LAMC1 intron 18519826 rs2027085 chr1 183108611 T G 1.34E-04 Colorectal cancer LAMC1 intron 23266556 rs729819 chr1 183109034 G A 1.27E-04 Colorectal cancer LAMC1 intron 23266556 rs1062044 chr1 183112412 A G 1.59E-04 Colorectal cancer LAMC1 UTR-3 23266556 rs944971 chr1 183112505 T C 2.65E-04 Colorectal cancer LAMC1 UTR-3 23266556 rs944970 chr1 183112566 T C 1.58E-04 Colorectal cancer LAMC1 UTR-3 23266556 rs3738829 chr1 183113862 C T 1.31E-04 Colorectal cancer LAMC1 UTR-3 23266556 rs1547715 chr1 183113952 A G 1.46E-04 Colorectal cancer LAMC1 UTR-3 23266556 rs1547714 chr1 183114119 C T 1.51E-04 Colorectal cancer LAMC1 UTR-3 23266556 rs1051473 chr1 183114146 T C 1.40E-04 Colorectal cancer LAMC1 UTR-3 23266556 rs7473 chr1 183114634 G A 1.43E-04 Colorectal cancer LAMC1 UTR-3 23266556 rs12034436 chr1 183114797 A G 1.24E-04 Colorectal cancer LAMC1 nearGene-3 23266556 rs10911262 chr1 183114956 A G 8.45E-04 Colorectal cancer LAMC1 nearGene-3 23266556 rs12565776 chr1 183116531 A G 5.00E-06 Systemic lupus erythematosus / / 24871463 rs17479287 chr1 183143422 G A 1.10E-04 IgE levels in asthmatics / / 23967269 rs479994 chr1 183161729 C T 9.60E-05 Non-alcoholic fatty liver disease histology (other) LAMC2 intron 20708005 rs1028771 chr1 183170948 A C 4.00E-06 Coronary heart disease LAMC2 intron 21347282 rs10494560 chr1 183172548 C T 5.70E-04 Type 2 diabetes and 6 quantitative traits LAMC2 intron 17848626 rs525410 chr1 183176430 A G 6.00E-07 Systemic lupus erythematosus LAMC2 intron 21408207 rs16860537 chr1 183180260 A G 5.00E-06 Systemic lupus erythematosus and Systemic sclerosis LAMC2 intron 23740937 rs10911279 chr1 183182188 C G 3.89E-05 Type 2 diabetes LAMC2 intron 17463246 rs875794 chr1 183184848 T G 2.92E-05 Type 2 diabetes LAMC2 intron 17463246 rs875795 chr1 183184960 C T 3.76E-05 Type 2 diabetes LAMC2 intron 17463246 rs942617 chr1 183185406 G C 3.43E-05 Type 2 diabetes LAMC2 intron 17463246 rs3768600 chr1 183186096 G A 5.71E-05 Type 2 diabetes LAMC2 intron 17463246 rs16860582 chr1 183190451 T C 2.97E-04 Alcohol dependence LAMC2 intron 20201924 rs12044752 chr1 183193694 C T 3.76E-05 Type 2 diabetes LAMC2 intron 17463246 rs16860609 chr1 183196217 C A 8.28E-04 Multiple complex diseases LAMC2 intron 17554300 rs3768597 chr1 183198013 C T 3.20E-04 Response to cytidine analogues (gemcitabine) LAMC2 intron 24483146 rs1047981 chr1 183206573 G A 3.18E-05 Type 2 diabetes LAMC2 cds-synon 17463246 rs3768593 chr1 183212548 T G 2.62E-05 Type 2 diabetes LAMC2 UTR-3 17463246 rs549191 chr1 183220937 A G 8.32E-06 Type 2 diabetes NM/T2 UTR-3 17463246 rs503243 chr1 183222013 G A 7.36E-06 Type 2 diabetes NM/T2 intron 17463246 rs9660718 chr1 183241736 T A 7.74E-05 Multiple complex diseases NM/T2 intron 17554300 rs4652795 chr1 183266182 C T 5.00E-06 Obesity-related traits NM/T2 intron 23251661 rs16860763 chr1 183270797 G T 2.53E-05 Acute lymphoblastic leukemia (childhood) NM/T2 intron 19684603 rs6687056 chr1 183272295 T C 8.52E-04 Schizophrenia NM/T2 intron 19197363 rs17483344 chr1 183273348 G A 6.23E-04 Type 2 diabetes NM/T2 intron 17463246 rs602182 chr1 183279029 G T 9.06E-04 Heart Failure NM/T2 intron pha002884 rs634375 chr1 183327866 C T 7.03E-04 Multiple complex diseases NM/T2 intron 17554300 rs2022013 chr1 183353853 C T 1.08E-07 Systemic lupus erythematosus NM/T2 intron 18204446 rs2078087 chr1 183358405 C T 4.66E-04 Sudden cardiac arrest NM/T2 intron 21658281 rs2078087 chr1 183358405 C T 1.00E-06 Obesity-related traits NM/T2 intron 23251661 rs1819628 chr1 183358440 T C 2.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NM/T2 intron 20877124 rs10494563 chr1 183376980 G T 4.99E-06 Obesity-related traits NM/T2 intron 23251661 rs2788048 chr1 183389877 A G 4.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2788056 chr1 183400890 T C 6.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2702199 chr1 183401880 T C 6.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2226099 chr1 183449357 C T 1.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SMG7 intron 20877124 rs2226099 chr1 183449357 C T 8.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SMG7 intron 20877124 rs3842897 chr1 183503664 A G 5.05E-05 Cognitive impairment induced by topiramate SMG7 intron 22091778 rs699246 chr1 183516100 G C 8.94E-30 Lymphocyte counts SMG7 intron 22286170 rs16861259 chr1 183593328 C T 8.12E-04 Type 2 diabetes / / 17463246 rs2231241 chr1 183596703 G A 8.80E-05 Systemic lupus erythematosus ARPC5 cds-synon 23273568 rs11811536 chr1 183604258 C A 1.10E-04 Systemic lupus erythematosus ARPC5 intron 23273568 rs10911390 chr1 183616884 C T 6.00E-06 Systemic lupus erythematosus APOBEC4 missense 23273568 rs1174657 chr1 183616926 T C 1.70E-04 Asperger disorder APOBEC4 missense 21182207 rs1174658 chr1 183617105 A G 1.70E-04 Asperger disorder APOBEC4 missense 21182207 rs10911398 chr1 183646886 A C 7.43E-04 Type 2 diabetes RGL1 intron 17463246 rs4507976 chr1 183666920 G A 2.86E-04 Multiple complex diseases RGL1 intron 17554300 rs6424904 chr1 183668132 A G 3.90E-04 Asperger disorder RGL1 intron 21182207 rs10911419 chr1 183675931 G A 6.07E-04 Multiple complex diseases RGL1 intron 17554300 rs3820689 chr1 183711483 C T 3.10E-04 Type 2 diabetes and 6 quantitative traits RGL1 intron 17848626 rs6664373 chr1 183737203 T C 9.45E-04 Multiple complex diseases RGL1 intron 17554300 rs1926834 chr1 183739363 C T 6.05E-04 Multiple complex diseases RGL1 intron 17554300 rs4388664 chr1 183804680 C T 8.18E-04 Myopia (pathological) RGL1 intron 21095009 rs2491439 chr1 183807275 A G 6.48E-04 Type 2 diabetes RGL1 intron 17463246 rs11806497 chr1 183812807 G A,C,T 5.41E-04 Substance dependence RGL1 intron 21818250 rs3010058 chr1 183820769 A G 2.50E-08 Metabolite levels RGL1 intron 23281178 rs9425321 chr1 183830901 C T 7.00E-06 Urinary metabolites RGL1 intron 21572414 rs9425322 chr1 183834061 G A 2.76E-06 Response to antidepressants RGL1 intron 20360315 rs9425323 chr1 183834276 C T 1.53E-06 Response to antidepressants RGL1 intron 20360315 rs4651156 chr1 183837032 A G 3.00E-06 Response to antidepressants RGL1 intron 20360315 rs9425326 chr1 183839005 T C 4.22E-06 Response to antidepressants RGL1 intron 20360315 rs9425616 chr1 183841103 G C 2.21E-06 Response to antidepressants RGL1 intron 20360315 rs9425617 chr1 183841784 T A 2.14E-06 Response to antidepressants RGL1 intron 20360315 rs10797917 chr1 183841796 T G 4.34E-06 Response to antidepressants RGL1 intron 20360315 rs10797919 chr1 183852914 G C 9.00E-06 Attention deficit hyperactivity disorder and conduct disorder RGL1 intron 18951430 rs12562685 chr1 183885270 C T 6.96E-04 Type 2 diabetes RGL1 intron 17463246 rs10911469 chr1 183888858 G A 2.37E-04 Lymphocyte counts RGL1 intron 22286170 rs12563980 chr1 183889552 C T 8.45E-04 Type 2 diabetes RGL1 intron 17463246 rs7554987 chr1 183889607 T C 7.90E-04 Type 2 diabetes RGL1 intron 17463246 rs17503785 chr1 183903789 C G 2.49E-04 Birth weight / / 17255346 rs2986574 chr1 183906614 G A 6.00E-06 Parkinson's disease GLT25D2 UTR-3 17052657 rs3010040 chr1 183908222 C T 1.20E-05 Parkinson's disease GLT25D2 intron 17052657 rs2296713 chr1 183909717 G A 1.20E-05 Parkinson's disease GLT25D2 cds-synon 17052657 rs1887279 chr1 183910160 C T 6.00E-06 Parkinson's disease GLT25D2 intron 17052657 rs1887277 chr1 183932459 A C 3.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GLT25D2 intron 20877124 rs149948023 chr1 183938537 G A 0.00024 Prostate cancer (non-advanced prostate cancer) GLT25D2 missense 23555315 rs724427 chr1 183939985 A T 8.60E-05 White matter hyperintensity burden GLT25D2 intron 21681796 rs10911491 chr1 183984495 T C 2.00E-05 Urinary metabolites GLT25D2 intron 21572414 rs12077047 chr1 183984717 T A 2.20E-05 Urinary metabolites GLT25D2 intron 21572414 rs756199 chr1 184002874 A G 7.00E-06 Height GLT25D2 intron 20189936 rs3814333 chr1 184007119 C T 2.00E-13 Height / / 23563607 rs2274432 chr1 184020945 G A 8.00E-09 Height TSEN15 missense 18391951 rs2274432 chr1 184020945 G A 3.87E-05 Height TSEN15 missense 19570815 rs1046934 chr1 184023529 A C 2.00E-31 Height TSEN15 missense 20881960 rs1926921 chr1 184032403 G A 4.96E-04 White matter integrity TSEN15 intron 22425255 rs12411231 chr1 184049394 C T 9.73E-04 Multiple complex diseases / / 17554300 rs1327144 chr1 184051573 A C 4.09E-05 Height / / pha003011 rs10752931 chr1 184067280 T C 8.03E-04 White matter integrity / / 22425255 rs971572 chr1 184068508 C A 9.00E-09 Venous thromboembolism (gene x gene interaction) / / 23509962 rs16822455 chr1 184070494 G A 2.64E-04 Multiple complex diseases / / 17554300 rs1887296 chr1 184072250 C T 1.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1887296 chr1 184072250 C T 8.33E-04 White matter integrity / / 22425255 rs6424925 chr1 184128264 G A 3.98E-04 White matter integrity / / 22425255 rs6694958 chr1 184149821 A G 5.23E-04 Smoking initiation / / 24665060 rs2194698 chr1 184171449 C A 6.10E-06 Urinary metabolites / / 21572414 rs1863155 chr1 184177245 C T 7.00E-06 Urinary metabolites / / 21572414 rs1863155 chr1 184177245 C T 3.46E-05 Erythrocyte counts / / pha003099 rs16822576 chr1 184180060 A C 2.46E-04 Smoking initiation / / 24665060 rs35605894 chr1 184180060 A AC 2.46E-04 Smoking initiation / / 24665060 rs1409808 chr1 184189782 A G 7.40E-04 Smoking initiation / / 24665060 rs1409810 chr1 184190439 G A 4.49E-04 Smoking initiation / / 24665060 rs12132917 chr1 184192775 T C 4.23E-04 Smoking initiation / / 24665060 rs1854085 chr1 184192838 C T 7.63E-04 Smoking initiation / / 24665060 rs1930294 chr1 184195232 G T 2.23E-05 Smoking initiation / / 24665060 rs10494576 chr1 184197960 C G 7.94E-05 Smoking initiation / / 24665060 rs10494577 chr1 184205173 C A 7.01E-04 Smoking initiation / / 24665060 rs7528912 chr1 184205246 G C 1.77E-04 Smoking initiation / / 24665060 rs2378840 chr1 184219848 C T 4.77E-04 Smoking initiation / / 24665060 rs12117439 chr1 184261349 C T 1.19E-04 Smoking initiation / / 24665060 rs10911556 chr1 184283376 G A 1.99E-04 Smoking initiation / / 24665060 rs12096575 chr1 184288820 G A 1.66E-04 Smoking initiation / / 24665060 rs10911560 chr1 184292242 A G 6.73E-04 Obesity (extreme) / / 21935397 rs1930293 chr1 184294167 T C 6.68E-04 Obesity (extreme) / / 21935397 rs1930293 chr1 184294167 T C 5.69E-04 Smoking initiation / / 24665060 rs12074351 chr1 184300413 A G 6.73E-04 Obesity (extreme) / / 21935397 rs12059311 chr1 184302494 G A 6.36E-04 Obesity (extreme) / / 21935397 rs12083933 chr1 184304868 C T 1.10E-05 Urinary metabolites / / 21572414 rs4390140 chr1 184324403 C T 1.10E-05 Urinary metabolites / / 21572414 rs10911583 chr1 184332991 G A 7.59E-05 Insulin Resistance / / pha003062 rs10911593 chr1 184358935 A G 2.00E-05 Urinary metabolites C1orf21 intron 21572414 rs4326589 chr1 184358996 C T 8.30E-06 Urinary metabolites C1orf21 intron 21572414 rs4631655 chr1 184361316 G C 5.30E-05 Coronary heart disease C1orf21 intron 21966275 rs7415961 chr1 184363103 T C 1.70E-05 Urinary metabolites C1orf21 intron 21572414 rs6424950 chr1 184363837 T C 1.40E-05 Urinary metabolites C1orf21 intron 21572414 rs11799574 chr1 184391279 C A 5.16E-04 Response to taxane treatment (placlitaxel) C1orf21 intron 23006423 rs12145326 chr1 184394956 C T 5.16E-04 Response to taxane treatment (placlitaxel) C1orf21 intron 23006423 rs41470944 chr1 184402229 C A 1.53E-04 Multiple complex diseases C1orf21 intron 17554300 rs16823149 chr1 184402508 A G 5.50E-08 Colorectal cancer C1orf21 intron 20610541 rs16823195 chr1 184430842 G A 5.10E-05 Multiple complex diseases C1orf21 intron 17554300 rs6684430 chr1 184433058 T A 2.46E-04 Multiple complex diseases C1orf21 intron 17554300 rs10489724 chr1 184440480 T C 5.56E-05 Multiple complex diseases C1orf21 intron 17554300 rs10489725 chr1 184440541 T C 3.07E-04 Blood pressure C1orf21 intron 17255346 rs10489725 chr1 184440541 T C 2.16E-04 Multiple complex diseases C1orf21 intron 17554300 rs10489726 chr1 184440620 C T 2.91E-04 Blood pressure C1orf21 intron 17255346 rs10489726 chr1 184440620 C T 2.77E-04 Multiple complex diseases C1orf21 intron 17554300 rs4651208 chr1 184442054 T C 6.34E-05 Pulmonary function in asthmatics C1orf21 intron 23541324 rs6683932 chr1 184447624 C A 7.41E-05 Multiple complex diseases C1orf21 intron 17554300 rs2001270 chr1 184493884 A G 1.00E-04 Alcoholism (heaviness of drinking) C1orf21 intron 21529783 rs10911611 chr1 184537821 T C 1.00E-04 Cognitive impairment induced by topiramate C1orf21 intron 22091778 rs10911611 chr1 184537821 T C 1.00E-04 Cognitive impairment induced by topiramate C1orf21 intron 22091778 rs10911611 chr1 184537821 T C 2.73E-05 Cognitive impairment induced by topiramate C1orf21 intron 22091778 rs17255321 chr1 184560541 C A 4.19E-04 Response to taxane treatment (placlitaxel) C1orf21 intron 23006423 rs12032371 chr1 184563169 C T 2.33E-04 Alzheimer's disease (late onset) C1orf21 intron 21379329 rs6695173 chr1 184577317 T G 4.29E-04 Blood pressure C1orf21 intron 17255346 rs10797981 chr1 184609820 G A 8.68E-05 Body Mass Index / / pha003009 rs73046798 chr1 184619002 C T 1.03E-04 Acne (severe) / / 24927181 rs4651229 chr1 184623559 G A 8.58E-05 Multiple complex diseases / / 17554300 rs73046800 chr1 184624354 G A 1.05E-04 Acne (severe) / / 24927181 rs10911628 chr1 184649503 C A 2.00E-13 Systemic lupus erythematosus / / 24871463 rs6663178 chr1 184661642 G A 6.88E-06 Obesity-related traits EDEM3 UTR-3 23251661 rs3736757 chr1 184677464 G A 6.00E-06 Obesity-related traits EDEM3 cds-synon 23251661 rs1040666 chr1 184694583 C A 9.05E-06 Obesity-related traits EDEM3 intron 23251661 rs861588 chr1 184738494 G A 4.50E-06 Urinary metabolites / / 21572414 rs861601 chr1 184745264 G A 4.44E-06 Obesity-related traits / / 23251661 rs570441 chr1 184760001 T C 7.23E-06 Obesity-related traits / / 23251661 rs7360 chr1 184760433 C T 4.27E-06 Obesity-related traits FAM129A UTR-3 23251661 rs682331 chr1 184761365 A G 4.00E-06 Obesity-related traits FAM129A UTR-3 23251661 rs35704242 chr1 184764824 C T 6.32E-05 Major depressive disorder FAM129A missense 21621269 rs338563 chr1 184776403 C T 7.04E-04 Obesity (extreme) FAM129A intron 21935397 rs338565 chr1 184777101 G A 7.05E-04 Obesity (extreme) FAM129A intron 21935397 rs543912 chr1 184777177 C A 7.04E-04 Obesity (extreme) FAM129A intron 21935397 rs338566 chr1 184777467 A T 6.30E-04 Obesity (extreme) FAM129A intron 21935397 rs338567 chr1 184777813 T C 7.03E-04 Obesity (extreme) FAM129A intron 21935397 rs338568 chr1 184777880 C A 7.03E-04 Obesity (extreme) FAM129A intron 21935397 rs10797988 chr1 184783699 C T 6.38E-04 Obesity (extreme) FAM129A intron 21935397 rs10797988 chr1 184783699 C T 8.43E-06 Obesity-related traits FAM129A intron 23251661 rs10797989 chr1 184794386 C G 6.73E-04 Obesity (extreme) FAM129A intron 21935397 rs520605 chr1 184795779 C T 5.30E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FAM129A intron 24023788 rs4651234 chr1 184799343 C T 7.59E-04 Obesity (extreme) FAM129A intron 21935397 rs481215 chr1 184800395 T G 9.19E-04 Obesity (extreme) FAM129A intron 21935397 rs906285 chr1 184800630 G A 7.47E-04 Obesity (extreme) FAM129A intron 21935397 rs484847 chr1 184800757 T C 9.26E-04 Obesity (extreme) FAM129A intron 21935397 rs671114 chr1 184812433 A C 5.95E-04 Type 2 diabetes FAM129A intron 17846126 rs685595 chr1 184813262 A G 5.58E-04 Type 2 diabetes FAM129A intron 17846126 rs580869 chr1 184813775 G A 6.03E-04 Type 2 diabetes FAM129A intron 17846126 rs688292 chr1 184813885 C T 6.03E-04 Type 2 diabetes FAM129A intron 17846126 rs688292 chr1 184813885 C T 3.86E-05 Bladder cancer FAM129A intron 19648920 rs234654 chr1 184849148 T C 3.01E-05 Insulin Resistance FAM129A intron pha003062 rs234654 chr1 184849148 T C 5.82E-05 Insulin-related traits FAM129A intron pha003063 rs10911659 chr1 184905261 C T 9.44E-04 Multiple complex diseases FAM129A intron 17554300 rs234091 chr1 184919549 T A 2.00E-05 Schizophrenia(treatment response to risperidone) FAM129A intron 19850283 rs7512071 chr1 184921581 T C 1.10E-05 Urinary metabolites FAM129A intron 21572414 rs4651243 chr1 184922863 G A 2.29E-04 Multiple complex diseases FAM129A intron 17554300 rs7355169 chr1 184923061 C G 1.10E-05 Urinary metabolites FAM129A intron 21572414 rs234110 chr1 184943837 A G 1.04E-04 Hearing function / / 17255346 rs3753573 chr1 185014002 G A 2.00E-06 Obesity-related traits / / 23251661 rs34982714 chr1 185071735 A AC 3.50E-08 Urinary metabolites RNF2 UTR-3 21572414 rs12096987 chr1 185201061 T C 8.87E-05 Obsessive-compulsive disorder SWT1 intron 24821223 rs10798004 chr1 185265149 G A 1.81E-04 Celiac disease / / 23936387 rs11803823 chr1 185298185 T G 1.32E-04 Multiple complex diseases LOC100288079 intron 17554300 rs6424976 chr1 185317357 T C 6.28E-04 Type 2 diabetes / / 17463246 rs6689206 chr1 185325547 T G 9.31E-04 Type 2 diabetes / / 17463246 rs7545878 chr1 185326860 T G 9.62E-05 Postoperative ventricular dysfunction / / 21980348 rs7512337 chr1 185335532 T C 9.59E-05 Postoperative ventricular dysfunction / / 21980348 rs7548599 chr1 185336295 G A 4.89E-04 Type 2 diabetes / / 17463246 rs4651254 chr1 185341597 T C 6.18E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs10911713 chr1 185347488 C T 8.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs10911717 chr1 185369231 C T 7.85E-05 Postoperative ventricular dysfunction / / 21980348 rs10911722 chr1 185381591 C T 8.26E-05 Postoperative ventricular dysfunction / / 21980348 rs10752951 chr1 185383982 G A 5.68E-04 Multiple complex diseases / / 17554300 rs7552672 chr1 185413074 C T 7.69E-05 Serum metabolites / / 19043545 rs4323662 chr1 185430494 G T 6.78E-06 Odorant perception / / 23910658 rs4323662 chr1 185430494 G T 1.89E-05 Celiac disease / / 23936387 rs12039912 chr1 185438634 A G 2.69E-05 Sleep duration / / 22105623 rs17643861 chr1 185440175 G A 7.09E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs16824178 chr1 185456941 G A 2.97E-04 Multiple complex diseases / / 17554300 rs6663267 chr1 185464267 A G 2.76E-04 Type 2 diabetes / / 17463246 rs2181006 chr1 185465874 G T 3.55E-04 Type 2 diabetes / / 17463246 rs958564 chr1 185468919 A G 7.99E-04 Type 2 diabetes / / 17463246 rs7542383 chr1 185510221 C T 2.38E-04 Multiple complex diseases / / 17554300 rs1321996 chr1 185515461 A G 6.56E-05 Type 2 diabetes / / 17463246 rs534817 chr1 185520600 G A 1.55E-05 Type 2 diabetes / / 17463246 rs10798019 chr1 185522687 A C 9.76E-04 Alzheimer's disease / / 24755620 rs1321999 chr1 185524918 A G 2.15E-04 Type 2 diabetes / / 17463246 rs1321999 chr1 185524918 A G 2.07E-04 Insulin resistance / / 21901158 rs1321999 chr1 185524918 A G 8.02E-04 Obesity (extreme) / / 21935397 rs2821436 chr1 185525592 C G 1.28E-04 Type 2 diabetes / / 17463246 rs10911755 chr1 185526043 A C 3.89E-04 Type 2 diabetes / / 17463246 rs10911755 chr1 185526043 A C 4.83E-04 Insulin resistance / / 21901158 rs10911755 chr1 185526043 A C 7.90E-04 Obesity (extreme) / / 21935397 rs41453048 chr1 185529717 T C 4.61E-04 Type 2 diabetes / / 17463246 rs41453048 chr1 185529717 T C 5.70E-04 Insulin resistance / / 21901158 rs516040 chr1 185530242 A T 6.70E-05 Type 2 diabetes / / 17463246 rs11586588 chr1 185533305 G A 2.21E-04 Type 2 diabetes / / 17463246 rs11586588 chr1 185533305 G A 9.19E-04 Obesity (extreme) / / 21935397 rs556035 chr1 185533785 T C 3.14E-04 Alzheimer's disease / / 24755620 rs472975 chr1 185534476 A G 3.83E-05 Educational attainment / / 21694764 rs2842580 chr1 185536609 C A 3.39E-04 Alzheimer's disease / / 24755620 rs11583193 chr1 185540618 C A 6.49E-04 Obesity (extreme) / / 21935397 rs12402607 chr1 185543875 A G 6.66E-04 Obesity (extreme) / / 21935397 rs193087 chr1 185551100 G A 0.00001051 Sarcoidosis / / 22952805 rs12090554 chr1 185552348 G A 7.89E-07 Ventricular fibrillation in acute MI / / 20622880 rs12048982 chr1 185553146 T G 6.90E-04 Obesity (extreme) / / 21935397 rs12046138 chr1 185553524 G A 6.92E-04 Obesity (extreme) / / 21935397 rs193088 chr1 185554476 T C 9.24E-04 Alzheimer's disease / / 24755620 rs179776 chr1 185554489 T C 6.12E-05 Type 2 diabetes / / 17463246 rs333711 chr1 185561895 A G 7.81E-05 Type 2 diabetes / / 17463246 rs333713 chr1 185563418 G A 7.82E-05 Type 2 diabetes / / 17463246 rs333713 chr1 185563418 G A 8.12E-05 Insulin resistance / / 21901158 rs1407273 chr1 185578272 T C 3.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10798024 chr1 185603772 T G 9.59E-04 Multiple complex diseases / / 17554300 rs74133262 chr1 185684623 C T 1.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs11589747 chr1 185715394 C T 1.21E-05 Postoperative ventricular dysfunction HMCN1 intron 21980348 rs10489713 chr1 185724616 C T 0.00000292 Internal carotid artery thickness (near walls) HMCN1 intron 23487405 rs13375391 chr1 185794883 G A 9.00E-06 QRS duration HMCN1 intron 23534349 rs16824658 chr1 185864512 A G 3.76E-07 Gallstones HMCN1 intron 17632509 rs60502467 chr1 185878632 A G 0.00081 Breast cancer HMCN1 missense 23555315 rs6425015 chr1 186034964 C A 3.14E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10911810 chr1 186036398 T C 0.000000148 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2064790 chr1 186037691 A T 4.37E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2064789 chr1 186037769 G A 4.41E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2383430 chr1 186037949 C T 7.41E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs970578 chr1 186038467 C T 4.25E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs761905 chr1 186039006 C T 3.98E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs761904 chr1 186039340 G A 4.03E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs761903 chr1 186039428 G A 0.000000129 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10911811 chr1 186040062 G C 1.49E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2383431 chr1 186042623 C T 1.45E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10752960 chr1 186043232 G T 1.46E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs975398 chr1 186044237 G A 1.13E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10752961 chr1 186044847 T C 4.85E-08 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7550425 chr1 186045280 C G 1.21E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2383432 chr1 186046748 G A 6.93E-10 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10911812 chr1 186048208 T G 1.18E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10798035 chr1 186050417 A G 3.52E-08 Nonsyndromic striae distensae (stretch marks) HMCN1 missense 23633020 rs7530133 chr1 186051168 A T 9.35E-10 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10798036 chr1 186052962 C G 6.90E-10 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10911814 chr1 186053440 A G 1.07E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs4651295 chr1 186054055 A G 1.11E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10911815 chr1 186054796 A G 1.48E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs6425016 chr1 186055177 A G 2.28E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs6425017 chr1 186055371 A G 1.61E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs6687977 chr1 186059551 A G 6.45E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs1998088 chr1 186061099 G A 2.01E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs4651297 chr1 186061950 G A 1.87E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2073308 chr1 186063143 A T 3.16E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs4651298 chr1 186063863 T C 3.50E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2180480 chr1 186064781 A T 2.82E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs61831302 chr1 186064858 A C 0.0000287 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs1022670 chr1 186064868 A G 3.90E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2891228 chr1 186065216 C T 4.40E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2891229 chr1 186065382 C T 4.46E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2038601 chr1 186065539 T G 8.38E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs1853249 chr1 186067296 A C 2.57E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs1590273 chr1 186067895 A G 2.65E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs1830627 chr1 186068248 A G 2.73E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs1923460 chr1 186068597 A G 2.76E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10911819 chr1 186069140 C T 0.000000164 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2383433 chr1 186070778 A G 9.82E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs716756 chr1 186070902 A G 5.50E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs716755 chr1 186071053 T G 3.71E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10911820 chr1 186073181 C A 5.34E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7527490 chr1 186074918 A G 2.53E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7552781 chr1 186075520 C T 6.81E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs6701244 chr1 186076291 C T 0.000000197 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7511761 chr1 186077302 C A 2.89E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs1555495 chr1 186077463 A G 3.92E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10911821 chr1 186080269 G C 7.69E-08 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7555520 chr1 186081918 C T 1.45E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7555906 chr1 186082316 C G 2.35E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs4651299 chr1 186082509 C T 1.89E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs4233125 chr1 186082632 G A 5.21E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs12078938 chr1 186083534 C T 0.000000136 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs12078939 chr1 186083536 C A 0.000000136 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs720971 chr1 186085768 T C 1.74E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs720972 chr1 186085897 C A 2.01E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10157742 chr1 186086578 G A 1.42E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10157924 chr1 186087544 G C 1.89E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7543494 chr1 186093558 T G 3.27E-09 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs77123846 chr1 186101317 G A 0.0000128 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10911827 chr1 186101964 C T 0.0000797 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs10489753 chr1 186108672 G A 2.90E-04 Stroke HMCN1 intron pha002887 rs17531405 chr1 186113852 G C 4.69E-04 Type 2 diabetes HMCN1 intron 17463246 rs6703518 chr1 186116797 G T 0.000000881 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7512168 chr1 186119056 T C 0.000000709 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs1322376 chr1 186120139 T G 0.000000507 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7545010 chr1 186126099 A G 0.00000076 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7525679 chr1 186126793 G A 0.0000171 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs6673026 chr1 186132451 G C 0.00000784 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2208692 chr1 186133290 C A 0.00000499 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs72707469 chr1 186134561 C T 0.00000793 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs6680616 chr1 186135081 C G 0.00000961 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs78002252 chr1 186135231 A C 0.0000488 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs6425021 chr1 186135236 G A 0.000000237 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7549613 chr1 186136289 T C 0.00000468 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs2383457 chr1 186136572 T C 0.00000956 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs11582026 chr1 186140907 A G 0.00000447 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs4651302 chr1 186141301 G A 0.000000785 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs12120763 chr1 186141836 G T 0.0000142 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs12123389 chr1 186142073 A G 0.00000492 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7554865 chr1 186143052 T C 0.00000602 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs7554872 chr1 186143082 T C 0.0000109 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs911743 chr1 186144104 A C 0.00000668 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs61831358 chr1 186146175 A G 0.0000723 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs11579683 chr1 186149017 G A 0.0000127 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs1407434 chr1 186149032 G A 3.59E-04 Lung function (forced vital capacity) HMCN1 intron 24023788 rs10911836 chr1 186149235 C T 0.00000726 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs16825040 chr1 186151493 C G 0.00000401 Nonsyndromic striae distensae (stretch marks) HMCN1 intron 23633020 rs680638 chr1 186156514 C T 1.26E-04 Bipolar disorder,schizoaffective HMCN1 intron 19567891 rs1322375 chr1 186163076 T C 3.78E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs1885522 chr1 186172443 C A 4.02E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs676236 chr1 186173178 A G 2.77E-04 Bipolar disorder,schizoaffective / / 19567891 rs595888 chr1 186174823 C T 6.71E-04 Bipolar disorder,schizoaffective / / 19567891 rs13375677 chr1 186178238 T C 6.34E-05 Personality dimensions / / 18957941 rs1743664 chr1 186190201 T G 6.87E-05 Personality dimensions / / 18957941 rs586281 chr1 186199484 G A 6.18E-06 Personality dimensions / / 18957941 rs586281 chr1 186199484 G A 6.20E-06 Personality dimensions / / 21173776 rs6671112 chr1 186232656 A C 7.90E-05 Response to statin therapy / / 20339536 rs6671112 chr1 186232656 A C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1285115 chr1 186237510 C T 8.90E-05 Response to statin therapy / / 20339536 rs857584 chr1 186241738 T C 8.00E-05 Response to statin therapy / / 20339536 rs704308 chr1 186242675 A C 5.70E-05 Response to statin therapy / / 20339536 rs704308 chr1 186242675 A C 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs3820182 chr1 186290333 G A 6.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TPR intron 20877124 rs58030082 chr1 186313108 C T 0.000013 Breast cancer TPR missense 23555315 rs11806304 chr1 186372865 A G 9.60E-04 Response to cytidine analogues (gemcitabine) C1orf27 intron 24483146 rs6665157 chr1 186379265 G A 3.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C1orf27 intron 20877124 rs6665157 chr1 186379265 G A 9.25E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C1orf27 intron 20877124 rs6665157 chr1 186379265 G A 8.00E-06 Hypertension C1orf27 intron 22384028 rs6425029 chr1 186406546 G T 5.69E-04 Multiple complex diseases / / 17554300 rs1882926 chr1 186411579 C A 4.22E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs6672638 chr1 186417484 T C 1.86E-05 Response to tocilizumab in rheumatoid arthritis PDC intron 22491018 rs12062743 chr1 186447591 C T 2.58E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs497285 chr1 186454429 C A 2.94E-05 Serum alpha1-antitrypsin levels / / 23990791 rs480075 chr1 186456336 A G 9.91E-04 Type 2 diabetes / / 17463246 rs480075 chr1 186456336 A G 3.20E-04 Type 2 diabetes / / 17463249 rs480075 chr1 186456336 A G 3.24E-04 Multiple complex diseases / / 17554300 rs480075 chr1 186456336 A G 2.76E-05 Serum alpha1-antitrypsin levels / / 23990791 rs10911877 chr1 186506612 G A 7.88E-04 Insulin resistance / / 21901158 rs7542810 chr1 186532231 G A 5.84E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs1569879 chr1 186547952 C T 9.01E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs1013665 chr1 186548140 C T 1.05E-05 Serum alpha1-antitrypsin levels / / 23990791 rs4140432 chr1 186550535 T G 7.28E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs10798052 chr1 186577925 C T 7.20E-04 Insulin resistance / / 21901158 rs11584662 chr1 186580824 G T 4.92E-05 Male-pattern baldness / / 18849994 rs17520924 chr1 186593131 C T 4.86E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10489396 chr1 186598211 C T 5.88E-04 Insulin resistance / / 21901158 rs10489397 chr1 186598610 C A 3.31E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs7514491 chr1 186599018 T C 1.19E-05 Serum alpha1-antitrypsin levels / / 23990791 rs2383513 chr1 186599524 T C 1.73E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs11811047 chr1 186601141 G A 5.99E-04 Insulin resistance / / 21901158 rs12405141 chr1 186623470 A G 8.24E-04 Type 2 diabetes / / 17463246 rs12405141 chr1 186623470 A G 3.04E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs10911901 chr1 186624006 A C 1.03E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs9783017 chr1 186627831 C T 9.56E-04 Type 2 diabetes / / 17463246 rs10911902 chr1 186632317 C T 6.54E-04 Type 2 diabetes / / 17463246 rs10911902 chr1 186632317 C T 2.00E-06 Schizophrenia / / 18347602 rs4648310 chr1 186640525 T C 5.90E-06 Blood pressure PTGS2 nearGene-3 21060006 rs4648310 chr1 186640525 T C 5.90E-06 Blood pressure PTGS2 nearGene-3 21060006 rs2206593 chr1 186642429 A G 4.60E-06 Serum alpha1-antitrypsin levels PTGS2 UTR-3 23990791 rs5275 chr1 186643058 A G 2.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTGS2 UTR-3 20877124 rs2745557 chr1 186649221 A G 2.43E-05 Serum alpha1-antitrypsin levels PTGS2 intron 23990791 rs20417 chr1 186650321 C G 1 Drug response to Rofecoxib PTGS2 nearGene-5 15138244 rs20417 chr1 186650321 C G 1 Drug response to Rofecoxib PTGS2 nearGene-5 15150618 rs20417 chr1 186650321 C G 1 Drug response to Rofecoxib PTGS2 nearGene-5 15767339 rs20417 chr1 186650321 C G 1 Drug response to Rofecoxib PTGS2 nearGene-5 16678543 rs20417 chr1 186650321 C G 1 Drug response to Rofecoxib PTGS2 nearGene-5 17495879 rs2745559 chr1 186652002 A C 3.03E-05 Serum alpha1-antitrypsin levels / / 23990791 rs10911905 chr1 186652395 T G 2.23E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs34093265 chr1 186652395 T TG 2.23E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs2143417 chr1 186653787 G T 3.65E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs1119065 chr1 186658072 C T 1.03E-05 Serum alpha1-antitrypsin levels / / 23990791 rs2383529 chr1 186669092 A G 7.19E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs6665419 chr1 186674561 C A 2.51E-04 Multiple complex diseases / / 17554300 rs12401885 chr1 186682875 T C 3.57E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs2205953 chr1 186692562 T C 7.78E-04 Alcohol dependence / / 21314694 rs12088741 chr1 186718317 T A 3.92E-04 Multiple complex diseases / / 17554300 rs4140564 chr1 186725003 G A 3.00E-06 Knee osteoarthritis / / 18471798 rs10489401 chr1 186742947 A G 6.32E-05 Urate levels / / 23263486 rs4651330 chr1 186816650 C A 4.96E-04 Alzheimer's disease PLA2G4A intron 17998437 rs10752979 chr1 186835995 A G 9.05E-04 Alzheimer's disease PLA2G4A intron 17998437 rs2223307 chr1 186844926 C T 7.33E-04 Response to taxane treatment (placlitaxel) PLA2G4A intron 23006423 rs2223309 chr1 186848093 G A 5.80E-04 Insulin resistance PLA2G4A intron 21901158 rs1980444 chr1 186850960 T C 2.10E-06 Glioma (high-grade) PLA2G4A intron 19578366 rs12042344 chr1 186858135 T C 9.20E-04 Insulin resistance PLA2G4A intron 21901158 rs12720541 chr1 186870072 G T 9.00E-06 Epilepsy (generalized) PLA2G4A intron 22949513 rs6698103 chr1 186870546 G C 7.87E-04 Suicide attempts in bipolar disorder PLA2G4A intron 21423239 rs10798069 chr1 186875459 G T 8.41E-05 Partial epilepsies PLA2G4A intron 20522523 rs10798069 chr1 186875459 G T 1.00E-04 Cognitive impairment induced by topiramate PLA2G4A intron 22091778 rs6686848 chr1 186887107 C A 1.11E-04 Suicide attempts in bipolar disorder PLA2G4A intron 21423239 rs6674263 chr1 186936162 A T 6.63E-07 Red blood cell traits PLA2G4A intron 23222517 rs6672835 chr1 186940756 A T 9.91E-07 Red blood cell traits PLA2G4A intron 23222517 rs12720690 chr1 186948221 G T 0.000000869 Cholesterol,total PLA2G4A intron 23063622 rs10489410 chr1 186954195 T G 5.44E-07 Lipoproteins PLA2G4A intron pha003079 rs761516 chr1 186961326 T G 5.15E-05 Alcohol dependence / / 21314694 rs1474797 chr1 186967193 A G 1.13E-04 Opioid sensitivity / / 23183491 rs6689013 chr1 186980818 A C 7.40E-06 Urinary metabolites / / 21572414 rs10752993 chr1 186981339 C T 3.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2207215 chr1 186985141 C T 3.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4233126 chr1 186999604 A T 1.19E-04 Type 2 diabetes / / 17463246 rs4233126 chr1 186999604 A T 8.27E-05 Serum metabolites / / 19043545 rs1884022 chr1 187002419 A C 3.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7540422 chr1 187005310 A G 6.07E-05 Information processing speed / / 21130836 rs1297676 chr1 187041011 T C 9.90E-05 Serum metabolites / / 19043545 rs2144438 chr1 187054897 T C 6.70E-06 Urinary metabolites / / 21572414 rs7511950 chr1 187055561 A G 7.96E-05 Arthritis (juvenile idiopathic) / / 22354554 rs10911998 chr1 187057847 C T 4.49E-05 Autism / / 24189344 rs1008407 chr1 187062807 A G 1.00E-04 Information processing speed / / 21130836 rs10798085 chr1 187066811 T G 3.40E-06 Urinary metabolites / / 21572414 rs118654 chr1 187070355 G T 4.30E-06 Urinary metabolites / / 21572414 rs230611 chr1 187093666 T A 7.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs230607 chr1 187096481 C A 7.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs230607 chr1 187096481 C A 9.91E-05 Body Composition / / pha003012 rs230607 chr1 187096481 C A 3.28E-05 Body Mass Index / / pha003021 rs12564176 chr1 187130516 A G 5.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12133085 chr1 187135612 C A 2.66E-06 Carotenoid and tocopherol levels / / 19185284 rs10494592 chr1 187158604 T G 2.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs330746 chr1 187233123 T C 5.29E-05 Body Composition / / pha003012 rs330746 chr1 187233123 T C 6.89E-05 Body Mass Index / / pha003021 rs330749 chr1 187237164 G A 5.58E-05 Body Composition / / pha003012 rs330749 chr1 187237164 G A 7.23E-05 Body Mass Index / / pha003021 rs4651370 chr1 187239092 T A 0.00000528 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4651370 chr1 187239092 T A 2.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11807539 chr1 187243386 G A 9.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2453727 chr1 187247150 C T 4.72E-04 Schizophrenia / / 19197363 rs7523591 chr1 187261732 T A 0.000195 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7523591 chr1 187261732 T A 1.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7532843 chr1 187264446 T C 0.0001919 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7532843 chr1 187264446 T C 1.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12143542 chr1 187266802 G A 4.03E-05 Body Composition / / pha003012 rs12143542 chr1 187266802 G A 8.26E-05 Body Mass Index / / pha003021 rs12118757 chr1 187267705 T C 0.0001454 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12118757 chr1 187267705 T C 1.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12117650 chr1 187275669 G A 0.0001029 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12117650 chr1 187275669 G A 1.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12733231 chr1 187276220 A G 0.0001016 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12733231 chr1 187276220 A G 1.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12739992 chr1 187277743 G A 0.00009412 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12739992 chr1 187277743 G A 9.41E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12125797 chr1 187279673 T C 0.00009253 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12125797 chr1 187279673 T C 9.25E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10752999 chr1 187279690 A C 2.82E-05 Body Composition / / pha003012 rs10752999 chr1 187279690 A C 5.69E-05 Body Mass Index / / pha003021 rs12134274 chr1 187289832 A C 0.0003694 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12134274 chr1 187289832 A C 3.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12142623 chr1 187290406 C A 0.00001358 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12142623 chr1 187290406 C A 4.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6683451 chr1 187292608 A C 9.77E-05 Lipoproteins / / pha003079 rs1032538 chr1 187295508 C T 1.37E-05 Body Composition / / pha003012 rs1032538 chr1 187295508 C T 7.90E-05 Body Mass Index / / pha003021 rs1285496 chr1 187295740 C A 1.14E-05 Body Composition / / pha003012 rs1285496 chr1 187295740 C A 6.57E-05 Body Mass Index / / pha003021 rs1148757 chr1 187320698 G A 3.76E-04 Taste perception / / 22132133 rs2802475 chr1 187327396 A G 3.02E-05 Body Composition / / pha003012 rs2489646 chr1 187329086 A C 6.42E-05 Body Composition / / pha003012 rs931590 chr1 187341438 T C 3.09E-07 Body Composition / / pha003012 rs931590 chr1 187341438 T C 1.12E-06 Body Mass Index / / pha003021 rs4409608 chr1 187353527 A G 2.63E-07 Body Composition / / pha003012 rs4409608 chr1 187353527 A G 1.09E-06 Body Mass Index / / pha003021 rs11583351 chr1 187355994 A G 1.94E-05 Body Composition / / pha003012 rs11583351 chr1 187355994 A G 7.56E-05 Body Mass Index / / pha003021 rs4651377 chr1 187381112 G A 2.23E-05 Glycosylated haemoglobin levels / / 17255346 rs7552942 chr1 187382298 T C 1.37E-05 Glycosylated haemoglobin levels / / 17255346 rs7516204 chr1 187389942 T C 8.95E-05 Glycosylated haemoglobin levels / / 17255346 rs12142409 chr1 187390668 G A 2.33E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2244067 chr1 187412042 A T 7.00E-06 Metabolite levels (5-HIAA) / / 23319000 rs1938512 chr1 187422872 C A 3.45E-04 Alcohol dependence / / 24277619 rs12137534 chr1 187428231 A G 5.43E-04 Type 2 diabetes / / 17463246 rs12088162 chr1 187429753 A T 2.44E-04 Type 2 diabetes / / 17463246 rs10798113 chr1 187432059 G A 9.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs1892543 chr1 187434767 C T 5.23E-05 Serum metabolites / / 19043545 rs1938522 chr1 187435580 G T 5.27E-05 Serum metabolites / / 19043545 rs2249494 chr1 187435909 G T 8.16E-04 Type 2 diabetes / / 17463246 rs10732980 chr1 187440916 A G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4651390 chr1 187445049 C A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs16827144 chr1 187467969 A T 2.17E-04 Multiple complex diseases / / 17554300 rs12028808 chr1 187478809 T G 7.04E-05 Type 2 diabetes / / 23300278 rs7555613 chr1 187479735 A C 0.0008761 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7555613 chr1 187479735 A C 8.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10912086 chr1 187490224 A C 0.0008598 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10912086 chr1 187490224 A C 8.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12130665 chr1 187495140 T C 0.0008718 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12130665 chr1 187495140 T C 8.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12134218 chr1 187495399 A G 0.0008694 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12134218 chr1 187495399 A G 8.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1538481 chr1 187498000 T A 0.0008852 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1538481 chr1 187498000 T A 8.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10912090 chr1 187500052 C T 0.0008782 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10912090 chr1 187500052 C T 8.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10912092 chr1 187509488 C T 0.00088 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10912092 chr1 187509488 C T 8.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2891285 chr1 187522674 T C 8.96E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2383655 chr1 187533238 G A 5.51E-04 Multiple complex diseases / / 17554300 rs10494599 chr1 187534561 A G 7.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs1339083 chr1 187552665 T C 3.24E-05 Orofacial clefts / / 22419666 rs12127474 chr1 187557096 T C 9.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs12075120 chr1 187573295 G A 2.67E-05 Orofacial clefts / / 22419666 rs12075120 chr1 187573295 G A 1.44E-05 Creatinine levels / / pha003069 rs1416478 chr1 187574028 G A 3.92E-05 Psoriasis / / 18364390 rs2383658 chr1 187581303 G A 7.37E-05 Orofacial clefts / / 22419666 rs12746529 chr1 187588239 T C 9.01E-06 Creatinine levels / / pha003069 rs16827381 chr1 187599437 G A 7.25E-05 Type 2 diabetes / / 17463246 rs6686371 chr1 187607131 C A 1.20E-05 Urinary metabolites / / 21572414 rs6686651 chr1 187607223 G A 2.34E-04 Smoking initiation / / 24665060 rs10753015 chr1 187611232 G A 7.90E-06 Urinary metabolites / / 21572414 rs12749748 chr1 187623971 T C 1.10E-05 Urinary metabolites / / 21572414 rs12749748 chr1 187623971 T C 2.85E-05 Creatinine levels / / pha003069 rs10494602 chr1 187628458 C T 4.07E-05 Creatinine levels / / pha003069 rs17613702 chr1 187651919 C T 8.41E-05 Smoking initiation / / 24665060 rs2891292 chr1 187652296 C T 7.85E-04 Smoking initiation / / 24665060 rs3120952 chr1 187656368 C T 6.50E-07 Urinary metabolites / / 21572414 rs3127494 chr1 187657248 G A 5.30E-07 Urinary metabolites / / 21572414 rs953554 chr1 187661530 T C 6.00E-06 Smoking initiation / / 24665060 rs3120959 chr1 187662571 A G 1.92E-04 Fibrinogen / / 17255346 rs16827441 chr1 187668728 T C 5.06E-04 Smoking initiation / / 24665060 rs6685655 chr1 187677162 G A 7.80E-05 Smoking initiation / / 24665060 rs4501794 chr1 187677281 G T 8.29E-04 Multiple complex diseases / / 17554300 rs6425114 chr1 187681358 A C 7.48E-05 Creatinine levels / / pha003069 rs4233130 chr1 187685344 A G 8.96E-05 Smoking initiation / / 24665060 rs4498762 chr1 187689619 A G 4.16E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs6671961 chr1 187690536 A T 2.10E-05 Urinary metabolites / / 21572414 rs147535159 chr1 187692731 T C 0.0000996 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs151023900 chr1 187693831 A G 0.00000439 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs117260858 chr1 187696963 T C 0.00000433 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs117232653 chr1 187702935 T C 0.0000044 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs79918766 chr1 187703615 C T 0.0000044 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6701697 chr1 187707768 C G 3.08E-04 Smoking initiation / / 24665060 rs75445209 chr1 187707926 G A 0.00000453 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6673165 chr1 187710134 T A 0.00000435 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10912159 chr1 187711459 G A 8.55E-05 Socioeconomic Factors / / pha003066 rs10912160 chr1 187711717 G A 9.28E-08 Metabolite levels / / 23281178 rs6697553 chr1 187713440 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10912162 chr1 187715179 G C 8.22E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs118069725 chr1 187721126 G T 0.00000545 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs117902173 chr1 187721954 C A 0.00000354 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10753026 chr1 187724610 G A 1.10E-06 Urinary metabolites / / 21572414 rs77850287 chr1 187725322 G A 0.00000254 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs114735216 chr1 187725506 G A 0.00000262 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs139733258 chr1 187726488 C T 0.00000255 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs116411447 chr1 187729331 T C 0.00000272 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs3095425 chr1 187729787 T G 1.20E-05 Urinary metabolites / / 21572414 rs3127511 chr1 187730546 G C 6.40E-07 Urinary metabolites / / 21572414 rs147066159 chr1 187736279 A G 0.00000247 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1158512 chr1 187744623 C T 1.41E-04 Smoking initiation / / 24665060 rs3123045 chr1 187747787 T C 4.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3123045 chr1 187747787 T C 7.92E-04 Smoking initiation / / 24665060 rs117122963 chr1 187747891 G A 0.00000259 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs967778 chr1 187748399 C T 1.85E-04 Smoking initiation / / 24665060 rs10912174 chr1 187749447 T C 6.57E-04 Smoking initiation / / 24665060 rs116883766 chr1 187752522 G A 0.00000151 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs116229031 chr1 187754464 C A 0.00000186 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1476901 chr1 187760345 T C 8.88E-05 Schizophrenia / / 19571809 rs10798148 chr1 187779509 T C 9.20E-05 Personality dimensions / / 18957941 rs2495474 chr1 187813938 T G 5.94E-05 Serum metabolites / / 19043545 rs2430149 chr1 187821262 C T 8.72E-05 Serum metabolites / / 19043545 rs2215698 chr1 187822931 A G 6.52E-06 Serum metabolites / / 19043545 rs2430144 chr1 187823537 A G 7.83E-05 Body Mass Index / / pha003014 rs2430129 chr1 187840553 C T 9.68E-06 Serum metabolites / / 19043545 rs800820 chr1 187846268 T C 1.59E-05 Serum metabolites / / 19043545 rs776797 chr1 187888914 G A 8.03E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs655167 chr1 187902981 A G 7.00E-06 Hypothyroidism / / 22493691 rs1432437 chr1 187908413 A G 5.41E-04 Type 2 diabetes / / 17463246 rs1159069 chr1 187912258 C T 6.95E-04 Type 2 diabetes / / 17463246 rs1159069 chr1 187912258 C T 8.86E-04 Multiple complex diseases / / 17554300 rs2195856 chr1 187922876 A C 3.21E-04 Type 2 diabetes / / 17463246 rs7539069 chr1 187940867 A G 6.60E-05 HIV-1 control / / 20041166 rs12404590 chr1 187984417 C A 2.76E-04 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs4650751 chr1 188012281 T G 6.02E-04 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs7544859 chr1 188013287 A G 2.53E-04 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs12131117 chr1 188015078 T C 6.50E-04 Acute lung injury / / 22295056 rs1323012 chr1 188037933 G A,C,T 4.59E-04 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs10798164 chr1 188048096 T G 4.03E-04 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs7523908 chr1 188048430 G C 4.03E-04 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs1407709 chr1 188062679 T C 4.00E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs6676981 chr1 188075597 C A 7.12E-04 Multiple complex diseases / / 17554300 rs10489764 chr1 188085833 T C 8.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12756923 chr1 188097356 T C 7.59E-04 Multiple complex diseases / / 17554300 rs10912249 chr1 188098441 A G 7.72E-04 Multiple complex diseases / / 17554300 rs1923808 chr1 188102053 C T 8.94E-04 HIV-1 viral setpoint / / 17641165 rs1323004 chr1 188108625 G A 8.94E-04 HIV-1 viral setpoint / / 17641165 rs12129062 chr1 188117353 C T 1.04E-05 Major depressive disorder / / 19107115 rs7554161 chr1 188124782 T C 8.91E-04 Multiple complex diseases / / 17554300 rs354252 chr1 188129116 G C 8.00E-04 Multiple complex diseases / / 17554300 rs12040679 chr1 188134928 C T 9.47E-04 Multiple complex diseases / / 17554300 rs10494612 chr1 188155305 C T 2.95E-04 Multiple complex diseases / / 17554300 rs1487492 chr1 188162030 A G 5.69E-04 HIV-1 viral setpoint / / 17641165 rs12128431 chr1 188162228 G A 6.97E-05 Acute lung injury / / 22295056 rs12143302 chr1 188162327 C A 6.97E-05 Acute lung injury / / 22295056 rs7414437 chr1 188169106 A G 5.81E-05 Heart Rate / / pha003053 rs10494611 chr1 188171319 C G 5.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12140374 chr1 188175132 T C 7.45E-04 Acute lung injury / / 22295056 rs11810998 chr1 188178381 T G 2.81E-05 Major depressive disorder / / 19107115 rs11810998 chr1 188178381 T G 7.31E-04 Acute lung injury / / 22295056 rs12143522 chr1 188187052 G C 6.64E-04 Acute lung injury / / 22295056 rs6425147 chr1 188192177 G A 3.17E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs3010654 chr1 188248649 T C 7.27E-05 Response to methylphenidate treatment / / 21130132 rs12136061 chr1 188275062 C T 1.10E-04 IgE levels in asthmatics / / 23967269 rs10494608 chr1 188285804 T C 4.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10912319 chr1 188297287 C T 7.63E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4463623 chr1 188300868 C T 1.00E-06 Hypertension / / 22384028 rs4434808 chr1 188308289 C T 3.00E-06 Hypertension / / 22384028 rs12126176 chr1 188314941 C G 3.18E-04 Insulin resistance / / 21901158 rs1387343 chr1 188328650 C T 8.00E-06 Hypertension / / 22384028 rs12031313 chr1 188352158 T C 2.00E-05 Urinary metabolites / / 21572414 rs12125250 chr1 188379428 C A 4.00E-06 Economic and political preferences / / 22566634 rs12569034 chr1 188381951 A C 2.20E-05 Urinary metabolites / / 21572414 rs12142669 chr1 188383316 T C 3.00E-06 Obesity-related traits / / 23251661 rs10798210 chr1 188384464 T C 2.65E-06 Obesity-related traits / / 23251661 rs1472002 chr1 188390606 T G 8.19E-05 Cognitive performance / / 19734545 rs1472002 chr1 188390606 T G 2.00E-05 HIV-1 control / / 20041166 rs284046 chr1 188425733 A C 6.28E-04 Nicotine dependence / / 17158188 rs10912417 chr1 188457478 G A 7.45E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2170561 chr1 188463044 T A 0.0000034 Amygdala reactivity / / 22856363 rs12048929 chr1 188465070 G A 5.57E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12038869 chr1 188469106 C T 5.02E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs284113 chr1 188477749 G T 1.10E-05 Hypertension / / 22384028 rs12123962 chr1 188478589 G A 9.33E-04 Aortic root size / / 21223598 rs1906768 chr1 188490214 A C 5.21E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12022365 chr1 188509218 A G 5.21E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs900334 chr1 188512442 C A 6.55E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10912450 chr1 188533300 G A 8.97E-05 Multiple complex diseases / / 17554300 rs2312283 chr1 188629757 A G 7.96E-05 Insulin resistance / / 21901158 rs34906964 chr1 188629757 A AT 7.96E-05 Insulin resistance / / 21901158 rs10921075 chr1 188678917 C A,T 7.50E-05 Progressive supranuclear palsy / / 21685912 rs4551597 chr1 188764543 T C 9.54E-05 Alzheimer's disease (late onset) / / 21379329 rs12029028 chr1 188788576 G T 6.69E-04 Taste perception / / 22132133 rs16829481 chr1 188852259 C T 2.93E-05 Multiple complex diseases / / 17554300 rs16829586 chr1 188876279 C T 8.45E-05 Orofacial clefts / / 22419666 rs9651064 chr1 188929353 T C 0.0008608 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9651064 chr1 188929353 T C 8.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9651065 chr1 188930161 A G 0.0008638 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9651065 chr1 188930161 A G 8.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1373936 chr1 188961641 A C 6.45E-05 ldl cholesterol / / pha003076 rs2053675 chr1 188967356 A G 6.58E-05 ldl cholesterol / / pha003076 rs10921102 chr1 188994596 G A 8.98E-05 ldl cholesterol / / pha003076 rs10921112 chr1 188997868 C A 6.27E-05 Serum metabolites / / 19043545 rs7528687 chr1 189007626 A G 0.0007254 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7528687 chr1 189007626 A G 7.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6428096 chr1 189010340 T C 3.65E-05 Serum metabolites / / 19043545 rs6428096 chr1 189010340 T C 8.13E-04 Response to TNF antagonist treatment / / 21061259 rs12046366 chr1 189022599 G T 4.55E-05 Serum metabolites / / 19043545 rs12046366 chr1 189022599 G T 7.97E-04 Response to TNF antagonist treatment / / 21061259 rs10921184 chr1 189029198 C T 7.88E-05 Parkinson's disease / / 21812969 rs4508010 chr1 189034273 G A 7.62E-05 Serum metabolites / / 19043545 rs4508010 chr1 189034273 G A 9.11E-04 Response to TNF antagonist treatment / / 21061259 rs1912910 chr1 189047232 G C 9.18E-04 Response to TNF antagonist treatment / / 21061259 rs2175550 chr1 189079402 C T 2.63E-05 Serum metabolites / / 19043545 rs2175550 chr1 189079402 C T 5.58E-04 Response to TNF antagonist treatment / / 21061259 rs10754040 chr1 189079982 C T 2.69E-05 Serum metabolites / / 19043545 rs10754040 chr1 189079982 C T 6.95E-04 Response to TNF antagonist treatment / / 21061259 rs12138517 chr1 189138755 T G 4.40E-05 Iron levels / / 21208937 rs1539388 chr1 189147180 T G 8.28E-05 Serum metabolites / / 19043545 rs1342553 chr1 189180993 A G 9.33E-05 Serum metabolites / / 19043545 rs1342553 chr1 189180993 A G 1.27E-04 Progressive supranuclear palsy / / 21685912 rs1342554 chr1 189181078 C T 8.57E-05 Serum metabolites / / 19043545 rs4313401 chr1 189384373 A G 6.41E-05 Serum metabolites / / 19043545 rs11800563 chr1 189432044 C G 8.46E-05 Serum metabolites / / 19043545 rs578175605 chr1 189432044 C CAAATCACTT 8.46E-05 Serum metabolites / / 19043545 rs10922227 chr1 189520505 G A 4.34E-05 Serum metabolites / / 19043545 rs12132580 chr1 189523652 T C 4.98E-05 Orofacial clefts / / 22419666 rs12127810 chr1 189526779 C T 1.93E-04 Insulin resistance / / 21901158 rs10489759 chr1 189589339 C T 8.00E-08 Immune response to smallpox vaccine (IL-6) / / 22542470 rs10737562 chr1 189723623 A G 7.00E-06 Systemic lupus erythematosus / / 21408207 rs12566065 chr1 189736833 T C 1.26E-05 Serum metabolites / / 19043545 rs12742200 chr1 189758533 G A 5.77E-04 Tourette syndrome / / 22889924 rs11578153 chr1 189758772 C T 6.05E-05 Serum albumin level / / pha003084 rs2418508 chr1 189761051 A G 1.71E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1517100 chr1 189786171 G A 8.18E-04 Schizophrenia / / 21674006 rs10800667 chr1 189788319 A G 5.02E-04 Depression (quantitative trait) / / 20800221 rs12138327 chr1 189791316 C T 5.08E-04 Heart Failure / / pha002884 rs1568133 chr1 189822612 G A 2.18E-04 Multiple complex diseases / / 17554300 rs2944697 chr1 189830133 G T 3.85E-05 Cognitive performance / / 19734545 rs3005708 chr1 189835520 G A 1.39E-04 Multiple complex diseases / / 17554300 rs1356344 chr1 189837106 C G 4.42E-04 Multiple complex diseases / / 17554300 rs1400544 chr1 189861404 A T 6.00E-06 Subclinical atherosclerosis / / 17903303 rs10920278 chr1 189970400 T G 8.53E-05 Serum metabolites / / 19043545 rs10737578 chr1 189983720 T C 2.92E-05 Body Mass Index / / pha002896 rs4845211 chr1 189986745 C A 3.51E-05 Body Mass Index / / pha002896 rs4845214 chr1 189990412 G A 5.96E-05 Body Mass Index / / pha002896 rs9970628 chr1 189994233 C T 3.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs1935881 chr1 190066386 T C 6.00E-06 Echocardiographic traits / / 17903301 rs17375108 chr1 190070919 T C 4.89E-04 Alzheimer's disease (late onset) FAM5C intron 21379329 rs7540848 chr1 190096421 A G 0.0000231 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FAM5C intron 22628534 rs1418808 chr1 190104227 C T 0.0000284 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FAM5C intron 22628534 rs10920654 chr1 190131750 C T 4.94E-05 Brain structure FAM5C intron 22504417 rs16832159 chr1 190146211 T A 4.25E-04 Multiple complex diseases FAM5C intron 17554300 rs12041138 chr1 190149198 G A 0.0000239 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FAM5C intron 22628534 rs815330 chr1 190164775 C T 5.13E-05 Body Mass Index FAM5C intron pha003015 rs6681246 chr1 190186387 G A 0.0000423 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FAM5C intron 22628534 rs2419063 chr1 190256835 A G 8.96E-05 Orofacial clefts FAM5C intron 22419666 rs567393 chr1 190259941 T C 4.80E-04 Atrial fibrillation FAM5C intron 21846873 rs655598 chr1 190287713 G A 1.32E-04 Stroke FAM5C intron pha002887 rs1540513 chr1 190301532 C T 9.10E-04 Multiple complex diseases FAM5C intron 17554300 rs1540513 chr1 190301532 C T 4.07E-05 Orofacial clefts FAM5C intron 22419666 rs718609 chr1 190307072 G A 0.0000311 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FAM5C intron 22628534 rs980180 chr1 190317108 A G 3.88E-04 Multiple complex diseases FAM5C intron 17554300 rs1148613 chr1 190337300 A C 2.94E-04 Alzheimer's disease FAM5C intron 17998437 rs725106 chr1 190347665 G A 4.35E-04 Alzheimer's disease FAM5C intron 17998437 rs17377331 chr1 190369508 G C 1.32E-04 Coronary Artery Disease FAM5C intron 17634449 rs17377331 chr1 190369508 G C 7.77E-05 Cytomegalovirus antibody response FAM5C intron 21993531 rs2490271 chr1 190442971 G A 3.44E-04 Crohn's disease FAM5C intron 17435756 rs1093016 chr1 190458764 C T 3.10E-04 Intelligence (childhood) / / 23358156 rs1093016 chr1 190458764 C T 8.16E-04 Iron levels / / pha002876 rs1604355 chr1 190459007 C G 1.29E-04 Cardiovascular disease / / 17903304 rs814941 chr1 190466822 G A 1.22E-05 Serum metabolites / / 19043545 rs814942 chr1 190467230 G A 1.31E-05 Serum metabolites / / 19043545 rs814948 chr1 190470311 A G 1.22E-05 Serum metabolites / / 19043545 rs814950 chr1 190470470 C G 1.22E-05 Serum metabolites / / 19043545 rs17378957 chr1 190501099 T C 9.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs755805 chr1 190503966 C T 4.63E-04 Iron levels / / pha002876 rs814958 chr1 190514183 T C 6.77E-04 Iron levels / / pha002876 rs814953 chr1 190522976 T G 4.12E-04 Type 2 diabetes / / 17463246 rs12072620 chr1 190528074 T C 3.26E-06 Adiponectin levels / / 20887962 rs1501501 chr1 190528445 C T 3.26E-06 Adiponectin levels / / 20887962 rs814951 chr1 190531999 C T 5.88E-04 Response to gemcitabine in pancreatic cancer / / 22142827 rs749390 chr1 190560021 C T 7.27E-04 Smoking quantity / / 24665060 rs520227 chr1 190569312 G C 4.00E-04 Type 2 diabetes / / 17463246 rs520227 chr1 190569312 G C 0.0000846 Oxaliplatin induced mucositis in response to colorectal cancer treatment / / 22310351 rs598359 chr1 190569947 G A 5.54E-04 Type 2 diabetes / / 17463246 rs2149028 chr1 190570848 C A 6.38E-06 Vitiligo / / 22561518 rs584161 chr1 190577336 T G 4.48E-04 Premature ovarian failure / / 19508998 rs720630 chr1 190588300 G A 4.13E-04 Type 2 diabetes / / 17463246 rs1590496 chr1 190641200 T C 1.90E-05 Urinary metabolites LOC440704 intron 21572414 rs6678095 chr1 190647315 T C 6.96E-05 Serum metabolites LOC440704 intron 19043545 rs4845171 chr1 190653611 A G 1.10E-05 Urinary metabolites LOC440704 intron 21572414 rs1998710 chr1 190670884 C T 2.80E-06 Urinary metabolites LOC440704 intron 21572414 rs4845172 chr1 190671884 A G 6.65E-05 Monocyte chemoattractant protein-1 LOC440704 intron pha003071 rs1408839 chr1 190681784 A G 2.30E-06 Urinary metabolites LOC440704 intron 21572414 rs573068 chr1 190713300 G A 2.95E-05 Alzheimer's disease LOC440704 intron 24755620 rs490184 chr1 190713980 G A 4.50E-06 Urinary metabolites LOC440704 intron 21572414 rs10494642 chr1 190745969 T C 8.60E-04 Type 2 diabetes and 6 quantitative traits LOC440704 intron 17848626 rs10494642 chr1 190745969 T C 7.65E-05 Cognitive impairment induced by topiramate LOC440704 intron 22091778 rs16832771 chr1 190760788 C T 9.05E-05 Myopia (pathological) LOC440704 intron 21640322 rs527579 chr1 190768685 T C 2.80E-05 Urinary metabolites LOC440704 intron 21572414 rs568537 chr1 190780134 T A 1.50E-05 Urinary metabolites / / 21572414 rs2438406 chr1 190800881 C G 1.70E-05 Response to statin therapy / / 20339536 rs10920808 chr1 190813083 A C 5.30E-06 Response to statin therapy / / 20339536 rs10494649 chr1 190813289 T C 2.00E-04 Response to interferon beta in multiple sclerosis / / 18195134 rs4845251 chr1 190815260 G T 1.30E-05 Response to statin therapy / / 20339536 rs12146125 chr1 190818105 G T 1.40E-05 Response to statin therapy / / 20339536 rs10920810 chr1 190818216 A C 1.50E-05 Response to statin therapy / / 20339536 rs10800972 chr1 190818256 A C 1.40E-05 Response to statin therapy / / 20339536 rs2419925 chr1 190819195 A T 1.30E-05 Response to statin therapy / / 20339536 rs2118650 chr1 190823688 G T 8.00E-06 Response to statin therapy / / 20339536 rs1936992 chr1 190825536 G A 8.30E-06 Response to statin therapy / / 20339536 rs2105423 chr1 190832971 A G 7.70E-06 Response to statin therapy / / 20339536 rs1438533 chr1 190833559 C T 6.40E-06 Response to statin therapy / / 20339536 rs1370882 chr1 190833695 T C 6.30E-06 Response to statin therapy / / 20339536 rs7521393 chr1 190833868 C T 6.20E-06 Response to statin therapy / / 20339536 rs1438532 chr1 190834267 T G 6.10E-06 Response to statin therapy / / 20339536 rs1438531 chr1 190834358 T C 6.00E-06 Response to statin therapy / / 20339536 rs1438530 chr1 190834375 A G 6.30E-06 Response to statin therapy / / 20339536 rs1156627 chr1 190835000 G A 6.40E-06 Response to statin therapy / / 20339536 rs1156626 chr1 190835135 T G 6.40E-06 Response to statin therapy / / 20339536 rs1156625 chr1 190835394 T C 6.30E-06 Response to statin therapy / / 20339536 rs1370880 chr1 190836891 G A 4.20E-06 Response to statin therapy / / 20339536 rs1370879 chr1 190837105 G A 4.00E-06 Response to statin therapy / / 20339536 rs1170703 chr1 190837514 T C 4.10E-06 Response to statin therapy / / 20339536 rs2053302 chr1 190841673 T C 4.00E-06 Response to statin therapy / / 20339536 rs2118652 chr1 190841987 T C 4.40E-06 Response to statin therapy / / 20339536 rs6684247 chr1 190847263 G A 3.90E-06 Response to statin therapy / / 20339536 rs10800986 chr1 190848743 T C 3.90E-06 Response to statin therapy / / 20339536 rs1025717 chr1 190851794 G T 5.60E-06 Response to statin therapy / / 20339536 rs7535458 chr1 190853596 C T 6.10E-06 Response to statin therapy / / 20339536 rs1030922 chr1 190854351 G A 6.70E-06 Response to statin therapy / / 20339536 rs1170712 chr1 190855787 A T 8.00E-06 Response to statin therapy / / 20339536 rs10800989 chr1 190855881 C T 7.00E-06 Response to statin therapy / / 20339536 rs6686343 chr1 190856627 A C 7.10E-06 Response to statin therapy / / 20339536 rs10920829 chr1 190857871 C A 7.50E-06 Response to statin therapy / / 20339536 rs1936993 chr1 190860403 A G 1.80E-05 Response to statin therapy / / 20339536 rs6699971 chr1 190860691 A G 1.20E-05 Response to statin therapy / / 20339536 rs10920831 chr1 190862150 C T 8.20E-06 Response to statin therapy / / 20339536 rs12039354 chr1 190862268 G A 8.60E-06 Response to statin therapy / / 20339536 rs12135498 chr1 190863011 G A 2.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1936980 chr1 190876141 T C 2.50E-05 Response to statin therapy / / 20339536 rs4845175 chr1 190879904 T C 2.00E-05 Response to statin therapy / / 20339536 rs11588821 chr1 190886773 T C 3.76E-05 Alzheimer's disease / / 17998437 rs11588831 chr1 190886816 T G 6.68E-05 Alzheimer's disease / / 17998437 rs1936987 chr1 190889685 T C 8.40E-06 Alzheimer's disease / / 17998437 rs12145615 chr1 190891132 A T 2.90E-05 Response to statin therapy / / 20339536 rs10920836 chr1 190891339 C G 3.10E-05 Response to statin therapy / / 20339536 rs10920837 chr1 190893221 G C 2.70E-05 Response to statin therapy / / 20339536 rs4845257 chr1 190893913 T G 2.60E-05 Response to statin therapy / / 20339536 rs2420144 chr1 190900121 T A 7.21E-06 Alzheimer's disease / / 17998437 rs12025636 chr1 190901190 A G 1.40E-05 Response to statin therapy / / 20339536 rs12403605 chr1 190903993 A G 1.07E-05 Alzheimer's disease / / 17998437 rs12403877 chr1 190904400 A T 8.57E-06 Alzheimer's disease / / 17998437 rs12738693 chr1 190912603 A C 6.11E-05 Alzheimer's disease / / 17998437 rs12567544 chr1 190913478 C A 6.70E-06 Response to statin therapy / / 20339536 rs7549733 chr1 190916669 G A 7.00E-06 Response to statin therapy / / 20339536 rs10753960 chr1 190919126 C T 7.10E-06 Response to statin therapy / / 20339536 rs1431137 chr1 190923645 T C 6.80E-06 Response to statin therapy / / 20339536 rs1924720 chr1 190929421 G T 1.70E-05 Response to statin therapy / / 20339536 rs1431141 chr1 190934017 T C 1.30E-05 Response to statin therapy / / 20339536 rs10800994 chr1 190934888 G C 1.30E-05 Response to statin therapy / / 20339536 rs6666860 chr1 190949620 C A 3.60E-05 Response to statin therapy / / 20339536 rs10753970 chr1 191005777 A G 2.54E-05 Serum metabolites / / 19043545 rs10753970 chr1 191005777 A G 7.10E-05 Response to statin therapy / / 20339536 rs7555707 chr1 191013299 G A 7.00E-04 Smoking initiation / / 24665060 rs1454353 chr1 191093816 T C 9.50E-05 Response to statin therapy / / 20339536 rs2168081 chr1 191095755 T C 8.30E-05 Response to statin therapy / / 20339536 rs1073289 chr1 191097285 A G 7.60E-05 Response to statin therapy / / 20339536 rs4845268 chr1 191102082 T G 3.07E-05 Serum metabolites / / 19043545 rs4845268 chr1 191102082 T G 7.60E-05 Response to statin therapy / / 20339536 rs10920895 chr1 191102174 G C 7.49E-05 Serum metabolites / / 19043545 rs1993302 chr1 191110795 T C 5.30E-05 Response to statin therapy / / 20339536 rs6675143 chr1 191112084 C T 6.20E-05 Response to statin therapy / / 20339536 rs10753973 chr1 191113703 C T 5.78E-04 Type 2 diabetes / / 17463246 rs10753973 chr1 191113703 C T 1.84E-05 Serum metabolites / / 19043545 rs10753973 chr1 191113703 C T 5.40E-05 Response to statin therapy / / 20339536 rs10753974 chr1 191115638 C T 5.30E-05 Response to statin therapy / / 20339536 rs1563191 chr1 191117749 A G 6.50E-05 Response to statin therapy / / 20339536 rs1454356 chr1 191133789 C A 8.90E-05 Response to statin therapy / / 20339536 rs1454356 chr1 191133789 C A 0.0000642 Uterine leiomyomata / / 23040493 rs7528993 chr1 191145878 G C 5.71E-04 Multiple complex diseases / / 17554300 rs10494652 chr1 191150439 C T 3.05E-04 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs1246813 chr1 191220906 T C 3.29E-05 F-cell distribution / / 21326311 rs1931204 chr1 191277082 C T 3.83E-05 Serum metabolites / / 19043545 rs6690512 chr1 191340943 G A 7.68E-04 Alcohol dependence / / 24277619 rs6700152 chr1 191397516 A G 1.55E-05 F-cell distribution / / 21326311 rs524646 chr1 191401978 G A 1.67E-04 Multiple complex diseases / / 17554300 rs16833511 chr1 191410505 T G 2.10E-05 Non-small cell lung cancer / / 21866343 rs491685 chr1 191423124 T A 1.83E-04 Acute lung injury / / 22295056 rs650957 chr1 191429227 C T 1.23E-04 Attention deficit hyperactivity disorder / / 22012869 rs11800005 chr1 191430223 A G 9.97E-05 Glucose levels / / pha003058 rs562619 chr1 191438525 A G 1.20E-05 Urinary metabolites / / 21572414 rs634828 chr1 191459679 A G 4.14E-05 Femoral neck bone geometry / / 22087292 rs620765 chr1 191460132 G A 5.90E-06 Urinary metabolites / / 21572414 rs10920957 chr1 191462474 A C 6.21E-05 Alzheimer's disease (late onset) / / 21379329 rs637642 chr1 191478482 G A 6.59E-05 Alzheimer's disease (late onset) / / 21379329 rs1338029 chr1 191491194 T G 2.19E-04 Alzheimer's disease (late onset) / / 21379329 rs658232 chr1 191497548 C T 2.35E-04 Coronary Artery Disease / / 17634449 rs658232 chr1 191497548 C T 2.10E-06 Urinary metabolites / / 21572414 rs6657109 chr1 191499342 A G 3.16E-04 Multiple complex diseases / / 17554300 rs655205 chr1 191499720 T C 4.30E-06 Urinary metabolites / / 21572414 rs1892294 chr1 191502099 C T 9.41E-05 Alzheimer's disease (late onset) / / 21379329 rs629563 chr1 191505973 G A 2.89E-04 Coronary Artery Disease / / 17634449 rs631450 chr1 191506986 C T 9.50E-06 Urinary metabolites / / 21572414 rs633095 chr1 191513228 A G 6.84E-04 Type 2 diabetes / / 17463246 rs633095 chr1 191513228 A G 1.30E-05 Urinary metabolites / / 21572414 rs12751302 chr1 191546574 C T 1.61E-06 Major depression (suicidal thoughts and behavior) / / 21750702 rs1954602 chr1 191558022 G T 5.95E-04 Type 2 diabetes / / 17463246 rs10801047 chr1 191559356 A T 3.00E-08 Crohn's disease / / 17554261 rs10801047 chr1 191559356 A T 8.15E-05 Multiple complex diseases / / 17554300 rs10801047 chr1 191559356 A T 2.70E-05 Urinary metabolites / / 21572414 rs1890232 chr1 191564481 A G 5.81E-04 Type 2 diabetes / / 17463246 rs6698540 chr1 191622277 A T 7.30E-09 Urinary metabolites / / 21572414 rs6698540 chr1 191622277 A T 2.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1338035 chr1 191627004 C T 9.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10494658 chr1 191689375 T G 2.00E-05 Urinary metabolites / / 21572414 rs6428063 chr1 191694194 C T 1.30E-05 Urinary metabolites / / 21572414 rs2814623 chr1 191695246 A G 2.20E-05 Urinary metabolites / / 21572414 rs2785761 chr1 191719427 T G 8.50E-06 Urinary metabolites / / 21572414 rs10494659 chr1 191719473 A G 5.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7536312 chr1 191727360 G A 6.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10494661 chr1 191728182 A T 1.20E-05 Urinary metabolites / / 21572414 rs1509702 chr1 191741681 G C 9.60E-06 Urinary metabolites / / 21572414 rs6696942 chr1 191804265 T C 9.00E-05 Cognitive test performance / / 20125193 rs16833847 chr1 191819881 A G 4.30E-04 Nicotine dependence / / 17158188 rs4845294 chr1 191848287 A G 1.77E-04 Smoking initiation / / 24665060 rs12082046 chr1 191866249 A C 4.95E-04 Coronary heart disease / / 21971053 rs17403780 chr1 191939788 T A 1.00E-06 IgG glycosylation / / 23382691 rs17403780 chr1 191939788 T A 6.00E-06 IgG glycosylation / / 23382691 rs17403780 chr1 191939788 T A 7.00E-06 IgG glycosylation / / 23382691 rs10921053 chr1 191968069 A G 3.21E-04 Obesity (extreme) / / 21935397 rs7367454 chr1 191979895 A T 8.68E-04 Multiple complex diseases / / 17554300 rs7349065 chr1 191980100 G A 9.94E-04 Multiple complex diseases / / 17554300 rs6428079 chr1 191983858 A C 3.28E-04 Obesity (extreme) / / 21935397 rs12040845 chr1 191998251 T C 4.41E-04 Multiple complex diseases / / 17554300 rs7529541 chr1 191999509 A C 1.20E-05 Urinary metabolites / / 21572414 rs12040119 chr1 192037153 C T 6.61E-04 Type 2 diabetes / / 17463246 rs12033842 chr1 192048703 G A 4.55E-04 Type 2 diabetes / / 17463246 rs2999599 chr1 192049086 T C 8.05E-04 Multiple complex diseases / / 17554300 rs3012198 chr1 192050674 C A 6.56E-04 Obesity (extreme) / / 21935397 rs4399135 chr1 192056067 G A 8.84E-04 Multiple complex diseases / / 17554300 rs10921078 chr1 192059022 G A 0.0000717 Gains in maximal O2 uptake response / / 21183627 rs4360506 chr1 192059386 T C 4.48E-04 Multiple complex diseases / / 17554300 rs10921079 chr1 192060886 A G 7.90E-04 Multiple complex diseases / / 17554300 rs4620521 chr1 192074537 A G 9.05E-04 Multiple complex diseases / / 17554300 rs12736318 chr1 192091291 A G 7.90E-04 Obesity (extreme) / / 21935397 rs1578102 chr1 192170251 C G 9.21E-04 Type 2 diabetes / / 17463246 rs876582 chr1 192174155 T C 6.60E-04 Type 2 diabetes / / 17463246 rs1175128 chr1 192199554 T C 4.71E-04 Hemoglobin concentration / / 20534544 rs1175106 chr1 192208913 C T 2.51E-04 Hemoglobin concentration / / 20534544 rs946421 chr1 192211842 C T 1.35E-05 Hemoglobin concentration / / 20534544 rs1175154 chr1 192230089 G A 1.11E-05 Hemoglobin concentration / / 20534544 rs1175126 chr1 192236376 A G 1.11E-05 Hemoglobin concentration / / 20534544 rs17523810 chr1 192245030 C T 7.96E-04 Type 2 diabetes / / 17463246 rs1175121 chr1 192246590 G A 4.66E-05 Hemoglobin concentration / / 20534544 rs1175119 chr1 192249116 C A 2.31E-04 Hemoglobin concentration / / 20534544 rs1339129 chr1 192283229 T C 3.22E-05 Hemoglobin concentration / / 20534544 rs6663865 chr1 192296038 T C 3.22E-05 Hemoglobin concentration RGS21 intron 20534544 rs12126995 chr1 192315253 A G 5.64E-04 Type 2 diabetes RGS21 intron 17463246 rs9645337 chr1 192322860 A G 5.64E-04 Type 2 diabetes RGS21 intron 17463246 rs1936671 chr1 192323753 G A 5.87E-04 Type 2 diabetes RGS21 intron 17463246 rs12048512 chr1 192353005 T C 2.74E-04 Myopia (pathological) / / 21095009 rs9988643 chr1 192362674 C T 2.30E-06 Urinary metabolites / / 21572414 rs6428099 chr1 192369866 T C 1.10E-06 Urinary metabolites / / 21572414 rs2369810 chr1 192370110 T C 1.60E-06 Urinary metabolites / / 21572414 rs1936701 chr1 192375206 A G 4.10E-06 Urinary metabolites / / 21572414 rs4658007 chr1 192378406 G A 1.60E-06 Urinary metabolites / / 21572414 rs7545141 chr1 192384797 C A 1.10E-06 Urinary metabolites / / 21572414 rs10754006 chr1 192390633 G A 1.90E-06 Urinary metabolites / / 21572414 rs1936692 chr1 192391249 G C 1.10E-06 Urinary metabolites / / 21572414 rs1317165 chr1 192419760 C T 2.20E-05 Urinary metabolites / / 21572414 rs4378188 chr1 192420005 A T 3.70E-04 Type 2 diabetes / / 17463246 rs10921152 chr1 192420060 A G 2.90E-05 Urinary metabolites / / 21572414 rs10494666 chr1 192421227 C T 2.20E-05 Urinary metabolites / / 21572414 rs10921159 chr1 192424634 T C 2.00E-05 Urinary metabolites / / 21572414 rs12067906 chr1 192431998 T C 9.00E-07 Blood pressure / / 22763476 rs10921164 chr1 192439681 G A 1.55E-04 Multiple complex diseases / / 17554300 rs10801121 chr1 192478874 G A 2.91E-04 Multiple complex diseases / / 17554300 rs10801121 chr1 192478874 G A 6.05E-05 Type 1 diabetes / / 18978792 rs10754012 chr1 192492895 A G 1.96E-06 Multiple sclerosis / / 17660530 rs10754012 chr1 192492895 A G 3.42E-05 Type 1 diabetes / / 18978792 rs2209014 chr1 192506082 G A 2.16E-04 Type 1 diabetes / / 21980299 rs10489868 chr1 192511183 T C 7.61E-04 Multiple complex diseases / / 17554300 rs72734930 chr1 192512559 G A 3.70E-04 Celiac disease / / 22057235 rs2760524 chr1 192530548 A G 5.17E-06 Multiple sclerosis / / 17660530 rs2760524 chr1 192530548 A G 9.77E-06 Multiple sclerosis / / 19525953 rs2760524 chr1 192530548 A G 1.60E-06 Multiple sclerosis / / 21833088 rs2816316 chr1 192536813 C A 3.00E-11 Celiac disease / / 18311140 rs2816316 chr1 192536813 C A 2.00E-17 Celiac disease / / 20190752 rs2816316 chr1 192536813 C A 2.00E-17 Asthma / / 21150878 rs2816316 chr1 192536813 C A 2.20E-17 Celiac disease and Rheumatoid arthritis / / 21383967 rs2816316 chr1 192536813 C A 2.20E-17 Multiple sclerosis / / 22190364 rs1323296 chr1 192537508 A G 1.90E-05 Urinary metabolites / / 21572414 rs10489870 chr1 192540520 C G 0.00000133 HDL cholesterol / / 23063622 rs1323292 chr1 192541021 G A 2.00E-08 Multiple sclerosis / / 21833088 rs1359062 chr1 192541472 C G 5.88E-05 Multiple sclerosis / / 17660530 rs1359062 chr1 192541472 C G 2.50E-25 Celiac disease / / 22057235 rs10921202 chr1 192547052 G T 3.96E-05 Celiac disease RGS1 intron 23936387 rs2760535 chr1 192549912 G A 6.50E-04 Schizophrenia / / 19197363 rs2984921 chr1 192551624 G A 6.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2984921 chr1 192551624 G A 6.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16834472 chr1 192553685 G C 5.83E-05 Type 2 diabetes / / 17463246 rs6428106 chr1 192554431 G T 2.95E-07 Chronic kidney disease / / 21931561 rs6428109 chr1 192554617 A C 1.09E-04 Type 2 diabetes / / 17463246 rs10489873 chr1 192559646 G A 2.15E-04 Acute lung injury / / 22295056 rs10489873 chr1 192559646 G A 7.42E-06 Crohn's disease and psoriasis / / 22482804 rs1407818 chr1 192561712 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10921206 chr1 192567674 T C 8.39E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10921216 chr1 192583913 T C 6.94E-04 Multiple complex diseases / / 17554300 rs6673310 chr1 192597985 G C 5.52E-04 Multiple complex diseases / / 17554300 rs4147220 chr1 192598515 T G 4.10E-06 Urinary metabolites / / 21572414 rs4147220 chr1 192598515 T G 0.0000904 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7511974 chr1 192599633 C A 0.0000137 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6428126 chr1 192603046 C G 0.0000163 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs3795618 chr1 192603657 G T 0.0000274 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10921224 chr1 192604314 C A 0.0000297 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4338337 chr1 192609256 A T 0.0000369 Nonsyndromic striae distensae (stretch marks) RGS13 intron 23633020 rs4357510 chr1 192612394 A C,T 0.0000722 Nonsyndromic striae distensae (stretch marks) RGS13 intron 23633020 rs4658062 chr1 192616195 G A 1.20E-05 stroke (ischemic) RGS13 intron 17434096 rs4658064 chr1 192618028 G C 3.73E-04 Type 2 diabetes RGS13 intron 17463246 rs4658064 chr1 192618028 G C 9.00E-04 Acute lymphoblastic leukemia (childhood) RGS13 intron 20189245 rs4658064 chr1 192618028 G C 1.00E-05 Urinary metabolites RGS13 intron 21572414 rs6700053 chr1 192618413 T G 1.34E-04 Type 2 diabetes RGS13 intron 17463246 rs6700053 chr1 192618413 T G 7.05E-05 Multiple complex diseases RGS13 intron 17554300 rs116406040 chr1 192623389 A G 0.0000804 Nonsyndromic striae distensae (stretch marks) RGS13 intron 23633020 rs7544449 chr1 192625901 C T 2.58E-04 Type 2 diabetes RGS13 intron 17463246 rs7544449 chr1 192625901 C T 2.61E-04 Multiple complex diseases RGS13 intron 17554300 rs17585105 chr1 192697412 A G 4.95E-04 Multiple complex diseases / / 17554300 rs10801153 chr1 192763948 G A 2.10E-06 Malaria / / 19465909 rs4657836 chr1 192777178 C A 0.000000196 HDL cholesterol RGS2 nearGene-5 23063622 rs4606 chr1 192781172 C G 1 Drug response to Clozapine RGS2 UTR-3 18347610 rs4606 chr1 192781172 C G 1 Drug response to Olanzapine RGS2 UTR-3 18347610 rs4606 chr1 192781172 C G 1 Drug response to Risperidone RGS2 UTR-3 18347610 rs7550636 chr1 192806241 T C 4.00E-06 Coronary artery calcification / / 23870195 rs16834927 chr1 192835293 T C 3.58E-05 Multiple complex diseases / / 17554300 rs10921286 chr1 192889452 C T 1.85E-04 Lymphocyte counts / / 22286170 rs842796 chr1 192902415 T C 4.28E-05 Parkinson's disease / / 17052657 rs842796 chr1 192902415 T C 2.24E-06 Substance dependence phenotypes / / 24832863 rs842814 chr1 192911972 G T 2.32E-05 Multiple complex diseases / / 17554300 rs10921295 chr1 192937049 A G 7.58E-04 Multiple complex diseases / / 17554300 rs12025826 chr1 192940642 G A 7.57E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs9427573 chr1 192995213 C T 5.00E-06 Cannabis dependence UCHL5 intron 21668797 rs6661522 chr1 193010623 T C 8.57E-04 Parkinson's disease UCHL5 intron 17052657 rs2887640 chr1 193027834 A C 6.91E-04 Multiple complex diseases UCHL5 intron 17554300 rs12123511 chr1 193083501 G T 1.66E-04 Multiple complex diseases / / 17554300 rs10801186 chr1 193143779 A G 6.44E-04 Multiple complex diseases CDC73 intron 17554300 rs28930674 chr1 193150219 A G 9.39E-04 Multiple complex diseases B3GALT2 cds-synon 17554300 rs10494675 chr1 193150873 T C 4.07E-04 Multiple complex diseases B3GALT2 intron 17554300 rs12122868 chr1 193158483 G A 3.14E-04 Smoking initiation CDC73 intron 24665060 rs817137 chr1 193275029 G A 6.41E-05 Multiple complex diseases / / 17554300 rs1749432 chr1 193291244 T A 4.51E-08 Narcolepsy / / 19629137 rs17601491 chr1 193367233 A G 2.80E-04 Multiple complex diseases / / 17554300 rs12758913 chr1 193437106 G A 7.00E-04 Multiple complex diseases / / 17554300 rs7516749 chr1 193439175 G A 4.51E-04 Multiple complex diseases / / 17554300 rs11808338 chr1 193443701 G A 2.20E-05 Urinary metabolites / / 21572414 rs7554157 chr1 193489169 C T 6.71E-05 Parkinson's disease / / 17052657 rs1007460 chr1 193510827 T C 1.70E-07 Urinary metabolites / / 21572414 rs10801204 chr1 193531058 C T 1.10E-06 Urinary metabolites / / 21572414 rs10801205 chr1 193531084 A G 2.60E-06 Urinary metabolites / / 21572414 rs6668266 chr1 193584062 T C 2.00E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs6668266 chr1 193584062 T C 0.0000306 Panic disorder / / 23149450 rs6668266 chr1 193584062 T C 3.06E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs1339307 chr1 193589444 A G 7.00E-06 Asthma / / 21790008 rs6678275 chr1 193625233 G C 3.00E-07 Alzheimer's disease (late onset) / / 24162737 rs6695669 chr1 193630577 G A 3.52E-04 Alzheimer's disease / / 17998437 rs16835685 chr1 193663276 A G 2.52E-04 Multiple complex diseases / / 17554300 rs16835697 chr1 193682630 A G 2.30E-05 Urinary metabolites / / 21572414 rs12122818 chr1 193686395 A C 3.88E-04 Esophageal adenocarcinoma / / 24121790 rs6691652 chr1 193717698 G T 8.16E-04 Alzheimer's disease / / 17998437 rs6691652 chr1 193717698 G T 1.02E-04 Insulin resistance / / 21901158 rs6697313 chr1 193722284 A G 1.43E-04 Insulin resistance / / 21901158 rs2025934 chr1 193734900 G A 3.00E-06 Subcutaneous adipose tissue / / 22589738 rs1326851 chr1 193736204 G A 9.47E-04 Bipolar disorder / / 19259986 rs6664259 chr1 193737549 A G 7.10E-05 Insulin resistance / / 21901158 rs1160521 chr1 193738279 G A 7.38E-04 Bipolar disorder / / 19259986 rs968309 chr1 193752801 C T 9.42E-04 Bipolar disorder / / 19259986 rs1328179 chr1 193753223 C T 5.61E-05 Type 2 diabetes and other traits / / 19734900 rs10921443 chr1 193783317 G T 3.33E-05 Job-related exhaustion / / 23620144 rs9287130 chr1 193830644 T G 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs578374 chr1 193883832 C A 1.94E-04 Multiple complex diseases / / 17554300 rs7542605 chr1 193884958 T C 8.72E-09 Metabolite levels / / 23281178 rs10921464 chr1 193889533 C T 6.68E-06 Major depressive disorder / / 20516156 rs10921464 chr1 193889533 C T 8.72E-09 Metabolite levels / / 23281178 rs10801266 chr1 193893686 G A 8.72E-09 Metabolite levels / / 23281178 rs4255367 chr1 193895092 A G 8.72E-09 Metabolite levels / / 23281178 rs4409629 chr1 193895239 T C 8.72E-09 Metabolite levels / / 23281178 rs4330903 chr1 193895333 C T 8.72E-09 Metabolite levels / / 23281178 rs606149 chr1 193921548 C T 3.00E-06 Major depressive disorder / / 20516156 rs606149 chr1 193921548 C T 0.00000219 Major depressive disorder age at onset>25 / / 22915352 rs7541634 chr1 193944200 T C 5.70E-06 Urinary metabolites / / 21572414 rs1442421 chr1 194025452 C T 8.55E-05 Schizophrenia / / 19571809 rs634899 chr1 194035948 T C 1.80E-05 Meningococcal disease / / 20694013 rs2506058 chr1 194106280 C T 1.90E-04 Telomere length / / 23900074 rs2506058 chr1 194106280 C T 9.09E-05 Socioeconomic Factors / / pha003067 rs16836478 chr1 194157661 T C 4.94E-04 Multiple complex diseases / / 17554300 rs302211 chr1 194172222 A G 8.07E-04 Type 2 diabetes / / 17463246 rs16836545 chr1 194203301 T C 1.96E-05 Multiple complex diseases / / 17554300 rs2029250 chr1 194254120 G A 2.00E-05 Urinary metabolites / / 21572414 rs2506048 chr1 194258816 T C 5.60E-04 Multiple complex diseases / / 17554300 rs12090292 chr1 194265219 T C 2.20E-05 Urinary metabolites / / 21572414 rs16836639 chr1 194268571 T C 1.30E-05 Urinary metabolites / / 21572414 rs1018626 chr1 194269455 G A 2.61E-05 Partial epilepsies / / 20522523 rs6428217 chr1 194304659 G C 6.06E-04 Type 2 diabetes / / 17463246 rs6664256 chr1 194308977 T C 9.97E-04 Type 2 diabetes / / 17463246 rs4276898 chr1 194320639 A G 2.34E-05 Information processing speed / / 21130836 rs4261097 chr1 194322244 T A 6.01E-04 Type 2 diabetes / / 17463246 rs17622017 chr1 194341208 C T 6.69E-04 Tuberculosis / / 22239941 rs12121745 chr1 194412218 A G 5.30E-04 White matter integrity / / 22425255 rs10494705 chr1 194436341 G T 5.30E-04 White matter integrity / / 22425255 rs6673013 chr1 194461499 C T 2.20E-04 Multiple complex diseases / / 17554300 rs4266861 chr1 194486776 C T 1.72E-04 Multiple complex diseases / / 17554300 rs11586374 chr1 194491453 C A 1.02E-04 Multiple complex diseases / / 17554300 rs3001167 chr1 194530914 A G 3.00E-06 Obesity-related traits / / 23251661 rs3001156 chr1 194550938 C A 1.97E-04 Parkinson's disease / / 17052657 rs3001156 chr1 194550938 C A 9.20E-06 Glioma (high-grade) / / 19578366 rs3001156 chr1 194550938 C A 9.46E-05 Asthma / / 20159242 rs10494709 chr1 194584977 T C 2.05E-04 Scoliosis / / 21216876 rs13376197 chr1 194591753 T C 6.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs10801343 chr1 194639330 T G 6.71E-04 Multiple complex diseases / / 17554300 rs4253903 chr1 194648188 T C 9.71E-04 Multiple complex diseases / / 17554300 rs7520494 chr1 194660182 G A 8.70E-04 Multiple complex diseases / / 17554300 rs6428261 chr1 194679640 T A 9.90E-04 Multiple complex diseases / / 17554300 rs4446945 chr1 194713204 G A 1.38E-04 Multiple complex diseases / / 17554300 rs7550967 chr1 194783067 T C 2.51E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1011550 chr1 194801684 G A 4.05E-04 Body mass index / / 21701565 rs4657943 chr1 194846016 G A 7.37E-04 Taste perception / / 22132133 rs339626 chr1 194853172 G T 1.70E-04 IgE levels / / 17255346 rs6695766 chr1 194910364 G A 4.20E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs10494716 chr1 194915839 A T 0.0000639 Sarcoidosis / / 22952805 rs1032828 chr1 194916701 C A 9.02E-04 Obesity (extreme) / / 21935397 rs11583374 chr1 194965856 T C 9.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs12569023 chr1 194987069 G A 1.60E-05 Urinary metabolites / / 21572414 rs4657796 chr1 195052937 T A,C,G 6.14E-04 Type 2 diabetes / / 17463246 rs696392 chr1 195053221 T C 4.95E-05 Suicidal ideation / / 20877300 rs12755016 chr1 195166911 A C 4.23E-04 Alzheimer's disease / / 17998437 rs687523 chr1 195170004 A G 5.53E-06 Asthma / / 21790008 rs4657976 chr1 195265767 A G 8.25E-04 Multiple complex diseases / / 17554300 rs6428282 chr1 195267072 C A 7.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1359381 chr1 195310452 C T 7.61E-04 Smoking quantity / / 24665060 rs12731553 chr1 195316969 T G 2.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs1348101 chr1 195322984 T A 1.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs16838299 chr1 195343282 G A 1.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs17668176 chr1 195343788 C T 7.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs16838301 chr1 195347168 G A 1.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs12729977 chr1 195348938 C T 5.14E-07 Multiple complex diseases / / 17554300 rs1987929 chr1 195367222 T C 9.62E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs1324713 chr1 195376935 C T 2.09E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs6702266 chr1 195376972 C T 1.00E-04 Adverse response to radiation therapy / / 23719583 rs6702266 chr1 195376972 C T 3.65E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs3845556 chr1 195439716 C T 7.28E-04 Acute lung injury / / 22295056 rs10801420 chr1 195457300 C A 1.50E-05 Urinary metabolites / / 21572414 rs1548286 chr1 195516792 C G 9.48E-04 Multiple complex diseases / / 17554300 rs2400604 chr1 195531171 C T 6.86E-04 Multiple complex diseases / / 17554300 rs1890645 chr1 195531423 T C 4.00E-06 Neonatal lupus / / 20662065 rs11804696 chr1 195600211 C G 4.92E-05 Serum metabolites / / 19043545 rs1556455 chr1 195629083 G A 9.69E-05 Personality dimensions / / 18957941 rs1159275 chr1 195649242 G T 8.67E-06 Personality dimensions / / 18957941 rs1159275 chr1 195649242 G T 3.64E-05 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs1159275 chr1 195649242 G T 8.70E-06 Personality dimensions / / 21173776 rs10754146 chr1 195659214 A C 3.64E-05 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs10754147 chr1 195672584 A G 4.35E-04 Multiple complex diseases / / 17554300 rs17672688 chr1 195686601 G A 1.53E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10801449 chr1 195708999 T C 1.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10218626 chr1 195790084 G A 4.98E-04 Multiple complex diseases / / 17554300 rs6677435 chr1 195790658 G A 9.00E-06 Cocaine dependence / / 23958962 rs4488010 chr1 195807493 T C 7.18E-04 Smoking initiation / / 24665060 rs6679891 chr1 195826738 G A 1.47E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16838980 chr1 195832253 T G 1.67E-05 Anxiety in major depressive disorder / / 24047446 rs12140768 chr1 195836268 T C 1.73E-04 Multiple complex diseases / / 17554300 rs12140768 chr1 195836268 T C 2.29E-04 Cognitive decline / / 23732972 rs3008578 chr1 195864604 A T 6.30E-04 Smoking initiation / / 24665060 rs3010144 chr1 195867138 G T 6.30E-04 Smoking initiation / / 24665060 rs3008576 chr1 195869123 T C 6.30E-04 Smoking initiation / / 24665060 rs3010150 chr1 195873063 C T 4.13E-04 Smoking initiation / / 24665060 rs1451920 chr1 195874790 T A 7.21E-04 Type 2 diabetes / / 17463246 rs3008572 chr1 195876292 C T 4.50E-04 Smoking initiation / / 24665060 rs16839109 chr1 195877256 A G 7.16E-04 Multiple complex diseases / / 17554300 rs2923911 chr1 195883861 A C 3.43E-04 Smoking initiation / / 24665060 rs10921984 chr1 195891127 C T 7.51E-05 Waist-Hip Ratio / / pha003013 rs10921984 chr1 195891127 C T 7.52E-05 Waist-Hip Ratio / / pha003028 rs41373250 chr1 195900235 C G,T 1.10E-05 Urinary metabolites / / 21572414 rs7517337 chr1 195914273 A G 2.00E-06 Total ventricular volume / / 21116278 rs4295871 chr1 195916887 A G 8.60E-06 Urinary metabolites / / 21572414 rs4483387 chr1 195917003 G T 1.70E-05 Urinary metabolites / / 21572414 rs4658011 chr1 195932083 G A 0.000279 Salmonella-induced pyroptosis / / 22837397 rs12043048 chr1 195934306 C T 0.00035 Salmonella-induced pyroptosis / / 22837397 rs10921998 chr1 195934627 G A 1.83E-04 Multiple complex diseases / / 17554300 rs979769 chr1 195940328 C G 3.20E-05 Cognitive function / / 24684796 rs17686400 chr1 195951286 C T 1.41E-04 Obesity (extreme) / / 21935397 rs1562943 chr1 195963926 C A 9.88E-04 Multiple complex diseases / / 17554300 rs17686963 chr1 195974790 G A 8.31E-05 Obesity (extreme) / / 21935397 rs17687163 chr1 195985385 A C 7.38E-05 Obesity (extreme) / / 21935397 rs12737611 chr1 195987589 C T 7.26E-05 Obesity (extreme) / / 21935397 rs12735954 chr1 195990946 A G 6.89E-05 Obesity (extreme) / / 21935397 rs1008082 chr1 195997563 T C 5.08E-06 Serum metabolites / / 19043545 rs1008082 chr1 195997563 T C 8.75E-06 Bleomycin sensitivity / / 21106707 rs12128800 chr1 196004403 T A 1.71E-05 Bipolar disorder and schizophrenia / / 20889312 rs1451916 chr1 196024294 A C 7.38E-05 Left ventricular hypertrophy / / pha003052 rs375562694 chr1 196024294 A AT 7.38E-05 Left ventricular hypertrophy / / pha003052 rs549773131 chr1 196024294 A AT 7.38E-05 Left ventricular hypertrophy / / pha003052 rs10922013 chr1 196027872 G T 9.92E-06 Bipolar disorder / / 19488044 rs10922013 chr1 196027872 G T 4.23E-05 Bipolar Disorder / / pha002858 rs7512769 chr1 196042662 T A 8.39E-05 Bipolar disorder / / 19488044 rs7512769 chr1 196042662 T A 2.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs11579497 chr1 196061711 G A 2.60E-05 Alcohol dependence / / 19581569 rs11579497 chr1 196061711 G A 3.10E-07 Urinary metabolites / / 21572414 rs10922025 chr1 196068493 A C 2.00E-07 Urinary metabolites / / 21572414 rs6678032 chr1 196069199 T C 1.80E-07 Urinary metabolites / / 21572414 rs6696438 chr1 196084492 C T 5.86E-05 Schizophrenia / / 19197363 rs12036795 chr1 196089818 A C 3.94E-05 Alcohol dependence / / 19581569 rs12136161 chr1 196098354 A T 7.99E-04 Multiple complex diseases / / 17554300 rs12136161 chr1 196098354 A T 7.37E-05 Bipolar disorder and schizophrenia / / 20889312 rs6676015 chr1 196099926 A G 5.95E-04 Multiple complex diseases / / 17554300 rs12087473 chr1 196100216 A G 4.12E-04 Multiple complex diseases / / 17554300 rs12087473 chr1 196100216 A G 7.37E-05 Bipolar disorder and schizophrenia / / 20889312 rs7535849 chr1 196101014 A G 3.66E-04 Alzheimer's disease / / 17998437 rs7535849 chr1 196101014 A G 7.50E-07 Urinary metabolites / / 21572414 rs7535849 chr1 196101014 A G 2.36E-04 Alzheimer's disease / / pha002879 rs7534836 chr1 196105786 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10754180 chr1 196136924 A G 4.51E-05 Cognitive performance / / 19734545 rs2094027 chr1 196150447 T A 1.70E-05 Urinary metabolites / / 21572414 rs2094028 chr1 196150496 C T 1.34E-05 Serum metabolites / / 19043545 rs1325307 chr1 196151387 C G 1.70E-05 Urinary metabolites / / 21572414 rs10922047 chr1 196152634 A G 1.60E-05 Urinary metabolites / / 21572414 rs1886629 chr1 196154898 C T 0.00000553 Bisphosphonate-induced osteonecrosis of the jaw / / 22267851 rs1886630 chr1 196155111 G A 2.70E-05 Urinary metabolites / / 21572414 rs7511738 chr1 196155872 G T 1.70E-05 Urinary metabolites / / 21572414 rs1925327 chr1 196163629 C A 1.70E-05 Urinary metabolites / / 21572414 rs1325300 chr1 196167779 C A 3.06E-04 Alzheimer's disease (late onset) / / 21379329 rs1325301 chr1 196167828 A G 3.92E-04 Alzheimer's disease (late onset) / / 21379329 rs1925334 chr1 196170958 C T 1.60E-05 Urinary metabolites / / 21572414 rs10922049 chr1 196172936 C T 4.62E-05 Multiple complex diseases / / 17554300 rs10922049 chr1 196172936 C T 2.10E-05 Urinary metabolites / / 21572414 rs1925335 chr1 196180344 A G 9.91E-24 Narcolepsy / / 19629137 rs1998712 chr1 196187665 G A 4.38E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10157380 chr1 196187709 G T 7.77E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10158703 chr1 196187968 C G 6.62E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7529369 chr1 196208890 C T 5.67E-05 Age-related macular degeneration KCNT2 intron pha002890 rs12727325 chr1 196223735 G A 1.99E-04 Rheumatoid arthritis KCNT2 intron 21452313 rs2477354 chr1 196239368 A G 3.94E-04 Response to cytadine analogues (cytosine arabinoside) KCNT2 intron 24483146 rs2477357 chr1 196251522 T C 7.40E-04 Response to cytadine analogues (cytosine arabinoside) KCNT2 intron 24483146 rs12058062 chr1 196256498 G A 3.94E-04 Response to cytadine analogues (cytosine arabinoside) KCNT2 intron 24483146 rs12407399 chr1 196291977 T C 5.19E-05 Age-related macular degeneration KCNT2 intron pha002890 rs7554267 chr1 196304863 G T 7.80E-13 Age-related macular degeneration KCNT2 intron pha002869 rs7554267 chr1 196304863 G T 7.93E-12 Age-related macular degeneration KCNT2 intron pha002890 rs10494742 chr1 196346553 A G 4.52E-05 Age-related macular degeneration KCNT2 intron pha002890 rs2027368 chr1 196351150 A C 3.60E-08 Age-related macular degeneration KCNT2 intron 23326517 rs2027368 chr1 196351150 A C 5.66E-24 Age-related macular degeneration KCNT2 intron pha002869 rs2027368 chr1 196351150 A C 1.54E-23 Age-related macular degeneration KCNT2 intron pha002890 rs1769996 chr1 196353041 C T 3.90E-08 Age-related macular degeneration KCNT2 intron 23326517 rs1769996 chr1 196353041 C T 4.44E-08 End-stage coagulation KCNT2 intron 23381943 rs10737670 chr1 196357746 A G 2.30E-08 Age-related macular degeneration KCNT2 intron 23326517 rs10737670 chr1 196357746 A G 9.84E-09 End-stage coagulation KCNT2 intron 23381943 rs10801530 chr1 196361497 G T 2.40E-08 Age-related macular degeneration KCNT2 intron 23326517 rs10801530 chr1 196361497 G T 9.89E-09 End-stage coagulation KCNT2 intron 23381943 rs10801531 chr1 196363544 G A 2.10E-08 Age-related macular degeneration KCNT2 intron 23326517 rs10801531 chr1 196363544 G A 5.20E-09 End-stage coagulation KCNT2 intron 23381943 rs10801532 chr1 196364176 A G 2.50E-08 Age-related macular degeneration KCNT2 intron 23326517 rs10801532 chr1 196364176 A G 9.92E-09 End-stage coagulation KCNT2 intron 23381943 rs7535696 chr1 196371432 T C 2.50E-08 Age-related macular degeneration KCNT2 intron 23326517 rs7535696 chr1 196371432 T C 1.15E-08 End-stage coagulation KCNT2 intron 23381943 rs7535696 chr1 196371432 T C 8.60E-25 Age-related macular degeneration KCNT2 intron pha002869 rs7535696 chr1 196371432 T C 2.97E-24 Age-related macular degeneration KCNT2 intron pha002890 rs16839884 chr1 196375060 G A 2.58E-06 Age-related macular degeneration KCNT2 intron pha002869 rs16839884 chr1 196375060 G A 1.57E-05 Age-related macular degeneration KCNT2 intron pha002890 rs16839886 chr1 196376474 T G 7.26E-06 Age-related macular degeneration KCNT2 intron pha002869 rs16839886 chr1 196376474 T G 4.01E-05 Age-related macular degeneration KCNT2 intron pha002890 rs3928857 chr1 196383601 T C 2.90E-08 Age-related macular degeneration KCNT2 intron 23326517 rs3928857 chr1 196383601 T C 1.01E-08 End-stage coagulation KCNT2 intron 23381943 rs3855964 chr1 196384116 T G 3.10E-08 Age-related macular degeneration KCNT2 intron 23326517 rs3855964 chr1 196384116 T G 1.01E-08 End-stage coagulation KCNT2 intron 23381943 rs3927686 chr1 196385649 T C 3.10E-08 Age-related macular degeneration KCNT2 intron 23326517 rs3927686 chr1 196385649 T C 1.54E-08 End-stage coagulation KCNT2 intron 23381943 rs3927686 chr1 196385649 T C 4.28E-25 Age-related macular degeneration KCNT2 intron pha002869 rs3927686 chr1 196385649 T C 1.85E-24 Age-related macular degeneration KCNT2 intron pha002890 rs12729649 chr1 196387632 G A 3.00E-08 Age-related macular degeneration KCNT2 intron 23326517 rs12729649 chr1 196387632 G A 1.56E-08 End-stage coagulation KCNT2 intron 23381943 rs12069983 chr1 196387741 C A 3.00E-08 Age-related macular degeneration KCNT2 intron 23326517 rs12069983 chr1 196387741 C A 1.56E-08 End-stage coagulation KCNT2 intron 23381943 rs12069983 chr1 196387741 C A 2.07E-06 Age-related macular degeneration KCNT2 intron 23577725 rs12069990 chr1 196387809 C T 3.10E-08 Age-related macular degeneration KCNT2 intron 23326517 rs12069990 chr1 196387809 C T 1.34E-08 End-stage coagulation KCNT2 intron 23381943 rs16839906 chr1 196391866 T C 5.33E-05 Age-related macular degeneration KCNT2 intron pha002890 rs10801533 chr1 196395871 G A 2.46E-04 Scoliosis KCNT2 intron 21216876 rs10801533 chr1 196395871 G A 4.39E-11 Age-related macular degeneration KCNT2 intron pha002869 rs10801533 chr1 196395871 G A 1.21E-11 Age-related macular degeneration KCNT2 intron pha002890 rs1538687 chr1 196397775 C T 8.72E-04 Type 2 diabetes KCNT2 intron 17463246 rs1538687 chr1 196397775 C T 3.90E-08 Age-related macular degeneration KCNT2 intron 23326517 rs1538687 chr1 196397775 C T 6.67E-09 End-stage coagulation KCNT2 intron 23381943 rs1538687 chr1 196397775 C T 1.17E-06 Age-related macular degeneration KCNT2 intron 23577725 rs1538686 chr1 196397819 G A 5.96E-04 Type 2 diabetes KCNT2 intron 17463246 rs1538686 chr1 196397819 G A 9.64E-05 Body Mass Index KCNT2 intron pha003019 rs1538686 chr1 196397819 G A 8.43E-05 Body Mass Index KCNT2 intron pha003020 rs2878557 chr1 196402773 T C 4.00E-08 Age-related macular degeneration KCNT2 intron 23326517 rs2878557 chr1 196402773 T C 1.50E-08 End-stage coagulation KCNT2 intron 23381943 rs2878557 chr1 196402773 T C 5.80E-25 Age-related macular degeneration KCNT2 intron pha002869 rs2878557 chr1 196402773 T C 5.19E-24 Age-related macular degeneration KCNT2 intron pha002890 rs7531611 chr1 196405652 T C 8.27E-04 Type 2 diabetes KCNT2 intron 17463246 rs7531611 chr1 196405652 T C 3.10E-08 End-stage coagulation KCNT2 intron 23381943 rs10754187 chr1 196416252 A G 3.90E-08 Age-related macular degeneration KCNT2 intron 23326517 rs10754187 chr1 196416252 A G 1.62E-08 End-stage coagulation KCNT2 intron 23381943 rs10494743 chr1 196425133 A G 2.15E-11 Age-related macular degeneration KCNT2 intron pha002869 rs10494743 chr1 196425133 A G 6.58E-12 Age-related macular degeneration KCNT2 intron pha002890 rs10494743 chr1 196425133 A G 6.96E-05 Body Mass Index KCNT2 intron pha003019 rs10494743 chr1 196425133 A G 7.53E-05 Body Mass Index KCNT2 intron pha003020 rs10801537 chr1 196426841 A G 1.70E-08 Age-related macular degeneration KCNT2 intron 23326517 rs10801537 chr1 196426841 A G 1.66E-08 End-stage coagulation KCNT2 intron 23381943 rs11807331 chr1 196427811 T C 1.60E-08 Age-related macular degeneration KCNT2 intron 23326517 rs11807331 chr1 196427811 T C 1.66E-08 End-stage coagulation KCNT2 intron 23381943 rs10922071 chr1 196433870 G A 1.30E-08 Age-related macular degeneration KCNT2 intron 23326517 rs10922071 chr1 196433870 G A 1.66E-08 End-stage coagulation KCNT2 intron 23381943 rs10801538 chr1 196438949 A G 3.05E-04 Scoliosis KCNT2 intron 21216876 rs10801538 chr1 196438949 A G 2.02E-11 Age-related macular degeneration KCNT2 intron pha002869 rs10801538 chr1 196438949 A G 6.25E-12 Age-related macular degeneration KCNT2 intron pha002890 rs10801538 chr1 196438949 A G 7.52E-05 Body Mass Index KCNT2 intron pha003019 rs10801538 chr1 196438949 A G 7.77E-05 Body Mass Index KCNT2 intron pha003020 rs12065463 chr1 196464754 T C 8.60E-09 Age-related macular degeneration KCNT2 intron 23326517 rs12065463 chr1 196464754 T C 3.72E-08 End-stage coagulation KCNT2 intron 23381943 rs1339951 chr1 196482357 C A 4.86E-05 Age-related macular degeneration KCNT2 intron pha002890 rs12743252 chr1 196493740 A G 3.15E-05 Relative hand skill KCNT2 intron 24068947 rs4388642 chr1 196494547 T C 4.60E-09 Age-related macular degeneration KCNT2 intron 23326517 rs12043743 chr1 196502836 T A 8.70E-06 Urinary metabolites KCNT2 intron 21572414 rs10922082 chr1 196513694 G A 1.50E-08 Age-related macular degeneration KCNT2 intron 23326517 rs10922082 chr1 196513694 G A 3.47E-06 Age-related macular degeneration (extreme sampling) KCNT2 intron 23577725 rs10922082 chr1 196513694 G A 7.18E-07 Age-related macular degeneration KCNT2 intron 23577725 rs6704166 chr1 196514176 A T 3.30E-09 Age-related macular degeneration KCNT2 intron 23326517 rs10922083 chr1 196516398 C T 1.50E-08 Age-related macular degeneration KCNT2 intron 23326517 rs10754192 chr1 196519023 T C 4.96E-05 Age-related macular degeneration KCNT2 intron pha002890 rs10922084 chr1 196525314 A C 1.40E-08 Age-related macular degeneration KCNT2 intron 23326517 rs4515738 chr1 196540893 T C 5.30E-04 Multiple complex diseases KCNT2 intron 17554300 rs10494744 chr1 196542567 T C 4.40E-12 Age-related macular degeneration KCNT2 intron pha002869 rs10494744 chr1 196542567 T C 1.35E-11 Age-related macular degeneration KCNT2 intron pha002890 rs4294368 chr1 196547688 C T 5.30E-05 Age-related macular degeneration KCNT2 intron pha002890 rs16840224 chr1 196569681 C T 2.80E-09 Age-related macular degeneration KCNT2 intron 23326517 rs16840224 chr1 196569681 C T 3.08E-06 Age-related macular degeneration (extreme sampling) KCNT2 intron 23577725 rs16840224 chr1 196569681 C T 7.74E-07 Age-related macular degeneration KCNT2 intron 23577725 rs10754196 chr1 196570706 A G 3.50E-09 Age-related macular degeneration KCNT2 intron 23326517 rs10754196 chr1 196570706 A G 4.44E-27 Age-related macular degeneration KCNT2 intron pha002869 rs10754196 chr1 196570706 A G 2.45E-26 Age-related macular degeneration KCNT2 intron pha002890 rs10754198 chr1 196573505 A T 1.10E-11 Age-related macular degeneration KCNT2 intron 23326517 rs10801551 chr1 196580039 G A 9.00E-09 Age-related macular degeneration / / 23326517 rs10801551 chr1 196580039 G A 2.80E-11 End-stage coagulation / / 23381943 rs10801551 chr1 196580039 G A 1.04E-14 Age-related macular degeneration / / 23577725 rs10801551 chr1 196580039 G A 8.19E-10 Age-related macular degeneration (extreme sampling) / / 23577725 rs4657825 chr1 196584321 A G 8.70E-10 Age-related macular degeneration / / 23326517 rs4657825 chr1 196584321 A G 5.29E-13 End-stage coagulation / / 23381943 rs12061508 chr1 196584468 G A 3.70E-09 Age-related macular degeneration / / 23326517 rs12061508 chr1 196584468 G A 1.46E-12 End-stage coagulation / / 23381943 rs12061508 chr1 196584468 G A 1.28E-14 Age-related macular degeneration / / 23577725 rs12061508 chr1 196584468 G A 8.13E-10 Age-related macular degeneration (extreme sampling) / / 23577725 rs944041 chr1 196585217 A G 5.21E-04 Multiple complex diseases / / 17554300 rs12029571 chr1 196603302 A G 1.10E-10 Age-related macular degeneration / / 23326517 rs12029571 chr1 196603302 A G 1.52E-11 End-stage coagulation / / 23381943 rs17573790 chr1 196609396 A C 2.40E-08 Age-related macular degeneration / / 23326517 rs505102 chr1 196619502 T C 2.28E-06 Age-related macular degeneration CFH nearGene-5 22125219 rs505102 chr1 196619502 T C 1.05E-08 Circulating myeloperoxidase levels (serum) CFH nearGene-5 23620142 rs505102 chr1 196619502 T C 9.09E-46 Age-related macular degeneration CFH nearGene-5 pha002869 rs505102 chr1 196619502 T C 1.07E-40 Age-related macular degeneration CFH nearGene-5 pha002890 rs3753394 chr1 196620917 C T 7.00E-11 Complement C3 and C4 levels CFH nearGene-5 23028341 rs7524776 chr1 196623337 T C 8.10E-09 Age-related macular degeneration CFH intron 23326517 rs6680396 chr1 196632470 A G 3.10E-11 Age-related macular degeneration CFH intron 23326517 rs6680396 chr1 196632470 A G 2.60E-12 End-stage coagulation CFH intron 23381943 rs6680396 chr1 196632470 A G 6.65E-43 Circulating myeloperoxidase levels (serum) CFH intron 23620142 rs529825 chr1 196635106 G A 3.20E-12 Age-related macular degeneration CFH intron 23326517 rs529825 chr1 196635106 G A 6.91E-13 End-stage coagulation CFH intron 23381943 rs800292 chr1 196642233 G A 4.90E-07 Age-related macular degeneration CFH missense 20861866 rs800292 chr1 196642233 G A 4.23E-15 Age-related macular degeneration CFH missense 21909106 rs800292 chr1 196642233 G A 1.37E-06 Age-related macular degeneration CFH missense 22125219 rs800292 chr1 196642233 G A 1.20E-12 Age-related macular degeneration CFH missense 23326517 rs800292 chr1 196642233 G A 1.46E-12 End-stage coagulation CFH missense 23381943 rs800292 chr1 196642233 G A 1.65E-10 Age-related macular degeneration (extreme sampling) CFH missense 23577725 rs800292 chr1 196642233 G A 4.41E-15 Age-related macular degeneration CFH missense 23577725 rs800292 chr1 196642233 G A 5.00E-41 Circulating myeloperoxidase levels (serum) CFH missense 23620142 rs800292 chr1 196642233 G A 5.05E-11 Age-related macular degeneration CFH missense pha000001 rs800292 chr1 196642233 G A 1.68E-07 Age-related macular degeneration CFH missense pha002856 rs800292 chr1 196642233 G A 2.21E-47 Age-related macular degeneration CFH missense pha002869 rs800292 chr1 196642233 G A 9.78E-42 Age-related macular degeneration CFH missense pha002890 rs1329424 chr1 196646176 T G 6.00E-16 Age-related macular degeneration CFH intron 20385819 rs1329424 chr1 196646176 T G 2.00E-31 Age-related macular degeneration CFH intron 23326517 rs572515 chr1 196646261 A G 5.40E-15 Age-related macular degeneration CFH intron 20861866 rs572515 chr1 196646261 A G 2.80E-31 Age-related macular degeneration CFH intron 23326517 rs572515 chr1 196646261 A G 1.18E-22 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs572515 chr1 196646261 A G 4.07E-30 Age-related macular degeneration CFH intron 23577725 rs572515 chr1 196646261 A G 4.10E-21 Age-related macular degeneration CFH intron pha000001 rs572515 chr1 196646261 A G 1.22E-15 Age-related macular degeneration CFH intron pha002856 rs12127759 chr1 196648613 C T 6.30E-11 Age-related macular degeneration CFH intron 23326517 rs16840419 chr1 196651745 A G 6.60E-11 Age-related macular degeneration CFH intron 23326517 rs3766404 chr1 196651832 T C 1.80E-05 Nephropathy CFH intron 21399633 rs3766404 chr1 196651832 T C 7.60E-11 Age-related macular degeneration CFH intron 23326517 rs3766404 chr1 196651832 T C 2.50E-23 Age-related macular degeneration CFH intron pha002869 rs3766404 chr1 196651832 T C 2.44E-21 Age-related macular degeneration CFH intron pha002890 rs16840422 chr1 196652834 C T 7.80E-11 Age-related macular degeneration CFH intron 23326517 rs1061147 chr1 196654324 A C 7.00E-32 Age-related macular degeneration CFH cds-synon 23326517 rs1329422 chr1 196655280 C G 2.90E-31 Age-related macular degeneration CFH intron 23326517 rs2300430 chr1 196655713 T C 6.10E-31 Age-related macular degeneration CFH intron 23326517 rs10801553 chr1 196655743 A C 3.00E-31 Age-related macular degeneration CFH intron 23326517 rs10801553 chr1 196655743 A C 2.44E-29 Age-related macular degeneration CFH intron 23577725 rs10801553 chr1 196655743 A C 7.04E-23 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs1329421 chr1 196656205 A T 3.00E-31 Age-related macular degeneration CFH intron 23326517 rs10801554 chr1 196657655 C T 3.40E-31 Age-related macular degeneration CFH intron 23326517 rs7529589 chr1 196658279 T C 1.50E-14 Age-related macular degeneration CFH intron 20861866 rs7529589 chr1 196658279 T C 5.00E-31 Age-related macular degeneration CFH intron 23326517 rs7529589 chr1 196658279 T C 2.67E-19 Age-related macular degeneration CFH intron pha000001 rs7529589 chr1 196658279 T C 1.60E-14 Age-related macular degeneration CFH intron pha002856 rs482934 chr1 196658497 G T 5.00E-31 Age-related macular degeneration CFH intron 23326517 rs1061170 chr1 196659237 C T 4.00E-117 Age-related macular degeneration CFH missense 20385826 rs1061170 chr1 196659237 C T 1.00E-261 Age-related macular degeneration CFH missense 21665990 rs1061170 chr1 196659237 C T 1.88E-05 Age-related macular degeneration CFH missense 21909106 rs1061170 chr1 196659237 C T 1.00E-108 Age-related macular degeneration (CNV) CFH missense 22705344 rs1061170 chr1 196659237 C T 5.00E-67 Age-related macular degeneration (GA) CFH missense 22705344 rs1061170 chr1 196659237 C T 2.40E-28 Age-related macular degeneration CFH missense 23326517 rs10801555 chr1 196660261 A G 2.75E-05 Type 2 diabetes CFH intron 17463246 rs10801555 chr1 196660261 A G 2.14E-08 Age-related macular degeneration CFH intron 22125219 rs10801555 chr1 196660261 A G 2.00E-47 Age-related macular degeneration CFH intron 22694956 rs10801555 chr1 196660261 A G 6.10E-31 Age-related macular degeneration CFH intron 23326517 rs10801555 chr1 196660261 A G 1.52E-22 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs10801555 chr1 196660261 A G 7.63E-30 Age-related macular degeneration CFH intron 23577725 rs10801555 chr1 196660261 A G 3.74E-84 Age-related macular degeneration CFH intron pha002869 rs10801555 chr1 196660261 A G 1.33E-71 Age-related macular degeneration CFH intron pha002890 rs10801556 chr1 196660464 A G 1.20E-22 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs10801556 chr1 196660464 A G 1.38E-29 Age-related macular degeneration CFH intron 23577725 rs10922094 chr1 196661505 G C 4.30E-31 Age-related macular degeneration CFH intron 23326517 rs12124794 chr1 196661538 A T 4.50E-10 Age-related macular degeneration CFH intron 23326517 rs12124794 chr1 196661538 A T 4.38E-12 End-stage coagulation CFH intron 23381943 rs10922096 chr1 196662459 T C 6.80E-12 Age-related macular degeneration CFH intron 23326517 rs12041668 chr1 196663047 C T 3.60E-10 Age-related macular degeneration CFH intron 23326517 rs12041668 chr1 196663047 C T 1.53E-11 End-stage coagulation CFH intron 23381943 rs514943 chr1 196663913 C T 1.32E-29 Age-related macular degeneration CFH intron 23577725 rs514943 chr1 196663913 C T 6.00E-23 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs10922102 chr1 196668287 C T 3.50E-31 Age-related macular degeneration CFH intron 23326517 rs2860102 chr1 196668319 A T 3.60E-31 Age-related macular degeneration CFH intron 23326517 rs4658046 chr1 196670757 C T 2.10E-29 Age-related macular degeneration CFH intron 23326517 rs10754199 chr1 196670839 A G 3.16E-08 Age-related macular degeneration CFH intron 22125219 rs10754199 chr1 196670839 A G 1.17E-85 Age-related macular degeneration CFH intron pha002869 rs10754199 chr1 196670839 A G 7.71E-73 Age-related macular degeneration CFH intron pha002890 rs12038333 chr1 196672454 G A 1.10E-14 Age-related macular degeneration CFH intron 20861866 rs12038333 chr1 196672454 G A 3.00E-31 Age-related macular degeneration CFH intron 23326517 rs12038333 chr1 196672454 G A 2.77E-20 Age-related macular degeneration CFH intron pha000001 rs12038333 chr1 196672454 G A 4.47E-15 Age-related macular degeneration CFH intron pha002856 rs12045503 chr1 196672473 C T 2.90E-31 Age-related macular degeneration CFH intron 23326517 rs9970784 chr1 196673802 C T 4.20E-30 Age-related macular degeneration CFH intron 23326517 rs1831282 chr1 196673993 A C 7.55E-04 Type 2 diabetes CFH intron 17463246 rs1831282 chr1 196673993 A C 4.10E-05 Age-related macular degeneration CFH intron 20861866 rs1831282 chr1 196673993 A C 4.50E-30 Age-related macular degeneration CFH intron 23326517 rs1831282 chr1 196673993 A C 1.00E-31 Age-related macular degeneration CFH intron 23577725 rs1831282 chr1 196673993 A C 9.00E-24 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs203687 chr1 196674270 C T 4.00E-30 Age-related macular degeneration CFH intron 23326517 rs203687 chr1 196674270 C T 2.11E-30 Age-related macular degeneration CFH intron 23577725 rs203687 chr1 196674270 C T 3.52E-22 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs2019727 chr1 196674714 T A 1.40E-09 Age-related macular degeneration CFH intron 20861866 rs2019727 chr1 196674714 T A 1.00E-10 Age-related macular degeneration CFH intron 23326517 rs2019727 chr1 196674714 T A 1.39E-12 Age-related macular degeneration CFH intron 23577725 rs2019727 chr1 196674714 T A 4.39E-11 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs2019727 chr1 196674714 T A 2.99E-12 Age-related macular degeneration CFH intron pha000002 rs2019724 chr1 196674917 T C 5.27E-09 Age-related macular degeneration CFH intron 22125219 rs2019724 chr1 196674917 T C 3.60E-30 Age-related macular degeneration CFH intron 23326517 rs2019724 chr1 196674917 T C 2.07E-88 Age-related macular degeneration CFH intron pha002869 rs2019724 chr1 196674917 T C 9.52E-75 Age-related macular degeneration CFH intron pha002890 rs1887973 chr1 196675179 G A,C 3.90E-30 Age-related macular degeneration CFH intron 23326517 rs6428357 chr1 196675571 A G 3.80E-05 Age-related macular degeneration CFH intron 20861866 rs6428357 chr1 196675571 A G 7.36E-09 Age-related macular degeneration CFH intron 22125219 rs6428357 chr1 196675571 A G 4.20E-30 Age-related macular degeneration CFH intron 23326517 rs6428357 chr1 196675571 A G 2.20E-23 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs6428357 chr1 196675571 A G 2.20E-31 Age-related macular degeneration CFH intron 23577725 rs6695321 chr1 196675861 A G 3.70E-10 Age-related macular degeneration CFH intron 23326517 rs6695321 chr1 196675861 A G 1.73E-13 Age-related macular degeneration CFH intron 23577725 rs6695321 chr1 196675861 A G 2.47E-09 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs10733086 chr1 196676935 A T 6.46E-04 Type 2 diabetes CFH intron 17463246 rs10733086 chr1 196676935 A T 2.20E-05 Age-related macular degeneration CFH intron 20861866 rs10733086 chr1 196676935 A T 1.10E-29 Age-related macular degeneration CFH intron 23326517 rs10733086 chr1 196676935 A T 1.04E-29 Age-related macular degeneration CFH intron 23577725 rs10733086 chr1 196676935 A T 7.89E-23 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs1410997 chr1 196677163 C A 1.10E-29 Age-related macular degeneration CFH intron 23326517 rs203685 chr1 196677945 C A 1.20E-29 Age-related macular degeneration CFH intron 23326517 rs10737680 chr1 196679455 A C 2.00E-76 Age-related macular degeneration CFH intron 20385819 rs10737680 chr1 196679455 A C 8.70E-26 Age-related macular degeneration CFH intron 23326517 rs10737680 chr1 196679455 A C 1.33E-09 End-stage coagulation CFH intron 23381943 rs10737680 chr1 196679455 A C 1E-434 Age-related macular degeneration CFH intron 23455636 rs10737680 chr1 196679455 A C 1.38E-26 Age-related macular degeneration CFH intron 23577725 rs10737680 chr1 196679455 A C 1.81E-21 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs1831281 chr1 196680814 C T 3.60E-10 Age-related macular degeneration CFH intron 23326517 rs1831281 chr1 196680814 C T 7.20E-13 End-stage coagulation CFH intron 23381943 rs203674 chr1 196684625 G T 1.50E-17 Age-related macular degeneration CFH intron 20861866 rs203674 chr1 196684625 G T 1.10E-29 Age-related macular degeneration CFH intron 23326517 rs203674 chr1 196684625 G T 1.29E-25 Age-related macular degeneration CFH intron pha000001 rs203674 chr1 196684625 G T 6.04E-18 Age-related macular degeneration CFH intron pha002856 rs3753395 chr1 196686652 A T 1.00E-25 Age-related macular degeneration CFH intron 23326517 rs3753395 chr1 196686652 A T 1.33E-09 End-stage coagulation CFH intron 23381943 rs6677604 chr1 196686918 G A 3.00E-10 Nephropathy CFH intron 21399633 rs6677604 chr1 196686918 G A 2.30E-10 Age-related macular degeneration CFH intron 23326517 rs6677604 chr1 196686918 G A 9.46E-38 Age-related macular degeneration CFH intron pha002869 rs6677604 chr1 196686918 G A 1.65E-32 Age-related macular degeneration CFH intron pha002890 rs10922106 chr1 196691464 A G 1.00E-25 Age-related macular degeneration CFH intron 23326517 rs10922106 chr1 196691464 A G 1.33E-09 End-stage coagulation CFH intron 23381943 rs393955 chr1 196692470 C A 1.10E-29 Age-related macular degeneration CFH intron 23326517 rs381974 chr1 196692672 A G 1.10E-29 Age-related macular degeneration CFH intron 23326517 rs381974 chr1 196692672 A G 1.35E-05 Schizophrenia CFH intron 24043878 rs379489 chr1 196693451 A G 4.75E-09 Age-related macular degeneration CFH intron 22125219 rs379489 chr1 196693451 A G 1.49E-21 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs379489 chr1 196693451 A G 5.64E-29 Age-related macular degeneration CFH intron 23577725 rs403846 chr1 196696737 T C 1.10E-29 Age-related macular degeneration CFH intron 23326517 rs403846 chr1 196696737 T C 1.74E-31 Age-related macular degeneration CFH intron 23577725 rs403846 chr1 196696737 T C 9.09E-24 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs419137 chr1 196696875 G T 1.06E-10 Age-related macular degeneration CFH intron pha002869 rs419137 chr1 196696875 G T 2.33E-09 Age-related macular degeneration CFH intron pha002890 rs1410996 chr1 196696933 G A 2.00E-111 Age-related macular degeneration CFH intron 20385826 rs1410996 chr1 196696933 G A 1.10E-25 Age-related macular degeneration CFH intron 23326517 rs1410996 chr1 196696933 G A 1.00E-09 End-stage coagulation CFH intron 23381943 rs395544 chr1 196698272 A G 7.60E-04 Type 2 diabetes CFH intron 17463246 rs395544 chr1 196698272 A G 3.80E-05 Age-related macular degeneration CFH intron 20861866 rs395544 chr1 196698272 A G 1.20E-29 Age-related macular degeneration CFH intron 23326517 rs395544 chr1 196698272 A G 1.74E-23 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs395544 chr1 196698272 A G 2.61E-31 Age-related macular degeneration CFH intron 23577725 rs1576340 chr1 196698711 G T 5.40E-10 Age-related macular degeneration CFH intron 23326517 rs1576340 chr1 196698711 G T 6.68E-09 End-stage coagulation CFH intron 23381943 rs12144939 chr1 196698945 G A,T 2.40E-11 Age-related macular degeneration CFH intron 23326517 rs380390 chr1 196701051 G C 4.00E-08 Age-related macular degeneration CFH intron 15761122 rs380390 chr1 196701051 G C 3.40E-14 Age-related macular degeneration CFH intron 20861866 rs380390 chr1 196701051 G C 5.50E-30 Age-related macular degeneration CFH intron 23326517 rs380390 chr1 196701051 G C 1.75E-19 Age-related macular degeneration CFH intron pha000002 rs7540032 chr1 196701284 C T 1.70E-25 Age-related macular degeneration CFH intron 23326517 rs7540032 chr1 196701284 C T 9.02E-10 End-stage coagulation CFH intron 23381943 rs2284664 chr1 196702525 C T 3.89E-04 Hemoglobin concentration CFH intron 20534544 rs2284664 chr1 196702525 C T 4.27E-05 Age-related macular degeneration CFH intron 22125219 rs2284664 chr1 196702525 C T 5.00E-10 Age-related macular degeneration CFH intron 23326517 rs2284664 chr1 196702525 C T 2.38E-13 End-stage coagulation CFH intron 23381943 rs2284664 chr1 196702525 C T 2.81E-41 Age-related macular degeneration CFH intron pha002869 rs2284664 chr1 196702525 C T 2.28E-36 Age-related macular degeneration CFH intron pha002890 rs1329428 chr1 196702810 C T 1.40E-06 Age-related macular degeneration CFH intron 15761122 rs1329428 chr1 196702810 C T 3.00E-64 Age-related macular degeneration CFH intron 20861866 rs1329428 chr1 196702810 C T 1.02E-08 Age-related macular degeneration CFH intron 22125219 rs1329428 chr1 196702810 C T 2.10E-25 Age-related macular degeneration CFH intron 23326517 rs1329428 chr1 196702810 C T 6.89E-10 End-stage coagulation CFH intron 23381943 rs1329428 chr1 196702810 C T 1.35E-16 Age-related macular degeneration CFH intron pha000002 rs1329428 chr1 196702810 C T 8.92E-92 Age-related macular degeneration CFH intron pha002869 rs1329428 chr1 196702810 C T 6.93E-76 Age-related macular degeneration CFH intron pha002890 rs434536 chr1 196705167 C T 9.83E-04 Multiple complex diseases CFH intron 17554300 rs424535 chr1 196709223 A T 9.90E-05 Age-related macular degeneration CFH intron 20861866 rs424535 chr1 196709223 A T 3.80E-09 Age-related macular degeneration CFH intron 23326517 rs424535 chr1 196709223 A T 1.56E-14 Age-related macular degeneration CFH intron 23577725 rs424535 chr1 196709223 A T 2.38E-11 Age-related macular degeneration (extreme sampling) CFH intron 23577725 rs1065489 chr1 196709774 G T 4.74E-05 Meningococcal disease CFH missense 20694013 rs11582939 chr1 196710157 C T 6.13E-05 Meningococcal disease CFH intron 20694013 rs16840522 chr1 196710916 T C 2.00E-10 Age-related macular degeneration CFH intron 23326517 rs10801560 chr1 196714600 C A 2.50E-10 Age-related macular degeneration CFH intron 23326517 rs10801560 chr1 196714600 C A 2.80E-13 End-stage coagulation CFH intron 23381943 rs10801561 chr1 196714670 T A 2.50E-10 Age-related macular degeneration CFH intron 23326517 rs10801561 chr1 196714670 T A 2.80E-13 End-stage coagulation CFH intron 23381943 rs402032 chr1 196718214 C G 5.90E-09 Age-related macular degeneration / / 23326517 rs395998 chr1 196739837 C T 9.10E-30 Age-related macular degeneration / / 23326517 rs426736 chr1 196760417 A G 5.00E-13 Meningococcal disease CFHR3 intron 20694013 rs411854 chr1 196762117 A G 4.00E-12 Age-related macular degeneration CFHR3 intron 23326517 rs9427913 chr1 196765467 T G 1.40E-26 Age-related macular degeneration / / 23326517 rs436719 chr1 196787744 T G 5.40E-09 Age-related macular degeneration CFHR1 nearGene-5 23326517 rs432007 chr1 196792464 A C 8.90E-27 Age-related macular degeneration CFHR1 intron 23326517 rs438781 chr1 196796240 T A 1.90E-25 Age-related macular degeneration CFHR1 intron 23326517 rs1738740 chr1 196808640 A T 1.40E-26 Age-related macular degeneration / / 23326517 rs6679884 chr1 196817998 G A 3.60E-10 Age-related macular degeneration / / 23326517 rs503002 chr1 196820287 A G 6.10E-09 Age-related macular degeneration / / 23326517 rs10754206 chr1 196820924 T G 6.80E-27 Age-related macular degeneration / / 23326517 rs1964645 chr1 196822014 T C 4.20E-10 Age-related macular degeneration / / 23326517 rs1964645 chr1 196822014 T C 2.76E-13 End-stage coagulation / / 23381943 rs1963605 chr1 196822168 C A 3.30E-10 Age-related macular degeneration / / 23326517 rs1963605 chr1 196822168 C A 1.75E-13 End-stage coagulation / / 23381943 rs16840607 chr1 196823030 T G 2.10E-08 Age-related macular degeneration / / 23326517 rs10922144 chr1 196823300 C A,G,T 2.07E-04 Age-related macular degeneration / / 22125219 rs10922144 chr1 196823300 C A,G,T 4.10E-10 Age-related macular degeneration / / 23326517 rs10922144 chr1 196823300 C A,G,T 1.21E-13 End-stage coagulation / / 23381943 rs10922144 chr1 196823300 C A,G,T 3.90E-37 Age-related macular degeneration / / pha002869 rs10922144 chr1 196823300 C A,G,T 1.53E-32 Age-related macular degeneration / / pha002890 rs7542235 chr1 196823613 A G 8.30E-11 Age-related macular degeneration / / 23326517 rs7542235 chr1 196823613 A G 1.08E-12 Age-related macular degeneration / / 23577725 rs7542235 chr1 196823613 A G 6.80E-12 Age-related macular degeneration (extreme sampling) / / 23577725 rs16840639 chr1 196824773 T C 8.50E-11 Age-related macular degeneration / / 23326517 rs7519758 chr1 196825287 C T 8.10E-11 Age-related macular degeneration / / 23326517 rs7412359 chr1 196832925 G A 1.80E-09 Age-related macular degeneration / / 23326517 rs10922146 chr1 196834636 C T 6.10E-10 Age-related macular degeneration / / 23326517 rs10922146 chr1 196834636 C T 1.44E-13 End-stage coagulation / / 23381943 rs12047098 chr1 196835106 T C 6.20E-10 Age-related macular degeneration / / 23326517 rs12047098 chr1 196835106 T C 1.44E-13 End-stage coagulation / / 23381943 rs7552547 chr1 196836999 T G 2.10E-09 Age-related macular degeneration / / 23326517 rs6657442 chr1 196838060 T C 1.92E-04 Age-related macular degeneration / / 22125219 rs6657442 chr1 196838060 T C 6.90E-10 Age-related macular degeneration / / 23326517 rs6657442 chr1 196838060 T C 3.77E-13 End-stage coagulation / / 23381943 rs6657442 chr1 196838060 T C 1.30E-38 Age-related macular degeneration / / pha002869 rs6657442 chr1 196838060 T C 2.07E-33 Age-related macular degeneration / / pha002890 rs7413265 chr1 196839163 G T 6.60E-10 Age-related macular degeneration / / 23326517 rs7413265 chr1 196839163 G T 1.44E-13 End-stage coagulation / / 23381943 rs7413265 chr1 196839163 G T 1.05E-11 Age-related macular degeneration / / 23577725 rs7413265 chr1 196839163 G T 1.75E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs7516560 chr1 196839430 T C 1.70E-09 Age-related macular degeneration / / 23326517 rs7516560 chr1 196839430 T C 2.39E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs7516560 chr1 196839430 T C 6.02E-08 Age-related macular degeneration / / 23577725 rs7514704 chr1 196839991 A G 1.80E-09 Age-related macular degeneration / / 23326517 rs7519492 chr1 196840125 T C 1.80E-09 Age-related macular degeneration / / 23326517 rs7517126 chr1 196840272 A G 1.60E-09 Age-related macular degeneration / / 23326517 rs7517126 chr1 196840272 A G 5.99E-20 Age-related macular degeneration / / pha002890 rs7517587 chr1 196840765 A G 1.80E-09 Age-related macular degeneration / / 23326517 rs13375144 chr1 196841690 C T 1.80E-09 Age-related macular degeneration / / 23326517 rs13375144 chr1 196841690 C T 5.05E-19 Age-related macular degeneration / / pha002890 rs13375150 chr1 196841839 C T 1.90E-09 Age-related macular degeneration / / 23326517 rs13374399 chr1 196842006 G A 2.00E-09 Age-related macular degeneration / / 23326517 rs13375236 chr1 196842271 C T 1.00E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs13375236 chr1 196842271 C T 2.01E-08 Age-related macular degeneration / / 23577725 rs2336502 chr1 196842574 T C 2.40E-08 Age-related macular degeneration / / 23326517 rs2133138 chr1 196843171 G A 2.00E-09 Age-related macular degeneration / / 23326517 rs2133138 chr1 196843171 G A 3.36E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs2133138 chr1 196843171 G A 6.04E-08 Age-related macular degeneration / / 23577725 rs2336503 chr1 196843420 C A 1.50E-09 Age-related macular degeneration / / 23326517 rs2336503 chr1 196843420 C A 3.85E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs2336503 chr1 196843420 C A 4.52E-08 Age-related macular degeneration / / 23577725 rs6428363 chr1 196843711 G A 1.74E-10 Age-related macular degeneration / / 23577725 rs6428363 chr1 196843711 G A 2.06E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs6428364 chr1 196844049 C T 1.50E-09 Age-related macular degeneration / / 23326517 rs6428364 chr1 196844049 C T 5.13E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs6428364 chr1 196844049 C T 7.80E-08 Age-related macular degeneration / / 23577725 rs6428365 chr1 196844131 C A 1.70E-09 Age-related macular degeneration / / 23326517 rs6428366 chr1 196844167 A G 1.80E-09 Age-related macular degeneration / / 23326517 rs6428366 chr1 196844167 A G 1.40E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs6428366 chr1 196844167 A G 4.13E-08 Age-related macular degeneration / / 23577725 rs6428367 chr1 196844192 T C 1.80E-09 Age-related macular degeneration / / 23326517 rs6428367 chr1 196844192 T C 1.12E-07 Age-related macular degeneration / / 23577725 rs6428367 chr1 196844192 T C 3.37E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs6428368 chr1 196844310 T C 1.90E-09 Age-related macular degeneration / / 23326517 rs6428369 chr1 196844335 T C 1.90E-09 Age-related macular degeneration / / 23326517 rs6428369 chr1 196844335 T C 3.45E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs6428369 chr1 196844335 T C 9.57E-08 Age-related macular degeneration / / 23577725 rs6428370 chr1 196844593 A G 7.00E-06 Acute lymphoblastic leukemia (childhood) / / 19684603 rs6428370 chr1 196844593 A G 7.00E-06 Nasopharyngeal carcinoma / / 20512145 rs6428370 chr1 196844593 A G 1.60E-08 Age-related macular degeneration / / 23326517 rs6428370 chr1 196844593 A G 3.99E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs6428370 chr1 196844593 A G 4.22E-10 Age-related macular degeneration / / 23577725 rs12240143 chr1 196845017 T C 1.60E-08 Age-related macular degeneration / / 23326517 rs1021636 chr1 196845273 A G 2.13E-08 Age-related macular degeneration (extreme sampling) / / 23577725 rs1021636 chr1 196845273 A G 5.17E-12 Age-related macular degeneration / / 23577725 rs12240148 chr1 196845307 T C 2.30E-09 Age-related macular degeneration / / 23326517 rs6695525 chr1 196845521 T G 2.70E-25 Age-related macular degeneration / / 23326517 rs10801575 chr1 196852781 T C 1.20E-09 Age-related macular degeneration / / 20861866 rs10801575 chr1 196852781 T C 8.31E-14 Age-related macular degeneration / / pha000001 rs10801575 chr1 196852781 T C 7.31E-11 Age-related macular degeneration / / pha002856 rs10801575 chr1 196852781 T C 1.13E-19 Age-related macular degeneration / / pha002890 rs7366238 chr1 196860797 A G 1.70E-09 Age-related macular degeneration CFHR4 intron 23326517 rs7366238 chr1 196860797 A G 7.29E-16 End-stage coagulation CFHR4 intron 23381943 rs6685931 chr1 196867233 T C 2.13E-10 Age-related macular degeneration CFHR4 intron 22125219 rs6685931 chr1 196867233 T C 5.50E-27 Age-related macular degeneration CFHR4 intron 23326517 rs6685931 chr1 196867233 T C 2.61E-73 Age-related macular degeneration CFHR4 intron pha002869 rs6685931 chr1 196867233 T C 1.42E-61 Age-related macular degeneration CFHR4 intron pha002890 rs10922147 chr1 196877689 C G 1.10E-08 Age-related macular degeneration CFHR4 intron 23326517 rs10922147 chr1 196877689 C G 3.88E-19 End-stage coagulation CFHR4 intron 23381943 rs1409153 chr1 196880005 C T 3.60E-27 Age-related macular degeneration CFHR4 intron 23326517 rs1853883 chr1 196881600 G C 3.41E-18 Age-related macular degeneration CFHR4 intron 21197116 rs1853883 chr1 196881600 G C 2.20E-23 Age-related macular degeneration CFHR4 intron 23326517 rs1853883 chr1 196881600 G C 3.34E-17 Age-related macular degeneration (extreme sampling) CFHR4 intron 23577725 rs1853883 chr1 196881600 G C 8.16E-23 Age-related macular degeneration CFHR4 intron 23577725 rs1853883 chr1 196881600 G C 1.08E-22 Age-related macular degeneration CFHR4 intron pha000001 rs1853883 chr1 196881600 G C 4.85E-15 Age-related macular degeneration CFHR4 intron pha002856 rs7522952 chr1 196882344 A G 2.34E-17 Age-related macular degeneration CFHR4 intron pha002869 rs7522952 chr1 196882344 A G 5.97E-16 Age-related macular degeneration CFHR4 intron pha002890 rs7525447 chr1 196882436 T C 1.10E-08 Age-related macular degeneration CFHR4 intron 23326517 rs7533270 chr1 196882503 G A 1.10E-08 Age-related macular degeneration CFHR4 intron 23326517 rs1853882 chr1 196885344 C G 5.90E-08 Age-related macular degeneration CFHR4 intron 20861866 rs1853882 chr1 196885344 C G 1.10E-08 Age-related macular degeneration CFHR4 intron 23326517 rs1853882 chr1 196885344 C G 4.26E-11 Age-related macular degeneration CFHR4 intron pha000002 rs10801580 chr1 196885685 T C 1.34E-07 Age-related macular degeneration (extreme sampling) CFHR4 intron 23577725 rs10801580 chr1 196885685 T C 1.72E-11 Age-related macular degeneration CFHR4 intron 23577725 rs4915559 chr1 196886770 T C 1.20E-08 Age-related macular degeneration CFHR4 intron 23326517 rs4915559 chr1 196886770 T C 7.00E-19 End-stage coagulation CFHR4 intron 23381943 rs1971579 chr1 196887181 T G 3.40E-10 Age-related macular degeneration CFHR4 intron 20861866 rs1971579 chr1 196887181 T G 3.43E-10 Age-related macular degeneration CFHR4 intron pha000002 rs10494745 chr1 196887457 G A 3.30E-09 Age-related macular degeneration CFHR4 missense 23326517 rs7548070 chr1 196892322 G A 4.93E-21 Age-related macular degeneration / / pha002869 rs7548070 chr1 196892322 G A 2.60E-19 Age-related macular degeneration / / pha002890 rs4086175 chr1 196894326 T C 9.60E-09 Age-related macular degeneration / / 23326517 rs4915318 chr1 196897088 C A 3.99E-05 Age-related macular degeneration / / 22125219 rs4915318 chr1 196897088 C A 1.00E-08 Age-related macular degeneration / / 23326517 rs4915318 chr1 196897088 C A 2.53E-18 End-stage coagulation / / 23381943 rs4915318 chr1 196897088 C A 5.91E-34 Age-related macular degeneration / / pha002869 rs4915318 chr1 196897088 C A 5.49E-30 Age-related macular degeneration / / pha002890 rs7538501 chr1 196901753 C T 1.10E-08 Age-related macular degeneration / / 23326517 rs7538501 chr1 196901753 C T 2.02E-20 Age-related macular degeneration / / pha002869 rs7538501 chr1 196901753 C T 7.55E-19 Age-related macular degeneration / / pha002890 rs2986127 chr1 196904671 T C 4.40E-10 Age-related macular degeneration / / 23326517 rs432366 chr1 196912191 C G 3.60E-08 Age-related macular degeneration / / 23326517 rs1853881 chr1 196915745 A C 3.10E-11 Age-related macular degeneration CFHR2 intron 23326517 rs6674522 chr1 196916359 G C 4.91E-06 Age-related macular degeneration CFHR2 intron 23577725 rs6674522 chr1 196916359 G C 5.00E-06 Age-related macular degeneration (extreme sampling) CFHR2 intron 23577725 rs12066959 chr1 196917899 G A 1.19E-18 End-stage coagulation CFHR2 intron 23381943 rs201886468 chr1 196917899 G GTA 1.19E-18 End-stage coagulation CFHR2 intron 23381943 rs4085749 chr1 196920148 C T 1.18E-18 End-stage coagulation CFHR2 cds-synon 23381943 rs3828032 chr1 196920178 C T 2.90E-08 Age-related macular degeneration CFHR2 intron 23326517 rs3790414 chr1 196920299 T A 1.00E-05 Age-related macular degeneration CFHR2 intron 20861866 rs3790414 chr1 196920299 T A 1.17E-18 End-stage coagulation CFHR2 intron 23381943 rs3790414 chr1 196920299 T A 2.51E-06 Age-related macular degeneration CFHR2 intron pha000001 rs3790414 chr1 196920299 T A 6.21E-05 Age-related macular degeneration CFHR2 intron pha002856 rs9427934 chr1 196922860 G A 3.10E-08 Age-related macular degeneration CFHR2 intron 23326517 rs7531555 chr1 196929310 C T 4.30E-05 Age-related macular degeneration / / 20861866 rs7531555 chr1 196929310 C T 1.01E-18 End-stage coagulation / / 23381943 rs7531555 chr1 196929310 C T 4.87E-06 Age-related macular degeneration / / pha000001 rs9427938 chr1 196933245 C T 4.10E-08 Age-related macular degeneration / / 23326517 rs6428379 chr1 196937536 T C 5.05E-09 Age-related macular degeneration / / 22125219 rs6428379 chr1 196937536 T C 1.90E-22 Age-related macular degeneration / / 23326517 rs6667243 chr1 196941493 T C 1.92E-08 Age-related macular degeneration / / 22125219 rs6667243 chr1 196941493 T C 5.50E-20 Age-related macular degeneration / / 23326517 rs6667243 chr1 196941493 T C 1.10E-16 Age-related macular degeneration (extreme sampling) / / 23577725 rs6667243 chr1 196941493 T C 2.16E-21 Age-related macular degeneration / / 23577725 rs6667243 chr1 196941493 T C 3.34E-66 Age-related macular degeneration / / pha002869 rs6667243 chr1 196941493 T C 1.13E-57 Age-related macular degeneration / / pha002890 rs6675769 chr1 196941661 G A 4.10E-20 Age-related macular degeneration / / 23326517 rs10801582 chr1 196944357 G A 1.99E-18 End-stage coagulation / / 23381943 rs12755054 chr1 196947030 T C 1.70E-09 Age-related macular degeneration CFHR5 intron 23326517 rs12755054 chr1 196947030 T C 6.05E-10 End-stage coagulation CFHR5 intron 23381943 rs12755054 chr1 196947030 T C 1.13E-09 Age-related macular degeneration CFHR5 intron 23577725 rs12755054 chr1 196947030 T C 8.69E-09 Age-related macular degeneration (extreme sampling) CFHR5 intron 23577725 rs12731209 chr1 196947139 C T 2.00E-05 Age-related macular degeneration CFHR5 intron 20861866 rs12731209 chr1 196947139 C T 3.35E-08 Age-related macular degeneration CFHR5 intron pha000001 rs12731209 chr1 196947139 C T 1.30E-05 Age-related macular degeneration CFHR5 intron pha002856 rs1759016 chr1 196952498 C T 1.60E-06 Age-related macular degeneration CFHR5 intron 20861866 rs1759016 chr1 196952498 C T 2.00E-09 Age-related macular degeneration CFHR5 intron 23326517 rs1759016 chr1 196952498 C T 6.05E-10 End-stage coagulation CFHR5 intron 23381943 rs1759016 chr1 196952498 C T 2.07E-09 Age-related macular degeneration CFHR5 intron pha000001 rs1759016 chr1 196952498 C T 4.71E-07 Age-related macular degeneration CFHR5 intron pha002856 rs1750311 chr1 196954225 C A 2.00E-09 Age-related macular degeneration CFHR5 intron 23326517 rs1750311 chr1 196954225 C A 6.05E-10 End-stage coagulation CFHR5 intron 23381943 rs10922152 chr1 196963006 T A 2.60E-12 Age-related macular degeneration CFHR5 intron 20861866 rs10922152 chr1 196963006 T A 2.20E-16 Age-related macular degeneration CFHR5 intron 23326517 rs10922152 chr1 196963006 T A 2.63E-17 Age-related macular degeneration CFHR5 intron pha000001 rs10922152 chr1 196963006 T A 5.21E-12 Age-related macular degeneration CFHR5 intron pha002856 rs12116643 chr1 196973183 T C 5.00E-30 End-stage coagulation CFHR5 intron 23381943 rs10922153 chr1 196978615 T G 3.80E-12 Age-related macular degeneration CFHR5 UTR-3 20861866 rs10922153 chr1 196978615 T G 2.80E-16 Age-related macular degeneration CFHR5 UTR-3 23326517 rs10922153 chr1 196978615 T G 2.63E-17 Age-related macular degeneration CFHR5 UTR-3 pha000001 rs10922153 chr1 196978615 T G 5.21E-12 Age-related macular degeneration CFHR5 UTR-3 pha002856 rs6663083 chr1 196980660 T C 2.40E-12 Age-related macular degeneration / / 20861866 rs6663083 chr1 196980660 T C 2.90E-16 Age-related macular degeneration / / 23326517 rs6663083 chr1 196980660 T C 2.70E-17 Age-related macular degeneration / / pha000001 rs6663083 chr1 196980660 T C 5.47E-12 Age-related macular degeneration / / pha002856 rs7555070 chr1 196982154 C T 3.08E-04 Age-related macular degeneration / / 22125219 rs7555070 chr1 196982154 C T 2.60E-09 Age-related macular degeneration / / 23326517 rs7555070 chr1 196982154 C T 6.40E-10 End-stage coagulation / / 23381943 rs7555070 chr1 196982154 C T 5.69E-24 Age-related macular degeneration / / pha002869 rs7555070 chr1 196982154 C T 5.60E-22 Age-related macular degeneration / / pha002890 rs1332666 chr1 196984679 A G 1.93E-07 Age-related macular degeneration / / 22125219 rs1332666 chr1 196984679 A G 9.46E-04 Tourette syndrome / / 22889924 rs1332666 chr1 196984679 A G 3.90E-16 Age-related macular degeneration / / 23326517 rs1332666 chr1 196984679 A G 1.19E-50 Age-related macular degeneration / / pha002869 rs1332666 chr1 196984679 A G 3.74E-45 Age-related macular degeneration / / pha002890 rs12125782 chr1 196993119 A T 2.43E-09 End-stage coagulation / / 23381943 rs2336597 chr1 196993339 A G 3.61E-04 Multiple complex diseases / / 17554300 rs1360558 chr1 196993973 G A 4.27E-13 End-stage coagulation / / 23381943 rs2336596 chr1 196995092 G A 5.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs1332667 chr1 196995848 G T 9.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs1332667 chr1 196995848 G T 1.29E-21 End-stage coagulation / / 23381943 rs12075161 chr1 197001099 T A 5.90E-30 End-stage coagulation / / 23381943 rs10737685 chr1 197004484 A G 8.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs10737685 chr1 197004484 A G 1.29E-21 End-stage coagulation / / 23381943 rs6702252 chr1 197005212 G A 1.29E-21 End-stage coagulation / / 23381943 rs1332668 chr1 197005736 C T 1.29E-21 End-stage coagulation / / 23381943 rs200940460 chr1 197005736 C CT 1.29E-21 End-stage coagulation / / 23381943 rs698859 chr1 197008365 C T 2.27E-12 End-stage coagulation F13B UTR-3 23381943 rs5990 chr1 197008597 A C 1.29E-21 End-stage coagulation F13B intron 23381943 rs12134960 chr1 197009508 G C 5.90E-30 End-stage coagulation F13B intron 23381943 rs5998 chr1 197009798 A G 1.29E-21 End-stage coagulation F13B cds-synon 23381943 rs10484502 chr1 197010475 G A 1.29E-21 End-stage coagulation F13B intron 23381943 rs857025 chr1 197010795 C T 2.27E-12 End-stage coagulation F13B intron 23381943 rs10754209 chr1 197011577 T A 1.29E-21 End-stage coagulation F13B intron 23381943 rs7518773 chr1 197011636 A G 1.22E-21 End-stage coagulation F13B intron 23381943 rs10754210 chr1 197012111 G A 7.22E-14 Age-related macular degeneration F13B intron pha002869 rs10754210 chr1 197012111 G A 1.56E-14 Age-related macular degeneration F13B intron pha002890 rs2990510 chr1 197020658 T G 4.30E-06 Age-related macular degeneration F13B intron 20861866 rs2990510 chr1 197020658 T G 6.00E-06 Erectile dysfunction F13B intron 22704111 rs2990510 chr1 197020658 T G 4.24E-07 Age-related macular degeneration F13B intron pha000001 rs2990510 chr1 197020658 T G 4.80E-06 Age-related macular degeneration F13B intron pha000002 rs2990510 chr1 197020658 T G 9.94E-06 Age-related macular degeneration F13B intron pha002856 rs10801586 chr1 197021189 C T 1.96E-30 End-stage coagulation F13B intron 23381943 rs1611982 chr1 197022768 G A 1.29E-21 End-stage coagulation F13B intron 23381943 rs1412635 chr1 197023048 G A 7.72E-22 End-stage coagulation F13B intron 23381943 rs2298883 chr1 197028634 A G 1.91E-30 End-stage coagulation F13B intron 23381943 rs1615413 chr1 197030317 A G 1.29E-21 End-stage coagulation F13B intron 23381943 rs6003 chr1 197031021 C T 6.80E-05 Age-related macular degeneration F13B missense 20861866 rs6003 chr1 197031021 C T 3.65E-09 Age-related macular degeneration F13B missense pha000001 rs6003 chr1 197031021 C T 5.97E-06 Age-related macular degeneration F13B missense pha002856 rs6003 chr1 197031021 C T 4.16E-11 Age-related macular degeneration F13B missense pha002869 rs6003 chr1 197031021 C T 2.53E-10 Age-related macular degeneration F13B missense pha002890 rs1759006 chr1 197031664 T C 2.30E-05 Age-related macular degeneration F13B intron 20861866 rs1759006 chr1 197031664 T C 6.06E-09 Age-related macular degeneration F13B intron pha000002 rs5996 chr1 197032345 C A,G 1.89E-12 End-stage coagulation F13B intron 23381943 rs2298882 chr1 197034826 T G 1.29E-21 End-stage coagulation F13B intron 23381943 rs1412632 chr1 197036868 G A 7.20E-05 Age-related macular degeneration F13B nearGene-5 20861866 rs1412632 chr1 197036868 G A 1.42E-08 Age-related macular degeneration F13B nearGene-5 pha000001 rs1412632 chr1 197036868 G A 9.67E-06 Age-related macular degeneration F13B nearGene-5 pha002856 rs1412631 chr1 197037237 T C 5.50E-05 Age-related macular degeneration F13B nearGene-5 20861866 rs1412631 chr1 197037237 T C 2.17E-09 Age-related macular degeneration F13B nearGene-5 pha000001 rs1412631 chr1 197037237 T C 4.76E-06 Age-related macular degeneration F13B nearGene-5 pha002856 rs1332660 chr1 197053141 T C 6.07E-30 End-stage coagulation ASPM nearGene-3 23381943 rs12677 chr1 197053373 G A 6.80E-05 Age-related macular degeneration ASPM UTR-3 20861866 rs12677 chr1 197053373 G A 3.65E-09 Age-related macular degeneration ASPM UTR-3 pha000001 rs12677 chr1 197053373 G A 5.97E-06 Age-related macular degeneration ASPM UTR-3 pha002856 rs955927 chr1 197060783 A T 2.87E-11 End-stage coagulation ASPM intron 23381943 rs6700180 chr1 197064496 G A 1.32E-20 End-stage coagulation ASPM intron 23381943 rs10737686 chr1 197068200 C T 1.58E-30 End-stage coagulation ASPM intron 23381943 rs3762271 chr1 197070442 G T 1.05E-11 End-stage coagulation ASPM missense 23381943 rs12138336 chr1 197070521 C G 4.79E-10 End-stage coagulation ASPM missense 23381943 rs10922162 chr1 197070776 C T 8.90E-05 Age-related macular degeneration ASPM cds-synon 20861866 rs10922162 chr1 197070776 C T 2.00E-30 End-stage coagulation ASPM cds-synon 23381943 rs10801589 chr1 197076194 C T 3.83E-21 End-stage coagulation ASPM intron 23381943 rs10922163 chr1 197077391 T C 4.15E-21 End-stage coagulation ASPM intron 23381943 rs12034362 chr1 197077516 T C 1.55E-30 End-stage coagulation ASPM intron 23381943 rs12034362 chr1 197077516 T C 4.45E-14 Age-related macular degeneration ASPM intron pha002869 rs12034362 chr1 197077516 T C 7.46E-13 Age-related macular degeneration ASPM intron pha002890 rs2026429 chr1 197079671 C A 7.66E-12 Age-related macular degeneration ASPM intron pha002869 rs2026429 chr1 197079671 C A 6.24E-11 Age-related macular degeneration ASPM intron pha002890 rs12085377 chr1 197081682 G A 1.55E-30 End-stage coagulation ASPM intron 23381943 rs10922168 chr1 197086130 T C 1.55E-30 End-stage coagulation ASPM intron 23381943 rs4915337 chr1 197091537 A T 6.80E-05 Age-related macular degeneration ASPM cds-synon 20861866 rs4915337 chr1 197091537 A T 3.65E-09 Age-related macular degeneration ASPM cds-synon pha000001 rs4915337 chr1 197091537 A T 5.97E-06 Age-related macular degeneration ASPM cds-synon pha002856 rs12042442 chr1 197096135 T C 1.54E-30 End-stage coagulation ASPM intron 23381943 rs3737110 chr1 197101303 C A 1.14E-12 End-stage coagulation ASPM intron 23381943 rs4915344 chr1 197102745 A G 1.54E-30 End-stage coagulation ASPM intron 23381943 rs1888991 chr1 197110822 A G 6.80E-05 Age-related macular degeneration ASPM intron 20861866 rs1888991 chr1 197110822 A G 3.65E-09 Age-related macular degeneration ASPM intron pha000001 rs1888991 chr1 197110822 A G 5.97E-06 Age-related macular degeneration ASPM intron pha002856 rs6677082 chr1 197112533 G A 7.40E-05 Age-related macular degeneration ASPM cds-synon 20861866 rs6677082 chr1 197112533 G A 3.99E-09 Age-related macular degeneration ASPM cds-synon pha000001 rs6677082 chr1 197112533 G A 4.57E-09 Age-related macular degeneration ASPM cds-synon pha000002 rs6677082 chr1 197112533 G A 6.47E-06 Age-related macular degeneration ASPM cds-synon pha002856 rs1127661 chr1 197123043 T C 6.41E-11 End-stage coagulation ZBTB41 UTR-3 23381943 rs4639796 chr1 197126649 G A 8.90E-05 Age-related macular degeneration ZBTB41 UTR-3 20861866 rs4639796 chr1 197126649 G A 8.09E-28 End-stage coagulation ZBTB41 UTR-3 23381943 rs12028827 chr1 197127491 A C 8.09E-28 End-stage coagulation ZBTB41 UTR-3 23381943 rs12724106 chr1 197127578 A G 7.80E-05 Diabetic retinopathy ZBTB41 UTR-3 21441570 rs12128631 chr1 197128726 G A 1.32E-27 End-stage coagulation ZBTB41 cds-synon 23381943 rs12137359 chr1 197129981 C T 1.02E-27 End-stage coagulation ZBTB41 intron 23381943 rs12137359 chr1 197129981 C T 2.05E-13 Age-related macular degeneration ZBTB41 intron pha002869 rs12137359 chr1 197129981 C T 2.68E-12 Age-related macular degeneration ZBTB41 intron pha002890 rs4244139 chr1 197131374 G A 9.62E-20 End-stage coagulation ZBTB41 intron 23381943 rs6677930 chr1 197135466 C A 1.35E-19 End-stage coagulation ZBTB41 intron 23381943 rs4520444 chr1 197141988 G T 3.64E-11 Age-related macular degeneration ZBTB41 intron pha002869 rs4520444 chr1 197141988 G T 8.05E-12 Age-related macular degeneration ZBTB41 intron pha002890 rs6656448 chr1 197143278 C T 7.60E-05 Age-related macular degeneration ZBTB41 intron 20861866 rs6656448 chr1 197143278 C T 8.77E-09 Age-related macular degeneration ZBTB41 intron pha000001 rs6656448 chr1 197143278 C T 5.63E-06 Age-related macular degeneration ZBTB41 intron pha002856 rs10922177 chr1 197153767 T C 4.24E-09 End-stage coagulation ZBTB41 intron 23381943 rs7410943 chr1 197155021 A G 3.00E-19 End-stage coagulation ZBTB41 intron 23381943 rs10494747 chr1 197163928 A T 6.98E-12 End-stage coagulation ZBTB41 intron 23381943 rs10754218 chr1 197165014 G A 7.79E-12 End-stage coagulation ZBTB41 intron 23381943 rs10801596 chr1 197165267 G A 2.13E-13 End-stage coagulation ZBTB41 intron 23381943 rs7516246 chr1 197165712 C T 2.11E-13 End-stage coagulation ZBTB41 intron 23381943 rs6690022 chr1 197170027 A G 1.15E-10 End-stage coagulation / / 23381943 rs6690022 chr1 197170027 A G 5.06E-05 Age-related macular degeneration / / pha002856 rs7544067 chr1 197179710 C T 1.15E-10 End-stage coagulation CRB1 intron 23381943 rs1415216 chr1 197185649 C T 1.15E-10 End-stage coagulation CRB1 intron 23381943 rs10922187 chr1 197187605 C T 1.60E-10 End-stage coagulation CRB1 intron 23381943 rs4915406 chr1 197195650 C T 7.85E-11 End-stage coagulation CRB1 intron 23381943 rs1764629 chr1 197216632 A G 7.20E-05 Age-related macular degeneration CRB1 intron 20861866 rs1764629 chr1 197216632 A G 5.01E-06 Age-related macular degeneration CRB1 intron pha000002 rs17616836 chr1 197216681 G A 6.47E-04 Type 2 diabetes CRB1 intron 17463246 rs10754220 chr1 197244290 G A 2.85E-10 Age-related macular degeneration CRB1 intron pha002869 rs10754220 chr1 197244290 G A 4.20E-11 Age-related macular degeneration CRB1 intron pha002890 rs7542212 chr1 197245860 A G 5.60E-04 Coronary Artery Disease CRB1 intron 17634449 rs7542212 chr1 197245860 A G 8.54E-11 End-stage coagulation CRB1 intron 23381943 rs3790380 chr1 197246968 C A 1.18E-10 End-stage coagulation CRB1 intron 23381943 rs1009188 chr1 197257090 T C 7.11E-04 Type 2 diabetes CRB1 intron 17463246 rs482526 chr1 197268763 A C 5.07E-05 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs664767 chr1 197280295 A C 5.07E-05 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs1415214 chr1 197283185 C T 5.92E-05 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs1415214 chr1 197283185 C T 9.74E-05 Age-related macular degeneration CRB1 intron pha002890 rs1764623 chr1 197288308 G T 4.64E-05 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs550098 chr1 197297408 A G 2.87E-05 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs580067 chr1 197298373 T C 2.77E-05 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs1615444 chr1 197299315 C T 2.72E-05 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs1764786 chr1 197300496 A G 2.65E-05 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs2821131 chr1 197302402 T G 1.99E-05 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs2786115 chr1 197302690 A G 7.07E-06 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs2786113 chr1 197304081 T G 1.18E-04 Type 2 diabetes CRB1 intron 17463246 rs2786113 chr1 197304081 T G 1.87E-05 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs2786111 chr1 197306099 C T 5.00E-06 Lupus nephritis in systemic lupus erythematosus CRB1 intron 24925725 rs2786106 chr1 197311228 T C 9.32E-04 Alzheimer's disease CRB1 intron 24755620 rs949571 chr1 197313189 C T 3.31E-05 Age-related macular degeneration CRB1 intron pha002890 rs2786098 chr1 197325908 T A,C,G 2.00E-13 Asthma CRB1 intron 20032318 rs12083773 chr1 197343763 T C 5.88E-04 Insulin resistance CRB1 intron 21901158 rs2759662 chr1 197361571 G A 8.44E-04 Response to taxane treatment (placlitaxel) CRB1 intron 23006423 rs10922215 chr1 197363948 G A 6.78E-04 Response to taxane treatment (placlitaxel) CRB1 intron 23006423 rs2476020 chr1 197368281 T G 1.01E-05 Post-operative nausea and vomiting CRB1 intron 21694509 rs11802794 chr1 197372250 C A 1.11E-07 Post-operative nausea and vomiting CRB1 intron 21694509 rs11802794 chr1 197372250 C A 6.78E-04 Response to taxane treatment (placlitaxel) CRB1 intron 23006423 rs11799515 chr1 197372437 G T 8.60E-04 Response to taxane treatment (placlitaxel) CRB1 intron 23006423 rs9659183 chr1 197438606 G T 7.94E-05 Post-operative nausea and vomiting CRB1 intron 21694509 rs4915551 chr1 197508901 G A 2.80E-05 Body mass index (asthmatics) DENND1B intron 23517042 rs10754224 chr1 197512789 A C 3.19E-04 Height DENND1B intron 17255346 rs2111931 chr1 197529218 C T 2.90E-04 Body mass index (asthmatics) DENND1B intron 23517042 rs2111932 chr1 197530550 T C 5.82E-04 Multiple complex diseases DENND1B intron 17554300 rs11583319 chr1 197555860 A G 8.40E-04 Response to taxane treatment (placlitaxel) DENND1B intron 23006423 rs41340645 chr1 197613888 A C 2.09E-04 Multiple complex diseases DENND1B intron 17554300 rs6688289 chr1 197615058 C T 2.92E-04 Response to taxane treatment (placlitaxel) DENND1B intron 23006423 rs1775453 chr1 197629342 C T 2.00E-07 Serum protein levels (sST2) DENND1B intron 23999434 rs2488389 chr1 197631141 G A 8.00E-13 Inflammatory bowel disease DENND1B intron 23128233 rs2488411 chr1 197658799 C T 3.83E-04 Height DENND1B intron 17255346 rs1891497 chr1 197659555 A G 5.11E-04 Height DENND1B intron 17255346 rs12092948 chr1 197689967 T C 3.39E-07 Post-operative nausea and vomiting DENND1B intron 21694509 rs41322944 chr1 197695793 C G 3.25E-04 Multiple complex diseases DENND1B intron 17554300 rs16841904 chr1 197701992 C T 2.07E-09 Primary biliary cirrhosis DENND1B intron 21399635 rs2488401 chr1 197702401 C T 1.88E-04 Response to taxane treatment (placlitaxel) DENND1B intron 23006423 rs2488393 chr1 197722240 C T 4.29E-12 Primary biliary cirrhosis DENND1B intron 22961000 rs10922273 chr1 197725373 C T 6.61E-05 Coronary heart disease DENND1B intron pha003031 rs1998598 chr1 197727642 A G 9.00E-09 Crohn's disease DENND1B intron 21102463 rs35511146 chr1 197729087 T TA 2.80E-04 Urinary metabolites DENND1B intron 21572414 rs1775456 chr1 197733055 G A 3.00E-07 Asthma DENND1B intron 21907864 rs1775456 chr1 197733055 G A 5.20E-04 Body mass index (asthmatics) DENND1B intron 23517042 rs1924518 chr1 197738327 A G 2.90E-04 Body mass index (asthmatics) DENND1B intron 23517042 rs1775444 chr1 197740690 T C 5.80E-04 Body mass index (asthmatics) DENND1B intron 23517042 rs1539414 chr1 197743506 G A 4.70E-05 Crohn's disease DENND1B intron 20570966 rs1539414 chr1 197743506 G A 2.32E-09 Primary biliary cirrhosis DENND1B intron 21399635 rs1539414 chr1 197743506 G A 9.79E-05 Post-operative nausea and vomiting DENND1B intron 21694509 rs1539414 chr1 197743506 G A 0.0000023 Primary biliary cirrhosis (anti-mitochondrial antibody positive) DENND1B intron 22936693 rs1539414 chr1 197743506 G A 0.00000346 Primary biliary cirrhosis DENND1B intron 22936693 rs1539414 chr1 197743506 G A 0.0000345 Primary biliary cirrhosis in females DENND1B intron 22936693 rs1539414 chr1 197743506 G A 2.01E-04 Response to taxane treatment (placlitaxel) DENND1B intron 23006423 rs9427672 chr1 197754741 A G 0.000267 Primary biliary cirrhosis / / 22936693 rs12134279 chr1 197781198 C T 2.00E-14 Primary biliary cirrhosis / / 21399635 rs12121863 chr1 197785420 A G 7.42E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10754233 chr1 197816787 G A 5.13E-05 Multiple complex diseases / / 17554300 rs10922306 chr1 197823360 A G 7.55E-07 Age-related macular degeneration / / pha002869 rs10922306 chr1 197823360 A G 1.79E-06 Age-related macular degeneration / / pha002890 rs10922313 chr1 197836347 T C 3.56E-06 Age-related macular degeneration / / pha002869 rs10922313 chr1 197836347 T C 4.57E-06 Age-related macular degeneration / / pha002890 rs10801629 chr1 197844367 C T 2.70E-04 Alcohol dependence / / 20201924 rs10801629 chr1 197844367 C T 0.00000413 Alcohol dependence / / 23691058 rs10922323 chr1 197862321 T C 3.60E-04 Alcohol dependence / / 20201924 rs10922323 chr1 197862321 T C 0.00000646 Alcohol dependence / / 23691058 rs12138550 chr1 197866357 C T 2.60E-05 Urinary metabolites / / 21572414 rs545711 chr1 197939323 A T 3.96E-04 Multiple complex diseases / / 17554300 rs3850618 chr1 197946606 A G 5.84E-04 Multiple complex diseases / / 17554300 rs10922349 chr1 197964577 A T 1.70E-05 Urinary metabolites / / 21572414 rs12404040 chr1 197967676 C T 1.70E-05 Urinary metabolites / / 21572414 rs1543511 chr1 197968019 T C 9.44E-05 Height / / 17255346 rs1543511 chr1 197968019 T C 5.50E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12064633 chr1 197974876 T A 9.00E-04 Type 2 diabetes / / 17463246 rs11580655 chr1 197988761 T C 7.59E-04 Alzheimer's disease / / 17998437 rs2359378 chr1 198022138 C T 1.65E-04 Multiple complex diseases / / 17554300 rs1233839 chr1 198034569 C T 6.80E-04 Telomere length / / 23900074 rs12141081 chr1 198069359 C T 2.77E-04 Multiple complex diseases / / 17554300 rs12141081 chr1 198069359 C T 6.04E-04 Aortic root size / / 21223598 rs12135790 chr1 198079359 T A 1.92E-04 Multiple complex diseases / / 17554300 rs1938378 chr1 198146240 T A 2.60E-05 Urinary metabolites NEK7 intron 21572414 rs10494765 chr1 198215042 T G 4.74E-04 Nicotine dependence NEK7 intron 17158188 rs1475423 chr1 198223490 A T 1.88E-04 Nicotine dependence NEK7 intron 17158188 rs1927252 chr1 198233907 C A 3.60E-07 Bipolar disorder NEK7 intron 21738484 rs16842730 chr1 198273889 G A 1.26E-04 Nicotine dependence NEK7 intron 17158188 rs16842733 chr1 198274100 A G 4.42E-04 Nicotine dependence NEK7 intron 17158188 rs10494769 chr1 198274361 A G 2.84E-04 Nicotine dependence NEK7 intron 17158188 rs12407433 chr1 198274908 A T 7.33E-04 Nicotine dependence NEK7 intron 17158188 rs16842754 chr1 198277135 C A 5.25E-04 Nicotine dependence NEK7 intron 17158188 rs1139949 chr1 198289927 G C 3.61E-04 Body mass index NEK7 UTR-3 17255346 rs1139949 chr1 198289927 G C 5.80E-04 Type 2 diabetes NEK7 UTR-3 17463246 rs6660793 chr1 198311960 C T 3.03E-04 Body mass index / / 17255346 rs6660793 chr1 198311960 C T 3.98E-04 Type 2 diabetes / / 17463246 rs1556016 chr1 198315826 A T 6.56E-04 Bipolar disorder / / 19259986 rs16842856 chr1 198317345 C T 4.01E-04 Multiple complex diseases / / 17554300 rs6428453 chr1 198325457 G T 2.61E-04 Body mass index / / 17255346 rs6428453 chr1 198325457 G T 6.56E-04 Type 2 diabetes / / 17463246 rs963564 chr1 198334894 G A 5.01E-04 Type 2 diabetes / / 17463246 rs963564 chr1 198334894 G A 5.45E-04 Multiple complex diseases / / 17554300 rs16842978 chr1 198369123 A T 2.11E-04 Body mass index / / 17255346 rs16842978 chr1 198369123 A T 8.21E-04 Type 2 diabetes / / 17463246 rs7550723 chr1 198373152 C T 2.81E-04 Body mass index / / 17255346 rs7550723 chr1 198373152 C T 9.79E-04 Type 2 diabetes / / 17463246 rs16843001 chr1 198373326 T C 2.21E-04 Nicotine dependence / / 17158188 rs4915286 chr1 198379069 A T 5.21E-04 Type 2 diabetes / / 17463246 rs7554576 chr1 198392334 G A 5.18E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12078566 chr1 198393815 G A 2.95E-04 Atopic dermatitis / / 21666691 rs12078566 chr1 198393815 G A 5.49E-04 Heart Failure / / pha002885 rs12036304 chr1 198407610 A T 3.46E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs16843093 chr1 198416675 A G 1.64E-04 Nicotine dependence / / 17158188 rs12085366 chr1 198417004 T C 1.46E-05 Atopic dermatitis / / 21666691 rs10922421 chr1 198417152 G T 0.0000502 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2813164 chr1 198421408 A G 8.30E-07 Bipolar disorder / / 19416921 rs4351678 chr1 198435983 A G 4.95E-04 Type 2 diabetes / / 17463246 rs16843150 chr1 198450275 T G 3.66E-05 Smoking initiation / / 24665060 rs10158064 chr1 198457080 T G 3.49E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4915292 chr1 198461064 C T 0.0000668 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12041939 chr1 198462661 C T 0.00000363 Femoral neck bone mineral density (premenopausal) / / 23074152 rs16843188 chr1 198466351 G A 1.20E-04 Multiple complex diseases / / 17554300 rs10922438 chr1 198469162 G A 6.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs12058080 chr1 198481371 C T 6.01E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs2359847 chr1 198484209 C T 6.01E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs16843226 chr1 198484784 A G 6.01E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs12083381 chr1 198485706 T C 6.01E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs10494777 chr1 198489457 T C 6.01E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs10922446 chr1 198494473 C T 6.01E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) ATP6V1G3 intron 23648065 rs6428467 chr1 198511122 A C 2.00E-04 Interstitial lung disease ATP6V1G3 nearGene-5 23583980 rs16843298 chr1 198518546 C A 2.90E-06 Body mass index / / 19584900 rs16843298 chr1 198518546 C A 9.90E-05 Body mass index / / 19584900 rs17659788 chr1 198521135 A G 9.20E-05 Parkinson's disease (age of onset) / / 19772629 rs12144380 chr1 198564497 T C 7.75E-05 Leukocyte Counts / / pha003091 rs4915310 chr1 198580255 G A 1.51E-04 Alzheimer's disease (late onset) / / 21379329 rs12127588 chr1 198595506 G A 6.76E-10 Blood cell counts and other traits / / 20139978 rs12127588 chr1 198595506 G A 7.00E-10 Blood cell counts and other traits / / 20139978 rs34090688 chr1 198595506 G GA 6.76E-10 Blood cell counts and other traits / / 20139978 rs34090688 chr1 198595506 G GA 7.00E-10 Blood cell counts and other traits / / 20139978 rs11582374 chr1 198596234 G T 0.000698627 Primary sclerosing cholangitis / / 23603763 rs1409362 chr1 198618500 A G 7.81E-04 Alzheimer's disease PTPRC intron 22005930 rs1326271 chr1 198619759 G A 7.85E-04 Alzheimer's disease PTPRC intron 22005930 rs7522020 chr1 198637853 G T 3.50E-04 Alzheimer's disease PTPRC intron 22005930 rs17668708 chr1 198640488 C T 1.70E-05 Rheumatoid arthritis PTPRC intron 24390342 rs17668708 chr1 198640488 C T 1.80E-05 Rheumatoid arthritis PTPRC intron 24390342 rs2359952 chr1 198656407 A G 4.00E-07 Ulcerative colitis PTPRC intron 24837172 rs12127625 chr1 198656771 C T 0.0000381 Primary sclerosing cholangitis PTPRC intron 23603763 rs2182419 chr1 198660143 G A 8.63E-04 Multiple complex diseases PTPRC intron 17554300 rs10919560 chr1 198690691 A G 8.49E-05 Self-reported allergy PTPRC intron 23817569 rs1011338 chr1 198692364 T C 2.00E-04 Multiple complex diseases PTPRC intron 17554300 rs10919563 chr1 198700442 G A 1.08E-04 Multiple complex diseases PTPRC intron 17554300 rs10919563 chr1 198700442 G A 3.30E-04 Rheumatoid arthritis PTPRC intron 22446963 rs10919563 chr1 198700442 G A 1.25E-10 Rheumatoid arthritis PTPRC intron 23143596 rs10919563 chr1 198700442 G A 7.18E-05 Rheumatoid arthritis PTPRC intron 24449572 rs11589894 chr1 198705081 A G 7.79E-05 Self-reported allergy PTPRC intron 23817569 rs874909 chr1 198719973 T C 1.07E-04 Alzheimer's disease PTPRC intron 22005930 rs874909 chr1 198719973 T C 5.32E-04 Self-reported allergy PTPRC intron 23817569 rs17670373 chr1 198722841 A G 2.70E-04 Alzheimer's disease PTPRC intron 22005930 rs17670373 chr1 198722841 A G 5.20E-04 Self-reported allergy PTPRC intron 23817569 rs4915157 chr1 198730501 C T 2.88E-04 Insulin resistance / / 21901158 rs6696533 chr1 198733567 T C 2.51E-04 Alzheimer's disease / / 22005930 rs12568099 chr1 198750422 C T 3.74E-04 Multiple complex diseases / / 17554300 rs12568099 chr1 198750422 C T 9.80E-06 Bipolar disorder / / 19416921 rs2784103 chr1 198760554 T C 7.82E-04 Alzheimer's disease / / 22005930 rs2759643 chr1 198764636 A T 7.00E-05 Asthma and hay fever / / 24388013 rs2759646 chr1 198768756 G A 5.61E-04 Alzheimer's disease / / 22005930 rs2759647 chr1 198768785 A T 5.58E-04 Alzheimer's disease / / 22005930 rs2784114 chr1 198771170 C T 9.96E-05 Self-reported allergy / / 23817569 rs1452 chr1 198771400 A G 7.90E-05 Self-reported allergy / / 23817569 rs2784113 chr1 198773703 G T 7.74E-05 Self-reported allergy / / 23817569 rs12043681 chr1 198775474 T C 6.17E-04 Coronary heart disease / / 21606135 rs9427431 chr1 198777472 T C 5.52E-04 Coronary heart disease LOC100131234 intron 21606135 rs1407684 chr1 198777754 T C 5.35E-04 Coronary heart disease LOC100131234 intron 21606135 rs2014863 chr1 198809601 C T 0.000021 Rheumatoid arthritis LOC100131234 intron 23143596 rs1322916 chr1 198876258 T C 1.35E-05 Asthma LOC100131234 intron 23181788 rs10489689 chr1 198889074 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC100131234 intron 22628534 rs6658650 chr1 198921640 G A 8.83E-05 Serum metabolites / / 19043545 rs1892432 chr1 198940624 T C 9.47E-04 White matter integrity / / 22425255 rs1892433 chr1 198961568 G A 2.60E-05 Urinary metabolites / / 21572414 rs10919614 chr1 198974825 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10919615 chr1 198974904 C T 8.47E-07 Red blood cell traits / / 23222517 rs1124025 chr1 198979818 C G 4.51E-04 Type 2 diabetes / / 17463246 rs1124025 chr1 198979818 C G 3.73E-07 Red blood cell traits / / 23222517 rs12757682 chr1 198981241 T C 2.59E-05 Hypertension / / 19609347 rs12748299 chr1 198983324 C G 1.66E-05 Hypertension / / 19609347 rs2186188 chr1 198991093 A G 4.76E-04 Smoking quantity / / 24665060 rs12125200 chr1 198992043 A G 2.33E-07 Red blood cell traits / / 23222517 rs2360962 chr1 199004709 A T 1.16E-08 Red blood cell traits / / 23222517 rs7529925 chr1 199007208 C T 8.00E-09 Red blood cell traits / / 23222517 rs1434282 chr1 199010721 C T 1.48E-08 Red blood cell traits / / 23222517 rs1036332 chr1 199012478 A C 1.67E-07 Red blood cell traits / / 23222517 rs962793 chr1 199034906 A G 5.30E-05 Kawasaki disease / / 22081228 rs322921 chr1 199058893 A T 5.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs322895 chr1 199093876 T C 0.00016 Erectile dysfunction after radiotherapy for prostate cancer / / 23021708 rs10800612 chr1 199139429 C T 2.62E-05 Serum metabolites / / 19043545 rs6684332 chr1 199150453 C T 2.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10800613 chr1 199158242 C A 1.38E-05 Serum metabolites / / 19043545 rs10494785 chr1 199161762 T C 3.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12402922 chr1 199171803 C T 4.12E-05 Serum metabolites / / 19043545 rs6684754 chr1 199171827 T A 1.14E-05 Serum metabolites / / 19043545 rs10494786 chr1 199195892 T C 1.56E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs10494787 chr1 199213194 C G 3.64E-17 Multiple complex diseases / / 17554300 rs11579522 chr1 199266874 A G 5.31E-05 Autism spectrum disorders (language delay) / / 21519539 rs1561144 chr1 199298683 T C 4.50E-05 Diabetic retinopathy / / 21441570 rs6677813 chr1 199303910 G C 4.80E-05 Diabetic retinopathy / / 21441570 rs1325184 chr1 199312280 C T 2.83E-04 Type 2 diabetes / / 17463246 rs1327067 chr1 199314285 G A 4.86E-04 Multiple complex diseases / / 17554300 rs576141 chr1 199329274 A G 6.40E-04 Response to alcohol consumption (flushing response) / / 24277619 rs16844716 chr1 199356516 A C 9.00E-06 Dialysis-related mortality / / 21546767 rs693911 chr1 199357586 G C 6.26E-05 Major depressive disorder (broad) / / 20038947 rs595113 chr1 199359440 C A 6.02E-05 Major depressive disorder (broad) / / 20038947 rs493474 chr1 199360977 C T 4.13E-05 Major depressive disorder (broad) / / 20038947 rs638079 chr1 199362153 C T 5.86E-05 Major depressive disorder (broad) / / 20038947 rs571609 chr1 199362216 C T 5.84E-05 Major depressive disorder (broad) / / 20038947 rs4562659 chr1 199364111 G T 5.83E-05 Major depressive disorder (broad) / / 20038947 rs543505 chr1 199373716 T C 1.80E-05 Bipolar disorder and schizophrenia / / 20889312 rs661480 chr1 199374488 C A 7.43E-05 Major depressive disorder (broad) / / 20038947 rs661480 chr1 199374488 C A 1.26E-05 Bipolar disorder and schizophrenia / / 20889312 rs585476 chr1 199377000 A C 7.64E-05 Major depressive disorder (broad) / / 20038947 rs628061 chr1 199378212 C T 5.94E-05 Major depressive disorder (broad) / / 20038947 rs528227 chr1 199386880 T C 7.65E-05 Major depressive disorder (broad) / / 20038947 rs516182 chr1 199395968 G A 8.07E-05 Major depressive disorder (broad) / / 20038947 rs826937 chr1 199396278 A G 8.08E-05 Major depressive disorder (broad) / / 20038947 rs580169 chr1 199407512 T C 8.06E-05 Major depressive disorder (broad) / / 20038947 rs729439 chr1 199422097 C G 7.83E-05 Major depressive disorder (broad) / / 20038947 rs1337730 chr1 199429509 G A 2.63E-05 Major depressive disorder (broad) / / 20038947 rs7535498 chr1 199431121 T C 9.32E-05 Major depressive disorder (broad) / / 20038947 rs4915175 chr1 199431778 G C 9.39E-05 Major depressive disorder (broad) / / 20038947 rs7542074 chr1 199435387 A C 6.65E-05 Bipolar disorder and schizophrenia / / 20889312 rs1572565 chr1 199441665 A G 0.00005 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer / / 21245432 rs12045830 chr1 199513565 G A 9.00E-05 Diabetic retinopathy / / 21441570 rs945877 chr1 199519005 G A 4.07E-05 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs2786742 chr1 199558644 T A 5.41E-05 Bipolar disorder and schizophrenia / / 20889312 rs10919737 chr1 199644492 A G 5.97E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17162624 chr1 199655861 T C 1.32E-04 Birth weight / / 17255346 rs2435241 chr1 199690834 C G 3.25E-04 Type 2 diabetes / / 17463246 rs1030519 chr1 199715370 A G 5.90E-06 Urinary metabolites / / 21572414 rs17162712 chr1 199717132 T A 3.04E-05 Multiple complex diseases / / 17554300 rs17162712 chr1 199717132 T A 7.54E-04 Insulin resistance / / 21901158 rs1346680 chr1 199772234 A G 7.95E-05 Cognitive impairment induced by topiramate / / 22091778 rs9427689 chr1 199782481 C G 7.40E-06 Urinary metabolites / / 21572414 rs987648 chr1 199783024 T C 1.67E-05 Cognitive impairment induced by topiramate / / 22091778 rs12027362 chr1 199792844 G A 9.26E-04 Coronary heart disease / / 21971053 rs12096427 chr1 199822974 A G 2.91E-05 Cognitive test performance / / 20125193 rs12096427 chr1 199822974 A G 6.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1425791 chr1 199832023 A G 2.79E-05 Cognitive test performance / / 20125193 rs17664308 chr1 199839998 T C 1.48E-05 Pancreatic cancer / / pha002889 rs10919761 chr1 199858391 G A 2.91E-05 Cognitive test performance / / 20125193 rs6677214 chr1 199889671 T G 3.87E-04 Coronary heart disease / / 21971053 rs12029406 chr1 199905828 C T 4.59E-04 Smoking initiation / / 24665060 rs12029406 chr1 199905828 C T 1.04E-07 Pancreatic cancer / / pha002889 rs1991245 chr1 199925306 G A 4.01E-04 Smoking initiation / / 24665060 rs10737565 chr1 199953766 A G 8.05E-04 Multiple complex diseases / / 17554300 rs4465241 chr1 199963622 T C 4.79E-07 Pancreatic cancer / / pha002889 rs10919791 chr1 199965168 G A 6.37E-10 Pancreatic cancer / / pha002889 rs4244145 chr1 199971261 G A 1.98E-05 Pancreatic cancer / / pha002889 rs4379703 chr1 199974728 A G 1.75E-04 Multiple complex diseases / / 17554300 rs2816939 chr1 199985700 T C 4.83E-04 Alzheimer's disease (late onset) / / 21379329 rs2816939 chr1 199985700 T C 9.58E-06 Pancreatic cancer / / pha002889 rs2821347 chr1 199985792 C T 4.83E-04 Alzheimer's disease (late onset) / / 21379329 rs2821347 chr1 199985792 C T 1.16E-05 Pancreatic cancer / / pha002889 rs2737621 chr1 199997403 T C 3.42E-05 Pancreatic cancer NR5A2 intron pha002889 rs2737660 chr1 200002067 T G 1.48E-05 Pancreatic cancer NR5A2 intron pha002874 rs2737660 chr1 200002067 T G 2.64E-05 Pancreatic cancer NR5A2 intron pha002889 rs3790844 chr1 200007432 A G 2.00E-10 Pancreatic cancer NR5A2 intron 20101243 rs3790844 chr1 200007432 A G 2.00E-10 Nasopharyngeal carcinoma NR5A2 intron 20512145 rs3790844 chr1 200007432 A G 2.45E-10 Pancreatic cancer NR5A2 intron pha002889 rs3790843 chr1 200010824 C T 9.00E-05 Cognitive function NR5A2 intron 24684796 rs3790843 chr1 200010824 C T 6.69E-09 Pancreatic cancer NR5A2 intron pha002889 rs4495736 chr1 200013513 T G 2.82E-04 Suicide attempts in bipolar disorder NR5A2 intron 21423239 rs2821367 chr1 200016146 T C 1.89E-06 Pancreatic cancer NR5A2 intron pha002889 rs2737640 chr1 200020261 C T 4.62E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) NR5A2 intron 24023788 rs2737641 chr1 200022667 G A 3.30E-05 Creatinine levels NR5A2 intron pha003069 rs2821378 chr1 200023141 G A 5.03E-04 Insulin resistance NR5A2 intron 21901158 rs2821379 chr1 200024300 G A 5.33E-05 Brain derived neurotrophic factor levels,in serum NR5A2 intron 22047184 rs2737645 chr1 200025886 T C 2.52E-05 Brain derived neurotrophic factor levels,in serum NR5A2 intron 22047184 rs2821384 chr1 200031716 G A 3.91E-05 Insulin resistance NR5A2 intron 21901158 rs3006246 chr1 200032080 C A 0.0000526 Type 2 diabetes NR5A2 intron 22325160 rs2821388 chr1 200033769 A G 7.63E-05 Brain derived neurotrophic factor levels,in serum NR5A2 intron 22047184 rs2816916 chr1 200034969 A G 7.97E-05 Brain derived neurotrophic factor levels,in serum NR5A2 intron 22047184 rs3828112 chr1 200042031 T C 3.78E-05 Neuroblastoma NR5A2 intron pha002895 rs2821319 chr1 200061056 C T 0.00029 Coronary artery calcification NR5A2 intron 23727086 rs2253771 chr1 200068658 C T 7.00E-05 Orofacial clefts NR5A2 intron 22419666 rs3762398 chr1 200090120 G A 9.89E-05 Height NR5A2 intron pha003011 rs3762397 chr1 200090219 C T 2.78E-07 Bone mass and geometry NR5A2 intron 17903296 rs2816958 chr1 200101920 A G 2.00E-17 Ulcerative colitis NR5A2 intron 23128233 rs2737618 chr1 200107425 G A 6.68E-06 Uric acid levels NR5A2 intron 21294900 rs2816953 chr1 200107550 A G 1.60E-05 Urinary metabolites NR5A2 intron 21572414 rs10919819 chr1 200112916 C T 9.06E-05 Epilepsy (remission after treatment) NR5A2 intron 23962720 rs2737627 chr1 200114642 G A 7.89E-05 Epilepsy (remission after treatment) NR5A2 intron 23962720 rs3790794 chr1 200119079 A T 4.18E-04 Smoking quantity NR5A2 intron 24665060 rs10494809 chr1 200132084 C T 0.000003 Stressful life events NR5A2 intron 23237013 rs10494810 chr1 200136582 G A 6.00E-04 Type 2 diabetes and 6 quantitative traits NR5A2 intron 17848626 rs10494810 chr1 200136582 G A 4.30E-04 Obesity-related traits NR5A2 intron 17903300 rs7556640 chr1 200142532 C T 7.19E-05 Multiple complex diseases NR5A2 intron 17554300 rs41348946 chr1 200150164 G A 5.71E-04 Multiple complex diseases / / 17554300 rs12562944 chr1 200162670 C T 4.79E-05 Hemoglobin / / pha003098 rs12562944 chr1 200162670 C T 5.64E-05 Erythrocyte counts / / pha003099 rs12128246 chr1 200197618 A C 1.58E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10800685 chr1 200213790 G A 2.40E-05 Urinary metabolites / / 21572414 rs10800686 chr1 200218981 T C 2.40E-05 Urinary metabolites / / 21572414 rs12562086 chr1 200219020 C T 1.20E-05 Urinary metabolites / / 21572414 rs12047019 chr1 200222777 A G 2.20E-05 Urinary metabolites / / 21572414 rs12047019 chr1 200222777 A G 7.23E-04 Smoking cessation / / 24665060 rs10919870 chr1 200234381 A C 1.13E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10919870 chr1 200234381 A C 2.05E-04 Lung function (forced vital capacity) / / 24023788 rs41377147 chr1 200243838 C T 3.93E-05 Multiple complex diseases / / 17554300 rs10919876 chr1 200247025 T C 2.00E-04 Lung function (forced vital capacity) / / 24023788 rs10919876 chr1 200247025 T C 3.05E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2185277 chr1 200263870 C T 5.59E-04 Multiple complex diseases / / 17554300 rs6427818 chr1 200267231 T C 9.91E-04 Multiple complex diseases / / 17554300 rs940398 chr1 200269369 T C 6.20E-04 Multiple complex diseases / / 17554300 rs2790125 chr1 200285880 T C 4.46E-04 Multiple complex diseases / / 17554300 rs2790125 chr1 200285880 T C 9.08E-05 Serum metabolites / / 19043545 rs2808489 chr1 200286485 C T 4.17E-04 Multiple complex diseases / / 17554300 rs2808473 chr1 200293042 C T 2.22E-04 Depression (quantitative trait) / / 20800221 rs10919897 chr1 200300037 C A 1.82E-04 Multiple complex diseases / / 17554300 rs2808477 chr1 200300299 G A 3.42E-04 Multiple complex diseases / / 17554300 rs2808477 chr1 200300299 G A 2.32E-05 Serum metabolites / / 19043545 rs2790109 chr1 200311868 C G 3.28E-04 Glycosylated haemoglobin levels / / 17255346 rs2808484 chr1 200318170 C T 2.50E-05 Urinary metabolites C1orf98 intron 21572414 rs2808500 chr1 200330479 A G 2.40E-05 Urinary metabolites C1orf98 intron 21572414 rs2808502 chr1 200331702 A G 1.34E-04 Multiple complex diseases C1orf98 intron 17554300 rs2808502 chr1 200331702 A G 2.64E-05 Serum metabolites C1orf98 intron 19043545 rs1572768 chr1 200368352 G T 1.30E-05 Urinary metabolites / / 21572414 rs12117955 chr1 200425433 C A 2.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs12058730 chr1 200437506 A G 2.69E-05 Anxiety in major depressive disorder / / 24047446 rs9287107 chr1 200438701 A G 9.51E-05 Body mass (lean) / / 19268274 rs12146113 chr1 200443118 G A 4.90E-05 Parkinson's disease (age of onset) / / 19772629 rs16846760 chr1 200446986 G A 1.90E-05 Urinary metabolites / / 21572414 rs6427833 chr1 200469505 T C 3.59E-04 Type 2 diabetes / / 17463246 rs6680807 chr1 200471464 C A 9.97E-05 Left ventricular hypertrophy / / pha003052 rs10919966 chr1 200502569 T C 1.58E-04 Type 2 diabetes / / 17463246 rs6682828 chr1 200507096 G A 7.03E-04 Multiple complex diseases / / 17554300 rs6686605 chr1 200508568 C T 2.94E-04 Type 2 diabetes / / 17463246 rs10919973 chr1 200520443 G C 8.78E-04 Type 2 diabetes / / 17463246 rs6693825 chr1 200531923 T C 8.78E-04 Type 2 diabetes KIF14 intron 17463246 rs7518491 chr1 200534009 A G 8.78E-04 Type 2 diabetes KIF14 intron 17463246 rs7543730 chr1 200534248 C T 9.12E-04 Type 2 diabetes KIF14 cds-synon 17463246 rs10753877 chr1 200549590 T C 9.12E-04 Type 2 diabetes KIF14 intron 17463246 rs6699100 chr1 200552388 C T 9.12E-04 Type 2 diabetes KIF14 intron 17463246 rs4504918 chr1 200557767 C T 2.76E-04 Type 2 diabetes KIF14 intron 17463246 rs6665951 chr1 200558363 T C 1.84E-04 Type 2 diabetes KIF14 cds-synon 17463246 rs12117521 chr1 200560094 C T 8.78E-04 Type 2 diabetes KIF14 intron 17463246 rs2808238 chr1 200574959 T C 4.21E-04 Smoking initiation KIF14 intron 24665060 rs2794410 chr1 200575794 A G 8.78E-04 Type 2 diabetes KIF14 intron 17463246 rs2794410 chr1 200575794 A G 5.47E-04 Smoking initiation KIF14 intron 24665060 rs10800716 chr1 200580709 A T 8.78E-04 Type 2 diabetes KIF14 intron 17463246 rs2808241 chr1 200583380 T G 2.48E-04 Smoking initiation KIF14 intron 24665060 rs201051794 chr1 200592547 A AACT 4.13E-04 Type 2 diabetes / / 17463246 rs2808250 chr1 200592547 A T 4.13E-04 Type 2 diabetes / / 17463246 rs12744758 chr1 200593138 G A 7.51E-04 Type 2 diabetes / / 17463246 rs4915447 chr1 200593468 T A 9.04E-04 Type 2 diabetes / / 17463246 rs2808257 chr1 200594005 C T 0.0000013 Inter-adventitial common carotid artery diameter / / 23246012 rs12728040 chr1 200595879 G A 7.51E-04 Type 2 diabetes / / 17463246 rs7529962 chr1 200596977 T C 2.56E-04 Type 2 diabetes / / 17463246 rs2809361 chr1 200622353 C T 1.36E-04 Amyotrophic lateral sclerosis (sporadic) DDX59 intron 24529757 rs6656619 chr1 200640792 T C 5.09E-04 Type 2 diabetes / / 17463246 rs6656619 chr1 200640792 T C 4.71E-04 Schizophrenia / / 20832056 rs4387211 chr1 200645938 A T 4.23E-04 Schizophrenia / / 20832056 rs6700559 chr1 200646073 C T 6.18E-04 Type 2 diabetes / / 17463246 rs6700559 chr1 200646073 C T 3.58E-04 Schizophrenia / / 20832056 rs6700559 chr1 200646073 C T 0.000000765 Coronary artery disease / / 23202125 rs7535122 chr1 200672699 A G 7.10E-06 Electrocardiographic conduction measures / / 19389651 rs7512898 chr1 200672906 G T 5.00E-06 Electrocardiographic conduction measures / / 19389651 rs6660197 chr1 200703541 C T 6.78E-05 Epilepsy / / 22116939 rs10449265 chr1 200703906 T A 4.91E-04 Multiple complex diseases / / 17554300 rs10494819 chr1 200704754 C T 3.17E-04 Type 2 diabetes / / 17463246 rs17750695 chr1 200721265 A G 1.50E-05 Anxiety in major depressive disorder CAMSAP2 intron 24047446 rs6658596 chr1 200748921 C T 7.92E-04 Multiple complex diseases CAMSAP2 intron 17554300 rs12742404 chr1 200811765 A G 6.39E-06 Epilepsy CAMSAP2 intron 22116939 rs16830092 chr1 200823498 T C 8.17E-04 Insulin resistance CAMSAP2 intron 21901158 rs2292096 chr1 200826769 A G 1.00E-08 Epilepsy CAMSAP2 intron 22116939 rs2292096 chr1 200826769 A G 0.0000589 Coronary artery disease CAMSAP2 intron 23202125 rs6702767 chr1 200844547 A G 0.00000097 Myopia (Age of onset) / / 23468642 rs3753955 chr1 200857774 T C 7.70E-04 Type 2 diabetes / / 17463246 rs3767494 chr1 200871216 G A 5.50E-04 Coronary Artery Disease C1orf106 intron 17634449 rs7554511 chr1 200877562 C A 1.89E-07 Multiple complex diseases C1orf106 intron 17554300 rs7554511 chr1 200877562 C A 1.00E-06 Ulcerative colitis C1orf106 intron 19915572 rs7554511 chr1 200877562 C A 2.00E-07 Crohn's disease C1orf106 intron 21102463 rs7554511 chr1 200877562 C A 2.00E-13 Ulcerative colitis C1orf106 intron 21297633 rs7554511 chr1 200877562 C A 1.00E-32 Inflammatory bowel disease C1orf106 intron 23128233 rs4915463 chr1 200879302 A G 6.34E-04 Amyotrophic Lateral Sclerosis C1orf106 intron 17362836 rs10800746 chr1 200881392 C T 2.60E-08 Celiac disease C1orf106 intron 22057235 rs7522462 chr1 200881595 G A 5.68E-07 Multiple complex diseases C1orf106 intron 17554300 rs7522462 chr1 200881595 G A 2.00E-09 Multiple sclerosis C1orf106 intron 21833088 rs7522462 chr1 200881595 G A 8.30E-04 Multiple sclerosis C1orf106 intron 24234648 rs378672 chr1 200886333 C G 1.52E-04 Multiple complex diseases / / 17554300 rs378672 chr1 200886333 C G 3.60E-05 Ankylosing spondylitis / / 21743469 rs404339 chr1 200886891 C G 4.30E-06 Multiple complex diseases / / 17554300 rs296543 chr1 200889833 T C 6.52E-05 Age-related macular degeneration / / pha000002 rs296547 chr1 200892137 T C 4.00E-09 Celiac disease / / 20190752 rs296547 chr1 200892137 T C 4.00E-09 Asthma / / 21150878 rs296547 chr1 200892137 T C 4.11E-09 Celiac disease and Rheumatoid arthritis / / 21383967 rs296547 chr1 200892137 T C 4.11E-09 Multiple sclerosis / / 22190364 rs296513 chr1 200906473 G A 1.65E-04 Multiple complex diseases / / 17554300 rs11579874 chr1 200920362 G A 7.90E-06 Multiple complex diseases / / 17554300 rs1572789 chr1 200932305 G A 9.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs11584383 chr1 200935866 T C 4.21E-04 Type 2 diabetes / / 17463246 rs11584383 chr1 200935866 T C 2.90E-05 Multiple complex diseases / / 17554300 rs11584383 chr1 200935866 T C 1.00E-11 Crohn's disease / / 18587394 rs11584383 chr1 200935866 T C 2.00E-07 Ulcerative colitis / / 20228799 rs11584383 chr1 200935866 T C 1.00E-11 Asthma / / 21150878 rs11584383 chr1 200935866 T C 1.43E-11 Multiple sclerosis / / 22190364 rs11584383 chr1 200935866 T C 4.54E-05 Smoking quantity / / 24665060 rs10494828 chr1 200957032 G A 5.13E-05 Age-related macular degeneration KIF21B intron pha000002 rs2297909 chr1 200960307 G A 8.10E-10 Crohn's disease KIF21B intron 18587394 rs2297909 chr1 200960307 G A 5.00E-12 Ankylosing spondylitis KIF21B intron 21743469 rs2297909 chr1 200960307 G A 2.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) KIF21B intron 23453885 rs6687260 chr1 200980698 A G 5.60E-04 Multiple complex diseases KIF21B intron 17554300 rs6700264 chr1 200984022 A G 6.66E-04 Multiple complex diseases KIF21B intron 17554300 rs12122721 chr1 200984480 G A 9.90E-06 Multiple complex diseases KIF21B intron 17554300 rs12122721 chr1 200984480 G A 1.00E-06 Multiple sclerosis KIF21B intron 21833088 rs17419032 chr1 200998531 C T 1.21E-05 Multiple complex diseases / / 17554300 rs11583328 chr1 201002173 G A 6.06E-05 Multiple complex diseases / / 17554300 rs3767498 chr1 201020727 A G 6.89E-04 Smoking initiation CAC/1S intron 24665060 rs2297903 chr1 201031307 A C 9.77E-04 Suicide attempts in bipolar disorder CAC/1S intron 21423239 rs9427712 chr1 201041198 G A 3.70E-04 Response to taxane treatment (placlitaxel) CAC/1S intron 23006423 rs9427713 chr1 201041364 G A 2.66E-04 Response to taxane treatment (placlitaxel) CAC/1S intron 23006423 rs2886329 chr1 201041480 A G 1.50E-05 Response to antidepressants CAC/1S intron 19736353 rs3820422 chr1 201045473 A G 3.34E-07 Schizophrenia CAC/1S intron 21926974 rs2365293 chr1 201075245 T C 2.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/1S intron 20877124 rs2281845 chr1 201081943 C T 8.00E-17 Permanent tooth development CAC/1S nearGene-5 21931568 rs1536127 chr1 201086894 C A 8.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs7547762 chr1 201088245 A G 2.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs942703 chr1 201092979 C T 2.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs6704363 chr1 201096383 A G 3.80E-06 Primary tooth development (number of teeth) / / 23704328 rs2057579 chr1 201099275 T C 2.60E-06 Primary tooth development (time to first tooth eruption) / / 23704328 rs10800760 chr1 201100439 G A 2.82E-04 Suicide attempts in bipolar disorder / / 21041247 rs12025414 chr1 201100496 A G 2.82E-04 Suicide attempts in bipolar disorder / / 21041247 rs11589642 chr1 201100748 G A 2.82E-04 Suicide attempts in bipolar disorder / / 21041247 rs6697303 chr1 201101413 C T 3.81E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs6694122 chr1 201121523 T C 2.04E-04 Substance dependence TMEM9 intron 21818250 rs7542768 chr1 201125326 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6413916 chr1 201139616 G A 2.07E-04 Multiple complex diseases / / 17554300 rs831768 chr1 201149033 C T 4.07E-05 Cognitive impairment induced by topiramate / / 22091778 rs16847994 chr1 201156566 C T 3.08E-04 Coronary Artery Disease / / 17634449 rs831752 chr1 201157146 C A 2.86E-05 Cognitive impairment induced by topiramate / / 22091778 rs1107128 chr1 201163191 G T 2.00E-04 Cognitive impairment induced by topiramate IGFN1 intron 22091778 rs4915221 chr1 201166383 G A 1.00E-04 Cognitive impairment induced by topiramate IGFN1 missense 22091778 rs2365299 chr1 201169554 T G 2.00E-04 Cognitive impairment induced by topiramate IGFN1 intron 22091778 rs832159 chr1 201173150 C A 4.28E-04 Multiple complex diseases IGFN1 intron 17554300 rs832159 chr1 201173150 C A 6.23E-04 Alzheimer's disease IGFN1 intron 17998437 rs4396148 chr1 201174822 C A 7.07E-04 Multiple complex diseases IGFN1 intron 17554300 rs4396148 chr1 201174822 C A 5.58E-04 Alzheimer's disease IGFN1 intron 17998437 rs3738268 chr1 201187828 T C 2.00E-04 Information processing speed IGFN1 intron 21130836 rs2039959 chr1 201188739 T G 8.98E-04 Multiple complex diseases IGFN1 intron 17554300 rs4915224 chr1 201190307 A G 2.00E-04 Information processing speed IGFN1 intron 21130836 rs6687300 chr1 201193499 G T 3.86E-04 Amyotrophic Lateral Sclerosis IGFN1 intron 17362836 rs6687494 chr1 201193668 G T 7.52E-05 Information processing speed IGFN1 intron 21130836 rs2365642 chr1 201235086 A G 4.11E-06 Waist circumference / / 19557197 rs7517345 chr1 201256533 G A 6.79E-04 Response to taxane treatment (placlitaxel) PKP1 intron 23006423 rs16848229 chr1 201257373 A G 9.80E-04 Response to taxane treatment (placlitaxel) PKP1 intron 23006423 rs832174 chr1 201258519 A T 8.95E-04 Response to taxane treatment (placlitaxel) PKP1 intron 23006423 rs860554 chr1 201262432 C T 5.00E-08 Panic disorder PKP1 intron 19165232 rs832147 chr1 201269687 C G 6.81E-05 Asthma PKP1 intron 11022011 rs34626929 chr1 201282334 G A 0.000000594 Triglycerides PKP1 missense 23063622 rs6690976 chr1 201305625 C T 0.000603 Salmonella-induced pyroptosis / / 22837397 rs12126907 chr1 201312033 A G 3.81E-05 Psoriasis / / 20953187 rs16848403 chr1 201315182 A G 0.00057 Salmonella-induced pyroptosis / / 22837397 rs2275863 chr1 201328824 G A 7.40E-05 Alcoholism (heaviness of drinking) TNNT2 intron 21529783 rs3729842 chr1 201337170 A G 3.04E-04 Type 2 diabetes TNNT2 intron 17846125 rs6427901 chr1 201340813 G A 9.70E-04 Amyotrophic lateral sclerosis (sporadic) TNNT2 intron 24529757 rs868407 chr1 201341341 C T 6.70E-05 Coronary heart disease TNNT2 intron 21966275 rs6663175 chr1 201341850 C T 7.25E-10 Triglycerides TNNT2 intron 23063622 rs3020556 chr1 201343115 C G 5.51E-08 Cardiac Troponin-T levels TNNT2 intron 23247143 rs12564445 chr1 201345487 G A 5.00E-08 Cardiac Troponin-T levels TNNT2 intron 23247143 rs2799686 chr1 201347315 A G 1.60E-05 Alcoholism (heaviness of drinking) TNNT2 nearGene-5 21529783 rs3738281 chr1 201358304 C A 2.11E-04 Height LAD1 missense 17255346 rs12408988 chr1 201410585 A G 1.56E-04 Alzheimer's disease (late onset) / / 21379329 rs7525711 chr1 201419375 G A 3.96E-04 Alzheimer's disease (late onset) / / 21379329 rs7553988 chr1 201421082 A G 9.53E-04 Alzheimer's disease / / 24755620 rs10920205 chr1 201422201 G A 7.30E-05 Memory performance / / 22105620 rs10753902 chr1 201422348 T C 4.60E-04 Alzheimer's disease (late onset) / / 21379329 rs371169997 chr1 201422348 TAA T 4.60E-04 Alzheimer's disease (late onset) / / 21379329 rs16848610 chr1 201423658 A C 1.93E-05 Asthma / / 11022011 rs3887566 chr1 201423940 G C 3.10E-05 Memory performance / / 22105620 rs12090950 chr1 201429381 G A 1.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs12090950 chr1 201429381 G A 4.64E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs6669318 chr1 201431075 A G 4.75E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs515384 chr1 201464807 T C 1.42E-04 Scoliosis CSRP1 intron 21216876 rs603836 chr1 201465839 T C 6.73E-04 Amyotrophic Lateral Sclerosis CSRP1 intron 17362836 rs10800784 chr1 201466057 A G 1.10E-04 Aortic root size CSRP1 intron 21223598 rs623791 chr1 201475209 C T 0.000042 Colorectal adenoma (excluding hyperplasic) CSRP1 intron 23677573 rs623791 chr1 201475209 C T 0.000042 Colorectal adenoma (including hyperplasic) CSRP1 intron 23677573 rs2038972 chr1 201475727 A C 0.0000375 Colorectal adenoma (excluding hyperplasic) CSRP1 intron 23677573 rs2038972 chr1 201475727 A C 0.0000375 Colorectal adenoma (including hyperplasic) CSRP1 intron 23677573 rs4915235 chr1 201490926 T G 4.71E-05 Blood pressure / / 17255346 rs7552162 chr1 201496207 A G 7.75E-04 Type 2 diabetes / / 17463246 rs4915537 chr1 201500825 C T 3.08E-04 Blood pressure / / 17255346 rs17469306 chr1 201503355 T C 8.09E-04 Type 2 diabetes / / 17463246 rs633696 chr1 201547000 T C 8.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs1267131 chr1 201547094 A C 5.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs1267131 chr1 201547094 A C 8.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs617053 chr1 201547532 G A 6.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs617053 chr1 201547532 G A 5.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs511201 chr1 201549296 A G 4.70E-04 Suicide attempts in bipolar disorder / / 21041247 rs511201 chr1 201549296 A G 8.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs516701 chr1 201549933 A G 8.54E-12 Narcolepsy / / 19629137 rs585041 chr1 201551007 T A 5.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs585041 chr1 201551007 T A 6.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs677390 chr1 201551788 A G 5.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs608356 chr1 201560163 A G 5.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs625436 chr1 201561675 A G 3.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs685982 chr1 201562604 T A 5.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs2068824 chr1 201594665 T C 6.00E-06 Celiac disease / / 23936387 rs495198 chr1 201606116 G A 2.19E-06 Asthma / / 11022011 rs724220 chr1 201630461 T G 2.46E-05 Blood Pressure /V1 intron pha002903 rs586688 chr1 201630955 G A 8.00E-06 Obesity-related traits /V1 intron 23251661 rs492563 chr1 201631471 T C 1.81E-04 Alzheimer's disease /V1 intron 17998437 rs647130 chr1 201637982 C T 2.87E-04 Alzheimer's disease /V1 intron 17998437 rs7523519 chr1 201647654 G T 6.35E-04 Alzheimer's disease /V1 intron 24755620 rs602668 chr1 201657709 C T 8.18E-06 Alzheimer's disease /V1 intron 17998437 rs654631 chr1 201658449 A G 1.30E-05 Alzheimer's disease /V1 intron 17998437 rs606114 chr1 201664101 T C 3.24E-05 Alzheimer's disease /V1 intron 17998437 rs12034680 chr1 201667862 G A 6.16E-04 Alzheimer's disease /V1 intron 24755620 rs239967 chr1 201692871 G A 5.80E-08 Metabolite levels /V1 intron 23281178 rs7535989 chr1 201732694 T G 1.70E-04 Amyotrophic lateral sclerosis (sporadic) /V1 intron 24529757 rs7551784 chr1 201767249 C T 4.32E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) /V1 intron 22566498 rs4379719 chr1 201775746 G A 2.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) /V1 intron 23648065 rs1043823 chr1 201845432 C T 5.64E-05 Caffeine consumption IPO9 UTR-3 21490707 rs2820315 chr1 201872264 C T 0.00000168 Coronary artery disease LMOD1 intron 23202125 rs2819346 chr1 201882087 A C 9.82E-04 Type 2 diabetes LMOD1 intron 17463246 rs2819346 chr1 201882087 A C 1.56E-04 Multiple complex diseases LMOD1 intron 17554300 rs4494199 chr1 201884668 A G 2.90E-04 Coronary heart disease LMOD1 intron 21966275 rs2819348 chr1 201884952 T C 3.00E-06 Breast size LMOD1 intron 22747683 rs2820300 chr1 201908678 A G 7.45E-04 Multiple complex diseases LMOD1 intron 17554300 rs2820300 chr1 201908678 A G 2.53E-10 LDL cholesterol LMOD1 intron 23063622 rs2819368 chr1 201910563 C T 9.84E-15 LDL cholesterol LMOD1 intron 23063622 rs2820301 chr1 201912822 G A 1.19E-10 LDL cholesterol LMOD1 intron 23063622 rs2819371 chr1 201915658 A C 1.60E-12 LDL cholesterol / / 23063622 rs2820304 chr1 201918527 T G 5.57E-05 Parkinson's disease / / 17052657 rs2820306 chr1 201923805 A G 7.91E-04 Myopia (pathological) / / 21095009 rs12090635 chr1 201936324 A G 5.87E-04 Suicide attempts in bipolar disorder TIMM17A intron 21423239 rs12754196 chr1 201940216 C T 3.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs7529387 chr1 201950038 G A 9.70E-15 Butyrylcholinesterase levels / / 21862451 rs4950806 chr1 201952574 T C 9.00E-16 Butyrylcholinesterase levels RNPEP intron 21862451 rs11590299 chr1 201953596 T A 9.40E-16 Butyrylcholinesterase levels RNPEP intron 21862451 rs6689324 chr1 201954697 C T 9.40E-16 Butyrylcholinesterase levels RNPEP intron 21862451 rs11586632 chr1 201955614 G A 9.40E-16 Butyrylcholinesterase levels RNPEP intron 21862451 rs4950752 chr1 201956427 G A 9.40E-16 Butyrylcholinesterase levels RNPEP intron 21862451 rs10800805 chr1 201959738 G A 9.40E-16 Butyrylcholinesterase levels RNPEP intron 21862451 rs2819358 chr1 201976402 T G 5.58E-04 Osteoarthritis (knee and hip) LOC100289488 intron 21177295 rs2819358 chr1 201976402 T G 6.13E-05 Osteoarthritis (knee and hip) LOC100289488 intron 21177295 rs2819358 chr1 201976402 T G 1.39E-04 Pancreatic cancer LOC100289488 intron pha002874 rs2819361 chr1 201980119 C G 2.90E-04 Obesity (extreme) ELF3 intron 21935397 rs2819365 chr1 201983242 C T 6.98E-05 Lung adenocarcinoma ELF3 intron 19836008 rs6661833 chr1 202037007 C A 7.53E-05 Waist Circumference / / pha003023 rs9427727 chr1 202038945 T C 9.77E-05 Schizophrenia / / 19197363 rs4436440 chr1 202052013 T A 5.16E-07 Asthma / / 11022011 rs10800812 chr1 202055938 A G 1.62E-08 Asthma / / 11022011 rs4329563 chr1 202090641 C G 1.35E-04 Response to TNF antagonist treatment / / 21061259 rs6701064 chr1 202093735 G T 6.28E-04 Response to TNF antagonist treatment GPR37L1 intron 21061259 rs12069950 chr1 202101443 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17435204 chr1 202106996 T C 2.67E-04 Nicotine dependence ARL8A intron 17158188 rs10920357 chr1 202151566 A G 2.75E-04 Response to taxane treatment (placlitaxel) PTPRVP intron 23006423 rs1823696 chr1 202167176 C T 5.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LGR6 intron 20877124 rs17489300 chr1 202179042 A C 9.52E-04 Multiple complex diseases LGR6 intron 17554300 rs116439821 chr1 202184821 C T 1.55E-05 Cocaine dependence LGR6 intron 23958962 rs6678914 chr1 202187176 G A 1.00E-08 Breast cancer LGR6 intron 23535733 rs896549 chr1 202205323 A G 5.17E-05 Cognitive performance LGR6 intron 19734545 rs2993444 chr1 202239771 C T 1.00E-04 Information processing speed LGR6 intron 21130836 rs2924100 chr1 202243688 A G 1.00E-04 Information processing speed LGR6 intron 21130836 rs788829 chr1 202265521 G A 2.00E-04 Information processing speed LGR6 intron 21130836 rs705768 chr1 202281006 G T 9.43E-05 Erythrocyte counts LGR6 intron pha003101 rs11583656 chr1 202370997 C T 6.86E-04 Multiple complex diseases PPP1R12B intron 17554300 rs12734001 chr1 202390914 C T 2.79E-07 Asthma PPP1R12B intron 21790008 rs12734001 chr1 202390914 C T 4.03E-05 Parkinson's disease PPP1R12B intron 21812969 rs12734001 chr1 202390914 C T 3.51E-09 Prion diseases PPP1R12B intron 22210626 rs12734001 chr1 202390914 C T 6.06E-15 Gender PPP1R12B intron 22362730 rs12734001 chr1 202390914 C T 2.32E-05 Celiac disease PPP1R12B intron 23936387 rs12739262 chr1 202391743 C T 1.00E-06 Obesity-related traits PPP1R12B intron 23251661 rs805911 chr1 202440419 C T 1.91E-04 Multiple complex diseases PPP1R12B intron 17554300 rs3817222 chr1 202464760 C T 2.18E-07 Asthma PPP1R12B missense 21790008 rs3817222 chr1 202464760 C T 1.02E-30 Gender PPP1R12B missense 22362730 rs3817227 chr1 202464842 A G 6.06E-15 Gender PPP1R12B intron 22362730 rs12734338 chr1 202469723 T C 8.98E-04 Amyotrophic Lateral Sclerosis PPP1R12B intron 17362836 rs12734338 chr1 202469723 T C 1.46E-05 HIV-1 viral setpoint PPP1R12B intron 17641165 rs12734338 chr1 202469723 T C 2.60E-05 HIV-1 control PPP1R12B intron 20041166 rs12734338 chr1 202469723 T C 1.70E-06 Asthma PPP1R12B intron 20698975 rs12734338 chr1 202469723 T C 3.57E-31 Gender PPP1R12B intron 22362730 rs12734338 chr1 202469723 T C 3.00E-07 Celiac disease PPP1R12B intron 23936387 rs12734338 chr1 202469723 T C 3.00E-07 Coronary heart disease PPP1R12B intron 24778558 rs12741415 chr1 202474774 G A 1.76E-25 Gender PPP1R12B intron 22362730 rs12743401 chr1 202476648 T C 9.13E-04 Amyotrophic Lateral Sclerosis PPP1R12B intron 17362836 rs12743401 chr1 202476648 T C 1.46E-05 HIV-1 viral setpoint PPP1R12B intron 17641165 rs12743401 chr1 202476648 T C 4.20E-06 Asthma PPP1R12B intron 20698975 rs12743401 chr1 202476648 T C 1.02E-30 Gender PPP1R12B intron 22362730 rs4084639 chr1 202510164 G C 6.06E-15 Gender PPP1R12B intron 22362730 rs3881953 chr1 202528021 G A 5.53E-04 Amyotrophic Lateral Sclerosis PPP1R12B missense 17362836 rs3881953 chr1 202528021 G A 4.26E-31 Gender PPP1R12B missense 22362730 rs585658 chr1 202573179 C T 0.000032 Mean arterial pressure SYT2 intron 22510845 rs16830648 chr1 202595153 A G 2.91E-04 Multiple complex diseases SYT2 intron 17554300 rs10494835 chr1 202602197 C T 3.30E-04 Heroin addiction SYT2 intron 20520587 rs12404969 chr1 202622426 C T 2.00E-05 Urinary metabolites SYT2 intron 21572414 rs2153441 chr1 202628576 T C 7.68E-05 Bipolar disorder and schizophrenia SYT2 intron 20889312 rs7517181 chr1 202629745 T C 2.60E-05 Urinary metabolites SYT2 intron 21572414 rs10920452 chr1 202641340 G A 7.54E-04 Type 2 diabetes SYT2 intron 17463246 rs11588808 chr1 202667492 A G 2.30E-05 Urinary metabolites SYT2 intron 21572414 rs7529811 chr1 202688077 A G 6.12E-05 Bipolar disorder and schizophrenia / / 20889312 rs3820153 chr1 202725286 A G 5.09E-04 Type 2 diabetes KDM5B intron 17463246 rs12132801 chr1 202726145 G A 2.00E-04 Cognitive impairment induced by topiramate KDM5B intron 22091778 rs7519148 chr1 202734579 A G 5.13E-05 Bipolar disorder and schizophrenia KDM5B intron 20889312 rs12132992 chr1 202761823 C G 2.13E-04 Type 2 diabetes KDM5B intron 17463246 rs17497724 chr1 202808605 A G 5.75E-05 Cognitive test performance / / 20125193 rs6699298 chr1 202853593 C T 9.19E-04 Obesity (extreme) RABIF intron 21935397 rs3806346 chr1 202859600 A G 8.99E-04 Obesity (extreme) / / 21935397 rs3766572 chr1 202860067 T C 8.87E-04 Obesity (extreme) / / 21935397 rs12089566 chr1 202861342 A G 1.39E-04 Smoking initiation / / 24665060 rs10920519 chr1 202866331 A C 8.84E-04 Obesity (extreme) KLHL12 intron 21935397 rs7542125 chr1 202871238 T C 8.79E-04 Obesity (extreme) KLHL12 intron 21935397 rs10800877 chr1 202884063 C T 4.81E-04 Smoking initiation KLHL12 intron 24665060 rs10800880 chr1 202892917 T C 9.61E-04 Obesity (extreme) KLHL12 intron 21935397 rs10800891 chr1 202947596 T C 1.98E-05 Multiple complex diseases / / 17554300 rs16850854 chr1 202956588 G T 8.83E-04 Multiple complex diseases / / 17554300 rs1046529 chr1 202992954 T C 9.44E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines TMEM183A UTR-3 21844884 rs10920553 chr1 203008286 C G 4.80E-06 Urinary metabolites LOC100507405 cds-synon 21572414 rs3820151 chr1 203046534 A G 2.40E-05 Brain structure PPFIA4 UTR-3 22504417 rs115855025 chr1 203054980 C T 0.00089 Breast cancer MYOG missense 23555315 rs58592594 chr1 203058476 C T 3.64E-04 Alcohol consumption / / 23743675 rs1038984 chr1 203058842 G A 3.32E-04 Alcohol consumption / / 23743675 rs7549561 chr1 203106390 A G 0.000163432 Hypertension (early onset hypertension) ADORA1 intron 22479346 rs10800901 chr1 203111304 A G 5.97E-04 Multiple complex diseases ADORA1 intron 17554300 rs3766560 chr1 203118394 C T 2.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADORA1 intron 20877124 rs17465037 chr1 203130671 G A 6.27E-04 Amyotrophic lateral sclerosis (sporadic) ADORA1 intron 24529757 rs3753472 chr1 203131533 T C 8.17E-04 Amyotrophic Lateral Sclerosis ADORA1 intron 17362836 rs16851020 chr1 203133652 G T 4.14E-05 Asthma ADORA1 intron 11022011 rs16851020 chr1 203133652 G T 1.90E-05 Urinary metabolites ADORA1 intron 21572414 rs16851020 chr1 203133652 G T 9.96E-05 Blood pressure (response to angiotensin II receptor blocker) ADORA1 intron 24192120 rs2250509 chr1 203138970 A G 1.80E-04 Type 2 diabetes MYBPH intron 17463246 rs2071580 chr1 203149154 C T 6.50E-05 Schizophrenia(age at onset) CHI3L1 intron 21688384 rs4950928 chr1 203155882 G C 1.00E-13 YKL-40 levels CHI3L1 UTR-5 18403759 rs6691378 chr1 203157122 G A 3.76E-05 Asthma CHI3L1 nearGene-5 11022011 rs4950929 chr1 203160126 G T 1.32E-12 Asthma / / 11022011 rs946263 chr1 203165381 G A 9.74E-13 Asthma / / 11022011 rs2153101 chr1 203168474 A T 9.74E-13 Asthma / / 11022011 rs946264 chr1 203169492 A C 4.90E-04 Multiple complex diseases / / 17554300 rs2486949 chr1 203173356 T C 4.73E-05 Cognitive impairment induced by topiramate / / 22091778 rs2486949 chr1 203173356 T C 2.19E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12042412 chr1 203173656 C T 0.000121631 Hypertension (early onset hypertension) / / 22479346 rs2244385 chr1 203191262 C G 7.40E-04 Alzheimer's disease CHIT1 intron 22005930 rs2486067 chr1 203191866 C T 5.29E-04 Alzheimer's disease CHIT1 intron 22005930 rs2486961 chr1 203191904 C T 5.22E-04 Alzheimer's disease CHIT1 intron 22005930 rs2486962 chr1 203191920 G A 2.00E-04 Cognitive impairment induced by topiramate CHIT1 intron 22091778 rs2486068 chr1 203193134 T G 3.85E-04 Alzheimer's disease CHIT1 intron 22005930 rs137852607 chr1 203194834 C T 0.00076 Breast cancer CHIT1 missense 23555315 rs2486070 chr1 203195689 G A 2.93E-04 Alzheimer's disease CHIT1 intron 22005930 rs2486071 chr1 203196479 A C 1.98E-04 Alzheimer's disease CHIT1 intron 22005930 rs17533071 chr1 203200196 T C 4.50E-05 Response to Vitamin E supplementation CHIT1 nearGene-5 22437554 rs2494283 chr1 203202902 T C 1.10E-05 Urinary metabolites / / 21572414 rs2494286 chr1 203206709 T A 1.20E-05 Urinary metabolites / / 21572414 rs2494287 chr1 203207520 T C 1.50E-05 Urinary metabolites / / 21572414 rs2494292 chr1 203215064 A T 2.50E-05 Urinary metabolites / / 21572414 rs2486925 chr1 203234037 T G 1.50E-05 Urinary metabolites / / 21572414 rs884926 chr1 203295794 G A 1.42E-05 Height / / pha003010 rs884926 chr1 203295794 G A 9.02E-06 Height / / pha003011 rs6665383 chr1 203299849 G C 2.27E-04 Multiple complex diseases / / 17554300 rs6665383 chr1 203299849 G C 9.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs6428000 chr1 203300916 C T 2.60E-05 Urinary metabolites / / 21572414 rs2364940 chr1 203307072 T G 3.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs7543493 chr1 203308406 T C 8.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs12739111 chr1 203308801 T C 2.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs12757745 chr1 203308968 G A 8.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs12757745 chr1 203308968 G A 7.16E-05 Height / / pha003010 rs12757745 chr1 203308968 G A 3.12E-05 Height / / pha003011 rs12723309 chr1 203309028 G A 2.50E-05 Urinary metabolites / / 21572414 rs3738020 chr1 203309512 G T 3.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs3738021 chr1 203309616 T C 1.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs2886220 chr1 203309752 T C 2.14E-04 Suicide attempts in bipolar disorder FMOD UTR-3 21423239 rs7208 chr1 203309880 G A 2.16E-04 Suicide attempts in bipolar disorder FMOD UTR-3 21423239 rs10800912 chr1 203312960 G A 7.52E-04 Suicide attempts in bipolar disorder FMOD intron 21423239 rs10800913 chr1 203315893 G A 8.54E-04 Alcohol consumption (maxi-drinks) FMOD intron 24277619 rs1891174 chr1 203323636 G A 4.92E-04 Multiple complex diseases / / 17554300 rs12756933 chr1 203338525 G T 6.50E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6697045 chr1 203347210 A G 4.82E-05 Cognitive test performance / / 20125193 rs7543408 chr1 203352135 G C 6.03E-04 Type 2 diabetes / / 17463246 rs6428009 chr1 203361173 G C 6.92E-05 Schizophrenia / / pha002859 rs10920631 chr1 203367047 T C 5.06E-05 Cognitive test performance / / 20125193 rs879446 chr1 203371570 C T 1.20E-05 Urinary metabolites / / 21572414 rs1539143 chr1 203372485 G A 1.00E-06 Obesity-related traits / / 23251661 rs13328676 chr1 203377559 G C 5.40E-05 Pericardial fat / / 22589742 rs1417925 chr1 203403117 T G 4.30E-06 Urinary metabolites / / 21572414 rs6681328 chr1 203404635 G A 4.90E-05 Pericardial fat / / 22589742 rs999051 chr1 203411859 T C 5.60E-06 Urinary metabolites / / 21572414 rs9439 chr1 203455902 A C 0.00019 Breast cancer PRELP missense 23555315 rs2242204 chr1 203457961 T C 8.50E-06 Urinary metabolites PRELP UTR-3 21572414 rs2242203 chr1 203458037 A T 6.10E-06 Urinary metabolites PRELP UTR-3 21572414 rs16851713 chr1 203460673 T C 4.30E-06 Urinary metabolites PRELP nearGene-3 21572414 rs2279127 chr1 203472941 A G 5.28E-05 Nephrolithiasis OPTC intron 22396660 rs2279127 chr1 203472941 A G 4.30E-06 Pericardial fat OPTC intron 22589742 rs13303252 chr1 203485142 C T 8.16E-04 Body mass index / / 21701565 rs6688116 chr1 203492121 A G 1.14E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13303128 chr1 203492720 C T 9.00E-06 Metabolite levels (MHPG) / / 23319000 rs2802782 chr1 203571766 T G 2.17E-04 Obesity (extreme) / / 21935397 rs6593903 chr1 203584850 C T 0.0000273 Height (Pygmy height) / / 22570615 rs9645427 chr1 203587406 G C 9.12E-04 Obesity (extreme) / / 21935397 rs12120868 chr1 203587538 G T 4.71E-04 Obesity (extreme) / / 21935397 rs4951276 chr1 203599192 T A 8.17E-04 Lymphocyte counts ATP2B4 intron 22286170 rs10736845 chr1 203650786 T C 2.10E-07 Red blood cell traits ATP2B4 intron 23222517 rs10751451 chr1 203650978 C T 2.75E-07 Red blood cell traits ATP2B4 intron 23222517 rs11240734 chr1 203651824 C T 1.18E-11 Red blood cell traits ATP2B4 intron 23222517 rs1541252 chr1 203651927 T C 5.13E-07 Red blood cell traits ATP2B4 UTR-5 23222517 rs1541252 chr1 203651927 T C 9.00E-08 Mean corpuscular hemoglobin concentration ATP2B4 UTR-5 23263863 rs1541253 chr1 203652040 T C 3.05E-07 Red blood cell traits ATP2B4 UTR-5 23222517 rs1541254 chr1 203652140 C G 2.33E-11 Red blood cell traits ATP2B4 UTR-5 23222517 rs1419114 chr1 203652444 A G 4.61E-11 Red blood cell traits ATP2B4 cds-synon 23222517 rs4951070 chr1 203652698 T C 2.46E-07 Red blood cell traits ATP2B4 intron 23222517 rs10900585 chr1 203654024 G T 2.00E-10 Malaria ATP2B4 intron 22895189 rs6658130 chr1 203654568 G A 2.10E-07 Red blood cell traits ATP2B4 intron 23222517 rs6594006 chr1 203654738 A G 1.17E-11 Red blood cell traits ATP2B4 intron 23222517 rs6594007 chr1 203654772 A G 9.97E-12 Red blood cell traits ATP2B4 intron 23222517 rs6594008 chr1 203654851 T C 1.77E-07 Red blood cell traits ATP2B4 intron 23222517 rs7539122 chr1 203655043 C T 9.90E-12 Red blood cell traits ATP2B4 intron 23222517 rs7551442 chr1 203655121 A G 9.72E-12 Red blood cell traits ATP2B4 intron 23222517 rs7551560 chr1 203655270 A G 1.00E-11 Red blood cell traits ATP2B4 intron 23222517 rs7554335 chr1 203655743 A G 2.29E-07 Red blood cell traits ATP2B4 intron 23222517 rs4951375 chr1 203655785 T G 1.80E-07 Red blood cell traits ATP2B4 intron 23222517 rs2365860 chr1 203656230 G T 1.37E-11 Red blood cell traits ATP2B4 intron 23222517 rs10900588 chr1 203656814 G A 8.85E-07 Red blood cell traits ATP2B4 intron 23222517 rs10900589 chr1 203656974 A T 2.47E-11 Red blood cell traits ATP2B4 intron 23222517 rs2365858 chr1 203657749 C G 1.49E-11 Red blood cell traits ATP2B4 intron 23222517 rs4951377 chr1 203658471 A G 1.05E-11 Red blood cell traits ATP2B4 intron 23222517 rs4951378 chr1 203658782 A G 1.36E-11 Red blood cell traits ATP2B4 intron 23222517 rs4951074 chr1 203660781 A G 1.80E-08 Malaria ATP2B4 intron 22895189 rs4951074 chr1 203660781 A G 6.33E-11 Red blood cell traits ATP2B4 intron 23222517 rs4951381 chr1 203660838 A G 2.26E-11 Red blood cell traits ATP2B4 intron 23222517 rs2228445 chr1 203667409 T C 2.65E-07 Red blood cell traits ATP2B4 cds-synon 23222517 rs4951107 chr1 203687154 T G 3.74E-05 Parkinson's disease (motor and cognition) ATP2B4 intron 22658654 rs4951107 chr1 203687154 T G 3.74E-05 Immune response to anthrax vaccine ATP2B4 intron 22658931 rs11808688 chr1 203689314 A G 4.27E-05 Parkinson's disease (motor and cognition) ATP2B4 intron 22658654 rs11808688 chr1 203689314 A G 4.27E-05 Immune response to anthrax vaccine ATP2B4 intron 22658931 rs970 chr1 203712996 T C 6.52E-04 Iron levels ATP2B4 UTR-3 pha002876 rs3820195 chr1 203740462 G A 4.98E-04 Alzheimer's disease LAX1 intron 22005930 rs3737975 chr1 203740803 G C 7.72E-04 Alzheimer's disease LAX1 intron 22005930 rs3737973 chr1 203741368 C A 5.15E-04 Multiple complex diseases LAX1 intron 17554300 rs2185079 chr1 203747772 G A 7.80E-04 Smoking cessation / / 24665060 rs12240088 chr1 203752854 A G 9.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs13375815 chr1 203754922 C T 9.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs2365866 chr1 203758129 A C 9.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs6697388 chr1 203767822 T G 5.35E-04 Response to cytidine analogues (gemcitabine) ZBED6 missense 24483146 rs7552670 chr1 203768328 T C 0.000439 Breast cancer early age of onset ZBED6 missense 18463975 rs7511676 chr1 203770210 T G 5.35E-04 Response to cytidine analogues (gemcitabine) ZC3H11A intron 24483146 rs12145049 chr1 203777741 C T 2.41E-05 Height ZC3H11A intron pha003011 rs7547408 chr1 203784788 C T 4.37E-04 Multiple complex diseases ZC3H11A intron 17554300 rs16830289 chr1 203802051 G A 3.89E-04 Multiple complex diseases ZC3H11A intron 17554300 rs12723861 chr1 203807500 A G 0.0000958 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity ZC3H11A intron 22945461 rs12723861 chr1 203807500 A G 5.95E-05 Height ZC3H11A intron pha003011 rs11240620 chr1 203881082 C T 9.31E-04 Alzheimer's disease / / 17998437 rs6685964 chr1 203906128 A T 9.56E-04 Insulin resistance / / 21901158 rs1935588 chr1 203910220 G A 6.14E-04 Bone mass and geometry / / 17903296 rs2886616 chr1 203912438 C T 8.03E-05 Blood Pressure / / pha003045 rs12064551 chr1 203924763 C T 9.48E-04 Insulin resistance / / 21901158 rs4434893 chr1 203928412 G A 9.03E-04 Multiple complex diseases / / 17554300 rs2096196 chr1 203932993 C A,T 9.30E-05 Height / / 18391952 rs12408223 chr1 203948660 A G 2.34E-04 Cholesterol / / 17255346 rs4301679 chr1 204005018 C T 9.05E-04 Obesity (extreme) LINC00303 intron 21935397 rs4951290 chr1 204006104 T G 8.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs4951291 chr1 204006538 T C 5.30E-06 Colorectal cancer LINC00303 intron 19011631 rs4951291 chr1 204006538 T C 1.32E-05 Bone mineral density LINC00303 intron 19181680 rs4951039 chr1 204006597 G A 5.80E-06 Colorectal cancer / / 19011631 rs4951039 chr1 204006597 G A 6.47E-05 Bone mineral density / / 19181680 rs12133634 chr1 204014607 T C 3.44E-04 Obesity (extreme) / / 21935397 rs12133665 chr1 204014693 T C 3.40E-04 Obesity (extreme) / / 21935397 rs10900544 chr1 204015718 A G 1.66E-05 Bone mineral density / / 19181680 rs6673836 chr1 204031363 G A 1.00E-04 Smoking quantity / / 24665060 rs12046258 chr1 204039160 G A 4.93E-05 Prostate cancer / / 18264096 rs17404350 chr1 204057142 C G 6.50E-07 Urinary metabolites SOX13 intron 21572414 rs3795579 chr1 204069838 G T 6.28E-04 Smoking initiation SOX13 intron 24665060 rs3795579 chr1 204069838 G T 8.36E-04 Iron levels SOX13 intron pha002876 rs2293336 chr1 204082002 C T 5.61E-05 Serum metabolites SOX13 intron 19043545 rs2037679 chr1 204082938 C T 4.97E-04 Response to cytidine analogues (gemcitabine) SOX13 intron 24483146 rs1917540 chr1 204101681 C T 6.45E-06 Periodontitis (CDC/AAP) ETNK2 intron 24024966 rs2293335 chr1 204103618 G A 5.00E-06 Periodontitis (CDC/AAP) ETNK2 intron 24024966 rs11240680 chr1 204109473 G A 7.94E-06 Periodontitis (CDC/AAP) ETNK2 intron 24024966 rs3795578 chr1 204112984 G A 7.00E-06 Response to acetaminophen (hepatotoxicity) ETNK2 intron 21177773 rs940651 chr1 204115586 G C 2.20E-05 Urinary metabolites ETNK2 intron 21572414 rs1997034 chr1 204118360 T C 2.17E-04 Multiple complex diseases ETNK2 intron 17554300 rs1997034 chr1 204118360 T C 6.95E-04 Bipolar disorder,schizoaffective ETNK2 intron 19567891 rs1997034 chr1 204118360 T C 0.000104004 Hypertension (early onset hypertension) ETNK2 intron 22479346 rs11571093 chr1 204123671 G C 2.67E-04 Multiple complex diseases REN nearGene-3 17554300 rs11571087 chr1 204126245 A T 0.0000013 HDL cholesterol REN intron 23236364 rs11571111 chr1 204130233 C A 2.95E-10 Cholesterol,total REN intron 23063622 rs11571111 chr1 204130233 C A 4.79E-08 Triglycerides REN intron 23063622 rs11571111 chr1 204130233 C A 8.78E-17 HDL cholesterol REN intron 23063622 rs6676670 chr1 204132816 G A,T 1.24E-04 Hearing function REN intron 17255346 rs6668858 chr1 204135788 G A 0.000000206 Cholesterol,total REN nearGene-5 23063622 rs6668858 chr1 204135788 G A 2.66E-08 Triglycerides REN nearGene-5 23063622 rs6668858 chr1 204135788 G A 6.19E-13 HDL cholesterol REN nearGene-5 23063622 rs16853062 chr1 204140218 T A 1.18E-04 Multiple complex diseases / / 17554300 rs11240692 chr1 204149077 C G 8.41E-04 Parkinson's disease / / 16252231 rs12040249 chr1 204158228 G A 7.23E-04 Parkinson's disease / / 16252231 rs7538038 chr1 204161026 A G 3.78E-04 Hearing function KISS1 intron 17255346 rs4951316 chr1 204161490 T C 3.18E-04 Hearing function KISS1 intron 17255346 rs2510 chr1 204161591 T C 1.53E-04 Hearing function KISS1 intron 17255346 rs12097666 chr1 204162212 T C 2.87E-04 Hearing function KISS1 intron 17255346 rs4951319 chr1 204162230 T C 2.51E-04 Hearing function KISS1 intron 17255346 rs3924586 chr1 204166043 C T 1.88E-04 Hearing function KISS1 nearGene-5 17255346 rs4534452 chr1 204185184 A G 6.81E-04 Alzheimer's disease / / 17998437 rs7546241 chr1 204193774 G A 2.20E-05 Urinary metabolites PLEKHA6 intron 21572414 rs11240700 chr1 204195956 T C 2.40E-05 Urinary metabolites PLEKHA6 intron 21572414 rs4581328 chr1 204196327 A C 2.40E-05 Urinary metabolites PLEKHA6 intron 21572414 rs4614318 chr1 204196482 C T 2.40E-05 Urinary metabolites PLEKHA6 intron 21572414 rs4434894 chr1 204203651 C A 2.40E-05 Urinary metabolites PLEKHA6 intron 21572414 rs6702751 chr1 204211793 A C 1.50E-05 Urinary metabolites PLEKHA6 intron 21572414 rs4951056 chr1 204232972 C T 1.80E-06 Urinary metabolites PLEKHA6 intron 21572414 rs10793760 chr1 204238403 G A 1.50E-05 Urinary metabolites PLEKHA6 intron 21572414 rs7551075 chr1 204239603 T C 4.00E-06 Urinary metabolites PLEKHA6 intron 21572414 rs11240713 chr1 204244886 C G 1.50E-05 Urinary metabolites PLEKHA6 intron 21572414 rs4951059 chr1 204258019 T C 1.38E-04 Multiple complex diseases PLEKHA6 intron 17554300 rs16853233 chr1 204261060 A G 2.80E-05 Personality dimensions PLEKHA6 intron 18957941 rs7534537 chr1 204274519 T C 3.00E-06 Palmitoleic acid (16:1n-7) plasma levels PLEKHA6 intron 23362303 rs57159858 chr1 204280535 C T 3.63E-12 Metabolite levels PLEKHA6 intron 22286219 rs4245727 chr1 204283624 C G 1.40E-05 Malaria PLEKHA6 intron 19465909 rs4951067 chr1 204318983 C T 3.43E-04 Schizophrenia PLEKHA6 intron 20832056 rs4951068 chr1 204318997 C T 3.43E-04 Schizophrenia PLEKHA6 intron 20832056 rs16853492 chr1 204326479 G A 7.54E-04 Multiple complex diseases PLEKHA6 intron 17554300 rs1398152 chr1 204334076 C A 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs11240732 chr1 204345392 T C 5.33E-05 Hypertension / / 19609347 rs3106364 chr1 204355244 T G 6.03E-05 Hemoglobin / / pha003098 rs1512113 chr1 204359597 T C 0.000295709 Hypertension (early onset hypertension) / / 22479346 rs11240738 chr1 204367303 A G 4.05E-04 Multiple complex diseases / / 17554300 rs3014622 chr1 204367668 G C 1.09E-05 Creutzfeldt-Jakob disease (variant) / / 22137330 rs12119503 chr1 204386463 T C 1.91E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12061474 chr1 204389314 C T 1.27E-05 Multiple complex diseases / / 17554300 rs4951373 chr1 204392257 G A 1.60E-04 Alcohol dependence PIK3C2B UTR-3 20201924 rs4951373 chr1 204392257 G A 6.40E-05 Alcohol dependence PIK3C2B UTR-3 20201924 rs4951373 chr1 204392257 G A 0.000594232 Hypertension (early onset hypertension) PIK3C2B UTR-3 22479346 rs4951373 chr1 204392257 G A 6.42E-05 Alcoholism PIK3C2B UTR-3 pha002892 rs16853737 chr1 204425826 G A 8.90E-05 HIV-1 control PIK3C2B intron 20041166 rs2137255 chr1 204426373 C T 4.57E-04 Alcohol dependence PIK3C2B intron 21314694 rs1553920 chr1 204445035 T C 1.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIK3C2B intron 20877124 rs6594014 chr1 204449434 A G 4.90E-05 Cognitive performance PIK3C2B intron 19734545 rs10494852 chr1 204457786 C T 1.98E-04 Alzheimer's disease PIK3C2B intron 24755620 rs11240751 chr1 204462050 A G 2.05E-04 Alzheimer's disease / / 24755620 rs10900594 chr1 204470129 G C 3.54E-08 Lymphocyte counts / / 22286170 rs2926537 chr1 204472279 C T 6.99E-05 Multiple complex diseases / / 17554300 rs4951393 chr1 204489557 C A 4.85E-04 Alzheimer's disease MDM4 intron 24755620 rs4252685 chr1 204496856 C A 3.51E-04 Alzheimer's disease MDM4 intron 24755620 rs898388 chr1 204500257 G A 9.82E-04 Multiple complex diseases MDM4 intron 17554300 rs10458588 chr1 204505487 T C 9.48E-05 Cognitive performance MDM4 intron 19734545 rs4252725 chr1 204513256 A G 3.70E-04 Alzheimer's disease MDM4 intron 24755620 rs2369244 chr1 204515299 G C 2.02E-04 Alzheimer's disease MDM4 intron 24755620 rs2290854 chr1 204516025 A G 1.00E-07 Breast Cancer in BRCA1 mutation carriers MDM4 intron 23544013 rs2290854 chr1 204516025 A G 1.21E-07 Breast Cancer in BRCA1 mutation carriers MDM4 intron 23544013 rs2290854 chr1 204516025 A G 1.39E-07 Breast Cancer in BRCA1 mutation carriers MDM4 intron 23544013 rs2290854 chr1 204516025 A G 2.15E-04 Breast Cancer in BRCA1 mutation carriers MDM4 intron 23544013 rs2290854 chr1 204516025 A G 3.58E-05 Breast Cancer in BRCA1 mutation carriers MDM4 intron 23544013 rs2290854 chr1 204516025 A G 3.91E-04 Alzheimer's disease MDM4 intron 24755620 rs1563828 chr1 204516577 A G 2.25E-04 Alzheimer's disease MDM4 intron 24755620 rs4245739 chr1 204518842 C A 2.00E-11 Prostate cancer MDM4 UTR-3 23535732 rs4245739 chr1 204518842 C A 2.00E-12 Breast cancer MDM4 UTR-3 23535733 rs4245739 chr1 204518842 C A 4.00E-06 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) MDM4 UTR-3 24325915 rs4245739 chr1 204518842 C A 8.01E-04 Alzheimer's disease MDM4 UTR-3 24755620 rs10900596 chr1 204522457 T C 4.11E-04 Alzheimer's disease MDM4 UTR-3 24755620 rs10900597 chr1 204522489 C T 2.20E-04 Alzheimer's disease MDM4 UTR-3 24755620 rs12039454 chr1 204542580 T C 2.34E-04 Alzheimer's disease / / 24755620 rs10793766 chr1 204549496 C T 1.70E-04 Alzheimer's disease / / 24755620 rs16854023 chr1 204551830 T C 2.33E-04 Multiple complex diseases / / 17554300 rs6679717 chr1 204560677 A G 2.85E-04 Alzheimer's disease / / 24755620 rs4951409 chr1 204560990 T A 8.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs7532236 chr1 204561617 C T 2.96E-04 Alzheimer's disease / / 24755620 rs6682208 chr1 204566183 T C 1.64E-04 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs6682208 chr1 204566183 T C 2.65E-04 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs6682208 chr1 204566183 T C 4.00E-07 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs6682208 chr1 204566183 T C 4.25E-07 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs6682208 chr1 204566183 T C 5.43E-06 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs6682208 chr1 204566183 T C 5.06E-04 Alzheimer's disease / / 24755620 rs10900601 chr1 204572050 A G 7.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs12143943 chr1 204572071 G A 5.00E-06 Cognitive performance / / 19734545 rs11584700 chr1 204576983 A G 8.00E-12 Educational attainment / / 23722424 rs898387 chr1 204579373 G A 4.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs898386 chr1 204579697 A G 3.81E-05 Cognitive performance / / 19734545 rs898386 chr1 204579697 A G 4.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs2045624 chr1 204584385 G C 9.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs3789043 chr1 204589150 C T 1.83E-04 Multiple complex diseases LRRN2 UTR-5 17554300 rs884108 chr1 204591237 A G 7.24E-04 Suicide attempts in bipolar disorder LRRN2 intron 21041247 rs12094388 chr1 204592174 A G 2.86E-04 Alzheimer's disease (late onset) LRRN2 intron 21379329 rs4951084 chr1 204606974 C G 1.75E-04 Suicide attempts in bipolar disorder LRRN2 intron 21041247 rs4951087 chr1 204609194 A G 1.25E-05 Psoriasis LRRN2 intron 18364390 rs10900418 chr1 204614166 T C 7.61E-04 Type 2 diabetes LRRN2 intron 17463246 rs11801229 chr1 204614475 A G 5.28E-04 Alcohol dependence LRRN2 intron 21314694 rs17335469 chr1 204632163 T C 4.05E-05 ldl cholesterol LRRN2 intron pha003076 rs2149819 chr1 204632333 T C 2.48E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LRRN2 intron 20031582 rs17413714 chr1 204633340 A C 2.23E-04 Obesity (extreme) LRRN2 intron 21935397 rs16854208 chr1 204675641 C A,G 1.44E-04 Multiple complex diseases / / 17554300 rs868506 chr1 204682411 T G 4.11E-04 Type 2 diabetes / / 17463246 rs12239515 chr1 204703480 A G 4.70E-05 Parkinson's disease (familial) / / 18985386 rs12239515 chr1 204703480 A G 0.000551351 Hypertension (early onset hypertension) / / 22479346 rs1329632 chr1 204705517 C T 0.000551351 Hypertension (early onset hypertension) / / 22479346 rs2012130 chr1 204717211 C T 2.47E-05 Odorant perception / / 23910658 rs7551603 chr1 204734495 G A 1.10E-05 Urinary metabolites / / 21572414 rs7544209 chr1 204734807 T C 4.90E-06 Urinary metabolites / / 21572414 rs11240266 chr1 204743826 T C 1.30E-05 Urinary metabolites / / 21572414 rs6593907 chr1 204746302 T C 1.30E-05 Urinary metabolites / / 21572414 rs4951117 chr1 204778847 T A 2.10E-05 Urinary metabolites / / 21572414 rs7552806 chr1 204784018 A C 3.00E-06 Dental caries / / 23064961 rs7552806 chr1 204784018 A C 3.00E-06 Dental caries / / 23064961 rs4483476 chr1 204788353 T C 5.12E-04 Multiple complex diseases / / 17554300 rs2208843 chr1 204789624 G A 5.83E-05 Crohn's disease and psoriasis / / 22482804 rs10458589 chr1 204792001 T C 6.16E-04 Multiple complex diseases / / 17554300 rs10458591 chr1 204792210 T C 5.13E-04 Multiple complex diseases / / 17554300 rs7525016 chr1 204792995 C T 6.41E-04 Multiple complex diseases / / 17554300 rs4951129 chr1 204796564 A T 2.05E-04 Multiple complex diseases NFASC nearGene-5 17554300 rs750087 chr1 204810161 G A 9.36E-04 Response to taxane treatment (placlitaxel) NFASC intron 23006423 rs4951135 chr1 204815612 T C 8.37E-04 Schizophrenia NFASC intron 19197363 rs12239394 chr1 204825794 A C 2.38E-05 Cognitive impairment induced by topiramate NFASC intron 22091778 rs12043259 chr1 204828041 C G 2.00E-11 Addiction NFASC intron 23533358 rs2759281 chr1 204866365 T C 2.98E-04 Alzheimer's disease (late onset) NFASC intron 21379329 rs12025272 chr1 204869559 A G 3.12E-04 Myopia (pathological) NFASC intron 21095009 rs2247208 chr1 204877652 G A 8.00E-06 Amyotrophic lateral sclerosis (sporadic) NFASC intron 24529757 rs2887480 chr1 204881338 C T 3.60E-04 Iron levels NFASC intron pha002876 rs6593917 chr1 204890731 A G 1.61E-04 Blood pressure NFASC intron 17255346 rs2802814 chr1 204906922 T C 5.48E-04 Multiple complex diseases NFASC intron 17554300 rs2802814 chr1 204906922 T C 4.59E-05 Erythrocyte counts NFASC intron pha003099 rs12044157 chr1 204917271 G A 6.43E-04 Type 2 diabetes NFASC intron 17463246 rs4951147 chr1 204919232 G A 1.83E-05 Hemoglobin NFASC intron pha003098 rs4951147 chr1 204919232 G A 1.00E-04 Erythrocyte counts NFASC intron pha003099 rs6696330 chr1 204946387 C T 8.57E-04 Multiple complex diseases NFASC intron 17554300 rs2802841 chr1 204975735 G A 1.50E-04 Endometriosis NFASC intron 21151130 rs2802837 chr1 204993935 A G 6.67E-05 Attention deficit hyperactivity disorder / / 23728934 rs2794867 chr1 204994110 C A 5.87E-05 Height / / pha003010 rs2794867 chr1 204994110 C A 4.91E-05 Height / / pha003011 rs10793722 chr1 205019380 G T 2.10E-05 Urinary metabolites CNTN2 intron 21572414 rs3753855 chr1 205040726 A G 8.80E-04 Multiple complex diseases CNTN2 intron 17554300 rs12117194 chr1 205040943 C G 2.79E-04 Blood pressure CNTN2 intron 17255346 rs6662930 chr1 205041465 T C 1.88E-07 Red blood cell traits CNTN2 intron 23222517 rs6696846 chr1 205041952 C T 2.68E-07 Red blood cell traits CNTN2 intron 23222517 rs1042831 chr1 205043250 G C 3.06E-07 Red blood cell traits CNTN2 UTR-3 23222517 rs1572993 chr1 205045087 G A 6.63E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain CNTN2 UTR-3 20154673 rs7523477 chr1 205048383 T C 2.00E-04 Stroke / / pha002886 rs7523477 chr1 205048383 T C 7.71E-05 Waist Circumference / / pha003024 rs11240352 chr1 205051711 G C 8.83E-07 Red blood cell traits / / 23222517 rs4950979 chr1 205052939 G A 9.92E-05 Weight TMEM81 cds-synon pha003026 rs7520752 chr1 205054114 A G 9.13E-07 Red blood cell traits / / 23222517 rs2369526 chr1 205054406 C T 1.97E-04 Blood pressure / / 17255346 rs12139373 chr1 205054879 A C 9.42E-08 Red blood cell traits / / 23222517 rs10158848 chr1 205061192 C T 8.74E-07 Red blood cell traits RBBP5 intron 23222517 rs3738154 chr1 205063949 C T 4.11E-04 Insulin resistance RBBP5 intron 21901158 rs11577406 chr1 205065733 G T 4.73E-07 Red blood cell traits RBBP5 intron 23222517 rs11240357 chr1 205070522 C T 8.89E-04 Multiple complex diseases RBBP5 intron 17554300 rs11240358 chr1 205070573 G A 4.12E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain RBBP5 intron 20154673 rs11240358 chr1 205070573 G A 8.91E-04 Response to taxane treatment (placlitaxel) RBBP5 intron 23006423 rs3738155 chr1 205074424 C T 3.24E-07 Red blood cell traits RBBP5 intron 23222517 rs12125465 chr1 205074854 C A 3.13E-07 Red blood cell traits RBBP5 intron 23222517 rs4950982 chr1 205078247 T C 7.95E-04 Stroke RBBP5 intron pha002886 rs4950982 chr1 205078247 T C 8.24E-05 Waist Circumference RBBP5 intron pha003024 rs11240360 chr1 205083865 T C 2.05E-07 Red blood cell traits RBBP5 intron 23222517 rs7515178 chr1 205084120 G A 8.51E-05 IgE levels in asthmatics (D.p. specific) RBBP5 intron 23967269 rs6700182 chr1 205092374 A G 8.24E-05 Waist Circumference / / pha003024 rs3862948 chr1 205099959 C A 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6675633 chr1 205100480 G A 3.82E-07 Red blood cell traits / / 23222517 rs3862949 chr1 205103070 A T 5.66E-07 Red blood cell traits / / 23222517 rs10900450 chr1 205106238 C G 6.07E-04 Multiple complex diseases / / 17554300 rs10900450 chr1 205106238 C G 5.50E-07 Red blood cell traits / / 23222517 rs4394715 chr1 205108393 T G 2.42E-07 Red blood cell traits / / 23222517 rs11240368 chr1 205110929 T C 9.01E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs11240368 chr1 205110929 T C 8.24E-05 Waist Circumference / / pha003024 rs2836 chr1 205111761 A C 2.25E-04 Blood pressure DSTYK UTR-3 17255346 rs2836 chr1 205111761 A C 5.18E-08 Red blood cell traits DSTYK UTR-3 23222517 rs11240369 chr1 205115099 G A 2.21E-07 Red blood cell traits DSTYK UTR-3 23222517 rs11240370 chr1 205118336 T G 8.15E-07 Red blood cell traits DSTYK intron 23222517 rs12142514 chr1 205122529 A G 2.68E-05 Glaucoma (primary open-angle) DSTYK intron 22605921 rs12142514 chr1 205122529 A G 5.15E-07 Red blood cell traits DSTYK intron 23222517 rs10751431 chr1 205128059 C T 1.41E-07 Red blood cell traits DSTYK intron 23222517 rs4951172 chr1 205137578 G A 1.21E-07 Red blood cell traits DSTYK intron 23222517 rs10900456 chr1 205145005 C T 2.31E-07 Red blood cell traits DSTYK intron 23222517 rs11240376 chr1 205146460 A G 1.72E-07 Red blood cell traits DSTYK intron 23222517 rs10900461 chr1 205153208 C T 3.78E-07 Red blood cell traits DSTYK intron 23222517 rs10900462 chr1 205153312 G A 1.80E-07 Red blood cell traits DSTYK intron 23222517 rs3851285 chr1 205155753 C T 2.25E-07 Red blood cell traits DSTYK intron 23222517 rs10900464 chr1 205157100 T C 1.73E-07 Red blood cell traits DSTYK intron 23222517 rs12042196 chr1 205157759 C T 8.36E-05 Schizophrenia DSTYK intron 19571811 rs10900465 chr1 205158183 C T 2.49E-07 Red blood cell traits DSTYK intron 23222517 rs6692706 chr1 205158561 G T 2.93E-07 Red blood cell traits DSTYK intron 23222517 rs10900468 chr1 205163057 A G 2.71E-07 Red blood cell traits DSTYK intron 23222517 rs10900468 chr1 205163057 A G 5.30E-05 Blood Pressure DSTYK intron pha003046 rs10900468 chr1 205163057 A G 9.14E-05 Blood Pressure DSTYK intron pha003048 rs11588199 chr1 205164580 C T 2.19E-07 Red blood cell traits DSTYK intron 23222517 rs12129162 chr1 205164650 A G 2.96E-07 Red blood cell traits DSTYK intron 23222517 rs4333898 chr1 205169613 C T 2.49E-07 Red blood cell traits DSTYK intron 23222517 rs11240384 chr1 205172175 C T 2.66E-07 Red blood cell traits DSTYK intron 23222517 rs11240385 chr1 205173101 A G 2.49E-07 Red blood cell traits DSTYK intron 23222517 rs6682400 chr1 205173519 T G 1.28E-07 Red blood cell traits DSTYK intron 23222517 rs11240388 chr1 205177617 G A 1.49E-07 Red blood cell traits DSTYK intron 23222517 rs11240390 chr1 205179457 A G 2.34E-07 Red blood cell traits DSTYK intron 23222517 rs76872152 chr1 205180410 C T 5.00E-06 Obesity-related traits DSTYK missense 23251661 rs10900472 chr1 205181526 T C 6.61E-04 Multiple complex diseases / / 17554300 rs10900472 chr1 205181526 T C 1.89E-07 Red blood cell traits / / 23222517 rs6659069 chr1 205182031 A G 7.98E-08 Red blood cell traits / / 23222517 rs6664706 chr1 205182563 T C 4.75E-08 Red blood cell traits / / 23222517 rs12140422 chr1 205187981 G A 7.94E-09 Red blood cell traits / / 23222517 rs7531256 chr1 205191202 T G 2.26E-04 Blood pressure / / 17255346 rs7531256 chr1 205191202 T G 1.87E-09 Red blood cell traits / / 23222517 rs7513642 chr1 205195831 C T 4.42E-04 Multiple complex diseases / / 17554300 rs896320 chr1 205205347 T C 1.10E-07 Red blood cell traits TMCC2 intron 23222517 rs1172161 chr1 205206495 C T 1.76E-04 Blood pressure TMCC2 intron 17255346 rs1172161 chr1 205206495 C T 1.23E-08 Red blood cell traits TMCC2 intron 23222517 rs1172159 chr1 205207512 T C 1.51E-07 Red blood cell traits TMCC2 intron 23222517 rs1078362 chr1 205209530 A G 8.41E-08 Red blood cell traits TMCC2 intron 23222517 rs1172140 chr1 205213024 G A 1.01E-08 Red blood cell traits TMCC2 intron 23222517 rs1172139 chr1 205213962 G A 1.28E-04 Blood pressure TMCC2 intron 17255346 rs1172139 chr1 205213962 G A 4.84E-09 Red blood cell traits TMCC2 intron 23222517 rs748012 chr1 205216573 G A 6.76E-09 Red blood cell traits TMCC2 intron 23222517 rs4400674 chr1 205218425 C A 9.40E-08 Red blood cell traits TMCC2 intron 23222517 rs1172156 chr1 205220087 G A 1.39E-07 Red blood cell traits TMCC2 intron 23222517 rs1172154 chr1 205220639 T G 2.10E-08 Red blood cell traits TMCC2 intron 23222517 rs1172153 chr1 205220661 T C 2.56E-08 Red blood cell traits TMCC2 intron 23222517 rs1172152 chr1 205220718 T A 1.80E-08 Red blood cell traits TMCC2 intron 23222517 rs1172151 chr1 205221659 T G 2.93E-07 Red blood cell traits TMCC2 intron 23222517 rs1172150 chr1 205221861 A G 3.18E-08 Red blood cell traits TMCC2 intron 23222517 rs1172149 chr1 205224758 A G 2.00E-08 Red blood cell traits TMCC2 intron 23222517 rs1172147 chr1 205225457 G A 2.15E-08 Red blood cell traits TMCC2 intron 23222517 rs1151785 chr1 205232299 C T 6.01E-08 Red blood cell traits TMCC2 intron 23222517 rs1151784 chr1 205232447 C T 1.76E-08 Red blood cell traits TMCC2 intron 23222517 rs1172111 chr1 205232980 G A 3.03E-08 Red blood cell traits TMCC2 intron 23222517 rs1177720 chr1 205234428 C T 3.29E-07 Red blood cell traits TMCC2 intron 23222517 rs7367930 chr1 205235512 A G 4.08E-08 Red blood cell traits TMCC2 intron 23222517 rs1668873 chr1 205235990 G A 1.00E-20 Mean platelet volume TMCC2 intron 19820697 rs1668873 chr1 205235990 G A 1.40E-20 Mean platelet volume TMCC2 intron 22423221 rs1668873 chr1 205235990 G A 3.24E-09 Red blood cell traits TMCC2 intron 23222517 rs4951182 chr1 205236233 A C 3.03E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain TMCC2 intron 20154673 rs1768587 chr1 205236432 C T 1.07E-08 Red blood cell traits TMCC2 intron 23222517 rs1668871 chr1 205237137 T C 1.78E-05 Blood pressure TMCC2 intron 17255346 rs1668871 chr1 205237137 T C 3.00E-14 Platelet counts TMCC2 intron 22139419 rs1668871 chr1 205237137 T C 1.26E-08 Red blood cell traits TMCC2 intron 23222517 rs1768586 chr1 205238275 A G 1.75E-04 Blood pressure TMCC2 cds-synon 17255346 rs1768586 chr1 205238275 A G 6.89E-09 Red blood cell traits TMCC2 cds-synon 23222517 rs1779411 chr1 205238530 C T 4.64E-08 Red blood cell traits TMCC2 cds-synon 23222517 rs1768585 chr1 205239121 C G 2.30E-08 Red blood cell traits TMCC2 intron 23222517 rs1668869 chr1 205239779 G C 9.52E-09 Red blood cell traits TMCC2 intron 23222517 rs1668867 chr1 205240251 C T 1.81E-08 Red blood cell traits TMCC2 cds-synon 23222517 rs4951184 chr1 205240659 T A 1.91E-08 Red blood cell traits TMCC2 intron 23222517 rs1172132 chr1 205242901 A G 4.04E-07 Red blood cell traits / / 23222517 rs1172130 chr1 205244953 G A 4.00E-27 Mean platelet volume / / 22139419 rs1172130 chr1 205244953 G A 7.03E-09 Red blood cell traits / / 23222517 rs1172130 chr1 205244953 G A 6.00E-13 Mean platelet volume / / 24026423 rs1172129 chr1 205244972 T A 3.23E-08 Red blood cell traits / / 23222517 rs1172137 chr1 205246061 G T 7.84E-07 Red blood cell traits / / 23222517 rs1172136 chr1 205247097 T G 7.12E-09 Red blood cell traits / / 23222517 rs1779410 chr1 205248759 A G 8.21E-10 Red blood cell traits / / 23222517 rs9660992 chr1 205249450 A G 1.27E-05 Blood pressure / / 17255346 rs9660992 chr1 205249450 A G 7.08E-10 Red blood cell traits / / 23222517 rs9660992 chr1 205249450 A G 3.00E-13 Mean platelet volume / / 24026423 rs12092492 chr1 205251880 T C 4.07E-08 Red blood cell traits / / 23222517 rs1151787 chr1 205254238 G A 5.04E-09 Red blood cell traits / / 23222517 rs1180734 chr1 205255438 T C 1.33E-08 Red blood cell traits / / 23222517 rs1562866 chr1 205257338 T C 7.30E-04 Asthma / / 20698975 rs1562866 chr1 205257338 T C 3.38E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1172122 chr1 205261174 T C 5.65E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs10157145 chr1 205261963 T C 4.12E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs10157145 chr1 205261963 T C 4.72E-05 Waist-Hip Ratio / / pha003029 rs17345816 chr1 205262868 A T 1.40E-08 Red blood cell traits / / 23222517 rs12128254 chr1 205268097 C T 2.26E-08 Red blood cell traits / / 23222517 rs17345997 chr1 205279612 C T 7.21E-06 Acute lymphoblastic leukemia (childhood) NUAK2 intron 19684603 rs963550 chr1 205330243 A C 1.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1984292 chr1 205336543 C G 6.68E-05 Relative hand skill / / 24068947 rs6676552 chr1 205336875 C T 6.10E-05 Relative hand skill / / 24068947 rs16855560 chr1 205389460 T C 6.01E-04 Coronary Artery Disease LEMD1 intron 17634449 rs12145634 chr1 205398564 G A 6.48E-04 Common variable immunodeficiency / / 21497890 rs10900493 chr1 205423893 G A 2.49E-05 F-cell distribution / / 21326311 rs6682726 chr1 205426620 G A 4.32E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4279903 chr1 205439769 G A 4.85E-04 Smoking initiation / / 24665060 rs12041346 chr1 205442885 T C 2.62E-04 Multiple complex diseases / / 17554300 rs12041346 chr1 205442885 T C 2.98E-05 Smoking initiation / / 24665060 rs2027288 chr1 205444187 A G 1.53E-04 Smoking initiation / / 24665060 rs6680582 chr1 205458163 T A 5.00E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2027286 chr1 205459511 T C 4.23E-04 Alzheimer's disease / / 17998437 rs2867890 chr1 205469756 A G 6.10E-06 Urinary metabolites / / 21572414 rs12127944 chr1 205483595 C G 4.00E-06 IgG glycosylation CDK18 intron 23382691 rs12127944 chr1 205483595 C G 6.00E-06 IgG glycosylation CDK18 intron 23382691 rs12042887 chr1 205499355 C A 3.45E-04 Lung function (forced expiratory volume in 1 second) CDK18 intron 17255346 rs12759507 chr1 205546615 C T 9.21E-04 Depression (quantitative trait) MFSD4 intron 20800221 rs7526132 chr1 205554085 G C 3.87E-05 Response to acetaminophen (hepatotoxicity) MFSD4 missense 21177773 rs7515820 chr1 205554095 A C 8.95E-04 Alcohol dependence MFSD4 cds-synon 21314694 rs10900518 chr1 205607514 C T 6.48E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2153903 chr1 205616849 G A 8.04E-06 Triglycerides / / 19074352 rs2153903 chr1 205616849 G A 8.04E-06 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs12409639 chr1 205638222 G A 2.00E-19 Prostate-specific antigen levels SLC45A3 intron 23269536 rs16856139 chr1 205638464 C T 2.49E-08 Parkinson's disease SLC45A3 intron 22438815 rs16856139 chr1 205638464 C T 2.00E-11 Prostate-specific antigen levels SLC45A3 intron 24919509 rs12132270 chr1 205660940 C T 3.03E-05 Parkinson's disease / / 21738487 rs1172198 chr1 205662718 G A 1.58E-09 Lymphocyte counts / / 22286170 rs12748961 chr1 205676263 T C 4.00E-08 White blood cell types / / 21738478 rs16856186 chr1 205678126 T G 9.00E-06 Pulmonary function decline / / 22424883 rs951366 chr1 205685352 T C 7.10E-04 Multiple complex diseases NUCKS1 UTR-3 17554300 rs823094 chr1 205689807 T G 2.00E-07 Pubertal anthropometrics NUCKS1 intron 23449627 rs188212039 chr1 205712530 G A 5.00E-06 Serum dimethylarginine levels (symmetric) NUCKS1 intron 24159190 rs823128 chr1 205713378 G A 7.00E-08 Parkinson's disease NUCKS1 intron 19915575 rs823128 chr1 205713378 G A 1.38E-11 Parkinson's disease NUCKS1 intron 22438815 rs823114 chr1 205719532 G A 2.12E-06 Parkinson's disease NUCKS1 nearGene-5 21738487 rs823114 chr1 205719532 G A 3.00E-06 Parkinson's disease NUCKS1 nearGene-5 24842889 rs823121 chr1 205724302 G A 8.27E-06 Multiple complex diseases / / 17554300 rs823122 chr1 205725028 C T 3.59E-08 Parkinson's disease / / 22438815 rs823122 chr1 205725028 C T 7.51E-05 Tuberculosis / / 24057671 rs823123 chr1 205725346 C T 6.53E-05 Tuberculosis / / 24057671 rs708723 chr1 205739266 C T 6.68E-05 Parkinson's disease RAB7L1 UTR-3 22451204 rs947211 chr1 205752665 A G 2.00E-12 Parkinson's disease / / 19915576 rs947211 chr1 205752665 A G 2.55E-05 Parkinson's disease / / 21738487 rs947211 chr1 205752665 A G 1.52E-12 Prion diseases / / 22210626 rs947211 chr1 205752665 A G 9.61E-11 Parkinson's disease / / 22438815 rs947211 chr1 205752665 A G 6.68E-04 Parkinson's disease / / 24842889 rs10494874 chr1 205754688 G C 3.03E-04 Coronary heart disease / / 21606135 rs12565968 chr1 205755046 G A 5.57E-05 Schizophrenia(age at onset) / / 21688384 rs6679073 chr1 205756484 C A 1.13E-04 Coronary heart disease / / 21606135 rs6679073 chr1 205756484 C A 7.90E-04 Alzheimer's disease / / 22005930 rs823154 chr1 205762406 C T 1.73E-05 Multiple complex diseases SLC41A1 intron 17554300 rs823156 chr1 205764640 G A 1.00E-07 Parkinson's disease SLC41A1 intron 21738487 rs823156 chr1 205764640 G A 2.09E-12 Parkinson's disease SLC41A1 intron 22438815 rs2224 chr1 205769551 G A 5.07E-04 Multiple complex diseases SLC41A1 intron 17554300 rs823066 chr1 205771173 A G 8.90E-05 Parkinson's disease SLC41A1 intron 21738487 rs708730 chr1 205777780 G A 2.10E-07 Parkinson's disease SLC41A1 intron 21738487 rs708730 chr1 205777780 G A 2.07E-07 Parkinson's disease SLC41A1 intron 22438815 rs823091 chr1 205792836 T C 7.69E-04 Multiple complex diseases / / 17554300 rs823088 chr1 205794175 C T 4.28E-04 Multiple complex diseases / / 17554300 rs16856400 chr1 205803724 A C 9.05E-04 Multiple complex diseases PM20D1 intron 17554300 rs954206 chr1 205807504 C T 7.91E-04 Alzheimer's disease PM20D1 intron 22005930 rs11240572 chr1 205808013 C A 6.11E-07 Parkinson's disease PM20D1 intron 19915575 rs11240572 chr1 205808013 C A 2.25E-17 Parkinson's disease PM20D1 intron 22438815 rs11240574 chr1 205813672 T C 4.83E-04 Alzheimer's disease (late onset) PM20D1 intron 21379329 rs7517009 chr1 205815992 C T 7.49E-06 Response to statin treatment (atorvastatin),change in cholesterol levels PM20D1 intron 20031582 rs12028467 chr1 205859798 G C 6.86E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) LOC284581 intron 24236485 rs7365031 chr1 205867013 T C 9.29E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12757540 chr1 205887389 C A 1.90E-05 Urinary metabolites SLC26A9 intron 21572414 rs3811429 chr1 205887774 A G 6.54E-05 Serum albumin level SLC26A9 intron pha003084 rs12727528 chr1 205894602 G A 1.70E-04 Multiple complex diseases SLC26A9 intron 17554300 rs11240594 chr1 205896235 G A 1.00E-07 Response to antipsychotic treatment SLC26A9 intron 21107309 rs7512462 chr1 205899595 T C 9.33E-04 Myopia (pathological) SLC26A9 intron 21095009 rs7512462 chr1 205899595 T C 2.03E-08 Cystic fibrosis (meconium ileus) SLC26A9 intron 22466613 rs7512462 chr1 205899595 T C 2.90E-07 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs7512462 chr1 205899595 T C 6.86E-05 Tunica Media SLC26A9 intron pha003034 rs7521316 chr1 205907796 T C 5.34E-07 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs2036100 chr1 205907872 C G 7.40E-08 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs1874361 chr1 205908186 A C 1.60E-08 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs11240598 chr1 205908630 C G 1.28E-06 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs7555534 chr1 205908867 C T 8.80E-08 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs6593975 chr1 205909276 C T 6.57E-07 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs6593976 chr1 205909285 A C 6.16E-07 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs61814953 chr1 205910080 T C 8.04E-08 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs6673820 chr1 205910604 A G 2.40E-05 Response to statin therapy SLC26A9 intron 20339536 rs6673820 chr1 205910604 A G 2.41E-07 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs6661355 chr1 205910631 C T 2.30E-05 Response to statin therapy SLC26A9 intron 20339536 rs6661355 chr1 205910631 C T 1.48E-07 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs7415921 chr1 205910883 G T 1.80E-07 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs1342061 chr1 205911385 T A 1.09E-07 Cystic fibrosis-related diabetes SLC26A9 intron 23670970 rs1342062 chr1 205912786 G T 1.70E-06 Cystic fibrosis-related diabetes / / 23670970 rs1342063 chr1 205912859 C T 2.96E-08 Cystic fibrosis-related diabetes / / 23670970 rs1342064 chr1 205913073 T C 3.27E-08 Cystic fibrosis-related diabetes / / 23670970 rs4951030 chr1 205913747 T A 5.56E-07 Cystic fibrosis-related diabetes / / 23670970 rs4951271 chr1 205913848 A G 1.73E-08 Cystic fibrosis-related diabetes / / 23670970 rs4077468 chr1 205914757 A G 9.44E-09 Cystic fibrosis (meconium ileus) / / 22466613 rs4077468 chr1 205914757 A G 1.00E-09 Cystic fibrosis-related diabetes / / 23670970 rs4077469 chr1 205914885 C T 2.50E-08 Cystic fibrosis-related diabetes / / 23670970 rs12047830 chr1 205916699 G A 3.26E-06 Cystic fibrosis (meconium ileus) / / 22466613 rs7419153 chr1 205917309 G A 9.00E-05 Response to statin therapy / / 20339536 rs7419153 chr1 205917309 G A 1.22E-07 Cystic fibrosis (meconium ileus) / / 22466613 rs7419153 chr1 205917309 G A 2.00E-06 Cystic fibrosis-related diabetes / / 23670970 rs7419153 chr1 205917309 G A 4.44E-05 Tunica Media / / pha003034 rs7418300 chr1 205918020 C G 1.65E-06 Cystic fibrosis-related diabetes / / 23670970 rs28373064 chr1 206223556 A G 9.22E-05 Cognitive impairment induced by topiramate / / 22091778 rs28607590 chr1 206230548 G C 2.00E-04 Cognitive impairment induced by topiramate AVPR1B intron 22091778 rs2244510 chr1 206595069 T C 1.35E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11120040 chr1 206601326 C T 7.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2297539 chr1 206603535 G A 2.00E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4845104 chr1 206609320 T C 3.24E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2483064 chr1 206614772 A G 5.06E-05 Heart Rate / / pha003053 rs6701879 chr1 206617766 T C 3.30E-04 Mathematical ability / / 20039944 rs2336938 chr1 206618799 A C 1.31E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2336938 chr1 206618799 A C 7.09E-05 Heart Rate / / pha003053 rs10158553 chr1 206621247 T G 0.00000877 Femoral neck bone mineral density (premenopausal) / / 23074152 rs10158553 chr1 206621247 T G 0.000455 Lumbar spine bone mineral density (premenopausal) / / 23074152 rs2480408 chr1 206624018 G A 8.19E-30 Narcolepsy / / 19629137 rs2483058 chr1 206626828 C G 4.10E-04 Atrial fibrillation / / 21846873 rs2483058 chr1 206626828 C G 9.00E-07 Cholesterol and Triglycerides / / 23031429 rs3813982 chr1 206629674 A G 2.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs3813982 chr1 206629674 A G 5.14E-05 Heart Rate / / pha003053 rs7546842 chr1 206630721 G A 3.00E-04 Multiple complex diseases / / 17554300 rs41303986 chr1 206643795 C T 3.46E-04 Taste perception IKBKE UTR-5 22132133 rs2297546 chr1 206648037 C G 8.10E-05 Parkinson's disease (age of onset) IKBKE intron 19772629 rs11118087 chr1 206656577 G A 0.00039 Coronary artery calcification IKBKE intron 23727086 rs944775 chr1 206668593 T C 5.81E-05 Celiac disease IKBKE intron 23936387 rs15672 chr1 206669958 G A 6.81E-05 Celiac disease IKBKE UTR-3 23936387 rs3860295 chr1 206676331 G A 1.16E-04 Celiac disease / / 23936387 rs11118968 chr1 206698249 G A 2.45E-07 Autism RASSF5 intron 22843504 rs9661909 chr1 206714818 C T 2.07E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) RASSF5 intron 23648065 rs11811181 chr1 206724737 G A 1.81E-05 Brain structure RASSF5 intron 22504417 rs12569261 chr1 206727260 A G 1.10E-05 Brain structure RASSF5 intron 22504417 rs2210517 chr1 206729593 G A 2.04E-05 Brain structure RASSF5 intron 22504417 rs10442694 chr1 206733417 C T 6.92E-05 Migraine RASSF5 intron 23793025 rs3813973 chr1 206775390 G A 1.60E-05 Urinary metabolites EIF2D intron 21572414 rs6685813 chr1 206784809 T C 1.82E-05 Cognitive test performance EIF2D intron 20125193 rs6677934 chr1 206788458 A G 8.11E-05 Alcohol withdrawal symptoms / / 22072270 rs7546458 chr1 206797993 A C 3.81E-04 Multiple complex diseases / / 17554300 rs12140898 chr1 206846600 T C 7.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs10863787 chr1 206876797 C G 8.93E-04 Suicide attempts in bipolar disorder MAPKAPK2 intron 21423239 rs12060808 chr1 206877337 C T 6.61E-04 Suicide attempts in bipolar disorder MAPKAPK2 intron 21423239 rs4548444 chr1 206890138 A G 8.27E-05 Blood Pressure MAPKAPK2 intron pha002898 rs4147011 chr1 206912501 A G 5.44E-05 Taste perception / / 22132133 rs4845133 chr1 206915334 C G 9.11E-04 Alcohol dependence / / 21314694 rs11119451 chr1 206925681 G C 4.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs3024505 chr1 206939904 G A 1.00E-12 Ulcerative colitis / / 18836448 rs3024505 chr1 206939904 G A 2.00E-09 Type 1 diabetes / / 19430480 rs3024505 chr1 206939904 G A 1.00E-08 Ulcerative colitis / / 20228799 rs3024505 chr1 206939904 G A 2.00E-14 Crohn's disease / / 21102463 rs3024505 chr1 206939904 G A 6.00E-17 Ulcerative colitis / / 21297633 rs3024505 chr1 206939904 G A 5.00E-10 Type 1 diabetes autoantibodies / / 21829393 rs3024505 chr1 206939904 G A 4.00E-08 Multiple sclerosis / / 22190364 rs3024505 chr1 206939904 G A 7.00E-42 Inflammatory bowel disease / / 23128233 rs3024493 chr1 206943968 C A 8.00E-08 Ulcerative colitis IL10 intron 19915572 rs3024493 chr1 206943968 C A 1.00E-12 Ulcerative colitis IL10 intron 20228798 rs3024493 chr1 206943968 C A 2.01E-08 Type 1 diabetes IL10 intron 21980299 rs1554286 chr1 206944233 A G 8.28E-04 Coronary Artery Disease IL10 intron 17634449 rs1554286 chr1 206944233 A G 3.48E-04 Lymphocyte counts IL10 intron 22286170 rs1518111 chr1 206944645 T C 4.00E-18 Behcet's disease IL10 intron 20622878 rs3024490 chr1 206945311 A C 3.02E-07 Behcet's disease IL10 intron 23291587 rs3024490 chr1 206945311 A C 2.22E-07 Behcet's disease IL10 intron pha002888 rs1800871 chr1 206946634 A G 1.00E-14 Behcet's disease IL10 nearGene-5 20622879 rs1800871 chr1 206946634 A G 3.02E-07 Behcet's disease IL10 nearGene-5 23291587 rs1800894 chr1 206946666 C T 0.000851 Colorectal cancer vs. adenoma controls (females) IL10 nearGene-5 22532847 rs17351243 chr1 206959527 G A 8.42E-05 Ulcerative colitis / / 19915573 rs12075255 chr1 206961628 A G 1.87E-05 Ulcerative colitis / / 19915573 rs885334 chr1 206962416 C T 1.98E-05 Ulcerative colitis / / 19915573 rs11583394 chr1 206968893 C T 5.60E-06 Ulcerative colitis / / 19915573 rs2243173 chr1 207011458 T A 8.67E-04 Multiple complex diseases IL19 intron 17554300 rs4845144 chr1 207016648 G A 3.72E-04 Multiple complex diseases / / 17554300 rs574773 chr1 207032751 C T 2.00E-06 Economic and political preferences / / 22566634 rs2981573 chr1 207040577 G A 1.01E-04 Multiple complex diseases IL20 intron 17554300 rs291089 chr1 207059121 G A 1.16E-08 Metabolite levels / / 23281178 rs1713235 chr1 207061772 C T 1.12E-08 Metabolite levels / / 23281178 rs372258579 chr1 207061772 CT CCT,CTG 1.12E-08 Metabolite levels / / 23281178 rs12022348 chr1 207064400 A G 1.95E-08 Metabolite levels / / 23281178 rs3860300 chr1 207064918 C G 1.95E-08 Metabolite levels / / 23281178 rs6540701 chr1 207065770 T C 1.95E-08 Metabolite levels / / 23281178 rs6540703 chr1 207065806 T A 1.95E-08 Metabolite levels / / 23281178 rs4845147 chr1 207066383 C T 1.95E-08 Metabolite levels / / 23281178 rs1856748 chr1 207067840 T C 2.07E-08 Metabolite levels / / 23281178 rs1150253 chr1 207071595 G A 9.04E-08 Metabolite levels IL24 intron 23281178 rs291109 chr1 207072151 T C 2.82E-08 Metabolite levels IL24 intron 23281178 rs1150254 chr1 207072515 T C 9.17E-08 Metabolite levels IL24 intron 23281178 rs1150256 chr1 207073133 G A 9.50E-08 Metabolite levels IL24 intron 23281178 rs1150258 chr1 207074905 T A,C,G 9.50E-08 Metabolite levels IL24 missense 23281178 rs291107 chr1 207075171 T C 2.82E-08 Metabolite levels IL24 intron 23281178 rs94872 chr1 207086845 T C 2.26E-08 Metabolite levels FAIM3 intron 23281178 rs483850 chr1 207089971 T A 5.57E-09 Metabolite levels FAIM3 intron 23281178 rs1356495 chr1 207093202 C A,G,T 0.000384 Salmonella-induced pyroptosis FAIM3 intron 22837397 rs291100 chr1 207104813 T C 6.50E-04 IgA nephropathy PIGR intron 12740691 rs291102 chr1 207106478 G A 3.00E-04 IgA nephropathy PIGR missense 12740691 rs291102 chr1 207106478 G A 6.84E-05 stroke (ischemic) PIGR missense 17434096 rs503746 chr1 207109425 A G 3.00E-04 IgA nephropathy PIGR intron 12740691 rs291097 chr1 207110888 G A 6.84E-05 stroke (ischemic) PIGR cds-synon 17434096 rs291096 chr1 207110936 T C 3.00E-04 IgA nephropathy PIGR cds-synon 12740691 rs291092 chr1 207113230 T G 4.42E-04 Type 2 diabetes PIGR intron 17463246 rs291092 chr1 207113230 T G 3.96E-04 Multiple complex diseases PIGR intron 17554300 rs291091 chr1 207113679 T C 6.78E-09 Metabolite levels PIGR intron 23281178 rs12136238 chr1 207118422 G A 5.50E-04 IgA nephropathy PIGR intron 12740691 rs2275529 chr1 207119853 C A 5.50E-04 IgA nephropathy PIGR nearGene-5 12740691 rs4844555 chr1 207120930 C T 6.66E-09 Metabolite levels PIGR nearGene-5 23281178 rs11119938 chr1 207141792 C G 2.27E-04 Multiple complex diseases FCAMR intron 17554300 rs1856746 chr1 207143422 A G 8.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) FCAMR intron 23648065 rs12066378 chr1 207144619 T C 4.19E-04 Multiple complex diseases / / 17554300 rs2353550 chr1 207146837 A G 2.90E-06 Glioma (high-grade) / / 19578366 rs6687771 chr1 207156274 T C 4.14E-04 Multiple complex diseases / / 17554300 rs2791708 chr1 207162433 T C 7.67E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs2054780 chr1 207221612 C T 9.69E-05 Age-related macular degeneration YOD1 UTR-3 21197116 rs2054780 chr1 207221612 C T 4.60E-05 Age-related macular degeneration YOD1 UTR-3 pha002856 rs2243816 chr1 207241281 G A 9.18E-05 Age-related macular degeneration PFKFB2 intron pha002856 rs17258746 chr1 207252647 T A 1.24E-04 Body mass index PFKFB2 UTR-3 21701565 rs17258746 chr1 207252647 T A 1.88E-04 Body mass index PFKFB2 UTR-3 21701565 rs12088135 chr1 207252911 C T 6.19E-04 Alcohol dependence PFKFB2 UTR-3 21314694 rs6673422 chr1 207253487 A G 2.94E-04 Body mass index PFKFB2 UTR-3 21701565 rs6673422 chr1 207253487 A G 6.24E-05 Body mass index PFKFB2 UTR-3 21701565 rs4142863 chr1 207255654 C T 3.06E-04 Body mass index / / 21701565 rs4142863 chr1 207255654 C T 7.66E-04 Body mass index / / 21701565 rs12045707 chr1 207256205 C T 5.29E-04 Body mass index / / 21701565 rs2353545 chr1 207261196 A G 3.42E-04 Body mass index C4BPB nearGene-5 21701565 rs2353545 chr1 207261196 A G 9.53E-05 Body mass index C4BPB nearGene-5 21701565 rs3813948 chr1 207269858 T C 4.00E-10 C4b binding protein levels C4BPB intron 20212171 rs2842704 chr1 207289436 G A 8.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C4BPA intron 20877124 rs9943077 chr1 207295298 T C 1.59E-04 Body mass index C4BPA intron 21701565 rs9943077 chr1 207295298 T C 4.57E-05 Body mass index C4BPA intron 21701565 rs891373 chr1 207414244 T C 8.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs7545125 chr1 207424727 A G 5.60E-04 Addiction / / 17099884 rs2564978 chr1 207494416 T C 5.00E-05 Asthma (aspirin-intolerant) CD55 nearGene-5 21072201 rs2564978 chr1 207494416 T C 0.0005 H1N1 influenza A virus infection CD55 nearGene-5 22693232 rs6667140 chr1 207570177 A G 8.57E-05 Coronary heart disease / / pha003030 rs12734973 chr1 207596652 T C 3.08E-06 Elbow pain / / pha003008 rs17045328 chr1 207652176 A G 7.00E-06 Type 2 diabetes CR2 intron 21490949 rs4317805 chr1 207652992 A G 7.73E-04 Suicide attempts in bipolar disorder CR2 intron 21423239 rs4317805 chr1 207652992 A G 7.25E-05 Hypertension CR2 intron pha003042 rs2182912 chr1 207660344 T A 6.19E-05 Alzheimer's disease CR2 intron 19734903 rs2182912 chr1 207660344 T A 5.30E-05 Alzheimer's disease (late onset) CR2 intron 21460841 rs7519408 chr1 207661289 G C 3.10E-06 Urinary metabolites CR2 intron 21572414 rs11117913 chr1 207668235 C T 8.65E-04 Multiple complex diseases CR1 nearGene-5 17554300 rs4844597 chr1 207671269 C T 5.79E-05 Alzheimer's disease CR1 intron 19734903 rs4844597 chr1 207671269 C T 4.70E-05 Alzheimer's disease (late onset) CR1 intron 21460841 rs4274065 chr1 207671476 C T 5.90E-05 Alzheimer's disease CR1 intron 19734903 rs4274065 chr1 207671476 C T 4.70E-05 Alzheimer's disease (late onset) CR1 intron 21460841 rs4310446 chr1 207676604 C T 3.07E-05 Alzheimer's disease (late onset) CR1 intron 21460841 rs9429945 chr1 207676768 T C 8.99E-05 Alzheimer's disease (late onset) CR1 intron 21460841 rs4844599 chr1 207679229 T G 1.63E-10 Inflammatory biomarkers CR1 intron 22291609 rs12567973 chr1 207681501 C G,T 1.50E-10 Inflammatory biomarkers CR1 intron 22291609 rs12567990 chr1 207681685 C T 1.50E-10 Inflammatory biomarkers CR1 intron 22291609 rs11117956 chr1 207684359 T G 2.56E-10 Inflammatory biomarkers CR1 intron 22291609 rs11117959 chr1 207684519 A G 1.50E-10 Inflammatory biomarkers CR1 intron 22291609 rs10863358 chr1 207690871 G C 3.57E-10 Inflammatory biomarkers CR1 intron 22291609 rs6656401 chr1 207692049 A G 3.00E-10 Alzheimer's disease CR1 intron 19734903 rs6656401 chr1 207692049 A G 5.16E-09 Alzheimer's disease (late onset) CR1 intron 21460841 rs6656401 chr1 207692049 A G 6.00E-24 Alzheimer's disease (late onset) CR1 intron 24162737 rs3886100 chr1 207739127 A G 7.93E-10 Inflammatory biomarkers CR1 intron 22291609 rs17046851 chr1 207747984 A G 2.84E-10 Inflammatory biomarkers CR1 intron 22291609 rs650877 chr1 207748793 A G 8.98E-10 Inflammatory biomarkers CR1 intron 22291609 rs12757487 chr1 207749188 G A 6.19E-10 Inflammatory biomarkers CR1 intron 22291609 rs599948 chr1 207752239 T C 2.22E-09 Inflammatory biomarkers CR1 intron 22291609 rs601356 chr1 207752550 T G 3.71E-09 Inflammatory biomarkers CR1 intron 22291609 rs614709 chr1 207753275 T C 3.69E-09 Inflammatory biomarkers CR1 intron 22291609 rs2274566 chr1 207753345 C T 7.66E-10 Inflammatory biomarkers CR1 intron 22291609 rs2274567 chr1 207753621 A G 1.72E-10 Inflammatory biomarkers CR1 missense 22291609 rs12034598 chr1 207757515 A G 9.00E-14 Inflammatory biomarkers CR1 intron 22291609 rs646817 chr1 207757936 A G 3.74E-10 Inflammatory biomarkers CR1 intron 22291609 rs11118131 chr1 207761196 C T 3.00E-10 Inflammatory biomarkers CR1 intron 22291609 rs3738468 chr1 207762358 G A 3.03E-10 Inflammatory biomarkers CR1 intron 22291609 rs10779330 chr1 207762674 G A 3.04E-10 Inflammatory biomarkers CR1 intron 22291609 rs11118135 chr1 207770428 A G 4.03E-10 Inflammatory biomarkers CR1 intron 22291609 rs12141045 chr1 207772154 T C 4.10E-10 Inflammatory biomarkers CR1 intron 22291609 rs11118136 chr1 207772408 A G 4.12E-10 Inflammatory biomarkers CR1 intron 22291609 rs7539922 chr1 207773339 G A 6.05E-10 Inflammatory biomarkers CR1 intron 22291609 rs677066 chr1 207773991 T C 1.08E-09 Inflammatory biomarkers CR1 intron 22291609 rs11118157 chr1 207778319 C A 1.09E-09 Inflammatory biomarkers CR1 intron 22291609 rs11118166 chr1 207781995 A G 7.75E-10 Inflammatory biomarkers CR1 intron 22291609 rs11118167 chr1 207782154 T C 6.83E-10 Inflammatory biomarkers CR1 intron 22291609 rs6691117 chr1 207782931 A G 1.01E-09 Inflammatory biomarkers CR1 missense 22291609 rs12032275 chr1 207783507 C T 1.42E-09 Inflammatory biomarkers CR1 intron 22291609 rs3818361 chr1 207784968 A G 9.18E-06 Type 2 diabetes and other traits CR1 intron 19734900 rs3818361 chr1 207784968 A G 3.00E-10 Alzheimer's disease CR1 intron 19734903 rs3818361 chr1 207784968 A G 4.00E-14 Alzheimer's disease CR1 intron 21460840 rs3818361 chr1 207784968 A G 3.53E-09 Alzheimer's disease (late onset) CR1 intron 21460841 rs3818361 chr1 207784968 A G 9.20E-06 Prion diseases CR1 intron 22210626 rs7519119 chr1 207786152 G A 5.87E-10 Inflammatory biomarkers CR1 intron 22291609 rs7542544 chr1 207786223 C A 1.07E-09 Inflammatory biomarkers CR1 intron 22291609 rs6701713 chr1 207786289 A G 8.71E-06 Type 2 diabetes and other traits CR1 intron 19734900 rs6701713 chr1 207786289 A G 6.39E-06 Alzheimer's disease CR1 intron 19734903 rs6701713 chr1 207786289 A G 5.00E-10 Alzheimer's disease (late onset) CR1 intron 21460841 rs10429953 chr1 207788578 A G 7.07E-10 Inflammatory biomarkers CR1 intron 22291609 rs12734030 chr1 207793964 C T 1.84E-09 Inflammatory biomarkers CR1 intron 22291609 rs36066893 chr1 207793964 C CT 1.84E-09 Inflammatory biomarkers CR1 intron 22291609 rs2296160 chr1 207795320 A G 3.40E-06 Alzheimer's disease CR1 missense 19734903 rs2296160 chr1 207795320 A G 8.03E-09 Alzheimer's disease (late onset) CR1 missense 21460841 rs1408078 chr1 207800555 T C 3.40E-06 Alzheimer's disease CR1 intron 19734903 rs1408078 chr1 207800555 T C 8.03E-09 Alzheimer's disease (late onset) CR1 intron 21460841 rs4844610 chr1 207802552 A C 9.29E-06 Alzheimer's disease CR1 intron 19734903 rs4844610 chr1 207802552 A C 8.27E-09 Alzheimer's disease (late onset) CR1 intron 21460841 rs11803956 chr1 207803021 T C 7.49E-10 Inflammatory biomarkers CR1 intron 22291609 rs12041437 chr1 207803264 C A 7.47E-10 Inflammatory biomarkers CR1 intron 22291609 rs12034383 chr1 207803595 G A 2.00E-28 Erythrocyte sedimentation rate CR1 intron 21700265 rs12034383 chr1 207803595 G A 7.41E-10 Inflammatory biomarkers CR1 intron 22291609 rs12034383 chr1 207803595 G A 1.65E-05 LDL lipoproteins CR1 intron pha002902 rs1408077 chr1 207804141 A C 8.32E-06 Type 2 diabetes and other traits CR1 intron 19734900 rs1408077 chr1 207804141 A C 9.05E-06 Alzheimer's disease CR1 intron 19734903 rs1408077 chr1 207804141 A C 1.91E-08 Alzheimer's disease (late onset) CR1 intron 21460841 rs1408077 chr1 207804141 A C 7.24E-04 Response to cytadine analogues (cytosine arabinoside) CR1 intron 24483146 rs11803366 chr1 207806989 T C 1.47E-09 Inflammatory biomarkers CR1 intron 22291609 rs1323720 chr1 207823161 T C 6.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CR1L intron 20877124 rs1323722 chr1 207823405 C T 6.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CR1L intron 20877124 rs10863461 chr1 207840776 G A 6.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CR1L intron 20877124 rs7527798 chr1 207872290 T C 2.00E-09 Erythrocyte sedimentation rate CR1L intron 21700265 rs4844614 chr1 207875175 G T 2.00E-07 LDL cholesterol CR1L intron 19060910 rs4844614 chr1 207875175 G T 2.00E-07 Coronary heart disease CR1L intron 21347282 rs4844614 chr1 207875175 G T 2.38E-07 LDL lipoproteins CR1L intron pha002902 rs2724387 chr1 207932617 T G 3.32E-04 Amyotrophic lateral sclerosis (sporadic) CD46 intron 24529757 rs17006738 chr1 207936103 G A 1.62E-04 IgE levels CD46 intron 17255346 rs7545126 chr1 207938236 C T 9.00E-06 Obesity-related traits CD46 intron 23251661 rs11118555 chr1 207940853 T A 4.00E-26 Heart rate CD46 intron 23583979 rs2724375 chr1 207997973 C A 3.65E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12731740 chr1 208024820 C T 3.00E-09 Biomedical quantitative traits / / 19396169 rs2796241 chr1 208027459 C A 2.20E-05 Urinary metabolites / / 21572414 rs1967689 chr1 208039471 G C 5.00E-06 Age-related macular degeneration / / 23326517 rs2952 chr1 208049077 C T 2.33E-05 Osteoarthritis (knee and hip) / / 21177295 rs2952 chr1 208049077 C T 4.74E-05 Osteoarthritis (knee and hip) / / 21177295 rs2556 chr1 208060359 G A 2.35E-04 Suicide attempts in bipolar disorder CD34 UTR-3 21041247 rs2262269 chr1 208067651 A C 2.00E-04 Schizophrenia (treatment refractory) CD34 intron 22479419 rs2488250 chr1 208069877 G A 0.0006409 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CD34 intron 23233654 rs2488250 chr1 208069877 G A 6.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) CD34 intron 23233662 rs11118918 chr1 208095688 G T 1.43E-05 Diabetic nephropathy / / 21150874 rs11118918 chr1 208095688 G T 5.51E-04 Type 2 diabetes / / 22238593 rs2745960 chr1 208095701 T A 0.0004795 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2745960 chr1 208095701 T A 4.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12041505 chr1 208097796 G A 3.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs2473653 chr1 208101656 C T 0.0004845 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2473653 chr1 208101656 C T 4.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs560752 chr1 208106568 T C 9.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11580454 chr1 208124349 G A 0.0001566 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11580454 chr1 208124349 G A 1.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11118958 chr1 208125204 G C 0.000415 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11118958 chr1 208125204 G C 4.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2745967 chr1 208128722 G A 7.00E-08 Resting heart rate / / 20639392 rs11578508 chr1 208129065 A G 4.00E-10 Heart rate / / 23583979 rs12023412 chr1 208165338 C G 1.10E-05 Urinary metabolites / / 21572414 rs651480 chr1 208171368 C T 2.06E-05 Hearing function / / 17255346 rs3901316 chr1 208178218 T C 8.20E-06 Urinary metabolites / / 21572414 rs556625 chr1 208195981 C T 1.13E-04 Intracranial aneurysm PLX/2 UTR-3 22286173 rs591305 chr1 208197882 G C 1.23E-05 Response to methylphenidate treatment PLX/2 UTR-3 21130132 rs7520548 chr1 208205643 C A 0.000384 Salmonella-induced pyroptosis PLX/2 intron 22837397 rs2785622 chr1 208214504 T C 8.43E-04 Coronary Artery Disease PLX/2 intron 17634449 rs2274446 chr1 208252456 C T 7.37E-05 Lactate dehydrogenase levels PLX/2 intron 20981236 rs12083980 chr1 208278877 C T 8.71E-05 Multiple sclerosis (age of onset) PLX/2 intron 19010793 rs11118986 chr1 208279228 G A 5.89E-05 Multiple sclerosis (age of onset) PLX/2 intron 19010793 rs6671923 chr1 208325802 G A 5.19E-04 Multiple complex diseases PLX/2 intron 17554300 rs6671923 chr1 208325802 G A 3.50E-06 Fasting plasma glucose PLX/2 intron 19060907 rs1262049 chr1 208332650 T A 9.07E-04 Multiple complex diseases PLX/2 intron 17554300 rs2801201 chr1 208338095 G A 8.34E-08 Multiple complex diseases PLX/2 intron 17554300 rs2801201 chr1 208338095 G A 8.02E-06 Telomere length PLX/2 intron 20139977 rs11118997 chr1 208339601 G A 9.47E-04 Multiple complex diseases PLX/2 intron 17554300 rs4406633 chr1 208350952 G A 6.90E-04 Schizophrenia (treatment refractory) PLX/2 intron 22479419 rs2489774 chr1 208361527 C T 4.44E-04 Multiple complex diseases PLX/2 intron 17554300 rs2489774 chr1 208361527 C T 8.67E-04 Coronary Artery Disease PLX/2 intron 17634449 rs11590686 chr1 208368201 C T 2.30E-05 Schizophrenia (treatment refractory) PLX/2 intron 22479419 rs7525987 chr1 208373312 T C 2.47E-04 Multiple complex diseases PLX/2 intron 17554300 rs3748735 chr1 208390469 C T 2.12E-04 Amyotrophic Lateral Sclerosis PLX/2 missense 17362836 rs1262046 chr1 208400492 C T 1.87E-06 Cognitive decline PLX/2 intron 23207651 rs2782934 chr1 208408503 A G 6.12E-05 Response to statin treatment (atorvastatin),change in cholesterol levels PLX/2 intron 20031582 rs2782934 chr1 208408503 A G 7.05E-04 Myocardial Infarction PLX/2 intron pha002883 rs1272623 chr1 208410635 T G 5.67E-05 Cognitive test performance PLX/2 intron 20125193 rs11588788 chr1 208442000 G A 5.50E-05 Parkinson's disease (age of onset) / / 19772629 rs2590691 chr1 208445800 C T 6.70E-06 Urinary metabolites / / 21572414 rs2590691 chr1 208445800 C T 7.79E-05 Blood Pressure / / pha003044 rs2440902 chr1 208446359 G A 4.20E-06 Urinary metabolites / / 21572414 rs1781026 chr1 208463935 A G 4.53E-05 Blood Pressure / / pha003044 rs718242 chr1 208464910 A C 5.45E-05 Blood Pressure / / pha003044 rs7515725 chr1 208470708 T C 7.64E-05 Blood Pressure / / pha003044 rs6540465 chr1 208479203 T C 5.14E-06 Multiple complex diseases / / 17554300 rs6702300 chr1 208485874 G A 0.000278861 Hypertension (early onset hypertension) / / 22479346 rs17259513 chr1 208510207 T C 9.33E-04 Multiple complex diseases / / 17554300 rs6695225 chr1 208513728 G A 8.87E-05 Blood Pressure / / pha003044 rs17012410 chr1 208517277 G A 3.76E-04 Rheumatoid arthritis / / 21452313 rs6694253 chr1 208518783 G C 0.0001518 Sarcoidosis / / 22952805 rs12406933 chr1 208525983 C T 6.25E-04 Smoking initiation / / 24665060 rs6677524 chr1 208535774 T G 2.59E-04 Multiple complex diseases / / 17554300 rs10779476 chr1 208543562 C T 1.00E-04 Prostate cancer / / 21743057 rs696985 chr1 208547582 G T 1.00E-05 Prostate cancer / / 21743057 rs696984 chr1 208548174 T C 5.00E-06 Prostate cancer / / 21743057 rs696983 chr1 208548223 T C 1.00E-04 Prostate cancer / / 21743057 rs696981 chr1 208549846 C T 3.00E-05 Prostate cancer / / 21743057 rs701642 chr1 208551533 C T 3.00E-05 Prostate cancer / / 21743057 rs698993 chr1 208553707 A T 5.30E-06 Urinary metabolites / / 21572414 rs701641 chr1 208554185 C T 5.30E-06 Urinary metabolites / / 21572414 rs12409730 chr1 208555807 G A 2.00E-05 Urinary metabolites / / 21572414 rs12409730 chr1 208555807 G A 3.33E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs696979 chr1 208558547 T C 3.04E-04 Premature ovarian failure / / 19508998 rs710417 chr1 208578200 G A 7.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs696948 chr1 208589905 C T 2.03E-04 Multiple complex diseases / / 17554300 rs12124696 chr1 208591203 T C 1.88E-04 HIV-1 viral setpoint / / 17641165 rs17012564 chr1 208629207 A G 6.70E-07 Urinary metabolites / / 21572414 rs696958 chr1 208634002 G A 8.88E-05 Parkinson's disease / / 21248740 rs1392096 chr1 208635549 A G 0.00000742 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs841503 chr1 208662959 C A 2.50E-07 Multiple sclerosis / / 17660530 rs17259784 chr1 208757586 G C 6.00E-06 Cardiac hypertrophy / / 21348951 rs2185383 chr1 208779683 C A 3.65E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs17012951 chr1 208798145 C A 6.87E-04 Multiple complex diseases / / 17554300 rs17012953 chr1 208798856 A G 1.68E-71 Multiple complex diseases / / 17554300 rs17012962 chr1 208800712 A G 4.28E-04 Multiple complex diseases / / 17554300 rs17012964 chr1 208801107 A G 4.18E-04 Multiple complex diseases / / 17554300 rs2275515 chr1 208801568 T C 2.43E-04 Multiple complex diseases / / 17554300 rs12145940 chr1 208818206 C A 4.93E-05 Neuroblastoma / / pha002895 rs6680293 chr1 208830499 T C 2.25E-04 Coronary Artery Disease / / 17634449 rs1166879 chr1 208897416 C T 5.01E-05 Brain lesion load / / 19010793 rs4844438 chr1 208914856 A G 9.20E-04 Alcohol dependence / / 24277619 rs12403851 chr1 208922357 A G 4.40E-05 Height / / pha003010 rs11803397 chr1 208929786 A C 6.81E-04 Multiple complex diseases / / 17554300 rs12565978 chr1 208935416 T C 4.09E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs17259916 chr1 208937403 G T 4.01E-04 Smoking initiation / / 24665060 rs11585869 chr1 208938237 C T 2.16E-04 Smoking initiation / / 24665060 rs11119132 chr1 208992432 C A,G,T 9.60E-04 Type 2 diabetes / / 17463246 rs11119132 chr1 208992432 C A,G,T 1.26E-04 Multiple complex diseases / / 17554300 rs12408989 chr1 209007778 C A 1.45E-04 Alzheimer's disease (late onset) / / 21379329 rs2225933 chr1 209054831 C T 0.00000107 Common carotid artery thickness (far walls) / / 23487405 rs17260000 chr1 209057061 A G 3.63E-04 Tourette syndrome / / 22889924 rs11119150 chr1 209065259 T C 4.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12566014 chr1 209081485 T C 9.98E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10157571 chr1 209092473 C T 2.24E-04 Celiac disease / / 23936387 rs11577857 chr1 209105367 G A 2.00E-04 Information processing speed / / 21130836 rs11582344 chr1 209105966 C G 1.70E-05 Urinary metabolites / / 21572414 rs12037214 chr1 209146127 T C 7.67E-05 Parent of origin effect on language impairment (child trend) LOC100506899 intron 24571439 rs1924252 chr1 209153924 T C 2.13E-04 Parkinson's disease / / 16252231 rs1924251 chr1 209160036 A G 7.11E-04 Multiple complex diseases / / 17554300 rs7549301 chr1 209162412 C T 7.17E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs4844743 chr1 209192139 C T 3.45E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs12030256 chr1 209203866 T C 2.44E-04 Alcohol dependence / / 20201924 rs12037818 chr1 209209120 G C 5.45E-05 Odorant perception / / 23910658 rs17014015 chr1 209237451 C T 9.10E-05 Diabetic nephropathy / / 21150874 rs17014015 chr1 209237451 C T 2.05E-04 Type 2 diabetes / / 22238593 rs7534677 chr1 209240296 C G 4.90E-04 Obesity (extreme) / / 21935397 rs1411406 chr1 209258715 G T 4.10E-06 Urinary metabolites / / 21572414 rs6540507 chr1 209269627 A G 5.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10494917 chr1 209273939 A G 1.30E-05 Urinary metabolites / / 21572414 rs35577903 chr1 209277772 G T 2.20E-05 Urinary metabolites / / 21572414 rs11119220 chr1 209283460 A G 0.000866 Salmonella-induced pyroptosis / / 22837397 rs4424511 chr1 209316630 C T 5.75E-06 Recombination rate / / 21698098 rs4382726 chr1 209334217 G A 4.00E-06 Response to amphetamines / / 22952603 rs17014126 chr1 209335997 C T 7.35E-04 Multiple complex diseases / / 17554300 rs4844776 chr1 209342457 C A 6.37E-06 Response to amphetamines / / 22952603 rs1933612 chr1 209342622 G A 1.68E-04 Type 2 diabetes / / 17463246 rs17014148 chr1 209362100 G A 4.15E-04 Multiple complex diseases / / 17554300 rs6657861 chr1 209365397 A G 0.000478 Salmonella-induced pyroptosis / / 22837397 rs2153043 chr1 209426304 T C 2.20E-05 Urinary metabolites / / 21572414 rs2788151 chr1 209435926 T C 6.42E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2265733 chr1 209446729 C T 2.60E-05 Urinary metabolites / / 21572414 rs2660648 chr1 209449439 A G 1.10E-05 Urinary metabolites / / 21572414 rs2843171 chr1 209456475 T C 8.20E-06 Urinary metabolites / / 21572414 rs1553623 chr1 209460346 T C 1.63E-04 Alzheimer's disease (late onset) / / 21379329 rs6665154 chr1 209577743 G A 7.94E-05 Post-operative nausea and vomiting / / 21694509 rs1988163 chr1 209581483 C A 3.12E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs7531215 chr1 209589686 A G 1.89E-04 Type 2 diabetes / / 17463246 rs7531215 chr1 209589686 A G 1.26E-04 Multiple complex diseases / / 17554300 rs6691406 chr1 209590546 G A 3.36E-05 Multiple complex diseases / / 17554300 rs17014465 chr1 209600258 A C 8.89E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10779506 chr1 209603360 G C 7.50E-04 Multiple complex diseases MIR205HG intron 17554300 rs2294938 chr1 209603996 A G 4.79E-04 Multiple complex diseases MIR205HG intron 17554300 rs2294938 chr1 209603996 A G 2.90E-06 Glioma (high-grade) MIR205HG intron 19578366 rs1157819 chr1 209604734 T A 6.00E-04 Chronic fatigue syndrome MIR205HG intron 21912186 rs2249632 chr1 209605102 A G 6.14E-04 Multiple complex diseases MIR205HG intron 17554300 rs12045481 chr1 209621687 G A 6.17E-05 Body Mass Index / / pha003020 rs7526722 chr1 209632204 C T 3.15E-04 Amyotrophic lateral sclerosis / / 23624525 rs742254 chr1 209652946 A C 6.67E-06 Waist-Hip Ratio / / pha003013 rs742254 chr1 209652946 A C 9.41E-05 Waist Circumference / / pha003025 rs742254 chr1 209652946 A C 3.56E-06 Waist-Hip Ratio / / pha003028 rs2092253 chr1 209670324 G A 3.51E-04 Sarcoidosis / / 19165924 rs2092253 chr1 209670324 G A 1.67E-05 Waist-Hip Ratio / / pha003013 rs2092253 chr1 209670324 G A 8.59E-06 Waist-Hip Ratio / / pha003028 rs1120599 chr1 209670782 T C 3.84E-05 Amyotrophic lateral sclerosis / / 23624525 rs12750212 chr1 209682096 G A 1.00E-05 Tanning / / 19340012 rs2356932 chr1 209706685 A G 2.40E-04 Amyotrophic lateral sclerosis / / 23624525 rs6703183 chr1 209712889 T C 3.00E-08 Amyotrophic lateral sclerosis / / 23624525 rs6703522 chr1 209713138 T C 2.37E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs996146 chr1 209720842 C T 1.65E-05 Bone mineral traits,in men / / 21427758 rs996146 chr1 209720842 C T 5.19E-05 Bone mineral traits,in men / / 21427758 rs996146 chr1 209720842 C T 6.39E-05 Bone mineral traits,in men / / 21427758 rs6673693 chr1 209723420 T G 6.00E-04 Crohn's disease / / 17684544 rs12130212 chr1 209727257 T A 2.00E-06 Obesity (extreme) / / 21935397 rs10746420 chr1 209728590 T C 5.50E-06 Urinary metabolites / / 21572414 rs880782 chr1 209779953 G A 9.11E-05 Meningococcal disease CAMK1G intron 20694013 rs880782 chr1 209779953 G A 2.18E-05 Tunica Media CAMK1G intron pha003038 rs1049607 chr1 209788703 T C 4.15E-04 Type 2 diabetes LAMB3 cds-synon 17463246 rs2076227 chr1 209789086 G A 3.97E-04 Type 2 diabetes LAMB3 intron 17463246 rs742372 chr1 209828912 A T 3.60E-06 Urinary metabolites / / 21572414 rs11580294 chr1 209839374 G A 1.07E-04 Multiple complex diseases / / 17554300 rs11808911 chr1 209871977 C T 3.29E-04 Response to taxane treatment (placlitaxel) HSD11B1 intron 23006423 rs11119328 chr1 209885318 C A 8.12E-05 Orofacial clefts HSD11B1 intron 22863734 rs846906 chr1 209887718 T C 1.41E-05 Bladder cancer (smoking interaction) HSD11B1 intron 24662972 rs17015076 chr1 209912593 C T 8.94E-06 Cleft lip / / 20436469 rs3765240 chr1 209918151 G A 6.18E-05 Cognitive test performance / / 20125193 rs3765240 chr1 209918151 G A 8.00E-06 Orofacial clefts / / 22863734 rs3817821 chr1 209918503 A T 9.14E-04 Multiple complex diseases / / 17554300 rs627670 chr1 209929299 G A 9.95E-05 Cognitive test performance / / 20125193 rs627670 chr1 209929299 G A 1.04E-05 Orofacial clefts / / 22863734 rs909710 chr1 209930694 G A 8.79E-06 Orofacial clefts TRAF3IP3 intron 22863734 rs10489341 chr1 209932121 C T 9.20E-05 Asthma TRAF3IP3 intron 20698975 rs17015169 chr1 209936914 C T 1.66E-07 Cleft lip TRAF3IP3 cds-synon 20436469 rs17015169 chr1 209936914 C T 8.14E-09 Orofacial clefts TRAF3IP3 cds-synon 22863734 rs590223 chr1 209946707 G A 1.92E-06 Orofacial clefts TRAF3IP3 intron 22863734 rs1044516 chr1 209959614 G T 3.93E-07 Cleft lip IRF6 UTR-3 20436469 rs2235372 chr1 209960436 G A 1.00E-05 Urinary metabolites IRF6 UTR-3 21572414 rs2235372 chr1 209960436 G A 1.31E-04 Insulin resistance IRF6 UTR-3 21901158 rs742215 chr1 209961023 T A 1.40E-05 Urinary metabolites IRF6 UTR-3 21572414 rs2073485 chr1 209962794 G A 6.11E-11 Cleft lip IRF6 intron 20436469 rs2073485 chr1 209962794 G A 2.12E-10 Orofacial clefts IRF6 intron 22863734 rs674433 chr1 209964875 G T 1.81E-04 Insulin resistance IRF6 intron 21901158 rs17015218 chr1 209967915 A G 2.24E-04 Insulin resistance IRF6 intron 21901158 rs2013196 chr1 209968411 C T 8.31E-04 Multiple complex diseases IRF6 intron 17554300 rs2013196 chr1 209968411 C T 3.08E-05 Calcium intake levels and metabolic syndrome IRF6 intron 22170361 rs2013162 chr1 209968684 C A 2.24E-11 Cleft lip IRF6 cds-synon 20436469 rs17015226 chr1 209970096 C G 3.98E-04 Insulin resistance IRF6 intron 21901158 rs7555285 chr1 209970355 G C 2.74E-04 Insulin resistance IRF6 intron 21901158 rs861020 chr1 209977111 A G 8.20E-05 Orofacial clefts IRF6 intron 20023658 rs861020 chr1 209977111 A G 1.32E-09 Cleft lip IRF6 intron 20436469 rs861020 chr1 209977111 A G 3.00E-12 Orofacial clefts IRF6 intron 22863734 rs6540560 chr1 209982073 C T 2.80E-05 Urinary metabolites / / 21572414 rs6540560 chr1 209982073 C T 7.37E-04 Insulin resistance / / 21901158 rs6696825 chr1 209982372 A G 2.00E-05 Urinary metabolites / / 21572414 rs10863790 chr1 209988047 A C 1.00E-14 Cleft lip / / 20436469 rs642961 chr1 209989270 A G 6.83E-04 Type 2 diabetes / / 17463246 rs642961 chr1 209989270 A G 2.00E-06 Orofacial clefts / / 19270707 rs3753513 chr1 209999790 G A 3.99E-05 Calcium intake levels and metabolic syndrome / / 22170361 rs9308411 chr1 210005713 C T 6.92E-04 Type 2 diabetes DIEXF intron 17463246 rs17015309 chr1 210007218 C T 2.16E-05 Post-operative nausea and vomiting DIEXF intron 21694509 rs126280 chr1 210019824 A G 1.09E-08 Cleft lip DIEXF intron 20436469 rs126280 chr1 210019824 A G 8.11E-11 Orofacial clefts DIEXF intron 22863734 rs11119354 chr1 210024097 G A 4.81E-05 Calcium intake levels and metabolic syndrome DIEXF intron 22170361 rs6689839 chr1 210027026 G A 9.30E-05 Cleft lip DIEXF UTR-3 20436469 rs6689839 chr1 210027026 G A 1.98E-05 Orofacial clefts DIEXF UTR-3 22863734 rs2049998 chr1 210031154 G A 6.77E-04 Type 2 diabetes / / 17463246 rs2064163 chr1 210048819 G T 2.44E-08 Cleft lip / / 20436469 rs2064163 chr1 210048819 G T 2.08E-08 Orofacial clefts / / 22863734 rs12063989 chr1 210049893 T C 1.06E-09 Cleft lip / / 20436469 rs7540457 chr1 210053549 C G 3.09E-05 Multiple complex diseases / / 17554300 rs932347 chr1 210055630 C T 3.07E-05 Cleft lip / / 20436469 rs932347 chr1 210055630 C T 1.38E-06 Orofacial clefts / / 22863734 rs4844913 chr1 210068117 G A 1.87E-06 Cleft lip / / 20436469 rs4844913 chr1 210068117 G A 7.99E-07 Orofacial clefts / / 22863734 rs9429830 chr1 210110537 T C 1.74E-06 Cleft lip SYT14 nearGene-5 20436469 rs9429830 chr1 210110537 T C 2.20E-07 Orofacial clefts SYT14 nearGene-5 22863734 rs10863800 chr1 210123774 A G 5.37E-04 Smoking initiation SYT14 intron 24665060 rs11590161 chr1 210165928 G C 2.30E-05 Urinary metabolites SYT14 intron 21572414 rs7543650 chr1 210170975 A T 2.50E-05 Urinary metabolites SYT14 intron 21572414 rs11119388 chr1 210174417 A G 4.57E-09 Cleft lip SYT14 intron 20436469 rs227193 chr1 210212424 T C 8.94E-04 Multiple complex diseases SYT14 intron 17554300 rs12561877 chr1 210215414 C T 2.39E-05 Smoking initiation SYT14 intron 24665060 rs227178 chr1 210216946 C T 9.64E-04 Multiple complex diseases SYT14 intron 17554300 rs227178 chr1 210216946 C T 2.96E-06 Cleft lip SYT14 intron 20436469 rs227178 chr1 210216946 C T 1.01E-06 Orofacial clefts SYT14 intron 22863734 rs701948 chr1 210233610 C T 9.01E-04 Multiple complex diseases SYT14 intron 17554300 rs170555 chr1 210241616 T C 2.05E-04 Schizophrenia SYT14 intron 21674006 rs17318744 chr1 210244470 A G 7.30E-04 Response to cytadine analogues (cytosine arabinoside) SYT14 intron 24483146 rs227201 chr1 210247816 A G 9.85E-04 Multiple complex diseases SYT14 intron 17554300 rs227200 chr1 210249486 G C 9.09E-04 Multiple complex diseases SYT14 intron 17554300 rs11119409 chr1 210293333 C T 8.14E-04 Multiple complex diseases SYT14 intron 17554300 rs923561 chr1 210302595 G A 2.90E-05 Monocyte chemoattractant protein-1 SYT14 intron pha003071 rs11119414 chr1 210305881 A G 6.77E-04 Multiple complex diseases SYT14 intron 17554300 rs1002382 chr1 210312760 G A 1.02E-04 Myocardial Infarction SYT14 intron pha002873 rs4537554 chr1 210331585 C T 2.79E-04 Myocardial Infarction SYT14 intron pha002873 rs17188190 chr1 210337726 G A 2.18E-05 Monocyte chemoattractant protein-1 SYT14 nearGene-3 pha003071 rs2485893 chr1 210348155 A G 9.85E-07 Cleft lip / / 20436469 rs2485893 chr1 210348155 A G 8.86E-07 Orofacial clefts / / 22863734 rs2485893 chr1 210348155 A G 7.87E-05 Glucose levels / / pha003061 rs10779526 chr1 210352196 T C 8.70E-07 Cleft lip / / 20436469 rs10779526 chr1 210352196 T C 8.18E-07 Orofacial clefts / / 22863734 rs10779526 chr1 210352196 T C 7.10E-05 Glucose levels / / pha003061 rs12567108 chr1 210354442 G A 2.26E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs2485885 chr1 210356013 G A 3.92E-04 Type 2 diabetes / / 17463246 rs1014370 chr1 210356238 G A 2.37E-04 Type 2 diabetes / / 17463246 rs12094311 chr1 210369136 A G 1.24E-07 Cleft lip / / 20436469 rs12094311 chr1 210369136 A G 8.89E-08 Orofacial clefts / / 22863734 rs12060567 chr1 210370590 G A 3.17E-07 Cleft lip / / 20436469 rs12060567 chr1 210370590 G A 1.62E-07 Orofacial clefts / / 22863734 rs2485901 chr1 210370761 T G 3.00E-06 Glioma (high-grade) / / 19578366 rs2494183 chr1 210386585 G A 2.09E-04 Multiple complex diseases / / 17554300 rs2494184 chr1 210386892 T C 8.35E-04 Acne (severe) / / 24399259 rs590380 chr1 210463071 G A 2.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs689248 chr1 210463122 C T 2.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs588197 chr1 210463515 A T 2.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs587203 chr1 210463786 G A 1.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs608791 chr1 210464638 C T 2.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs12739013 chr1 210468160 A G 8.16E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs12138216 chr1 210480361 G A 7.93E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12138216 chr1 210480361 G A 4.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs615285 chr1 210484981 G A 2.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs4844997 chr1 210486895 T C 4.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs4430327 chr1 210499394 C T 9.61E-05 Cholesterol / / pha003073 rs3765886 chr1 210516146 G A 3.20E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs1338289 chr1 210519658 G A 3.97E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs17016002 chr1 210522686 C T 4.46E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs10863822 chr1 210528535 C G 3.51E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs7527939 chr1 210536025 C T 6.00E-09 Schizophrenia HHAT intron 23142968 rs12141780 chr1 210536722 C T 9.83E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs3765877 chr1 210537625 C T 4.11E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs10489386 chr1 210541178 A T 5.58E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs12087955 chr1 210547489 A C 4.98E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs12062126 chr1 210547517 C T 5.14E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs12120970 chr1 210548548 C G 7.02E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs12143463 chr1 210556982 T A 7.58E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs3765866 chr1 210559105 G A 7.68E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs3765865 chr1 210559381 A G 6.30E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs12145699 chr1 210561861 G A 6.10E-04 Multiple complex diseases HHAT intron 17554300 rs12046133 chr1 210562168 A G 8.24E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs2294843 chr1 210566557 A G 8.10E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs1997783 chr1 210567820 C T 5.38E-05 Cholesterol HHAT intron pha003073 rs12024862 chr1 210569102 A G 9.94E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs10489385 chr1 210572437 C T 3.79E-04 Multiple complex diseases HHAT intron 17554300 rs10489385 chr1 210572437 C T 5.98E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs3753230 chr1 210575444 G A 6.22E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs10863825 chr1 210577134 T C 4.38E-04 Multiple complex diseases HHAT intron 17554300 rs10863825 chr1 210577134 T C 8.86E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs11119485 chr1 210577359 A G 8.46E-04 Suicide attempts in bipolar disorder HHAT intron 21423239 rs11119496 chr1 210605675 C T 1.80E-05 Urinary metabolites HHAT intron 21572414 rs926576 chr1 210608164 C T 1.81E-04 Multiple complex diseases HHAT intron 17554300 rs11119499 chr1 210611316 G A 4.06E-04 Response to cytadine analogues (cytosine arabinoside) HHAT intron 24483146 rs11119499 chr1 210611316 G A 9.17E-04 Response to cytidine analogues (gemcitabine) HHAT intron 24483146 rs3819985 chr1 210622790 C T 2.60E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) HHAT intron 24023788 rs17260438 chr1 210662875 G A 2.22E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) HHAT intron 24023788 rs17416565 chr1 210669415 T G 1.19E-04 Multiple complex diseases HHAT intron 17554300 rs17016468 chr1 210736837 C T 3.49E-04 Multiple complex diseases HHAT intron 17554300 rs2501909 chr1 210738604 C G 2.80E-05 Urinary metabolites HHAT intron 21572414 rs12133319 chr1 210794866 G A 4.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HHAT intron 20877124 rs4504959 chr1 210801879 T G 6.02E-05 Information processing speed HHAT intron 21130836 rs4951687 chr1 210807047 A G 1.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HHAT intron 20877124 rs4951687 chr1 210807047 A G 6.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HHAT intron 20877124 rs4951488 chr1 210808270 G A 5.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HHAT intron 20877124 rs12096661 chr1 210819646 A C 5.44E-04 Response to taxane treatment (placlitaxel) HHAT intron 23006423 rs4951508 chr1 210829477 T C 2.25E-04 Vaspin levels HHAT intron 22907691 rs4951508 chr1 210829477 T C 0.0002249 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit HHAT intron 22907730 rs4472816 chr1 210830320 T C 2.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HHAT intron 20877124 rs4472816 chr1 210830320 T C 5.89E-04 Response to taxane treatment (placlitaxel) HHAT intron 23006423 rs4472816 chr1 210830320 T C 9.91E-05 HDL cholesterol HHAT intron pha003075 rs10746432 chr1 210837691 A G 8.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HHAT intron 20877124 rs11119565 chr1 210839684 C T 2.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HHAT intron 20877124 rs4366378 chr1 210847740 A C 2.13E-05 stroke (ischemic) HHAT UTR-3 17434096 rs10863850 chr1 210848224 A G 2.04E-04 Schizophrenia(treatment response to risperidone) HHAT UTR-3 19850283 rs1135317 chr1 210857457 A G 3.88E-04 Multiple complex diseases KCNH1 cds-synon 17554300 rs2357921 chr1 210858222 C T 8.04E-05 Brain derived neurotrophic factor levels,in serum KCNH1 intron 22047184 rs4628571 chr1 210858403 C T 1.70E-04 Multiple complex diseases KCNH1 intron 17554300 rs4628571 chr1 210858403 C T 5.87E-05 Brain derived neurotrophic factor levels,in serum KCNH1 intron 22047184 rs4628571 chr1 210858403 C T 1.00E-05 Anger KCNH1 intron 24489884 rs12141923 chr1 210860558 C T 6.24E-05 Brain derived neurotrophic factor levels,in serum KCNH1 intron 22047184 rs17260690 chr1 210871341 C A 4.14E-04 Smoking initiation KCNH1 intron 24665060 rs1934620 chr1 210898263 A G 8.00E-06 Smooth-surface caries KCNH1 intron 23470693 rs10863854 chr1 210913912 C T 8.47E-05 Serum metabolites KCNH1 intron 19043545 rs4951563 chr1 210923061 A G 1.73E-05 Chronic obstructive pulmonary disease KCNH1 intron 19300482 rs4951563 chr1 210923061 A G 1.73E-05 Response to statin treatment (atorvastatin),change in cholesterol levels KCNH1 intron 20031582 rs1934636 chr1 210929893 C A 0.000045 Prostate cancer KCNH1 intron 22532847 rs2185385 chr1 210930809 A G 8.49E-05 Serum metabolites KCNH1 intron 19043545 rs1418973 chr1 210994339 G A 7.09E-04 Stroke KCNH1 intron pha002887 rs4951669 chr1 211032696 C G 2.70E-05 Parkinson's disease (age of onset) KCNH1 intron 19772629 rs1343144 chr1 211043895 A C 5.78E-04 Multiple complex diseases KCNH1 intron 17554300 rs7552646 chr1 211069694 A G 2.76E-05 Cognitive performance KCNH1 intron 19734545 rs1501562 chr1 211072392 C T 1.60E-05 Inflammatory demyelinating disease KCNH1 intron 19850125 rs6656271 chr1 211081403 A G 3.61E-04 Response to taxane treatment (placlitaxel) KCNH1 intron 23006423 rs1777242 chr1 211087197 G C 7.20E-07 Red blood cell traits KCNH1 intron 23222517 rs12121565 chr1 211098815 G T 9.00E-06 Urinary metabolites KCNH1 intron 21572414 rs6702809 chr1 211114607 C T 5.90E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) KCNH1 intron 24192120 rs1501558 chr1 211126407 G A 3.06E-04 Alcohol dependence KCNH1 intron 20201924 rs33985151 chr1 211166032 T C 2.30E-05 Urinary metabolites KCNH1 intron 21572414 rs1501550 chr1 211168759 G A 2.00E-06 Circulating vasoactive peptide levels KCNH1 intron 23381795 rs1501551 chr1 211176922 C T 2.92E-04 Premature ovarian failure KCNH1 intron 19508998 rs1501551 chr1 211176922 C T 6.18E-04 Alcohol dependence KCNH1 intron 20201924 rs6662529 chr1 211222705 C T 7.75E-05 Response to taxane treatment (placlitaxel) KCNH1 intron 23006423 rs4072301 chr1 211225288 C T 7.40E-06 Urinary metabolites KCNH1 intron 21572414 rs11119672 chr1 211228477 C T 3.90E-06 Urinary metabolites KCNH1 intron 21572414 rs4628570 chr1 211239659 C T 2.40E-05 Urinary metabolites KCNH1 intron 21572414 rs17267442 chr1 211272818 C T 7.16E-04 Response to taxane treatment (placlitaxel) KCNH1 intron 23006423 rs6687686 chr1 211275293 C T 1.08E-04 Parkinson's disease KCNH1 intron 21248740 rs1538287 chr1 211311244 C T 2.64E-05 Longevity / / 21612516 rs6540664 chr1 211331893 G A 4.45E-05 Longevity / / 21612516 rs3120780 chr1 211348635 A G 1.91E-05 Non-word repetition / / 23738518 rs12134651 chr1 211351513 A G 3.67E-04 Alzheimer's disease (late onset) / / 21379329 rs12731366 chr1 211378802 G A 9.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3111253 chr1 211412408 C G 0.0001744 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs3111253 chr1 211412408 C G 1.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3111257 chr1 211420319 T C 5.89E-05 Sodium levels / / pha003093 rs17267491 chr1 211463815 C T 9.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) RCOR3 intron 23233662 rs12729996 chr1 211469497 A C,T 9.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) RCOR3 intron 23233662 rs12754607 chr1 211470727 C G 9.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) RCOR3 intron 23233662 rs12754747 chr1 211470827 C T 0.0008509 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RCOR3 intron 23233654 rs12754747 chr1 211470827 C T 8.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) RCOR3 intron 23233662 rs17188937 chr1 211475333 A C 0.0008027 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RCOR3 intron 23233654 rs17188937 chr1 211475333 A C 8.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) RCOR3 intron 23233662 rs12041498 chr1 211485060 A T 0.0002083 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RCOR3 intron 23233654 rs12041498 chr1 211485060 A T 2.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) RCOR3 intron 23233662 rs6540681 chr1 211493573 A G 6.80E-04 Alcohol dependence / / 20201924 rs12723208 chr1 211510894 A G 4.40E-07 Glioma (high-grade) TRAF5 intron 19578366 rs12723208 chr1 211510894 A G 0.0006104 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRAF5 intron 23233654 rs12723208 chr1 211510894 A G 6.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRAF5 intron 23233662 rs2280079 chr1 211517202 G A 0.0006086 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRAF5 intron 23233654 rs2280079 chr1 211517202 G A 6.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRAF5 intron 23233662 rs4951522 chr1 211527481 G A 0.00002317 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRAF5 intron 23233654 rs4951522 chr1 211527481 G A 2.32E-05 Methotrexate clearance (acute lymphoblastic leukemia) TRAF5 intron 23233662 rs10494936 chr1 211528806 T C 0.00002319 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRAF5 intron 23233654 rs10494936 chr1 211528806 T C 2.32E-05 Methotrexate clearance (acute lymphoblastic leukemia) TRAF5 intron 23233662 rs12752670 chr1 211530480 G A 0.000609 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRAF5 intron 23233654 rs12752670 chr1 211530480 G A 6.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRAF5 intron 23233662 rs6684874 chr1 211532060 A T 0.00002565 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRAF5 intron 23233654 rs6684874 chr1 211532060 A T 2.57E-05 Methotrexate clearance (acute lymphoblastic leukemia) TRAF5 intron 23233662 rs2292483 chr1 211533027 G A 0.00002572 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRAF5 intron 23233654 rs2292483 chr1 211533027 G A 2.57E-05 Methotrexate clearance (acute lymphoblastic leukemia) TRAF5 intron 23233662 rs17267554 chr1 211540144 C T 2.60E-05 Lymphocyte counts TRAF5 intron 22286170 rs17267554 chr1 211540144 C T 0.0006538 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRAF5 intron 23233654 rs17267554 chr1 211540144 C T 6.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRAF5 intron 23233662 rs17267561 chr1 211540941 G A 0.0006549 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRAF5 intron 23233654 rs17267561 chr1 211540941 G A 6.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRAF5 intron 23233662 rs12124008 chr1 211643872 T C 1.46E-04 Myocardial Infarction / / pha002883 rs11119748 chr1 211652185 C G 9.20E-04 Multiple complex diseases RD3 UTR-3 17554300 rs17017536 chr1 211656238 G A 2.08E-04 Multiple complex diseases RD3 intron 17554300 rs10863899 chr1 211666218 A G 2.50E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) RD3 UTR-5 23648065 rs7527396 chr1 211667857 G A 7.21E-04 Multiple complex diseases RD3 nearGene-5 17554300 rs1578838 chr1 211671118 T G 8.37E-05 Cognitive test performance / / 20125193 rs755448 chr1 211672506 G A 2.37E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs11119754 chr1 211678947 T C 9.90E-05 Cognitive test performance / / 20125193 rs2166104 chr1 211690818 A T 9.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs2166104 chr1 211690818 A T 7.13E-06 Retinopathy in non-diabetics / / 23393555 rs2120671 chr1 211690993 A C 9.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs7553035 chr1 211691706 G T 4.00E-06 Retinopathy in non-diabetics / / 23393555 rs6669700 chr1 211697052 G A 8.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs1614866 chr1 211700658 G A 1.00E-06 Coronary heart disease / / 21347282 rs1614866 chr1 211700658 G A 1.00E-06 Coronary heart disease / / 21347282 rs7527626 chr1 211705386 T C 6.16E-04 Aortic root size / / 21223598 rs1777826 chr1 211709083 A G 1.40E-05 Post-operative nausea and vomiting / / 21694509 rs1285978 chr1 211718203 C T 8.74E-05 Alzheimer's disease (age of onset) / / 22005931 rs12041727 chr1 211727371 T A 2.27E-05 Suicide attempts in bipolar disorder / / 21423239 rs7530862 chr1 211736470 T C 7.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs17017750 chr1 211738180 G C 9.25E-05 Suicide attempts in bipolar disorder / / 21423239 rs2278652 chr1 211751025 A G 9.03E-04 Suicide attempts in bipolar disorder SLC30A1 intron 21423239 rs12030478 chr1 211755204 C T 1.69E-06 Rheumatoid arthritis / / 19503088 rs17017782 chr1 211763053 A G 4.84E-05 Suicide attempts in bipolar disorder / / 21423239 rs9429874 chr1 211767738 A C 8.46E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12727395 chr1 211769306 T C 8.58E-06 Alzheimer's disease / / 22832961 rs4951536 chr1 211776439 A C 9.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs4951536 chr1 211776439 A C 3.42E-05 Weight / / pha003026 rs4951536 chr1 211776439 A C 8.80E-05 Weight / / pha003027 rs894853 chr1 211807505 C G 7.36E-04 Multiple complex diseases / / 17554300 rs10158309 chr1 211813550 C T 7.97E-04 Multiple complex diseases / / 17554300 rs2028706 chr1 211831380 A C 8.32E-04 Obesity (extreme) NEK2 nearGene-3 21935397 rs12027312 chr1 211832965 T G 5.10E-04 Alzheimer's disease NEK2 intron 22005930 rs12037104 chr1 211833095 C T 3.74E-04 Alzheimer's disease NEK2 intron 22005930 rs1373292 chr1 211833926 G A 9.31E-04 Amyotrophic Lateral Sclerosis NEK2 intron 17827064 rs12039766 chr1 211835267 C A 3.80E-04 Alzheimer's disease NEK2 intron 22005930 rs12031285 chr1 211836789 T C 7.98E-04 Obesity (extreme) NEK2 cds-synon 21935397 rs11119789 chr1 211837396 C T 4.39E-04 Obesity (extreme) NEK2 intron 21935397 rs10159325 chr1 211838131 G C 6.64E-04 Obesity (extreme) NEK2 intron 21935397 rs6698450 chr1 211844020 C G 6.95E-04 Obesity (extreme) NEK2 intron 21935397 rs11119792 chr1 211849969 C T 5.64E-04 Obesity (extreme) NEK2 nearGene-5 21935397 rs701924 chr1 211854180 T C 6.75E-04 Sarcoidosis / / 19165924 rs7551769 chr1 211856410 G A 4.80E-04 Obesity (extreme) / / 21935397 rs10494939 chr1 211856495 T C 6.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10494939 chr1 211856495 T C 4.55E-04 Obesity (extreme) / / 21935397 rs7516751 chr1 211859913 G A 4.78E-04 Alzheimer's disease / / 22005930 rs6661565 chr1 211859925 G A 8.19E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7553543 chr1 211865655 A G 4.81E-04 Alzheimer's disease / / 22005930 rs7540628 chr1 211891444 A G 1.91E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11119805 chr1 211918244 T A 3.00E-09 Stearic acid (18:0) plasma levels LPGAT1 UTR-3 23362303 rs6673226 chr1 211934111 G A 2.29E-04 Body mass index LPGAT1 intron 21701565 rs6673226 chr1 211934111 G A 5.10E-04 Body mass index LPGAT1 intron 21701565 rs12023263 chr1 211943879 C T 3.55E-04 Body mass index LPGAT1 intron 21701565 rs12023263 chr1 211943879 C T 5.82E-04 Body mass index LPGAT1 intron 21701565 rs4951552 chr1 211979135 A C 1.53E-04 Body mass index LPGAT1 intron 21701565 rs4951552 chr1 211979135 A C 2.62E-04 Body mass index LPGAT1 intron 21701565 rs11119813 chr1 211979205 T G 1.68E-04 Type 2 diabetes LPGAT1 intron 17463246 rs6540709 chr1 211990542 A G 1.14E-04 Type 2 diabetes LPGAT1 intron 17463246 rs7534335 chr1 212008445 T G 2.76E-04 Type 2 diabetes / / 17463246 rs12058008 chr1 212046447 A G 1.67E-04 Body mass index / / 21701565 rs12058008 chr1 212046447 A G 2.21E-04 Body mass index / / 21701565 rs11119822 chr1 212056593 G A 1.28E-04 Body mass index / / 21701565 rs11119822 chr1 212056593 G A 1.43E-04 Body mass index / / 21701565 rs7540019 chr1 212079778 A G 8.66E-04 Myopia (pathological) / / 21095009 rs2808382 chr1 212091948 G C 4.90E-06 Urinary metabolites / / 21572414 rs2788135 chr1 212125260 G A 2.80E-04 Stroke INTS7 intron pha002886 rs17018280 chr1 212125430 T G 6.53E-04 Multiple complex diseases INTS7 intron 17554300 rs2788131 chr1 212133675 A C 3.74E-04 Type 2 diabetes INTS7 intron 17463246 rs34836942 chr1 212148999 C T 7.53E-04 Multiple complex diseases INTS7 intron 17554300 rs34836942 chr1 212148999 C T 8.64E-04 Alzheimer's disease INTS7 intron 17998437 rs17018311 chr1 212155008 T C 2.00E-08 Temperament (bipolar disorder) INTS7 intron 22365631 rs2993535 chr1 212155192 A G 1.30E-06 Urinary metabolites INTS7 intron 21572414 rs3010029 chr1 212197844 A G 1.80E-06 Urinary metabolites INTS7 intron 21572414 rs17018378 chr1 212210027 G A 4.92E-04 Multiple complex diseases DTL intron 17554300 rs10863936 chr1 212237798 G A 2.00E-09 Height DTL intron 20881960 rs10863938 chr1 212262467 T C 2.68E-04 Stroke DTL intron pha002886 rs1586660 chr1 212266531 C G 1.80E-06 Urinary metabolites DTL intron 21572414 rs3135474 chr1 212273639 C T 2.41E-04 Stroke DTL missense pha002886 rs7545292 chr1 212279058 G T 4.65E-04 Stroke / / pha002886 rs11119860 chr1 212332294 T C 5.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs11119861 chr1 212338360 A G 7.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs11119865 chr1 212344323 C T 4.69E-04 Type 2 diabetes / / 17463246 rs11119865 chr1 212344323 C T 5.90E-04 Multiple complex diseases / / 17554300 rs11119866 chr1 212344489 A G 7.96E-04 Multiple complex diseases / / 17554300 rs7550051 chr1 212345669 G A 8.16E-04 Myocardial Infarction / / pha002883 rs6680653 chr1 212347352 C T 5.18E-05 Relative hand skill / / 24068947 rs4325202 chr1 212351181 C T 4.73E-05 Relative hand skill / / 24068947 rs1472224 chr1 212351319 T C 4.66E-05 Relative hand skill / / 24068947 rs10436976 chr1 212360408 A G 8.73E-05 Hypertension (essential hypertension) / / 22184326 rs1967114 chr1 212375336 G A 7.95E-04 Multiple complex diseases / / 17554300 rs11119881 chr1 212379741 A C 1.98E-05 Major depressive disorder / / 19107115 rs6540731 chr1 212392163 G A 9.00E-06 Intelligence (childhood) / / 23358156 rs7519168 chr1 212393385 A C 6.05E-04 Multiple complex diseases / / 17554300 rs3816912 chr1 212399849 G A 6.04E-04 Multiple complex diseases / / 17554300 rs11119887 chr1 212407562 C T 4.00E-04 Multiple complex diseases / / 17554300 rs12145451 chr1 212425291 C A 5.74E-04 Heart Failure / / pha002884 rs10494951 chr1 212429259 G A 6.83E-04 Type 2 diabetes / / 17463246 rs12728266 chr1 212430756 A G 1.10E-04 Type 2 diabetes / / 17463246 rs903119 chr1 212434241 A G 1.15E-04 Height / / 17255346 rs351393 chr1 212476519 A G 1.80E-05 Urinary metabolites PPP2R5A intron 21572414 rs1473321 chr1 212579055 T C 2.80E-05 Urinary metabolites TMEM206 intron 21572414 rs612414 chr1 212602176 G T 0.000010661 Alcohol dependence / / 23089632 rs583058 chr1 212610755 T C 0.0000142 Alcohol dependence NENF intron 23089632 rs4804 chr1 212619339 T C 0.000715 Alcohol dependence NENF cds-synon 23089632 rs4804 chr1 212619339 T C 8.36E-06 Alcohol dependence NENF cds-synon 23089632 rs483954 chr1 212620214 A G 0.0000039 Alcohol dependence / / 23089632 rs483954 chr1 212620214 A G 0.00063 Alcohol dependence / / 23089632 rs675065 chr1 212634583 A G 4.26E-04 Alcohol dependence / / 24277619 rs1021379 chr1 212700204 C T 9.09E-06 Lymphocyte counts / / 22286170 rs2942354 chr1 212708371 A C 8.12E-04 Multiple complex diseases / / 17554300 rs631569 chr1 212717106 G A 3.86E-04 Type 2 diabetes / / 17463246 rs1195474 chr1 212738202 A T 6.16E-05 Multiple complex diseases ATF3 nearGene-5 17554300 rs1195474 chr1 212738202 A T 1.43E-05 Serum metabolites ATF3 nearGene-5 19043545 rs10863981 chr1 212756363 G A 4.06E-04 Alzheimer's disease (late onset) ATF3 intron 21379329 rs4543871 chr1 212757658 T C 2.54E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) ATF3 intron 23648065 rs4543871 chr1 212757658 T C 5.17E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) ATF3 intron 23648065 rs1105899 chr1 212758604 C T 1.80E-05 Urinary metabolites ATF3 intron 21572414 rs1567710 chr1 212768428 C T 8.77E-04 HIV-1 viral setpoint ATF3 intron 17641165 rs11119986 chr1 212769955 G A 4.07E-04 Multiple complex diseases ATF3 intron 17554300 rs10494954 chr1 212778507 T C 8.46E-04 Multiple complex diseases ATF3 intron 17554300 rs3123536 chr1 212809606 C T 0.000525 Salmonella-induced pyroptosis / / 22837397 rs17019510 chr1 212816729 A G 8.69E-05 Bipolar disorder / / 18317468 rs2501846 chr1 212841934 T C 9.24E-04 Tourette syndrome / / 22889924 rs4951633 chr1 212842330 G T 2.50E-05 Urinary metabolites / / 21572414 rs12128789 chr1 212852832 T C 5.28E-04 Multiple complex diseases / / 17554300 rs17019567 chr1 212855923 A G 4.33E-07 IgE levels / / 22075330 rs3768547 chr1 212871081 T A 3.14E-04 Lung function (forced expiratory volume in 1 second) BATF3 intron 17255346 rs3768547 chr1 212871081 T A 2.96E-04 Multiple complex diseases BATF3 intron 17554300 rs9658807 chr1 212876902 A G 6.33E-05 IgE levels / / 22075330 rs7555918 chr1 212885805 A G 2.94E-04 Insulin resistance / / 21901158 rs6681171 chr1 212892113 T G 1.41E-05 Type 1 diabetes / / 21980299 rs10863988 chr1 212894474 G A 2.12E-04 Multiple complex diseases / / 17554300 rs10863988 chr1 212894474 G A 3.50E-06 Urinary metabolites / / 21572414 rs11800991 chr1 212894578 C T 1.00E-04 Insulin resistance / / 21901158 rs11800642 chr1 212909744 A G 3.23E-06 HIV-1 control NSL1 UTR-3 20041166 rs2271148 chr1 212913168 T C 7.68E-04 Response to taxane treatment (placlitaxel) NSL1 intron 23006423 rs6702101 chr1 212913590 C T 7.86E-06 HIV-1 control NSL1 intron 20041166 rs12125867 chr1 212917980 G A 2.44E-04 Multiple complex diseases NSL1 intron 17554300 rs12125867 chr1 212917980 G A 5.90E-06 Urinary metabolites NSL1 intron 21572414 rs1507358 chr1 212925361 T C 5.90E-06 Urinary metabolites NSL1 intron 21572414 rs1507357 chr1 212925429 C A 4.92E-04 Multiple complex diseases NSL1 intron 17554300 rs6540762 chr1 212925857 C T 8.97E-06 HIV-1 control NSL1 intron 20041166 rs12404618 chr1 212927009 A G 5.90E-06 Urinary metabolites NSL1 intron 21572414 rs12404885 chr1 212927167 A G 8.97E-06 HIV-1 control NSL1 intron 20041166 rs11120014 chr1 212933545 A G 8.97E-06 HIV-1 control NSL1 intron 20041166 rs11808846 chr1 212943581 A G 8.97E-06 HIV-1 control NSL1 intron 20041166 rs6687672 chr1 212944877 C G 6.64E-04 Multiple complex diseases NSL1 intron 17554300 rs7516312 chr1 212946919 T C 5.32E-04 Multiple complex diseases NSL1 intron 17554300 rs10863997 chr1 212947520 G A 2.62E-05 HIV-1 control NSL1 intron 20041166 rs3738798 chr1 212965469 C T 8.97E-06 HIV-1 control TATDN3 intron 20041166 rs17019726 chr1 212969128 A G 2.69E-04 Multiple complex diseases TATDN3 intron 17554300 rs10494955 chr1 212971978 C G 2.51E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) TATDN3 intron 17982456 rs12128410 chr1 212972599 C T 7.55E-04 Multiple complex diseases TATDN3 intron 17554300 rs12128410 chr1 212972599 C T 1.17E-05 HIV-1 control TATDN3 intron 20041166 rs12128410 chr1 212972599 C T 2.70E-05 Urinary metabolites TATDN3 intron 21572414 rs1532951 chr1 212978197 T G 3.40E-05 HIV-1 control TATDN3 intron 20041166 rs7515115 chr1 212986554 T C 5.07E-04 Multiple complex diseases TATDN3 intron 17554300 rs7515115 chr1 212986554 T C 1.23E-05 HIV-1 control TATDN3 intron 20041166 rs6694190 chr1 213005012 G A 2.13E-04 Multiple complex diseases C1orf227 intron 17554300 rs6694190 chr1 213005012 G A 1.20E-05 Urinary metabolites C1orf227 intron 21572414 rs963328 chr1 213037661 G T 5.00E-05 Type 2 diabetes FLVCR1 intron 17903298 rs963328 chr1 213037661 G T 3.01E-05 Blood Pressure and Arterial Stiffness FLVCR1 intron 17903302 rs963328 chr1 213037661 G T 3.52E-04 Lymphocyte counts FLVCR1 intron 22286170 rs1587175 chr1 213065262 A T 8.10E-04 Type 2 diabetes and 6 quantitative traits FLVCR1 intron 17848626 rs1284852 chr1 213073013 C T 2.60E-06 Urinary metabolites FLVCR1 nearGene-3 21572414 rs12760321 chr1 213083261 T C 2.79E-04 Type 2 diabetes / / 17463246 rs1284864 chr1 213094034 G A 6.75E-05 Prostate cancer / / pha002878 rs1890933 chr1 213097217 A C 1.50E-05 Urinary metabolites / / 21572414 rs6663614 chr1 213097941 C A 4.01E-04 Insulin resistance / / 21901158 rs6656706 chr1 213120103 C T 9.07E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs3002288 chr1 213126565 G A 7.00E-08 Eye color VASH2 intron 23548203 rs3738804 chr1 213134651 C T 9.72E-05 Parent of origin effect on language impairment (paternal) VASH2 intron 24571439 rs6679892 chr1 213138075 C A 7.53E-04 Amyotrophic Lateral Sclerosis VASH2 intron 17362836 rs6679892 chr1 213138075 C A 2.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VASH2 intron 20877124 rs7511930 chr1 213146944 A G 7.22E-04 Amyotrophic Lateral Sclerosis VASH2 intron 17362836 rs7511930 chr1 213146944 A G 5.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VASH2 intron 20877124 rs6688043 chr1 213160145 T C 2.28E-04 Multiple complex diseases VASH2 intron 17554300 rs3002284 chr1 213181916 T C 8.70E-04 Iris characteristics ANGEL2 intron 21835309 rs74825882 chr1 213186688 C G 0.000076 Breast cancer (ER positive) ANGEL2 missense 23555315 rs4951477 chr1 213232555 A C 2.77E-04 Multiple complex diseases RPS6KC1 intron 17554300 rs11120089 chr1 213278325 A G 4.88E-04 Schizophrenia RPS6KC1 intron 19197363 rs6692144 chr1 213307456 T C 6.57E-04 Multiple complex diseases RPS6KC1 intron 17554300 rs1391549 chr1 213371127 C T 6.06E-04 Multiple complex diseases RPS6KC1 intron 17554300 rs2817978 chr1 213373306 G A 8.54E-04 Multiple complex diseases RPS6KC1 intron 17554300 rs1498356 chr1 213382584 T G 3.77E-04 Multiple complex diseases RPS6KC1 intron 17554300 rs3924768 chr1 213401648 T C 3.98E-04 Multiple complex diseases RPS6KC1 intron 17554300 rs17020327 chr1 213420895 T C 7.02E-04 Multiple complex diseases RPS6KC1 intron 17554300 rs1187802 chr1 213456220 A G 5.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11576637 chr1 213503630 T A,C,G 7.95E-04 Schizophrenia / / 19197363 rs1187768 chr1 213511147 G A 9.94E-04 Type 2 diabetes / / 17463246 rs10864043 chr1 213521433 A G 8.95E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1187767 chr1 213524560 T G 8.44E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1656023 chr1 213525900 T C 2.53E-04 Obesity (extreme) / / 21935397 rs1656022 chr1 213527242 G A 2.45E-14 Multiple complex diseases / / 17554300 rs1656022 chr1 213527242 G A 2.59E-04 Obesity (extreme) / / 21935397 rs1656021 chr1 213527588 C T 2.60E-04 Obesity (extreme) / / 21935397 rs1699196 chr1 213529216 T A 6.52E-05 Cytomegalovirus antibody response / / 21993531 rs1187782 chr1 213545274 A T 1.40E-05 Urinary metabolites / / 21572414 rs1187780 chr1 213547278 C T 1.60E-05 Urinary metabolites / / 21572414 rs2359700 chr1 213548789 C T 6.05E-04 Multiple complex diseases / / 17554300 rs1434890 chr1 213556162 G A 5.80E-06 Urinary metabolites / / 21572414 rs11809986 chr1 213558937 A G 0.00019 Coronary artery calcification / / 23727086 rs1187770 chr1 213563818 C A 2.30E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs320462 chr1 213586276 G C 5.99E-05 Response to citalopram treatment / / 19846067 rs12045355 chr1 213603105 G A 3.64E-04 Smoking cessation / / 24665060 rs320451 chr1 213617738 C T 9.20E-05 Smoking cessation / / 24665060 rs1158048 chr1 213629388 G A 7.52E-04 Body mass index / / 21701565 rs1158048 chr1 213629388 G A 2.30E-04 Smoking cessation / / 24665060 rs12036568 chr1 213636801 C T 6.94E-04 Body mass index / / 21701565 rs12036568 chr1 213636801 C T 4.51E-05 Smoking cessation / / 24665060 rs6667442 chr1 213638762 T A 2.60E-05 Smoking cessation / / 24665060 rs320466 chr1 213651724 T C 4.92E-04 Fat body mass / / 24064335 rs17702239 chr1 213659876 G A 0.000104 Breast cancer early age of onset / / 18463975 rs12137618 chr1 213659901 G T 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2165130 chr1 213666824 G T 3.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2173482 chr1 213666889 C G 3.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1561499 chr1 213709450 C A 6.69E-05 Serum metabolites / / 19043545 rs967352 chr1 213721111 C T 3.84E-04 Smoking initiation / / 24665060 rs2218115 chr1 213724325 G T 2.83E-05 Serum metabolites / / 19043545 rs320391 chr1 213725260 T C 2.30E-05 Serum metabolites / / 19043545 rs412878 chr1 213729352 T A 9.68E-05 Serum metabolites / / 19043545 rs4073191 chr1 213747787 T C 8.37E-24 Varicose Veins / / pha001412 rs17021056 chr1 213769092 T C 5.53E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6692095 chr1 213776884 C T 4.56E-04 Smoking quantity / / 24665060 rs11120170 chr1 213779196 G A 3.60E-04 Alcohol dependence / / 20201924 rs12135768 chr1 213798251 G A 1.95E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4655454 chr1 213805502 A G 1.90E-05 Glioma (high-grade) / / 19578366 rs7529857 chr1 213811721 T G 7.64E-04 Pemphigus vulgaris / / 22437316 rs12144639 chr1 213817311 G A 5.70E-06 Orofacial clefts / / 22419666 rs6693655 chr1 213827269 T C 7.18E-04 Myopia (pathological) / / 21095009 rs7526094 chr1 213833093 G A 2.70E-05 Urinary metabolites / / 21572414 rs4655303 chr1 213834643 A T 5.00E-06 Metabolite levels (5-HIAA) / / 23319000 rs1509865 chr1 213840987 C G 1.95E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17706439 chr1 213855588 G A 3.00E-06 RR interval (heart rate) / / 20031603 rs4655461 chr1 213864971 G A 9.52E-06 C-reactive protein / / 22492993 rs10864064 chr1 213877776 T G 7.38E-06 C-reactive protein / / 22492993 rs6540801 chr1 213887376 G C 9.85E-05 Formal thought disorder in schizophrenia / / 22648509 rs6540801 chr1 213887376 G C 7.70E-04 Smoking quantity / / 24665060 rs6657203 chr1 213893501 G T 6.56E-05 Formal thought disorder in schizophrenia / / 22648509 rs1704198 chr1 213910494 T G 4.00E-07 Obesity / / 23818313 rs11803653 chr1 213914914 G A 9.57E-05 Formal thought disorder in schizophrenia / / 22648509 rs2664687 chr1 213915461 G A 2.10E-06 Urinary metabolites / / 21572414 rs12041173 chr1 213932821 T C 2.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1891058 chr1 213937382 G A 8.09E-05 Smoking initiation / / 24665060 rs17759253 chr1 213941794 G A 4.75E-04 Alzheimer's disease (late onset) / / 21379329 rs12117411 chr1 213952992 T C 1.70E-05 Urinary metabolites / / 21572414 rs12724110 chr1 213962023 C T 2.66E-04 Insulin resistance / / 21901158 rs12058083 chr1 213968815 A G 2.80E-05 Urinary metabolites / / 21572414 rs1891060 chr1 213969354 C T 1.41E-05 HIV-1 viral setpoint / / 17641165 rs12758106 chr1 213991265 T C 2.66E-04 Insulin resistance / / 21901158 rs2236580 chr1 214026324 C T 8.69E-05 Major depressive disorder PROX1-AS1 intron 21621269 rs853750 chr1 214044159 A C 7.26E-05 Post-operative nausea and vomiting PROX1-AS1 intron 21694509 rs9662330 chr1 214069479 C T 3.46E-04 HIV-1 viral setpoint PROX1-AS1 intron 17641165 rs1073570 chr1 214095944 C T 9.40E-04 Multiple complex diseases PROX1-AS1 intron 17554300 rs7550337 chr1 214099716 T C 8.15E-04 Multiple complex diseases PROX1-AS1 intron 17554300 rs1159179 chr1 214108641 T C 9.06E-04 Insulin resistance PROX1-AS1 intron 21901158 rs11120231 chr1 214110152 C A 4.66E-04 Rheumatoid arthritis PROX1-AS1 intron 21452313 rs7554295 chr1 214110402 C T 6.45E-04 Insulin resistance PROX1-AS1 intron 21901158 rs340849 chr1 214118090 C A 8.00E-06 Alzheimer's disease PROX1-AS1 intron 22159054 rs340846 chr1 214121096 T C 4.84E-04 Rheumatoid arthritis PROX1-AS1 intron 21452313 rs17762150 chr1 214124818 C T 3.64E-05 HIV-1 progression PROX1-AS1 intron 20064070 rs6665854 chr1 214125024 C A 5.93E-04 Multiple complex diseases PROX1-AS1 intron 17554300 rs17762192 chr1 214125127 G C 7.13E-05 HIV-1 progression PROX1-AS1 intron 20064070 rs1367951 chr1 214125513 A G 6.69E-05 HIV-1 progression PROX1-AS1 intron 20064070 rs6698217 chr1 214130413 A C 4.90E-06 Urinary metabolites PROX1-AS1 intron 21572414 rs17712208 chr1 214150445 T A 0.0000039 Type 2 diabetes / / 22885922 rs17712208 chr1 214150445 T A 3.22E-12 Fasting blood glucose / / 22885924 rs17021749 chr1 214150482 C T 1.10E-06 Cognitive impairment induced by topiramate / / 22091778 rs2075423 chr1 214154719 G T 0.0000071 Fasting blood glucose / / 22885922 rs2075423 chr1 214154719 G T 0.0000093 Type 2 diabetes (males) / / 22885922 rs2075423 chr1 214154719 G T 0.00001 Type 2 diabetes (females) / / 22885922 rs2075423 chr1 214154719 G T 0.00039 HOMA-B / / 22885922 rs2075423 chr1 214154719 G T 8.10E-09 Type 2 diabetes / / 22885922 rs2075423 chr1 214154719 G T 2.00E-06 Type 2 diabetes / / 24509480 rs13376660 chr1 214154985 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs340878 chr1 214157049 G C 0.00000094 Fasting blood glucose / / 22885924 rs340874 chr1 214159256 T C 7.11E-04 HIV-1 viral setpoint / / 17641165 rs340874 chr1 214159256 T C 5.00E-06 Fasting glucose-related traits / / 20081858 rs340874 chr1 214159256 T C 7.00E-12 Fasting insulin-related traits / / 20081858 rs340874 chr1 214159256 T C 4.00E-09 Fasting glucose-related traits (interaction with BMI) / / 22581228 rs340874 chr1 214159256 T C 4.10E-10 Type 2 diabetes / / 22885922 rs340874 chr1 214159256 T C 0.0000435 Fasting insulin-related traits / / 22885924 rs340874 chr1 214159256 T C 1.78E-11 Fasting blood glucose / / 22885924 rs340835 chr1 214163675 G A 2.73E-04 Multiple complex diseases PROX1 intron 17554300 rs340835 chr1 214163675 G A 9.61E-04 Stroke PROX1 intron pha002887 rs11120251 chr1 214239318 G A 6.25E-04 Schizophrenia(age at onset) / / 21688384 rs1440620 chr1 214261350 T C 1.00E-06 Dietary macronutrient intake / / 23372041 rs1440620 chr1 214261350 T C 9.98E-04 Alcohol dependence / / 24277619 rs920489 chr1 214287420 T C 1.20E-05 Urinary metabolites / / 21572414 rs1795040 chr1 214288429 A G 7.72E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1660383 chr1 214288897 G A 1.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs1660382 chr1 214289118 G A 1.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs1660381 chr1 214289767 T C 2.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs1660380 chr1 214289779 A G 2.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs1660378 chr1 214290242 T C 2.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs1660377 chr1 214290301 T A 2.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs1795037 chr1 214290542 G A 2.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs1440619 chr1 214291051 G A 2.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs12568811 chr1 214291944 A G 2.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs1795036 chr1 214292309 G A 2.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs1795035 chr1 214292353 C T 2.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs1795034 chr1 214292589 T C 2.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs1795033 chr1 214293994 T G 3.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1660375 chr1 214294554 G A 3.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs7550684 chr1 214305863 T C 2.78E-04 Multiple complex diseases / / 17554300 rs1223802 chr1 214348346 G A 7.83E-04 Type 2 diabetes / / 22158537 rs2218196 chr1 214350457 A G 5.99E-04 Multiple complex diseases / / 17554300 rs11589520 chr1 214350621 A G 7.38E-04 Multiple complex diseases / / 17554300 rs2196944 chr1 214359057 C G 3.20E-04 Multiple complex diseases / / 17554300 rs6699206 chr1 214368330 G A 1.78E-05 Cognitive performance / / 19734545 rs1660367 chr1 214406939 T C 1.39E-05 Cognitive performance / / 19734545 rs6665548 chr1 214416824 A G 3.92E-04 Multiple complex diseases / / 17554300 rs6665548 chr1 214416824 A G 6.04E-04 Alcohol dependence / / 21314694 rs6682783 chr1 214418139 G T 7.23E-05 Cognitive impairment induced by topiramate / / 22091778 rs766499 chr1 214439328 A C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs766499 chr1 214439328 A C 7.09E-05 Creatinine levels / / pha003069 rs9308433 chr1 214457009 T C 2.00E-06 IgG glycosylation SMYD2 intron 23382691 rs9308433 chr1 214457009 T C 4.00E-06 IgG glycosylation SMYD2 intron 23382691 rs9970083 chr1 214457286 G T 2.80E-05 Creatinine levels SMYD2 intron pha003069 rs11120288 chr1 214462988 A G 9.97E-05 Lipid levels SMYD2 intron pha003082 rs6677732 chr1 214490228 A G 8.09E-04 Multiple complex diseases SMYD2 intron 17554300 rs12124666 chr1 214491961 C T 7.95E-04 Multiple complex diseases SMYD2 intron 17554300 rs12124666 chr1 214491961 C T 4.05E-05 Creatinine levels SMYD2 intron pha003069 rs1134647 chr1 214492286 G A 4.00E-05 Creatinine levels SMYD2 missense pha003069 rs7419021 chr1 214502374 T C 9.87E-04 Multiple complex diseases SMYD2 intron 17554300 rs1472441 chr1 214527252 G A 3.42E-06 Statin-induced myopathy PTPN14 UTR-3 21826682 rs7543972 chr1 214529786 A G 1.85E-05 Multiple complex diseases PTPN14 UTR-3 17554300 rs7543972 chr1 214529786 A G 3.53E-06 Height PTPN14 UTR-3 22021425 rs3002309 chr1 214544632 A C 4.29E-05 Statin-induced myopathy PTPN14 intron 21826682 rs3013444 chr1 214559440 C T 7.05E-06 Height PTPN14 intron 22021425 rs6657368 chr1 214567378 A G 3.19E-04 Multiple complex diseases PTPN14 intron 17554300 rs12748605 chr1 214571527 C G 0.000144 Salmonella-induced pyroptosis PTPN14 intron 22837397 rs6657749 chr1 214576513 C T 2.99E-05 Attention deficit hyperactivity disorder PTPN14 intron 18980221 rs6657749 chr1 214576513 C T 4.68E-06 Attention deficit hyperactivity disorder PTPN14 intron pha002875 rs11120313 chr1 214581206 C A 4.53E-06 Blood pressure PTPN14 intron 21378095 rs17732428 chr1 214610504 A G 5.87E-05 Blood Pressure PTPN14 intron pha003048 rs6698007 chr1 214624286 T G 2.92E-04 Bipolar disorder PTPN14 intron 18317468 rs12757404 chr1 214629616 A G 2.00E-06 Lipid traits PTPN14 intron 24386095 rs17734395 chr1 214673445 C T 3.87E-04 Multiple complex diseases PTPN14 intron 17554300 rs17042140 chr1 214674925 T C 4.00E-06 Thyroid stimulating hormone PTPN14 intron 24722205 rs6540844 chr1 214680378 C T 2.00E-06 Urinary metabolites PTPN14 intron 21572414 rs4326598 chr1 214710841 C T 3.10E-07 Urinary metabolites PTPN14 intron 21572414 rs12747035 chr1 214719346 G A 2.00E-05 Urinary metabolites PTPN14 intron 21572414 rs7535253 chr1 214744893 T C 8.31E-04 Aortic root size / / 21223598 rs7535253 chr1 214744893 T C 8.13E-04 Alzheimer's disease / / 22005930 rs7523691 chr1 214745193 C T 1.95E-05 Multiple complex diseases / / 17554300 rs2807644 chr1 214747257 A C 2.84E-05 Cognitive impairment induced by topiramate / / 22091778 rs2807644 chr1 214747257 A C 6.38E-04 Stroke / / pha002886 rs12097854 chr1 214817364 T C 5.39E-04 Type 2 diabetes CENPF intron 17463246 rs12097854 chr1 214817364 T C 5.26E-04 Multiple complex diseases CENPF intron 17554300 rs3748697 chr1 214820099 A G 7.92E-05 Cognitive impairment induced by topiramate CENPF missense 22091778 rs3748697 chr1 214820099 A G 8.50E-04 Stroke CENPF missense pha002886 rs3748698 chr1 214820299 A G 2.55E-04 Amyotrophic Lateral Sclerosis CENPF cds-synon 17362836 rs438034 chr1 214830617 A G 5.00E-06 Response to antineoplastic agents CENPF missense 21659360 rs438034 chr1 214830617 A G 3.76E-05 Cognitive impairment induced by topiramate CENPF missense 22091778 rs438034 chr1 214830617 A G 8.93E-04 Stroke CENPF missense pha002886 rs417774 chr1 214833425 G A 6.68E-05 Cognitive impairment induced by topiramate CENPF intron 22091778 rs335561 chr1 214865123 C T 3.52E-04 Multiple complex diseases / / 17554300 rs7553478 chr1 214870992 C T 1.68E-04 Multiple complex diseases / / 17554300 rs1858650 chr1 214939861 G A 2.88E-05 Weight loss (gastric bypass surgery) / / 23633212 rs6695352 chr1 214954939 T C 4.00E-06 Migraine without aura / / 23793025 rs6695352 chr1 214954939 T C 5.81E-04 Migraine / / 23793025 rs11805072 chr1 214984422 G A 4.90E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11807086 chr1 215064388 G A 8.95E-04 Iron levels / / pha002876 rs1336948 chr1 215068688 C T 3.65E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs6540871 chr1 215095284 T C 8.76E-04 HIV-1 viral setpoint / / 17641165 rs7534785 chr1 215102422 G A 5.29E-04 Alcohol dependence / / 21314694 rs6684902 chr1 215113661 G A 8.46E-05 Blood Pressure / / pha003039 rs1377185 chr1 215120353 C T 4.56E-05 Major depressive disorder / / 21621269 rs1377185 chr1 215120353 C T 3.16E-05 Major depressive disorder / / pha002850 rs556648 chr1 215120596 G A 9.05E-05 Major depressive disorder / / 21621269 rs556648 chr1 215120596 G A 3.84E-05 Major depressive disorder / / pha002850 rs549523 chr1 215127770 A G 5.97E-05 Blood Pressure / / pha003039 rs1452628 chr1 215139887 A T 2.10E-05 Urinary metabolites / / 21572414 rs61819972 chr1 215167654 T G 0.00008829 Sarcoidosis / / 22952805 rs56152266 chr1 215168036 A G 0.00008829 Sarcoidosis / / 22952805 rs61819973 chr1 215168874 T G 0.00008829 Sarcoidosis / / 22952805 rs61819974 chr1 215169703 T C 0.00008589 Sarcoidosis / / 22952805 rs10494989 chr1 215188239 G A 2.40E-05 Lipid traits KCNK2 intron 17903299 rs12064317 chr1 215227041 G T 6.10E-05 White matter hyperintensity burden KCNK2 intron 21681796 rs12066755 chr1 215231442 A T 7.70E-05 White matter hyperintensity burden KCNK2 intron 21681796 rs6665177 chr1 215231468 A G 6.20E-05 White matter hyperintensity burden KCNK2 intron 21681796 rs12088480 chr1 215246836 C T 7.80E-05 White matter hyperintensity burden KCNK2 intron 21681796 rs11120483 chr1 215247294 A G 7.70E-05 White matter hyperintensity burden KCNK2 intron 21681796 rs7528988 chr1 215248417 C T 9.78E-04 Obesity (extreme) KCNK2 intron 21935397 rs11120504 chr1 215307777 G T 8.68E-05 Melanoma KCNK2 intron 21926416 rs12567520 chr1 215329267 G A 3.31E-04 Alzheimer's disease (late onset) KCNK2 intron 21379329 rs17024342 chr1 215342573 C T 1.42E-04 Multiple complex diseases KCNK2 cds-synon 17554300 rs12038695 chr1 215377957 C A 7.35E-05 Melanoma KCNK2 intron 21926416 rs12753507 chr1 215380352 G A 7.51E-05 Melanoma KCNK2 intron 21926416 rs12753507 chr1 215380352 G A 8.91E-05 Receptive language ability KCNK2 intron 24687471 rs6540886 chr1 215398012 A G 8.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNK2 intron 20877124 rs946487 chr1 215415383 A G 6.49E-04 Multiple complex diseases / / 17554300 rs10494997 chr1 215460047 G A 1.36E-05 Triglycerides / / pha002904 rs11120550 chr1 215491234 G A 5.25E-04 Multiple complex diseases / / 17554300 rs6678266 chr1 215507774 G C 3.17E-05 Multiple complex diseases / / 17554300 rs11120565 chr1 215516983 T C 5.04E-04 Multiple complex diseases / / 17554300 rs2089427 chr1 215570581 A G 7.82E-05 Melanoma / / 21926416 rs1319603 chr1 215631500 T C 6.28E-04 Multiple complex diseases / / 17554300 rs1911546 chr1 215649097 C T 3.66E-04 Alcohol dependence / / 21314694 rs2677112 chr1 215825167 T G 8.56E-04 Alcohol dependence USH2A intron 21314694 rs4655413 chr1 215828499 C T 4.56E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) USH2A intron 24023788 rs11120594 chr1 215839090 G A 1.00E-05 Alcoholism (heaviness of drinking) USH2A intron 21529783 rs2797234 chr1 215848587 T C 1.20E-04 Alzheimer's disease USH2A cds-synon 24755620 rs2797235 chr1 215848641 T C 1.88E-05 Cognitive test performance / / 20125193 rs11120597 chr1 215850892 G A 8.89E-04 Depression (quantitative trait) USH2A intron 20800221 rs1857226 chr1 215888712 G T 7.36E-04 Alzheimer's disease USH2A intron 17998437 rs2797218 chr1 215893303 A G 3.55E-05 Erythrocyte counts USH2A intron pha003099 rs2820710 chr1 215897099 T G 1.90E-05 Erythrocyte counts USH2A intron pha003099 rs17025239 chr1 215898222 G A 9.87E-04 Myopia (pathological) USH2A intron 21095009 rs12406638 chr1 215902239 G A 8.37E-05 Hemoglobin USH2A intron pha003098 rs12406638 chr1 215902239 G A 1.34E-05 Erythrocyte counts USH2A intron pha003099 rs4330896 chr1 215904873 G A 8.03E-05 Glucose levels USH2A intron pha002899 rs4330896 chr1 215904873 G A 2.24E-05 Erythrocyte counts USH2A intron pha003099 rs2797221 chr1 215912642 T C 8.30E-05 Blood pressure USH2A intron 21060006 rs2797221 chr1 215912642 T C 8.60E-07 Blood pressure USH2A intron 21060006 rs2820727 chr1 215928321 C T 5.59E-05 Hemoglobin USH2A intron pha003098 rs11120620 chr1 215928483 T C 1.90E-05 Glucose levels USH2A intron pha002899 rs17025389 chr1 215941805 C T 4.38E-04 Response to statin treatment (atorvastatin),change in cholesterol levels USH2A intron 20031582 rs6540910 chr1 215949580 T A 9.39E-04 Multiple complex diseases USH2A intron 17554300 rs6665799 chr1 215955937 T G 1.98E-04 Lung function (forced expiratory volume in 1 second) USH2A intron 24023788 rs12063584 chr1 216053570 C G 5.24E-06 Height USH2A intron 20400458 rs7513600 chr1 216054304 T G 4.12E-04 Acute lung injury USH2A intron 22295056 rs12136954 chr1 216055493 T C 5.97E-04 Insulin resistance USH2A intron 21901158 rs17025548 chr1 216056348 A G 8.00E-06 IgG glycosylation USH2A intron 23382691 rs1556940 chr1 216056779 T C 8.96E-05 Monocyte counts USH2A intron pha003089 rs1325523 chr1 216074957 C A 8.81E-06 Response to citalopram treatment USH2A intron 19846067 rs11120695 chr1 216080130 G T 5.91E-04 Celiac disease USH2A intron 23936387 rs942837 chr1 216099194 T C 1.39E-04 Suicide attempts in bipolar disorder USH2A intron 21041247 rs513746 chr1 216102796 T C 1.41E-04 Suicide attempts in bipolar disorder USH2A intron 21041247 rs517577 chr1 216103270 A G 1.41E-04 Suicide attempts in bipolar disorder USH2A intron 21041247 rs662355 chr1 216103777 G C 1.43E-04 Suicide attempts in bipolar disorder USH2A intron 21041247 rs647908 chr1 216104726 A C 1.45E-04 Suicide attempts in bipolar disorder USH2A intron 21041247 rs498911 chr1 216104980 A C 2.38E-04 Suicide attempts in bipolar disorder USH2A intron 21041247 rs646576 chr1 216105016 A G 1.45E-04 Suicide attempts in bipolar disorder USH2A intron 21041247 rs492474 chr1 216112208 T G 1.51E-04 Suicide attempts in bipolar disorder USH2A intron 21041247 rs772713 chr1 216113287 A C 1.76E-04 Suicide attempts in bipolar disorder USH2A intron 21041247 rs6690523 chr1 216139575 A C 8.54E-04 Coronary heart disease USH2A intron 21971053 rs1992099 chr1 216167644 T C 5.75E-04 Insulin resistance USH2A intron 21901158 rs10864219 chr1 216172380 A G 6.03E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines USH2A missense 21844884 rs12126638 chr1 216175696 T C 9.56E-05 Nicotine smoking USH2A intron 19268276 rs7541086 chr1 216176250 G A 3.30E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines USH2A intron 21844884 rs6696269 chr1 216181197 T C 3.40E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines USH2A intron 21844884 rs17645898 chr1 216215944 G A 1.38E-05 Bipolar disorder USH2A intron 17486107 rs17026081 chr1 216269176 C T 4.94E-04 Lung function (forced vital capacity) USH2A intron 24023788 rs421821 chr1 216282495 A G 8.06E-05 Height USH2A intron pha003011 rs301734 chr1 216292566 G T 1.89E-04 Type 2 diabetes USH2A intron 17463246 rs637374 chr1 216293543 A G 2.40E-14 Health and aging,CVD and cancer age of onset USH2A intron 22174011 rs637374 chr1 216293543 A G 3.00E-09 Health and aging,CVD and cancer age of onset USH2A intron 22174011 rs532342 chr1 216298635 T C 1.00E-04 Information processing speed USH2A intron 21130836 rs17026130 chr1 216298733 C G 4.78E-04 Type 2 diabetes USH2A intron 17463246 rs10495017 chr1 216300399 G A 6.74E-04 Type 2 diabetes USH2A intron 17463246 rs448588 chr1 216313208 G A 4.32E-05 Information processing speed USH2A intron 21130836 rs17026170 chr1 216314566 C T 2.51E-04 Type 2 diabetes USH2A intron 17463246 rs594799 chr1 216317495 T C 4.32E-05 Information processing speed USH2A intron 21130836 rs301755 chr1 216332012 C T 1.35E-05 Information processing speed USH2A intron 21130836 rs1805049 chr1 216348764 C T 1.58E-05 Height / / pha003011 rs2274117 chr1 216363137 G A 1.72E-05 Height USH2A intron pha003011 rs407590 chr1 216368414 T C 6.23E-05 Height USH2A intron pha003010 rs407590 chr1 216368414 T C 4.64E-07 Height USH2A intron pha003011 rs148135241 chr1 216373416 A C 0.000038 Prostate cancer (advanced) USH2A missense 23555315 rs3754064 chr1 216384908 G T 4.55E-07 Height USH2A intron pha003011 rs2669057 chr1 216400022 C T 2.49E-05 Height USH2A intron pha003010 rs2669057 chr1 216400022 C T 4.38E-08 Height USH2A intron pha003011 rs773498 chr1 216400158 C T 4.01E-05 Height USH2A intron pha003011 rs600535 chr1 216403499 A G 2.49E-05 Height USH2A intron pha003010 rs600535 chr1 216403499 A G 4.38E-08 Height USH2A intron pha003011 rs3767693 chr1 216410939 T G 4.20E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines USH2A intron 21844884 rs6703090 chr1 216431593 G A 6.53E-04 Insulin resistance USH2A intron 21901158 rs386654 chr1 216431962 G A 3.21E-05 Height USH2A intron pha003010 rs386654 chr1 216431962 G A 8.18E-08 Height USH2A intron pha003011 rs700022 chr1 216435996 T C 5.66E-06 Height USH2A intron pha003011 rs11120747 chr1 216438500 G A 2.23E-05 Height USH2A intron pha003011 rs2168924 chr1 216440105 G A 6.03E-04 Type 2 diabetes USH2A intron 17463246 rs2168924 chr1 216440105 G A 2.90E-06 Urinary metabolites USH2A intron 21572414 rs10779667 chr1 216452846 G A 6.39E-05 Height USH2A intron pha003011 rs1159143 chr1 216454483 T G 9.72E-07 Height USH2A intron pha003011 rs700025 chr1 216461304 T C 1.54E-05 Glycosylated haemoglobin levels USH2A intron 17255346 rs17042212 chr1 216473745 A G 8.75E-07 Height USH2A intron pha003011 rs11801737 chr1 216492391 A G 2.00E-05 Height USH2A intron pha003011 rs7532570 chr1 216504269 A G 6.00E-06 IgG glycosylation USH2A intron 23382691 rs1606357 chr1 216521091 C T 2.93E-05 Height USH2A intron pha003011 rs2809299 chr1 216540541 T C 0.00013 Coronary artery calcification USH2A intron 23727086 rs1588656 chr1 216549082 C A 8.04E-04 Type 2 diabetes USH2A intron 17463246 rs17026635 chr1 216552367 C T 6.33E-07 Lipid traits USH2A intron 21777205 rs7545826 chr1 216612801 C T 4.24E-04 Type 2 diabetes / / 17463246 rs4548509 chr1 216630824 A G 9.49E-08 Metabolite levels / / 23281178 rs10495024 chr1 216632948 T C 6.00E-06 Testosterone levels / / 22675492 rs4338426 chr1 216649667 C T 2.20E-05 Response to antidepressants / / 19736353 rs7548662 chr1 216656646 G A 2.93E-04 Blood pressure / / 17255346 rs7548662 chr1 216656646 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11582478 chr1 216670203 T G 9.18E-04 Myopia (pathological) / / 21095009 rs4360581 chr1 216671992 C T 8.10E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11117608 chr1 216701242 G A 4.15E-04 Suicide attempts in bipolar disorder ESRRG intron 21423239 rs4846514 chr1 216702685 T C 7.31E-04 Type 2 diabetes ESRRG intron 17463246 rs6696225 chr1 216705965 T C 1.34E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ESRRG intron 23648065 rs1833036 chr1 216707012 G T 1.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ESRRG intron 23648065 rs6694260 chr1 216712891 C A 5.40E-04 Schizophrenia ESRRG intron 19197363 rs2377098 chr1 216715514 G T 3.33E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ESRRG intron 23648065 rs12145418 chr1 216716320 G T 2.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ESRRG intron 23648065 rs12757165 chr1 216716537 A G 1.00E-07 Cardiac hypertrophy ESRRG intron 21348951 rs6658528 chr1 216722090 C T 4.65E-06 Statin-induced myopathy ESRRG intron 21826682 rs73089908 chr1 216725230 T G 5.64E-14 Metabolite levels ESRRG intron 22286219 rs10442688 chr1 216726333 T C 6.60E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ESRRG intron 23648065 rs4846528 chr1 216727323 C T 3.43E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ESRRG intron 23648065 rs7553212 chr1 216738788 A C,G,T 7.00E-06 Alcohol consumption ESRRG intron 23743675 rs1984137 chr1 216745245 A G 1.48E-04 Lung function (forced vital capacity) ESRRG intron 24023788 rs1984137 chr1 216745245 A G 3.59E-05 Height ESRRG intron pha003010 rs1984137 chr1 216745245 A G 8.71E-05 Height ESRRG intron pha003011 rs17669622 chr1 216756821 G A 9.00E-07 Mean arterial pressure (alcohol consumption interaction) ESRRG intron 24376456 rs4124653 chr1 216785099 G A 4.68E-04 Acute lung injury ESRRG intron 22295056 rs7553463 chr1 216788184 G A 4.68E-04 Acute lung injury ESRRG intron 22295056 rs1498276 chr1 216788927 T C 4.68E-04 Acute lung injury ESRRG intron 22295056 rs6673566 chr1 216789386 T G 4.68E-04 Acute lung injury ESRRG intron 22295056 rs6673588 chr1 216789443 T G 3.83E-05 Ulcerative colitis ESRRG intron 19915573 rs6673588 chr1 216789443 T G 4.68E-04 Acute lung injury ESRRG intron 22295056 rs1857413 chr1 216812324 C T 6.91E-04 Response to cytadine analogues (cytosine arabinoside) ESRRG intron 24483146 rs1817998 chr1 216813244 C T 7.28E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ESRRG intron 24023788 rs12023399 chr1 216819427 C G 7.17E-05 Schizophrenia ESRRG intron 20832056 rs946465 chr1 216840371 C T 2.05E-04 Lung function (forced expiratory volume in 1 second) ESRRG intron 24023788 rs10779275 chr1 216843588 C T 1.80E-05 Urinary metabolites ESRRG intron 21572414 rs10127480 chr1 216844423 T C 2.67E-04 Lung function (forced expiratory volume in 1 second) ESRRG intron 24023788 rs10779276 chr1 216857387 A G 9.01E-05 Height ESRRG intron pha003010 rs2813711 chr1 216879911 A G 2.36E-05 Bone mineral traits,in men ESRRG intron 21427758 rs2813711 chr1 216879911 A G 3.68E-05 Bone mineral traits,in men ESRRG intron 21427758 rs2813711 chr1 216879911 A G 7.13E-05 Bone mineral traits,in men ESRRG intron 21427758 rs1416617 chr1 216910472 G A 7.53E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ESRRG intron 20031582 rs10779279 chr1 216925972 G A 3.98E-05 Multiple complex diseases ESRRG intron 17554300 rs6604643 chr1 216927468 A G 4.71E-04 Multiple complex diseases ESRRG intron 17554300 rs6604644 chr1 216940621 A G 7.74E-05 Creatinine levels ESRRG intron pha003069 rs2813694 chr1 216942781 A C 6.00E-05 Prostate cancer ESRRG intron 21743057 rs6702277 chr1 216956685 C T 7.70E-05 Fasting plasma glucose ESRRG intron 19060907 rs7355008 chr1 216966601 T C 9.82E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) ESRRG intron 23648065 rs12723353 chr1 216984496 T G 7.31E-05 HIV-1 control ESRRG intron 20041166 rs3738490 chr1 216998464 A G 3.25E-04 White matter integrity ESRRG intron 22425255 rs2164613 chr1 217003419 C T 5.98E-05 HIV-1 control ESRRG intron 20041166 rs1561186 chr1 217007348 C T 2.83E-04 Tourette syndrome ESRRG intron 22889924 rs10492953 chr1 217009575 A G 1.68E-04 Tourette syndrome ESRRG intron 22889924 rs10492953 chr1 217009575 A G 4.87E-04 Lung function (forced expiratory volume in 1 second) ESRRG intron 24023788 rs1542003 chr1 217019565 T C 2.22E-04 Tourette syndrome ESRRG intron 22889924 rs11117697 chr1 217021466 G A 8.19E-04 Tourette syndrome ESRRG intron 22889924 rs11117697 chr1 217021466 G A 1.89E-04 Lung function (forced expiratory volume in 1 second) ESRRG intron 24023788 rs12086350 chr1 217025695 T C 1.35E-04 Multiple complex diseases ESRRG intron 17554300 rs7537872 chr1 217028528 T C 9.30E-04 Multiple complex diseases ESRRG intron 17554300 rs11572550 chr1 217040549 C A 4.91E-04 Multiple complex diseases ESRRG intron 17554300 rs1436899 chr1 217057482 A G 7.12E-04 Nicotine smoking ESRRG intron 19268276 rs1436900 chr1 217058479 C T 7.00E-06 optic disc size (cup) ESRRG intron 20395239 rs12029460 chr1 217064861 A C 2.48E-05 Multiple complex diseases ESRRG intron 17554300 rs4436447 chr1 217070040 A C 2.09E-04 Amyotrophic lateral sclerosis (sporadic) ESRRG intron 24529757 rs2576206 chr1 217071322 G A 7.00E-06 Urinary metabolites ESRRG intron 21572414 rs1025652 chr1 217082139 T A 9.59E-05 Cervical cancer ESRRG intron 24700089 rs4348786 chr1 217082283 C T 1.57E-05 Esophageal cancer (squamous cell) ESRRG intron 22960999 rs4348786 chr1 217082283 C T 9.59E-05 Cervical cancer ESRRG intron 24700089 rs1436879 chr1 217082385 C T 9.14E-04 Depression (quantitative trait) ESRRG intron 20800221 rs11572505 chr1 217094044 T C 1.10E-04 Alcohol dependence ESRRG intron 20201924 rs4335430 chr1 217100231 C T 4.31E-06 Brain infarcts,covert MRI-defined ESRRG intron 20044523 rs2818781 chr1 217136773 C T 2.20E-04 Type 2 diabetes ESRRG intron 17846126 rs11117745 chr1 217173648 T G 1.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ESRRG UTR-5 20877124 rs2789567 chr1 217177525 C T 3.60E-09 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ESRRG intron 20877124 rs2789571 chr1 217180432 G T 9.18E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ESRRG intron 20877124 rs17686866 chr1 217185265 C A 0.0000038 Preeclampsia ESRRG intron 22748001 rs17686866 chr1 217185265 C A 8.99E-06 Preeclampsia ESRRG intron 23551011 rs2818752 chr1 217185558 G A 4.77E-07 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ESRRG intron 20877124 rs6604651 chr1 217195463 A G 7.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ESRRG intron 20877124 rs2377360 chr1 217200883 G A 9.00E-06 Major depressive disorder ESRRG intron 23377640 rs7527281 chr1 217203091 C A 2.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ESRRG intron 20877124 rs4846811 chr1 217246640 T G 5.77E-04 Multiple complex diseases ESRRG intron 17554300 rs6696046 chr1 217253266 T C 1.40E-05 Urinary metabolites ESRRG intron 21572414 rs1339220 chr1 217265073 G T 1.13E-04 Multiple complex diseases ESRRG intron 17554300 rs830307 chr1 217270667 A C 3.52E-05 Brain derived neurotrophic factor levels,in serum ESRRG intron 22047184 rs830307 chr1 217270667 A C 3.02E-05 Cognitive impairment induced by topiramate ESRRG intron 22091778 rs12033461 chr1 217272629 T C 1.00E-04 Information processing speed ESRRG intron 21130836 rs12026424 chr1 217274676 G C 9.00E-04 Acute lymphoblastic leukemia (childhood) ESRRG intron 20189245 rs11117772 chr1 217281640 T C 4.59E-04 Depression (quantitative trait) ESRRG intron 20800221 rs987445 chr1 217282499 G T 4.56E-04 Depression (quantitative trait) ESRRG intron 20800221 rs987445 chr1 217282499 G T 2.98E-07 Cognitive impairment induced by topiramate ESRRG intron 22091778 rs1354221 chr1 217285309 A G 6.78E-05 Cognitive impairment induced by topiramate ESRRG intron 22091778 rs11576806 chr1 217290281 C T 6.67E-05 Bipolar disorder ESRRG intron 20451256 rs11576172 chr1 217324654 G A 7.53E-04 Coronary heart disease / / 21971053 rs7555255 chr1 217350383 T C 3.88E-05 Receptive language ability / / 24687471 rs11117791 chr1 217355588 G A 3.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17045405 chr1 217356154 T C 4.00E-05 Coffee consumption / / 21357676 rs1827438 chr1 217359640 A T 8.66E-05 Personality dimensions / / 23903073 rs1393385 chr1 217368088 T C 1.14E-04 Multiple complex diseases / / 17554300 rs1502342 chr1 217376665 T G 4.22E-04 Type 2 diabetes / / 17463246 rs1502342 chr1 217376665 T G 4.39E-04 Multiple complex diseases / / 17554300 rs12049257 chr1 217377070 A C 4.38E-04 Type 2 diabetes / / 17463246 rs12049257 chr1 217377070 A C 9.07E-04 Multiple complex diseases / / 17554300 rs1502367 chr1 217396359 C G 9.79E-04 Type 2 diabetes / / 17463246 rs11117808 chr1 217396792 C A 1.00E-06 Urinary metabolites / / 21572414 rs11117811 chr1 217398583 G A 3.49E-04 Type 2 diabetes / / 17463246 rs11117811 chr1 217398583 G A 3.12E-04 Multiple complex diseases / / 17554300 rs4131971 chr1 217423490 G C 3.02E-04 Type 2 diabetes / / 17463246 rs4846828 chr1 217429631 G A 1.47E-04 Smoking cessation / / 18519826 rs4846828 chr1 217429631 G A 2.29E-05 Smoking cessation / / 18519826 rs4146799 chr1 217435636 G A 8.05E-06 Asthma / / 21790008 rs4498862 chr1 217439859 A G 2.06E-05 Cognitive impairment induced by topiramate / / 22091778 rs11117833 chr1 217447992 T C 8.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs6604543 chr1 217452415 A G 8.43E-04 Suicide attempts in bipolar disorder / / 21041247 rs4846406 chr1 217453219 G A 8.05E-06 Asthma / / 21790008 rs4846411 chr1 217461144 C A 8.05E-06 Asthma / / 21790008 rs12758898 chr1 217471995 C T 6.52E-06 Parkinson's disease / / 21738487 rs34588585 chr1 217478881 A AT 4.47E-04 Multiple complex diseases / / 17554300 rs6671908 chr1 217478881 A T 4.47E-04 Multiple complex diseases / / 17554300 rs2646806 chr1 217479640 T C 1.79E-04 Smoking cessation / / 18519826 rs2815205 chr1 217486452 C T 6.62E-04 Type 2 diabetes / / 17463246 rs2815206 chr1 217489760 G A 8.77E-04 Type 2 diabetes / / 17463246 rs12354289 chr1 217490684 A C 5.65E-05 Multiple complex diseases / / 17554300 rs2173289 chr1 217510208 T A 3.37E-04 Gallstones / / 17632509 rs17046085 chr1 217522491 A G 9.63E-04 Multiple complex diseases / / 17554300 rs1497828 chr1 217527024 C G 4.00E-06 Dialysis-related mortality / / 21546767 rs2646821 chr1 217528236 C T 5.69E-05 Smoking cessation / / 18519826 rs11809557 chr1 217563420 G A 2.04E-04 Multiple complex diseases / / 17554300 rs17046325 chr1 217572751 T C 4.78E-05 Smoking cessation / / 18519826 rs2646849 chr1 217584106 A T 5.90E-06 Urinary metabolites / / 21572414 rs12128013 chr1 217599330 G C 6.65E-05 Serum metabolites / / 19043545 rs7520483 chr1 217604777 G A 8.03E-05 Serum metabolites GPATCH2 intron 19043545 rs265130 chr1 217616105 T C 1.20E-05 Urinary metabolites GPATCH2 intron 21572414 rs265128 chr1 217616760 T A 8.31E-05 Response to metformin GPATCH2 intron 21186350 rs4846415 chr1 217680035 C T 2.46E-04 Heart Failure GPATCH2 intron pha002884 rs2059397 chr1 217718132 C G 6.00E-06 Visceral adipose tissue adjusted for BMI GPATCH2 intron 22589738 rs2042525 chr1 217739036 T C 9.02E-05 Hypertension (essential hypertension) GPATCH2 intron 22184326 rs6704368 chr1 217775681 A T 8.77E-04 Alzheimer's disease GPATCH2 intron 24755620 rs10495065 chr1 217833200 C G 4.34E-04 Type 2 diabetes SPATA17 intron 17463246 rs6692477 chr1 217842129 A G 1.50E-05 Lipid levels SPATA17 intron 18193043 rs10863335 chr1 217842887 A G 9.12E-05 Suicide attempts in bipolar disorder SPATA17 intron 21423239 rs4347270 chr1 217888972 A G 4.40E-05 Coronary heart disease SPATA17 intron 21606135 rs4347270 chr1 217888972 A G 8.85E-04 Alzheimer's disease SPATA17 intron 24755620 rs4846429 chr1 217890974 T A 3.17E-04 Suicide attempts in bipolar disorder SPATA17 intron 21423239 rs10495072 chr1 217892890 T C 8.84E-04 Alzheimer's disease SPATA17 intron 24755620 rs6673733 chr1 217916357 A G 4.54E-04 Alzheimer's disease SPATA17 intron 24755620 rs10495074 chr1 217931665 A G 5.32E-05 Alzheimer's disease SPATA17 intron 24755620 rs17726462 chr1 217951156 A G 1.12E-04 Alzheimer's disease SPATA17 intron 24755620 rs11578620 chr1 217985428 T C 1.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPATA17 intron 20877124 rs6674883 chr1 218008788 G A 3.18E-04 Type 2 diabetes SPATA17 intron 17463246 rs6674883 chr1 218008788 G A 5.62E-04 Response to taxane treatment (placlitaxel) SPATA17 intron 23006423 rs12409486 chr1 218016827 A G 1.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPATA17 intron 20877124 rs1567449 chr1 218018956 C T 6.80E-04 Alcohol consumption (maxi-drinks) SPATA17 intron 24277619 rs12759918 chr1 218021137 C T 6.67E-04 Alcohol consumption (maxi-drinks) SPATA17 intron 24277619 rs12748013 chr1 218024308 G A 3.60E-06 Urinary metabolites SPATA17 intron 21572414 rs11117953 chr1 218036817 G A 7.11E-05 Left ventricular hypertrophy SPATA17 intron pha003052 rs17739539 chr1 218054687 C T 4.66E-05 Tuberculosis / / 22306650 rs17739539 chr1 218054687 C T 2.70E-04 Tuberculosis / / 24057671 rs11117970 chr1 218072745 A C 5.38E-05 Serum metabolites / / 19043545 rs4846446 chr1 218075115 G A 9.58E-05 Serum metabolites / / 19043545 rs10495084 chr1 218079260 G C 3.76E-04 Smoking quantity / / 24665060 rs871378 chr1 218085255 G A 1.74E-04 Heart Failure / / pha002884 rs6685632 chr1 218090414 A G 5.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs6604568 chr1 218094151 G A 2.33E-05 Eating disorders / / 22911880 rs10495085 chr1 218105019 C T 1.40E-04 IgE levels in asthmatics / / 23967269 rs17691163 chr1 218128141 G A 8.00E-06 Urinary metabolites / / 21572414 rs17691163 chr1 218128141 G A 3.88E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs7546897 chr1 218147287 C T 4.60E-04 Alzheimer's disease / / 22005930 rs7546902 chr1 218147297 C T 7.09E-04 Alzheimer's disease / / 22005930 rs2171963 chr1 218169961 G A 8.67E-04 Myocardial Infarction / / pha002873 rs1490331 chr1 218198027 T C 5.10E-04 Myocardial Infarction / / pha002873 rs17047227 chr1 218198395 C T 4.40E-06 Phospholipid levels (plasma) / / 21829377 rs11118018 chr1 218215033 A T 5.36E-04 Type 2 diabetes / / 17463246 rs4846459 chr1 218230035 C T 6.99E-04 Type 2 diabetes / / 17463246 rs12127278 chr1 218248260 A G 1.99E-04 Amyotrophic lateral sclerosis / / 20801718 rs10863373 chr1 218251692 G T 4.08E-04 Longevity / / 22279548 rs2130586 chr1 218254376 A C 5.29E-04 Smoking initiation / / 24665060 rs10157529 chr1 218263870 T C 7.79E-04 Type 2 diabetes / / 17463246 rs6658076 chr1 218347150 T C 3.22E-05 Type 2 diabetes / / 17463246 rs10495096 chr1 218348909 T C 3.45E-04 Hearing function / / 17255346 rs10495096 chr1 218348909 T C 4.81E-04 Type 2 diabetes / / 17463246 rs10495096 chr1 218348909 T C 3.65E-05 Schizophrenia / / 20832056 rs10863379 chr1 218354793 G T 9.50E-04 Alzheimer's disease / / 17998437 rs7553207 chr1 218370200 T C 1.24E-05 Bone mineral density / / 19181680 rs11118052 chr1 218379881 G A 5.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs10863384 chr1 218428101 A C 4.51E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1338445 chr1 218439928 T C 2.81E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs11118070 chr1 218465933 A C 2.64E-04 Alzheimer's disease (late onset) RRP15 intron 21379329 rs1933641 chr1 218468961 T C 2.38E-188 Multiple complex diseases RRP15 intron 17554300 rs11118083 chr1 218500591 G A 2.69E-04 Alzheimer's disease (late onset) RRP15 intron 21379329 rs17047682 chr1 218523025 A G 9.20E-05 Lung adenocarcinoma TGFB2 intron 22797724 rs17047703 chr1 218525588 C A 2.17E-04 Hearing function TGFB2 intron 17255346 rs3892225 chr1 218553297 A G 3.41E-05 Response to tocilizumab in rheumatoid arthritis TGFB2 intron 22491018 rs10482751 chr1 218556297 T C 2.32E-04 Celiac disease TGFB2 intron 23936387 rs12029576 chr1 218559475 C A 1.99E-04 Celiac disease TGFB2 intron 23936387 rs1342586 chr1 218597859 C T 4.96E-05 Heart Rate TGFB2 intron pha003053 rs4846480 chr1 218598469 A T 8.00E-09 Chronic obstructive pulmonary disease (severe) TGFB2 intron 24621683 rs6684205 chr1 218609702 A G 2.00E-12 Height TGFB2 intron 20881960 rs10482821 chr1 218610434 C A 9.31E-06 Multiple complex diseases TGFB2 intron 17554300 rs900 chr1 218614905 A T 5.20E-08 Height TGFB2 UTR-3 21194676 rs900 chr1 218614905 A T 6.00E-10 Height TGFB2 UTR-3 21194676 rs623356 chr1 218647386 T C 6.15E-05 Magnesium levels / / pha003092 rs6665024 chr1 218690577 G A 8.01E-04 Taste perception / / 22132133 rs11118120 chr1 218705761 A C 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1018040 chr1 218705814 T A 1.24E-04 Body mass index / / 17255346 rs1018040 chr1 218705814 T A 5.28E-04 Multiple complex diseases / / 17554300 rs1018040 chr1 218705814 T A 5.00E-06 Attention deficit hyperactivity disorder / / 18821565 rs1018040 chr1 218705814 T A 8.00E-06 Hyperactive-impulsive symptoms / / 18821565 rs12563275 chr1 218706772 T C 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs12563275 chr1 218706772 T C 3.37E-05 Alzheimer's disease (age of onset) / / 22005931 rs512589 chr1 218708110 A G 8.50E-06 Bipolar disorder / / 20451256 rs2047163 chr1 218708603 C A 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2047163 chr1 218708603 C A 3.42E-05 Alzheimer's disease (age of onset) / / 22005931 rs987074 chr1 218715320 G C 3.91E-05 Alzheimer's disease (age of onset) / / 22005931 rs4846489 chr1 218718037 T C 4.38E-05 Alzheimer's disease (age of onset) / / 22005931 rs11118121 chr1 218719755 T C 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs11118121 chr1 218719755 T C 4.74E-05 Alzheimer's disease (age of onset) / / 22005931 rs11118123 chr1 218720002 G A 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs10863400 chr1 218723535 T C 2.80E-05 Urinary metabolites / / 21572414 rs1603059 chr1 218727857 T C 7.00E-04 Bipolar disorder / / 19259986 rs259474 chr1 218759983 A G 1.74E-04 Type 2 diabetes / / 17463246 rs259474 chr1 218759983 A G 5.33E-04 Multiple complex diseases / / 17554300 rs17048238 chr1 218761681 C T 9.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs996221 chr1 218788434 A C 5.14E-04 Type 2 diabetes / / 17463246 rs6690218 chr1 218832257 T C 5.70E-06 Urinary metabolites / / 21572414 rs11485142 chr1 218833214 A C 1.41E-06 Hearing function / / 21493956 rs11485142 chr1 218833214 A C 2.10E-05 Urinary metabolites / / 21572414 rs1159268 chr1 218844906 G A 4.00E-08 Acne (severe) / / 24927181 rs28463616 chr1 218854635 T C 0.0000889 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs28627122 chr1 218855367 A G 0.0000852 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6696363 chr1 218855636 T C 0.0000958 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs993925 chr1 218860068 C T 1.00E-08 Pulmonary function / / 21946350 rs1383756 chr1 218872624 C T 4.71E-05 Aging (time to event) / / 21782286 rs17571465 chr1 218890658 A T 7.77E-04 Multiple complex diseases / / 17554300 rs2378002 chr1 218922358 G T 1.99E-07 Esophageal cancer (squamous cell) / / 22960999 rs12037343 chr1 218931905 G T 3.00E-06 Smooth-surface caries / / 24556642 rs7542694 chr1 218931976 C T 1.20E-05 Urinary metabolites / / 21572414 rs17048517 chr1 218934929 C A 2.95E-06 Smooth-surface caries / / 24556642 rs6541199 chr1 218938961 C T 2.12E-05 Prion diseases / / 22210626 rs10495107 chr1 218970504 G A 2.38E-04 Type 2 diabetes / / 17846124 rs12033283 chr1 218992800 G A 7.42E-06 Smooth-surface caries / / 24556642 rs7552186 chr1 218995273 C T 3.00E-08 Height / / 23563607 rs642836 chr1 219023654 G A 2.19E-04 Multiple complex diseases / / 17554300 rs17048805 chr1 219065882 G T 0.0006807 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17048805 chr1 219065882 G T 6.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17048811 chr1 219067810 C T 0.0006763 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17048811 chr1 219067810 C T 6.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9661984 chr1 219083060 T G 7.42E-04 Alcohol dependence / / 24277619 rs2275335 chr1 219086396 T C 7.10E-07 Iron levels / / 21208937 rs11118175 chr1 219089313 A G 5.67E-04 Iron levels / / pha002876 rs12728902 chr1 219095005 G C 1.28E-05 Reading and spelling / / 23738518 rs626518 chr1 219101848 C T 2.50E-04 Alzheimer's disease (late onset) / / 21379329 rs2788271 chr1 219117743 T G 2.35E-05 Alzheimer's disease (late onset) / / 21379329 rs11118180 chr1 219117863 A C 1.94E-04 Alzheimer's disease (late onset) / / 21379329 rs10495117 chr1 219135058 C T 9.85E-06 Bilirubin levels,in serum / / 19389676 rs618171 chr1 219149298 A G 2.00E-07 Bilirubin levels,in serum / / 19389676 rs11581158 chr1 219150622 C T 1.54E-06 Alzheimer's disease (late onset) / / 21379329 rs7540160 chr1 219176608 A G 9.91E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs10495127 chr1 219208920 T C 1.38E-04 Alzheimer's disease (late onset) / / 21379329 rs1625084 chr1 219217875 C T 5.71E-04 Smoking cessation / / 24665060 rs1256682 chr1 219222502 A G 7.55E-04 Smoking cessation / / 24665060 rs945761 chr1 219235064 T C 3.85E-04 Coronary heart disease / / 21971053 rs1256598 chr1 219243302 A T 4.73E-04 Smoking cessation / / 24665060 rs17579646 chr1 219248069 T G 2.27E-06 Alzheimer's disease (late onset) / / 21379329 rs1256638 chr1 219248086 A G 6.06E-04 Smoking cessation / / 24665060 rs1256617 chr1 219257488 G T 8.03E-04 Alzheimer's disease LOC643723 intron 22005930 rs1256623 chr1 219261001 C G 7.19E-04 Alzheimer's disease LOC643723 intron 22005930 rs1256567 chr1 219265380 T A 9.95E-04 Alzheimer's disease LOC643723 intron 22005930 rs1256568 chr1 219265915 C T 7.35E-04 Alzheimer's disease LOC643723 intron 22005930 rs1146772 chr1 219273409 C T 7.26E-04 Alzheimer's disease LOC643723 intron 22005930 rs12141207 chr1 219273881 A G 1.01E-05 Mammographic density LOC643723 intron 22532574 rs10863427 chr1 219283784 A G 6.45E-04 Alzheimer's disease LOC643723 intron 22005930 rs17049050 chr1 219294927 G C 9.56E-04 Multiple complex diseases LOC643723 intron 17554300 rs7545152 chr1 219298539 G A 7.06E-05 Cognitive impairment induced by topiramate LOC643723 intron 22091778 rs10863429 chr1 219299794 T C 4.74E-04 Obesity (extreme) LOC643723 intron 21935397 rs11118219 chr1 219301677 T G 3.87E-04 Alzheimer's disease LOC643723 intron 22005930 rs12119171 chr1 219305114 T C 5.26E-04 Alzheimer's disease LOC643723 intron 22005930 rs12067803 chr1 219306923 A G 7.08E-04 Obesity (extreme) LOC643723 intron 21935397 rs7543820 chr1 219307899 G A 7.73E-04 Obesity (extreme) LOC643723 intron 21935397 rs6657093 chr1 219308575 A T 2.52E-04 Alzheimer's disease LOC643723 intron 22005930 rs6655927 chr1 219312063 G C 2.51E-04 Alzheimer's disease LOC643723 intron 22005930 rs12119303 chr1 219314550 G T 2.84E-04 Alzheimer's disease LOC643723 intron 22005930 rs12134260 chr1 219314816 C T 2.51E-04 Alzheimer's disease LOC643723 intron 22005930 rs1404360 chr1 219318128 A G 7.36E-04 Alzheimer's disease LOC643723 intron 22005930 rs7523306 chr1 219320846 G A 8.02E-04 Obesity (extreme) LOC643723 intron 21935397 rs7539768 chr1 219321179 T G 8.06E-04 Obesity (extreme) LOC643723 intron 21935397 rs12079503 chr1 219323278 T C 8.10E-04 Obesity (extreme) LOC643723 intron 21935397 rs12128311 chr1 219325068 T C 2.26E-04 Alzheimer's disease LOC643723 intron 22005930 rs6692337 chr1 219325343 C G 3.27E-04 Alzheimer's disease LOC643723 intron 22005930 rs11118226 chr1 219326056 A C 2.23E-04 Alzheimer's disease LOC643723 intron 22005930 rs1404361 chr1 219326734 T A 2.22E-04 Alzheimer's disease LOC643723 intron 22005930 rs4846532 chr1 219329357 G A 2.67E-04 Alzheimer's disease LOC643723 intron 22005930 rs6657059 chr1 219332058 T G 8.55E-04 Obesity (extreme) LOC643723 intron 21935397 rs6660443 chr1 219332903 T C 2.36E-04 Alzheimer's disease LOC643723 intron 22005930 rs11118229 chr1 219333297 C T 8.62E-04 Obesity (extreme) LOC643723 intron 21935397 rs11590608 chr1 219335219 C T 6.13E-04 Alzheimer's disease LOC643723 intron 22005930 rs3748633 chr1 219337051 C G 2.26E-04 Alzheimer's disease LOC643723 intron 22005930 rs3748635 chr1 219337088 A T 8.83E-04 Obesity (extreme) LOC643723 intron 21935397 rs9308387 chr1 219337294 C T 2.24E-04 Alzheimer's disease LOC643723 intron 22005930 rs3849291 chr1 219338066 A G 2.23E-04 Alzheimer's disease LOC643723 intron 22005930 rs4846533 chr1 219338934 C T 2.21E-04 Alzheimer's disease LOC643723 intron 22005930 rs4846534 chr1 219338962 C T 2.20E-04 Alzheimer's disease LOC643723 intron 22005930 rs1847661 chr1 219343805 C A 6.07E-04 Alzheimer's disease LOC643723 intron 22005930 rs1524633 chr1 219345242 T C 2.22E-04 Alzheimer's disease LOC643723 intron 22005930 rs1505257 chr1 219347790 T A 2.26E-04 Alzheimer's disease LYPLAL1 intron 22005930 rs7536671 chr1 219350309 T C 2.78E-04 Alzheimer's disease LYPLAL1 intron 22005930 rs12140499 chr1 219350848 G A 2.26E-04 Alzheimer's disease LYPLAL1 intron 22005930 rs6699816 chr1 219355789 A G 9.31E-04 Obesity (extreme) LYPLAL1 intron 21935397 rs12119484 chr1 219360387 T C 2.19E-04 Alzheimer's disease LYPLAL1 intron 22005930 rs11118233 chr1 219361486 T C 6.65E-04 Alzheimer's disease LYPLAL1 intron 22005930 rs2049423 chr1 219364661 T G 3.12E-04 Alzheimer's disease LYPLAL1 intron 22005930 rs11118234 chr1 219367962 A G 3.99E-04 Alzheimer's disease LYPLAL1 intron 22005930 rs12093892 chr1 219368348 G T 9.84E-04 Obesity (extreme) LYPLAL1 intron 21935397 rs1474375 chr1 219382194 T A 2.52E-04 Alzheimer's disease LYPLAL1 intron 22005930 rs6692892 chr1 219383192 T C 6.92E-04 Alzheimer's disease LYPLAL1 intron 22005930 rs1568804 chr1 219391205 T C 1.91E-04 Alzheimer's disease / / 22005930 rs4846539 chr1 219392381 G A 2.84E-04 Alzheimer's disease / / 22005930 rs10863439 chr1 219394080 A C 4.54E-04 Alzheimer's disease / / 22005930 rs17588395 chr1 219412715 G A 1.71E-06 Mammographic density / / 22532574 rs885533 chr1 219415464 A G 3.37E-04 Alzheimer's disease / / 22005930 rs869543 chr1 219416279 A C 9.32E-04 Alzheimer's disease / / 22005930 rs11118246 chr1 219419437 A G 2.52E-04 Alzheimer's disease / / 22005930 rs2177625 chr1 219423223 C A 1.53E-04 Alzheimer's disease / / 22005930 rs6690356 chr1 219430484 C T 1.52E-04 Alzheimer's disease / / 22005930 rs4339871 chr1 219433030 G A 4.02E-04 Parkinson's disease / / 17052657 rs6695675 chr1 219436911 C T 1.46E-04 Alzheimer's disease / / 22005930 rs7543459 chr1 219438661 G C 1.05E-04 Alzheimer's disease / / 22005930 rs7554977 chr1 219439134 C T 1.04E-04 Alzheimer's disease / / 22005930 rs12033194 chr1 219441669 A G 1.01E-04 Alzheimer's disease / / 22005930 rs7524519 chr1 219442625 A G 2.57E-04 Longevity / / 22279548 rs12138304 chr1 219443893 C T 7.98E-04 Alzheimer's disease / / 22005930 rs6679287 chr1 219444769 A G 7.87E-04 Alzheimer's disease / / 22005930 rs12740853 chr1 219445621 C T 9.34E-05 Alzheimer's disease / / 22005930 rs11118250 chr1 219446253 G A 9.07E-05 Alzheimer's disease / / 22005930 rs10495125 chr1 219446991 C G 4.89E-05 Alzheimer's disease / / 22005930 rs6541215 chr1 219447464 G A 1.14E-04 Alzheimer's disease / / 22005930 rs12137855 chr1 219448378 C T 1.06E-04 Nonalcoholic fatty liver disease / / 21423719 rs11118251 chr1 219448564 C T 1.16E-04 Alzheimer's disease / / 22005930 rs11118252 chr1 219448632 C T 1.16E-04 Alzheimer's disease / / 22005930 rs17589136 chr1 219454837 T C 1.44E-04 Alzheimer's disease / / 22005930 rs2186259 chr1 219455914 A C 1.10E-04 Alzheimer's disease / / 22005930 rs6699635 chr1 219456604 A T 1.47E-04 Alzheimer's disease / / 22005930 rs10779348 chr1 219459871 G T 5.35E-04 Alzheimer's disease / / 22005930 rs12080335 chr1 219459987 T C 6.01E-04 Obesity (extreme) / / 21935397 rs10863443 chr1 219460657 A T 1.35E-04 Alzheimer's disease / / 22005930 rs2186256 chr1 219460925 A G 1.35E-04 Alzheimer's disease / / 22005930 rs12238967 chr1 219461975 C T 1.54E-04 Alzheimer's disease / / 22005930 rs11118258 chr1 219462603 C G 1.35E-04 Alzheimer's disease / / 22005930 rs11809367 chr1 219462839 A G 1.04E-04 Alzheimer's disease / / 22005930 rs17523824 chr1 219463061 G A 1.54E-04 Alzheimer's disease / / 22005930 rs17005229 chr1 219463484 G A 6.16E-04 Obesity (extreme) / / 21935397 rs10863444 chr1 219464144 T C 1.34E-04 Alzheimer's disease / / 22005930 rs12029233 chr1 219465099 G A 3.86E-04 Alzheimer's disease / / 22005930 rs12078797 chr1 219465410 A G 5.15E-06 ldl cholesterol / / pha003077 rs6665677 chr1 219470417 T G 1.23E-05 Sleep duration / / 22105623 rs12135929 chr1 219474601 A G 1.98E-04 Alzheimer's disease (late onset) / / 21460841 rs9943060 chr1 219478193 G A 2.09E-04 Blood pressure / / 17255346 rs9943060 chr1 219478193 G A 9.29E-06 Sleep duration / / 22105623 rs11118262 chr1 219479112 T C 1.14E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6675063 chr1 219479214 A T 7.14E-06 Sleep duration / / 22105623 rs7538186 chr1 219480797 T C 6.52E-06 Sleep duration / / 22105623 rs10157397 chr1 219484329 G A 6.36E-04 Multiple complex diseases / / 17554300 rs12122774 chr1 219488567 C T 4.94E-04 Multiple complex diseases / / 17554300 rs11118271 chr1 219488759 A T 6.12E-06 Sleep duration / / 22105623 rs7552206 chr1 219492898 C A 8.81E-04 Multiple complex diseases / / 17554300 rs7514670 chr1 219493082 T A 7.54E-06 Sleep duration / / 22105623 rs7539990 chr1 219497545 G A 7.30E-06 Sleep duration / / 22105623 rs1455703 chr1 219500145 C T 5.10E-04 Multiple complex diseases / / 17554300 rs10495124 chr1 219502193 G A 2.78E-06 Diabetes Mellitus / / pha003059 rs11118277 chr1 219507866 G A 1.60E-05 Sleep duration / / 22105623 rs11118283 chr1 219523445 A T 1.83E-05 Sleep duration / / 22105623 rs1340092 chr1 219523477 G A 1.91E-04 Blood pressure / / 17255346 rs1340092 chr1 219523477 G A 1.01E-04 Type 2 diabetes / / 17463246 rs1340092 chr1 219523477 G A 1.84E-05 Sleep duration / / 22105623 rs6541220 chr1 219529395 G A 1.93E-05 Sleep duration / / 22105623 rs12137276 chr1 219530826 A G 6.90E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17591522 chr1 219533768 G A 3.42E-06 Diabetes Mellitus / / pha003059 rs1856716 chr1 219534574 T C 1.60E-04 Blood pressure / / 17255346 rs17005330 chr1 219535477 G C 1.19E-04 Multiple complex diseases / / 17554300 rs6704463 chr1 219547825 G T 3.42E-06 Diabetes Mellitus / / pha003059 rs6671991 chr1 219557811 G T 8.25E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10863456 chr1 219562683 G A 8.78E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1547502 chr1 219564357 T C 9.60E-05 ldl cholesterol / / pha003077 rs1598472 chr1 219571519 T C 9.60E-04 Multiple complex diseases / / 17554300 rs12032159 chr1 219586415 G A 5.46E-05 Alzheimer's disease / / 21098978 rs11118298 chr1 219588105 A G 5.53E-05 Serum metabolites / / 19043545 rs2124328 chr1 219588237 A C 5.07E-05 Alzheimer's disease / / 21098978 rs2791559 chr1 219588803 A G 4.13E-05 Multiple complex diseases / / 17554300 rs2791559 chr1 219588803 A G 2.52E-05 Alzheimer's disease / / 21098978 rs2791559 chr1 219588803 A G 9.29E-05 ldl cholesterol / / pha003077 rs2820455 chr1 219596070 C T 1.03E-04 Smoking cessation / / 24665060 rs2791563 chr1 219596488 A G 6.96E-05 Smoking cessation / / 24665060 rs7523871 chr1 219596699 T C 3.18E-04 Type 2 diabetes / / 17463246 rs7514932 chr1 219608812 T G 8.69E-04 Multiple complex diseases / / 17554300 rs2168333 chr1 219616208 T G 2.52E-05 Type 2 diabetes / / 17463246 rs2605082 chr1 219619538 A G 1.55E-04 Type 2 diabetes / / 17463246 rs17005614 chr1 219634811 T G 5.00E-05 Sarcoidosis / / 19165924 rs2820436 chr1 219640680 A C 0.00055 Fasting blood glucose / / 22885924 rs2820436 chr1 219640680 A C 2.10E-09 Fasting insulin-related traits / / 22885924 rs2605100 chr1 219644224 A G 4.39E-04 HIV-1 viral setpoint / / 17641165 rs2605100 chr1 219644224 A G 3.00E-08 Adiposity / / 19557161 rs12022722 chr1 219651133 C T 2.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs12022722 chr1 219651133 C T 4.86E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1563355 chr1 219653101 T C 1.34E-04 Type 2 diabetes / / 17846124 rs2605110 chr1 219654392 C T 5.00E-05 Type 2 diabetes / / 17846124 rs4623705 chr1 219654722 G A 3.14E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11118316 chr1 219657163 G A 3.00E-09 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs1417066 chr1 219673828 G A 1.00E-06 Osteoarthritis / / 22763110 rs1417066 chr1 219673828 G A 1.00E-06 Cortical thickness / / 22792071 rs2791553 chr1 219676042 A G 5.00E-07 Adiponectin levels / / 22479202 rs6672377 chr1 219678736 A C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2820464 chr1 219693220 G A 7.00E-09 Waist-hip ratio / / 23563607 rs2785980 chr1 219700519 T C 3.70E-05 Kidney function and endocine traits / / 17903292 rs2785980 chr1 219700519 T C 2.00E-08 Fasting insulin-related traits (interaction with BMI) / / 22581228 rs78696400 chr1 219715108 A G 0.0000896 Menopause (age at onset) / / 23424626 rs4846565 chr1 219722104 G A 1.76E-09 Fasting insulin-related traits / / 22885924 rs3001032 chr1 219727779 T C 4.00E-08 Adiponectin levels / / 22479202 rs11118343 chr1 219739907 T G 8.43E-11 Axial length / / 24144296 rs4428898 chr1 219739966 G A 9.13E-09 Myopia (pathological) / / 22685421 rs4428898 chr1 219739966 G A 9.40E-06 Myopia (severe) / / 23933737 rs4428898 chr1 219739966 G A 4.32E-10 Axial length / / 24144296 rs12046004 chr1 219741333 G C 8.93E-11 Axial length / / 24144296 rs10779361 chr1 219742744 C T 9.35E-11 Axial length / / 24144296 rs11118346 chr1 219743719 C T 2.00E-12 Height / / 20881960 rs11118346 chr1 219743719 C T 2.71E-10 Axial length / / 24144296 rs11118347 chr1 219744249 G T 2.62E-10 Axial length / / 24144296 rs2050595 chr1 219746646 T A 1.63E-10 Axial length / / 24144296 rs2820446 chr1 219748818 C G 2.00E-06 Type 2 diabetes / / 24509480 rs2494192 chr1 219749261 G A 1.51E-06 Waist-hip ratio / / 20935629 rs4846567 chr1 219750717 G T 5.00E-33 Waist-hip ratio / / 20935629 rs2820443 chr1 219753509 T C 7.00E-16 Sexual dimorphism in anthropometric traits / / 23754948 rs6677960 chr1 219754982 G A 4.05E-11 Axial length / / 24144296 rs4373767 chr1 219759682 C T 6.14E-08 Myopia (pathological) / / 22685421 rs4373767 chr1 219759682 C T 7.46E-06 Myopia (severe) / / 23933737 rs4373767 chr1 219759682 C T 1.66E-11 Axial length / / 24144296 rs994767 chr1 219775432 A G 1.00E-11 Axial length / / 24144296 rs11118356 chr1 219777110 C T 1.12E-11 Axial length / / 24144296 rs10863469 chr1 219777468 T C 1.11E-11 Axial length / / 24144296 rs11118358 chr1 219778115 T C 3.16E-11 Axial length / / 24144296 rs10779363 chr1 219786890 C T 1.47E-07 Myopia (pathological) / / 22685421 rs10779363 chr1 219786890 C T 5.15E-06 Myopia (severe) / / 23933737 rs10779363 chr1 219786890 C T 5.13E-11 Axial length / / 24144296 rs10746387 chr1 219787214 A G 4.49E-11 Axial length / / 24144296 rs10746388 chr1 219787322 T A 3.75E-11 Axial length / / 24144296 rs10779364 chr1 219787413 G C 5.35E-11 Axial length / / 24144296 rs10779365 chr1 219787507 A T 3.88E-11 Axial length / / 24144296 rs11118365 chr1 219788166 T G 3.89E-11 Axial length / / 24144296 rs7525202 chr1 219788519 G A 3.89E-11 Axial length / / 24144296 rs7541594 chr1 219789435 A G 8.59E-11 Axial length / / 24144296 rs7544369 chr1 219789462 T C 2.46E-07 Myopia (pathological) / / 22685421 rs7544369 chr1 219789462 T C 5.93E-11 Axial length / / 24144296 rs11118367 chr1 219790221 C T 8.36E-11 Axial length / / 24144296 rs1009859 chr1 219791822 G A 1.52E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs10458468 chr1 219821478 C T 1.50E-06 Urinary metabolites / / 21572414 rs10779377 chr1 219881894 C T 9.39E-04 Multiple complex diseases / / 17554300 rs6700439 chr1 219893091 A G 4.66E-06 Uric acid levels / / 21294900 rs12035718 chr1 219926135 G A 2.30E-05 Urinary metabolites / / 21572414 rs17006538 chr1 219926717 C T 9.89E-05 Multiple complex diseases / / 17554300 rs17006539 chr1 219926845 G C 4.74E-05 Multiple complex diseases / / 17554300 rs4846589 chr1 219931859 T C 8.20E-06 Urinary metabolites / / 21572414 rs946109 chr1 219934317 C T 5.42E-05 Orofacial clefts / / 22419666 rs7535102 chr1 219947840 A G 7.72E-06 White blood cell count / / 21738479 rs2066418 chr1 219980552 G A 2.35E-08 Response to tamoxifen in breast cancer / / 22180457 rs1891561 chr1 220008024 T C 1.56E-04 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs10863513 chr1 220075257 G A 8.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2378331 chr1 220078828 A G 5.67E-05 Cognitive impairment induced by topiramate / / 22091778 rs4846607 chr1 220093188 G A 8.45E-04 Aortic root size SLC30A10 intron 21223598 rs138775009 chr1 220098929 C G 1.97E-04 Acne (severe) SLC30A10 intron 24927181 rs12129498 chr1 220107917 A G 2.71E-05 Alcohol and nictotine co-dependence / / 20158304 rs950455 chr1 220108918 G A 3.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7530353 chr1 220111321 T C 7.54E-05 Glycosylated haemoglobin levels / / 17255346 rs11118465 chr1 220119384 A C 2.20E-04 Response to antidepressants / / 19736353 rs1391565 chr1 220128228 C G 1.67E-05 IgE levels / / 22075330 rs10779390 chr1 220137006 G A 7.59E-04 Type 2 diabetes / / 17463246 rs2027504 chr1 220140714 T C 8.54E-04 Type 2 diabetes / / 17463246 rs148551457 chr1 220180562 T C 0.00042 Prostate cancer EPRS missense 23555315 rs2789788 chr1 220275378 G A 7.80E-05 Brain derived neurotrophic factor levels,in serum IARS2 intron 22047184 rs79314046 chr1 220364850 C T 0.00003554 Sarcoidosis RAB3GAP2 intron 22952805 rs6541128 chr1 220489544 C T 6.27E-05 Height / / pha003011 rs6541130 chr1 220491151 A G 6.31E-05 Height / / pha003011 rs7524270 chr1 220500958 A C 3.60E-05 Personality dimensions / / 18957941 rs7534648 chr1 220501017 G T 2.25E-05 Personality dimensions / / 18957941 rs11118527 chr1 220504423 C T 4.87E-04 Multiple complex diseases / / 17554300 rs9970755 chr1 220510703 T C 2.41E-04 Multiple complex diseases / / 17554300 rs9803782 chr1 220523521 T G 6.77E-04 Type 2 diabetes / / 23300278 rs12041182 chr1 220544573 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs975639 chr1 220582320 G A 2.37E-05 Multiple complex diseases / / 17554300 rs975639 chr1 220582320 G A 0.000613 Salmonella-induced pyroptosis / / 22837397 rs1856430 chr1 220582970 A T 0.000451 Salmonella-induced pyroptosis / / 22837397 rs1578049 chr1 220590437 G T 8.30E-05 Personality dimensions / / 18957941 rs1578049 chr1 220590437 G T 1.56E-05 Bipolar disorder / / 20451256 rs7512221 chr1 220601623 C T 7.44E-07 Alcohol and nictotine co-dependence / / 20158304 rs7512221 chr1 220601623 C T 6.60E-06 Subcutaneous adipose tissue volume in HIV-infected men / / 21897333 rs12042936 chr1 220604517 G A 2.48E-04 Type 2 diabetes / / 17463246 rs7553380 chr1 220626086 A G 5.29E-06 Alcohol and nictotine co-dependence / / 20158304 rs12563333 chr1 220658234 C T 6.00E-08 Bipolar disorder / / 22205951 rs7530302 chr1 220664952 G A 1.90E-09 Alcohol and nictotine co-dependence / / 20158304 rs7530302 chr1 220664952 G A 3.70E-04 Alcohol and nictotine co-dependence / / 20158304 rs7530302 chr1 220664952 G A 6.87E-06 Alcohol and nictotine co-dependence / / 20158304 rs6704108 chr1 220692822 A G 3.82E-06 White blood cell count / / 21738479 rs17008084 chr1 220793423 C T 3.91E-06 White blood cell count MARK1 intron 21738479 rs6670387 chr1 220796478 T C 4.12E-06 White blood cell count MARK1 intron 21738479 rs3849285 chr1 220799606 T A 6.41E-06 White blood cell count MARK1 intron 21738479 rs7523054 chr1 220817281 A G 3.10E-06 White blood cell count MARK1 intron 21738479 rs3897868 chr1 220846039 C T 5.25E-06 White blood cell count / / 21738479 rs3897869 chr1 220846080 T C 8.44E-06 White blood cell count / / 21738479 rs425437 chr1 220868508 A G 1.86E-13 Lymphocyte counts C1orf115 intron 22286170 rs796486 chr1 220885612 C A 3.00E-04 White blood cell types / / 21738478 rs12127880 chr1 220903765 G A 2.19E-06 Cognitive test performance / / 20125193 rs337161 chr1 220914920 G T 3.00E-06 Response to antipsychotic therapy (extrapyramidal side effects) / / 19875103 rs12133663 chr1 220920083 G A 3.34E-04 Body mass index / / 17255346 rs371348 chr1 220928376 T C 4.98E-04 Smoking initiation MARCH2 cds-synon 24665060 rs1494373 chr1 220929356 T C 6.00E-06 Response to antipsychotic therapy (extrapyramidal side effects) MARCH2 intron 19875103 rs6659246 chr1 220931227 C A 2.37E-04 Alcohol dependence MARCH2 intron 20201924 rs10779415 chr1 220935808 C T 8.31E-04 Alcohol dependence MARCH2 intron 20201924 rs3795536 chr1 220935977 G A 6.19E-04 Alcohol dependence MARCH2 intron 20201924 rs3795535 chr1 220936372 G A 7.16E-05 Smoking initiation MARCH2 missense 24665060 rs11118597 chr1 220936568 G A 4.46E-04 Alcohol dependence MARCH2 intron 20201924 rs1874115 chr1 220964639 T C 2.09E-11 Multiple complex diseases MARCH1 intron 17554300 rs2642438 chr1 220970028 A G 4.20E-06 Phospholipid levels (plasma) MARCH1 missense 21829377 rs2642442 chr1 220973563 C T 5.00E-13 Cholesterol,total MARCH1 intron 20686565 rs2642442 chr1 220973563 C T 6.00E-11 LDL cholesterol MARCH1 intron 20686565 rs2642442 chr1 220973563 C T 3.00E-11 Cholesterol,total MARCH1 intron 24097068 rs2642442 chr1 220973563 C T 5.00E-11 LDL cholesterol MARCH1 intron 24097068 rs2642444 chr1 220974218 A G 2.43E-04 Parkinson's disease MARCH1 intron 21044948 rs6693017 chr1 220977333 T G 3.00E-07 Monocyte early outgrowth colony forming units MARCH1 intron 21493818 rs2642420 chr1 220977650 C A 1.03E-04 IgE levels MARCH1 intron 17255346 rs17649913 chr1 220983402 T C 2.30E-05 Urinary metabolites MARCH1 intron 21572414 rs11118607 chr1 220984364 C T 2.85E-04 Alcohol dependence MARCH1 intron 21314694 rs4143772 chr1 220988346 G A 1.12E-05 F-cell distribution / / 21326311 rs17596947 chr1 220993464 G T 1.50E-05 Urinary metabolites / / 21572414 rs2279638 chr1 221001787 G A 7.49E-06 F-cell distribution / / 21326311 rs12073837 chr1 221010205 C T 2.00E-06 F-cell distribution / / 21326311 rs11118618 chr1 221011546 C T 9.30E-04 Parkinson's disease / / 21044948 rs1577545 chr1 221020746 T C 1.72E-04 Lymphocyte counts / / 22286170 rs11118620 chr1 221028508 T C 7.00E-06 Heart failure / / 20445134 rs1389750 chr1 221040171 T G 4.10E-04 Type 2 diabetes / / 17463246 rs2807880 chr1 221043003 T C 1.10E-05 Urinary metabolites / / 21572414 rs2807857 chr1 221052640 T C 9.01E-05 Alzheimer's disease / / 22832961 rs17597773 chr1 221054761 C G 3.97E-05 Telomere length HLX intron 20139977 rs868058 chr1 221056390 A T 9.12E-05 Alzheimer's disease HLX intron 22832961 rs11578466 chr1 221057739 C G 3.31E-04 Hearing function HLX missense 17255346 rs2807862 chr1 221064481 G T 3.48E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6541166 chr1 221069370 A C 1.06E-04 Hearing function / / 17255346 rs4846672 chr1 221079666 A G 6.86E-05 Multiple complex diseases / / 17554300 rs7542375 chr1 221111780 T G 2.00E-06 Obesity-related traits / / 23251661 rs4846676 chr1 221152602 T C 3.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4846676 chr1 221152602 T C 2.74E-05 Height / / pha003011 rs2784262 chr1 221153278 G A 2.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2784264 chr1 221155819 A G 2.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2808219 chr1 221157900 T C 3.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17009262 chr1 221200503 G A 4.73E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13375635 chr1 221228069 C T 5.05E-04 Multiple complex diseases / / 17554300 rs12125058 chr1 221277508 C T 4.65E-05 Major depressive disorder (broad) / / 20038947 rs1442459 chr1 221287861 C A 5.56E-05 Major depressive disorder (broad) / / 20038947 rs4846689 chr1 221377435 A C 0.0000436 Uterine leiomyomata / / 23040493 rs17578266 chr1 221401679 C G 9.52E-05 Obesity (extreme) / / 21935397 rs4415570 chr1 221472909 T C 6.59E-04 Parkinson's disease / / 16252231 rs12402910 chr1 221495487 T C 2.02E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2996005 chr1 221496601 T C 7.24E-04 Multiple complex diseases / / 17554300 rs2996003 chr1 221500943 T C 4.85E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6704281 chr1 221507646 C T 4.94E-04 Suicide attempts in bipolar disorder C1orf140 intron 21041247 rs6704281 chr1 221507646 C T 3.74E-04 Smoking cessation C1orf140 intron 24665060 rs6704485 chr1 221507861 C G 4.94E-04 Suicide attempts in bipolar disorder C1orf140 intron 21041247 rs6704485 chr1 221507861 C G 2.48E-04 Smoking cessation C1orf140 intron 24665060 rs4313406 chr1 221511715 T C 4.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs4313406 chr1 221511715 T C 4.70E-04 Smoking cessation / / 24665060 rs6690986 chr1 221513236 T C 4.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs6671621 chr1 221517472 C G 4.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs4465211 chr1 221518582 A G 4.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs10863604 chr1 221521421 C G 4.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs10863605 chr1 221523403 A G 4.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs12044275 chr1 221526452 A G 1.60E-05 Urinary metabolites / / 21572414 rs12733856 chr1 221551539 C A 3.00E-06 Heart failure / / 20400778 rs3123736 chr1 221553536 G C 1.78E-04 Multiple complex diseases / / 17554300 rs3131543 chr1 221554800 A G 5.31E-04 Multiple complex diseases / / 17554300 rs1380251 chr1 221569175 G A 1.64E-06 Personality dimensions / / 18957941 rs1380251 chr1 221569175 G A 1.60E-06 Personality dimensions / / 21173776 rs1903136 chr1 221577849 G A 7.20E-07 Urinary metabolites / / 21572414 rs1993629 chr1 221578009 A G 1.00E-06 Urinary metabolites / / 21572414 rs3131533 chr1 221579628 A G 2.14E-05 F-cell distribution / / 21326311 rs1459222 chr1 221581795 G T 1.50E-05 Urinary metabolites / / 21572414 rs9726422 chr1 221604980 A G 1.80E-05 Personality dimensions / / 18957941 rs10465658 chr1 221606691 A G 6.13E-06 Personality dimensions / / 18957941 rs12032381 chr1 221617076 A C 6.00E-06 Dupuytren's disease / / 20971583 rs12032381 chr1 221617076 A C 0.00041 Prostate cancer / / 23555315 rs4846348 chr1 221702709 T C 1.27E-04 Amyotrophic lateral sclerosis / / 20801718 rs11118748 chr1 221715136 C T 4.99E-04 Type 2 diabetes / / 17463246 rs11118748 chr1 221715136 C T 1.84E-05 Alcohol and nictotine co-dependence / / 20158304 rs12025878 chr1 221843191 C T 3.86E-04 Lung function (forced vital capacity) / / 24023788 rs13376254 chr1 221849425 T C 3.86E-04 Lung function (forced vital capacity) / / 24023788 rs10863647 chr1 221856899 A G 2.80E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2090649 chr1 221867157 T C 8.65E-04 Multiple complex diseases / / 17554300 rs6655992 chr1 221868913 A C 2.90E-05 Urinary metabolites / / 21572414 rs11118832 chr1 221884371 T C 6.70E-04 Schizophrenia DUSP10 intron 19197363 rs11118838 chr1 221897346 A C 9.48E-04 Multiple complex diseases DUSP10 intron 17554300 rs6604668 chr1 221901624 T C 8.47E-04 Multiple complex diseases DUSP10 intron 17554300 rs11118858 chr1 221952958 G T 3.70E-05 Multiple complex diseases / / 17554300 rs10495178 chr1 221960438 G C 8.04E-05 Multiple complex diseases / / 17554300 rs10495179 chr1 221969368 C T 8.26E-05 Asthma / / 11022011 rs11118864 chr1 221979367 C T 2.88E-05 Asthma / / 11022011 rs3934724 chr1 221979762 T C 8.95E-04 Multiple complex diseases / / 17554300 rs4584399 chr1 221984235 T C 1.30E-04 Multiple complex diseases / / 17554300 rs4317815 chr1 221985915 A C 2.91E-04 Multiple complex diseases / / 17554300 rs12125690 chr1 222010866 A G 9.20E-04 Endometriosis / / 21151130 rs4579763 chr1 222012950 A C 7.53E-05 Multiple complex diseases / / 17554300 rs10495182 chr1 222027431 T C 7.73E-04 Multiple complex diseases / / 17554300 rs10495182 chr1 222027431 T C 6.07E-04 Bipolar disorder / / 19259986 rs12144971 chr1 222032485 C T 6.26E-05 Celiac disease / / 23936387 rs7551298 chr1 222037066 T C 4.50E-04 Multiple complex diseases / / 17554300 rs12130910 chr1 222038372 G A 5.04E-06 Mathematical ability / / 24801482 rs4240931 chr1 222039055 C T 6.26E-05 Celiac disease / / 23936387 rs4846732 chr1 222045181 T C 4.05E-04 Multiple complex diseases / / 17554300 rs6691170 chr1 222045446 G T 1.00E-09 Colorectal cancer / / 20972440 rs11811613 chr1 222055403 A G 2.16E-04 Celiac disease / / 23936387 rs11118883 chr1 222061022 G A 1.27E-04 Colorectal cancer / / 24737748 rs4846734 chr1 222072998 A G 4.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11118885 chr1 222075459 T C 4.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2378489 chr1 222076208 A C 9.48E-05 Alzheimer's disease (age of onset) / / 22005931 rs2378493 chr1 222076840 G A 9.10E-05 Alzheimer's disease (age of onset) / / 22005931 rs7520703 chr1 222084187 C A 4.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2260032 chr1 222105479 G A 8.86E-04 White matter integrity / / 22425255 rs2790760 chr1 222109518 G A 3.77E-05 Celiac disease / / 23936387 rs6687758 chr1 222164948 A G 2.00E-09 Colorectal cancer / / 20972440 rs6687758 chr1 222164948 A G 6.00E-08 Progressive supranuclear palsy / / 21685912 rs6687758 chr1 222164948 A G 9.00E-09 Colorectal cancer / / 24836286 rs2970199 chr1 222177454 C T 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2800860 chr1 222183226 C T 8.01E-04 Taste perception / / 22132133 rs12139468 chr1 222183756 T C 4.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs17442148 chr1 222187794 T C 1.20E-05 Kawasaki disease / / 22446962 rs2584315 chr1 222206887 G A 9.27E-05 Prostate cancer / / pha002877 rs2584316 chr1 222211329 A G 6.35E-05 Prostate cancer / / pha002877 rs1442440 chr1 222239534 T C 2.28E-04 Obesity (extreme) / / 21935397 rs7513781 chr1 222239932 T C 5.85E-04 Obesity (extreme) / / 21935397 rs7556050 chr1 222239992 A G 5.77E-04 Obesity (extreme) / / 21935397 rs1339875 chr1 222240322 T G 7.59E-04 Obesity (extreme) / / 21935397 rs1856620 chr1 222240379 T C 7.49E-04 Obesity (extreme) / / 21935397 rs1339876 chr1 222240418 A T 7.38E-04 Obesity (extreme) / / 21935397 rs7548749 chr1 222241688 G A 5.61E-04 Obesity (extreme) / / 21935397 rs12038701 chr1 222242777 G A 7.32E-04 Obesity (extreme) / / 21935397 rs11118934 chr1 222243455 T C 2.77E-04 Obesity (extreme) / / 21935397 rs12134885 chr1 222244380 T C 2.73E-04 Obesity (extreme) / / 21935397 rs10863680 chr1 222244880 T C 2.72E-04 Obesity (extreme) / / 21935397 rs10863681 chr1 222245258 A G 6.00E-06 Metabolite levels (HVA-5-HIAA Factor score) / / 23319000 rs12135862 chr1 222245387 T C 5.53E-06 Metabolite levels (MHPG) / / 23319000 rs10863682 chr1 222247975 T C 3.61E-05 Obesity (extreme) / / 21935397 rs1890757 chr1 222248682 A C 1.11E-04 Obesity (extreme) / / 21935397 rs1890758 chr1 222248823 A G 1.14E-04 Obesity (extreme) / / 21935397 rs12096184 chr1 222250435 A G 1.11E-04 Obesity (extreme) / / 21935397 rs11118936 chr1 222251043 A G 1.11E-04 Obesity (extreme) / / 21935397 rs10863684 chr1 222251332 G A 3.67E-05 Obesity (extreme) / / 21935397 rs11118937 chr1 222251427 T C 3.67E-05 Obesity (extreme) / / 21935397 rs7525314 chr1 222251508 C T 1.10E-04 Obesity (extreme) / / 21935397 rs12138480 chr1 222252021 G A 3.60E-05 Obesity (extreme) / / 21935397 rs1890759 chr1 222254624 T A 1.45E-04 Obesity (extreme) / / 21935397 rs10863685 chr1 222255923 A G 1.45E-04 Obesity (extreme) / / 21935397 rs1591912 chr1 222256140 A G 1.45E-04 Obesity (extreme) / / 21935397 rs10495184 chr1 222259677 C A 3.28E-05 Obesity (extreme) / / 21935397 rs12561821 chr1 222261229 T C 6.16E-05 Obesity (extreme) / / 21935397 rs11118942 chr1 222265553 G A 3.01E-04 Obesity (extreme) / / 21935397 rs11118943 chr1 222266606 G A 3.23E-04 Obesity (extreme) / / 21935397 rs12125086 chr1 222268856 C T 3.37E-04 Obesity (extreme) / / 21935397 rs6702063 chr1 222270724 C T 3.42E-04 Obesity (extreme) / / 21935397 rs873549 chr1 222271767 C T 6.00E-23 Keloid / / 20711176 rs6678715 chr1 222277283 G C 1.30E-04 Obesity (extreme) / / 21935397 rs10863689 chr1 222282485 T C 2.59E-04 Obesity (extreme) / / 21935397 rs10779468 chr1 222282882 T C 2.60E-04 Obesity (extreme) / / 21935397 rs291906 chr1 222388787 T C 2.55E-04 Alzheimer's disease (late onset) / / 21379329 rs158710 chr1 222396017 G A 3.23E-04 Alzheimer's disease (late onset) / / 21379329 rs1155471 chr1 222504752 A G 4.03E-05 Anxiety in major depressive disorder / / 24047446 rs1386579 chr1 222574834 T C 6.65E-04 Aortic root size / / 21223598 rs10495191 chr1 222694436 A T 1.46E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs4481859 chr1 222732656 T G 9.43E-04 Response to taxane treatment (placlitaxel) TAF1A intron 23006423 rs10495194 chr1 222733971 C T 8.20E-05 Response to taxane treatment (placlitaxel) TAF1A intron 23006423 rs2936032 chr1 222751791 C T 5.40E-05 Alcohol dependence TAF1A intron 22096494 rs3008647 chr1 222759007 T C 1.27E-04 Response to taxane treatment (placlitaxel) TAF1A intron 23006423 rs17464836 chr1 222762128 A C 9.68E-05 Smoking quantity TAF1A intron 24665060 rs17464857 chr1 222762709 T G 1.40E-05 Multiple complex diseases TAF1A intron 17554300 rs17464857 chr1 222762709 T G 9.12E-04 Response to taxane treatment (placlitaxel) TAF1A intron 23006423 rs17464857 chr1 222762709 T G 0.000877 Coronary artery disease with myocardial infarction TAF1A intron 23202125 rs2936041 chr1 222762773 T A 1.03E-04 Response to taxane treatment (placlitaxel) TAF1A intron 23006423 rs17511318 chr1 222762958 A G 9.12E-04 Response to taxane treatment (placlitaxel) TAF1A intron 23006423 rs2936040 chr1 222763661 T A 1.45E-04 Multiple sclerosis / / 17660530 rs3008653 chr1 222764791 G C 1.11E-04 Response to taxane treatment (placlitaxel) LOC100506161 intron 23006423 rs3008654 chr1 222766609 A G 3.93E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1909194 chr1 222770703 A G 6.83E-04 Multiple complex diseases / / 17554300 rs1909194 chr1 222770703 A G 9.12E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1909194 chr1 222770703 A G 1.97E-04 Smoking quantity / / 24665060 rs3002130 chr1 222772139 C T 3.93E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3008598 chr1 222779948 T C 9.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4846770 chr1 222795569 C G 7.21E-08 Multiple complex diseases MIA3 intron 17554300 rs3008621 chr1 222804046 G A 1.00E-04 Multiple complex diseases MIA3 intron 17554300 rs3008621 chr1 222804046 G A 1.92E-06 Coronary Artery Disease MIA3 intron 17634449 rs2133188 chr1 222813753 G T 1.68E-04 Multiple complex diseases MIA3 intron 17554300 rs2133189 chr1 222814442 C T 1.37E-05 Multiple complex diseases MIA3 intron 17554300 rs2133189 chr1 222814442 C T 1.38E-05 Coronary Artery Disease MIA3 intron 17634449 rs2133189 chr1 222814442 C T 2.73E-07 Coronary heart disease MIA3 intron 22319020 rs17465637 chr1 222823529 A C 1.00E-05 Multiple complex diseases MIA3 intron 17554300 rs17465637 chr1 222823529 A C 1.00E-06 Coronary heart disease MIA3 intron 17634449 rs17465637 chr1 222823529 A C 1.00E-09 Myocardial infarction (early onset) MIA3 intron 19198609 rs17465637 chr1 222823529 A C 1.00E-09 Coronary heart disease MIA3 intron 21347282 rs17465637 chr1 222823529 A C 1.00E-08 Coronary heart disease MIA3 intron 21378990 rs17465637 chr1 222823529 A C 1.36E-08 Pericardial fat MIA3 intron 22589742 rs2291832 chr1 222826481 G A 4.90E-07 Coronary heart disease MIA3 intron 21966275 rs4240934 chr1 222904298 T C 1.57E-04 Multiple complex diseases BROX intron 17554300 rs9286760 chr1 222919682 G A 6.68E-05 Age-related macular degeneration FAM177B intron pha000002 rs6683071 chr1 222923351 A G 4.00E-06 Cognitive performance FAM177B missense 19734545 rs77190419 chr1 222947382 A T 0.00004694 Sarcoidosis / / 22952805 rs17163573 chr1 223089435 C T 7.34E-04 Type 2 diabetes DISP1 intron 17463246 rs10495205 chr1 223123348 G A 4.39E-04 Type 2 diabetes DISP1 intron 17846124 rs2789909 chr1 223171725 G T 1.53E-10 Multiple complex diseases DISP1 intron 17554300 rs851193 chr1 223294851 T C 7.51E-04 Multiple complex diseases TLR5 intron 17554300 rs851192 chr1 223295254 G C 9.64E-04 Multiple complex diseases TLR5 intron 17554300 rs851191 chr1 223308965 A C 6.51E-04 Multiple complex diseases TLR5 intron 17554300 rs1341987 chr1 223309213 C G 4.34E-05 Multiple complex diseases TLR5 intron 17554300 rs2096142 chr1 223311845 T C 3.78E-05 Multiple complex diseases TLR5 intron 17554300 rs2096141 chr1 223311940 A T 3.86E-05 Multiple complex diseases TLR5 intron 17554300 rs851171 chr1 223349020 G A 5.88E-04 Alcohol dependence / / 21314694 rs4661250 chr1 223399328 A G 3.84E-04 Lung function (forced expiratory volume in 1 second) SUSD4 intron 17255346 rs851212 chr1 223417224 C T 0.0000431 Nonsyndromic striae distensae (stretch marks) SUSD4 intron 23633020 rs712856 chr1 223468336 A G 2.64E-04 Lung function (forced expiratory volume in 1 second) SUSD4 intron 24023788 rs17163777 chr1 223468732 C T 4.66E-04 Multiple complex diseases SUSD4 intron 17554300 rs17163777 chr1 223468732 C T 8.96E-05 Amyotrophic lateral sclerosis (sporadic) SUSD4 intron 24529757 rs17161994 chr1 223469434 C G 9.46E-05 Chronic obstructive pulmonary disease SUSD4 intron 19300482 rs17161994 chr1 223469434 C G 9.46E-05 Response to statin treatment (atorvastatin),change in cholesterol levels SUSD4 intron 20031582 rs825113 chr1 223498145 G A 4.57E-04 Lung function (forced expiratory volume in 1 second) SUSD4 intron 24023788 rs1772283 chr1 223553189 T C 2.35E-04 Myocardial Infarction / / pha002873 rs1772290 chr1 223579329 C A,G,T 1.70E-05 Urinary metabolites / / 21572414 rs1095174 chr1 223581572 T C 9.67E-05 Body Mass Index / / pha003015 rs17162072 chr1 223594970 G A 6.33E-04 Insulin resistance / / 21901158 rs825148 chr1 223595240 C T 1.25E-77 Multiple complex diseases / / 17554300 rs825134 chr1 223603882 G T 3.08E-05 Multiple complex diseases / / 17554300 rs4233518 chr1 223636166 C T 8.46E-04 Multiple complex diseases / / 17554300 rs6671793 chr1 223637721 G T 3.78E-05 Coronary heart disease / / pha003055 rs6604713 chr1 223641831 G T 6.21E-04 Multiple complex diseases / / 17554300 rs4285687 chr1 223653432 G A 2.58E-05 Longevity / / 22279548 rs11261291 chr1 223656191 T A 7.29E-04 Smoking cessation / / 24665060 rs10495209 chr1 223656537 C T 4.49E-05 Smoking cessation / / 24665060 rs7527013 chr1 223662541 G A 1.46E-04 Smoking cessation / / 24665060 rs6690293 chr1 223663505 A G 2.30E-04 Smoking cessation / / 24665060 rs6685694 chr1 223663555 C T 2.63E-04 Smoking cessation / / 24665060 rs4623692 chr1 223663828 C T 3.04E-04 Smoking cessation / / 24665060 rs12046541 chr1 223663935 T G 2.45E-04 Smoking cessation / / 24665060 rs4661273 chr1 223665468 G A 4.82E-04 Smoking cessation / / 24665060 rs6682926 chr1 223665536 G A 5.70E-04 Smoking cessation / / 24665060 rs6604719 chr1 223670323 T G 3.30E-04 Smoking cessation / / 24665060 rs4512641 chr1 223673932 A G 3.43E-04 Smoking cessation / / 24665060 rs4511103 chr1 223680537 G A 1.55E-04 Smoking cessation / / 24665060 rs4325124 chr1 223682051 T C 6.87E-05 Smoking cessation / / 24665060 rs4603130 chr1 223686766 G A 1.90E-04 Smoking cessation / / 24665060 rs7554045 chr1 223687990 A T 8.91E-05 Smoking cessation / / 24665060 rs17162209 chr1 223693162 G A 8.41E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2404354 chr1 223840398 C T 9.60E-04 Type 2 diabetes / / 22238593 rs7525504 chr1 223867631 G A 6.50E-04 Interstitial lung disease / / 23583980 rs17596 chr1 223905532 G A 3.75E-06 Interstitial lung disease CAPN2 cds-synon 23583980 rs12066704 chr1 223931068 C T 2.55E-04 Glycosylated haemoglobin levels CAPN2 intron 17255346 rs1222138 chr1 223931411 G A 1.82E-04 Glycosylated haemoglobin levels CAPN2 intron 17255346 rs17598 chr1 223933079 C T 2.38E-04 Glycosylated haemoglobin levels CAPN2 cds-synon 17255346 rs1153942 chr1 223970745 T G 2.74E-04 Response to cytidine analogues (gemcitabine) TP53BP2 intron 24483146 rs41345146 chr1 224020068 G T 3.07E-05 Multiple complex diseases TP53BP2 intron 17554300 rs17319010 chr1 224089383 A C 6.06E-15 Gender / / 22362730 rs10916197 chr1 224230307 T C 4.58E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs10916197 chr1 224230307 T C 3.84E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4551564 chr1 224237716 C A 5.43E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs6604882 chr1 224240939 C A 2.28E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6604882 chr1 224240939 C A 8.86E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6663154 chr1 224246746 T G 9.60E-05 Major depressive disorder / / 22472876 rs7531519 chr1 224251838 A C 8.04E-04 Type 2 diabetes / / 17463246 rs7513964 chr1 224255757 G A 4.85E-04 Tourette syndrome / / 22889924 rs10916248 chr1 224256348 A T 5.00E-06 QT interval (interaction) / / 23459443 rs10916260 chr1 224264382 C T 2.35E-04 Smoking cessation / / 24665060 rs10799505 chr1 224351023 C T 3.66E-08 Lymphocyte counts / / 22286170 rs7530205 chr1 224487290 T C 9.10E-04 Heart Failure NVL intron pha002884 rs4653579 chr1 224518354 T C 5.30E-26 Progranulin levels NVL nearGene-5 21087763 rs4653579 chr1 224518354 T C 5.30E-26 Myocardial infarction NVL nearGene-5 21211798 rs11579964 chr1 224538940 C T 4.00E-06 Major depressive disorder / / 21042317 rs11579964 chr1 224538940 C T 1.01E-07 Major depressive disorder / / 22472876 rs11579964 chr1 224538940 C T 4.40E-06 Depression (quantitative trait) / / 23290196 rs12121977 chr1 224599977 G T 3.81E-04 Premature ovarian failure WDR26 intron 19508998 rs10799576 chr1 224644549 C T 4.05E-06 Pulmonary function LOC100506354 intron 20010835 rs12731630 chr1 224650947 T C 8.69E-05 HIV-1 viral setpoint LOC100506354 intron 22174851 rs2404785 chr1 224659778 G A 3.56E-05 Elbow pain LOC100506354 intron pha003008 rs2405028 chr1 224673659 A G 3.56E-05 Elbow pain LOC100506354 intron pha003008 rs10916625 chr1 224682884 A G 3.72E-05 Elbow pain LOC100506354 intron pha003008 rs791504 chr1 224694877 A T 3.41E-04 Multiple complex diseases LOC100506354 intron 17554300 rs7541917 chr1 224707101 G A 1.69E-04 Multiple complex diseases LOC100506354 intron 17554300 rs7550648 chr1 224707177 C T 3.15E-05 Multiple complex diseases LOC100506354 intron 17554300 rs10916631 chr1 224708052 C T 1.82E-04 Multiple complex diseases LOC100506354 intron 17554300 rs3738367 chr1 224708588 C T 2.50E-04 Multiple complex diseases LOC100506354 intron 17554300 rs72760323 chr1 224767537 G A 0.00006681 Sarcoidosis / / 22952805 rs16849891 chr1 224777150 A G 1.09E-05 Panic disorder / / 19165232 rs16850250 chr1 224804649 G A 2.32E-04 Smoking cessation CNIH3 UTR-5 24665060 rs6695864 chr1 224820292 G T 7.54E-05 Major depressive disorder (broad) CNIH3 intron 20038947 rs924362 chr1 224821550 C T 6.93E-04 Myopia (pathological) CNIH3 intron 21095009 rs10429870 chr1 224840799 C T 4.83E-04 Coronary heart disease CNIH3 intron 21606135 rs298730 chr1 224841244 A G 1.16E-04 Aortic root size CNIH3 intron 21223598 rs298733 chr1 224842251 C A 6.90E-04 Aortic root size CNIH3 intron 21223598 rs930323 chr1 224865790 C G 1.20E-04 Blood Phenotypes CNIH3 intron 17903294 rs930323 chr1 224865790 C G 3.10E-04 Alzheimer's disease CNIH3 intron 17998437 rs17573714 chr1 224875392 G A 2.77E-04 Alzheimer's disease CNIH3 intron 17998437 rs12025142 chr1 224876101 C A 8.45E-04 Coronary heart disease CNIH3 intron 21606135 rs4653593 chr1 224881970 A G 4.72E-04 Alzheimer's disease CNIH3 intron 17998437 rs6679040 chr1 224910507 G A 9.07E-08 Metabolite levels CNIH3 intron 23281178 rs1010735 chr1 224915429 T G 4.18E-05 Soluble levels of adhesion molecules CNIH3 intron pha003072 rs6660579 chr1 224916592 C T 2.63E-05 Cognitive test performance CNIH3 intron 20125193 rs6660579 chr1 224916592 C T 0.0000078 Preeclampsia CNIH3 intron 22432041 rs6660579 chr1 224916592 C T 4.69E-05 Amyotrophic lateral sclerosis (sporadic) CNIH3 intron 24529757 rs2802561 chr1 224948813 T C 3.71E-04 Multiple complex diseases / / 17554300 rs2802562 chr1 224950129 C T 9.54E-04 Multiple complex diseases / / 17554300 rs2997477 chr1 224984367 G C 7.13E-08 Narcolepsy / / 19629137 rs12081821 chr1 224991534 A G 7.02E-04 Multiple complex diseases / / 17554300 rs11810181 chr1 225008581 T C 1.02E-05 Erythrocyte counts / / pha003101 rs2662928 chr1 225011642 A G 8.79E-05 Asthma / / 11022011 rs1892121 chr1 225018101 A G 6.78E-05 Asthma / / 11022011 rs10799281 chr1 225079770 A G 9.29E-05 Coronary restenosis / / 21878436 rs12563323 chr1 225084219 C T 8.70E-06 Urinary metabolites / / 21572414 rs16857749 chr1 225088095 T C 2.30E-05 Urinary metabolites / / 21572414 rs2449266 chr1 225108715 A G 9.67E-05 Smoking quantity / / 24665060 rs6686694 chr1 225310170 G A 4.60E-04 Blood pressure D/H14 intron 21422096 rs16844054 chr1 225311160 G C 8.80E-04 Type 2 diabetes D/H14 intron 17463246 rs12754230 chr1 225392252 C T 3.65E-04 Type 2 diabetes D/H14 intron 17463246 rs10495234 chr1 225493583 G A 3.21E-04 Multiple complex diseases D/H14 intron 17554300 rs648011 chr1 225508712 C T 8.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) D/H14 intron 23648065 rs3856145 chr1 225528183 C A 2.76E-04 Celiac disease D/H14 missense 23936387 rs12753933 chr1 225528648 T A 2.05E-04 Multiple complex diseases D/H14 intron 17554300 rs16844799 chr1 225549008 T C 0.00005446 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) D/H14 intron 23233654 rs16844799 chr1 225549008 T C 5.45E-05 Methotrexate clearance (acute lymphoblastic leukemia) D/H14 intron 23233662 rs3856154 chr1 225565015 T C 7.29E-04 Common variable immunodeficiency D/H14 missense 21497890 rs6661263 chr1 225575588 C G 6.85E-04 Multiple complex diseases D/H14 intron 17554300 rs16844841 chr1 225590675 A C 4.00E-06 IgG glycosylation LBR UTR-3 23382691 rs16844846 chr1 225592927 T G 4.00E-06 IgG glycosylation LBR intron 23382691 rs16844846 chr1 225592927 T G 6.00E-06 IgG glycosylation LBR intron 23382691 rs17557867 chr1 225598855 G A 2.70E-05 Urinary metabolites LBR intron 21572414 rs4653637 chr1 225624016 G A 2.90E-04 Asthma / / 20698975 rs6702538 chr1 225624513 A C 1.30E-04 Multiple complex diseases / / 17554300 rs6426075 chr1 225637606 A G 1.00E-05 Urinary metabolites / / 21572414 rs6426075 chr1 225637606 A G 0.000759 Salmonella-induced pyroptosis / / 22837397 rs947034 chr1 225647649 G A 5.87E-05 Psoriasis / / 20953190 rs10799312 chr1 225653150 A G 0.000316 Salmonella-induced pyroptosis / / 22837397 rs3893032 chr1 225656388 A C 0.000235 Salmonella-induced pyroptosis / / 22837397 rs10799316 chr1 225668031 G A 5.00E-04 Multiple complex diseases / / 17554300 rs9804142 chr1 225673847 C T 6.57E-05 Multiple complex diseases / / 17554300 rs3795443 chr1 225675003 A G 4.56E-05 Alcohol and nictotine co-dependence E/H UTR-3 20158304 rs954534 chr1 225676330 T C 6.30E-04 Amyotrophic lateral sclerosis (sporadic) E/H UTR-3 24529757 rs1629896 chr1 225685928 A G 4.82E-06 Osteoarthritis E/H intron 22763110 rs10799319 chr1 225703485 A G 5.12E-05 Multiple complex diseases E/H intron 17554300 rs7555139 chr1 225716241 G A 4.31E-05 Multiple complex diseases E/H intron 17554300 rs510293 chr1 225732239 A T 3.53E-05 Multiple complex diseases E/H intron 17554300 rs499782 chr1 225768228 C T 3.59E-04 Multiple complex diseases E/H intron 17554300 rs17502774 chr1 225775962 A G 7.14E-04 Type 2 diabetes E/H intron 17463246 rs526201 chr1 225780166 C T 6.98E-04 Parkinson's disease E/H intron 17052657 rs2840958 chr1 225805043 A G 5.05E-05 Multiple complex diseases E/H intron 17554300 rs12140001 chr1 225809414 T A 6.07E-05 Personality dimensions E/H intron 18957941 rs2639703 chr1 225812911 T C 8.46E-06 Multiple complex diseases E/H intron 17554300 rs2840967 chr1 225824028 C T 3.70E-04 Asthma E/H intron 20698975 rs2615060 chr1 225873612 C A 3.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs10915864 chr1 225901006 A G 2.00E-06 Obesity-related traits / / 23251661 rs12044217 chr1 225902582 C T 1.78E-04 Longevity / / 22279548 rs12044217 chr1 225902582 C T 4.00E-04 Myasthenia gravis / / 23055271 rs16845221 chr1 225924178 C T 2.42E-04 Multiple complex diseases / / 17554300 rs16845250 chr1 225946690 T C 9.81E-05 Smoking initiation / / 24665060 rs12118223 chr1 225951441 A T 6.34E-04 Bulimia nervosa / / 23568457 rs12403575 chr1 225961384 A G 2.53E-04 Taste perception / / 22132133 rs4653433 chr1 225974531 A G 5.44E-07 Asthma SRP9 intron 21804549 rs10157103 chr1 225988818 C T 2.04E-04 Multiple complex diseases / / 17554300 rs10799324 chr1 225994515 C A 7.18E-04 Multiple complex diseases / / 17554300 rs4653436 chr1 225995211 G A 1 Drug response to Warfarin / / 19794411 rs868966 chr1 226006098 G A 7.50E-05 Calcium levels EPHX1 intron pha003085 rs3753658 chr1 226012686 G T 4.11E-04 Response to taxane treatment (placlitaxel) EPHX1 intron 23006423 rs3753661 chr1 226014342 T G 2.42E-04 Birth weight EPHX1 intron 17255346 rs3766934 chr1 226015017 G T 3.28E-04 Birth weight EPHX1 intron 17255346 rs1051740 chr1 226019633 T C 1 Drug response to Carbamazepine EPHX1 missense 15692831 rs1051740 chr1 226019633 T C 1 Drug response to Warfarin EPHX1 missense 19794411 rs1051740 chr1 226019633 T C 1 Drug response to Phenytoin EPHX1 missense 19952982 rs1131873 chr1 226019653 G A 1 Drug response to Warfarin EPHX1 cds-synon 19794411 rs2260863 chr1 226019774 G C 1 Drug response to Warfarin EPHX1 intron 19794411 rs2740170 chr1 226024797 T C 1.51E-05 Prion diseases EPHX1 intron 22210626 rs2234922 chr1 226026406 A G 1 Drug response to Carbamazepine EPHX1 missense 15692831 rs2234922 chr1 226026406 A G 1 Drug response to Warfarin EPHX1 missense 19794411 rs2234922 chr1 226026406 A G 1 Drug response to Phenytoin EPHX1 missense 19952982 rs4149227 chr1 226032530 C A 8.21E-04 Response to cytidine analogues (gemcitabine) EPHX1 intron 24483146 rs4149230 chr1 226033030 G C 8.21E-04 Response to cytidine analogues (gemcitabine) EPHX1 cds-synon 24483146 rs10158985 chr1 226050609 C A 0.000137 Oxaliplatin induced nausea/vomiting in response to colorectal cancer treatment TMEM63A intron 22310351 rs360094 chr1 226064846 A G 7.33E-05 Serum metabolites TMEM63A intron 19043545 rs360098 chr1 226066690 G C 4.08E-05 Serum metabolites TMEM63A intron 19043545 rs1223245 chr1 226082425 A G 5.00E-06 Preschool internalizing problems / / 24839885 rs14868 chr1 226107787 T C 3.62E-05 Basophils PYCR2 UTR-3 pha003087 rs12754943 chr1 226228627 C T 7.67E-05 Type 2 diabetes / / 17463246 rs6664668 chr1 226255954 G A 6.96E-06 Alcohol and nictotine co-dependence H3F3A intron 20158304 rs10915928 chr1 226266440 G A 3.93E-04 Type 2 diabetes / / 17463246 rs11577282 chr1 226287622 T G 3.91E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs12136759 chr1 226321051 A G 3.67E-04 Type 2 diabetes / / 17463246 rs12136759 chr1 226321051 A G 4.65E-04 Coronary Artery Disease / / 17634449 rs1043641 chr1 226332993 C T 1.33E-05 Iron status biomarkers ACBD3 UTR-3 19084217 rs2306121 chr1 226353521 T A 6.13E-04 Coronary Artery Disease ACBD3 intron 17634449 rs10915955 chr1 226363155 G A 1.69E-05 Multiple complex diseases ACBD3 intron 17554300 rs9660924 chr1 226371939 C T 2.19E-04 Coronary Artery Disease ACBD3 intron 17634449 rs16860148 chr1 226376731 A G 1.09E-04 Multiple complex diseases / / 17554300 rs10753415 chr1 226385623 T C 5.08E-05 Crohn's disease / / 18587394 rs10495244 chr1 226387618 G A 4.02E-05 Multiple complex diseases / / 17554300 rs41357249 chr1 226397002 T C 1.30E-04 Alzheimer's disease / / 17998437 rs10915971 chr1 226508645 C T 8.28E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs3219142 chr1 226552068 G A 7.86E-05 Longevity PARP1 intron 20304771 rs1136410 chr1 226555302 A G 9.97E-04 Multiple complex diseases PARP1 missense 17554300 rs3219123 chr1 226555348 G A 6.23E-06 Alcohol and nictotine co-dependence PARP1 intron 20158304 rs2027440 chr1 226563859 C T 3.50E-04 Type 2 diabetes and 6 quantitative traits PARP1 intron 17848626 rs3219090 chr1 226564691 T C 9.00E-08 Melanoma PARP1 intron 21983785 rs3219060 chr1 226572483 G T 5.63E-08 LDL cholesterol PARP1 intron 23063622 rs6426461 chr1 226613233 T C 2.58E-04 Smoking quantity / / 24665060 rs10799353 chr1 226662799 G A 1.53E-05 Femoral neck bone geometry / / 22087292 rs7551258 chr1 226671906 T C 7.61E-04 Multiple complex diseases / / 17554300 rs7551258 chr1 226671906 T C 2.10E-05 Urinary metabolites / / 21572414 rs7551258 chr1 226671906 T C 3.46E-04 Smoking quantity / / 24665060 rs506128 chr1 226702300 G A 9.64E-05 Blood Pressure / / pha003040 rs584297 chr1 226708481 T C 3.26E-05 F-cell distribution / / 21326311 rs708741 chr1 226737202 A G 0.00001502 Sarcoidosis C1orf95 intron 22952805 rs837748 chr1 226737845 A G 0.00007737 Sarcoidosis C1orf95 intron 22952805 rs603609 chr1 226738546 C T 3.38E-06 Multiple complex diseases C1orf95 intron 17554300 rs708743 chr1 226739447 C T 0.00001323 Sarcoidosis C1orf95 intron 22952805 rs650932 chr1 226740876 C A 0.00002543 Sarcoidosis C1orf95 intron 22952805 rs708745 chr1 226743163 A G 0.00006972 Sarcoidosis C1orf95 intron 22952805 rs588782 chr1 226744139 T C 0.0000632 Sarcoidosis C1orf95 intron 22952805 rs660449 chr1 226748670 T C 0.00002907 Sarcoidosis C1orf95 intron 22952805 rs7525939 chr1 226755971 C T 4.62E-04 Alzheimer's disease C1orf95 intron 21059989 rs7525939 chr1 226755971 C T 5.29E-06 Alzheimer's disease C1orf95 intron 21059989 rs654318 chr1 226760438 C G 7.42E-04 Acute lung injury C1orf95 intron 22295056 rs17580122 chr1 226778586 G T 8.75E-06 Type 2 diabetes C1orf95 intron 17463246 rs1050492 chr1 226820500 G A 8.29E-04 Alcohol dependence ITPKB UTR-3 21314694 rs10495246 chr1 226826484 C A 1.93E-06 Glaucoma (primary open-angle) ITPKB intron 22605921 rs1288934 chr1 226828038 A G 6.79E-05 Prion diseases ITPKB intron 22210626 rs3768373 chr1 226836036 C T 2.77E-05 Multiple complex diseases ITPKB intron 17554300 rs3768373 chr1 226836036 C T 4.67E-05 Cognitive impairment induced by topiramate ITPKB intron 22091778 rs200050925 chr1 226837127 T A 2.10E-12 Metabolite levels ITPKB intron 22286219 rs10916025 chr1 226855889 G C 6.00E-06 Subcutaneous adipose tissue ITPKB intron 22589738 rs708766 chr1 226865254 A C 8.59E-05 Orofacial clefts ITPKB intron 22419666 rs3768408 chr1 226910340 C T 1.00E-04 Cognitive impairment induced by topiramate ITPKB intron 22091778 rs708772 chr1 226912891 T C 5.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ITPKB intron 20877124 rs10495249 chr1 226919119 A G 9.48E-04 Multiple complex diseases ITPKB intron 17554300 rs6667260 chr1 226923938 A C 0.00008 Coronary artery calcification ITPKB missense 23727086 rs10916034 chr1 226952315 T C 5.96E-04 Obesity (extreme) / / 21935397 rs12729579 chr1 226956181 C T 2.89E-04 White matter integrity / / 22425255 rs835673 chr1 226960025 T C 2.40E-04 White matter integrity / / 22425255 rs12033364 chr1 226965174 G A 4.87E-04 White matter integrity / / 22425255 rs10495250 chr1 226973381 G A 3.57E-05 Gaucher disease severity / / 22388998 rs7547071 chr1 227014390 C T 3.97E-04 Aortic root size / / 21223598 rs1150896 chr1 227047256 T C 9.88E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6687807 chr1 227111521 A G 4.07E-04 Multiple complex diseases / / 17554300 rs6660932 chr1 227124660 C T 6.37E-05 Cognitive performance / / 19734545 rs12593 chr1 227172290 C T 2.85E-04 Suicide attempts in bipolar disorder ADCK3 cds-synon 21041247 rs141270350 chr1 227174318 C T 1.20E-09 Breast cancer(er negative) ADCK3 cds-synon 23555315 rs1186 chr1 227177731 A T 3.55E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs3768425 chr1 227178127 A G 3.56E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs1045290 chr1 227178700 A G 3.56E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs1045289 chr1 227178713 C T 3.56E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs1045287 chr1 227178962 T C 3.56E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs1045285 chr1 227179054 G A 3.56E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs1062908 chr1 227181554 C G 3.57E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs373548817 chr1 227181554 CA CCA,CGG 3.57E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs1045252 chr1 227181555 A G 3.58E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs3795449 chr1 227181838 T G 3.58E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs3795451 chr1 227181923 C T 3.59E-04 Suicide attempts in bipolar disorder CDC42BPA UTR-3 21041247 rs1343743 chr1 227183125 C T 3.65E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs10495273 chr1 227183359 T G 3.65E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs10916075 chr1 227184074 G A 3.67E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs11587443 chr1 227187896 T C 3.68E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs7541033 chr1 227188371 C A 3.48E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs12409428 chr1 227189969 T C 3.72E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs6684821 chr1 227190233 G A 3.74E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs2297418 chr1 227192579 A C 3.80E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs6426559 chr1 227195876 T C 3.71E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs11588904 chr1 227196211 T C 3.72E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs12403236 chr1 227196502 C G 3.74E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs12409755 chr1 227196949 A T 3.66E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs6693535 chr1 227197685 G A 3.49E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs6659424 chr1 227197875 A G 3.31E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs1929862 chr1 227199718 G A 3.30E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs6704144 chr1 227201030 G C 3.29E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs6665290 chr1 227201106 C T 3.03E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs17600669 chr1 227201871 A G 6.55E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs17600725 chr1 227204231 A G 6.90E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs2104861 chr1 227208621 C T 6.27E-04 Suicide attempts in bipolar disorder CDC42BPA intron 21041247 rs2104861 chr1 227208621 C T 6.67E-06 Monocyte counts CDC42BPA intron pha003089 rs12122759 chr1 227217340 T C 2.00E-04 Multiple complex diseases CDC42BPA intron 17554300 rs1319103 chr1 227219314 A G 8.57E-04 Parkinson's disease CDC42BPA intron 17052657 rs7521639 chr1 227223736 T C 1.90E-05 HIV-1 control CDC42BPA intron 20041166 rs6681959 chr1 227241676 C G 1.35E-04 Multiple complex diseases CDC42BPA intron 17554300 rs10495266 chr1 227247016 G C 5.19E-04 Sarcoidosis CDC42BPA intron 21540310 rs7526822 chr1 227263491 C T 1.89E-04 Multiple complex diseases CDC42BPA intron 17554300 rs9426545 chr1 227302912 A G 6.98E-04 Heart Failure CDC42BPA intron pha002885 rs629571 chr1 227304838 T C 7.04E-04 Heart Failure CDC42BPA intron pha002885 rs16847143 chr1 227308031 G A 7.91E-05 Multiple complex diseases CDC42BPA intron 17554300 rs10495256 chr1 227342798 G T 3.91E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CDC42BPA intron 20031582 rs1913342 chr1 227361072 G A 2.98E-04 Multiple complex diseases CDC42BPA intron 17554300 rs12035998 chr1 227374760 G A 7.71E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CDC42BPA intron 20031582 rs1877619 chr1 227401170 T C 2.93E-04 Multiple complex diseases CDC42BPA intron 17554300 rs16847490 chr1 227421999 T A 2.90E-12 Multiple complex diseases CDC42BPA intron 17554300 rs2813950 chr1 227426072 G A 2.30E-05 Urinary metabolites CDC42BPA intron 21572414 rs16847561 chr1 227469549 C T 2.69E-05 Amyotrophic lateral sclerosis CDC42BPA intron 19193627 rs10495252 chr1 227471891 T C 2.21E-04 Multiple complex diseases CDC42BPA intron 17554300 rs7549619 chr1 227506948 C A 2.30E-04 Multiple complex diseases / / 17554300 rs12047613 chr1 227544843 T A 9.97E-06 Response to amphetamines / / 22952603 rs3014268 chr1 227558822 G A 1.95E-04 Multiple complex diseases / / 17554300 rs7533453 chr1 227576220 C A 1.40E-05 Coffee consumption / / 21357676 rs3000777 chr1 227584651 G A 5.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11799974 chr1 227624312 T C 5.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16847830 chr1 227626402 G T 6.97E-04 Multiple complex diseases / / 17554300 rs2819513 chr1 227630987 G A 2.34E-05 Hemoglobin / / pha003096 rs2819513 chr1 227630987 G A 2.45E-05 Hematocrit / / pha003097 rs10495275 chr1 227642119 T C 1.89E-06 Pancreatic cancer / / 22158540 rs953537 chr1 227655222 T C 1.00E-04 Asperger disorder / / 21182207 rs953537 chr1 227655222 T C 1.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs10916150 chr1 227655314 G A 3.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs9628651 chr1 227661082 A C 3.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs12410462 chr1 227667790 G A 4.00E-07 Major depressive disorder / / 23377640 rs2819522 chr1 227668181 G A 2.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs2814086 chr1 227669393 G C 3.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs1495850 chr1 227669682 T A 4.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs1390403 chr1 227673227 C A 3.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs7549565 chr1 227679714 G T 3.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs1390401 chr1 227797950 A G 5.00E-09 Height ZNF678 intron 18391952 rs12070036 chr1 227819514 G A 9.89E-05 Multiple complex diseases ZNF678 intron 17554300 rs1045407 chr1 227847233 A G 3.38E-04 Type 2 diabetes ZNF678 UTR-3 17463246 rs6671682 chr1 227880275 C T 9.18E-05 Attention deficit hyperactivity disorder / / 22420046 rs10799445 chr1 227911883 A C 2.00E-13 Height / / 20881960 rs3087908 chr1 227920103 G A 2.22E-05 B cell non-Hodgkin lymphoma JMJD4 missense 23749188 rs2236359 chr1 227935444 A G 3.70E-05 Hypothyroidism S/P47 missense 22493691 rs12077397 chr1 227940738 C T 1.47E-04 Type 2 diabetes S/P47 intron 17463246 rs10916205 chr1 227957591 C T 8.20E-05 Hypothyroidism S/P47 intron 22493691 rs754224 chr1 227963491 G T 2.08E-05 Bladder cancer S/P47 intron 19648920 rs11590137 chr1 227981505 G A 3.05E-04 Multiple complex diseases / / 17554300 rs6679942 chr1 227992928 C T 7.18E-05 Multiple complex diseases / / 17554300 rs4341357 chr1 227995023 T A 0.000658 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4341357 chr1 227995023 T A 6.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1582114 chr1 228016370 A G 5.25E-04 Multiple complex diseases PRSS38 intron 17554300 rs12047364 chr1 228023201 C G 2.45E-04 Multiple complex diseases PRSS38 intron 17554300 rs11589239 chr1 228037278 C T 6.25E-04 Multiple complex diseases / / 17554300 rs10157777 chr1 228068143 G A 1.15E-05 Response to methylphenidate treatment / / 21130132 rs945699 chr1 228093319 A G 2.00E-08 Amyotrophic lateral sclerosis / / 17671248 rs12725747 chr1 228106921 G A 2.71E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10127943 chr1 228110064 G A 7.26E-05 Body Mass Index WNT9A intron pha003014 rs7529664 chr1 228122132 C T 8.96E-04 Multiple complex diseases WNT9A intron 17554300 rs7529664 chr1 228122132 C T 7.56E-04 Taste perception WNT9A intron 22132133 rs681239 chr1 228139672 A G 9.43E-05 Fibrinogen / / pha003068 rs708121 chr1 228208257 A G 4.90E-04 Endometriosis WNT3A intron 23104006 rs3121310 chr1 228224824 A G 1.70E-04 Endometriosis WNT3A intron 21151130 rs3768331 chr1 228282695 C T 5.48E-04 Suicide attempts in bipolar disorder ARF1 intron 21423239 rs16848404 chr1 228412537 G A 7.50E-04 Rheumatoid arthritis OBSCN intron 21452313 rs947087 chr1 228415594 G A 0.000896857 Hypertension (early onset hypertension) OBSCN intron 22479346 rs4653935 chr1 228474817 G A 0.000378548 Hypertension (early onset hypertension) OBSCN intron 22479346 rs564636 chr1 228483369 C T 1.39E-06 Recombination rate OBSCN intron 21698098 rs287614 chr1 228489101 C A 8.59E-05 Age-related macular degeneration OBSCN intron 21197116 rs1150910 chr1 228492044 G A 7.33E-05 Age-related macular degeneration OBSCN intron 21197116 rs435776 chr1 228494790 G A 5.30E-06 Age-related macular degeneration OBSCN missense pha000001 rs113376653 chr1 228505275 C T 0.000072 Prostate cancer (advanced) OBSCN missense 23555315 rs3795801 chr1 228505739 G A 0.000486527 Hypertension (early onset hypertension) OBSCN missense 22479346 rs4653549 chr1 228529606 G A 0.000644782 Hypertension (early onset hypertension) OBSCN intron 22479346 rs11578798 chr1 228543303 T A 8.75E-04 Alcohol dependence OBSCN intron 21314694 rs147709306 chr1 228548255 G C 0.000015 Prostate cancer (advanced) OBSCN missense 23555315 rs472594 chr1 228601638 T C 4.04E-05 Blood Pressure TRIM17 intron pha002898 rs4653551 chr1 228627913 G A 3.01E-06 Non-obstructive azoospermia / / 22541561 rs16848614 chr1 228633197 T C 0.000896046 Hypertension (early onset hypertension) / / 22479346 rs16848614 chr1 228633197 T C 7.33E-06 Body Mass Index / / pha003007 rs16848614 chr1 228633197 T C 4.62E-05 Waist Circumference / / pha003025 rs16848614 chr1 228633197 T C 2.97E-05 Weight / / pha003027 rs10733022 chr1 228660501 C A 0.00089 Prostate cancer / / 23555315 rs1925714 chr1 228703289 A G 2.00E-07 Tuberculosis / / 24057671 rs11586639 chr1 228715705 A G 7.54E-05 Kawasaki disease / / 22446961 rs10916338 chr1 228715923 G A 4.74E-06 Tuberculosis / / 24057671 rs2182200 chr1 228716166 C A 1.82E-05 Tuberculosis / / 24057671 rs7415895 chr1 228741147 A G 8.30E-05 Type 1 diabetes / / 18978792 rs12044139 chr1 228807528 A T 2.20E-04 Multiple complex diseases RHOU intron 17554300 rs12144495 chr1 228810937 T G 8.38E-04 Acute lung injury RHOU intron 22295056 rs2295256 chr1 228874049 C T 5.60E-04 Acute lung injury RHOU intron 22295056 rs4391637 chr1 228878379 A C 5.47E-04 Acute lung injury RHOU intron 22295056 rs1062060 chr1 228880021 C T 4.20E-05 Crohn's disease RHOU UTR-3 20570966 rs1062060 chr1 228880021 C T 4.76E-04 Acute lung injury RHOU UTR-3 22295056 rs11578216 chr1 228880098 T A 6.06E-04 Acute lung injury RHOU UTR-3 22295056 rs6426514 chr1 228880115 G A 2.00E-06 Type 2 diabetes RHOU UTR-3 23300278 rs11580020 chr1 228880466 G A 8.60E-04 Acute lung injury RHOU UTR-3 22295056 rs4654650 chr1 228895860 T C 2.44E-04 Type 2 diabetes / / 17463246 rs9426534 chr1 228896420 T A 2.69E-04 Type 2 diabetes / / 17463246 rs6691235 chr1 228901242 T G 4.09E-05 Body mass index / / 17255346 rs6688686 chr1 228901263 A G 3.77E-05 Body mass index / / 17255346 rs728370 chr1 228903818 C T 2.60E-04 Myasthenia gravis / / 23055271 rs241324 chr1 228916634 A G 2.80E-04 Myasthenia gravis / / 23055271 rs12749124 chr1 228945692 T C 2.91E-05 Hemoglobin / / pha003096 rs241301 chr1 228962427 T C 3.05E-06 Basophils / / pha003087 rs2639760 chr1 228966621 A G 4.58E-06 Basophils / / pha003087 rs2748092 chr1 228968757 G A 2.42E-05 Response to methylphenidate treatment / / 21130132 rs801112 chr1 228996622 T C 5.00E-06 Endometriosis / / 20844546 rs801114 chr1 228997835 T G 6.00E-12 Basal cell carcinoma / / 18849993 rs801114 chr1 228997835 T G 6.00E-12 Nasopharyngeal carcinoma / / 20512145 rs801114 chr1 228997835 T G 2.00E-13 Basal cell carcinoma / / 24403052 rs71074 chr1 229003739 T C 2.43E-05 Basophils / / pha003087 rs1341715 chr1 229018916 A G 4.04E-06 Basophils / / pha003087 rs11585386 chr1 229019148 C T 5.00E-06 Aging / / 22773346 rs6674543 chr1 229021947 T G 8.15E-04 Insulin resistance / / 21901158 rs2236591 chr1 229039470 C T 4.41E-05 Basophils / / pha003087 rs12078733 chr1 229041874 T C 6.41E-05 Basophils / / pha003087 rs603404 chr1 229105145 A G 7.80E-05 Alcohol dependence / / 20201924 rs603404 chr1 229105145 A G 9.00E-05 Alcohol dependence / / 20201924 rs603404 chr1 229105145 A G 7.84E-05 Alcoholism / / pha002892 rs603404 chr1 229105145 A G 9.02E-05 Alcoholism / / pha002893 rs778381 chr1 229106195 G A 8.30E-06 Urinary metabolites / / 21572414 rs10916397 chr1 229110404 T G 1.52E-15 Multiple complex diseases / / 17554300 rs7529576 chr1 229114198 G A 5.30E-05 Glioma (high-grade) / / 19578366 rs10916399 chr1 229118735 G A 4.49E-04 Multiple complex diseases / / 17554300 rs10916407 chr1 229149821 G A 1.24E-04 Parkinson's disease / / 17052657 rs1458762 chr1 229157752 T C 3.46E-04 Parkinson's disease / / 17052657 rs4654712 chr1 229195093 T A 4.06E-05 Vaspin levels / / 22907691 rs10916422 chr1 229227923 G A 4.12E-04 Body mass index / / 21701565 rs17140127 chr1 229243687 C T 2.23E-04 Body mass index / / 21701565 rs17583896 chr1 229250187 T C 1.67E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs1551623 chr1 229256752 C T 3.44E-04 Alzheimer's disease / / 17998437 rs11809337 chr1 229258221 G A 6.93E-05 Inflammation / / pha002897 rs10916424 chr1 229262842 G A 2.96E-04 Hearing function / / 17255346 rs9726077 chr1 229272490 G A 2.40E-04 Primary sclerosing cholangitis / / 19944697 rs10916434 chr1 229282011 C T 2.40E-04 Primary sclerosing cholangitis / / 19944697 rs9793739 chr1 229285858 G A 4.00E-06 Dental caries / / 23259602 rs9793739 chr1 229285858 G A 5.00E-07 Dental caries / / 23259602 rs9287024 chr1 229291651 T G 4.14E-06 Asthma / / 11022011 rs365684 chr1 229305602 C T 2.45E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs12023401 chr1 229334294 A G 6.73E-04 Prostate cancer / / 23023329 rs16849553 chr1 229336846 T C 7.00E-07 Mean arterial pressure (alcohol consumption interaction) / / 24376456 rs16849568 chr1 229339670 T C 2.08E-07 Multiple complex diseases / / 17554300 rs2988738 chr1 229360505 T C 0.00000448 Change in depression severity with Norepinephrine reuptake inhibitors (NRI) / / 23091423 rs932927 chr1 229362876 G A 3.41E-05 Creatinine levels / / pha003069 rs365462 chr1 229372577 A G 2.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs9435863 chr1 229372913 T C 3.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs9435864 chr1 229372934 A G 6.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs9435865 chr1 229377014 T C 8.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs201183839 chr1 229396071 AC A,AAA 9.94E-05 Parkinson's disease / / 17052657 rs201820188 chr1 229396071 A C 9.94E-05 Parkinson's disease / / 17052657 rs2036773 chr1 229396071 A AA,AC 9.94E-05 Parkinson's disease / / 17052657 rs237779 chr1 229435276 A G 8.75E-05 Blood Pressure RAB4A intron pha003049 rs9435840 chr1 229461882 A C 5.60E-04 Multiple complex diseases C1orf96 intron 17554300 rs163771 chr1 229469350 G A 6.80E-05 Eating disorders (purging via substances) C1orf96 intron 23568457 rs238098 chr1 229508716 T C 1.67E-04 Cholesterol / / 17255346 rs1002063 chr1 229537513 A G 3.23E-05 HIV-1 viral setpoint / / 21490045 rs41307728 chr1 229594003 C T 0.00068 Prostate cancer NUP133 missense 23555315 rs446924 chr1 229666990 C T 4.32E-05 IgE levels in asthmatics (D.p. specific) ABCB10 intron 23967269 rs10916517 chr1 229702505 G A 3.50E-04 Multiple complex diseases / / 17554300 rs12049351 chr1 229718001 C G 1.00E-06 Circulating myeloperoxidase levels (plasma) / / 23620142 rs35065129 chr1 229722395 A AG 1.10E-06 Urinary metabolites / / 21572414 rs6701445 chr1 229724800 T C 2.24E-05 Longevity / / 21612516 rs2295625 chr1 229730452 G A 7.54E-05 Prion diseases TAF5L cds-synon 22210626 rs10916527 chr1 229746970 T C 2.00E-05 Urinary metabolites TAF5L intron 21572414 rs2273574 chr1 229750343 T G 6.98E-04 Stroke TAF5L intron pha002886 rs3811473 chr1 229772693 T G 1.87E-04 Attention deficit hyperactivity disorder URB2 missense pha002875 rs3955545 chr1 229776053 C T 1.50E-05 Urinary metabolites URB2 intron 21572414 rs3955545 chr1 229776053 C T 1.80E-04 Attention deficit hyperactivity disorder URB2 intron pha002875 rs6704530 chr1 229797040 A C 1.40E-04 Type 2 diabetes / / 17463246 rs12403112 chr1 229798874 C T 2.09E-04 Type 2 diabetes / / 17463246 rs12738647 chr1 229803654 C T 7.67E-04 Smoking initiation / / 24665060 rs12062780 chr1 229804873 G A 3.15E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10495285 chr1 229804995 C G 4.00E-07 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4925506 chr1 229811989 C T 2.95E-08 Autism / / 22935194 rs17595207 chr1 229888090 G T 1.79E-04 Multiple complex diseases / / 17554300 rs670054 chr1 229888337 C A 3.52E-05 Insulin Resistance / / pha003062 rs670054 chr1 229888337 C A 5.01E-05 Insulin-related traits / / pha003063 rs643009 chr1 229910737 G A 9.41E-04 Iron levels / / pha002876 rs640333 chr1 229913100 G A 5.23E-05 Multiple complex diseases / / 17554300 rs557208 chr1 229916660 T C 1.44E-05 Multiple complex diseases / / 17554300 rs527081 chr1 229917648 C G 1.77E-05 Multiple complex diseases / / 17554300 rs481515 chr1 229921700 T C 2.71E-05 Multiple complex diseases / / 17554300 rs479531 chr1 229921927 T C 2.10E-05 Multiple complex diseases / / 17554300 rs2780629 chr1 229929298 A G 3.18E-05 Multiple complex diseases / / 17554300 rs541010 chr1 229935677 A G 2.94E-05 Multiple complex diseases / / 17554300 rs603991 chr1 229956480 C T 5.10E-05 Multiple complex diseases / / 17554300 rs16850412 chr1 229984950 G A 2.70E-05 Urinary metabolites / / 21572414 rs2780623 chr1 230013938 G A 6.64E-05 HIV-1 viral setpoint / / 21490045 rs12117248 chr1 230076169 T C 4.19E-05 Cytomegalovirus antibody response / / 21993531 rs10779848 chr1 230136986 T C 7.56E-04 Multiple complex diseases / / 17554300 rs12410483 chr1 230146177 A G 5.37E-04 Coronary heart disease / / 21606135 rs4411137 chr1 230146467 C A 2.81E-04 Coronary heart disease / / 21606135 rs4295887 chr1 230152083 G A 5.84E-05 Cognitive test performance / / 20125193 rs11122617 chr1 230161993 C T 2.29E-04 Multiple complex diseases / / 17554300 rs7529252 chr1 230206891 G A 8.56E-06 Multiple complex diseases GALNT2 intron 17554300 rs1474926 chr1 230207406 C A 0.000043 Body mass index GALNT2 intron 23001569 rs6684432 chr1 230209790 T C 1.36E-05 Serum vitamin D-binding protein levels GALNT2 intron 24740207 rs6673349 chr1 230211398 G A 8.70E-04 Multiple complex diseases GALNT2 intron 17554300 rs11122275 chr1 230212533 G A 3.92E-04 Multiple complex diseases GALNT2 intron 17554300 rs7520640 chr1 230228980 G T 6.97E-04 Multiple complex diseases GALNT2 intron 17554300 rs7519655 chr1 230229324 A C 3.85E-04 Multiple complex diseases GALNT2 intron 17554300 rs10779824 chr1 230231256 C T 5.72E-05 Alcohol consumption GALNT2 intron 23743675 rs7529009 chr1 230232080 A G 5.62E-05 Multiple complex diseases GALNT2 intron 17554300 rs910821 chr1 230232241 T A 1.06E-04 Alcohol consumption GALNT2 intron 23743675 rs12726525 chr1 230235032 G A 6.58E-05 Alcohol consumption GALNT2 intron 23743675 rs10746509 chr1 230237282 C T 6.77E-05 Multiple complex diseases GALNT2 intron 17554300 rs10864690 chr1 230237540 T A 9.11E-05 Multiple complex diseases GALNT2 intron 17554300 rs1998068 chr1 230238063 C G 7.73E-05 Multiple complex diseases GALNT2 intron 17554300 rs1998067 chr1 230238507 A G 4.74E-04 Multiple complex diseases GALNT2 intron 17554300 rs1998066 chr1 230238569 T C 2.02E-04 Multiple complex diseases GALNT2 intron 17554300 rs12035297 chr1 230238821 C T 7.69E-05 Alcohol consumption GALNT2 intron 23743675 rs1474839 chr1 230241400 G A 6.82E-04 Multiple complex diseases GALNT2 intron 17554300 rs1967707 chr1 230241456 G A 1.54E-04 Multiple complex diseases GALNT2 intron 17554300 rs12751815 chr1 230242580 C T 4.52E-04 Multiple complex diseases GALNT2 intron 17554300 rs12751815 chr1 230242580 C T 1.01E-04 Alcohol consumption GALNT2 intron 23743675 rs12732392 chr1 230244966 A G 1.09E-04 Alcohol consumption GALNT2 intron 23743675 rs1022663 chr1 230245200 T C 0.0000062 Coronary artery calcification GALNT2 intron 23727086 rs11585739 chr1 230245900 T C 1.42E-04 Multiple complex diseases GALNT2 intron 17554300 rs12724775 chr1 230247123 G A 9.70E-05 Alcohol consumption GALNT2 intron 23743675 rs6659923 chr1 230247564 A G 9.72E-04 Multiple complex diseases GALNT2 intron 17554300 rs7550262 chr1 230248739 G A 2.40E-05 Urinary metabolites GALNT2 intron 21572414 rs12086347 chr1 230263373 G A,T 1.05E-04 Alcohol consumption GALNT2 intron 23743675 rs11122361 chr1 230263959 G A 8.06E-04 Amyotrophic Lateral Sclerosis GALNT2 intron 17362836 rs10864699 chr1 230264607 G A 1.83E-04 Alcohol consumption GALNT2 intron 23743675 rs7541570 chr1 230265342 T C 2.44E-04 Alcohol consumption GALNT2 intron 23743675 rs4846904 chr1 230279410 G A 1.00E-06 Lipid levels GALNT2 intron 19936222 rs4846904 chr1 230279410 G A 3.90E-04 Lipid levels GALNT2 intron 19936222 rs4846904 chr1 230279410 G A 5.40E-05 Lipid levels GALNT2 intron 19936222 rs4846904 chr1 230279410 G A 5.50E-06 Lipid levels GALNT2 intron 19936222 rs4846908 chr1 230285056 G A 4.80E-05 Lipid levels GALNT2 intron 19936222 rs4846908 chr1 230285056 G A 0.000000759 HDL cholesterol GALNT2 intron 23063622 rs1998064 chr1 230287128 T G 7.20E-06 Urinary metabolites GALNT2 intron 21572414 rs2144300 chr1 230294916 C T 6.56E-05 Type 2 diabetes GALNT2 intron 17463246 rs2144300 chr1 230294916 C T 3.00E-14 HDL cholesterol GALNT2 intron 18193043 rs2144300 chr1 230294916 C T 8.00E-07 Triglycerides GALNT2 intron 18193043 rs2144300 chr1 230294916 C T 6.32E-05 Smoking cessation GALNT2 intron 18519826 rs2144300 chr1 230294916 C T 7.60E-05 Response to statin therapy GALNT2 intron 20339536 rs2144300 chr1 230294916 C T 3.00E-14 Coronary heart disease GALNT2 intron 21347282 rs2144300 chr1 230294916 C T 3.37E-16 HDL cholesterol GALNT2 intron 23063622 rs2144300 chr1 230294916 C T 6.39E-09 Triglycerides GALNT2 intron 23063622 rs2144300 chr1 230294916 C T 0.0000467 HDL cholesterol GALNT2 intron 23236364 rs2144300 chr1 230294916 C T 3.00E-06 Circulating myeloperoxidase levels (serum) GALNT2 intron 23620142 rs17315646 chr1 230295307 C G 8.94E-05 Type 2 diabetes GALNT2 intron 17463246 rs17315646 chr1 230295307 C G 5.71E-05 Smoking cessation GALNT2 intron 18519826 rs17315646 chr1 230295307 C G 7.50E-05 Response to statin therapy GALNT2 intron 20339536 rs17315646 chr1 230295307 C G 6.99E-12 HDL cholesterol GALNT2 intron 23063622 rs17315646 chr1 230295307 C G 8.57E-08 Triglycerides GALNT2 intron 23063622 rs4846914 chr1 230295691 G A 8.53E-05 Type 2 diabetes GALNT2 intron 17463246 rs4846914 chr1 230295691 G A 2.50E-09 Lipid levels GALNT2 intron 18193043 rs4846914 chr1 230295691 G A 2.00E-13 HDL cholesterol GALNT2 intron 18193044 rs4846914 chr1 230295691 G A 7.00E-15 Triglycerides GALNT2 intron 18193044 rs4846914 chr1 230295691 G A 1.80E-04 Smoking cessation GALNT2 intron 18519826 rs4846914 chr1 230295691 G A 4.00E-08 HDL cholesterol GALNT2 intron 19060906 rs4846914 chr1 230295691 G A 7.60E-05 Response to statin therapy GALNT2 intron 20339536 rs4846914 chr1 230295691 G A 2.00E-14 Triglycerides GALNT2 intron 20686565 rs4846914 chr1 230295691 G A 4.00E-21 HDL cholesterol GALNT2 intron 20686565 rs4846914 chr1 230295691 G A 2.00E-13 Coronary heart disease GALNT2 intron 21347282 rs4846914 chr1 230295691 G A 8.91E-04 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) GALNT2 intron 21541012 rs4846914 chr1 230295691 G A 3.96E-08 Triglycerides GALNT2 intron 23063622 rs4846914 chr1 230295691 G A 4.28E-16 HDL cholesterol GALNT2 intron 23063622 rs4846914 chr1 230295691 G A 4.00E-41 HDL cholesterol GALNT2 intron 24097068 rs4846914 chr1 230295691 G A 7.00E-31 Triglycerides GALNT2 intron 24097068 rs10127775 chr1 230295789 A G,T 8.61E-05 Type 2 diabetes GALNT2 intron 17463246 rs10127775 chr1 230295789 A G,T 7.60E-05 Response to statin therapy GALNT2 intron 20339536 rs10127775 chr1 230295789 A G,T 1.00E-09 Metabolite levels (atherosclerosis) GALNT2 intron 22916037 rs2281719 chr1 230297659 C T 3.73E-04 Type 2 diabetes GALNT2 intron 17463246 rs2281719 chr1 230297659 C T 8.10E-05 Response to statin therapy GALNT2 intron 20339536 rs2281719 chr1 230297659 C T 8.51E-04 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) GALNT2 intron 21541012 rs2281719 chr1 230297659 C T 0.00000013 Triglycerides GALNT2 intron 23063622 rs2281719 chr1 230297659 C T 3.77E-15 HDL cholesterol GALNT2 intron 23063622 rs10779835 chr1 230299949 T C 1.60E-06 Lipid levels GALNT2 intron 19936222 rs10779835 chr1 230299949 T C 3.50E-05 Lipid levels GALNT2 intron 19936222 rs10779835 chr1 230299949 T C 5.30E-04 Lipid levels GALNT2 intron 19936222 rs10779835 chr1 230299949 T C 8.30E-05 Response to statin therapy GALNT2 intron 20339536 rs4846918 chr1 230300586 C T 3.20E-05 Lipoprotein A [Lp(a)] levels in plasma GALNT2 intron 21592478 rs4846918 chr1 230300586 C T 0.000000422 HDL cholesterol GALNT2 intron 22629316 rs4846918 chr1 230300586 C T 0.000019 HDL cholesterol (female) GALNT2 intron 22629316 rs4846918 chr1 230300586 C T 2.71E-12 HDL cholesterol GALNT2 intron 23063622 rs4846918 chr1 230300586 C T 6.65E-08 Triglycerides GALNT2 intron 23063622 rs2296065 chr1 230301776 G A 3.80E-05 Lipoprotein A [Lp(a)] levels in plasma GALNT2 intron 21592478 rs2296065 chr1 230301776 G A 0.000000415 Triglycerides in females GALNT2 intron 23063622 rs2296065 chr1 230301776 G A 0.000288 HDL cholesterol (male) GALNT2 intron 23063622 rs2296065 chr1 230301776 G A 1.36E-09 HDL cholesterol (female) GALNT2 intron 23063622 rs2296065 chr1 230301776 G A 4.37E-08 Triglycerides GALNT2 intron 23063622 rs2296065 chr1 230301776 G A 9.61E-13 HDL cholesterol GALNT2 intron 23063622 rs2296065 chr1 230301776 G A 3.86E-05 HDL particle features GALNT2 intron pha002900 rs10489615 chr1 230304988 A G 7.00E-05 Response to statin therapy GALNT2 intron 20339536 rs10489615 chr1 230304988 A G 4.00E-09 HDL cholesterol GALNT2 intron 20864672 rs1321257 chr1 230305312 G A 6.40E-05 Response to statin therapy GALNT2 intron 20339536 rs4846922 chr1 230307182 T C 4.00E-08 Metabolic syndrome GALNT2 intron 22399527 rs609526 chr1 230308906 T A 2.63E-04 Type 2 diabetes GALNT2 intron 17463246 rs609526 chr1 230308906 T A 2.49E-05 Smoking cessation GALNT2 intron 18519826 rs609526 chr1 230308906 T A 2.61E-12 HDL cholesterol GALNT2 intron 23063622 rs609526 chr1 230308906 T A 2.25E-04 Blood pressure (response to calcium channel blocker) GALNT2 intron 24192120 rs611841 chr1 230309481 C A 3.54E-08 HDL cholesterol GALNT2 intron 23063622 rs611841 chr1 230309481 C A 5.57E-08 Triglycerides GALNT2 intron 23063622 rs611229 chr1 230324067 T G 1.53E-09 HDL cholesterol GALNT2 intron 23063622 rs611229 chr1 230324067 T G 4.93E-06 HDL particle features GALNT2 intron pha002900 rs612577 chr1 230324364 T C 3.72E-05 Lipoprotein A [Lp(a)] levels in plasma GALNT2 intron 21592478 rs6703306 chr1 230351829 A G 3.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT2 intron 20877124 rs12076454 chr1 230378663 C T 3.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT2 intron 20877124 rs3789630 chr1 230387498 C T 3.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT2 intron 20877124 rs3761944 chr1 230388989 G C 8.00E-06 Hematology traits GALNT2 intron 23303382 rs12139970 chr1 230406460 G T 2.86E-06 HDL particle features GALNT2 intron pha002900 rs12030266 chr1 230427458 A C 4.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1386584 chr1 230436520 A G 2.48E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs11586112 chr1 230454674 C A 9.56E-04 Alzheimer's disease / / 17998437 rs7523232 chr1 230462848 C G 4.97E-05 Type 2 diabetes PGBD5 intron 17463246 rs828463 chr1 230513128 G A 5.28E-04 Smoking quantity PGBD5 intron 24665060 rs701170 chr1 230517993 C A 9.93E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) PGBD5 intron 24023788 rs270851 chr1 230535437 G A 7.15E-05 Blood pressure PGBD5 intron 17255346 rs11122509 chr1 230551909 T C 0.000855417 Hypertension (early onset hypertension) PGBD5 intron 22479346 rs4846967 chr1 230575433 A C 7.69E-04 Smoking quantity / / 24665060 rs853010 chr1 230631025 T G 1.27E-04 Blood pressure / / 17255346 rs853006 chr1 230652782 T G 1.60E-05 Urinary metabolites / / 21572414 rs701157 chr1 230674826 T C 4.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs853444 chr1 230682813 A G 1.40E-06 Urinary metabolites / / 21572414 rs853444 chr1 230682813 A G 4.59E-04 Obesity (extreme) / / 21935397 rs853448 chr1 230686473 A C 6.74E-06 Body Mass Index / / pha003015 rs11122534 chr1 230688466 A G 2.77E-05 Celiac disease / / 23936387 rs11804015 chr1 230704291 T C 8.01E-05 Body Mass Index / / pha003015 rs10779846 chr1 230706208 C T 7.08E-04 Type 2 diabetes / / 17463246 rs200591 chr1 230706923 G A 4.54E-06 Body Mass Index / / pha003015 rs200591 chr1 230706923 G A 3.05E-05 Weight / / pha003027 rs740492 chr1 230711435 C T 1.54E-05 Body Mass Index / / pha003015 rs11122546 chr1 230719896 C A 9.95E-05 Myocardial Infarction / / pha002873 rs16852057 chr1 230724960 G A 4.81E-04 Multiple complex diseases / / 17554300 rs11122547 chr1 230725720 T C 4.64E-05 Myocardial Infarction / / pha002873 rs17659489 chr1 230749245 C T 2.20E-05 Urinary metabolites / / 21572414 rs853464 chr1 230749646 G A 2.81E-05 Body Mass Index / / pha003015 rs853464 chr1 230749646 G A 9.05E-05 Weight / / pha003027 rs11122556 chr1 230752309 C G 1.60E-04 Multiple complex diseases / / 17554300 rs853469 chr1 230759310 T C 5.49E-05 Body Mass Index / / pha003015 rs1078198 chr1 230774477 T C 8.49E-05 ldl cholesterol / / pha003077 rs1078197 chr1 230774851 T C 3.99E-05 ldl cholesterol / / pha003077 rs1359866 chr1 230795177 T C 5.49E-04 Smoking cessation COG2 intron 24665060 rs12143647 chr1 230808246 C T 3.20E-04 Suicidal ideation COG2 intron 22030708 rs2479131 chr1 230818841 G T 4.09E-04 Alzheimer's disease COG2 intron 17998437 rs41342047 chr1 230821996 C T 1.44E-04 Multiple complex diseases COG2 intron 17554300 rs143526339 chr1 230822832 C G 0.00015 Breast cancer COG2 missense 23555315 rs943580 chr1 230837044 G A 2.10E-08 Blood pressure / / 22100073 rs3789670 chr1 230843714 C T 5.40E-05 Blood pressure AGT intron 22100073 rs3789671 chr1 230843800 G T 1.10E-07 Blood pressure AGT intron 22100073 rs2478543 chr1 230844310 T C 1.20E-08 Blood pressure AGT intron 22100073 rs6687360 chr1 230844992 C T 8.20E-09 Blood pressure AGT intron 22100073 rs699 chr1 230845794 A G 1 Drug response to Atenolol AGT missense 11593098 rs699 chr1 230845794 A G 1 Drug response to Losartan AGT missense 11593098 rs699 chr1 230845794 A G 1.10E-08 Blood pressure AGT missense 22100073 rs699 chr1 230845794 A G 1 Drug response to Atenolol AGT missense 8728305 rs699 chr1 230845794 A G 1 Drug response to Lisinopril AGT missense 8728305 rs699 chr1 230845794 A G 1 Drug response to Nifedipine AGT missense 8728305 rs4762 chr1 230845977 G A 1 Drug response to Atenolol AGT missense 11593098 rs4762 chr1 230845977 G A 1 Drug response to Losartan AGT missense 11593098 rs11568026 chr1 230847523 A G 0.000000663 HDL cholesterol AGT intron 23063622 rs11568023 chr1 230848179 G A 7.16E-05 Multiple complex diseases AGT intron 17554300 rs2004776 chr1 230848702 C T 1.21E-06 Blood pressure AGT intron 22100073 rs2004776 chr1 230848702 C T 6.70E-14 Blood pressure AGT intron 22100073 rs2004776 chr1 230848702 C T 7.10E-10 Blood pressure AGT intron 22100073 rs2004776 chr1 230848702 C T 9.03E-13 Blood pressure AGT intron 22100073 rs2004776 chr1 230848702 C T 1.40E-04 Blood pressure (age interaction) AGT intron 24954895 rs2493134 chr1 230849359 T C 7.00E-09 Blood pressure AGT intron 22100073 rs2148582 chr1 230849799 A G 1.60E-08 Blood pressure AGT intron 22100073 rs5051 chr1 230849872 C T 2.30E-08 Blood pressure AGT UTR-5 22100073 rs5049 chr1 230850083 C T 5.90E-06 Blood pressure AGT UTR-5 22100073 rs5046 chr1 230850398 G A 5.20E-06 Blood pressure AGT nearGene-5 22100073 rs2071405 chr1 230850658 C T 5.70E-06 Blood pressure AGT nearGene-5 22100073 rs2071404 chr1 230850940 C A 6.00E-06 Blood pressure AGT nearGene-5 22100073 rs1977414 chr1 230852551 C T 2.40E-06 Blood pressure / / 22100073 rs16852515 chr1 230877144 A C 1.50E-05 Multiple complex diseases / / 17554300 rs16852515 chr1 230877144 A C 4.20E-05 Personality dimensions / / 18957941 rs6541330 chr1 230884363 T C 5.22E-05 Platelet counts CAPN9 intron pha003100 rs28359608 chr1 230895340 C A 9.85E-04 Amyotrophic lateral sclerosis (sporadic) CAPN9 missense 24529757 rs12038826 chr1 230922951 T C 7.00E-06 Myopia (pathological) CAPN9 intron 23049088 rs4477283 chr1 230932442 C T 1.25E-04 Amyotrophic lateral sclerosis CAPN9 intron 20801718 rs12139410 chr1 230933107 A G 5.14E-05 Insulin Resistance CAPN9 intron pha003062 rs1202524 chr1 230951172 G A 0.000023 Endometrial cancer / / 22426144 rs1202529 chr1 230955097 G C 0.000032 Endometrial cancer (Type 1 endometrial cancer) / / 22426144 rs1202529 chr1 230955097 G C 0.000055 Endometrial cancer / / 22426144 rs4847021 chr1 230959298 C T 2.22E-04 Multiple complex diseases / / 17554300 rs11122614 chr1 230967445 G A 9.71E-05 Insulin Resistance / / pha003062 rs11122614 chr1 230967445 G A 7.42E-05 Insulin-related traits / / pha003063 rs11122616 chr1 230978726 A G 1.10E-05 Urinary metabolites C1orf198 intron 21572414 rs1202558 chr1 230983656 C T 4.32E-04 Response to taxane treatment (placlitaxel) C1orf198 intron 23006423 rs1202570 chr1 230992134 A G 2.90E-05 Urinary metabolites C1orf198 intron 21572414 rs1202570 chr1 230992134 A G 9.24E-05 Orofacial clefts C1orf198 intron 22419666 rs1202577 chr1 230998112 T C 9.50E-06 Urinary metabolites C1orf198 intron 21572414 rs1202580 chr1 231000791 A G 7.34E-04 Response to taxane treatment (placlitaxel) C1orf198 intron 23006423 rs1202582 chr1 231001233 T C 6.07E-04 Response to taxane treatment (placlitaxel) C1orf198 intron 23006423 rs1202584 chr1 231002150 A G 9.53E-04 Response to taxane treatment (placlitaxel) C1orf198 intron 23006423 rs185614261 chr1 231004221 G A 0.000021 Breast cancer C1orf198 missense 23555315 rs9431872 chr1 231018941 A C 1.10E-05 Cognitive function / / 24684796 rs7550054 chr1 231062006 G A 6.97E-04 Multiple complex diseases TTC13 intron 17554300 rs4846886 chr1 231087400 G T 4.24E-05 HIV-1 viral setpoint TTC13 intron 22174851 rs6541240 chr1 231090578 G A 5.20E-05 Type 2 diabetes TTC13 intron 17293876 rs10864649 chr1 231132597 G C 6.30E-05 Multiple complex diseases ARV1 intron 17554300 rs12032403 chr1 231149298 A G 1.36E-04 Taste perception / / 22132133 rs10864659 chr1 231187053 T C 3.98E-04 Multiple complex diseases / / 17554300 rs6696857 chr1 231198028 C T 6.38E-04 Multiple complex diseases / / 17554300 rs4369216 chr1 231198332 A C 2.23E-05 Hirschsprung's disease / / 19196962 rs4463650 chr1 231199849 T G 6.58E-04 Multiple complex diseases / / 17554300 rs4388693 chr1 231220364 G A 3.06E-06 Leprosy / / pha002872 rs12043426 chr1 231241824 A C 3.50E-06 Primary sclerosing cholangitis / / 21151127 rs2883720 chr1 231255113 C T 5.07E-05 Multiple complex diseases / / 17554300 rs7514972 chr1 231262876 T C 2.30E-04 Multiple complex diseases / / 17554300 rs7514972 chr1 231262876 T C 2.82E-04 Lymphocyte counts / / 22286170 rs12023396 chr1 231270636 A G 4.00E-07 Obesity-related traits / / 23251661 rs9431646 chr1 231273550 G A 7.35E-04 Obesity (extreme) / / 21935397 rs9431933 chr1 231273656 C T 9.08E-04 Obesity (extreme) / / 21935397 rs9431934 chr1 231274460 C T 9.06E-04 Obesity (extreme) / / 21935397 rs6689582 chr1 231284128 G A 5.08E-04 Alzheimer's disease / / 22005930 rs1321132 chr1 231291359 G A 1.87E-04 Smoking initiation / / 24665060 rs9431660 chr1 231311867 A G 7.19E-05 White matter integrity TRIM67 intron 22425255 rs1406869 chr1 231313859 T C 8.84E-05 Heart Rate TRIM67 intron pha003054 rs9431663 chr1 231314221 A G 1.20E-04 Neuroticism TRIM67 intron 17667963 rs12563076 chr1 231327666 T A 3.19E-04 Smoking initiation TRIM67 intron 24665060 rs491182 chr1 231362923 G A 2.50E-05 Urinary metabolites C1orf131 intron 21572414 rs16854120 chr1 231504359 C T 5.79E-04 Multiple complex diseases EGLN1 intron 17554300 rs12030600 chr1 231605379 G A 9.10E-06 Urinary metabolites / / 21572414 rs1769800 chr1 231620545 T C 1.89E-04 Self-reported allergy / / 23817569 rs1769801 chr1 231622949 T C 2.63E-04 Self-reported allergy / / 23817569 rs1765774 chr1 231628292 A G 1.30E-05 Urinary metabolites / / 21572414 rs1765794 chr1 231656418 G A 8.98E-04 Self-reported allergy / / 23817569 rs1059595 chr1 231658301 A G 7.14E-04 Alcohol dependence / / 21314694 rs1059595 chr1 231658301 A G 2.50E-05 Urinary metabolites / / 21572414 rs766288 chr1 231693688 G T 9.16E-05 Self-reported allergy TS/X intron 23817569 rs1655304 chr1 231731343 G C 4.89E-04 Self-reported allergy LOC100287814 intron 23817569 rs1765778 chr1 231732356 G A 6.10E-04 Self-reported allergy LOC100287814 intron 23817569 rs1655297 chr1 231733687 C T 2.54E-04 Self-reported allergy LOC100287814 intron 23817569 rs1655296 chr1 231733795 G T 2.88E-04 Self-reported allergy LOC100287814 intron 23817569 rs1655295 chr1 231734001 T A 2.46E-04 Self-reported allergy LOC100287814 intron 23817569 rs6656071 chr1 231737700 C T 3.01E-04 Self-reported allergy LOC100287814 intron 23817569 rs6679985 chr1 231737829 G C 3.37E-04 Self-reported allergy LOC100287814 intron 23817569 rs6674294 chr1 231738385 T C 3.18E-04 Self-reported allergy LOC100287814 intron 23817569 rs6683094 chr1 231738565 G A 3.18E-04 Self-reported allergy LOC100287814 intron 23817569 rs1025527 chr1 231749845 A G 2.26E-04 Self-reported allergy TS/X-DISC1 intron 23817569 rs1025526 chr1 231750641 C T 1.78E-04 Self-reported allergy TS/X-DISC1 intron 23817569 rs9661331 chr1 231752306 C T 1.41E-04 Self-reported allergy TS/X-DISC1 intron 23817569 rs6541275 chr1 231752942 A G 1.89E-04 Self-reported allergy TS/X-DISC1 intron 23817569 rs6541279 chr1 231753463 G C 2.31E-04 Self-reported allergy TS/X-DISC1 intron 23817569 rs4603118 chr1 231754600 A G 2.26E-04 Self-reported allergy TS/X-DISC1 intron 23817569 rs6656080 chr1 231755265 G A 2.19E-04 Self-reported allergy TS/X-DISC1 intron 23817569 rs1030711 chr1 231755461 A T 5.92E-04 Self-reported allergy TS/X-DISC1 intron 23817569 rs9659663 chr1 231757060 A G 1.02E-04 Self-reported allergy TS/X-DISC1 intron 23817569 rs823167 chr1 231767230 G A 8.37E-04 Self-reported allergy DISC1 intron 23817569 rs823165 chr1 231769446 T A 6.43E-05 Self-reported allergy DISC1 intron 23817569 rs823163 chr1 231771108 A G 1.31E-04 Self-reported allergy DISC1 intron 23817569 rs1094656 chr1 231773675 T C 2.04E-04 Self-reported allergy DISC1 intron 23817569 rs1094655 chr1 231774362 A G 1.48E-04 Self-reported allergy DISC1 intron 23817569 rs823161 chr1 231775017 G A 1.56E-04 Self-reported allergy DISC1 intron 23817569 rs980394 chr1 231779507 G A 9.02E-05 Self-reported allergy DISC1 intron 23817569 rs11122318 chr1 231806852 T C 2.30E-04 Self-reported allergy DISC1 intron 23817569 rs12030517 chr1 231808385 T C 1.52E-04 Self-reported allergy DISC1 intron 23817569 rs12042938 chr1 231816842 C T 4.00E-36 Neuranatomic and neurocognitive phenotypes DISC1 intron 21483430 rs12042938 chr1 231816842 C T 9.93E-04 Self-reported allergy DISC1 intron 23817569 rs12044355 chr1 231844347 A C 8.34E-04 Multiple complex diseases DISC1 intron 17554300 rs12044355 chr1 231844347 A C 9.00E-06 Alzheimer's disease DISC1 intron 19118814 rs12044355 chr1 231844347 A C 9.20E-06 Alzheimer's disease (late onset) DISC1 intron 21460841 rs11122324 chr1 231859181 G A 1.87E-04 Multiple complex diseases DISC1 UTR-3 17554300 rs2793086 chr1 231899704 T G 9.00E-06 Response to antineoplastic agents DISC1 intron 21659360 rs16854954 chr1 231912592 T C 7.72E-05 Schizophrenia DISC1 intron 20185149 rs10495310 chr1 231918776 A C 2.34E-04 Alzheimer's disease (late onset) DISC1 intron 21379329 rs17817356 chr1 231920221 G A 1.86E-04 Fibrinogen DISC1 intron 17255346 rs11590192 chr1 231922845 T C 8.22E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) DISC1 intron 23648065 rs4459095 chr1 231985580 A G 1.27E-04 Smoking cessation DISC1 intron 18519826 rs9432024 chr1 232007219 T C 0.00000167 Schizophrenia DISC1 intron 22440650 rs10864698 chr1 232017889 G A 9.83E-04 Type 2 diabetes DISC1 intron 17463246 rs9431714 chr1 232021248 G A 1.60E-05 Urinary metabolites DISC1 intron 21572414 rs16855598 chr1 232054181 T C 3.85E-04 Multiple complex diseases DISC1 intron 17554300 rs701158 chr1 232073128 A G 8.85E-04 Alzheimer's disease DISC1 intron 24755620 rs872624 chr1 232074900 G A 2.01E-04 Smoking cessation DISC1 intron 18519826 rs872624 chr1 232074900 G A 7.03E-05 Smoking cessation DISC1 intron 18519826 rs1094401 chr1 232083585 A C 4.00E-04 Acute lymphoblastic leukemia (childhood) DISC1 intron 20189245 rs16855725 chr1 232088232 G T 4.80E-04 Multiple complex diseases DISC1 intron 17554300 rs821597 chr1 232102264 G A 1.53E-04 Smoking quantity DISC1 intron 24665060 rs821600 chr1 232117026 G A 3.04E-04 Smoking quantity DISC1 intron 24665060 rs821662 chr1 232121135 T C 1.97E-04 Smoking quantity DISC1 intron 24665060 rs821663 chr1 232121222 C T 2.46E-04 Smoking quantity DISC1 intron 24665060 rs16855881 chr1 232124689 T C 3.60E-04 Multiple complex diseases DISC1 intron 17554300 rs821654 chr1 232127354 A G 7.47E-04 Smoking quantity DISC1 intron 24665060 rs3121910 chr1 232137193 T G 7.34E-04 Smoking quantity DISC1 intron 24665060 rs1754605 chr1 232137674 T C 6.51E-04 Smoking quantity DISC1 intron 24665060 rs866596 chr1 232146930 A G 3.95E-04 Smoking quantity DISC1 intron 24665060 rs821627 chr1 232147168 C T 2.96E-05 Smoking quantity DISC1 intron 24665060 rs866055 chr1 232147568 A G 9.06E-05 Smoking quantity DISC1 intron 24665060 rs1475514 chr1 232153793 G A 4.76E-04 Smoking quantity DISC1 intron 24665060 rs16856202 chr1 232155151 T G 8.00E-06 Amyotrophic lateral sclerosis DISC1 intron 19451621 rs1411771 chr1 232174775 T C 0.0000206 Antithrombin DISC1 UTR-3 23705025 rs2026298 chr1 232232335 C T 8.47E-04 Multiple complex diseases / / 17554300 rs1576618 chr1 232244331 C T 1.40E-06 Response to statin therapy / / 20339536 rs9729778 chr1 232246001 C T 4.30E-04 Alzheimer's disease (late onset) / / 21379329 rs10746514 chr1 232246027 G A 1.00E-06 Response to statin therapy / / 20339536 rs9308486 chr1 232246418 A G 1.90E-05 Response to statin therapy / / 20339536 rs9308486 chr1 232246418 A G 4.42E-05 Bleomycin sensitivity / / 21106707 rs9724918 chr1 232248087 C T 5.48E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9724918 chr1 232248087 C T 2.50E-05 Response to statin therapy / / 20339536 rs17832313 chr1 232266181 T C 8.05E-05 Orofacial clefts / / 22419666 rs867844 chr1 232266278 T A 4.30E-05 Response to statin therapy / / 20339536 rs1888601 chr1 232266922 C T 4.30E-05 Response to statin therapy / / 20339536 rs11122432 chr1 232270985 A G 3.99E-04 Multiple complex diseases / / 17554300 rs10864720 chr1 232271232 C T 4.00E-05 Response to statin therapy / / 20339536 rs12039526 chr1 232272599 C T 5.10E-05 Response to statin therapy / / 20339536 rs9662589 chr1 232277611 A C 7.40E-04 Multiple complex diseases / / 17554300 rs9308490 chr1 232308565 G C 7.84E-06 Serum metabolites / / 19043545 rs9727900 chr1 232311020 C T 2.50E-05 Weight / / pha003026 rs12754490 chr1 232312344 T C 6.47E-05 Bipolar disorder and schizophrenia / / 20889312 rs1571755 chr1 232314505 C T 1.00E-04 Information processing speed / / 21130836 rs16856660 chr1 232321591 C T 7.10E-05 Multiple complex diseases / / 17554300 rs6605044 chr1 232349755 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4649384 chr1 232394263 T G 2.87E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9286807 chr1 232403070 T C 2.06E-04 Smoking quantity / / 24665060 rs11803212 chr1 232415093 G A 1.29E-04 Celiac disease / / 23936387 rs16856730 chr1 232422283 T C 3.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9725031 chr1 232444455 C T 8.00E-06 Post-traumatic stress disorder / / 24677629 rs4649292 chr1 232463715 G A 2.41E-04 HIV-1 viral setpoint / / 17641165 rs789367 chr1 232472932 G T 4.86E-05 Sarcoidosis / / 19165924 rs662242 chr1 232477392 T C 5.97E-05 Smoking quantity / / 24665060 rs607869 chr1 232484231 T A 4.46E-04 Smoking quantity / / 24665060 rs592557 chr1 232489950 C T 4.00E-04 Nicotine dependence / / 17407593 rs16856874 chr1 232494124 G A 6.63E-05 Pancreatic cancer / / pha002874 rs645925 chr1 232496302 G A 0.0000714 Tuberculosis with early age of onset / / 22551897 rs644690 chr1 232505285 T C 4.40E-04 Myasthenia gravis / / 23055271 rs3120768 chr1 232512873 A G 7.84E-05 Smoking quantity / / 24665060 rs789357 chr1 232516302 C T 4.50E-07 Urinary metabolites / / 21572414 rs669408 chr1 232519150 A C 1.00E-06 Immunoglobulin A / / 20694011 rs612191 chr1 232522748 T C 4.74E-04 Sarcoidosis / / 19165924 rs612191 chr1 232522748 T C 1.30E-06 Urinary metabolites / / 21572414 rs647578 chr1 232523442 A G 1.30E-06 Urinary metabolites / / 21572414 rs10158347 chr1 232529744 A G 9.37E-04 Type 2 diabetes / / 22158537 rs12043279 chr1 232540311 G A 9.90E-04 Alzheimer's disease SIPA1L2 intron 17998437 rs946132 chr1 232553739 C T 8.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SIPA1L2 intron 20877124 rs12758343 chr1 232566207 C T 1.09E-04 Lung function (forced expiratory volume in 1 second) SIPA1L2 intron 17255346 rs1547741 chr1 232568293 A G 2.40E-04 HIV-1 viral setpoint SIPA1L2 intron 17641165 rs6664207 chr1 232575539 G A 1.00E-04 Cognitive impairment induced by topiramate SIPA1L2 intron 22091778 rs6664207 chr1 232575539 G A 2.63E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SIPA1L2 intron 24023788 rs573140 chr1 232577281 T G 0.00000658 Bipolar disorder SIPA1L2 intron 23637625 rs17794366 chr1 232583916 G A 6.90E-04 Myopia (pathological) SIPA1L2 intron 21095009 rs6674092 chr1 232638409 G A 2.40E-05 Urinary metabolites SIPA1L2 intron 21572414 rs4649382 chr1 232641169 T C 4.12E-04 Multiple complex diseases SIPA1L2 intron 17554300 rs3795366 chr1 232650750 A G 9.47E-05 Waist-Hip Ratio SIPA1L2 cds-synon pha003029 rs12753793 chr1 232657870 T C 3.07E-04 Multiple complex diseases / / 17554300 rs6666357 chr1 232667977 C T 8.24E-04 Multiple complex diseases / / 17554300 rs789633 chr1 232673154 C T 6.61E-05 Waist-Hip Ratio / / pha003029 rs16857596 chr1 232673626 A G 1.39E-04 Aortic root size / / 21223598 rs789666 chr1 232686897 G A 5.11E-05 Paget's disease / / 20436471 rs16857696 chr1 232704719 T G 5.81E-04 Multiple complex diseases / / 17554300 rs16857696 chr1 232704719 T G 2.83E-04 Coronary heart disease / / 21606135 rs10797579 chr1 232718667 G T 9.19E-04 Type 2 diabetes / / 17463246 rs12036860 chr1 232725909 C G 5.10E-05 Body mass (lean) / / 19268274 rs16857720 chr1 232726069 A G 4.37E-05 Body mass (lean) / / 19268274 rs16857721 chr1 232726276 G T 3.69E-05 Body mass (lean) / / 19268274 rs4649274 chr1 232735234 G A 2.88E-04 Type 2 diabetes / / 17463246 rs10495332 chr1 232756026 T C 8.00E-06 Smooth-surface caries / / 24556642 rs7527321 chr1 232767895 T C 8.94E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10797586 chr1 232769870 T C 6.78E-04 Multiple complex diseases / / 17554300 rs6672248 chr1 232773900 A G 2.20E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17807087 chr1 232787894 A C 0.00000614 Transmission distortion / / 22377632 rs2184345 chr1 232811111 T C 1.64E-05 Myopia (pathological) / / 21640322 rs6699751 chr1 232811429 T C 5.00E-04 Alcohol dependence / / 20201924 rs4308924 chr1 232827343 T C 7.97E-05 Asthma / / 11022011 rs6676329 chr1 232859200 T C 2.04E-04 Multiple complex diseases / / 17554300 rs2644465 chr1 232895309 T G 1.49E-04 Type 2 diabetes / / 17463246 rs974935 chr1 232906829 C G 1.40E-05 Urinary metabolites / / 21572414 rs2814501 chr1 232911400 G A 0.000774 Salmonella-induced pyroptosis / / 22837397 rs2201591 chr1 232917823 C A 1.60E-05 Urinary metabolites / / 21572414 rs2644469 chr1 232921039 T C 9.81E-04 Multiple complex diseases / / 17554300 rs2644473 chr1 232924699 A T 2.10E-05 Urinary metabolites / / 21572414 rs2795467 chr1 232930057 A G 7.38E-04 Multiple complex diseases / / 17554300 rs2795467 chr1 232930057 A G 0.000466 Salmonella-induced pyroptosis / / 22837397 rs2795463 chr1 232932567 G A 2.10E-05 Urinary metabolites / / 21572414 rs1948529 chr1 232933687 G A 2.10E-05 Urinary metabolites / / 21572414 rs12567597 chr1 232941354 G T 2.94E-04 Suicide attempts in bipolar disorder KIAA1383 cds-synon 21423239 rs1874400 chr1 232990563 G A 2.60E-04 Heart Failure / / pha002884 rs2753393 chr1 233005854 A G 8.00E-06 Urinary metabolites / / 21572414 rs12062989 chr1 233011667 T A,C 6.00E-04 Multiple complex diseases / / 17554300 rs9424490 chr1 233021870 C G 3.62E-05 Nicotine smoking / / 19268276 rs7515204 chr1 233024567 T G 4.03E-04 Multiple complex diseases / / 17554300 rs10465473 chr1 233036385 C T 2.95E-04 Cholesterol / / 17255346 rs1073282 chr1 233039521 A G 9.13E-04 Type 2 diabetes / / 17463246 rs9424612 chr1 233040857 T C 1.18E-04 Cholesterol / / 17255346 rs2104042 chr1 233045461 A G 1.17E-04 Cholesterol / / 17255346 rs2104043 chr1 233045499 A G 1.18E-04 Cholesterol / / 17255346 rs714576 chr1 233046240 A G 2.67E-04 Cholesterol / / 17255346 rs714576 chr1 233046240 A G 8.13E-04 Type 2 diabetes / / 17463246 rs2224402 chr1 233052341 A G 3.10E-04 Breast cancer and prostate cancer / / 17903305 rs2224402 chr1 233052341 A G 8.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4141442 chr1 233098875 T C 7.55E-04 Alcohol dependence NTPCR intron 20201924 rs7523847 chr1 233100404 C A 6.14E-04 Alcohol dependence NTPCR intron 20201924 rs41309639 chr1 233122127 C T 0.000027 Breast cancer PCNXL2 missense 23555315 rs11579920 chr1 233163578 C T 5.20E-06 Urinary metabolites PCNXL2 intron 21572414 rs6676202 chr1 233171297 A G 5.90E-06 Urinary metabolites PCNXL2 intron 21572414 rs3820118 chr1 233173456 G A 1.22E-04 Lymphocyte counts PCNXL2 intron 22286170 rs6424271 chr1 233176596 T C 2.70E-05 HIV-1 control PCNXL2 intron 20041166 rs12082991 chr1 233268087 G A 1.46E-04 Sudden cardiac arrest PCNXL2 intron 21658281 rs1016405 chr1 233272372 C T 4.04E-06 Telomere length PCNXL2 intron 23900074 rs1125642 chr1 233279349 G A 3.61E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) PCNXL2 intron 24236485 rs1125642 chr1 233279349 G A 9.76E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) PCNXL2 intron 24236485 rs2477859 chr1 233281297 T C 8.97E-04 Nicotine smoking PCNXL2 intron 19268276 rs12036544 chr1 233312157 C A 3.04E-05 Waist-Hip Ratio PCNXL2 intron pha003013 rs12036544 chr1 233312157 C A 7.61E-05 Waist-Hip Ratio PCNXL2 intron pha003028 rs4649444 chr1 233339211 C A 1.00E-06 Homeostasis model assessment of beta-cell function (interaction) PCNXL2 intron 24204828 rs16858849 chr1 233339427 A G 9.19E-06 Homeostasis model assessment of beta-cell function (interaction) PCNXL2 intron 24204828 rs12027542 chr1 233340154 A G 4.00E-07 Type 2 diabetes PCNXL2 intron 21490949 rs701177 chr1 233357608 T C 8.32E-05 Coronary heart disease PCNXL2 intron pha003055 rs701177 chr1 233357608 T C 2.23E-05 Eosinophil counts PCNXL2 intron pha003088 rs701176 chr1 233362930 G A 4.74E-05 Longevity PCNXL2 intron 22279548 rs701173 chr1 233368289 A G 1.41E-06 Eosinophil counts PCNXL2 intron pha003088 rs10489808 chr1 233397267 G A 5.16E-04 Multiple complex diseases PCNXL2 intron 17554300 rs1033322 chr1 233400424 A G 9.61E-04 Stroke PCNXL2 intron pha002886 rs12135534 chr1 233407177 C A 9.84E-06 Insulin resistance PCNXL2 intron 21901158 rs11583596 chr1 233410047 G A 3.19E-05 Insulin resistance PCNXL2 intron 21901158 rs1294327 chr1 233426676 G T 3.78E-05 Stroke PCNXL2 intron pha002886 rs6667845 chr1 233429825 G A 6.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PCNXL2 intron 20877124 rs1294338 chr1 233438952 G T 5.10E-05 Parkinson's disease (age of onset) / / 19772629 rs1294338 chr1 233438952 G T 3.69E-06 Brain structure / / 22504417 rs7513538 chr1 233475385 T C 7.91E-04 Amyotrophic Lateral Sclerosis KIAA1804 intron 17362836 rs6665230 chr1 233477868 A C 4.35E-04 Amyotrophic Lateral Sclerosis KIAA1804 intron 17362836 rs6665230 chr1 233477868 A C 5.03E-04 Response to taxane treatment (placlitaxel) KIAA1804 intron 23006423 rs7526011 chr1 233479064 T C 7.06E-04 Response to taxane treatment (placlitaxel) KIAA1804 intron 23006423 rs1533777 chr1 233479355 T C 2.26E-04 Response to taxane treatment (placlitaxel) KIAA1804 intron 23006423 rs926007 chr1 233483006 A G 7.32E-04 Obesity (extreme) KIAA1804 intron 21935397 rs6678607 chr1 233483731 G C 7.67E-04 Obesity (extreme) KIAA1804 intron 21935397 rs6703635 chr1 233483754 C G,T 7.77E-04 Obesity (extreme) KIAA1804 intron 21935397 rs10797448 chr1 233484687 C T 8.88E-04 Obesity (extreme) KIAA1804 intron 21935397 rs6424180 chr1 233489308 A T 9.45E-04 Obesity (extreme) KIAA1804 intron 21935397 rs7539016 chr1 233489499 A G 4.27E-04 Parkinson's disease KIAA1804 intron 17052657 rs7539016 chr1 233489499 A G 9.49E-04 Obesity (extreme) KIAA1804 intron 21935397 rs7549137 chr1 233489529 G A 9.50E-04 Obesity (extreme) KIAA1804 intron 21935397 rs10910133 chr1 233489993 G A 9.50E-04 Obesity (extreme) KIAA1804 intron 21935397 rs10797449 chr1 233490138 G A 9.51E-04 Obesity (extreme) KIAA1804 intron 21935397 rs2049183 chr1 233490408 T A 9.53E-04 Obesity (extreme) KIAA1804 intron 21935397 rs1294255 chr1 233501358 G C 1.90E-05 Breast cancer and prostate cancer KIAA1804 intron 17903305 rs4649309 chr1 233522265 T C 6.07E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs10910153 chr1 233530532 G T 7.21E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6673933 chr1 233545582 A G 3.75E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17205291 chr1 233548331 C G 6.86E-05 Cardiovascular disease / / 22029572 rs12119248 chr1 233571079 C T 4.26E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12139945 chr1 233573008 A G 8.60E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4233060 chr1 233624614 G A 2.57E-05 Multiple sclerosis (age of onset) / / 19010793 rs4129547 chr1 233628771 A G 3.56E-04 Alzheimer's disease / / 24755620 rs10797464 chr1 233633797 G T 6.93E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10797465 chr1 233633819 G T 5.82E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10910200 chr1 233643856 G C 6.00E-06 Diabetic retinopathy / / 21441570 rs4649325 chr1 233644713 T C 5.71E-04 Acute lung injury / / 22295056 rs10910204 chr1 233653024 C A 4.01E-04 Multiple complex diseases / / 17554300 rs6693442 chr1 233653780 G C 1.23E-04 Multiple complex diseases / / 17554300 rs780212 chr1 233654847 T C 5.69E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs1497090 chr1 233659290 G A 1.30E-05 Multiple complex diseases / / 17554300 rs780222 chr1 233661003 A G 9.50E-05 HIV-1 viral setpoint / / 22174851 rs2000179 chr1 233663942 C T 5.81E-05 Cognitive test performance / / 20125193 rs12731522 chr1 233679176 A G 5.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1390969 chr1 233690105 T A 5.47E-04 Multiple complex diseases / / 17554300 rs12740439 chr1 233695394 G A 6.77E-04 Multiple complex diseases / / 17554300 rs11800854 chr1 233719984 G A 3.00E-07 Periodontal microbiota / / 22699663 rs11800854 chr1 233719984 G A 4.00E-06 Periodontal microbiota / / 22699663 rs1773950 chr1 233735468 C T 5.22E-05 Creatinine levels / / pha003069 rs12119367 chr1 233738404 A C 9.36E-04 Stroke / / pha002887 rs12071360 chr1 233744579 T C 3.56E-05 Cocaine dependence / / 23958962 rs12071360 chr1 233744579 T C 8.33E-11 Cocaine dependence / / 23958962 rs41495154 chr1 233754237 G A 2.70E-04 Multiple complex diseases KCNK1 intron 17554300 rs701206 chr1 233757721 C T 3.58E-05 Multiple complex diseases KCNK1 intron 17554300 rs701228 chr1 233768990 G C 1.60E-04 Multiple complex diseases KCNK1 intron 17554300 rs6667354 chr1 233784222 T G 7.90E-05 Cognitive impairment induced by topiramate KCNK1 intron 22091778 rs2282428 chr1 233786170 C T 5.75E-05 QT interval KCNK1 intron 16648850 rs12144885 chr1 233788316 T C 1.60E-05 Cognitive impairment induced by topiramate KCNK1 intron 22091778 rs10732966 chr1 233794839 T C 3.64E-04 Suicide attempts in bipolar disorder KCNK1 intron 21423239 rs544750 chr1 233799509 G A 2.07E-04 Suicide attempts in bipolar disorder KCNK1 intron 21423239 rs630938 chr1 233800484 C T 3.28E-04 Suicide attempts in bipolar disorder KCNK1 intron 21423239 rs701234 chr1 233803982 C G 3.69E-04 Suicide attempts in bipolar disorder KCNK1 intron 21423239 rs532657 chr1 233813072 G T 5.09E-04 Multiple complex diseases / / 17554300 rs659340 chr1 233815677 C A 3.85E-04 Multiple complex diseases / / 17554300 rs595191 chr1 233823925 A G 2.50E-04 Asperger disorder / / 21182207 rs595191 chr1 233823925 A G 1.70E-05 Cognitive impairment induced by topiramate / / 22091778 rs651185 chr1 233871030 C T 7.55E-04 Multiple complex diseases / / 17554300 rs680337 chr1 233874633 A G 4.17E-05 Cognitive test performance / / 20125193 rs587531 chr1 233878427 T A 5.67E-04 Multiple complex diseases / / 17554300 rs6676367 chr1 233887113 T C 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6687540 chr1 233893329 G C 1.41E-04 Cognitive decline / / 23732972 rs16859591 chr1 233927721 A G 1.91E-04 Multiple complex diseases / / 17554300 rs16859594 chr1 233927868 T C 6.95E-04 Insulin resistance / / 21901158 rs7539340 chr1 234021539 A G 9.20E-05 Multiple complex diseases / / 17554300 rs10157596 chr1 234023144 T C 7.23E-04 Multiple complex diseases / / 17554300 rs6702789 chr1 234064302 G A 3.17E-04 Type 2 diabetes SLC35F3 intron 17463246 rs6702789 chr1 234064302 G A 1.57E-04 Lymphocyte counts SLC35F3 intron 22286170 rs9435539 chr1 234142548 T C 1.00E-04 Cognitive impairment induced by topiramate SLC35F3 intron 22091778 rs6586363 chr1 234143175 A G 3.00E-04 Cognitive impairment induced by topiramate SLC35F3 intron 22091778 rs9435540 chr1 234143998 G A 3.00E-04 Cognitive impairment induced by topiramate SLC35F3 intron 22091778 rs748910 chr1 234177506 G A 5.26E-04 Aortic root size SLC35F3 intron 21223598 rs9435500 chr1 234198222 G A 9.86E-05 Cognitive impairment induced by topiramate SLC35F3 intron 22091778 rs4281379 chr1 234210250 C G 2.21E-04 White matter integrity SLC35F3 intron 22425255 rs9435557 chr1 234217852 A G 2.17E-04 White matter integrity SLC35F3 intron 22425255 rs12032360 chr1 234218147 A C 2.00E-04 Cognitive impairment induced by topiramate SLC35F3 intron 22091778 rs12032360 chr1 234218147 A C 2.00E-04 Cognitive impairment induced by topiramate SLC35F3 intron 22091778 rs2045518 chr1 234230388 A G 9.20E-04 Alcohol dependence SLC35F3 intron 21314694 rs4484982 chr1 234245611 G C 2.00E-04 Cognitive impairment induced by topiramate SLC35F3 intron 22091778 rs4484982 chr1 234245611 G C 2.00E-04 Cognitive impairment induced by topiramate SLC35F3 intron 22091778 rs4484982 chr1 234245611 G C 2.00E-04 Cognitive impairment induced by topiramate SLC35F3 intron 22091778 rs10797527 chr1 234250281 A G 3.00E-04 Cognitive impairment induced by topiramate SLC35F3 intron 22091778 rs12071173 chr1 234280906 T C 1.41E-04 Multiple complex diseases SLC35F3 intron 17554300 rs12074312 chr1 234285974 G T 1.00E-04 Information processing speed SLC35F3 intron 21130836 rs16842714 chr1 234316313 T C 1.18E-04 Multiple complex diseases SLC35F3 intron 17554300 rs1543468 chr1 234348425 T C 2.50E-05 Kidney function and endocine traits SLC35F3 intron 17903292 rs10910389 chr1 234364285 C A 7.90E-04 Endometriosis SLC35F3 intron 21151130 rs12119646 chr1 234382599 T C 4.25E-05 Left ventricular hypertrophy SLC35F3 intron pha003052 rs12024374 chr1 234384658 G A 4.80E-05 Left ventricular hypertrophy SLC35F3 intron pha003052 rs7552485 chr1 234415806 T C 7.26E-04 Myocardial Infarction SLC35F3 intron pha002873 rs594349 chr1 234427534 A C 3.55E-06 Substance dependence phenotypes SLC35F3 intron 24832863 rs1570105 chr1 234429727 G A 6.23E-05 Blood Pressure SLC35F3 intron pha003049 rs517527 chr1 234431320 T C 4.35E-05 Job-related exhaustion SLC35F3 intron 23620144 rs16842939 chr1 234448530 G T 1.50E-05 Urinary metabolites SLC35F3 intron 21572414 rs1407149 chr1 234452980 G A 1.46E-04 Amyotrophic Lateral Sclerosis SLC35F3 intron 17827064 rs12133361 chr1 234461183 C T 5.04E-04 Depression (quantitative trait) / / 20800221 rs3001707 chr1 234481678 A G 0.0000704 Tuberculosis with early age of onset / / 22551897 rs2991957 chr1 234493015 A G 2.92E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3001702 chr1 234493686 A G 2.92E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6693224 chr1 234503369 G C 2.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs6702834 chr1 234507000 A C 2.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs6698335 chr1 234507382 C T 3.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs4300255 chr1 234510262 A G 3.89E-04 Multiple complex diseases C1orf31 intron 17554300 rs6586385 chr1 234511213 G C 7.46E-04 Alzheimer's disease C1orf31 intron 17998437 rs6586385 chr1 234511213 G C 9.94E-04 Suicide attempts in bipolar disorder C1orf31 intron 21423239 rs6695813 chr1 234515608 A C 3.57E-04 Suicide attempts in bipolar disorder C1orf31 intron 21423239 rs6669190 chr1 234525940 T C 7.56E-04 Alzheimer's disease / / 17998437 rs2175594 chr1 234529552 C T 5.43E-04 Multiple complex diseases TARBP1 cds-synon 17554300 rs2175593 chr1 234529570 G A 8.22E-04 Multiple complex diseases TARBP1 cds-synon 17554300 rs1039993 chr1 234529879 T C 2.44E-04 Suicide attempts in bipolar disorder TARBP1 intron 21423239 rs17576781 chr1 234537924 T C 1.74E-04 Suicide attempts in bipolar disorder TARBP1 intron 21423239 rs12073170 chr1 234541801 A G 8.25E-04 Myopia (pathological) TARBP1 cds-synon 21095009 rs4920180 chr1 234572637 G A 0.000791 Salmonella-induced pyroptosis TARBP1 intron 22837397 rs2273875 chr1 234573357 G C 2.14E-04 Smoking quantity TARBP1 intron 24665060 rs3768286 chr1 234581891 C T 4.05E-04 Response to taxane treatment (placlitaxel) TARBP1 intron 23006423 rs10489896 chr1 234583618 C T 6.00E-06 Cognitive test performance TARBP1 intron 17903297 rs1334814 chr1 234584926 A C 7.60E-04 Response to taxane treatment (placlitaxel) TARBP1 intron 23006423 rs270504 chr1 234601586 G A 5.50E-05 Major depressive disorder TARBP1 intron 21042317 rs544470 chr1 234613050 T C 2.44E-04 Lymphocyte counts TARBP1 intron 22286170 rs12082553 chr1 234613114 T C 6.43E-04 Multiple complex diseases TARBP1 intron 17554300 rs271738 chr1 234662890 G A 5.00E-06 Bipolar disorder / / 22688191 rs271742 chr1 234666319 T C 4.41E-04 Response to taxane treatment (placlitaxel) LOC100506795 intron 23006423 rs79169886 chr1 234691374 T C 0.00004709 Sarcoidosis / / 22952805 rs4362021 chr1 234696177 T A 4.84E-04 Type 2 diabetes / / 17463246 rs9970996 chr1 234701910 G A 0.000654682 Hypertension (early onset hypertension) / / 22479346 rs9970996 chr1 234701910 G A 9.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs138621343 chr1 234703342 G A 0.00004061 Sarcoidosis / / 22952805 rs744487 chr1 234726012 A C 5.00E-06 Coronary heart disease / / 21347282 rs11581667 chr1 234726356 C T 4.00E-06 IgG glycosylation / / 23382691 rs17578989 chr1 234737989 T C 2.23E-05 Esophageal cancer (squamous cell) / / 22960999 rs1329125 chr1 234740880 C T 3.05E-05 Prostate cancer IRF2BP2 UTR-3 22923026 rs7537526 chr1 234767290 A G 7.04E-04 Telomere length LINC00184 intron 23900074 rs9803801 chr1 234769793 C T 5.14E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs12058613 chr1 234782449 A G 6.89E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs673283 chr1 234792524 G A 8.85E-05 Glucose levels / / pha003057 rs482329 chr1 234816554 G C 6.00E-06 Life threatening arrhythmia / / 22247754 rs588965 chr1 234820827 G T 6.61E-04 Bipolar disorder / / 19259986 rs1753579 chr1 234837359 T C 5.44E-05 Glucose levels / / pha003057 rs615086 chr1 234838501 C T 3.89E-05 Serum metabolites / / 19043545 rs7518033 chr1 234856227 A T 6.85E-04 Multiple complex diseases / / 17554300 rs514230 chr1 234858597 A T 5.00E-14 Cholesterol,total / / 20686565 rs514230 chr1 234858597 A T 9.00E-12 LDL cholesterol / / 20686565 rs514230 chr1 234858597 A T 5.00E-14 Cholesterol,total / / 24097068 rs514230 chr1 234858597 A T 9.00E-12 LDL cholesterol / / 24097068 rs7554650 chr1 234874740 C G 1.67E-04 Bone mass and geometry / / 17903296 rs2587531 chr1 234892797 C T 7.91E-04 Type 2 diabetes / / 17463246 rs2587529 chr1 234903271 G T 3.97E-04 Smoking initiation / / 24665060 rs10910502 chr1 234906812 T A 5.36E-04 Smoking initiation / / 24665060 rs2439500 chr1 234906829 C T 4.54E-05 Hodgkin's lymphoma / / 24149102 rs3914503 chr1 234956342 A G 6.23E-05 Alzheimer's disease / / 17998437 rs2796160 chr1 234966277 A C 7.36E-04 Heart Failure / / pha002885 rs2673949 chr1 234976206 A G 2.82E-04 Multiple complex diseases / / 17554300 rs2069084 chr1 234984988 G A 6.00E-06 HIV-1 control / / 20041166 rs2802955 chr1 235015199 C T 3.65E-06 LDL lipoproteins / / pha002902 rs11586083 chr1 235090973 T C 1.90E-04 Alzheimer's disease (late onset) / / 21379329 rs908327 chr1 235092600 A C 5.00E-10 Immune reponse to smallpox (secreted IL-2) / / 22610502 rs2802928 chr1 235094931 A G 4.90E-04 Alcohol dependence / / 20201924 rs10910536 chr1 235097045 C A 1.94E-06 Height / / pha003011 rs6586361 chr1 235119382 G T 3.02E-05 Coronary Artery Disease / / 17634449 rs3924208 chr1 235130526 C T 2.54E-04 Coronary Artery Disease / / 17634449 rs9662936 chr1 235248412 C T 7.77E-05 HIV-1 control / / 20041166 rs11577354 chr1 235267127 G A 7.00E-06 Obesity-related traits / / 23251661 rs7411516 chr1 235272357 C T 1.23E-04 Vaspin levels / / 22907691 rs7411516 chr1 235272357 C T 0.0001228 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs4329572 chr1 235290922 C A 1.00E-04 Alcoholism (heaviness of drinking) TOMM20 intron 21529783 rs12117563 chr1 235384838 G A 1.22E-04 Multiple complex diseases ARID4B intron 17554300 rs13374091 chr1 235582924 T G 8.46E-04 Response to cytadine analogues (cytosine arabinoside) TBCE intron 24483146 rs16832594 chr1 235583589 T C 8.46E-04 Response to cytadine analogues (cytosine arabinoside) TBCE intron 24483146 rs16832599 chr1 235586331 T A 8.46E-04 Response to cytadine analogues (cytosine arabinoside) TBCE intron 24483146 rs6429082 chr1 235600129 T C 3.00E-07 Adiposity TBCE intron 19557161 rs10925824 chr1 235645079 T C 6.23E-06 Carotenoid and tocopherol levels B3GALNT2 intron 19185284 rs10802790 chr1 235701864 G C 5.00E-05 Iris characteristics / / 21835309 rs291353 chr1 235720898 C T 6.00E-06 Aging traits GNG4 intron 17903295 rs2481094 chr1 235732496 C T 2.79E-05 Triglycerides GNG4 intron pha003080 rs6674438 chr1 235738515 T C 1.04E-04 HIV-1 viral setpoint GNG4 intron 17641165 rs2841880 chr1 235738814 T C 2.71E-06 Triglycerides GNG4 intron pha003080 rs2841873 chr1 235743992 T G 1.46E-05 Triglycerides GNG4 intron pha003080 rs2774316 chr1 235754243 G C 3.58E-06 Hirschsprung's disease GNG4 intron 19196962 rs881070 chr1 235756737 C T 5.25E-04 Smoking initiation GNG4 intron 24665060 rs10926189 chr1 235760817 C T 9.95E-05 Chronic obstructive pulmonary disease GNG4 intron 19300482 rs10926189 chr1 235760817 C T 5.20E-05 IgE levels in asthmatics (D.f. specific) GNG4 intron 23967269 rs17547995 chr1 235766162 C T 8.95E-05 Post-operative nausea and vomiting GNG4 intron 21694509 rs6429207 chr1 235798334 A C 2.39E-04 Birth weight GNG4 intron 17255346 rs6429207 chr1 235798334 A C 3.03E-05 Cytomegalovirus antibody response GNG4 intron 21993531 rs1891978 chr1 235809170 G A 2.75E-04 Alzheimer's disease GNG4 intron 17998437 rs1891978 chr1 235809170 G A 8.70E-07 Urinary metabolites GNG4 intron 21572414 rs11810173 chr1 235832555 C T 9.37E-05 Body Composition LYST intron pha003012 rs13373917 chr1 235838759 C T 2.16E-04 Multiple complex diseases LYST intron 17554300 rs7517694 chr1 235840294 G A 2.69E-04 Multiple complex diseases LYST intron 17554300 rs16848869 chr1 235890146 T C 4.70E-04 Multiple complex diseases LYST intron 17554300 rs1078859 chr1 235912025 C A 0.000114217 Hypertension (early onset hypertension) LYST intron 22479346 rs12089846 chr1 235959705 A C 7.83E-04 Heart Failure LYST intron pha002885 rs2385029 chr1 236044714 G A 1.40E-05 Urinary metabolites / / 21572414 rs6683202 chr1 236051938 G A 2.70E-07 Urinary metabolites / / 21572414 rs6659936 chr1 236055605 A C 9.66E-04 Multiple complex diseases / / 17554300 rs6657655 chr1 236055833 C T 8.83E-04 Longevity / / 22279548 rs6665519 chr1 236066472 T G 7.03E-04 Alzheimer's disease / / 17998437 rs4660126 chr1 236077778 A G 4.77E-04 HIV-1 viral setpoint / / 17641165 rs17616115 chr1 236118351 A G 7.91E-06 Height / / pha003010 rs17616115 chr1 236118351 A G 3.20E-05 Height / / pha003011 rs17616115 chr1 236118351 A G 2.33E-06 Lung function (forced expiratory volume in 1 second) / / pha003102 rs17616115 chr1 236118351 A G 5.23E-06 Lung function (forced vital capacity) / / pha003104 rs4659618 chr1 236150459 A G 8.70E-05 Diabetic retinopathy NID1 intron 21441570 rs3754237 chr1 236177182 A G 4.44E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) NID1 intron 24023788 rs3768080 chr1 236179869 A G 7.00E-08 Cutaneous nevi NID1 intron 21478494 rs17552351 chr1 236181854 T C 4.06E-05 Cytomegalovirus antibody response NID1 intron 21993531 rs12411075 chr1 236182924 C T 0.0008027 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NID1 intron 23233654 rs12411075 chr1 236182924 C T 8.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) NID1 intron 23233662 rs10754833 chr1 236184931 T C 4.33E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) NID1 intron 24023788 rs12024223 chr1 236185054 A G 1.45E-04 Multiple complex diseases NID1 intron 17554300 rs12401457 chr1 236186697 G A 0.0007991 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NID1 intron 23233654 rs12401457 chr1 236186697 G A 7.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) NID1 intron 23233662 rs3738533 chr1 236187365 T C 0.0007969 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NID1 intron 23233654 rs3738533 chr1 236187365 T C 7.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) NID1 intron 23233662 rs746997 chr1 236195181 A G 9.69E-04 Type 2 diabetes NID1 intron 17463246 rs1570828 chr1 236206080 A G 3.42E-05 Bipolar disorder and schizophrenia NID1 intron 20889312 rs10803248 chr1 236206443 T C 3.00E-05 Bipolar disorder and schizophrenia NID1 intron 20889312 rs10803248 chr1 236206443 T C 8.98E-04 Telomere length NID1 intron 23900074 rs6702978 chr1 236224569 A G 7.41E-05 Bipolar disorder and schizophrenia NID1 intron 20889312 rs12093542 chr1 236229347 C A 2.74E-06 Multiple complex diseases / / 17554300 rs12093542 chr1 236229347 C A 6.42E-04 Aortic root size / / 21223598 rs10754850 chr1 236234626 C A 1.70E-05 Bipolar disorder and schizophrenia / / 20889312 rs6682352 chr1 236272711 C T 4.16E-05 Cognitive performance / / 19734545 rs6688981 chr1 236295833 A G 9.03E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6689258 chr1 236296079 A G 3.40E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10802285 chr1 236311886 T C 5.58E-05 Alzheimer's disease (late onset) GPR137B intron 21379329 rs7520258 chr1 236313127 T C 5.00E-07 Response to antipsychotic treatment in schizophrenia (working memory) GPR137B intron 21107309 rs10924380 chr1 236315070 G A 1.10E-04 Intelligence (childhood) GPR137B intron 23358156 rs2094045 chr1 236328010 T G 9.67E-06 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) GPR137B intron 24023788 rs7537965 chr1 236329513 T C 2.68E-04 Rheumatoid arthritis GPR137B intron 21452313 rs7537965 chr1 236329513 T C 8.11E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) GPR137B intron 24023788 rs6702348 chr1 236335567 A G 2.99E-05 Rheumatoid arthritis GPR137B intron 21452313 rs4659635 chr1 236338226 G A 5.70E-05 Erythrocyte counts GPR137B intron pha003090 rs2385203 chr1 236346213 C T 8.29E-04 Type 2 diabetes GPR137B intron 17463246 rs188136623 chr1 236389655 C A 0.000029 Prostate cancer (advanced) ERO1LB missense 23555315 rs1405630 chr1 236420117 G T 2.21E-04 Lung function (forced expiratory volume in 1 second) ERO1LB intron 24023788 rs6662005 chr1 236439916 G A 1.26E-05 Pancreatic cancer ERO1LB intron 23180869 rs11587363 chr1 236444658 T C 2.53E-05 Major depressive disorder ERO1LB intron 22472876 rs16833556 chr1 236450108 C T 6.70E-04 Multiple complex diseases / / 17554300 rs10924993 chr1 236459785 T G 7.00E-07 Asthma (childhood onset) / / 17611496 rs34210603 chr1 236474797 T TC 5.98E-04 Stroke / / pha002887 rs7554436 chr1 236474797 T C 5.98E-04 Stroke / / pha002887 rs12040004 chr1 236494471 G A 0.000314083 Hypertension (early onset hypertension) / / 22479346 rs12404278 chr1 236510995 C T 0.0007395 Hypertension (early onset hypertension) / / 22479346 rs10925109 chr1 236521008 C T 0.000668143 Hypertension (early onset hypertension) / / 22479346 rs12027455 chr1 236534653 A G 0.000240634 Hypertension (early onset hypertension) / / 22479346 rs6673040 chr1 236545893 T G 7.89E-06 Major depressive disorder / / 22472876 rs4659657 chr1 236546142 G A 6.09E-06 Major depressive disorder / / 22472876 rs1025977 chr1 236547422 T G 8.00E-06 Major depressive disorder / / 22472876 rs4659660 chr1 236552530 A G 6.42E-06 Major depressive disorder / / 22472876 rs4659664 chr1 236555310 A T 2.39E-05 Major depressive disorder / / 22472876 rs10802533 chr1 236557412 T G 1.02E-05 Major depressive disorder EDARADD nearGene-5 22472876 rs966365 chr1 236557771 G A 7.80E-06 Major depressive disorder EDARADD missense 22472876 rs966364 chr1 236557928 G A 9.55E-06 Major depressive disorder EDARADD intron 22472876 rs608825 chr1 236568770 C T 5.50E-04 Volumetric brain MRI EDARADD intron 17903297 rs648236 chr1 236605833 G C 4.77E-04 Multiple complex diseases EDARADD intron 17554300 rs646040 chr1 236606292 A G 2.39E-04 Multiple complex diseases EDARADD intron 17554300 rs17582358 chr1 236616134 G A 2.60E-04 Acute lung injury EDARADD intron 22295056 rs4659456 chr1 236657887 C G 1.60E-04 Type 2 diabetes / / 17463246 rs6689881 chr1 236672004 T C 2.49E-04 Myocardial Infarction / / pha002883 rs16833729 chr1 236673695 A G 3.77E-04 Multiple complex diseases / / 17554300 rs10925154 chr1 236676682 C T 8.94E-05 Multiple complex diseases / / 17554300 rs1266379 chr1 236681719 T C 0.000124 Salmonella-induced pyroptosis LGALS8 intron 22837397 rs4659682 chr1 236682248 A G 0.00000103 Attention deficit-hyperactivity disorder (ADHD) DSM-IV scale,preschool edition LGALS8 intron 23049896 rs819415 chr1 236694490 C T 4.10E-04 Multiple complex diseases LGALS8 intron 17554300 rs1891241 chr1 236698470 G A 0.000245 Salmonella-induced pyroptosis LGALS8 intron 22837397 rs1041934 chr1 236700823 T C 0.000296 Salmonella-induced pyroptosis LGALS8 cds-synon 22837397 rs2737706 chr1 236700982 T C 0.000315 Salmonella-induced pyroptosis LGALS8 intron 22837397 rs16833819 chr1 236701492 T C 0.000297 Salmonella-induced pyroptosis LGALS8 intron 22837397 rs16833820 chr1 236701525 C T 0.000282 Salmonella-induced pyroptosis LGALS8 intron 22837397 rs2472126 chr1 236702374 G A,C 0.000506 Salmonella-induced pyroptosis LGALS8 cds-synon 22837397 rs2758994 chr1 236703767 C T 0.000142 Salmonella-induced pyroptosis LGALS8 intron 22837397 rs2799410 chr1 236707007 C T 0.000191 Salmonella-induced pyroptosis LGALS8 intron 22837397 rs1124907 chr1 236707816 C T 0.000205 Salmonella-induced pyroptosis LGALS8 intron 22837397 rs2243963 chr1 236708940 T C 0.000257 Salmonella-induced pyroptosis LGALS8 intron 22837397 rs15701 chr1 236711323 T C 0.000221 Salmonella-induced pyroptosis LGALS8 cds-synon 22837397 rs1160 chr1 236711586 G A 0.0002 Salmonella-induced pyroptosis LGALS8 UTR-3 22837397 rs1041940 chr1 236711882 G T 0.000233 Salmonella-induced pyroptosis LGALS8 UTR-3 22837397 rs1041944 chr1 236711981 C T 0.000214 Salmonella-induced pyroptosis LGALS8 UTR-3 22837397 rs2758998 chr1 236713828 G A 0.000341 Salmonella-induced pyroptosis LGALS8 UTR-3 22837397 rs6989 chr1 236714064 A C 0.000275 Salmonella-induced pyroptosis LGALS8 UTR-3 22837397 rs2254487 chr1 236714335 C T 0.00013 Salmonella-induced pyroptosis LGALS8 UTR-3 22837397 rs2540 chr1 236714916 T C 0.000451 Salmonella-induced pyroptosis LGALS8 UTR-3 22837397 rs2275685 chr1 236716959 C T 0.000182 Salmonella-induced pyroptosis HEATR1 cds-synon 22837397 rs2275687 chr1 236717926 T C 0.000128 Salmonella-induced pyroptosis HEATR1 missense 22837397 rs6668926 chr1 236718561 G A 0.000131 Salmonella-induced pyroptosis HEATR1 intron 22837397 rs1126627 chr1 236718620 T C 0.000166 Salmonella-induced pyroptosis HEATR1 missense 22837397 rs2759005 chr1 236720833 C T 0.000136 Salmonella-induced pyroptosis HEATR1 intron 22837397 rs6661946 chr1 236723108 C T 4.11E-06 Nicotine smoking HEATR1 missense 19268276 rs10754577 chr1 236723178 C A 0.000217 Salmonella-induced pyroptosis HEATR1 intron 22837397 rs1407519 chr1 236724974 A C 5.98E-04 Suicide attempts in bipolar disorder HEATR1 intron 21423239 rs1358959 chr1 236725048 A G 6.50E-04 Suicide attempts in bipolar disorder HEATR1 intron 21423239 rs7544230 chr1 236729834 G A 3.95E-04 Suicide attempts in bipolar disorder HEATR1 intron 21423239 rs2799430 chr1 236732054 A G 6.24E-04 Multiple complex diseases HEATR1 intron 17554300 rs2799428 chr1 236736564 T A 0.000735 Salmonella-induced pyroptosis HEATR1 intron 22837397 rs2853599 chr1 236736751 T A 0.000676 Salmonella-induced pyroptosis HEATR1 intron 22837397 rs16833940 chr1 236736997 A G 1.84E-04 Suicide attempts in bipolar disorder HEATR1 intron 21423239 rs10495379 chr1 236737396 T C 8.72E-04 Suicide attempts in bipolar disorder HEATR1 intron 21423239 rs16833958 chr1 236742166 A G 8.77E-04 Suicide attempts in bipolar disorder HEATR1 intron 21423239 rs3738541 chr1 236749626 C T 7.74E-04 Endometrial cancer HEATR1 cds-synon 24096698 rs2794753 chr1 236757507 A G 0.0000807 Salmonella-induced pyroptosis HEATR1 intron 22837397 rs965399 chr1 236768404 A G 0.00000749 LDL cholesterol particle diameter / / 23263444 rs10925170 chr1 236775649 G T 0.00000402 HDL cholesterol particle diameter / / 23263444 rs1743998 chr1 236794970 A G 6.53E-04 Multiple complex diseases / / 17554300 rs577193 chr1 236802016 C G 8.91E-05 Multiple complex diseases / / 17554300 rs1998352 chr1 236803020 T C 2.00E-04 Information processing speed / / 21130836 rs10925178 chr1 236803753 G A 3.83E-05 Dental caries / / 21940522 rs10925185 chr1 236817010 T C 1.89E-05 Dental caries / / 21940522 rs568851 chr1 236817124 A G 9.20E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs475488 chr1 236821847 G A 1.60E-04 Nicotine dependence / / 17407593 rs3905125 chr1 236864459 C T 1.52E-04 Multiple complex diseases ACTN2 intron 17554300 rs1366990 chr1 236881703 T A,C,G 7.27E-04 Body mass index ACTN2 intron 21701565 rs819639 chr1 236893599 G A 2.20E-04 Type 2 diabetes ACTN2 intron 17846124 rs7542508 chr1 236900018 G A 7.89E-04 Multiple complex diseases ACTN2 intron 17554300 rs4659711 chr1 236902364 C T 5.40E-04 Multiple complex diseases ACTN2 intron 17554300 rs12048046 chr1 236912057 T C 3.00E-06 Periodontitis (CDC/AAP) ACTN2 intron 24024966 rs2297956 chr1 236912286 G A 4.99E-05 Autism ACTN2 intron 19812673 rs2297955 chr1 236912597 A G 3.42E-06 Periodontitis (CDC/AAP) ACTN2 intron 24024966 rs4659713 chr1 236915207 G A 0.000307601 Hypertension (early onset hypertension) ACTN2 intron 22479346 rs10737811 chr1 236916352 G A 0.000307601 Hypertension (early onset hypertension) ACTN2 intron 22479346 rs6687802 chr1 236938367 A G 2.83E-05 Post-operative nausea and vomiting / / 21694509 rs7526063 chr1 236971998 C T 4.42E-06 Alcohol and nictotine co-dependence MTR intron 20158304 rs4659727 chr1 237006914 A G 5.20E-05 Response to lithium treatment in bipolar disorder MTR intron 19448189 rs1805087 chr1 237048500 A G 1 Drug response to Ethanol MTR missense 10498402 rs1805087 chr1 237048500 A G 1.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) MTR missense 21239504 rs2275565 chr1 237048676 G T 2.00E-10 Homocysteine levels MTR intron 23824729 rs10158822 chr1 237050176 T G 6.30E-05 Response to lithium treatment in bipolar disorder MTR intron 19448189 rs11806016 chr1 237069315 C T 3.87E-06 Dental caries / / 21940522 rs12068674 chr1 237077363 T C 6.70E-06 Personality dimensions / / 21173776 rs4006371 chr1 237077657 C T 6.70E-06 Personality dimensions / / 21173776 rs4006372 chr1 237077815 C T 6.60E-06 Personality dimensions / / 21173776 rs16834552 chr1 237079692 C T 6.60E-06 Personality dimensions / / 21173776 rs7548398 chr1 237081002 A G 4.90E-06 Personality dimensions / / 21173776 rs6701337 chr1 237081727 T C 2.10E-06 Personality dimensions / / 21173776 rs6698815 chr1 237081792 A G 6.80E-06 Personality dimensions / / 21173776 rs6686536 chr1 237081844 C T 6.90E-06 Personality dimensions / / 21173776 rs6661736 chr1 237082203 G C 7.00E-06 Personality dimensions / / 21173776 rs10495388 chr1 237093109 A C,G,T 8.00E-06 Personality dimensions / / 21173776 rs7411668 chr1 237093697 C T 5.70E-06 Personality dimensions / / 21173776 rs736759 chr1 237093840 G A 5.80E-06 Personality dimensions / / 21173776 rs7545717 chr1 237110626 A G 2.58E-04 Telomere length / / 23900074 rs16834612 chr1 237114288 T G 1.28E-04 Telomere length / / 23900074 rs1252112 chr1 237114552 T C 1.00E-04 Multiple complex diseases / / 17554300 rs1252114 chr1 237116376 T A 6.88E-04 Multiple complex diseases / / 17554300 rs1252131 chr1 237132873 G A 1.10E-04 Multiple complex diseases / / 17554300 rs1252138 chr1 237140960 T G 2.86E-05 Nonalcoholic fatty liver disease / / 21423719 rs1252171 chr1 237144513 T G 9.20E-06 Urinary metabolites / / 21572414 rs16848861 chr1 237144914 A G 4.73E-06 Blood pressure / / 21378095 rs575297527 chr1 237144914 A ACGCGCCG 4.73E-06 Blood pressure / / 21378095 rs4659485 chr1 237145918 T C 1.90E-05 Type 2 diabetes / / 22238593 rs1625040 chr1 237146379 A G 2.60E-05 Longevity (90 years and older) / / 24688116 rs1625040 chr1 237146379 A G 3.50E-04 Longevity (85 years and older) / / 24688116 rs1252145 chr1 237153919 A G 2.85E-05 Orofacial clefts / / 22419666 rs12047281 chr1 237161467 C T 2.20E-04 Scoliosis / / 21216876 rs1252160 chr1 237165077 A G 7.01E-04 HIV-1 viral setpoint / / 17641165 rs12410379 chr1 237166773 C T 5.26E-04 Alzheimer's disease / / 22005930 rs12724972 chr1 237177572 T C 7.90E-04 Myocardial Infarction / / pha002883 rs12239401 chr1 237194523 C T 5.24E-05 Weight / / pha003026 rs41445947 chr1 237194728 G T 2.28E-04 Alzheimer's disease / / 17998437 rs10802580 chr1 237194922 A G 2.87E-05 Alzheimer's disease / / 17998437 rs10802581 chr1 237198593 G A 5.33E-04 Alzheimer's disease / / 17998437 rs11583513 chr1 237199183 C T 5.35E-04 Heart Failure / / pha002885 rs2385576 chr1 237199775 T G 2.31E-05 Weight / / pha003026 rs1881548 chr1 237207189 A G 5.81E-05 Body Mass Index RYR2 intron pha003006 rs1881548 chr1 237207189 A G 4.24E-05 Waist Circumference RYR2 intron pha003024 rs6678625 chr1 237210003 C T 9.37E-04 Multiple complex diseases RYR2 intron 17554300 rs10925299 chr1 237213764 C T 6.45E-04 Suicide attempts in bipolar disorder RYR2 intron 21423239 rs4659488 chr1 237215263 T C 0.0000478 Panic disorder RYR2 intron 23149450 rs4659488 chr1 237215263 T C 4.78E-05 Serum tamsulosin hydrochloride concentration RYR2 intron 23151678 rs4659488 chr1 237215263 T C 0.00024 Coronary artery calcification RYR2 intron 23727086 rs1124814 chr1 237216056 A G 0.0000436 Panic disorder RYR2 intron 23149450 rs1124814 chr1 237216056 A G 4.36E-05 Serum tamsulosin hydrochloride concentration RYR2 intron 23151678 rs9428374 chr1 237248102 C A 2.90E-06 Urinary metabolites RYR2 intron 21572414 rs10802587 chr1 237248454 G A 1.46E-04 Multiple complex diseases RYR2 intron 17554300 rs6428989 chr1 237248703 A G 7.70E-06 Urinary metabolites RYR2 intron 21572414 rs10925310 chr1 237251005 T C 2.03E-05 Glycosylated haemoglobin levels RYR2 intron 17255346 rs12131634 chr1 237257824 C T 1.62E-04 Lung function (forced vital capacity) RYR2 intron 24023788 rs16834810 chr1 237258799 G A 1.38E-04 Schizophrenia(age at onset) RYR2 intron 21688384 rs16834810 chr1 237258799 G A 3.30E-06 Stroke (ischemic) RYR2 intron 22384361 rs7551249 chr1 237261761 G A 4.76E-04 Hemoglobin concentration RYR2 intron 20534544 rs6701985 chr1 237266311 A G 8.21E-04 Multiple complex diseases RYR2 intron 17554300 rs7554607 chr1 237266603 A G 2.00E-06 Acute lymphoblastic leukemia (childhood) RYR2 intron 19684603 rs7554607 chr1 237266603 A G 2.00E-06 Nasopharyngeal carcinoma RYR2 intron 20512145 rs16834822 chr1 237267334 G T 2.10E-06 Schizophrenia(age at onset) RYR2 intron 21688384 rs16834824 chr1 237267370 C T 2.33E-06 Schizophrenia(age at onset) RYR2 intron 21688384 rs1980798 chr1 237272139 T G 4.66E-06 Glycemic traits (pregnancy) RYR2 intron 23903356 rs2485558 chr1 237278525 G C 1.53E-05 Psoriasis RYR2 intron 20953188 rs41454545 chr1 237282751 C G 2.12E-04 Multiple complex diseases RYR2 intron 17554300 rs2485570 chr1 237285607 G T 2.08E-26 Narcolepsy RYR2 intron 19629137 rs10754593 chr1 237326348 G C 3.00E-04 Asthma (childhood onset) RYR2 intron 21359210 rs1106159 chr1 237348427 A G 5.21E-06 Obesity-related traits RYR2 intron 23251661 rs6668069 chr1 237349657 C T 4.76E-06 Obesity-related traits RYR2 intron 23251661 rs6683225 chr1 237349738 T C 2.00E-06 Obesity-related traits RYR2 intron 23251661 rs268786 chr1 237355985 C A 8.00E-06 Obesity-related traits RYR2 intron 23251661 rs187910 chr1 237359988 A G 3.10E-06 Obesity-related traits RYR2 intron 23251661 rs6683160 chr1 237390732 A C 3.31E-05 IgE levels in asthmatics RYR2 intron 23967269 rs679735 chr1 237405093 T C 4.24E-05 Serum metabolites RYR2 intron 19043545 rs918241 chr1 237420086 C A 4.52E-05 Leukocyte Counts RYR2 intron pha003091 rs10495392 chr1 237422989 C T 4.33E-05 Alcohol and nictotine co-dependence RYR2 intron 20158304 rs4659491 chr1 237433239 T C 5.78E-06 Leukocyte Counts RYR2 intron pha003091 rs11802494 chr1 237460954 T C 4.11E-05 Cognitive test performance RYR2 intron 20125193 rs12066348 chr1 237462804 G A 6.11E-07 Lipid levels RYR2 intron 19913121 rs7514372 chr1 237478709 A G 9.41E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs6670163 chr1 237536584 T G 2.00E-05 Type 2 diabetes RYR2 intron 17293876 rs17682073 chr1 237547223 A G 0.000069 Coronary artery calcification RYR2 intron 23727086 rs10925402 chr1 237559453 G A 1.02E-04 Body mass index RYR2 intron 17255346 rs10925405 chr1 237561361 C T 1.20E-05 Response to antidepressants RYR2 intron 19736353 rs7537614 chr1 237597309 A G 2.70E-05 Urinary metabolites RYR2 intron 21572414 rs7529251 chr1 237598416 C T 3.00E-07 IgG glycosylation RYR2 intron 23382691 rs17633019 chr1 237599023 G A 3.30E-04 Atrial fibrillation RYR2 intron 21846873 rs12087410 chr1 237605491 C G 7.80E-05 Malaria RYR2 intron 19465909 rs2100969 chr1 237613274 A G 1.35E-05 Serum metabolites RYR2 intron 19043545 rs2100969 chr1 237613274 A G 5.08E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs2086209 chr1 237613571 C T 5.85E-05 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs16835265 chr1 237617365 G A,T 0.00000062 Cholesterol,total RYR2 intron 23063622 rs4258212 chr1 237617399 A C 1.35E-05 Serum metabolites RYR2 intron 19043545 rs4258212 chr1 237617399 A C 5.59E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs3765097 chr1 237617757 C T 4.99E-04 Response to taxane treatment (placlitaxel) RYR2 cds-synon 23006423 rs2045955 chr1 237620049 T C 1.67E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs11588591 chr1 237620954 G A 1.23E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs1478912 chr1 237621239 T C 6.00E-06 Response to taxane treatment (docetaxel) RYR2 intron 23006423 rs3753617 chr1 237624783 A C 4.13E-05 HDL particle features RYR2 intron pha002900 rs4436381 chr1 237635103 A C 5.76E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs4329502 chr1 237635303 C A 8.67E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs4397648 chr1 237635321 T C 8.67E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs4625270 chr1 237635416 T C 8.67E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs4329503 chr1 237635564 C T 8.57E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs16835307 chr1 237648143 C T 2.24E-05 Multiple complex diseases RYR2 intron 17554300 rs16835307 chr1 237648143 C T 2.12E-04 Blood pressure (response to angiotensin II receptor blocker) RYR2 intron 24192120 rs2805429 chr1 237684278 C G 4.10E-05 Personality dimensions RYR2 intron 18957941 rs2805434 chr1 237686126 A G 3.50E-05 Personality dimensions RYR2 intron 18957941 rs2805446 chr1 237693190 T C 2.50E-05 Orofacial clefts RYR2 intron 22419666 rs2805446 chr1 237693190 T C 1.60E-04 Intelligence (childhood) RYR2 intron 23358156 rs10925451 chr1 237702709 A G 2.90E-05 Electrocardiographic conduction measures RYR2 intron 19389651 rs2257101 chr1 237703314 T G 4.20E-04 Insulin resistance RYR2 intron 21901158 rs2257096 chr1 237703401 A G 8.05E-04 Suicide attempts in bipolar disorder RYR2 intron 21423239 rs2257096 chr1 237703401 A G 6.61E-04 Insulin resistance RYR2 intron 21901158 rs2618672 chr1 237704539 C T 2.12E-04 Multiple complex diseases RYR2 intron 17554300 rs2779383 chr1 237713081 A G 2.00E-05 Prostate cancer RYR2 intron 21743057 rs3766851 chr1 237713312 T A 7.32E-06 Sleep duration RYR2 intron 22105623 rs2127148 chr1 237723828 T G 9.63E-04 Multiple complex diseases RYR2 intron 17554300 rs2805396 chr1 237732395 G A 1.67E-05 Sleep duration RYR2 intron 22105623 rs6683048 chr1 237788786 G A 3.90E-11 Autism,gender differences RYR2 intron 21151189 rs7531957 chr1 237789656 T G 0.0000642 Gains in maximal O2 uptake response RYR2 intron 21183627 rs939698 chr1 237790680 G A 3.60E-04 Cardiovascular disease RYR2 intron 17903304 rs476078 chr1 237796092 T C 5.59E-05 Major depressive disorder (broad) RYR2 intron 20038947 rs10802626 chr1 237796837 G A 9.07E-05 Non-alcoholic fatty liver disease histology (other) RYR2 intron 20708005 rs10925480 chr1 237797757 A G 9.18E-05 Major depressive disorder (broad) RYR2 intron 20038947 rs7526807 chr1 237797973 C T 8.42E-05 Major depressive disorder (broad) RYR2 intron 20038947 rs7538471 chr1 237797997 A G 3.21E-05 Major depressive disorder (broad) RYR2 intron 20038947 rs1023214 chr1 237802065 A G 1.25E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) RYR2 intron 24023788 rs10495399 chr1 237812083 T G 4.39E-15 LDL cholesterol RYR2 intron 23063622 rs16835603 chr1 237818049 A G 0.00000177 Cholesterol,total RYR2 intron 23063622 rs3766882 chr1 237819869 G A 1.51E-04 Multiple complex diseases RYR2 intron 17554300 rs1571980 chr1 237827504 T C 4.35E-19 LDL cholesterol RYR2 intron 23063622 rs6657332 chr1 237830895 G T 6.92E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer RYR2 intron 21483023 rs876793 chr1 237852083 T C 3.00E-07 Lipid traits RYR2 intron 24386095 rs12040571 chr1 237869704 C A 4.80E-05 Iron levels RYR2 intron 21208937 rs10925500 chr1 237892645 C A 1.42E-04 Alzheimer's disease RYR2 intron 17998437 rs10925500 chr1 237892645 C A 2.58E-05 Alzheimer's disease RYR2 intron pha002879 rs16835702 chr1 237908488 A G 2.70E-06 Lipid traits RYR2 intron 24386095 rs16835705 chr1 237908911 G A 4.20E-06 Lipid traits RYR2 intron 24386095 rs2685289 chr1 237909539 C T 0.000001 Triglycerides RYR2 intron 23063622 rs2819770 chr1 237911004 C T 4.00E-06 Exercise treadmill test traits RYR2 intron 17903301 rs2056387 chr1 237924112 C A 5.17E-06 ECG dimensions,brachial artery endothelial function,treadmill exercise responses RYR2 intron 17903301 rs2056387 chr1 237924112 C A 1.10E-04 Breast cancer and prostate cancer RYR2 intron 17903305 rs2249287 chr1 237937874 C T 1.46E-04 Response to taxane treatment (placlitaxel) RYR2 intron 23006423 rs12737847 chr1 237945870 T C 4.39E-04 Alcohol dependence RYR2 intron 20201924 rs2275690 chr1 237949456 T C 6.92E-05 Blood Pressure RYR2 intron pha003039 rs12043362 chr1 237960958 G A 1.20E-04 Gallstones RYR2 intron 17632509 rs2819742 chr1 237990122 A G 2.00E-07 Response to cerivastatin RYR2 intron 21386754 rs2275692 chr1 237993724 C T 1.20E-05 Urinary metabolites RYR2 intron 21572414 rs16835894 chr1 237996594 C T 6.56E-04 Glycemic traits (pregnancy) RYR2 UTR-3 23903356 rs1316429 chr1 238001895 G C 1.19E-04 Diabetic nephropathy / / 21150874 rs1316429 chr1 238001895 G C 2.75E-04 Type 2 diabetes / / 22238593 rs1539208 chr1 238012770 C T 2.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs16835926 chr1 238013174 A G 3.69E-04 Multiple complex diseases / / 17554300 rs7525233 chr1 238013507 T A 8.24E-04 Multiple complex diseases / / 17554300 rs2819751 chr1 238015523 C A 2.52E-04 Alzheimer's disease / / 24755620 rs6680230 chr1 238015805 T C 5.81E-04 Multiple complex diseases / / 17554300 rs547984 chr1 238096886 A C 6.00E-05 Glaucoma (primary open-angle) / / 19625618 rs540782 chr1 238097039 C G 6.00E-05 Glaucoma (primary open-angle) / / 19625618 rs693421 chr1 238099090 T G 4.00E-05 Glaucoma (primary open-angle) / / 19625618 rs2499604 chr1 238103501 C T 2.00E-06 Non-alcoholic fatty liver disease histology (AST) / / 20708005 rs2499601 chr1 238104895 C T 9.00E-05 Glaucoma (primary open-angle) / / 19625618 rs9428707 chr1 238215702 A C 6.69E-04 Acute lung injury / / 22295056 rs16836337 chr1 238264117 C T 7.17E-04 Aortic root size / / 21223598 rs16836338 chr1 238264227 A G 7.58E-04 Aortic root size / / 21223598 rs12078672 chr1 238274904 T C 2.51E-06 Sickle cell anemia (severity) / / 20029952 rs16836366 chr1 238281405 C T 8.61E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16836376 chr1 238285307 T C 2.10E-05 Urinary metabolites / / 21572414 rs1338924 chr1 238295979 C T 6.53E-04 Acute lung injury / / 22295056 rs10925572 chr1 238297453 G A 8.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs16836417 chr1 238299841 C A 3.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs11799391 chr1 238300172 A C 8.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs10925573 chr1 238300214 T G 2.09E-05 Response to citalopram treatment / / 19846067 rs10925573 chr1 238300214 T G 7.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs16836421 chr1 238300737 A G 8.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs1338926 chr1 238305858 A G 4.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs1572706 chr1 238307309 A C 7.18E-04 Acute lung injury / / 22295056 rs1416386 chr1 238307856 A G 9.26E-04 Acute lung injury / / 22295056 rs1416385 chr1 238307907 C T 8.69E-04 Acute lung injury / / 22295056 rs1361277 chr1 238308602 C T 6.82E-04 Acute lung injury / / 22295056 rs1361277 chr1 238308602 C T 2.00E-08 White matter microstructure (global fractional anisotropy) / / 24736177 rs1933980 chr1 238310901 A G 4.05E-04 Acute lung injury / / 22295056 rs2392788 chr1 238311490 T A 3.49E-04 Acute lung injury / / 22295056 rs7547681 chr1 238311680 G A 4.16E-04 Acute lung injury / / 22295056 rs10925576 chr1 238312176 T C 3.52E-04 Acute lung injury / / 22295056 rs1338927 chr1 238317672 G A 3.34E-04 Acute lung injury / / 22295056 rs7555833 chr1 238322892 A G 3.93E-04 Acute lung injury / / 22295056 rs6668206 chr1 238326067 T G 4.11E-04 Acute lung injury / / 22295056 rs11582096 chr1 238326284 A G 3.93E-04 Acute lung injury / / 22295056 rs4659514 chr1 238329027 A C 4.33E-04 Acute lung injury / / 22295056 rs6429059 chr1 238331873 G T 1.03E-04 Acute lung injury / / 22295056 rs7542442 chr1 238334913 G C 5.96E-04 Acute lung injury / / 22295056 rs2392790 chr1 238336236 G C 6.32E-04 Acute lung injury / / 22295056 rs1572703 chr1 238339110 A G 2.80E-06 Digit length ratio / / 20303062 rs7533568 chr1 238339776 T C 8.20E-04 Acute lung injury / / 22295056 rs1338922 chr1 238346577 C T 5.31E-04 Acute lung injury / / 22295056 rs4998092 chr1 238353122 T C 6.57E-04 Acute lung injury / / 22295056 rs1287293 chr1 238367608 A G 5.42E-04 Multiple complex diseases / / 17554300 rs1976011 chr1 238369006 T C 1.39E-04 Progressive supranuclear palsy / / 21685912 rs551741 chr1 238374449 A G 5.53E-04 Acute lung injury / / 22295056 rs10495406 chr1 238380730 G A 5.70E-04 Acute lung injury / / 22295056 rs1481139 chr1 238382824 A T 7.90E-04 Acute lung injury / / 22295056 rs12757674 chr1 238383960 G A 6.84E-04 Acute lung injury / / 22295056 rs10925593 chr1 238386808 T A 6.58E-04 Acute lung injury / / 22295056 rs970522 chr1 238424735 T C 6.62E-05 Post-operative nausea and vomiting / / 21694509 rs6672666 chr1 238432884 T C 5.14E-05 Post-operative nausea and vomiting / / 21694509 rs10495407 chr1 238439308 G A 2.10E-04 Statin-induced myopathy / / 21826682 rs12094201 chr1 238442713 A G 6.22E-04 Major depressive disorder / / 22472876 rs16836693 chr1 238474019 A C 6.00E-07 Urinary metabolites / / 21572414 rs16836698 chr1 238474457 C A 2.70E-06 Urinary metabolites / / 21572414 rs259603 chr1 238480079 G A 1.57E-11 Multiple complex diseases / / 17554300 rs16836768 chr1 238509470 T G 8.36E-04 Heart Failure / / pha002885 rs11583706 chr1 238521637 G T 9.20E-08 Glioma (high-grade) / / 19578366 rs7531928 chr1 238540226 T C 5.45E-05 Triglycerides / / pha003080 rs1021358 chr1 238544006 A G 3.46E-06 Alzheimer's disease / / 17998437 rs6678429 chr1 238549714 C T 5.07E-04 Heart Failure / / pha002884 rs923542 chr1 238559897 C A 2.12E-05 Alcohol consumption / / 23953852 rs7417996 chr1 238562060 A C 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1021356 chr1 238573691 A G 0.0000049 post-traumatic stress disorder / / 22869035 rs1021356 chr1 238573691 A G 4.93E-06 Schizophrenia / / 22883433 rs6662339 chr1 238574814 C T 0.0000423 post-traumatic stress disorder / / 22869035 rs6662339 chr1 238574814 C T 4.23E-05 Schizophrenia / / 22883433 rs6689284 chr1 238575717 G A 0.0000315 post-traumatic stress disorder / / 22869035 rs6689284 chr1 238575717 G A 3.15E-05 Schizophrenia / / 22883433 rs6665978 chr1 238575867 C T 0.0000315 post-traumatic stress disorder / / 22869035 rs6665978 chr1 238575867 C T 3.15E-05 Schizophrenia / / 22883433 rs12118091 chr1 238576614 T G 0.0000049 post-traumatic stress disorder / / 22869035 rs12118091 chr1 238576614 T G 4.93E-06 Schizophrenia / / 22883433 rs113508478 chr1 238576715 C T 0.0000074 post-traumatic stress disorder / / 22869035 rs113508478 chr1 238576715 C T 0.00000735 post-traumatic stress disorder / / 22869035 rs1418211 chr1 238582307 C G 9.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs1418210 chr1 238582365 C A 9.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs12077464 chr1 238605552 A C 2.20E-04 Multiple complex diseases / / 17554300 rs12096077 chr1 238620372 G T 6.72E-06 C-reactive protein / / 22492993 rs6701617 chr1 238668477 T C 1.54E-06 Serum selenium levels / / 23698163 rs6692700 chr1 238669776 C A 1.51E-06 Serum selenium levels / / 23698163 rs6692700 chr1 238669776 C A 2.00E-06 Serum selenium levels / / 23698163 rs10925672 chr1 238669969 G C 1.54E-06 Serum selenium levels / / 23698163 rs6429079 chr1 238672294 A G 2.34E-06 Serum selenium levels / / 23698163 rs12045395 chr1 238675402 C G 2.56E-06 Serum selenium levels / / 23698163 rs10802701 chr1 238675515 G A 2.61E-06 Serum selenium levels / / 23698163 rs10754644 chr1 238724741 A G 7.00E-06 Economic and political preferences (feminism/equality) / / 22566634 rs646969 chr1 238729943 T G 1.90E-06 Urinary metabolites / / 21572414 rs624912 chr1 238741253 T C 3.35E-05 Cholesterol / / pha003073 rs624912 chr1 238741253 T C 6.84E-05 Cholesterol / / pha003078 rs535914 chr1 238763098 T C 1.02E-05 Socioeconomic Factors / / pha003067 rs614831 chr1 238766807 G A 1.22E-05 Socioeconomic Factors / / pha003067 rs7517092 chr1 238771226 T C 1.59E-04 Alcohol dependence / / 20201924 rs474167 chr1 238773561 A G 5.89E-05 Diabetes Mellitus / / pha003059 rs574819 chr1 238777528 T C 5.89E-05 Diabetes Mellitus / / pha003059 rs6678175 chr1 238817430 A G 7.77E-05 Cardiovascular disease / / pha003065 rs16837283 chr1 238818794 T C 9.69E-04 Alcohol dependence / / 24277619 rs7547641 chr1 238822032 A G 3.60E-05 Cardiovascular disease / / pha003065 rs10159091 chr1 238890311 G C 2.00E-04 Multiple complex diseases / / 17554300 rs2689154 chr1 238908353 C G 6.00E-06 Pancreatic cancer / / 22158540 rs2689171 chr1 238918413 A T 4.56E-04 Type 2 diabetes / / 17463246 rs10925756 chr1 238919928 G T 9.23E-04 Multiple complex diseases / / 17554300 rs3001438 chr1 238920004 G A 4.41E-04 Type 2 diabetes / / 17463246 rs3011571 chr1 238921903 T C 2.74E-04 Type 2 diabetes / / 17463246 rs2841409 chr1 238923765 G C 9.49E-04 Major depressive disorder / / 22472876 rs2689128 chr1 238931277 T C 7.92E-04 Tourette syndrome / / 22889924 rs16837451 chr1 238947387 A G 1.20E-05 Urinary metabolites / / 21572414 rs10495421 chr1 238952622 C T 2.46E-05 Diabetes Mellitus / / pha003060 rs869035 chr1 239003522 G A 7.99E-04 Tourette syndrome / / 22889924 rs9428739 chr1 239034512 T C 5.89E-04 Multiple complex diseases / / 17554300 rs1915279 chr1 239075714 A G 2.00E-06 Treatment response for severe sepsis / / 22310353 rs7513289 chr1 239093239 G A 1.05E-05 Diabetes Mellitus / / pha003060 rs10925783 chr1 239097333 C T 3.14E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1915260 chr1 239109813 G A 8.64E-06 Diabetes Mellitus / / pha003060 rs9428791 chr1 239121351 A G 3.84E-04 Body mass index / / 17255346 rs2883158 chr1 239124181 C T 7.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2883158 chr1 239124181 C T 4.69E-05 Diabetes Mellitus / / pha003060 rs17621797 chr1 239130988 C A 2.23E-04 Multiple complex diseases / / 17554300 rs16837650 chr1 239164093 C T 3.95E-04 Smoking cessation / / 24665060 rs1915250 chr1 239183774 C T 3.05E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs7550941 chr1 239191297 G C 4.86E-05 Personality dimensions / / 18957941 rs10754661 chr1 239201173 C T 3.50E-04 Multiple complex diseases / / 17554300 rs6667563 chr1 239203938 T C 2.12E-04 Multiple complex diseases / / 17554300 rs2883159 chr1 239204302 C T 1.98E-04 Multiple complex diseases / / 17554300 rs1915252 chr1 239206398 G A 1.86E-04 Multiple complex diseases / / 17554300 rs10925809 chr1 239230295 A G 6.29E-05 Lipoproteins / / pha003079 rs1509691 chr1 239253606 T G 1.50E-05 Urinary metabolites / / 21572414 rs12410287 chr1 239261262 C T 5.59E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7541537 chr1 239313573 C A 2.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4659904 chr1 239317135 A G 1.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10754667 chr1 239336071 A C 2.09E-05 Hypertension (early onset hypertension) / / 22479346 rs6703086 chr1 239343728 A G 0.000152712 Hypertension (early onset hypertension) / / 22479346 rs6703086 chr1 239343728 A G 7.55E-05 Body Fat Distribution / / pha003017 rs6703086 chr1 239343728 A G 3.87E-05 Body Fat Distribution / / pha003018 rs2039801 chr1 239356155 T G 5.71E-05 Type 2 diabetes / / 17463246 rs1339738 chr1 239397104 C T 7.00E-06 IgG glycosylation / / 23382691 rs2820026 chr1 239423724 C T 2.51E-04 Type 2 diabetes / / 17463246 rs2820026 chr1 239423724 C T 3.38E-06 Multiple complex diseases / / 17554300 rs9428826 chr1 239430497 C T 1.44E-04 Type 2 diabetes / / 17463246 rs9428826 chr1 239430497 C T 2.25E-06 Multiple complex diseases / / 17554300 rs2790622 chr1 239436135 A C 1.89E-04 Type 2 diabetes / / 17463246 rs2790622 chr1 239436135 A C 9.45E-07 Multiple complex diseases / / 17554300 rs2820037 chr1 239436542 A T 2.53E-04 Type 2 diabetes / / 17463246 rs2820037 chr1 239436542 A T 8.00E-07 Hypertension / / 17554300 rs2820037 chr1 239436542 A T 8.00E-07 Coronary heart disease / / 21347282 rs2820038 chr1 239436607 C T 2.53E-04 Type 2 diabetes / / 17463246 rs2820038 chr1 239436607 C T 9.13E-07 Multiple complex diseases / / 17554300 rs2820038 chr1 239436607 C T 2.80E-05 Urinary metabolites / / 21572414 rs2820046 chr1 239439310 T A 3.14E-04 Type 2 diabetes / / 17463246 rs2820046 chr1 239439310 T A 1.12E-06 Multiple complex diseases / / 17554300 rs4634896 chr1 239485654 A C 4.79E-04 Multiple complex diseases / / 17554300 rs12049599 chr1 239496469 A G 6.44E-05 Lymphocyte counts / / pha003094 rs10925871 chr1 239506077 G A 6.38E-05 Systemic sclerosis / / 21750679 rs12036333 chr1 239519066 G A 0.00000131 Cytarabine sensitivity / / 23538338 rs6429135 chr1 239523874 G A 4.04E-04 Multiple complex diseases / / 17554300 rs6678395 chr1 239575774 C T 8.58E-05 Bone mineral density LOC100505872 intron 19181680 rs6671410 chr1 239597345 G T 2.30E-06 Intelligence LOC100505872 intron 21826061 rs6677208 chr1 239601969 A C 3.00E-06 Platelet counts LOC100505872 intron 21507922 rs2354398 chr1 239608049 A T 3.40E-06 Urinary metabolites LOC100505872 intron 21572414 rs10754671 chr1 239632055 T C 6.42E-05 Intelligence LOC100505872 intron 21826061 rs13373941 chr1 239644171 T G 8.00E-06 Obesity-related traits LOC100505872 intron 23251661 rs12139491 chr1 239685723 A G 1.81E-05 Insulin-related traits LOC100505872 intron pha003063 rs10925917 chr1 239717119 A G 7.88E-05 Sudden cardiac arrest / / 21658281 rs12406060 chr1 239720458 T C 7.87E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1984207 chr1 239726247 A G 7.85E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs12135445 chr1 239743257 G A 4.71E-04 Alcohol dependence / / 24277619 rs12135445 chr1 239743257 G A 9.97E-05 Body Mass Index / / pha003020 rs12135445 chr1 239743257 G A 5.03E-05 Insulin Resistance / / pha003062 rs12135445 chr1 239743257 G A 3.87E-05 Insulin-related traits / / pha003063 rs1899617 chr1 239748949 G A 3.46E-04 Multiple complex diseases / / 17554300 rs10802779 chr1 239760713 T C 4.36E-05 Fibrinogen / / pha003068 rs16838569 chr1 239776089 G A 6.00E-04 Obesity (extreme) / / 21935397 rs10925928 chr1 239777139 T G 2.77E-04 Obesity (extreme) / / 21935397 rs12080951 chr1 239778660 C T 2.64E-04 Alcohol dependence / / 24277619 rs6690612 chr1 239781166 T C 3.48E-04 Multiple complex diseases / / 17554300 rs2355230 chr1 239785165 C A 9.16E-10 Post-operative nausea and vomiting / / 21694509 rs2165870 chr1 239785420 A G 5.50E-05 Post-operative nausea and vomiting / / 21694509 rs10754677 chr1 239833100 G A 4.62E-04 Sudden cardiac arrest CHRM3 intron 21658281 rs1867266 chr1 239839305 T G 4.46E-04 Smoking initiation CHRM3 intron 24665060 rs7523711 chr1 239854977 A T 5.85E-04 Multiple complex diseases CHRM3 intron 17554300 rs6694025 chr1 239862101 C T 3.57E-04 Multiple complex diseases CHRM3 intron 17554300 rs7527723 chr1 239907420 A G 6.23E-04 Multiple complex diseases CHRM3 intron 17554300 rs645248 chr1 239907731 G C 1.69E-04 Multiple complex diseases CHRM3 intron 17554300 rs685550 chr1 239924408 G A 8.27E-04 Obesity (extreme) CHRM3 intron 21935397 rs12059546 chr1 239970097 A G 4.00E-08 Epilepsy (generalized) CHRM3 intron 22949513 rs4463655 chr1 239984294 T C 6.47E-04 Type 2 diabetes CHRM3 intron 17463246 rs7548522 chr1 239998625 C T 5.45E-04 Suicide attempts in bipolar disorder CHRM3 intron 21423239 rs10925985 chr1 240000988 T C 0.0005996 Sarcoidosis CHRM3 intron 22952805 rs6682181 chr1 240040098 A G 2.16E-04 Multiple complex diseases CHRM3 intron 17554300 rs536477 chr1 240045908 A G 3.00E-09 Venous thromboembolism (gene x gene interaction) CHRM3 intron 23509962 rs10495448 chr1 240055473 G A 1.30E-04 Response to taxane treatment (placlitaxel) CHRM3 intron 23006423 rs6666471 chr1 240091765 G A 5.15E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs7531091 chr1 240094975 G A 4.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1471351 chr1 240114540 C T 2.97E-04 Type 2 diabetes / / 17463246 rs1984165 chr1 240118265 T C 9.94E-04 Type 2 diabetes / / 17463246 rs10495451 chr1 240137811 C T 2.03E-04 Premature ovarian failure / / 19508998 rs6677092 chr1 240173282 T C 1.24E-07 Multiple complex diseases RPS7P5 intron 17554300 rs6677092 chr1 240173282 T C 8.21E-05 Serum metabolites RPS7P5 intron 19043545 rs10926064 chr1 240173998 C T 2.57E-05 Melanoma RPS7P5 intron 21926416 rs10802825 chr1 240176600 A G 6.68E-05 Serum metabolites / / 19043545 rs1891230 chr1 240187633 A G 2.50E-04 Alzheimer's disease (late onset) / / 21379329 rs922307 chr1 240190387 G A 8.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12088486 chr1 240195776 C A 8.83E-06 Longevity / / 21612516 rs12733694 chr1 240218134 T C 9.15E-05 Melanoma / / 21926416 rs7548944 chr1 240228959 C G 2.80E-05 Urinary metabolites / / 21572414 rs4659562 chr1 240240025 A G 5.89E-04 Type 2 diabetes / / 17463246 rs12143985 chr1 240258525 C T 1.30E-05 Urinary metabolites FMN2 intron 21572414 rs11810574 chr1 240283736 A G 4.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients FMN2 intron 23400010 rs1982530 chr1 240298817 T C 2.34E-04 Birth weight FMN2 intron 17255346 rs10926141 chr1 240308382 C A 2.59E-04 Type 2 diabetes FMN2 intron 17463246 rs10926145 chr1 240314586 A G 9.46E-04 Type 2 diabetes FMN2 intron 17463246 rs1891231 chr1 240315515 G A 2.67E-04 Amyotrophic Lateral Sclerosis FMN2 intron 17362836 rs12092459 chr1 240338133 A C 3.64E-06 Left ventricular mass FMN2 intron 21212386 rs7511696 chr1 240339918 T C 4.79E-04 Type 2 diabetes FMN2 intron 17463246 rs11591010 chr1 240340616 T C 7.85E-04 Type 2 diabetes FMN2 intron 17463246 rs2124724 chr1 240354069 G T 3.16E-05 IgE levels FMN2 intron 17255346 rs2124724 chr1 240354069 G T 1.41E-04 Amyotrophic Lateral Sclerosis FMN2 intron 17362836 rs12057575 chr1 240357637 A G 8.67E-04 HIV-1 viral setpoint FMN2 intron 17641165 rs1037666 chr1 240358485 C T 4.00E-06 Amyotrophic Lateral Sclerosis FMN2 intron 17362836 rs140911005 chr1 240370313 G A 0.000006 Prostate cancer (advanced) FMN2 missense 23555315 rs6429189 chr1 240382784 C T 5.45E-04 Amyotrophic Lateral Sclerosis FMN2 intron 17362836 rs17626030 chr1 240435787 T C 2.90E-05 Urinary metabolites FMN2 intron 21572414 rs4659953 chr1 240439717 C T 8.84E-04 Type 2 diabetes FMN2 intron 17463246 rs4659568 chr1 240441142 A G 9.70E-07 Urinary metabolites FMN2 intron 21572414 rs4659568 chr1 240441142 A G 2.05E-05 Body Mass Index FMN2 intron pha003006 rs4659568 chr1 240441142 A G 1.49E-06 Body Mass Index FMN2 intron pha003014 rs4659568 chr1 240441142 A G 5.32E-05 Weight FMN2 intron pha003026 rs10495462 chr1 240442817 T C 3.71E-05 Body Mass Index FMN2 intron pha003014 rs17672135 chr1 240445596 T C 2.00E-06 Coronary heart disease FMN2 intron 17554300 rs17672135 chr1 240445596 T C 1.04E-04 Coronary Artery Disease FMN2 intron 17634449 rs17672135 chr1 240445596 T C 2.00E-06 Coronary heart disease FMN2 intron 21347282 rs1456648 chr1 240445712 T G 4.44E-05 Multiple complex diseases FMN2 intron 17554300 rs1542400 chr1 240446096 T G 2.40E-06 Urinary metabolites FMN2 intron 21572414 rs6673167 chr1 240448434 G T 1.09E-04 Multiple complex diseases FMN2 intron 17554300 rs6664907 chr1 240448468 T C 2.08E-08 Triglycerides FMN2 intron 23063622 rs1456649 chr1 240451605 G C 1.66E-31 HDL cholesterol FMN2 intron 23063622 rs1456649 chr1 240451605 G C 6.08E-86 Triglycerides FMN2 intron 23063622 rs1456649 chr1 240451605 G C 7.36E-11 LDL cholesterol FMN2 intron 23063622 rs988832 chr1 240456022 T C 8.47E-04 Rheumatoid arthritis FMN2 intron 21452313 rs988832 chr1 240456022 T C 9.81E-05 Body Mass Index FMN2 intron pha003006 rs6659900 chr1 240456751 T C 3.81E-05 Body Mass Index FMN2 intron pha003006 rs6659900 chr1 240456751 T C 5.98E-06 Body Mass Index FMN2 intron pha003014 rs7526497 chr1 240457973 G T 4.88E-04 Alzheimer's disease FMN2 intron 22005930 rs16839760 chr1 240461521 C A 3.75E-04 Alzheimer's disease FMN2 intron 22005930 rs1598676 chr1 240470604 T G 5.42E-04 Alzheimer's disease FMN2 intron 22005930 rs994277 chr1 240472692 G A 1.00E-05 Urinary metabolites FMN2 intron 21572414 rs6701541 chr1 240475346 A G 1.42E-54 Multiple complex diseases FMN2 intron 17554300 rs6701541 chr1 240475346 A G 0.00000149 Triglycerides FMN2 intron 23063622 rs6701177 chr1 240477294 G A 1.06E-05 Body Mass Index FMN2 intron pha003006 rs6701177 chr1 240477294 G A 4.09E-06 Body Mass Index FMN2 intron pha003014 rs6701177 chr1 240477294 G A 6.10E-05 Weight FMN2 intron pha003026 rs4433380 chr1 240478385 A G 3.23E-04 Alzheimer's disease FMN2 intron 22005930 rs4233480 chr1 240479065 A G 5.80E-06 Urinary metabolites FMN2 intron 21572414 rs12240157 chr1 240480132 A G 4.62E-04 Alzheimer's disease FMN2 intron 22005930 rs13376476 chr1 240484422 T A 5.03E-04 Alzheimer's disease FMN2 intron 22005930 rs13374744 chr1 240486721 C T 3.03E-04 Alzheimer's disease FMN2 intron 22005930 rs6664970 chr1 240489585 A G 4.56E-04 Alzheimer's disease FMN2 intron 22005930 rs4330908 chr1 240489952 G C 5.55E-09 Triglycerides FMN2 intron 23063622 rs6686353 chr1 240492543 G A,C,T 9.10E-07 Urinary metabolites FMN2 intron 21572414 rs12122068 chr1 240497598 T C 2.10E-05 Urinary metabolites FMN2 intron 21572414 rs10926223 chr1 240498247 T C 2.30E-05 Urinary metabolites FMN2 intron 21572414 rs16839838 chr1 240500388 T C 7.69E-04 Alzheimer's disease FMN2 intron 22005930 rs16839844 chr1 240500412 G A 7.76E-04 Alzheimer's disease FMN2 intron 22005930 rs12406544 chr1 240503031 C A 7.64E-04 Alzheimer's disease FMN2 intron 22005930 rs12407532 chr1 240505407 C T 2.84E-04 Alzheimer's disease FMN2 intron 22005930 rs12406031 chr1 240514103 G T 3.96E-04 Alzheimer's disease FMN2 intron 22005930 rs2068307 chr1 240516361 G T 5.70E-05 Body Mass Index FMN2 intron pha003014 rs9725819 chr1 240519677 T C 3.64E-04 Alzheimer's disease FMN2 intron 22005930 rs12095342 chr1 240524580 C T 1.90E-05 Urinary metabolites FMN2 intron 21572414 rs9660912 chr1 240527029 G T 8.33E-04 Stroke FMN2 intron pha002886 rs12723298 chr1 240527080 C T 7.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FMN2 intron 20877124 rs10926234 chr1 240532005 T C 8.33E-05 Orofacial clefts FMN2 intron 22419666 rs9662927 chr1 240538952 G A 1 Drug response to Etoposide FMN2 intron 17537913 rs10802866 chr1 240541011 C T 1 Drug response to Etoposide FMN2 intron 17537913 rs9661599 chr1 240548069 A T 1 Drug response to Etoposide FMN2 intron 17537913 rs9662388 chr1 240552223 G A 1 Drug response to Etoposide FMN2 intron 17537913 rs1537849 chr1 240554447 C T 1 Drug response to Etoposide FMN2 intron 17537913 rs2184711 chr1 240554988 G A 1 Drug response to Etoposide FMN2 intron 17537913 rs9730073 chr1 240556035 T C 1 Drug response to Etoposide FMN2 intron 17537913 rs12562192 chr1 240559446 A C,T 1 Drug response to Etoposide FMN2 intron 17537913 rs10926240 chr1 240559938 C T 1 Drug response to Etoposide FMN2 intron 17537913 rs10802867 chr1 240564513 A G 2.80E-04 Alcohol dependence FMN2 intron 20201924 rs10802867 chr1 240564513 A G 1.00E-04 Cognitive impairment induced by topiramate FMN2 intron 22091778 rs9287234 chr1 240566373 G A 7.90E-06 Bone mass and geometry FMN2 intron 17903296 rs1889869 chr1 240583596 A G 1.00E-04 Cognitive impairment induced by topiramate FMN2 intron 22091778 rs1889869 chr1 240583596 A G 1.00E-04 Cognitive impairment induced by topiramate FMN2 intron 22091778 rs9287237 chr1 240597214 G T 2.00E-09 Bone mineral density FMN2 intron 23437003 rs10926254 chr1 240599099 A G 6.30E-04 Alcohol dependence FMN2 intron 20201924 rs2356386 chr1 240601269 A G 4.93E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines FMN2 intron 21844884 rs12091371 chr1 240605052 G A 7.00E-08 Alzheimer's disease (cognitive decline) FMN2 intron 23535033 rs11590081 chr1 240612986 G T 2.98E-04 Response to statin treatment (atorvastatin),change in cholesterol levels FMN2 intron 20031582 rs10754705 chr1 240613766 G T 1.21E-04 Acute lymphoblastic leukemia (childhood) FMN2 intron 22076464 rs10754705 chr1 240613766 G T 1.36E-04 Amyotrophic lateral sclerosis (sporadic) FMN2 intron 24529757 rs16840114 chr1 240625431 A G 9.00E-06 Anger FMN2 intron 24489884 rs16840114 chr1 240625431 A G 9.10E-06 Anger FMN2 intron 24489884 rs16840117 chr1 240625834 A G 3.01E-04 Fibrinogen FMN2 intron 17255346 rs9287243 chr1 240633273 A G 9.41E-04 Alzheimer's disease FMN2 intron 22005930 rs9727156 chr1 240633672 T C 9.72E-04 Alzheimer's disease FMN2 intron 22005930 rs879081 chr1 240639558 C T 3.64E-04 Alzheimer's disease (late onset) / / 21379329 rs9729366 chr1 240639611 A G 2.62E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs11578184 chr1 240643167 A C 2.89E-04 Alzheimer's disease (late onset) / / 21379329 rs12734326 chr1 240644644 C T 0.0000071 Asthma / / 23040885 rs1414654 chr1 240649079 T G 8.10E-04 Body mass index / / 21701565 rs16840259 chr1 240666644 T G 4.60E-04 Multiple complex diseases GREM2 intron 17554300 rs12143400 chr1 240679670 T C 4.87E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) GREM2 intron 24236485 rs3748540 chr1 240693711 C T 7.88E-05 Pulmonary function in asthmatics GREM2 intron 23541324 rs12129547 chr1 240695255 C T 1.99E-04 IgE levels GREM2 intron 17255346 rs4587552 chr1 240698245 C T 6.04E-05 Insulin-related traits GREM2 intron 19902172 rs10495471 chr1 240706107 A G 2.00E-07 Immune response to smallpox vaccine (IL-6) GREM2 intron 22542470 rs12069813 chr1 240712898 A G 9.26E-04 Alzheimer's disease GREM2 intron 24755620 rs1320590 chr1 240716710 A G 5.62E-05 Bipolar disorder and schizophrenia GREM2 intron 20889312 rs10737846 chr1 240718920 C T 3.03E-04 Alzheimer's disease (late onset) GREM2 intron 21379329 rs10737846 chr1 240718920 C T 4.16E-04 Alzheimer's disease GREM2 intron 24755620 rs7543336 chr1 240736355 C T 3.25E-04 Alzheimer's disease GREM2 intron 22005930 rs10926301 chr1 240736540 A G 9.54E-04 Alzheimer's disease GREM2 intron 22005930 rs12126125 chr1 240783716 A G 6.34E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6689991 chr1 240786782 C T 9.32E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16840459 chr1 240810197 C T 4.53E-04 Type 2 diabetes / / 17463246 rs7526951 chr1 240819499 G A 3.94E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4659996 chr1 240846124 G A 7.00E-06 ankle-brachial index / / 22199011 rs4660000 chr1 240848817 G A 3.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs16840493 chr1 240867476 C T 5.74E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs6678643 chr1 240885642 G A 7.98E-04 Depression (quantitative trait) / / 20800221 rs7531849 chr1 240894583 A C 3.08E-06 Longevity / / 20304771 rs7531849 chr1 240894583 A C 3.04E-05 Pancreatic cancer / / pha002874 rs4443878 chr1 240904418 C T 1.33E-06 Longevity LOC100506929 intron 20304771 rs4611001 chr1 240904628 A G 1.33E-06 Longevity LOC100506929 intron 20304771 rs4611001 chr1 240904628 A G 3.09E-05 Aging (time to event) LOC100506929 intron 21782286 rs6679652 chr1 240908767 C T 6.55E-05 Rheumatoid arthritis / / 21452313 rs16848948 chr1 240919970 T C 5.41E-05 Creutzfeldt-Jakob disease (variant) / / 22137330 rs12097299 chr1 240943132 C T 3.23E-05 Hypertension RGS7 intron 19609347 rs16840647 chr1 240963070 A G 4.02E-07 Creutzfeldt-Jakob disease (variant) RGS7 intron 22137330 rs16840647 chr1 240963070 A G 4.56E-04 Smoking initiation RGS7 intron 24665060 rs7544372 chr1 240987754 C T 9.00E-06 Obesity-related traits RGS7 intron 23251661 rs785970 chr1 241003474 G A 1.41E-05 Aging (time to event) RGS7 intron 21782286 rs4660010 chr1 241039187 G A 6.42E-04 Schizophrenia RGS7 intron 19197363 rs261833 chr1 241046905 T C 1.30E-05 Urinary metabolites RGS7 intron 21572414 rs3856237 chr1 241047490 A C 1.30E-05 Urinary metabolites RGS7 intron 21572414 rs12083487 chr1 241047702 C T 5.00E-06 Urinary metabolites RGS7 intron 21572414 rs2446621 chr1 241050218 T C 2.86E-04 Bipolar disorder RGS7 intron 18317468 rs2446621 chr1 241050218 T C 6.70E-06 Urinary metabolites RGS7 intron 21572414 rs17698283 chr1 241050375 G A 4.08E-06 Glucose levels RGS7 intron pha003058 rs17698283 chr1 241050375 G A 2.46E-05 Glucose levels RGS7 intron pha003061 rs187783 chr1 241053122 C T 4.30E-06 Urinary metabolites RGS7 intron 21572414 rs12751419 chr1 241058174 A G 6.31E-05 Glucose levels RGS7 intron pha003058 rs261858 chr1 241096756 T C 1.57E-04 Schizophrenia RGS7 intron 19197363 rs6697598 chr1 241105515 T C 9.52E-05 Amyotrophic lateral sclerosis (sporadic) RGS7 intron 24529757 rs4660017 chr1 241139151 C T 1.28E-04 Multiple complex diseases RGS7 intron 17554300 rs4659586 chr1 241139692 A T 2.42E-04 Multiple complex diseases RGS7 intron 17554300 rs2502448 chr1 241164526 T C 0.0001 High platelet reactivity in patients with type 2 diabetes during acetylsalicylic acid (ASA) treatment (defined as CEPI-CT score of <193 s) RGS7 intron 23054467 rs2502448 chr1 241164526 T C 0.00025 Coronary artery calcification RGS7 intron 23727086 rs628208 chr1 241170977 A G 5.62E-04 Type 2 diabetes RGS7 intron 17463246 rs601675 chr1 241183612 A G 0.000332 Rate of forced expiratory volume in 1 second (FEV1) decline (young adult women) RGS7 intron 23527081 rs938927 chr1 241215740 G A 3.52E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer RGS7 intron 21483023 rs2493010 chr1 241236721 A G 5.12E-05 Multiple complex diseases RGS7 intron 17554300 rs9428859 chr1 241239862 G A 6.84E-05 Post-operative nausea and vomiting RGS7 intron 21694509 rs2492990 chr1 241255581 T G 7.20E-04 Response to taxane treatment (placlitaxel) RGS7 intron 23006423 rs2492988 chr1 241257765 G A 8.47E-04 Response to taxane treatment (placlitaxel) RGS7 intron 23006423 rs2492987 chr1 241259007 T C 2.07E-05 Post-operative nausea and vomiting RGS7 intron 21694509 rs12086317 chr1 241264216 A G 8.53E-04 Alcohol dependence RGS7 intron 24277619 rs10158567 chr1 241288510 G A 7.16E-04 Alcohol dependence RGS7 intron 21314694 rs10158567 chr1 241288510 G A 1.60E-05 Urinary metabolites RGS7 intron 21572414 rs4131804 chr1 241288878 G T 6.70E-06 Urinary metabolites RGS7 intron 21572414 rs4660034 chr1 241329258 G A 7.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RGS7 intron 20877124 rs4660035 chr1 241329693 C T 0.000452 Salmonella-induced pyroptosis RGS7 intron 22837397 rs7527775 chr1 241338661 G A 0.000717 Salmonella-induced pyroptosis RGS7 intron 22837397 rs4266869 chr1 241339787 C G 2.70E-05 Urinary metabolites RGS7 intron 21572414 rs4659592 chr1 241372527 C A 3.09E-07 Post-operative nausea and vomiting RGS7 intron 21694509 rs72760508 chr1 241376522 A T 0.00009449 Sarcoidosis RGS7 intron 22952805 rs12566189 chr1 241377328 G T 0.0000916 Sarcoidosis RGS7 intron 22952805 rs2140065 chr1 241390758 C T 3.61E-05 Coronary heart disease RGS7 intron pha003031 rs2815859 chr1 241394043 C G 8.03E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs2815858 chr1 241394361 C T 7.10E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs2815856 chr1 241395193 A G 2.39E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs2686230 chr1 241395328 G A 2.19E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs2815854 chr1 241395811 T G 2.25E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs9428500 chr1 241397089 T C 2.19E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs2815851 chr1 241397662 G A 2.07E-05 Triglycerides RGS7 intron pha003080 rs1915886 chr1 241398598 A G 3.63E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs1915888 chr1 241398712 C T 3.18E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs4290050 chr1 241399513 G A 3.31E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs4378194 chr1 241399532 T C 1.93E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs9428866 chr1 241399554 T C 2.69E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs2815842 chr1 241399761 A G 2.05E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs2815841 chr1 241399845 G A 2.56E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs2686240 chr1 241400004 C T 1.99E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs2815834 chr1 241401288 G A 1.77E-05 Triglycerides RGS7 intron pha003080 rs4359023 chr1 241403497 G A 2.90E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs4359023 chr1 241403497 G A 3.14E-05 Triglycerides RGS7 intron pha003081 rs4359023 chr1 241403497 G A 6.09E-05 Lipid levels RGS7 intron pha003082 rs2880130 chr1 241415658 T C 6.56E-04 Smoking initiation RGS7 intron 24665060 rs61553648 chr1 241418981 A G 0.00009448 Sarcoidosis RGS7 intron 22952805 rs10926441 chr1 241421106 G C 9.05E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs10754721 chr1 241421370 G A 8.07E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs10802938 chr1 241421610 A G 8.29E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs10926443 chr1 241421911 A G 6.72E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs10926444 chr1 241421976 A T 6.83E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs10802939 chr1 241423655 G A 7.21E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs10754722 chr1 241425762 A G 6.87E-04 Suicide attempts in bipolar disorder RGS7 intron 21423239 rs1996806 chr1 241433465 C T 7.39E-04 Multiple complex diseases RGS7 intron 17554300 rs10926448 chr1 241434468 C A 3.10E-04 Multiple complex diseases RGS7 intron 17554300 rs10926448 chr1 241434468 C A 7.44E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines RGS7 intron 21844884 rs12090898 chr1 241452500 C T 7.31E-05 Major depressive disorder RGS7 intron 19107115 rs7550277 chr1 241454335 T C 8.60E-04 Suicidal ideation RGS7 intron 22030708 rs10737858 chr1 241455974 A G 3.69E-04 Smoking initiation RGS7 intron 24665060 rs6684760 chr1 241458229 G C 4.86E-04 Insulin resistance RGS7 intron 21901158 rs7355007 chr1 241459462 A G 1.61E-05 Insulin-related traits RGS7 intron 19902172 rs6668091 chr1 241511550 A G 2.60E-05 Anger RGS7 intron 24489884 rs10737863 chr1 241513635 T C 3.37E-04 Multiple complex diseases RGS7 intron 17554300 rs7554279 chr1 241523480 G A 1.10E-06 Urinary metabolites / / 21572414 rs2185627 chr1 241530588 G A 8.90E-04 Multiple complex diseases / / 17554300 rs1592072 chr1 241539109 T C 8.80E-04 Multiple complex diseases / / 17554300 rs1341446 chr1 241541888 G A 3.71E-05 Bipolar disorder / / 21771265 rs4660080 chr1 241542793 G A 1.11E-05 Bipolar disorder / / 21771265 rs1557078 chr1 241550350 C T 2.95E-05 Bipolar disorder / / 21771265 rs1935094 chr1 241569327 C T 1.36E-05 Esophageal cancer (squamous cell) / / 22960999 rs2341942 chr1 241570018 C T 8.21E-05 Erythrocyte counts / / pha003101 rs1341449 chr1 241576302 C A 8.16E-04 Heart Failure / / pha002885 rs1539100 chr1 241586018 C T 2.35E-04 Type 2 diabetes / / 17463246 rs1891129 chr1 241586687 T C 4.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4659607 chr1 241667244 G T 3.45E-04 Parkinson's disease FH intron 17052657 rs6678986 chr1 241684831 A G 9.33E-04 Alcohol dependence FH nearGene-5 24277619 rs4659609 chr1 241697084 G A 6.80E-04 Multiple complex diseases KMO intron 17554300 rs10802970 chr1 241702689 A C 4.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KMO intron 20877124 rs6677357 chr1 241706007 G A 9.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KMO intron 20877124 rs6661244 chr1 241709304 T C 8.92E-04 Multiple complex diseases KMO intron 17554300 rs3007737 chr1 241720559 T C 7.43E-04 Multiple complex diseases KMO intron 17554300 rs3753214 chr1 241724922 T C 2.20E-04 Asthma KMO intron 20698975 rs2275163 chr1 241730054 C T 9.42E-04 Response to alcohol consumption (flushing response) KMO intron 24277619 rs850678 chr1 241747139 A T 2.93E-05 Personality dimensions KMO intron 22628180 rs648708 chr1 241747838 T C 2.93E-05 Personality dimensions KMO intron 22628180 rs659887 chr1 241748003 T C 2.95E-05 Personality dimensions KMO intron 22628180 rs655970 chr1 241754836 A G 2.96E-05 Personality dimensions KMO intron 22628180 rs1053221 chr1 241755567 T C 1.00E-06 Obesity-related traits KMO UTR-3 23251661 rs640718 chr1 241755925 A G 1.00E-04 Prostate cancer KMO UTR-3 21743057 rs3193688 chr1 241758566 G C 1.13E-06 Obesity-related traits KMO UTR-3 23251661 rs1053183 chr1 241758631 A G 2.97E-05 Personality dimensions KMO UTR-3 22628180 rs6413960 chr1 241830086 A G 5.58E-05 Serum metabolites WDR64 intron 19043545 rs6413960 chr1 241830086 A G 9.71E-05 Insulin resistance WDR64 intron 21901158 rs6429287 chr1 241830538 T C 7.32E-05 Body Mass Index WDR64 intron pha003006 rs9428890 chr1 241868349 G A 2.49E-04 Alcohol dependence WDR64 intron 21314694 rs12569163 chr1 241878547 T G 2.00E-06 Radiation response WDR64 intron 20923822 rs7519667 chr1 241885307 C T 2.71E-05 Response to taxane treatment (placlitaxel) WDR64 intron 23006423 rs9782914 chr1 241892235 T C 4.30E-04 Non-substance related behavioral disinhibition WDR64 intron 23942779 rs9782914 chr1 241892235 T C 8.00E-06 Behavioural disinhibition (generation interaction) WDR64 intron 23942779 rs9782914 chr1 241892235 T C 9.40E-06 Illicit drug use WDR64 intron 23942779 rs10926554 chr1 241894086 C A 1.80E-04 Non-substance related behavioral disinhibition WDR64 intron 23942779 rs10926554 chr1 241894086 C A 3.00E-06 Illicit drug use WDR64 intron 23942779 rs10926554 chr1 241894086 C A 5.90E-05 Nicotine use WDR64 intron 23942779 rs10926556 chr1 241897899 T A 4.50E-05 Personality dimensions WDR64 intron 18957941 rs4658506 chr1 241945917 C T 1.06E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy WDR64 intron 23834954 rs3902093 chr1 241995903 C A 9.34E-04 Alzheimer's disease / / 17998437 rs4149868 chr1 242016838 T C 8.04E-05 Bipolar disorder and schizophrenia EXO1 intron 20889312 rs148510810 chr1 242030355 G A 0.00028 Prostate cancer EXO1 missense 23555315 rs4149967 chr1 242035574 G C 0.00000102 Cholesterol,total EXO1 missense 23063622 rs1635502 chr1 242039382 A G 0.00028 Coronary artery calcification EXO1 intron 23727086 rs1635501 chr1 242040775 C T 8.00E-10 Menopause (age at onset) EXO1 intron 22267201 rs1776148 chr1 242042545 A G 9.20E-05 Amyotrophic lateral sclerosis EXO1 missense 20801717 rs4408133 chr1 242049649 G C 0.0000074 Type 2 diabetes EXO1 intron 22325160 rs4658535 chr1 242059221 G A 4.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs5009401 chr1 242076590 G A 3.26E-05 Squamous cell carcinoma / / 23341777 rs4658573 chr1 242094314 A C 4.59E-05 Brain structure / / 22504417 rs112610111 chr1 242159566 C T 0.00041 Prostate cancer MAP1LC3C missense 23555315 rs6673338 chr1 242200884 G A 1.34E-04 Multiple complex diseases / / 17554300 rs10754748 chr1 242208009 G A 0.000356 Antisocial behavior / / 23077488 rs1589263 chr1 242235655 A G 1.60E-05 Major depressive disorder / / 21621269 rs7528333 chr1 242238751 T C 1.38E-05 HIV-1 viral setpoint / / 22174851 rs2164422 chr1 242266434 T C 3.08E-04 Type 2 diabetes PLD5 intron 17463246 rs984985 chr1 242269283 C T 9.04E-04 Suicide attempts in bipolar disorder PLD5 intron 21423239 rs4658619 chr1 242271323 T G 1.90E-05 Glioma (high-grade) PLD5 intron 19578366 rs10803016 chr1 242274908 G T 2.58E-04 Suicide attempts in bipolar disorder PLD5 intron 21423239 rs10803016 chr1 242274908 G T 7.00E-06 Coronary artery calcification PLD5 intron 23870195 rs6663013 chr1 242276117 A G 1.60E-04 Suicide attempts in bipolar disorder PLD5 intron 21423239 rs2574669 chr1 242281003 A C 3.99E-04 Suicide attempts in bipolar disorder PLD5 intron 21423239 rs2574669 chr1 242281003 A C 1.12E-05 Socioeconomic Factors PLD5 intron pha003067 rs2636254 chr1 242282285 T C 4.55E-04 Multiple complex diseases PLD5 intron 17554300 rs2217881 chr1 242318471 A G 1.72E-04 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs316838 chr1 242320660 G A 1.21E-05 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs316838 chr1 242320660 G A 2.09E-04 Response to cytadine analogues (cytosine arabinoside) PLD5 intron 24483146 rs12124834 chr1 242323886 A T 8.70E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PLD5 intron 21844884 rs316850 chr1 242327693 A G 6.77E-04 Multiple complex diseases PLD5 intron 17554300 rs695021 chr1 242328222 C T 2.08E-05 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs695021 chr1 242328222 C T 3.63E-04 Response to cytadine analogues (cytosine arabinoside) PLD5 intron 24483146 rs1393299 chr1 242329791 C T 8.69E-04 Response to cytadine analogues (cytosine arabinoside) PLD5 intron 24483146 rs316896 chr1 242329814 C T 1.85E-04 Multiple complex diseases PLD5 intron 17554300 rs316895 chr1 242331083 G A 8.61E-05 Multiple complex diseases PLD5 intron 17554300 rs12139740 chr1 242332976 C T 3.79E-04 Multiple complex diseases PLD5 intron 17554300 rs316871 chr1 242342884 G A 4.14E-05 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs316871 chr1 242342884 G A 4.20E-04 Response to cytadine analogues (cytosine arabinoside) PLD5 intron 24483146 rs376621 chr1 242345821 C T 3.42E-04 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs12135329 chr1 242347587 T C 2.08E-04 Multiple complex diseases PLD5 intron 17554300 rs316833 chr1 242347608 G A 3.69E-05 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs316823 chr1 242356028 T C 2.88E-04 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs316823 chr1 242356028 T C 4.63E-04 Response to cytadine analogues (cytosine arabinoside) PLD5 intron 24483146 rs420194 chr1 242357360 C T 7.66E-05 Multiple complex diseases PLD5 intron 17554300 rs427498 chr1 242357455 A C 4.43E-04 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs402098 chr1 242363698 C G 2.88E-04 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs402098 chr1 242363698 C G 4.63E-04 Response to cytadine analogues (cytosine arabinoside) PLD5 intron 24483146 rs2653165 chr1 242366282 G A 9.00E-06 Response to cytadine analogues (cytosine arabinoside) PLD5 intron 24483146 rs400838 chr1 242398159 G A 2.97E-04 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs390956 chr1 242398403 G A 5.94E-04 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs380005 chr1 242400313 A T 3.62E-04 Response to cytidine analogues (gemcitabine) PLD5 intron 24483146 rs2259017 chr1 242455489 G A 2.19E-04 Multiple complex diseases PLD5 intron 17554300 rs7521223 chr1 242499648 C T 1.06E-04 Multiple complex diseases PLD5 intron 17554300 rs2919024 chr1 242522042 A G 7.00E-06 IgG glycosylation PLD5 intron 23382691 rs1439523 chr1 242531654 T C 4.00E-06 IgG glycosylation PLD5 intron 23382691 rs2809985 chr1 242562721 A G 3.81E-04 Nicotine smoking PLD5 intron 19268276 rs12410712 chr1 242567214 T C 1.61E-05 Brain structure PLD5 intron 22504417 rs2055538 chr1 242602516 T C 9.82E-04 Multiple complex diseases PLD5 intron 17554300 rs2055536 chr1 242603059 A G 0.0000996 post-traumatic stress disorder PLD5 intron 22869035 rs2055536 chr1 242603059 A G 9.96E-05 Schizophrenia PLD5 intron 22883433 rs2810030 chr1 242603249 G A 0.0000971 post-traumatic stress disorder PLD5 intron 22869035 rs2810030 chr1 242603249 G A 9.71E-05 Schizophrenia PLD5 intron 22883433 rs2810034 chr1 242606388 T C 4.87E-04 Response to TNF antagonist treatment PLD5 intron 21061259 rs10926745 chr1 242621027 T C 5.85E-04 Response to TNF antagonist treatment PLD5 intron 21061259 rs6673239 chr1 242627621 T A 2.00E-04 Nonalcoholic fatty liver disease PLD5 intron 21423719 rs872216 chr1 242635682 G A 6.67E-04 Multiple complex diseases PLD5 intron 17554300 rs872216 chr1 242635682 G A 5.85E-04 Smoking quantity PLD5 intron 24665060 rs2809987 chr1 242659943 T C 8.45E-04 Myopia (pathological) PLD5 intron 21095009 rs2654856 chr1 242669380 C T 8.27E-04 Alzheimer's disease PLD5 intron 24755620 rs7551349 chr1 242695639 C T 7.76E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7551349 chr1 242695639 C T 5.62E-04 Multiple complex diseases / / 17554300 rs10926781 chr1 242758744 A G 8.86E-04 Multiple complex diseases / / 17554300 rs12123434 chr1 242761026 C T 7.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12123434 chr1 242761026 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7527225 chr1 242765473 G A 6.77E-04 Schizophrenia / / 19197363 rs6674901 chr1 242798937 T A 6.88E-04 Multiple complex diseases / / 17554300 rs10926800 chr1 242801209 C T 9.46E-05 Telomere length / / 21573004 rs10926800 chr1 242801209 C T 1.48E-04 Tourette syndrome / / 22889924 rs1413214 chr1 242805821 G A 3.82E-04 Tourette syndrome / / 22889924 rs1413213 chr1 242805900 C T 3.52E-04 Tourette syndrome / / 22889924 rs6692131 chr1 242854431 T C 2.22E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10803073 chr1 242859680 C T 4.30E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10803073 chr1 242859680 C T 1.10E-05 Urinary metabolites / / 21572414 rs10803074 chr1 242864143 A T 3.93E-05 Bipolar disorder / / 22925353 rs1413202 chr1 242872032 A C 8.02E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1413202 chr1 242872032 A C 2.80E-05 Cognitive test performance / / 20125193 rs1413202 chr1 242872032 A C 4.62E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs10926828 chr1 242873595 T C 2.30E-05 Alcohol consumption (maxi-drinks) / / 24277619 rs6657754 chr1 242873955 C A 4.10E-05 Alcohol consumption (maxi-drinks) / / 24277619 rs6676375 chr1 242874885 T C 8.00E-07 Tuberculosis / / 24057671 rs10803075 chr1 242874959 G A 7.21E-04 Multiple complex diseases / / 17554300 rs2019842 chr1 242917941 C T 4.47E-04 Alzheimer's disease / / 17998437 rs2184186 chr1 242918428 A G 8.35E-04 Alzheimer's disease / / 17998437 rs9943068 chr1 242946169 C T 9.66E-04 Multiple complex diseases / / 17554300 rs914951 chr1 242952078 T G 8.79E-06 Bone mass and geometry / / 17903296 rs12752277 chr1 242955437 C T 1.23E-06 Obesity-related traits / / 23251661 rs12751297 chr1 242955563 G A 1.00E-06 Obesity-related traits / / 23251661 rs2809867 chr1 242956230 A G 1.34E-06 Obesity-related traits / / 23251661 rs1556557 chr1 242980016 G A 1.77E-24 Gender / / 22362730 rs12739153 chr1 242982864 G T 6.06E-15 Gender / / 22362730 rs4658859 chr1 242996817 T G 1.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs2027040 chr1 242997944 G C 1.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs4658860 chr1 243000992 G T 1.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs9428546 chr1 243002546 C T 2.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs914945 chr1 243003189 A C 2.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs914944 chr1 243003522 C T 1.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs914942 chr1 243003907 C T 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs10803092 chr1 243004286 A G 1.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs10926882 chr1 243004326 T C 1.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs10926883 chr1 243004424 G T 3.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs4658862 chr1 243004714 A G 1.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs4658863 chr1 243004789 T C 1.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs6429381 chr1 243005376 T C 2.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs1333692 chr1 243005814 T G 1.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs1333691 chr1 243005986 T C 1.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs12023105 chr1 243006334 C A 3.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs10127533 chr1 243006696 T C 1.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs12143316 chr1 243007084 C T 1.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs12737815 chr1 243008648 A T 1.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs6429382 chr1 243009528 C G 2.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs1413217 chr1 243009592 C T 2.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs10737885 chr1 243010342 A G 2.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs4658500 chr1 243017513 G C 1.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs4658867 chr1 243019476 C T 6.74E-05 Suicide attempts in bipolar disorder / / 21423239 rs4658868 chr1 243019840 C G 1.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs7549075 chr1 243021165 T G 1.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs10926895 chr1 243023342 T G 1.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs6429385 chr1 243024869 G A 1.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs12024121 chr1 243025115 G T 1.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs10926897 chr1 243027762 A G 1.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs10926898 chr1 243027814 G T 2.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs12074294 chr1 243032018 C G 3.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs4658504 chr1 243041047 T C 2.64E-04 Schizophrenia / / 19197363 rs10157714 chr1 243044002 T C 1.45E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6429388 chr1 243044281 A C 1.50E-04 Multiple complex diseases / / 17554300 rs10926906 chr1 243049874 C G 2.09E-05 Schizophrenia / / 19571811 rs4658507 chr1 243056401 G A 5.70E-04 Sarcoidosis / / 19165924 rs2502344 chr1 243070731 G A 6.81E-15 Gender / / 22362730 rs3003542 chr1 243087106 T C 5.53E-04 Fibrinogen / / 17255346 rs10803102 chr1 243114662 G A 1.58E-04 Vaspin levels / / 22907691 rs10803102 chr1 243114662 G A 0.0001579 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs3013386 chr1 243117502 A T 1.20E-05 Urinary metabolites / / 21572414 rs12723357 chr1 243118512 T C 1.87E-14 Gender / / 22362730 rs1081091 chr1 243121042 G C 7.92E-06 Multiple complex diseases / / 17554300 rs3013398 chr1 243142966 C T 8.60E-14 Gender / / 22362730 rs2105146 chr1 243290642 G A 3.00E-06 Bronchopulmonary dysplasia CEP170 intron 23897914 rs2105146 chr1 243290642 G A 3.20E-06 Bronchopulmonary dysplasia CEP170 intron 23897914 rs55716084 chr1 243290642 G A 3.00E-06 Bronchopulmonary dysplasia CEP170 intron 23897914 rs55716084 chr1 243290642 G A 3.20E-06 Bronchopulmonary dysplasia CEP170 intron 23897914 rs3753542 chr1 243304012 T C 9.70E-06 Bronchopulmonary dysplasia CEP170 intron 23897914 rs4658538 chr1 243309191 A G 9.50E-06 Bronchopulmonary dysplasia CEP170 intron 23897914 rs7531823 chr1 243394551 T C 9.23E-04 Response to cytadine analogues (cytosine arabinoside) CEP170 intron 24483146 rs6669104 chr1 243396119 C T 7.86E-04 Response to alcohol consumption (flushing response) CEP170 intron 24277619 rs12741781 chr1 243428152 T G 4.92E-06 Nasopharyngeal carcinoma SDCCAG8 intron 23209447 rs3818802 chr1 243449881 G A 2.44E-05 Schizophrenia SDCCAG8 intron 21926974 rs11807162 chr1 243454680 G A 0.000136 Salmonella-induced pyroptosis SDCCAG8 intron 22837397 rs10926984 chr1 243462153 T G 3.94E-06 Obesity (early onset extreme) SDCCAG8 intron 20421936 rs12145833 chr1 243483754 T G 5.00E-07 Obesity (early onset extreme) SDCCAG8 intron 20421936 rs2802723 chr1 243498312 T C 1.34E-05 Nasopharyngeal carcinoma SDCCAG8 intron 23209447 rs2783963 chr1 243501583 A G 8.68E-06 Obesity (early onset extreme) SDCCAG8 intron 20421936 rs2490393 chr1 243522906 A G 9.58E-05 HIV-1 viral setpoint SDCCAG8 intron 21490045 rs1538774 chr1 243544827 C G 3.00E-08 Schizophrenia SDCCAG8 intron 23974872 rs10927013 chr1 243589156 G T 8.09E-09 Schizophrenia,schizoaffective disorder or bipolar disorder SDCCAG8 intron 24166486 rs10803142 chr1 243598234 G A 3.80E-05 Intelligence (childhood) SDCCAG8 intron 23358156 rs2039839 chr1 243598670 A G 1.28E-08 Schizophrenia,schizoaffective disorder or bipolar disorder SDCCAG8 intron 24166486 rs7551067 chr1 243606579 T A 8.56E-04 Multiple complex diseases SDCCAG8 intron 17554300 rs6703335 chr1 243608967 A G 4.70E-04 Primary sclerosing cholangitis SDCCAG8 intron 19944697 rs6703335 chr1 243608967 A G 5.00E-08 Schizophrenia SDCCAG8 intron 21926974 rs6703335 chr1 243608967 A G 4.00E-09 Schizophrenia,schizoaffective disorder or bipolar disorder SDCCAG8 intron 24166486 rs3006925 chr1 243609927 T C 8.39E-05 HIV-1 viral setpoint SDCCAG8 intron 21490045 rs10803143 chr1 243615589 C T 4.23E-05 Body Composition SDCCAG8 intron pha003012 rs10927025 chr1 243639218 C T 1.40E-05 Urinary metabolites SDCCAG8 intron 21572414 rs2994339 chr1 243641420 A G 5.48E-04 Multiple complex diseases SDCCAG8 intron 17554300 rs2994329 chr1 243647921 C T 2.00E-04 Cognitive impairment induced by topiramate SDCCAG8 intron 22091778 rs6429427 chr1 243657201 T C 2.40E-09 LDL cholesterol AKT3 intron 23063622 rs6429427 chr1 243657201 T C 8.04E-10 Cholesterol,total AKT3 intron 23063622 rs3006927 chr1 243657399 C T 7.16E-04 Type 2 diabetes AKT3 intron 17463246 rs14403 chr1 243663893 C T 2.00E-08 Schizophrenia AKT3 UTR-3 23974872 rs7523742 chr1 243688150 A G 6.75E-05 Type 2 diabetes AKT3 intron 17463246 rs320309 chr1 243781174 A G 8.14E-05 stroke (ischemic) AKT3 intron 17434096 rs320320 chr1 243835186 A G 1.00E-07 Menarche (age at onset) AKT3 intron 23599027 rs320320 chr1 243835186 A G 1.18E-07 Menarche (age at onset) AKT3 intron 23599027 rs320320 chr1 243835186 A G 5.00E-06 Menarche (age at onset) AKT3 intron 23599027 rs10803155 chr1 243894782 A G 1.33E-05 stroke (ischemic) AKT3 intron 17434096 rs1545654 chr1 243916478 A T 1.33E-05 stroke (ischemic) AKT3 intron 17434096 rs897960 chr1 243933568 G A 3.83E-05 stroke (ischemic) AKT3 intron 17434096 rs4132509 chr1 243943084 C A 2.00E-06 RR interval (heart rate) AKT3 intron 20031603 rs4593807 chr1 244004392 G A 3.12E-05 stroke (ischemic) AKT3 intron 17434096 rs4430311 chr1 244015993 C T 6.00E-06 Post-traumatic stress disorder (asjusted for relatedness) / / 23726511 rs2953331 chr1 244024268 A G 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2953329 chr1 244025999 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7553354 chr1 244044810 A C 7.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4658601 chr1 244056489 C T 9.71E-04 Tourette syndrome / / 22889924 rs4658405 chr1 244061500 A G 8.99E-04 Tourette syndrome / / 22889924 rs10927088 chr1 244064564 A G 5.78E-04 Type 2 diabetes / / 17463246 rs11584607 chr1 244069010 A G 7.40E-05 Diabetic retinopathy / / 21441570 rs2454224 chr1 244143789 T A 7.30E-05 Diabetic retinopathy LOC339529 intron 21441570 rs4658609 chr1 244155726 G T 4.57E-05 Glucose levels LOC339529 intron pha003058 rs4658609 chr1 244155726 G T 3.71E-05 Hemoglobin LOC339529 intron pha003096 rs4658609 chr1 244155726 G T 3.67E-05 Hematocrit LOC339529 intron pha003097 rs6671359 chr1 244157930 G A 8.77E-04 Type 2 diabetes LOC339529 intron 17463246 rs479338 chr1 244159143 G A 4.80E-06 Diabetic retinopathy LOC339529 intron 21441570 rs536441 chr1 244160904 G A 1.50E-05 Diabetic retinopathy LOC339529 intron 21441570 rs10927097 chr1 244161794 A G 7.80E-06 Diabetic retinopathy LOC339529 intron 21441570 rs1711347 chr1 244161982 G A 8.50E-07 Diabetic retinopathy LOC339529 intron 21441570 rs520971 chr1 244162694 T C 8.10E-06 Diabetic retinopathy LOC339529 intron 21441570 rs523878 chr1 244163092 G A 1.50E-05 Diabetic retinopathy LOC339529 intron 21441570 rs551361 chr1 244163731 A T 7.80E-06 Diabetic retinopathy LOC339529 intron 21441570 rs12119867 chr1 244164997 T C 2.39E-06 Thiazide-induced adverse metabolic effects in hypertensive patients LOC339529 intron 23400010 rs1009375 chr1 244167131 T C 7.00E-05 Diabetic retinopathy LOC339529 intron 21441570 rs12126763 chr1 244167170 C T 6.63E-06 Thiazide-induced adverse metabolic effects in hypertensive patients LOC339529 intron 23400010 rs12126831 chr1 244167389 C A 6.16E-06 Thiazide-induced adverse metabolic effects in hypertensive patients LOC339529 intron 23400010 rs12119931 chr1 244167665 G T 5.92E-06 Thiazide-induced adverse metabolic effects in hypertensive patients LOC339529 intron 23400010 rs12127679 chr1 244167801 C T 1.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients LOC339529 intron 23400010 rs1319790 chr1 244168236 C T 6.11E-06 Thiazide-induced adverse metabolic effects in hypertensive patients LOC339529 intron 23400010 rs1156644 chr1 244168335 G A,T 5.64E-06 Thiazide-induced adverse metabolic effects in hypertensive patients LOC339529 intron 23400010 rs11582480 chr1 244169011 C A 5.70E-05 Diabetic retinopathy LOC339529 intron 21441570 rs10927099 chr1 244169756 T C 5.55E-06 Thiazide-induced adverse metabolic effects in hypertensive patients LOC339529 intron 23400010 rs512825 chr1 244170194 A G 6.20E-07 Diabetic retinopathy LOC339529 intron 21441570 rs12122270 chr1 244170455 G T 3.19E-06 Thiazide-induced adverse metabolic effects in hypertensive patients LOC339529 intron 23400010 rs11580734 chr1 244173339 G C 1.10E-05 Diabetic retinopathy / / 21441570 rs10927101 chr1 244173872 C A 2.00E-06 Diabetic retinopathy LOC339529 intron 21441570 rs10927102 chr1 244174161 T A 7.30E-06 Diabetic retinopathy / / 21441570 rs476141 chr1 244176424 G T 1.00E-07 Diabetic retinopathy LOC339529 intron 21441570 rs10927113 chr1 244198499 G A 5.73E-04 Multiple complex diseases LOC339529 intron 17554300 rs2454234 chr1 244256545 C G 7.38E-04 Type 2 diabetes / / 17463246 rs2454234 chr1 244256545 C G 3.10E-05 Primary sclerosing cholangitis / / 19944697 rs6695226 chr1 244309299 A G 5.07E-04 Schizophrenia / / 19197363 rs12239526 chr1 244312700 G A 2.07E-04 Acute lung injury / / 22295056 rs913992 chr1 244314476 C T 1.30E-04 Alcohol dependence / / 20201924 rs913992 chr1 244314476 C T 4.40E-04 Alcohol dependence / / 20201924 rs12087666 chr1 244334507 T C 5.32E-04 Multiple complex diseases / / 17554300 rs7522710 chr1 244377850 T C 6.34E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12048859 chr1 244389589 C T 2.31E-05 ldl cholesterol / / pha003076 rs12048859 chr1 244389589 C T 4.41E-05 Cholesterol / / pha003078 rs10429923 chr1 244390492 C A 1.93E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10429924 chr1 244390564 C T 1.00E-06 Schizophrenia / / 22885689 rs879065 chr1 244392845 A G 5.08E-04 Iron levels / / pha002876 rs4297276 chr1 244403107 C T 7.26E-04 Smoking cessation / / 24665060 rs12025435 chr1 244482404 G A 1.08E-05 Smoking initiation / / 24665060 rs12403791 chr1 244498500 T C 1.33E-05 Cognitive performance / / 19734545 rs10927198 chr1 244505481 A T 1.00E-05 Urinary metabolites / / 21572414 rs4658624 chr1 244508697 A G 4.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs4658627 chr1 244511176 G A 9.60E-06 Male-pattern baldness / / 18849994 rs4658627 chr1 244511176 G A 6.00E-06 Asthma (childhood onset) / / 22560479 rs10803199 chr1 244515378 C T 5.41E-05 Alzheimer's disease (age of onset) / / 22005931 rs4658635 chr1 244529403 A G 6.06E-04 Iron levels C1orf100 intron pha002876 rs3101457 chr1 244533214 G A 3.00E-07 Smoking behavior C1orf100 intron 22832964 rs10927230 chr1 244564283 C T 6.50E-06 Urinary metabolites / / 21572414 rs12404398 chr1 244564738 T C 3.40E-06 Urinary metabolites / / 21572414 rs2306084 chr1 244573030 C A 8.51E-06 Obesity-related traits ADSS intron 23251661 rs10927232 chr1 244576507 T C 4.10E-06 Urinary metabolites ADSS intron 21572414 rs10927232 chr1 244576507 T C 6.50E-06 Obesity-related traits ADSS intron 23251661 rs3102460 chr1 244576717 C T 4.00E-06 Obesity-related traits ADSS intron 23251661 rs3101468 chr1 244577558 G A 2.41E-04 Type 2 diabetes ADSS intron 17463246 rs12087973 chr1 244578462 C T 5.92E-06 Obesity-related traits ADSS intron 23251661 rs12408001 chr1 244591695 A G 1.40E-05 Urinary metabolites ADSS intron 21572414 rs4132572 chr1 244592435 T C 6.13E-06 Obesity-related traits ADSS intron 23251661 rs3127462 chr1 244597892 C T 2.84E-04 Stroke ADSS intron pha002886 rs6695703 chr1 244598159 A G 2.20E-06 Urinary metabolites ADSS intron 21572414 rs3003212 chr1 244612252 A G 6.47E-04 Stroke ADSS intron pha002886 rs3003211 chr1 244612984 T C 1.61E-04 Stroke ADSS intron pha002886 rs3006009 chr1 244630447 C T 1.35E-05 Cognitive test performance C1orf101 intron 20125193 rs10927277 chr1 244767326 G C 2.13E-04 Obesity (extreme) C1orf101 intron 21935397 rs7540302 chr1 244775026 C T 4.76E-05 Soluble levels of adhesion molecules C1orf101 intron pha003072 rs10803228 chr1 244777718 A G 2.40E-05 Urinary metabolites C1orf101 intron 21572414 rs1995391 chr1 244809662 A G 1.00E-05 Urinary metabolites / / 21572414 rs987179 chr1 244809936 G A 6.23E-06 Osteoarthritis / / 22763110 rs6429499 chr1 244812498 T C 1.00E-05 Urinary metabolites / / 21572414 rs10927306 chr1 244885285 G A 3.90E-04 Sarcoidosis / / 19165924 rs12119043 chr1 244924191 C G 2.06E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12088062 chr1 244974586 C T 1.50E-07 Glioma (high-grade) / / 19578366 rs12088062 chr1 244974586 C T 2.75E-05 Personality dimensions / / 23903073 rs11801533 chr1 245002430 C A 5.61E-05 Bipolar Disorder COX20 intron pha002863 rs11579106 chr1 245008115 C T 5.52E-04 Celiac disease COX20 UTR-3 23936387 rs4658673 chr1 245042312 G A 1.24E-04 Parkinson's disease / / 17052657 rs4658673 chr1 245042312 G A 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs756034 chr1 245099499 G A 5.83E-04 Multiple complex diseases / / 17554300 rs2050632 chr1 245159567 C T 3.70E-04 Cognition,early reading ability EFCAB2 intron 17684495 rs11580510 chr1 245205876 C G,T 1.84E-04 Alzheimer's disease EFCAB2 intron 24755620 rs638797 chr1 245217530 T G 2.33E-04 Type 2 diabetes EFCAB2 intron 17463246 rs4658693 chr1 245239342 T C 6.57E-04 Multiple complex diseases EFCAB2 intron 17554300 rs6429521 chr1 245246340 G A 0.0000221 Polycystic ovary syndrome EFCAB2 intron 22951595 rs6429521 chr1 245246340 G A 2.21E-05 Intracranial aneurysm EFCAB2 intron 22961961 rs2886208 chr1 245271418 G A 3.63E-04 Smoking initiation EFCAB2 intron 24665060 rs3897400 chr1 245282154 C T 7.30E-04 Smoking initiation EFCAB2 intron 24665060 rs6693918 chr1 245283910 C T 4.52E-05 Monocyte chemoattractant protein-1 EFCAB2 intron pha003071 rs4658702 chr1 245290111 G A 7.00E-06 Urinary metabolites / / 21572414 rs4233443 chr1 245307601 C T 7.60E-05 Diabetic retinopathy / / 21441570 rs6671796 chr1 245358619 G A 2.59E-05 Telomere length KIF26B intron 21573004 rs6428904 chr1 245363423 A G 4.48E-06 HDL cholesterol KIF26B intron pha003074 rs6428904 chr1 245363423 A G 5.02E-06 HDL cholesterol KIF26B intron pha003075 rs7527554 chr1 245371026 A G 1.22E-05 HDL cholesterol KIF26B intron pha003075 rs4465244 chr1 245381632 T A 2.72E-04 Multiple complex diseases KIF26B intron 17554300 rs10924125 chr1 245388149 C T 8.57E-04 Stroke KIF26B intron pha002886 rs4658732 chr1 245418431 C G 3.48E-04 Aortic root size KIF26B intron 21223598 rs10802205 chr1 245449935 C T 1.89E-05 Hearing impairment KIF26B intron 19047183 rs11811491 chr1 245477121 A G 6.78E-05 IgE levels KIF26B intron 17255346 rs4658748 chr1 245481432 G A 3.69E-05 Height KIF26B intron pha003011 rs6428914 chr1 245486835 C A 5.34E-05 Insulin-related traits KIF26B intron pha003063 rs4658753 chr1 245491406 C T 0.0000911 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes KIF26B intron 22628534 rs1148917 chr1 245528415 G A 0.000228901 Hypertension (early onset hypertension) KIF26B intron 22479346 rs1173847 chr1 245528780 A C 3.39E-04 Amyotrophic lateral sclerosis (sporadic) KIF26B intron 24529757 rs1093961 chr1 245576457 T C 4.79E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) KIF26B intron 17982456 rs1704415 chr1 245593672 G A 3.77E-05 Sarcoidosis KIF26B intron 19165924 rs1093937 chr1 245608819 G A 3.59E-04 Alzheimer's disease (late onset) KIF26B intron 21379329 rs12094249 chr1 245612896 G A 1.32E-04 Alzheimer's disease (late onset) KIF26B intron 21379329 rs12035552 chr1 245621118 C T 3.42E-06 Triglycerides KIF26B intron 19074352 rs12035552 chr1 245621118 C T 3.42E-06 Polyunsaturated fatty acid levels,in plasma KIF26B intron 19148276 rs669314 chr1 245625652 C T 2.34E-04 Smoking quantity KIF26B intron 24665060 rs1173657 chr1 245626039 A G 2.40E-04 Response to taxane treatment (placlitaxel) KIF26B intron 23006423 rs1093932 chr1 245626278 T C 9.70E-04 Response to taxane treatment (placlitaxel) KIF26B intron 23006423 rs1173658 chr1 245626920 C T 2.40E-04 Response to taxane treatment (placlitaxel) KIF26B intron 23006423 rs1538472 chr1 245636059 A G 4.54E-05 Breast cancer KIF26B intron pha002853 rs6662923 chr1 245641061 G A 0.0006211 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KIF26B intron 23233654 rs6662923 chr1 245641061 G A 6.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIF26B intron 23233662 rs6687098 chr1 245641147 A G 0.000609 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KIF26B intron 23233654 rs6687098 chr1 245641147 A G 6.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIF26B intron 23233662 rs10924209 chr1 245645242 T G 0.0004823 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KIF26B intron 23233654 rs10924209 chr1 245645242 T G 4.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIF26B intron 23233662 rs7520037 chr1 245646929 C A 2.83E-04 Cholesterol KIF26B intron 17255346 rs7520037 chr1 245646929 C A 0.000774 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KIF26B intron 23233654 rs7520037 chr1 245646929 C A 7.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIF26B intron 23233662 rs12121903 chr1 245647361 G A 0.0007766 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KIF26B intron 23233654 rs12121903 chr1 245647361 G A 7.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIF26B intron 23233662 rs12136713 chr1 245647425 C T 0.0006586 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KIF26B intron 23233654 rs12136713 chr1 245647425 C T 6.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIF26B intron 23233662 rs2363902 chr1 245654625 C T 1.60E-04 Statin-induced myopathy KIF26B intron 21826682 rs1416472 chr1 245677320 C T 2.21E-05 Coronary restenosis KIF26B intron 21878436 rs6662614 chr1 245681650 G A 6.43E-05 Smoking quantity KIF26B intron 24665060 rs9919234 chr1 245703990 G T 3.02E-04 Taste perception KIF26B intron 22132133 rs9919234 chr1 245703990 G T 3.77E-06 Hippocampal volume in schizophrenia KIF26B intron 23805179 rs10924245 chr1 245733608 G T 7.00E-06 Schizophrenia KIF26B intron 23212062 rs1715794 chr1 245768212 C T 1.75E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) KIF26B intron 24236485 rs1715794 chr1 245768212 C T 3.90E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) KIF26B intron 24236485 rs10924249 chr1 245770642 G T 5.22E-05 Alzheimer's disease (age of onset) KIF26B intron 22005931 rs7555351 chr1 245772529 A G 4.72E-05 Smoking cessation KIF26B intron 24665060 rs10754458 chr1 245774993 A G 3.75E-05 Coronary heart disease KIF26B intron pha003056 rs10924254 chr1 245776322 G T 1.40E-04 Smoking cessation KIF26B intron 24665060 rs1715789 chr1 245779716 A G 1.54E-04 Type 2 diabetes KIF26B intron 17463246 rs1715784 chr1 245781414 G A 2.90E-05 Urinary metabolites KIF26B intron 21572414 rs1715783 chr1 245781591 G T 2.20E-05 Urinary metabolites KIF26B intron 21572414 rs1771513 chr1 245786747 A G 1.80E-05 Urinary metabolites KIF26B intron 21572414 rs7527246 chr1 245816347 T C 1.27E-04 Type 2 diabetes KIF26B intron 17463246 rs3737920 chr1 245830019 G A 1.35E-04 Type 2 diabetes KIF26B intron 17463246 rs10924303 chr1 245847034 C T 6.50E-09 Glioma (high-grade) KIF26B intron 19578366 rs6700721 chr1 245854173 G A 2.69E-04 Multiple complex diseases KIF26B intron 17554300 rs6701023 chr1 245854503 G C 4.15E-04 Multiple complex diseases KIF26B intron 17554300 rs10924306 chr1 245857065 G A 7.21E-04 Multiple complex diseases KIF26B intron 17554300 rs2185368 chr1 245915582 A G 2.71E-04 Response to taxane treatment (placlitaxel) SMYD3 intron 23006423 rs12088988 chr1 245926038 T G 6.50E-04 Multiple complex diseases SMYD3 intron 17554300 rs2817506 chr1 245926485 C T 4.47E-04 Multiple complex diseases SMYD3 intron 17554300 rs2791380 chr1 245928778 G C 3.00E-04 Multiple complex diseases SMYD3 intron 17554300 rs2247524 chr1 245932792 G A 3.01E-04 Response to taxane treatment (placlitaxel) SMYD3 intron 23006423 rs2817478 chr1 245960086 T C 8.82E-05 Insulin resistance SMYD3 intron 21901158 rs2791393 chr1 245960306 G A 7.20E-06 Urinary metabolites SMYD3 intron 21572414 rs2791393 chr1 245960306 G A 4.53E-05 Insulin resistance SMYD3 intron 21901158 rs2817475 chr1 245962202 C T 4.67E-04 Nicotine smoking SMYD3 intron 19268276 rs10924342 chr1 245989211 C G 4.04E-05 Multiple complex diseases SMYD3 intron 17554300 rs7537586 chr1 245997603 A G 8.96E-05 Multiple complex diseases SMYD3 intron 17554300 rs6689627 chr1 245997919 T C 3.35E-04 Multiple complex diseases SMYD3 intron 17554300 rs9728248 chr1 246005798 C A 1.84E-04 Substance dependence SMYD3 intron 21818250 rs10924366 chr1 246027410 T C 9.35E-04 Multiple complex diseases SMYD3 intron 17554300 rs4654164 chr1 246054787 G T 3.52E-04 Lung function (forced vital capacity) SMYD3 intron 24023788 rs9728343 chr1 246057046 C T 2.87E-04 Lung function (forced vital capacity) SMYD3 intron 24023788 rs4654068 chr1 246058909 T C 1.79E-05 Height SMYD3 intron pha003010 rs4654068 chr1 246058909 T C 7.99E-07 Height SMYD3 intron pha003011 rs4654068 chr1 246058909 T C 3.34E-05 Waist Circumference SMYD3 intron pha003023 rs6426327 chr1 246089811 G A 8.41E-05 Bipolar disorder SMYD3 intron 19488044 rs2275312 chr1 246090818 C T 5.28E-05 Bipolar disorder and schizophrenia SMYD3 intron 20889312 rs2275313 chr1 246091115 C G 6.74E-05 Bipolar disorder SMYD3 intron 19488044 rs2275313 chr1 246091115 C G 6.18E-05 Bipolar disorder and schizophrenia SMYD3 intron 20889312 rs2275313 chr1 246091115 C G 6.98E-05 Bipolar Disorder SMYD3 intron pha002858 rs7355113 chr1 246097984 T C 9.30E-05 Response to statin therapy SMYD3 intron 20339536 rs12131373 chr1 246098014 C T 4.74E-04 Obesity (extreme) SMYD3 intron 21935397 rs12562286 chr1 246099686 G A 9.40E-05 Response to statin therapy SMYD3 intron 20339536 rs1544149 chr1 246125283 C T 1.82E-04 HIV-1 viral setpoint SMYD3 intron 17641165 rs4654179 chr1 246144436 C T 6.53E-05 Diabetic nephropathy SMYD3 intron pha002864 rs1538294 chr1 246146328 A G 7.53E-04 HIV-1 viral setpoint SMYD3 intron 17641165 rs4654180 chr1 246148791 C A 3.68E-05 Diabetic nephropathy SMYD3 intron pha002864 rs10802308 chr1 246152478 C T 1.29E-04 Multiple complex diseases SMYD3 intron 17554300 rs2105158 chr1 246162256 C A 2.06E-05 Diabetic nephropathy SMYD3 intron pha002864 rs12084862 chr1 246203214 G A 8.20E-06 Migraine SMYD3 intron 20802479 rs6693295 chr1 246223120 C T 6.00E-06 Migraine with aura SMYD3 intron 23793025 rs6693295 chr1 246223120 C T 9.00E-06 Migraine - clinic-based SMYD3 intron 23793025 rs61839075 chr1 246241574 G T 0.00003939 Sarcoidosis SMYD3 intron 22952805 rs6692380 chr1 246310748 T G 6.11E-04 Type 2 diabetes SMYD3 intron 17463246 rs4654092 chr1 246319482 A G 1.74E-05 Prostate cancer SMYD3 intron pha002877 rs4654216 chr1 246330176 C T 7.70E-04 Multiple complex diseases SMYD3 intron 17554300 rs10924545 chr1 246364592 T C 9.15E-04 Multiple complex diseases SMYD3 intron 17554300 rs7539358 chr1 246369599 A G 7.08E-04 Multiple complex diseases SMYD3 intron 17554300 rs10802346 chr1 246372880 G C 7.17E-05 Fractional exhaled nitric oxide (childhood) SMYD3 intron 24315451 rs10802346 chr1 246372880 G C 8.00E-06 Fractional exhaled nitric oxide (childhood) SMYD3 intron 24315451 rs10924556 chr1 246378041 A G 4.88E-04 Multiple complex diseases SMYD3 intron 17554300 rs4636424 chr1 246393636 A G 4.59E-04 Multiple complex diseases SMYD3 intron 17554300 rs10924576 chr1 246394175 T C 2.25E-04 Multiple complex diseases SMYD3 intron 17554300 rs10924577 chr1 246394232 T C 3.85E-04 Multiple complex diseases SMYD3 intron 17554300 rs10924579 chr1 246394320 G A 3.41E-04 Multiple complex diseases SMYD3 intron 17554300 rs2027372 chr1 246454368 A G 2.40E-06 Glioma (high-grade) SMYD3 intron 19578366 rs10924690 chr1 246483783 G A 3.40E-08 Glioma (high-grade) SMYD3 intron 19578366 rs10924692 chr1 246489492 C T 5.85E-04 Multiple complex diseases SMYD3 intron 17554300 rs4654103 chr1 246525619 T G 1.60E-05 Glioma (high-grade) SMYD3 intron 19578366 rs1339965 chr1 246550861 A G 5.92E-04 Heart Failure SMYD3 intron pha002885 rs10924727 chr1 246586841 A C 9.05E-06 Creatinine levels SMYD3 intron pha003069 rs10924730 chr1 246602240 C T 2.28E-05 Multiple complex diseases SMYD3 intron 17554300 rs7517207 chr1 246657606 A G 7.85E-04 Smoking initiation SMYD3 intron 24665060 rs11800820 chr1 246661236 C T 4.00E-06 Obesity-related traits SMYD3 intron 23251661 rs6668455 chr1 246664442 T G 7.82E-04 Suicide attempts in bipolar disorder SMYD3 intron 21423239 rs7520453 chr1 246670481 C G 7.27E-04 Suicide attempts in bipolar disorder SMYD3 missense 21423239 rs3120701 chr1 246706139 C T 1.86E-05 Alcohol and nictotine co-dependence TFB2M intron 20158304 rs4545307 chr1 246708846 G A 3.46E-04 Type 2 diabetes TFB2M intron 17463246 rs6663956 chr1 246757449 T C 2.27E-04 Multiple complex diseases CNST intron 17554300 rs6663956 chr1 246757449 T C 1.64E-04 Lymphocyte counts CNST intron 22286170 rs3129539 chr1 246801648 G A 9.61E-04 Parkinson's disease CNST intron 17052657 rs3129539 chr1 246801648 G A 1.07E-04 Multiple complex diseases CNST intron 17554300 rs7534740 chr1 246823857 G A 1.24E-05 Femoral neck bone geometry CNST intron 22087292 rs4130648 chr1 246829616 T C 2.45E-04 Type 2 diabetes CNST UTR-3 17463246 rs4335342 chr1 246830488 T C 4.91E-04 Type 2 diabetes CNST UTR-3 17463246 rs6657743 chr1 246893948 C T 4.95E-05 Post-operative nausea and vomiting SCCPDH intron 21694509 rs7526237 chr1 246898134 C T 1.23E-04 Osteoarthritis (knee and hip) SCCPDH intron 21177295 rs7526237 chr1 246898134 C T 3.76E-04 Osteoarthritis (knee and hip) SCCPDH intron 21177295 rs7526237 chr1 246898134 C T 4.53E-05 Osteoarthritis (knee and hip) SCCPDH intron 21177295 rs4130317 chr1 246919472 C T 8.09E-04 Myocardial Infarction SCCPDH intron pha002873 rs6685364 chr1 246939943 T C 7.04E-04 Myocardial Infarction LOC100130097 missense pha002873 rs11584835 chr1 246973094 A G 7.10E-04 White matter integrity / / 22425255 rs7515514 chr1 246973156 G A 7.78E-04 White matter integrity / / 22425255 rs7524529 chr1 246973158 C T 7.78E-04 White matter integrity / / 22425255 rs7531852 chr1 246973283 T C 8.63E-04 White matter integrity / / 22425255 rs3007302 chr1 246992317 G A 7.37E-04 Multiple complex diseases / / 17554300 rs2996550 chr1 247000748 A G 1.06E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6685066 chr1 247001166 A G 7.52E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs5021094 chr1 247006160 G T 7.27E-05 Response to taxane treatment (placlitaxel) AHCTF1 intron 23006423 rs6688227 chr1 247010734 C T 6.85E-05 Response to taxane treatment (placlitaxel) AHCTF1 intron 23006423 rs6426183 chr1 247012724 T C 4.60E-06 Ankle-brachial index AHCTF1 intron 22199011 rs7530860 chr1 247018184 A G 4.35E-04 Response to taxane treatment (placlitaxel) AHCTF1 intron 23006423 rs1630829 chr1 247023866 C T 6.56E-04 Response to taxane treatment (placlitaxel) AHCTF1 intron 23006423 rs2642990 chr1 247048834 T C 5.26E-04 Suicide attempts in bipolar disorder AHCTF1 missense 21423239 rs1779969 chr1 247069949 T C 0.00079 Erectile dysfunction after radiotherapy for prostate cancer AHCTF1 intron 23021708 rs1039010 chr1 247081383 A G 8.42E-04 Suicide attempts in bipolar disorder AHCTF1 intron 21423239 rs6673828 chr1 247139343 G A 1.91E-04 Response to taxane treatment (placlitaxel) ZNF695 intron 23006423 rs1691228 chr1 247142532 C T 8.10E-06 Digit length ratio ZNF695 intron 20303062 rs34759714 chr1 247146733 G GT 5.50E-04 Urinary metabolites ZNF695 intron 21572414 rs4971307 chr1 247188448 C T 2.40E-05 Urinary metabolites ZNF670-ZNF695 intron 21572414 rs10924897 chr1 247202032 G T 4.68E-06 Response to taxane treatment (placlitaxel) ZNF670 intron 23006423 rs7547915 chr1 247203606 T C 4.68E-06 Response to taxane treatment (placlitaxel) ZNF670 intron 23006423 rs12141355 chr1 247204494 G C 4.68E-06 Response to taxane treatment (placlitaxel) ZNF670 intron 23006423 rs7549105 chr1 247205056 A G 4.42E-05 Response to taxane treatment (placlitaxel) ZNF670 intron 23006423 rs4925540 chr1 247214878 A C 2.00E-06 Response to taxane treatment (docetaxel) ZNF670 intron 23006423 rs1573897 chr1 247215054 T C 2.00E-05 Response to taxane treatment (placlitaxel) ZNF670 intron 23006423 rs4634944 chr1 247225034 T C 4.68E-06 Response to taxane treatment (placlitaxel) ZNF670 intron 23006423 rs10924899 chr1 247226344 G A 4.47E-04 Response to taxane treatment (placlitaxel) ZNF670 intron 23006423 rs7542852 chr1 247226986 T G 4.34E-06 Response to taxane treatment (placlitaxel) ZNF670 intron 23006423 rs4925622 chr1 247240863 T C 6.69E-05 Response to taxane treatment (placlitaxel) ZNF670 intron 23006423 rs12135374 chr1 247251453 A G 3.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6669242 chr1 247251482 A G 1.74E-04 Alzheimer's disease (late onset) / / 21379329 rs6426220 chr1 247276394 A G 4.17E-05 Heart Rate / / pha003051 rs12093759 chr1 247305873 C T 4.91E-05 Alzheimer's disease (late onset) ZNF124 intron 21379329 rs7521596 chr1 247308691 T C 6.20E-05 Alzheimer's disease (late onset) ZNF124 intron 21379329 rs11806327 chr1 247320868 G A 2.41E-05 Multiple complex diseases ZNF124 intron 17554300 rs6659481 chr1 247344204 A T 1.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs3738443 chr1 247348189 C T 4.00E-06 Alcohol dependence / / 21314694 rs10754538 chr1 247352621 T C 8.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs10924967 chr1 247390862 G A 3.51E-04 Multiple complex diseases / / 17554300 rs1192835 chr1 247409018 A C 1.16E-04 Hearing function / / 17255346 rs1771928 chr1 247438521 C T 2.93E-05 Hearing function / / 17255346 rs12023478 chr1 247450565 C T 1.63E-04 Celiac disease / / 23936387 rs1057996 chr1 247459414 C T 2.27E-05 Hearing function / / 17255346 rs875883 chr1 247460356 C T 1.40E-05 Urinary metabolites / / 21572414 rs2153631 chr1 247462048 A G 5.70E-06 Urinary metabolites / / 21572414 rs9725334 chr1 247462273 A G 5.60E-06 Urinary metabolites / / 21572414 rs1616299 chr1 247462701 C T 1.70E-05 Urinary metabolites / / 21572414 rs12023326 chr1 247471121 T C 2.13E-04 Celiac disease ZNF496 intron 23936387 rs139561401 chr1 247471846 G A 0.000058 Breast cancer ZNF496 missense 23555315 rs10924984 chr1 247485932 A G 3.46E-05 Hearing function ZNF496 intron 17255346 rs6692645 chr1 247486421 G C 7.90E-06 Urinary metabolites ZNF496 intron 21572414 rs6426239 chr1 247486736 C T 2.13E-04 Celiac disease ZNF496 intron 23936387 rs6690864 chr1 247490707 G A 2.15E-04 Celiac disease ZNF496 intron 23936387 rs10924987 chr1 247491143 C T 9.91E-05 Celiac disease ZNF496 intron 23936387 rs10924990 chr1 247507908 C T 1.70E-05 Urinary metabolites / / 21572414 rs10399672 chr1 247536083 C T 9.42E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11802371 chr1 247542838 A G 1.11E-04 Diabetic nephropathy / / pha002866 rs7555997 chr1 247547334 C A 3.46E-05 Depression (quantitative trait) / / 23290196 rs7529058 chr1 247575768 G A 6.65E-04 Type 2 diabetes / / 17463246 rs7529058 chr1 247575768 G A 8.11E-04 Alzheimer's disease / / 17998437 rs10925015 chr1 247583677 G C 8.00E-06 Word reading NLRP3 intron 23738518 rs4925650 chr1 247584075 G A 8.40E-06 Word reading NLRP3 intron 23738518 rs1539019 chr1 247600301 A C 1.00E-08 Fibrinogen NLRP3 intron 20031576 rs1539019 chr1 247600301 A C 7.74E-07 Fibrinogen NLRP3 intron 20978265 rs12143966 chr1 247601357 G A 1.10E-05 Urinary metabolites NLRP3 intron 21572414 rs12239046 chr1 247601595 T C 3.26E-07 Fibrinogen NLRP3 intron 20978265 rs12239046 chr1 247601595 T C 1.00E-15 C-reactive protein NLRP3 intron 21300955 rs4925659 chr1 247603463 G A 5.26E-08 Fibrinogen NLRP3 intron 20978265 rs10157379 chr1 247605599 C T 1.00E-19 Fibrinogen NLRP3 intron 23969696 rs12065526 chr1 247614407 G A 7.51E-04 Smoking cessation OR2B11 missense 24665060 rs12745508 chr1 247617979 G A,C,T 4.20E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs10754561 chr1 247622800 T C 4.11E-04 Multiple complex diseases / / 17554300 rs4604732 chr1 247623872 C T 2.00E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs6663238 chr1 247624971 C T 2.70E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4472786 chr1 247636518 G A 6.20E-05 Gallbladder cancer / / 22318345 rs10754564 chr1 247662398 T C 6.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4472787 chr1 247666165 A G 2.43E-04 Multiple complex diseases / / 17554300 rs7550918 chr1 247675559 C T 3.00E-11 Platelet counts / / 22139419 rs7550918 chr1 247675559 C T 4.00E-05 Platelet counts / / 24026423 rs1881797 chr1 247689532 C T 7.00E-06 Acute lymphoblastic leukemia (childhood) LOC148824 intron 19684603 rs1881797 chr1 247689532 C T 7.00E-06 Nasopharyngeal carcinoma LOC148824 intron 20512145 rs1105489 chr1 247710867 G A 2.36E-04 White matter integrity / / 22425255 rs3844081 chr1 247723670 C T 7.84E-05 Body Fat Distribution C1orf150 intron pha003017 rs1151694 chr1 247728962 C T 2.53E-05 ldl cholesterol C1orf150 intron pha003077 rs1151694 chr1 247728962 C T 2.89E-05 Cholesterol C1orf150 intron pha003083 rs10925083 chr1 247745227 C T 1.48E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10802523 chr1 247745313 G T 2.08E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1176046 chr1 247748235 C T 5.53E-05 ldl cholesterol / / pha003077 rs1176046 chr1 247748235 C T 5.32E-05 Cholesterol / / pha003083 rs868724 chr1 247753207 G T 3.50E-05 Response to statin therapy / / 20339536 rs1151685 chr1 247753334 A G 3.50E-05 Response to statin therapy / / 20339536 rs4002806 chr1 247761306 T C 4.00E-05 Response to statin therapy / / 20339536 rs7523061 chr1 247762328 C T 4.20E-05 Response to statin therapy / / 20339536 rs7523061 chr1 247762328 C T 8.74E-05 Myopia (pathological) / / 21640322 rs4925690 chr1 247764393 A G 7.60E-05 Response to statin therapy / / 20339536 rs147517990 chr1 247769412 C A 0.00081 Breast cancer OR2G3 missense 23555315 rs1144815 chr1 247781569 C T 8.90E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1144812 chr1 247785143 T C 5.52E-04 Multiple complex diseases / / 17554300 rs61115794 chr1 247795252 C A,G 1.11E-13 Metabolite levels / / 22286219 rs28503794 chr1 247802038 G C 9.67E-05 Cognitive test performance / / 20125193 rs1176067 chr1 247849862 G C 2.90E-05 Urinary metabolites / / 21572414 rs7553300 chr1 247896286 G A 1.90E-05 Urinary metabolites / / 21572414 rs2892286 chr1 247967505 G A 9.11E-04 Type 2 diabetes / / 17463246 rs2892286 chr1 247967505 G A 1.13E-04 Multiple complex diseases / / 17554300 rs10788727 chr1 247999379 T C 6.82E-04 Aortic root size / / 21223598 rs10888255 chr1 248004687 C G 2.68E-04 Response to statin treatment (atorvastatin),change in cholesterol levels OR11L1 missense 20031582 rs10888256 chr1 248004775 C T 3.69E-04 Response to statin treatment (atorvastatin),change in cholesterol levels OR11L1 missense 20031582 rs4607924 chr1 248004848 G C 2.38E-04 Response to statin treatment (atorvastatin),change in cholesterol levels OR11L1 missense 20031582 rs6690724 chr1 248008668 C T 3.76E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1339847 chr1 248039294 G A 1.99E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy TRIM58 missense 23834954 rs3811444 chr1 248039451 C T 6.00E-09 Platelet counts TRIM58 missense 22139419 rs3811444 chr1 248039451 C T 5.00E-10 Red blood cell traits TRIM58 missense 23222517 rs4925753 chr1 248040104 C T 5.36E-05 Hypertension TRIM58 UTR-3 pha003041 rs11204538 chr1 248046272 C T 2.00E-08 Blood cell counts and other traits / / 20139978 rs11204538 chr1 248046272 C T 2.33E-08 Blood cell counts and other traits / / 20139978 rs10888267 chr1 248059423 C T 9.66E-06 Longevity OR2W3 missense 20304771 rs6695104 chr1 248060894 C A 3.90E-05 HDL particle features / / pha002900 rs2225891 chr1 248111078 T C 6.17E-04 Smoking quantity OR2L13 intron 24665060 rs10888287 chr1 248117416 T G 1.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OR2L13 intron 20877124 rs10888287 chr1 248117416 T G 5.53E-05 Diabetic nephropathy OR2L13 intron 21150874 rs10888287 chr1 248117416 T G 5.03E-04 Type 2 diabetes OR2L13 intron 22238593 rs10888307 chr1 248124660 G T 7.78E-05 Post-operative nausea and vomiting OR2L13 intron 21694509 rs11204575 chr1 248124858 G A 5.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OR2L13 intron 20877124 rs12041241 chr1 248134289 C A 1.67E-05 Parkinson's disease (motor and cognition) OR2L13 intron 22658654 rs12041241 chr1 248134289 C A 1.67E-05 Immune response to anthrax vaccine OR2L13 intron 22658931 rs4451578 chr1 248138217 T G 3.18E-05 Parkinson's disease (motor and cognition) OR2L13 intron 22658654 rs4451578 chr1 248138217 T G 3.18E-05 Immune response to anthrax vaccine OR2L13 intron 22658931 rs4268383 chr1 248138520 A G 3.17E-04 Sudden cardiac arrest OR2L13 intron 21658281 rs4268383 chr1 248138520 A G 3.18E-05 Parkinson's disease (motor and cognition) OR2L13 intron 22658654 rs4268383 chr1 248138520 A G 3.18E-05 Immune response to anthrax vaccine OR2L13 intron 22658931 rs11576203 chr1 248148188 C T 1.07E-04 Lung function (forced expiratory volume in 1 second) OR2L13 intron 24023788 rs11576203 chr1 248148188 C T 3.96E-04 Lung function (forced vital capacity) OR2L13 intron 24023788 rs1933162 chr1 248179029 C T 3.69E-04 Lung function (forced vital capacity) OR2L13 intron 24023788 rs7531785 chr1 248210872 C T 0.000636 Salmonella-induced pyroptosis OR2L13 intron 22837397 rs7527770 chr1 248227201 A C 6.28E-05 Hemoglobin OR2L13 intron pha003098 rs7527770 chr1 248227201 A C 1.37E-05 Erythrocyte counts OR2L13 intron pha003099 rs10749643 chr1 248264018 C T 9.14E-05 HIV-1 control / / 20041166 rs4523547 chr1 248341792 C A 6.18E-05 Erythrocyte counts / / pha003099 rs7537031 chr1 248342837 C A 9.77E-07 Common traits (Other) / / 20585627 rs9435891 chr1 248344598 T C 1.95E-09 Common traits (Other) / / 20585627 rs4615870 chr1 248349215 C T 4.29E-05 Panic disorder / / 19165232 rs10788759 chr1 248350776 A G 1.78E-09 Common traits (Other) / / 20585627 rs7550630 chr1 248362311 C T 2.04E-15 Common traits (Other) / / 20585627 rs4916113 chr1 248377292 C T 3.09E-15 Common traits (Other) / / 20585627 rs7349159 chr1 248386242 C T 6.03E-14 Common traits (Other) / / 20585627 rs4642918 chr1 248411057 G T 1.60E-05 Glioma (high-grade) / / 19578366 rs4642918 chr1 248411057 G T 7.59E-14 Common traits (Other) / / 20585627 rs6587440 chr1 248415662 A G 3.50E-05 Glioma (high-grade) / / 19578366 rs6587440 chr1 248415662 A G 1.41E-20 Common traits (Other) / / 20585627 rs10888354 chr1 248455512 G A 3.35E-05 Glucose levels / / pha003057 rs4309013 chr1 248480768 C T 1.10E-05 Glioma (high-grade) / / 19578366 rs4309013 chr1 248480768 C T 5.37E-23 Common traits (Other) / / 20585627 rs7555310 chr1 248487638 A G 5.60E-05 Glioma (high-grade) OR2M7 missense 19578366 rs7555310 chr1 248487638 A G 1.91E-22 Common traits (Other) OR2M7 missense 20585627 rs4559542 chr1 248489980 C T 1.78E-08 Common traits (Other) / / 20585627 rs4244187 chr1 248493511 T C 9.55E-23 Common traits (Other) / / 20585627 rs4481887 chr1 248496863 A G 7.00E-24 Common traits (Other) / / 20585627 rs1538703 chr1 248519821 T G 2.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs946761 chr1 248521032 T C 6.73E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs1544175 chr1 248524262 G A 7.94E-09 Common traits (Other) / / 20585627 rs6587475 chr1 248578622 C T 9.14E-05 Cognitive decline / / 22054870 rs4916176 chr1 248860641 A C 5.06E-09 Longevity,exceptional / / 20595579 rs14851 chr1 249104845 G T 0.000493 Salmonella-induced pyroptosis SH3BP5L UTR-3 22837397 rs11205415 chr1 249120684 T G 1.10E-06 Urinary metabolites / / 21572414 rs12032643 chr1 249168436 G A 1.00E-09 Myopia (pathological) / / 23049088 rs11542478 chr2 38938 A C 9.00E-06 Information processing speed FAM110C UTR-3 21130836 rs11542478 chr2 38938 A C 6.16E-04 Suicide attempts in bipolar disorder FAM110C UTR-3 21423239 rs436446 chr2 106409 T C 1.92E-06 Suicide attempts in bipolar disorder / / 21423239 rs300797 chr2 107140 G A 1.93E-06 Suicide attempts in bipolar disorder / / 21423239 rs300780 chr2 110819 C T 4.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs300778 chr2 111964 C A 1.91E-06 Suicide attempts in bipolar disorder / / 21423239 rs300774 chr2 112496 A C 2.99E-05 Type 2 diabetes / / 17463246 rs300774 chr2 112496 A C 5.00E-08 Suicide attempts in bipolar disorder / / 21423239 rs300773 chr2 115035 C T 1.60E-05 Type 2 diabetes / / 17463246 rs300773 chr2 115035 C T 5.79E-06 Suicide attempts in bipolar disorder / / 21423239 rs393008 chr2 125639 A G 5.73E-06 Suicide attempts in bipolar disorder / / 21423239 rs441469 chr2 129028 G A 6.33E-05 Type 2 diabetes / / 17463246 rs441469 chr2 129028 G A 6.90E-06 Suicide attempts in bipolar disorder / / 21423239 rs375613 chr2 130618 G A,C 6.54E-05 Type 2 diabetes / / 17463246 rs375613 chr2 130618 G A,C 7.94E-06 Suicide attempts in bipolar disorder / / 21423239 rs300729 chr2 131788 G C 3.84E-05 Type 2 diabetes / / 17463246 rs300729 chr2 131788 G C 7.97E-06 Suicide attempts in bipolar disorder / / 21423239 rs300728 chr2 131828 G A 7.98E-06 Suicide attempts in bipolar disorder / / 21423239 rs300727 chr2 132469 C A 1.02E-05 Suicide attempts in bipolar disorder / / 21423239 rs300726 chr2 132490 C G 1.04E-05 Suicide attempts in bipolar disorder / / 21423239 rs300723 chr2 134131 C T 1.05E-05 Suicide attempts in bipolar disorder / / 21423239 rs300722 chr2 134249 A C 2.18E-05 Type 2 diabetes / / 17463246 rs300722 chr2 134249 A C 8.92E-06 Suicide attempts in bipolar disorder / / 21423239 rs300721 chr2 134436 A T 1.39E-05 Suicide attempts in bipolar disorder / / 21423239 rs300720 chr2 134472 A G 1.06E-05 Suicide attempts in bipolar disorder / / 21423239 rs300719 chr2 136203 C T 9.94E-06 Suicide attempts in bipolar disorder / / 21423239 rs300717 chr2 136638 G A 1.06E-05 Suicide attempts in bipolar disorder / / 21423239 rs300715 chr2 137962 T C 1.03E-05 Suicide attempts in bipolar disorder / / 21423239 rs300712 chr2 138903 A T 9.00E-06 Suicide attempts in bipolar disorder / / 21423239 rs300710 chr2 139574 T C 6.33E-05 Type 2 diabetes / / 17463246 rs300710 chr2 139574 T C 7.60E-06 Suicide attempts in bipolar disorder / / 21423239 rs300709 chr2 139743 A G 6.66E-05 Type 2 diabetes / / 17463246 rs300709 chr2 139743 A G 2.11E-05 Suicide attempts in bipolar disorder / / 21423239 rs300709 chr2 139743 A G 2.00E-05 Urinary metabolites / / 21572414 rs300708 chr2 140449 A G 6.34E-06 Suicide attempts in bipolar disorder / / 21423239 rs300707 chr2 141324 G T 6.37E-06 Suicide attempts in bipolar disorder / / 21423239 rs437409 chr2 142137 G A 8.61E-06 Suicide attempts in bipolar disorder / / 21423239 rs405258 chr2 145646 T A 8.47E-06 Suicide attempts in bipolar disorder / / 21423239 rs6732024 chr2 148410 A G 5.26E-06 Suicide attempts in bipolar disorder / / 21423239 rs409572 chr2 153302 A G 5.22E-06 Suicide attempts in bipolar disorder / / 21423239 rs300739 chr2 161605 A G 1.44E-05 Suicide attempts in bipolar disorder / / 21423239 rs10460597 chr2 165976 T C 7.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs6707786 chr2 166224 T G 9.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs6707786 chr2 166224 T G 0.00065 Endometrial cancer / / 22426144 rs300732 chr2 166725 A G 9.68E-06 Suicide attempts in bipolar disorder / / 21423239 rs300734 chr2 167167 T G 1.16E-05 Suicide attempts in bipolar disorder / / 21423239 rs6708206 chr2 167187 A C 7.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs300735 chr2 167739 C G 1.09E-05 Suicide attempts in bipolar disorder / / 21423239 rs300737 chr2 170576 T C 7.23E-04 Type 2 diabetes / / 17463246 rs300737 chr2 170576 T C 1.16E-05 Suicide attempts in bipolar disorder / / 21423239 rs1810329 chr2 176395 A T 7.19E-05 Suicide attempts in bipolar disorder / / 21423239 rs300692 chr2 181415 C T 3.24E-05 Suicide attempts in bipolar disorder / / 21423239 rs300701 chr2 187396 C G 3.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs440617 chr2 189818 C T 1.56E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs384526 chr2 193882 A G 1.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs385909 chr2 199678 A G 6.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs453447 chr2 205446 C A 5.80E-06 Urinary metabolites / / 21572414 rs300703 chr2 239416 C T 2.70E-05 Type 2 diabetes SH3YL1 intron 17903298 rs10181051 chr2 242800 T C 5.38E-05 Neuroblastoma SH3YL1 intron pha002895 rs10167992 chr2 263270 T C 6.90E-04 Response to TNF antagonist treatment SH3YL1 intron 21061259 rs6742672 chr2 301784 G A 7.11E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4643574 chr2 315215 A G 5.00E-06 Cognitive performance / / 20125193 rs1858308 chr2 354241 T G 3.98E-05 Serum metabolites / / 19043545 rs6740249 chr2 355800 T C 4.37E-05 Alcohol dependence / / 21314694 rs4639527 chr2 416815 A G 3.31E-04 Multiple complex diseases / / 17554300 rs10460598 chr2 429880 T G 7.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4854307 chr2 443281 T C 2.00E-06 Body mass index / / 24861553 rs971999 chr2 469266 C T 9.96E-05 Body mass index / / 23669352 rs2724913 chr2 481504 G A 1.31E-04 Age-related macular degeneration / / 22125219 rs4854313 chr2 483114 G A 1.15E-04 Type 2 diabetes / / 20818381 rs2974256 chr2 535043 C T 3.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17041996 chr2 550338 A G 1.70E-04 Multiple complex diseases / / 17554300 rs17042043 chr2 581414 A C 2.25E-04 Smoking initiation / / 24665060 rs6712649 chr2 584523 G A 1.16E-04 Age-related macular degeneration / / 22125219 rs11686772 chr2 584563 C T 1.16E-04 Age-related macular degeneration / / 22125219 rs17042062 chr2 585129 C T 9.69E-05 Age-related macular degeneration / / 22125219 rs4402801 chr2 585333 G A 9.69E-05 Age-related macular degeneration / / 22125219 rs2683992 chr2 600575 G A,C,T 8.75E-04 Obesity (extreme) / / 21935397 rs2683992 chr2 600575 G A,C,T 0.0000554 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867105 chr2 601905 T G 8.75E-04 Obesity (extreme) / / 21935397 rs2867105 chr2 601905 T G 0.0000518 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12996547 chr2 602036 C T 1.00E-09 Obesity / / 23563607 rs12996547 chr2 602036 C T 5.10E-11 Obesity / / 23563607 rs2903497 chr2 607049 C T 4.87E-04 Multiple complex diseases / / 17554300 rs2947415 chr2 609177 A G 0.0000389 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17728164 chr2 609326 C T 9.76E-04 Prostate cancer mortality / / 20978177 rs2867131 chr2 610603 T C 1.05E-06 Body mass index / / 19557197 rs2867131 chr2 610603 T C 1.08E-04 Obesity (extreme) / / 21935397 rs2867131 chr2 610603 T C 0.0000152 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2947411 chr2 614168 A G 2.32E-06 Body mass index / / 19557197 rs2947411 chr2 614168 A G 2.00E-08 Menarche (age at onset) / / 21102462 rs2947411 chr2 614168 A G 1.91E-04 Obesity (extreme) / / 21935397 rs2947411 chr2 614168 A G 0.000000301 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2860323 chr2 614210 A G 2.26E-06 Body mass index / / 19557197 rs2860323 chr2 614210 A G 1.91E-04 Obesity (extreme) / / 21935397 rs2860323 chr2 614210 A G 0.00000029 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7567570 chr2 615140 T C 2.23E-06 Body mass index / / 19557197 rs7567570 chr2 615140 T C 1.91E-04 Obesity (extreme) / / 21935397 rs7567570 chr2 615140 T C 0.000000342 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7559547 chr2 615627 C T 0.000000283 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7563362 chr2 620297 A G 0.000000135 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7570232 chr2 621185 T C 0.000000236 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6548237 chr2 621461 A C 1.02E-06 Body mass index / / 19557197 rs6548237 chr2 621461 A C 2.97E-04 Obesity (extreme) / / 21935397 rs6548237 chr2 621461 A C 0.000000279 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs939584 chr2 621558 C T 7.18E-05 Obesity (extreme) / / 21935397 rs6717005 chr2 621910 A C 0.00000023 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1320332 chr2 621954 T C 0.000000229 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1320331 chr2 622161 G C 1.12E-06 Body mass index / / 19557197 rs1320331 chr2 622161 G C 3.82E-04 Obesity (extreme) / / 21935397 rs1320331 chr2 622161 G C 0.000000226 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1320330 chr2 622225 T G 1.06E-06 Body mass index / / 19557197 rs1320330 chr2 622225 T G 3.29E-04 Obesity (extreme) / / 21935397 rs1320330 chr2 622225 T G 0.000000224 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs939583 chr2 622531 C T 1.16E-06 Body mass index / / 19557197 rs939583 chr2 622531 C T 4.06E-04 Obesity (extreme) / / 21935397 rs939583 chr2 622531 C T 0.00000022 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs939583 chr2 622531 C T 1.00E-07 Body mass index / / 24064335 rs939582 chr2 622723 A G 1.20E-06 Body mass index / / 19557197 rs939582 chr2 622723 A G 4.13E-04 Obesity (extreme) / / 21935397 rs939582 chr2 622723 A G 0.000000214 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867125 chr2 622827 T C 1.15E-06 Body mass index / / 19557197 rs2867125 chr2 622827 T C 1.10E-10 Smoking behavior / / 20418888 rs2867125 chr2 622827 T C 3.00E-49 Body mass index / / 20935630 rs2867125 chr2 622827 T C 4.19E-04 Obesity (extreme) / / 21935397 rs2867125 chr2 622827 T C 2.77E-49 Body mass index / / 23001569 rs2867125 chr2 622827 T C 0.00000015 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867124 chr2 622857 A G 0.000000239 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4854339 chr2 623212 T C 0.000000216 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4854340 chr2 623216 G A 0.000000216 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs939581 chr2 623224 C T 0.000000216 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11127483 chr2 623691 G A 1.88E-06 Body mass index / / 19557197 rs11127483 chr2 623691 G A 2.26E-04 Obesity (extreme) / / 21935397 rs11687052 chr2 623740 A G 0.000000211 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11127484 chr2 623798 T C 1.18E-06 Body mass index / / 19557197 rs11127484 chr2 623798 T C 3.70E-04 Obesity (extreme) / / 21935397 rs11127484 chr2 623798 T C 0.000000159 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6719518 chr2 623935 C T 1.17E-06 Body mass index / / 19557197 rs6719518 chr2 623935 C T 3.50E-04 Obesity (extreme) / / 21935397 rs6719518 chr2 623935 C T 0.000000205 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6728726 chr2 623976 T C 1.74E-06 Body mass index / / 19557197 rs6728726 chr2 623976 T C 0.000000198 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6711012 chr2 624034 G C 1.15E-06 Body mass index / / 19557197 rs6711012 chr2 624034 G C 3.43E-04 Obesity (extreme) / / 21935397 rs6711012 chr2 624034 G C 3.00E-40 Obesity / / 23563607 rs6711012 chr2 624034 G C 6.00E-35 Obesity / / 23563607 rs6711012 chr2 624034 G C 0.0000002 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6731872 chr2 624205 T G 0.000000198 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867123 chr2 624524 G C 1.13E-06 Body mass index / / 19557197 rs2867123 chr2 624524 G C 3.35E-04 Obesity (extreme) / / 21935397 rs2867123 chr2 624524 G C 0.00000019 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867122 chr2 624581 A C 1.12E-06 Body mass index / / 19557197 rs2867122 chr2 624581 A C 3.30E-04 Obesity (extreme) / / 21935397 rs2867122 chr2 624581 A C 0.00000017 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2903492 chr2 624678 G A 1.12E-06 Body mass index / / 19557197 rs2903492 chr2 624678 G A 3.27E-04 Obesity (extreme) / / 21935397 rs2903492 chr2 624678 G A 6.00E-15 Body mass index / / 23563607 rs2903492 chr2 624678 G A 0.00000017 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7576624 chr2 625029 C T 1.12E-06 Body mass index / / 19557197 rs7576624 chr2 625029 C T 1.21E-04 Obesity (extreme) / / 21935397 rs7576624 chr2 625029 C T 0.000000155 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs112863468 chr2 625057 C CT 1.05E-06 Body mass index / / 19557197 rs112863468 chr2 625057 C CT 1.19E-04 Obesity (extreme) / / 21935397 rs112863468 chr2 625057 C CT 0.000000141 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7576635 chr2 625057 C T 1.05E-06 Body mass index / / 19557197 rs7576635 chr2 625057 C T 1.19E-04 Obesity (extreme) / / 21935397 rs7576635 chr2 625057 C T 0.000000141 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12476198 chr2 625347 T C 9.61E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6744646 chr2 628504 A G 1.07E-06 Body mass index / / 19557197 rs6744646 chr2 628504 A G 1.18E-04 Obesity (extreme) / / 21935397 rs6744646 chr2 628504 A G 0.000000092 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6744653 chr2 628524 A G 1.07E-06 Body mass index / / 19557197 rs6744653 chr2 628524 A G 1.17E-04 Obesity (extreme) / / 21935397 rs6744653 chr2 628524 A G 9.14E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6739303 chr2 628749 C T 7.48E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12463617 chr2 629244 A C 2.95E-04 Obesity (extreme) / / 21935397 rs12463617 chr2 629244 A C 2.00E-13 Obesity (early onset extreme) / / 23563609 rs12463617 chr2 629244 A C 8.52E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12463617 chr2 629244 A C 3.00E-17 Body mass index / / 23669352 rs12463617 chr2 629244 A C 2.00E-12 Body mass index / / 24861553 rs6743060 chr2 629510 C A 1.03E-06 Body mass index / / 19557197 rs6743060 chr2 629510 C A 1.15E-04 Obesity (extreme) / / 21935397 rs6743060 chr2 629510 C A 6.53E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6748821 chr2 629601 A G 6.23E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6752470 chr2 629694 T A 1.07E-06 Body mass index / / 19557197 rs6752470 chr2 629694 T A 1.14E-04 Obesity (extreme) / / 21935397 rs6752470 chr2 629694 T A 5.53E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6732341 chr2 629817 G C 4.49E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6749087 chr2 629818 A T 6.86E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6752706 chr2 629831 T C 1.16E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12995480 chr2 629881 T C 1.15E-06 Body mass index / / 19557197 rs12995480 chr2 629881 T C 1.12E-04 Obesity (extreme) / / 21935397 rs12995480 chr2 629881 T C 4.35E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6732471 chr2 629914 G A 1.16E-06 Body mass index / / 19557197 rs6732471 chr2 629914 G A 1.11E-04 Obesity (extreme) / / 21935397 rs6732471 chr2 629914 G A 0.000000042 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12995666 chr2 629959 T C 5.02E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13007080 chr2 630024 A C 1.15E-06 Body mass index / / 19557197 rs13007080 chr2 630024 A C 1.10E-04 Obesity (extreme) / / 21935397 rs13007080 chr2 630024 A C 5.95E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13007086 chr2 630034 A T 1.15E-06 Body mass index / / 19557197 rs13007086 chr2 630034 A T 1.09E-04 Obesity (extreme) / / 21935397 rs13007086 chr2 630034 A T 5.94E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs66906321 chr2 630070 T C 5.09E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs73139123 chr2 630075 C T 0.00000005 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6731225 chr2 630224 A T 4.15E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6725549 chr2 630323 C A 1.28E-06 Body mass index / / 19557197 rs6725549 chr2 630323 C A 9.59E-05 Obesity (extreme) / / 21935397 rs6725549 chr2 630323 C A 3.88E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6731348 chr2 630339 A C 1.33E-06 Body mass index / / 19557197 rs6731348 chr2 630339 A C 9.47E-05 Obesity (extreme) / / 21935397 rs6731348 chr2 630339 A C 3.77E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6725686 chr2 630436 C A 3.77E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6735024 chr2 630509 T C 3.75E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6735049 chr2 630569 T C 1.12E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6731688 chr2 630662 A C 1.35E-06 Body mass index / / 19557197 rs6731688 chr2 630662 A C 9.42E-05 Obesity (extreme) / / 21935397 rs6731688 chr2 630662 A C 3.67E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13008590 chr2 630788 A G 3.73E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs5017305 chr2 630902 A T 1.88E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs202116406 chr2 630903 A ATG 1.88E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs5017304 chr2 630903 A G 1.88E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs5017303 chr2 630995 T G 1.36E-06 Body mass index / / 19557197 rs5017303 chr2 630995 T G 9.31E-05 Obesity (extreme) / / 21935397 rs5017303 chr2 630995 T G 6.09E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs5017300 chr2 631099 C G 1.39E-06 Body mass index / / 19557197 rs5017300 chr2 631099 C G 9.26E-05 Obesity (extreme) / / 21935397 rs7579427 chr2 631183 C A 3.09E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7588007 chr2 631255 T C 3.09E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7569102 chr2 631335 G T 0.000000037 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7569210 chr2 631462 G A 2.78E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7585056 chr2 631528 A G 1.42E-06 Body mass index / / 19557197 rs7585056 chr2 631528 A G 9.21E-05 Obesity (extreme) / / 21935397 rs7585056 chr2 631528 A G 2.77E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7579971 chr2 631603 C T 5.18E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10865548 chr2 631606 A G 2.88E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10865549 chr2 631759 G A 0.000000028 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11127485 chr2 632028 C T 1.39E-06 Body mass index / / 19557197 rs11127485 chr2 632028 C T 2.00E-07 Obesity (early onset extreme) / / 20421936 rs11127485 chr2 632028 C T 9.10E-05 Obesity (extreme) / / 21935397 rs11127485 chr2 632028 C T 1.16E-06 Body mass index / / 22344219 rs11127485 chr2 632028 C T 0.000000036 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11127486 chr2 632101 C T 2.66E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12623218 chr2 632146 T A 1.40E-06 Body mass index / / 19557197 rs12623218 chr2 632146 T A 8.95E-05 Obesity (extreme) / / 21935397 rs12623218 chr2 632146 T A 2.64E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12992154 chr2 632300 G T 1.38E-06 Body mass index / / 19557197 rs12992154 chr2 632300 G T 8.90E-05 Obesity (extreme) / / 21935397 rs12992154 chr2 632300 G T 2.93E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13021737 chr2 632348 A G 1.36E-06 Body mass index / / 19557197 rs13021737 chr2 632348 A G 8.79E-05 Obesity (extreme) / / 21935397 rs13021737 chr2 632348 A G 2.64E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13027828 chr2 632379 T G 2.65E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13028252 chr2 632529 T C 1.77E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13022164 chr2 632536 A G 1.47E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13012571 chr2 632550 C T 1.35E-06 Body mass index / / 19557197 rs13012571 chr2 632550 C T 8.70E-05 Obesity (extreme) / / 21935397 rs13012571 chr2 632550 C T 1.42E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13028310 chr2 632591 T C 1.76E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13028310 chr2 632591 T C 1.63E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13022337 chr2 632609 A G 1.76E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13013021 chr2 632723 C T 3.04E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34119520 chr2 632760 T C 3.03E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12993295 chr2 632808 G T 2.44E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35802221 chr2 632904 A G 2.43E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62105303 chr2 632922 G A 2.73E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62105304 chr2 632925 A G 2.82E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4854342 chr2 634476 G C 0.000000115 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6548238 chr2 634905 T C 1.00E-18 Body mass index / / 19079261 rs6548238 chr2 634905 T C 1.40E-18 Smoking behavior / / 20418888 rs6548238 chr2 634905 T C 7.10E-07 Menarche (age at onset) / / 21102462 rs6548238 chr2 634905 T C 4.48E-04 Obesity (extreme) / / 21935397 rs6548238 chr2 634905 T C 2.27E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6548239 chr2 635154 G A 2.29E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6734363 chr2 635200 G A 1.27E-06 Body mass index / / 19557197 rs6734363 chr2 635200 G A 8.50E-05 Obesity (extreme) / / 21935397 rs6734363 chr2 635200 G A 4.31E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6755502 chr2 635721 T C 1.27E-06 Body mass index / / 19557197 rs6755502 chr2 635721 T C 8.45E-05 Obesity (extreme) / / 21935397 rs6755502 chr2 635721 T C 2.41E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6746275 chr2 635857 C A 0.000000116 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6751993 chr2 635864 A G 0.000000114 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6751994 chr2 635866 A G 0.000000115 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6749375 chr2 636017 C T 1.62E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35142762 chr2 636790 T C 2.61E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35796073 chr2 636819 C A 2.64E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6548240 chr2 636929 C A 1.76E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13387939 chr2 637498 C A 3.04E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13396119 chr2 637508 T C 3.08E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13388043 chr2 637597 C T 9.17E-07 Body mass index / / 19557197 rs13388043 chr2 637597 C T 8.36E-05 Obesity (extreme) / / 21935397 rs13388043 chr2 637597 C T 0.000000027 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13393304 chr2 637830 A G 9.91E-07 Body mass index / / 19557197 rs13393304 chr2 637830 A G 8.27E-05 Obesity (extreme) / / 21935397 rs13393304 chr2 637830 A G 0.000000027 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4854344 chr2 638144 G T 9.61E-07 Body mass index / / 19557197 rs4854344 chr2 638144 G T 5.00E-05 Weight / / 19851299 rs4854344 chr2 638144 G T 2.90E-10 Smoking behavior / / 20418888 rs4854344 chr2 638144 G T 8.22E-05 Obesity (extreme) / / 21935397 rs4854344 chr2 638144 G T 7.36E-13 Obesity / / 22484627 rs4854344 chr2 638144 G T 2.77E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4854345 chr2 638190 A G 2.77E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7561556 chr2 638560 T C 2.77E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7606023 chr2 638566 C G 2.77E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4854346 chr2 638918 A C 2.77E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7564708 chr2 639055 T C 2.91E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62105327 chr2 639060 T A 4.01E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7564711 chr2 639061 T G 1.27E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11127487 chr2 639900 C T 2.82E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10166979 chr2 640701 A G 2.82E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10865550 chr2 641718 T G 2.87E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10865551 chr2 641863 T A 2.98E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12714413 chr2 642253 T C 3.03E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7601028 chr2 642499 C G 2.49E-04 Obesity (extreme) / / 21935397 rs7601028 chr2 642499 C G 3.03E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7591067 chr2 642846 G A 3.04E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7604609 chr2 643303 C G 9.89E-07 Body mass index / / 19557197 rs7604609 chr2 643303 C G 8.15E-05 Obesity (extreme) / / 21935397 rs7604609 chr2 643303 C G 3.04E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7560127 chr2 643315 T C 3.05E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7594220 chr2 643320 G A 9.77E-09 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7604752 chr2 643428 C A 0.000000031 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7560246 chr2 643469 T C 3.12E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7561317 chr2 644953 A G 2.00E-18 Weight / / 19079260 rs7561317 chr2 644953 A G 4.00E-17 Body mass index / / 19079260 rs7561317 chr2 644953 A G 9.43E-07 Body mass index / / 19557197 rs7561317 chr2 644953 A G 2.40E-10 Smoking behavior / / 20418888 rs7561317 chr2 644953 A G 8.04E-05 Obesity (extreme) / / 21935397 rs7561317 chr2 644953 A G 3.15E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7567368 chr2 645082 T C 5.95E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7558910 chr2 645122 C G 5.95E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7559018 chr2 645203 C T 2.86E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7567710 chr2 645372 T G 2.87E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7559447 chr2 645646 C T 2.71E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11127488 chr2 646061 T C 2.66E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11127489 chr2 646081 C T 2.33E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11127490 chr2 646110 C T 2.32E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11127491 chr2 646145 T C 1.01E-06 Body mass index / / 19557197 rs11127491 chr2 646145 T C 8.01E-05 Obesity (extreme) / / 21935397 rs11127491 chr2 646145 T C 2.48E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10172769 chr2 646345 G A 2.66E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10189761 chr2 646364 T A 2.72E-06 Body mass index / / 19557197 rs10189761 chr2 646364 T A 1.27E-04 Obesity (extreme) / / 21935397 rs10189761 chr2 646364 T A 6.00E-24 Obesity / / 23563607 rs10189761 chr2 646364 T A 2.66E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10190052 chr2 646674 T C 1.02E-06 Body mass index / / 19557197 rs10190052 chr2 646674 T C 7.80E-05 Obesity (extreme) / / 21935397 rs10190052 chr2 646674 T C 2.94E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10190052 chr2 646674 T C 2.00E-07 Type 2 diabetes / / 24509480 rs10173167 chr2 646767 G A 9.97E-07 Body mass index / / 19557197 rs10173167 chr2 646767 G A 7.74E-05 Obesity (extreme) / / 21935397 rs10173167 chr2 646767 G A 2.31E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7571957 chr2 646803 T C 9.63E-07 Body mass index / / 19557197 rs7571957 chr2 646803 T C 7.68E-05 Obesity (extreme) / / 21935397 rs7571957 chr2 646803 T C 2.41E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7571967 chr2 646839 T G 2.28E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10190313 chr2 647577 A G 8.01E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10193244 chr2 647580 T C 1.00E-06 Body mass index / / 19557197 rs10193244 chr2 647580 T C 7.65E-05 Obesity (extreme) / / 21935397 rs10193244 chr2 647580 T C 8.74E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4854348 chr2 647760 A G 9.90E-07 Body mass index / / 19557197 rs4854348 chr2 647760 A G 7.62E-05 Obesity (extreme) / / 21935397 rs4854348 chr2 647760 A G 2.38E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4854349 chr2 647861 T C 9.62E-07 Body mass index / / 19557197 rs4854349 chr2 647861 T C 7.59E-05 Obesity (extreme) / / 21935397 rs4854349 chr2 647861 T C 2.39E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7570198 chr2 648198 C T 9.43E-07 Body mass index / / 19557197 rs7570198 chr2 648198 C T 7.52E-05 Obesity (extreme) / / 21935397 rs7570198 chr2 648198 C T 2.38E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4407278 chr2 648607 C T 0.000000336 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4423631 chr2 648758 T C 8.90E-07 Body mass index / / 19557197 rs4423631 chr2 648758 T C 7.43E-05 Obesity (extreme) / / 21935397 rs4423631 chr2 648758 T C 2.81E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4452188 chr2 648810 A G 8.69E-07 Body mass index / / 19557197 rs4452188 chr2 648810 A G 7.37E-05 Obesity (extreme) / / 21935397 rs4452188 chr2 648810 A G 3.82E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1320338 chr2 649347 T G 8.29E-07 Body mass index / / 19557197 rs1320338 chr2 649347 T G 7.70E-05 Obesity (extreme) / / 21935397 rs1320338 chr2 649347 T G 3.16E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2903489 chr2 649638 C T 3.45E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1320337 chr2 649867 A T 8.39E-07 Body mass index / / 19557197 rs1320337 chr2 649867 A T 7.77E-05 Obesity (extreme) / / 21935397 rs1320337 chr2 649867 A T 3.18E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1320336 chr2 650012 G A 8.36E-07 Body mass index / / 19557197 rs1320336 chr2 650012 G A 7.84E-05 Obesity (extreme) / / 21935397 rs1320336 chr2 650012 G A 0.000000034 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867108 chr2 650143 T C 8.43E-07 Body mass index / / 19557197 rs2867108 chr2 650143 T C 8.00E-05 Obesity (extreme) / / 21935397 rs2867108 chr2 650143 T C 5.64E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13386517 chr2 650479 G C 8.47E-07 Body mass index / / 19557197 rs13386517 chr2 650479 G C 8.08E-05 Obesity (extreme) / / 21935397 rs13386517 chr2 650479 G C 5.69E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13401686 chr2 650519 A G 8.37E-07 Body mass index / / 19557197 rs13401686 chr2 650519 A G 8.16E-05 Obesity (extreme) / / 21935397 rs13401686 chr2 650519 A G 1.71E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13386627 chr2 650560 G C 8.28E-07 Body mass index / / 19557197 rs13386627 chr2 650560 G C 8.23E-05 Obesity (extreme) / / 21935397 rs13386627 chr2 650560 G C 0.000000036 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4613321 chr2 650647 A G 8.22E-07 Body mass index / / 19557197 rs4613321 chr2 650647 A G 8.39E-05 Obesity (extreme) / / 21935397 rs4613321 chr2 650647 A G 3.66E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13386964 chr2 650828 G A 8.21E-07 Body mass index / / 19557197 rs13386964 chr2 650828 G A 8.56E-05 Obesity (extreme) / / 21935397 rs13386964 chr2 650828 G A 3.74E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13387091 chr2 650980 G A 0.000000039 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867109 chr2 651030 T G 8.18E-07 Body mass index / / 19557197 rs2867109 chr2 651030 T G 8.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs2867109 chr2 651030 T G 8.74E-05 Obesity (extreme) / / 21935397 rs2867109 chr2 651030 T G 3.76E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867110 chr2 651105 G C 8.54E-07 Body mass index / / 19557197 rs2867110 chr2 651105 G C 8.82E-05 Obesity (extreme) / / 21935397 rs2867110 chr2 651105 G C 3.82E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867111 chr2 651286 A C 0.000000125 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2903490 chr2 651290 A G 0.000000136 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867112 chr2 651349 T G 8.00E-07 Body mass index / / 19557197 rs2867112 chr2 651349 T G 9.66E-05 Obesity (extreme) / / 21935397 rs2867112 chr2 651349 T G 0.000000131 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867113 chr2 651365 G A 8.02E-07 Body mass index / / 19557197 rs2867113 chr2 651365 G A 9.86E-05 Obesity (extreme) / / 21935397 rs2867113 chr2 651365 G A 8.49E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867114 chr2 651380 C T 0.00000296 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2867115 chr2 651382 T C 0.00000358 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12714414 chr2 651407 T C 8.11E-07 Body mass index / / 19557197 rs12714414 chr2 651407 T C 8.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs12714414 chr2 651407 T C 1.01E-04 Obesity (extreme) / / 21935397 rs12714414 chr2 651407 T C 5.87E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12714415 chr2 651430 T C 8.14E-07 Body mass index / / 19557197 rs12714415 chr2 651430 T C 1.03E-04 Obesity (extreme) / / 21935397 rs12714415 chr2 651430 T C 5.89E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6719980 chr2 651507 T C 8.12E-07 Body mass index / / 19557197 rs6719980 chr2 651507 T C 1.05E-04 Obesity (extreme) / / 21935397 rs6719980 chr2 651507 T C 0.00000007 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1879523 chr2 651599 A T 7.77E-09 Obesity / / 23563607 rs7608050 chr2 652247 G A 8.13E-07 Body mass index / / 19557197 rs7608050 chr2 652247 G A 1.08E-04 Obesity (extreme) / / 21935397 rs7608050 chr2 652247 G A 0.000000025 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6760274 chr2 652272 G A 3.76E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7574359 chr2 652542 T C 8.23E-07 Body mass index / / 19557197 rs7574359 chr2 652542 T C 1.12E-04 Obesity (extreme) / / 21935397 rs7574359 chr2 652542 T C 7.73E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7570993 chr2 652565 A G 0.000000119 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4429506 chr2 652576 C A 0.000000167 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10192350 chr2 652607 T C 0.000000131 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13415094 chr2 653093 T C 8.13E-07 Body mass index / / 19557197 rs13415094 chr2 653093 T C 1.16E-04 Obesity (extreme) / / 21935397 rs13415094 chr2 653093 T C 0.000000065 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13396935 chr2 653195 G A 8.10E-07 Body mass index / / 19557197 rs13396935 chr2 653195 G A 1.19E-04 Obesity (extreme) / / 21935397 rs13396935 chr2 653195 G A 0.000000069 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13412194 chr2 653245 A C 3.78E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13412197 chr2 653250 A G 3.74E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13397165 chr2 653354 G A 8.13E-07 Body mass index / / 19557197 rs13397165 chr2 653354 G A 1.22E-04 Obesity (extreme) / / 21935397 rs13397165 chr2 653354 G A 7.03E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35913461 chr2 653575 C T 7.13E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35628463 chr2 653581 G A 0.000000071 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10188118 chr2 653623 C G 0.0000733 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10188334 chr2 653874 C T 8.11E-07 Body mass index / / 19557197 rs10188334 chr2 653874 C T 9.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs10188334 chr2 653874 C T 1.27E-04 Obesity (extreme) / / 21935397 rs10188334 chr2 653874 C T 2.53E-08 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12999373 chr2 663483 G A 2.00E-06 Uric acid levels / / 22229870 rs12999373 chr2 663483 G A 3.00E-06 Response to fenofibrate (adiponectin levels) / / 23149075 rs11673780 chr2 664719 A G 3.30E-04 Type 2 diabetes / / 17463246 rs1320333 chr2 679179 C T 8.00E-06 Obesity-related traits / / 23251661 rs1320333 chr2 679179 C T 5.70E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4372938 chr2 716503 T C 3.05E-05 Body Mass Index / / pha003019 rs4372938 chr2 716503 T C 1.46E-05 Body Mass Index / / pha003022 rs3924384 chr2 726564 T C 1.50E-05 Sickle cell anemia (severity) / / 20029952 rs7580986 chr2 729948 G T 2.35E-06 Sickle cell anemia (severity) / / 20029952 rs4335978 chr2 750078 A G 9.77E-05 Atopic dermatitis / / 23042114 rs4380275 chr2 773278 C T 5.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs6729766 chr2 824614 T A 0.000797 Salmonella-induced pyroptosis LOC339822 intron 22837397 rs12466616 chr2 877633 G A 9.88E-05 Smoking initiation / / 24665060 rs6744291 chr2 941020 C G 6.29E-12 Multiple complex diseases / / 17554300 rs4971347 chr2 943636 C T 0.000027 Oxaliplatin induced diarrhea in response to colorectal cancer treatment / / 22310351 rs6710556 chr2 969866 T C 9.72E-04 Multiple complex diseases SNTG2 intron 17554300 rs11127542 chr2 1004430 T C 2.20E-04 Multiple complex diseases SNTG2 intron 17554300 rs10201045 chr2 1025239 A G 9.62E-04 Type 2 diabetes SNTG2 intron 17463246 rs10203650 chr2 1025268 T C 7.50E-04 Type 2 diabetes SNTG2 intron 17463246 rs4971371 chr2 1076684 C T 5.57E-04 Alcohol dependence SNTG2 intron 21314694 rs13389243 chr2 1099654 C T 7.08E-04 Depression (quantitative trait) SNTG2 intron 20800221 rs7579535 chr2 1150095 A C 1.12E-05 Eosinophil counts SNTG2 intron pha003088 rs4971396 chr2 1153552 T G 7.93E-06 Eosinophil counts SNTG2 intron pha003088 rs7579446 chr2 1206464 G C 3.22E-04 Height SNTG2 intron 17255346 rs7579446 chr2 1206464 G C 8.86E-04 Type 2 diabetes SNTG2 intron 17463246 rs4971418 chr2 1216394 A G 5.56E-04 Multiple complex diseases SNTG2 intron 17554300 rs6548209 chr2 1228487 T G 3.29E-04 Cognitive decline SNTG2 intron 23732972 rs10192365 chr2 1231315 A G 7.26E-05 Cognitive decline SNTG2 intron 23732972 rs11674954 chr2 1283031 T G 3.55E-04 Amyotrophic Lateral Sclerosis SNTG2 intron 17362836 rs7424980 chr2 1284020 T C 4.52E-04 Tourette syndrome SNTG2 intron 22889924 rs13411595 chr2 1287872 T C 6.40E-05 Response to taxane treatment (placlitaxel) SNTG2 intron 23006423 rs11211641 chr2 1287922 T A,G 9.33E-04 Response to taxane treatment (placlitaxel) SNTG2 intron 23006423 rs6738955 chr2 1288297 C T 1.76E-04 Response to taxane treatment (placlitaxel) SNTG2 intron 23006423 rs7421044 chr2 1291096 G A 9.26E-04 Response to taxane treatment (placlitaxel) SNTG2 intron 23006423 rs12467819 chr2 1293260 G A 9.30E-06 Urinary metabolites SNTG2 intron 21572414 rs11211670 chr2 1367035 G C 1.60E-05 Urinary metabolites SNTG2 intron 21572414 rs13387242 chr2 1376021 G A 1.80E-05 Urinary metabolites / / 21572414 rs9326164 chr2 1393107 A G 2.85E-04 Multiple complex diseases / / 17554300 rs11675434 chr2 1407815 C T 2.00E-16 Thyroid peroxidase antibody positivity / / 24586183 rs11675434 chr2 1407815 C T 7.00E-13 Thyroid peroxidase antibody levels / / 24586183 rs2071403 chr2 1417244 A G 1.00E-10 Thyroid peroxidase antibody positivity TPO UTR-5 24722205 rs1514687 chr2 1437988 T G 2.00E-07 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) TPO intron 24554482 rs1126797 chr2 1497803 C A,G,T 2.48E-05 Major depressive disorder TPO missense 20516156 rs11896517 chr2 1518112 T C 2.00E-09 Health and aging,CVD and cancer age of onset TPO intron 22174011 rs17732233 chr2 1519064 C T 4.97E-05 Alcohol and nictotine co-dependence TPO intron 20158304 rs1126799 chr2 1520676 T C 2.31E-04 Alzheimer's disease (late onset) TPO missense 21379329 rs4927594 chr2 1525558 C T 3.32E-05 Major depressive disorder TPO intron 20516156 rs4927632 chr2 1545110 G A 2.04E-05 Alcohol and nictotine co-dependence TPO intron 20158304 rs6705087 chr2 1550309 T C 4.80E-06 Alcohol and nictotine co-dependence / / 20158304 rs10206020 chr2 1557927 T C 8.96E-04 Type 2 diabetes / / 17463246 rs10206020 chr2 1557927 T C 3.00E-06 IgG glycosylation / / 23382691 rs10206020 chr2 1557927 T C 4.00E-06 IgG glycosylation / / 23382691 rs6721243 chr2 1580250 A G 2.05E-04 Cholesterol / / 17255346 rs7564265 chr2 1582242 A G 2.31E-05 Gaucher disease severity / / 22388998 rs11127330 chr2 1621676 C T 2.40E-05 Urinary metabolites / / 21572414 rs11692295 chr2 1623765 T C 9.80E-06 Urinary metabolites / / 21572414 rs9309692 chr2 1625121 C A 4.20E-05 Response to statin therapy / / 20339536 rs1544846 chr2 1676388 C T 5.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PXDN intron 20877124 rs6548062 chr2 1698030 A G 8.87E-04 Type 2 diabetes PXDN intron 17463246 rs7588729 chr2 1708502 C A 8.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PXDN intron 20877124 rs13401942 chr2 1711624 A G 1.95E-04 Multiple complex diseases PXDN intron 17554300 rs10469992 chr2 1760091 C T 2.50E-05 Urinary metabolites / / 21572414 rs2382560 chr2 1762828 T C 1.70E-05 Urinary metabolites / / 21572414 rs7563388 chr2 1773193 G A 0.000749763 Hypertension (early onset hypertension) / / 22479346 rs6745451 chr2 1776761 C T 8.23E-05 Hypertension (early onset hypertension) / / 22479346 rs6735179 chr2 1777150 A G 6.85E-05 Personality dimensions / / 18957941 rs6735179 chr2 1777150 A G 1.00E-07 Response to antipsychotic treatment / / 20195266 rs6548056 chr2 1813322 C T 8.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MYT1L intron 20877124 rs6548056 chr2 1813322 C T 4.26E-04 Common variable immunodeficiency MYT1L intron 21497890 rs6548056 chr2 1813322 C T 3.69E-04 Coronary heart disease MYT1L intron 21971053 rs4645032 chr2 1820060 T C 2.97E-04 Obesity (extreme) MYT1L intron 21935397 rs7560247 chr2 1883389 T C 4.44E-05 Hypertension MYT1L intron pha003041 rs11127306 chr2 1887049 G A 5.24E-05 Hypertension MYT1L intron pha003041 rs11885419 chr2 1891930 A G 0.0000313 Colorectal adenoma (excluding hyperplasic) MYT1L intron 23677573 rs11885419 chr2 1891930 A G 0.0000313 Colorectal adenoma (including hyperplasic) MYT1L intron 23677573 rs10184726 chr2 1924946 C T 1.60E-05 Urinary metabolites MYT1L intron 21572414 rs2241685 chr2 1925993 C T 8.00E-06 Attention deficit hyperactivity disorder MYT1L intron 18839057 rs13389573 chr2 1936113 T G 4.19E-04 Type 2 diabetes MYT1L intron 17463246 rs11687068 chr2 1948949 T C 6.98E-04 Type 2 diabetes MYT1L intron 17463246 rs11687068 chr2 1948949 T C 8.50E-04 Multiple complex diseases MYT1L intron 17554300 rs13417303 chr2 1950897 C T 6.33E-04 Insulin resistance MYT1L intron 21901158 rs1991773 chr2 1957476 C T 2.21E-04 Multiple complex diseases MYT1L intron 17554300 rs6733654 chr2 1963271 G A 3.51E-05 Soluble levels of adhesion molecules MYT1L intron pha003072 rs10185662 chr2 1964906 C T 9.56E-04 Multiple complex diseases MYT1L intron 17554300 rs891878 chr2 1992624 T G 1.47E-04 Response to cytidine analogues (gemcitabine) MYT1L intron 24483146 rs1560625 chr2 1993024 T G 6.23E-04 Response to cytidine analogues (gemcitabine) MYT1L intron 24483146 rs13389846 chr2 1996027 T C 9.57E-05 Pulmonary function MYT1L intron 20010835 rs17039313 chr2 2084964 T C 7.16E-04 Response to cytidine analogues (gemcitabine) MYT1L intron 24483146 rs1643413 chr2 2104124 A G 2.60E-05 Urinary metabolites MYT1L intron 21572414 rs1620250 chr2 2128585 T C 1.55E-05 Pulmonary function MYT1L intron 20010835 rs12998803 chr2 2129071 T C 4.42E-04 Aortic root size MYT1L intron 21223598 rs17247373 chr2 2135309 C A 3.24E-04 Aortic root size MYT1L intron 21223598 rs11687473 chr2 2165519 C A 6.63E-04 Response to cytidine analogues (gemcitabine) MYT1L intron 24483146 rs17039365 chr2 2197239 T C 4.59E-04 Hypertension (young onset) MYT1L intron 24892410 rs10495483 chr2 2198752 G C 9.70E-04 Bipolar disorder MYT1L intron 19259986 rs7596980 chr2 2199705 C T 7.52E-04 Hypertension (young onset) MYT1L intron 24892410 rs6748501 chr2 2204179 T C 1.00E-04 Cognitive impairment induced by topiramate MYT1L intron 22091778 rs1582414 chr2 2216368 G T 2.88E-04 Type 2 diabetes MYT1L intron 17846125 rs10184190 chr2 2233492 A C 1.79E-04 Amyotrophic lateral sclerosis (sporadic) MYT1L intron 24529757 rs4853946 chr2 2236281 T C 2.73E-04 Abdominal aortic aneurysm MYT1L intron 22055160 rs10168134 chr2 2257724 T C 7.88E-04 Alzheimer's disease MYT1L intron 17998437 rs6753548 chr2 2268764 C G 7.65E-04 Alzheimer's disease MYT1L intron 17998437 rs10190125 chr2 2294426 G A 1.68E-04 Longevity MYT1L intron 22279548 rs12612846 chr2 2381297 G A 6.24E-04 Multiple complex diseases / / 17554300 rs11884676 chr2 2381613 G A 8.27E-05 Orofacial clefts / / 22419666 rs11884676 chr2 2381613 G A 1.93E-05 Glucose levels / / pha003061 rs17720273 chr2 2390619 C G 0.00000474 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment / / 23392654 rs17720273 chr2 2390619 C G 4.74E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs13411814 chr2 2399524 G A 4.10E-05 Glucose levels / / pha003057 rs1567675 chr2 2403590 C A 1.18E-04 Multiple complex diseases / / 17554300 rs6741513 chr2 2417721 A G 2.48E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs7577250 chr2 2437074 A G 3.71E-05 Body Mass Index / / pha003019 rs7577250 chr2 2437074 A G 6.72E-06 Body Mass Index / / pha003020 rs7577250 chr2 2437074 A G 8.02E-06 Insulin Resistance / / pha003062 rs7577250 chr2 2437074 A G 1.96E-05 Insulin-related traits / / pha003063 rs12616839 chr2 2438630 C A 5.61E-05 Body Mass Index / / pha003019 rs12616839 chr2 2438630 C A 9.92E-06 Body Mass Index / / pha003020 rs12616839 chr2 2438630 C A 1.21E-05 Insulin Resistance / / pha003062 rs12616839 chr2 2438630 C A 2.71E-05 Insulin-related traits / / pha003063 rs13013201 chr2 2473647 G A 8.23E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs823538 chr2 2493770 A G 3.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7593925 chr2 2512230 A G 9.02E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs823557 chr2 2512660 T C 5.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10199521 chr2 2519513 C T 3.00E-06 Diabetic retinopathy / / 21441570 rs10199521 chr2 2519513 C T 5.44E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs10199516 chr2 2519521 C T 3.40E-06 Diabetic retinopathy / / 21441570 rs10199516 chr2 2519521 C T 5.46E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs13023303 chr2 2520359 G T 9.50E-06 Urinary metabolites / / 21572414 rs2668843 chr2 2521301 G A 3.70E-06 Diabetic retinopathy / / 21441570 rs938141 chr2 2521840 G A 4.10E-06 Diabetic retinopathy / / 21441570 rs10495489 chr2 2532159 T A 9.78E-04 Multiple complex diseases / / 17554300 rs11676482 chr2 2533488 C G 1.44E-05 Response to citalopram treatment / / 19846067 rs2037148 chr2 2540292 A C 6.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2037147 chr2 2540386 T C 1.06E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1980145 chr2 2540775 A G 3.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7568276 chr2 2545078 A G 2.69E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs181867028 chr2 2545734 A T 8.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs2037146 chr2 2564549 A G 9.68E-04 Type 2 diabetes / / 17463246 rs11127343 chr2 2564992 C T 9.12E-04 Type 2 diabetes / / 17463246 rs869759 chr2 2571142 C T 4.39E-05 Alzheimer's disease (late onset) / / 21379329 rs13004123 chr2 2577912 C A,G,T 1.89E-04 Alzheimer's disease (late onset) / / 21379329 rs2598592 chr2 2590381 C T 7.00E-06 White matter integrity / / 23218918 rs12995456 chr2 2594614 A C 7.60E-05 Glioma (high-grade) / / 19578366 rs4853911 chr2 2601765 G A 7.69E-05 Smoking initiation / / 24665060 rs7556672 chr2 2605757 G T 6.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1584644 chr2 2606830 G C 6.16E-04 Alzheimer's disease / / 17998437 rs752787 chr2 2609713 T A 8.02E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2891741 chr2 2613960 A G 3.69E-04 Alzheimer's disease / / 17998437 rs13031108 chr2 2633258 T C 3.76E-05 Eosinophil counts / / pha003088 rs3814051 chr2 2640865 G T 0.000324532 Hypertension (early onset hypertension) / / 22479346 rs4853887 chr2 2650131 G A 1.25E-05 Multiple complex diseases / / 17554300 rs10202240 chr2 2666966 G A 4.01E-05 Cognitive performance / / 19734545 rs6714525 chr2 2699840 T A 7.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1993081 chr2 2701665 T C 2.32E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1993082 chr2 2705929 G A 7.29E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1993082 chr2 2705929 G A 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6548077 chr2 2718978 G A,C,T 8.29E-05 Alzheimer's disease (late onset) / / 21379329 rs12466602 chr2 2742748 C T 3.15E-04 Multiple complex diseases / / 17554300 rs2053908 chr2 2750095 T A 1.20E-04 Type 2 diabetes / / 17463246 rs17038881 chr2 2754703 T C 0.0002049 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17038881 chr2 2754703 T C 2.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13389878 chr2 2757162 G A 0.00013 Erectile dysfunction after radiotherapy for prostate cancer / / 23021708 rs11693002 chr2 2761323 G C 0.000031 Erectile dysfunction after radiotherapy for prostate cancer / / 23021708 rs13431590 chr2 2761577 A G 8.19E-04 Tourette syndrome / / 22889924 rs1031348 chr2 2764201 C A 2.42E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs934555 chr2 2811664 T C 8.40E-06 Urinary metabolites / / 21572414 rs823220 chr2 2827276 C T 1.10E-05 Urinary metabolites / / 21572414 rs823220 chr2 2827276 C T 4.13E-04 Insulin resistance / / 21901158 rs823221 chr2 2827345 A G 1.10E-05 Urinary metabolites / / 21572414 rs823223 chr2 2827974 G A 1.10E-05 Urinary metabolites / / 21572414 rs823223 chr2 2827974 G A 7.87E-04 Insulin resistance / / 21901158 rs823224 chr2 2828104 T C 1.20E-05 Urinary metabolites / / 21572414 rs823231 chr2 2831484 C T 7.32E-04 Smoking initiation / / 24665060 rs10200599 chr2 2838270 G A 2.30E-05 Memory performance / / 22105620 rs10200599 chr2 2838270 G A 3.10E-05 Smoking initiation / / 24665060 rs935630 chr2 2839594 C T 2.00E-05 Memory performance / / 22105620 rs13403149 chr2 2843308 G A 7.00E-06 Smoking initiation / / 24665060 rs10202957 chr2 2844858 A T 1.34E-04 Smoking initiation / / 24665060 rs13401708 chr2 2845963 C T 8.35E-05 Smoking initiation / / 24665060 rs823243 chr2 2848102 T C 8.00E-04 Alcohol dependence / / 20201924 rs13022869 chr2 2879216 G T 0.0005812 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13022869 chr2 2879216 G T 5.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1656326 chr2 2880229 A G 0.000232 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1656326 chr2 2880229 A G 2.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11694272 chr2 2892309 T C 0.0004301 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11694272 chr2 2892309 T C 4.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7569351 chr2 2892642 G A 0.0005114 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7569351 chr2 2892642 G A 5.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11691324 chr2 2895033 C T 0.0005864 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11691324 chr2 2895033 C T 5.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17040523 chr2 2895193 C T 0.00000055 Independent stressful life events / / 23237013 rs17040523 chr2 2895193 C T 0.0000013 Stressful life events / / 23237013 rs17491951 chr2 2926013 G A 7.00E-06 White matter integrity (interaction) / / 23218918 rs7594094 chr2 2942376 G A 3.06E-05 Parkinson's disease (motor and cognition) / / 22658654 rs7594094 chr2 2942376 G A 3.06E-05 Immune response to anthrax vaccine / / 22658931 rs1667059 chr2 2946331 C T 1.89E-04 Parkinson's disease / / 17052657 rs1667029 chr2 2950289 T C 1.54E-04 Parkinson's disease / / 17052657 rs1463147 chr2 2970688 C A 6.70E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17437842 chr2 2978905 C T 8.24E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs17490371 chr2 3011244 C G 4.30E-06 Urinary metabolites / / 21572414 rs2031028 chr2 3012290 A G 3.00E-06 Urinary metabolites / / 21572414 rs12470135 chr2 3012947 C T 1.80E-05 Urinary metabolites / / 21572414 rs1406534 chr2 3029935 A C 2.40E-06 Urinary metabolites / / 21572414 rs7371570 chr2 3067917 G A 8.62E-04 Schizophrenia / / 19197363 rs11902160 chr2 3068334 C T 5.26E-05 Cognitive performance / / 19734545 rs7420489 chr2 3071419 A G 5.35E-05 Cognitive performance / / 19734545 rs6709268 chr2 3079139 C A 8.60E-06 Type 2 diabetes / / 21647700 rs62119855 chr2 3079363 C T 9.09E-06 Stroke (ischemic) / / 21957438 rs7371392 chr2 3083625 A G 8.49E-06 Stroke (ischemic) / / 21957438 rs10169682 chr2 3086833 C T 2.63E-06 Stroke (ischemic) / / 21957438 rs12714371 chr2 3087454 T A 9.03E-06 Stroke (ischemic) / / 21957438 rs4854189 chr2 3098843 G A 2.09E-06 Stroke (ischemic) / / 21957438 rs1453822 chr2 3099075 T G 6.18E-06 Stroke (ischemic) / / 21957438 rs13023918 chr2 3116598 A G 6.74E-05 HDL cholesterol / / pha003075 rs13023918 chr2 3116598 A G 7.78E-05 Lipid levels / / pha003082 rs4854192 chr2 3120184 G A 8.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs7565101 chr2 3127370 A G 3.27E-04 Blood pressure / / 17255346 rs2887312 chr2 3152466 G A 8.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11677255 chr2 3153038 C A 7.53E-04 Aortic root size / / 21223598 rs6730025 chr2 3163738 G A 0.0008131 Hypertension (early onset hypertension) / / 22479346 rs13021132 chr2 3172438 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs13021132 chr2 3172438 C T 1.34E-05 Insulin Resistance / / pha003062 rs13021132 chr2 3172438 C T 2.22E-06 Insulin-related traits / / pha003063 rs10208086 chr2 3175992 G A 3.04E-06 Insulin Resistance / / pha003062 rs10208086 chr2 3175992 G A 6.73E-08 Insulin-related traits / / pha003063 rs4854106 chr2 3213822 A G 9.03E-05 Amyotrophic lateral sclerosis (sporadic) TSSC1 intron 24529757 rs7595382 chr2 3220709 G A 4.10E-05 Insulin Resistance TSSC1 intron pha003062 rs7595382 chr2 3220709 G A 9.54E-07 Insulin-related traits TSSC1 intron pha003063 rs2694103 chr2 3243238 G A 1.62E-04 Response to taxane treatment (placlitaxel) TSSC1 intron 23006423 rs1869417 chr2 3249933 T C 9.97E-05 Insulin-related traits TSSC1 intron pha003063 rs2694093 chr2 3258174 C T 8.23E-04 Multiple complex diseases TSSC1 intron 17554300 rs2694074 chr2 3265710 T A 1.80E-06 Nasopharyngeal carcinoma TSSC1 intron 23209447 rs2694075 chr2 3265893 T C 9.23E-04 Multiple complex diseases TSSC1 intron 17554300 rs2694079 chr2 3277639 G A 9.26E-04 Multiple complex diseases TSSC1 intron 17554300 rs10206606 chr2 3305635 G A 8.75E-05 Serum metabolites TSSC1 intron 19043545 rs7563810 chr2 3322170 A G 1.00E-04 Coronary heart disease TSSC1 intron 21378986 rs6548153 chr2 3326045 C A 0.0000901 Nicotine dependence (smoking) TSSC1 intron 22377092 rs12623730 chr2 3334003 C T 0.0000859 Nicotine dependence (smoking) TSSC1 intron 22377092 rs2324582 chr2 3339350 G A 1.92E-04 Schizophrenia TSSC1 intron 20832056 rs6712776 chr2 3352449 A G 2.90E-05 Hypertension TSSC1 intron 19609347 rs6712776 chr2 3352449 A G 8.29E-04 Aortic root size TSSC1 intron 21223598 rs4854182 chr2 3366890 C T 2.50E-05 Urinary metabolites TSSC1 intron 21572414 rs10865541 chr2 3392075 T A,C 6.00E-06 Obesity-related traits TRAPPC12 cds-synon 23251661 rs10865541 chr2 3392075 T A,C 5.23E-05 Receptive language ability TRAPPC12 cds-synon 24687471 rs10165099 chr2 3402591 T C 3.43E-05 Receptive language ability TRAPPC12 intron 24687471 rs4627605 chr2 3411923 G A 4.73E-05 Receptive language ability TRAPPC12 intron 24687471 rs4971502 chr2 3414029 A G 9.40E-05 Receptive language ability TRAPPC12 intron 24687471 rs13020433 chr2 3417577 G A 7.06E-05 Receptive language ability TRAPPC12 intron 24687471 rs6739163 chr2 3419011 G A 7.13E-05 HIV-1 control TRAPPC12 intron 20041166 rs7558487 chr2 3425514 G C 6.67E-05 Receptive language ability TRAPPC12 intron 24687471 rs10206964 chr2 3425948 T C 6.63E-05 Receptive language ability TRAPPC12 intron 24687471 rs7579868 chr2 3431157 T G 5.85E-05 Receptive language ability TRAPPC12 intron 24687471 rs4971505 chr2 3432550 T G 5.62E-05 Receptive language ability TRAPPC12 intron 24687471 rs7585799 chr2 3464810 C T 4.57E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRAPPC12 intron 20877124 rs9678657 chr2 3497167 G A 9.73E-04 Multiple complex diseases / / 17554300 rs4591372 chr2 3503566 T A 5.81E-04 Smoking quantity ADI1 intron 24665060 rs9798096 chr2 3508994 C T 2.50E-04 Celiac disease ADI1 intron 23936387 rs4595985 chr2 3581514 T C 6.62E-05 Longevity LOC100506014 intron 20304771 rs10153531 chr2 3589803 A G 8.05E-05 Longevity / / 20304771 rs7589966 chr2 3696636 T C 1.30E-05 Urinary metabolites / / 21572414 rs4849975 chr2 3701336 G A 7.83E-05 Intelligence / / 21826061 rs11894441 chr2 3701972 G A 9.80E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17445240 chr2 3703041 A G 2.68E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17445240 chr2 3703041 A G 5.49E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs17445240 chr2 3703041 A G 5.01E-07 Response to inhaled corticosteroid treatment in asthma (percentage change of FEV1) / / 24792382 rs13418767 chr2 3704830 G T 5.02E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs13418767 chr2 3704830 G T 2.77E-06 Response to inhaled corticosteroid treatment in asthma (percentage change of FEV1) / / 24792382 rs6754459 chr2 3707423 C T 1.92E-04 Response to cytidine analogues (gemcitabine) ALLC intron 24483146 rs6754459 chr2 3707423 C T 5.73E-07 Response to inhaled corticosteroid treatment in asthma (percentage change of FEV1) ALLC intron 24792382 rs17017879 chr2 3713658 G C 3.40E-04 Fibrinogen ALLC intron 17255346 rs17017879 chr2 3713658 G C 4.52E-05 Response to cytidine analogues (gemcitabine) ALLC intron 24483146 rs11687349 chr2 3717496 T G 5.68E-04 Response to cytidine analogues (gemcitabine) ALLC intron 24483146 rs11123610 chr2 3723026 G A 4.00E-07 Response to inhaled corticosteroid treatment in asthma (percentage change of FEV1) ALLC intron 24792382 rs6743352 chr2 3732546 T C 2.80E-05 Amyotrophic Lateral Sclerosis ALLC intron 17827064 rs6730148 chr2 3748971 T C 2.00E-06 Obesity-related traits ALLC intron 23251661 rs6730396 chr2 3749119 T C 1.40E-13 Health and aging,CVD and cancer age of onset ALLC missense 22174011 rs6730396 chr2 3749119 T C 1.90E-32 Health and aging,CVD and cancer age of onset ALLC missense 22174011 rs6730396 chr2 3749119 T C 2.90E-28 Health and aging,CVD and cancer age of onset ALLC missense 22174011 rs11682163 chr2 3749546 T C 0.0000076 Primary sclerosing cholangitis ALLC intron 22521342 rs6542651 chr2 3759830 T C 2.84E-05 Parkinson's disease DCDC2C intron 19915575 rs6542651 chr2 3759830 T C 3.34E-06 Parkinson's disease DCDC2C intron pha002868 rs17017928 chr2 3769141 G A 4.96E-23 Narcolepsy DCDC2C intron 19629137 rs357957 chr2 3783688 G A 6.49E-04 Multiple complex diseases DCDC2C intron 17554300 rs357958 chr2 3783716 A G 6.14E-04 Multiple complex diseases DCDC2C intron 17554300 rs17017966 chr2 3792530 T C 0.0001101 Sarcoidosis DCDC2C intron 22952805 rs357973 chr2 3798725 A G 9.30E-05 Type 2 diabetes DCDC2C intron 17463248 rs357971 chr2 3799594 C G 9.10E-05 Type 2 diabetes DCDC2C intron 17463248 rs357968 chr2 3800496 C T 8.51E-04 Parkinson's disease DCDC2C intron 17052657 rs6761325 chr2 3812539 T G 9.80E-04 Acute lung injury DCDC2C intron 22295056 rs10195488 chr2 3824135 T C 5.62E-05 Height / / pha003011 rs13021385 chr2 3826387 T C 4.49E-05 Height / / pha003011 rs17018026 chr2 3836760 G A 3.42E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs11886534 chr2 3837303 A G 7.87E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs11677370 chr2 3841420 T A 3.00E-06 Type 2 diabetes / / 21490949 rs2034730 chr2 3882177 A G 2.77E-04 Schizophrenia / / 20832056 rs897067 chr2 3891792 T C 2.56E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs897065 chr2 3892049 A G 1.79E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs4850000 chr2 3918124 T C 5.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4850005 chr2 3953682 G A 4.65E-05 Type 2 diabetes / / 17463246 rs1565806 chr2 3970561 C T 9.51E-04 Response to alcohol consumption (flushing response) / / 24277619 rs11123630 chr2 4123851 C T 7.53E-05 Multiple complex diseases / / 17554300 rs4849943 chr2 4124656 C A 4.28E-04 Smoking quantity / / 24665060 rs12478345 chr2 4135272 A G 2.74E-04 Smoking quantity / / 24665060 rs1024026 chr2 4135981 C T 6.80E-04 Smoking quantity / / 24665060 rs12464429 chr2 4136781 A G 1.70E-05 Urinary metabolites / / 21572414 rs6759055 chr2 4137992 T G 3.88E-04 Alzheimer's disease / / 24755620 rs12476453 chr2 4140215 C A 1.20E-04 Multiple complex diseases / / 17554300 rs6709996 chr2 4160920 G A 5.65E-04 Multiple complex diseases / / 17554300 rs1437700 chr2 4170619 A G 2.38E-04 Fibrinogen / / 17255346 rs7601231 chr2 4176692 G T 4.30E-04 Sudden cardiac arrest / / 21658281 rs11692873 chr2 4183357 G A 5.92E-04 Multiple complex diseases / / 17554300 rs6714273 chr2 4188698 C T 6.56E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4850057 chr2 4220499 T C 2.48E-05 Multiple complex diseases / / 17554300 rs17018897 chr2 4290344 A G 3.11E-05 Multiple complex diseases / / 17554300 rs11686135 chr2 4318976 T C 4.00E-06 Pulmonary function decline / / 22424883 rs6716364 chr2 4325172 C T 2.23E-05 Atopy / / 21625490 rs11123636 chr2 4327104 G T 7.31E-05 Post-operative nausea and vomiting / / 21694509 rs7586198 chr2 4327339 T C 2.34E-04 Schizophrenia / / 19197363 rs6760082 chr2 4329378 G A 6.87E-05 Serum metabolites / / 19043545 rs10171541 chr2 4344241 A G 6.88E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs2030265 chr2 4349367 C T 2.60E-05 Urinary metabolites / / 21572414 rs4585039 chr2 4353141 C A 2.20E-04 Schizophrenia / / 19197363 rs11123646 chr2 4377723 A C 4.97E-05 Post-operative nausea and vomiting / / 21694509 rs4328647 chr2 4379490 T A 6.57E-05 Serum metabolites / / 19043545 rs6542705 chr2 4402182 A C 7.98E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs3908110 chr2 4416841 C A,T 1.87E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs637295 chr2 4429392 C T 0.0002 Coronary artery calcification / / 23727086 rs619773 chr2 4449917 G A 4.21E-04 White matter integrity / / 22425255 rs9973340 chr2 4469132 C T 3.40E-04 Height / / 17255346 rs2677912 chr2 4471138 A G 3.68E-05 Height / / 17255346 rs634273 chr2 4474196 G A 9.86E-04 Response to alcohol consumption (flushing response) / / 24277619 rs631806 chr2 4485914 A G 5.85E-04 Alzheimer's disease / / 17998437 rs7596238 chr2 4492173 G A 9.06E-06 Personality dimensions / / 23658558 rs1453592 chr2 4516591 G A 5.06E-05 Multiple complex diseases / / 17554300 rs648196 chr2 4517511 G T 3.06E-04 Alcohol dependence / / 20201924 rs648196 chr2 4517511 G T 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17555205 chr2 4541099 A G 1.64E-05 Coronary heart disease / / pha003031 rs6750002 chr2 4567844 A G 8.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1453600 chr2 4583424 G A 6.77E-04 Type 2 diabetes / / 17463246 rs1670530 chr2 4592241 C T 4.10E-04 Alcohol dependence / / 20201924 rs1479234 chr2 4593371 T C 1.00E-04 Information processing speed / / 21130836 rs10495505 chr2 4601562 C T 2.71E-04 Type 2 diabetes / / 17463246 rs6712089 chr2 4602607 A G 8.47E-04 Type 2 diabetes / / 17463246 rs2169943 chr2 4679290 G A 4.32E-05 Bipolar disorder LOC727982 intron 18317468 rs2619192 chr2 4700632 T G 4.52E-05 Bipolar disorder LOC727982 intron 18317468 rs17019595 chr2 4704141 A G 1.25E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs9308788 chr2 4711095 T A 3.94E-04 Bipolar disorder / / 19259986 rs10495507 chr2 4734920 C A 8.20E-04 Bipolar disorder / / 19259986 rs2218537 chr2 4737590 G A 6.51E-04 Type 2 diabetes / / 22158537 rs2592086 chr2 4805579 A G 7.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs825941 chr2 4807167 A T 2.18E-04 Type 2 diabetes / / 17463246 rs17019777 chr2 4807209 A G 9.20E-06 Urinary metabolites / / 21572414 rs825939 chr2 4807737 T C 7.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs825937 chr2 4808027 C A 4.07E-04 Multiple complex diseases / / 17554300 rs825937 chr2 4808027 C A 2.00E-07 Blood pressure / / 24954895 rs825932 chr2 4811626 A G 9.14E-04 Multiple complex diseases / / 17554300 rs825915 chr2 4818674 A G 1.44E-05 Bilirubin levels,in serum / / 19389676 rs12711955 chr2 4832338 A G 7.84E-04 Response to alcohol consumption (flushing response) / / 24277619 rs17582650 chr2 4855471 A G 4.75E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1975386 chr2 4855697 A G 6.91E-04 Prostate cancer mortality / / 20978177 rs735671 chr2 4860237 C T 6.67E-04 Coronary heart disease / / 21971053 rs1866608 chr2 4865185 A G 2.24E-06 Rheumatoid arthritis / / 19503088 rs1371473 chr2 4878144 T C 6.95E-04 Coronary heart disease / / 21971053 rs1821990 chr2 4882122 C T 6.21E-04 Coronary heart disease / / 21971053 rs934993 chr2 4886084 C T 4.33E-04 Coronary heart disease / / 21971053 rs13002818 chr2 4889204 T C 2.46E-04 Telomere length / / 23900074 rs6747617 chr2 4889925 G A 7.58E-05 Coronary heart disease / / 21971053 rs6754512 chr2 4894603 A G 6.23E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7600533 chr2 4897836 C T 3.25E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10495513 chr2 4916939 G A 2.09E-04 Coronary heart disease / / 21971053 rs6542644 chr2 4930330 T C 1.94E-04 Coronary heart disease / / 21971053 rs6746310 chr2 4952797 A C 1.30E-08 Urinary metabolites / / 21572414 rs17586945 chr2 4956957 G A 7.30E-06 Urinary metabolites / / 21572414 rs934989 chr2 4957344 A G 4.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs2255816 chr2 4958322 A T 4.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs2620437 chr2 4958988 G A 4.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs12615696 chr2 4962469 A G 9.19E-04 Coronary heart disease / / 21971053 rs12464103 chr2 4974780 G A 2.63E-05 Brain lesion load / / 19010793 rs28668317 chr2 5166220 G A 1.54E-05 Smoking initiation / / 24665060 rs8179663 chr2 5173840 A G 6.52E-04 Smoking initiation / / 24665060 rs4552162 chr2 5181373 G A 7.14E-04 Smoking initiation / / 24665060 rs4669203 chr2 5197986 G C 1.00E-04 Prostate cancer / / 21743057 rs12613788 chr2 5215885 C T 8.00E-05 Prostate cancer / / 21743057 rs16863306 chr2 5218148 G C 8.00E-05 Prostate cancer / / 21743057 rs12997987 chr2 5222191 C T 9.50E-04 Multiple complex diseases / / 17554300 rs10187299 chr2 5241031 A T 4.21E-04 Alzheimer's disease / / 17998437 rs10187299 chr2 5241031 A T 7.53E-05 Aortic root size / / 21223598 rs10181839 chr2 5241229 T C 4.44E-04 Alzheimer's disease / / 17998437 rs10181839 chr2 5241229 T C 7.98E-05 Aortic root size / / 21223598 rs1584832 chr2 5253424 A C 3.17E-04 Gallstones / / 17632509 rs1075309 chr2 5253598 C T 7.00E-07 Tuberculosis / / 24057671 rs4670034 chr2 5271928 C T 4.31E-04 Alzheimer's disease / / 17998437 rs17331611 chr2 5293171 C A 2.80E-05 Urinary metabolites / / 21572414 rs7609160 chr2 5326832 T A 7.71E-04 Alzheimer's disease / / 17998437 rs9287678 chr2 5340675 A G 9.32E-04 Alzheimer's disease / / 17998437 rs10210050 chr2 5344984 G A 7.96E-04 Alzheimer's disease / / 17998437 rs13419667 chr2 5412077 G A 1.14E-06 Multiple complex diseases / / 17554300 rs13385805 chr2 5413937 C T 2.24E-04 Multiple complex diseases / / 17554300 rs13004938 chr2 5437543 A G 9.00E-06 Obesity-related traits / / 23251661 rs10190732 chr2 5464761 G T 1.57E-05 Alzheimer's disease / / 21627779 rs9287696 chr2 5465154 G A 3.55E-05 Aging (time to event) / / 21782286 rs955146 chr2 5494048 T C 4.17E-05 Smoking initiation / / 24665060 rs940515 chr2 5494291 A G 1.77E-04 Smoking initiation / / 24665060 rs940516 chr2 5494701 T A 4.51E-04 Smoking initiation / / 24665060 rs11677035 chr2 5495963 C T 7.78E-04 Smoking initiation / / 24665060 rs1524490 chr2 5508545 C A 8.65E-05 Post-operative nausea and vomiting / / 21694509 rs700952 chr2 5510754 C T 8.57E-06 Type 2 diabetes / / 23300278 rs17356557 chr2 5512416 T C 1.38E-06 Type 2 diabetes / / 23300278 rs10170790 chr2 5515545 C T 2.31E-05 Post-operative nausea and vomiting / / 21694509 rs10170790 chr2 5515545 C T 7.74E-05 Insulin-related traits / / pha003063 rs1524483 chr2 5559013 T G 9.59E-04 Major depressive disorder / / 22472876 rs792087 chr2 5576619 T A 3.45E-04 Multiple complex diseases / / 17554300 rs792083 chr2 5579202 T C 5.76E-04 Multiple complex diseases / / 17554300 rs2462394 chr2 5579420 G A 5.51E-04 Multiple complex diseases / / 17554300 rs4644991 chr2 5588753 T C 8.77E-05 Cognitive impairment induced by topiramate / / 22091778 rs813779 chr2 5590257 T C 5.81E-05 Heart Failure / / pha002885 rs10929584 chr2 5611872 A G 3.50E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4669393 chr2 5623567 C T 1.82E-04 Alzheimer's disease / / 24755620 rs11894081 chr2 5664008 G T 4.00E-09 Crohn's disease / / 23266558 rs920185 chr2 5679036 C A 9.69E-05 Response to methylphenidate treatment / / 21130132 rs920185 chr2 5679036 C A 2.50E-05 Urinary metabolites / / 21572414 rs13409347 chr2 5680264 G T 8.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs10929647 chr2 5688365 C A 2.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs10929647 chr2 5688365 C A 8.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs2882274 chr2 5688981 T C 2.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs13432623 chr2 5689218 C T 2.70E-05 Urinary metabolites / / 21572414 rs13390174 chr2 5689457 T C 2.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs13390174 chr2 5689457 T C 7.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs17363613 chr2 5733431 C A 8.41E-05 Pancreatic cancer / / pha002874 rs16864022 chr2 5795413 A G 2.90E-05 Urinary metabolites / / 21572414 rs6740618 chr2 5818277 T G 6.42E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6740458 chr2 5818713 A T 6.58E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6735027 chr2 5818895 C A 3.52E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs12621309 chr2 5819288 G A 7.04E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs10929756 chr2 5819517 C T 6.38E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4547512 chr2 5821748 G T 6.61E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6734206 chr2 5824158 C G 7.51E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs10206204 chr2 5825923 G T 6.56E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6432221 chr2 5828702 T G 7.74E-04 Type 2 diabetes / / 17463246 rs7604153 chr2 5852483 A G 2.37E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7604153 chr2 5852483 A G 3.62E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16864067 chr2 5860331 G A 3.50E-06 Urinary metabolites / / 21572414 rs1864263 chr2 5860402 T A 0.000194 Breast cancer early age of onset / / 18463975 rs1366733 chr2 5890171 C T 7.02E-04 Multiple complex diseases / / 17554300 rs13391560 chr2 5891097 A G 6.64E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs2722602 chr2 5891437 C T 3.83E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs16864170 chr2 5907880 T C 2.00E-07 Chronic kidney disease / / 20383146 rs1560238 chr2 5925857 C T 0.0000174 post-traumatic stress disorder / / 22869035 rs1560238 chr2 5925857 C T 1.74E-05 Schizophrenia / / 22883433 rs16864200 chr2 5926156 C T 0.0000169 post-traumatic stress disorder / / 22869035 rs16864200 chr2 5926156 C T 1.69E-05 Schizophrenia / / 22883433 rs16864209 chr2 5928093 T C 0.0000169 post-traumatic stress disorder / / 22869035 rs16864209 chr2 5928093 T C 1.69E-05 Schizophrenia / / 22883433 rs10495524 chr2 5931302 G A 8.88E-04 Schizophrenia / / 19197363 rs2722583 chr2 5942145 C A 2.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1429238 chr2 5958708 C T 7.13E-04 Type 2 diabetes / / 17463246 rs1366740 chr2 5966363 G A 4.51E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1864261 chr2 5967398 T C 7.81E-04 Type 2 diabetes / / 17463246 rs2709447 chr2 5973504 A C 3.36E-04 Schizophrenia / / 19197363 rs2709464 chr2 5985695 T C 8.90E-05 Coffee consumption / / 21357676 rs1346612 chr2 5985923 C T 2.05E-04 Type 2 diabetes / / 17846124 rs7583513 chr2 5992237 G A 1.40E-05 Multiple complex diseases / / 17554300 rs2564024 chr2 6005500 T A 1.56E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2564024 chr2 6005500 T A 2.94E-04 Type 2 diabetes / / 17463246 rs2564024 chr2 6005500 T A 2.11E-04 Alzheimer's disease / / 17998437 rs2564024 chr2 6005500 T A 6.97E-05 Serum metabolites / / 19043545 rs12617498 chr2 6010582 G C 7.94E-04 Alzheimer's disease / / 17998437 rs2564032 chr2 6020651 T C 7.54E-04 Multiple complex diseases / / 17554300 rs2564039 chr2 6029014 T C 7.18E-04 Alzheimer's disease / / 17998437 rs16864476 chr2 6039064 G T 7.75E-04 Multiple complex diseases / / 17554300 rs16864477 chr2 6039177 G A 3.75E-04 Multiple complex diseases / / 17554300 rs4257373 chr2 6052307 A G 4.24E-04 Multiple complex diseases / / 17554300 rs7586540 chr2 6052751 G A 5.00E-06 Coronary artery calcification / / 23870195 rs10495528 chr2 6057847 T C 7.28E-05 Diabetic retinopathy / / 20871662 rs10495528 chr2 6057847 T C 1.19E-05 Body Mass Index / / pha003007 rs10495528 chr2 6057847 T C 9.72E-05 Body Fat Distribution / / pha003016 rs4293540 chr2 6060989 T C 7.94E-06 Coronary artery calcification / / 23870195 rs7563310 chr2 6061966 A G 7.25E-05 Bipolar disorder,schizoaffective / / 19567891 rs6748570 chr2 6073449 C T 2.62E-05 Bipolar disorder,schizoaffective LOC150622 intron 19567891 rs4349325 chr2 6078420 A G 8.30E-05 Non-alcoholic fatty liver disease histology (other) LOC150622 intron 20708005 rs34648212 chr2 6081657 A T 9.74E-04 Multiple complex diseases LOC150622 intron 17554300 rs13432692 chr2 6085200 C T 7.02E-06 Prostate cancer LOC150622 intron 24185611 rs12470944 chr2 6100997 A G 4.24E-05 Serum metabolites LOC150622 intron 19043545 rs6432462 chr2 6122449 T C 1.82E-05 Multiple complex diseases / / 17554300 rs1405262 chr2 6134940 T C 6.00E-06 HIV-1 control / / 20041166 rs941009 chr2 6141286 T C 6.05E-04 Stroke / / pha002887 rs2609186 chr2 6160591 G A 2.00E-04 Dietary macronutrient intake / / 23636237 rs7566764 chr2 6169727 C T 1.79E-05 Body mass (lean) / / 19268274 rs1918043 chr2 6175170 T A 2.04E-05 Body mass (lean) / / 19268274 rs1918043 chr2 6175170 T A 6.06E-04 Insulin resistance / / 21901158 rs1918041 chr2 6175506 G A 1.92E-05 Body mass (lean) / / 19268274 rs751051 chr2 6177737 G A 3.34E-05 Body mass (lean) / / 19268274 rs2609103 chr2 6181855 G A 8.07E-05 Body mass (lean) / / 19268274 rs2693818 chr2 6204508 C T 5.87E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs12052388 chr2 6224960 T G 0.000244 Salmonella-induced pyroptosis / / 22837397 rs2693871 chr2 6234129 A G 6.22E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2249724 chr2 6235208 A C 6.22E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2350906 chr2 6249264 G A 9.11E-05 Multiple complex diseases / / 17554300 rs1852319 chr2 6252585 A G 1.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1852319 chr2 6252585 A G 5.64E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2693889 chr2 6254752 A G 6.33E-05 Blood Pressure / / pha002903 rs16864796 chr2 6295756 A G 2.57E-04 Multiple complex diseases / / 17554300 rs6722570 chr2 6300140 C T 8.79E-04 Heart Failure / / pha002885 rs10168477 chr2 6330449 T G 3.38E-05 Coronary heart disease / / pha003033 rs10495535 chr2 6381852 G A 3.40E-06 Urinary metabolites / / 21572414 rs2351100 chr2 6396424 T C 1.71E-05 Insulin-related traits / / 19902172 rs10193208 chr2 6398203 C T 1.18E-04 Multiple complex diseases / / 17554300 rs4669054 chr2 6398413 T A 4.48E-05 Body mass (lean) / / 19268274 rs10208141 chr2 6398527 T C 2.15E-04 Multiple complex diseases / / 17554300 rs4538171 chr2 6402296 C T 5.66E-04 Multiple complex diseases / / 17554300 rs16865007 chr2 6419606 C T 2.74E-04 Multiple complex diseases / / 17554300 rs6761025 chr2 6433173 G A 2.70E-05 Urinary metabolites / / 21572414 rs4337447 chr2 6434587 T C 4.37E-04 Intracranial aneurysm / / 20613766 rs2044652 chr2 6441964 G C 4.77E-04 Multiple complex diseases / / 17554300 rs16865017 chr2 6449121 A G 4.82E-04 Multiple complex diseases / / 17554300 rs7591996 chr2 6461421 A C 1.00E-08 Osteosarcoma / / 23727862 rs13403411 chr2 6478838 G A 5.20E-06 Osteosarcoma / / 23727862 rs13394549 chr2 6495748 G A 1.43E-04 Gallstones / / 17632509 rs16865088 chr2 6512470 G C 4.91E-04 Multiple complex diseases / / 17554300 rs11899039 chr2 6515225 T A 8.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs6739653 chr2 6522333 G A 7.80E-04 Alcohol dependence / / 20201924 rs10208273 chr2 6523994 A G 2.93E-07 Osteosarcoma / / 23727862 rs11692553 chr2 6528496 A T 6.36E-05 Serum metabolites / / 19043545 rs1564032 chr2 6529504 T C 6.60E-04 Alcohol dependence / / 20201924 rs6713599 chr2 6533326 C T 2.80E-05 Urinary metabolites / / 21572414 rs6723180 chr2 6551857 A G 5.90E-04 Alcohol dependence / / 20201924 rs6726264 chr2 6551873 T C 5.90E-04 Alcohol dependence / / 20201924 rs13027881 chr2 6555933 G A 3.76E-06 Parkinson's disease / / pha002868 rs6734894 chr2 6556781 G A 4.63E-06 Parkinson's disease / / pha002868 rs7577180 chr2 6561446 C T 6.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4669069 chr2 6570758 T C 0.00003 Follicular lymphoma / / 23025665 rs1462061 chr2 6606787 G A 3.45E-04 Alzheimer's disease / / 17998437 rs306196 chr2 6627807 A G 7.59E-04 Multiple complex diseases / / 17554300 rs4668498 chr2 6641549 T G 7.72E-04 Insulin resistance / / 21901158 rs16865301 chr2 6657760 C T 7.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs17386094 chr2 6661264 A C 2.60E-05 Urinary metabolites / / 21572414 rs12465667 chr2 6661877 T C 1.05E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4669075 chr2 6679793 C A 7.33E-04 Alzheimer's disease / / 24755620 rs10495537 chr2 6694519 C T 5.00E-07 Visceral adipose tissue adjusted for BMI / / 22589738 rs1870131 chr2 6695161 C T 2.63E-05 stroke (ischemic) / / 17434096 rs962528 chr2 6697088 C T 8.00E-06 Visceral fat / / 22589738 rs1350342 chr2 6703089 G A 3.09E-04 Atopy / / 21625490 rs12998104 chr2 6729633 C T 5.08E-04 Depression (quantitative trait) / / 20800221 rs12998104 chr2 6729633 C T 2.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs13401852 chr2 6733673 G A 4.78E-04 Depression (quantitative trait) / / 20800221 rs13401852 chr2 6733673 G A 7.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs13393305 chr2 6734181 A G 4.69E-04 Depression (quantitative trait) / / 20800221 rs13383761 chr2 6735155 C T 5.52E-04 Depression (quantitative trait) / / 20800221 rs13383761 chr2 6735155 C T 6.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs6732257 chr2 6739006 C A 3.91E-04 Depression (quantitative trait) / / 20800221 rs6732257 chr2 6739006 C A 4.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs1461312 chr2 6743067 A T 3.87E-04 Depression (quantitative trait) / / 20800221 rs1461312 chr2 6743067 A T 3.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs6717016 chr2 6747503 G A 3.81E-04 Depression (quantitative trait) / / 20800221 rs6717016 chr2 6747503 G A 6.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs13387837 chr2 6754148 G A 4.13E-04 Depression (quantitative trait) / / 20800221 rs13387837 chr2 6754148 G A 6.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs10204937 chr2 6758874 A G 5.95E-04 Depression (quantitative trait) / / 20800221 rs10204937 chr2 6758874 A G 6.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs4668504 chr2 6758957 G A 2.74E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7575004 chr2 6761631 C T 5.96E-04 Depression (quantitative trait) / / 20800221 rs7584788 chr2 6769318 C T 5.19E-04 Bone mass and geometry / / 17903296 rs7584788 chr2 6769318 C T 4.54E-04 Depression (quantitative trait) / / 20800221 rs7584788 chr2 6769318 C T 2.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs12692323 chr2 6772729 T A 4.30E-04 Depression (quantitative trait) / / 20800221 rs12692323 chr2 6772729 T A 3.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs376286195 chr2 6774326 C CTTA 1.69E-04 Depression (quantitative trait) / / 20800221 rs376286195 chr2 6774326 C CTTA 0.0000073 Cytarabine sensitivity / / 23538338 rs6714052 chr2 6774326 C A,T 1.69E-04 Depression (quantitative trait) / / 20800221 rs6714052 chr2 6774326 C A,T 0.0000073 Cytarabine sensitivity / / 23538338 rs76628858 chr2 6774326 C CTTA 1.69E-04 Depression (quantitative trait) / / 20800221 rs76628858 chr2 6774326 C CTTA 0.0000073 Cytarabine sensitivity / / 23538338 rs13421943 chr2 6777264 C T 3.93E-04 Depression (quantitative trait) / / 20800221 rs7561212 chr2 6781149 G A 1.95E-04 Depression (quantitative trait) / / 20800221 rs7561212 chr2 6781149 G A 5.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs1505696 chr2 6851269 T C 9.40E-05 Longevity / / 22279548 rs307992 chr2 6851976 T C 9.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs307993 chr2 6852369 G A 9.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs307995 chr2 6852972 T C 8.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs307996 chr2 6853387 T C 8.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs307997 chr2 6853468 T C 8.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs13413734 chr2 6866483 A G 9.30E-06 Brachial circumference / / 22479309 rs1870744 chr2 6871849 T C 9.74E-04 Alzheimer's disease / / 24755620 rs11681428 chr2 6880984 T C 9.95E-04 Alzheimer's disease LINC00487 intron 24755620 rs17650774 chr2 6913020 A G 2.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs11683777 chr2 6922783 C T 5.77E-05 Depression (quantitative trait) / / 23290196 rs905968 chr2 6935239 C T 7.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs16865587 chr2 6935623 C T 1.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs4668508 chr2 6936085 G A 7.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs7588087 chr2 6936616 T A 2.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs2174519 chr2 6937310 T C 4.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs10200467 chr2 6937593 C T 6.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs6742876 chr2 6937744 T C 4.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs6742989 chr2 6937849 T C 4.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs4613245 chr2 6938163 C T 3.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs4458187 chr2 6938308 A G 5.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs16865600 chr2 6939346 G A 4.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs1505695 chr2 6940217 T C 5.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs113498426 chr2 6940819 A AT 7.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs1847735 chr2 6940819 A T 7.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs1505694 chr2 6940956 C T 7.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs7600900 chr2 6941288 A C 7.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs7606696 chr2 6941519 T C 7.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs6712193 chr2 6942043 G A 7.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs1448871 chr2 6942690 A G 4.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs10495544 chr2 6956133 A C 6.51E-05 Serum metabolites / / 19043545 rs113470953 chr2 6976394 T C 3.57E-05 Intracerebral hemorrhage / / 24656865 rs10495545 chr2 6990020 C T 8.88E-05 AIDS progression CMPK2 cds-synon 19115949 rs4669112 chr2 7028652 C T 1.62E-04 Smoking cessation RSAD2 intron 18519826 rs16865717 chr2 7032618 T C 9.00E-09 Venous thromboembolism (gene x gene interaction) RSAD2 intron 23509962 rs4669114 chr2 7036621 A G 2.11E-05 Sudden cardiac arrest RSAD2 UTR-3 21658281 rs1013864 chr2 7051171 G A 1.21E-05 Graves' disease / / 21841780 rs3806609 chr2 7056183 T C 2.00E-05 Graves' disease LOC386597 intron 21841780 rs771274 chr2 7060629 C T 2.22E-04 Graves' disease RNF144A intron 21841780 rs10495547 chr2 7062123 G A 4.12E-05 Schizophrenia RNF144A intron 20832056 rs720388 chr2 7068927 T C 1.80E-04 Aortic root size RNF144A intron 21223598 rs1797557 chr2 7080792 C T 4.65E-04 Aortic root size RNF144A intron 21223598 rs3772022 chr2 7085569 C T 3.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RNF144A intron 20877124 rs3772019 chr2 7096989 A G 8.60E-06 Urinary metabolites RNF144A intron 21572414 rs771315 chr2 7097523 T C 4.76E-05 Smoking cessation RNF144A intron 18519826 rs3772017 chr2 7097845 C G 1.20E-04 Smoking cessation RNF144A intron 18519826 rs3772017 chr2 7097845 C G 2.20E-05 Urinary metabolites RNF144A intron 21572414 rs3772016 chr2 7098007 C G 2.50E-05 Urinary metabolites RNF144A intron 21572414 rs771318 chr2 7101720 A G 4.92E-04 Multiple complex diseases RNF144A intron 17554300 rs771319 chr2 7101811 C T 4.94E-04 Multiple complex diseases RNF144A intron 17554300 rs771320 chr2 7104166 A C 2.22E-04 Smoking quantity RNF144A intron 24665060 rs3772002 chr2 7111899 G T 5.76E-04 Smoking quantity RNF144A intron 24665060 rs3836204 chr2 7111899 G GT 5.76E-04 Smoking quantity RNF144A intron 24665060 rs543410060 chr2 7111899 G GT 5.76E-04 Smoking quantity RNF144A intron 24665060 rs3771997 chr2 7119618 G A 7.84E-04 Smoking quantity RNF144A intron 24665060 rs11685858 chr2 7142180 G C 6.89E-04 Multiple complex diseases RNF144A intron 17554300 rs6741819 chr2 7147973 C T 9.50E-04 Multiple complex diseases RNF144A intron 17554300 rs6741819 chr2 7147973 C T 2.00E-07 Response to antipsychotic treatment RNF144A intron 20195266 rs2460405 chr2 7149509 A G 1.37E-04 Body mass index RNF144A intron 21701565 rs447721 chr2 7150330 C T 3.49E-04 Lung function (forced expiratory volume in 1 second) RNF144A intron 17255346 rs447721 chr2 7150330 C T 1.35E-04 Body mass index RNF144A intron 21701565 rs445411 chr2 7150527 T C 2.05E-04 Body mass index RNF144A intron 21701565 rs381214 chr2 7150654 C T 1.35E-04 Body mass index RNF144A intron 21701565 rs388773 chr2 7150758 G A,C,T 3.34E-04 Body mass index RNF144A intron 21701565 rs412098 chr2 7151074 A G 4.98E-04 Amyotrophic lateral sclerosis (sporadic) RNF144A intron 24529757 rs420013 chr2 7161586 C A 1.21E-04 Stroke RNF144A intron pha002887 rs16865853 chr2 7171364 C T 7.19E-05 Blood pressure (response to angiotensin II receptor blocker) RNF144A intron 24192120 rs16865867 chr2 7186608 G A 7.40E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs6722170 chr2 7187199 A G 7.40E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs309295 chr2 7188238 G A 4.10E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs89983 chr2 7195192 C A 4.89E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs309271 chr2 7202496 T G 9.04E-04 Stroke / / pha002887 rs6746899 chr2 7203328 A G 7.14E-04 Multiple complex diseases / / 17554300 rs6431850 chr2 7248419 C T 1.78E-04 Cholesterol / / 17255346 rs7557365 chr2 7346878 C T 8.41E-04 Multiple complex diseases / / 17554300 rs4669156 chr2 7350916 C A 2.91E-04 Multiple complex diseases / / 17554300 rs1404845 chr2 7353714 C A 1.16E-04 Multiple complex diseases / / 17554300 rs1016516 chr2 7371689 A G 1.97E-04 Multiple complex diseases / / 17554300 rs2140855 chr2 7387447 C T 5.20E-04 Body mass index / / 21701565 rs7599262 chr2 7396577 G T 6.35E-05 Body Fat Distribution / / pha003017 rs7599262 chr2 7396577 G T 5.55E-05 Body Fat Distribution / / pha003018 rs10182781 chr2 7431359 T C 4.66E-06 Coronary heart disease / / 22319020 rs17681533 chr2 7439390 C T 3.11E-04 Multiple complex diseases / / 17554300 rs4669177 chr2 7445627 T C 2.43E-04 Multiple complex diseases / / 17554300 rs1430289 chr2 7454360 T C 7.49E-05 Multiple complex diseases / / 17554300 rs10179297 chr2 7460260 T C 5.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs11682970 chr2 7477186 T C 4.81E-05 Post-operative nausea and vomiting / / 21694509 rs2352714 chr2 7490156 A G 8.20E-05 Major depressive disorder / / pha002850 rs12469647 chr2 7502642 A G 2.30E-05 Urinary metabolites / / 21572414 rs13030633 chr2 7517620 C T 9.87E-06 Metabolite levels (Dihydroxy docosatrienoic acid) / / 23934736 rs12623931 chr2 7520946 A C 1.70E-06 Urinary metabolites / / 21572414 rs1367272 chr2 7561886 C T 1.77E-04 adolescent idiopathic scoliosis LOC100506274 intron 24023777 rs8179776 chr2 7564293 T G 7.50E-05 Temporomandibular joint disorders LOC100506274 intron 23746317 rs7608732 chr2 7583311 A C 2.40E-04 Celiac disease LOC100506274 intron 23936387 rs12692335 chr2 7606695 C T 0.000069 Uterine leiomyomata / / 23040493 rs6431885 chr2 7656440 T C 9.46E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6431885 chr2 7656440 T C 5.79E-05 Blood Pressure / / pha003049 rs10519830 chr2 7657807 A G 9.15E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7604664 chr2 7659087 G A 5.43E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs985268 chr2 7659201 G A 5.43E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7589284 chr2 7702036 C T 8.52E-05 Femoral neck bone geometry / / 22087292 rs11682922 chr2 7794936 G T 3.45E-07 Insulin-related traits / / 22791750 rs1720971 chr2 7822218 T C 7.78E-04 Insulin resistance / / 21901158 rs812811 chr2 7829406 A G 4.98E-04 Type 2 diabetes / / 17463246 rs772438 chr2 7831600 C G 2.62E-04 Type 2 diabetes / / 17463246 rs11676467 chr2 7833261 C T 5.46E-05 Cognitive test performance / / 20125193 rs10495558 chr2 7836151 T C 2.84E-04 Type 2 diabetes / / 17463246 rs10495558 chr2 7836151 T C 5.30E-05 Response to statin therapy / / 20339536 rs2948927 chr2 7856399 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2948926 chr2 7862742 G T 7.94E-05 Smoking initiation / / 24665060 rs41506246 chr2 7873892 G C 2.84E-05 Smoking initiation / / 24665060 rs12692341 chr2 7883907 G A 4.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs812810 chr2 7886879 C T 8.09E-04 Iron levels / / pha002876 rs10206339 chr2 7891122 A G 4.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs13395925 chr2 7893850 G A 7.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs772428 chr2 7897634 G A 1.32E-04 Body mass index / / 21701565 rs13386694 chr2 7899580 A G 5.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs13386820 chr2 7899688 A C 5.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs10929497 chr2 7899972 A G 6.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs13392332 chr2 7899987 T A 8.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs2140456 chr2 7921457 G A 7.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs954498 chr2 7922920 G T 4.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs10200068 chr2 7928447 C T 5.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs6760840 chr2 7930884 G T 3.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs11683873 chr2 7931803 G A 4.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs867399 chr2 7933490 C T 4.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs17440033 chr2 7934583 C T 5.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs12105768 chr2 7942739 G A 3.00E-06 Urinary metabolites / / 21572414 rs7561052 chr2 7949693 C T 4.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs10166962 chr2 7950796 G A 3.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs12692343 chr2 7951843 C T 4.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs1014431 chr2 7957112 T A 4.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs798443 chr2 7968275 G A 4.65E-05 Serum metabolites / / 19043545 rs2193071 chr2 8036260 G A 4.00E-06 Obesity-related traits / / 23251661 rs4669226 chr2 8053597 A G 5.00E-06 Multiple sclerosis / / 23412934 rs41009 chr2 8095158 A G 7.74E-04 Type 2 diabetes LOC339788 intron 17463246 rs6431912 chr2 8097807 C T 4.65E-05 Multiple complex diseases LOC339788 intron 17554300 rs193932 chr2 8107383 T C 8.75E-05 Type 2 diabetes LOC339788 intron 17463246 rs193931 chr2 8107435 G A 8.02E-05 Type 2 diabetes LOC339788 intron 17463246 rs193929 chr2 8107620 G T 6.55E-05 Type 2 diabetes LOC339788 intron 17463246 rs41007 chr2 8109043 C T 7.87E-05 Type 2 diabetes LOC339788 intron 17463246 rs13430914 chr2 8114648 G A 2.51E-05 Type 2 diabetes LOC339788 intron 17463246 rs17433703 chr2 8115300 C T 2.17E-05 Type 2 diabetes LOC339788 intron 17463246 rs1974696 chr2 8115782 G A 8.12E-05 Type 2 diabetes LOC339788 intron 17463246 rs6736759 chr2 8158653 A G 1.16E-04 Multiple complex diseases LINC00299 intron 17554300 rs7579823 chr2 8160356 C T 5.70E-05 HIV-1 control LINC00299 intron 20041166 rs6752439 chr2 8162049 T C 5.70E-05 HIV-1 control LINC00299 intron 20041166 rs6431918 chr2 8166518 G A 2.98E-04 Multiple complex diseases LINC00299 intron 17554300 rs7600576 chr2 8229484 C G 7.30E-05 Personality dimensions LINC00299 intron 18957941 rs6712604 chr2 8235239 T C 2.14E-05 Partial epilepsies LINC00299 intron 20522523 rs12479058 chr2 8278854 G T 3.73E-06 Schizophrenia LINC00299 intron 22037555 rs7591430 chr2 8287950 T C 6.53E-05 Schizophrenia LINC00299 intron 19571809 rs7591430 chr2 8287950 T C 5.64E-05 Schizophrenia LINC00299 intron pha002859 rs4669243 chr2 8302971 T C 1.43E-06 Nasopharyngeal carcinoma LINC00299 intron 23209447 rs4668564 chr2 8308813 C T 6.23E-06 Nasopharyngeal carcinoma LINC00299 intron 23209447 rs17389911 chr2 8365872 A G 4.40E-04 Multiple complex diseases LINC00299 intron 17554300 rs7595804 chr2 8424313 T C 3.54E-04 Suicide attempts in bipolar disorder LINC00299 intron 21423239 rs6747626 chr2 8424848 T C 2.07E-04 Suicide attempts in bipolar disorder LINC00299 intron 21423239 rs3097276 chr2 8432132 C T 3.16E-05 IgE levels LINC00299 intron 22075330 rs3102947 chr2 8434185 G C 2.00E-07 IgE levels LINC00299 intron 22075330 rs2931130 chr2 8434948 A G 2.34E-04 Glycosylated haemoglobin levels / / 17255346 rs2931130 chr2 8434948 A G 3.27E-05 IgE levels / / 22075330 rs346835 chr2 8438693 C T 2.30E-07 Self-reported allergy LINC00299 intron 23817569 rs10165200 chr2 8439629 G A 4.43E-04 Self-reported allergy LINC00299 intron 23817569 rs13416555 chr2 8441735 C G 1.19E-07 Self-reported allergy LINC00299 intron 23817569 rs10174949 chr2 8442248 G A 1.00E-07 Self-reported allergy LINC00299 intron 23817569 rs891058 chr2 8442547 G A 1.41E-07 Self-reported allergy LINC00299 intron 23817569 rs10178845 chr2 8443803 G A 1.31E-07 Self-reported allergy LINC00299 intron 23817569 rs3111414 chr2 8443859 C G 1.68E-04 Self-reported allergy LINC00299 intron 23817569 rs4315494 chr2 8446377 A G 1.18E-04 Obesity (early onset extreme) LINC00299 intron 23563609 rs4315494 chr2 8446377 A G 8.69E-04 Amyotrophic lateral sclerosis (sporadic) LINC00299 intron 24529757 rs367023 chr2 8450123 A G 2.02E-07 Self-reported allergy LINC00299 intron 23817569 rs439614 chr2 8451479 C T 3.74E-04 Self-reported allergy LINC00299 intron 23817569 rs13395467 chr2 8451498 A G 3.66E-07 Self-reported allergy LINC00299 intron 23817569 rs404236 chr2 8456003 A G 4.88E-05 IgE levels LINC00299 intron 22075330 rs3097289 chr2 8459193 T C 4.65E-05 IgE levels LINC00299 intron 22075330 rs3856439 chr2 8459404 C T 2.69E-07 Self-reported allergy LINC00299 intron 23817569 rs2562016 chr2 8459808 G C 4.58E-05 IgE levels LINC00299 intron 22075330 rs10210006 chr2 8466486 C G 4.07E-07 Self-reported allergy LINC00299 intron 23817569 rs2914424 chr2 8466915 T A 3.72E-05 IgE levels LINC00299 intron 22075330 rs3102956 chr2 8467444 A G 3.68E-05 IgE levels LINC00299 intron 22075330 rs7567352 chr2 8471236 C T 2.36E-06 Self-reported allergy / / 23817569 rs2931136 chr2 8481299 A T 5.74E-06 Self-reported allergy / / 23817569 rs9287698 chr2 8487296 C T 9.46E-05 Cognitive impairment induced by topiramate / / 22091778 rs9287698 chr2 8487296 C T 5.51E-06 Self-reported allergy / / 23817569 rs1807241 chr2 8488143 G C 9.96E-06 Self-reported allergy / / 23817569 rs41403046 chr2 8497069 C T 3.56E-04 Multiple complex diseases / / 17554300 rs6431935 chr2 8501473 A C 2.76E-04 Self-reported allergy / / 23817569 rs4669253 chr2 8502239 G A 2.04E-04 Self-reported allergy / / 23817569 rs12623235 chr2 8508080 G A 2.36E-04 Type 2 diabetes / / 17463246 rs6761309 chr2 8520508 G A 2.92E-05 Serum metabolites / / 19043545 rs7425561 chr2 8521327 T A 8.51E-05 Serum metabolites / / 19043545 rs13008689 chr2 8530256 G A 4.35E-05 Serum metabolites / / 19043545 rs13008689 chr2 8530256 G A 1.00E-06 Longevity / / 20834067 rs4076706 chr2 8531037 G A 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs409169 chr2 8556084 A G 3.17E-04 Self-reported allergy / / 23817569 rs1017920 chr2 8559180 G A 5.48E-04 Stroke / / pha002887 rs1032840 chr2 8560247 A G 3.00E-05 Cognitive function / / 24684796 rs1872602 chr2 8561695 T G 1.80E-05 Odorant perception / / 23910658 rs2630720 chr2 8571477 G A 3.06E-04 Testicular dysgenesis syndrome / / 22140272 rs6715753 chr2 8577361 A T 9.70E-04 Insulin resistance / / 21901158 rs10929532 chr2 8684458 T C 9.45E-05 Insulin resistance / / 21901158 rs11680487 chr2 8684540 G T 1.22E-04 Insulin resistance / / 21901158 rs345901 chr2 8691839 A G 9.80E-06 Urinary metabolites / / 21572414 rs3856444 chr2 8745998 C G 1.65E-07 Red blood cell traits / / 23222517 rs13398673 chr2 8753026 A G 2.80E-05 Urinary metabolites / / 21572414 rs12993630 chr2 8753269 C T 3.81E-07 Red blood cell traits / / 23222517 rs3896594 chr2 8762414 T G 8.19E-07 Red blood cell traits / / 23222517 rs4669318 chr2 8770564 G A 5.70E-04 Obesity (extreme) / / 21935397 rs1344807 chr2 8775493 G A 9.98E-05 Cognitive performance / / 19734545 rs4442969 chr2 8809061 C T 4.79E-05 Orofacial clefts / / 22419666 rs10188643 chr2 8810425 C T 2.06E-05 Orofacial clefts / / 22419666 rs10189304 chr2 8828645 G A 2.60E-05 Urinary metabolites / / 21572414 rs4668589 chr2 8850817 G A 3.53E-04 Aortic root size / / 21223598 rs9789497 chr2 8858736 T C 4.24E-04 Type 2 diabetes / / 17463246 rs6753855 chr2 8863392 A G 2.14E-06 Platelet counts / / 21507922 rs1550250 chr2 8917977 G A 2.51E-04 Type 2 diabetes KIDINS220 intron 17463246 rs12329306 chr2 8926883 C T 2.60E-04 Type 2 diabetes KIDINS220 intron 17463246 rs7587928 chr2 8949070 T C 2.00E-07 Neutrophil count KIDINS220 intron 21507922 rs13008971 chr2 8980472 A C 6.00E-07 Schizophrenia / / 21926974 rs11894892 chr2 8981020 C A 9.70E-05 Basophils / / pha003087 rs10495560 chr2 8989184 C T 7.77E-04 Type 2 diabetes / / 17463246 rs2221868 chr2 9177204 T C 5.32E-04 Type 2 diabetes / / 17463246 rs16866900 chr2 9247025 A C 6.72E-04 Type 2 diabetes / / 17463246 rs907159 chr2 9250007 T C 2.50E-05 Urinary metabolites / / 21572414 rs1109670 chr2 9250038 C A 9.00E-06 Multiple sclerosis / / 19010793 rs1109670 chr2 9250038 C A 8.04E-04 Body mass index / / 21701565 rs2015061 chr2 9256210 T C 1.14E-27 Narcolepsy / / 19629137 rs9636252 chr2 9259598 T C 3.00E-06 IgG glycosylation / / 23382691 rs6743450 chr2 9269554 A G 6.05E-04 Rheumatoid arthritis / / 21452313 rs6743450 chr2 9269554 A G 7.86E-04 Body mass index / / 21701565 rs6743450 chr2 9269554 A G 8.05E-04 Body mass index / / 21701565 rs6736097 chr2 9281704 C T 9.17E-04 Rheumatoid arthritis / / 21452313 rs1344185 chr2 9290324 A G 4.53E-04 Alzheimer's disease (late onset) / / 21379329 rs10198885 chr2 9307900 C G 1.37E-04 Multiple complex diseases / / 17554300 rs6431983 chr2 9310604 A C 1.00E-04 Information processing speed / / 21130836 rs4669378 chr2 9315483 T C 7.10E-05 Obesity,menopause / / 21424828 rs41359346 chr2 9320577 G A 4.74E-04 Multiple complex diseases / / 17554300 rs12692379 chr2 9324513 C T 2.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6743148 chr2 9340227 A C 5.95E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16866958 chr2 9352517 G A 2.64E-04 Alzheimer's disease (late onset) ASAP2 intron 21379329 rs9287705 chr2 9353255 G T 1.05E-05 Coronary heart disease ASAP2 intron pha003035 rs12479189 chr2 9354669 G A 8.89E-05 Waist-Hip Ratio ASAP2 intron pha003013 rs12479189 chr2 9354669 G A 1.38E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs11897394 chr2 9357533 T C 3.34E-05 Coronary heart disease ASAP2 intron pha003035 rs2666219 chr2 9403822 C T 2.13E-04 Alzheimer's disease (late onset) ASAP2 intron 21379329 rs7605582 chr2 9416090 G A 2.00E-04 Cognitive impairment induced by topiramate ASAP2 intron 22091778 rs10192751 chr2 9419106 G T 4.08E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs10193254 chr2 9419583 G A 6.79E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs4669381 chr2 9422788 A G 1.77E-05 Waist Circumference ASAP2 intron pha003025 rs4669381 chr2 9422788 A G 9.91E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs12472609 chr2 9427591 A G 5.18E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs7588636 chr2 9430778 G A 9.82E-05 Body Mass Index ASAP2 intron pha003007 rs7588636 chr2 9430778 G A 7.98E-06 Waist Circumference ASAP2 intron pha003025 rs7588636 chr2 9430778 G A 8.08E-05 Weight ASAP2 intron pha003027 rs7588636 chr2 9430778 G A 7.83E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs3811600 chr2 9437413 C T 4.89E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs10203328 chr2 9459986 T G 9.19E-05 Waist-Hip Ratio ASAP2 intron pha003013 rs10203328 chr2 9459986 T G 1.48E-05 Waist Circumference ASAP2 intron pha003025 rs10203328 chr2 9459986 T G 6.42E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs12475160 chr2 9463454 C T 5.87E-05 Body Mass Index ASAP2 intron pha003007 rs12475160 chr2 9463454 C T 5.29E-06 Waist Circumference ASAP2 intron pha003025 rs12475160 chr2 9463454 C T 2.87E-05 Weight ASAP2 intron pha003027 rs12475160 chr2 9463454 C T 7.05E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs10181704 chr2 9465687 G T 3.24E-05 Waist Circumference ASAP2 intron pha003025 rs10181704 chr2 9465687 G T 9.97E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs7569295 chr2 9467815 C T 9.98E-05 Waist-Hip Ratio ASAP2 intron pha003013 rs7569295 chr2 9467815 C T 1.68E-05 Waist Circumference ASAP2 intron pha003025 rs7569295 chr2 9467815 C T 6.93E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs116567340 chr2 9485625 G A 9.39E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) ASAP2 intron 24159190 rs116252892 chr2 9489788 G A 9.65E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) ASAP2 intron 24159190 rs2709580 chr2 9514573 T C 4.48E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs2709586 chr2 9517647 A G 5.82E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs10186062 chr2 9542286 G A 6.94E-05 Waist-Hip Ratio ASAP2 intron pha003013 rs10186062 chr2 9542286 G A 2.53E-05 Waist-Hip Ratio ASAP2 intron pha003028 rs10929579 chr2 9547171 G A 4.40E-04 Lymphocyte counts ITGB1BP1 intron 22286170 rs12474647 chr2 9554280 A T 2.49E-04 Coronary heart disease ITGB1BP1 intron 21606135 rs12151757 chr2 9595145 T C 8.00E-04 Type 2 diabetes CPSF3 intron 17463246 rs116264366 chr2 9618822 G A 8.44E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) IAH1 intron 24159190 rs56237316 chr2 9637331 A G 0.000023 Prostate cancer ADAM17 cds-synon 23555315 rs56237316 chr2 9637331 A G 0.000029 Prostate cancer (non-advanced prostate cancer) ADAM17 cds-synon 23555315 rs12467921 chr2 9643688 A G 9.12E-06 Stroke (ischemic) ADAM17 intron 22941190 rs55794209 chr2 9645632 C A 3.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) ADAM17 intron 24159190 rs2276338 chr2 9645789 C T 8.66E-06 Stroke (ischemic) ADAM17 intron 22941190 rs7580419 chr2 9646388 C T 8.93E-06 Stroke (ischemic) ADAM17 intron 22941190 rs10211522 chr2 9648215 C T 9.25E-06 Stroke (ischemic) ADAM17 intron 22941190 rs17590793 chr2 9648374 G C 9.65E-06 Stroke (ischemic) ADAM17 intron 22941190 rs10929587 chr2 9662820 T A 8.60E-04 Primary sclerosing cholangitis ADAM17 intron 19944697 rs2230818 chr2 9667930 T A,C 8.63E-09 Triglycerides ADAM17 STOP-GAIN 23063622 rs17362650 chr2 9676413 T C 8.00E-06 Alcohol dependence (age at onset) ADAM17 intron 24962325 rs17525614 chr2 9679854 T C 7.51E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ADAM17 intron 20031582 rs10179642 chr2 9683696 T C 2.00E-04 Cognitive impairment induced by topiramate ADAM17 intron 22091778 rs6432018 chr2 9721896 C A 8.00E-07 Heart rate variability traits / / 22174390 rs10495572 chr2 9734859 G C 6.74E-04 Multiple complex diseases YWHAQ intron 17554300 rs10495571 chr2 9736066 A G 6.05E-04 Multiple complex diseases YWHAQ intron 17554300 rs74416513 chr2 9745256 C T 4.63E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) YWHAQ intron 24159190 rs16867083 chr2 9767441 T C 4.88E-04 Multiple complex diseases YWHAQ intron 17554300 rs17362902 chr2 9768564 A G 1.23E-04 Multiple complex diseases YWHAQ intron 17554300 rs4669402 chr2 9779413 G C 5.45E-04 Coronary heart disease / / 21606135 rs4669403 chr2 9782132 C A,T 3.91E-04 Smoking initiation / / 24665060 rs868095 chr2 9783689 G A 0.000798 Salmonella-induced pyroptosis / / 22837397 rs16867116 chr2 9815766 C T 4.36E-04 Insulin resistance / / 21901158 rs13422603 chr2 9823306 G C 8.03E-04 Multiple complex diseases / / 17554300 rs6741886 chr2 9832407 G A 7.77E-05 Major depressive disorder / / 21621269 rs1877947 chr2 9881989 G A 1.59E-04 Multiple complex diseases / / 17554300 rs4668644 chr2 9890804 A G 6.77E-05 Major depressive disorder / / 19107115 rs13412895 chr2 9893454 T C 6.24E-05 Major depressive disorder / / 19107115 rs16867155 chr2 9902902 A G 1.63E-04 Smoking initiation / / 24665060 rs4145374 chr2 9903788 T A,C 2.14E-04 Smoking initiation / / 24665060 rs13395893 chr2 9913515 T G 9.90E-04 Type 2 diabetes / / 23209189 rs4669458 chr2 9922283 T C 4.11E-05 Anxiety and major depressive disorder / / 24047446 rs2357266 chr2 9924387 A G 4.00E-06 Self-rated health / / 20707712 rs17363477 chr2 9931094 A G 5.67E-05 Recombination rate / / 21698098 rs4669466 chr2 9937035 A G 1.31E-05 Type 2 diabetes / / 17463246 rs16867169 chr2 9941529 T A 4.80E-06 Urinary metabolites / / 21572414 rs16867170 chr2 9948475 T G 2.27E-04 Multiple complex diseases / / 17554300 rs16867173 chr2 9948737 T C 1.94E-04 Multiple complex diseases / / 17554300 rs908296 chr2 9954768 T C 6.60E-04 Multiple complex diseases / / 17554300 rs4027379 chr2 9964370 C T 9.61E-05 Cognitive decline / / 22054870 rs287980 chr2 9971366 G A 5.88E-05 Cholesterol / / 17255346 rs1469544 chr2 9988348 T G 5.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) TAF1B intron 23648065 rs16867195 chr2 9989442 A G 6.07E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) TAF1B intron 23648065 rs1014509 chr2 9996156 T C 5.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) TAF1B intron 23648065 rs438762 chr2 10035870 T A 1.71E-05 Lymphocyte counts TAF1B intron 22286170 rs112736747 chr2 10059654 C G 7.16E-06 Osteoarthritis TAF1B intron 21871595 rs3828260 chr2 10094442 C A 6.79E-05 Lipoproteins GRHL1 intron pha003079 rs2303918 chr2 10094992 A G 6.18E-04 Multiple complex diseases GRHL1 intron 17554300 rs6708858 chr2 10098227 T C 3.03E-05 Serum metabolites GRHL1 intron 19043545 rs1897164 chr2 10111901 T C 3.42E-05 Bilirubin levels,in serum GRHL1 intron 19389676 rs11902236 chr2 10117868 C T 3.00E-08 Prostate cancer GRHL1 intron 23535732 rs3791760 chr2 10118424 T C 0.00087 Salmonella-induced pyroptosis GRHL1 intron 22837397 rs2011516 chr2 10120605 A G 3.54E-04 Alzheimer's disease GRHL1 intron 22005930 rs6756056 chr2 10160082 C T 8.27E-05 Femoral neck bone geometry / / 22087292 rs6727702 chr2 10175442 C A 9.28E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4669519 chr2 10179042 A G 8.27E-04 Parkinson's disease / / 17052657 rs4233877 chr2 10241915 T G 0.000399401 Hypertension (early onset hypertension) / / 22479346 rs6741290 chr2 10264709 T C 8.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RRM2 intron 20877124 rs2241113 chr2 10275746 A C 2.73E-04 Type 2 diabetes / / 17463246 rs2241113 chr2 10275746 A C 1.40E-10 Blood pressure / / 21996601 rs717886 chr2 10275814 T C 1.98E-04 Type 2 diabetes / / 17463246 rs2110641 chr2 10291414 G C 3.10E-08 Blood pressure C2orf48 intron 21996601 rs10197121 chr2 10293689 C T 5.93E-04 Type 2 diabetes C2orf48 intron 17463246 rs10197121 chr2 10293689 C T 3.27E-07 Blood pressure C2orf48 intron 21996601 rs13424629 chr2 10296486 T C 3.83E-07 Blood pressure C2orf48 intron 21996601 rs4668669 chr2 10348018 C T 0.0000404 Placental abruption C2orf48 intron 23205182 rs7566637 chr2 10422939 C T 3.20E-05 Major depressive disorder (broad) / / 20038947 rs2884208 chr2 10440987 T C 1.42E-05 Cognitive test performance / / 20125193 rs6734475 chr2 10450398 G A 6.19E-04 Amyotrophic lateral sclerosis (sporadic) HPCAL1 intron 24529757 rs11694489 chr2 10462852 C T 5.81E-06 Response to tocilizumab in rheumatoid arthritis HPCAL1 intron 22491018 rs16856119 chr2 10467823 C T 3.58E-06 Response to tocilizumab in rheumatoid arthritis HPCAL1 intron 22491018 rs1003652 chr2 10468296 A C 0.00089889 Hypertension (early onset hypertension) HPCAL1 intron 22479346 rs6745569 chr2 10476532 T C 1.49E-05 Hemoglobin HPCAL1 intron pha003096 rs6745569 chr2 10476532 T C 4.41E-05 Hematocrit HPCAL1 intron pha003097 rs1558628 chr2 10478422 T C 9.96E-06 Hemoglobin HPCAL1 intron pha003096 rs1558628 chr2 10478422 T C 3.68E-05 Hematocrit HPCAL1 intron pha003097 rs4669573 chr2 10478936 A G 2.46E-04 Multiple complex diseases HPCAL1 intron 17554300 rs4669573 chr2 10478936 A G 3.67E-06 Alzheimer's disease HPCAL1 intron 21059989 rs4669573 chr2 10478936 A G 5.26E-05 Alzheimer's disease HPCAL1 intron 21059989 rs6758633 chr2 10480201 T C 3.03E-06 Hemoglobin HPCAL1 intron pha003096 rs6758633 chr2 10480201 T C 2.02E-05 Hematocrit HPCAL1 intron pha003097 rs6743846 chr2 10480415 C T 3.03E-06 Hemoglobin HPCAL1 intron pha003096 rs6743846 chr2 10480415 C T 2.02E-05 Hematocrit HPCAL1 intron pha003097 rs10197851 chr2 10485409 A G 1.02E-04 Alzheimer's disease HPCAL1 intron 21059989 rs10197851 chr2 10485409 A G 7.13E-06 Alzheimer's disease HPCAL1 intron 21059989 rs10181190 chr2 10489290 C T 2.30E-05 Urinary metabolites HPCAL1 intron 21572414 rs2884210 chr2 10501681 G T 8.20E-06 Magnesium levels HPCAL1 intron pha003092 rs11677361 chr2 10502733 A G 6.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HPCAL1 intron 20877124 rs6755271 chr2 10510040 A G 1.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HPCAL1 intron 20877124 rs6721270 chr2 10521126 A G 6.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HPCAL1 intron 20877124 rs6721270 chr2 10521126 A G 7.37E-04 Response to taxane treatment (placlitaxel) HPCAL1 intron 23006423 rs10198351 chr2 10524780 C T 6.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HPCAL1 intron 20877124 rs10198351 chr2 10524780 C T 6.45E-04 Response to taxane treatment (placlitaxel) HPCAL1 intron 23006423 rs11888704 chr2 10530325 G T 3.63E-05 Cognitive decline HPCAL1 intron 22054870 rs4142237 chr2 10530550 A G 1 Drug response to Etoposide HPCAL1 intron 17537913 rs13383253 chr2 10557093 G A 8.21E-05 HDL cholesterol HPCAL1 intron pha003074 rs3755256 chr2 10566414 G A 4.50E-07 Biliary atresia HPCAL1 intron 20460270 rs6432097 chr2 10595578 T C 3.87E-04 Multiple complex diseases / / 17554300 rs11890785 chr2 10619702 C T 0.000133 Salmonella-induced pyroptosis / / 22837397 rs818185 chr2 10648857 T C 6.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17436529 chr2 10655141 A G 4.31E-06 Bleomycin sensitivity / / 21106707 rs10185605 chr2 10656284 C T 2.78E-04 Taste perception / / 22132133 rs13013488 chr2 10657025 A T 6.12E-05 Aortic root size / / 21223598 rs2540275 chr2 10667749 G A 1.92E-04 Alcohol dependence / / 20201924 rs2270308 chr2 10675371 C T 1.18E-04 Multiple complex diseases / / 17554300 rs736725 chr2 10689889 G C 7.07E-05 Type 1 diabetes / / 18978792 rs6736915 chr2 10700239 T C 7.92E-05 Body mass (lean) / / 19268274 rs4668690 chr2 10713932 G A 5.12E-04 Type 2 diabetes NOL10 intron 17463246 rs4668690 chr2 10713932 G A 8.05E-05 Systemic sclerosis NOL10 intron 21750679 rs10490187 chr2 10737673 G A 6.80E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) NOL10 intron 17982456 rs12476937 chr2 10761985 C T 3.53E-05 Intracerebral hemorrhage NOL10 intron 24656865 rs7422405 chr2 10850929 G A 4.55E-05 Systemic sclerosis / / 21750679 rs4669621 chr2 10886098 C T 2.82E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ATP6V1C2 intron 20877124 rs1198872 chr2 10903412 C T 2.00E-06 Cardiac Troponin-T levels ATP6V1C2 intron 23247143 rs6432144 chr2 10916958 C T 7.02E-04 Aortic root size ATP6V1C2 intron 21223598 rs1106184 chr2 10963527 T C 8.80E-05 Longevity and age-related phenotypes / / 17903295 rs4669638 chr2 11021731 T A,C,G 5.89E-04 Response to TNF antagonist treatment / / 21061259 rs1317768 chr2 11024620 G A 2.55E-05 Bipolar disorder / / 20451256 rs7576288 chr2 11025705 G A 6.99E-04 Taste perception / / 22132133 rs7580382 chr2 11026953 G A 5.03E-05 Bipolar disorder / / 20451256 rs1317760 chr2 11031056 G A 2.13E-05 Bipolar disorder / / 20451256 rs16856887 chr2 11064628 A T 5.60E-06 Serum metabolites / / 19043545 rs16856924 chr2 11083596 G C 6.57E-04 Multiple complex diseases / / 17554300 rs7594176 chr2 11083972 T A 6.80E-04 Multiple complex diseases / / 17554300 rs2003298 chr2 11086150 T C 0.000121 Gains in maximal O2 uptake response / / 21183627 rs6730326 chr2 11091780 G T 2.00E-05 Urinary metabolites / / 21572414 rs10202936 chr2 11093401 T C 8.71E-05 Lymphocyte counts / / 22286170 rs4669654 chr2 11103496 G T 4.31E-04 Multiple complex diseases / / 17554300 rs13390165 chr2 11118836 C T 1.29E-05 Body mass (lean) / / 19268274 rs6432159 chr2 11127974 A G 4.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs10195742 chr2 11135890 C T 4.74E-04 Multiple complex diseases / / 17554300 rs13022057 chr2 11151452 C T 2.70E-05 Urinary metabolites / / 21572414 rs12472523 chr2 11154270 C A 1.30E-04 Type 2 diabetes / / 17463246 rs6432163 chr2 11159080 A C 9.20E-05 HIV-1 control / / 20041166 rs17456970 chr2 11169028 G A 8.14E-04 Lymphocyte counts / / 22286170 rs11677588 chr2 11189849 G A 2.64E-04 Cholesterol / / 17255346 rs2357889 chr2 11199971 C T 4.14E-04 Schizophrenia / / 19197363 rs6432168 chr2 11215734 A G 1.94E-05 Cognitive test performance / / 20125193 rs6739054 chr2 11220562 A G 2.00E-06 Cognitive performance / / 20125193 rs4668712 chr2 11226507 G A 4.50E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4669687 chr2 11229946 A G 4.84E-04 Myopia (pathological) / / 21095009 rs925748 chr2 11247813 T C 3.92E-05 Alzheimer's disease FLJ33534 intron 17998437 rs12478033 chr2 11248242 T C 2.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FLJ33534 intron 20877124 rs12692432 chr2 11255340 C T 6.00E-06 Metabolite levels (HVA/MHPG ratio) FLJ33534 intron 23319000 rs9287725 chr2 11257494 C T 2.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FLJ33534 intron 20877124 rs16857178 chr2 11257505 G A 9.00E-06 Obesity-related traits FLJ33534 intron 23251661 rs7608117 chr2 11265972 T G 8.91E-05 Pulmonary function FLJ33534 intron 20010835 rs13002429 chr2 11267366 T C 5.53E-05 Pulmonary function FLJ33534 intron 20010835 rs17366322 chr2 11272784 G T 7.26E-05 Pulmonary function / / 20010835 rs12470798 chr2 11281101 C G 8.93E-05 Pulmonary function C2orf50 intron 20010835 rs1828930 chr2 11291036 C T 9.15E-05 Pulmonary function / / 20010835 rs7581322 chr2 11293336 T G 8.16E-05 Pulmonary function / / 20010835 rs12996399 chr2 11313839 G A 8.75E-05 Pulmonary function PQLC3 intron 20010835 rs17366517 chr2 11320668 A G 2.69E-04 Multiple complex diseases / / 17554300 rs13423864 chr2 11347249 T C 9.57E-04 Alzheimer's disease ROCK2 intron 22005930 rs2056103 chr2 11364756 T A 9.28E-04 Alzheimer's disease ROCK2 intron 22005930 rs13393192 chr2 11368666 T C 8.93E-04 Alzheimer's disease ROCK2 intron 22005930 rs13397757 chr2 11370768 A G 8.94E-04 Alzheimer's disease ROCK2 intron 22005930 rs13404430 chr2 11381113 C A 6.36E-04 Alzheimer's disease ROCK2 intron 22005930 rs12479227 chr2 11394353 C T 3.03E-05 Sudden cardiac arrest ROCK2 intron 21658281 rs16857307 chr2 11397128 T C 5.82E-04 Multiple complex diseases ROCK2 intron 17554300 rs6743710 chr2 11501680 C T 2.92E-04 Alzheimer's disease LOC650157 intron 22005930 rs10189756 chr2 11503081 T C 4.00E-04 Alzheimer's disease LOC650157 intron 22005930 rs6716724 chr2 11510948 A G 6.00E-07 Sudden cardiac arrest LOC650157 intron 21658281 rs4260216 chr2 11535523 G T 1.36E-05 Odorant perception / / 23910658 rs11687681 chr2 11572815 G A 1.62E-04 Longevity / / 22279548 rs13407457 chr2 11655487 G T 3.60E-05 Endometriosis / / 21151130 rs13407457 chr2 11655487 G T 2.50E-05 Endometriosis / / 23104006 rs6758730 chr2 11677449 A G 1.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GREB1 intron 20877124 rs6758730 chr2 11677449 A G 1.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GREB1 intron 20877124 rs4669749 chr2 11692664 C A 2.00E-05 Electrocardiographic traits and heart rate variability GREB1 intron 17903306 rs4669751 chr2 11706693 T C 1.36E-04 Height GREB1 missense 17255346 rs7578132 chr2 11718858 T C 1.00E-05 Urinary metabolites GREB1 intron 21572414 rs12470971 chr2 11725241 G A 8.10E-06 Endometriosis GREB1 intron 23104006 rs13394619 chr2 11727507 G A 6.00E-09 Endometriosis GREB1 splice-3 23104006 rs12476319 chr2 11748406 T C 5.00E-04 Alcohol dependence GREB1 intron 21314694 rs73175262 chr2 11758431 G A 7.00E-08 Obesity-related traits GREB1 missense 23251661 rs73175262 chr2 11758431 G A 9.00E-06 Obesity-related traits GREB1 missense 23251661 rs7562399 chr2 11767282 G A 3.75E-04 Alzheimer's disease GREB1 intron 17998437 rs7562399 chr2 11767282 G A 7.74E-04 Alcohol dependence GREB1 intron 20201924 rs3792034 chr2 11768174 G A 3.53E-04 Multiple complex diseases GREB1 intron 17554300 rs7564647 chr2 11770685 A G 1.43E-04 Type 2 diabetes GREB1 intron 17463246 rs7567094 chr2 11787239 A C 8.87E-05 Type 2 diabetes / / 17463246 rs11676470 chr2 11815723 G T 1.11E-04 Smoking initiation / / 24665060 rs6721977 chr2 11823437 A C 1.41E-04 Coronary heart disease / / 21606135 rs11889370 chr2 11855096 T C 4.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12692445 chr2 11855712 A G 5.30E-05 Iron levels / / 21208937 rs11894146 chr2 11879174 T C 8.51E-05 Cognitive test performance / / 20125193 rs4076055 chr2 11889385 G T 0.000330734 Hypertension (early onset hypertension) LPIN1 intron 22479346 rs10192566 chr2 11890428 C G 1 Drug response to Rosiglitazone LPIN1 intron 18693052 rs7595221 chr2 11896975 G A 0.000251703 Hypertension (early onset hypertension) LPIN1 intron 22479346 rs2118403 chr2 11986791 A G 5.08E-05 Platelet counts / / pha003100 rs2716640 chr2 11987932 G A 3.11E-04 Insulin resistance / / 21901158 rs6735995 chr2 11991593 T C 4.68E-04 Multiple complex diseases / / 17554300 rs10495585 chr2 11992128 A C 9.42E-05 Cleft lip / / 20436469 rs373256169 chr2 11992128 AG AAG,ACC 9.42E-05 Cleft lip / / 20436469 rs10929773 chr2 12029322 G A 7.70E-05 Response to statin therapy / / 20339536 rs17605562 chr2 12037179 C T 9.00E-06 Hair morphology / / 19896111 rs4027132 chr2 12037492 G A 3.12E-06 Multiple complex diseases / / 17554300 rs4027132 chr2 12037492 G A 6.63E-06 Bipolar disorder,schizoaffective / / 19567891 rs4027132 chr2 12037492 G A 3.00E-06 Bipolar disorder / / 21254220 rs10183830 chr2 12038710 T G 7.80E-05 Response to statin therapy / / 20339536 rs4668743 chr2 12039694 T C 7.82E-04 Obesity (extreme) / / 21935397 rs16857996 chr2 12041594 C T 5.50E-05 Response to statin therapy / / 20339536 rs12472797 chr2 12045272 C T 1.78E-05 Multiple complex diseases / / 17554300 rs10204395 chr2 12045457 A C 6.02E-04 Multiple complex diseases / / 17554300 rs10204395 chr2 12045457 A C 5.40E-05 Response to statin therapy / / 20339536 rs10207016 chr2 12045540 T C 5.30E-05 Response to statin therapy / / 20339536 rs7607539 chr2 12048160 C T 2.11E-05 Elbow pain / / pha003008 rs12468031 chr2 12081764 C T 1.22E-04 Birth weight / / 17255346 rs2716625 chr2 12089229 T C 8.39E-05 Orofacial clefts / / 22419666 rs2033877 chr2 12095888 G A 5.93E-05 Orofacial clefts / / 22419666 rs1036668 chr2 12132638 G T 9.71E-04 Alcohol dependence / / 24277619 rs10210269 chr2 12144035 G A 4.07E-04 Coronary Artery Disease / / 17634449 rs12692450 chr2 12147176 G C 8.49E-05 Serum metabolites / / 19043545 rs41378155 chr2 12149681 A G 3.38E-04 Type 2 diabetes / / 17463246 rs12472165 chr2 12150406 C G 7.24E-04 Type 2 diabetes / / 17463246 rs11690527 chr2 12181825 C T 0.000000899 Asthma / / 22694930 rs6432254 chr2 12196768 A G 5.24E-04 Multiple complex diseases / / 17554300 rs7562854 chr2 12199218 T C 7.52E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs10495588 chr2 12203273 G A 8.70E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs16858228 chr2 12212445 A G 1.00E-06 Obesity-related traits / / 23251661 rs10803743 chr2 12221688 C A 3.92E-04 Multiple complex diseases / / 17554300 rs10166582 chr2 12225930 C A 7.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6711682 chr2 12229669 A G 1.50E-04 Multiple complex diseases / / 17554300 rs6432261 chr2 12229926 A G 2.83E-04 Multiple complex diseases / / 17554300 rs6731006 chr2 12239782 A G 8.21E-04 Multiple complex diseases / / 17554300 rs6731006 chr2 12239782 A G 8.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2278550 chr2 12247311 C G 8.72E-04 Multiple complex diseases LOC100506457 intron 17554300 rs6432264 chr2 12247650 C G 9.82E-04 Type 2 diabetes LOC100506457 intron 17463246 rs6432264 chr2 12247650 C G 3.38E-04 Multiple complex diseases LOC100506457 intron 17554300 rs1470013 chr2 12248589 A G 3.20E-05 Amyotrophic lateral sclerosis (sporadic) LOC100506457 intron 24529757 rs17551536 chr2 12252350 A G 5.00E-06 Bronchopulmonary dysplasia LOC100506457 intron 23897914 rs6741502 chr2 12256332 C A 1.19E-04 Suicide attempts in bipolar disorder LOC100506457 intron 21423239 rs10929785 chr2 12264126 T C 8.75E-05 Suicide attempts in bipolar disorder LOC100506457 intron 21423239 rs7601706 chr2 12265210 C A 2.06E-04 Suicide attempts in bipolar disorder LOC100506457 intron 21423239 rs17551939 chr2 12268748 A C 8.49E-05 Bipolar Disorder LOC100506457 intron pha002863 rs16858314 chr2 12269747 A G 4.10E-06 Urinary metabolites LOC100506457 intron 21572414 rs916522 chr2 12279879 C A 6.82E-05 Nephrolithiasis / / 22396660 rs916524 chr2 12280396 T C 1.90E-04 Multiple complex diseases / / 17554300 rs916524 chr2 12280396 T C 8.18E-04 Coronary heart disease / / 21606135 rs1821897 chr2 12283275 G C 7.05E-04 Type 2 diabetes / / 17463246 rs16858333 chr2 12285268 T C 1.50E-05 Urinary metabolites / / 21572414 rs1971516 chr2 12291656 A G 3.71E-04 Alzheimer's disease (late onset) / / 21379329 rs13399680 chr2 12295638 C T 4.66E-05 Serum metabolites / / 19043545 rs731395 chr2 12296582 G A 1.58E-05 Vaspin levels / / 22907691 rs731395 chr2 12296582 G A 0.0000158 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs3954862 chr2 12304753 T C 1.30E-05 Vaspin levels / / 22907691 rs3954862 chr2 12304753 T C 0.000013 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs3954862 chr2 12304753 T C 0.0001575 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs3906767 chr2 12305222 C T 1.30E-05 Vaspin levels / / 22907691 rs3906767 chr2 12305222 C T 0.000013 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs3906767 chr2 12305222 C T 0.0001575 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs10197240 chr2 12307205 A G 2.81E-04 Multiple complex diseases / / 17554300 rs4669821 chr2 12315199 T G 5.55E-05 Height / / pha003010 rs6432267 chr2 12318466 G A 1.03E-04 Type 2 diabetes / / 17463246 rs6432267 chr2 12318466 G A 4.25E-05 Multiple complex diseases / / 17554300 rs10172170 chr2 12319000 A G 1.51E-04 Multiple complex diseases / / 17554300 rs7558139 chr2 12322604 T C 3.11E-05 Serum metabolites / / 19043545 rs10803744 chr2 12323369 G A 9.92E-05 Vaspin levels / / 22907691 rs10803744 chr2 12323369 G A 0.0000992 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs17618039 chr2 12326837 A T 2.10E-05 Urinary metabolites / / 21572414 rs10495593 chr2 12329347 G T 5.10E-05 Lipid traits / / 17903299 rs10495594 chr2 12330399 G A 5.10E-05 Lipid traits / / 17903299 rs1225214 chr2 12335338 G A 2.55E-05 Serum metabolites / / 19043545 rs1542327 chr2 12354664 T C 5.84E-04 Heart Failure / / pha002884 rs1453488 chr2 12366908 C T 4.35E-05 Pulmonary function in asthmatics / / 23541324 rs4669834 chr2 12369870 A G 5.13E-05 Pulmonary function in asthmatics / / 23541324 rs4669835 chr2 12372623 A G 2.02E-05 Height / / pha003010 rs12992291 chr2 12387305 T C 8.15E-04 Parkinson's disease / / 16252231 rs12992291 chr2 12387305 T C 3.30E-06 Urinary metabolites / / 21572414 rs10803746 chr2 12397133 G A 8.14E-04 Smoking initiation / / 24665060 rs1020605 chr2 12397435 T C 1.21E-04 Aortic root size / / 21223598 rs1020605 chr2 12397435 T C 7.54E-04 Smoking initiation / / 24665060 rs2380426 chr2 12399050 C T 1.58E-04 Aortic root size / / 21223598 rs2380426 chr2 12399050 C T 2.25E-04 Vaspin levels / / 22907691 rs2380426 chr2 12399050 C T 0.0002247 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs1901851 chr2 12401923 A C 1.85E-04 Aortic root size / / 21223598 rs6720800 chr2 12401985 T C 1.73E-04 Aortic root size / / 21223598 rs12623366 chr2 12402467 G T 1.41E-04 Aortic root size / / 21223598 rs16858543 chr2 12403280 G A 1.79E-04 Aortic root size / / 21223598 rs10495595 chr2 12406806 T C 3.72E-05 Aortic root size / / 21223598 rs12989835 chr2 12409041 G T 1.88E-04 Aortic root size / / 21223598 rs10205200 chr2 12409153 T C 1.00E-04 Bipolar disorder / / 18317468 rs10205200 chr2 12409153 T C 8.43E-05 Aortic root size / / 21223598 rs10164492 chr2 12411048 T G 7.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2034680 chr2 12414595 C G 6.96E-05 Aortic root size / / 21223598 rs7567643 chr2 12415940 C T 1.29E-04 Aortic root size / / 21223598 rs10754960 chr2 12418070 A G 1.30E-04 Aortic root size / / 21223598 rs6432275 chr2 12418532 C T 1.83E-04 Aortic root size / / 21223598 rs7578740 chr2 12418752 C T 2.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12105920 chr2 12420336 C T 2.09E-04 Aortic root size / / 21223598 rs10188552 chr2 12420990 G A 2.06E-04 Aortic root size / / 21223598 rs9287745 chr2 12421602 G A 2.10E-04 Aortic root size / / 21223598 rs11681455 chr2 12421708 T G 2.16E-04 Aortic root size / / 21223598 rs11681455 chr2 12421708 T G 4.28E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2164876 chr2 12430628 A G 1.86E-04 Aortic root size / / 21223598 rs723504 chr2 12431440 T C 2.14E-04 Aortic root size / / 21223598 rs723504 chr2 12431440 T C 5.43E-05 Tunica Media / / pha003034 rs4669836 chr2 12433491 A G 2.13E-04 Aortic root size / / 21223598 rs6761842 chr2 12434250 A C 2.15E-04 Aortic root size / / 21223598 rs6761857 chr2 12434277 A G 2.18E-04 Aortic root size / / 21223598 rs6710595 chr2 12434358 T C 4.78E-04 Multiple complex diseases / / 17554300 rs6710595 chr2 12434358 T C 2.14E-04 Aortic root size / / 21223598 rs2380431 chr2 12438193 T C 1.07E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs16858622 chr2 12440201 G A 1.87E-04 Aortic root size / / 21223598 rs1031455 chr2 12442537 T C 6.28E-05 Multiple complex diseases / / 17554300 rs6733870 chr2 12445505 T C 2.85E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1002296 chr2 12450707 A G 4.77E-04 Multiple complex diseases / / 17554300 rs1002297 chr2 12450840 A T 2.60E-05 Urinary metabolites / / 21572414 rs10929800 chr2 12452560 A G 2.20E-05 Urinary metabolites / / 21572414 rs11684242 chr2 12453068 T C 1.20E-05 Urinary metabolites / / 21572414 rs16858693 chr2 12475214 A G 1.14E-04 Multiple complex diseases / / 17554300 rs6432284 chr2 12485992 C T 4.26E-04 Multiple complex diseases / / 17554300 rs11690119 chr2 12511957 C T 7.55E-04 HIV-1 viral setpoint / / 17641165 rs10929808 chr2 12568996 G A 4.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs10176670 chr2 12585727 T G 7.38E-05 Circulating vasoactive peptide levels / / 23381795 rs7592226 chr2 12611100 G A 1.28E-04 Multiple complex diseases / / 17554300 rs1547587 chr2 12619109 A G 4.16E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs6757329 chr2 12625305 G C 7.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs1534422 chr2 12640741 G A 2.00E-06 Type 1 diabetes / / 19430480 rs1534422 chr2 12640741 G A 0.000000176 Graves' disease and Hashimoto's thyroiditis / / 22922229 rs1534422 chr2 12640741 G A 0.00000469 Graves' disease / / 22922229 rs13013085 chr2 12676426 G A 3.75E-05 Multiple sclerosis / / 17660530 rs6432315 chr2 12720311 T C 3.40E-05 HIV-1 control / / 20041166 rs4668771 chr2 12727616 T C 4.84E-05 Multiple complex diseases / / 17554300 rs4538172 chr2 12728266 A G 1.19E-21 Varicose Veins / / pha001412 rs11675322 chr2 12735727 G A 1.85E-05 Mammographic density / / 22532574 rs2139380 chr2 12741369 T G 3.49E-04 Smoking quantity / / 24665060 rs11677151 chr2 12759532 C T 3.98E-06 Mammographic density / / 22532574 rs16859166 chr2 12760843 G A 6.18E-04 Type 2 diabetes / / 17463246 rs7568831 chr2 12763243 A G 8.86E-05 Information processing speed / / 21130836 rs6432321 chr2 12778345 T C 2.25E-04 Alcohol dependence / / 24277619 rs11694463 chr2 12781621 T C 6.10E-05 Nicotine dependence / / 17158188 rs11694463 chr2 12781621 T C 6.28E-05 Mammographic density / / 22532574 rs559703 chr2 12787237 A G 2.35E-05 Information processing speed / / 21130836 rs559703 chr2 12787237 A G 7.86E-04 Smoking quantity / / 24665060 rs2113810 chr2 12789884 G A 2.97E-05 Myopia (severe) / / 23933737 rs6432322 chr2 12794840 T C 2.41E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs654004 chr2 12827258 C T 4.64E-05 Telomere length / / 20139977 rs625842 chr2 12828973 A C 6.24E-04 Schizophrenia / / 19197363 rs624895 chr2 12829246 T A 2.48E-05 Telomere length / / 20139977 rs501596 chr2 12833928 A G 8.11E-04 Schizophrenia / / 19197363 rs477599 chr2 12834170 G A 2.88E-05 Telomere length / / 20139977 rs645490 chr2 12841445 T G 5.00E-04 Primary nonsyndromic vesicoureteric reflex / / 19959718 rs6719434 chr2 12862905 T C 5.50E-05 Pericardial fat TRIB2 intron 22589742 rs2278117 chr2 12863770 G A 2.30E-05 Pericardial fat TRIB2 intron 22589742 rs2042567 chr2 12878642 T C 6.90E-05 Pericardial fat TRIB2 intron 22589742 rs2042566 chr2 12878668 C T 6.70E-05 Pericardial fat TRIB2 intron 22589742 rs1469215 chr2 12886320 G T 5.80E-05 Pericardial fat / / 22589742 rs1974923 chr2 12887702 T C 2.60E-07 Pericardial fat / / 22589742 rs2113818 chr2 12890860 T C 3.60E-07 Pericardial fat / / 22589742 rs2059428 chr2 12892929 C T 6.40E-05 Pericardial fat / / 22589742 rs2059427 chr2 12893977 C T 4.40E-05 Pericardial fat / / 22589742 rs12616457 chr2 12896713 G A 2.10E-06 Pericardial fat / / 22589742 rs2380453 chr2 12897291 C G 1.90E-06 Pericardial fat / / 22589742 rs5022058 chr2 12897548 C G 1.90E-06 Pericardial fat / / 22589742 rs7562714 chr2 12898382 G A 1.90E-06 Pericardial fat / / 22589742 rs4669869 chr2 12898460 T C 6.20E-08 Pericardial fat / / 22589742 rs13011003 chr2 12901052 C A 1.80E-06 Pericardial fat / / 22589742 rs4669872 chr2 12901482 G C 3.30E-05 Pericardial fat / / 22589742 rs973977 chr2 12905490 C T 3.30E-05 Pericardial fat / / 22589742 rs890075 chr2 12910044 T C 8.30E-08 Pericardial fat / / 22589742 rs890074 chr2 12910084 G A 8.30E-08 Pericardial fat / / 22589742 rs4669873 chr2 12914541 A G 4.20E-07 Pericardial fat / / 22589742 rs4669874 chr2 12915120 T C 4.20E-07 Pericardial fat / / 22589742 rs4669875 chr2 12915867 G C 1.20E-05 Pericardial fat / / 22589742 rs7581972 chr2 12916919 T C 4.70E-07 Pericardial fat / / 22589742 rs2161996 chr2 12917543 A T 4.10E-07 Pericardial fat / / 22589742 rs4669876 chr2 12918300 C T 3.50E-05 Pericardial fat / / 22589742 rs10200958 chr2 12919215 C T 4.00E-07 Pericardial fat / / 22589742 rs6432331 chr2 12924111 A G 3.80E-07 Pericardial fat / / 22589742 rs6432334 chr2 12928927 T G 3.80E-07 Pericardial fat / / 22589742 rs1863176 chr2 12931092 G C 4.20E-07 Pericardial fat / / 22589742 rs6727552 chr2 12932307 G T 4.10E-05 Pericardial fat / / 22589742 rs10200527 chr2 12933917 T C 2.70E-05 Pericardial fat / / 22589742 rs10198180 chr2 12936190 G A 4.00E-05 Pericardial fat / / 22589742 rs7580835 chr2 12938819 G A 4.00E-07 Pericardial fat / / 22589742 rs2194724 chr2 12942042 T C 4.90E-06 Pericardial fat / / 22589742 rs12692486 chr2 12948146 T C 3.90E-07 Pericardial fat / / 22589742 rs732805 chr2 12948901 G A 3.90E-07 Pericardial fat / / 22589742 rs4583433 chr2 12949571 G T 3.90E-07 Pericardial fat / / 22589742 rs1469218 chr2 12950092 C G 3.90E-07 Pericardial fat / / 22589742 rs1469217 chr2 12950124 T C 3.90E-07 Pericardial fat / / 22589742 rs6730819 chr2 12951196 C T 3.90E-07 Pericardial fat / / 22589742 rs12623251 chr2 12951321 C T 4.60E-06 Pericardial fat / / 22589742 rs10175345 chr2 12951414 T G 3.90E-07 Pericardial fat / / 22589742 rs2113815 chr2 12951705 G A 3.90E-07 Pericardial fat / / 22589742 rs2113814 chr2 12951752 C T 4.00E-07 Pericardial fat / / 22589742 rs2113813 chr2 12951767 C T 4.00E-07 Pericardial fat / / 22589742 rs2113812 chr2 12951779 A G 4.00E-07 Pericardial fat / / 22589742 rs6432336 chr2 12951950 G A 4.00E-07 Pericardial fat / / 22589742 rs7597914 chr2 12952193 A G 4.00E-07 Pericardial fat / / 22589742 rs2113811 chr2 12952494 A G 5.30E-07 Pericardial fat / / 22589742 rs11685678 chr2 12953264 G A 2.50E-05 Pericardial fat / / 22589742 rs4668789 chr2 12954404 G A 4.10E-07 Pericardial fat / / 22589742 rs13000123 chr2 12954826 C T 4.10E-07 Pericardial fat / / 22589742 rs10929832 chr2 12955682 C T 4.10E-07 Pericardial fat / / 22589742 rs1544853 chr2 12955770 A C 4.10E-07 Pericardial fat / / 22589742 rs1544852 chr2 12955849 T C 4.10E-07 Pericardial fat / / 22589742 rs1544851 chr2 12955898 C T 4.10E-07 Pericardial fat / / 22589742 rs7598770 chr2 12956329 T C 4.10E-07 Pericardial fat / / 22589742 rs6751241 chr2 12957120 T C 4.40E-07 Pericardial fat / / 22589742 rs7586442 chr2 12957620 C G 4.40E-07 Pericardial fat / / 22589742 rs7586563 chr2 12957754 C T 4.40E-07 Pericardial fat / / 22589742 rs4668792 chr2 12959810 C T 4.50E-07 Pericardial fat / / 22589742 rs10191751 chr2 12962315 A G 8.80E-05 Pericardial fat / / 22589742 rs10194305 chr2 12962365 T A 2.80E-07 Pericardial fat / / 22589742 rs10179809 chr2 12962585 C A 2.70E-07 Pericardial fat / / 22589742 rs10192149 chr2 12962678 A G 2.90E-08 Pericardial fat / / 22589742 rs17465721 chr2 12962818 C T 8.00E-05 Pericardial fat / / 22589742 rs6432340 chr2 12963117 T C 2.80E-08 Pericardial fat / / 22589742 rs12621238 chr2 12964066 T C 2.70E-08 Pericardial fat / / 22589742 rs10186351 chr2 12964428 C T 2.70E-08 Pericardial fat / / 22589742 rs10198628 chr2 12964497 A G 5.00E-14 Pericardial fat / / 22589742 rs10164960 chr2 12965159 G A 4.70E-08 Pericardial fat / / 22589742 rs10204312 chr2 12965413 T C 2.90E-08 Pericardial fat / / 22589742 rs6432341 chr2 12965814 C G 4.00E-08 Pericardial fat / / 22589742 rs7572835 chr2 12966506 G A 4.10E-08 Pericardial fat / / 22589742 rs2098823 chr2 12968025 C A 8.20E-08 Pericardial fat / / 22589742 rs4669884 chr2 12968885 C T 1.70E-05 Pericardial fat / / 22589742 rs10180496 chr2 12968900 A G 1.00E-07 Dental caries / / 23064961 rs7558700 chr2 12969893 C G 1.50E-07 Pericardial fat / / 22589742 rs7558818 chr2 12969972 C T 1.30E-07 Pericardial fat / / 22589742 rs7584581 chr2 12969987 G C 1.80E-07 Pericardial fat / / 22589742 rs7559029 chr2 12970155 C A 1.80E-07 Pericardial fat / / 22589742 rs10184321 chr2 12970372 A C 6.30E-08 Pericardial fat / / 22589742 rs12617714 chr2 12971271 A G 1.30E-05 Pericardial fat / / 22589742 rs4669885 chr2 12973019 C A,G 6.30E-08 Pericardial fat / / 22589742 rs12999821 chr2 12973540 A G 6.30E-08 Pericardial fat / / 22589742 rs4669886 chr2 12974244 A G 7.50E-06 Pericardial fat / / 22589742 rs4669887 chr2 12976179 T G 1.00E-04 Schizophrenia / / 19197363 rs4669887 chr2 12976179 T G 3.30E-05 Pericardial fat / / 22589742 rs4669889 chr2 12980591 T C 6.40E-08 Pericardial fat / / 22589742 rs6732344 chr2 12984438 G A 5.80E-08 Pericardial fat / / 22589742 rs12468536 chr2 12984962 G A 7.50E-08 Pericardial fat / / 22589742 rs10929833 chr2 12984999 T C 6.20E-08 Pericardial fat / / 22589742 rs890070 chr2 12985129 G T 6.30E-08 Pericardial fat / / 22589742 rs950612 chr2 12990034 G C 8.00E-05 Pericardial fat / / 22589742 rs1554443 chr2 12991744 C G 2.20E-06 Pericardial fat / / 22589742 rs10188224 chr2 12995782 T G 4.80E-06 Pericardial fat / / 22589742 rs4669892 chr2 12997563 G C 2.90E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs4669893 chr2 12998152 G C 3.20E-06 Pericardial fat / / 22589742 rs7556962 chr2 13000040 T C 3.30E-06 Pericardial fat / / 22589742 rs6747537 chr2 13000397 C T 4.60E-05 Pericardial fat / / 22589742 rs1357060 chr2 13002998 T C 3.60E-06 Pericardial fat / / 22589742 rs1521249 chr2 13008754 T C 4.10E-06 Pericardial fat / / 22589742 rs17465771 chr2 13016168 G C 2.60E-05 Pericardial fat / / 22589742 rs10182783 chr2 13021683 G A 3.37E-05 Serum alpha1-antitrypsin levels / / 23990791 rs6432342 chr2 13022260 A G 3.50E-05 Pericardial fat / / 22589742 rs1879543 chr2 13024831 C T 6.30E-05 Pericardial fat / / 22589742 rs1949631 chr2 13027074 A G 5.85E-04 Multiple complex diseases / / 17554300 rs956596 chr2 13027660 A G 3.90E-05 Pericardial fat / / 22589742 rs6739633 chr2 13028547 C T 8.00E-05 HIV-1 viral setpoint / / 22174851 rs1357061 chr2 13035974 T C 6.52E-04 Multiple complex diseases / / 17554300 rs1521246 chr2 13037918 A C 4.70E-05 Pericardial fat / / 22589742 rs6432343 chr2 13039946 A G 5.70E-05 Pericardial fat / / 22589742 rs6728142 chr2 13041090 T C 4.54E-05 Serum alpha1-antitrypsin levels / / 23990791 rs1521247 chr2 13041412 C G 5.50E-05 Pericardial fat / / 22589742 rs13430556 chr2 13042709 T C 3.82E-05 Serum alpha1-antitrypsin levels / / 23990791 rs13388631 chr2 13042823 G C 3.56E-05 Serum alpha1-antitrypsin levels / / 23990791 rs10172921 chr2 13042870 G A 3.30E-05 Serum alpha1-antitrypsin levels / / 23990791 rs779339 chr2 13043884 A G 5.20E-05 Pericardial fat / / 22589742 rs13390247 chr2 13045563 T C 4.20E-05 Serum alpha1-antitrypsin levels / / 23990791 rs779343 chr2 13049099 T C 6.80E-05 Pericardial fat / / 22589742 rs13400830 chr2 13054564 A G 7.83E-06 Serum alpha1-antitrypsin levels / / 23990791 rs16859504 chr2 13055358 G A 8.38E-06 Serum alpha1-antitrypsin levels / / 23990791 rs983037 chr2 13080220 A C 9.59E-06 Schizophrenia / / 19197363 rs779379 chr2 13080607 A G 1.49E-04 Acute lung injury / / 22295056 rs779388 chr2 13085166 C T 3.44E-05 Coronary heart disease / / pha003031 rs7584450 chr2 13089072 A G 7.85E-05 Serum metabolites / / 19043545 rs711870 chr2 13089226 C A 6.51E-04 Acute lung injury / / 22295056 rs999059 chr2 13102424 T C 6.91E-04 Schizophrenia / / 19197363 rs779406 chr2 13102613 A G 3.66E-04 Acute lung injury / / 22295056 rs779409 chr2 13104553 C G 3.34E-04 Acute lung injury / / 22295056 rs779411 chr2 13105269 T C 3.34E-04 Acute lung injury / / 22295056 rs2459337 chr2 13108712 G C 2.80E-04 Acute lung injury LOC100506474 intron 22295056 rs12692488 chr2 13134803 A G 3.06E-04 Iron levels LOC100506474 intron pha002876 rs4668795 chr2 13167258 A C 3.60E-05 Coronary heart disease / / pha003031 rs1818595 chr2 13168232 A G 7.01E-04 Schizophrenia / / 19197363 rs4346352 chr2 13222498 C T 7.05E-05 Coronary heart disease / / pha003031 rs4669910 chr2 13289018 C T 3.40E-05 HIV-1 control / / 20041166 rs16859919 chr2 13300659 G T 2.70E-04 Multiple complex diseases / / 17554300 rs10203818 chr2 13367633 G A 4.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13403000 chr2 13368225 C T 2.22E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13403000 chr2 13368225 C T 5.28E-05 Coronary heart disease / / pha003031 rs9678154 chr2 13384186 A G 5.40E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16860506 chr2 13663029 T C 9.53E-04 Multiple complex diseases / / 17554300 rs16860575 chr2 13722414 T C 2.90E-05 Urinary metabolites / / 21572414 rs16860590 chr2 13722980 T G 2.40E-05 Urinary metabolites / / 21572414 rs2048401 chr2 13836169 T C 1.40E-05 Urinary metabolites / / 21572414 rs2175342 chr2 13839480 G T 2.50E-05 Urinary metabolites / / 21572414 rs1446542 chr2 13846734 T C 2.33E-05 Progressive supranuclear palsy / / 21685912 rs1588477 chr2 13892092 A C 7.45E-05 Multiple complex diseases / / 17554300 rs6432417 chr2 13951524 A G 4.74E-04 Acne (severe) / / 24927181 rs1000826 chr2 13984302 G A 4.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs10495625 chr2 13986304 T C 2.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1598106 chr2 14029748 C G 2.00E-07 IgG glycosylation / / 23382691 rs6752124 chr2 14040624 G A 4.15E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6752124 chr2 14040624 G A 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs11900844 chr2 14041017 C T 0.000199 Salmonella-induced pyroptosis / / 22837397 rs17312849 chr2 14059424 C T 8.73E-04 Multiple complex diseases / / 17554300 rs747193 chr2 14081761 A G 5.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs91166 chr2 14081905 T C 9.79E-05 Serum metabolites / / 19043545 rs401974 chr2 14082017 T C 3.02E-04 Longevity / / 22279548 rs549213 chr2 14094791 T C 9.10E-04 Type 2 diabetes / / 17463246 rs10495619 chr2 14153031 C G 1.70E-05 Urinary metabolites / / 21572414 rs391769 chr2 14162065 A G 1.70E-05 Urinary metabolites / / 21572414 rs16861159 chr2 14212802 C T 4.83E-04 Multiple complex diseases / / 17554300 rs360474 chr2 14227970 G A 7.32E-05 Height / / 17255346 rs16861195 chr2 14254307 T A 7.78E-04 Alzheimer's disease / / 17998437 rs16861198 chr2 14254391 G A 6.33E-04 Alzheimer's disease / / 17998437 rs6432444 chr2 14258368 A G 6.45E-05 Blood Pressure / / pha003050 rs10174530 chr2 14271246 T C 1.44E-04 Alzheimer's disease / / 17998437 rs7572783 chr2 14287044 G A 4.33E-04 Alzheimer's disease / / 17998437 rs10179956 chr2 14294926 G T 1.15E-04 Alzheimer's disease / / 17998437 rs13384764 chr2 14303716 C T 3.79E-04 Alzheimer's disease / / 17998437 rs10495633 chr2 14312862 T C 7.17E-04 Diabetic retinopathy / / 20871662 rs7571070 chr2 14334195 C T 3.36E-05 Cortisol secretion,in saliva / / 21316860 rs1839208 chr2 14365186 G T 3.85E-05 Personality dimensions / / 22628180 rs12692521 chr2 14366696 C A,G,T 3.85E-05 Personality dimensions / / 22628180 rs10200546 chr2 14382112 G C 2.64E-04 Multiple complex diseases / / 17554300 rs16861531 chr2 14398052 G C 7.00E-07 Response to antidepressant treatment / / 22041458 rs1900855 chr2 14416772 A C 7.89E-04 Multiple complex diseases / / 17554300 rs7585523 chr2 14432623 C T 5.80E-04 Multiple complex diseases / / 17554300 rs13385301 chr2 14473903 C A 6.97E-05 IgE levels / / 22075330 rs10495639 chr2 14475689 C T 7.02E-05 IgE levels / / 22075330 rs11888369 chr2 14477599 T C 8.63E-05 IgE levels / / 22075330 rs13416263 chr2 14481038 G A 8.80E-05 IgE levels / / 22075330 rs13419213 chr2 14485156 A G 8.98E-05 IgE levels / / 22075330 rs13410836 chr2 14487799 T C 9.01E-05 IgE levels / / 22075330 rs10203925 chr2 14491335 T C 9.06E-05 IgE levels / / 22075330 rs13428704 chr2 14492900 A T 9.06E-05 IgE levels / / 22075330 rs1850135 chr2 14510134 C A 3.20E-05 Multiple complex diseases / / 17554300 rs11884512 chr2 14526931 G C 3.73E-05 IgE levels / / 22075330 rs4145975 chr2 14571744 T C 7.70E-05 Obesity,menopause / / 21424828 rs4426508 chr2 14580815 C G 3.90E-06 Urinary metabolites / / 21572414 rs2056150 chr2 14603290 A G 1.03E-05 Prostate cancer / / 24185611 rs2865931 chr2 14610061 G A 8.40E-05 Glucose levels / / pha003061 rs10929915 chr2 14651888 G A 2.39E-04 Multiple complex diseases / / 17554300 rs12473205 chr2 14658053 C A 4.15E-05 Prostate cancer / / 22923026 rs13408950 chr2 14682175 T G 5.14E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2380614 chr2 14685560 C T 6.93E-05 Serum metabolites / / 19043545 rs4670003 chr2 14686152 G A 1.28E-04 Type 2 diabetes / / 17463246 rs4670003 chr2 14686152 G A 7.90E-05 Serum metabolites / / 19043545 rs16861832 chr2 14687525 C T 9.07E-04 Multiple complex diseases / / 17554300 rs10188924 chr2 14687890 A C 2.06E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6724180 chr2 14691935 A G 8.66E-05 Serum metabolites / / 19043545 rs2380619 chr2 14710487 A T 1.14E-04 Type 2 diabetes / / 17463246 rs7602441 chr2 14801501 G A 8.62E-05 Stroke / / 22306652 rs7602441 chr2 14801501 G A 7.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs1434975 chr2 14805442 G A 2.46E-05 HIV-1 progression to AIDS and death / / 21811574 rs1369242 chr2 14827944 T C 1.60E-06 Urinary metabolites / / 21572414 rs7607607 chr2 14881995 A C 8.96E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs188141385 chr2 14975369 A G 4.16E-10 TNF-alpha (TNF-a) / / 23696881 rs2679421 chr2 14985079 A C 2.52E-05 Fibrinogen / / 17255346 rs1540790 chr2 15002176 C G 4.18E-05 Fibrinogen / / 17255346 rs10176935 chr2 15004104 T C 3.00E-05 Fibrinogen / / 17255346 rs1878847 chr2 15006960 C T 1.40E-06 Urinary metabolites / / 21572414 rs11886100 chr2 15008308 A C 2.00E-06 Urinary metabolites / / 21572414 rs10173791 chr2 15033404 T C 1.20E-05 Urinary metabolites / / 21572414 rs10173791 chr2 15033404 T C 7.33E-04 Tourette syndrome / / 22889924 rs17433057 chr2 15036267 C T 4.02E-05 Aging (time to event) / / 21782286 rs1518793 chr2 15036358 T C 7.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12622607 chr2 15053752 T C 3.88E-04 Smoking quantity / / 24665060 rs1568282 chr2 15066177 C T 6.78E-05 Longevity / / 22279548 rs10200717 chr2 15068315 A C 8.75E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11887847 chr2 15074706 A G 5.94E-04 Multiple complex diseases / / 17554300 rs10172951 chr2 15079571 A G 2.53E-04 Multiple complex diseases / / 17554300 rs793824 chr2 15081118 G T 5.46E-06 Odorant perception / / 23910658 rs715121 chr2 15082832 T C 1.83E-04 Multiple complex diseases / / 17554300 rs13411450 chr2 15084108 T C 9.05E-05 Multiple complex diseases / / 17554300 rs6432494 chr2 15102839 C T 6.90E-06 Urinary metabolites / / 21572414 rs4670047 chr2 15106804 C T 6.02E-05 Epilepsy / / 22116939 rs7587023 chr2 15110323 C T 4.37E-05 Epilepsy / / 22116939 rs1344741 chr2 15125286 C T 3.89E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs6737611 chr2 15131647 A G 4.00E-05 Prostate cancer / / 21743057 rs6748326 chr2 15148338 C T 9.48E-05 Post-operative nausea and vomiting / / 21694509 rs4668845 chr2 15162318 G A 7.40E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2890484 chr2 15176554 C G 6.26E-04 Type 2 diabetes / / 17463246 rs1816319 chr2 15212093 G A 2.16E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1178199 chr2 15217710 T G 1.62E-04 Insulin resistance / / 21901158 rs13391879 chr2 15229630 T C 9.73E-05 Left ventricular hypertrophy / / pha003052 rs1346874 chr2 15246192 G A 6.74E-04 Insulin resistance / / 21901158 rs11695054 chr2 15254827 G A 7.60E-04 Type 2 diabetes / / 17463246 rs7598924 chr2 15255532 A G 5.11E-05 Tunica Media / / pha003037 rs9287654 chr2 15256140 T A 4.50E-04 Type 2 diabetes / / 17463246 rs1990851 chr2 15256606 A G 1.74E-06 Renal cell carcinoma / / 23184150 rs2216537 chr2 15263472 C T 6.84E-04 Type 2 diabetes / / 17463246 rs11688502 chr2 15278561 A G 4.69E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10192667 chr2 15284746 C T 2.57E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7572179 chr2 15295998 G C 1.49E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4294976 chr2 15297306 G T 6.66E-04 Premature ovarian failure / / 19508998 rs4668880 chr2 15303803 C T 7.25E-04 Acute lung injury / / 22295056 rs1469017 chr2 15311954 A G 2.99E-05 Information processing speed NBAS intron 21130836 rs6730450 chr2 15322577 G A 6.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NBAS intron 20877124 rs13007229 chr2 15342428 T C 8.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NBAS intron 20877124 rs10183588 chr2 15353916 A C 8.43E-05 Serum metabolites NBAS intron 19043545 rs4668885 chr2 15357213 T C 8.69E-05 Information processing speed NBAS intron 21130836 rs12616994 chr2 15373675 T C 4.20E-05 Information processing speed NBAS intron 21130836 rs2042144 chr2 15393316 T C 0.0004293 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs2042144 chr2 15393316 T C 4.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs6711181 chr2 15400577 A G 0.0007672 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs6711181 chr2 15400577 A G 7.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs4668891 chr2 15401476 C T 0.000763 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs4668891 chr2 15401476 C T 7.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs10929356 chr2 15402016 T G 0.0005329 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs10929356 chr2 15402016 T G 5.33E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs929735 chr2 15403932 C T 0.0007583 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs929735 chr2 15403932 C T 7.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs1989380 chr2 15404109 G C 0.0007569 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs1989380 chr2 15404109 G C 7.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs6431689 chr2 15404546 T C 0.000752 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs6431689 chr2 15404546 T C 7.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs16862470 chr2 15405213 G A 4.89E-04 Multiple complex diseases NBAS intron 17554300 rs6738994 chr2 15405663 G T 0.000743 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs6738994 chr2 15405663 G T 7.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs11904632 chr2 15406044 C A 0.0007415 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs11904632 chr2 15406044 C A 7.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs11904635 chr2 15406061 C A 0.0007403 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs11904635 chr2 15406061 C A 7.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs7605754 chr2 15406506 T A 0.000701 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs7605754 chr2 15406506 T A 7.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs10929357 chr2 15410107 A G 0.0003826 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs10929357 chr2 15410107 A G 3.83E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs4465744 chr2 15410130 A G 0.0005373 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs4465744 chr2 15410130 A G 5.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs962616 chr2 15413179 G A 0.0006686 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs962616 chr2 15413179 G A 6.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs962617 chr2 15413276 G A 0.0006676 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs962617 chr2 15413276 G A 6.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs3805093 chr2 15418054 A C 0.000343 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs3805093 chr2 15418054 A C 3.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs721858 chr2 15419856 T A 0.0004689 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs721858 chr2 15419856 T A 4.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs3828463 chr2 15419945 A C 0.0003412 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs3828463 chr2 15419945 A C 3.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs10193783 chr2 15420523 G A 0.0006446 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs10193783 chr2 15420523 G A 6.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs7575687 chr2 15421848 G C 0.0006373 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs7575687 chr2 15421848 G C 6.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs7340328 chr2 15425781 T G 0.0004549 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs7340328 chr2 15425781 T G 4.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs10199552 chr2 15427592 G T 0.0004546 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs10199552 chr2 15427592 G T 4.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs12613488 chr2 15433328 G T 0.0006299 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs12613488 chr2 15433328 G T 6.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs7598652 chr2 15434967 T C 0.0004818 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs7598652 chr2 15434967 T C 4.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs7584861 chr2 15435181 C G 0.0004815 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs7584861 chr2 15435181 C G 4.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs12993786 chr2 15437707 C T 0.0006368 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs12993786 chr2 15437707 C T 6.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs10181295 chr2 15441492 G A 0.0003352 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs10181295 chr2 15441492 G A 3.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs1076509 chr2 15441821 C T 0.0003356 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs1076509 chr2 15441821 C T 3.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs741570 chr2 15442041 G A 0.0003387 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs741570 chr2 15442041 G A 3.39E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs10199885 chr2 15443121 T C 0.000251 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs10199885 chr2 15443121 T C 2.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs6431690 chr2 15443525 T C 0.0002513 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs6431690 chr2 15443525 T C 2.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs6708720 chr2 15447902 C T 0.0003362 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs6708720 chr2 15447902 C T 3.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs1318102 chr2 15448311 A T 0.0004764 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs1318102 chr2 15448311 A T 4.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs10206116 chr2 15450646 T C 0.0003546 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs10206116 chr2 15450646 T C 3.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs888636 chr2 15456209 G A 0.0005074 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs888636 chr2 15456209 G A 5.07E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs10803672 chr2 15464726 A G 0.0005284 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs10803672 chr2 15464726 A G 5.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs7599455 chr2 15468791 G A 0.0007033 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBAS intron 23233654 rs7599455 chr2 15468791 G A 7.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBAS intron 23233662 rs13405125 chr2 15479175 T C 5.10E-04 Aortic root size NBAS intron 21223598 rs7572081 chr2 15509146 A G 5.14E-07 Cisplatin and carboplatin cytotoxicity,in blood cell lines NBAS intron 21844884 rs2049718 chr2 15518589 C T 1.66E-04 Smoking cessation NBAS intron 18519826 rs16862653 chr2 15542352 C T 7.35E-04 Type 2 diabetes NBAS missense 17463246 rs2031011 chr2 15548390 T C 1.36E-04 Smoking cessation NBAS intron 18519826 rs2031011 chr2 15548390 T C 4.83E-05 Serum metabolites NBAS intron 19043545 rs7568678 chr2 15596203 C T 1.39E-04 Smoking cessation NBAS intron 18519826 rs2241237 chr2 15656157 T A 1.00E-04 Smoking cessation NBAS intron 18519826 rs2241237 chr2 15656157 T A 3.85E-04 Smoking cessation NBAS intron 18519826 rs7581919 chr2 15664756 C T 8.00E-06 Conduct disorder (symptom count) NBAS intron 20585324 rs7581919 chr2 15664756 C T 7.44E-04 Iron levels NBAS intron pha002876 rs6710456 chr2 15669939 T C 6.85E-05 Smoking cessation NBAS intron 18519826 rs11694485 chr2 15676154 C T 5.05E-06 Smoking cessation NBAS intron 18519826 rs3755130 chr2 15729583 G A 1.20E-05 Urinary metabolites / / 21572414 rs3755132 chr2 15729820 T G 1.00E-14 Wilms tumor / / 22544364 rs2302930 chr2 15737343 A G 3.10E-06 Wilms tumor DDX1 intron 22544364 rs2302931 chr2 15737480 C A 3.10E-06 Wilms tumor DDX1 intron 22544364 rs4668942 chr2 15750443 T C 3.10E-06 Wilms tumor DDX1 intron 22544364 rs7594193 chr2 15750640 A G 3.10E-06 Wilms tumor DDX1 intron 22544364 rs3770466 chr2 15758293 T C 3.10E-06 Wilms tumor DDX1 intron 22544364 rs3770467 chr2 15762935 G A 3.14E-06 Wilms tumor DDX1 intron 22544364 rs41264163 chr2 15763788 C T 3.14E-06 Wilms tumor DDX1 intron 22544364 rs4668945 chr2 15764078 G C 3.34E-06 Wilms tumor DDX1 intron 22544364 rs6734471 chr2 15765425 C T 3.34E-06 Wilms tumor DDX1 intron 22544364 rs6743036 chr2 15767761 G A 3.34E-06 Wilms tumor DDX1 intron 22544364 rs6743630 chr2 15768256 G A 3.34E-06 Wilms tumor DDX1 intron 22544364 rs3770470 chr2 15770507 G T 3.34E-06 Wilms tumor DDX1 intron 22544364 rs3770471 chr2 15770775 C T 3.34E-06 Wilms tumor DDX1 intron 22544364 rs4668948 chr2 15771586 A C 2.55E-06 Wilms tumor / / 22544364 rs4668949 chr2 15771615 C T 1.51E-06 Wilms tumor / / 22544364 rs976015 chr2 15772546 C G 3.14E-06 Wilms tumor / / 22544364 rs16862822 chr2 15772958 G A 3.34E-06 Wilms tumor / / 22544364 rs976233 chr2 15774115 C T 3.34E-06 Wilms tumor / / 22544364 rs16862823 chr2 15775210 T C 3.14E-06 Wilms tumor / / 22544364 rs807624 chr2 15782471 G T 1.00E-14 Wilms tumor / / 22544364 rs6724800 chr2 15786243 A G 1.86E-06 Wilms tumor / / 22544364 rs16862838 chr2 15788191 C T 1.71E-06 Wilms tumor / / 22544364 rs4668458 chr2 15789441 G A 2.22E-06 Wilms tumor / / 22544364 rs6431721 chr2 15791937 C T 2.66E-06 Wilms tumor / / 22544364 rs807571 chr2 15809109 G A 3.30E-04 Age-related macular degeneration / / 22125219 rs7579979 chr2 15812261 A G 1.31E-05 IgE levels / / 22075330 rs10929380 chr2 15812577 G A 1.34E-05 IgE levels / / 22075330 rs7593726 chr2 15813840 C T 1.72E-05 IgE levels / / 22075330 rs7582338 chr2 15818041 A G 5.88E-05 Insulin resistance / / 21901158 rs6739656 chr2 15832258 G C 4.31E-04 Coronary heart disease / / 21606135 rs6754458 chr2 15834052 A G 4.72E-04 Coronary heart disease / / 21606135 rs1862101 chr2 15843840 T C 8.11E-06 Ulcerative colitis / / 19915573 rs1862101 chr2 15843840 T C 5.80E-05 Lipid traits / / 22028671 rs6746441 chr2 15856372 A G 2.72E-06 Ulcerative colitis / / 19915573 rs7591368 chr2 15862330 C A 6.07E-07 Ulcerative colitis / / 19915573 rs6431731 chr2 15863002 C T 4.00E-08 Chronic kidney disease / / 22479191 rs2380671 chr2 15867707 A G 9.14E-05 Bipolar disorder and schizophrenia / / 20889312 rs2080799 chr2 15872327 T C 6.74E-05 Chronic obstructive pulmonary disease / / 19300482 rs2080799 chr2 15872327 T C 6.74E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2080798 chr2 15872385 T C 1.63E-05 Chronic obstructive pulmonary disease / / 19300482 rs2080798 chr2 15872385 T C 1.63E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1345564 chr2 15895707 C A 6.59E-05 Prostate cancer / / 22923026 rs2693010 chr2 15902138 G A 2.27E-05 Cognitive impairment induced by topiramate / / 22091778 rs2112101 chr2 15902679 T C 2.90E-05 Asthma or chronic obstructive pulmonary disease / / 24993907 rs12464087 chr2 15902912 G A 7.68E-04 Type 2 diabetes / / 17463246 rs2544531 chr2 15904041 A G 6.39E-04 Type 2 diabetes / / 17463246 rs6728667 chr2 15904705 G A 1.32E-05 Asthma or chronic obstructive pulmonary disease / / 24993907 rs6728750 chr2 15904734 G A 1.10E-05 Asthma or chronic obstructive pulmonary disease / / 24993907 rs2544534 chr2 15906466 T C 2.23E-06 Asthma or chronic obstructive pulmonary disease / / 24993907 rs1477253 chr2 15910457 T C 1.18E-06 Asthma or chronic obstructive pulmonary disease / / 24993907 rs2693008 chr2 15913019 G C 2.23E-06 Asthma or chronic obstructive pulmonary disease / / 24993907 rs2544523 chr2 15920323 T C 1.00E-06 Asthma or chronic obstructive pulmonary disease / / 24993907 rs2693019 chr2 15922288 T C 1.36E-06 Asthma or chronic obstructive pulmonary disease / / 24993907 rs1363058 chr2 15923441 C T 1.60E-05 Asthma or chronic obstructive pulmonary disease / / 24993907 rs2544527 chr2 15926168 T C 9.00E-06 Pulmonary function / / 21946350 rs2544527 chr2 15926168 T C 2.00E-07 Pulmonary function (interaction) / / 23284291 rs2544527 chr2 15926168 T C 9.89E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs2544527 chr2 15926168 T C 1.85E-05 Asthma or chronic obstructive pulmonary disease / / 24993907 rs2693026 chr2 15926593 A G 5.72E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs2380674 chr2 15931387 T C 9.30E-04 Multiple complex diseases / / 17554300 rs11894034 chr2 15940948 T C 1.90E-06 Urinary metabolites / / 21572414 rs4668996 chr2 15953381 T C 6.42E-04 Type 2 diabetes / / 17463246 rs2380694 chr2 15958803 T C 6.42E-06 Hair morphology / / 19896111 rs7586898 chr2 15961599 G C 2.00E-06 Hair morphology / / 19896111 rs7595922 chr2 15965628 T C 3.30E-04 Rheumatoid arthritis / / 21452313 rs11678237 chr2 15986586 C A 1.36E-04 Multiple complex diseases / / 17554300 rs2890494 chr2 15992495 G A 4.76E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11688136 chr2 16010659 A C 6.61E-04 Alzheimer's disease / / 17998437 rs2380707 chr2 16012630 A G 5.22E-04 Bone mass and geometry / / 17903296 rs10929397 chr2 16020019 T A,C 1.90E-05 Urinary metabolites / / 21572414 rs4669011 chr2 16029727 G A 1.99E-04 Multiple complex diseases / / 17554300 rs755915 chr2 16030231 A G 7.02E-04 Multiple complex diseases / / 17554300 rs2254328 chr2 16030567 A G 2.71E-04 Multiple complex diseases / / 17554300 rs746104 chr2 16031027 C T 2.28E-04 Multiple complex diseases / / 17554300 rs10495647 chr2 16035256 A G 3.37E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11676479 chr2 16036368 T C 5.08E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11676479 chr2 16036368 T C 9.30E-05 Iron levels / / 21208937 rs10803675 chr2 16056139 G A 1.62E-04 Type 2 diabetes / / 17463246 rs10803675 chr2 16056139 G A 8.23E-04 Multiple complex diseases / / 17554300 rs11886063 chr2 16080157 C G 5.92E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6719419 chr2 16127922 G A 1.94E-04 Multiple complex diseases / / 17554300 rs6706117 chr2 16131782 A G 5.34E-04 Alcohol dependence / / 20201924 rs3815884 chr2 16137572 C T 7.54E-04 Multiple complex diseases / / 17554300 rs2114802 chr2 16137611 C T 1.80E-05 Urinary metabolites / / 21572414 rs13396055 chr2 16142703 G A 4.67E-04 Multiple complex diseases / / 17554300 rs13396055 chr2 16142703 G A 2.90E-05 Urinary metabolites / / 21572414 rs41459549 chr2 16169350 C T 6.48E-04 Multiple complex diseases / / 17554300 rs6716719 chr2 16169371 A C 1.25E-04 Multiple complex diseases / / 17554300 rs11896089 chr2 16171139 T A 7.30E-05 Response to statin therapy / / 20339536 rs11896089 chr2 16171139 T A 0.00000472 HDL cholesterol particle diameter / / 23263444 rs10194143 chr2 16176894 T C 1.00E-04 Prostate cancer / / 21743057 rs55678912 chr2 16191545 C T 7.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs7569161 chr2 16193273 A G 3.93E-08 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs7579022 chr2 16193461 G C 4.90E-04 Multiple complex diseases / / 17554300 rs72770595 chr2 16196085 A G 6.04E-08 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs72770598 chr2 16197939 T A 4.58E-08 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs72770600 chr2 16198363 T C 4.58E-08 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs72770601 chr2 16198672 C T 5.94E-08 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs7608858 chr2 16201566 C T 1.51E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs4668486 chr2 16243192 A C 4.33E-05 Multiple sclerosis / / 19525953 rs4047461 chr2 16358715 T G 4.92E-04 Multiple complex diseases / / 17554300 rs340718 chr2 16403550 G A 7.68E-04 Type 2 diabetes / / 17463246 rs12474170 chr2 16405448 G A 2.50E-05 Urinary metabolites / / 21572414 rs2163063 chr2 16430070 G A 4.84E-05 Blood Pressure / / pha003049 rs1429405 chr2 16433074 G A 6.69E-05 Blood Pressure / / pha003049 rs7569508 chr2 16433908 T C 4.07E-04 Alzheimer's disease / / 24755620 rs340738 chr2 16438076 A G 1.92E-06 Blood Pressure / / pha003049 rs1567967 chr2 16469070 G C 7.13E-04 Type 2 diabetes / / 17463246 rs340742 chr2 16471243 C A 4.58E-04 Smoking cessation / / 24665060 rs629526 chr2 16475090 T C 5.45E-04 Smoking cessation / / 24665060 rs680603 chr2 16488267 C T 2.47E-05 Sleep duration / / 22105623 rs13385414 chr2 16546282 A G 6.69E-04 Smoking initiation / / 24665060 rs1156704 chr2 16557140 C T 6.53E-05 Orofacial clefts / / 22419666 rs16982292 chr2 16589611 G T 8.06E-04 Multiple complex diseases / / 17554300 rs1367158 chr2 16590965 T A,C 3.23E-05 Weight / / pha003026 rs1367158 chr2 16590965 T A,C 5.18E-05 Weight / / pha003027 rs11884584 chr2 16598521 C A 1.64E-05 Height / / pha003011 rs2115849 chr2 16600041 T C 1.03E-05 Height / / pha003011 rs4832591 chr2 16606596 A G 7.21E-05 Height / / pha003010 rs4832591 chr2 16606596 A G 6.04E-06 Height / / pha003011 rs2115850 chr2 16609693 A G 8.72E-05 Height / / pha003010 rs2115850 chr2 16609693 A G 8.25E-06 Height / / pha003011 rs934224 chr2 16613889 C T 8.29E-05 Elbow pain / / pha003008 rs934224 chr2 16613889 C T 6.37E-05 Height / / pha003010 rs934224 chr2 16613889 C T 2.27E-06 Height / / pha003011 rs934224 chr2 16613889 C T 2.80E-05 Weight / / pha003026 rs6746008 chr2 16621135 G T 6.60E-07 Height / / pha003010 rs6746008 chr2 16621135 G T 6.24E-08 Height / / pha003011 rs7563815 chr2 16624337 C T 2.95E-06 Height / / pha003010 rs7563815 chr2 16624337 C T 2.11E-07 Height / / pha003011 rs4832615 chr2 16630784 T C 3.77E-05 Height / / pha003010 rs4832615 chr2 16630784 T C 2.49E-06 Height / / pha003011 rs13012094 chr2 16631289 C T 7.70E-06 Height / / pha003010 rs13012094 chr2 16631289 C T 2.15E-06 Height / / pha003011 rs10185113 chr2 16632751 A G 6.03E-05 Height / / pha003010 rs10185113 chr2 16632751 A G 1.32E-05 Height / / pha003011 rs1346751 chr2 16639566 C T 8.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy) / / 24554482 rs4832633 chr2 16648888 G A 1.90E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs4832633 chr2 16648888 G A 5.80E-05 Height / / pha003010 rs4832633 chr2 16648888 G A 6.15E-06 Height / / pha003011 rs4393752 chr2 16652659 T C 7.61E-05 Height / / pha003011 rs16982439 chr2 16655641 C T 3.66E-04 Type 2 diabetes / / 17463246 rs1346752 chr2 16676846 T C 2.88E-05 Height / / pha003011 rs1430054 chr2 16680691 A G 2.86E-05 Height / / pha003011 rs1430055 chr2 16680789 G A 2.79E-07 Esophageal cancer (squamous cell) / / 22960999 rs12463697 chr2 16686128 A G 6.68E-05 Height / / pha003010 rs12463697 chr2 16686128 A G 1.68E-06 Height / / pha003011 rs4240228 chr2 16688759 G T 3.04E-05 Height / / pha003011 rs6705856 chr2 16698235 C T 9.94E-05 Height / / pha003011 rs4560110 chr2 16702136 A G 2.96E-05 Height / / pha003011 rs4832647 chr2 16705396 A G 9.40E-05 Orofacial clefts / / 22863734 rs4497881 chr2 16706891 C A 7.63E-05 Cleft lip / / 20436469 rs4497881 chr2 16706891 C A 1.77E-06 Orofacial clefts / / 22863734 rs4441471 chr2 16715408 A G 3.37E-05 Cleft lip / / 20436469 rs4441471 chr2 16715408 A G 8.00E-07 Orofacial clefts / / 22863734 rs6761778 chr2 16717466 C T 2.87E-07 Facial morphology / / 22341974 rs2067702 chr2 16718894 A G 2.87E-07 Facial morphology / / 22341974 rs6752432 chr2 16720447 C T 2.01E-04 Type 2 diabetes / / 17463246 rs6741506 chr2 16720735 G C 1.52E-04 Type 2 diabetes / / 17463246 rs4832657 chr2 16726739 C T 2.68E-07 Facial morphology / / 22341974 rs10168963 chr2 16729410 C T 5.43E-05 Cognitive test performance / / 20125193 rs15653 chr2 16731510 G A 5.35E-06 Orofacial clefts FAM49A UTR-3 22863734 rs555725386 chr2 16731510 G GT 5.35E-06 Orofacial clefts FAM49A UTR-3 22863734 rs5007483 chr2 16733525 G T 4.42E-07 Facial morphology FAM49A UTR-3 22341974 rs7552 chr2 16733928 A G 3.25E-07 Facial morphology FAM49A UTR-3 22341974 rs12997119 chr2 16734284 T C 2.52E-07 Facial morphology FAM49A intron 22341974 rs6743040 chr2 16734999 T C 1.92E-04 Type 2 diabetes FAM49A intron 17463246 rs7573656 chr2 16735432 G A 3.01E-07 Facial morphology FAM49A intron 22341974 rs7586823 chr2 16741442 C T 8.51E-05 Intelligence FAM49A intron 21826061 rs6743717 chr2 16791265 G A 4.57E-05 Amyotrophic Lateral Sclerosis FAM49A intron 17827064 rs11679606 chr2 16795418 A G 1.30E-04 Type 2 diabetes FAM49A intron 17463249 rs11679606 chr2 16795418 A G 1.29E-04 Multiple complex diseases FAM49A intron 17554300 rs6723770 chr2 16795666 T C 1.35E-04 Multiple complex diseases FAM49A intron 17554300 rs11897395 chr2 16807587 C A 4.53E-04 Parkinson's disease FAM49A intron 17052657 rs9306896 chr2 16813028 G C 8.77E-05 Multiple complex diseases FAM49A intron 17554300 rs41347856 chr2 16867615 G A 8.98E-04 Multiple complex diseases / / 17554300 rs17645454 chr2 16896822 C T 7.18E-05 Type 2 diabetes / / 17463246 rs1722426 chr2 16907892 C A 3.94E-04 Heart Failure / / pha002885 rs6732082 chr2 16909022 A G 4.20E-07 Urinary metabolites / / 21572414 rs11674035 chr2 16921112 T C 0.0001 Migraine / / 22678113 rs1862059 chr2 16926228 C T 0.0001 Migraine / / 22678113 rs16982730 chr2 16946721 T G 9.02E-04 Type 2 diabetes / / 17463246 rs11096693 chr2 16949116 G C 9.28E-04 Type 2 diabetes / / 17463246 rs11690985 chr2 16949922 C T 5.28E-04 Type 2 diabetes / / 17463246 rs11693345 chr2 16950112 A G 5.85E-04 Type 2 diabetes / / 17463246 rs16982758 chr2 16950440 A C 7.69E-04 Type 2 diabetes / / 17463246 rs11682177 chr2 16956880 T C 6.25E-04 Type 2 diabetes / / 17463246 rs2341997 chr2 16971986 T C 3.30E-05 Anger / / 24489884 rs2341997 chr2 16971986 T C 4.29E-05 Heart Rate / / pha003051 rs2160938 chr2 16995726 G C 4.95E-04 Multiple complex diseases / / 17554300 rs4140716 chr2 17015790 C T 7.16E-04 Aortic root size / / 21223598 rs2042077 chr2 17019622 G A 4.91E-05 Erythrocyte counts / / pha003101 rs34823620 chr2 17021774 T C 9.52E-04 Multiple complex diseases / / 17554300 rs2216451 chr2 17024097 C A 3.40E-05 Erythrocyte counts / / pha003101 rs11096709 chr2 17103115 C G 5.82E-04 Type 2 diabetes / / 17463246 rs2042079 chr2 17105852 C T 4.91E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2042079 chr2 17105852 C T 2.85E-06 Bipolar disorder / / 17486107 rs2042079 chr2 17105852 C T 1.20E-05 Parkinson's disease / / 19915575 rs2042079 chr2 17105852 C T 3.40E-05 Parkinson's disease / / pha002868 rs4832481 chr2 17122737 A C 3.61E-05 Erythrocyte counts / / pha003101 rs6707000 chr2 17128879 A G 8.15E-04 Rheumatoid arthritis / / 21452313 rs1515966 chr2 17216459 T C 4.72E-04 Parkinson's disease / / 17052657 rs1515966 chr2 17216459 T C 6.92E-04 HIV-1 viral setpoint / / 17641165 rs1356186 chr2 17227509 A G 2.76E-05 Bipolar disorder / / 17486107 rs11690007 chr2 17258880 T C 4.29E-04 Type 2 diabetes / / 17463246 rs7340478 chr2 17271133 G A 1.91E-04 Aortic root size / / 21223598 rs10495658 chr2 17303288 T G 0.0000399 Schizophrenia / / 23637625 rs13006099 chr2 17305810 G A 3.77E-04 Body mass index / / 21701565 rs2342551 chr2 17314547 C T 6.40E-04 Multiple complex diseases / / 17554300 rs12987450 chr2 17344959 G C 5.71E-04 Multiple complex diseases / / 17554300 rs1588173 chr2 17346118 C A 6.89E-04 Multiple complex diseases / / 17554300 rs12620480 chr2 17353506 G C 5.62E-04 Body mass index / / 21701565 rs484687 chr2 17359400 T C 8.35E-04 Suicide attempts in bipolar disorder / / 21041247 rs10195119 chr2 17365709 C T 3.99E-04 Multiple complex diseases / / 17554300 rs13401551 chr2 17373951 G A 3.89E-04 Multiple complex diseases / / 17554300 rs10182258 chr2 17379728 G A,C,T 3.42E-04 Multiple complex diseases / / 17554300 rs12467252 chr2 17384658 C T 5.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs11898524 chr2 17386806 T C 5.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs11893015 chr2 17387162 C T 5.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs13031560 chr2 17388290 T C 5.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs1589272 chr2 17389900 G A 4.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs10495660 chr2 17396548 T G 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs11674840 chr2 17397895 A G 4.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs1519969 chr2 17399452 T A 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs1519968 chr2 17399486 A C 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs7419572 chr2 17399740 G A 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs16983357 chr2 17399921 G C 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs11693140 chr2 17400070 A T 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs2030358 chr2 17400329 T C 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs2030357 chr2 17400393 A G 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs11673738 chr2 17401389 T A 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs11677772 chr2 17401741 G T 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs1507986 chr2 17402996 C T 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs2174865 chr2 17403582 C G 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs13020402 chr2 17403829 C T 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs13018947 chr2 17403887 G C 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs11889338 chr2 17427585 G A 9.00E-06 Alzheimer's disease / / 22159054 rs6740500 chr2 17430803 C T 2.50E-04 White matter integrity / / 22425255 rs7602088 chr2 17530815 A G 3.67E-06 Asthma / / 21790008 rs3112233 chr2 17556532 A C 2.90E-05 Orofacial clefts / / 22419666 rs12185578 chr2 17609239 T A 9.00E-06 Subcutaneous adipose tissue / / 22589738 rs17380100 chr2 17681504 T C 5.75E-05 Cognitive test performance / / 20125193 rs17380121 chr2 17683231 G T 7.81E-05 Alcohol consumption / / 23953852 rs446947 chr2 17712696 A T 6.65E-05 Serum metabolites / / 19043545 rs426590 chr2 17738199 C T 6.65E-05 Serum metabolites VSNL1 intron 19043545 rs16983673 chr2 17766142 C T 6.81E-04 Amyotrophic Lateral Sclerosis VSNL1 intron 17362836 rs16983681 chr2 17768968 C T 6.43E-04 Alzheimer's disease VSNL1 intron 22005930 rs1033301 chr2 17773998 A C 9.73E-07 Alzheimer's disease VSNL1 intron 22005930 rs4038129 chr2 17774746 A G 9.58E-07 Alzheimer's disease VSNL1 intron 22005930 rs4038131 chr2 17775032 A G 6.00E-07 Alzheimer's disease VSNL1 intron 22005930 rs1949510 chr2 17778129 C T 2.16E-06 Alzheimer's disease VSNL1 intron 22005930 rs1426510 chr2 17782556 A T 4.36E-05 Serum metabolites VSNL1 intron 19043545 rs13006235 chr2 17790442 C G 7.72E-04 Alzheimer's disease VSNL1 intron 22005930 rs7560823 chr2 17879411 T C 4.06E-05 Post-operative nausea and vomiting SMC6 intron 21694509 rs11897477 chr2 17902381 C G 7.81E-04 Alzheimer's disease SMC6 intron 22005930 rs7574887 chr2 17948649 T C 0.00019 Cognitive impairment (no dementia) GEN1 intron 23042215 rs2615048 chr2 17958762 G A 9.24E-21 Lymphocyte counts GEN1 intron 22286170 rs13394205 chr2 17986027 C A 1.08E-05 Multiple complex diseases / / 17554300 rs214034 chr2 17988658 A C 7.00E-06 Response to amphetamines / / 22952603 rs12710647 chr2 17989466 T A,C,G 1.05E-04 Gallstones / / 17632509 rs1564010 chr2 17991857 A G 2.69E-04 Multiple complex diseases / / 17554300 rs4302214 chr2 18016788 C T 3.59E-04 Multiple complex diseases / / 17554300 rs1063 chr2 18026245 G A 9.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs11680328 chr2 18037807 T A 5.00E-05 Obesity (extreme) / / 21935397 rs6758546 chr2 18038812 A G 9.24E-06 Obesity (extreme) / / 21935397 rs6758546 chr2 18038812 A G 4.70E-05 Body Mass Index / / pha003009 rs7583266 chr2 18083850 G A 7.44E-05 Rheumatoid arthritis KCNS3 intron 17804836 rs1564004 chr2 18098857 C T 8.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNS3 intron 20877124 rs1564004 chr2 18098857 C T 6.00E-04 Bipolar disorder KCNS3 intron 24387768 rs1461949 chr2 18102223 G A 7.45E-04 Suicide attempts in bipolar disorder KCNS3 intron 21423239 rs1461946 chr2 18106179 G A 6.66E-04 Suicide attempts in bipolar disorder KCNS3 intron 21423239 rs2045720 chr2 18110711 T C 6.72E-04 Suicide attempts in bipolar disorder KCNS3 intron 21423239 rs4832524 chr2 18113623 A G 6.50E-04 Suicide attempts in bipolar disorder KCNS3 missense 21423239 rs3747515 chr2 18113789 G A 3.60E-04 Suicide attempts in bipolar disorder KCNS3 UTR-3 21423239 rs1031771 chr2 18114932 C T 2.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs6712999 chr2 18115305 C G 9.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs6713395 chr2 18115603 C G 9.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs6713633 chr2 18115776 C A 9.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs11889711 chr2 18117236 C T 8.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs4832526 chr2 18117419 C T 8.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs1471342 chr2 18122198 C T 7.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs11689375 chr2 18129524 T C 8.98E-04 Multiple complex diseases / / 17554300 rs7590044 chr2 18178394 C G 4.70E-06 Urinary metabolites / / 21572414 rs12052676 chr2 18189056 T G 1.95E-05 Smoking initiation / / 24665060 rs2710005 chr2 18214457 G A 4.89E-04 Smoking initiation / / 24665060 rs16984191 chr2 18223548 C T 5.33E-05 Odorant perception / / 23910658 rs4832534 chr2 18227620 G A 3.34E-04 Smoking initiation / / 24665060 rs2345089 chr2 18230779 A G 1.05E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16984239 chr2 18234446 C A 2.00E-06 Amyotrophic lateral sclerosis / / 17362836 rs16984239 chr2 18234446 C A 1.70E-06 Amyotrophic lateral sclerosis (sporadic) / / 19740415 rs4832537 chr2 18235029 C A 7.06E-05 QT interval / / 22726844 rs1962539 chr2 18235611 C A 2.38E-04 Iron levels / / pha002876 rs3924803 chr2 18235971 T G 4.00E-05 Temperament (bipolar disorder) / / 22365631 rs7560267 chr2 18239971 T G 2.50E-05 Temperament (bipolar disorder) / / 22365631 rs4075511 chr2 18243534 A C 3.00E-06 Temperament (bipolar disorder) / / 22365631 rs6748095 chr2 18247868 G C 2.20E-05 Temperament (bipolar disorder) / / 22365631 rs6748095 chr2 18247868 G C 8.30E-06 QT interval / / 22726844 rs13015992 chr2 18256919 A C 3.78E-04 Type 2 diabetes / / 17463246 rs7580025 chr2 18265521 C T 5.45E-04 Iron levels / / pha002876 rs11899855 chr2 18268451 G A 1.60E-05 Urinary metabolites / / 21572414 rs7578543 chr2 18270135 C T 2.60E-05 Urinary metabolites / / 21572414 rs4832407 chr2 18271334 G A 6.87E-04 Type 2 diabetes / / 17463246 rs13395500 chr2 18275620 G C 8.77E-05 Serum metabolites / / 19043545 rs17388890 chr2 18276766 T C 8.61E-04 Multiple complex diseases / / 17554300 rs2345493 chr2 18292201 G T 5.22E-05 Pulmonary function / / 20010834 rs12471785 chr2 18314546 G A 7.04E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs11684345 chr2 18316158 T C 7.73E-05 Femoral neck bone geometry / / 22087292 rs2345496 chr2 18316641 A G 7.31E-04 Multiple complex diseases / / 17554300 rs1377068 chr2 18329769 A G 4.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10495679 chr2 18352405 G T 5.36E-04 Diabetic retinopathy / / 20871662 rs1993163 chr2 18360228 T C 1.01E-04 Body mass index / / 17255346 rs13023396 chr2 18361283 A G 6.85E-05 Type 2 diabetes / / 17463246 rs2345513 chr2 18366716 A C 5.46E-05 Body mass index / / 17255346 rs1377085 chr2 18367133 A G 2.21E-04 Body mass index / / 17255346 rs4832549 chr2 18368355 G A 1.74E-04 Body mass index / / 17255346 rs4832551 chr2 18371880 A G 2.53E-04 Body mass index / / 17255346 rs1013260 chr2 18381993 T C 7.18E-05 Orofacial clefts / / 22419666 rs16984512 chr2 18413287 C G 3.67E-04 Blood pressure / / 17255346 rs12710680 chr2 18422013 A G 7.20E-05 Cognitive function / / 24684796 rs16984594 chr2 18451111 A G 1.07E-04 Body mass index / / 17255346 rs16984606 chr2 18451405 T C 1.34E-04 Body mass index / / 17255346 rs16984606 chr2 18451405 T C 3.80E-04 Multiple complex diseases / / 17554300 rs1452420 chr2 18470759 C A 3.45E-04 Type 2 diabetes / / 17463246 rs7606861 chr2 18484044 G A 3.46E-04 Body mass index / / 17255346 rs10205974 chr2 18486802 A G 1.90E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6721414 chr2 18494495 G C 8.00E-04 Chronic fatigue syndrome / / 21912186 rs16984751 chr2 18520021 G A 3.36E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16984751 chr2 18520021 G A 4.32E-04 Myopia (pathological) / / 21095009 rs1489694 chr2 18533217 A G 1.40E-05 Urinary metabolites / / 21572414 rs7580332 chr2 18540644 A G 9.00E-06 Amyotrophic lateral sclerosis / / 18084291 rs876030 chr2 18544954 G A 5.59E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11096532 chr2 18551509 G A 5.97E-06 Hearing function / / 17255346 rs12104719 chr2 18565886 T C 0.00008648 Sarcoidosis / / 22952805 rs6761216 chr2 18567007 C G 0.0005101 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6761216 chr2 18567007 C G 5.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4832576 chr2 18569545 C G 9.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4832433 chr2 18569645 A C 0.0006666 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4832433 chr2 18569645 A C 6.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4832578 chr2 18571007 C T 9.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13393337 chr2 18571609 T G 9.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13397559 chr2 18573398 A T 9.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4240217 chr2 18573767 T C 9.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7570270 chr2 18576488 C A 9.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10191509 chr2 18576516 T G 9.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7584064 chr2 18576603 A C 9.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6531096 chr2 18576647 C T 9.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7584173 chr2 18576687 A T 9.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4510230 chr2 18576980 A G 9.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4335948 chr2 18577104 C T 9.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6723572 chr2 18578097 T C 9.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1356321 chr2 18578853 C T 0.00005212 Sarcoidosis / / 22952805 rs1356320 chr2 18578880 A G 9.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6728574 chr2 18579741 T G 9.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6710668 chr2 18579818 C T 9.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6710757 chr2 18579846 C T 9.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6731646 chr2 18579967 T G 0.0008982 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6731646 chr2 18579967 T G 8.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6728709 chr2 18580069 A G 0.0008972 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6728709 chr2 18580069 A G 8.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6731858 chr2 18580130 T C 0.0008975 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6731858 chr2 18580130 T C 8.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9678808 chr2 18580434 G C 0.0004236 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9678808 chr2 18580434 G C 4.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs969030 chr2 18582725 G A 8.25E-05 Hearing function / / 17255346 rs969030 chr2 18582725 G A 0.00008658 Sarcoidosis / / 22952805 rs17690910 chr2 18585657 T C 0.0008314 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1489680 chr2 18590088 G A 0.00003777 Sarcoidosis / / 22952805 rs13432451 chr2 18590537 G A 0.0004508 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13432451 chr2 18590537 G A 4.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4372901 chr2 18590974 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7558548 chr2 18594360 A G 9.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs16984968 chr2 18603773 A G 7.60E-06 Urinary metabolites / / 21572414 rs6732003 chr2 18610381 T C 5.07E-04 Aortic root size / / 21223598 rs9808546 chr2 18621953 T C 2.20E-05 Urinary metabolites / / 21572414 rs13428828 chr2 18626184 C T 2.70E-05 Urinary metabolites / / 21572414 rs7589253 chr2 18648687 A G 1.10E-05 Urinary metabolites / / 21572414 rs6745120 chr2 18681809 G A 1.89E-05 Cognitive test performance / / 20125193 rs2345724 chr2 18685074 A G 9.04E-06 Alopecia areata / / 22027810 rs16985182 chr2 18699750 A G 3.19E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2272519 chr2 18711750 C T 7.20E-05 Amyotrophic Lateral Sclerosis / / 17362836 rs4462780 chr2 18725175 C A 5.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs16985278 chr2 18734072 C T 4.97E-04 Stroke / / pha002887 rs2252736 chr2 18787470 T C 8.27E-05 Glucose levels / / pha003058 rs16985374 chr2 18828102 C G 6.31E-06 Odorant perception / / 23910658 rs12053481 chr2 18832346 C A 4.87E-05 Stroke / / pha002887 rs1445130 chr2 18834651 A G 1.00E-07 Bulimia nervosa / / 23568457 rs4602226 chr2 18839561 C G 0.0008627 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4602226 chr2 18839561 C G 8.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1550771 chr2 18860375 T C 5.40E-04 Alcohol dependence / / 20201924 rs4832620 chr2 18953108 C T 5.47E-04 Coronary Artery Disease / / 17634449 rs11892969 chr2 18973451 G A 5.35E-04 Alzheimer's disease / / 17998437 rs6531119 chr2 18993027 C T 5.85E-04 Stroke / / pha002887 rs7570667 chr2 19074654 A G 6.95E-04 Rheumatoid arthritis / / 21452313 rs7602667 chr2 19096952 C A 3.17E-05 Cognitive performance / / 19734545 rs1876040 chr2 19134748 A G 6.00E-08 Cognitive performance / / 20125193 rs1317019 chr2 19140546 G A 7.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1343785 chr2 19163825 A G 2.10E-05 Urinary metabolites / / 21572414 rs17704720 chr2 19170212 C T 9.09E-04 Alzheimer's disease / / 22005930 rs17755914 chr2 19183676 G A 3.41E-04 Alzheimer's disease / / 22005930 rs884895 chr2 19184996 G A 7.40E-05 Alcoholism (heaviness of drinking) / / 21529783 rs4832642 chr2 19249694 T C 7.40E-05 Hematology traits / / 23303382 rs16985872 chr2 19257397 T C 7.12E-04 Coronary heart disease / / 21606135 rs4666451 chr2 19286943 G A 2.00E-07 Breast cancer / / 17529967 rs12710696 chr2 19320803 T C 6.06E-04 Multiple complex diseases / / 17554300 rs12710696 chr2 19320803 T C 5.00E-08 Breast cancer / / 23535733 rs12464722 chr2 19341657 C T 6.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12710701 chr2 19344757 T C 1.76E-05 Serum metabolites / / 19043545 rs12105891 chr2 19354741 T G 5.18E-04 Multiple complex diseases / / 17554300 rs12105891 chr2 19354741 T G 8.01E-05 Serum metabolites / / 19043545 rs11904265 chr2 19358483 T C 8.00E-04 Smoking cessation / / 24665060 rs2118381 chr2 19368078 G A 7.55E-05 Serum metabolites / / 19043545 rs851340 chr2 19369285 A T 6.74E-05 Serum metabolites / / 19043545 rs16981939 chr2 19376903 T C 5.48E-05 Cocaine dependence / / 23958962 rs16981939 chr2 19376903 T C 5.55E-04 Cocaine dependence / / 23958962 rs13034680 chr2 19435346 C A 4.36E-05 Vitiligo / / 19890347 rs851365 chr2 19469209 T C 1.40E-05 Urinary metabolites / / 21572414 rs851357 chr2 19473075 C T 1.58E-05 Coronary Artery Disease / / 17634449 rs851357 chr2 19473075 C T 1.60E-05 Urinary metabolites / / 21572414 rs17439558 chr2 19473547 T C 9.51E-06 Bipolar disorder and schizophrenia / / 20889312 rs17439558 chr2 19473547 T C 8.84E-04 Response to TNF antagonist treatment / / 21061259 rs851352 chr2 19475331 C T 8.30E-06 Urinary metabolites / / 21572414 rs984899 chr2 19485726 G C 1.60E-05 Urinary metabolites / / 21572414 rs1965786 chr2 19486628 T C 1.70E-05 Urinary metabolites / / 21572414 rs703323 chr2 19489081 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1727177 chr2 19492579 T C 5.94E-08 Corneal structure / / 22003120 rs10514626 chr2 19497993 G A 4.65E-06 Longevity / / 21612516 rs703315 chr2 19501213 T A 5.40E-06 Urinary metabolites / / 21572414 rs6725667 chr2 19524172 T G 3.14E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs6735941 chr2 19524457 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6531166 chr2 19540002 A G 8.61E-05 Cognitive impairment induced by topiramate / / 22091778 rs17441606 chr2 19568435 C A 5.25E-04 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs7603289 chr2 19582775 T C 1.66E-04 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs1522493 chr2 19598472 A G 2.26E-04 Stroke / / pha002886 rs16986388 chr2 19616496 C T 3.96E-04 Multiple complex diseases / / 17554300 rs2198161 chr2 19625636 G A 6.86E-05 Nephrolithiasis / / 22396660 rs703297 chr2 19625818 C T 4.11E-05 Nephrolithiasis / / 22396660 rs703297 chr2 19625818 C T 6.60E-04 Stroke / / pha002886 rs13398721 chr2 19629304 T C 2.00E-07 non-small cell lung cancer / / 23478653 rs17495469 chr2 19629832 A G 2.00E-04 Polycystic ovary syndrome / / 22178785 rs7596217 chr2 19650271 C T 9.46E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs13386398 chr2 19665118 C T 9.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs4666491 chr2 19705084 G A 9.11E-04 Depression (quantitative trait) / / 20800221 rs10208877 chr2 19723280 C T 5.28E-04 Multiple complex diseases / / 17554300 rs824506 chr2 19730376 T C 4.23E-05 Post-operative nausea and vomiting / / 21694509 rs1427547 chr2 19739976 T C 1.04E-04 Blood pressure / / 21909110 rs11897302 chr2 19774399 T C 0.00000778 Carotid intima media thickness / / 23152477 rs1344650 chr2 19776038 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7586564 chr2 19788211 C T 3.28E-04 Iron levels / / pha002876 rs1427540 chr2 19790551 A T 4.58E-04 Type 2 diabetes / / 17463246 rs1427540 chr2 19790551 A T 3.55E-04 Alzheimer's disease / / 17998437 rs7573038 chr2 19800918 A T 8.92E-04 Multiple complex diseases / / 17554300 rs1453194 chr2 19872803 G A,C,T 3.93E-04 Multiple complex diseases / / 17554300 rs6531190 chr2 19878796 T C 1.64E-04 Multiple complex diseases / / 17554300 rs6531193 chr2 19889227 C T 6.69E-04 Iron levels / / pha002876 rs17562209 chr2 19911287 C T 6.91E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2167796 chr2 19915600 C A 2.08E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs16986953 chr2 19942473 G A 0.000000896 Coronary artery disease / / 23202125 rs16986953 chr2 19942473 G A 0.00000406 Coronary artery disease with myocardial infarction / / 23202125 rs16986953 chr2 19942473 G A 0.000552 Coronary artery disease (CAD) age >50 / / 23202125 rs16986953 chr2 19942473 G A 1.67E-08 Coronary artery disease (CAD) age <=50 / / 23202125 rs16986953 chr2 19942473 G A 1.89E-08 Coronary artery disease (CAD) (males) / / 23202125 rs2123536 chr2 19945577 T C 7.00E-11 Coronary heart disease / / 22751097 rs4666562 chr2 19948931 G A 7.25E-05 Multiple complex diseases / / 17554300 rs7569689 chr2 19951724 G A 7.61E-04 Coronary Artery Disease / / 17634449 rs1453200 chr2 19952128 T C 8.45E-04 Multiple complex diseases / / 17554300 rs16987000 chr2 19952459 A G 2.12E-04 Multiple complex diseases / / 17554300 rs17621899 chr2 19952635 A T 2.49E-04 Coronary Artery Disease / / 17634449 rs17564315 chr2 19958496 G A 8.56E-04 Multiple complex diseases / / 17554300 rs17564315 chr2 19958496 G A 7.00E-07 Inflammatory biomarkers / / 22228203 rs9306885 chr2 19988832 T C 3.80E-04 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs6728440 chr2 19999346 G A 2.00E-07 Inflammatory biomarkers / / 22228203 rs11694666 chr2 20014876 T C 3.73E-04 Multiple complex diseases / / 17554300 rs1866182 chr2 20022983 T A 1.20E-05 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs1866183 chr2 20023099 T A 1.02E-05 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs10200435 chr2 20034313 G A 8.96E-05 Smoking initiation / / 24665060 rs6725359 chr2 20035911 C T 5.58E-04 Multiple complex diseases / / 17554300 rs16987151 chr2 20043254 A G 1.66E-05 Personality dimensions / / 18957941 rs11096623 chr2 20046065 A G 8.27E-04 Multiple complex diseases / / 17554300 rs2083141 chr2 20050793 C G 5.99E-04 Multiple complex diseases / / 17554300 rs2083141 chr2 20050793 C G 3.22E-04 Smoking initiation / / 24665060 rs6750471 chr2 20052298 C T 0.0000134 Circulating PCSK9 levels / / 22460556 rs10184466 chr2 20054057 G A 1.15E-04 Gallstones / / 17632509 rs964864 chr2 20059031 G A 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs964864 chr2 20059031 G A 2.05E-04 Lung function (forced vital capacity) / / 24023788 rs11676372 chr2 20072512 C T 3.60E-04 Aortic root size FLJ12334 intron 21223598 rs1370586 chr2 20090469 G A 7.24E-04 Multiple complex diseases / / 17554300 rs2304589 chr2 20101487 G A 1.80E-05 Lipid traits TTC32 cds-synon 17903299 rs2304589 chr2 20101487 G A 6.35E-04 Bipolar disorder TTC32 cds-synon 19259986 rs2278528 chr2 20101832 C G 2.00E-05 Lipid traits / / 17903299 rs3731661 chr2 20110856 G A 1.00E-04 Cognitive impairment induced by topiramate WDR35 UTR-3 22091778 rs1381817 chr2 20179220 C T 1.87E-07 Lymphocyte counts WDR35 intron 22286170 rs11674251 chr2 20216509 T C 9.01E-42 Non-small cell lung cancer / / 21866343 rs1191812 chr2 20224999 A C 1.00E-05 Information processing speed LOC100506455 intron 21130836 rs12471796 chr2 20256192 G A 1.40E-05 Major depressive disorder / / 19065144 rs12471796 chr2 20256192 G A 2.77E-06 Major depressive disorder / / 21621269 rs12471796 chr2 20256192 G A 1.51E-05 Major depressive disorder / / pha002850 rs12472043 chr2 20256838 G A 0.00000519 Major depressive disorder / / 23149448 rs1513831 chr2 20256856 G T 7.00E-06 Information processing speed / / 21130836 rs1513831 chr2 20256856 G T 0.0000418 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs11694170 chr2 20260512 T C 7.00E-06 Information processing speed / / 21130836 rs11694170 chr2 20260512 T C 0.0000418 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7565124 chr2 20261685 G A 1.10E-05 Major depressive disorder / / 19065144 rs7565124 chr2 20261685 G A 2.00E-06 Major depressive disorder / / 21621269 rs7565124 chr2 20261685 G A 1.38E-05 Major depressive disorder / / pha002850 rs2126551 chr2 20270027 A G 0.0000217 Major depressive disorder / / 23149448 rs878983 chr2 20277748 C T 8.60E-05 Information processing speed / / 21130836 rs11689490 chr2 20281927 T C 1.00E-04 Information processing speed / / 21130836 rs13384258 chr2 20322005 T C 3.44E-05 Orofacial clefts / / 22419666 rs13384258 chr2 20322005 T C 1.11E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs13384258 chr2 20322005 T C 5.68E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6531209 chr2 20334723 G T 3.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4666360 chr2 20335709 G A 4.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4666360 chr2 20335709 G A 5.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4666360 chr2 20335709 G A 3.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs4666366 chr2 20340155 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs981396 chr2 20346651 G A 4.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs981395 chr2 20346774 T G 2.91E-05 HIV-1 control / / 20041166 rs10495703 chr2 20350783 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs977130 chr2 20351391 A C 0.0000854 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs11899121 chr2 20367973 G C 3.50E-06 Parkinson's disease (age of onset) / / 19772629 rs11894335 chr2 20368196 A G 3.35E-06 Triglycerides / / pha003080 rs870526 chr2 20369562 C T 7.70E-06 Parkinson's disease (age of onset) / / 19772629 rs2090033 chr2 20372497 C T 5.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs6419087 chr2 20377392 C A 2.90E-05 Urinary metabolites / / 21572414 rs13428318 chr2 20378882 T G 1.00E-04 Information processing speed / / 21130836 rs13428318 chr2 20378882 T G 4.47E-05 Triglycerides / / pha003080 rs6742663 chr2 20395160 A G 6.68E-06 Hearing function / / 21493956 rs6756290 chr2 20395611 G T 7.98E-06 Hearing function / / 21493956 rs2348475 chr2 20397114 C T 8.28E-06 Hearing function / / 21493956 rs11895809 chr2 20399054 A G 8.30E-06 Hearing function / / 21493956 rs4666374 chr2 20399764 A T 1.21E-04 Acne (severe) / / 24927181 rs4350703 chr2 20400269 T A 7.35E-06 Hearing function / / 21493956 rs1043419 chr2 20448561 A G 4.16E-05 Attention deficit hyperactivity disorder PUM2 UTR-3 pha002875 rs10164749 chr2 20472847 G A 9.95E-05 Premature ovarian failure PUM2 intron 19508998 rs10164749 chr2 20472847 G A 9.95E-05 Other erythrocyte phenotypes PUM2 intron 19862010 rs10195153 chr2 20551993 G A 7.46E-04 Multiple complex diseases / / 17554300 rs4666383 chr2 20572094 T C 4.43E-05 Myocardial Infarction / / pha002873 rs10514649 chr2 20582635 G A 6.49E-06 Job-related exhaustion / / 23620144 rs343155 chr2 20592798 G A 1.50E-05 Breast cancer / / 17529974 rs343155 chr2 20592798 G A 2.71E-05 Brain structure / / 22504417 rs16987610 chr2 20605249 A G 8.91E-04 Alzheimer's disease / / 17998437 rs16987610 chr2 20605249 A G 3.53E-05 Brain structure / / 22504417 rs343140 chr2 20605810 C A 5.74E-04 Type 2 diabetes / / 17463246 rs1010415 chr2 20627875 G A 6.56E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs3892295 chr2 20628882 T G 3.17E-05 Cognitive impairment induced by topiramate / / 22091778 rs6531240 chr2 20665361 C T 1.36E-04 Insulin resistance / / 21901158 rs11901246 chr2 20665400 G T 3.48E-04 Multiple complex diseases / / 17554300 rs959058 chr2 20675601 T C 6.73E-05 Bipolar disorder,affective / / 20528957 rs959058 chr2 20675601 T C 3.02E-04 White matter integrity / / 22425255 rs2084919 chr2 20678496 T C 6.23E-05 Depression (quantitative trait) / / 23290196 rs12997261 chr2 20682303 T G 3.62E-04 Rheumatoid arthritis / / 21452313 rs342070 chr2 20685471 C T 1.04E-05 Systemic sclerosis / / 21750679 rs13021401 chr2 20688519 C T 3.00E-06 Systemic sclerosis / / 21750679 rs931257 chr2 20688941 A C 4.69E-04 Rheumatoid arthritis / / 21452313 rs4666412 chr2 20695707 T C 8.04E-05 Height / / pha003010 rs4666412 chr2 20695707 T C 3.82E-07 Height / / pha003011 rs342096 chr2 20696256 G T 0.000314 Schizophrenia / / 22440650 rs342136 chr2 20709989 C T 6.14E-04 Lymphocyte counts / / 22286170 rs7568542 chr2 20719241 T C 8.95E-04 Multiple complex diseases / / 17554300 rs4666415 chr2 20720237 A G 0.000539 Height (Pygmy height) / / 22570615 rs10495705 chr2 20741344 T C 4.64E-05 Serum metabolites / / 19043545 rs2348868 chr2 20751009 G A 5.74E-04 Multiple complex diseases / / 17554300 rs2117842 chr2 20761069 G A,C 6.75E-04 Obesity (early onset extreme) / / 23563609 rs16987836 chr2 20763911 T C 2.35E-04 Multiple complex diseases / / 17554300 rs16987893 chr2 20806453 G T 0.000848 Height (Pygmy height) / / 22570615 rs4666441 chr2 20813657 G A 3.51E-04 Type 2 diabetes / / 17463246 rs1047163 chr2 20817812 A G 8.20E-05 Multiple complex diseases HS1BP3 UTR-3 17554300 rs896733 chr2 20819316 G T 2.87E-05 Asthma HS1BP3 intron 22561531 rs7570901 chr2 20861207 A G 2.02E-04 Cocaine dependence / / 23958962 rs1013363 chr2 20863286 C T 2.08E-04 Cocaine dependence / / 23958962 rs13394027 chr2 20882056 G A 8.17E-04 Multiple complex diseases / / 17554300 rs13394027 chr2 20882056 G A 3.68E-12 Lymphocyte counts / / 22286170 rs13385191 chr2 20888265 A G 8.00E-08 Prostate cancer C2orf43 intron 20676098 rs340600 chr2 20892006 G T 1.80E-07 Digit length ratio C2orf43 intron 20303062 rs6724513 chr2 20892483 A G 1.60E-07 Digit length ratio C2orf43 intron 20303062 rs12467020 chr2 20894422 C G 1.44E-04 Type 2 diabetes C2orf43 intron 17463246 rs4971516 chr2 20903015 T C 3.36E-04 Type 2 diabetes C2orf43 intron 17463246 rs4971516 chr2 20903015 T C 2.00E-40 LDL cholesterol C2orf43 intron 21059979 rs4971516 chr2 20903015 T C 2.00E-52 LDL cholesterol C2orf43 intron 21059979 rs6729843 chr2 20927997 T C 2.28E-05 Heart Rate C2orf43 intron pha003051 rs4971546 chr2 20934623 T C 2.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C2orf43 intron 20877124 rs4971546 chr2 20934623 T C 4.93E-05 Cognitive impairment induced by topiramate C2orf43 intron 22091778 rs4971547 chr2 20945762 G A 6.42E-07 Brachial circumference C2orf43 intron 22479309 rs17721572 chr2 20962670 C T 6.47E-07 Brachial circumference C2orf43 intron 22479309 rs17665125 chr2 20963639 T A 2.13E-07 Brachial circumference C2orf43 intron 22479309 rs564896 chr2 20977533 T C 8.20E-04 Type 2 diabetes and 6 quantitative traits C2orf43 intron 17848626 rs1898432 chr2 21053915 C T 4.44E-05 Multiple complex diseases / / 17554300 rs7573184 chr2 21059262 G C 2.10E-05 Serum metabolites / / 19043545 rs12619737 chr2 21076149 C T 7.50E-05 Response to statin therapy / / 20339536 rs880973 chr2 21078879 A G 8.70E-05 Response to statin therapy / / 20339536 rs1437401 chr2 21084166 C G,T 8.40E-05 Response to statin therapy / / 20339536 rs7569328 chr2 21100778 C T 1.00E-07 Coronary heart disease / / 21347282 rs6722139 chr2 21101382 C A 2.66E-05 Cognitive impairment induced by topiramate / / 22091778 rs12994068 chr2 21118983 A C 9.38E-04 Alzheimer's disease / / 17998437 rs6711016 chr2 21123352 C A 1.94E-04 Type 2 diabetes / / 17463246 rs6711016 chr2 21123352 C A 2.17E-14 Metabolite levels / / 22286219 rs6711016 chr2 21123352 C A 6.24E-04 Acute lung injury / / 22295056 rs6711016 chr2 21123352 C A 4.00E-08 Metabolic syndrome / / 22399527 rs6711016 chr2 21123352 C A 0.00000246 VLDL cholesterol particle diameter / / 23263444 rs10198175 chr2 21133883 A G 2.38E-08 Triglycerides / / 19060911 rs10198175 chr2 21133883 A G 4.58E-07 LDL lipoproteins / / pha002902 rs56296027 chr2 21134011 T C 1.83E-15 Metabolite levels / / 22286219 rs4341893 chr2 21135577 A G 1.90E-07 LDL lipoproteins / / pha002902 rs13414987 chr2 21141832 C A 1.10E-13 Metabolic syndrome phenotype / / 22022282 rs13414987 chr2 21141832 C A 2.40E-10 Metabolic syndrome phenotype / / 22022282 rs4296389 chr2 21142994 C T 3.70E-11 Metabolite levels / / 22286219 rs4426495 chr2 21143982 C T 5.86E-13 Metabolite levels / / 22286219 rs10180633 chr2 21144829 G T 5.88E-13 Metabolite levels / / 22286219 rs10183548 chr2 21145499 G A 6.97E-13 Metabolite levels / / 22286219 rs6732011 chr2 21146521 G T 6.22E-11 Metabolite levels / / 22286219 rs3923037 chr2 21148274 A C 3.97E-04 Alzheimer's disease (late onset) / / 21379329 rs3923037 chr2 21148274 A C 7.64E-13 Metabolite levels / / 22286219 rs3923037 chr2 21148274 A C 2.29E-07 LDL lipoproteins / / pha002902 rs3923037 chr2 21148274 A C 2.34E-06 Triglycerides / / pha002904 rs4665639 chr2 21186891 A G 2.60E-05 LDL lipoproteins / / pha002902 rs7604788 chr2 21190024 C T 8.98E-12 Metabolite levels / / 22286219 rs6728178 chr2 21193946 G A 1.04E-04 Alzheimer's disease (late onset) / / 21379329 rs6728178 chr2 21193946 G A 1.70E-17 Metabolite levels / / 22286219 rs6728178 chr2 21193946 G A 0.000000019 VLDL cholesterol particle diameter / / 23263444 rs6728178 chr2 21193946 G A 2.02E-06 HDL particle features / / pha002900 rs6728178 chr2 21193946 G A 2.13E-08 LDL lipoproteins / / pha002902 rs6728178 chr2 21193946 G A 3.70E-08 Triglycerides / / pha002904 rs17041676 chr2 21194905 A G 6.26E-04 Multiple complex diseases / / 17554300 rs10495712 chr2 21196112 A G 1.15E-08 Triglycerides / / 19060911 rs10495712 chr2 21196112 A G 1.03E-07 LDL lipoproteins / / pha002902 rs6733447 chr2 21198136 G A 3.93E-05 LDL lipoproteins / / pha002902 rs11902417 chr2 21198900 G A 3.57E-04 Type 2 diabetes / / 17463246 rs11902417 chr2 21198900 G A 4.00E-07 HDL cholesterol / / 20864672 rs11902417 chr2 21198900 G A 1.61E-17 Metabolite levels / / 22286219 rs11902417 chr2 21198900 G A 0.00000023 Triglycerides in females / / 23063622 rs11902417 chr2 21198900 G A 1.07E-11 Triglycerides in males / / 23063622 rs11902417 chr2 21198900 G A 1.23E-14 HDL cholesterol / / 23063622 rs11902417 chr2 21198900 G A 2.11E-14 Cholesterol,total / / 23063622 rs11902417 chr2 21198900 G A 4.00E-20 Triglycerides / / 23063622 rs11902417 chr2 21198900 G A 4.56E-12 LDL cholesterol / / 23063622 rs11902417 chr2 21198900 G A 2.07E-08 VLDL cholesterol particle diameter / / 23263444 rs10184054 chr2 21203877 C G 1.51E-17 Metabolite levels / / 22286219 rs10184054 chr2 21203877 C G 1.88E-08 VLDL cholesterol particle diameter / / 23263444 rs6544366 chr2 21204025 G T 3.10E-04 Type 2 diabetes / / 17463246 rs6544366 chr2 21204025 G T 2.00E-07 Triglycerides / / 20864672 rs6544366 chr2 21204025 G T 1.59E-17 Metabolite levels / / 22286219 rs6544366 chr2 21204025 G T 1.88E-08 VLDL cholesterol particle diameter / / 23263444 rs4564803 chr2 21205502 G T 1.48E-17 Metabolite levels / / 22286219 rs4564803 chr2 21205502 G T 1.86E-08 VLDL cholesterol particle diameter / / 23263444 rs6754295 chr2 21206183 T G 3.00E-08 Triglycerides / / 19060911 rs6754295 chr2 21206183 T G 4.00E-08 HDL cholesterol / / 19060911 rs6754295 chr2 21206183 T G 3.90E-47 Lipid levels / / 19936222 rs6754295 chr2 21206183 T G 4.00E-08 Coronary heart disease / / 21347282 rs6754295 chr2 21206183 T G 1.49E-04 Alzheimer's disease (late onset) / / 21379329 rs6754295 chr2 21206183 T G 1.28E-17 Metabolite levels / / 22286219 rs6754295 chr2 21206183 T G 1.81E-08 VLDL cholesterol particle diameter / / 23263444 rs6754295 chr2 21206183 T G 3.78E-06 HDL particle features / / pha002900 rs6754295 chr2 21206183 T G 1.40E-08 LDL lipoproteins / / pha002902 rs6754295 chr2 21206183 T G 9.47E-08 Triglycerides / / pha002904 rs7557067 chr2 21208211 A G 9.00E-12 Triglycerides / / 19060906 rs7557067 chr2 21208211 A G 1.47E-17 Metabolite levels / / 22286219 rs7557067 chr2 21208211 A G 0.000000017 VLDL cholesterol particle diameter / / 23263444 rs62122481 chr2 21216815 C A 3.03E-13 Metabolite levels / / 22286219 rs13392272 chr2 21217490 C T 6.98E-14 Metabolite levels / / 22286219 rs6725189 chr2 21219001 G T 4.01E-05 ldl cholesterol / / pha003076 rs4665710 chr2 21221035 A C 9.17E-18 Metabolite levels / / 22286219 rs952275 chr2 21221399 T G 1.50E-14 Metabolite levels / / 22286219 rs1801695 chr2 21224853 C G,T 0.0000458 HDL cholesterol APOB missense 23063622 rs1042034 chr2 21225281 C T 4.96E-06 Lipoprotein-associated phospholipase A2 activity and mass APOB missense 20442857 rs1042034 chr2 21225281 C T 1.00E-30 HDL cholesterol APOB missense 20686565 rs1042034 chr2 21225281 C T 1.00E-45 Triglycerides APOB missense 20686565 rs1042034 chr2 21225281 C T 9.80E-18 Metabolite levels APOB missense 22286219 rs1042034 chr2 21225281 C T 0.000000971 Triglycerides (females) APOB missense 22629316 rs1042034 chr2 21225281 C T 0.0000154 Triglycerides (males) APOB missense 22629316 rs1042034 chr2 21225281 C T 2.23E-10 Triglycerides APOB missense 22629316 rs1042034 chr2 21225281 C T 1.78E-28 Triglycerides APOB missense 23063622 rs1042034 chr2 21225281 C T 1.96E-24 Triglycerides APOB missense 23063622 rs1042034 chr2 21225281 C T 2.07E-11 LDL cholesterol APOB missense 23063622 rs1042034 chr2 21225281 C T 6.60E-13 Cholesterol,total APOB missense 23063622 rs1042034 chr2 21225281 C T 8.05E-20 HDL cholesterol APOB missense 23063622 rs1042034 chr2 21225281 C T 0.000000252 VLDL cholesterol particle diameter APOB missense 23263444 rs1042031 chr2 21225753 C T 1.88E-11 Cholesterol,total APOB missense 23063622 rs1042031 chr2 21225753 C T 5.60E-12 LDL cholesterol APOB missense 23063622 rs2678379 chr2 21226560 A G 1.05E-17 Metabolite levels APOB intron 22286219 rs2678379 chr2 21226560 A G 1.23E-15 HDL cholesterol APOB intron 23063622 rs2678379 chr2 21226560 A G 2.92E-10 LDL cholesterol APOB intron 23063622 rs2678379 chr2 21226560 A G 5.05E-22 Triglycerides APOB intron 23063622 rs2678379 chr2 21226560 A G 9.35E-12 Cholesterol,total APOB intron 23063622 rs2678379 chr2 21226560 A G 0.000000254 VLDL cholesterol particle diameter APOB intron 23263444 rs1800479 chr2 21227383 C G 3.15E-11 LDL cholesterol APOB intron 23063622 rs1800479 chr2 21227383 C G 6.51E-10 Cholesterol,total APOB intron 23063622 rs12713558 chr2 21229039 C T 5.80E-05 Multiple complex diseases APOB cds-synon 17554300 rs5742904 chr2 21229160 C T 7.53E-14 LDL cholesterol APOB missense 22629316 rs5742904 chr2 21229160 C T 1.04E-46 LDL cholesterol APOB missense 23063622 rs5742904 chr2 21229160 C T 1.21E-11 Cholesterol,total APOB missense 23063622 rs676210 chr2 21231524 G A 4.40E-04 Response to ximelagatran treatment APOB missense 17505501 rs676210 chr2 21231524 G A 1.00E-08 Lipid levels APOB missense 19936222 rs676210 chr2 21231524 G A 1.50E-09 Lipid levels APOB missense 19936222 rs676210 chr2 21231524 G A 2.05E-10 Lipid levels APOB missense 19936222 rs676210 chr2 21231524 G A 3.70E-64 Lipid levels APOB missense 19936222 rs676210 chr2 21231524 G A 8.60E-56 Lipid levels APOB missense 19936222 rs676210 chr2 21231524 G A 5.93E-06 Lipoprotein-associated phospholipase A2 activity and mass APOB missense 20442857 rs676210 chr2 21231524 G A 4.08E-12 Metabolite levels APOB missense 22286219 rs676210 chr2 21231524 G A 2.97E-10 LDL cholesterol APOB missense 23063622 rs676210 chr2 21231524 G A 3.23E-24 Triglycerides APOB missense 23063622 rs676210 chr2 21231524 G A 5.34E-20 HDL cholesterol APOB missense 23063622 rs676210 chr2 21231524 G A 6.14E-12 Cholesterol,total APOB missense 23063622 rs676210 chr2 21231524 G A 3.00E-47 LDL (oxidized) APOB missense 23247145 rs676210 chr2 21231524 G A 0.000000256 VLDL cholesterol particle diameter APOB missense 23263444 rs676210 chr2 21231524 G A 4.05E-30 LDL cholesterol (Oxidized) APOB missense 23696881 rs676210 chr2 21231524 G A 4.78E-06 HDL particle features APOB missense pha002900 rs676210 chr2 21231524 G A 2.60E-07 LDL lipoproteins APOB missense pha002902 rs676210 chr2 21231524 G A 3.36E-08 Triglycerides APOB missense pha002904 rs6413458 chr2 21231592 G A 2.00E-07 Lipoprotein-associated phospholipase A2 activity and mass APOB cds-synon 23118302 rs693 chr2 21232195 G A 7.00E-07 Triglycerides APOB cds-synon 17463246 rs693 chr2 21232195 G A 3.10E-09 Lipid levels APOB cds-synon 18193043 rs693 chr2 21232195 G A 1.00E-21 LDL cholesterol APOB cds-synon 18193044 rs693 chr2 21232195 G A 2.00E-07 Triglycerides APOB cds-synon 18193044 rs693 chr2 21232195 G A 4.40E-08 LDL cholesterol APOB cds-synon 18262040 rs693 chr2 21232195 G A 3.00E-11 LDL cholesterol APOB cds-synon 19060910 rs693 chr2 21232195 G A 4.00E-17 LDL cholesterol APOB cds-synon 19060911 rs693 chr2 21232195 G A 9.00E-23 Cholesterol,total APOB cds-synon 19060911 rs693 chr2 21232195 G A 4.10E-08 Lipid levels APOB cds-synon 19802338 rs693 chr2 21232195 G A 3.86E-08 Lipid levels APOB cds-synon 19913121 rs693 chr2 21232195 G A 5.69E-06 Lipid levels APOB cds-synon 19913121 rs693 chr2 21232195 G A 1.00E-21 Coronary heart disease APOB cds-synon 21347282 rs693 chr2 21232195 G A 3.06E-08 Cardiovascular disease risk factors APOB cds-synon 21943158 rs693 chr2 21232195 G A 2.30E-14 Metabolite levels APOB cds-synon 22286219 rs693 chr2 21232195 G A 0.00000102 Triglycerides APOB cds-synon 23063622 rs693 chr2 21232195 G A 2.69E-44 Cholesterol,total APOB cds-synon 23063622 rs693 chr2 21232195 G A 5.84E-47 LDL cholesterol APOB cds-synon 23063622 rs693 chr2 21232195 G A 0.00028 LDL cholesterol APOB cds-synon 23100282 rs693 chr2 21232195 G A 2.99E-11 LDL lipoproteins APOB cds-synon pha002902 rs1041968 chr2 21232804 G A 6.20E-08 Lipid levels APOB cds-synon 19802338 rs1041968 chr2 21232804 G A 5.32E-08 Lipid levels APOB cds-synon 19913121 rs1041968 chr2 21232804 G A 7.80E-06 Lipid levels APOB cds-synon 19913121 rs1041968 chr2 21232804 G A 2.19E-14 Metabolite levels APOB cds-synon 22286219 rs1041968 chr2 21232804 G A 1.75E-32 Cholesterol,total APOB cds-synon 23063622 rs1041968 chr2 21232804 G A 3.88E-33 LDL cholesterol APOB cds-synon 23063622 rs533617 chr2 21233972 T C 0.0000618 Type 2 diabetes APOB missense 22325160 rs533617 chr2 21233972 T C 1.19E-12 Triglycerides APOB missense 23063622 rs533617 chr2 21233972 T C 3.85E-11 HDL cholesterol APOB missense 23063622 rs533617 chr2 21233972 T C 7.00E-19 LDL cholesterol APOB missense 23063622 rs533617 chr2 21233972 T C 9.42E-21 Cholesterol,total APOB missense 23063622 rs12720847 chr2 21235375 G A 0.00000046 Triglycerides APOB cds-synon 23063622 rs3749054 chr2 21237238 A T 1.93E-11 LDL cholesterol APOB intron 23063622 rs3749054 chr2 21237238 A T 7.80E-11 Cholesterol,total APOB intron 23063622 rs673548 chr2 21237544 G A 2.00E-08 Metabolic traits APOB intron 19060910 rs673548 chr2 21237544 G A 1.10E-08 Triglycerides APOB intron 19060911 rs673548 chr2 21237544 G A 1.60E-22 Lipid levels APOB intron 19936222 rs673548 chr2 21237544 G A 1.70E-14 Lipid levels APOB intron 19936222 rs673548 chr2 21237544 G A 1.70E-18 Lipid levels APOB intron 19936222 rs673548 chr2 21237544 G A 4.00E-19 Lipid levels APOB intron 19936222 rs673548 chr2 21237544 G A 4.28E-10 Lipid levels APOB intron 19936222 rs673548 chr2 21237544 G A 4.40E-08 Lipid levels APOB intron 19936222 rs673548 chr2 21237544 G A 4.80E-42 Lipid levels APOB intron 19936222 rs673548 chr2 21237544 G A 2.47E-12 Metabolite levels APOB intron 22286219 rs673548 chr2 21237544 G A 1.00E-10 Metabolic syndrome APOB intron 22399527 rs673548 chr2 21237544 G A 0.0000111 HDL cholesterol (female) APOB intron 22629316 rs673548 chr2 21237544 G A 0.0000799 HDL cholesterol (male) APOB intron 22629316 rs673548 chr2 21237544 G A 6.45E-09 HDL cholesterol APOB intron 22629316 rs673548 chr2 21237544 G A 1.00E-13 Metabolite levels (atherosclerosis) APOB intron 22916037 rs673548 chr2 21237544 G A 1.61E-24 Triglycerides APOB intron 23063622 rs673548 chr2 21237544 G A 1.84E-10 LDL cholesterol APOB intron 23063622 rs673548 chr2 21237544 G A 5.64E-12 Cholesterol,total APOB intron 23063622 rs673548 chr2 21237544 G A 6.24E-18 HDL cholesterol APOB intron 23063622 rs673548 chr2 21237544 G A 8.59E-29 Triglycerides APOB intron 23063622 rs673548 chr2 21237544 G A 0.000000354 VLDL cholesterol particle diameter APOB intron 23263444 rs673548 chr2 21237544 G A 3.40E-06 HDL particle features APOB intron pha002900 rs673548 chr2 21237544 G A 2.28E-07 LDL lipoproteins APOB intron pha002902 rs673548 chr2 21237544 G A 2.01E-08 Triglycerides APOB intron pha002904 rs2854725 chr2 21237786 T G 3.53E-09 LDL cholesterol APOB intron 23063622 rs2854725 chr2 21237786 T G 4.64E-10 Cholesterol,total APOB intron 23063622 rs11680233 chr2 21240031 A C 1.77E-12 Metabolite levels APOB intron 22286219 rs11126598 chr2 21240364 A G 1.54E-12 Metabolite levels APOB intron 22286219 rs12713956 chr2 21241505 A G 2.21E-04 Cholesterol APOB intron 17255346 rs12713956 chr2 21241505 A G 2.27E-12 LDL cholesterol APOB intron 23063622 rs12713956 chr2 21241505 A G 9.75E-12 Cholesterol,total APOB intron 23063622 rs12713956 chr2 21241505 A G 4.00E-08 LDL cholesterol APOB intron 23726366 rs12720828 chr2 21241744 C T 7.07E-12 Cholesterol,total APOB intron 23063622 rs12720828 chr2 21241744 C T 7.08E-12 LDL cholesterol APOB intron 23063622 rs10199768 chr2 21244000 G T 1.61E-04 Lipid levels APOB intron 19913121 rs10199768 chr2 21244000 G T 6.58E-07 Lipid levels APOB intron 19913121 rs10199768 chr2 21244000 G T 8.00E-15 Cardiovascular disease risk factors APOB intron 21943158 rs10199768 chr2 21244000 G T 9.79E-12 Metabolite levels APOB intron 22286219 rs10199768 chr2 21244000 G T 1.23E-48 Cholesterol,total APOB intron 23063622 rs10199768 chr2 21244000 G T 3.50E-49 LDL cholesterol APOB intron 23063622 rs3791980 chr2 21245329 G T 2.93E-11 Metabolite levels APOB intron 22286219 rs1801700 chr2 21245813 G A 0.0000169 Triglycerides APOB cds-synon 23063622 rs12720838 chr2 21247211 C T 1.88E-13 LDL cholesterol APOB intron 23063622 rs12720838 chr2 21247211 C T 2.78E-13 Cholesterol,total APOB intron 23063622 rs12691202 chr2 21249716 C T 1.32E-12 LDL cholesterol APOB missense 23063622 rs12691202 chr2 21249716 C T 2.05E-14 Cholesterol,total APOB missense 23063622 rs679899 chr2 21250914 G A 1.13E-20 LDL cholesterol APOB missense 23063622 rs679899 chr2 21250914 G A 3.32E-22 Cholesterol,total APOB missense 23063622 rs679899 chr2 21250914 G A 0.00014 LDL cholesterol APOB missense 23100282 rs679899 chr2 21250914 G A 9.04E-05 LDL lipoproteins APOB missense pha002902 rs570877 chr2 21251040 T G 1.54E-14 Cholesterol,total APOB intron 23063622 rs570877 chr2 21251040 T G 2.14E-15 LDL cholesterol APOB intron 23063622 rs12714214 chr2 21251367 G A 5.78E-04 Multiple complex diseases APOB missense 17554300 rs1469513 chr2 21259562 T C 2.72E-04 Type 2 diabetes APOB intron 17463246 rs1469513 chr2 21259562 T C 3.05E-11 Metabolite levels APOB intron 22286219 rs520354 chr2 21259612 A G 1.23E-21 Cholesterol,total APOB intron 23063622 rs520354 chr2 21259612 A G 9.57E-21 LDL cholesterol APOB intron 23063622 rs550619 chr2 21260601 G A 6.90E-04 Atrial fibrillation APOB intron 21846873 rs550619 chr2 21260601 G A 1.14E-15 LDL cholesterol APOB intron 23063622 rs550619 chr2 21260601 G A 5.06E-15 Cholesterol,total APOB intron 23063622 rs597331 chr2 21262427 G A 3.59E-13 LDL cholesterol APOB intron 23063622 rs597331 chr2 21262427 G A 6.88E-14 Cholesterol,total APOB intron 23063622 rs12720788 chr2 21262871 A T 0.0000238 LDL cholesterol APOB intron 23063622 rs531819 chr2 21263639 T G 3.21E-07 Lipid levels APOB intron 19913121 rs531819 chr2 21263639 T G 4.91E-08 Lipid levels APOB intron 19913121 rs531819 chr2 21263639 T G 5.80E-05 Response to statin therapy APOB intron 20339536 rs531819 chr2 21263639 T G 3.12E-45 LDL cholesterol APOB intron 23063622 rs531819 chr2 21263639 T G 3.16E-27 LDL cholesterol (female) APOB intron 23063622 rs531819 chr2 21263639 T G 4.59E-15 LDL cholesterol (male) APOB intron 23063622 rs531819 chr2 21263639 T G 9.60E-45 Cholesterol,total APOB intron 23063622 rs9282603 chr2 21263886 A G 0.00002 Breast cancer(er negative) APOB missense 23555315 rs1367117 chr2 21263900 G A 1 Drug response to Atenolol APOB missense 15453913 rs1367117 chr2 21263900 G A 1 Drug response to Irbesartan APOB missense 15453913 rs1367117 chr2 21263900 G A 2.63E-08 Lipid levels APOB missense 19913121 rs1367117 chr2 21263900 G A 2.94E-05 Lipid levels APOB missense 19913121 rs1367117 chr2 21263900 G A 2.10E-17 Lipid levels APOB missense 19936222 rs1367117 chr2 21263900 G A 6.46E-25 Lipid levels APOB missense 19936222 rs1367117 chr2 21263900 G A 4.00E-114 LDL cholesterol APOB missense 20686565 rs1367117 chr2 21263900 G A 4.00E-96 Cholesterol,total APOB missense 20686565 rs1367117 chr2 21263900 G A 0.000685 HDL cholesterol APOB missense 23063622 rs1367117 chr2 21263900 G A 0.000692 Triglycerides APOB missense 23063622 rs1367117 chr2 21263900 G A 3.97E-58 LDL cholesterol APOB missense 23063622 rs1367117 chr2 21263900 G A 8.84E-62 Cholesterol,total APOB missense 23063622 rs1367117 chr2 21263900 G A 1.00E-182 LDL cholesterol APOB missense 24097068 rs1367117 chr2 21263900 G A 3.00E-139 Cholesterol,total APOB missense 24097068 rs12720841 chr2 21264734 T C 0.00000112 Triglycerides APOB intron 23063622 rs12714264 chr2 21265518 A T 3.04E-05 Type 2 diabetes APOB intron 17463246 rs12714264 chr2 21265518 A T 1.23E-07 Lipid levels APOB intron 19913121 rs12714264 chr2 21265518 A T 1.60E-07 Lipid levels APOB intron 19913121 rs12714264 chr2 21265518 A T 9.50E-05 Response to statin therapy APOB intron 20339536 rs12714264 chr2 21265518 A T 7.00E-04 Coronary heart disease APOB intron 21966275 rs12720826 chr2 21265695 T C 4.26E-08 LDL cholesterol APOB intron 23236364 rs12720826 chr2 21265695 T C 5.20E-09 Cholesterol,total APOB intron 23236364 rs12720799 chr2 21266164 C T 0.00000112 Triglycerides APOB intron 23063622 rs1800481 chr2 21267210 A G 4.95E-08 Lipid levels APOB nearGene-5 19913121 rs1800481 chr2 21267210 A G 7.41E-07 Lipid levels APOB nearGene-5 19913121 rs1800481 chr2 21267210 A G 2.24E-28 LDL cholesterol APOB nearGene-5 23063622 rs1800481 chr2 21267210 A G 4.24E-28 Cholesterol,total APOB nearGene-5 23063622 rs934197 chr2 21267461 G A 2.53E-05 Lipid levels APOB nearGene-5 19913121 rs934197 chr2 21267461 G A 3.43E-08 Lipid levels APOB nearGene-5 19913121 rs934197 chr2 21267461 G A 2.88E-34 LDL cholesterol APOB nearGene-5 22629316 rs934197 chr2 21267461 G A 3.11E-14 LDL cholesterol (male) APOB nearGene-5 22629316 rs934197 chr2 21267461 G A 8.51E-24 LDL cholesterol (female) APOB nearGene-5 22629316 rs934197 chr2 21267461 G A 2.81E-61 Cholesterol,total APOB nearGene-5 23063622 rs934197 chr2 21267461 G A 7.69E-59 LDL cholesterol APOB nearGene-5 23063622 rs617314 chr2 21268219 A C 0.000371 Cholesterol,total APOB nearGene-5 23063622 rs585967 chr2 21270554 A C 2.48E-07 Lipid levels / / 19913121 rs585967 chr2 21270554 A C 3.28E-08 Lipid levels / / 19913121 rs585967 chr2 21270554 A C 4.00E-05 Response to statin therapy / / 20339536 rs585967 chr2 21270554 A C 2.49E-46 LDL cholesterol / / 23063622 rs585967 chr2 21270554 A C 3.49E-45 Cholesterol,total / / 23063622 rs17398765 chr2 21270751 A G 1.39E-17 Cholesterol,total / / 23063622 rs17398765 chr2 21270751 A G 7.17E-19 LDL cholesterol / / 23063622 rs1713222 chr2 21271323 A G 1.00E-08 LDL cholesterol / / 18262040 rs1713222 chr2 21271323 A G 3.18E-17 Triglycerides / / 19060911 rs1713222 chr2 21271323 A G 5.10E-12 Lipid levels / / 19802338 rs1713222 chr2 21271323 A G 5.70E-08 Lipid levels / / 19802338 rs1713222 chr2 21271323 A G 1.80E-13 Lipid levels / / 19936222 rs1713222 chr2 21271323 A G 7.08E-11 Lipid levels / / 19936222 rs1713222 chr2 21271323 A G 4.40E-05 Response to statin therapy / / 20339536 rs1713222 chr2 21271323 A G 6.10E-13 Metabolic syndrome phenotype / / 22022282 rs1713222 chr2 21271323 A G 8.70E-13 Metabolic syndrome phenotype / / 22022282 rs1713222 chr2 21271323 A G 9.33E-08 LDL lipoproteins / / pha002902 rs1713222 chr2 21271323 A G 3.30E-05 ldl cholesterol / / pha003076 rs7575840 chr2 21273490 G T 1.24E-04 Type 2 diabetes / / 17463246 rs7575840 chr2 21273490 G T 5.40E-14 Lipid levels / / 18193043 rs7575840 chr2 21273490 G T 1.90E-09 LDL cholesterol / / 18262040 rs7575840 chr2 21273490 G T 1.54E-05 Lipid levels / / 19913121 rs7575840 chr2 21273490 G T 7.84E-08 Lipid levels / / 19913121 rs7575840 chr2 21273490 G T 1.35E-47 Cholesterol,total / / 23063622 rs7575840 chr2 21273490 G T 2.37E-39 LDL cholesterol / / 23063622 rs515135 chr2 21286057 T C 3.10E-14 Lipid levels / / 18193043 rs515135 chr2 21286057 T C 5.00E-29 LDL cholesterol / / 19060906 rs515135 chr2 21286057 T C 1.10E-05 Response to statin therapy / / 20339536 rs515135 chr2 21286057 T C 2.00E-20 LDL cholesterol / / 20864672 rs515135 chr2 21286057 T C 5.00E-29 Coronary heart disease / / 21347282 rs515135 chr2 21286057 T C 0.000257 Coronary artery disease (CAD) age <=50 / / 23202125 rs515135 chr2 21286057 T C 0.000666 Triglycerides / / 23202125 rs515135 chr2 21286057 T C 1.80E-10 Coronary artery disease / / 23202125 rs515135 chr2 21286057 T C 1.96E-09 Coronary artery disease with myocardial infarction / / 23202125 rs515135 chr2 21286057 T C 2.93E-09 Coronary artery disease (CAD) (males) / / 23202125 rs515135 chr2 21286057 T C 3.14E-109 LDL cholesterol / / 23202125 rs515135 chr2 21286057 T C 5.42E-08 Coronary artery disease (CAD) age >50 / / 23202125 rs515135 chr2 21286057 T C 8.38E-92 Cholesterol,total / / 23202125 rs515135 chr2 21286057 T C 9.12E-04 Coronary artery disease / / 24262325 rs563290 chr2 21288226 G A 7.60E-18 Lipid levels / / 18193043 rs563290 chr2 21288226 G A 1.33E-11 Lipid levels / / 19913121 rs563290 chr2 21288226 G A 7.38E-13 Lipid levels / / 19913121 rs563290 chr2 21288226 G A 1.10E-05 Response to statin therapy / / 20339536 rs563290 chr2 21288226 G A 3.96E-32 LDL cholesterol / / 23063622 rs563290 chr2 21288226 G A 6.18E-30 Cholesterol,total / / 23063622 rs562338 chr2 21288321 A G 9.77E-05 Cholesterol / / 17255346 rs562338 chr2 21288321 A G 2.28E-08 Type 2 diabetes / / 17463246 rs562338 chr2 21288321 A G 8.58E-13 Cardiovascular disease / / 18179892 rs562338 chr2 21288321 A G 6.00E-22 LDL cholesterol / / 18193043 rs562338 chr2 21288321 A G 1.00E-09 LDL cholesterol / / 18262040 rs562338 chr2 21288321 A G 1.21E-11 Lipid levels / / 19913121 rs562338 chr2 21288321 A G 6.00E-13 Lipid levels / / 19913121 rs562338 chr2 21288321 A G 1.10E-05 Response to statin therapy / / 20339536 rs562338 chr2 21288321 A G 6.00E-22 Coronary heart disease / / 21347282 rs562338 chr2 21288321 A G 1.10E-05 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs562338 chr2 21288321 A G 3.81E-16 LDL cholesterol (male) / / 22629316 rs562338 chr2 21288321 A G 7.60E-34 LDL cholesterol / / 22629316 rs562338 chr2 21288321 A G 9.28E-21 LDL cholesterol (female) / / 22629316 rs562338 chr2 21288321 A G 1.21E-51 LDL cholesterol / / 23063622 rs562338 chr2 21288321 A G 4.03E-53 Cholesterol,total / / 23063622 rs562338 chr2 21288321 A G 0.0000002 Cholesterol,total / / 23236364 rs562338 chr2 21288321 A G 6.54E-08 LDL cholesterol / / 23236364 rs581411 chr2 21289432 G A 1.10E-05 Response to statin therapy / / 20339536 rs668948 chr2 21291529 G A 1.10E-05 Response to statin therapy / / 20339536 rs541041 chr2 21294975 G A 1.27E-04 Cholesterol / / 17255346 rs541041 chr2 21294975 G A 1.46E-08 Triglycerides / / 19060911 rs541041 chr2 21294975 G A 8.00E-06 Response to statin therapy / / 20339536 rs541041 chr2 21294975 G A 5.48E-10 Cholesterol,total / / 23063622 rs478588 chr2 21297149 A G 1.40E-05 Response to statin therapy / / 20339536 rs565202 chr2 21297447 A G 1.70E-04 Response to antidepressants / / 19736353 rs1429974 chr2 21300770 C A 4.93E-15 Triglycerides / / 19060911 rs1429974 chr2 21300770 C A 2.18E-06 LDL lipoproteins / / pha002902 rs7567217 chr2 21303470 T C 9.50E-06 Response to statin therapy / / 20339536 rs568938 chr2 21303616 C T 1.00E-05 Response to statin therapy / / 20339536 rs568938 chr2 21303616 C T 1.62E-07 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs754524 chr2 21311541 T G 3.48E-11 Triglycerides / / 19060911 rs754524 chr2 21311541 T G 1.69E-07 Lipid levels / / 19913121 rs754524 chr2 21311541 T G 3.11E-05 Lipid levels / / 19913121 rs754524 chr2 21311541 T G 4.09E-42 Cholesterol,total / / 23063622 rs754524 chr2 21311541 T G 5.69E-41 LDL cholesterol / / 23063622 rs754524 chr2 21311541 T G 2.03E-07 LDL lipoproteins / / pha002902 rs754523 chr2 21311691 A G 8.30E-12 Lipid levels / / 18193043 rs754523 chr2 21311691 A G 1.25E-15 Triglycerides / / 19060911 rs754523 chr2 21311691 A G 1.11E-06 Lipid levels / / 19913121 rs754523 chr2 21311691 A G 2.86E-09 Lipid levels / / 19913121 rs754523 chr2 21311691 A G 1.05E-14 Total cholesterol in males / / 23063622 rs754523 chr2 21311691 A G 3.44E-30 Total cholesterol in females / / 23063622 rs754523 chr2 21311691 A G 3.83E-47 Cholesterol,total / / 23063622 rs754523 chr2 21311691 A G 4.29E-42 LDL cholesterol / / 23063622 rs754523 chr2 21311691 A G 0.00025 LDL cholesterol / / 23100282 rs754523 chr2 21311691 A G 1.12E-06 LDL lipoproteins / / pha002902 rs614303 chr2 21313577 G A 9.80E-06 Response to statin therapy / / 20339536 rs312944 chr2 21325188 A T 1.10E-05 Response to statin therapy / / 20339536 rs17399838 chr2 21368217 A G 4.20E-05 Response to statin therapy / / 20339536 rs17399838 chr2 21368217 A G 4.94E-04 Smoking quantity / / 24665060 rs312970 chr2 21369815 A T 1.84E-05 Type 2 diabetes / / 17463246 rs312970 chr2 21369815 A T 2.70E-05 Response to statin therapy / / 20339536 rs312970 chr2 21369815 A T 2.33E-05 Smoking quantity / / 24665060 rs11687710 chr2 21371068 T C 3.51E-04 Type 2 diabetes / / 17463246 rs837137 chr2 21377935 A G 2.70E-05 Response to statin therapy / / 20339536 rs111826230 chr2 21378453 A G 0.0000547 Menopause (age at onset) / / 23424626 rs312985 chr2 21378805 A G 8.37E-05 Cholesterol / / 17255346 rs312985 chr2 21378805 A G 1.69E-10 Triglycerides / / 19060911 rs312985 chr2 21378805 A G 2.20E-08 Lipid levels / / 19802338 rs312985 chr2 21378805 A G 2.40E-13 Lipid levels / / 19802338 rs312985 chr2 21378805 A G 1.18E-17 Lipid levels / / 19936222 rs312985 chr2 21378805 A G 2.50E-05 Response to statin therapy / / 20339536 rs312985 chr2 21378805 A G 1.41E-04 Smoking quantity / / 24665060 rs532300 chr2 21381608 C A 2.00E-05 Response to statin therapy / / 20339536 rs527034 chr2 21382786 C A 2.08E-04 Cholesterol / / 17255346 rs527034 chr2 21382786 C A 4.35E-06 Type 2 diabetes / / 17463246 rs527034 chr2 21382786 C A 2.00E-05 Response to statin therapy / / 20339536 rs527034 chr2 21382786 C A 1.03E-04 Smoking quantity / / 24665060 rs4560142 chr2 21383717 C T 1.16E-04 Cholesterol / / 17255346 rs4560142 chr2 21383717 C T 1.01E-05 Type 2 diabetes / / 17463246 rs4560142 chr2 21383717 C T 8.30E-09 LDL cholesterol / / 18262040 rs4560142 chr2 21383717 C T 2.00E-05 Response to statin therapy / / 20339536 rs4560142 chr2 21383717 C T 7.87E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs4560142 chr2 21383717 C T 5.85E-05 Smoking quantity / / 24665060 rs4591370 chr2 21383742 A G 1.16E-04 Cholesterol / / 17255346 rs4591370 chr2 21383742 A G 8.72E-06 Type 2 diabetes / / 17463246 rs4591370 chr2 21383742 A G 8.20E-09 LDL cholesterol / / 18262040 rs4591370 chr2 21383742 A G 2.00E-05 Response to statin therapy / / 20339536 rs4591370 chr2 21383742 A G 6.92E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs4591370 chr2 21383742 A G 0.000000029 Cholesterol,total / / 23063622 rs4591370 chr2 21383742 A G 4.79E-05 Smoking quantity / / 24665060 rs1652421 chr2 21383848 A G 1.70E-05 Response to statin therapy / / 20339536 rs1652420 chr2 21383881 A T 1.60E-05 Response to statin therapy / / 20339536 rs1712247 chr2 21383951 C T 1.16E-04 Cholesterol / / 17255346 rs1712247 chr2 21383951 C T 1.36E-05 Type 2 diabetes / / 17463246 rs1712247 chr2 21383951 C T 1.50E-05 Response to statin therapy / / 20339536 rs1712247 chr2 21383951 C T 6.06E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs1712247 chr2 21383951 C T 4.26E-05 Smoking quantity / / 24665060 rs548506 chr2 21385541 A G 1.50E-05 Response to statin therapy / / 20339536 rs1652419 chr2 21385649 C T 1.00E-05 Response to statin therapy / / 20339536 rs1712250 chr2 21386058 C T 1.00E-05 Response to statin therapy / / 20339536 rs1367120 chr2 21386304 T C 1.00E-05 Response to statin therapy / / 20339536 rs1367119 chr2 21386375 A C,G,T 1.00E-05 Response to statin therapy / / 20339536 rs522963 chr2 21386957 T C 1.00E-05 Response to statin therapy / / 20339536 rs522250 chr2 21387113 T C 1.20E-05 Response to statin therapy / / 20339536 rs529697 chr2 21387948 G T 1.80E-05 Response to statin therapy / / 20339536 rs1652418 chr2 21388456 T C 2.20E-05 Response to statin therapy / / 20339536 rs538928 chr2 21389019 A G 1.01E-04 Cholesterol / / 17255346 rs538928 chr2 21389019 A G 8.75E-06 Type 2 diabetes / / 17463246 rs538928 chr2 21389019 A G 2.70E-08 LDL cholesterol / / 18262040 rs538928 chr2 21389019 A G 1.90E-05 Response to statin therapy / / 20339536 rs538928 chr2 21389019 A G 7.33E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs560844 chr2 21389108 A G 3.00E-05 Response to statin therapy / / 20339536 rs563696 chr2 21389430 T A 2.90E-05 Response to statin therapy / / 20339536 rs4635554 chr2 21389659 T G 6.40E-05 Response to statin therapy / / 20339536 rs4635554 chr2 21389659 T G 2.00E-07 Hypertriglyceridemia / / 20657596 rs479545 chr2 21389897 T C 3.20E-05 Response to statin therapy / / 20339536 rs501863 chr2 21390000 G A 2.90E-05 Response to statin therapy / / 20339536 rs480732 chr2 21390149 A T 3.10E-05 Response to statin therapy / / 20339536 rs480787 chr2 21390169 A C,G,T 2.50E-05 Response to statin therapy / / 20339536 rs483436 chr2 21390407 G A 3.20E-05 Response to statin therapy / / 20339536 rs486139 chr2 21390674 G A 2.30E-05 Response to statin therapy / / 20339536 rs538528 chr2 21391740 T C 2.20E-05 Response to statin therapy / / 20339536 rs540439 chr2 21391978 C T 2.20E-05 Response to statin therapy / / 20339536 rs563280 chr2 21392153 T G 2.20E-05 Response to statin therapy / / 20339536 rs576203 chr2 21393623 A G 1.01E-04 Cholesterol / / 17255346 rs576203 chr2 21393623 A G 8.88E-06 Type 2 diabetes / / 17463246 rs576203 chr2 21393623 A G 9.00E-09 LDL cholesterol / / 18262040 rs576203 chr2 21393623 A G 2.20E-05 Response to statin therapy / / 20339536 rs576203 chr2 21393623 A G 8.45E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs576203 chr2 21393623 A G 3.61E-05 Smoking quantity / / 24665060 rs488507 chr2 21393689 G T 9.50E-05 Cholesterol / / 17255346 rs488507 chr2 21393689 G T 2.00E-08 LDL cholesterol / / 18262040 rs488507 chr2 21393689 G T 2.00E-05 Response to statin therapy / / 20339536 rs488507 chr2 21393689 G T 6.37E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs578095 chr2 21393866 A G 1.60E-05 Response to statin therapy / / 20339536 rs496100 chr2 21394614 A G 1.40E-05 Response to statin therapy / / 20339536 rs553523 chr2 21394798 T G 1.30E-05 Response to statin therapy / / 20339536 rs554414 chr2 21394892 T C 1.10E-05 Response to statin therapy / / 20339536 rs556504 chr2 21395261 C G 1.10E-05 Response to statin therapy / / 20339536 rs559967 chr2 21395598 A G 1.20E-05 Response to statin therapy / / 20339536 rs561850 chr2 21395805 A G 1.20E-05 Response to statin therapy / / 20339536 rs473269 chr2 21395830 T C 1.10E-05 Response to statin therapy / / 20339536 rs477146 chr2 21396334 A G 1.00E-05 Response to statin therapy / / 20339536 rs1652417 chr2 21396517 T C 1.00E-05 Response to statin therapy / / 20339536 rs1712251 chr2 21396551 G A 1.00E-05 Response to statin therapy / / 20339536 rs1652416 chr2 21396609 A G 1.10E-05 Response to statin therapy / / 20339536 rs483621 chr2 21397035 T A 1.10E-05 Response to statin therapy / / 20339536 rs506585 chr2 21397182 G A 8.13E-05 Cholesterol / / 17255346 rs506585 chr2 21397182 G A 9.01E-06 Type 2 diabetes / / 17463246 rs506585 chr2 21397182 G A 1.00E-08 LDL cholesterol / / 18262040 rs506585 chr2 21397182 G A 6.33E-11 Triglycerides / / 19060911 rs506585 chr2 21397182 G A 7.70E-14 Lipid levels / / 19802338 rs506585 chr2 21397182 G A 9.30E-09 Lipid levels / / 19802338 rs506585 chr2 21397182 G A 1.20E-25 Lipid levels / / 19936222 rs506585 chr2 21397182 G A 1.50E-22 Lipid levels / / 19936222 rs506585 chr2 21397182 G A 2.80E-31 Lipid levels / / 19936222 rs506585 chr2 21397182 G A 1.30E-05 Response to statin therapy / / 20339536 rs506585 chr2 21397182 G A 6.84E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs506585 chr2 21397182 G A 7.84E-05 Smoking quantity / / 24665060 rs507616 chr2 21397321 G C 1.20E-05 Response to statin therapy / / 20339536 rs531380 chr2 21397561 C G 1.20E-05 Response to statin therapy / / 20339536 rs532225 chr2 21397637 T C 1.30E-05 Response to statin therapy / / 20339536 rs560408 chr2 21398379 T C 1.30E-05 Response to statin therapy / / 20339536 rs541569 chr2 21398768 G A 1.30E-05 Response to statin therapy / / 20339536 rs544039 chr2 21398985 C A 1.30E-05 Response to statin therapy / / 20339536 rs478442 chr2 21399216 G T 9.09E-05 Cholesterol / / 17255346 rs478442 chr2 21399216 G T 9.84E-06 Type 2 diabetes / / 17463246 rs478442 chr2 21399216 G T 8.10E-09 LDL cholesterol / / 18262040 rs478442 chr2 21399216 G T 1.40E-05 Response to statin therapy / / 20339536 rs478442 chr2 21399216 G T 8.50E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs478442 chr2 21399216 G T 1.08E-04 Smoking quantity / / 24665060 rs570033 chr2 21399567 C G 1.40E-05 Response to statin therapy / / 20339536 rs574438 chr2 21399961 T C 1.40E-05 Response to statin therapy / / 20339536 rs5002500 chr2 21399974 C G 1.70E-05 Response to statin therapy / / 20339536 rs574461 chr2 21400013 A G 1.40E-05 Response to statin therapy / / 20339536 rs494315 chr2 21400950 C T 1.30E-05 Response to statin therapy / / 20339536 rs494465 chr2 21401010 C T 1.20E-05 Response to statin therapy / / 20339536 rs567071 chr2 21405790 G A 7.70E-10 Lipid levels / / 19802338 rs567071 chr2 21405790 G A 7.39E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs486246 chr2 21406751 G A 9.70E-06 Response to statin therapy / / 20339536 rs504616 chr2 21414020 C G 9.90E-06 Response to statin therapy / / 20339536 rs503662 chr2 21414142 T C 6.93E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs10221876 chr2 21419809 A T 1.20E-05 Response to statin therapy / / 20339536 rs1878512 chr2 21420358 C A 1.61E-04 Cholesterol / / 17255346 rs1878512 chr2 21420358 C A 1.50E-05 Response to statin therapy / / 20339536 rs1878512 chr2 21420358 C A 9.95E-05 Smoking quantity / / 24665060 rs17041988 chr2 21420697 A G 1.40E-05 Response to statin therapy / / 20339536 rs10206521 chr2 21420828 T C 7.80E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs7578527 chr2 21422403 G A 1.50E-05 Response to statin therapy / / 20339536 rs17042000 chr2 21422928 C T 1.50E-05 Response to statin therapy / / 20339536 rs10169543 chr2 21423989 T C 6.64E-05 Cholesterol / / 17255346 rs10169543 chr2 21423989 T C 2.00E-05 Response to statin therapy / / 20339536 rs12712940 chr2 21426743 C A 2.00E-05 Response to statin therapy / / 20339536 rs312051 chr2 21429055 G C 9.70E-05 Response to statin therapy / / 20339536 rs7605304 chr2 21445569 G A 0.000509 Height (Pygmy height) / / 22570615 rs949790 chr2 21449987 G A 2.37E-09 Triglycerides / / 19060911 rs386397 chr2 21451827 A G 3.52E-04 Smoking quantity / / 24665060 rs7566040 chr2 21454424 G T 3.16E-04 Smoking quantity / / 24665060 rs13398007 chr2 21469336 C T 6.74E-10 Triglycerides / / 19060911 rs13398007 chr2 21469336 C T 2.30E-09 Lipid levels / / 19802338 rs13398007 chr2 21469336 C T 9.30E-05 Tooth agenesis (maxillary third molar) / / 24172245 rs11689154 chr2 21473385 A G 5.57E-04 Smoking initiation / / 24665060 rs312049 chr2 21475944 T C 7.12E-04 Smoking quantity / / 24665060 rs17397220 chr2 21501219 C A 5.36E-05 Bipolar disorder and schizophrenia / / 20889312 rs10199484 chr2 21513546 T C 9.56E-05 Bipolar disorder / / 19488044 rs10199484 chr2 21513546 T C 8.89E-05 Alzheimer's disease (age of onset) / / 22005931 rs10171175 chr2 21515070 G A 1.78E-04 Body mass index / / 17255346 rs721064 chr2 21518442 A G 2.59E-05 Bipolar disorder / / 18317468 rs721064 chr2 21518442 A G 1.11E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs418451 chr2 21521637 G T 8.12E-05 Bipolar disorder / / 19488044 rs423277 chr2 21526322 T G 8.76E-05 Alzheimer's disease (age of onset) / / 22005931 rs219531 chr2 21528396 G C 9.86E-05 Bipolar disorder / / 19488044 rs219543 chr2 21535673 A G 0.000014 Height (Pygmy height) / / 22570615 rs13427673 chr2 21536873 G A 1.80E-04 Body mass index / / 17255346 rs2337901 chr2 21537251 C T 0.000000103 Cholesterol,total / / 23063622 rs4665702 chr2 21538345 G A 2.09E-05 Alzheimer's disease (age of onset) / / 22005931 rs219550 chr2 21539585 A G 2.71E-04 Iron levels / / pha002876 rs219553 chr2 21577743 G A 7.00E-06 Erectile dysfunction and prostate cancer treatment / / 20932654 rs892459 chr2 21584340 G C 8.64E-05 Serum metabolites / / 19043545 rs6706688 chr2 21612470 G A 3.26E-05 Multiple complex diseases / / 17554300 rs17042324 chr2 21674321 T C 5.87E-05 Cognitive impairment induced by topiramate / / 22091778 rs17042333 chr2 21675325 G C 7.91E-05 Multiple complex diseases / / 17554300 rs17042410 chr2 21688064 A G 1.09E-08 Multiple complex diseases / / 17554300 rs890082 chr2 21693244 T C 2.21E-05 Cognitive performance / / 19734545 rs979572 chr2 21696409 T G 1.20E-04 Type 2 diabetes / / 17846124 rs13392037 chr2 21703101 C T 6.42E-05 Schizophrenia / / 20832056 rs17042457 chr2 21703314 C G 6.42E-05 Schizophrenia / / 20832056 rs10490611 chr2 21707203 A G 6.42E-05 Schizophrenia / / 20832056 rs2194560 chr2 21768741 A G 3.00E-04 Hearing function / / 17255346 rs2194562 chr2 21769639 G A 2.08E-04 White matter integrity / / 22425255 rs4665932 chr2 21785061 C A 8.34E-06 Hearing function / / 17255346 rs970127 chr2 21793966 C T 1.70E-05 Hearing function / / 17255346 rs17042603 chr2 21798418 A G 0.0000018 Confectionary intake / / 23408455 rs918897 chr2 21825860 A G 2.46E-05 Gallbladder cancer / / 22318345 rs1117324 chr2 21840093 C T 3.00E-07 Response to antipsychotic treatment / / 20195266 rs10495717 chr2 21925067 T C 1.31E-04 Stroke LOC645949 intron pha002887 rs7568769 chr2 21943231 C T 1.12E-04 Age-related macular degeneration / / 22125219 rs6733000 chr2 21952204 C T 3.03E-04 Crohn's disease / / 17435756 rs10180600 chr2 22283986 T C 1.26E-04 Alzheimer's disease (late onset) / / 21379329 rs7600502 chr2 22297003 A G 3.00E-09 C-reactive protein and white blood cell count / / 22788528 rs7561156 chr2 22335940 A G 1.00E-04 Prostate cancer / / 21743057 rs7576134 chr2 22336150 G A 1.00E-04 Prostate cancer / / 21743057 rs4533497 chr2 22336757 A G 1.00E-04 Prostate cancer / / 21743057 rs2138885 chr2 22336964 G A 1.00E-04 Prostate cancer / / 21743057 rs7601596 chr2 22348539 G T 3.00E-05 Prostate cancer / / 21743057 rs1554268 chr2 22431110 C T 7.61E-04 Multiple complex diseases / / 17554300 rs1554268 chr2 22431110 C T 1.94E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10193722 chr2 22439514 A C 9.73E-05 Schizophrenia / / 24253340 rs10164909 chr2 22517197 G A 9.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4665502 chr2 22547633 C G 0.0001118 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4665502 chr2 22547633 C G 1.12E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10188288 chr2 22567357 T C 0.000114 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10188288 chr2 22567357 T C 1.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17391760 chr2 22568159 G T 2.00E-04 Information processing speed / / 21130836 rs17043657 chr2 22568473 T C 0.0001113 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17043657 chr2 22568473 T C 1.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7569716 chr2 22568713 A T 1.00E-07 Chronic obstructive pulmonary disease (moderate to severe) / / 24621683 rs10192983 chr2 22569908 A G 0.0001137 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10192983 chr2 22569908 A G 1.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1509379 chr2 22576085 A C 6.75E-05 Schizophrenia / / 19571809 rs1509379 chr2 22576085 A C 3.82E-05 Bipolar disorder and schizophrenia / / 20889312 rs1605834 chr2 22576100 A G 1.61E-05 Schizophrenia / / 19571809 rs1605834 chr2 22576100 A G 8.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs1605834 chr2 22576100 A G 5.11E-05 Schizophrenia / / pha002857 rs13424767 chr2 22612275 T C 1.02E-05 Schizophrenia / / 19571809 rs1396725 chr2 22612638 G A 2.54E-05 Schizophrenia / / 19571809 rs1509355 chr2 22613819 C T 2.72E-05 Schizophrenia / / 19571809 rs13413863 chr2 22615313 A G 5.96E-05 Schizophrenia / / 19571809 rs6741194 chr2 22616209 G T 1.73E-05 Schizophrenia / / 19571809 rs1949038 chr2 22616534 T C 2.58E-05 Schizophrenia / / 19571809 rs1509360 chr2 22616777 G A 2.63E-04 Multiple complex diseases / / 17554300 rs1509360 chr2 22616777 G A 1.80E-05 Schizophrenia / / 19571809 rs6749647 chr2 22618537 G T 4.72E-05 Schizophrenia / / 19571809 rs1509384 chr2 22644836 A G 8.50E-04 Lipid traits / / 17903299 rs1876766 chr2 22665048 C T 4.74E-04 Multiple complex diseases / / 17554300 rs4533498 chr2 22688256 A G 5.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2339516 chr2 22704855 G A 7.95E-04 Multiple complex diseases / / 17554300 rs882012 chr2 22711827 G A 5.40E-04 Multiple complex diseases / / 17554300 rs937932 chr2 22712316 T G 8.17E-04 Multiple complex diseases / / 17554300 rs937932 chr2 22712316 T G 5.62E-04 Premature ovarian failure / / 19508998 rs17043947 chr2 22736987 C T 2.00E-07 Self-rated health / / 20707712 rs13006508 chr2 22741939 A G 3.57E-05 Schizophrenia / / 19571809 rs6735294 chr2 22742356 T C 7.12E-05 Schizophrenia / / 19571809 rs6544021 chr2 22753225 T C 2.93E-04 Diabetic retinopathy / / 20871662 rs4988826 chr2 22756232 A G 6.02E-05 Multiple complex diseases / / 17554300 rs1703818 chr2 22764544 T G 9.40E-05 Temperament (bipolar disorder) / / 22365631 rs2062339 chr2 22777008 A G 2.40E-05 Temperament (bipolar disorder) / / 22365631 rs6748330 chr2 22778763 G A 3.30E-05 Temperament (bipolar disorder) / / 22365631 rs2220153 chr2 22779339 A G 2.10E-05 Temperament (bipolar disorder) / / 22365631 rs1032114 chr2 22789633 G A 3.80E-05 Temperament (bipolar disorder) / / 22365631 rs12052295 chr2 22806507 C T 7.00E-05 Temperament (bipolar disorder) / / 22365631 rs11688379 chr2 22816936 A T 6.70E-05 Temperament (bipolar disorder) / / 22365631 rs13015955 chr2 22822159 G A 4.00E-07 Coronary heart disease / / 21347282 rs7588192 chr2 22828898 C T 8.74E-04 Multiple complex diseases / / 17554300 rs1466556 chr2 22896073 T C 9.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs1534608 chr2 22903486 G A 7.92E-04 Multiple complex diseases / / 17554300 rs1534608 chr2 22903486 G A 7.55E-05 HIV-1 viral setpoint / / 22174851 rs3849399 chr2 22911727 T C 2.61E-04 Type 2 diabetes / / 17463246 rs719503 chr2 22918437 G A 4.00E-04 Premature ovarian failure / / 19508998 rs2204727 chr2 22975606 T C 8.31E-04 Coronary Artery Disease / / 17634449 rs13421717 chr2 23052800 C T 6.37E-05 Multiple complex diseases / / 17554300 rs4389355 chr2 23068640 G A 6.54E-05 Coronary heart disease / / pha003031 rs7560236 chr2 23076783 C T 1.15E-07 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs17321444 chr2 23108116 C T 3.90E-05 Triglycerides / / pha002904 rs2001795 chr2 23115536 T C 1.12E-05 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs10189050 chr2 23124558 C A 9.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs10189050 chr2 23124558 C A 4.00E-06 Obesity-related traits / / 23251661 rs1542190 chr2 23149442 T C 3.90E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6718432 chr2 23169705 T C 6.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17393543 chr2 23171228 A G 2.10E-05 Urinary metabolites / / 21572414 rs10187446 chr2 23174168 T G 4.23E-05 Monocyte counts / / pha003089 rs713514 chr2 23175970 C T 3.22E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6737109 chr2 23179531 T C 4.77E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1348864 chr2 23182262 A C 1.80E-05 Vitamin D concentrations / / 20600896 rs1348864 chr2 23182262 A C 1.80E-05 Vitamin D concentrations / / 20600896 rs2681019 chr2 23187504 C A 8.00E-08 Dialysis-related mortality / / 21546767 rs2592768 chr2 23196362 A G 3.91E-04 Smoking initiation / / 24665060 rs17044558 chr2 23219872 A T 4.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs1446881 chr2 23223292 A G 9.18E-04 Myocardial Infarction / / pha002883 rs13004805 chr2 23227284 C T 3.72E-04 Multiple complex diseases / / 17554300 rs13427835 chr2 23231002 G C 1.72E-04 Hearing function / / 17255346 rs13427835 chr2 23231002 G C 1.10E-05 Urinary metabolites / / 21572414 rs13015418 chr2 23231787 T G 7.78E-05 Personality dimensions / / 18957941 rs2681035 chr2 23234259 C T 7.29E-04 Multiple complex diseases / / 17554300 rs41458646 chr2 23238943 A G 8.00E-06 Alzheimer's disease (late onset) / / 22881374 rs2121450 chr2 23241481 G A 7.07E-06 Height / / 22021425 rs12466477 chr2 23242926 T C 4.54E-05 Height / / 22021425 rs1473333 chr2 23243972 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17044682 chr2 23260912 T C 1.08E-04 Aortic root size / / 21223598 rs11689205 chr2 23282771 G A 4.30E-07 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs1446875 chr2 23300822 T C 2.85E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs13036116 chr2 23302096 G A 3.21E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11689706 chr2 23340784 C T 3.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs7591791 chr2 23345329 A T 1.50E-05 Urinary metabolites / / 21572414 rs1817020 chr2 23360557 G T 2.50E-05 Urinary metabolites / / 21572414 rs1562751 chr2 23360855 T A 5.44E-04 Depression (quantitative trait) / / 20800221 rs1562752 chr2 23361001 C A 5.46E-04 Depression (quantitative trait) / / 20800221 rs1449965 chr2 23364711 G A 8.24E-05 Depression (quantitative trait) / / 20800221 rs10194644 chr2 23369473 C T 5.54E-04 Depression (quantitative trait) / / 20800221 rs10197888 chr2 23370317 C T 5.54E-04 Depression (quantitative trait) / / 20800221 rs6716929 chr2 23402150 C T 8.28E-04 Depression (quantitative trait) / / 20800221 rs6721782 chr2 23403834 C G 7.42E-04 Depression (quantitative trait) / / 20800221 rs1562755 chr2 23409862 A G 4.91E-05 Gallstones / / 17632509 rs1375864 chr2 23410734 G C 9.27E-05 Depression (quantitative trait) / / 20800221 rs1449984 chr2 23414651 A G 7.00E-06 Depression (quantitative trait) / / 20800221 rs1449984 chr2 23414651 A G 6.60E-06 Depression (quantitative trait) / / 23290196 rs10495740 chr2 23431541 T G 2.72E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10495741 chr2 23432044 A G 2.80E-04 Multiple complex diseases / / 17554300 rs1449968 chr2 23442158 T G 2.91E-05 Depression (quantitative trait) / / 20800221 rs9789344 chr2 23476896 A G 8.00E-04 Depression (quantitative trait) / / 20800221 rs2577734 chr2 23494356 C A 9.27E-04 Depression (quantitative trait) / / 20800221 rs1438131 chr2 23506782 G A 8.06E-10 Multiple sclerosis / / 17660530 rs17726419 chr2 23520112 C T 1.47E-05 Sudden cardiac arrest / / 21658281 rs10187596 chr2 23520587 G A 3.78E-04 Depression (quantitative trait) / / 20800221 rs1469974 chr2 23522173 G A 5.06E-05 Depression (quantitative trait) / / 20800221 rs17675487 chr2 23522489 A G 5.19E-05 Depression (quantitative trait) / / 20800221 rs9789743 chr2 23524378 C G 5.48E-05 Depression (quantitative trait) / / 20800221 rs9789522 chr2 23524674 G C 5.52E-05 Depression (quantitative trait) / / 20800221 rs1002159 chr2 23538632 C A 9.43E-05 Obesity (extreme) / / 21935397 rs1002158 chr2 23538843 T G 6.83E-06 Obesity (extreme) / / 21935397 rs2033768 chr2 23542578 T C 6.20E-04 Obesity (extreme) / / 21935397 rs2577720 chr2 23548614 A C 4.41E-04 Alzheimer's disease / / 17998437 rs2577720 chr2 23548614 A C 8.00E-06 F-cell distribution / / 21326311 rs2723120 chr2 23548656 T C 4.93E-04 Type 2 diabetes / / 17463246 rs2723120 chr2 23548656 T C 1.57E-04 Alzheimer's disease / / 17998437 rs2723120 chr2 23548656 T C 6.27E-04 Obesity (extreme) / / 21935397 rs6720873 chr2 23551770 G A 5.16E-04 Obesity (extreme) / / 21935397 rs998157 chr2 23553314 G A 6.02E-06 White blood cell count / / 21738479 rs1122899 chr2 23555150 T C 6.07E-04 Obesity (extreme) / / 21935397 rs2723124 chr2 23558014 C A 6.28E-04 Obesity (extreme) / / 21935397 rs2577711 chr2 23571849 C T 6.34E-04 Obesity (extreme) / / 21935397 rs2723140 chr2 23572757 A G 6.36E-04 Obesity (extreme) / / 21935397 rs6749822 chr2 23581558 C T 9.49E-04 Obesity (extreme) / / 21935397 rs6720565 chr2 23581619 G A 9.63E-04 Alzheimer's disease / / 17998437 rs6720565 chr2 23581619 G A 9.46E-04 Obesity (extreme) / / 21935397 rs2577705 chr2 23589439 A G 4.30E-05 Obesity (extreme) / / 21935397 rs2577704 chr2 23592145 G A 3.00E-06 IgG glycosylation / / 23382691 rs2577704 chr2 23592145 G A 5.00E-06 IgG glycosylation / / 23382691 rs2577703 chr2 23592219 C T 5.80E-05 Obesity (extreme) / / 21935397 rs2577756 chr2 23601556 A G 2.34E-05 Obesity (extreme) / / 21935397 rs13397583 chr2 23606030 C T 2.20E-05 Celiac disease / / 17558408 rs11125011 chr2 23610838 G A 4.14E-04 Multiple complex diseases KLHL29 intron 17554300 rs1030907 chr2 23615027 T C 2.59E-05 Obesity (extreme) KLHL29 intron 21935397 rs6742888 chr2 23616057 T C 4.07E-04 Multiple complex diseases KLHL29 intron 17554300 rs920271 chr2 23620246 T C 3.21E-04 Obesity (extreme) KLHL29 intron 21935397 rs2577748 chr2 23624262 T C 4.15E-04 Obesity (extreme) KLHL29 intron 21935397 rs2577744 chr2 23628311 T A 4.59E-04 Obesity (extreme) KLHL29 intron 21935397 rs12621454 chr2 23633569 A G 4.83E-04 Obesity (extreme) KLHL29 intron 21935397 rs2723111 chr2 23634300 A G 7.70E-04 Obesity (extreme) KLHL29 intron 21935397 rs6544822 chr2 23635949 C T 3.98E-04 Obesity (extreme) KLHL29 intron 21935397 rs737565 chr2 23651204 C A 9.29E-04 Multiple complex diseases KLHL29 intron 17554300 rs6544861 chr2 23676505 C A 2.13E-04 Multiple complex diseases KLHL29 intron 17554300 rs6742202 chr2 23716694 A C 7.09E-04 Body mass index KLHL29 intron 21701565 rs1653763 chr2 23724991 T G 1.27E-05 Major depressive disorder KLHL29 intron 19107115 rs1653765 chr2 23729232 A G 6.93E-05 Major depressive disorder KLHL29 intron 19107115 rs17045504 chr2 23733781 A G 2.55E-05 Height KLHL29 intron 22021425 rs1613177 chr2 23743160 G A 6.33E-04 Body mass index KLHL29 intron 21701565 rs748860 chr2 23754948 C T 7.40E-05 Hypothyroidism KLHL29 intron 22493691 rs4665609 chr2 23774752 A C 4.20E-06 Prostate cancer (early onset) KLHL29 intron 24740154 rs10165828 chr2 23781787 C T 8.60E-05 Diabetic retinopathy KLHL29 intron 21441570 rs1709339 chr2 23783753 A G 2.00E-05 Smoking behavior KLHL29 intron 20418888 rs1560591 chr2 23784121 A G 8.90E-05 Diabetic retinopathy KLHL29 intron 21441570 rs17045705 chr2 23829271 C T 2.90E-04 Cholesterol KLHL29 intron 17255346 rs3795933 chr2 23878191 G A 2.20E-04 Primary sclerosing cholangitis KLHL29 intron 19944697 rs1991083 chr2 23887437 C T 3.60E-05 Height KLHL29 intron 21998595 rs6715626 chr2 23891551 G A 6.02E-04 Amyotrophic Lateral Sclerosis KLHL29 intron 17827064 rs889862 chr2 23897996 C T 4.48E-05 Amyotrophic Lateral Sclerosis KLHL29 intron 17827064 rs4665630 chr2 23898317 C T 1.00E-07 Coronary heart disease KLHL29 intron 21347282 rs3795942 chr2 23919375 C T 4.79E-06 Obesity-related traits KLHL29 cds-synon 23251661 rs3795948 chr2 23926659 T C 9.68E-06 Obesity-related traits KLHL29 cds-synon 23251661 rs2712102 chr2 23932461 C T 8.40E-05 Crohn's disease / / 20570966 rs12478744 chr2 23947589 A G 1.10E-06 Obesity-related traits / / 23251661 rs7608623 chr2 23948953 G T 6.00E-07 Obesity-related traits / / 23251661 rs2551324 chr2 23978800 C G 6.80E-06 Urinary metabolites ATAD2B intron 21572414 rs35379186 chr2 24044352 T C 1.70E-05 Urinary metabolites ATAD2B intron 21572414 rs2339928 chr2 24049453 G A 7.90E-05 Serum metabolites ATAD2B intron 19043545 rs2712089 chr2 24080274 A G 3.20E-06 Urinary metabolites ATAD2B intron 21572414 rs17711796 chr2 24123539 C T 2.20E-05 Urinary metabolites ATAD2B intron 21572414 rs11674248 chr2 24154192 A C 3.00E-06 Obesity-related traits / / 23251661 rs7572949 chr2 24162018 T C 4.92E-06 Obesity-related traits / / 23251661 rs7561273 chr2 24247514 A G 4.48E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7561273 chr2 24247514 A G 6.00E-06 Quantitative traits / / 19197348 rs7561273 chr2 24247514 A G 0.0000609 Coronary artery disease / / 23202125 rs2339940 chr2 24251787 G T 6.29E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs11902184 chr2 24281484 G A 1.55E-04 Lung function (forced expiratory volume in 1 second) FKBP1B intron 17255346 rs2303289 chr2 24342242 C G 4.60E-04 Lymphocyte counts PFN4 intron 22286170 rs6754391 chr2 24369019 T C 4.86E-04 Type 2 diabetes LOC375190 intron 17463246 rs6754391 chr2 24369019 T C 5.85E-04 Multiple complex diseases LOC375190 intron 17554300 rs6723962 chr2 24391733 A G 6.60E-04 Multiple complex diseases LOC375190 intron 17554300 rs2288073 chr2 24413298 A G 2.00E-09 Venous thromboembolism (gene x gene interaction) C2orf84 missense 23509962 rs7564420 chr2 24414002 A G 3.28E-04 Multiple complex diseases / / 17554300 rs2303291 chr2 24431184 C T 8.84E-05 Parkinson's disease ITSN2 missense 17052657 rs2303296 chr2 24432839 A G 2.64E-04 Parkinson's disease ITSN2 cds-synon 17052657 rs2303297 chr2 24432937 C T 2.64E-04 Parkinson's disease ITSN2 intron 17052657 rs6746005 chr2 24434345 G A 9.88E-04 Alzheimer's disease ITSN2 intron 22005930 rs2551182 chr2 24440417 C T 4.75E-05 Male-pattern baldness ITSN2 intron 18849994 rs6707781 chr2 24441883 T G 8.41E-04 Alzheimer's disease ITSN2 intron 22005930 rs2543662 chr2 24443271 C A 2.96E-05 Parkinson's disease ITSN2 UTR-3 17052657 rs1203 chr2 24443330 A G 8.51E-04 Alzheimer's disease ITSN2 UTR-3 22005930 rs10495747 chr2 24514996 T C 3.78E-05 Male-pattern baldness ITSN2 intron 18849994 rs6707600 chr2 24521766 C T 3.00E-06 Response to antipsychotic treatment in schizophrenia (working memory) ITSN2 intron 21107309 rs2702042 chr2 24546542 C T 5.76E-04 Type 2 diabetes ITSN2 intron 17463246 rs2702042 chr2 24546542 C T 7.28E-04 Multiple complex diseases ITSN2 intron 17554300 rs12470303 chr2 24619883 A G 3.84E-04 Multiple complex diseases / / 17554300 rs7595372 chr2 24632122 T G 8.07E-04 Alzheimer's disease / / 22005930 rs729921 chr2 24633124 T G 8.35E-04 Alzheimer's disease / / 22005930 rs894466 chr2 24633771 T C 7.46E-04 Alzheimer's disease / / 22005930 rs4581852 chr2 24638256 C A 6.60E-04 Alzheimer's disease / / 22005930 rs2584940 chr2 24641639 T G 7.36E-04 Alzheimer's disease / / 22005930 rs2702089 chr2 24643291 C T 5.12E-04 Alzheimer's disease / / 22005930 rs11125582 chr2 24646213 G A 4.52E-04 Alzheimer's disease / / 22005930 rs11125583 chr2 24646278 C A 4.92E-04 Alzheimer's disease / / 22005930 rs2249387 chr2 24649801 C G 4.59E-04 Alzheimer's disease / / 22005930 rs6705716 chr2 24651341 C T 3.42E-04 Alzheimer's disease / / 22005930 rs2702050 chr2 24652464 T C 3.79E-04 Alzheimer's disease / / 22005930 rs2702051 chr2 24652896 C A 3.61E-04 Alzheimer's disease / / 22005930 rs2584944 chr2 24652999 T C 3.51E-04 Alzheimer's disease / / 22005930 rs10200838 chr2 24656627 G A 6.39E-05 Alzheimer's disease / / 22005930 rs2012222 chr2 24658162 G A 5.66E-05 Alzheimer's disease / / 22005930 rs1545257 chr2 24658794 G A 2.11E-04 Alzheimer's disease / / 22005930 rs2584937 chr2 24674385 T C 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1031092 chr2 24680249 T G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1031089 chr2 24692010 G A 1.75E-05 Heart Rate / / pha003054 rs2165738 chr2 24692809 C G 1.11E-04 Multiple complex diseases / / 17554300 rs2165738 chr2 24692809 C G 4.00E-06 Type 1 diabetes / / 18978792 rs2702132 chr2 24698726 G A 5.31E-05 Heart Rate / / pha003054 rs17734306 chr2 24722438 A G 1.42E-04 Glycosylated haemoglobin levels / / 17255346 rs1545255 chr2 24739410 A G 6.41E-04 Multiple complex diseases / / 17554300 rs1545255 chr2 24739410 A G 3.70E-04 Myasthenia gravis / / 23055271 rs6723622 chr2 24789640 G A 9.05E-04 Multiple complex diseases / / 17554300 rs995647 chr2 24810255 G A 5.70E-05 Heart Rate NCOA1 intron pha003054 rs6720514 chr2 24826619 T C 8.75E-05 Glycosylated haemoglobin levels NCOA1 intron 17255346 rs6545667 chr2 24874502 C G 0.000000565 Triglycerides NCOA1 intron 23063622 rs17791703 chr2 24881271 T C 2.16E-05 Multiple complex diseases NCOA1 intron 17554300 rs2119115 chr2 24886781 A C 1.46E-04 Glycosylated haemoglobin levels NCOA1 intron 17255346 rs17046499 chr2 24954055 T C 9.72E-04 Suicide attempts in bipolar disorder NCOA1 intron 21423239 rs6761875 chr2 24972217 T C 6.45E-04 Lymphocyte counts NCOA1 intron 22286170 rs9309308 chr2 24994570 T C 1.25E-04 Multiple complex diseases / / 17554300 rs9309308 chr2 24994570 T C 8.62E-05 Caffeine consumption / / 21490707 rs2891409 chr2 25017357 G T 2.29E-04 Heart rate CENPO intron 23583979 rs41523444 chr2 25017708 G C 1.63E-05 Bipolar Disorder CENPO intron pha002858 rs35213472 chr2 25018509 T C 6.98E-05 Bipolar Disorder CENPO intron pha002858 rs11895026 chr2 25036858 C A 1.00E-13 Height CENPO intron 23563607 rs11125797 chr2 25037626 G T 7.18E-05 Multiple complex diseases CENPO intron 17554300 rs2082881 chr2 25038268 G A 3.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) CENPO intron 23648065 rs2278483 chr2 25040082 C T 7.49E-05 Caffeine consumption CENPO intron 21490707 rs1550115 chr2 25041620 C T 3.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) CENPO intron 23648065 rs17799872 chr2 25044957 G A 8.21E-04 Obesity (extreme) CENPO UTR-3 21935397 rs13390269 chr2 25068793 G A 6.81E-04 Obesity (extreme) ADCY3 intron 21935397 rs17046666 chr2 25070351 G C 6.92E-04 Obesity (extreme) ADCY3 intron 21935397 rs6545758 chr2 25074874 T C 7.01E-04 Alzheimer's disease ADCY3 intron 22005930 rs6760328 chr2 25077991 T C 3.20E-05 Major depressive disorder ADCY3 intron 21042317 rs1541984 chr2 25082414 G A 3.20E-05 Major depressive disorder ADCY3 intron 21042317 rs7597157 chr2 25089166 C T 6.50E-05 Major depressive disorder ADCY3 intron 21042317 rs13407913 chr2 25097644 A G 3.00E-06 Body mass index (non-asthmatics) ADCY3 intron 23517042 rs2033655 chr2 25101092 G A 1.90E-05 Major depressive disorder ADCY3 intron 21042317 rs2033654 chr2 25103108 C A 2.00E-06 Body mass index (non-asthmatics) ADCY3 intron 23517042 rs12986610 chr2 25106265 C T 5.80E-05 Major depressive disorder ADCY3 intron 21042317 rs7586879 chr2 25116977 C T 4.00E-08 Body mass index ADCY3 intron 23583978 rs6545800 chr2 25118885 C T 9.34E-04 Multiple complex diseases ADCY3 intron 17554300 rs6545800 chr2 25118885 C T 6.00E-16 Inflammatory bowel disease ADCY3 intron 23128233 rs7565468 chr2 25130092 C T 7.40E-05 Major depressive disorder ADCY3 intron 21042317 rs6545814 chr2 25131316 A G 1.87E-04 Smoking cessation ADCY3 intron 18519826 rs6545814 chr2 25131316 A G 1.00E-13 Body mass index ADCY3 intron 22344219 rs6545814 chr2 25131316 A G 1.00E-10 Body mass index ADCY3 intron 24861553 rs11900505 chr2 25131986 A C 8.91E-04 Multiple complex diseases ADCY3 intron 17554300 rs2384061 chr2 25135620 G A 7.96E-06 Smoking cessation ADCY3 intron 18519826 rs2384061 chr2 25135620 G A 8.75E-06 Smoking cessation ADCY3 intron 18519826 rs2384061 chr2 25135620 G A 6.30E-06 Major depressive disorder ADCY3 intron 21042317 rs11676272 chr2 25141538 A G 5.88E-10 Body mass index ADCY3 missense 22344219 rs6752378 chr2 25150116 C A 2.81E-11 Obesity / / 22484627 rs10182181 chr2 25150296 A G 3.43E-05 Height / / 22021425 rs10182181 chr2 25150296 A G 1.00E-17 Obesity / / 23563607 rs10182181 chr2 25150296 A G 3.00E-14 Obesity / / 23563607 rs713586 chr2 25158008 T C 6.00E-22 Body mass index / / 20935630 rs713586 chr2 25158008 T C 6.69E-04 Type 2 diabetes / / 22238593 rs713586 chr2 25158008 T C 1.02E-05 Body mass index / / 22344219 rs713586 chr2 25158008 T C 6.17E-22 Body mass index / / 23001569 rs713586 chr2 25158008 T C 2.56E-05 Age-related macular degeneration / / 23577725 rs713587 chr2 25158281 C T 4.00E-06 Body mass index (non-asthmatics) / / 23517042 rs17046742 chr2 25165825 G A 3.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1172294 chr2 25169200 A G 1.00E-08 Pubertal anthropometrics D/JC27 UTR-3 23449627 rs4665736 chr2 25187599 C T 7.00E-16 Height D/JC27 intron 20881960 rs6749646 chr2 25193998 A T 6.93E-04 Obesity (extreme) D/JC27 intron 21935397 rs13388020 chr2 25196266 G C 6.83E-04 Obesity (extreme) D/JC27-AS1 intron 21935397 rs6733301 chr2 25276284 G A 8.00E-07 Height EFR3B intron 18391951 rs478222 chr2 25301755 A T 4.00E-09 Type 1 diabetes EFR3B intron 21980299 rs567359 chr2 25304574 A G 3.64E-04 Multiple complex diseases EFR3B intron 17554300 rs1530016 chr2 25305756 C T 3.00E-06 Body mass index (non-asthmatics) EFR3B intron 23517042 rs12233132 chr2 25328703 C T 3.24E-05 Height EFR3B intron pha003011 rs12233134 chr2 25329016 C T 4.39E-04 Type 2 diabetes EFR3B intron 22238593 rs4665284 chr2 25339658 G A 2.76E-05 Height EFR3B intron pha003011 rs7575363 chr2 25342914 A G 5.66E-04 Obesity (extreme) EFR3B intron 21935397 rs6718083 chr2 25362194 G A 8.77E-04 Parkinson's disease EFR3B intron 17052657 rs6718083 chr2 25362194 G A 1.80E-05 Height EFR3B intron pha003011 rs1561288 chr2 25369002 C T 5.00E-08 Body mass index EFR3B intron 23669352 rs1561288 chr2 25369002 C T 1.48E-05 Height EFR3B intron pha003011 rs1561289 chr2 25369040 C T 8.77E-04 Parkinson's disease EFR3B intron 17052657 rs1561289 chr2 25369040 C T 1.48E-05 Height EFR3B intron pha003011 rs13428823 chr2 25373298 G A 6.00E-12 Height EFR3B intron 23563607 rs1866146 chr2 25380573 G A 5.86E-04 Multiple complex diseases EFR3B UTR-3 17554300 rs1866146 chr2 25380573 G A 1.40E-07 Height EFR3B UTR-3 21194676 rs1866146 chr2 25380573 G A 2.50E-12 Height EFR3B UTR-3 21194676 rs1866146 chr2 25380573 G A 3.30E-06 Height EFR3B UTR-3 21194676 rs1866146 chr2 25380573 G A 9.33E-04 Obesity (extreme) EFR3B UTR-3 21935397 rs934778 chr2 25389224 A G 9.05E-04 Obesity (extreme) POMC intron 21935397 rs934778 chr2 25389224 A G 3.75E-05 Triglycerides POMC intron pha002904 rs874401 chr2 25402280 G A 8.54E-05 Suicide attempts in bipolar disorder / / 21423239 rs4665771 chr2 25404327 T C 1.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs4665773 chr2 25404975 C A 1.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs4665774 chr2 25404982 T G 1.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs4665775 chr2 25407121 A G 8.44E-05 Suicide attempts in bipolar disorder / / 21423239 rs10186053 chr2 25410190 A G 1.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs4665777 chr2 25410896 C T 1.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs4665778 chr2 25410970 A T 1.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs17046917 chr2 25412032 T G 1.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs4665779 chr2 25412672 A G 9.93E-05 Suicide attempts in bipolar disorder / / 21423239 rs12619868 chr2 25412845 T C 1.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs4665287 chr2 25413309 C T 1.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs4665287 chr2 25413309 C T 3.66E-05 Body Mass Index / / pha002896 rs12617514 chr2 25419691 C T 1.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs12617514 chr2 25419691 C T 3.66E-05 Body Mass Index / / pha002896 rs10202360 chr2 25420865 A C 2.24E-05 Suicide attempts in bipolar disorder / / 21423239 rs12619264 chr2 25421803 C T 3.36E-05 Suicide attempts in bipolar disorder / / 21423239 rs12612413 chr2 25426846 G T 7.53E-05 Suicide attempts in bipolar disorder / / 21423239 rs12468449 chr2 25432277 T C 9.05E-05 Suicide attempts in bipolar disorder / / 21423239 rs12624309 chr2 25437885 C A 7.63E-05 Suicide attempts in bipolar disorder / / 21423239 rs4665783 chr2 25448050 A G 7.35E-05 Suicide attempts in bipolar disorder / / 21423239 rs2164411 chr2 25452906 G A 4.66E-13 Multiple complex diseases / / 17554300 rs2164411 chr2 25452906 G A 9.57E-05 Suicide attempts in bipolar disorder / / 21423239 rs13420827 chr2 25453968 C G 2.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs13420827 chr2 25453968 C G 1.10E-04 Iris characteristics / / 21835309 rs11681447 chr2 25472784 C T 1.12E-04 Multiple complex diseases DNMT3A intron 17554300 rs1465825 chr2 25478453 C T 1.52E-04 Multiple complex diseases DNMT3A intron 17554300 rs11694842 chr2 25482970 A G 4.19E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) DNMT3A intron 23648065 rs13428812 chr2 25492467 A G 9.00E-10 Crohn's disease DNMT3A intron 21102463 rs12999687 chr2 25512438 T G 0.000000683 Body mass index DNMT3A intron 22885924 rs6546071 chr2 25532021 C T 4.78E-04 Multiple complex diseases DNMT3A intron 17554300 rs10196664 chr2 25589466 A G 6.06E-04 Multiple complex diseases / / 17554300 rs1010658 chr2 25595194 T C 4.72E-05 Multiple myeloma / / 22120009 rs1010658 chr2 25595194 T C 4.00E-06 Multiple myeloma / / 23955597 rs1010659 chr2 25595397 C T 3.83E-05 Multiple myeloma / / 22120009 rs11126027 chr2 25596144 G C 6.18E-06 Multiple myeloma / / 22120009 rs562908097 chr2 25596322 TG T 6.07E-06 Multiple myeloma / / 22120009 rs562908097 chr2 25596322 TG T 2.52E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs7586928 chr2 25596322 T C 6.07E-06 Multiple myeloma / / 22120009 rs7586928 chr2 25596322 T C 2.52E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs732075 chr2 25596431 T G 6.00E-06 Multiple myeloma / / 22120009 rs732076 chr2 25596509 A C 5.95E-06 Multiple myeloma / / 22120009 rs2304426 chr2 25602142 G A 1.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DTNB intron 20877124 rs2304426 chr2 25602142 G A 7.77E-04 Multiple myeloma DTNB intron 22120009 rs2304427 chr2 25602310 C T 8.95E-04 White matter integrity DTNB intron 22425255 rs55924491 chr2 25605023 C G 1.28E-07 Multiple myeloma DTNB intron 22120009 rs6761076 chr2 25607758 T C 1.81E-07 Multiple myeloma DTNB intron 22120009 rs62131107 chr2 25612725 G T 1.15E-04 Multiple myeloma DTNB intron 22120009 rs7558082 chr2 25612814 C T 5.39E-07 Multiple myeloma DTNB intron 22120009 rs7577599 chr2 25613146 T C 3.37E-07 Multiple myeloma DTNB intron 22120009 rs7577599 chr2 25613146 T C 6.00E-06 Multiple myeloma (IgH translocation) DTNB intron 23502783 rs7577599 chr2 25613146 T C 1.00E-08 Multiple myeloma DTNB intron 23955597 rs1865693 chr2 25620477 G A 1.21E-04 Multiple myeloma DTNB intron 22120009 rs17046986 chr2 25620900 C T 1.22E-04 Multiple myeloma DTNB intron 22120009 rs7571570 chr2 25621530 C T 1.47E-04 Multiple myeloma DTNB intron 22120009 rs7571570 chr2 25621530 C T 4.00E-07 Multiple myeloma DTNB intron 23955597 rs6724910 chr2 25622439 C T 1.12E-04 Multiple myeloma DTNB intron 22120009 rs1369704 chr2 25623590 T C 7.30E-05 Multiple myeloma DTNB intron 22120009 rs2384232 chr2 25623749 G A 8.85E-05 Multiple myeloma DTNB intron 22120009 rs2384232 chr2 25623749 G A 3.00E-07 Multiple myeloma DTNB intron 23955597 rs10206012 chr2 25624186 G A 6.97E-05 Multiple myeloma DTNB intron 22120009 rs6546148 chr2 25625005 A G 6.87E-05 Multiple myeloma DTNB intron 22120009 rs7583617 chr2 25625859 T C 9.58E-05 Multiple myeloma DTNB intron 22120009 rs7570164 chr2 25626236 C T 6.75E-05 Multiple myeloma DTNB intron 22120009 rs7586918 chr2 25626385 T C 8.78E-05 Multiple myeloma DTNB intron 22120009 rs7586918 chr2 25626385 T C 2.00E-07 Multiple myeloma DTNB intron 23955597 rs12622767 chr2 25627916 A G 7.74E-06 Multiple myeloma DTNB intron 22120009 rs6756177 chr2 25628897 G A 3.24E-05 Multiple myeloma DTNB intron 22120009 rs6546149 chr2 25629438 C G 2.24E-05 Multiple myeloma DTNB intron 22120009 rs60462983 chr2 25629525 A G 5.26E-06 Multiple myeloma DTNB intron 22120009 rs10180663 chr2 25633242 T C 1.10E-05 Multiple myeloma DTNB intron 22120009 rs10180663 chr2 25633242 T C 2.00E-06 Multiple myeloma (IgH translocation) DTNB intron 23502783 rs10180663 chr2 25633242 T C 9.00E-08 Multiple myeloma DTNB intron 23955597 rs10189164 chr2 25633368 G C 4.92E-04 Multiple myeloma DTNB intron 22120009 rs6731296 chr2 25634827 C T 5.87E-05 Multiple myeloma DTNB intron 22120009 rs7605235 chr2 25654049 G A 7.47E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines DTNB intron 21844884 rs7605235 chr2 25654049 G A 7.58E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines DTNB intron 21844884 rs6746082 chr2 25659244 A C 4.00E-07 Multiple myeloma DTNB intron 22120009 rs6746082 chr2 25659244 A C 7.00E-09 Multiple myeloma DTNB intron 23955597 rs7589394 chr2 25661744 C G 4.65E-07 Multiple myeloma DTNB intron 22120009 rs1006752 chr2 25663991 C T 7.10E-06 Multiple myeloma DTNB intron 22120009 rs1006752 chr2 25663991 C T 7.00E-07 Multiple myeloma DTNB intron 23955597 rs2036653 chr2 25666969 A T 2.57E-07 Multiple myeloma DTNB intron 22120009 rs6721434 chr2 25669517 G A 9.82E-04 Iron levels DTNB intron pha002876 rs6712045 chr2 25669973 T G 2.90E-06 Multiple myeloma DTNB intron 22120009 rs13390436 chr2 25670777 C T 2.28E-07 Multiple myeloma DTNB intron 22120009 rs6546183 chr2 25671806 G A 4.87E-07 Multiple myeloma DTNB intron 22120009 rs6546183 chr2 25671806 G A 1.00E-07 Multiple myeloma DTNB intron 23955597 rs6546184 chr2 25672469 C T 2.84E-07 Multiple myeloma DTNB intron 22120009 rs13397493 chr2 25672692 C T 2.86E-07 Multiple myeloma DTNB intron 22120009 rs6733060 chr2 25677997 G C 3.54E-06 Multiple myeloma DTNB intron 22120009 rs113288889 chr2 25681552 C T 6.91E-06 Multiple myeloma DTNB intron 22120009 rs13387987 chr2 25682416 G A 3.11E-07 Multiple myeloma DTNB intron 22120009 rs6546199 chr2 25683447 A G 5.18E-04 Alzheimer's disease DTNB intron 24755620 rs2384235 chr2 25684118 T C 4.50E-04 Alzheimer's disease DTNB intron 24755620 rs13386804 chr2 25692112 G T 9.23E-04 Alzheimer's disease DTNB intron 24755620 rs6737282 chr2 25697403 A G 5.70E-04 Alzheimer's disease DTNB intron 24755620 rs4665791 chr2 25698847 G A 2.58E-06 Multiple myeloma DTNB intron 22120009 rs504855 chr2 25700434 G A 9.31E-04 Alzheimer's disease DTNB intron 24755620 rs6751254 chr2 25705428 T C 3.97E-04 Lung function (forced vital capacity) DTNB intron 24023788 rs2055718 chr2 25710090 G A 9.80E-04 Alzheimer's disease DTNB intron 24755620 rs1507705 chr2 25714916 C T 6.03E-04 Multiple myeloma DTNB intron 22120009 rs7577573 chr2 25716597 G A 7.31E-06 Multiple myeloma DTNB intron 22120009 rs679112 chr2 25718052 G A 7.23E-06 Multiple myeloma DTNB intron 22120009 rs6728820 chr2 25724886 T C 1.21E-04 Multiple myeloma DTNB intron 22120009 rs6725828 chr2 25725057 A C 8.46E-05 Multiple myeloma DTNB intron 22120009 rs545065 chr2 25726123 T C 3.73E-04 Multiple myeloma DTNB intron 22120009 rs9309386 chr2 25727910 G A 9.80E-04 Type 2 diabetes DTNB intron 17846124 rs551405 chr2 25729007 G C 1.56E-04 Multiple myeloma DTNB intron 22120009 rs1965239 chr2 25729721 A G 1.52E-04 Multiple myeloma DTNB intron 22120009 rs671826 chr2 25730069 T C 1.54E-04 Multiple myeloma DTNB intron 22120009 rs683662 chr2 25730344 A G 1.53E-04 Multiple myeloma DTNB intron 22120009 rs517506 chr2 25730404 A G 1.53E-04 Multiple myeloma DTNB intron 22120009 rs517403 chr2 25730439 G A 1.51E-04 Multiple myeloma DTNB intron 22120009 rs2384237 chr2 25731389 A C 3.17E-04 Multiple myeloma DTNB intron 22120009 rs2384238 chr2 25731413 A T 3.17E-04 Multiple myeloma DTNB intron 22120009 rs372492988 chr2 25731413 A ATT 3.17E-04 Multiple myeloma DTNB intron 22120009 rs56398912 chr2 25731413 A ATT 3.17E-04 Multiple myeloma DTNB intron 22120009 rs503169 chr2 25735072 A G 1.54E-04 Multiple myeloma DTNB intron 22120009 rs519177 chr2 25737041 A G 1.67E-04 Multiple myeloma DTNB intron 22120009 rs596173 chr2 25740991 C T 6.04E-04 Multiple myeloma DTNB intron 22120009 rs498963 chr2 25741061 T G 6.06E-04 Multiple myeloma DTNB intron 22120009 rs670343 chr2 25744731 G A 6.55E-04 Multiple myeloma DTNB intron 22120009 rs6546237 chr2 25749376 T C 3.25E-04 Multiple myeloma DTNB intron 22120009 rs1848307 chr2 25752181 C T 7.44E-04 Multiple myeloma DTNB intron 22120009 rs624622 chr2 25752979 C T 7.85E-04 Multiple myeloma DTNB intron 22120009 rs537986 chr2 25754005 A G 7.92E-04 Multiple myeloma DTNB intron 22120009 rs539879 chr2 25754235 T C 7.74E-04 Multiple myeloma DTNB intron 22120009 rs636586 chr2 25754670 C A 7.83E-04 Multiple myeloma DTNB intron 22120009 rs6731902 chr2 25755200 T G 8.25E-04 Multiple myeloma DTNB intron 22120009 rs936012 chr2 25755848 C T 7.19E-04 Multiple myeloma DTNB intron 22120009 rs483490 chr2 25756264 A G 8.07E-04 Multiple myeloma DTNB intron 22120009 rs3100636 chr2 25757080 G C 8.45E-04 Multiple myeloma DTNB intron 22120009 rs3105720 chr2 25757091 C T 8.45E-04 Multiple myeloma DTNB intron 22120009 rs682888 chr2 25757709 T C 8.57E-04 Multiple myeloma DTNB intron 22120009 rs503594 chr2 25757803 C T 8.57E-04 Multiple myeloma DTNB intron 22120009 rs670576 chr2 25758132 A G 8.59E-04 Multiple myeloma DTNB intron 22120009 rs80307750 chr2 25758677 C T 8.62E-04 Multiple myeloma DTNB intron 22120009 rs111628494 chr2 25758974 G A 8.91E-04 Multiple myeloma DTNB intron 22120009 rs637519 chr2 25760891 G A 7.97E-04 Multiple myeloma DTNB intron 22120009 rs508262 chr2 25761044 G A 8.66E-04 Multiple myeloma DTNB intron 22120009 rs840001 chr2 25763590 C G 7.19E-04 Multiple myeloma DTNB intron 22120009 rs486217 chr2 25767561 A G 8.00E-04 Multiple myeloma DTNB intron 22120009 rs659323 chr2 25771379 A T 8.35E-04 Multiple myeloma DTNB intron 22120009 rs658414 chr2 25771561 C T 7.75E-04 Multiple myeloma DTNB intron 22120009 rs478237 chr2 25775885 A G 8.36E-04 Multiple myeloma DTNB intron 22120009 rs76471080 chr2 25778179 C A 8.25E-04 Multiple myeloma DTNB intron 22120009 rs12473635 chr2 25778637 T C 8.22E-04 Multiple myeloma DTNB intron 22120009 rs61712781 chr2 25779495 T C 8.20E-04 Multiple myeloma DTNB intron 22120009 rs6737159 chr2 25781453 T C 8.16E-04 Multiple myeloma DTNB intron 22120009 rs2123826 chr2 25789144 A G 7.86E-05 Multiple myeloma DTNB intron 22120009 rs11678268 chr2 25837156 T C 4.14E-06 Cognitive impairment induced by topiramate DTNB intron 22091778 rs858648 chr2 25867203 G T 1.57E-07 Cognitive impairment induced by topiramate DTNB intron 22091778 rs704789 chr2 25874261 C T 2.84E-07 Cognitive impairment induced by topiramate DTNB intron 22091778 rs11684202 chr2 25887558 A G 6.00E-06 Coronary heart disease DTNB intron 21347282 rs11684202 chr2 25887558 A G 1.30E-05 Urinary metabolites DTNB intron 21572414 rs6738958 chr2 25892403 T G 7.30E-06 Urinary metabolites DTNB intron 21572414 rs11676342 chr2 25923407 G T 4.60E-06 Nasopharyngeal carcinoma / / 23209447 rs2384259 chr2 25929371 T G 8.40E-06 Urinary metabolites / / 21572414 rs41521945 chr2 25938077 A T 1.67E-04 Multiple complex diseases / / 17554300 rs1076000 chr2 25977356 G A 8.40E-04 Multiple complex diseases ASXL2 intron 17554300 rs7581916 chr2 25988915 G C 7.99E-05 Hearing function ASXL2 intron 17255346 rs17680828 chr2 25990640 T C 9.56E-05 Multiple complex diseases ASXL2 intron 17554300 rs17047144 chr2 26018106 G A 2.28E-04 Hearing function ASXL2 intron 17255346 rs12713741 chr2 26207421 G A 8.93E-05 Serum metabolites / / 19043545 rs112288323 chr2 26228207 C T 2.00E-06 Metabolite levels (HVA/MHPG ratio) / / 23319000 rs6734513 chr2 26232521 G C 7.20E-06 Urinary metabolites / / 21572414 rs68184094 chr2 26249899 T A 2.00E-06 Metabolite levels (HVA) / / 23319000 rs68184094 chr2 26249899 T A 4.00E-06 Metabolite levels (HVA-5-HIAA Factor score) / / 23319000 rs13388915 chr2 26272602 G A 8.00E-06 Immune response to smallpox vaccine (IL-6) RAB10 intron 22542470 rs13395488 chr2 26280029 G A 9.43E-06 Multiple complex diseases RAB10 intron 17554300 rs10048683 chr2 26320519 G A 6.36E-05 Lymphocyte counts RAB10 intron 22286170 rs9332419 chr2 26322040 A G 0.00000617 Preeclampsia RAB10 intron 22432041 rs34792425 chr2 26341570 A C 6.52E-06 Metabolite levels (MHPG) RAB10 intron 23319000 rs11126375 chr2 26344787 G A 0.00000913 Preeclampsia RAB10 intron 22432041 rs1025543 chr2 26385788 T C 1.14E-04 Body mass index / / 21701565 rs1025542 chr2 26385849 G A 1.60E-04 Body mass index / / 21701565 rs17593512 chr2 26417829 G A 1.22E-04 Type 2 diabetes HADHA intron 17463246 rs137852769 chr2 26418053 C G 0.0000052 Breast cancer (ER positive) HADHA missense 23555315 rs137852769 chr2 26418053 C G 0.00044 Breast cancer HADHA missense 23555315 rs4665319 chr2 26424583 A C 1.80E-05 Coronary heart disease HADHA intron 21966275 rs17527979 chr2 26428132 C T 4.57E-04 Alzheimer's disease HADHA intron 17998437 rs6745226 chr2 26493597 C A 8.58E-04 Body mass index HADHB intron 21701565 rs6753473 chr2 26526419 T G 2.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs6753473 chr2 26526419 T G 4.00E-06 Non-small cell lung cancer / / 23144319 rs13000148 chr2 26526763 T C 4.95E-04 Alzheimer's disease / / 17998437 rs11902679 chr2 26527798 C T 2.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs1897115 chr2 26554063 C T 5.87E-04 Tourette syndrome GPR113 intron 22889924 rs11899781 chr2 26580137 C T 1.91E-04 Multiple complex diseases EPT1 intron 17554300 rs3820937 chr2 26616624 G C 2.27E-05 Sudden cardiac arrest EPT1 UTR-3 21658281 rs10179397 chr2 26635328 A C 5.78E-04 Response to taxane treatment (placlitaxel) CCDC164 intron 23006423 rs17529722 chr2 26635442 G A 5.10E-04 Type 2 diabetes CCDC164 intron 17463246 rs13409838 chr2 26638983 A C 2.44E-04 Multiple complex diseases CCDC164 intron 17554300 rs4450561 chr2 26653457 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) CCDC164 intron 20708005 rs3795958 chr2 26667130 A G 2.00E-06 Metabolite levels (HVA) CCDC164 missense 23319000 rs3795958 chr2 26667130 A G 4.00E-06 Metabolite levels (HVA/MHPG ratio) CCDC164 missense 23319000 rs2280515 chr2 26677303 G T 2.68E-04 Alcohol dependence CCDC164 intron 21314694 rs4416176 chr2 26682646 T C 4.00E-04 Multiple complex diseases OTOF intron 17554300 rs13031842 chr2 26711136 C T 5.97E-04 Type 2 diabetes OTOF intron 17463246 rs13029647 chr2 26731244 T C 6.51E-04 Type 2 diabetes OTOF intron 17463246 rs4665865 chr2 26738696 C A 1.32E-04 Acute lymphoblastic leukemia (childhood) OTOF intron 22076464 rs11682534 chr2 26762046 A G 4.00E-05 Lipid levels OTOF intron 18193043 rs6547102 chr2 26773867 C T 8.79E-04 Obesity (extreme) OTOF intron 21935397 rs10192160 chr2 26778638 C G 3.72E-05 Non-word repetition OTOF intron 23738518 rs1011108 chr2 26782621 C T 2.00E-06 Periodontal microbiota OTOF nearGene-5 22699663 rs1148949 chr2 26796919 G A 4.06E-05 Non-word repetition C2orf70 intron 23738518 rs2272464 chr2 26799031 G A 8.73E-04 Amyotrophic Lateral Sclerosis C2orf70 cds-synon 17362836 rs6727852 chr2 26840492 T C 6.30E-05 Vitiligo CIB4 intron 22951725 rs1662992 chr2 26848046 T C 2.23E-05 Vitiligo CIB4 intron 22951725 rs11694917 chr2 26864607 C T 5.35E-04 Type 2 diabetes / / 17463246 rs1275953 chr2 26880402 C T 7.50E-05 Bipolar disorder and schizophrenia / / 20889312 rs1275951 chr2 26883482 C T 6.30E-05 Bipolar disorder and schizophrenia / / 20889312 rs1275945 chr2 26886068 C T 4.61E-05 Bipolar disorder and schizophrenia / / 20889312 rs1731227 chr2 26886523 G A 7.96E-05 Bipolar disorder and schizophrenia / / 20889312 rs1275964 chr2 26892931 G A 3.02E-05 Bipolar disorder and schizophrenia / / 20889312 rs1009221 chr2 26894589 A G 1.81E-04 Arthritis (juvenile idiopathic) / / 22354554 rs1275985 chr2 26911745 C T 1.02E-05 Multiple complex diseases / / 17554300 rs1275986 chr2 26912079 C A 6.51E-06 Multiple complex diseases / / 17554300 rs1275986 chr2 26912079 C A 3.09E-06 Kawasaki disease / / 21221998 rs1275988 chr2 26914364 C T 7.97E-06 Multiple complex diseases / / 17554300 rs1275988 chr2 26914364 C T 3.18E-06 Kawasaki disease / / 21221998 rs1275982 chr2 26919089 C T 6.97E-06 Multiple complex diseases KCNK3 intron 17554300 rs11126666 chr2 26928811 G A 9.80E-04 Type 2 diabetes KCNK3 intron 17463246 rs11126666 chr2 26928811 G A 1.35E-05 Multiple complex diseases KCNK3 intron 17554300 rs11126666 chr2 26928811 G A 3.85E-06 Kawasaki disease KCNK3 intron 21221998 rs11126666 chr2 26928811 G A 5.23E-05 Insulin-related traits KCNK3 intron pha003063 rs1275935 chr2 26961857 G T 2.56E-04 Smoking initiation / / 24665060 rs11126681 chr2 26963378 A G 3.39E-04 Multiple complex diseases / / 17554300 rs870535 chr2 26964015 T C 5.73E-04 Multiple complex diseases / / 17554300 rs870535 chr2 26964015 T C 4.53E-04 Smoking initiation / / 24665060 rs828273 chr2 26972205 G A 3.76E-04 Multiple complex diseases / / 17554300 rs3845684 chr2 26979671 T C 8.28E-05 Smoking initiation / / 24665060 rs2060390 chr2 27024478 G A 8.60E-05 Glioma (high-grade) / / 19578366 rs999087 chr2 27033604 C T 1.32E-04 Smoking initiation / / 24665060 rs2117275 chr2 27043309 G A 1.11E-04 Smoking initiation / / 24665060 rs7606808 chr2 27044227 C T 3.10E-05 Smoking initiation / / 24665060 rs7602471 chr2 27050727 G A 4.13E-04 Smoking initiation / / 24665060 rs1368892 chr2 27054551 A G 1.24E-04 Smoking initiation / / 24665060 rs4513249 chr2 27058451 G T 2.79E-04 Multiple complex diseases / / 17554300 rs3885083 chr2 27058657 A G 9.08E-05 Smoking initiation / / 24665060 rs4665360 chr2 27059011 T C 4.90E-04 Smoking initiation / / 24665060 rs1560860 chr2 27061253 T C 9.99E-05 Smoking initiation / / 24665060 rs6547275 chr2 27064577 T C 2.25E-04 Smoking initiation / / 24665060 rs11887277 chr2 27083269 T C 5.00E-06 Obesity-related traits DPYSL5 intron 23251661 rs6756245 chr2 27083489 T C 5.76E-06 Obesity-related traits DPYSL5 intron 23251661 rs827884 chr2 27094842 C G 6.67E-04 Multiple complex diseases DPYSL5 intron 17554300 rs12618836 chr2 27137616 G A 9.07E-05 Gallstones DPYSL5 intron 17632509 rs9309559 chr2 27141515 A C 6.16E-04 Aortic root size DPYSL5 intron 21223598 rs10196501 chr2 27147272 A G 4.78E-04 Smoking initiation DPYSL5 intron 24665060 rs1371614 chr2 27152874 C T 2.00E-12 Fasting glucose-related traits (interaction with BMI) DPYSL5 intron 22581228 rs1371614 chr2 27152874 C T 7.09E-11 Fasting blood glucose DPYSL5 intron 22885924 rs1371614 chr2 27152874 C T 4.79E-04 Lung function (forced expiratory volume in 1 second) DPYSL5 intron 24023788 rs7564363 chr2 27191473 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6716275 chr2 27227707 A G 8.06E-05 Gallstones MAPRE3 intron 17632509 rs1124649 chr2 27260469 G A 0.000000516 Fasting blood glucose TMEM214 missense 22885924 rs3754734 chr2 27299598 G T 1.59E-04 Coronary Artery Disease / / 17634449 rs1866559 chr2 27335586 T C 5.30E-05 Electrocardiographic traits and heart rate variability CGREF1 intron 17903306 rs7588926 chr2 27342894 C T 9.00E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2304678 chr2 27353507 G C 1.67E-07 Hirschsprung's disease ABHD1 missense 19196962 rs1275512 chr2 27371203 A G 5.00E-05 Prostate cancer / / 21743057 rs6709602 chr2 27405497 C T 3.23E-05 F-cell distribution / / 21326311 rs6709602 chr2 27405497 C T 7.23E-05 Hypertension (essential hypertension) / / 22184326 rs1659700 chr2 27414134 T C 1.32E-04 Cholesterol / / 17255346 rs1275501 chr2 27419282 T G 6.92E-05 Hypertension (essential hypertension) / / 22184326 rs1659685 chr2 27420690 C T 4.08E-05 Hypertension (essential hypertension) / / 22184326 rs140443329 chr2 27424304 C T 0.00023 Breast cancer SLC5A6 missense 23555315 rs1395 chr2 27424636 G A 2.92E-08 Urate levels SLC5A6 missense 23263486 rs1395 chr2 27424636 G A 8.00E-11 Blood metabolite levels SLC5A6 missense 24816252 rs2580761 chr2 27426362 G A 2.60E-05 Hypertension (essential hypertension) SLC5A6 intron 22184326 rs1275522 chr2 27426878 C T 6.33E-05 Hypertension (essential hypertension) SLC5A6 intron 22184326 rs1275528 chr2 27430781 A G 8.79E-05 Hypertension (essential hypertension) SLC5A6 intron 22184326 rs11608 chr2 27435374 G A 7.01E-05 Hypertension (essential hypertension) C2orf28 UTR-5 22184326 rs11126918 chr2 27438710 G A 3.70E-05 Hypertension (essential hypertension) C2orf28 intron 22184326 rs4665958 chr2 27443196 A G 9.54E-05 Hypertension (essential hypertension) CAD intron 22184326 rs7593448 chr2 27449293 C G 5.87E-11 Triglycerides CAD intron 23063622 rs3769143 chr2 27450724 G A 6.20E-05 Hypertension (essential hypertension) CAD intron 22184326 rs13399758 chr2 27455726 T C 2.73E-05 Cholesterol CAD intron 17255346 rs4665960 chr2 27467598 C T 2.03E-05 Hypertension (essential hypertension) / / 22184326 rs1561535 chr2 27471025 C T 2.18E-05 Hypertension (essential hypertension) / / 22184326 rs9653564 chr2 27472618 G A 3.26E-05 Hypertension (essential hypertension) / / 22184326 rs1992291 chr2 27504312 A G 1.38E-05 Hypertension (essential hypertension) / / 22184326 rs11686131 chr2 27508710 C T 5.93E-06 Hypertension (essential hypertension) TRIM54 intron 22184326 rs4665376 chr2 27509032 T C 4.15E-05 Hypertension (essential hypertension) TRIM54 intron 22184326 rs4665962 chr2 27515105 A G 7.09E-06 Hypertension (essential hypertension) TRIM54 intron 22184326 rs13404327 chr2 27519153 G T 4.43E-05 Hypertension (essential hypertension) TRIM54 intron 22184326 rs13404327 chr2 27519153 G T 1.35E-09 Urate levels TRIM54 intron 23263486 rs13404446 chr2 27519254 G A 3.39E-05 Hypertension (essential hypertension) TRIM54 intron 22184326 rs13404446 chr2 27519254 G A 1.87E-04 Lymphocyte counts TRIM54 intron 22286170 rs13404446 chr2 27519254 G A 3.09E-09 Fasting blood glucose TRIM54 intron 22885924 rs13404446 chr2 27519254 G A 1.36E-09 Urate levels TRIM54 intron 23263486 rs7575245 chr2 27527321 G A 4.75E-05 Hypertension (essential hypertension) TRIM54 intron 22184326 rs4665963 chr2 27528692 T C 4.73E-05 Hypertension (essential hypertension) TRIM54 intron 22184326 rs4665963 chr2 27528692 T C 4.06E-13 Triglycerides TRIM54 intron 23063622 rs4665963 chr2 27528692 T C 1.21E-09 Urate levels TRIM54 intron 23263486 rs4665965 chr2 27536380 T C 5.68E-05 Hypertension (essential hypertension) MPV17 intron 22184326 rs4665965 chr2 27536380 T C 1.83E-09 Fasting blood glucose MPV17 intron 22885924 rs4665965 chr2 27536380 T C 9.18E-10 Urate levels MPV17 intron 23263486 rs1975384 chr2 27542041 C T 8.15E-06 Hypertension (essential hypertension) MPV17 intron 22184326 rs1122227 chr2 27544285 C T 2.32E-05 Hypertension (essential hypertension) MPV17 intron 22184326 rs1122227 chr2 27544285 C T 9.44E-11 Triglycerides MPV17 intron 23063622 rs1049817 chr2 27550967 A G 1.45E-06 Lipid levels GTF3C2 cds-synon 19913121 rs1049817 chr2 27550967 A G 3.10E-06 Response to statin therapy GTF3C2 cds-synon 20339536 rs1049817 chr2 27550967 A G 1.20E-07 Urate levels GTF3C2 cds-synon 20884846 rs1049817 chr2 27550967 A G 9.70E-30 Triglycerides GTF3C2 cds-synon 23063622 rs1049817 chr2 27550967 A G 1.05E-16 Urate levels GTF3C2 cds-synon 23263486 rs3739095 chr2 27556721 G A 2.90E-07 Response to statin therapy GTF3C2 intron 20339536 rs3739095 chr2 27556721 G A 1.40E-10 Urate levels GTF3C2 intron 20884846 rs3739095 chr2 27556721 G A 4.54E-21 Urate levels GTF3C2 intron 23263486 rs11684134 chr2 27558252 A G 2.10E-06 Response to statin therapy GTF3C2 intron 20339536 rs11684134 chr2 27558252 A G 7.10E-09 Urate levels GTF3C2 intron 20884846 rs11684134 chr2 27558252 A G 5.51E-18 Urate levels GTF3C2 intron 23263486 rs11689803 chr2 27566520 T A 8.50E-06 Response to statin therapy GTF3C2 intron 20339536 rs11689803 chr2 27566520 T A 4.87E-13 Urate levels GTF3C2 intron 23263486 rs6743819 chr2 27567407 G T 3.60E-06 Response to statin therapy GTF3C2 intron 20339536 rs6743819 chr2 27567407 G T 1.40E-07 Urate levels GTF3C2 intron 20884846 rs6743819 chr2 27567407 G T 5.50E-17 Urate levels GTF3C2 intron 23263486 rs10205219 chr2 27568565 T C 3.70E-06 Response to statin therapy GTF3C2 intron 20339536 rs10205219 chr2 27568565 T C 1.40E-07 Urate levels GTF3C2 intron 20884846 rs10205219 chr2 27568565 T C 5.45E-17 Urate levels GTF3C2 intron 23263486 rs4665969 chr2 27574953 T C 3.60E-06 Response to statin therapy GTF3C2 intron 20339536 rs4665969 chr2 27574953 T C 1.30E-07 Urate levels GTF3C2 intron 20884846 rs4665969 chr2 27574953 T C 1.15E-16 Urate levels GTF3C2 intron 23263486 rs6760828 chr2 27579231 T C 3.70E-06 Response to statin therapy GTF3C2 intron 20339536 rs6760828 chr2 27579231 T C 1.20E-07 Urate levels GTF3C2 intron 20884846 rs6760828 chr2 27579231 T C 9.10E-17 Urate levels GTF3C2 intron 23263486 rs55795546 chr2 27580983 A G 4.51E-05 Intracerebral hemorrhage / / 24656865 rs7586601 chr2 27584666 A G 1.40E-07 Response to statin therapy / / 20339536 rs7586601 chr2 27584666 A G 2.80E-10 Urate levels / / 20884846 rs7586601 chr2 27584666 A G 3.72E-37 Triglycerides / / 23063622 rs7586601 chr2 27584666 A G 7.52E-20 Urate levels / / 23263486 rs1058065 chr2 27587724 G A 4.00E-06 IgG glycosylation EIF2B4 cds-synon 23382691 rs2280737 chr2 27589810 T C 1.30E-05 Response to statin therapy EIF2B4 intron 20339536 rs2280737 chr2 27589810 T C 2.50E-07 Urate levels EIF2B4 intron 20884846 rs2280737 chr2 27589810 T C 4.31E-16 Urate levels EIF2B4 intron 23263486 rs56402945 chr2 27591708 G A 4.37E-05 Intracerebral hemorrhage EIF2B4 intron 24656865 rs7602534 chr2 27592423 C T 1.50E-05 Response to statin therapy EIF2B4 intron 20339536 rs7602534 chr2 27592423 C T 3.40E-07 Urate levels EIF2B4 intron 20884846 rs7602534 chr2 27592423 C T 4.17E-16 Urate levels EIF2B4 intron 23263486 rs1528533 chr2 27595756 G C 1.40E-05 Response to statin therapy SNX17 intron 20339536 rs1528533 chr2 27595756 G C 1.90E-07 Urate levels SNX17 intron 20884846 rs1528533 chr2 27595756 G C 2.11E-22 Triglycerides SNX17 intron 23063622 rs1528533 chr2 27595756 G C 1.58E-15 Urate levels SNX17 intron 23263486 rs4665972 chr2 27598097 T C 3.62E-14 Metabolite levels SNX17 intron 22286219 rs4665972 chr2 27598097 T C 1.00E-06 Breast size SNX17 intron 22747683 rs4665972 chr2 27598097 T C 1.00E-08 Triglycerides SNX17 intron 23726366 rs4665972 chr2 27598097 T C 1.05E-08 Triglycerides SNX17 intron 23726366 rs13472 chr2 27600239 G A 1.40E-05 Response to statin therapy ZNF513 UTR-3 20339536 rs13472 chr2 27600239 G A 2.20E-07 Urate levels ZNF513 UTR-3 20884846 rs13472 chr2 27600239 G A 9.21E-29 Triglycerides ZNF513 UTR-3 23063622 rs13472 chr2 27600239 G A 5.06E-16 Urate levels ZNF513 UTR-3 23263486 rs4582 chr2 27604279 A G 1.30E-05 Response to statin therapy PPM1G UTR-3 20339536 rs4582 chr2 27604279 A G 6.64E-13 Urate levels PPM1G UTR-3 23263486 rs2384629 chr2 27606098 A G 3.74E-09 Urate levels PPM1G intron 23263486 rs1647284 chr2 27608115 C T 1.30E-05 Response to statin therapy PPM1G intron 20339536 rs1647284 chr2 27608115 C T 1.70E-07 Urate levels PPM1G intron 20884846 rs1647284 chr2 27608115 C T 1.54E-15 Urate levels PPM1G intron 23263486 rs76823937 chr2 27611154 T C 4.83E-05 Intracerebral hemorrhage PPM1G intron 24656865 rs7594812 chr2 27611469 A G 1.30E-05 Response to statin therapy PPM1G intron 20339536 rs7594812 chr2 27611469 A G 1.60E-07 Urate levels PPM1G intron 20884846 rs7594812 chr2 27611469 A G 1.36E-15 Urate levels PPM1G intron 23263486 rs12476704 chr2 27613031 C A 1.40E-05 Response to statin therapy PPM1G intron 20339536 rs12476704 chr2 27613031 C A 1.60E-07 Urate levels PPM1G intron 20884846 rs12476704 chr2 27613031 C A 5.67E-16 Urate levels PPM1G intron 23263486 rs11891554 chr2 27613617 G A 0.000000224 Fasting blood glucose PPM1G intron 22885924 rs11891554 chr2 27613617 G A 4.77E-05 Intracerebral hemorrhage PPM1G intron 24656865 rs2911712 chr2 27626945 A T 1.30E-05 Response to statin therapy PPM1G intron 20339536 rs2911712 chr2 27626945 A T 1.30E-07 Urate levels PPM1G intron 20884846 rs2911712 chr2 27626945 A T 1.62E-15 Urate levels PPM1G intron 23263486 rs62131866 chr2 27627704 G A 3.87E-05 Intracerebral hemorrhage PPM1G intron 24656865 rs7563162 chr2 27631191 C T 1.30E-05 Response to statin therapy PPM1G intron 20339536 rs7563162 chr2 27631191 C T 1.30E-07 Urate levels PPM1G intron 20884846 rs7563162 chr2 27631191 C T 2.30E-15 Urate levels PPM1G intron 23263486 rs62131868 chr2 27631558 T C 3.72E-05 Intracerebral hemorrhage PPM1G intron 24656865 rs6717803 chr2 27634511 A G 3.75E-05 Intracerebral hemorrhage / / 24656865 rs1728918 chr2 27635463 A G 5.11E-13 Metabolite levels / / 22286219 rs1728918 chr2 27635463 A G 5.00E-16 Crohn's disease / / 23128233 rs1060525 chr2 27635582 A G 1.30E-05 Response to statin therapy / / 20339536 rs1060525 chr2 27635582 A G 1.60E-07 Urate levels / / 20884846 rs1060525 chr2 27635582 A G 1.70E-15 Urate levels / / 23263486 rs2010087 chr2 27637235 C T 1.50E-05 Response to statin therapy / / 20339536 rs2010087 chr2 27637235 C T 1.30E-07 Urate levels / / 20884846 rs2010087 chr2 27637235 C T 5.72E-16 Urate levels / / 23263486 rs4665976 chr2 27640325 A G 1.30E-05 Response to statin therapy / / 20339536 rs4665976 chr2 27640325 A G 1.30E-07 Urate levels / / 20884846 rs4665976 chr2 27640325 A G 1.58E-15 Urate levels / / 23263486 rs11675428 chr2 27642734 A C 5.86E-04 Parkinson's disease / / 17052657 rs11675428 chr2 27642734 A C 1.94E-08 Urate levels / / 23263486 rs1728922 chr2 27644464 A C 1.30E-05 Response to statin therapy / / 20339536 rs1728922 chr2 27644464 A C 1.20E-07 Urate levels / / 20884846 rs1728922 chr2 27644464 A C 1.99E-15 Urate levels / / 23263486 rs6547626 chr2 27646770 C T 1.30E-05 Response to statin therapy / / 20339536 rs6547626 chr2 27646770 C T 1.10E-07 Urate levels / / 20884846 rs6547626 chr2 27646770 C T 1.92E-15 Urate levels / / 23263486 rs62131869 chr2 27647453 G A 4.37E-05 Intracerebral hemorrhage / / 24656865 rs4665978 chr2 27648726 T C 1.30E-07 Response to statin therapy / / 20339536 rs4665978 chr2 27648726 T C 1.80E-10 Urate levels / / 20884846 rs4665978 chr2 27648726 T C 1.16E-19 Urate levels / / 23263486 rs780100 chr2 27652153 G T 1.50E-05 Response to statin therapy NRBP1 intron 20339536 rs780100 chr2 27652153 G T 3.40E-08 Urate levels NRBP1 intron 20884846 rs780100 chr2 27652153 G T 1.84E-15 Urate levels NRBP1 intron 23263486 rs704791 chr2 27657167 T C 1.50E-05 Response to statin therapy NRBP1 intron 20339536 rs704791 chr2 27657167 T C 3.90E-08 Urate levels NRBP1 intron 20884846 rs704791 chr2 27657167 T C 2.16E-15 Urate levels NRBP1 intron 23263486 rs780102 chr2 27659491 T C 1.50E-05 Response to statin therapy NRBP1 intron 20339536 rs780102 chr2 27659491 T C 3.30E-08 Urate levels NRBP1 intron 20884846 rs780102 chr2 27659491 T C 2.24E-15 Urate levels NRBP1 intron 23263486 rs1260341 chr2 27663215 T A 1.40E-05 Response to statin therapy NRBP1 intron 20339536 rs1260341 chr2 27663215 T A 3.20E-08 Urate levels NRBP1 intron 20884846 rs1260341 chr2 27663215 T A 1.88E-15 Urate levels NRBP1 intron 23263486 rs1260342 chr2 27663416 G T 1.50E-05 Response to statin therapy NRBP1 intron 20339536 rs1260342 chr2 27663416 G T 3.20E-08 Urate levels NRBP1 intron 20884846 rs1260342 chr2 27663416 G T 1.95E-15 Urate levels NRBP1 intron 23263486 rs62131871 chr2 27667184 G A 2.83E-05 Intracerebral hemorrhage KRTCAP3 intron 24656865 rs11541994 chr2 27667297 A AA,AG 9.40E-06 Response to statin therapy IFT172 UTR-3 20339536 rs11541994 chr2 27667297 A AA,AG 2.90E-08 Urate levels IFT172 UTR-3 20884846 rs11541994 chr2 27667297 A AA,AG 2.03E-15 Urate levels IFT172 UTR-3 23263486 rs4803 chr2 27667297 A G 9.40E-06 Response to statin therapy IFT172 UTR-3 20339536 rs4803 chr2 27667297 A G 2.90E-08 Urate levels IFT172 UTR-3 20884846 rs4803 chr2 27667297 A G 2.03E-15 Urate levels IFT172 UTR-3 23263486 rs780104 chr2 27677691 G A 1.20E-05 Response to statin therapy IFT172 intron 20339536 rs780104 chr2 27677691 G A 2.90E-08 Urate levels IFT172 intron 20884846 rs780104 chr2 27677691 G A 2.24E-15 Urate levels IFT172 intron 23263486 rs6734392 chr2 27677778 C T 2.83E-05 Intracerebral hemorrhage IFT172 intron 24656865 rs780106 chr2 27681598 A C 8.50E-06 Response to statin therapy IFT172 intron 20339536 rs780106 chr2 27681598 A C 3.10E-08 Urate levels IFT172 intron 20884846 rs780106 chr2 27681598 A C 1.17E-15 Urate levels IFT172 intron 23263486 rs780107 chr2 27684734 A G 9.20E-06 Response to statin therapy IFT172 intron 20339536 rs780107 chr2 27684734 A G 2.90E-08 Urate levels IFT172 intron 20884846 rs780107 chr2 27684734 A G 1.25E-15 Urate levels IFT172 intron 23263486 rs780110 chr2 27685388 G A 4.30E-08 Response to statin therapy IFT172 intron 20339536 rs780110 chr2 27685388 G A 3.80E-11 Urate levels IFT172 intron 20884846 rs780110 chr2 27685388 G A 0.00000172 Body mass index IFT172 intron 22885924 rs780110 chr2 27685388 G A 3.82E-20 Fasting blood glucose IFT172 intron 22885924 rs780110 chr2 27685388 G A 9.11E-20 Urate levels IFT172 intron 23263486 rs1647276 chr2 27688601 C T 8.70E-06 Response to statin therapy IFT172 intron 20339536 rs1647276 chr2 27688601 C T 2.70E-08 Urate levels IFT172 intron 20884846 rs1647276 chr2 27688601 C T 1.39E-15 Urate levels IFT172 intron 23263486 rs1647266 chr2 27693485 T C 6.30E-06 Response to statin therapy IFT172 intron 20339536 rs1647266 chr2 27693485 T C 2.80E-08 Urate levels IFT172 intron 20884846 rs1647266 chr2 27693485 T C 1.42E-15 Urate levels IFT172 intron 23263486 rs780117 chr2 27698343 C G 8.50E-06 Response to statin therapy IFT172 intron 20339536 rs780117 chr2 27698343 C G 2.60E-08 Urate levels IFT172 intron 20884846 rs780117 chr2 27698343 C G 1.16E-15 Urate levels IFT172 intron 23263486 rs56047188 chr2 27699789 C T 4.56E-05 Intracerebral hemorrhage IFT172 intron 24656865 rs1260345 chr2 27703495 A G 3.10E-05 Response to statin therapy IFT172 intron 20339536 rs1260345 chr2 27703495 A G 7.03E-13 Urate levels IFT172 intron 23263486 rs2272417 chr2 27706640 T C 4.50E-05 Response to statin therapy IFT172 intron 20339536 rs2272417 chr2 27706640 T C 7.05E-06 Schizophrenia IFT172 intron 21926974 rs2272417 chr2 27706640 T C 3.39E-13 Urate levels IFT172 intron 23263486 rs58979173 chr2 27711157 A C 4.88E-05 Intracerebral hemorrhage IFT172 intron 24656865 rs7583698 chr2 27712408 C T 4.72E-05 Intracerebral hemorrhage IFT172 intron 24656865 rs8395 chr2 27715207 T A 8.30E-06 Response to statin therapy FNDC4 UTR-3 20339536 rs8395 chr2 27715207 T A 7.73E-13 Urate levels FNDC4 UTR-3 23263486 rs2303369 chr2 27715416 C T 6.80E-06 Response to statin therapy FNDC4 intron 20339536 rs2303369 chr2 27715416 C T 2.30E-08 Urate levels FNDC4 intron 20884846 rs2303369 chr2 27715416 C T 2.00E-12 Menopause (age at onset) FNDC4 intron 22267201 rs2303369 chr2 27715416 C T 5.17E-16 Urate levels FNDC4 intron 23263486 rs704795 chr2 27716494 G A 6.00E-06 Response to statin therapy FNDC4 intron 20339536 rs704795 chr2 27716494 G A 1.90E-08 Urate levels FNDC4 intron 20884846 rs704795 chr2 27716494 G A 1.50E-15 Urate levels FNDC4 intron 23263486 rs780090 chr2 27718474 T C 0.000000563 Cholesterol,total GCKR nearGene-5 23063622 rs780090 chr2 27718474 T C 9.30E-16 Triglycerides GCKR nearGene-5 23063622 rs780090 chr2 27718474 T C 6.01E-16 Urate levels GCKR nearGene-5 23263486 rs813592 chr2 27721971 T C 1.50E-06 Response to statin therapy GCKR intron 20339536 rs813592 chr2 27721971 T C 1.30E-08 Urate levels GCKR intron 20884846 rs813592 chr2 27721971 T C 4.96E-28 Triglycerides GCKR intron 23063622 rs813592 chr2 27721971 T C 2.70E-15 Urate levels GCKR intron 23263486 rs813592 chr2 27721971 T C 0.0000271 Schizophrenia GCKR intron 23637625 rs1260320 chr2 27722416 G A 1.40E-06 Response to statin therapy GCKR intron 20339536 rs1260320 chr2 27722416 G A 1.20E-08 Urate levels GCKR intron 20884846 rs1260320 chr2 27722416 G A 1.53E-15 Urate levels GCKR intron 23263486 rs2293572 chr2 27728777 C G 2.80E-06 Response to statin therapy GCKR intron 20339536 rs2293572 chr2 27728777 C G 1.10E-08 Urate levels GCKR intron 20884846 rs2293572 chr2 27728777 C G 3.75E-27 Triglycerides GCKR intron 23063622 rs2293572 chr2 27728777 C G 4.94E-16 Urate levels GCKR intron 23263486 rs2293571 chr2 27729480 G A 2.80E-06 Response to statin therapy GCKR intron 20339536 rs2293571 chr2 27729480 G A 1.30E-08 Urate levels GCKR intron 20884846 rs2293571 chr2 27729480 G A 3.21E-04 Lymphocyte counts GCKR intron 22286170 rs2293571 chr2 27729480 G A 6.40E-16 Urate levels GCKR intron 23263486 rs8179219 chr2 27730817 G A 4.87E-05 Intracerebral hemorrhage GCKR intron 24656865 rs1260326 chr2 27730940 T C 5.60E-22 Lipid levels GCKR missense 18193043 rs1260326 chr2 27730940 T C 4.00E-08 Waist circumference and related phenotypes GCKR missense 18454146 rs1260326 chr2 27730940 T C 2.30E-06 Crohn's disease GCKR missense 18587394 rs1260326 chr2 27730940 T C 2.00E-31 Triglycerides GCKR missense 19060906 rs1260326 chr2 27730940 T C 4.00E-10 Metabolic traits GCKR missense 19060910 rs1260326 chr2 27730940 T C 5.17E-17 Triglycerides GCKR missense 19060911 rs1260326 chr2 27730940 T C 1.82E-09 Uric acid levels GCKR missense 19503597 rs1260326 chr2 27730940 T C 1.30E-16 Lipid levels GCKR missense 19802338 rs1260326 chr2 27730940 T C 1.60E-06 Lipid levels GCKR missense 19802338 rs1260326 chr2 27730940 T C 9.90E-07 Lipid levels GCKR missense 19802338 rs1260326 chr2 27730940 T C 1.83E-07 Lipid levels GCKR missense 19913121 rs1260326 chr2 27730940 T C 1.00E-37 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 2.79E-28 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 2.87E-11 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 2.90E-35 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 3.40E-09 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 3.48E-29 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 3.60E-24 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 3.67E-17 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 4.45E-32 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 6.10E-15 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 6.20E-14 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 6.30E-36 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 7.20E-10 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 7.60E-16 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 7.78E-17 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 8.00E-28 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 8.39E-21 Lipid levels GCKR missense 19936222 rs1260326 chr2 27730940 T C 3.00E-10 Two-hour glucose challenge GCKR missense 20081857 rs1260326 chr2 27730940 T C 1.11E-11 Blood cell counts and other traits GCKR missense 20139978 rs1260326 chr2 27730940 T C 4.00E-09 Blood cell counts and other traits GCKR missense 20139978 rs1260326 chr2 27730940 T C 4.36E-09 Blood cell counts and other traits GCKR missense 20139978 rs1260326 chr2 27730940 T C 7.30E-05 Response to statin therapy GCKR missense 20339536 rs1260326 chr2 27730940 T C 3.00E-14 Chronic kidney disease GCKR missense 20383146 rs1260326 chr2 27730940 T C 7.00E-09 Hypertriglyceridemia GCKR missense 20657596 rs1260326 chr2 27730940 T C 6.00E-133 Triglycerides GCKR missense 20686565 rs1260326 chr2 27730940 T C 7.00E-27 Cholesterol,total GCKR missense 20686565 rs1260326 chr2 27730940 T C 2.04E-17 Protein C levels GCKR missense 20802025 rs1260326 chr2 27730940 T C 5.90E-17 Urate levels GCKR missense 20884846 rs1260326 chr2 27730940 T C 5.00E-40 C-reactive protein GCKR missense 21300955 rs1260326 chr2 27730940 T C 1.70E-28 FVII levels GCKR missense 21676895 rs1260326 chr2 27730940 T C 5.60E-25 FVII levels GCKR missense 21676895 rs1260326 chr2 27730940 T C 4.36E-09 Hepatitis B GCKR missense 21750111 rs1260326 chr2 27730940 T C 7.66E-14 Urate levels GCKR missense 21768215 rs1260326 chr2 27730940 T C 1.44E-08 Phospholipid levels (plasma) GCKR missense 21829377 rs1260326 chr2 27730940 T C 2.00E-08 Cardiovascular disease risk factors GCKR missense 21943158 rs1260326 chr2 27730940 T C 4.00E-13 Liver enzyme levels (gamma-glutamyl transferase) GCKR missense 22001757 rs1260326 chr2 27730940 T C 1.20E-08 Metabolic syndrome phenotype GCKR missense 22022282 rs1260326 chr2 27730940 T C 8.10E-16 Metabolic syndrome phenotype GCKR missense 22022282 rs1260326 chr2 27730940 T C 9.00E-10 Platelet counts GCKR missense 22139419 rs1260326 chr2 27730940 T C 2.61E-04 Triglycerides GCKR missense 22171074 rs1260326 chr2 27730940 T C 3.00E-18 Metabolite levels GCKR missense 22286219 rs1260326 chr2 27730940 T C 4.48E-12 Chronic kidney disease GCKR missense 22479191 rs1260326 chr2 27730940 T C 3.00E-09 Non-albumin protein levels GCKR missense 22558069 rs1260326 chr2 27730940 T C 1.27E-18 Triglycerides (males) GCKR missense 22629316 rs1260326 chr2 27730940 T C 1.75E-20 Triglycerides (females) GCKR missense 22629316 rs1260326 chr2 27730940 T C 6.79E-35 Triglycerides GCKR missense 22629316 rs1260326 chr2 27730940 T C 2.17E-41 Fasting blood glucose GCKR missense 22885924 rs1260326 chr2 27730940 T C 2.74E-22 Fasting insulin-related traits GCKR missense 22885924 rs1260326 chr2 27730940 T C 9.04E-15 2-hour glucose tolerance test GCKR missense 22885924 rs1260326 chr2 27730940 T C 1.00E-12 Metabolite levels (atherosclerosis) GCKR missense 22916037 rs1260326 chr2 27730940 T C 2.00E-08 Serum albumin level GCKR missense 23022100 rs1260326 chr2 27730940 T C 3.00E-14 Serum albumin level GCKR missense 23022100 rs1260326 chr2 27730940 T C 4.00E-06 Serum total protein level GCKR missense 23022100 rs1260326 chr2 27730940 T C 4.00E-19 Serum albumin level GCKR missense 23022100 rs1260326 chr2 27730940 T C 6.00E-08 Serum total protein level GCKR missense 23022100 rs1260326 chr2 27730940 T C 1.17E-42 Triglycerides in males GCKR missense 23063622 rs1260326 chr2 27730940 T C 2.33E-19 Cholesterol,total GCKR missense 23063622 rs1260326 chr2 27730940 T C 3.90E-38 Triglycerides in females GCKR missense 23063622 rs1260326 chr2 27730940 T C 4.05E-88 Triglycerides GCKR missense 23063622 rs1260326 chr2 27730940 T C 5.08E-98 Triglycerides GCKR missense 23063622 rs1260326 chr2 27730940 T C 5.00E-06 Lipoprotein-associated phospholipase A2 activity and mass GCKR missense 23118302 rs1260326 chr2 27730940 T C 1.34E-08 Triglycerides GCKR missense 23236364 rs1260326 chr2 27730940 T C 1.00E-44 Urate levels GCKR missense 23263486 rs1260326 chr2 27730940 T C 5.41E-09 C-reactive protein GCKR missense 23505291 rs1260326 chr2 27730940 T C 2.00E-13 Hypertriglyceridemia GCKR missense 23505323 rs1260326 chr2 27730940 T C 1.30E-04 Glomerular filtration rate GCKR missense 23535967 rs1260326 chr2 27730940 T C 1.50E-04 Glomerular filtration rate GCKR missense 23535967 rs1260326 chr2 27730940 T C 2.00E-04 Glomerular filtration rate GCKR missense 23535967 rs1260326 chr2 27730940 T C 2.30E-05 Glomerular filtration rate GCKR missense 23535967 rs1260326 chr2 27730940 T C 2.70E-04 Glomerular filtration rate GCKR missense 23535967 rs1260326 chr2 27730940 T C 3.70E-04 Glomerular filtration rate GCKR missense 23535967 rs1260326 chr2 27730940 T C 4.30E-04 Glomerular filtration rate GCKR missense 23535967 rs1260326 chr2 27730940 T C 5.00E-07 Glomerular filtration rate GCKR missense 23535967 rs1260326 chr2 27730940 T C 8.90E-05 Glomerular filtration rate GCKR missense 23535967 rs1260326 chr2 27730940 T C 1.45E-08 Glycemic traits (pregnancy) GCKR missense 23903356 rs1260326 chr2 27730940 T C 2.31E-07 Glycemic traits (pregnancy) GCKR missense 23903356 rs1260326 chr2 27730940 T C 2.62E-11 Glycemic traits (pregnancy) GCKR missense 23903356 rs1260326 chr2 27730940 T C 2.94E-11 Glycemic traits (pregnancy) GCKR missense 23903356 rs1260326 chr2 27730940 T C 3.73E-04 Glycemic traits (pregnancy) GCKR missense 23903356 rs1260326 chr2 27730940 T C 6.00E-11 Glycemic traits (pregnancy) GCKR missense 23903356 rs1260326 chr2 27730940 T C 6.00E-13 Glycemic traits (pregnancy) GCKR missense 23903356 rs1260326 chr2 27730940 T C 7.38E-05 Glycemic traits (pregnancy) GCKR missense 23903356 rs1260326 chr2 27730940 T C 2.00E-239 Triglycerides GCKR missense 24097068 rs1260326 chr2 27730940 T C 3.00E-42 Cholesterol,total GCKR missense 24097068 rs1260326 chr2 27730940 T C 3.00E-07 Lipid traits GCKR missense 24386095 rs1260326 chr2 27730940 T C 1.00E-77 Blood metabolite levels GCKR missense 24816252 rs1260326 chr2 27730940 T C 3.00E-148 Blood metabolite ratios GCKR missense 24816252 rs1260326 chr2 27730940 T C 6.00E-14 Blood metabolite levels GCKR missense 24816252 rs1260326 chr2 27730940 T C 3.56E-10 Triglycerides GCKR missense pha002904 rs1260326 chr2 27730940 T C 1.80E-05 Cholesterol GCKR missense pha003073 rs1260326 chr2 27730940 T C 3.35E-05 Cholesterol GCKR missense pha003078 rs1260326 chr2 27730940 T C 3.89E-05 Triglycerides GCKR missense pha003080 rs3817588 chr2 27731212 T C 4.10E-08 Non-albumin protein levels GCKR intron 22558069 rs3817588 chr2 27731212 T C 1.70E-10 Urate levels GCKR intron 23263486 rs4425043 chr2 27733452 G A 2.70E-06 Response to statin therapy GCKR intron 20339536 rs4425043 chr2 27733452 G A 1.20E-08 Urate levels GCKR intron 20884846 rs4425043 chr2 27733452 G A 2.89E-04 FVII levels GCKR intron 21676895 rs4425043 chr2 27733452 G A 9.30E-06 FVII levels GCKR intron 21676895 rs4425043 chr2 27733452 G A 8.55E-16 Urate levels GCKR intron 23263486 rs6547692 chr2 27734972 G A 1.11E-11 Metabolite levels GCKR intron 22286219 rs62131877 chr2 27740328 C T 2.95E-05 Intracerebral hemorrhage GCKR intron 24656865 rs780096 chr2 27741072 C G 6.22E-13 Metabolite levels GCKR intron 22286219 rs780095 chr2 27741105 A G 6.25E-13 Metabolite levels GCKR intron 22286219 rs780094 chr2 27741237 T C 1.00E-15 Type 2 diabetes GCKR intron 17463246 rs780094 chr2 27741237 T C 1.88E-05 Multiple complex diseases GCKR intron 17554300 rs780094 chr2 27741237 T C 5.00E-07 LDL cholesterol GCKR intron 18179892 rs780094 chr2 27741237 T C 6.00E-32 Triglycerides GCKR intron 18193043 rs780094 chr2 27741237 T C 3.00E-14 Triglycerides GCKR intron 18193044 rs780094 chr2 27741237 T C 7.00E-15 C-reactive protein GCKR intron 18439548 rs780094 chr2 27741237 T C 1.50E-07 Crohn's disease GCKR intron 18587394 rs780094 chr2 27741237 T C 3.00E-20 Triglycerides GCKR intron 19060911 rs780094 chr2 27741237 T C 1.00E-09 Uric acid levels GCKR intron 19503597 rs780094 chr2 27741237 T C 1.50E-15 Lipid levels GCKR intron 19802338 rs780094 chr2 27741237 T C 1.07E-17 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 1.56E-13 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 1.70E-09 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 2.60E-19 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 2.67E-13 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 2.87E-16 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 3.10E-17 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 3.30E-12 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 3.79E-19 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 4.50E-08 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 6.98E-10 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 8.60E-18 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 9.80E-13 Lipid levels GCKR intron 19936222 rs780094 chr2 27741237 T C 3.06E-06 Response to statin treatment (atorvastatin),change in cholesterol levels GCKR intron 20031582 rs780094 chr2 27741237 T C 3.00E-24 Fasting insulin-related traits GCKR intron 20081858 rs780094 chr2 27741237 T C 4.00E-20 Fasting insulin-related traits GCKR intron 20081858 rs780094 chr2 27741237 T C 6.00E-38 Fasting insulin-related traits GCKR intron 20081858 rs780094 chr2 27741237 T C 5.00E-06 Blood cell counts and other traits GCKR intron 20139978 rs780094 chr2 27741237 T C 5.12E-06 Blood cell counts and other traits GCKR intron 20139978 rs780094 chr2 27741237 T C 3.80E-07 Fasting glucose-related traits GCKR intron 20152958 rs780094 chr2 27741237 T C 1.20E-14 Response to statin therapy GCKR intron 20339536 rs780094 chr2 27741237 T C 9.30E-06 Calcium levels GCKR intron 20705733 rs780094 chr2 27741237 T C 1.89E-16 Protein C levels GCKR intron 20802025 rs780094 chr2 27741237 T C 4.70E-17 Urate levels GCKR intron 20884846 rs780094 chr2 27741237 T C 1.00E-05 Height GCKR intron 21194676 rs780094 chr2 27741237 T C 1.50E-05 Height GCKR intron 21194676 rs780094 chr2 27741237 T C 2.20E-11 Height GCKR intron 21194676 rs780094 chr2 27741237 T C 5.00E-07 Coronary heart disease GCKR intron 21347282 rs780094 chr2 27741237 T C 2.56E-04 Nonalcoholic fatty liver disease GCKR intron 21423719 rs780094 chr2 27741237 T C 6.44E-13 Urate levels GCKR intron 21768215 rs780094 chr2 27741237 T C 9.00E-09 Phospholipid levels (plasma) GCKR intron 21829377 rs780094 chr2 27741237 T C 1.20E-04 Type 2 diabetes GCKR intron 21874001 rs780094 chr2 27741237 T C 6.00E-53 Metabolic traits GCKR intron 21886157 rs780094 chr2 27741237 T C 7.10E-04 Urate (in serum),gout GCKR intron 21983786 rs780094 chr2 27741237 T C 2.04E-16 Metabolite levels GCKR intron 22286219 rs780094 chr2 27741237 T C 0.000000212 Type 2 diabetes GCKR intron 22325160 rs780094 chr2 27741237 T C 6.00E-20 Metabolic syndrome GCKR intron 22399527 rs780094 chr2 27741237 T C 3.00E-10 Fasting insulin-related traits (interaction with BMI) GCKR intron 22581228 rs780094 chr2 27741237 T C 4.00E-24 Fasting glucose-related traits (interaction with BMI) GCKR intron 22581228 rs780094 chr2 27741237 T C 0.00000076 HOMA-IR GCKR intron 22885922 rs780094 chr2 27741237 T C 0.000047 Type 2 diabetes (males) GCKR intron 22885922 rs780094 chr2 27741237 T C 7.10E-14 Fasting insulin-related traits GCKR intron 22885922 rs780094 chr2 27741237 T C 1.04E-10 2-hour glucose tolerance test GCKR intron 22885924 rs780094 chr2 27741237 T C 2.58E-37 Fasting blood glucose GCKR intron 22885924 rs780094 chr2 27741237 T C 7.37E-20 Fasting insulin-related traits GCKR intron 22885924 rs780094 chr2 27741237 T C 1.80E-13 Cholesterol,total GCKR intron 23063622 rs780094 chr2 27741237 T C 3.00E-78 Triglycerides GCKR intron 23063622 rs780094 chr2 27741237 T C 6.52E-39 Urate levels GCKR intron 23263486 rs780094 chr2 27741237 T C 0.000000039 C-reactive protein GCKR intron 23505291 rs780094 chr2 27741237 T C 7.00E-09 Triglycerides GCKR intron 23726366 rs780094 chr2 27741237 T C 2.09E-04 Glycemic traits (pregnancy) GCKR intron 23903356 rs780094 chr2 27741237 T C 2.53E-06 Glycemic traits (pregnancy) GCKR intron 23903356 rs780094 chr2 27741237 T C 3.30E-06 Glycemic traits (pregnancy) GCKR intron 23903356 rs780094 chr2 27741237 T C 3.42E-11 Glycemic traits (pregnancy) GCKR intron 23903356 rs780094 chr2 27741237 T C 1.00E-10 Calcium levels GCKR intron 24068962 rs780094 chr2 27741237 T C 1.00E-05 Type 2 diabetes GCKR intron 24509480 rs780094 chr2 27741237 T C 5.03E-09 Triglycerides GCKR intron pha002904 rs780094 chr2 27741237 T C 5.59E-05 Cholesterol GCKR intron pha003073 rs780094 chr2 27741237 T C 9.61E-05 Cholesterol GCKR intron pha003078 rs780093 chr2 27742603 T C 1.50E-17 Lipid levels GCKR intron 18193043 rs780093 chr2 27742603 T C 2.94E-09 Uric acid levels GCKR intron 19503597 rs780093 chr2 27742603 T C 1.30E-14 Response to statin therapy GCKR intron 20339536 rs780093 chr2 27742603 T C 7.00E-06 Calcium levels GCKR intron 20705733 rs780093 chr2 27742603 T C 5.63E-17 Protein C levels GCKR intron 20802025 rs780093 chr2 27742603 T C 4.00E-17 Urate levels GCKR intron 20884846 rs780093 chr2 27742603 T C 5.00E-11 Crohn's disease GCKR intron 21102463 rs780093 chr2 27742603 T C 2.00E-12 Waist Circumference - Triglycerides (WC-TG) GCKR intron 21386085 rs780093 chr2 27742603 T C 3.00E-10 Triglycerides-Blood Pressure (TG-BP) GCKR intron 21386085 rs780093 chr2 27742603 T C 7.49E-13 Urate levels GCKR intron 21768215 rs780093 chr2 27742603 T C 2.04E-08 Phospholipid levels (plasma) GCKR intron 21829377 rs780093 chr2 27742603 T C 8.20E-04 Urate (in serum),gout GCKR intron 21983786 rs780093 chr2 27742603 T C 1.64E-16 Metabolite levels GCKR intron 22286219 rs780093 chr2 27742603 T C 5.00E-06 Breast size GCKR intron 22747683 rs780093 chr2 27742603 T C 2.00E-16 Sex hormone-binding globulin levels GCKR intron 22829776 rs780093 chr2 27742603 T C 7.00E-08 Sex hormone-binding globulin levels GCKR intron 22829776 rs780093 chr2 27742603 T C 9.00E-11 Sex hormone-binding globulin levels GCKR intron 22829776 rs780093 chr2 27742603 T C 2.41E-78 Triglycerides GCKR intron 23063622 rs780093 chr2 27742603 T C 2.52E-13 Cholesterol,total GCKR intron 23063622 rs780093 chr2 27742603 T C 3.65E-39 Urate levels GCKR intron 23263486 rs780093 chr2 27742603 T C 1.00E-09 Palmitoleic acid (16:1n-7) plasma levels GCKR intron 23362303 rs780093 chr2 27742603 T C 3.00E-06 Palmitic acid (16:0) plasma levels GCKR intron 23362303 rs780093 chr2 27742603 T C 6.79E-08 C-reactive protein GCKR intron 23505291 rs780093 chr2 27742603 T C 3.37E-07 Glycemic traits (pregnancy) GCKR intron 23903356 rs780093 chr2 27742603 T C 8.85E-10 Glycemic traits (pregnancy) GCKR intron 23903356 rs780092 chr2 27743154 A G 5.00E-18 Metabolite levels GCKR intron 21909109 rs780092 chr2 27743154 A G 5.00E-27 Triglycerides GCKR intron 21909109 rs780092 chr2 27743154 A G 2.84E-07 Non-albumin protein levels GCKR intron 22558069 rs780092 chr2 27743154 A G 8.46E-10 Urate levels GCKR intron 23263486 rs780092 chr2 27743154 A G 2.85E-06 Glycemic traits (pregnancy) GCKR intron 23903356 rs780092 chr2 27743154 A G 6.63E-07 Glycemic traits (pregnancy) GCKR intron 23903356 rs780092 chr2 27743154 A G 2.00E-09 Lipid traits GCKR intron 24023260 rs814295 chr2 27743215 A G 3.11E-07 Non-albumin protein levels GCKR intron 22558069 rs814295 chr2 27743215 A G 0.000000281 Cholesterol,total GCKR intron 23063622 rs814295 chr2 27743215 A G 4.97E-15 Triglycerides GCKR intron 23063622 rs814295 chr2 27743215 A G 3.23E-09 Urate levels GCKR intron 23263486 rs814295 chr2 27743215 A G 1.23E-06 Glycemic traits (pregnancy) GCKR intron 23903356 rs11681351 chr2 27743423 G A 1.40E-06 Response to statin therapy GCKR intron 20339536 rs11681351 chr2 27743423 G A 1.60E-08 Urate levels GCKR intron 20884846 rs11681351 chr2 27743423 G A 0.000077 post-traumatic stress disorder GCKR intron 22869035 rs11681351 chr2 27743423 G A 7.70E-05 Schizophrenia GCKR intron 22883433 rs11681351 chr2 27743423 G A 2.22E-25 Triglycerides GCKR intron 23063622 rs11681351 chr2 27743423 G A 7.62E-15 Urate levels GCKR intron 23263486 rs704790 chr2 27746410 G A 2.28E-08 Triglycerides GCKR UTR-3 23063622 rs8179252 chr2 27746832 A C 8.82E-04 Multiple complex diseases GCKR nearGene-3 17554300 rs8179252 chr2 27746832 A C 1.60E-06 Response to statin therapy GCKR nearGene-3 20339536 rs8179252 chr2 27746832 A C 0.000077 post-traumatic stress disorder GCKR nearGene-3 22869035 rs8179252 chr2 27746832 A C 7.70E-05 Schizophrenia GCKR nearGene-3 22883433 rs8179252 chr2 27746832 A C 1.02E-14 Urate levels GCKR nearGene-3 23263486 rs1260334 chr2 27748597 C A 1.37E-12 Metabolite levels / / 22286219 rs1260333 chr2 27748624 A G 3.19E-08 Uric acid levels / / 19503597 rs1260333 chr2 27748624 A G 7.20E-10 Lipid levels / / 19802338 rs1260333 chr2 27748624 A G 1.40E-11 Response to statin therapy / / 20339536 rs1260333 chr2 27748624 A G 1.57E-13 Protein C levels / / 20802025 rs1260333 chr2 27748624 A G 2.00E-19 Triglycerides / / 20864672 rs1260333 chr2 27748624 A G 4.30E-13 Urate levels / / 20884846 rs1260333 chr2 27748624 A G 6.36E-12 Urate levels / / 21768215 rs1260333 chr2 27748624 A G 7.67E-07 Phospholipid levels (plasma) / / 21829377 rs1260333 chr2 27748624 A G 1.35E-11 Metabolite levels / / 22286219 rs1260333 chr2 27748624 A G 5.02E-33 Urate levels / / 23263486 rs1260333 chr2 27748624 A G 2.87E-06 Glycemic traits (pregnancy) / / 23903356 rs1260333 chr2 27748624 A G 3.33E-10 Glycemic traits (pregnancy) / / 23903356 rs1260333 chr2 27748624 A G 4.71E-07 Glycemic traits (pregnancy) / / 23903356 rs1260333 chr2 27748624 A G 7.81E-10 Glycemic traits (pregnancy) / / 23903356 rs1313566 chr2 27748904 G A 1.36E-12 Metabolite levels / / 22286219 rs200826320 chr2 27750545 AT A 1.81E-12 Metabolite levels / / 22286219 rs2950835 chr2 27750545 A G 1.81E-12 Metabolite levels / / 22286219 rs2911711 chr2 27750546 T A 1.40E-11 Response to statin therapy / / 20339536 rs2911711 chr2 27750546 T A 1.53E-13 Protein C levels / / 20802025 rs2911711 chr2 27750546 T A 4.10E-13 Urate levels / / 20884846 rs2911711 chr2 27750546 T A 6.99E-12 Urate levels / / 21768215 rs2911711 chr2 27750546 T A 7.65E-07 Phospholipid levels (plasma) / / 21829377 rs2911711 chr2 27750546 T A 2.43E-12 Metabolite levels / / 22286219 rs2911711 chr2 27750546 T A 4.55E-33 Urate levels / / 23263486 rs2911711 chr2 27750546 T A 2.53E-09 Glycemic traits (pregnancy) / / 23903356 rs2911711 chr2 27750546 T A 5.66E-07 Glycemic traits (pregnancy) / / 23903356 rs6753534 chr2 27752871 C T 1.33E-13 Metabolite levels / / 22286219 rs4665987 chr2 27755825 G A 4.70E-08 Response to statin therapy / / 20339536 rs4665987 chr2 27755825 G A 1.38E-10 Protein C levels / / 20802025 rs4665987 chr2 27755825 G A 3.90E-07 Urate levels / / 20884846 rs4665987 chr2 27755825 G A 4.55E-08 Urate levels / / 21768215 rs4665987 chr2 27755825 G A 1.66E-12 Metabolite levels / / 22286219 rs4665987 chr2 27755825 G A 8.80E-05 Renal function-related traits (urea) / / 22797727 rs4665987 chr2 27755825 G A 4.35E-13 Urate levels / / 23263486 rs12473139 chr2 27765587 T C 1.61E-12 Metabolite levels / / 22286219 rs4665991 chr2 27766284 G A 1.00E-07 Response to statin therapy / / 20339536 rs4665991 chr2 27766284 G A 1.83E-10 Protein C levels / / 20802025 rs4665991 chr2 27766284 G A 6.48E-08 Urate levels / / 21768215 rs4665991 chr2 27766284 G A 1.34E-12 Metabolite levels / / 22286219 rs4665991 chr2 27766284 G A 7.11E-13 Urate levels / / 23263486 rs12995461 chr2 27778167 A C 1.63E-12 Metabolite levels / / 22286219 rs10169065 chr2 27778560 A G 9.14E-11 Metabolite levels / / 22286219 rs10179872 chr2 27778572 G A 9.14E-11 Metabolite levels / / 22286219 rs4665382 chr2 27783801 T C 1.10E-07 Response to statin therapy / / 20339536 rs4665382 chr2 27783801 T C 2.12E-10 Protein C levels / / 20802025 rs4665382 chr2 27783801 T C 7.92E-08 Urate levels / / 21768215 rs4665382 chr2 27783801 T C 1.56E-12 Metabolite levels / / 22286219 rs4665382 chr2 27783801 T C 6.13E-13 Urate levels / / 23263486 rs4665382 chr2 27783801 T C 1.93E-06 Glycemic traits (pregnancy) / / 23903356 rs7570476 chr2 27784658 C T 1.63E-12 Metabolite levels / / 22286219 rs10208529 chr2 27786188 A T 9.20E-08 Response to statin therapy / / 20339536 rs10208529 chr2 27786188 A T 2.18E-10 Protein C levels / / 20802025 rs10208529 chr2 27786188 A T 8.74E-08 Urate levels / / 21768215 rs10208529 chr2 27786188 A T 2.26E-11 Metabolite levels / / 22286219 rs10208529 chr2 27786188 A T 6.28E-13 Urate levels / / 23263486 rs4665383 chr2 27791555 C G 9.20E-08 Response to statin therapy / / 20339536 rs4665383 chr2 27791555 C G 8.78E-11 Protein C levels / / 20802025 rs4665383 chr2 27791555 C G 9.24E-08 Urate levels / / 21768215 rs4665383 chr2 27791555 C G 1.66E-12 Metabolite levels / / 22286219 rs4665383 chr2 27791555 C G 6.35E-13 Urate levels / / 23263486 rs7577311 chr2 27793921 G T 1.65E-12 Metabolite levels / / 22286219 rs10205364 chr2 27794233 C T 0.0000912 post-traumatic stress disorder / / 22869035 rs10205364 chr2 27794233 C T 9.12E-05 Schizophrenia / / 22883433 rs1919125 chr2 27801403 C G 0.000093 post-traumatic stress disorder C2orf16 missense 22869035 rs1919125 chr2 27801403 C G 9.30E-05 Schizophrenia C2orf16 missense 22883433 rs1919126 chr2 27801418 C A 0.0000902 post-traumatic stress disorder C2orf16 missense 22869035 rs1919126 chr2 27801418 C A 9.02E-05 Schizophrenia C2orf16 missense 22883433 rs1919126 chr2 27801418 C A 4.24E-09 Triglycerides C2orf16 missense 23063622 rs1919127 chr2 27801493 T C 1.24E-08 Triglycerides C2orf16 missense 19060911 rs1919127 chr2 27801493 T C 2.00E-07 Response to statin therapy C2orf16 missense 20339536 rs1919127 chr2 27801493 T C 2.27E-10 Protein C levels C2orf16 missense 20802025 rs1919127 chr2 27801493 T C 1.17E-07 Urate levels C2orf16 missense 21768215 rs1919127 chr2 27801493 T C 2.20E-12 Metabolite levels C2orf16 missense 22286219 rs1919127 chr2 27801493 T C 7.33E-13 Urate levels C2orf16 missense 23263486 rs1919127 chr2 27801493 T C 5.24E-06 Glycemic traits (pregnancy) C2orf16 missense 23903356 rs1919127 chr2 27801493 T C 5.76E-05 Triglycerides C2orf16 missense pha002904 rs1919128 chr2 27801759 A G 8.70E-08 Response to statin therapy C2orf16 missense 20339536 rs1919128 chr2 27801759 A G 2.24E-10 Protein C levels C2orf16 missense 20802025 rs1919128 chr2 27801759 A G 2.00E-09 Waist Circumference - Triglycerides (WC-TG) C2orf16 missense 21386085 rs1919128 chr2 27801759 A G 9.29E-08 Urate levels C2orf16 missense 21768215 rs1919128 chr2 27801759 A G 1.75E-12 Metabolite levels C2orf16 missense 22286219 rs1919128 chr2 27801759 A G 1.22E-33 Triglycerides C2orf16 missense 23063622 rs1919128 chr2 27801759 A G 5.85E-13 Urate levels C2orf16 missense 23263486 rs1919128 chr2 27801759 A G 0.00001 C-reactive protein C2orf16 missense 23505291 rs1919128 chr2 27801759 A G 6.38E-06 Glycemic traits (pregnancy) C2orf16 missense 23903356 rs13026621 chr2 27807624 G A 0.0000902 post-traumatic stress disorder ZNF512 intron 22869035 rs13026621 chr2 27807624 G A 9.02E-05 Schizophrenia ZNF512 intron 22883433 rs12478841 chr2 27811722 A G 8.30E-08 Response to statin therapy ZNF512 intron 20339536 rs12478841 chr2 27811722 A G 2.11E-10 Protein C levels ZNF512 intron 20802025 rs12478841 chr2 27811722 A G 1.17E-07 Urate levels ZNF512 intron 21768215 rs12478841 chr2 27811722 A G 1.65E-12 Metabolite levels ZNF512 intron 22286219 rs12478841 chr2 27811722 A G 6.85E-13 Urate levels ZNF512 intron 23263486 rs12478841 chr2 27811722 A G 3.16E-06 Glycemic traits (pregnancy) ZNF512 intron 23903356 rs6760250 chr2 27812252 G A 8.80E-08 Response to statin therapy ZNF512 intron 20339536 rs6760250 chr2 27812252 G A 2.08E-10 Protein C levels ZNF512 intron 20802025 rs6760250 chr2 27812252 G A 1.18E-07 Urate levels ZNF512 intron 21768215 rs6760250 chr2 27812252 G A 1.70E-12 Metabolite levels ZNF512 intron 22286219 rs6760250 chr2 27812252 G A 6.73E-13 Urate levels ZNF512 intron 23263486 rs6760250 chr2 27812252 G A 2.72E-06 Glycemic traits (pregnancy) ZNF512 intron 23903356 rs13022873 chr2 27815510 A C 8.20E-08 Response to statin therapy ZNF512 intron 20339536 rs13022873 chr2 27815510 A C 1.99E-10 Protein C levels ZNF512 intron 20802025 rs13022873 chr2 27815510 A C 5.00E-09 Waist Circumference - Triglycerides (WC-TG) ZNF512 intron 21386085 rs13022873 chr2 27815510 A C 1.16E-07 Urate levels ZNF512 intron 21768215 rs13022873 chr2 27815510 A C 1.50E-12 Metabolite levels ZNF512 intron 22286219 rs13022873 chr2 27815510 A C 6.22E-11 Urate levels ZNF512 intron 23263486 rs13022873 chr2 27815510 A C 3.32E-06 Glycemic traits (pregnancy) ZNF512 intron 23903356 rs12467476 chr2 27825715 T C 7.90E-08 Response to statin therapy ZNF512 intron 20339536 rs12467476 chr2 27825715 T C 1.88E-10 Protein C levels ZNF512 intron 20802025 rs12467476 chr2 27825715 T C 1.17E-07 Urate levels ZNF512 intron 21768215 rs12467476 chr2 27825715 T C 1.69E-12 Metabolite levels ZNF512 intron 22286219 rs12467476 chr2 27825715 T C 5.52E-13 Urate levels ZNF512 intron 23263486 rs12467476 chr2 27825715 T C 3.25E-06 Glycemic traits (pregnancy) ZNF512 intron 23903356 rs12464616 chr2 27827092 C T 1.70E-12 Metabolite levels ZNF512 intron 22286219 rs6547735 chr2 27831607 T C 0.000000019 Triglycerides ZNF512 intron 23063622 rs2384656 chr2 27832055 A G 5.50E-08 Response to statin therapy ZNF512 intron 20339536 rs2384656 chr2 27832055 A G 1.71E-10 Protein C levels ZNF512 intron 20802025 rs2384656 chr2 27832055 A G 1.16E-07 Urate levels ZNF512 intron 21768215 rs2384656 chr2 27832055 A G 2.97E-12 Metabolite levels ZNF512 intron 22286219 rs2384656 chr2 27832055 A G 7.07E-13 Urate levels ZNF512 intron 23263486 rs2384656 chr2 27832055 A G 4.42E-06 Glycemic traits (pregnancy) ZNF512 intron 23903356 rs12987055 chr2 27834152 T C 1.72E-12 Metabolite levels ZNF512 intron 22286219 rs13020949 chr2 27836605 C T 1.57E-12 Metabolite levels ZNF512 intron 22286219 rs4666000 chr2 27839369 T C 5.10E-07 Response to statin therapy ZNF512 intron 20339536 rs4666000 chr2 27839369 T C 5.95E-10 Protein C levels ZNF512 intron 20802025 rs4666000 chr2 27839369 T C 6.12E-08 Urate levels ZNF512 intron 21768215 rs4666000 chr2 27839369 T C 2.99E-11 Metabolite levels ZNF512 intron 22286219 rs4666000 chr2 27839369 T C 4.17E-11 Urate levels ZNF512 intron 23263486 rs4666000 chr2 27839369 T C 3.79E-06 Glycemic traits (pregnancy) ZNF512 intron 23903356 rs2068834 chr2 27839539 T C 8.30E-07 Response to statin therapy ZNF512 intron 20339536 rs2068834 chr2 27839539 T C 7.16E-10 Protein C levels ZNF512 intron 20802025 rs2068834 chr2 27839539 T C 6.35E-08 Urate levels ZNF512 intron 21768215 rs2068834 chr2 27839539 T C 2.68E-11 Metabolite levels ZNF512 intron 22286219 rs2068834 chr2 27839539 T C 0.000006444 2-hour glucose tolerance test ZNF512 intron 22885924 rs2068834 chr2 27839539 T C 1.24E-09 Body mass index ZNF512 intron 22885924 rs2068834 chr2 27839539 T C 9.68E-20 Fasting blood glucose ZNF512 intron 22885924 rs2068834 chr2 27839539 T C 8.98E-33 Triglycerides ZNF512 intron 23063622 rs2068834 chr2 27839539 T C 4.28E-11 Urate levels ZNF512 intron 23263486 rs2068834 chr2 27839539 T C 0.000028 C-reactive protein ZNF512 intron 23505291 rs2068834 chr2 27839539 T C 3.01E-06 Glycemic traits (pregnancy) ZNF512 intron 23903356 rs4666002 chr2 27840640 G C 6.30E-08 Response to statin therapy ZNF512 intron 20339536 rs4666002 chr2 27840640 G C 1.07E-10 Protein C levels ZNF512 intron 20802025 rs4666002 chr2 27840640 G C 1.90E-12 Metabolite levels ZNF512 intron 22286219 rs4666002 chr2 27840640 G C 7.00E-11 Phospholipid levels (plasma) ZNF512 intron 22359512 rs4666002 chr2 27840640 G C 3.52E-10 Urate levels ZNF512 intron 23263486 rs1881396 chr2 27844601 T G 3.80E-05 Mathematical ability ZNF512 UTR-3 20039944 rs1528404 chr2 27846603 T C 1.70E-04 Lymphocyte counts / / 22286170 rs4665384 chr2 27848397 A G 0.000000108 Triglycerides / / 23063622 rs12615690 chr2 27851120 T C 7.33E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CCDC121 intron 20031582 rs3749147 chr2 27851918 G A 3.30E-08 Response to statin therapy GPN1 missense 20339536 rs3749147 chr2 27851918 G A 3.04E-11 Protein C levels GPN1 missense 20802025 rs3749147 chr2 27851918 G A 1.00E-09 Waist Circumference - Triglycerides (WC-TG) GPN1 missense 21386085 rs3749147 chr2 27851918 G A 2.56E-07 Urate levels GPN1 missense 21768215 rs3749147 chr2 27851918 G A 1.11E-12 Metabolite levels GPN1 missense 22286219 rs3749147 chr2 27851918 G A 1.62E-09 Urate levels GPN1 missense 23263486 rs13002853 chr2 27853245 C G 3.20E-08 Response to statin therapy GPN1 intron 20339536 rs13002853 chr2 27853245 C G 3.39E-11 Protein C levels GPN1 intron 20802025 rs13002853 chr2 27853245 C G 2.76E-07 Urate levels GPN1 intron 21768215 rs13002853 chr2 27853245 C G 1.20E-12 Metabolite levels GPN1 intron 22286219 rs13002853 chr2 27853245 C G 8.92E-12 Urate levels GPN1 intron 23263486 rs6547740 chr2 27854369 G A 7.87E-04 Prostate cancer mortality GPN1 intron 20978177 rs34502053 chr2 27854524 G A 8.78E-13 Metabolite levels GPN1 intron 22286219 rs4666005 chr2 27855239 A G 7.12E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GPN1 intron 20031582 rs4666005 chr2 27855239 A G 0.0000683 post-traumatic stress disorder GPN1 intron 22869035 rs4666005 chr2 27855239 A G 6.83E-05 Schizophrenia GPN1 intron 22883433 rs1528402 chr2 27857517 G A 0.0000298 post-traumatic stress disorder GPN1 intron 22869035 rs1528402 chr2 27857517 G A 2.98E-05 Schizophrenia GPN1 intron 22883433 rs111571364 chr2 27859317 G T 8.00E-06 Periodontitis (CDC/AAP) GPN1 intron 24024966 rs114940462 chr2 27861618 G T 3.98E-05 Intracerebral hemorrhage GPN1 intron 24656865 rs2272406 chr2 27892023 A T 8.40E-06 Response to statin therapy SLC4A1AP intron 20339536 rs2272406 chr2 27892023 A T 1.89E-08 Protein C levels SLC4A1AP intron 20802025 rs2272406 chr2 27892023 A T 5.80E-09 Urate levels SLC4A1AP intron 23263486 rs2178198 chr2 27895073 C T 1.58E-12 Urate levels SLC4A1AP intron 23263486 rs17006206 chr2 27907473 A G 2.00E-06 Alzheimer's disease SLC4A1AP intron 22159054 rs13023094 chr2 27910706 A C 1.70E-05 Response to statin therapy SLC4A1AP intron 20339536 rs13023094 chr2 27910706 A C 2.52E-08 Protein C levels SLC4A1AP intron 20802025 rs13023094 chr2 27910706 A C 7.05E-05 Nephrolithiasis SLC4A1AP intron 22396660 rs13023094 chr2 27910706 A C 0.000021 Endometrial cancer SLC4A1AP intron 22426144 rs13023094 chr2 27910706 A C 8.12E-09 Urate levels SLC4A1AP intron 23263486 rs13030973 chr2 27928797 T C 5.90E-06 Response to statin therapy / / 20339536 rs13030973 chr2 27928797 T C 4.77E-08 Protein C levels / / 20802025 rs13030973 chr2 27928797 T C 1.62E-08 Urate levels / / 23263486 rs6727388 chr2 27932587 A G 6.30E-06 Response to statin therapy / / 20339536 rs6727388 chr2 27932587 A G 4.80E-08 Protein C levels / / 20802025 rs6727388 chr2 27932587 A G 1.49E-08 Urate levels / / 23263486 rs4616435 chr2 27933642 C T 6.20E-06 Response to statin therapy / / 20339536 rs4616435 chr2 27933642 C T 4.82E-08 Protein C levels / / 20802025 rs4616435 chr2 27933642 C T 1.48E-08 Urate levels / / 23263486 rs6727215 chr2 27934731 G A 6.20E-06 Response to statin therapy / / 20339536 rs6727215 chr2 27934731 G A 4.84E-08 Protein C levels / / 20802025 rs6727215 chr2 27934731 G A 1.65E-08 Urate levels / / 23263486 rs867282 chr2 27951658 T C 9.06E-08 Body mass index / / 22885924 rs2384655 chr2 27952235 A T 1.10E-12 Metabolite levels / / 22286219 rs12994085 chr2 27952406 C T 3.14E-11 Metabolite levels / / 22286219 rs12993377 chr2 27952767 G C 1.86E-11 Metabolite levels / / 22286219 rs6753736 chr2 27958855 C G 1.49E-11 Metabolite levels / / 22286219 rs13023194 chr2 27967260 G C 5.40E-06 Response to statin therapy / / 20339536 rs13023194 chr2 27967260 G C 1.04E-15 Fasting blood glucose / / 22885924 rs13023194 chr2 27967260 G C 1.89E-09 Urate levels / / 23263486 rs9967838 chr2 27968454 A C 2.85E-11 Metabolite levels / / 22286219 rs9677663 chr2 27972445 G A 4.74E-11 Metabolite levels / / 22286219 rs12104449 chr2 27972833 A G 6.10E-13 Urate levels / / 23263486 rs57238885 chr2 27974260 C G,T 1.52E-10 Metabolite levels / / 22286219 rs10201247 chr2 27974971 A G 2.72E-11 Metabolite levels / / 22286219 rs6547796 chr2 27975394 T C 4.75E-11 Metabolite levels / / 22286219 rs10209020 chr2 27980944 C T 6.60E-11 Metabolite levels / / 22286219 rs12471347 chr2 27981655 G C 2.13E-11 Metabolite levels / / 22286219 rs12477908 chr2 27987046 A C 1.65E-11 Metabolite levels / / 22286219 rs13013484 chr2 27988821 G A 1.92E-11 Metabolite levels / / 22286219 rs13013484 chr2 27988821 G A 0.000000109 Body mass index / / 22885924 rs3736594 chr2 27995781 A C 1.91E-11 Metabolite levels MRPL33 intron 22286219 rs3736594 chr2 27995781 A C 1.00E-15 Fasting glucose-related traits (interaction with BMI) MRPL33 intron 22581228 rs3736594 chr2 27995781 A C 9.68E-04 Response to cytadine analogues (cytosine arabinoside) MRPL33 intron 24483146 rs3792253 chr2 28002002 T C 9.97E-10 Triglycerides MRPL33 intron 23063622 rs13030345 chr2 28003174 G T 7.60E-06 Response to statin therapy / / 20339536 rs13030345 chr2 28003174 G T 0.0000041 Endometrial cancer / / 22426144 rs13030345 chr2 28003174 G T 0.000002507 2-hour glucose tolerance test / / 22885924 rs13030345 chr2 28003174 G T 5.00E-25 Triglycerides / / 23063622 rs13030345 chr2 28003174 G T 1.44E-08 Urate levels / / 23263486 rs4666014 chr2 28019175 G A 2.03E-09 Triglycerides RBKS intron 23063622 rs4666014 chr2 28019175 G A 8.12E-04 Response to cytadine analogues (cytosine arabinoside) RBKS intron 24483146 rs11127125 chr2 28023120 T C 2.10E-04 Response to cytadine analogues (cytosine arabinoside) RBKS intron 24483146 rs4665392 chr2 28029649 A G 2.66E-04 Response to cytadine analogues (cytosine arabinoside) RBKS intron 24483146 rs12617171 chr2 28038799 C T 1.30E-05 Lipid levels RBKS intron 18193043 rs4666020 chr2 28046028 G A 4.60E-04 Amyotrophic Lateral Sclerosis RBKS intron 17362836 rs4666022 chr2 28057823 T C 3.71E-04 Response to cytadine analogues (cytosine arabinoside) RBKS intron 24483146 rs11901133 chr2 28069713 T G 8.73E-04 Response to cytadine analogues (cytosine arabinoside) RBKS intron 24483146 rs11127129 chr2 28076708 C G 4.70E-07 Lipid levels RBKS intron 18193043 rs11127129 chr2 28076708 C G 0.000000126 Triglycerides RBKS intron 23063622 rs898034 chr2 28090820 T C 2.36E-09 Triglycerides RBKS intron 23063622 rs6708889 chr2 28107692 C T 3.29E-10 Triglycerides RBKS intron 23063622 rs2305929 chr2 28113911 A G 1.30E-05 Response to statin therapy BRE intron 20339536 rs2305929 chr2 28113911 A G 1.00E-10 Fasting blood glucose BRE intron 22885924 rs2305929 chr2 28113911 A G 5.38E-21 Triglycerides BRE intron 23063622 rs1458396 chr2 28136351 A G 7.52E-04 Response to cytadine analogues (cytosine arabinoside) BRE intron 24483146 rs898031 chr2 28203294 C T 7.19E-04 Myopia (pathological) BRE intron 21095009 rs7577342 chr2 28205581 C T 4.09E-04 Type 2 diabetes BRE intron 17463246 rs73923981 chr2 28235764 G A 0.0000732 Menopause (age at onset) BRE intron 23424626 rs10495761 chr2 28235955 T C 9.13E-04 Amyotrophic Lateral Sclerosis BRE intron 17362836 rs10173528 chr2 28288392 C T 6.15E-04 Myopia (pathological) BRE intron 21095009 rs17006489 chr2 28304630 A G 7.37E-11 Metabolite levels BRE intron 22286219 rs2337700 chr2 28306943 G A 1.29E-04 Response to cholinesterase inhibitors in Alzheimer's disease BRE intron 23374588 rs3863 chr2 28319134 A G 6.53E-04 Alzheimer's disease BRE intron 24755620 rs7572644 chr2 28320033 T C 5.10E-05 Multiple sclerosis BRE intron 17660530 rs6705961 chr2 28325201 C T 8.53E-04 Alzheimer's disease BRE intron 17998437 rs1948922 chr2 28342153 A G 5.26E-04 Multiple complex diseases BRE intron 17554300 rs1948922 chr2 28342153 A G 4.76E-05 Hemoglobin BRE intron pha003096 rs4401177 chr2 28344285 G A 2.77E-09 Urate levels BRE intron 23263486 rs7601155 chr2 28347682 C T 2.00E-07 Waist circumference BRE intron 23966867 rs12053063 chr2 28350611 A G 5.41E-04 Multiple complex diseases BRE intron 17554300 rs2048047 chr2 28358981 C T 2.96E-04 Glaucoma (primary open-angle) BRE intron 22605921 rs1038694 chr2 28373552 A G 2.08E-05 Hemoglobin BRE intron pha003096 rs1038694 chr2 28373552 A G 9.18E-05 Hematocrit BRE intron pha003097 rs13405885 chr2 28375772 G A 9.57E-05 Hematocrit BRE intron pha003097 rs4666040 chr2 28380295 A G 8.34E-05 Multiple sclerosis BRE intron 17660530 rs17006590 chr2 28389846 A C 9.58E-04 Prostate cancer mortality BRE intron 20978177 rs17759746 chr2 28394293 T C 0.000123 Ovarian cancer BRE intron 22794196 rs4666042 chr2 28421461 G A 8.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BRE intron 20877124 rs17709034 chr2 28424472 C T 6.16E-09 Urate levels BRE intron 23263486 rs6732163 chr2 28428466 A G 4.60E-04 Longevity BRE intron 22279548 rs7349418 chr2 28443050 C T 1.59E-08 Urate levels BRE intron 23263486 rs6711937 chr2 28497276 C T 6.78E-05 Glaucoma (primary open-angle) BRE intron 22605921 rs10495763 chr2 28510347 A G 5.40E-04 Type 2 diabetes and 6 quantitative traits BRE intron 17848626 rs10189899 chr2 28520083 A G 5.82E-05 Major depressive disorder BRE intron pha002850 rs4666052 chr2 28530720 A G 7.97E-04 Amyotrophic Lateral Sclerosis BRE intron 17827064 rs1546029 chr2 28542934 A G 3.78E-04 Prostate cancer mortality BRE intron 20978177 rs884437 chr2 28570398 A G 6.49E-05 Cognitive test performance / / 20125193 rs10184619 chr2 28582597 C T 5.85E-06 Crohn's disease and psoriasis / / 22482804 rs7602568 chr2 28584315 T C 3.02E-05 Cognitive test performance / / 20125193 rs906805 chr2 28604879 A G 5.98E-08 Multiple complex diseases / / 17554300 rs13392378 chr2 28607344 G A 2.90E-05 Urinary metabolites / / 21572414 rs925255 chr2 28614794 C T 3.00E-15 Inflammatory bowel disease FLJ31356 intron 23128233 rs7606480 chr2 28632377 G A 6.41E-06 Multiple complex diseases FOSL2 intron 17554300 rs1396733 chr2 28642747 C A 2.23E-06 Multiple complex diseases / / 17554300 rs7590263 chr2 28645802 C T 9.49E-06 Multiple complex diseases / / 17554300 rs12478126 chr2 28645948 C T 1.11E-05 Multiple complex diseases / / 17554300 rs6547853 chr2 28646801 G A 8.00E-07 Type 1 diabetes / / 21980299 rs6547854 chr2 28655788 T C 6.32E-04 Type 2 diabetes / / 17463246 rs2879177 chr2 28658231 A C 3.32E-04 Type 2 diabetes / / 17463246 rs2338013 chr2 28662264 G A 6.39E-05 Multiple complex diseases / / 17554300 rs2972052 chr2 28662493 A G 0.00033 Salmonella-induced pyroptosis / / 22837397 rs2940787 chr2 28663333 G T 3.36E-05 Parkinson's disease / / 17052657 rs2940799 chr2 28669749 C G 3.65E-04 Alzheimer's disease / / 17998437 rs2972050 chr2 28671048 A G 0.000716 Salmonella-induced pyroptosis / / 22837397 rs1581035 chr2 28686332 G A 4.45E-04 Longevity / / 22279548 rs11127158 chr2 28690849 A C 8.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7579759 chr2 28693648 A C 1.97E-08 Narcolepsy / / 19629137 rs875789 chr2 28700759 G A 5.02E-04 Smoking quantity / / 24665060 rs10203313 chr2 28714750 C T 6.20E-06 Urinary metabolites / / 21572414 rs10203313 chr2 28714750 C T 3.87E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11127160 chr2 28716955 C A 5.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12621347 chr2 28726440 G C 2.00E-05 Urinary metabolites PLB1 intron 21572414 rs12621347 chr2 28726440 G C 4.26E-04 Response to taxane treatment (placlitaxel) PLB1 intron 23006423 rs4398231 chr2 28728254 A G 2.40E-05 Urinary metabolites PLB1 intron 21572414 rs4398231 chr2 28728254 A G 4.26E-04 Response to taxane treatment (placlitaxel) PLB1 intron 23006423 rs12478824 chr2 28731702 T C 4.50E-04 Response to taxane treatment (placlitaxel) PLB1 intron 23006423 rs6748157 chr2 28733361 A G 1.80E-05 Urinary metabolites PLB1 intron 21572414 rs6748157 chr2 28733361 A G 9.79E-05 Response to taxane treatment (placlitaxel) PLB1 intron 23006423 rs13023754 chr2 28735998 T C 4.04E-04 Response to taxane treatment (placlitaxel) PLB1 intron 23006423 rs6547856 chr2 28744077 G A 1.13E-04 Acute lung injury PLB1 intron 22295056 rs9309663 chr2 28768427 C T 2.28E-05 Suicidal ideation PLB1 intron 20877300 rs10170463 chr2 28773874 C A 3.59E-04 Multiple complex diseases PLB1 intron 17554300 rs1997267 chr2 28774319 C T 3.74E-05 Waist-Hip Ratio PLB1 intron pha003029 rs11679308 chr2 28786640 T C 9.54E-05 Waist-Hip Ratio PLB1 intron pha003029 rs10186460 chr2 28789643 T C 7.20E-05 Body Composition PLB1 intron pha003012 rs2338545 chr2 28799775 A G 6.30E-05 Type 2 diabetes PLB1 intron 17463248 rs2338545 chr2 28799775 A G 2.95E-04 Alzheimer's disease PLB1 intron 22005930 rs7595633 chr2 28803240 A G 5.79E-05 Coronary heart disease PLB1 intron pha003035 rs10171857 chr2 28807342 G A 8.24E-05 HIV-1 viral setpoint PLB1 intron 22174851 rs6547861 chr2 28831271 A G 5.62E-05 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) PLB1 intron 21541012 rs11127182 chr2 28851116 A G 2.77E-04 Nicotine smoking PLB1 intron 19268276 rs4530322 chr2 28852926 A G 4.30E-06 Glaucoma (primary open-angle) PLB1 intron 20835238 rs6719289 chr2 28856801 A G 5.13E-04 Multiple complex diseases PLB1 intron 17554300 rs6719289 chr2 28856801 A G 2.82E-04 Nicotine smoking PLB1 intron 19268276 rs6738334 chr2 28866928 A G 4.58E-04 Type 2 diabetes / / 17463246 rs11682523 chr2 28898837 C T 3.60E-05 Basophils / / pha003087 rs11887648 chr2 28920335 C T 2.17E-04 Multiple complex diseases / / 17554300 rs4233728 chr2 28977274 A G 9.16E-04 HIV-1 viral setpoint PPP1CB intron 17641165 rs13399528 chr2 28982827 C G 5.67E-04 Multiple complex diseases PPP1CB intron 17554300 rs10191120 chr2 28997936 A G 1.60E-04 Multiple complex diseases PPP1CB intron 17554300 rs3768666 chr2 29005870 C T 4.74E-04 Lymphocyte counts PPP1CB intron 22286170 rs10210252 chr2 29017870 C T 3.37E-04 Multiple complex diseases PPP1CB intron 17554300 rs6737027 chr2 29070805 C T 4.60E-05 Multiple complex diseases SPDYA intron 17554300 rs7589735 chr2 29099752 G A 8.80E-06 Urinary metabolites / / 21572414 rs4632299 chr2 29112102 G A 8.50E-06 Urinary metabolites / / 21572414 rs13014379 chr2 29112852 T C 6.10E-06 Chronic kidney disease / / 22479191 rs6547889 chr2 29128322 T C 2.40E-05 Urinary metabolites WDR43 intron 21572414 rs1140697 chr2 29152456 A G 7.56E-05 Serum metabolites WDR43 cds-synon 19043545 rs4666143 chr2 29172991 T C 5.87E-05 Weight / / pha003026 rs6714085 chr2 29184267 A G 2.39E-04 Obesity (extreme) / / 21935397 rs4666156 chr2 29196713 G C 1.04E-04 Obesity (extreme) / / 21935397 rs4666157 chr2 29196785 T C 1.03E-04 Obesity (extreme) / / 21935397 rs17007459 chr2 29247845 C A 2.52E-10 Narcolepsy FAM179A intron 19629137 rs13008299 chr2 29247997 T G 7.00E-08 Diastolic blood pressure (alcohol consumption interaction) FAM179A intron 24376456 rs17007460 chr2 29251134 C T 4.99E-06 Multiple sclerosis (brain glutamate levels) FAM179A intron 20802204 rs6734543 chr2 29273583 T A 8.20E-06 Urinary metabolites FAM179A intron 21572414 rs882632 chr2 29280761 C T 2.00E-06 Major depressive disorder / / 20125088 rs10182566 chr2 29287708 C T 7.18E-04 Suicide attempts in bipolar disorder C2orf71 UTR-3 21041247 rs13031086 chr2 29288481 C T 8.61E-04 Suicide attempts in bipolar disorder C2orf71 intron 21041247 rs17744052 chr2 29289411 A G 6.01E-04 Suicide attempts in bipolar disorder C2orf71 intron 21041247 rs17744093 chr2 29294754 G C 5.69E-04 Suicide attempts in bipolar disorder C2orf71 missense 21041247 rs10200693 chr2 29295016 A G 8.02E-04 Suicide attempts in bipolar disorder C2orf71 cds-synon 21041247 rs13385188 chr2 29295676 G A 7.90E-04 Suicide attempts in bipolar disorder C2orf71 cds-synon 21041247 rs7562696 chr2 29303600 A G 7.30E-04 Multiple complex diseases / / 17554300 rs3213947 chr2 29366830 A G 6.42E-06 Glucose levels CLIP4 intron pha003057 rs3100239 chr2 29375902 T C 8.25E-04 Parkinson's disease CLIP4 intron 17052657 rs3112920 chr2 29380711 C T 2.60E-05 Urinary metabolites CLIP4 intron 21572414 rs2123443 chr2 29382038 C T 3.09E-05 Glucose levels CLIP4 intron pha003057 rs2305450 chr2 29383374 G A 3.69E-05 Major depression (suicidal thoughts and behavior) CLIP4 intron 21750702 rs12620500 chr2 29392680 C T 9.80E-04 Depression (quantitative trait) CLIP4 intron 20800221 rs12620500 chr2 29392680 C T 4.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CLIP4 intron 20877124 rs4622670 chr2 29446202 G A 2.00E-04 Amyotrophic lateral sclerosis ALK intron 17671248 rs7572088 chr2 29481036 C G 8.08E-05 Serum metabolites ALK intron 19043545 rs2339379 chr2 29481537 T C 6.16E-05 Serum metabolites ALK intron 19043545 rs17007760 chr2 29486702 G A 3.02E-04 Alzheimer's disease ALK intron 24755620 rs12617579 chr2 29489620 C T 3.81E-05 Nicotine smoking ALK intron 19268276 rs35228363 chr2 29497967 G A 0.00025 Prostate cancer ALK missense 23555315 rs4666189 chr2 29502690 T C 9.93E-04 Multiple complex diseases ALK intron 17554300 rs10432706 chr2 29534165 C A 6.08E-05 Cognitive test performance ALK intron 20125193 rs17007869 chr2 29535061 G A 9.04E-05 Formal thought disorder in schizophrenia ALK intron 22648509 rs2276549 chr2 29541104 C T 3.22E-05 Serum metabolites ALK intron 19043545 rs17007916 chr2 29562741 G A 7.75E-04 Multiple complex diseases ALK intron 17554300 rs17007920 chr2 29570906 T C 4.98E-05 Height ALK intron pha003011 rs10204572 chr2 29580466 T C 6.61E-05 Amyotrophic lateral sclerosis (sporadic) ALK intron 24529757 rs4146673 chr2 29582433 T C 8.85E-08 Metabolite levels ALK intron 23281178 rs1534544 chr2 29596488 G T 8.52E-06 Insulin-related traits ALK intron pha003063 rs10186332 chr2 29607480 G A 5.87E-05 Insulin-related traits ALK intron pha003063 rs4666212 chr2 29613214 C T 2.30E-05 Urinary metabolites ALK intron 21572414 rs11127220 chr2 29618678 C A 3.48E-04 Body mass index ALK intron 17255346 rs7421353 chr2 29641874 T C 7.49E-05 HDL cholesterol ALK intron pha003075 rs4128317 chr2 29659854 A C 0.0000735 Oxaliplatin induced mucositis in response to colorectal cancer treatment ALK intron 22310351 rs6547929 chr2 29666856 C T 1.60E-05 Urinary metabolites ALK intron 21572414 rs4322797 chr2 29666976 T C 9.20E-06 Urinary metabolites ALK intron 21572414 rs4322797 chr2 29666976 T C 0.000420356 Hypertension (early onset hypertension) ALK intron 22479346 rs4408683 chr2 29667326 G A 8.30E-06 Urinary metabolites ALK intron 21572414 rs4456659 chr2 29670834 A G 3.55E-04 Obesity (extreme) ALK intron 21935397 rs4497832 chr2 29670877 T C 4.43E-04 Obesity (extreme) ALK intron 21935397 rs4341891 chr2 29671104 T G 5.64E-04 Obesity (extreme) ALK intron 21935397 rs4589706 chr2 29671127 T C 5.48E-04 Obesity (extreme) ALK intron 21935397 rs10779969 chr2 29671801 A C 5.14E-04 Obesity (extreme) ALK intron 21935397 rs4366858 chr2 29672547 C T 4.18E-04 Obesity (extreme) ALK intron 21935397 rs4299298 chr2 29672756 T C 4.12E-04 Obesity (extreme) ALK intron 21935397 rs6547930 chr2 29672940 C T 4.10E-04 Obesity (extreme) ALK intron 21935397 rs11127225 chr2 29673607 T C 4.07E-04 Obesity (extreme) ALK intron 21935397 rs4233736 chr2 29676965 T C 3.76E-04 Obesity (extreme) ALK intron 21935397 rs4233737 chr2 29677036 C G 9.70E-04 Obesity (extreme) ALK intron 21935397 rs4602182 chr2 29677522 T C 6.84E-04 Obesity (extreme) ALK intron 21935397 rs7580476 chr2 29683558 C T 6.33E-04 Alcohol consumption (maxi-drinks) ALK intron 24277619 rs3923028 chr2 29685596 C T 2.00E-05 Major depressive disorder ALK intron 19065144 rs3923028 chr2 29685596 C T 3.11E-05 Major depressive disorder ALK intron 21621269 rs3923028 chr2 29685596 C T 3.80E-05 Major depressive disorder ALK intron pha002850 rs12714281 chr2 29691960 T C 0.000810007 Hypertension (early onset hypertension) ALK intron 22479346 rs12714281 chr2 29691960 T C 1.87E-04 Homeostasis model assessment of insulin resistance (interaction) ALK intron 24204828 rs12714281 chr2 29691960 T C 2.73E-04 Fasting insulin (interaction) ALK intron 24204828 rs4493213 chr2 29698164 T C 0.000458398 Hypertension (early onset hypertension) ALK intron 22479346 rs4503951 chr2 29698383 G A 1.70E-05 Urinary metabolites ALK intron 21572414 rs6547933 chr2 29700165 T C 0.00047798 Hypertension (early onset hypertension) ALK intron 22479346 rs7426089 chr2 29702682 A G 2.35E-04 Schizophrenia ALK intron 19197363 rs7426089 chr2 29702682 A G 3.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ALK intron 20877124 rs4299297 chr2 29705020 A C 0.000466927 Hypertension (early onset hypertension) ALK intron 22479346 rs4665461 chr2 29707986 C T 5.13E-04 Obesity (extreme) ALK intron 21935397 rs11684392 chr2 29725676 C T 3.00E-06 Asthma ALK intron 21790008 rs6719507 chr2 29733801 G A 4.95E-04 Obesity (extreme) ALK intron 21935397 rs4468777 chr2 29743581 T G 3.63E-04 Obesity (extreme) ALK intron 21935397 rs7578465 chr2 29743733 T C 4.87E-04 Obesity (extreme) ALK intron 21935397 rs7578465 chr2 29743733 T C 0.0005799 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ALK intron 23233654 rs7578465 chr2 29743733 T C 5.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) ALK intron 23233662 rs7562040 chr2 29743822 C G 3.35E-04 Obesity (extreme) ALK intron 21935397 rs7562040 chr2 29743822 C G 0.0005739 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ALK intron 23233654 rs7562040 chr2 29743822 C G 5.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) ALK intron 23233662 rs10168427 chr2 29744983 C T 3.75E-04 Obesity (extreme) ALK intron 21935397 rs12467802 chr2 29747174 C T 7.40E-05 Alcohol dependence ALK intron 21703634 rs12467802 chr2 29747174 C T 6.54E-05 Schizophrenia (cytomegalovirus infection interaction) ALK intron 23358160 rs7571895 chr2 29751631 C A 0.000247 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ALK intron 23233654 rs7571895 chr2 29751631 C A 2.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) ALK intron 23233662 rs7592571 chr2 29767894 C A 8.53E-06 Alcohol dependence ALK intron 21703634 rs6547946 chr2 29780633 C G 0.0000056 Mean arterial pressure ALK intron 22510845 rs4280415 chr2 29783021 T C 0.0000197 Migraine ALK intron 22678113 rs4280415 chr2 29783021 T C 1.97E-05 Migraine ALK intron 22683712 rs10193521 chr2 29785679 G A 5.27E-05 Alcohol dependence ALK intron 21703634 rs12473275 chr2 29785781 G A 6.11E-05 Alcohol dependence ALK intron 21703634 rs12473275 chr2 29785781 G A 9.24E-05 Schizophrenia (cytomegalovirus infection interaction) ALK intron 23358160 rs6547949 chr2 29791841 A G 9.61E-04 Obesity (extreme) ALK intron 21935397 rs13014477 chr2 29795988 T G 7.50E-05 Vaspin levels ALK intron 22907691 rs13014477 chr2 29795988 T G 0.0000264 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit ALK intron 22907730 rs13014477 chr2 29795988 T G 0.000075 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks ALK intron 22907730 rs12621412 chr2 29796202 A G 0.000017 Mean arterial pressure ALK intron 22510845 rs6709634 chr2 29814009 C T 8.78E-05 Insulin Resistance ALK intron pha003062 rs6547957 chr2 29816800 G A 1.30E-05 Diabetes Mellitus ALK intron pha003059 rs6547957 chr2 29816800 G A 1.54E-05 Insulin Resistance ALK intron pha003062 rs6547957 chr2 29816800 G A 8.70E-05 Insulin-related traits ALK intron pha003063 rs6733973 chr2 29820586 T C 7.21E-06 Insulin Resistance ALK intron pha003062 rs6733973 chr2 29820586 T C 4.38E-05 Insulin-related traits ALK intron pha003063 rs4666255 chr2 29823652 A G 6.02E-06 Insulin Resistance ALK intron pha003062 rs4666255 chr2 29823652 A G 2.90E-05 Insulin-related traits ALK intron pha003063 rs6547960 chr2 29830234 T C 1.43E-05 Insulin Resistance ALK intron pha003062 rs6547960 chr2 29830234 T C 7.77E-05 Insulin-related traits ALK intron pha003063 rs2879504 chr2 29861246 A G 7.86E-05 Insulin Resistance ALK intron pha003062 rs13392455 chr2 29871128 C T 1.08E-04 Smoking cessation ALK intron 24665060 rs7577363 chr2 29876343 G A 7.37E-05 Multiple sclerosis ALK intron 17660530 rs6547967 chr2 29880877 C T 7.80E-05 HIV-1 control ALK intron 20041166 rs2631962 chr2 29922364 A G 9.68E-04 Type 2 diabetes ALK intron 17463246 rs2541194 chr2 29947235 A G 6.76E-04 Type 2 diabetes ALK intron 17463246 rs2257135 chr2 29948698 G A 2.84E-04 Type 2 diabetes ALK intron 17463246 rs2631955 chr2 29954416 T C 4.37E-04 Type 2 diabetes ALK intron 17463246 rs12998454 chr2 29954652 A C 9.91E-04 Type 2 diabetes ALK intron 17463246 rs4666270 chr2 29989203 T G 1.00E-04 Cognitive impairment induced by topiramate ALK intron 22091778 rs2339478 chr2 29995801 C T 9.19E-05 ldl cholesterol ALK intron pha003077 rs11694445 chr2 30034279 A G 4.48E-04 Prostate cancer mortality ALK intron 20978177 rs10187657 chr2 30042217 A G 2.65E-04 Multiple complex diseases ALK intron 17554300 rs10187657 chr2 30042217 A G 4.70E-06 Urinary metabolites ALK intron 21572414 rs4132594 chr2 30045521 G A 4.90E-05 Heart Rate ALK intron pha003053 rs4264531 chr2 30048387 C T 3.75E-04 Multiple complex diseases ALK intron 17554300 rs13012046 chr2 30068116 T G 2.15E-05 Coronary heart disease ALK intron pha003031 rs4075920 chr2 30075051 G A 4.03E-05 Suicidal ideation ALK intron 20877300 rs12616992 chr2 30080818 C T 2.67E-05 Receptive language ability ALK intron 24687471 rs12613938 chr2 30087465 C T 1.91E-05 Receptive language ability ALK intron 24687471 rs12620548 chr2 30090341 T C 7.82E-05 Cognitive impairment induced by topiramate ALK intron 22091778 rs12620548 chr2 30090341 T C 3.23E-05 Receptive language ability ALK intron 24687471 rs7574859 chr2 30094209 T G 1.80E-05 Urinary metabolites ALK intron 21572414 rs4280420 chr2 30106142 C T 7.91E-05 Type 2 diabetes ALK intron 17463246 rs4280420 chr2 30106142 C T 2.49E-04 Multiple complex diseases ALK intron 17554300 rs4520995 chr2 30118386 T C 4.23E-04 Alcohol consumption (maxi-drinks) ALK intron 24277619 rs6754787 chr2 30141950 C G 1.05E-04 Multiple complex diseases ALK intron 17554300 rs11693432 chr2 30180109 G C 3.21E-04 Multiple complex diseases / / 17554300 rs4359705 chr2 30200798 T C 2.15E-05 Coronary heart disease / / pha003030 rs4952125 chr2 30210861 A G 3.73E-05 Coronary heart disease / / pha003030 rs7575487 chr2 30237620 T G 7.21E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs12465875 chr2 30272550 G A 7.74E-04 Acute lung injury / / 22295056 rs2009666 chr2 30273188 C T 7.74E-04 Acute lung injury / / 22295056 rs2290052 chr2 30273535 G A 7.06E-04 Acute lung injury / / 22295056 rs12464374 chr2 30273759 T C 7.06E-04 Acute lung injury / / 22295056 rs12475473 chr2 30273791 C T 6.83E-04 Acute lung injury / / 22295056 rs7584886 chr2 30275074 T C 6.83E-04 Acute lung injury / / 22295056 rs12477758 chr2 30276651 T C 6.83E-04 Acute lung injury / / 22295056 rs12473767 chr2 30277205 C T 6.83E-04 Acute lung injury / / 22295056 rs1108288 chr2 30277518 C G 8.82E-04 Acute lung injury / / 22295056 rs17009105 chr2 30278431 A G 6.33E-04 Acute lung injury / / 22295056 rs935482 chr2 30279202 C A 4.78E-04 Acute lung injury / / 22295056 rs12468948 chr2 30280388 G A 7.17E-04 Acute lung injury / / 22295056 rs1447524 chr2 30282981 G A 6.97E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1597036 chr2 30283564 C T 3.37E-04 Acute lung injury / / 22295056 rs6731342 chr2 30284800 T G 5.45E-04 Acute lung injury / / 22295056 rs12465311 chr2 30287512 G A 6.48E-04 Acute lung injury / / 22295056 rs1900589 chr2 30292775 A G 9.70E-04 Acute lung injury / / 22295056 rs1137288 chr2 30381505 T C 2.00E-04 Cognitive impairment induced by topiramate YPEL5 cds-synon 22091778 rs961440 chr2 30398039 C T 5.25E-05 Multiple complex diseases / / 17554300 rs11681599 chr2 30426437 G A 1.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs17736058 chr2 30426554 T C 3.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs4952108 chr2 30429735 C T 1.16E-07 Primary biliary cirrhosis / / 21399635 rs7579944 chr2 30445026 T C 1.00E-08 Celiac disease and Rheumatoid arthritis / / 21383967 rs1355208 chr2 30445322 A G 3.40E-05 Celiac disease / / 17558408 rs1355208 chr2 30445322 A G 3.48E-08 Celiac disease and Rheumatoid arthritis / / 21383967 rs955214 chr2 30445926 G A 4.17E-04 Obesity (extreme) / / 21935397 rs1396836 chr2 30446083 T C 4.54E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs906868 chr2 30448344 G T 7.19E-08 Celiac disease and Rheumatoid arthritis / / 21383967 rs10175798 chr2 30449594 G A 1.00E-09 Rheumatoid arthritis / / 24390342 rs10175798 chr2 30449594 G A 4.00E-08 Rheumatoid arthritis / / 24390342 rs2362540 chr2 30452959 C A 1.27E-04 Parkinson's disease / / 21248740 rs3738863 chr2 30457561 A G 1.82E-06 Primary biliary cirrhosis LBH intron 21399635 rs1473591 chr2 30462979 A C 5.86E-05 Lung adenocarcinoma LBH intron 19836008 rs11676884 chr2 30466066 C T 2.23E-04 Multiple complex diseases LBH intron 17554300 rs4384829 chr2 30466802 G A 3.90E-04 Multiple complex diseases LBH intron 17554300 rs4564821 chr2 30474255 C T 1.79E-04 Multiple complex diseases LBH intron 17554300 rs13386455 chr2 30480865 A G 6.36E-05 Asthma LBH UTR-3 pha003128 rs12467407 chr2 30507340 C T 5.84E-04 Multiple complex diseases / / 17554300 rs6708166 chr2 30526780 G A 1.00E-06 vWF and FVIII levels / / 21810271 rs13014895 chr2 30540833 T C 8.80E-06 Urinary metabolites / / 21572414 rs13014895 chr2 30540833 T C 4.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6730942 chr2 30540988 A T 8.80E-06 Urinary metabolites / / 21572414 rs7578949 chr2 30569355 T C 2.58E-05 Serum albumin level / / pha003084 rs6740257 chr2 30577757 T C 6.48E-05 Cognitive test performance / / 20125193 rs829586 chr2 30626447 A C 5.89E-04 Alzheimer's disease / / 17998437 rs829604 chr2 30635580 C G 6.84E-05 Self-reported allergy / / 23817569 rs17394352 chr2 30638988 T A 5.03E-05 Self-reported allergy / / 23817569 rs829699 chr2 30643811 T C 5.96E-05 Self-reported allergy / / 23817569 rs829584 chr2 30677275 A G 2.13E-04 Aortic root size LCLAT1 intron 21223598 rs829573 chr2 30682630 T A 1.92E-04 Aortic root size LCLAT1 intron 21223598 rs1357849 chr2 30696207 A G 7.44E-05 Serum metabolites LCLAT1 intron 19043545 rs829642 chr2 30699970 T C 4.80E-05 Alcohol dependence LCLAT1 intron 20201924 rs829642 chr2 30699970 T C 4.80E-05 Alcoholism LCLAT1 intron pha002892 rs829646 chr2 30719326 T C 6.30E-05 Alcohol dependence LCLAT1 intron 20201924 rs829646 chr2 30719326 T C 6.34E-05 Alcoholism LCLAT1 intron pha002892 rs4952147 chr2 30776270 G A 2.20E-04 Alcohol dependence LCLAT1 intron 20201924 rs4952152 chr2 30797350 G A 4.26E-04 Aortic root size LCLAT1 intron 21223598 rs12052683 chr2 30857850 G T 3.51E-04 Multiple complex diseases LCLAT1 intron 17554300 rs12613783 chr2 30858736 A G 1.27E-04 Multiple complex diseases LCLAT1 intron 17554300 rs12613783 chr2 30858736 A G 9.41E-05 Cognitive impairment induced by topiramate LCLAT1 intron 22091778 rs12467646 chr2 30863092 C T 9.22E-04 Aortic root size LCLAT1 cds-synon 21223598 rs2609954 chr2 30871808 G A 1.00E-04 Alcohol dependence / / 20201924 rs7583600 chr2 30872064 T G 8.83E-05 Multiple complex diseases / / 17554300 rs6548026 chr2 30872366 C T 9.39E-05 Multiple complex diseases / / 17554300 rs2602777 chr2 30879524 G A 7.05E-04 Tourette syndrome / / 22889924 rs2602772 chr2 30885263 C A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1562417 chr2 30910849 C T 2.06E-04 Alzheimer's disease (late onset) / / 21379329 rs543134 chr2 30917735 T G 2.75E-05 Serum metabolites / / 19043545 rs2681686 chr2 30925674 T A 1.80E-05 Urinary metabolites / / 21572414 rs2681687 chr2 30926706 C T 1.40E-05 Urinary metabolites / / 21572414 rs7599134 chr2 30927012 T C 7.00E-06 Urinary metabolites / / 21572414 rs11887038 chr2 30955086 G A 1.00E-04 Cognitive impairment induced by topiramate CAPN13 intron 22091778 rs7607943 chr2 30956721 G T 3.61E-05 Cognitive impairment induced by topiramate CAPN13 intron 22091778 rs509380 chr2 30959262 G T 9.13E-04 Multiple complex diseases CAPN13 intron 17554300 rs509380 chr2 30959262 G T 2.89E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAPN13 intron 20877124 rs1879276 chr2 30959827 C T 5.19E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAPN13 intron 20877124 rs2609914 chr2 30961997 C A 9.07E-04 Alzheimer's disease CAPN13 intron 17998437 rs10153751 chr2 30962675 T G 7.46E-05 Body Mass Index CAPN13 intron pha003020 rs35438878 chr2 30962675 T TG 7.46E-05 Body Mass Index CAPN13 intron pha003020 rs765716 chr2 30971264 C G 7.23E-04 Type 2 diabetes CAPN13 intron 17463246 rs765716 chr2 30971264 C G 5.15E-04 Multiple complex diseases CAPN13 intron 17554300 rs17010141 chr2 30974575 A C 5.57E-05 Iron levels CAPN13 intron 19880490 rs17010141 chr2 30974575 A C 5.57E-05 Iron levels CAPN13 intron pha002876 rs12052795 chr2 30983696 G A 5.82E-04 Alzheimer's disease CAPN13 intron 17998437 rs17324662 chr2 30986645 C T 4.75E-05 Alzheimer's disease CAPN13 intron 17998437 rs6548032 chr2 30988375 A G 2.36E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs13003439 chr2 30990328 G T 3.21E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs7592480 chr2 30990941 A G 3.18E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs17010236 chr2 30992719 G T 2.36E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs17010236 chr2 30992719 G T 3.15E-05 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs17324843 chr2 30992877 G A 2.91E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs17324843 chr2 30992877 G A 3.16E-05 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs200944264 chr2 30993308 T A 0.00076 Prostate cancer CAPN13 missense 23555315 rs4952179 chr2 30995027 T C 6.86E-05 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs1568403 chr2 31001167 A G 2.20E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs1568403 chr2 31001167 A G 9.64E-06 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs17010264 chr2 31001605 G C 1.86E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs17010264 chr2 31001605 G C 9.70E-06 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs6754923 chr2 31002130 C G 1.53E-04 Multiple complex diseases CAPN13 intron 17554300 rs6754923 chr2 31002130 C G 4.99E-05 Serum metabolites CAPN13 intron 19043545 rs6754923 chr2 31002130 C G 2.61E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs4952181 chr2 31002221 T A 1.41E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs4952181 chr2 31002221 T A 9.82E-06 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs17041560 chr2 31003019 G A 2.68E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs2030383 chr2 31005078 T A,G 2.40E-05 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs2030384 chr2 31005079 T G 2.50E-05 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs2030385 chr2 31005129 C T 1.17E-05 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs2030385 chr2 31005129 C T 2.34E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs4597573 chr2 31005176 T C 2.88E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs4597574 chr2 31005297 T C 8.68E-05 Colorectal cancer CAPN13 intron 19723657 rs4597574 chr2 31005297 T C 2.91E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs2030386 chr2 31005412 G A 4.56E-05 Serum metabolites CAPN13 intron 19043545 rs2030386 chr2 31005412 G A 1.26E-05 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs2030386 chr2 31005412 G A 1.96E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs6548034 chr2 31005484 A G 2.95E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs6548035 chr2 31005871 A G 1.24E-05 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs6548035 chr2 31005871 A G 2.26E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs6710242 chr2 31006133 T C 1.18E-05 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs6710242 chr2 31006133 T C 2.20E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs11675229 chr2 31006239 C T 2.87E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs17010271 chr2 31006636 C T 2.87E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs6548036 chr2 31006724 C G 1.29E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs6548036 chr2 31006724 C G 7.37E-06 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs2090734 chr2 31007389 A T 2.81E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs6754455 chr2 31007679 C T 2.80E-04 Suicide attempts in bipolar disorder CAPN13 intron 21041247 rs6732918 chr2 31009479 G A 8.01E-05 Lung function (forced vital capacity) CAPN13 intron 24023788 rs17010323 chr2 31022617 G A 8.17E-04 Parkinson's disease CAPN13 intron 17052657 rs17010323 chr2 31022617 G A 1.50E-04 Amyotrophic Lateral Sclerosis CAPN13 intron 17362836 rs6735205 chr2 31027576 C G 1.90E-07 Urinary metabolites CAPN13 intron 21572414 rs10173959 chr2 31028945 T C 5.90E-06 Urinary metabolites CAPN13 intron 21572414 rs10176484 chr2 31029096 T A 1.70E-05 Urinary metabolites CAPN13 intron 21572414 rs1879282 chr2 31029835 C T 4.00E-06 Urinary metabolites CAPN13 intron 21572414 rs7592727 chr2 31030024 C T 5.10E-06 Urinary metabolites CAPN13 intron 21572414 rs6548038 chr2 31037485 T C 6.30E-06 Urinary metabolites / / 21572414 rs939370 chr2 31048782 C T 3.18E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs939370 chr2 31048782 C T 1.00E-04 Erythrocyte counts / / pha003090 rs939369 chr2 31048811 C T 2.60E-05 Urinary metabolites / / 21572414 rs2194448 chr2 31064313 C T 1.17E-04 Gallstones / / 17632509 rs10490517 chr2 31086198 C A 2.41E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10490517 chr2 31086198 C A 8.66E-05 Erythrocyte counts / / pha003090 rs2194452 chr2 31093502 A G 8.94E-04 Acute lung injury / / 22295056 rs2216824 chr2 31094245 C A 8.94E-04 Acute lung injury / / 22295056 rs13429869 chr2 31099832 C T 8.35E-04 Acute lung injury / / 22295056 rs10167990 chr2 31101646 C A 8.35E-04 Acute lung injury / / 22295056 rs10191298 chr2 31101982 G A 8.96E-04 Acute lung injury / / 22295056 rs2042491 chr2 31103730 C T 8.31E-04 Acute lung injury / / 22295056 rs2042490 chr2 31103788 G A 8.31E-04 Acute lung injury / / 22295056 rs10175111 chr2 31103996 C A 9.73E-05 Bipolar disorder / / 20451256 rs10175111 chr2 31103996 C A 5.63E-04 Acute lung injury / / 22295056 rs17010429 chr2 31105974 C A 6.30E-04 Acute lung injury / / 22295056 rs3755527 chr2 31107154 A G 9.40E-05 Glioma (high-grade) / / 19578366 rs10184608 chr2 31107181 T C 4.85E-04 Acute lung injury / / 22295056 rs3732337 chr2 31114972 C T 6.41E-04 Coronary heart disease / / 21971053 rs17321093 chr2 31117795 C T 1.61E-04 Myopia (pathological) / / 21095009 rs4952192 chr2 31122598 C T 5.64E-04 Coronary heart disease / / 21971053 rs17010471 chr2 31142852 T C 2.42E-05 Prostate cancer GALNT14 intron 22923026 rs10205350 chr2 31146497 G T 3.94E-07 Autism GALNT14 intron 22843504 rs2010334 chr2 31236491 G A 1.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT14 intron 20877124 rs17010574 chr2 31243964 G C 3.67E-06 Asthma (childhood onset) GALNT14 intron 23829686 rs10209881 chr2 31246249 T C 1.90E-05 Urinary metabolites GALNT14 intron 21572414 rs10197865 chr2 31246546 C T 5.48E-05 IgE levels in asthmatics GALNT14 intron 23967269 rs6752303 chr2 31247485 T C 1.90E-05 Urinary metabolites GALNT14 intron 21572414 rs9679162 chr2 31247514 G T 1.60E-05 Urinary metabolites GALNT14 intron 21572414 rs5009910 chr2 31249014 T C 2.80E-05 Urinary metabolites GALNT14 intron 21572414 rs4952029 chr2 31249105 C G 4.49E-05 Brain derived neurotrophic factor levels,in serum GALNT14 intron 22047184 rs7608731 chr2 31249974 T C 8.15E-05 IgE levels in asthmatics GALNT14 intron 23967269 rs1862968 chr2 31254348 C T 1.10E-04 IgE levels in asthmatics GALNT14 intron 23967269 rs9308914 chr2 31263433 C A 1.00E-04 IgE levels in asthmatics GALNT14 intron 23967269 rs11681174 chr2 31278254 A G 9.24E-05 Acute lung injury GALNT14 intron 22295056 rs10211370 chr2 31280917 C T 1.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT14 intron 20877124 rs4630806 chr2 31292715 C T 2.20E-05 Urinary metabolites GALNT14 intron 21572414 rs2098787 chr2 31296644 A G 0.00000726 Otitis media (children 3 years old or younger) GALNT14 intron 23133572 rs1862981 chr2 31297524 T G 9.67E-05 Non-alcoholic fatty liver disease histology (other) GALNT14 intron 20708005 rs1862981 chr2 31297524 T G 0.0000051 Otitis media (children 3 years old or younger) GALNT14 intron 23133572 rs1000916 chr2 31314555 T C 9.00E-06 HIV-1 viral setpoint GALNT14 intron 22174851 rs10193546 chr2 31315414 G A 1.35E-04 Lymphocyte counts GALNT14 intron 22286170 rs4561706 chr2 31316509 C T 2.51E-05 HIV-1 viral setpoint GALNT14 intron 22174851 rs10490519 chr2 31318351 T C 0.000524663 Hypertension (early onset hypertension) GALNT14 intron 22479346 rs2216831 chr2 31318838 G A 4.66E-05 HIV-1 viral setpoint GALNT14 intron 22174851 rs11888670 chr2 31320834 T C 0.000210111 Hypertension (early onset hypertension) GALNT14 intron 22479346 rs11687856 chr2 31340646 G A 1.16E-22 Narcolepsy GALNT14 intron 19629137 rs10165977 chr2 31344193 A G 0.0000192 Polycystic ovary syndrome GALNT14 intron 22951595 rs10165977 chr2 31344193 A G 1.92E-05 Intracranial aneurysm GALNT14 intron 22961961 rs2216832 chr2 31348390 A G 4.60E-05 Smoking initiation GALNT14 intron 24665060 rs956747 chr2 31374733 A G 2.10E-05 Urinary metabolites / / 21572414 rs956747 chr2 31374733 A G 1.36E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6543610 chr2 31376654 G C 1.00E-07 Methotrexate phramacokinetics (acute lymphoblastic leukemia) / / 19901119 rs17010768 chr2 31377294 C T 7.44E-04 Multiple complex diseases / / 17554300 rs6747497 chr2 31380113 G C 8.54E-04 Type 2 diabetes / / 17463246 rs1443712 chr2 31392316 C A 8.36E-05 Cognitive performance / / 19734545 rs17010928 chr2 31415054 G A 0.0000985 Otitis media (children 3 years old or younger) CAPN14 intron 23133572 rs17010928 chr2 31415054 G A 2.65E-04 Celiac disease CAPN14 intron 23936387 rs10192210 chr2 31415077 G A 5.58E-05 Schizophrenia CAPN14 intron 19571809 rs10192210 chr2 31415077 G A 3.52E-05 Schizophrenia CAPN14 intron pha002859 rs34438079 chr2 31426449 T TG 2.42E-04 Myopia (pathological) CAPN14 intron 21095009 rs7559123 chr2 31426449 T G 2.42E-04 Myopia (pathological) CAPN14 intron 21095009 rs6728152 chr2 31431651 T C 0.000175 Otitis media (children 3 years old or younger) CAPN14 intron 23133572 rs6736278 chr2 31442875 C T 9.80E-05 Myopia (pathological) / / 21095009 rs13408922 chr2 31444826 C A 0.00000132 Otitis media (children 3 years old or younger) / / 23133572 rs13386745 chr2 31445615 A G 0.00000163 Otitis media (children 3 years old or younger) / / 23133572 rs13386850 chr2 31445691 A C 0.00000132 Otitis media (children 3 years old or younger) / / 23133572 rs13386968 chr2 31445795 A G 8.18E-04 Myopia (pathological) / / 21095009 rs601255 chr2 31452231 G A 1.52E-04 Multiple complex diseases / / 17554300 rs590557 chr2 31461395 G A 1.40E-04 Testosterone levels EHD3 intron 22675492 rs649729 chr2 31464385 T A 1.00E-12 Mean platelet volume EHD3 intron 22139419 rs649729 chr2 31464385 T A 4.00E-06 Mean platelet volume EHD3 intron 24026423 rs647316 chr2 31464829 A G 3.00E-11 Mean platelet volume EHD3 intron 19820697 rs647316 chr2 31464829 A G 3.20E-11 Mean platelet volume EHD3 intron 22423221 rs649509 chr2 31465278 C A 7.03E-05 Testosterone levels EHD3 intron 22675492 rs597800 chr2 31474242 G C 5.00E-07 Estradiol levels EHD3 intron 22675492 rs611076 chr2 31474903 G A 7.94E-05 Testosterone levels EHD3 intron 22675492 rs654091 chr2 31477589 G A 7.87E-05 Testosterone levels EHD3 intron 22675492 rs671403 chr2 31479234 G A 5.01E-05 Testosterone levels EHD3 intron 22675492 rs672364 chr2 31479425 G A 3.35E-05 Testosterone levels EHD3 intron 22675492 rs622107 chr2 31481640 T C 9.43E-05 Testosterone levels EHD3 intron 22675492 rs625132 chr2 31482300 A G 9.00E-14 Platelet counts EHD3 intron 22139419 rs625132 chr2 31482300 A G 8.00E-05 Platelet counts EHD3 intron 24026423 rs669292 chr2 31485332 T C 1.40E-04 Testosterone levels EHD3 intron 22675492 rs617163 chr2 31488554 C T 3.92E-05 Testosterone levels EHD3 intron 22675492 rs644503 chr2 31489826 G C 3.41E-05 Testosterone levels EHD3 UTR-3 22675492 rs1560268 chr2 31537931 T C 2.00E-04 Glycosylated haemoglobin levels / / 17255346 rs2064816 chr2 31541391 T C 2.58E-04 Type 2 diabetes / / 17463246 rs207420 chr2 31544724 T C 8.00E-06 Personality dimensions / / 21173776 rs12478111 chr2 31550180 G A 8.35E-05 Socioeconomic Factors / / pha003066 rs10490361 chr2 31553549 G C 8.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs6543626 chr2 31556986 C T 6.62E-05 Major depressive disorder (broad) XDH nearGene-3 20038947 rs4952085 chr2 31570689 G A 9.34E-04 Longevity XDH intron 22279548 rs4952085 chr2 31570689 G A 5.18E-05 Left ventricular hypertrophy XDH intron pha003052 rs1884725 chr2 31571786 A G 6.81E-05 Left ventricular hypertrophy XDH cds-synon pha003052 rs17011353 chr2 31588437 C T 9.43E-04 Type 2 diabetes XDH intron 17463246 rs2295475 chr2 31589847 G A 5.22E-06 Obesity-related traits XDH cds-synon 23251661 rs761926 chr2 31590785 C G 4.00E-06 Obesity-related traits XDH intron 23251661 rs13398137 chr2 31594789 A C 5.59E-04 Type 2 diabetes XDH intron 17463246 rs2163059 chr2 31603134 A G 9.99E-06 Colorectal cancer XDH intron 21242260 rs206846 chr2 31610311 C G 3.49E-05 Serum metabolites XDH intron 19043545 rs11678276 chr2 31665108 G A 7.62E-04 Smoking quantity / / 24665060 rs4952218 chr2 31731120 A T 9.60E-04 Multiple complex diseases / / 17554300 rs2281546 chr2 31757024 T G 2.85E-05 Lung adenocarcinoma SRD5A2 intron 19836008 rs4952220 chr2 31765556 C A 2.82E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SRD5A2 intron 24023788 rs2268797 chr2 31783752 C T 2.80E-17 Inflammatory biomarkers SRD5A2 intron 24182552 rs2300701 chr2 31787008 A G 1.35E-05 Serum metabolites SRD5A2 intron 19043545 rs2300702 chr2 31788018 C G 1.60E-17 Inflammatory biomarkers SRD5A2 intron 24182552 rs806645 chr2 31807940 T C 6.60E-05 Serum metabolites SRD5A2 nearGene-5 19043545 rs559555 chr2 31810974 T A 1.00E-44 Blood metabolite ratios / / 24816252 rs559555 chr2 31810974 T A 4.00E-22 Blood metabolite levels / / 24816252 rs559555 chr2 31810974 T A 7.00E-19 Blood metabolite levels / / 24816252 rs13027103 chr2 31891571 G A 3.98E-05 Major depressive disorder (broad) / / 20038947 rs7567093 chr2 31891733 A G 2.69E-05 Lung adenocarcinoma / / 19836008 rs223655 chr2 32011895 T C 3.08E-05 Lung adenocarcinoma / / 19836008 rs223657 chr2 32014315 G A 2.37E-05 Lung adenocarcinoma / / 19836008 rs10490358 chr2 32082097 G C 9.20E-04 Multiple complex diseases / / 17554300 rs974229 chr2 32084711 C T 7.06E-04 Multiple complex diseases / / 17554300 rs160802 chr2 32105386 A G 3.57E-05 Lung adenocarcinoma MEMO1 intron 19836008 rs17011668 chr2 32110725 T C 5.00E-05 Prostate cancer MEMO1 intron 21743057 rs2064813 chr2 32212935 T G 3.76E-04 Lung function (forced expiratory volume in 1 second) MEMO1 intron 24023788 rs6748621 chr2 32262201 T C 1.10E-16 Inflammatory biomarkers DPY30 intron 24182552 rs6737500 chr2 32263087 C T 1.10E-16 Inflammatory biomarkers DPY30 intron 24182552 rs12989936 chr2 32268586 T C 2.30E-17 Inflammatory biomarkers / / 24182552 rs7577696 chr2 32278782 A G 3.00E-19 Inflammatory biomarkers / / 24182552 rs2280967 chr2 32289746 T C 3.20E-16 Inflammatory biomarkers SPAST intron 24182552 rs6760105 chr2 32307386 A G 3.60E-16 Inflammatory biomarkers SPAST intron 24182552 rs11691939 chr2 32339561 C T 5.80E-04 Lymphocyte counts SPAST intron 22286170 rs7580118 chr2 32398134 T C 8.11E-04 Type 2 diabetes SLC30A6 intron 17463246 rs17011863 chr2 32407674 C G 6.19E-05 Schizophrenia SLC30A6 intron 19571809 rs212745 chr2 32412832 C G 2.10E-15 Inflammatory biomarkers SLC30A6 intron 24182552 rs212679 chr2 32431107 C A 1.90E-15 Inflammatory biomarkers SLC30A6 intron 24182552 rs212701 chr2 32444054 T C 2.43E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) SLC30A6 intron 23648065 rs177083 chr2 32447718 C T 2.43E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) SLC30A6 UTR-3 23648065 rs212704 chr2 32450348 C T 3.20E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) NLRC4 intron 23648065 rs212713 chr2 32457537 C T 1.50E-10 Inflammatory biomarkers NLRC4 intron 24182552 rs455060 chr2 32475109 G A 2.43E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) NLRC4 cds-synon 23648065 rs479333 chr2 32489158 C G 1.30E-15 Inflammatory biomarkers NLRC4 intron 24182552 rs390480 chr2 32510072 G T 5.80E-04 Response to taxane treatment (placlitaxel) YIPF4 intron 23006423 rs2366894 chr2 32713706 A T 9.43E-04 Parkinson's disease BIRC6 missense 17052657 rs1031261 chr2 32865521 G C 2.00E-06 Hippocampal atrophy TTC27 intron 22745009 rs17012044 chr2 32881702 G A 9.46E-05 Schizophrenia TTC27 intron 20832056 rs2295730 chr2 32897147 G T 3.42E-05 Eosinophil counts TTC27 intron pha003088 rs7594173 chr2 32900330 A G 1.23E-05 Blood pressure TTC27 intron 24001895 rs13009977 chr2 32915597 A C 1.72E-05 Calcium levels TTC27 intron pha003085 rs3769589 chr2 32918720 G A 1.81E-06 Orofacial clefts TTC27 intron 19270707 rs6743661 chr2 32933095 T G 1.10E-04 Alcohol dependence TTC27 intron 20201924 rs11124288 chr2 32937182 C A 4.89E-05 Calcium levels TTC27 intron pha003085 rs3769583 chr2 32968121 C T 5.01E-04 Bipolar disorder TTC27 intron 19259986 rs1448225 chr2 32970453 T C 3.13E-05 Orofacial clefts TTC27 intron 19270707 rs3769578 chr2 32976251 G T 9.46E-04 Multiple complex diseases TTC27 intron 17554300 rs2839744 chr2 32981163 G A 3.79E-05 Orofacial clefts TTC27 intron 19270707 rs2273665 chr2 32983526 C T 3.79E-05 Orofacial clefts TTC27 cds-synon 19270707 rs2218898 chr2 32985073 T C 7.22E-04 Multiple complex diseases TTC27 intron 17554300 rs7558757 chr2 32994874 T C 8.70E-04 Multiple complex diseases TTC27 intron 17554300 rs4952294 chr2 33013440 T A 1.48E-05 Lipoprotein-associated phospholipase A2 activity and mass TTC27 intron 20442857 rs3769567 chr2 33034057 A C 1.37E-05 Orofacial clefts TTC27 intron 19270707 rs927088 chr2 33037217 G A 2.17E-04 Glycemic traits (pregnancy) TTC27 intron 23903356 rs927088 chr2 33037217 G A 8.10E-04 Glycemic traits (pregnancy) TTC27 intron 23903356 rs3820915 chr2 33045629 G C 2.77E-04 Hearing function TTC27 intron 17255346 rs3820915 chr2 33045629 G C 0.000031 Mean arterial pressure TTC27 intron 22510845 rs13033415 chr2 33054282 G A 5.74E-06 Glycemic traits (pregnancy) LINC00486 intron 23903356 rs13033415 chr2 33054282 G A 6.99E-06 Glycemic traits (pregnancy) LINC00486 intron 23903356 rs10173066 chr2 33057305 C G 3.15E-04 Hearing function LINC00486 intron 17255346 rs10173066 chr2 33057305 C G 5.87E-04 Glycemic traits (pregnancy) LINC00486 intron 23903356 rs10173352 chr2 33057389 G A 2.17E-06 Orofacial clefts LINC00486 intron 19270707 rs10173352 chr2 33057389 G A 3.77E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LINC00486 intron 24023788 rs6707573 chr2 33058768 C T 7.74E-05 Glycemic traits (pregnancy) LINC00486 intron 23903356 rs6543679 chr2 33062481 C T 2.37E-04 Hearing function LINC00486 intron 17255346 rs7565366 chr2 33065405 C G 9.33E-04 Multiple complex diseases LINC00486 intron 17554300 rs897510 chr2 33081584 G A 9.94E-05 Hearing function LINC00486 intron 17255346 rs35070884 chr2 33107259 T C 5.38E-04 Multiple complex diseases LINC00486 intron 17554300 rs4952315 chr2 33108465 T G 4.49E-05 Lymphocyte counts LINC00486 intron 22286170 rs13033107 chr2 33119383 A G 1.36E-04 Body mass index LINC00486 intron 17255346 rs6752373 chr2 33120234 G A 2.26E-04 Body mass index LINC00486 intron 17255346 rs6728021 chr2 33121504 A G 4.00E-08 Immune response to smallpox vaccine (IL-6) LINC00486 intron 22610502 rs6716986 chr2 33127080 T C 6.81E-04 Multiple complex diseases LINC00486 intron 17554300 rs17012387 chr2 33178646 A G 8.01E-04 Multiple complex diseases LTBP1 intron 17554300 rs219145 chr2 33211514 C G 3.94E-06 Brachial circumference LTBP1 intron 22479309 rs219157 chr2 33217287 T C 9.99E-05 Relative hand skill LTBP1 intron 24068947 rs219158 chr2 33218037 A G 9.70E-05 Relative hand skill LTBP1 intron 24068947 rs219159 chr2 33218120 C T 9.71E-05 Relative hand skill LTBP1 intron 24068947 rs219186 chr2 33242555 C T 8.14E-04 Stroke LTBP1 intron pha002887 rs2123917 chr2 33248411 G A 1.84E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LTBP1 intron 24023788 rs7423562 chr2 33272454 A C 4.18E-04 Alzheimer's disease (late onset) LTBP1 intron 21379329 rs7423562 chr2 33272454 A C 9.41E-05 Orofacial clefts LTBP1 intron 22419666 rs368929 chr2 33296836 G A 3.19E-04 Multiple complex diseases LTBP1 intron 17554300 rs11896749 chr2 33297929 C T 2.60E-04 Alzheimer's disease (late onset) LTBP1 intron 21379329 rs11896749 chr2 33297929 C T 7.29E-05 Orofacial clefts LTBP1 intron 22419666 rs11896749 chr2 33297929 C T 1.14E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LTBP1 intron 24023788 rs542631 chr2 33301947 T G 7.34E-05 Cognitive performance LTBP1 intron 19734545 rs542631 chr2 33301947 T G 1.00E-07 Immune reponse to smallpox (secreted IFN-alpha) LTBP1 intron 22610502 rs17397408 chr2 33333871 A G 2.40E-05 Urinary metabolites LTBP1 intron 21572414 rs218193 chr2 33344570 T G 1.20E-04 Multiple complex diseases LTBP1 intron 17554300 rs1545552 chr2 33360338 A G 2.00E-10 Height LTBP1 intron 23563607 rs6714546 chr2 33361425 A G 2.00E-09 Height LTBP1 intron 20881960 rs6705263 chr2 33362643 T G 1.83E-04 Alzheimer's disease (late onset) LTBP1 intron 21379329 rs6737948 chr2 33365244 G A 1.40E-04 Vaspin levels LTBP1 intron 22907691 rs6737948 chr2 33365244 G A 0.00014 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks LTBP1 intron 22907730 rs10432656 chr2 33375032 C T 5.40E-05 HIV-1 control LTBP1 intron 20041166 rs10432656 chr2 33375032 C T 1.43E-05 Cholesterol LTBP1 intron pha003073 rs10432656 chr2 33375032 C T 1.42E-05 Cholesterol LTBP1 intron pha003078 rs10432656 chr2 33375032 C T 2.63E-05 Triglycerides LTBP1 intron pha003080 rs7572753 chr2 33387540 T C 4.20E-04 Intelligence (childhood) LTBP1 intron 23358156 rs17012623 chr2 33390188 T G 9.60E-04 Iron levels LTBP1 intron pha002876 rs4670307 chr2 33432201 A G 7.80E-05 Cognitive function LTBP1 intron 24684796 rs4671024 chr2 33445658 G A 8.40E-05 Diabetic retinopathy LTBP1 intron 21441570 rs2290448 chr2 33447202 C T 8.10E-05 Diabetic retinopathy LTBP1 cds-synon 21441570 rs17642074 chr2 33447979 A G 8.40E-05 Diabetic retinopathy LTBP1 intron 21441570 rs4671035 chr2 33449367 C G 8.00E-05 Diabetic retinopathy LTBP1 intron 21441570 rs4670322 chr2 33455742 A G 5.13E-05 Parkinson's disease LTBP1 intron pha002865 rs4630744 chr2 33461375 A G 8.60E-05 Diabetic retinopathy LTBP1 intron 21441570 rs3769528 chr2 33471192 A G 8.00E-08 Height LTBP1 intron 20189936 rs3769528 chr2 33471192 A G 3.49E-06 Orofacial clefts LTBP1 intron 22419666 rs3731575 chr2 33477964 C T 3.18E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) LTBP1 intron 24023788 rs1453845 chr2 33496281 C T 5.00E-04 Acute lymphoblastic leukemia (childhood) LTBP1 intron 20189245 rs817531 chr2 33498044 T G 1.56E-04 Type 2 diabetes LTBP1 intron 17463246 rs6739506 chr2 33506363 C T 1.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LTBP1 intron 20877124 rs4670408 chr2 33516152 C T 1.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LTBP1 intron 20877124 rs41464348 chr2 33527299 G A 9.16E-04 Type 2 diabetes LTBP1 intron 17463246 rs41464348 chr2 33527299 G A 7.00E-06 Height LTBP1 intron 19893584 rs1453842 chr2 33536962 A T 7.55E-04 Type 2 diabetes LTBP1 intron 17463246 rs723042 chr2 33541702 A G 6.41E-05 Lactate dehydrogenase levels LTBP1 intron 20981236 rs2167972 chr2 33556839 T C 8.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LTBP1 intron 20877124 rs2167972 chr2 33556839 T C 8.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LTBP1 intron 20877124 rs10495786 chr2 33559429 T C 1.18E-04 Response to cholinesterase inhibitors in Alzheimer's disease LTBP1 intron 23374588 rs17012889 chr2 33598217 A C 4.93E-04 Multiple complex diseases LTBP1 intron 17554300 rs17012898 chr2 33601649 A C 3.79E-04 Multiple complex diseases LTBP1 intron 17554300 rs6719824 chr2 33604048 A C 3.69E-05 Cortisol secretion,in saliva LTBP1 intron 21316860 rs6719824 chr2 33604048 A C 3.46E-05 Orofacial clefts LTBP1 intron 22419666 rs6742198 chr2 33607071 G A 4.10E-05 Alzheimer's disease (late onset) LTBP1 intron 21379329 rs6757228 chr2 33616240 C A 6.43E-05 Amyotrophic lateral sclerosis (sporadic) LTBP1 intron 24529757 rs602622 chr2 33658226 C G 9.09E-04 Multiple complex diseases / / 17554300 rs6543714 chr2 33682603 T G 8.94E-05 Lung adenocarcinoma RASGRP3 intron 19836008 rs6543714 chr2 33682603 T G 3.20E-06 Urinary metabolites RASGRP3 intron 21572414 rs2124437 chr2 33682737 G T 7.78E-04 Oral cancers (chewing tobacco related) RASGRP3 intron 22503698 rs10779917 chr2 33686494 G A 2.70E-05 Urinary metabolites RASGRP3 intron 21572414 rs17013034 chr2 33688129 C T 1.10E-05 Blood Pressure RASGRP3 intron pha003045 rs17013034 chr2 33688129 C T 8.58E-06 Blood Pressure RASGRP3 intron pha003047 rs13385731 chr2 33701890 T C 1.00E-15 Systemic lupus erythematosus RASGRP3 intron 19838193 rs13385731 chr2 33701890 T C 4.00E-06 Systemic lupus erythematosus RASGRP3 intron 23273568 rs1378725 chr2 33708414 T C 4.23E-04 Multiple complex diseases RASGRP3 intron 17554300 rs17013126 chr2 33709961 T C 7.97E-04 Multiple complex diseases RASGRP3 intron 17554300 rs7561821 chr2 33715742 T G 1.88E-04 Alcohol consumption (maxi-drinks) RASGRP3 intron 24277619 rs10495789 chr2 33719109 A G 9.81E-06 Multiple complex diseases RASGRP3 intron 17554300 rs6761582 chr2 33733554 T C 1.70E-05 Urinary metabolites RASGRP3 intron 21572414 rs6746494 chr2 33733719 C G 6.59E-06 Serum metabolites RASGRP3 intron 19043545 rs2305576 chr2 33745208 T C 8.34E-05 Taste perception RASGRP3 intron 22132133 rs4258776 chr2 33772525 G A 2.70E-05 Urinary metabolites RASGRP3 intron 21572414 rs11690827 chr2 33773739 A T 9.94E-04 Type 2 diabetes RASGRP3 intron 17463246 rs6543722 chr2 33832523 C A 8.47E-05 Height / / pha003011 rs1839158 chr2 33855431 C G 1 Drug response to Etoposide / / 17537913 rs10200581 chr2 33861293 C A 7.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2012014 chr2 33862493 T A 9.34E-05 Aortic root size / / 21223598 rs2004037 chr2 33862803 A T 7.85E-04 Acute lung injury / / 22295056 rs6711516 chr2 33895267 G T 1.77E-04 Taste perception / / 22132133 rs11904039 chr2 33897454 A G 1.83E-04 Acute lung injury / / 22295056 rs1550992 chr2 33931075 A G 3.42E-04 Gallstones / / 17632509 rs12988770 chr2 33940918 G A 4.33E-04 Taste perception / / 22132133 rs6706223 chr2 33944002 G A 1.25E-04 Taste perception / / 22132133 rs4670906 chr2 33946932 G A 3.80E-06 Parkinson's disease (familial) / / 18985386 rs17338665 chr2 33947012 A G 2.18E-04 Multiple complex diseases / / 17554300 rs11684598 chr2 33952621 G A 4.58E-05 Taste perception / / 22132133 rs4257379 chr2 33965251 G T 3.19E-04 Taste perception / / 22132133 rs6749326 chr2 33975365 G A 8.96E-05 LDL lipoproteins / / pha002902 rs6758248 chr2 33977878 G A 2.10E-04 Taste perception / / 22132133 rs4670279 chr2 33991952 A G 7.08E-04 Taste perception / / 22132133 rs4313958 chr2 34023020 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17013939 chr2 34036757 C A 6.38E-04 Multiple complex diseases / / 17554300 rs7579548 chr2 34056734 T G 8.51E-06 Glycemic traits (pregnancy) / / 23903356 rs773828 chr2 34103546 A C 4.70E-04 Schizophrenia / / 19197363 rs773823 chr2 34115251 T C 7.10E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs773820 chr2 34116688 G T 7.33E-05 Leukocyte Counts / / pha003091 rs2687208 chr2 34136251 C G 7.94E-04 Multiple complex diseases / / 17554300 rs11675822 chr2 34147919 C T 9.84E-04 Multiple complex diseases / / 17554300 rs7561310 chr2 34150347 G A 2.26E-04 Multiple complex diseases / / 17554300 rs9284729 chr2 34237001 T G 4.00E-05 Pericardial fat / / 22589742 rs2216963 chr2 34259736 A G 8.42E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6720882 chr2 34264101 A G 2.14E-04 Aortic root size / / 21223598 rs6728854 chr2 34273136 C A 8.07E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6543803 chr2 34273293 C T 8.07E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1425005 chr2 34283170 G A 4.93E-04 Premature ovarian failure / / 19508998 rs9308945 chr2 34284852 A G 3.00E-10 Hypertension (young onset) / / 19421330 rs6711736 chr2 34284984 G A 3.00E-10 Hypertension (young onset) / / 19421330 rs6729869 chr2 34285194 T A 3.00E-10 Hypertension (young onset) / / 19421330 rs17339029 chr2 34285885 A G 6.97E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1593293 chr2 34289199 A G 2.43E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1816151 chr2 34291679 A G 2.00E-05 Urinary metabolites / / 21572414 rs13393038 chr2 34293353 T A 2.60E-05 Urinary metabolites / / 21572414 rs9308946 chr2 34302827 T G 0.000895778 Hypertension (early onset hypertension) / / 22479346 rs10495809 chr2 34305257 G A 3.00E-10 Hypertension (young onset) / / 19421330 rs17014711 chr2 34326938 G A 6.07E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6708860 chr2 34333297 G A 5.59E-05 Cognitive test performance / / 20125193 rs17470247 chr2 34381971 A G 1.91E-04 Vaspin levels / / 22907691 rs17470247 chr2 34381971 A G 0.0001914 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs2193800 chr2 34390610 G A 2.27E-05 Blood Pressure / / pha003043 rs1541636 chr2 34427633 A G 7.28E-04 Taste perception / / 22132133 rs1541636 chr2 34427633 A G 2.24E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1541636 chr2 34427633 A G 9.44E-06 Blood Pressure / / pha003043 rs1988964 chr2 34429224 A G 6.34E-05 Multiple complex diseases / / 17554300 rs1988964 chr2 34429224 A G 2.20E-05 Urinary metabolites / / 21572414 rs6543818 chr2 34445158 C A 9.16E-05 Response to methylphenidate treatment / / 21130132 rs2161025 chr2 34453722 C T 2.50E-05 Urinary metabolites / / 21572414 rs972053 chr2 34458232 G C 2.50E-05 Urinary metabolites / / 21572414 rs7574426 chr2 34460541 A G 9.40E-06 Urinary metabolites / / 21572414 rs11124366 chr2 34467962 C T 3.20E-06 Urinary metabolites / / 21572414 rs2371922 chr2 34474517 C T 4.47E-05 Blood Pressure / / pha003043 rs11687656 chr2 34475820 T G 2.80E-05 Urinary metabolites / / 21572414 rs13407683 chr2 34477438 G A 4.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6733379 chr2 34480075 G T 4.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs6719309 chr2 34499749 A C 2.08E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs1978414 chr2 34505480 C T 2.66E-04 Type 2 diabetes / / 17463246 rs249084 chr2 34515140 C A 6.71E-04 Type 2 diabetes / / 17463246 rs111344 chr2 34516450 T C 5.28E-04 Type 2 diabetes / / 17463246 rs9967777 chr2 34517688 C G 3.30E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs9967777 chr2 34517688 C G 1.10E-05 Urinary metabolites / / 21572414 rs12613086 chr2 34519779 A G 1.20E-05 Multiple complex diseases / / 17554300 rs6721933 chr2 34542730 G T 9.65E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs249103 chr2 34548229 A T 6.45E-04 Type 2 diabetes / / 17463246 rs10495813 chr2 34564586 T C 8.84E-05 Body Mass Index / / pha003020 rs10495813 chr2 34564586 T C 8.64E-05 Waist Circumference / / pha003024 rs12712380 chr2 34566647 C T 3.44E-04 Type 2 diabetes / / 17463246 rs41319450 chr2 34567302 C G 2.98E-04 Type 2 diabetes / / 17463246 rs12623550 chr2 34599529 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1583366 chr2 34601927 A G 4.78E-04 Multiple complex diseases / / 17554300 rs1434126 chr2 34610836 C T 9.24E-04 Alzheimer's disease / / 22005930 rs1434126 chr2 34610836 C T 6.88E-04 Tourette syndrome / / 22889924 rs6543833 chr2 34631032 C G 8.00E-08 Ovarian reserve / / 22116950 rs17248142 chr2 34638921 A T 7.74E-04 Multiple complex diseases / / 17554300 rs2887971 chr2 34644109 T C 8.86E-04 Multiple complex diseases / / 17554300 rs892458 chr2 34667749 T C 1.30E-04 Heart Failure / / pha002884 rs10495822 chr2 34672921 G T 8.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1519911 chr2 34685280 C T 2.10E-05 Urinary metabolites / / 21572414 rs4670084 chr2 34691069 G C 5.40E-06 Urinary metabolites / / 21572414 rs7583467 chr2 34691083 G A 4.99E-04 Heart Failure / / pha002884 rs11889782 chr2 34722626 A G 1.11E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10495824 chr2 34750545 A G 1.10E-05 Urinary metabolites / / 21572414 rs1022390 chr2 34751803 A C 6.60E-06 Urinary metabolites / / 21572414 rs2371401 chr2 34803638 A C 4.02E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs41495350 chr2 34817771 G T 5.64E-04 Multiple complex diseases / / 17554300 rs41431451 chr2 34868864 T C 1.76E-04 Multiple complex diseases / / 17554300 rs1358358 chr2 34891689 G A 8.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs7575839 chr2 34902177 A G 8.35E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1527616 chr2 34909001 C T 3.29E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs11683103 chr2 34912850 G A 8.60E-06 Alzheimer's disease (late onset) / / 20885792 rs11683103 chr2 34912850 G A 8.60E-06 Alzheimer's disease (late onset) / / 21460841 rs3856481 chr2 34946284 C G 6.13E-04 Alzheimer's disease / / 17998437 rs380322 chr2 35043996 C T 8.60E-04 Taste perception / / 22132133 rs72795093 chr2 35054313 T C 8.97E-06 Response to amphetamines / / 22952603 rs6725256 chr2 35055879 C T 7.39E-06 Response to amphetamines / / 22952603 rs7559552 chr2 35058421 A C 8.55E-06 Response to amphetamines / / 22952603 rs7608287 chr2 35069807 G T 2.48E-06 Response to amphetamines / / 22952603 rs280691 chr2 35073607 T C 1.66E-05 Creatinine levels / / pha003069 rs72796913 chr2 35074300 T C 1.74E-06 Response to amphetamines / / 22952603 rs72796914 chr2 35075575 C G 1.63E-06 Response to amphetamines / / 22952603 rs72796917 chr2 35078778 C T 1.26E-06 Response to amphetamines / / 22952603 rs72796929 chr2 35090946 T C 1.09E-06 Response to amphetamines / / 22952603 rs280754 chr2 35092762 C T 6.17E-05 Creatinine levels / / pha003069 rs7600259 chr2 35093293 T G 1.00E-06 Response to amphetamines / / 22952603 rs6727092 chr2 35103218 A G 6.80E-06 Response to amphetamines / / 22952603 rs12467773 chr2 35107431 T C 7.98E-06 Response to amphetamines / / 22952603 rs72778810 chr2 35117772 T C 3.38E-06 Response to amphetamines / / 22952603 rs1911544 chr2 35143864 T C 1.58E-04 Ovarian cancer in BRCA1 mutation carriers / / 23544013 rs1395697 chr2 35144127 A C 9.02E-04 Type 2 diabetes / / 17463246 rs6543889 chr2 35197402 T A 1.02E-04 Cholesterol / / 17255346 rs11124408 chr2 35198305 T C 5.74E-05 Cholesterol / / 17255346 rs11124408 chr2 35198305 T C 7.15E-05 Gallstones / / 17632509 rs11124408 chr2 35198305 T C 5.40E-04 Coronary heart disease / / 21606135 rs10184960 chr2 35201802 G C 1.17E-04 Cholesterol / / 17255346 rs10184960 chr2 35201802 G C 9.08E-04 Type 2 diabetes / / 17463246 rs1377421 chr2 35213052 G C 5.86E-04 Multiple complex diseases / / 17554300 rs1377421 chr2 35213052 G C 7.40E-04 Smoking initiation / / 24665060 rs17387182 chr2 35224451 C T 7.75E-04 Alcohol dependence / / 20201924 rs17398711 chr2 35235120 C T 7.54E-05 Alcohol dependence / / 20201924 rs17398711 chr2 35235120 C T 7.54E-05 Alcoholism / / pha002891 rs896824 chr2 35237370 A G 1.58E-04 Cholesterol / / 17255346 rs6710736 chr2 35248047 A G 3.02E-04 Cholesterol / / 17255346 rs6710736 chr2 35248047 A G 8.92E-04 Type 2 diabetes / / 17463246 rs6739609 chr2 35248062 G A 3.02E-04 Cholesterol / / 17255346 rs6739609 chr2 35248062 G A 6.03E-04 Type 2 diabetes / / 17463246 rs1453266 chr2 35250422 T C 3.04E-04 Cholesterol / / 17255346 rs1453266 chr2 35250422 T C 9.58E-04 Type 2 diabetes / / 17463246 rs1453267 chr2 35250716 A G 7.66E-04 Type 2 diabetes / / 17463246 rs3920465 chr2 35292658 C A 4.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12712411 chr2 35293343 T G 9.30E-04 Myocardial Infarction / / pha002873 rs1955381 chr2 35295078 G A 6.02E-04 Type 2 diabetes / / 17463246 rs13005421 chr2 35298411 G A 5.46E-04 Smoking initiation / / 24665060 rs1922357 chr2 35304850 A T 3.70E-04 Type 2 diabetes / / 17463246 rs17016225 chr2 35370851 A G 4.19E-04 Serum selenium levels / / 23698163 rs1439845 chr2 35411425 G A 2.00E-04 Smoking behavior / / 20418888 rs4670450 chr2 35435104 G A 4.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17016345 chr2 35447145 G A 2.71E-08 Multiple complex diseases / / 17554300 rs726698 chr2 35455341 A T 1.15E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs726698 chr2 35455341 A T 2.20E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs12712425 chr2 35465744 G A 6.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6750486 chr2 35526918 C T 6.00E-06 Conduct disorder (symptom count) / / 20585324 rs6543930 chr2 35572015 T C 1.61E-04 Alzheimer's disease / / 22005930 rs7586043 chr2 35572711 G A 2.94E-04 Alzheimer's disease / / 22005930 rs7590763 chr2 35575340 T C 3.66E-04 Alzheimer's disease / / 22005930 rs7584802 chr2 35577771 C T 2.76E-04 Alzheimer's disease / / 22005930 rs6751791 chr2 35581997 G A 2.21E-04 Alzheimer's disease / / 22005930 rs17016489 chr2 35585929 C A 2.43E-04 Multiple complex diseases / / 17554300 rs7587787 chr2 35588953 C G 2.83E-04 Alzheimer's disease / / 22005930 rs6756976 chr2 35589317 T A 2.61E-04 Alzheimer's disease / / 22005930 rs17823215 chr2 35589972 A G 2.27E-04 Alzheimer's disease / / 22005930 rs17772161 chr2 35590409 C G 2.62E-04 Alzheimer's disease / / 22005930 rs7598399 chr2 35591234 G A 2.25E-04 Alzheimer's disease / / 22005930 rs12993283 chr2 35592405 C T 3.86E-04 Alzheimer's disease / / 22005930 rs17399446 chr2 35600932 T A 4.91E-04 Alzheimer's disease / / 22005930 rs4577259 chr2 35607078 A G 4.50E-04 Alzheimer's disease / / 22005930 rs17016558 chr2 35614444 T C 1.28E-04 Schizophrenia / / 19197363 rs4670466 chr2 35622544 A T 2.13E-04 Type 2 diabetes / / 17463246 rs4670467 chr2 35622660 G A 2.06E-04 Type 2 diabetes / / 17463246 rs6756157 chr2 35624746 T C 7.35E-04 Schizophrenia / / 19197363 rs4254484 chr2 35643579 A G 8.98E-04 Multiple complex diseases / / 17554300 rs13012972 chr2 35644367 T C 7.59E-04 Type 2 diabetes / / 17463246 rs11885690 chr2 35654708 T C 1.33E-05 Biliary atresia / / 20460270 rs4513272 chr2 35659858 A G 3.51E-05 Weight / / pha003026 rs13402855 chr2 35662797 C T 2.00E-06 Metabolite levels (5-HIAA) / / 23319000 rs2719085 chr2 35674924 G A 3.55E-05 Weight / / pha003026 rs4297857 chr2 35675611 C A 8.94E-05 Body Mass Index / / pha003006 rs4297857 chr2 35675611 C A 6.29E-05 Body Mass Index / / pha003014 rs4297857 chr2 35675611 C A 1.01E-06 Waist Circumference / / pha003024 rs4297857 chr2 35675611 C A 4.87E-07 Weight / / pha003026 rs2714589 chr2 35676713 C T 3.67E-05 Weight / / pha003026 rs2719121 chr2 35713309 G A 8.23E-05 Body Mass Index / / pha003014 rs11681520 chr2 35737252 C G 7.82E-04 Alzheimer's disease / / 17998437 rs1583756 chr2 35753511 T C 9.03E-05 Height / / pha003011 rs1439706 chr2 35764414 T C 5.75E-06 Asthma (childhood onset) / / 23829686 rs7591339 chr2 35825598 C T 6.40E-04 Type 2 diabetes / / 17463246 rs1371418 chr2 35830334 G A 6.58E-04 Type 2 diabetes / / 17463246 rs1371419 chr2 35833642 T C 5.19E-04 Body mass index / / 21701565 rs7570146 chr2 35844752 G T 8.96E-04 Type 2 diabetes / / 17463246 rs1439691 chr2 35851282 A C 6.67E-04 Type 2 diabetes / / 17463246 rs10495843 chr2 35859342 G T 7.90E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1439693 chr2 35859748 T C 9.52E-04 Parkinson's disease / / 17052657 rs17328874 chr2 35863393 A G 8.59E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1439697 chr2 35880978 T C 1.55E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6744761 chr2 35933774 A G 4.97E-05 Type 2 diabetes / / 17463246 rs9308980 chr2 35937722 G C 1.90E-05 Urinary metabolites / / 21572414 rs1401220 chr2 35944694 A G 9.99E-05 Type 2 diabetes / / 17463246 rs1401220 chr2 35944694 A G 2.30E-05 Urinary metabolites / / 21572414 rs1401219 chr2 35944777 G A 1.24E-04 Type 2 diabetes / / 17463246 rs1401219 chr2 35944777 G A 2.30E-05 Urinary metabolites / / 21572414 rs6737499 chr2 35945993 T C 1.20E-05 Urinary metabolites / / 21572414 rs4016189 chr2 35967123 G C 2.70E-06 Urinary metabolites / / 21572414 rs17017391 chr2 36001197 C A 2.14E-05 Tunica Media / / pha003036 rs7557606 chr2 36014002 A G 2.80E-05 Urinary metabolites / / 21572414 rs10166465 chr2 36020005 T C 7.24E-05 Menopause (age at onset) / / 19448619 rs7592322 chr2 36077340 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6751249 chr2 36079256 T C 1.23E-05 Bladder cancer / / 24163127 rs17017699 chr2 36084515 T C 1.52E-04 Multiple complex diseases / / 17554300 rs10173700 chr2 36097070 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1401775 chr2 36098961 T C 8.83E-05 Panic disorder / / 19165232 rs2968576 chr2 36123261 T G 4.95E-04 Taste perception / / 22132133 rs1533969 chr2 36125308 G A 2.14E-05 Parkinson's disease / / 19915575 rs2949065 chr2 36132943 C T 3.61E-05 Parkinson's disease / / 19915575 rs12712470 chr2 36135030 C T 9.58E-05 Elbow pain / / pha003008 rs12712470 chr2 36135030 C T 5.95E-05 Waist Circumference / / pha003024 rs12712470 chr2 36135030 C T 4.12E-05 Weight / / pha003026 rs1533971 chr2 36136638 G A 9.78E-05 Elbow pain / / pha003008 rs1533971 chr2 36136638 G A 5.52E-05 Waist Circumference / / pha003024 rs1533971 chr2 36136638 G A 3.68E-05 Weight / / pha003026 rs11900940 chr2 36150624 C T 2.14E-05 Waist Circumference / / pha003024 rs11900940 chr2 36150624 C T 6.10E-05 Weight / / pha003026 rs2968624 chr2 36162477 A G 2.53E-04 Smoking initiation / / 24665060 rs2968625 chr2 36163832 A G 4.03E-04 Alcohol dependence / / 20201924 rs17017873 chr2 36166844 G C 2.14E-04 Obesity (early onset extreme) / / 23563609 rs2949081 chr2 36169533 G T 4.03E-04 Alcohol dependence / / 20201924 rs2968629 chr2 36170939 C T 9.63E-05 Body Mass Index / / pha003019 rs13409385 chr2 36176752 C T 1.67E-05 Alzheimer's disease (late onset) / / 21379329 rs13016974 chr2 36180191 C G 8.01E-04 Multiple complex diseases / / 17554300 rs2020327 chr2 36193739 T C 8.67E-04 Type 2 diabetes / / 17463246 rs2020327 chr2 36193739 T C 4.70E-04 Multiple complex diseases / / 17554300 rs833764 chr2 36194180 T C 1.95E-05 Body Mass Index / / pha003019 rs833764 chr2 36194180 T C 9.09E-05 Body Mass Index / / pha003022 rs1705046 chr2 36211712 A G 6.82E-05 Body Mass Index / / pha003019 rs833787 chr2 36224052 T C 4.94E-06 Body Mass Index / / pha003019 rs833787 chr2 36224052 T C 6.49E-05 Body Mass Index / / pha003020 rs833787 chr2 36224052 T C 9.05E-06 Body Mass Index / / pha003022 rs305188 chr2 36251327 G C 4.69E-04 Type 2 diabetes / / 17463246 rs7566742 chr2 36257825 C A 1.35E-04 Type 2 diabetes / / 17463246 rs2251598 chr2 36261471 G T 2.74E-04 Taste perception / / 22132133 rs1873117 chr2 36263467 T C 3.84E-04 Nicotine dependence / / 17158188 rs4670135 chr2 36270756 C T 3.90E-05 HIV-1 control / / 20041166 rs305208 chr2 36274603 G A 4.25E-04 Type 2 diabetes / / 17463246 rs305205 chr2 36276269 G T 9.97E-04 Type 2 diabetes / / 17463246 rs305204 chr2 36276750 T C 8.08E-04 Type 2 diabetes / / 17463246 rs305203 chr2 36277969 G A 9.05E-04 Type 2 diabetes / / 17463246 rs305202 chr2 36278224 G A 7.98E-04 Type 2 diabetes / / 17463246 rs177541 chr2 36283088 G A 5.79E-04 Type 2 diabetes / / 17463246 rs2666128 chr2 36287452 C T 3.46E-05 Parkinson's disease / / pha002868 rs10495863 chr2 36288320 G A 9.88E-04 Type 2 diabetes / / 17463246 rs10495863 chr2 36288320 G A 6.00E-07 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs2666138 chr2 36331157 G A 3.00E-07 Alopecia areata / / 22027810 rs1686103 chr2 36354621 A C 3.26E-05 Parkinson's disease / / pha002868 rs17018354 chr2 36383466 G A 5.42E-04 Type 2 diabetes / / 17463246 rs12614272 chr2 36386902 T C 4.13E-05 Lymphocyte counts / / pha003094 rs12614272 chr2 36386902 T C 2.29E-05 Neutrophil count / / pha003095 rs11674150 chr2 36447481 G A 6.62E-04 Multiple complex diseases / / 17554300 rs11124503 chr2 36455837 G A 3.11E-04 Multiple complex diseases / / 17554300 rs1529267 chr2 36464050 T C 4.64E-05 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs1919818 chr2 36480422 T C 4.95E-04 Insulin resistance / / 21901158 rs2246009 chr2 36483942 A G 7.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs2699168 chr2 36484948 A G 7.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs2552000 chr2 36489670 C G 7.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs2551999 chr2 36489820 T C 7.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs6704972 chr2 36490624 G T 6.38E-04 Alzheimer's disease / / 17998437 rs12104793 chr2 36491004 G A 5.77E-04 Alzheimer's disease / / 17998437 rs2552046 chr2 36491041 A C 3.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs2699179 chr2 36493401 G T 8.55E-04 Alzheimer's disease / / 17998437 rs1881777 chr2 36494095 C G 1.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs1881778 chr2 36494176 C T 1.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs1881778 chr2 36494176 C T 8.59E-04 Acute lung injury / / 22295056 rs2699181 chr2 36495030 C T 2.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs2194577 chr2 36496233 C T 2.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs2194577 chr2 36496233 C T 7.54E-04 Acute lung injury / / 22295056 rs726946 chr2 36497171 C T 2.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs726947 chr2 36497312 C T 2.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs17387739 chr2 36498265 C T 2.02E-04 Alzheimer's disease / / 17998437 rs2699184 chr2 36500798 T C 2.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs2699184 chr2 36500798 T C 9.01E-04 Acute lung injury / / 22295056 rs2699185 chr2 36501147 C T 1.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs2699185 chr2 36501147 C T 9.01E-04 Acute lung injury / / 22295056 rs2552037 chr2 36505165 A C 1.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs2552035 chr2 36507300 G A 5.74E-05 Suicide attempts in bipolar disorder / / 21423239 rs2552034 chr2 36507357 C T 5.61E-05 Suicide attempts in bipolar disorder / / 21423239 rs2552029 chr2 36509516 A C 3.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs2552028 chr2 36510643 A G 3.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs2552028 chr2 36510643 A G 7.54E-04 Acute lung injury / / 22295056 rs2699190 chr2 36510725 A T 5.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs2552027 chr2 36511930 C G 4.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs2552027 chr2 36511930 C G 7.54E-04 Acute lung injury / / 22295056 rs2243925 chr2 36513791 G A 5.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs2161905 chr2 36516173 G A 5.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs2699193 chr2 36516663 A G 1.25E-04 Alzheimer's disease / / 17998437 rs2699193 chr2 36516663 A G 4.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs6544004 chr2 36518699 A G 8.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs6733100 chr2 36520350 A G 8.02E-05 Alzheimer's disease / / 17998437 rs6733100 chr2 36520350 A G 7.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs2699187 chr2 36521759 A G 3.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs1863080 chr2 36526436 T G 8.00E-06 Anthropometric traits / / 19260139 rs4670143 chr2 36549966 T C 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs10490672 chr2 36571139 A C 6.14E-04 Alcohol dependence / / 21314694 rs4670544 chr2 36580631 C T 0.000681658 Hypertension (early onset hypertension) / / 22479346 rs9308991 chr2 36596663 C G 9.38E-04 Multiple complex diseases CRIM1 intron 17554300 rs11124511 chr2 36602368 C T 1.60E-05 Urinary metabolites CRIM1 intron 21572414 rs3770939 chr2 36617528 G A 7.72E-04 Response to taxane treatment (placlitaxel) CRIM1 intron 23006423 rs12466450 chr2 36620953 C T 1.00E-04 Anxiety spectrum disorders CRIM1 intron 20368705 rs3770935 chr2 36625388 C T 4.67E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) CRIM1 intron 23648065 rs4670145 chr2 36627725 A G 8.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) CRIM1 intron 23648065 rs3770924 chr2 36631779 A G 1.30E-04 IgE levels in asthmatics CRIM1 intron 23967269 rs7562790 chr2 36673555 T G 8.00E-09 Ventricular conduction CRIM1 intron 21076409 rs7562790 chr2 36673555 T G 4.90E-06 Urinary metabolites CRIM1 intron 21572414 rs7562790 chr2 36673555 T G 6.00E-04 Taste perception CRIM1 intron 22132133 rs848512 chr2 36675530 A G 1.00E-06 IgE levels in asthmatics CRIM1 intron 23967269 rs3770876 chr2 36679028 T G 8.40E-06 Urinary metabolites CRIM1 intron 21572414 rs711254 chr2 36680848 A G 6.73E-06 IgE levels in asthmatics CRIM1 intron 23967269 rs3770866 chr2 36690093 C T 4.50E-04 Insulin resistance CRIM1 intron 21901158 rs4670560 chr2 36702052 C T 6.81E-04 Insulin resistance CRIM1 intron 21901158 rs3770839 chr2 36717620 G A 0.0000806 Salmonella-induced pyroptosis CRIM1 intron 22837397 rs3899034 chr2 36717819 G A 0.0000955 Salmonella-induced pyroptosis CRIM1 intron 22837397 rs848529 chr2 36732171 T C 0.0002711 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CRIM1 intron 23233654 rs848529 chr2 36732171 T C 2.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) CRIM1 intron 23233662 rs884215 chr2 36742955 A G 2.69E-05 Bipolar disorder CRIM1 intron 19488044 rs884215 chr2 36742955 A G 2.34E-05 Bipolar Disorder CRIM1 intron pha002863 rs2287082 chr2 36745012 C A 1.20E-05 Urinary metabolites CRIM1 intron 21572414 rs17480811 chr2 36745949 C A 0.0002713 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CRIM1 intron 23233654 rs17480811 chr2 36745949 C A 2.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) CRIM1 intron 23233662 rs848523 chr2 36747656 T C 2.10E-05 Blood Phenotypes CRIM1 intron 17903294 rs17018986 chr2 36751421 A G 0.0002827 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CRIM1 intron 23233654 rs17018986 chr2 36751421 A G 2.83E-04 Methotrexate clearance (acute lymphoblastic leukemia) CRIM1 intron 23233662 rs3821153 chr2 36753122 T G 8.05E-04 Insulin resistance CRIM1 intron 21901158 rs17019000 chr2 36755937 T C 0.0002869 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CRIM1 intron 23233654 rs17019000 chr2 36755937 T C 2.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) CRIM1 intron 23233662 rs17019002 chr2 36756196 G A 0.0002866 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CRIM1 intron 23233654 rs17019002 chr2 36756196 G A 2.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) CRIM1 intron 23233662 rs11681392 chr2 36758100 G T 1.60E-05 Urinary metabolites CRIM1 intron 21572414 rs882842 chr2 36758284 A C 0.0003078 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CRIM1 intron 23233654 rs882842 chr2 36758284 A C 3.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) CRIM1 intron 23233662 rs848516 chr2 36764402 A G 0.000246 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CRIM1 intron 23233654 rs848516 chr2 36764402 A G 2.46E-04 Methotrexate clearance (acute lymphoblastic leukemia) CRIM1 intron 23233662 rs848607 chr2 36770192 G A 1.86E-04 Alzheimer's disease CRIM1 intron 22005930 rs981355 chr2 36770401 C T 3.23E-05 Lipoproteins CRIM1 intron pha003079 rs848606 chr2 36770736 G T 1.28E-04 Alzheimer's disease CRIM1 intron 22005930 rs12712508 chr2 36771309 A G 8.20E-04 Alzheimer's disease CRIM1 intron 22005930 rs848605 chr2 36773260 G A 2.39E-04 Alzheimer's disease CRIM1 intron 22005930 rs848603 chr2 36773868 C T 2.17E-04 Alzheimer's disease CRIM1 intron 22005930 rs10189344 chr2 36778887 A C 1.33E-04 Lymphocyte counts / / 22286170 rs1533948 chr2 36781138 A G 1.53E-05 Lipoproteins FEZ2 intron pha003079 rs848641 chr2 36785169 C T 8.00E-04 Body mass index FEZ2 intron 24827717 rs13406184 chr2 36791226 T C 4.07E-05 Lipoproteins FEZ2 intron pha003079 rs848619 chr2 36810769 T C 4.35E-05 Lipoproteins FEZ2 intron pha003079 rs12105545 chr2 36814201 G A 2.85E-05 Lipoproteins FEZ2 intron pha003079 rs918066 chr2 36838600 T C 9.92E-05 Lipoproteins / / pha003079 rs10164588 chr2 36839723 T A 5.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs4670153 chr2 36848313 G C 2.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs12464610 chr2 36849808 C T 3.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs7422754 chr2 36851079 A G 4.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs11124523 chr2 36851264 C T 5.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs7600979 chr2 36854548 C T 7.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs4595955 chr2 36882586 T C 3.98E-05 Parkinson's disease (motor and cognition) / / 22658654 rs4595955 chr2 36882586 T C 3.98E-05 Immune response to anthrax vaccine / / 22658931 rs13021543 chr2 36883858 A G 9.80E-05 Parkinson's disease (motor and cognition) / / 22658654 rs13021543 chr2 36883858 A G 9.80E-05 Immune response to anthrax vaccine / / 22658931 rs6755881 chr2 36895652 C G 2.76E-04 Multiple complex diseases / / 17554300 rs6713334 chr2 36904442 C A 1.34E-04 Multiple complex diseases / / 17554300 rs11124529 chr2 36913267 C T 9.32E-04 Insulin resistance / / 21901158 rs6544028 chr2 36928030 T C 2.62E-04 Age-related macular degeneration VIT intron 22125219 rs9308994 chr2 36930788 G C 3.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) VIT intron 17982456 rs10460526 chr2 36932843 C T 9.43E-04 Stroke VIT intron pha002887 rs4670165 chr2 36942266 C A 2.79E-04 Multiple complex diseases VIT intron 17554300 rs4670165 chr2 36942266 C A 1.10E-05 Urinary metabolites VIT intron 21572414 rs1015695 chr2 36959885 A G 2.80E-05 Urinary metabolites VIT intron 21572414 rs2372711 chr2 36962557 A G 4.18E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines VIT intron 21844884 rs12469652 chr2 36977116 A G 3.95E-05 Parkinson's disease VIT intron 21812969 rs4670600 chr2 36979512 A G 3.41E-05 Triglycerides VIT intron pha002904 rs12997998 chr2 36980698 A C 1.20E-05 Urinary metabolites VIT intron 21572414 rs1468811 chr2 36993811 T C 3.64E-04 Multiple complex diseases VIT intron 17554300 rs4670605 chr2 36996398 A G 3.43E-04 Type 2 diabetes VIT intron 17463246 rs17494117 chr2 37015371 C T 4.10E-05 Serum albumin level VIT intron pha003084 rs974966 chr2 37048522 A G 2.00E-05 Hypothyroidism / / 22493691 rs2372715 chr2 37049287 G A 7.84E-04 Multiple complex diseases / / 17554300 rs888053 chr2 37049563 A T 6.00E-05 Hypothyroidism / / 22493691 rs3770781 chr2 37078839 A G 5.08E-04 Myopia (pathological) STRN intron 21095009 rs2540923 chr2 37094945 A G 1.50E-05 HIV-1 control STRN intron 20041166 rs2691111 chr2 37102129 G A 1.50E-05 HIV-1 control STRN intron 20041166 rs13430716 chr2 37136517 A G 1.50E-05 HIV-1 control STRN intron 20041166 rs11124552 chr2 37142754 A G 2.68E-05 Multiple complex diseases STRN intron 17554300 rs11124555 chr2 37176213 G A 2.01E-05 HIV-1 viral setpoint STRN intron 22174851 rs3770775 chr2 37180207 C A 3.50E-04 Lipopolysaccharide induced cytokine levels STRN intron 23823136 rs3770770 chr2 37192866 C T 9.80E-04 Multiple complex diseases STRN intron 17554300 rs3770770 chr2 37192866 C T 9.65E-04 Response to cytidine analogues (gemcitabine) STRN intron 24483146 rs1007823 chr2 37230728 T A,C,G 6.01E-05 Kawasaki disease HEATR5B cds-synon 22081228 rs17038861 chr2 37233265 T G 2.34E-04 Multiple complex diseases HEATR5B intron 17554300 rs17020136 chr2 37248015 T C 2.00E-09 Ventricular conduction HEATR5B intron 21076409 rs1008838 chr2 37252235 A G 7.81E-04 Alzheimer's disease HEATR5B intron 24755620 rs7581702 chr2 37252852 G C 2.05E-04 Multiple complex diseases HEATR5B intron 17554300 rs2372914 chr2 37264675 T C 9.28E-06 Stroke HEATR5B intron 22306652 rs13423928 chr2 37277811 A G 6.80E-04 Alzheimer's disease HEATR5B intron 24755620 rs4233920 chr2 37336720 A G 4.89E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) EIF2AK2 intron 24023788 rs4648195 chr2 37363968 CG C 7.79E-04 Type 2 diabetes EIF2AK2 intron 17463246 rs4648196 chr2 37363968 C G 7.79E-04 Type 2 diabetes EIF2AK2 intron 17463246 rs2254958 chr2 37376291 G A 9.13E-05 Cardiovascular disease EIF2AK2 UTR-5 pha003065 rs11124565 chr2 37410316 T G 2.61E-05 Schizophrenia SULT6B1 intron 20832056 rs11895771 chr2 37412935 T G 7.97E-06 Schizophrenia SULT6B1 intron 20832056 rs11895771 chr2 37412935 T G 3.95E-04 Alcohol dependence SULT6B1 intron 21314694 rs6724820 chr2 37414431 A C 7.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SULT6B1 intron 20877124 rs7340131 chr2 37416494 G A,C 4.95E-04 Multiple complex diseases / / 17554300 rs2239650 chr2 37438764 A G 8.22E-04 Acute lung injury CEBPZ intron 22295056 rs2041840 chr2 37467264 T C 9.00E-06 Chronic lymphocytic leukemia C2orf56 intron 24292274 rs1056021 chr2 37480249 A G 3.28E-04 Lung function (forced expiratory volume in 1 second) PRKD3 UTR-3 17255346 rs3770764 chr2 37489877 G A 1.98E-04 Height PRKD3 intron 17255346 rs2300885 chr2 37496276 T A,C,G 1.50E-05 Urinary metabolites PRKD3 intron 21572414 rs2160394 chr2 37499406 C T 1.40E-05 Urinary metabolites PRKD3 intron 21572414 rs141998414 chr2 37513340 C T 0.000058 Breast cancer(er negative) PRKD3 missense 23555315 rs141998414 chr2 37513340 C T 0.0002 Breast cancer PRKD3 missense 23555315 rs2287091 chr2 37513586 A G 1.27E-04 Multiple complex diseases PRKD3 intron 17554300 rs10204434 chr2 37513670 A G 1.96E-04 Multiple complex diseases PRKD3 intron 17554300 rs10181140 chr2 37513763 G T 7.70E-05 Personality dimensions PRKD3 intron 18957941 rs10181140 chr2 37513763 G T 7.59E-04 Suicide attempts in bipolar disorder PRKD3 intron 21041247 rs6754376 chr2 37527164 A G 6.91E-05 Panic disorder PRKD3 intron 19165232 rs4670688 chr2 37541060 A G 4.00E-06 Urinary metabolites PRKD3 intron 21572414 rs1158219 chr2 37546820 T A 3.51E-05 Bipolar disorder / / 19488044 rs1158219 chr2 37546820 T A 3.60E-05 Bipolar Disorder / / pha002858 rs6734118 chr2 37559355 C A 3.35E-05 Type 1 diabetes / / 18978792 rs6734118 chr2 37559355 C A 0.00018856 Primary sclerosing cholangitis / / 23603763 rs6708524 chr2 37572687 G A 9.58E-05 Bipolar disorder and schizophrenia QPCT intron 20889312 rs3821142 chr2 37575287 C T 9.78E-05 Bipolar disorder and schizophrenia QPCT intron 20889312 rs10179447 chr2 37578208 G A 9.80E-05 Bipolar disorder and schizophrenia QPCT intron 20889312 rs2373000 chr2 37592628 C T 7.00E-09 Schizophrenia QPCT intron 23974872 rs3770748 chr2 37595525 A G 5.86E-04 Response to cytidine analogues (gemcitabine) QPCT intron 24483146 rs3770745 chr2 37596089 C T 1.68E-08 Chronic lymphocytic leukemia QPCT intron 23770605 rs7582749 chr2 37599337 C G 3.70E-04 Crohn's disease QPCT intron 17684544 rs6544071 chr2 37600793 G A 8.04E-04 Insulin resistance / / 21901158 rs1024816 chr2 37601208 A G 1.72E-06 Osteoarthritis / / 22763110 rs6713585 chr2 37624938 G A 3.54E-04 Insulin resistance / / 21901158 rs10173794 chr2 37629222 A G 7.50E-05 Major depressive disorder / / 21621269 rs13002028 chr2 37646632 A C 4.40E-04 Major depressive disorder / / 21042317 rs4490163 chr2 37655077 T C 5.36E-04 Tourette syndrome / / 22889924 rs888098 chr2 37684741 C T 5.87E-05 Cognitive test performance / / 20125193 rs2192947 chr2 37690633 T C 4.59E-04 Smoking quantity / / 24665060 rs6724538 chr2 37728018 G T 5.20E-06 Urinary metabolites / / 21572414 rs960902 chr2 37731665 G A 8.00E-06 Response to TNF-alpha inhibitors in rheumatoid arthritis / / 22569225 rs10178620 chr2 37743379 G T 3.86E-05 Cognitive test performance / / 20125193 rs4352210 chr2 37750980 A G 2.00E-06 RR interval (heart rate) / / 20031603 rs6730320 chr2 37804964 G T 8.24E-05 Serum metabolites / / 19043545 rs4140806 chr2 37831162 T C 3.80E-04 Type 2 diabetes / / 17463249 rs917732 chr2 37831553 A G 4.81E-05 Sudden cardiac arrest / / 21658281 rs10490281 chr2 37848297 G A 8.31E-04 Multiple complex diseases / / 17554300 rs6729121 chr2 37855222 T C 6.44E-05 Inflammation / / pha002897 rs17021160 chr2 37864069 G T 2.80E-05 Urinary metabolites / / 21572414 rs2079998 chr2 37865070 C T 2.40E-05 Urinary metabolites / / 21572414 rs12475180 chr2 37888538 A G 5.15E-04 Alzheimer's disease CDC42EP3 intron 17998437 rs6757232 chr2 37904904 A T 2.71E-04 Multiple complex diseases / / 17554300 rs10195538 chr2 37917363 A G 1.38E-04 Multiple complex diseases / / 17554300 rs4670766 chr2 37940542 T C 2.00E-06 Total ventricular volume / / 21116278 rs12616929 chr2 37947741 T G 0.0002132 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12616929 chr2 37947741 T G 2.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1035025 chr2 37949160 T C 8.89E-06 Coronary heart disease / / pha003031 rs1476873 chr2 37949251 A G 6.98E-04 Schizophrenia / / 19197363 rs13012266 chr2 37957480 T C 7.00E-06 Metabolite levels (HVA/MHPG ratio) / / 23319000 rs6725186 chr2 37958369 G A 8.15E-04 Insulin resistance / / 21901158 rs6733157 chr2 37960368 C T 1.91E-06 Coronary heart disease / / pha003031 rs17511102 chr2 37960613 A T 2.00E-18 Height / / 20881960 rs17511102 chr2 37960613 A T 2.00E-08 Height / / 23563607 rs604381 chr2 37977017 G T 8.00E-06 Conduct disorder (interaction) / / 18846501 rs2373298 chr2 37987192 G T 2.26E-06 Esophageal cancer (squamous cell) / / 22960999 rs7593725 chr2 37996799 A G 2.75E-04 Acute lung injury / / 22295056 rs13410013 chr2 37998488 C T 2.72E-04 Acute lung injury / / 22295056 rs9973697 chr2 37999684 G A 6.38E-04 Acute lung injury / / 22295056 rs10209437 chr2 38000571 T C 5.07E-04 Acute lung injury / / 22295056 rs10197084 chr2 38000588 C G 5.93E-04 Acute lung injury / / 22295056 rs10495872 chr2 38003615 A G 3.02E-05 Pulmonary function / / 17903307 rs6727100 chr2 38004431 G T 3.26E-04 Multiple complex diseases / / 17554300 rs13404698 chr2 38009280 A G 5.83E-04 Acute lung injury / / 22295056 rs6718541 chr2 38009492 A G 7.49E-04 Acute lung injury / / 22295056 rs6544107 chr2 38009648 C T 6.23E-04 Acute lung injury / / 22295056 rs10165941 chr2 38010925 G A 7.43E-05 Coronary heart disease / / pha003031 rs934222 chr2 38012814 C A 6.44E-05 Coronary heart disease / / pha003031 rs877053 chr2 38012935 G A 5.45E-04 HIV-1 viral setpoint / / 17641165 rs13007266 chr2 38018438 C T 1.12E-08 Metabolite levels / / 23281178 rs1579491 chr2 38018661 G A 6.77E-04 Coronary heart disease / / 21606135 rs1579491 chr2 38018661 G A 1.48E-04 Major depressive disorder / / 22472876 rs867574 chr2 38021498 T C 4.42E-05 Multiple sclerosis / / 20598377 rs1367150 chr2 38035290 T G 0.000773 Salmonella-induced pyroptosis / / 22837397 rs4670779 chr2 38044344 C T 4.00E-06 Bone mineral density (spine) / / 19079262 rs11899949 chr2 38049069 A G 6.70E-05 Diabetic retinopathy / / 21441570 rs10191189 chr2 38053651 C T 6.14E-05 Alzheimer's disease / / 22832961 rs10167502 chr2 38053726 A T 5.00E-05 Alzheimer's disease / / 22832961 rs1430014 chr2 38060583 T G 5.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1864432 chr2 38064671 C T 7.97E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17411119 chr2 38066683 T C 7.59E-05 Prostate cancer / / pha002877 rs7598641 chr2 38066716 T C 6.12E-05 Prostate cancer / / pha002877 rs766231 chr2 38067593 T C 3.79E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2707243 chr2 38071114 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs9967771 chr2 38092624 C T 6.94E-04 Multiple complex diseases / / 17554300 rs2707237 chr2 38095622 G A 5.40E-06 Urinary metabolites / / 21572414 rs17021567 chr2 38108094 A C 5.63E-04 Coronary heart disease / / 21606135 rs1430023 chr2 38110077 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6706045 chr2 38115194 T C 5.70E-06 Urinary metabolites / / 21572414 rs1991582 chr2 38125923 C G,T 1.80E-05 Urinary metabolites / / 21572414 rs884342 chr2 38128777 T G 0.0000956 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1430035 chr2 38133608 A G 4.76E-05 Prion diseases / / 22210626 rs4670791 chr2 38146418 G A 1.45E-04 Prion diseases / / 22210626 rs6716296 chr2 38174964 A G 8.89E-06 Brain structure FAM82A1 intron 22504417 rs2197561 chr2 38178362 T C 9.89E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) FAM82A1 intron 23648065 rs1446296 chr2 38216416 T G 7.14E-04 White matter integrity FAM82A1 intron 22425255 rs10181021 chr2 38221095 A C,G 8.66E-04 White matter integrity FAM82A1 intron 22425255 rs2373327 chr2 38222086 A G 2.40E-04 Endometriosis FAM82A1 intron 21151130 rs1374196 chr2 38228668 A G 7.26E-05 Age-related macular degeneration FAM82A1 intron pha000002 rs17021897 chr2 38272813 A G 4.86E-05 HDL cholesterol FAM82A1 intron pha003075 rs6741148 chr2 38277832 T G 4.00E-06 Erectile dysfunction and prostate cancer treatment FAM82A1 intron 20932654 rs1800440 chr2 38298139 T C 1.30E-05 Systemic lupus erythematosus CYP1B1 missense pha002867 rs1056836 chr2 38298203 C G 1 Drug response to Docetaxel / / 18187806 rs1056836 chr2 38298203 C G 1 Drug response to Paclitaxel / / 19474787 rs4646430 chr2 38306415 C G 8.52E-06 Duodenal ulcer / / 22387998 rs162556 chr2 38306454 G A 4.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4646429 chr2 38306935 C T 8.25E-06 Duodenal ulcer / / 22387998 rs10175338 chr2 38307643 G T 1.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10175338 chr2 38307643 G T 9.25E-06 Duodenal ulcer / / 22387998 rs17022010 chr2 38331931 A T 5.30E-04 Coronary heart disease / / 21606135 rs232535 chr2 38332303 C T 1.61E-04 Coronary heart disease / / 21606135 rs3795980 chr2 38350814 G T 6.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs3795980 chr2 38350814 G T 6.86E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10204598 chr2 38351969 G A 2.81E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2432662 chr2 38352174 C T 8.57E-04 Coronary heart disease / / 21606135 rs17491111 chr2 38353487 T C 3.63E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs232620 chr2 38358664 A G 4.03E-04 Coronary heart disease / / 21606135 rs10469900 chr2 38367083 T C 5.51E-04 Suicide attempts in bipolar disorder CYP1B1-AS1 intron 21041247 rs10188379 chr2 38371476 G C 7.19E-04 Suicide attempts in bipolar disorder CYP1B1-AS1 intron 21041247 rs918804 chr2 38373364 A T 6.72E-04 Suicide attempts in bipolar disorder CYP1B1-AS1 intron 21041247 rs170818 chr2 38374567 C T 2.50E-04 Coronary heart disease CYP1B1-AS1 intron 21606135 rs10196846 chr2 38379110 C A 0.0000569 Amyotrophic lateral sclerosis CYP1B1-AS1 intron 23587638 rs232576 chr2 38386220 A G 4.18E-06 Coronary heart disease CYP1B1-AS1 intron 21606135 rs232574 chr2 38387227 C A 4.54E-04 Lung function (forced vital capacity) CYP1B1-AS1 intron 24023788 rs232569 chr2 38394363 C T 4.89E-05 Coronary heart disease CYP1B1-AS1 intron 21606135 rs2194381 chr2 38404795 T C 9.17E-04 Type 2 diabetes CYP1B1-AS1 intron 17463246 rs13385748 chr2 38405869 G A 4.11E-04 Type 2 diabetes CYP1B1-AS1 intron 17463246 rs2447738 chr2 38411167 C T 3.66E-05 Coronary heart disease / / 21606135 rs183487 chr2 38414541 T C 6.45E-04 Substance dependence / / 21818250 rs232587 chr2 38420853 T A 6.36E-05 Coronary heart disease / / 21606135 rs17022251 chr2 38431991 T C 1.98E-06 Multiple complex diseases / / 17554300 rs13432312 chr2 38490324 T C 8.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12468478 chr2 38509407 G A 1.64E-05 Smoking cessation / / 18519826 rs12468478 chr2 38509407 G A 6.80E-05 Personality dimensions / / 18957941 rs875653 chr2 38512522 C T 2.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs875654 chr2 38512710 T C 4.95E-04 Suicide attempts in bipolar disorder / / 21041247 rs13417898 chr2 38516428 T C 7.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs11883614 chr2 38517488 A C 5.42E-05 Smoking cessation / / 18519826 rs11894455 chr2 38517515 C T 8.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs4670861 chr2 38520856 T C 8.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs3755025 chr2 38521058 T C 8.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs2305245 chr2 38537626 A C 3.42E-04 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs12712583 chr2 38542573 T C 3.30E-04 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs10202238 chr2 38542790 T C 6.37E-04 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs1022076 chr2 38544049 C T 3.29E-04 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs6544157 chr2 38546918 G A 8.24E-05 Cognitive test performance ATL2 intron 20125193 rs7593981 chr2 38549537 T A 3.25E-04 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs7606701 chr2 38549847 A C 3.36E-04 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs9808407 chr2 38550413 C A 3.23E-04 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs6745929 chr2 38553453 C T 1.06E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs4589732 chr2 38555830 C G 9.25E-05 Smoking cessation ATL2 intron 18519826 rs4589732 chr2 38555830 C G 7.19E-05 Serum metabolites ATL2 intron 19043545 rs4589732 chr2 38555830 C G 2.64E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs1375010 chr2 38557660 G A 2.62E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs10177042 chr2 38563527 C G 1.26E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs13431831 chr2 38565044 G C 3.78E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs11884107 chr2 38565390 C T 3.75E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs11679270 chr2 38568808 C A 2.32E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs11679271 chr2 38568827 C T 2.31E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs10198323 chr2 38571255 T C 8.87E-06 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs11687138 chr2 38573690 G A 2.87E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs6737169 chr2 38577701 T C 8.86E-06 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs6716350 chr2 38586074 C T 8.99E-06 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs11900967 chr2 38588138 T A 2.91E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs11687878 chr2 38589747 G T 2.92E-05 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs6760123 chr2 38602511 C T 8.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ATL2 intron 20877124 rs6760123 chr2 38602511 C T 2.91E-04 Suicide attempts in bipolar disorder ATL2 intron 21041247 rs6760123 chr2 38602511 C T 8.28E-05 Body Mass Index ATL2 intron pha002896 rs3806552 chr2 38605393 A C 3.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs3806551 chr2 38606219 G C 2.79E-04 Suicide attempts in bipolar disorder / / 21041247 rs10182455 chr2 38611011 G A 2.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs10198160 chr2 38611930 T C 7.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10197684 chr2 38620569 C T 1.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10197684 chr2 38620569 C T 1.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1027880 chr2 38626307 T C 8.86E-04 Parkinson's disease / / 17052657 rs13392984 chr2 38634844 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17022657 chr2 38657595 G A 2.50E-05 Urinary metabolites / / 21572414 rs12997019 chr2 38682719 T C 3.40E-04 Alcohol dependence / / 21314694 rs17022787 chr2 38702122 T C 8.79E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs13424546 chr2 38723049 G A 6.33E-05 Celiac disease / / 23936387 rs4670257 chr2 38726650 G A 8.60E-04 Parkinson's disease / / 17052657 rs4490160 chr2 38728911 G A 9.21E-04 Parkinson's disease / / 17052657 rs12622497 chr2 38749083 T C 5.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs3731843 chr2 38749920 C A 3.27E-05 Serum metabolites / / 19043545 rs10164547 chr2 38760294 C T 7.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs17421399 chr2 38769087 A C 4.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs17493321 chr2 38772507 G A 2.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs7571463 chr2 38772915 C T 4.91E-04 Gallstones / / 17632509 rs7571463 chr2 38772915 C T 2.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs7574556 chr2 38773108 G T 1.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs12328034 chr2 38789682 A G 4.69E-04 Acute lung injury / / 22295056 rs10495880 chr2 38799896 G A 9.09E-04 Suicide attempts in bipolar disorder HNRPLL intron 21423239 rs17493538 chr2 38806329 A C 1.10E-04 Suicide attempts in bipolar disorder HNRPLL intron 21423239 rs4268910 chr2 38807177 C G 4.24E-04 Suicide attempts in bipolar disorder HNRPLL intron 21423239 rs6544169 chr2 38814517 G A 5.88E-04 Suicide attempts in bipolar disorder HNRPLL intron 21423239 rs6721860 chr2 38818221 C T 2.02E-04 Suicide attempts in bipolar disorder HNRPLL intron 21423239 rs6544170 chr2 38820522 T C 7.16E-05 Multiple sclerosis HNRPLL intron 20598377 rs6544170 chr2 38820522 T C 4.46E-05 Suicide attempts in bipolar disorder HNRPLL intron 21423239 rs1864828 chr2 38824781 T A 4.21E-05 Suicide attempts in bipolar disorder HNRPLL intron 21423239 rs17421743 chr2 38825407 G C 5.12E-04 Suicide attempts in bipolar disorder HNRPLL intron 21423239 rs6757844 chr2 38832850 C G 6.48E-05 Suicide attempts in bipolar disorder / / 21423239 rs7578356 chr2 38862223 A C 7.73E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs13384427 chr2 38901790 C T 9.37E-04 Parkinson's disease GALM intron 16252231 rs17576472 chr2 38903022 T A 4.57E-05 Multiple complex diseases GALM intron 17554300 rs17023042 chr2 38912786 C G 8.24E-04 Multiple complex diseases GALM intron 17554300 rs17422091 chr2 38914242 G C 9.60E-05 White matter hyperintensity burden GALM intron 21681796 rs6741892 chr2 38916970 A T 5.00E-06 5-HTT brain serotonin transporter levels GALM missense 21339755 rs1965752 chr2 38943609 G A 3.33E-04 Coronary heart disease GALM intron 21606135 rs11124646 chr2 38954419 A G 3.26E-04 Multiple complex diseases GALM intron 17554300 rs6728394 chr2 38955866 G A 4.67E-04 Multiple complex diseases GALM intron 17554300 rs3097714 chr2 38960491 A G 6.17E-04 Tourette syndrome GALM intron 22889924 rs3097713 chr2 38964531 A G 1.70E-05 Urinary metabolites / / 21572414 rs3134628 chr2 38977612 A G 8.80E-05 White matter hyperintensity burden SRSF7 intron 21681796 rs12621103 chr2 38978764 T C 8.80E-05 White matter hyperintensity burden / / 21681796 rs1562855 chr2 39008468 C T 4.70E-05 White matter hyperintensity burden GEMIN6 intron 21681796 rs1056104 chr2 39008949 G A 0.00000574 Nicotine dependence (smoking) GEMIN6 missense 23643383 rs3099968 chr2 39033590 T C 9.31E-04 Tourette syndrome DHX57 intron 22889924 rs3112215 chr2 39037813 G A 4.50E-05 White matter hyperintensity burden DHX57 intron 21681796 rs12479213 chr2 39101209 C A 9.00E-06 Obesity-related traits DHX57 intron 23251661 rs3099950 chr2 39109558 G A 8.00E-06 Amyotrophic lateral sclerosis MORN2 missense 19451621 rs368451 chr2 39166576 T C 3.75E-05 Odorant perception ARHGEF33 intron 23910658 rs12473092 chr2 39204040 C T 9.70E-06 Urinary metabolites / / 21572414 rs6704656 chr2 39210398 A T 2.10E-05 Urinary metabolites SOS1 UTR-3 21572414 rs13031871 chr2 39252851 T G 5.79E-04 Type 2 diabetes SOS1 intron 22158537 rs11674846 chr2 39271729 T C 3.74E-04 Type 2 diabetes SOS1 intron 22158537 rs2373497 chr2 39288098 G A 1.40E-05 Urinary metabolites SOS1 intron 21572414 rs6758330 chr2 39288183 T C 8.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SOS1 intron 20877124 rs6758330 chr2 39288183 T C 2.10E-05 Urinary metabolites SOS1 intron 21572414 rs2060989 chr2 39293530 G A 3.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SOS1 intron 20877124 rs7564481 chr2 39330377 G A 6.96E-04 Insulin resistance SOS1 intron 21901158 rs10184855 chr2 39361586 G A 9.02E-05 Lymphocyte counts / / 22286170 rs10171977 chr2 39373207 T C 3.76E-05 Body Mass Index / / pha003006 rs6735427 chr2 39376798 C T 7.19E-04 Multiple complex diseases / / 17554300 rs1567423 chr2 39385155 G T 4.26E-04 Tourette syndrome / / 22889924 rs11124661 chr2 39401658 A G 5.69E-04 Multiple complex diseases / / 17554300 rs2136638 chr2 39409854 T C 7.78E-04 Multiple complex diseases CDKL4 intron 17554300 rs11689688 chr2 39416457 C A 3.73E-04 Multiple complex diseases CDKL4 intron 17554300 rs12712633 chr2 39444235 C G 9.49E-04 Multiple complex diseases CDKL4 intron 17554300 rs6707666 chr2 39459570 C G 7.03E-04 Multiple complex diseases / / 17554300 rs4516411 chr2 39468676 T G 8.24E-04 Multiple complex diseases / / 17554300 rs4516411 chr2 39468676 T G 2.07E-05 Odorant perception / / 23910658 rs2058863 chr2 39580377 G A 4.01E-05 stroke (ischemic) MAP4K3 intron 17434096 rs4670934 chr2 39644134 C T 3.20E-11 Multiple complex diseases MAP4K3 intron 17554300 rs9677244 chr2 39692393 G A 4.70E-05 Coffee consumption LOC728730 intron 21357676 rs12621670 chr2 39748858 C T 7.44E-05 Cognitive impairment induced by topiramate LOC728730 intron 22091778 rs17023903 chr2 39754116 C T 2.97E-04 Multiple complex diseases LOC728730 intron 17554300 rs7597939 chr2 39814690 A G 1.20E-05 HIV-1 control LOC728730 intron 20041166 rs2716697 chr2 39841502 A G 7.06E-06 Obesity-related traits / / 23251661 rs7587205 chr2 39843197 G T 4.00E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs17475620 chr2 39843875 A G 8.45E-04 Acute lung injury / / 22295056 rs885252 chr2 39850633 A C 7.90E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6751438 chr2 39857134 G T 6.62E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2540255 chr2 39900326 C T 4.73E-04 Lung function (forced expiratory volume in 1 second) TMEM178 intron 24023788 rs2540249 chr2 39905856 A C 2.98E-04 Lung function (forced expiratory volume in 1 second) TMEM178 intron 24023788 rs2540249 chr2 39905856 A C 4.70E-04 Lung function (forced vital capacity) TMEM178 intron 24023788 rs2540249 chr2 39905856 A C 6.79E-05 Elbow pain TMEM178 intron pha003008 rs13427136 chr2 39911151 T C 1.63E-04 Arthritis (juvenile idiopathic) TMEM178 intron 22354554 rs17024218 chr2 39939536 T C 2.00E-06 Obesity-related traits TMEM178 intron 23251661 rs2716734 chr2 39947721 C T 2.00E-06 Erectile dysfunction and prostate cancer treatment / / 20932654 rs10490332 chr2 39951909 C T 9.10E-05 Multiple complex diseases / / 17554300 rs10490332 chr2 39951909 C T 3.15E-06 Obesity-related traits / / 23251661 rs2716727 chr2 39953746 T C 2.61E-05 Personality dimensions / / 18957941 rs2716727 chr2 39953746 T C 4.50E-04 Obesity (extreme) / / 21935397 rs1861243 chr2 39956836 T C 8.52E-04 Type 2 diabetes / / 17463246 rs1861243 chr2 39956836 T C 4.35E-04 Multiple complex diseases / / 17554300 rs1861243 chr2 39956836 T C 5.36E-06 Personality dimensions / / 18957941 rs2540226 chr2 39959060 A C 9.23E-04 Type 2 diabetes / / 17463246 rs2540226 chr2 39959060 A C 1.79E-04 Multiple complex diseases / / 17554300 rs2540226 chr2 39959060 A C 3.00E-06 Personality dimensions / / 18957941 rs2540226 chr2 39959060 A C 3.90E-06 Personality dimensions / / 21173776 rs4670955 chr2 39963122 T C 7.95E-05 Personality dimensions / / 18957941 rs4670958 chr2 39980724 C T 6.93E-04 Multiple complex diseases THUMPD2 intron 17554300 rs4670958 chr2 39980724 C T 9.85E-06 Personality dimensions THUMPD2 intron 18957941 rs12470473 chr2 40005290 T C 1.30E-05 Personality dimensions THUMPD2 intron 18957941 rs75820127 chr2 40013335 A G 2.46E-05 Intracerebral hemorrhage / / 24656865 rs10490333 chr2 40024643 A G 9.64E-05 Personality dimensions / / 18957941 rs1003447 chr2 40027918 A G 6.86E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12475386 chr2 40094081 C T 9.95E-05 Cognitive performance / / 19734545 rs7566309 chr2 40096398 A G 6.00E-04 Alcohol dependence / / 24277619 rs7603007 chr2 40111773 A T 2.70E-05 Urinary metabolites / / 21572414 rs6721181 chr2 40115696 C T 6.00E-07 Asthma (childhood onset) / / 23829686 rs4670981 chr2 40119060 T G 2.70E-05 Cognitive impairment induced by topiramate / / 22091778 rs12469949 chr2 40121335 A G 3.15E-05 Cognitive impairment induced by topiramate / / 22091778 rs12469949 chr2 40121335 A G 4.21E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs12469949 chr2 40121335 A G 4.51E-04 Lung function (forced vital capacity) / / 24023788 rs7598492 chr2 40122972 G A 1.31E-04 Multiple complex diseases / / 17554300 rs7601303 chr2 40123232 G C 9.36E-05 Multiple complex diseases / / 17554300 rs13385459 chr2 40123904 C A 0.0000293 Tuberculosis with late age of onset / / 22551897 rs2888638 chr2 40136231 T G 1.03E-05 Osteosarcoma / / 23727862 rs17024600 chr2 40141610 T A 1.98E-04 Multiple complex diseases / / 17554300 rs12621187 chr2 40145915 T C 1.80E-05 Urinary metabolites LOC100128590 intron 21572414 rs17024612 chr2 40152867 A G 1.35E-04 Multiple complex diseases LOC100128590 intron 17554300 rs17024614 chr2 40152918 T C 1.50E-04 Multiple complex diseases LOC100128590 intron 17554300 rs10181603 chr2 40159265 T C 1.00E-04 Multiple complex diseases LOC100128590 intron 17554300 rs17024636 chr2 40166131 C T 1.12E-04 Multiple complex diseases LOC100128590 intron 17554300 rs725374 chr2 40167128 A T 3.08E-06 Multiple complex diseases LOC100128590 intron 17554300 rs11124710 chr2 40168578 G A 1.00E-04 Cognitive impairment induced by topiramate LOC100128590 intron 22091778 rs75847378 chr2 40181517 G A 7.00E-07 Alzheimer's disease LOC100128590 intron 24770881 rs10865162 chr2 40222206 C T 7.89E-05 Cognitive impairment induced by topiramate LOC100128590 intron 22091778 rs17024775 chr2 40225327 A G 4.53E-04 Multiple complex diseases LOC100128590 intron 17554300 rs17024784 chr2 40226489 T G 3.61E-04 Multiple complex diseases LOC100128590 intron 17554300 rs17024784 chr2 40226489 T G 8.89E-05 Glaucoma (primary open-angle) LOC100128590 intron 22605921 rs12476349 chr2 40264408 T C 3.26E-04 Acute lung injury LOC100128590 intron 22295056 rs2192724 chr2 40270387 A C 1.58E-04 Alzheimer's disease (late onset) LOC100128590 intron 21379329 rs6705905 chr2 40270534 T G 2.40E-05 Urinary metabolites LOC100128590 intron 21572414 rs6544307 chr2 40299464 C T 5.83E-04 Suicide attempts in bipolar disorder LOC100128590 intron 21041247 rs12614752 chr2 40316473 T G 2.94E-04 Suicide attempts in bipolar disorder LOC100128590 intron 21041247 rs12151560 chr2 40318880 T C 4.06E-04 Suicide attempts in bipolar disorder LOC100128590 intron 21041247 rs917977 chr2 40321189 T C 4.04E-04 Suicide attempts in bipolar disorder LOC100128590 intron 21041247 rs13032715 chr2 40325029 T C 2.84E-04 Suicide attempts in bipolar disorder LOC100128590 intron 21041247 rs759359 chr2 40329105 G T 3.77E-05 Height LOC100128590 intron 22021425 rs6736628 chr2 40332851 G C 2.29E-04 Smoking initiation LOC100128590 intron 24665060 rs2888655 chr2 40338067 G A 7.32E-04 Multiple complex diseases LOC100128590 intron 17554300 rs17500300 chr2 40348737 A C 3.53E-04 Iron levels SLC8A1 intron pha002876 rs2110927 chr2 40354688 C T 5.34E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SLC8A1 intron 23648065 rs2160364 chr2 40357323 T C 9.64E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SLC8A1 intron 23648065 rs765554 chr2 40358175 G A 2.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SLC8A1 intron 23648065 rs2110922 chr2 40363644 C A 9.03E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SLC8A1 intron 23648065 rs2058693 chr2 40376453 T G 8.81E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SLC8A1 intron 23648065 rs435923 chr2 40377632 C A 6.72E-04 Insulin resistance SLC8A1 intron 21901158 rs409620 chr2 40378344 T C 4.67E-04 Alzheimer's disease (late onset) SLC8A1 intron 21379329 rs13425134 chr2 40381369 A G 9.20E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SLC8A1 intron 23648065 rs452369 chr2 40384733 C T 9.20E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SLC8A1 intron 23648065 rs1861427 chr2 40387489 A G 7.16E-05 Prostate cancer SLC8A1 intron pha002877 rs2072530 chr2 40391516 G A 3.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC8A1 intron 20877124 rs1005213 chr2 40391789 G T 2.02E-04 Multiple complex diseases SLC8A1 intron 17554300 rs17025372 chr2 40395937 T C 5.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC8A1 intron 20877124 rs404005 chr2 40396078 C T 3.00E-07 HIV-associated dementia SLC8A1 intron 22628157 rs12993486 chr2 40396296 T C 8.79E-05 Cognitive decline SLC8A1 intron 22054870 rs2072529 chr2 40397165 A G 5.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC8A1 intron 20877124 rs105288 chr2 40400127 A G 1.58E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC8A1 intron 20463552 rs105287 chr2 40400179 A G 3.18E-04 Multiple complex diseases SLC8A1 intron 17554300 rs417591 chr2 40400312 A G 1.58E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC8A1 intron 20463552 rs385341 chr2 40400489 G A 6.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC8A1 intron 20877124 rs106706 chr2 40403104 A G 8.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC8A1 intron 20877124 rs446538 chr2 40403803 T C 6.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC8A1 intron 20877124 rs581477 chr2 40406679 T C 1.58E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC8A1 intron 20463552 rs581568 chr2 40406745 T C 3.02E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC8A1 intron 20463552 rs379410 chr2 40410269 T C 8.15E-04 Type 2 diabetes SLC8A1 intron 17463246 rs379410 chr2 40410269 T C 2.56E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC8A1 intron 20463552 rs376535 chr2 40411717 C T 4.38E-05 Cognitive decline SLC8A1 intron 22054870 rs391631 chr2 40413713 A T 1.15E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC8A1 intron 20463552 rs417873 chr2 40414959 T A 1.26E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC8A1 intron 20463552 rs430314 chr2 40415673 G A,T 9.10E-04 Type 2 diabetes SLC8A1 intron 17463246 rs430314 chr2 40415673 G A,T 1.32E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC8A1 intron 20463552 rs389109 chr2 40416919 C T 3.26E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC8A1 intron 20463552 rs12104840 chr2 40420129 G A 5.89E-04 Insulin resistance SLC8A1 intron 21901158 rs368577 chr2 40424897 C T 5.48E-04 Multiple complex diseases SLC8A1 intron 17554300 rs11674102 chr2 40429442 A G 4.95E-05 Multiple complex diseases SLC8A1 intron 17554300 rs17504446 chr2 40430611 A C 1.26E-04 Insulin resistance SLC8A1 intron 21901158 rs415695 chr2 40469240 T C 8.96E-04 Multiple complex diseases SLC8A1 intron 17554300 rs371909 chr2 40469705 G C 5.15E-05 Multiple complex diseases SLC8A1 intron 17554300 rs7593406 chr2 40475441 G T 6.31E-04 Insulin resistance SLC8A1 intron 21901158 rs405884 chr2 40482717 G C 3.35E-04 Type 2 diabetes SLC8A1 intron 17463246 rs3749056 chr2 40484945 T C 4.00E-06 QRS duration in Tripanosoma cruzi seropositivity SLC8A1 intron 24324551 rs434082 chr2 40485074 C T 5.68E-04 Type 2 diabetes SLC8A1 intron 17463246 rs434082 chr2 40485074 C T 8.51E-04 Hypertension,salt-sensitive SLC8A1 intron 21573014 rs421576 chr2 40490009 A C 5.39E-05 Acute lung injury SLC8A1 intron 22295056 rs403630 chr2 40492788 A C 1.85E-04 Acute lung injury SLC8A1 intron 22295056 rs13419087 chr2 40495934 A G 4.21E-04 Acute lung injury SLC8A1 intron 22295056 rs13021772 chr2 40497458 A T 6.59E-04 Acute lung injury SLC8A1 intron 22295056 rs7583177 chr2 40502259 G A 9.43E-04 Acute lung injury SLC8A1 intron 22295056 rs10210665 chr2 40532749 T C 9.85E-05 Cognitive impairment induced by topiramate SLC8A1 intron 22091778 rs2110743 chr2 40538968 A G 6.20E-06 Urinary metabolites SLC8A1 intron 21572414 rs2160236 chr2 40557276 G C 8.00E-04 Suicide attempts in bipolar disorder SLC8A1 intron 21041247 rs10490051 chr2 40571426 T C 9.65E-04 Multiple complex diseases SLC8A1 intron 17554300 rs10490051 chr2 40571426 T C 1.35E-05 Orofacial clefts SLC8A1 intron 22419666 rs12611608 chr2 40577162 G C 6.78E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SLC8A1 intron 21844884 rs10180986 chr2 40578171 T A 1.00E-04 Prostate cancer SLC8A1 intron 21743057 rs17025867 chr2 40578559 G A 2.00E-07 Obesity (early onset extreme) SLC8A1 intron 23563609 rs13405065 chr2 40583595 G A 7.01E-04 Multiple complex diseases SLC8A1 intron 17554300 rs6544331 chr2 40591189 C G 1.00E-07 Urinary metabolites SLC8A1 intron 21572414 rs34408472 chr2 40592311 G A 8.90E-08 Urinary metabolites SLC8A1 intron 21572414 rs6544334 chr2 40596524 A C 3.85E-07 Body mass (lean) SLC8A1 intron 19268274 rs7581611 chr2 40598884 T C 6.60E-05 Body mass (lean) SLC8A1 intron 19268274 rs12472012 chr2 40605768 C T 4.02E-04 Insulin resistance SLC8A1 intron 21901158 rs1477004 chr2 40612072 A G 9.34E-05 Orofacial clefts SLC8A1 intron 22419666 rs2373859 chr2 40617820 C T 8.85E-05 Orofacial clefts SLC8A1 intron 22419666 rs10490046 chr2 40630678 A C 7.23E-05 Alcohol consumption SLC8A1 intron 23743675 rs10490045 chr2 40631355 T C 6.40E-05 Alcohol consumption SLC8A1 intron 23743675 rs12614757 chr2 40633859 A G 8.70E-06 Urinary metabolites SLC8A1 intron 21572414 rs9789765 chr2 40634834 A T 4.58E-04 Alcohol dependence SLC8A1 intron 21314694 rs6755144 chr2 40636240 A G 4.04E-05 Alcohol consumption SLC8A1 intron 23743675 rs13017237 chr2 40639297 G A 8.47E-04 Multiple complex diseases SLC8A1 intron 17554300 rs6705173 chr2 40641699 T C 4.83E-04 Alzheimer's disease (late onset) SLC8A1 intron 21379329 rs13414307 chr2 40649084 A G 3.30E-05 Type 2 diabetes SLC8A1 intron 17460697 rs7579930 chr2 40649916 A C 6.93E-06 Obesity-related traits SLC8A1 intron 23251661 rs4629203 chr2 40662546 T C 3.00E-06 Obesity-related traits SLC8A1 intron 23251661 rs1990609 chr2 40667007 C T 8.85E-04 Iron levels SLC8A1 intron pha002876 rs17026033 chr2 40670651 G C 8.41E-04 Type 2 diabetes SLC8A1 intron 17463246 rs17026039 chr2 40670694 G C 8.39E-04 Type 2 diabetes SLC8A1 intron 17463246 rs6544340 chr2 40682153 T C 4.65E-05 Serum metabolites SLC8A1 intron 19043545 rs7597373 chr2 40687437 C A 3.85E-04 Multiple complex diseases SLC8A1 intron 17554300 rs2373864 chr2 40688262 A G 5.07E-05 Serum metabolites SLC8A1 intron 19043545 rs11679585 chr2 40691468 C A 0.0000573 Narcolepsy (non-HLA narcolepsy) SLC8A1 intron 23459209 rs17026106 chr2 40738497 T C 2.01E-04 Schizophrenia SLC8A1 intron 20832056 rs13017279 chr2 40757454 C T 1.17E-04 Schizophrenia / / 20832056 rs17026152 chr2 40757655 G A 1.30E-04 Schizophrenia / / 20832056 rs13017846 chr2 40757791 A G 2.60E-04 Schizophrenia / / 20832056 rs13017846 chr2 40757791 A G 8.00E-14 QT interval / / 22726844 rs17026155 chr2 40760283 C T 1.50E-04 Schizophrenia / / 20832056 rs17026156 chr2 40760965 T C 1.65E-04 Schizophrenia / / 20832056 rs13010889 chr2 40764015 C A 8.75E-05 Schizophrenia / / 20832056 rs7561779 chr2 40778289 T G 7.55E-05 Potassium levels / / pha003086 rs7561779 chr2 40778289 T G 9.25E-05 Eosinophil counts / / pha003088 rs17026180 chr2 40783776 A C 1.20E-05 Multiple complex diseases / / 17554300 rs10490258 chr2 40805954 C T 1.50E-05 Blood Phenotypes / / 17903294 rs42807 chr2 40835285 T G 4.29E-05 Insulin resistance / / 21901158 rs6755751 chr2 40870602 T C 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs12468195 chr2 40882419 C T 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs17026460 chr2 40884647 C T 4.53E-04 Hemoglobin concentration / / 20534544 rs6717047 chr2 40890903 T C 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs983123 chr2 40940616 G A 5.15E-04 Hemoglobin concentration / / 20534544 rs2192820 chr2 40948842 G T 2.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1107932 chr2 40949168 T C 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1107932 chr2 40949168 T C 5.15E-04 Hemoglobin concentration / / 20534544 rs4952645 chr2 40949606 T G 1.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs12105490 chr2 40959809 T C 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs12466466 chr2 40977474 T C 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs6708921 chr2 40982517 C G 4.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs4603810 chr2 40987687 G A 3.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs4603810 chr2 40987687 G A 2.60E-05 Urinary metabolites / / 21572414 rs1456587 chr2 40989264 C T 2.72E-04 Type 2 diabetes / / 17463246 rs1456587 chr2 40989264 C T 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs4552230 chr2 40990316 C T 1.40E-05 Urinary metabolites / / 21572414 rs7566371 chr2 40990662 T G 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs6722048 chr2 41036518 G A 7.99E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs11124763 chr2 41037903 T C 5.89E-04 Multiple complex diseases / / 17554300 rs1456596 chr2 41078726 G A 5.54E-04 Alzheimer's disease / / 24755620 rs7592667 chr2 41087391 C T 8.99E-04 Alzheimer's disease / / 24755620 rs4952654 chr2 41093123 T C 3.34E-04 Smoking cessation / / 24665060 rs982428 chr2 41107020 G A 7.20E-04 Type 2 diabetes / / 17463246 rs1981804 chr2 41199040 G A 4.02E-04 Alzheimer's disease / / 24755620 rs11124777 chr2 41207286 C T 8.77E-04 Multiple complex diseases / / 17554300 rs12472025 chr2 41217822 T C 2.90E-05 Parkinson's disease (familial) / / 18985386 rs17027130 chr2 41273631 T C 3.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs1991099 chr2 41304560 G C 6.48E-04 Multiple complex diseases / / 17554300 rs17027254 chr2 41391252 C T 9.18E-05 Type 2 diabetes / / 17463246 rs9646981 chr2 41403446 T C 8.05E-06 Type 2 diabetes / / 17463246 rs12712739 chr2 41416322 T A 2.00E-05 Urinary metabolites / / 21572414 rs13014596 chr2 41418224 A G 3.94E-06 Type 2 diabetes / / 17463246 rs7579184 chr2 41423097 C T 6.39E-06 Type 2 diabetes / / 17463246 rs11687208 chr2 41424692 T C 1.57E-05 Type 2 diabetes / / 17463246 rs881024 chr2 41438438 A G 3.55E-05 Type 2 diabetes / / 17463246 rs11894180 chr2 41474388 A C 3.27E-04 Type 2 diabetes / / 17463246 rs10168228 chr2 41475622 G C 4.45E-04 Type 2 diabetes / / 17463246 rs17689334 chr2 41481639 G A 1.41E-04 Type 2 diabetes / / 17463246 rs17027360 chr2 41486554 A G 3.30E-04 Alcohol dependence / / 20201924 rs4140752 chr2 41487071 G A 8.00E-07 Immune response to measles-mumps-rubella vaccine / / 24811271 rs10490379 chr2 41503910 A C 3.93E-04 Multiple complex diseases / / 17554300 rs1441231 chr2 41505473 T C 8.20E-04 Alcohol dependence / / 20201924 rs1508116 chr2 41526122 T C 1.30E-04 Lipid traits / / 17903299 rs12612547 chr2 41528139 A C 3.46E-04 Type 2 diabetes / / 17463246 rs17027408 chr2 41529807 G A 2.64E-04 Alzheimer's disease / / 22005930 rs13385952 chr2 41531398 T C 9.00E-04 Atrial fibrillation / / 21846873 rs13385952 chr2 41531398 T C 1.24E-04 Alzheimer's disease / / 22005930 rs10490380 chr2 41532189 G T 6.13E-04 Type 2 diabetes / / 17463246 rs10490380 chr2 41532189 G T 5.40E-04 Multiple complex diseases / / 17554300 rs17027420 chr2 41534961 C A 2.05E-04 Type 2 diabetes / / 17463246 rs13415944 chr2 41535003 G C 1.25E-04 Type 2 diabetes / / 17463246 rs13415944 chr2 41535003 G C 2.89E-05 Diabetes (gestational) / / 22233651 rs4952451 chr2 41544368 G A 9.95E-04 Alzheimer's disease / / 22005930 rs2374232 chr2 41546907 T G 4.31E-04 Multiple complex diseases / / 17554300 rs2023545 chr2 41551957 C A 2.78E-04 Multiple complex diseases / / 17554300 rs7569590 chr2 41556442 C A 7.91E-05 Bipolar disorder / / 19488044 rs7569590 chr2 41556442 C A 7.17E-04 Alzheimer's disease / / 22005930 rs7569590 chr2 41556442 C A 3.30E-05 Bipolar Disorder / / pha002863 rs6750424 chr2 41560726 T C 3.08E-04 Multiple complex diseases / / 17554300 rs2048178 chr2 41561475 T A 1.23E-04 Multiple complex diseases / / 17554300 rs2048178 chr2 41561475 T A 7.08E-04 Alzheimer's disease / / 22005930 rs7565096 chr2 41562110 A C 2.53E-04 Multiple complex diseases / / 17554300 rs7565096 chr2 41562110 A C 8.07E-04 Alzheimer's disease / / 22005930 rs6745177 chr2 41564729 T A 5.28E-04 Multiple complex diseases / / 17554300 rs4952453 chr2 41569885 C T 9.13E-05 Multiple complex diseases / / 17554300 rs4952453 chr2 41569885 C T 6.86E-04 Alzheimer's disease / / 22005930 rs1508114 chr2 41572171 C T 7.20E-04 Alzheimer's disease / / 22005930 rs2063179 chr2 41574085 T C 7.95E-04 Alzheimer's disease / / 22005930 rs6727419 chr2 41579722 T C 6.83E-04 Multiple complex diseases / / 17554300 rs7584371 chr2 41581176 T C 6.62E-04 Alzheimer's disease / / 22005930 rs12465106 chr2 41583244 A C 7.46E-04 Alzheimer's disease / / 22005930 rs7577619 chr2 41593738 C T 3.09E-04 Multiple complex diseases / / 17554300 rs2068390 chr2 41603674 T C 5.22E-04 Multiple complex diseases / / 17554300 rs2068390 chr2 41603674 T C 5.00E-04 Alzheimer's disease / / 22005930 rs6544414 chr2 41615490 A C 4.36E-04 Alzheimer's disease / / 22005930 rs12052737 chr2 41616692 T C 6.59E-04 Alzheimer's disease / / 22005930 rs10495891 chr2 41617543 C T 6.54E-04 Alzheimer's disease / / 22005930 rs1396133 chr2 41617969 C T 4.59E-04 Alzheimer's disease / / 22005930 rs12616486 chr2 41620948 C G 6.53E-04 Alzheimer's disease / / 22005930 rs4245772 chr2 41633212 G A 8.69E-04 Multiple complex diseases / / 17554300 rs4281952 chr2 41633705 T C 4.74E-04 Multiple complex diseases / / 17554300 rs4952362 chr2 41636730 G C 9.84E-04 Alzheimer's disease / / 22005930 rs4952462 chr2 41636754 T G 5.28E-04 Alzheimer's disease / / 22005930 rs1995738 chr2 41637415 T G 9.78E-04 Multiple complex diseases / / 17554300 rs11124811 chr2 41638727 A T 6.33E-04 Alzheimer's disease / / 22005930 rs1508119 chr2 41640295 T C 5.63E-04 Alzheimer's disease / / 22005930 rs4952364 chr2 41641558 A C 6.13E-04 Alzheimer's disease / / 22005930 rs1354982 chr2 41641880 G C 5.19E-04 Alzheimer's disease / / 22005930 rs1354983 chr2 41642035 C G 7.52E-04 Alzheimer's disease / / 22005930 rs1354984 chr2 41642045 A C 6.72E-04 Alzheimer's disease / / 22005930 rs1508120 chr2 41643650 A C 4.55E-04 Alzheimer's disease / / 22005930 rs4952464 chr2 41646813 G A 6.07E-04 Alzheimer's disease / / 22005930 rs7589089 chr2 41650011 A G 4.93E-04 Multiple complex diseases / / 17554300 rs906549 chr2 41653824 C T 6.58E-04 Alzheimer's disease / / 22005930 rs1508123 chr2 41654633 T A 6.23E-04 Alzheimer's disease / / 22005930 rs10191557 chr2 41658224 G C 8.12E-04 Multiple complex diseases / / 17554300 rs1157103 chr2 41659303 C T 9.50E-04 Alzheimer's disease / / 22005930 rs1508128 chr2 41661763 A G 6.82E-04 Multiple complex diseases / / 17554300 rs12465424 chr2 41662810 T C 2.47E-04 Multiple complex diseases / / 17554300 rs12469176 chr2 41662827 A G 3.99E-04 Multiple complex diseases / / 17554300 rs12996069 chr2 41704150 A G 4.12E-04 Smoking initiation / / 24665060 rs4985357 chr2 41733169 G T 3.06E-04 Birth weight / / 17255346 rs13423625 chr2 41737267 G A 3.32E-04 Smoking initiation / / 24665060 rs11124821 chr2 41761764 C T 1.92E-04 Birth weight / / 17255346 rs6755297 chr2 41762080 T C 1.98E-04 Smoking initiation / / 24665060 rs12620138 chr2 41765955 G A 4.61E-05 Birth weight / / 17255346 rs11124822 chr2 41774145 G A 3.20E-04 Birth weight / / 17255346 rs10164666 chr2 41775517 C T 2.82E-04 Smoking initiation / / 24665060 rs2195495 chr2 41798912 A G 1.91E-04 Birth weight / / 17255346 rs6544449 chr2 41802979 G A 3.84E-04 Smoking initiation / / 24665060 rs12712786 chr2 41806534 C T 3.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs12712787 chr2 41806652 A G 9.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs2163050 chr2 41826738 G A 3.93E-04 Alzheimer's disease (late onset) / / 21379329 rs10865177 chr2 41829089 G A 8.91E-04 Multiple complex diseases / / 17554300 rs7603075 chr2 41832878 T C 3.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs7562541 chr2 41832918 A G 3.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs10205791 chr2 41839007 C T 7.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs7599301 chr2 41840956 C G 4.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs17028125 chr2 41853654 T C 2.79E-04 Type 2 diabetes / / 17463246 rs17028125 chr2 41853654 T C 5.86E-04 Multiple complex diseases / / 17554300 rs10197606 chr2 41878796 A G 1.95E-05 Parkinson's disease / / 16252231 rs9789345 chr2 41898188 A G 6.94E-05 Parkinson's disease / / 16252231 rs12712806 chr2 41906810 T C 6.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs6745319 chr2 41909765 C T 2.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs11674789 chr2 41911100 C A 3.76E-05 Parkinson's disease / / 16252231 rs6724520 chr2 41911525 A G 4.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs1920510 chr2 41913030 G A 6.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs10490649 chr2 41913548 C T 9.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10210110 chr2 41915477 G A 7.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs4493315 chr2 41917871 T C 3.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs4952502 chr2 41921628 G A 2.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs1920498 chr2 41925981 C T 4.19E-04 Parkinson's disease / / 16252231 rs1920498 chr2 41925981 C T 1.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs6746652 chr2 41927815 A G 3.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs6734033 chr2 41931415 C T 5.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs11685994 chr2 41934148 G C 1.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs17028447 chr2 41934802 G T 4.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs17610091 chr2 41934824 T G 4.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs13000158 chr2 41935905 C T 4.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs13000173 chr2 41935967 A C 2.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs6747554 chr2 41936183 T C 4.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs6761925 chr2 41936886 A G 8.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs6733623 chr2 41937036 C A,T 8.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs6736655 chr2 41937090 G A 9.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs4952373 chr2 41941110 A C 4.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs4952508 chr2 41945351 T C 7.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs17028520 chr2 41946732 A G 7.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs11896334 chr2 41947118 A C 1.00E-04 Information processing speed / / 21130836 rs12994941 chr2 41950726 T C 0.0000269 Colorectal cancer (males) / / 22532847 rs11692045 chr2 41950953 A G 1.54E-05 Hypertension / / 19609347 rs2141650 chr2 41953699 G A 7.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs10490643 chr2 41957014 C T 8.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs7568362 chr2 41957254 C A 9.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs6749718 chr2 41962044 T C 2.50E-05 Urinary metabolites / / 21572414 rs41518745 chr2 41976511 T C 3.60E-04 Insulin resistance / / 21901158 rs4563280 chr2 41976547 A C 8.58E-06 Gaucher disease severity / / 22388998 rs7572321 chr2 41979425 T C 4.13E-04 Alzheimer's disease / / 22005930 rs17028687 chr2 41995339 A G 7.70E-04 Alzheimer's disease / / 22005930 rs4381822 chr2 41996612 A G 9.32E-05 Leukocyte Counts / / pha003091 rs4952374 chr2 41997648 T C 7.97E-05 HDL cholesterol / / pha003075 rs17465239 chr2 42004689 C T 9.90E-07 Urinary metabolites / / 21572414 rs719593 chr2 42004997 A G 5.00E-06 Conduct disorder (interaction) / / 18846501 rs7581374 chr2 42006280 C G 7.75E-05 Type 2 diabetes / / 17463246 rs6704827 chr2 42015775 T G 7.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs4952513 chr2 42017861 T C 7.20E-05 Cognitive function / / 24684796 rs10211025 chr2 42028633 A G 9.70E-07 Asthma / / 24406073 rs12328045 chr2 42035110 A C 4.60E-06 Asthma / / 24406073 rs12471624 chr2 42046593 A T 1.80E-05 Urinary metabolites / / 21572414 rs4535089 chr2 42069298 T G 8.91E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs4305317 chr2 42080624 T G 2.00E-06 Rheumatoid arthritis / / 21156761 rs4305317 chr2 42080624 T G 4.00E-08 Rheumatoid arthritis / / 21156761 rs7423989 chr2 42100184 T A 8.43E-04 Body mass index / / 21701565 rs11676056 chr2 42100538 A G 3.25E-04 Body mass index / / 21701565 rs11676056 chr2 42100538 A G 7.35E-04 Body mass index / / 21701565 rs4952528 chr2 42112333 G A 1.40E-05 Urinary metabolites LOC388942 intron 21572414 rs4641988 chr2 42112720 C T 1.40E-05 Urinary metabolites LOC388942 intron 21572414 rs765678 chr2 42115621 G C 8.30E-06 Urinary metabolites LOC388942 intron 21572414 rs11886254 chr2 42118216 G C 2.70E-05 Urinary metabolites LOC388942 intron 21572414 rs7563575 chr2 42121185 G A 2.50E-05 Urinary metabolites / / 21572414 rs2374380 chr2 42122150 G C,T 8.27E-05 Major depressive disorder (broad) / / 20038947 rs4952533 chr2 42129211 G C 8.93E-05 Major depressive disorder (broad) / / 20038947 rs4952534 chr2 42129595 A C 7.70E-06 Urinary metabolites / / 21572414 rs4952535 chr2 42131523 G A 0.000101 Gains in maximal O2 uptake response / / 21183627 rs2374341 chr2 42133432 C T 1.80E-05 Urinary metabolites / / 21572414 rs2374342 chr2 42133542 A C 9.20E-04 Multiple complex diseases / / 17554300 rs2374342 chr2 42133542 A C 9.90E-06 Urinary metabolites / / 21572414 rs7580660 chr2 42136788 C T 9.60E-05 Endometriosis / / 21151130 rs2276698 chr2 42160388 G A 7.16E-05 Lung adenocarcinoma / / 19836008 rs4952548 chr2 42164215 A C 2.80E-05 Urinary metabolites C2orf91 UTR-3 21572414 rs4952548 chr2 42164215 A C 1.21E-04 Orofacial clefts C2orf91 UTR-3 22863734 rs7556683 chr2 42170854 T C 7.50E-06 Digit length ratio C2orf91 intron 20303062 rs4952561 chr2 42209530 T C 9.47E-05 Femoral neck bone geometry / / 22087292 rs7584262 chr2 42250549 C T 1.00E-09 Bone mineral density / / 22504420 rs11887431 chr2 42267462 C T 3.66E-05 Parkinson's disease / / 16252231 rs4952590 chr2 42276921 C T 2.00E-06 Atopy PKDCC intron 19961619 rs11891490 chr2 42285915 G A 6.78E-04 Type 2 diabetes / / 17463246 rs10454141 chr2 42313092 C T 2.34E-04 Lung function (forced vital capacity) / / 24023788 rs17029233 chr2 42343144 A T 3.07E-19 Varicose Veins / / pha001414 rs6733455 chr2 42350487 C T 7.08E-04 Alcohol dependence / / 21314694 rs4531983 chr2 42360204 A G 5.88E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4952936 chr2 42370455 T C 3.71E-05 Vitiligo / / 19890347 rs13412252 chr2 42373747 C T 6.37E-06 Intracerebral hemorrhage / / 24656865 rs17670415 chr2 42416503 C T 3.52E-04 Multiple complex diseases EML4 intron 17554300 rs997288 chr2 42525582 C G 6.31E-04 Body mass index EML4 intron 21701565 rs1874449 chr2 42667585 T G 6.30E-05 Bulimia nervosa / / 23568457 rs11685479 chr2 42694337 G A 8.70E-05 ldl cholesterol KCNG3 intron pha003077 rs2029899 chr2 42718898 G A 2.37E-04 Acute lung injury KCNG3 intron 22295056 rs17029761 chr2 42728604 A G 3.64E-04 Acute lung injury / / 22295056 rs9808148 chr2 42737734 T C 1.71E-04 Acute lung injury / / 22295056 rs924114 chr2 42739333 C T 2.61E-04 Acute lung injury / / 22295056 rs4953391 chr2 42740675 A C 6.16E-04 Acute lung injury / / 22295056 rs4953392 chr2 42740881 A G 6.83E-04 Acute lung injury / / 22295056 rs13398888 chr2 42753496 A T 1.72E-04 Acute lung injury / / 22295056 rs1874448 chr2 42761106 A G 3.19E-04 Blood pressure / / 17255346 rs12996453 chr2 42762739 G C 1.77E-04 Blood pressure / / 17255346 rs17029781 chr2 42767044 T C 4.25E-05 Longevity / / 20304771 rs17679678 chr2 42859714 G A 3.40E-05 Longevity MTA3 intron 20304771 rs6544586 chr2 42900991 G A 1.08E-04 Blood pressure MTA3 intron 17255346 rs930421 chr2 42981239 A G 6.00E-06 Attention deficit hyperactivity disorder / / 18821565 rs6719977 chr2 42985803 T C 2.00E-06 Hyperactive-impulsive symptoms / / 18821565 rs6719977 chr2 42985803 T C 6.10E-05 Diabetes Mellitus / / pha003060 rs2374443 chr2 43012336 C T 4.62E-05 Anxiety and major depressive disorder HAAO intron 24047446 rs12613026 chr2 43014289 C T 6.49E-06 Parkinson's disease HAAO intron 21812969 rs6717237 chr2 43043116 G A 6.65E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs1347929 chr2 43050311 C T 1.68E-05 Heart Rate / / pha003054 rs13395650 chr2 43076271 G A 8.00E-04 Body mass index / / 21701565 rs6720920 chr2 43079958 G A 9.01E-05 Multiple complex diseases / / 17554300 rs4332966 chr2 43083831 T G 2.72E-04 Systolic blood pressure / / 21909115 rs4953676 chr2 43121726 C A 3.00E-04 Obesity (extreme) / / 21935397 rs4245824 chr2 43127717 T C 1.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4953682 chr2 43128748 C G 5.07E-04 Obesity (extreme) / / 21935397 rs12986863 chr2 43132547 C T 4.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4952947 chr2 43138933 G A 1.03E-04 Obesity (extreme) / / 21935397 rs1078100 chr2 43146800 T C 2.23E-04 Substance dependence / / 21818250 rs12712870 chr2 43161180 A G 1.90E-05 Urinary metabolites / / 21572414 rs7603548 chr2 43165147 T C 9.21E-06 Intelligence / / 21826061 rs6544619 chr2 43184729 C T 3.00E-07 Diastolic blood pressure / / 19430483 rs10176316 chr2 43199311 C T 4.53E-04 Alzheimer's disease / / 22005930 rs6710906 chr2 43200107 C A 5.87E-04 Insulin resistance / / 21901158 rs9808138 chr2 43200625 G C 5.57E-04 Alzheimer's disease / / 22005930 rs6544624 chr2 43213996 G A 6.30E-06 Urinary metabolites / / 21572414 rs7593685 chr2 43215855 T C 9.40E-04 Coronary Artery Disease / / 17634449 rs11124912 chr2 43223032 A C 4.70E-04 Type 2 diabetes / / 17463246 rs17030257 chr2 43232117 C T 6.30E-04 Breast cancer / / 19330027 rs11686640 chr2 43239425 C T 2.50E-06 Urinary metabolites / / 21572414 rs921072 chr2 43242143 G C 1.13E-04 Type 2 diabetes / / 17463246 rs6748564 chr2 43246767 T G 3.10E-06 Urinary metabolites / / 21572414 rs2121355 chr2 43253242 T A 1.70E-05 Urinary metabolites / / 21572414 rs9973820 chr2 43278048 G A 5.06E-04 Insulin resistance / / 21901158 rs7582239 chr2 43286610 G T 1.61E-04 Multiple complex diseases / / 17554300 rs6711874 chr2 43288810 A G 5.09E-04 Multiple complex diseases / / 17554300 rs17030342 chr2 43299383 G A 4.23E-04 Coronary heart disease / / 21606135 rs17030347 chr2 43301017 T C 2.68E-04 Multiple complex diseases / / 17554300 rs747094 chr2 43305391 C T 2.97E-04 Alzheimer's disease / / 17998437 rs2374482 chr2 43305926 G A 9.73E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs6718520 chr2 43325570 A G 3.00E-08 Multiple sclerosis LOC100506047 intron 22190364 rs6718520 chr2 43325570 A G 1.20E-05 Multiple sclerosis LOC100506047 intron 24234648 rs4567998 chr2 43330109 C A 0.000000004 Joint damage severity in rheumatoid arthritis / / 23696630 rs4575770 chr2 43330140 C T 4.08E-09 Joint damage severity in rheumatoid arthritis / / 23696630 rs6709667 chr2 43330320 C T 4.20E-09 Joint damage severity in rheumatoid arthritis / / 23696630 rs4952660 chr2 43332143 A C 4.86E-09 Joint damage severity in rheumatoid arthritis / / 23696630 rs73925919 chr2 43334791 A G 0.00000022 Joint damage severity in rheumatoid arthritis / / 23696630 rs10199639 chr2 43347127 C G 9.22E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12466022 chr2 43359061 C A 6.00E-10 Multiple sclerosis / / 21833088 rs12466022 chr2 43359061 C A 4.20E-05 Multiple sclerosis / / 24234648 rs882502 chr2 43363752 T C 0.000513 Salmonella-induced pyroptosis / / 22837397 rs7568470 chr2 43424046 T G 4.11E-05 Serum metabolites / / 19043545 rs10174764 chr2 43429806 G A 2.15E-05 Multiple complex diseases / / 17554300 rs6749927 chr2 43484556 A G 2.92E-05 Orofacial clefts THADA intron 22863734 rs6712357 chr2 43494990 A C 9.40E-04 Type 2 diabetes THADA intron 17463246 rs7561670 chr2 43506259 G A 1.60E-05 Orofacial clefts THADA intron 22863734 rs11900952 chr2 43514036 G A 2.25E-05 Cleft lip THADA intron 20436469 rs11900952 chr2 43514036 G A 1.03E-06 Orofacial clefts THADA intron 22863734 rs11891936 chr2 43532302 C T 2.93E-09 Polycystic ovary syndrome THADA intron 21151128 rs7590268 chr2 43540125 T G 9.00E-08 Orofacial clefts THADA intron 20023658 rs7590268 chr2 43540125 T G 1.00E-08 Orofacial clefts THADA intron 22863734 rs7590268 chr2 43540125 T G 0.0000719 Facial morphology THADA intron 23028347 rs11690012 chr2 43542480 G C 5.90E-05 Arthritis (juvenile idiopathic) THADA intron 22354554 rs13035011 chr2 43544117 C T 3.70E-08 Orofacial clefts THADA intron 22863734 rs17030684 chr2 43548128 G A 3.46E-07 Polycystic ovary syndrome THADA intron 21151128 rs35338810 chr2 43548946 C T 6.44E-06 Orofacial clefts THADA intron 22863734 rs1465618 chr2 43553949 T C 2.00E-08 Prostate cancer THADA intron 19767753 rs1465618 chr2 43553949 T C 2.00E-08 Nasopharyngeal carcinoma THADA intron 20512145 rs1465618 chr2 43553949 T C 0.00016 Prostate cancer THADA intron 23555315 rs4340576 chr2 43555506 T C 2.71E-07 Polycystic ovary syndrome THADA intron 21151128 rs12468394 chr2 43561161 C A 1.20E-09 Polycystic ovary syndrome THADA intron 21151128 rs12468394 chr2 43561161 C A 2.45E-12 Polycystic ovary syndrome THADA intron 22885925 rs6729902 chr2 43576968 C T 2.48E-07 Orofacial clefts THADA intron 22863734 rs3901678 chr2 43587451 G T 3.97E-07 Hair morphology THADA intron 19896111 rs6732426 chr2 43587504 C T 7.96E-05 Multiple complex diseases THADA intron 17554300 rs6732426 chr2 43587504 C T 1.00E-07 Hair morphology THADA intron 19896111 rs17030720 chr2 43589094 T C 4.79E-04 Multiple complex diseases THADA intron 17554300 rs6544648 chr2 43600058 C T 1.91E-06 Orofacial clefts THADA intron 22863734 rs11899863 chr2 43618819 C T 9.50E-11 Type 2 diabetes THADA intron 22885922 rs12477823 chr2 43620320 G A 2.15E-06 Orofacial clefts THADA intron 22863734 rs7596480 chr2 43621162 C T 1.99E-06 Orofacial clefts THADA intron 22863734 rs6544652 chr2 43626212 C T 2.12E-06 Orofacial clefts THADA intron 22863734 rs7600177 chr2 43628055 C T 2.65E-06 Orofacial clefts THADA intron 22863734 rs17030752 chr2 43630493 T C 7.02E-05 Orofacial clefts THADA intron 22863734 rs6544653 chr2 43632950 C T 7.50E-04 Multiple complex diseases THADA intron 17554300 rs9677398 chr2 43634135 C A 3.78E-06 Orofacial clefts THADA intron 22863734 rs13402827 chr2 43634468 T C 6.37E-06 Response to amphetamines THADA intron 22952603 rs6544656 chr2 43635143 G A 2.27E-06 Orofacial clefts THADA intron 22863734 rs7567607 chr2 43638185 C T 1.06E-08 Polycystic ovary syndrome THADA intron 21151128 rs7567607 chr2 43638185 C T 0.000039 Prostate cancer THADA intron 23555315 rs7567607 chr2 43638185 C T 0.00062 Prostate cancer (non-advanced prostate cancer) THADA intron 23555315 rs13429458 chr2 43638838 A C 8.51E-06 Hair morphology THADA intron 19896111 rs13429458 chr2 43638838 A C 2.00E-23 Polycystic ovary syndrome THADA intron 21151128 rs13429458 chr2 43638838 A C 4.00E-13 Polycystic ovary syndrome THADA intron 22885925 rs13429458 chr2 43638838 A C 6.00E-06 Response to amphetamines THADA intron 22952603 rs7568365 chr2 43638855 C T 3.02E-08 Polycystic ovary syndrome THADA intron 21151128 rs13417665 chr2 43638888 T C 9.68E-06 Response to amphetamines THADA intron 22952603 rs7582497 chr2 43638947 T C 6.07E-08 Polycystic ovary syndrome THADA intron 21151128 rs10176241 chr2 43648176 A G 1.08E-06 Polycystic ovary syndrome THADA intron 21151128 rs10176241 chr2 43648176 A G 2.25E-05 Cognitive impairment induced by topiramate THADA intron 22091778 rs7575024 chr2 43666991 T C 8.96E-05 Type 1 diabetes THADA intron 18978792 rs7586101 chr2 43669851 T C 5.49E-04 Multiple complex diseases THADA intron 17554300 rs10445925 chr2 43670144 G C 1.40E-06 Orofacial clefts THADA intron 22863734 rs6744642 chr2 43671904 T C 1.24E-06 Polycystic ovary syndrome THADA intron 21151128 rs7556744 chr2 43672795 A G 7.44E-04 Multiple complex diseases THADA intron 17554300 rs10200833 chr2 43673316 C G 0.000471 Type 2 diabetes THADA intron 22325160 rs35114568 chr2 43675292 C A 1.73E-06 Orofacial clefts THADA intron 22863734 rs2046916 chr2 43686207 C T 3.21E-06 Orofacial clefts THADA intron 22863734 rs17030835 chr2 43686245 C G 1.30E-04 Type 2 diabetes THADA intron 17463246 rs17030845 chr2 43687879 C T 1.00E-10 Platelet counts THADA intron 22139419 rs6544660 chr2 43688496 C T 5.89E-04 Multiple complex diseases THADA intron 17554300 rs7561287 chr2 43689071 A G 6.72E-04 Type 2 diabetes THADA intron 17463246 rs7561287 chr2 43689071 A G 4.34E-04 Multiple complex diseases THADA intron 17554300 rs10203174 chr2 43690030 C T 0.0000087 Fasting blood glucose THADA intron 22885922 rs10203174 chr2 43690030 C T 0.0000098 HOMA-B THADA intron 22885922 rs10203174 chr2 43690030 C T 9.50E-12 Type 2 diabetes THADA intron 22885922 rs10203174 chr2 43690030 C T 4.80E-05 Type 2 diabetes THADA intron 24509480 rs13405158 chr2 43705286 T C 0.00064 Type 2 diabetes (females) THADA intron 22885922 rs13405158 chr2 43705286 T C 5.20E-10 Type 2 diabetes (males) THADA intron 22885922 rs12478601 chr2 43721508 C T 3.00E-23 Polycystic ovary syndrome THADA intron 21151128 rs12478601 chr2 43721508 C T 3.37E-10 Polycystic ovary syndrome THADA intron 22885925 rs13431070 chr2 43721954 G A 9.79E-04 Type 2 diabetes THADA intron 17463246 rs7578597 chr2 43732823 T C 1.00E-09 Type 2 diabetes THADA missense 18372903 rs7578597 chr2 43732823 T C 1.00E-09 Coronary heart disease THADA missense 21347282 rs7578597 chr2 43732823 T C 1.00E-09 Type 2 diabetes THADA missense 21647700 rs7578597 chr2 43732823 T C 0.000000291 Type 2 diabetes THADA missense 22325160 rs7578597 chr2 43732823 T C 1.10E-09 Type 2 diabetes THADA missense 23300278 rs1038822 chr2 43738173 T C 1.89E-08 Polycystic ovary syndrome THADA intron 21151128 rs6753942 chr2 43749436 T G 7.80E-04 Alzheimer's disease THADA intron 22005930 rs17030980 chr2 43751480 T C 9.93E-04 Alzheimer's disease THADA intron 22005930 rs17031005 chr2 43761299 A G 5.46E-05 Type 1 diabetes THADA intron 18978792 rs17031016 chr2 43764442 T C 4.04E-04 Type 2 diabetes THADA intron 17463246 rs7559891 chr2 43767039 G A 1.92E-07 Polycystic ovary syndrome THADA intron 21151128 rs1873555 chr2 43779665 T C 3.95E-07 Polycystic ovary syndrome THADA intron 21151128 rs1873555 chr2 43779665 T C 2.52E-05 Orofacial clefts THADA intron 22863734 rs7596052 chr2 43781826 G A 1.07E-04 Multiple complex diseases THADA intron 17554300 rs7596052 chr2 43781826 G A 1.23E-06 Polycystic ovary syndrome THADA intron 21151128 rs10165527 chr2 43782868 C T 1.29E-04 Multiple complex diseases THADA intron 17554300 rs10165527 chr2 43782868 C T 1.90E-06 Polycystic ovary syndrome THADA intron 21151128 rs6725776 chr2 43783141 A G 3.95E-05 Orofacial clefts THADA intron 22863734 rs6726014 chr2 43783294 A T 1.00E-06 Polycystic ovary syndrome THADA intron 21151128 rs881477 chr2 43791563 T C 9.59E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) THADA intron 22566498 rs17031053 chr2 43796811 T A 1.00E-04 Prostate cancer THADA intron 21743057 rs10211106 chr2 43798053 C T 7.83E-05 Orofacial clefts THADA intron 22863734 rs3752355 chr2 43799070 C T 1.00E-04 Cognitive impairment induced by topiramate THADA intron 22091778 rs3752355 chr2 43799070 C T 3.26E-05 Cognitive impairment induced by topiramate THADA intron 22091778 rs2374551 chr2 43802380 C G 2.06E-06 Polycystic ovary syndrome THADA intron 21151128 rs6731009 chr2 43803428 T C 2.06E-04 Type 2 diabetes THADA intron 17463246 rs6731009 chr2 43803428 T C 4.94E-07 Polycystic ovary syndrome THADA intron 21151128 rs17031076 chr2 43803468 T A,C 1.00E-04 Prostate cancer THADA intron 21743057 rs10495903 chr2 43806918 C T 1.60E-04 Multiple complex diseases THADA intron 17554300 rs10495903 chr2 43806918 C T 2.00E-14 Crohn's disease THADA intron 21102463 rs10495903 chr2 43806918 C T 8.00E-12 Inflammatory bowel disease THADA intron 23128233 rs17031088 chr2 43807090 T C 2.45E-04 Multiple complex diseases THADA intron 17554300 rs11890152 chr2 43807368 C G 1.54E-04 Type 2 diabetes THADA intron 17463246 rs10179648 chr2 43808065 C T 4.19E-08 Polycystic ovary syndrome THADA intron 21151128 rs10179648 chr2 43808065 C T 2.00E-04 Cognitive impairment induced by topiramate THADA intron 22091778 rs10179648 chr2 43808065 C T 2.00E-04 Cognitive impairment induced by topiramate THADA intron 22091778 rs10179648 chr2 43808065 C T 9.97E-05 Cognitive impairment induced by topiramate THADA intron 22091778 rs17031092 chr2 43809248 T G 3.39E-04 Multiple complex diseases THADA intron 17554300 rs11897432 chr2 43817505 G A 2.36E-06 Orofacial clefts THADA intron 22863734 rs11897432 chr2 43817505 G A 8.00E-07 DNA methylation (variation) THADA intron 23725790 rs7558302 chr2 43836687 C T 6.11E-08 Polycystic ovary syndrome / / 21151128 rs17031133 chr2 43844833 G A 1.58E-04 Multiple complex diseases / / 17554300 rs6749617 chr2 43845329 A T 2.77E-04 Multiple complex diseases / / 17554300 rs11886047 chr2 43850590 T C 6.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs6544678 chr2 43861551 T C 2.00E-05 Urinary metabolites / / 21572414 rs10174938 chr2 43873144 A C 7.49E-04 Prostate cancer mortality PLEKHH2 intron 20978177 rs17335631 chr2 43873505 C A 6.37E-05 Serum metabolites PLEKHH2 intron 19043545 rs17335631 chr2 43873505 C A 8.41E-05 Orofacial clefts PLEKHH2 intron 20023658 rs17335631 chr2 43873505 C A 1.44E-04 Orofacial clefts PLEKHH2 intron 22863734 rs7592384 chr2 43926465 G T 5.27E-04 Orofacial clefts PLEKHH2 intron 22863734 rs7573490 chr2 43928768 A G 0.000876 Salmonella-induced pyroptosis PLEKHH2 intron 22837397 rs4952676 chr2 43929983 G A 4.19E-04 Orofacial clefts PLEKHH2 intron 22863734 rs6759851 chr2 43930616 G C 9.87E-04 Prostate cancer mortality PLEKHH2 intron 20978177 rs4953002 chr2 43931176 T C 5.75E-04 Orofacial clefts PLEKHH2 cds-synon 22863734 rs6716551 chr2 43935725 T C 7.49E-04 Prostate cancer mortality PLEKHH2 intron 20978177 rs11695642 chr2 43952695 G T 3.10E-06 Iron levels PLEKHH2 intron 21208937 rs7561861 chr2 43962562 G T 7.64E-05 Prostate cancer PLEKHH2 intron 18264096 rs1368086 chr2 43965007 C T 7.93E-04 Bipolar disorder PLEKHH2 intron 19259986 rs17414390 chr2 43976263 T C 4.92E-04 Multiple complex diseases PLEKHH2 intron 17554300 rs10495907 chr2 43998726 G A 0.0000238 Coronary artery disease / / 23202125 rs725238 chr2 43999182 C T 3.70E-04 Myasthenia gravis / / 23055271 rs3762571 chr2 43999734 T G 3.30E-04 Myasthenia gravis / / 23055271 rs2288709 chr2 44004010 T C 5.30E-04 Type 2 diabetes DYNC2LI1 missense 23209189 rs3765000 chr2 44014301 A G 8.58E-05 Cortisol secretion,in saliva DYNC2LI1 intron 21316860 rs4953017 chr2 44024282 T A 7.37E-04 Multiple complex diseases DYNC2LI1 intron 17554300 rs3792015 chr2 44025628 T C 2.85E-22 Narcolepsy DYNC2LI1 intron 19629137 rs4952679 chr2 44029821 C T 9.82E-05 Cortisol secretion,in saliva DYNC2LI1 intron 21316860 rs4953019 chr2 44043393 G A 5.99E-05 Lipid levels ABCG5 intron 19913121 rs10205816 chr2 44044255 A G 9.70E-07 Iron levels ABCG5 intron 21208937 rs10439467 chr2 44048346 C T 0.0000482 LDL cholesterol ABCG5 intron 23063622 rs4148188 chr2 44050687 C T 4.60E-04 Alzheimer's disease (late onset) ABCG5 intron 21379329 rs4148187 chr2 44050888 G A 4.60E-04 Alzheimer's disease (late onset) ABCG5 intron 21379329 rs4289236 chr2 44054123 G A 2.67E-04 Alzheimer's disease (late onset) ABCG5 intron 21379329 rs17031687 chr2 44055387 C T 0.00000038 LDL cholesterol ABCG5 intron 23063622 rs17031687 chr2 44055387 C T 0.00000148 Cholesterol,total ABCG5 intron 23063622 rs6756629 chr2 44065090 G A,C,T 2.00E-11 Cholesterol,total ABCG5 missense 19060911 rs6756629 chr2 44065090 G A,C,T 3.00E-10 LDL cholesterol ABCG5 missense 19060911 rs6756629 chr2 44065090 G A,C,T 3.00E-10 Coronary heart disease ABCG5 missense 21347282 rs11887534 chr2 44066247 G C,T 1.00E-14 Gallstones ABCG8 missense 17632509 rs11887534 chr2 44066247 G C,T 2.78E-11 Lipid levels ABCG8 missense 19936222 rs11887534 chr2 44066247 G C,T 3.48E-10 Lipid levels ABCG8 missense 19936222 rs10179921 chr2 44068291 C T 8.82E-05 Cholesterol ABCG8 intron pha003078 rs17031710 chr2 44070893 A T 0.000000018 LDL cholesterol ABCG8 intron 23063622 rs17031710 chr2 44070893 A T 0.000000773 Triglycerides ABCG8 intron 23063622 rs17031710 chr2 44070893 A T 8.48E-10 Cholesterol,total ABCG8 intron 23063622 rs6748810 chr2 44070935 A G 3.19E-04 Multiple complex diseases ABCG8 intron 17554300 rs4299376 chr2 44072576 G T 1.20E-09 Gallstones ABCG8 intron 17632509 rs4299376 chr2 44072576 G T 7.60E-08 Lipid levels ABCG8 intron 19913121 rs4299376 chr2 44072576 G T 8.70E-10 Lipid levels ABCG8 intron 19913121 rs4299376 chr2 44072576 G T 9.74E-14 Lipid levels ABCG8 intron 19936222 rs4299376 chr2 44072576 G T 2.00E-47 LDL cholesterol ABCG8 intron 20686565 rs4299376 chr2 44072576 G T 4.00E-45 Cholesterol,total ABCG8 intron 20686565 rs4299376 chr2 44072576 G T 1.40E-06 Coronary heart disease ABCG8 intron 21966275 rs4299376 chr2 44072576 G T 2.25E-32 LDL cholesterol ABCG8 intron 23063622 rs4299376 chr2 44072576 G T 2.32E-30 Cholesterol,total ABCG8 intron 23063622 rs4299376 chr2 44072576 G T 0.000000015 LDL cholesterol ABCG8 intron 23100282 rs4299376 chr2 44072576 G T 0.00000013 Apolipoprotein B levels ABCG8 intron 23100282 rs4299376 chr2 44072576 G T 1.50E-08 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) ABCG8 intron 23103227 rs4299376 chr2 44072576 G T 3.00E-73 Cholesterol,total ABCG8 intron 24097068 rs4299376 chr2 44072576 G T 4.00E-72 LDL cholesterol ABCG8 intron 24097068 rs41360247 chr2 44073656 T C 4.07E-09 Gallstones ABCG8 intron 17632509 rs41360247 chr2 44073656 T C 6.00E-25 Phytosterol levels ABCG8 intron 20529992 rs6544713 chr2 44073881 T C 2.00E-20 LDL cholesterol ABCG8 intron 19060906 rs6544713 chr2 44073881 T C 2.00E-20 Coronary heart disease ABCG8 intron 21347282 rs6544713 chr2 44073881 T C 0.00000153 Coronary artery disease (CAD) age >50 ABCG8 intron 23202125 rs6544713 chr2 44073881 T C 0.0000443 Coronary artery disease with myocardial infarction ABCG8 intron 23202125 rs6544713 chr2 44073881 T C 0.000155 Coronary artery disease (CAD) age <=50 ABCG8 intron 23202125 rs6544713 chr2 44073881 T C 1.17E-44 Cholesterol,total ABCG8 intron 23202125 rs6544713 chr2 44073881 T C 1.21E-10 Coronary artery disease (CAD) (males) ABCG8 intron 23202125 rs6544713 chr2 44073881 T C 2.37E-47 LDL cholesterol ABCG8 intron 23202125 rs6544713 chr2 44073881 T C 2.76E-10 Coronary artery disease ABCG8 intron 23202125 rs4953023 chr2 44074000 G A 3.40E-09 Gallstones ABCG8 intron 17632509 rs4953023 chr2 44074000 G A 0.00000642 LDL cholesterol (female) ABCG8 intron 22629316 rs4953023 chr2 44074000 G A 0.000862 LDL cholesterol (male) ABCG8 intron 22629316 rs4953023 chr2 44074000 G A 2.41E-08 LDL cholesterol ABCG8 intron 22629316 rs4953023 chr2 44074000 G A 0.0000023 LDL cholesterol (male) ABCG8 intron 23063622 rs4953023 chr2 44074000 G A 0.000354 Total cholesterol in males ABCG8 intron 23063622 rs4953023 chr2 44074000 G A 3.67E-13 LDL cholesterol (female) ABCG8 intron 23063622 rs4953023 chr2 44074000 G A 5.43E-19 LDL cholesterol ABCG8 intron 23063622 rs4953023 chr2 44074000 G A 6.67E-17 Cholesterol,total ABCG8 intron 23063622 rs4953023 chr2 44074000 G A 6.93E-14 Total cholesterol in females ABCG8 intron 23063622 rs4245791 chr2 44074431 C T 1.78E-04 Multiple complex diseases ABCG8 intron 17554300 rs4245791 chr2 44074431 C T 2.90E-08 Gallstones ABCG8 intron 17632509 rs4245791 chr2 44074431 C T 3.33E-08 Lipid levels ABCG8 intron 20370913 rs4245791 chr2 44074431 C T 2.00E-50 Phytosterol levels ABCG8 intron 20529992 rs4245791 chr2 44074431 C T 1.00E-09 LDL cholesterol ABCG8 intron 23726366 rs17424122 chr2 44075217 T A 5.00E-04 Gallstones ABCG8 intron 17632509 rs4148217 chr2 44099433 C A,G,T 4.91E-11 LDL cholesterol ABCG8 missense 23063622 rs4148217 chr2 44099433 C A,G,T 6.63E-11 Cholesterol,total ABCG8 missense 23063622 rs4148218 chr2 44099582 G A 4.52E-11 LDL cholesterol ABCG8 intron 23063622 rs4148218 chr2 44099582 G A 6.08E-12 Cholesterol,total ABCG8 intron 23063622 rs2955279 chr2 44112422 C T 7.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12465555 chr2 44118189 A G 3.72E-04 Type 2 diabetes LRPPRC intron 17463246 rs12465555 chr2 44118189 A G 3.27E-05 Amyotrophic lateral sclerosis LRPPRC intron 19193627 rs12465555 chr2 44118189 A G 3.05E-05 Non-word repetition LRPPRC intron 23738518 rs13387221 chr2 44135314 G A 9.00E-06 Intelligence (childhood) LRPPRC intron 23358156 rs4390811 chr2 44176225 G C 4.73E-05 Response to taxane treatment (placlitaxel) LRPPRC intron 23006423 rs10206724 chr2 44185345 G A 3.68E-04 Response to taxane treatment (placlitaxel) LRPPRC intron 23006423 rs6723119 chr2 44187204 A G 5.94E-04 Response to taxane treatment (placlitaxel) LRPPRC intron 23006423 rs10190161 chr2 44187829 A C 9.50E-06 Urinary metabolites LRPPRC intron 21572414 rs10190161 chr2 44187829 A C 6.43E-04 Response to taxane treatment (placlitaxel) LRPPRC intron 23006423 rs10865195 chr2 44189607 C T 8.77E-04 Response to taxane treatment (placlitaxel) LRPPRC intron 23006423 rs11124960 chr2 44215710 C T 6.23E-05 Amyotrophic lateral sclerosis LRPPRC intron 19193627 rs6730684 chr2 44231918 C G 8.24E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6759184 chr2 44231969 A G 6.44E-05 Nonalcoholic fatty liver disease / / 21423719 rs6759184 chr2 44231969 A G 4.43E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9284745 chr2 44291333 C T 7.75E-04 Schizophrenia / / 19197363 rs7565605 chr2 44292977 C T 4.83E-04 Multiple complex diseases / / 17554300 rs7565605 chr2 44292977 C T 0.00067 Salmonella-induced pyroptosis / / 22837397 rs7570865 chr2 44305057 C A,G,T 3.95E-04 Multiple complex diseases / / 17554300 rs6544738 chr2 44305240 G A 8.38E-04 Multiple complex diseases / / 17554300 rs10193534 chr2 44306584 G C 7.09E-04 Multiple complex diseases / / 17554300 rs7607908 chr2 44307450 A G 5.10E-04 Type 2 diabetes / / 17463246 rs7606187 chr2 44315927 T C 1.42E-04 Parkinson's disease / / 17052657 rs6726274 chr2 44318652 A G 1.43E-04 Schizophrenia / / 20832056 rs7355599 chr2 44322757 A G 2.34E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7355599 chr2 44322757 A G 4.54E-05 Lung function (forced vital capacity) / / 24023788 rs2333825 chr2 44326923 A G 2.68E-06 Cardiovascular disease / / 18179892 rs6732415 chr2 44337872 G A 5.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs10495913 chr2 44343676 G A 7.59E-05 AIDS / / 19754311 rs11124972 chr2 44351536 T G 7.96E-05 Glucose levels / / pha003061 rs7593878 chr2 44358504 A C 5.44E-05 Obsessive-compulsive disorder / / 24821223 rs7593878 chr2 44358504 A C 5.44E-05 Obsessive-compulsive disorder / / 24821223 rs11894015 chr2 44359828 C A,G,T 2.10E-05 Urinary metabolites / / 21572414 rs6544744 chr2 44392252 G C 2.48E-04 Alzheimer's disease / / 17998437 rs6544745 chr2 44392271 C A 4.90E-04 Type 2 diabetes / / 17463246 rs10180864 chr2 44392395 G A 1.71E-04 Type 2 diabetes / / 17463246 rs7595470 chr2 44402467 T C 8.91E-05 Alzheimer's disease PPM1B intron 17998437 rs13008237 chr2 44404902 T C 1.23E-04 Alzheimer's disease PPM1B intron 17998437 rs6544746 chr2 44407985 G A 5.20E-04 Alzheimer's disease PPM1B intron 17998437 rs2053458 chr2 44443079 C G 9.57E-04 Alcohol dependence PPM1B intron 21314694 rs11124981 chr2 44462133 T A 2.40E-05 Alzheimer's disease PPM1B nearGene-3 17998437 rs4953076 chr2 44480950 G C 4.00E-09 Height / / 23563607 rs12712916 chr2 44482099 A C 3.92E-05 Alzheimer's disease / / 17998437 rs12712916 chr2 44482099 A C 1.50E-05 Urinary metabolites / / 21572414 rs3738985 chr2 44502788 A C 3.69E-04 Alzheimer's disease SLC3A1 cds-synon 17998437 rs3738985 chr2 44502788 A C 9.00E-06 Urinary metabolites SLC3A1 cds-synon 21572414 rs3768919 chr2 44512971 G A,C,T 1.80E-06 Urinary metabolites SLC3A1 intron 21572414 rs3768919 chr2 44512971 G A,C,T 2.29E-05 Asthma SLC3A1 intron 23181788 rs6706053 chr2 44517662 T C 1.70E-06 Urinary metabolites SLC3A1 intron 21572414 rs6706053 chr2 44517662 T C 1.07E-05 Asthma SLC3A1 intron 23181788 rs3738984 chr2 44531484 C T 6.40E-06 Urinary metabolites SLC3A1 intron 21572414 rs3738983 chr2 44531635 T C 8.03E-04 Type 2 diabetes SLC3A1 intron 17463246 rs1946932 chr2 44543125 C G 8.76E-05 Bipolar disorder and schizophrenia SLC3A1 intron 20889312 rs1946932 chr2 44543125 C G 3.84E-05 Bipolar disorder SLC3A1 intron 22925353 rs1372079 chr2 44543317 C T 4.79E-05 Bipolar disorder SLC3A1 intron 22925353 rs1372078 chr2 44543389 T A 1.10E-05 Urinary metabolites SLC3A1 intron 21572414 rs1142523 chr2 44545576 T C 8.36E-05 Cognitive test performance PREPL UTR-3 20125193 rs8410 chr2 44546016 C A,G,T 8.68E-05 Bipolar disorder and schizophrenia PREPL UTR-3 20889312 rs698761 chr2 44547574 G A 2.10E-05 Urinary metabolites SLC3A1 missense 21572414 rs2241869 chr2 44549229 G A 1.80E-05 Urinary metabolites PREPL intron 21572414 rs4953085 chr2 44554724 A G 8.42E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) PREPL intron 23648065 rs4953088 chr2 44564518 A G 7.60E-06 Urinary metabolites PREPL intron 21572414 rs4953092 chr2 44565293 G A 1.30E-05 Urinary metabolites PREPL intron 21572414 rs2289463 chr2 44565447 A T 1.70E-05 Urinary metabolites PREPL intron 21572414 rs12472538 chr2 44566872 C A 5.34E-05 Odorant perception PREPL intron 23910658 rs698774 chr2 44584314 G A 1.80E-05 Urinary metabolites PREPL intron 21572414 rs786613 chr2 44590066 G C 1.40E-05 Urinary metabolites CAMKMT intron 21572414 rs786616 chr2 44592975 G C 1.50E-05 Urinary metabolites CAMKMT intron 21572414 rs1067344 chr2 44620810 T G 3.49E-04 Alcohol dependence CAMKMT intron 21314694 rs1067386 chr2 44644257 G T 8.10E-06 Urinary metabolites CAMKMT intron 21572414 rs1067383 chr2 44645911 G A 2.20E-05 Urinary metabolites CAMKMT intron 21572414 rs1584885 chr2 44647038 G T 2.07E-05 Bipolar disorder and schizophrenia CAMKMT intron 20889312 rs17498753 chr2 44647831 A G 5.69E-05 Bipolar disorder CAMKMT intron 19488044 rs17498753 chr2 44647831 A G 1.00E-06 Bipolar disorder CAMKMT intron 21738484 rs17498753 chr2 44647831 A G 6.93E-05 Bipolar Disorder CAMKMT intron pha002858 rs13414205 chr2 44662475 C T 7.00E-08 Immune reponse to smallpox (secreted TNF-alpha) CAMKMT intron 22610502 rs1085447 chr2 44670996 A G 1.40E-05 Urinary metabolites CAMKMT intron 21572414 rs1067409 chr2 44673057 T C 8.17E-04 Multiple complex diseases CAMKMT intron 17554300 rs17498998 chr2 44674151 T C 1.47E-04 Body mass index CAMKMT intron 17255346 rs1067405 chr2 44674861 T C 2.50E-05 Lung adenocarcinoma CAMKMT intron 22797724 rs2166453 chr2 44693424 C T 5.76E-05 Bipolar disorder and schizophrenia CAMKMT intron 20889312 rs698813 chr2 44705615 A G 1.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel) CAMKMT intron 24025145 rs698822 chr2 44720752 A G 2.44E-04 Multiple complex diseases CAMKMT intron 17554300 rs17581117 chr2 44724992 G A 4.19E-04 Type 2 diabetes CAMKMT intron 17463246 rs698838 chr2 44738763 C T 5.40E-05 Lung adenocarcinoma CAMKMT intron 22797724 rs1223222 chr2 44756361 C A 6.60E-05 Lung adenocarcinoma CAMKMT intron 22797724 rs2341459 chr2 44768202 T C 8.00E-10 Height CAMKMT intron 20881960 rs10170837 chr2 44771535 T G 8.50E-05 Lung adenocarcinoma CAMKMT intron 22797724 rs10201401 chr2 44810480 G A 3.27E-04 Tourette syndrome CAMKMT intron 22889924 rs786180 chr2 44900846 G A 3.65E-05 Hemoglobin CAMKMT intron pha003096 rs653231 chr2 44903040 G A 2.60E-07 Urinary metabolites CAMKMT intron 21572414 rs343975 chr2 44911681 C G 6.00E-07 Urinary metabolites CAMKMT intron 21572414 rs343978 chr2 44916344 C T 1.33E-04 IgE levels CAMKMT intron 17255346 rs343955 chr2 44944877 G A 1.13E-05 Hemoglobin CAMKMT intron pha003096 rs343955 chr2 44944877 G A 5.40E-05 Hematocrit CAMKMT intron pha003097 rs343964 chr2 44966378 A G 4.60E-05 Hemoglobin CAMKMT intron pha003096 rs12473962 chr2 44974370 C A 3.50E-04 Myasthenia gravis CAMKMT intron 23055271 rs343935 chr2 44991100 T C 9.20E-04 Type 2 diabetes and 6 quantitative traits CAMKMT intron 17848626 rs343936 chr2 44992550 T C 4.75E-05 Hemoglobin CAMKMT intron pha003096 rs11679997 chr2 44993487 C T 3.14E-05 Bone mineral traits,in men CAMKMT intron 21427758 rs11679997 chr2 44993487 C T 6.73E-05 Bone mineral traits,in men CAMKMT intron 21427758 rs10495921 chr2 45003555 A G 2.66E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10203604 chr2 45087265 C T 0.0000451 Tuberculosis with late age of onset / / 22551897 rs11674185 chr2 45095097 G A 0.0000727 Tuberculosis with late age of onset / / 22551897 rs529177 chr2 45100208 T G 1.60E-05 Urinary metabolites / / 21572414 rs737447 chr2 45106017 T G 3.29E-05 Response to metformin / / 21186350 rs4952726 chr2 45107621 T C 3.73E-05 Response to metformin / / 21186350 rs6740875 chr2 45117702 G A 6.10E-04 Multiple complex diseases / / 17554300 rs7561677 chr2 45129440 C T 1.03E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs518853 chr2 45141218 G A 9.69E-04 Type 2 diabetes / / 17463246 rs528301 chr2 45154908 G A 5.00E-06 Alcohol and nictotine co-dependence / / 22488850 rs1983312 chr2 45187127 G A 5.80E-04 Rheumatoid arthritis / / 21452313 rs895636 chr2 45188353 C T 1.00E-12 Metabolite levels / / 21909109 rs340514 chr2 45189011 C T 3.52E-04 Type 2 diabetes / / 17463246 rs4953156 chr2 45189763 G A 9.03E-04 Rheumatoid arthritis / / 21452313 rs6705604 chr2 45216585 G A 3.38E-04 Cognitive decline / / 23732972 rs2290030 chr2 45232686 A C 3.31E-04 Multiple complex diseases SIX2 UTR-3 17554300 rs2290030 chr2 45232686 A C 9.54E-04 Amyotrophic lateral sclerosis (sporadic) SIX2 UTR-3 24529757 rs1447106 chr2 45239021 T C 5.18E-04 Type 2 diabetes / / 17846125 rs921120 chr2 45273041 A G 8.23E-05 Coronary heart disease / / pha003030 rs4355165 chr2 45285952 G T 5.00E-04 HIV-1 viral setpoint / / 17641165 rs2959233 chr2 45311515 G A 6.01E-04 Type 2 diabetes / / 17463246 rs2959236 chr2 45312967 T C 5.47E-04 Alcohol dependence / / 20201924 rs908568 chr2 45336379 C T 9.29E-05 Serum metabolites / / 19043545 rs868714 chr2 45336859 T G 8.78E-05 Serum metabolites / / 19043545 rs868714 chr2 45336859 T G 9.67E-05 Relative hand skill in reading disability / / 24068947 rs13027491 chr2 45340575 T A 9.73E-05 Relative hand skill in reading disability / / 24068947 rs17337049 chr2 45369224 C T 7.40E-05 Memory performance / / 22105620 rs992618 chr2 45387774 C T 4.06E-05 Prostate cancer / / 23023329 rs10206235 chr2 45389301 A G 6.80E-05 HIV-1 control / / 20041166 rs12712936 chr2 45390835 G A 0.00000893 Cytarabine sensitivity / / 23538338 rs10209754 chr2 45404169 T C 3.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) UNQ6975 intron 20877124 rs10209754 chr2 45404169 T C 6.12E-04 Aortic root size UNQ6975 intron 21223598 rs6720296 chr2 45408269 A C 3.93E-04 Rheumatoid arthritis UNQ6975 intron 21452313 rs12476824 chr2 45413394 A G 3.10E-05 Height UNQ6975 intron pha003010 rs12476824 chr2 45413394 A G 6.08E-05 Height UNQ6975 intron pha003011 rs7569588 chr2 45420082 G T 7.00E-04 Amyotrophic lateral sclerosis UNQ6975 intron 17671248 rs7569588 chr2 45420082 G T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes UNQ6975 intron 22628534 rs11125007 chr2 45426104 G A 4.50E-04 Cocaine dependence UNQ6975 intron 23958962 rs11125007 chr2 45426104 G A 9.04E-05 Cocaine dependence UNQ6975 intron 23958962 rs4953208 chr2 45437361 A G 9.81E-04 Type 2 diabetes UNQ6975 intron 17463246 rs11125013 chr2 45465435 A G 7.18E-04 Response to taxane treatment (placlitaxel) UNQ6975 intron 23006423 rs7595329 chr2 45483869 T C 0.000634 fMRI brain tests in schizophrenia / / 22440650 rs7594273 chr2 45493703 T C 3.21E-05 IgE levels / / 17255346 rs918810 chr2 45494927 G A 1.66E-04 IgE levels / / 17255346 rs7579209 chr2 45498718 C T 3.42E-04 IgE levels / / 17255346 rs870575 chr2 45503260 G A 5.90E-07 Parkinson's disease / / 20711177 rs12476712 chr2 45506771 C T 3.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs7561692 chr2 45509817 T C 8.35E-04 Iron levels / / pha002876 rs2042474 chr2 45510971 T C 4.93E-06 Vitiligo / / 22951725 rs1862890 chr2 45514154 T C 4.77E-06 Vitiligo / / 22951725 rs6737073 chr2 45530679 C G 2.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1862893 chr2 45546106 G T 8.22E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs12473388 chr2 45549305 T C 3.22E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs16909 chr2 45551530 A G 5.68E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4245803 chr2 45574206 G A 4.30E-04 Alcohol dependence / / 20201924 rs10167668 chr2 45582319 A G 1.12E-06 Alcohol and nictotine co-dependence / / 20158304 rs2067981 chr2 45595266 A G 4.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2067981 chr2 45595266 A G 9.44E-05 Cognitive test performance / / 20125193 rs1862071 chr2 45600699 G A 2.20E-05 Urinary metabolites / / 21572414 rs4952763 chr2 45608066 C T 2.04E-04 Multiple complex diseases / / 17554300 rs2216506 chr2 45635465 T C 8.70E-04 Alcohol dependence SRBD1 intron 20201924 rs3213787 chr2 45646824 A G 3.00E-09 Glaucoma SRBD1 intron 20363506 rs3770251 chr2 45668670 T C 2.82E-05 Vitiligo SRBD1 intron 19890347 rs3755076 chr2 45669349 T C 8.71E-05 Multiple complex diseases SRBD1 intron 17554300 rs17394081 chr2 45692947 C T 1.59E-05 Type 2 diabetes SRBD1 intron 17463246 rs17394081 chr2 45692947 C T 2.40E-04 Multiple complex diseases SRBD1 intron 17554300 rs6712896 chr2 45707814 A C 1.57E-04 Smoking initiation SRBD1 intron 24665060 rs17322265 chr2 45719992 C T 2.12E-05 Common variable immunodeficiency SRBD1 intron 21497890 rs10427402 chr2 45744392 G T 2.37E-04 Multiple complex diseases SRBD1 intron 17554300 rs4476395 chr2 45748712 C A 7.99E-04 Multiple complex diseases SRBD1 intron 17554300 rs4425122 chr2 45749523 C T 5.04E-04 Type 2 diabetes SRBD1 intron 17463246 rs4425122 chr2 45749523 C T 4.59E-04 Multiple complex diseases SRBD1 intron 17554300 rs2112040 chr2 45752214 G A 8.70E-05 Glioma (high-grade) SRBD1 intron 19578366 rs2082876 chr2 45769170 C A 4.28E-05 Glaucoma (primary open-angle) SRBD1 intron 22605921 rs748573 chr2 45770394 C G 3.59E-04 Multiple complex diseases SRBD1 intron 17554300 rs6708810 chr2 45774050 G A 4.90E-04 Type 2 diabetes SRBD1 intron 17463246 rs6708810 chr2 45774050 G A 4.74E-04 Multiple complex diseases SRBD1 intron 17554300 rs6710581 chr2 45779218 C A 7.01E-04 Type 2 diabetes SRBD1 intron 17463246 rs6710581 chr2 45779218 C A 4.30E-04 Multiple complex diseases SRBD1 intron 17554300 rs718731 chr2 45831537 A G 2.00E-04 Information processing speed SRBD1 intron 21130836 rs1403450 chr2 45843275 G A 6.06E-04 Myopia (pathological) / / 21095009 rs6713298 chr2 45850077 C T 7.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7565326 chr2 45850809 C T 5.13E-05 Multiple complex diseases / / 17554300 rs12622230 chr2 45855315 A C 4.02E-05 Alcohol dependence / / 20201924 rs12622230 chr2 45855315 A C 4.02E-05 Alcoholism / / pha002891 rs2344662 chr2 45864710 A C 2.27E-05 Anxiety in major depressive disorder / / 24047446 rs3731949 chr2 45900565 C T 3.20E-04 Myopia (pathological) PRKCE intron 21095009 rs542413 chr2 45922031 G A 3.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PRKCE intron 20877124 rs11674329 chr2 45928086 A C 0.000530036 Hypertension (early onset hypertension) PRKCE intron 22479346 rs6743119 chr2 45959960 T C 5.81E-04 Type 2 diabetes PRKCE intron 17463246 rs4953246 chr2 45980110 T C 6.51E-04 Obesity (extreme) PRKCE intron 21935397 rs938661 chr2 45981920 T C 8.30E-06 Urinary metabolites PRKCE intron 21572414 rs867286 chr2 45982030 G A 3.30E-05 Bipolar disorder and schizophrenia PRKCE intron 20889312 rs867286 chr2 45982030 G A 4.39E-04 Obesity (extreme) PRKCE intron 21935397 rs884401 chr2 45982608 T C 9.92E-04 Obesity (extreme) PRKCE intron 21935397 rs884400 chr2 45982645 T C 1.70E-05 Urinary metabolites PRKCE intron 21572414 rs884399 chr2 45982925 G T 4.22E-04 Obesity (extreme) PRKCE intron 21935397 rs4953249 chr2 45992857 G A 7.30E-06 Major depression (suicidal thoughts and behavior) PRKCE intron 21750702 rs4953251 chr2 45994586 C T 5.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PRKCE intron 20877124 rs3924521 chr2 45995181 G A 0.00034 Breast cancer PRKCE intron 23555315 rs3924523 chr2 45995350 A G 2.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) PRKCE intron 17982456 rs13404973 chr2 45997411 G A 1.62E-04 Autism spectrum disorders (language delay) PRKCE intron 21519539 rs13405086 chr2 45997519 G A 1.62E-04 Autism spectrum disorders (language delay) PRKCE intron 21519539 rs7558342 chr2 46015851 T G 1.13E-05 Serum metabolites PRKCE intron 19043545 rs11898074 chr2 46018223 A C 4.49E-04 Response to cholinesterase inhibitors in Alzheimer's disease PRKCE intron 23374588 rs11898209 chr2 46018533 A G 2.40E-05 Hypothyroidism PRKCE intron 22493691 rs6743144 chr2 46026901 A G 2.10E-05 Urinary metabolites PRKCE intron 21572414 rs4953260 chr2 46033719 C T 8.60E-05 Hypothyroidism PRKCE intron 22493691 rs7593800 chr2 46039147 C T 8.03E-05 Biliary atresia PRKCE intron 20460270 rs3886870 chr2 46042478 G A 2.43E-05 Hypertension PRKCE intron pha003041 rs3886870 chr2 46042478 G A 7.00E-06 Hypertension PRKCE intron pha003042 rs935672 chr2 46045959 C T 4.10E-04 Type 2 diabetes PRKCE intron 17463246 rs12328510 chr2 46051529 C G 2.30E-05 Parkinson's disease (age of onset) PRKCE intron 19772629 rs6747706 chr2 46052497 A C 7.79E-05 Alzheimer's disease (age of onset) PRKCE intron 22005931 rs13409215 chr2 46053362 C G 7.29E-05 Alzheimer's disease (age of onset) PRKCE intron 22005931 rs935661 chr2 46055357 G T 4.20E-04 Type 2 diabetes and 6 quantitative traits PRKCE intron 17848626 rs10865208 chr2 46056502 C T 8.61E-04 Type 2 diabetes PRKCE intron 17463246 rs935656 chr2 46064857 C T 1.63E-04 Coronary Artery Disease PRKCE intron 17634449 rs7593255 chr2 46074687 C T 1.53E-04 Multiple complex diseases PRKCE intron 17554300 rs1947195 chr2 46085325 C T 2.38E-05 Alzheimer's disease (age of onset) PRKCE intron 22005931 rs1992932 chr2 46087873 T C 9.73E-05 Progressive supranuclear palsy PRKCE intron 21685912 rs10189339 chr2 46093760 G A 1.49E-05 Progressive supranuclear palsy PRKCE intron 21685912 rs12467641 chr2 46102141 A T 3.11E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs11125041 chr2 46108945 C T 1.63E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs13431763 chr2 46110574 G A 1.34E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs878812 chr2 46133791 T C 2.51E-04 Multiple complex diseases PRKCE intron 17554300 rs13417518 chr2 46136825 G T 3.09E-06 Left ventricular mass PRKCE intron 21212386 rs6720958 chr2 46158523 C A 1.20E-05 Urinary metabolites PRKCE intron 21572414 rs13036100 chr2 46158690 G A 9.87E-04 Multiple complex diseases PRKCE intron 17554300 rs13023787 chr2 46174736 A G 5.59E-04 Smoking initiation PRKCE intron 24665060 rs11903566 chr2 46175313 G A 0.00000359 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes PRKCE intron 22628534 rs6750700 chr2 46176403 C A 4.15E-04 Body mass index PRKCE intron 17255346 rs6751349 chr2 46176962 C A 8.00E-06 QT interval PRKCE intron 23166209 rs12471357 chr2 46179662 T C 6.03E-06 Response to tocilizumab in rheumatoid arthritis PRKCE intron 22491018 rs2595199 chr2 46187460 T C 3.14E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) PRKCE intron 24023788 rs7607360 chr2 46194334 A G 2.00E-04 Cognitive impairment induced by topiramate PRKCE intron 22091778 rs13396424 chr2 46205039 T G 8.00E-06 Metabolite levels (X-11787) PRKCE intron 23934736 rs2595211 chr2 46206752 T G 9.02E-04 Nicotine dependence PRKCE intron 17158188 rs6705717 chr2 46207966 G A 9.94E-04 Type 2 diabetes PRKCE intron 17463246 rs2122112 chr2 46219949 T G 9.76E-05 Cognitive performance PRKCE intron 19734545 rs11903923 chr2 46258941 C T 9.26E-04 Rheumatoid arthritis PRKCE intron 21452313 rs1470598 chr2 46269567 A G 6.93E-04 Nicotine smoking PRKCE intron 19268276 rs6751805 chr2 46287743 A G 3.19E-04 Blood pressure PRKCE intron 17255346 rs12712962 chr2 46294811 T C 8.32E-04 Response to cytidine analogues (gemcitabine) PRKCE intron 24483146 rs12712963 chr2 46294981 A G 1.92E-04 Multiple complex diseases PRKCE intron 17554300 rs12712963 chr2 46294981 A G 1.32E-04 Response to cytidine analogues (gemcitabine) PRKCE intron 24483146 rs12712963 chr2 46294981 A G 4.25E-04 Response to cytadine analogues (cytosine arabinoside) PRKCE intron 24483146 rs13432276 chr2 46311960 A C 3.62E-05 Gaucher disease severity PRKCE intron 22388998 rs2345955 chr2 46320880 C T 8.20E-04 Nicotine smoking PRKCE intron 19268276 rs2345955 chr2 46320880 C T 1.69E-05 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs2345955 chr2 46320880 C T 7.27E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12373805 chr2 46321094 G A 7.52E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12373805 chr2 46321094 G A 9.20E-06 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs10167555 chr2 46321106 T G 3.47E-05 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs10167555 chr2 46321106 T G 6.95E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs10202504 chr2 46321333 C G 1.60E-05 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs10202504 chr2 46321333 C G 7.89E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs4953309 chr2 46322766 C G 3.81E-05 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs4953309 chr2 46322766 C G 6.07E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12477342 chr2 46327870 C T 1.35E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12477342 chr2 46327870 C T 7.30E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12477409 chr2 46327960 G C 1.24E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12477409 chr2 46327960 G C 7.23E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs7568264 chr2 46328552 A G 1.95E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs7568264 chr2 46328552 A G 6.66E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs1116246 chr2 46329867 G A 1.31E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs1116246 chr2 46329867 G A 6.87E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12712969 chr2 46332169 C T 1.42E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12712969 chr2 46332169 C T 6.78E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12712969 chr2 46332169 C T 7.00E-06 Pulmonary function decline PRKCE intron 22424883 rs12712970 chr2 46333694 G A 1.62E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12712970 chr2 46333694 G A 8.62E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs11680282 chr2 46334021 C G 8.86E-04 Body mass index PRKCE intron 21701565 rs11684352 chr2 46334632 A G 7.09E-04 Body mass index PRKCE intron 21701565 rs1597156 chr2 46338714 C T 1.84E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs1597156 chr2 46338714 C T 8.31E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs1375055 chr2 46340378 G A 1.81E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs1375055 chr2 46340378 G A 8.13E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs1375054 chr2 46340462 G T 8.80E-04 Body mass index PRKCE intron 21701565 rs3768752 chr2 46343003 C A 1.67E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs3768752 chr2 46343003 C A 7.88E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12619351 chr2 46343735 G T 3.01E-04 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12619351 chr2 46343735 G T 9.83E-05 Suicide attempts in bipolar disorder PRKCE intron 21041247 rs12616328 chr2 46345345 G A 5.84E-04 Multiple complex diseases PRKCE intron 17554300 rs3768751 chr2 46346716 T C 2.96E-04 Suicide attempts in bipolar disorder PRKCE intron 21423239 rs3768751 chr2 46346716 T C 1.58E-10 Red blood cell traits PRKCE intron 23222517 rs3768750 chr2 46347023 G A 3.70E-04 Suicide attempts in bipolar disorder PRKCE intron 21423239 rs3768750 chr2 46347023 G A 3.01E-10 Red blood cell traits PRKCE intron 23222517 rs17034581 chr2 46347196 A T 3.02E-08 Red blood cell traits PRKCE intron 23222517 rs4952800 chr2 46347606 G A 4.07E-04 Suicide attempts in bipolar disorder PRKCE intron 21423239 rs4952800 chr2 46347606 G A 4.89E-10 Red blood cell traits PRKCE intron 23222517 rs2218660 chr2 46347792 T G 2.58E-04 Suicide attempts in bipolar disorder PRKCE intron 21423239 rs2218660 chr2 46347792 T G 4.84E-10 Red blood cell traits PRKCE intron 23222517 rs17737466 chr2 46348878 C T 9.76E-04 Tourette syndrome PRKCE intron 22889924 rs3768747 chr2 46352058 A C 3.31E-09 Red blood cell traits PRKCE intron 23222517 rs3754569 chr2 46352453 G T 5.86E-11 Red blood cell traits PRKCE intron 23222517 rs10495927 chr2 46352499 A G 1.43E-07 Red blood cell traits PRKCE intron 23222517 rs10495928 chr2 46353166 A G 7.00E-13 Hemoglobin PRKCE intron 19862010 rs10495928 chr2 46353166 A G 3.81E-08 Blood cell counts and other traits PRKCE intron 20139978 rs10495928 chr2 46353166 A G 4.61E-06 Blood cell counts and other traits PRKCE intron 20139978 rs10495928 chr2 46353166 A G 5.00E-06 Blood cell counts and other traits PRKCE intron 20139978 rs10495928 chr2 46353166 A G 1.02E-13 Red blood cell traits PRKCE intron 23222517 rs10495928 chr2 46353166 A G 2.76E-04 Red blood cell traits PRKCE intron 23935956 rs10495928 chr2 46353166 A G 4.45E-04 Red blood cell traits PRKCE intron 23935956 rs4952801 chr2 46354245 T A,C 1.56E-08 Red blood cell traits PRKCE intron 23222517 rs4953318 chr2 46355051 A C 1.18E-12 Other erythrocyte phenotypes PRKCE intron 19862010 rs4953318 chr2 46355051 A C 3.00E-19 Red blood cell traits PRKCE intron 23222517 rs13008603 chr2 46355848 C A 1.39E-08 Other erythrocyte phenotypes PRKCE intron 19862010 rs13008603 chr2 46355848 C A 2.31E-08 Red blood cell traits PRKCE intron 23222517 rs13008603 chr2 46355848 C A 4.00E-09 Red blood cell traits PRKCE intron 23446634 rs17737768 chr2 46357133 T C 5.46E-09 Red blood cell traits PRKCE intron 23222517 rs10184620 chr2 46358535 A G 7.23E-09 Other erythrocyte phenotypes PRKCE intron 19862010 rs10184620 chr2 46358535 A G 9.92E-08 Red blood cell traits PRKCE intron 23222517 rs17034610 chr2 46359079 A G 6.90E-04 Body mass index PRKCE intron 21701565 rs10168349 chr2 46360907 G C 4.00E-15 Hematocrit PRKCE intron 19862010 rs10168349 chr2 46360907 G C 5.00E-07 Blood cell counts and other traits PRKCE intron 20139978 rs10168349 chr2 46360907 G C 5.07E-07 Blood cell counts and other traits PRKCE intron 20139978 rs10168349 chr2 46360907 G C 2.75E-14 Red blood cell traits PRKCE intron 23222517 rs12105417 chr2 46361255 A C 1.45E-10 Red blood cell traits PRKCE intron 23222517 rs10183887 chr2 46361808 T A 6.13E-09 Red blood cell traits PRKCE intron 23222517 rs10198247 chr2 46362677 A G 1.07E-10 Red blood cell traits PRKCE intron 23222517 rs13406773 chr2 46362868 T C 4.58E-09 Red blood cell traits PRKCE intron 23222517 rs13406901 chr2 46363066 T G 6.47E-09 Red blood cell traits PRKCE intron 23222517 rs11690961 chr2 46363336 A C 4.39E-09 Red blood cell traits PRKCE intron 23222517 rs6724315 chr2 46363699 T C 1.86E-08 Red blood cell traits PRKCE intron 23222517 rs13410378 chr2 46363807 T C 1.36E-07 Red blood cell traits PRKCE intron 23222517 rs12992366 chr2 46365920 G A 7.34E-09 Other erythrocyte phenotypes PRKCE intron 19862010 rs12992366 chr2 46365920 G A 5.76E-09 Red blood cell traits PRKCE intron 23222517 rs2053797 chr2 46370892 G A 6.81E-05 Multiple complex diseases PRKCE intron 17554300 rs2053797 chr2 46370892 G A 7.04E-09 Red blood cell traits PRKCE intron 23222517 rs3754568 chr2 46371214 T C 4.65E-07 Red blood cell traits PRKCE intron 23222517 rs10495929 chr2 46372174 G A 1.70E-08 Red blood cell traits PRKCE intron 23222517 rs12990867 chr2 46372411 G A 6.19E-10 Red blood cell traits PRKCE intron 23222517 rs17034641 chr2 46372644 G A 7.58E-05 Multiple complex diseases PRKCE intron 17554300 rs17034641 chr2 46372644 G A 4.61E-09 Red blood cell traits PRKCE intron 23222517 rs10495930 chr2 46372675 A G 1.72E-08 Red blood cell traits PRKCE intron 23222517 rs6544874 chr2 46374385 G A 5.99E-08 Red blood cell traits PRKCE intron 23222517 rs4953321 chr2 46383399 G T 3.51E-04 Multiple complex diseases PRKCE intron 17554300 rs10205024 chr2 46385339 A G 0.00000168 Central corneal thickness PRKCE intron 22661486 rs10205024 chr2 46385339 A G 1.68E-06 Testosterone levels PRKCE intron 22675492 rs3820729 chr2 46392775 C T 8.33E-07 Red blood cell traits PRKCE intron 23222517 rs281472 chr2 46403837 A G 4.80E-05 Cognitive test performance PRKCE intron 20125193 rs14138 chr2 46414446 G A 3.52E-05 Post-operative nausea and vomiting PRKCE UTR-3 21694509 rs281500 chr2 46417808 C G 1.70E-04 Height / / 17255346 rs281498 chr2 46419958 T C 1.20E-06 Urinary metabolites / / 21572414 rs714104 chr2 46464796 A G 9.18E-04 Multiple complex diseases / / 17554300 rs17745066 chr2 46488081 G A 5.93E-04 Tourette syndrome / / 22889924 rs1867787 chr2 46525391 G C 1.90E-07 Renal cell carcinoma EPAS1 intron 21131975 rs10211665 chr2 46526096 T C 1.90E-07 Renal cell carcinoma EPAS1 intron 21131975 rs11125068 chr2 46527816 A G 2.30E-08 Renal cell carcinoma EPAS1 intron 21131975 rs2346417 chr2 46528961 T A 8.20E-08 Renal cell carcinoma EPAS1 intron 21131975 rs1867783 chr2 46529302 G C 1.30E-06 Renal cell carcinoma EPAS1 intron 21131975 rs11894252 chr2 46533376 T C 9.10E-09 Renal cell carcinoma EPAS1 intron 21131975 rs11894252 chr2 46533376 T C 1.80E-08 Renal cell carcinoma EPAS1 intron 22010048 rs11684885 chr2 46533552 T G 9.00E-09 Renal cell carcinoma EPAS1 intron 21131975 rs1867784 chr2 46534220 T C 6.20E-09 Renal cell carcinoma EPAS1 intron 21131975 rs1867785 chr2 46534338 A G 8.80E-09 Renal cell carcinoma EPAS1 intron 21131975 rs2121266 chr2 46535924 C A 1.40E-08 Renal cell carcinoma EPAS1 intron 21131975 rs4952818 chr2 46537056 C T 2.80E-08 Renal cell carcinoma EPAS1 intron 21131975 rs7579899 chr2 46537604 A G 2.00E-09 Renal cell carcinoma EPAS1 intron 21131975 rs17034950 chr2 46538794 G A 8.20E-08 Renal cell carcinoma EPAS1 intron 21131975 rs11689011 chr2 46541176 T C 2.60E-08 Renal cell carcinoma EPAS1 intron 21131975 rs10495932 chr2 46545818 G T 8.33E-04 Multiple complex diseases EPAS1 intron 17554300 rs2044456 chr2 46546316 A G 4.40E-07 Renal cell carcinoma EPAS1 intron 21131975 rs4953340 chr2 46548064 C G 5.20E-08 Renal cell carcinoma EPAS1 intron 21131975 rs9973653 chr2 46548109 G T 1.60E-07 Renal cell carcinoma EPAS1 intron 21131975 rs2034327 chr2 46549040 G C 7.20E-07 Renal cell carcinoma EPAS1 intron 21131975 rs2121267 chr2 46549389 T C 6.60E-05 Kidney function and endocine traits EPAS1 intron 17903292 rs2121267 chr2 46549389 T C 3.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) EPAS1 intron 17982456 rs2121267 chr2 46549389 T C 2.20E-06 Renal cell carcinoma EPAS1 intron 21131975 rs895436 chr2 46550492 G C 6.70E-06 Renal cell carcinoma EPAS1 intron 21131975 rs4952819 chr2 46550718 G C 1.83E-04 Multiple complex diseases EPAS1 intron 17554300 rs4952819 chr2 46550718 G C 6.80E-06 Renal cell carcinoma EPAS1 intron 21131975 rs7582701 chr2 46550769 G C 1.00E-06 IgG glycosylation EPAS1 intron 23382691 rs7582701 chr2 46550769 G C 2.00E-06 IgG glycosylation EPAS1 intron 23382691 rs7582701 chr2 46550769 G C 4.00E-06 IgG glycosylation EPAS1 intron 23382691 rs7582701 chr2 46550769 G C 4.00E-06 IgG glycosylation EPAS1 intron 23382691 rs4953342 chr2 46552047 A G 3.62E-05 Brain structure EPAS1 intron 22504417 rs4953343 chr2 46552177 G C 3.20E-06 Renal cell carcinoma EPAS1 intron 21131975 rs4953345 chr2 46552601 T A 9.10E-06 Renal cell carcinoma EPAS1 intron 21131975 rs4952820 chr2 46553966 A G 4.00E-06 Renal cell carcinoma EPAS1 intron 21131975 rs11125071 chr2 46554533 C G 4.00E-06 Renal cell carcinoma EPAS1 intron 21131975 rs1868089 chr2 46554646 C T 4.20E-06 Renal cell carcinoma EPAS1 intron 21131975 rs12613519 chr2 46555221 A G 8.70E-06 Renal cell carcinoma EPAS1 intron 21131975 rs12613526 chr2 46555263 A G 8.60E-06 Renal cell carcinoma EPAS1 intron 21131975 rs10208823 chr2 46555670 T C 3.50E-06 Renal cell carcinoma EPAS1 intron 21131975 rs12712973 chr2 46556633 A C 8.50E-06 Renal cell carcinoma EPAS1 intron 21131975 rs12620992 chr2 46556761 G C 5.10E-06 Renal cell carcinoma EPAS1 intron 21131975 rs6706717 chr2 46556824 A G 5.20E-06 Renal cell carcinoma EPAS1 intron 21131975 rs11900910 chr2 46557600 C T 9.00E-06 Renal cell carcinoma EPAS1 intron 21131975 rs9679290 chr2 46557644 G C 3.38E-04 Multiple complex diseases EPAS1 intron 17554300 rs9679290 chr2 46557644 G C 7.30E-06 Renal cell carcinoma EPAS1 intron 21131975 rs35366004 chr2 46557962 G T 7.70E-06 Renal cell carcinoma EPAS1 intron 21131975 rs4953346 chr2 46558208 T G 1.40E-05 Renal cell carcinoma EPAS1 intron 21131975 rs4953347 chr2 46558225 A G 1.30E-05 Renal cell carcinoma EPAS1 intron 21131975 rs4953348 chr2 46558432 A G 1.40E-05 Renal cell carcinoma EPAS1 intron 21131975 rs6758592 chr2 46558541 T C 2.20E-05 Renal cell carcinoma EPAS1 intron 21131975 rs12617313 chr2 46559776 A T 1.90E-05 Renal cell carcinoma EPAS1 intron 21131975 rs11125072 chr2 46560084 T A 1.70E-05 Renal cell carcinoma EPAS1 intron 21131975 rs4953349 chr2 46560644 T A,G 2.30E-05 Renal cell carcinoma EPAS1 intron 21131975 rs6726454 chr2 46561202 A G 1.70E-05 Renal cell carcinoma EPAS1 intron 21131975 rs6726570 chr2 46561309 A G 1.70E-05 Renal cell carcinoma EPAS1 intron 21131975 rs4145837 chr2 46561816 G A 1.80E-05 Renal cell carcinoma EPAS1 intron 21131975 rs6706003 chr2 46563392 C G 3.40E-05 Renal cell carcinoma EPAS1 intron 21131975 rs4953351 chr2 46564583 C A 7.20E-05 Renal cell carcinoma EPAS1 intron 21131975 rs12614710 chr2 46565091 T G 2.70E-05 Renal cell carcinoma EPAS1 intron 21131975 rs4953352 chr2 46565522 T C 5.30E-05 Renal cell carcinoma EPAS1 intron 21131975 rs4035887 chr2 46567227 A G 9.30E-04 Renal cell carcinoma EPAS1 intron 21131975 rs4953353 chr2 46567276 G T 3.41E-04 Hemoglobin concentration EPAS1 intron 20534544 rs2346175 chr2 46571310 T C 2.00E-04 Renal cell carcinoma EPAS1 intron 21131975 rs10191091 chr2 46573210 C T 8.15E-06 Hearing function EPAS1 intron 21493956 rs6715787 chr2 46576172 C G 3.50E-04 Renal cell carcinoma EPAS1 intron 21131975 rs17035010 chr2 46576488 C T 7.50E-05 Renal cell carcinoma EPAS1 intron 21131975 rs17035013 chr2 46576573 T C 1.80E-04 Renal cell carcinoma EPAS1 intron 21131975 rs6544887 chr2 46577212 T C 2.18E-06 Hearing function EPAS1 intron 21493956 rs6544888 chr2 46577265 A C 2.19E-06 Hearing function EPAS1 intron 21493956 rs6544889 chr2 46577299 G A 2.18E-06 Hearing function EPAS1 intron 21493956 rs4953356 chr2 46578924 G T 3.79E-06 Hearing function EPAS1 intron 21493956 rs6743087 chr2 46579348 T C 3.50E-04 Renal cell carcinoma EPAS1 intron 21131975 rs6756667 chr2 46579409 A G 6.14E-06 Hemoglobin concentration EPAS1 intron 20534544 rs6756667 chr2 46579409 A G 9.30E-04 Renal cell carcinoma EPAS1 intron 21131975 rs6756667 chr2 46579409 A G 3.73E-06 Hearing function EPAS1 intron 21493956 rs6756667 chr2 46579409 A G 2.00E-04 Cognitive impairment induced by topiramate EPAS1 intron 22091778 rs6756667 chr2 46579409 A G 9.87E-05 Body Mass Index EPAS1 intron pha003006 rs6756667 chr2 46579409 A G 6.85E-05 Weight EPAS1 intron pha003026 rs1562451 chr2 46579730 C T 3.50E-04 Renal cell carcinoma EPAS1 intron 21131975 rs1562452 chr2 46580444 G A 2.61E-06 Hearing function EPAS1 intron 21493956 rs1562452 chr2 46580444 G A 8.60E-05 Cognitive impairment induced by topiramate EPAS1 intron 22091778 rs1562452 chr2 46580444 G A 9.76E-05 Cognitive impairment induced by topiramate EPAS1 intron 22091778 rs1562453 chr2 46580474 T C 6.30E-04 Renal cell carcinoma EPAS1 intron 21131975 rs1562453 chr2 46580474 T C 3.76E-06 Hearing function EPAS1 intron 21493956 rs6735812 chr2 46581074 C G 4.47E-06 Hearing function EPAS1 intron 21493956 rs4953358 chr2 46581453 C G 7.50E-04 Renal cell carcinoma EPAS1 intron 21131975 rs4953358 chr2 46581453 C G 4.56E-06 Hearing function EPAS1 intron 21493956 rs7599883 chr2 46581544 T A 3.50E-04 Renal cell carcinoma EPAS1 intron 21131975 rs4953359 chr2 46581643 C T 4.63E-06 Hearing function EPAS1 intron 21493956 rs7589621 chr2 46582382 G A 7.15E-05 Hemoglobin concentration EPAS1 intron 20534544 rs7589621 chr2 46582382 G A 3.40E-04 Renal cell carcinoma EPAS1 intron 21131975 rs6712143 chr2 46582891 A G 3.40E-04 Renal cell carcinoma EPAS1 intron 21131975 rs6743991 chr2 46583235 C A 4.27E-06 Hearing function EPAS1 intron 21493956 rs2278753 chr2 46583593 G A 6.60E-04 Renal cell carcinoma EPAS1 intron 21131975 rs10176396 chr2 46584573 C T 3.20E-04 Renal cell carcinoma EPAS1 intron 21131975 rs6707241 chr2 46584852 C T 8.40E-04 Renal cell carcinoma EPAS1 intron 21131975 rs6707241 chr2 46584852 C T 7.32E-06 Hearing function EPAS1 intron 21493956 rs6740096 chr2 46585888 A T 8.40E-04 Renal cell carcinoma EPAS1 intron 21131975 rs6740096 chr2 46585888 A T 7.34E-06 Hearing function EPAS1 intron 21493956 rs7583554 chr2 46587097 T C 1.93E-05 Hemoglobin concentration EPAS1 intron 20534544 rs7583554 chr2 46587097 T C 6.80E-04 Renal cell carcinoma EPAS1 intron 21131975 rs4953360 chr2 46589179 A G 6.70E-04 Renal cell carcinoma EPAS1 intron 21131975 rs6755594 chr2 46589295 A G 9.00E-04 Renal cell carcinoma EPAS1 intron 21131975 rs13412887 chr2 46589487 C G 0.00031 Coronary artery calcification EPAS1 intron 23727086 rs3768729 chr2 46592006 T C 9.62E-05 Hemoglobin concentration EPAS1 intron 20534544 rs3768729 chr2 46592006 T C 6.70E-04 Renal cell carcinoma EPAS1 intron 21131975 rs3768730 chr2 46592524 G T 3.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EPAS1 intron 20877124 rs3768730 chr2 46592524 G T 3.54E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EPAS1 intron 20877124 rs1374749 chr2 46596433 G A 1.38E-04 Hemoglobin concentration EPAS1 intron 20534544 rs1374749 chr2 46596433 G A 6.84E-05 Waist Circumference EPAS1 intron pha003024 rs1374749 chr2 46596433 G A 5.61E-05 Waist Circumference EPAS1 intron pha003025 rs1374749 chr2 46596433 G A 5.61E-05 Weight EPAS1 intron pha003026 rs6753127 chr2 46597296 T C 3.51E-05 Body Mass Index EPAS1 intron pha003014 rs1992846 chr2 46597581 C T 4.11E-04 Hemoglobin concentration EPAS1 intron 20534544 rs7583088 chr2 46603165 A G 7.30E-06 Hemoglobin concentration EPAS1 intron 20534544 rs7583088 chr2 46603165 A G 2.99E-04 Myopia (pathological) EPAS1 intron 21095009 rs7583088 chr2 46603165 A G 5.35E-05 Body Mass Index EPAS1 intron pha003006 rs7583088 chr2 46603165 A G 2.59E-05 Waist Circumference EPAS1 intron pha003024 rs7583088 chr2 46603165 A G 8.73E-05 Waist Circumference EPAS1 intron pha003025 rs7583088 chr2 46603165 A G 2.73E-05 Weight EPAS1 intron pha003026 rs17035085 chr2 46605287 A G 5.96E-06 Hair morphology EPAS1 intron 19896111 rs13019268 chr2 46610212 A C 9.76E-05 Hemoglobin concentration EPAS1 intron 20534544 rs7577700 chr2 46610605 T G 3.93E-06 Hair morphology EPAS1 intron 19896111 rs1868092 chr2 46614202 G A 2.95E-07 Hemoglobin concentration LOC100652809 intron 20534544 rs1868092 chr2 46614202 G A 7.58E-05 Body Mass Index LOC100652809 intron pha003006 rs1868092 chr2 46614202 G A 5.72E-05 Waist Circumference LOC100652809 intron pha003024 rs1868092 chr2 46614202 G A 8.15E-05 Waist Circumference LOC100652809 intron pha003025 rs1868092 chr2 46614202 G A 5.35E-05 Weight LOC100652809 intron pha003026 rs11689694 chr2 46617182 T C 6.83E-05 Hemoglobin concentration LOC100652809 intron 20534544 rs17035106 chr2 46633478 G A,C,T 6.38E-06 Hair morphology / / 19896111 rs12623288 chr2 46634645 G A 3.00E-06 Hair morphology / / 19896111 rs13011481 chr2 46635648 T C 9.78E-06 Hemoglobin concentration / / 20534544 rs13011481 chr2 46635648 T C 2.54E-04 Myopia (pathological) / / 21095009 rs12615428 chr2 46636277 T G 2.04E-05 Hemoglobin concentration / / 20534544 rs1447563 chr2 46637364 A C 5.15E-08 Hemoglobin concentration / / 20534544 rs2346177 chr2 46642249 G A 2.00E-06 Coronary heart disease / / 21347282 rs1530623 chr2 46651680 C T 1.90E-04 Multiple complex diseases / / 17554300 rs11125075 chr2 46656344 A G,T 6.10E-08 Hemoglobin concentration / / 20534544 rs7587138 chr2 46657089 G A 2.50E-05 Urinary metabolites / / 21572414 rs7571742 chr2 46660306 A G 4.89E-05 Brain structure / / 22504417 rs7559484 chr2 46660445 T C 4.48E-05 Brain structure / / 22504417 rs12986899 chr2 46660752 A C 1.56E-05 Brain structure / / 22504417 rs7556828 chr2 46663172 G A 3.89E-05 Brain structure / / 22504417 rs1530628 chr2 46670941 T C 4.98E-05 Brain structure / / 22504417 rs7565770 chr2 46683683 A C 2.61E-05 Abdominal aortic aneurysm / / 22055160 rs7565770 chr2 46683683 A C 2.89E-05 Brain structure / / 22504417 rs1530621 chr2 46688688 T C 2.88E-05 Brain structure / / 22504417 rs2121698 chr2 46709571 C T 3.33E-05 Brain structure LOC388946 intron 22504417 rs4953388 chr2 46713201 G A 1.59E-09 Hemoglobin concentration / / 20534544 rs7590802 chr2 46723219 C A 8.56E-06 Hemoglobin concentration / / 20534544 rs6544898 chr2 46732771 A G 6.65E-05 Serum metabolites / / 19043545 rs4953396 chr2 46736794 C A 1.03E-04 Parkinson's disease / / 17052657 rs4953396 chr2 46736794 C A 7.88E-09 Hemoglobin concentration / / 20534544 rs12470532 chr2 46738846 T C 8.07E-04 Multiple complex diseases / / 17554300 rs12470532 chr2 46738846 T C 2.54E-05 Serum metabolites / / 19043545 rs3814045 chr2 46739157 A G 2.62E-05 Serum metabolites ATP6V1E2 UTR-3 19043545 rs896210 chr2 46746745 G A 5.47E-04 Amyotrophic Lateral Sclerosis ATP6V1E2 UTR-5 17362836 rs896210 chr2 46746745 G A 8.95E-08 Hemoglobin concentration ATP6V1E2 UTR-5 20534544 rs4952830 chr2 46746963 A G 0.00000674 Preeclampsia ATP6V1E2 UTR-5 22432041 rs2012022 chr2 46748395 T C 5.76E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs41395646 chr2 46756431 A G 7.31E-04 Multiple complex diseases / / 17554300 rs1001745 chr2 46775059 T C 6.23E-07 Lymphocyte counts RHOQ intron 22286170 rs17818399 chr2 46826026 A C 3.00E-07 Height PIGF intron 20966902 rs1451156 chr2 46832602 C T 8.89E-06 Hemoglobin concentration PIGF intron 20534544 rs6713104 chr2 46838005 T C 2.00E-04 Information processing speed PIGF intron 21130836 rs13000706 chr2 46838247 C G 2.05E-11 Lymphocyte counts PIGF intron 22286170 rs3213985 chr2 46840735 T C 2.00E-04 Information processing speed PIGF intron 21130836 rs1531133 chr2 46843631 A G 1.11E-05 Hemoglobin concentration PIGF intron 20534544 rs982414 chr2 46845576 A G 9.14E-09 Hemoglobin concentration CRIPT intron 20534544 rs6735530 chr2 46848446 T C 2.04E-07 Hemoglobin concentration CRIPT intron 20534544 rs12105006 chr2 46862586 T C 2.29E-06 Hemoglobin concentration / / 20534544 rs10495934 chr2 46874746 G A 5.48E-05 Hemoglobin concentration / / 20534544 rs6712910 chr2 46876958 G A 8.68E-05 Hemoglobin concentration / / 20534544 rs7575099 chr2 46879599 G C 2.38E-04 Multiple complex diseases / / 17554300 rs10204096 chr2 46883739 C T 5.75E-04 Body mass index / / 21701565 rs4953404 chr2 46886142 G A 1.00E-06 Pulse pressure (alcohol consumption interaction) / / 24376456 rs4953404 chr2 46886142 G A 8.00E-07 Pulse pressure (alcohol consumption interaction) / / 24376456 rs6742593 chr2 46890538 T C 6.58E-05 Cervical cancer / / 24700089 rs17035495 chr2 46898352 T C 5.48E-04 Multiple complex diseases / / 17554300 rs10178013 chr2 46902040 T C 2.80E-05 Urinary metabolites / / 21572414 rs10495936 chr2 46908199 C T 5.70E-05 Magnesium levels / / pha003092 rs3814041 chr2 46908571 C A 3.40E-05 Magnesium levels / / pha003092 rs7596521 chr2 46918665 A G 8.65E-05 Hemoglobin concentration / / 20534544 rs12474201 chr2 46921285 G A 3.00E-13 Height / / 20881960 rs11676737 chr2 46929873 T C 3.06E-04 Hemoglobin concentration SOCS5 intron 20534544 rs13025984 chr2 46938789 T C 3.06E-04 Hemoglobin concentration SOCS5 intron 20534544 rs4952843 chr2 46957845 A G 3.06E-04 Hemoglobin concentration SOCS5 intron 20534544 rs11695058 chr2 46978349 A G 9.96E-07 Lymphocyte counts SOCS5 intron 22286170 rs17823065 chr2 46988073 T C 6.49E-04 Multiple complex diseases SOCS5 UTR-3 17554300 rs10495938 chr2 46991159 G C 8.25E-05 Iron status biomarkers / / 19084217 rs11125091 chr2 47009746 T C 1.29E-04 Hemoglobin concentration / / 20534544 rs9309137 chr2 47011834 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs76351433 chr2 47022543 A C 2.00E-07 Chronic obstructive pulmonary disease / / 21685187 rs17035674 chr2 47030868 T C 5.76E-04 Multiple complex diseases / / 17554300 rs10514803 chr2 47089473 T C 7.01E-04 Type 2 diabetes / / 17463246 rs10514803 chr2 47089473 T C 1.28E-05 Lipid traits / / 24023261 rs12990097 chr2 47095205 G C 1.20E-04 Major depressive disorder / / 22472876 rs4953434 chr2 47095489 G A 5.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6715234 chr2 47114100 T A,C,G 1.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs11690921 chr2 47153762 C T 7.01E-04 Colorectal cancer MCFD2 intron 24737748 rs4300885 chr2 47159082 C T 2.95E-04 Multiple complex diseases MCFD2 intron 17554300 rs17035912 chr2 47171322 A G 3.72E-04 Smoking initiation TTC7A intron 24665060 rs7593939 chr2 47178571 A G 4.93E-04 Taste perception TTC7A intron 22132133 rs17035931 chr2 47182032 A C 2.21E-05 Major depressive disorder TTC7A intron 20516156 rs6726941 chr2 47184447 C T 7.70E-04 Major depressive disorder TTC7A intron 21042317 rs13387604 chr2 47184989 A G 9.01E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy TTC7A intron 24578207 rs13387604 chr2 47184989 A G 9.01E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy TTC7A intron 24578207 rs17540003 chr2 47221105 C T 0.00032 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TTC7A intron 23233654 rs17540003 chr2 47221105 C T 3.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) TTC7A intron 23233662 rs17481321 chr2 47224927 C A 0.0003492 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TTC7A intron 23233654 rs17481321 chr2 47224927 C A 3.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) TTC7A intron 23233662 rs17481349 chr2 47225186 T C 0.0003592 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TTC7A intron 23233654 rs17481349 chr2 47225186 T C 3.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) TTC7A intron 23233662 rs17540504 chr2 47226183 G A 6.26E-04 Alzheimer's disease TTC7A intron 22005930 rs17540504 chr2 47226183 G A 0.0003822 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TTC7A intron 23233654 rs17540504 chr2 47226183 G A 3.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) TTC7A intron 23233662 rs17036033 chr2 47227768 G A 3.90E-04 Major depressive disorder TTC7A intron 21042317 rs2007462 chr2 47229025 T C 1.79E-04 Alzheimer's disease TTC7A intron 22005930 rs2007462 chr2 47229025 T C 0.0006673 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TTC7A intron 23233654 rs2007462 chr2 47229025 T C 6.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) TTC7A intron 23233662 rs17540615 chr2 47229380 C T 1.96E-04 Alzheimer's disease TTC7A intron 22005930 rs17540615 chr2 47229380 C T 0.0005478 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TTC7A intron 23233654 rs17540615 chr2 47229380 C T 5.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) TTC7A intron 23233662 rs17540621 chr2 47229839 G C 2.00E-06 Response to statin therapy TTC7A intron 20339536 rs13407983 chr2 47233048 G A 1.37E-04 Smoking initiation TTC7A intron 24665060 rs10193261 chr2 47239142 G T 1.70E-05 Response to statin therapy TTC7A intron 20339536 rs13426848 chr2 47239473 T C 2.78E-04 Alzheimer's disease TTC7A intron 22005930 rs10194115 chr2 47240012 G T 5.20E-06 Response to statin therapy TTC7A intron 20339536 rs10194115 chr2 47240012 G T 5.00E-07 Erectile dysfunction and prostate cancer treatment TTC7A intron 20932654 rs7581528 chr2 47240149 G A 4.82E-04 Alzheimer's disease TTC7A intron 22005930 rs7581528 chr2 47240149 G A 0.0008638 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TTC7A intron 23233654 rs7581528 chr2 47240149 G A 8.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) TTC7A intron 23233662 rs10196993 chr2 47240485 G C 5.50E-06 Response to statin therapy TTC7A intron 20339536 rs17036119 chr2 47249966 C T 5.74E-04 Multiple complex diseases TTC7A intron 17554300 rs4952863 chr2 47257977 T C 5.94E-04 Response to taxane treatment (placlitaxel) TTC7A intron 23006423 rs7578472 chr2 47260839 T C 2.70E-05 Urinary metabolites TTC7A intron 21572414 rs11695952 chr2 47262695 A G 6.69E-04 Response to taxane treatment (placlitaxel) TTC7A intron 23006423 rs12712986 chr2 47273668 G A 9.33E-05 Bipolar disorder TTC7A intron 20451256 rs17036168 chr2 47279605 C T 1.00E-04 Cognitive impairment induced by topiramate TTC7A intron 22091778 rs17036168 chr2 47279605 C T 2.00E-04 Cognitive impairment induced by topiramate TTC7A intron 22091778 rs17541472 chr2 47280156 G A 3.24E-04 Response to taxane treatment (placlitaxel) TTC7A intron 23006423 rs2436772 chr2 47283557 G A 4.26E-05 Response to taxane treatment (placlitaxel) TTC7A intron 23006423 rs10460536 chr2 47283793 T C 2.00E-04 Cognitive impairment induced by topiramate TTC7A intron 22091778 rs10460536 chr2 47283793 T C 8.13E-05 Cognitive impairment induced by topiramate TTC7A intron 22091778 rs13393256 chr2 47286759 A C 3.33E-04 Multiple complex diseases TTC7A intron 17554300 rs13393256 chr2 47286759 A C 4.89E-04 Response to taxane treatment (placlitaxel) TTC7A intron 23006423 rs6734192 chr2 47286857 C T 6.56E-04 Suicide attempts in bipolar disorder TTC7A intron 21423239 rs4953456 chr2 47290570 T C 1.33E-05 Cognitive impairment induced by topiramate TTC7A intron 22091778 rs4953456 chr2 47290570 T C 4.53E-05 Cognitive impairment induced by topiramate TTC7A intron 22091778 rs4953456 chr2 47290570 T C 4.56E-05 Cognitive impairment induced by topiramate TTC7A intron 22091778 rs4953456 chr2 47290570 T C 2.91E-06 Systemic lupus erythematosus and Systemic sclerosis TTC7A intron 23740937 rs6704853 chr2 47293507 G A 9.17E-05 Cognitive impairment induced by topiramate TTC7A intron 22091778 rs6704853 chr2 47293507 G A 9.55E-05 Cognitive impairment induced by topiramate TTC7A intron 22091778 rs1549981 chr2 47294762 G A 7.90E-04 Lymphocyte counts TTC7A intron 22286170 rs7569495 chr2 47298430 T C 1.47E-05 Eosinophil counts TTC7A intron pha003088 rs4953463 chr2 47322330 G A 5.29E-05 Cognitive impairment induced by topiramate C2orf61 intron 22091778 rs2347604 chr2 47323152 A C 2.02E-05 Cognitive impairment induced by topiramate C2orf61 intron 22091778 rs371711248 chr2 47323152 AA AAA,ACC 2.02E-05 Cognitive impairment induced by topiramate C2orf61 intron 22091778 rs17036272 chr2 47346185 C A 1.70E-05 Urinary metabolites C2orf61 intron 21572414 rs1880583 chr2 47348347 C T 4.09E-05 Body Mass Index C2orf61 intron pha002896 rs7596776 chr2 47355143 G A 1.90E-05 Urinary metabolites C2orf61 intron 21572414 rs2030772 chr2 47359666 A T 9.10E-06 Urinary metabolites C2orf61 intron 21572414 rs726117 chr2 47372425 G A 7.41E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) C2orf61 intron 23648065 rs815811 chr2 47377472 C T 7.00E-06 Urinary metabolites C2orf61 intron 21572414 rs815807 chr2 47381245 G A 1.50E-05 Urinary metabolites C2orf61 intron 21572414 rs17036307 chr2 47381408 T G 8.96E-05 Multiple complex diseases C2orf61 intron 17554300 rs11884600 chr2 47384601 A G 7.86E-04 Type 2 diabetes / / 22238593 rs815815 chr2 47399064 C T 7.00E-07 Dialysis-related mortality CALM2 intron 21546767 rs815815 chr2 47399064 C T 2.30E-05 Urinary metabolites CALM2 intron 21572414 rs815815 chr2 47399064 C T 0.000435 Alpha-2-adrenoceptor-mediated vasoconstriction CALM2 intron 23337848 rs1723482 chr2 47406539 C T 5.12E-04 Type 2 diabetes / / 17846125 rs1723482 chr2 47406539 C T 5.50E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs4953476 chr2 47433465 T A 1.40E-04 Obesity (extreme) / / 21935397 rs7598661 chr2 47468955 A G 2.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10191479 chr2 47469711 C T 5.80E-04 Type 2 diabetes / / 17463246 rs12620038 chr2 47476135 C G 4.00E-04 Pancreatic cancer / / 23180869 rs904160 chr2 47477584 T C 7.60E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs72806423 chr2 47479014 A T 9.74E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs10186190 chr2 47480107 A G 0.00004874 Sarcoidosis / / 22952805 rs10209762 chr2 47480133 C T 0.00006715 Sarcoidosis / / 22952805 rs10210258 chr2 47480419 G C 0.00008367 Sarcoidosis / / 22952805 rs10190105 chr2 47481641 A G 9.00E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs12612772 chr2 47482167 G A 9.30E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs10165172 chr2 47512078 T C 5.81E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4952887 chr2 47646968 C T 3.74E-05 Bone mineral density MSH2 intron 19181680 rs10514805 chr2 47679978 G A 7.30E-05 Stroke MSH2 intron pha002886 rs3771281 chr2 47692281 C T 1.97E-05 Paget's disease MSH2 intron 20436471 rs10188090 chr2 47709153 G A 5.24E-05 Paget's disease MSH2 intron 20436471 rs17036636 chr2 47721328 T C 7.72E-05 Bone mineral density / / 19181680 rs6708696 chr2 47773540 A G 2.69E-04 Multiple complex diseases KCNK12 intron 17554300 rs6708696 chr2 47773540 A G 6.10E-05 Bone mineral density KCNK12 intron 19181680 rs3814360 chr2 47800603 A T 2.35E-04 Smoking initiation LOC100652825 UTR-3 24665060 rs11682393 chr2 47804497 T A 5.76E-04 Multiple complex diseases / / 17554300 rs4245815 chr2 47819972 G A 7.07E-05 Lung cancer / / 18978787 rs4245815 chr2 47819972 G A 6.62E-04 Alcohol dependence / / 20201924 rs11694783 chr2 47826681 G A 2.49E-05 HIV-1 viral setpoint / / 22174851 rs17036703 chr2 47826830 G A 6.14E-05 HIV-1 viral setpoint / / 22174851 rs4953514 chr2 47829230 A G 4.60E-05 HIV-1 viral setpoint / / 22174851 rs12468025 chr2 47831793 C T 3.30E-08 Urinary metabolites / / 21572414 rs11676321 chr2 47834080 G A 1.90E-07 Urinary metabolites / / 21572414 rs6544997 chr2 47844505 A G 7.00E-06 Vitiligo / / 19890347 rs11892597 chr2 47856243 A C 5.18E-05 Serum metabolites / / 19043545 rs11887626 chr2 47856328 T G 1.40E-04 Pulmonary function / / 23932459 rs4952894 chr2 47857914 A G 0.0000567 Tuberculosis with late age of onset / / 22551897 rs4952894 chr2 47857914 A G 4.76E-04 Smoking quantity / / 24665060 rs4266057 chr2 47866656 C T 4.32E-04 Alzheimer's disease / / 22005930 rs1574378 chr2 47874352 T A 2.62E-04 Alzheimer's disease / / 22005930 rs1882450 chr2 47874603 G C 1.83E-04 Alzheimer's disease / / 22005930 rs1574380 chr2 47874713 C T 2.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2091750 chr2 47874961 T G 5.09E-05 Alzheimer's disease / / 22005930 rs13413097 chr2 47876798 G A 2.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1400633 chr2 47884002 G C,T 5.63E-06 Alzheimer's disease / / 22005930 rs2969775 chr2 47885476 G T 2.00E-06 Alzheimer's disease / / 22005930 rs2944778 chr2 47885601 T G 1.73E-04 Alzheimer's disease / / 22005930 rs2705766 chr2 47890331 T C 1.74E-04 Alzheimer's disease / / 22005930 rs2705766 chr2 47890331 T C 5.56E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs2969772 chr2 47894472 A G 2.86E-05 Alzheimer's disease / / 22005930 rs4588237 chr2 47942902 A G 7.66E-05 Chronic obstructive pulmonary disease / / 19300482 rs797700 chr2 47948101 C T 0.0000817 Asthma / / 22694930 rs2098242 chr2 47956819 C T 2.65E-04 Type 2 diabetes / / 17463246 rs3136279 chr2 48017768 C A 6.81E-05 Type 2 diabetes MSH6 intron 17846126 rs3136329 chr2 48024876 C T 3.33E-04 Obesity (extreme) MSH6 intron 21935397 rs3136337 chr2 48028465 C T 4.36E-04 Obesity (extreme) MSH6 intron 21935397 rs530262234 chr2 48032312 GTCTC G 5.00E-04 Gamma gluatamyl transferase levels (interaction with age) MSH6 intron 22010049 rs7562048 chr2 48032312 G A 5.00E-04 Gamma gluatamyl transferase levels (interaction with age) MSH6 intron 22010049 rs10490303 chr2 48039484 T G 2.25E-05 Lymphocyte counts FBXO11 intron pha003094 rs10490303 chr2 48039484 T G 7.11E-05 Neutrophil count FBXO11 intron pha003095 rs330787 chr2 48041377 A G 4.64E-05 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) FBXO11 intron 23103227 rs330787 chr2 48041377 A G 0.0000464 Otitis media (children 3 years old or younger) FBXO11 intron 23133572 rs4381823 chr2 48047335 A G 6.00E-06 Schizophrenia FBXO11 intron 23894747 rs12463595 chr2 48098708 C T 3.52E-05 Schizophrenia FBXO11 intron 24253340 rs13035558 chr2 48131936 T C 8.43E-05 Schizophrenia FBXO11 intron 24253340 rs7588761 chr2 48150587 C T 1.51E-05 Lymphocyte counts / / pha003094 rs7588761 chr2 48150587 C T 8.36E-05 Neutrophil count / / pha003095 rs4552231 chr2 48167631 A C 2.24E-04 Alzheimer's disease (late onset) / / 21379329 rs34198350 chr2 48169382 C T 8.00E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs6729916 chr2 48174199 T C 1.71E-05 Body mass index / / 19584900 rs6729916 chr2 48174199 T C 2.06E-05 Body mass index / / 19584900 rs6729916 chr2 48174199 T C 3.77E-04 Alzheimer's disease (late onset) / / 21379329 rs6729916 chr2 48174199 T C 6.12E-05 Intelligence / / 21826061 rs6729916 chr2 48174199 T C 2.45E-05 Lymphocyte counts / / pha003094 rs6729916 chr2 48174199 T C 3.85E-05 Neutrophil count / / pha003095 rs6717617 chr2 48192962 G C 1.47E-05 Body mass index / / 19584900 rs6717617 chr2 48192962 G C 9.80E-06 Body mass index / / 19584900 rs10199698 chr2 48193108 T C 3.23E-04 Alzheimer's disease (late onset) / / 21379329 rs10199698 chr2 48193108 T C 7.15E-05 Intelligence / / 21826061 rs10199698 chr2 48193108 T C 1.50E-05 Lymphocyte counts / / pha003094 rs10199698 chr2 48193108 T C 3.19E-05 Neutrophil count / / pha003095 rs10183748 chr2 48197968 C T 1.03E-05 Body mass index / / 19584900 rs10183748 chr2 48197968 C T 1.11E-05 Body mass index / / 19584900 rs10183748 chr2 48197968 C T 3.67E-04 Alzheimer's disease (late onset) / / 21379329 rs10183748 chr2 48197968 C T 7.35E-05 Intelligence / / 21826061 rs10183748 chr2 48197968 C T 1.50E-05 Lymphocyte counts / / pha003094 rs10183748 chr2 48197968 C T 3.12E-05 Neutrophil count / / pha003095 rs10207319 chr2 48198049 A T 1.03E-05 Body mass index / / 19584900 rs10207319 chr2 48198049 A T 1.11E-05 Body mass index / / 19584900 rs11693533 chr2 48209986 G A 2.80E-04 Obesity (extreme) / / 21935397 rs11695693 chr2 48223309 A G 2.59E-04 Obesity (extreme) / / 21935397 rs11692660 chr2 48244584 C A 6.93E-04 Obesity (extreme) / / 21935397 rs6745620 chr2 48245742 C T 7.07E-04 Obesity (extreme) / / 21935397 rs17037087 chr2 48246555 G T 7.18E-04 Obesity (extreme) / / 21935397 rs11682328 chr2 48248101 T C 7.36E-04 Obesity (extreme) / / 21935397 rs11681243 chr2 48251156 G T 7.30E-04 Obesity (extreme) / / 21935397 rs11687232 chr2 48251493 T C 7.26E-04 Obesity (extreme) / / 21935397 rs11677590 chr2 48275068 T G 6.70E-04 Obesity (extreme) / / 21935397 rs11693696 chr2 48285147 C T 4.97E-04 Obesity (extreme) / / 21935397 rs11680404 chr2 48296105 G A 4.09E-04 Obesity (extreme) / / 21935397 rs11689818 chr2 48298991 T G 3.76E-04 Obesity (extreme) / / 21935397 rs6755400 chr2 48300851 A G 4.51E-04 Nicotine dependence / / 17158188 rs7561696 chr2 48303851 A G 3.73E-04 Obesity (extreme) / / 21935397 rs11687989 chr2 48306647 G A 3.71E-04 Obesity (extreme) / / 21935397 rs1878078 chr2 48318158 T C 7.80E-05 Glioma (high-grade) / / 19578366 rs7583719 chr2 48337970 G A 3.04E-04 Obesity (extreme) / / 21935397 rs17396793 chr2 48365018 G A 3.11E-04 Obesity (extreme) / / 21935397 rs7581510 chr2 48379578 A G 3.25E-04 Obesity (extreme) / / 21935397 rs6733558 chr2 48395486 A G 2.77E-04 Obesity (extreme) / / 21935397 rs11676381 chr2 48413924 G A 2.76E-04 Obesity (extreme) / / 21935397 rs11691493 chr2 48414153 C T 2.76E-04 Obesity (extreme) / / 21935397 rs11683689 chr2 48423881 C A 2.64E-04 Obesity (extreme) / / 21935397 rs13431982 chr2 48432921 T C 2.50E-04 Obesity (extreme) / / 21935397 rs10495950 chr2 48434764 T G 2.51E-04 Obesity (extreme) / / 21935397 rs17325048 chr2 48436566 A C 2.52E-04 Obesity (extreme) / / 21935397 rs11681876 chr2 48445328 A G 2.99E-04 Obesity (extreme) / / 21935397 rs11680162 chr2 48456974 C T 3.34E-04 Obesity (extreme) / / 21935397 rs3750272 chr2 48461993 A G 7.20E-04 Stroke / / pha002887 rs7574310 chr2 48465627 C T 6.29E-04 Multiple complex diseases / / 17554300 rs17397094 chr2 48467708 C G 8.60E-04 Obesity (extreme) / / 21935397 rs952468 chr2 48470132 T G 8.78E-04 Obesity (extreme) / / 21935397 rs6747738 chr2 48471369 C T 8.84E-04 Obesity (extreme) / / 21935397 rs17325209 chr2 48479210 G A 8.68E-04 Obesity (extreme) / / 21935397 rs11695923 chr2 48487207 C T 8.28E-04 Obesity (extreme) / / 21935397 rs11682838 chr2 48641155 A G 6.80E-04 Obesity (extreme) / / 21935397 rs4606978 chr2 48643436 A C 6.22E-06 Triglycerides / / pha003080 rs17397442 chr2 48644275 C T 7.71E-05 Suicide attempts in bipolar disorder / / 21423239 rs17397442 chr2 48644275 C T 7.94E-05 Lipid levels / / pha003082 rs10454142 chr2 48646399 T C 1.00E-07 Sex hormone-binding globulin levels / / 22829776 rs17325537 chr2 48646751 C G 1.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs17037329 chr2 48646827 A C 1.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs7565792 chr2 48649705 T C 7.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs4316980 chr2 48650308 C T 5.71E-05 Triglycerides / / pha003080 rs4561709 chr2 48714938 T G 1.18E-04 Suicide attempts in bipolar disorder PPP1R21 intron 21423239 rs35284764 chr2 48777878 T C 7.48E-04 Multiple complex diseases STON1 intron 17554300 rs876968 chr2 48778865 G T 6.32E-04 Multiple complex diseases STON1 intron 17554300 rs6705602 chr2 48781222 G A 3.63E-04 Alzheimer's disease STON1 intron 22005930 rs149954327 chr2 48809144 T G 1.53E-09 Body mass index STON1 missense 23555315 rs2293276 chr2 48819197 A G 7.19E-05 Waist Circumference STON1 intron pha003023 rs2140551 chr2 48822381 G A 7.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) STON1 cds-synon 20877124 rs3749146 chr2 48824501 C T 3.00E-06 Amyotrophic lateral sclerosis (sporadic) STON1 UTR-3 24529757 rs13018198 chr2 48824698 T C 2.27E-04 Response to taxane treatment (placlitaxel) STON1 UTR-3 23006423 rs11693317 chr2 48832414 T G 9.78E-04 Response to taxane treatment (placlitaxel) STON1-GTF2A1L intron 23006423 rs7604334 chr2 48832433 A G 7.39E-04 Response to taxane treatment (placlitaxel) STON1-GTF2A1L intron 23006423 rs17326067 chr2 48847097 C T 4.89E-04 Coronary heart disease GTF2A1L intron 21606135 rs13028463 chr2 48847174 G A 5.04E-04 Response to taxane treatment (placlitaxel) GTF2A1L intron 23006423 rs1589749 chr2 48862498 A G 7.03E-04 Coronary heart disease GTF2A1L intron 21606135 rs2349099 chr2 48862902 C T 7.09E-04 Type 2 diabetes GTF2A1L intron 17463246 rs2349099 chr2 48862902 C T 9.88E-04 Coronary heart disease GTF2A1L intron 21606135 rs11689544 chr2 48909171 G A 1.12E-04 Type 2 diabetes STON1-GTF2A1L intron 17463246 rs17326321 chr2 48937576 G A 5.20E-04 Taste perception LHCGR intron 22132133 rs4490239 chr2 48948802 T C 4.70E-04 Stroke LHCGR intron pha002887 rs10495959 chr2 48959537 T C 6.14E-04 Multiple complex diseases LHCGR intron 17554300 rs4319975 chr2 48959603 A G 2.75E-04 Multiple complex diseases LHCGR intron 17554300 rs12471286 chr2 48966160 C G 6.20E-08 Urinary metabolites LHCGR intron 21572414 rs35960650 chr2 48974634 G T 9.00E-06 Urinary metabolites LHCGR intron 21572414 rs13405728 chr2 48978159 A G 8.00E-21 Polycystic ovary syndrome LHCGR intron 21151128 rs13405728 chr2 48978159 A G 4.00E-09 Polycystic ovary syndrome LHCGR intron 22885925 rs13405728 chr2 48978159 A G 1.44E-04 Response to cholinesterase inhibitors in Alzheimer's disease LHCGR intron 23374588 rs4073368 chr2 48982358 G A 4.60E-07 Urinary metabolites LHCGR intron 21572414 rs2301267 chr2 48984391 C T 9.33E-04 Obesity (extreme) STON1-GTF2A1L intron 21935397 rs4334540 chr2 48996317 C G 8.00E-04 Type 2 diabetes STON1-GTF2A1L intron 17463246 rs4245820 chr2 48996544 A G 8.84E-04 Type 2 diabetes STON1-GTF2A1L intron 17463246 rs11125182 chr2 48999658 G A 8.76E-04 Coronary Artery Disease STON1-GTF2A1L intron 17634449 rs13426172 chr2 48999782 A G 1.53E-04 Obesity (extreme) STON1-GTF2A1L intron 21935397 rs4507141 chr2 49000425 C A 1.10E-05 Urinary metabolites STON1-GTF2A1L intron 21572414 rs4414727 chr2 49030009 T A 3.01E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4482537 chr2 49052255 C T 3.18E-05 Erythrocyte counts / / pha003101 rs10490128 chr2 49093258 A G 1.40E-05 Urinary metabolites / / 21572414 rs733726 chr2 49096835 C T 6.51E-05 Cognitive performance / / 19734545 rs981273 chr2 49120549 A G 1.30E-05 Urinary metabolites / / 21572414 rs2192615 chr2 49122094 C T 8.09E-05 Hypertension / / 21082022 rs4952929 chr2 49139350 G C 2.60E-05 Urinary metabolites / / 21572414 rs11891861 chr2 49156580 T G 6.49E-05 Parkinson's disease / / 17052657 rs989373 chr2 49158325 T C 7.40E-04 Alcohol dependence / / 20201924 rs6706144 chr2 49170577 A G 2.40E-05 Urinary metabolites / / 21572414 rs7591064 chr2 49177601 C T 5.00E-06 Radiation response / / 20923822 rs2268363 chr2 49201328 A G 5.00E-08 Erectile dysfunction and prostate cancer treatment FSHR intron 20932654 rs2268361 chr2 49201612 C T 1.00E-12 Polycystic ovary syndrome FSHR intron 22885925 rs3788981 chr2 49245561 A C 0.00025 Breast cancer early age of onset FSHR intron 18463975 rs2349415 chr2 49247832 T C 2.35E-12 Polycystic ovary syndrome FSHR intron 22885925 rs3913668 chr2 49268462 A G 3.08E-04 Smoking cessation FSHR intron 24665060 rs10865238 chr2 49268804 A G 2.19E-12 Polycystic ovary syndrome FSHR intron 22885925 rs1504189 chr2 49279932 T C 3.05E-06 Cognitive test performance FSHR intron 20125193 rs4971622 chr2 49292811 A T 8.83E-04 Suicide attempts in bipolar disorder FSHR intron 21041247 rs1504155 chr2 49402250 A C 4.00E-04 Obesity-related traits / / 17903300 rs12987821 chr2 49468791 A C 7.67E-04 Smoking cessation / / 24665060 rs10495970 chr2 49491810 G A 5.00E-07 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) / / 24554482 rs9636436 chr2 49498006 G A 2.00E-07 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) / / 24554482 rs1365867 chr2 49548375 G A 4.15E-04 Smoking initiation / / 24665060 rs817088 chr2 49575829 T G 8.33E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1882345 chr2 49630281 T C 9.47E-04 Alzheimer's disease / / 22005930 rs1921617 chr2 49646072 T A 7.10E-06 Fasting plasma glucose / / 19060907 rs1344648 chr2 49647376 G A 1.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs817004 chr2 49648928 T C 8.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs817008 chr2 49650161 G C 1.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs6545112 chr2 49651185 A G 1.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs1358420 chr2 49652112 C T 1.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs817010 chr2 49652176 G C 8.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs817012 chr2 49652722 A T 9.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs1544914 chr2 49654260 T C 1.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs1544915 chr2 49654581 G A 1.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs1405969 chr2 49676328 A G 1.70E-05 Urinary metabolites / / 21572414 rs7593459 chr2 49695700 A T 1.60E-06 Bipolar disorder / / 19416921 rs12713060 chr2 49699199 C A 1.40E-05 Urinary metabolites / / 21572414 rs13005268 chr2 49699762 C G 3.00E-06 Urinary metabolites / / 21572414 rs1527912 chr2 49701071 T C 3.30E-06 Urinary metabolites / / 21572414 rs11125247 chr2 49701614 A T 6.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs13419824 chr2 49705607 G T 2.70E-06 Urinary metabolites / / 21572414 rs11888995 chr2 49714129 T C 2.37E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs12987465 chr2 49715021 G A 7.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs12987465 chr2 49715021 G A 5.33E-05 Erythrocyte counts / / pha003101 rs2098986 chr2 49718822 C G 2.50E-05 Urinary metabolites / / 21572414 rs12996690 chr2 49724966 T C 8.45E-05 Erythrocyte counts / / pha003101 rs6756236 chr2 49728396 A C 2.28E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs7589821 chr2 49731956 G A 1.79E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1553127 chr2 49732935 T C 1.85E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs1553127 chr2 49732935 T C 5.80E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs1405965 chr2 49737819 A G 2.27E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs1405965 chr2 49737819 A G 3.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs6709183 chr2 49749038 C T 7.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs4971621 chr2 49752589 T C 6.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs1995172 chr2 49790063 C T 0.0000195 Panic disorder / / 23149450 rs1995172 chr2 49790063 C T 1.95E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs13429217 chr2 49808562 C T 9.28E-05 Height / / pha003010 rs4971624 chr2 49836326 C A 4.60E-04 Multiple complex diseases / / 17554300 rs7577053 chr2 49849708 T C 2.00E-05 Urinary metabolites / / 21572414 rs1391749 chr2 49852392 A C 2.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs2350699 chr2 49871330 G A 1.54E-05 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs10495981 chr2 49883809 T C 8.92E-05 Cholesterol / / pha003073 rs13383039 chr2 49885175 C G 8.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs12713068 chr2 49887106 A G 7.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs2059713 chr2 49888607 T G 6.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs6545125 chr2 49888676 G A 3.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs560021053 chr2 49904128 TA T 8.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs881422 chr2 49904128 T A 8.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs2882478 chr2 49904589 A G 8.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs17180320 chr2 49908670 C G 3.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs12623969 chr2 49909418 G A 2.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs4527245 chr2 49910253 G C 6.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs17180439 chr2 49914910 G C 4.50E-06 Urinary metabolites / / 21572414 rs1518826 chr2 49926570 T C 8.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs4402808 chr2 49933279 C T 8.52E-04 Prostate cancer mortality / / 20978177 rs10200783 chr2 49936924 G C 9.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs10196361 chr2 49942227 A C 8.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs10185615 chr2 49944565 A C 8.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs12475071 chr2 49948420 A C 6.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs17489085 chr2 49952622 T G 1.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs17039212 chr2 49955497 C A 9.00E-06 Systemic lupus erythematosus / / 19165918 rs17039212 chr2 49955497 C A 2.86E-04 Prostate cancer mortality / / 20978177 rs4971626 chr2 49956426 A C 9.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs4971627 chr2 49956489 A G 8.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs951840 chr2 49961169 T C 5.22E-05 Multiple complex diseases / / 17554300 rs7355306 chr2 49962464 A G 7.73E-04 Multiple complex diseases / / 17554300 rs10204924 chr2 49962785 G C 3.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs7593733 chr2 49963077 C A 9.04E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12328055 chr2 49971239 G A 2.93E-05 Cognitive impairment induced by topiramate / / 22091778 rs12328060 chr2 49971406 G A 8.60E-05 Tuberculosis / / 24057671 rs11125273 chr2 49971708 C G 1.20E-06 Urinary metabolites / / 21572414 rs1914779 chr2 49986278 C T 4.51E-05 Cognitive impairment induced by topiramate / / 22091778 rs1518823 chr2 49990368 C T 4.37E-04 Prostate cancer mortality / / 20978177 rs11903512 chr2 50005959 T C 8.58E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17039332 chr2 50022072 T C 5.21E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7562270 chr2 50032071 A G 9.30E-05 Height / / pha003010 rs17039367 chr2 50083603 G A 9.76E-04 Type 2 diabetes / / 17463246 rs17039375 chr2 50088431 T A 7.48E-04 Type 2 diabetes / / 17463246 rs2068489 chr2 50089009 C G 8.57E-04 Type 2 diabetes / / 17463246 rs10495985 chr2 50092761 T C 6.81E-04 Type 2 diabetes / / 17463246 rs10495985 chr2 50092761 T C 9.27E-05 Caffeine consumption / / 21490707 rs11893681 chr2 50122480 G T 8.46E-04 Type 2 diabetes / / 17463246 rs10495987 chr2 50153280 A C 5.66E-05 Bipolar disorder NRXN1 intron 20451256 rs11681792 chr2 50184394 C T 4.00E-07 Behavioural disinhibition (generation interaction) NRXN1 intron 23942779 rs11681792 chr2 50184394 C T 6.70E-04 Behavioural disinhibition (generation interaction) NRXN1 intron 23942779 rs17439001 chr2 50189443 A C 9.29E-05 Self-reported allergy NRXN1 intron 23817569 rs11889551 chr2 50202953 G T 2.96E-05 HIV-1 viral setpoint NRXN1 intron 22174851 rs2112073 chr2 50209558 C T 7.06E-05 HIV-1 viral setpoint NRXN1 intron 22174851 rs1363025 chr2 50215373 G A 7.55E-05 HIV-1 viral setpoint NRXN1 intron 22174851 rs7604754 chr2 50230334 C T 8.44E-05 Caffeine consumption NRXN1 intron 21490707 rs10196324 chr2 50236619 A T 6.42E-05 Diabetic nephropathy NRXN1 intron pha002864 rs6753833 chr2 50247149 A G 1.87E-05 Caffeine consumption NRXN1 intron 21490707 rs17494917 chr2 50250758 A G 3.78E-05 Caffeine consumption NRXN1 intron 21490707 rs9677968 chr2 50251100 A G 3.34E-05 Smoking cessation NRXN1 intron 18519826 rs1895132 chr2 50259734 G A,C 1.53E-04 Multiple complex diseases NRXN1 intron 17554300 rs10191808 chr2 50268555 T G 4.72E-05 Cognitive performance NRXN1 intron 19734545 rs17495366 chr2 50268616 T C 3.12E-05 Attention deficit hyperactivity disorder NRXN1 intron 20732627 rs2351155 chr2 50307245 G A 1.31E-05 Cognitive performance NRXN1 intron 19734545 rs2351155 chr2 50307245 G A 1.87E-05 Blood Pressure NRXN1 intron pha003040 rs970896 chr2 50308985 C A 8.90E-04 Type 2 diabetes and 6 quantitative traits NRXN1 intron 17848626 rs1523355 chr2 50328062 G T 2.90E-05 Urinary metabolites NRXN1 intron 21572414 rs13430861 chr2 50328375 C A 5.70E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) NRXN1 intron 24236485 rs1452762 chr2 50330068 A G 6.27E-04 Coronary Artery Disease NRXN1 intron 17634449 rs17039291 chr2 50330318 T A 8.47E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) NRXN1 intron 24236485 rs10490241 chr2 50332310 C A,G,T 6.08E-05 Cognitive performance NRXN1 intron 19734545 rs921573 chr2 50334183 C A 1.93E-04 Smoking cessation NRXN1 intron 18519826 rs7606758 chr2 50357734 T C 7.14E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) NRXN1 intron 24236485 rs13008902 chr2 50358675 T G 3.68E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) NRXN1 intron 24236485 rs11675607 chr2 50365727 G A 1.23E-04 Smoking cessation NRXN1 intron 18519826 rs2602003 chr2 50388284 A G 8.24E-04 Multiple complex diseases NRXN1 intron 17554300 rs7599263 chr2 50390615 T C 4.03E-05 Lipoproteins NRXN1 intron pha003079 rs9309179 chr2 50458179 G A 1.48E-04 Smoking cessation NRXN1 intron 18519826 rs1356888 chr2 50516018 T C 1.00E-06 Longevity NRXN1 intron 20834067 rs7569775 chr2 50532337 T C 8.16E-04 HIV-1 viral setpoint NRXN1 intron 17641165 rs10048731 chr2 50668760 T C 2.30E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NRXN1 intron 20877124 rs10048731 chr2 50668760 T C 3.89E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NRXN1 intron 20877124 rs1015823 chr2 50687878 C T 2.43E-05 Cognitive test performance NRXN1 intron 20125193 rs3213756 chr2 50692560 A G 8.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NRXN1 intron 20877124 rs6721498 chr2 50713012 G A 1 Drug response to Nicotine NRXN1 intron 18270208 rs17476669 chr2 50726471 G A 7.92E-06 Waist circumference NRXN1 intron 19557197 rs6734480 chr2 50726529 C G 3.82E-04 Type 2 diabetes NRXN1 intron 17846125 rs6734480 chr2 50726529 C G 2.90E-06 Urinary metabolites NRXN1 intron 21572414 rs6734480 chr2 50726529 C G 7.11E-04 Alzheimer's disease NRXN1 intron 22005930 rs6754640 chr2 50731318 G A 1.00E-06 Temperament NRXN1 intron 22832960 rs10176705 chr2 50744774 C T 9.00E-06 Personality dimensions NRXN1 intron 20691247 rs6750634 chr2 50760503 G A 4.00E-06 Metabolite levels (HVA/MHPG ratio) NRXN1 intron 23319000 rs12053235 chr2 50777896 T A 5.78E-06 Metabolite levels (MHPG) NRXN1 intron 23319000 rs34288758 chr2 50796550 C A 4.52E-06 Metabolite levels (MHPG) NRXN1 intron 23319000 rs725288 chr2 50805475 C T 1.41E-04 Smoking cessation NRXN1 intron 24665060 rs4467312 chr2 50826484 T C 7.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NRXN1 intron 20877124 rs12476492 chr2 50840322 A G 0.000005 Major depressive disorder age at onset<15 NRXN1 intron 22915352 rs9752732 chr2 50882657 C T 8.00E-05 Blood Pressure NRXN1 intron pha003049 rs4971689 chr2 50921932 C G 0.0000175 Skin total naphthyl-keratin adduct (NKA) levels in workers exposed to naphthalene NRXN1 intron 22391508 rs4971689 chr2 50921932 C G 0.0000276 Skin naphthyl-keratin adduct (NKA) levels in workers exposed to naphthalene NRXN1 intron 22391508 rs12618157 chr2 50937036 A G 6.10E-07 Amyotrophic Lateral Sclerosis NRXN1 intron 17362836 rs17502019 chr2 50961916 G C 6.14E-04 Multiple complex diseases NRXN1 intron 17554300 rs3842845 chr2 50976171 A C 4.19E-04 Type 2 diabetes NRXN1 intron 17463246 rs3901491 chr2 50976485 T G 1.88E-04 Parkinson's disease NRXN1 intron 17052657 rs3901491 chr2 50976485 T G 1.70E-05 Urinary metabolites NRXN1 intron 21572414 rs17502934 chr2 50994255 G T 6.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NRXN1 intron 20877124 rs3892750 chr2 50996952 C T 3.10E-06 Urinary metabolites NRXN1 intron 21572414 rs3850333 chr2 51002929 A G 6.36E-05 Schizophrenia NRXN1 intron 19571811 rs9750635 chr2 51036712 T C 1.03E-04 Hemoglobin concentration NRXN1 intron 20534544 rs3850337 chr2 51039097 A T 8.76E-04 Multiple complex diseases NRXN1 intron 17554300 rs9309201 chr2 51042342 C T 8.85E-06 Elbow pain NRXN1 intron pha003008 rs17569702 chr2 51059836 T C 3.15E-06 Multiple sclerosis (brain glutamate levels) NRXN1 intron 20802204 rs2193225 chr2 51079482 T C 1 Drug response to Nicotine NRXN1 intron 18270208 rs1558799 chr2 51095053 G A 2.65E-05 Multiple sclerosis (brain glutamate levels) NRXN1 intron 20802204 rs6545185 chr2 51125058 A G 2.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NRXN1 intron 20877124 rs6545185 chr2 51125058 A G 9.86E-05 Elbow pain NRXN1 intron pha003008 rs6741326 chr2 51129285 G A 3.03E-04 Hemoglobin concentration NRXN1 intron 20534544 rs7558540 chr2 51140228 C T 3.03E-04 Hemoglobin concentration NRXN1 intron 20534544 rs7558540 chr2 51140228 C T 3.91E-04 Body mass index NRXN1 intron 21701565 rs7423296 chr2 51149072 T C 3.03E-04 Hemoglobin concentration NRXN1 intron 20534544 rs10490165 chr2 51188566 T C 4.15E-26 Narcolepsy NRXN1 intron 19629137 rs12623467 chr2 51225089 C T 1.48E-05 Nicotine dependence NRXN1 intron 17158188 rs6749209 chr2 51238652 A G 3.03E-04 Hemoglobin concentration NRXN1 intron 20534544 rs12467557 chr2 51242270 A G 6.88E-05 Nicotine dependence NRXN1 intron 17158188 rs13382584 chr2 51247294 T C 7.12E-04 Alcohol dependence NRXN1 intron 20201924 rs10490162 chr2 51247657 T C 5.66E-05 Nicotine dependence NRXN1 intron 17158188 rs2352545 chr2 51266982 C T 9.33E-05 Depression (quantitative trait) / / 23290196 rs2111380 chr2 51270610 A T 8.65E-05 Depression (quantitative trait) / / 23290196 rs11889082 chr2 51272118 A G 1.22E-06 Cardiovascular disease / / 18179892 rs4971723 chr2 51279135 T C 7.79E-05 Depression (quantitative trait) / / 23290196 rs6545190 chr2 51282609 G T 9.25E-05 Depression (quantitative trait) / / 23290196 rs10180695 chr2 51292332 T C 7.78E-05 Depression (quantitative trait) / / 23290196 rs34888568 chr2 51304476 G A 3.33E-05 Multiple complex diseases / / 17554300 rs17041243 chr2 51314528 T G 5.04E-04 Multiple complex diseases / / 17554300 rs17041373 chr2 51388866 G T 7.84E-04 Multiple complex diseases / / 17554300 rs3732051 chr2 51427174 C T 7.91E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6718224 chr2 51468494 G A 2.52E-04 Type 2 diabetes / / 17463246 rs2098441 chr2 51476956 A G 7.69E-04 Suicide attempts in bipolar disorder / / 21041247 rs2098446 chr2 51481255 G A 7.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs10490146 chr2 51512492 A G 3.66E-04 Birth weight / / 17255346 rs4971738 chr2 51512724 C T 5.60E-04 Alzheimer's disease / / 17998437 rs10490145 chr2 51513683 G A 0.000460588 Hypertension (early onset hypertension) / / 22479346 rs2216133 chr2 51514659 T C 9.98E-05 Rheumatoid arthritis / / 17804836 rs723713 chr2 51517775 G T 5.68E-05 Multiple complex diseases / / 17554300 rs10490144 chr2 51519281 T C 7.53E-04 Type 2 diabetes / / 17463246 rs10490142 chr2 51520327 C T 1.46E-04 Birth weight / / 17255346 rs17041533 chr2 51520800 C T 1.72E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs13405861 chr2 51521625 A G 5.59E-05 Alzheimer's disease / / 17998437 rs7602908 chr2 51528298 G A 1.57E-04 Birth weight / / 17255346 rs17524147 chr2 51566704 T C 2.45E-04 Type 2 diabetes / / 17463246 rs17590125 chr2 51581507 G T 4.13E-04 Type 2 diabetes / / 17463246 rs1206397 chr2 51667739 C A 3.00E-07 Cognitive performance / / 19734545 rs13022923 chr2 51680339 G A 3.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs991902 chr2 51689676 T G 3.48E-05 Diabetic nephropathy / / pha002852 rs2160407 chr2 51691387 C T 7.96E-04 Multiple complex diseases / / 17554300 rs2839839 chr2 51691484 A C 7.09E-05 Diabetic nephropathy / / pha002852 rs6739884 chr2 51702486 A G 1.96E-04 Hearing function / / 17255346 rs1406428 chr2 51736994 C T 2.00E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs1528805 chr2 51738393 C T 6.45E-04 Coronary heart disease / / 21971053 rs10495996 chr2 51743688 A G 6.08E-05 Bipolar disorder / / 17486107 rs1534611 chr2 51747186 T C 3.68E-04 Coronary heart disease / / 21971053 rs2697999 chr2 51756961 G A 8.30E-06 Cognitive impairment induced by topiramate / / 22091778 rs17864534 chr2 51764360 T C 6.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs3915321 chr2 51764718 C T 4.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs3915322 chr2 51765008 G A 4.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs2354378 chr2 51765416 C T 4.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs11680441 chr2 51767398 G A 4.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs7592062 chr2 51768912 A G 7.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs2950945 chr2 51768939 G A 7.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs1997326 chr2 51769196 G T 5.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs1919434 chr2 51771417 T C 3.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs1528817 chr2 51771557 A G 3.21E-04 Suicide attempts in bipolar disorder / / 21041247 rs12995836 chr2 51772064 C T 8.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs13001767 chr2 51772415 G T 1.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs2698031 chr2 51772808 A G 3.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs1358580 chr2 51773028 A G 3.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs1528816 chr2 51775261 G A 3.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs1528815 chr2 51775273 G C 3.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs1528814 chr2 51775511 T C 3.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs2715081 chr2 51775814 C T 2.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs11563043 chr2 51777241 C G 2.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs11563162 chr2 51778608 G A 2.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs202114406 chr2 51778608 G GT 2.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs372843652 chr2 51778608 GT G 2.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs78062703 chr2 51778608 GTT G 2.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs2715084 chr2 51778654 T C 2.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs2715086 chr2 51778721 T A 2.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs2715088 chr2 51778828 T C 2.57E-04 Suicide attempts in bipolar disorder / / 21041247 rs2715089 chr2 51779120 C A 2.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs2222779 chr2 51780150 A G 6.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs2698029 chr2 51780259 G T 1.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs2715079 chr2 51781034 G A 1.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs2698028 chr2 51781853 C T 1.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs2715077 chr2 51782284 C A 2.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs2698026 chr2 51782507 G A 2.70E-04 Suicide attempts in bipolar disorder / / 21041247 rs2950942 chr2 51785617 C T 2.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs2715062 chr2 51786142 G A 4.53E-04 Suicide attempts in bipolar disorder / / 21041247 rs2698024 chr2 51786520 G A 4.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs2698022 chr2 51787982 C A 3.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs1919433 chr2 51791380 G C 5.69E-04 Suicide attempts in bipolar disorder / / 21041247 rs1919432 chr2 51791446 C T 3.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs1569190 chr2 51791767 G T 7.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs1609361 chr2 51792223 A G 4.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs1528813 chr2 51792896 A T 6.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs1528812 chr2 51793338 G C 4.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs1406429 chr2 51794327 C T 6.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs1581667 chr2 51794752 C T 4.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs2698014 chr2 51795922 T G 4.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs2715057 chr2 51795951 C T 4.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs1528811 chr2 51796148 C T 4.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs1528810 chr2 51796267 C T 5.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs1528809 chr2 51796413 G A 5.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs2698011 chr2 51797785 G T 5.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs2698011 chr2 51797785 G T 5.33E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2715076 chr2 51799271 C A 5.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs11563154 chr2 51803683 G C 3.57E-04 Multiple complex diseases / / 17554300 rs2204729 chr2 51804042 A G 1.44E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4971754 chr2 51804524 G A 3.24E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2354382 chr2 51826920 T C 4.54E-05 Interstitial lung disease / / 23583980 rs2459335 chr2 51838229 T C 1.40E-05 Urinary metabolites / / 21572414 rs2459335 chr2 51838229 T C 3.50E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs952893 chr2 51876227 C T 0.000141 Transmission distortion / / 22377632 rs6714367 chr2 51914354 C T 0.000836903 Hypertension (early onset hypertension) / / 22479346 rs17864603 chr2 51989400 T C 5.27E-06 Hearing function / / 21493956 rs17862772 chr2 51991896 A G 1.03E-05 Bipolar disorder and schizophrenia / / 20889312 rs10194873 chr2 52009536 T C 7.89E-06 Soluble levels of adhesion molecules / / pha003072 rs11686436 chr2 52017764 C T 1.06E-05 Leukocyte Counts / / pha003091 rs1541980 chr2 52035257 A G 9.00E-05 Psoriasis / / 20953190 rs1435808 chr2 52036315 G A 3.35E-05 Prion diseases / / 22210626 rs11563262 chr2 52040359 G T 7.00E-05 Prostate cancer / / 21743057 rs7603003 chr2 52042513 A G 3.49E-05 Psoriasis / / 20953190 rs7603003 chr2 52042513 A G 2.88E-04 Osteoarthritis (knee and hip) / / 21177295 rs7603003 chr2 52042513 A G 4.18E-05 Osteoarthritis (knee and hip) / / 21177295 rs1017418 chr2 52048162 G C 0.00006733 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1017418 chr2 52048162 G C 5.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3861566 chr2 52065162 C T 1.30E-05 Post-operative nausea and vomiting / / 21694509 rs11562986 chr2 52065967 G A 4.93E-06 Esophageal cancer (squamous cell) / / 22960999 rs1435805 chr2 52068507 T C 5.66E-05 Post-operative nausea and vomiting / / 21694509 rs1369670 chr2 52073620 A G 8.43E-05 Post-operative nausea and vomiting / / 21694509 rs13035243 chr2 52083589 A G 1.09E-05 Premature ovarian failure / / 19508998 rs13035243 chr2 52083589 A G 1.09E-05 Other erythrocyte phenotypes / / 19862010 rs11125392 chr2 52107116 A T 2.00E-05 Urinary metabolites / / 21572414 rs17042362 chr2 52223396 A G 6.84E-04 Stroke / / pha002886 rs10209646 chr2 52262658 T G 7.57E-04 Type 2 diabetes / / 17463246 rs10209646 chr2 52262658 T G 2.10E-05 Urinary metabolites / / 21572414 rs10209718 chr2 52262676 T C 2.70E-04 Type 2 diabetes / / 17463246 rs10209718 chr2 52262676 T C 1.60E-05 Urinary metabolites / / 21572414 rs7582556 chr2 52262713 G C 2.10E-05 Urinary metabolites / / 21572414 rs7582793 chr2 52262932 G A 6.46E-04 Acute lung injury / / 22295056 rs7595947 chr2 52264332 A G 6.09E-04 Type 2 diabetes / / 17463246 rs13397279 chr2 52274871 A C 5.64E-04 Response to TNF antagonist treatment / / 21061259 rs10167057 chr2 52288297 G C 3.02E-05 Multiple complex diseases / / 17554300 rs17042508 chr2 52305747 A G 2.90E-05 Urinary metabolites / / 21572414 rs13390640 chr2 52332457 A G 9.50E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7594573 chr2 52371363 C T 3.24E-04 Smoking cessation / / 24665060 rs13398003 chr2 52378299 T C 2.00E-05 Urinary metabolites / / 21572414 rs10180287 chr2 52382382 G T 4.31E-04 Smoking cessation / / 24665060 rs11892271 chr2 52383698 C T 6.27E-05 Myopia (pathological) / / 23049088 rs12621097 chr2 52384668 C T 2.10E-05 Urinary metabolites / / 21572414 rs12621097 chr2 52384668 C T 7.35E-04 Smoking cessation / / 24665060 rs7606800 chr2 52395370 G A 9.80E-06 Urinary metabolites / / 21572414 rs12713179 chr2 52397517 A G 4.38E-04 Smoking cessation / / 24665060 rs1922192 chr2 52401421 T C 7.93E-04 Smoking cessation / / 24665060 rs12466271 chr2 52420941 C T 1.13E-05 Smoking cessation / / 24665060 rs6710228 chr2 52427816 G T 5.87E-05 Alzheimer's disease / / 17998437 rs2141847 chr2 52430934 G A 5.51E-05 Smoking cessation / / 24665060 rs1922185 chr2 52441782 C G 4.28E-04 Smoking cessation / / 24665060 rs11679267 chr2 52451702 G A 5.74E-04 Smoking cessation / / 24665060 rs4533502 chr2 52452204 G A 3.77E-04 Smoking cessation / / 24665060 rs6726230 chr2 52461739 G A 5.21E-05 Smoking cessation / / 24665060 rs12995337 chr2 52461984 G A 4.66E-05 Smoking cessation / / 24665060 rs4303750 chr2 52463610 C T 9.48E-05 Smoking cessation / / 24665060 rs7586327 chr2 52469618 C T 6.82E-04 Smoking cessation / / 24665060 rs12622126 chr2 52476027 G T 4.76E-04 Smoking cessation / / 24665060 rs12472885 chr2 52479251 A G 1.90E-05 Iron levels / / 21208937 rs2141844 chr2 52493926 A G 7.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2141844 chr2 52493926 A G 1.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs6707935 chr2 52497171 C G 9.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs10196182 chr2 52505020 T A 3.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs13405875 chr2 52505554 C A 3.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs1997492 chr2 52506774 C T 3.90E-05 Suicide attempts in bipolar disorder / / 21423239 rs2355817 chr2 52508314 G A 3.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs13389926 chr2 52511386 T C 4.11E-08 Metabolite levels / / 23281178 rs13389926 chr2 52511386 T C 8.26E-05 Diabetes Mellitus / / pha003060 rs17042688 chr2 52511794 G T 1.00E-06 Estradiol plasma levels (breast cancer) / / 23518928 rs17786474 chr2 52511887 G A 3.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs10164659 chr2 52518281 C T 5.78E-08 Metabolite levels / / 23281178 rs1922210 chr2 52521126 A G 5.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs1922210 chr2 52521126 A G 7.72E-04 Alzheimer's disease / / 24755620 rs10205333 chr2 52523725 A G 7.30E-06 Urinary metabolites / / 21572414 rs12475021 chr2 52535407 T G 5.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12475021 chr2 52535407 T G 1.36E-06 Estradiol plasma levels (breast cancer) / / 23518928 rs6739969 chr2 52540726 G A 7.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs1424786 chr2 52546156 A G 4.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs2552317 chr2 52550366 G T 5.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs2727880 chr2 52554652 C T 1.82E-04 Type 2 diabetes / / 17463246 rs2727890 chr2 52559485 T A 3.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs4346424 chr2 52565737 C A 7.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs6720308 chr2 52588102 A C 7.44E-05 Serum albumin level / / pha003084 rs17788159 chr2 52599360 T C 0.0000604 Panic disorder LOC100506300 intron 23149450 rs17788159 chr2 52599360 T C 6.04E-05 Serum tamsulosin hydrochloride concentration LOC100506300 intron 23151678 rs10173797 chr2 52614168 A G 3.74E-04 Suicide attempts in bipolar disorder LOC100506300 intron 21423239 rs2552352 chr2 52615845 T C 4.03E-04 Suicide attempts in bipolar disorder LOC100506300 intron 21423239 rs1424802 chr2 52644897 T C 6.25E-06 Serum albumin level / / pha003084 rs2552347 chr2 52653026 G A 8.70E-05 Serum albumin level / / pha003084 rs10193067 chr2 52690413 A C 3.61E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10176819 chr2 52692796 G A 5.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs10189311 chr2 52692942 T C 4.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs12614961 chr2 52694381 T C 5.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs7560361 chr2 52694473 T C 4.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs7599425 chr2 52694499 C G 8.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs12611666 chr2 52694638 C T 5.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs11125427 chr2 52694728 A G 3.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs10191908 chr2 52695215 A G 4.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs10168435 chr2 52695364 C T 5.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs4971827 chr2 52695754 C T 7.74E-05 Coronary Artery Disease / / 17634449 rs6759941 chr2 52696996 G T 8.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs12619788 chr2 52703590 G A 8.00E-06 Economic and political preferences (immigration/crime) / / 22566634 rs6545278 chr2 52706052 T G 8.00E-07 Conotruncal heart defects / / 24800985 rs1526687 chr2 52713807 T G 5.00E-06 Cardiac Troponin-T levels / / 23247143 rs6545286 chr2 52785456 A G 1.29E-04 Alzheimer's disease (late onset) / / 21379329 rs1526676 chr2 52790493 C T 8.90E-06 Urinary metabolites / / 21572414 rs12475183 chr2 52792937 A G 9.85E-04 Multiple complex diseases / / 17554300 rs2356194 chr2 52807474 A G 8.60E-06 Urinary metabolites / / 21572414 rs11895971 chr2 52820363 A G 1.31E-05 Waist-Hip Ratio / / pha003029 rs1021175 chr2 52824147 T C 5.00E-06 Urinary metabolites / / 21572414 rs17043120 chr2 52826401 A G 1.79E-05 Waist-Hip Ratio / / pha003029 rs10203946 chr2 52829150 A G 4.40E-05 Serum metabolites / / 19043545 rs1843032 chr2 52841312 A G 3.70E-06 Urinary metabolites / / 21572414 rs2168094 chr2 52891554 G C 6.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1454398 chr2 52900416 T C 8.14E-04 Coronary Artery Disease / / 17634449 rs1601166 chr2 52909704 A G 1.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs350779 chr2 52944722 C T 9.84E-05 Alzheimer's disease (late onset) / / 21379329 rs1349882 chr2 52949318 G T 5.00E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12713213 chr2 52958528 G A 7.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs17043319 chr2 52961642 A G 3.16E-09 Metabolite levels / / 23281178 rs17043323 chr2 52963904 G A 1.27E-08 Metabolite levels / / 23281178 rs17043328 chr2 52965456 C T 1.27E-08 Metabolite levels / / 23281178 rs13404836 chr2 52966539 G C 8.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs1319797 chr2 52969029 G A 3.40E-05 Body Mass Index / / pha003006 rs1319797 chr2 52969029 G A 3.17E-05 Waist Circumference / / pha003024 rs1319797 chr2 52969029 G A 6.00E-05 Weight / / pha003026 rs1384919 chr2 52974459 G C 7.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs1971201 chr2 53003740 T C 8.73E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs1451464 chr2 53006126 G A 2.70E-05 Urinary metabolites / / 21572414 rs1349500 chr2 53006435 T C 1.80E-05 Urinary metabolites / / 21572414 rs2603394 chr2 53007471 T C 2.40E-05 Urinary metabolites / / 21572414 rs785286 chr2 53013320 A G 1.60E-05 Urinary metabolites / / 21572414 rs7607342 chr2 53027798 C T 2.71E-05 Body Mass Index / / pha003014 rs11888200 chr2 53119838 T C 2.10E-04 Coronary Artery Disease / / 17634449 rs2839750 chr2 53129090 A C 4.02E-13 Narcolepsy / / 19629137 rs10175099 chr2 53146216 A G 2.08E-06 Serum metabolites / / 19043545 rs17043835 chr2 53154158 G C 5.92E-05 Serum metabolites / / 19043545 rs4672085 chr2 53154899 G A 3.62E-04 Rheumatoid arthritis / / 21452313 rs1510107 chr2 53160137 C G 1.00E-05 Blood Phenotypes / / 17903294 rs7577197 chr2 53174956 C T 9.09E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs17043867 chr2 53180043 A G 6.88E-04 Parkinson's disease / / 16252231 rs17043868 chr2 53180166 G T 4.02E-05 Serum metabolites / / 19043545 rs2288639 chr2 53188267 A G 5.57E-06 Serum metabolites / / 19043545 rs1446439 chr2 53219203 T C 2.09E-04 Multiple complex diseases / / 17554300 rs6545316 chr2 53223038 A G 9.73E-04 Coronary Artery Disease / / 17634449 rs17044013 chr2 53234943 A T 1.08E-05 Serum metabolites / / 19043545 rs1160297 chr2 53237320 G C 1.00E-06 Hemostatic factors and hematological phenotypes / / 17903294 rs10184575 chr2 53237372 A C 7.33E-07 Red blood cell traits / / 23222517 rs1446442 chr2 53246064 T C 8.70E-05 Body Mass Index / / pha003014 rs1446445 chr2 53256694 C A 8.74E-04 Myopia (pathological) / / 21095009 rs10496010 chr2 53261856 G A 9.16E-04 Type 2 diabetes / / 17846124 rs2357013 chr2 53266129 C T 6.00E-06 Hemostatic factors and hematological phenotypes / / 17903294 rs2357014 chr2 53270575 T C 2.56E-04 Insulin resistance / / 21901158 rs9653536 chr2 53352630 A G 3.71E-04 Height / / 17255346 rs17044134 chr2 53358680 T G 3.57E-04 Coronary Artery Disease / / 17634449 rs2034254 chr2 53358953 A G 1.83E-04 IgE levels / / 17255346 rs17189210 chr2 53361731 T G 5.89E-04 Coronary Artery Disease / / 17634449 rs10496014 chr2 53371251 A G 6.30E-05 Glioma (high-grade) / / 19578366 rs4233969 chr2 53384500 C T 1.90E-05 Urinary metabolites / / 21572414 rs11687654 chr2 53389666 T C 3.96E-04 Multiple complex diseases / / 17554300 rs9309245 chr2 53397048 C G 1.77E-05 Type 2 diabetes / / 23945395 rs17267852 chr2 53401300 C G 7.66E-04 Multiple complex diseases / / 17554300 rs10209546 chr2 53408321 G T 4.17E-04 Multiple complex diseases / / 17554300 rs1364669 chr2 53452495 C A 1.10E-04 Multiple complex diseases / / 17554300 rs195574 chr2 53473426 T C 6.10E-04 Primary sclerosing cholangitis / / 19944697 rs996712 chr2 53502775 A C,G,T 8.00E-06 Obesity-related traits / / 23251661 rs4672305 chr2 53507604 A C 2.95E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11678259 chr2 53508689 T G 1.09E-04 Smoking initiation / / 24665060 rs10202079 chr2 53514022 A G 2.20E-05 Urinary metabolites / / 21572414 rs4671350 chr2 53518480 G A 1.30E-05 Urinary metabolites / / 21572414 rs992874 chr2 53532456 A G 3.18E-05 HIV-1 viral setpoint / / 22174851 rs993161 chr2 53538638 T C 1.60E-05 Urinary metabolites / / 21572414 rs17039520 chr2 53538850 C T 2.76E-04 Multiple complex diseases / / 17554300 rs4672329 chr2 53541547 C T 2.48E-04 Multiple complex diseases / / 17554300 rs7576932 chr2 53549075 T G 5.15E-04 Multiple complex diseases / / 17554300 rs12475695 chr2 53636324 C A 2.29E-04 Rheumatoid arthritis / / 21452313 rs12713247 chr2 53637182 C T 0.0000304 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12713247 chr2 53637182 C T 3.04E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4672412 chr2 53647050 T C 2.23E-05 Reading and spelling / / 23738518 rs2172645 chr2 53647729 A C 2.00E-05 Reading and spelling / / 23738518 rs17044651 chr2 53655867 T A 7.79E-04 Multiple complex diseases / / 17554300 rs17044653 chr2 53655977 C T 3.84E-04 Multiple complex diseases / / 17554300 rs10496023 chr2 53656677 A G 4.09E-04 Multiple complex diseases / / 17554300 rs1521937 chr2 53662216 A C 4.12E-04 Parkinson's disease / / 17052657 rs1521937 chr2 53662216 A C 0.0002515 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1521937 chr2 53662216 A C 2.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17189393 chr2 53663698 A G 0.0002307 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17189393 chr2 53663698 A G 2.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12713250 chr2 53666367 G C 0.000238 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12713250 chr2 53666367 G C 2.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6545346 chr2 53667806 C T 0.0002708 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6545346 chr2 53667806 C T 2.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs745685 chr2 53691289 G A 0.0005099 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs745685 chr2 53691289 G A 5.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs903228 chr2 53692049 G C 2.42E-08 Multiple complex diseases / / 17554300 rs1568546 chr2 53692326 C T 0.000516 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1568546 chr2 53692326 C T 5.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1318578 chr2 53703155 C A 0.0003631 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1318578 chr2 53703155 C A 3.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17044787 chr2 53704264 C G 9.20E-06 Left ventricular mass / / 21212386 rs10164725 chr2 53706224 T C 0.000744405 Hypertension (early onset hypertension) / / 22479346 rs4672452 chr2 53730641 G A 2.79E-04 Type 2 diabetes / / 17463246 rs7586411 chr2 53731496 G A 4.45E-04 Type 2 diabetes / / 17463246 rs7586356 chr2 53731637 C T 6.66E-04 Type 2 diabetes / / 17463246 rs17268019 chr2 53735050 A G 0.000285 Salmonella-induced pyroptosis / / 22837397 rs6743847 chr2 53738599 G A 5.17E-04 Type 2 diabetes / / 17463246 rs17268047 chr2 53747437 T A 9.99E-04 Obesity (extreme) / / 21935397 rs56148675 chr2 53756542 T C 5.00E-06 Bulimia nervosa / / 23568457 rs2357359 chr2 53756556 G A 3.96E-04 Obesity (extreme) / / 21935397 rs13407662 chr2 53782559 C T 5.00E-08 Stroke (ischemic) / / 23041239 rs10460550 chr2 53788277 T C 2.86E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs718349 chr2 53791087 G T 3.33E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs7566120 chr2 53796167 G A 2.92E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs17044935 chr2 53808311 T C 4.37E-04 Type 2 diabetes / / 17463246 rs6715066 chr2 53826209 G A 6.59E-04 Multiple complex diseases / / 17554300 rs759719 chr2 53829044 C G 7.89E-04 Obesity (extreme) / / 21935397 rs2357490 chr2 53832072 C T 2.35E-05 Heart Rate / / pha003053 rs10490459 chr2 53833291 G C 7.10E-04 Schizophrenia / / 21674006 rs6753258 chr2 53846547 C T 5.10E-04 Type 2 diabetes / / 17463246 rs12619100 chr2 53850382 T C 7.68E-06 Serum albumin level / / pha003084 rs11125512 chr2 53850774 A G 2.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7597885 chr2 53852975 A G 3.44E-04 Multiple complex diseases / / 17554300 rs17578196 chr2 53856374 T C 3.51E-04 Multiple complex diseases / / 17554300 rs6752239 chr2 53859017 A G 9.54E-04 Multiple complex diseases / / 17554300 rs1468983 chr2 53859679 C G,T 7.65E-04 Multiple complex diseases / / 17554300 rs12618833 chr2 53864413 C T 2.96E-06 Schizophrenia / / 24253340 rs997644 chr2 53867187 G T 2.49E-06 Schizophrenia / / 24253340 rs10865275 chr2 53877867 C G 6.12E-04 Alzheimer's disease / / 24755620 rs2160930 chr2 53882527 A G 2.02E-04 Alzheimer's disease (late onset) / / 21379329 rs11889094 chr2 53889867 C T 1.33E-04 Alzheimer's disease (late onset) / / 21379329 rs2287512 chr2 53898032 T C 4.90E-05 Schizophrenia ASB3 intron 24253340 rs7557799 chr2 53901897 A T 8.23E-04 Multiple complex diseases ASB3 intron 17554300 rs7556791 chr2 53906935 A G 8.53E-04 Alzheimer's disease ASB3 intron 24755620 rs7583622 chr2 53931190 G A 5.26E-05 Multiple sclerosis ASB3 intron 17660530 rs6705712 chr2 53954681 C G 8.85E-04 Multiple complex diseases ASB3 intron 17554300 rs6705712 chr2 53954681 C G 0.0000569 Panic disorder ASB3 intron 23149450 rs6705712 chr2 53954681 C G 5.69E-05 Serum tamsulosin hydrochloride concentration ASB3 intron 23151678 rs6714424 chr2 53956980 C A 1.59E-05 Lymphocyte counts ASB3 intron 22286170 rs10188142 chr2 53958136 C T 7.50E-04 Multiple complex diseases ASB3 intron 17554300 rs10188142 chr2 53958136 C T 0.0000554 Panic disorder ASB3 intron 23149450 rs10188142 chr2 53958136 C T 5.54E-05 Serum tamsulosin hydrochloride concentration ASB3 intron 23151678 rs3821081 chr2 53965389 G A 2.67E-04 Multiple complex diseases ASB3 intron 17554300 rs3821081 chr2 53965389 G A 0.0000803 Panic disorder ASB3 intron 23149450 rs3821081 chr2 53965389 G A 8.03E-05 Serum tamsulosin hydrochloride concentration ASB3 intron 23151678 rs3770393 chr2 53972693 G A 0.0000749 Panic disorder ASB3 intron 23149450 rs3770393 chr2 53972693 G A 7.49E-05 Serum tamsulosin hydrochloride concentration ASB3 intron 23151678 rs12613353 chr2 53974223 T G 0.0000898 Panic disorder ASB3 intron 23149450 rs12613353 chr2 53974223 T G 8.98E-05 Serum tamsulosin hydrochloride concentration ASB3 intron 23151678 rs2542588 chr2 54018924 C T 0.0000434 Panic disorder ERLEC1 intron 23149450 rs2542588 chr2 54018924 C T 4.34E-05 Serum tamsulosin hydrochloride concentration ERLEC1 intron 23151678 rs2287344 chr2 54034251 G A 1.42E-04 Tourette syndrome ERLEC1 intron 22889924 rs2542571 chr2 54041983 G T 3.36E-05 Response to taxane treatment (placlitaxel) ERLEC1 intron 23006423 rs698853 chr2 54053872 A G 7.37E-04 Parkinson's disease GPR75-ASB3 intron 17052657 rs698853 chr2 54053872 A G 7.11E-06 Multiple sclerosis GPR75-ASB3 intron 17660530 rs805438 chr2 54056188 T A 7.39E-05 Multiple complex diseases GPR75-ASB3 intron 17554300 rs805438 chr2 54056188 T A 0.0000341 Panic disorder GPR75-ASB3 intron 23149450 rs805438 chr2 54056188 T A 3.41E-05 Serum tamsulosin hydrochloride concentration GPR75-ASB3 intron 23151678 rs2080721 chr2 54056270 C G 0.0000484 Panic disorder GPR75-ASB3 intron 23149450 rs2080721 chr2 54056270 C G 4.84E-05 Serum tamsulosin hydrochloride concentration GPR75-ASB3 intron 23151678 rs805439 chr2 54056574 C T 9.91E-05 Multiple complex diseases GPR75-ASB3 intron 17554300 rs805439 chr2 54056574 C T 0.0000215 Panic disorder GPR75-ASB3 intron 23149450 rs805439 chr2 54056574 C T 2.15E-05 Serum tamsulosin hydrochloride concentration GPR75-ASB3 intron 23151678 rs12617599 chr2 54058082 G C,T 0.0000737 Panic disorder GPR75-ASB3 intron 23149450 rs12617599 chr2 54058082 G C,T 7.37E-05 Serum tamsulosin hydrochloride concentration GPR75-ASB3 intron 23151678 rs805360 chr2 54164848 G T 1.79E-04 Alzheimer's disease (late onset) PSME4 intron 21379329 rs17045435 chr2 54174258 A G 7.58E-04 Multiple complex diseases PSME4 intron 17554300 rs1363060 chr2 54284584 G A 1.01E-05 Heart Rate LOC100506338 intron pha003051 rs41385746 chr2 54305030 T C 6.33E-05 Multiple sclerosis LOC100506338 intron 17660530 rs34498089 chr2 54308826 A G 3.13E-05 Multiple sclerosis LOC100506338 intron 17660530 rs17039547 chr2 54333729 A C 4.57E-05 Multiple sclerosis / / 17660530 rs1559040 chr2 54347750 C T 4.00E-08 Sudden cardiac arrest ACYP2 intron 21658281 rs10206954 chr2 54358517 C T 2.01E-04 Amyotrophic Lateral Sclerosis ACYP2 intron 17362836 rs10186140 chr2 54362975 T C 9.45E-05 Heart Rate ACYP2 intron pha003051 rs7572559 chr2 54372118 G A 5.25E-04 Amyotrophic Lateral Sclerosis ACYP2 intron 17362836 rs10201710 chr2 54372931 T C 2.66E-04 Amyotrophic Lateral Sclerosis ACYP2 intron 17362836 rs13399590 chr2 54382335 A G 2.66E-04 Amyotrophic Lateral Sclerosis ACYP2 intron 17362836 rs3738855 chr2 54386075 T C 3.44E-04 Amyotrophic Lateral Sclerosis ACYP2 intron 17362836 rs11893929 chr2 54418017 C T 2.25E-05 Schizophrenia ACYP2 intron 24253340 rs13417493 chr2 54420617 G A 3.18E-05 Schizophrenia ACYP2 intron 24253340 rs1399513 chr2 54424601 A C 9.09E-06 Schizophrenia ACYP2 intron 24253340 rs1727504 chr2 54428134 C T 3.76E-05 Aging (time to event) ACYP2 intron 21782286 rs11886559 chr2 54437400 G T 2.34E-05 Schizophrenia ACYP2 intron 24253340 rs11894205 chr2 54442697 C T 5.17E-05 Schizophrenia ACYP2 intron 24253340 rs843652 chr2 54469703 T C 8.22E-05 Serum metabolites ACYP2 intron 19043545 rs11125529 chr2 54475866 C A 4.48E-08 Telomere length ACYP2 intron 23535734 rs10165485 chr2 54481636 T C 5.16E-05 Sodium levels TSPYL6 UTR-3 pha003093 rs13407991 chr2 54530993 A G 8.85E-04 Tourette syndrome ACYP2 intron 22889924 rs4600702 chr2 54598757 C G 1.26E-05 Aging (time to event) / / 21782286 rs13407315 chr2 54615040 T C 3.44E-05 Duodenal ulcer / / 22387998 rs6545397 chr2 54615526 A G 7.25E-04 Smoking initiation / / 24665060 rs13425775 chr2 54616446 A G 6.48E-04 Coronary heart disease / / 21971053 rs4359699 chr2 54623790 T C 4.36E-06 Bone mineral density / / 24249740 rs6743995 chr2 54625873 T G 3.49E-04 Multiple complex diseases / / 17554300 rs6734097 chr2 54651933 C T 3.00E-08 Bone mineral density (spine) / / 19801982 rs4315567 chr2 54655944 T G 3.60E-05 Bone mineral density (spine) / / 19079262 rs7607093 chr2 54659174 T G 4.00E-08 Bone mineral density (spine) / / 19801982 rs4233949 chr2 54659707 C G 4.50E-08 Bone mineral density (spine) / / 19801982 rs4233949 chr2 54659707 C G 9.10E-06 Urinary metabolites / / 21572414 rs4233949 chr2 54659707 C G 2.00E-18 Bone mineral density / / 22504420 rs4233949 chr2 54659707 C G 0.000492 Lumbar spine bone mineral density (premenopausal) / / 23074152 rs4233949 chr2 54659707 C G 1.71E-05 Bone mineral density / / 24249740 rs4233949 chr2 54659707 C G 8.21E-04 Bone mineral density / / 24249740 rs6744982 chr2 54659980 C G 6.10E-06 Urinary metabolites / / 21572414 rs6752877 chr2 54661569 G T 2.90E-08 Bone mineral density (spine) / / 19801982 rs4558622 chr2 54664296 A C 1.70E-05 Urinary metabolites / / 21572414 rs11898505 chr2 54684557 A G 8.00E-07 Bone mineral density (spine) SPTBN1 intron 18445777 rs11898505 chr2 54684557 A G 4.00E-06 Bone mineral density (spine) SPTBN1 intron 19079262 rs11898505 chr2 54684557 A G 2.00E-08 Bone mineral density (spine) SPTBN1 intron 19801982 rs11898505 chr2 54684557 A G 4.00E-13 Bone properties (heel) SPTBN1 intron 24430505 rs11898505 chr2 54684557 A G 6.00E-06 Bone properties (heel) SPTBN1 intron 24430505 rs4557020 chr2 54718181 T C 3.00E-07 Myopia (pathological) SPTBN1 intron 22685421 rs10496031 chr2 54723203 C A 3.39E-04 Parkinson's disease SPTBN1 intron 17052657 rs17045939 chr2 54738233 A C 4.37E-04 Acute lung injury SPTBN1 intron 22295056 rs17045941 chr2 54738392 C G 3.91E-04 Insulin resistance SPTBN1 intron 21901158 rs17045949 chr2 54746887 G C 4.38E-04 Aortic root size SPTBN1 intron 21223598 rs4671950 chr2 54759730 G A 1.00E-04 Prostate cancer SPTBN1 intron 21743057 rs11895933 chr2 54767792 A G 1.00E-04 Prostate cancer SPTBN1 intron 21743057 rs3936082 chr2 54777920 T C 1.38E-04 Multiple complex diseases SPTBN1 intron 17554300 rs4455199 chr2 54792110 T C 7.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPTBN1 intron 20877124 rs4455199 chr2 54792110 T C 3.87E-04 Rheumatoid arthritis SPTBN1 intron 21452313 rs6734445 chr2 54797798 C T 4.44E-05 Bipolar disorder SPTBN1 intron 19488044 rs6734445 chr2 54797798 C T 8.30E-04 Asthma SPTBN1 intron 20698975 rs6734445 chr2 54797798 C T 4.13E-05 Bipolar Disorder SPTBN1 intron pha002863 rs4671961 chr2 54798596 G A 3.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPTBN1 intron 20877124 rs10204932 chr2 54799127 G A 1.83E-05 Sleep duration SPTBN1 intron 22105623 rs7584223 chr2 54818895 T C 6.40E-04 Asthma SPTBN1 intron 20698975 rs7608414 chr2 54844995 G A 9.32E-05 Calcium levels SPTBN1 intron pha003085 rs6545435 chr2 54859403 C T 1.60E-04 Asthma SPTBN1 intron 20698975 rs2941579 chr2 54861825 T C 4.11E-05 Schizophrenia SPTBN1 intron pha002857 rs3106204 chr2 54863352 T G 1.85E-04 Rheumatoid arthritis SPTBN1 intron 21452313 rs966003 chr2 54884870 C T 3.36E-04 Bipolar disorder,affective SPTBN1 intron 20528957 rs2971880 chr2 54885640 T A 2.33E-04 Bipolar disorder,affective SPTBN1 intron 20528957 rs13414727 chr2 54891126 C T 9.17E-04 Multiple complex diseases SPTBN1 intron 17554300 rs2971884 chr2 54904463 G A 7.79E-05 Attention deficit hyperactivity disorder / / pha002875 rs17046149 chr2 54910872 T C 3.06E-05 Bipolar disorder,affective / / 20528957 rs2941577 chr2 54914459 C T 7.89E-04 Type 2 diabetes / / 17463246 rs2941577 chr2 54914459 C T 9.89E-05 Attention deficit hyperactivity disorder / / pha002875 rs6717369 chr2 54915044 T C 2.46E-04 Bipolar disorder,affective / / 20528957 rs6717369 chr2 54915044 T C 8.71E-04 Rheumatoid arthritis / / 21452313 rs6717369 chr2 54915044 T C 3.01E-05 Height / / pha003010 rs6717369 chr2 54915044 T C 6.10E-06 Height / / pha003011 rs4671969 chr2 54915617 T C 1.95E-04 Bipolar disorder,affective / / 20528957 rs2666035 chr2 54938838 T A 4.88E-05 Attention deficit hyperactivity disorder / / pha002875 rs2666036 chr2 54942538 G A 6.64E-05 Height / / pha003010 rs2666036 chr2 54942538 G A 7.97E-05 Height / / pha003011 rs9309258 chr2 54943642 C T 5.97E-04 Acute lung injury / / 22295056 rs17046257 chr2 54949785 G A 4.76E-04 Acute lung injury / / 22295056 rs6732751 chr2 54957416 G A 7.22E-05 Bipolar disorder,affective EML6 intron 20528957 rs6732751 chr2 54957416 G A 6.84E-04 Acute lung injury EML6 intron 22295056 rs7582640 chr2 54957773 C T 4.77E-04 Acute lung injury EML6 intron 22295056 rs6708082 chr2 54958830 A G 1.23E-04 Bipolar disorder,affective EML6 intron 20528957 rs6708082 chr2 54958830 A G 4.77E-04 Acute lung injury EML6 intron 22295056 rs6740110 chr2 54959092 C G 1.36E-04 Bipolar disorder,affective EML6 intron 20528957 rs6740110 chr2 54959092 C G 4.77E-04 Acute lung injury EML6 intron 22295056 rs10169439 chr2 54959690 T C 4.17E-04 Acute lung injury EML6 intron 22295056 rs6545440 chr2 54959862 A T 4.77E-04 Acute lung injury EML6 intron 22295056 rs13428703 chr2 54960680 G A 4.65E-04 Acute lung injury EML6 intron 22295056 rs6752720 chr2 54962352 G A 8.29E-04 Acute lung injury EML6 intron 22295056 rs6753004 chr2 54962723 C A 8.29E-04 Acute lung injury EML6 intron 22295056 rs10194108 chr2 54964021 A G 6.20E-04 Acute lung injury EML6 intron 22295056 rs13401661 chr2 54972648 C T 8.69E-05 Pancreatic cancer EML6 intron pha002889 rs2631835 chr2 54975471 T C 9.92E-05 Multiple complex diseases EML6 intron 17554300 rs1848924 chr2 54976770 A G 2.05E-04 Multiple complex diseases EML6 intron 17554300 rs12615703 chr2 54987142 C A 3.92E-04 Multiple complex diseases EML6 intron 17554300 rs17046292 chr2 54991442 A T 6.51E-04 Multiple complex diseases EML6 intron 17554300 rs4671975 chr2 54991712 G A 4.78E-04 Multiple complex diseases EML6 intron 17554300 rs2116441 chr2 54995746 A G 1.00E-04 Multiple complex diseases EML6 intron 17554300 rs2116441 chr2 54995746 A G 8.58E-04 Taste perception EML6 intron 22132133 rs165051 chr2 55019723 C G 9.51E-04 Multiple complex diseases EML6 intron 17554300 rs2578715 chr2 55034113 C T 1.66E-06 Height EML6 intron pha003010 rs2578715 chr2 55034113 C T 2.30E-05 Height EML6 intron pha003011 rs2631837 chr2 55038830 A G 1.09E-07 Height EML6 intron pha003010 rs2631837 chr2 55038830 A G 8.19E-06 Height EML6 intron pha003011 rs2567839 chr2 55042463 A G 9.59E-05 Height EML6 intron pha003010 rs2567839 chr2 55042463 A G 7.89E-05 Height EML6 intron pha003011 rs2567840 chr2 55046042 C T 8.38E-05 Height EML6 intron pha003010 rs10197243 chr2 55052493 C T 1.50E-05 Urinary metabolites EML6 intron 21572414 rs17046387 chr2 55052949 T G 2.75E-04 Type 2 diabetes EML6 intron 17463246 rs1549840 chr2 55063113 C T 4.68E-04 Multiple complex diseases EML6 intron 17554300 rs10173697 chr2 55066310 T C 4.00E-05 Type 2 diabetes EML6 intron 17460697 rs2116435 chr2 55072474 G A 6.33E-05 Heart Rate EML6 intron pha003053 rs4613325 chr2 55073464 G A 3.07E-04 Alzheimer's disease EML6 intron 17998437 rs12465327 chr2 55074429 C A 9.38E-05 Suicide attempts in bipolar disorder EML6 intron 21423239 rs2165006 chr2 55075394 T C 1.64E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs6545449 chr2 55076441 T C 3.05E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs12713278 chr2 55077061 A G 1.20E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs4671979 chr2 55079242 G T 9.34E-05 Suicide attempts in bipolar disorder EML6 intron 21423239 rs13033818 chr2 55079388 C T 2.80E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs13033668 chr2 55079454 A G 4.56E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs2033411 chr2 55079654 A T 1.12E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs12713280 chr2 55081376 C T 6.00E-06 Economic and political preferences EML6 intron 22566634 rs7596552 chr2 55082903 T G 1.44E-05 Suicide attempts in bipolar disorder EML6 intron 21423239 rs10496033 chr2 55084583 C T 8.00E-06 Suicide attempts in bipolar disorder EML6 intron 21423239 rs10188555 chr2 55086183 T C 7.73E-06 Suicide attempts in bipolar disorder EML6 intron 21423239 rs1371020 chr2 55087887 C T 5.06E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs1371020 chr2 55087887 C T 0.0007356 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) EML6 intron 23233654 rs1371020 chr2 55087887 C T 7.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) EML6 intron 23233662 rs2358155 chr2 55091029 C T 1.81E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs6545450 chr2 55091223 A C 5.43E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs2006878 chr2 55091375 G A 2.90E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs723975 chr2 55092926 G A 2.96E-05 Personality dimensions EML6 intron 22628180 rs17417731 chr2 55093784 T A 2.75E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs4671981 chr2 55093859 C G 2.91E-05 Personality dimensions EML6 intron 22628180 rs11677058 chr2 55097549 A G 6.76E-05 Cognitive test performance EML6 intron 20125193 rs13385982 chr2 55103265 G T 2.07E-04 Alcohol dependence EML6 intron 20201924 rs2163618 chr2 55111689 G A 3.04E-04 Alcohol dependence EML6 intron 20201924 rs10171653 chr2 55127601 A G 0.0000923 Carotid intima media thickness EML6 intron 23152477 rs7355716 chr2 55133564 G A 1.47E-04 Acute lymphoblastic leukemia (childhood) EML6 intron 22076464 rs4671992 chr2 55134309 C T 9.22E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs2304685 chr2 55144103 C G 8.49E-04 Bipolar disorder EML6 intron 19259986 rs10176018 chr2 55153731 A G 3.98E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs6726292 chr2 55156630 G A 1.00E-06 Obesity (extreme) EML6 intron 19553259 rs13394146 chr2 55176112 C T 5.43E-04 Suicide attempts in bipolar disorder EML6 intron 21423239 rs10746530 chr2 55181893 G A 1.25E-04 Scoliosis EML6 intron 21216876 rs11898145 chr2 55182968 C A 5.23E-05 Orofacial clefts EML6 intron 22419666 rs7584992 chr2 55183627 G A 1.62E-05 Height EML6 intron pha003010 rs17046514 chr2 55185862 G A 1.70E-05 Urinary metabolites EML6 intron 21572414 rs12623902 chr2 55186229 T C 7.04E-04 Obesity (extreme) EML6 intron 21935397 rs17346629 chr2 55186394 A C 7.04E-04 Obesity (extreme) EML6 cds-synon 21935397 rs6741304 chr2 55188195 G A 4.96E-04 Obesity (extreme) EML6 intron 21935397 rs2255112 chr2 55200800 T G 4.42E-04 Smoking initiation RTN4 intron 24665060 rs2580765 chr2 55204028 A C 4.29E-04 Smoking initiation RTN4 intron 24665060 rs2580770 chr2 55214912 C G 7.35E-04 Multiple complex diseases RTN4 intron 17554300 rs2580771 chr2 55215825 G A 1.64E-04 Multiple complex diseases RTN4 intron 17554300 rs2919129 chr2 55216545 C A 1.52E-04 Smoking initiation RTN4 intron 24665060 rs2580772 chr2 55218805 G T 1.64E-04 Smoking initiation RTN4 intron 24665060 rs17046570 chr2 55220584 C T 9.62E-05 Coronary heart disease RTN4 intron 24778558 rs6755468 chr2 55240026 A C 3.35E-04 Smoking initiation RTN4 intron 24665060 rs10496037 chr2 55257677 C T 4.79E-05 Triglycerides RTN4 intron pha003081 rs2968794 chr2 55290651 G C 1.45E-04 Smoking initiation / / 24665060 rs7575107 chr2 55305986 T G 7.86E-04 Acute lung injury / / 22295056 rs6724138 chr2 55314518 G A 4.05E-04 Endometrial cancer / / 24096698 rs6724138 chr2 55314518 G A 7.82E-05 Endometrial cancer / / 24096698 rs12464796 chr2 55327407 C T 2.52E-05 HDL cholesterol / / pha003075 rs12464877 chr2 55327550 G T 4.10E-06 HDL cholesterol / / pha003075 rs2968778 chr2 55338420 C T 4.18E-05 HDL cholesterol / / pha003075 rs10496039 chr2 55346785 T C 3.88E-05 HDL cholesterol / / pha003075 rs11892071 chr2 55349726 A C 7.50E-06 Hypertension / / pha003041 rs10168457 chr2 55357427 C T 3.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7349405 chr2 55391294 C A 2.37E-04 Insulin resistance / / 21901158 rs7349405 chr2 55391294 C A 6.94E-05 Hypertension / / pha003041 rs1133182 chr2 55402225 C T 8.43E-04 Multiple complex diseases C2orf63 UTR-3 17554300 rs7588591 chr2 55418935 C A 2.00E-06 Bipolar disorder (body mass index interaction) C2orf63 intron 24322204 rs1437391 chr2 55446356 A G 3.47E-04 IgE levels C2orf63 intron 17255346 rs1561231 chr2 55455867 T C 9.68E-04 Weight loss (gastric bypass surgery) C2orf63 intron 23643386 rs17046820 chr2 55510799 A T 2.92E-04 Multiple complex diseases / / 17554300 rs2589113 chr2 55516323 T G 2.00E-08 Height CCDC88A UTR-3 21998595 rs6746287 chr2 55538097 A G 0.0006513 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CCDC88A intron 23233654 rs6746287 chr2 55538097 A G 6.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) CCDC88A intron 23233662 rs10518764 chr2 55576469 T C 6.84E-06 Multiple complex diseases CCDC88A intron 17554300 rs3861571 chr2 55582236 G A 1.90E-05 Lipid levels CCDC88A intron 19016617 rs3861571 chr2 55582236 G A 2.84E-06 Lipid levels CCDC88A intron 19016617 rs3861571 chr2 55582236 G A 5.58E-04 Lipid levels CCDC88A intron 19016617 rs17046963 chr2 55600755 T C 3.03E-04 Multiple complex diseases CCDC88A intron 17554300 rs4672035 chr2 55636351 T C 1.94E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCDC88A intron 20877124 rs4672040 chr2 55640649 G A 6.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCDC88A intron 20877124 rs4672045 chr2 55658147 G A 4.46E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13028756 chr2 55668771 A C 7.80E-04 Multiple complex diseases / / 17554300 rs7593229 chr2 55680496 G A 6.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6719033 chr2 55684494 C T 1.01E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1037509 chr2 55687597 C T 2.13E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4671246 chr2 55688713 C T 1.96E-04 Dental caries / / 21940522 rs13032503 chr2 55739093 C T 6.57E-05 Mammographic density / / 22532574 rs12992408 chr2 55749085 T G 7.18E-05 Blood Pressure CCDC104 intron pha002903 rs10496050 chr2 55806313 C T 1.28E-05 Blood Pressure SMEK2 intron pha002903 rs782586 chr2 55836165 A C 1.20E-06 Blood Pressure SMEK2 intron pha002903 rs782588 chr2 55841640 T C 1.23E-06 Blood Pressure SMEK2 intron pha002903 rs782588 chr2 55841640 T C 9.80E-05 Weight SMEK2 intron pha003027 rs782590 chr2 55843413 C T 4.00E-08 Metabolic syndrome SMEK2 intron 22399527 rs2291336 chr2 55845351 T A,C 9.14E-05 Coronary Artery Disease / / 17634449 rs782602 chr2 55849309 A G 8.02E-07 Blood Pressure / / pha002903 rs706548 chr2 55850106 C G 4.80E-04 Height / / 21998595 rs2627759 chr2 55853341 T C 5.00E-06 Blood Pressure / / pha002903 rs782652 chr2 55862775 C A 9.38E-06 Blood Pressure PNPT1 UTR-3 pha002903 rs1373228 chr2 55871285 G A 2.17E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PNPT1 intron 20031582 rs2627775 chr2 55877113 C T 7.58E-05 Weight PNPT1 intron pha003027 rs2627775 chr2 55877113 C T 4.99E-05 ldl cholesterol PNPT1 intron pha003077 rs7559307 chr2 55882672 T C 8.24E-04 Multiple complex diseases PNPT1 intron 17554300 rs6545513 chr2 55884864 G A 4.94E-04 Multiple complex diseases PNPT1 intron 17554300 rs782606 chr2 55886602 T C 5.82E-06 Blood Pressure PNPT1 intron pha002903 rs782606 chr2 55886602 T C 2.70E-05 Weight PNPT1 intron pha003027 rs7575170 chr2 55886780 C T 5.42E-05 Weight PNPT1 intron pha003027 rs7575170 chr2 55886780 C T 2.66E-05 Cardiovascular disease PNPT1 intron pha003065 rs2586954 chr2 55892261 A C 1.40E-05 Blood Pressure PNPT1 intron pha002903 rs2586954 chr2 55892261 A C 2.17E-05 Weight PNPT1 intron pha003027 rs782637 chr2 55894247 T C 2.68E-05 Blood Pressure PNPT1 intron pha002903 rs12474717 chr2 55943217 G T 2.98E-05 Suicide attempts in bipolar disorder / / 21041247 rs4672066 chr2 55956223 A G 7.17E-06 Lung function (forced vital capacity) / / 24929828 rs4672066 chr2 55956223 A G 2.93E-04 Heart Failure / / pha002884 rs10178492 chr2 55958891 T C 1.20E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2163237 chr2 55973732 C T 5.00E-06 IgG glycosylation / / 23382691 rs1583116 chr2 55983929 C T 3.43E-06 Left ventricular mass / / 21212386 rs1583116 chr2 55983929 C T 6.67E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1579496 chr2 55986436 C A,G,T 2.93E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4672069 chr2 55987857 C G 8.28E-06 Lung function (forced vital capacity) / / 24929828 rs4233963 chr2 55988293 T C 4.12E-05 Lung function (forced vital capacity) / / 24929828 rs11694759 chr2 55988681 T G 1.80E-05 Lung function (forced vital capacity) / / 24929828 rs11887339 chr2 55988948 A G 1.96E-05 Lung function (forced vital capacity) / / 24929828 rs1961386 chr2 55992905 A G 1.31E-05 Lung function (forced vital capacity) / / 24929828 rs934274 chr2 55994818 A G 5.85E-06 Lung function (forced vital capacity) / / 24929828 rs934275 chr2 55994856 T C 6.88E-06 Lung function (forced vital capacity) / / 24929828 rs11693187 chr2 55996787 G A 5.91E-06 Lung function (forced vital capacity) / / 24929828 rs11676678 chr2 55996959 T A 3.42E-06 Lung function (forced vital capacity) / / 24929828 rs13404193 chr2 55997646 A G 2.96E-05 Lung function (forced vital capacity) / / 24929828 rs11694790 chr2 55997871 C T 1.16E-06 Lung function (forced vital capacity) / / 24929828 rs934276 chr2 55998008 T C 1.80E-06 Lung function (forced vital capacity) / / 24929828 rs934277 chr2 55998173 C T 1.14E-06 Lung function (forced vital capacity) / / 24929828 rs12614845 chr2 55998590 T C 1.29E-06 Lung function (forced vital capacity) / / 24929828 rs11684982 chr2 55998850 A T 1.80E-06 Lung function (forced vital capacity) / / 24929828 rs4671259 chr2 56000183 A G 7.24E-06 Lung function (forced vital capacity) / / 24929828 rs7560508 chr2 56002372 C T 3.55E-05 Lung function (forced vital capacity) / / 24929828 rs1430198 chr2 56002404 G A 3.55E-05 Lung function (forced vital capacity) / / 24929828 rs1430199 chr2 56002685 G A 1.16E-06 Lung function (forced vital capacity) / / 24929828 rs1430200 chr2 56002923 T C 2.90E-06 Lung function (forced vital capacity) / / 24929828 rs9309269 chr2 56003053 G A 3.24E-06 Lung function (forced vital capacity) / / 24929828 rs6742316 chr2 56003988 A T 3.75E-05 Lung function (forced vital capacity) / / 24929828 rs6723918 chr2 56004139 A G 3.89E-05 Lung function (forced vital capacity) / / 24929828 rs7577894 chr2 56008904 T C 1.00E-06 Amyotrophic lateral sclerosis / / 19451621 rs11125600 chr2 56009670 C G 3.50E-05 Lung function (forced vital capacity) / / 24929828 rs9309270 chr2 56010084 T C 3.33E-06 Lung function (forced vital capacity) / / 24929828 rs77406423 chr2 56010606 A C 3.56E-05 Lung function (forced vital capacity) / / 24929828 rs7602081 chr2 56020185 T C 6.59E-06 Lung function (forced vital capacity) / / 24929828 rs1430191 chr2 56033427 C T 1.05E-05 Lung function (forced vital capacity) / / 24929828 rs10196888 chr2 56036226 A G 1.06E-04 Suicide attempts in bipolar disorder / / 21041247 rs10196888 chr2 56036226 A G 7.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs1346781 chr2 56037076 C T 5.73E-06 Lung function (forced vital capacity) / / 24929828 rs6723695 chr2 56038066 T C 1.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs6723695 chr2 56038066 T C 7.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs7577580 chr2 56038729 T G 1.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs7577580 chr2 56038729 T G 7.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs6730839 chr2 56048107 G C 1.53E-06 Height / / 22216288 rs6759150 chr2 56048194 A T 2.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs6759150 chr2 56048194 A T 8.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs13394642 chr2 56049955 A G 1.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs13394642 chr2 56049955 A G 8.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs11903784 chr2 56052485 G T 3.87E-05 Lung function (forced vital capacity) / / 24929828 rs1594308 chr2 56054052 T G 3.65E-05 Lung function (forced vital capacity) / / 24929828 rs6733730 chr2 56054216 G C 1.92E-06 Lung function (forced vital capacity) / / 24929828 rs6545526 chr2 56055436 T G 1.90E-06 Lung function (forced vital capacity) / / 24929828 rs143080645 chr2 56059152 T C 3.11E-05 Lung function (forced vital capacity) / / 24929828 rs57692404 chr2 56060659 C T 3.00E-05 Lung function (forced vital capacity) / / 24929828 rs543949007 chr2 56061295 CT C 6.74E-06 Lung function (forced vital capacity) / / 24929828 rs7609520 chr2 56061295 C T 6.74E-06 Lung function (forced vital capacity) / / 24929828 rs148288741 chr2 56063907 A T 2.79E-05 Lung function (forced vital capacity) / / 24929828 rs116371971 chr2 56065354 C G 2.72E-05 Lung function (forced vital capacity) / / 24929828 rs1430201 chr2 56069405 T A 2.90E-05 Lung function (forced vital capacity) / / 24929828 rs934278 chr2 56070352 G A 2.56E-06 Lung function (forced vital capacity) / / 24929828 rs6545527 chr2 56073809 T C 4.05E-06 Lung function (forced vital capacity) / / 24929828 rs6743114 chr2 56074525 A G 9.28E-06 Lung function (forced vital capacity) / / 24929828 rs7607070 chr2 56078417 A T 3.36E-06 Lung function (forced vital capacity) / / 24929828 rs116212307 chr2 56078555 G A 4.23E-05 Lung function (forced vital capacity) / / 24929828 rs11694213 chr2 56088667 T A 8.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1367226 chr2 56089540 A G 4.00E-08 Height / / 20881960 rs1367226 chr2 56089540 A G 2.26E-06 Lung function (forced vital capacity) / / 24929828 rs11125607 chr2 56090113 T A 4.39E-06 Lung function (forced vital capacity) / / 24929828 rs17047272 chr2 56090337 A G 4.35E-05 Lung function (forced vital capacity) / / 24929828 rs1346787 chr2 56092612 C T 4.53E-04 Alzheimer's disease (late onset) EFEMP1 nearGene-3 21379329 rs1346787 chr2 56092612 C T 6.12E-06 Lung function (forced vital capacity) EFEMP1 nearGene-3 24929828 rs77784128 chr2 56094394 G A 2.98E-05 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs3791679 chr2 56096892 A G 6.00E-11 Height EFEMP1 intron 18391951 rs3791679 chr2 56096892 A G 6.00E-09 Height EFEMP1 intron 20189936 rs3791679 chr2 56096892 A G 1.71E-06 Osteoarthritis EFEMP1 intron 22763110 rs3791679 chr2 56096892 A G 8.00E-16 Height EFEMP1 intron 23563607 rs17047275 chr2 56098569 G C 4.89E-04 Multiple complex diseases EFEMP1 intron 17554300 rs75943405 chr2 56099672 G A 1.09E-05 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs17047277 chr2 56100846 C G 3.68E-06 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs17047281 chr2 56102552 T C 2.02E-05 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs75915915 chr2 56107760 C T 1.78E-05 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs74968080 chr2 56107904 A G 1.64E-05 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs78077363 chr2 56107976 C T 3.46E-06 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs3791675 chr2 56111309 C T 2.00E-12 Height EFEMP1 intron 18391952 rs3791675 chr2 56111309 C T 2.00E-09 Height EFEMP1 intron 19396169 rs3791675 chr2 56111309 C T 4.00E-06 Height EFEMP1 intron 19893584 rs3791675 chr2 56111309 C T 3.00E-07 Height EFEMP1 intron 20397748 rs3791675 chr2 56111309 C T 3.00E-35 Height EFEMP1 intron 20881960 rs17047300 chr2 56112168 G A 1.20E-05 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs1367228 chr2 56112440 C A 2.00E-09 Venous thromboembolism (gene x gene interaction) EFEMP1 intron 23509962 rs75000414 chr2 56113746 C T 6.24E-06 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs10496055 chr2 56115859 G A 1.08E-05 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs1430193 chr2 56120853 A T 2.00E-12 Lung function (forced vital capacity) EFEMP1 intron 24929828 rs4487120 chr2 56132276 A T 5.46E-04 Multiple complex diseases EFEMP1 intron 17554300 rs7559906 chr2 56133040 C T 5.65E-04 Multiple complex diseases EFEMP1 intron 17554300 rs2033316 chr2 56140531 A G 7.30E-05 Alcoholism (heaviness of drinking) EFEMP1 intron 21529783 rs3762515 chr2 56150864 C T 9.50E-05 White matter hyperintensity burden EFEMP1 UTR-5 21681796 rs2868440 chr2 56158646 C T 3.75E-05 Lung function (forced vital capacity) / / 24929828 rs7563487 chr2 56163875 C T 3.21E-05 Lung function (forced vital capacity) / / 24929828 rs12617071 chr2 56166830 T G 2.80E-05 Lung function (forced vital capacity) / / 24929828 rs17047337 chr2 56166944 C A 3.60E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs557947133 chr2 56166944 C CT 3.60E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs17278953 chr2 56167809 G A 7.21E-04 Multiple complex diseases / / 17554300 rs11694304 chr2 56182118 G C 5.03E-07 Lung function (forced vital capacity) / / 24929828 rs72811742 chr2 56182666 C T 1.83E-05 Lung function (forced vital capacity) / / 24929828 rs6749890 chr2 56183651 C G 1.30E-05 Lung function (forced vital capacity) / / 24929828 rs17279016 chr2 56183856 C T 1.58E-06 Lung function (forced vital capacity) / / 24929828 rs2163714 chr2 56184748 C A 4.31E-05 Lung function (forced vital capacity) / / 24929828 rs17279030 chr2 56185872 A C 9.42E-04 Multiple complex diseases / / 17554300 rs1432562 chr2 56186182 G A 9.63E-07 Lung function (forced vital capacity) / / 24929828 rs1465684 chr2 56186525 C A 4.04E-05 Lung function (forced vital capacity) / / 24929828 rs62164511 chr2 56195696 A G 2.00E-07 Lung function (forced vital capacity) / / 24929828 rs17279203 chr2 56198160 T C 1.65E-04 Multiple complex diseases / / 17554300 rs17047369 chr2 56198401 A G 3.54E-04 Obesity (extreme) / / 21935397 rs6545535 chr2 56214516 A G 9.34E-05 Blood Pressure / / pha002903 rs7558150 chr2 56216904 T G 4.64E-04 Multiple complex diseases / / 17554300 rs13029542 chr2 56228351 C T 4.30E-04 Alcohol dependence / / 20201924 rs4672084 chr2 56229384 C T 1.31E-04 Alzheimer's disease (late onset) / / 21379329 rs6741589 chr2 56239995 C T 9.08E-04 Alzheimer's disease / / 22005930 rs4553860 chr2 56244096 A G 4.90E-04 Alcohol dependence / / 20201924 rs1347093 chr2 56246340 G T 4.50E-04 Alcohol dependence / / 20201924 rs1347093 chr2 56246340 G T 4.10E-04 Alzheimer's disease / / 22005930 rs10469875 chr2 56261491 G C 2.28E-05 Lung function (forced vital capacity) / / 24929828 rs1432547 chr2 56300279 A G 3.66E-04 Type 2 diabetes / / 17463246 rs10166672 chr2 56330148 A G 8.05E-04 Alzheimer's disease / / 22005930 rs10210015 chr2 56332639 T C 8.54E-04 Alzheimer's disease / / 22005930 rs2868993 chr2 56335979 C T 7.90E-05 HIV-1 control / / 20041166 rs17268563 chr2 56361233 G A 1.72E-04 Multiple complex diseases / / 17554300 rs6751715 chr2 56363377 T C 1.00E-06 HIV-1 control / / 20041166 rs2111469 chr2 56376308 C T 8.58E-05 Serum metabolites / / 19043545 rs2111469 chr2 56376308 C T 4.90E-05 HIV-1 control / / 20041166 rs11685990 chr2 56381388 T C 3.67E-05 Height / / 22021425 rs17190037 chr2 56381660 C T 3.43E-05 Type 2 diabetes / / 17463246 rs10176451 chr2 56396433 C T 8.03E-04 HIV-1 viral setpoint / / 17641165 rs13024922 chr2 56398230 A C,T 2.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13024922 chr2 56398230 A C,T 9.78E-04 Heart Failure / / pha002884 rs1861774 chr2 56402808 A C 5.71E-05 Information processing speed / / 21130836 rs1861774 chr2 56402808 A C 3.53E-05 Heart Rate / / pha003053 rs7423933 chr2 56415771 G A 2.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCDC85A intron 20877124 rs1016339 chr2 56421972 C T 2.65E-04 Alzheimer's disease (late onset) CCDC85A intron 21379329 rs1016339 chr2 56421972 C T 1.03E-04 Longevity CCDC85A intron 22279548 rs12613794 chr2 56425702 C T 8.00E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCDC85A intron 20877124 rs17190086 chr2 56435657 G T 7.89E-04 Smoking initiation CCDC85A intron 24665060 rs17047588 chr2 56436865 G C 2.17E-04 Multiple complex diseases CCDC85A intron 17554300 rs10490395 chr2 56448266 A C 4.70E-04 Crohn's disease CCDC85A intron 17684544 rs17268688 chr2 56454266 C T 7.50E-05 Major depressive disorder CCDC85A intron 21042317 rs12996636 chr2 56461523 A T 6.60E-05 Parkinson's disease (age of onset) CCDC85A intron 19772629 rs4672101 chr2 56475484 G A,C 0.0000329 Colorectal adenoma (excluding hyperplasic) CCDC85A intron 23677573 rs4672101 chr2 56475484 G A,C 0.0000329 Colorectal adenoma (including hyperplasic) CCDC85A intron 23677573 rs759615 chr2 56480571 C T 5.11E-05 Multiple complex diseases CCDC85A intron 17554300 rs1468914 chr2 56480917 G A 8.74E-05 Multiple complex diseases CCDC85A intron 17554300 rs13016868 chr2 56488460 T G 0.000164 Salmonella-induced pyroptosis CCDC85A intron 22837397 rs13004757 chr2 56490661 C A 4.10E-06 Recombination rate CCDC85A intron 21698098 rs214042 chr2 56502903 A C 1.26E-04 Major depressive disorder CCDC85A intron 22472876 rs7603700 chr2 56525027 C A 6.98E-04 Multiple complex diseases CCDC85A intron 17554300 rs9808416 chr2 56563822 C T 2.00E-05 Alcoholism (heaviness of drinking) CCDC85A intron 21529783 rs7561980 chr2 56585774 A G 1.44E-04 Lung function (forced expiratory volume in 1 second) CCDC85A intron 24023788 rs10168390 chr2 56589215 C T 4.29E-04 Multiple complex diseases CCDC85A intron 17554300 rs17268785 chr2 56592083 A G 1.00E-10 Menarche (age at onset) CCDC85A intron 21102462 rs17047854 chr2 56598309 G A 5.80E-04 Menarche (age at onset) CCDC85A intron 23599027 rs17047859 chr2 56600669 A C 1.55E-04 Alcohol dependence CCDC85A intron 21314694 rs2193488 chr2 56608816 G A 7.21E-04 Alcohol consumption (maxi-drinks) CCDC85A intron 24277619 rs17047868 chr2 56609371 G A 6.00E-05 Alcohol dependence CCDC85A intron 22096494 rs11902680 chr2 56611725 C A 5.67E-04 Alcohol consumption (maxi-drinks) CCDC85A UTR-3 24277619 rs41449651 chr2 56615699 G A 4.95E-04 Multiple complex diseases / / 17554300 rs7563921 chr2 56619366 T A 1.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4671281 chr2 56628301 A T 3.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17038123 chr2 56629071 C A 5.80E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs17038122 chr2 56629093 A G 3.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11694963 chr2 56638627 T C 6.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7582028 chr2 56638856 C T 7.43E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7582028 chr2 56638856 C T 8.48E-05 Blood Pressure / / pha003043 rs7600814 chr2 56643955 C T 5.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1861776 chr2 56656894 A G 1.84E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs10202807 chr2 56666949 T C 1.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1117260 chr2 56667121 T C 6.63E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2869826 chr2 56669447 A G 7.23E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs956157 chr2 56673449 T C 4.40E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs986787 chr2 56676363 G A 6.18E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs11885335 chr2 56679612 G A 2.05E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17047946 chr2 56680920 G T 1.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13397156 chr2 56682547 C A 2.82E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13397156 chr2 56682547 C A 2.64E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs4614971 chr2 56687629 G A 5.23E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1465360 chr2 56688264 A G 3.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1465359 chr2 56688330 A G 1.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17047975 chr2 56688397 A G 7.40E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs13382678 chr2 56689048 G A 1.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10193613 chr2 56695597 A C 5.21E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1017272 chr2 56696778 C T 4.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1030334 chr2 56700945 C G,T 6.66E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1030333 chr2 56701022 C A 4.59E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs17047986 chr2 56701657 T C 6.00E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10490404 chr2 56702495 C T 5.98E-05 Multiple complex diseases / / 17554300 rs10490404 chr2 56702495 C T 1.60E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2033015 chr2 56702871 T A 2.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs879807 chr2 56708945 G A 2.64E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2113866 chr2 56716928 A C 9.82E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13406625 chr2 56722007 T C 7.40E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs890100 chr2 56734035 C A 6.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs890099 chr2 56734070 G A 2.32E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs982116 chr2 56739650 A G 9.01E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7605943 chr2 56741751 T A 2.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17048045 chr2 56743132 T G 9.03E-04 Multiple complex diseases / / 17554300 rs2162025 chr2 56746396 A T 2.62E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10490407 chr2 56746524 C T 9.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9309282 chr2 56746631 C T 7.69E-13 Metabolite levels / / 22286219 rs17268931 chr2 56750209 C T 2.53E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs987576 chr2 56752025 A G 6.25E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1477521 chr2 56754479 T C 3.81E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6718973 chr2 56756857 T C 2.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7580218 chr2 56759264 T G 2.06E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7580549 chr2 56759547 T C 1.46E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1304899 chr2 56759863 C G 1.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2870064 chr2 56760592 A G 5.37E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4671282 chr2 56761626 A G 6.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4672130 chr2 56761998 A G 2.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs996846 chr2 56764646 A G 1.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1160085 chr2 56765050 G A 8.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1156972 chr2 56765635 A C 2.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17048108 chr2 56766538 C A 9.64E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1156672 chr2 56770848 C T 2.24E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17039629 chr2 56771307 C A 6.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17190394 chr2 56771330 T C 3.16E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10490411 chr2 56772337 T C 1.40E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10208385 chr2 56778009 C T 4.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10210929 chr2 56778360 C T 5.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6721009 chr2 56778687 A T 6.52E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2194794 chr2 56787100 C T 5.38E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6719712 chr2 56788339 A G 4.76E-04 Insulin resistance / / 21901158 rs6719808 chr2 56788428 A G 9.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17048168 chr2 56792506 T C 2.62E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2162024 chr2 56798007 A G 2.51E-04 Type 2 diabetes / / 17463246 rs17048179 chr2 56798398 G A 3.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4672140 chr2 56798910 G A 2.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11125642 chr2 56814463 G T 2.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2870066 chr2 56822558 C A 3.47E-04 Rheumatoid arthritis / / 21452313 rs2112027 chr2 56836621 T C 8.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs737030 chr2 56843605 G A 3.03E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6545584 chr2 56849161 G A 4.37E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6722231 chr2 56854346 A C 5.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6757997 chr2 56896324 C T 7.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6728372 chr2 56899555 T C 8.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17269015 chr2 56906260 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2042119 chr2 56924658 A G 5.61E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4672150 chr2 56928639 G A 3.23E-05 Coronary heart disease / / pha003056 rs10200459 chr2 56940693 G A 2.51E-04 Smoking cessation / / 24665060 rs2682843 chr2 56974139 A G 2.60E-05 Urinary metabolites / / 21572414 rs17696789 chr2 57015668 T G 1.30E-05 Platelet counts / / 21507922 rs17697039 chr2 57022855 T C 3.26E-05 Brain structure / / 22504417 rs1468958 chr2 57041772 T C 8.06E-05 Schizophrenia / / pha002859 rs1023598 chr2 57051996 G A 9.64E-04 Response to alcohol consumption (flushing response) / / 24277619 rs2111724 chr2 57091538 C T 7.60E-06 Urinary metabolites / / 21572414 rs2111724 chr2 57091538 C T 7.38E-05 Asthma / / 23181788 rs11125665 chr2 57093359 G T 1.93E-04 Parkinson's disease / / 21248740 rs768329 chr2 57098139 C T 5.44E-04 Smoking initiation / / 24665060 rs6545606 chr2 57101446 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6545606 chr2 57101446 G A 1.74E-06 Elbow pain / / pha003008 rs12479315 chr2 57107235 A G 1.86E-05 Serum alpha1-antitrypsin levels / / 23990791 rs2216407 chr2 57110146 C A 1.92E-05 Serum alpha1-antitrypsin levels / / 23990791 rs12467061 chr2 57128280 C T 1.97E-04 Parkinson's disease / / 21248740 rs13021125 chr2 57135241 A G 1.40E-04 Parkinson's disease / / 21248740 rs7589657 chr2 57147590 C T 4.24E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs10183114 chr2 57148302 A G 4.92E-04 Multiple complex diseases / / 17554300 rs17048515 chr2 57158169 G A 2.24E-04 Multiple complex diseases / / 17554300 rs2865267 chr2 57167414 G T 6.45E-04 Multiple complex diseases / / 17554300 rs7578236 chr2 57174489 C T 8.15E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs7578236 chr2 57174489 C T 8.58E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs2865272 chr2 57178928 T C 9.38E-05 Elbow pain / / pha003008 rs17048557 chr2 57192672 C G 1.61E-04 Multiple complex diseases / / 17554300 rs2163048 chr2 57225631 A G 1.00E-04 Information processing speed / / 21130836 rs1424642 chr2 57296558 A C 1.34E-07 Type 2 diabetes / / 23945395 rs7557284 chr2 57341448 G A 6.14E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1424646 chr2 57345571 T G 5.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17189459 chr2 57368572 T C 8.92E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs368972698 chr2 57368572 T TTTTTAGATACTGAAAGTATGTTTCCA 8.92E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs56913484 chr2 57368572 T TTTTTAGATACTGAAAGTATGTTTCCA 8.92E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs989586 chr2 57382439 A G 8.48E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs966115 chr2 57387855 G T 2.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6545625 chr2 57393245 C T 2.98E-04 Body mass index / / 17255346 rs1424626 chr2 57394885 A T 4.44E-05 Aortic root size / / 21223598 rs1424627 chr2 57396264 C T 5.93E-05 Elbow pain / / pha003008 rs6545627 chr2 57397423 T C 7.29E-05 Elbow pain / / pha003008 rs1424638 chr2 57407649 T C 5.68E-05 Body mass index / / 17255346 rs7604249 chr2 57436631 T C 9.01E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs4233968 chr2 57487947 G A 3.20E-05 Cardiovascular disease / / pha003065 rs17048747 chr2 57532112 A G 0.0002066 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17048747 chr2 57532112 A G 2.07E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10204326 chr2 57589477 A G 4.94E-04 Smoking initiation / / 24665060 rs1401257 chr2 57626992 G T 3.65E-04 Alzheimer's disease / / 24755620 rs1518684 chr2 57627453 A G 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7597800 chr2 57665438 T C 9.37E-04 Alzheimer's disease / / 17998437 rs6746641 chr2 57668829 C A 7.52E-06 Height / / 20400458 rs7589636 chr2 57690033 A G 3.98E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs17048844 chr2 57696957 T C 4.53E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs17048844 chr2 57696957 T C 7.02E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs1518685 chr2 57703467 C T 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs820951 chr2 57738696 A G 1.12E-04 Alzheimer's disease / / 22005930 rs820950 chr2 57738723 G A 1.31E-04 Alzheimer's disease / / 22005930 rs820949 chr2 57738847 T A 1.92E-04 Alzheimer's disease / / 22005930 rs1881020 chr2 57739441 G A 9.19E-05 Alzheimer's disease / / 22005930 rs820984 chr2 57757646 A G 7.99E-04 Alzheimer's disease / / 22005930 rs13392012 chr2 57763213 T C 3.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs13392012 chr2 57763213 T C 7.63E-05 Suicide attempts in bipolar disorder / / 21041247 rs6746753 chr2 57763858 G C 3.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs6746753 chr2 57763858 G C 8.13E-05 Suicide attempts in bipolar disorder / / 21041247 rs13389335 chr2 57764968 A T 3.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs13389335 chr2 57764968 A T 7.60E-05 Suicide attempts in bipolar disorder / / 21041247 rs13410921 chr2 57771012 A C 3.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs13410921 chr2 57771012 A C 7.59E-05 Suicide attempts in bipolar disorder / / 21041247 rs9309297 chr2 57771807 G C 3.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs9309297 chr2 57771807 G C 7.81E-05 Suicide attempts in bipolar disorder / / 21041247 rs9309298 chr2 57772923 A G 3.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs9309298 chr2 57772923 A G 8.29E-05 Suicide attempts in bipolar disorder / / 21041247 rs9309299 chr2 57775502 G C 1.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs9309299 chr2 57775502 G C 3.13E-04 Suicide attempts in bipolar disorder / / 21041247 rs10166539 chr2 57775779 G A 1.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs10166539 chr2 57775779 G A 3.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs9309301 chr2 57775902 G A 1.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs9309301 chr2 57775902 G A 3.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs10496069 chr2 57776656 A T 1.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs10496069 chr2 57776656 A T 3.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs10153799 chr2 57780042 T G 3.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs10153799 chr2 57780042 T G 3.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs6747684 chr2 57781712 A G 9.74E-05 Information processing speed / / 21130836 rs13412537 chr2 57783284 C G 1.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs13412537 chr2 57783284 C G 3.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs11125721 chr2 57826028 G A 1.10E-05 Urinary metabolites / / 21572414 rs17810870 chr2 57842453 C T 3.45E-05 Basophils / / pha003087 rs1405826 chr2 57845016 T C 7.76E-05 Basophils / / pha003087 rs10496070 chr2 57848179 A T 3.73E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs2612305 chr2 57858053 C T 1.02E-04 Type 2 diabetes / / 17463246 rs6728612 chr2 57859236 C T 3.81E-05 Basophils / / pha003087 rs1960633 chr2 57882582 T A 1.92E-04 Smoking initiation / / 24665060 rs2311731 chr2 57884793 T G 9.99E-04 Multiple complex diseases / / 17554300 rs10496073 chr2 57901385 A G 5.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs17049036 chr2 57901997 G A 8.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs6759349 chr2 57912777 C T 1.91E-05 Body Mass Index / / pha003006 rs6759349 chr2 57912777 C T 3.40E-05 Body Mass Index / / pha003014 rs6759349 chr2 57912777 C T 7.67E-05 Weight / / pha003026 rs1350691 chr2 57930971 A T 4.28E-05 Type 2 diabetes / / 17463246 rs3732135 chr2 57933881 G A 9.50E-05 Body Mass Index / / pha003006 rs13026414 chr2 57934055 C T 2.00E-09 Epilepsy (generalized) / / 22949513 rs1380703 chr2 57941287 A G 1.10E-05 Longevity and age-related phenotypes / / 17903295 rs10496077 chr2 57943044 T C 7.05E-06 Lipoproteins / / pha003079 rs17049112 chr2 57978620 T C 3.42E-04 IgE levels / / 17255346 rs11682175 chr2 57987593 T C 2.19E-04 Alzheimer's disease (late onset) / / 21379329 rs11682175 chr2 57987593 T C 4.07E-06 Schizophrenia / / 21926974 rs2717055 chr2 58044220 G A 3.25E-05 Bipolar disorder / / 19488044 rs2717055 chr2 58044220 G A 4.33E-05 Bipolar Disorder / / pha002858 rs1106090 chr2 58068741 G A 3.36E-05 Lipoproteins / / pha003079 rs2717068 chr2 58094873 A C 4.00E-07 Epilepsy (generalized) / / 22949513 rs7583473 chr2 58101921 C T 4.33E-06 Lipoproteins / / pha003079 rs1533725 chr2 58111922 T G 6.04E-04 Multiple complex diseases / / 17554300 rs2678914 chr2 58117926 C G 3.45E-04 Multiple complex diseases / / 17554300 rs2678917 chr2 58120553 T A 3.61E-04 Multiple complex diseases / / 17554300 rs2717001 chr2 58137618 C T 1.00E-04 Schizophrenia / / 21747397 rs17829368 chr2 58145771 T C 2.71E-04 Blood pressure / / 17255346 rs10189138 chr2 58153676 G T 0.000142 Schizophrenia / / 23637625 rs2717023 chr2 58161355 C T 9.21E-05 Serum metabolites / / 19043545 rs2717025 chr2 58163146 G T 1.43E-04 Multiple complex diseases / / 17554300 rs2717025 chr2 58163146 G T 2.39E-05 Brain structure / / 22504417 rs2717026 chr2 58163178 A G 2.54E-05 Brain structure / / 22504417 rs2717029 chr2 58165595 G T 1.13E-04 Multiple complex diseases / / 17554300 rs2717031 chr2 58166468 T C 4.62E-05 Bipolar disorder / / 19488044 rs2717036 chr2 58168098 T C 8.36E-05 Bipolar disorder / / 19488044 rs2717038 chr2 58168831 A G 1.40E-04 Multiple complex diseases / / 17554300 rs2717038 chr2 58168831 A G 1.81E-05 Brain structure / / 22504417 rs2717039 chr2 58169166 G T 1.48E-04 Multiple complex diseases / / 17554300 rs2717039 chr2 58169166 G T 1.35E-05 Brain structure / / 22504417 rs2678897 chr2 58169418 G A 9.31E-05 Bipolar disorder / / 19488044 rs10172295 chr2 58201202 G A 2.45E-04 Multiple complex diseases / / 17554300 rs10496084 chr2 58220320 C T 8.36E-05 Lipoproteins / / pha003079 rs2312147 chr2 58222928 T C 3.00E-07 Schizophrenia / / 19571808 rs2312147 chr2 58222928 T C 1.90E-09 Schizophrenia / / 21791550 rs2312147 chr2 58222928 T C 0.00000039 Psychosis / / 23164818 rs2312147 chr2 58222928 T C 0.00023 Schizophrenia / / 23164818 rs1016771 chr2 58335681 T C 9.11E-06 Bipolar disorder VRK2 intron 19488044 rs1016771 chr2 58335681 T C 1.26E-05 Bipolar Disorder VRK2 intron pha002858 rs2043890 chr2 58350571 G A 1.52E-05 Bipolar disorder VRK2 intron 19488044 rs2043890 chr2 58350571 G A 1.53E-05 Bipolar Disorder VRK2 intron pha002858 rs17614198 chr2 58384827 A G 9.98E-05 Insulin-related traits VRK2 intron pha003063 rs848291 chr2 58388696 A G 9.65E-06 Bipolar disorder FANCL cds-synon 19488044 rs848291 chr2 58388696 A G 3.41E-05 Bipolar Disorder FANCL cds-synon pha002858 rs848286 chr2 58394543 T C 2.79E-04 Type 2 diabetes FANCL intron 17463246 rs848280 chr2 58412472 T C 9.23E-05 Bipolar disorder FANCL intron 19488044 rs17049406 chr2 58429870 A T 1.02E-04 Multiple complex diseases FANCL intron 17554300 rs2110664 chr2 58462731 C A 8.36E-04 Cervical cancer FANCL intron 23817570 rs10490251 chr2 58498481 G A 7.36E-04 Type 2 diabetes / / 17463246 rs11885675 chr2 58522661 T A 9.48E-04 Alcohol dependence / / 21314694 rs11125750 chr2 58577971 T C 4.00E-04 Obesity (extreme) / / 21935397 rs6761469 chr2 58581018 A G 4.00E-04 Obesity (extreme) / / 21935397 rs11902397 chr2 58586412 A G 7.33E-04 Smoking cessation / / 24665060 rs887956 chr2 58597957 A C 6.32E-04 Smoking cessation / / 24665060 rs17049487 chr2 58601888 G C 8.68E-04 Alzheimer's disease / / 22005930 rs4399710 chr2 58617762 G A 3.57E-04 Obesity (extreme) / / 21935397 rs10490246 chr2 58631933 G C 3.57E-04 Alzheimer's disease / / 22005930 rs2192663 chr2 58633553 C T 4.24E-04 Obesity (extreme) / / 21935397 rs7340335 chr2 58639078 A G 4.34E-04 Obesity (extreme) / / 21935397 rs10179027 chr2 58652438 A T 7.76E-04 Obesity (extreme) / / 21935397 rs12613228 chr2 58662069 G A 4.25E-04 Alzheimer's disease / / 22005930 rs6757755 chr2 58668007 C G 5.24E-04 Bipolar disorder / / 19259986 rs1016756 chr2 58677349 G A 6.34E-04 Alzheimer's disease / / 22005930 rs17399334 chr2 58690295 A G 5.11E-05 Intelligence / / 21826061 rs12618801 chr2 58779404 G A 2.23E-05 Intelligence FLJ30838 intron 21826061 rs17269098 chr2 58779689 A G 6.03E-05 Intelligence FLJ30838 intron 21826061 rs2902140 chr2 58820417 C T 3.89E-04 Taste perception FLJ30838 intron 22132133 rs12713385 chr2 58824981 G C 5.19E-04 Alzheimer's disease FLJ30838 intron 22005930 rs7607950 chr2 58826638 A G 4.08E-04 Alzheimer's disease FLJ30838 intron 22005930 rs17049584 chr2 58828331 G C 2.15E-04 Type 2 diabetes FLJ30838 intron 17463246 rs7569678 chr2 58830445 A G 7.45E-05 Intelligence FLJ30838 intron 21826061 rs17269126 chr2 58832407 A G 2.27E-04 Type 2 diabetes FLJ30838 intron 17463246 rs6731302 chr2 58833493 A G 2.00E-09 Obesity FLJ30838 intron 23563607 rs12619586 chr2 58838242 A G 4.30E-04 Alzheimer's disease FLJ30838 intron 22005930 rs6545694 chr2 58847953 A G 3.69E-04 Tourette syndrome FLJ30838 intron 22889924 rs13011109 chr2 58857419 G C 7.72E-04 Response to statin treatment (atorvastatin),change in cholesterol levels FLJ30838 intron 20031582 rs1922786 chr2 58863573 A G 2.13E-04 Tourette syndrome FLJ30838 intron 22889924 rs10187702 chr2 58869775 T C 7.58E-04 Alzheimer's disease FLJ30838 intron 22005930 rs7591633 chr2 58872058 A G 7.98E-04 Smoking initiation FLJ30838 intron 24665060 rs1159609 chr2 58882418 T G 0.00000227 Body mass index FLJ30838 intron 23001569 rs17049635 chr2 58883053 A G 3.53E-04 Multiple complex diseases FLJ30838 intron 17554300 rs13025286 chr2 58887240 G A 7.87E-04 Type 2 diabetes FLJ30838 intron 17463246 rs1861411 chr2 58904177 A G 5.14E-04 Body mass index FLJ30838 intron 24861553 rs10204803 chr2 58904855 C T 7.58E-04 Multiple complex diseases FLJ30838 intron 17554300 rs17615494 chr2 58950363 G T 2.96E-04 Alzheimer's disease FLJ30838 intron 22005930 rs2708149 chr2 58951187 A G 2.59E-04 Tourette syndrome FLJ30838 intron 22889924 rs13428870 chr2 58956557 T G 3.42E-04 Alzheimer's disease FLJ30838 intron 22005930 rs6741951 chr2 58959112 G A 4.10E-04 Alzheimer's disease FLJ30838 intron 22005930 rs17049712 chr2 58961136 C T 4.38E-04 Alzheimer's disease FLJ30838 intron 22005930 rs12622165 chr2 58964083 C A 4.83E-04 Alzheimer's disease FLJ30838 intron 22005930 rs1641155 chr2 58965211 T G 3.05E-04 Alzheimer's disease FLJ30838 intron 22005930 rs2708147 chr2 58970323 G C 5.41E-04 Alzheimer's disease FLJ30838 intron 22005930 rs17049722 chr2 58976863 C T 2.76E-04 Type 2 diabetes FLJ30838 intron 17463246 rs6759519 chr2 58981325 A G 1.03E-04 Type 2 diabetes FLJ30838 intron 17463246 rs6759519 chr2 58981325 A G 9.09E-04 Tourette syndrome FLJ30838 intron 22889924 rs6759757 chr2 58981525 A G 6.42E-04 Type 2 diabetes FLJ30838 intron 17463246 rs6731121 chr2 58991868 G T 3.55E-04 Type 2 diabetes FLJ30838 intron 17463246 rs10204566 chr2 58999505 G A 1.00E-05 Myasthenia gravis FLJ30838 intron 23055271 rs6719884 chr2 59036916 A C 3.00E-06 Myasthenia gravis FLJ30838 intron 23055271 rs12617233 chr2 59039998 T C 5.54E-09 Body mass index FLJ30838 intron 23001569 rs12386185 chr2 59042739 C G 9.01E-04 Response to taxane treatment (placlitaxel) FLJ30838 intron 23006423 rs2160206 chr2 59047919 T G 2.38E-04 Stroke FLJ30838 intron pha002887 rs10182324 chr2 59047973 C T 8.65E-04 Multiple complex diseases FLJ30838 intron 17554300 rs10182324 chr2 59047973 C T 9.46E-04 Response to taxane treatment (placlitaxel) FLJ30838 intron 23006423 rs17049763 chr2 59064879 C G 6.60E-04 Obesity (extreme) FLJ30838 intron 21935397 rs7593324 chr2 59065808 G A 6.60E-04 Obesity (extreme) FLJ30838 intron 21935397 rs7593324 chr2 59065808 G A 3.56E-04 Iron levels FLJ30838 intron pha002876 rs7592415 chr2 59072516 A G 1.56E-04 Breast cancer FLJ30838 intron pha002853 rs17552189 chr2 59072969 C T 8.50E-05 Alcohol dependence FLJ30838 intron 20201924 rs17552189 chr2 59072969 C T 4.00E-06 Cannabis dependence FLJ30838 intron 21668797 rs17552189 chr2 59072969 C T 8.46E-05 Alcoholism FLJ30838 intron pha002892 rs4140883 chr2 59079538 C T 5.91E-05 Cognitive performance FLJ30838 intron 19734545 rs4140883 chr2 59079538 C T 2.34E-04 Stroke FLJ30838 intron pha002887 rs10198586 chr2 59082438 G A 4.14E-04 Response to taxane treatment (placlitaxel) FLJ30838 intron 23006423 rs11125762 chr2 59091613 A G 8.68E-04 Type 2 diabetes FLJ30838 intron 17463246 rs6719683 chr2 59094190 G A 7.98E-04 Iron levels FLJ30838 intron pha002876 rs12996396 chr2 59103234 C T 6.49E-04 Type 2 diabetes FLJ30838 intron 17463246 rs2192692 chr2 59104524 G A 1.60E-04 Stroke FLJ30838 intron pha002887 rs42846 chr2 59108940 C G 2.00E-05 Urinary metabolites FLJ30838 intron 21572414 rs42843 chr2 59110328 T G 5.88E-04 Multiple complex diseases FLJ30838 intron 17554300 rs42843 chr2 59110328 T G 1.10E-05 Urinary metabolites FLJ30838 intron 21572414 rs42836 chr2 59113179 A C 8.61E-04 Multiple complex diseases FLJ30838 intron 17554300 rs42833 chr2 59116852 A T 7.60E-06 Urinary metabolites FLJ30838 intron 21572414 rs2160091 chr2 59145840 A G 4.37E-05 Cholesterol FLJ30838 intron pha003073 rs2160091 chr2 59145840 A G 5.06E-05 Cholesterol FLJ30838 intron pha003078 rs6736768 chr2 59176413 A G 7.23E-05 Body Mass Index FLJ30838 intron pha003019 rs713457 chr2 59178687 C T 9.09E-04 Coronary Artery Disease FLJ30838 intron 17634449 rs17049848 chr2 59184123 G A 6.20E-05 Parkinson's disease FLJ30838 intron 21248740 rs17049848 chr2 59184123 G A 3.87E-05 Body Mass Index FLJ30838 intron pha003019 rs17049848 chr2 59184123 G A 4.73E-05 Body Mass Index FLJ30838 intron pha003020 rs111835151 chr2 59202029 G C 2.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) FLJ30838 intron 24159190 rs111835151 chr2 59202029 G C 9.49E-06 Serum dimethylarginine levels (asymmetric) FLJ30838 intron 24159190 rs114458406 chr2 59205731 T G 5.81E-06 Serum dimethylarginine levels (asymmetric) FLJ30838 intron 24159190 rs7577730 chr2 59205954 T G 7.42E-06 Stroke (ischemic) FLJ30838 intron 21957438 rs74618786 chr2 59214179 T C 2.74E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) FLJ30838 intron 24159190 rs59121803 chr2 59224977 T G 6.95E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) FLJ30838 intron 24159190 rs17620941 chr2 59234869 G A 2.58E-04 Type 2 diabetes FLJ30838 intron 17463246 rs7590342 chr2 59260404 A G 7.07E-04 White matter integrity FLJ30838 intron 22425255 rs991964 chr2 59282591 T C 9.00E-06 Uterine fibroids FLJ30838 intron 21460842 rs991964 chr2 59282591 T C 2.40E-05 Urinary metabolites FLJ30838 intron 21572414 rs991964 chr2 59282591 T C 3.90E-05 Cognitive function FLJ30838 intron 24684796 rs10490103 chr2 59290759 C T 1.59E-05 Alzheimer's disease (late onset) / / 21379329 rs887912 chr2 59302877 T C 2.00E-12 Body mass index / / 20935630 rs887912 chr2 59302877 T C 1.79E-12 Body mass index / / 23001569 rs887912 chr2 59302877 T C 1.00E-10 Obesity / / 23563607 rs887912 chr2 59302877 T C 6.00E-09 Obesity / / 23563607 rs2863776 chr2 59302990 A T 4.40E-05 Cognitive function / / 24684796 rs11686642 chr2 59339111 C T 5.89E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13402382 chr2 59354311 A G 5.66E-05 Blood Pressure / / pha003048 rs11691214 chr2 59435619 A T 2.20E-05 Urinary metabolites / / 21572414 rs2192567 chr2 59456623 G T 9.80E-06 Urinary metabolites / / 21572414 rs10177858 chr2 59465454 C T 7.29E-04 Response to TNF antagonist treatment / / 21061259 rs13403641 chr2 59467224 G C 1.80E-06 Urinary metabolites / / 21572414 rs10170742 chr2 59470345 A C 6.34E-05 Schizophrenia / / 19197363 rs2192563 chr2 59473060 G A 5.90E-06 Urinary metabolites / / 21572414 rs10490113 chr2 59499347 A C 5.00E-06 Breast cancer / / 17903305 rs10490113 chr2 59499347 A C 5.00E-06 Nasopharyngeal carcinoma / / 20512145 rs7588177 chr2 59509155 T C 7.10E-06 Urinary metabolites / / 21572414 rs10202074 chr2 59514746 T A 4.80E-06 Urinary metabolites / / 21572414 rs12464814 chr2 59515129 A G 1.20E-05 Urinary metabolites / / 21572414 rs10182747 chr2 59519869 A C 1.30E-05 Urinary metabolites / / 21572414 rs6545733 chr2 59529413 G A 1.50E-05 Urinary metabolites / / 21572414 rs2561893 chr2 59560414 T C 2.60E-05 Urinary metabolites / / 21572414 rs2540015 chr2 59565198 T C 8.60E-07 Urinary metabolites / / 21572414 rs17644588 chr2 59580326 G A 7.28E-04 Nicotine dependence / / 17158188 rs7606152 chr2 59586372 A G 3.40E-05 Response to statin therapy / / 20339536 rs13420083 chr2 59603700 T C 6.80E-06 Urinary metabolites / / 21572414 rs4432437 chr2 59605576 T C 4.22E-05 Chronic obstructive pulmonary disease / / 19300482 rs7577424 chr2 59610711 C T 4.78E-05 Response to Vitamin E supplementation / / 22437554 rs17645334 chr2 59661788 C T 1.47E-04 Alzheimer's disease (late onset) / / 21379329 rs12464531 chr2 59673530 T C 0.00019174 Hypertension (early onset hypertension) / / 22479346 rs13018470 chr2 59694749 C T 0.0000683 Panic disorder / / 23149450 rs13018470 chr2 59694749 C T 6.83E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs2110565 chr2 59749401 A G 6.15E-05 Pulmonary function in asthmatics / / 23541324 rs2674061 chr2 59753331 C T 6.07E-05 Alcohol consumption / / 23743675 rs2540099 chr2 59753741 C T 6.37E-05 Alcohol consumption / / 23743675 rs2540098 chr2 59753809 C T 6.53E-05 Alcohol consumption / / 23743675 rs56093216 chr2 59753972 T C 6.78E-05 Alcohol consumption / / 23743675 rs2540097 chr2 59755664 A G 6.62E-05 Alcohol consumption / / 23743675 rs2540096 chr2 59756854 T C 5.01E-05 Alcohol consumption / / 23743675 rs2674041 chr2 59757501 G A 6.63E-05 Alcohol consumption / / 23743675 rs2540089 chr2 59762371 C T 5.45E-05 Alcohol consumption / / 23743675 rs2540088 chr2 59762560 C G 4.87E-05 Alcohol consumption / / 23743675 rs2540087 chr2 59762594 C A 5.34E-05 Alcohol consumption / / 23743675 rs2674067 chr2 59765684 A G 7.35E-05 Alcohol consumption / / 23743675 rs2674046 chr2 59768141 C T 5.61E-05 Alcohol consumption / / 23743675 rs2674047 chr2 59768685 T A 6.60E-05 Alcohol consumption / / 23743675 rs2674048 chr2 59769012 C T 7.00E-05 Alcohol consumption / / 23743675 rs2540083 chr2 59769150 G A 6.68E-05 Alcohol consumption / / 23743675 rs7571858 chr2 59769273 G T 3.48E-05 Alcohol consumption / / 23743675 rs2674050 chr2 59769317 C T 6.85E-05 Alcohol consumption / / 23743675 rs2674052 chr2 59770353 T G 6.82E-05 Alcohol consumption / / 23743675 rs2674079 chr2 59771479 A C,T 6.42E-05 Alcohol consumption / / 23743675 rs10195005 chr2 59771640 G A 4.64E-05 Alcohol consumption / / 23743675 rs996762 chr2 59772059 C G 6.38E-04 Multiple complex diseases / / 17554300 rs2418867 chr2 59772602 C T 4.59E-05 Alcohol consumption / / 23743675 rs887942 chr2 59775168 G C 2.61E-05 Alcohol consumption / / 23743675 rs2215906 chr2 59775565 C T 3.16E-05 Alcohol consumption / / 23743675 rs721250 chr2 59777016 C T 2.94E-05 Alcohol consumption / / 23743675 rs10203166 chr2 59789705 C T 4.00E-06 IgG glycosylation / / 23382691 rs2539669 chr2 59794609 A G 5.52E-06 Asthma / / 21790008 rs17050261 chr2 59804348 G C 2.46E-04 Smoking initiation / / 24665060 rs6728994 chr2 59811884 C T 7.14E-04 Response to alcohol consumption (flushing response) / / 24277619 rs6760859 chr2 59812464 A G 2.64E-04 Parkinson's disease / / 17052657 rs2539706 chr2 59819545 G A 6.56E-04 Parkinson's disease / / 17052657 rs2539706 chr2 59819545 G A 8.87E-04 Multiple complex diseases / / 17554300 rs2539703 chr2 59831289 C T 7.62E-04 Parkinson's disease / / 17052657 rs2539684 chr2 59849513 T G 2.46E-04 Fibrinogen / / 17255346 rs2674063 chr2 59853322 T C,G 2.29E-04 Fibrinogen / / 17255346 rs2539682 chr2 59853699 A G 8.88E-05 Fibrinogen / / 17255346 rs13019632 chr2 59858364 T C 1.53E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs13019632 chr2 59858364 T C 1.59E-05 Lung function (forced vital capacity) / / 24023788 rs13019632 chr2 59858364 T C 2.51E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1005741 chr2 59859867 G A 1.22E-04 Fibrinogen / / 17255346 rs1005741 chr2 59859867 G A 8.80E-05 HIV-1 control / / 20041166 rs17596277 chr2 59888538 G A 2.95E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs17596277 chr2 59888538 G A 1.05E-04 Lung function (forced vital capacity) / / 24023788 rs17596277 chr2 59888538 G A 1.51E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2110330 chr2 59903052 A G 2.71E-04 Fibrinogen / / 17255346 rs2110330 chr2 59903052 A G 3.78E-04 Multiple complex diseases / / 17554300 rs1372878 chr2 59904565 G A 2.84E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs17596662 chr2 59911911 G A,T 2.32E-04 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs1112604 chr2 59928561 G A 8.03E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7598185 chr2 59952259 C A 1.20E-05 Height / / 21998595 rs11125807 chr2 59952937 C T 1.94E-04 Self-reported allergy / / 23817569 rs17050390 chr2 59953668 G C 2.19E-04 Self-reported allergy / / 23817569 rs9309316 chr2 59955616 A C 4.95E-04 Type 2 diabetes / / 17463246 rs9309316 chr2 59955616 A C 4.61E-04 Multiple complex diseases / / 17554300 rs17050411 chr2 59979504 T C 9.96E-04 Alcohol dependence / / 24277619 rs10187463 chr2 59985441 C T 2.48E-04 Age-related macular degeneration / / 22125219 rs11125811 chr2 59987774 T C 7.02E-04 Alcohol dependence / / 24277619 rs11125813 chr2 59991047 G A 7.91E-04 Type 2 diabetes / / 17463246 rs17327578 chr2 59998044 C T 8.48E-04 Type 2 diabetes / / 17463246 rs1899491 chr2 60000394 G T 7.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs367668284 chr2 60009701 G GGT 1.14E-11 Metabolite levels / / 22286219 rs1019265 chr2 60012569 A G 3.94E-05 Bipolar disorder / / 20451256 rs1019264 chr2 60012802 G A 3.23E-04 Obesity (extreme) / / 21935397 rs7590023 chr2 60020374 G A 2.57E-05 Bipolar disorder / / 20451256 rs7562462 chr2 60023703 T A,C,G 7.34E-05 Bipolar disorder / / 20451256 rs1372876 chr2 60025963 A C 2.25E-05 Bipolar disorder / / 20451256 rs4671355 chr2 60029072 T C 2.59E-05 Bipolar disorder / / 20451256 rs6545754 chr2 60029857 A G 3.80E-05 Bipolar disorder / / 20451256 rs4672319 chr2 60030580 A G 2.88E-05 Bipolar disorder / / 20451256 rs4671356 chr2 60034937 T C 3.74E-05 Bipolar disorder / / 20451256 rs730402 chr2 60094706 G A 6.85E-05 Serum metabolites / / 19043545 rs730402 chr2 60094706 G A 1.03E-04 Cognitive function / / 24684796 rs17328175 chr2 60105275 A G 7.51E-05 IgE levels / / 22075330 rs11684416 chr2 60110498 C G 9.49E-04 Acute lung injury / / 22295056 rs12991146 chr2 60111222 C A 2.18E-05 Smoking initiation / / 24665060 rs6545764 chr2 60112225 C T 8.75E-05 Aging (time to event) / / 21782286 rs6728812 chr2 60112579 C T 2.10E-05 Smoking initiation / / 24665060 rs6545765 chr2 60119744 T C 9.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs145433814 chr2 60126311 G A 6.00E-06 Eating disorders (purging via substances) / / 23568457 rs17050481 chr2 60126601 G A 3.45E-04 Multiple complex diseases / / 17554300 rs1019614 chr2 60131157 A G 2.57E-05 Brain lesion load / / 19010793 rs1344293 chr2 60133158 G T 1.50E-05 Urinary metabolites / / 21572414 rs17050485 chr2 60133565 C T 5.12E-04 Prostate cancer mortality / / 20978177 rs13025366 chr2 60142688 T G 1.99E-05 Blood Pressure / / pha003048 rs7576017 chr2 60159532 A G 3.98E-05 Brain lesion load / / 19010793 rs12468914 chr2 60159756 T C 8.13E-05 Brain lesion load / / 19010793 rs4672333 chr2 60191297 A G 5.34E-05 Blood Pressure / / pha003048 rs6736566 chr2 60195954 A C 1.00E-04 Prostate cancer / / 21743057 rs13033133 chr2 60198537 C T 5.51E-04 Type 2 diabetes / / 17463246 rs13033133 chr2 60198537 C T 2.13E-04 Multiple complex diseases / / 17554300 rs13033133 chr2 60198537 C T 2.30E-05 Urinary metabolites / / 21572414 rs12617593 chr2 60198798 G A 7.19E-04 Type 2 diabetes / / 17463246 rs12617593 chr2 60198798 G A 2.41E-04 Multiple complex diseases / / 17554300 rs4672335 chr2 60202239 G A 1.78E-05 Brain lesion load / / 19010793 rs1863160 chr2 60202617 T C 5.00E-05 Prostate cancer / / 21743057 rs12476853 chr2 60203980 G C 4.02E-05 Multiple complex diseases / / 17554300 rs1863159 chr2 60206554 C T 3.10E-05 Body mass index / / 20818722 rs2419411 chr2 60215475 C T 7.65E-05 Blood Pressure / / pha003048 rs4672337 chr2 60217093 G T 1.70E-04 Multiple complex diseases / / 17554300 rs11896330 chr2 60235568 G A 7.59E-05 Brain lesion load / / 19010793 rs12373776 chr2 60237213 C T 6.83E-04 Smoking initiation / / 24665060 rs4672341 chr2 60241822 C A 3.98E-05 Brain lesion load / / 19010793 rs4672341 chr2 60241822 C A 7.37E-04 Smoking initiation / / 24665060 rs11888990 chr2 60255313 G A 1.39E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs13016030 chr2 60268260 G A 6.39E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs6712720 chr2 60281608 G C 4.00E-06 Monocyte early outgrowth colony forming units / / 21493818 rs2192580 chr2 60290360 T C 1.50E-05 Urinary metabolites / / 21572414 rs41454851 chr2 60317395 C T 5.33E-04 Multiple complex diseases / / 17554300 rs17027385 chr2 60317433 G C 3.97E-04 Multiple complex diseases / / 17554300 rs2419643 chr2 60318058 G A 4.01E-04 Alzheimer's disease (late onset) / / 21379329 rs17027670 chr2 60321554 G A 2.10E-04 Multiple complex diseases / / 17554300 rs17027920 chr2 60324502 C T 3.74E-04 Multiple complex diseases / / 17554300 rs17028210 chr2 60328685 C G 2.70E-05 Multiple complex diseases / / 17554300 rs6726368 chr2 60330305 G C 7.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs972337 chr2 60331399 C T 8.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs887930 chr2 60333732 G A 3.42E-04 Alzheimer's disease (late onset) / / 21379329 rs17039713 chr2 60336589 G T 4.29E-05 Vascular dementia / / 22116812 rs10490066 chr2 60409379 C A 7.20E-06 Urinary metabolites / / 21572414 rs1473099 chr2 60449710 A G 8.83E-05 Osteoarthritis / / 19508968 rs359268 chr2 60459806 T C 1.00E-06 Hypersomnia (HLA-DQB1*06:02 negative) / / 23646285 rs359233 chr2 60470926 A G 4.15E-04 Fibrinogen / / 17255346 rs113567488 chr2 60490322 T TG 4.96E-04 Type 2 diabetes / / 17463246 rs9309323 chr2 60490322 T G 4.96E-04 Type 2 diabetes / / 17463246 rs4671378 chr2 60494312 T C 9.21E-04 Type 2 diabetes / / 17463246 rs4671379 chr2 60495038 T C 3.52E-04 Type 2 diabetes / / 17463246 rs10202231 chr2 60500144 T A 7.00E-07 Response to antipsychotic treatment / / 20195266 rs2160067 chr2 60500415 A G 6.47E-04 Type 2 diabetes / / 17463246 rs2110398 chr2 60500484 T C 5.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2110398 chr2 60500484 T C 4.75E-06 Acne (severe) / / 24927181 rs4672381 chr2 60514946 C T 8.55E-04 Type 2 diabetes / / 17463246 rs4671386 chr2 60514993 C A 2.00E-06 Acne (severe) / / 24927181 rs6545803 chr2 60534199 G T 7.87E-05 Caffeine consumption / / 21490707 rs6545803 chr2 60534199 G T 6.00E-06 Nevirapine-induced rash / / 21810746 rs9309324 chr2 60546132 T G 1.93E-05 Multiple complex diseases / / 17554300 rs1512228 chr2 60561931 T C 9.43E-04 Multiple complex diseases / / 17554300 rs9784100 chr2 60562714 G C 2.33E-05 Multiple complex diseases / / 17554300 rs243088 chr2 60568745 A T 4.70E-10 Type 2 diabetes / / 22885922 rs243088 chr2 60568745 A T 6.50E-10 Type 2 diabetes (males) / / 22885922 rs243088 chr2 60568745 A T 3.00E-06 Type 2 diabetes / / 24509480 rs243083 chr2 60573870 A G 0.000011 Type 2 diabetes / / 22885922 rs12999941 chr2 60579624 C T 4.59E-05 Multiple complex diseases / / 17554300 rs9309325 chr2 60580831 A G 6.50E-05 Multiple complex diseases / / 17554300 rs9309325 chr2 60580831 A G 7.56E-05 Platelet counts / / 23263863 rs7573683 chr2 60581094 T C 6.82E-04 Multiple complex diseases / / 17554300 rs6731582 chr2 60583202 T C 6.90E-04 Multiple complex diseases / / 17554300 rs243023 chr2 60583727 T C 1.35E-05 Parkinson's disease / / 17052657 rs243021 chr2 60584819 G A 3.00E-15 Type 2 diabetes / / 20581827 rs243021 chr2 60584819 G A 3.00E-15 Type 2 diabetes / / 21647700 rs243021 chr2 60584819 G A 0.0000053 Type 2 diabetes / / 22885922 rs243021 chr2 60584819 G A 3.00E-15 Type 2 diabetes / / 23300278 rs243019 chr2 60585806 T C 0.000000022 Type 2 diabetes / / 22885922 rs243018 chr2 60586707 C G 6.67E-06 Multiple complex diseases / / 17554300 rs243016 chr2 60588713 A T 9.64E-06 Response to taxane treatment (placlitaxel) / / 23006423 rs243015 chr2 60588871 G A 5.88E-04 Multiple complex diseases / / 17554300 rs243015 chr2 60588871 G A 2.00E-05 Urinary metabolites / / 21572414 rs243052 chr2 60590257 G A 5.10E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs243050 chr2 60592027 G A 2.72E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs243044 chr2 60595793 G T 2.57E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs243039 chr2 60597565 G A 2.98E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs243037 chr2 60599100 C G 1.04E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1003690 chr2 60599988 T C 6.80E-05 Personality dimensions / / 18957941 rs243033 chr2 60603602 G C 9.40E-05 F-cell distribution / / 17767159 rs243032 chr2 60603950 G A 4.20E-07 F-cell distribution / / 17767159 rs243032 chr2 60603950 G A 2.76E-11 Other erythrocyte phenotypes / / 19862010 rs243032 chr2 60603950 G A 3.47E-09 Red blood cell traits / / 23222517 rs173373 chr2 60605919 C T 7.00E-09 F-cell distribution / / 17767159 rs173373 chr2 60605919 C T 2.86E-11 Other erythrocyte phenotypes / / 19862010 rs173373 chr2 60605919 C T 7.48E-11 Red blood cell traits / / 23222517 rs243030 chr2 60606571 C T 1.70E-08 F-cell distribution / / 17767159 rs243030 chr2 60606571 C T 3.10E-05 Subclinical atherosclerosis / / 17903303 rs243030 chr2 60606571 C T 2.61E-11 Other erythrocyte phenotypes / / 19862010 rs243030 chr2 60606571 C T 6.72E-11 Red blood cell traits / / 23222517 rs243029 chr2 60606654 C T 4.20E-08 F-cell distribution / / 17767159 rs243029 chr2 60606654 C T 2.64E-11 Other erythrocyte phenotypes / / 19862010 rs243029 chr2 60606654 C T 6.47E-10 Red blood cell traits / / 23222517 rs243027 chr2 60607007 T G 2.20E-10 F-cell distribution / / 17767159 rs243027 chr2 60607007 T G 2.26E-08 Other erythrocyte phenotypes / / 19862010 rs243027 chr2 60607007 T G 2.20E-10 F-cell distribution / / 21326311 rs243027 chr2 60607007 T G 9.50E-10 Red blood cell traits / / 23222517 rs13027161 chr2 60607728 T C 3.50E-08 F-cell distribution / / 17767159 rs13027161 chr2 60607728 T C 3.44E-08 Fetal hemoglobin levels / / 18245381 rs13027161 chr2 60607728 T C 2.21E-11 Other erythrocyte phenotypes / / 19862010 rs13027161 chr2 60607728 T C 4.43E-04 Alzheimer's disease (late onset) / / 21379329 rs13027161 chr2 60607728 T C 7.15E-12 Red blood cell traits / / 23222517 rs2668729 chr2 60608383 G A 3.20E-08 F-cell distribution / / 17767159 rs2668729 chr2 60608383 G A 2.56E-10 Other erythrocyte phenotypes / / 19862010 rs2668729 chr2 60608383 G A 1.20E-10 Red blood cell traits / / 23222517 rs2540917 chr2 60608759 T C 5.60E-09 F-cell distribution / / 17767159 rs2540917 chr2 60608759 T C 1.00E-14 Mean corpuscular volume / / 19862010 rs2540917 chr2 60608759 T C 2.46E-11 Red blood cell traits / / 23222517 rs2540916 chr2 60608930 T C 1.60E-07 F-cell distribution / / 17767159 rs2540916 chr2 60608930 T C 2.61E-10 Other erythrocyte phenotypes / / 19862010 rs2540916 chr2 60608930 T C 1.73E-10 Red blood cell traits / / 23222517 rs9967849 chr2 60609474 C T 7.60E-09 F-cell distribution / / 17767159 rs9967849 chr2 60609474 C T 3.27E-11 Other erythrocyte phenotypes / / 19862010 rs9967849 chr2 60609474 C T 6.38E-11 Red blood cell traits / / 23222517 rs1553934 chr2 60609896 G C 1.80E-08 F-cell distribution / / 17767159 rs1553934 chr2 60609896 G C 4.38E-08 Fetal hemoglobin levels / / 18245381 rs1553934 chr2 60609896 G C 3.45E-11 Other erythrocyte phenotypes / / 19862010 rs1553934 chr2 60609896 G C 3.05E-11 Red blood cell traits / / 23222517 rs2540914 chr2 60610411 A C 3.40E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs2540913 chr2 60610812 T C 1.12E-09 Fetal hemoglobin levels / / 18245381 rs2540913 chr2 60610812 T C 2.64E-11 Other erythrocyte phenotypes / / 19862010 rs2540913 chr2 60610812 T C 9.38E-11 Red blood cell traits / / 23222517 rs925483 chr2 60611285 G A 2.60E-09 F-cell distribution / / 17767159 rs925483 chr2 60611285 G A 7.51E-08 Fetal hemoglobin levels / / 18245381 rs925483 chr2 60611285 G A 4.52E-11 Other erythrocyte phenotypes / / 19862010 rs925483 chr2 60611285 G A 1.10E-10 Red blood cell traits / / 23222517 rs925484 chr2 60611437 C G 3.10E-09 F-cell distribution / / 17767159 rs925484 chr2 60611437 C G 4.54E-11 Other erythrocyte phenotypes / / 19862010 rs925484 chr2 60611437 C G 8.45E-11 Red blood cell traits / / 23222517 rs2137281 chr2 60612008 C T 9.40E-10 F-cell distribution / / 17767159 rs2137281 chr2 60612008 C T 2.94E-08 Fetal hemoglobin levels / / 18245381 rs2137281 chr2 60612008 C T 2.70E-11 Other erythrocyte phenotypes / / 19862010 rs2137281 chr2 60612008 C T 2.92E-10 Red blood cell traits / / 23222517 rs2137282 chr2 60612070 T A 7.40E-05 F-cell distribution / / 17767159 rs2137282 chr2 60612070 T A 1.30E-08 Red blood cell traits / / 23222517 rs2244030 chr2 60612238 A G 4.84E-07 Red blood cell traits / / 23222517 rs2137283 chr2 60612457 C A 1.70E-09 F-cell distribution / / 17767159 rs2137283 chr2 60612457 C A 2.83E-11 Other erythrocyte phenotypes / / 19862010 rs2137283 chr2 60612457 C A 3.61E-11 Red blood cell traits / / 23222517 rs243082 chr2 60613123 C T 7.90E-05 F-cell distribution / / 17767159 rs243081 chr2 60613776 G A 2.50E-12 F-cell distribution / / 17767159 rs243081 chr2 60613776 G A 7.20E-09 Red blood cell traits / / 23222517 rs243080 chr2 60614572 G A 2.70E-08 F-cell distribution / / 17767159 rs243080 chr2 60614572 G A 4.02E-09 Other erythrocyte phenotypes / / 19862010 rs243080 chr2 60614572 G A 2.39E-09 Red blood cell traits / / 23222517 rs243079 chr2 60615028 A C 2.00E-09 F-cell distribution / / 17767159 rs243079 chr2 60615028 A C 1.33E-08 Fetal hemoglobin levels / / 18245381 rs243079 chr2 60615028 A C 5.32E-08 Red blood cell traits / / 23222517 rs243078 chr2 60615303 A G 1.30E-08 F-cell distribution / / 17767159 rs243078 chr2 60615303 A G 3.09E-08 Fetal hemoglobin levels / / 18245381 rs243078 chr2 60615303 A G 4.08E-10 Red blood cell traits / / 23222517 rs243077 chr2 60616682 A G 6.80E-04 F-cell distribution / / 17767159 rs243076 chr2 60617563 G A 1.40E-08 F-cell distribution / / 17767159 rs243076 chr2 60617563 G A 2.74E-11 Other erythrocyte phenotypes / / 19862010 rs243076 chr2 60617563 G A 1.39E-11 Red blood cell traits / / 23222517 rs243075 chr2 60617571 T C 6.10E-04 F-cell distribution / / 17767159 rs243074 chr2 60617761 G A 5.80E-07 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs243074 chr2 60617761 G A 2.79E-07 Red blood cell traits / / 23222517 rs243073 chr2 60618690 T C 4.50E-04 F-cell distribution / / 17767159 rs243073 chr2 60618690 T C 8.10E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs243072 chr2 60618796 G C 7.20E-07 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs243072 chr2 60618796 G C 7.82E-07 Red blood cell traits / / 23222517 rs243071 chr2 60619028 A G 7.20E-07 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs243071 chr2 60619028 A G 5.26E-07 Red blood cell traits / / 23222517 rs13401861 chr2 60619814 T C 4.00E-04 F-cell distribution / / 17767159 rs243070 chr2 60620286 T A 1.70E-05 F-cell distribution / / 17767159 rs243070 chr2 60620286 T A 4.00E-13 Red blood cell traits / / 23222517 rs243069 chr2 60620834 A C 6.20E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs243067 chr2 60621643 G T 1.10E-08 F-cell distribution / / 17767159 rs243067 chr2 60621643 G T 6.05E-11 Other erythrocyte phenotypes / / 19862010 rs243067 chr2 60621643 G T 7.49E-11 Red blood cell traits / / 23222517 rs243066 chr2 60621766 A G 5.40E-10 F-cell distribution / / 17767159 rs243066 chr2 60621766 A G 6.07E-11 Other erythrocyte phenotypes / / 19862010 rs243066 chr2 60621766 A G 8.20E-11 Red blood cell traits / / 23222517 rs243065 chr2 60622064 G C 3.10E-09 F-cell distribution / / 17767159 rs243065 chr2 60622064 G C 2.67E-09 Red blood cell traits / / 23222517 rs7589285 chr2 60622491 A T 5.60E-04 F-cell distribution / / 17767159 rs243063 chr2 60622899 A T 6.90E-09 F-cell distribution / / 17767159 rs243063 chr2 60622899 A T 7.44E-11 Other erythrocyte phenotypes / / 19862010 rs243063 chr2 60622899 A T 1.18E-10 Red blood cell traits / / 23222517 rs243062 chr2 60623676 G A 4.20E-10 F-cell distribution / / 17767159 rs243061 chr2 60623698 T C 2.00E-09 F-cell distribution / / 17767159 rs184839 chr2 60625400 G C 7.80E-07 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs184839 chr2 60625400 G C 5.49E-07 Red blood cell traits / / 23222517 rs13011022 chr2 60626822 G A 1.40E-09 F-cell distribution / / 17767159 rs13011022 chr2 60626822 G A 9.36E-07 Red blood cell traits / / 23222517 rs11125841 chr2 60627565 A G 3.30E-08 F-cell distribution / / 17767159 rs888082 chr2 60629609 G A 3.10E-09 F-cell distribution / / 17767159 rs888082 chr2 60629609 G A 1.93E-09 Fetal hemoglobin levels / / 18245381 rs888082 chr2 60629609 G A 5.47E-09 Red blood cell traits / / 23222517 rs929645 chr2 60629866 C A 1.30E-04 Multiple complex diseases / / 17554300 rs12995080 chr2 60631229 G A 1.20E-05 F-cell distribution / / 17767159 rs13009393 chr2 60633364 G A 2.20E-10 F-cell distribution / / 17767159 rs13009393 chr2 60633364 G A 9.40E-11 Other erythrocyte phenotypes / / 19862010 rs13009393 chr2 60633364 G A 2.05E-10 Red blood cell traits / / 23222517 rs12464462 chr2 60636416 A G 1.90E-09 F-cell distribution / / 17767159 rs12464462 chr2 60636416 A G 4.33E-11 Other erythrocyte phenotypes / / 19862010 rs12464462 chr2 60636416 A G 3.46E-09 Red blood cell traits / / 23222517 rs12472541 chr2 60636497 C A 3.90E-04 F-cell distribution / / 17767159 rs12472541 chr2 60636497 C A 1.09E-07 Red blood cell traits / / 23222517 rs17027944 chr2 60636614 C A 1.08E-07 Red blood cell traits / / 23222517 rs10445937 chr2 60637656 G A 1.38E-04 Multiple complex diseases / / 17554300 rs10445937 chr2 60637656 G A 3.10E-09 F-cell distribution / / 17767159 rs10445937 chr2 60637656 G A 5.81E-09 Fetal hemoglobin levels / / 18245381 rs10445937 chr2 60637656 G A 3.68E-11 Other erythrocyte phenotypes / / 19862010 rs10445937 chr2 60637656 G A 3.22E-09 Red blood cell traits / / 23222517 rs17330904 chr2 60639733 T C 5.10E-04 F-cell distribution / / 17767159 rs12476132 chr2 60639904 G A 2.90E-09 F-cell distribution / / 17767159 rs12476132 chr2 60639904 G A 3.68E-11 Other erythrocyte phenotypes / / 19862010 rs12476132 chr2 60639904 G A 2.96E-09 Red blood cell traits / / 23222517 rs11125842 chr2 60640807 A G 8.30E-08 F-cell distribution / / 17767159 rs11125842 chr2 60640807 A G 1.50E-07 Red blood cell traits / / 23222517 rs13028240 chr2 60641329 G A 1.40E-05 F-cell distribution / / 17767159 rs13028240 chr2 60641329 G A 5.10E-07 Red blood cell traits / / 23222517 rs13028240 chr2 60641329 G A 3.93E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs12463461 chr2 60642899 G T 9.23E-11 Red blood cell traits / / 23222517 rs12997266 chr2 60649143 G A 1.90E-09 F-cell distribution LOC100506891 intron 17767159 rs12104736 chr2 60650716 C G 9.00E-09 F-cell distribution LOC100506891 intron 17767159 rs12104736 chr2 60650716 C G 5.01E-07 Red blood cell traits LOC100506891 intron 23222517 rs13013119 chr2 60652061 C T 3.70E-05 F-cell distribution / / 17767159 rs1035831 chr2 60653572 T C 2.50E-05 Urinary metabolites / / 21572414 rs10490070 chr2 60655679 A G 9.60E-05 F-cell distribution / / 17767159 rs10490070 chr2 60655679 A G 6.06E-05 Cognitive test performance / / 20125193 rs10490070 chr2 60655679 A G 3.77E-10 Red blood cell traits / / 23222517 rs13011256 chr2 60656992 G A 4.50E-05 F-cell distribution / / 17767159 rs13011256 chr2 60656992 G A 6.54E-07 Red blood cell traits / / 23222517 rs11894442 chr2 60657018 T C 3.60E-08 F-cell distribution / / 17767159 rs11894442 chr2 60657018 T C 9.52E-08 Red blood cell traits / / 23222517 rs1861431 chr2 60657825 C A 2.50E-05 Urinary metabolites / / 21572414 rs6718203 chr2 60659307 C G 7.00E-04 F-cell distribution / / 17767159 rs17402905 chr2 60660308 T C 8.00E-05 F-cell distribution / / 17767159 rs17402905 chr2 60660308 T C 4.30E-07 Red blood cell traits / / 23222517 rs17402912 chr2 60660522 A G 4.60E-05 F-cell distribution / / 17767159 rs17402912 chr2 60660522 A G 7.26E-11 Red blood cell traits / / 23222517 rs17331017 chr2 60662149 C A 6.40E-05 F-cell distribution / / 17767159 rs17331017 chr2 60662149 C A 3.76E-07 Red blood cell traits / / 23222517 rs8179712 chr2 60663798 C T 6.98E-05 Schizophrenia / / 21747397 rs1011407 chr2 60665768 A G 4.10E-04 F-cell distribution / / 17767159 rs1011406 chr2 60666075 C G 6.90E-04 F-cell distribution / / 17767159 rs12474693 chr2 60668432 C T 3.68E-10 Fetal hemoglobin levels / / 18245381 rs12474693 chr2 60668432 C T 9.87E-07 Red blood cell traits / / 23222517 rs10490071 chr2 60668890 G A 5.30E-05 F-cell distribution / / 17767159 rs10490071 chr2 60668890 G A 4.40E-10 Red blood cell traits / / 23222517 rs11884411 chr2 60669494 T C 1.90E-09 F-cell distribution / / 17767159 rs11884411 chr2 60669494 T C 2.98E-09 Fetal hemoglobin levels / / 18245381 rs11884411 chr2 60669494 T C 9.84E-08 Red blood cell traits / / 23222517 rs10490072 chr2 60669931 T C 3.10E-04 F-cell distribution / / 17767159 rs10490072 chr2 60669931 T C 5.57E-11 Red blood cell traits / / 23222517 rs12468946 chr2 60670477 A G 7.30E-09 F-cell distribution / / 17767159 rs17028192 chr2 60671339 C T 3.10E-04 F-cell distribution / / 17767159 rs13034649 chr2 60672255 C T 5.70E-05 F-cell distribution / / 17767159 rs13034649 chr2 60672255 C T 4.44E-11 Red blood cell traits / / 23222517 rs13034231 chr2 60677968 C A 5.93E-07 Red blood cell traits BCL11A nearGene-3 23222517 rs2058703 chr2 60679226 G A 4.23E-06 Platelet CD36 surface expression BCL11A UTR-3 21478428 rs17331129 chr2 60679942 T C 1.00E-05 F-cell distribution BCL11A intron 17767159 rs17331129 chr2 60679942 T C 2.01E-11 Fetal hemoglobin levels BCL11A intron 18245381 rs4672393 chr2 60697654 C A 2.00E-06 Urinary metabolites BCL11A intron 21572414 rs12477097 chr2 60698397 A C 4.10E-04 F-cell distribution BCL11A intron 17767159 rs12477097 chr2 60698397 A C 2.60E-07 Urinary metabolites BCL11A intron 21572414 rs12477097 chr2 60698397 A C 4.45E-08 Fetal hemoglobin levels BCL11A intron 22936743 rs4672394 chr2 60698461 C T 1.50E-06 Urinary metabolites BCL11A intron 21572414 rs733628 chr2 60702766 T C 5.70E-04 F-cell distribution BCL11A intron 17767159 rs7581162 chr2 60704484 T A 8.76E-07 Red blood cell traits BCL11A intron 23222517 rs7593947 chr2 60704933 A T 2.60E-05 Type 2 diabetes BCL11A intron 17463246 rs7593947 chr2 60704933 A T 4.18E-05 Bipolar disorder BCL11A intron 19488044 rs7593947 chr2 60704933 A T 6.07E-08 Red blood cell traits BCL11A intron 23222517 rs7593947 chr2 60704933 A T 8.46E-05 Bipolar Disorder BCL11A intron pha002863 rs34737760 chr2 60705608 C G 2.50E-04 F-cell distribution BCL11A intron 17767159 rs45445891 chr2 60706259 T G 3.90E-04 F-cell distribution BCL11A intron 17767159 rs12992182 chr2 60707038 C A 2.50E-04 F-cell distribution BCL11A intron 17767159 rs12997966 chr2 60707182 G A 2.10E-04 F-cell distribution BCL11A intron 17767159 rs7579014 chr2 60707894 G A 1.20E-06 F-cell distribution BCL11A intron 17767159 rs7579014 chr2 60707894 G A 7.08E-14 Fetal hemoglobin levels BCL11A intron 18245381 rs35908689 chr2 60707941 C G 2.50E-04 F-cell distribution BCL11A intron 17767159 rs6732518 chr2 60708597 C T 1.10E-21 F-cell distribution BCL11A intron 17767159 rs6732518 chr2 60708597 C T 2.87E-09 F-cell distribution BCL11A intron 21326311 rs6732518 chr2 60708597 C T 2.20E-17 Fetal hemoglobin levels BCL11A intron 22936743 rs13019832 chr2 60710571 G A 7.60E-12 F-cell distribution BCL11A intron 17767159 rs13019832 chr2 60710571 G A 2.96E-09 Other erythrocyte phenotypes BCL11A intron 19862010 rs11692396 chr2 60710738 G A 7.90E-12 F-cell distribution BCL11A intron 17767159 rs10189857 chr2 60713235 A G 2.00E-07 F-cell distribution BCL11A intron 21326311 rs10189857 chr2 60713235 A G 5.12E-07 Red blood cell traits BCL11A intron 23222517 rs6545816 chr2 60714861 A C 2.00E-07 F-cell distribution BCL11A intron 21326311 rs6545817 chr2 60715179 C T 2.00E-07 F-cell distribution BCL11A intron 21326311 rs13024177 chr2 60716308 G C 5.90E-04 F-cell distribution BCL11A intron 17767159 rs13031396 chr2 60717399 G T 2.10E-04 F-cell distribution BCL11A intron 17767159 rs1427407 chr2 60718043 T G 6.00E-31 F-cell distribution BCL11A intron 17767159 rs1427407 chr2 60718043 T G 2.00E-07 F-cell distribution BCL11A intron 21326311 rs7599488 chr2 60718347 C T 2.00E-07 F-cell distribution BCL11A intron 21326311 rs1896293 chr2 60718848 G T 2.00E-07 F-cell distribution BCL11A intron 17767159 rs1896294 chr2 60719074 C T 1.70E-10 F-cell distribution BCL11A intron 17767159 rs1896294 chr2 60719074 C T 2.00E-07 F-cell distribution BCL11A intron 21326311 rs766431 chr2 60719918 A G 2.70E-07 F-cell distribution BCL11A intron 17767159 rs766432 chr2 60719970 C A 1.80E-28 F-cell distribution BCL11A intron 17767159 rs766432 chr2 60719970 C A 1.00E-29 Fetal hemoglobin levels BCL11A intron 20018918 rs766432 chr2 60719970 C A 1.00E-10 Beta thalassemia/Hemoglobin E disease BCL11A intron 20183929 rs766432 chr2 60719970 C A 2.00E-07 F-cell distribution BCL11A intron 21326311 rs766432 chr2 60719970 C A 5.36E-58 Fetal hemoglobin levels BCL11A intron 22936743 rs766432 chr2 60719970 C A 9.00E-07 Sickle cell anemia (haemolysis) BCL11A intron 23406172 rs11886868 chr2 60720246 C T 4.20E-11 F-cell distribution BCL11A intron 17767159 rs11886868 chr2 60720246 C T 7.00E-35 Fetal hemoglobin levels BCL11A intron 18245381 rs11886868 chr2 60720246 C T 2.00E-07 F-cell distribution BCL11A intron 21326311 rs10195871 chr2 60720589 A G 5.40E-11 F-cell distribution BCL11A intron 17767159 rs10195871 chr2 60720589 A G 2.00E-07 F-cell distribution BCL11A intron 21326311 rs10195871 chr2 60720589 A G 2.14E-49 Fetal hemoglobin levels BCL11A intron 22936743 rs10172646 chr2 60720757 G A 4.30E-11 F-cell distribution BCL11A intron 17767159 rs10172646 chr2 60720757 G A 2.85E-33 Fetal hemoglobin levels BCL11A intron 18245381 rs10172646 chr2 60720757 G A 2.00E-07 F-cell distribution BCL11A intron 21326311 rs4671393 chr2 60720951 A G 2.60E-27 F-cell distribution BCL11A intron 17767159 rs4671393 chr2 60720951 A G 2.00E-07 F-cell distribution BCL11A intron 21326311 rs7584113 chr2 60721311 A G 2.90E-10 F-cell distribution BCL11A intron 17767159 rs7584113 chr2 60721311 A G 2.00E-07 F-cell distribution BCL11A intron 21326311 rs7557939 chr2 60721347 G A 4.60E-11 F-cell distribution BCL11A intron 17767159 rs7557939 chr2 60721347 G A 2.00E-07 F-cell distribution BCL11A intron 21326311 rs6706648 chr2 60722040 C T 9.30E-08 F-cell distribution BCL11A intron 17767159 rs6706648 chr2 60722040 C T 2.00E-07 F-cell distribution BCL11A intron 21326311 rs6706648 chr2 60722040 C T 3.97E-39 Fetal hemoglobin levels BCL11A intron 22936743 rs6738440 chr2 60722241 A G 6.00E-06 F-cell distribution BCL11A intron 17767159 rs6738440 chr2 60722241 A G 2.00E-07 F-cell distribution BCL11A intron 21326311 rs6738440 chr2 60722241 A G 2.95E-23 Fetal hemoglobin levels BCL11A intron 22936743 rs7565301 chr2 60723266 G A 2.00E-07 F-cell distribution BCL11A intron 21326311 rs6729815 chr2 60723672 T C 2.00E-07 F-cell distribution BCL11A intron 21326311 rs1896295 chr2 60724086 T C 2.00E-07 F-cell distribution BCL11A intron 21326311 rs1896296 chr2 60724087 G T 2.00E-07 F-cell distribution BCL11A intron 21326311 rs7606173 chr2 60725451 G C 4.71E-09 Other erythrocyte phenotypes BCL11A intron 19862010 rs7606173 chr2 60725451 G C 2.00E-07 F-cell distribution BCL11A intron 21326311 rs6709302 chr2 60727629 G A 1.10E-05 F-cell distribution BCL11A intron 17767159 rs6709302 chr2 60727629 G A 8.90E-10 F-cell distribution BCL11A intron 21326311 rs6709302 chr2 60727629 G A 3.42E-22 Fetal hemoglobin levels BCL11A intron 22936743 rs10184550 chr2 60729294 G A 3.83E-10 Fetal hemoglobin levels BCL11A intron 22936743 rs2556378 chr2 60762502 T G 7.00E-06 Attention deficit hyperactivity disorder BCL11A intron 22012869 rs13382983 chr2 60789053 G A 1.40E-05 Urinary metabolites / / 21572414 rs2901066 chr2 60797896 A C 2.61E-04 Insulin resistance / / 21901158 rs357002 chr2 60810195 A G 2.50E-05 Urinary metabolites / / 21572414 rs356999 chr2 60811584 A G 4.10E-04 Suicidal ideation / / 22030708 rs356998 chr2 60811719 G A 2.60E-05 Urinary metabolites / / 21572414 rs842775 chr2 60853939 C G 2.63E-04 Type 2 diabetes / / 17463246 rs6705125 chr2 60881975 C T 9.99E-04 Type 2 diabetes / / 17463246 rs2118480 chr2 60886477 G A 1.50E-04 Arthritis (juvenile idiopathic) / / 22354554 rs17031423 chr2 60893016 T C 4.49E-05 Job-related exhaustion / / 23620144 rs2420382 chr2 60896740 A C 8.15E-06 Job-related exhaustion / / 23620144 rs7589998 chr2 60924020 A G 5.00E-06 Obesity-related traits / / 23251661 rs13395150 chr2 60975288 A C 8.84E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7600065 chr2 61019699 C T 5.54E-06 Rheumatoid arthritis PAPOLG intron 19503088 rs13034020 chr2 61043834 A G 3.00E-06 Hodgkin's lymphoma / / 24920014 rs13034020 chr2 61043834 A G 1.66E-05 Cardiovascular disease / / pha003065 rs1432295 chr2 61066666 G A 2.00E-08 Hodgkin's lymphoma / / 21037568 rs1432295 chr2 61066666 G A 1.00E-06 Hodgkin's lymphoma / / 24149102 rs17538840 chr2 61077817 T A 1.60E-05 Urinary metabolites FLJ16341 intron 21572414 rs702873 chr2 61081542 C T 9.30E-08 Rheumatoid arthritis FLJ16341 intron 19503088 rs702873 chr2 61081542 C T 4.00E-09 Psoriasis FLJ16341 intron 20953190 rs702873 chr2 61081542 C T 2.00E-07 Psoriatic arthritis FLJ16341 intron 22170493 rs62149416 chr2 61083506 T C 1.80E-17 Psoriasis FLJ16341 intron 23143594 rs842633 chr2 61089317 G A 1.11E-04 Multiple complex diseases FLJ16341 intron 17554300 rs842636 chr2 61091950 G A 6.00E-06 Psoriasis FLJ16341 intron 20953189 rs842639 chr2 61095245 G A 4.31E-04 Schizophrenia FLJ16341 intron 19197363 rs10203477 chr2 61104985 A T 3.18E-05 Parkinson's disease FLJ16341 intron 17052657 rs842647 chr2 61119471 G A 5.24E-04 Schizophrenia REL intron 19197363 rs6545836 chr2 61122973 G A 2.30E-05 Urinary metabolites REL intron 21572414 rs34695944 chr2 61124850 T C 1.76E-08 Rheumatoid arthritis (CCP positive) REL intron 23143596 rs34695944 chr2 61124850 T C 8.54E-11 Rheumatoid arthritis REL intron 23143596 rs34695944 chr2 61124850 T C 2.00E-15 Rheumatoid arthritis REL intron 24390342 rs34695944 chr2 61124850 T C 4.00E-16 Rheumatoid arthritis REL intron 24390342 rs13031237 chr2 61136129 G T 6.01E-10 Rheumatoid arthritis REL intron 19503088 rs13031237 chr2 61136129 G T 8.00E-07 Rheumatoid arthritis REL intron 20453842 rs13031237 chr2 61136129 G T 2.00E-12 Celiac disease and Rheumatoid arthritis REL intron 21383967 rs13031237 chr2 61136129 G T 1.30E-06 Rheumatoid arthritis REL intron 22446963 rs13031237 chr2 61136129 G T 1.26E-11 Rheumatoid arthritis (CCP positive) REL intron 23143596 rs13031237 chr2 61136129 G T 1.40E-09 Rheumatoid arthritis REL intron 23143596 rs13017599 chr2 61164331 G A 2.00E-12 Rheumatoid arthritis / / 19503088 rs13017599 chr2 61164331 G A 1.00E-08 Psoriatic arthritis / / 22170493 rs13017599 chr2 61164331 G A 2.00E-12 Multiple sclerosis / / 22190364 rs13017599 chr2 61164331 G A 0.00019 Primary sclerosing cholangitis / / 22521342 rs6726160 chr2 61164729 T G 6.37E-05 Parkinson's disease / / 17052657 rs6726160 chr2 61164729 T G 1.47E-07 Celiac disease and Rheumatoid arthritis / / 21383967 rs6706689 chr2 61171045 A G 1.50E-04 Parkinson's disease PUS10 intron 17052657 rs6706689 chr2 61171045 A G 7.18E-08 Celiac disease and Rheumatoid arthritis PUS10 intron 21383967 rs12479056 chr2 61175312 T C 0.00000076 Primary sclerosing cholangitis PUS10 cds-synon 23603763 rs10208137 chr2 61178171 G A 1.80E-05 Urinary metabolites PUS10 intron 21572414 rs10176601 chr2 61179160 T C 2.10E-05 Urinary metabolites PUS10 intron 21572414 rs13003464 chr2 61186829 A G 1.57E-07 Crohn's disease PUS10 intron 18587394 rs13003464 chr2 61186829 A G 4.00E-13 Celiac disease PUS10 intron 20190752 rs13003464 chr2 61186829 A G 7.00E-09 Ulcerative colitis PUS10 intron 20228799 rs13003464 chr2 61186829 A G 4.00E-13 Asthma PUS10 intron 21150878 rs13003464 chr2 61186829 A G 3.71E-13 Celiac disease and Rheumatoid arthritis PUS10 intron 21383967 rs13003464 chr2 61186829 A G 4.30E-16 Celiac disease PUS10 intron 22057235 rs13003464 chr2 61186829 A G 3.71E-13 Multiple sclerosis PUS10 intron 22190364 rs13003464 chr2 61186829 A G 5.00E-09 Crohn's disease PUS10 intron 22412388 rs13003464 chr2 61186829 A G 4.30E-16 Celiac disease PUS10 intron 23143596 rs1864268 chr2 61202169 C G 9.74E-06 Response to platinum-based chemotherapy in small-cell lung cancer PUS10 intron 20463552 rs7608910 chr2 61204856 A G 2.00E-14 Ulcerative colitis PUS10 intron 21297633 rs7608910 chr2 61204856 A G 9.00E-32 Inflammatory bowel disease PUS10 intron 23128233 rs10188217 chr2 61217542 T C 6.36E-08 Crohn's disease PUS10 intron 18587394 rs10188217 chr2 61217542 T C 1.00E-11 Crohn's disease and celiac disease PUS10 intron 21298027 rs10181042 chr2 61224259 C T 3.90E-05 Type 2 diabetes PUS10 intron 17463246 rs10181042 chr2 61224259 C T 2.52E-04 Multiple complex diseases PUS10 intron 17554300 rs10181042 chr2 61224259 C T 7.00E-09 Crohn's disease PUS10 intron 21102463 rs9309333 chr2 61232705 G A 6.90E-04 Alzheimer's disease PUS10 intron 17998437 rs2564118 chr2 61233289 A G 1.95E-04 Type 2 diabetes PUS10 intron 17463246 rs12713431 chr2 61249676 A G 3.46E-04 Coronary Artery Disease PEX13 intron 17634449 rs1177234 chr2 61260063 C A 2.23E-04 Type 2 diabetes PEX13 intron 17463246 rs3108630 chr2 61268160 G A 2.08E-04 Type 2 diabetes PEX13 intron 17463246 rs1177279 chr2 61295122 A G 2.82E-04 Schizophrenia KIAA1841 intron 19197363 rs1177298 chr2 61306754 C A 4.61E-04 Type 2 diabetes KIAA1841 intron 17463246 rs1177264 chr2 61340450 G T 5.06E-05 Type 2 diabetes KIAA1841 intron 17463246 rs1177290 chr2 61346133 A G 1.99E-05 Type 2 diabetes KIAA1841 intron 17463246 rs1177274 chr2 61368532 T G 5.30E-05 Cognitive test performance / / 20125193 rs720201 chr2 61376463 T C 7.18E-04 Type 2 diabetes C2orf74 intron 17463246 rs720201 chr2 61376463 T C 3.52E-04 Response to platinum-based chemotherapy in small-cell lung cancer C2orf74 intron 20463552 rs1177309 chr2 61385248 A G 8.23E-05 Type 2 diabetes C2orf74 intron 17463246 rs3889717 chr2 61390791 A G 1.05E-04 Type 2 diabetes C2orf74 intron 17463246 rs1729662 chr2 61391305 G A 7.38E-05 Cognitive test performance C2orf74 intron 20125193 rs1729662 chr2 61391305 G A 3.35E-04 Coronary heart disease C2orf74 intron 21971053 rs777585 chr2 61412559 C T 2.07E-04 Type 2 diabetes AHSA2 intron 17463246 rs1059541 chr2 61414470 C G 4.57E-05 Response to platinum-based chemotherapy in small-cell lung cancer AHSA2 UTR-3 20463552 rs777587 chr2 61427675 A G 2.25E-04 Type 2 diabetes USP34 intron 17463246 rs7591772 chr2 61462400 C G 1.50E-04 Type 2 diabetes USP34 intron 17463246 rs17007356 chr2 61465504 G T 1.69E-05 Response to platinum-based chemotherapy in small-cell lung cancer USP34 intron 20463552 rs78404002 chr2 61466603 C T 0.0000342 Rheumatoid arthritis USP34 intron 23143596 rs10496091 chr2 61482261 G A 9.98E-05 Body Mass Index USP34 intron pha003006 rs10496091 chr2 61482261 G A 7.22E-06 Weight USP34 intron pha003026 rs10496091 chr2 61482261 G A 7.14E-05 Weight USP34 intron pha003027 rs2167566 chr2 61519408 T G 4.90E-05 Squamous cell carcinoma USP34 intron 23341777 rs2600672 chr2 61536740 G A 9.66E-04 Type 2 diabetes USP34 intron 17463246 rs2694619 chr2 61536901 C T 2.27E-04 Type 2 diabetes USP34 intron 17463246 rs2694618 chr2 61536984 C T 2.36E-04 Type 2 diabetes USP34 intron 17463246 rs17008218 chr2 61538054 T A 0.0000439 Rheumatoid arthritis USP34 intron 23143596 rs11680679 chr2 61540612 T C 5.54E-04 Major depressive disorder USP34 intron 22472876 rs1584301 chr2 61586132 T C 7.77E-05 Response to platinum-based chemotherapy in small-cell lung cancer USP34 intron 20463552 rs17008755 chr2 61604429 A G 4.48E-05 Response to platinum-based chemotherapy in small-cell lung cancer USP34 intron 20463552 rs10196146 chr2 61605379 C A 1.07E-04 Type 2 diabetes USP34 intron 17463246 rs17008940 chr2 61618598 C T 1.10E-04 Response to platinum-based chemotherapy in small-cell lung cancer USP34 intron 20463552 rs10496093 chr2 61618660 C T 1.10E-04 Response to platinum-based chemotherapy in small-cell lung cancer USP34 intron 20463552 rs4387777 chr2 61629635 C T 3.40E-05 Bipolar disorder USP34 intron 21771265 rs2463100 chr2 61659199 G C 7.12E-04 Type 2 diabetes USP34 intron 17463246 rs778139 chr2 61684564 G A 9.91E-04 Alcohol consumption (maxi-drinks) USP34 intron 24277619 rs1050567 chr2 61705663 C T 1.29E-04 Response to platinum-based chemotherapy in small-cell lung cancer XPO1 UTR-3 20463552 rs1050567 chr2 61705663 C T 2.89E-05 Attention deficit hyperactivity disorder XPO1 UTR-3 22420046 rs17009924 chr2 61727985 T C 0.0000947 Rheumatoid arthritis XPO1 intron 23143596 rs7563678 chr2 61741811 T C 1.13E-04 Type 2 diabetes XPO1 intron 17463246 rs3732171 chr2 61749690 C T 1.00E-04 Type 2 diabetes XPO1 intron 17463246 rs6545883 chr2 61772257 A G 5.00E-06 Tuberculosis / / 20694014 rs78534076 chr2 61776131 G C,T 0.0000491 Rheumatoid arthritis / / 23143596 rs778753 chr2 61780200 T A 1.16E-05 Tuberculosis / / 20694014 rs778757 chr2 61782047 C T 4.05E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs778764 chr2 61785680 C T 1.25E-05 Tuberculosis / / 20694014 rs9679654 chr2 61836773 T C 9.85E-05 Waist Circumference / / pha003024 rs9679654 chr2 61836773 T C 3.72E-05 Waist Circumference / / pha003025 rs7594191 chr2 61840018 C T 3.18E-04 Type 2 diabetes / / 17463246 rs1345207 chr2 61874015 G A 8.82E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2421332 chr2 61876965 T C 3.00E-09 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs4233975 chr2 61899141 G A 0.0000191 HDL cholesterol particle diameter / / 23263444 rs6705537 chr2 61919772 C A 9.58E-09 Multiple complex diseases / / 17554300 rs4672448 chr2 61928100 A C 4.82E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs1186868 chr2 61991238 G A 7.00E-35 Fetal Hemoglobin levels / / 18245381 rs10166783 chr2 62017085 G A 1.00E-04 Hemoglobin concentration / / 20534544 rs1534645 chr2 62027085 C A 2.62E-04 Hemoglobin concentration / / 20534544 rs2178293 chr2 62034474 A G 2.62E-04 Hemoglobin concentration / / 20534544 rs11688210 chr2 62036610 C T 3.71E-04 Hemoglobin concentration / / 20534544 rs7589969 chr2 62044253 G T 4.08E-04 Hemoglobin concentration / / 20534544 rs11125895 chr2 62069358 T C 3.71E-04 Hemoglobin concentration FAM161A missense 20534544 rs17014577 chr2 62071338 T C 1.30E-05 Urinary metabolites FAM161A intron 21572414 rs2272429 chr2 62107632 G A 5.19E-04 Hemoglobin concentration CCT4 intron 20534544 rs6756087 chr2 62118385 G A 5.23E-04 Type 2 diabetes / / 22158537 rs6722228 chr2 62159728 G A 2.07E-04 Coronary heart disease COMMD1 intron 21971053 rs7579874 chr2 62190001 C A 0.0001 Migraine COMMD1 intron 22678113 rs6755858 chr2 62197878 T C 5.50E-04 Multiple complex diseases COMMD1 intron 17554300 rs4672473 chr2 62240786 G T 0.0003 Migraine COMMD1 intron 22678113 rs17018107 chr2 62279008 C T 5.82E-04 Type 2 diabetes COMMD1 intron 17463246 rs6743108 chr2 62298745 C T 5.49E-05 Cognitive performance COMMD1 intron 19734545 rs7572994 chr2 62418558 C T 6.00E-05 Cognitive performance / / 19734545 rs7605321 chr2 62432133 G A 6.00E-04 Alcohol dependence B3GNT2 intron 20201924 rs11900673 chr2 62452661 C T 1.00E-08 Rheumatoid arthritis / / 22446963 rs13385025 chr2 62461120 G A 1.20E-05 Rheumatoid arthritis / / 24390342 rs13385025 chr2 62461120 G A 9.00E-07 Rheumatoid arthritis / / 24390342 rs11689568 chr2 62491643 C T 8.10E-06 Urinary metabolites / / 21572414 rs10200191 chr2 62497170 G A 2.10E-05 Urinary metabolites / / 21572414 rs10200191 chr2 62497170 G A 2.88E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10200712 chr2 62497902 C T 3.74E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs569393016 chr2 62497902 CGGAA C 3.74E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11676235 chr2 62502387 G T 2.60E-05 Urinary metabolites / / 21572414 rs4563212 chr2 62503017 C T 2.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4672495 chr2 62521244 G T 3.20E-09 Ankylosing spondylitis / / 20062062 rs7596545 chr2 62530227 C T 5.83E-04 Multiple complex diseases / / 17554300 rs10779949 chr2 62549445 C A 0.000244692 Primary sclerosing cholangitis / / 23603763 rs10865331 chr2 62551472 A G 5.32E-04 Multiple complex diseases / / 17554300 rs10865331 chr2 62551472 A G 2.00E-19 Ankylosing spondylitis / / 20062062 rs10865331 chr2 62551472 A G 7.00E-34 Ankylosing spondylitis / / 21743469 rs10865331 chr2 62551472 A G 4.50E-04 Myasthenia gravis / / 23055271 rs10865331 chr2 62551472 A G 1.00E-09 Crohn's disease / / 23128233 rs10865331 chr2 62551472 A G 4.70E-10 Psoriasis / / 23143594 rs4671421 chr2 62599559 A G 2.43E-05 Body Mass Index / / pha003020 rs4671421 chr2 62599559 A G 5.87E-05 Waist Circumference / / pha003024 rs75792394 chr2 62609078 G T 6.47E-06 Cocaine dependence / / 23958962 rs6545929 chr2 62610179 G A 7.82E-04 Multiple complex diseases / / 17554300 rs6706698 chr2 62706695 T C 2.40E-05 Urinary metabolites / / 21572414 rs6545944 chr2 62708186 G A 3.50E-06 Urinary metabolites / / 21572414 rs6545946 chr2 62713533 C T 7.00E-09 Crohn's disease / / 22412388 rs10202106 chr2 62720041 T C 9.95E-05 Schizophrenia / / 19571809 rs6545950 chr2 62751619 A G 1.70E-05 Urinary metabolites / / 21572414 rs1997247 chr2 62757555 G A 9.70E-07 Alcohol and nictotine co-dependence / / 20158304 rs6738968 chr2 62783777 C T 1.30E-05 Urinary metabolites / / 21572414 rs2049674 chr2 62783842 C T 7.48E-05 Multiple complex diseases / / 17554300 rs17025954 chr2 62805224 A G 0.0000074 Asthma (exacerbation) / / 23706709 rs1038570 chr2 62890171 C A 8.99E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7591708 chr2 63022050 T C 2.03E-05 Inflammation EHBP1 intron pha002897 rs6714241 chr2 63069112 T G 9.57E-04 Type 2 diabetes EHBP1 intron 17463246 rs1877026 chr2 63072208 A G 2.06E-05 Alcohol and nictotine co-dependence EHBP1 intron 20158304 rs11901070 chr2 63126755 T C 3.60E-05 Lung cancer EHBP1 intron 18385738 rs721048 chr2 63131731 G A 8.00E-09 Prostate cancer EHBP1 intron 18264098 rs721048 chr2 63131731 G A 8.00E-09 Nasopharyngeal carcinoma EHBP1 intron 20512145 rs2710646 chr2 63134879 C A 2.27E-06 Inflammation EHBP1 intron pha002897 rs2710642 chr2 63149557 G A 6.00E-09 LDL cholesterol EHBP1 intron 24097068 rs6545977 chr2 63301164 G A 5.00E-07 Prostate cancer / / 19767753 rs6545977 chr2 63301164 G A 5.00E-07 Nasopharyngeal carcinoma / / 20512145 rs6545977 chr2 63301164 G A 0.000006 Prostate cancer / / 23555315 rs6545977 chr2 63301164 G A 0.000017 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs13010733 chr2 63363355 T G 2.25E-04 Age-related macular degeneration WDPCP intron 22125219 rs13431765 chr2 63417729 T G 5.38E-05 Inflammation WDPCP intron pha002897 rs11125954 chr2 63474793 T C 4.34E-05 Glycosylated haemoglobin levels WDPCP intron 17255346 rs7585088 chr2 63484884 T C 6.54E-05 Glycosylated haemoglobin levels WDPCP intron 17255346 rs17474840 chr2 63485359 A G 6.70E-04 Urinary albumin excretion rate in type 1 diabetes WDPCP intron 24595857 rs1517408 chr2 63490493 A G 2.32E-04 Glycosylated haemoglobin levels WDPCP intron 17255346 rs2699393 chr2 63491438 G A 1.76E-04 Glycosylated haemoglobin levels WDPCP intron 17255346 rs2138798 chr2 63511435 G T 8.00E-07 Obesity-related traits WDPCP intron 23251661 rs7566860 chr2 63564683 T C 1.40E-04 Age-related macular degeneration WDPCP intron 22125219 rs11683229 chr2 63596836 A G 6.00E-06 Protein quantitative trait loci WDPCP intron 18464913 rs33977056 chr2 63744282 G A 0.0000224 Skin naphthyl-keratin adduct (NKA) levels in workers exposed to naphthalene WDPCP intron 22391508 rs2421954 chr2 63754275 T C 1.51E-04 Cardiovascular disease WDPCP intron 17903304 rs2278718 chr2 63815801 A C 7.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) MDH1 UTR-5 23648065 rs4671070 chr2 64012860 C T 2.80E-04 Type 2 diabetes / / 17463246 rs4671072 chr2 64087027 T A 7.74E-04 Multiple complex diseases UGP2 intron 17554300 rs3934536 chr2 64089373 G T 5.77E-05 Multiple complex diseases UGP2 intron 17554300 rs4616468 chr2 64104132 C T 4.66E-04 Multiple complex diseases UGP2 intron 17554300 rs12993544 chr2 64105553 A G 6.70E-04 Alcohol dependence UGP2 intron 20201924 rs11558741 chr2 64124722 C A 2.40E-05 Brain derived neurotrophic factor levels,in serum VPS54 missense 22047184 rs12999675 chr2 64136069 C A 8.75E-04 Multiple complex diseases VPS54 intron 17554300 rs17555655 chr2 64144829 T A 1.44E-04 Multiple complex diseases VPS54 intron 17554300 rs6736556 chr2 64180957 C T 2.40E-05 Brain derived neurotrophic factor levels,in serum VPS54 intron 22047184 rs6757168 chr2 64194247 C T 3.40E-05 Brain derived neurotrophic factor levels,in serum VPS54 intron 22047184 rs7560265 chr2 64196920 C T 7.06E-05 Brain derived neurotrophic factor levels,in serum VPS54 intron 22047184 rs6546043 chr2 64207445 C A 5.17E-05 Brain derived neurotrophic factor levels,in serum VPS54 intron 22047184 rs329478 chr2 64257746 T C 9.20E-04 Type 2 diabetes / / 17463246 rs193031 chr2 64260458 C G 9.60E-06 Aortic stiffness / / 22068335 rs13007342 chr2 64271155 T A 3.62E-04 Multiple complex diseases / / 17554300 rs17028360 chr2 64276197 A G 7.57E-05 Suicide attempts in bipolar disorder / / 21041247 rs10171434 chr2 64279606 C T 3.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs10171434 chr2 64279606 C T 2.50E-05 Urinary metabolites / / 21572414 rs7560803 chr2 64281498 G A 5.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs13429819 chr2 64283986 A G 5.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs17028375 chr2 64312142 T C 1.72E-09 Esophageal cancer / / 21642993 rs10496105 chr2 64320746 G A 8.08E-05 Type 2 diabetes and other traits PELI1 UTR-3 19734900 rs7604693 chr2 64349202 C A 2.00E-06 Kawasaki disease PELI1 intron 21221998 rs6733160 chr2 64364632 T C 7.00E-06 Allergic dermatitis (nickel) PELI1 intron 23921680 rs6710681 chr2 64413221 T C 1.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00309 intron 20877124 rs6710681 chr2 64413221 T C 2.00E-04 Chronic fatigue syndrome LINC00309 intron 21912186 rs6751738 chr2 64418379 C A 4.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00309 intron 20877124 rs1973848 chr2 64418456 T C 4.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00309 intron 20877124 rs10496108 chr2 64419656 A G 1.10E-04 Multiple complex diseases LINC00309 intron 17554300 rs12987393 chr2 64421514 T C 7.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00309 intron 20877124 rs6758601 chr2 64425094 G A 5.64E-04 Insulin resistance LINC00309 intron 21901158 rs1529102 chr2 64495627 G A 6.00E-06 Breast size / / 22747683 rs2698530 chr2 64503895 A C 1.00E-07 Iron status biomarkers / / 21483845 rs2698530 chr2 64503895 A C 2.00E-07 Iron status biomarkers / / 21483845 rs2698530 chr2 64503895 A C 4.00E-06 Iron status biomarkers / / 21483845 rs2698538 chr2 64507742 G A 8.08E-04 Type 2 diabetes / / 17463246 rs2433383 chr2 64517384 C T 6.89E-04 Depression (quantitative trait) / / 20800221 rs919123 chr2 64553440 A C 3.90E-04 Alcohol dependence / / 20201924 rs919123 chr2 64553440 A C 4.80E-04 Alcohol dependence / / 20201924 rs1365475 chr2 64559621 G A 5.75E-04 Type 2 diabetes / / 17463246 rs919122 chr2 64559966 G A 4.21E-04 Type 2 diabetes / / 17463246 rs2059630 chr2 64565907 T A 2.92E-04 Type 2 diabetes / / 17463246 rs1426698 chr2 64566825 G T 3.97E-04 Type 2 diabetes / / 17463246 rs12477412 chr2 64567680 T G 3.30E-04 Tourette syndrome / / 22889924 rs6546069 chr2 64595483 G C 1.26E-04 Smoking initiation / / 24665060 rs13411839 chr2 64607432 C G 8.77E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10176971 chr2 64618975 T C 7.08E-05 Smoking cessation / / 18519826 rs1426707 chr2 64619247 A C 7.53E-06 Smoking cessation / / 18519826 rs10496112 chr2 64623733 T G 3.30E-05 Blood Phenotypes / / 17903294 rs872241 chr2 64630299 A G 7.88E-05 Cognitive impairment induced by topiramate / / 22091778 rs13391261 chr2 64656409 G A 2.38E-04 Hemoglobin concentration / / 20534544 rs4671582 chr2 64661404 T C 1.03E-04 Hemoglobin concentration / / 20534544 rs7591656 chr2 64662732 T C 2.46E-04 Hemoglobin concentration / / 20534544 rs9309360 chr2 64663169 C T 9.97E-05 Cognitive impairment induced by topiramate / / 22091778 rs6733373 chr2 64665661 T C 2.38E-04 Hemoglobin concentration / / 20534544 rs10496113 chr2 64665970 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10496113 chr2 64665970 A G 8.23E-05 ldl cholesterol / / pha003076 rs10496114 chr2 64668253 G T 9.43E-04 Type 2 diabetes / / 17463246 rs10496114 chr2 64668253 G T 2.38E-04 Hemoglobin concentration / / 20534544 rs6761063 chr2 64672218 T A 9.43E-04 Type 2 diabetes / / 17463246 rs6729083 chr2 64680967 A G 4.76E-04 Hemoglobin concentration / / 20534544 rs13391620 chr2 64684663 A G 9.84E-04 Type 2 diabetes LGALSL intron 17463246 rs17743505 chr2 64684755 A G 5.20E-06 Urinary metabolites LGALSL intron 21572414 rs10496117 chr2 64687665 C A 2.66E-05 Cognitive impairment induced by topiramate LGALSL UTR-3 22091778 rs10496117 chr2 64687665 C A 9.52E-05 Cognitive impairment induced by topiramate LGALSL UTR-3 22091778 rs7355543 chr2 64693013 A C 2.05E-04 Response to TNF antagonist treatment / / 21061259 rs7355543 chr2 64693013 A C 1.80E-06 Urinary metabolites / / 21572414 rs6546073 chr2 64698397 G A 4.25E-04 Multiple complex diseases / / 17554300 rs12713521 chr2 64817256 G A 4.83E-04 Lung function (forced expiratory volume in 1 second) AFTPH intron 24023788 rs9653500 chr2 64820616 A G 2.00E-04 Multiple complex diseases / / 17554300 rs13020375 chr2 64829151 G A 3.81E-04 Sudden cardiac arrest / / 21658281 rs6546090 chr2 64839984 G T 5.27E-04 Multiple complex diseases / / 17554300 rs7557491 chr2 64852557 C A 4.85E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7591336 chr2 64868170 T A 7.19E-04 Multiple complex diseases SERTAD2 intron 17554300 rs7591336 chr2 64868170 T A 7.47E-04 Aortic root size SERTAD2 intron 21223598 rs17029216 chr2 64917229 C T 5.69E-05 Multiple complex diseases / / 17554300 rs2136451 chr2 64993045 G A 5.79E-04 Smoking cessation / / 24665060 rs17608651 chr2 65004346 G A 7.36E-04 Multiple complex diseases / / 17554300 rs10469881 chr2 65007992 T C 5.20E-04 Type 2 diabetes / / 17463246 rs929698 chr2 65008756 A C 3.59E-04 Parkinson's disease / / 17052657 rs7579416 chr2 65009646 C T 6.77E-04 Smoking initiation / / 24665060 rs17029460 chr2 65026936 C T 4.07E-04 Multiple complex diseases / / 17554300 rs11683197 chr2 65027624 T C 5.00E-06 Visceral fat / / 22589738 rs17661512 chr2 65050524 C T 2.90E-06 Urinary metabolites / / 21572414 rs6738590 chr2 65059603 A G 1.40E-04 Coronary heart disease / / 21606135 rs741477 chr2 65066311 A G 3.10E-05 Alzheimer's disease (late onset) / / 21460841 rs2048262 chr2 65101579 A C 6.16E-04 Multiple complex diseases / / 17554300 rs6546108 chr2 65103983 G A 4.05E-05 Height / / pha003010 rs918197 chr2 65106350 C T 6.49E-05 Height / / pha003010 rs11126023 chr2 65113153 G A 2.20E-05 Urinary metabolites / / 21572414 rs13022383 chr2 65130948 G A 4.17E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13027905 chr2 65131511 A G 3.02E-04 Type 2 diabetes / / 17463246 rs4140738 chr2 65132099 G A 4.42E-04 Type 2 diabetes LOC400958 intron 17463246 rs4140738 chr2 65132099 G A 5.80E-06 Urinary metabolites LOC400958 intron 21572414 rs2008831 chr2 65132540 C T 1.23E-04 Amyotrophic Lateral Sclerosis LOC400958 intron 17362836 rs34610365 chr2 65135673 A T 1.53E-04 Type 2 diabetes LOC400958 intron 17463246 rs41537649 chr2 65138117 G T 1.78E-04 Type 2 diabetes LOC400958 intron 17463246 rs41537649 chr2 65138117 G T 6.50E-06 Urinary metabolites LOC400958 intron 21572414 rs10490210 chr2 65170482 G A 1.16E-05 Type 2 diabetes / / 17463246 rs7576477 chr2 65174146 G C 2.67E-05 Type 2 diabetes / / 17463246 rs7590631 chr2 65174408 T G 1.40E-05 Type 2 diabetes / / 17463246 rs4671635 chr2 65180817 G A 3.88E-05 Waist Circumference / / pha003023 rs2017320 chr2 65193391 C T 7.19E-05 Waist Circumference / / pha003023 rs10211524 chr2 65208074 G A 4.49E-22 Metabolite levels / / 22286219 rs10211524 chr2 65208074 G A 3.00E-10 Metabolite levels (atherosclerosis) / / 22916037 rs10211524 chr2 65208074 G A 6.00E-16 Blood metabolite levels / / 24816252 rs10194107 chr2 65213822 T C 4.02E-12 Metabolite levels / / 22286219 rs10170033 chr2 65215257 C T 3.68E-12 Metabolite levels / / 22286219 rs2007061 chr2 65219030 T C 1.51E-12 Metabolite levels SLC1A4 intron 22286219 rs2160387 chr2 65220910 T C 3.00E-22 Metabolite levels SLC1A4 intron 22286219 rs1541580 chr2 65221184 C T 9.57E-13 Metabolite levels SLC1A4 intron 22286219 rs3770707 chr2 65226461 C A 1.14E-10 Metabolite levels SLC1A4 intron 22286219 rs3770706 chr2 65226463 G A 1.14E-10 Metabolite levels SLC1A4 intron 22286219 rs3770705 chr2 65230739 T C 0.00000437 Change in depression severity with antidepressants (NRI or SRI) SLC1A4 intron 23091423 rs2422358 chr2 65231806 A T 4.77E-17 Metabolite levels SLC1A4 intron 22286219 rs6546119 chr2 65235333 T G 6.85E-04 Multiple complex diseases SLC1A4 intron 17554300 rs1058922 chr2 65250541 A T 9.00E-06 Urinary metabolites SLC1A4 UTR-3 21572414 rs2422435 chr2 65257849 G A 4.19E-04 Smoking quantity / / 24665060 rs2302647 chr2 65283174 G A 2.00E-04 Asthma (aspirin-intolerant) / / 21072201 rs2302647 chr2 65283174 G A 5.00E-05 Asthma (aspirin-intolerant) / / 21072201 rs2241161 chr2 65290842 C A 9.39E-05 Schizophrenia CEP68 intron 24253340 rs2252867 chr2 65296280 T C 7.00E-05 Asthma (aspirin-intolerant) CEP68 intron 21072201 rs2252867 chr2 65296280 T C 9.00E-05 Asthma (aspirin-intolerant) CEP68 intron 21072201 rs7572857 chr2 65296798 G A 3.00E-05 Asthma (aspirin-intolerant) CEP68 missense 21072201 rs7572857 chr2 65296798 G A 6.00E-05 Asthma (aspirin-intolerant) CEP68 missense 21072201 rs2723087 chr2 65298282 T A 4.00E-04 Asthma (aspirin-intolerant) CEP68 intron 21072201 rs2723087 chr2 65298282 T A 9.00E-05 Asthma (aspirin-intolerant) CEP68 intron 21072201 rs2723090 chr2 65300995 G A 5.50E-06 Urinary metabolites CEP68 intron 21572414 rs6741255 chr2 65306905 C T 1.00E-04 Asthma (aspirin-intolerant) CEP68 intron 21072201 rs6741255 chr2 65306905 C T 5.00E-05 Asthma (aspirin-intolerant) CEP68 intron 21072201 rs1420185 chr2 65315903 G A 6.55E-04 Type 2 diabetes RAB1A intron 17463246 rs10187798 chr2 65333300 A G 1.00E-06 Urinary metabolites RAB1A intron 21572414 rs11885480 chr2 65336170 T C 4.40E-07 Urinary metabolites RAB1A intron 21572414 rs6546134 chr2 65431194 T C 7.58E-04 Type 2 diabetes / / 17463246 rs7581784 chr2 65435028 C A 9.49E-04 Type 2 diabetes / / 17463246 rs3771099 chr2 65476400 G T 6.20E-05 Hypertension (early onset hypertension) ACTR2 intron 22479346 rs4671646 chr2 65487672 G A 0.00017526 Hypertension (early onset hypertension) ACTR2 intron 22479346 rs268864 chr2 65489742 G A 0.000384216 Hypertension (early onset hypertension) ACTR2 intron 22479346 rs2287064 chr2 65491802 G A 0.00017526 Hypertension (early onset hypertension) ACTR2 intron 22479346 rs4671124 chr2 65495283 A G 7.38E-04 Amyotrophic lateral sclerosis (sporadic) ACTR2 intron 24529757 rs7561932 chr2 65545068 T C 7.71E-04 Response to cytadine analogues (cytosine arabinoside) SPRED2 intron 24483146 rs10170788 chr2 65546879 C T 4.20E-05 Response to Vitamin E supplementation SPRED2 intron 22437554 rs6546146 chr2 65556324 C A 0.000000603 Rheumatoid arthritis (CCP positive) SPRED2 intron 23143596 rs6546146 chr2 65556324 C A 0.0000008 Rheumatoid arthritis SPRED2 intron 23143596 rs6727281 chr2 65558588 C T 8.36E-04 Type 2 diabetes SPRED2 intron 17463246 rs2271198 chr2 65559027 A G 0.0000722 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs2271198 chr2 65559027 A G 7.22E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs17533992 chr2 65561543 T G 1.46E-04 Type 2 diabetes SPRED2 intron 17463246 rs10186240 chr2 65577651 T G 1.22E-05 Serum metabolites SPRED2 intron 19043545 rs10186240 chr2 65577651 T G 0.000051 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs10186240 chr2 65577651 T G 5.10E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs7559283 chr2 65578368 C T 0.0000504 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs7559283 chr2 65578368 C T 5.04E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs6711791 chr2 65579228 G T 0.0000118 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs6711791 chr2 65579228 G T 1.18E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs11126034 chr2 65580221 T C 9.35E-04 Multiple complex diseases SPRED2 intron 17554300 rs1396210 chr2 65584274 A G 0.0000412 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs1396210 chr2 65584274 A G 4.12E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs6738087 chr2 65592325 T C 0.0000348 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs6738087 chr2 65592325 T C 3.48E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs934734 chr2 65595586 G A 3.52E-05 Serum metabolites SPRED2 intron 19043545 rs934734 chr2 65595586 G A 5.00E-10 Rheumatoid arthritis SPRED2 intron 20453842 rs934734 chr2 65595586 G A 5.30E-10 Celiac disease and Rheumatoid arthritis SPRED2 intron 21383967 rs934734 chr2 65595586 G A 4.69E-05 Height SPRED2 intron 22021425 rs934734 chr2 65595586 G A 5.30E-10 Multiple sclerosis SPRED2 intron 22190364 rs934734 chr2 65595586 G A 5.50E-07 Rheumatoid arthritis SPRED2 intron 22446963 rs934734 chr2 65595586 G A 5.30E-10 Rheumatoid arthritis SPRED2 intron 23143596 rs934734 chr2 65595586 G A 0.0000119 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs934734 chr2 65595586 G A 1.19E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs934734 chr2 65595586 G A 2.00E-08 Rheumatoid arthritis SPRED2 intron 24782177 rs10188658 chr2 65597400 G A 1.77E-05 Height SPRED2 intron 22021425 rs11673987 chr2 65597671 A G 3.49E-08 Rheumatoid arthritis SPRED2 intron 23143596 rs17534153 chr2 65598222 C T 1.69E-05 Bipolar disorder SPRED2 intron 17486107 rs1858036 chr2 65598241 A G 7.48E-10 Rheumatoid arthritis (CCP positive) SPRED2 intron 23143596 rs1858037 chr2 65598300 T A 1.00E-08 Rheumatoid arthritis SPRED2 intron 24390342 rs1858037 chr2 65598300 T A 2.00E-09 Rheumatoid arthritis SPRED2 intron 24390342 rs1858037 chr2 65598300 T A 3.00E-15 Rheumatoid arthritis SPRED2 intron 24390342 rs268122 chr2 65602109 A T 4.20E-05 Serum metabolites SPRED2 intron 19043545 rs268122 chr2 65602109 A T 0.0000334 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs268122 chr2 65602109 A T 3.34E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs1866051 chr2 65602149 T C 0.00000878 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs1866051 chr2 65602149 T C 8.78E-06 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs174847 chr2 65605194 C T 0.000028 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs174847 chr2 65605194 C T 2.80E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs11689314 chr2 65605408 G T 0.0000275 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs11689314 chr2 65605408 G T 2.75E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs1194849 chr2 65606653 T C 2.75E-08 Celiac disease and Rheumatoid arthritis SPRED2 intron 21383967 rs1194849 chr2 65606653 T C 5.20E-04 Common variable immunodeficiency SPRED2 intron 21497890 rs1194849 chr2 65606653 T C 0.0000202 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs1194849 chr2 65606653 T C 2.02E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs268139 chr2 65606991 A C 0.0000199 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs268139 chr2 65606991 A C 1.99E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs198478 chr2 65607011 A G 0.0000197 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs198478 chr2 65607011 A G 1.97E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs268138 chr2 65607294 A G 1.99E-05 Serum metabolites SPRED2 intron 19043545 rs268138 chr2 65607294 A G 0.0000153 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs268138 chr2 65607294 A G 1.53E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs268136 chr2 65607543 C A,G,T 0.0000193 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs268136 chr2 65607543 C A,G,T 1.93E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs874952 chr2 65608525 G A 3.30E-04 Multiple complex diseases SPRED2 intron 17554300 rs1876518 chr2 65608909 C T 2.00E-08 Celiac disease and Rheumatoid arthritis SPRED2 intron 21383967 rs1876518 chr2 65608909 C T 0.000019 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs1876518 chr2 65608909 C T 1.90E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs268133 chr2 65609550 A C 5.46E-05 Erythrocyte counts SPRED2 intron pha003101 rs268132 chr2 65609677 T C 1.12E-04 Arthritis (juvenile idiopathic) SPRED2 intron 22354554 rs268132 chr2 65609677 T C 0.0000189 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs268132 chr2 65609677 T C 1.89E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs268131 chr2 65610471 T A 8.27E-04 Type 2 diabetes SPRED2 intron 17463246 rs268131 chr2 65610471 T A 5.80E-05 Serum metabolites SPRED2 intron 19043545 rs268131 chr2 65610471 T A 0.0000187 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs268131 chr2 65610471 T A 1.87E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs702875 chr2 65614197 T C 0.00000779 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs702875 chr2 65614197 T C 7.79E-06 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs1039764 chr2 65614613 T C 0.0000187 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs1039764 chr2 65614613 T C 1.87E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs17534670 chr2 65615428 G A 3.68E-05 Serum metabolites SPRED2 intron 19043545 rs17534670 chr2 65615428 G A 0.00000778 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs17534670 chr2 65615428 G A 7.78E-06 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs4303705 chr2 65619710 C T 0.0000187 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs4303705 chr2 65619710 C T 1.87E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs2661796 chr2 65627406 T C 0.0000186 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs2661796 chr2 65627406 T C 1.86E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs2661797 chr2 65633190 G A 0.0000185 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs2661797 chr2 65633190 G A 1.85E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs10496125 chr2 65635206 C A 6.18E-14 Lymphocyte counts SPRED2 intron 22286170 rs10496125 chr2 65635206 C A 1.84E-05 Erythrocyte counts SPRED2 intron pha003101 rs2661798 chr2 65635688 A T 2.94E-05 Serum metabolites SPRED2 intron 19043545 rs2661798 chr2 65635688 A T 0.0000223 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs2661798 chr2 65635688 A T 2.23E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs2661794 chr2 65639543 C A 0.0000366 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPRED2 intron 23233654 rs2661794 chr2 65639543 C A 3.66E-05 Methotrexate clearance (acute lymphoblastic leukemia) SPRED2 intron 23233662 rs6740462 chr2 65667272 C A 2.00E-08 Inflammatory bowel disease / / 23128233 rs6712418 chr2 65695395 C T 8.61E-04 Multiple complex diseases / / 17554300 rs6712418 chr2 65695395 C T 2.45E-04 Alzheimer's disease / / 17998437 rs840969 chr2 65702803 T C 8.59E-05 Crohn's disease / / 23850713 rs2244364 chr2 65710328 T C 0.0002439 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2244364 chr2 65710328 T C 2.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2244255 chr2 65710864 A G 0.0002395 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2244255 chr2 65710864 A G 2.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2244238 chr2 65711298 T G 0.0002896 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2244238 chr2 65711298 T G 2.90E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs840943 chr2 65715832 T C 0.0006324 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs840943 chr2 65715832 T C 6.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs840944 chr2 65715983 C A 0.0006183 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs840944 chr2 65715983 C A 6.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13432799 chr2 65722087 A G 3.23E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs13432799 chr2 65722087 A G 4.87E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs840958 chr2 65726198 G C 4.26E-04 Multiple complex diseases / / 17554300 rs840962 chr2 65727567 A C 8.57E-05 Bipolar disorder / / 18317468 rs702933 chr2 65741615 T C 9.16E-05 Caffeine consumption / / 21490707 rs702938 chr2 65747442 A G 6.02E-05 Major depressive disorder / / 22472876 rs3845816 chr2 65758355 A G 2.94E-05 Major depressive disorder / / 22472876 rs702891 chr2 65758450 C G 3.55E-05 Major depressive disorder / / 22472876 rs702891 chr2 65758450 C G 4.60E-04 Pulmonary function / / 23932459 rs3845817 chr2 65758525 T C 2.00E-06 Bipolar disorder / / 21926972 rs3845817 chr2 65758525 T C 1.98E-05 Major depressive disorder / / 22472876 rs3845817 chr2 65758525 T C 0.00000145 Bipolar disorder / / 23070075 rs3911862 chr2 65759671 A G 3.09E-05 Major depressive disorder / / 22472876 rs3911862 chr2 65759671 A G 0.0000565 Bipolar disorder / / 23637625 rs702909 chr2 65767247 G T 1.89E-05 Major depressive disorder / / 22472876 rs702919 chr2 65772291 C T 2.57E-05 Major depressive disorder / / 22472876 rs13003991 chr2 65772956 C G 4.07E-07 Bipolar disorder / / 22182935 rs13003991 chr2 65772956 C G 2.09E-05 Major depressive disorder / / 22472876 rs11678288 chr2 65774687 T A 4.58E-07 Bipolar disorder / / 22182935 rs11678288 chr2 65774687 T A 2.03E-05 Major depressive disorder / / 22472876 rs1673450 chr2 65783593 A G 6.18E-05 Body mass (lean) / / 19268274 rs897876 chr2 65791581 C T 2.00E-07 Hypertension (young onset) / / 24892410 rs1673442 chr2 65793878 A G 1.68E-04 Bipolar disorder / / 18317468 rs1673441 chr2 65794114 A G 9.14E-05 Bipolar disorder / / 18317468 rs11902125 chr2 65838800 G A 1.30E-06 Cystic fibrosis-related diabetes / / 23670970 rs1457451 chr2 65862378 G A 3.00E-06 Iron status biomarkers / / 19084217 rs4671136 chr2 65869241 T C 1.80E-04 Multiple complex diseases / / 17554300 rs1345351 chr2 65902188 G A 9.93E-04 Type 2 diabetes / / 17463246 rs1019365 chr2 65924908 C T 4.70E-05 Memory performance / / 22105620 rs2860851 chr2 65932417 T C 6.00E-05 Prostate cancer / / 21743057 rs13431495 chr2 65975754 G T 6.74E-05 Progressive supranuclear palsy / / 21685912 rs3845820 chr2 65976244 T G 3.44E-04 Taste perception / / 22132133 rs6546180 chr2 66006558 T C 2.52E-04 Myopia (pathological) / / 21095009 rs10179158 chr2 66012032 T C 5.76E-04 Myopia (pathological) / / 21095009 rs11682069 chr2 66014828 A G 6.60E-05 Response to statin therapy / / 20339536 rs10198911 chr2 66019696 A G 5.60E-05 Response to statin therapy / / 20339536 rs11693109 chr2 66021675 A C 4.30E-05 Response to statin therapy / / 20339536 rs10496130 chr2 66025474 T C 4.40E-05 Response to statin therapy / / 20339536 rs13396492 chr2 66025650 G A 4.80E-05 Response to statin therapy / / 20339536 rs6727797 chr2 66026431 T C 3.70E-05 Response to statin therapy / / 20339536 rs6727797 chr2 66026431 T C 6.42E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13406620 chr2 66028199 C T 5.80E-05 Response to statin therapy / / 20339536 rs17030858 chr2 66035660 T A 6.15E-05 Suicide attempts in bipolar disorder / / 21423239 rs17030866 chr2 66039793 G A 5.47E-04 Myopia (pathological) / / 21095009 rs6743363 chr2 66045064 G A 4.94E-04 Hemoglobin concentration / / 20534544 rs7595869 chr2 66066927 T C 6.76E-04 Multiple complex diseases / / 17554300 rs11686582 chr2 66077576 A T 8.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs12995236 chr2 66077753 G A 3.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs13412059 chr2 66077869 A G 6.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs13386707 chr2 66077918 C T 5.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs12713551 chr2 66078147 A G 5.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs6716340 chr2 66078264 T C 6.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs13414975 chr2 66078299 A G 7.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs10490586 chr2 66081606 A G 3.43E-05 Height / / 22021425 rs10490587 chr2 66081693 T C 8.97E-04 Schizophrenia / / 19197363 rs2194782 chr2 66082204 A G 1.60E-05 Crohn's disease / / 20570966 rs6719655 chr2 66089359 T C 8.91E-05 Coronary Artery Disease / / 17634449 rs17031012 chr2 66096120 C A 6.81E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10183336 chr2 66097560 G A 4.35E-04 Multiple complex diseases / / 17554300 rs12471713 chr2 66104282 G C 4.89E-06 Melanoma / / 21926416 rs17031071 chr2 66129494 G A 2.96E-04 Cholesterol / / 17255346 rs719832 chr2 66138791 A G 4.49E-05 Serum metabolites / / 19043545 rs6717463 chr2 66140128 A G 2.15E-05 Serum metabolites / / 19043545 rs6728803 chr2 66148466 A G 6.80E-07 Type 2 diabetes / / 21647700 rs17031166 chr2 66167064 G C 4.98E-06 Testicular cancer / / 19483682 rs1549383 chr2 66167564 G A 1.01E-06 Testicular cancer / / 19483682 rs1549383 chr2 66167564 G A 3.44E-06 Testicular cancer / / 21551455 rs17604526 chr2 66172199 G A 4.79E-05 Intelligence / / 21826061 rs6716270 chr2 66201731 T C 4.24E-04 Multiple complex diseases / / 17554300 rs6546200 chr2 66204736 C G 8.64E-05 Femoral neck bone geometry / / 22087292 rs1484475 chr2 66208119 A T 4.12E-05 Femoral neck bone geometry / / 22087292 rs13395694 chr2 66208800 C A 6.18E-06 Waist-hip ratio / / 20935629 rs10203404 chr2 66209299 A G 8.08E-05 Femoral neck bone geometry / / 22087292 rs10180226 chr2 66209485 G T 7.65E-05 Femoral neck bone geometry / / 22087292 rs10199102 chr2 66211303 T C 8.06E-05 Serum metabolites / / 19043545 rs13429325 chr2 66228401 G C 3.60E-05 Parkinson's disease (familial) / / 18985386 rs17031294 chr2 66236037 T G 1.76E-04 Multiple complex diseases / / 17554300 rs2699783 chr2 66258701 T C 6.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2699783 chr2 66258701 T C 7.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs2627857 chr2 66302093 G A 7.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs13409331 chr2 66305945 A G 9.11E-04 Multiple complex diseases / / 17554300 rs4671716 chr2 66358238 T C 3.73E-04 Alzheimer's disease (late onset) / / 21379329 rs11687648 chr2 66376064 T C 6.20E-04 Obesity (extreme) / / 21935397 rs1906900 chr2 66379789 G A 5.96E-04 Obesity (extreme) / / 21935397 rs10198265 chr2 66380826 C T 5.93E-04 Obesity (extreme) / / 21935397 rs6712489 chr2 66382388 A G 5.92E-04 Obesity (extreme) / / 21935397 rs7573350 chr2 66384249 T C 5.92E-04 Obesity (extreme) / / 21935397 rs13424573 chr2 66385433 A T 5.92E-04 Obesity (extreme) / / 21935397 rs6748113 chr2 66387107 A C 5.92E-04 Obesity (extreme) / / 21935397 rs7600569 chr2 66388139 A G 5.86E-04 Obesity (extreme) / / 21935397 rs2861009 chr2 66388290 T C 5.84E-04 Obesity (extreme) / / 21935397 rs6761361 chr2 66390890 A C 5.80E-04 Obesity (extreme) / / 21935397 rs12613969 chr2 66391046 A G 6.02E-04 Obesity (extreme) / / 21935397 rs1320859 chr2 66391442 C A 6.00E-04 Obesity (extreme) / / 21935397 rs10200852 chr2 66391832 G A 5.98E-04 Obesity (extreme) / / 21935397 rs10177124 chr2 66391841 A G 5.96E-04 Obesity (extreme) / / 21935397 rs2954974 chr2 66391895 G C 1.25E-04 Obesity (extreme) / / 21935397 rs1320861 chr2 66392262 T C 5.97E-04 Obesity (extreme) / / 21935397 rs1320862 chr2 66392325 G A 5.98E-04 Obesity (extreme) / / 21935397 rs1997383 chr2 66393650 T C 5.86E-04 Obesity (extreme) / / 21935397 rs1906901 chr2 66397457 G A 6.62E-04 Parkinson's disease / / 17052657 rs10496132 chr2 66397547 C T 6.62E-04 Parkinson's disease / / 17052657 rs12612632 chr2 66401580 C T 6.89E-05 Sarcoidosis / / 19165924 rs1038703 chr2 66426280 T G 0.00067 Salmonella-induced pyroptosis / / 22837397 rs2971817 chr2 66427978 A G 0.000518 Salmonella-induced pyroptosis / / 22837397 rs2971816 chr2 66428152 A G 0.000304 Salmonella-induced pyroptosis / / 22837397 rs2932245 chr2 66429851 G A 0.000746 Salmonella-induced pyroptosis / / 22837397 rs2951288 chr2 66430063 A G 0.000652 Salmonella-induced pyroptosis / / 22837397 rs2971814 chr2 66431813 T C 0.0000817 Salmonella-induced pyroptosis / / 22837397 rs6728427 chr2 66449706 C G 7.65E-04 Type 2 diabetes / / 17463246 rs11896357 chr2 66454478 C T 2.75E-04 Type 2 diabetes / / 17463246 rs1565328 chr2 66498775 A G 1.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11689807 chr2 66504005 A G 3.31E-05 Brain lesion load / / 19010793 rs10166869 chr2 66536557 G T 6.54E-04 Multiple complex diseases / / 17554300 rs4414666 chr2 66537344 G T 2.02E-05 Suicide attempts in bipolar disorder / / 21423239 rs4588174 chr2 66537359 A G 4.25E-05 Suicide attempts in bipolar disorder / / 21423239 rs2971834 chr2 66546314 A G 6.84E-05 Suicide attempts in bipolar disorder / / 21423239 rs2969694 chr2 66548543 C G 4.74E-05 Suicide attempts in bipolar disorder / / 21423239 rs6546221 chr2 66551522 C T 5.87E-04 Multiple complex diseases / / 17554300 rs2971826 chr2 66557236 C T 3.59E-04 Multiple complex diseases / / 17554300 rs1878944 chr2 66563484 T A 9.48E-05 Suicide attempts in bipolar disorder / / 21423239 rs1878945 chr2 66563517 G T 9.33E-05 Suicide attempts in bipolar disorder / / 21423239 rs2946371 chr2 66566690 A G 7.42E-04 Multiple complex diseases / / 17554300 rs2860235 chr2 66567896 T C 1.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs1519111 chr2 66571467 C G 5.05E-04 Multiple complex diseases / / 17554300 rs1401453 chr2 66581403 A C 1.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs2971811 chr2 66583690 G T 1.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs1401451 chr2 66584645 C G 1.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs10865352 chr2 66586934 C T 1.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs10211254 chr2 66591968 T A 5.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs2946370 chr2 66592411 C T 7.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs2222252 chr2 66592742 C T 6.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs6741807 chr2 66593273 G C 7.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs10182624 chr2 66602521 T G 9.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs1467229 chr2 66605631 T G 7.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs952203 chr2 66643773 A G 1.21E-04 Alzheimer's disease (late onset) / / 21379329 rs2049019 chr2 66671858 C A 8.13E-04 Response to cytidine analogues (gemcitabine) MEIS1 intron 24483146 rs11126079 chr2 66676367 G C 5.96E-04 Response to cytidine analogues (gemcitabine) MEIS1 intron 24483146 rs1519102 chr2 66677816 G C 8.47E-04 Response to cytidine analogues (gemcitabine) MEIS1 intron 24483146 rs1519103 chr2 66677881 G T 5.76E-04 Response to cytidine analogues (gemcitabine) MEIS1 intron 24483146 rs6716792 chr2 66687843 C A 7.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MEIS1 intron 20877124 rs6755563 chr2 66693328 T C 5.08E-04 Type 2 diabetes MEIS1 intron 17463246 rs6755563 chr2 66693328 T C 2.10E-04 Response to alcohol consumption (flushing response) MEIS1 intron 24277619 rs10203407 chr2 66698796 G A 7.66E-05 Alzheimer's disease (late onset) MEIS1 intron 21379329 rs6730722 chr2 66703251 A G 8.69E-04 Alzheimer's disease MEIS1 intron 24755620 rs7595378 chr2 66705785 C A 7.04E-04 Alzheimer's disease MEIS1 intron 24755620 rs17032114 chr2 66714597 A G 1.27E-04 Alzheimer's disease (late onset) MEIS1 intron 21379329 rs17032119 chr2 66715272 T G 8.02E-05 Type 2 diabetes MEIS1 intron 17463246 rs12471916 chr2 66715364 T G 5.04E-04 Type 2 diabetes MEIS1 intron 17463246 rs7563565 chr2 66716592 C T 1.34E-04 Alzheimer's disease (late onset) MEIS1 intron 21379329 rs10166707 chr2 66719503 A G 8.89E-04 Alzheimer's disease MEIS1 intron 24755620 rs2139246 chr2 66721860 G A 3.08E-04 Alzheimer's disease (late onset) MEIS1 intron 21379329 rs12619205 chr2 66725867 G A 4.64E-04 Aspirin exacerbated respiratory disease in asthmatics MEIS1 intron 23180272 rs13023583 chr2 66725940 T C 6.84E-04 Aspirin exacerbated respiratory disease in asthmatics MEIS1 intron 23180272 rs4300815 chr2 66746532 C A 8.87E-09 PR segment MEIS1 intron 24850809 rs4430933 chr2 66749610 A G 3.11E-08 PR segment MEIS1 intron 24850809 rs6742861 chr2 66750152 T C 8.29E-09 PR segment MEIS1 intron 24850809 rs11677371 chr2 66756413 A G 5.60E-09 PR interval MEIS1 intron 21347284 rs11677371 chr2 66756413 A G 3.24E-08 PR segment MEIS1 intron 24850809 rs3891585 chr2 66756976 A G 4.89E-09 PR interval MEIS1 intron 21347284 rs3891585 chr2 66756976 A G 1.00E-11 PR interval MEIS1 intron 23139255 rs3891585 chr2 66756976 A G 2.30E-08 PR segment MEIS1 intron 24850809 rs11693646 chr2 66759843 G A 4.92E-09 PR segment MEIS1 intron 24850809 rs11678354 chr2 66760079 T A 5.00E-09 PR segment MEIS1 intron 24850809 rs4433986 chr2 66760311 A G 5.19E-09 PR interval MEIS1 intron 21347284 rs4433986 chr2 66760311 A G 3.07E-08 PR segment MEIS1 intron 24850809 rs7603236 chr2 66762411 C T 3.93E-09 PR interval MEIS1 intron 21347284 rs7603236 chr2 66762411 C T 4.10E-08 PR segment MEIS1 intron 24850809 rs12469063 chr2 66764308 A G 6.52E-12 Restless legs syndrome MEIS1 intron 17637780 rs10865355 chr2 66764997 A G 2.94E-09 PR interval MEIS1 intron 21347284 rs10865355 chr2 66764997 A G 4.51E-08 PR segment MEIS1 intron 24850809 rs17625724 chr2 66768975 G A 9.13E-09 PR segment MEIS1 intron 24850809 rs11678796 chr2 66770035 G A 1.06E-08 PR segment MEIS1 intron 24850809 rs11897119 chr2 66772000 T C 5.00E-11 PR interval MEIS1 intron 20062060 rs3772026 chr2 66779866 G A 2.14E-08 PR segment MEIS1 intron 24850809 rs2300478 chr2 66781453 T G 7.41E-04 Type 2 diabetes MEIS1 intron 17463246 rs2300478 chr2 66781453 T G 3.00E-28 Restless legs syndrome MEIS1 intron 17637780 rs2300478 chr2 66781453 T G 3.00E-49 Restless legs syndrome MEIS1 intron 21779176 rs12614369 chr2 66792109 A G 3.60E-05 Malaria MEIS1 intron 19465909 rs10195834 chr2 66827052 G A 5.47E-05 Elbow pain / / pha003008 rs2861113 chr2 66831411 C T 1.39E-05 Elbow pain / / pha003008 rs1981736 chr2 66836319 G A 1.40E-05 Elbow pain / / pha003008 rs6756458 chr2 66868074 C T 1.68E-05 Elbow pain / / pha003008 rs11695019 chr2 66878488 A G 3.32E-05 F-cell distribution / / 21326311 rs11695019 chr2 66878488 A G 9.77E-05 Triglycerides / / pha003081 rs9941639 chr2 66896718 G T 2.86E-05 Elbow pain / / pha003008 rs7593598 chr2 66900322 C T 1.10E-05 Elbow pain / / pha003008 rs6745277 chr2 66900737 G A 7.96E-06 Elbow pain / / pha003008 rs6751774 chr2 66907476 C T 2.84E-04 Type 2 diabetes / / 17463246 rs1468817 chr2 66916737 C T 2.99E-04 Birth weight / / 17255346 rs6705424 chr2 66936494 T C 9.49E-05 Weight / / pha003026 rs10490191 chr2 66937329 G A 5.53E-05 Body Mass Index / / pha003014 rs10490191 chr2 66937329 G A 7.75E-05 Weight / / pha003026 rs12622301 chr2 66950851 T C 1.93E-05 Body Mass Index / / pha003014 rs12622301 chr2 66950851 T C 4.79E-05 Waist Circumference / / pha003024 rs12622301 chr2 66950851 T C 2.29E-05 Weight / / pha003026 rs12622301 chr2 66950851 T C 9.61E-05 Cardiovascular disease / / pha003064 rs1111233 chr2 66956502 A G 7.33E-05 Waist Circumference / / pha003024 rs1111233 chr2 66956502 A G 7.38E-05 Weight / / pha003026 rs1111233 chr2 66956502 A G 8.88E-05 Weight / / pha003027 rs1111233 chr2 66956502 A G 2.44E-05 Cardiovascular disease / / pha003064 rs2901879 chr2 66966066 C T 7.00E-07 Colorectal cancer (diet interaction) / / 24743840 rs11126097 chr2 67007492 A T 9.66E-04 Multiple complex diseases / / 17554300 rs10168064 chr2 67008311 C T 8.92E-04 Multiple complex diseases / / 17554300 rs9309394 chr2 67008629 T C 9.29E-05 Sarcoidosis / / 19165924 rs2194659 chr2 67014761 C T 6.60E-05 Multiple complex diseases / / 17554300 rs2194659 chr2 67014761 C T 2.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2194659 chr2 67014761 C T 5.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13018425 chr2 67050752 T C 7.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs3919596 chr2 67060126 A C 4.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs4671160 chr2 67060284 T A 5.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs1559600 chr2 67061154 A G 7.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6704842 chr2 67061235 T C 4.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs6747693 chr2 67061831 C T 4.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs1559604 chr2 67067641 T C 4.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs4671750 chr2 67071459 C T 4.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs1126147 chr2 67090833 G A 4.76E-04 Parkinson's disease / / 17052657 rs10519071 chr2 67144798 G T 7.81E-05 Alzheimer's disease (late onset) / / 21379329 rs1420369 chr2 67155259 A G 5.66E-04 Premature ovarian failure / / 19508998 rs12471464 chr2 67204642 T C 1.74E-05 Major depressive disorder / / 20516156 rs1362486 chr2 67208563 C A 0.0000277 Tuberculosis with late age of onset / / 22551897 rs1362475 chr2 67258675 A G 5.84E-05 Myopia (severe) / / 23933737 rs10519086 chr2 67262646 T G 9.15E-05 Alzheimer's disease / / 22005930 rs13016756 chr2 67265594 C T 2.50E-05 Urinary metabolites / / 21572414 rs12619502 chr2 67266506 T C 1.69E-04 Alzheimer's disease / / 22005930 rs746784 chr2 67271291 A G 5.19E-04 Smoking cessation / / 24665060 rs990255 chr2 67279175 A C 4.69E-04 Depression (quantitative trait) / / 20800221 rs7594674 chr2 67279960 G A 6.50E-04 Neuroticism / / 17667963 rs7594674 chr2 67279960 G A 4.01E-04 Smoking cessation / / 24665060 rs17032937 chr2 67280371 A G 5.80E-04 Multiple complex diseases / / 17554300 rs11676618 chr2 67282576 G T 8.41E-06 Periodontitis (CDC/AAP) / / 24024966 rs2861317 chr2 67290263 G A 7.63E-06 Periodontitis (CDC/AAP) / / 24024966 rs17032961 chr2 67290698 A G 4.34E-04 Depression (quantitative trait) / / 20800221 rs10179160 chr2 67291715 T C 8.57E-05 Platelet counts / / pha003100 rs1420365 chr2 67294779 C T 4.81E-05 Hypertension / / pha003042 rs1833219 chr2 67297409 A C 8.00E-06 Periodontitis (CDC/AAP) / / 24024966 rs17032968 chr2 67298283 C T 7.94E-04 Multiple complex diseases / / 17554300 rs4671772 chr2 67299855 G A 6.73E-05 Type 2 diabetes / / 17463246 rs17032971 chr2 67299931 C T 7.89E-04 Multiple complex diseases / / 17554300 rs13405122 chr2 67302866 C T 7.57E-05 Cognitive test performance / / 20125193 rs17033002 chr2 67305081 G T 4.52E-04 Depression (quantitative trait) / / 20800221 rs3821130 chr2 67307202 T C 4.53E-04 Depression (quantitative trait) / / 20800221 rs752939 chr2 67311169 G T 4.53E-04 Depression (quantitative trait) / / 20800221 rs752938 chr2 67311224 C G 4.53E-04 Depression (quantitative trait) / / 20800221 rs6741648 chr2 67313661 G A 4.53E-04 Depression (quantitative trait) / / 20800221 rs10196486 chr2 67323400 A G 5.69E-05 Blood Pressure / / pha003047 rs17033084 chr2 67332744 G C 3.86E-04 Depression (quantitative trait) / / 20800221 rs1921291 chr2 67340471 T C 7.82E-05 Blood Pressure / / pha003047 rs11897312 chr2 67340843 C T 1.39E-04 Type 2 diabetes / / 17463246 rs1921290 chr2 67341817 G T 8.76E-05 Blood Pressure / / pha003047 rs6721279 chr2 67368780 C T 7.21E-04 Smoking cessation LOC644838 intron 24665060 rs7600464 chr2 67381644 C T 7.60E-05 Hypertension LOC644838 intron pha003042 rs10199442 chr2 67387721 C A 2.12E-04 Smoking cessation LOC644838 intron 24665060 rs13403463 chr2 67402182 G A 1.11E-04 Blood pressure LOC644838 intron 17255346 rs13004577 chr2 67404326 A G 2.47E-04 Alzheimer's disease LOC644838 intron 17998437 rs13004577 chr2 67404326 A G 2.90E-06 Urinary metabolites LOC644838 intron 21572414 rs10183986 chr2 67438040 G A 8.21E-05 Cognitive performance LOC644838 intron 19734545 rs875037 chr2 67456700 T C 1.27E-04 Blood pressure / / 17255346 rs1483342 chr2 67467982 T C 1.52E-05 Blood pressure / / 17255346 rs2062204 chr2 67472545 A C 3.79E-05 Blood pressure / / 17255346 rs13012056 chr2 67472630 G A 1.06E-06 Kawasaki disease / / 21221998 rs17601386 chr2 67476026 G A 1.29E-04 Blood pressure / / 17255346 rs17033369 chr2 67506724 T C 1.60E-08 Non-obstructive azoospermia / / 22541561 rs12053284 chr2 67518237 G A 2.20E-05 Urinary metabolites / / 21572414 rs12713595 chr2 67523685 G A 1.65E-05 Blood pressure / / 17255346 rs10865359 chr2 67525436 A G 1.50E-05 Urinary metabolites / / 21572414 rs7572809 chr2 67539226 G A 9.94E-04 Depression (quantitative trait) / / 20800221 rs2128769 chr2 67542454 T C 7.88E-05 Blood pressure / / 17255346 rs6739392 chr2 67601971 A T 4.00E-06 Waist-hip ratio / / 23966867 rs2035565 chr2 67619656 C T 5.46E-07 Pancreatic cancer / / 22158540 rs6740919 chr2 67620055 C G 5.17E-05 Pulmonary function / / 17903307 rs13036061 chr2 67630476 T C 3.07E-04 Heart Failure ETAA1 missense pha002885 rs632647 chr2 67668847 G A 1.00E-04 Information processing speed / / 21130836 rs600524 chr2 67673780 G A 3.09E-04 Obesity (extreme) / / 21935397 rs600579 chr2 67673823 A T 3.12E-04 Obesity (extreme) / / 21935397 rs650129 chr2 67673930 C G 6.30E-04 Obesity (extreme) / / 21935397 rs12470994 chr2 67674506 C A 5.01E-04 Smoking initiation / / 24665060 rs13033289 chr2 67674538 A G 9.10E-04 Myocardial Infarction / / pha002883 rs6756612 chr2 67711468 A G 0.000203442 Hypertension (early onset hypertension) / / 22479346 rs1521043 chr2 67716030 T G 0.0002678 Hypertension (early onset hypertension) / / 22479346 rs4089733 chr2 67717239 A G 0.000113157 Hypertension (early onset hypertension) / / 22479346 rs7584345 chr2 67718290 C T 0.000408443 Hypertension (early onset hypertension) / / 22479346 rs17606508 chr2 67718362 T C 6.16E-09 Metabolite levels / / 23281178 rs17033681 chr2 67723565 A G 0.00089507 Hypertension (early onset hypertension) / / 22479346 rs1357011 chr2 67737672 A C 8.01E-05 HIV-1 viral setpoint / / 17641165 rs10490718 chr2 67744258 G T 4.09E-04 Type 2 diabetes / / 17463246 rs6739215 chr2 67749650 G A 4.00E-04 Primary sclerosing cholangitis / / 19944697 rs17033724 chr2 67751727 G A 8.03E-04 Multiple complex diseases / / 17554300 rs1607905 chr2 67757721 C G 2.20E-05 Urinary metabolites / / 21572414 rs2683687 chr2 67758663 A G 5.94E-04 Type 2 diabetes / / 17463246 rs2683687 chr2 67758663 A G 6.43E-04 HIV-1 viral setpoint / / 17641165 rs6546313 chr2 67771628 A C 3.10E-04 Primary sclerosing cholangitis / / 19944697 rs2861638 chr2 67776518 A C 4.50E-04 Endometriosis / / 21151130 rs13005138 chr2 67800265 G C 1.70E-05 Urinary metabolites / / 21572414 rs12997331 chr2 67804851 G C 2.80E-05 Urinary metabolites / / 21572414 rs41407847 chr2 67804935 G A 7.48E-04 Multiple complex diseases / / 17554300 rs12620828 chr2 67806472 A G,T 4.52E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs17033861 chr2 67828078 G A 1.53E-04 Coronary heart disease / / 21606135 rs13398112 chr2 67828614 T C 2.09E-04 Coronary heart disease / / 21606135 rs17034013 chr2 67863024 T C 2.76E-04 Multiple complex diseases / / 17554300 rs1367477 chr2 67864013 A G 8.31E-04 Multiple complex diseases / / 17554300 rs980226 chr2 67864313 G T 1.30E-05 Urinary metabolites / / 21572414 rs9309401 chr2 67864597 C T 7.69E-04 Multiple complex diseases / / 17554300 rs4141819 chr2 67864675 C T 9.00E-08 Endometriosis / / 23104006 rs10490726 chr2 67866542 G A 1.11E-05 Calcium levels / / pha003085 rs7572685 chr2 67870225 C T 7.11E-04 Multiple complex diseases / / 17554300 rs12476951 chr2 67880148 C T 9.34E-05 Bipolar disorder and schizophrenia / / 20889312 rs4671821 chr2 67890323 T C 8.20E-05 HIV-1 control / / 20041166 rs4671825 chr2 67908846 T C 1.68E-05 Bipolar disorder / / 19488044 rs4671825 chr2 67908846 T C 8.68E-05 Bipolar disorder and schizophrenia / / 20889312 rs4671826 chr2 67908949 C T 7.90E-06 Bipolar disorder / / 19488044 rs4671826 chr2 67908949 C T 6.60E-05 HIV-1 control / / 20041166 rs4671826 chr2 67908949 C T 2.66E-05 Bipolar disorder and schizophrenia / / 20889312 rs9309403 chr2 67911513 A G 3.90E-05 HIV-1 control / / 20041166 rs11675008 chr2 67916875 A G 3.56E-05 Major depressive disorder (broad) / / 20038947 rs11692071 chr2 67916928 T G 2.66E-05 Major depressive disorder (broad) / / 20038947 rs4671836 chr2 67918196 A G 2.58E-05 Major depressive disorder (broad) / / 20038947 rs10165761 chr2 67919554 T C 1.52E-05 Bipolar disorder and schizophrenia / / 20889312 rs1978657 chr2 67919897 C T 9.62E-06 Bipolar disorder and schizophrenia / / 20889312 rs4671839 chr2 67920930 T C 8.68E-05 Major depressive disorder (broad) / / 20038947 rs10169649 chr2 67921037 T A 5.69E-05 Major depressive disorder (broad) / / 20038947 rs4671840 chr2 67921216 A G 5.17E-05 Major depressive disorder (broad) / / 20038947 rs4671840 chr2 67921216 A G 0.000033 Major depressive disorder / / 23149448 rs4671841 chr2 67921411 A C 1.35E-05 Major depressive disorder (broad) / / 20038947 rs6735177 chr2 67924370 C A 1.10E-05 Iron levels / / 21208937 rs1367467 chr2 67932298 A G 1.30E-05 Major depressive disorder (broad) / / 20038947 rs989720 chr2 67932740 T C 1.48E-05 Major depressive disorder (broad) / / 20038947 rs1430770 chr2 67933079 G A 1.25E-05 Major depressive disorder (broad) / / 20038947 rs1430771 chr2 67933177 C G 4.64E-05 Major depressive disorder (broad) / / 20038947 rs13403823 chr2 67939457 C T 5.58E-06 Major depressive disorder (broad) / / 20038947 rs724566 chr2 67942202 T C 3.36E-05 Personality dimensions / / 22628180 rs724568 chr2 67942480 C A 5.00E-06 Major depressive disorder (broad) / / 20038947 rs17034213 chr2 67945022 A G 7.80E-06 Urinary metabolites / / 21572414 rs4671842 chr2 67945371 T C 7.87E-05 Major depressive disorder (broad) / / 20038947 rs1367458 chr2 67946328 C T 8.28E-05 Bipolar disorder and schizophrenia / / 20889312 rs10865363 chr2 67946891 C T 6.96E-06 Major depressive disorder (broad) / / 20038947 rs737358 chr2 67950632 G A 6.61E-06 Major depressive disorder (broad) / / 20038947 rs737359 chr2 67950714 C T 9.13E-05 Bipolar disorder and schizophrenia / / 20889312 rs934311 chr2 67950790 A G 3.70E-04 Hearing function / / 17255346 rs4671197 chr2 67952811 T C 7.97E-05 Major depressive disorder (broad) / / 20038947 rs4671197 chr2 67952811 T C 2.96E-04 Epilepsy / / 22116939 rs6758822 chr2 67956823 T C 7.59E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12477687 chr2 67957066 C T 5.33E-05 Bipolar disorder and schizophrenia / / 20889312 rs13432159 chr2 67973887 T G 9.00E-08 Response to antidepressant treatment / / 22041458 rs6724422 chr2 67976788 C T 1.90E-05 Urinary metabolites / / 21572414 rs6724422 chr2 67976788 C T 4.00E-07 Response to antidepressant treatment / / 22041458 rs12713602 chr2 67977997 A G 3.28E-05 Coronary heart disease / / pha003056 rs17034385 chr2 68003307 T C 1.89E-04 Lung function (forced vital capacity) / / 24023788 rs17616984 chr2 68022793 C T 3.13E-05 White matter integrity / / 22425255 rs1346866 chr2 68024446 G A 7.89E-04 Insulin resistance / / 21901158 rs11126158 chr2 68031007 G C 5.16E-04 Insulin resistance / / 21901158 rs6715551 chr2 68035962 T C 2.84E-04 Parkinson's disease / / 17052657 rs6747972 chr2 68070225 A G 9.00E-11 Restless legs syndrome / / 21779176 rs17034461 chr2 68088399 C A 7.75E-04 Multiple complex diseases / / 17554300 rs1910370 chr2 68095097 G A 7.78E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs17034538 chr2 68100458 C T 2.30E-05 Gaucher disease severity / / 22388998 rs17034763 chr2 68204413 C T 3.77E-04 Alcohol dependence / / 24277619 rs1921592 chr2 68207810 C A 3.94E-05 Cognitive test performance / / 20125193 rs974366 chr2 68214370 C T 5.46E-05 Cognitive test performance / / 20125193 rs6546347 chr2 68219788 G C 1.90E-04 Multiple complex diseases / / 17554300 rs1921589 chr2 68223525 G A 7.30E-05 Myopia (pathological) / / 21095009 rs1503244 chr2 68224343 T C 2.46E-04 Iron levels / / pha002876 rs17034837 chr2 68235872 G T 7.95E-04 Multiple complex diseases / / 17554300 rs146109287 chr2 68237913 T C 2.00E-07 Age-related nuclear cataracts / / 24951543 rs1921586 chr2 68241345 A G 1.49E-04 Myopia (pathological) / / 21095009 rs7558466 chr2 68250296 G T 8.58E-04 Iron levels / / pha002876 rs11681944 chr2 68322579 G A 0.0000328 Antithrombin / / 23705025 rs17034987 chr2 68338613 G A 3.69E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1075454 chr2 68342443 T C 8.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4078978 chr2 68359897 C T 2.00E-18 Immune reponse to smallpox (secreted IFN-alpha) WDR92 intron 22610502 rs6546357 chr2 68379038 G A 4.85E-05 Lymphocyte counts WDR92 intron 22286170 rs78556816 chr2 68386026 C T 1.00E-06 PR interval in Tripanosoma cruzi seropositivity PNO1 intron 24324551 rs6733029 chr2 68434157 T C 3.70E-04 Pulmonary function PPP3R1 intron 23932459 rs1822469 chr2 68454685 C T 9.00E-05 Height PPP3R1 intron 21194676 rs1822469 chr2 68454685 C T 9.30E-07 Height PPP3R1 intron 21194676 rs41427451 chr2 68492037 C T 5.42E-06 White blood cell count / / 21738479 rs2120335 chr2 68495002 G A 4.11E-05 Bipolar disorder / / 20451256 rs6546367 chr2 68495243 G A 4.27E-05 Bipolar disorder / / 20451256 rs10188159 chr2 68526730 T A 1.40E-04 Smoking initiation CNRIP1 intron 24665060 rs13025842 chr2 68546449 G A 5.72E-05 Coronary heart disease CNRIP1 cds-synon pha003030 rs9309413 chr2 68570772 G C,T 2.00E-09 Metabolite levels / / 19043545 rs7578047 chr2 68579931 A G 4.00E-06 Anger / / 24489884 rs7563924 chr2 68589234 T C 3.39E-04 Type 2 diabetes / / 17463246 rs17035378 chr2 68598955 T C 8.00E-09 Celiac disease PLEK intron 20190752 rs17035378 chr2 68598955 T C 8.00E-09 Asthma PLEK intron 21150878 rs17035378 chr2 68598955 T C 7.79E-09 Celiac disease and Rheumatoid arthritis PLEK intron 21383967 rs17035378 chr2 68598955 T C 7.79E-09 Multiple sclerosis PLEK intron 22190364 rs34515106 chr2 68607978 A C 0.000000215 Triglycerides PLEK missense 23063622 rs34515106 chr2 68607978 A C 0.000000467 Cholesterol,total PLEK missense 23063622 rs140933780 chr2 68613681 C T 0.00013 Prostate cancer (advanced) PLEK missense 23555315 rs6750761 chr2 68618216 G C 1.50E-04 Type 2 diabetes and 6 quantitative traits PLEK intron 17848626 rs10178792 chr2 68643625 T A 7.02E-04 Smoking cessation / / 24665060 rs10167650 chr2 68645560 T G 1.30E-04 Celiac disease / / 22057235 rs7592330 chr2 68646783 G A 2.00E-07 Multiple sclerosis / / 22190364 rs7595037 chr2 68647095 C T 5.00E-11 Multiple sclerosis / / 21833088 rs7595037 chr2 68647095 C T 1.60E-05 Multiple sclerosis / / 24234648 rs7602709 chr2 68649298 C T 8.38E-04 Multiple complex diseases / / 17554300 rs6759808 chr2 68650997 G A 4.00E-06 Obesity-related traits / / 23251661 rs11126184 chr2 68652174 C A 0.00000141 Obstructive sleep apnea / / 23155414 rs11126185 chr2 68652580 G A 5.00E-06 Obesity-related traits / / 23251661 rs7421154 chr2 68665945 C T 2.73E-04 Alzheimer's disease / / 22005930 rs7420089 chr2 68758389 C T 2.27E-05 Type 1 diabetes APLF intron 21980299 rs7560955 chr2 68770276 A G 7.50E-06 Urinary metabolites APLF intron 21572414 rs10193445 chr2 68804125 T A 2.10E-05 Urinary metabolites APLF intron 21572414 rs7593112 chr2 68808208 T C 2.00E-05 Urinary metabolites / / 21572414 rs12988094 chr2 68822422 T A 2.10E-05 Urinary metabolites / / 21572414 rs10179623 chr2 68823305 C G 2.80E-05 Urinary metabolites / / 21572414 rs7576538 chr2 68950454 A G 9.43E-04 Multiple complex diseases / / 17554300 rs7593402 chr2 68972726 G A 9.98E-04 Rheumatoid arthritis ARHGAP25 intron 21452313 rs4068868 chr2 68976604 G T 7.38E-04 Type 2 diabetes ARHGAP25 intron 17463246 rs13032797 chr2 69001171 C T 0.00000391 LDL cholesterol particle diameter ARHGAP25 intron 23263444 rs2311412 chr2 69010557 T C 1.70E-06 Urinary metabolites ARHGAP25 intron 21572414 rs11677065 chr2 69013007 T C 4.40E-05 Multiple complex diseases ARHGAP25 intron 17554300 rs11694733 chr2 69013166 C T 1.54E-04 Multiple complex diseases ARHGAP25 intron 17554300 rs11694785 chr2 69013251 C T 3.16E-04 Multiple complex diseases ARHGAP25 intron 17554300 rs7558602 chr2 69024789 T C 8.25E-05 HDL cholesterol ARHGAP25 intron pha003074 rs115522963 chr2 69033583 C T 3.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) ARHGAP25 intron 24159190 rs6743599 chr2 69036054 A G 6.33E-04 Type 2 diabetes ARHGAP25 intron 17463246 rs6743599 chr2 69036054 A G 5.43E-04 Response to taxane treatment (placlitaxel) ARHGAP25 intron 23006423 rs6707620 chr2 69058599 G C 4.29E-04 Multiple complex diseases / / 17554300 rs10496166 chr2 69063909 G A 4.00E-06 RR interval (heart rate) / / 20031603 rs4605401 chr2 69111016 T C 7.30E-04 Primary sclerosing cholangitis / / 19944697 rs6747865 chr2 69154946 G A 6.06E-04 Alzheimer's disease / / 22005930 rs2871928 chr2 69155271 A G 8.66E-04 Alzheimer's disease / / 22005930 rs4254535 chr2 69198388 T C 7.05E-06 Lung cancer / / 18978787 rs4254535 chr2 69198388 T C 5.00E-06 Lung cancer / / 19654303 rs4254535 chr2 69198388 T C 5.00E-06 Nasopharyngeal carcinoma / / 20512145 rs7586849 chr2 69199829 G A,T 5.90E-04 Multiple complex diseases / / 17554300 rs4462818 chr2 69208302 T G 6.45E-05 Tunica Media / / pha003034 rs4462818 chr2 69208302 T G 9.29E-05 Tunica Media / / pha003037 rs4462818 chr2 69208302 T G 7.56E-06 Serum albumin level / / pha003084 rs6716266 chr2 69245228 T G 1.00E-08 Asthma (childhood onset) ANTXR1 intron 17611496 rs4366940 chr2 69267134 G A 1.20E-05 Response to statin therapy ANTXR1 intron 20339536 rs12465132 chr2 69269894 G A 3.20E-05 Response to statin therapy ANTXR1 intron 20339536 rs12465994 chr2 69270261 G A 2.00E-05 Response to statin therapy ANTXR1 intron 20339536 rs11126214 chr2 69272116 C T 1.60E-05 Response to statin therapy ANTXR1 intron 20339536 rs11900784 chr2 69272496 A T 0.00000309 Nicotine dependence (smoking) ANTXR1 intron 23542338 rs7579629 chr2 69282532 C G 2.70E-05 Response to statin therapy ANTXR1 intron 20339536 rs12464309 chr2 69284111 G T 5.40E-05 Response to statin therapy ANTXR1 intron 20339536 rs4315565 chr2 69287943 A G 1.00E-08 Height ANTXR1 intron 21998595 rs12473368 chr2 69292224 G C 5.60E-05 Response to statin therapy ANTXR1 intron 20339536 rs1106518 chr2 69328218 G A 5.67E-05 Asthma ANTXR1 intron 23181788 rs6710260 chr2 69330118 A G 6.64E-04 Obesity (extreme) ANTXR1 intron 21935397 rs6710260 chr2 69330118 A G 0.000262779 Hypertension (early onset hypertension) ANTXR1 intron 22479346 rs6710260 chr2 69330118 A G 2.53E-05 Age-related macular degeneration ANTXR1 intron pha002856 rs4241349 chr2 69330284 G A 9.91E-04 Obesity (extreme) ANTXR1 intron 21935397 rs4241349 chr2 69330284 G A 3.26E-05 Hypertension (early onset hypertension) ANTXR1 intron 22479346 rs10179227 chr2 69330445 A G 0.000266695 Hypertension (early onset hypertension) ANTXR1 intron 22479346 rs12611797 chr2 69333577 G T 0.0001658 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ANTXR1 intron 23233654 rs12611797 chr2 69333577 G T 1.66E-04 Methotrexate clearance (acute lymphoblastic leukemia) ANTXR1 intron 23233662 rs11689690 chr2 69334220 C T 0.0001679 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ANTXR1 intron 23233654 rs11689690 chr2 69334220 C T 1.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) ANTXR1 intron 23233662 rs7564112 chr2 69343149 C T 1.53E-04 Obesity (extreme) ANTXR1 intron 21935397 rs13026824 chr2 69349219 G C 3.76E-04 Fibrinogen ANTXR1 intron 17255346 rs4358156 chr2 69354700 T C 2.49E-04 Fibrinogen ANTXR1 intron 17255346 rs13016276 chr2 69391521 T G 7.21E-05 Fibrinogen ANTXR1 intron 17255346 rs7599536 chr2 69396953 A G 6.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ANTXR1 intron 20877124 rs10182789 chr2 69410325 T G 8.40E-05 Heart Rate ANTXR1 intron pha003051 rs10189815 chr2 69414496 A G 1.89E-04 Fibrinogen ANTXR1 intron 17255346 rs4464317 chr2 69437291 C T 5.80E-06 Menarche (age at onset) ANTXR1 intron 19282985 rs4464317 chr2 69437291 C T 6.17E-05 Cortisol secretion,in saliva ANTXR1 intron 21316860 rs4384823 chr2 69437475 C T 8.26E-06 Menarche (age at onset) ANTXR1 intron 19282985 rs4484064 chr2 69444521 C T 8.19E-04 Type 2 diabetes ANTXR1 intron 17463246 rs4365492 chr2 69446251 G A 8.22E-04 Type 2 diabetes ANTXR1 intron 17463246 rs4365492 chr2 69446251 G A 5.67E-04 Multiple complex diseases ANTXR1 intron 17554300 rs11887039 chr2 69486729 G A 5.86E-04 Multiple complex diseases / / 17554300 rs6546493 chr2 69489816 A G 5.91E-04 Depression (quantitative trait) / / 20800221 rs4128633 chr2 69498192 C T 1.09E-05 Multiple complex diseases / / 17554300 rs13399511 chr2 69619363 C T 7.72E-04 Smoking initiation / / 24665060 rs10496170 chr2 69707752 A G 7.07E-04 Bipolar disorder AAK1 intron 19259986 rs41320747 chr2 69716915 G T 8.51E-04 Multiple complex diseases AAK1 intron 17554300 rs7577851 chr2 69723710 C T 9.00E-06 Parkinson's disease (age of onset) AAK1 intron 19772629 rs3771543 chr2 69784255 C T 4.30E-04 Smoking initiation AAK1 intron 24665060 rs13431612 chr2 69800579 T C 4.47E-04 Response to taxane treatment (placlitaxel) AAK1 intron 23006423 rs12987661 chr2 69813458 T C 6.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) AAK1 intron 23934736 rs2312215 chr2 69839825 T A 7.59E-04 Diabetic retinopathy AAK1 intron 20871662 rs6721715 chr2 69910110 A G 3.30E-04 Acute lung injury / / 22295056 rs12620484 chr2 69918942 A G 3.10E-04 Acute lung injury / / 22295056 rs12620484 chr2 69918942 A G 3.43E-05 Erythrocyte counts / / pha003099 rs35907069 chr2 69940780 G A 3.05E-04 Alzheimer's disease / / 22005930 rs6726789 chr2 69942011 A C 3.75E-05 Odorant perception / / 23910658 rs7597155 chr2 69985435 G A 5.00E-06 Palmitoleic acid (16:1n-7) plasma levels ANXA4 intron 23362303 rs13412112 chr2 69990290 T G 3.89E-05 Lung function (forced expiratory volume in 1 second) ANXA4 intron 24023788 rs721566 chr2 70013733 A G 2.06E-04 Smoking initiation ANXA4 intron 24665060 rs10496171 chr2 70015181 C T 9.94E-04 Multiple complex diseases ANXA4 intron 17554300 rs2228203 chr2 70033584 C T 6.10E-05 Smoking initiation ANXA4 missense 24665060 rs17037076 chr2 70033649 G A 3.50E-05 Smoking initiation ANXA4 intron 24665060 rs2124009 chr2 70034465 G C 9.08E-05 Smoking initiation ANXA4 intron 24665060 rs10173964 chr2 70043387 C T 2.00E-04 Multiple complex diseases ANXA4 intron 17554300 rs2290452 chr2 70047644 G A 1.94E-04 Smoking initiation ANXA4 intron 24665060 rs146778617 chr2 70052624 G T 0.000006 Prostate cancer ANXA4 missense 23555315 rs146778617 chr2 70052624 G T 0.000034 Prostate cancer (non-advanced prostate cancer) ANXA4 missense 23555315 rs7572381 chr2 70055042 T G 1.19E-04 Multiple complex diseases / / 17554300 rs2278933 chr2 70056365 A C 7.98E-05 Smoking initiation / / 24665060 rs4420721 chr2 70063527 C T 1.98E-04 Smoking initiation GMCL1 intron 24665060 rs17037145 chr2 70072464 A G 2.04E-04 Multiple complex diseases GMCL1 intron 17554300 rs17037193 chr2 70103504 T C 3.15E-04 Smoking initiation GMCL1 intron 24665060 rs2124007 chr2 70107409 A G 1.60E-04 Smoking initiation / / 24665060 rs7588986 chr2 70108071 C T 1.10E-04 Multiple complex diseases / / 17554300 rs1056482 chr2 70108256 T A 8.26E-05 Serum metabolites / / 19043545 rs2054046 chr2 70117074 T C 2.35E-05 Smoking initiation / / 24665060 rs10205487 chr2 70151471 A G 5.02E-04 Multiple sclerosis MXD1 intron 17660530 rs6731423 chr2 70173327 A C 1.85E-05 Erythrocyte counts / / pha003099 rs7583236 chr2 70182805 T C 4.00E-06 Obesity-related traits / / 23251661 rs140244507 chr2 70187809 G A 0.000093 Breast cancer ASPRV1 missense 23555315 rs116939658 chr2 70213304 C T 2.76E-05 Atopic dermatitis PCBP1-AS1 intron 23042114 rs117950954 chr2 70291839 G A 5.25E-05 Atopic dermatitis PCBP1-AS1 intron 23042114 rs6708331 chr2 70368923 G A 6.00E-06 Obesity-related traits / / 23251661 rs11677137 chr2 70389900 A G 1.80E-05 Urinary metabolites C2orf42 intron 21572414 rs7568216 chr2 70416197 C T 3.66E-05 HIV-1 viral setpoint C2orf42 intron 22174851 rs6750410 chr2 70417730 A G 4.84E-05 HIV-1 viral setpoint C2orf42 intron 22174851 rs7589857 chr2 70418339 T C 2.40E-05 Suicide attempts in bipolar disorder / / 21423239 rs7575953 chr2 70418368 C G 2.69E-05 Suicide attempts in bipolar disorder / / 21423239 rs11694045 chr2 70419373 T G 1.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs11690691 chr2 70426325 C T 8.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs10210930 chr2 70429805 C T 4.47E-04 Coronary heart disease / / 21606135 rs1059408 chr2 70436818 C T 9.48E-04 Type 2 diabetes TIA1 UTR-3 17463246 rs2289920 chr2 70442792 T C 2.86E-04 Multiple complex diseases TIA1 intron 17554300 rs6546578 chr2 70493210 T C 6.47E-05 Lipid levels PCYOX1 intron 19913121 rs6546579 chr2 70493282 G T 7.84E-05 Lipid levels PCYOX1 intron 19913121 rs6751173 chr2 70505908 G A 3.53E-04 Coronary heart disease PCYOX1 UTR-3 21606135 rs14234 chr2 70524142 A G 7.26E-05 Lymphocyte counts FAM136A UTR-3 22286170 rs13399467 chr2 70545542 C G 4.57E-04 Coronary heart disease / / 21606135 rs6751950 chr2 70560939 C T 2.16E-05 Brain structure / / 22504417 rs4852161 chr2 70562650 T C 1.40E-05 Brain structure / / 22504417 rs13394815 chr2 70564002 C A 9.21E-05 Multiple complex diseases / / 17554300 rs13394815 chr2 70564002 C A 2.38E-06 Brain structure / / 22504417 rs17654413 chr2 70572108 T C 9.05E-04 Type 2 diabetes / / 17463246 rs1871238 chr2 70574318 G T 1.86E-04 Brain structure / / 22504417 rs1478644 chr2 70576997 A G 7.44E-05 Brain structure / / 22504417 rs17615746 chr2 70579074 A G 5.66E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11690566 chr2 70581314 C T 6.74E-04 Multiple complex diseases / / 17554300 rs1551951 chr2 70596291 C T 1.07E-04 Parkinson's disease / / 21248740 rs4852569 chr2 70639236 A G 9.00E-05 Smoking initiation / / 24665060 rs1904212 chr2 70639877 T G 3.53E-04 Smoking initiation / / 24665060 rs6546600 chr2 70640522 T C 3.53E-04 Smoking initiation / / 24665060 rs6546602 chr2 70640754 C T 3.69E-04 Smoking initiation / / 24665060 rs12713695 chr2 70641028 C T 2.83E-04 Smoking initiation / / 24665060 rs4852573 chr2 70642013 C A 3.57E-04 Smoking initiation / / 24665060 rs6546604 chr2 70642807 G A 6.77E-04 Multiple complex diseases / / 17554300 rs6724948 chr2 70643919 G C 1.99E-04 Smoking initiation / / 24665060 rs3911081 chr2 70648684 A G 9.50E-05 Glioma (high-grade) / / 19578366 rs509664 chr2 70655613 G A 8.52E-04 Alzheimer's disease / / 22005930 rs494537 chr2 70659116 G A 8.44E-04 Alzheimer's disease / / 22005930 rs2461861 chr2 70664385 G A 8.63E-04 Alzheimer's disease / / 22005930 rs187293906 chr2 70665662 C T 5.00E-06 Acne (severe) / / 24927181 rs2461522 chr2 70665675 A G 9.37E-04 Alzheimer's disease / / 22005930 rs473698 chr2 70675581 C G 9.81E-04 Alzheimer's disease TGFA UTR-3 22005930 rs538118 chr2 70676639 A G 9.67E-04 Alzheimer's disease TGFA UTR-3 22005930 rs10172814 chr2 70680950 A G 0.00018 Coronary artery calcification TGFA intron 23727086 rs2278791 chr2 70683753 T C 0.0005 Coronary artery calcification TGFA intron 23727086 rs6749533 chr2 70691766 T C 4.36E-04 Smoking cessation TGFA intron 24665060 rs3771514 chr2 70697667 G A 8.00E-06 Obesity-related traits TGFA intron 23251661 rs3771512 chr2 70697720 C A 3.10E-04 Type 2 diabetes TGFA intron 17463246 rs3771502 chr2 70717507 A G 0.0000449 Polycystic ovary syndrome TGFA intron 22951595 rs3771502 chr2 70717507 A G 4.49E-05 Intracranial aneurysm TGFA intron 22961961 rs3911080 chr2 70719919 G A 1.00E-04 Cognitive impairment induced by topiramate TGFA intron 22091778 rs404420 chr2 70733526 T C 7.39E-04 Type 2 diabetes TGFA intron 17463246 rs7582571 chr2 70733788 A C 7.25E-05 Multiple complex diseases TGFA intron 17554300 rs454305 chr2 70736219 A G 5.00E-06 Neutrophil count TGFA intron 21507922 rs10198315 chr2 70742173 T G 5.76E-04 Multiple complex diseases TGFA intron 17554300 rs4521071 chr2 70743939 T C 5.75E-04 Multiple complex diseases TGFA intron 17554300 rs13393308 chr2 70744323 C T 1.60E-04 Multiple complex diseases TGFA intron 17554300 rs428225 chr2 70759161 T C 2.00E-04 Information processing speed TGFA intron 21130836 rs432203 chr2 70764688 C A 1.00E-06 Longevity TGFA intron 20834067 rs4852650 chr2 70775085 A G 1.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TGFA intron 20877124 rs17040266 chr2 70789532 A C 3.80E-04 Multiple complex diseases / / 17554300 rs2215021 chr2 70796257 A G 4.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2190649 chr2 70796476 C T 2.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3915035 chr2 70801709 G A 3.29E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs382925 chr2 70806369 C T 5.62E-04 Fibrinogen / / 17255346 rs17005910 chr2 70809246 C T 5.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11680093 chr2 70810066 C T 1.54E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11680093 chr2 70810066 C T 3.87E-04 Iron levels / / pha002876 rs2108482 chr2 70825461 C T 2.92E-05 Sudden cardiac arrest / / 21658281 rs11678699 chr2 70830411 T C 2.52E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2902451 chr2 70857059 T G 2.00E-05 Urinary metabolites / / 21572414 rs11903517 chr2 70865531 G T 7.06E-04 Multiple complex diseases / / 17554300 rs740389 chr2 70896100 A T 1.60E-05 Urinary metabolites ADD2 intron 21572414 rs740390 chr2 70897322 A G 3.30E-06 Urinary metabolites ADD2 intron 21572414 rs6750771 chr2 70901548 G A 3.30E-06 Urinary metabolites ADD2 intron 21572414 rs12470211 chr2 70912868 G A 3.53E-04 Alzheimer's disease ADD2 intron 22005930 rs11682965 chr2 70933659 T A 6.14E-04 Alzheimer's disease ADD2 intron 22005930 rs17006175 chr2 70941813 C G 4.33E-05 Receptive language ability ADD2 intron 24687471 rs3755369 chr2 70942964 G A 5.23E-05 Receptive language ability ADD2 intron 24687471 rs3771450 chr2 70943138 T G 1.84E-04 Alzheimer's disease ADD2 intron 22005930 rs3771449 chr2 70943418 A G 1.71E-04 Alzheimer's disease ADD2 intron 22005930 rs7597774 chr2 70943850 A C 2.05E-07 Dilated cardiomyopathy ADD2 intron 20975947 rs3755368 chr2 70944349 T C 2.56E-04 Alzheimer's disease ADD2 intron 22005930 rs3755365 chr2 70944565 A G 5.26E-04 Alzheimer's disease ADD2 intron 22005930 rs2052273 chr2 70944880 A G 3.47E-04 Amyotrophic lateral sclerosis (sporadic) ADD2 intron 24529757 rs3755361 chr2 70945251 T C 2.43E-04 Alzheimer's disease ADD2 intron 22005930 rs3771439 chr2 70949766 T A 1.98E-05 Serum metabolites ADD2 intron 19043545 rs3771434 chr2 70951723 C T 4.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADD2 intron 20877124 rs7584508 chr2 70952091 C A 1.28E-05 Lipoproteins ADD2 intron pha003079 rs1014592 chr2 70953985 G C 9.60E-04 Alzheimer's disease ADD2 intron 22005930 rs2192969 chr2 70956939 T C 9.59E-04 Alzheimer's disease ADD2 intron 22005930 rs3771426 chr2 70957503 A G 8.00E-05 Hypertension ADD2 intron 18003638 rs3771424 chr2 70958885 C T 4.06E-04 Smoking initiation ADD2 intron 24665060 rs3755353 chr2 70959327 G A 1.77E-06 Testicular cancer ADD2 intron 19483682 rs3771423 chr2 70959750 A G 8.00E-04 Alzheimer's disease ADD2 intron 22005930 rs3771412 chr2 70965438 A T 7.74E-04 Alzheimer's disease ADD2 intron 22005930 rs11126291 chr2 70965799 T G 5.77E-04 Suicide attempts in bipolar disorder ADD2 intron 21041247 rs3755352 chr2 70969783 A T 5.81E-04 Suicide attempts in bipolar disorder ADD2 intron 21041247 rs2052272 chr2 70970762 A T 8.12E-04 Alzheimer's disease ADD2 intron 22005930 rs6740913 chr2 70971685 A G 7.60E-04 Alzheimer's disease ADD2 intron 22005930 rs1861451 chr2 70973247 A G 4.67E-04 Smoking initiation ADD2 intron 24665060 rs3821251 chr2 70974700 T C 7.86E-04 Alzheimer's disease ADD2 intron 22005930 rs3755351 chr2 70974890 G T 1.70E-05 Hypertension ADD2 intron 18003638 rs3771409 chr2 70976012 T A 7.34E-04 Alzheimer's disease ADD2 intron 22005930 rs6741841 chr2 70980163 T C 8.21E-04 Alzheimer's disease ADD2 intron 22005930 rs3771408 chr2 70981146 A G 9.63E-05 Alzheimer's disease ADD2 intron 22005930 rs2863801 chr2 70991738 C T 1.36E-04 Multiple complex diseases ADD2 intron 17554300 rs2863801 chr2 70991738 C T 7.71E-04 Alzheimer's disease ADD2 intron 22005930 rs6707940 chr2 70998237 A G 1.72E-04 Alzheimer's disease / / 22005930 rs6749482 chr2 71001502 G A 6.04E-04 Alzheimer's disease / / 22005930 rs17655355 chr2 71005101 C G 3.62E-04 Alzheimer's disease FIGLA intron 22005930 rs12616540 chr2 71005727 A G 6.57E-04 Alzheimer's disease FIGLA intron 22005930 rs9646990 chr2 71005951 T C 6.62E-04 Alzheimer's disease FIGLA intron 22005930 rs7596564 chr2 71006246 G A 2.74E-04 Alzheimer's disease FIGLA intron 22005930 rs2024454 chr2 71006389 T C 6.15E-04 Alzheimer's disease FIGLA intron 22005930 rs6546626 chr2 71006632 G A 3.77E-04 Alzheimer's disease FIGLA intron 22005930 rs6709934 chr2 71007411 T C 6.51E-04 Alzheimer's disease FIGLA intron 22005930 rs13023269 chr2 71008396 T C 6.53E-04 Alzheimer's disease FIGLA intron 22005930 rs2080394 chr2 71009449 C T 4.12E-04 Alzheimer's disease FIGLA intron 22005930 rs6546629 chr2 71009593 G C 8.31E-04 Alzheimer's disease FIGLA intron 22005930 rs17038448 chr2 71011558 C T 7.02E-04 Alzheimer's disease FIGLA intron 22005930 rs7566700 chr2 71012946 C A 6.75E-04 Alzheimer's disease FIGLA intron 22005930 rs7566814 chr2 71013039 C T 7.74E-04 Alzheimer's disease FIGLA intron 22005930 rs10184254 chr2 71014322 T C 5.43E-04 Alzheimer's disease FIGLA intron 22005930 rs6546634 chr2 71016498 C A 6.00E-04 Alzheimer's disease FIGLA intron 22005930 rs17656087 chr2 71040352 A C 7.99E-04 Multiple complex diseases CLEC4F intron 17554300 rs2075221 chr2 71044211 C T 1.24E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CLEC4F missense 20031582 rs2863804 chr2 71052118 T C 4.96E-04 Multiple complex diseases / / 17554300 rs2110978 chr2 71052229 T C 6.75E-05 Multiple complex diseases / / 17554300 rs741326 chr2 71058835 A G 4.14E-05 Schizophrenia / / 19571811 rs4852708 chr2 71063942 C T 9.00E-06 IgG glycosylation / / 23382691 rs17006471 chr2 71068623 T C 3.04E-05 Cognitive impairment induced by topiramate / / 22091778 rs17006471 chr2 71068623 T C 1.11E-08 Atopic dermatitis / / 23886662 rs11889897 chr2 71076472 C T 0.0000105 Skin 2-naphthyl-keratin adduct (2NKA) levels in workers exposed to naphthalene / / 22391508 rs10167243 chr2 71090525 A G 7.88E-05 Atopic dermatitis / / 23042114 rs6723162 chr2 71102286 A T 2.18E-04 Body mass index / / 21701565 rs6723162 chr2 71102286 A T 6.99E-04 Body mass index / / 21701565 rs7594319 chr2 71118757 A G 1.81E-04 Body mass index / / 21701565 rs7594319 chr2 71118757 A G 2.61E-04 Body mass index / / 21701565 rs3771395 chr2 71133014 G A 2.00E-07 Corneal astigmatism VAX2 intron 23322567 rs10489991 chr2 71138371 C A 0.0000244 Tuberculosis with early age of onset VAX2 intron 22551897 rs11681519 chr2 71138685 T C 7.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VAX2 intron 20877124 rs11126309 chr2 71149293 C A 3.48E-04 Body mass index VAX2 intron 21701565 rs4852238 chr2 71152500 A C 4.19E-04 Body mass index VAX2 intron 21701565 rs6748268 chr2 71152850 T C 4.96E-05 Progressive supranuclear palsy VAX2 intron 21685912 rs10185490 chr2 71166840 A G 2.05E-04 Scoliosis ATP6V1B1 intron 21216876 rs11695103 chr2 71167025 G A 4.33E-04 Body mass index ATP6V1B1 intron 21701565 rs10165187 chr2 71167577 G A 4.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ATP6V1B1 intron 20877124 rs10165187 chr2 71167577 G A 5.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ATP6V1B1 intron 20877124 rs17006555 chr2 71169978 G C 0.000000361 HDL cholesterol ATP6V1B1 intron 23063622 rs10210235 chr2 71182900 T C 8.57E-05 Arthritis (juvenile idiopathic) ATP6V1B1 intron 22354554 rs3771383 chr2 71206626 G T 1.00E-04 Cognitive impairment induced by topiramate ANKRD53 intron 22091778 rs3771383 chr2 71206626 G T 4.89E-05 Glucose levels ANKRD53 intron pha003061 rs6760496 chr2 71234671 G A 5.53E-05 Weight / / pha003026 rs10196871 chr2 71235034 A G 4.32E-05 Suicide attempts in bipolar disorder / / 21041247 rs10188275 chr2 71235122 T C 4.32E-05 Suicide attempts in bipolar disorder / / 21041247 rs10189222 chr2 71236047 T C 4.45E-05 Suicide attempts in bipolar disorder / / 21041247 rs10179209 chr2 71236072 G A 4.51E-05 Suicide attempts in bipolar disorder / / 21041247 rs13420242 chr2 71263768 T C 8.34E-04 Insulin resistance / / 21901158 rs6724815 chr2 71285340 G A 3.23E-04 Alzheimer's disease / / 22005930 rs6725116 chr2 71285678 C T 3.97E-04 Hearing function / / 17255346 rs10167593 chr2 71285874 A C 2.10E-05 Urinary metabolites / / 21572414 rs9636399 chr2 71288912 T C 9.70E-06 Urinary metabolites / / 21572414 rs11126315 chr2 71291058 T C 1.90E-04 Multiple complex diseases / / 17554300 rs1458868 chr2 71376201 C T 2.70E-04 Birth weight MPHOSPH10 intron 17255346 rs115361918 chr2 71376471 G A 0.00032 Breast cancer (ER positive) MPHOSPH10 missense 23555315 rs357732 chr2 71381652 C T 8.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs370068 chr2 71403181 G C 3.04E-04 Gallstones / / 17632509 rs413693 chr2 71403616 T G 4.24E-04 Parkinson's disease / / 17052657 rs413693 chr2 71403616 T G 2.00E-06 Smoking behavior / / 20418888 rs413693 chr2 71403616 T G 3.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs413693 chr2 71403616 T G 1.48E-06 Left ventricular hypertrophy / / pha003052 rs450964 chr2 71408869 T C 9.79E-05 Serum metabolites / / 19043545 rs411758 chr2 71409237 A C 4.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs10210663 chr2 71409358 A G 7.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs3732238 chr2 71413984 A G 7.68E-04 Suicide attempts in bipolar disorder PAIP2B UTR-3 21423239 rs3821248 chr2 71414007 A G 7.56E-04 Suicide attempts in bipolar disorder PAIP2B UTR-3 21423239 rs3187463 chr2 71414645 A G 7.86E-04 Suicide attempts in bipolar disorder PAIP2B UTR-3 21423239 rs17006730 chr2 71416054 G A 7.84E-04 Suicide attempts in bipolar disorder PAIP2B intron 21423239 rs12615297 chr2 71431885 G A 2.46E-05 Monocyte counts PAIP2B intron pha003089 rs11692793 chr2 71432288 A G 4.60E-05 Monocyte counts PAIP2B intron pha003089 rs2418896 chr2 71436269 G A 1.80E-04 Rheumatoid arthritis PAIP2B intron 22446963 rs2418896 chr2 71436269 G A 2.76E-06 Left ventricular hypertrophy PAIP2B intron pha003052 rs741472 chr2 71436854 G A 8.13E-05 Alzheimer's disease PAIP2B intron 21098978 rs741472 chr2 71436854 G A 7.80E-04 Suicide attempts in bipolar disorder PAIP2B intron 21423239 rs6724890 chr2 71440847 C T 7.36E-04 Suicide attempts in bipolar disorder PAIP2B intron 21423239 rs4852772 chr2 71443645 A G 2.45E-04 Tourette syndrome PAIP2B intron 22889924 rs763713 chr2 71448455 G T 2.11E-04 Suicide attempts in bipolar disorder PAIP2B intron 21423239 rs2216372 chr2 71453160 G T 1.56E-04 Suicide attempts in bipolar disorder PAIP2B intron 21423239 rs6708352 chr2 71457571 T C 1.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs6546680 chr2 71463434 C G 5.10E-10 Non-obstructive azoospermia / / 22197933 rs6713034 chr2 71467971 G A 8.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs7594256 chr2 71469011 A G 1.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs17006807 chr2 71470998 T C 9.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs1870384 chr2 71471154 C T 7.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs1870385 chr2 71471456 T C 6.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs6750088 chr2 71478223 T A 7.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs2900806 chr2 71478797 C G 7.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs12987627 chr2 71485220 G A 5.67E-05 Taste perception / / 22132133 rs2609505 chr2 71488944 G T 4.91E-04 Tourette syndrome / / 22889924 rs2542530 chr2 71489804 G T 1.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs1544698 chr2 71490153 T C 6.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs6741028 chr2 71495162 G T 8.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs2542532 chr2 71495639 T C 2.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs1585290 chr2 71497654 T C 2.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs1458870 chr2 71505109 C G 2.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs2058897 chr2 71518186 T A 3.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs6546681 chr2 71518537 C G 3.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs7419694 chr2 71522113 T G 3.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs7598689 chr2 71522165 G A 3.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs6708788 chr2 71522879 T C 2.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs12612930 chr2 71525785 T C 2.00E-10 Height / / 23456168 rs72909550 chr2 71526524 G T 9.86E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2670746 chr2 71526624 T C 2.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs2670745 chr2 71526817 G A 1.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs2542545 chr2 71528842 G T 1.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs2542546 chr2 71528850 T C 1.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs7609266 chr2 71530558 G C 6.35E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2542547 chr2 71531413 C T 1.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs2670740 chr2 71531856 A G 1.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs2542485 chr2 71533729 G A 2.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs17743264 chr2 71534811 G C 8.62E-04 Parkinson's disease / / 16252231 rs17743264 chr2 71534811 G C 7.84E-04 Multiple complex diseases / / 17554300 rs2670734 chr2 71538826 C A 1.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs2670733 chr2 71539398 G T 1.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs1073877 chr2 71541660 G A 1.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs7584059 chr2 71548684 C G 1.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs2542489 chr2 71558113 G A 1.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs2257136 chr2 71558924 G T 1.33E-04 Suicide attempts in bipolar disorder ZNF638 UTR-5 21423239 rs3771381 chr2 71560665 A T 9.68E-04 Multiple complex diseases ZNF638 intron 17554300 rs2542490 chr2 71561053 G A 1.11E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs17692517 chr2 71563549 T G 8.67E-06 PR interval in Tripanosoma cruzi seropositivity ZNF638 intron 24324551 rs72909586 chr2 71567349 T C 5.70E-06 PR interval in Tripanosoma cruzi seropositivity ZNF638 intron 24324551 rs1990773 chr2 71567986 C G 1.56E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs7581030 chr2 71572455 C T 3.71E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs2670752 chr2 71573808 G A 4.95E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs2058899 chr2 71580129 G A 2.60E-05 Urinary metabolites ZNF638 intron 21572414 rs2542501 chr2 71583191 A G 8.80E-04 Tourette syndrome ZNF638 intron 22889924 rs2542505 chr2 71587797 C T 1.24E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs2542508 chr2 71588442 C T 1.03E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs2542511 chr2 71592444 G T 8.73E-05 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs6753560 chr2 71593535 G A 7.89E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs3755335 chr2 71594219 G A 7.81E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs2542513 chr2 71595238 C A 1.33E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs2542516 chr2 71598107 G A 1.31E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs17693250 chr2 71601434 T G 2.60E-05 Urinary metabolites ZNF638 intron 21572414 rs1024890 chr2 71601522 C T 1.76E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs2058900 chr2 71604238 T A 1.32E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs1990775 chr2 71610016 A G 1.10E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs7557781 chr2 71613914 A G 9.72E-06 PR interval in Tripanosoma cruzi seropositivity ZNF638 intron 24324551 rs6745147 chr2 71614454 A G 1.05E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs10208242 chr2 71614947 A G 4.32E-04 Taste perception ZNF638 intron 22132133 rs2542528 chr2 71615534 C T 1.04E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs13392164 chr2 71618323 A G 1.37E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs12713748 chr2 71620563 A G 1.28E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs13424541 chr2 71625767 G A 1.43E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs3771371 chr2 71627539 C T 4.10E-06 Urinary metabolites ZNF638 intron 21572414 rs3732235 chr2 71631109 A G 1.45E-04 Suicide attempts in bipolar disorder ZNF638 missense 21423239 rs3732234 chr2 71631296 T C 1.22E-04 Suicide attempts in bipolar disorder ZNF638 intron 21423239 rs13032033 chr2 71657168 G A 7.70E-05 Memory performance ZNF638 intron 22105620 rs4852259 chr2 71682950 C G 9.70E-06 Bipolar disorder DYSF intron 18317468 rs56988800 chr2 71688118 C A 1.00E-07 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs80255579 chr2 71690472 C A 5.41E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs74836064 chr2 71690528 G A 1.64E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs4362586 chr2 71690647 T C 1.69E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs4542877 chr2 71690715 G A 1.71E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs4629186 chr2 71690800 C T 1.75E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs11692280 chr2 71690860 G A 1.08E-05 Systemic sclerosis DYSF intron 21750679 rs74776753 chr2 71690944 G A 1.78E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs75252201 chr2 71691063 G A 1.80E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs111519406 chr2 71691099 G A 1.80E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs78624083 chr2 71691457 G C 1.88E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs78130680 chr2 71691604 C T 9.31E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs4538230 chr2 71691896 T A 1.90E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs4322872 chr2 71691899 A G 1.90E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs4547553 chr2 71691940 G A 1.91E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs4353676 chr2 71691942 A G 1.89E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs72896814 chr2 71692152 A G 1.11E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs80137915 chr2 71692195 G A 1.89E-06 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs79523511 chr2 71692883 C G 1.82E-07 PR interval in Tripanosoma cruzi seropositivity DYSF intron 24324551 rs12477276 chr2 71703364 A G 4.20E-06 Left ventricular hypertrophy DYSF intron pha003052 rs7574062 chr2 71716494 C T 2.62E-04 IgE levels DYSF intron 17255346 rs4852261 chr2 71722096 A G 4.73E-05 Prostate cancer DYSF intron pha002878 rs9309455 chr2 71733764 T C 5.85E-04 Multiple complex diseases DYSF intron 17554300 rs9309457 chr2 71733941 A G 2.66E-05 Parent of origin effect on language impairment (paternal) DYSF intron 24571439 rs11903960 chr2 71743376 T C 7.35E-04 Multiple complex diseases DYSF intron 17554300 rs11675613 chr2 71759702 C T 5.70E-04 Suicide attempts in bipolar disorder DYSF intron 21423239 rs4564797 chr2 71760554 G A 4.47E-04 Suicide attempts in bipolar disorder DYSF intron 21423239 rs4852806 chr2 71774011 T C 6.78E-05 Parent of origin effect on language impairment (paternal) DYSF intron 24571439 rs11690146 chr2 71779115 C T 2.40E-04 Suicide attempts in bipolar disorder DYSF intron 21423239 rs7568834 chr2 71806112 T C 8.95E-05 Cleft lip DYSF intron 20436469 rs1529409 chr2 71830689 T C 1.40E-05 Multiple sclerosis DYSF intron 17660530 rs13030767 chr2 71836525 T C 5.53E-05 Type 2 diabetes DYSF intron 17463246 rs1863810 chr2 71842536 G T 1.00E-04 Information processing speed DYSF intron 21130836 rs9677779 chr2 71903036 G A 2.87E-06 HIV-1 control DYSF intron 20041166 rs11126341 chr2 71916661 T C 4.78E-05 Epilepsy (remission after treatment) / / 23962720 rs7598653 chr2 71941150 A G 2.95E-06 White blood cell count / / 21738479 rs2900976 chr2 71958480 C T 1.00E-06 Protein quantitative trait loci / / 18464913 rs4123814 chr2 71975921 T G 1.10E-05 Urinary metabolites / / 21572414 rs1563740 chr2 71984140 T A 1.40E-05 Urinary metabolites / / 21572414 rs10865387 chr2 71994680 T A 2.40E-05 Urinary metabolites / / 21572414 rs12623780 chr2 71999008 C T 6.50E-06 Urinary metabolites / / 21572414 rs6754058 chr2 72005585 C T 2.90E-05 Urinary metabolites / / 21572414 rs2419778 chr2 72030760 G A 2.70E-05 Urinary metabolites / / 21572414 rs17007417 chr2 72035671 T C 9.70E-05 Creatinine levels / / pha003069 rs1471219 chr2 72066907 A G 2.27E-05 Lung adenocarcinoma / / 19836008 rs10192419 chr2 72074476 T C 1.39E-05 Lung adenocarcinoma / / 19836008 rs1380264 chr2 72101981 G C 1.62E-04 Type 2 diabetes / / 17463246 rs6716321 chr2 72110992 C G 4.33E-04 Type 2 diabetes / / 17463246 rs7584466 chr2 72111530 T C 8.11E-05 Coronary Artery Disease / / 17634449 rs2901028 chr2 72111683 T G 0.000841 Salmonella-induced pyroptosis / / 22837397 rs17486127 chr2 72111879 G C 4.15E-06 Lipid traits / / 21777205 rs7597548 chr2 72164912 G C 7.60E-06 Urinary metabolites / / 21572414 rs61220700 chr2 72181187 T C 4.57E-27 Metabolite levels / / 22286219 rs1517397 chr2 72189250 T C 9.42E-05 Tunica Media / / pha003034 rs4852833 chr2 72236929 G A 2.82E-05 Cognitive impairment induced by topiramate / / 22091778 rs955788 chr2 72237360 G A 7.32E-05 Cognitive impairment induced by topiramate / / 22091778 rs1878503 chr2 72251751 G A 1.69E-04 Scoliosis / / 21216876 rs4852838 chr2 72254272 C T 8.94E-05 Type 2 diabetes / / 17463246 rs13382212 chr2 72263628 T C 4.01E-04 Type 2 diabetes / / 17463246 rs4852279 chr2 72264864 A G 3.37E-04 Type 2 diabetes / / 17463246 rs741161 chr2 72268093 T A 9.21E-05 Type 2 diabetes / / 17463246 rs741161 chr2 72268093 T A 4.81E-04 Multiple complex diseases / / 17554300 rs17007727 chr2 72303473 T C 6.40E-05 HIV-1 control / / 20041166 rs13406776 chr2 72305463 G A 6.40E-05 HIV-1 control / / 20041166 rs10168803 chr2 72319253 C T 4.13E-04 Tourette syndrome / / 22889924 rs10194900 chr2 72325404 A C 1.33E-04 Tourette syndrome / / 22889924 rs2041666 chr2 72353573 G T 8.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2420201 chr2 72356370 G A 0.0006367 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CYP26B1 UTR-3 23233654 rs2420201 chr2 72356370 G A 6.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) CYP26B1 UTR-3 23233662 rs6546748 chr2 72383868 C T 4.92E-05 Intracerebral hemorrhage / / 24656865 rs10202129 chr2 72385492 G A 2.99E-05 Intracerebral hemorrhage / / 24656865 rs10174010 chr2 72387539 T C 1.48E-05 Intracerebral hemorrhage / / 24656865 rs11126362 chr2 72393138 C T 0.00006108 Sarcoidosis / / 22952805 rs194243 chr2 72394749 A G 0.00005191 Sarcoidosis / / 22952805 rs194242 chr2 72394893 A G 0.0000714 Sarcoidosis / / 22952805 rs1860853 chr2 72395048 A G 0.00003531 Sarcoidosis / / 22952805 rs35934538 chr2 72395048 AG A 0.00003531 Sarcoidosis / / 22952805 rs1860852 chr2 72395049 G A 0.00003223 Sarcoidosis / / 22952805 rs41414 chr2 72405827 A T 0.00008301 Sarcoidosis / / 22952805 rs41412 chr2 72407263 T C 0.00007478 Sarcoidosis EXOC6B intron 22952805 rs41407 chr2 72415803 C A 0.00005671 Sarcoidosis EXOC6B intron 22952805 rs41405 chr2 72416489 G C 0.00006077 Sarcoidosis EXOC6B intron 22952805 rs41403 chr2 72418689 C A 0.00002379 Sarcoidosis EXOC6B intron 22952805 rs13339845 chr2 72419864 A G 9.64E-04 Multiple complex diseases EXOC6B intron 17554300 rs41400 chr2 72420204 C T 0.00003973 Sarcoidosis EXOC6B intron 22952805 rs41398 chr2 72422160 T C 0.00005376 Sarcoidosis EXOC6B intron 22952805 rs41397 chr2 72422386 C A 0.00004422 Sarcoidosis EXOC6B intron 22952805 rs41394 chr2 72424868 T C 0.00004751 Sarcoidosis EXOC6B intron 22952805 rs41393 chr2 72425292 A G 0.00002684 Sarcoidosis EXOC6B intron 22952805 rs28278 chr2 72425439 C G 0.00003801 Sarcoidosis EXOC6B intron 22952805 rs41391 chr2 72427480 C A 0.00005338 Sarcoidosis EXOC6B intron 22952805 rs41390 chr2 72427905 G C 0.00005894 Sarcoidosis EXOC6B intron 22952805 rs41389 chr2 72428379 C T 0.00005981 Sarcoidosis EXOC6B intron 22952805 rs41388 chr2 72428488 A G 0.00007119 Sarcoidosis EXOC6B intron 22952805 rs17673916 chr2 72487364 T C 1.50E-05 Urinary metabolites EXOC6B intron 21572414 rs10175915 chr2 72488160 T A 1.50E-05 Urinary metabolites EXOC6B intron 21572414 rs10175915 chr2 72488160 T A 4.28E-05 Blood pressure EXOC6B intron 21909110 rs17725024 chr2 72498920 T C 6.30E-06 Urinary metabolites EXOC6B intron 21572414 rs6719255 chr2 72500375 G A 7.20E-06 Urinary metabolites EXOC6B intron 21572414 rs10204415 chr2 72507640 T C 8.99E-04 Response to cytadine analogues (cytosine arabinoside) EXOC6B intron 24483146 rs11126370 chr2 72725947 G A 7.40E-04 Alcohol dependence EXOC6B intron 20201924 rs2138683 chr2 72735509 G A 4.90E-04 Alcohol dependence EXOC6B intron 20201924 rs10496185 chr2 72748616 A G 1.03E-05 Bilirubin levels,in serum EXOC6B intron 19389676 rs12471136 chr2 72789317 A G 8.00E-04 Alcohol dependence EXOC6B intron 20201924 rs1446890 chr2 72795730 G A 8.80E-04 Alcohol dependence EXOC6B intron 20201924 rs10203912 chr2 72933110 T C 4.14E-04 Multiple complex diseases EXOC6B intron 17554300 rs7593084 chr2 73013836 C T 5.04E-04 Multiple complex diseases EXOC6B intron 17554300 rs4852896 chr2 73073494 A C 5.90E-04 Multiple complex diseases / / 17554300 rs1161267 chr2 73122181 G A 2.69E-04 Blood pressure / / 21909110 rs768851 chr2 73378241 G A 5.55E-05 Elbow pain / / pha003008 rs2043092 chr2 73407076 C T 1.30E-04 Myasthenia gravis / / 23055271 rs11886257 chr2 73416873 C T 3.93E-06 Elbow pain / / pha003008 rs7599223 chr2 73427103 A G 7.20E-06 Elbow pain / / pha003008 rs7557285 chr2 73442812 G A 5.06E-06 Elbow pain SMYD5 intron pha003008 rs2303904 chr2 73447775 A G 7.68E-04 Nicotine smoking SMYD5 intron 19268276 rs3188114 chr2 73454256 G A 1.93E-04 Nicotine smoking SMYD5 UTR-3 19268276 rs1474298 chr2 73466592 G A 3.42E-05 Elbow pain CCT7 intron pha003008 rs7557055 chr2 73472670 G A 1.80E-06 Elbow pain CCT7 intron pha003008 rs502930 chr2 73492220 T C 9.13E-04 Myopia (pathological) FBXO41 intron 21095009 rs6718864 chr2 73574591 A G 9.03E-06 F-cell distribution / / 21326311 rs1918863 chr2 73644481 A G 1.60E-05 Urinary metabolites ALMS1 intron 21572414 rs2421549 chr2 73658573 T C 2.12E-04 Alzheimer's disease ALMS1 intron 24755620 rs7585004 chr2 73666645 G C 1.80E-05 Urinary metabolites ALMS1 intron 21572414 rs12104768 chr2 73674966 T C 3.60E-37 Urinary metabolites (H-NMR features) ALMS1 intron 24586186 rs6546837 chr2 73677898 G C 3.28E-08 Chronic kidney disease ALMS1 missense 21931561 rs10496192 chr2 73679866 T C 2.53E-04 Diabetic retinopathy ALMS1 missense 20871662 rs34183407 chr2 73681179 C T 1.32E-72 Cholesterol,total ALMS1 missense 23063622 rs34183407 chr2 73681179 C T 2.39E-78 HDL cholesterol ALMS1 missense 23063622 rs34183407 chr2 73681179 C T 3.20E-14 Triglycerides ALMS1 missense 23063622 rs34183407 chr2 73681179 C T 5.58E-49 LDL cholesterol ALMS1 missense 23063622 rs6749680 chr2 73685852 G A 7.00E-04 Iron levels ALMS1 intron pha002876 rs7607014 chr2 73730174 A G 6.90E-06 Urinary metabolites ALMS1 intron 21572414 rs7598660 chr2 73740425 G A 1.38E-04 Type 2 diabetes ALMS1 intron 17463246 rs9309473 chr2 73743982 A G 1.00E-11 Metabolite levels ALMS1 intron 21931564 rs11884776 chr2 73746923 C T 6.00E-17 Urinary metabolites (H-NMR features) ALMS1 cds-synon 24586186 rs10469966 chr2 73752368 G A 1.00E-51 Blood metabolite levels ALMS1 intron 24816252 rs13008860 chr2 73774019 G A 2.80E-04 Iron levels ALMS1 intron pha002876 rs6546847 chr2 73785358 A G 1.00E-17 Urinary metabolites (H-NMR features) ALMS1 intron 24586186 rs6546847 chr2 73785358 A G 5.00E-161 Urinary metabolites (H-NMR features) ALMS1 intron 24586186 rs13391552 chr2 73818936 G A 5.00E-252 Metabolic traits ALMS1 intron 21886157 rs1052161 chr2 73828538 G A 4.49E-04 Iron levels ALMS1 missense pha002876 rs1052162 chr2 73829372 C T 8.00E-06 Urinary metabolites ALMS1 cds-synon 21572414 rs17349853 chr2 73831714 T G 3.04E-04 Iron levels ALMS1 intron pha002876 rs6546857 chr2 73837955 A G 1.00E-23 Metabolite levels (X-11787) / / 23934736 rs6745480 chr2 73840055 G A 5.40E-06 Urinary metabolites / / 21572414 rs13538 chr2 73868328 A G 5.00E-14 Chronic kidney disease /T8 missense 20383146 rs13538 chr2 73868328 A G 6.98E-10 Chronic kidney disease /T8 missense 22479191 rs13538 chr2 73868328 A G 1.70E-08 Glomerular filtration rate /T8 missense 23535967 rs13538 chr2 73868328 A G 1.80E-08 Glomerular filtration rate /T8 missense 23535967 rs13538 chr2 73868328 A G 1.80E-09 Glomerular filtration rate /T8 missense 23535967 rs13538 chr2 73868328 A G 2.80E-08 Glomerular filtration rate /T8 missense 23535967 rs13538 chr2 73868328 A G 3.90E-08 Glomerular filtration rate /T8 missense 23535967 rs13538 chr2 73868328 A G 4.00E-05 Glomerular filtration rate /T8 missense 23535967 rs13538 chr2 73868328 A G 5.10E-09 Glomerular filtration rate /T8 missense 23535967 rs13538 chr2 73868328 A G 5.60E-05 Glomerular filtration rate /T8 missense 23535967 rs13538 chr2 73868328 A G 6.10E-09 Glomerular filtration rate /T8 missense 23535967 rs13538 chr2 73868328 A G 2.00E-23 Metabolite levels (X-11787) /T8 missense 23934736 rs13538 chr2 73868328 A G 4.00E-66 Metabolite levels /T8 missense 24625756 rs13538 chr2 73868328 A G 5E-498 Blood metabolite ratios /T8 missense 24816252 rs13538 chr2 73868328 A G 8.00E-157 Blood metabolite levels /T8 missense 24816252 rs10206899 chr2 73900900 T C 1.00E-15 Creatinine levels ALMS1P intron 20383145 rs10206899 chr2 73900900 T C 2.00E-09 Glomerular filtration rate ALMS1P intron 23535967 rs10206899 chr2 73900900 T C 4.00E-08 Glomerular filtration rate ALMS1P intron 23535967 rs10206899 chr2 73900900 T C 6.00E-09 Glomerular filtration rate ALMS1P intron 23535967 rs10206899 chr2 73900900 T C 2.00E-14 Blood metabolite levels ALMS1P intron 24816252 rs10206899 chr2 73900900 T C 5E-481 Blood metabolite levels ALMS1P intron 24816252 rs10206899 chr2 73900900 T C 8.00E-123 Blood metabolite levels ALMS1P intron 24816252 rs2421678 chr2 73964214 C T 8.18E-04 Alzheimer's disease TPRKB intron 24755620 rs4514898 chr2 73966271 C T 3.00E-23 Urinary metabolites (H-NMR features) / / 24586186 rs2567599 chr2 73994074 G A 2.89E-04 Alzheimer's disease DUSP11 intron 24755620 rs3813229 chr2 74056564 A G 1.40E-29 Urinary metabolites (H-NMR features) STAMBP UTR-5 24586186 rs7609273 chr2 74070843 T C 4.11E-04 Multiple complex diseases STAMBP intron 17554300 rs13384232 chr2 74087710 C A 2.29E-04 Multiple complex diseases STAMBP intron 17554300 rs571878872 chr2 74087710 CA C 2.29E-04 Multiple complex diseases STAMBP intron 17554300 rs7557701 chr2 74125550 G A 1.99E-04 Alzheimer's disease ACTG2 intron 24755620 rs7586415 chr2 74129389 T C 3.63E-04 Alzheimer's disease ACTG2 intron 24755620 rs6546878 chr2 74175324 C A 1.02E-05 Mathematical ability DGUOK intron 24801482 rs4777 chr2 74185876 A T 5.97E-04 Type 2 diabetes DGUOK UTR-3 17463246 rs10169997 chr2 74194587 A G 1.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs4852324 chr2 74202578 T C 6.00E-14 Systemic lupus erythematosus / / 23273568 rs4852324 chr2 74202578 T C 6.90E-05 Cognitive function / / 24684796 rs4852324 chr2 74202578 T C 3.84E-05 Hemoglobin / / pha003098 rs6705628 chr2 74208362 C T 7.00E-17 Systemic lupus erythematosus / / 23273568 rs6714060 chr2 74210442 C T 3.99E-05 Telomere length / / 23001564 rs6714060 chr2 74210442 C T 2.30E-05 Cognitive function / / 24684796 rs10496194 chr2 74215977 C G 1.42E-05 Telomere length / / 23001564 rs6546886 chr2 74245777 T C 3.00E-06 Dialysis-related mortality / / 21546767 rs6756474 chr2 74282706 T C 2.41E-04 Sudden cardiac arrest TET3 intron 21658281 rs12991192 chr2 74309666 T C 1.86E-04 Sudden cardiac arrest TET3 intron 21658281 rs13021880 chr2 74310787 C G 0.0006931 Sarcoidosis TET3 intron 22952805 rs828872 chr2 74313080 T C 3.36E-04 White matter integrity TET3 intron 22425255 rs13025827 chr2 74337353 T C 8.62E-04 Aortic root size / / 21223598 rs6758220 chr2 74337584 G A 6.78E-04 Aortic root size / / 21223598 rs6758220 chr2 74337584 G A 8.91E-06 Hemoglobin / / pha003096 rs6758220 chr2 74337584 G A 5.74E-06 Hematocrit / / pha003097 rs3099824 chr2 74342567 A G 6.44E-06 Carotenoid and tocopherol levels / / 19185284 rs7594992 chr2 74364946 G A 1.81E-04 Multiple complex diseases BOLA3 intron 17554300 rs828888 chr2 74372678 A C 1.08E-05 Intelligence BOLA3 intron 21826061 rs828887 chr2 74373044 G A 3.93E-04 Myopia (pathological) BOLA3 intron 21095009 rs828887 chr2 74373044 G A 7.95E-05 Intelligence BOLA3 intron 21826061 rs828884 chr2 74374641 C T 4.63E-05 Intelligence BOLA3 intron 21826061 rs828883 chr2 74375457 G A 2.42E-04 Response to TNF antagonist treatment BOLA3-AS1 intron 21061259 rs828882 chr2 74375804 C T 1.94E-04 Response to TNF antagonist treatment BOLA3-AS1 intron 21061259 rs4083173 chr2 74401657 A G 8.97E-04 Myopia (pathological) MOB1A intron 21095009 rs1667601 chr2 74406055 G T 2.30E-04 Iris characteristics / / 21835309 rs828860 chr2 74411281 G A 2.79E-04 Myopia (pathological) / / 21095009 rs7340453 chr2 74428015 T C 5.74E-05 Intelligence MTHFD2 intron 21826061 rs828903 chr2 74436721 A G 2.89E-05 Intelligence MTHFD2 intron 21826061 rs12053233 chr2 74451762 C T 1.91E-04 Tourette syndrome SLC4A5 intron 22889924 rs13006863 chr2 74463566 C T 5.00E-07 Immune reponse to smallpox (secreted TNF-alpha) SLC4A5 intron 22610502 rs13006863 chr2 74463566 C T 3.00E-06 Post-traumatic stress disorder (asjusted for relatedness) SLC4A5 intron 23726511 rs3771725 chr2 74485896 T G 5.06E-04 Smoking initiation SLC4A5 intron 24665060 rs6722230 chr2 74489062 G A 2.06E-04 Response to cytidine analogues (gemcitabine) SLC4A5 intron 24483146 rs6722230 chr2 74489062 G A 3.90E-05 Response to cytadine analogues (cytosine arabinoside) SLC4A5 intron 24483146 rs17009792 chr2 74489323 C T 7.45E-05 Type 2 diabetes SLC4A5 missense 17463246 rs17009792 chr2 74489323 C T 1.68E-04 Response to cytidine analogues (gemcitabine) SLC4A5 missense 24483146 rs17009792 chr2 74489323 C T 4.13E-05 Response to cytadine analogues (cytosine arabinoside) SLC4A5 missense 24483146 rs2109356 chr2 74490502 C T 3.03E-04 Smoking initiation SLC4A5 intron 24665060 rs6723819 chr2 74501510 A G 2.41E-04 Smoking initiation SLC4A5 intron 24665060 rs7560244 chr2 74515158 G A 1.20E-04 Response to cytidine analogues (gemcitabine) SLC4A5 intron 24483146 rs3771738 chr2 74540917 C T 9.78E-04 Multiple complex diseases SLC4A5 intron 17554300 rs7581836 chr2 74577397 T G 2.18E-04 Smoking initiation / / 24665060 rs12328185 chr2 74621660 A G 5.99E-04 Multiple complex diseases / / 17554300 rs17009922 chr2 74622037 C G 7.24E-04 Multiple complex diseases / / 17554300 rs10187051 chr2 74639591 T C 9.43E-05 Personality dimensions / / 18957941 rs10187076 chr2 74639637 T C 9.45E-05 Personality dimensions / / 18957941 rs3732293 chr2 74649934 A C 1.50E-06 Major depressive disorder WDR54 intron 21042317 rs1063588 chr2 74690378 C T 3.57E-04 IgE levels MOGS missense 17255346 rs1063588 chr2 74690378 C T 6.93E-05 Multiple complex diseases MOGS missense 17554300 rs1047911 chr2 74699778 C A 3.45E-04 IgE levels MRPL53 missense 17255346 rs6546909 chr2 74746322 A T 2.91E-05 Multiple complex diseases DQX1 cds-synon 17554300 rs10779958 chr2 74755778 A C 2.97E-06 Osteoarthritis AUP1 intron 22763110 rs17010021 chr2 74761539 T A 1.00E-05 Anorexia nervosa LOXL3 missense 23568457 rs17010022 chr2 74763258 C G 2.44E-04 Multiple complex diseases LOXL3 cds-synon 17554300 rs7569357 chr2 74778644 C T 3.34E-04 Multiple complex diseases DOK1 intron 17554300 rs11126435 chr2 74789700 A T 3.06E-05 Multiple complex diseases C2orf65 intron 17554300 rs363685 chr2 74814836 C T 5.70E-05 Volumetric brain MRI C2orf65 intron 17903297 rs363691 chr2 74841569 C T 1.95E-04 Multiple complex diseases C2orf65 intron 17554300 rs363611 chr2 74906200 C T 5.75E-04 Multiple complex diseases SEMA4F intron 17554300 rs363612 chr2 74911073 T C 6.79E-04 Multiple complex diseases / / 17554300 rs363612 chr2 74911073 T C 2.00E-04 Smoking initiation / / 24665060 rs363617 chr2 74918692 T C 2.30E-04 Multiple complex diseases / / 17554300 rs7355739 chr2 74926935 A C 4.40E-04 Multiple complex diseases / / 17554300 rs2041835 chr2 74927197 A G 5.00E-04 Multiple complex diseases / / 17554300 rs363620 chr2 74928350 C A 4.51E-04 Multiple complex diseases / / 17554300 rs11126440 chr2 74929490 A G 3.94E-04 Multiple complex diseases / / 17554300 rs363624 chr2 74930842 A G 5.48E-04 Multiple complex diseases / / 17554300 rs363625 chr2 74930899 A G 4.62E-04 Multiple complex diseases / / 17554300 rs1137 chr2 74939176 T C 4.00E-06 Myopia (pathological) / / 22685421 rs6546920 chr2 74971385 A G 5.21E-04 Acute lung injury / / 22295056 rs205611 chr2 74972081 A G 1.74E-04 Multiple complex diseases / / 17554300 rs205611 chr2 74972081 A G 1.00E-06 Iris characteristics / / 21835309 rs17739760 chr2 74990671 G A 2.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs3980420 chr2 75030680 T C 2.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs6546929 chr2 75031011 A G 2.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs3771798 chr2 75064392 T C 1.04E-05 Post-operative nausea and vomiting HK2 intron 21694509 rs28362967 chr2 75074055 G T 4.41E-04 Type 2 diabetes HK2 intron 17463246 rs28362967 chr2 75074055 G T 7.00E-04 Acute lymphoblastic leukemia (childhood) HK2 intron 20189245 rs10496195 chr2 75074932 A C 1.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HK2 intron 20877124 rs681900 chr2 75074967 T C 3.00E-06 Femoral neck bone geometry HK2 intron 22087292 rs680545 chr2 75075255 G A 5.92E-06 Sickle cell anemia (severity) HK2 intron 20029952 rs3771783 chr2 75082895 G A 1.00E-04 Bipolar disorder HK2 intron 17486107 rs3771781 chr2 75085163 C T 3.25E-05 Common variable immunodeficiency HK2 intron 21497890 rs3732300 chr2 75099381 T C 1.12E-04 Nicotine dependence HK2 intron 17158188 rs1869340 chr2 75102176 A G 5.82E-07 Schizophrenia HK2 intron 21926974 rs17741356 chr2 75113903 A G 2.64E-04 Response to statin treatment (atorvastatin),change in cholesterol levels HK2 intron 20031582 rs923273 chr2 75114730 C T 4.62E-04 Insulin resistance HK2 intron 21901158 rs12989728 chr2 75138842 C A 9.11E-04 Insulin resistance / / 21901158 rs17010519 chr2 75142302 C T 1.15E-05 Suicide attempts in depression or bipolar disorder / / 24964207 rs4853081 chr2 75165905 A T 9.36E-05 Type 2 diabetes / / 17463246 rs11902447 chr2 75166777 C T 1.16E-04 Type 2 diabetes / / 17463246 rs2287102 chr2 75186337 A G 1.93E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) POLE4 intron 23648065 rs17040394 chr2 75187831 G A 3.76E-05 Multiple complex diseases POLE4 intron 17554300 rs3886110 chr2 75207832 G T 1.31E-04 Type 2 diabetes / / 17463246 rs7602776 chr2 75218331 T A 9.28E-05 Type 2 diabetes / / 17463246 rs7571034 chr2 75238361 C G 3.89E-04 Type 2 diabetes / / 17463246 rs4366930 chr2 75242863 G T 3.31E-04 Type 2 diabetes / / 17463246 rs13012537 chr2 75269064 T C 2.16E-05 Type 2 diabetes / / 17463246 rs13012537 chr2 75269064 T C 3.09E-06 Lymphocyte counts / / 22286170 rs754978 chr2 75271796 A C 5.42E-05 Type 2 diabetes / / 17463246 rs4439987 chr2 75287106 G A 4.70E-04 Multiple complex diseases TACR1 intron 17554300 rs4439987 chr2 75287106 G A 1.61E-04 Parkinson's disease TACR1 intron 21248740 rs13404785 chr2 75290700 A G 5.86E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) TACR1 intron 23648065 rs3755457 chr2 75291510 G A 9.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) TACR1 intron 23648065 rs13417600 chr2 75329306 A G 7.16E-05 Relative hand skill TACR1 intron 24068947 rs3771815 chr2 75335078 A C 7.10E-05 Relative hand skill TACR1 intron 24068947 rs3771816 chr2 75338308 T A 5.54E-05 Relative hand skill TACR1 intron 24068947 rs3771817 chr2 75338380 A G 5.56E-05 Relative hand skill TACR1 intron 24068947 rs10210154 chr2 75338843 A T 5.57E-05 Relative hand skill TACR1 intron 24068947 rs7587891 chr2 75339492 T C 7.19E-05 Relative hand skill TACR1 intron 24068947 rs10172781 chr2 75341547 A G 3.71E-05 Relative hand skill TACR1 intron 24068947 rs741418 chr2 75363186 G A 2.07E-04 Response to taxane treatment (placlitaxel) TACR1 intron 23006423 rs17010823 chr2 75372955 C G 2.48E-04 IgE levels TACR1 intron 17255346 rs17010825 chr2 75374199 C T 2.48E-04 IgE levels TACR1 intron 17255346 rs3771863 chr2 75419714 C T 3.00E-09 Brain connectivity TACR1 intron 23471985 rs10204684 chr2 75419745 C A 8.81E-04 Alzheimer's disease TACR1 intron 24755620 rs2287231 chr2 75449129 G A 1.10E-05 Urinary metabolites / / 21572414 rs1468900 chr2 75449983 A G 1.32E-04 Alcohol dependence / / 20201924 rs13406588 chr2 75451356 A G 5.12E-04 Alzheimer's disease / / 24755620 rs6546958 chr2 75452466 T C 2.30E-05 Urinary metabolites / / 21572414 rs7568535 chr2 75459144 T C 9.89E-05 Chronic Hepatitis C infection / / 21725309 rs765684 chr2 75459668 A G 9.00E-07 Sexual dimorphism in anthropometric traits / / 23754948 rs2422153 chr2 75505999 G A 1.68E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17040426 chr2 75512782 T C 4.95E-04 Multiple complex diseases / / 17554300 rs2192927 chr2 75518372 T C 2.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17011067 chr2 75546024 A T 1.31E-06 Recombination rate / / 21698098 rs10172219 chr2 75559706 G A 5.92E-04 Multiple complex diseases / / 17554300 rs4853138 chr2 75574188 T G 5.09E-04 Multiple complex diseases / / 17554300 rs6749524 chr2 75588230 T C 2.39E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7599681 chr2 75652821 G A 2.09E-04 Alzheimer's disease / / 17998437 rs10201616 chr2 75675860 T C 7.70E-05 Cognitive test performance / / 20125193 rs10208759 chr2 75681330 G A 6.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10208759 chr2 75681330 G A 5.51E-05 Height / / pha003010 rs11126472 chr2 75720372 C T 2.34E-05 Multiple sclerosis (brain glutamate levels) FAM176A missense 20802204 rs11126472 chr2 75720372 C T 1.97E-05 Height FAM176A missense pha003010 rs11126472 chr2 75720372 C T 9.55E-06 Height FAM176A missense pha003011 rs17011416 chr2 75744392 C T 7.53E-04 Type 2 diabetes FAM176A intron 17463246 rs6754778 chr2 75764175 C T 1.78E-04 Taste perception FAM176A intron 22132133 rs10515917 chr2 75769810 C T 1.93E-05 Taste perception FAM176A intron 22132133 rs2422173 chr2 75777968 G A 4.91E-05 Waist-Hip Ratio FAM176A intron pha003013 rs2422173 chr2 75777968 G A 8.01E-05 Waist Circumference FAM176A intron pha003024 rs2422173 chr2 75777968 G A 4.40E-05 Waist Circumference FAM176A intron pha003025 rs2422173 chr2 75777968 G A 8.08E-05 Waist-Hip Ratio FAM176A intron pha003028 rs2422173 chr2 75777968 G A 6.12E-05 Waist-Hip Ratio FAM176A intron pha003029 rs12053306 chr2 75780007 G T 2.96E-05 Body Mass Index FAM176A intron pha003020 rs11126477 chr2 75786771 A G 1.28E-05 Body Mass Index FAM176A intron pha003006 rs11126477 chr2 75786771 A G 5.33E-05 Body Mass Index FAM176A intron pha003007 rs11126477 chr2 75786771 A G 9.03E-05 Body Mass Index FAM176A intron pha003019 rs11126477 chr2 75786771 A G 9.40E-05 Waist Circumference FAM176A intron pha003024 rs759255 chr2 75788396 C A 1.44E-04 Alzheimer's disease (late onset) FAM176A intron 21379329 rs17011455 chr2 75790489 T C 5.00E-06 Presence of antiphospholipid antibodies FAM176A intron 23509613 rs17011478 chr2 75792143 C T 6.00E-06 Obesity-related traits FAM176A intron 23251661 rs10175794 chr2 75792626 T A 8.83E-04 Coronary Artery Disease FAM176A intron 17634449 rs7595746 chr2 75797440 C T 6.93E-04 Myocardial Infarction / / pha002883 rs6709627 chr2 75802151 C A 1.70E-04 Alzheimer's disease (late onset) / / 21379329 rs6709627 chr2 75802151 C A 3.86E-05 Odorant perception / / 23910658 rs12994560 chr2 75805048 C T 4.73E-05 Body Mass Index / / pha003006 rs1075860 chr2 75814139 G A 5.48E-05 Multiple complex diseases / / 17554300 rs1075860 chr2 75814139 G A 6.22E-04 Lymphocyte counts / / 22286170 rs7562126 chr2 75832877 G C 1.81E-05 Intracerebral hemorrhage / / 24656865 rs7562242 chr2 75832989 G A 1.70E-05 Intracerebral hemorrhage / / 24656865 rs35644534 chr2 75833517 C T 2.02E-05 Intracerebral hemorrhage / / 24656865 rs740270 chr2 75837011 G T 1.79E-05 Intracerebral hemorrhage / / 24656865 rs35951645 chr2 75838889 T A 1.52E-05 Intracerebral hemorrhage / / 24656865 rs6733242 chr2 75843485 C T 3.43E-04 Multiple complex diseases / / 17554300 rs875755 chr2 75844679 T C 1.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs886767 chr2 75844958 G A 9.81E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11690080 chr2 75845448 T C 2.87E-04 Blood pressure / / 17255346 rs11690080 chr2 75845448 T C 1.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10166389 chr2 75846545 A G 3.14E-04 Type 2 diabetes / / 17463246 rs7588344 chr2 75846558 T C 8.57E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs714479 chr2 75847704 C A 7.70E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs10206430 chr2 75847993 T G 2.40E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2422229 chr2 75848679 A G 7.18E-04 Type 2 diabetes / / 17463246 rs6547013 chr2 75850735 T C 4.31E-04 Type 2 diabetes / / 17463246 rs10182133 chr2 75856492 A C 0.000561 5-fluorouracil induced nausea/vomiting in response to colorectal cancer treatment / / 22310351 rs1017051 chr2 75865277 T C 6.60E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs12105510 chr2 75869828 T C 5.62E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7588016 chr2 75876340 T C 2.14E-05 Cognitive performance MRPL19 intron 19734545 rs13405970 chr2 75882754 A G 9.99E-04 Tourette syndrome MRPL19 UTR-3 22889924 rs17011662 chr2 75918648 T C 2.71E-05 Cognitive performance GCFC2 intron 19734545 rs2298948 chr2 75926565 T C 5.00E-08 Hippocampal atrophy GCFC2 intron 22745009 rs4355145 chr2 75956005 G A 1.00E-05 Urinary metabolites / / 21572414 rs7582041 chr2 75973757 G T 1.78E-05 Cholesterol / / 17255346 rs11675641 chr2 75977535 A C 5.27E-05 Parkinson's disease / / 21738487 rs10183217 chr2 75997264 A G 7.34E-06 Cholesterol / / 17255346 rs17011759 chr2 76000091 A G 1.01E-04 Cholesterol / / 17255346 rs17011759 chr2 76000091 A G 1.00E-05 Urinary metabolites / / 21572414 rs17011786 chr2 76003360 A T 1.40E-05 Urinary metabolites / / 21572414 rs7573143 chr2 76004385 A G 2.98E-04 Cholesterol / / 17255346 rs7573143 chr2 76004385 A G 0.000894 Salmonella-induced pyroptosis / / 22837397 rs6760389 chr2 76031113 G T 6.39E-04 Type 2 diabetes / / 17463246 rs6760389 chr2 76031113 G T 3.60E-06 Urinary metabolites / / 21572414 rs4361150 chr2 76035099 G A 1.00E-06 Urinary metabolites / / 21572414 rs6733843 chr2 76049781 C T 5.57E-04 Multiple complex diseases / / 17554300 rs6751526 chr2 76120604 T G 4.08E-04 Multiple complex diseases / / 17554300 rs6720541 chr2 76146755 G A 9.38E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2583527 chr2 76184281 C T 0.0001666 Sarcoidosis / / 22952805 rs2583526 chr2 76184816 C T 1.00E-06 Smoking initiation / / 24665060 rs12467779 chr2 76196574 G A 4.84E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4853182 chr2 76197787 C T 4.66E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs12471016 chr2 76204989 C T 4.00E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1441655 chr2 76209508 C A 0.0005553 Sarcoidosis / / 22952805 rs1441654 chr2 76220274 C A 4.14E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs317226 chr2 76222000 G C 0.0003279 Sarcoidosis / / 22952805 rs4853189 chr2 76232326 C T 5.06E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs436000 chr2 76240361 G T 8.00E-07 Economic and political preferences (fairness) / / 22566634 rs431838 chr2 76300058 C A 4.75E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs406952 chr2 76307345 T C 7.61E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1660568 chr2 76308359 T C 7.04E-04 Alzheimer's disease / / 24755620 rs443713 chr2 76310384 A C 7.61E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs411150 chr2 76313589 A T 8.98E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs317294 chr2 76334174 T G 8.98E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10204325 chr2 76375711 C T 1.00E-07 Economic and political preferences (fairness) / / 22566634 rs12473082 chr2 76382733 T G 6.98E-04 Alzheimer's disease / / 24755620 rs4852395 chr2 76383940 T C 3.56E-04 Gallstones / / 17632509 rs6711215 chr2 76385487 A T 7.76E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13417780 chr2 76408283 G A 1.26E-06 Panic disorder / / 19165232 rs1916870 chr2 76430941 T G 6.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs6761061 chr2 76438298 A G 8.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs10168901 chr2 76479233 C G 5.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs17703039 chr2 76485985 A G 2.89E-05 Relative hand skill / / 24068947 rs7609022 chr2 76487107 T G 8.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs2860732 chr2 76488564 A G 5.52E-04 Smoking quantity / / 24665060 rs12464573 chr2 76494928 C T 4.62E-04 Smoking quantity / / 24665060 rs10194221 chr2 76495414 A C 3.19E-04 Smoking quantity / / 24665060 rs17754447 chr2 76495893 T C 3.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs1526654 chr2 76498511 A G 6.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs11684308 chr2 76500077 C A 5.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs13012492 chr2 76500871 T G 5.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs1524209 chr2 76503762 A G 7.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs11126513 chr2 76506460 G T 1.28E-06 Malignant mesothelioma / / 23827383 rs10519328 chr2 76507201 C T 1.28E-06 Malignant mesothelioma / / 23827383 rs1526627 chr2 76509398 G C 4.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs17754897 chr2 76509864 G A 8.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs6743740 chr2 76511383 G A 2.64E-04 Birth weight / / 17255346 rs17012460 chr2 76513387 A G 1.30E-06 Malignant mesothelioma / / 23827383 rs17012460 chr2 76513387 A G 7.36E-04 Smoking quantity / / 24665060 rs1526620 chr2 76516021 C T 2.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs1526619 chr2 76517005 A G 5.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs6747727 chr2 76535474 A C 2.85E-04 Birth weight / / 17255346 rs1830149 chr2 76562339 C T 1.25E-04 Multiple complex diseases / / 17554300 rs4853241 chr2 76579521 T C 6.99E-04 Smoking quantity / / 24665060 rs6547078 chr2 76588942 C T 9.15E-04 Alzheimer's disease / / 24755620 rs17012588 chr2 76606274 A G 6.49E-04 Smoking quantity / / 24665060 rs1519894 chr2 76633531 C G 1.77E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs1519894 chr2 76633531 C G 7.70E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs12105972 chr2 76648560 G C 1.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs10168327 chr2 76667565 A G 1.78E-04 Type 2 diabetes / / 17463246 rs13035292 chr2 76678784 C A 5.24E-04 Multiple complex diseases / / 17554300 rs13035292 chr2 76678784 C A 7.36E-05 Post-operative nausea and vomiting / / 21694509 rs12466278 chr2 76712612 T A 8.16E-04 Multiple complex diseases / / 17554300 rs74529274 chr2 76759575 C T 9.00E-06 Response to amphetamines / / 22952603 rs12052843 chr2 76760606 C T 7.34E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1921254 chr2 76762485 A G 2.50E-05 Urinary metabolites / / 21572414 rs7603063 chr2 76776659 T C 3.52E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7592517 chr2 76777279 C T 1.31E-04 Type 2 diabetes / / 20818381 rs74511629 chr2 76783069 A G 9.97E-06 Response to amphetamines / / 22952603 rs77131518 chr2 76784978 A G 9.94E-06 Response to amphetamines / / 22952603 rs2139502 chr2 76786845 C T 1.42E-04 Type 2 diabetes / / 20818381 rs6742896 chr2 76787450 G T 9.99E-06 Response to amphetamines / / 22952603 rs6716298 chr2 76860212 C A 6.72E-05 Socioeconomic Factors / / pha003066 rs13002499 chr2 76874809 C T 6.66E-05 Socioeconomic Factors / / pha003066 rs17013020 chr2 76914970 A G 7.89E-06 Hypertension / / pha003041 rs17013020 chr2 76914970 A G 3.74E-05 Blood Pressure / / pha003045 rs17013020 chr2 76914970 A G 1.86E-05 Blood Pressure / / pha003047 rs17013053 chr2 76942709 T C 4.88E-08 Multiple complex diseases / / 17554300 rs10865426 chr2 76948804 A T 0.000107679 Primary sclerosing cholangitis / / 23603763 rs12232994 chr2 76955993 T C,G 7.44E-05 Obesity (extreme) / / 21935397 rs10169851 chr2 76956494 G C 9.27E-04 Obesity (extreme) / / 21935397 rs971120 chr2 76961518 C T 2.81E-04 Type 2 diabetes / / 17463246 rs7584499 chr2 76961857 T G 5.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs13406374 chr2 76961961 G A 8.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs7569282 chr2 76966652 G A 4.81E-05 Obesity (extreme) / / 21935397 rs4853267 chr2 76967644 G C 4.67E-05 Obesity (extreme) / / 21935397 rs12993991 chr2 76968250 A T 5.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs969933 chr2 76968595 A G 9.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs2056207 chr2 76969273 A G 4.74E-05 Obesity (extreme) / / 21935397 rs2056208 chr2 76969378 C T 4.82E-05 Obesity (extreme) / / 21935397 rs2056209 chr2 76969542 T G 4.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs17013121 chr2 76969799 G T 5.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs6745704 chr2 76969818 T C 4.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs6730814 chr2 76969846 C T 4.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs2056210 chr2 76971440 C T 8.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs2056211 chr2 76971574 G A 9.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs13396159 chr2 76976577 A G 4.94E-04 Obesity (extreme) LRRTM4 intron 21935397 rs13403042 chr2 76978268 A T 7.81E-04 Obesity (extreme) LRRTM4 intron 21935397 rs10186864 chr2 76982894 T C 8.80E-05 White matter hyperintensity burden LRRTM4 intron 21681796 rs7601238 chr2 76990988 C T 3.78E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13030721 chr2 76994317 C G 6.50E-06 Urinary metabolites LRRTM4 intron 21572414 rs6718624 chr2 76994539 A G 2.90E-06 Urinary metabolites LRRTM4 intron 21572414 rs13008894 chr2 76994984 T C 8.10E-07 Urinary metabolites LRRTM4 intron 21572414 rs7560515 chr2 76995467 T C 1.80E-06 Urinary metabolites LRRTM4 intron 21572414 rs12995505 chr2 76996310 G A,C,T 2.20E-06 Urinary metabolites LRRTM4 intron 21572414 rs4853272 chr2 77013724 C A 3.15E-05 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs4853272 chr2 77013724 C A 3.12E-04 Obesity (extreme) LRRTM4 intron 21935397 rs6743728 chr2 77015014 T C 7.94E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6743728 chr2 77015014 T C 2.96E-04 Obesity (extreme) LRRTM4 intron 21935397 rs10207067 chr2 77018564 G C 2.10E-06 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13428376 chr2 77018951 C T 2.07E-06 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs4853274 chr2 77019490 G C 1.79E-06 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10178612 chr2 77020219 T C 1.80E-06 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1517781 chr2 77021031 C T 2.19E-06 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1517782 chr2 77021226 C A 9.95E-07 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10170138 chr2 77021928 C T 9.27E-07 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10221841 chr2 77022492 A G 2.53E-06 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10221606 chr2 77022651 C T 1.49E-06 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs11126566 chr2 77030315 A G 1.43E-06 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs11126572 chr2 77032027 T C 2.49E-06 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs17333150 chr2 77050462 C T 2.94E-06 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs7607019 chr2 77085351 A G 6.60E-06 Type 2 diabetes LRRTM4 intron 23209189 rs10520167 chr2 77093691 T G 8.75E-04 Multiple complex diseases LRRTM4 intron 17554300 rs721390 chr2 77094790 G T 6.24E-04 Type 2 diabetes LRRTM4 intron 17463246 rs17405232 chr2 77097164 T C 4.41E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs17333446 chr2 77120146 A G 2.11E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs4852420 chr2 77129922 T C 5.10E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs17013364 chr2 77153600 G A 5.86E-05 HIV-1 control LRRTM4 intron 20041166 rs11886263 chr2 77157183 C G 3.16E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs4852423 chr2 77159948 T C 3.01E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13413625 chr2 77160723 T A 3.37E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13417401 chr2 77161916 T C 3.21E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs9973564 chr2 77166432 C T 3.00E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs9973567 chr2 77166479 C G 3.02E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs9309507 chr2 77167848 G C 2.79E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs11884377 chr2 77168745 A C 4.72E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10193677 chr2 77169750 G C 5.12E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10193590 chr2 77169802 C G 5.85E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs140227592 chr2 77169802 C CAGTG,CTGTGTG,CTGTGTGTGTGTGTGTG 5.85E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs61077287 chr2 77169802 C CTGTGTGTGTGTGTGTGTG 5.85E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10170002 chr2 77169883 A T 6.92E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs17013381 chr2 77169988 T C 6.25E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10520170 chr2 77170201 A G 9.02E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs17013387 chr2 77172669 A C 4.99E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1921627 chr2 77172693 T C 1.00E-05 Type 2 diabetes LRRTM4 intron 23209189 rs10520173 chr2 77173236 G A 9.23E-04 Bipolar disorder LRRTM4 intron 19259986 rs10204605 chr2 77174354 T C 5.06E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10205089 chr2 77174845 T C 4.97E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10195940 chr2 77175595 G A 9.76E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10199630 chr2 77177049 G A 8.19E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs11885408 chr2 77181715 G T 7.77E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13414920 chr2 77182065 A C 4.77E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13025838 chr2 77185856 T C 5.86E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs17013449 chr2 77187116 C G 4.40E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10193253 chr2 77197919 C T 3.83E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1446728 chr2 77198725 G C 5.63E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1446714 chr2 77205297 T C 5.38E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6750979 chr2 77209051 G T 4.99E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6547106 chr2 77209245 T C 4.07E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6547107 chr2 77209379 C T 1.87E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10520175 chr2 77209969 C G 6.47E-04 Bipolar disorder LRRTM4 intron 19259986 rs10520175 chr2 77209969 C G 3.42E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6758707 chr2 77210780 C G 2.10E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1446717 chr2 77211342 G A 2.86E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6547108 chr2 77211611 A G 2.08E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6547109 chr2 77211682 C A 1.53E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6737296 chr2 77212204 A G 1.81E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs7561189 chr2 77213066 C T 1.27E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13021476 chr2 77213436 A G 1.45E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs2044485 chr2 77214849 A T 4.05E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6547111 chr2 77215023 G C 1.73E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1374392 chr2 77215388 C T 3.16E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1446718 chr2 77215735 A C 1.16E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1446720 chr2 77215788 T C 1.40E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs17040496 chr2 77216522 A G 1.75E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1374394 chr2 77221590 T G 6.24E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1470504 chr2 77222810 A C 8.10E-04 Type 2 diabetes LRRTM4 intron 23209189 rs13388552 chr2 77222934 A G 4.30E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1470506 chr2 77223938 C T 4.00E-07 IgG glycosylation LRRTM4 intron 23382691 rs1470506 chr2 77223938 C T 6.00E-06 IgG glycosylation LRRTM4 intron 23382691 rs10205987 chr2 77224331 A C 1.99E-05 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs12988557 chr2 77226087 G A 8.60E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs17334184 chr2 77226747 C A 1.19E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10520177 chr2 77228622 T C 9.00E-04 Type 2 diabetes and 6 quantitative traits LRRTM4 intron 17848626 rs6547113 chr2 77229227 C G,T 6.73E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6706194 chr2 77229559 A G 7.70E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs4853290 chr2 77232873 G A 4.44E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1446706 chr2 77233822 G A 5.68E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10165789 chr2 77233847 C A 2.25E-05 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs17013615 chr2 77241510 A G 4.41E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1348828 chr2 77245603 C G 2.46E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6547115 chr2 77246331 A G 8.00E-06 IgG glycosylation LRRTM4 intron 23382691 rs12713890 chr2 77247271 A C 6.52E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1542187 chr2 77251959 C T 7.02E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13033902 chr2 77264354 T C 4.91E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1982340 chr2 77285117 C T 5.05E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs7607753 chr2 77286529 C G 2.40E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs10175781 chr2 77287190 C T 1.07E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13001302 chr2 77289484 T G 1.96E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs7570003 chr2 77290609 G A 6.00E-06 Urinary metabolites LRRTM4 intron 21572414 rs10198799 chr2 77290690 T C 7.40E-06 Urinary metabolites LRRTM4 intron 21572414 rs13412552 chr2 77292449 C A 5.80E-06 Urinary metabolites LRRTM4 intron 21572414 rs6730095 chr2 77298456 G T 7.20E-04 Multiple complex diseases LRRTM4 intron 17554300 rs6730095 chr2 77298456 G T 5.90E-06 Urinary metabolites LRRTM4 intron 21572414 rs6750737 chr2 77334007 G A 2.90E-06 Urinary metabolites LRRTM4 intron 21572414 rs13386913 chr2 77375303 C T 0.0000027 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) LRRTM4 intron 23080225 rs10171377 chr2 77437279 T G 6.47E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6740940 chr2 77461887 C T 2.95E-05 Cocaine dependence LRRTM4 intron 23958962 rs2901836 chr2 77466517 T G 6.45E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs1946879 chr2 77466683 G A 6.50E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13007978 chr2 77468373 T C 7.84E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6705164 chr2 77468540 T C 8.10E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs13031572 chr2 77468655 A C 8.09E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs6751463 chr2 77469401 G A 8.17E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs2861012 chr2 77470040 C T 8.15E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs7603914 chr2 77470724 G T 8.10E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs7563141 chr2 77494953 G T 7.20E-05 Malaria LRRTM4 intron 19465909 rs12611712 chr2 77497242 A G 4.13E-04 Multiple complex diseases LRRTM4 intron 17554300 rs7599090 chr2 77539865 C A 2.62E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs436659 chr2 77540502 G A 7.14E-05 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs7602394 chr2 77540524 C A 1.04E-04 Suicide attempts in bipolar disorder LRRTM4 intron 21423239 rs192634 chr2 77595904 G A 3.59E-04 Alzheimer's disease (late onset) LRRTM4 intron 21379329 rs2439567 chr2 77603802 A C 1.05E-05 Lung function (forced expiratory volume in 1 second) LRRTM4 intron pha003103 rs415838 chr2 77612535 G A 3.98E-06 Lung function (forced expiratory volume in 1 second) LRRTM4 intron pha003103 rs443237 chr2 77626445 T C 1.11E-05 Lung function (forced expiratory volume in 1 second) LRRTM4 intron pha003103 rs433156 chr2 77627119 A C 3.29E-06 Lung function (forced expiratory volume in 1 second) LRRTM4 intron pha003103 rs290018 chr2 77630480 G A 1.61E-06 Lung function (forced expiratory volume in 1 second) LRRTM4 intron pha003103 rs290017 chr2 77633146 G T 1.57E-07 Lung function (forced expiratory volume in 1 second) LRRTM4 intron pha003103 rs290016 chr2 77633888 T C 5.76E-07 Lung function (forced expiratory volume in 1 second) LRRTM4 intron pha003103 rs13395897 chr2 77666733 A G 3.76E-05 Serum alpha1-antitrypsin levels LRRTM4 intron 23990791 rs6749190 chr2 77669850 C A 9.60E-04 Iron levels LRRTM4 intron pha002876 rs17594539 chr2 77672435 T G 8.05E-05 Alzheimer's disease LRRTM4 intron 22832961 rs12989961 chr2 77673919 T A 6.46E-04 Insulin resistance LRRTM4 intron 21901158 rs2861078 chr2 77697995 G A 7.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LRRTM4 intron 20877124 rs12997025 chr2 77711560 G T 5.15E-04 Type 2 diabetes LRRTM4 intron 22158537 rs1922817 chr2 77712607 G T 2.80E-04 Osteoarthritis LRRTM4 intron 19508968 rs11126611 chr2 77714052 T C 3.41E-04 Type 2 diabetes LRRTM4 intron 22158537 rs11126613 chr2 77722435 C T 3.47E-04 Type 2 diabetes LRRTM4 intron 22158537 rs17595137 chr2 77728001 G C 3.16E-04 Type 2 diabetes LRRTM4 intron 22158537 rs11885676 chr2 77732482 T C 2.49E-04 Type 2 diabetes LRRTM4 intron 22158537 rs689553 chr2 77735664 T C 3.12E-04 Type 2 diabetes LRRTM4 intron 22158537 rs17752074 chr2 77750589 G A 2.40E-05 Urinary metabolites / / 21572414 rs2901850 chr2 77783575 G T 4.58E-07 Facial morphology / / 22341974 rs4473409 chr2 77787896 T G 8.10E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs61354037 chr2 77800399 T C 2.20E-39 Metabolite levels / / 22286219 rs4558608 chr2 77850353 T C 9.85E-05 Schizophrenia / / 19571809 rs4485592 chr2 77857764 G A 2.91E-05 Body Mass Index / / pha003019 rs4485592 chr2 77857764 G A 3.73E-05 Body Mass Index / / pha003022 rs12052417 chr2 77872197 C T 5.87E-05 Body Mass Index / / pha003019 rs12052417 chr2 77872197 C T 6.38E-05 Body Mass Index / / pha003022 rs11684020 chr2 77878741 T C 3.86E-04 Smoking cessation / / 24665060 rs7598757 chr2 77928314 A G 1.42E-04 Type 2 diabetes / / 17463246 rs1994391 chr2 77989565 C T 3.10E-05 Postoperative ventricular dysfunction / / 21980348 rs13410776 chr2 77990389 T G 9.87E-06 Cognitive impairment induced by topiramate / / 22091778 rs1017931 chr2 78003283 G C 4.09E-05 Postoperative ventricular dysfunction / / 21980348 rs2054834 chr2 78013268 G T 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2171325 chr2 78025576 G T 8.39E-06 Postoperative ventricular dysfunction / / 21980348 rs2861215 chr2 78046792 C T 4.70E-05 Volumetric brain MRI / / 17903297 rs7606314 chr2 78048214 C T 1.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7595103 chr2 78075244 G A 7.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs10205106 chr2 78084926 C T 2.32E-05 Sarcoidosis / / 19165924 rs11126639 chr2 78093107 T C 1.99E-04 White matter integrity / / 22425255 rs4594471 chr2 78094407 T C 2.44E-04 White matter integrity / / 22425255 rs10183550 chr2 78097679 G A 2.31E-04 White matter integrity / / 22425255 rs10865432 chr2 78117502 C A 1.93E-04 Epilepsy / / 22116939 rs1897616 chr2 78120305 C T 3.68E-04 Epilepsy / / 22116939 rs10172925 chr2 78124090 G A 1.47E-04 Epilepsy / / 22116939 rs6547168 chr2 78125714 T C 3.46E-06 Serum metabolites / / 19043545 rs7602889 chr2 78133560 T C 1.30E-05 Epilepsy / / 22116939 rs4853352 chr2 78139549 G A 5.50E-06 Epilepsy / / 22116939 rs4853355 chr2 78144479 G A 3.88E-04 Epilepsy / / 22116939 rs1433197 chr2 78145340 T C 6.06E-04 Epilepsy / / 22116939 rs1368502 chr2 78170534 G A 4.43E-04 Alzheimer's disease (late onset) / / 21379329 rs1368502 chr2 78170534 G A 2.15E-04 Epilepsy / / 22116939 rs10174468 chr2 78179866 G A 4.43E-04 Alzheimer's disease (late onset) / / 21379329 rs1074192 chr2 78199268 C T 6.97E-05 Epilepsy / / 22116939 rs1609077 chr2 78214766 T C 6.34E-04 Epilepsy / / 22116939 rs2163873 chr2 78221253 T G 8.01E-04 Epilepsy / / 22116939 rs1405588 chr2 78262099 G A 5.20E-04 Coronary heart disease / / 21971053 rs1527194 chr2 78263883 T C 7.08E-04 Epilepsy / / 22116939 rs17014915 chr2 78294642 T C 4.25E-05 Suicide attempts in bipolar disorder / / 21041247 rs17014922 chr2 78296074 T C 4.28E-05 Suicide attempts in bipolar disorder / / 21041247 rs2164851 chr2 78302215 G A 1.49E-04 Epilepsy / / 22116939 rs11126651 chr2 78304795 T G 2.70E-04 Alcohol dependence / / 20201924 rs11126651 chr2 78304795 T G 8.80E-04 Alcohol dependence / / 20201924 rs7573381 chr2 78305622 A G 6.30E-04 Alcohol dependence / / 20201924 rs1437985 chr2 78311781 T C 3.57E-04 Epilepsy / / 22116939 rs6547183 chr2 78314039 T C 3.59E-04 Epilepsy / / 22116939 rs1550248 chr2 78316507 T C 5.27E-04 Multiple complex diseases / / 17554300 rs1550248 chr2 78316507 T C 4.21E-05 Cardiovascular disease / / pha003065 rs7593405 chr2 78328532 C T 1.04E-04 Alzheimer's disease (late onset) / / 21379329 rs10173591 chr2 78332806 C T 4.93E-04 Epilepsy / / 22116939 rs1370637 chr2 78341245 C A 5.57E-04 Epilepsy / / 22116939 rs13425498 chr2 78352550 C T 2.60E-04 Alzheimer's disease / / 22005930 rs1437982 chr2 78361627 C T 2.38E-04 Alzheimer's disease / / 22005930 rs10175966 chr2 78368924 C T 3.34E-04 Alzheimer's disease / / 22005930 rs12994771 chr2 78373181 G A 3.57E-04 Alzheimer's disease / / 22005930 rs13020811 chr2 78375148 C T 3.85E-04 Alzheimer's disease / / 22005930 rs6716814 chr2 78376184 C T 3.99E-04 Alzheimer's disease / / 22005930 rs12713950 chr2 78381506 G T 5.04E-04 Alzheimer's disease / / 22005930 rs6547194 chr2 78457741 G T 8.56E-04 Multiple complex diseases / / 17554300 rs1405274 chr2 78500655 C T 4.20E-05 Major depressive disorder / / 21042317 rs1818965 chr2 78501560 A G 6.70E-05 Major depressive disorder / / 21042317 rs17015127 chr2 78521092 A G 7.70E-05 Major depressive disorder / / 21042317 rs6743486 chr2 78523914 C T 8.80E-05 Major depressive disorder / / 21042317 rs2037723 chr2 78539666 G A 2.88E-06 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2037723 chr2 78539666 G A 3.00E-06 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2037723 chr2 78539666 G A 8.91E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs6754754 chr2 78562013 G A 1.29E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6754754 chr2 78562013 G A 1.58E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1114583 chr2 78593396 C T 2.26E-04 Cognition,early reading ability / / 17684495 rs2861609 chr2 78633880 A G 4.64E-05 Body Composition / / pha003012 rs10181697 chr2 78702648 T C 9.13E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17643690 chr2 78758875 C T 5.60E-06 Urinary metabolites / / 21572414 rs17585586 chr2 78993517 A G 6.82E-04 Multiple complex diseases / / 17554300 rs1521952 chr2 79013457 A G 5.40E-05 Eosinophil counts / / pha003088 rs4853413 chr2 79021429 T C 6.56E-04 Multiple complex diseases / / 17554300 rs4853414 chr2 79069569 C T 1.61E-04 Major depressive disorder / / 22472876 rs6744850 chr2 79113589 A C 1.91E-04 Type 2 diabetes / / 17463246 rs4853422 chr2 79116722 C T 8.85E-05 HIV-1 viral setpoint / / 22174851 rs10169228 chr2 79121549 A G 4.97E-04 Smoking initiation / / 24665060 rs1915751 chr2 79122483 T C 3.77E-04 Taste perception / / 22132133 rs17648900 chr2 79135349 A G 6.42E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7585834 chr2 79141188 A C 1.51E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2861680 chr2 79152922 G A 7.69E-04 Smoking initiation / / 24665060 rs9309542 chr2 79160592 G T 1.42E-05 Eosinophil counts / / pha003088 rs9309543 chr2 79160617 G A 1.42E-05 Eosinophil counts / / pha003088 rs1261226 chr2 79166443 T C 1.19E-05 Bone mass and geometry / / 17903296 rs1261226 chr2 79166443 T C 4.00E-05 Eosinophil counts / / pha003088 rs12986641 chr2 79183413 T C 1.19E-06 Contrast sensitivity / / 24152035 rs12986856 chr2 79183516 T C 3.67E-07 Contrast sensitivity / / 24152035 rs17692905 chr2 79184629 C T 3.78E-07 Contrast sensitivity / / 24152035 rs13000084 chr2 79185415 C A 5.86E-07 Contrast sensitivity / / 24152035 rs17692957 chr2 79185685 C T 3.54E-07 Contrast sensitivity / / 24152035 rs13001435 chr2 79185904 G T 5.86E-07 Contrast sensitivity / / 24152035 rs13007327 chr2 79186313 G A 5.86E-07 Contrast sensitivity / / 24152035 rs13007459 chr2 79186563 C A 3.54E-07 Contrast sensitivity / / 24152035 rs34474458 chr2 79186758 C T 5.87E-07 Contrast sensitivity / / 24152035 rs13008392 chr2 79186785 G A 5.87E-07 Contrast sensitivity / / 24152035 rs35919794 chr2 79187128 A T 5.87E-07 Contrast sensitivity / / 24152035 rs36072286 chr2 79187137 T C 3.55E-07 Contrast sensitivity / / 24152035 rs35743083 chr2 79187151 T C 5.87E-07 Contrast sensitivity / / 24152035 rs11674703 chr2 79187381 T C 5.86E-07 Contrast sensitivity / / 24152035 rs13014457 chr2 79187457 C T 5.86E-07 Contrast sensitivity / / 24152035 rs11679961 chr2 79187489 A C 5.86E-07 Contrast sensitivity / / 24152035 rs11691084 chr2 79187502 C T 5.86E-07 Contrast sensitivity / / 24152035 rs11691141 chr2 79187588 C G 5.87E-07 Contrast sensitivity / / 24152035 rs71424840 chr2 79188272 T C 5.84E-07 Contrast sensitivity / / 24152035 rs11683300 chr2 79190060 A G 2.45E-07 Contrast sensitivity / / 24152035 rs11695755 chr2 79190073 C T 2.43E-07 Contrast sensitivity / / 24152035 rs10520219 chr2 79190408 G A 8.35E-06 Contrast sensitivity / / 24152035 rs11679452 chr2 79190517 T C 1.94E-07 Contrast sensitivity / / 24152035 rs17015957 chr2 79191047 A G 7.68E-06 Contrast sensitivity / / 24152035 rs55857353 chr2 79191129 C T 1.97E-07 Contrast sensitivity / / 24152035 rs17015960 chr2 79192643 A G 8.57E-06 Contrast sensitivity / / 24152035 rs35119416 chr2 79193163 T G 3.06E-07 Contrast sensitivity / / 24152035 rs56330221 chr2 79193372 A G 9.65E-06 Contrast sensitivity / / 24152035 rs11677315 chr2 79194293 T C 9.11E-08 Contrast sensitivity / / 24152035 rs11693972 chr2 79194668 C G 2.37E-06 Contrast sensitivity / / 24152035 rs11683503 chr2 79198168 T C 1.00E-07 Contrast sensitivity / / 24152035 rs34611177 chr2 79201918 A T 2.14E-07 Contrast sensitivity / / 24152035 rs17749826 chr2 79213468 G A 4.32E-07 Contrast sensitivity / / 24152035 rs10520222 chr2 79214891 C T 9.07E-07 Contrast sensitivity / / 24152035 rs11676773 chr2 79215748 A G 1.89E-07 Contrast sensitivity / / 24152035 rs13008188 chr2 79216796 G A 4.30E-07 Contrast sensitivity / / 24152035 rs11694350 chr2 79219390 G A 3.08E-07 Contrast sensitivity / / 24152035 rs1666768 chr2 79223215 G A 0.000274 Salmonella-induced pyroptosis / / 22837397 rs811526 chr2 79227099 A C 1.93E-05 Response to hepatitis C treatment / / 19684573 rs789304 chr2 79227147 G C 1.10E-05 Urinary metabolites / / 21572414 rs10520227 chr2 79230585 G A 5.40E-06 Urinary metabolites / / 21572414 rs375644 chr2 79241810 C T 1.80E-06 Urinary metabolites / / 21572414 rs17016215 chr2 79252307 G A 5.77E-04 Multiple complex diseases / / 17554300 rs17016215 chr2 79252307 G A 6.29E-05 Femoral neck bone geometry / / 22087292 rs283838 chr2 79263703 G A 9.20E-06 Menarche (age at onset) / / 19448622 rs283843 chr2 79268213 C A 2.90E-05 Urinary metabolites / / 21572414 rs283849 chr2 79271035 T G 4.30E-06 Urinary metabolites / / 21572414 rs364446 chr2 79291934 C T 2.88E-04 Schizophrenia / / 19197363 rs6710553 chr2 79300863 C T 1.34E-04 Multiple complex diseases / / 17554300 rs1608234 chr2 79303418 T C 6.25E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1036392 chr2 79342811 C T 1.69E-05 Multiple complex diseases / / 17554300 rs7603333 chr2 79357595 G A,T 8.75E-05 Schizophrenia / / 19197363 rs17753959 chr2 79359874 G A 8.91E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3819315 chr2 79364601 C T 9.95E-05 Monocyte chemoattractant protein-1 / / pha003071 rs879021 chr2 79364824 C A 7.32E-05 Schizophrenia / / 19197363 rs1589614 chr2 79370426 C T 8.60E-05 Alzheimer's disease (late onset) / / 21379329 rs17016435 chr2 79405396 A G 5.53E-05 Biliary atresia / / 20460270 rs10496214 chr2 79417943 G T 6.88E-04 Schizophrenia / / 19197363 rs4853444 chr2 79450316 C A 3.69E-04 Parkinson's disease / / 17052657 rs4853451 chr2 79508165 G A 3.92E-05 Taste perception / / 22132133 rs12470852 chr2 79509022 G C 4.22E-04 Acute lung injury / / 22295056 rs11126705 chr2 79509292 C T 2.01E-04 Acute lung injury / / 22295056 rs12623159 chr2 79516586 T A 1.73E-04 Acute lung injury / / 22295056 rs11126706 chr2 79517133 A G 1.62E-04 Acute lung injury / / 22295056 rs6733601 chr2 79517346 G A 6.37E-04 Multiple complex diseases / / 17554300 rs11126707 chr2 79517637 G A 1.17E-04 Acute lung injury / / 22295056 rs732258 chr2 79518553 C T 1.35E-04 Acute lung injury / / 22295056 rs12471468 chr2 79521952 A G 1.03E-04 Acute lung injury / / 22295056 rs12465102 chr2 79525033 T A 2.83E-04 Acute lung injury / / 22295056 rs1434205 chr2 79525428 T C 8.41E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6760650 chr2 79529472 C T 1.74E-04 Acute lung injury / / 22295056 rs6760878 chr2 79529552 G C 3.13E-04 Acute lung injury / / 22295056 rs10200371 chr2 79530813 A G 3.05E-04 Acute lung injury / / 22295056 rs13397704 chr2 79536354 G A 8.37E-04 Acute lung injury / / 22295056 rs13427217 chr2 79537984 A T 1.34E-04 Acute lung injury / / 22295056 rs13418113 chr2 79538168 T G 1.25E-04 Acute lung injury / / 22295056 rs13418113 chr2 79538168 T G 9.14E-05 Blood Pressure / / pha003039 rs13409348 chr2 79539988 G C 3.00E-06 Bipolar disorder / / 19416921 rs13409348 chr2 79539988 G C 1.08E-04 Acute lung injury / / 22295056 rs13385415 chr2 79543430 T A 5.02E-04 Acute lung injury / / 22295056 rs10200167 chr2 79544256 T C 1.56E-04 Alzheimer's disease / / 24755620 rs1434172 chr2 79553119 C A 1.34E-04 Acute lung injury / / 22295056 rs1562886 chr2 79562459 T C 2.13E-04 Smoking cessation / / 24665060 rs1368965 chr2 79567440 C A 5.07E-05 Potassium levels / / pha003086 rs4852472 chr2 79571761 C T 6.57E-04 Alzheimer's disease / / 17998437 rs2100290 chr2 79632347 A G 2.00E-06 Alcohol consumption / / 23942779 rs2100290 chr2 79632347 A G 2.80E-04 Nicotine use / / 23942779 rs399885 chr2 79687252 A C 5.00E-07 Response to antipsychotic treatment / / 20195266 rs1864548 chr2 79689572 T C 3.70E-04 Rheumatoid arthritis / / 22446963 rs7598481 chr2 79697456 C T 9.37E-05 Cognitive impairment induced by topiramate / / 22091778 rs1864549 chr2 79699411 C A 6.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17040658 chr2 79708518 A G 9.50E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs7570469 chr2 79709354 C T 6.00E-07 Response to antipsychotic treatment / / 20195266 rs11900604 chr2 79715879 T G 3.22E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17017222 chr2 79733001 C T 7.34E-05 Multiple complex diseases / / 17554300 rs41503545 chr2 79735130 T A 5.89E-04 Multiple complex diseases / / 17554300 rs10206130 chr2 79750591 G T 2.80E-06 Urinary metabolites CTN/2 intron 21572414 rs10206130 chr2 79750591 G T 4.13E-05 Sudden cardiac arrest CTN/2 intron 21658281 rs6719738 chr2 79760238 T C 7.40E-06 Urinary metabolites CTN/2 intron 21572414 rs17017233 chr2 79772054 T C 8.64E-05 Multiple complex diseases CTN/2 intron 17554300 rs17017233 chr2 79772054 T C 1.06E-04 Blood pressure (response to calcium channel blocker) CTN/2 intron 24192120 rs880813 chr2 79776291 C A 8.20E-04 Alzheimer's disease CTN/2 intron 22005930 rs7597912 chr2 79778112 T C 3.17E-05 Sudden cardiac arrest CTN/2 intron 21658281 rs10520246 chr2 79781669 G T 1.50E-04 Breast cancer and prostate cancer CTN/2 intron 17903305 rs10520247 chr2 79781797 G C 2.80E-05 Breast cancer and prostate cancer CTN/2 intron 17903305 rs2685159 chr2 79782036 A G 3.19E-04 Multiple complex diseases CTN/2 intron 17554300 rs2685159 chr2 79782036 A G 1.52E-04 Blood pressure (response to calcium channel blocker) CTN/2 intron 24192120 rs2685162 chr2 79783547 T C 8.82E-04 Alzheimer's disease CTN/2 intron 22005930 rs1972755 chr2 79784187 T C 8.54E-04 Alzheimer's disease CTN/2 intron 22005930 rs1430641 chr2 79785578 C G 6.55E-04 Alzheimer's disease CTN/2 intron 22005930 rs2566540 chr2 79786393 A T 6.91E-04 Alzheimer's disease CTN/2 intron 22005930 rs2566541 chr2 79793629 C A 9.91E-04 Alzheimer's disease CTN/2 intron 22005930 rs17017285 chr2 79800992 T C 5.69E-04 Multiple complex diseases CTN/2 intron 17554300 rs2685150 chr2 79803425 A G 7.27E-04 Alzheimer's disease CTN/2 intron 22005930 rs1549761 chr2 79811084 C A 6.46E-04 Alzheimer's disease CTN/2 intron 22005930 rs11126737 chr2 79811402 G A 9.64E-04 Alzheimer's disease CTN/2 intron 22005930 rs7598670 chr2 79813622 T C 6.77E-04 Alzheimer's disease CTN/2 intron 22005930 rs6740609 chr2 79855622 C T 6.92E-05 Cognitive test performance CTN/2 intron 20125193 rs6740609 chr2 79855622 C T 4.48E-04 Hemoglobin concentration CTN/2 intron 20534544 rs12464912 chr2 79890172 T C 7.14E-05 Lung adenocarcinoma CTN/2 intron 19836008 rs6759387 chr2 79891085 T A 1.42E-04 Type 2 diabetes CTN/2 intron 17463246 rs4422182 chr2 79905813 G A 0.0005935 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CTN/2 intron 23233654 rs4422182 chr2 79905813 G A 5.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) CTN/2 intron 23233662 rs2089815 chr2 79905975 T G 0.0005893 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CTN/2 intron 23233654 rs2089815 chr2 79905975 T G 5.89E-04 Methotrexate clearance (acute lymphoblastic leukemia) CTN/2 intron 23233662 rs12471455 chr2 79910349 G A 9.45E-06 Pancreatic cancer CTN/2 intron pha002889 rs11695685 chr2 79922802 C T 5.00E-07 Protein quantitative trait loci CTN/2 intron 18464913 rs13028762 chr2 79930269 T C 3.91E-04 Smoking cessation CTN/2 intron 24665060 rs6547265 chr2 79940319 G C 5.30E-06 Urinary metabolites CTN/2 intron 21572414 rs6547265 chr2 79940319 G C 5.50E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CTN/2 intron 22566498 rs11693318 chr2 79956356 C A 1.33E-05 Pancreatic cancer CTN/2 intron 23180869 rs1567532 chr2 79956550 C T 9.55E-06 Pancreatic cancer CTN/2 intron 23180869 rs7565556 chr2 79963405 G C 5.40E-04 Type 2 diabetes and 6 quantitative traits CTN/2 intron 17848626 rs6724922 chr2 79971248 C T 2.27E-05 Waist-Hip Ratio CTN/2 intron pha003029 rs4541274 chr2 79973436 T C 7.04E-04 Longevity CTN/2 intron 22279548 rs6547273 chr2 79985605 T G 1.91E-05 Heart Rate CTN/2 intron pha003054 rs7592956 chr2 79992038 C T 2.70E-05 Urinary metabolites CTN/2 intron 21572414 rs1912697 chr2 79993340 G T 1.00E-05 Urinary metabolites CTN/2 intron 21572414 rs6751684 chr2 80023852 C A 1.16E-04 Amyotrophic lateral sclerosis (sporadic) CTN/2 intron 24529757 rs868032 chr2 80034570 T C 6.73E-04 Multiple complex diseases CTN/2 intron 17554300 rs2941752 chr2 80047419 G A 1.20E-05 Urinary metabolites CTN/2 intron 21572414 rs4852531 chr2 80049718 C T 8.23E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CTN/2 intron 24023788 rs2861914 chr2 80081182 T G 1.60E-04 Type 2 diabetes CTN/2 intron 17463246 rs713261 chr2 80095412 C T 9.90E-04 Multiple complex diseases CTN/2 intron 17554300 rs2916508 chr2 80111797 G T 3.96E-04 Age-related macular degeneration CTN/2 intron 22125219 rs986211 chr2 80112641 C T 1.06E-05 Age-related macular degeneration CTN/2 intron 22125219 rs2974173 chr2 80121731 G T 3.25E-04 Hemoglobin concentration CTN/2 intron 20534544 rs17018130 chr2 80134512 A G 4.12E-04 Multiple complex diseases CTN/2 intron 17554300 rs2974179 chr2 80138245 A G 1.67E-04 Hemoglobin concentration CTN/2 intron 20534544 rs2916530 chr2 80156246 G A 1.69E-04 Coronary Artery Disease CTN/2 intron 17634449 rs2974142 chr2 80162195 C T 4.21E-05 HDL particle features CTN/2 intron pha002900 rs2974133 chr2 80180508 G T 2.45E-05 Prion diseases CTN/2 intron 22210626 rs3905417 chr2 80181443 G A 2.20E-05 Urinary metabolites CTN/2 intron 21572414 rs4591366 chr2 80182551 C T 9.14E-05 HDL cholesterol CTN/2 intron pha003075 rs6745989 chr2 80182604 G A 5.41E-06 Panic disorder CTN/2 intron 19165232 rs6745989 chr2 80182604 G A 2.67E-25 Narcolepsy CTN/2 intron 19629137 rs747921 chr2 80185885 A G 6.38E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) CTN/2 intron 23648065 rs12990844 chr2 80187793 C T 7.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CTN/2 intron 20877124 rs6752828 chr2 80187969 C T 3.90E-04 Myopia (pathological) CTN/2 intron 21095009 rs2861913 chr2 80192435 A G 1.12E-04 Multiple sclerosis CTN/2 intron 17660530 rs2861913 chr2 80192435 A G 6.95E-05 Personality dimensions CTN/2 intron 18957941 rs2861913 chr2 80192435 A G 2.75E-05 Serum metabolites CTN/2 intron 19043545 rs6719499 chr2 80193386 G A 2.45E-05 Coronary heart disease CTN/2 intron pha003031 rs13001262 chr2 80194080 C T 6.40E-05 Coronary heart disease CTN/2 intron pha003031 rs13028697 chr2 80194625 T C 3.01E-05 Intelligence CTN/2 intron 21826061 rs13028697 chr2 80194625 T C 9.74E-05 Coronary heart disease CTN/2 intron pha003031 rs542255 chr2 80196736 T G 5.52E-05 Coronary heart disease CTN/2 intron pha003031 rs671772 chr2 80197462 T C 6.83E-05 Coronary heart disease CTN/2 intron pha003032 rs17261321 chr2 80197843 G T 9.60E-05 Coronary heart disease CTN/2 intron pha003030 rs598453 chr2 80214554 C T 7.55E-05 Coronary heart disease CTN/2 intron pha003030 rs556003 chr2 80216399 C T 4.75E-05 Coronary heart disease CTN/2 intron pha003032 rs491062 chr2 80218984 C A 8.58E-06 Coronary heart disease CTN/2 intron pha003032 rs571094 chr2 80220009 A C 8.50E-06 Urinary metabolites CTN/2 intron 21572414 rs1368909 chr2 80228740 T C 1.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) CTN/2 intron 23648065 rs6741085 chr2 80230424 T G 4.97E-04 Response to taxane treatment (placlitaxel) CTN/2 intron 23006423 rs423412 chr2 80236251 A G 0.00008141 Sarcoidosis CTN/2 intron 22952805 rs719487 chr2 80238531 C T 3.00E-06 Urinary metabolites CTN/2 intron 21572414 rs921637 chr2 80259424 G A 3.30E-04 Aortic root size CTN/2 intron 21223598 rs4852549 chr2 80280680 G A 1.64E-04 Multiple complex diseases CTN/2 intron 17554300 rs13394835 chr2 80280710 C A 2.81E-04 Multiple complex diseases CTN/2 intron 17554300 rs6738962 chr2 80281173 A G 1.00E-08 Alzheimer's disease (cognitive decline) CTN/2 intron 23535033 rs13427272 chr2 80285936 G A 6.10E-07 Fasting plasma glucose CTN/2 intron 19060907 rs716487 chr2 80310648 A G 1.10E-04 Rheumatoid arthritis CTN/2 intron 21673997 rs6720989 chr2 80329535 G A 2.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CTN/2 intron 20877124 rs6720989 chr2 80329535 G A 2.05E-04 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs7575007 chr2 80330233 G C 2.03E-04 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs7592938 chr2 80331554 T C 2.27E-04 Cholesterol CTN/2 intron 17255346 rs10496237 chr2 80331812 C T 2.03E-04 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs1031442 chr2 80332151 T C 1.62E-04 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs1552308 chr2 80333464 G A 1.79E-04 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs7570587 chr2 80334824 C T 9.83E-05 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs1017633 chr2 80340091 C A 8.99E-05 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs1017632 chr2 80340234 G A 9.27E-05 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs1319228 chr2 80344073 G A 5.28E-05 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs2902111 chr2 80346212 C T 6.62E-05 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs1319241 chr2 80392892 C T 1.83E-04 Cholesterol CTN/2 intron 17255346 rs17018760 chr2 80398707 C T 7.17E-05 Cholesterol CTN/2 intron 17255346 rs11893350 chr2 80399212 C T 5.53E-05 Cholesterol CTN/2 intron 17255346 rs1530397 chr2 80415634 A C 3.70E-05 Cholesterol CTN/2 intron 17255346 rs7570531 chr2 80420696 T C 2.50E-05 Cholesterol CTN/2 intron 17255346 rs961408 chr2 80421277 A G 3.57E-05 Cholesterol CTN/2 intron 17255346 rs1446107 chr2 80434401 A G 1.53E-05 Cholesterol CTN/2 intron 17255346 rs1446108 chr2 80434636 G A 2.11E-05 Cholesterol CTN/2 intron 17255346 rs7590636 chr2 80445512 G A 1.79E-05 Cholesterol CTN/2 intron 17255346 rs1006607 chr2 80448882 A G 1.94E-05 Cholesterol CTN/2 intron 17255346 rs2120408 chr2 80450284 A G 2.16E-05 Cholesterol CTN/2 intron 17255346 rs1965834 chr2 80451078 G A 1.44E-05 Cholesterol CTN/2 intron 17255346 rs1965833 chr2 80451184 T C 3.88E-05 Cholesterol CTN/2 intron 17255346 rs2165975 chr2 80452104 G A 2.88E-05 Cholesterol CTN/2 intron 17255346 rs2587148 chr2 80463850 G A 5.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CTN/2 intron 20877124 rs1079319 chr2 80510040 G T 4.16E-05 Cholesterol CTN/2 intron 17255346 rs1930 chr2 80514672 C T 1.90E-04 Blood pressure CTN/2 intron 21572416 rs6733871 chr2 80529956 T C 4.69E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy LRRTM1 missense 23834954 rs12465382 chr2 80567348 A G 3.36E-04 Smoking initiation CTN/2 intron 24665060 rs1443896 chr2 80572750 G A 1.83E-04 Smoking initiation CTN/2 intron 24665060 rs6739985 chr2 80575448 G T 1.70E-04 Smoking initiation CTN/2 intron 24665060 rs13431891 chr2 80605790 A G 4.06E-08 Eye color CTN/2 intron 23486544 rs7557554 chr2 80651461 C T 6.92E-04 Type 2 diabetes CTN/2 intron 17463246 rs1444541 chr2 80656878 G A 5.57E-05 Soluble levels of adhesion molecules CTN/2 intron pha003072 rs6747004 chr2 80668722 T G 2.80E-05 Urinary metabolites CTN/2 intron 21572414 rs3290 chr2 80677131 G C 5.16E-04 Type 2 diabetes CTN/2 intron 17463246 rs17019221 chr2 80703605 A G 6.19E-05 Smoking cessation CTN/2 intron 18519826 rs11886059 chr2 80716608 T C 3.73E-04 Multiple complex diseases CTN/2 intron 17554300 rs13409724 chr2 80752502 T C 7.97E-04 Suicide attempts in bipolar disorder CTN/2 intron 21423239 rs12611756 chr2 80761192 A C 5.88E-05 Cardiovascular disease CTN/2 intron 22029572 rs13423141 chr2 80770808 C T 8.74E-05 Alcohol dependence CTN/2 intron 20201924 rs13423141 chr2 80770808 C T 8.74E-05 Alcoholism CTN/2 intron pha002891 rs7605261 chr2 80771190 T G 5.73E-04 Alcohol dependence CTN/2 intron 20201924 rs1816456 chr2 80786499 T G 0.000393 Salmonella-induced pyroptosis CTN/2 intron 22837397 rs1434064 chr2 80798914 G C 7.35E-05 Smoking cessation CTN/2 intron 18519826 rs1560862 chr2 80800793 G A 0.0000598 Tuberculosis with late age of onset CTN/2 intron 22551897 rs3770340 chr2 80813664 G A 4.83E-04 Sarcoidosis CTN/2 intron 19165924 rs216645 chr2 80825711 A T 1.26E-04 Smoking cessation CTN/2 intron 18519826 rs216645 chr2 80825711 A T 7.93E-04 Smoking cessation CTN/2 intron 18519826 rs216645 chr2 80825711 A T 7.17E-04 Alzheimer's disease CTN/2 intron 24755620 rs17019480 chr2 80834949 G A 2.98E-04 Smoking initiation CTN/2 intron 24665060 rs17019531 chr2 80858726 C T 0.000807 Salmonella-induced pyroptosis CTN/2 intron 22837397 rs13382374 chr2 80885470 T C 7.53E-04 Depression (quantitative trait) / / 20800221 rs7574764 chr2 80898579 T C 7.43E-04 Depression (quantitative trait) / / 20800221 rs13404209 chr2 80900868 C G 7.36E-04 Depression (quantitative trait) / / 20800221 rs6718076 chr2 80900986 G A 1.44E-04 Type 2 diabetes / / 17463246 rs1370339 chr2 80915114 C T 5.68E-05 Anorexia nervosa / / 24514567 rs17019600 chr2 80915734 C A 5.10E-05 Ulcerative colitis / / 19915572 rs11684938 chr2 80924920 A G 5.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6757169 chr2 80939019 A G 6.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7593517 chr2 80942676 G A 2.36E-04 Multiple complex diseases / / 17554300 rs7607618 chr2 80942951 T C 3.88E-04 Multiple complex diseases / / 17554300 rs10490511 chr2 80948763 G A 7.03E-04 Multiple complex diseases / / 17554300 rs1265750 chr2 80951823 T C 9.16E-05 Blood Pressure / / pha002903 rs6547332 chr2 81018887 G A 8.69E-04 Nicotine dependence / / 17158188 rs4852592 chr2 81040532 G A 8.56E-05 Body Mass Index / / pha003006 rs6547333 chr2 81099320 A T 2.36E-04 Nicotine dependence / / 17158188 rs17019859 chr2 81125236 G A 1.81E-04 Nicotine dependence / / 17158188 rs7583676 chr2 81171004 C A 4.52E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs2862358 chr2 81180603 T G 5.80E-05 Personality dimensions / / 18957941 rs4462808 chr2 81191209 G T 1.31E-04 Osteoarthritis / / 19508968 rs4389353 chr2 81201683 C T 3.37E-04 Osteoarthritis / / 19508968 rs6547341 chr2 81241412 C T 6.69E-05 Body Composition / / pha003012 rs12465939 chr2 81241811 C A,T 3.94E-06 Socioeconomic Factors / / pha003066 rs3979242 chr2 81261916 G A 7.70E-05 Body Composition / / pha003012 rs11126794 chr2 81321126 C T 7.93E-05 Personality dimensions / / 18957941 rs1968758 chr2 81420899 G T 2.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13430688 chr2 81421951 A G 1.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4852611 chr2 81425437 C A 8.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs921963 chr2 81426483 C A 2.65E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2010447 chr2 81427187 C T 3.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6710284 chr2 81440526 T C 4.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1379387 chr2 81442038 G A 7.03E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7557024 chr2 81461019 A G 8.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7557987 chr2 81469658 T G 9.69E-05 Body Mass Index / / pha003009 rs4349373 chr2 81471682 C T 7.72E-05 Body Mass Index / / pha003009 rs6707716 chr2 81485448 T C 4.42E-28 Narcolepsy / / 19629137 rs7581118 chr2 81505707 C T 7.73E-05 Body Mass Index / / pha003009 rs13424413 chr2 81562649 G A 1.35E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10208516 chr2 81574758 G A 7.00E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12467913 chr2 81637683 A T 0.0004676 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12467913 chr2 81637683 A T 4.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1435883 chr2 81642505 A G 6.14E-05 Blood Pressure / / pha002903 rs11887827 chr2 81666154 A G 8.27E-14 Multiple complex diseases / / 17554300 rs10496265 chr2 81668808 T C 1.00E-08 Aging traits / / 17903295 rs12468325 chr2 81690580 C G 9.73E-04 Multiple complex diseases LOC100507201 intron 17554300 rs6752979 chr2 81741750 G A 4.74E-05 Blood Pressure / / pha002903 rs10496262 chr2 81751124 C A 3.00E-07 Aging traits / / 17903295 rs764977 chr2 81757391 T C 8.76E-05 Blood Pressure / / pha002903 rs6756959 chr2 81772723 G A 2.20E-06 Orthostatic hypotension / / 24124408 rs6715049 chr2 81772994 T C 3.50E-06 Orthostatic hypotension / / 24124408 rs6715049 chr2 81772994 T C 6.31E-05 Blood Pressure / / pha002903 rs17020478 chr2 81818331 A G 5.25E-04 Multiple complex diseases / / 17554300 rs7570909 chr2 81819551 T C 9.77E-05 Blood Pressure / / pha002903 rs17020502 chr2 81828061 G A 2.00E-05 Urinary metabolites / / 21572414 rs17020502 chr2 81828061 G A 3.70E-06 Orthostatic hypotension / / 24124408 rs11126825 chr2 81844064 A G 2.00E-05 Urinary metabolites / / 21572414 rs6736587 chr2 81855725 A C 5.00E-08 Orthostatic hypotension / / 24124408 rs12615721 chr2 81856526 G A 8.00E-06 Pulmonary function decline / / 22424883 rs12052359 chr2 81872922 C A 9.66E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12052359 chr2 81872922 C A 7.00E-06 Bilirubin levels / / 22085899 rs11883603 chr2 81902711 T A 2.70E-05 Urinary metabolites / / 21572414 rs12612468 chr2 81935992 A C 6.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs11674927 chr2 81938574 T G 8.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs1432187 chr2 81946409 A C 9.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs6706099 chr2 81955364 C T 5.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs6734974 chr2 81955456 A G 7.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs17020736 chr2 81967942 T A 2.70E-05 Urinary metabolites / / 21572414 rs2705635 chr2 81991586 G A 2.60E-05 Urinary metabolites / / 21572414 rs1108797 chr2 81992578 A G 2.40E-05 Urinary metabolites / / 21572414 rs1221178 chr2 81992756 A G 2.10E-05 Urinary metabolites / / 21572414 rs1368038 chr2 82027767 T C 5.37E-04 Multiple complex diseases / / 17554300 rs10166510 chr2 82035216 A G 7.38E-04 Smoking initiation / / 24665060 rs17563144 chr2 82035849 C T 1.90E-05 Urinary metabolites / / 21572414 rs12470539 chr2 82046122 A C 8.85E-04 Multiple complex diseases / / 17554300 rs2862590 chr2 82078480 G T 6.73E-05 Otosclerosis / / 19230858 rs2862591 chr2 82078577 C A 1.30E-05 Urinary metabolites / / 21572414 rs991869 chr2 82086880 C G 3.20E-06 Urinary metabolites / / 21572414 rs1897403 chr2 82110525 G A,C 1.90E-05 Urinary metabolites / / 21572414 rs11895085 chr2 82135708 G A 8.60E-06 Urinary metabolites / / 21572414 rs10520308 chr2 82149614 T G 4.59E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2685708 chr2 82168870 A G 9.30E-05 Bipolar disorder / / 17486107 rs2862675 chr2 82224685 A G 6.87E-04 Rheumatoid arthritis / / 21452313 rs17568078 chr2 82225677 A G 3.64E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs17021319 chr2 82227252 T C 6.15E-05 Intelligence / / 21826061 rs6729973 chr2 82232407 A G 6.85E-05 Intelligence / / 21826061 rs4852655 chr2 82235644 C T 8.56E-04 Schizophrenia / / 19197363 rs11687765 chr2 82325531 C A 7.80E-04 Body mass index / / 21701565 rs9309592 chr2 82331757 G T 5.55E-04 Body mass index / / 21701565 rs1529593 chr2 82372848 G A 4.93E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7560758 chr2 82382462 A G 4.40E-04 Multiple complex diseases / / 17554300 rs17021536 chr2 82416690 G A 5.90E-04 Multiple complex diseases / / 17554300 rs2163361 chr2 82427505 A T 8.29E-04 Multiple complex diseases / / 17554300 rs7586694 chr2 82658348 G A 1.94E-05 Post-operative nausea and vomiting / / 21694509 rs11681331 chr2 82717155 C A 6.39E-05 Lung adenocarcinoma / / 19836008 rs6706386 chr2 82741007 C G 9.26E-04 Coronary Artery Disease / / 17634449 rs17021922 chr2 82768466 C T 9.37E-04 Coronary Artery Disease / / 17634449 rs6547436 chr2 82811606 G A 8.98E-04 Coronary Artery Disease / / 17634449 rs1910233 chr2 82867347 T G 9.17E-04 Myopia (pathological) / / 21095009 rs1393503 chr2 82883841 T G 5.52E-04 Myopia (pathological) / / 21095009 rs1393504 chr2 82883860 G T 5.95E-04 Myopia (pathological) / / 21095009 rs6731289 chr2 82892794 C A 2.46E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6731289 chr2 82892794 C A 8.45E-04 Myopia (pathological) / / 21095009 rs6731289 chr2 82892794 C A 7.40E-05 Alcoholism (heaviness of drinking) / / 21529783 rs10520355 chr2 82913165 T C 1.00E-06 Urinary metabolites / / 21572414 rs1393501 chr2 82921559 C A 4.36E-04 Myopia (pathological) / / 21095009 rs4852691 chr2 82924585 G C 1.40E-05 Urinary metabolites / / 21572414 rs1502598 chr2 82925182 A T 1.40E-05 Urinary metabolites / / 21572414 rs12476792 chr2 82935393 G A 2.30E-05 Urinary metabolites / / 21572414 rs2134370 chr2 82939886 A G 5.43E-04 Myopia (pathological) / / 21095009 rs13415522 chr2 82943212 T C 2.60E-05 Urinary metabolites / / 21572414 rs17022257 chr2 82947063 A G 5.16E-04 Smoking quantity / / 24665060 rs17022279 chr2 82956407 C G 9.98E-04 Self-reported allergy / / 23817569 rs17022288 chr2 82957817 C T 9.76E-05 Smoking quantity / / 24665060 rs12328118 chr2 82957950 A G 4.93E-05 Vaspin levels / / 22907691 rs12328118 chr2 82957950 A G 0.0000493 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs17022321 chr2 82960647 C G 9.31E-04 Self-reported allergy / / 23817569 rs6547441 chr2 82965627 G A 1.46E-04 Vaspin levels / / 22907691 rs6547441 chr2 82965627 G A 0.0001456 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs1393509 chr2 82978565 G A 1.46E-04 Vaspin levels / / 22907691 rs1393509 chr2 82978565 G A 0.0001456 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs11692714 chr2 82981654 T C 6.20E-05 Vaspin levels / / 22907691 rs11692714 chr2 82981654 T C 0.000062 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs17022382 chr2 82989156 T C 1.46E-04 Vaspin levels / / 22907691 rs17022382 chr2 82989156 T C 0.0001456 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs17022383 chr2 82991635 G A 6.20E-05 Vaspin levels / / 22907691 rs17022383 chr2 82991635 G A 0.000062 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs7558379 chr2 83004733 A G 4.81E-04 Myopia (pathological) / / 21095009 rs7571839 chr2 83011373 T C 1.46E-04 Vaspin levels / / 22907691 rs7571839 chr2 83011373 T C 0.0001456 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs13012745 chr2 83020550 T C 4.76E-04 Myopia (pathological) / / 21095009 rs17022444 chr2 83029469 C G 1.00E-10 Response to antipsychotic therapy (extrapyramidal side effects) / / 19875103 rs17022457 chr2 83039280 C T 4.00E-04 Self-reported allergy / / 23817569 rs972827 chr2 83040357 G A 1.20E-04 Myopia (pathological) / / 21095009 rs17022458 chr2 83040659 T C 3.94E-04 Self-reported allergy / / 23817569 rs974260 chr2 83041653 C T 2.82E-04 Myopia (pathological) / / 21095009 rs17022478 chr2 83044252 T C 3.85E-04 Self-reported allergy / / 23817569 rs7594284 chr2 83049370 A G 1.23E-04 Myopia (pathological) / / 21095009 rs17022522 chr2 83052914 C G 4.04E-04 Self-reported allergy / / 23817569 rs17022524 chr2 83053130 T C 4.24E-04 Self-reported allergy / / 23817569 rs17022543 chr2 83058079 T C 5.04E-04 Self-reported allergy / / 23817569 rs17022550 chr2 83058433 A G 4.96E-04 Self-reported allergy / / 23817569 rs17022562 chr2 83060790 C T 4.92E-04 Self-reported allergy / / 23817569 rs17022565 chr2 83061820 T A 5.72E-04 Self-reported allergy / / 23817569 rs17022569 chr2 83062465 C T 8.41E-04 Self-reported allergy / / 23817569 rs34405784 chr2 83062465 C CG 8.41E-04 Self-reported allergy / / 23817569 rs17022576 chr2 83064503 G C 6.04E-04 Self-reported allergy / / 23817569 rs17022577 chr2 83065273 T C 6.05E-04 Self-reported allergy / / 23817569 rs17022578 chr2 83065850 C T 6.36E-04 Self-reported allergy / / 23817569 rs17022583 chr2 83066047 G A 6.45E-04 Self-reported allergy / / 23817569 rs17022587 chr2 83068625 C T 6.79E-04 Self-reported allergy / / 23817569 rs10520359 chr2 83070326 T C 7.24E-04 Self-reported allergy / / 23817569 rs1609470 chr2 83077717 A T 5.98E-04 Type 2 diabetes / / 17463246 rs9917294 chr2 83082439 G A 8.20E-05 Endometriosis / / 21151130 rs11126880 chr2 83084350 A T 1.43E-04 Self-reported allergy / / 23817569 rs17022662 chr2 83085078 C T 1.44E-04 Self-reported allergy / / 23817569 rs17022668 chr2 83091427 G T 8.07E-04 Self-reported allergy / / 23817569 rs17040798 chr2 83278233 A C 4.48E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10496288 chr2 83292565 T C 2.00E-09 Hypertension / / 21626137 rs10496289 chr2 83293380 C T 2.00E-09 Hypertension / / 21626137 rs17040804 chr2 83293667 C T 6.51E-04 Multiple complex diseases / / 17554300 rs2043074 chr2 83301097 T C 6.38E-05 Intelligence / / 21826061 rs2043074 chr2 83301097 T C 2.93E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs724302 chr2 83315550 C T 9.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17023156 chr2 83332983 T C 9.11E-05 Intelligence / / 21826061 rs17023156 chr2 83332983 T C 8.98E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs963064 chr2 83335815 A G 9.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1430275 chr2 83336271 A G 2.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1946554 chr2 83336680 A T 6.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10496292 chr2 83340360 G A 3.08E-05 Bilirubin levels,in serum / / 19389676 rs17023205 chr2 83340623 C T 2.86E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10496293 chr2 83342154 A G 4.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17023229 chr2 83352379 T G 3.08E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs17023252 chr2 83357496 A G 6.70E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1430282 chr2 83416683 C A 6.70E-05 Intelligence / / 21826061 rs1430282 chr2 83416683 C A 8.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12619752 chr2 83429829 A G 2.92E-04 Hemoglobin concentration / / 20534544 rs11126894 chr2 83436237 T G 4.08E-04 Hemoglobin concentration / / 20534544 rs7422290 chr2 83472006 C T 4.08E-04 Hemoglobin concentration / / 20534544 rs7420983 chr2 83474151 C T 4.01E-04 Hemoglobin concentration / / 20534544 rs6547469 chr2 83474832 G A 4.08E-04 Hemoglobin concentration / / 20534544 rs7595346 chr2 83484387 A T 2.16E-04 Multiple complex diseases / / 17554300 rs6547479 chr2 83515924 C A,G 2.05E-04 Hemoglobin concentration / / 20534544 rs12232909 chr2 83546161 A G 2.85E-04 Hemoglobin concentration / / 20534544 rs12232909 chr2 83546161 A G 4.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs6745924 chr2 83551072 G C 4.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs7425554 chr2 83553973 C T 5.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs6760584 chr2 83556740 T G 8.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs7422781 chr2 83560840 A G 6.75E-05 Hemoglobin concentration / / 20534544 rs6749875 chr2 83592850 G A 9.93E-05 Hemoglobin concentration / / 20534544 rs1991542 chr2 83601285 C T 6.63E-05 Mammographic density / / 22532574 rs1121554 chr2 83608066 A G 0.0000091 Amygdala reactivity / / 22856363 rs1035979 chr2 83614035 C T 7.31E-06 Height / / pha003010 rs1035979 chr2 83614035 C T 1.09E-06 Height / / pha003011 rs1429381 chr2 83618557 C A 7.30E-06 Height / / pha003010 rs1429381 chr2 83618557 C A 1.09E-06 Height / / pha003011 rs767504 chr2 83625349 T C 9.86E-06 Height / / pha003010 rs767504 chr2 83625349 T C 1.35E-06 Height / / pha003011 rs1896848 chr2 83633730 G T 9.18E-06 Height / / pha003010 rs1896848 chr2 83633730 G T 1.06E-06 Height / / pha003011 rs1541835 chr2 83635578 C T 4.36E-05 Height / / pha003010 rs1541835 chr2 83635578 C T 6.90E-06 Height / / pha003011 rs11887003 chr2 83656820 T C 5.72E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2361508 chr2 83679699 A G 2.03E-05 Height / / pha003011 rs6547499 chr2 83687160 T C 9.77E-04 Multiple complex diseases / / 17554300 rs1366828 chr2 83753456 C T 1.66E-04 Alzheimer's disease (late onset) / / 21379329 rs993735 chr2 83763856 G A 2.84E-04 Alzheimer's disease (late onset) / / 21379329 rs728849 chr2 83797177 A G 8.92E-05 Alzheimer's disease (late onset) / / 21379329 rs6722452 chr2 83807370 T A 6.60E-06 Urinary metabolites / / 21572414 rs1386306 chr2 83809305 G A 1.90E-05 Urinary metabolites / / 21572414 rs11900533 chr2 83811171 T C 6.60E-06 Urinary metabolites / / 21572414 rs6747341 chr2 83823026 G A 6.60E-06 Urinary metabolites / / 21572414 rs6739790 chr2 83838519 A G 4.52E-04 Alzheimer's disease (late onset) / / 21379329 rs2362235 chr2 83850912 A C 3.71E-04 Alzheimer's disease (late onset) / / 21379329 rs2122456 chr2 83991599 T C 3.16E-04 Multiple complex diseases / / 17554300 rs2218792 chr2 84001716 G A 1.55E-04 Lung function (forced vital capacity) / / 24023788 rs1450253 chr2 84012407 C T 5.48E-04 Multiple complex diseases / / 17554300 rs3111387 chr2 84015498 A G 3.37E-05 Lung function (forced vital capacity) / / 24023788 rs4832336 chr2 84057963 G A 5.10E-04 Alcohol dependence / / 20201924 rs13415661 chr2 84061712 A G 9.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs10211421 chr2 84064563 C T 8.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs10084165 chr2 84065043 G A 8.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs4832340 chr2 84065388 C T 7.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs4832341 chr2 84065659 G C 8.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs4832342 chr2 84065703 T A 8.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs9309610 chr2 84067982 C T 8.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs13413484 chr2 84069655 T C 8.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs7574955 chr2 84072347 C G 1.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs13423886 chr2 84074312 A G 4.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs6724077 chr2 84077868 C T 8.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs6752715 chr2 84078006 A C 2.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs4423611 chr2 84079690 C A 7.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs7569405 chr2 84093827 A G 7.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs6704961 chr2 84095691 A G 2.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs4476361 chr2 84097557 T G 2.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs12714113 chr2 84105498 G C 2.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs2885856 chr2 84195984 T C 4.23E-08 Height / / pha003010 rs2885856 chr2 84195984 T C 8.45E-08 Height / / pha003011 rs13398848 chr2 84245168 A G 1.00E-06 Conduct disorder (symptom count) / / 20585324 rs13398848 chr2 84245168 A G 5.00E-06 Conduct disorder (symptom count) / / 20585324 rs1447537 chr2 84246586 G A 4.00E-06 RR interval (heart rate) / / 20031603 rs11885459 chr2 84349389 C G 4.78E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12612847 chr2 84350015 G A 4.77E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1534238 chr2 84350917 T A 3.00E-06 Response to antipsychotic treatment / / 20195266 rs1405384 chr2 84358932 A C 2.53E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12466737 chr2 84377246 T C 7.43E-04 Acute lung injury / / 22295056 rs1358193 chr2 84377388 A T 2.87E-04 Acute lung injury / / 22295056 rs12463924 chr2 84378959 C T 9.23E-04 Acute lung injury / / 22295056 rs10496308 chr2 84419732 T C 6.70E-05 Cholesterol / / pha003073 rs10496308 chr2 84419732 T C 1.78E-05 ldl cholesterol / / pha003076 rs6547537 chr2 84444886 A G 4.00E-06 IgG glycosylation / / 23382691 rs17024868 chr2 84537078 C T 5.18E-04 Multiple complex diseases / / 17554300 rs1947463 chr2 84579493 T A 9.04E-04 Multiple complex diseases / / 17554300 rs6747898 chr2 84618750 C T 5.38E-04 Multiple complex diseases / / 17554300 rs17024989 chr2 84634026 G C 4.34E-04 Type 2 diabetes / / 17463246 rs17757829 chr2 84666634 T C 4.37E-04 Multiple complex diseases SUCLG1 intron 17554300 rs1599306 chr2 84672482 A G 9.39E-04 Multiple complex diseases SUCLG1 intron 17554300 rs7561462 chr2 84686757 A G 7.59E-06 Coronary artery calcification SUCLG1 nearGene-5 23870195 rs7581224 chr2 84709215 G T 2.00E-06 Coronary artery calcification / / 23870195 rs4831979 chr2 84725380 A T 2.59E-04 Multiple complex diseases / / 17554300 rs17758259 chr2 84759082 G A 2.78E-04 Suicide attempts in bipolar disorder D/H6 intron 21423239 rs13034783 chr2 84782750 T C 1.00E-04 Cognitive impairment induced by topiramate D/H6 intron 22091778 rs7601121 chr2 84795954 G A 4.33E-04 Multiple complex diseases D/H6 intron 17554300 rs13002679 chr2 84800898 T C 2.42E-04 Vaspin levels D/H6 intron 22907691 rs13002679 chr2 84800898 T C 0.0002415 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit D/H6 intron 22907730 rs1811537 chr2 84815236 G A 2.69E-04 Multiple complex diseases D/H6 intron 17554300 rs17759625 chr2 84815684 A G 6.12E-04 Alcohol dependence D/H6 intron 21314694 rs4020077 chr2 84828002 G A 3.96E-04 Multiple complex diseases D/H6 intron 17554300 rs1460710 chr2 84830909 T A 1.75E-04 Multiple complex diseases D/H6 intron 17554300 rs7570369 chr2 84831767 G A 5.47E-04 Multiple complex diseases D/H6 intron 17554300 rs12997105 chr2 84833628 G C 5.05E-04 Multiple complex diseases D/H6 intron 17554300 rs4832104 chr2 84839270 C A 5.46E-04 Multiple complex diseases D/H6 intron 17554300 rs11889456 chr2 84846683 A G 7.13E-04 Multiple complex diseases D/H6 intron 17554300 rs11889456 chr2 84846683 A G 2.50E-05 Urinary metabolites D/H6 intron 21572414 rs11676670 chr2 84852011 C T 4.24E-04 Multiple complex diseases D/H6 intron 17554300 rs10210186 chr2 84854846 C T 1.80E-05 Urinary metabolites D/H6 intron 21572414 rs6726617 chr2 84859888 T G 6.35E-04 Multiple complex diseases D/H6 intron 17554300 rs3890771 chr2 84860330 A T 4.95E-04 Multiple complex diseases D/H6 intron 17554300 rs4313996 chr2 84862843 C A 1.75E-04 Multiple complex diseases D/H6 intron 17554300 rs7572042 chr2 84867252 C T 2.77E-04 Multiple complex diseases D/H6 intron 17554300 rs7593359 chr2 84874964 T C 2.79E-07 Multiple complex diseases D/H6 intron 17554300 rs12992282 chr2 84880695 G A 3.46E-05 Body Mass Index D/H6 cds-synon pha003015 rs17025409 chr2 84897501 A G 4.61E-04 Response to statin treatment (atorvastatin),change in cholesterol levels D/H6 missense 20031582 rs1192285 chr2 84926484 C T 7.00E-06 Urinary metabolites D/H6 intron 21572414 rs1192266 chr2 84936200 A G 7.00E-06 Urinary metabolites D/H6 intron 21572414 rs1192340 chr2 84948021 G A 2.40E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines D/H6 intron 21844884 rs1192324 chr2 84961735 G A 1.20E-05 Urinary metabolites D/H6 intron 21572414 rs1192380 chr2 84995108 C A 9.81E-04 Suicide attempts in bipolar disorder D/H6 intron 21423239 rs1192372 chr2 85011546 T C 9.90E-05 Longevity and age-related phenotypes D/H6 intron 17903295 rs1192316 chr2 85013202 G A 7.70E-04 Type 2 diabetes and 6 quantitative traits D/H6 intron 17848626 rs41365348 chr2 85015348 T C 5.80E-04 Multiple complex diseases D/H6 intron 17554300 rs1192367 chr2 85033835 C G 3.60E-04 Type 2 diabetes and 6 quantitative traits D/H6 intron 17848626 rs7573165 chr2 85034733 T C 0.000767 Salmonella-induced pyroptosis D/H6 intron 22837397 rs7584208 chr2 85046475 G A 4.96E-04 Multiple complex diseases D/H6 cds-synon 17554300 rs10514645 chr2 85077774 A G 3.30E-04 Stroke C2orf89 intron pha002886 rs1979403 chr2 85168571 T C 9.84E-05 Cognitive test performance / / 20125193 rs1979403 chr2 85168571 T C 0.000847 Salmonella-induced pyroptosis / / 22837397 rs7583930 chr2 85190907 T C 6.47E-05 Cognitive test performance / / 20125193 rs2272514 chr2 85286519 T G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) KCMF1 UTR-3 17982456 rs2568225 chr2 85379914 T C 8.70E-04 Response to taxane treatment (placlitaxel) TCF7L1 intron 23006423 rs2583547 chr2 85414140 G A 6.54E-04 Tourette syndrome TCF7L1 intron 22889924 rs6709476 chr2 85443924 G A 5.57E-05 Nicotine smoking TCF7L1 intron 19268276 rs6547600 chr2 85447830 C T 6.77E-05 Heart Rate TCF7L1 intron pha003054 rs6758778 chr2 85471980 G A 7.72E-05 Femoral neck bone geometry TCF7L1 intron 22087292 rs6758778 chr2 85471980 G A 1.44E-05 Hemoglobin TCF7L1 intron pha003096 rs17763853 chr2 85480715 A G 1.40E-05 Urinary metabolites TCF7L1 intron 21572414 rs6736348 chr2 85506104 G A 5.54E-05 Hemoglobin TCF7L1 intron pha003096 rs10206876 chr2 85508065 C A 8.39E-06 Bipolar disorder TCF7L1 intron 17486107 rs7600828 chr2 85510295 C G 8.96E-04 Type 2 diabetes TCF7L1 intron 17463246 rs17026157 chr2 85511646 A T 8.48E-04 Multiple complex diseases TCF7L1 intron 17554300 rs4832155 chr2 85523220 G A 9.35E-05 Dengue shock syndrome TCF7L1 intron 22001756 rs4832159 chr2 85523541 T G 9.35E-05 Dengue shock syndrome TCF7L1 intron 22001756 rs6737773 chr2 85524369 A G 4.27E-08 CD8+ T cell IFN-gamma response to smallpox vaccine TCF7L1 intron 22661280 rs6741339 chr2 85532205 C G 7.73E-04 Type 2 diabetes TCF7L1 intron 17463246 rs4832163 chr2 85541083 T C 4.37E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1053561 chr2 85546052 A G 4.09E-04 Type 2 diabetes TGOLN2 UTR-3 17463246 rs1053561 chr2 85546052 A G 8.85E-04 Multiple complex diseases TGOLN2 UTR-3 17554300 rs1053561 chr2 85546052 A G 1.34E-04 Amyotrophic lateral sclerosis (sporadic) TGOLN2 UTR-3 24529757 rs1061782 chr2 85546615 C T 5.61E-04 Type 2 diabetes TGOLN2 UTR-3 17463246 rs1061782 chr2 85546615 C T 9.14E-04 Multiple complex diseases TGOLN2 UTR-3 17554300 rs4459734 chr2 85547429 G T 1.69E-04 Amyotrophic Lateral Sclerosis TGOLN2 UTR-3 17362836 rs4247303 chr2 85554080 G A 4.64E-04 Amyotrophic Lateral Sclerosis TGOLN2 missense 17362836 rs10460585 chr2 85555262 T G 5.82E-04 Amyotrophic Lateral Sclerosis TGOLN2 UTR-5 17362836 rs3923229 chr2 85562172 C T 3.81E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6747513 chr2 85565634 T C 3.10E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs15413 chr2 85569379 C T 1.09E-05 Lung function (forced expiratory volume in 1 second) RETSAT UTR-3 pha003103 rs17734981 chr2 85588447 C G 2.99E-04 Type 2 diabetes ELMOD3 intron 17463246 rs17026285 chr2 85616758 T C 2.63E-05 Type 2 diabetes ELMOD3 intron 17463246 rs7581471 chr2 85626706 T C 9.51E-04 Alzheimer's disease CAPG intron 22005930 rs11696093 chr2 85636195 T C 7.11E-04 Amyotrophic Lateral Sclerosis CAPG intron 17362836 rs7577642 chr2 85699750 C T 7.00E-06 Protein quantitative trait loci / / 18464913 rs960066 chr2 85700924 G T 9.71E-05 Body mass index / / 17255346 rs11688246 chr2 85705677 C A 1.00E-07 Estradiol plasma levels (breast cancer) / / 23518928 rs11680227 chr2 85707654 A G 2.23E-04 Body mass index / / 17255346 rs6750610 chr2 85731858 T C 3.76E-04 Lung function (forced vital capacity) / / 24023788 rs17792131 chr2 85733192 C T 2.96E-06 Osteoporosis / / 20548944 rs10496316 chr2 85747371 T C 3.60E-04 Lymphocyte counts / / 22286170 rs3755015 chr2 85764041 G A 1.10E-04 Coronary heart disease / / 21966275 rs699664 chr2 85780536 C T 3.12E-04 Body mass index GGCX missense 17255346 rs12714145 chr2 85787341 C T 1 Drug response to Warfarin GGCX intron 19794411 rs10187424 chr2 85794297 T C 3.00E-15 Prostate cancer / / 21743467 rs6757263 chr2 85803542 T C 2.22E-04 Lymphocyte counts VAMP8 nearGene-5 22286170 rs1010 chr2 85808982 T A,C,G 5.70E-04 Coronary heart disease VAMP8 UTR-3 21966275 rs1561198 chr2 85809989 C T 0.000000166 Coronary artery disease (CAD) (males) / / 23202125 rs1561198 chr2 85809989 C T 0.000000177 Coronary artery disease with myocardial infarction / / 23202125 rs1561198 chr2 85809989 C T 1.22E-10 Coronary artery disease / / 23202125 rs1561198 chr2 85809989 C T 1.43E-09 Coronary artery disease (CAD) age <=50 / / 23202125 rs1561198 chr2 85809989 C T 6.05E-04 Coronary artery disease / / 24262325 rs1254901 chr2 85811229 G A 3.60E-04 Iris characteristics / / 21835309 rs12714147 chr2 85813834 A G 0.0000392 GGCX expression in mammary artery VAMP5 intron 23202125 rs6643 chr2 85824251 T C 6.58E-04 Glycosylated haemoglobin levels RNF181 missense 17255346 rs2232750 chr2 85824468 C T 7.06E-05 Lymphocyte counts RNF181 intron 22286170 rs1130866 chr2 85893741 G A 6.58E-05 Lung adenocarcinoma SFTPB missense 19836008 rs4616480 chr2 85897768 G A 9.00E-04 Type 2 diabetes SFTPB nearGene-5 17463246 rs10181739 chr2 85921552 G A 6.21E-06 Glycemic traits (pregnancy) GNLY STOP-GAIN 23903356 rs10181739 chr2 85921552 G A 6.44E-06 Glycemic traits (pregnancy) GNLY STOP-GAIN 23903356 rs13413829 chr2 85930208 G A 6.59E-06 Glycemic traits (pregnancy) / / 23903356 rs13413829 chr2 85930208 G A 6.78E-06 Glycemic traits (pregnancy) / / 23903356 rs13383848 chr2 85932617 T C 4.59E-06 Glycemic traits (pregnancy) / / 23903356 rs13383848 chr2 85932617 T C 5.42E-06 Glycemic traits (pregnancy) / / 23903356 rs13422837 chr2 85934595 T C 4.42E-06 Glycemic traits (pregnancy) / / 23903356 rs13422837 chr2 85934595 T C 5.23E-06 Glycemic traits (pregnancy) / / 23903356 rs4525696 chr2 85938000 T C 4.45E-05 Amyotrophic lateral sclerosis / / 20801718 rs6759087 chr2 85948793 G A 6.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs11126997 chr2 85949396 A G 3.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs13014588 chr2 85950232 A C 5.14E-05 Suicide attempts in bipolar disorder / / 21423239 rs13030230 chr2 85953030 C A 5.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs9677221 chr2 85968147 T A 8.40E-06 Parkinson's disease (familial) / / 18985386 rs11126998 chr2 85978786 G C 2.74E-04 Multiple complex diseases / / 17554300 rs4832198 chr2 85995648 C T 7.49E-04 Multiple complex diseases ATOH8 intron 17554300 rs869778 chr2 86010243 A G 0.00018 Coronary artery calcification ATOH8 intron 23727086 rs13386681 chr2 86013029 C T 0.00012 Coronary artery calcification ATOH8 intron 23727086 rs1518990 chr2 86079341 T C 6.34E-04 Type 2 diabetes ST3GAL5 intron 17463246 rs2366947 chr2 86088009 T C 1.54E-05 Hypertension (essential hypertension) ST3GAL5 intron 22184326 rs1533605 chr2 86092253 T C 5.16E-05 Hypertension (essential hypertension) ST3GAL5 intron 22184326 rs4553826 chr2 86095201 G A 2.44E-05 Hypertension (essential hypertension) ST3GAL5 intron 22184326 rs6721125 chr2 86104729 C T 1.71E-05 Hypertension (essential hypertension) ST3GAL5 intron 22184326 rs6753350 chr2 86105498 A G 1.78E-05 Hypertension (essential hypertension) ST3GAL5 intron 22184326 rs2679722 chr2 86135154 G A 2.15E-04 Cognitive decline / / 23732972 rs7593080 chr2 86145787 C T 2.42E-04 Cognitive decline / / 23732972 rs2164878 chr2 86153855 C T 8.23E-05 Cognitive decline / / 23732972 rs6547647 chr2 86155271 C T 9.45E-05 Autism spectrum disorders (language delay) / / 21519539 rs6547647 chr2 86155271 C T 8.23E-05 Cognitive decline / / 23732972 rs7576135 chr2 86160562 C T 9.45E-05 Autism spectrum disorders (language delay) / / 21519539 rs7576135 chr2 86160562 C T 9.07E-05 Cognitive decline / / 23732972 rs11691934 chr2 86165443 T C 1.08E-04 Parkinson's disease / / 17052657 rs11691934 chr2 86165443 T C 0.00004 Salmonella-induced pyroptosis / / 22837397 rs13431245 chr2 86167602 T C 3.63E-05 Pancreatic cancer / / 23180869 rs2366958 chr2 86169989 T C 6.16E-04 Obesity (extreme) / / 21935397 rs2366958 chr2 86169989 T C 3.47E-04 Cognitive decline / / 23732972 rs1370699 chr2 86172274 A G 1.73E-04 Parkinson's disease / / 17052657 rs9309628 chr2 86172328 T C 5.57E-04 Obesity (extreme) / / 21935397 rs735738 chr2 86177322 T C 5.59E-04 Obesity (extreme) / / 21935397 rs11891625 chr2 86182258 C T 4.72E-04 Prostate cancer mortality / / 20978177 rs4514874 chr2 86182648 T C 4.28E-04 Prostate cancer mortality / / 20978177 rs1438155 chr2 86183897 A G 4.72E-04 Prostate cancer mortality / / 20978177 rs78239085 chr2 86260785 C T 0.00069 Prostate cancer POLR1A missense 23555315 rs34892520 chr2 86269163 C T 6.99E-04 Cocaine dependence POLR1A missense 23958962 rs311581 chr2 86282960 A G 4.10E-08 Lymphocyte counts POLR1A intron 22286170 rs2288118 chr2 86310110 C T 2.11E-04 Breast cancer POLR1A intron pha002853 rs715334 chr2 86322071 G A 9.07E-04 Parkinson's disease POLR1A intron 17052657 rs10779967 chr2 86330726 A G 5.61E-05 Breast cancer POLR1A intron pha002853 rs1075622 chr2 86337930 T C 1.59E-04 Breast cancer PTCD3 intron pha002853 rs17618119 chr2 86343316 G A 4.80E-06 Urinary metabolites PTCD3 intron 21572414 rs2367202 chr2 86345536 A G 2.09E-04 Breast cancer PTCD3 intron pha002853 rs1424520 chr2 86349004 G A 8.52E-05 Rheumatoid arthritis PTCD3 intron 17804836 rs1025104 chr2 86350664 A G 1.60E-04 Breast cancer PTCD3 intron pha002853 rs2241437 chr2 86360573 T G 3.00E-06 Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure) PTCD3 intron 21130132 rs11395 chr2 86365607 T C 9.10E-04 Parkinson's disease PTCD3 UTR-3 17052657 rs11395 chr2 86365607 T C 7.09E-04 Multiple complex diseases PTCD3 UTR-3 17554300 rs3731818 chr2 86368804 G A 6.21E-04 Parkinson's disease PTCD3 UTR-3 17052657 rs10191567 chr2 86385397 T C 3.89E-04 Fibrinogen IMMT intron 17255346 rs9917140 chr2 86392665 T A 2.08E-04 Smoking cessation IMMT intron 18519826 rs7561888 chr2 86392768 A G 0.00000546 Antisocial behavior IMMT intron 23077488 rs10496318 chr2 86402813 C G 6.00E-04 Type 2 diabetes and 6 quantitative traits IMMT intron 17848626 rs2367204 chr2 86404411 A G 6.20E-04 Type 2 diabetes and 6 quantitative traits IMMT intron 17848626 rs10175330 chr2 86414114 C A 1.79E-04 Smoking cessation IMMT intron 18519826 rs4422155 chr2 86423019 C T 1.42E-04 Parkinson's disease / / 17052657 rs3770059 chr2 86436067 C A 5.88E-05 Tunica Media MRPL35 intron pha003034 rs17510310 chr2 86443208 C T 0.00000663 Antisocial behavior REEP1 UTR-3 23077488 rs749581 chr2 86448231 T C 0.000104 Salmonella-induced pyroptosis REEP1 intron 22837397 rs4832257 chr2 86453919 C T 0.000155 Salmonella-induced pyroptosis REEP1 intron 22837397 rs13000103 chr2 86455492 C T 0.000487 Salmonella-induced pyroptosis REEP1 intron 22837397 rs13017143 chr2 86466549 T C 2.88E-04 Cognitive decline REEP1 intron 23732972 rs6547667 chr2 86475443 T C 5.87E-04 Smoking initiation REEP1 intron 24665060 rs9677502 chr2 86480938 A C,G 9.95E-05 Cognitive test performance REEP1 intron 20125193 rs11691807 chr2 86483021 G A 4.70E-05 Smoking cessation REEP1 intron 18519826 rs17510512 chr2 86485315 T C 4.30E-05 Major depressive disorder REEP1 intron 21042317 rs13023154 chr2 86516984 G A 4.95E-05 Pulmonary function REEP1 intron 20010835 rs13023154 chr2 86516984 G A 3.46E-04 Cognitive decline REEP1 intron 23732972 rs6716825 chr2 86538070 T C 3.28E-04 Alzheimer's disease (late onset) REEP1 intron 21379329 rs11675985 chr2 86558975 T G 1.40E-05 Urinary metabolites REEP1 intron 21572414 rs12471787 chr2 86566701 A G 9.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) REEP1 nearGene-5 20877124 rs6547678 chr2 86613175 G A 3.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6713586 chr2 86632902 T A,C 1.09E-04 Vaspin levels / / 22907691 rs6713586 chr2 86632902 T A,C 0.0001088 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs2030259 chr2 86683642 A G 4.14E-04 Epilepsy KDM3A missense 22116939 rs2030259 chr2 86683642 A G 9.12E-05 Glucose levels KDM3A missense pha002899 rs2367575 chr2 86720841 C T 3.19E-04 Epilepsy / / 22116939 rs17027280 chr2 86733287 C T 2.60E-05 Urinary metabolites CHMP3 intron 21572414 rs13023294 chr2 86812177 A G 2.49E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) RNF103-CHMP3 intron 24023788 rs11127047 chr2 86826508 C T 3.14E-05 Psoriasis RNF103-CHMP3 intron 18364390 rs41368845 chr2 86835932 A G 0.0000053 Mean arterial pressure RNF103 intron 22510845 rs114532231 chr2 86860631 C T 2.00E-06 Serum dimethylarginine levels (asymmetric) RNF103-CHMP3 intron 24159190 rs1018311 chr2 86903017 C T 9.33E-04 Prostate cancer mortality RNF103-CHMP3 intron 20978177 rs1850138 chr2 86989466 A T 8.91E-07 Red blood cell traits RMND5A intron 23222517 rs938486 chr2 86994719 C T 8.39E-07 Red blood cell traits RMND5A intron 23222517 rs1193 chr2 87002229 C T 9.69E-07 Red blood cell traits RMND5A UTR-3 23222517 rs1049458 chr2 87003197 C G 6.61E-07 Red blood cell traits RMND5A UTR-3 23222517 rs938487 chr2 87009488 A G 1.61E-06 Alzheimer's disease (late onset) / / 21379329 rs3810831 chr2 87018547 A G 5.63E-05 Alzheimer's disease (late onset) CD8A UTR-5 21379329 rs6753271 chr2 87029673 T C 6.64E-05 Parent of origin effect on language impairment (child trend) CD8A intron 24571439 rs6547705 chr2 87044316 G A 1.00E-08 Progressive supranuclear palsy CD8B intron 21685912 rs13001400 chr2 87048702 T G 5.40E-06 Urinary metabolites CD8B intron 21572414 rs4832049 chr2 87053719 T C 6.90E-07 Urinary metabolites CD8B intron 21572414 rs6749703 chr2 87055249 A G 9.38E-05 Serum metabolites CD8B intron 19043545 rs4240205 chr2 87056805 A G 2.10E-05 Urinary metabolites CD8B intron 21572414 rs6709175 chr2 87108211 T C 3.62E-05 Alcohol and nictotine co-dependence LOC100286979 intron 20158304 rs3732347 chr2 88292394 C G 1.10E-06 Bilirubin levels / / 19414484 rs7609117 chr2 88297789 G A 1.60E-05 Bilirubin levels / / 19414484 rs12714206 chr2 88299844 C T 1.60E-05 Bilirubin levels / / 19414484 rs2885493 chr2 88306346 T C 5.40E-07 Bilirubin levels / / 19414484 rs12714207 chr2 88315793 C T 5.00E-07 Bilirubin levels / / 19414484 rs10192766 chr2 88315993 A G 1.50E-05 Bilirubin levels / / 19414484 rs7594862 chr2 88339743 T C 1.20E-05 Bilirubin levels KRCC1 intron 19414484 rs539337359 chr2 88344018 TAA T 1.30E-05 Bilirubin levels KRCC1 intron 19414484 rs6705301 chr2 88344018 T C 1.30E-05 Bilirubin levels KRCC1 intron 19414484 rs9309641 chr2 88355735 C T 1.20E-06 Bilirubin levels / / 19414484 rs894200 chr2 88359580 G T 9.50E-06 Bilirubin levels / / 19414484 rs2919856 chr2 88388538 A T 2.00E-06 IgG glycosylation SMYD1 intron 23382691 rs2970911 chr2 88395824 G A 7.03E-04 Alcohol dependence SMYD1 intron 21314694 rs2970888 chr2 88411793 C A 9.89E-04 Alcohol consumption (maxi-drinks) SMYD1 UTR-3 24277619 rs1372299 chr2 88416221 C T 8.61E-05 Height / / pha003011 rs2919872 chr2 88428571 C T 8.98E-05 Lipoprotein A [Lp(a)] levels in plasma / / 21592478 rs2970902 chr2 88429183 G C 0.00001992 Sarcoidosis / / 22952805 rs12470985 chr2 88432394 G T 0.00002941 Sarcoidosis / / 22952805 rs35103143 chr2 88434736 A C 0.00002167 Sarcoidosis / / 22952805 rs6735524 chr2 88436001 G A 6.74E-04 Prostate cancer mortality / / 20978177 rs34185550 chr2 88436839 T C 0.00008586 Sarcoidosis / / 22952805 rs4410295 chr2 88439557 A C 0.00003006 Sarcoidosis / / 22952805 rs7590305 chr2 88513131 C T 1.39E-04 Celiac disease / / 23936387 rs1914728 chr2 88516080 T G 9.95E-05 Post-operative nausea and vomiting / / 21694509 rs7564776 chr2 88530735 G C 5.90E-05 Parkinson's disease (age of onset) / / 19772629 rs6736170 chr2 88547402 C T 9.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs6547764 chr2 88550275 A G 9.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs1258411 chr2 88618096 A G 2.29E-04 Body mass index / / 17255346 rs1258411 chr2 88618096 A G 4.94E-04 Rheumatoid arthritis / / 21452313 rs1258410 chr2 88618519 T C 3.65E-05 Body mass index / / 17255346 rs1258408 chr2 88619494 T C 4.44E-05 Multiple complex diseases / / 17554300 rs1258407 chr2 88619599 T C 3.65E-05 Body mass index / / 17255346 rs1258396 chr2 88625879 T C 2.83E-04 Body mass index / / 17255346 rs1659249 chr2 88628756 T A 4.54E-05 Body mass index / / 17255346 rs1713941 chr2 88629360 C T 2.47E-04 Multiple complex diseases / / 17554300 rs1258419 chr2 88631170 C T 4.07E-04 Body mass index / / 17255346 rs1258425 chr2 88651217 A G 3.55E-05 Body mass index / / 17255346 rs1659258 chr2 88659588 A G 2.00E-08 Visceral fat / / 22589738 rs10221815 chr2 88697965 A G 1.86E-04 Body mass index / / 17255346 rs10221875 chr2 88700165 A G 5.54E-04 Coronary heart disease / / 21606135 rs13425454 chr2 88709968 T C 1.10E-05 Urinary metabolites / / 21572414 rs13425454 chr2 88709968 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs17037654 chr2 88716724 T C 2.90E-04 Multiple complex diseases / / 17554300 rs7604265 chr2 88728059 C G 7.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs6721576 chr2 88738507 C T 9.75E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6722564 chr2 88739292 C T 3.03E-04 Multiple complex diseases / / 17554300 rs1438903 chr2 88743779 G A 8.35E-04 Multiple complex diseases / / 17554300 rs1016839 chr2 88770768 A G 4.08E-04 Multiple complex diseases / / 17554300 rs6759954 chr2 88784492 T C 3.98E-04 Spine bone size / / 23207799 rs11677224 chr2 88789815 T C 3.92E-05 Multiple complex diseases / / 17554300 rs7595875 chr2 88817092 T C 2.50E-05 Urinary metabolites / / 21572414 rs4449134 chr2 88846961 A G 2.42E-04 Type 2 diabetes / / 17463246 rs4449134 chr2 88846961 A G 8.53E-04 Multiple complex diseases / / 17554300 rs6739095 chr2 88880064 T A 1.10E-05 Urinary metabolites EIF2AK3 intron 21572414 rs7571971 chr2 88895351 T C 4.00E-13 Progressive supranuclear palsy EIF2AK3 intron 21685912 rs1913671 chr2 88899883 T C 1.10E-05 Urinary metabolites EIF2AK3 intron 21572414 rs867529 chr2 88913273 G C 1.40E-10 Height EIF2AK3 missense 21194676 rs867529 chr2 88913273 G C 1.50E-06 Height EIF2AK3 missense 21194676 rs867529 chr2 88913273 G C 1.70E-04 Height EIF2AK3 missense 21194676 rs11684404 chr2 88924622 T C 1.00E-13 Height EIF2AK3 intron 20881960 rs11684404 chr2 88924622 T C 9.20E-06 Urinary metabolites EIF2AK3 intron 21572414 rs13411467 chr2 88977106 T C 8.17E-04 Multiple complex diseases / / 17554300 rs938372 chr2 88999769 C T 9.92E-04 Parkinson's disease RPIA intron 17052657 rs7572313 chr2 89080394 C A 8.13E-04 Multiple complex diseases ANKRD36BP2 intron 17554300 rs1843217 chr2 89124238 T C 2.91E-05 Bipolar Disorder LOC100132330 intron pha002863 rs2847840 chr2 90077496 A G 8.82E-04 Type 2 diabetes / / 17463246 rs191753171 chr2 91697808 C G 4.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs10201588 chr2 95358799 C T 9.81E-04 Multiple complex diseases / / 17554300 rs10202262 chr2 95444917 C T 4.88E-05 Height ANKRD20A8P intron pha003010 rs10202262 chr2 95444917 C T 7.75E-05 Height ANKRD20A8P intron pha003011 rs12185570 chr2 95457829 T C 9.54E-04 Obesity (extreme) ANKRD20A8P intron 21935397 rs17842087 chr2 95479775 T C 9.56E-04 Obesity (extreme) ANKRD20A8P intron 21935397 rs17802433 chr2 95537630 G T 6.06E-15 Gender TEKT4 missense 22362730 rs4854239 chr2 95586249 T G 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC442028 intron 22628534 rs12474195 chr2 95595941 T C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC442028 intron 22628534 rs4564804 chr2 95628045 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10172167 chr2 95629038 T G 3.22E-05 Alcohol dependence / / 21314694 rs10445976 chr2 95676438 C T 4.22E-04 Obesity (extreme) / / 21935397 rs1316873 chr2 95698646 C G 3.44E-04 Obesity (extreme) MAL intron 21935397 rs17119064 chr2 95721459 C T 3.39E-04 Obesity (extreme) / / 21935397 rs872580 chr2 95722909 C A 3.60E-05 HIV-1 control / / 20041166 rs3112986 chr2 95729338 A G 4.30E-05 HIV-1 control / / 20041166 rs3112996 chr2 95812372 G A 3.60E-05 HIV-1 control / / 20041166 rs3112996 chr2 95812372 G A 8.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3105104 chr2 95816365 G A 3.60E-05 HIV-1 control ZNF514 intron 20041166 rs3105104 chr2 95816365 G A 9.23E-04 Response to taxane treatment (placlitaxel) ZNF514 intron 23006423 rs3112997 chr2 95818151 G A 3.60E-05 HIV-1 control ZNF514 intron 20041166 rs3112228 chr2 95835614 C T 3.60E-05 HIV-1 control ZNF2 intron 20041166 rs3112229 chr2 95838674 A G 8.57E-04 Response to taxane treatment (placlitaxel) ZNF2 intron 23006423 rs3112230 chr2 95846158 T C 3.60E-05 HIV-1 control ZNF2 intron 20041166 rs3105105 chr2 95848018 T C 3.60E-05 HIV-1 control ZNF2 UTR-3 20041166 rs3105105 chr2 95848018 T C 9.23E-04 Response to taxane treatment (placlitaxel) ZNF2 UTR-3 23006423 rs1875402 chr2 95848354 G A 3.60E-05 HIV-1 control ZNF2 UTR-3 20041166 rs1875402 chr2 95848354 G A 6.58E-04 Response to taxane treatment (placlitaxel) ZNF2 UTR-3 23006423 rs2320624 chr2 95856611 A G 3.60E-05 HIV-1 control / / 20041166 rs2320624 chr2 95856611 A G 9.32E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2320625 chr2 95862736 T C 0.000619 Height (Pygmy height) / / 22570615 rs13385838 chr2 95868247 G A 4.81E-04 Obesity (extreme) / / 21935397 rs13387294 chr2 95888434 T G 6.08E-04 Obesity (extreme) / / 21935397 rs6725821 chr2 95897767 T C 3.60E-05 HIV-1 control / / 20041166 rs6748967 chr2 95914095 G A 3.60E-05 HIV-1 control / / 20041166 rs6748967 chr2 95914095 G A 9.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1966272 chr2 95926154 C A 3.60E-05 HIV-1 control / / 20041166 rs1966272 chr2 95926154 C A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1966272 chr2 95926154 C A 9.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4854249 chr2 95930630 A G 3.60E-05 HIV-1 control / / 20041166 rs954078 chr2 95937997 T C 0.0003123 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs954078 chr2 95937997 T C 3.12E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9989786 chr2 95967746 A G 5.60E-05 HIV-1 control KCNIP3 intron 20041166 rs4854251 chr2 96037247 T G 5.53E-05 Abdominal aortic aneurysm KCNIP3 intron 24046328 rs10874471 chr2 96038093 T C 5.53E-05 Abdominal aortic aneurysm KCNIP3 intron 24046328 rs10515920 chr2 96334397 G T 7.25E-05 Multiple complex diseases / / 17554300 rs11676901 chr2 96370571 A C 4.29E-05 Cognitive test performance / / 20125193 rs749458 chr2 96795857 T C 5.75E-05 IgE levels ASTL missense 22075330 rs11886999 chr2 96841793 T C 8.00E-06 Cardiac Troponin-T levels / / 23247143 rs4907304 chr2 96898296 T C 6.62E-05 IgE levels LOC285033 intron 22075330 rs12617019 chr2 96905568 T C 6.71E-04 Multiple complex diseases / / 17554300 rs1044594 chr2 96937296 G C 9.61E-04 Multiple complex diseases CIAO1 UTR-3 17554300 rs17479466 chr2 96962859 A G 6.46E-04 Multiple complex diseases SNRNP200 intron 17554300 rs4907310 chr2 96980113 C T 7.73E-04 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs17633463 chr2 97016334 G A 6.25E-05 Multiple complex diseases NCAPH intron 17554300 rs3731935 chr2 97020049 T C 7.72E-04 Multiple complex diseases NCAPH cds-synon 17554300 rs4426565 chr2 97051981 C T 4.35E-04 Smoking initiation / / 24665060 rs687950 chr2 97069612 G C 8.46E-04 Multiple complex diseases / / 17554300 rs1870340 chr2 97116953 A G 3.29E-114 Multiple complex diseases / / 17554300 rs6753667 chr2 97160382 G A 1.75E-05 Colorectal cancer / / 21242260 rs2579502 chr2 97198800 T C 8.04E-04 Multiple complex diseases / / 17554300 rs2579502 chr2 97198800 T C 1.48E-05 Colorectal cancer / / 21242260 rs2438709 chr2 97199694 A G 0.0000741 Follicular lymphoma / / 23025665 rs4907240 chr2 97228039 G A 4.00E-06 Event-related brain oscillations / / 21184583 rs2314109 chr2 97243532 C T 6.72E-04 Multiple complex diseases / / 17554300 rs2314109 chr2 97243532 C T 1.35E-05 Colorectal cancer / / 21242260 rs17685664 chr2 97315570 C T 9.93E-06 Colorectal cancer FER1L5 intron 21242260 rs13029764 chr2 97328874 A G 4.97E-04 Multiple complex diseases FER1L5 intron 17554300 rs2280355 chr2 97366303 A G 1.02E-05 Orofacial clefts FER1L5 intron 19270707 rs2271893 chr2 97405440 G A 2.00E-10 Bipolar disorder LMAN2L intron 22182935 rs2271893 chr2 97405440 G A 2.08E-05 Major depressive disorder LMAN2L intron 22472876 rs2271893 chr2 97405440 G A 0.0000185 Bipolar disorder LMAN2L intron 23637625 rs6746896 chr2 97410949 A G 2.00E-06 Bipolar disorder / / 21926972 rs6746896 chr2 97410949 A G 3.57E-08 Bipolar disorder / / 22182935 rs6746896 chr2 97410949 A G 2.26E-05 Major depressive disorder / / 22472876 rs6746896 chr2 97410949 A G 0.000000114 Bipolar disorder / / 23070075 rs2314398 chr2 97413488 C G 3.00E-06 Bipolar disorder / / 18711365 rs2678381 chr2 97441266 G A 8.53E-04 Type 2 diabetes CNNM4 intron 17463246 rs9948 chr2 97500800 G C,T 6.00E-06 Erectile dysfunction and prostate cancer treatment CNNM3 UTR-3 20932654 rs12613171 chr2 97553747 G A 6.38E-05 Odorant perception FAM178B intron 23910658 rs17119645 chr2 97553909 T C 3.80E-04 Smoking cessation FAM178B intron 24665060 rs7603256 chr2 97567389 C T 8.30E-04 Suicide attempts in bipolar disorder FAM178B intron 21423239 rs6576990 chr2 97572798 T C 9.68E-04 Suicide attempts in bipolar disorder FAM178B intron 21423239 rs6734673 chr2 97577241 T C 9.73E-04 Suicide attempts in bipolar disorder FAM178B intron 21423239 rs6717064 chr2 97577343 C A 9.99E-04 Suicide attempts in bipolar disorder FAM178B intron 21423239 rs7592101 chr2 97579507 T C 9.67E-04 Suicide attempts in bipolar disorder FAM178B intron 21423239 rs11900466 chr2 97585936 C T 1.18E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer FAM178B intron 21483023 rs3903548 chr2 97591670 T C 9.86E-05 Suicide attempts in bipolar disorder FAM178B intron 21423239 rs3903548 chr2 97591670 T C 1.18E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer FAM178B intron 21483023 rs11889996 chr2 97594366 A T 2.65E-04 Suicide attempts in bipolar disorder FAM178B intron 21423239 rs11676858 chr2 97597577 A G 8.62E-04 Alzheimer's disease FAM178B intron 17998437 rs13383143 chr2 97599266 C T 7.76E-04 Suicide attempts in bipolar disorder FAM178B intron 21423239 rs532711393 chr2 97605748 AC A 1.57E-05 Body Mass Index FAM178B intron pha003020 rs7594227 chr2 97605748 A G 1.57E-05 Body Mass Index FAM178B intron pha003020 rs1257022 chr2 97614936 C T 7.40E-05 Breast cancer FAM178B intron 19330027 rs1796043 chr2 97623413 G A 7.24E-05 Soluble levels of adhesion molecules FAM178B intron pha003072 rs1730122 chr2 97630540 T C 0.0000881 Primary sclerosing cholangitis FAM178B intron 23603763 rs10179966 chr2 97845100 C T 6.80E-05 Body Mass Index ANKRD36 intron pha003019 rs10179966 chr2 97845100 C T 4.86E-06 Body Mass Index ANKRD36 intron pha003020 rs17842456 chr2 98014319 T C 8.53E-04 Type 2 diabetes / / 17463246 rs11901495 chr2 98017804 G A 9.48E-04 Type 2 diabetes / / 17463246 rs11901495 chr2 98017804 G A 7.97E-05 Body Mass Index / / pha003019 rs11901495 chr2 98017804 G A 6.03E-06 Body Mass Index / / pha003020 rs10207116 chr2 98018281 G A 4.22E-05 Body Mass Index / / pha003019 rs10207116 chr2 98018281 G A 2.45E-06 Body Mass Index / / pha003020 rs2922564 chr2 98152475 C T 3.00E-05 Pericardial fat ANKRD36B intron 22589742 rs11690658 chr2 98163203 G T 3.90E-05 Pericardial fat ANKRD36B intron 22589742 rs11691779 chr2 98166928 C A 3.90E-05 Pericardial fat ANKRD36B intron 22589742 rs12712056 chr2 98170122 T C 3.70E-05 Pericardial fat ANKRD36B intron 22589742 rs6718109 chr2 98175863 T C 4.00E-05 Pericardial fat ANKRD36B intron 22589742 rs3931133 chr2 98176340 G A 3.90E-05 Pericardial fat ANKRD36B intron 22589742 rs12994535 chr2 98208691 G T 4.20E-05 Pericardial fat / / 22589742 rs3906948 chr2 98225437 A G 3.50E-05 Pericardial fat / / 22589742 rs2309166 chr2 98239486 C A 2.70E-05 Pericardial fat / / 22589742 rs4069489 chr2 98239649 A G 4.70E-05 Pericardial fat / / 22589742 rs4069493 chr2 98239803 T C 2.30E-05 Pericardial fat / / 22589742 rs4069494 chr2 98239804 G A 3.60E-05 Pericardial fat / / 22589742 rs1800649 chr2 98264857 C T 9.90E-05 Pericardial fat / / 22589742 rs11692435 chr2 98275354 G A 4.06E-04 Stroke ACTR1B missense pha002887 rs11123849 chr2 98286235 T C 3.98E-04 Myocardial Infarction / / pha002883 rs2290127 chr2 98319035 C T 8.74E-04 Coronary Artery Disease LOC728537 intron 17634449 rs11687510 chr2 98334679 C T 8.10E-05 Tourette syndrome ZAP70 intron 22889924 rs13033383 chr2 98339513 C T 7.55E-04 Tourette syndrome ZAP70 intron 22889924 rs1466020 chr2 98365250 G A 7.27E-05 Multiple complex diseases / / 17554300 rs930607 chr2 98371458 G A 7.10E-05 Multiple complex diseases / / 17554300 rs5865 chr2 98373006 C T 6.33E-04 Multiple complex diseases TMEM131 UTR-3 17554300 rs17022209 chr2 98394211 A C 4.69E-05 Cognitive impairment induced by topiramate TMEM131 intron 22091778 rs2309316 chr2 98524859 A C 4.82E-05 Multiple complex diseases TMEM131 intron 17554300 rs12712174 chr2 98531455 T A 6.05E-05 Multiple complex diseases TMEM131 intron 17554300 rs6709571 chr2 98531626 C G 5.36E-05 Multiple complex diseases TMEM131 intron 17554300 rs10191101 chr2 98534065 C T 7.57E-04 Multiple complex diseases TMEM131 intron 17554300 rs11690482 chr2 98560164 A G 5.32E-05 Multiple complex diseases TMEM131 intron 17554300 rs7598116 chr2 98575891 G C 5.01E-05 Multiple complex diseases TMEM131 intron 17554300 rs6726775 chr2 98586842 C A 4.69E-05 Cognitive impairment induced by topiramate TMEM131 intron 22091778 rs2017028 chr2 98589451 G T 8.28E-05 Multiple complex diseases TMEM131 intron 17554300 rs298906 chr2 98674859 G A 5.98E-04 Smoking initiation / / 24665060 rs6705251 chr2 98714445 G A 2.62E-04 Multiple complex diseases VWA3B intron 17554300 rs2053918 chr2 98730815 A C 8.40E-05 Glioma (high-grade) VWA3B intron 19578366 rs7598069 chr2 98761391 A G 3.35E-05 Multiple complex diseases VWA3B intron 17554300 rs17426403 chr2 98763159 C T 8.74E-04 Alzheimer's disease VWA3B intron 17998437 rs13399675 chr2 98789352 G A 1.10E-04 Smoking initiation VWA3B intron 24665060 rs10187244 chr2 98816010 T A 2.38E-06 Multiple complex diseases VWA3B intron 17554300 rs7603439 chr2 98827156 T G 2.00E-04 Breast cancer VWA3B intron pha002853 rs4132466 chr2 98835962 C T 3.93E-05 Heart Rate VWA3B intron pha003054 rs7601049 chr2 98844674 C G 2.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) VWA3B missense 21239504 rs11889349 chr2 98853173 G A 2.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) VWA3B missense 21239504 rs12470615 chr2 98858308 C G 2.48E-04 Multiple complex diseases VWA3B intron 17554300 rs4608580 chr2 98861057 C T 7.91E-05 Nicotine smoking VWA3B intron 19268276 rs13395774 chr2 98880845 C A 9.74E-04 Heart Failure VWA3B intron pha002885 rs6715989 chr2 98912271 G A 1.69E-04 Breast cancer VWA3B intron pha002853 rs7571001 chr2 98949400 T C 1.95E-04 Breast cancer / / pha002853 rs7571110 chr2 98949483 T C 5.25E-04 Multiple complex diseases / / 17554300 rs17429208 chr2 98961589 A G 7.56E-04 Multiple complex diseases CNGA3 nearGene-5 17554300 rs10865016 chr2 98989304 G A 9.67E-06 Nicotine smoking CNGA3 intron 19268276 rs13424165 chr2 98993035 A T 9.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) CNGA3 intron 23233662 rs2174353 chr2 98993635 A G 4.67E-05 Obesity (extreme) CNGA3 intron 21935397 rs78303077 chr2 98998983 G C 0.0000521 Nonsyndromic striae distensae (stretch marks) CNGA3 intron 23633020 rs3769745 chr2 99001403 C T 6.71E-05 Bipolar disorder CNGA3 intron 22925353 rs3754895 chr2 99004173 G T 7.07E-04 Multiple complex diseases CNGA3 intron 17554300 rs114841490 chr2 99009030 A G 0.0000193 Nonsyndromic striae distensae (stretch marks) CNGA3 intron 23633020 rs77969922 chr2 99016808 G A 0.0000134 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs112907291 chr2 99082569 C T 0.00004549 Sarcoidosis INPP4A intron 22952805 rs17032120 chr2 99082938 C T 2.32E-04 Multiple complex diseases INPP4A intron 17554300 rs17032120 chr2 99082938 C T 9.92E-05 Formal thought disorder in schizophrenia INPP4A intron 22648509 rs12617721 chr2 99083892 A C 7.00E-06 Bipolar disorder (mood-incongruent) INPP4A intron 23092984 rs17504837 chr2 99136127 A G 1.50E-05 Urinary metabolites INPP4A intron 21572414 rs3769714 chr2 99150802 G C 8.16E-04 Multiple complex diseases INPP4A intron 17554300 rs3769714 chr2 99150802 G C 5.58E-05 Insulin resistance INPP4A intron 21901158 rs3820942 chr2 99172854 G A 0.0000682 Nonsyndromic striae distensae (stretch marks) INPP4A intron 23633020 rs3754876 chr2 99185867 C T 0.0000682 Nonsyndromic striae distensae (stretch marks) INPP4A intron 23633020 rs12618769 chr2 99239931 C T 1.00E-06 Bipolar disorder MGAT4A UTR-3 21738484 rs7560357 chr2 99247820 T G 4.50E-07 Bipolar disorder MGAT4A intron 21738484 rs13021375 chr2 99254031 G A 4.21E-04 Smoking quantity MGAT4A intron 24665060 rs56386350 chr2 99264073 C T 0.00001904 Sarcoidosis MGAT4A intron 22952805 rs11679648 chr2 99272802 G A 0.00005153 Sarcoidosis MGAT4A intron 22952805 rs55634708 chr2 99284927 T C 0.00002527 Sarcoidosis MGAT4A intron 22952805 rs56371690 chr2 99287729 G A 0.00001815 Sarcoidosis MGAT4A intron 22952805 rs17448190 chr2 99290399 C T 0.00001843 Sarcoidosis MGAT4A intron 22952805 rs56305624 chr2 99290856 G A 0.00001831 Sarcoidosis MGAT4A intron 22952805 rs76909086 chr2 99295731 C T 0.0000221 Sarcoidosis MGAT4A intron 22952805 rs62158010 chr2 99307430 T C 0.0002983 Sarcoidosis MGAT4A intron 22952805 rs55633363 chr2 99308148 G C 0.0002948 Sarcoidosis MGAT4A intron 22952805 rs62158012 chr2 99309914 A C 0.000005693 Sarcoidosis MGAT4A intron 22952805 rs56027617 chr2 99311272 C T 0.0002738 Sarcoidosis MGAT4A intron 22952805 rs56945529 chr2 99311400 C G 0.00002863 Sarcoidosis MGAT4A intron 22952805 rs62158015 chr2 99312106 A G 0.0003141 Sarcoidosis MGAT4A intron 22952805 rs55646762 chr2 99312981 T C 0.0003437 Sarcoidosis MGAT4A intron 22952805 rs56354279 chr2 99313344 G A 0.0003422 Sarcoidosis MGAT4A intron 22952805 rs12467276 chr2 99315067 T C 0.0002177 Sarcoidosis MGAT4A intron 22952805 rs62158019 chr2 99316339 G A 0.00001749 Sarcoidosis MGAT4A intron 22952805 rs12464653 chr2 99317157 C A 0.0001881 Sarcoidosis MGAT4A intron 22952805 rs12469616 chr2 99317188 T C 0.0001881 Sarcoidosis MGAT4A intron 22952805 rs882164 chr2 99317689 T C 0.0001881 Sarcoidosis MGAT4A intron 22952805 rs56363239 chr2 99321237 A T 0.0001095 Sarcoidosis MGAT4A intron 22952805 rs7577636 chr2 99337309 C T 1.67E-04 Multiple complex diseases MGAT4A intron 17554300 rs4851150 chr2 99339122 C T 6.92E-04 Multiple complex diseases MGAT4A intron 17554300 rs41445250 chr2 99357165 A G 1.41E-04 Multiple complex diseases / / 17554300 rs11123751 chr2 99369757 A C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6706340 chr2 99369845 G A 1.06E-04 Multiple complex diseases / / 17554300 rs7578035 chr2 99382892 T G 3.00E-06 Bipolar disorder / / 21926972 rs7578035 chr2 99382892 T G 0.00000413 Bipolar disorder / / 23070075 rs13000014 chr2 99383330 G A 2.96E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7573844 chr2 99384024 G C 2.31E-05 Multiple complex diseases / / 17554300 rs12615689 chr2 99384371 G A 4.28E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs35979410 chr2 99404465 G A 1.11E-04 Alzheimer's disease / / 17998437 rs1356424 chr2 99425838 C T 3.91E-04 Suicide attempts in bipolar disorder C2orf55 intron 21041247 rs1568213 chr2 99432063 T A 2.58E-04 Suicide attempts in bipolar disorder C2orf55 intron 21041247 rs12712034 chr2 99458933 G A 9.68E-08 Metabolite levels C2orf55 intron 23281178 rs6733011 chr2 99465502 A G 3.00E-06 Bipolar disorder C2orf55 intron 19416921 rs4851164 chr2 99480327 C T 6.89E-04 Suicide attempts in bipolar disorder C2orf55 intron 21041247 rs4851164 chr2 99480327 C T 7.04E-04 Alzheimer's disease C2orf55 intron 22005930 rs4851165 chr2 99485421 C T 4.09E-04 Suicide attempts in bipolar disorder C2orf55 intron 21041247 rs17022034 chr2 99486848 A T 6.95E-04 Suicide attempts in bipolar disorder C2orf55 intron 21041247 rs4851166 chr2 99493735 C T 7.02E-04 Suicide attempts in bipolar disorder C2orf55 intron 21041247 rs4851166 chr2 99493735 C T 8.14E-04 Alzheimer's disease C2orf55 intron 22005930 rs17022036 chr2 99496928 G T 7.12E-04 Suicide attempts in bipolar disorder C2orf55 intron 21041247 rs17022036 chr2 99496928 G T 8.08E-04 Alzheimer's disease C2orf55 intron 22005930 rs1574516 chr2 99501318 C T 7.23E-04 Suicide attempts in bipolar disorder C2orf55 intron 21041247 rs10167015 chr2 99570707 G A 6.46E-04 Multiple complex diseases / / 17554300 rs6542847 chr2 99573471 A G 1.38E-04 Major depressive disorder / / 22472876 rs9679602 chr2 99577827 A G 8.30E-04 Multiple complex diseases / / 17554300 rs13396584 chr2 99611768 T G 1.19E-04 Schizophrenia / / 20832056 rs4850895 chr2 99644472 C T 1.83E-04 Response to radiotherapy in cancer (late toxicity) TSGA10 intron 24785509 rs4850895 chr2 99644472 C T 8.24E-04 Response to radiotherapy in cancer (late toxicity) TSGA10 intron 24785509 rs896886 chr2 99652713 A G 8.90E-04 Multiple complex diseases TSGA10 intron 17554300 rs896886 chr2 99652713 A G 5.11E-06 Lymphocyte counts TSGA10 intron 22286170 rs12613624 chr2 99732741 G A 5.74E-04 Multiple complex diseases TSGA10 intron 17554300 rs4851187 chr2 99745860 A C 2.27E-04 Multiple complex diseases TSGA10 intron 17554300 rs4850896 chr2 99754442 G C 2.99E-08 Metabolite levels TSGA10 intron 23281178 rs4851189 chr2 99770044 T C 2.99E-08 Metabolite levels TSGA10 intron 23281178 rs2632277 chr2 99778985 T C 2.52E-04 Multiple complex diseases LIPT1 cds-synon 17554300 rs2309582 chr2 99784307 G A 2.87E-04 Type 2 diabetes / / 17463246 rs11689265 chr2 99799267 A G 2.40E-04 Multiple complex diseases MRPL30 intron 17554300 rs13009147 chr2 99803998 T G 7.70E-04 Iris characteristics MRPL30 intron 21835309 rs10865030 chr2 99804642 T C 2.99E-08 Metabolite levels MRPL30 cds-synon 23281178 rs17851998 chr2 99804642 T TC,TT 2.99E-08 Metabolite levels MRPL30 cds-synon 23281178 rs7586635 chr2 99827733 A G 4.64E-04 Multiple complex diseases / / 17554300 rs7579999 chr2 99857670 G A 5.67E-08 Metabolite levels / / 23281178 rs17022433 chr2 99873658 T A 9.15E-07 Major depressive disorder / / 22472876 rs2200578 chr2 99876244 C T 4.00E-07 IgG glycosylation / / 23382691 rs4850899 chr2 99877465 A G 6.76E-05 Lymphocyte counts / / 22286170 rs1955393 chr2 99886301 G A 1.20E-06 Major depressive disorder / / 22472876 rs901596 chr2 99888457 C T 1.80E-06 Major depressive disorder / / 22472876 rs12464785 chr2 99938942 A G 6.18E-07 Major depressive disorder TXNDC9 intron 22472876 rs2309617 chr2 99976291 C A 8.37E-04 Type 2 diabetes EIF5B intron 17463246 rs2290255 chr2 99999097 C A 4.17E-07 Major depressive disorder EIF5B intron 22472876 rs2290261 chr2 100021184 A G 4.63E-07 Major depressive disorder REV1 intron 22472876 rs1053544 chr2 100022270 G A 3.95E-07 Major depressive disorder REV1 intron 22472876 rs717454 chr2 100022772 T C 4.10E-07 Major depressive disorder REV1 intron 22472876 rs3792146 chr2 100051522 C T 6.11E-05 Major depressive disorder REV1 intron 22472876 rs3087386 chr2 100055506 A G 6.02E-05 Major depressive disorder REV1 missense 22472876 rs3792137 chr2 100061748 C A 4.53E-07 Major depressive disorder REV1 intron 22472876 rs11899745 chr2 100064072 A G 4.41E-07 Major depressive disorder REV1 intron 22472876 rs7594838 chr2 100067554 C T 5.51E-05 Major depressive disorder REV1 intron 22472876 rs7567674 chr2 100067578 G A 5.69E-05 Major depressive disorder REV1 intron 22472876 rs4851206 chr2 100068069 T C 4.84E-07 Major depressive disorder REV1 intron 22472876 rs10172752 chr2 100069385 T G 5.93E-05 Major depressive disorder REV1 intron 22472876 rs7585019 chr2 100077327 G C 4.78E-07 Major depressive disorder REV1 intron 22472876 rs769105 chr2 100077966 G A 4.21E-07 Major depressive disorder REV1 intron 22472876 rs1011633 chr2 100094799 C T 3.71E-07 Major depressive disorder REV1 intron 22472876 rs6714244 chr2 100105312 A G 6.11E-05 Major depressive disorder REV1 intron 22472876 rs6715321 chr2 100109001 C T 4.66E-07 Major depressive disorder / / 22472876 rs2122749 chr2 100119654 C T 5.59E-04 Taste perception / / 22132133 rs1901284 chr2 100146040 C T 9.40E-04 Multiple complex diseases / / 17554300 rs12620982 chr2 100238379 C T 5.56E-05 Body Fat Distribution AFF3 intron pha003017 rs10514777 chr2 100264229 A G 8.55E-04 Coronary Artery Disease AFF3 intron 17634449 rs11676683 chr2 100275925 A C 5.80E-04 Alcohol dependence AFF3 intron 24277619 rs4851222 chr2 100288931 G A 5.80E-04 Alcohol dependence AFF3 intron 24277619 rs12466624 chr2 100315732 C T 9.51E-04 Suicide attempts in bipolar disorder AFF3 intron 21423239 rs10469849 chr2 100318617 T C 8.34E-04 Suicide attempts in bipolar disorder AFF3 intron 21423239 rs75275885 chr2 100326745 A T 6.61E-05 Epilepsy (remission after treatment) AFF3 intron 23962720 rs17022970 chr2 100338954 C T 5.67E-05 Multiple complex diseases AFF3 intron 17554300 rs79702182 chr2 100361583 A G 2.48E-05 Epilepsy (remission after treatment) AFF3 intron 23962720 rs940458 chr2 100377774 G T 7.00E-05 Coronary heart disease AFF3 intron pha003032 rs2163042 chr2 100380563 C T 9.65E-04 Suicide attempts in bipolar disorder AFF3 intron 21423239 rs10185087 chr2 100424310 C T 1.34E-05 Coronary heart disease AFF3 intron pha003032 rs1366765 chr2 100441349 G A 4.87E-06 Coronary heart disease AFF3 intron pha003032 rs7425117 chr2 100445030 C T 4.67E-06 Coronary heart disease AFF3 intron pha003032 rs1346620 chr2 100452928 C T 1.09E-05 Coronary heart disease AFF3 intron pha003032 rs11677260 chr2 100455547 C T 8.23E-04 Tourette syndrome AFF3 intron 22889924 rs7583877 chr2 100460654 C T 1.00E-08 Type 1 diabetes nephropathy AFF3 intron 23028342 rs7583877 chr2 100460654 C T 3.00E-07 Type 1 diabetes nephropathy AFF3 intron 23028342 rs17436594 chr2 100480432 A G 9.51E-04 Type 2 diabetes AFF3 intron 17463246 rs11886157 chr2 100545935 T A 8.76E-05 Multiple complex diseases AFF3 intron 17554300 rs17023310 chr2 100547380 T C 4.89E-04 Multiple complex diseases AFF3 intron 17554300 rs13393937 chr2 100551588 C T 1.92E-04 Smoking initiation AFF3 intron 24665060 rs4578903 chr2 100551590 G T 2.79E-10 Multiple complex diseases AFF3 intron 17554300 rs11897706 chr2 100558451 T C 6.67E-04 Smoking initiation AFF3 intron 24665060 rs7423759 chr2 100562328 C T 1.64E-04 Type 2 diabetes AFF3 intron 17463246 rs11887597 chr2 100576807 T C 1.08E-04 Bone mineral traits,in men AFF3 intron 21427758 rs11887597 chr2 100576807 T C 2.42E-05 Bone mineral traits,in men AFF3 intron 21427758 rs11887597 chr2 100576807 T C 5.64E-04 Bone mineral traits,in men AFF3 intron 21427758 rs13383014 chr2 100578606 C T 7.29E-04 Smoking initiation AFF3 intron 24665060 rs10187195 chr2 100581325 A G 8.83E-05 Smoking initiation AFF3 intron 24665060 rs10198187 chr2 100581552 G C 5.67E-04 Smoking initiation AFF3 intron 24665060 rs7576469 chr2 100584535 T C 5.04E-04 Smoking initiation AFF3 intron 24665060 rs4129805 chr2 100586506 A G 3.70E-04 Smoking initiation AFF3 intron 24665060 rs2001722 chr2 100592415 T C 8.44E-05 Smoking initiation AFF3 intron 24665060 rs13385193 chr2 100599407 T C 3.32E-04 Smoking initiation AFF3 intron 24665060 rs17023393 chr2 100609269 A G 3.08E-04 Smoking initiation AFF3 intron 24665060 rs17437101 chr2 100615241 G A 1.25E-04 Smoking initiation AFF3 intron 24665060 rs6736239 chr2 100621265 C T 3.60E-04 Smoking initiation AFF3 intron 24665060 rs10198062 chr2 100635663 A T 5.64E-05 Smoking initiation AFF3 intron 24665060 rs11685341 chr2 100636757 C T 8.80E-04 Multiple complex diseases AFF3 intron 17554300 rs7605430 chr2 100647552 C G 5.04E-04 Multiple complex diseases AFF3 intron 17554300 rs13402289 chr2 100659389 C T 1.89E-05 Educational attainment AFF3 intron 21694764 rs13402299 chr2 100659409 C T 6.89E-05 Blood Pressure AFF3 intron pha003040 rs17352801 chr2 100664685 G A 5.51E-05 Smoking initiation AFF3 intron 24665060 rs17437338 chr2 100666351 C G 8.86E-05 Smoking initiation AFF3 intron 24665060 rs17352808 chr2 100667168 G A 4.58E-05 Smoking initiation AFF3 intron 24665060 rs4851244 chr2 100671449 T C 6.06E-05 Blood Pressure AFF3 intron pha003040 rs13392222 chr2 100672408 A C 5.35E-05 Smoking initiation AFF3 intron 24665060 rs10209110 chr2 100672692 C T 0.000000011 Rheumatoid arthritis AFF3 intron 23143596 rs10209110 chr2 100672692 C T 6.79E-08 Rheumatoid arthritis (CCP positive) AFF3 intron 23143596 rs7582731 chr2 100686486 T C 0.00063 Breast cancer AFF3 intron 23555315 rs4851250 chr2 100729293 T C 4.00E-05 Blood Pressure AFF3 intron pha003040 rs6749757 chr2 100730111 C A 9.03E-05 Multiple complex diseases AFF3 intron 17554300 rs11694875 chr2 100732845 C T 2.58E-05 Multiple complex diseases AFF3 intron 17554300 rs6743817 chr2 100735567 A G 1.87E-04 Smoking initiation AFF3 intron 24665060 rs10199628 chr2 100735856 T C 5.51E-05 Smoking initiation AFF3 intron 24665060 rs17023516 chr2 100736650 T C 6.48E-05 Smoking initiation AFF3 intron 24665060 rs6745099 chr2 100739441 C G 1.15E-04 Smoking initiation AFF3 intron 24665060 rs6748652 chr2 100740059 C T 5.12E-04 Smoking initiation AFF3 intron 24665060 rs6732141 chr2 100743492 G C 1.68E-05 Type 1 diabetes nephropathy AFF3 intron 23028342 rs11692215 chr2 100746573 C T 7.56E-04 Response to taxane treatment (placlitaxel) AFF3 intron 23006423 rs4851252 chr2 100757280 C T 4.34E-05 Multiple complex diseases AFF3 intron 17554300 rs11681966 chr2 100759457 C A 5.89E-05 Multiple complex diseases / / 17554300 rs12712065 chr2 100761105 C G 8.43E-06 Type 1 diabetes nephropathy / / 23028342 rs11690905 chr2 100761473 A G 5.35E-05 Multiple complex diseases / / 17554300 rs12712067 chr2 100763900 G T 4.81E-05 Multiple complex diseases / / 17554300 rs10496344 chr2 100764125 T C 3.39E-05 Multiple complex diseases / / 17554300 rs11123813 chr2 100765692 C T 2.08E-05 Multiple complex diseases / / 17554300 rs4851256 chr2 100775045 T C 1.49E-04 Multiple complex diseases / / 17554300 rs7593261 chr2 100789907 T C 8.73E-05 Multiple complex diseases / / 17554300 rs11902705 chr2 100795207 G A 1.23E-04 Multiple complex diseases / / 17554300 rs4851262 chr2 100796248 A C 4.99E-04 Multiple complex diseases / / 17554300 rs6722241 chr2 100803778 T C 8.85E-05 Blood Pressure / / pha003040 rs6712515 chr2 100806514 T C 2.00E-11 Rheumatoid arthritis (CCP positive) / / 23143596 rs6712515 chr2 100806514 T C 2.82E-11 Rheumatoid arthritis / / 23143596 rs11676922 chr2 100806940 T A 1.00E-14 Rheumatoid arthritis / / 20453842 rs11676922 chr2 100806940 T A 1.00E-14 Celiac disease and Rheumatoid arthritis / / 21383967 rs11676922 chr2 100806940 T A 1.00E-14 Multiple sclerosis / / 22190364 rs11676922 chr2 100806940 T A 1.10E-06 Rheumatoid arthritis / / 22446963 rs11676922 chr2 100806940 T A 2.00E-08 Rheumatoid arthritis / / 24782177 rs4851264 chr2 100810188 T C 5.00E-11 Educational attainment / / 23722424 rs7566527 chr2 100811970 C T 8.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6740838 chr2 100813499 T G 5.12E-06 Type 1 diabetes / / 21980299 rs6740838 chr2 100813499 T G 0.000000883 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs6740838 chr2 100813499 T G 0.00000535 Oligoarticular juvenile idiopathic arthritis / / 23603761 rs6740838 chr2 100813499 T G 1.23E-05 Blood Pressure / / pha003040 rs893245 chr2 100814893 C T 9.43E-07 Non-albumin protein levels / / 22558069 rs4851266 chr2 100818479 C T 8.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4851266 chr2 100818479 C T 5.00E-11 Educational attainment / / 23722424 rs9653442 chr2 100825367 C T 5.00E-06 Type 1 diabetes LOC150577 intron 17554260 rs9653442 chr2 100825367 C T 4.44E-06 Multiple complex diseases LOC150577 intron 17554300 rs9653442 chr2 100825367 C T 6.38E-05 Type 1 diabetes LOC150577 intron 18978792 rs9653442 chr2 100825367 C T 1.00E-14 Rheumatoid arthritis LOC150577 intron 24390342 rs9653442 chr2 100825367 C T 2.00E-18 Rheumatoid arthritis LOC150577 intron 24390342 rs9653442 chr2 100825367 C T 2.80E-05 Rheumatoid arthritis LOC150577 intron 24390342 rs11686372 chr2 100827907 C A 1.80E-05 Blood Pressure LOC150577 intron pha003040 rs11686372 chr2 100827907 C A 3.62E-05 Blood Pressure LOC150577 intron pha003048 rs4303732 chr2 100830040 T C 2.92E-05 Blood Pressure LOC150577 intron pha003040 rs4303732 chr2 100830040 T C 4.79E-05 Blood Pressure LOC150577 intron pha003048 rs4851269 chr2 100830348 T C 7.00E-04 Rheumatoid arthritis LOC150577 intron 23918589 rs4851269 chr2 100830348 T C 2.38E-05 Blood Pressure LOC150577 intron pha003040 rs1160542 chr2 100832155 G A 9.00E-04 Rheumatoid arthritis LOC150577 intron 23918589 rs1160542 chr2 100832155 G A 4.46E-05 Blood Pressure LOC150577 intron pha003040 rs1160543 chr2 100832182 C T 6.41E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LOC150577 intron 20031582 rs13432804 chr2 100833898 C T 1.20E-05 Urinary metabolites LOC150577 intron 21572414 rs10194635 chr2 100834217 T A 0.00000081 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) LOC150577 intron 23603761 rs10865035 chr2 100835734 A G 2.00E-06 Rheumatoid arthritis LOC150577 intron 20453842 rs10865035 chr2 100835734 A G 1.37E-05 Rheumatoid arthritis LOC150577 intron 24449572 rs2309837 chr2 100837567 T C 3.57E-06 Multiple complex diseases LOC150577 intron 17554300 rs2871344 chr2 100839430 A G 8.65E-04 Response to taxane treatment (placlitaxel) LOC150577 intron 23006423 rs6542920 chr2 100845088 A G 7.94E-07 Non-albumin protein levels LOC150577 intron 22558069 rs6542920 chr2 100845088 A G 3.00E-04 Rheumatoid arthritis LOC150577 intron 23918589 rs4851273 chr2 100848321 A G 6.46E-07 Non-albumin protein levels LOC150577 intron 22558069 rs7597861 chr2 100853187 G A 1.00E-04 Lipid traits LOC150577 intron 17903299 rs7597861 chr2 100853187 G A 1.17E-07 Non-albumin protein levels LOC150577 intron 22558069 rs12474386 chr2 100857017 G A 2.28E-07 Non-albumin protein levels LOC150577 intron 22558069 rs6739695 chr2 100859622 A G 1.01E-07 Non-albumin protein levels LOC150577 intron 22558069 rs10865036 chr2 100860595 T C 1.25E-05 Multiple complex diseases LOC150577 intron 17554300 rs10865036 chr2 100860595 T C 1.01E-07 Non-albumin protein levels LOC150577 intron 22558069 rs12611915 chr2 100862195 G C 9.50E-06 Urinary metabolites LOC150577 intron 21572414 rs2309811 chr2 100862359 A G 1.01E-07 Non-albumin protein levels LOC150577 intron 22558069 rs6737502 chr2 100862903 C T 1.22E-07 Non-albumin protein levels LOC150577 intron 22558069 rs6542921 chr2 100864498 C A 1.26E-07 Non-albumin protein levels LOC150577 intron 22558069 rs12053126 chr2 100864646 T A 9.28E-05 Glaucoma (primary open-angle) LOC150577 intron 22605921 rs4851274 chr2 100870862 T C 1.07E-07 Non-albumin protein levels / / 22558069 rs2067783 chr2 100877370 T C 9.02E-05 Cognitive performance / / 19734545 rs10173499 chr2 100877652 T C 3.40E-06 Urinary metabolites / / 21572414 rs6724490 chr2 100880539 A G 2.80E-06 Urinary metabolites / / 21572414 rs12467008 chr2 100882451 C T 2.60E-05 Urinary metabolites / / 21572414 rs4851288 chr2 100920451 T C 6.00E-04 Type 2 diabetes LONRF2 intron 17463246 rs1437967 chr2 100929072 C G 6.00E-04 Type 2 diabetes LONRF2 intron 17463246 rs6731549 chr2 100939937 T G 9.19E-04 Response to alcohol consumption (flushing response) / / 24277619 rs4851295 chr2 100945605 T C 4.90E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17023990 chr2 100951210 C T 9.44E-04 Multiple complex diseases / / 17554300 rs13031508 chr2 100952757 A G 6.40E-04 Response to alcohol consumption (flushing response) / / 24277619 rs2164847 chr2 100958715 C T 6.40E-04 Response to alcohol consumption (flushing response) / / 24277619 rs4850927 chr2 100969067 A G 1.32E-05 Glaucoma (primary open-angle) / / 22605921 rs11685401 chr2 100976685 A G 3.43E-04 Response to alcohol consumption (flushing response) / / 24277619 rs4640404 chr2 100980523 A G 9.17E-04 Type 2 diabetes / / 17463246 rs6542947 chr2 100999647 C G 8.70E-04 Type 2 diabetes / / 17463246 rs7587333 chr2 101006787 T C 7.63E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1030901 chr2 101007314 G A 9.80E-05 Response to alcohol consumption (flushing response) / / 24277619 rs1057056 chr2 101009082 C T 3.19E-05 Amyotrophic lateral sclerosis (sporadic) CHST10 UTR-3 24529757 rs150069978 chr2 101023110 C T 0.00011 Prostate cancer (advanced) CHST10 missense 23555315 rs4149510 chr2 101023635 G A 7.25E-05 Intelligence CHST10 intron 21826061 rs4851313 chr2 101029002 G A 4.33E-04 Response to alcohol consumption (flushing response) CHST10 intron 24277619 rs1519661 chr2 101088260 G A 6.91E-05 Body Mass Index NMS intron pha003006 rs753439 chr2 101088840 T C 6.91E-05 Body Mass Index NMS intron pha003006 rs1519654 chr2 101096960 C T 1.88E-05 Body Mass Index NMS cds-synon pha003006 rs10183360 chr2 101103384 C T 9.47E-05 Body Mass Index / / pha003006 rs1519662 chr2 101143618 C T 2.41E-05 Body Mass Index / / pha003006 rs12469806 chr2 101191950 G A 2.56E-04 Obesity (extreme) PDCL3 intron 21935397 rs2970991 chr2 101322193 C G 3.23E-04 Type 2 diabetes / / 17463246 rs6741485 chr2 101388261 C T 3.90E-04 Multiple complex diseases / / 17554300 rs7565981 chr2 101424331 G A 4.00E-08 Creutzfeldt-Jakob disease (variant) / / 22137330 rs7580771 chr2 101428119 G T 7.84E-05 Heart Rate / / pha003054 rs13028398 chr2 101440837 T C 9.32E-04 Coronary Artery Disease NPAS2 intron 17634449 rs3849381 chr2 101451819 T C 6.13E-04 Suicide attempts in bipolar disorder NPAS2 intron 21423239 rs7585886 chr2 101517465 C T 3.35E-05 Amyotrophic lateral sclerosis (sporadic) NPAS2 intron 24529757 rs2117714 chr2 101521777 G A 7.99E-04 Sleep quality NPAS2 intron 23728906 rs356653 chr2 101539790 G A 7.00E-04 Chronic fatigue syndrome NPAS2 intron 21912186 rs356652 chr2 101540415 T G 2.82E-05 Cognitive test performance NPAS2 intron 20125193 rs356652 chr2 101540415 T G 9.43E-05 Erythrocyte counts NPAS2 intron pha003099 rs3754675 chr2 101549843 T C 9.08E-05 Erythrocyte counts NPAS2 intron pha003099 rs3768984 chr2 101550987 A C 2.56E-05 Rheumatoid arthritis NPAS2 intron 17804836 rs6542999 chr2 101553757 T G 9.92E-11 Triglycerides NPAS2 intron 23063622 rs7605570 chr2 101558904 T C 8.31E-04 Suicide attempts in bipolar disorder NPAS2 intron 21423239 rs7605434 chr2 101558984 A G 0.00009399 Sarcoidosis NPAS2 intron 22952805 rs4851384 chr2 101561638 G A 2.50E-05 Urinary metabolites NPAS2 intron 21572414 rs10191450 chr2 101570735 G A 8.11E-04 Type 2 diabetes NPAS2 intron 17463246 rs882272 chr2 101576199 G A 1.29E-04 Type 2 diabetes NPAS2 intron 17463246 rs895520 chr2 101577937 G A 1.28E-04 Type 2 diabetes NPAS2 intron 17463246 rs12622050 chr2 101579454 G A 1.04E-05 Sodium levels NPAS2 intron pha003093 rs34628006 chr2 101580552 A G 0.00000211 Triglycerides NPAS2 missense 23063622 rs7581886 chr2 101581246 C T 5.05E-04 Suicide attempts in bipolar disorder NPAS2 intron 21423239 rs2305160 chr2 101591304 A G 0.00044 Prostate cancer NPAS2 missense 23555315 rs1542178 chr2 101595475 A G 9.50E-05 Response to treatment for acute lymphoblastic leukemia NPAS2 intron 19176441 rs3768991 chr2 101599767 T C 0.00037 Coronary artery calcification NPAS2 intron 23727086 rs2278729 chr2 101668857 G A 7.15E-04 Multiple complex diseases TBC1D8 intron 17554300 rs2278729 chr2 101668857 G A 2.00E-05 Memory (short-term) TBC1D8 intron 20038948 rs2278729 chr2 101668857 G A 1.00E-07 Osteoporosis TBC1D8 intron 20548944 rs2278729 chr2 101668857 G A 1.47E-04 Response to TNF antagonist treatment TBC1D8 intron 21061259 rs2121367 chr2 101683487 C G 4.39E-05 Response to TNF antagonist treatment TBC1D8 intron 21061259 rs4851400 chr2 101696649 G A 4.96E-04 Type 2 diabetes TBC1D8 intron 17463246 rs7608232 chr2 101699063 C A 6.09E-04 Alcohol dependence TBC1D8 intron 21314694 rs2309938 chr2 101699594 A C 7.40E-05 Lung adenocarcinoma TBC1D8 intron 19836008 rs732136 chr2 101740231 T G 6.70E-04 Multiple complex diseases TBC1D8 intron 17554300 rs17025300 chr2 101759350 T C 5.44E-05 Stroke (ischemic) TBC1D8 intron 22941190 rs733830 chr2 101778319 T C 7.33E-04 Response to TNF antagonist treatment / / 21061259 rs1192817 chr2 101826261 G T 4.28E-05 Orofacial clefts / / 22419666 rs6724417 chr2 101830675 T C 3.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13015194 chr2 101881980 T G 1.50E-04 Iris characteristics C2orf29 intron 21835309 rs6713930 chr2 101890427 G A 3.70E-06 Urinary metabolites / / 21572414 rs1192793 chr2 101897871 C T 5.21E-05 Glucose levels RNF149 intron pha003058 rs935065 chr2 101899130 T C 5.20E-05 Glucose levels RNF149 intron pha003058 rs6711606 chr2 101922170 T G 4.00E-06 Pancreatic cancer RNF149 intron 20686608 rs4851422 chr2 101958295 G A 3.13E-05 Creutzfeldt-Jakob disease (variant) / / 22137330 rs4851423 chr2 101958326 G T 2.52E-05 Glucose levels / / pha003061 rs11677377 chr2 101973286 G T 4.74E-05 Glucose levels CREG2 intron pha003058 rs11677377 chr2 101973286 G T 4.87E-06 Glucose levels CREG2 intron pha003061 rs4850969 chr2 101985733 T C 7.55E-06 Multiple complex diseases CREG2 intron 17554300 rs7591123 chr2 101993105 T A 3.50E-05 Coffee consumption CREG2 intron 21357676 rs12712097 chr2 101994030 C T 7.94E-04 Multiple complex diseases CREG2 intron 17554300 rs12620464 chr2 102029646 T C 1.40E-05 Urinary metabolites RFX8 intron 21572414 rs12620464 chr2 102029646 T C 4.09E-05 Neuroticism RFX8 intron 23229837 rs12620464 chr2 102029646 T C 1.00E-06 Estradiol plasma levels (breast cancer) RFX8 intron 23518928 rs7565429 chr2 102036455 C T 1.80E-05 Urinary metabolites RFX8 intron 21572414 rs7583866 chr2 102064729 G A 4.04E-04 Aortic root size RFX8 intron 21223598 rs12712105 chr2 102065250 C G 2.36E-04 Aortic root size RFX8 intron 21223598 rs4850977 chr2 102065944 A G 4.47E-04 Aortic root size RFX8 intron 21223598 rs4850978 chr2 102066005 C A 4.43E-04 Aortic root size RFX8 intron 21223598 rs7574003 chr2 102081119 G A 8.64E-04 Type 2 diabetes RFX8 intron 17463246 rs1995826 chr2 102129420 C T 0.000702508 Hypertension (early onset hypertension) / / 22479346 rs11687533 chr2 102178726 C T 2.54E-05 Anxiety and major depressive disorder / / 24047446 rs6720988 chr2 102234065 T C 7.16E-05 Height / / 17255346 rs6720988 chr2 102234065 T C 4.37E-05 Cholesterol / / pha003078 rs2310128 chr2 102235312 A T 3.56E-05 Serum metabolites / / 19043545 rs10496357 chr2 102255114 T C 2.00E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10496357 chr2 102255114 T C 2.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10194088 chr2 102274615 T A 2.33E-04 Multiple complex diseases / / 17554300 rs41330544 chr2 102292519 C T 2.72E-05 Multiple complex diseases / / 17554300 rs7559442 chr2 102378381 G A 8.33E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MAP4K4 intron 21844884 rs6744704 chr2 102385820 C T 3.21E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MAP4K4 intron 21844884 rs17026045 chr2 102387089 A G 4.83E-04 Multiple complex diseases MAP4K4 intron 17554300 rs10175849 chr2 102389708 A G 6.38E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MAP4K4 intron 21844884 rs3771903 chr2 102479029 G A 2.80E-04 Iris characteristics MAP4K4 intron 21835309 rs7568226 chr2 102534237 T A 1.10E-04 Iris characteristics / / 21835309 rs1019031 chr2 102574838 G T 2.00E-05 Iris characteristics / / 21835309 rs191222274 chr2 102576839 G A 4.99E-05 Acne (severe) / / 24927181 rs1990146 chr2 102579754 G A 7.32E-04 Multiple complex diseases / / 17554300 rs2190359 chr2 102580363 A G 4.34E-04 Multiple complex diseases / / 17554300 rs12468239 chr2 102605161 C T 9.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4321386 chr2 102613013 C G 9.00E-08 Follicle stimulating hormone IL1R2 intron 24049095 rs4851526 chr2 102618370 A G 5.20E-05 Psoriasis IL1R2 intron 20953189 rs4851526 chr2 102618370 A G 4.39E-05 Behcet's disease IL1R2 intron pha002888 rs4851527 chr2 102622376 A G 2.26E-05 Crohn's disease and psoriasis IL1R2 intron 22482804 rs3218872 chr2 102628509 T C 1.63E-04 Alzheimer's disease IL1R2 intron 17998437 rs3218873 chr2 102628561 G A 1.70E-04 Alzheimer's disease IL1R2 intron 17998437 rs28385681 chr2 102633524 T G 0.000000731 Cholesterol,total IL1R2 intron 23063622 rs2072478 chr2 102636526 A T 7.00E-04 Alzheimer's disease IL1R2 intron 17998437 rs4851531 chr2 102648609 C T 3.70E-04 Iris characteristics / / 21835309 rs2310173 chr2 102663628 T G 5.00E-07 Ankylosing spondylitis / / 20062062 rs2310173 chr2 102663628 T G 3.00E-12 Ulcerative colitis / / 21297633 rs2310173 chr2 102663628 T G 3.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs4851536 chr2 102671681 T G 9.13E-04 Major depressive disorder / / 22472876 rs9967745 chr2 102676129 C T 4.81E-04 Type 2 diabetes / / 17463246 rs868251 chr2 102683386 C T 1.13E-05 Cognitive performance / / 19734545 rs13427957 chr2 102689031 C T 2.34E-04 Self-reported allergy / / 23817569 rs12624116 chr2 102690727 C T 7.37E-05 Left ventricular hypertrophy / / pha003052 rs1558644 chr2 102691310 A G 5.20E-05 Left ventricular hypertrophy / / pha003052 rs58340896 chr2 102691535 G C 0.0000774 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs871376 chr2 102711172 T C 8.19E-05 Self-reported allergy / / 23817569 rs12991050 chr2 102712652 A G 4.74E-04 Self-reported allergy / / 23817569 rs10490571 chr2 102717337 C T 9.79E-05 Inflammation / / pha002897 rs13029804 chr2 102723017 A C 4.81E-04 Self-reported allergy / / 23817569 rs11679849 chr2 102726012 A G 3.40E-04 Intelligence (childhood) / / 23358156 rs11679849 chr2 102726012 A G 5.54E-04 Self-reported allergy / / 23817569 rs12712127 chr2 102726661 A G 3.00E-08 Fibrinogen / / 23969696 rs10208542 chr2 102732315 G C 1.80E-13 Serum protein levels (sST2) / / 23999434 rs13007967 chr2 102732778 A G 3.34E-11 Serum protein levels (sST2) / / 23999434 rs12712129 chr2 102733585 G A 3.39E-11 Serum protein levels (sST2) / / 23999434 rs1465325 chr2 102734551 A G 2.05E-09 Self-reported allergy / / 23817569 rs871195 chr2 102734837 C A 2.07E-13 Serum protein levels (sST2) / / 23999434 rs1465324 chr2 102735612 G A 1.43E-10 Self-reported allergy / / 23817569 rs13029169 chr2 102735741 G A 2.19E-13 Serum protein levels (sST2) / / 23999434 rs13012334 chr2 102736020 A G 2.23E-13 Serum protein levels (sST2) / / 23999434 rs7557377 chr2 102736588 C T 2.25E-13 Serum protein levels (sST2) / / 23999434 rs12328681 chr2 102736867 G T 6.30E-10 Self-reported allergy / / 23817569 rs6712813 chr2 102738026 C T 2.36E-13 Serum protein levels (sST2) / / 23999434 rs6727859 chr2 102738164 A G 2.38E-13 Serum protein levels (sST2) / / 23999434 rs6727985 chr2 102738275 A G 2.38E-13 Serum protein levels (sST2) / / 23999434 rs10172039 chr2 102738785 C A 1.57E-10 Self-reported allergy / / 23817569 rs12619383 chr2 102741718 A G 0.0000255 Asthma / / 22694930 rs12619383 chr2 102741718 A G 1.87E-09 Self-reported allergy / / 23817569 rs12620132 chr2 102742115 A G 1.41E-09 Self-reported allergy / / 23817569 rs2310186 chr2 102743180 T G 2.38E-13 Serum protein levels (sST2) / / 23999434 rs12470623 chr2 102744015 A T 2.26E-13 Serum protein levels (sST2) / / 23999434 rs6752379 chr2 102746705 G A 6.58E-14 Serum protein levels (sST2) / / 23999434 rs13387400 chr2 102750020 G A 1.51E-09 Self-reported allergy / / 23817569 rs2310187 chr2 102750428 G T 5.61E-14 Serum protein levels (sST2) / / 23999434 rs6706048 chr2 102754809 G C 4.60E-06 Urinary metabolites / / 21572414 rs13035227 chr2 102763837 T C 1.72E-13 Serum protein levels (sST2) / / 23999434 rs2110727 chr2 102764294 G A 0.00054756 Primary sclerosing cholangitis / / 23603763 rs2110727 chr2 102764294 G A 2.63E-10 Self-reported allergy / / 23817569 rs6754776 chr2 102764778 C G 2.16E-15 Serum protein levels (sST2) / / 23999434 rs1558641 chr2 102765865 G A 2.84E-10 Self-reported allergy / / 23817569 rs1558640 chr2 102765878 G A 3.18E-10 Self-reported allergy / / 23817569 rs949963 chr2 102769786 C T 8.32E-07 Asthma / / 21804549 rs949963 chr2 102769786 C T 4.04E-10 Self-reported allergy / / 23817569 rs2287049 chr2 102770738 A G 5.50E-07 Urinary metabolites IL1R1 intron 21572414 rs871657 chr2 102771341 C T 7.08E-07 Asthma IL1R1 intron 21804549 rs871657 chr2 102771341 C T 4.50E-10 Self-reported allergy IL1R1 intron 23817569 rs3917237 chr2 102772451 G A 5.26E-08 Cholesterol,total IL1R1 intron 23063622 rs2287048 chr2 102773999 C T 1.86E-10 Self-reported allergy IL1R1 intron 23817569 rs2287047 chr2 102774054 G A 1.35E-05 Aging (time to event) IL1R1 intron 21782286 rs13019803 chr2 102776202 C T 6.00E-20 Serum protein levels (sST2) IL1R1 intron 23999434 rs3917254 chr2 102776518 G A 1.14E-15 Serum protein levels (sST2) IL1R1 intron 23999434 rs3917273 chr2 102779719 A T 6.29E-05 Self-reported allergy IL1R1 intron 23817569 rs3917285 chr2 102781166 T A 3.07E-13 Self-reported allergy IL1R1 intron 23817569 rs3917291 chr2 102782166 G A 1.20E-14 Serum protein levels (sST2) IL1R1 intron 23999434 rs997049 chr2 102782433 T A 6.99E-05 Self-reported allergy IL1R1 intron 23817569 rs2160227 chr2 102783355 G T 1.93E-05 Cognitive impairment induced by topiramate IL1R1 intron 22091778 rs2160227 chr2 102783355 G T 2.00E-04 Cognitive impairment induced by topiramate IL1R1 intron 22091778 rs2160227 chr2 102783355 G T 5.03E-05 Self-reported allergy IL1R1 intron 23817569 rs13020778 chr2 102784574 T C 1.20E-04 Self-reported allergy IL1R1 intron 23817569 rs3917296 chr2 102784833 A G 7.15E-12 Serum protein levels (sST2) IL1R1 intron 23999434 rs951192 chr2 102785854 A C 1.26E-05 Self-reported allergy IL1R1 intron 23817569 rs3917304 chr2 102788125 G T 1.58E-05 Self-reported allergy IL1R1 intron 23817569 rs3771200 chr2 102788774 G A 4.26E-05 Self-reported allergy IL1R1 intron 23817569 rs3917314 chr2 102790863 A C 1.98E-14 Serum protein levels (sST2) IL1R1 intron 23999434 rs3917318 chr2 102792760 A G 1.15E-05 Self-reported allergy IL1R1 intron 23817569 rs3917320 chr2 102792875 A C 2.13E-14 Serum protein levels (sST2) IL1R1 cds-synon 23999434 rs3917325 chr2 102793907 T G 2.21E-14 Serum protein levels (sST2) IL1R1 UTR-3 23999434 rs3732134 chr2 102794217 C G 9.34E-04 Type 2 diabetes IL1R1 UTR-3 17463246 rs2110726 chr2 102794282 G A 3.41E-05 Self-reported allergy IL1R1 UTR-3 23817569 rs3917328 chr2 102794541 C T 2.21E-14 Serum protein levels (sST2) IL1R1 UTR-3 23999434 rs7582198 chr2 102799834 A G 1.13E-05 Self-reported allergy / / 23817569 rs1030021 chr2 102801478 A C 9.93E-06 Self-reported allergy / / 23817569 rs10181869 chr2 102801852 C A 1.02E-05 Self-reported allergy / / 23817569 rs10184597 chr2 102802255 C T 9.43E-06 Self-reported allergy / / 23817569 rs2241132 chr2 102804035 C A 2.68E-15 Serum protein levels (sST2) IL1RL2 intron 23999434 rs1558648 chr2 102810168 T G 4.00E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs12987222 chr2 102814116 G T 1.19E-15 Serum protein levels (sST2) IL1RL2 intron 23999434 rs3771195 chr2 102816022 C T 2.62E-04 Self-reported allergy IL1RL2 intron 23817569 rs3771192 chr2 102816140 C A 1.95E-04 Self-reported allergy IL1RL2 intron 23817569 rs11123912 chr2 102816536 G A 1.13E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs12474258 chr2 102816695 C T 4.71E-08 Self-reported allergy IL1RL2 intron 23817569 rs12474258 chr2 102816695 C T 1.65E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs11678651 chr2 102817154 G T 8.46E-04 Type 2 diabetes IL1RL2 intron 17463246 rs1922302 chr2 102819049 T G 4.65E-08 Self-reported allergy IL1RL2 intron 23817569 rs1922302 chr2 102819049 T G 1.58E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs2310239 chr2 102824201 G A 6.93E-04 Type 2 diabetes IL1RL2 intron 17463246 rs13021607 chr2 102824726 G A 8.86E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs11123913 chr2 102825479 T C 1.07E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs10490570 chr2 102827739 C T 8.15E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs1922291 chr2 102828817 A G 6.43E-08 Self-reported allergy IL1RL2 intron 23817569 rs1922291 chr2 102828817 A G 1.57E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs12989930 chr2 102829822 T C 7.87E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs12996377 chr2 102830478 T A 1.32E-12 Serum protein levels (sST2) IL1RL2 intron 23999434 rs13002813 chr2 102831280 T C 7.74E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs6743219 chr2 102831711 T C 7.67E-08 Self-reported allergy IL1RL2 intron 23817569 rs6743219 chr2 102831711 T C 1.54E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs13028635 chr2 102832284 C T 7.65E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs1922294 chr2 102835909 G A 4.20E-04 Parkinson's disease IL1RL2 intron 17052657 rs917994 chr2 102837414 G A 4.71E-08 Self-reported allergy IL1RL2 intron 23817569 rs917994 chr2 102837414 G A 1.52E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs12992518 chr2 102837598 C T 7.06E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs3771185 chr2 102840507 T C 2.07E-06 Self-reported allergy IL1RL2 intron 23817569 rs12473710 chr2 102840979 T C 6.58E-06 Self-reported allergy IL1RL2 intron 23817569 rs12472862 chr2 102840994 A G 6.35E-06 Self-reported allergy IL1RL2 intron 23817569 rs17637748 chr2 102841715 A G 1.86E-06 Self-reported allergy IL1RL2 intron 23817569 rs2310241 chr2 102841949 A C 2.00E-06 Self-reported allergy IL1RL2 intron 23817569 rs2302621 chr2 102842124 G T 3.40E-08 Self-reported allergy IL1RL2 intron 23817569 rs2302621 chr2 102842124 G T 1.48E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs13033782 chr2 102843833 G A 5.31E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs3755285 chr2 102844020 T C 0.00000513 Asthma IL1RL2 intron 22694930 rs3755285 chr2 102844020 T C 1.20E-12 Serum protein levels (sST2) IL1RL2 intron 23999434 rs3755285 chr2 102844020 T C 1.42E-05 Asthma IL1RL2 intron pha003127 rs1997502 chr2 102844249 A G 5.08E-11 Self-reported allergy IL1RL2 intron 23817569 rs1997502 chr2 102844249 A G 2.92E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs12995229 chr2 102846907 A G 9.24E-18 Serum protein levels (sST2) IL1RL2 intron 23999434 rs6758443 chr2 102848062 G T 5.82E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs955754 chr2 102849081 T C 3.58E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs12987900 chr2 102849348 G A 1.30E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs6709635 chr2 102850439 G A 2.30E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs6754556 chr2 102850924 A T 2.22E-11 Serum protein levels (sST2) IL1RL2 intron 23999434 rs2302612 chr2 102851708 T C 2.00E-11 Serum protein levels (sST2) IL1RL2 missense 23999434 rs13002972 chr2 102851861 G A 9.30E-17 Serum protein levels (sST2) IL1RL2 intron 23999434 rs10167431 chr2 102852802 T C 5.04E-07 Self-reported allergy IL1RL2 intron 23817569 rs10167431 chr2 102852802 T C 1.04E-08 Serum protein levels (sST2) IL1RL2 intron 23999434 rs2287040 chr2 102852980 C T 7.28E-04 Type 2 diabetes IL1RL2 intron 17463246 rs13017475 chr2 102853208 C T 7.83E-17 Serum protein levels (sST2) IL1RL2 intron 23999434 rs13014084 chr2 102854765 A G 4.09E-16 Serum protein levels (sST2) IL1RL2 intron 23999434 rs12993937 chr2 102855831 G A,C,T 3.33E-19 Serum protein levels (sST2) / / 23999434 rs10178214 chr2 102858921 G T 2.57E-11 Self-reported allergy / / 23817569 rs13027294 chr2 102860074 G C 1.77E-11 Self-reported allergy / / 23817569 rs1558625 chr2 102862164 A G 1.40E-08 Serum protein levels (sST2) / / 23999434 rs1035131 chr2 102862641 T G 2.63E-04 Height / / 17255346 rs1035131 chr2 102862641 T G 9.00E-08 Urinary metabolites / / 21572414 rs2110661 chr2 102863221 G A 8.90E-08 Urinary metabolites / / 21572414 rs13018912 chr2 102864310 G T 2.86E-20 Serum protein levels (sST2) / / 23999434 rs12997225 chr2 102864748 A C 2.82E-20 Serum protein levels (sST2) / / 23999434 rs11677452 chr2 102865236 A T 3.42E-11 Self-reported allergy / / 23817569 rs9646944 chr2 102865875 G C 2.78E-11 Self-reported allergy / / 23817569 rs12712133 chr2 102866273 A G 2.70E-05 Urinary metabolites / / 21572414 rs10186746 chr2 102866377 G A 0.0000236 Primary biliary cirrhosis in females / / 22936693 rs10186746 chr2 102866377 G A 0.000024 Primary biliary cirrhosis / / 22936693 rs10186746 chr2 102866377 G A 0.0000662 Primary biliary cirrhosis (anti-mitochondrial antibody positive) / / 22936693 rs10200410 chr2 102870871 G A 2.08E-05 Self-reported allergy / / 23817569 rs1345301 chr2 102875587 A G 1.88E-05 Self-reported allergy / / 23817569 rs1345301 chr2 102875587 A G 5.00E-06 Waist circumference / / 23966867 rs2310243 chr2 102877560 A G 1.95E-05 Self-reported allergy / / 23817569 rs13405355 chr2 102878206 C T 1.95E-05 Self-reported allergy / / 23817569 rs12475055 chr2 102878891 A C 6.00E-06 Urinary metabolites / / 21572414 rs12475055 chr2 102878891 A C 1.95E-05 Self-reported allergy / / 23817569 rs10189629 chr2 102879464 C A 2.48E-07 Asthma / / 21804549 rs10189629 chr2 102879464 C A 2.00E-16 Self-reported allergy / / 23817569 rs12995644 chr2 102880027 C A 3.97E-22 Serum protein levels (sST2) / / 23999434 rs11123915 chr2 102880823 G T 1.76E-12 Serum protein levels (sST2) / / 23999434 rs1882510 chr2 102883618 C T 9.03E-23 Serum protein levels (sST2) / / 23999434 rs1882511 chr2 102883721 G A 1.29E-23 Serum protein levels (sST2) / / 23999434 rs11692065 chr2 102883975 C T 1.56E-07 Asthma / / 21804549 rs11692065 chr2 102883975 C T 2.07E-16 Self-reported allergy / / 23817569 rs10200945 chr2 102884757 A T 1.60E-12 Serum protein levels (sST2) / / 23999434 rs4851563 chr2 102885535 A T 2.20E-05 Urinary metabolites / / 21572414 rs11674302 chr2 102887128 T C 1.69E-06 Asthma / / 20860503 rs11674302 chr2 102887128 T C 7.75E-07 Asthma / / 21804549 rs11674302 chr2 102887128 T C 2.29E-16 Self-reported allergy / / 23817569 rs13015695 chr2 102888441 C A,T 2.17E-22 Serum protein levels (sST2) / / 23999434 rs1922288 chr2 102888565 T C 2.04E-23 Serum protein levels (sST2) / / 23999434 rs10469856 chr2 102888829 A T 8.87E-13 Serum protein levels (sST2) / / 23999434 rs9308855 chr2 102890795 A G 1.09E-23 Serum protein levels (sST2) / / 23999434 rs1115281 chr2 102891107 C G 6.95E-13 Serum protein levels (sST2) / / 23999434 rs9308856 chr2 102895442 A G 2.58E-04 Multiple complex diseases / / 17554300 rs12469892 chr2 102895784 G A 7.05E-23 Serum protein levels (sST2) / / 23999434 rs12989419 chr2 102900754 A C 4.72E-37 Serum protein levels (sST2) / / 23999434 rs13024772 chr2 102902173 G A 2.59E-37 Serum protein levels (sST2) / / 23999434 rs6747153 chr2 102903827 A G 8.03E-23 Serum protein levels (sST2) / / 23999434 rs13407644 chr2 102905351 A G 1.97E-37 Serum protein levels (sST2) / / 23999434 rs13017541 chr2 102906176 C T 1.25E-37 Serum protein levels (sST2) / / 23999434 rs13024003 chr2 102907761 G C 1.17E-37 Serum protein levels (sST2) / / 23999434 rs4851003 chr2 102909277 T C 1.83E-04 Height / / 17255346 rs13009757 chr2 102912174 C T 2.67E-34 Serum protein levels (sST2) / / 23999434 rs1476984 chr2 102912269 C T 4.99E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs951774 chr2 102912664 C A 3.78E-24 Serum protein levels (sST2) / / 23999434 rs11690644 chr2 102914214 A G 3.59E-16 Self-reported allergy / / 23817569 rs10515922 chr2 102914654 A G 5.12E-09 Serum protein levels (sST2) / / 23999434 rs7600901 chr2 102915571 A G 2.74E-20 Serum protein levels (sST2) / / 23999434 rs11693697 chr2 102915662 T C 7.00E-11 Serum protein levels (sST2) / / 23999434 rs4399750 chr2 102917788 T C 1.04E-67 Serum protein levels (sST2) / / 23999434 rs1362347 chr2 102919585 C T 1.14E-31 Serum protein levels (sST2) / / 23999434 rs4090473 chr2 102922987 C G 9.95E-68 Serum protein levels (sST2) / / 23999434 rs11685424 chr2 102926981 G A 4.15E-66 Serum protein levels (sST2) / / 23999434 rs1558622 chr2 102930147 G A 9.75E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs10189711 chr2 102930881 A G 9.68E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12712135 chr2 102930948 A G 2.70E-70 Serum protein levels (sST2) IL1RL1 intron 23999434 rs953934 chr2 102932293 C T 5.00E-04 Bone mass and geometry IL1RL1 intron 17903296 rs953934 chr2 102932293 C T 2.56E-70 Serum protein levels (sST2) IL1RL1 intron 23999434 rs950881 chr2 102932512 G T 2.04E-14 Self-reported allergy IL1RL1 intron 23817569 rs950880 chr2 102932562 C A 1.11E-09 Self-reported allergy IL1RL1 intron 23817569 rs950880 chr2 102932562 C A 7.00E-94 Serum protein levels (sST2) IL1RL1 intron 23999434 rs11123918 chr2 102935237 T C 8.88E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs10182639 chr2 102935805 C A 8.99E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs11690443 chr2 102936131 T A 9.18E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs974389 chr2 102936981 G A 9.44E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs4142132 chr2 102937482 G A 9.43E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12987782 chr2 102937966 G A 1.47E-31 Serum protein levels (sST2) IL1RL1 intron 23999434 rs13001301 chr2 102938998 C T 1.49E-31 Serum protein levels (sST2) IL1RL1 intron 23999434 rs13001325 chr2 102939036 C T 1.33E-09 Self-reported allergy IL1RL1 intron 23817569 rs13001325 chr2 102939036 C T 8.64E-94 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1420088 chr2 102939434 T C 9.45E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs11123920 chr2 102939833 C T 9.44E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs6706844 chr2 102940412 T C 9.44E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12996772 chr2 102947201 A T 9.44E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs17695648 chr2 102948181 A G 1.59E-31 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1420103 chr2 102948632 A C 1.00E-35 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1420102 chr2 102948819 C T 9.44E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12466380 chr2 102948939 A G 9.45E-68 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12479210 chr2 102949161 C T 2.51E-09 Self-reported allergy IL1RL1 intron 23817569 rs12479210 chr2 102949161 C T 9.42E-94 Serum protein levels (sST2) IL1RL1 intron 23999434 rs13019081 chr2 102950822 A C 2.51E-09 Self-reported allergy IL1RL1 intron 23817569 rs13019081 chr2 102950822 A C 9.47E-94 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1997467 chr2 102951073 A G 1.06E-67 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1997466 chr2 102951467 C G 1.21E-67 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1362350 chr2 102951798 G C 1.43E-67 Serum protein levels (sST2) IL1RL1 intron 23999434 rs200540641 chr2 102951851 G GA 1.13E-35 Serum protein levels (sST2) IL1RL1 intron 23999434 rs2310220 chr2 102951851 G A 1.13E-35 Serum protein levels (sST2) IL1RL1 intron 23999434 rs397969654 chr2 102951851 G GA 1.13E-35 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1362349 chr2 102951972 G C 9.54E-67 Serum protein levels (sST2) IL1RL1 intron 23999434 rs3755278 chr2 102952217 T C 1.52E-31 Serum protein levels (sST2) IL1RL1 intron 23999434 rs17026974 chr2 102952360 G A 6.99E-04 Alzheimer's disease IL1RL1 intron 17998437 rs17026974 chr2 102952360 G A 3.57E-06 Self-reported allergy IL1RL1 intron 23817569 rs17026974 chr2 102952360 G A 3.26E-40 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12712141 chr2 102953067 T C 1.06E-66 Serum protein levels (sST2) IL1RL1 intron 23999434 rs17639215 chr2 102953444 G A 2.00E-30 Serum protein levels (sST2) IL1RL1 intron 23999434 rs3771180 chr2 102953617 G T 2.00E-15 Asthma IL1RL1 intron 21804549 rs3771180 chr2 102953617 G T 1.65E-13 Self-reported allergy IL1RL1 intron 23817569 rs3771179 chr2 102953892 T G 1.51E-31 Serum protein levels (sST2) IL1RL1 intron 23999434 rs985523 chr2 102954376 G A 6.56E-28 Serum protein levels (sST2) IL1RL1 intron 23999434 rs13431828 chr2 102954653 C T 2.00E-04 Asthma IL1RL1 UTR-5 19910030 rs13431828 chr2 102954653 C T 1.26E-07 Asthma IL1RL1 UTR-5 20860503 rs13431828 chr2 102954653 C T 2.77E-08 Asthma IL1RL1 UTR-5 21804549 rs13431828 chr2 102954653 C T 1.51E-15 Self-reported allergy IL1RL1 UTR-5 23817569 rs13408569 chr2 102955056 G C 3.79E-08 Asthma IL1RL1 intron 21804549 rs13408569 chr2 102955056 G C 1.83E-15 Self-reported allergy IL1RL1 intron 23817569 rs13408661 chr2 102955082 G A 3.78E-08 Asthma IL1RL1 intron 21804549 rs13408661 chr2 102955082 G A 1.00E-09 Asthma IL1RL1 intron 23028483 rs13408661 chr2 102955082 G A 1.91E-15 Self-reported allergy IL1RL1 intron 23817569 rs1041973 chr2 102955468 C A 3.50E-04 Asthma IL1RL1 missense 19910030 rs1041973 chr2 102955468 C A 3.00E-05 Upper aerodigestive tract cancers IL1RL1 missense 21437268 rs1041973 chr2 102955468 C A 1.43E-06 Self-reported allergy IL1RL1 missense 23817569 rs873022 chr2 102955683 G T 3.29E-06 Self-reported allergy IL1RL1 intron 23817569 rs873022 chr2 102955683 G T 5.40E-40 Serum protein levels (sST2) IL1RL1 intron 23999434 rs3771177 chr2 102955860 G T 3.29E-06 Self-reported allergy IL1RL1 intron 23817569 rs3771177 chr2 102955860 G T 5.55E-40 Serum protein levels (sST2) IL1RL1 intron 23999434 rs13029918 chr2 102957291 A G 2.00E-39 Serum protein levels (sST2) IL1RL1 intron 23999434 rs10173081 chr2 102957348 C T 1.42E-08 Asthma IL1RL1 intron 21804549 rs10173081 chr2 102957348 C T 2.19E-15 Self-reported allergy IL1RL1 intron 23817569 rs3732129 chr2 102957532 T C 3.20E-06 Self-reported allergy IL1RL1 intron 23817569 rs3732129 chr2 102957532 T C 6.35E-40 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1420101 chr2 102957716 C T 5.00E-14 Eosinophil counts IL1RL1 intron 19198610 rs1420101 chr2 102957716 C T 3.25E-09 Self-reported allergy IL1RL1 intron 23817569 rs1420101 chr2 102957716 C T 4.33E-92 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1420101 chr2 102957716 C T 6.00E-04 Ulcerative colitis IL1RL1 intron 24837172 rs6719130 chr2 102958236 C T 1.07E-27 Serum protein levels (sST2) IL1RL1 intron 23999434 rs13016771 chr2 102959080 G A 1.53E-31 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12999517 chr2 102959260 T C 3.12E-27 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12905 chr2 102960007 G A 2.52E-06 Self-reported allergy IL1RL1 UTR-3 23817569 rs12905 chr2 102960007 G A 1.04E-39 Serum protein levels (sST2) IL1RL1 UTR-3 23999434 rs3771175 chr2 102960210 T A 1.87E-15 Self-reported allergy IL1RL1 UTR-3 23817569 rs3771175 chr2 102960210 T A 5.00E-11 Allergic sensitization IL1RL1 UTR-3 23817571 rs3821204 chr2 102960281 C G 2.35E-06 Self-reported allergy IL1RL1 UTR-3 23817569 rs3821204 chr2 102960281 C G 8.01E-38 Serum protein levels (sST2) IL1RL1 UTR-3 23999434 rs12712142 chr2 102960584 C A 2.22E-10 Self-reported allergy IL1RL1 UTR-3 23817569 rs12712142 chr2 102960584 C A 1.68E-84 Serum protein levels (sST2) IL1RL1 UTR-3 23999434 rs2160203 chr2 102960824 A G 3.29E-09 Self-reported allergy IL1RL1 UTR-3 23817569 rs1946131 chr2 102961929 C T 2.21E-27 Serum protein levels (sST2) IL1RL1 intron 23999434 rs62152663 chr2 102962346 C G 0.00012 Schizophrenia IL1RL1 intron 22440650 rs12989197 chr2 102962739 G A 2.20E-27 Serum protein levels (sST2) IL1RL1 intron 23999434 rs6543119 chr2 102963072 A T 3.55E-84 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12996097 chr2 102963628 G A 2.17E-27 Serum protein levels (sST2) IL1RL1 intron 23999434 rs13028993 chr2 102963949 T C 2.17E-27 Serum protein levels (sST2) IL1RL1 intron 23999434 rs13017455 chr2 102964742 C T 1.36E-10 Self-reported allergy IL1RL1 intron 23817569 rs13017455 chr2 102964742 C T 6.92E-84 Serum protein levels (sST2) IL1RL1 intron 23999434 rs17027006 chr2 102965332 G C 1.80E-06 Self-reported allergy IL1RL1 intron 23817569 rs17027006 chr2 102965332 G C 1.36E-36 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12999542 chr2 102965392 A C 2.00E-27 Serum protein levels (sST2) IL1RL1 intron 23999434 rs12469506 chr2 102965871 C T 6.10E-07 Self-reported allergy IL1RL1 intron 23817569 rs12469506 chr2 102965871 C T 1.05E-41 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1921622 chr2 102966067 G A 5.18E-11 Self-reported allergy IL1RL1 intron 23817569 rs1921622 chr2 102966067 G A 6.06E-31 Serum protein levels (sST2) IL1RL1 intron 23999434 rs1921622 chr2 102966067 G A 6.58E-05 Blood Pressure IL1RL1 intron pha003045 rs1921622 chr2 102966067 G A 4.41E-05 Blood Pressure IL1RL1 intron pha003047 rs10208293 chr2 102966310 G A 2.80E-09 Self-reported allergy IL1RL1 intron 23817569 rs10208293 chr2 102966310 G A 2.28E-24 Serum protein levels (sST2) IL1RL1 intron 23999434 rs10197862 chr2 102966549 A G 6.31E-08 Asthma IL1RL1 intron 21804549 rs10197862 chr2 102966549 A G 2.81E-15 Self-reported allergy IL1RL1 intron 23817569 rs10197862 chr2 102966549 A G 4.00E-11 Asthma and hay fever IL1RL1 intron 24388013 rs1861245 chr2 102966906 C T 2.94E-17 Serum protein levels (sST2) IL1RL1 intron 23999434 rs13424006 chr2 102967236 T C 5.68E-07 Self-reported allergy IL1RL1 intron 23817569 rs13424006 chr2 102967236 T C 3.25E-17 Serum protein levels (sST2) IL1RL1 intron 23999434 rs6751967 chr2 102967413 T C 5.87E-07 Self-reported allergy IL1RL1 intron 23817569 rs6751967 chr2 102967413 T C 3.39E-17 Serum protein levels (sST2) IL1RL1 intron 23999434 rs552531342 chr2 102967587 A AT 2.62E-07 Self-reported allergy IL1RL1 intron 23817569 rs552531342 chr2 102967587 A AT 3.54E-17 Serum protein levels (sST2) IL1RL1 intron 23999434 rs6749114 chr2 102967587 A C 2.62E-07 Self-reported allergy IL1RL1 intron 23817569 rs6749114 chr2 102967587 A C 3.54E-17 Serum protein levels (sST2) IL1RL1 intron 23999434 rs11123923 chr2 102967844 C A 1.07E-10 Self-reported allergy IL1RL1 intron 23817569 rs11123923 chr2 102967844 C A 4.89E-81 Serum protein levels (sST2) IL1RL1 intron 23999434 rs4988955 chr2 102967928 A G 4.41E-07 Self-reported allergy IL1RL1 intron 23817569 rs4988955 chr2 102967928 A G 3.67E-17 Serum protein levels (sST2) IL1RL1 intron 23999434 rs4988956 chr2 102968007 G A 6.88E-07 Self-reported allergy IL1RL1 missense 23817569 rs4988956 chr2 102968007 G A 3.66E-17 Serum protein levels (sST2) IL1RL1 missense 23999434 rs4988957 chr2 102968075 T C 4.87E-07 Self-reported allergy IL1RL1 cds-synon 23817569 rs4988957 chr2 102968075 T C 3.66E-17 Serum protein levels (sST2) IL1RL1 cds-synon 23999434 rs10204137 chr2 102968212 A G 1.40E-08 Asthma IL1RL1 missense 20860503 rs10204137 chr2 102968212 A G 3.66E-17 Serum protein levels (sST2) IL1RL1 missense 23999434 rs4988958 chr2 102968285 T C 4.01E-07 Self-reported allergy IL1RL1 cds-synon 23817569 rs4988958 chr2 102968285 T C 3.84E-17 Serum protein levels (sST2) IL1RL1 cds-synon 23999434 rs10192157 chr2 102968356 C T 2.11E-08 Asthma IL1RL1 missense 20860503 rs10192157 chr2 102968356 C T 4.01E-07 Self-reported allergy IL1RL1 missense 23817569 rs10192157 chr2 102968356 C T 4.06E-17 Serum protein levels (sST2) IL1RL1 missense 23999434 rs10206753 chr2 102968362 T C 1.54E-08 Asthma IL1RL1 missense 20860503 rs10206753 chr2 102968362 T C 4.01E-07 Self-reported allergy IL1RL1 missense 23817569 rs10206753 chr2 102968362 T C 4.33E-17 Serum protein levels (sST2) IL1RL1 missense 23999434 rs9807989 chr2 102971200 T C 6.00E-08 Asthma / / 22561531 rs13015714 chr2 102971865 G T 4.00E-09 Celiac disease / / 18311140 rs13015714 chr2 102971865 G T 1.63E-04 Crohn's disease and Celiac disease / / 21298027 rs13015714 chr2 102971865 G T 8.00E-18 Atopic dermatitis / / 23042114 rs13015714 chr2 102971865 G T 4.47E-33 Serum protein levels (sST2) / / 23999434 rs7603730 chr2 102974371 A C 1.61E-07 Self-reported allergy / / 23817569 rs7603730 chr2 102974371 A C 6.09E-17 Serum protein levels (sST2) / / 23999434 rs12998521 chr2 102974417 G T 5.22E-11 Self-reported allergy / / 23817569 rs12998521 chr2 102974417 G T 1.27E-80 Serum protein levels (sST2) / / 23999434 rs10170583 chr2 102974764 G A 1.59E-07 Self-reported allergy / / 23817569 rs10170583 chr2 102974764 G A 1.13E-16 Serum protein levels (sST2) / / 23999434 rs10176664 chr2 102976172 G A 3.65E-07 Self-reported allergy / / 23817569 rs10176664 chr2 102976172 G A 5.15E-17 Serum protein levels (sST2) / / 23999434 rs3755276 chr2 102978459 C T 8.10E-07 Asthma / / 21804549 rs3755276 chr2 102978459 C T 3.94E-07 Self-reported allergy / / 23817569 rs3755276 chr2 102978459 C T 4.88E-17 Serum protein levels (sST2) / / 23999434 rs2287037 chr2 102979028 C T 4.83E-11 Self-reported allergy / / 23817569 rs2287037 chr2 102979028 C T 1.26E-80 Serum protein levels (sST2) / / 23999434 rs10515921 chr2 102981018 T G 1.85E-25 Serum protein levels (sST2) IL18R1 intron 23999434 rs1362348 chr2 102984624 C G 8.46E-07 Asthma IL18R1 intron 21804549 rs1362348 chr2 102984624 C G 3.93E-07 Self-reported allergy IL18R1 intron 23817569 rs1362348 chr2 102984624 C G 4.11E-17 Serum protein levels (sST2) IL18R1 intron 23999434 rs2058622 chr2 102985424 A G 2.88E-35 Serum protein levels (sST2) IL18R1 intron 23999434 rs3771172 chr2 102985812 C T 2.47E-07 Self-reported allergy IL18R1 intron 23817569 rs3771172 chr2 102985812 C T 1.27E-35 Serum protein levels (sST2) IL18R1 intron 23999434 rs3771171 chr2 102985950 T C 1.39E-07 Self-reported allergy IL18R1 intron 23817569 rs3771171 chr2 102985950 T C 1.28E-35 Serum protein levels (sST2) IL18R1 intron 23999434 rs3771170 chr2 102985980 T A 2.91E-35 Serum protein levels (sST2) IL18R1 intron 23999434 rs2160202 chr2 102986154 G A 2.47E-07 Self-reported allergy IL18R1 intron 23817569 rs2160202 chr2 102986154 G A 1.29E-35 Serum protein levels (sST2) IL18R1 intron 23999434 rs2058623 chr2 102986170 C T 2.95E-35 Serum protein levels (sST2) IL18R1 intron 23999434 rs3771167 chr2 102986188 A G 6.07E-23 Serum protein levels (sST2) IL18R1 intron 23999434 rs3771166 chr2 102986222 G A 3.00E-09 Asthma IL18R1 intron 20860503 rs3771166 chr2 102986222 G A 3.40E-09 Asthma IL18R1 intron 21907864 rs3771166 chr2 102986222 G A 3.40E-09 Asthma IL18R1 intron 22561531 rs3771166 chr2 102986222 G A 3.82E-07 Self-reported allergy IL18R1 intron 23817569 rs3771166 chr2 102986222 G A 3.43E-16 Serum protein levels (sST2) IL18R1 intron 23999434 rs3771166 chr2 102986222 G A 2.80E-04 Asthma (childhood,severe) IL18R1 intron 24241537 rs1974675 chr2 102986375 G A 3.55E-07 Self-reported allergy IL18R1 intron 23817569 rs1974675 chr2 102986375 G A 3.52E-16 Serum protein levels (sST2) IL18R1 intron 23999434 rs6728945 chr2 102986471 T C 6.86E-23 Serum protein levels (sST2) IL18R1 intron 23999434 rs1465321 chr2 102986618 T C 3.03E-35 Serum protein levels (sST2) IL18R1 intron 23999434 rs11465596 chr2 102987093 C A 2.70E-24 Serum protein levels (sST2) IL18R1 intron 23999434 rs11465597 chr2 102987213 A G 4.34E-04 Multiple complex diseases IL18R1 intron 17554300 rs11465597 chr2 102987213 A G 1.10E-05 Urinary metabolites IL18R1 intron 21572414 rs11465597 chr2 102987213 A G 6.02E-24 Serum protein levels (sST2) IL18R1 intron 23999434 rs7579737 chr2 102987361 A G 3.52E-04 Multiple complex diseases IL18R1 intron 17554300 rs7579737 chr2 102987361 A G 1.20E-05 Urinary metabolites IL18R1 intron 21572414 rs17027029 chr2 102990648 G C 0.0000997 Asthma IL18R1 intron 23666277 rs17027029 chr2 102990648 G C 5.17E-11 Self-reported allergy IL18R1 intron 23817569 rs3771164 chr2 102991786 A T 3.73E-11 Self-reported allergy IL18R1 intron 23817569 rs2270297 chr2 102992675 T C 1.45E-31 Serum protein levels (sST2) IL18R1 intron 23999434 rs7558013 chr2 102992806 G T 2.81E-09 Serum protein levels (sST2) IL18R1 intron 23999434 rs6753717 chr2 102993161 A C 1.49E-31 Serum protein levels (sST2) IL18R1 intron 23999434 rs6750020 chr2 102994714 G A 1.51E-31 Serum protein levels (sST2) IL18R1 intron 23999434 rs17027037 chr2 102994884 A G 1.18E-07 Self-reported allergy IL18R1 intron 23817569 rs17027037 chr2 102994884 A G 7.14E-34 Serum protein levels (sST2) IL18R1 intron 23999434 rs2080289 chr2 102995020 G A 1.17E-07 Self-reported allergy IL18R1 intron 23817569 rs2080289 chr2 102995020 G A 7.36E-34 Serum protein levels (sST2) IL18R1 intron 23999434 rs11683700 chr2 102996805 C T 9.63E-08 Self-reported allergy IL18R1 intron 23817569 rs11683700 chr2 102996805 C T 8.58E-34 Serum protein levels (sST2) IL18R1 intron 23999434 rs3213733 chr2 102997884 C A 6.26E-05 Prion diseases IL18R1 intron 22210626 rs3213733 chr2 102997884 C A 4.34E-10 Self-reported allergy IL18R1 intron 23817569 rs1035130 chr2 103001402 C T 1.26E-07 Self-reported allergy IL18R1 cds-synon 23817569 rs1035130 chr2 103001402 C T 1.15E-33 Serum protein levels (sST2) IL18R1 cds-synon 23999434 rs2241116 chr2 103003265 C A 2.38E-24 Serum protein levels (sST2) IL18R1 intron 23999434 rs3771161 chr2 103003961 C A 4.65E-10 Self-reported allergy IL18R1 intron 23817569 rs4851570 chr2 103006387 A G 1.27E-07 Self-reported allergy IL18R1 intron 23817569 rs4851570 chr2 103006387 A G 1.44E-33 Serum protein levels (sST2) IL18R1 intron 23999434 rs4851004 chr2 103009537 C T 1.41E-06 Asthma IL18R1 intron 20860503 rs3771158 chr2 103009894 A G 4.45E-10 Self-reported allergy IL18R1 intron 23817569 rs2287034 chr2 103010588 C A 7.75E-07 Self-reported allergy IL18R1 intron 23817569 rs2287034 chr2 103010588 C A 2.22E-34 Serum protein levels (sST2) IL18R1 intron 23999434 rs2287033 chr2 103011237 T C 1.24E-06 Asthma IL18R1 intron 20860503 rs4851005 chr2 103011552 C T 7.61E-07 Esophageal cancer (squamous cell) IL18R1 intron 22960999 rs4851005 chr2 103011552 C T 6.06E-07 Self-reported allergy IL18R1 intron 23817569 rs4851005 chr2 103011552 C T 2.30E-35 Serum protein levels (sST2) IL18R1 intron 23999434 rs3732127 chr2 103013750 G C 4.62E-10 Self-reported allergy IL18R1 UTR-3 23817569 rs1135354 chr2 103014302 T G 1.80E-07 Self-reported allergy IL18R1 UTR-3 23817569 rs1135354 chr2 103014302 T G 1.93E-33 Serum protein levels (sST2) IL18R1 UTR-3 23999434 rs1420094 chr2 103015687 C T 1.18E-06 Asthma / / 20860503 rs17027087 chr2 103015918 C T 7.82E-07 Self-reported allergy / / 23817569 rs17027087 chr2 103015918 C T 8.44E-33 Serum protein levels (sST2) / / 23999434 rs3732123 chr2 103018077 C G 8.63E-04 Alzheimer's disease / / 17998437 rs3732123 chr2 103018077 C G 2.32E-07 Self-reported allergy / / 23817569 rs3732123 chr2 103018077 C G 4.92E-33 Serum protein levels (sST2) / / 23999434 rs12991737 chr2 103018128 T A 5.04E-08 Self-reported allergy / / 23817569 rs10202813 chr2 103019740 G T 7.48E-10 Self-reported allergy / / 23817569 rs1035127 chr2 103019919 A G 1.23E-04 Crohn's disease and Celiac disease / / 21298027 rs1035127 chr2 103019919 A G 5.65E-31 Serum protein levels (sST2) / / 23999434 rs10197310 chr2 103020030 T A 5.25E-10 Self-reported allergy / / 23817569 rs4851007 chr2 103024813 T G 2.11E-04 Crohn's disease and Celiac disease / / 21298027 rs4851007 chr2 103024813 T G 5.63E-31 Serum protein levels (sST2) / / 23999434 rs4851575 chr2 103025203 G A 5.15E-31 Serum protein levels (sST2) / / 23999434 rs10181785 chr2 103025274 C T 6.68E-10 Self-reported allergy / / 23817569 rs12712148 chr2 103025547 G A 7.47E-10 Self-reported allergy / / 23817569 rs11687768 chr2 103025738 A G 6.68E-10 Self-reported allergy / / 23817569 rs7586983 chr2 103028066 C T 6.20E-10 Self-reported allergy / / 23817569 rs11693955 chr2 103029165 A T 2.04E-07 Self-reported allergy / / 23817569 rs11693955 chr2 103029165 A T 4.38E-33 Serum protein levels (sST2) / / 23999434 rs1807782 chr2 103033147 C T 4.08E-31 Serum protein levels (sST2) / / 23999434 rs11465670 chr2 103034440 T C 3.37E-16 Serum protein levels (sST2) IL18RAP nearGene-5 23999434 rs1420106 chr2 103035044 A G 2.53E-04 Crohn's disease and Celiac disease IL18RAP nearGene-5 21298027 rs1420106 chr2 103035044 A G 4.04E-31 Serum protein levels (sST2) IL18RAP nearGene-5 23999434 rs7600961 chr2 103035455 G A 3.25E-16 Serum protein levels (sST2) IL18RAP intron 23999434 rs2293223 chr2 103035468 C T 6.67E-10 Self-reported allergy IL18RAP intron 23817569 rs2293225 chr2 103035889 C T 8.02E-24 Serum protein levels (sST2) IL18RAP intron 23999434 rs3771156 chr2 103036677 C T 3.08E-07 Self-reported allergy IL18RAP intron 23817569 rs3771156 chr2 103036677 C T 4.56E-33 Serum protein levels (sST2) IL18RAP intron 23999434 rs3755268 chr2 103038527 C G 4.04E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs3755267 chr2 103038587 T G 1.49E-04 Crohn's disease and Celiac disease IL18RAP intron 21298027 rs3755267 chr2 103038587 T G 4.04E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs3817465 chr2 103039584 A T 3.42E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs2272127 chr2 103039873 C G 4.09E-10 Self-reported allergy IL18RAP intron 23817569 rs2272128 chr2 103039929 G A 3.00E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs6759479 chr2 103040047 A C 4.80E-05 Allergic sensitization IL18RAP intron 23817571 rs6759588 chr2 103040159 A G 3.00E-17 Serum protein levels (sST2) IL18RAP intron 23999434 rs887972 chr2 103040945 G A 6.07E-08 Self-reported allergy IL18RAP intron 23817569 rs887972 chr2 103040945 G A 7.31E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs887971 chr2 103041167 T C 9.94E-08 Self-reported allergy IL18RAP intron 23817569 rs887971 chr2 103041167 T C 7.00E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs3755266 chr2 103042712 G A 8.71E-07 Asthma IL18RAP intron 20860503 rs11694658 chr2 103045020 A G 4.18E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs2160232 chr2 103046880 G A 4.27E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs6716784 chr2 103048467 T G 4.42E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs2310300 chr2 103049074 A G 8.92E-07 Asthma IL18RAP intron 20860503 rs2041756 chr2 103049910 A G 5.24E-04 Multiple complex diseases IL18RAP intron 17554300 rs2041756 chr2 103049910 A G 3.25E-05 Crohn's disease and Celiac disease IL18RAP intron 21298027 rs2041756 chr2 103049910 A G 4.54E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs10166330 chr2 103050390 C T 5.17E-10 Self-reported allergy IL18RAP intron 23817569 rs6543134 chr2 103050458 T G 4.54E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs2110735 chr2 103050925 A G 4.54E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs11681718 chr2 103051144 A G 1.34E-06 Self-reported allergy IL18RAP intron 23817569 rs11681718 chr2 103051144 A G 1.26E-33 Serum protein levels (sST2) IL18RAP intron 23999434 rs4851582 chr2 103051558 T C 5.37E-06 Self-reported allergy IL18RAP intron 23817569 rs4851582 chr2 103051558 T C 1.25E-33 Serum protein levels (sST2) IL18RAP intron 23999434 rs2110734 chr2 103052206 C T 2.52E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs6746271 chr2 103052995 G C 2.52E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs10176820 chr2 103054420 T C 4.40E-10 Self-reported allergy IL18RAP intron 23817569 rs2058660 chr2 103054449 G A 2.00E-12 Crohn's disease IL18RAP intron 21102463 rs2058660 chr2 103054449 G A 2.52E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs11465698 chr2 103054577 T C 6.65E-16 Serum protein levels (sST2) IL18RAP intron 23999434 rs11465699 chr2 103054767 G A 2.00E-08 Serum protein levels (sST2) IL18RAP intron 23999434 rs2058658 chr2 103054803 T C 2.52E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs17027166 chr2 103055420 G A 7.25E-07 Self-reported allergy IL18RAP intron 23817569 rs17027166 chr2 103055420 G A 1.28E-33 Serum protein levels (sST2) IL18RAP intron 23999434 rs4851009 chr2 103055644 G A 2.53E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs10490204 chr2 103056534 A C 1.16E-06 Self-reported allergy IL18RAP intron 23817569 rs10490204 chr2 103056534 A C 1.28E-33 Serum protein levels (sST2) IL18RAP intron 23999434 rs17027173 chr2 103057043 G A 6.88E-09 Serum protein levels (sST2) IL18RAP intron 23999434 rs17027179 chr2 103057159 C T 1.07E-06 Self-reported allergy IL18RAP intron 23817569 rs17027179 chr2 103057159 C T 1.29E-33 Serum protein levels (sST2) IL18RAP intron 23999434 rs2075186 chr2 103057251 G T 5.29E-10 Self-reported allergy IL18RAP intron 23817569 rs10490203 chr2 103059237 T G 1.07E-06 Self-reported allergy IL18RAP intron 23817569 rs10490203 chr2 103059237 T G 1.30E-33 Serum protein levels (sST2) IL18RAP intron 23999434 rs1558650 chr2 103060024 T A 2.53E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs13401597 chr2 103060818 C G 3.92E-08 Triglycerides IL18RAP intron 23063622 rs3771150 chr2 103060851 G A 1.07E-06 Self-reported allergy IL18RAP intron 23817569 rs3771150 chr2 103060851 G A 1.31E-33 Serum protein levels (sST2) IL18RAP intron 23999434 rs11694360 chr2 103061147 G A 2.14E-06 Self-reported allergy IL18RAP intron 23817569 rs11694360 chr2 103061147 G A 1.40E-39 Serum protein levels (sST2) IL18RAP intron 23999434 rs11123928 chr2 103061286 G A 1.83E-06 Self-reported allergy IL18RAP intron 23817569 rs11123928 chr2 103061286 G A 1.40E-39 Serum protein levels (sST2) IL18RAP intron 23999434 rs7597017 chr2 103062116 A G 1.84E-06 Self-reported allergy IL18RAP intron 23817569 rs7597017 chr2 103062116 A G 1.41E-39 Serum protein levels (sST2) IL18RAP intron 23999434 rs6543135 chr2 103062406 C T 9.89E-09 Serum protein levels (sST2) IL18RAP intron 23999434 rs6734736 chr2 103062880 C T 2.53E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs6708413 chr2 103063369 G A 6.22E-04 Multiple complex diseases IL18RAP intron 17554300 rs6708413 chr2 103063369 G A 1.45E-06 Crohn's disease IL18RAP intron 18587394 rs6708413 chr2 103063369 G A 2.05E-05 Crohn's disease and Celiac disease IL18RAP intron 21298027 rs6708413 chr2 103063369 G A 2.53E-31 Serum protein levels (sST2) IL18RAP intron 23999434 rs11465724 chr2 103063855 C T 1.47E-04 Type 2 diabetes IL18RAP intron 17463246 rs11465730 chr2 103066858 A G 5.13E-38 Serum protein levels (sST2) IL18RAP intron 23999434 rs7559479 chr2 103068787 G A 7.18E-04 Multiple complex diseases IL18RAP UTR-3 17554300 rs7559479 chr2 103068787 G A 3.03E-05 Crohn's disease and Celiac disease IL18RAP UTR-3 21298027 rs7559479 chr2 103068787 G A 3.42E-31 Serum protein levels (sST2) IL18RAP UTR-3 23999434 rs6741230 chr2 103069631 C T 7.55E-16 Serum protein levels (sST2) / / 23999434 rs917997 chr2 103070568 T C 6.80E-05 Celiac disease / / 17558408 rs917997 chr2 103070568 T C 1.11E-05 Crohn's disease / / 18587394 rs917997 chr2 103070568 T C 1.00E-15 Celiac disease / / 20190752 rs917997 chr2 103070568 T C 1.00E-15 Asthma / / 21150878 rs917997 chr2 103070568 T C 2.17E-05 Crohn's disease and Celiac disease / / 21298027 rs917997 chr2 103070568 T C 1.11E-15 Celiac disease and Rheumatoid arthritis / / 21383967 rs917997 chr2 103070568 T C 1.11E-15 Multiple sclerosis / / 22190364 rs917997 chr2 103070568 T C 3.00E-20 Inflammatory bowel disease / / 23128233 rs917997 chr2 103070568 T C 3.36E-31 Serum protein levels (sST2) / / 23999434 rs4070554 chr2 103074493 A G 3.16E-31 Serum protein levels (sST2) / / 23999434 rs6761825 chr2 103075561 T C 3.11E-31 Serum protein levels (sST2) / / 23999434 rs6705001 chr2 103076210 A G 3.08E-31 Serum protein levels (sST2) / / 23999434 rs6543141 chr2 103076351 G A 3.06E-31 Serum protein levels (sST2) / / 23999434 rs11690532 chr2 103076426 C T 9.03E-23 Serum protein levels (sST2) / / 23999434 rs6705385 chr2 103076569 A C 6.48E-38 Serum protein levels (sST2) / / 23999434 rs6705498 chr2 103076670 A G 6.52E-38 Serum protein levels (sST2) / / 23999434 rs6719196 chr2 103076888 G T 6.59E-38 Serum protein levels (sST2) / / 23999434 rs4851589 chr2 103077145 A G 6.18E-04 Multiple complex diseases / / 17554300 rs4241210 chr2 103078740 G A 2.97E-31 Serum protein levels (sST2) / / 23999434 rs6720564 chr2 103079297 T C 2.95E-31 Serum protein levels (sST2) / / 23999434 rs17027230 chr2 103079330 C T 1.70E-06 Self-reported allergy / / 23817569 rs17027230 chr2 103079330 C T 2.85E-33 Serum protein levels (sST2) / / 23999434 rs10210176 chr2 103079516 C A 5.85E-10 Self-reported allergy / / 23817569 rs6717915 chr2 103079619 A C 2.92E-31 Serum protein levels (sST2) / / 23999434 rs6718157 chr2 103079814 A T 2.92E-31 Serum protein levels (sST2) / / 23999434 rs917996 chr2 103082273 C A 2.91E-31 Serum protein levels (sST2) / / 23999434 rs741284 chr2 103083324 G C 4.47E-10 Self-reported allergy / / 23817569 rs12463588 chr2 103085257 C G 3.21E-37 Serum protein levels (sST2) / / 23999434 rs2310302 chr2 103086049 G C 3.62E-37 Serum protein levels (sST2) / / 23999434 rs12469887 chr2 103086758 T C 4.08E-37 Serum protein levels (sST2) / / 23999434 rs990171 chr2 103086770 A C 1.20E-16 Celiac disease / / 22057235 rs990171 chr2 103086770 A C 5.02E-31 Serum protein levels (sST2) / / 23999434 rs10172116 chr2 103087573 C T 5.48E-10 Self-reported allergy / / 23817569 rs4140786 chr2 103088176 G T 5.70E-37 Serum protein levels (sST2) / / 23999434 rs1403552 chr2 103088777 C T 5.62E-10 Self-reported allergy / / 23817569 rs10201184 chr2 103089078 G C 7.08E-37 Serum protein levels (sST2) / / 23999434 rs4851011 chr2 103089678 C T 7.24E-04 Lymphocyte counts / / 22286170 rs4851011 chr2 103089678 C T 2.45E-06 Self-reported allergy / / 23817569 rs4851011 chr2 103089678 C T 1.23E-32 Serum protein levels (sST2) / / 23999434 rs17027255 chr2 103090127 C T 2.54E-06 Self-reported allergy SLC9A4 UTR-5 23817569 rs17027255 chr2 103090127 C T 1.24E-32 Serum protein levels (sST2) SLC9A4 UTR-5 23999434 rs17027258 chr2 103091540 A G 7.00E-06 White blood cell types SLC9A4 intron 21738478 rs17027258 chr2 103091540 A G 2.63E-06 Self-reported allergy SLC9A4 intron 23817569 rs17027258 chr2 103091540 A G 1.31E-32 Serum protein levels (sST2) SLC9A4 intron 23999434 rs13030642 chr2 103091585 C A 7.34E-10 Self-reported allergy SLC9A4 intron 23817569 rs1468791 chr2 103092021 A G 3.11E-31 Serum protein levels (sST2) SLC9A4 intron 23999434 rs13018263 chr2 103092270 T C 6.33E-05 Prion diseases SLC9A4 intron 22210626 rs13018263 chr2 103092270 T C 5.84E-08 Self-reported allergy SLC9A4 intron 23817569 rs1468790 chr2 103092441 G C 7.43E-08 Self-reported allergy SLC9A4 intron 23817569 rs1468790 chr2 103092441 G C 6.78E-13 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1468788 chr2 103092513 C T 7.48E-08 Self-reported allergy SLC9A4 intron 23817569 rs1468788 chr2 103092513 C T 6.80E-13 Serum protein levels (sST2) SLC9A4 intron 23999434 rs7597819 chr2 103092906 A G 3.51E-31 Serum protein levels (sST2) SLC9A4 intron 23999434 rs6737668 chr2 103093081 C T 3.56E-31 Serum protein levels (sST2) SLC9A4 intron 23999434 rs10469840 chr2 103093243 T C 2.34E-29 Serum protein levels (sST2) SLC9A4 intron 23999434 rs759382 chr2 103094213 G T 8.84E-04 Multiple complex diseases SLC9A4 intron 17554300 rs759382 chr2 103094213 G T 2.03E-04 Crohn's disease and Celiac disease SLC9A4 intron 21298027 rs759382 chr2 103094213 G T 5.35E-20 Serum protein levels (sST2) SLC9A4 intron 23999434 rs759381 chr2 103094323 A T 4.62E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs11692304 chr2 103095404 G A 2.20E-12 Serum protein levels (sST2) SLC9A4 cds-synon 23999434 rs6543146 chr2 103096695 T G 8.53E-18 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1030026 chr2 103098178 A C 1.27E-17 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1523198 chr2 103098474 C T 2.17E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs6751666 chr2 103098571 A G 8.54E-04 Type 2 diabetes SLC9A4 intron 17463246 rs2140316 chr2 103098676 T A 1.94E-17 Serum protein levels (sST2) SLC9A4 intron 23999434 rs17027293 chr2 103098840 A G 8.76E-04 Type 2 diabetes SLC9A4 intron 17463246 rs17027295 chr2 103098871 G A 5.65E-04 Type 2 diabetes SLC9A4 intron 17463246 rs6543148 chr2 103100219 A G 5.65E-04 Type 2 diabetes SLC9A4 intron 17463246 rs7566613 chr2 103100495 G A 5.65E-04 Type 2 diabetes SLC9A4 intron 17463246 rs10175045 chr2 103103232 T C 2.16E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs10207579 chr2 103103289 C T 6.87E-11 Serum protein levels (sST2) SLC9A4 intron 23999434 rs41348650 chr2 103104199 G A 6.72E-04 Type 2 diabetes SLC9A4 intron 17463246 rs7567885 chr2 103108852 T G 1.56E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1403548 chr2 103110375 C T 1.56E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs12712153 chr2 103111761 C T 1.56E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs11687071 chr2 103111920 G A 1.56E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs7566063 chr2 103112565 C A 1.56E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs7591872 chr2 103112641 G C 1.56E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs7591878 chr2 103112658 G A 1.56E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs12987295 chr2 103115838 G A 1.82E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs17772203 chr2 103115860 C G 3.77E-04 Type 2 diabetes SLC9A4 intron 17463246 rs4851012 chr2 103115915 C T 1.83E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851600 chr2 103116223 C G 1.83E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851014 chr2 103116276 C T 1.83E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851602 chr2 103116305 G A 8.97E-17 Serum protein levels (sST2) SLC9A4 intron 23999434 rs12995030 chr2 103116466 C G 1.81E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs6728288 chr2 103117268 A T 1.80E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs2075193 chr2 103118027 G A 1.78E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs2075192 chr2 103118228 A G 1.77E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs2075191 chr2 103118299 G T 1.77E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs2075190 chr2 103118559 A T 1.76E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851604 chr2 103118881 G A 9.85E-11 Serum protein levels (sST2) SLC9A4 intron 23999434 rs11690932 chr2 103119029 G A 1.73E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs2075187 chr2 103120311 G A 1.62E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851016 chr2 103120400 C T 1.60E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851017 chr2 103120769 C A 1.55E-08 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851605 chr2 103120868 A G 1.11E-10 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851606 chr2 103120889 G A 1.10E-10 Serum protein levels (sST2) SLC9A4 intron 23999434 rs7605606 chr2 103121536 G A 1.08E-15 Serum protein levels (sST2) SLC9A4 intron 23999434 rs13019784 chr2 103123301 A G 9.84E-22 Serum protein levels (sST2) SLC9A4 intron 23999434 rs9989842 chr2 103123633 C G 1.11E-20 Serum protein levels (sST2) SLC9A4 intron 23999434 rs9989749 chr2 103123642 G A 9.57E-22 Serum protein levels (sST2) SLC9A4 intron 23999434 rs6708949 chr2 103123965 G C 9.36E-22 Serum protein levels (sST2) SLC9A4 intron 23999434 rs6724109 chr2 103125018 C G 4.05E-22 Serum protein levels (sST2) SLC9A4 intron 23999434 rs6751949 chr2 103125138 G A 4.08E-22 Serum protein levels (sST2) SLC9A4 intron 23999434 rs6724322 chr2 103125182 C T 4.13E-22 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851607 chr2 103125632 C T 4.16E-22 Serum protein levels (sST2) SLC9A4 intron 23999434 rs10195948 chr2 103125736 T C 4.19E-22 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851608 chr2 103125984 C T 1.79E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs12712155 chr2 103127963 A T 1.71E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851609 chr2 103128866 T C 1.72E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs11676371 chr2 103129692 G C 1.75E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1476999 chr2 103131679 G A 1.86E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs2192758 chr2 103132269 C G 1.81E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs2192757 chr2 103132378 C T 1.84E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs2216000 chr2 103132640 G C 1.90E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs6714379 chr2 103133310 A G 1.73E-20 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851610 chr2 103134652 C G,T 4.23E-12 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1523204 chr2 103135637 G A 1.94E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1523203 chr2 103135759 A G 1.99E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851611 chr2 103135938 A T 2.02E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1403550 chr2 103136309 T C 2.04E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1403551 chr2 103136446 T G 2.04E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs2058656 chr2 103137026 T G 1.80E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851612 chr2 103137880 C G 1.80E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851613 chr2 103137990 T C 2.12E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs6750851 chr2 103138761 A G 2.14E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs6750971 chr2 103138825 A G 2.04E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs10193407 chr2 103139298 C T 1.73E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs11123935 chr2 103139751 A G 1.64E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851614 chr2 103140398 C T 2.49E-32 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1357471 chr2 103140472 C T 2.02E-32 Serum protein levels (sST2) SLC9A4 intron 23999434 rs2015478 chr2 103141447 A G 1.35E-32 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1024798 chr2 103141651 G C 1.14E-21 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4241211 chr2 103143159 T G 9.24E-33 Serum protein levels (sST2) SLC9A4 intron 23999434 rs12712156 chr2 103144020 A C 5.42E-33 Serum protein levels (sST2) SLC9A4 intron 23999434 rs3849364 chr2 103144242 T C 4.85E-33 Serum protein levels (sST2) SLC9A4 intron 23999434 rs3849365 chr2 103144391 G A 2.61E-34 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1005042 chr2 103145359 A G 2.88E-33 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1005043 chr2 103145426 A G 2.62E-33 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851018 chr2 103146615 C T 2.62E-33 Serum protein levels (sST2) SLC9A4 intron 23999434 rs4851615 chr2 103146999 G T 8.39E-22 Serum protein levels (sST2) SLC9A4 intron 23999434 rs741285 chr2 103148169 C T 2.61E-33 Serum protein levels (sST2) SLC9A4 intron 23999434 rs1014286 chr2 103149100 G A 3.00E-33 Serum protein levels (sST2) SLC9A4 missense 23999434 rs2008159 chr2 103149162 A G 2.61E-33 Serum protein levels (sST2) SLC9A4 UTR-3 23999434 rs2008157 chr2 103149182 A G 2.61E-33 Serum protein levels (sST2) SLC9A4 UTR-3 23999434 rs1829849 chr2 103149698 A C 2.89E-33 Serum protein levels (sST2) SLC9A4 UTR-3 23999434 rs6737119 chr2 103151109 G A 3.05E-33 Serum protein levels (sST2) / / 23999434 rs6709284 chr2 103151164 C G 3.22E-33 Serum protein levels (sST2) / / 23999434 rs6724213 chr2 103151219 A C 6.41E-22 Serum protein levels (sST2) / / 23999434 rs2177317 chr2 103151319 A G 3.73E-33 Serum protein levels (sST2) / / 23999434 rs2871474 chr2 103151441 G A 5.95E-21 Serum protein levels (sST2) / / 23999434 rs4851616 chr2 103151862 C T 6.30E-22 Serum protein levels (sST2) / / 23999434 rs4851617 chr2 103152060 C T 6.62E-33 Serum protein levels (sST2) / / 23999434 rs10172553 chr2 103152975 C T 1.54E-21 Serum protein levels (sST2) / / 23999434 rs4292112 chr2 103153780 G A 1.24E-32 Serum protein levels (sST2) / / 23999434 rs6761291 chr2 103155069 C T 1.75E-21 Serum protein levels (sST2) / / 23999434 rs11685483 chr2 103159093 A C 3.18E-21 Serum protein levels (sST2) / / 23999434 rs6739426 chr2 103160443 A G 4.64E-21 Serum protein levels (sST2) / / 23999434 rs10490202 chr2 103160832 C G,T 5.15E-32 Serum protein levels (sST2) / / 23999434 rs11899041 chr2 103161053 T A 7.64E-21 Serum protein levels (sST2) / / 23999434 rs12712157 chr2 103165129 T C 5.59E-20 Serum protein levels (sST2) / / 23999434 rs10194822 chr2 103165504 T G 3.05E-21 Serum protein levels (sST2) / / 23999434 rs1303960 chr2 103165832 G A 5.17E-20 Serum protein levels (sST2) / / 23999434 rs2215998 chr2 103166043 A G 2.95E-21 Serum protein levels (sST2) / / 23999434 rs7581853 chr2 103167724 C T 6.23E-31 Serum protein levels (sST2) / / 23999434 rs10193009 chr2 103168977 C T 6.23E-31 Serum protein levels (sST2) / / 23999434 rs11123937 chr2 103169682 G A 6.52E-31 Serum protein levels (sST2) / / 23999434 rs12712159 chr2 103169982 G A 7.02E-31 Serum protein levels (sST2) / / 23999434 rs10196579 chr2 103170181 C T 3.48E-21 Serum protein levels (sST2) / / 23999434 rs997056 chr2 103170919 A G 8.39E-31 Serum protein levels (sST2) / / 23999434 rs2310295 chr2 103171066 G A 4.21E-21 Serum protein levels (sST2) / / 23999434 rs2110737 chr2 103172263 T A 1.09E-30 Serum protein levels (sST2) / / 23999434 rs2005881 chr2 103173059 G A 1.05E-19 Serum protein levels (sST2) / / 23999434 rs10210658 chr2 103175749 T G 1.86E-30 Serum protein levels (sST2) / / 23999434 rs4851619 chr2 103176411 C T 1.67E-19 Serum protein levels (sST2) / / 23999434 rs6761871 chr2 103176797 A C 1.51E-19 Serum protein levels (sST2) / / 23999434 rs6711140 chr2 103177295 T C 9.80E-12 Multiple complex diseases / / 17554300 rs10202404 chr2 103177414 C T 7.61E-21 Serum protein levels (sST2) / / 23999434 rs4851019 chr2 103177565 T A 7.61E-21 Serum protein levels (sST2) / / 23999434 rs12469973 chr2 103182273 A G 2.80E-05 Urinary metabolites / / 21572414 rs9308860 chr2 103207959 C G 3.50E-04 Self-reported allergy / / 23817569 rs6725806 chr2 103216172 T A,G 3.21E-08 Serum protein levels (sST2) / / 23999434 rs2192665 chr2 103216578 G C 2.99E-04 Type 2 diabetes / / 17463246 rs17774619 chr2 103216776 C T 1.09E-04 Type 2 diabetes / / 17463246 rs873625 chr2 103219213 A G 7.30E-04 Type 2 diabetes / / 17463246 rs3806581 chr2 103235312 T C 4.27E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1016160 chr2 103245025 A G 4.68E-14 Serum protein levels (sST2) SLC9A2 intron 23999434 rs2192669 chr2 103251554 T C 1.91E-22 Serum protein levels (sST2) SLC9A2 intron 23999434 rs17775170 chr2 103251927 G A 3.50E-12 Serum protein levels (sST2) SLC9A2 intron 23999434 rs17775237 chr2 103253943 G T 2.83E-04 Type 2 diabetes SLC9A2 intron 17463246 rs17775404 chr2 103257932 G A 2.04E-04 Type 2 diabetes SLC9A2 intron 17463246 rs4851622 chr2 103260445 T G 8.79E-04 Multiple complex diseases SLC9A2 intron 17554300 rs4140834 chr2 103268442 T C 6.33E-04 White matter integrity SLC9A2 intron 22425255 rs10178585 chr2 103272957 G A 6.60E-06 Personality dimensions SLC9A2 intron 21173776 rs13400836 chr2 103287261 A C 7.97E-04 Tourette syndrome SLC9A2 intron 22889924 rs6726894 chr2 103296936 C G 1.01E-04 Alcohol dependence SLC9A2 intron 21314694 rs33993717 chr2 103335441 A G 5.00E-06 Response to amphetamines MFSD9 missense 22952603 rs2732824 chr2 103347857 A G 2.20E-05 Temperament (bipolar disorder) MFSD9 intron 22365631 rs2540317 chr2 103349807 A G 3.40E-04 Type 2 diabetes MFSD9 intron 17846126 rs2540317 chr2 103349807 A G 7.40E-05 Temperament (bipolar disorder) MFSD9 intron 22365631 rs2540316 chr2 103350040 C T 1.00E-04 Temperament (bipolar disorder) MFSD9 intron 22365631 rs955916 chr2 103351779 A G 1.30E-04 Attention deficit hyperactivity disorder MFSD9 intron pha002875 rs12465996 chr2 103388594 C T 5.00E-06 IgG glycosylation TMEM182 intron 23382691 rs12052617 chr2 103478635 G A 2.92E-05 Alcohol and nictotine co-dependence / / 20158304 rs1024787 chr2 103487128 C T 1.18E-04 Glycosylated haemoglobin levels / / 17255346 rs10188760 chr2 103511907 G C 5.58E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs13402330 chr2 103512292 T A 6.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs11691730 chr2 103561126 G A 4.65E-05 Alcohol and nictotine co-dependence / / 20158304 rs17206765 chr2 103565013 C T 1.29E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2310351 chr2 103572929 T G 4.10E-05 Major depressive disorder / / 21042317 rs1878530 chr2 103573730 G A 5.50E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12105421 chr2 103576088 C T 5.00E-07 Psychosis (atypical) / / 24132900 rs10496361 chr2 103583057 T C 2.64E-04 Cognition,early reading ability / / 17684495 rs10496361 chr2 103583057 T C 3.02E-05 Tunica Media / / pha003036 rs17812637 chr2 103585664 G A 1.60E-06 Urinary metabolites / / 21572414 rs7587833 chr2 103617979 G T 7.44E-04 Premature ovarian failure / / 19508998 rs9308861 chr2 103619483 T C 8.66E-04 Premature ovarian failure / / 19508998 rs10187137 chr2 103674434 C G 7.52E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1528063 chr2 103675293 T C 8.24E-04 Multiple complex diseases / / 17554300 rs817742 chr2 103728170 A G 1.09E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs3915280 chr2 103757033 A G 8.36E-04 Body mass index / / 21701565 rs17028262 chr2 103760153 T C 3.33E-04 Multiple complex diseases / / 17554300 rs1528066 chr2 103762222 A G 7.98E-04 Multiple complex diseases / / 17554300 rs6735786 chr2 103770238 C T 2.00E-06 Bone mineral density (hip) / / 19079262 rs4319952 chr2 103773825 C T 5.07E-05 Blood Pressure / / pha003048 rs10496366 chr2 103787192 A T 2.69E-04 Multiple complex diseases / / 17554300 rs10469858 chr2 103979257 A G 2.85E-06 Orofacial clefts / / 22419666 rs1901480 chr2 104253005 G A 2.60E-05 Urinary metabolites / / 21572414 rs264943 chr2 104298541 C A 7.00E-06 HIV-1 viral setpoint / / 22174851 rs17343583 chr2 104302099 A G 5.56E-04 Schizophrenia / / 19197363 rs17029130 chr2 104420998 T C 3.58E-04 Alzheimer's disease / / 22005930 rs17029138 chr2 104422253 G A 1.95E-04 Alzheimer's disease / / 22005930 rs938872 chr2 104427959 G A 8.40E-04 Alzheimer's disease / / 22005930 rs11675380 chr2 104429265 A G 3.46E-04 Alzheimer's disease / / 22005930 rs11691973 chr2 104429441 C T 3.48E-04 Alzheimer's disease / / 22005930 rs11889814 chr2 104432494 A C 2.03E-04 Alzheimer's disease / / 22005930 rs17029167 chr2 104433462 G A 2.00E-04 Alzheimer's disease / / 22005930 rs17029176 chr2 104434484 T C 8.59E-04 Alzheimer's disease / / 22005930 rs2067640 chr2 104436997 C T 1.80E-04 Alzheimer's disease / / 22005930 rs17029187 chr2 104437560 G A 1.73E-04 Alzheimer's disease / / 22005930 rs17029204 chr2 104441663 A T 1.86E-04 Alzheimer's disease / / 22005930 rs17029208 chr2 104441685 C T 1.71E-04 Alzheimer's disease / / 22005930 rs11686245 chr2 104443126 G A 1.85E-04 Alzheimer's disease / / 22005930 rs2678665 chr2 104443637 A G 8.78E-04 Alzheimer's disease / / 22005930 rs2570494 chr2 104445272 T G 8.78E-04 Alzheimer's disease / / 22005930 rs11694523 chr2 104446668 C T 1.54E-04 Alzheimer's disease / / 22005930 rs2610700 chr2 104447239 C T 8.80E-04 Alzheimer's disease / / 22005930 rs2610696 chr2 104449526 C T 9.09E-04 Alzheimer's disease / / 22005930 rs1837714 chr2 104450445 C A,G 8.89E-04 Alzheimer's disease / / 22005930 rs1441100 chr2 104450471 A G 8.89E-04 Alzheimer's disease / / 22005930 rs2570491 chr2 104450970 G A 8.94E-04 Alzheimer's disease / / 22005930 rs1550536 chr2 104451134 C G 6.94E-04 Alzheimer's disease / / 22005930 rs2570490 chr2 104451549 T C 8.92E-04 Alzheimer's disease / / 22005930 rs2570489 chr2 104451881 A G 9.83E-04 Alzheimer's disease / / 22005930 rs7559425 chr2 104463080 T C 5.17E-04 Alzheimer's disease / / 22005930 rs2007689 chr2 104472913 A T 2.66E-04 Alzheimer's disease / / 22005930 rs17029303 chr2 104475374 C T 5.04E-04 Alzheimer's disease / / 22005930 rs12616008 chr2 104554763 A G 8.22E-05 Erythrocyte counts / / pha003099 rs2119507 chr2 104573005 C T 4.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs2570483 chr2 104575444 A G 4.03E-04 Iron levels / / pha002876 rs1036736 chr2 104578533 T C 4.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs2582974 chr2 104578923 T C 6.00E-05 Multiple myeloma / / 23955597 rs12613775 chr2 104580503 C T 4.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs10193430 chr2 104587351 T A 4.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs11903187 chr2 104589138 G A 4.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs6758152 chr2 104667738 T G 3.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs7567271 chr2 104671174 T A 4.65E-04 Multiple complex diseases / / 17554300 rs2889276 chr2 104714131 C T 7.63E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2889277 chr2 104714865 G A 3.57E-05 Type 2 diabetes / / 17846125 rs9308872 chr2 104734791 C T 1.32E-06 Myocardial Infarction / / pha002873 rs10189155 chr2 104736252 C G 5.03E-06 Suicide attempts in bipolar disorder / / 21423239 rs13404302 chr2 104742560 G A 5.29E-06 Suicide attempts in bipolar disorder / / 21423239 rs10188554 chr2 104743617 G A 7.91E-07 Myocardial Infarction / / pha002873 rs2376062 chr2 104751980 C T 6.55E-05 Suicide attempts in bipolar disorder / / 21423239 rs7369597 chr2 104758840 C T 6.69E-06 Myocardial Infarction / / pha002873 rs4402785 chr2 104766351 C T 1.95E-05 Myocardial Infarction / / pha002873 rs12712184 chr2 104781580 T C 7.00E-05 Glioma (high-grade) / / 19578366 rs4851671 chr2 104798368 A G 5.08E-04 Multiple complex diseases / / 17554300 rs11890236 chr2 104808712 T C 9.00E-06 Obesity-related traits / / 23251661 rs12712185 chr2 104827991 A T 4.82E-05 Major depressive disorder (broad) / / 20038947 rs4450624 chr2 104846492 T C 5.44E-04 Parkinson's disease / / 16252231 rs4851675 chr2 104856148 C A 6.15E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10176377 chr2 104970824 C T 2.26E-04 Multiple complex diseases / / 17554300 rs17029726 chr2 104972046 T A 1.54E-04 Multiple complex diseases / / 17554300 rs12469405 chr2 104972131 C G 3.35E-04 Multiple complex diseases / / 17554300 rs17029753 chr2 104981980 A G 8.10E-05 Multiple complex diseases / / 17554300 rs17029754 chr2 104982118 G A 1.29E-05 Multiple complex diseases / / 17554300 rs7570682 chr2 104983267 G A 3.11E-06 Multiple complex diseases / / 17554300 rs7570682 chr2 104983267 G A 3.00E-06 Bipolar disorder / / 21254220 rs6732355 chr2 104984277 C A 4.00E-05 Multiple complex diseases / / 17554300 rs12620263 chr2 105008715 A G 3.93E-05 Multiple complex diseases LOC100287010 intron 17554300 rs13423425 chr2 105009335 T G 3.64E-05 Multiple complex diseases LOC100287010 intron 17554300 rs908916 chr2 105012664 C T 4.61E-05 Multiple complex diseases LOC100287010 intron 17554300 rs7425226 chr2 105019418 C A 6.00E-04 Acute lymphoblastic leukemia (childhood) LOC100287010 intron 20189245 rs12622294 chr2 105019902 C G 4.00E-04 Acute lymphoblastic leukemia (childhood) LOC100287010 intron 20189245 rs13396253 chr2 105027124 A G 9.62E-05 Endometrial cancer LOC100287010 intron 24096698 rs1033302 chr2 105093698 G A 3.16E-05 Elbow pain LOC150568 intron pha003008 rs9646956 chr2 105101407 C T 5.99E-04 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs12616824 chr2 105103068 C T 6.83E-04 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs10184670 chr2 105103344 C T 1.21E-04 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs6743147 chr2 105105033 G T 2.25E-04 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs6743263 chr2 105105148 G A 2.29E-04 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs11889267 chr2 105106375 C T 6.36E-04 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs11123992 chr2 105106747 G A 1.91E-04 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs10203249 chr2 105107335 G A 1.43E-04 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs10187071 chr2 105109288 C T 8.31E-05 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs6753471 chr2 105110002 T C 7.76E-05 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs10166195 chr2 105110550 G A 1.29E-04 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs12620665 chr2 105114879 A G 1.84E-04 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs1439671 chr2 105116184 T C 7.65E-05 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs7564645 chr2 105117317 G A 5.20E-05 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs1439670 chr2 105118594 C T 4.02E-04 Multiple complex diseases LOC150568 intron 17554300 rs734849 chr2 105120553 G A 8.97E-05 Suicide attempts in bipolar disorder LOC150568 intron 21423239 rs12104638 chr2 105129022 C T 2.74E-04 Multiple complex diseases / / 17554300 rs1866555 chr2 105141788 C T 7.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6738747 chr2 105144490 G A 6.37E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17029922 chr2 105147650 G A 1.20E-06 Urinary metabolites / / 21572414 rs17624303 chr2 105148418 C T 9.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1946878 chr2 105153455 G A 2.10E-05 Urinary metabolites / / 21572414 rs13429262 chr2 105154379 G A 2.10E-05 Urinary metabolites / / 21572414 rs13429262 chr2 105154379 G A 9.76E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13405030 chr2 105154863 C T 7.25E-04 Alzheimer's disease / / 22005930 rs7608295 chr2 105158182 A T 8.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17624523 chr2 105158638 A G 8.00E-06 Response to taxane treatment (docetaxel) / / 23006423 rs17029932 chr2 105158776 G A 9.91E-05 Alcohol dependence / / 21703634 rs17670403 chr2 105160828 C T 4.30E-06 Urinary metabolites / / 21572414 rs17670403 chr2 105160828 C T 2.52E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1530129 chr2 105163835 C T 2.87E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1530128 chr2 105164449 A G 2.78E-04 Coronary heart disease / / 21606135 rs2083350 chr2 105165756 C A 8.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs714753 chr2 105167888 G A 2.20E-05 Urinary metabolites / / 21572414 rs714753 chr2 105167888 G A 3.52E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6733728 chr2 105170353 T C 3.31E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1530126 chr2 105172500 G C 1.60E-05 Urinary metabolites / / 21572414 rs1561513 chr2 105173128 C A 2.10E-05 Urinary metabolites / / 21572414 rs1561513 chr2 105173128 C A 5.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1439675 chr2 105175815 A G 5.17E-04 Multiple complex diseases / / 17554300 rs1439675 chr2 105175815 A G 1.10E-05 Urinary metabolites / / 21572414 rs7586619 chr2 105176835 T A 1.40E-05 Urinary metabolites / / 21572414 rs7586619 chr2 105176835 T A 6.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17029958 chr2 105177640 C T 5.71E-04 Multiple complex diseases / / 17554300 rs13005764 chr2 105184355 A G 2.15E-04 Coronary heart disease / / 21606135 rs6716044 chr2 105188004 G T 4.79E-05 Type 2 diabetes and other traits / / 19734900 rs13422332 chr2 105189283 C T 1.20E-05 Urinary metabolites / / 21572414 rs13422332 chr2 105189283 C T 0.000399 Salmonella-induced pyroptosis / / 22837397 rs7598356 chr2 105189350 C A 0.000669 Salmonella-induced pyroptosis / / 22837397 rs10496386 chr2 105190420 G A 6.51E-04 Multiple complex diseases / / 17554300 rs1517862 chr2 105300588 G A 2.95E-04 Gallstones / / 17632509 rs6543265 chr2 105306305 T C 2.74E-04 Type 2 diabetes / / 17463246 rs1517860 chr2 105324489 G T 2.84E-04 Type 2 diabetes / / 17463246 rs6732043 chr2 105341106 A C 3.49E-04 Type 2 diabetes / / 22158537 rs6735165 chr2 105341214 T C 3.52E-04 Type 2 diabetes / / 22158537 rs4851712 chr2 105354926 C A 8.85E-05 Post-operative nausea and vomiting / / 21694509 rs3811547 chr2 105363267 T C 4.22E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6543267 chr2 105365247 T C 2.52E-04 Multiple complex diseases LOC284998 intron 17554300 rs6758786 chr2 105367587 C T 6.58E-04 Suicide attempts in bipolar disorder LOC284998 intron 21423239 rs12615966 chr2 105378957 C T 7.00E-06 Pancreatic cancer / / 20686608 rs1349512 chr2 105435369 T C 6.13E-04 Amyotrophic Lateral Sclerosis LOC100506421 intron 17362836 rs6714493 chr2 105436880 T G 6.13E-04 Amyotrophic Lateral Sclerosis LOC100506421 intron 17362836 rs3739154 chr2 105455303 T C 9.99E-04 Tourette syndrome LOC100506421 intron 22889924 rs6725560 chr2 105475330 A G 0.00000094 Urinary concentrations of arsenic metabolites (percentage monomethylarsonic acid) / / 22383894 rs2060783 chr2 105490397 A C 7.22E-04 Alzheimer's disease / / 24755620 rs7579394 chr2 105500046 T G 2.55E-04 Alzheimer's disease / / 24755620 rs1026220 chr2 105504322 A G 7.94E-04 Alzheimer's disease / / 24755620 rs715197 chr2 105512925 C T 2.50E-05 Urinary metabolites / / 21572414 rs6714749 chr2 105521412 T G 9.38E-05 Serum metabolites / / 19043545 rs1005999 chr2 105523791 C T 1.98E-07 Primary biliary cirrhosis / / 23000144 rs1005999 chr2 105523791 C T 0.000000198 Facial morphology / / 23028347 rs12611661 chr2 105589679 T C 3.33E-05 Hypertension / / 21082022 rs4266037 chr2 105730749 A G 7.92E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4567954 chr2 105730986 T G 8.93E-05 Multiple complex diseases / / 17554300 rs4567954 chr2 105730986 T G 7.43E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6760606 chr2 105735837 A G 3.25E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs3923277 chr2 105737154 A G 9.90E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7567068 chr2 105742131 C T 3.25E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4378828 chr2 105745533 C T 5.50E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12616980 chr2 105746795 T C 3.25E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10191425 chr2 105754747 A C 2.73E-04 Depression (quantitative trait) / / 20800221 rs7597760 chr2 105766388 C T 9.71E-04 Multiple complex diseases / / 17554300 rs4605389 chr2 105771650 T C 3.31E-04 Depression (quantitative trait) / / 20800221 rs7583476 chr2 105778288 A T 3.16E-04 Depression (quantitative trait) / / 20800221 rs7569958 chr2 105778430 C T 3.18E-04 Depression (quantitative trait) / / 20800221 rs13411784 chr2 105779411 A C 3.62E-04 Depression (quantitative trait) / / 20800221 rs1437400 chr2 105787410 G A 3.91E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2679882 chr2 105791078 T C 1.68E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13388299 chr2 105791914 T C 5.86E-04 Depression (quantitative trait) / / 20800221 rs2679870 chr2 105792850 G A 8.34E-05 Basophils / / pha003087 rs6710490 chr2 105797265 A G 2.77E-04 Multiple complex diseases / / 17554300 rs6710490 chr2 105797265 A G 2.65E-04 Smoking cessation / / 24665060 rs2679851 chr2 105798292 A G 4.84E-04 Alzheimer's disease (late onset) / / 21379329 rs7584136 chr2 105833093 A C 7.13E-05 Pancreatic cancer / / pha002889 rs6712932 chr2 105837598 T C 6.00E-06 Type 2 diabetes / / 17668382 rs6712932 chr2 105837598 T C 6.00E-06 Coronary heart disease / / 21347282 rs17636747 chr2 105877870 C T 4.00E-06 Preeclampsia / / 23551011 rs2460255 chr2 105882061 G A 1.67E-08 Lymphocyte counts / / 22286170 rs3816133 chr2 105890632 T C 1.63E-04 Multiple complex diseases TGFBRAP1 intron 17554300 rs1020064 chr2 105897740 T G 7.00E-06 AIDS TGFBRAP1 intron 19754311 rs2576742 chr2 105898822 T A 3.19E-04 Multiple complex diseases TGFBRAP1 intron 17554300 rs2576742 chr2 105898822 T A 3.77E-04 Insulin resistance TGFBRAP1 intron 21901158 rs3792044 chr2 105899702 A C 8.35E-04 Body mass index TGFBRAP1 intron 21701565 rs3792048 chr2 105901673 C T 2.13E-07 Multiple complex diseases TGFBRAP1 intron 17554300 rs920217 chr2 105904662 T C 4.44E-04 Multiple complex diseases TGFBRAP1 intron 17554300 rs2679895 chr2 105906480 C G 3.79E-04 Multiple complex diseases TGFBRAP1 intron 17554300 rs2679895 chr2 105906480 C G 7.05E-04 Insulin resistance TGFBRAP1 intron 21901158 rs1030877 chr2 105910513 G A 6.00E-06 Obesity-related traits TGFBRAP1 intron 23251661 rs2576748 chr2 105911258 C A 6.75E-05 Insulin resistance TGFBRAP1 intron 21901158 rs2679892 chr2 105918066 G A 1.68E-04 Body mass index TGFBRAP1 intron 21701565 rs2679892 chr2 105918066 G A 3.54E-04 Body mass index TGFBRAP1 intron 21701565 rs17689220 chr2 105918129 T C 2.84E-04 Multiple complex diseases TGFBRAP1 intron 17554300 rs893249 chr2 105925311 T C 1.90E-04 Alzheimer's disease TGFBRAP1 intron 17998437 rs6727677 chr2 105935166 A G 1.56E-04 Body mass index TGFBRAP1 intron 21701565 rs6727677 chr2 105935166 A G 4.17E-05 Body mass index TGFBRAP1 intron 21701565 rs2679874 chr2 105939430 C T 1.12E-04 Body mass index TGFBRAP1 intron 21701565 rs2679874 chr2 105939430 C T 4.38E-04 Body mass index TGFBRAP1 intron 21701565 rs2033727 chr2 105953909 G C 6.09E-04 Multiple complex diseases / / 17554300 rs2033727 chr2 105953909 G C 1.30E-05 Urinary metabolites / / 21572414 rs10190186 chr2 105997385 A G 3.44E-04 Multiple complex diseases FHL2 intron 17554300 rs4374396 chr2 106024451 A G 2.50E-05 Urinary metabolites FHL2 intron 21572414 rs10203748 chr2 106076110 T C 1.17E-05 Celiac disease / / 23936387 rs13425033 chr2 106076625 T G 1.43E-103 Multiple complex diseases / / 17554300 rs7604966 chr2 106077691 T C 4.33E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs13385109 chr2 106080007 A T 3.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs6711988 chr2 106080746 T C 3.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs9989768 chr2 106081221 T C 3.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs6725019 chr2 106086944 G A 4.21E-05 Alzheimer's disease / / 17998437 rs17030964 chr2 106094387 C A 6.36E-04 Alzheimer's disease / / 17998437 rs1518614 chr2 106103606 A C 2.50E-05 Urinary metabolites / / 21572414 rs11897323 chr2 106104410 A G 4.90E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17030992 chr2 106119090 A G 9.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17030997 chr2 106119878 A T 2.98E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs112811927 chr2 106126543 C CTAGTTCTCTCT 3.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17031034 chr2 106126543 C G,T 3.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs71823776 chr2 106126543 C CTAGTTCTCTCT 3.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs939008 chr2 106133488 G A 7.77E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10203692 chr2 106155992 C T 3.23E-04 Multiple complex diseases / / 17554300 rs2122961 chr2 106157527 C A 9.55E-04 Multiple complex diseases / / 17554300 rs2889452 chr2 106158126 C G 4.91E-04 Multiple complex diseases / / 17554300 rs6726692 chr2 106160606 A G 1.12E-04 Asthma / / 23181788 rs6742097 chr2 106166317 G A 7.84E-05 Blood Pressure / / pha003050 rs17031236 chr2 106172001 T G 3.10E-04 Type 2 diabetes / / 21874001 rs10496397 chr2 106184438 C T 6.17E-04 Parkinson's disease / / 17052657 rs7601184 chr2 106216861 C A 3.81E-05 Hypertension LOC285000 intron pha003042 rs12474808 chr2 106237751 G A 7.20E-05 Lung adenocarcinoma / / 22797724 rs7597575 chr2 106238347 G A 3.53E-04 Multiple complex diseases / / 17554300 rs6543324 chr2 106244673 G A 9.07E-04 Alzheimer's disease / / 17998437 rs4851821 chr2 106260780 C T 3.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs4851823 chr2 106261304 T C 3.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs4851080 chr2 106262152 C G 8.70E-04 Multiple complex diseases / / 17554300 rs4851080 chr2 106262152 C G 3.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs7572653 chr2 106263078 C T 4.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs10164674 chr2 106264353 C G 1.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs369074322 chr2 106264353 CG C 1.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs10180552 chr2 106265647 A T 4.19E-05 Multiple complex diseases / / 17554300 rs10180552 chr2 106265647 A T 1.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs4851824 chr2 106266677 A G 1.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs4851825 chr2 106266695 T C 8.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs4851826 chr2 106267064 A G 7.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs7581613 chr2 106267227 A G 9.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs12477950 chr2 106273727 A T 1.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs7563743 chr2 106287156 A C 1.52E-05 Psoriasis / / 20953190 rs12478876 chr2 106288854 C G 1.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs10179463 chr2 106294462 T C 2.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs1823645 chr2 106301594 G A 3.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs1037381 chr2 106303243 A G 5.57E-04 Multiple complex diseases / / 17554300 rs1037381 chr2 106303243 A G 5.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs1037381 chr2 106303243 A G 0.0000399 Aging / / 22445811 rs11884955 chr2 106310212 T C 5.96E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs13019064 chr2 106311180 C T 1.32E-04 Multiple complex diseases / / 17554300 rs13429323 chr2 106343072 T C 1.92E-04 Height / / 17255346 rs6752668 chr2 106347216 T C 1.03E-04 Height / / 17255346 rs6739767 chr2 106348958 C G 9.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs6743613 chr2 106349806 C T 4.47E-05 Suicide attempts in bipolar disorder / / 21423239 rs6746639 chr2 106350031 C T 1.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs997522 chr2 106366232 G A 4.10E-05 Inflammatory demyelinating disease NCK2 intron 19850125 rs997522 chr2 106366232 G A 7.12E-05 Calcium levels NCK2 intron pha003085 rs12987484 chr2 106367561 T C 1.17E-04 Arthritis (juvenile idiopathic) NCK2 intron 22354554 rs11687998 chr2 106384133 C T 7.35E-04 Type 2 diabetes NCK2 intron 17463246 rs1367404 chr2 106386865 G T 3.66E-04 Alzheimer's disease NCK2 intron 17998437 rs7589589 chr2 106391154 G C 1.20E-04 Alzheimer's disease NCK2 intron 17998437 rs7589589 chr2 106391154 G C 8.13E-05 Serum metabolites NCK2 intron 19043545 rs4851864 chr2 106391338 G A 9.24E-04 Multiple complex diseases NCK2 intron 17554300 rs10198057 chr2 106392799 G T 2.08E-04 Alzheimer's disease NCK2 intron 17998437 rs17201484 chr2 106394809 G C 3.04E-04 Alzheimer's disease NCK2 intron 17998437 rs17201484 chr2 106394809 G C 8.95E-05 Serum metabolites NCK2 intron 19043545 rs1897169 chr2 106397624 A G 3.97E-04 Alzheimer's disease NCK2 intron 17998437 rs6732799 chr2 106401954 C T 4.18E-05 Prion diseases NCK2 intron 22210626 rs7588033 chr2 106408233 C T 3.79E-05 Prion diseases NCK2 intron 22210626 rs4851090 chr2 106411386 T C 9.36E-05 Multiple complex diseases NCK2 intron 17554300 rs17031793 chr2 106413031 C T 5.22E-04 Suicide attempts in bipolar disorder NCK2 intron 21423239 rs2047699 chr2 106413077 C T 5.34E-05 Prion diseases NCK2 intron 22210626 rs6719896 chr2 106428404 C G 3.42E-04 Alzheimer's disease NCK2 intron 17998437 rs1549769 chr2 106429319 A C 2.87E-04 Multiple complex diseases NCK2 intron 17554300 rs7589790 chr2 106433909 C G 3.53E-04 Type 2 diabetes NCK2 intron 17463246 rs7589790 chr2 106433909 C G 1.54E-04 Alzheimer's disease NCK2 intron 17998437 rs12995333 chr2 106436366 G T 4.43E-04 Type 2 diabetes NCK2 intron 17463246 rs12995333 chr2 106436366 G T 9.90E-05 Alzheimer's disease NCK2 intron 17998437 rs6725519 chr2 106445209 C T 2.42E-04 Alzheimer's disease NCK2 intron 17998437 rs3954042 chr2 106453347 T C 3.97E-04 Multiple complex diseases NCK2 intron 17554300 rs7589561 chr2 106454085 C T 2.02E-05 Osteoarthritis (knee and hip) NCK2 intron 21177295 rs7589561 chr2 106454085 C T 5.53E-04 Osteoarthritis (knee and hip) NCK2 intron 21177295 rs4851877 chr2 106455387 A C 3.26E-04 Multiple complex diseases NCK2 intron 17554300 rs4851095 chr2 106455549 T C 7.10E-04 Multiple complex diseases NCK2 intron 17554300 rs2377339 chr2 106457291 A G 2.24E-04 Fibrinogen NCK2 intron 17255346 rs2377339 chr2 106457291 A G 1.00E-11 Addiction NCK2 intron 23533358 rs2377339 chr2 106457291 A G 2.00E-08 Addiction NCK2 intron 23533358 rs6543344 chr2 106467506 C G 8.26E-04 Multiple complex diseases NCK2 intron 17554300 rs6543344 chr2 106467506 C G 0.00006658 Sarcoidosis NCK2 intron 22952805 rs3754807 chr2 106469333 A T 8.89E-05 Serum metabolites NCK2 intron 19043545 rs3769504 chr2 106477092 A G 9.03E-04 Type 2 diabetes NCK2 intron 17463246 rs3769503 chr2 106477285 T C 9.93E-04 Multiple complex diseases NCK2 intron 17554300 rs6704555 chr2 106477781 G A 1.74E-04 Multiple complex diseases NCK2 intron 17554300 rs9646946 chr2 106477946 A G 4.84E-04 Multiple complex diseases NCK2 intron 17554300 rs3769501 chr2 106479806 C G 5.46E-06 Kawasaki disease NCK2 intron 21221998 rs3769497 chr2 106490021 C A 7.01E-04 Multiple complex diseases NCK2 intron 17554300 rs3754801 chr2 106493191 G A 6.12E-05 Serum metabolites NCK2 intron 19043545 rs6729522 chr2 106527661 A T 3.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs1477515 chr2 106530293 T C 3.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs1477516 chr2 106533298 G A 7.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs13428604 chr2 106533687 T C 7.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs1477517 chr2 106533914 C G 5.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs17031993 chr2 106535038 G A 5.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs4281921 chr2 106535966 C T 5.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs11895604 chr2 106536134 G A 4.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs1465491 chr2 106549469 A G 1.20E-05 Urinary metabolites / / 21572414 rs10490696 chr2 106551322 T C 8.21E-05 Blood Pressure / / pha003043 rs17665024 chr2 106555857 A G 5.24E-05 Cognitive impairment induced by topiramate / / 22091778 rs10490697 chr2 106558545 A G 1.47E-04 Hemoglobin concentration / / 20534544 rs11892293 chr2 106567399 A G 8.68E-04 Alzheimer's disease / / 22005930 rs7605392 chr2 106584728 T C 6.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7609295 chr2 106586012 A G 1.82E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1111513 chr2 106587548 T C 8.23E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1109164 chr2 106605186 G A 3.20E-04 Hemoglobin concentration / / 20534544 rs1109164 chr2 106605186 G A 9.11E-05 Depression (quantitative trait) / / 20800221 rs1669539 chr2 106615274 T C 1.00E-06 Systolic blood pressure in sickle cell anemia / / 24058526 rs4851109 chr2 106617615 G C 5.45E-05 Sudden cardiac arrest / / 21658281 rs17032192 chr2 106644772 T G 1.09E-06 Obesity and osteoporosis / / 19714249 rs1869058 chr2 106670527 G A 7.65E-05 Multiple complex diseases / / 17554300 rs17032247 chr2 106674925 G A 3.98E-05 Gaucher disease severity / / 22388998 rs17271098 chr2 106692818 G A 4.16E-04 Smoking initiation C2orf40 intron 24665060 rs7573766 chr2 106705717 C A 9.50E-04 Multiple complex diseases / / 17554300 rs10206195 chr2 106714038 T C 9.10E-04 Alcohol dependence UXS1 intron 21314694 rs17032398 chr2 106722953 T C 6.90E-06 Urinary metabolites UXS1 intron 21572414 rs17213510 chr2 106742778 T C 3.75E-04 Alzheimer's disease (late onset) UXS1 intron 21379329 rs17032647 chr2 106822764 C T 2.45E-04 Stroke / / pha002887 rs11124097 chr2 106878601 A G 3.73E-05 Alzheimer's disease (late onset) / / 21379329 rs11694824 chr2 106886684 A G 2.78E-04 Alzheimer's disease (late onset) / / 21379329 rs11673736 chr2 106886935 T C 1.55E-04 Smoking initiation / / 24665060 rs7419384 chr2 106887870 A G 3.39E-04 Alzheimer's disease (late onset) / / 21379329 rs6746840 chr2 106932170 T C 3.69E-04 Type 2 diabetes / / 17463246 rs4574118 chr2 106948443 C G 3.99E-04 Type 2 diabetes / / 17463246 rs4574118 chr2 106948443 C G 1.80E-07 Colorectal cancer / / 20610541 rs11677201 chr2 106951208 C T 6.76E-04 Type 2 diabetes / / 17463246 rs4384785 chr2 107121966 G A 2.67E-04 Heart rate / / 23583979 rs12472491 chr2 107189537 A C 4.72E-08 Metabolite levels / / 23281178 rs2035030 chr2 107203992 C T 4.84E-04 Response to alcohol consumption (flushing response) / / 24277619 rs13017273 chr2 107210805 A G 0.0000872 Panic disorder / / 23149450 rs13017273 chr2 107210805 A G 8.72E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs17033012 chr2 107241221 A G 0.000045 Panic disorder / / 23149450 rs17033012 chr2 107241221 A G 4.50E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs13025573 chr2 107243678 G A 2.90E-05 Malaria / / 19465909 rs17033088 chr2 107258436 T G 0.0000814 Panic disorder / / 23149450 rs17033088 chr2 107258436 T G 8.14E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs1006472 chr2 107329516 A C 1.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs1006472 chr2 107329516 A C 4.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs898457 chr2 107339458 A G 1.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs898457 chr2 107339458 A G 5.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs898456 chr2 107339629 G A 1.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs898456 chr2 107339629 G A 5.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs13393451 chr2 107341293 G A 1.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs13393451 chr2 107341293 G A 4.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs13391600 chr2 107343100 T C 1.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs13391600 chr2 107343100 T C 5.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs11124131 chr2 107349612 A C 1.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs11124131 chr2 107349612 A C 4.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs2377685 chr2 107387872 T G 3.02E-05 Suicide attempts in bipolar disorder / / 21041247 rs1349065 chr2 107388308 C G 3.11E-05 Suicide attempts in bipolar disorder / / 21041247 rs1349065 chr2 107388308 C G 7.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs11894298 chr2 107388503 T C 3.20E-05 Suicide attempts in bipolar disorder / / 21041247 rs11894451 chr2 107388822 T C 3.29E-05 Suicide attempts in bipolar disorder / / 21041247 rs11887836 chr2 107388889 C G 3.39E-05 Suicide attempts in bipolar disorder / / 21041247 rs11888992 chr2 107389053 C G 3.44E-05 Suicide attempts in bipolar disorder / / 21041247 rs6747891 chr2 107389951 G A 3.46E-05 Suicide attempts in bipolar disorder / / 21041247 rs1448103 chr2 107391080 G A 3.52E-05 Suicide attempts in bipolar disorder / / 21041247 rs17033251 chr2 107393541 T C 3.78E-05 Suicide attempts in bipolar disorder / / 21041247 rs1448105 chr2 107395235 T A 3.86E-05 Suicide attempts in bipolar disorder / / 21041247 rs728241 chr2 107398133 G A 4.84E-05 Suicide attempts in bipolar disorder / / 21041247 rs728239 chr2 107398255 T C 4.88E-05 Suicide attempts in bipolar disorder / / 21041247 rs728240 chr2 107398456 G T 5.23E-05 Suicide attempts in bipolar disorder / / 21041247 rs10202530 chr2 107420011 G T 6.41E-04 Type 2 diabetes ST6GAL2 UTR-3 17463246 rs10191793 chr2 107425876 A G 6.05E-07 Esophageal cancer (squamous cell) ST6GAL2 intron 22960999 rs7607635 chr2 107446918 A C 6.41E-04 Type 2 diabetes ST6GAL2 intron 17463246 rs6712885 chr2 107448206 T C 1.10E-04 Type 2 diabetes and 6 quantitative traits ST6GAL2 intron 17848626 rs7608410 chr2 107450390 C T 1.17E-04 Type 2 diabetes ST6GAL2 intron 17463246 rs7608410 chr2 107450390 C T 2.34E-05 Gallstones ST6GAL2 intron 17632509 rs2034357 chr2 107454575 G A 7.77E-05 stroke (ischemic) ST6GAL2 intron 17434096 rs2377689 chr2 107465840 C A 1.70E-05 Type 2 diabetes ST6GAL2 intron 17903298 rs2377690 chr2 107466177 G A 9.97E-04 Type 2 diabetes ST6GAL2 intron 17463246 rs1448113 chr2 107467932 A G 9.40E-04 Type 2 diabetes and 6 quantitative traits ST6GAL2 intron 17848626 rs11679344 chr2 107477619 G A 7.58E-04 Suicide attempts in bipolar disorder ST6GAL2 intron 21423239 rs12712262 chr2 107516533 C A 8.02E-04 Type 2 diabetes / / 17463246 rs2012505 chr2 107517229 C T 8.91E-04 Coronary heart disease / / 21971053 rs11684876 chr2 107581130 G A 2.38E-04 Smoking initiation / / 24665060 rs724841 chr2 107620242 G A 5.96E-06 Alopecia areata / / 22027810 rs2971635 chr2 107636446 A C 6.29E-04 Myocardial Infarction / / pha002873 rs2949214 chr2 107644525 T G 4.82E-04 Myocardial Infarction / / pha002873 rs1357692 chr2 107678488 G T 9.00E-06 Alzheimer's disease / / 22832961 rs1357694 chr2 107678669 A G 1.33E-05 Alzheimer's disease / / 22832961 rs1916920 chr2 107678998 G C 1.79E-05 Alzheimer's disease / / 22832961 rs2030674 chr2 107679236 G A 2.31E-05 Alzheimer's disease / / 22832961 rs1916921 chr2 107679295 G A 2.90E-05 Alzheimer's disease / / 22832961 rs2030675 chr2 107679474 C T 4.15E-05 Alzheimer's disease / / 22832961 rs2030676 chr2 107679548 G T 7.09E-04 Acute lung injury / / 22295056 rs2030677 chr2 107679740 G A 4.16E-05 Alzheimer's disease / / 22832961 rs2971646 chr2 107680611 C T 9.19E-05 Coronary heart disease / / pha003031 rs2971892 chr2 107684059 G A 4.16E-05 Alzheimer's disease / / 22832961 rs2971650 chr2 107684415 A G 4.18E-05 Alzheimer's disease / / 22832961 rs2971894 chr2 107684957 T C 4.32E-05 Alzheimer's disease / / 22832961 rs1524288 chr2 107685863 T G 4.34E-05 Alzheimer's disease / / 22832961 rs1029864 chr2 107784393 T C 1.20E-04 Myasthenia gravis / / 23055271 rs1990410 chr2 107786595 G T 1.40E-05 Urinary metabolites / / 21572414 rs2079917 chr2 107790491 C T 3.60E-04 Myasthenia gravis / / 23055271 rs17033948 chr2 107795589 G A 5.82E-04 Multiple complex diseases / / 17554300 rs2889744 chr2 107796734 T C 6.39E-05 Intelligence / / 21826061 rs6708562 chr2 107800965 G A 1.47E-04 Myocardial Infarction / / pha002883 rs2079918 chr2 107804217 T G 4.80E-05 Myocardial Infarction / / pha002883 rs2191586 chr2 107805650 A T 1.44E-04 Progressive supranuclear palsy / / 21685912 rs3922303 chr2 107812973 C T 3.75E-04 Myocardial Infarction / / pha002883 rs7584779 chr2 107836502 A G 6.80E-06 Urinary metabolites / / 21572414 rs4676115 chr2 107873999 T C 2.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs9308906 chr2 107877680 C G 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs6707325 chr2 107878129 T C 1.80E-05 Urinary metabolites / / 21572414 rs6713136 chr2 107880580 A T 2.50E-05 Urinary metabolites / / 21572414 rs10174248 chr2 107880858 T G 2.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs6543500 chr2 107882272 G A 2.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs7587131 chr2 107883105 G A 3.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs2109591 chr2 107887371 T C 3.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs12712283 chr2 107890207 G A 3.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs2191581 chr2 107896351 A G 3.50E-05 Intelligence / / 21826061 rs7578096 chr2 107898194 C G 5.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs6747330 chr2 107908592 C T 4.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs1990406 chr2 107909895 T C 2.00E-05 Urinary metabolites / / 21572414 rs4133137 chr2 107919607 G T 4.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs7597997 chr2 107921929 G T 2.00E-05 Urinary metabolites / / 21572414 rs266177 chr2 108051515 T C 8.77E-04 Alzheimer's disease / / 17998437 rs266153 chr2 108108336 A G 8.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs962954 chr2 108207340 G C 2.40E-04 Acute lung injury / / 22295056 rs10174350 chr2 108212733 A T 1.99E-04 Acute lung injury / / 22295056 rs17034491 chr2 108215198 C T 1.95E-04 Acute lung injury / / 22295056 rs13394586 chr2 108218010 A C 3.55E-04 Acute lung injury / / 22295056 rs1516208 chr2 108223574 C T 3.55E-04 Acute lung injury / / 22295056 rs973012 chr2 108223896 C T 3.51E-04 Acute lung injury / / 22295056 rs13430109 chr2 108226258 C A 3.51E-04 Acute lung injury / / 22295056 rs1516212 chr2 108230222 T C 4.26E-04 Acute lung injury / / 22295056 rs12476210 chr2 108234761 G A 4.26E-04 Acute lung injury / / 22295056 rs13404416 chr2 108236884 A T 4.26E-04 Acute lung injury / / 22295056 rs13392942 chr2 108240403 C T 4.26E-04 Acute lung injury / / 22295056 rs10187339 chr2 108240740 T C 4.26E-04 Acute lung injury / / 22295056 rs1400119 chr2 108246961 C A 4.26E-04 Acute lung injury / / 22295056 rs4676143 chr2 108247679 A G 4.26E-04 Acute lung injury / / 22295056 rs10199917 chr2 108252979 G C,T 6.50E-04 Acute lung injury / / 22295056 rs7584635 chr2 108255727 C A 1.53E-04 Acute lung injury / / 22295056 rs7587729 chr2 108255977 G A 1.53E-04 Acute lung injury / / 22295056 rs12162388 chr2 108257811 G A 1.53E-04 Acute lung injury / / 22295056 rs7560475 chr2 108259662 T C 1.53E-04 Acute lung injury / / 22295056 rs17021589 chr2 108266984 A C 1.49E-04 Acute lung injury / / 22295056 rs11890899 chr2 108268872 T C 1.58E-04 Acute lung injury / / 22295056 rs10204774 chr2 108272629 A G 3.43E-04 Acute lung injury / / 22295056 rs1158610 chr2 108273375 T C 4.59E-04 Acute lung injury / / 22295056 rs13403714 chr2 108273515 C T 4.59E-04 Acute lung injury / / 22295056 rs4586601 chr2 108276459 C A 4.64E-04 Acute lung injury / / 22295056 rs13409811 chr2 108280266 G A 3.85E-04 Acute lung injury / / 22295056 rs11123669 chr2 108286602 T C 4.98E-04 Acute lung injury / / 22295056 rs10205519 chr2 108290016 G A 5.43E-04 Acute lung injury / / 22295056 rs1516200 chr2 108303380 C T 7.84E-06 Multiple complex diseases / / 17554300 rs832182 chr2 108326760 G A 3.11E-05 Bipolar disorder / / 19488044 rs832182 chr2 108326760 G A 3.68E-05 Bipolar disorder / / 22925353 rs700844 chr2 108327724 A G 4.39E-05 Bipolar disorder / / 19488044 rs700844 chr2 108327724 A G 5.88E-05 Bipolar disorder / / 22925353 rs831983 chr2 108379520 C A 5.43E-04 Myocardial Infarction / / pha002883 rs328026 chr2 108380531 C T 5.60E-06 Alcohol and nictotine co-dependence / / 22488850 rs1583938 chr2 108411119 A C 8.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs6542736 chr2 108415702 G A 8.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs6542736 chr2 108415702 G A 0.00000731 Preeclampsia / / 22432041 rs13414755 chr2 108417526 C A 8.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs13415031 chr2 108417601 G C 7.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs17021776 chr2 108424627 T C 2.75E-04 Suicide attempts in bipolar disorder / / 21041247 rs6734993 chr2 108556518 C T 8.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs7594860 chr2 108564754 C T 7.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs13020302 chr2 108599710 T C 1.60E-05 Urinary metabolites / / 21572414 rs3806536 chr2 108602755 T C 3.44E-04 Alzheimer's disease (late onset) / / 21379329 rs333238 chr2 108603628 A G 4.20E-04 Suicide attempts in bipolar disorder SLC5A7 intron 21041247 rs333236 chr2 108603967 G A 4.24E-04 Suicide attempts in bipolar disorder SLC5A7 intron 21041247 rs333236 chr2 108603967 G A 6.47E-06 Asthma SLC5A7 intron 22561531 rs333235 chr2 108607100 C T 4.47E-04 Suicide attempts in bipolar disorder SLC5A7 intron 21041247 rs333234 chr2 108607394 T C 2.49E-04 Alzheimer's disease (late onset) SLC5A7 intron 21379329 rs2450280 chr2 108608018 T C 4.67E-04 Suicide attempts in bipolar disorder SLC5A7 intron 21041247 rs333217 chr2 108610264 A G 8.12E-04 Suicide attempts in bipolar disorder SLC5A7 intron 21041247 rs10496417 chr2 108631729 A G 4.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1467280 chr2 108685905 G T 9.12E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1486179 chr2 108739564 G T 8.00E-05 Tunica Media / / pha003034 rs750523 chr2 108746221 T C 1.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs17035697 chr2 108761525 G A 8.60E-05 Cognitive test performance / / 20125193 rs11677324 chr2 108771042 G A 2.08E-05 Cognitive performance / / 19734545 rs1563119 chr2 108785867 C T 6.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs855044 chr2 108816273 T C 3.39E-04 Obesity (extreme) / / 21935397 rs2219078 chr2 108875198 G A 1.20E-07 Longevity,exceptional SULT1C3 missense 20595579 rs4638749 chr2 108884042 G A 6.00E-07 Blood pressure / / 24954895 rs2100405 chr2 108891096 C T 8.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4149425 chr2 108917596 T C 4.83E-04 Response to alcohol consumption (flushing response) SULT1C2 intron 24277619 rs1879494 chr2 108938515 C A 1.25E-06 Hemoglobin concentration / / 20534544 rs12477830 chr2 108938735 A G 4.33E-05 Hemoglobin concentration / / 20534544 rs12477830 chr2 108938735 A G 7.00E-06 Asthma / / 21790008 rs7598552 chr2 108940070 T C 2.70E-06 Hemoglobin concentration SULT1C2P1 intron 20534544 rs12476238 chr2 108940336 T C 1.47E-04 Hemoglobin concentration SULT1C2P1 intron 20534544 rs10173535 chr2 108965694 G T 3.46E-04 Smoking cessation SULT1C2P1 intron 24665060 rs10167564 chr2 108988625 G A 5.48E-05 Hemoglobin concentration / / 20534544 rs1402467 chr2 108994808 C G 1 Drug response to Docetaxel SULT1C4 missense 20038957 rs1402467 chr2 108994808 C G 1 Drug response to Thalidomide SULT1C4 missense 20038957 rs4149432 chr2 108995325 T G 5.48E-05 Hemoglobin concentration SULT1C4 intron 20534544 rs4149436 chr2 108999786 T C 5.48E-05 Hemoglobin concentration SULT1C4 intron 20534544 rs4149437 chr2 109001623 T C 2.47E-04 Hemoglobin concentration SULT1C4 intron 20534544 rs4149438 chr2 109002048 C A 5.48E-05 Hemoglobin concentration SULT1C4 intron 20534544 rs13390901 chr2 109025011 G T 4.45E-04 Hemoglobin concentration / / 20534544 rs6755756 chr2 109028656 A G 4.45E-04 Hemoglobin concentration / / 20534544 rs4395219 chr2 109034995 C T 3.89E-04 Smoking cessation / / 24665060 rs6708372 chr2 109053818 C T 7.27E-04 Smoking cessation / / 24665060 rs7601939 chr2 109080914 G T 6.38E-04 Smoking cessation GCC2 intron 24665060 rs2577620 chr2 109089952 A G 5.91E-04 Smoking cessation GCC2 intron 24665060 rs2577594 chr2 109105194 A G 9.96E-04 Multiple complex diseases GCC2 intron 17554300 rs6754683 chr2 109156275 G A 8.84E-06 Osteoarthritis LIMS1 intron 22763110 rs826686 chr2 109239407 C T 5.18E-04 Multiple complex diseases LIMS1 intron 17554300 rs12478500 chr2 109414103 T C 1.21E-04 Hemoglobin concentration CCDC138 intron 20534544 rs1073893 chr2 109489365 A G 2.30E-04 Type 2 diabetes and 6 quantitative traits CCDC138 intron 17848626 rs765089 chr2 109498997 T C 6.40E-05 Glaucoma (primary open-angle) / / 20835238 rs1478515 chr2 109500929 C T 4.76E-04 Hemoglobin concentration / / 20534544 rs1478515 chr2 109500929 C T 5.40E-05 Glaucoma (primary open-angle) / / 20835238 rs1478516 chr2 109501066 A C 5.30E-05 Glaucoma (primary open-angle) / / 20835238 rs1478516 chr2 109501066 A C 2.11E-04 Glaucoma (primary open-angle) / / 22419738 rs260633 chr2 109525530 C T 2.50E-05 Colorectal cancer EDAR intron 21242260 rs6732336 chr2 109541853 C T 5.16E-04 Multiple complex diseases EDAR intron 17554300 rs260705 chr2 109571440 G A 8.04E-06 Arthritis (juvenile idiopathic) EDAR intron 22354554 rs13427084 chr2 109582678 G A 1.04E-05 Tunica Media EDAR intron pha003038 rs260693 chr2 109582711 C T 3.40E-04 Iron levels EDAR intron pha002876 rs10496426 chr2 109584780 G C 3.31E-04 Multiple complex diseases EDAR intron 17554300 rs10174201 chr2 109585248 A T 5.19E-05 IgE levels EDAR intron 22075330 rs11691107 chr2 109586437 C T 5.08E-05 IgE levels EDAR intron 22075330 rs11694335 chr2 109588356 C T 5.00E-05 IgE levels EDAR intron 22075330 rs260695 chr2 109588375 G C 4.58E-05 IgE levels EDAR intron 22075330 rs11676729 chr2 109591409 G A 4.43E-05 IgE levels EDAR intron 22075330 rs183780 chr2 109595182 T C 6.30E-07 Primary tooth development (number of teeth) EDAR intron 23704328 rs11690981 chr2 109616111 G A 3.52E-05 IgE levels / / 22075330 rs260617 chr2 109623949 A G 7.38E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4676049 chr2 109635257 C T 4.00E-08 Alzheimer's disease (late onset) / / 20885792 rs17034806 chr2 109635905 A G 5.14E-08 Alzheimer's disease (late onset) / / 20885792 rs13428296 chr2 109649394 T C 5.71E-05 Response to methylphenidate treatment / / 21130132 rs375099 chr2 109660277 G A 4.62E-07 Common variable immunodeficiency / / 21497890 rs4676060 chr2 109662043 C T 2.02E-04 Multiple complex diseases / / 17554300 rs6737482 chr2 109669494 T C 1.34E-05 Coronary heart disease / / pha003035 rs417999 chr2 109678210 A G 4.62E-04 Prostate cancer mortality / / 20978177 rs260659 chr2 109682341 C T 6.67E-04 Prostate cancer mortality / / 20978177 rs260654 chr2 109685399 G T 8.68E-04 Prostate cancer mortality / / 20978177 rs7565363 chr2 109755441 A G 1.12E-04 Sarcoidosis / / 19165924 rs7561185 chr2 109782233 T C 3.80E-04 Major depressive disorder / / 21042317 rs4676070 chr2 109788623 C T 5.02E-04 Multiple complex diseases / / 17554300 rs4676070 chr2 109788623 C T 3.40E-04 Major depressive disorder / / 21042317 rs4676258 chr2 109798726 C T 1.70E-04 Major depressive disorder / / 21042317 rs11893469 chr2 109807143 C T 4.70E-04 Major depressive disorder / / 21042317 rs11893469 chr2 109807143 C T 2.34E-04 Tourette syndrome / / 22889924 rs1430306 chr2 109807885 G A 3.80E-04 Major depressive disorder / / 21042317 rs10184308 chr2 109824220 A G 9.50E-06 Urinary metabolites / / 21572414 rs11893925 chr2 109825067 A G 1.80E-05 Urinary metabolites / / 21572414 rs12328666 chr2 109825516 A G 2.70E-05 Urinary metabolites / / 21572414 rs752272 chr2 109830103 T G 4.80E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7355687 chr2 109833540 T C 1.10E-05 Urinary metabolites / / 21572414 rs10204703 chr2 109848994 T C 6.49E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6760953 chr2 109856486 T C 2.93E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10177036 chr2 109869452 G T 2.00E-05 Urinary metabolites / / 21572414 rs12474431 chr2 109928591 A C 4.71E-04 Multiple complex diseases / / 17554300 rs11123739 chr2 109934924 C T 6.10E-04 Type 2 diabetes / / 17463246 rs6707697 chr2 109940324 T G 2.29E-07 Information processing speed / / 21130836 rs4676274 chr2 109948720 C T 7.27E-04 Alzheimer's disease / / 17998437 rs4676275 chr2 109953626 A T 2.10E-05 Urinary metabolites / / 21572414 rs12614506 chr2 109957204 C T 8.78E-04 Multiple complex diseases / / 17554300 rs4676283 chr2 109996227 C T 4.92E-05 Coronary heart disease / / pha003030 rs6737952 chr2 109997436 G A 4.76E-05 Coronary heart disease / / pha003030 rs6745464 chr2 110029298 C T 3.50E-05 Personality dimensions / / 18957941 rs10202141 chr2 110030964 C A 3.40E-05 Personality dimensions / / 18957941 rs9330310 chr2 110265558 G T 1.58E-05 Lymphocyte counts / / 22286170 rs9330311 chr2 110273380 C T 7.36E-06 Sleep duration / / 22105623 rs11692886 chr2 110274179 C T 0.000105 Schizophrenia / / 23637625 rs9711994 chr2 110278908 C T 1.93E-05 Prostate cancer / / 22923026 rs9330321 chr2 110290160 T C 7.78E-04 Schizophrenia / / 19197363 rs11541143 chr2 110302464 G A 8.13E-05 Schizophrenia (cytomegalovirus infection interaction) SEPT10 intron 23358160 rs4953788 chr2 110336043 A C 1.77E-04 Schizophrenia SEPT10 intron 19197363 rs892464 chr2 110343913 G T 6.24E-04 Schizophrenia SEPT10 intron 19197363 rs7601026 chr2 110439949 G A 2.01E-04 Acute lung injury / / 22295056 rs13384147 chr2 110448229 G A 3.48E-05 Height / / pha003011 rs17842650 chr2 110872851 G A 7.64E-04 Multiple complex diseases MALL intron 17554300 rs17463266 chr2 110958329 C T 9.06E-04 Amyotrophic lateral sclerosis (sporadic) NPHP1 intron 24529757 rs145479679 chr2 110959008 T G 0.000000084 Breast cancer(er negative) NPHP1 missense 23555315 rs7572507 chr2 111490731 C T 9.38E-04 Alcohol consumption (maxi-drinks) ACOXL intron 24277619 rs4290670 chr2 111543487 C T 2.33E-05 Triglycerides ACOXL intron pha003080 rs17464100 chr2 111567781 C T 2.00E-05 Urinary metabolites ACOXL intron 21572414 rs2612699 chr2 111586214 C T 7.03E-05 Response to cytidine analogues (gemcitabine) ACOXL intron 24483146 rs4494791 chr2 111587016 T C 6.83E-04 Amyotrophic Lateral Sclerosis ACOXL intron 17827064 rs2175824 chr2 111592407 G T 4.70E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs13417566 chr2 111592606 C A 4.72E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs12463442 chr2 111595489 A G 5.57E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs12463526 chr2 111595738 A G 5.95E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs1533295 chr2 111597991 A G 3.03E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs10210955 chr2 111599282 G C 2.20E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs4849121 chr2 111599706 G A 6.41E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs4849121 chr2 111599706 G A 4.00E-07 IgA nephropathy ACOXL intron 22197929 rs10180446 chr2 111601942 C G 3.37E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs1554006 chr2 111604113 A G 2.20E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs1554006 chr2 111604113 A G 8.63E-05 Response to cytidine analogues (gemcitabine) ACOXL intron 24483146 rs1554006 chr2 111604113 A G 8.76E-04 Response to cytadine analogues (cytosine arabinoside) ACOXL intron 24483146 rs13019266 chr2 111604642 T C 3.41E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs13019266 chr2 111604642 T C 2.41E-04 Response to cytidine analogues (gemcitabine) ACOXL intron 24483146 rs9917154 chr2 111606591 G C 3.50E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs7576541 chr2 111607401 C T 3.57E-04 Suicide attempts in bipolar disorder ACOXL intron 21041247 rs6732565 chr2 111607832 A G 3.00E-08 Rheumatoid arthritis ACOXL intron 24390342 rs6732565 chr2 111607832 A G 9.00E-09 Rheumatoid arthritis ACOXL intron 24390342 rs12151613 chr2 111609385 C T 7.20E-04 Response to taxane treatment (placlitaxel) ACOXL intron 23006423 rs10197140 chr2 111609943 T C 5.03E-04 Response to taxane treatment (placlitaxel) ACOXL intron 23006423 rs17465162 chr2 111613145 T C 6.41E-04 Response to taxane treatment (placlitaxel) ACOXL intron 23006423 rs4849134 chr2 111615015 A G 2.32E-04 Response to cytidine analogues (gemcitabine) ACOXL intron 24483146 rs4849135 chr2 111615079 T G 3.03E-04 Response to cytidine analogues (gemcitabine) ACOXL intron 24483146 rs13401811 chr2 111616104 G A 2.00E-18 Chronic lymphocytic leukemia ACOXL intron 23770605 rs1533298 chr2 111616304 C T 2.41E-04 Response to cytidine analogues (gemcitabine) ACOXL intron 24483146 rs1002016 chr2 111616912 G A 7.54E-04 Suicide attempts in bipolar disorder ACOXL intron 21423239 rs7596265 chr2 111617015 A G 4.30E-06 Urinary metabolites ACOXL intron 21572414 rs880506 chr2 111627300 G A 2.67E-04 Response to taxane treatment (placlitaxel) ACOXL intron 23006423 rs1872062 chr2 111630489 G T 4.92E-04 Response to taxane treatment (placlitaxel) ACOXL intron 23006423 rs6542190 chr2 111638063 T G 8.96E-04 Response to taxane treatment (placlitaxel) ACOXL intron 23006423 rs4849162 chr2 111639235 T C 8.56E-07 Red blood cell traits ACOXL intron 23222517 rs4849165 chr2 111639589 T C 8.82E-07 Red blood cell traits ACOXL intron 23222517 rs9308691 chr2 111641138 T C 2.67E-04 Response to taxane treatment (placlitaxel) ACOXL intron 23006423 rs10188079 chr2 111644475 C T 2.69E-04 Response to taxane treatment (placlitaxel) ACOXL intron 23006423 rs12622400 chr2 111657888 G T 3.90E-05 Pulmonary function ACOXL intron 20010835 rs323640 chr2 111659098 G C 7.27E-05 Multiple complex diseases ACOXL intron 17554300 rs12612914 chr2 111666929 G A 6.60E-05 Pulmonary function ACOXL intron 20010835 rs4849256 chr2 111685899 G T 5.03E-05 Pulmonary function ACOXL intron 20010835 rs3761708 chr2 111691530 G C 2.25E-05 Pulmonary function ACOXL intron 20010835 rs3789119 chr2 111707405 C T 4.00E-06 Economic and political preferences (immigration/crime) ACOXL intron 22566634 rs17041661 chr2 111721964 A G 5.86E-04 Type 2 diabetes ACOXL intron 17463246 rs4849303 chr2 111728482 C T 1.00E-06 Colorectal cancer (diet interaction) ACOXL intron 24743840 rs11123271 chr2 111740221 A G 6.82E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) ACOXL intron 23648065 rs6542248 chr2 111753228 C A 2.32E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) ACOXL intron 23648065 rs1483533 chr2 111757918 T C 7.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ACOXL intron 20877124 rs1384795 chr2 111771647 A G 6.50E-04 Schizophrenia ACOXL intron 19197363 rs1384795 chr2 111771647 A G 7.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ACOXL intron 20877124 rs1561476 chr2 111787027 C T 3.95E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) ACOXL intron 23648065 rs10194898 chr2 111792302 C A 6.96E-04 Aortic root size ACOXL intron 21223598 rs11123312 chr2 111796039 G A 1.98E-05 Blood pressure ACOXL intron 24001895 rs17549227 chr2 111796195 T C 1.06E-05 Brain structure ACOXL intron 22504417 rs17549227 chr2 111796195 T C 8.84E-05 Hematocrit ACOXL intron pha003097 rs6706577 chr2 111796833 A G 3.00E-05 Type 1 diabetes ACOXL intron 18978792 rs6706577 chr2 111796833 A G 8.50E-05 Serum metabolites ACOXL intron 19043545 rs17483466 chr2 111797458 A G 2.00E-10 Chronic lymphocytic leukemia ACOXL intron 18758461 rs17483466 chr2 111797458 A G 2.00E-10 Nasopharyngeal carcinoma ACOXL intron 20512145 rs17483466 chr2 111797458 A G 1.31E-05 Brain structure ACOXL intron 22504417 rs17483466 chr2 111797458 A G 5.00E-09 Chronic lymphocytic leukemia ACOXL intron 22700719 rs17483466 chr2 111797458 A G 4.96E-09 Erectile dysfunction ACOXL intron 22704111 rs17483466 chr2 111797458 A G 4.00E-17 Chronic lymphocytic leukemia ACOXL intron 23770605 rs17483466 chr2 111797458 A G 8.39E-05 Hematocrit ACOXL intron pha003097 rs3789080 chr2 111797531 C T 4.00E-06 Prostate cancer (gene x gene interaction) ACOXL intron 22219177 rs754352 chr2 111797920 A G 1.40E-05 Brain structure ACOXL intron 22504417 rs752834 chr2 111798658 G A 1.05E-05 Brain structure ACOXL intron 22504417 rs3827538 chr2 111807303 T C 5.30E-05 Oral cancers (chewing tobacco related) ACOXL intron 22503698 rs10187034 chr2 111812617 T C 1.76E-04 Multiple complex diseases ACOXL intron 17554300 rs875063 chr2 111813085 A C 9.68E-07 Red blood cell traits ACOXL intron 23222517 rs4849360 chr2 111815871 C T 1.74E-06 Bilirubin levels,in serum ACOXL intron 19389676 rs7599513 chr2 111823276 A C 3.34E-07 Red blood cell traits ACOXL intron 23222517 rs4849381 chr2 111834381 G C 6.13E-07 Red blood cell traits ACOXL intron 23222517 rs10181102 chr2 111835489 T C 4.68E-04 Smoking cessation ACOXL intron 24665060 rs7578982 chr2 111836538 T C 4.00E-07 White blood cell types ACOXL intron 21738478 rs7578982 chr2 111836538 T C 2.20E-07 Red blood cell traits ACOXL intron 23222517 rs7575878 chr2 111836664 A T 6.25E-08 Red blood cell traits ACOXL intron 23222517 rs1866493 chr2 111847078 A T 3.20E-07 Red blood cell traits ACOXL intron 23222517 rs10207392 chr2 111849659 A G 4.00E-11 Red blood cell traits ACOXL intron 23222517 rs11691193 chr2 111854524 C T 6.35E-04 Smoking cessation ACOXL intron 24665060 rs2018707 chr2 111856773 T C 4.52E-05 Hematocrit ACOXL intron pha003097 rs17040529 chr2 111859774 A G 1.61E-04 Multiple complex diseases ACOXL intron 17554300 rs11681263 chr2 111868010 C A 6.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ACOXL intron 20877124 rs1439287 chr2 111871897 G A 5.00E-15 Chronic lymphocytic leukemia ACOXL intron 24292274 rs2015454 chr2 111872148 A G 2.75E-04 Myocardial Infarction ACOXL intron pha002873 rs1837369 chr2 111874276 C T 6.78E-04 Multiple complex diseases ACOXL intron 17554300 rs10204044 chr2 111895544 C G 1.90E-05 Urinary metabolites BCL2L11 intron 21572414 rs17041869 chr2 111896243 A G 6.07E-05 Coronary heart disease BCL2L11 intron pha003055 rs724710 chr2 111907691 T C 0.000337267 Primary sclerosing cholangitis BCL2L11 cds-synon 23603763 rs724710 chr2 111907691 T C 1.79E-05 Tuberculosis BCL2L11 cds-synon 24057671 rs10169613 chr2 111934977 C T 6.30E-05 Immunoglobulin A / / 20694011 rs17558117 chr2 111940996 T A 5.98E-05 Attention deficit hyperactivity disorder / / 23728934 rs633605 chr2 111945241 C T 8.84E-05 Type 2 diabetes / / 17463246 rs6738028 chr2 111949327 G C 2.00E-08 Dehydroepiandrosterone sulphate levels / / 21533175 rs3747653 chr2 111966540 T C 2.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100505634 intron 20877124 rs3747653 chr2 111966540 T C 5.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100505634 intron 20877124 rs3747653 chr2 111966540 T C 2.30E-04 Stroke (pediatric) LOC100505634 intron 22990015 rs6720394 chr2 111989372 T G 4.00E-08 Primary sclerosing cholangitis LOC100505634 intron 21151127 rs13395957 chr2 112000058 T C 7.45E-05 Body Mass Index LOC100505634 intron pha003022 rs2271404 chr2 112003867 T C 3.00E-07 Atopic dermatitis LOC100505634 intron 23042114 rs17040893 chr2 112068777 C T 5.71E-05 Insulin resistance / / 21901158 rs1900710 chr2 112213244 C T 8.96E-07 Red blood cell traits LOC541471 intron 23222517 rs1900710 chr2 112213244 C T 2.50E-04 Celiac disease LOC541471 intron 23936387 rs12623041 chr2 112263142 C T 3.82E-05 Body Mass Index / / pha003006 rs12623041 chr2 112263142 C T 5.13E-05 Weight / / pha003026 rs17842119 chr2 112277492 T G 8.82E-04 White matter integrity / / 22425255 rs4616487 chr2 112319781 G A 3.88E-05 Cholesterol / / 17255346 rs1448190 chr2 112375963 A C 8.00E-06 Obesity-related traits / / 23251661 rs4848611 chr2 112388229 T C 7.26E-06 Erythrocyte counts / / pha003099 rs7593992 chr2 112395534 T C 8.11E-06 Erythrocyte counts / / pha003099 rs9308627 chr2 112397505 T C 6.45E-05 Erythrocyte counts / / pha003099 rs7596295 chr2 112400597 C T 6.94E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1399665 chr2 112425540 A G 3.24E-05 Self-reported allergy / / 23817569 rs1399665 chr2 112425540 A G 6.66E-04 Alcohol dependence / / 24277619 rs1399665 chr2 112425540 A G 1.41E-04 Smoking initiation / / 24665060 rs6754001 chr2 112428409 A G 0.0000152 Nicotine dependence (smoking) / / 22377092 rs1533380 chr2 112438826 C T 5.82E-05 Self-reported allergy / / 23817569 rs2311554 chr2 112440878 G C 5.29E-05 Self-reported allergy / / 23817569 rs9308631 chr2 112442431 G A 8.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9308631 chr2 112442431 G A 0.00000725 Nicotine dependence (smoking) / / 22377092 rs9308632 chr2 112442561 T C 0.0000107 Nicotine dependence (smoking) / / 22377092 rs9308632 chr2 112442561 T C 5.64E-05 Self-reported allergy / / 23817569 rs9308632 chr2 112442561 T C 9.00E-05 Smoking initiation / / 24665060 rs11122895 chr2 112470155 C T 2.00E-06 Allergic sensitization / / 23817571 rs6541824 chr2 112475467 G A 4.87E-05 Self-reported allergy / / 23817569 rs17040773 chr2 112500035 A C 2.00E-09 Bone mineral density / / 22504420 rs17040773 chr2 112500035 A C 8.53E-05 Tuberculosis / / 24057671 rs4848208 chr2 112624327 G A 3.97E-05 Self-reported allergy A/PC1 intron 23817569 rs4848819 chr2 112624436 C T 5.23E-05 Self-reported allergy A/PC1 intron 23817569 rs6742515 chr2 112625575 T C 0.00000769 Nicotine dependence (smoking) A/PC1 intron 22377092 rs4848209 chr2 112626638 A G 2.85E-05 Self-reported allergy A/PC1 intron 23817569 rs10197222 chr2 112627223 A G 0.00000899 Nicotine dependence (smoking) A/PC1 intron 22377092 rs1516637 chr2 112634339 C T 2.53E-05 Self-reported allergy A/PC1 intron 23817569 rs9653414 chr2 112634737 G A 0.00000799 Nicotine dependence (smoking) A/PC1 intron 22377092 rs9653414 chr2 112634737 G A 2.17E-05 Self-reported allergy A/PC1 intron 23817569 rs10175926 chr2 112636685 G A 5.35E-05 Self-reported allergy A/PC1 intron 23817569 rs3814026 chr2 112641666 T C 0.00016 Nicotine dependence (smoking) A/PC1 UTR-5 22377092 rs13016143 chr2 112649472 C T 3.30E-05 Personality dimensions / / 18957941 rs13016143 chr2 112649472 C T 8.62E-04 Depression (quantitative trait) / / 20800221 rs6736093 chr2 112655242 A G 6.08E-05 Cognitive decline MERTK nearGene-5 23732972 rs17174870 chr2 112665201 C T 1.00E-08 Multiple sclerosis MERTK intron 21833088 rs17174870 chr2 112665201 C T 1.20E-04 Multiple sclerosis MERTK intron 24234648 rs17779482 chr2 112665677 C T 6.31E-05 Cognitive decline MERTK intron 23732972 rs4374383 chr2 112770770 A G 1.00E-09 Hepatitis C induced liver fibrosis MERTK intron 22841784 rs4848967 chr2 112788418 G A 5.04E-05 Type 1 diabetes / / 21980299 rs11684476 chr2 112793981 T C 2.31E-04 Cognitive decline / / 23732972 rs77088208 chr2 112811013 C T 3.27E-06 Tuberculosis / / 22306650 rs4848979 chr2 112816236 G T 8.70E-05 Cognitive decline TMEM87B intron 23732972 rs4632347 chr2 112822084 A G 8.76E-05 Aging (time to event) TMEM87B intron 21782286 rs10165845 chr2 112843244 A G 6.88E-04 Amyotrophic lateral sclerosis (sporadic) TMEM87B intron 24529757 rs10204140 chr2 112859194 T C 5.80E-05 Relative hand skill TMEM87B intron 24068947 rs7591702 chr2 112860934 C G 7.41E-04 Type 2 diabetes TMEM87B intron 17463246 rs9308669 chr2 112864369 C G 6.73E-05 Serum metabolites TMEM87B intron 19043545 rs13431260 chr2 112866597 A T 9.99E-05 Relative hand skill TMEM87B intron 24068947 rs10180018 chr2 112868426 G A 5.39E-05 Heart Rate TMEM87B intron pha003054 rs12711736 chr2 112943070 C T 8.90E-04 Multiple complex diseases FBLN7 intron 17554300 rs10183121 chr2 112953542 A G 2.75E-05 Height / / pha003010 rs2254860 chr2 112995810 A G 7.07E-04 Response to alcohol consumption (flushing response) ZC3H8 intron 24277619 rs12465398 chr2 113009021 T C 7.71E-04 Response to alcohol consumption (flushing response) ZC3H8 intron 24277619 rs12622246 chr2 113021804 G A 7.07E-04 Response to alcohol consumption (flushing response) / / 24277619 rs4352239 chr2 113083283 A C 4.85E-05 Major depressive disorder (broad) ZC3H6 intron 20038947 rs7601200 chr2 113089267 T C 8.07E-04 White matter integrity ZC3H6 cds-synon 22425255 rs4299347 chr2 113098812 T C 5.96E-05 Major depressive disorder (broad) / / 20038947 rs4299347 chr2 113098812 T C 7.94E-04 White matter integrity / / 22425255 rs3811038 chr2 113240183 T C 1.77E-04 Height TTL intron 17255346 rs4849073 chr2 113300658 C G 1.07E-04 Smoking cessation POLR1B intron 18519826 rs4849073 chr2 113300658 C G 8.05E-04 Smoking cessation POLR1B intron 18519826 rs4849074 chr2 113301237 C G 1.83E-04 Smoking cessation POLR1B intron 18519826 rs719667 chr2 113342682 C T 9.67E-05 Body Fat Distribution CHCHD5 intron pha003016 rs3849317 chr2 113373950 C T 8.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17587043 chr2 113382134 C T 4.79E-04 Alzheimer's disease / / 17998437 rs885346 chr2 113415550 G T 9.20E-04 Type 2 diabetes and 6 quantitative traits SLC20A1 intron 17848626 rs6728935 chr2 113442808 T C 9.48E-05 Schizophrenia / / 24253340 rs4849101 chr2 113444837 C T 2.22E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs4849101 chr2 113444837 C T 4.91E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs4337479 chr2 113453206 A G 6.42E-04 Multiple complex diseases / / 17554300 rs10211073 chr2 113457049 A G 2.50E-05 Asthma (bronchodilator response) / / 22792082 rs908547 chr2 113470159 G A 9.67E-05 Cognitive test performance / / 20125193 rs908547 chr2 113470159 G A 1.69E-05 Caffeine consumption / / 21490707 rs908547 chr2 113470159 G A 3.64E-05 Waist-Hip Ratio / / pha003013 rs908547 chr2 113470159 G A 9.66E-05 Waist-Hip Ratio / / pha003028 rs4849113 chr2 113476596 C T 4.62E-05 Cognitive test performance / / 20125193 rs4849113 chr2 113476596 C T 5.52E-05 Waist-Hip Ratio / / pha003013 rs4849114 chr2 113476642 G A 6.79E-04 Multiple complex diseases / / 17554300 rs13386452 chr2 113479614 G A 2.77E-05 Waist-Hip Ratio / / pha003013 rs13386452 chr2 113479614 G A 9.04E-05 Body Fat Distribution / / pha003016 rs13386452 chr2 113479614 G A 3.37E-05 Waist-Hip Ratio / / pha003028 rs908551 chr2 113486079 C T 7.80E-05 Waist-Hip Ratio NT5DC4 intron pha003028 rs2048874 chr2 113523967 C T 2.35E-05 Type 2 diabetes / / 17463246 rs4848300 chr2 113527906 T C 4.08E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs6542095 chr2 113529183 C T 3.00E-06 Endometriosis / / 20844546 rs6542095 chr2 113529183 C T 8.01E-04 Body mass index / / 21701565 rs11677416 chr2 113529240 T C 7.00E-07 Response to antipsychotic treatment in schizophrenia (working memory) / / 21107309 rs3783550 chr2 113532885 G T 7.93E-04 Body mass index IL1A intron 21701565 rs17561 chr2 113537223 C A 2.87E-04 Amyotrophic Lateral Sclerosis IL1A missense 17827064 rs17561 chr2 113537223 C A 2.00E-04 Cognitive impairment induced by topiramate IL1A missense 22091778 rs142134831 chr2 113539232 G T 0.000000013 Breast cancer(er negative) IL1A missense 23555315 rs142134831 chr2 113539232 G T 0.0000082 Breast cancer IL1A missense 23555315 rs3783525 chr2 113541819 T A 7.93E-04 Body mass index IL1A intron 21701565 rs3783516 chr2 113545678 T C 5.41E-04 Type 2 diabetes / / 17463246 rs3783567 chr2 113545955 G A 0.00000143 Triglycerides / / 23063622 rs3783567 chr2 113545955 G A 0.00000163 LDL cholesterol / / 23063622 rs3783567 chr2 113545955 G A 4.41E-16 Cholesterol,total / / 23063622 rs3783567 chr2 113545955 G A 7.10E-14 HDL cholesterol / / 23063622 rs6746923 chr2 113553426 A G 1.80E-05 Alcoholism (heaviness of drinking) / / 21529783 rs11687733 chr2 113555788 C T 9.54E-06 Type 2 diabetes / / 17463246 rs12471565 chr2 113569920 A T 7.51E-04 Body mass index / / 21701565 rs6542097 chr2 113570581 G T 8.33E-06 Type 2 diabetes / / 17463246 rs12469600 chr2 113572357 T C 6.12E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs4849124 chr2 113576902 A G 0.000867451 Hypertension (early onset hypertension) / / 22479346 rs4849124 chr2 113576902 A G 5.40E-04 Endometriosis / / 23104006 rs4849124 chr2 113576902 A G 5.95E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs4849125 chr2 113576915 G A 5.97E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs3917385 chr2 113580094 G A 1.40E-04 Atrial fibrillation / / 21846873 rs3917365 chr2 113586469 A G 5.92E-04 Type 2 diabetes / / 17463246 rs16944 chr2 113594867 A G 1 Drug response to Clodronate IL1B nearGene-5 16257277 rs16944 chr2 113594867 A G 1 Drug response to Etidronic Acid IL1B nearGene-5 16257277 rs16944 chr2 113594867 A G 1 Drug response to Risedronate IL1B nearGene-5 16257277 rs16944 chr2 113594867 A G 1 Drug response to Tiludronate IL1B nearGene-5 16257277 rs16944 chr2 113594867 A G 2.73E-04 Parkinson's disease IL1B nearGene-5 22438815 rs13032029 chr2 113600415 C T 7.40E-04 Alzheimer's disease / / 17998437 rs13032029 chr2 113600415 C T 4.78E-05 Lymphocyte counts / / 22286170 rs2708914 chr2 113627234 T G 4.47E-04 Alcohol dependence / / 20201924 rs17042517 chr2 113639584 A G 3.34E-04 Alcohol dependence / / 21314694 rs2708973 chr2 113663873 A G 3.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy) / / 24554482 rs10864907 chr2 113683875 C T 4.84E-04 Multiple complex diseases / / 17554300 rs10864907 chr2 113683875 C T 3.90E-04 Pulmonary function / / 23932459 rs10864907 chr2 113683875 C T 7.00E-06 Pulmonary function / / 23932459 rs12467810 chr2 113691060 T C 8.17E-06 Response to amphetamines / / 22952603 rs12467847 chr2 113691404 A G 5.00E-06 Response to amphetamines / / 22952603 rs3923566 chr2 113706171 T C 3.43E-05 Amyotrophic lateral sclerosis / / 20801717 rs12468164 chr2 113712783 A G 9.45E-04 Multiple complex diseases / / 17554300 rs1374284 chr2 113753583 C T 1.30E-06 Urinary metabolites / / 21572414 rs6542108 chr2 113755190 T C 1.30E-06 Urinary metabolites / / 21572414 rs1446511 chr2 113762543 T C 0.000809 Salmonella-induced pyroptosis / / 22837397 rs4849142 chr2 113779875 G A 1.20E-06 Urinary metabolites IL36B UTR-3 21572414 rs6710007 chr2 113780930 G A 1.80E-06 Urinary metabolites IL36B intron 21572414 rs10496447 chr2 113782059 A G 4.05E-04 Amyotrophic Lateral Sclerosis IL36B intron 17827064 rs4849143 chr2 113787356 G C 6.44E-04 Suicide attempts in bipolar disorder IL36B intron 21041247 rs2305150 chr2 113789316 C T 7.72E-04 Suicide attempts in bipolar disorder IL36B UTR-5 21041247 rs6724667 chr2 113789641 G A 5.97E-04 Suicide attempts in bipolar disorder IL36B intron 21041247 rs2862772 chr2 113791482 G C 8.13E-04 Suicide attempts in bipolar disorder IL36B intron 21041247 rs1900287 chr2 113797565 G A 7.97E-04 Suicide attempts in bipolar disorder IL36B intron 21041247 rs2862774 chr2 113797677 A C 9.27E-05 Cytomegalovirus antibody response IL36B intron 21993531 rs2862774 chr2 113797677 A C 6.05E-04 Smoking quantity IL36B intron 24665060 rs2862776 chr2 113797924 G A 7.58E-04 Suicide attempts in bipolar disorder IL36B intron 21041247 rs7557928 chr2 113797968 T G 7.54E-04 Suicide attempts in bipolar disorder IL36B intron 21041247 rs4849144 chr2 113800049 A G 7.53E-04 Suicide attempts in bipolar disorder IL36B intron 21041247 rs4849144 chr2 113800049 A G 1.84E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) IL36B intron 24023788 rs4849144 chr2 113800049 A G 3.03E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) IL36B intron 24023788 rs7569284 chr2 113803563 G A 7.53E-04 Suicide attempts in bipolar disorder IL36B intron 21041247 rs9678578 chr2 113810947 T A 6.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs990524 chr2 113816481 C T 7.30E-04 Suicide attempts in bipolar disorder IL36RN intron 21041247 rs28938777 chr2 113819725 A G 0.00046 Prostate cancer IL36RN missense 23555315 rs2472188 chr2 113820814 C G 8.72E-06 Alcohol and nictotine co-dependence IL36RN UTR-3 20158304 rs12475161 chr2 113823626 T C 1.50E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs7558672 chr2 113825303 G A 2.78E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1446521 chr2 113827396 G A 5.93E-04 Suicide attempts in bipolar disorder IL1F10 intron 21041247 rs4849147 chr2 113829236 A T 5.72E-04 Suicide attempts in bipolar disorder IL1F10 intron 21041247 rs4849148 chr2 113829522 T C 1.74E-04 Multiple complex diseases IL1F10 intron 17554300 rs12711749 chr2 113829709 G A 1.00E-05 Urinary metabolites IL1F10 intron 21572414 rs12469822 chr2 113830563 G A 3.80E-05 Obesity,menopause IL1F10 intron 21424828 rs6761276 chr2 113832312 T C 7.00E-06 Protein quantitative trait loci IL1F10 missense 18464913 rs6761276 chr2 113832312 T C 4.56E-25 Inflammatory biomarkers IL1F10 missense 24182552 rs6743376 chr2 113832333 C A 2.00E-26 Inflammatory biomarkers IL1F10 missense 24182552 rs13386602 chr2 113834820 A C 6.12E-25 Inflammatory biomarkers / / 24182552 rs11678375 chr2 113835691 T C 6.19E-25 Inflammatory biomarkers / / 24182552 rs6759676 chr2 113836348 C T 6.15E-25 Inflammatory biomarkers / / 24182552 rs7574787 chr2 113837416 T G 4.12E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs12711751 chr2 113837765 T G 2.00E-05 Response to statin therapy / / 20339536 rs13409371 chr2 113838145 G A 4.36E-04 Multiple complex diseases / / 17554300 rs10181720 chr2 113838608 A G 3.80E-05 Response to statin therapy / / 20339536 rs10184259 chr2 113838628 T C 2.70E-05 Response to statin therapy / / 20339536 rs10184259 chr2 113838628 T C 4.36E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10169599 chr2 113838652 C T 2.80E-05 Response to statin therapy / / 20339536 rs1867829 chr2 113839151 G A 1.94E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10176274 chr2 113840575 C G 1.43E-04 Multiple complex diseases / / 17554300 rs17042828 chr2 113840934 T C 1.20E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs6734238 chr2 113841030 A G 2.00E-17 C-reactive protein / / 21300955 rs6734238 chr2 113841030 A G 7.41E-06 White blood cell count / / 21738479 rs6734238 chr2 113841030 A G 1.00E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs6734238 chr2 113841030 A G 9.00E-10 C-reactive protein / / 22939635 rs6734238 chr2 113841030 A G 6.00E-19 Fibrinogen / / 23969696 rs6722922 chr2 113841515 C T 5.88E-05 Multiple complex diseases / / 17554300 rs6750559 chr2 113841532 G A 2.16E-04 Multiple complex diseases / / 17554300 rs17042833 chr2 113842279 C T 1.10E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs17042842 chr2 113843481 A G 1.20E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs4496335 chr2 113844475 C T 2.13E-04 Multiple complex diseases / / 17554300 rs12328368 chr2 113847144 C G 1.69E-04 Multiple complex diseases / / 17554300 rs6738239 chr2 113850792 C A 1.75E-04 Multiple complex diseases / / 17554300 rs1446510 chr2 113851517 C T 1.40E-04 Multiple complex diseases / / 17554300 rs13404928 chr2 113866525 G A 3.44E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs315921 chr2 113872051 G A 2.60E-06 Fibrinogen / / 20978265 rs315920 chr2 113873018 C T 7.81E-05 Bipolar disorder / / 20451256 rs4251961 chr2 113874467 T C 1.80E-05 Fibrinogen IL1RN nearGene-5 20978265 rs4251961 chr2 113874467 T C 0.0000254 Interleukin-6 (IL-6) levels IL1RN nearGene-5 23505291 rs4251961 chr2 113874467 T C 0.00014 C-reactive protein IL1RN nearGene-5 23505291 rs2637988 chr2 113876779 G A 1.62E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) IL1RN intron 24023788 rs928940 chr2 113877495 G T 1.65E-05 Lymphocyte counts IL1RN intron 22286170 rs3213448 chr2 113879297 G A 6.96E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) IL1RN intron 24023788 rs2232352 chr2 113885094 C T 0.00032 Coronary artery calcification IL1RN intron 23727086 rs4252040 chr2 113889541 T G 9.62E-27 HDL cholesterol IL1RN intron 23063622 rs4252023 chr2 113890373 C T 2.00E-06 Obesity-related traits IL1RN cds-synon 23251661 rs397211 chr2 113892141 T C 4.00E-04 Psoriasis / / 20953187 rs315958 chr2 113900851 G T 3.12E-05 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs6760120 chr2 113932431 T C 3.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PSD4 intron 20877124 rs6760120 chr2 113932431 T C 4.31E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PSD4 intron 20877124 rs4849163 chr2 113935028 T C 3.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PSD4 intron 20877124 rs4849163 chr2 113935028 T C 4.62E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PSD4 intron 20877124 rs6753019 chr2 113948159 G A 5.89E-04 Alcohol dependence PSD4 intron 24277619 rs11123169 chr2 113967075 C T 8.06E-04 Multiple complex diseases / / 17554300 rs11123170 chr2 113978940 C G 3.00E-10 Renal function-related traits (BUN) PAX8 intron 22797727 rs11123172 chr2 113984303 T C 9.50E-06 Urinary metabolites PAX8 intron 21572414 rs2241975 chr2 113984503 C T 5.97E-04 Colorectal cancer PAX8 intron 24836286 rs4849179 chr2 113985170 C T 6.07E-04 Premature ovarian failure PAX8 intron 19508998 rs2863243 chr2 113989267 T C 2.30E-05 Urinary metabolites PAX8 intron 21572414 rs2863244 chr2 114000866 A G 5.87E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PAX8 intron 20031582 rs3768768 chr2 114001363 A G 2.32E-05 F-cell distribution PAX8 intron 21326311 rs4848320 chr2 114010791 C T 6.52E-05 Cognitive performance PAX8 intron 19734545 rs6734610 chr2 114017029 A G 1.04E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PAX8 intron 20031582 rs6734610 chr2 114017029 A G 6.40E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PAX8 intron 20031582 rs6542127 chr2 114022658 T C 9.25E-05 Chronic obstructive pulmonary disease PAX8 intron 19300482 rs6542127 chr2 114022658 T C 9.25E-05 Response to statin treatment (atorvastatin),change in cholesterol levels PAX8 intron 20031582 rs12476056 chr2 114050323 A G 7.18E-05 Personality dimensions / / 18957941 rs1191695 chr2 114083363 T C 7.20E-04 Alcohol dependence / / 20201924 rs1191680 chr2 114098412 C A 3.43E-04 Type 2 diabetes / / 17463246 rs1807281 chr2 114110054 G A 9.14E-04 Type 2 diabetes / / 17463246 rs12474753 chr2 114128721 C T 8.87E-06 Glucose levels / / pha003061 rs1823124 chr2 114136588 C A 7.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs1968616 chr2 114136781 A G 7.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs1968615 chr2 114137598 C A 7.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs4848334 chr2 114137966 A G 7.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs4439970 chr2 114138771 T C 7.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs2121374 chr2 114142218 G A 7.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs11123183 chr2 114145320 C T 7.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs11123184 chr2 114145327 C T 7.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs6717693 chr2 114146326 C G 7.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs11680681 chr2 114148097 C G 7.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs10197232 chr2 114148961 T C 8.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs12711768 chr2 114154369 A G 6.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs12711769 chr2 114154486 A G 6.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs13387994 chr2 114157319 G A 5.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs7604877 chr2 114161384 C T 6.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs1867870 chr2 114163647 A T 9.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs11899852 chr2 114260095 C T 3.91E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs761647 chr2 114273105 T C 8.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs1597245 chr2 114448217 G C 6.25E-05 Body mass (lean) / / 19268274 rs1044836 chr2 114464777 C T 3.16E-05 Waist Circumference / / pha003023 rs3762491 chr2 114489252 G A 7.69E-08 Coronary arterial lesions in patients with Kawasaki disease SLC35F5 intron 23677057 rs12329244 chr2 114516494 A T 2.15E-04 Multiple complex diseases / / 17554300 rs17633451 chr2 114528877 T G 1.70E-04 Multiple complex diseases / / 17554300 rs17633527 chr2 114530525 C G 7.10E-04 Smoking initiation / / 24665060 rs2140263 chr2 114616865 T A 2.90E-04 Type 2 diabetes LOC100506762 intron 17463246 rs7567097 chr2 114635685 C T 6.15E-05 Alzheimer's disease (age of onset) LOC100506762 intron 22005931 rs6720853 chr2 114637231 C T 5.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) LOC100506762 intron 23648065 rs11681425 chr2 114655601 G A 4.45E-04 Parkinson's disease ACTR3 intron 16252231 rs12618683 chr2 114672304 A G 5.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) ACTR3 intron 23648065 rs1825738 chr2 114708728 C T 9.80E-04 Type 2 diabetes ACTR3 intron 17463246 rs901466 chr2 114724122 C G 1.40E-05 Urinary metabolites / / 21572414 rs3912541 chr2 114725960 G A 4.87E-06 Blood Pressure / / pha003044 rs17046767 chr2 114757209 G C 1.93E-04 Bipolar disorder,schizoaffective LOC440900 intron 19567891 rs3982224 chr2 114759881 T C 6.53E-04 Acute lung injury LOC440900 intron 22295056 rs276828 chr2 114766658 G A 6.83E-04 Acute lung injury / / 22295056 rs276830 chr2 114767984 T C 8.68E-04 Acute lung injury / / 22295056 rs276835 chr2 114769417 G C 8.88E-04 Acute lung injury / / 22295056 rs276836 chr2 114770212 A G 9.16E-04 Acute lung injury / / 22295056 rs7581421 chr2 114770236 C T 7.99E-04 Acute lung injury / / 22295056 rs156726 chr2 114779558 T C 8.24E-04 Acute lung injury / / 22295056 rs156728 chr2 114780669 A G 7.85E-04 Acute lung injury / / 22295056 rs465316 chr2 114784936 A C 7.41E-04 Acute lung injury / / 22295056 rs400960 chr2 114785397 T G 7.87E-04 Acute lung injury / / 22295056 rs275419 chr2 114788869 C T 9.14E-04 Acute lung injury / / 22295056 rs1564856 chr2 114797318 T G 5.90E-04 Acute lung injury / / 22295056 rs6724135 chr2 114804521 A G 3.76E-04 Multiple complex diseases / / 17554300 rs923229 chr2 114830803 C A 3.00E-04 Acute lung injury / / 22295056 rs3912544 chr2 114840339 G T 2.82E-04 Acute lung injury / / 22295056 rs4089089 chr2 114846282 G A 2.36E-04 Acute lung injury / / 22295056 rs10460468 chr2 114851190 T C 2.36E-04 Acute lung injury / / 22295056 rs10191770 chr2 114937335 T C 9.30E-09 Mean arterial pressure / / 22510845 rs17759541 chr2 114937429 A G 7.22E-04 Smoking initiation / / 24665060 rs3132032 chr2 114979092 A T 4.86E-04 Acute lung injury / / 22295056 rs3105491 chr2 114980967 G T 2.00E-06 Systolic blood pressure in sickle cell anemia / / 24058526 rs3105489 chr2 114984090 T G 4.13E-05 Multiple complex diseases / / 17554300 rs17048253 chr2 114985292 C T 3.11E-04 Multiple complex diseases / / 17554300 rs3132039 chr2 114998082 G C 9.40E-04 Multiple complex diseases / / 17554300 rs4513299 chr2 115049818 C G 4.00E-06 Inflammatory biomarkers / / 22228203 rs6737251 chr2 115213675 T C 7.28E-05 C-Reactive Protein DPP10 intron pha003070 rs4849335 chr2 115217554 A C 6.01E-05 C-Reactive Protein DPP10 intron pha003070 rs4849336 chr2 115218922 C G 6.80E-07 Urinary metabolites DPP10 intron 21572414 rs4849337 chr2 115218975 C T 9.60E-07 Urinary metabolites DPP10 intron 21572414 rs1820924 chr2 115270207 C T 3.85E-05 Height DPP10 intron pha003011 rs10187644 chr2 115271841 C T 1.70E-04 Diabetic nephropathy DPP10 intron 20347642 rs1430108 chr2 115292826 T C 4.67E-04 Acute lung injury DPP10 intron 22295056 rs6542214 chr2 115294661 T C 1.09E-04 Acute lung injury DPP10 intron 22295056 rs4848368 chr2 115295816 G A 1.36E-04 Acute lung injury DPP10 intron 22295056 rs6741327 chr2 115303633 A T 8.29E-04 Obesity (extreme) DPP10 intron 21935397 rs6729737 chr2 115341833 G T 1.80E-05 Urinary metabolites DPP10 intron 21572414 rs17048495 chr2 115351504 T C 6.06E-04 Multiple complex diseases DPP10 intron 17554300 rs12996109 chr2 115394527 C T 3.98E-05 HDL particle features DPP10 intron pha002900 rs17783638 chr2 115408177 T C 2.73E-04 Hearing function DPP10 intron 17255346 rs17783638 chr2 115408177 T C 4.53E-04 Alzheimer's disease (late onset) DPP10 intron 21379329 rs13022574 chr2 115410964 C A 8.90E-05 Epilepsy (remission after treatment) DPP10 intron 23962720 rs17043351 chr2 115443094 T C 9.76E-04 Obesity (extreme) DPP10 intron 21935397 rs13032740 chr2 115453185 C T 8.21E-05 Cognitive impairment induced by topiramate DPP10 intron 22091778 rs7605779 chr2 115472604 T G 3.63E-05 Cognitive impairment induced by topiramate DPP10 intron 22091778 rs1435879 chr2 115492887 A G 3.05E-06 Asthma DPP10 intron 19910028 rs1435879 chr2 115492887 A G 1.02E-04 Obesity (extreme) DPP10 intron 21935397 rs11890570 chr2 115524203 T C 6.95E-05 Schizophrenia (cytomegalovirus infection interaction) DPP10 intron 23358160 rs319857 chr2 115530826 A G 6.67E-05 Blood Pressure DPP10 intron pha003045 rs12711807 chr2 115569596 C A 0.000043 Nonsyndromic striae distensae (stretch marks) DPP10 intron 23633020 rs12476637 chr2 115570313 C T 0.0000663 Nonsyndromic striae distensae (stretch marks) DPP10 intron 23633020 rs2420449 chr2 115573050 A G 8.17E-06 Neutrophil count DPP10 intron pha003095 rs12999750 chr2 115576519 A G 0.0000263 Nonsyndromic striae distensae (stretch marks) DPP10 intron 23633020 rs2102901 chr2 115578511 C G 0.0000364 Nonsyndromic striae distensae (stretch marks) DPP10 intron 23633020 rs6732028 chr2 115586939 A G 3.00E-06 Obesity-related traits DPP10 intron 23251661 rs1879124 chr2 115613577 A G 1.36E-05 Cardiovascular disease DPP10 intron pha003065 rs13007523 chr2 115622199 G A 5.78E-05 Celiac disease DPP10 intron 23936387 rs13000828 chr2 115638290 G A 1.40E-04 Celiac disease DPP10 intron 23936387 rs980316 chr2 115710826 T C 4.00E-04 Asthma DPP10 intron 19910030 rs980316 chr2 115710826 T C 3.66E-04 Myopia (pathological) DPP10 intron 21095009 rs980316 chr2 115710826 T C 5.08E-06 Inflammation DPP10 intron pha002897 rs980317 chr2 115710936 T C 1.60E-04 Asthma DPP10 intron 19910030 rs7421482 chr2 115716385 G T 2.70E-04 Asthma DPP10 intron 19910030 rs2175176 chr2 115720896 G T 6.55E-04 Myopia (pathological) DPP10 intron 21095009 rs12469474 chr2 115723034 G A 4.50E-04 Asthma DPP10 intron 19910030 rs1396932 chr2 115741748 A C 3.39E-04 Myopia (pathological) DPP10 intron 21095009 rs949577 chr2 115743547 A G 4.10E-04 Asthma DPP10 intron 19910030 rs949577 chr2 115743547 A G 8.34E-04 Stroke DPP10 intron pha002887 rs17043899 chr2 115757709 G T 6.11E-04 White matter integrity DPP10 intron 22425255 rs966859 chr2 115828493 T C 7.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DPP10 intron 20877124 rs10167935 chr2 115855507 C T 2.10E-06 Urinary metabolites DPP10 intron 21572414 rs4624391 chr2 115871266 A C 8.50E-06 Urinary metabolites DPP10 intron 21572414 rs958457 chr2 115897734 G A 9.71E-05 Serum metabolites DPP10 intron 19043545 rs17687793 chr2 115908178 T C 2.80E-05 Diabetic retinopathy DPP10 intron 21441570 rs17636812 chr2 115914194 A G 2.80E-05 Diabetic retinopathy DPP10 intron 21441570 rs11123288 chr2 115964006 G A 4.79E-04 Multiple complex diseases DPP10 intron 17554300 rs13386690 chr2 116023110 A G 5.14E-05 Multiple complex diseases DPP10 intron 17554300 rs11885726 chr2 116086938 C T 2.70E-05 Urinary metabolites DPP10 intron 21572414 rs10496489 chr2 116110269 A G 1.60E-05 Urinary metabolites DPP10 intron 21572414 rs17823359 chr2 116118583 G A 1.00E-05 Urinary metabolites DPP10 intron 21572414 rs17044256 chr2 116126879 T C 4.93E-04 Multiple complex diseases DPP10 intron 17554300 rs12478263 chr2 116145068 T A 1.60E-05 Urinary metabolites DPP10 intron 21572414 rs9308712 chr2 116148108 A G 6.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DPP10 intron 20877124 rs9308712 chr2 116148108 A G 7.41E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DPP10 intron 20877124 rs13022199 chr2 116154002 G A 8.94E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs6542260 chr2 116163121 C T 1.80E-05 Urinary metabolites DPP10 intron 21572414 rs2677290 chr2 116164570 C G 5.46E-09 Narcolepsy DPP10 intron 19629137 rs1717038 chr2 116165658 C T 1.40E-05 Urinary metabolites DPP10 intron 21572414 rs1717040 chr2 116168800 T C 1.37E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs1402446 chr2 116169391 A G 1.36E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs843393 chr2 116173796 G A 1.17E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs843390 chr2 116175152 G C 1.16E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs11675299 chr2 116177551 A G 4.28E-04 Multiple complex diseases DPP10 intron 17554300 rs843385 chr2 116177579 T C 1.20E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs843394 chr2 116188083 T G 1.34E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs7581748 chr2 116188604 A T 2.06E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs1717054 chr2 116189549 C T 1.37E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs1712005 chr2 116189892 G A 1.38E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs708647 chr2 116197757 G A 3.01E-05 Multiple complex diseases DPP10 intron 17554300 rs1517368 chr2 116230314 G T 1.43E-04 Multiple complex diseases DPP10 intron 17554300 rs11123306 chr2 116231781 A G 2.78E-06 Multiple complex diseases DPP10 intron 17554300 rs1375144 chr2 116241186 G A 2.43E-06 Multiple complex diseases DPP10 intron 17554300 rs1375144 chr2 116241186 G A 2.00E-06 Bipolar disorder DPP10 intron 21254220 rs2421104 chr2 116242265 G T 9.53E-06 Multiple complex diseases DPP10 intron 17554300 rs10496495 chr2 116243444 T C 2.42E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs17362720 chr2 116254100 G A 6.20E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs34559324 chr2 116255490 G A 1.89E-04 Multiple complex diseases DPP10 intron 17554300 rs6712054 chr2 116257658 C T 6.22E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs2166906 chr2 116261081 C T 2.14E-04 Multiple complex diseases DPP10 intron 17554300 rs7421696 chr2 116261143 C T 2.33E-04 Multiple complex diseases DPP10 intron 17554300 rs4538209 chr2 116261292 T G 2.64E-04 Multiple complex diseases DPP10 intron 17554300 rs13002945 chr2 116261621 A G 2.05E-04 Multiple complex diseases DPP10 intron 17554300 rs17044597 chr2 116267032 G A 2.95E-04 Multiple complex diseases DPP10 intron 17554300 rs17044605 chr2 116277985 A G 2.22E-04 Multiple complex diseases DPP10 intron 17554300 rs984066 chr2 116283668 G A 3.27E-04 Multiple complex diseases DPP10 intron 17554300 rs4849404 chr2 116284135 T C 3.23E-04 Multiple complex diseases DPP10 intron 17554300 rs4849406 chr2 116301591 G A 1.90E-04 Multiple complex diseases DPP10 intron 17554300 rs6741692 chr2 116303931 C G 4.64E-06 Multiple complex diseases DPP10 intron 17554300 rs6738130 chr2 116327375 C T 5.15E-04 Multiple complex diseases DPP10 intron 17554300 rs17454262 chr2 116366107 T C 2.85E-04 Suicide attempts in bipolar disorder DPP10 intron 21041247 rs17044776 chr2 116370016 A G 9.22E-05 Multiple complex diseases DPP10 intron 17554300 rs4849413 chr2 116373882 T C 1.30E-04 Multiple complex diseases DPP10 intron 17554300 rs13012337 chr2 116396780 A G 3.26E-05 Cognitive impairment induced by topiramate DPP10 intron 22091778 rs7568150 chr2 116422900 C A 9.80E-04 Multiple complex diseases DPP10 intron 17554300 rs7593933 chr2 116422975 G A 9.84E-04 Multiple complex diseases DPP10 intron 17554300 rs4075701 chr2 116429790 T C 1.63E-05 Blood Pressure and Arterial Stiffness DPP10 intron 17903302 rs10173996 chr2 116467283 T G 4.22E-04 Multiple complex diseases DPP10 intron 17554300 rs4849421 chr2 116473019 A T 4.93E-04 Multiple complex diseases DPP10 intron 17554300 rs13019180 chr2 116481940 T C 7.54E-05 Arthritis (juvenile idiopathic) DPP10 intron 22354554 rs12621324 chr2 116484040 G A 9.57E-06 Cognitive impairment induced by topiramate DPP10 intron 22091778 rs13033400 chr2 116486451 G A 7.76E-05 Arthritis (juvenile idiopathic) DPP10 intron 22354554 rs1545359 chr2 116494716 A G 7.01E-04 Multiple complex diseases DPP10 intron 17554300 rs2901396 chr2 116517742 A G 2.00E-04 Cognitive impairment induced by topiramate DPP10 intron 22091778 rs1374271 chr2 116534922 A G 1.15E-04 Arthritis (juvenile idiopathic) DPP10 intron 22354554 rs1374268 chr2 116548326 G A 9.27E-05 Cognitive impairment induced by topiramate DPP10 intron 22091778 rs6735355 chr2 116548526 A G 3.24E-04 Multiple complex diseases DPP10 intron 17554300 rs17044974 chr2 116550715 T G 4.23E-04 Multiple complex diseases DPP10 intron 17554300 rs736335 chr2 116594221 G C 6.38E-04 Acute lung injury DPP10 intron 22295056 rs272038 chr2 116635862 T C 9.36E-06 Coronary heart disease / / pha003033 rs272020 chr2 116644461 C T 2.22E-05 Coronary heart disease / / pha003033 rs272000 chr2 116655795 G C 9.00E-06 Attention deficit hyperactivity disorder / / 18821565 rs11890985 chr2 116668062 G A 5.63E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7581538 chr2 116669356 G A 5.16E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1447241 chr2 116696434 C T 4.11E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1447241 chr2 116696434 C T 7.79E-04 Stroke / / pha002887 rs17045635 chr2 116932105 C T 8.76E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs7598656 chr2 116968121 C T 4.33E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs2035324 chr2 116968656 T C 4.54E-05 Bipolar disorder / / 19488044 rs2010823 chr2 116976066 C T 9.25E-05 Erythrocyte counts / / pha003099 rs6735305 chr2 117054882 T C 6.27E-05 Erythrocyte counts / / pha003099 rs10496515 chr2 117071213 T C 3.92E-05 Alcohol and nictotine co-dependence / / 20158304 rs10496515 chr2 117071213 T C 6.59E-05 Erythrocyte counts / / pha003099 rs7586235 chr2 117080187 T C 2.31E-04 Multiple complex diseases / / 17554300 rs6751658 chr2 117100160 A G 7.66E-05 Partial epilepsies / / 20522523 rs11123348 chr2 117126557 G A 7.03E-05 Partial epilepsies / / 20522523 rs11674077 chr2 117147179 C G 3.39E-04 Type 2 diabetes / / 17463246 rs10864945 chr2 117154934 C T 1.86E-04 Type 2 diabetes / / 17463246 rs4849472 chr2 117179890 G T 2.81E-04 Type 2 diabetes / / 17463246 rs4849476 chr2 117183690 T C 9.14E-04 Type 2 diabetes / / 17463246 rs1388407 chr2 117183853 C T 3.57E-04 Type 2 diabetes / / 17463246 rs17045920 chr2 117183972 G A 1.44E-04 Type 2 diabetes / / 17463246 rs17550669 chr2 117197204 C T 9.48E-06 Bipolar disorder / / 20451256 rs2421599 chr2 117231442 A G 1.91E-05 Body Mass Index / / pha003014 rs2901472 chr2 117231705 C A 1.44E-05 Body Mass Index / / pha003014 rs2901472 chr2 117231705 C A 9.62E-05 Waist Circumference / / pha003024 rs2421604 chr2 117254763 G A 7.57E-04 Aortic root size / / 21223598 rs10208988 chr2 117258826 G C 5.12E-04 Aortic root size / / 21223598 rs10208991 chr2 117258847 G T 6.74E-04 Aortic root size / / 21223598 rs7597707 chr2 117259370 A G 4.85E-04 Aortic root size / / 21223598 rs1948365 chr2 117259824 G C 4.28E-04 Aortic root size / / 21223598 rs2421608 chr2 117297533 T A 1.80E-05 Biomarkers / / 17903293 rs6542326 chr2 117307471 T G 5.81E-04 Multiple complex diseases / / 17554300 rs17046130 chr2 117316787 C G 5.82E-04 Multiple complex diseases / / 17554300 rs1442772 chr2 117352829 G A 1.70E-04 Multiple complex diseases / / 17554300 rs7604050 chr2 117420021 A G 7.54E-04 Parkinson's disease / / 17052657 rs7584028 chr2 117473782 T C 3.38E-05 Lactate dehydrogenase levels / / 20981236 rs6705249 chr2 117521855 A G 6.75E-05 Postoperative ventricular dysfunction / / 21980348 rs11674647 chr2 117695131 G C 2.10E-05 Urinary metabolites / / 21572414 rs4305291 chr2 117721773 A G 6.51E-04 Multiple complex diseases / / 17554300 rs6726455 chr2 117822575 C T 2.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1437434 chr2 117844244 A G 2.71E-04 Body mass index / / 17255346 rs17046639 chr2 117846628 T C 5.59E-04 Multiple complex diseases / / 17554300 rs332880 chr2 117867857 C T 9.26E-05 LDL lipoproteins / / pha002902 rs332925 chr2 117899586 T C 2.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2035171 chr2 117911357 A G 5.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2035171 chr2 117911357 A G 3.62E-04 Rheumatoid arthritis / / 21452313 rs10192798 chr2 117912256 A C 3.89E-04 Alzheimer's disease / / 24755620 rs332885 chr2 117922305 G A 5.02E-04 Alzheimer's disease / / 24755620 rs6725378 chr2 117922791 C G 9.91E-04 Multiple complex diseases / / 17554300 rs17046690 chr2 117937229 C A 6.29E-04 Multiple complex diseases / / 17554300 rs1350986 chr2 117941086 G A 7.96E-04 Alzheimer's disease / / 24755620 rs7578803 chr2 117944522 A G 5.28E-04 Alzheimer's disease / / 24755620 rs10179218 chr2 117946885 C A 0.000000774 Brain activation patterns in response to human facial expressions-for the positive faces task / / 22828495 rs10179218 chr2 117946885 C A 1.85E-08 Brain activation patterns in response to human facial expressions-for the negative faces task / / 22828495 rs10179218 chr2 117946885 C A 1.85E-08 Airflow obstruction / / 22837378 rs1869309 chr2 118067708 G A 1.39E-04 Multiple complex diseases / / 17554300 rs10496537 chr2 118081209 A C 4.63E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10496537 chr2 118081209 A C 7.67E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4849549 chr2 118101770 G A 3.00E-04 Multiple complex diseases / / 17554300 rs6742148 chr2 118103005 C A 9.30E-04 Multiple complex diseases / / 17554300 rs4308131 chr2 118110978 C T 2.74E-04 Multiple complex diseases / / 17554300 rs10177579 chr2 118111305 C A 9.84E-04 Multiple complex diseases / / 17554300 rs334826 chr2 118131773 C T 5.52E-04 Multiple complex diseases / / 17554300 rs334828 chr2 118132313 C G 5.50E-04 Multiple complex diseases / / 17554300 rs334829 chr2 118132332 T C 8.48E-04 Multiple complex diseases / / 17554300 rs334830 chr2 118132422 A G 7.60E-04 Multiple complex diseases / / 17554300 rs6723614 chr2 118138788 A G 3.85E-04 Multiple complex diseases / / 17554300 rs2138480 chr2 118142725 A G 1.19E-04 Cholesterol / / 17255346 rs1516236 chr2 118148428 C T 8.17E-04 Multiple complex diseases / / 17554300 rs1400127 chr2 118152277 G C 8.84E-04 Multiple complex diseases / / 17554300 rs2421933 chr2 118152322 G A 9.51E-04 Multiple complex diseases / / 17554300 rs1516240 chr2 118152405 A G 7.15E-04 Multiple complex diseases / / 17554300 rs6754148 chr2 118153550 G A 9.84E-04 Multiple complex diseases / / 17554300 rs1516232 chr2 118157316 T G 1.13E-04 Cholesterol / / 17255346 rs1356216 chr2 118162561 T G 4.61E-05 Cholesterol / / 17255346 rs2901595 chr2 118178076 A T 7.32E-04 Acute lung injury / / 22295056 rs6753313 chr2 118180523 T C 5.26E-05 Cholesterol / / 17255346 rs6706581 chr2 118181078 G A 3.63E-04 Multiple complex diseases / / 17554300 rs2421931 chr2 118181548 T C 1.80E-04 Cholesterol / / 17255346 rs6760213 chr2 118187490 T C 0.0000997 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1996290 chr2 118195566 G T 0.0000713 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11884677 chr2 118196387 G A 3.01E-04 Multiple complex diseases / / 17554300 rs6741941 chr2 118197899 C A 0.0000735 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6745193 chr2 118198312 C A,T 0.0000373 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2421930 chr2 118201104 C G 1.56E-04 Multiple complex diseases / / 17554300 rs1581200 chr2 118203404 G A 0.0000753 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6542370 chr2 118205154 A T 0.0000742 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4337486 chr2 118205547 T C 0.0000957 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs949917 chr2 118207795 G A 4.92E-04 Multiple complex diseases / / 17554300 rs6716125 chr2 118211048 C T 0.0000734 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4410306 chr2 118212353 T C 1.50E-04 Multiple complex diseases / / 17554300 rs6706078 chr2 118213631 C T 0.0000788 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6542373 chr2 118214397 C T 0.0000764 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1121106 chr2 118223350 A G 4.47E-04 Multiple complex diseases / / 17554300 rs290890 chr2 118255036 A G 2.51E-04 Multiple complex diseases / / 17554300 rs11892804 chr2 118272407 G T 4.17E-04 Multiple complex diseases / / 17554300 rs4849561 chr2 118274002 T C 4.35E-04 Coronary heart disease / / 21606135 rs1515991 chr2 118279545 C T 8.12E-08 Metabolite levels / / 23281178 rs7606639 chr2 118280239 G C 4.41E-04 Multiple complex diseases / / 17554300 rs10496542 chr2 118280812 C G 6.59E-04 Multiple complex diseases / / 17554300 rs1515993 chr2 118281020 G C 5.48E-04 Multiple complex diseases / / 17554300 rs17766363 chr2 118314622 C T 2.65E-04 Cholesterol / / 17255346 rs17766737 chr2 118318454 G A 5.92E-05 Cholesterol / / 17255346 rs1606944 chr2 118355063 C A 7.21E-05 Multiple complex diseases / / 17554300 rs1515998 chr2 118356097 A T 1.73E-04 Multiple complex diseases / / 17554300 rs13034275 chr2 118364695 A G 1.10E-06 Iron levels / / 21208937 rs3849326 chr2 118371828 A G 7.73E-04 Multiple complex diseases / / 17554300 rs2244671 chr2 118396232 A G 2.00E-04 Information processing speed / / 21130836 rs10490637 chr2 118416015 G A 9.74E-05 Blood Pressure / / pha003045 rs10490637 chr2 118416015 G A 2.43E-05 Blood Pressure / / pha003047 rs17047229 chr2 118422427 G A 8.22E-04 Multiple complex diseases / / 17554300 rs12475536 chr2 118448025 C T 4.94E-06 Blood Pressure / / pha003045 rs12475536 chr2 118448025 C T 3.34E-06 Blood Pressure / / pha003047 rs1477450 chr2 118448486 G A 2.06E-07 Schizophrenia / / 22037555 rs918860 chr2 118455405 G A 6.77E-06 Blood Pressure / / pha003045 rs918860 chr2 118455405 G A 1.69E-06 Blood Pressure / / pha003047 rs999496 chr2 118468300 G A 3.17E-06 Blood Pressure / / pha003045 rs999496 chr2 118468300 G A 7.96E-07 Blood Pressure / / pha003047 rs4849613 chr2 118474016 C T 7.20E-05 LDL lipoproteins / / pha002902 rs12477316 chr2 118484690 C T 6.29E-06 Blood Pressure / / pha003045 rs12477316 chr2 118484690 C T 4.36E-06 Blood Pressure / / pha003047 rs7579150 chr2 118485871 G A 6.29E-06 Blood Pressure / / pha003045 rs7579150 chr2 118485871 G A 4.36E-06 Blood Pressure / / pha003047 rs10490635 chr2 118486980 G A 7.19E-05 Multiple complex diseases / / 17554300 rs6753213 chr2 118491813 G A 2.05E-04 Coronary heart disease / / 21606135 rs1433527 chr2 118534387 C A 5.10E-05 Volumetric brain MRI / / 17903297 rs2422047 chr2 118535538 A G 9.42E-05 Waist-Hip Ratio / / pha003029 rs41385550 chr2 118549036 A C 8.00E-04 Multiple complex diseases / / 17554300 rs7581935 chr2 118557033 G T 9.79E-04 Stroke / / pha002886 rs6737733 chr2 118575468 C T 4.70E-04 Multiple complex diseases DDX18 intron 17554300 rs6737733 chr2 118575468 C T 8.11E-05 Schizophrenia DDX18 intron 19197363 rs6737733 chr2 118575468 C T 2.84E-05 Lymphocyte counts DDX18 intron 22286170 rs17508045 chr2 118576719 T C 6.49E-05 Cognitive impairment induced by topiramate DDX18 intron 22091778 rs6731372 chr2 118586360 G A 5.94E-04 Parkinson's disease DDX18 intron 16252231 rs9973563 chr2 118596118 G C 6.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs6718141 chr2 118597049 A G 7.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs6542399 chr2 118601340 A G 3.10E-06 Urinary metabolites / / 21572414 rs6712766 chr2 118611789 G A 8.42E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1072231 chr2 118634348 T C 4.20E-07 Urinary metabolites / / 21572414 rs6739723 chr2 118666956 T C 3.75E-04 Type 2 diabetes / / 17463246 rs13020654 chr2 118679847 C T 8.77E-04 Alzheimer's disease CCDC93 intron 22005930 rs17583214 chr2 118702952 G C 8.93E-04 Alzheimer's disease CCDC93 intron 22005930 rs7589588 chr2 118711354 C T 8.97E-04 Alzheimer's disease CCDC93 intron 22005930 rs4142224 chr2 118716190 C T 1.83E-04 Alcohol dependence CCDC93 intron 21314694 rs10490628 chr2 118730290 C T 4.19E-04 Smoking initiation CCDC93 intron 24665060 rs10173849 chr2 118765370 C A 5.94E-04 Smoking initiation CCDC93 intron 24665060 rs6542423 chr2 118771872 T C 1.86E-04 Multiple complex diseases / / 17554300 rs1547999 chr2 118778628 A G 9.65E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17047645 chr2 118797340 T C 1.52E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17047648 chr2 118804752 T C 2.99E-04 Multiple complex diseases / / 17554300 rs1808457 chr2 118820268 T C 2.05E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1808457 chr2 118820268 T C 2.78E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17586455 chr2 118825726 T A 8.04E-04 Alzheimer's disease / / 22005930 rs17047697 chr2 118827810 G A 1.90E-06 Urinary metabolites / / 21572414 rs4849674 chr2 118827859 A G 3.50E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4849674 chr2 118827859 A G 9.12E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10490626 chr2 118835841 G A 2.00E-12 LDL cholesterol / / 24097068 rs10490626 chr2 118835841 G A 6.00E-09 Cholesterol,total / / 24097068 rs7566605 chr2 118836025 C G 7.43E-04 Type 2 diabetes / / 17463246 rs17047733 chr2 118841325 T C 2.55E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17047733 chr2 118841325 T C 4.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12464355 chr2 118849850 A G 1.19E-08 Cholesterol,total INSIG2 intron 23063622 rs17528324 chr2 118856156 G A 4.13E-06 Migraine INSIG2 intron 20802479 rs11889497 chr2 118862464 T G 4.27E-05 Suicide attempts in bipolar disorder INSIG2 intron 21423239 rs13409050 chr2 118863770 G A 4.18E-05 Suicide attempts in bipolar disorder INSIG2 intron 21423239 rs11902948 chr2 118871510 T C 6.54E-05 Suicide attempts in bipolar disorder / / 21423239 rs10207953 chr2 118871901 T C 3.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs2113485 chr2 118874146 G A 4.42E-04 Heart Failure / / pha002885 rs11673894 chr2 118876072 G T 9.71E-05 Chronic obstructive pulmonary disease / / 19300482 rs11673894 chr2 118876072 G T 9.71E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11673894 chr2 118876072 G T 5.15E-04 Alzheimer's disease / / 22005930 rs17047778 chr2 118878300 A G 7.17E-05 Suicide attempts in bipolar disorder / / 21423239 rs13396907 chr2 118880093 G A 5.43E-05 Suicide attempts in bipolar disorder / / 21423239 rs13390830 chr2 118880329 T C 7.74E-05 Suicide attempts in bipolar disorder / / 21423239 rs17047787 chr2 118881068 G A 8.20E-05 Suicide attempts in bipolar disorder / / 21423239 rs10168587 chr2 118884724 T C 5.02E-04 Multiple complex diseases / / 17554300 rs17047801 chr2 118887503 C T 5.11E-05 Cervical cancer / / 24700089 rs6726538 chr2 118889229 T A 3.00E-06 Cervical cancer / / 24700089 rs17047805 chr2 118891996 C T 4.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs10200637 chr2 118892254 G A 1.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs17047806 chr2 118892531 G A 5.00E-05 Cognitive function / / 24684796 rs4084828 chr2 118893347 C T 0.0005858 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4084828 chr2 118893347 C T 5.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11123477 chr2 118927760 C T 0.000185 Common carotid artery thickness (average of near and far wall measures) / / 23487405 rs12613995 chr2 118986516 T C 4.60E-04 Multiple complex diseases / / 17554300 rs10864971 chr2 119000652 C T 8.60E-05 Alcoholism (heaviness of drinking) / / 21529783 rs2422239 chr2 119029079 G A 2.54E-07 Primary biliary cirrhosis / / 23000144 rs2422239 chr2 119029079 G A 0.000000254 Facial morphology / / 23028347 rs4077791 chr2 119037954 G A 3.31E-04 Height / / 17255346 rs1878526 chr2 119038598 G A 1.00E-10 Bone mineral density / / 22504420 rs2422241 chr2 119043036 G A 9.23E-08 Primary biliary cirrhosis / / 23000144 rs2422241 chr2 119043036 G A 9.22E-08 Facial morphology / / 23028347 rs9308765 chr2 119043209 G A 5.10E-05 Kidney function and endocine traits / / 17903292 rs12622690 chr2 119086841 C T 0.0005542 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12622690 chr2 119086841 C T 5.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12986939 chr2 119089007 G A 0.0005452 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12986939 chr2 119089007 G A 5.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13400406 chr2 119104699 T C 6.80E-05 Creatinine levels / / pha003069 rs4276037 chr2 119104977 G A 0.00001152 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4276037 chr2 119104977 G A 4.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4560125 chr2 119106057 A G 2.54E-05 Creatinine levels / / pha003069 rs12711904 chr2 119107986 A T 0.0004636 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12711904 chr2 119107986 A T 4.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4128289 chr2 119108415 A G 0.0004724 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4128289 chr2 119108415 A G 4.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7587899 chr2 119108916 A G 0.0004975 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7587899 chr2 119108916 A G 4.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4613284 chr2 119110676 A G 0.0005538 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4613284 chr2 119110676 A G 5.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs566437806 chr2 119110676 AT A 0.0005538 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs566437806 chr2 119110676 AT A 5.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4849697 chr2 119110846 A G 9.41E-05 Creatinine levels / / pha003069 rs4594452 chr2 119112560 C T 4.95E-05 Creatinine levels / / pha003069 rs4470352 chr2 119113791 G C 0.0006135 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4470352 chr2 119113791 G C 6.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4470353 chr2 119113876 G A 0.0006341 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4470353 chr2 119113876 G A 6.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4641945 chr2 119124162 C T 0.0007785 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4641945 chr2 119124162 C T 7.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12467546 chr2 119129071 A G 0.0008588 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12467546 chr2 119129071 A G 8.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6542456 chr2 119138025 A G 2.90E-05 Urinary metabolites / / 21572414 rs6708595 chr2 119147509 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6708595 chr2 119147509 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6708595 chr2 119147509 G T 4.75E-06 Creatinine levels / / pha003069 rs7599033 chr2 119150692 C T 1.47E-05 Aging (time to event) / / 21782286 rs4073566 chr2 119161638 C A 0.0000861 Percentage fat mass / / 23436924 rs6711863 chr2 119166256 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6711863 chr2 119166256 C T 3.89E-05 Cognitive impairment induced by topiramate / / 22091778 rs1437690 chr2 119218881 C T 5.02E-04 Prostate cancer mortality / / 20978177 rs1965130 chr2 119220906 T C 0.000177 Salmonella-induced pyroptosis / / 22837397 rs1370509 chr2 119269428 C T 2.85E-04 Smoking cessation / / 24665060 rs12711907 chr2 119272649 T C 6.97E-04 Smoking cessation / / 24665060 rs1000950 chr2 119279230 A C 4.09E-04 Smoking cessation / / 24665060 rs7594303 chr2 119279975 C T 5.83E-04 Smoking cessation / / 24665060 rs6758889 chr2 119284856 A G 6.44E-04 Smoking cessation / / 24665060 rs1437684 chr2 119286308 T C 9.78E-05 Smoking cessation / / 24665060 rs11674141 chr2 119293076 C T 1.00E-05 Urinary metabolites / / 21572414 rs7571800 chr2 119296554 C T 7.50E-04 Smoking cessation / / 24665060 rs7598288 chr2 119297173 G A 4.20E-06 Urinary metabolites / / 21572414 rs7601764 chr2 119297984 G A 1.40E-05 Urinary metabolites / / 21572414 rs7601764 chr2 119297984 G A 6.51E-04 Smoking cessation / / 24665060 rs6733132 chr2 119305178 C T 4.60E-05 Serum metabolites / / 19043545 rs6733132 chr2 119305178 C T 1.90E-06 Urinary metabolites / / 21572414 rs4849710 chr2 119307659 G A 7.65E-04 Type 2 diabetes / / 17463246 rs4849710 chr2 119307659 G A 4.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10427226 chr2 119315217 G C 8.60E-07 Urinary metabolites / / 21572414 rs10496549 chr2 119327151 A G 5.34E-04 Multiple complex diseases / / 17554300 rs7604059 chr2 119331523 A G 1.10E-06 Urinary metabolites / / 21572414 rs1437689 chr2 119335378 T C 9.84E-04 Type 2 diabetes / / 17463246 rs536979 chr2 119343455 T C 3.65E-04 Self-reported allergy / / 23817569 rs13017945 chr2 119344750 C T 7.59E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs511923 chr2 119345850 G A 2.97E-04 Self-reported allergy / / 23817569 rs538554 chr2 119359591 A G 3.30E-04 Self-reported allergy / / 23817569 rs651477 chr2 119395691 T C 7.00E-06 Multiple sclerosis / / 19010793 rs162679 chr2 119407150 T C 8.86E-04 White matter integrity / / 22425255 rs11891602 chr2 119424298 A C 3.90E-06 Urinary metabolites / / 21572414 rs17050305 chr2 119462837 T C 1.99E-05 Multiple complex diseases / / 17554300 rs455682 chr2 119469401 G A 8.47E-04 Multiple complex diseases / / 17554300 rs1551133 chr2 119536884 C A 2.38E-05 Chronic obstructive pulmonary disease / / 19300482 rs1551133 chr2 119536884 C A 8.63E-04 Schizophrenia / / 21747397 rs4849721 chr2 119544022 G T 4.50E-05 Iron levels / / 21208937 rs41466144 chr2 119553132 G A 5.80E-05 Cognitive function / / 24684796 rs4849724 chr2 119568625 G C 6.28E-04 Multiple complex diseases / / 17554300 rs6759783 chr2 119639040 A G 8.22E-04 Type 2 diabetes / / 17463246 rs6759783 chr2 119639040 A G 9.14E-04 Multiple complex diseases / / 17554300 rs2083244 chr2 119661221 T C 3.23E-05 Melanoma / / 21926416 rs4849731 chr2 119661546 G A 1.44E-04 Multiple complex diseases / / 17554300 rs41408750 chr2 119665464 G A 4.32E-04 Insulin resistance / / 21901158 rs1898705 chr2 119665962 G A 2.84E-04 Schizophrenia / / 19197363 rs1898705 chr2 119665962 G A 1.76E-06 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs11693199 chr2 119732042 T C 2.86E-05 Triglycerides MARCO intron pha003080 rs1371562 chr2 119732948 G T 3.23E-05 Triglycerides MARCO intron pha003080 rs3731611 chr2 119742611 G T 9.70E-07 Non-obstructive azoospermia MARCO intron 22541561 rs12987402 chr2 119748796 C T 7.76E-04 Type 2 diabetes MARCO intron 17463246 rs7573929 chr2 119764127 C A 1.15E-04 Multiple complex diseases / / 17554300 rs1124830 chr2 119764462 G C 5.81E-04 Type 2 diabetes / / 17463246 rs1124830 chr2 119764462 G C 4.80E-05 Cognitive function / / 24684796 rs13031336 chr2 119765265 C T 9.09E-05 Insulin resistance / / 21901158 rs6542491 chr2 119765660 C G 7.40E-05 Cognitive function / / 24684796 rs17010531 chr2 119781128 G C 2.16E-04 Multiple complex diseases / / 17554300 rs111583672 chr2 119784066 A AG 8.71E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2422392 chr2 119798273 A G 9.90E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12479083 chr2 119809478 A T 1.54E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs13410962 chr2 119812759 C T 6.56E-04 Smoking initiation / / 24665060 rs17011073 chr2 119814011 A G 6.27E-05 Panic disorder / / 19165232 rs12616925 chr2 119826388 A G 4.93E-04 Multiple complex diseases / / 17554300 rs1439950 chr2 119827462 G A 9.48E-04 Multiple complex diseases / / 17554300 rs17189298 chr2 119845317 G A 3.00E-07 T-tau levels / / 20932310 rs330763 chr2 119864163 A G 0.000511492 Hypertension (early onset hypertension) / / 22479346 rs330768 chr2 119865356 C T 2.70E-05 Urinary metabolites / / 21572414 rs895403 chr2 119868412 A C 4.73E-04 Multiple complex diseases / / 17554300 rs921047 chr2 119870766 G A 1.80E-05 Urinary metabolites / / 21572414 rs11674898 chr2 119879640 C T 9.25E-04 Response to TNF antagonist treatment / / 21061259 rs7557802 chr2 119894965 C T 3.61E-04 Depression (quantitative trait) / / 20800221 rs7597287 chr2 119903969 G C 1.98E-05 Cocaine dependence / / 23958962 rs13020121 chr2 119904953 G A 4.08E-06 Cocaine dependence / / 23958962 rs13020121 chr2 119904953 G A 5.37E-04 Cocaine dependence / / 23958962 rs745884 chr2 119909385 C A 3.74E-05 Cocaine dependence / / 23958962 rs745888 chr2 119910314 C T 6.30E-05 Cocaine dependence / / 23958962 rs745888 chr2 119910314 C T 6.63E-05 Stroke / / pha002887 rs6758051 chr2 119914101 T G 5.10E-06 Cocaine dependence C1QL2 UTR-3 23958962 rs7579840 chr2 119921881 A G 1.96E-05 Multiple complex diseases / / 17554300 rs7584975 chr2 119942569 C T 5.74E-05 Lymphocyte counts / / pha003094 rs11123504 chr2 119942886 G A 1.46E-04 Alcohol dependence / / 21314694 rs4849770 chr2 119957026 G A 1.88E-04 Alcohol dependence / / 21314694 rs838090 chr2 119997159 T C 3.96E-04 Suicide attempts in bipolar disorder STEAP3 intron 21423239 rs838086 chr2 120001502 C A 3.44E-05 Cognitive test performance STEAP3 intron 20125193 rs17805141 chr2 120005569 C T 1.84E-05 Cocaine dependence STEAP3 cds-synon 23958962 rs734846 chr2 120008556 T G 6.09E-04 Depression (quantitative trait) STEAP3 intron 20800221 rs734845 chr2 120008735 A C 6.06E-04 Depression (quantitative trait) STEAP3 intron 20800221 rs895406 chr2 120009220 C T 9.78E-04 Suicide attempts in bipolar disorder STEAP3 intron 21423239 rs895405 chr2 120009327 C G,T 2.94E-04 Suicide attempts in bipolar disorder STEAP3 intron 21423239 rs72840936 chr2 120023692 G C 3.00E-06 Cocaine dependence / / 23958962 rs3816343 chr2 120063684 C T 2.00E-04 Cognitive impairment induced by topiramate C2orf76 intron 22091778 rs7578714 chr2 120096359 T C 0.000161045 Hypertension (early onset hypertension) C2orf76 intron 22479346 rs11893035 chr2 120121834 T C 9.22E-05 Cognitive impairment induced by topiramate C2orf76 intron 22091778 rs12613135 chr2 120122340 T C 9.22E-05 Cognitive impairment induced by topiramate C2orf76 intron 22091778 rs3731607 chr2 120125058 C T 0.00068 Prostate cancer DBI missense 23555315 rs956309 chr2 120128482 C T 1.64E-04 Schizophrenia DBI intron 24043878 rs1374313 chr2 120145655 T C 9.00E-07 Obesity-related traits / / 23251661 rs2422465 chr2 120166000 G A 7.40E-06 Urinary metabolites / / 21572414 rs2579643 chr2 120217456 T C 3.08E-05 Post-operative nausea and vomiting SCTR intron 21694509 rs17016143 chr2 120226549 T G 1.19E-04 Multiple complex diseases SCTR intron 17554300 rs2918939 chr2 120226922 G A 8.40E-04 Suicide attempts in bipolar disorder SCTR intron 21423239 rs10200558 chr2 120264821 G A 9.86E-04 Multiple complex diseases SCTR intron 17554300 rs2579612 chr2 120271783 C T 1.14E-06 Hepatitis B SCTR intron 24162738 rs2579621 chr2 120294700 A C 7.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2587695 chr2 120321817 A G 9.69E-04 Multiple complex diseases PCDP1 intron 17554300 rs2587695 chr2 120321817 A G 3.00E-07 Attention deficit hyperactivity disorder PCDP1 intron 18839057 rs4586634 chr2 120328072 C A 1.21E-04 Type 2 diabetes PCDP1 intron 22158537 rs7596441 chr2 120329410 C G 1.30E-04 Type 2 diabetes PCDP1 intron 22158537 rs11676752 chr2 120330571 T A 5.24E-04 Multiple complex diseases PCDP1 intron 17554300 rs721791 chr2 120335484 A C 2.83E-05 Type 2 diabetes PCDP1 intron 22158537 rs17049444 chr2 120337094 A G 1.29E-04 Type 2 diabetes PCDP1 intron 22158537 rs6706143 chr2 120338999 C T 1.36E-04 Type 2 diabetes PCDP1 intron 22158537 rs4340526 chr2 120339740 A C 2.94E-05 Type 2 diabetes PCDP1 intron 22158537 rs13403341 chr2 120342697 G C 3.63E-05 Type 2 diabetes PCDP1 intron 22158537 rs11684429 chr2 120343559 G C 1.18E-04 Type 2 diabetes PCDP1 intron 22158537 rs10187631 chr2 120343832 G A 1.38E-04 Type 2 diabetes PCDP1 intron 22158537 rs6726971 chr2 120344873 T A 1.42E-04 Type 2 diabetes PCDP1 intron 22158537 rs10189169 chr2 120346507 T C 1.02E-04 Type 2 diabetes PCDP1 intron 22158537 rs17049538 chr2 120346763 C T 1.31E-04 Type 2 diabetes PCDP1 intron 22158537 rs17049543 chr2 120347102 A G 1.43E-04 Type 2 diabetes PCDP1 intron 22158537 rs2001656 chr2 120347226 G A,C 3.23E-05 Type 2 diabetes PCDP1 intron 22158537 rs11123528 chr2 120348676 G A 6.24E-05 Type 2 diabetes PCDP1 intron 22158537 rs11681601 chr2 120348766 C G 1.47E-04 Type 2 diabetes PCDP1 intron 22158537 rs4260253 chr2 120350266 A G 1.37E-04 Type 2 diabetes PCDP1 intron 22158537 rs4480991 chr2 120350391 C T 1.35E-04 Type 2 diabetes PCDP1 intron 22158537 rs6756018 chr2 120355007 G A 1.49E-04 Type 2 diabetes PCDP1 intron 22158537 rs2860875 chr2 120364042 T C 1.72E-04 Type 2 diabetes PCDP1 intron 22158537 rs13004936 chr2 120401427 T A 1.03E-04 Type 2 diabetes PCDP1 intron 22158537 rs939775 chr2 120408400 T C 1.04E-04 Type 2 diabetes PCDP1 intron 22158537 rs1521911 chr2 120409351 C T 1.82E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PCDP1 intron 20877124 rs1521911 chr2 120409351 C T 9.38E-05 Type 2 diabetes PCDP1 intron 22158537 rs11686014 chr2 120409616 G T 1.20E-04 Type 2 diabetes PCDP1 missense 22158537 rs10186515 chr2 120411247 T A 3.83E-04 Type 2 diabetes PCDP1 intron 22158537 rs6711244 chr2 120415348 C T 1.27E-04 Type 2 diabetes / / 22158537 rs11678053 chr2 120416787 C T 2.27E-04 Type 2 diabetes / / 22158537 rs7596716 chr2 120418222 G A 4.27E-04 Alzheimer's disease (late onset) / / 21379329 rs7596716 chr2 120418222 G A 1.88E-04 Type 2 diabetes / / 22158537 rs1879711 chr2 120418594 C A 2.84E-04 Type 2 diabetes / / 22158537 rs112839760 chr2 120435557 G GG,GT 1.64E-04 Alzheimer's disease (late onset) / / 21379329 rs1568538 chr2 120435557 G T 1.64E-04 Alzheimer's disease (late onset) / / 21379329 rs10183197 chr2 120440653 A C 4.51E-04 Multiple complex diseases / / 17554300 rs6708153 chr2 120462953 G A 5.84E-04 Type 2 diabetes / / 22158537 rs4849798 chr2 120465494 G T 5.94E-04 Type 2 diabetes / / 22158537 rs4849799 chr2 120465777 T G 6.91E-04 Type 2 diabetes / / 22158537 rs6542543 chr2 120466940 G A 8.76E-04 Type 2 diabetes / / 22158537 rs10167582 chr2 120490901 A G 3.28E-04 Multiple complex diseases / / 17554300 rs13401620 chr2 120513133 G A 2.00E-06 Breast size / / 22747683 rs61012141 chr2 120513133 G GTGCA 2.00E-06 Breast size / / 22747683 rs17667952 chr2 120577816 A G 1.60E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) PTPN4 intron 24023788 rs6730447 chr2 120682525 A C 5.80E-05 Kawasaki disease PTPN4 intron 22446962 rs6722377 chr2 120938032 G A 2.06E-04 Multiple complex diseases / / 17554300 rs4848580 chr2 121001117 C T 4.00E-04 Response to antidepressants / / 19736353 rs3980213 chr2 121004979 A G 6.10E-04 Alcohol dependence / / 20201924 rs4849842 chr2 121012666 T A 8.99E-04 Multiple complex diseases RALB intron 17554300 rs1370379 chr2 121014589 C T 5.00E-04 Alcohol dependence RALB intron 20201924 rs3931841 chr2 121041314 A G 1.64E-04 Multiple complex diseases RALB intron 17554300 rs3931840 chr2 121041347 A C 6.40E-04 Alcohol dependence RALB intron 20201924 rs3931840 chr2 121041347 A C 5.00E-04 Body mass index RALB intron 24827717 rs2289172 chr2 121046116 C G 4.06E-04 Multiple complex diseases RALB intron 17554300 rs4849849 chr2 121046573 T C 9.35E-04 Multiple complex diseases RALB intron 17554300 rs11689112 chr2 121049166 G T 2.30E-05 Lymphocyte counts RALB intron 22286170 rs12477565 chr2 121081260 G T 2.25E-06 Prostate cancer / / 24185611 rs17625845 chr2 121089731 T C 5.00E-10 Breast size / / 22747683 rs7576192 chr2 121118031 A G 0.000000148 Preeclampsia / / 22432041 rs7579169 chr2 121118124 T C 0.000000358 Preeclampsia / / 22432041 rs12711941 chr2 121123383 T G 0.000000426 Preeclampsia / / 22432041 rs11887035 chr2 121124076 C T 3.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4366914 chr2 121135655 A G 1.60E-05 Urinary metabolites / / 21572414 rs10048787 chr2 121155192 G A 3.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs4456710 chr2 121175888 C T 2.96E-04 Iron levels / / pha002876 rs7563732 chr2 121193756 C T 9.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs7581710 chr2 121195181 A G 2.00E-07 Obesity / / 21552555 rs4300832 chr2 121197341 C A 7.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4504000 chr2 121214402 C T 7.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4848596 chr2 121226137 G A 5.77E-04 Multiple complex diseases / / 17554300 rs6542599 chr2 121228177 C T 3.79E-04 Smoking quantity / / 24665060 rs4848597 chr2 121231350 C T 8.74E-05 Hypertension / / pha003041 rs940677 chr2 121235399 G T 2.37E-06 Hypertension / / pha003041 rs4849887 chr2 121245122 T C 3.00E-11 Breast size / / 22747683 rs4849887 chr2 121245122 T C 4.00E-11 Breast cancer / / 23535729 rs4849898 chr2 121261473 C T 2.29E-04 Multiple complex diseases / / 17554300 rs17050244 chr2 121282630 A G 5.00E-07 Age-related macular degeneration / / 23326517 rs940683 chr2 121284956 T C 4.92E-05 Body Mass Index / / pha003009 rs6721654 chr2 121301911 C T 7.00E-06 Age-related macular degeneration / / 23326517 rs2311597 chr2 121305771 A G 1.59E-08 Urate levels / / 23263486 rs17050272 chr2 121306440 G A 2.00E-10 Urate levels / / 23263486 rs2030746 chr2 121309488 C T 3.38E-08 Urate levels / / 23263486 rs2030746 chr2 121309488 C T 4.00E-08 Cholesterol,total / / 24097068 rs2030746 chr2 121309488 C T 9.00E-09 LDL cholesterol / / 24097068 rs6706968 chr2 121310269 A C 1.48E-08 Urate levels / / 23263486 rs11677557 chr2 121317747 A G 6.81E-05 Type 2 diabetes / / 17463246 rs3860374 chr2 121348224 C T 2.01E-04 Type 2 diabetes / / 17463246 rs3860374 chr2 121348224 C T 5.20E-06 Urinary metabolites / / 21572414 rs6746992 chr2 121348472 G A 5.20E-06 Urinary metabolites / / 21572414 rs10460460 chr2 121349814 G A 1.00E-05 Urinary metabolites / / 21572414 rs7568190 chr2 121353658 A C 3.56E-04 Type 2 diabetes / / 17463246 rs1568836 chr2 121357095 A G 2.03E-04 Multiple complex diseases / / 17554300 rs7570994 chr2 121357915 T C 8.02E-04 Multiple complex diseases / / 17554300 rs13395978 chr2 121387909 T C 8.50E-05 Triglycerides / / 19074352 rs1979165 chr2 121445220 C T 7.54E-06 Bone mineral density / / 19181680 rs1109002 chr2 121460980 G A 2.96E-07 Bone mineral density / / 19181680 rs1078382 chr2 121462747 G T 9.94E-04 Multiple complex diseases / / 17554300 rs2871636 chr2 121465200 C A 8.35E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4848104 chr2 121466356 C A 9.05E-04 Multiple complex diseases / / 17554300 rs4848106 chr2 121466496 T C 6.70E-04 Multiple complex diseases / / 17554300 rs4848107 chr2 121466599 C A 5.43E-04 Multiple complex diseases / / 17554300 rs4848107 chr2 121466599 C A 9.82E-04 Alzheimer's disease / / 24755620 rs10496562 chr2 121469965 T C 8.72E-04 Alzheimer's disease / / 24755620 rs12463908 chr2 121470971 A C 8.16E-04 Alzheimer's disease / / 24755620 rs930727 chr2 121478431 G C 6.99E-04 Multiple complex diseases / / 17554300 rs4848624 chr2 121518479 C T 9.91E-04 Myopia (pathological) / / 21095009 rs4848115 chr2 121526871 T C 6.32E-04 Heart Failure / / pha002884 rs10169929 chr2 121553197 A T 4.95E-05 Brain derived neurotrophic factor levels,in serum GLI2 nearGene-5 22047184 rs4848637 chr2 121579245 G A 7.82E-05 Post-operative nausea and vomiting GLI2 intron 21694509 rs3943552 chr2 121582057 C T 6.20E-05 Tardive dyskinesia GLI2 intron 20939080 rs277554 chr2 121631384 T C 5.53E-04 Alzheimer's disease GLI2 intron 17998437 rs277552 chr2 121632454 G A 9.46E-04 Response to taxane treatment (placlitaxel) GLI2 intron 23006423 rs277536 chr2 121652747 C T 3.26E-04 Schizophrenia GLI2 intron 19197363 rs935428 chr2 121674413 A G 2.30E-07 Facial morphology GLI2 intron 22341974 rs10206938 chr2 121675238 A G 2.20E-07 Facial morphology GLI2 intron 22341974 rs895547 chr2 121676655 T C 3.45E-04 Gallstones GLI2 intron 17632509 rs2166565 chr2 121692477 A G 5.96E-04 Type 2 diabetes GLI2 intron 17463246 rs2166565 chr2 121692477 A G 1.10E-07 Facial morphology GLI2 intron 22341974 rs11122834 chr2 121701289 T C 5.00E-06 Erectile dysfunction and prostate cancer treatment GLI2 intron 20932654 rs1466042 chr2 121702919 A G 7.16E-04 Type 2 diabetes GLI2 intron 17463246 rs1466042 chr2 121702919 A G 1.00E-07 Facial morphology GLI2 intron 22341974 rs1107445 chr2 121703133 G C 1.40E-04 Multiple complex diseases GLI2 intron 17554300 rs2311803 chr2 121703623 A G 2.87E-04 Multiple complex diseases GLI2 intron 17554300 rs4848658 chr2 121707390 C T 1.00E-07 Facial morphology GLI2 intron 22341974 rs11122835 chr2 121708159 T G 1.00E-07 Facial morphology GLI2 intron 22341974 rs10864866 chr2 121708663 A G 9.90E-08 Facial morphology GLI2 intron 22341974 rs11681136 chr2 121709091 G A 9.90E-08 Facial morphology GLI2 intron 22341974 rs17005499 chr2 121709441 G A 8.07E-04 Multiple complex diseases GLI2 intron 17554300 rs12711535 chr2 121709536 C T 6.09E-04 Type 2 diabetes GLI2 intron 17463246 rs12711535 chr2 121709536 C T 1.00E-07 Facial morphology GLI2 intron 22341974 rs12711536 chr2 121709786 C T 9.70E-08 Facial morphology GLI2 intron 22341974 rs2084234 chr2 121710855 T G 9.70E-08 Facial morphology GLI2 intron 22341974 rs11122837 chr2 121711860 G A 9.60E-08 Facial morphology GLI2 intron 22341974 rs11689760 chr2 121712260 A C 9.60E-08 Facial morphology GLI2 intron 22341974 rs280199 chr2 121733476 T C 1.73E-04 Amyotrophic Lateral Sclerosis GLI2 intron 17827064 rs149091975 chr2 121744056 G A 0.00025 Prostate cancer (non-advanced prostate cancer) GLI2 missense 23555315 rs735370 chr2 121762093 C T 2.45E-04 Taste perception / / 22132133 rs13399257 chr2 121786460 A G 9.73E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs280213 chr2 121788630 G T 1.00E-04 Prostate cancer / / 21743057 rs7608862 chr2 121788901 C T 1.00E-04 Prostate cancer / / 21743057 rs280215 chr2 121789026 T C 1.00E-04 Prostate cancer / / 21743057 rs1867907 chr2 121790225 C T 1.00E-04 Prostate cancer / / 21743057 rs1446847 chr2 121795010 T C 5.42E-06 Left ventricular mass / / 21212386 rs2249979 chr2 121807776 G A 7.04E-06 Multiple complex diseases / / 17554300 rs4848143 chr2 121812224 A G 9.00E-06 Capecitabine sensitivity / / 22864933 rs2677510 chr2 121824898 T C 3.00E-04 HIV(mother-to-child transmission) / / 20487506 rs4848683 chr2 121826718 T C 1.65E-04 Alzheimer's disease (late onset) / / 21379329 rs13384487 chr2 121829977 G A 5.58E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs13404741 chr2 121831765 T C 4.65E-04 Alzheimer's disease (late onset) / / 21379329 rs1105064 chr2 121836157 T A 1.46E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12464700 chr2 121856450 T C 1.52E-04 Alzheimer's disease (late onset) / / 21379329 rs17005883 chr2 121882281 G A 7.52E-04 Multiple complex diseases / / 17554300 rs4848687 chr2 121923127 A G 4.92E-04 Multiple complex diseases / / 17554300 rs11694438 chr2 121933873 C T 9.54E-05 Type 2 diabetes / / 17463246 rs11679589 chr2 121935057 T A 2.27E-04 Type 2 diabetes / / 17463246 rs11679589 chr2 121935057 T A 8.08E-05 Alzheimer's disease / / 17998437 rs4848692 chr2 121940001 G A 1.71E-04 Type 2 diabetes / / 17463246 rs4848692 chr2 121940001 G A 2.83E-05 Alzheimer's disease / / 17998437 rs17006044 chr2 121942844 A G 8.41E-04 Multiple complex diseases / / 17554300 rs12467309 chr2 121943357 C T 2.38E-04 Alzheimer's disease / / 17998437 rs12467309 chr2 121943357 C T 2.59E-04 Alzheimer's disease / / pha002879 rs11682545 chr2 121945825 C T 3.95E-06 Alzheimer's disease / / 17998437 rs11122849 chr2 121945933 A G 2.68E-05 Type 2 diabetes / / 17463246 rs12478773 chr2 121946407 A G 5.21E-05 Blood Pressure / / pha003047 rs7570949 chr2 121968685 C T 2.98E-04 Type 2 diabetes / / 17463246 rs1078442 chr2 121988924 C A 0.0000793 Percentage fat mass,diabetics removed TFCP2L1 intron 23436924 rs17006292 chr2 122018763 C A 5.00E-09 Behcet's disease TFCP2L1 intron 23001997 rs6712340 chr2 122031769 C T 1.44E-05 Gallstones TFCP2L1 intron 17632509 rs6717937 chr2 122043586 C A 5.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs7576294 chr2 122045545 G A 9.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs2713245 chr2 122046743 G T 7.67E-04 Multiple complex diseases / / 17554300 rs2713243 chr2 122047043 C A 9.19E-04 Multiple complex diseases / / 17554300 rs2580337 chr2 122053982 A G 8.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs2580333 chr2 122054963 C G 4.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs2580330 chr2 122058534 A G 1.43E-04 Multiple complex diseases / / 17554300 rs2580360 chr2 122063744 A T 4.53E-05 Suicide attempts in bipolar disorder / / 21423239 rs2919051 chr2 122095640 C T 4.28E-05 Coronary heart disease CLASP1 UTR-3 pha003055 rs12622810 chr2 122103861 C T 5.40E-04 Bipolar disorder,schizoaffective CLASP1 intron 19567891 rs9653407 chr2 122120270 A G 4.19E-04 Bipolar disorder,schizoaffective CLASP1 intron 19567891 rs10496565 chr2 122148174 A G 3.32E-04 Lung function (forced expiratory volume in 1 second) CLASP1 intron 24023788 rs12711551 chr2 122163006 T C 8.43E-04 Bipolar disorder,schizoaffective CLASP1 intron 19567891 rs934760 chr2 122286442 A G 6.30E-05 Weight loss (gastric bypass surgery) CLASP1 intron 23643386 rs11122861 chr2 122353610 G A 7.50E-04 Bipolar disorder,schizoaffective CLASP1 intron 19567891 rs7558771 chr2 122391833 A G 8.35E-04 Bipolar disorder,schizoaffective CLASP1 intron 19567891 rs6723029 chr2 122419911 T G 1.65E-04 Multiple complex diseases LOC254128 intron 17554300 rs7562021 chr2 122511856 T C 2.87E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs11122867 chr2 122515214 G T 1.63E-04 Obesity (extreme) TSN intron 21935397 rs12328818 chr2 122520557 A T 2.26E-04 Multiple complex diseases TSN intron 17554300 rs12618503 chr2 122537773 C T 5.09E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7577075 chr2 122578042 A G 6.92E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7577075 chr2 122578042 A G 3.99E-04 Stroke / / pha002887 rs6761482 chr2 122594780 G A 7.74E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs10460462 chr2 122599806 G T 7.86E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6724570 chr2 122599911 G A 2.31E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6753114 chr2 122600116 A G 2.32E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs10460453 chr2 122601302 T C 2.32E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7595430 chr2 122610306 C G 6.67E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs13028433 chr2 122615008 T C 6.81E-04 Type 2 diabetes / / 17463246 rs4267513 chr2 122615926 C T 7.85E-04 Type 2 diabetes / / 17463246 rs4267514 chr2 122616181 C T 8.46E-04 Type 2 diabetes / / 17463246 rs4848163 chr2 122616961 G C 3.25E-04 Type 2 diabetes / / 17463246 rs4848163 chr2 122616961 G C 2.41E-04 Multiple complex diseases / / 17554300 rs4848733 chr2 122647656 C T 7.61E-05 Bipolar disorder / / 20451256 rs4848733 chr2 122647656 C T 8.06E-08 Metabolite levels / / 23281178 rs6754238 chr2 122647744 G A 6.90E-04 Multiple complex diseases / / 17554300 rs4368337 chr2 122662107 C T 8.43E-05 Bipolar disorder / / 19488044 rs4241112 chr2 122662212 T C 6.06E-05 Attention deficit hyperactivity disorder / / 18980221 rs4241112 chr2 122662212 T C 9.25E-06 Attention deficit hyperactivity disorder / / pha002875 rs7594821 chr2 122710665 G A 8.30E-04 Multiple complex diseases / / 17554300 rs7594821 chr2 122710665 G A 3.58E-04 Alzheimer's disease / / 17998437 rs1517712 chr2 122734147 C T 3.90E-04 Multiple complex diseases / / 17554300 rs4848739 chr2 122755302 A C 1.06E-04 Multiple complex diseases / / 17554300 rs17779391 chr2 122776465 C T 3.76E-05 Attention deficit hyperactivity disorder / / pha002875 rs2678160 chr2 122783985 T C 1.47E-04 Multiple complex diseases / / 17554300 rs1712861 chr2 122786238 G A 3.95E-04 Multiple complex diseases / / 17554300 rs1517711 chr2 122812115 G A 4.75E-04 Multiple complex diseases / / 17554300 rs1712842 chr2 122819883 A G 1.38E-04 Multiple complex diseases / / 17554300 rs6734612 chr2 122820360 A T 3.10E-04 Multiple complex diseases / / 17554300 rs908678 chr2 122832639 T A 6.13E-05 Multiple complex diseases / / 17554300 rs1922179 chr2 122847139 C T 3.20E-04 Alcohol dependence / / 20201924 rs12623552 chr2 122854657 G A 2.89E-04 Multiple complex diseases / / 17554300 rs1560603 chr2 122870285 T C 1.53E-04 Multiple complex diseases / / 17554300 rs7596715 chr2 122871314 G A 1.75E-04 Multiple complex diseases / / 17554300 rs1922182 chr2 122884594 C A 2.49E-04 Multiple complex diseases / / 17554300 rs11685781 chr2 122909011 G T 1.31E-04 Attention deficit hyperactivity disorder / / pha002875 rs6731435 chr2 122928698 T C 1.99E-04 Multiple complex diseases / / 17554300 rs1545015 chr2 122930682 A G 3.67E-04 Type 2 diabetes / / 17463246 rs1545016 chr2 122932022 C A 5.76E-05 Coronary restenosis / / 21878436 rs1897439 chr2 122936000 A G 4.04E-04 Multiple complex diseases / / 17554300 rs1432312 chr2 122936737 T C 4.22E-05 Information processing speed / / 21130836 rs1432312 chr2 122936737 T C 7.82E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs4848174 chr2 122943468 C T 1.93E-04 Vaspin levels / / 22907691 rs4848174 chr2 122943468 C T 0.0001934 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs2163656 chr2 122951824 C T 7.71E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7597014 chr2 122952356 C T 4.56E-04 Aortic root size / / 21223598 rs1432302 chr2 122953150 C T 3.96E-05 Prostate-specific antigen levels / / 23359319 rs1079949 chr2 122955771 G T 3.26E-05 Monocyte chemoattractant protein-1 / / pha003071 rs10496584 chr2 123126479 A G 4.00E-06 Lentiform nucleus volume / / 22903471 rs2037892 chr2 123127789 G A 5.00E-06 Lentiform nucleus volume / / 22903471 rs33920762 chr2 123135010 T C 6.80E-05 Multiple complex diseases / / 17554300 rs1919922 chr2 123136890 C T 5.00E-06 Lentiform nucleus volume / / 22903471 rs4848768 chr2 123141545 A G 6.00E-06 Lentiform nucleus volume / / 22903471 rs6720918 chr2 123157046 T A 1.90E-04 Breast cancer and prostate cancer / / 17903305 rs4848180 chr2 123170441 C T 4.36E-04 Urinary albumin excretion rate in type 1 diabetes / / 24595857 rs10496586 chr2 123186585 C T 3.90E-04 Crohn's disease / / 17684544 rs1580069 chr2 123200413 G A 6.10E-04 Smoking cessation / / 24665060 rs13419434 chr2 123208669 T A 9.10E-05 Age-related macular degeneration / / 20861866 rs17007761 chr2 123225623 C A 1.00E-08 Immune reponse to smallpox (secreted IFN-alpha) / / 22610502 rs1527243 chr2 123291022 C T 1.00E-06 Erectile dysfunction and prostate cancer treatment / / 20932654 rs10201094 chr2 123306329 C G 2.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs10201094 chr2 123306329 C G 3.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs2091427 chr2 123307057 C G 2.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs2091427 chr2 123307057 C G 3.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs1080548 chr2 123308174 C T 2.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs1080548 chr2 123308174 C T 3.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs11695611 chr2 123314768 C T 2.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs11695611 chr2 123314768 C T 3.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs9308637 chr2 123315041 C T 2.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs9308637 chr2 123315041 C T 3.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs1561552 chr2 123319001 T G 1.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs1561552 chr2 123319001 T G 2.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs7573865 chr2 123319451 G C 1.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs7573865 chr2 123319451 G C 2.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs9308638 chr2 123320028 T G 1.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs9308638 chr2 123320028 T G 2.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs766757 chr2 123320715 C T 2.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs766757 chr2 123320715 C T 2.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs7581875 chr2 123321994 C T 1.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs7581875 chr2 123321994 C T 2.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs1527255 chr2 123322387 C A 1.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs1527255 chr2 123322387 C A 2.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs6541834 chr2 123324533 G T 1.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs6541834 chr2 123324533 G T 2.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs11122916 chr2 123326143 C T 1.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs11122916 chr2 123326143 C T 2.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs6759289 chr2 123326947 A C 1.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs6759289 chr2 123326947 A C 2.63E-04 Suicide attempts in bipolar disorder / / 21041247 rs13425998 chr2 123328891 T C 1.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs13425998 chr2 123328891 T C 2.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs10195812 chr2 123329724 C T 1.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs10195812 chr2 123329724 C T 2.53E-04 Suicide attempts in bipolar disorder / / 21041247 rs1527253 chr2 123331847 T C 1.53E-04 Suicide attempts in bipolar disorder / / 21041247 rs1527253 chr2 123331847 T C 2.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs999492 chr2 123332354 A C 1.13E-04 Suicide attempts in bipolar disorder / / 21041247 rs999492 chr2 123332354 A C 2.48E-04 Suicide attempts in bipolar disorder / / 21041247 rs2272315 chr2 123334253 A G 2.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs2272315 chr2 123334253 A G 9.55E-05 Suicide attempts in bipolar disorder / / 21041247 rs1439838 chr2 123335740 A T 2.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs1439838 chr2 123335740 A T 7.70E-05 Suicide attempts in bipolar disorder / / 21041247 rs10445851 chr2 123336313 T G 1.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs10445851 chr2 123336313 T G 2.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs10864879 chr2 123342393 G C 1.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs10864879 chr2 123342393 G C 8.77E-05 Suicide attempts in bipolar disorder / / 21041247 rs1304771 chr2 123345060 G A 1.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs1304771 chr2 123345060 G A 1.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs10171928 chr2 123352317 C T 1.13E-04 Suicide attempts in bipolar disorder / / 21041247 rs10171928 chr2 123352317 C T 1.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs2418570 chr2 123352917 A G 1.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs2418570 chr2 123352917 A G 9.12E-05 Suicide attempts in bipolar disorder / / 21041247 rs1405604 chr2 123354282 A G 1.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs1405604 chr2 123354282 A G 2.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs6753885 chr2 123358926 T A 1.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs6753885 chr2 123358926 T A 1.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs2043940 chr2 123366899 T C 1.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs2043940 chr2 123366899 T C 1.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs1595755 chr2 123371222 T C 1.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs1595755 chr2 123371222 T C 1.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs1918273 chr2 123375001 G T 1.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs1918273 chr2 123375001 G T 6.88E-05 Suicide attempts in bipolar disorder / / 21041247 rs1371489 chr2 123381819 C T 1.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs1371489 chr2 123381819 C T 6.06E-05 Suicide attempts in bipolar disorder / / 21041247 rs11684281 chr2 123382031 G T 1.21E-04 Suicide attempts in bipolar disorder / / 21041247 rs11684281 chr2 123382031 G T 1.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs11897702 chr2 123389709 C T 1.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs11897702 chr2 123389709 C T 4.73E-05 Suicide attempts in bipolar disorder / / 21041247 rs987707 chr2 123392303 C T 2.16E-05 Suicide attempts in bipolar disorder / / 21041247 rs987707 chr2 123392303 C T 9.50E-05 Suicide attempts in bipolar disorder / / 21041247 rs17039782 chr2 123393571 T C 1.96E-05 Suicide attempts in bipolar disorder / / 21041247 rs17039782 chr2 123393571 T C 9.31E-05 Suicide attempts in bipolar disorder / / 21041247 rs4848185 chr2 123394405 A G 1.78E-05 Suicide attempts in bipolar disorder / / 21041247 rs4848185 chr2 123394405 A G 9.12E-05 Suicide attempts in bipolar disorder / / 21041247 rs9646894 chr2 123395432 A G 7.64E-05 Aging (time to event) / / 21782286 rs13400652 chr2 123395877 C T 5.72E-05 Nicotine smoking / / 19268276 rs7582802 chr2 123397312 G A 8.39E-04 Depression (quantitative trait) / / 20800221 rs7594595 chr2 123401043 C A 8.71E-04 Depression (quantitative trait) / / 20800221 rs7608903 chr2 123401189 T C 8.79E-04 Depression (quantitative trait) / / 20800221 rs1595757 chr2 123403621 T C 9.20E-04 Depression (quantitative trait) / / 20800221 rs10166255 chr2 123407250 T C 9.24E-04 Depression (quantitative trait) / / 20800221 rs11893130 chr2 123414629 A G 8.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs10201125 chr2 123431555 C T 8.41E-04 Depression (quantitative trait) / / 20800221 rs7598320 chr2 123431921 G A 9.70E-04 Alzheimer's disease / / 17998437 rs7598320 chr2 123431921 G A 3.06E-06 Recombination rate / / 21698098 rs6541846 chr2 123432820 A G 8.53E-04 Depression (quantitative trait) / / 20800221 rs2418650 chr2 123438579 C A 9.19E-04 Depression (quantitative trait) / / 20800221 rs10166571 chr2 123440796 C T 9.56E-04 Depression (quantitative trait) / / 20800221 rs4528763 chr2 123451593 C G 6.23E-04 Alzheimer's disease / / 17998437 rs893743 chr2 123451795 A G 3.57E-05 Cognitive test performance / / 20125193 rs12619304 chr2 123472119 A G 5.26E-04 Alzheimer's disease / / 17998437 rs7604792 chr2 123490225 T C 8.05E-05 Cognitive test performance / / 20125193 rs10496595 chr2 123502497 C T 1.95E-04 HIV-1 viral setpoint / / 17641165 rs6749889 chr2 123503566 T C 2.00E-04 HIV-1 viral setpoint / / 17641165 rs6541855 chr2 123506815 T C 2.00E-04 HIV-1 viral setpoint / / 17641165 rs12327981 chr2 123512526 T G 2.01E-04 HIV-1 viral setpoint / / 17641165 rs296034 chr2 123602800 C T 0.000316 Breast cancer early age of onset / / 18463975 rs17008837 chr2 123639466 A G 4.82E-05 Bipolar disorder,affective / / 20528957 rs17367118 chr2 123641611 G A 9.00E-06 Attention deficit hyperactivity disorder / / 18821565 rs17008879 chr2 123655136 G T 4.92E-05 Bipolar disorder,affective / / 20528957 rs1850585 chr2 123663290 T C 4.88E-04 Premature ovarian failure / / 19508998 rs1850585 chr2 123663290 T C 1.06E-04 Bipolar disorder,affective / / 20528957 rs17008943 chr2 123684959 C G 1.08E-04 Bipolar disorder,affective / / 20528957 rs1527978 chr2 123704606 C T 4.88E-04 Premature ovarian failure / / 19508998 rs17008994 chr2 123720609 T C 6.20E-05 Bipolar disorder,affective / / 20528957 rs17009003 chr2 123721422 C T 2.01E-05 Bipolar disorder,affective / / 20528957 rs17009017 chr2 123727810 A G 1.29E-04 Bipolar disorder,affective / / 20528957 rs17009035 chr2 123732130 C A 7.89E-05 Bipolar disorder,affective / / 20528957 rs7571273 chr2 123796040 G A 9.00E-05 Serum metabolites / / 19043545 rs299566 chr2 123802996 T A 5.37E-04 Multiple complex diseases / / 17554300 rs12470896 chr2 123803856 G A 6.93E-05 Cognitive decline / / 22054870 rs299575 chr2 123808961 A G 1.00E-05 Smoking behavior / / 20418888 rs299584 chr2 123810650 C T 6.00E-04 Multiple complex diseases / / 17554300 rs1507666 chr2 123815985 A T 2.00E-04 Type 2 diabetes / / 17846126 rs1395931 chr2 123818973 A G 2.90E-05 Type 2 diabetes / / 17846126 rs17039820 chr2 123825356 C A 8.02E-06 Personality dimensions / / 23658558 rs299541 chr2 123826562 G A 3.02E-05 Vascular dementia / / 22116812 rs13011089 chr2 123828854 T G 4.98E-05 HIV-1 control / / 20041166 rs10183651 chr2 123857742 C T 8.33E-05 Vascular dementia / / 22116812 rs7608162 chr2 123888744 A C 9.72E-04 Alzheimer's disease / / 22005930 rs11122943 chr2 123898116 C T 8.82E-04 Alzheimer's disease / / 22005930 rs6709545 chr2 123906154 A G 9.21E-04 Alzheimer's disease / / 22005930 rs1515155 chr2 123925670 T G 8.00E-04 Alzheimer's disease / / 22005930 rs1515156 chr2 123925693 T C 7.60E-04 Alzheimer's disease / / 22005930 rs10168304 chr2 124000929 A T 9.07E-04 Type 2 diabetes / / 17463246 rs1519277 chr2 124018799 C T 5.10E-04 Taste perception / / 22132133 rs17184604 chr2 124050854 G A 9.24E-04 Multiple complex diseases / / 17554300 rs2030833 chr2 124075367 G A 7.25E-20 Varicose Veins / / pha001412 rs2030833 chr2 124075367 G A 7.47E-07 Pure-tone audiometry / / pha001968 rs1607514 chr2 124090707 G A 5.31E-04 Type 2 diabetes / / 17463246 rs993934 chr2 124109213 A G 7.38E-04 Type 2 diabetes / / 17463246 rs7604683 chr2 124128700 A G 3.94E-04 Type 2 diabetes / / 17463246 rs6541897 chr2 124154449 G A 9.43E-05 Multiple complex diseases / / 17554300 rs6541898 chr2 124154796 G A 8.80E-05 Multiple complex diseases / / 17554300 rs1980357 chr2 124155289 G C 3.44E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs12475652 chr2 124156469 A C 7.86E-05 Multiple complex diseases / / 17554300 rs5029700 chr2 124156844 G A 7.20E-05 Multiple complex diseases / / 17554300 rs12468931 chr2 124157877 G A 9.13E-05 Multiple complex diseases / / 17554300 rs6743440 chr2 124158880 T A 6.53E-05 Multiple complex diseases / / 17554300 rs6723718 chr2 124163193 G A 8.44E-05 Multiple complex diseases / / 17554300 rs1405093 chr2 124169595 A G 2.11E-04 Multiple complex diseases / / 17554300 rs6751285 chr2 124169811 C T 5.52E-05 Multiple complex diseases / / 17554300 rs13000960 chr2 124172605 A G 7.17E-05 Multiple complex diseases / / 17554300 rs11122979 chr2 124174155 G C 5.24E-05 Multiple complex diseases / / 17554300 rs1358053 chr2 124177870 T C 7.80E-05 Multiple complex diseases / / 17554300 rs2419737 chr2 124187984 G A 6.04E-05 Multiple complex diseases / / 17554300 rs7585580 chr2 124190566 C T 4.01E-05 Multiple complex diseases / / 17554300 rs2900971 chr2 124191768 T A 5.29E-05 Multiple complex diseases / / 17554300 rs7581320 chr2 124220901 T C 9.07E-05 Multiple complex diseases / / 17554300 rs6725855 chr2 124224582 T C 2.65E-04 Multiple complex diseases / / 17554300 rs4848866 chr2 124242210 G A 3.29E-04 Multiple complex diseases / / 17554300 rs12185746 chr2 124246717 C T 2.72E-04 Multiple complex diseases / / 17554300 rs11122985 chr2 124250217 C T 7.12E-04 Multiple complex diseases / / 17554300 rs10496614 chr2 124276444 T C 3.52E-05 Waist-Hip Ratio / / pha003028 rs2419976 chr2 124280149 T C 6.39E-04 Stroke / / pha002887 rs9678660 chr2 124291689 C A 5.93E-08 Metabolite levels / / 23281178 rs7556991 chr2 124301185 G A 8.64E-08 Metabolite levels / / 23281178 rs6748146 chr2 124302649 G A 1.83E-04 Obesity (extreme) / / 21935397 rs11890814 chr2 124311198 G T 5.93E-08 Metabolite levels / / 23281178 rs11899792 chr2 124332702 G A 5.22E-08 Metabolite levels / / 23281178 rs2419986 chr2 124336412 G A 2.08E-05 Waist-Hip Ratio / / pha003013 rs2419986 chr2 124336412 G A 2.72E-06 Waist-Hip Ratio / / pha003028 rs4848873 chr2 124357086 C G 9.66E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs17010303 chr2 124361576 A G 4.23E-05 Waist-Hip Ratio / / pha003013 rs17010303 chr2 124361576 A G 5.47E-06 Waist-Hip Ratio / / pha003028 rs2707549 chr2 124403557 C A 2.30E-04 Pulmonary function / / 23932459 rs2670610 chr2 124429542 G A 2.87E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2256248 chr2 124433560 G A 8.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2256248 chr2 124433560 G A 9.90E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs2670605 chr2 124436630 A G 9.66E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs7593488 chr2 124481347 G A 5.84E-04 Tourette syndrome / / 22889924 rs12620260 chr2 124481367 C T 6.10E-06 Urinary metabolites / / 21572414 rs13006237 chr2 124515041 G A 9.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs1513788 chr2 124526322 G A 1.00E-04 Information processing speed / / 21130836 rs925796 chr2 124665077 A G 6.86E-04 Smoking initiation / / 24665060 rs12469604 chr2 124678253 G A 4.46E-04 Alzheimer's disease (late onset) / / 21379329 rs7577143 chr2 124706091 A G 9.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs1214060 chr2 124718604 C G 1.60E-05 Urinary metabolites / / 21572414 rs1214045 chr2 124723224 A C 9.82E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1400064 chr2 124729011 A C,G,T 6.87E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11123013 chr2 124739150 G T 4.80E-06 Urinary metabolites / / 21572414 rs1921817 chr2 124749962 T C 1.07E-05 Orofacial clefts / / 22419666 rs4848905 chr2 124754515 C T 6.81E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13431665 chr2 124754742 A G 5.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17010780 chr2 124814804 T G 5.97E-04 Type 2 diabetes CNT/P5 intron 17463246 rs17010827 chr2 124835210 C T 9.30E-05 Psoriasis CNT/P5 intron 19169255 rs7571072 chr2 124841261 G A 3.28E-04 Schizophrenia (cytomegalovirus infection interaction) CNT/P5 intron 23358160 rs7571072 chr2 124841261 G A 5.01E-05 Soluble levels of adhesion molecules CNT/P5 intron pha003072 rs1347876 chr2 124847337 C A 3.51E-05 Soluble levels of adhesion molecules CNT/P5 intron pha003072 rs17278676 chr2 124849389 T G 4.40E-05 Soluble levels of adhesion molecules CNT/P5 intron pha003072 rs12105596 chr2 124858946 G A 3.30E-04 Smoking initiation CNT/P5 intron 24665060 rs12105790 chr2 124860820 G A 2.36E-04 Smoking initiation CNT/P5 intron 24665060 rs7577916 chr2 124869709 T C 9.49E-05 Soluble levels of adhesion molecules CNT/P5 intron pha003072 rs17010871 chr2 124874645 G A 1.79E-07 Multiple complex diseases CNT/P5 intron 17554300 rs17010872 chr2 124875274 C T 8.68E-04 Multiple complex diseases CNT/P5 intron 17554300 rs7592198 chr2 124879107 T C 6.78E-04 Smoking initiation CNT/P5 intron 24665060 rs10496628 chr2 124892592 C T 7.65E-05 Soluble levels of adhesion molecules CNT/P5 intron pha003072 rs17010907 chr2 124893260 C G 9.10E-05 Response to statin therapy CNT/P5 intron 20339536 rs4456715 chr2 124894409 G C 3.92E-04 Smoking initiation CNT/P5 intron 24665060 rs960537 chr2 124913517 G A 5.61E-04 Multiple complex diseases CNT/P5 intron 17554300 rs1529289 chr2 124915643 G T 4.40E-05 Serum metabolites CNT/P5 intron 19043545 rs1530104 chr2 124922297 A G 9.65E-05 Serum metabolites CNT/P5 intron 19043545 rs2699367 chr2 124922818 C T 9.65E-05 Serum metabolites CNT/P5 intron 19043545 rs4848917 chr2 124925587 G A 2.00E-04 Cognitive impairment induced by topiramate CNT/P5 intron 22091778 rs7558429 chr2 124944244 C T 2.45E-04 Major depressive disorder CNT/P5 intron 22472876 rs17011049 chr2 124944824 C T 7.44E-04 Multiple complex diseases CNT/P5 intron 17554300 rs7569367 chr2 124946945 C T 2.19E-04 Major depressive disorder CNT/P5 intron 22472876 rs1170612 chr2 124983056 T C 6.00E-06 Schizophrenia CNT/P5 intron 22885689 rs1170612 chr2 124983056 T C 9.00E-06 Schizophrenia CNT/P5 intron 22885689 rs1367248 chr2 124998364 G T 3.00E-06 Tonometry CNT/P5 intron 17903302 rs779985 chr2 125004689 T C 3.87E-05 Psoriasis CNT/P5 intron 18364390 rs17011309 chr2 125044669 C T 3.40E-04 Multiple complex diseases CNT/P5 intron 17554300 rs780020 chr2 125051230 C T 0.00041 Endometrial cancer CNT/P5 intron 22426144 rs780023 chr2 125052071 C T 8.13E-04 Stroke CNT/P5 intron pha002886 rs733112 chr2 125061838 C A 7.60E-05 Information processing speed CNT/P5 intron 21130836 rs733112 chr2 125061838 C A 1.09E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) CNT/P5 intron 23648065 rs2553634 chr2 125068032 G A 8.58E-05 ldl cholesterol CNT/P5 intron pha003077 rs779979 chr2 125078104 A C 2.49E-04 Alzheimer's disease CNT/P5 intron 22005930 rs2553628 chr2 125083298 G A 5.94E-04 Alzheimer's disease CNT/P5 intron 22005930 rs2565748 chr2 125086667 C T 6.08E-04 Alzheimer's disease CNT/P5 intron 22005930 rs7582767 chr2 125108364 A G 1.53E-06 Telomere length CNT/P5 intron 23001564 rs7578650 chr2 125112975 A G 1.40E-05 Cognitive performance CNT/P5 intron 19734545 rs2565763 chr2 125143493 G A,T 7.72E-05 Fibrinogen CNT/P5 intron pha003068 rs2059980 chr2 125146329 C T 5.00E-06 Cognitive test performance CNT/P5 intron 20125193 rs780005 chr2 125147162 C T 8.00E-06 Urinary metabolites CNT/P5 intron 21572414 rs4848931 chr2 125148667 C T 4.87E-04 Suicide attempts in bipolar disorder CNT/P5 intron 21423239 rs1864468 chr2 125150792 G A 4.54E-04 Suicide attempts in bipolar disorder CNT/P5 intron 21423239 rs1367244 chr2 125154334 G A 4.86E-04 Suicide attempts in bipolar disorder CNT/P5 intron 21423239 rs1835353 chr2 125163827 G T 8.30E-05 Lipid traits CNT/P5 intron 17903299 rs2420864 chr2 125217386 T C 2.77E-08 Meningococcal disease CNT/P5 intron 20694013 rs2421083 chr2 125246092 G A 4.92E-05 Attention deficit hyperactivity disorder CNT/P5 intron 22420046 rs11899928 chr2 125256736 T C 3.00E-06 IgG glycosylation CNT/P5 intron 23382691 rs11899928 chr2 125256736 T C 8.00E-06 IgG glycosylation CNT/P5 intron 23382691 rs11899928 chr2 125256736 T C 9.00E-06 IgG glycosylation CNT/P5 intron 23382691 rs17727261 chr2 125281910 C T 5.00E-07 Response to antipsychotic treatment CNT/P5 missense 19721433 rs13021885 chr2 125291837 C T 8.00E-06 IgG glycosylation CNT/P5 intron 23382691 rs12464032 chr2 125297608 G A 3.79E-05 Parkinson's disease CNT/P5 intron 21738487 rs12470517 chr2 125299661 T C 4.07E-05 Parkinson's disease CNT/P5 intron 21738487 rs1504009 chr2 125303280 T C 3.83E-05 Parkinson's disease CNT/P5 intron 21738487 rs2047877 chr2 125317108 G A 7.39E-04 Parkinson's disease CNT/P5 intron 16252231 rs17392176 chr2 125322648 C T 4.70E-05 Response to statin therapy CNT/P5 intron 20339536 rs17392197 chr2 125324525 A G 9.00E-06 Urinary metabolites CNT/P5 intron 21572414 rs2901331 chr2 125327950 G A 6.00E-06 Response to statin therapy CNT/P5 intron 20339536 rs17320299 chr2 125327962 G A 1.67E-06 Tunica Media CNT/P5 intron pha003034 rs6739605 chr2 125329041 A C 1.40E-05 Response to statin therapy CNT/P5 intron 20339536 rs17320347 chr2 125329445 G A 1.40E-05 Response to statin therapy CNT/P5 intron 20339536 rs6757796 chr2 125344186 A G 7.20E-04 Multiple complex diseases CNT/P5 intron 17554300 rs4355122 chr2 125346337 C T 3.93E-06 Fibrinogen CNT/P5 intron pha003068 rs1454133 chr2 125383348 G T 9.78E-04 Depression (quantitative trait) CNT/P5 intron 20800221 rs4848252 chr2 125385662 A G 7.62E-04 Depression (quantitative trait) CNT/P5 intron 20800221 rs1587788 chr2 125391317 T C 9.84E-04 Depression (quantitative trait) CNT/P5 intron 20800221 rs2219107 chr2 125391574 T G 8.50E-04 Depression (quantitative trait) CNT/P5 intron 20800221 rs7599787 chr2 125391858 A G 9.84E-04 Depression (quantitative trait) CNT/P5 intron 20800221 rs12995183 chr2 125392103 T C 8.16E-04 Depression (quantitative trait) CNT/P5 intron 20800221 rs11675141 chr2 125394477 T G 7.80E-04 Depression (quantitative trait) CNT/P5 intron 20800221 rs70996085 chr2 125394477 T TTCTCTTTTTCTCCTCTCCTCTG 7.80E-04 Depression (quantitative trait) CNT/P5 intron 20800221 rs4848966 chr2 125426455 T G 7.55E-04 Crohn's disease CNT/P5 intron 23266558 rs13386176 chr2 125428294 G A 2.30E-05 Coffee consumption CNT/P5 intron 21357676 rs13002390 chr2 125451034 T C 3.32E-07 White blood cell count CNT/P5 intron 21738479 rs1454134 chr2 125453333 G A 9.23E-04 Suicide attempts in bipolar disorder CNT/P5 intron 21423239 rs1454134 chr2 125453333 G A 3.14E-06 White blood cell count CNT/P5 intron 21738479 rs10178249 chr2 125454396 A G 7.19E-07 White blood cell count CNT/P5 intron 21738479 rs1993273 chr2 125455265 A G 6.48E-07 White blood cell count CNT/P5 intron 21738479 rs1993272 chr2 125455299 T C 1.57E-06 White blood cell count CNT/P5 intron 21738479 rs11902093 chr2 125455912 C G 2.03E-06 White blood cell count CNT/P5 intron 21738479 rs6755119 chr2 125456247 C G 3.69E-06 White blood cell count CNT/P5 intron 21738479 rs7580383 chr2 125457240 A G 2.59E-06 White blood cell count CNT/P5 intron 21738479 rs7580383 chr2 125457240 A G 4.79E-04 Iron levels CNT/P5 intron pha002876 rs13407611 chr2 125457258 A G,T 6.62E-07 White blood cell count CNT/P5 intron 21738479 rs12619535 chr2 125530115 A G 2.42E-05 Bipolar disorder,affective CNT/P5 intron 20528957 rs922863 chr2 125533271 G A 2.74E-05 Bipolar disorder,affective CNT/P5 intron 20528957 rs10170205 chr2 125556113 T C 8.73E-04 Coronary heart disease CNT/P5 intron 21606135 rs1840201 chr2 125648688 C T 8.44E-04 Alzheimer's disease CNT/P5 intron 17998437 rs10190995 chr2 125741700 C T 7.95E-04 Acute lung injury / / 22295056 rs4622728 chr2 125806843 T C 6.62E-05 Cognitive test performance / / 20125193 rs4622728 chr2 125806843 T C 6.22E-06 Osteoarthritis / / 22763110 rs4459741 chr2 125861848 C T 5.30E-04 Multiple complex diseases / / 17554300 rs17012349 chr2 125966414 A T 6.12E-04 Multiple complex diseases / / 17554300 rs313252 chr2 126025268 C G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1903127 chr2 126030322 C T 7.90E-06 Urinary metabolites / / 21572414 rs1459166 chr2 126034009 G A 9.75E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs6735587 chr2 126038422 T G 7.90E-06 Urinary metabolites / / 21572414 rs6735587 chr2 126038422 T G 6.13E-04 Smoking quantity / / 24665060 rs313289 chr2 126069381 G A 6.60E-04 Cognition,early reading ability / / 17684495 rs191115 chr2 126092815 G A 1.23E-04 Bone mass and geometry / / 17903296 rs313262 chr2 126105052 C A 6.19E-04 Smoking quantity / / 24665060 rs1369523 chr2 126139282 C T 1.72E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1836676 chr2 126142204 G A 1.72E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs9308661 chr2 126193494 G A 4.65E-05 Tunica Media / / pha003037 rs12469322 chr2 126207171 T G 7.17E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10490484 chr2 126249714 A C 1.32E-07 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs13001190 chr2 126273115 A G 7.77E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6542008 chr2 126361391 A T 2.90E-04 Type 2 diabetes / / 17463246 rs6728958 chr2 126365222 C T 4.88E-04 Type 2 diabetes / / 17463246 rs13432902 chr2 126393876 G A 5.67E-04 Type 2 diabetes / / 17463246 rs1863680 chr2 126398345 C T 5.61E-04 Type 2 diabetes / / 17463246 rs1863681 chr2 126398388 A C 4.82E-04 Type 2 diabetes / / 17463246 rs6542010 chr2 126412342 C T 1.78E-08 Multiple complex diseases / / 17554300 rs11890262 chr2 126495166 T C 2.29E-06 White blood cell count / / 21738479 rs17634652 chr2 126568436 C T 3.99E-04 Multiple complex diseases / / 17554300 rs6744897 chr2 126609672 G C 5.69E-04 Multiple complex diseases / / 17554300 rs13390236 chr2 126626867 C T 5.87E-04 Multiple complex diseases / / 17554300 rs2124311 chr2 126667866 T C 7.40E-04 Multiple complex diseases / / 17554300 rs12621193 chr2 126670324 G A 3.48E-04 Longevity / / 22279548 rs7557872 chr2 126679292 G A 6.23E-06 C-reactive protein / / 22492993 rs17013251 chr2 126728027 G A 3.60E-05 HIV-1 control / / 20041166 rs10496652 chr2 126736747 A G 5.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs6542033 chr2 126761171 C T 3.05E-05 Cognitive impairment induced by topiramate / / 22091778 rs1455620 chr2 126788428 G A 5.57E-05 Cognitive impairment induced by topiramate / / 22091778 rs4144048 chr2 126793525 G A,T 6.20E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs2219206 chr2 126793798 G A 1.56E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs7581039 chr2 126794403 A G 9.31E-05 Cognitive impairment induced by topiramate / / 22091778 rs4375873 chr2 126828247 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1484448 chr2 126962441 G A 7.04E-05 Cognitive impairment induced by topiramate / / 22091778 rs17013423 chr2 126968866 A G 5.82E-04 Multiple complex diseases / / 17554300 rs360252 chr2 127012268 C T 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs360235 chr2 127044904 C A 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs360290 chr2 127080061 T C 1.65E-04 Cardiovascular disease risk factors / / 21239051 rs360292 chr2 127080267 A G 1.50E-04 Cardiovascular disease risk factors / / 21239051 rs360293 chr2 127080509 G A 1.42E-04 Cardiovascular disease risk factors / / 21239051 rs360295 chr2 127080649 T C 1.42E-04 Cardiovascular disease risk factors / / 21239051 rs360296 chr2 127080693 A G 1.87E-04 Cardiovascular disease risk factors / / 21239051 rs360297 chr2 127080768 C G 1.87E-04 Cardiovascular disease risk factors / / 21239051 rs360299 chr2 127081160 G A 1.87E-04 Cardiovascular disease risk factors / / 21239051 rs360300 chr2 127081235 A G 1.87E-04 Cardiovascular disease risk factors / / 21239051 rs360301 chr2 127081303 G A 1.87E-04 Cardiovascular disease risk factors / / 21239051 rs360302 chr2 127081339 G A 1.92E-04 Cardiovascular disease risk factors / / 21239051 rs360303 chr2 127081480 A G 1.87E-04 Cardiovascular disease risk factors / / 21239051 rs360307 chr2 127082208 T C 1.86E-04 Cardiovascular disease risk factors / / 21239051 rs360308 chr2 127082310 A G 1.86E-04 Cardiovascular disease risk factors / / 21239051 rs360309 chr2 127082816 C A 1.86E-04 Cardiovascular disease risk factors / / 21239051 rs360312 chr2 127083064 A G 1.86E-04 Cardiovascular disease risk factors / / 21239051 rs360313 chr2 127083091 A G 1.86E-04 Cardiovascular disease risk factors / / 21239051 rs360316 chr2 127083873 T A 1.86E-04 Cardiovascular disease risk factors / / 21239051 rs360317 chr2 127083960 T C 1.86E-04 Cardiovascular disease risk factors / / 21239051 rs360318 chr2 127083982 T C 1.86E-04 Cardiovascular disease risk factors / / 21239051 rs360319 chr2 127084247 T C 1.86E-04 Cardiovascular disease risk factors / / 21239051 rs360320 chr2 127084470 C G 1.88E-04 Cardiovascular disease risk factors / / 21239051 rs360321 chr2 127085132 C T 1.71E-04 Cardiovascular disease risk factors / / 21239051 rs360322 chr2 127085528 C T 1.88E-04 Cardiovascular disease risk factors / / 21239051 rs11684492 chr2 127090306 C T 1.80E-04 Cardiovascular disease risk factors / / 21239051 rs359687 chr2 127115202 C T 8.71E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs360370 chr2 127118187 G A 8.71E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs360376 chr2 127119787 G T 8.30E-04 Cognition,early reading ability / / 17684495 rs11684427 chr2 127122556 G A 1.01E-04 Cardiovascular disease risk factors / / 21239051 rs11690602 chr2 127123871 C A 9.45E-05 Cardiovascular disease risk factors / / 21239051 rs11695746 chr2 127124573 T C 8.15E-05 Cardiovascular disease risk factors / / 21239051 rs12999792 chr2 127125038 G A 8.16E-05 Cardiovascular disease risk factors / / 21239051 rs17013755 chr2 127127222 A G 8.75E-04 Multiple complex diseases / / 17554300 rs359708 chr2 127127934 A G 4.29E-05 Cardiovascular disease risk factors / / 21239051 rs13034238 chr2 127130382 T C 4.30E-05 Cardiovascular disease risk factors / / 21239051 rs359706 chr2 127131081 T C 3.63E-05 Cardiovascular disease risk factors / / 21239051 rs359688 chr2 127137005 G A 7.48E-04 Premature ovarian failure / / 19508998 rs359688 chr2 127137005 G A 4.16E-05 Cardiovascular disease risk factors / / 21239051 rs13002032 chr2 127147760 G A 5.14E-05 Cardiovascular disease risk factors / / 21239051 rs13001771 chr2 127148980 A G 4.72E-05 Cardiovascular disease risk factors / / 21239051 rs2896866 chr2 127177054 C T 9.15E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12621460 chr2 127187736 A G 9.15E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs715915 chr2 127233566 G A 1.00E-04 Prostate cancer / / 21743057 rs10928884 chr2 127234126 T C 1.00E-04 Prostate cancer / / 21743057 rs7606197 chr2 127240800 A G 9.82E-04 Insulin resistance / / 21901158 rs6750543 chr2 127299285 A G 9.72E-04 Multiple complex diseases / / 17554300 rs10201742 chr2 127328773 A C 8.00E-07 Bone mineral density (BMD),in women / / 20164292 rs1550404 chr2 127330954 T G 1.00E-06 Intelligence / / 22449649 rs10211158 chr2 127341354 T C 9.40E-05 Parkinson's disease / / 21738487 rs7590496 chr2 127357688 C A 3.93E-04 Alcohol dependence / / 20201924 rs6747825 chr2 127372728 G T 1.60E-04 Smoking initiation / / 24665060 rs6711490 chr2 127372889 T A,G 4.72E-04 Smoking initiation / / 24665060 rs10180510 chr2 127376329 T C 7.24E-04 Multiple complex diseases / / 17554300 rs6723263 chr2 127378514 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs3811541 chr2 127413135 A G 1.81E-04 Vaspin levels GYPC nearGene-5 22907691 rs3811541 chr2 127413135 A G 0.0000314 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit GYPC nearGene-5 22907730 rs3811541 chr2 127413135 A G 0.0001811 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks GYPC nearGene-5 22907730 rs13008888 chr2 127414593 G C 7.75E-05 Femoral neck bone geometry GYPC intron 22087292 rs6729097 chr2 127414661 C T 5.50E-05 Femoral neck bone geometry GYPC intron 22087292 rs11894065 chr2 127415578 C T 3.78E-04 Multiple complex diseases GYPC intron 17554300 rs10928979 chr2 127420228 A G 1.28E-05 Femoral neck bone geometry GYPC intron 22087292 rs7599354 chr2 127443771 G T 9.19E-06 Hemoglobin GYPC UTR-5 pha003098 rs7599354 chr2 127443771 G T 5.62E-05 Erythrocyte counts GYPC UTR-5 pha003101 rs935019 chr2 127446489 A G 1.43E-12 Multiple complex diseases GYPC intron 17554300 rs7597899 chr2 127457760 T C 9.64E-06 Panic disorder / / 19165232 rs1000858 chr2 127459321 C T 8.66E-06 Tunica Media / / pha003034 rs2203724 chr2 127472032 G A 8.63E-05 Sodium levels / / pha003093 rs10164664 chr2 127473880 C A 8.63E-05 Sodium levels / / pha003093 rs10210965 chr2 127497136 A G 6.20E-05 Personality dimensions / / 18957941 rs10206681 chr2 127497422 C G 6.90E-05 Personality dimensions / / 18957941 rs11690317 chr2 127503370 G A 5.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs11674717 chr2 127503457 A G 4.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs7419450 chr2 127507256 G A 8.15E-04 Parkinson's disease / / 16252231 rs1914458 chr2 127515846 C T 3.56E-05 Suicide attempts in bipolar disorder / / 21423239 rs6732878 chr2 127516475 C G 7.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs6732888 chr2 127516506 C A 8.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs1914460 chr2 127531518 A C 4.48E-04 Multiple complex diseases / / 17554300 rs4322791 chr2 127556548 A G 7.32E-04 Multiple complex diseases / / 17554300 rs6745340 chr2 127558480 A G 8.39E-04 Multiple complex diseases / / 17554300 rs10167103 chr2 127578744 A G 0.00005 Pancreatic cancer and survival / / 22665904 rs10197495 chr2 127587337 T C 8.00E-05 Schizophrenia / / 19571809 rs4413107 chr2 127621402 T C 7.53E-04 Depression (quantitative trait) / / 20800221 rs6733840 chr2 127659981 T C 6.02E-05 Panic disorder / / 19165232 rs13418717 chr2 127662897 T A 3.00E-06 Heart failure / / 20445134 rs10496658 chr2 127663497 C T 1.53E-04 Multiple complex diseases / / 17554300 rs13382758 chr2 127667403 T C 2.32E-05 Waist-Hip Ratio / / pha003013 rs13382758 chr2 127667403 T C 4.60E-05 Waist-Hip Ratio / / pha003028 rs4662692 chr2 127696077 T C 8.94E-04 Multiple complex diseases / / 17554300 rs11896939 chr2 127701950 G C 8.56E-04 Multiple complex diseases / / 17554300 rs11889584 chr2 127707412 A G 4.98E-04 Multiple complex diseases / / 17554300 rs10168813 chr2 127711477 C A 5.13E-04 Multiple complex diseases / / 17554300 rs1510528 chr2 127712231 C T 4.55E-04 Multiple complex diseases / / 17554300 rs11888349 chr2 127713065 C G 3.84E-04 Multiple complex diseases / / 17554300 rs12053575 chr2 127726891 T C 2.95E-04 Multiple complex diseases / / 17554300 rs7556956 chr2 127727338 T C 5.31E-04 Multiple complex diseases / / 17554300 rs7557069 chr2 127727448 T C 6.27E-04 Multiple complex diseases / / 17554300 rs12999411 chr2 127732462 G A 7.17E-05 Cognitive performance / / 19734545 rs831360 chr2 127737632 A C,G 3.46E-04 Multiple complex diseases / / 17554300 rs546230 chr2 127739268 G T 5.98E-04 Multiple complex diseases / / 17554300 rs496421 chr2 127743858 C T 4.65E-04 Multiple complex diseases / / 17554300 rs472489 chr2 127744101 C G 4.27E-04 Multiple complex diseases / / 17554300 rs518477 chr2 127749274 T C 1.00E-04 Information processing speed / / 21130836 rs12993006 chr2 127758448 C T 4.00E-06 Systemic lupus erythematosus / / 24871463 rs9287568 chr2 127771006 A G 5.64E-04 Multiple complex diseases / / 17554300 rs11899372 chr2 127773880 G T 1.86E-08 Autism / / 22935194 rs1137845 chr2 127821207 G A 1.20E-04 Alcohol dependence BIN1 cds-synon 20201924 rs1060743 chr2 127826533 A G 5.95E-04 Alzheimer's disease BIN1 cds-synon 17998437 rs1060743 chr2 127826533 A G 1.11E-05 Alzheimer's disease (late onset) BIN1 cds-synon 21460841 rs17014873 chr2 127830219 A C 0.0000501 Amyotrophic lateral sclerosis BIN1 intron 23587638 rs10194375 chr2 127839781 C A 7.91E-05 Alzheimer's disease (late onset) BIN1 intron 21379329 rs10200967 chr2 127841769 C T 5.86E-05 Alzheimer's disease (late onset) BIN1 intron 21460841 rs17014923 chr2 127841930 C T 4.72E-04 Multiple complex diseases BIN1 intron 17554300 rs11678252 chr2 127851697 A G 4.29E-04 White matter integrity BIN1 intron 22425255 rs10207628 chr2 127852021 G A,C 4.01E-04 Multiple complex diseases BIN1 intron 17554300 rs10207628 chr2 127852021 G A,C 1.00E-06 Alzheimer's disease BIN1 intron 22005930 rs873270 chr2 127859418 T C 9.94E-04 Alzheimer's disease BIN1 intron 24755620 rs754107 chr2 127860830 C G 5.45E-05 Type 2 diabetes BIN1 intron 17463246 rs754107 chr2 127860830 C G 4.62E-04 Alzheimer's disease BIN1 intron 17998437 rs754107 chr2 127860830 C G 1.60E-09 Progranulin levels BIN1 intron 21087763 rs754107 chr2 127860830 C G 1.60E-09 Myocardial infarction BIN1 intron 21211798 rs3856378 chr2 127872347 G C 1.62E-04 Alzheimer's disease (late onset) / / 21460841 rs4663098 chr2 127873035 T C 2.46E-07 Alzheimer's disease (late onset) / / 21460841 rs4663098 chr2 127873035 T C 5.31E-04 Alzheimer's disease / / 24755620 rs3845674 chr2 127875389 T G 2.43E-07 Alzheimer's disease (late onset) / / 21460841 rs4663100 chr2 127878438 C G 2.41E-07 Alzheimer's disease (late onset) / / 21460841 rs13004848 chr2 127887560 T C 2.04E-04 Alzheimer's disease (late onset) / / 21460841 rs11689089 chr2 127887865 T C 1.53E-05 Alzheimer's disease (late onset) / / 21460841 rs12989701 chr2 127887985 C A 3.00E-10 Alzheimer's disease (late onset) / / 21390209 rs12989701 chr2 127887985 C A 1.86E-04 Alzheimer's disease (late onset) / / 21460841 rs12989701 chr2 127887985 C A 0.00065 Breast cancer / / 23555315 rs12989701 chr2 127887985 C A 6.47E-04 Alzheimer's disease / / 24755620 rs11685593 chr2 127888121 C T 5.92E-05 Alzheimer's disease (late onset) / / 21379329 rs11685593 chr2 127888121 C T 1.66E-05 Alzheimer's disease (late onset) / / 21460841 rs11680911 chr2 127888757 A C 8.46E-11 Alzheimer's disease (late onset) / / 21460841 rs11680911 chr2 127888757 A C 6.31E-11 Alzheimer's disease / / 22832961 rs7561528 chr2 127889637 G A 3.01E-06 Type 2 diabetes and other traits / / 19734900 rs7561528 chr2 127889637 G A 2.50E-04 Alzheimer's disease (late onset) / / 21379329 rs7561528 chr2 127889637 G A 4.00E-14 Alzheimer's disease (late onset) / / 21460841 rs7561528 chr2 127889637 G A 1.13E-07 Alzheimer's disease / / 21627779 rs7561528 chr2 127889637 G A 6.00E-11 Alzheimer's disease / / 22832961 rs7561528 chr2 127889637 G A 5.47E-05 Alzheimer's disease / / 24755620 rs6710467 chr2 127889932 G A 1.81E-04 Alzheimer's disease (late onset) / / 21460841 rs4663104 chr2 127890786 G C 1.64E-05 Alzheimer's disease (late onset) / / 21460841 rs6733839 chr2 127892810 C T 7.00E-44 Alzheimer's disease (late onset) / / 24162737 rs744373 chr2 127894615 A G 3.20E-06 Type 2 diabetes and other traits / / 19734900 rs744373 chr2 127894615 A G 1.00E-10 Alzheimer's disease (late onset) / / 21390209 rs744373 chr2 127894615 A G 3.00E-14 Alzheimer's disease / / 21460840 rs744373 chr2 127894615 A G 3.61E-10 Alzheimer's disease (late onset) / / 21460841 rs744373 chr2 127894615 A G 2.00E-09 Alzheimer's disease / / 21627779 rs744373 chr2 127894615 A G 1.59E-11 Prion diseases / / 22210626 rs744373 chr2 127894615 A G 1.39E-04 Alzheimer's disease (late onset) / / 23565137 rs744373 chr2 127894615 A G 6.88E-06 Alzheimer's disease / / 24755620 rs6431223 chr2 127895487 G A 8.94E-07 Alzheimer's disease (late onset) / / 21460841 rs1469980 chr2 127896023 C T 3.94E-05 Potassium levels / / pha003086 rs2118507 chr2 127903692 T C 9.72E-05 ldl cholesterol / / pha003076 rs4663109 chr2 127922292 A G 2.89E-08 Protein C levels / / 20802025 rs7587554 chr2 127924191 C T 6.85E-06 Depression (quantitative trait) / / 23290196 rs12620339 chr2 127930976 C T 1.36E-04 Type 2 diabetes / / 17463246 rs10171361 chr2 127935585 A G 2.39E-05 Multiple complex diseases / / 17554300 rs4510165 chr2 127936284 C T 1.40E-08 Protein C levels / / 20802025 rs13035268 chr2 127937551 G A 6.47E-05 Insulin Resistance / / pha003062 rs4662573 chr2 127941798 T C 1.60E-06 Retinopathy in non-diabetics CYP27C1 UTR-3 23393555 rs4284778 chr2 127946326 T C 7.24E-09 Protein C levels CYP27C1 intron 20802025 rs1566821 chr2 127946431 T G 7.67E-04 Type 2 diabetes CYP27C1 intron 17463246 rs1566821 chr2 127946431 T G 9.79E-04 Alzheimer's disease CYP27C1 intron 17998437 rs4284779 chr2 127946500 T C 9.50E-09 Protein C levels CYP27C1 intron 20802025 rs4321325 chr2 127950997 C T 9.59E-15 Protein C levels CYP27C1 intron 20802025 rs2102237 chr2 127951834 G A 2.84E-22 Varicose Veins CYP27C1 intron pha001412 rs7568070 chr2 127953054 A C 3.66E-14 Protein C levels CYP27C1 cds-synon 20802025 rs11683427 chr2 127956543 A G 2.09E-15 Protein C levels CYP27C1 intron 20802025 rs11890243 chr2 127958041 C A 2.02E-17 Protein C levels CYP27C1 intron 20802025 rs7585314 chr2 127962493 T C 3.83E-21 Protein C levels CYP27C1 intron 20802025 rs12463909 chr2 127971738 G C 6.21E-04 Type 2 diabetes / / 17463246 rs4560059 chr2 127972228 T C 9.01E-09 Protein C levels / / 20802025 rs4662710 chr2 127976817 C G 2.08E-08 Protein C levels / / 20802025 rs1504136 chr2 127977118 T C 8.52E-23 Protein C levels / / 20802025 rs7567389 chr2 127982645 A T 2.00E-06 Self-rated health / / 20707712 rs7567389 chr2 127982645 A T 9.70E-21 Protein C levels / / 20802025 rs4359587 chr2 127987049 G A 4.14E-04 Type 2 diabetes / / 17463246 rs1566822 chr2 127987391 A G 1.95E-08 Protein C levels / / 20802025 rs4300780 chr2 127989971 A G 7.66E-04 Type 2 diabetes / / 17463246 rs4300780 chr2 127989971 A G 0.000832 Height (Pygmy height) / / 22570615 rs6738690 chr2 127992725 T C 5.44E-22 Protein C levels / / 20802025 rs4662713 chr2 127994103 C T 1.34E-21 Protein C levels / / 20802025 rs1604817 chr2 127999921 C T 9.87E-26 Protein C levels / / 20802025 rs4536600 chr2 128002572 G A 3.03E-26 Protein C levels / / 20802025 rs2174270 chr2 128006078 C T 6.76E-09 Protein C levels / / 20802025 rs12465955 chr2 128007074 A T 7.07E-09 Protein C levels / / 20802025 rs6430936 chr2 128007686 A C 5.83E-22 Protein C levels / / 20802025 rs4662717 chr2 128013504 C T 7.26E-09 Protein C levels / / 20802025 rs4662717 chr2 128013504 C T 7.31E-05 Waist-Hip Ratio / / pha003013 rs4662718 chr2 128015367 C T 7.04E-22 Protein C levels ERCC3 intron 20802025 rs1566823 chr2 128018192 A G 7.03E-13 Protein C levels ERCC3 intron 20802025 rs1143407 chr2 128023884 T C 0.000562 Height (Pygmy height) ERCC3 intron 22570615 rs4150496 chr2 128029503 C T 6.78E-14 Protein C levels ERCC3 intron 20802025 rs4150496 chr2 128029503 C T 7.16E-05 ldl cholesterol ERCC3 intron pha003076 rs2134794 chr2 128030879 A C 5.62E-15 Lymphocyte counts ERCC3 intron 22286170 rs4150479 chr2 128032386 G C 7.39E-04 Smoking initiation ERCC3 intron 24665060 rs4150477 chr2 128032546 G A 7.65E-14 Protein C levels ERCC3 intron 20802025 rs4150474 chr2 128033327 C A 2.71E-21 Protein C levels ERCC3 intron 20802025 rs4150471 chr2 128034539 A G 2.66E-21 Protein C levels ERCC3 intron 20802025 rs1011019 chr2 128037560 A G 2.55E-21 Protein C levels ERCC3 intron 20802025 rs4150454 chr2 128038544 T C 6.32E-13 Protein C levels ERCC3 intron 20802025 rs4150441 chr2 128040915 T C 5.98E-13 Protein C levels ERCC3 intron 20802025 rs3768866 chr2 128045415 G A 3.37E-14 Protein C levels ERCC3 intron 20802025 rs4150407 chr2 128049631 T C 1.72E-08 Protein C levels ERCC3 intron 20802025 rs4150402 chr2 128050134 T C 8.33E-22 Protein C levels ERCC3 intron 20802025 rs7556675 chr2 128053747 C T 7.11E-20 Protein C levels ERCC3 nearGene-5 20802025 rs4233583 chr2 128060068 C A 3.77E-14 Protein C levels MAP3K2 UTR-3 20802025 rs3088374 chr2 128062048 T C 3.81E-10 Protein C levels MAP3K2 UTR-3 20802025 rs6731176 chr2 128071003 C T 1.78E-09 Protein C levels MAP3K2 intron 20802025 rs9636237 chr2 128076022 T C 6.44E-13 Protein C levels MAP3K2 intron 20802025 rs4662720 chr2 128076607 T C 3.17E-21 Protein C levels MAP3K2 intron 20802025 rs3732209 chr2 128079806 A G 1.01E-21 Protein C levels MAP3K2 cds-synon 20802025 rs12622436 chr2 128081682 C A 3.42E-14 Protein C levels MAP3K2 intron 20802025 rs6430937 chr2 128082232 C T 3.19E-04 Type 2 diabetes MAP3K2 intron 17463246 rs6430937 chr2 128082232 C T 0.00041 Coronary artery calcification MAP3K2 intron 23727086 rs12613413 chr2 128086354 C T 0.00036 Coronary artery calcification MAP3K2 intron 23727086 rs6732279 chr2 128089540 G T 3.30E-14 Protein C levels MAP3K2 intron 20802025 rs10496661 chr2 128090144 G T 3.41E-21 Protein C levels MAP3K2 intron 20802025 rs4662722 chr2 128102569 T C 4.98E-13 Protein C levels / / 20802025 rs4662580 chr2 128102806 C A 5.59E-13 Protein C levels / / 20802025 rs6716392 chr2 128107470 T C 0.000675 Height (Pygmy height) / / 22570615 rs12479003 chr2 128118553 C T 3.10E-14 Protein C levels / / 20802025 rs12479003 chr2 128118553 C T 7.16E-05 ldl cholesterol / / pha003076 rs11680949 chr2 128123562 C G 3.59E-21 Protein C levels / / 20802025 rs7589451 chr2 128128775 T C 5.13E-13 Protein C levels / / 20802025 rs11691088 chr2 128131853 A G 1.15E-21 Protein C levels / / 20802025 rs9789510 chr2 128137012 G A 2.90E-14 Protein C levels / / 20802025 rs7607907 chr2 128144286 T C 8.15E-21 Protein C levels / / 20802025 rs13029237 chr2 128147854 C T 2.79E-14 Protein C levels / / 20802025 rs8179521 chr2 128150924 A G 8.00E-07 Asthma (childhood onset) / / 17611496 rs11679414 chr2 128151003 G A 8.15E-22 Protein C levels / / 20802025 rs7580658 chr2 128159261 G A 2.10E-14 Protein C levels / / 20802025 rs7580658 chr2 128159261 G A 5.83E-05 ldl cholesterol / / pha003076 rs6430938 chr2 128162623 C T 3.45E-22 Protein C levels / / 20802025 rs6430938 chr2 128162623 C T 7.80E-04 Aortic root size / / 21223598 rs7599210 chr2 128164177 G A 1.20E-31 Protein C levels / / 20802025 rs6753288 chr2 128169899 G A 1.13E-31 Protein C levels / / 20802025 rs6753288 chr2 128169899 G A 9.41E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2069898 chr2 128174227 T C 2.26E-24 Protein C levels PROC nearGene-5 20802025 rs2069904 chr2 128175779 G A 2.29E-24 Protein C levels PROC nearGene-5 20802025 rs1799808 chr2 128175862 C T 6.03E-17 Protein C levels PROC nearGene-5 20802025 rs1799810 chr2 128176040 A T 9.00E-06 Self-rated health PROC UTR-5 20707712 rs1799810 chr2 128176040 A T 4.36E-36 Protein C levels PROC UTR-5 20802025 rs1158867 chr2 128177377 C T 4.00E-36 Protein C levels PROC intron 20802025 rs1158867 chr2 128177377 C T 4.00E-36 Asthma PROC intron 21907864 rs2069916 chr2 128178415 C T 7.14E-15 Protein C levels PROC intron 20802025 rs2069916 chr2 128178415 C T 5.88E-05 Waist-Hip Ratio PROC intron pha003013 rs2069916 chr2 128178415 C T 9.46E-05 Waist-Hip Ratio PROC intron pha003028 rs2069916 chr2 128178415 C T 3.72E-05 ldl cholesterol PROC intron pha003076 rs2069919 chr2 128179553 G A 1 Drug response to Warfarin PROC intron 19794411 rs6710535 chr2 128190960 C G 1.70E-14 Protein C levels / / 20802025 rs12468304 chr2 128193812 C T 1.28E-13 Protein C levels / / 20802025 rs6754772 chr2 128195244 G A 2.38E-12 Protein C levels / / 20802025 rs6754999 chr2 128195387 G A 2.73E-14 Protein C levels / / 20802025 rs6754999 chr2 128195387 G A 1.60E-05 Waist-Hip Ratio / / pha003013 rs6754999 chr2 128195387 G A 1.65E-05 Waist-Hip Ratio / / pha003028 rs6755028 chr2 128195442 G A 4.81E-26 Protein C levels / / 20802025 rs1473623 chr2 128196220 T C 4.83E-26 Protein C levels / / 20802025 rs11683986 chr2 128196398 C T 5.41E-21 Protein C levels / / 20802025 rs6749002 chr2 128196424 T G 4.67E-26 Protein C levels / / 20802025 rs12994586 chr2 128218364 T C 4.07E-06 Height / / pha003010 rs17261845 chr2 128223757 T A 1.66E-09 Protein C levels / / 20802025 rs17261859 chr2 128224791 T G 5.21E-09 Protein C levels / / 20802025 rs7590705 chr2 128225228 A G 2.13E-06 Height / / pha003010 rs7590705 chr2 128225228 A G 2.02E-06 Height / / pha003011 rs4662582 chr2 128226841 G A 7.73E-11 Protein C levels / / 20802025 rs777569 chr2 128229148 A T 1.55E-09 Protein C levels / / 20802025 rs334160 chr2 128243335 T C 1.84E-09 Protein C levels IWS1 intron 20802025 rs334159 chr2 128243462 T C 1.61E-09 Protein C levels IWS1 intron 20802025 rs334158 chr2 128246152 T C 1.61E-09 Protein C levels IWS1 intron 20802025 rs334156 chr2 128247640 T C 1.61E-09 Protein C levels IWS1 intron 20802025 rs334152 chr2 128249441 C T 1.61E-09 Protein C levels IWS1 intron 20802025 rs6722447 chr2 128252234 G A 6.48E-11 Protein C levels IWS1 intron 20802025 rs334151 chr2 128253571 C T 1.61E-09 Protein C levels IWS1 intron 20802025 rs334146 chr2 128258208 C A 1.60E-09 Protein C levels IWS1 intron 20802025 rs1549767 chr2 128259371 C T 6.01E-11 Protein C levels IWS1 intron 20802025 rs334144 chr2 128259657 A C 1.63E-09 Protein C levels IWS1 intron 20802025 rs334143 chr2 128263476 C T 1.60E-09 Protein C levels IWS1 intron 20802025 rs12621149 chr2 128266844 A C 7.02E-11 Protein C levels IWS1 intron 20802025 rs2679409 chr2 128270109 C T 1.58E-09 Protein C levels IWS1 intron 20802025 rs334138 chr2 128272468 A G 1.59E-09 Protein C levels IWS1 intron 20802025 rs334137 chr2 128272674 A G 1.67E-09 Protein C levels IWS1 intron 20802025 rs2460106 chr2 128273004 T A 1.54E-09 Protein C levels IWS1 intron 20802025 rs777554 chr2 128279047 C A 1.51E-09 Protein C levels IWS1 intron 20802025 rs7582598 chr2 128289856 G A 2.10E-08 Protein C levels / / 20802025 rs7570609 chr2 128289963 A C 2.57E-05 Basophils / / pha003087 rs9287540 chr2 128297727 T G 1.67E-08 Protein C levels MYO7B intron 20802025 rs2052954 chr2 128299017 C T 3.03E-08 Protein C levels MYO7B intron 20802025 rs2163348 chr2 128299079 A G 1.79E-08 Protein C levels MYO7B intron 20802025 rs1864552 chr2 128299527 C A 1.89E-08 Protein C levels MYO7B intron 20802025 rs1019842 chr2 128305196 T C 2.84E-08 Protein C levels MYO7B intron 20802025 rs6727506 chr2 128308167 G T 4.80E-09 Protein C levels MYO7B intron 20802025 rs10803588 chr2 128328375 C T 4.90E-12 Protein C levels MYO7B intron 20802025 rs10803588 chr2 128328375 C T 7.05E-05 Waist-Hip Ratio MYO7B intron pha003013 rs10803588 chr2 128328375 C T 9.58E-05 Waist-Hip Ratio MYO7B intron pha003028 rs968756 chr2 128334470 C T 9.56E-04 Suicide attempts in bipolar disorder MYO7B intron 21423239 rs12477670 chr2 128334526 A G 5.72E-11 Protein C levels MYO7B intron 20802025 rs13407823 chr2 128338714 A G 1.37E-11 Protein C levels MYO7B intron 20802025 rs4662739 chr2 128339226 G C 1.39E-11 Protein C levels MYO7B intron 20802025 rs4662740 chr2 128339456 G T 1.40E-11 Protein C levels MYO7B intron 20802025 rs11693296 chr2 128340855 G A 7.00E-06 Asthma MYO7B intron 21790008 rs10928772 chr2 128341603 T G 2.20E-10 Protein C levels MYO7B intron 20802025 rs4662743 chr2 128350808 C T 5.28E-09 Protein C levels MYO7B intron 20802025 rs4662744 chr2 128350965 C T 5.44E-09 Protein C levels MYO7B intron 20802025 rs7558838 chr2 128351346 T C 5.72E-09 Protein C levels MYO7B intron 20802025 rs6715608 chr2 128353705 A T 1.01E-08 Protein C levels MYO7B intron 20802025 rs777437 chr2 128357647 C T 1.45E-10 Protein C levels MYO7B intron 20802025 rs11691981 chr2 128364684 G A 1.10E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) MYO7B intron 24023788 rs777433 chr2 128368235 T C 6.81E-05 White matter integrity MYO7B intron 22425255 rs777435 chr2 128369896 A G 3.35E-08 Protein C levels MYO7B intron 20802025 rs930139 chr2 128370466 C T 1.34E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) MYO7B intron 24023788 rs2288657 chr2 128395498 C T 0.000000036 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) / / 23080225 rs2288657 chr2 128395498 C T 7.01E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs78022502 chr2 128396167 A C 2.00E-06 Alzheimer's disease (cognitive decline) LIMS2 UTR-3 23535033 rs2244871 chr2 128398840 T C 1.17E-04 White matter integrity LIMS2 intron 22425255 rs3771295 chr2 128404860 A G 1.00E-04 Renal cell carcinoma GPR17 intron 22010048 rs17015535 chr2 128502585 A T 6.00E-06 Coronary artery calcification WDR33 intron 23870195 rs13013415 chr2 128519797 T C 2.82E-06 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) WDR33 intron 24023788 rs13013415 chr2 128519797 T C 3.00E-06 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) WDR33 intron 24023788 rs11557685 chr2 128522383 T C 7.48E-05 Amyotrophic lateral sclerosis (sporadic) WDR33 cds-synon 24529757 rs17600177 chr2 128524807 T C 7.21E-05 Alzheimer's disease (late onset) WDR33 intron 21379329 rs3771291 chr2 128527705 C A 9.17E-05 Alzheimer's disease (late onset) WDR33 intron 21379329 rs6722353 chr2 128552970 G A 2.92E-05 Post-operative nausea and vomiting WDR33 intron 21694509 rs6430952 chr2 128554348 G T 7.73E-04 Multiple complex diseases WDR33 intron 17554300 rs335136 chr2 128567755 T C 3.44E-05 Hearing function WDR33 intron 17255346 rs335136 chr2 128567755 T C 1.10E-04 Taste perception WDR33 intron 22132133 rs2109312 chr2 128575831 C T 3.00E-05 Breast cancer and prostate cancer / / 17903305 rs7562358 chr2 128587317 C T 1.64E-04 Taste perception / / 22132133 rs1045832 chr2 128621094 A G 3.89E-04 Suicide attempts in bipolar disorder AMMECR1L UTR-3 21041247 rs13411546 chr2 128622491 G A 7.11E-04 Suicide attempts in bipolar disorder AMMECR1L UTR-3 21041247 rs2118204 chr2 128624111 T C 5.99E-04 Suicide attempts in bipolar disorder AMMECR1L intron 21041247 rs7572242 chr2 128625164 C T 5.42E-04 Suicide attempts in bipolar disorder AMMECR1L intron 21041247 rs7566163 chr2 128635987 G A 2.32E-04 Suicide attempts in bipolar disorder AMMECR1L intron 21041247 rs2405635 chr2 128637225 A G 2.28E-04 Suicide attempts in bipolar disorder AMMECR1L intron 21041247 rs10183605 chr2 128642367 C G 2.77E-04 Suicide attempts in bipolar disorder AMMECR1L UTR-5 21041247 rs10496665 chr2 128668557 A G 1.39E-12 Alcohol consumption / / pha001402 rs10754933 chr2 128841017 C T 8.52E-04 Multiple complex diseases / / 17554300 rs13387889 chr2 128888208 C T 8.69E-08 Metabolite levels UGGT1 intron 23281178 rs10194565 chr2 128897455 A G 8.69E-08 Metabolite levels UGGT1 intron 23281178 rs7423842 chr2 128906495 C A 8.69E-08 Metabolite levels UGGT1 intron 23281178 rs6430995 chr2 128918538 C T 2.30E-05 Urinary metabolites UGGT1 intron 21572414 rs6720058 chr2 128930582 C G 8.69E-08 Metabolite levels UGGT1 intron 23281178 rs6738050 chr2 128930836 T C 8.69E-08 Metabolite levels UGGT1 intron 23281178 rs10175339 chr2 128941073 G A 8.69E-08 Metabolite levels UGGT1 intron 23281178 rs10496667 chr2 128998223 G A 8.10E-04 Lipid traits / / 24386095 rs13414154 chr2 129012073 G A 3.10E-05 Psychosis (methamphetamine induced) / / 23594818 rs2290113 chr2 129024313 A G 1 Drug response to Etoposide HS6ST1 UTR-3 17537913 rs1375347 chr2 129050909 A G 8.11E-05 Cleft lip HS6ST1 intron 20436469 rs12986656 chr2 129059084 A G 8.20E-06 Urinary metabolites HS6ST1 intron 21572414 rs840875 chr2 129068234 T C 7.60E-04 Multiple complex diseases HS6ST1 intron 17554300 rs10496668 chr2 129104968 C T 0.0006563 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10496668 chr2 129104968 C T 6.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17016161 chr2 129108613 C T 0.0003175 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17016161 chr2 129108613 C T 3.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs882275 chr2 129125972 C A 9.78E-06 Monocyte chemoattractant protein-1 / / pha003071 rs4534993 chr2 129129169 T A 1.30E-05 Urinary metabolites / / 21572414 rs13418523 chr2 129131075 C T 7.40E-05 Monocyte chemoattractant protein-1 / / pha003071 rs880713 chr2 129131614 A G 1.11E-05 Pulmonary function / / 17903307 rs17016212 chr2 129134764 C T 9.50E-05 Response to statin therapy / / 20339536 rs17216354 chr2 129161203 C A 9.27E-04 Multiple complex diseases / / 17554300 rs4662810 chr2 129181780 T A 2.80E-05 Urinary metabolites / / 21572414 rs4662814 chr2 129189563 G T 9.22E-04 Type 2 diabetes / / 17463246 rs4662814 chr2 129189563 G T 1.40E-05 Urinary metabolites / / 21572414 rs714527 chr2 129204472 C T 8.80E-06 Urinary metabolites / / 21572414 rs17283348 chr2 129222649 T G 0.000315394 Hypertension (early onset hypertension) / / 22479346 rs4662827 chr2 129226743 C T 0.000315394 Hypertension (early onset hypertension) / / 22479346 rs1992249 chr2 129230661 T G 0.000733389 Hypertension (early onset hypertension) / / 22479346 rs2011526 chr2 129235584 G A 9.19E-05 Hypertension (early onset hypertension) / / 22479346 rs4662830 chr2 129374229 G A 1.10E-06 Urinary metabolites / / 21572414 rs6747443 chr2 129397486 C T 2.81E-04 Type 2 diabetes / / 17463246 rs10176941 chr2 129406233 A G 2.30E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs10928826 chr2 129444023 C A 3.32E-04 Multiple complex diseases / / 17554300 rs10928827 chr2 129457798 A G 8.59E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs4662834 chr2 129478842 A G 5.00E-06 Bleomycin sensitivity / / 21106707 rs12996713 chr2 129483106 C T 9.72E-05 Biliary atresia / / 20460270 rs6744496 chr2 129489556 G A 1.37E-04 Multiple sclerosis / / 17660530 rs10496671 chr2 129493459 T C 2.67E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7561966 chr2 129504351 A G 3.00E-06 Palmitic acid (16:0) plasma levels / / 23362303 rs7425326 chr2 129540093 T C 8.50E-06 Iron levels / / 21208937 rs11678720 chr2 129542628 G A 2.42E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11690223 chr2 129542735 C A 3.07E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11690256 chr2 129542767 C T 2.00E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs59424068 chr2 129546527 G A 7.94E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs2406272 chr2 129561915 C A 5.09E-06 Cognitive impairment induced by topiramate / / 22091778 rs10496673 chr2 129594921 C A 8.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1251101 chr2 129623137 G T 1.59E-04 IgE levels / / 17255346 rs1562319 chr2 129628406 C T 4.62E-04 Taste perception / / 22132133 rs10803597 chr2 129647350 T G 4.67E-04 IgE levels / / 17255346 rs920280 chr2 129652413 G A 6.03E-05 Serum metabolites / / 19043545 rs2264824 chr2 129688698 A G 1.10E-05 Urinary metabolites / / 21572414 rs2246289 chr2 129700617 T C 1.60E-05 Urinary metabolites / / 21572414 rs2465821 chr2 129717684 G A 1.20E-05 Urinary metabolites / / 21572414 rs10187505 chr2 129739813 C T 8.50E-06 Urinary metabolites / / 21572414 rs17048943 chr2 129746292 C T 9.30E-06 Urinary metabolites / / 21572414 rs17048958 chr2 129752049 C G 9.60E-06 Urinary metabolites / / 21572414 rs17049003 chr2 129766337 T C 1.70E-06 Urinary metabolites / / 21572414 rs17049005 chr2 129766414 G A 7.10E-07 Urinary metabolites / / 21572414 rs1519441 chr2 129785207 A G 6.87E-05 Height / / pha003011 rs11682667 chr2 129819469 T C 7.06E-06 Alcohol dependence / / 23089632 rs1401630 chr2 129847487 A G 7.25E-06 Height / / pha003011 rs13428187 chr2 129864132 G A 7.30E-05 Waist Circumference / / pha003023 rs10496676 chr2 129915151 A G 6.02E-05 Body Mass Index / / pha003022 rs908849 chr2 129921407 G A 4.53E-04 Stroke / / pha002886 rs2919747 chr2 129965276 A G 6.01E-04 Type 2 diabetes / / 17463246 rs1251207 chr2 129981872 G T 4.79E-05 Alcohol withdrawal symptoms / / 22072270 rs1251207 chr2 129981872 G T 5.44E-05 Leukocyte Counts / / pha003091 rs13033188 chr2 129982956 C T 8.33E-06 Alcohol dependence (age at onset) / / 24962325 rs1251209 chr2 129983014 A G 6.50E-06 Alcohol dependence (age at onset) / / 24962325 rs2119515 chr2 129983131 G A 9.42E-06 Alcohol dependence (age at onset) / / 24962325 rs1251210 chr2 129983541 G A 9.42E-06 Alcohol dependence (age at onset) / / 24962325 rs1270481 chr2 129983664 T C 5.12E-06 Alcohol dependence (age at onset) / / 24962325 rs735987 chr2 129984402 G A 1.22E-06 Alcohol dependence (age at onset) / / 24962325 rs1251214 chr2 129985114 C A 9.24E-07 Alcohol dependence (age at onset) / / 24962325 rs1251215 chr2 129985154 C T 9.24E-07 Alcohol dependence (age at onset) / / 24962325 rs1268546 chr2 129985182 T C 9.24E-07 Alcohol dependence (age at onset) / / 24962325 rs1251216 chr2 129985210 G C 9.24E-07 Alcohol dependence (age at onset) / / 24962325 rs2406641 chr2 129985425 A G 9.24E-07 Alcohol dependence (age at onset) / / 24962325 rs1251205 chr2 129987520 T A 9.24E-07 Alcohol dependence (age at onset) / / 24962325 rs12472824 chr2 129989847 C T 8.18E-06 Alcohol dependence (age at onset) / / 24962325 rs4662907 chr2 129990197 G A 5.69E-06 Alcohol dependence (age at onset) / / 24962325 rs13033217 chr2 129990869 T C 5.38E-04 Substance dependence phenotypes / / 24832863 rs13033217 chr2 129990869 T C 7.18E-06 Substance dependence phenotypes / / 24832863 rs13033217 chr2 129990869 T C 5.69E-06 Alcohol dependence (age at onset) / / 24962325 rs1078826 chr2 129991012 G A 5.69E-06 Alcohol dependence (age at onset) / / 24962325 rs1660895 chr2 129994332 A T 7.00E-07 Alcohol dependence (age at onset) / / 24962325 rs35878075 chr2 129995501 G A 6.78E-06 Alcohol dependence (age at onset) / / 24962325 rs879533 chr2 129996746 T A 7.46E-07 Alcohol dependence (age at onset) / / 24962325 rs1734330 chr2 129996988 A T 7.46E-07 Alcohol dependence (age at onset) / / 24962325 rs3856372 chr2 129997083 T A 6.04E-06 Alcohol dependence (age at onset) / / 24962325 rs894110 chr2 129997543 C G 7.64E-07 Alcohol dependence (age at onset) / / 24962325 rs935085 chr2 129998033 T C 7.64E-07 Alcohol dependence (age at onset) / / 24962325 rs2952621 chr2 129998443 T C 9.51E-06 Alcohol dependence / / 23089632 rs2952621 chr2 129998443 T C 1.77E-08 Substance dependence phenotypes / / 24832863 rs2952621 chr2 129998443 T C 3.85E-05 Substance dependence phenotypes / / 24832863 rs2952621 chr2 129998443 T C 7.64E-07 Alcohol dependence (age at onset) / / 24962325 rs1251172 chr2 129999190 G A 7.64E-07 Alcohol dependence (age at onset) / / 24962325 rs4662640 chr2 129999796 A C 6.77E-06 Alcohol dependence (age at onset) / / 24962325 rs4662641 chr2 130000272 G A 6.77E-06 Alcohol dependence (age at onset) / / 24962325 rs10167178 chr2 130001725 C T 6.77E-06 Alcohol dependence (age at onset) / / 24962325 rs1441141 chr2 130002073 A G 6.77E-06 Alcohol dependence (age at onset) / / 24962325 rs6708498 chr2 130002186 C T 5.97E-06 Alcohol dependence (age at onset) / / 24962325 rs1441142 chr2 130003278 G A 6.77E-06 Alcohol dependence (age at onset) / / 24962325 rs1251179 chr2 130003735 A G 1.25E-06 Alcohol dependence (age at onset) / / 24962325 rs837827 chr2 130004151 G A 9.77E-07 Alcohol dependence (age at onset) / / 24962325 rs6756671 chr2 130007175 G A 9.70E-06 Alcohol dependence (age at onset) / / 24962325 rs2197022 chr2 130007750 G T 1.97E-04 Substance dependence phenotypes / / 24832863 rs2197022 chr2 130007750 G T 2.53E-06 Substance dependence phenotypes / / 24832863 rs11681435 chr2 130023641 G T 9.41E-06 Periodontitis (PAL4Q3) / / 24024966 rs837899 chr2 130024033 G A 6.21E-05 Alcohol withdrawal symptoms / / 22072270 rs837898 chr2 130024589 A G 9.33E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs12474348 chr2 130033707 G A 6.40E-04 Type 2 diabetes / / 17463246 rs837841 chr2 130034012 C A 8.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs7567687 chr2 130034326 C T 8.00E-06 Periodontitis (PAL4Q3) / / 24024966 rs7567687 chr2 130034326 C T 8.00E-07 Periodontitis (PAL4Q3) / / 24024966 rs7567687 chr2 130034326 C T 8.64E-06 Substance dependence phenotypes / / 24832863 rs12471876 chr2 130034680 A C 6.40E-04 Type 2 diabetes / / 17463246 rs1251193 chr2 130051445 A G 4.22E-05 Type 2 diabetes / / 17463246 rs2582998 chr2 130054847 T C 3.95E-05 Type 2 diabetes / / 17463246 rs755569 chr2 130077270 G A 1.76E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs755569 chr2 130077270 G A 3.69E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs837857 chr2 130086211 G A 3.15E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2165437 chr2 130098870 G A 8.00E-05 Personality dimensions / / 18957941 rs837891 chr2 130104550 G A 1.50E-05 Urinary metabolites / / 21572414 rs6751134 chr2 130106089 G A 6.10E-06 Urinary metabolites / / 21572414 rs4387734 chr2 130107101 T C 4.00E-06 Urinary metabolites / / 21572414 rs4662917 chr2 130111078 T C 1.40E-05 Urinary metabolites / / 21572414 rs1568765 chr2 130119905 G A 2.20E-05 Urinary metabolites / / 21572414 rs1097701 chr2 130147336 G A 0.000188 Oxaliplatin induced neuropathy in response to colorectal cancer treatment / / 22310351 rs11685900 chr2 130190199 C T 1.63E-04 Multiple complex diseases / / 17554300 rs10205941 chr2 130191184 A G 0.0001972 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10205941 chr2 130191184 A G 1.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10205941 chr2 130191184 A G 1.66E-04 Smoking quantity / / 24665060 rs17518713 chr2 130191927 C T 0.0003592 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17518713 chr2 130191927 C T 3.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17578014 chr2 130191969 T A 0.0003091 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17578014 chr2 130191969 T A 3.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2406819 chr2 130194452 G A 0.0003954 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2406819 chr2 130194452 G A 3.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs876890 chr2 130195492 A T 0.000274 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs876890 chr2 130195492 A T 2.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs876890 chr2 130195492 A T 9.00E-05 Smoking quantity / / 24665060 rs10174187 chr2 130200925 A G 0.0000806 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10174187 chr2 130200925 A G 8.06E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10174187 chr2 130200925 A G 3.57E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10174187 chr2 130200925 A G 4.18E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs10496679 chr2 130201113 G A 0.0002619 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10496679 chr2 130201113 G A 2.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17049483 chr2 130201986 C T 9.00E-04 Nicotine dependence / / 17158188 rs17049483 chr2 130201986 C T 0.0003429 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17049483 chr2 130201986 C T 3.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1453139 chr2 130203714 A C,T 0.000345 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1453139 chr2 130203714 A C,T 3.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11893564 chr2 130203864 T A 0.0003472 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11893564 chr2 130203864 T A 3.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12993231 chr2 130206377 A G 0.0002634 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12993231 chr2 130206377 A G 2.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11897269 chr2 130207348 A G 0.0003522 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2406820 chr2 130208064 T C 6.55E-05 Cognitive performance / / 19734545 rs6431079 chr2 130210384 G A 0.0007313 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6431079 chr2 130210384 G A 7.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12473149 chr2 130211900 A T 0.0003901 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12473149 chr2 130211900 A T 3.90E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12475156 chr2 130212942 T A 0.0003467 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12475156 chr2 130212942 T A 3.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12475298 chr2 130213293 T A 0.0002811 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12475298 chr2 130213293 T A 2.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12474448 chr2 130213420 A G 0.0002811 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12474448 chr2 130213420 A G 2.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1982452 chr2 130213585 T C 0.000281 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1982452 chr2 130213585 T C 2.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10803605 chr2 130213965 C T 0.0002816 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10803605 chr2 130213965 C T 2.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1453159 chr2 130215047 G A 0.000281 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1453159 chr2 130215047 G A 2.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1453158 chr2 130215115 G T 0.0003138 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1453158 chr2 130215115 G T 3.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4662941 chr2 130215877 A G 0.0000602 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4662941 chr2 130215877 A G 6.02E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4662942 chr2 130215888 T C 0.0000601 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4662942 chr2 130215888 T C 6.01E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4662945 chr2 130216043 A G 0.00006 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4662945 chr2 130216043 A G 6.00E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4662945 chr2 130216043 A G 3.00E-06 Response to cytidine analogues (gemcitabine) / / 24483146 rs4662945 chr2 130216043 A G 8.16E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4662945 chr2 130216043 A G 4.71E-04 Smoking quantity / / 24665060 rs7603887 chr2 130216073 A G 8.16E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7603887 chr2 130216073 A G 3.37E-04 Smoking quantity / / 24665060 rs17519343 chr2 130217568 G A 0.0002824 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17519343 chr2 130217568 G A 2.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2406822 chr2 130218178 C T 0.0002407 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2406822 chr2 130218178 C T 2.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2406822 chr2 130218178 C T 2.71E-04 Smoking quantity / / 24665060 rs4427966 chr2 130221148 G A 0.0002523 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4427966 chr2 130221148 G A 2.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1377387 chr2 130221208 T C 0.000284 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1377387 chr2 130221208 T C 2.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11889563 chr2 130225962 T C 0.0002849 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11889563 chr2 130225962 T C 2.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1031429 chr2 130226437 T C 0.0002561 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1031429 chr2 130226437 T C 2.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12463574 chr2 130231715 C G 0.0005546 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12463574 chr2 130231715 C G 5.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12996362 chr2 130233480 C T 0.00000671 Lumbar spine bone mineral density (premenopausal) / / 23074152 rs11888580 chr2 130235218 C T 0.0005763 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11888580 chr2 130235218 C T 5.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12478202 chr2 130240631 C T 0.0005917 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12478202 chr2 130240631 C T 5.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12479366 chr2 130241743 C A 0.0005915 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12479366 chr2 130241743 C A 5.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11680033 chr2 130245943 C T 9.69E-05 Suicide attempts in bipolar disorder / / 21423239 rs4662951 chr2 130256272 C T 7.63E-05 Femoral neck bone geometry / / 22087292 rs10200446 chr2 130258186 C T 9.49E-05 Femoral neck bone geometry / / 22087292 rs11692339 chr2 130259988 T C 6.14E-05 Cognitive test performance / / 20125193 rs10172641 chr2 130270113 T C 4.74E-04 Smoking initiation / / 24665060 rs1349734 chr2 130271206 C T 2.48E-05 Bilirubin levels,in serum / / 19389676 rs13026874 chr2 130300787 G A 3.41E-04 Smoking initiation / / 24665060 rs2214271 chr2 130323107 C T 0.0008277 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2214271 chr2 130323107 C T 8.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs739659 chr2 130326385 G A 6.15E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2247277 chr2 130326644 C T 6.19E-05 Insulin resistance / / 21901158 rs2188910 chr2 130336129 G T 9.80E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2188909 chr2 130336225 C G 8.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2704565 chr2 130336741 T C 6.40E-05 Insulin resistance / / 21901158 rs1859063 chr2 130363731 T C 3.34E-04 Attention deficit hyperactivity disorder / / 22012869 rs17049647 chr2 130377385 C A 0.00000712 Aging / / 22445811 rs3109315 chr2 130384718 C T 1.63E-05 Personality dimensions / / 22628180 rs3109315 chr2 130384718 C T 0.0000176 VLDL cholesterol particle diameter / / 23263444 rs3094428 chr2 130400856 C T 7.81E-04 Multiple complex diseases / / 17554300 rs11681113 chr2 130407220 C G 2.70E-04 Multiple complex diseases / / 17554300 rs3109270 chr2 130425068 A C 5.75E-04 Smoking initiation / / 24665060 rs3109276 chr2 130428389 T G 2.48E-04 Smoking initiation / / 24665060 rs3108978 chr2 130431535 A G 4.24E-04 Smoking initiation / / 24665060 rs2407015 chr2 130432067 T C 5.19E-04 Smoking initiation / / 24665060 rs6725384 chr2 130433313 T C 0.0000415 Lumbar spine bone mineral density (premenopausal) / / 23074152 rs10928920 chr2 130437195 A C 3.68E-04 Smoking initiation / / 24665060 rs4662981 chr2 130460115 A G 2.91E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10928927 chr2 130468366 C T 3.00E-07 Chronic obstructive pulmonary disease / / 21685187 rs4233595 chr2 130483910 G A 0.0002 Migraine / / 22678113 rs6710206 chr2 130491622 G A 0.0002 Migraine / / 22678113 rs7578253 chr2 130534281 T C 7.20E-04 Multiple complex diseases / / 17554300 rs7575461 chr2 130534330 A G 6.05E-04 Coronary heart disease / / 21606135 rs6431110 chr2 130535743 A G 1.53E-04 Multiple complex diseases / / 17554300 rs3924460 chr2 130539467 A G 7.40E-04 Multiple complex diseases / / 17554300 rs3990701 chr2 130547748 A G 3.55E-05 Panic disorder / / 19165232 rs2464786 chr2 130550135 G A 2.59E-05 Alcohol dependence / / 21703634 rs2707653 chr2 130562942 C T 6.09E-05 Alcohol dependence / / 21703634 rs7591571 chr2 130583859 A G 8.15E-05 Hematocrit / / pha003097 rs7421552 chr2 130603995 A G 2.40E-05 Myasthenia gravis / / 23055271 rs4662999 chr2 130616955 G T 5.97E-05 LDL lipoproteins / / pha002902 rs7566086 chr2 130618373 G T 1.10E-05 Urinary metabolites / / 21572414 rs6724110 chr2 130628425 T C 9.49E-05 Squamous cell carcinoma / / 23341777 rs4662667 chr2 130643612 G A 3.56E-04 Type 2 diabetes / / 17463246 rs4662667 chr2 130643612 G A 1.49E-04 Vaspin levels / / 22907691 rs4662667 chr2 130643612 G A 0.0001493 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs11687226 chr2 130645042 G A 1.81E-04 Fibrinogen / / 17255346 rs11687226 chr2 130645042 G A 8.02E-04 Type 2 diabetes / / 17463246 rs4233600 chr2 130646173 T C 1.81E-04 Fibrinogen / / 17255346 rs10197035 chr2 130646434 G C 1.23E-04 Type 2 diabetes / / 17463246 rs1316468 chr2 130647012 G A 1.51E-04 Type 2 diabetes / / 17463246 rs7558713 chr2 130664784 A G 7.10E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10445703 chr2 130667081 T A 6.00E-05 Prostate cancer / / 21743057 rs10192960 chr2 130674793 G T 6.00E-05 Prostate cancer / / 21743057 rs10928942 chr2 130683344 G A 4.75E-04 Alzheimer's disease (late onset) LOC389033 intron 21379329 rs10496681 chr2 130683532 A G 8.30E-04 Type 2 diabetes and 6 quantitative traits LOC389033 intron 17848626 rs6431119 chr2 130693921 C A 1.17E-04 Smoking initiation / / 24665060 rs6760544 chr2 130694072 A C 6.22E-05 Smoking initiation / / 24665060 rs1922633 chr2 130701189 G A 6.95E-05 Smoking initiation / / 24665060 rs6707259 chr2 130703962 C T 1.13E-04 Smoking initiation / / 24665060 rs4381734 chr2 130761737 C T 5.12E-04 Smoking initiation / / 24665060 rs2084784 chr2 130916415 A G 0.000272 Antisocial behavior SMPD4 intron 23077488 rs10198499 chr2 130943513 T C 1.60E-04 HDL particle features MZT2B intron 21283740 rs13000721 chr2 130952038 G A 0.000077 Antisocial behavior TUBA3E missense 23077488 rs7559051 chr2 131050872 G A 9.50E-04 Insulin resistance / / 21901158 rs2292850 chr2 131102538 A C 5.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IMP4 intron 20877124 rs3739122 chr2 131131525 C T 6.35E-04 Alzheimer's disease PTPN18 UTR-3 24755620 rs272128 chr2 131487673 A C 4.87E-05 Blood Pressure GPR148 missense pha003047 rs13400337 chr2 131489113 C T 6.10E-06 Iris characteristics / / 21835309 rs272146 chr2 131537733 C A 7.73E-04 Alcohol dependence / / 24277619 rs13395546 chr2 131545192 A G 1.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) / / 23934736 rs272111 chr2 131546505 A C 3.45E-05 Aortic root size / / 21223598 rs272112 chr2 131546685 T C 2.82E-05 Aortic root size / / 21223598 rs1430706 chr2 131565647 G A 5.51E-04 Aortic root size / / 21223598 rs1542604 chr2 131593045 G A 6.85E-05 Body mass (lean) / / 19268274 rs6715179 chr2 131623166 A C 6.28E-04 Taste perception / / 22132133 rs11887132 chr2 131678879 G T 3.95E-05 Coronary restenosis ARHGEF4 intron 21878436 rs11687441 chr2 131701797 A C,G,T 4.92E-04 Multiple complex diseases ARHGEF4 intron 17554300 rs13021106 chr2 131741691 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ARHGEF4 intron 22628534 rs4569521 chr2 131747953 T G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ARHGEF4 intron 22628534 rs2313160 chr2 131837242 C A 8.05E-04 Type 2 diabetes FAM168B intron 17463246 rs7597771 chr2 131852643 G T 1.97E-04 Multiple complex diseases / / 17554300 rs1852556 chr2 132095028 T C 3.36E-05 Statin-induced myopathy / / 21826682 rs2272355 chr2 132164854 T C 8.98E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6430791 chr2 132166208 C T 6.56E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs7573518 chr2 132166387 G A 7.29E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs7584315 chr2 132166606 C T 8.34E-05 Cognitive impairment induced by topiramate / / 22091778 rs7589111 chr2 132170888 G A 3.06E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs6739473 chr2 132171917 A C 4.89E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs941332 chr2 132188005 C T 5.25E-04 Smoking quantity / / 24665060 rs12472079 chr2 132298468 C A 9.95E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10928743 chr2 132346663 C G 5.47E-05 Lymphocyte counts / / 22286170 rs4850224 chr2 132410986 T C 3.72E-05 Calcium levels / / pha003085 rs7585022 chr2 132497214 T C 6.27E-04 Type 2 diabetes C2orf27A intron 17463246 rs4080478 chr2 132648802 G C 3.45E-14 Multiple complex diseases / / 17554300 rs16848400 chr2 132751852 G T 1.38E-04 Multiple complex diseases / / 17554300 rs16848398 chr2 132755417 G A 1.87E-04 Multiple complex diseases / / 17554300 rs16831128 chr2 133144392 A G 4.00E-07 Conduct disorder (symptom count) / / 20585324 rs16831128 chr2 133144392 A G 5.00E-06 Conduct disorder (symptom count) / / 20585324 rs41334446 chr2 133148734 G T 4.91E-04 Multiple complex diseases / / 17554300 rs11684939 chr2 133152621 G A 0.0006351 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11684939 chr2 133152621 G A 6.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11690367 chr2 133158276 T G 4.12E-06 Multiple complex diseases / / 17554300 rs2315377 chr2 133159427 C T 8.68E-04 Psoriasis / / 20953187 rs6720935 chr2 133165560 C T 6.90E-04 Pulmonary function / / 23932459 rs7592134 chr2 133173065 A G 4.39E-04 Fibrinogen / / 17255346 rs13420028 chr2 133188106 T G 1.00E-10 Hypertension GPR39 intron 21626137 rs10188442 chr2 133189239 C T 1.00E-10 Hypertension GPR39 intron 21626137 rs3748861 chr2 133196452 C A 2.63E-05 Smoking initiation GPR39 intron 24665060 rs4417767 chr2 133205288 A C 6.73E-04 Type 2 diabetes GPR39 intron 17463246 rs4953981 chr2 133216079 T C 4.18E-04 Type 2 diabetes GPR39 intron 17463246 rs7605278 chr2 133216314 A C 6.96E-04 Multiple complex diseases GPR39 intron 17554300 rs4508654 chr2 133216413 A G 8.71E-04 Type 2 diabetes GPR39 intron 17463246 rs4525746 chr2 133220163 C T 7.69E-04 Type 2 diabetes GPR39 intron 17463246 rs13030799 chr2 133267847 A G 2.70E-05 Urinary metabolites GPR39 intron 21572414 rs10496687 chr2 133269261 G A 5.67E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GPR39 intron 22566498 rs4395295 chr2 133277683 C T 4.05E-05 Orofacial clefts GPR39 intron 22419666 rs16833598 chr2 133283250 C T 6.33E-04 Multiple complex diseases GPR39 intron 17554300 rs6710643 chr2 133283943 T C 5.31E-04 Heart Failure GPR39 intron pha002884 rs9287421 chr2 133313845 C T 1.69E-04 Dental caries GPR39 intron 21940522 rs3109144 chr2 133320414 C T 1.90E-05 Urinary metabolites GPR39 intron 21572414 rs3109154 chr2 133342529 C T 7.78E-05 Heart Failure GPR39 intron pha002884 rs3109157 chr2 133348083 A G 3.58E-05 Body Fat Distribution GPR39 intron pha003017 rs3109157 chr2 133348083 A G 2.74E-05 Body Fat Distribution GPR39 intron pha003018 rs4547577 chr2 133393808 A C 1.30E-05 Urinary metabolites GPR39 intron 21572414 rs10166009 chr2 133471789 C T 8.70E-06 Urinary metabolites NCKAP5 intron 21572414 rs10166009 chr2 133471789 C T 3.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) NCKAP5 intron 23648065 rs6736839 chr2 133478977 T C 4.28E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs4953986 chr2 133482699 T C 2.66E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs11692408 chr2 133484964 A G 2.76E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs7596376 chr2 133487103 A C 1.30E-05 Urinary metabolites NCKAP5 intron 21572414 rs4953987 chr2 133491425 A G 3.08E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs17397163 chr2 133491553 A G 8.15E-05 Hypertension NCKAP5 intron pha003042 rs560418667 chr2 133492750 A AT 1.98E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs560418667 chr2 133492750 A AT 7.89E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs61240058 chr2 133492750 A AT 1.98E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs61240058 chr2 133492750 A AT 7.89E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs984521 chr2 133492750 A G,T 1.98E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs984521 chr2 133492750 A G,T 7.89E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs16840576 chr2 133494705 C G 5.40E-06 Urinary metabolites NCKAP5 intron 21572414 rs7606532 chr2 133505873 A C 0.0002 Migraine NCKAP5 intron 22678113 rs10496693 chr2 133532709 G A 3.24E-06 Cardiovascular disease NCKAP5 intron 18179892 rs17325719 chr2 133542585 C G 4.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) NCKAP5 missense 21239504 rs1026076 chr2 133602119 A G 4.16E-05 Type 2 diabetes NCKAP5 intron 17463246 rs16842572 chr2 133612814 C G 1.80E-05 Iron levels NCKAP5 intron 21208937 rs12464177 chr2 133627136 T C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes NCKAP5 intron 22628534 rs1037173 chr2 133630242 T C 4.04E-04 Type 2 diabetes NCKAP5 intron 17463246 rs13005482 chr2 133635429 A G 2.73E-04 Type 2 diabetes NCKAP5 intron 17463246 rs17326398 chr2 133635545 C A 8.39E-04 Type 2 diabetes NCKAP5 intron 17463246 rs1020429 chr2 133661411 T C 5.80E-04 Premature ovarian failure NCKAP5 intron 19508998 rs13016800 chr2 133698894 C A 2.27E-04 Type 2 diabetes NCKAP5 intron 17463246 rs7589684 chr2 133735222 C G 2.00E-04 Type 2 diabetes and 6 quantitative traits NCKAP5 intron 17848626 rs6727803 chr2 133739616 G A 7.07E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21423239 rs6704839 chr2 133742332 A G 1.60E-04 Type 2 diabetes and 6 quantitative traits NCKAP5 intron 17848626 rs1437898 chr2 133746630 A C 8.00E-06 Multiple sclerosis (age of onset) NCKAP5 intron 19010793 rs12475645 chr2 133754360 A G 2.53E-04 Alzheimer's disease (late onset) NCKAP5 intron 21379329 rs4953868 chr2 133769673 G A 5.78E-04 Suicide attempts in bipolar disorder NCKAP5 intron 21041247 rs1437903 chr2 133771658 C A 6.60E-06 Orofacial clefts NCKAP5 intron 22419666 rs13395693 chr2 133806124 T C 6.18E-04 Amyotrophic Lateral Sclerosis NCKAP5 intron 17362836 rs13395693 chr2 133806124 T C 5.49E-04 Type 2 diabetes NCKAP5 intron 17463246 rs13395811 chr2 133806232 T C 3.72E-04 Type 2 diabetes NCKAP5 intron 17463246 rs13413161 chr2 133822742 A G 0.0000044 Internal carotid artery thickness (average of near and far walls) NCKAP5 intron 23487405 rs10174856 chr2 133830379 T C 2.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NCKAP5 intron 20877124 rs16847317 chr2 133841199 T C 7.63E-04 Alzheimer's disease NCKAP5 intron 22005930 rs1370596 chr2 133851844 T C 3.70E-06 Thyroid function NCKAP5 intron 20826269 rs1437895 chr2 133852801 G A 5.00E-06 Thyroid function NCKAP5 intron 20826269 rs1476150 chr2 133876395 G C 3.66E-05 Menarche (age at onset) NCKAP5 intron 23599027 rs1476150 chr2 133876395 G C 4.51E-05 Menarche (age at onset) NCKAP5 intron 23599027 rs16857192 chr2 133897009 G C 2.56E-04 Multiple complex diseases NCKAP5 intron 17554300 rs13427795 chr2 133901426 T C 0.00000087 Internal carotid artery thickness (far walls) NCKAP5 intron 23487405 rs13427795 chr2 133901426 T C 0.00000105 Internal carotid artery thickness (average of near and far walls) NCKAP5 intron 23487405 rs13427795 chr2 133901426 T C 0.00000275 Internal carotid artery thickness (near walls) NCKAP5 intron 23487405 rs13432172 chr2 133903318 A G 0.00000039 Internal carotid artery thickness (average of near and far walls) NCKAP5 intron 23487405 rs13432172 chr2 133903318 A G 0.00000041 Internal carotid artery thickness (far walls) NCKAP5 intron 23487405 rs13432172 chr2 133903318 A G 0.00000079 Internal carotid artery thickness (near walls) NCKAP5 intron 23487405 rs12691834 chr2 133952040 G A 2.38E-05 Tuberculosis NCKAP5 intron 24057671 rs13029552 chr2 133957689 A C 7.43E-05 Aging (time to event) NCKAP5 intron 21782286 rs1836216 chr2 133966177 C T 4.23E-04 Diabetic retinopathy NCKAP5 intron 20871662 rs10496699 chr2 133977005 A G 7.19E-04 Parkinson's disease NCKAP5 intron 17052657 rs6749561 chr2 134000064 A G 4.91E-05 Bipolar disorder NCKAP5 intron 19488044 rs6749561 chr2 134000064 A G 1.72E-05 Bipolar disorder and schizophrenia NCKAP5 intron 20889312 rs6749561 chr2 134000064 A G 3.67E-05 Bipolar Disorder NCKAP5 intron pha002858 rs17800749 chr2 134003754 C T 9.11E-06 Bipolar disorder NCKAP5 intron 19488044 rs17800749 chr2 134003754 C T 1.81E-05 Bipolar disorder and schizophrenia NCKAP5 intron 20889312 rs17800749 chr2 134003754 C T 1.81E-05 Bipolar Disorder NCKAP5 intron pha002858 rs10496702 chr2 134005569 G A 7.83E-04 Type 2 diabetes NCKAP5 intron 17463246 rs10496702 chr2 134005569 G A 1.22E-05 Bipolar disorder NCKAP5 intron 19488044 rs10496702 chr2 134005569 G A 7.00E-07 Bipolar disorder and schizophrenia NCKAP5 intron 20889312 rs10496702 chr2 134005569 G A 1.20E-05 Bipolar Disorder NCKAP5 intron pha002858 rs13430905 chr2 134011993 C T 8.41E-04 Type 2 diabetes NCKAP5 intron 17463246 rs13430905 chr2 134011993 C T 1.11E-05 Bipolar disorder NCKAP5 intron 19488044 rs13430905 chr2 134011993 C T 1.42E-06 Bipolar disorder and schizophrenia NCKAP5 intron 20889312 rs13430905 chr2 134011993 C T 1.07E-05 Bipolar Disorder NCKAP5 intron pha002858 rs13431418 chr2 134012499 C T 8.09E-04 Type 2 diabetes NCKAP5 intron 17463246 rs13431418 chr2 134012499 C T 1.18E-05 Bipolar disorder NCKAP5 intron 19488044 rs13431418 chr2 134012499 C T 1.03E-06 Bipolar disorder and schizophrenia NCKAP5 intron 20889312 rs13431418 chr2 134012499 C T 1.15E-05 Bipolar Disorder NCKAP5 intron pha002858 rs7600871 chr2 134014961 C T 1.16E-05 Bipolar disorder NCKAP5 intron 19488044 rs7600871 chr2 134014961 C T 8.79E-07 Bipolar disorder and schizophrenia NCKAP5 intron 20889312 rs7600871 chr2 134014961 C T 1.20E-05 Bipolar Disorder NCKAP5 intron pha002858 rs10193871 chr2 134017053 T C 4.18E-06 Bipolar disorder NCKAP5 intron 19488044 rs10193871 chr2 134017053 T C 6.33E-06 Bipolar disorder and schizophrenia NCKAP5 intron 20889312 rs10193871 chr2 134017053 T C 6.98E-06 Bipolar Disorder NCKAP5 intron pha002858 rs1985935 chr2 134028503 C T 2.58E-05 Alzheimer's disease NCKAP5 intron 22005930 rs1430170 chr2 134033399 T C 1.99E-04 Alzheimer's disease NCKAP5 intron 22005930 rs1367207 chr2 134035868 A G 1.10E-04 Alzheimer's disease NCKAP5 intron 22005930 rs6430407 chr2 134039363 G C 6.18E-04 Alzheimer's disease NCKAP5 intron 22005930 rs7577925 chr2 134040519 G A 3.00E-06 Attention deficit hyperactivity disorder NCKAP5 intron 18821565 rs7577925 chr2 134040519 G A 6.87E-04 Alzheimer's disease NCKAP5 intron 22005930 rs13399558 chr2 134043215 T A 1.89E-05 Bipolar disorder NCKAP5 intron 19488044 rs13399558 chr2 134043215 T A 4.99E-05 Bipolar disorder and schizophrenia NCKAP5 intron 20889312 rs13399558 chr2 134043215 T A 1.34E-05 Bipolar Disorder NCKAP5 intron pha002858 rs13412008 chr2 134044193 G T 4.04E-05 Bipolar disorder NCKAP5 intron 19488044 rs13412008 chr2 134044193 G T 4.53E-05 Bipolar disorder and schizophrenia NCKAP5 intron 20889312 rs13412008 chr2 134044193 G T 2.65E-05 Bipolar Disorder NCKAP5 intron pha002858 rs12469282 chr2 134044781 A T 6.76E-05 Type 2 diabetes NCKAP5 intron 17463246 rs12469282 chr2 134044781 A T 2.71E-05 Bipolar disorder NCKAP5 intron 19488044 rs12469282 chr2 134044781 A T 2.57E-05 Bipolar disorder and schizophrenia NCKAP5 intron 20889312 rs12469282 chr2 134044781 A T 2.24E-05 Bipolar Disorder NCKAP5 intron pha002858 rs1549739 chr2 134044803 G C 2.08E-04 Alzheimer's disease NCKAP5 intron 22005930 rs1344726 chr2 134046163 A G 2.20E-04 Alzheimer's disease NCKAP5 intron 22005930 rs16823369 chr2 134053137 G A 5.16E-04 Aortic root size NCKAP5 intron 21223598 rs2289076 chr2 134128159 G A 5.07E-05 Atopy NCKAP5 intron 21625490 rs9287428 chr2 134196068 T C 2.00E-04 Type 2 diabetes NCKAP5 intron 17846126 rs2012254 chr2 134201563 T C 2.60E-04 Multiple complex diseases NCKAP5 intron 17554300 rs7604549 chr2 134206763 T C 2.00E-04 Type 2 diabetes NCKAP5 intron 17846126 rs6430419 chr2 134210040 T C 2.03E-04 Multiple complex diseases NCKAP5 intron 17554300 rs16825174 chr2 134213436 C T 9.95E-04 Multiple complex diseases NCKAP5 intron 17554300 rs16825174 chr2 134213436 C T 2.72E-04 Lung function (forced vital capacity) NCKAP5 intron 24023788 rs1821625 chr2 134230217 G T 7.00E-06 Multiple sclerosis NCKAP5 intron 23412934 rs1865585 chr2 134238128 G C 9.98E-04 Multiple complex diseases NCKAP5 intron 17554300 rs16826005 chr2 134266001 A G 1.00E-07 Hypersomnia (HLA-DQB1*06:02 negative) NCKAP5 intron 23646285 rs16826050 chr2 134271218 T A,C 3.72E-05 Cognitive impairment induced by topiramate NCKAP5 intron 22091778 rs12471007 chr2 134273472 G C 1.09E-07 Hypersomnia (HLA-DQB1*06:02 negative) NCKAP5 intron 23646285 rs2043234 chr2 134314782 C T 4.46E-06 Hypersomnia (HLA-DQB1*06:02 negative) NCKAP5 intron 23646285 rs13412991 chr2 134323037 T C 0.0002 Migraine NCKAP5 intron 22678113 rs11675147 chr2 134327168 G A 5.19E-05 Post-operative nausea and vomiting / / 21694509 rs6430432 chr2 134344666 G A 5.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17817136 chr2 134349496 C T 2.00E-05 Parkinson's disease (age of onset) / / 19772629 rs6715224 chr2 134350570 C T 4.33E-04 Gallbladder cancer / / 22318345 rs17817190 chr2 134351648 T G 2.50E-06 Parkinson's disease (age of onset) / / 19772629 rs7588567 chr2 134363032 T C 4.00E-07 Glaucoma (primary open-angle) / / 22419738 rs4347888 chr2 134424634 T A 1.70E-04 Multiple complex diseases / / 17554300 rs16827706 chr2 134427207 A G 8.41E-04 Taste perception / / 22132133 rs16827735 chr2 134428450 G T 3.13E-04 Multiple complex diseases / / 17554300 rs7567288 chr2 134434824 T C 2.00E-12 Height / / 20881960 rs7571689 chr2 134436669 A G 2.90E-05 Urinary metabolites / / 21572414 rs1901439 chr2 134437471 T C 0.0000267 Alcohol craving with or without dependence / / 22481050 rs1901440 chr2 134437959 C A 3.00E-06 Response to gemcitabine in pancreatic cancer / / 22293537 rs6430443 chr2 134442532 A G 8.61E-04 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs4522658 chr2 134487163 G A 3.40E-05 Type 2 diabetes / / 21647700 rs6414015 chr2 134513100 C T 8.47E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs1446750 chr2 134513621 G A 5.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4425130 chr2 134514686 G A 1.35E-04 Attention deficit hyperactivity disorder / / 22420046 rs4425130 chr2 134514686 G A 5.52E-05 Body Mass Index / / pha003014 rs12472557 chr2 134528080 G A 6.36E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs6722456 chr2 134529091 G A 4.00E-08 Palmitoleic acid (16:1n-7) plasma levels / / 23362303 rs1446741 chr2 134529661 G T 2.49E-04 Schizophrenia / / 19197363 rs16829231 chr2 134531622 T C 7.70E-05 Glioma (high-grade) / / 19578366 rs16829231 chr2 134531622 T C 8.00E-06 Smoking behavior / / 20418888 rs16829241 chr2 134532622 C A 8.30E-05 Endometriosis / / 21151130 rs7585252 chr2 134540328 A G 1.74E-05 Wegener's granulomatosis / / 23740775 rs4589813 chr2 134549860 T G 0.000224485 Hypertension (early onset hypertension) / / 22479346 rs16829491 chr2 134563476 C T 2.30E-05 Urinary metabolites / / 21572414 rs10928460 chr2 134563712 C A 2.60E-05 Urinary metabolites / / 21572414 rs895535 chr2 134565505 G A 9.52E-05 Hypertension (early onset hypertension) / / 22479346 rs11896627 chr2 134567325 A G 3.70E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17770239 chr2 134584179 A G 4.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17770239 chr2 134584179 A G 1.64E-04 Alzheimer's disease / / 22005930 rs1446746 chr2 134586564 C G 4.93E-04 Alzheimer's disease / / 22005930 rs2197604 chr2 134594234 C T 5.80E-05 Alzheimer's disease / / 22005930 rs41343844 chr2 134618121 A G 9.28E-06 Type 2 diabetes / / 23209189 rs6711228 chr2 134644096 C T 6.58E-05 Breast cancer / / pha002853 rs13429789 chr2 134644309 G T 3.62E-06 Personality dimensions / / 22628180 rs7582472 chr2 134644794 T C 1.59E-06 Personality dimensions / / 22628180 rs7594893 chr2 134645345 G C 1.89E-04 Smoking quantity / / 24665060 rs12464286 chr2 134651226 G A 8.40E-04 Alzheimer's disease / / 17998437 rs1446732 chr2 134657740 C A 7.38E-05 Type 2 diabetes / / 17846126 rs1446732 chr2 134657740 C A 5.87E-04 Alzheimer's disease / / 17998437 rs10803542 chr2 134678803 C G 7.99E-04 Alzheimer's disease / / 17998437 rs13389356 chr2 134695073 T A 5.30E-04 Depression (quantitative trait) / / 20800221 rs930621 chr2 134702078 C T 8.74E-05 Type 2 diabetes / / 17846126 rs16829861 chr2 134729700 A G 2.61E-05 Postoperative ventricular dysfunction / / 21980348 rs10208875 chr2 134753056 A G 2.79E-05 Sodium levels / / pha003093 rs7561901 chr2 134768634 C G,T 7.03E-05 Sodium levels / / pha003093 rs2046475 chr2 134775344 T C 5.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6719360 chr2 134788709 G A 4.65E-05 Sodium levels / / pha003093 rs11899367 chr2 134794256 C T 8.86E-04 Type 2 diabetes / / 17463246 rs11899367 chr2 134794256 C T 5.45E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3891480 chr2 134800060 T C 2.03E-05 Sodium levels / / pha003093 rs1519305 chr2 134813786 G A 4.61E-05 Sodium levels / / pha003093 rs1715008 chr2 134817016 C T 6.41E-05 Cleft lip / / 20436469 rs1715008 chr2 134817016 C T 1.66E-06 Sodium levels / / pha003093 rs11688332 chr2 134830720 G T 2.96E-07 Sodium levels / / pha003093 rs1257370 chr2 134831118 C A 3.57E-05 Sodium levels / / pha003093 rs200893282 chr2 134831119 A AG 2.96E-07 Sodium levels / / pha003093 rs4953900 chr2 134831119 A G 2.96E-07 Sodium levels / / pha003093 rs10175819 chr2 134832158 T C 2.09E-07 Sodium levels / / pha003093 rs11684754 chr2 134833871 G A 2.66E-07 Sodium levels / / pha003093 rs1466567 chr2 134846788 G A 8.00E-04 Multiple complex diseases / / 17554300 rs1879019 chr2 134872037 A G 4.89E-04 Alzheimer's disease / / 17998437 rs1879018 chr2 134872561 T C 8.82E-04 Type 2 diabetes / / 17463246 rs4600717 chr2 134889971 G A 8.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7601756 chr2 134893447 G A 7.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2139310 chr2 134912172 C T 7.27E-04 Multiple complex diseases / / 17554300 rs11692586 chr2 134917005 A G 9.70E-04 Multiple complex diseases / / 17554300 rs10496721 chr2 134932459 G T 8.13E-05 Cholesterol / / pha003083 rs4953906 chr2 134955210 C T 2.53E-04 Smoking cessation / / 24665060 rs13017917 chr2 134961089 G A 1.59E-06 Rheumatoid arthritis / / 19503088 rs2593708 chr2 134979415 C T 2.79E-05 Alzheimer's disease / / 21098978 rs2593708 chr2 134979415 C T 9.42E-07 Sodium levels / / pha003093 rs1965183 chr2 134979966 A G 4.05E-05 Recombination rate / / 21698098 rs16830230 chr2 134983770 A G 5.61E-04 Alzheimer's disease / / 24755620 rs1257220 chr2 135015347 A G 1.80E-10 N-glycan levels,in plasma MGAT5 intron 21908519 rs1257220 chr2 135015347 A G 1.86E-10 N-glycan levels,in plasma MGAT5 intron 21908519 rs1257220 chr2 135015347 A G 2.65E-09 N-glycan levels,in plasma MGAT5 intron 21908519 rs1257220 chr2 135015347 A G 3.46E-09 N-glycan levels,in plasma MGAT5 intron 21908519 rs16830280 chr2 135017417 A T 3.57E-05 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3791259 chr2 135018065 C T 2.06E-04 Glycosylated haemoglobin levels MGAT5 intron 17255346 rs3791259 chr2 135018065 C T 3.18E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3791261 chr2 135018206 T G 4.60E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3791266 chr2 135018736 C G 3.42E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3828175 chr2 135018797 A G 3.52E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3828176 chr2 135022328 A T 9.16E-06 Glycosylated haemoglobin levels MGAT5 intron 17255346 rs3828176 chr2 135022328 A T 3.69E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs373081440 chr2 135022365 CA CCA,CTG 2.17E-05 Glycosylated haemoglobin levels MGAT5 intron 17255346 rs373081440 chr2 135022365 CA CCA,CTG 3.90E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3791269 chr2 135022365 C T 2.17E-05 Glycosylated haemoglobin levels MGAT5 intron 17255346 rs3791269 chr2 135022365 C T 3.90E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3791271 chr2 135022414 T C 3.93E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs6735741 chr2 135022906 A G 8.33E-05 Glycosylated haemoglobin levels MGAT5 intron 17255346 rs6735741 chr2 135022906 A G 4.09E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3791273 chr2 135024482 G C 1.40E-05 Glycosylated haemoglobin levels MGAT5 intron 17255346 rs3791273 chr2 135024482 G C 4.20E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3791275 chr2 135024680 A G 4.16E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3791276 chr2 135024716 A C 4.15E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs3791278 chr2 135025868 G A 6.05E-04 Suicide attempts in bipolar disorder MGAT5 intron 21041247 rs4953911 chr2 135068794 T A 2.00E-07 Multiple sclerosis (severity) MGAT5 intron 20117844 rs10172155 chr2 135094416 G A 1.83E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) MGAT5 intron 24023788 rs2290049 chr2 135114889 A G 2.26E-04 Myopia (pathological) MGAT5 intron 21095009 rs12613306 chr2 135127474 A G 3.69E-04 Myopia (pathological) MGAT5 intron 21095009 rs12467609 chr2 135143287 C T 7.00E-06 Subcutaneous adipose tissue MGAT5 intron 22589738 rs3748900 chr2 135160755 G A 1.07E-04 Parkinson's disease MGAT5 intron 17052657 rs4954142 chr2 135161934 A G 8.52E-04 Parkinson's disease MGAT5 intron 17052657 rs2118844 chr2 135167600 G A 3.56E-05 Parkinson's disease MGAT5 intron 17052657 rs3791316 chr2 135183298 C T 9.88E-04 Response to cytidine analogues (gemcitabine) MGAT5 intron 24483146 rs610624 chr2 135213762 T C 3.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM163 UTR-3 20877124 rs10179686 chr2 135214570 C T 9.43E-04 Obesity (extreme) TMEM163 intron 21935397 rs10179686 chr2 135214570 C T 8.00E-06 Large artery stroke TMEM163 intron 24262325 rs1840413 chr2 135236250 T C 4.34E-04 Gallstones TMEM163 intron 17632509 rs494905 chr2 135240324 G A 1.41E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer TMEM163 intron 22872573 rs507968 chr2 135253960 T A 3.53E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer TMEM163 intron 22872573 rs16830708 chr2 135254442 C G,T 0.000885 Salmonella-induced pyroptosis TMEM163 intron 22837397 rs491200 chr2 135257289 C T 2.92E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer TMEM163 intron 22872573 rs662438 chr2 135260903 C T 4.46E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer TMEM163 intron 22872573 rs540053 chr2 135261737 C T 3.39E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer TMEM163 intron 22872573 rs579076 chr2 135266560 C T 9.86E-05 Non-alcoholic fatty liver disease histology (other) TMEM163 intron 20708005 rs624817 chr2 135278207 T C 3.40E-05 Type 2 diabetes TMEM163 intron 23209189 rs637993 chr2 135278886 G A 1.06E-04 Cognitive function TMEM163 intron 24684796 rs512375 chr2 135285279 G T 1.30E-04 Coronary Artery Disease TMEM163 intron 17634449 rs655472 chr2 135290221 T C 8.86E-07 Coronary Artery Disease TMEM163 intron 17634449 rs666614 chr2 135290453 G C 1.19E-06 Coronary Artery Disease TMEM163 intron 17634449 rs621341 chr2 135295180 T C 3.84E-04 Parkinson's disease TMEM163 intron 22438815 rs621341 chr2 135295180 T C 6.90E-07 Type 2 diabetes TMEM163 intron 23209189 rs2924943 chr2 135300482 G A 1.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM163 intron 20877124 rs17498551 chr2 135323853 A G 1.34E-04 Multiple complex diseases TMEM163 intron 17554300 rs842362 chr2 135341120 G A 1.17E-04 Alzheimer's disease (late onset) TMEM163 intron 21379329 rs6750788 chr2 135362981 A G 3.28E-04 Alzheimer's disease (late onset) TMEM163 intron 21379329 rs35564151 chr2 135372951 G A 1.08E-05 Type 2 diabetes TMEM163 intron 23209189 rs6430527 chr2 135386581 C T 2.80E-04 Coronary Artery Disease TMEM163 intron 17634449 rs7560738 chr2 135419163 A G 2.60E-05 Urinary metabolites TMEM163 intron 21572414 rs998451 chr2 135429288 G A 9.22E-07 Type 2 diabetes TMEM163 intron 23209189 rs6745983 chr2 135430709 G A 2.75E-04 Coronary Artery Disease TMEM163 intron 17634449 rs10171677 chr2 135446390 A G 8.23E-05 Type 2 diabetes TMEM163 intron 23209189 rs10928513 chr2 135456759 C T 5.69E-05 Type 2 diabetes TMEM163 intron 23209189 rs6747870 chr2 135469769 A G 9.98E-04 Multiple complex diseases TMEM163 intron 17554300 rs6723108 chr2 135479980 G T 1.93E-05 Amyotrophic lateral sclerosis / / 19193627 rs6723108 chr2 135479980 G T 7.02E-06 Parkinson's disease / / 22438815 rs6723108 chr2 135479980 G T 7.00E-08 Type 2 diabetes / / 23209189 rs4346444 chr2 135486894 T G 4.56E-04 Multiple complex diseases / / 17554300 rs4346444 chr2 135486894 T G 8.05E-04 Smoking cessation / / 24665060 rs1942055 chr2 135498924 G C 1.84E-05 Lung function (forced vital capacity) / / 24929828 rs16831005 chr2 135537332 T C 1.64E-06 Body mass index / / 19584900 rs16831005 chr2 135537332 T C 6.38E-06 Body mass index / / 19584900 rs6430538 chr2 135539967 C T 2.00E-07 Parkinson's disease / / 22451204 rs7599054 chr2 135540546 A G 5.45E-04 Parkinson's disease / / 17052657 rs6710823 chr2 135592381 G A 7.00E-09 Parkinson's disease / / 21292315 rs6710823 chr2 135592381 G A 1.91E-05 Parkinson's disease / / 22438815 rs6710823 chr2 135592381 G A 1.35E-09 Parkinson's disease / / 22451204 rs10198552 chr2 135599876 T C 7.00E-07 Obesity-related traits ACMSD intron 23251661 rs6430553 chr2 135631400 C T 6.00E-12 Blood metabolite levels ACMSD intron 24816252 rs2166480 chr2 135637338 G A 6.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) ACMSD intron 17982456 rs10928525 chr2 135736138 C G 8.50E-04 Response to cytadine analogues (cytosine arabinoside) YSK4 intron 24483146 rs16831235 chr2 135745129 G A 7.01E-04 Response to cytadine analogues (cytosine arabinoside) YSK4 missense 24483146 rs1530559 chr2 135755629 A G 3.37E-08 Fasting insulin-related traits YSK4 intron 22885924 rs6754977 chr2 135756378 C T 1.44E-05 Age-related macular degeneration YSK4 cds-synon pha000001 rs16831243 chr2 135762344 C T 3.91E-05 Paget's disease YSK4 intron 20436471 rs7582173 chr2 135763318 G A 4.10E-05 Paget's disease YSK4 intron 20436471 rs16831256 chr2 135781035 C T 8.46E-04 Depression (quantitative trait) YSK4 intron 20800221 rs4954218 chr2 135803425 G T 8.23E-05 Serum metabolites / / 19043545 rs4954218 chr2 135803425 G T 1.00E-09 Corneal structure / / 21979947 rs61369044 chr2 135808469 A C 1.95E-35 Metabolite levels RAB3GAP1 nearGene-5 22286219 rs16831311 chr2 135816439 A G 5.07E-04 Multiple complex diseases RAB3GAP1 intron 17554300 rs16831315 chr2 135825074 T C 8.35E-04 Multiple complex diseases RAB3GAP1 intron 17554300 rs16831315 chr2 135825074 T C 2.70E-05 Personality dimensions RAB3GAP1 intron 18957941 rs7570971 chr2 135837906 C A 1.00E-08 Cholesterol,total RAB3GAP1 intron 20686565 rs7570971 chr2 135837906 C A 2.00E-08 Type 2 diabetes RAB3GAP1 intron 23209189 rs7570971 chr2 135837906 C A 1.00E-13 Cholesterol,total RAB3GAP1 intron 24097068 rs7570971 chr2 135837906 C A 8.00E-45 Blood metabolite levels RAB3GAP1 intron 24816252 rs6728452 chr2 135839805 C T 7.57E-04 Depression (quantitative trait) RAB3GAP1 intron 20800221 rs1869829 chr2 135877562 A G 7.42E-06 Paget's disease RAB3GAP1 intron 20436471 rs7603310 chr2 135902220 C T 3.40E-04 Sudden cardiac arrest RAB3GAP1 intron 21658281 rs6730157 chr2 135907088 A G 2.16E-08 Lipid levels RAB3GAP1 intron 20370913 rs6730157 chr2 135907088 A G 1.69E-05 Paget's disease RAB3GAP1 intron 20436471 rs6730157 chr2 135907088 A G 4.93E-12 Sudden cardiac death RAB3GAP1 intron 23593153 rs3739028 chr2 135907846 T C 5.28E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) RAB3GAP1 intron 24192120 rs6430563 chr2 135967778 A G 5.19E-05 Personality dimensions ZRANB3 intron 18957941 rs1900741 chr2 136002500 C T 3.13E-05 Paget's disease ZRANB3 intron 20436471 rs1561277 chr2 136092061 C A 4.95E-06 Paget's disease ZRANB3 intron 20436471 rs1469950 chr2 136128254 A G 7.06E-05 Personality dimensions ZRANB3 intron 18957941 rs16831601 chr2 136151774 C T 9.76E-05 Personality dimensions ZRANB3 intron 18957941 rs16831751 chr2 136264631 A G 4.54E-05 Personality dimensions ZRANB3 intron 18957941 rs16831751 chr2 136264631 A G 8.78E-04 Depression (quantitative trait) ZRANB3 intron 20800221 rs3806502 chr2 136288273 C T 7.59E-05 Triglycerides ZRANB3 intron pha003080 rs4954265 chr2 136324225 A G 1.00E-04 Cognitive impairment induced by topiramate R3HDM1 intron 22091778 rs4954265 chr2 136324225 A G 7.95E-05 Triglycerides R3HDM1 intron pha003080 rs6723890 chr2 136366433 A G 9.56E-04 Prostate cancer mortality R3HDM1 intron 20978177 rs12465802 chr2 136381348 G A 7.98E-09 Lipid levels R3HDM1 intron 20370913 rs10187054 chr2 136388473 T C 3.83E-04 Multiple complex diseases R3HDM1 intron 17554300 rs12466487 chr2 136407078 T C 2.49E-06 Multiple complex diseases R3HDM1 intron 17554300 rs1446585 chr2 136407479 A G 8.16E-06 Paget's disease R3HDM1 intron 20436471 rs1446584 chr2 136419961 A G 8.09E-04 Multiple complex diseases R3HDM1 intron 17554300 rs4954280 chr2 136420690 A G 7.20E-04 Multiple complex diseases R3HDM1 intron 17554300 rs4954280 chr2 136420690 A G 5.87E-08 Lipid levels R3HDM1 intron 20370913 rs1374330 chr2 136420908 A C 4.74E-05 Paget's disease R3HDM1 intron 20436471 rs313519 chr2 136439517 A C 2.64E-05 Paget's disease R3HDM1 intron 20436471 rs313528 chr2 136445869 G A 5.02E-06 Paget's disease R3HDM1 intron 20436471 rs7570283 chr2 136447707 T C 4.22E-04 Response to cytidine analogues (gemcitabine) R3HDM1 intron 24483146 rs7592050 chr2 136459227 A G 4.36E-07 Multiple complex diseases R3HDM1 intron 17554300 rs6739713 chr2 136488978 A G 6.25E-06 Paget's disease / / 20436471 rs1438307 chr2 136499166 G T 2.33E-05 Paget's disease / / 20436471 rs6430585 chr2 136506927 A C 7.99E-04 Multiple complex diseases UBXN4 intron 17554300 rs6430585 chr2 136506927 A C 1.78E-06 Paget's disease UBXN4 intron 20436471 rs6430585 chr2 136506927 A C 1.00E-06 Corneal structure UBXN4 intron 21979947 rs16831992 chr2 136509460 G C 1.90E-06 Phospholipid levels (plasma) UBXN4 intron 21829377 rs9287442 chr2 136522710 A G 2.25E-06 Paget's disease UBXN4 intron 20436471 rs10496736 chr2 136536113 C G 1.60E-12 Health and aging,CVD and cancer age of onset UBXN4 intron 22174011 rs10496736 chr2 136536113 C G 3.60E-14 Health and aging,CVD and cancer age of onset UBXN4 intron 22174011 rs10496736 chr2 136536113 C G 4.80E-11 Health and aging,CVD and cancer age of onset UBXN4 intron 22174011 rs1469996 chr2 136542560 A G 3.75E-06 Paget's disease UBXN4 UTR-3 20436471 rs16832011 chr2 136545299 A G 3.00E-07 Phospholipid levels (plasma) LCT nearGene-3 21829377 rs1042712 chr2 136545844 C G 5.54E-13 Multiple complex diseases LCT UTR-3 17554300 rs4954633 chr2 136546635 C T 9.78E-05 Serum albumin level LCT intron pha003084 rs2015532 chr2 136555525 T G 6.53E-05 Multiple complex diseases LCT intron 17554300 rs2322659 chr2 136555659 T C 3.34E-04 Multiple complex diseases LCT missense 17554300 rs2322659 chr2 136555659 T C 8.60E-05 Celiac disease LCT missense 17558408 rs2322659 chr2 136555659 T C 8.88E-06 Waist circumference LCT missense 19557197 rs2322659 chr2 136555659 T C 5.31E-06 Paget's disease LCT missense 20436471 rs2322659 chr2 136555659 T C 9.80E-05 Coronary heart disease LCT missense 21966275 rs3769013 chr2 136556182 T C 5.84E-04 Multiple complex diseases LCT intron 17554300 rs3769012 chr2 136556480 G A 7.04E-04 Multiple complex diseases LCT intron 17554300 rs3769012 chr2 136556480 G A 8.14E-04 Alzheimer's disease LCT intron 17998437 rs872151 chr2 136556805 C T 7.70E-05 Personality dimensions LCT intron 18957941 rs2322660 chr2 136557319 C T 9.82E-06 Waist circumference LCT intron 19557197 rs2322660 chr2 136557319 C T 7.08E-09 Lipid levels LCT intron 20370913 rs748841 chr2 136558157 C T 9.85E-06 Waist circumference LCT intron 19557197 rs2304371 chr2 136561557 G A 7.38E-04 Multiple complex diseases LCT cds-synon 17554300 rs12988076 chr2 136569848 C A 8.41E-04 Response to cytidine analogues (gemcitabine) LCT intron 24483146 rs4954445 chr2 136571982 T A 8.10E-05 Personality dimensions LCT intron 18957941 rs892715 chr2 136576577 T C 8.50E-06 Waist circumference LCT intron 19557197 rs7579771 chr2 136580260 T A 9.14E-06 Waist circumference LCT intron 19557197 rs2164210 chr2 136580287 T C 8.44E-06 Waist circumference LCT intron 19557197 rs745500 chr2 136583192 G A 9.71E-06 Waist circumference LCT intron 19557197 rs2236783 chr2 136594158 G A 4.02E-06 Waist circumference LCT cds-synon 19557197 rs4988218 chr2 136613461 T C 8.05E-04 Depression (quantitative trait) MCM6 intron 20800221 rs309180 chr2 136614255 G A 8.39E-09 Lipid levels MCM6 intron 20370913 rs4988163 chr2 136628121 G T 2.19E-04 Multiple complex diseases MCM6 intron 17554300 rs16832138 chr2 136637350 G A 2.90E-05 Personality dimensions / / 18957941 rs632632 chr2 136638216 T C 1.03E-08 Lipid levels / / 20370913 rs632632 chr2 136638216 T C 8.07E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7561565 chr2 136640787 T G 8.70E-05 Multiple complex diseases / / 17554300 rs7581814 chr2 136641593 C G 1.03E-04 Multiple complex diseases / / 17554300 rs309168 chr2 136670298 C T 8.80E-06 Waist circumference DARS intron 19557197 rs309160 chr2 136685228 C T 8.33E-06 Waist circumference DARS intron 19557197 rs309160 chr2 136685228 C T 1.99E-05 Paget's disease DARS intron 20436471 rs309161 chr2 136688749 G A 4.16E-04 Sudden cardiac arrest DARS intron 21658281 rs309164 chr2 136691825 T C 3.90E-04 Response to cytidine analogues (gemcitabine) DARS intron 24483146 rs7573555 chr2 136694905 T C 5.70E-05 Multiple complex diseases DARS intron 17554300 rs7573555 chr2 136694905 T C 9.79E-04 Alzheimer's disease DARS intron 17998437 rs6743537 chr2 136702601 G A 1.82E-04 Multiple complex diseases DARS intron 17554300 rs6754311 chr2 136707982 T C 4.56E-06 Waist circumference DARS intron 19557197 rs6430594 chr2 136719173 A G 1.00E-05 Multiple complex diseases DARS intron 17554300 rs3768998 chr2 136720344 G T 5.82E-04 Asparaginase sensitivity in blood cell lines DARS intron 21072045 rs12615624 chr2 136721603 A G 5.13E-04 Response to cytidine analogues (gemcitabine) DARS intron 24483146 rs13404551 chr2 136721995 T C 6.01E-06 Waist circumference DARS intron 19557197 rs13404551 chr2 136721995 T C 2.94E-04 Response to cytidine analogues (gemcitabine) DARS intron 24483146 rs689002 chr2 136734614 A G 1.55E-04 Multiple complex diseases DARS intron 17554300 rs689002 chr2 136734614 A G 6.03E-06 White blood cell count DARS intron 21738479 rs834734 chr2 136735998 C T 1.23E-06 White blood cell count DARS intron 21738479 rs687670 chr2 136740900 T C 5.55E-06 Waist circumference DARS intron 19557197 rs309134 chr2 136755684 G A 5.40E-06 Waist circumference LOC100131316 intron 19557197 rs309134 chr2 136755684 G A 6.99E-04 Response to cytidine analogues (gemcitabine) LOC100131316 intron 24483146 rs309137 chr2 136765951 T C 3.48E-06 Waist circumference / / 19557197 rs309137 chr2 136765951 T C 5.45E-05 Paget's disease / / 20436471 rs12471781 chr2 136770509 G A 6.25E-05 Multiple complex diseases / / 17554300 rs6714750 chr2 136783169 A G 1.93E-06 Waist circumference / / 19557197 rs12475139 chr2 136786651 T A 9.80E-06 Waist circumference / / 19557197 rs6716536 chr2 136787402 C T 5.85E-06 Waist circumference / / 19557197 rs7371606 chr2 136806774 G A 4.85E-04 Multiple complex diseases / / 17554300 rs11693502 chr2 136808949 C T 5.43E-04 Multiple complex diseases / / 17554300 rs1533649 chr2 136814109 G A 0.00061 Endometrial cancer / / 22426144 rs2011946 chr2 136817616 C A 4.15E-06 Alcohol dependence / / 20202923 rs2011946 chr2 136817616 C A 2.00E-06 Smoking behavior / / 20418888 rs2011946 chr2 136817616 C A 6.73E-05 Alcohol dependence / / 21703634 rs932206 chr2 136825272 C T 3.90E-07 Type 2 diabetes / / 17293876 rs932206 chr2 136825272 C T 3.90E-07 Type 2 diabetes / / 19184112 rs932206 chr2 136825272 C T 1.31E-06 Paget's disease / / 20436471 rs2734871 chr2 136869873 G A 7.08E-04 Multiple complex diseases / / 17554300 rs10191360 chr2 136884679 T C 8.20E-04 Coronary heart disease / / 21966275 rs6710778 chr2 136886141 C T 6.28E-05 Multiple complex diseases / / 17554300 rs62160907 chr2 136889725 G A 0.0000926 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7574456 chr2 136890059 C T 2.70E-04 Coronary heart disease / / 21966275 rs17382303 chr2 136893225 T G 8.40E-05 Multiple complex diseases / / 17554300 rs17382303 chr2 136893225 T G 0.0000763 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4954564 chr2 136895508 A G 5.37E-05 Caffeine consumption / / 21490707 rs62160908 chr2 136896864 C T 0.0000453 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11683586 chr2 136897386 C T 0.0000447 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2176717 chr2 136899859 C T 5.86E-04 Schizophrenia / / 19197363 rs953387 chr2 136907170 A C 7.17E-05 Caffeine consumption / / 21490707 rs11691305 chr2 136907854 C G 0.000033 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62160909 chr2 136913134 A G 0.0000362 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs80238030 chr2 136914692 T A 0.0000296 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62160911 chr2 136919509 A G 0.0000237 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17382372 chr2 136921761 G A 6.81E-05 Multiple complex diseases / / 17554300 rs17382372 chr2 136921761 G A 0.0000431 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11687597 chr2 136926146 A G 0.000049 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17466923 chr2 136927678 G T 0.0000485 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs16833150 chr2 136927857 A G 4.11E-04 Alzheimer's disease / / 17998437 rs62160934 chr2 136941539 T A 0.0000576 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62160935 chr2 136941699 T C 0.0000307 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1123848 chr2 136945029 C T 2.46E-05 Caffeine consumption / / 21490707 rs1519529 chr2 136974257 C G 1.60E-04 Multiple complex diseases / / 17554300 rs882300 chr2 136976255 T C 3.00E-07 Electrocardiographic traits / / 17903306 rs882300 chr2 136976255 T C 1.00E-07 Multiple sclerosis / / 19525953 rs6430612 chr2 137006198 C T 2.66E-05 Elbow pain / / pha003008 rs4477975 chr2 137009006 A G 9.68E-05 Alcohol dependence / / 21703634 rs9677195 chr2 137013195 A G 8.22E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10221893 chr2 137013606 C T 2.66E-05 Elbow pain / / pha003008 rs6430614 chr2 137013930 G A 3.09E-05 Height / / pha003011 rs4452212 chr2 137015991 G A 2.00E-06 Telomere length / / 20421499 rs4074120 chr2 137026587 T C 7.41E-05 Height / / pha003010 rs4074120 chr2 137026587 T C 9.52E-06 Height / / pha003011 rs6725197 chr2 137031229 T C 2.02E-04 Multiple complex diseases / / 17554300 rs4516492 chr2 137055404 G A 9.83E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4516492 chr2 137055404 G A 4.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13003740 chr2 137087324 A G 8.76E-05 Atopic dermatitis / / 23042114 rs5011377 chr2 137087576 A G 9.95E-05 Atopic dermatitis / / 23042114 rs12614381 chr2 137091269 A C 1.48E-05 Schizophrenia / / 19571811 rs16833840 chr2 137116544 G A 0.000034 Salmonella-induced pyroptosis / / 22837397 rs6430635 chr2 137148547 A G 8.58E-04 Multiple complex diseases / / 17554300 rs13032229 chr2 137149254 A G 9.93E-04 Multiple complex diseases / / 17554300 rs16833988 chr2 137149620 A T 2.50E-05 Urinary metabolites / / 21572414 rs16834001 chr2 137152113 C T 4.15E-04 Multiple complex diseases / / 17554300 rs635018 chr2 137159866 A G 5.92E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs543721 chr2 137161557 G T 4.23E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs6706755 chr2 137162063 C G 5.34E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9646660 chr2 137164476 A G 9.79E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6430637 chr2 137184835 G A 7.58E-05 Monocyte counts / / pha003089 rs16834223 chr2 137194436 A G 4.20E-05 Alcoholism (heaviness of drinking) / / 21529783 rs7561441 chr2 137197151 C G 3.02E-04 Multiple complex diseases / / 17554300 rs10496746 chr2 137207082 C T 2.60E-05 Alcoholism (heaviness of drinking) / / 21529783 rs2033172 chr2 137240304 A G 6.20E-05 Alcoholism (heaviness of drinking) / / 21529783 rs12465885 chr2 137269312 T C 8.53E-04 Obesity (extreme) / / 21935397 rs876338 chr2 137289147 T C 9.46E-04 Obesity (extreme) / / 21935397 rs10496749 chr2 137305977 T C 5.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs16835520 chr2 137316141 A G 1.54E-04 Sudden cardiac arrest / / 21658281 rs934299 chr2 137338940 G T 9.00E-06 Cognitive test performance / / 17903297 rs7576758 chr2 137391962 A G 9.20E-04 Multiple complex diseases / / 17554300 rs6711718 chr2 137407012 T C 5.14E-05 Left ventricular hypertrophy / / pha003052 rs16836044 chr2 137418255 A C 4.33E-04 Type 2 diabetes / / 17463246 rs7606972 chr2 137456700 G T 2.08E-05 Cognitive decline / / 22054870 rs4618106 chr2 137463721 C T 9.48E-05 Aortic root size / / 21223598 rs10496752 chr2 137465223 C T 1.15E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs16836162 chr2 137465622 A G 0.0000126 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1593762 chr2 137476801 A G 2.39E-05 Cognitive decline / / 22054870 rs12622368 chr2 137483980 T C 0.0000189 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4603825 chr2 137484231 G C 0.0000721 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1427617 chr2 137487339 T C 0.0000502 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1427616 chr2 137487498 G A 0.0000714 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11683556 chr2 137489778 G A 0.0000442 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1582861 chr2 137491121 C T 3.00E-06 Subcutaneous adipose tissue / / 22589738 rs12476818 chr2 137493912 T C 9.60E-05 Left ventricular hypertrophy / / pha003052 rs16836228 chr2 137495620 C T 7.78E-04 Type 2 diabetes / / 17463246 rs16836228 chr2 137495620 C T 2.45E-04 Multiple complex diseases / / 17554300 rs12479021 chr2 137495815 T G 7.44E-05 Left ventricular hypertrophy / / pha003052 rs59556655 chr2 137501797 A G 0.0000395 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs72617041 chr2 137502939 C T 0.0000448 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1991413 chr2 137507257 G T 0.0000275 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs16836383 chr2 137508441 A G 0.0000152 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1896477 chr2 137508544 C T 0.00000295 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10496753 chr2 137509024 T G 0.0000154 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6732148 chr2 137509604 G T 0.000049 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1346369 chr2 137511278 A G 0.0000157 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6430669 chr2 137516790 G A 0.0000846 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2001872 chr2 137522044 A G 1.91E-04 Vaspin levels / / 22907691 rs2001872 chr2 137522044 A G 0.000191 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs2001872 chr2 137522044 A G 0.0000063 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs3863015 chr2 137522567 G A 0.000016 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62161461 chr2 137522814 G T 0.0000876 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs77055332 chr2 137522867 G C 0.0000188 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1427602 chr2 137529247 T C 5.24E-05 Paget's disease / / 20436471 rs16836631 chr2 137539487 C G 3.27E-04 Type 2 diabetes / / 17463246 rs1427593 chr2 137555224 T C 7.00E-06 Pancreatic cancer / / 20686608 rs2435389 chr2 137586694 A G 6.90E-06 Iron levels / / 21208937 rs2059973 chr2 137598039 G A 4.42E-05 Cognitive decline / / 22054870 rs12613655 chr2 137601781 G A 4.20E-06 Iron levels / / 21208937 rs10496759 chr2 137603404 C G 4.20E-05 Cognitive decline / / 22054870 rs13015892 chr2 137610035 G A 1.50E-05 Cognitive decline / / 22054870 rs1560359 chr2 137619887 C A 2.06E-04 Coronary heart disease / / 21971053 rs10928576 chr2 137629096 A G 4.38E-04 Multiple complex diseases / / 17554300 rs16837222 chr2 137629273 G A 4.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs518743 chr2 137662855 T C 7.54E-04 Multiple complex diseases / / 17554300 rs12469179 chr2 137704727 G A 6.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs524398 chr2 137715259 T C 2.45E-05 Cognitive decline / / 22054870 rs16837695 chr2 137719415 A C 6.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7585449 chr2 137719956 A G 7.00E-04 Multiple complex diseases / / 17554300 rs7591845 chr2 137720806 T G 7.42E-04 Multiple complex diseases / / 17554300 rs1344712 chr2 137729014 A G 7.70E-04 Multiple complex diseases / / 17554300 rs1030622 chr2 137744509 T C 6.67E-05 Cognitive decline / / 22054870 rs6750400 chr2 137767548 C T 2.28E-04 Obesity (extreme) THSD7B intron 21935397 rs979976 chr2 137768702 A C 8.00E-06 Corneal astigmatism THSD7B intron 23761726 rs2116538 chr2 137769420 G A 4.44E-04 Longevity THSD7B intron 22279548 rs2116538 chr2 137769420 G A 1.63E-05 Corneal astigmatism THSD7B intron 23761726 rs1432237 chr2 137808507 A G 4.44E-06 Osteoarthritis THSD7B intron 22763110 rs1368061 chr2 137868769 G A 9.30E-05 Personality dimensions THSD7B intron 18957941 rs1368061 chr2 137868769 G A 7.74E-04 Response to taxane treatment (placlitaxel) THSD7B intron 23006423 rs1432219 chr2 137868836 A C 8.77E-04 Response to taxane treatment (placlitaxel) THSD7B intron 23006423 rs974528 chr2 137870582 T C 6.80E-05 Personality dimensions THSD7B intron 18957941 rs974528 chr2 137870582 T C 4.61E-04 Response to taxane treatment (placlitaxel) THSD7B intron 23006423 rs892877 chr2 137873347 A G 4.00E-06 Liver enzyme levels (aspartate transaminase) THSD7B intron 24124411 rs1469622 chr2 137875875 T C 4.50E-05 Tooth agenesis (maxillary third molar) THSD7B intron 24172245 rs1469622 chr2 137875875 T C 8.00E-06 Tooth agenesis (third molar) THSD7B intron 24172245 rs35019443 chr2 137875875 T TC 4.50E-05 Tooth agenesis (maxillary third molar) THSD7B intron 24172245 rs35019443 chr2 137875875 T TC 8.00E-06 Tooth agenesis (third molar) THSD7B intron 24172245 rs1432205 chr2 137896264 C A 2.40E-05 Tooth agenesis (third molar) THSD7B intron 24172245 rs984295 chr2 137898753 G A 5.86E-06 Liver enzyme levels (aspartate transaminase) THSD7B intron 24124411 rs1991735 chr2 137904014 G A 5.61E-04 Obesity (extreme) THSD7B intron 21935397 rs7573893 chr2 137916325 T C 1.54E-04 Attention deficit hyperactivity disorder THSD7B intron 22420046 rs4954474 chr2 137917922 T A 8.32E-06 White blood cell count THSD7B missense 21738479 rs11899922 chr2 137919366 A G 2.00E-04 Spine bone size THSD7B intron 21947420 rs12987197 chr2 137970642 A G 7.19E-04 Suicide attempts in bipolar disorder THSD7B intron 21423239 rs4610107 chr2 137980318 G A 7.76E-06 Serum metabolites THSD7B intron 19043545 rs17197674 chr2 137984147 G A 1.70E-05 Serum metabolites THSD7B intron 19043545 rs10200345 chr2 137998775 C A 2.31E-05 Cognitive performance THSD7B intron 19734545 rs10207592 chr2 138002133 A G 4.70E-04 Alzheimer's disease (late onset) THSD7B intron 21379329 rs17346940 chr2 138011809 A G 8.45E-04 Obesity (extreme) THSD7B intron 21935397 rs10490733 chr2 138038497 T C 3.20E-05 Blood Phenotypes THSD7B intron 17903294 rs11688662 chr2 138048340 A G 5.84E-04 Obesity (extreme) THSD7B intron 21935397 rs6730418 chr2 138048455 T C 9.81E-05 Serum metabolites THSD7B intron 19043545 rs6749316 chr2 138073500 C T 4.54E-05 Attention deficit hyperactivity disorder THSD7B intron 22420046 rs17738873 chr2 138073795 A G 4.74E-04 Obesity (extreme) THSD7B intron 21935397 rs10496769 chr2 138081065 A G 2.15E-04 Blood pressure THSD7B intron 17255346 rs10204990 chr2 138096989 A G 4.77E-04 Alzheimer's disease THSD7B intron 22005930 rs718632 chr2 138102805 C T 9.21E-04 Bipolar disorder THSD7B intron 19259986 rs13405020 chr2 138142164 G C 7.00E-06 Non-small cell lung cancer THSD7B intron 23144319 rs2889092 chr2 138179576 A G 4.83E-05 Insulin resistance THSD7B intron 21901158 rs10190462 chr2 138201585 C T 2.40E-04 Blood pressure THSD7B intron 17255346 rs1869324 chr2 138227442 G A 5.40E-04 Alcohol dependence THSD7B intron 20201924 rs1869324 chr2 138227442 G A 4.71E-07 Alcohol dependence THSD7B intron 21703634 rs1869324 chr2 138227442 G A 3.68E-04 Alzheimer's disease THSD7B intron 22005930 rs2375511 chr2 138249452 C A 6.10E-04 Alcohol dependence THSD7B intron 20201924 rs13419109 chr2 138294928 T C 5.16E-04 Insulin resistance THSD7B intron 21901158 rs17742691 chr2 138321018 G C 4.66E-04 Alzheimer's disease THSD7B intron 22005930 rs7597076 chr2 138364637 T C 3.25E-04 Suicide attempts in bipolar disorder THSD7B intron 21423239 rs881639 chr2 138398906 T C 9.26E-04 Stroke THSD7B intron pha002887 rs10496784 chr2 138412985 G T 3.63E-05 Bilirubin levels,in serum THSD7B intron 19389676 rs12053559 chr2 138416391 T G 5.54E-05 Serum metabolites THSD7B intron 19043545 rs12994131 chr2 138418875 A G 3.39E-06 Recombination rate THSD7B intron 21698098 rs12617524 chr2 138468383 C T 4.14E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7561701 chr2 138472227 C G,T 1.48E-06 Asthma (childhood onset) / / 23829686 rs16839623 chr2 138579212 A G 8.77E-04 Multiple complex diseases / / 17554300 rs6730857 chr2 138600801 G A 6.19E-04 Multiple complex diseases / / 17554300 rs6430755 chr2 138644649 G A 7.78E-04 Type 2 diabetes / / 17463246 rs6430755 chr2 138644649 G A 5.90E-04 Multiple complex diseases / / 17554300 rs7590072 chr2 138650882 C T 3.65E-04 Multiple complex diseases / / 17554300 rs7590072 chr2 138650882 C T 7.52E-04 Body mass index / / 21701565 rs7590072 chr2 138650882 C T 7.70E-04 Body mass index / / 21701565 rs7557873 chr2 138654786 G C 8.50E-04 Type 2 diabetes / / 17463246 rs7557873 chr2 138654786 G C 3.82E-04 Multiple complex diseases / / 17554300 rs7557873 chr2 138654786 G C 7.81E-04 Body mass index / / 21701565 rs964203 chr2 138655271 C T 2.22E-04 Multiple complex diseases / / 17554300 rs964203 chr2 138655271 C T 7.64E-04 Body mass index / / 21701565 rs964203 chr2 138655271 C T 8.89E-04 Body mass index / / 21701565 rs1840647 chr2 138656320 T G 1.58E-04 Multiple complex diseases / / 17554300 rs1840647 chr2 138656320 T G 8.72E-04 Body mass index / / 21701565 rs7596424 chr2 138657891 C T 6.77E-04 Multiple complex diseases / / 17554300 rs6727027 chr2 138667408 T C 7.51E-04 Body mass index / / 21701565 rs897525 chr2 138670221 C T 7.91E-04 Multiple complex diseases / / 17554300 rs897525 chr2 138670221 C T 8.08E-04 Body mass index / / 21701565 rs1840658 chr2 138673651 T G 8.79E-04 Type 2 diabetes / / 17463246 rs1840658 chr2 138673651 T G 2.40E-04 Multiple complex diseases / / 17554300 rs1840658 chr2 138673651 T G 3.39E-04 Body mass index / / 21701565 rs1840658 chr2 138673651 T G 4.15E-04 Body mass index / / 21701565 rs1840658 chr2 138673651 T G 7.07E-04 Body mass index / / 21701565 rs13419499 chr2 138674287 A G 3.88E-04 Body mass index / / 21701565 rs13419499 chr2 138674287 A G 5.64E-04 Body mass index / / 21701565 rs6724601 chr2 138676851 C A 3.41E-04 Multiple complex diseases / / 17554300 rs6724601 chr2 138676851 C A 3.25E-04 Body mass index / / 21701565 rs6724601 chr2 138676851 C A 4.63E-04 Body mass index / / 21701565 rs6724601 chr2 138676851 C A 8.39E-04 Body mass index / / 21701565 rs4564833 chr2 138681621 T C 1.65E-06 Telomere length / / 23001564 rs1973077 chr2 138686213 A G 1.74E-04 Attention deficit hyperactivity disorder / / 22420046 rs921858 chr2 138691067 A G 4.30E-04 Body mass index / / 21701565 rs921858 chr2 138691067 A G 4.97E-04 Body mass index / / 21701565 rs3113210 chr2 138704063 C G 3.91E-04 Bipolar disorder,schizoaffective / / 19567891 rs3113240 chr2 138709568 A G 7.63E-04 Parkinson's disease / / 17052657 rs6755148 chr2 138717628 G C 2.09E-04 Parkinson's disease / / 17052657 rs3791244 chr2 138731765 G A 7.00E-10 Asthma (childhood onset) HNMT intron 17611496 rs3100700 chr2 138732194 G C 6.73E-04 Multiple complex diseases HNMT intron 17554300 rs3113205 chr2 138732281 C G 3.80E-05 Malaria HNMT intron 19465909 rs1996872 chr2 138818601 T C 0.0000353 Breast cancer early age of onset / / 18463975 rs1996872 chr2 138818601 T C 5.90E-05 Personality dimensions / / 18957941 rs1996873 chr2 138818642 G A 9.54E-04 Multiple complex diseases / / 17554300 rs10205475 chr2 138838295 G C 5.50E-05 Personality dimensions / / 18957941 rs1533906 chr2 138861772 C T 1.71E-04 Multiple complex diseases / / 17554300 rs1522909 chr2 138871234 G A 1.61E-04 Multiple complex diseases / / 17554300 rs2204181 chr2 138898229 G T 3.09E-04 Alzheimer's disease / / 22005930 rs2204181 chr2 138898229 G T 3.68E-05 Coronary heart disease / / pha003032 rs28569024 chr2 139008811 C T 9.36E-04 White matter integrity / / 22425255 rs4643591 chr2 139020862 A G 8.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11885046 chr2 139022658 G A 8.40E-06 Urinary metabolites / / 21572414 rs4399769 chr2 139049380 C T 1.40E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4276077 chr2 139076753 C G 4.78E-04 Multiple complex diseases / / 17554300 rs11904825 chr2 139116542 G A 9.52E-05 Blood Pressure / / pha003043 rs145745331 chr2 139116542 GA G 9.52E-05 Blood Pressure / / pha003043 rs13405108 chr2 139258603 G A 6.29E-05 Nephrolithiasis / / 22396660 rs6720716 chr2 139268802 A G 6.14E-05 Fibrinogen SPOPL intron pha003068 rs10170310 chr2 139278922 G A 1.00E-07 Response to antipsychotic treatment SPOPL intron 23241943 rs10803568 chr2 139290914 T C 7.41E-05 Fibrinogen SPOPL intron pha003068 rs13388206 chr2 139332931 A G 2.23E-04 Fibrinogen / / 17255346 rs7584853 chr2 139344740 G A,C,T 1.20E-04 Multiple complex diseases / / 17554300 rs58938945 chr2 139399354 A G 8.00E-06 Metabolite levels (MHPG) / / 23319000 rs10496799 chr2 139427669 T C 1.40E-05 Longevity and age-related phenotypes NXPH2 UTR-3 17903295 rs4954946 chr2 139442521 T C 4.90E-04 Lung function (forced expiratory volume in 1 second) NXPH2 intron 24023788 rs7594476 chr2 139447600 C G 5.48E-05 Hypertension NXPH2 intron 19609347 rs7594562 chr2 139447623 C T 2.55E-04 Lung function (forced expiratory volume in 1 second) NXPH2 intron 24023788 rs12691954 chr2 139465406 C T 4.26E-04 Lung function (forced expiratory volume in 1 second) NXPH2 intron 24023788 rs10496800 chr2 139488901 C T 7.20E-04 Heart Failure NXPH2 intron pha002884 rs10928663 chr2 139489417 C T 7.46E-04 Multiple complex diseases NXPH2 intron 17554300 rs11692663 chr2 139490568 T A 9.93E-04 Multiple complex diseases NXPH2 intron 17554300 rs11686876 chr2 139502153 T A 1.02E-04 Response to statin treatment (atorvastatin),change in cholesterol levels NXPH2 intron 20031582 rs10193564 chr2 139512134 C T 3.19E-04 Amyotrophic lateral sclerosis (sporadic) NXPH2 intron 24529757 rs17599328 chr2 139516703 A G 3.98E-05 Prion diseases NXPH2 intron 22210626 rs10200922 chr2 139530239 A G 2.51E-04 Suicide attempts in bipolar disorder NXPH2 intron 21423239 rs4954956 chr2 139544577 C T 8.00E-06 Breast cancer / / 17529967 rs13399914 chr2 139603975 C T 2.70E-05 Urinary metabolites / / 21572414 rs10192531 chr2 139612158 C T 2.40E-05 Urinary metabolites / / 21572414 rs17659751 chr2 139615945 A G 2.90E-05 Urinary metabolites / / 21572414 rs1485069 chr2 139636679 T A 5.03E-04 Multiple complex diseases / / 17554300 rs10496802 chr2 139644872 C A 4.00E-05 Type 2 diabetes / / 17903298 rs10496803 chr2 139651484 T G 0.000386 Salmonella-induced pyroptosis / / 22837397 rs11886636 chr2 139655616 C T 7.83E-04 Type 2 diabetes / / 17463246 rs11886636 chr2 139655616 C T 8.85E-04 Multiple complex diseases / / 17554300 rs1601352 chr2 139661244 A C 7.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs9636231 chr2 139671955 G A 8.00E-06 Alcohol dependence / / 21956439 rs1485058 chr2 139675535 C T 6.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs6738511 chr2 139676195 C A 6.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs6757538 chr2 139677323 A C 6.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs1872385 chr2 139681884 G C 6.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs1872384 chr2 139682249 A G 6.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs936760 chr2 139682405 G A 9.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs1385413 chr2 139683585 T C 6.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs4954976 chr2 139685716 T C 6.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs1485057 chr2 139686312 C T 6.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs2062362 chr2 139686409 G T 6.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs1485055 chr2 139686615 G T 5.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs1471784 chr2 139688324 T C 5.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs10460247 chr2 139694251 A G 6.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs6730163 chr2 139699780 T C 5.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs936764 chr2 139705705 G A 9.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs1351924 chr2 139708230 T C 7.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs10803574 chr2 139710863 G A 9.52E-06 Alcohol dependence / / 21703634 rs10803574 chr2 139710863 G A 1.80E-04 Alcohol dependence / / 21956439 rs1485086 chr2 139722479 G C 9.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs4954643 chr2 139722786 T C 9.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs7563596 chr2 139729909 C A 2.72E-04 Aortic root size / / 21223598 rs3922799 chr2 139758906 G A 6.48E-05 Alcohol dependence / / 21703634 rs1351916 chr2 139763448 T A 2.00E-04 Type 2 diabetes / / 17846126 rs647111 chr2 139775063 A T 7.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs1505846 chr2 139778282 C T 9.39E-06 Alcohol dependence / / 21703634 rs1505846 chr2 139778282 C T 2.00E-04 Alcohol dependence / / 21956439 rs16841529 chr2 139801479 C T 5.17E-06 Multiple complex diseases / / 17554300 rs1605136 chr2 139804141 A G 7.51E-05 Alcohol dependence / / 21703634 rs11688290 chr2 139808906 C T 3.18E-05 Alcohol dependence / / 21703634 rs9287508 chr2 139815873 C T 5.23E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9287508 chr2 139815873 C T 9.57E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs16841575 chr2 139823059 C T 5.54E-04 Multiple complex diseases / / 17554300 rs924952 chr2 139832149 G T 5.24E-04 Multiple complex diseases / / 17554300 rs4954647 chr2 139859202 T G 3.62E-05 Amyotrophic lateral sclerosis / / 19193627 rs2099575 chr2 139866554 T C 4.55E-05 Amyotrophic lateral sclerosis / / 19193627 rs12465063 chr2 139870976 T C,G 8.15E-04 Multiple complex diseases / / 17554300 rs12613183 chr2 139876065 T C 3.18E-04 Multiple complex diseases / / 17554300 rs1437329 chr2 139886095 T C 9.35E-05 Cognitive test performance / / 20125193 rs10196730 chr2 139914818 C A 1.91E-05 Major depressive disorder / / 22472876 rs10196730 chr2 139914818 C A 6.94E-05 Cervical cancer / / 24700089 rs1437296 chr2 139938408 G A 2.64E-05 Major depressive disorder / / 22472876 rs10181724 chr2 139959808 C T 1.59E-05 Major depressive disorder / / 22472876 rs1437305 chr2 139961825 G A 1.97E-05 Major depressive disorder / / 22472876 rs934707 chr2 139976061 G T 3.17E-05 Major depressive disorder / / 22472876 rs736666 chr2 140031202 G A 2.31E-04 Alzheimer's disease / / 22005930 rs6742944 chr2 140036852 G A 5.68E-04 Aortic root size / / 21223598 rs11675037 chr2 140046970 A T 2.62E-04 Alzheimer's disease / / 22005930 rs11675255 chr2 140050223 C T 9.76E-05 Alzheimer's disease / / 22005930 rs1371110 chr2 140056052 A G 4.65E-05 Bone mineral density / / 19181680 rs1399645 chr2 140147832 C T 9.00E-07 Male infertility / / 19478329 rs13033247 chr2 140203973 A G 5.60E-04 Multiple complex diseases / / 17554300 rs7421449 chr2 140205110 A C,G,T 0.0000141 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11890914 chr2 140220527 T C 0.0000919 Polycystic ovary syndrome / / 22951595 rs11890914 chr2 140220527 T C 9.19E-05 Intracranial aneurysm / / 22961961 rs10496820 chr2 140224777 C T 5.71E-04 Multiple complex diseases / / 17554300 rs10496821 chr2 140272019 G A 7.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs2376446 chr2 140301222 C T 0.000743 Salmonella-induced pyroptosis / / 22837397 rs345619 chr2 140308150 C T 0.000417 Salmonella-induced pyroptosis / / 22837397 rs345618 chr2 140309392 C T 0.000533 Salmonella-induced pyroptosis / / 22837397 rs6430841 chr2 140318199 A G 2.73E-04 Multiple complex diseases / / 17554300 rs1347729 chr2 140323265 C A 0.000729 Salmonella-induced pyroptosis / / 22837397 rs11896674 chr2 140393064 T C 5.71E-04 Multiple complex diseases / / 17554300 rs7574941 chr2 140448156 T C 4.55E-05 Bipolar disorder and schizophrenia / / 20889312 rs11897599 chr2 140449566 A G 4.01E-05 Bipolar disorder and schizophrenia / / 20889312 rs7562605 chr2 140491257 A C 0.00064 Salmonella-induced pyroptosis / / 22837397 rs76747997 chr2 140511671 T C 0.0000223 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4954663 chr2 140559497 A G 0.000675 Salmonella-induced pyroptosis / / 22837397 rs1464300 chr2 140594138 C T 6.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17731496 chr2 140605034 C T 9.30E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs16842994 chr2 140626731 C G 2.00E-06 Methotrexate phramacokinetics (acute lymphoblastic leukemia) / / 19901119 rs1520086 chr2 140627411 C T 1.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1607666 chr2 140627913 G A 9.47E-04 Parkinson's disease / / 17052657 rs10928729 chr2 140629263 G A 3.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10928730 chr2 140631904 T G 5.82E-04 Smoking initiation / / 24665060 rs9287528 chr2 140655121 G T 0.000013 Antisocial behavior / / 23077488 rs12620585 chr2 140655950 T C 6.34E-04 Coronary heart disease / / 21971053 rs11901615 chr2 140657370 T C 0.0000158 Antisocial behavior / / 23077488 rs7591869 chr2 140659840 A G 2.56E-05 Iron status biomarkers / / 19084217 rs1401941 chr2 140678237 C A 4.49E-04 Type 2 diabetes / / 17463246 rs12469257 chr2 140681274 A G 1.22E-04 Coronary heart disease / / 21971053 rs11682155 chr2 140695463 C T 4.84E-05 Cognitive performance / / 19734545 rs12479038 chr2 140699470 T C 1.36E-04 Coronary heart disease / / 21971053 rs16843075 chr2 140705119 G A 2.50E-04 Type 2 diabetes / / 17463246 rs13035203 chr2 140709142 C T 8.60E-06 Urinary metabolites / / 21572414 rs10174598 chr2 140713355 T C 2.74E-05 Interstitial lung disease / / 23583980 rs1920523 chr2 140722815 A T 1.30E-05 Urinary metabolites / / 21572414 rs7586146 chr2 140772874 C T 6.13E-04 Multiple complex diseases / / 17554300 rs1527853 chr2 140799875 T C 5.14E-04 Body mass index / / 21701565 rs16843268 chr2 140820905 G A 0.0000039 Mean arterial pressure / / 22510845 rs4954821 chr2 140892675 C G 7.37E-04 Type 2 diabetes / / 17463246 rs2950613 chr2 140913383 C G 3.49E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6715982 chr2 140945164 G A 8.19E-04 Smoking initiation / / 24665060 rs11883474 chr2 141041323 T G 1.95E-05 Panic disorder LRP1B intron 19165232 rs10496839 chr2 141049869 C T 1.01E-05 Myopia (pathological) LRP1B intron 23049088 rs17477276 chr2 141079858 T C 9.27E-05 Response to methylphenidate treatment LRP1B intron 21130132 rs11897270 chr2 141190436 C T 3.54E-04 Smoking quantity LRP1B intron 24665060 rs10496844 chr2 141195126 C T 4.92E-04 Multiple complex diseases LRP1B intron 17554300 rs1518444 chr2 141197873 C T 2.84E-04 Smoking quantity LRP1B intron 24665060 rs1518443 chr2 141197983 T C 5.43E-04 Smoking quantity LRP1B intron 24665060 rs1878741 chr2 141199904 C T 2.89E-04 Smoking quantity LRP1B intron 24665060 rs6747180 chr2 141212126 T C 4.67E-04 Smoking quantity LRP1B intron 24665060 rs72899866 chr2 141226309 T A 5.00E-06 Periodontitis (CDC/AAP) LRP1B intron 24024966 rs3923350 chr2 141239598 G T 5.00E-04 Obesity-related traits LRP1B intron 17903300 rs3923350 chr2 141239598 G T 5.89E-04 Nicotine smoking LRP1B intron 19268276 rs183373550 chr2 141269442 C G 7.00E-06 Serum dimethylarginine levels (symmetric) LRP1B intron 24159190 rs1905925 chr2 141296612 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) LRP1B intron 20708005 rs13032617 chr2 141312831 A G 6.02E-04 Multiple complex diseases LRP1B intron 17554300 rs2380887 chr2 141321183 C A 7.57E-05 IgE levels LRP1B intron 22075330 rs6723267 chr2 141330806 C G 4.27E-05 IgE levels LRP1B intron 22075330 rs17806210 chr2 141332832 A G 5.48E-05 IgE levels LRP1B intron 22075330 rs6732761 chr2 141334737 A C 2.65E-05 IgE levels LRP1B intron 22075330 rs10928758 chr2 141343336 A C 8.74E-05 Monocyte counts LRP1B intron pha003089 rs492190 chr2 141355107 A G 4.79E-05 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs16844322 chr2 141361994 A G 7.08E-04 Response to alcohol consumption (flushing response) LRP1B intron 24277619 rs491391 chr2 141362058 A C 3.00E-07 optic disc size (disc) LRP1B intron 20395239 rs491391 chr2 141362058 A C 2.96E-04 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs493102 chr2 141362222 G T 8.50E-05 Cognitive function LRP1B intron 24684796 rs487419 chr2 141377607 T C 3.89E-04 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs547663 chr2 141382827 A C 5.30E-04 Multiple complex diseases LRP1B intron 17554300 rs10166217 chr2 141398489 T G 4.33E-05 Post-operative nausea and vomiting LRP1B intron 21694509 rs514478 chr2 141409166 A G 7.64E-05 Post-operative nausea and vomiting LRP1B intron 21694509 rs16844441 chr2 141424422 C T 6.99E-05 Tuberculosis LRP1B intron 24057671 rs2165506 chr2 141448312 A G 1.10E-05 Post-operative nausea and vomiting LRP1B intron 21694509 rs1441460 chr2 141466384 G A 3.40E-05 Post-operative nausea and vomiting LRP1B intron 21694509 rs436323 chr2 141478468 C T 3.84E-05 Post-operative nausea and vomiting LRP1B intron 21694509 rs9287300 chr2 141532786 G A 3.43E-05 Neuroblastoma LRP1B intron pha002895 rs6735489 chr2 141551350 A C 2.27E-05 Neuroblastoma LRP1B intron pha002895 rs13432282 chr2 141572109 G T 5.13E-05 Neuroblastoma LRP1B intron pha002895 rs13420111 chr2 141581332 A G 3.90E-05 Neuroblastoma LRP1B intron pha002895 rs6725365 chr2 141592580 T C 9.56E-04 Suicide attempts in bipolar disorder LRP1B intron 21423239 rs2200488 chr2 141600366 C T 1.09E-05 Post-operative nausea and vomiting LRP1B intron 21694509 rs12467730 chr2 141604351 A G 1.44E-04 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs11901880 chr2 141605983 G A 1.07E-04 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs10496855 chr2 141638380 T G 4.90E-05 Asthma LRP1B intron 20159242 rs10496856 chr2 141639391 A G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) LRP1B intron 17982456 rs12691579 chr2 141640478 T G 1.86E-04 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs12691580 chr2 141647612 T A 3.82E-04 Multiple complex diseases LRP1B intron 17554300 rs2016582 chr2 141652239 C T 9.49E-05 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs12987986 chr2 141655736 A G 8.59E-06 Post-operative nausea and vomiting LRP1B intron 21694509 rs2033290 chr2 141657878 A C 5.98E-04 Response to cytidine analogues (gemcitabine) LRP1B intron 24483146 rs1366801 chr2 141660295 A G 6.09E-04 Multiple complex diseases LRP1B intron 17554300 rs10170474 chr2 141662215 A C 3.27E-05 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs1469481 chr2 141664879 G A 2.80E-05 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs2380945 chr2 141668323 A G 1.41E-05 Bladder cancer (smoking interaction) LRP1B intron 24662972 rs10496859 chr2 141668678 A C 4.26E-05 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs10496860 chr2 141671250 T C 8.77E-05 Post-operative nausea and vomiting LRP1B intron 21694509 rs2052910 chr2 141713645 A C 7.10E-05 Psoriasis LRP1B intron 18364390 rs16845018 chr2 141714746 G A 7.96E-05 Cognitive test performance LRP1B intron 20125193 rs16845018 chr2 141714746 G A 5.64E-04 Smoking cessation LRP1B intron 24665060 rs16845023 chr2 141717063 G C 9.82E-06 Multiple complex diseases LRP1B intron 17554300 rs13016717 chr2 141717646 A G 4.03E-05 Cognitive test performance LRP1B intron 20125193 rs1346641 chr2 141718996 G T 7.82E-05 Cognitive test performance LRP1B intron 20125193 rs12474609 chr2 141721142 A T 6.00E-09 Aging LRP1B intron 19367585 rs4954683 chr2 141741590 T C 9.00E-06 IgG glycosylation LRP1B intron 23382691 rs10928087 chr2 141742103 A G 1.13E-04 Response to cytadine analogues (cytosine arabinoside) LRP1B intron 24483146 rs16845089 chr2 141743077 C T 2.88E-05 Response to cytadine analogues (cytosine arabinoside) LRP1B intron 24483146 rs12624219 chr2 141755731 A C 3.69E-04 Type 2 diabetes LRP1B intron 17463246 rs16845115 chr2 141756592 A C 3.69E-04 Type 2 diabetes LRP1B intron 17463246 rs1474407 chr2 141757246 C T 7.46E-05 Cognitive test performance LRP1B intron 20125193 rs1474407 chr2 141757246 C T 1.48E-04 Alzheimer's disease (late onset) LRP1B intron 21379329 rs1525590 chr2 141769764 G A 4.12E-04 Schizophrenia(treatment response to risperidone) LRP1B intron 19850283 rs17521615 chr2 141776841 C T 2.22E-04 Type 2 diabetes LRP1B intron 17463246 rs6429856 chr2 141779955 G A 5.92E-04 Alcohol consumption (maxi-drinks) LRP1B intron 24277619 rs10210358 chr2 141795620 A G 2.00E-06 Erectile dysfunction and prostate cancer treatment LRP1B intron 20932654 rs16845177 chr2 141797709 T G 7.08E-04 Multiple complex diseases LRP1B intron 17554300 rs1474406 chr2 141800073 C T 7.38E-04 Suicide attempts in bipolar disorder LRP1B intron 21423239 rs13422816 chr2 141805232 C A 6.16E-04 Taste perception LRP1B intron 22132133 rs6755234 chr2 141809737 C A 2.86E-05 Parkinson's disease LRP1B intron 21738487 rs2380922 chr2 141810244 T C 8.56E-06 Parkinson's disease LRP1B intron 21738487 rs16845233 chr2 141813216 C A 8.11E-04 Depression (quantitative trait) LRP1B intron 20800221 rs1525583 chr2 141819422 G A 1.99E-05 Parkinson's disease LRP1B intron 21738487 rs16845274 chr2 141826995 T A 9.22E-04 Depression (quantitative trait) LRP1B intron 20800221 rs4954687 chr2 141832339 T C 2.82E-05 Parkinson's disease LRP1B intron 21738487 rs1357966 chr2 141833621 G A 2.82E-05 Parkinson's disease LRP1B intron 21738487 rs2140872 chr2 141841860 T C 2.18E-05 Parkinson's disease LRP1B intron 21738487 rs3856355 chr2 141843386 G C 6.50E-04 Suicide attempts in bipolar disorder LRP1B intron 21423239 rs4954880 chr2 141846346 T C 8.05E-06 Parkinson's disease LRP1B intron 21738487 rs12996731 chr2 141857090 G A 9.84E-05 Parkinson's disease LRP1B intron 21738487 rs1882642 chr2 141861910 A G 6.27E-06 Parkinson's disease LRP1B intron 21738487 rs12691592 chr2 141878501 C A 3.54E-04 Response to taxane treatment (placlitaxel) LRP1B intron 23006423 rs2222233 chr2 141919943 C T 1.35E-05 Hepatocellular carcinoma LRP1B intron 22807686 rs1249458 chr2 141929225 G A 8.34E-06 Hepatocellular carcinoma LRP1B intron 22807686 rs1714259 chr2 141932472 C T 1.06E-06 Hepatocellular carcinoma LRP1B intron 22807686 rs7424161 chr2 141942235 C T 8.76E-06 Hepatocellular carcinoma LRP1B intron 22807686 rs300373 chr2 141976620 G A 1.20E-04 Multiple complex diseases LRP1B intron 17554300 rs7558514 chr2 141977173 G A 1.12E-04 Alcohol dependence LRP1B intron 21314694 rs9283437 chr2 141998560 C A 4.18E-05 Height LRP1B intron pha003010 rs434276 chr2 142013959 C A 6.90E-05 Height LRP1B intron pha003010 rs300397 chr2 142030590 C A 1.02E-04 Schizophrenia LRP1B intron 20832056 rs2683815 chr2 142078003 C T 1.19E-04 Multiple complex diseases LRP1B intron 17554300 rs11886422 chr2 142146201 G A 1.84E-05 Telomere length LRP1B intron 23001564 rs4422109 chr2 142165632 T A 4.84E-04 Smoking initiation LRP1B intron 24665060 rs4954702 chr2 142172366 G A 4.52E-04 White matter integrity LRP1B intron 22425255 rs4954702 chr2 142172366 G A 7.39E-04 Smoking cessation LRP1B intron 24665060 rs11892609 chr2 142180729 C T 5.32E-04 Parkinson's disease LRP1B intron 17052657 rs12105292 chr2 142187915 C T 9.21E-05 Waist-Hip Ratio LRP1B intron pha003029 rs4507038 chr2 142188957 G A 9.21E-05 Waist-Hip Ratio LRP1B intron pha003029 rs4352181 chr2 142195346 G A 8.19E-04 White matter integrity LRP1B intron 22425255 rs4401160 chr2 142227602 A G 4.35E-04 Tourette syndrome LRP1B intron 22889924 rs12472911 chr2 142228509 C T 2.00E-07 Menarche (age at onset) LRP1B intron 21102462 rs6745352 chr2 142229279 T A 5.44E-04 Multiple complex diseases LRP1B intron 17554300 rs10496880 chr2 142237435 T C 8.73E-06 Blood Pressure LRP1B intron pha003049 rs10496881 chr2 142244913 G T 1.94E-04 Birth weight LRP1B intron 17255346 rs16846274 chr2 142251849 C T 2.22E-04 Birth weight LRP1B intron 17255346 rs11677666 chr2 142277072 G A 0.00007403 Sarcoidosis LRP1B intron 22952805 rs16846416 chr2 142290687 C T 3.23E-04 Type 2 diabetes LRP1B intron 17463246 rs13007647 chr2 142293363 A C 5.74E-04 Multiple complex diseases LRP1B intron 17554300 rs16855058 chr2 142307179 C T 5.90E-04 Age at menarche,age at menopause LRP1B intron 22131368 rs2381190 chr2 142342699 A G 4.25E-04 Multiple complex diseases LRP1B intron 17554300 rs16855065 chr2 142363641 C A 6.44E-05 Blood Pressure LRP1B intron pha003050 rs16855067 chr2 142363876 T C 6.24E-04 Type 2 diabetes LRP1B intron 17463246 rs2890601 chr2 142404955 A G 4.31E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LRP1B intron 24023788 rs16846817 chr2 142430307 A C 9.44E-08 Metabolite levels LRP1B intron 23281178 rs354856 chr2 142433670 T C 9.44E-08 Metabolite levels LRP1B intron 23281178 rs164979 chr2 142436459 C T 4.42E-07 Post-operative nausea and vomiting LRP1B intron 21694509 rs7560557 chr2 142437151 G A 4.58E-04 Lung function (forced expiratory volume in 1 second) LRP1B intron 17255346 rs7560557 chr2 142437151 G A 4.00E-04 Premature ovarian failure LRP1B intron 19508998 rs7560557 chr2 142437151 G A 9.44E-08 Metabolite levels LRP1B intron 23281178 rs9653179 chr2 142446465 T C 7.31E-05 Serum metabolites LRP1B intron 19043545 rs16846925 chr2 142467266 C T 6.55E-05 Suicide attempts in bipolar disorder LRP1B intron 21423239 rs17801458 chr2 142468472 C T 4.71E-04 Type 2 diabetes LRP1B intron 17463246 rs17801458 chr2 142468472 C T 2.46E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LRP1B intron 20031582 rs17801458 chr2 142468472 C T 1.40E-05 Urinary metabolites LRP1B intron 21572414 rs978601 chr2 142470905 T G 3.96E-04 Type 2 diabetes LRP1B intron 17463246 rs16846962 chr2 142475665 C T 4.47E-04 Suicide attempts in bipolar disorder LRP1B intron 21423239 rs1347659 chr2 142478064 A G 9.71E-04 Suicide attempts in bipolar disorder LRP1B intron 21423239 rs1898422 chr2 142495019 C A 1.30E-05 Urinary metabolites LRP1B intron 21572414 rs1898422 chr2 142495019 C A 3.24E-04 Longevity LRP1B intron 22279548 rs2217963 chr2 142495229 T C 8.10E-06 Urinary metabolites LRP1B intron 21572414 rs10803486 chr2 142495805 G A 2.60E-05 Urinary metabolites LRP1B intron 21572414 rs1036506 chr2 142504546 C T 2.00E-05 Urinary metabolites LRP1B intron 21572414 rs10496894 chr2 142506366 C T 3.41E-05 Corneal structure LRP1B intron 22003120 rs10928122 chr2 142530120 G T 6.63E-04 Alcohol dependence LRP1B intron 20201924 rs6429923 chr2 142578483 T C 1.94E-04 Cognitive decline LRP1B intron 23732972 rs13431583 chr2 142594611 T C 5.38E-06 C-reactive protein LRP1B intron 22492993 rs13004344 chr2 142606736 A G 2.40E-05 Urinary metabolites LRP1B intron 21572414 rs13018903 chr2 142608963 A G 1.71E-06 C-reactive protein LRP1B intron 22492993 rs1898016 chr2 142609604 G A 2.46E-04 Amyotrophic Lateral Sclerosis LRP1B intron 17827064 rs16847370 chr2 142612131 T C 7.24E-06 C-reactive protein LRP1B intron 22492993 rs13430058 chr2 142615596 A G 2.98E-05 C-reactive protein LRP1B intron 22492993 rs7586153 chr2 142616136 T A 9.73E-06 C-reactive protein LRP1B intron 22492993 rs13385804 chr2 142617164 A C 5.59E-06 C-reactive protein LRP1B intron 22492993 rs16847412 chr2 142618914 T C 1.20E-05 C-reactive protein LRP1B intron 22492993 rs10496905 chr2 142636460 A G 6.40E-05 Glioma (high-grade) LRP1B intron 19578366 rs10496905 chr2 142636460 A G 6.12E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LRP1B intron 20877124 rs983540 chr2 142658129 T C 3.95E-04 Type 2 diabetes LRP1B intron 17463246 rs7564502 chr2 142739121 G A 8.49E-04 Multiple complex diseases LRP1B intron 17554300 rs16847914 chr2 142765005 C T 5.22E-04 Type 2 diabetes LRP1B intron 17463246 rs1191974 chr2 142768518 C T 8.51E-04 Suicide attempts in bipolar disorder LRP1B intron 21423239 rs1449479 chr2 142830294 C T 6.54E-04 Type 2 diabetes LRP1B intron 17463246 rs7583748 chr2 142855291 G A 1.00E-04 Body mass index LRP1B intron 24348519 rs1001628 chr2 142868147 T G 6.10E-05 Glioma (high-grade) LRP1B intron 19578366 rs1375613 chr2 142874253 T A 3.75E-04 Multiple complex diseases LRP1B intron 17554300 rs970600 chr2 142878897 C T 6.73E-05 Response to hepatitis C treatment LRP1B intron 19684573 rs12477787 chr2 142933399 G A 3.54E-05 Telomere length / / 23001564 rs13408409 chr2 142947513 G A 1.20E-06 Urinary metabolites / / 21572414 rs2890652 chr2 142959931 T C 1.00E-10 Body mass index / / 20935630 rs2890652 chr2 142959931 T C 1.35E-10 Body mass index / / 23001569 rs1523704 chr2 142963976 T C 3.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4473327 chr2 142989440 G A 4.49E-04 Depression (quantitative trait) / / 20800221 rs4297822 chr2 142994927 T G 4.32E-04 Depression (quantitative trait) / / 20800221 rs6744481 chr2 143052039 A G 6.87E-04 Smoking initiation / / 24665060 rs4662491 chr2 143110338 A C 6.61E-04 Acute lung injury / / 22295056 rs4355053 chr2 143220554 C T 6.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs4311004 chr2 143220907 A G 7.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs13416800 chr2 143222005 T C 7.41E-05 Kawasaki disease / / 22081228 rs13407187 chr2 143223382 C T 5.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs7601564 chr2 143224339 A T 6.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs13006196 chr2 143226133 A G 6.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs10172919 chr2 143231156 A G 3.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs4330055 chr2 143231622 A G 9.33E-05 Kawasaki disease / / 22081228 rs1900539 chr2 143235183 C G 7.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs4386266 chr2 143236253 T C 6.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs41320848 chr2 143448194 C T 6.49E-05 Multiple complex diseases / / 17554300 rs7598800 chr2 143475728 T G 1.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7598800 chr2 143475728 T G 5.85E-05 Sodium levels / / pha003093 rs7598906 chr2 143475832 T C 5.37E-05 Sodium levels / / pha003093 rs6712291 chr2 143550868 T C 5.25E-04 Eye color / / 23118974 rs13023887 chr2 143600166 C A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1439876 chr2 143638594 G A 1.46E-04 Lung function (forced expiratory volume in 1 second) KYNU intron 17255346 rs16858223 chr2 143650771 C T 8.39E-04 Bipolar disorder,schizoaffective KYNU intron 19567891 rs164732 chr2 143667100 C T 3.69E-04 Lung function (forced expiratory volume in 1 second) KYNU intron 17255346 rs351694 chr2 143704314 T C 7.32E-04 Suicide attempts in bipolar disorder KYNU intron 21423239 rs351696 chr2 143705360 G A 6.38E-04 Suicide attempts in bipolar disorder KYNU intron 21423239 rs12997823 chr2 143709091 A G 4.34E-04 Multiple complex diseases KYNU intron 17554300 rs12997823 chr2 143709091 A G 8.63E-04 Suicide attempts in bipolar disorder KYNU intron 21423239 rs13024113 chr2 143711005 A G 7.66E-04 Suicide attempts in bipolar disorder KYNU intron 21423239 rs16855215 chr2 143724281 T G 4.14E-05 Aortic root size KYNU intron 21223598 rs1050950 chr2 143746849 C A 7.18E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) KYNU intron 23648065 rs1371514 chr2 143749073 G A 7.18E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) KYNU intron 23648065 rs12466715 chr2 143751071 A G 9.24E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) KYNU intron 23648065 rs352892 chr2 143757925 C A 2.80E-05 Response to lithium treatment in bipolar disorder KYNU intron 19448189 rs352892 chr2 143757925 C A 3.43E-05 Schizophrenia KYNU intron 19571809 rs352892 chr2 143757925 C A 5.04E-05 Schizophrenia KYNU intron pha002859 rs7425446 chr2 143777498 T A 4.10E-05 Iron levels KYNU intron 21208937 rs2304700 chr2 143791014 G T 2.06E-04 Multiple complex diseases KYNU intron 17554300 rs12477146 chr2 143793814 G A 9.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) KYNU intron 23233662 rs2043931 chr2 143795681 C A 1.04E-05 Statin-induced myopathy KYNU intron 21826682 rs7598467 chr2 143796057 G A 9.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) KYNU intron 23233662 rs3768844 chr2 143796694 A G 1.38E-05 Multiple complex diseases KYNU intron 17554300 rs3845642 chr2 143799003 G A 0.0003734 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KYNU intron 23233654 rs3845642 chr2 143799003 G A 3.73E-04 Methotrexate clearance (acute lymphoblastic leukemia) KYNU intron 23233662 rs3816193 chr2 143799907 G A 1.45E-05 Multiple complex diseases KYNU nearGene-3 17554300 rs354707 chr2 143886437 T A 4.10E-04 Type 2 diabetes / / 17463246 rs16858596 chr2 143890281 G A 5.30E-04 Alcohol dependence ARHGAP15 intron 20201924 rs827219 chr2 143892794 C T 7.14E-04 Schizophrenia ARHGAP15 intron 19197363 rs6430004 chr2 143893576 G A 5.89E-04 Tourette syndrome ARHGAP15 intron 22889924 rs9917392 chr2 143895878 C T 3.66E-07 Type 2 diabetes ARHGAP15 intron 17463246 rs10189773 chr2 143896500 A G 6.62E-07 Type 2 diabetes ARHGAP15 intron 17463246 rs354694 chr2 143925517 G A 5.87E-04 Obesity (extreme) ARHGAP15 intron 21935397 rs354696 chr2 143931505 G A 4.29E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) ARHGAP15 intron 23648065 rs1869009 chr2 143934549 G A 3.03E-04 Body mass index ARHGAP15 intron 17255346 rs7595079 chr2 143951325 T C 6.36E-04 Response to cytadine analogues (cytosine arabinoside) ARHGAP15 intron 24483146 rs11681284 chr2 144057444 T C 2.00E-04 Cognitive impairment induced by topiramate ARHGAP15 intron 22091778 rs12691674 chr2 144093331 T C 2.23E-06 Smooth-surface caries ARHGAP15 intron 24556642 rs17229397 chr2 144095037 T A 1.97E-06 Smooth-surface caries ARHGAP15 intron 24556642 rs10176394 chr2 144096374 T C 2.00E-06 Smooth-surface caries ARHGAP15 intron 24556642 rs10496946 chr2 144102594 C T 2.01E-06 Smooth-surface caries ARHGAP15 intron 24556642 rs532311971 chr2 144102594 CAAT C 2.01E-06 Smooth-surface caries ARHGAP15 intron 24556642 rs562827965 chr2 144102594 CAAT C 2.01E-06 Smooth-surface caries ARHGAP15 intron 24556642 rs11676611 chr2 144128555 G C 6.57E-04 Response to taxane treatment (placlitaxel) ARHGAP15 intron 23006423 rs2381466 chr2 144133509 A G 5.29E-04 Multiple complex diseases ARHGAP15 intron 17554300 rs13405986 chr2 144161734 A G 9.37E-04 Multiple complex diseases ARHGAP15 intron 17554300 rs13405986 chr2 144161734 A G 2.37E-05 Hemoglobin ARHGAP15 intron pha003098 rs13405986 chr2 144161734 A G 2.89E-05 Erythrocyte counts ARHGAP15 intron pha003099 rs11897813 chr2 144167920 T C 4.25E-04 Type 2 diabetes ARHGAP15 intron 17463246 rs16822484 chr2 144177579 T C 1.00E-04 Prostate cancer ARHGAP15 intron 21743057 rs10180461 chr2 144263033 T C 4.95E-05 Erythrocyte counts ARHGAP15 intron pha003099 rs6731747 chr2 144308396 T A 8.63E-04 Type 2 diabetes ARHGAP15 intron 17463246 rs4662339 chr2 144318832 T C 7.23E-04 Type 2 diabetes ARHGAP15 intron 17463246 rs12992706 chr2 144363659 C T 4.46E-04 Type 2 diabetes ARHGAP15 intron 17463246 rs6716352 chr2 144368257 G A 9.82E-06 Liver disease in chronic hepatitis B virus infection ARHGAP15 intron 24065354 rs10496950 chr2 144372973 C G 3.85E-04 Nicotine smoking ARHGAP15 intron 19268276 rs2731553 chr2 144373941 A C 4.26E-05 Intracerebral hemorrhage ARHGAP15 intron 24656865 rs11693600 chr2 144380542 C T 1.68E-04 Nicotine smoking ARHGAP15 intron 19268276 rs13422906 chr2 144398052 T A 0.0007186 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ARHGAP15 intron 23233654 rs13422906 chr2 144398052 T A 7.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) ARHGAP15 intron 23233662 rs13430960 chr2 144409949 C T 6.69E-04 Heart Failure ARHGAP15 intron pha002885 rs6750487 chr2 144415905 G A 8.22E-04 Heart Failure ARHGAP15 intron pha002885 rs10928195 chr2 144428608 C G 4.00E-06 Quantitative traits ARHGAP15 intron 19197348 rs12999020 chr2 144501505 T C 7.54E-05 Cognitive test performance ARHGAP15 intron 20125193 rs13420376 chr2 144572005 C T 1.37E-05 Response to metformin / / 21186350 rs13018437 chr2 144613766 G A 0.000000853 Nicotine dependence (smoking) / / 23542338 rs1257351 chr2 144631168 G T 1.20E-04 Sudden cardiac arrest / / 21658281 rs17834780 chr2 144638809 G A 5.28E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6713567 chr2 144647829 T C 7.85E-04 Multiple complex diseases / / 17554300 rs787151 chr2 144655836 A G 2.75E-05 Nicotine smoking / / 19268276 rs787176 chr2 144668249 C T 0.000000605 Nicotine dependence (smoking) / / 23542338 rs768145 chr2 144684875 C T 6.67E-04 Schizophrenia / / 21674006 rs1011397 chr2 144690117 C T 8.00E-06 Obesity-related traits / / 23251661 rs16823406 chr2 144781851 T C 6.67E-04 Multiple complex diseases GTDC1 intron 17554300 rs16823411 chr2 144783214 T C 4.55E-04 Body mass index GTDC1 intron 21701565 rs16823411 chr2 144783214 T C 5.39E-04 Body mass index GTDC1 intron 21701565 rs12615549 chr2 144796925 C G 4.54E-04 Body mass index GTDC1 intron 21701565 rs12615549 chr2 144796925 C G 5.64E-04 Body mass index GTDC1 intron 21701565 rs7602624 chr2 144805815 A G 4.96E-04 Body mass index GTDC1 intron 21701565 rs7602624 chr2 144805815 A G 7.22E-04 Body mass index GTDC1 intron 21701565 rs4662366 chr2 144820057 A G 2.03E-04 Body mass index GTDC1 intron 21701565 rs4662366 chr2 144820057 A G 2.25E-04 Body mass index GTDC1 intron 21701565 rs4662366 chr2 144820057 A G 9.17E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) GTDC1 intron 24236485 rs10496957 chr2 144854774 G C 4.61E-04 Body mass index GTDC1 intron 21701565 rs10496957 chr2 144854774 G C 7.03E-04 Body mass index GTDC1 intron 21701565 rs1429098 chr2 144889825 C A 4.48E-04 Body mass index GTDC1 intron 21701565 rs1429098 chr2 144889825 C A 5.39E-04 Body mass index GTDC1 intron 21701565 rs3731958 chr2 144899559 C A 0.000011 Prostate cancer GTDC1 missense 23555315 rs12463773 chr2 144908230 T A 3.41E-09 Schizophrenia GTDC1 intron 22037555 rs6760118 chr2 144912781 A G 1.21E-04 Multiple complex diseases GTDC1 intron 17554300 rs4662368 chr2 144919040 C G 6.18E-04 Body mass index GTDC1 intron 21701565 rs4662368 chr2 144919040 C G 6.67E-04 Body mass index GTDC1 intron 21701565 rs13415860 chr2 144919272 A T 7.79E-04 Body mass index GTDC1 intron 21701565 rs1344628 chr2 144919995 A G 3.49E-04 Body mass index GTDC1 intron 21701565 rs1344628 chr2 144919995 A G 4.04E-04 Body mass index GTDC1 intron 21701565 rs6716723 chr2 144963831 G A 4.19E-04 Body mass index GTDC1 intron 21701565 rs6716723 chr2 144963831 G A 4.35E-04 Body mass index GTDC1 intron 21701565 rs10928206 chr2 144965236 G C 2.40E-06 Body mass index GTDC1 intron 21701565 rs10928206 chr2 144965236 G C 3.89E-06 Body mass index GTDC1 intron 21701565 rs16823583 chr2 144969618 T C 4.17E-04 Body mass index GTDC1 intron 21701565 rs16823583 chr2 144969618 T C 4.70E-04 Body mass index GTDC1 intron 21701565 rs1012272 chr2 144993201 C T 2.01E-04 Multiple complex diseases GTDC1 intron 17554300 rs997840 chr2 145058077 A G 4.15E-04 Body mass index GTDC1 intron 21701565 rs997840 chr2 145058077 A G 4.70E-04 Body mass index GTDC1 intron 21701565 rs10496963 chr2 145079065 T C 1.65E-06 Cognitive test performance GTDC1 intron 20125193 rs2081776 chr2 145080938 T C 1.00E-04 Information processing speed GTDC1 intron 21130836 rs12991836 chr2 145141541 A C 1.10E-06 Schizophrenia ZEB2 nearGene-3 21791550 rs12991836 chr2 145141541 A C 0.0000011 Psychosis ZEB2 nearGene-3 23164818 rs12991836 chr2 145141541 A C 1.00E-08 Schizophrenia ZEB2 nearGene-3 23974872 rs11888238 chr2 145152235 T C 5.03E-05 Renal cell carcinoma ZEB2 intron 23184150 rs10185359 chr2 145155731 T C 4.63E-04 Renal cell carcinoma ZEB2 intron 23184150 rs7560525 chr2 145169563 A G 2.07E-05 Renal cell carcinoma ZEB2 intron 23184150 rs72858437 chr2 145171259 T C 4.80E-04 Renal cell carcinoma ZEB2 intron 23184150 rs10210063 chr2 145182957 C G 1.70E-06 Renal cell carcinoma ZEB2 intron 23184150 rs10192562 chr2 145184316 A G 2.38E-06 Renal cell carcinoma ZEB2 intron 23184150 rs10164806 chr2 145193326 C T 1.92E-06 Renal cell carcinoma ZEB2 intron 23184150 rs13401103 chr2 145198623 G A 6.10E-07 Renal cell carcinoma ZEB2 intron 23184150 rs72858474 chr2 145198889 G A 4.89E-07 Renal cell carcinoma ZEB2 intron 23184150 rs6708471 chr2 145202600 G C 6.70E-04 Multiple complex diseases ZEB2 intron 17554300 rs16823732 chr2 145204758 G A 1.44E-04 Sudden cardiac arrest ZEB2 intron 21658281 rs16823732 chr2 145204758 G A 1.58E-06 Renal cell carcinoma ZEB2 intron 23184150 rs16823732 chr2 145204758 G A 3.55E-05 Amyotrophic lateral sclerosis (sporadic) ZEB2 intron 24529757 rs10187892 chr2 145205693 G C 9.03E-05 Smoking initiation ZEB2 intron 24665060 rs12105918 chr2 145208193 T C 2.00E-08 Renal cell carcinoma ZEB2 intron 23184150 rs12105521 chr2 145208336 G A,T 7.28E-07 Renal cell carcinoma ZEB2 intron 23184150 rs72858496 chr2 145209916 C T 5.76E-07 Renal cell carcinoma ZEB2 intron 23184150 rs731108 chr2 145213638 G C 1.34E-06 Renal cell carcinoma ZEB2 intron 23184150 rs993765 chr2 145214761 C T 1.48E-04 Multiple complex diseases ZEB2 intron 17554300 rs13389578 chr2 145216048 T C 3.58E-06 Renal cell carcinoma ZEB2 intron 23184150 rs13401515 chr2 145216132 A T 2.43E-06 Renal cell carcinoma ZEB2 intron 23184150 rs13382811 chr2 145223620 C T 6.00E-10 Myopia (severe) ZEB2 intron 23933737 rs6755392 chr2 145242122 A G 3.55E-05 Myopia (severe) ZEB2 intron 23933737 rs13398550 chr2 145245815 A G 2.60E-05 Urinary metabolites ZEB2 intron 21572414 rs2052807 chr2 145296263 A C 2.08E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs4662376 chr2 145297016 A T 2.27E-04 Fibrinogen / / 17255346 rs4662377 chr2 145297087 A T 1.80E-04 Fibrinogen / / 17255346 rs1365778 chr2 145305277 A G 6.73E-04 Tourette syndrome / / 22889924 rs7355746 chr2 145351821 T C 5.00E-07 Obesity-related traits / / 23251661 rs10496964 chr2 145359909 C T 9.00E-09 Epilepsy (generalized) / / 22949513 rs10496965 chr2 145381331 C T 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs980772 chr2 145442190 G T 8.04E-04 Alcohol consumption (maxi-drinks) DKFZp686O1327 intron 24277619 rs2195115 chr2 145446205 G A 9.52E-04 Alcohol consumption (maxi-drinks) DKFZp686O1327 intron 24277619 rs10496966 chr2 145458762 A G 8.04E-04 Alcohol consumption (maxi-drinks) DKFZp686O1327 intron 24277619 rs4471836 chr2 145475145 G A 8.04E-04 Alcohol consumption (maxi-drinks) DKFZp686O1327 intron 24277619 rs1351734 chr2 145486593 T C 9.42E-04 Alcohol consumption (maxi-drinks) DKFZp686O1327 intron 24277619 rs7603516 chr2 145504693 T G 3.10E-04 Crohn's disease DKFZp686O1327 intron 17435756 rs11883829 chr2 145519623 A G 7.98E-04 Alcohol consumption (maxi-drinks) DKFZp686O1327 intron 24277619 rs10496968 chr2 145524246 C T 7.98E-04 Alcohol consumption (maxi-drinks) DKFZp686O1327 intron 24277619 rs17479071 chr2 145602015 A G 2.13E-04 White matter integrity DKFZp686O1327 intron 22425255 rs11690035 chr2 145603306 C T 6.90E-04 Multiple complex diseases DKFZp686O1327 intron 17554300 rs1534482 chr2 145716881 G A 7.02E-05 Multiple complex diseases DKFZp686O1327 intron 17554300 rs17408036 chr2 145752599 T C 2.71E-04 Self-reported allergy DKFZp686O1327 intron 23817569 rs2252641 chr2 145801461 T C 1.87E-05 Type 2 diabetes DKFZp686O1327 intron 17463246 rs2252641 chr2 145801461 T C 5.63E-07 Esophageal cancer (squamous cell) DKFZp686O1327 intron 22960999 rs2252641 chr2 145801461 T C 0.00000419 Coronary artery disease (CAD) (males) DKFZp686O1327 intron 23202125 rs2252641 chr2 145801461 T C 0.0000644 Coronary artery disease (CAD) age >50 DKFZp686O1327 intron 23202125 rs2252641 chr2 145801461 T C 0.000503 Coronary artery disease with myocardial infarction DKFZp686O1327 intron 23202125 rs2252641 chr2 145801461 T C 2.53E-08 Coronary artery disease DKFZp686O1327 intron 23202125 rs2252641 chr2 145801461 T C 1.19E-05 Coronary artery disease DKFZp686O1327 intron 24262325 rs955944 chr2 145813161 A C 2.84E-04 Substance dependence DKFZp686O1327 intron 21818250 rs4662414 chr2 145818432 A G 3.05E-05 Type 2 diabetes DKFZp686O1327 intron 17463246 rs1852682 chr2 145833813 C T 4.35E-04 Multiple complex diseases LOC100505498 intron 17554300 rs16824481 chr2 145852801 G T 6.03E-05 Type 2 diabetes LOC100505498 intron 17463246 rs1997287 chr2 145875289 C T 4.29E-05 Duodenal ulcer LOC100505498 intron 22387998 rs41443345 chr2 145898342 A G 9.93E-04 Multiple complex diseases LOC100505498 intron 17554300 rs1085638 chr2 145909831 T C 5.84E-04 Multiple complex diseases LOC100505498 intron 17554300 rs2044369 chr2 145925068 A G 6.70E-05 Multiple complex diseases LOC100505498 intron 17554300 rs2197361 chr2 145978802 A C 3.49E-04 Multiple complex diseases / / 17554300 rs1445300 chr2 146015947 A G 2.70E-04 Heart Failure / / pha002885 rs1822881 chr2 146044052 A G 4.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs11687420 chr2 146045565 A T 4.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs10180522 chr2 146071853 A C 7.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs7590923 chr2 146087653 T C 2.21E-04 Fibrinogen / / 17255346 rs13407123 chr2 146092756 T C 8.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs10445672 chr2 146105254 T C 8.00E-06 Obesity-related traits / / 23251661 rs1996289 chr2 146108380 A G 5.69E-04 Stroke / / pha002886 rs4422110 chr2 146114898 C T 2.63E-11 Common traits (Other) / / 20585627 rs1040173 chr2 146120511 C T 2.88E-09 Common traits (Other) / / 20585627 rs10427255 chr2 146125523 C T 1.00E-11 Common traits (Other) / / 20585627 rs17410058 chr2 146134774 T C 1.02E-08 Common traits (Other) / / 20585627 rs1006134 chr2 146135619 A G 3.80E-09 Common traits (Other) / / 20585627 rs16824898 chr2 146153407 G A 9.08E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1516140 chr2 146156141 G A 2.59E-04 Fibrinogen / / 17255346 rs1516140 chr2 146156141 G A 8.19E-05 Lung adenocarcinoma / / 19836008 rs1516140 chr2 146156141 G A 1.40E-05 Cognitive test performance / / 20125193 rs6721116 chr2 146156197 G A 1.62E-10 Common traits (Other) / / 20585627 rs2840149 chr2 146257174 T A 5.28E-04 Multiple complex diseases / / 17554300 rs10185841 chr2 146261295 C T 7.75E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10496982 chr2 146308114 A C 3.00E-04 Chronic fatigue syndrome / / 21912186 rs6715269 chr2 146346812 T C 5.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs6430090 chr2 146347459 A G 3.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs6430091 chr2 146349378 C T 7.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs1484917 chr2 146349854 A G 7.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs7577837 chr2 146352036 A C 5.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs7571848 chr2 146353184 T A 5.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs10175928 chr2 146353440 C T 5.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs12468287 chr2 146354294 C A 2.52E-05 Multiple complex diseases / / 17554300 rs12468287 chr2 146354294 C A 7.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs2381750 chr2 146382236 G T 8.60E-04 Alcohol dependence / / 20201924 rs4632277 chr2 146404349 T C 9.48E-05 Height / / pha003010 rs2704788 chr2 146511295 G T 3.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11901196 chr2 146516614 T C 1.10E-06 Urinary metabolites / / 21572414 rs13426482 chr2 146522210 T G 2.60E-07 Urinary metabolites / / 21572414 rs12614611 chr2 146524499 A C 3.69E-04 Alzheimer's disease (late onset) / / 21379329 rs16825480 chr2 146529549 T C 1.10E-07 Urinary metabolites / / 21572414 rs11904072 chr2 146557524 G T 4.70E-07 Urinary metabolites / / 21572414 rs16855387 chr2 146558543 A C 2.10E-06 Urinary metabolites / / 21572414 rs1228065 chr2 146567912 C T 2.90E-07 Urinary metabolites / / 21572414 rs1228054 chr2 146572097 C T 2.10E-06 Urinary metabolites / / 21572414 rs10221780 chr2 146588323 A G 7.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1228080 chr2 146602659 T C 1.30E-05 White blood cell types / / 21738478 rs1228075 chr2 146608872 G A 6.35E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16825695 chr2 146642195 G A 1.15E-06 Multiple complex diseases / / 17554300 rs11902459 chr2 146644346 A G 2.32E-04 Alzheimer's disease (late onset) / / 21379329 rs1317530 chr2 146660741 T C 1.10E-05 Hepatocellular carcinoma / / 22807686 rs997033 chr2 146672778 A G 8.60E-05 Arthritis (juvenile idiopathic) / / 22354554 rs1515238 chr2 146679403 C T 2.45E-05 Hepatocellular carcinoma / / 22807686 rs17412774 chr2 146773948 A C 1.10E-12 Myopia (Age of onset) / / 23468642 rs222816 chr2 146888064 G T 9.20E-04 Type 2 diabetes / / 17463246 rs222811 chr2 146891073 A G 2.42E-15 Varicose Veins / / pha001416 rs2113773 chr2 146924233 C T 4.08E-05 Blood Pressure / / pha003044 rs2194675 chr2 146932243 A G 6.70E-05 Blood Pressure / / pha003044 rs7608936 chr2 146933934 T G 4.78E-05 Multiple complex diseases / / 17554300 rs11692798 chr2 146997640 C T 5.08E-04 Alcohol dependence / / 24277619 rs987214 chr2 147004927 G A 1.69E-04 Multiple complex diseases / / 17554300 rs987214 chr2 147004927 G A 2.70E-05 Age-related macular degeneration / / pha000002 rs10490590 chr2 147017856 C G 6.51E-05 Age-related macular degeneration / / pha000002 rs13013481 chr2 147026018 A G 3.30E-04 Smoking initiation / / 24665060 rs4662459 chr2 147083675 G A 5.84E-06 Myopia (pathological) / / 21640322 rs13017430 chr2 147093298 T C 6.81E-04 Smoking cessation / / 24665060 rs2381936 chr2 147094369 C T 3.43E-05 Serum metabolites / / 19043545 rs2381936 chr2 147094369 C T 3.49E-04 Smoking cessation / / 24665060 rs6752130 chr2 147100152 G A 2.57E-04 Smoking cessation / / 24665060 rs1074530 chr2 147108688 T C 3.77E-05 Serum metabolites / / 19043545 rs10184605 chr2 147116314 G A 7.07E-04 Multiple complex diseases / / 17554300 rs2381870 chr2 147118058 G A 2.42E-04 Smoking cessation / / 24665060 rs13007824 chr2 147173705 C T 5.26E-04 Smoking cessation / / 24665060 rs13033055 chr2 147182442 A G 1.11E-04 Smoking cessation / / 24665060 rs4362505 chr2 147189398 A G 3.92E-04 Smoking cessation / / 24665060 rs12990755 chr2 147218495 A C 7.00E-05 Glioma (high-grade) / / 19578366 rs10928296 chr2 147232233 G A 1.42E-04 Multiple complex diseases / / 17554300 rs34072689 chr2 147235262 G A 6.76E-04 Smoking cessation / / 24665060 rs6715004 chr2 147242774 T C 1.74E-04 Smoking cessation / / 24665060 rs9967847 chr2 147262167 C A 4.56E-04 Type 2 diabetes / / 17463246 rs72864420 chr2 147273313 G A 1.63E-15 Blood pressure / / 21909110 rs10191269 chr2 147294113 C T 3.25E-04 Type 2 diabetes / / 17463246 rs6720072 chr2 147365709 A G 7.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs11895389 chr2 147366942 A G 7.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs12617086 chr2 147368035 T C 9.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs6707771 chr2 147369819 G C 9.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs10928302 chr2 147372024 C T 8.00E-06 HIV-1 control / / 20041166 rs10928302 chr2 147372024 C T 9.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs10928304 chr2 147380400 G C 9.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs12475739 chr2 147383718 T G 5.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs7579221 chr2 147385255 G A 8.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs7591307 chr2 147389019 G A 8.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs6705842 chr2 147393723 T G 7.80E-06 HIV-1 control / / 20041166 rs6739325 chr2 147398530 A G 9.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs7559942 chr2 147415821 A T 7.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs12328053 chr2 147416456 T G 5.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs4662263 chr2 147422813 C T 6.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs4233576 chr2 147428977 A G 1.15E-06 Multiple complex diseases / / 17554300 rs12691747 chr2 147437780 C T 5.71E-04 Multiple complex diseases / / 17554300 rs12691747 chr2 147437780 C T 9.18E-05 Body mass (lean) / / 19268274 rs6726569 chr2 147455149 A G 9.36E-04 Multiple complex diseases / / 17554300 rs6726569 chr2 147455149 A G 4.65E-05 Body mass (lean) / / 19268274 rs10184858 chr2 147465195 G A 9.73E-04 Multiple complex diseases / / 17554300 rs12691748 chr2 147465721 G A 8.79E-04 Multiple complex diseases / / 17554300 rs4525630 chr2 147509889 C G 2.05E-04 Nicotine dependence / / 17158188 rs7588130 chr2 147512772 T C 0.000539275 Hypertension (early onset hypertension) / / 22479346 rs12479440 chr2 147524052 C T 6.07E-05 Kawasaki disease / / 22446961 rs7568410 chr2 147530335 G T 4.73E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs5000314 chr2 147531594 T A 6.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6430138 chr2 147541992 C T 8.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4539741 chr2 147587955 G A 9.31E-05 Bipolar disorder and schizophrenia / / 20889312 rs2037109 chr2 147626142 T C 8.42E-05 HDL cholesterol / / pha003075 rs75638626 chr2 147708864 T C 8.00E-06 Age-related nuclear cataracts / / 24951543 rs1515263 chr2 147750175 T C 1.37E-04 Prion diseases / / 22210626 rs1546602 chr2 147766421 C A 1.67E-04 Prion diseases / / 22210626 rs12467678 chr2 147795055 T C 9.38E-04 Multiple complex diseases / / 17554300 rs1515264 chr2 147795431 G A 8.59E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs1515264 chr2 147795431 G A 8.59E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs1499919 chr2 147862399 G C 8.39E-04 Insulin resistance / / 21901158 rs16827224 chr2 148105737 T C 2.27E-04 Sarcoidosis / / 19165924 rs1996848 chr2 148106509 G C 4.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16827299 chr2 148148960 A G 2.22E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16827303 chr2 148150029 G T 2.22E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1371040 chr2 148165153 A G 6.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6708612 chr2 148165723 C T 3.92E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1438887 chr2 148166428 A C 1.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1438889 chr2 148174697 G C 0.0008391 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1438889 chr2 148174697 G C 8.39E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs728621 chr2 148175799 T C 7.48E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1550312 chr2 148183865 C A 3.26E-05 Alzheimer's disease (age of onset) / / 22005931 rs1371031 chr2 148185872 T G 9.81E-04 Multiple complex diseases / / 17554300 rs12998722 chr2 148203843 C T 2.77E-05 Alzheimer's disease (age of onset) / / 22005931 rs1438877 chr2 148213063 G A 6.04E-05 Alzheimer's disease (age of onset) / / 22005931 rs1438880 chr2 148214367 C T 5.82E-04 Multiple complex diseases / / 17554300 rs4662505 chr2 148215682 C T 3.53E-09 Narcolepsy / / 19629137 rs7557911 chr2 148217792 A T 5.45E-05 Alzheimer's disease (age of onset) / / 22005931 rs7609293 chr2 148222332 A T 5.26E-05 Alzheimer's disease (age of onset) / / 22005931 rs4662515 chr2 148267476 A G 3.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs723529 chr2 148276923 G A 2.24E-05 Obesity (extreme) / / 21935397 rs6757820 chr2 148279693 T C 1.51E-05 Neuroticism / / 23229837 rs10197459 chr2 148282050 C T 2.69E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6753791 chr2 148287864 C G 6.11E-05 Serum metabolites / / 19043545 rs12691757 chr2 148291965 G A 4.02E-05 Serum metabolites / / 19043545 rs12691758 chr2 148292124 T G 5.52E-05 Serum metabolites / / 19043545 rs41409647 chr2 148295775 C A 5.20E-04 Multiple complex diseases / / 17554300 rs16827511 chr2 148305357 C A 1.36E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs12464146 chr2 148318521 T C 1.36E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs12464146 chr2 148318521 T C 2.44E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs10497013 chr2 148319755 C T 6.14E-04 Multiple complex diseases / / 17554300 rs10181805 chr2 148337163 C A 2.88E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4427955 chr2 148377892 T C 3.57E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4425033 chr2 148389870 A G 8.96E-05 Serum metabolites / / 19043545 rs11679403 chr2 148390620 G A 8.73E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs13410698 chr2 148403641 G A 7.03E-05 Serum metabolites / / 19043545 rs11896365 chr2 148416474 A G 8.65E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs951910 chr2 148421180 A G 2.43E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4662290 chr2 148431885 G T 2.19E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4662539 chr2 148432679 T C 2.39E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1919445 chr2 148454344 T C 6.54E-04 Multiple complex diseases / / 17554300 rs12104985 chr2 148455068 G A 3.76E-04 Type 2 diabetes / / 17463246 rs10497018 chr2 148457312 A T 8.27E-04 Parkinson's disease / / 17052657 rs7584099 chr2 148478336 A G 5.00E-07 Response to statin therapy / / 20339536 rs10177533 chr2 148484063 C T 4.65E-05 Sudden cardiac arrest / / 21658281 rs4641882 chr2 148503815 T G 9.61E-04 Multiple complex diseases / / 17554300 rs13026223 chr2 148517019 T C 9.80E-05 Cognitive function / / 24684796 rs7605932 chr2 148517301 C T 2.28E-04 Parkinson's disease / / 17052657 rs7605932 chr2 148517301 C T 2.00E-05 Cognitive function / / 24684796 rs1919440 chr2 148520066 A G 5.80E-05 Cognitive function / / 24684796 rs10170800 chr2 148522847 C T 4.60E-05 Cognitive function / / 24684796 rs10497022 chr2 148530745 C T 7.60E-05 Cognitive function / / 24684796 rs1528839 chr2 148531200 A C 4.80E-05 Cognitive function / / 24684796 rs1424949 chr2 148542963 T G 3.99E-08 Urate levels / / 23263486 rs12479193 chr2 148557911 A G 4.99E-08 Urate levels / / 23263486 rs12472058 chr2 148558041 C T 4.72E-08 Urate levels / / 23263486 rs4972326 chr2 148558848 A G 4.65E-08 Urate levels / / 23263486 rs7605029 chr2 148559921 A G 4.29E-08 Urate levels / / 23263486 rs986508 chr2 148562031 T C 3.17E-08 Urate levels / / 23263486 rs13032660 chr2 148562909 C A 3.59E-08 Urate levels / / 23263486 rs1863153 chr2 148564193 T C 3.60E-08 Urate levels / / 23263486 rs1863152 chr2 148564405 A G 3.79E-08 Urate levels / / 23263486 rs6734998 chr2 148566321 G A 4.18E-08 Urate levels / / 23263486 rs1991169 chr2 148566919 T C 3.70E-08 Urate levels / / 23263486 rs12990959 chr2 148572160 T C 3.71E-08 Urate levels / / 23263486 rs11894371 chr2 148575872 A C 2.43E-08 Urate levels / / 23263486 rs1364658 chr2 148607808 G C 2.73E-04 Parkinson's disease ACVR2A intron 17052657 rs1014064 chr2 148612154 A G 3.76E-08 Urate levels ACVR2A intron 23263486 rs10803523 chr2 148615831 T G 2.74E-08 Urate levels ACVR2A intron 23263486 rs2113793 chr2 148623453 T G 4.76E-08 Urate levels ACVR2A intron 23263486 rs929939 chr2 148627528 C A 6.15E-04 Parkinson's disease ACVR2A intron 17052657 rs929939 chr2 148627528 C A 3.16E-08 Urate levels ACVR2A intron 23263486 rs6711673 chr2 148643259 A C 3.10E-08 Urate levels ACVR2A intron 23263486 rs13033696 chr2 148645327 A G 4.55E-08 Urate levels ACVR2A intron 23263486 rs2161983 chr2 148649386 G A 2.95E-08 Urate levels ACVR2A intron 23263486 rs13019809 chr2 148650473 G A 2.44E-08 Urate levels ACVR2A intron 23263486 rs1128919 chr2 148657117 G A 3.68E-08 Urate levels ACVR2A cds-synon 23263486 rs12987286 chr2 148663568 G T 3.27E-04 Parkinson's disease ACVR2A intron 17052657 rs3768689 chr2 148669774 G C 8.47E-04 Parkinson's disease ACVR2A intron 17052657 rs13026650 chr2 148674201 G A 2.87E-08 Urate levels ACVR2A intron 23263486 rs3764955 chr2 148674797 G C 3.15E-08 Urate levels ACVR2A intron 23263486 rs2303392 chr2 148680427 G C 9.16E-04 Parkinson's disease ACVR2A intron 17052657 rs12620026 chr2 148683919 A T 4.63E-05 Panic disorder ACVR2A intron 19165232 rs1345994 chr2 148695126 T G 1.93E-08 Urate levels ORC4 intron 23263486 rs10460259 chr2 148704721 A C 6.15E-04 Parkinson's disease ORC4 intron 17052657 rs13012311 chr2 148707032 C T 1.54E-08 Urate levels ORC4 intron 23263486 rs13027200 chr2 148709653 A G 2.41E-08 Urate levels ORC4 intron 23263486 rs12463798 chr2 148716099 G T 1.45E-08 Urate levels ORC4 intron 23263486 rs2307394 chr2 148716428 T C 8.39E-04 Parkinson's disease ORC4 missense 17052657 rs2307394 chr2 148716428 T C 2.00E-08 Urate levels ORC4 missense 23263486 rs6729465 chr2 148723126 A C 1.64E-08 Urate levels ORC4 intron 23263486 rs11901963 chr2 148726771 A T 1.34E-08 Urate levels ORC4 intron 23263486 rs13027706 chr2 148732703 A G 2.11E-08 Urate levels ORC4 intron 23263486 rs7594075 chr2 148739823 G C 1.85E-08 Urate levels ORC4 intron 23263486 rs13004041 chr2 148741621 C T 2.38E-08 Urate levels ORC4 intron 23263486 rs17693310 chr2 148747978 G A 5.86E-05 Sudden cardiac arrest ORC4 intron 21658281 rs12463554 chr2 148751612 C T 3.33E-08 Urate levels ORC4 intron 23263486 rs13008838 chr2 148754825 A G 2.89E-08 Urate levels ORC4 intron 23263486 rs13035475 chr2 148754862 T G 1.72E-08 Urate levels ORC4 intron 23263486 rs13014936 chr2 148755237 C T 1.71E-08 Urate levels ORC4 intron 23263486 rs13022962 chr2 148756624 G A 1.46E-08 Urate levels ORC4 intron 23263486 rs12053401 chr2 148756668 A T 1.58E-08 Urate levels ORC4 intron 23263486 rs13028348 chr2 148757144 A G 1.51E-08 Urate levels ORC4 intron 23263486 rs1598207 chr2 148757870 A G 1.76E-08 Urate levels ORC4 intron 23263486 rs7598361 chr2 148758479 A G 3.22E-08 Urate levels ORC4 intron 23263486 rs2382201 chr2 148765496 C T 3.34E-08 Urate levels ORC4 intron 23263486 rs12989250 chr2 148776438 G A 3.19E-08 Urate levels ORC4 intron 23263486 rs1975748 chr2 148776859 A C 2.06E-08 Urate levels ORC4 intron 23263486 rs897172 chr2 148778272 A G 6.09E-04 Parkinson's disease ORC4 UTR-5 17052657 rs1015096 chr2 148782358 T C 2.64E-08 Urate levels MBD5 intron 23263486 rs13007770 chr2 148784324 C T 3.26E-08 Urate levels MBD5 intron 23263486 rs2890915 chr2 148789543 C T 3.88E-08 Urate levels MBD5 intron 23263486 rs13013887 chr2 148825780 A G 5.65E-04 Parkinson's disease MBD5 intron 17052657 rs1234413 chr2 148844369 C T 9.50E-05 Parkinson's disease MBD5 intron 21738487 rs10928374 chr2 148852035 A G 9.31E-05 Parkinson's disease MBD5 intron 21738487 rs41477845 chr2 148875566 C T 6.35E-04 Prostate cancer mortality MBD5 intron 20978177 rs10497031 chr2 148918835 A G 3.73E-04 Stroke MBD5 intron pha002887 rs16828443 chr2 148971603 C T 7.32E-04 Multiple complex diseases MBD5 intron 17554300 rs2044760 chr2 148989731 T C 6.90E-07 Urinary metabolites MBD5 intron 21572414 rs2044761 chr2 148989742 A G 7.00E-07 Urinary metabolites MBD5 intron 21572414 rs6746932 chr2 149012777 T C 2.00E-06 Urinary metabolites MBD5 intron 21572414 rs2890917 chr2 149015704 T A 6.10E-07 Urinary metabolites MBD5 intron 21572414 rs6731657 chr2 149019793 A G 1.04E-04 Self-reported allergy MBD5 intron 23817569 rs2656318 chr2 149075242 G A 5.86E-04 Multiple complex diseases MBD5 intron 17554300 rs17276501 chr2 149087536 C T 2.37E-04 Multiple complex diseases MBD5 intron 17554300 rs12617242 chr2 149164048 C T 2.93E-05 Heart Rate MBD5 intron pha003054 rs1404184 chr2 149268503 T A 5.05E-04 Smoking cessation MBD5 intron 24665060 rs1404183 chr2 149268931 G A 4.09E-04 Alzheimer's disease (late onset) MBD5 intron 21379329 rs16828726 chr2 149271642 G A 4.08E-04 Alzheimer's disease (late onset) / / 21379329 rs10928399 chr2 149277896 C T 7.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs6756002 chr2 149284523 C T 4.90E-05 Suicide attempts in bipolar disorder / / 21423239 rs12997473 chr2 149284887 A G 3.68E-05 Suicide attempts in bipolar disorder / / 21423239 rs13003024 chr2 149285093 C T 9.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs764386 chr2 149285506 G A 1.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs4972369 chr2 149287440 C T 3.28E-05 Suicide attempts in bipolar disorder / / 21423239 rs4284768 chr2 149290719 T G 7.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs2382231 chr2 149290943 C T 1.18E-05 Suicide attempts in bipolar disorder / / 21423239 rs7599758 chr2 149293880 C T 3.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs13003132 chr2 149295930 C T 1.32E-05 Suicide attempts in bipolar disorder / / 21423239 rs13009428 chr2 149296505 C A 2.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs16828791 chr2 149296887 C T 4.42E-05 Suicide attempts in bipolar disorder / / 21423239 rs16828816 chr2 149305525 A T 2.68E-05 Suicide attempts in bipolar disorder / / 21423239 rs7578059 chr2 149312470 G A 8.69E-05 Suicide attempts in bipolar disorder / / 21423239 rs16828836 chr2 149312728 T C 6.07E-05 Suicide attempts in bipolar disorder / / 21423239 rs930652 chr2 149317494 C T 1.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs7597133 chr2 149317833 G A 1.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs4972375 chr2 149324132 C A 2.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs7606475 chr2 149325251 C T 2.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs13010027 chr2 149326704 G A 3.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs13010027 chr2 149326704 G A 7.73E-04 Smoking initiation / / 24665060 rs10928406 chr2 149329952 G T 2.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs10928407 chr2 149329961 C G 3.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs6746352 chr2 149352353 C T 3.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs10172817 chr2 149380586 C T 3.76E-04 Multiple complex diseases / / 17554300 rs10191411 chr2 149387968 T C 4.00E-06 Protein quantitative trait loci / / 18464913 rs2121433 chr2 149557860 T C 1.00E-06 Alzheimer's disease biomarkers / / 21123754 rs4499362 chr2 149568396 C T 1.00E-06 Alzheimer's disease biomarkers / / 21123754 rs10171238 chr2 149568729 C T 2.99E-05 AIDS progression / / 19115949 rs7606125 chr2 149589885 T C 3.19E-04 Multiple complex diseases / / 17554300 rs17296534 chr2 149590486 G A 5.64E-05 Type 2 diabetes / / 17463246 rs6710001 chr2 149816918 A G 4.86E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6738277 chr2 149853960 A G 5.14E-04 Iron levels / / pha002876 rs6736802 chr2 149858734 A C 1.25E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6721330 chr2 149858906 C A 6.51E-05 Hepatocellular carcinoma / / 22807686 rs6435220 chr2 149861679 G A 4.18E-04 Iron levels / / pha002876 rs6435387 chr2 149865250 A G 3.40E-04 Schizophrenia / / 21926974 rs6435387 chr2 149865250 A G 8.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs6435387 chr2 149865250 A G 0.0000428 Schizophrenia / / 23637625 rs7577450 chr2 149875961 A G 8.32E-05 Alcoholism / / pha002893 rs17347194 chr2 149888184 C T 3.05E-04 Iron levels / / pha002876 rs4667369 chr2 149891845 G C 3.05E-05 Schizophrenia / / 19571811 rs10929935 chr2 149892614 T C 6.30E-04 Alcohol dependence / / 20201924 rs10929935 chr2 149892614 T C 7.30E-05 Alcohol dependence / / 20201924 rs10929935 chr2 149892614 T C 5.43E-04 Iron levels / / pha002876 rs10929935 chr2 149892614 T C 7.26E-05 Alcoholism / / pha002893 rs16822509 chr2 149894724 T C 3.20E-05 Alcohol dependence / / 20201924 rs16822509 chr2 149894724 T C 3.22E-05 Alcoholism / / pha002893 rs10201643 chr2 149905641 T G 2.00E-05 Alcohol dependence LYPD6B intron 20201924 rs10201643 chr2 149905641 T G 1.96E-05 Alcoholism LYPD6B intron pha002893 rs10803789 chr2 149932430 C A 7.05E-04 Myopia (pathological) LYPD6B intron 21095009 rs6432716 chr2 149940220 A G 3.18E-04 Multiple complex diseases LYPD6B intron 17554300 rs13406443 chr2 149941679 G A 1.42E-04 Multiple complex diseases LYPD6B intron 17554300 rs13005197 chr2 149946582 T C 9.24E-04 Myopia (pathological) LYPD6B intron 21095009 rs10497052 chr2 149954253 G A 4.09E-04 Myopia (pathological) LYPD6B intron 21095009 rs1404683 chr2 149988911 G T 5.05E-06 Lipid levels LYPD6B intron 19016617 rs6737636 chr2 149990087 C T 1.74E-04 Substance dependence LYPD6B intron 21818250 rs7584841 chr2 150097468 G A 8.46E-05 Longevity / / 20304771 rs17529158 chr2 150101440 C G 9.82E-05 Type 2 diabetes / / 17463246 rs6433988 chr2 150143750 T C 3.57E-04 Type 2 diabetes / / 17463246 rs10432496 chr2 150147278 C T 6.00E-08 Immune reponse to smallpox (secreted IL-2) / / 22610502 rs1420356 chr2 150188932 A G 3.18E-05 Longevity LYPD6 intron 20304771 rs10206766 chr2 150194002 G T 6.58E-05 Serum metabolites LYPD6 intron 19043545 rs1196698 chr2 150212010 A G 5.29E-04 Myopia (pathological) LYPD6 intron 21095009 rs13027838 chr2 150233741 C T 0.0000273 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LYPD6 intron 22628534 rs1196686 chr2 150242490 A G 1.55E-04 Type 2 diabetes LYPD6 intron 17463246 rs13035027 chr2 150382765 C A 4.49E-04 Multiple complex diseases / / 17554300 rs7578361 chr2 150397218 G T 8.00E-06 Acute lymphoblastic leukemia (childhood) / / 23007406 rs7578361 chr2 150397218 G T 9.89E-05 Asthma / / 23181788 rs7578361 chr2 150397218 G T 9.89E-05 Cognitive decline / / 23207651 rs10170236 chr2 150457624 G A 4.00E-06 Acute lymphoblastic leukemia (childhood) / / 23007406 rs4667413 chr2 150477548 C T 5.95E-04 Aortic root size / / 21223598 rs12474343 chr2 150491821 G T 3.40E-04 Aortic root size / / 21223598 rs711892 chr2 150504096 C G 7.36E-04 Multiple complex diseases / / 17554300 rs1526284 chr2 150508359 T G 1.71E-04 Celiac disease / / 23936387 rs16827293 chr2 150509332 C T 5.00E-06 Waist-to-hip circumference ratio (interaction) / / 23192594 rs6734346 chr2 150509388 G A 9.71E-05 Multiple complex diseases / / 17554300 rs17801127 chr2 150564484 C T 2.00E-07 Liver enzyme levels (alanine transaminase) / / 24124411 rs7560430 chr2 150572567 A G 9.60E-05 Erythrocyte counts / / pha003099 rs10490076 chr2 150600709 T G 2.56E-05 Bipolar disorder and schizophrenia / / 20889312 rs17745212 chr2 150603989 C T 3.87E-05 Bipolar disorder and schizophrenia / / 20889312 rs1012307 chr2 150655221 A C 8.00E-07 Asthma (sex interaction) FLJ32955 intron 24824216 rs13000594 chr2 150667047 A C 2.62E-05 Cognitive performance FLJ32955 intron 19734545 rs10201238 chr2 150668782 A G 5.68E-04 Multiple complex diseases FLJ32955 intron 17554300 rs2068460 chr2 150674955 T G 9.30E-05 Bipolar disorder and schizophrenia FLJ32955 intron 20889312 rs12990176 chr2 150677076 T G 4.85E-05 Femoral neck bone geometry FLJ32955 intron 22087292 rs9288698 chr2 150683337 T G 5.84E-04 Suicide attempts in bipolar disorder FLJ32955 intron 21041247 rs11889862 chr2 150697148 A G 2.00E-06 Menopause (age at onset) FLJ32955 intron 19448619 rs17296897 chr2 150718561 G A 2.92E-05 Personality dimensions / / 22628180 rs1437949 chr2 150726008 A G 3.07E-05 Personality dimensions / / 22628180 rs1437960 chr2 150727220 A T 3.09E-05 Personality dimensions / / 22628180 rs10171287 chr2 150729453 G A 3.65E-05 Personality dimensions / / 22628180 rs967618 chr2 150735158 G A 3.01E-05 Personality dimensions / / 22628180 rs1437940 chr2 150738516 A T 3.00E-05 Personality dimensions / / 22628180 rs11902738 chr2 150740332 T C 2.99E-05 Personality dimensions / / 22628180 rs1437959 chr2 150773549 A G 2.24E-05 Prostate cancer / / pha002878 rs1437956 chr2 150782730 A T 4.46E-04 Multiple complex diseases / / 17554300 rs1437956 chr2 150782730 A T 3.09E-05 Vaspin levels / / 22907691 rs331125 chr2 150870450 T C 0.0000454 Asthma / / 22694930 rs331124 chr2 150870860 C T 2.19E-05 Prostate cancer / / pha002878 rs732227 chr2 150877992 T C 0.000049 Asthma / / 22694930 rs4533492 chr2 150891651 A G 1.20E-04 Arthritis (juvenile idiopathic) / / 22354554 rs330646 chr2 150903121 C T 8.71E-05 Arthritis (juvenile idiopathic) / / 22354554 rs108136 chr2 150909115 T G 1.49E-04 Arthritis (juvenile idiopathic) / / 22354554 rs330625 chr2 150911159 A G 3.13E-05 Arthritis (juvenile idiopathic) / / 22354554 rs330624 chr2 150912703 A G 1.54E-04 Arthritis (juvenile idiopathic) / / 22354554 rs330630 chr2 150948703 T C 3.00E-06 Alcohol dependence / / 21956439 rs11903537 chr2 150966084 A G 1.69E-05 Telomere length / / 23001564 rs494023 chr2 150977990 G C 8.42E-04 Type 2 diabetes / / 17463246 rs3106778 chr2 150979368 T C 7.17E-04 Type 2 diabetes / / 17463246 rs16827839 chr2 150987418 G A 9.91E-04 Major depressive disorder / / 22472876 rs492161 chr2 150991740 G C 1.10E-05 Urinary metabolites / / 21572414 rs13013440 chr2 151063726 A G 3.23E-04 Body mass index / / 17255346 rs971810 chr2 151064165 C A 1.04E-04 Type 2 diabetes / / 17463246 rs13024803 chr2 151077809 A G 8.12E-05 Cognitive impairment induced by topiramate / / 22091778 rs6716455 chr2 151126403 G A 7.00E-07 Alcoholism (alcohol use disorder factor score) / / 21529783 rs6716455 chr2 151126403 G A 9.00E-06 Alcoholism (alcohol dependence factor score) / / 21529783 rs13002889 chr2 151148928 G A 3.17E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs16828065 chr2 151188117 A C 6.94E-04 Multiple complex diseases / / 17554300 rs1441974 chr2 151201613 A G 0.0000356 Breast cancer early age of onset / / 18463975 rs12994436 chr2 151210898 G A 6.40E-05 Body mass index / / 17255346 rs6760903 chr2 151218033 G A 3.97E-05 Body mass index / / 17255346 rs6760903 chr2 151218033 G A 3.57E-05 Atopic dermatitis / / 21666691 rs2119753 chr2 151224579 A G 0.000227 Salmonella-induced pyroptosis / / 22837397 rs7564866 chr2 151237763 C T 0.000461 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7564866 chr2 151237763 C T 4.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17434952 chr2 151278840 A G 1.30E-05 Urinary metabolites / / 21572414 rs17435000 chr2 151289661 G T 4.69E-04 Aortic root size / / 21223598 rs17435000 chr2 151289661 G T 5.60E-06 Urinary metabolites / / 21572414 rs2334310 chr2 151291604 A C 5.37E-05 Multiple sclerosis (age of onset) / / 19010793 rs816889 chr2 151325295 A G 0.000102 Coronary artery disease RND3 UTR-3 23202125 rs2222760 chr2 151345113 G A 5.37E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs1533664 chr2 151548341 A G 8.04E-05 Glucose levels / / pha003057 rs1125937 chr2 151606387 T C 8.47E-05 Multiple complex diseases / / 17554300 rs6734792 chr2 151624882 C T 6.04E-05 Bipolar disorder / / 17486107 rs6757804 chr2 151635832 C T 6.00E-08 Endometriosis / / 23472165 rs7560163 chr2 151637936 C G 7.00E-09 Type 2 diabetes / / 22238593 rs12475182 chr2 151638802 C T 2.56E-04 Schizophrenia / / 21747397 rs1519764 chr2 151639218 C G 8.10E-06 Urinary metabolites / / 21572414 rs962052 chr2 151644203 C T 8.60E-07 Urinary metabolites / / 21572414 rs1010330 chr2 151646872 G C 1.50E-05 Urinary metabolites / / 21572414 rs2190375 chr2 151650314 G A 2.45E-04 Parkinson's disease / / 17052657 rs1519772 chr2 151667708 C T 1.00E-05 Urinary metabolites / / 21572414 rs10489979 chr2 151682012 G A 9.39E-05 Coronary heart disease / / 21971053 rs2097935 chr2 151691144 G A 1.48E-04 Coronary heart disease / / 21971053 rs6433010 chr2 151718133 C T 0.000656595 Hypertension (early onset hypertension) / / 22479346 rs10195263 chr2 151725792 G A 3.00E-08 Immune reponse to smallpox (secreted IFN-alpha) / / 22610502 rs12467192 chr2 151726959 C T 0.000345115 Hypertension (early onset hypertension) / / 22479346 rs1005274 chr2 151728377 G A 0.000273704 Hypertension (early onset hypertension) / / 22479346 rs1005274 chr2 151728377 G A 5.21E-05 Calcium levels / / pha003085 rs6433018 chr2 151729571 G A 0.00046308 Hypertension (early onset hypertension) / / 22479346 rs6433018 chr2 151729571 G A 3.27E-05 Calcium levels / / pha003085 rs12618428 chr2 151732979 A G 7.72E-07 Osteoarthritis / / 22763110 rs960615 chr2 151733201 C T 3.20E-05 Hypothyroidism / / 22493691 rs7585613 chr2 151741365 C T 7.08E-05 Pulmonary function / / 19300500 rs7558214 chr2 151741406 G A 7.09E-05 Pulmonary function / / 19300500 rs16828833 chr2 151743498 G T 7.10E-05 Pulmonary function / / 19300500 rs16828835 chr2 151744452 T A 7.12E-05 Pulmonary function / / 19300500 rs2190367 chr2 151749834 C T 7.16E-05 Pulmonary function / / 19300500 rs7570251 chr2 151752329 T C 7.26E-05 Pulmonary function / / 19300500 rs16828857 chr2 151753548 C A 7.19E-05 Pulmonary function / / 19300500 rs10188669 chr2 151753903 G A 1.70E-05 Urinary metabolites / / 21572414 rs16828865 chr2 151754602 T C 7.91E-05 Pulmonary function / / 19300500 rs16828883 chr2 151756711 C T 8.49E-05 Pulmonary function / / 19300500 rs7601783 chr2 151758242 G A 8.46E-05 Pulmonary function / / 19300500 rs7602001 chr2 151758422 G A 8.46E-05 Pulmonary function / / 19300500 rs11687663 chr2 151758445 T C 8.86E-04 Stroke / / pha002887 rs917237 chr2 151764512 G A 1.37E-05 Bone mineral density / / 19181680 rs917238 chr2 151773679 C G 8.62E-04 Acute lung injury / / 22295056 rs1548632 chr2 151776216 C T 6.91E-05 Bone mineral density / / 19181680 rs12692888 chr2 151781053 T C 1.60E-05 Urinary metabolites / / 21572414 rs1019035 chr2 151802844 C T 9.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs2062365 chr2 151835990 T C 4.21E-05 Bone mineral density / / 19181680 rs1905744 chr2 151836205 T G 2.57E-05 Bone mineral density / / 19181680 rs16829215 chr2 151871445 C T 2.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4664875 chr2 151871888 T C 4.06E-04 Substance dependence / / 21818250 rs7603077 chr2 151885556 A G 5.21E-06 Bone mineral density / / 19181680 rs1463609 chr2 151895088 A G 6.36E-06 Bone mineral density / / 19181680 rs2880167 chr2 151898262 T C 1.17E-04 Multiple complex diseases / / 17554300 rs13034178 chr2 151902601 A T 9.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6433132 chr2 151908948 T C 1.20E-27 Narcolepsy / / 19629137 rs1994256 chr2 151919436 C G 4.72E-04 Type 2 diabetes / / 17463246 rs10169306 chr2 151926472 G A 8.33E-05 Height / / pha003011 rs13026867 chr2 151931439 T C 5.81E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2046422 chr2 151938118 T C 9.31E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs13034554 chr2 151940137 A G 1.17E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs720066 chr2 151946149 G A 1.44E-05 Height / / pha003010 rs720066 chr2 151946149 G A 6.60E-06 Height / / pha003011 rs749691 chr2 151954166 G A 3.09E-04 Multiple complex diseases / / 17554300 rs749691 chr2 151954166 G A 5.54E-06 Height / / pha003010 rs749691 chr2 151954166 G A 2.67E-06 Height / / pha003011 rs1485099 chr2 151960452 T C 5.93E-05 Height / / pha003010 rs1485099 chr2 151960452 T C 1.28E-05 Height / / pha003011 rs816710 chr2 151984277 C T 3.91E-05 Height / / pha003010 rs816710 chr2 151984277 C T 5.44E-05 Height / / pha003011 rs289932 chr2 152006025 C T 5.42E-07 Autism / / 22843504 rs289932 chr2 152006025 C T 9.25E-05 Cervical cancer / / 24700089 rs289851 chr2 152023517 G A 8.56E-05 Height / / pha003011 rs16829682 chr2 152024706 G A 1.46E-04 Multiple complex diseases / / 17554300 rs112116 chr2 152035710 T C 1.03E-05 Height / / pha003010 rs112116 chr2 152035710 T C 5.44E-07 Height / / pha003011 rs289854 chr2 152050243 G A 1.03E-05 Height / / pha003010 rs289854 chr2 152050243 G A 5.44E-07 Height / / pha003011 rs289858 chr2 152052326 G A 2.81E-07 Autism / / 22843504 rs289858 chr2 152052326 G A 1.83E-05 Height / / pha003010 rs289858 chr2 152052326 G A 4.05E-06 Height / / pha003011 rs389797 chr2 152059484 G A 9.48E-04 Acute lung injury / / 22295056 rs289864 chr2 152061883 C A 8.81E-04 Acute lung injury / / 22295056 rs289871 chr2 152065396 C A 7.42E-05 Height / / pha003010 rs289871 chr2 152065396 C A 5.71E-06 Height / / pha003011 rs289827 chr2 152070336 G T 1.41E-05 Height / / pha003011 rs289903 chr2 152084705 G A 3.57E-05 Height / / pha003010 rs289903 chr2 152084705 G A 3.56E-06 Height / / pha003011 rs2218880 chr2 152099885 G A 2.89E-05 Height / / pha003011 rs11683285 chr2 152111965 G A 7.46E-04 Acute lung injury RBM43 intron 22295056 rs2271811 chr2 152117780 T C 2.30E-05 Height RBM43 intron pha003011 rs16829835 chr2 152123703 A C 7.83E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6433327 chr2 152154732 A G 2.34E-05 Height / / pha003011 rs6726634 chr2 152159880 G A 6.50E-05 Height / / pha003011 rs3771891 chr2 152218185 T G 2.03E-05 Height TNFAIP6 intron pha003010 rs3771891 chr2 152218185 T G 1.05E-07 Height TNFAIP6 intron pha003011 rs3771895 chr2 152224339 G A 6.17E-04 Suicide attempts in bipolar disorder TNFAIP6 intron 21041247 rs10432476 chr2 152225088 T C 6.09E-04 Suicide attempts in bipolar disorder TNFAIP6 intron 21041247 rs10432476 chr2 152225088 T C 0.000422 Height (Pygmy height) TNFAIP6 intron 22570615 rs1046668 chr2 152226570 A G 8.16E-05 Coronary Artery Disease TNFAIP6 missense 17634449 rs10197940 chr2 152253918 T C 5.00E-06 Lung cancer / / 23143601 rs2444263 chr2 152311570 G A 2.65E-04 Multiple complex diseases RIF1 missense 17554300 rs7422009 chr2 152313539 C T 6.78E-04 White matter integrity RIF1 intron 22425255 rs2444274 chr2 152324789 G C 4.42E-04 Multiple complex diseases RIF1 intron 17554300 rs16830061 chr2 152330148 A G 4.71E-04 White matter integrity RIF1 intron 22425255 rs16830067 chr2 152331745 T G 8.85E-04 Multiple complex diseases RIF1 UTR-3 17554300 rs16830067 chr2 152331745 T G 5.29E-04 White matter integrity RIF1 UTR-3 22425255 rs16830086 chr2 152338989 C T 3.80E-04 Multiple complex diseases / / 17554300 rs11680579 chr2 152340685 G A 8.42E-04 Type 2 diabetes / / 17463246 rs16830090 chr2 152342481 A G 4.45E-04 White matter integrity NEB intron 22425255 rs13031275 chr2 152346494 A C 5.63E-06 Waist Circumference NEB cds-synon pha003023 rs13031275 chr2 152346494 A C 1.01E-05 Waist-Hip Ratio NEB cds-synon pha003029 rs34368668 chr2 152363484 G A 0.000000577 LDL cholesterol NEB missense 23063622 rs12996964 chr2 152393422 T C 9.00E-05 Fibrinogen NEB intron 17255346 rs11902616 chr2 152467001 C T 3.43E-05 Serum selenium levels NEB intron 23698163 rs6717213 chr2 152476130 C T 3.23E-05 Serum selenium levels NEB cds-synon 23698163 rs10186482 chr2 152481977 A G 6.87E-05 Response to acetaminophen (hepatotoxicity) NEB intron 21177773 rs76767949 chr2 152499355 T C 0.00032 Prostate cancer NEB missense 23555315 rs11885813 chr2 152511515 T A 1.71E-05 Sleep duration NEB intron 22105623 rs10192459 chr2 152517979 T C 2.53E-05 Sleep duration NEB intron 22105623 rs117271684 chr2 152521983 A G 0.00069 Prostate cancer NEB missense 23555315 rs117048449 chr2 152534545 T C 0.00069 Prostate cancer NEB missense 23555315 rs13025954 chr2 152585020 C T 1.66E-04 Birth weight NEB intron 17255346 rs12472627 chr2 152633114 C T 4.82E-04 Alcohol dependence / / 21314694 rs17198087 chr2 152681044 G C 1.42E-04 Multiple complex diseases ARL5A intron 17554300 rs35017924 chr2 152685966 G A 9.10E-11 Urinary metabolites / / 21572414 rs2344734 chr2 152691829 C G 3.61E-05 Neuroticism CACNB4 UTR-3 23229837 rs3754533 chr2 152697463 G T 9.56E-04 Multiple complex diseases CACNB4 intron 17554300 rs13424831 chr2 152707252 C T 1.10E-04 Bladder cancer CACNB4 intron 19648920 rs9646794 chr2 152710431 T A 9.49E-04 Coronary heart disease CACNB4 intron 21606135 rs2461835 chr2 152741984 C T 1.50E-07 Urinary metabolites CACNB4 intron 21572414 rs12471646 chr2 152775308 G A 4.10E-06 Urinary metabolites CACNB4 intron 21572414 rs6729612 chr2 152780167 C T 1.40E-05 Urinary metabolites CACNB4 intron 21572414 rs6734642 chr2 152806855 T C 2.80E-05 Urinary metabolites CACNB4 intron 21572414 rs7558481 chr2 152817193 G C 1.80E-05 Urinary metabolites CACNB4 intron 21572414 rs2345160 chr2 152819262 G A 2.20E-07 Urinary metabolites CACNB4 intron 21572414 rs11893938 chr2 152836455 A G 9.60E-08 Urinary metabolites CACNB4 intron 21572414 rs17270394 chr2 152844074 A C 2.87E-04 Depression (quantitative trait) CACNB4 intron 20800221 rs1519708 chr2 152872455 A G 2.45E-05 Statin-induced myopathy CACNB4 intron 21826682 rs13421383 chr2 152879348 C T 3.19E-04 Type 2 diabetes CACNB4 intron 17463246 rs16830608 chr2 152880509 A C 6.08E-06 Multiple complex diseases CACNB4 intron 17554300 rs4664076 chr2 152921491 G A 2.19E-05 Hypertension CACNB4 intron 22384028 rs10930910 chr2 152930618 T C 3.83E-04 Obesity (extreme) CACNB4 intron 21935397 rs2345633 chr2 152946604 T C 7.54E-04 Type 2 diabetes CACNB4 intron 17463246 rs3820706 chr2 152957411 T C 2.00E-09 Adverse response to chemotherapy in breast cancer (alopecia) CACNB4 nearGene-5 24025145 rs12472524 chr2 152972696 A G 7.90E-04 Obesity (extreme) / / 21935397 rs10200655 chr2 152974960 T A 7.28E-04 Obesity (extreme) STAM2 UTR-3 21935397 rs10497095 chr2 152977988 G A 7.63E-04 Obesity (extreme) STAM2 intron 21935397 rs3820702 chr2 152980853 T A 6.97E-04 Obesity (extreme) STAM2 intron 21935397 rs16830728 chr2 152981335 G T 3.00E-08 Adverse response to chemotherapy in breast cancer (alopecia) STAM2 intron 24025145 rs17398246 chr2 152981827 G A 2.25E-04 Response to taxane treatment (placlitaxel) STAM2 intron 23006423 rs4664531 chr2 152986041 T C 3.31E-04 Obesity (extreme) STAM2 intron 21935397 rs12623355 chr2 152986593 C T 5.56E-04 Obesity (extreme) STAM2 intron 21935397 rs12613984 chr2 152987546 A C 5.91E-04 Obesity (extreme) STAM2 intron 21935397 rs3768651 chr2 152990721 T A,C,G 1.96E-04 Schizophrenia STAM2 intron 19197363 rs3768651 chr2 152990721 T A,C,G 6.30E-04 Obesity (extreme) STAM2 intron 21935397 rs3768650 chr2 152990932 A G 6.31E-04 Obesity (extreme) STAM2 intron 21935397 rs12612031 chr2 152992237 G A 7.29E-04 Obesity (extreme) STAM2 intron 21935397 rs12621378 chr2 152995177 C T 1.60E-04 Schizophrenia STAM2 intron 19197363 rs12621378 chr2 152995177 C T 6.43E-04 Obesity (extreme) STAM2 intron 21935397 rs12612557 chr2 152995261 T G 6.42E-04 Obesity (extreme) STAM2 intron 21935397 rs11893841 chr2 152998552 G A 1.61E-04 Schizophrenia STAM2 intron 19197363 rs11893841 chr2 152998552 G A 5.91E-04 Obesity (extreme) STAM2 intron 21935397 rs12617139 chr2 153000337 T A 8.92E-04 Obesity (extreme) STAM2 intron 21935397 rs3768649 chr2 153003104 G C 9.05E-04 Obesity (extreme) STAM2 intron 21935397 rs3768648 chr2 153003412 T C 5.11E-04 Obesity (extreme) STAM2 intron 21935397 rs4664535 chr2 153004253 G A 8.99E-04 Obesity (extreme) STAM2 intron 21935397 rs4664536 chr2 153004385 C A 8.66E-04 Obesity (extreme) STAM2 intron 21935397 rs10184862 chr2 153005844 A G 6.55E-04 Obesity (extreme) STAM2 intron 21935397 rs13003423 chr2 153006452 G C 8.87E-04 Obesity (extreme) STAM2 intron 21935397 rs6650779 chr2 153007034 A G 8.85E-04 Obesity (extreme) STAM2 intron 21935397 rs6650771 chr2 153009131 A G 8.42E-04 Obesity (extreme) STAM2 intron 21935397 rs10930958 chr2 153009409 C T 8.39E-04 Obesity (extreme) STAM2 intron 21935397 rs10930959 chr2 153009469 A G 8.81E-04 Obesity (extreme) STAM2 intron 21935397 rs6731625 chr2 153020612 A G 8.82E-04 Obesity (extreme) STAM2 intron 21935397 rs4664084 chr2 153022071 C T 8.77E-04 Obesity (extreme) STAM2 intron 21935397 rs6738680 chr2 153024113 G A 8.62E-04 Obesity (extreme) STAM2 intron 21935397 rs4611639 chr2 153025030 G C 2.83E-04 Obesity (extreme) STAM2 intron 21935397 rs12328733 chr2 153029067 G A 4.92E-04 Obesity (extreme) STAM2 intron 21935397 rs10497097 chr2 153030869 G A 4.93E-04 Obesity (extreme) STAM2 intron 21935397 rs2345639 chr2 153031113 T C 9.15E-04 Obesity (extreme) STAM2 intron 21935397 rs4368329 chr2 153032593 G A 8.82E-04 Obesity (extreme) / / 21935397 rs6740224 chr2 153032790 A C 6.19E-04 Obesity (extreme) / / 21935397 rs10803946 chr2 153033517 C A 4.93E-04 Obesity (extreme) / / 21935397 rs4664089 chr2 153045036 A G 4.38E-04 Obesity (extreme) / / 21935397 rs6713219 chr2 153079708 T C 6.77E-04 Multiple complex diseases / / 17554300 rs11883562 chr2 153083897 T C 5.42E-04 Multiple complex diseases / / 17554300 rs10497098 chr2 153090971 T A 5.70E-04 Multiple complex diseases / / 17554300 rs4664544 chr2 153092375 C T 3.96E-05 Schizophrenia / / 24253340 rs11679305 chr2 153102914 T C 6.57E-04 Obesity (extreme) / / 21935397 rs6433928 chr2 153110731 T A 4.93E-04 Multiple complex diseases / / 17554300 rs12988834 chr2 153129366 G A 5.72E-05 Schizophrenia / / 24253340 rs12997179 chr2 153147789 G A 4.39E-04 Obesity (extreme) / / 21935397 rs2345814 chr2 153150197 A T 4.28E-04 Obesity (extreme) / / 21935397 rs2881225 chr2 153150727 C T 5.68E-04 Obesity (extreme) / / 21935397 rs4308089 chr2 153153159 A G 6.00E-04 Obesity (extreme) / / 21935397 rs17326775 chr2 153153555 A G 5.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4664560 chr2 153153733 T C 7.91E-04 Obesity (extreme) / / 21935397 rs7568759 chr2 153154612 G A 8.71E-04 Obesity (extreme) / / 21935397 rs11674860 chr2 153154680 T G 7.93E-04 Obesity (extreme) / / 21935397 rs12693313 chr2 153157043 G A 6.15E-04 Obesity (extreme) / / 21935397 rs5005667 chr2 153162835 T C 7.32E-04 Obesity (extreme) / / 21935397 rs2345876 chr2 153164514 G A 5.64E-04 Obesity (extreme) / / 21935397 rs2345877 chr2 153164790 C T 8.00E-04 Obesity (extreme) / / 21935397 rs12693320 chr2 153166172 T A 7.08E-04 Obesity (extreme) / / 21935397 rs16830964 chr2 153208493 A C 1.13E-06 Schizophrenia FMNL2 intron 24253340 rs4254462 chr2 153219836 T C 0.000706191 Hypertension (early onset hypertension) FMNL2 intron 22479346 rs4664574 chr2 153221287 G T 1.39E-06 Schizophrenia FMNL2 intron 24253340 rs11674872 chr2 153225799 A G 3.44E-04 Bipolar disorder,schizoaffective FMNL2 intron 19567891 rs16831009 chr2 153232345 A G 2.44E-06 Schizophrenia FMNL2 intron 24253340 rs16831018 chr2 153237345 C T 1.31E-04 Multiple complex diseases FMNL2 intron 17554300 rs16831028 chr2 153241206 G A 5.16E-04 Bipolar disorder,schizoaffective FMNL2 intron 19567891 rs16831043 chr2 153248346 C T 7.23E-04 Type 2 diabetes FMNL2 intron 17463246 rs2345875 chr2 153253445 A G 7.23E-04 Type 2 diabetes FMNL2 intron 17463246 rs7586834 chr2 153282226 C T 4.40E-06 Lipid levels FMNL2 intron 18193043 rs7600624 chr2 153282375 A G 5.65E-06 Alzheimer's disease (late onset) FMNL2 intron 21379329 rs3811575 chr2 153282883 A G 9.05E-04 Response to cytidine analogues (gemcitabine) FMNL2 intron 24483146 rs6434028 chr2 153287902 T C 8.54E-04 Response to cytidine analogues (gemcitabine) FMNL2 intron 24483146 rs6727037 chr2 153292174 G A 6.18E-04 Response to cytidine analogues (gemcitabine) FMNL2 intron 24483146 rs6727037 chr2 153292174 G A 8.50E-04 Response to cytadine analogues (cytosine arabinoside) FMNL2 intron 24483146 rs7582905 chr2 153296210 T C 2.94E-04 Type 2 diabetes FMNL2 intron 17463246 rs12623070 chr2 153318339 T C 3.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FMNL2 intron 20877124 rs2068886 chr2 153339823 T C 8.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FMNL2 intron 20877124 rs16831263 chr2 153371873 T G 4.28E-05 Bipolar disorder and schizophrenia FMNL2 intron 20889312 rs6434081 chr2 153373267 G A 9.67E-05 Alzheimer's disease (late onset) FMNL2 intron 21379329 rs7591606 chr2 153373875 T C 2.66E-06 Alzheimer's disease (late onset) FMNL2 intron 21379329 rs4664593 chr2 153378652 G A 5.96E-05 Bone mineral density FMNL2 intron 19181680 rs16831280 chr2 153379527 C T 8.81E-04 Multiple complex diseases FMNL2 intron 17554300 rs9288108 chr2 153386833 C A 2.18E-04 Cholesterol FMNL2 intron 17255346 rs9288108 chr2 153386833 C A 3.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FMNL2 intron 20877124 rs17327752 chr2 153388487 G A 8.85E-04 Prostate cancer mortality FMNL2 intron 20978177 rs2346182 chr2 153388948 G T 5.79E-05 Bone mineral density FMNL2 intron 19181680 rs12474927 chr2 153391582 A G 4.58E-04 Alzheimer's disease (late onset) FMNL2 intron 21379329 rs2577182 chr2 153393747 C T 8.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FMNL2 intron 20877124 rs2577181 chr2 153393766 C G 7.40E-06 Urinary metabolites FMNL2 intron 21572414 rs2577180 chr2 153393947 C T 1.14E-04 Alzheimer's disease (late onset) FMNL2 intron 21379329 rs10172230 chr2 153398476 A C 1.34E-04 Cholesterol FMNL2 intron 17255346 rs10172230 chr2 153398476 A C 5.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FMNL2 intron 20877124 rs2083098 chr2 153407808 T C 0.00001827 Sarcoidosis FMNL2 intron 22952805 rs2083099 chr2 153407834 A G 0.00001827 Sarcoidosis FMNL2 intron 22952805 rs10497104 chr2 153408076 A G 7.24E-04 Response to alcohol consumption (flushing response) FMNL2 intron 24277619 rs11675841 chr2 153436570 C T 5.00E-06 IgG glycosylation FMNL2 intron 23382691 rs11675841 chr2 153436570 C T 6.00E-06 IgG glycosylation FMNL2 intron 23382691 rs11675841 chr2 153436570 C T 8.00E-06 IgG glycosylation FMNL2 intron 23382691 rs16823807 chr2 153438660 C G 9.20E-05 Pulmonary function FMNL2 intron 23932459 rs2304556 chr2 153473794 T G 1.10E-04 Stroke (ischemic) FMNL2 intron 22384361 rs2304556 chr2 153473794 T G 1.20E-07 Stroke (ischemic) FMNL2 intron 22384361 rs4664599 chr2 153492765 T C 6.16E-04 Multiple complex diseases FMNL2 intron 17554300 rs2272535 chr2 153493286 G A 4.46E-04 Insulin resistance FMNL2 intron 21901158 rs11883762 chr2 153493435 G T 6.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FMNL2 intron 20877124 rs3762503 chr2 153522963 T C 7.58E-04 Multiple complex diseases PRPF40A intron 17554300 rs3762503 chr2 153522963 T C 1.68E-04 Bipolar disorder,schizoaffective PRPF40A intron 19567891 rs9288125 chr2 153523111 A C 9.10E-06 Biomarkers PRPF40A intron 17903293 rs4664604 chr2 153573408 C G 8.40E-06 Biomarkers PRPF40A intron 17903293 rs2450 chr2 153584421 T G 1.28E-04 Blood pressure ARL6IP6 intron 21422096 rs2450 chr2 153584421 T G 1.77E-04 Blood pressure ARL6IP6 intron 21422096 rs2450 chr2 153584421 T G 3.26E-05 Blood pressure ARL6IP6 intron 21422096 rs1986743 chr2 153586899 A G 1.60E-05 Biomarkers ARL6IP6 intron 17903293 rs1986743 chr2 153586899 A G 2.70E-07 Stroke (ischemic) ARL6IP6 intron 22384361 rs1986743 chr2 153586899 A G 3.90E-04 Stroke (ischemic) ARL6IP6 intron 22384361 rs1427404 chr2 153675372 A G 2.80E-05 Urinary metabolites / / 21572414 rs6728402 chr2 153696433 T C 2.48E-26 Narcolepsy / / 19629137 rs11692152 chr2 153721508 G A 2.12E-06 Primary biliary cirrhosis / / 21399635 rs11692152 chr2 153721508 G A 9.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10497117 chr2 153723217 A T 9.93E-04 Bipolar disorder / / 19259986 rs16831902 chr2 153733371 A G 3.21E-06 Primary biliary cirrhosis / / 21399635 rs77197937 chr2 153741268 A G 5.44E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs78683678 chr2 153749368 C T 5.00E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs1427399 chr2 153750590 C T 5.48E-04 Multiple complex diseases / / 17554300 rs2347039 chr2 153803234 C T 3.29E-04 Type 2 diabetes / / 17463246 rs1357643 chr2 153804455 C T 2.08E-05 Multiple complex diseases / / 17554300 rs1357643 chr2 153804455 C T 4.47E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11688483 chr2 153804944 A G 5.80E-04 Type 2 diabetes / / 17463246 rs4664633 chr2 153811011 C T 1.70E-05 Personality dimensions / / 18957941 rs7601781 chr2 153814233 A C 8.00E-06 Personality dimensions / / 18957941 rs4664635 chr2 153830935 C G 4.10E-05 Personality dimensions / / 18957941 rs1347395 chr2 153872845 A G 1.82E-04 Substance dependence / / 21818250 rs11680004 chr2 153881415 G C 2.80E-05 Urinary metabolites / / 21572414 rs7586868 chr2 153886686 T C 1.89E-05 Sleep duration / / 22105623 rs12618138 chr2 153887010 T C 1.86E-05 Sleep duration / / 22105623 rs12618169 chr2 153887095 T C 1.67E-05 Sleep duration / / 22105623 rs12618194 chr2 153887190 T G 1.85E-05 Sleep duration / / 22105623 rs16832055 chr2 153888496 A G 1.81E-05 Sleep duration / / 22105623 rs1897163 chr2 153921054 G A 1.09E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13415190 chr2 153931617 G A 8.23E-06 Personality dimensions / / 22628180 rs2347399 chr2 153943546 A G 8.21E-06 Personality dimensions / / 22628180 rs1158394 chr2 153947283 A G 8.73E-06 Personality dimensions / / 22628180 rs7424363 chr2 153959957 A G 3.40E-05 Cognitive test performance / / 20125193 rs13008859 chr2 153960537 T C 8.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2347343 chr2 153984022 A G 7.99E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2007857 chr2 153987922 G A 5.38E-04 Coronary heart disease / / 21606135 rs13025412 chr2 153989587 C T 9.53E-04 Coronary heart disease / / 21606135 rs7562599 chr2 154003158 G A 0.0000214 Ovarian cancer / / 22794196 rs11679885 chr2 154024363 T G 9.80E-05 Cognitive test performance / / 20125193 rs11679885 chr2 154024363 T G 5.15E-04 White matter integrity / / 22425255 rs13414678 chr2 154029978 A G 8.24E-05 Glucose levels / / pha003061 rs892747 chr2 154032484 A G 6.27E-05 Glucose levels / / pha003061 rs13402721 chr2 154061956 A T 2.81E-05 Nonalcoholic fatty liver disease / / 21423719 rs967496 chr2 154084952 C T 6.04E-04 Schizophrenia / / 21674006 rs2141799 chr2 154092871 G A 4.40E-05 Bipolar disorder / / 18317468 rs1921765 chr2 154138237 A G 0.000177071 Hypertension (early onset hypertension) / / 22479346 rs1074167 chr2 154188996 G A 3.58E-05 Personality dimensions / / 22628180 rs10176073 chr2 154195066 A G 2.71E-04 Hearing function / / 17255346 rs11682518 chr2 154223946 G T 8.55E-04 Antisocial behavior / / 20345837 rs13397414 chr2 154231414 A G 3.00E-04 Alzheimer's disease (late onset) / / 21460841 rs13398643 chr2 154235295 C T 5.24E-05 Suicide attempts in bipolar disorder / / 21423239 rs10196515 chr2 154240309 C A 2.93E-05 Type 1 diabetes / / 18978792 rs13415573 chr2 154245354 C T 2.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs10497122 chr2 154245633 A G 8.78E-04 Tourette syndrome / / 22889924 rs10196785 chr2 154271299 T C 7.16E-05 Smoking cessation / / 24665060 rs13418009 chr2 154272542 A G 7.90E-04 Alcohol dependence / / 20201924 rs11673716 chr2 154273475 G A 2.06E-05 Osteosarcoma / / 23727862 rs7567863 chr2 154283374 T C 9.00E-05 Schizophrenia / / 19571811 rs11684991 chr2 154308037 C G 8.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs11675619 chr2 154317201 T G 7.77E-04 Acute lung injury / / 22295056 rs3910524 chr2 154317387 T G 7.77E-04 Acute lung injury / / 22295056 rs3910523 chr2 154317529 C T 7.77E-04 Acute lung injury / / 22295056 rs11692573 chr2 154318295 C A 7.77E-04 Acute lung injury / / 22295056 rs3910522 chr2 154330785 C A 2.97E-04 Major depressive disorder / / 22472876 rs12466830 chr2 154348863 T C 5.80E-05 Diabetic retinopathy / / 21441570 rs1658555 chr2 154367348 C T 4.31E-05 Blood pressure / / 17255346 rs12615845 chr2 154371198 C T 6.50E-05 Diabetic retinopathy / / 21441570 rs1221754 chr2 154372766 T C 6.83E-05 Major depressive disorder (broad) / / 20038947 rs1221754 chr2 154372766 T C 4.89E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9784007 chr2 154374874 G A 2.00E-04 Multiple complex diseases / / 17554300 rs1370674 chr2 154375056 A C 1.51E-05 Major depressive disorder (broad) / / 20038947 rs10189720 chr2 154405080 A C 2.48E-04 Blood pressure / / 17255346 rs13013028 chr2 154419722 T C 6.50E-05 Diabetic retinopathy / / 21441570 rs7589528 chr2 154420012 A G 6.40E-05 Diabetic retinopathy / / 21441570 rs7589528 chr2 154420012 A G 9.46E-04 White matter integrity / / 22425255 rs7589528 chr2 154420012 A G 7.70E-04 Tourette syndrome / / 22889924 rs12612002 chr2 154422529 T C 6.50E-05 Diabetic retinopathy / / 21441570 rs7593582 chr2 154423542 G T 6.30E-05 Diabetic retinopathy / / 21441570 rs1940268 chr2 154436735 G A 7.87E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs12693773 chr2 154456308 A G 1.40E-05 Urinary metabolites / / 21572414 rs4335901 chr2 154460874 A G 1.70E-05 Urinary metabolites / / 21572414 rs713119 chr2 154507989 A G 0.000172209 Hypertension (early onset hypertension) / / 22479346 rs1546676 chr2 154509239 G A 0.00011652 Hypertension (early onset hypertension) / / 22479346 rs1519643 chr2 154519448 G A 0.000161315 Hypertension (early onset hypertension) / / 22479346 rs7591719 chr2 154540911 T C 6.40E-06 Urinary metabolites / / 21572414 rs7591719 chr2 154540911 T C 8.91E-06 Odorant perception / / 23910658 rs12995533 chr2 154545453 C T 9.20E-06 Urinary metabolites / / 21572414 rs12995533 chr2 154545453 C T 0.000279122 Hypertension (early onset hypertension) / / 22479346 rs1401743 chr2 154546923 G A 2.52E-05 IgE levels / / 22075330 rs4664152 chr2 154549105 C T 0.0005111 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4664152 chr2 154549105 C T 5.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10209743 chr2 154552031 A C 0.0006648 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10209743 chr2 154552031 A C 6.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13013240 chr2 154553429 G A 1.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10931753 chr2 154568757 G C 5.00E-06 Blood trace element (Zn levels) / / 23720494 rs1022386 chr2 154582806 C T 6.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1372393 chr2 154692811 A G 5.70E-06 Urinary metabolites / / 21572414 rs1372393 chr2 154692811 A G 4.26E-04 White matter integrity / / 22425255 rs11893783 chr2 154732137 G C 2.12E-05 Multiple complex diseases GALNT13 intron 17554300 rs17585462 chr2 154743167 T C 3.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT13 intron 20877124 rs16834756 chr2 154745009 A G 4.89E-05 Partial epilepsies GALNT13 intron 20522523 rs16834756 chr2 154745009 A G 3.68E-06 Epilepsy GALNT13 intron 22116939 rs7591589 chr2 154745902 C A,G 1.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT13 intron 20877124 rs17585476 chr2 154746555 T C 3.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT13 intron 20877124 rs9636324 chr2 154750741 A G 4.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT13 intron 20877124 rs12612456 chr2 154751502 G A 4.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT13 intron 20877124 rs13030825 chr2 154816802 T C 1.82E-04 Vaspin levels GALNT13 intron 22907691 rs13030825 chr2 154816802 T C 0.0001815 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit GALNT13 intron 22907730 rs10931861 chr2 154824970 C G 1.12E-04 Smoking cessation GALNT13 intron 18519826 rs10931862 chr2 154830754 A G 3.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT13 intron 20877124 rs6761233 chr2 154837081 A G 1.48E-04 Vaspin levels GALNT13 intron 22907691 rs6761233 chr2 154837081 A G 0.0001484 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit GALNT13 intron 22907730 rs12693888 chr2 154842662 G A 1.11E-04 Smoking cessation GALNT13 intron 18519826 rs1013694 chr2 154861348 A G 1.45E-04 Smoking cessation GALNT13 intron 18519826 rs7565078 chr2 154889520 G T 4.47E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) GALNT13 intron 24236485 rs7608978 chr2 154889809 A G 1.77E-06 Smoking cessation GALNT13 intron 18519826 rs10490534 chr2 154937930 T G 9.08E-05 Tuberculosis GALNT13 intron 20694014 rs12615781 chr2 154951309 T C 5.64E-04 Type 2 diabetes GALNT13 intron 17846124 rs12693918 chr2 154961754 G T 9.75E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) GALNT13 intron 24236485 rs16836124 chr2 155002847 T C 6.00E-06 Obesity-related traits GALNT13 intron 23251661 rs12995536 chr2 155016816 C T 1.85E-04 Multiple complex diseases GALNT13 intron 17554300 rs1468995 chr2 155017425 C A 6.07E-04 Multiple complex diseases GALNT13 intron 17554300 rs958672 chr2 155070567 A T 2.00E-06 Aging traits GALNT13 intron 17903295 rs11892473 chr2 155077962 A G 4.00E-06 Coronary heart disease GALNT13 intron 21971053 rs16836327 chr2 155100016 G C 7.42E-04 Type 2 diabetes GALNT13 intron 17463246 rs7593783 chr2 155120573 C T 7.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT13 intron 20877124 rs7593783 chr2 155120573 C T 2.81E-05 Telomere length GALNT13 intron 23001564 rs16836453 chr2 155165241 G A 2.72E-05 Response to methylphenidate treatment GALNT13 intron 21130132 rs16836472 chr2 155170821 G A 4.79E-04 Multiple complex diseases GALNT13 intron 17554300 rs12693973 chr2 155171139 T G 2.00E-06 Body mass index GALNT13 intron 24348519 rs3856384 chr2 155173891 A C 3.92E-04 Type 2 diabetes GALNT13 intron 17463246 rs2348924 chr2 155190478 G T 1.10E-04 Statin-induced myopathy GALNT13 intron 21826682 rs707040 chr2 155226677 T C 6.00E-06 Sudden cardiac arrest GALNT13 intron 21658281 rs12617950 chr2 155234278 C A 7.34E-04 Alzheimer's disease GALNT13 intron 17998437 rs12621256 chr2 155234318 A G 4.00E-06 Liver enzyme levels (alanine transaminase) GALNT13 intron 24124411 rs707050 chr2 155248550 G T 9.67E-05 Non-alcoholic fatty liver disease histology (other) GALNT13 intron 20708005 rs13026208 chr2 155252653 T C 4.26E-04 Oral cancers (chewing tobacco related) GALNT13 intron 22503698 rs13420537 chr2 155298395 T C 9.57E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines GALNT13 intron 21844884 rs17815112 chr2 155314294 G A 0.000752 Salmonella-induced pyroptosis / / 22837397 rs17815112 chr2 155314294 G A 8.74E-04 Tourette syndrome / / 22889924 rs10932055 chr2 155322559 T C 9.64E-06 Coronary heart disease / / pha003031 rs707107 chr2 155322696 T G 3.36E-05 Multiple complex diseases / / 17554300 rs707107 chr2 155322696 T G 1.31E-05 Coronary heart disease / / pha003031 rs12470887 chr2 155324303 T C 3.97E-05 Multiple complex diseases / / 17554300 rs11899646 chr2 155330994 G A 2.69E-05 Multiple complex diseases / / 17554300 rs11899646 chr2 155330994 G A 3.05E-05 Coronary heart disease / / pha003031 rs1429261 chr2 155342678 C T 3.69E-05 Tunica Media / / pha003034 rs249693 chr2 155345145 T C 1.32E-05 Bipolar disorder and schizophrenia / / 20889312 rs1366748 chr2 155362422 A G 7.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10497139 chr2 155368924 C G 6.19E-04 Multiple complex diseases / / 17554300 rs16837781 chr2 155370777 T C 7.76E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16837790 chr2 155372611 A G 9.76E-04 Multiple complex diseases / / 17554300 rs12328466 chr2 155375036 G A 9.67E-06 Bipolar disorder and schizophrenia / / 20889312 rs2691795 chr2 155391135 C T 0.0000779 Polycystic ovary syndrome / / 22951595 rs2691795 chr2 155391135 C T 7.79E-05 Intracranial aneurysm / / 22961961 rs1220526 chr2 155460781 G A 2.21E-04 Multiple complex diseases / / 17554300 rs774505 chr2 155471901 G A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1429252 chr2 155476165 C G 1.49E-05 Aortic root size / / 21223598 rs10497142 chr2 155538402 A T 8.80E-05 Coffee consumption / / 21357676 rs16838055 chr2 155590364 T C 2.88E-04 Smoking quantity KCNJ3 intron 24665060 rs2121089 chr2 155609387 C A 3.71E-04 Response to statin treatment (atorvastatin),change in cholesterol levels KCNJ3 intron 20031582 rs17640676 chr2 155647819 G T 2.09E-05 Response to acetaminophen (hepatotoxicity) KCNJ3 intron 21177773 rs1037091 chr2 155652357 C T 9.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) KCNJ3 intron 23648065 rs13005001 chr2 155661146 G T 2.87E-06 Lung adenocarcinoma KCNJ3 intron 19836008 rs2652461 chr2 155687982 T G 0.000656679 Hypertension (early onset hypertension) KCNJ3 intron 22479346 rs2937600 chr2 155702768 A G 4.04E-04 Suicide attempts in bipolar disorder KCNJ3 intron 21041247 rs1900132 chr2 155703068 A G 4.05E-04 Suicide attempts in bipolar disorder KCNJ3 intron 21041247 rs4467223 chr2 155706411 T A 5.00E-05 Prostate cancer KCNJ3 intron 21743057 rs17642086 chr2 155711357 T C 4.00E-05 Prostate cancer KCNJ3 cds-synon 21743057 rs1979004 chr2 155713421 T A 4.00E-05 Prostate cancer / / 21743057 rs765439 chr2 155750882 C T 1.65E-06 Parent of origin effect on language impairment (maternal) / / 24571439 rs977869 chr2 155757249 G A 2.37E-06 Parent of origin effect on language impairment (maternal) / / 24571439 rs13011654 chr2 155844952 C T 4.38E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12986694 chr2 155941970 G A 4.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17644050 chr2 155946659 G C 4.38E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13004840 chr2 155996947 C T 8.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13014709 chr2 156023943 T C 8.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7576616 chr2 156066815 T C 8.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs949781 chr2 156069998 T C 9.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10497148 chr2 156083344 A G 5.77E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10497148 chr2 156083344 A G 7.65E-05 Alcohol consumption / / pha001399 rs1486073 chr2 156163802 G A 9.10E-04 Multiple complex diseases / / 17554300 rs2046502 chr2 156229886 G A 8.62E-04 Multiple complex diseases / / 17554300 rs4544377 chr2 156256701 G A 8.70E-04 Schizophrenia / / 19197363 rs4544377 chr2 156256701 G A 2.00E-06 Systemic lupus erythematosus / / 24871463 rs1601527 chr2 156261310 A C 3.39E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2350797 chr2 156283312 G A 7.24E-07 Height / / pha003010 rs2350797 chr2 156283312 G A 5.18E-06 Height / / pha003011 rs1524909 chr2 156381959 A G 2.10E-05 Urinary metabolites / / 21572414 rs877055 chr2 156401129 T A 2.30E-05 Urinary metabolites / / 21572414 rs16839220 chr2 156403868 G C 5.23E-04 Multiple complex diseases / / 17554300 rs2691775 chr2 156434090 A G 6.60E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs278879 chr2 156441981 A G 2.57E-04 Multiple complex diseases / / 17554300 rs843229 chr2 156444948 C T 7.80E-04 Multiple complex diseases / / 17554300 rs843220 chr2 156449681 G A 6.90E-04 Multiple complex diseases / / 17554300 rs10932616 chr2 156450256 G A 1.12E-04 Smoking initiation / / 24665060 rs10432531 chr2 156461906 A G 3.32E-04 Smoking initiation / / 24665060 rs2691787 chr2 156466403 G A 7.63E-04 Multiple complex diseases / / 17554300 rs13033671 chr2 156480214 C T 0.000191922 Hypertension (early onset hypertension) / / 22479346 rs843236 chr2 156483829 C A 6.66E-05 Personality dimensions / / 18957941 rs7571452 chr2 156502613 T C 8.69E-04 Multiple complex diseases / / 17554300 rs4407211 chr2 156506516 T C 3.24E-06 Alcohol consumption / / 23953852 rs2677485 chr2 156535156 T C 5.50E-07 Alcohol consumption / / 23953852 rs35349447 chr2 156574981 T C 3.93E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs12373770 chr2 156579123 T A 7.51E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2350817 chr2 156579598 T A 4.29E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs4664774 chr2 156579660 T G 3.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2139035 chr2 156584446 T A 6.70E-04 Type 2 diabetes / / 17463246 rs1980211 chr2 156586568 G A 7.68E-05 White matter integrity / / 22425255 rs2056242 chr2 156594333 G A 7.99E-04 White matter integrity / / 22425255 rs4429429 chr2 156598046 T C 4.44E-05 Cognitive impairment induced by topiramate / / 22091778 rs13026792 chr2 156616143 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2882513 chr2 156625848 A G 1.68E-04 White matter integrity / / 22425255 rs1914650 chr2 156636709 G A 5.58E-04 Stroke / / pha002887 rs1316293 chr2 156659919 A G 2.21E-04 White matter integrity / / 22425255 rs13028096 chr2 156663777 A G 8.20E-06 Urinary metabolites / / 21572414 rs13033779 chr2 156686079 C T 2.80E-05 Urinary metabolites / / 21572414 rs11885215 chr2 156711077 T C 8.15E-04 Multiple complex diseases / / 17554300 rs10193997 chr2 156754055 T C 1.59E-05 stroke (ischemic) / / 17434096 rs10198409 chr2 156756235 A G 1.59E-05 stroke (ischemic) / / 17434096 rs1402071 chr2 156759291 C T 8.45E-05 stroke (ischemic) / / 17434096 rs3843321 chr2 156762304 G C 0.00038 Coronary artery calcification / / 23727086 rs2141234 chr2 156819295 C T 2.84E-06 Rheumatoid arthritis / / 19503088 rs17238525 chr2 156819585 T C 9.37E-05 Cognitive performance / / 19734545 rs17238525 chr2 156819585 T C 0.0000362 Amyotrophic lateral sclerosis / / 23587638 rs4664191 chr2 156852749 T C 4.22E-04 Alzheimer's disease / / 24755620 rs13026547 chr2 156856257 G A 4.06E-04 Alzheimer's disease / / 24755620 rs6436115 chr2 156856880 A G 3.74E-04 Alzheimer's disease / / 24755620 rs11680065 chr2 156862613 A G 2.40E-05 Urinary metabolites / / 21572414 rs7570959 chr2 156885750 T C 4.17E-05 Multiple complex diseases / / 17554300 rs1918172 chr2 156888500 C G 5.00E-06 Attention deficit hyperactivity disorder / / 18821565 rs2882618 chr2 156893877 C A 7.47E-04 Multiple complex diseases / / 17554300 rs7560427 chr2 156900299 G T 3.10E-05 Type 2 diabetes / / 17463246 rs7560427 chr2 156900299 G T 9.53E-04 Multiple complex diseases / / 17554300 rs17244395 chr2 156916525 T C 1.02E-04 Type 2 diabetes / / 17463246 rs7578557 chr2 156917835 T C 2.71E-04 Type 2 diabetes / / 17463246 rs7578557 chr2 156917835 T C 8.85E-05 Serum metabolites / / 19043545 rs17244514 chr2 156918824 A C 8.24E-05 Type 2 diabetes / / 17463246 rs2204584 chr2 156919338 A G 1.76E-04 Type 2 diabetes / / 17463246 rs10497175 chr2 156924881 C A 2.80E-05 Triglycerides / / 19074352 rs10497175 chr2 156924881 C A 2.80E-05 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs16839962 chr2 156925286 A T 9.00E-06 Response to statin therapy / / 20339536 rs10497174 chr2 156926773 C T 3.34E-04 Premature ovarian failure / / 19508998 rs13032427 chr2 156926963 C T 1.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12471552 chr2 156933377 G A 8.50E-05 Response to statin therapy / / 20339536 rs10177924 chr2 156933553 A G 3.00E-06 Smoking initiation / / 24665060 rs1113061 chr2 156948356 A G 5.20E-06 Urinary metabolites / / 21572414 rs13426050 chr2 156968533 G A 1.00E-05 Urinary metabolites / / 21572414 rs10196668 chr2 156970611 G T 2.09E-05 Body Mass Index / / pha003014 rs10196668 chr2 156970611 G T 2.19E-05 Insulin-related traits / / pha003063 rs12694551 chr2 156990306 C A 8.51E-05 Prion diseases / / 22210626 rs10167400 chr2 157003970 C G 7.50E-06 Urinary metabolites / / 21572414 rs4664800 chr2 157011778 G A 4.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11678568 chr2 157024097 G A 4.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10932915 chr2 157049799 G A 6.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2351535 chr2 157094848 G A 6.30E-06 Urinary metabolites / / 21572414 rs17188434 chr2 157096776 T C 1.00E-09 Menarche (age at onset) / / 21102462 rs4369815 chr2 157126964 T G 9.65E-05 Coronary heart disease / / pha003032 rs16840221 chr2 157168951 G C 5.40E-06 Urinary metabolites / / 21572414 rs707130 chr2 157197583 T C 4.13E-04 Type 2 diabetes / / 17463246 rs707130 chr2 157197583 T C 3.08E-06 Lipid traits / / 24023261 rs9288592 chr2 157383945 C G 8.88E-04 Multiple complex diseases GPD2 intron 17554300 rs2288760 chr2 157427322 A T 3.87E-04 Multiple complex diseases GPD2 intron 17554300 rs1368246 chr2 157449118 T G 3.78E-04 Smoking quantity / / 24665060 rs6706895 chr2 157452216 G C 7.90E-05 Chronic obstructive pulmonary disease / / 19300482 rs6706895 chr2 157452216 G C 7.90E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6729636 chr2 157475254 C A 1.80E-05 Urinary metabolites / / 21572414 rs16840621 chr2 157505920 A G 3.61E-04 Multiple complex diseases / / 17554300 rs7602743 chr2 157529654 G A 9.86E-05 Vascular dementia / / 22116812 rs7601713 chr2 157552860 A C 2.00E-06 QT interval / / 20031603 rs1543932 chr2 157565192 G A 7.12E-05 Gallstones / / 17632509 rs6436652 chr2 157649957 T C 7.10E-05 Bone mineral density (BMD),in women / / 20164292 rs9288624 chr2 157650780 C T 7.90E-05 Bone mineral density (BMD),in women / / 20164292 rs11683474 chr2 157672828 A T 1.51E-06 Alcohol and nictotine co-dependence / / 20158304 rs11683474 chr2 157672828 A T 2.00E-06 Alcohol and nictotine co-dependence / / 20158304 rs723802 chr2 157676466 A C 0.0002 Coronary artery calcification / / 23727086 rs10175224 chr2 157686431 G A 4.41E-04 Multiple complex diseases / / 17554300 rs295796 chr2 157753371 A T 8.53E-04 Blood pressure / / 21422096 rs295796 chr2 157753371 A T 9.65E-06 Blood pressure / / 21422096 rs295813 chr2 157763863 A G 1.24E-06 Blood pressure / / 21422096 rs295813 chr2 157763863 A G 1.68E-04 Blood pressure / / 21422096 rs295813 chr2 157763863 A G 3.76E-04 Blood pressure / / 21422096 rs295813 chr2 157763863 A G 4.77E-06 Blood pressure / / 21422096 rs10497160 chr2 157785404 T C 8.34E-04 Multiple complex diseases / / 17554300 rs1033225 chr2 157806151 T C 3.16E-06 Blood pressure / / 21422096 rs1033225 chr2 157806151 T C 3.39E-04 Blood pressure / / 21422096 rs1033224 chr2 157806453 A T 6.82E-04 Blood pressure / / 21422096 rs1033224 chr2 157806453 A T 8.29E-06 Blood pressure / / 21422096 rs1600754 chr2 157815667 G A 6.40E-05 Personality dimensions / / 18957941 rs7562882 chr2 157849626 C T 3.36E-04 Stroke / / pha002887 rs6747313 chr2 157873775 C A 1.95E-04 Birth weight / / 17255346 rs16841208 chr2 157889223 A G 8.44E-06 Multiple complex diseases / / 17554300 rs1481385 chr2 157906208 A G 8.30E-05 Diabetic nephropathy / / pha002866 rs1225828 chr2 157930736 C T 6.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs13403315 chr2 157935103 C T 8.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13401572 chr2 157947400 G A 6.52E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2623033 chr2 158086901 G A 9.65E-05 Suicide attempts in bipolar disorder / / 21423239 rs834135 chr2 158094105 A G 2.60E-05 Urinary metabolites / / 21572414 rs16841426 chr2 158117300 C T 6.16E-04 Response to taxane treatment (placlitaxel) GALNT5 intron 23006423 rs16841428 chr2 158117405 T C 6.16E-04 Response to taxane treatment (placlitaxel) GALNT5 intron 23006423 rs16841450 chr2 158123570 G A 8.12E-04 Response to taxane treatment (placlitaxel) GALNT5 intron 23006423 rs1156560 chr2 158137003 C T 9.83E-04 Response to taxane treatment (placlitaxel) GALNT5 intron 23006423 rs2289940 chr2 158141186 C G 9.90E-07 Urinary metabolites GALNT5 intron 21572414 rs13422538 chr2 158141687 T A 3.00E-06 Urinary metabolites GALNT5 intron 21572414 rs2121347 chr2 158141753 T C 6.30E-06 Urinary metabolites GALNT5 intron 21572414 rs2353292 chr2 158158514 C T 2.99E-04 Oral cancers (chewing tobacco related) GALNT5 intron 22503698 rs2166488 chr2 158159836 A G 2.10E-04 Blood pressure GALNT5 intron 21422096 rs2166488 chr2 158159836 A G 2.80E-04 Blood pressure GALNT5 intron 21422096 rs12623628 chr2 158211662 G A 5.30E-04 Multiple complex diseases / / 17554300 rs16841822 chr2 158324190 A G 5.54E-07 Odorant perception / / 23910658 rs6707470 chr2 158346570 A G 4.50E-05 Urate levels / / 23263486 rs6714869 chr2 158377885 A T 3.85E-05 Multiple complex diseases / / 17554300 rs7568889 chr2 158393020 C T 1.60E-05 Urinary metabolites ACVR1C intron 21572414 rs12328809 chr2 158409104 C T 5.71E-04 Response to cytadine analogues (cytosine arabinoside) ACVR1C intron 24483146 rs747282 chr2 158549742 C T 0.00039789 Hypertension (early onset hypertension) / / 22479346 rs3017019 chr2 158570520 A C 0.000499229 Hypertension (early onset hypertension) / / 22479346 rs6756623 chr2 158574077 T C 3.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6756623 chr2 158574077 T C 7.93E-05 Hypertension (early onset hypertension) / / 22479346 rs17182166 chr2 158596197 G T 5.23E-05 Response to hepatitis C treatment ACVR1 intron 19684573 rs16842025 chr2 158624661 T A 2.61E-04 Multiple complex diseases ACVR1 intron 17554300 rs10497192 chr2 158671700 C T 1.79E-05 Height ACVR1 intron pha003010 rs16842130 chr2 158687087 C T 2.22E-04 Multiple complex diseases ACVR1 intron 17554300 rs10933443 chr2 158694121 C T 1.47E-05 Height ACVR1 intron pha003010 rs13398650 chr2 158694380 G A 8.49E-04 Tourette syndrome ACVR1 intron 22889924 rs9288700 chr2 158735265 G A 1.69E-05 Lung function (forced vital capacity) / / pha003104 rs16842228 chr2 158736061 G T 6.08E-04 Multiple complex diseases / / 17554300 rs16842228 chr2 158736061 G T 6.67E-05 Lung function (forced vital capacity) / / pha003104 rs16842230 chr2 158737086 A G 5.72E-05 Lung function (forced vital capacity) / / pha003104 rs4363980 chr2 158750040 T G 5.74E-04 Longevity / / 22279548 rs16842252 chr2 158753577 A G 9.16E-05 Lung function (forced vital capacity) / / pha003104 rs1441134 chr2 158757201 G A 1.21E-05 Cognitive performance / / 19734545 rs12472133 chr2 158765030 T C 9.37E-05 Cognitive performance / / 19734545 rs10183640 chr2 158780204 G A 5.00E-07 Sudden cardiac arrest / / 21658281 rs6720264 chr2 158791560 A G 6.69E-05 Chronic obstructive pulmonary disease / / 19300482 rs12694942 chr2 158810435 G T 8.89E-04 Type 2 diabetes / / 17463246 rs17420138 chr2 158876913 C T 2.30E-09 Autism,gender differences UPP2 intron 21151189 rs6759948 chr2 158889593 A G 2.89E-04 Multiple complex diseases UPP2 intron 17554300 rs6731503 chr2 158891190 C T 1.83E-05 Cognitive impairment induced by topiramate UPP2 intron 22091778 rs7605276 chr2 158893323 T G 7.11E-06 Leprosy UPP2 intron 22019778 rs2098044 chr2 158894887 C G 4.51E-05 Serum metabolites UPP2 intron 19043545 rs2355164 chr2 158899542 C T 1.17E-04 HIV-1 viral setpoint UPP2 intron 17641165 rs10206564 chr2 158925959 G T 1.90E-05 Urinary metabolites UPP2 intron 21572414 rs6713742 chr2 158972155 T C 2.29E-05 Alzheimer's disease UPP2 intron 17998437 rs2074955 chr2 158977794 A G 1.00E-07 P-tau181p levels UPP2 intron 20932310 rs7595811 chr2 159020696 T C 7.80E-05 Monocyte counts / / pha003089 rs17193070 chr2 159031448 A G 3.40E-05 Multiple complex diseases CCDC148 intron 17554300 rs1357182 chr2 159032245 T C 6.06E-04 Multiple complex diseases CCDC148 intron 17554300 rs7591479 chr2 159039836 A T 5.30E-05 Suicide attempts in bipolar disorder CCDC148 intron 21423239 rs11692534 chr2 159043307 C G 1.92E-05 Suicide attempts in bipolar disorder CCDC148 intron 21423239 rs16842723 chr2 159044634 C G 8.71E-04 Multiple complex diseases CCDC148 intron 17554300 rs7592105 chr2 159047406 G A 5.89E-05 Suicide attempts in bipolar disorder CCDC148 intron 21423239 rs4233674 chr2 159058679 G A 5.47E-04 Rheumatoid arthritis CCDC148 intron 21452313 rs12104564 chr2 159066643 T C 0.00002987 Sarcoidosis CCDC148 intron 22952805 rs6723111 chr2 159070404 A G 9.20E-04 Rheumatoid arthritis CCDC148 intron 21452313 rs4664932 chr2 159071260 C T 6.02E-04 Response to taxane treatment (placlitaxel) CCDC148 intron 23006423 rs4664935 chr2 159072395 A G 5.80E-04 Multiple complex diseases CCDC148 intron 17554300 rs57622652 chr2 159074856 T A 0.00002125 Sarcoidosis CCDC148 intron 22952805 rs1521875 chr2 159075504 G C 0.0001218 Sarcoidosis CCDC148 intron 22952805 rs4664936 chr2 159075984 T C 0.0001048 Sarcoidosis CCDC148 intron 22952805 rs958671 chr2 159077019 A C 0.0001016 Sarcoidosis CCDC148 intron 22952805 rs4126019 chr2 159079471 G A 0.0000387 Sarcoidosis CCDC148 intron 22952805 rs113153326 chr2 159080566 C G 0.0001805 Sarcoidosis CCDC148 intron 22952805 rs62175430 chr2 159080781 G A 0.00001673 Sarcoidosis CCDC148 intron 22952805 rs149273273 chr2 159081022 T C 0.00005484 Sarcoidosis CCDC148 intron 22952805 rs139670759 chr2 159081040 G A 0.0001183 Sarcoidosis CCDC148 intron 22952805 rs76492695 chr2 159082873 T A 0.0000462 Sarcoidosis CCDC148 intron 22952805 rs147670480 chr2 159082954 C G 0.00002175 Sarcoidosis CCDC148 intron 22952805 rs111613161 chr2 159082976 C A 0.00007599 Sarcoidosis CCDC148 intron 22952805 rs2204087 chr2 159085798 T C 0.0000663 Sarcoidosis CCDC148 intron 22952805 rs4315473 chr2 159085899 T C 0.0000309 Sarcoidosis CCDC148 intron 22952805 rs2204088 chr2 159086035 G A 0.00007109 Sarcoidosis CCDC148 intron 22952805 rs6730499 chr2 159086525 C T 0.00001314 Sarcoidosis CCDC148 intron 22952805 rs35432923 chr2 159091148 A G 0.000004362 Sarcoidosis CCDC148 intron 22952805 rs2356081 chr2 159118048 T A 1.07E-04 Tuberculosis CCDC148 intron 22306650 rs2602189 chr2 159141224 A C 2.20E-04 Alcohol dependence CCDC148 intron 20201924 rs2602189 chr2 159141224 A C 7.40E-04 Alcohol dependence CCDC148 intron 20201924 rs9288710 chr2 159151010 T C 4.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCDC148 intron 20877124 rs13391688 chr2 159244723 A T 2.93E-05 Multiple complex diseases CCDC148 intron 17554300 rs10190089 chr2 159249741 A G 4.35E-04 Multiple complex diseases CCDC148 intron 17554300 rs10190089 chr2 159249741 A G 7.10E-05 Personality dimensions CCDC148 intron 18957941 rs2111880 chr2 159339424 G A 2.46E-04 Alzheimer's disease (late onset) PKP4 intron 21379329 rs16842973 chr2 159370243 G A 2.63E-04 Suicide attempts in bipolar disorder PKP4 intron 21423239 rs6730686 chr2 159374984 G A 9.11E-05 Serum metabolites PKP4 intron 19043545 rs16843004 chr2 159387110 A G 2.79E-04 Suicide attempts in bipolar disorder PKP4 intron 21423239 rs3771603 chr2 159411420 G A 3.90E-04 Depression (quantitative trait) PKP4 intron 20800221 rs3771604 chr2 159414979 A G 6.16E-05 Serum metabolites PKP4 intron 19043545 rs2214903 chr2 159429406 A G 6.26E-04 Smoking initiation PKP4 intron 24665060 rs3755413 chr2 159436702 A G 1.40E-05 Serum metabolites PKP4 intron 19043545 rs2051946 chr2 159454789 T G 4.63E-05 Serum metabolites PKP4 intron 19043545 rs17421757 chr2 159458601 G A 8.40E-04 Alcohol dependence PKP4 intron 20201924 rs2007493 chr2 159464191 C G 5.11E-04 Smoking initiation PKP4 intron 24665060 rs3771643 chr2 159466149 T C 2.31E-05 Serum metabolites PKP4 intron 19043545 rs3771645 chr2 159467028 C T 7.34E-05 Serum metabolites PKP4 intron 19043545 rs7607370 chr2 159469727 C T 1.03E-04 Suicide attempts in bipolar disorder PKP4 intron 21423239 rs3771651 chr2 159483540 T G 1.73E-04 Suicide attempts in bipolar disorder PKP4 intron 21423239 rs11893227 chr2 159483770 T G 4.21E-04 Suicide attempts in bipolar disorder PKP4 intron 21423239 rs2528635 chr2 159496390 G A 6.65E-06 Serum metabolites PKP4 intron 19043545 rs10180408 chr2 159496587 C A 9.18E-04 Insulin resistance PKP4 intron 21901158 rs2711070 chr2 159502533 G C 1.43E-05 Serum metabolites PKP4 intron 19043545 rs2528582 chr2 159511163 A G 3.10E-04 Smoking initiation PKP4 intron 24665060 rs2711072 chr2 159523803 C G 6.71E-06 Serum metabolites PKP4 intron 19043545 rs2158831 chr2 159525930 C T 2.34E-05 Serum metabolites PKP4 intron 19043545 rs2528593 chr2 159531909 A G 1.15E-04 Self-reported allergy PKP4 intron 23817569 rs16843194 chr2 159532354 A G 5.67E-04 Suicide attempts in bipolar disorder PKP4 intron 21423239 rs2711040 chr2 159534889 C T 1.97E-04 Self-reported allergy PKP4 intron 23817569 rs2528609 chr2 159558658 A C 4.41E-05 Self-reported allergy / / 23817569 rs757928 chr2 159577391 T C 3.95E-05 Taste perception / / 22132133 rs2528630 chr2 159586588 G C 3.13E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13007462 chr2 159591062 T C 6.77E-06 Obesity-related traits / / 23251661 rs4664262 chr2 159593394 C T 2.68E-06 Obesity-related traits / / 23251661 rs6705792 chr2 159602186 T C 9.23E-06 Obesity-related traits / / 23251661 rs6437198 chr2 159613196 T C 4.04E-06 Obesity-related traits / / 23251661 rs1515926 chr2 159622208 T C 2.39E-06 Obesity-related traits / / 23251661 rs2356507 chr2 159639345 C T 5.81E-06 Obesity-related traits / / 23251661 rs2356508 chr2 159644006 A C 1.00E-05 Cognitive function / / 24684796 rs17810584 chr2 159664703 C T 1.50E-05 Urinary metabolites DAPL1 intron 21572414 rs6716178 chr2 159667328 G A 7.81E-06 Obesity-related traits DAPL1 intron 23251661 rs4665011 chr2 159668758 A C 4.19E-06 Obesity-related traits DAPL1 intron 23251661 rs16843372 chr2 159670449 T C 1.00E-06 Obesity-related traits DAPL1 intron 23251661 rs6757197 chr2 159723506 G T 7.36E-07 Parkinson's disease / / 17052657 rs13035632 chr2 159750298 T C 6.11E-06 Alcohol consumption / / 23953852 rs13035632 chr2 159750298 T C 7.37E-04 Smoking initiation / / 24665060 rs17727768 chr2 159762132 A G 4.51E-04 Smoking initiation / / 24665060 rs939998 chr2 159770970 C T 1.03E-05 Alcohol consumption / / 23953852 rs6738420 chr2 159785940 T C 5.79E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6725288 chr2 159787453 C T 2.70E-04 Multiple complex diseases / / 17554300 rs1719079 chr2 159841372 G A 8.14E-04 Amyotrophic Lateral Sclerosis TANC1 intron 17362836 rs1719079 chr2 159841372 G A 7.37E-05 Coronary heart disease TANC1 intron pha003030 rs10497203 chr2 159851423 A C 8.84E-11 Response to radiotherapy in prostate cancer (toxicity) TANC1 intron 24974847 rs16843534 chr2 159851549 G A 7.43E-04 Alzheimer's disease TANC1 intron 22005930 rs16843536 chr2 159857642 A G 7.82E-04 Alzheimer's disease TANC1 UTR-5 22005930 rs6735689 chr2 159870038 C T 7.25E-04 Alzheimer's disease TANC1 intron 22005930 rs264607 chr2 159888711 G A 7.53E-05 Body mass (lean) TANC1 intron 19268274 rs7582141 chr2 159899489 G T 5.00E-11 Response to radiotherapy in prostate cancer (toxicity) TANC1 intron 24974847 rs6432512 chr2 159899913 C T 1.97E-10 Response to radiotherapy in prostate cancer (toxicity) TANC1 intron 24974847 rs16843641 chr2 159918378 T C 1.28E-09 Gallstones TANC1 intron 17632509 rs264588 chr2 159936391 C A 3.08E-10 Response to radiotherapy in prostate cancer (toxicity) TANC1 intron 24974847 rs264631 chr2 159950865 C G 6.40E-10 Response to radiotherapy in prostate cancer (toxicity) TANC1 intron 24974847 rs13414916 chr2 159954420 C T 3.78E-04 Type 2 diabetes TANC1 intron 17463246 rs10198413 chr2 159955575 C T 3.86E-04 Type 2 diabetes TANC1 intron 17463246 rs171935 chr2 159956520 C T 3.26E-05 Waist Circumference TANC1 intron pha003023 rs264591 chr2 159975516 T C 9.48E-04 Lymphocyte counts TANC1 intron 22286170 rs4665026 chr2 159984702 G A 2.00E-05 Urinary metabolites TANC1 intron 21572414 rs6754934 chr2 159990664 G A 2.19E-04 Age-related macular degeneration TANC1 intron 22125219 rs1421385 chr2 159994048 G A 1.52E-05 Response to hepatitis C treatment TANC1 intron 19684573 rs3796105 chr2 160025639 A C 7.14E-04 Response to taxane treatment (placlitaxel) TANC1 intron 23006423 rs17494000 chr2 160041993 C T 1.30E-05 Urinary metabolites TANC1 intron 21572414 rs12617786 chr2 160047009 G A 8.27E-04 Suicide attempts in bipolar disorder TANC1 intron 21041247 rs6432515 chr2 160054932 G A 3.63E-04 Myopia (pathological) TANC1 intron 21095009 rs6754390 chr2 160061217 G C 1.00E-06 Urinary metabolites TANC1 intron 21572414 rs4233678 chr2 160061429 A G 9.22E-04 Type 2 diabetes TANC1 intron 17463246 rs13022357 chr2 160069756 A G 1.00E-06 Sudden cardiac arrest TANC1 intron 21658281 rs3815475 chr2 160114315 G A 8.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WDSUB1 cds-synon 20877124 rs10490001 chr2 160139048 C T 7.28E-04 Tourette syndrome WDSUB1 intron 22889924 rs174244 chr2 160164187 A C 3.92E-04 Alzheimer's disease (late onset) / / 21379329 rs174240 chr2 160164716 C T 8.36E-05 Alzheimer's disease (late onset) / / 21379329 rs174230 chr2 160175310 T C 2.98E-07 Sudden cardiac arrest / / 21738491 rs4665058 chr2 160190209 A C 2.00E-10 Sudden cardiac arrest BAZ2B intron 21738491 rs11884022 chr2 160201955 T C 3.74E-04 Alzheimer's disease (late onset) BAZ2B intron 21379329 rs3771684 chr2 160202268 C T 0.00000871 Antisocial behavior BAZ2B intron 23077488 rs1011770 chr2 160238718 A G 1.25E-07 Gallstones BAZ2B intron 17632509 rs11690975 chr2 160247739 T C 2.75E-04 Multiple complex diseases BAZ2B intron 17554300 rs7585587 chr2 160251665 C T 4.35E-04 Multiple complex diseases BAZ2B intron 17554300 rs3755436 chr2 160282783 A G 0.000644 Height (Pygmy height) BAZ2B intron 22570615 rs3755437 chr2 160282976 C T 0.000644 Height (Pygmy height) BAZ2B intron 22570615 rs10207442 chr2 160285473 T C 2.66E-04 Fibrinogen BAZ2B intron 17255346 rs10187471 chr2 160289911 A G 7.40E-05 HIV-1 control BAZ2B intron 20041166 rs13417010 chr2 160295732 C T 7.40E-05 HIV-1 control BAZ2B intron 20041166 rs10202670 chr2 160310246 A G 7.80E-05 HIV-1 control BAZ2B missense 20041166 rs918970 chr2 160340922 A C 3.10E-27 Health and aging,CVD and cancer age of onset BAZ2B intron 22174011 rs918970 chr2 160340922 A C 3.90E-15 Health and aging,CVD and cancer age of onset BAZ2B intron 22174011 rs918970 chr2 160340922 A C 4.10E-33 Health and aging,CVD and cancer age of onset BAZ2B intron 22174011 rs918970 chr2 160340922 A C 5.30E-09 Health and aging,CVD and cancer age of onset BAZ2B intron 22174011 rs4665075 chr2 160343075 A C 8.59E-04 Multiple complex diseases BAZ2B intron 17554300 rs4665077 chr2 160402769 G A 3.24E-04 Smoking initiation BAZ2B intron 24665060 rs10489997 chr2 160405498 C T 1.94E-04 Response to gemcitabine in pancreatic cancer BAZ2B intron 22142827 rs1549386 chr2 160414526 C A 2.18E-04 Smoking initiation BAZ2B intron 24665060 rs2113861 chr2 160441744 T C 9.60E-04 Type 2 diabetes BAZ2B intron 17463246 rs12991516 chr2 160442065 G A 4.41E-04 Type 2 diabetes BAZ2B intron 17463246 rs357027 chr2 160491675 T C 1.35E-04 Multiple complex diseases / / 17554300 rs12466258 chr2 160514481 G A 5.84E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17814581 chr2 160616232 A G 6.02E-04 Smoking initiation MARCH7 intron 24665060 rs17815029 chr2 160626898 T C 5.55E-04 Smoking initiation CD302 UTR-3 24665060 rs3771720 chr2 160630922 C T 5.16E-05 Multiple complex diseases CD302 intron 17554300 rs1896270 chr2 160658739 T G 4.85E-05 Cognitive impairment induced by topiramate LY75-CD302 intron 22091778 rs13307 chr2 160659996 G A 6.89E-04 Smoking initiation LY75 UTR-3 24665060 rs12463589 chr2 160663435 T C 2.64E-04 Smoking initiation LY75 intron 24665060 rs2114630 chr2 160664459 A G 6.63E-05 Cognitive impairment induced by topiramate LY75 intron 22091778 rs2556088 chr2 160664907 T G 9.51E-04 Response to alcohol consumption (flushing response) LY75 intron 24277619 rs2556086 chr2 160708446 C A 2.98E-04 Multiple complex diseases LY75 intron 17554300 rs2357691 chr2 160725139 C T 8.10E-04 Multiple complex diseases LY75 intron 17554300 rs12692570 chr2 160726599 G A 6.08E-05 Bipolar disorder LY75 intron 22925353 rs2292387 chr2 160734722 C T 3.23E-04 Multiple complex diseases LY75 intron 17554300 rs2292388 chr2 160735008 C T 2.17E-04 Multiple complex diseases LY75 intron 17554300 rs1511224 chr2 160750861 T C 2.70E-04 Multiple complex diseases LY75 intron 17554300 rs1511224 chr2 160750861 T C 4.54E-05 Bipolar disorder LY75 intron 22925353 rs16844494 chr2 160770425 G A 1.24E-04 Multiple complex diseases / / 17554300 rs6715456 chr2 160773499 C T 1.66E-04 Multiple complex diseases / / 17554300 rs7566824 chr2 160790774 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs769369 chr2 160795256 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs3828322 chr2 160807597 A T 1.25E-04 Multiple complex diseases PLA2R1 intron 17554300 rs6432570 chr2 160808314 T C 8.74E-04 Multiple complex diseases PLA2R1 intron 17554300 rs12692578 chr2 160829503 T C 4.45E-05 Cognitive impairment induced by topiramate PLA2R1 intron 22091778 rs3828324 chr2 160834991 T C 7.46E-04 Multiple complex diseases PLA2R1 intron 17554300 rs3828324 chr2 160834991 T C 2.24E-04 Smoking initiation PLA2R1 intron 24665060 rs979129 chr2 160840151 T A,C,G 2.53E-04 Smoking initiation PLA2R1 intron 24665060 rs12692579 chr2 160841139 G A 4.02E-04 Multiple complex diseases PLA2R1 intron 17554300 rs1546512 chr2 160841307 C T 1.74E-05 Intelligence PLA2R1 intron 21826061 rs6757188 chr2 160843623 T C 3.01E-04 Multiple complex diseases PLA2R1 intron 17554300 rs3792167 chr2 160845582 G C 7.62E-04 Multiple complex diseases PLA2R1 intron 17554300 rs3792168 chr2 160846472 T C 4.93E-04 Smoking initiation PLA2R1 intron 24665060 rs1397712 chr2 160866165 C A 5.48E-05 Type 2 diabetes PLA2R1 intron 17463246 rs2667011 chr2 160867059 G A 3.34E-14 Bilirubin levels,in serum PLA2R1 intron 20639394 rs2667012 chr2 160867553 C A 2.34E-04 Multiple complex diseases PLA2R1 intron 17554300 rs2666997 chr2 160876151 G A 8.33E-04 Multiple complex diseases PLA2R1 intron 17554300 rs17830558 chr2 160878364 T G 4.80E-04 Breast cancer (survival) PLA2R1 intron 22232737 rs3792185 chr2 160878783 T G 5.96E-04 Multiple complex diseases PLA2R1 intron 17554300 rs3749117 chr2 160885442 T C 1.00E-04 Information processing speed PLA2R1 missense 21130836 rs3749117 chr2 160885442 T C 1.70E-05 Waist-Hip Ratio PLA2R1 missense pha003029 rs3792189 chr2 160885872 C A 7.17E-05 Serum metabolites PLA2R1 intron 19043545 rs3792189 chr2 160885872 C A 7.15E-05 Waist-Hip Ratio PLA2R1 intron pha003029 rs3792192 chr2 160886875 G A 9.47E-05 Information processing speed PLA2R1 intron 21130836 rs3792192 chr2 160886875 G A 3.59E-05 Waist-Hip Ratio PLA2R1 intron pha003029 rs17241282 chr2 160891009 T C 8.97E-05 Information processing speed PLA2R1 intron 21130836 rs6722275 chr2 160893260 C T 1.85E-05 Waist-Hip Ratio PLA2R1 intron pha003029 rs10929965 chr2 160906931 A G 9.47E-04 Type 2 diabetes PLA2R1 intron 17463246 rs2715928 chr2 160913599 A G 8.79E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PLA2R1 intron 20031582 rs2667033 chr2 160913693 A G 1.48E-04 Stroke PLA2R1 intron pha002887 rs16844715 chr2 160915106 C T 4.26E-04 Type 2 diabetes PLA2R1 intron 17463246 rs4664308 chr2 160917497 A G 9.00E-29 Nephropathy (idiopathic membranous) PLA2R1 intron 21323541 rs2667026 chr2 160921555 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs13403826 chr2 160963372 T C 1.69E-05 Cognitive impairment induced by topiramate ITGB6 intron 22091778 rs10497212 chr2 160964700 T G 7.70E-04 Crohn's disease ITGB6 intron 17684544 rs6432593 chr2 160965146 G A 3.40E-04 Stroke ITGB6 intron pha002887 rs6432594 chr2 160965335 A G 2.94E-05 Cognitive impairment induced by topiramate ITGB6 intron 22091778 rs6729540 chr2 160965347 G C 9.85E-04 Type 2 diabetes ITGB6 intron 17463246 rs7583743 chr2 160983889 A G 7.65E-04 Type 2 diabetes ITGB6 intron 17463246 rs7569555 chr2 160987608 G T 8.31E-04 Type 2 diabetes ITGB6 intron 17463246 rs6432603 chr2 161000343 T C 6.92E-04 Type 2 diabetes ITGB6 intron 17463246 rs983916 chr2 161015066 T G 1.00E-04 Information processing speed ITGB6 intron 21130836 rs2925763 chr2 161016776 A C 3.09E-04 Type 2 diabetes ITGB6 intron 17463246 rs2305818 chr2 161029218 G A 8.80E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ITGB6 cds-synon 20031582 rs2925758 chr2 161071031 G A 7.66E-04 Type 2 diabetes / / 17463246 rs10205184 chr2 161074672 T C 4.53E-05 Cognitive test performance / / 20125193 rs17242280 chr2 161080519 T C 9.28E-04 Type 2 diabetes / / 17463246 rs10181181 chr2 161087411 T C 1.57E-06 Type 2 diabetes / / 20418489 rs2925757 chr2 161101169 G A 2.10E-04 Crohn's disease / / 17684544 rs2925757 chr2 161101169 G A 7.94E-08 Type 2 diabetes / / 20418489 rs10170600 chr2 161118687 T C 8.38E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs3772070 chr2 161133471 T C 3.20E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) RBMS1 intron 23648065 rs7572970 chr2 161136656 A G 3.26E-05 Multiple complex diseases RBMS1 intron 17554300 rs7572970 chr2 161136656 A G 2.61E-07 Type 2 diabetes RBMS1 intron 20418489 rs1020731 chr2 161144055 G A 9.42E-05 Multiple complex diseases RBMS1 intron 17554300 rs1020731 chr2 161144055 G A 9.44E-08 Type 2 diabetes RBMS1 intron 20418489 rs1020732 chr2 161144239 G A 2.18E-04 Multiple complex diseases RBMS1 intron 17554300 rs12692590 chr2 161153197 C G 3.19E-04 Multiple complex diseases RBMS1 intron 17554300 rs12692592 chr2 161163381 G T 1.03E-06 Multiple complex diseases RBMS1 intron 17554300 rs12692592 chr2 161163381 G T 1.01E-07 Type 2 diabetes RBMS1 intron 20418489 rs4077463 chr2 161166234 A G 7.17E-07 Multiple complex diseases RBMS1 intron 17554300 rs4077463 chr2 161166234 A G 6.41E-08 Type 2 diabetes RBMS1 intron 20418489 rs4077463 chr2 161166234 A G 6.55E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) RBMS1 intron 23648065 rs7593730 chr2 161171454 T C 2.02E-07 Multiple complex diseases RBMS1 intron 17554300 rs7593730 chr2 161171454 T C 4.00E-08 Type 2 diabetes RBMS1 intron 20418489 rs7593730 chr2 161171454 T C 4.00E-08 Type 2 diabetes RBMS1 intron 21647700 rs7593730 chr2 161171454 T C 0.0000015 Type 2 diabetes RBMS1 intron 22885922 rs7593730 chr2 161171454 T C 4.70E-04 Type 2 diabetes RBMS1 intron 24509480 rs4589705 chr2 161176136 T A 9.85E-04 Type 2 diabetes RBMS1 intron 17463246 rs4589705 chr2 161176136 T A 3.66E-07 Multiple complex diseases RBMS1 intron 17554300 rs4589705 chr2 161176136 T A 7.24E-08 Type 2 diabetes RBMS1 intron 20418489 rs4664013 chr2 161184164 G C 2.47E-04 Multiple complex diseases RBMS1 intron 17554300 rs4410242 chr2 161192070 A G 6.55E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) RBMS1 intron 23648065 rs10165319 chr2 161192805 T C 1.62E-04 Multiple complex diseases RBMS1 intron 17554300 rs7425274 chr2 161203395 T C 8.18E-04 Depression (quantitative trait) RBMS1 intron 20800221 rs7425274 chr2 161203395 T C 5.23E-04 Taste perception RBMS1 intron 22132133 rs9287795 chr2 161209788 C G 5.56E-07 Multiple complex diseases RBMS1 intron 17554300 rs6718526 chr2 161214175 T C 2.40E-06 Type 2 diabetes RBMS1 intron 17463249 rs6718526 chr2 161214175 T C 4.43E-07 Multiple complex diseases RBMS1 intron 17554300 rs6718526 chr2 161214175 T C 2.10E-04 Coronary heart disease RBMS1 intron 21966275 rs6718526 chr2 161214175 T C 2.02E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) RBMS1 intron 23648065 rs6755940 chr2 161220126 A C 4.22E-04 Tourette syndrome RBMS1 intron 22889924 rs11693602 chr2 161224658 C T 4.00E-07 Multiple complex diseases RBMS1 intron 17554300 rs10929982 chr2 161236277 C T 9.84E-07 Multiple complex diseases RBMS1 intron 17554300 rs12998587 chr2 161242295 T C 7.21E-04 Multiple complex diseases RBMS1 intron 17554300 rs4664323 chr2 161259685 C T 2.97E-04 Cholesterol RBMS1 intron 17255346 rs7423892 chr2 161329644 C T 3.91E-04 Parkinson's disease RBMS1 intron 17052657 rs10178094 chr2 161336406 C A 5.99E-04 Parkinson's disease RBMS1 intron 17052657 rs7569522 chr2 161346447 A G 3.01E-05 Multiple complex diseases RBMS1 intron 17554300 rs7569522 chr2 161346447 A G 0.000041 Type 2 diabetes RBMS1 intron 22885922 rs7569522 chr2 161346447 A G 0.000095 Type 2 diabetes (females) RBMS1 intron 22885922 rs10192369 chr2 161380888 G A 9.00E-06 Amyotrophic lateral sclerosis / / 19451621 rs13382644 chr2 161386729 G A 2.10E-04 Alcohol dependence / / 20201924 rs6432628 chr2 161395188 C T 9.10E-05 Alcohol dependence / / 20201924 rs6432628 chr2 161395188 C T 9.13E-05 Alcoholism / / pha002892 rs7598938 chr2 161406793 C T 5.00E-04 Alcohol dependence / / 20201924 rs13034284 chr2 161409559 C T 1.80E-05 Alcohol dependence / / 20201924 rs13034284 chr2 161409559 C T 1.85E-05 Alcoholism / / pha002892 rs4622746 chr2 161409668 C G 4.37E-04 Multiple complex diseases / / 17554300 rs13410476 chr2 161410542 G A 1.20E-04 Alcohol dependence / / 20201924 rs9967749 chr2 161420179 A G 8.10E-05 Alcohol dependence / / 20201924 rs9967749 chr2 161420179 A G 8.13E-05 Alcoholism / / pha002892 rs11681327 chr2 161424684 A G 4.80E-05 Alcohol dependence / / 20201924 rs11681327 chr2 161424684 A G 4.77E-05 Alcoholism / / pha002892 rs4420713 chr2 161425657 G C 2.39E-04 Insulin resistance / / 21901158 rs7603576 chr2 161431604 A G 4.70E-05 Alcohol dependence / / 20201924 rs7603576 chr2 161431604 A G 4.65E-05 Alcoholism / / pha002892 rs13010247 chr2 161432066 T C 2.83E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4533480 chr2 161437980 A G 8.75E-04 Cocaine dependence / / 23958962 rs13408402 chr2 161509693 G A 2.35E-04 Tourette syndrome / / 22889924 rs4664354 chr2 161544316 G T 9.84E-05 Post-operative nausea and vomiting / / 21694509 rs4664354 chr2 161544316 G T 1.59E-05 Coronary heart disease / / pha003056 rs6718138 chr2 161555610 T C 9.39E-04 Stroke / / pha002886 rs7608578 chr2 161573231 A C 4.03E-06 Post-operative nausea and vomiting / / 21694509 rs10497216 chr2 161588479 A T 1.98E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1480577 chr2 161598210 C A 3.36E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs1480577 chr2 161598210 C A 3.25E-05 Coronary heart disease / / pha003056 rs4664366 chr2 161600547 A G 1.62E-05 Coronary heart disease / / pha003056 rs17220405 chr2 161608769 C T 4.90E-04 Alcohol dependence / / 20201924 rs558692 chr2 161667127 C A 8.90E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs270981 chr2 161684107 A G 7.21E-04 Multiple complex diseases / / 17554300 rs555332203 chr2 161686114 TG T 3.57E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs6720147 chr2 161686114 T A 3.57E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs16845258 chr2 161722879 G C 7.67E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs12052592 chr2 161724866 A G 3.68E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs270952 chr2 161727711 T G 8.20E-05 Cognitive function / / 24684796 rs13403103 chr2 161739579 C T 4.92E-05 Tourette syndrome / / 22889924 rs10208407 chr2 161757129 G A 2.00E-06 Obesity-related traits / / 23251661 rs13406739 chr2 161770575 G A 9.15E-05 Relative hand skill / / 24068947 rs12470772 chr2 161775489 C T 1.78E-07 Post-operative nausea and vomiting / / 21694509 rs12470772 chr2 161775489 C T 4.40E-05 Kawasaki disease / / 22446962 rs13015721 chr2 161776405 T C 3.02E-05 Post-operative nausea and vomiting / / 21694509 rs1722636 chr2 161781773 C T 6.00E-07 Subcutaneous adipose tissue / / 22589738 rs1829975 chr2 161785169 C T 6.00E-06 Treatment response for severe sepsis / / 22310353 rs10208511 chr2 161863052 A G 2.34E-04 Depression (quantitative trait) / / 20800221 rs4664393 chr2 161884425 T A 3.11E-04 Alzheimer's disease / / 22005930 rs16845445 chr2 161885696 A G 2.92E-04 Alzheimer's disease / / 22005930 rs7422349 chr2 161885827 C T 3.07E-04 Alzheimer's disease / / 22005930 rs2884354 chr2 161885862 G A 3.07E-04 Alzheimer's disease / / 22005930 rs7425907 chr2 161885981 A C 3.07E-04 Alzheimer's disease / / 22005930 rs2357982 chr2 161886103 C G 3.11E-04 Alzheimer's disease / / 22005930 rs2357982 chr2 161886103 C G 3.00E-06 Presence of antiphospholipid antibodies / / 23509613 rs2674942 chr2 161888612 C T 3.26E-04 Alzheimer's disease / / 22005930 rs2674943 chr2 161888650 A G 3.27E-04 Alzheimer's disease / / 22005930 rs2674944 chr2 161889038 G A 3.28E-04 Alzheimer's disease / / 22005930 rs2551691 chr2 161889193 T C 3.14E-04 Alzheimer's disease / / 22005930 rs2551691 chr2 161889193 T C 0.00000295 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2551691 chr2 161889193 T C 9.03E-05 Breast cancer / / pha002853 rs2551688 chr2 161890305 T C 3.25E-04 Alzheimer's disease / / 22005930 rs2551689 chr2 161891144 G T 3.22E-04 Alzheimer's disease / / 22005930 rs2113521 chr2 161891928 A T 1.99E-04 Alzheimer's disease / / 22005930 rs2113523 chr2 161892055 G C 3.20E-04 Alzheimer's disease / / 22005930 rs197271 chr2 161893148 C G 3.18E-04 Alzheimer's disease / / 22005930 rs197272 chr2 161894556 G T 2.47E-04 Alzheimer's disease / / 22005930 rs197273 chr2 161894663 A G 1.00E-07 Dietary macronutrient intake / / 23372041 rs197275 chr2 161896152 T C 2.65E-04 Alzheimer's disease / / 22005930 rs197275 chr2 161896152 T C 0.0000122 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs197275 chr2 161896152 T C 4.42E-05 Breast cancer / / pha002853 rs197276 chr2 161897009 A T 3.11E-04 Alzheimer's disease / / 22005930 rs197277 chr2 161897159 T A,C 2.89E-04 Alzheimer's disease / / 22005930 rs4664396 chr2 161901650 A G 4.00E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4664397 chr2 161901948 G A 3.32E-05 Cortisol secretion,in saliva / / 21316860 rs197265 chr2 161902484 G A 3.97E-04 Alzheimer's disease / / 22005930 rs197265 chr2 161902484 G A 0.000000823 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs197264 chr2 161903399 T C 7.37E-04 Alzheimer's disease / / 22005930 rs197260 chr2 161905151 G T 8.56E-04 Alzheimer's disease / / 22005930 rs197266 chr2 161905590 G C 9.42E-04 Alzheimer's disease / / 22005930 rs197269 chr2 161908132 A C 9.18E-04 Alzheimer's disease / / 22005930 rs197270 chr2 161908442 T C 9.58E-04 Alzheimer's disease / / 22005930 rs13399728 chr2 161909369 A G 9.53E-04 Alzheimer's disease / / 22005930 rs10803775 chr2 161912187 A T 9.67E-04 Alzheimer's disease / / 22005930 rs9287806 chr2 161913992 G A 9.74E-04 Alzheimer's disease / / 22005930 rs9287806 chr2 161913992 G A 0.0000175 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2216847 chr2 161914280 T G 0.00000422 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs889922 chr2 161917192 C T 0.0000215 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1025105 chr2 161922656 A G 0.0000238 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6432670 chr2 161938839 T C 9.90E-04 Alzheimer's disease / / 22005930 rs6432670 chr2 161938839 T C 0.0000954 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7564141 chr2 161943290 T C 0.0000706 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7591506 chr2 161960925 T G 6.74E-04 Parkinson's disease / / 17052657 rs7591506 chr2 161960925 T G 9.81E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2194505 chr2 161963254 C T 0.0000706 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10221957 chr2 161971984 T G 2.20E-05 Tourette syndrome / / 22889924 rs1267070 chr2 161988483 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7568498 chr2 162029113 T G 2.00E-08 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) TANK intron 24554482 rs889916 chr2 162032662 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes TANK intron 22628534 rs10183710 chr2 162057981 C T 6.27E-05 Tourette syndrome TANK intron 22889924 rs1267075 chr2 162059817 G A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes TANK intron 22628534 rs7309 chr2 162092640 G A 5.58E-04 Parkinson's disease TANK UTR-3 17052657 rs7309 chr2 162092640 G A 4.00E-08 Educational attainment TANK UTR-3 23722424 rs1267043 chr2 162125294 A C 3.01E-05 Coronary heart disease / / pha003030 rs2113480 chr2 162186610 T C 6.18E-05 Suicide attempts in bipolar disorder PSMD14 intron 21423239 rs1559496 chr2 162215094 C G 3.73E-04 Multiple complex diseases PSMD14 intron 17554300 rs1116173 chr2 162226838 A G 7.34E-05 Suicide attempts in bipolar disorder PSMD14 intron 21423239 rs3769959 chr2 162249206 A G 1.89E-05 Multiple complex diseases PSMD14 intron 17554300 rs2216941 chr2 162258705 T A 9.75E-04 Multiple complex diseases PSMD14 intron 17554300 rs1110587 chr2 162264277 T C 1.22E-05 Coronary heart disease PSMD14 intron pha003030 rs13432654 chr2 162300286 A G 4.35E-05 Information processing speed / / 21130836 rs6432689 chr2 162379760 C T 8.22E-05 Coronary heart disease / / pha003030 rs2020027 chr2 162425878 G A 1.10E-05 Urinary metabolites / / 21572414 rs2389549 chr2 162462209 T C 5.50E-06 Urinary metabolites / / 21572414 rs1567420 chr2 162475601 T C 4.70E-06 Urinary metabolites / / 21572414 rs1567421 chr2 162475617 G T 4.70E-06 Urinary metabolites / / 21572414 rs16846050 chr2 162563553 G A 1.30E-05 Urinary metabolites SLC4A10 intron 21572414 rs12476631 chr2 162566936 T C 1.10E-05 Urinary metabolites SLC4A10 intron 21572414 rs16846073 chr2 162586548 C G 7.80E-06 Urinary metabolites SLC4A10 intron 21572414 rs7581747 chr2 162615115 T C 7.00E-07 Urinary metabolites SLC4A10 intron 21572414 rs13022437 chr2 162622285 G A 1.80E-06 Urinary metabolites SLC4A10 intron 21572414 rs9636284 chr2 162680512 C T 2.61E-05 Hypertension SLC4A10 intron 21082022 rs2084543 chr2 162696414 C T 6.47E-06 Hypertension SLC4A10 cds-synon 21082022 rs16846179 chr2 162749056 T G 2.14E-05 Hypertension SLC4A10 intron 21082022 rs16846221 chr2 162820220 G T 4.90E-04 Alcohol dependence SLC4A10 intron 20201924 rs12986853 chr2 162825174 C T 2.72E-04 Smoking initiation SLC4A10 intron 24665060 rs12617656 chr2 162851147 T C 1.00E-08 Rheumatoid arthritis DPP4 intron 24782177 rs12617656 chr2 162851147 T C 2.00E-21 Rheumatoid arthritis DPP4 intron 24782177 rs2970933 chr2 162854276 T C 4.00E-06 Dietary macronutrient intake DPP4 intron 23372041 rs2909448 chr2 162866255 C T 0.0000414 LDL cholesterol DPP4 intron 23063622 rs2268888 chr2 162885450 C T 7.90E-04 Alcohol dependence DPP4 intron 20201924 rs6741949 chr2 162910223 G C 3.00E-07 Hippocampal volume DPP4 intron 22504421 rs10490422 chr2 162916413 G T 1.19E-04 Coronary Artery Disease DPP4 intron 17634449 rs10490422 chr2 162916413 G T 5.92E-18 Gallbladder disease DPP4 intron pha001404 rs2300753 chr2 162928465 C A 1.99E-04 Response to cholinesterase inhibitors in Alzheimer's disease DPP4 intron 23374588 rs2270447 chr2 162959748 T C 8.00E-07 Common traits (Other) / / 20585627 rs2160711 chr2 162977965 A G 7.16E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2111485 chr2 163110536 A G 5.00E-15 Vitiligo / / 22561518 rs2111485 chr2 163110536 A G 2.00E-08 Inflammatory bowel disease / / 23128233 rs2111485 chr2 163110536 A G 0.000833548 Primary sclerosing cholangitis / / 23603763 rs1990760 chr2 163124051 C T 2.00E-11 Type 1 diabetes IFIH1 missense 17554260 rs1990760 chr2 163124051 C T 7.00E-09 Type 1 diabetes IFIH1 missense 19430480 rs1990760 chr2 163124051 C T 7.00E-10 Immunoglobulin A IFIH1 missense 20694011 rs1990760 chr2 163124051 C T 2.00E-14 Type 1 diabetes autoantibodies IFIH1 missense 21829393 rs1990760 chr2 163124051 C T 2.21E-08 Type 1 diabetes IFIH1 missense 21980299 rs1990760 chr2 163124051 C T 2.00E-11 Multiple sclerosis IFIH1 missense 22190364 rs1990760 chr2 163124051 C T 2.55E-04 Vitiligo IFIH1 missense 22561518 rs3747517 chr2 163128824 T C 2.34E-05 Multiple complex diseases IFIH1 missense 17554300 rs10930046 chr2 163137983 T C 4.68E-05 Neuroticism IFIH1 missense 23229837 rs3788964 chr2 163207480 T C 3.03E-04 Nicotine smoking GCA intron 19268276 rs3788964 chr2 163207480 T C 1.46E-05 Fibrinogen GCA intron pha003068 rs16846675 chr2 163260410 A G 5.31E-04 Multiple complex diseases KCNH7 intron 17554300 rs17716942 chr2 163260691 T C 1.00E-13 Psoriasis KCNH7 intron 20953190 rs17716942 chr2 163260691 T C 3.30E-18 Psoriasis KCNH7 intron 23143594 rs12464272 chr2 163305723 T A 8.32E-04 Obesity (extreme) KCNH7 intron 21935397 rs6734436 chr2 163311202 T C 8.12E-04 Obesity (extreme) KCNH7 intron 21935397 rs16846727 chr2 163316843 G A 8.10E-04 Obesity (extreme) KCNH7 intron 21935397 rs16846732 chr2 163319131 T A 7.08E-04 Obesity (extreme) KCNH7 intron 21935397 rs13403568 chr2 163320513 C G 4.92E-04 Multiple complex diseases KCNH7 intron 17554300 rs16846743 chr2 163321014 C T 6.88E-04 Obesity (extreme) KCNH7 intron 21935397 rs6758303 chr2 163325803 G C 5.97E-04 Obesity (extreme) KCNH7 intron 21935397 rs7594587 chr2 163330094 A T 5.56E-04 Obesity (extreme) KCNH7 intron 21935397 rs6715546 chr2 163331395 T G 5.55E-04 Obesity (extreme) KCNH7 intron 21935397 rs985621 chr2 163339633 G A 5.48E-04 Obesity (extreme) KCNH7 intron 21935397 rs1485978 chr2 163345284 G A 4.80E-04 Obesity (extreme) KCNH7 intron 21935397 rs12052788 chr2 163346563 T C 3.65E-04 Obesity (extreme) KCNH7 intron 21935397 rs1352070 chr2 163357883 A G 4.71E-04 Obesity (extreme) KCNH7 intron 21935397 rs1026992 chr2 163368279 C T 3.66E-05 Multiple complex diseases KCNH7 intron 17554300 rs16846856 chr2 163396985 T C 6.80E-06 Urinary metabolites KCNH7 intron 21572414 rs13422156 chr2 163397521 T G 2.30E-05 Urinary metabolites KCNH7 intron 21572414 rs12471221 chr2 163401685 G A 6.90E-06 Urinary metabolites KCNH7 intron 21572414 rs11884875 chr2 163403303 A G 7.10E-06 Urinary metabolites KCNH7 intron 21572414 rs901303 chr2 163416447 G A 4.28E-04 Obesity (extreme) KCNH7 intron 21935397 rs10439292 chr2 163417299 G A 9.58E-05 Atopic dermatitis KCNH7 intron 23042114 rs17401811 chr2 163420104 A T 5.62E-05 Atopic dermatitis KCNH7 intron 23042114 rs13002126 chr2 163420361 T C 6.14E-05 Atopic dermatitis KCNH7 intron 23042114 rs1843553 chr2 163420535 C T 6.16E-05 Atopic dermatitis KCNH7 intron 23042114 rs10497226 chr2 163421016 G C 6.18E-05 Atopic dermatitis KCNH7 intron 23042114 rs13403935 chr2 163422403 T C 8.55E-05 Atopic dermatitis KCNH7 intron 23042114 rs10930065 chr2 163558854 C T 1.51E-05 Multiple complex diseases KCNH7 intron 17554300 rs10168953 chr2 163604529 A C 8.51E-05 Orofacial clefts KCNH7 intron 22419666 rs1434996 chr2 163625587 A G 1.00E-04 Cognitive impairment induced by topiramate KCNH7 intron 22091778 rs1017406 chr2 163643407 C A 2.70E-05 Urinary metabolites KCNH7 intron 21572414 rs184270 chr2 163710934 A T 9.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs4461275 chr2 163732409 C T 1.40E-06 Urinary metabolites / / 21572414 rs10203602 chr2 163734130 T C 1.10E-06 Urinary metabolites / / 21572414 rs10451557 chr2 163739071 C T 5.96E-04 Rheumatoid arthritis / / 21452313 rs1364562 chr2 163741726 T C 9.20E-07 Urinary metabolites / / 21572414 rs307869 chr2 163761591 T A 1.70E-06 Urinary metabolites / / 21572414 rs1424760 chr2 163781787 C T 4.00E-08 Phospholipid levels (plasma) / / 22359512 rs307861 chr2 163782427 T G 6.27E-04 Type 2 diabetes / / 17463246 rs1424762 chr2 163819564 C A 1.93E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs10930082 chr2 163820529 A G 2.40E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1834224 chr2 163821538 C T 2.42E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7585233 chr2 163821969 C T 2.45E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12692664 chr2 163822494 T A 4.20E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs201294656 chr2 163822494 T TAA 4.20E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6739611 chr2 163822855 G A 1.64E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2113698 chr2 163823516 G A 1.65E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1424763 chr2 163824857 A G 1.71E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1424764 chr2 163825082 C T 1.73E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6756025 chr2 163827128 C A 3.31E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6432742 chr2 163838586 T C 9.95E-04 Type 2 diabetes / / 17463246 rs4390782 chr2 163865002 G A 0.000803 Salmonella-induced pyroptosis / / 22837397 rs918932 chr2 163894302 C T 5.08E-05 Osteoarthritis (knee and hip) / / 21177295 rs10178838 chr2 163895823 A G 3.22E-05 Type 2 diabetes / / 17463246 rs12471596 chr2 163904571 A G 8.17E-04 Multiple complex diseases / / 17554300 rs1546031 chr2 163918006 T C 4.60E-04 Multiple complex diseases / / 17554300 rs16848037 chr2 163921145 A C 6.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs12468570 chr2 163943612 G T 1.72E-05 Type 2 diabetes / / 17463246 rs12692684 chr2 163966971 G A 6.80E-04 Multiple complex diseases / / 17554300 rs12692684 chr2 163966971 G A 3.42E-04 Bipolar disorder / / 18317468 rs35862965 chr2 163975466 AT A 3.39E-04 Multiple complex diseases / / 17554300 rs3956504 chr2 163975466 A C 3.39E-04 Multiple complex diseases / / 17554300 rs1586627 chr2 163977186 A G 5.62E-04 Multiple complex diseases / / 17554300 rs13400223 chr2 163990193 T C 2.05E-04 Multiple complex diseases / / 17554300 rs4575739 chr2 163992253 G T 4.11E-05 Type 2 diabetes / / 17463246 rs4462794 chr2 163993331 C T 1.43E-05 Type 2 diabetes / / 17463246 rs12477351 chr2 163997527 C T 1.02E-04 Type 2 diabetes / / 17463246 rs12465028 chr2 164041305 C T 9.20E-05 Type 2 diabetes / / 17463246 rs16848135 chr2 164041560 A G 8.80E-04 Type 2 diabetes / / 17463246 rs41423844 chr2 164047646 T A 7.92E-05 Type 2 diabetes / / 17463246 rs13389923 chr2 164048659 A G 8.17E-04 Myocardial Infarction / / pha002883 rs6730724 chr2 164068919 C G 7.80E-05 Type 2 diabetes / / 17463246 rs16848219 chr2 164104566 G A 2.97E-05 Multiple complex diseases / / 17554300 rs7559172 chr2 164145941 A G 8.94E-04 Type 2 diabetes / / 17463246 rs1221517 chr2 164173070 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1922092 chr2 164209580 C T 3.35E-04 Multiple complex diseases / / 17554300 rs16848321 chr2 164212164 T C 9.09E-05 Multiple complex diseases / / 17554300 rs16848323 chr2 164212362 A C 5.43E-04 Multiple complex diseases / / 17554300 rs4668300 chr2 164295936 C A 7.99E-05 Basophils / / pha003087 rs9287831 chr2 164300859 C T 1.76E-04 Gallstones / / 17632509 rs9287831 chr2 164300859 C T 4.59E-05 Basophils / / pha003087 rs12476047 chr2 164317876 T C 3.00E-06 Response to antipsychotic treatment / / 19680635 rs6732555 chr2 164330382 C T 9.31E-05 Basophils / / pha003087 rs7598913 chr2 164373280 A G 5.01E-04 Body mass index / / 21701565 rs10175821 chr2 164373852 G A 8.38E-04 Multiple complex diseases / / 17554300 rs13018106 chr2 164375202 G C 6.85E-04 Type 2 diabetes / / 17463246 rs13018106 chr2 164375202 G C 3.14E-04 Body mass index / / 21701565 rs6761831 chr2 164388639 G A 4.07E-04 Body mass index / / 21701565 rs1440465 chr2 164390510 A G 1.98E-04 Multiple complex diseases / / 17554300 rs2952065 chr2 164395131 A G 4.51E-04 Body mass index / / 21701565 rs2704357 chr2 164405728 T C 4.48E-04 Body mass index / / 21701565 rs16848648 chr2 164434950 A C 5.20E-06 Urinary metabolites / / 21572414 rs17806246 chr2 164435741 A C 4.30E-06 Urinary metabolites / / 21572414 rs12692697 chr2 164441947 A C 1.49E-04 Fibrinogen / / 17255346 rs12692700 chr2 164444305 T C 1.30E-05 Urinary metabolites / / 21572414 rs7572130 chr2 164460947 A G 2.03E-04 Type 2 diabetes / / 17463246 rs6731290 chr2 164488243 A G 1.80E-05 Urinary metabolites FIGN intron 21572414 rs982393 chr2 164490529 A T 8.00E-08 Folate pathway vitamin levels FIGN intron 19744961 rs16848743 chr2 164496367 T C 4.65E-04 Multiple complex diseases FIGN intron 17554300 rs1371827 chr2 164501773 C A,G 2.00E-05 Urinary metabolites FIGN intron 21572414 rs10177481 chr2 164506159 T C 1.40E-05 Urinary metabolites FIGN intron 21572414 rs1460665 chr2 164587447 A G 2.80E-05 Urinary metabolites FIGN intron 21572414 rs1460675 chr2 164600455 G A 1.60E-05 Urinary metabolites / / 21572414 rs10202492 chr2 164621524 A G 6.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16848941 chr2 164675913 T C 8.04E-05 Major depressive disorder / / 21621269 rs1370493 chr2 164701057 T C 6.64E-05 Tunica Media / / pha003034 rs12994524 chr2 164720199 C T 4.78E-05 Major depressive disorder / / 21621269 rs10930111 chr2 164725276 A C 8.24E-05 Major depressive disorder / / 21621269 rs10497248 chr2 164752462 T C 2.00E-05 Urinary metabolites / / 21572414 rs10184708 chr2 164768717 T C 8.66E-05 Major depressive disorder / / 21621269 rs768017 chr2 164791764 G C 4.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs165274 chr2 164830609 A G 9.85E-04 Type 2 diabetes / / 17463246 rs6724503 chr2 164884641 T C 2.76E-04 Smoking initiation / / 24665060 rs2176241 chr2 164885707 T G 7.59E-04 Depression (quantitative trait) / / 20800221 rs2176241 chr2 164885707 T G 3.66E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12624028 chr2 164891028 T C 7.01E-04 Smoking initiation / / 24665060 rs12692709 chr2 164894561 T C 5.75E-06 Major depressive disorder / / 21621269 rs16849225 chr2 164906820 C T 4.00E-11 Blood pressure / / 21572416 rs13002573 chr2 164915208 A G 2.00E-08 Blood pressure / / 21909110 rs393093 chr2 164926908 G A 3.30E-05 Major depressive disorder / / 22472876 rs12470735 chr2 164933379 T C 3.70E-04 Myocardial Infarction / / pha002873 rs268269 chr2 164941139 C A 6.47E-04 Smoking initiation / / 24665060 rs1446468 chr2 164963486 T C 6.00E-12 Blood pressure / / 21909110 rs13014943 chr2 164973229 T C 1.20E-04 Multiple complex diseases / / 17554300 rs12473215 chr2 164990257 T A 4.44E-05 Sarcoidosis / / 19165924 rs7601389 chr2 165002610 T G 9.23E-05 Cognitive impairment induced by topiramate / / 22091778 rs967184 chr2 165019579 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1446465 chr2 165035811 A C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1121308 chr2 165042064 T C 8.01E-04 Prostate cancer mortality / / 20978177 rs4667731 chr2 165047345 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs13027527 chr2 165078704 G A 7.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11891401 chr2 165086747 T A 2.00E-06 Blood pressure / / 24954895 rs13398947 chr2 165090463 C T 9.88E-05 Hemoglobin / / pha003096 rs13398947 chr2 165090463 C T 3.22E-05 Hematocrit / / pha003097 rs13000630 chr2 165093965 T G 8.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs375188791 chr2 165093965 T TAG 8.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4667736 chr2 165100379 A G 2.33E-06 Cognitive impairment induced by topiramate / / 22091778 rs4667736 chr2 165100379 A G 2.95E-05 Cognitive impairment induced by topiramate / / 22091778 rs9287843 chr2 165107298 C T 2.50E-06 Cognitive impairment induced by topiramate / / 22091778 rs9287843 chr2 165107298 C T 3.03E-05 Cognitive impairment induced by topiramate / / 22091778 rs16849404 chr2 165130868 G A 4.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2165094 chr2 165173034 A T 4.12E-06 Blood pressure / / 21909110 rs561673 chr2 165314131 T C 3.37E-04 Type 2 diabetes / / 17463246 rs12466514 chr2 165320390 T C 3.35E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1521526 chr2 165329726 A C 4.85E-05 Coronary Artery Disease / / 17634449 rs17353055 chr2 165334869 G A 3.32E-04 Coronary Artery Disease / / 17634449 rs670757 chr2 165352165 C T 7.31E-05 Erythrocyte counts GRB14 intron pha003099 rs671689 chr2 165352405 G A 8.21E-05 Erythrocyte counts GRB14 intron pha003099 rs570657 chr2 165356343 A G 3.52E-05 Major depressive disorder (broad) GRB14 intron 20038947 rs4667463 chr2 165358672 A G 3.52E-05 Major depressive disorder (broad) GRB14 intron 20038947 rs582447 chr2 165366592 A C 2.74E-05 Major depressive disorder (broad) GRB14 intron 20038947 rs17437781 chr2 165424837 A G 5.04E-05 Major depressive disorder (broad) GRB14 intron 20038947 rs1521527 chr2 165427825 G C 3.95E-05 Major depressive disorder (broad) GRB14 intron 20038947 rs11677541 chr2 165429235 G A,C,T 6.15E-05 Major depressive disorder (broad) GRB14 intron 20038947 rs1521522 chr2 165437544 C G 7.36E-05 Major depressive disorder (broad) GRB14 intron 20038947 rs4423615 chr2 165438230 G A 5.29E-05 Nicotine smoking GRB14 intron 19268276 rs4423615 chr2 165438230 G A 6.78E-05 Nicotine smoking GRB14 intron 19268276 rs4319945 chr2 165452742 C T 0.0000962 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity GRB14 intron 22945461 rs3923113 chr2 165501849 A C 1.00E-08 Type 2 diabetes / / 21874001 rs3923113 chr2 165501849 A C 1.80E-09 Type 2 diabetes (females) / / 22885922 rs3923113 chr2 165501849 A C 2.60E-10 Type 2 diabetes / / 22885922 rs3923113 chr2 165501849 A C 1.00E-08 Type 2 diabetes / / 23300278 rs3923113 chr2 165501849 A C 2.00E-06 Type 2 diabetes / / 24509480 rs12692735 chr2 165504565 G T 1.10E-06 Type 2 diabetes / / 21874001 rs10930133 chr2 165506724 T A 1.20E-06 Type 2 diabetes / / 21874001 rs6713419 chr2 165508300 T C 1.10E-06 Type 2 diabetes / / 21874001 rs10184004 chr2 165508389 C T 3.50E-06 Type 2 diabetes / / 21874001 rs7607886 chr2 165509579 G A 4.23E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs10179126 chr2 165511794 C G 1.50E-06 Type 2 diabetes / / 21874001 rs10195252 chr2 165513091 T C 2.00E-10 Triglycerides / / 20686565 rs10195252 chr2 165513091 T C 4.00E-34 Waist-hip ratio / / 20935629 rs10195252 chr2 165513091 T C 2.60E-06 Type 2 diabetes / / 21874001 rs10195252 chr2 165513091 T C 4.20E-13 Type 2 diabetes / / 22885922 rs10195252 chr2 165513091 T C 1.26E-16 Fasting insulin-related traits / / 22885924 rs7592412 chr2 165526338 T C 1.10E-06 Type 2 diabetes / / 21874001 rs13432797 chr2 165526587 G C 3.00E-06 Type 2 diabetes / / 21874001 rs1128249 chr2 165528624 G T 0.000000017 Type 2 diabetes / / 22885922 rs13389219 chr2 165528876 C T 3.60E-06 Type 2 diabetes / / 21874001 rs13389219 chr2 165528876 C T 0.0000002 HDL cholesterol / / 22885922 rs13389219 chr2 165528876 C T 0.000005 LDL cholesterol / / 22885922 rs13389219 chr2 165528876 C T 0.000034 Cholesterol,total / / 22885922 rs13389219 chr2 165528876 C T 0.00027 Fasting insulin-related traits / / 22885922 rs13389219 chr2 165528876 C T 1.10E-10 Type 2 diabetes / / 22885922 rs13389219 chr2 165528876 C T 3.10E-10 Triglycerides / / 22885922 rs13389219 chr2 165528876 C T 3.00E-08 Waist-hip ratio / / 23563607 rs13389219 chr2 165528876 C T 9.50E-05 Waist-hip ratio / / 23966867 rs6717858 chr2 165539661 T C 6.00E-16 Sexual dimorphism in anthropometric traits / / 23754948 rs12328675 chr2 165540800 T C 6.80E-05 Response to statin therapy / / 20339536 rs12328675 chr2 165540800 T C 3.00E-10 HDL cholesterol / / 20686565 rs12328675 chr2 165540800 T C 2.00E-15 HDL cholesterol / / 24097068 rs3769869 chr2 165543199 A G 1.43E-05 Lung function (forced expiratory volume in 1 second) COBLL1 intron pha003102 rs10490694 chr2 165548569 G A 4.78E-09 Lipid levels COBLL1 intron 19936222 rs10490694 chr2 165548569 G A 6.70E-05 Response to statin therapy COBLL1 intron 20339536 rs7607980 chr2 165551201 T C 4.00E-20 Fasting insulin-related traits (interaction with BMI) COBLL1 missense 22581228 rs150990193 chr2 165552167 T C 0.000021 Breast cancer(er negative) COBLL1 missense 23555315 rs3769870 chr2 165564484 A G 0.000462193 Hypertension (early onset hypertension) COBLL1 intron 22479346 rs3769871 chr2 165565319 C T 7.88E-04 Type 2 diabetes COBLL1 intron 17463246 rs3769872 chr2 165565548 C T 0.000536011 Hypertension (early onset hypertension) COBLL1 intron 22479346 rs10221833 chr2 165577164 G C 6.00E-06 Response to statin therapy COBLL1 intron 20339536 rs13410987 chr2 165580775 C T 1.60E-05 Response to statin therapy COBLL1 intron 20339536 rs369788854 chr2 165580775 CGTT C 1.60E-05 Response to statin therapy COBLL1 intron 20339536 rs1122004 chr2 165585585 C T 8.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COBLL1 intron 20877124 rs7574791 chr2 165590459 C T 1.43E-04 Stroke COBLL1 intron pha002887 rs10178921 chr2 165603512 T C 6.20E-05 Response to statin therapy COBLL1 intron 20339536 rs427059 chr2 165606954 T C 6.80E-05 Response to statin therapy COBLL1 intron 20339536 rs1509099 chr2 165628004 A C 2.10E-05 Urinary metabolites COBLL1 intron 21572414 rs355900 chr2 165638070 T C 8.65E-04 Amyotrophic Lateral Sclerosis COBLL1 intron 17362836 rs11691338 chr2 165640188 T G 2.60E-05 Urinary metabolites COBLL1 intron 21572414 rs718573 chr2 165652687 T C 9.76E-04 Schizophrenia (cytomegalovirus infection interaction) COBLL1 intron 23358160 rs10930136 chr2 165663986 T G 1.00E-06 Urinary metabolites COBLL1 intron 21572414 rs16849792 chr2 165664637 C T 1.50E-05 Urinary metabolites COBLL1 intron 21572414 rs6736779 chr2 165665144 T C 1.60E-05 Urinary metabolites COBLL1 intron 21572414 rs10173063 chr2 165665490 G A 2.14E-04 Type 2 diabetes COBLL1 intron 17463246 rs10173063 chr2 165665490 G A 1.00E-06 Urinary metabolites COBLL1 intron 21572414 rs355810 chr2 165685646 G A 5.46E-04 Amyotrophic Lateral Sclerosis COBLL1 intron 17362836 rs7569506 chr2 165710110 T C 8.20E-04 Type 2 diabetes / / 17463246 rs7569506 chr2 165710110 T C 1.00E-06 Urinary metabolites / / 21572414 rs13396952 chr2 165737057 G A 3.89E-05 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs10497251 chr2 165739014 T C 3.39E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13424957 chr2 165750390 C T 3.00E-06 Coronary heart disease / / 21347282 rs13424957 chr2 165750390 C T 2.63E-05 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs3817135 chr2 165753118 A G 1.77E-04 Glycosylated haemoglobin levels / / 17255346 rs6432806 chr2 165821681 G A 5.45E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2077846 chr2 165855130 G A 2.68E-06 Bilirubin levels,in serum / / 19389676 rs776488 chr2 165890733 A C 2.00E-07 Common traits (Other) / / 20585627 rs776495 chr2 165895586 T G 0.00000351 Fetal hemoglobin levels / / 22936743 rs62174866 chr2 165928113 A T 6.65E-06 Osteoarthritis / / 21871595 rs62174867 chr2 165929310 C T 6.65E-06 Osteoarthritis / / 21871595 rs62174869 chr2 165930578 C G 3.44E-06 Osteoarthritis / / 21871595 rs62174894 chr2 165936973 G A 6.54E-06 Osteoarthritis / / 21871595 rs3816195 chr2 165956508 T G 5.29E-04 Alcohol dependence SCN3A intron 24277619 rs62174897 chr2 165958651 A G 1.41E-06 Osteoarthritis SCN3A intron 21871595 rs1347992 chr2 165961865 T C 4.85E-04 Alcohol dependence SCN3A intron 24277619 rs17829596 chr2 165985503 T C 5.70E-05 Crohn's disease SCN3A intron 20570966 rs17829596 chr2 165985503 T C 3.63E-05 Brain structure SCN3A intron 22504417 rs62174901 chr2 165988343 T C 9.01E-07 Osteoarthritis SCN3A intron 21871595 rs62174906 chr2 166008357 A G 6.66E-07 Osteoarthritis SCN3A intron 21871595 rs7556825 chr2 166020649 T C 3.60E-05 Multiple complex diseases SCN3A intron 17554300 rs12615864 chr2 166031792 G A 1.00E-04 Prostate cancer SCN3A intron 21743057 rs139585434 chr2 166032837 G A 0.000000161 Prostate-specific antigen SCN3A missense 23555315 rs2028891 chr2 166067658 T G 1.40E-04 Alcohol dependence / / 24277619 rs6718960 chr2 166095728 A G 0.0000196 LDL cholesterol particle diameter SCN2A nearGene-5 23263444 rs17182784 chr2 166100967 C T 0.0000196 LDL cholesterol particle diameter SCN2A intron 23263444 rs1439805 chr2 166106557 C A 5.93E-05 Coronary heart disease SCN2A intron pha003031 rs2119067 chr2 166127283 C T 4.40E-05 Alzheimer's disease (late onset) SCN2A intron 20885792 rs2119067 chr2 166127283 C T 4.40E-05 Alzheimer's disease (late onset) SCN2A intron 21460841 rs2119067 chr2 166127283 C T 1.53E-05 Coronary heart disease SCN2A intron pha003030 rs2119067 chr2 166127283 C T 8.34E-07 Coronary heart disease SCN2A intron pha003031 rs10184275 chr2 166127928 G A 2.20E-05 Alzheimer's disease (late onset) SCN2A intron 20885792 rs10184275 chr2 166127928 G A 2.20E-05 Alzheimer's disease (late onset) SCN2A intron 21460841 rs10184275 chr2 166127928 G A 4.34E-07 Coronary heart disease SCN2A intron pha003030 rs10184275 chr2 166127928 G A 1.11E-07 Coronary heart disease SCN2A intron pha003031 rs353121 chr2 166129323 G A 2.58E-05 Coronary heart disease SCN2A intron pha003030 rs353121 chr2 166129323 G A 3.43E-07 Coronary heart disease SCN2A intron pha003031 rs353119 chr2 166130379 C T 2.58E-05 Coronary heart disease SCN2A intron pha003030 rs353119 chr2 166130379 C T 3.43E-07 Coronary heart disease SCN2A intron pha003031 rs353111 chr2 166137029 T G 1.07E-05 Coronary heart disease SCN2A intron pha003031 rs16850317 chr2 166144414 T G 5.00E-06 Periodontitis (DPAL) SCN2A intron 24024966 rs7607897 chr2 166156941 A G 7.11E-04 Response to cytidine analogues (gemcitabine) SCN2A intron 24483146 rs2116658 chr2 166166672 C T 1.48E-05 Parkinson's disease SCN2A intron pha002868 rs2304016 chr2 166168503 A G 1 Drug response to Carbamazepine SCN2A intron 18784617 rs2304016 chr2 166168503 A G 1 Drug response to Lamotrigine SCN2A intron 18784617 rs2304016 chr2 166168503 A G 1 Drug response to Oxcarbazepine SCN2A intron 18784617 rs2304016 chr2 166168503 A G 1 Drug response to Phenytoin SCN2A intron 18784617 rs2304016 chr2 166168503 A G 1 Drug response to Topiramate SCN2A intron 18784617 rs13025009 chr2 166170073 A G 2.16E-05 Parkinson's disease SCN2A intron pha002868 rs13387970 chr2 166193965 C A 8.26E-04 Response to cytidine analogues (gemcitabine) SCN2A intron 24483146 rs3910176 chr2 166205485 G T 6.48E-04 Smoking cessation SCN2A intron 24665060 rs764660 chr2 166213297 T G 7.83E-06 Parkinson's disease SCN2A intron pha002868 rs12692769 chr2 166258977 C T 2.30E-05 Urinary metabolites / / 21572414 rs1432546 chr2 166260790 A G 1.30E-05 Urinary metabolites / / 21572414 rs6432823 chr2 166263130 C T 6.72E-04 Smoking cessation / / 24665060 rs16850599 chr2 166266634 G T 9.62E-04 Rheumatoid arthritis / / 21452313 rs13385399 chr2 166269095 T G 7.86E-04 Smoking cessation / / 24665060 rs1355995 chr2 166274594 A G 5.54E-04 Rheumatoid arthritis / / 21452313 rs11683781 chr2 166288740 C T 4.33E-04 Smoking cessation / / 24665060 rs687415 chr2 166303598 C T 3.66E-04 HIV-1 viral setpoint / / 17641165 rs687415 chr2 166303598 C T 0.0000315 Alcohol craving with or without dependence / / 22481050 rs13413326 chr2 166332752 T C 3.11E-04 Multiple complex diseases CSRNP3 intron 17554300 rs6432832 chr2 166370826 A C 9.00E-06 Longevity (85 years and older) CSRNP3 intron 24688116 rs6432834 chr2 166374932 A C 4.49E-04 Multiple complex diseases CSRNP3 intron 17554300 rs10427253 chr2 166399158 G T 0.0006544 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CSRNP3 intron 23233654 rs10427253 chr2 166399158 G T 6.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) CSRNP3 intron 23233662 rs7588295 chr2 166407511 A G 0.00000624 Bisphosphonate-induced osteonecrosis of the jaw CSRNP3 intron 22267851 rs10803799 chr2 166440547 A C 1.16E-04 Substance dependence CSRNP3 intron 21818250 rs13389345 chr2 166455078 G A 2.64E-04 Multiple complex diseases CSRNP3 intron 17554300 rs1869473 chr2 166491207 G A 8.71E-05 Alzheimer's disease (late onset) CSRNP3 intron 21379329 rs1820325 chr2 166534206 A G 1.57E-04 Vaspin levels CSRNP3 intron 22907691 rs1820325 chr2 166534206 A G 0.0001568 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks CSRNP3 intron 22907730 rs777346 chr2 166535918 C T 2.40E-08 Bone mineral density (paediatric,total body less head) CSRNP3 cds-synon 24945404 rs2194754 chr2 166539042 A G 4.80E-08 Bone mineral density (paediatric,total body less head) CSRNP3 UTR-3 24945404 rs777355 chr2 166554037 G A 2.70E-09 Bone mineral density (paediatric,total body less head) / / 24945404 rs777355 chr2 166554037 G A 4.00E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs1863196 chr2 166557510 A G 2.70E-08 Bone mineral density (paediatric,total body less head) / / 24945404 rs12185748 chr2 166576956 C T 1.10E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs12185748 chr2 166576956 C T 3.90E-10 Bone mineral density (paediatric,total body less head) / / 24945404 rs7586085 chr2 166577489 A G 1.30E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs7586085 chr2 166577489 A G 7.00E-10 Bone mineral density (paediatric,total body less head) / / 24945404 rs6726821 chr2 166578114 T G 1.00E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs6726821 chr2 166578114 T G 2.00E-06 Bone mineral density (paediatric,upper limb) / / 24945404 rs6726821 chr2 166578114 T G 4.00E-10 Bone mineral density (paediatric,total body less head) / / 24945404 rs6726821 chr2 166578114 T G 7.00E-08 Bone mineral density (paediatric,total body less head) / / 24945404 rs6710388 chr2 166583141 C T 1.90E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs6710388 chr2 166583141 C T 7.00E-10 Bone mineral density (paediatric,total body less head) / / 24945404 rs6710518 chr2 166583244 C T 5.00E-10 Bone mineral density / / 21533022 rs6710518 chr2 166583244 C T 1.90E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs6710518 chr2 166583244 C T 7.00E-10 Bone mineral density (paediatric,total body less head) / / 24945404 rs1346003 chr2 166597357 C G 4.50E-09 Bone mineral density (paediatric,total body less head) / / 24945404 rs1346004 chr2 166601046 G A 4.00E-30 Bone mineral density / / 22504420 rs1346004 chr2 166601046 G A 1.83E-05 Bone mineral density / / 24249740 rs1346004 chr2 166601046 G A 1.09E-07 Bone mineral density (paediatric,upper limb) / / 24945404 rs1346004 chr2 166601046 G A 4.50E-09 Bone mineral density (paediatric,total body less head) / / 24945404 rs1346004 chr2 166601046 G A 4.51E-09 Bone mineral density (paediatric,total body less head) / / 24945404 rs1346004 chr2 166601046 G A 5.00E-07 Bone mineral density (paediatric,lower limb) / / 24945404 rs1895701 chr2 166603087 T C 1.04E-05 Bone mineral density / / 24249740 rs1895701 chr2 166603087 T C 4.10E-08 Bone mineral density (paediatric,total body less head) / / 24945404 rs13430211 chr2 166622598 C G 4.40E-08 Bone mineral density (paediatric,total body less head) GALNT3 intron 24945404 rs16851009 chr2 166630707 C T 4.17E-05 Parkinson's disease GALNT3 intron 16252231 rs6745114 chr2 166658586 T C 2.19E-04 Smoking initiation / / 24665060 rs10497268 chr2 166664256 T C 8.16E-04 Alzheimer's disease / / 17998437 rs10930182 chr2 166688188 T C 6.19E-05 Melanoma / / 21926416 rs2060167 chr2 166689342 T C 5.33E-05 Melanoma / / 21926416 rs1560594 chr2 166699798 A G 6.23E-05 Melanoma / / 21926416 rs2304003 chr2 166714081 T C 9.11E-05 Melanoma / / 21926416 rs2304003 chr2 166714081 T C 9.00E-06 Social communication problems / / 24564958 rs16851169 chr2 166715698 G A 9.55E-04 Alzheimer's disease LOC100506124 intron 17998437 rs3762550 chr2 166736005 T G 5.41E-04 Multiple complex diseases TTC21B intron 17554300 rs714705 chr2 166750639 G A 4.68E-04 Multiple complex diseases TTC21B intron 17554300 rs714705 chr2 166750639 G A 6.53E-04 Alzheimer's disease TTC21B intron 17998437 rs13022554 chr2 166752432 A G 3.45E-04 Smoking initiation TTC21B intron 24665060 rs3749030 chr2 166774101 T C 1.00E-04 Information processing speed TTC21B intron 21130836 rs6731900 chr2 166811765 A G 4.00E-06 Memory (short-term) TTC21B nearGene-5 20038948 rs6731900 chr2 166811765 A G 4.61E-04 Smoking initiation TTC21B nearGene-5 24665060 rs12612363 chr2 166838065 C T 1.32E-04 Multiple complex diseases / / 17554300 rs565348 chr2 166873299 A C 1.00E-05 Memory (short-term) SCN1A intron 20038948 rs13383881 chr2 166885387 A G 9.73E-06 Personality dimensions SCN1A intron 23658558 rs3812718 chr2 166909544 C T 1 Drug response to Carbamazepine SCN1A intron 17436242 rs3812718 chr2 166909544 C T 1 Drug response to Phenytoin SCN1A intron 17436242 rs545331 chr2 166913962 G A 4.62E-05 Partial epilepsies SCN1A intron 20522523 rs10930201 chr2 166915335 C A 3.00E-05 Memory (short-term) SCN1A intron 20038948 rs13405797 chr2 166919162 G A 1.30E-06 Personality dimensions SCN1A intron 23658558 rs1841548 chr2 166920430 A G 1.09E-06 Personality dimensions SCN1A intron 23658558 rs13397210 chr2 166922028 C T 1.17E-06 Personality dimensions SCN1A intron 23658558 rs11692675 chr2 166926428 T C 4.78E-06 Mesial temporal lobe epilepsy with hippocampal sclerosis SCN1A intron 24014518 rs11692675 chr2 166926428 T C 4.87E-07 Mesial temporal lobe epilepsy with hippocampal sclerosis SCN1A intron 24014518 rs1020852 chr2 166927659 C T 1.68E-06 Personality dimensions SCN1A intron 23658558 rs13406905 chr2 166937368 A C 8.66E-04 Multiple complex diseases SCN1A intron 17554300 rs16851485 chr2 166937561 G A 3.74E-04 Multiple complex diseases SCN1A intron 17554300 rs12998106 chr2 166938753 C T 8.92E-06 Response to amphetamines SCN1A intron 22952603 rs11903891 chr2 166941733 G T 9.69E-06 Response to amphetamines SCN1A intron 22952603 rs11904006 chr2 166942140 C T 6.00E-06 Response to amphetamines SCN1A intron 22952603 rs11890028 chr2 166943277 T G 4.00E-06 Epilepsy (generalized) SCN1A intron 22949513 rs7587026 chr2 166978750 C A 3.00E-09 Mesial temporal lobe epilepsy with hippocampal sclerosis SCN1A intron 24014518 rs7587026 chr2 166978750 C A 4.00E-08 Mesial temporal lobe epilepsy with hippocampal sclerosis SCN1A intron 24014518 rs533202 chr2 166983181 A C 0.000205 Salmonella-induced pyroptosis SCN1A intron 22837397 rs534798 chr2 166985056 G A 0.000179 Salmonella-induced pyroptosis SCN1A intron 22837397 rs490463 chr2 166985967 T C 0.000577 Salmonella-induced pyroptosis SCN1A intron 22837397 rs514358 chr2 166987922 T C 0.000106 Salmonella-induced pyroptosis SCN1A intron 22837397 rs11681716 chr2 167017706 G A 7.13E-04 Tourette syndrome / / 22889924 rs10210369 chr2 167028525 T C 1.50E-05 Urinary metabolites / / 21572414 rs4667510 chr2 167028720 G A 9.64E-04 Type 2 diabetes / / 17463246 rs4667510 chr2 167028720 G A 1.20E-05 Urinary metabolites / / 21572414 rs16851722 chr2 167033344 G T 9.11E-04 Prostate cancer mortality / / 20978177 rs9917323 chr2 167046309 A G 5.30E-04 Type 2 diabetes / / 17463246 rs9917323 chr2 167046309 A G 2.20E-05 Urinary metabolites / / 21572414 rs4303728 chr2 167056428 G A 7.20E-04 Prostate cancer mortality SCN9A intron 20978177 rs16851785 chr2 167063771 G A 1.06E-04 Multiple complex diseases SCN9A intron 17554300 rs6725008 chr2 167076378 C T 8.58E-04 Type 2 diabetes SCN9A intron 17463246 rs6725008 chr2 167076378 C T 1.60E-05 Urinary metabolites SCN9A intron 21572414 rs7600169 chr2 167080979 A G 2.90E-06 Urinary metabolites SCN9A intron 21572414 rs6746030 chr2 167099158 A G 5.11E-04 Multiple complex diseases / / 17554300 rs4286289 chr2 167161711 C A 6.89E-04 Smoking initiation SCN9A intron 24665060 rs4438497 chr2 167177359 T C 7.00E-06 Dental caries SCN9A intron 23259602 rs6432908 chr2 167217864 G A 2.63E-05 Longevity SCN9A intron 20304771 rs17766561 chr2 167218821 G T 1.60E-05 Gaucher disease severity SCN9A intron 22388998 rs1540874 chr2 167220024 G A 2.64E-05 Longevity SCN9A intron 20304771 rs7590179 chr2 167220868 G T 2.62E-05 Longevity SCN9A intron 20304771 rs16852031 chr2 167223238 C A 4.34E-04 Multiple complex diseases SCN9A intron 17554300 rs6721003 chr2 167223512 A G 2.44E-05 Longevity SCN9A intron 20304771 rs4384809 chr2 167224518 G T 3.13E-05 Longevity SCN9A intron 20304771 rs17766807 chr2 167224695 T C 3.38E-05 Gaucher disease severity SCN9A intron 22388998 rs10930218 chr2 167228744 T G 2.40E-04 Iris characteristics SCN9A intron 21835309 rs10179640 chr2 167240987 A G 4.49E-05 Longevity / / 20304771 rs6710634 chr2 167243437 G A 4.64E-05 Longevity / / 20304771 rs1406275 chr2 167264978 G T 4.15E-04 Cognitive impairment induced by topiramate SCN7A intron 22091778 rs3791253 chr2 167286044 A G 7.99E-04 Type 2 diabetes SCN7A intron 17463246 rs7597971 chr2 167288172 G A 7.00E-04 Bipolar disorder SCN7A intron 24387768 rs11680374 chr2 167310925 A T 4.50E-05 Type 2 diabetes SCN7A intron 17463246 rs11680374 chr2 167310925 A T 9.37E-04 Multiple complex diseases SCN7A intron 17554300 rs11888208 chr2 167313451 T C 7.69E-04 Glycosylated haemoglobin levels SCN7A missense 17255346 rs11888208 chr2 167313451 T C 4.98E-06 Response to tocilizumab in rheumatoid arthritis SCN7A missense 22491018 rs13017982 chr2 167326652 T C 4.98E-06 Response to tocilizumab in rheumatoid arthritis SCN7A intron 22491018 rs11893208 chr2 167337735 A G 5.28E-04 Cognitive impairment induced by topiramate SCN7A intron 22091778 rs10930226 chr2 167346017 A T 8.12E-04 Lymphocyte counts / / 22286170 rs10497287 chr2 167372934 G A 9.20E-05 Type 2 diabetes / / 17463246 rs16852235 chr2 167377808 A T 5.19E-05 Multiple complex diseases / / 17554300 rs13015447 chr2 167377978 A C 7.00E-06 Amyotrophic lateral sclerosis / / 19451621 rs4233808 chr2 167475482 G A 8.20E-05 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction) / / 24280104 rs9287871 chr2 167506317 G A 9.56E-04 Type 2 diabetes / / 17463246 rs10497293 chr2 167515013 A C 4.44E-05 Information processing speed / / 21130836 rs2390416 chr2 167549402 C A 9.34E-05 Information processing speed / / 21130836 rs16852625 chr2 167607932 A G 2.69E-04 Type 2 diabetes / / 17463246 rs17774426 chr2 167620243 C G 2.40E-06 Urinary metabolites / / 21572414 rs7557536 chr2 167632838 G A 1.90E-04 Type 2 diabetes / / 17463246 rs7420023 chr2 167669615 C T 8.20E-04 Type 2 diabetes / / 17463246 rs12617566 chr2 167727209 G A 1.30E-04 Suicidal ideation / / 22030708 rs10930260 chr2 167842657 A C 3.22E-04 Type 2 diabetes XIRP2 intron 17463246 rs4493277 chr2 167844513 C T 5.96E-04 Multiple complex diseases XIRP2 intron 17554300 rs16852938 chr2 167926937 C A 4.14E-05 Type 2 diabetes XIRP2 intron 17463246 rs11888129 chr2 167949138 A C 1.79E-04 Insulin resistance XIRP2 intron 21901158 rs6432978 chr2 167989231 A T 5.71E-05 Type 2 diabetes XIRP2 intron 17463246 rs10497310 chr2 168009405 A G 2.22E-05 Parkinson's disease XIRP2 intron 21248740 rs6432983 chr2 168062531 G T 8.58E-04 Myocardial Infarction XIRP2 intron pha002873 rs7602119 chr2 168084857 C T 4.69E-04 Myocardial Infarction XIRP2 intron pha002873 rs10497323 chr2 168099738 T C 0.000008 Apolipoprotein B levels response after 40mg daily simvastatin treatment XIRP2 cds-synon 23100282 rs10497323 chr2 168099738 T C 0.000099 LDL cholesterol response after 40mg daily simvastatin treatment XIRP2 cds-synon 23100282 rs10497323 chr2 168099738 T C 5.06E-04 Myocardial Infarction XIRP2 cds-synon pha002873 rs3749004 chr2 168107491 A G 0.000038 LDL cholesterol response after 40mg daily simvastatin treatment XIRP2 missense 23100282 rs3749004 chr2 168107491 A G 0.000047 Apolipoprotein B levels response after 40mg daily simvastatin treatment XIRP2 missense 23100282 rs10497324 chr2 168159351 A G 2.00E-09 DNA methylation (parent-of-origin) / / 23725790 rs6726067 chr2 168180484 A G 8.51E-04 Multiple complex diseases / / 17554300 rs6756322 chr2 168286361 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6759323 chr2 168292597 C T 5.95E-04 Multiple complex diseases / / 17554300 rs16853644 chr2 168352843 G A 5.30E-04 Type 2 diabetes / / 17463246 rs1227126 chr2 168396016 T C 9.10E-04 Insulin resistance / / 21901158 rs16853726 chr2 168396030 A G 5.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs16853735 chr2 168396526 A G 4.99E-04 Multiple complex diseases / / 17554300 rs16853738 chr2 168402076 C T 2.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs1227136 chr2 168403680 T C 3.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs1897339 chr2 168408438 T G 3.50E-04 Alcohol dependence / / 20201924 rs1897339 chr2 168408438 T G 5.43E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1147147 chr2 168494937 T C 2.98E-05 Serum metabolites / / 19043545 rs16854016 chr2 168508395 A C 8.03E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1448837 chr2 168514672 A G 1.77E-05 Cognitive impairment induced by topiramate / / 22091778 rs935638 chr2 168516699 G A 6.06E-06 Cardiac Troponin-T levels / / 23247143 rs7605048 chr2 168544776 A C 4.73E-04 Acute lung injury / / 22295056 rs13408808 chr2 168565693 A G 8.00E-06 Obesity-related traits / / 23251661 rs2044682 chr2 168574523 C A 2.34E-04 Major depressive disorder / / 22472876 rs4667970 chr2 168596313 G A 7.54E-04 Multiple complex diseases / / 17554300 rs11691258 chr2 168639838 A G 8.78E-06 Obesity-related traits / / 23251661 rs13410278 chr2 168641637 A G 1.78E-05 HIV-1 viral setpoint / / 21490045 rs1004368 chr2 168641970 A G 2.00E-06 Obesity-related traits / / 23251661 rs836692 chr2 168645406 C T 3.22E-04 Bipolar disorder / / 19259986 rs6740435 chr2 168648612 C T 9.12E-04 HIV-1 viral setpoint / / 17641165 rs6740435 chr2 168648612 C T 8.81E-06 HIV-1 viral setpoint / / 21490045 rs12992718 chr2 168649399 C A 2.91E-04 HIV-1 viral setpoint / / 17641165 rs12992718 chr2 168649399 C A 3.88E-06 HIV-1 viral setpoint / / 21490045 rs836664 chr2 168772522 A G 1.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs7576460 chr2 168775061 C A 1.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs11894600 chr2 168784354 C A 1.69E-04 Cognitive decline / / 23732972 rs935381 chr2 168824134 C T 7.47E-05 Chronic obstructive pulmonary disease STK39 intron 19300482 rs9287889 chr2 168840454 C T 9.00E-04 Response to interferon beta in multiple sclerosis STK39 intron 18195134 rs16854534 chr2 168868236 C T 1.43E-04 Multiple complex diseases STK39 intron 17554300 rs16854674 chr2 168935864 A G 4.92E-04 Multiple complex diseases STK39 intron 17554300 rs6712819 chr2 168954776 C T 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes STK39 intron 22628534 rs2278785 chr2 168996775 T C 8.40E-05 Blood pressure STK39 intron 19114657 rs3769402 chr2 168999344 A T 8.83E-04 Suicide attempts in bipolar disorder STK39 intron 21423239 rs1517331 chr2 169002591 T C 5.36E-05 Hypertension (essential hypertension) STK39 intron 22184326 rs1850438 chr2 169002622 G A 5.13E-05 Blood Pressure STK39 intron pha003043 rs3769396 chr2 169002934 T C 4.35E-04 Suicide attempts in bipolar disorder STK39 intron 21423239 rs3769395 chr2 169004125 C T 4.37E-04 Suicide attempts in bipolar disorder STK39 intron 21423239 rs3769394 chr2 169005378 A C 1.10E-05 Blood pressure STK39 intron 19114657 rs3769392 chr2 169013674 T C 3.70E-05 Blood pressure STK39 intron 19114657 rs3754781 chr2 169015476 G A 1.70E-05 Blood pressure STK39 intron 19114657 rs3754777 chr2 169015914 C T 1.30E-05 Blood pressure STK39 intron 19114657 rs3754776 chr2 169016171 G C 2.24E-04 Multiple complex diseases STK39 intron 17554300 rs1400644 chr2 169022613 A G 9.10E-06 Blood pressure STK39 intron 19114657 rs1400645 chr2 169022981 G A 8.90E-06 Blood pressure STK39 intron 19114657 rs10497337 chr2 169027149 G A 6.30E-05 Blood pressure STK39 intron 19114657 rs11890527 chr2 169031488 T C 7.48E-04 Smoking initiation STK39 intron 24665060 rs6749447 chr2 169041386 T G 2.00E-07 Blood pressure STK39 intron 19114657 rs6734514 chr2 169041559 C T 8.40E-05 Blood pressure STK39 intron 19114657 rs4668044 chr2 169041770 A G 9.10E-05 Blood pressure STK39 intron 19114657 rs4667570 chr2 169047506 T C 8.81E-04 Multiple complex diseases STK39 intron 17554300 rs7605161 chr2 169059591 A C 6.74E-04 Multiple complex diseases STK39 intron 17554300 rs4438452 chr2 169071348 C T 9.97E-06 Lung cancer STK39 intron 19414679 rs11675180 chr2 169076787 T C 3.56E-04 Smoking initiation STK39 intron 24665060 rs2271741 chr2 169078534 A C 0.0000684 Migraine STK39 intron 22678113 rs2271741 chr2 169078534 A C 6.84E-05 Migraine STK39 intron 22683712 rs10176669 chr2 169084859 T C 1.74E-06 Lung cancer STK39 intron 19414679 rs2390669 chr2 169091942 A C 1.37E-09 Parkinson's disease STK39 intron 22438815 rs950535 chr2 169095854 G A 9.56E-05 Intelligence STK39 intron 21826061 rs16855187 chr2 169108932 A G 7.26E-04 Multiple complex diseases / / 17554300 rs2102808 chr2 169117025 G T 4.00E-10 Parkinson's disease / / 21292315 rs2102808 chr2 169117025 G T 9.97E-08 Parkinson's disease / / 22438815 rs2102808 chr2 169117025 G T 3.31E-11 Parkinson's disease / / 22451204 rs1400637 chr2 169136489 C A 4.92E-05 Parkinson's disease / / 21738487 rs9917256 chr2 169143035 G A 3.72E-06 Parkinson's disease / / 21738487 rs9917256 chr2 169143035 G A 3.00E-06 Parkinson's disease / / 22451204 rs4668059 chr2 169166282 T C 4.45E-05 Bipolar disorder / / 21926972 rs4668059 chr2 169166282 T C 0.00023 Bipolar disorder / / 23070075 rs16855271 chr2 169176370 G A 2.54E-05 Bipolar disorder and schizophrenia / / 20889312 rs16855271 chr2 169176370 G A 9.00E-06 Schizophrenia / / pha002857 rs13421263 chr2 169182294 C T 7.49E-05 Erythrocyte counts / / pha003099 rs10186996 chr2 169185199 A G 4.01E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2246881 chr2 169209915 G A 4.96E-04 Smoking quantity / / 24665060 rs2044958 chr2 169220101 C A 6.78E-04 Type 2 diabetes / / 17463246 rs10497339 chr2 169226124 G C 8.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12475373 chr2 169252269 C A 5.07E-05 Hypertension / / 19609347 rs17806793 chr2 169299532 T C 3.08E-04 Multiple complex diseases / / 17554300 rs1124893 chr2 169300048 G A 3.82E-04 Multiple complex diseases / / 17554300 rs1124893 chr2 169300048 G A 6.40E-06 Urinary metabolites / / 21572414 rs1377504 chr2 169303242 A G 4.26E-04 Multiple complex diseases / / 17554300 rs16855373 chr2 169338808 G C 8.43E-04 Multiple complex diseases CERS6 intron 17554300 rs16855373 chr2 169338808 G C 1.89E-04 Major depressive disorder CERS6 intron 22472876 rs1901836 chr2 169361038 C T 5.03E-04 Multiple complex diseases CERS6 intron 17554300 rs7599295 chr2 169367516 T A 4.11E-04 Multiple complex diseases CERS6 intron 17554300 rs13393173 chr2 169389091 G A 4.00E-06 Response to TNF antagonist treatment CERS6 intron 18615156 rs11682385 chr2 169407091 G C 1.90E-08 Metabolite levels CERS6 intron 23281178 rs16855460 chr2 169407912 A G 5.74E-06 Left ventricular mass CERS6 intron 21212386 rs989106 chr2 169428016 T C 4.44E-04 Multiple complex diseases CERS6 intron 17554300 rs16855517 chr2 169428063 G A 3.20E-07 Left ventricular mass CERS6 intron 21212386 rs41345348 chr2 169433030 C A 8.80E-04 Multiple complex diseases CERS6 intron 17554300 rs1002666 chr2 169478018 T C 1.04E-04 Cognition,early reading ability CERS6 intron 17684495 rs4294968 chr2 169498212 T C 6.87E-05 ldl cholesterol CERS6 intron pha003076 rs1806328 chr2 169506879 G A 5.47E-04 Coronary heart disease CERS6 intron 21606135 rs6707065 chr2 169509692 C A,G 3.52E-04 Depression (quantitative trait) CERS6 intron 20800221 rs16855658 chr2 169511104 A G 3.98E-05 HDL cholesterol CERS6 intron pha003074 rs7565629 chr2 169516830 G T 3.40E-05 Sphingolipid levels CERS6 intron 19798445 rs10930335 chr2 169530546 G A 9.60E-05 Diabetic nephropathy CERS6 intron pha002866 rs7601307 chr2 169537411 C T 7.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CERS6 intron 20877124 rs1863144 chr2 169547991 A G 6.14E-04 Suicide attempts in bipolar disorder CERS6 intron 21423239 rs4668100 chr2 169587361 T C 0.0004132 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CERS6 intron 23233654 rs4668100 chr2 169587361 T C 4.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) CERS6 intron 23233662 rs6717260 chr2 169593638 G T 0.00000329 Common carotid artery thickness (average of near and far wall measures) CERS6 intron 23487405 rs4668102 chr2 169597668 C T 6.11E-04 Type 2 diabetes CERS6 intron 17463246 rs7584527 chr2 169602748 C G 1.13E-04 Type 2 diabetes CERS6 intron 17463246 rs2390732 chr2 169605967 G A 7.10E-13 Fasting blood glucose CERS6 intron 22885924 rs16855775 chr2 169613939 G A 1.90E-06 Multiple complex diseases CERS6 intron 17554300 rs829957 chr2 169658834 G T 6.06E-04 Type 2 diabetes NOSTRIN intron 17463246 rs17265949 chr2 169664458 A C 6.37E-04 Multiple complex diseases NOSTRIN intron 17554300 rs830031 chr2 169669031 T C 4.37E-05 Hemoglobin NOSTRIN intron pha003098 rs482435 chr2 169676045 G A 0.0000173 LDL cholesterol particle diameter NOSTRIN intron 23263444 rs10198693 chr2 169683061 G A 2.61E-05 Hemoglobin NOSTRIN intron pha003098 rs481067 chr2 169692369 G T 4.51E-04 Response to taxane treatment (placlitaxel) NOSTRIN intron 23006423 rs532779 chr2 169703751 T A 3.20E-07 Fasting glucose-related traits NOSTRIN intron 20152958 rs16856065 chr2 169719329 C T 3.50E-04 Multiple complex diseases NOSTRIN intron 17554300 rs12993143 chr2 169719500 T G 8.71E-05 Schizophrenia(age at onset) NOSTRIN intron 21688384 rs3931 chr2 169721381 A G 3.95E-04 Alzheimer's disease (late onset) NOSTRIN cds-synon 21379329 rs853770 chr2 169749841 T C 3.45E-05 Schizophrenia / / 19571809 rs13431652 chr2 169753415 T C 2.58E-12 Metabolite levels / / 22286219 rs13431652 chr2 169753415 T C 1.82E-07 Glycemic traits (pregnancy) / / 23903356 rs13431652 chr2 169753415 T C 6.99E-08 Glycemic traits (pregnancy) / / 23903356 rs12475700 chr2 169753676 G A 6.63E-15 Metabolite levels / / 22286219 rs12623237 chr2 169756058 G A 4.51E-04 Glycemic traits (pregnancy) G6PC2 nearGene-5 23903356 rs1402837 chr2 169757354 C T 5.00E-10 Glycated Hemoglobin levels G6PC2 nearGene-5 19096518 rs1402837 chr2 169757354 C T 4.19E-08 Glycemic traits (pregnancy) G6PC2 nearGene-5 23903356 rs1402837 chr2 169757354 C T 9.28E-07 Glycemic traits (pregnancy) G6PC2 nearGene-5 23903356 rs573225 chr2 169757541 G A 6.50E-06 Fasting plasma glucose G6PC2 nearGene-5 19060907 rs573225 chr2 169757541 G A 1.34E-15 Metabolite levels G6PC2 nearGene-5 22286219 rs573225 chr2 169757541 G A 1.09E-07 Glycemic traits (pregnancy) G6PC2 nearGene-5 23903356 rs573225 chr2 169757541 G A 1.31E-06 Glycemic traits (pregnancy) G6PC2 nearGene-5 23903356 rs560887 chr2 169763148 T C 4.00E-23 Fasting plasma glucose G6PC2 intron 18451265 rs560887 chr2 169763148 T C 1.00E-57 Fasting plasma glucose G6PC2 intron 19060907 rs560887 chr2 169763148 T C 6.00E-10 Metabolic traits G6PC2 intron 19060910 rs560887 chr2 169763148 T C 2.00E-66 Fasting glucose-related traits G6PC2 intron 20081858 rs560887 chr2 169763148 T C 9.00E-218 Fasting insulin-related traits G6PC2 intron 20081858 rs560887 chr2 169763148 T C 1.30E-15 Fasting glucose-related traits G6PC2 intron 20152958 rs560887 chr2 169763148 T C 2.00E-17 Metabolite levels G6PC2 intron 22286219 rs560887 chr2 169763148 T C 5.00E-26 Metabolic syndrome G6PC2 intron 22399527 rs560887 chr2 169763148 T C 2.00E-06 Fasting plasma glucose G6PC2 intron 22508271 rs560887 chr2 169763148 T C 2.00E-113 Fasting glucose-related traits (interaction with BMI) G6PC2 intron 22581228 rs560887 chr2 169763148 T C 1.04E-17 Glycated hemoglobin levels G6PC2 intron 22885924 rs560887 chr2 169763148 T C 1.40E-178 Fasting blood glucose G6PC2 intron 22885924 rs560887 chr2 169763148 T C 4.00E-15 Metabolite levels (atherosclerosis) G6PC2 intron 22916037 rs560887 chr2 169763148 T C 2.00E-16 Glycemic traits (pregnancy) G6PC2 intron 23903356 rs560887 chr2 169763148 T C 2.56E-13 Glycemic traits (pregnancy) G6PC2 intron 23903356 rs560887 chr2 169763148 T C 7.61E-14 Glycemic traits (pregnancy) G6PC2 intron 23903356 rs560887 chr2 169763148 T C 1.00E-17 Glycated hemoglobin levels G6PC2 intron 24405752 rs560887 chr2 169763148 T C 5.69E-10 Glucose levels G6PC2 intron pha002899 rs10166439 chr2 169763560 C T 6.51E-05 Progressive supranuclear palsy G6PC2 intron 21685912 rs146779637 chr2 169764368 C T 0.0003 Breast cancer (ER positive) G6PC2 STOP-GAIN 23555315 rs563694 chr2 169774071 C A 4.00E-07 Fasting plasma glucose / / 18521185 rs563694 chr2 169774071 C A 1.40E-06 Fasting plasma glucose / / 19060907 rs563694 chr2 169774071 C A 1.90E-15 Fasting glucose-related traits / / 20152958 rs563694 chr2 169774071 C A 3.35E-13 Metabolite levels / / 22286219 rs563694 chr2 169774071 C A 2.22E-09 Glycemic traits (pregnancy) / / 23903356 rs563694 chr2 169774071 C A 8.25E-10 Glycemic traits (pregnancy) / / 23903356 rs563694 chr2 169774071 C A 1.17E-07 Glucose levels / / pha002899 rs537183 chr2 169774646 C T 5.32E-13 Metabolite levels / / 22286219 rs537183 chr2 169774646 C T 2.14E-04 Glycemic traits (pregnancy) / / 23903356 rs537183 chr2 169774646 C T 2.27E-05 Glycemic traits (pregnancy) / / 23903356 rs502570 chr2 169774959 A G 5.35E-13 Metabolite levels / / 22286219 rs502570 chr2 169774959 A G 1.33E-04 Glycemic traits (pregnancy) / / 23903356 rs502570 chr2 169774959 A G 3.45E-04 Glycemic traits (pregnancy) / / 23903356 rs580670 chr2 169776121 T A 2.97E-12 Metabolite levels / / 22286219 rs580613 chr2 169776140 T A 4.72E-12 Metabolite levels / / 22286219 rs578763 chr2 169776360 G T 7.01E-13 Metabolite levels / / 22286219 rs475612 chr2 169776746 T C 1.04E-12 Metabolite levels / / 22286219 rs475612 chr2 169776746 T C 2.63E-04 Glycemic traits (pregnancy) / / 23903356 rs475612 chr2 169776746 T C 6.47E-04 Glycemic traits (pregnancy) / / 23903356 rs518598 chr2 169776914 T C 7.20E-12 Metabolite levels / / 22286219 rs557462 chr2 169777595 C T 5.02E-13 Metabolite levels / / 22286219 rs557462 chr2 169777595 C T 4.69E-05 Glycemic traits (pregnancy) / / 23903356 rs557462 chr2 169777595 C T 5.01E-06 Glycemic traits (pregnancy) / / 23903356 rs473351 chr2 169779896 T A,C,G 5.58E-12 Metabolite levels ABCB11 UTR-3 22286219 rs575671 chr2 169780818 A G 3.46E-12 Metabolite levels ABCB11 intron 22286219 rs486981 chr2 169782149 A G 2.86E-12 Metabolite levels ABCB11 intron 22286219 rs485094 chr2 169782353 A C 2.50E-12 Metabolite levels ABCB11 intron 22286219 rs484066 chr2 169782481 A T 5.90E-04 Coronary heart disease ABCB11 intron 21966275 rs483234 chr2 169782574 T C 3.70E-05 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs483234 chr2 169782574 T C 6.19E-04 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs569829 chr2 169782869 T C 2.09E-12 Metabolite levels ABCB11 intron 22286219 rs569805 chr2 169782880 A T 9.00E-08 Metabolic syndrome (bivariate traits) ABCB11 intron 21386085 rs569805 chr2 169782880 A T 2.09E-12 Metabolite levels ABCB11 intron 22286219 rs579060 chr2 169783039 G T 2.40E-10 Metabolic syndrome phenotype ABCB11 intron 22022282 rs579060 chr2 169783039 G T 4.10E-06 Metabolic syndrome phenotype ABCB11 intron 22022282 rs579060 chr2 169783039 G T 2.47E-12 Metabolite levels ABCB11 intron 22286219 rs579060 chr2 169783039 G T 4.22E-05 Amyotrophic lateral sclerosis (sporadic) ABCB11 intron 24529757 rs566879 chr2 169783209 A G 2.07E-12 Metabolite levels ABCB11 intron 22286219 rs16856247 chr2 169784413 C T 2.00E-15 Metabolite levels ABCB11 intron 21909109 rs508506 chr2 169784955 A C 1.10E-14 Fasting glucose-related traits ABCB11 intron 20152958 rs508506 chr2 169784955 A C 1.51E-12 Metabolite levels ABCB11 intron 22286219 rs508506 chr2 169784955 A C 1.47E-04 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs508506 chr2 169784955 A C 6.36E-04 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs494874 chr2 169789306 T C 1.18E-12 Metabolite levels ABCB11 intron 22286219 rs494874 chr2 169789306 T C 1.29E-05 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs494874 chr2 169789306 T C 4.07E-05 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs552976 chr2 169791438 A G 3.30E-16 Fasting glucose-related traits ABCB11 intron 20152958 rs552976 chr2 169791438 A G 8.00E-18 Glycated Hemoglobin levels ABCB11 intron 20858683 rs552976 chr2 169791438 A G 1.61E-12 Metabolite levels ABCB11 intron 22286219 rs552976 chr2 169791438 A G 8.16E-18 Glycated hemoglobin levels ABCB11 intron 22885924 rs552976 chr2 169791438 A G 3.78E-04 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs3755157 chr2 169792171 C T 3.00E-11 Glycated hemoglobin levels ABCB11 intron 24647736 rs472614 chr2 169792421 A G 9.10E-08 Fasting glucose-related traits ABCB11 intron 20152958 rs565412 chr2 169794283 G A 3.00E-08 Fasting glucose-related traits ABCB11 intron 20152958 rs567074 chr2 169794431 C T 8.20E-09 Fasting glucose-related traits ABCB11 intron 20152958 rs2544367 chr2 169796288 T C 1.30E-04 HDL particle features ABCB11 intron 21283740 rs2685805 chr2 169797060 A G 4.00E-09 Fasting glucose-related traits ABCB11 intron 20152958 rs2685812 chr2 169798171 A G 1.20E-08 Fasting glucose-related traits ABCB11 intron 20152958 rs2685813 chr2 169798439 T C 8.00E-09 Fasting glucose-related traits ABCB11 intron 20152958 rs2685814 chr2 169798619 T C 6.86E-05 Glucose levels ABCB11 intron pha002899 rs11568373 chr2 169801403 T C 2.85E-10 Cholesterol,total ABCB11 cds-synon 23063622 rs11568373 chr2 169801403 T C 3.41E-09 LDL cholesterol ABCB11 cds-synon 23063622 rs853789 chr2 169801488 A G 4.00E-16 Fasting glucose-related traits ABCB11 intron 20152958 rs853789 chr2 169801488 A G 5.06E-12 Metabolite levels ABCB11 intron 22286219 rs853789 chr2 169801488 A G 1.95E-66 Fasting blood glucose ABCB11 intron 22885924 rs853789 chr2 169801488 A G 2.42E-04 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs853789 chr2 169801488 A G 5.35E-04 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs853787 chr2 169802252 G T 1.50E-10 Fasting plasma glucose ABCB11 intron 19060907 rs853787 chr2 169802252 G T 1.65E-13 Metabolite levels ABCB11 intron 22286219 rs853787 chr2 169802252 G T 4.30E-04 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs853784 chr2 169803674 C T 1.80E-09 Fasting glucose-related traits ABCB11 intron 20152958 rs853780 chr2 169807482 C G 1.70E-08 Fasting glucose-related traits ABCB11 intron 20152958 rs853779 chr2 169809672 G T 3.30E-09 Fasting glucose-related traits ABCB11 intron 20152958 rs853778 chr2 169811224 T C 4.70E-13 Fasting plasma glucose ABCB11 intron 19060907 rs853778 chr2 169811224 T C 3.50E-09 Fasting glucose-related traits ABCB11 intron 20152958 rs853778 chr2 169811224 T C 1.45E-05 Glucose levels ABCB11 intron pha002899 rs853777 chr2 169812217 T C 5.94E-12 Metabolite levels ABCB11 intron 22286219 rs853776 chr2 169813353 C T 3.80E-09 Fasting glucose-related traits ABCB11 intron 20152958 rs853774 chr2 169813396 G A 1.92E-05 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs853774 chr2 169813396 G A 2.89E-04 Glycemic traits (pregnancy) ABCB11 intron 23903356 rs853773 chr2 169814347 A G 1.20E-09 Fasting glucose-related traits ABCB11 intron 20152958 rs853772 chr2 169814655 G T 1.40E-08 Fasting glucose-related traits ABCB11 intron 20152958 rs16856314 chr2 169823092 G A 0.00000088 Cholesterol,total ABCB11 intron 23063622 rs16856314 chr2 169823092 G A 3.78E-12 LDL cholesterol ABCB11 intron 23063622 rs2287623 chr2 169830155 G A 4.00E-12 Cholesterol,total ABCB11 intron 24097068 rs3770596 chr2 169840142 A T 3.67E-05 Cognitive test performance ABCB11 intron 20125193 rs16856332 chr2 169840574 T G 2.00E-09 Liver enzyme levels (alkaline phosphatase) ABCB11 intron 22001757 rs11568377 chr2 169853220 G A 4.00E-06 Systolic blood pressure in sickle cell anemia ABCB11 cds-synon 24058526 rs10211329 chr2 169858910 A C 1.17E-04 Multiple complex diseases ABCB11 intron 17554300 rs10200158 chr2 169860718 A G 7.87E-05 Multiple complex diseases ABCB11 intron 17554300 rs6709971 chr2 169867573 T C 1.74E-09 LDL cholesterol ABCB11 intron 23063622 rs6709971 chr2 169867573 T C 4.23E-09 Cholesterol,total ABCB11 intron 23063622 rs4148777 chr2 169869901 A G 9.07E-05 Chronic obstructive pulmonary disease ABCB11 cds-synon 19300482 rs3770601 chr2 169872644 C T 0.00000189 Fasting blood glucose ABCB11 intron 22885924 rs4148765 chr2 169889579 C T 5.79E-04 Type 2 diabetes ABCB11 nearGene-5 17463246 rs12620980 chr2 169931343 A G 3.04E-04 Smoking initiation DHRS9 intron 24665060 rs16856444 chr2 169953341 C T 9.03E-05 Multiple complex diseases / / 17554300 rs10515932 chr2 169954185 A G 5.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs6750251 chr2 169967174 C G 7.71E-04 Multiple complex diseases / / 17554300 rs6746604 chr2 169996556 G C 1.91E-05 Serum metabolites LRP2 intron 19043545 rs990627 chr2 169996654 C T 1.34E-05 Serum metabolites LRP2 intron 19043545 rs990626 chr2 169997051 G A 1.65E-05 Serum metabolites LRP2 cds-synon 19043545 rs2268380 chr2 169997399 G A 1.36E-05 Serum metabolites LRP2 intron 19043545 rs6733122 chr2 169999715 A G 9.55E-05 Serum metabolites LRP2 intron 19043545 rs2284681 chr2 170000522 C A 7.97E-05 Serum metabolites LRP2 intron 19043545 rs2075252 chr2 170010985 T C 1 Drug response to Cisplatin LRP2 missense 17457342 rs16856558 chr2 170046653 G A 2.61E-04 Type 2 diabetes LRP2 intron 17463246 rs10490131 chr2 170051167 A G 2.94E-04 Tuberculosis LRP2 intron 22239941 rs7578722 chr2 170052876 T C 7.16E-06 Interstitial lung disease LRP2 intron 23583980 rs2228171 chr2 170053505 C A,G,T 7.42E-06 Interstitial lung disease LRP2 missense 23583980 rs2228171 chr2 170053505 C A,G,T 7.42E-06 Interstitial lung disease LRP2 missense 23583980 rs2302696 chr2 170053580 C T 1.02E-05 Interstitial lung disease LRP2 intron 23583980 rs16856594 chr2 170054212 G T 0.000000538 LDL cholesterol LRP2 intron 23063622 rs16856594 chr2 170054212 G T 0.00000129 HDL cholesterol LRP2 intron 23063622 rs11898106 chr2 170055432 A G 0.00000211 LDL cholesterol LRP2 intron 23063622 rs11687903 chr2 170057722 T G 3.61E-05 Interstitial lung disease LRP2 intron 23583980 rs2239600 chr2 170058852 C T 3.86E-05 Serum metabolites LRP2 intron 19043545 rs2284675 chr2 170058959 G A 1.75E-05 Interstitial lung disease LRP2 intron 23583980 rs6709670 chr2 170059537 A G 7.85E-05 Self-reported allergy LRP2 intron 23817569 rs2052297 chr2 170071166 C T 6.95E-04 Type 2 diabetes LRP2 intron 17463246 rs2193193 chr2 170076081 G A 8.71E-05 Coronary heart disease LRP2 intron 21606135 rs2268370 chr2 170077563 A C 3.20E-04 Coronary heart disease LRP2 intron 21606135 rs143413559 chr2 170090014 T C 0.000056 Breast cancer LRP2 missense 23555315 rs2239594 chr2 170090331 C T 3.18E-05 Coronary heart disease LRP2 intron 21606135 rs10490130 chr2 170099111 A C 0.0000028 Glomerular filtration rate LRP2 intron 22962313 rs10490130 chr2 170099111 A C 9.32E-05 Cholesterol LRP2 intron pha003073 rs830957 chr2 170112098 C T 6.35E-05 Coronary heart disease LRP2 intron 21606135 rs830959 chr2 170113098 C T 7.76E-05 Coronary heart disease LRP2 intron 21606135 rs830960 chr2 170113396 C T 8.28E-05 Coronary heart disease LRP2 intron 21606135 rs2241190 chr2 170115588 T C 7.70E-04 Asthma LRP2 cds-synon 20698975 rs830994 chr2 170129528 G A 7.64E-04 Response to taxane treatment (placlitaxel) LRP2 cds-synon 23006423 rs830998 chr2 170133086 A C 9.00E-06 Anorexia nervosa LRP2 intron 21079607 rs831002 chr2 170133752 T C 3.01E-04 Coronary heart disease LRP2 intron 21606135 rs831004 chr2 170135742 C T 3.21E-06 Coronary heart disease LRP2 intron 21606135 rs831007 chr2 170138506 T C 4.58E-05 Coronary heart disease LRP2 intron 21606135 rs831008 chr2 170138896 C T 3.56E-04 Coronary heart disease LRP2 intron 21606135 rs111704488 chr2 170139387 A C 0.00022 Prostate cancer LRP2 missense 23555315 rs111704488 chr2 170139387 A C 0.00065 Prostate cancer (non-advanced prostate cancer) LRP2 missense 23555315 rs831017 chr2 170145426 G A 3.37E-04 Alzheimer's disease (late onset) LRP2 intron 21379329 rs831022 chr2 170149613 C T 2.99E-04 Alzheimer's disease (late onset) LRP2 intron 21379329 rs11887007 chr2 170149854 C A 2.30E-05 Urinary metabolites LRP2 intron 21572414 rs861239 chr2 170175109 T C 4.87E-05 Nephrolithiasis LRP2 intron 22396660 rs2229263 chr2 170175334 T C 4.51E-05 Nephrolithiasis LRP2 missense 22396660 rs10930352 chr2 170196990 T C 4.59E-05 Nephrolithiasis LRP2 intron 22396660 rs2673172 chr2 170204800 G T 8.10E-05 Renal function-related traits (urea) LRP2 intron 22797727 rs2544390 chr2 170204846 C T 3.74E-08 Blood cell counts and other traits LRP2 intron 20139978 rs2544390 chr2 170204846 C T 4.00E-08 Blood cell counts and other traits LRP2 intron 20139978 rs3770641 chr2 170205126 A T 4.11E-05 Personality dimensions LRP2 intron 22628180 rs6730118 chr2 170205350 A G 4.09E-05 Personality dimensions LRP2 intron 22628180 rs1990842 chr2 170208035 A C 3.29E-05 Personality dimensions LRP2 intron 22628180 rs10199676 chr2 170208975 G T 0.00086 Endometrial cancer LRP2 intron 22426144 rs2389557 chr2 170211377 G A 2.00E-05 Urinary metabolites LRP2 intron 21572414 rs830948 chr2 170214764 G A 2.44E-08 Cholesterol,total LRP2 intron 23063622 rs830948 chr2 170214764 G A 9.06E-11 LDL cholesterol LRP2 intron 23063622 rs2544371 chr2 170227070 A G 8.76E-05 Cognitive test performance / / 20125193 rs4233826 chr2 170233924 A G 1.96E-10 Multiple complex diseases / / 17554300 rs1399634 chr2 170244607 T A 4.20E-06 Diabetic retinopathy / / 23562823 rs4233828 chr2 170245307 A G 8.34E-04 Tourette syndrome / / 22889924 rs4668142 chr2 170264277 G T 3.60E-04 Diabetic retinopathy / / 23562823 rs4668142 chr2 170264277 G T 4.80E-06 Diabetic retinopathy / / 23562823 rs12465476 chr2 170285339 G T 1.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs16823058 chr2 170317904 T C 3.01E-04 Multiple complex diseases / / 17554300 rs16856972 chr2 170336797 G A 3.68E-04 Suicide attempts in bipolar disorder BBS5 intron 21423239 rs16856977 chr2 170337823 G C 2.98E-04 Suicide attempts in bipolar disorder BBS5 intron 21423239 rs16823068 chr2 170338986 C A 2.99E-04 Suicide attempts in bipolar disorder BBS5 intron 21423239 rs16856981 chr2 170341710 A G 1.92E-04 Suicide attempts in bipolar disorder BBS5 intron 21423239 rs12465387 chr2 170350067 G A 3.50E-04 Suicide attempts in bipolar disorder BBS5 intron 21423239 rs12619026 chr2 170354790 A G 1.69E-06 Systemic lupus erythematosus and Systemic sclerosis BBS5 intron 23740937 rs2293058 chr2 170370976 T C 1.79E-04 Suicide attempts in bipolar disorder KBTBD10 intron 21423239 rs13417370 chr2 170373591 G A 0.0007219 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KBTBD10 intron 23233654 rs13417370 chr2 170373591 G A 7.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) KBTBD10 intron 23233662 rs7349274 chr2 170386294 G A 3.44E-05 Alcohol consumption FASTKD1 UTR-3 23953852 rs6708481 chr2 170460536 A C 0.00029 Breast cancer PPIG UTR-5 23555315 rs12470910 chr2 170594091 A G 6.40E-06 Urinary metabolites KLHL23 intron 21572414 rs6725295 chr2 170599690 A C 8.29E-08 Lymphocyte counts KLHL23 intron 22286170 rs2114646 chr2 170624221 C A,T 6.00E-06 Obesity-related traits / / 23251661 rs12692925 chr2 170631928 G A 5.13E-05 Type 2 diabetes and other traits / / 19734900 rs10930375 chr2 170632807 C T 2.35E-04 Multiple complex diseases / / 17554300 rs11894266 chr2 170636642 C T 6.85E-07 Type 2 diabetes and other traits / / 19734900 rs11894266 chr2 170636642 C T 6.85E-07 Alzheimer's disease (late onset) / / 21460841 rs10930379 chr2 170644549 G A 1.56E-04 Multiple complex diseases / / 17554300 rs10930381 chr2 170652057 A G 4.81E-04 Multiple complex diseases / / 17554300 rs16823091 chr2 170670059 G A 2.74E-04 Multiple complex diseases METTL5 intron 17554300 rs3769769 chr2 170675765 C T 9.80E-06 Alcoholism (heaviness of drinking) METTL5 intron 21529783 rs17554448 chr2 170754854 A G 8.56E-05 Pulmonary function in asthmatics UBR3 intron 23541324 rs1031773 chr2 170771022 G A 3.80E-05 Parent of origin effect on language impairment (paternal) UBR3 intron 24571439 rs10189398 chr2 170882181 T C 5.10E-05 Acute lymphoblastic leukemia (childhood) UBR3 intron 19684603 rs10204475 chr2 170932522 T G 6.52E-04 Amyotrophic Lateral Sclerosis UBR3 intron 17362836 rs1381471 chr2 170954406 T C 3.80E-05 Alcoholism (heaviness of drinking) / / 21529783 rs10497352 chr2 170955771 G A 3.60E-05 Volumetric brain MRI / / 17903297 rs11883608 chr2 170961512 A G 4.70E-04 Type 2 diabetes / / 17463246 rs7576155 chr2 170982191 G C 2.25E-04 Obesity (extreme) / / 21935397 rs6711421 chr2 170988776 T C 2.24E-04 Obesity (extreme) / / 21935397 rs4667620 chr2 171000799 C T 2.89E-04 Smoking cessation / / 24665060 rs10930407 chr2 171026184 C T 6.01E-04 Body mass index / / 21701565 rs7580243 chr2 171030735 A C,T 9.97E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7561753 chr2 171033147 C G 1.10E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12692944 chr2 171033265 C G 9.26E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7599599 chr2 171036288 A G 1.10E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs6433172 chr2 171037018 T C 9.29E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs6755273 chr2 171037286 A G 9.30E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs7591238 chr2 171037558 T C 1.22E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs11893658 chr2 171038152 A G 9.29E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs2052633 chr2 171038286 A C 1.31E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs2032965 chr2 171040180 G T 1.38E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs533162322 chr2 171040180 G GT 1.38E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs11676415 chr2 171040453 C T 1.54E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs11687537 chr2 171040506 A G 1.61E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs2355342 chr2 171041500 G A 1.61E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs6705705 chr2 171042445 G C 1.61E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs1593240 chr2 171043087 A G 1.61E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs6742388 chr2 171044510 A G 1.61E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs12465008 chr2 171045237 G A 1.61E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs4668218 chr2 171048425 C T 1.61E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs2161915 chr2 171049486 T C 2.16E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs2113653 chr2 171049550 A C 2.57E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs6738892 chr2 171060729 C T 8.64E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs6739145 chr2 171060783 G A 1.90E-05 Urinary metabolites MYO3B intron 21572414 rs2355343 chr2 171064562 G A 6.09E-05 Height MYO3B intron pha003011 rs12476819 chr2 171066245 C T 8.36E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs6433178 chr2 171067956 C A 8.18E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO3B intron 22566498 rs1820292 chr2 171070175 G A 1.20E-05 Urinary metabolites MYO3B intron 21572414 rs4667626 chr2 171071369 C T 1.50E-05 Urinary metabolites MYO3B intron 21572414 rs6730459 chr2 171078637 G A 0.0000313 Migraine MYO3B intron 22678113 rs6730459 chr2 171078637 G A 3.13E-05 Migraine MYO3B intron 22683712 rs6721083 chr2 171081652 G C 7.43E-04 Coronary heart disease MYO3B intron 21606135 rs1401283 chr2 171135046 A G 6.26E-05 Hypertension (essential hypertension) MYO3B intron 22184326 rs1401286 chr2 171168630 A C 7.75E-05 Body Mass Index MYO3B intron pha003014 rs10930419 chr2 171168682 G A 6.07E-04 Insulin resistance MYO3B intron 21901158 rs11681687 chr2 171172273 A C 6.06E-04 Type 2 diabetes MYO3B intron 17463246 rs12613772 chr2 171172604 T C 6.08E-04 Type 2 diabetes MYO3B intron 17463246 rs1568269 chr2 171173261 T G 6.60E-04 Type 2 diabetes MYO3B intron 17463246 rs11696033 chr2 171173948 C T 4.85E-04 Type 2 diabetes MYO3B intron 17463246 rs9677051 chr2 171174236 C G 5.54E-04 Type 2 diabetes MYO3B intron 17463246 rs2113650 chr2 171176392 T C 3.73E-04 Multiple complex diseases MYO3B intron 17554300 rs2113650 chr2 171176392 T C 9.80E-05 Orofacial clefts MYO3B intron 22419666 rs2176593 chr2 171182976 A T 4.36E-04 Type 2 diabetes MYO3B intron 17463246 rs2176592 chr2 171183010 T C 1.45E-04 Type 2 diabetes MYO3B intron 17463246 rs10930420 chr2 171183104 A G 1.82E-04 Type 2 diabetes MYO3B intron 17463246 rs10930422 chr2 171208242 A C,G,T 8.12E-05 Type 2 diabetes MYO3B intron 17463246 rs876751 chr2 171221115 C A 9.65E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MYO3B intron 21844884 rs6761096 chr2 171223111 T C 0.00008973 Sarcoidosis MYO3B intron 22952805 rs17425473 chr2 171223154 A C 1.00E-05 Urinary metabolites MYO3B intron 21572414 rs12471833 chr2 171226982 C A 6.96E-06 Carotenoid and tocopherol levels MYO3B intron 19185284 rs17497539 chr2 171236060 G C 2.20E-05 Urinary metabolites MYO3B intron 21572414 rs17579512 chr2 171240711 T A 5.46E-05 Response to statin treatment (atorvastatin),change in cholesterol levels MYO3B intron 20031582 rs7561268 chr2 171256597 A C 2.00E-04 Information processing speed MYO3B intron 21130836 rs7561268 chr2 171256597 A C 2.00E-06 Obesity-related traits MYO3B intron 23251661 rs12477031 chr2 171287677 T C 7.14E-05 Serum metabolites MYO3B intron 19043545 rs17426142 chr2 171287710 A G 7.08E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MYO3B intron 20877124 rs17426191 chr2 171292972 C T 0.000484 Salmonella-induced pyroptosis MYO3B intron 22837397 rs2118674 chr2 171318894 A T 2.43E-04 Multiple complex diseases MYO3B intron 17554300 rs2118674 chr2 171318894 A T 4.00E-07 Palmitoleic acid (16:1n-7) plasma levels MYO3B intron 23362303 rs934861 chr2 171340688 G A 3.68E-05 Hemoglobin MYO3B intron pha003096 rs7583952 chr2 171343360 A C 9.59E-05 Parkinson's disease MYO3B intron 17052657 rs4668261 chr2 171344289 T C 2.00E-04 Information processing speed MYO3B intron 21130836 rs10185178 chr2 171356274 G A 1.03E-07 Multiple complex diseases MYO3B missense 17554300 rs10176755 chr2 171365889 A G 7.00E-06 Visceral fat MYO3B intron 22589738 rs10189774 chr2 171375497 A G 8.15E-04 Myopia (pathological) MYO3B intron 21095009 rs12466567 chr2 171393087 C T 0.0000133 Colorectal adenoma (excluding hyperplasic) MYO3B intron 23677573 rs12466567 chr2 171393087 C T 0.0000133 Colorectal adenoma (including hyperplasic) MYO3B intron 23677573 rs6730101 chr2 171409269 G A 5.37E-05 Height MYO3B intron pha003010 rs4482446 chr2 171409832 C T 2.30E-05 Urinary metabolites MYO3B intron 21572414 rs6752681 chr2 171412997 A G 8.20E-06 Urinary metabolites MYO3B intron 21572414 rs7578629 chr2 171414261 C A 7.60E-05 Height MYO3B intron pha003010 rs2192754 chr2 171418907 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes MYO3B intron 22628534 rs16858767 chr2 171429351 C T 3.80E-04 Lung function (forced expiratory volume in 1 second) MYO3B intron 17255346 rs13425835 chr2 171450161 A C 6.45E-06 Obesity-related traits MYO3B intron 23251661 rs6749331 chr2 171461132 T C 3.00E-06 Obesity-related traits MYO3B intron 23251661 rs6433223 chr2 171461637 A G 1.90E-05 Urinary metabolites MYO3B intron 21572414 rs2160231 chr2 171478402 C A 3.63E-04 Schizophrenia MYO3B intron 19197363 rs1861288 chr2 171499887 T C 3.93E-04 Obesity (extreme) MYO3B intron 21935397 rs10803851 chr2 171500167 C T 9.11E-04 Obesity (extreme) MYO3B intron 21935397 rs10192049 chr2 171534221 C T 4.95E-06 Vitiligo / / 22951725 rs2080401 chr2 171540823 A C 7.00E-06 Coronary heart disease / / 21347282 rs2080401 chr2 171540823 A C 6.85E-06 Vitiligo / / 22951725 rs7574074 chr2 171548493 C T 1.48E-05 Vitiligo / / 22951725 rs6704610 chr2 171559628 T G 6.29E-05 Cognitive impairment induced by topiramate / / 22091778 rs11680066 chr2 171566925 A G 4.08E-04 Multiple complex diseases / / 17554300 rs11895153 chr2 171575671 A G 5.81E-04 Smoking initiation / / 24665060 rs7608898 chr2 171598217 C T 3.07E-04 Smoking initiation / / 24665060 rs9973711 chr2 171635393 C T 4.67E-06 Insulin-related traits / / 22791750 rs1362487 chr2 171640942 T C 2.92E-04 Smoking initiation LOC285141 intron 24665060 rs3764916 chr2 171649402 C T 2.92E-04 Sudden cardiac arrest LOC285141 cds-synon 21658281 rs6736129 chr2 171662339 G A 1.37E-04 Sudden cardiac arrest / / 21658281 rs10191129 chr2 171688593 C G,T 6.19E-05 Sudden cardiac arrest GAD1 intron 21658281 rs3791853 chr2 171695070 A G 2.93E-04 Alcohol dependence GAD1 intron 21314694 rs4668338 chr2 171733225 G C 3.00E-06 Uric acid levels / / 18759275 rs2676145 chr2 171790387 A G 2.36E-05 Cognitive performance GORASP2 intron 19734545 rs1035839 chr2 171809485 C T 7.78E-04 Tourette syndrome GORASP2 intron 22889924 rs4668356 chr2 171822466 C G,T 1.00E-06 Cognitive performance GORASP2 cds-synon 19734545 rs4668356 chr2 171822466 C G,T 7.25E-04 Tourette syndrome GORASP2 cds-synon 22889924 rs2723253 chr2 171833910 C T 2.12E-05 Cognitive performance / / 19734545 rs2723253 chr2 171833910 C T 8.72E-04 Tourette syndrome / / 22889924 rs1045327 chr2 171849612 T C 8.36E-04 Multiple complex diseases TLK1 UTR-3 17554300 rs2883940 chr2 171853359 G A 8.13E-05 Cognitive performance TLK1 intron 19734545 rs2883940 chr2 171853359 G A 3.91E-04 Tourette syndrome TLK1 intron 22889924 rs1991370 chr2 171916120 C G 5.83E-04 Multiple complex diseases TLK1 intron 17554300 rs16823191 chr2 171930818 A G 6.49E-04 Tourette syndrome TLK1 intron 22889924 rs6761759 chr2 171944915 A G 5.83E-04 Multiple complex diseases TLK1 intron 17554300 rs10183486 chr2 171990971 C T 2.00E-14 Menopause (age at onset) TLK1 intron 22267201 rs7579424 chr2 171995065 T C 7.65E-04 Smoking initiation TLK1 intron 24665060 rs16859177 chr2 172006576 C T 4.04E-04 Alcohol dependence TLK1 intron 21314694 rs16859177 chr2 172006576 C T 1.88E-04 Tourette syndrome TLK1 intron 22889924 rs719548 chr2 172015052 G A 6.41E-04 Multiple complex diseases TLK1 intron 17554300 rs7572477 chr2 172026956 C A 1.00E-04 Cognitive impairment induced by topiramate TLK1 intron 22091778 rs218311 chr2 172057864 T C 5.72E-05 Cortisol secretion,in saliva TLK1 intron 21316860 rs218311 chr2 172057864 T C 8.98E-05 Rheumatoid arthritis TLK1 intron 21452313 rs6713640 chr2 172065645 C T 9.67E-04 Type 2 diabetes TLK1 intron 17463246 rs6713640 chr2 172065645 C T 8.70E-06 Urinary metabolites TLK1 intron 21572414 rs7568175 chr2 172066068 G T 8.94E-04 Type 2 diabetes TLK1 intron 17463246 rs1035250 chr2 172069140 T C 8.59E-05 Alzheimer's disease TLK1 intron 22832961 rs4668374 chr2 172069491 G T 4.80E-06 Urinary metabolites TLK1 intron 21572414 rs4668374 chr2 172069491 G T 3.80E-04 Sudden cardiac arrest TLK1 intron 21658281 rs4668374 chr2 172069491 G T 6.19E-04 Insulin resistance TLK1 intron 21901158 rs6724085 chr2 172073186 C T 5.10E-06 Urinary metabolites TLK1 intron 21572414 rs11674962 chr2 172077806 A C 8.53E-05 Alzheimer's disease TLK1 intron 22832961 rs10490605 chr2 172118473 C T 1.80E-05 Urinary metabolites / / 21572414 rs4667682 chr2 172127920 C T 5.00E-06 Hippocampal atrophy / / 22745009 rs4667682 chr2 172127920 C T 7.75E-05 Lipoproteins / / pha003079 rs17218608 chr2 172142609 T C 2.20E-05 Urinary metabolites / / 21572414 rs7564482 chr2 172160433 C T 5.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7564482 chr2 172160433 C T 2.84E-05 Waist-Hip Ratio / / pha003013 rs7564482 chr2 172160433 C T 2.33E-05 Waist Circumference / / pha003025 rs7564482 chr2 172160433 C T 3.30E-05 Waist-Hip Ratio / / pha003028 rs10460358 chr2 172295794 A G 8.18E-05 Alzheimer's disease DCAF17 intron 17998437 rs10515933 chr2 172325162 C T 9.46E-04 Bipolar disorder DCAF17 intron 19259986 rs12692966 chr2 172395221 C T 6.95E-06 Serum metabolites CYBRD1 intron 19043545 rs1399959 chr2 172432306 C T 1.99E-05 Suicidal ideation / / 20877300 rs1473995 chr2 172442904 C A 7.37E-06 Suicidal ideation / / 20877300 rs2356798 chr2 172456040 G T 3.90E-06 Personality dimensions / / 21173776 rs6433309 chr2 172518151 A G 6.95E-05 Tunica Media / / pha003036 rs10803863 chr2 172535337 T C 2.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs11678984 chr2 172535848 T G 2.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs17614941 chr2 172541378 T C 2.60E-05 Urinary metabolites / / 21572414 rs1554166 chr2 172541609 T G 7.39E-04 Multiple complex diseases / / 17554300 rs1554166 chr2 172541609 T G 2.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs6721680 chr2 172543913 G T 2.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs6757773 chr2 172549630 T A,C 2.50E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs2138348 chr2 172558172 G T 2.49E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs12185567 chr2 172560729 A C 2.49E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs312925 chr2 172563922 G A 2.49E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs312924 chr2 172564021 A T 2.49E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs312918 chr2 172569587 G C 2.51E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs17427473 chr2 172576011 A G 5.32E-04 Nicotine dependence DYNC1I2 intron 17158188 rs7597387 chr2 172577116 T C 2.66E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs10206062 chr2 172577276 A T 2.68E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs973889 chr2 172579954 A G 2.74E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs10207085 chr2 172585885 T G 2.76E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs2292815 chr2 172586651 C G 2.80E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs6722757 chr2 172591963 A G 2.96E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs6710698 chr2 172596078 G C 4.99E-04 Suicide attempts in bipolar disorder DYNC1I2 intron 21041247 rs4667694 chr2 172605399 G A 2.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs10166005 chr2 172607294 C T 2.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs10184866 chr2 172608956 T G 2.95E-04 Suicide attempts in bipolar disorder / / 21041247 rs4668412 chr2 172619770 A G 2.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs4668412 chr2 172619770 A G 6.89E-05 Height / / pha003010 rs10194102 chr2 172626143 G C 3.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs11904009 chr2 172627343 T G 3.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs10174525 chr2 172635697 T C 3.13E-04 Suicide attempts in bipolar disorder / / 21041247 rs6705200 chr2 172637600 A G 3.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs10497374 chr2 172640623 A G 3.16E-04 Suicide attempts in bipolar disorder SLC25A12 UTR-3 21041247 rs11757 chr2 172641045 C G 3.21E-04 Suicide attempts in bipolar disorder SLC25A12 UTR-3 21041247 rs12692973 chr2 172642057 C T 3.27E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs7608403 chr2 172646765 A C 3.63E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs10167419 chr2 172649826 A G 3.85E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs6758704 chr2 172655097 T C 3.88E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs6754817 chr2 172663394 C T 3.65E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs3770452 chr2 172668682 A G 3.58E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs3770451 chr2 172668715 T G 3.58E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs7586207 chr2 172671094 A G 3.60E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs1400816 chr2 172680678 A C 1.00E-06 Amyotrophic lateral sclerosis (sporadic) SLC25A12 intron 24529757 rs6759575 chr2 172689068 C T 3.64E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs908670 chr2 172690180 T C 3.73E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs908671 chr2 172690265 C G 3.74E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs4668414 chr2 172704291 A C 3.74E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs3770445 chr2 172708919 T C 3.81E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs1878583 chr2 172725301 A G 2.50E-06 Urinary metabolites SLC25A12 cds-synon 21572414 rs12692978 chr2 172725981 C T 3.89E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs6725388 chr2 172730015 G C 8.99E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs6724337 chr2 172735329 C T 3.72E-04 Suicide attempts in bipolar disorder SLC25A12 intron 21041247 rs10202823 chr2 172780132 T C 7.10E-04 Suicide attempts in bipolar disorder HAT1 intron 21041247 rs6750058 chr2 172786909 G T 3.68E-05 Multiple complex diseases HAT1 intron 17554300 rs73976541 chr2 172841213 C T 0.00082 Prostate cancer HAT1 missense 23555315 rs6752812 chr2 172851502 C A 7.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs17428076 chr2 172851936 C G 2.80E-09 Myopia (Age of onset) / / 23468642 rs2028671 chr2 172852839 C T 5.70E-06 Urinary metabolites / / 21572414 rs7584187 chr2 172866105 G A 7.09E-04 Multiple complex diseases METAP1D intron 17554300 rs17428174 chr2 172886148 T C 4.62E-04 Response to TNF antagonist treatment METAP1D intron 21061259 rs7606918 chr2 172895449 A G 2.89E-08 Menopause (age at onset) METAP1D intron 22267201 rs12052246 chr2 172895606 C A 5.05E-04 Multiple complex diseases METAP1D intron 17554300 rs788164 chr2 172913390 C G 7.02E-04 Multiple complex diseases METAP1D intron 17554300 rs788160 chr2 172946315 T G 5.90E-05 Alcoholism (heaviness of drinking) / / 21529783 rs2016394 chr2 172972971 G A 1.00E-08 Breast cancer / / 23535729 rs4972600 chr2 172981645 A G 8.22E-06 Cardiovascular disease / / pha003064 rs4972623 chr2 172994091 G A 8.01E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs6726793 chr2 173010595 T A 5.20E-04 Multiple complex diseases / / 17554300 rs2884155 chr2 173019144 A G 7.23E-05 Lymphocyte counts / / pha003094 rs4972740 chr2 173108443 C T 1.71E-04 Prostate cancer mortality / / 20978177 rs7574002 chr2 173124183 C T 2.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs7574225 chr2 173124237 G A 2.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs7588418 chr2 173127669 C T 3.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs4349318 chr2 173142480 G T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4349318 chr2 173142480 G T 7.71E-05 Cognitive impairment induced by topiramate / / 22091778 rs4316910 chr2 173150235 T C 3.18E-04 Multiple complex diseases / / 17554300 rs7574709 chr2 173152508 A C 9.94E-04 Prostate cancer mortality / / 20978177 rs7574709 chr2 173152508 A C 9.50E-06 Urinary metabolites / / 21572414 rs6749293 chr2 173166803 T C 4.56E-07 Primary biliary cirrhosis / / 23000144 rs6749293 chr2 173166803 T C 0.000000456 Facial morphology / / 23028347 rs6758468 chr2 173169580 T G 2.85E-04 Multiple complex diseases / / 17554300 rs6718565 chr2 173193070 G T 2.21E-04 Multiple complex diseases / / 17554300 rs6755520 chr2 173195634 A C 1.06E-04 Multiple complex diseases / / 17554300 rs4972809 chr2 173217091 A G 2.16E-04 Celiac disease / / 23936387 rs4972810 chr2 173217889 A G 1.93E-04 Celiac disease / / 23936387 rs10930551 chr2 173225814 T G 9.43E-04 Type 2 diabetes / / 17463246 rs4283388 chr2 173239722 C T 1.18E-07 Esophageal cancer (squamous cell) / / 22960999 rs13005010 chr2 173259273 G A 8.42E-04 Multiple complex diseases / / 17554300 rs10497382 chr2 173265462 T C 7.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs6707676 chr2 173273546 A C 1.01E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6711466 chr2 173274130 A G 2.69E-04 Type 2 diabetes / / 17463246 rs16860330 chr2 173278794 A T 1.22E-05 Glycosylated haemoglobin levels / / 17255346 rs17726737 chr2 173279650 T C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4972831 chr2 173282051 A G 8.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs7608097 chr2 173300053 T C 5.98E-04 Response to taxane treatment (placlitaxel) ITGA6 intron 23006423 rs12621278 chr2 173311553 A G 9.00E-23 Prostate cancer ITGA6 intron 19767753 rs12621278 chr2 173311553 A G 9.00E-23 Nasopharyngeal carcinoma ITGA6 intron 20512145 rs12621278 chr2 173311553 A G 0.000054 Prostate cancer ITGA6 intron 23555315 rs12621278 chr2 173311553 A G 0.00022 Prostate cancer (non-advanced prostate cancer) ITGA6 intron 23555315 rs12621278 chr2 173311553 A G 5.20E-05 Prostate cancer (early onset) ITGA6 intron 24740154 rs6726739 chr2 173320380 G A 6.79E-04 Multiple complex diseases ITGA6 intron 17554300 rs16860458 chr2 173331957 A G 3.44E-05 Parkinson's disease ITGA6 intron 21738487 rs2701268 chr2 173351199 G A 5.38E-04 Suicide attempts in bipolar disorder ITGA6 intron 21423239 rs2701268 chr2 173351199 G A 2.22E-04 Stroke ITGA6 intron pha002886 rs2737085 chr2 173352507 G T 0.000000203 Triglycerides ITGA6 missense 23063622 rs1574257 chr2 173373190 A G 1.22E-04 Alzheimer's disease (late onset) / / 21379329 rs11688498 chr2 173382300 C T 9.22E-05 Body Mass Index / / pha003020 rs7562865 chr2 173382865 T C 7.91E-05 Alzheimer's disease (late onset) / / 21379329 rs12052479 chr2 173404804 C A 1.22E-04 Alzheimer's disease (late onset) / / 21379329 rs3765065 chr2 173420254 T A 9.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs4972842 chr2 173429033 T A 2.04E-05 Telomere length PDK1 intron 23001564 rs3769321 chr2 173432354 A G 6.98E-04 Stroke PDK1 intron pha002886 rs13394924 chr2 173435757 C T 1.77E-04 Alzheimer's disease (late onset) PDK1 intron 21379329 rs6738196 chr2 173444462 C T 6.86E-04 Stroke PDK1 intron pha002886 rs16860693 chr2 173453278 T C 2.70E-04 Coronary heart disease PDK1 intron 21966275 rs12693005 chr2 173460640 T C 2.28E-04 Alzheimer's disease (late onset) PDK1 cds-synon 21379329 rs836589 chr2 173493078 A G 2.00E-06 Erectile dysfunction / / 22704111 rs74426112 chr2 173577908 C T 2.79E-04 Cocaine dependence / / 23958962 rs1349497 chr2 173592663 G C 3.98E-05 Response to taxane treatment (placlitaxel) LOC91149 intron 23006423 rs6755658 chr2 173635380 T C 5.22E-05 Bipolar disorder RAPGEF4 intron 19488044 rs16860884 chr2 173665907 A C 1.24E-04 Multiple complex diseases RAPGEF4 intron 17554300 rs3820852 chr2 173680085 C A 7.22E-05 Alzheimer's disease (late onset) RAPGEF4 intron 21379329 rs6715990 chr2 173694029 G A 9.59E-05 Alzheimer's disease (late onset) RAPGEF4 intron 21379329 rs2676510 chr2 173719520 G A 1.46E-04 Alzheimer's disease (late onset) RAPGEF4 intron 21379329 rs3769292 chr2 173726259 G A 8.44E-04 Multiple complex diseases RAPGEF4 intron 17554300 rs2676517 chr2 173749682 C T 5.64E-05 Alzheimer's disease (late onset) RAPGEF4 intron 21379329 rs13030842 chr2 173765808 T C 1.53E-04 Alzheimer's disease (late onset) RAPGEF4 intron 21379329 rs2553011 chr2 173779775 G A 1.37E-04 Alzheimer's disease (late onset) RAPGEF4 intron 21379329 rs2113807 chr2 173784658 A G 2.66E-04 Multiple complex diseases RAPGEF4 intron 17554300 rs2042561 chr2 173792625 G A 1.85E-04 Type 2 diabetes RAPGEF4 intron 17463246 rs2592941 chr2 173817340 G A 1.75E-04 Multiple complex diseases RAPGEF4 intron 17554300 rs2592941 chr2 173817340 G A 1.88E-05 Telomere length RAPGEF4 intron 20139977 rs3769247 chr2 173832803 A G 5.71E-04 Multiple complex diseases RAPGEF4 intron 17554300 rs750374 chr2 173834077 T C 4.34E-04 Type 2 diabetes RAPGEF4 intron 17463246 rs6752140 chr2 173834665 T C 4.43E-04 Type 2 diabetes RAPGEF4 intron 17463246 rs1026290 chr2 173841435 G A 4.60E-04 Myasthenia gravis RAPGEF4 intron 23055271 rs11685193 chr2 173864492 G A 6.26E-05 Serum metabolites RAPGEF4 intron 19043545 rs3769234 chr2 173867468 T C 7.11E-05 Serum metabolites RAPGEF4 intron 19043545 rs7604728 chr2 173867808 C T 0.0000153 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes RAPGEF4 intron 22628534 rs16861206 chr2 173892146 C T 4.10E-04 Multiple complex diseases RAPGEF4 intron 17554300 rs2305462 chr2 173895285 A G 7.67E-04 Amyotrophic Lateral Sclerosis RAPGEF4 intron 17827064 rs4972527 chr2 173915007 G A 5.99E-04 Smoking initiation RAPGEF4 intron 24665060 rs10187560 chr2 173925051 T C 8.98E-05 Breast cancer / / pha002853 rs11692252 chr2 173929607 T C 8.77E-04 Multiple complex diseases / / 17554300 rs989531 chr2 173933618 C T 2.87E-04 Multiple complex diseases / / 17554300 rs9636294 chr2 173954787 A G 1.75E-04 Multiple complex diseases ZAK intron 17554300 rs3769203 chr2 173955062 A G 9.02E-04 Response to taxane treatment (placlitaxel) ZAK intron 23006423 rs6758859 chr2 173965056 T C 1.19E-04 Multiple complex diseases ZAK intron 17554300 rs3754744 chr2 174002064 T C 3.80E-04 Response to taxane treatment (placlitaxel) ZAK intron 23006423 rs3754743 chr2 174002092 G T 4.12E-04 Response to taxane treatment (placlitaxel) ZAK intron 23006423 rs3769185 chr2 174013499 A G 7.08E-05 Amyotrophic lateral sclerosis ZAK intron 20801717 rs3769185 chr2 174013499 A G 0.0000453 Amyotrophic lateral sclerosis ZAK intron 23587638 rs3769185 chr2 174013499 A G 0.0000623 Amyotrophic lateral sclerosis ZAK intron 23587638 rs3769185 chr2 174013499 A G 7.31E-04 Glycemic traits (pregnancy) ZAK intron 23903356 rs3769185 chr2 174013499 A G 8.96E-04 Glycemic traits (pregnancy) ZAK intron 23903356 rs7575189 chr2 174015168 G A 6.98E-04 Multiple complex diseases ZAK intron 17554300 rs3769184 chr2 174019920 A G 1.68E-04 Glycemic traits (pregnancy) ZAK intron 23903356 rs3769184 chr2 174019920 A G 2.84E-04 Glycemic traits (pregnancy) ZAK intron 23903356 rs3769184 chr2 174019920 A G 4.19E-04 Stroke ZAK intron pha002886 rs7560960 chr2 174027123 T A 5.96E-04 Multiple complex diseases ZAK intron 17554300 rs1837470 chr2 174048371 A G 2.92E-05 Glycemic traits (pregnancy) ZAK intron 23903356 rs1837470 chr2 174048371 A G 4.04E-05 Glycemic traits (pregnancy) ZAK intron 23903356 rs3754741 chr2 174053219 A G 3.24E-04 Response to taxane treatment (placlitaxel) ZAK intron 23006423 rs2289399 chr2 174055731 A G 3.24E-04 Response to taxane treatment (placlitaxel) ZAK intron 23006423 rs8446 chr2 174090542 T C 5.17E-05 Parkinson's disease ZAK UTR-3 21248740 rs10182247 chr2 174094145 T C 1.24E-04 Parkinson's disease ZAK intron 21248740 rs3820831 chr2 174103428 C A 3.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZAK intron 20877124 rs6761224 chr2 174125960 T C 6.99E-04 Alcohol dependence ZAK intron 20201924 rs16861477 chr2 174135843 T A 6.86E-04 Suicide attempts in bipolar disorder MLK7-AS1 intron 21423239 rs1816811 chr2 174163320 G C 6.18E-04 Coronary heart disease / / 21606135 rs6712331 chr2 174165043 A C 5.54E-04 Coronary heart disease / / 21606135 rs7595292 chr2 174184206 A G 1.99E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1550623 chr2 174212894 G A 3.00E-08 Breast cancer / / 23535729 rs2288993 chr2 174230153 C G 6.63E-04 Lymphocyte counts CDCA7 intron 22286170 rs3816061 chr2 174232076 G A 7.19E-05 Multiple complex diseases CDCA7 intron 17554300 rs1047885 chr2 174233041 A G 3.06E-04 Multiple complex diseases CDCA7 UTR-3 17554300 rs6747034 chr2 174238868 A G 5.99E-04 Depression (quantitative trait) / / 20800221 rs1007833 chr2 174243438 A G 6.03E-05 Hemoglobin / / pha003098 rs7591287 chr2 174247919 A G 4.69E-05 Hemoglobin / / pha003098 rs10497394 chr2 174297659 C T 2.00E-08 Otitis media (chronic/recurrent) / / 23974705 rs1435767 chr2 174299698 A G 4.68E-05 Intracerebral hemorrhage / / 24656865 rs7574876 chr2 174315778 G T 2.30E-05 Urinary metabolites / / 21572414 rs2163960 chr2 174316051 C T 4.40E-05 Serum metabolites / / 19043545 rs10930597 chr2 174326845 C T 1.00E-08 Blood pressure measurement (high sodium and potassium intervention) / / 24165912 rs10930597 chr2 174326845 C T 4.00E-08 Blood pressure measurement (high sodium and potassium intervention) / / 24165912 rs10930597 chr2 174326845 C T 4.00E-08 Blood pressure measurement (low sodium intervention) / / 24165912 rs10930597 chr2 174326845 C T 5.00E-07 Blood pressure measurement (low sodium intervention) / / 24165912 rs10930597 chr2 174326845 C T 6.00E-06 Blood pressure measurement (high sodium and potassium intervention) / / 24165912 rs10930597 chr2 174326845 C T 7.00E-06 Blood pressure measurement (low sodium intervention) / / 24165912 rs1992013 chr2 174329983 T G 6.13E-06 White blood cell count / / 21738479 rs7349190 chr2 174336177 C T 7.45E-04 Multiple complex diseases / / 17554300 rs4597485 chr2 174337508 T A 8.20E-04 Multiple complex diseases / / 17554300 rs2358259 chr2 174348043 A G 1.39E-05 Age-related macular degeneration / / pha000001 rs7590983 chr2 174362349 T C 6.00E-06 Anthropometric traits / / 19260139 rs7581219 chr2 174363574 G A 1.08E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7584596 chr2 174450397 T C 5.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs577687 chr2 174451691 A G 3.22E-05 Tunica Media / / pha003037 rs4972593 chr2 174462854 T A 4.00E-08 End-stage renal disease in Type 1 diabetics / / 24029427 rs6711114 chr2 174477802 G A 9.62E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs755816 chr2 174480881 T C 2.50E-04 Multiple complex diseases / / 17554300 rs12476327 chr2 174490915 C A 8.10E-06 Urinary metabolites / / 21572414 rs13028485 chr2 174504924 G A 2.00E-06 Multiple myeloma (IgH translocation) / / 23502783 rs554934 chr2 174508541 C G 1.30E-05 Urinary metabolites / / 21572414 rs13001922 chr2 174516818 T C 1.70E-06 Urinary metabolites / / 21572414 rs6739381 chr2 174541290 G A 3.58E-05 Parkinson's disease / / 24842889 rs752280 chr2 174553435 A C 6.94E-05 Body Mass Index / / pha003009 rs752280 chr2 174553435 A C 8.13E-05 Waist Circumference / / pha003025 rs7575459 chr2 174587180 C T 8.54E-05 Cognitive decline / / 22054870 rs7602424 chr2 174705545 G T 4.97E-04 Type 2 diabetes / / 17463246 rs6433441 chr2 174706535 T C 2.00E-05 Type 2 diabetes / / 17463246 rs1024125 chr2 174708199 T C 2.25E-05 Type 2 diabetes / / 17463246 rs1024125 chr2 174708199 T C 8.54E-04 Response to TNF antagonist treatment / / 21061259 rs2137804 chr2 174733318 A G 4.98E-04 Smoking quantity / / 24665060 rs4972416 chr2 174737068 A G 8.70E-04 Type 2 diabetes / / 17463246 rs2048666 chr2 174748572 T C 3.87E-05 Type 2 diabetes / / 17463246 rs2048666 chr2 174748572 T C 1.55E-04 Multiple complex diseases / / 17554300 rs9287966 chr2 174755423 G A 1.34E-04 Type 2 diabetes / / 17463246 rs7589313 chr2 174771911 C A 3.35E-04 Multiple complex diseases SP3 UTR-3 17554300 rs6718080 chr2 174785819 C G 6.90E-04 Multiple complex diseases SP3 intron 17554300 rs12474886 chr2 174798136 C G 6.27E-04 Type 2 diabetes SP3 intron 17463246 rs1446572 chr2 174803714 T C 8.71E-04 Type 2 diabetes SP3 intron 17463246 rs4972622 chr2 174808216 C T 8.63E-04 Type 2 diabetes SP3 intron 17463246 rs7572596 chr2 174837877 T C 6.73E-04 Type 2 diabetes / / 17463246 rs12466262 chr2 174839747 C T 1.60E-05 Urinary metabolites / / 21572414 rs10497424 chr2 174840107 T C 8.32E-05 Cognitive test performance / / 20125193 rs16862246 chr2 174850890 G A 0.0000685 Panic disorder / / 23149450 rs16862246 chr2 174850890 G A 6.85E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs10497422 chr2 174852785 G T 1.58E-05 Alcohol dependence / / 19581569 rs2121362 chr2 174865857 C T 2.91E-04 Obesity (extreme) / / 21935397 rs7601227 chr2 174879174 T G 6.05E-04 Multiple complex diseases / / 17554300 rs1374315 chr2 174883399 G A 0.0000469 Migraine / / 22678113 rs1374315 chr2 174883399 G A 4.69E-05 Migraine / / 22683712 rs3813817 chr2 174891414 C T 9.27E-05 Cognitive impairment induced by topiramate LOC100128905 UTR-3 22091778 rs6756828 chr2 174919189 C T 4.23E-06 Hearing function / / 21493956 rs2044471 chr2 174931957 G A 6.79E-05 Information processing speed / / 21130836 rs6737629 chr2 174939168 C T 5.60E-08 Breast cancer OLA1 UTR-3 20852631 rs10930640 chr2 174997017 C T 7.21E-05 Bipolar disorder OLA1 intron 22925353 rs1595796 chr2 174998583 A G 6.40E-05 Schizophrenia OLA1 intron 19571808 rs4972431 chr2 174999188 C T 1.38E-07 Meningococcal disease OLA1 intron 20694013 rs11674895 chr2 175013963 C A 8.07E-05 Bipolar disorder OLA1 intron 22925353 rs2119137 chr2 175017714 A G 1.83E-04 Schizophrenia OLA1 intron 19197363 rs17319260 chr2 175026635 T A 1.50E-05 Urinary metabolites OLA1 intron 21572414 rs16862445 chr2 175026805 C T 7.12E-04 Multiple complex diseases OLA1 intron 17554300 rs4350713 chr2 175127653 A G 7.55E-04 Premature ovarian failure / / 19508998 rs13035792 chr2 175185780 C A 4.19E-05 Multiple complex diseases / / 17554300 rs7582977 chr2 175205513 T C 2.78E-04 Alzheimer's disease / / 24755620 rs7580375 chr2 175231574 A G 2.30E-05 Urinary metabolites CIR1 intron 21572414 rs6716400 chr2 175265912 T C 0.00018 Breast cancer SCRN3 missense 23555315 rs17255817 chr2 175289314 T C 7.05E-05 Cognitive test performance SCRN3 cds-synon 20125193 rs4972663 chr2 175316379 T C 7.37E-05 Hearing function GPR155 intron 17255346 rs7424769 chr2 175363694 C A 4.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs13008567 chr2 175422978 A T 4.19E-04 Multiple complex diseases / / 17554300 rs4972450 chr2 175436940 G A 0.0005859 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WIPF1 missense 23233654 rs4972450 chr2 175436940 G A 5.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) WIPF1 missense 23233662 rs1367217 chr2 175446734 C T 0.0006024 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WIPF1 intron 23233654 rs1367217 chr2 175446734 C T 6.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) WIPF1 intron 23233662 rs1430182 chr2 175457155 C T 9.98E-05 Bone mineral density WIPF1 intron 19181680 rs1430181 chr2 175459021 G T 0.0007225 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WIPF1 intron 23233654 rs1430181 chr2 175459021 G T 7.23E-04 Methotrexate clearance (acute lymphoblastic leukemia) WIPF1 intron 23233662 rs13427312 chr2 175463793 T G 2.62E-05 Brain derived neurotrophic factor levels,in serum WIPF1 intron 22047184 rs10221651 chr2 175466160 A G 1.29E-05 Brain derived neurotrophic factor levels,in serum WIPF1 intron 22047184 rs6756690 chr2 175466441 G A 1.48E-05 Brain derived neurotrophic factor levels,in serum WIPF1 intron 22047184 rs4595937 chr2 175471607 G T 1.08E-05 Brain derived neurotrophic factor levels,in serum WIPF1 intron 22047184 rs6745914 chr2 175475851 A G 1.68E-05 Brain derived neurotrophic factor levels,in serum WIPF1 intron 22047184 rs1991600 chr2 175495311 C T 8.06E-05 Insulin-related traits WIPF1 intron pha002901 rs6716254 chr2 175542474 T C 8.05E-06 Osteoarthritis WIPF1 intron 22763110 rs6738929 chr2 175562223 G T 9.25E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12620150 chr2 175565552 C T 2.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12472540 chr2 175575649 A G 5.61E-04 Stroke / / pha002886 rs2646143 chr2 175594381 A G 2.54E-04 Disc degeneration (lumbar) / / 24216480 rs2646179 chr2 175598518 C T 0.000018 Migraine / / 22678113 rs2646179 chr2 175598518 C T 1.80E-05 Migraine / / 22683712 rs7575145 chr2 175599106 T C 0.0000359 Migraine / / 22678113 rs7575145 chr2 175599106 T C 3.59E-05 Migraine / / 22683712 rs2123117 chr2 175602014 T C 9.60E-04 Multiple complex diseases / / 17554300 rs733187 chr2 175602377 G A 5.75E-06 Asthma (childhood onset) / / 23829686 rs6708544 chr2 175604194 G A 0.0000449 Migraine / / 22678113 rs6708544 chr2 175604194 G A 4.49E-05 Migraine / / 22683712 rs2600685 chr2 175627048 T C 0.0000519 Migraine CHR/1 intron 22678113 rs2600685 chr2 175627048 T C 5.19E-05 Migraine CHR/1 intron 22683712 rs1376872 chr2 175641528 A G 7.51E-04 Multiple complex diseases / / 17554300 rs2646157 chr2 175724102 G A 6.68E-06 Tuberculosis CHN1 intron 22306650 rs3771910 chr2 175747467 C T 9.96E-04 Parkinson's disease CHN1 intron 17052657 rs3771917 chr2 175836843 T C 5.25E-05 Statin-induced myopathy CHN1 intron 21826682 rs1150186 chr2 175893333 T C 3.08E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs1406752 chr2 175898417 A G 1.34E-05 Aging (time to event) / / 21782286 rs1153717 chr2 175906278 T C 3.37E-04 Age-related macular degeneration / / 22125219 rs1145068 chr2 175924184 C G 2.49E-04 Cholesterol / / 17255346 rs212373 chr2 175928683 C T 1.37E-04 Cholesterol / / 17255346 rs212371 chr2 175930305 C A 2.98E-04 Multiple complex diseases / / 17554300 rs1153697 chr2 175934881 T A 1.75E-04 Cholesterol / / 17255346 rs12615750 chr2 175935264 T C 9.17E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs212349 chr2 175944398 T C 6.20E-04 Alcohol consumption (maxi-drinks) ATF2 intron 24277619 rs35522805 chr2 175952130 G A 2.36E-04 Alcohol consumption (maxi-drinks) ATF2 intron 24277619 rs2072538 chr2 175962664 C T 2.36E-04 Alcohol consumption (maxi-drinks) ATF2 intron 24277619 rs1153681 chr2 175964587 G A 6.58E-04 Multiple complex diseases ATF2 intron 17554300 rs1153676 chr2 175980994 C A 3.36E-05 Lymphocyte counts ATF2 intron 22286170 rs1153676 chr2 175980994 C A 6.20E-04 Alcohol consumption (maxi-drinks) ATF2 intron 24277619 rs1153672 chr2 175986973 G A 6.07E-04 Multiple complex diseases ATF2 intron 17554300 rs13388308 chr2 176006027 C T 6.20E-04 Alcohol consumption (maxi-drinks) ATF2 intron 24277619 rs11888507 chr2 176012621 C T 2.82E-04 Cholesterol ATF2 intron 17255346 rs11894840 chr2 176017065 G C 7.22E-04 Multiple complex diseases ATF2 intron 17554300 rs17270532 chr2 176017196 A C 6.68E-04 Multiple complex diseases ATF2 intron 17554300 rs21818 chr2 176035845 G A 1.55E-04 Cholesterol / / 17255346 rs10497436 chr2 176175847 A G 5.89E-04 Multiple complex diseases / / 17554300 rs4972755 chr2 176239849 G A 3.00E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs16863160 chr2 176241475 C T 1.61E-05 Multiple complex diseases / / 17554300 rs2461772 chr2 176273267 T C 7.60E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs2461771 chr2 176277378 T C 7.70E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs2437910 chr2 176277484 G T 7.70E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs2461751 chr2 176289319 G A 8.00E-06 Electrocardiographic conduction measures / / 19389651 rs10930700 chr2 176320079 C T 8.88E-04 Type 2 diabetes / / 17463246 rs6736485 chr2 176381919 C T 9.53E-04 Multiple complex diseases / / 17554300 rs9646737 chr2 176389860 C T 1.00E-04 Prostate cancer / / 21743057 rs7603466 chr2 176391679 G A 6.02E-04 Multiple complex diseases / / 17554300 rs6723304 chr2 176398354 G A 1.00E-04 Prostate cancer / / 21743057 rs13024746 chr2 176403883 C T 5.00E-07 Urinary metabolites / / 21572414 rs7581058 chr2 176488243 A T 2.00E-04 Multiple complex diseases / / 17554300 rs4344900 chr2 176488944 G A 0.0000622 Primary sclerosing cholangitis / / 23603763 rs6720081 chr2 176502826 C T 1.80E-05 Urinary metabolites / / 21572414 rs7563215 chr2 176541561 G A 7.28E-04 Type 2 diabetes / / 17463246 rs10170575 chr2 176543105 C T 1.20E-06 Urinary metabolites / / 21572414 rs6734627 chr2 176552192 G T 1.50E-06 Urinary metabolites / / 21572414 rs1446825 chr2 176601473 T C 1.50E-05 Urinary metabolites / / 21572414 rs7604880 chr2 176613859 T C 5.39E-04 Multiple complex diseases / / 17554300 rs11685409 chr2 176618964 C T 3.31E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1348844 chr2 176631320 G T 9.54E-04 Parkinson's disease / / 17052657 rs10497444 chr2 176652167 A G 2.35E-05 Information processing speed / / 21130836 rs16863399 chr2 176653490 C A 6.12E-04 Multiple complex diseases / / 17554300 rs7566934 chr2 176654738 A G 7.00E-06 Information processing speed / / 21130836 rs6755005 chr2 176675516 A G 2.08E-05 Information processing speed / / 21130836 rs1446829 chr2 176677084 A G 7.09E-06 Information processing speed / / 21130836 rs1446797 chr2 176689882 G A 6.34E-04 Tourette syndrome / / 22889924 rs6737825 chr2 176707805 G A,T 9.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9287989 chr2 176717741 T C 4.00E-06 Periodontal microbiota / / 22699663 rs1816920 chr2 176723746 A G 0.0008976 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1816920 chr2 176723746 A G 8.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10165932 chr2 176727921 T A 0.0008816 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10165932 chr2 176727921 T A 8.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2884887 chr2 176730467 C T 9.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2034282 chr2 176733910 T C 9.49E-05 Monocyte counts / / pha003089 rs4972489 chr2 176734598 A C 8.00E-06 Obesity-related traits / / 23251661 rs1020410 chr2 176784138 T C 6.00E-07 Obesity-related traits / / 23251661 rs12621733 chr2 176791642 G A 5.47E-05 Monocyte chemoattractant protein-1 KIAA1715 UTR-3 pha003071 rs2166528 chr2 176806653 C T 3.87E-06 Heart Rate KIAA1715 intron pha003054 rs4369827 chr2 176809605 T C 8.48E-07 Obesity-related traits KIAA1715 intron 23251661 rs12613466 chr2 176817947 T C 9.16E-05 Monocyte chemoattractant protein-1 KIAA1715 intron pha003071 rs34897061 chr2 176829117 G C 0.00054 Breast cancer KIAA1715 missense 23555315 rs9646792 chr2 176838145 A C 3.65E-05 Interstitial lung disease KIAA1715 intron 23583980 rs12464144 chr2 176850319 G A 5.47E-05 Monocyte chemoattractant protein-1 KIAA1715 intron pha003071 rs4972801 chr2 176883266 G C 1.73E-05 Urate levels / / 23263486 rs12465451 chr2 176893529 T C 3.30E-07 Multiple complex diseases / / 17554300 rs974699 chr2 176900090 C T 2.97E-04 Bipolar disorder / / 18317468 rs1099941 chr2 176907320 C A 1.54E-05 Serum metabolites / / 19043545 rs1099942 chr2 176923881 C T 6.30E-06 Monocyte chemoattractant protein-1 / / pha003071 rs847126 chr2 176936834 A G 4.46E-05 Parkinson's disease / / 17052657 rs7601234 chr2 176981343 G T 1.00E-06 Amyotrophic lateral sclerosis (sporadic) HOXD10 nearGene-5 24529757 rs2592394 chr2 176991779 A G 5.00E-07 Magnesium levels / / 20700443 rs1348808 chr2 177000616 T C 1.63E-10 Narcolepsy HOXD-AS2 intron 19629137 rs1348807 chr2 177005757 C T 8.24E-05 Longevity / / 20304771 rs4972806 chr2 177012578 C T 8.00E-06 IgG glycosylation / / 23382691 rs7606110 chr2 177028551 T C 5.26E-04 Depression (quantitative trait) / / 20800221 rs2301301 chr2 177032267 T C 4.45E-04 Depression (quantitative trait) HOXD3 intron 20800221 rs13017511 chr2 177035395 A G 6.26E-04 Depression (quantitative trait) HOXD3 intron 20800221 rs711830 chr2 177037311 A C,G,T 2.20E-05 Urinary metabolites HOXD3 UTR-3 21572414 rs9141 chr2 177037970 T C 7.36E-04 Depression (quantitative trait) / / 20800221 rs2072590 chr2 177042633 A C 5.00E-14 Ovarian cancer HOXD-AS1 intron 20852632 rs2072590 chr2 177042633 A C 3.00E-10 Ovarian cancer HOXD-AS1 intron 23535730 rs2072590 chr2 177042633 A C 5.00E-11 Ovarian cancer HOXD-AS1 intron 23535730 rs1374325 chr2 177043971 G A 9.52E-04 Depression (quantitative trait) HOXD-AS1 intron 20800221 rs1374326 chr2 177058316 G A 9.68E-04 Alzheimer's disease / / 17998437 rs1026028 chr2 177070756 C A 3.41E-06 Alcohol dependence / / 23089632 rs2166512 chr2 177071181 T C 4.89E-06 Alcohol dependence / / 23089632 rs6714226 chr2 177076890 T G 2.50E-05 Urinary metabolites / / 21572414 rs973406 chr2 177109731 C A 4.26E-04 Multiple complex diseases / / 17554300 rs970797 chr2 177111819 T G 7.60E-08 Facial morphology / / 22341974 rs4346418 chr2 177198249 C T 8.89E-04 Taste perception MTX2 intron 22132133 rs2689949 chr2 177199125 A G 2.53E-04 Taste perception MTX2 intron 22132133 rs818361 chr2 177210511 T C 2.27E-11 Narcolepsy / / 19629137 rs16863736 chr2 177233102 G A 5.83E-04 Multiple complex diseases / / 17554300 rs17338026 chr2 177258204 A G 4.74E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs16863792 chr2 177281955 G A 3.65E-04 Smoking quantity / / 24665060 rs6712002 chr2 177307266 T C 7.43E-04 Smoking quantity / / 24665060 rs6433589 chr2 177308941 G A 8.92E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6731638 chr2 177313675 A C 1.03E-04 Smoking quantity / / 24665060 rs6747963 chr2 177318061 A G 3.30E-04 Smoking quantity / / 24665060 rs13416965 chr2 177321586 C A 2.14E-22 Narcolepsy / / 19629137 rs3898818 chr2 177340813 T C 2.00E-04 Smoking initiation / / 24665060 rs10497446 chr2 177376868 T C 4.38E-04 Alzheimer's disease / / 24755620 rs2969344 chr2 177382589 G A 2.63E-06 Insulin-related traits / / pha002901 rs17400244 chr2 177390453 T G 4.29E-04 Alzheimer's disease / / 17998437 rs1037222 chr2 177401438 G A 3.47E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1037222 chr2 177401438 G A 3.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1448539 chr2 177411799 T C 5.93E-05 Blood Pressure / / pha002903 rs1448537 chr2 177429661 A T 9.50E-05 Acute lung injury / / 22295056 rs2922336 chr2 177430878 A C 1.42E-04 Acute lung injury / / 22295056 rs2922338 chr2 177431607 T C 5.44E-06 Acute lung injury / / 22295056 rs1448522 chr2 177442640 G A 7.88E-07 Acute lung injury / / 22295056 rs2922346 chr2 177445709 A G 8.14E-07 Acute lung injury / / 22295056 rs12473379 chr2 177446323 C G 2.12E-07 Acute lung injury / / 22295056 rs4893896 chr2 177452904 A G 2.00E-06 Acute lung injury / / 22295056 rs4893900 chr2 177456444 G A 3.39E-06 Acute lung injury / / 22295056 rs4894166 chr2 177459411 A G 2.49E-04 Acute lung injury / / 22295056 rs7588541 chr2 177464995 T C 1.73E-04 Acute lung injury / / 22295056 rs4893907 chr2 177471223 T C 3.37E-06 Acute lung injury / / 22295056 rs1075120 chr2 177471457 C T 2.35E-06 Acute lung injury / / 22295056 rs4378837 chr2 177471763 T C 2.91E-06 Acute lung injury / / 22295056 rs1448528 chr2 177476850 A G 2.91E-06 Acute lung injury / / 22295056 rs11693766 chr2 177479968 C G 2.27E-04 Acute lung injury / / 22295056 rs2922309 chr2 177480054 A G 5.82E-04 Alzheimer's disease / / 17998437 rs2922309 chr2 177480054 A G 1.25E-04 Acute lung injury / / 22295056 rs2969363 chr2 177483123 G A 7.80E-05 Bipolar disorder / / 19488044 rs2969363 chr2 177483123 G A 3.13E-04 Alzheimer's disease (late onset) / / 21379329 rs2969363 chr2 177483123 G A 7.66E-05 Bipolar Disorder / / pha002858 rs16864122 chr2 177511440 C T 0.000000252 CD8+ T cell IFN-gamma response to smallpox vaccine / / 22661280 rs6433602 chr2 177519429 C T 2.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4893912 chr2 177523894 A G 1.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17345806 chr2 177531742 A G 7.70E-04 Acute lung injury / / 22295056 rs2710024 chr2 177532212 T C 1.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10497448 chr2 177532513 A C,G,T 7.70E-04 Acute lung injury / / 22295056 rs12991707 chr2 177533063 G C 7.70E-04 Acute lung injury / / 22295056 rs12997926 chr2 177533880 A G 7.83E-04 Acute lung injury / / 22295056 rs2362866 chr2 177538266 G A 1.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1513879 chr2 177558110 A G 9.81E-04 Acute lung injury / / 22295056 rs7567249 chr2 177558340 C T 9.81E-04 Acute lung injury / / 22295056 rs16864246 chr2 177559549 G A 5.02E-04 Smoking initiation / / 24665060 rs16864246 chr2 177559549 G A 8.57E-05 Body Mass Index / / pha003014 rs713285 chr2 177595862 A G 7.65E-05 Serum metabolites / / 19043545 rs1355847 chr2 177597274 C A 1.65E-05 Serum metabolites / / 19043545 rs4893916 chr2 177616216 A G 8.70E-06 Urinary metabolites / / 21572414 rs13021051 chr2 177616426 T C 4.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6758766 chr2 177630608 T G 1.70E-05 Urinary metabolites / / 21572414 rs11889984 chr2 177633313 T C 6.40E-06 Urinary metabolites / / 21572414 rs1533303 chr2 177677487 C T 8.18E-05 Cognitive performance / / 19734545 rs1534472 chr2 177677940 A G 3.08E-04 Multiple complex diseases / / 17554300 rs1534472 chr2 177677940 A G 8.39E-05 Cognitive performance / / 19734545 rs16864480 chr2 177680063 A G 4.92E-04 Tourette syndrome / / 22889924 rs840690 chr2 177681805 A C 7.31E-05 Multiple complex diseases / / 17554300 rs13032587 chr2 177683404 T C 3.82E-06 Post-operative nausea and vomiting / / 21694509 rs16864519 chr2 177687534 G A 1.13E-06 Post-operative nausea and vomiting / / 21694509 rs840706 chr2 177692572 A G 6.91E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1866131 chr2 177710534 T C 7.98E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6723196 chr2 177713373 A G 4.78E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1513870 chr2 177716131 A G 6.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs874416 chr2 177752461 C T 8.75E-04 Multiple complex diseases / / 17554300 rs6724100 chr2 177756733 T C 3.73E-04 Multiple complex diseases / / 17554300 rs10497473 chr2 177768589 C T 6.45E-04 Multiple complex diseases / / 17554300 rs11890791 chr2 177773103 C T 7.09E-04 Multiple complex diseases / / 17554300 rs16864700 chr2 177775920 G A 2.94E-04 Multiple complex diseases / / 17554300 rs16864702 chr2 177776684 G C 3.68E-04 Multiple complex diseases / / 17554300 rs10497471 chr2 177789538 A G 4.20E-04 Multiple complex diseases / / 17554300 rs6717501 chr2 177819209 C T 4.95E-06 Post-operative nausea and vomiting / / 21694509 rs16864835 chr2 177869199 G T 5.81E-04 Type 2 diabetes / / 17463246 rs4894230 chr2 177876027 A T 6.07E-04 Type 2 diabetes / / 17463246 rs4894232 chr2 177882193 G A 1.40E-05 Urinary metabolites / / 21572414 rs9287995 chr2 177884232 C T 6.02E-05 Pulmonary function in asthmatics / / 23541324 rs1104779 chr2 177890113 G A 9.00E-05 Coffee consumption / / 21357676 rs16864871 chr2 177902066 C G 6.24E-04 Multiple complex diseases / / 17554300 rs4894236 chr2 177905572 C T 1.27E-04 Telomere length / / 21573004 rs1529093 chr2 177909595 T C 2.00E-06 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1529098 chr2 177914806 G A 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12105278 chr2 177929191 C G 5.99E-04 Depression (quantitative trait) / / 20800221 rs17683237 chr2 177929684 C T 5.16E-04 Multiple complex diseases / / 17554300 rs1534682 chr2 177932237 T C 1.72E-04 Aortic root size / / 21223598 rs1529090 chr2 177935071 G A 9.02E-05 Aging (time to event) / / 21782286 rs4894243 chr2 177962141 C T 7.46E-05 Alcohol dependence / / 19581569 rs2706137 chr2 177991618 G A 3.82E-04 Gallstones / / 17632509 rs2706123 chr2 178029850 C T 6.60E-05 Hypothyroidism / / 22493691 rs12693115 chr2 178041663 T C 7.96E-04 Multiple complex diseases / / 17554300 rs13029183 chr2 178087851 A G 5.44E-05 Kawasaki disease HNRNPA3 UTR-3 22081228 rs1806686 chr2 178146269 C T 7.08E-04 Type 2 diabetes / / 17463246 rs1806686 chr2 178146269 C T 8.40E-04 Multiple complex diseases / / 17554300 rs1806686 chr2 178146269 C T 7.90E-06 Urinary metabolites / / 21572414 rs1806686 chr2 178146269 C T 3.66E-04 Smoking cessation / / 24665060 rs7568033 chr2 178148288 C G 2.30E-04 Gallstones / / 17632509 rs12105484 chr2 178172511 G T 0.00000193 Triglycerides LOC100130691 intron 23063622 rs4893825 chr2 178298687 T C 6.95E-04 Type 2 diabetes AGPS intron 17463246 rs17326999 chr2 178360075 G A 1.13E-04 Aortic root size AGPS intron 21223598 rs6433672 chr2 178378175 C A 5.80E-04 Multiple complex diseases AGPS intron 17554300 rs7588049 chr2 178390778 T C 6.56E-04 Multiple complex diseases AGPS intron 17554300 rs16865334 chr2 178398479 A G 1.65E-04 Multiple complex diseases AGPS intron 17554300 rs13004955 chr2 178398923 T A 6.22E-04 Type 2 diabetes AGPS intron 17463246 rs4893829 chr2 178399810 C T 6.03E-04 Multiple complex diseases AGPS intron 17554300 rs10803912 chr2 178407176 C A 3.89E-04 Multiple complex diseases AGPS UTR-3 17554300 rs2293475 chr2 178407897 T C 5.64E-04 Multiple complex diseases AGPS UTR-3 17554300 rs12988366 chr2 178417945 G T 3.73E-04 Multiple complex diseases / / 17554300 rs1348851 chr2 178418677 A G 9.04E-04 Multiple complex diseases / / 17554300 rs11889488 chr2 178426793 C T 8.98E-04 Multiple complex diseases / / 17554300 rs41493944 chr2 178454764 C T 4.03E-24 Narcolepsy / / 19629137 rs11689550 chr2 178456298 A G 8.28E-04 Type 2 diabetes / / 17463246 rs4893966 chr2 178470138 T C 6.62E-04 Type 2 diabetes / / 17463246 rs763757 chr2 178474768 C T 1.86E-04 Alzheimer's disease (late onset) / / 21379329 rs3731802 chr2 178475599 C T 1.63E-04 Alzheimer's disease (late onset) / / 21379329 rs2293471 chr2 178487729 T G 8.10E-04 Response to taxane treatment (placlitaxel) PDE11A nearGene-3 23006423 rs12618542 chr2 178494520 A G 1.00E-04 Information processing speed PDE11A intron 21130836 rs10469714 chr2 178498015 A G 9.02E-05 Information processing speed PDE11A intron 21130836 rs3770016 chr2 178540293 A G 1.28E-05 Information processing speed PDE11A intron 21130836 rs6739583 chr2 178553569 A T 2.58E-04 Prostate cancer mortality PDE11A intron 20978177 rs17400325 chr2 178565913 T C 1.90E-09 Myopia (Age of onset) PDE11A missense 23468642 rs13428806 chr2 178576681 G A 2.68E-07 Asthma PDE11A intron 20920776 rs13428806 chr2 178576681 G A 9.81E-04 Response to taxane treatment (placlitaxel) PDE11A intron 23006423 rs7573820 chr2 178586608 G A 9.26E-04 Multiple complex diseases PDE11A intron 17554300 rs3754993 chr2 178603588 G C 9.05E-05 Asthma PDE11A intron 20920776 rs4893839 chr2 178604146 T C 3.27E-06 Asthma PDE11A intron 20920776 rs11684634 chr2 178605770 C A 2.42E-08 Asthma PDE11A intron 20920776 rs11684634 chr2 178605770 C A 6.00E-05 Asthma PDE11A intron 20920776 rs1866210 chr2 178607273 G C 6.23E-05 Asthma PDE11A intron 20920776 rs1866209 chr2 178607359 G A 5.79E-06 Asthma PDE11A intron 20920776 rs998059 chr2 178612270 A C 1.31E-05 Asthma PDE11A intron 20920776 rs934798 chr2 178632479 A G 9.89E-04 Suicide attempts in bipolar disorder PDE11A intron 21423239 rs934798 chr2 178632479 A G 9.56E-05 Glucose levels PDE11A intron pha003058 rs41397549 chr2 178656825 T C 4.87E-04 Type 2 diabetes PDE11A intron 17463246 rs1946814 chr2 178679676 C T 4.43E-04 Aortic root size PDE11A intron 21223598 rs13413635 chr2 178680431 A G 3.00E-07 Heart rate PDE11A intron 23583979 rs6433698 chr2 178681534 C T 9.38E-05 Body Composition PDE11A intron pha003012 rs3821009 chr2 178682471 C T 5.16E-73 Multiple complex diseases PDE11A intron 17554300 rs3821010 chr2 178682655 A G 9.89E-05 Body Composition PDE11A intron pha003012 rs7567851 chr2 178684720 G C 3.00E-08 Height PDE11A intron 20881960 rs3770047 chr2 178685534 A G 8.66E-04 Suicide attempts in bipolar disorder PDE11A intron 21423239 rs934803 chr2 178690786 T C 0.000016 Coronary artery calcification PDE11A intron 23727086 rs934803 chr2 178690786 T C 7.01E-05 Eosinophil counts PDE11A intron pha003088 rs1438062 chr2 178695730 C T 6.15E-05 Body Composition PDE11A intron pha003012 rs753346 chr2 178697917 C T 1.05E-04 Lung function (forced vital capacity) PDE11A intron 24023788 rs753346 chr2 178697917 C T 2.68E-04 Lung function (forced expiratory volume in 1 second) PDE11A intron 24023788 rs6756606 chr2 178700057 G A 5.74E-05 Eosinophil counts PDE11A intron pha003088 rs17401468 chr2 178768683 T C 4.00E-04 Multiple complex diseases PDE11A intron 17554300 rs17401468 chr2 178768683 T C 8.22E-05 Basophils PDE11A intron pha003087 rs10497484 chr2 178776181 A G 1.02E-06 Paclitaxel sensitivity in NCI60 cancer cell lines PDE11A intron 21314952 rs1880916 chr2 178795430 G A 8.45E-05 Myopia (pathological) PDE11A intron 23049088 rs13389574 chr2 178808867 C A 9.85E-05 Cognitive test performance PDE11A intron 20125193 rs13390014 chr2 178809106 G A 9.85E-05 Cognitive test performance PDE11A intron 20125193 rs2573088 chr2 178836629 T C 1.06E-05 Asthma PDE11A intron 20920776 rs1546813 chr2 178873782 T G 9.84E-04 White matter integrity PDE11A intron 22425255 rs10206282 chr2 178883104 A AA,AG 4.74E-05 Multiple complex diseases PDE11A intron 17554300 rs374700253 chr2 178883104 A ACTTGACTTTAACTTGGCACA,ACTTGACTTTAACTTGGCACG 4.74E-05 Multiple complex diseases PDE11A intron 17554300 rs75997819 chr2 178883104 A G 4.74E-05 Multiple complex diseases PDE11A intron 17554300 rs2117740 chr2 178890329 A G 6.43E-06 Alcohol dependence (age at onset) PDE11A intron 24962325 rs11692993 chr2 178983208 A G 8.51E-04 Tourette syndrome RBM45 intron 22889924 rs16866133 chr2 179022610 T G 1.33E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs334102 chr2 179060313 A G 0.00006155 Sarcoidosis OSBPL6 intron 22952805 rs334103 chr2 179061110 T C 0.00009808 Sarcoidosis OSBPL6 intron 22952805 rs6719178 chr2 179087081 A T 6.06E-04 Coronary Artery Disease OSBPL6 intron 17634449 rs551368 chr2 179103588 A C 3.86E-04 Lung function (forced expiratory volume in 1 second) OSBPL6 intron 24023788 rs34479159 chr2 179104298 T C 6.00E-06 Breast size OSBPL6 intron 22747683 rs334601 chr2 179175022 T C 6.77E-06 Multiple complex diseases OSBPL6 intron 17554300 rs334595 chr2 179178506 A G 2.69E-04 Multiple complex diseases OSBPL6 intron 17554300 rs993598 chr2 179182695 G A 4.96E-04 Suicide attempts in bipolar disorder OSBPL6 intron 21423239 rs993598 chr2 179182695 G A 2.75E-05 Alcohol consumption OSBPL6 intron 23953852 rs12478760 chr2 179185051 A G 8.71E-04 Multiple complex diseases OSBPL6 UTR-5 17554300 rs7592114 chr2 179186529 G T 8.00E-05 Platelet counts OSBPL6 intron pha003100 rs1434087 chr2 179203797 G A 9.60E-04 Multiple complex diseases OSBPL6 cds-synon 17554300 rs1434091 chr2 179232560 A G 1.30E-05 Urinary metabolites OSBPL6 intron 21572414 rs1434094 chr2 179236048 T C 7.20E-06 Age-related macular degeneration OSBPL6 intron 20861866 rs10167053 chr2 179238993 C T 5.20E-05 Age-related macular degeneration OSBPL6 intron 20861866 rs6706354 chr2 179239068 A G 1.70E-05 Age-related macular degeneration OSBPL6 intron 20861866 rs6706354 chr2 179239068 A G 5.05E-05 Hemoglobin OSBPL6 intron pha003096 rs6706330 chr2 179242526 C T 5.60E-05 Age-related macular degeneration OSBPL6 intron 20861866 rs7580640 chr2 179248420 C T 3.00E-06 QT interval OSBPL6 intron 23166209 rs6736173 chr2 179251077 T C 5.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OSBPL6 intron 20877124 rs1434095 chr2 179254330 T C 1.00E-04 Intelligence (childhood) OSBPL6 intron 23358156 rs9283487 chr2 179296271 T C 3.00E-07 Multiple sclerosis (OCB status) PRKRA UTR-3 23472185 rs17225700 chr2 179336600 T C 2.45E-05 ldl cholesterol FKBP7 intron pha003077 rs2303536 chr2 179358665 A G 3.72E-04 Coronary heart disease PLEKHA3 cds-synon 21606135 rs3820979 chr2 179368982 A C 4.00E-04 Type 2 diabetes and 6 quantitative traits PLEKHA3 UTR-3 17848626 rs2366751 chr2 179427186 A G 3.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TTN cds-synon 20877124 rs3829746 chr2 179427536 T C 6.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TTN missense 20877124 rs10497518 chr2 179469386 A G 8.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TTN intron 20877124 rs12614435 chr2 179489726 A G 9.00E-04 Atrial fibrillation TTN intron 21846873 rs6723526 chr2 179498042 T C 6.90E-08 Health and aging,CVD and cancer age of onset TTN missense 22174011 rs2562832 chr2 179581835 C A 1.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) TTN missense 21239504 rs2627043 chr2 179582537 G T 0.000597 5-fluorouracil induced mucositis in response to colorectal cancer treatment TTN missense 22310351 rs17355446 chr2 179589241 G A 1.38E-05 Nicotine smoking TTN missense 19268276 rs72648951 chr2 179593761 T C 0.00021 Prostate cancer TTN missense 23555315 rs1883085 chr2 179604160 T G 1.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) TTN missense 21239504 rs2562829 chr2 179604366 T G 1.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) TTN missense 21239504 rs2627037 chr2 179606538 G A 1.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) TTN missense 21239504 rs10171049 chr2 179621864 G A 2.60E-05 Urinary metabolites TTN intron 21572414 rs12476289 chr2 179641975 C T 2.00E-06 QT interval TTN missense 20031603 rs2029395 chr2 179680221 T C 4.90E-05 Volumetric brain MRI / / 17903297 rs1489483 chr2 179688455 C T 4.58E-04 Alzheimer's disease / / 17998437 rs17362588 chr2 179721046 G A 4.00E-26 Heart rate CCDC141 missense 23583979 rs17362588 chr2 179721046 G A 4.75E-07 QRS duration CCDC141 missense 23583979 rs4894057 chr2 179735372 C T 2.00E-05 Urinary metabolites CCDC141 intron 21572414 rs1565287 chr2 179735946 A G 2.00E-05 Urinary metabolites CCDC141 intron 21572414 rs12693170 chr2 179737144 C A 1.90E-04 Blood pressure measurement (cold pressor test) CCDC141 intron 24165912 rs12693170 chr2 179737144 C A 3.76E-07 Blood pressure measurement (cold pressor test) CCDC141 intron 24165912 rs11693319 chr2 179738269 C T 2.00E-07 Blood pressure measurement (cold pressor test) CCDC141 intron 24165912 rs4894058 chr2 179738505 T C 2.90E-05 Triglycerides CCDC141 intron pha003080 rs6716304 chr2 179746322 G A 8.93E-04 Schizophrenia CCDC141 intron 19197363 rs6716304 chr2 179746322 G A 2.72E-05 Triglycerides CCDC141 intron pha003080 rs12693171 chr2 179748447 T C 1.80E-05 Urinary metabolites CCDC141 intron 21572414 rs1016799 chr2 179749332 C T 4.71E-07 Blood pressure measurement (cold pressor test) CCDC141 intron 24165912 rs13403584 chr2 179842062 T A 2.90E-04 Suicidal ideation CCDC141 intron 22030708 rs12474600 chr2 179884886 G A 4.57E-07 Receptive language ability CCDC141 intron 24687471 rs17362909 chr2 179900673 A G 7.85E-04 Response to cytadine analogues (cytosine arabinoside) CCDC141 intron 24483146 rs17362972 chr2 179909467 C T 5.43E-07 Receptive language ability CCDC141 intron 24687471 rs6709090 chr2 179923685 C T 8.45E-06 Receptive language ability / / 24687471 rs10497530 chr2 179924203 A G 8.31E-06 Receptive language ability / / 24687471 rs7575047 chr2 179932910 G A 9.85E-06 Receptive language ability / / 24687471 rs6433748 chr2 179933324 G A 9.93E-06 Receptive language ability / / 24687471 rs6433749 chr2 179933371 A C 9.94E-06 Receptive language ability / / 24687471 rs6433750 chr2 179933518 G A 9.97E-06 Receptive language ability / / 24687471 rs6433751 chr2 179933575 T C 9.98E-06 Receptive language ability / / 24687471 rs6433752 chr2 179933642 A T 1.00E-05 Receptive language ability / / 24687471 rs7578521 chr2 179933815 C T 1.00E-05 Receptive language ability / / 24687471 rs7579263 chr2 179934274 G A 1.02E-05 Receptive language ability / / 24687471 rs11893153 chr2 179934543 A G 9.48E-06 Receptive language ability / / 24687471 rs11903793 chr2 179934583 C G 1.09E-05 Receptive language ability / / 24687471 rs10497531 chr2 179935124 A T 1.09E-05 Receptive language ability / / 24687471 rs10497532 chr2 179935156 A G 1.23E-05 Receptive language ability / / 24687471 rs7582862 chr2 179935235 G C 1.04E-05 Receptive language ability / / 24687471 rs7609150 chr2 179935305 A G 9.95E-06 Receptive language ability / / 24687471 rs7596842 chr2 179935364 T C 9.62E-06 Receptive language ability / / 24687471 rs11885227 chr2 179935847 G A 7.38E-06 Receptive language ability / / 24687471 rs11896002 chr2 179935887 A C 7.19E-06 Receptive language ability / / 24687471 rs17363057 chr2 179936172 T G 5.22E-06 Receptive language ability / / 24687471 rs11885400 chr2 179936237 G T 5.61E-06 Receptive language ability / / 24687471 rs16866624 chr2 179936770 G C 5.96E-06 Receptive language ability / / 24687471 rs11897059 chr2 179939876 T C 1.36E-06 Receptive language ability / / 24687471 rs3816345 chr2 179974885 C T 2.85E-04 Height SESTD1 intron 17255346 rs10497534 chr2 180036775 G A 7.89E-05 Gallstones SESTD1 intron 17632509 rs10208593 chr2 180088968 C A 3.13E-04 Lymphocyte counts SESTD1 intron 22286170 rs1158446 chr2 180124327 A C 5.59E-05 Multiple complex diseases SESTD1 intron 17554300 rs17454527 chr2 180134018 C G 6.08E-06 Receptive language ability / / 24687471 rs10166788 chr2 180136431 G A 3.39E-04 Alzheimer's disease / / 22005930 rs10172996 chr2 180137861 G A 9.97E-04 Alzheimer's disease / / 22005930 rs6733818 chr2 180146275 G A 2.22E-04 Migraine / / 23793025 rs6733818 chr2 180146275 G A 7.00E-06 Migraine without aura / / 23793025 rs4365493 chr2 180173318 T C 6.50E-06 Urinary metabolites / / 21572414 rs10930865 chr2 180201455 A C 0.0001 Migraine / / 22678113 rs13403289 chr2 180216731 C A 6.00E-06 Presence of antiphospholipid antibodies / / 23509613 rs13403289 chr2 180216731 C A 4.10E-05 Crohn's disease (time to surgery) / / 23665963 rs13403289 chr2 180216731 C A 4.60E-05 Crohn's disease (need for surgery) / / 23665963 rs7425027 chr2 180220868 C T 7.31E-05 Hypertension (early onset hypertension) / / 22479346 rs13009904 chr2 180232128 C T 7.29E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7586173 chr2 180233627 T G 3.09E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7586173 chr2 180233627 T G 5.58E-05 Cholesterol / / pha003078 rs964327 chr2 180244477 A G 3.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs964327 chr2 180244477 A G 9.38E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1850523 chr2 180258493 T C 0.000016 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity / / 22945461 rs17363868 chr2 180272423 A G 2.11E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3856411 chr2 180286557 G A 2.56E-05 Personality dimensions / / 22628180 rs13390691 chr2 180326427 A T 7.10E-04 Multiple complex diseases ZNF385B intron 17554300 rs1517707 chr2 180330401 C G 7.11E-04 Multiple complex diseases ZNF385B intron 17554300 rs1517710 chr2 180336583 G A 5.99E-04 Type 2 diabetes ZNF385B intron 17463246 rs9973399 chr2 180338192 C A 3.41E-04 Multiple complex diseases ZNF385B intron 17554300 rs9973399 chr2 180338192 C A 2.30E-06 Parkinson's disease (familial) ZNF385B intron 18985386 rs6718486 chr2 180342873 C T 1.77E-04 Alzheimer's disease (late onset) ZNF385B intron 21379329 rs2271759 chr2 180348245 T G 2.05E-04 Prostate cancer mortality ZNF385B intron 20978177 rs2271759 chr2 180348245 T G 1.06E-04 Alzheimer's disease (late onset) ZNF385B intron 21379329 rs6708300 chr2 180352726 A G 1.23E-04 Prostate cancer mortality ZNF385B intron 20978177 rs12471789 chr2 180354193 C A 1.25E-04 Alzheimer's disease (late onset) ZNF385B intron 21379329 rs1517702 chr2 180366691 T A 3.83E-05 Attention deficit hyperactivity disorder ZNF385B intron pha002875 rs9288035 chr2 180370044 G A 4.04E-04 Suicide attempts in bipolar disorder ZNF385B intron 21423239 rs9288038 chr2 180374761 T G 9.50E-06 Urinary metabolites ZNF385B intron 21572414 rs13003114 chr2 180377479 T C 5.11E-05 Alzheimer's disease (late onset) ZNF385B intron 21379329 rs13003114 chr2 180377479 T C 8.92E-05 Parkinson's disease ZNF385B intron 21812969 rs17816020 chr2 180394948 A G 3.56E-05 Alzheimer's disease (late onset) ZNF385B intron 21379329 rs6715181 chr2 180396787 C T 1.10E-06 Prostate cancer mortality ZNF385B intron 20978177 rs6715297 chr2 180396869 C T 7.64E-04 Type 2 diabetes ZNF385B intron 17463246 rs6715297 chr2 180396869 C T 1.52E-06 Prostate cancer mortality ZNF385B intron 20978177 rs6715297 chr2 180396869 C T 9.65E-05 Alzheimer's disease (late onset) ZNF385B intron 21379329 rs1400822 chr2 180397455 C A,G,T 4.80E-05 Orofacial clefts ZNF385B intron 20023658 rs1400822 chr2 180397455 C A,G,T 1.71E-04 Alzheimer's disease (late onset) ZNF385B intron 21379329 rs16866767 chr2 180399670 G A 7.73E-04 Depression (quantitative trait) ZNF385B intron 20800221 rs6709838 chr2 180400813 C T 6.33E-04 Depression (quantitative trait) ZNF385B intron 20800221 rs11884072 chr2 180403128 T C 5.34E-04 Parkinson's disease ZNF385B intron 17052657 rs11884072 chr2 180403128 T C 5.12E-04 Depression (quantitative trait) ZNF385B intron 20800221 rs1546603 chr2 180435707 G A 5.60E-07 Urinary metabolites ZNF385B intron 21572414 rs1515308 chr2 180443444 T C 5.70E-05 Partial epilepsies ZNF385B intron 20522523 rs2138196 chr2 180452188 G A 5.97E-05 Partial epilepsies ZNF385B intron 20522523 rs11683314 chr2 180453399 C T 5.34E-05 Serum metabolites ZNF385B intron 19043545 rs16866832 chr2 180456562 T A 2.40E-04 Smoking cessation ZNF385B intron 24665060 rs16866836 chr2 180457484 A G 3.33E-05 Diabetes Mellitus ZNF385B intron pha003060 rs2887110 chr2 180464847 T A 3.50E-04 Smoking cessation ZNF385B intron 24665060 rs7608208 chr2 180481889 A G 3.44E-04 Body mass index ZNF385B intron 17255346 rs3112959 chr2 180492678 A G 0.000822 Salmonella-induced pyroptosis ZNF385B intron 22837397 rs925753 chr2 180492704 G C 3.10E-05 Serum metabolites ZNF385B intron 19043545 rs3112945 chr2 180501314 C T 7.54E-05 Coronary heart disease ZNF385B intron pha003035 rs2138193 chr2 180506934 T A 1.05E-05 Uric acid levels ZNF385B intron 21294900 rs10930879 chr2 180507781 T C 6.92E-06 Body mass index ZNF385B intron 17255346 rs6743733 chr2 180511629 T C 8.62E-04 Response to taxane treatment (placlitaxel) ZNF385B intron 23006423 rs2056109 chr2 180538442 A G 8.50E-04 Obesity (extreme) ZNF385B intron 21935397 rs7424112 chr2 180546233 T G 6.50E-04 Obesity (extreme) ZNF385B intron 21935397 rs932116 chr2 180555019 G C 7.38E-04 Obesity (extreme) ZNF385B intron 21935397 rs2222033 chr2 180556229 A C 3.60E-07 Urinary metabolites ZNF385B intron 21572414 rs2222033 chr2 180556229 A C 7.33E-04 Obesity (extreme) ZNF385B intron 21935397 rs16866933 chr2 180566678 G A 6.00E-14 Sudden cardiac arrest ZNF385B intron 21658281 rs2008230 chr2 180568986 A C 2.37E-05 Relative hand skill in reading disability ZNF385B intron 24068947 rs881737 chr2 180580275 T C 5.10E-04 Smoking initiation ZNF385B intron 24665060 rs1964081 chr2 180591421 T C 3.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZNF385B intron 20877124 rs4556941 chr2 180626921 T G 1.12E-04 Parkinson's disease ZNF385B intron 17052657 rs4556941 chr2 180626921 T G 8.00E-05 Amyotrophic Lateral Sclerosis ZNF385B intron 17362836 rs16866996 chr2 180658729 G C 1.05E-04 Multiple complex diseases ZNF385B intron 17554300 rs357708 chr2 180664033 A G 4.64E-05 HIV-1 control ZNF385B intron 20041166 rs6733426 chr2 180830958 A G 4.59E-05 Hemoglobin CWC22 intron pha003096 rs6733426 chr2 180830958 A G 4.30E-05 Hematocrit CWC22 intron pha003097 rs262302 chr2 180931461 T C 8.34E-04 Multiple complex diseases / / 17554300 rs4125973 chr2 180946075 T C 9.41E-04 Response to alcohol consumption (flushing response) / / 24277619 rs12623675 chr2 180972595 A G 5.69E-04 Alzheimer's disease / / 17998437 rs16867190 chr2 180976481 G T 3.47E-04 Response to alcohol consumption (flushing response) / / 24277619 rs17793860 chr2 180979913 T C 4.68E-04 Multiple complex diseases / / 17554300 rs17793860 chr2 180979913 T C 1.70E-05 Urinary metabolites / / 21572414 rs1518430 chr2 180989284 C G 1.16E-04 Alzheimer's disease / / 17998437 rs10497560 chr2 180995313 G A 6.37E-05 Information processing speed / / 21130836 rs16867209 chr2 180999625 C T 3.88E-05 Type 2 diabetes / / 17463246 rs6758849 chr2 181001230 A C 1.09E-05 Glycemic traits (pregnancy) / / 23903356 rs13404412 chr2 181003750 T C 3.66E-04 Glycemic traits (pregnancy) / / 23903356 rs982813 chr2 181005674 G C 5.29E-04 Glycemic traits (pregnancy) / / 23903356 rs11900518 chr2 181008960 T C 2.81E-04 Glycemic traits (pregnancy) / / 23903356 rs11900565 chr2 181009003 T C 1.60E-04 Glycemic traits (pregnancy) / / 23903356 rs11900565 chr2 181009003 T C 6.95E-04 Glycemic traits (pregnancy) / / 23903356 rs17180327 chr2 181016133 A G 6.80E-07 Schizophrenia / / 21926974 rs17180327 chr2 181016133 A G 0.0000129 Schizophrenia / / 23637625 rs11689740 chr2 181016851 C G 1.25E-04 Glycemic traits (pregnancy) / / 23903356 rs11689740 chr2 181016851 C G 4.41E-04 Glycemic traits (pregnancy) / / 23903356 rs16867220 chr2 181020320 G A 1.20E-04 Type 2 diabetes / / 17463246 rs1401105 chr2 181025248 A G 9.71E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs6433833 chr2 181027688 T C 3.14E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs2887172 chr2 181034436 G A 8.30E-06 Lipid traits / / 21777205 rs2887173 chr2 181036060 G A 2.10E-04 Alzheimer's disease (late onset) / / 21379329 rs16867225 chr2 181041286 G A 3.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs7597201 chr2 181042370 T G 4.31E-04 Multiple sclerosis (OCB status) / / 23785401 rs6433837 chr2 181069983 C T 3.92E-04 Glycemic traits (pregnancy) / / 23903356 rs13418455 chr2 181076749 C T 1.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs7580896 chr2 181083696 A G 1.30E-04 Breast cancer / / 22452962 rs7580896 chr2 181083696 A G 1.12E-05 Glycemic traits (pregnancy) / / 23903356 rs7580896 chr2 181083696 A G 6.42E-06 Glycemic traits (pregnancy) / / 23903356 rs10497564 chr2 181086493 C T 5.06E-05 Glycemic traits (pregnancy) / / 23903356 rs2368139 chr2 181090941 C T 9.39E-08 Glycemic traits (pregnancy) / / 23903356 rs2368141 chr2 181092024 T A 4.77E-06 Glycemic traits (pregnancy) / / 23903356 rs7578753 chr2 181100938 C A 5.43E-06 Glycemic traits (pregnancy) / / 23903356 rs2368110 chr2 181115711 G A 5.42E-04 Type 2 diabetes / / 17463246 rs3936728 chr2 181121917 A G 9.31E-06 Glycemic traits (pregnancy) / / 23903356 rs6755569 chr2 181177756 C T 2.01E-06 Glycemic traits (pregnancy) / / 23903356 rs2176588 chr2 181261617 A G 4.86E-05 Blood Pressure / / pha002898 rs934882 chr2 181339431 G A 4.30E-05 Crohn's disease / / 20570966 rs1072038 chr2 181349830 A G 3.86E-05 Asthma / / 11022011 rs1072038 chr2 181349830 A G 8.35E-05 Multiple complex diseases / / 17554300 rs1453054 chr2 181359907 T G 1.04E-04 Multiple complex diseases / / 17554300 rs16867321 chr2 181362379 C A,G,T 2.00E-06 Obesity / / 21552555 rs11888446 chr2 181370895 G A 7.01E-07 Multiple complex diseases / / 17554300 rs10497567 chr2 181403464 G A 4.00E-04 Type 2 diabetes / / 17846126 rs991055 chr2 181468010 G A 1.73E-04 Multiple complex diseases / / 17554300 rs7595450 chr2 181481806 G C 7.82E-04 Multiple complex diseases / / 17554300 rs11896300 chr2 181492024 C T 4.90E-05 Hypertension (early onset hypertension) / / 22479346 rs933784 chr2 181511500 T C 4.62E-04 Multiple complex diseases / / 17554300 rs918959 chr2 181513729 G A 2.00E-06 Systemic lupus erythematosus / / 21408207 rs13029379 chr2 181586726 C T 5.36E-04 Coronary Artery Disease / / 17634449 rs13029379 chr2 181586726 C T 5.56E-04 Stroke / / pha002887 rs4362518 chr2 181625664 A G 6.63E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11676386 chr2 181659620 C A 3.95E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6758984 chr2 181698136 A G 3.81E-05 Major depressive disorder / / 22472876 rs4233776 chr2 181718781 G A 9.62E-04 HIV-1 viral setpoint / / 17641165 rs7559620 chr2 181734782 A C 3.96E-04 Myocardial Infarction / / pha002873 rs4666644 chr2 181755429 G C 1.23E-05 Major depressive disorder / / 22472876 rs13031974 chr2 181757693 A G 1.73E-05 Major depressive disorder / / 22472876 rs10178015 chr2 181773176 G A 9.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs4263076 chr2 181779679 C T 8.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs4263076 chr2 181779679 C T 2.76E-05 Major depressive disorder / / 22472876 rs7578218 chr2 181855823 C G 5.44E-04 Type 2 diabetes UBE2E3 intron 17463246 rs7569991 chr2 181975252 T G 5.48E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs6433894 chr2 181977227 A G 2.75E-06 White blood cell count / / 21738479 rs6731186 chr2 181977953 T C 7.15E-06 White blood cell count / / 21738479 rs7588217 chr2 181988909 C T 3.39E-06 White blood cell count / / 21738479 rs13010713 chr2 181996045 A G 5.00E-11 Celiac disease / / 20190752 rs13010713 chr2 181996045 A G 5.00E-11 Asthma / / 21150878 rs13010713 chr2 181996045 A G 4.74E-11 Celiac disease and Rheumatoid arthritis / / 21383967 rs13010713 chr2 181996045 A G 4.74E-11 Multiple sclerosis / / 22190364 rs1018326 chr2 182007800 T C 2.00E-06 Ankylosing spondylitis / / 20062062 rs1018326 chr2 182007800 T C 3.91E-06 White blood cell count / / 21738479 rs1018326 chr2 182007800 T C 3.10E-16 Celiac disease / / 22057235 rs13025711 chr2 182019461 T C 2.47E-05 Asthma / / 23181788 rs11693055 chr2 182033294 A G 6.80E-05 Tooth agenesis (mandibular third molar) / / 24172245 rs4233792 chr2 182062313 T C 6.27E-04 Type 2 diabetes / / 17463246 rs4667158 chr2 182091564 T C 8.38E-04 Type 2 diabetes / / 17463246 rs16867404 chr2 182174452 G A 3.22E-04 Common variable immunodeficiency / / 21497890 rs16867406 chr2 182189405 C T 6.10E-05 Obsessive-compulsive disorder / / 24821223 rs16867406 chr2 182189405 C T 6.10E-05 Obsessive-compulsive disorder / / 24821223 rs17198619 chr2 182190558 G T 5.81E-04 Suicide attempts in bipolar disorder / / 21041247 rs16867410 chr2 182201746 G A 1.22E-04 Multiple complex diseases / / 17554300 rs16867420 chr2 182226778 T C 8.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs7602460 chr2 182261869 A G 6.00E-06 Atrioventricular conduction / / 21041692 rs12328393 chr2 182291035 A T 3.13E-06 Insulin-related traits / / 22791750 rs13389861 chr2 182291620 T C 4.67E-06 Insulin-related traits / / 22791750 rs1449263 chr2 182319301 C T 3.00E-23 White blood cell count / / 21738480 rs12988934 chr2 182323665 C T 2.00E-14 White blood cell types ITGA4 intron 21738478 rs1375493 chr2 182323766 G A 5.10E-07 Blood cell counts and traits,in red and white blood cells ITGA4 intron 21153663 rs2124440 chr2 182328214 G A 5.00E-17 Monocyte counts ITGA4 intron 23314186 rs1449264 chr2 182336474 T C 7.60E-04 Coronary heart disease ITGA4 intron 21966275 rs11694175 chr2 182338027 T C 1.96E-04 Alzheimer's disease ITGA4 intron 22005930 rs3770123 chr2 182344221 A C 5.21E-06 Osteoarthritis ITGA4 intron 21871595 rs155100 chr2 182350087 T A 2.20E-04 Alzheimer's disease ITGA4 intron 22005930 rs155104 chr2 182351216 T C 2.13E-04 Alzheimer's disease ITGA4 intron 22005930 rs155106 chr2 182351352 G T 2.87E-04 Alzheimer's disease ITGA4 intron 22005930 rs10172410 chr2 182352568 T C 2.90E-07 Osteoarthritis ITGA4 intron 21871595 rs2198731 chr2 182369945 A T 7.08E-04 Multiple complex diseases ITGA4 intron 17554300 rs3770112 chr2 182377541 G A 4.93E-08 Testicular cancer ITGA4 intron 19483682 rs1026404 chr2 182379191 A G 5.24E-04 Multiple complex diseases ITGA4 intron 17554300 rs3770110 chr2 182382367 G T 8.57E-04 Parkinson's disease ITGA4 intron 16252231 rs10514624 chr2 182418293 T C 1.21E-04 Multiple complex diseases CERKL intron 17554300 rs10490688 chr2 182422458 C A 2.84E-05 Multiple complex diseases CERKL intron 17554300 rs6706370 chr2 182427920 T A 4.35E-05 Multiple complex diseases CERKL intron 17554300 rs10427270 chr2 182436295 G C 7.93E-05 Multiple complex diseases CERKL intron 17554300 rs895901 chr2 182437094 T A 1.40E-05 Multiple complex diseases CERKL intron 17554300 rs993648 chr2 182455994 C T 3.00E-06 Response to iloperidone treatment (QT prolongation) CERKL intron 18521091 rs1116329 chr2 182465301 G A 7.40E-04 Aortic root size CERKL intron 21223598 rs10497581 chr2 182493051 T C 3.72E-04 Stroke (pediatric) CERKL intron 22990015 rs1441147 chr2 182511856 T C 3.00E-06 Lung function (forced expiratory volume in 1 second) CERKL intron 24023788 rs1441147 chr2 182511856 T C 9.00E-06 Lung function (forced vital capacity) CERKL intron 24023788 rs10207791 chr2 182522862 G A 1.35E-04 Multiple complex diseases CERKL nearGene-5 17554300 rs3755022 chr2 182536951 G A 1.60E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs3755022 chr2 182536951 G A 3.44E-04 Lung function (forced vital capacity) / / 24023788 rs12053195 chr2 182540683 T C 2.96E-04 Multiple complex diseases NEUROD1 nearGene-3 17554300 rs4666794 chr2 182554073 T C 2.04E-05 Iron status biomarkers / / 19084217 rs4666795 chr2 182554108 G A 2.30E-05 Iron status biomarkers / / 19084217 rs4666795 chr2 182554108 G A 0.0000377 Body mass index / / 23001569 rs4666572 chr2 182555564 C T 6.44E-05 Multiple complex diseases / / 17554300 rs2583008 chr2 182572502 T G 4.50E-04 Multiple complex diseases / / 17554300 rs2696328 chr2 182572614 G T 6.20E-04 Multiple complex diseases / / 17554300 rs1441158 chr2 182581409 A T 6.04E-04 Multiple complex diseases / / 17554300 rs11904490 chr2 182584021 C A 4.63E-05 Lipoproteins / / pha003079 rs12611771 chr2 182594588 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs16867495 chr2 182622603 A G 5.46E-04 Multiple complex diseases / / 17554300 rs10183527 chr2 182623490 A G 2.73E-04 Multiple complex diseases / / 17554300 rs13424337 chr2 182629582 A G 2.49E-04 Multiple complex diseases / / 17554300 rs13424337 chr2 182629582 A G 6.42E-04 Insulin resistance / / 21901158 rs6718469 chr2 182716326 G A 9.97E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs1157595 chr2 182749568 T C 4.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13419647 chr2 182781419 C T 4.16E-04 Multiple complex diseases SSFA2 intron 17554300 rs2303554 chr2 182792984 T A 7.48E-09 Statin-induced myopathy SSFA2 missense 21826682 rs6433943 chr2 182815579 A G 8.91E-05 Body Mass Index / / pha003022 rs1153744 chr2 182859734 C A 3.80E-04 Alzheimer's disease (late onset) PPP1R1C intron 21379329 rs1196185 chr2 182884959 T A 7.90E-05 Schizophrenia PPP1R1C intron 19571809 rs12989378 chr2 182896104 G A 1.68E-05 Telomere length PPP1R1C intron 23001564 rs6732434 chr2 182901257 A G 2.73E-04 Attention deficit hyperactivity disorder PPP1R1C intron 22012869 rs16822370 chr2 182906711 G T 5.55E-04 Alcohol dependence PPP1R1C intron 21314694 rs1882211 chr2 182981846 G C 7.98E-04 Type 2 diabetes PPP1R1C intron 17463246 rs2217616 chr2 182999648 T G 5.79E-04 Multiple complex diseases / / 17554300 rs1196058 chr2 183012930 A C 1.53E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PDE1A intron 20031582 rs1432523 chr2 183023484 A G 2.72E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PDE1A intron 20031582 rs1196067 chr2 183029612 A G 9.35E-04 Obesity (extreme) PDE1A intron 21935397 rs1432534 chr2 183057446 A C 8.75E-05 Chronic obstructive pulmonary disease PDE1A intron 19300482 rs1432534 chr2 183057446 A C 8.75E-05 Response to statin treatment (atorvastatin),change in cholesterol levels PDE1A intron 20031582 rs12467526 chr2 183065122 A G 2.57E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PDE1A intron 21844884 rs7578466 chr2 183113238 C T 3.63E-04 Multiple complex diseases PDE1A intron 17554300 rs6758334 chr2 183122038 T C 8.55E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines PDE1A intron 21844884 rs10193166 chr2 183133434 C A 9.42E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PDE1A intron 21844884 rs833142 chr2 183163148 A C 6.38E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PDE1A intron 20031582 rs2623410 chr2 183172364 T C 4.10E-06 Blood pressure PDE1A intron 21060006 rs2623410 chr2 183172364 T C 4.30E-05 Blood pressure PDE1A intron 21060006 rs2623410 chr2 183172364 T C 7.30E-04 Blood pressure PDE1A intron 21060006 rs11679657 chr2 183183111 G T 0.0000573 Tuberculosis with early age of onset PDE1A intron 22551897 rs12988258 chr2 183202412 G A 6.84E-04 Multiple complex diseases PDE1A intron 17554300 rs16823106 chr2 183216650 G T 7.47E-04 Multiple complex diseases PDE1A intron 17554300 rs16823120 chr2 183220865 A G 4.49E-04 Multiple complex diseases PDE1A intron 17554300 rs833115 chr2 183235574 C A 9.74E-04 Response to cytadine analogues (cytosine arabinoside) PDE1A intron 24483146 rs1898591 chr2 183242968 T G 0.000000793 LDL cholesterol PDE1A intron 23063622 rs2195611 chr2 183256567 C A 0.0001 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 PDE1A intron 21873659 rs1430148 chr2 183272699 C T 0.0000167 HDL cholesterol particle diameter PDE1A intron 23263444 rs1430147 chr2 183272945 C T 0.0000167 HDL cholesterol particle diameter PDE1A intron 23263444 rs10497600 chr2 183280294 T A 0.00000953 HDL cholesterol particle diameter PDE1A intron 23263444 rs41371048 chr2 183281664 G A 3.27E-04 Multiple complex diseases PDE1A intron 17554300 rs17343416 chr2 183286689 T C 6.93E-05 Smoking initiation PDE1A intron 24665060 rs10931012 chr2 183290028 G A 2.34E-04 Smoking initiation PDE1A intron 24665060 rs17356152 chr2 183292692 A G 0.0000087 HDL cholesterol particle diameter PDE1A intron 23263444 rs17265027 chr2 183293413 G A 0.00000269 HDL cholesterol particle diameter PDE1A intron 23263444 rs11686025 chr2 183293971 T C 0.00000732 HDL cholesterol particle diameter PDE1A intron 23263444 rs1946815 chr2 183298160 A G 0.00000209 HDL cholesterol particle diameter PDE1A intron 23263444 rs1583114 chr2 183299209 T G 0.00000228 HDL cholesterol particle diameter PDE1A intron 23263444 rs10207132 chr2 183300646 A G 0.00000299 HDL cholesterol particle diameter PDE1A intron 23263444 rs17356166 chr2 183300759 T C 0.00000633 HDL cholesterol particle diameter PDE1A intron 23263444 rs13407156 chr2 183302191 G C 0.00000273 HDL cholesterol particle diameter PDE1A intron 23263444 rs1992183 chr2 183303754 T C 1.96E-04 IgE levels PDE1A intron 17255346 rs17356207 chr2 183307827 A G 0.00000158 HDL cholesterol particle diameter PDE1A intron 23263444 rs16823254 chr2 183309282 T G 0.0000055 HDL cholesterol particle diameter PDE1A intron 23263444 rs16823257 chr2 183311380 A G 0.00000231 HDL cholesterol particle diameter PDE1A intron 23263444 rs1367203 chr2 183311523 A G 0.00000158 HDL cholesterol particle diameter PDE1A intron 23263444 rs6740889 chr2 183313207 T G 4.14E-04 IgE levels PDE1A intron 17255346 rs1125184 chr2 183320846 G A 0.00000563 HDL cholesterol particle diameter PDE1A intron 23263444 rs10497603 chr2 183336468 T C 5.11E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy PDE1A intron 23834954 rs7601804 chr2 183353582 A T 1.50E-04 Primary sclerosing cholangitis PDE1A intron 19944697 rs6433976 chr2 183376081 T C 4.06E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) PDE1A intron 24023788 rs2887208 chr2 183380753 T C 3.00E-04 Primary sclerosing cholangitis PDE1A intron 19944697 rs10182788 chr2 183400730 G A 3.31E-05 Serum metabolites / / 19043545 rs1430154 chr2 183401789 C G 3.32E-05 Serum metabolites / / 19043545 rs6758080 chr2 183442443 G A 1.32E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1527878 chr2 183446535 G A 1.98E-05 Serum metabolites / / 19043545 rs1527878 chr2 183446535 G A 6.30E-04 Smoking initiation / / 24665060 rs10497607 chr2 183458192 C T 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10497607 chr2 183458192 C T 4.75E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1527882 chr2 183461956 G A 1.92E-05 Bipolar disorder / / 20451256 rs1405945 chr2 183482466 T C 6.13E-06 Cognitive impairment induced by topiramate / / 22091778 rs7608820 chr2 183493891 T C 5.89E-04 Alzheimer's disease / / 17998437 rs10931027 chr2 183494672 T G 3.89E-04 Alzheimer's disease / / 17998437 rs17356672 chr2 183512335 A G 4.83E-04 Myocardial Infarction / / pha002883 rs288293 chr2 183631520 G A 1.20E-05 Coronary spasm D/JC10 intron 18075462 rs16823704 chr2 183667233 A C 7.45E-05 Type 2 diabetes / / 17463246 rs16823704 chr2 183667233 A C 1.03E-04 Progressive supranuclear palsy / / 21685912 rs10931041 chr2 183685562 C T 9.00E-06 Waist-to-hip circumference ratio (interaction) / / 23192594 rs17265803 chr2 183696519 T C 0.0000657 Schizophrenia / / 22440650 rs7606391 chr2 183760854 A C 8.13E-05 Brain lesion load / / 19010793 rs10164916 chr2 183767134 T G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1022337 chr2 183906786 T C 6.94E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs4666885 chr2 183939173 C T 5.32E-04 Type 2 diabetes / / 17463246 rs4666885 chr2 183939173 C T 1.03E-04 Hemoglobin concentration / / 20534544 rs2675043 chr2 183941444 T C 6.48E-05 Hemoglobin concentration / / 20534544 rs10460378 chr2 183957860 A C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes DUSP19 intron 22628534 rs11883456 chr2 183959461 G A 3.32E-05 Hemoglobin concentration DUSP19 intron 20534544 rs2138484 chr2 183977942 G A 4.44E-04 Type 2 diabetes / / 17463246 rs2138484 chr2 183977942 G A 1.67E-04 Hemoglobin concentration / / 20534544 rs2675058 chr2 183978549 A G 6.19E-06 Hemoglobin concentration / / 20534544 rs17704982 chr2 183981176 G A 2.77E-04 Lymphocyte counts / / 22286170 rs16823994 chr2 183981448 T C 8.14E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16824004 chr2 183985969 C T 7.54E-04 Insulin resistance / / 21901158 rs2251775 chr2 183988599 T C 8.58E-05 Hemoglobin concentration / / 20534544 rs2251775 chr2 183988599 T C 9.11E-04 Myocardial Infarction / / pha002873 rs1473617 chr2 183989863 C T 1.83E-05 Hemoglobin concentration NUP35 intron 20534544 rs10497622 chr2 183997890 A G 1.90E-04 Cholesterol NUP35 intron 17255346 rs2675098 chr2 184005606 G A 4.59E-04 Eye color NUP35 intron 23118974 rs2887233 chr2 184015089 G T 1.87E-04 Multiple complex diseases NUP35 intron 17554300 rs13410455 chr2 184023295 G A 2.44E-04 Cholesterol NUP35 intron 17255346 rs6434006 chr2 184024702 T C 8.58E-05 Hemoglobin concentration NUP35 intron 20534544 rs1882443 chr2 184046119 C T 8.58E-05 Hemoglobin concentration / / 20534544 rs6434019 chr2 184066858 C T 0.0008515 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6434019 chr2 184066858 C T 8.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10497624 chr2 184069020 C T 4.69E-04 Hemoglobin concentration / / 20534544 rs987607 chr2 184069487 A G 8.52E-04 Coronary Artery Disease / / 17634449 rs987607 chr2 184069487 A G 4.69E-04 Hemoglobin concentration / / 20534544 rs987607 chr2 184069487 A G 5.96E-06 Uric acid levels / / 21294900 rs987607 chr2 184069487 A G 3.51E-04 Myocardial Infarction / / pha002873 rs10931070 chr2 184084153 C G 1.95E-04 Birth weight / / 17255346 rs17758247 chr2 184085788 T C 6.99E-05 Height / / pha003011 rs4666621 chr2 184097520 A G 5.01E-04 Type 2 diabetes / / 17463246 rs1462529 chr2 184141848 A G 2.95E-05 Height / / pha003010 rs1462529 chr2 184141848 A G 1.67E-05 Height / / pha003011 rs842547 chr2 184262562 T C 8.17E-04 Multiple complex diseases / / 17554300 rs16824418 chr2 184275365 A C 8.78E-04 Type 2 diabetes / / 17463246 rs842565 chr2 184290177 T A 8.28E-04 Multiple complex diseases / / 17554300 rs1625832 chr2 184299168 A G 3.66E-04 Multiple complex diseases / / 17554300 rs1992179 chr2 184353455 T C 4.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13409979 chr2 184353810 G A 6.65E-06 Rheumatoid arthritis / / 19503088 rs13409979 chr2 184353810 G A 9.44E-06 Alopecia areata / / 22027810 rs4666630 chr2 184358804 G A 6.10E-06 Digit length ratio / / 20303062 rs1898582 chr2 184364553 G A 1.74E-04 Multiple complex diseases / / 17554300 rs1898582 chr2 184364553 G A 3.39E-04 Taste perception / / 22132133 rs9288091 chr2 184371403 G A 7.98E-05 Vaspin levels / / 22907691 rs9288091 chr2 184371403 G A 0.0000798 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs13426853 chr2 184391717 A G 2.95E-04 Multiple complex diseases / / 17554300 rs6712313 chr2 184392292 T C 2.67E-04 Multiple complex diseases / / 17554300 rs2368446 chr2 184407963 T C 5.30E-04 Alcohol dependence / / 20201924 rs2368423 chr2 184458832 G T 6.73E-05 Major depressive disorder (broad) / / 20038947 rs1406337 chr2 184476015 A G 7.60E-05 Height / / 17255346 rs13384559 chr2 184479350 A G 6.24E-05 Major depressive disorder (broad) / / 20038947 rs6737900 chr2 184483143 C T 6.16E-05 Major depressive disorder (broad) / / 20038947 rs6742026 chr2 184484253 C T 6.14E-05 Major depressive disorder (broad) / / 20038947 rs1463328 chr2 184502493 G A 4.09E-05 Coronary heart disease / / pha003030 rs4666636 chr2 184527836 T C 5.14E-05 Coronary heart disease / / pha003030 rs10931091 chr2 184533968 T C 3.45E-06 Heart Failure / / pha002885 rs7588905 chr2 184538604 G A 1.90E-04 Birth weight / / 17255346 rs10803967 chr2 184540102 G A 8.70E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13016089 chr2 184551466 A G 1.89E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1377767 chr2 184586627 G A 7.08E-04 Coronary heart disease / / 21606135 rs1733497 chr2 184623742 T C 5.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs826116 chr2 184750869 T C 9.85E-04 Multiple complex diseases / / 17554300 rs826140 chr2 184771169 C G 5.85E-05 Multiple complex diseases / / 17554300 rs826130 chr2 184793800 C T 3.79E-04 Birth weight / / 17255346 rs2165172 chr2 184800983 A G 0.00000908 HIV-1-specific cross-reactive neutralizing activity / / 23372753 rs10205814 chr2 184818243 G A 1.36E-04 Lung function (forced vital capacity) / / 24023788 rs4413128 chr2 184880887 C A 1.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4505485 chr2 184882169 A G 1.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6434057 chr2 184901392 G A 1.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12693368 chr2 184919967 C T 4.42E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1002331 chr2 184923473 T G 4.68E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1405193 chr2 184938401 C T 3.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1007465 chr2 184971481 A G 2.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1568958 chr2 184971569 G A 1.05E-04 Multiple complex diseases / / 17554300 rs2369200 chr2 184976536 T G 5.55E-04 Multiple complex diseases / / 17554300 rs1526208 chr2 185021912 G A 9.81E-06 Total ventricular volume / / 21116278 rs2887422 chr2 185033177 C A 1.40E-05 Urinary metabolites / / 21572414 rs1526197 chr2 185050101 A G 5.90E-06 Urinary metabolites / / 21572414 rs12471114 chr2 185067733 C T 6.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6738298 chr2 185093719 T G 1.88E-04 Type 2 diabetes / / 17846124 rs12621296 chr2 185099836 A G 8.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1455882 chr2 185107332 A G 8.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs985365 chr2 185111854 T C 8.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12988831 chr2 185114368 C T 8.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7558999 chr2 185127554 A T 2.59E-04 Multiple complex diseases / / 17554300 rs2198715 chr2 185212246 T C 8.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs17429535 chr2 185223403 T C 8.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs10203961 chr2 185224396 C T 8.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs7602691 chr2 185225038 A G 5.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10200357 chr2 185230499 A T 8.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs13015290 chr2 185232216 T A 8.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs12693375 chr2 185243700 C T 8.53E-04 Suicide attempts in bipolar disorder / / 21041247 rs12623744 chr2 185282393 T A 9.03E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs10931139 chr2 185289177 A G 1.86E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11691711 chr2 185293916 G A 2.00E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs12472209 chr2 185375265 G T 5.46E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs12477814 chr2 185400705 C T 6.71E-04 Alzheimer's disease / / 24755620 rs2033136 chr2 185405704 A C 5.26E-07 Multiple complex diseases / / 17554300 rs17430279 chr2 185436262 A G 4.00E-06 Obesity-related traits / / 23251661 rs181701 chr2 185445430 C T 5.81E-04 Multiple complex diseases / / 17554300 rs12693382 chr2 185467661 G A 0.0000692 Primary sclerosing cholangitis ZNF804A intron 23603763 rs17508595 chr2 185483108 C G 5.86E-04 Multiple complex diseases ZNF804A intron 17554300 rs359884 chr2 185486334 T C 9.70E-04 Alzheimer's disease ZNF804A intron 24755620 rs12613195 chr2 185489221 C G 1.01E-04 Multiple complex diseases ZNF804A intron 17554300 rs7597593 chr2 185533580 T C 8.77E-04 White matter integrity ZNF804A intron 22425255 rs7597593 chr2 185533580 T C 2.04E-06 Major depressive disorder ZNF804A intron 22472876 rs7597593 chr2 185533580 T C 8.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) ZNF804A intron 23453885 rs17508767 chr2 185535807 A G 5.21E-04 HIV-1 viral setpoint ZNF804A intron 17641165 rs2369595 chr2 185626426 C T 9.77E-04 White matter integrity ZNF804A intron 22425255 rs77224444 chr2 185627257 C G 0.0000929 Nonsyndromic striae distensae (stretch marks) ZNF804A intron 23633020 rs72901884 chr2 185629709 A C 0.0000998 Nonsyndromic striae distensae (stretch marks) ZNF804A intron 23633020 rs72905792 chr2 185726138 G A 0.0000803 Nonsyndromic striae distensae (stretch marks) ZNF804A intron 23633020 rs1820847 chr2 185742474 A G 4.46E-04 HIV-1 viral setpoint ZNF804A intron 17641165 rs7590852 chr2 185766912 T C 4.16E-06 Malaria ZNF804A intron 23717212 rs10497662 chr2 185769921 T C 4.11E-04 HIV-1 viral setpoint ZNF804A intron 17641165 rs17431742 chr2 185773401 C G 6.83E-04 Multiple complex diseases ZNF804A intron 17554300 rs725617 chr2 185778262 G A 4.60E-06 Malaria ZNF804A intron 23717212 rs1344706 chr2 185778428 A C 2.87E-04 Multiple complex diseases ZNF804A intron 17554300 rs1344706 chr2 185778428 A C 2.00E-07 Schizophrenia ZNF804A intron 18677311 rs1344706 chr2 185778428 A C 2.76E-04 Major depressive disorder ZNF804A intron 22472876 rs1583048 chr2 185783141 T C 2.93E-05 Information processing speed ZNF804A intron 21130836 rs1583048 chr2 185783141 T C 3.12E-04 Major depressive disorder ZNF804A intron 22472876 rs1583049 chr2 185792818 A G 1.74E-04 Type 2 diabetes ZNF804A intron 17463246 rs6726421 chr2 185796842 C G 9.20E-05 Multiple complex diseases ZNF804A intron 17554300 rs6755404 chr2 185797228 A C 1.00E-06 Malaria ZNF804A intron 23717212 rs4667002 chr2 185801755 A G 1.83E-04 Smoking quantity ZNF804A cds-synon 24665060 rs12693402 chr2 185808079 C T 7.81E-05 Response to lithium treatment in bipolar disorder / / 21961650 rs4380187 chr2 185811940 A C 6.00E-08 Schizophrenia / / 23974872 rs2163065 chr2 185853355 C T 7.90E-05 Multiple complex diseases / / 17554300 rs13386401 chr2 185865400 A G 9.57E-05 HIV-1 viral setpoint / / 17641165 rs13416716 chr2 185912017 C T 1.37E-05 HIV-1 viral setpoint / / 17641165 rs13392265 chr2 185994883 C T 9.73E-04 Multiple complex diseases / / 17554300 rs1483232 chr2 185995792 G A 5.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs11678036 chr2 186024735 C T 6.00E-06 IgG glycosylation / / 23382691 rs9288109 chr2 186025368 T C 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs9288109 chr2 186025368 T C 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs9288110 chr2 186025482 T C 1.85E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1038361 chr2 186031490 G A 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2369929 chr2 186101208 G A 9.79E-04 Multiple complex diseases / / 17554300 rs7577666 chr2 186116077 G A 2.02E-04 Smoking cessation / / 24665060 rs4487060 chr2 186148230 G A 2.99E-04 Smoking cessation / / 24665060 rs2113493 chr2 186152716 C T 8.45E-05 Smoking cessation / / 24665060 rs7608802 chr2 186162731 A G 3.06E-04 Smoking cessation / / 24665060 rs7608891 chr2 186162774 A G 3.00E-04 Smoking cessation / / 24665060 rs1364477 chr2 186184030 A G 6.00E-06 IgG glycosylation / / 23382691 rs13023579 chr2 186190812 G A 2.58E-04 Alzheimer's disease / / 24755620 rs850880 chr2 186205189 T C 0.00000009 Brain microstructure and intellectual performance / / 22723713 rs850906 chr2 186218867 T G 7.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1424528 chr2 186239607 A G 2.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs28801070 chr2 186244817 G A,C 7.26E-07 Multiple myeloma / / 22120009 rs62195162 chr2 186244945 A G 0.0000578 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10931170 chr2 186247637 C T 4.80E-05 Kawasaki disease / / 22446962 rs17403226 chr2 186253296 T C 1.00E-06 Urinary metabolites / / 21572414 rs16826790 chr2 186255088 C G 9.60E-07 Urinary metabolites / / 21572414 rs17403547 chr2 186291818 T G 4.82E-04 Parkinson's disease / / 17052657 rs16826853 chr2 186303297 A G 2.00E-05 Urinary metabolites / / 21572414 rs767036 chr2 186303487 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2059357 chr2 186325949 C G 1.14E-04 Gallstones / / 17632509 rs2059357 chr2 186325949 C G 5.20E-05 Mathematical ability / / 20039944 rs2081326 chr2 186338274 A G 3.50E-06 Urinary metabolites / / 21572414 rs2081326 chr2 186338274 A G 2.50E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4309546 chr2 186394606 A T 5.40E-06 Urinary metabolites / / 21572414 rs10445775 chr2 186423207 C T 3.10E-06 Urinary metabolites / / 21572414 rs2193612 chr2 186486890 A G 3.11E-04 Gallstones / / 17632509 rs11686018 chr2 186536737 C T 2.90E-05 Urinary metabolites / / 21572414 rs11693975 chr2 186538392 T A 9.15E-04 Multiple complex diseases / / 17554300 rs11693975 chr2 186538392 T A 2.20E-05 Urinary metabolites / / 21572414 rs4334457 chr2 186583961 T C 1.20E-05 Urinary metabolites / / 21572414 rs10202023 chr2 186591557 C T 8.48E-04 Multiple complex diseases / / 17554300 rs2193820 chr2 186693608 G A 5.29E-05 Multiple complex diseases FSIP2 intron 17554300 rs12616304 chr2 186756214 T C 9.06E-04 Acute lung injury / / 22295056 rs13021558 chr2 186777129 G A 1.48E-04 Acute lung injury / / 22295056 rs964744 chr2 186882149 C T 7.91E-05 Alcohol withdrawal symptoms / / 22072270 rs875161 chr2 186896504 A C 6.33E-04 Type 2 diabetes / / 17463246 rs6434158 chr2 186897066 A C 4.16E-04 Alzheimer's disease / / 17998437 rs10184559 chr2 186939737 T C 7.09E-04 Type 2 diabetes / / 17463246 rs10184559 chr2 186939737 T C 1.60E-05 Urinary metabolites / / 21572414 rs10189482 chr2 186960817 G A 8.30E-04 Type 2 diabetes / / 17463246 rs10189482 chr2 186960817 G A 1.20E-05 Urinary metabolites / / 21572414 rs10197403 chr2 186979237 T C 9.55E-04 Type 2 diabetes / / 17463246 rs4552153 chr2 186991136 T A 8.25E-04 Type 2 diabetes / / 17463246 rs4264536 chr2 186991571 A C 8.99E-04 Type 2 diabetes / / 17463246 rs4442964 chr2 186993455 T C 8.24E-04 Type 2 diabetes / / 17463246 rs12693436 chr2 187001076 G A 3.65E-04 Type 2 diabetes / / 17463246 rs16827526 chr2 187040829 T G 4.30E-05 Alcohol withdrawal symptoms / / 22072270 rs10497667 chr2 187043858 C G 1.40E-05 Urinary metabolites / / 21572414 rs34133588 chr2 187054504 A G 1.80E-05 Urinary metabolites / / 21572414 rs35942256 chr2 187055061 A G 1.80E-05 Urinary metabolites / / 21572414 rs2370672 chr2 187066334 C T 1.80E-05 Urinary metabolites / / 21572414 rs2370671 chr2 187066503 A G 2.50E-05 Urinary metabolites / / 21572414 rs7584724 chr2 187069917 T C 1.80E-05 Urinary metabolites / / 21572414 rs4461230 chr2 187071775 G A,T 1.80E-05 Urinary metabolites / / 21572414 rs16827602 chr2 187072508 T C 5.50E-06 Urinary metabolites / / 21572414 rs16827614 chr2 187079652 A C 1.90E-06 Urinary metabolites / / 21572414 rs3107174 chr2 187084689 C T 1.00E-05 Urinary metabolites / / 21572414 rs10931232 chr2 187125310 A G 1.20E-05 Urinary metabolites / / 21572414 rs13421948 chr2 187126560 T C 7.00E-05 Major depressive disorder / / 21042317 rs4522568 chr2 187149967 A C 7.20E-05 Major depressive disorder / / 21042317 rs4530331 chr2 187150058 G A 4.50E-05 Major depressive disorder / / 21042317 rs6744814 chr2 187156914 G A 5.60E-05 Major depressive disorder / / 21042317 rs10497668 chr2 187213730 T C 9.48E-05 Alcohol withdrawal symptoms / / 22072270 rs10497669 chr2 187225386 G A 7.59E-05 Brain lesion load / / 19010793 rs12467212 chr2 187264986 A G 6.50E-05 Major depressive disorder / / 21042317 rs3911238 chr2 187470344 G C 9.65E-05 Serum metabolites ITGAV intron 19043545 rs12620429 chr2 187489647 C A 9.55E-05 Brain lesion load ITGAV intron 19010793 rs7585471 chr2 187498562 A G 5.42E-05 Orofacial clefts ITGAV intron 22419666 rs1448427 chr2 187526672 G A 3.80E-05 Orofacial clefts ITGAV intron 22419666 rs3816386 chr2 187528635 A G 6.96E-04 Suicide attempts in bipolar disorder ITGAV intron 21423239 rs11685758 chr2 187533368 C T 8.49E-04 Suicide attempts in bipolar disorder ITGAV intron 21423239 rs4666713 chr2 187602188 T G 8.42E-07 Serum metabolites FAM171B intron 19043545 rs17750683 chr2 187620297 A T 1.53E-04 Suicide attempts in bipolar disorder FAM171B intron 21423239 rs13026081 chr2 187626338 C T 4.53E-04 Suicide attempts in bipolar disorder FAM171B cds-synon 21423239 rs4589713 chr2 187685145 C T 2.32E-04 Type 2 diabetes / / 17463246 rs10497673 chr2 187731384 T C 3.27E-05 stroke (ischemic) / / 17434096 rs17700953 chr2 187754997 C A 9.10E-05 Diabetic retinopathy / / 21441570 rs16828441 chr2 187784740 G T 2.50E-05 Bipolar disorder,affective / / 20528957 rs1562893 chr2 187802572 C T 5.60E-05 Diabetic retinopathy / / 21441570 rs4563188 chr2 187807952 G A 1.70E-05 Diabetic retinopathy / / 21441570 rs2370736 chr2 187880937 C A 1.90E-04 Prion diseases / / 22210626 rs17576323 chr2 188003118 T C 9.20E-05 Diabetic retinopathy / / 21441570 rs6712198 chr2 188119621 C T 3.60E-04 Multiple complex diseases / / 17554300 rs6721057 chr2 188131849 C A 3.63E-04 Multiple complex diseases / / 17554300 rs840616 chr2 188196469 T C 7.00E-07 Coronary heart disease / / 21378988 rs3771095 chr2 188211112 C T 6.80E-05 White matter hyperintensity burden CALCRL cds-synon 21681796 rs1706287 chr2 188224057 A G 2.10E-05 Urinary metabolites CALCRL intron 21572414 rs696574 chr2 188228516 T C 6.70E-05 White matter hyperintensity burden CALCRL intron 21681796 rs840617 chr2 188230333 A T 8.80E-05 White matter hyperintensity burden CALCRL intron 21681796 rs17464221 chr2 188278203 C T 2.23E-04 Gallstones CALCRL intron 17632509 rs113727256 chr2 188332602 T C 0.000011 Breast cancer (ER positive) TFPI missense 23555315 rs113727256 chr2 188332602 T C 0.00019 Breast cancer TFPI missense 23555315 rs4140885 chr2 188333064 G A 5.00E-08 Heart rate TFPI intron 23583979 rs7586970 chr2 188343497 T C 9.00E-06 Coronary heart disease TFPI missense 21378988 rs8176445 chr2 188362807 T C 5.53E-29 Cholesterol,total TFPI intron 23063622 rs8176445 chr2 188362807 T C 7.63E-13 LDL cholesterol TFPI intron 23063622 rs8176445 chr2 188362807 T C 8.38E-11 Triglycerides TFPI intron 23063622 rs8176433 chr2 188364825 C G 1.57E-19 Cholesterol,total TFPI intron 23063622 rs8176433 chr2 188364825 C G 1.89E-27 LDL cholesterol TFPI intron 23063622 rs2192825 chr2 188390819 C T 7.57E-05 Cognitive test performance TFPI intron 20125193 rs6434225 chr2 188461438 T C 1.46E-05 Menopause (age at onset) / / 19448619 rs12469114 chr2 188475822 G A 9.72E-04 Type 2 diabetes / / 17463246 rs7561970 chr2 188482933 A G 2.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs6712217 chr2 188500930 G A 2.29E-04 Coronary heart disease / / 21606135 rs13034939 chr2 188511096 A G 3.01E-04 Coronary heart disease / / 21606135 rs13388743 chr2 188573244 C T 8.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11675507 chr2 188594997 A G 3.54E-04 Parkinson's disease / / 17052657 rs11675507 chr2 188594997 A G 4.81E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2349872 chr2 188600305 G A 3.06E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1520475 chr2 188601258 C T 1.22E-04 Parkinson's disease / / 17052657 rs1402145 chr2 188601710 A C 3.49E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1402144 chr2 188607403 A G 3.64E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9288147 chr2 188609736 A G 4.00E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1520477 chr2 188611039 T C 3.94E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs4667192 chr2 188616978 T C 3.43E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs13032640 chr2 188618150 G A 3.33E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs6748449 chr2 188620681 C T 3.13E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs6715141 chr2 188623152 T C 2.70E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs6434236 chr2 188664170 C T 6.25E-05 Multiple complex diseases / / 17554300 rs4471853 chr2 188684507 A G 7.21E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs6728009 chr2 188700615 G T 2.64E-05 Coronary heart disease / / 21606135 rs12615952 chr2 188722417 C T 5.98E-04 Multiple complex diseases / / 17554300 rs1040172 chr2 188761539 T C 5.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1040172 chr2 188761539 T C 6.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16829362 chr2 188764415 A T 2.70E-05 Urinary metabolites / / 21572414 rs1317323 chr2 188798760 T C 1.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1317323 chr2 188798760 T C 3.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12469465 chr2 188800394 C T 1.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10170218 chr2 188814444 A C 5.10E-08 Post-traumatic stress disorder / / 24080187 rs17263610 chr2 188881350 C A 7.50E-06 Urinary metabolites / / 21572414 rs7569881 chr2 188953427 T C 5.76E-04 Acute lung injury / / 22295056 rs1439912 chr2 188957640 T C 2.09E-04 Vaspin levels / / 22907691 rs1439912 chr2 188957640 T C 0.0002087 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs893745 chr2 189088249 A G 2.53E-04 Smoking initiation / / 24665060 rs6759766 chr2 189113345 G A 1.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7582137 chr2 189122229 T C 1.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11688935 chr2 189175905 G A 2.10E-05 Type 2 diabetes GULP1 intron 17463249 rs11688935 chr2 189175905 G A 2.13E-05 Multiple complex diseases GULP1 intron 17554300 rs4128404 chr2 189179247 A G 9.96E-04 Type 2 diabetes GULP1 intron 17463246 rs10931347 chr2 189182307 A G 2.42E-05 Multiple complex diseases GULP1 intron 17554300 rs7566619 chr2 189199195 A G 2.00E-04 Cognitive impairment induced by topiramate GULP1 intron 22091778 rs10804020 chr2 189202876 A G 9.64E-04 Multiple complex diseases GULP1 intron 17554300 rs4274570 chr2 189266823 G A 1.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GULP1 intron 20877124 rs10931358 chr2 189270581 G C,T 4.68E-04 Type 2 diabetes GULP1 intron 17463246 rs10170220 chr2 189298118 C T 3.37E-04 Type 2 diabetes GULP1 intron 17463246 rs4667227 chr2 189306009 T C 4.35E-04 Type 2 diabetes GULP1 intron 17463246 rs13034731 chr2 189414364 C T 2.86E-04 Lung function (forced vital capacity) GULP1 intron 24023788 rs7425417 chr2 189425279 A G 6.26E-05 Type 2 diabetes GULP1 intron 17463246 rs3935690 chr2 189485156 T G 8.23E-04 Type 2 diabetes / / 17463246 rs3935690 chr2 189485156 T G 5.83E-04 Alzheimer's disease / / 17998437 rs11683183 chr2 189495871 A T 6.24E-04 Type 2 diabetes / / 17463246 rs1395868 chr2 189543514 G A 6.14E-04 Type 2 diabetes / / 17463246 rs10497681 chr2 189551707 A G 6.07E-04 Type 2 diabetes / / 17846124 rs10497681 chr2 189551707 A G 6.78E-05 Type 2 diabetes / / 17846125 rs10173369 chr2 189564693 G A 7.60E-04 Type 2 diabetes / / 17463246 rs1996987 chr2 189588449 T A 8.05E-04 Multiple complex diseases / / 17554300 rs1395864 chr2 189588880 A G 4.80E-04 Iris characteristics / / 21835309 rs10931378 chr2 189594624 C A,T 4.96E-04 Multiple complex diseases / / 17554300 rs781241 chr2 189607681 A G 6.82E-04 Multiple complex diseases DIRC1 intron 17554300 rs1400945 chr2 189614336 G A 4.47E-04 Type 2 diabetes DIRC1 intron 17463246 rs1589133 chr2 189644222 G C 1.81E-04 Multiple complex diseases DIRC1 intron 17554300 rs10166484 chr2 189648684 T C 3.43E-04 Multiple complex diseases DIRC1 intron 17554300 rs781288 chr2 189654868 A G 1.10E-04 Alzheimer's disease DIRC1 nearGene-5 17998437 rs940461 chr2 189670082 G A 5.44E-04 Type 2 diabetes / / 17463246 rs2708198 chr2 189671182 C T 8.25E-04 Type 2 diabetes / / 17463246 rs2690759 chr2 189671216 A G 5.77E-04 Alzheimer's disease / / 17998437 rs1518006 chr2 189697095 G A 6.52E-04 Multiple complex diseases / / 17554300 rs2675399 chr2 189718962 A G 6.00E-06 Obesity-related traits / / 23251661 rs4667253 chr2 189799682 T C 9.46E-04 Depression (quantitative trait) / / 20800221 rs7591905 chr2 189890114 C T 4.65E-06 Alzheimer's disease / / 21627779 rs10166301 chr2 189947814 C T 3.96E-05 Multiple complex diseases COL5A2 intron 17554300 rs17270952 chr2 190004843 C T 8.97E-04 Alzheimer's disease COL5A2 intron 17998437 rs1878085 chr2 190073366 A G 8.36E-04 Type 2 diabetes / / 17463246 rs1878085 chr2 190073366 A G 2.67E-04 Gallstones / / 17632509 rs4667272 chr2 190106465 T C 8.36E-04 Type 2 diabetes / / 17463246 rs10207860 chr2 190146586 C T 5.50E-05 Leukocyte Counts / / pha003091 rs1949604 chr2 190215928 G A 7.24E-04 Type 2 diabetes / / 17463246 rs10931414 chr2 190216503 G C 6.11E-04 Type 2 diabetes / / 17463246 rs10931418 chr2 190265035 C T 7.25E-04 Type 2 diabetes / / 17463246 rs11695159 chr2 190283215 C A 6.05E-04 Type 2 diabetes / / 17463246 rs13032853 chr2 190309412 T C 7.02E-04 Type 2 diabetes WDR75 intron 17463246 rs12693540 chr2 190352568 C T 9.80E-05 Parkinson's disease (familial) / / 18985386 rs11692009 chr2 190376388 G A 4.82E-04 Depression (quantitative trait) / / 20800221 rs10206036 chr2 190376873 G A 5.87E-04 Depression (quantitative trait) / / 20800221 rs17271148 chr2 190402222 G A 3.40E-04 Alcohol dependence / / 20201924 rs11539983 chr2 190425474 T C 5.70E-04 Alcohol dependence SLC40A1 UTR-3 20201924 rs10188230 chr2 190432613 T C 5.30E-04 Alcohol dependence SLC40A1 intron 20201924 rs930373 chr2 190443583 T C 6.95E-04 Type 2 diabetes SLC40A1 intron 17463246 rs11678005 chr2 190487106 C A,T 3.44E-04 Type 2 diabetes / / 17463246 rs11678005 chr2 190487106 C A,T 5.39E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4372939 chr2 190487474 G T 5.38E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6434355 chr2 190501523 C T 6.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs6756040 chr2 190502081 T C 3.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs6756913 chr2 190505766 G C 6.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs6761923 chr2 190507599 G C 5.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs7568449 chr2 190521054 C T 3.80E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11679767 chr2 190546300 A G 6.70E-05 Glioma (high-grade) ANKAR intron 19578366 rs7557519 chr2 190583187 C T 1.23E-04 Lymphocyte counts ANKAR intron 22286170 rs12053254 chr2 190607153 T C 6.00E-06 Obesity-related traits ANKAR intron 23251661 rs7606224 chr2 190643649 T C 1.28E-08 Bilirubin levels,in serum ORMDL1 intron 20639394 rs1899025 chr2 190649582 C T 8.40E-05 Glioma (high-grade) PMS1 intron 19578366 rs1899025 chr2 190649582 C T 1.80E-05 Hypertension PMS1 intron 22384028 rs5742967 chr2 190653750 C T 5.96E-06 Obesity-related traits PMS1 intron 23251661 rs5743030 chr2 190678545 G A 5.00E-06 Subcutaneous adipose tissue PMS1 intron 22589738 rs1233276 chr2 190684782 A G 8.98E-04 Suicide attempts in bipolar disorder PMS1 intron 21423239 rs5743185 chr2 190737838 G A 2.09E-11 Blood pressure PMS1 intron 21378095 rs5743185 chr2 190737838 G A 2.30E-10 Interleukin levels (IL10,IL1Ra,IL6),in plasma PMS1 intron 22205395 rs62184315 chr2 190771945 T C 4.00E-06 Alcohol dependence (age at onset) / / 24962325 rs7563391 chr2 190779803 G C 3.81E-06 Alcohol dependence (age at onset) / / 24962325 rs62184317 chr2 190781764 C T 3.81E-06 Alcohol dependence (age at onset) / / 24962325 rs7603201 chr2 190794653 A G 7.64E-05 Cognitive impairment induced by topiramate / / 22091778 rs2164252 chr2 190818454 G T 2.50E-05 Urinary metabolites / / 21572414 rs2168058 chr2 190818878 G A 2.80E-05 Urinary metabolites / / 21572414 rs6745182 chr2 190825226 T C 8.74E-06 Schizophrenia / / 21747397 rs16832254 chr2 190889261 G A 1.00E-05 Urinary metabolites / / 21572414 rs13010250 chr2 190900963 T C 2.10E-05 Urinary metabolites / / 21572414 rs2115552 chr2 190972205 G T 3.64E-04 Multiple complex diseases / / 17554300 rs13034723 chr2 190985680 G A 2.00E-08 Body mass index / / 22344221 rs13012077 chr2 191000031 C A,T 6.10E-04 Alzheimer's disease / / 22005930 rs2562817 chr2 191008125 T C 4.63E-04 Multiple complex diseases C2orf88 intron 17554300 rs4853684 chr2 191062951 A G 7.14E-05 Cytomegalovirus antibody response C2orf88 intron 21993531 rs16832420 chr2 191063071 G C 7.08E-05 Cytomegalovirus antibody response C2orf88 intron 21993531 rs11684995 chr2 191102249 G T 4.54E-05 Cytomegalovirus antibody response HIBCH intron 21993531 rs2099127 chr2 191102796 A C 4.50E-05 Cytomegalovirus antibody response HIBCH intron 21993531 rs11692448 chr2 191112241 G A 4.20E-05 Cytomegalovirus antibody response HIBCH intron 21993531 rs1072975 chr2 191121182 A T 8.18E-05 Aging (time to event) HIBCH intron 21782286 rs3791800 chr2 191149069 A C 4.22E-05 Cytomegalovirus antibody response HIBCH intron 21993531 rs4853689 chr2 191153014 A C 4.21E-05 Cytomegalovirus antibody response HIBCH intron 21993531 rs6752703 chr2 191164969 G A 4.13E-05 Cytomegalovirus antibody response HIBCH intron 21993531 rs2136569 chr2 191167414 T C 9.46E-04 Multiple complex diseases HIBCH intron 17554300 rs3791805 chr2 191172784 C G 3.98E-05 Cytomegalovirus antibody response HIBCH intron 21993531 rs291449 chr2 191177467 C T 7.03E-04 Multiple complex diseases HIBCH intron 17554300 rs4853693 chr2 191179508 T G 9.68E-05 Cytomegalovirus antibody response HIBCH intron 21993531 rs3791806 chr2 191182081 C T 3.96E-05 Cytomegalovirus antibody response HIBCH intron 21993531 rs291472 chr2 191190605 T C 6.76E-04 Multiple complex diseases / / 17554300 rs1882892 chr2 191213664 A G 7.99E-04 Alzheimer's disease INPP1 UTR-5 17998437 rs1882892 chr2 191213664 A G 8.90E-05 Serum metabolites INPP1 UTR-5 19043545 rs1882892 chr2 191213664 A G 7.18E-04 Lymphocyte counts INPP1 UTR-5 22286170 rs972689 chr2 191227492 A G 5.08E-04 Alzheimer's disease INPP1 intron 17998437 rs10931458 chr2 191390126 G A 4.10E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TMEM194B intron 24023788 rs10737936 chr2 191469731 T C 7.17E-04 HIV-1 viral setpoint / / 17641165 rs1023568 chr2 191515442 A T 1.20E-05 Subclinical atherosclerosis /B1 intron 17903303 rs2286896 chr2 191535576 T C 1.09E-11 Primary biliary cirrhosis /B1 intron 21399635 rs10931468 chr2 191538562 C A 2.00E-19 Primary biliary cirrhosis /B1 intron 21399635 rs3771317 chr2 191543962 T C 1.61E-12 Primary biliary cirrhosis /B1 intron 21399635 rs10202868 chr2 191563991 T C 2.70E-05 Urinary metabolites / / 21572414 rs7602459 chr2 191579425 A G 3.39E-04 Multiple complex diseases / / 17554300 rs7590384 chr2 191579573 T C 5.91E-04 Multiple complex diseases / / 17554300 rs6741418 chr2 191723719 C T 5.62E-05 Celiac disease / / 23936387 rs2355575 chr2 191728404 T G 6.13E-04 Myopia (pathological) / / 21095009 rs6734110 chr2 191838342 T C 4.92E-05 Acute lung injury STAT1 intron 21257790 rs2280232 chr2 191850766 C A 1.00E-04 Blood pressure STAT1 intron 21060006 rs2280232 chr2 191850766 C A 5.70E-05 Blood pressure STAT1 intron 21060006 rs12693591 chr2 191860502 C A 1.00E-04 Cognitive impairment induced by topiramate STAT1 intron 22091778 rs41382444 chr2 191880214 C T 5.01E-10 Primary biliary cirrhosis STAT1 nearGene-5 22936693 rs3024896 chr2 191896716 C T 6.19E-05 Insulin-related traits STAT4 intron pha002901 rs925847 chr2 191897540 C T 8.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) STAT4 intron 20877124 rs925847 chr2 191897540 C T 8.17E-05 Pulmonary function in asthmatics STAT4 intron 23541324 rs3821236 chr2 191902758 G A 8.00E-11 Systemic lupus erythematosus STAT4 intron 19165918 rs3821236 chr2 191902758 G A 3.00E-09 Systemic sclerosis STAT4 intron 20383147 rs3821236 chr2 191902758 G A 5.20E-13 Systemic lupus erythematosus STAT4 intron 21408207 rs3821236 chr2 191902758 G A 9.00E-08 Systemic sclerosis STAT4 intron 21779181 rs3821236 chr2 191902758 G A 8.49E-11 Hepatocellular carcinoma (hepatitis B virus related) STAT4 intron 23242368 rs6715106 chr2 191913034 A G 8.40E-09 Celiac disease STAT4 intron 22057235 rs6715106 chr2 191913034 A G 8.40E-09 Celiac disease STAT4 intron 23143596 rs16833215 chr2 191913799 A G 3.94E-06 Basophils STAT4 intron pha003087 rs11893432 chr2 191921874 C G 1.53E-11 Rheumatoid arthritis (CCP positive) STAT4 intron 23143596 rs1356381 chr2 191924413 G A 4.02E-05 Multiple complex diseases STAT4 intron 17554300 rs1517352 chr2 191931464 A C 5.90E-07 Systemic lupus erythematosus STAT4 intron 21408207 rs1517352 chr2 191931464 A C 3.00E-11 Inflammatory bowel disease STAT4 intron 23128233 rs1517352 chr2 191931464 A C 5.90E-07 Hepatocellular carcinoma (hepatitis B virus related) STAT4 intron 23242368 rs13426947 chr2 191933254 G A 7.19E-10 Rheumatoid arthritis STAT4 intron 23143596 rs13426947 chr2 191933254 G A 7.50E-09 Rheumatoid arthritis (CCP positive) STAT4 intron 23143596 rs10168266 chr2 191935804 C T 3.20E-08 Rheumatoid arthritis STAT4 intron 23028356 rs10168266 chr2 191935804 C T 9.61E-09 Rheumatoid arthritis STAT4 intron 23143596 rs10168266 chr2 191935804 C T 2.30E-20 Systemic lupus erythematosus STAT4 intron 23273568 rs10168266 chr2 191935804 C T 2.00E-17 Sjogren's syndrome STAT4 intron 24097066 rs7594501 chr2 191938600 G A 1.60E-09 Systemic lupus erythematosus STAT4 intron 23273568 rs16833239 chr2 191940260 G A 1.20E-09 Systemic lupus erythematosus STAT4 intron 23273568 rs7601754 chr2 191940451 G A 3.70E-06 Systemic lupus erythematosus STAT4 intron 18204446 rs7601754 chr2 191940451 G A 6.70E-05 Systemic lupus erythematosus STAT4 intron 19838193 rs7601754 chr2 191940451 G A 2.30E-06 Systemic lupus erythematosus STAT4 intron 21408207 rs7601754 chr2 191940451 G A 6.80E-10 Systemic lupus erythematosus STAT4 intron 23273568 rs7601754 chr2 191940451 G A 3.00E-11 Systemic lupus erythematosus and Systemic sclerosis STAT4 intron 23740937 rs3024921 chr2 191943272 A T 0.000000033 Primary biliary cirrhosis in females STAT4 intron 22936693 rs3024921 chr2 191943272 A T 2.39E-11 Primary biliary cirrhosis (anti-mitochondrial antibody positive) STAT4 intron 22936693 rs3024921 chr2 191943272 A T 4.45E-11 Primary biliary cirrhosis STAT4 intron 22936693 rs3024921 chr2 191943272 A T 2.59E-18 Primary biliary cirrhosis STAT4 intron 22961000 rs3024921 chr2 191943272 A T 0.00000666 Rheumatoid arthritis STAT4 intron 23143596 rs3024921 chr2 191943272 A T 5.76E-08 Hepatocellular carcinoma (hepatitis B virus related) STAT4 intron 23242368 rs11889341 chr2 191943742 C T 1.00E-12 Rheumatoid arthritis STAT4 intron 24390342 rs11889341 chr2 191943742 C T 2.00E-08 Rheumatoid arthritis STAT4 intron 24390342 rs11889341 chr2 191943742 C T 4.00E-19 Rheumatoid arthritis STAT4 intron 24390342 rs12998748 chr2 191948637 G A,C,T 2.60E-04 Celiac disease STAT4 intron 22057235 rs12998748 chr2 191948637 G A,C,T 0.00026 Celiac disease STAT4 intron 23143596 rs10931480 chr2 191954047 G A 1.88E-04 Arthritis (juvenile idiopathic) STAT4 intron 22354554 rs10931481 chr2 191954852 G A 8.10E-10 Systemic lupus erythematosus STAT4 intron 21408207 rs10931481 chr2 191954852 G A 8.10E-10 Hepatocellular carcinoma (hepatitis B virus related) STAT4 intron 23242368 rs7574865 chr2 191964633 T G 9.00E-14 Systemic lupus erythematosus STAT4 intron 18204098 rs7574865 chr2 191964633 T G 2.80E-09 Systemic lupus erythematosus STAT4 intron 18204446 rs7574865 chr2 191964633 T G 5.00E-42 Systemic lupus erythematosus STAT4 intron 19838193 rs7574865 chr2 191964633 T G 2.00E-06 Rheumatoid arthritis STAT4 intron 20453841 rs7574865 chr2 191964633 T G 3.00E-07 Rheumatoid arthritis STAT4 intron 20453842 rs7574865 chr2 191964633 T G 4.00E-10 Celiac disease and Rheumatoid arthritis STAT4 intron 21383967 rs7574865 chr2 191964633 T G 2.00E-20 Systemic lupus erythematosus STAT4 intron 21408207 rs7574865 chr2 191964633 T G 8.00E-06 Systemic lupus erythematosus STAT4 intron 21408207 rs7574865 chr2 191964633 T G 2.00E-13 Systemic sclerosis STAT4 intron 21750679 rs7574865 chr2 191964633 T G 1.40E-41 Multiple sclerosis STAT4 intron 22190364 rs7574865 chr2 191964633 T G 4.90E-07 Rheumatoid arthritis STAT4 intron 22446963 rs7574865 chr2 191964633 T G 1.00E-06 Primary biliary cirrhosis STAT4 intron 23000144 rs7574865 chr2 191964633 T G 4.00E-14 Systemic lupus erythematosus STAT4 intron 23053960 rs7574865 chr2 191964633 T G 9.61E-09 Rheumatoid arthritis STAT4 intron 23143596 rs7574865 chr2 191964633 T G 2.00E-10 Hepatocellular carcinoma (hepatitis B virus related) STAT4 intron 23242368 rs7574865 chr2 191964633 T G 1.00E-21 Systemic lupus erythematosus STAT4 intron 23273568 rs7574865 chr2 191964633 T G 6.64E-04 Rheumatoid arthritis STAT4 intron 24449572 rs7574865 chr2 191964633 T G 5.00E-09 Systemic lupus erythematosus STAT4 intron 24871463 rs10181656 chr2 191969879 G C 2.34E-13 Rheumatoid arthritis STAT4 intron 23143596 rs10174238 chr2 191973034 G A 0.00000239 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis STAT4 intron 23603761 rs10174238 chr2 191973034 G A 1.28E-13 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) STAT4 intron 23603761 rs10174238 chr2 191973034 G A 1.81E-10 Oligoarticular juvenile idiopathic arthritis STAT4 intron 23603761 rs6752770 chr2 191973563 A G 2.03E-06 Celiac disease and Rheumatoid arthritis STAT4 intron 21383967 rs6752770 chr2 191973563 A G 1.30E-06 Celiac disease STAT4 intron 22057235 rs6752770 chr2 191973563 A G 4.20E-04 Myasthenia gravis STAT4 intron 23055271 rs6752770 chr2 191973563 A G 0.0000013 Celiac disease STAT4 intron 23143596 rs9967792 chr2 191974435 T C 7.13E-05 Multiple complex diseases STAT4 intron 17554300 rs9967792 chr2 191974435 T C 1.84E-05 Type 1 diabetes STAT4 intron 18978792 rs4853543 chr2 191976634 A G 1.61E-04 Multiple complex diseases STAT4 intron 17554300 rs4853543 chr2 191976634 A G 2.24E-05 Type 1 diabetes STAT4 intron 18978792 rs10931483 chr2 191989250 A G 1.51E-04 Multiple complex diseases STAT4 intron 17554300 rs10931483 chr2 191989250 A G 3.62E-05 Type 1 diabetes STAT4 intron 18978792 rs6738544 chr2 191989356 A C 1.67E-04 Multiple complex diseases STAT4 intron 17554300 rs1551443 chr2 191996518 T C 1.70E-04 Multiple complex diseases STAT4 intron 17554300 rs1551443 chr2 191996518 T C 3.44E-05 Type 1 diabetes STAT4 intron 18978792 rs1584945 chr2 191998552 C T 2.88E-05 Multiple complex diseases STAT4 intron 17554300 rs1584945 chr2 191998552 C T 2.34E-05 Type 1 diabetes STAT4 intron 18978792 rs6744380 chr2 192001538 A G 1.22E-04 Type 1 diabetes STAT4 intron 21980299 rs2356350 chr2 192002538 G A 5.92E-05 Multiple complex diseases STAT4 intron 17554300 rs2356350 chr2 192002538 G A 8.87E-05 Type 1 diabetes STAT4 intron 18978792 rs7574070 chr2 192010488 A C 4.00E-08 Behcet's disease STAT4 intron 23001997 rs7574070 chr2 192010488 A C 1.00E-09 Behcet's disease STAT4 intron 23291587 rs7572482 chr2 192015072 A G 4.00E-08 Behcet's disease STAT4 intron 23001997 rs7572482 chr2 192015072 A G 2.92E-05 Behcet's disease STAT4 intron 23291587 rs7572482 chr2 192015072 A G 3.18E-05 Behcet's disease STAT4 intron pha002888 rs897200 chr2 192017771 T C 6.00E-09 Behcet's disease STAT4 nearGene-5 23001997 rs6741818 chr2 192053184 G T 3.51E-04 Alzheimer's disease / / 17998437 rs16833498 chr2 192069042 C T 4.75E-04 Type 2 diabetes / / 17463246 rs16833504 chr2 192077437 T C 2.00E-05 Multiple complex diseases / / 17554300 rs6434455 chr2 192085141 A G 3.30E-04 Alzheimer's disease (late onset) / / 21379329 rs13030978 chr2 192117238 C T 1.00E-11 Liver enzyme levels (gamma-glutamyl transferase) MYO1B intron 22001757 rs1823913 chr2 192118047 T C 9.00E-06 Obesity-related traits MYO1B intron 23251661 rs17439519 chr2 192130220 A G 1.35E-04 Lung function (forced vital capacity) MYO1B intron 24023788 rs17439519 chr2 192130220 A G 4.43E-04 Lung function (forced expiratory volume in 1 second) MYO1B intron 24023788 rs11688994 chr2 192130968 G A 1.79E-04 Blood pressure (response to calcium channel blocker) MYO1B intron 24192120 rs13427761 chr2 192133982 C G 1.79E-04 Blood pressure (response to calcium channel blocker) MYO1B intron 24192120 rs1378156 chr2 192137192 T A 3.45E-04 Blood pressure (response to calcium channel blocker) MYO1B intron 24192120 rs17511445 chr2 192144557 G A 1.85E-04 Blood pressure (response to calcium channel blocker) MYO1B intron 24192120 rs13002286 chr2 192150352 C T 1.85E-04 Blood pressure (response to calcium channel blocker) MYO1B intron 24192120 rs17412635 chr2 192159560 G A 3.45E-04 Blood pressure (response to calcium channel blocker) MYO1B intron 24192120 rs4853575 chr2 192160875 C T 1.79E-04 Blood pressure (response to calcium channel blocker) MYO1B cds-synon 24192120 rs4853578 chr2 192161941 G A 2.60E-04 Blood pressure (response to calcium channel blocker) MYO1B intron 24192120 rs10497714 chr2 192167280 A G 3.32E-04 Acute lung injury MYO1B intron 22295056 rs13032780 chr2 192222600 G A 5.31E-04 Alzheimer's disease MYO1B intron 22005930 rs16833765 chr2 192340920 A G 6.38E-05 Attention deficit hyperactivity disorder / / 22420046 rs12618512 chr2 192366684 A C 6.82E-04 Type 2 diabetes / / 17463246 rs10497719 chr2 192377594 G A 3.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17351803 chr2 192390014 T C 6.47E-05 Multiple complex diseases / / 17554300 rs2203748 chr2 192397191 T C 4.61E-04 Intracranial aneurysm / / 20613766 rs1517843 chr2 192405450 G A 5.21E-04 Alzheimer's disease / / 17998437 rs7596196 chr2 192461297 C A 5.32E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6706693 chr2 192465598 C T 9.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs4134381 chr2 192469816 G A 2.13E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs4318338 chr2 192470385 C T 2.86E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs4853629 chr2 192473543 C T 4.92E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs3935827 chr2 192479007 A G 4.35E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs4401164 chr2 192479674 A G 4.37E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs11899661 chr2 192490640 A G 4.36E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs6434494 chr2 192491453 A G 4.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs6434497 chr2 192506225 G T 9.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs5008133 chr2 192510265 T C 3.28E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs4592792 chr2 192532017 A G 7.53E-04 Alcohol dependence / / 24277619 rs12464838 chr2 192567912 G T 3.66E-06 Colorectal cancer / / 23266556 rs12469001 chr2 192567931 T A 3.42E-06 Colorectal cancer / / 23266556 rs6730901 chr2 192572805 T C 4.14E-06 Colorectal cancer / / 23266556 rs10931515 chr2 192575111 C G 9.09E-04 Colorectal cancer / / 23266556 rs10190843 chr2 192579683 G A 3.66E-06 Colorectal cancer / / 23266556 rs4425034 chr2 192580611 T C 3.63E-06 Colorectal cancer / / 23266556 rs4299283 chr2 192580887 A G 5.10E-06 Colorectal cancer / / 23266556 rs4477849 chr2 192580929 C T 3.48E-06 Colorectal cancer / / 23266556 rs4076769 chr2 192584206 G A 3.96E-06 Colorectal cancer / / 23266556 rs10202549 chr2 192585015 T C 3.56E-06 Colorectal cancer / / 23266556 rs13416906 chr2 192586829 G A 3.50E-06 Colorectal cancer / / 23266556 rs11903757 chr2 192587204 T C 4.00E-08 Colorectal cancer / / 23266556 rs12475675 chr2 192588314 G A 8.39E-06 Colorectal cancer / / 23266556 rs12463776 chr2 192588334 T C 3.00E-06 Colorectal cancer / / 23266556 rs6717663 chr2 192589385 T C 3.10E-06 Colorectal cancer / / 23266556 rs6717668 chr2 192589399 T C 3.39E-06 Colorectal cancer / / 23266556 rs6731095 chr2 192589442 A G 3.54E-06 Colorectal cancer / / 23266556 rs6759665 chr2 192589454 C A 1.72E-06 Colorectal cancer / / 23266556 rs12475230 chr2 192598024 C G 5.39E-04 Colorectal cancer / / 23266556 rs7568376 chr2 192621416 A G 9.19E-04 Acute lung injury / / 22295056 rs7593737 chr2 192640624 G A 4.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4366844 chr2 192663220 A G 7.06E-04 Acute lung injury / / 22295056 rs4853645 chr2 192704044 A T 0.0000417 Major depressive disorder SDPR intron 23149448 rs7583029 chr2 192712723 G A 8.50E-05 Major depressive disorder / / 21042317 rs6710083 chr2 192772592 G T 1.19E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11896499 chr2 192797035 A C 6.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7604868 chr2 192819448 C T 1.41E-05 Lung function (forced expiratory volume in 1 second) TMEFF2 intron 17255346 rs11680872 chr2 192830249 G A 2.90E-05 Lobular breast cancer (menopausal hormone therapy interaction) TMEFF2 intron 24080446 rs10497721 chr2 192914362 C A 6.68E-07 Type 2 diabetes and 6 quantitative traits TMEFF2 intron 17848626 rs10497721 chr2 192914362 C A 7.00E-07 Diabetes (incident) TMEFF2 intron 17903298 rs2356764 chr2 192927160 G A 4.90E-04 Tourette syndrome TMEFF2 intron 22889924 rs7556774 chr2 192954320 G A 6.67E-04 Type 2 diabetes TMEFF2 intron 17463246 rs13007495 chr2 192955505 T C 4.00E-06 Sudden cardiac arrest TMEFF2 intron 21658281 rs16834204 chr2 192966789 C G 1.07E-04 Bipolar disorder,schizoaffective TMEFF2 intron 19567891 rs7557901 chr2 192972529 A C 3.73E-04 Bipolar disorder,schizoaffective TMEFF2 intron 19567891 rs10497723 chr2 192992323 T C 8.45E-06 Type 2 diabetes TMEFF2 intron 17846124 rs10497723 chr2 192992323 T C 8.50E-06 Type 2 diabetes TMEFF2 intron 21647700 rs11888985 chr2 193035248 C T 4.94E-04 Multiple complex diseases TMEFF2 intron 17554300 rs10191803 chr2 193035723 T C 5.80E-06 Stroke (ischemic) TMEFF2 intron 22384361 rs2356960 chr2 193041060 G A 6.54E-05 Orofacial clefts TMEFF2 intron 22419666 rs12693642 chr2 193042710 T C 3.69E-04 Type 2 diabetes TMEFF2 intron 17463246 rs10931531 chr2 193046999 A C 9.64E-04 Type 2 diabetes TMEFF2 intron 17463246 rs10497726 chr2 193051320 C A 1.98E-05 Cardiovascular disease TMEFF2 intron 17903304 rs1113932 chr2 193052353 T C 5.01E-04 Type 2 diabetes TMEFF2 intron 17463246 rs1446397 chr2 193232686 G A 4.76E-04 Premature ovarian failure / / 19508998 rs1446397 chr2 193232686 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7581266 chr2 193257756 T C 5.04E-04 Multiple complex diseases / / 17554300 rs2357135 chr2 193261854 A G 7.47E-06 Cognitive impairment induced by topiramate / / 22091778 rs1017895 chr2 193284475 T C 5.10E-04 Multiple complex diseases / / 17554300 rs1038472 chr2 193300851 A T 5.50E-04 Multiple complex diseases / / 17554300 rs5837312 chr2 193302111 G T 7.88E-04 Multiple complex diseases / / 17554300 rs10931548 chr2 193302483 C A 5.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10931550 chr2 193302629 G A 6.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1385351 chr2 193333903 C T 4.00E-06 HIV-1 control / / 20041166 rs1601324 chr2 193337095 A G 1.34E-05 Type 2 diabetes / / 17463246 rs6713179 chr2 193345479 A G 4.30E-05 HIV-1 control / / 20041166 rs1994245 chr2 193360531 T C 1.00E-04 Prostate cancer / / 21743057 rs11896590 chr2 193364043 A G 1.48E-05 Type 2 diabetes / / 17463246 rs6723499 chr2 193420290 C T 7.62E-04 Taste perception / / 22132133 rs12617505 chr2 193427323 A G 4.30E-04 Taste perception / / 22132133 rs717622 chr2 193440645 T C 3.03E-04 Obesity (extreme) / / 21935397 rs1515349 chr2 193458579 A G 6.77E-05 Type 2 diabetes / / 17463246 rs17442387 chr2 193482971 A T 4.38E-04 Obesity (extreme) / / 21935397 rs7608493 chr2 193510649 C T 3.53E-04 Coronary heart disease / / 21971053 rs1946877 chr2 193528836 T C 1.86E-04 Multiple complex diseases / / 17554300 rs1898917 chr2 193538820 C T 9.02E-04 Type 2 diabetes / / 17463246 rs1898917 chr2 193538820 C T 2.04E-04 Multiple complex diseases / / 17554300 rs1898917 chr2 193538820 C T 4.32E-04 Coronary heart disease / / 21971053 rs13394988 chr2 193541827 C T 8.79E-04 Type 2 diabetes / / 17463246 rs13394988 chr2 193541827 C T 2.30E-04 Multiple complex diseases / / 17554300 rs1439664 chr2 193559014 C A 1.44E-04 Multiple complex diseases / / 17554300 rs1439664 chr2 193559014 C A 5.01E-04 Coronary heart disease / / 21971053 rs1439663 chr2 193559142 G T 8.89E-04 Type 2 diabetes / / 17463246 rs1439663 chr2 193559142 G T 3.08E-04 Multiple complex diseases / / 17554300 rs16834819 chr2 193559261 C T 5.73E-04 Multiple complex diseases / / 17554300 rs1595720 chr2 193567692 T C 9.64E-04 Type 2 diabetes / / 17463246 rs1595720 chr2 193567692 T C 2.49E-04 Multiple complex diseases / / 17554300 rs6730654 chr2 193602930 G C 3.79E-04 Multiple complex diseases / / 17554300 rs6730696 chr2 193603096 C T 2.71E-04 Multiple complex diseases / / 17554300 rs11686149 chr2 193629044 A C 1.17E-04 Multiple complex diseases PCGEM1 intron 17554300 rs16834896 chr2 193634064 G A 8.70E-04 Type 2 diabetes PCGEM1 intron 17463246 rs16834896 chr2 193634064 G A 1.16E-04 Multiple complex diseases PCGEM1 intron 17554300 rs16834896 chr2 193634064 G A 3.84E-04 Coronary heart disease PCGEM1 intron 21971053 rs1439652 chr2 193639244 C T 2.23E-04 Multiple complex diseases PCGEM1 intron 17554300 rs1439651 chr2 193639542 A C 2.51E-04 Multiple complex diseases PCGEM1 intron 17554300 rs1439651 chr2 193639542 A C 9.32E-05 Coronary heart disease PCGEM1 intron 21971053 rs7567586 chr2 193640080 T C 2.71E-04 Multiple complex diseases PCGEM1 intron 17554300 rs13419834 chr2 193640476 T C 2.37E-04 Multiple complex diseases / / 17554300 rs1125174 chr2 193675766 T G 2.94E-04 Multiple complex diseases / / 17554300 rs11894222 chr2 193681377 C T 2.43E-04 Multiple complex diseases / / 17554300 rs1596754 chr2 193693359 C A 3.26E-04 Multiple complex diseases / / 17554300 rs10176429 chr2 193694766 A T 4.76E-04 Multiple complex diseases / / 17554300 rs12328398 chr2 193695871 A G 5.02E-04 Multiple complex diseases / / 17554300 rs17654201 chr2 193724080 C T 3.50E-05 Celiac disease / / 17558408 rs10174573 chr2 193742173 C T 2.00E-06 Major depressive disorder / / 23377640 rs13014947 chr2 193742999 G A 2.20E-05 Urinary metabolites / / 21572414 rs12617870 chr2 193746283 G T 3.27E-04 Body mass index / / 17255346 rs1979001 chr2 193749305 C A 2.10E-06 Urinary metabolites / / 21572414 rs9288210 chr2 193764898 G A 3.59E-04 Blood pressure / / 17255346 rs9288210 chr2 193764898 G A 2.00E-05 Urinary metabolites / / 21572414 rs2197471 chr2 193797343 G A 8.83E-04 Obesity (extreme) / / 21935397 rs2203204 chr2 193797403 A G 8.82E-04 Obesity (extreme) / / 21935397 rs10203662 chr2 193799679 T G 8.77E-04 Obesity (extreme) / / 21935397 rs7585105 chr2 193801489 T C 8.76E-04 Obesity (extreme) / / 21935397 rs1596748 chr2 193802991 A G 8.74E-04 Obesity (extreme) / / 21935397 rs1596749 chr2 193803201 A G 8.73E-04 Obesity (extreme) / / 21935397 rs10931581 chr2 193803703 G A 8.68E-04 Obesity (extreme) / / 21935397 rs765278 chr2 193805824 T C 8.68E-04 Obesity (extreme) / / 21935397 rs12613154 chr2 193806575 A G 8.74E-04 Obesity (extreme) / / 21935397 rs13006519 chr2 193807276 G C 8.98E-04 Obesity (extreme) / / 21935397 rs1596751 chr2 193807860 C T 1.90E-05 Urinary metabolites / / 21572414 rs10931584 chr2 193808370 C T 9.08E-04 Obesity (extreme) / / 21935397 rs10204100 chr2 193809193 C G 9.15E-04 Obesity (extreme) / / 21935397 rs4850844 chr2 193810226 G A 9.22E-04 Obesity (extreme) / / 21935397 rs13010260 chr2 193812656 G A 9.43E-04 Obesity (extreme) / / 21935397 rs13011989 chr2 193813425 G A 1.90E-05 Urinary metabolites / / 21572414 rs13011989 chr2 193813425 G A 9.51E-04 Obesity (extreme) / / 21935397 rs986652 chr2 193815404 A T 9.58E-04 Obesity (extreme) / / 21935397 rs12995239 chr2 193817686 A G 2.80E-05 Urinary metabolites / / 21572414 rs12995239 chr2 193817686 A G 9.66E-04 Obesity (extreme) / / 21935397 rs10174037 chr2 193821132 T A 9.73E-04 Obesity (extreme) / / 21935397 rs1512755 chr2 193821255 T C 9.92E-04 Obesity (extreme) / / 21935397 rs10497737 chr2 193824185 G A 1.00E-05 Urinary metabolites / / 21572414 rs1979002 chr2 193838929 G T 2.80E-05 Urinary metabolites / / 21572414 rs7574968 chr2 193846114 T C 1.88E-04 Body mass index / / 17255346 rs2198962 chr2 193941673 A G 1.87E-04 Multiple complex diseases / / 17554300 rs10170968 chr2 193954551 G A 3.29E-10 Multiple complex diseases / / 17554300 rs7577834 chr2 193956481 C T 2.30E-05 Urinary metabolites / / 21572414 rs17662626 chr2 193984621 A G 5.00E-08 Schizophrenia / / 21926974 rs17662626 chr2 193984621 A G 5.00E-08 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs17662626 chr2 193984621 A G 0.0000779 Schizophrenia / / 23637625 rs17662759 chr2 193989223 T C 2.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs973885 chr2 193994278 G A 9.12E-04 Multiple complex diseases / / 17554300 rs973885 chr2 193994278 G A 6.74E-04 Tourette syndrome / / 22889924 rs1379470 chr2 193995316 A T 6.71E-04 Multiple complex diseases / / 17554300 rs1037709 chr2 193999951 T A 9.46E-04 Multiple complex diseases / / 17554300 rs1037710 chr2 193999991 C T 8.56E-04 Multiple complex diseases / / 17554300 rs1902745 chr2 194017714 C A 2.43E-04 Blood pressure / / 17255346 rs10189659 chr2 194236059 C T 1.43E-05 Cognitive impairment induced by topiramate / / 22091778 rs6434605 chr2 194244603 T G 5.95E-04 Type 2 diabetes / / 17463246 rs2247944 chr2 194254130 G A 7.29E-04 Type 2 diabetes / / 17463246 rs1530155 chr2 194257494 A G 9.87E-04 Type 2 diabetes / / 17463246 rs2251929 chr2 194316224 C G 8.87E-04 Type 2 diabetes / / 17463246 rs11893801 chr2 194426679 T A 1.98E-05 Multiple complex diseases / / 17554300 rs6757627 chr2 194518477 A G 2.46E-05 Smoking initiation / / 24665060 rs13018978 chr2 194652248 C A 5.02E-04 Depression (quantitative trait) / / 20800221 rs4473398 chr2 194660331 T G 5.12E-04 Depression (quantitative trait) / / 20800221 rs1358626 chr2 194663490 T C 5.13E-04 Depression (quantitative trait) / / 20800221 rs10497745 chr2 194679200 C A 4.91E-04 Depression (quantitative trait) / / 20800221 rs16835330 chr2 194706556 A G 4.80E-04 Depression (quantitative trait) / / 20800221 rs12991562 chr2 194707606 C T 4.79E-04 Depression (quantitative trait) / / 20800221 rs12991562 chr2 194707606 C T 5.76E-05 Cognitive impairment induced by topiramate / / 22091778 rs10209427 chr2 194715328 T C 4.76E-04 Depression (quantitative trait) / / 20800221 rs1358625 chr2 194716457 T C 4.78E-04 Depression (quantitative trait) / / 20800221 rs10931625 chr2 194722073 C T 4.80E-04 Depression (quantitative trait) / / 20800221 rs6740862 chr2 194727038 C T 4.82E-04 Depression (quantitative trait) / / 20800221 rs6434632 chr2 194730749 C T 4.86E-04 Depression (quantitative trait) / / 20800221 rs1534690 chr2 194733623 C T 4.53E-04 Depression (quantitative trait) / / 20800221 rs4850493 chr2 194735679 A T 4.80E-04 Depression (quantitative trait) / / 20800221 rs10184447 chr2 194736257 C T 4.88E-04 Depression (quantitative trait) / / 20800221 rs4850495 chr2 194739062 A G 2.89E-04 Depression (quantitative trait) / / 20800221 rs4850496 chr2 194739622 A G 1.61E-04 Depression (quantitative trait) / / 20800221 rs1529108 chr2 194739945 A G 2.90E-04 Depression (quantitative trait) / / 20800221 rs13029940 chr2 194744710 T C 3.03E-04 Depression (quantitative trait) / / 20800221 rs4402780 chr2 194746880 A G 3.14E-04 Depression (quantitative trait) / / 20800221 rs10179597 chr2 194747064 A G 2.55E-04 Depression (quantitative trait) / / 20800221 rs7561862 chr2 194749514 C T 7.58E-04 Depression (quantitative trait) / / 20800221 rs4468836 chr2 194785328 C A 9.84E-04 Depression (quantitative trait) / / 20800221 rs6750903 chr2 194805093 G A 8.12E-04 Depression (quantitative trait) / / 20800221 rs11892785 chr2 194810279 T C 6.30E-04 Depression (quantitative trait) / / 20800221 rs2176528 chr2 194872183 C G 4.00E-06 Bipolar disorder / / 21926972 rs2358004 chr2 195038817 G A 8.75E-04 Type 2 diabetes / / 17463246 rs10931639 chr2 195095507 G A 2.80E-04 Multiple complex diseases / / 17554300 rs10193826 chr2 195128137 C T 1.07E-04 Multiple complex diseases / / 17554300 rs4578878 chr2 195151349 C T 2.60E-05 Urinary metabolites / / 21572414 rs7577996 chr2 195198744 T C 7.97E-04 Multiple complex diseases / / 17554300 rs10931642 chr2 195259731 T C 3.81E-04 Multiple complex diseases / / 17554300 rs2360090 chr2 195344783 C T 5.38E-04 Multiple complex diseases / / 17554300 rs4404290 chr2 195461795 A G 9.64E-05 Triglycerides / / pha003081 rs12993717 chr2 195476042 C T 7.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1371555 chr2 195494177 T C 6.82E-05 Triglycerides / / pha003081 rs12613573 chr2 195499851 A T 2.58E-04 Multiple complex diseases / / 17554300 rs1595771 chr2 195518247 A C 3.64E-04 Multiple complex diseases / / 17554300 rs801350 chr2 195547393 G A 2.00E-08 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) / / 24554482 rs801378 chr2 195559997 A C 2.00E-08 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) / / 24554482 rs801301 chr2 195579293 T C 4.37E-04 Rheumatoid arthritis / / 21452313 rs801298 chr2 195581699 T C 5.49E-04 Celiac disease / / 23936387 rs1439937 chr2 195583436 C T 6.69E-04 Rheumatoid arthritis / / 21452313 rs13385784 chr2 195628811 A C 2.42E-04 Smoking initiation / / 24665060 rs13394699 chr2 195720651 T G 9.67E-04 Rheumatoid arthritis / / 21452313 rs12611555 chr2 195791620 A G 1.93E-04 Multiple complex diseases / / 17554300 rs11891594 chr2 195857383 A G 7.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs17821284 chr2 195857628 C G 1.89E-04 Acute lung injury / / 22295056 rs919538 chr2 195863427 G A 7.44E-05 Type 2 diabetes / / 17463246 rs1430692 chr2 195864023 C A 9.07E-05 Obesity (extreme) / / 21935397 rs6727001 chr2 195864232 T C 6.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1430690 chr2 195864806 T C 8.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10174127 chr2 195867032 C T 1.86E-04 Obesity (extreme) / / 21935397 rs1014395 chr2 195867099 A T 2.29E-04 Type 2 diabetes / / 17463246 rs2068896 chr2 195869035 T G 4.62E-04 Obesity (extreme) / / 21935397 rs10172965 chr2 195871819 C T 1.33E-04 Type 2 diabetes / / 17463246 rs10172965 chr2 195871819 C T 6.00E-06 Temperament / / 22832960 rs12472928 chr2 195874246 T C 6.87E-04 Type 2 diabetes / / 17463246 rs7584610 chr2 195875175 G A 6.67E-04 Type 2 diabetes / / 17463246 rs963653 chr2 195882875 T C 6.82E-04 Type 2 diabetes / / 17463246 rs1430678 chr2 195884021 C T 7.33E-05 Obesity (extreme) / / 21935397 rs12478266 chr2 195884251 T C 2.46E-04 Type 2 diabetes / / 17463246 rs6434727 chr2 195893626 A T 2.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs13391145 chr2 195903474 T C 5.60E-05 Personality dimensions / / 18957941 rs1835437 chr2 195914706 C T 3.20E-05 Personality dimensions / / 18957941 rs1835437 chr2 195914706 C T 2.70E-05 Urinary metabolites / / 21572414 rs11687841 chr2 195914876 T C 3.20E-05 Personality dimensions / / 18957941 rs11687841 chr2 195914876 T C 2.40E-05 Urinary metabolites / / 21572414 rs1599755 chr2 195974363 C T 1.10E-04 Multiple complex diseases / / 17554300 rs777733 chr2 195993166 G A 1.17E-04 Multiple complex diseases / / 17554300 rs777734 chr2 195993306 C A 4.39E-05 IgE levels in asthmatics / / 23967269 rs938066 chr2 196001454 T C 8.29E-04 Alzheimer's disease / / 17998437 rs777740 chr2 196001701 G A 3.10E-04 Alzheimer's disease / / 17998437 rs2217469 chr2 196002614 A G 3.41E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2130344 chr2 196011944 C A 3.04E-04 Smoking initiation / / 24665060 rs2063452 chr2 196012052 G A 2.00E-05 Blood pressure / / 19114657 rs7558137 chr2 196014263 T C 5.07E-04 Smoking initiation / / 24665060 rs7597587 chr2 196014587 G A 7.79E-04 Smoking initiation / / 24665060 rs10497749 chr2 196018044 T A 5.80E-05 Blood pressure / / 19114657 rs6736088 chr2 196018369 A G 2.00E-05 Blood pressure / / 19114657 rs7423326 chr2 196026920 T C 6.73E-04 Type 2 diabetes / / 17463246 rs1397746 chr2 196027829 C A 3.94E-04 Smoking initiation / / 24665060 rs6434742 chr2 196036903 A G 4.33E-07 Type 2 diabetes / / 17463246 rs1397744 chr2 196045183 T C 2.25E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7422772 chr2 196045499 G T 2.16E-04 Type 2 diabetes / / 17463246 rs7424669 chr2 196045518 T C 3.64E-05 Type 2 diabetes / / 17463246 rs6434746 chr2 196045676 A T 3.64E-05 Type 2 diabetes / / 17463246 rs6434754 chr2 196060439 A G 2.90E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1858305 chr2 196100505 C G 2.14E-04 Type 2 diabetes / / 17463246 rs16838948 chr2 196103245 A C 2.11E-05 Multiple complex diseases / / 17554300 rs2037597 chr2 196136553 G A 5.00E-05 Blood pressure / / 19114657 rs16839316 chr2 196162042 A C,G 1.59E-04 Multiple complex diseases / / 17554300 rs1489769 chr2 196164984 A C 1.60E-05 Blood pressure / / 19114657 rs12996090 chr2 196279513 A G 6.64E-05 Blood Pressure / / pha003040 rs4505549 chr2 196288136 T C 4.83E-06 Neuroblastoma / / pha002895 rs4505549 chr2 196288136 T C 1.20E-05 Blood Pressure / / pha003048 rs11674207 chr2 196305753 G A 6.62E-04 Type 2 diabetes / / 17463246 rs1542865 chr2 196309536 C A 7.20E-05 Celiac disease / / 17558408 rs7559362 chr2 196319300 G A 1.33E-06 Blood Pressure / / pha003048 rs16841230 chr2 196325214 T C 8.37E-04 Type 2 diabetes / / 17463246 rs6434780 chr2 196335282 G A 4.28E-04 Smoking initiation / / 24665060 rs7571836 chr2 196340492 A T 9.09E-05 Smoking initiation / / 24665060 rs1500608 chr2 196346799 G A 2.48E-04 Smoking initiation / / 24665060 rs4591358 chr2 196365890 T C 7.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs17177580 chr2 196373150 T C 9.41E-05 Blood Pressure / / pha003040 rs13002794 chr2 196381899 T C 7.35E-05 Blood Pressure / / pha003040 rs6434787 chr2 196449477 A G 2.70E-06 Urinary metabolites / / 21572414 rs10460389 chr2 196505964 C A 4.37E-04 Alcohol dependence / / 21314694 rs11682521 chr2 196517509 G A 3.40E-04 Alcohol dependence / / 20201924 rs11889699 chr2 196528101 A G 6.30E-06 Urinary metabolites SLC39A10 intron 21572414 rs7562020 chr2 196531031 G C 1.10E-05 Urinary metabolites SLC39A10 intron 21572414 rs41416845 chr2 196531667 T C 1.65E-08 Brain activation patterns in response to human facial expressions-for the negative faces task SLC39A10 intron 22828495 rs41416845 chr2 196531667 T C 1.65E-08 Airflow obstruction SLC39A10 intron 22837378 rs7424415 chr2 196536150 T C 1.00E-04 Alcohol dependence SLC39A10 intron 20201924 rs1866452 chr2 196536505 A G 1.90E-04 Alcohol dependence SLC39A10 intron 20201924 rs10178320 chr2 196542002 T C 1.50E-04 Alcohol dependence SLC39A10 intron 20201924 rs1561451 chr2 196549436 A G 8.90E-05 Alcohol dependence SLC39A10 intron 20201924 rs1561451 chr2 196549436 A G 8.86E-05 Alcoholism SLC39A10 intron pha002892 rs13029941 chr2 196553228 G A 5.40E-06 Urinary metabolites SLC39A10 intron 21572414 rs6706771 chr2 196565241 G T 1.90E-04 Alcohol dependence SLC39A10 intron 20201924 rs6714748 chr2 196566912 G A 1.98E-05 Neuroblastoma SLC39A10 intron pha002895 rs6714748 chr2 196566912 G A 9.67E-05 Body Fat Distribution SLC39A10 intron pha003017 rs2118839 chr2 196567176 C T 1.20E-05 Urinary metabolites SLC39A10 intron 21572414 rs16842044 chr2 196579896 A G 1.76E-04 Type 2 diabetes SLC39A10 intron 17463246 rs6756374 chr2 196587670 C A 1.10E-04 Alcohol dependence SLC39A10 intron 20201924 rs2118840 chr2 196594951 T C 6.30E-06 Urinary metabolites SLC39A10 intron 21572414 rs16840019 chr2 196661664 G T 8.53E-04 Type 2 diabetes D/H7 intron 17463246 rs6434799 chr2 196665083 C T 4.80E-04 Alcohol dependence D/H7 intron 20201924 rs6743998 chr2 196676489 T C 7.57E-04 Alcohol dependence D/H7 intron 21314694 rs16840255 chr2 196684883 C T 3.86E-04 Multiple complex diseases D/H7 intron 17554300 rs4850376 chr2 196696633 T C 2.00E-06 Urinary metabolites D/H7 intron 21572414 rs10497770 chr2 196715003 G A 1.88E-04 Vaspin levels D/H7 intron 22907691 rs10497770 chr2 196715003 G A 0.0001883 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks D/H7 intron 22907730 rs13028172 chr2 196732301 T G 1.70E-05 Urinary metabolites D/H7 intron 21572414 rs12469956 chr2 196739009 T A 5.76E-05 Type 2 diabetes D/H7 intron 17463246 rs16841387 chr2 196742920 C A 4.84E-06 Neuroblastoma D/H7 intron pha002895 rs341951 chr2 196747752 C G 4.66E-04 Multiple complex diseases D/H7 intron 17554300 rs419784 chr2 196762836 C T 8.58E-04 Multiple complex diseases D/H7 intron 17554300 rs6434804 chr2 196764393 T G 2.40E-05 Kidney function and endocine traits D/H7 intron 17903292 rs382397 chr2 196765294 G A 1.52E-04 Smoking quantity D/H7 intron 24665060 rs186895 chr2 196766509 C T 4.24E-05 Neuroblastoma D/H7 intron pha002895 rs16841838 chr2 196769109 A G 3.81E-04 Multiple complex diseases D/H7 intron 17554300 rs341933 chr2 196779131 A G 6.00E-06 Neuroblastoma D/H7 intron pha002895 rs1489802 chr2 196791276 T G 9.35E-05 Neuroblastoma D/H7 cds-synon pha002895 rs7570606 chr2 196791792 A G 7.53E-04 Multiple complex diseases D/H7 intron 17554300 rs1489800 chr2 196800091 A G 3.34E-04 Multiple complex diseases D/H7 intron 17554300 rs16842717 chr2 196810367 G A 7.79E-05 Neuroblastoma D/H7 intron pha002895 rs6719500 chr2 196825402 T C 2.39E-05 Neuroblastoma D/H7 missense pha002895 rs192646926 chr2 196825573 G A 0.0003 Prostate cancer D/H7 missense 23555315 rs17363011 chr2 196849453 C T 9.45E-05 Vaspin levels D/H7 intron 22907691 rs17363011 chr2 196849453 C T 0.0000945 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks D/H7 intron 22907730 rs1519616 chr2 196894380 G C 3.10E-06 Urinary metabolites D/H7 intron 21572414 rs6414150 chr2 196894770 A G 3.90E-06 Urinary metabolites D/H7 intron 21572414 rs6414150 chr2 196894770 A G 4.98E-05 Vaspin levels D/H7 intron 22907691 rs6414150 chr2 196894770 A G 0.0000498 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks D/H7 intron 22907730 rs4500968 chr2 196905455 A G 8.00E-07 Urinary metabolites D/H7 intron 21572414 rs12475846 chr2 196907795 T C 1.90E-06 Urinary metabolites D/H7 intron 21572414 rs4850381 chr2 196912067 A G 8.42E-05 Vaspin levels D/H7 intron 22907691 rs4850381 chr2 196912067 A G 0.0000842 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks D/H7 intron 22907730 rs6434817 chr2 196914283 A G 7.50E-07 Urinary metabolites D/H7 intron 21572414 rs16844650 chr2 196945385 C T 6.00E-06 Urinary metabolites / / 21572414 rs13414745 chr2 196945439 C T 6.70E-06 Urinary metabolites / / 21572414 rs4850654 chr2 196950670 T G 1.30E-06 Urinary metabolites / / 21572414 rs1401720 chr2 196961600 T C 4.88E-05 Body Fat Distribution / / pha003016 rs1401720 chr2 196961600 T C 6.04E-05 Body Fat Distribution / / pha003018 rs6725435 chr2 196964433 C G 4.00E-06 Urinary metabolites / / 21572414 rs12329286 chr2 196969777 T G 1.00E-06 Urinary metabolites / / 21572414 rs1568366 chr2 196976853 T C 2.50E-06 Urinary metabolites / / 21572414 rs2090671 chr2 196990913 C T 4.57E-05 Multiple complex diseases / / 17554300 rs6741307 chr2 196998315 C A,G,T 1.20E-06 Urinary metabolites STK17B UTR-3 21572414 rs7595582 chr2 197017505 A T 2.60E-06 Urinary metabolites STK17B intron 21572414 rs7586917 chr2 197018402 T C 6.70E-06 Urinary metabolites STK17B intron 21572414 rs4850669 chr2 197019260 G A 2.60E-06 Urinary metabolites STK17B intron 21572414 rs1519602 chr2 197027792 T G 1.50E-06 Urinary metabolites STK17B intron 21572414 rs4850676 chr2 197033562 C T 1.30E-06 Urinary metabolites STK17B intron 21572414 rs13001220 chr2 197057862 C T 2.99E-05 Neuroblastoma / / pha002895 rs4850679 chr2 197061152 C T 0.000429 Salmonella-induced pyroptosis / / 22837397 rs4850679 chr2 197061152 C T 5.83E-05 Neuroblastoma / / pha002895 rs4524133 chr2 197062707 A G 7.10E-05 Body Fat Distribution / / pha003016 rs2290512 chr2 197085823 C T 4.80E-04 Multiple complex diseases HECW2 intron 17554300 rs4241188 chr2 197097950 G A 0.00000077 Joint damage severity in rheumatoid arthritis HECW2 intron 23696630 rs10185953 chr2 197104208 T C 7.24E-04 Multiple complex diseases HECW2 intron 17554300 rs10185953 chr2 197104208 T C 5.20E-06 Bipolar disorder HECW2 intron 18317468 rs7575017 chr2 197109893 T G 4.90E-04 Multiple complex diseases HECW2 intron 17554300 rs6746308 chr2 197134790 G A 8.95E-04 Myopia (pathological) HECW2 intron 21095009 rs4850693 chr2 197135806 T C 7.98E-04 Myopia (pathological) HECW2 intron 21095009 rs4850695 chr2 197153259 G A 4.62E-06 Aging (time to event) HECW2 intron 21782286 rs6730618 chr2 197156918 T C 9.15E-05 Serum metabolites HECW2 intron 19043545 rs11888904 chr2 197164694 G A 5.15E-05 Serum metabolites HECW2 intron 19043545 rs11888904 chr2 197164694 G A 4.57E-04 Smoking initiation HECW2 intron 24665060 rs13394918 chr2 197164952 C T 6.20E-04 Smoking initiation HECW2 intron 24665060 rs13016354 chr2 197170701 G A 0.000000792 Left atrial diameter HECW2 intron 23275298 rs6713102 chr2 197174387 A G 3.51E-04 Lymphocyte counts HECW2 intron 22286170 rs2168369 chr2 197197092 A G 1.20E-05 Urinary metabolites HECW2 intron 21572414 rs16849755 chr2 197197233 C A,G,T 2.30E-05 Urinary metabolites HECW2 intron 21572414 rs4296447 chr2 197202607 C G 5.30E-06 Urinary metabolites HECW2 intron 21572414 rs11888148 chr2 197247574 A T 3.56E-06 Phospholipid levels (plasma) HECW2 intron 21829377 rs17831149 chr2 197263337 C T 1.10E-05 Urinary metabolites HECW2 intron 21572414 rs1528398 chr2 197311265 T C 2.59E-04 Smoking initiation HECW2 intron 24665060 rs1528398 chr2 197311265 T C 6.81E-05 Smoking quantity HECW2 intron 24665060 rs6721157 chr2 197315114 T C 6.13E-04 Schizophrenia HECW2 intron 19197363 rs1405886 chr2 197318105 T C 4.22E-04 Schizophrenia HECW2 intron 19197363 rs6728749 chr2 197322628 T C 7.57E-05 Cognitive impairment induced by topiramate HECW2 intron 22091778 rs6728749 chr2 197322628 T C 3.40E-04 Smoking initiation HECW2 intron 24665060 rs9677260 chr2 197327735 G T 1.76E-05 Amyotrophic lateral sclerosis (sporadic) HECW2 intron 24529757 rs16852469 chr2 197352884 A G 3.86E-04 Response to statin treatment (atorvastatin),change in cholesterol levels HECW2 intron 20031582 rs4341955 chr2 197404714 G A 2.87E-04 Coronary heart disease HECW2 intron 21971053 rs16855046 chr2 197470459 G A 6.10E-04 Taste perception / / 22132133 rs16855610 chr2 197504764 C A 3.40E-04 Taste perception CCDC150 intron 22132133 rs6434875 chr2 197522130 G C 4.57E-04 Schizophrenia(treatment response to risperidone) CCDC150 intron 19850283 rs10197202 chr2 197522966 G A 1.30E-05 Alcoholism (heaviness of drinking) CCDC150 intron 21529783 rs80346810 chr2 197576939 G A 0.0009 Breast cancer CCDC150 missense 23555315 rs3806507 chr2 197666152 G A 2.51E-04 Rheumatoid arthritis GTF3C3 nearGene-5 21452313 rs2289380 chr2 197669189 C T 3.02E-04 Gallbladder cancer C2orf66 UTR-3 22318345 rs7580839 chr2 197673035 C T 9.65E-05 Gallbladder cancer C2orf66 intron 22318345 rs1866186 chr2 197715078 G A 9.65E-05 Gallbladder cancer PGAP1 intron 22318345 rs636258 chr2 197747960 C T 9.69E-05 Gallbladder cancer PGAP1 intron 22318345 rs12693800 chr2 197777589 C T 3.58E-04 Type 2 diabetes PGAP1 intron 17463246 rs6733360 chr2 197833680 G A 7.32E-04 Multiple complex diseases / / 17554300 rs16860099 chr2 197850176 T C 2.31E-06 Personality dimensions / / 23658558 rs11888210 chr2 197850652 T C 2.23E-06 Personality dimensions / / 23658558 rs7595528 chr2 197860406 G C 1.20E-05 Urinary metabolites ANKRD44 intron 21572414 rs4850742 chr2 197863851 C T 4.29E-06 Systemic lupus erythematosus and Systemic sclerosis ANKRD44 intron 23740937 rs7584406 chr2 197878584 T A 6.41E-04 Multiple complex diseases ANKRD44 intron 17554300 rs10497802 chr2 197882236 G T 2.58E-06 Personality dimensions ANKRD44 intron 23658558 rs4850746 chr2 197883010 C T 0.0008885 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ANKRD44 intron 23233654 rs4850746 chr2 197883010 C T 8.89E-04 Methotrexate clearance (acute lymphoblastic leukemia) ANKRD44 intron 23233662 rs16860886 chr2 197897885 T C 1.32E-06 Personality dimensions ANKRD44 intron 23658558 rs16860949 chr2 197904195 C T 2.58E-06 Personality dimensions ANKRD44 intron 23658558 rs4850409 chr2 197915534 T C 4.57E-05 Cognitive test performance ANKRD44 intron 20125193 rs4850410 chr2 197920169 C T 6.06E-05 Cognitive test performance ANKRD44 intron 20125193 rs4850410 chr2 197920169 C T 2.60E-05 Urinary metabolites ANKRD44 intron 21572414 rs4372926 chr2 197926353 G A 8.13E-04 Schizophrenia ANKRD44 intron 19197363 rs12464023 chr2 197947389 C T 1.30E-05 Urinary metabolites ANKRD44 intron 21572414 rs930372 chr2 197947823 A C 0.0000687 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity ANKRD44 intron 22945461 rs12467303 chr2 197950027 G A 2.00E-05 Urinary metabolites ANKRD44 intron 21572414 rs7559008 chr2 197970654 C T 8.56E-06 Glaucoma (primary open-angle) ANKRD44 intron 22605921 rs2579398 chr2 197987782 A G 3.85E-05 Multiple complex diseases ANKRD44 intron 17554300 rs2697264 chr2 197997831 T C 9.04E-06 Multiple complex diseases ANKRD44 intron 17554300 rs2579382 chr2 198021089 C T 6.13E-04 Response to cytadine analogues (cytosine arabinoside) ANKRD44 intron 24483146 rs1534540 chr2 198026894 C T 9.59E-04 Response to cytadine analogues (cytosine arabinoside) ANKRD44 intron 24483146 rs6725302 chr2 198032683 A G 1.73E-15 Gallbladder disease ANKRD44 intron pha001404 rs2697239 chr2 198041518 C T 4.66E-04 Suicide attempts in bipolar disorder ANKRD44 intron 21041247 rs2697236 chr2 198045646 C G 8.17E-04 Suicide attempts in bipolar disorder ANKRD44 intron 21041247 rs2697235 chr2 198046264 G A 8.20E-04 Suicide attempts in bipolar disorder ANKRD44 intron 21041247 rs2697234 chr2 198047017 C T 8.20E-04 Suicide attempts in bipolar disorder ANKRD44 intron 21041247 rs2579409 chr2 198061658 G T 8.54E-04 Suicide attempts in bipolar disorder ANKRD44 intron 21041247 rs2579409 chr2 198061658 G T 1.00E-04 Cognitive impairment induced by topiramate ANKRD44 intron 22091778 rs2579408 chr2 198068879 G A 8.71E-04 Suicide attempts in bipolar disorder ANKRD44 intron 21041247 rs2712900 chr2 198069854 C T 8.74E-04 Suicide attempts in bipolar disorder ANKRD44 intron 21041247 rs2697306 chr2 198075674 G A 9.44E-04 Response to taxane treatment (placlitaxel) ANKRD44 intron 23006423 rs2697299 chr2 198081078 A G 4.35E-04 Body mass index ANKRD44 intron 21701565 rs2697299 chr2 198081078 A G 7.80E-04 Body mass index ANKRD44 intron 21701565 rs2697299 chr2 198081078 A G 4.39E-04 Response to taxane treatment (placlitaxel) ANKRD44 intron 23006423 rs6715021 chr2 198082707 G A 9.16E-04 Alzheimer's disease ANKRD44 intron 24755620 rs1881401 chr2 198087907 G A 8.87E-06 Cognitive impairment induced by topiramate ANKRD44 intron 22091778 rs1881400 chr2 198088063 G A 2.67E-05 Cognitive impairment induced by topiramate ANKRD44 intron 22091778 rs2697318 chr2 198092910 A C 3.80E-04 Body mass index ANKRD44 intron 17255346 rs2252542 chr2 198093900 C T 5.48E-04 Body mass index ANKRD44 intron 21701565 rs17390362 chr2 198094771 C T 4.47E-04 Response to taxane treatment (placlitaxel) ANKRD44 intron 23006423 rs2697290 chr2 198113157 A G 9.80E-06 Crohn's disease ANKRD44 intron 20570966 rs6434921 chr2 198120197 G A 1.34E-05 Serum metabolites ANKRD44 intron 19043545 rs2697276 chr2 198130354 A G 3.74E-05 Psoriasis ANKRD44 intron 20953190 rs4850776 chr2 198132451 G A 1.39E-05 Serum metabolites ANKRD44 intron 19043545 rs4850776 chr2 198132451 G A 5.00E-04 Response to taxane treatment (placlitaxel) ANKRD44 intron 23006423 rs4850777 chr2 198132524 G A 1.37E-05 Serum metabolites ANKRD44 intron 19043545 rs4850777 chr2 198132524 G A 9.57E-04 Response to taxane treatment (placlitaxel) ANKRD44 intron 23006423 rs12617121 chr2 198134059 G A 1.13E-05 Serum metabolites ANKRD44 intron 19043545 rs4850779 chr2 198134188 G A 1.46E-05 Serum metabolites ANKRD44 intron 19043545 rs4850779 chr2 198134188 G A 5.49E-04 Response to taxane treatment (placlitaxel) ANKRD44 intron 23006423 rs4850780 chr2 198134535 G A 1.39E-05 Serum metabolites ANKRD44 intron 19043545 rs2712867 chr2 198135412 T C 4.08E-05 Psoriasis ANKRD44 intron 20953190 rs11693873 chr2 198142210 T C 7.70E-06 Urinary metabolites ANKRD44 intron 21572414 rs10931777 chr2 198143591 C T 1.23E-07 Prostate cancer ANKRD44 intron 22923026 rs6727480 chr2 198143871 A G 3.79E-07 Prostate cancer ANKRD44 intron 22923026 rs2043016 chr2 198146381 C T 9.16E-05 Self-reported allergy ANKRD44 intron 23817569 rs12619296 chr2 198148767 A G 2.50E-05 Self-reported allergy ANKRD44 intron 23817569 rs1429419 chr2 198154547 G A 1.58E-05 Self-reported allergy ANKRD44 intron 23817569 rs1429418 chr2 198158151 G C 2.25E-04 Self-reported allergy ANKRD44 intron 23817569 rs1366837 chr2 198160501 T C 1.18E-04 Self-reported allergy ANKRD44 intron 23817569 rs2195510 chr2 198161195 A G 1.18E-04 Self-reported allergy ANKRD44 intron 23817569 rs1429414 chr2 198162430 G A 1.18E-04 Self-reported allergy ANKRD44 intron 23817569 rs1896857 chr2 198164530 A G 8.00E-06 Alcohol dependence (age at onset) ANKRD44 intron 24962325 rs6741380 chr2 198165121 G A 1.37E-04 Self-reported allergy ANKRD44 intron 23817569 rs6741380 chr2 198165121 G A 4.43E-05 Body Fat Distribution ANKRD44 intron pha003017 rs919433 chr2 198166565 G A 1.78E-04 Self-reported allergy ANKRD44 intron 23817569 rs2195507 chr2 198172336 T C 1.59E-05 Self-reported allergy ANKRD44 intron 23817569 rs13033821 chr2 198173536 T G 2.06E-04 Self-reported allergy ANKRD44 intron 23817569 rs4850429 chr2 198178409 G A 2.02E-04 Self-reported allergy / / 23817569 rs4850786 chr2 198178608 C T 2.19E-04 Self-reported allergy / / 23817569 rs6738721 chr2 198182334 A G 6.31E-06 Self-reported allergy / / 23817569 rs1560277 chr2 198187903 T C 4.45E-05 Self-reported allergy / / 23817569 rs2059922 chr2 198188903 C G 7.23E-06 Self-reported allergy / / 23817569 rs13032495 chr2 198189346 C T 2.93E-05 Self-reported allergy / / 23817569 rs1429412 chr2 198190894 A G 2.91E-05 Self-reported allergy / / 23817569 rs3843857 chr2 198195965 T C 3.04E-05 Self-reported allergy / / 23817569 rs7575389 chr2 198198489 A G 1.31E-05 Self-reported allergy / / 23817569 rs3097385 chr2 198199297 G A 1.02E-05 Self-reported allergy / / 23817569 rs2914982 chr2 198202793 G C 1.10E-05 Self-reported allergy / / 23817569 rs6759834 chr2 198204860 C T 4.01E-05 Self-reported allergy / / 23817569 rs12472355 chr2 198205840 C A 4.71E-05 Self-reported allergy / / 23817569 rs6711624 chr2 198207607 C G 5.27E-05 Self-reported allergy / / 23817569 rs13013049 chr2 198208664 C T 4.89E-05 Self-reported allergy / / 23817569 rs10931782 chr2 198211579 G A 4.75E-05 Self-reported allergy / / 23817569 rs788001 chr2 198213720 C T 4.54E-05 Self-reported allergy / / 23817569 rs17405525 chr2 198214183 G C 3.51E-06 Self-reported allergy / / 23817569 rs787997 chr2 198216271 A G 4.10E-05 Self-reported allergy / / 23817569 rs787995 chr2 198216853 T G 3.48E-05 Self-reported allergy / / 23817569 rs788004 chr2 198219032 C T 2.22E-05 Self-reported allergy / / 23817569 rs787994 chr2 198223121 T C 2.08E-05 Self-reported allergy / / 23817569 rs788011 chr2 198230771 A G 1.14E-05 Self-reported allergy / / 23817569 rs788010 chr2 198230949 T C 1.06E-05 Self-reported allergy / / 23817569 rs788008 chr2 198232639 C T 4.83E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs788007 chr2 198233676 T G 1.00E-05 Self-reported allergy / / 23817569 rs787980 chr2 198239225 C T 9.87E-06 Self-reported allergy / / 23817569 rs11888760 chr2 198243749 A T 7.45E-06 Self-reported allergy / / 23817569 rs4685 chr2 198257795 T C 6.61E-06 Self-reported allergy SF3B1 cds-synon 23817569 rs16865262 chr2 198263146 T C 1.30E-05 Prostate cancer SF3B1 intron 22923026 rs12621129 chr2 198265350 T C 8.38E-06 Self-reported allergy SF3B1 intron 23817569 rs788018 chr2 198265526 A G 8.68E-06 Self-reported allergy SF3B1 cds-synon 23817569 rs788018 chr2 198265526 A G 7.00E-04 Ulcerative colitis SF3B1 cds-synon 24837172 rs12151767 chr2 198274929 G A 1.10E-06 Self-reported allergy SF3B1 intron 23817569 rs3097384 chr2 198278834 T A 1.03E-05 Self-reported allergy SF3B1 intron 23817569 rs699319 chr2 198281776 C A 1.03E-05 Self-reported allergy SF3B1 intron 23817569 rs788023 chr2 198283305 T C 1.51E-05 Self-reported allergy SF3B1 cds-synon 23817569 rs2564372 chr2 198307813 C T 1.19E-06 Self-reported allergy / / 23817569 rs3849362 chr2 198308260 G A 1.24E-06 Self-reported allergy / / 23817569 rs2564383 chr2 198310862 A G 1.30E-05 Self-reported allergy / / 23817569 rs11902195 chr2 198316370 C G 8.41E-07 Self-reported allergy / / 23817569 rs3731570 chr2 198317783 C T 1.55E-06 Self-reported allergy / / 23817569 rs3754822 chr2 198327314 G A 1.84E-06 Prostate cancer COQ10B cds-synon 22923026 rs3754822 chr2 198327314 G A 4.43E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) COQ10B cds-synon 24023788 rs787983 chr2 198345797 G A 1.05E-05 Self-reported allergy / / 23817569 rs6745660 chr2 198349536 A G 8.72E-07 Self-reported allergy / / 23817569 rs788016 chr2 198352293 G A 8.69E-07 Self-reported allergy HSPD1 intron 23817569 rs2565163 chr2 198354414 T C 9.42E-06 Self-reported allergy HSPD1 intron 23817569 rs8539 chr2 198362018 T C 1.28E-05 Self-reported allergy HSPD1 cds-synon 23817569 rs17730989 chr2 198362524 C T 9.81E-07 Self-reported allergy HSPD1 intron 23817569 rs2605039 chr2 198362851 C A 2.06E-05 Self-reported allergy HSPD1 intron 23817569 rs6434930 chr2 198369370 T C 1.45E-05 Self-reported allergy HSPE1-MOB4 intron 23817569 rs6434930 chr2 198369370 T C 3.00E-04 Ulcerative colitis HSPE1-MOB4 intron 24837172 rs7601800 chr2 198395099 T C 1.49E-05 Self-reported allergy MOB4 intron 23817569 rs3792159 chr2 198403697 C T 1.44E-05 Self-reported allergy MOB4 intron 23817569 rs3792159 chr2 198403697 C T 1.00E-04 Ulcerative colitis MOB4 intron 24837172 rs3792158 chr2 198407177 A G 8.76E-07 Self-reported allergy MOB4 intron 23817569 rs7568250 chr2 198409611 G A 5.85E-06 Self-reported allergy MOB4 intron 23817569 rs1563340 chr2 198414713 A T 1.85E-05 Self-reported allergy MOB4 intron 23817569 rs17787829 chr2 198419798 T C 7.33E-07 Self-reported allergy / / 23817569 rs7582536 chr2 198436103 A G 1.07E-05 Self-reported allergy RFTN2 UTR-3 23817569 rs6434934 chr2 198437386 C G 1.55E-05 Self-reported allergy RFTN2 intron 23817569 rs10178946 chr2 198463090 G T 9.34E-06 Self-reported allergy RFTN2 intron 23817569 rs17731449 chr2 198465840 T C 6.54E-07 Self-reported allergy RFTN2 intron 23817569 rs11900232 chr2 198466273 T C 9.78E-06 Self-reported allergy RFTN2 intron 23817569 rs13411968 chr2 198467141 C T 9.78E-06 Self-reported allergy RFTN2 intron 23817569 rs6719483 chr2 198472886 A G 6.19E-06 Self-reported allergy RFTN2 intron 23817569 rs1455653 chr2 198478320 G A 4.95E-06 Self-reported allergy RFTN2 intron 23817569 rs6719729 chr2 198480072 G A 5.12E-06 Self-reported allergy RFTN2 intron 23817569 rs6719729 chr2 198480072 G A 9.33E-05 Body Fat Distribution RFTN2 intron pha003017 rs2045245 chr2 198485341 A C 5.83E-06 Self-reported allergy RFTN2 intron 23817569 rs6728904 chr2 198492837 C T 1.34E-07 Self-reported allergy RFTN2 intron 23817569 rs13396312 chr2 198493703 T A 9.66E-05 Insulin resistance RFTN2 intron 21901158 rs13396312 chr2 198493703 T A 3.31E-07 Self-reported allergy RFTN2 intron 23817569 rs3828317 chr2 198495431 G C 2.58E-07 Self-reported allergy RFTN2 intron 23817569 rs970552 chr2 198497512 T G 2.82E-07 Self-reported allergy RFTN2 intron 23817569 rs2045244 chr2 198506466 C T 2.68E-06 Prostate cancer RFTN2 intron 22923026 rs10497806 chr2 198508951 G A 1.53E-05 Self-reported allergy RFTN2 cds-synon 23817569 rs16866970 chr2 198511086 G A 2.84E-07 Self-reported allergy RFTN2 intron 23817569 rs10166328 chr2 198511917 A G 1.72E-05 Self-reported allergy RFTN2 intron 23817569 rs13413470 chr2 198512849 G A 2.90E-07 Self-reported allergy RFTN2 intron 23817569 rs7564924 chr2 198513877 C T 1.78E-05 Self-reported allergy RFTN2 intron 23817569 rs10196961 chr2 198513930 G A 3.08E-07 Self-reported allergy RFTN2 intron 23817569 rs11690491 chr2 198514924 C T 3.33E-07 Self-reported allergy RFTN2 intron 23817569 rs1598469 chr2 198515658 T C 1.67E-05 Self-reported allergy RFTN2 intron 23817569 rs13427590 chr2 198516821 C T 3.19E-07 Self-reported allergy RFTN2 intron 23817569 rs1902249 chr2 198521356 T C 1.52E-05 Self-reported allergy RFTN2 intron 23817569 rs13000656 chr2 198522126 T C 1.32E-05 Self-reported allergy RFTN2 intron 23817569 rs6708239 chr2 198525084 A G 1.46E-05 Self-reported allergy RFTN2 intron 23817569 rs6741314 chr2 198526088 G A 1.51E-05 Self-reported allergy RFTN2 intron 23817569 rs6757632 chr2 198530266 C T 1.81E-05 Self-reported allergy RFTN2 intron 23817569 rs6757852 chr2 198530293 G A 2.17E-07 Self-reported allergy RFTN2 intron 23817569 rs6757669 chr2 198530355 C T 1.50E-05 Self-reported allergy RFTN2 intron 23817569 rs6719832 chr2 198533369 A G 1.41E-05 Self-reported allergy RFTN2 intron 23817569 rs6748788 chr2 198533606 G T 2.07E-07 Self-reported allergy RFTN2 intron 23817569 rs7603839 chr2 198534708 G A 2.73E-07 Self-reported allergy RFTN2 intron 23817569 rs7340470 chr2 198545462 G A 7.54E-09 Self-reported allergy / / 23817569 rs12622674 chr2 198551812 G A 6.58E-09 Self-reported allergy / / 23817569 rs2341510 chr2 198558679 T C 5.73E-09 Self-reported allergy / / 23817569 rs6743671 chr2 198563642 T C 4.47E-09 Self-reported allergy / / 23817569 rs4850437 chr2 198569051 T G 9.63E-09 Self-reported allergy / / 23817569 rs10931791 chr2 198573612 A C 8.08E-07 Self-reported allergy / / 23817569 rs4850807 chr2 198575975 G A 7.74E-07 Self-reported allergy / / 23817569 rs4850808 chr2 198576142 T C 7.00E-09 Self-reported allergy / / 23817569 rs10931793 chr2 198577585 G A 8.02E-07 Self-reported allergy / / 23817569 rs4850809 chr2 198583403 C T 6.58E-07 Self-reported allergy / / 23817569 rs2037590 chr2 198584775 T A 6.67E-07 Self-reported allergy / / 23817569 rs10497807 chr2 198585087 G C 8.54E-09 Self-reported allergy / / 23817569 rs12472359 chr2 198587865 T C 2.27E-08 Self-reported allergy / / 23817569 rs700640 chr2 198590886 C T 2.91E-08 Self-reported allergy / / 23817569 rs700642 chr2 198600730 T G 4.02E-07 Self-reported allergy BOLL intron 23817569 rs700643 chr2 198601370 A G 4.02E-07 Self-reported allergy BOLL intron 23817569 rs700645 chr2 198605514 A G 4.02E-07 Self-reported allergy BOLL intron 23817569 rs700646 chr2 198608511 C T 4.11E-07 Self-reported allergy BOLL intron 23817569 rs770666 chr2 198611897 T A 2.88E-08 Self-reported allergy BOLL intron 23817569 rs2293255 chr2 198621506 T C 7.48E-07 Prostate cancer BOLL intron 22923026 rs700648 chr2 198622636 C T 2.66E-08 Self-reported allergy BOLL intron 23817569 rs700649 chr2 198622752 G A 2.43E-08 Self-reported allergy BOLL intron 23817569 rs700650 chr2 198624285 G A 2.33E-08 Self-reported allergy BOLL intron 23817569 rs771013 chr2 198625237 G A 2.33E-08 Self-reported allergy BOLL intron 23817569 rs700651 chr2 198631714 G A 4.00E-08 Intracranial aneurysm BOLL intron 18997786 rs700651 chr2 198631714 G A 0.00027 Prostate cancer BOLL intron 23555315 rs700651 chr2 198631714 G A 1.05E-06 Self-reported allergy BOLL intron 23817569 rs700653 chr2 198637433 A G 2.44E-08 Self-reported allergy BOLL intron 23817569 rs700654 chr2 198643421 G A 2.54E-08 Self-reported allergy BOLL intron 23817569 rs700655 chr2 198643631 G A 5.71E-08 Self-reported allergy BOLL intron 23817569 rs1851779 chr2 198647108 C T 5.41E-07 Prostate cancer BOLL intron 22923026 rs700658 chr2 198655007 A T 2.71E-06 Self-reported allergy / / 23817569 rs700659 chr2 198659923 T C 7.95E-08 Self-reported allergy / / 23817569 rs771016 chr2 198665520 C T 7.35E-08 Self-reported allergy / / 23817569 rs770657 chr2 198674184 C A 2.44E-06 Self-reported allergy PLCL1 intron 23817569 rs700667 chr2 198677508 T C 2.17E-06 Self-reported allergy PLCL1 intron 23817569 rs16824376 chr2 198684342 C T 5.00E-07 Prostate cancer PLCL1 intron 22923026 rs996427 chr2 198685609 G A 5.51E-07 Prostate cancer PLCL1 intron 22923026 rs700670 chr2 198687284 T C 2.31E-06 Self-reported allergy PLCL1 intron 23817569 rs696815 chr2 198688084 A C 2.21E-06 Self-reported allergy PLCL1 intron 23817569 rs700671 chr2 198690001 T C 2.28E-06 Self-reported allergy PLCL1 intron 23817569 rs771010 chr2 198691006 C G 5.91E-08 Self-reported allergy PLCL1 intron 23817569 rs4550664 chr2 198691405 A G 1.91E-06 Self-reported allergy PLCL1 intron 23817569 rs700672 chr2 198691455 G A 2.05E-06 Self-reported allergy PLCL1 intron 23817569 rs700674 chr2 198693703 C T 2.32E-06 Self-reported allergy PLCL1 intron 23817569 rs700675 chr2 198700216 G A 2.20E-06 Self-reported allergy PLCL1 intron 23817569 rs700677 chr2 198702424 C A 6.84E-07 Self-reported allergy PLCL1 intron 23817569 rs2574832 chr2 198704818 T G 2.18E-06 Self-reported allergy PLCL1 intron 23817569 rs700678 chr2 198705820 T C 2.66E-06 Self-reported allergy PLCL1 intron 23817569 rs700679 chr2 198706916 C T 6.89E-08 Self-reported allergy PLCL1 intron 23817569 rs700680 chr2 198707950 A T 2.07E-06 Self-reported allergy PLCL1 intron 23817569 rs700681 chr2 198711502 C A 2.00E-06 Self-reported allergy PLCL1 intron 23817569 rs700683 chr2 198712332 G A 1.86E-06 Self-reported allergy PLCL1 intron 23817569 rs700684 chr2 198713099 C T 2.00E-06 Self-reported allergy PLCL1 intron 23817569 rs6707521 chr2 198713231 G A 5.47E-07 Prostate cancer PLCL1 intron 22923026 rs700685 chr2 198715972 A G 1.87E-06 Self-reported allergy PLCL1 intron 23817569 rs7604700 chr2 198718630 A G 1.81E-06 Self-reported allergy PLCL1 intron 23817569 rs1435569 chr2 198718667 G C 1.82E-06 Self-reported allergy PLCL1 intron 23817569 rs700686 chr2 198721054 G A 1.82E-06 Self-reported allergy PLCL1 intron 23817569 rs700687 chr2 198721560 A T 1.83E-06 Self-reported allergy PLCL1 intron 23817569 rs696817 chr2 198722225 A G 1.77E-06 Self-reported allergy PLCL1 intron 23817569 rs700688 chr2 198723833 G A 1.78E-06 Self-reported allergy PLCL1 intron 23817569 rs770661 chr2 198725444 A G 1.73E-06 Self-reported allergy PLCL1 intron 23817569 rs700690 chr2 198727626 A G 1.68E-06 Self-reported allergy PLCL1 intron 23817569 rs700691 chr2 198727852 A G 5.48E-08 Self-reported allergy PLCL1 intron 23817569 rs700692 chr2 198728500 T C 1.70E-06 Self-reported allergy PLCL1 intron 23817569 rs1436131 chr2 198731230 T G 1.38E-06 Self-reported allergy PLCL1 intron 23817569 rs6753450 chr2 198735031 C T 4.05E-08 Self-reported allergy PLCL1 intron 23817569 rs10192466 chr2 198738019 G A 4.90E-08 Self-reported allergy PLCL1 intron 23817569 rs4850812 chr2 198743655 G T 1.54E-06 Self-reported allergy PLCL1 intron 23817569 rs1369511 chr2 198746115 G C 4.49E-08 Self-reported allergy PLCL1 intron 23817569 rs2060488 chr2 198751637 T G 1.50E-06 Self-reported allergy PLCL1 intron 23817569 rs1865586 chr2 198758868 A G 1.10E-06 Self-reported allergy PLCL1 intron 23817569 rs6734781 chr2 198759973 G A 1.52E-06 Self-reported allergy PLCL1 intron 23817569 rs6434943 chr2 198762192 T G 1.35E-06 Self-reported allergy PLCL1 intron 23817569 rs1435568 chr2 198762879 T C 1.35E-06 Self-reported allergy PLCL1 intron 23817569 rs6729473 chr2 198763928 G A 1.35E-06 Self-reported allergy PLCL1 intron 23817569 rs1369512 chr2 198767132 T A 4.29E-08 Self-reported allergy PLCL1 intron 23817569 rs10198606 chr2 198769739 C G,T 3.57E-08 Self-reported allergy PLCL1 intron 23817569 rs4850813 chr2 198775982 C T 1.25E-06 Self-reported allergy PLCL1 intron 23817569 rs1401095 chr2 198779867 C T 1.08E-06 Self-reported allergy PLCL1 intron 23817569 rs938929 chr2 198780860 A G 2.67E-08 Self-reported allergy PLCL1 intron 23817569 rs938929 chr2 198780860 A G 8.32E-05 Dermatomyositis PLCL1 intron 23983088 rs1589162 chr2 198782692 C T 1.29E-06 Self-reported allergy PLCL1 intron 23817569 rs4850816 chr2 198789765 C A 2.41E-08 Self-reported allergy PLCL1 intron 23817569 rs1401091 chr2 198790423 T G 1.34E-06 Self-reported allergy PLCL1 intron 23817569 rs1401092 chr2 198792320 C A 1.17E-06 Self-reported allergy PLCL1 intron 23817569 rs7557203 chr2 198795650 A G 1.25E-06 Self-reported allergy PLCL1 intron 23817569 rs11692344 chr2 198795863 T G 1.31E-08 Self-reported allergy PLCL1 intron 23817569 rs6434945 chr2 198797960 G C 1.36E-08 Self-reported allergy PLCL1 intron 23817569 rs1464211 chr2 198798630 G A 1.41E-06 Self-reported allergy PLCL1 intron 23817569 rs1607373 chr2 198800532 G A 4.43E-05 Smoking cessation PLCL1 intron 18519826 rs1607373 chr2 198800532 G A 1.53E-08 Self-reported allergy PLCL1 intron 23817569 rs4369854 chr2 198800630 T C 1.45E-06 Self-reported allergy PLCL1 intron 23817569 rs2880389 chr2 198801707 T C 1.57E-08 Self-reported allergy PLCL1 intron 23817569 rs1983359 chr2 198805098 C T 1.44E-06 Self-reported allergy PLCL1 intron 23817569 rs11887138 chr2 198805838 T A 1.39E-06 Self-reported allergy PLCL1 intron 23817569 rs10207433 chr2 198805930 G T 1.19E-08 Self-reported allergy PLCL1 intron 23817569 rs1401090 chr2 198808578 G A 1.30E-08 Self-reported allergy PLCL1 intron 23817569 rs1518366 chr2 198809196 G A 1.47E-08 Self-reported allergy PLCL1 intron 23817569 rs1914690 chr2 198809368 G A 1.45E-08 Self-reported allergy PLCL1 intron 23817569 rs1518365 chr2 198809410 T C 1.39E-06 Self-reported allergy PLCL1 intron 23817569 rs1518364 chr2 198809975 G A 1.43E-08 Self-reported allergy PLCL1 intron 23817569 rs1518364 chr2 198809975 G A 5.11E-05 Dermatomyositis PLCL1 intron 23983088 rs1518363 chr2 198810131 C T 1.46E-06 Self-reported allergy PLCL1 intron 23817569 rs1518361 chr2 198812874 A G 1.79E-06 Self-reported allergy PLCL1 intron 23817569 rs10189897 chr2 198813410 A G 1.52E-08 Self-reported allergy PLCL1 intron 23817569 rs1518360 chr2 198815303 C T 3.05E-05 Smoking cessation PLCL1 intron 18519826 rs1518360 chr2 198815303 C T 1.51E-08 Self-reported allergy PLCL1 intron 23817569 rs4410288 chr2 198819824 C T 1.32E-08 Self-reported allergy PLCL1 intron 23817569 rs1401096 chr2 198823828 A G 1.28E-06 Self-reported allergy PLCL1 intron 23817569 rs13408411 chr2 198825462 G A 1.43E-06 Self-reported allergy PLCL1 intron 23817569 rs10497809 chr2 198825668 G A 1.18E-08 Self-reported allergy PLCL1 intron 23817569 rs1356542 chr2 198835702 G T 1.10E-06 Self-reported allergy PLCL1 intron 23817569 rs7581202 chr2 198836777 A G 7.60E-06 Prostate cancer PLCL1 intron 22923026 rs7571869 chr2 198841615 T C 8.90E-09 Self-reported allergy PLCL1 intron 23817569 rs7587043 chr2 198841729 A C 8.47E-09 Self-reported allergy PLCL1 intron 23817569 rs13394871 chr2 198846337 G A 8.68E-09 Self-reported allergy PLCL1 intron 23817569 rs6726506 chr2 198846486 G T 1.42E-06 Self-reported allergy PLCL1 intron 23817569 rs1518359 chr2 198847383 C T 5.66E-09 Self-reported allergy PLCL1 intron 23817569 rs6434949 chr2 198855510 T A 7.09E-07 Self-reported allergy PLCL1 intron 23817569 rs10177758 chr2 198858917 A G 2.29E-04 Smoking cessation PLCL1 intron 18519826 rs10177758 chr2 198858917 A G 5.69E-09 Self-reported allergy PLCL1 intron 23817569 rs1866664 chr2 198860428 T C 5.44E-09 Self-reported allergy PLCL1 intron 23817569 rs1976772 chr2 198868201 G T 9.13E-07 Self-reported allergy PLCL1 intron 23817569 rs1440088 chr2 198871417 T G 6.45E-04 Type 2 diabetes PLCL1 intron 17463246 rs1595824 chr2 198874006 C A,T 3.59E-09 Self-reported allergy PLCL1 intron 23817569 rs1595825 chr2 198875464 G A 1.47E-06 Prostate cancer PLCL1 intron 22923026 rs976179 chr2 198880378 A T 2.27E-09 Self-reported allergy PLCL1 intron 23817569 rs976180 chr2 198880443 A G 1.59E-06 Self-reported allergy PLCL1 intron 23817569 rs1318867 chr2 198880481 C A 2.37E-09 Self-reported allergy PLCL1 intron 23817569 rs1025549 chr2 198881183 G A 1.05E-05 Alcohol consumption PLCL1 intron 23743675 rs1016883 chr2 198881668 G A 2.56E-06 Prostate cancer PLCL1 intron 22923026 rs1016883 chr2 198881668 G A 3.00E-08 Ulcerative colitis PLCL1 intron 23128233 rs11681663 chr2 198882952 G A 1.09E-05 Alcohol consumption PLCL1 intron 23743675 rs34692727 chr2 198883513 C T 1.13E-05 Alcohol consumption PLCL1 intron 23743675 rs11683222 chr2 198884028 C G 1.16E-05 Alcohol consumption PLCL1 intron 23743675 rs11683222 chr2 198884028 C G 2.77E-09 Self-reported allergy PLCL1 intron 23817569 rs2139049 chr2 198887660 G A 1.21E-05 Alcohol consumption PLCL1 intron 23743675 rs1978888 chr2 198889245 T C 1.15E-05 Alcohol consumption PLCL1 intron 23743675 rs2196171 chr2 198889807 T G 1.24E-05 Alcohol consumption PLCL1 intron 23743675 rs2196172 chr2 198889893 T G 2.17E-05 Alcohol consumption PLCL1 intron 23743675 rs2196172 chr2 198889893 T G 1.59E-09 Self-reported allergy PLCL1 intron 23817569 rs7592556 chr2 198891021 G A 7.08E-07 Self-reported allergy PLCL1 intron 23817569 rs1595823 chr2 198891799 C T 1.62E-05 Alcohol consumption PLCL1 intron 23743675 rs1595823 chr2 198891799 C T 3.82E-09 Self-reported allergy PLCL1 intron 23817569 rs10196612 chr2 198894139 T C 1.18E-05 Alcohol consumption PLCL1 intron 23743675 rs10196612 chr2 198894139 T C 2.19E-09 Self-reported allergy PLCL1 intron 23817569 rs10184395 chr2 198894285 G A 6.10E-07 Self-reported allergy PLCL1 intron 23817569 rs10184227 chr2 198894305 C T 1.11E-05 Alcohol consumption PLCL1 intron 23743675 rs10184227 chr2 198894305 C T 2.00E-09 Self-reported allergy PLCL1 intron 23817569 rs10166845 chr2 198896071 A G 1.16E-05 Alcohol consumption PLCL1 intron 23743675 rs6738825 chr2 198896895 A G 4.00E-09 Crohn's disease PLCL1 intron 21102463 rs6738825 chr2 198896895 A G 1.10E-05 Alcohol consumption PLCL1 intron 23743675 rs6738825 chr2 198896895 A G 1.93E-09 Self-reported allergy PLCL1 intron 23817569 rs6715070 chr2 198898265 G A 5.65E-07 Self-reported allergy PLCL1 intron 23817569 rs1541953 chr2 198898344 A T 1.06E-05 Alcohol consumption PLCL1 intron 23743675 rs1541953 chr2 198898344 A T 2.28E-09 Self-reported allergy PLCL1 intron 23817569 rs11889326 chr2 198899275 A C 1.05E-05 Alcohol consumption PLCL1 intron 23743675 rs1583792 chr2 198900288 C T 7.26E-06 Alcohol consumption PLCL1 intron 23743675 rs1371663 chr2 198900305 G A 2.60E-07 Self-reported allergy PLCL1 intron 23817569 rs1579695 chr2 198900363 G A 1.12E-05 Alcohol consumption PLCL1 intron 23743675 rs1579695 chr2 198900363 G A 1.30E-09 Self-reported allergy PLCL1 intron 23817569 rs1147169 chr2 198901395 T C 2.25E-07 Self-reported allergy PLCL1 intron 23817569 rs10190226 chr2 198901564 C T 1.86E-07 Self-reported allergy PLCL1 intron 23817569 rs962210 chr2 198902230 A T 6.11E-06 Alcohol consumption PLCL1 intron 23743675 rs10497811 chr2 198902909 A C 5.94E-06 Alcohol consumption PLCL1 intron 23743675 rs10497811 chr2 198902909 A C 7.01E-10 Self-reported allergy PLCL1 intron 23817569 rs1371664 chr2 198904465 T A 1.05E-05 Smoking cessation PLCL1 intron 18519826 rs1371664 chr2 198904465 T A 6.84E-04 Smoking cessation PLCL1 intron 18519826 rs1371664 chr2 198904465 T A 5.61E-06 Alcohol consumption PLCL1 intron 23743675 rs1371664 chr2 198904465 T A 7.65E-10 Self-reported allergy PLCL1 intron 23817569 rs2196176 chr2 198904914 A G 2.37E-07 Self-reported allergy PLCL1 intron 23817569 rs2196175 chr2 198905073 T A 6.98E-06 Alcohol consumption PLCL1 intron 23743675 rs2196174 chr2 198905172 A G 5.49E-06 Alcohol consumption PLCL1 intron 23743675 rs12329164 chr2 198905224 C G 4.49E-06 Alcohol consumption PLCL1 intron 23743675 rs892514 chr2 198905270 T C 2.19E-07 Self-reported allergy PLCL1 intron 23817569 rs10206714 chr2 198906481 C T 4.50E-06 Alcohol consumption PLCL1 intron 23743675 rs10206714 chr2 198906481 C T 7.56E-10 Self-reported allergy PLCL1 intron 23817569 rs9712275 chr2 198907143 C T 5.77E-06 Alcohol consumption PLCL1 intron 23743675 rs745899 chr2 198908040 A T 4.24E-06 Alcohol consumption PLCL1 intron 23743675 rs745899 chr2 198908040 A T 8.69E-10 Self-reported allergy PLCL1 intron 23817569 rs67031482 chr2 198911166 C T 4.00E-06 Alcohol consumption PLCL1 intron 23743675 rs10497812 chr2 198911245 G A 1.95E-07 Self-reported allergy PLCL1 intron 23817569 rs6732340 chr2 198912952 C G 4.63E-06 Alcohol consumption PLCL1 intron 23743675 rs10497813 chr2 198914072 G T 4.36E-06 Alcohol consumption PLCL1 intron 23743675 rs10497813 chr2 198914072 G T 6.00E-10 Self-reported allergy PLCL1 intron 23817569 rs2164071 chr2 198915467 T C 1.24E-07 Self-reported allergy PLCL1 intron 23817569 rs2117339 chr2 198915734 C T 4.40E-06 Alcohol consumption PLCL1 intron 23743675 rs2117339 chr2 198915734 C T 7.04E-10 Self-reported allergy PLCL1 intron 23817569 rs7420608 chr2 198915930 A T 1.06E-07 Self-reported allergy PLCL1 intron 23817569 rs11903129 chr2 198918591 A T 1.50E-07 Self-reported allergy PLCL1 intron 23817569 rs2342558 chr2 198920142 T C 1.10E-07 Self-reported allergy PLCL1 intron 23817569 rs13382697 chr2 198920560 A C 1.11E-07 Self-reported allergy PLCL1 intron 23817569 rs1837495 chr2 198921201 G A 1.12E-07 Self-reported allergy PLCL1 intron 23817569 rs11679484 chr2 198921604 C A 7.95E-08 Self-reported allergy PLCL1 intron 23817569 rs35062652 chr2 198927927 C T 6.13E-06 Alcohol consumption PLCL1 intron 23743675 rs11889006 chr2 198928647 A G 3.46E-07 Self-reported allergy PLCL1 intron 23817569 rs6434953 chr2 198929693 A G 3.48E-07 Self-reported allergy PLCL1 intron 23817569 rs6434954 chr2 198929716 T C 2.17E-07 Self-reported allergy PLCL1 intron 23817569 rs7572733 chr2 198929806 C T 6.97E-06 Alcohol consumption PLCL1 intron 23743675 rs7572733 chr2 198929806 C T 1.88E-09 Self-reported allergy PLCL1 intron 23817569 rs7572733 chr2 198929806 C T 6.00E-06 Dermatomyositis PLCL1 intron 23983088 rs7573001 chr2 198929896 G C 1.32E-07 Self-reported allergy PLCL1 intron 23817569 rs7587251 chr2 198930197 T G 6.06E-06 Alcohol consumption PLCL1 intron 23743675 rs7587251 chr2 198930197 T G 1.71E-09 Self-reported allergy PLCL1 intron 23817569 rs11690149 chr2 198933804 C T 6.18E-06 Alcohol consumption PLCL1 intron 23743675 rs11690205 chr2 198933948 C T 5.87E-06 Alcohol consumption PLCL1 intron 23743675 rs6745726 chr2 198934080 A G 2.46E-07 Self-reported allergy PLCL1 intron 23817569 rs1368989 chr2 198937082 T C 2.20E-07 Self-reported allergy PLCL1 intron 23817569 rs12105927 chr2 198937258 G A 2.85E-07 Self-reported allergy PLCL1 intron 23817569 rs7590828 chr2 198940251 C T 1.88E-07 Self-reported allergy PLCL1 intron 23817569 rs1866666 chr2 198940607 T C 7.79E-06 Alcohol consumption PLCL1 intron 23743675 rs1866666 chr2 198940607 T C 1.35E-09 Self-reported allergy PLCL1 intron 23817569 rs9973400 chr2 198941578 T C 8.29E-06 Alcohol consumption PLCL1 intron 23743675 rs1371665 chr2 198942568 C T 1.62E-04 Gallstones PLCL1 intron 17632509 rs1371665 chr2 198942568 C T 1.40E-06 Self-reported allergy PLCL1 intron 23817569 rs1036333 chr2 198943787 G T 1.11E-08 Self-reported allergy PLCL1 intron 23817569 rs6434955 chr2 198946551 G A 8.00E-06 Prostate cancer PLCL1 intron 22923026 rs1064213 chr2 198950240 G A 1.60E-04 Myasthenia gravis PLCL1 missense 23055271 rs1064213 chr2 198950240 G A 1.38E-08 Self-reported allergy PLCL1 missense 23817569 rs2033570 chr2 198952637 C T 1.20E-06 Self-reported allergy PLCL1 intron 23817569 rs11684176 chr2 198954774 C T 2.12E-08 Self-reported allergy PLCL1 intron 23817569 rs7595412 chr2 198962243 G A 2.00E-06 Hip bone size PLCL1 intron 18776929 rs1304358 chr2 198969583 C T 1.27E-05 Attention deficit hyperactivity disorder PLCL1 intron 22420046 rs4850820 chr2 198982211 C G 1.71E-04 Insulin resistance PLCL1 intron 21901158 rs10180112 chr2 198982858 C G 5.22E-04 Alcohol dependence PLCL1 intron 21314694 rs988583 chr2 198987935 C A 6.00E-06 Neutrophil count PLCL1 intron 21507922 rs16827916 chr2 199008443 C A 3.07E-04 Insulin resistance PLCL1 intron 21901158 rs1434288 chr2 199032498 C T 9.79E-05 Serum metabolites / / 19043545 rs3796096 chr2 199052600 G A 9.57E-04 Coronary Artery Disease / / 17634449 rs13429991 chr2 199067470 C A 9.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6716214 chr2 199068929 G A 5.58E-04 Taste perception / / 22132133 rs12693837 chr2 199099576 G T 4.54E-05 Birth weight / / 17255346 rs1456563 chr2 199108358 T C 6.13E-04 Alzheimer's disease / / 24755620 rs11674810 chr2 199108648 G A 6.49E-04 Alzheimer's disease / / 24755620 rs1456562 chr2 199109322 T C 6.49E-04 Alzheimer's disease / / 24755620 rs12052400 chr2 199110141 C A 6.20E-04 Alzheimer's disease / / 24755620 rs1456557 chr2 199122294 A G 8.41E-04 Insulin resistance / / 21901158 rs1379020 chr2 199137857 C T 5.51E-04 Alzheimer's disease / / 24755620 rs4850839 chr2 199148418 T C 6.98E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs13398206 chr2 199169096 T C 4.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs16829794 chr2 199176140 G A 7.69E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13022622 chr2 199184007 G A 4.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs2529663 chr2 199184482 A G 7.61E-05 Waist Circumference / / pha003025 rs2727767 chr2 199190385 A G 9.79E-05 Body Mass Index / / pha003007 rs2727767 chr2 199190385 A G 7.16E-05 Waist Circumference / / pha003025 rs12999347 chr2 199190773 G T 4.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs10804083 chr2 199368722 A G 5.27E-04 Type 2 diabetes / / 17463246 rs2054125 chr2 199385721 C T 2.00E-07 Educational attainment / / 23722424 rs1455341 chr2 199387776 A G 9.16E-04 Type 2 diabetes / / 17463246 rs1584987 chr2 199426633 C G 2.54E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs10497816 chr2 199444954 C T 1.51E-08 Multiple complex diseases / / 17554300 rs1455357 chr2 199475047 G T 8.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs16830242 chr2 199476070 A C 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1455356 chr2 199476479 G A 0.000052 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs16830272 chr2 199490528 G A 4.20E-04 Multiple complex diseases / / 17554300 rs16830272 chr2 199490528 G A 0.000022 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10497819 chr2 199504838 G A 4.21E-06 Multiple complex diseases / / 17554300 rs13393754 chr2 199518159 C T 8.24E-04 Type 2 diabetes / / 17463246 rs17229285 chr2 199523122 C T 2.00E-13 Ulcerative colitis / / 23128233 rs1455334 chr2 199542837 C A 6.43E-04 Type 2 diabetes / / 17463246 rs17826270 chr2 199558179 G A 3.08E-05 Tuberculosis / / 24057671 rs16830330 chr2 199561300 C T 1.81E-04 Multiple complex diseases / / 17554300 rs1400979 chr2 199564343 A G 4.75E-04 Obesity (extreme) / / 21935397 rs1400976 chr2 199566914 T C 3.61E-04 Alzheimer's disease (late onset) / / 21379329 rs1400976 chr2 199566914 T C 5.05E-04 Obesity (extreme) / / 21935397 rs1400975 chr2 199566963 G T 5.52E-04 Obesity (extreme) / / 21935397 rs1356485 chr2 199571750 T C 8.78E-04 Type 2 diabetes / / 17463246 rs6757941 chr2 199572092 G T 8.78E-04 Type 2 diabetes / / 17463246 rs6434980 chr2 199572550 T C 8.78E-04 Type 2 diabetes / / 17463246 rs1356494 chr2 199572896 A G 4.79E-04 Alzheimer's disease (late onset) / / 21379329 rs1356494 chr2 199572896 A G 5.21E-04 Obesity (extreme) / / 21935397 rs6434981 chr2 199573857 A C 8.78E-04 Type 2 diabetes / / 17463246 rs13020013 chr2 199575723 T C 4.61E-04 Obesity (extreme) / / 21935397 rs6434983 chr2 199576145 T C 4.85E-04 Alzheimer's disease (late onset) / / 21379329 rs6434983 chr2 199576145 T C 4.53E-04 Obesity (extreme) / / 21935397 rs1533540 chr2 199576537 T C 9.03E-04 Obesity (extreme) / / 21935397 rs1533541 chr2 199576852 A G 9.07E-04 Obesity (extreme) / / 21935397 rs1518099 chr2 199577125 G A 9.18E-04 Obesity (extreme) / / 21935397 rs6740484 chr2 199578617 T C 9.81E-04 Obesity (extreme) / / 21935397 rs16830366 chr2 199585556 C T 6.00E-06 Waist circumference / / 23966867 rs11893063 chr2 199601925 G A 2.00E-06 Brain cytoarchitecture / / 20308991 rs1400984 chr2 199609869 G A 9.56E-04 Obesity (extreme) / / 21935397 rs6705243 chr2 199620941 A G 8.19E-04 Obesity (extreme) / / 21935397 rs1533534 chr2 199623598 C T 8.31E-04 Obesity (extreme) / / 21935397 rs12617311 chr2 199632565 G A 6.00E-13 Menarche (age at onset) / / 21102462 rs1518081 chr2 199633768 T C 6.57E-04 Obesity (extreme) / / 21935397 rs16830444 chr2 199635641 G A 1.96E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1356488 chr2 199638378 T C 9.38E-04 Obesity (extreme) / / 21935397 rs12986948 chr2 199639932 A G 9.44E-04 Obesity (extreme) / / 21935397 rs11680034 chr2 199640420 T C 9.50E-04 Obesity (extreme) / / 21935397 rs7582813 chr2 199640495 C T 9.42E-04 Obesity (extreme) / / 21935397 rs12991894 chr2 199645740 G T 7.40E-04 Obesity (extreme) / / 21935397 rs1518070 chr2 199653885 C A 6.92E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs17233334 chr2 199655056 T A 9.05E-04 Obesity (extreme) / / 21935397 rs1013162 chr2 199655213 A G 9.03E-04 Obesity (extreme) / / 21935397 rs1878663 chr2 199655520 T G 9.00E-04 Obesity (extreme) / / 21935397 rs7587759 chr2 199657020 C T 2.32E-04 Celiac disease / / 23936387 rs10497823 chr2 199671852 G A 1.26E-06 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs10189905 chr2 199679110 T G 2.29E-05 Alcohol and nictotine co-dependence / / 20158304 rs10189905 chr2 199679110 T G 6.00E-07 Corneal astigmatism / / 22144915 rs12470251 chr2 199693101 T C 8.33E-04 Multiple complex diseases / / 17554300 rs3973185 chr2 199693694 G A 1.00E-06 Urinary metabolites / / 21572414 rs12614240 chr2 199753674 C T 2.40E-05 Diabetes (gestational) / / 22233651 rs1456520 chr2 199772591 C T 2.22E-06 Brain structure / / 22504417 rs6434989 chr2 199775467 C T 5.52E-05 Major depressive disorder / / 21621269 rs6650780 chr2 199797322 A G 2.38E-05 Brain structure / / 22504417 rs966744 chr2 199809716 G A 6.23E-05 Cognitive performance / / 19734545 rs1349504 chr2 199952123 C A 6.88E-04 Multiple complex diseases / / 17554300 rs1451487 chr2 199994868 T C 2.00E-04 Schizophrenia / / 19197363 rs12471454 chr2 200014483 T C 6.00E-06 Insomnia / / 23728906 rs1374360 chr2 200125150 C T 5.47E-04 Schizophrenia / / 19197363 rs2881208 chr2 200137608 T C 7.77E-05 Major depressive disorder SATB2 intron 21621269 rs2881208 chr2 200137608 T C 2.83E-05 Response to radiotherapy in cancer (late toxicity) SATB2 intron 24785509 rs2881208 chr2 200137608 T C 3.22E-04 Response to radiotherapy in cancer (late toxicity) SATB2 intron 24785509 rs2881208 chr2 200137608 T C 7.01E-05 Response to radiotherapy in cancer (late toxicity) SATB2 intron 24785509 rs2881208 chr2 200137608 T C 7.68E-05 Response to radiotherapy in cancer (late toxicity) SATB2 intron 24785509 rs2166517 chr2 200190213 T C 9.22E-04 Multiple complex diseases SATB2 intron 17554300 rs13426349 chr2 200198964 C T 9.55E-04 Multiple complex diseases SATB2 intron 17554300 rs3828186 chr2 200214273 T C 4.30E-06 Urinary metabolites SATB2 intron 21572414 rs1348812 chr2 200236425 G A 8.02E-04 Multiple complex diseases SATB2 intron 17554300 rs4673339 chr2 200273376 A G 1.64E-05 Blood Pressure SATB2 intron pha003046 rs1992950 chr2 200290359 A G 5.00E-06 Ulcerative colitis SATB2 intron 20228799 rs6752494 chr2 200313323 T C 2.50E-05 Iron levels SATB2 intron 21208937 rs6706918 chr2 200389985 G C 1.21E-04 Multiple complex diseases / / 17554300 rs17589374 chr2 200391220 A G 2.34E-05 Multiple complex diseases / / 17554300 rs41495246 chr2 200431658 A G 1.32E-30 Multiple complex diseases / / 17554300 rs1450566 chr2 200478921 G T 1.14E-06 Multiple complex diseases / / 17554300 rs4675721 chr2 200479539 T A 7.44E-07 Multiple complex diseases / / 17554300 rs6730854 chr2 200482025 G A 1.66E-06 Multiple complex diseases / / 17554300 rs4624324 chr2 200500431 T C 1.12E-06 Multiple complex diseases / / 17554300 rs4675773 chr2 200532141 C T 8.42E-04 Type 2 diabetes / / 17463246 rs12620740 chr2 200549085 T C 2.40E-05 Urinary metabolites / / 21572414 rs10211241 chr2 200567136 C T 7.62E-05 Aging (time to event) / / 21782286 rs6748229 chr2 200569338 A G 8.95E-04 Type 2 diabetes / / 17463246 rs10804092 chr2 200577141 G T 4.87E-09 Metabolite levels / / 23281178 rs1976879 chr2 200577895 C T 2.45E-08 Metabolite levels / / 23281178 rs2049369 chr2 200577970 G A 2.25E-08 Metabolite levels / / 23281178 rs2049370 chr2 200578170 T G 2.25E-08 Metabolite levels / / 23281178 rs1996948 chr2 200598114 C T 1.20E-05 Urinary metabolites / / 21572414 rs4672548 chr2 200603517 G C 3.90E-06 Urinary metabolites / / 21572414 rs6759018 chr2 200620763 T C 5.70E-06 Urinary metabolites / / 21572414 rs4530349 chr2 200621420 C T 7.30E-06 Urinary metabolites / / 21572414 rs1523816 chr2 200632991 A G 2.80E-05 Urinary metabolites FONG intron 21572414 rs12615435 chr2 200638509 T G 7.67E-04 Type 2 diabetes FONG intron 17463246 rs12615435 chr2 200638509 T G 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) FONG intron 23648065 rs7605378 chr2 200676926 A C 2.00E-08 Osteoporosis FONG intron 21573128 rs2346662 chr2 200679158 C T 2.55E-04 Multiple complex diseases FONG intron 17554300 rs769954 chr2 200692159 G C 2.77E-04 Multiple complex diseases FONG intron 17554300 rs17529642 chr2 200697530 T C 5.55E-05 Parkinson's disease FONG intron 21738487 rs2689766 chr2 200697539 A T 7.78E-04 Suicide attempts in bipolar disorder FONG intron 21423239 rs10497841 chr2 200701788 A C 8.58E-04 Type 2 diabetes FONG intron 17846125 rs2949006 chr2 200715388 T G 1.00E-08 Schizophrenia FONG intron 23974872 rs769951 chr2 200731990 C G 1.88E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs6761647 chr2 200741624 C T 8.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs281783 chr2 200751582 G A 1.80E-04 Multiple sclerosis / / 21833088 rs1704189 chr2 200763224 C G 2.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs188147 chr2 200783985 T C 2.70E-04 Suicide attempts in bipolar disorder C2orf69 intron 21423239 rs281787 chr2 200784238 A G 4.25E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) C2orf69 intron 24023788 rs281773 chr2 200813584 T C 5.95E-04 Suicide attempts in bipolar disorder TYW5 intron 21423239 rs1704193 chr2 200815296 C G 4.50E-04 Suicide attempts in bipolar disorder TYW5 intron 21423239 rs281767 chr2 200823281 C A 2.84E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) C2orf47 intron 24023788 rs17445724 chr2 200853425 T C 5.56E-05 Coronary heart disease / / pha003032 rs4673634 chr2 200863349 A C 4.58E-04 Schizophrenia / / 19197363 rs7565480 chr2 200868926 A G 5.20E-04 Schizophrenia / / 21674006 rs4673727 chr2 200995687 C T 1.10E-06 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs1106399 chr2 201003837 A C 7.36E-04 Schizophrenia / / 19197363 rs1106400 chr2 201004089 T C 7.36E-04 Schizophrenia / / 19197363 rs1569175 chr2 201021954 T C 9.00E-07 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs10445792 chr2 201078821 A C 9.47E-04 Rheumatoid arthritis / / 21452313 rs4673802 chr2 201082457 A G 8.52E-05 Coronary heart disease / / pha003032 rs1729413 chr2 201086663 T G 1.69E-05 Magnesium levels / / pha003092 rs1144429 chr2 201098576 T G 8.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs296796 chr2 201103451 A G 9.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs17531061 chr2 201113452 A C 3.90E-05 Asthma (bronchodilator response) / / 22792082 rs1808827 chr2 201117622 G A 3.62E-04 Multiple complex diseases / / 17554300 rs17630220 chr2 201125410 T G 8.40E-04 Type 2 diabetes / / 17463246 rs4673837 chr2 201131159 G A 1.14E-04 Alzheimer's disease / / 24755620 rs6739563 chr2 201134216 G T 6.63E-04 Rheumatoid arthritis / / 21452313 rs1347552 chr2 201137031 A G 9.57E-04 Alzheimer's disease / / 24755620 rs295136 chr2 201141002 G C 1.30E-04 Kidney function and endocine traits / / 17903292 rs11687313 chr2 201146399 G A 1.62E-04 Cholesterol / / 17255346 rs11691757 chr2 201148951 C T 5.54E-05 Alzheimer's disease / / 24755620 rs4672726 chr2 201149413 G A 6.50E-05 Alzheimer's disease / / 24755620 rs295137 chr2 201150040 C T 1.00E-06 Asthma (bronchodilator response) / / 22792082 rs12612420 chr2 201158122 G A 8.00E-06 Exercise (leisure time) / / 19727025 rs295139 chr2 201159988 T A 6.80E-06 Asthma (bronchodilator response) / / 22792082 rs4673905 chr2 201163783 A G 9.72E-06 Multiple complex diseases / / 17554300 rs159320 chr2 201187775 A G 7.70E-05 Asthma (bronchodilator response) SPATS2L intron 22792082 rs295114 chr2 201195602 C T 6.00E-06 Asthma (bronchodilator response) SPATS2L intron 22792082 rs883999 chr2 201203110 T C 2.47E-04 Amyotrophic lateral sclerosis (sporadic) SPATS2L intron 24529757 rs295142 chr2 201211716 A G 4.70E-06 Asthma (bronchodilator response) SPATS2L intron 22792082 rs7575286 chr2 201213507 A T 4.85E-04 Type 2 diabetes SPATS2L intron 17463246 rs1900706 chr2 201214071 C A 4.90E-06 Asthma (bronchodilator response) SPATS2L intron 22792082 rs1369841 chr2 201227060 A G 5.77E-04 Multiple complex diseases SPATS2L intron 17554300 rs3769459 chr2 201234572 T G 7.92E-04 Type 2 diabetes SPATS2L intron 17463246 rs12990174 chr2 201240305 G A 2.47E-04 Multiple complex diseases SPATS2L intron 17554300 rs7598349 chr2 201247479 G A 5.10E-05 Asthma (bronchodilator response) SPATS2L intron 22792082 rs3769451 chr2 201252335 A G 4.09E-06 Creatinine levels SPATS2L intron pha003069 rs3769450 chr2 201252355 A G 3.34E-04 Suicide attempts in bipolar disorder SPATS2L intron 21041247 rs3739118 chr2 201253769 G A 0.00041 Salmonella-induced pyroptosis SPATS2L intron 22837397 rs842825 chr2 201255134 G A 7.70E-04 Blood pressure SPATS2L intron 21228793 rs2278515 chr2 201282338 T C 0.000831 Salmonella-induced pyroptosis SPATS2L intron 22837397 rs13004353 chr2 201313988 T C 7.93E-04 Suicide attempts in bipolar disorder SPATS2L intron 21423239 rs10197006 chr2 201314326 T C 7.72E-04 Suicide attempts in bipolar disorder SPATS2L intron 21423239 rs10497862 chr2 201315107 A T 0.000695 Salmonella-induced pyroptosis SPATS2L intron 22837397 rs6730788 chr2 201327631 G A 0.000663794 Hypertension (early onset hypertension) SPATS2L intron 22479346 rs1561295 chr2 201330209 C A 0.000663794 Hypertension (early onset hypertension) SPATS2L intron 22479346 rs34526345 chr2 201334715 G A 2.54E-04 Taste perception SPATS2L missense 22132133 rs199940720 chr2 201337629 G T 0.000082 Prostate cancer (advanced) SPATS2L missense 23555315 rs2881745 chr2 201338052 A C,G,T 4.29E-06 Multiple complex diseases SPATS2L intron 17554300 rs733054 chr2 201344434 A G 4.18E-04 Schizophrenia SPATS2L UTR-3 20832056 rs13019534 chr2 201349631 G A 2.39E-06 Common variable immunodeficiency / / 21497890 rs10497864 chr2 201355533 A G 4.25E-04 Blood pressure KCTD18 intron 17255346 rs713397 chr2 201357624 T G 3.20E-04 HIV-1 viral setpoint KCTD18 intron 17641165 rs713397 chr2 201357624 T G 9.25E-05 Blood Pressure KCTD18 intron pha003047 rs11884301 chr2 201358423 C T 8.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCTD18 intron 20877124 rs12987074 chr2 201362931 C T 9.07E-05 Personality dimensions KCTD18 intron 18957941 rs17448345 chr2 201453751 G A 3.06E-04 Blood pressure AOX1 intron 17255346 rs2293525 chr2 201468732 C G 6.97E-04 Esophageal adenocarcinoma AOX1 intron 24121790 rs10187029 chr2 201469791 C G 6.29E-05 Lymphocyte counts AOX1 intron 22286170 rs6753463 chr2 201483977 G T 8.59E-04 Type 2 diabetes AOX1 intron 17463246 rs7597713 chr2 201490349 A G 4.34E-04 Smoking initiation AOX1 intron 24665060 rs3815502 chr2 201525920 C G 1.97E-04 Alcohol dependence AOX1 intron 21314694 rs55754655 chr2 201526330 A G 1 Drug response to Azathioprine AOX1 missense 19500084 rs2241080 chr2 201527239 G A 3.95E-05 Alcohol dependence AOX1 intron 21314694 rs2715898 chr2 201556388 C T 2.00E-04 Chronic fatigue syndrome / / 21912186 rs13428164 chr2 201562344 G A 2.73E-05 Fibrinogen AOX2P intron pha003068 rs2243822 chr2 201565450 G T 6.91E-05 Blood pressure AOX2P intron 17255346 rs2540055 chr2 201565685 A C 5.00E-05 Prostate cancer AOX2P intron 21743057 rs2348113 chr2 201568369 G C 5.00E-05 Prostate cancer AOX2P intron 21743057 rs2540052 chr2 201568999 C T 4.00E-05 Prostate cancer AOX2P intron 21743057 rs2540051 chr2 201571143 G A 8.60E-04 Suicide attempts in bipolar disorder AOX2P intron 21423239 rs2540051 chr2 201571143 G A 6.00E-08 Intelligence AOX2P intron 22449649 rs2715902 chr2 201575480 C T 7.56E-04 Suicide attempts in bipolar disorder AOX2P intron 21423239 rs7563911 chr2 201576284 A C,G,T 6.60E-05 Alcoholism (heaviness of drinking) AOX2P intron 21529783 rs950233 chr2 201594185 A G 5.75E-06 Non-obstructive azoospermia AOX2P intron 22541561 rs1001250 chr2 201624818 C T 5.15E-04 Parkinson's disease AOX2P intron 17052657 rs16834415 chr2 201631393 G A 2.60E-05 Urinary metabolites AOX2P intron 21572414 rs10181489 chr2 201635535 T C 2.80E-05 Lymphocyte counts AOX2P intron 22286170 rs12622452 chr2 201638647 A G 7.32E-04 Parkinson's disease / / 17052657 rs6720418 chr2 201641373 G C 7.32E-04 Parkinson's disease AOX2P intron 17052657 rs10515941 chr2 201643484 C A 3.36E-04 Type 2 diabetes AOX2P intron 17846124 rs10515941 chr2 201643484 C A 2.00E-05 Urinary metabolites AOX2P intron 21572414 rs13430864 chr2 201648639 T G 5.00E-07 Response to citalopram treatment AOX2P intron 22760553 rs10931922 chr2 201649795 T C 2.78E-04 Suicide attempts in bipolar disorder AOX2P intron 21423239 rs11674530 chr2 201650074 T A 3.54E-04 Suicide attempts in bipolar disorder AOX2P intron 21423239 rs16834587 chr2 201652048 A C 3.63E-04 Multiple complex diseases AOX2P intron 17554300 rs13423450 chr2 201652453 T C 3.33E-05 Response to citalopram treatment AOX2P intron 22760553 rs7609464 chr2 201652946 T C 3.78E-04 Suicide attempts in bipolar disorder AOX2P intron 21423239 rs13030323 chr2 201653966 T C 2.36E-04 Suicide attempts in bipolar disorder AOX2P intron 21423239 rs10931923 chr2 201659168 G A 2.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs12465041 chr2 201660050 C G 1.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs4674449 chr2 201664304 T C 2.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs4625890 chr2 201667523 A G 3.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs2270280 chr2 201677791 T C 2.87E-04 Suicide attempts in bipolar disorder BZW1 intron 21423239 rs12475785 chr2 201679931 G T 2.94E-04 Suicide attempts in bipolar disorder BZW1 intron 21423239 rs2881880 chr2 201683695 T C 2.46E-04 Suicide attempts in bipolar disorder BZW1 intron 21423239 rs12995928 chr2 201689742 C T 2.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs10804108 chr2 201697240 C G 9.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs7586299 chr2 201699860 G A 1.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs6719879 chr2 201701162 G C 1.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs13012316 chr2 201704064 T C 7.22E-04 Multiple complex diseases / / 17554300 rs13012316 chr2 201704064 T C 1.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs13028326 chr2 201710305 A T 4.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs3888610 chr2 201732117 C T 0.00004562 Sarcoidosis / / 22952805 rs7606251 chr2 201736734 T C 0.0000763 Sarcoidosis PPIL3 intron 22952805 rs11688943 chr2 201740268 T C 8.90E-08 Chronic lymphocytic leukemia PPIL3 intron 23770605 rs17467700 chr2 201745667 T C 2.70E-06 Urinary metabolites PPIL3 intron 21572414 rs16835473 chr2 201763483 C T 1.50E-04 Multiple complex diseases NIF3L1 intron 17554300 rs1912331 chr2 201783007 T C 6.36E-04 Multiple complex diseases ORC2 intron 17554300 rs16836577 chr2 201880513 C T 2.39E-04 Multiple complex diseases FAM126B intron 17554300 rs16836596 chr2 201931924 G T 4.64E-05 Multiple complex diseases FAM126B intron 17554300 rs12621441 chr2 201968940 G A 2.40E-05 Major depressive disorder / / 19065144 rs12621441 chr2 201968940 G A 3.22E-05 Major depressive disorder / / 21621269 rs12621441 chr2 201968940 G A 3.43E-05 Major depressive disorder / / pha002850 rs7583529 chr2 201988238 G A 6.45E-05 Longevity CFLAR intron 21612516 rs12620435 chr2 201995779 A G 6.14E-05 Multiple complex diseases CFLAR intron 17554300 rs4487072 chr2 202008298 C T 2.57E-04 Multiple complex diseases CFLAR intron 17554300 rs719125 chr2 202017860 G T 2.98E-04 Multiple complex diseases CFLAR intron 17554300 rs72931086 chr2 202042386 T G 0.00008672 Sarcoidosis / / 22952805 rs72931089 chr2 202042736 C A 0.00009111 Sarcoidosis / / 22952805 rs2098355 chr2 202042916 T C 0.00008672 Sarcoidosis / / 22952805 rs11900753 chr2 202044716 G A 0.00003573 Sarcoidosis / / 22952805 rs112223847 chr2 202046184 G T 0.00005836 Sarcoidosis CASP10 nearGene-5 22952805 rs41411846 chr2 202046265 T C 0.00003515 Sarcoidosis CASP10 nearGene-5 22952805 rs41332047 chr2 202046945 G A 0.00005836 Sarcoidosis CASP10 nearGene-5 22952805 rs16836789 chr2 202047833 C T 0.00003515 Sarcoidosis CASP10 UTR-5 22952805 rs17860398 chr2 202048219 C T 0.00005836 Sarcoidosis CASP10 intron 22952805 rs17468215 chr2 202049642 T C 0.00009842 Sarcoidosis CASP10 intron 22952805 rs41351447 chr2 202050153 G A 0.00004926 Sarcoidosis CASP10 intron 22952805 rs41339752 chr2 202051781 G A 7.02E-04 Multiple complex diseases CASP10 intron 17554300 rs17860400 chr2 202052617 A G 0.00003111 Sarcoidosis CASP10 intron 22952805 rs16836813 chr2 202052754 C T 0.00002886 Sarcoidosis CASP10 intron 22952805 rs56278081 chr2 202060086 C T 0.00009725 Sarcoidosis CASP10 intron 22952805 rs3731714 chr2 202060820 C T 2.94E-04 Multiple complex diseases CASP10 intron 17554300 rs13391950 chr2 202061050 C G 0.00008226 Sarcoidosis CASP10 intron 22952805 rs41343245 chr2 202061670 T C 0.00009725 Sarcoidosis CASP10 intron 22952805 rs41504752 chr2 202063350 G A 0.00009823 Sarcoidosis CASP10 intron 22952805 rs6435069 chr2 202078494 G A 5.07E-04 Multiple complex diseases CASP10 intron 17554300 rs12693932 chr2 202093395 T C 7.13E-04 Multiple complex diseases CASP10 intron 17554300 rs2037815 chr2 202101715 G A 6.83E-04 Multiple complex diseases CASP8 intron 17554300 rs3769825 chr2 202111380 A G 3.00E-09 Chronic lymphocytic leukemia CASP8 intron 23770605 rs35665714 chr2 202113552 CT C 3.93E-04 Insulin resistance CASP8 intron 21901158 rs6712381 chr2 202113552 C T 3.93E-04 Insulin resistance CASP8 intron 21901158 rs3769823 chr2 202122995 A G 0.0000488 post-traumatic stress disorder CASP8 missense 22869035 rs3769823 chr2 202122995 A G 4.88E-05 Schizophrenia CASP8 missense 22883433 rs4381764 chr2 202126863 T C 6.85E-05 Type 2 diabetes and other traits CASP8 intron 19734900 rs10084352 chr2 202127717 T C 9.35E-04 Insulin resistance CASP8 intron 21901158 rs10931936 chr2 202143928 T C 3.30E-09 Melanoma CASP8 intron 21983787 rs10931936 chr2 202143928 T C 4.74E-09 Esophageal cancer (squamous cell) CASP8 intron 22323360 rs11681399 chr2 202145606 A G 1.76E-04 Telomere length CASP8 intron 23900074 rs10804111 chr2 202145612 C T 0.00000381 Esophageal cancer (squamous cell) CASP8 intron 22323360 rs3769818 chr2 202151163 A G 0.00000289 Esophageal cancer (squamous cell) CASP8 intron 22323360 rs3769818 chr2 202151163 A G 0.0000334 post-traumatic stress disorder CASP8 intron 22869035 rs3769818 chr2 202151163 A G 3.34E-05 Schizophrenia CASP8 intron 22883433 rs1035142 chr2 202153078 T G 5.40E-10 Melanoma / / 21983787 rs1035142 chr2 202153078 T G 0.00000137 Esophageal cancer (squamous cell) / / 22323360 rs1035142 chr2 202153078 T G 7.61E-05 Chronic lymphocytic leukemia / / 24292274 rs700635 chr2 202153225 C A 2.40E-09 Melanoma ALS2CR12 UTR-3 21983787 rs700635 chr2 202153225 C A 0.00000169 Esophageal cancer (squamous cell) ALS2CR12 UTR-3 22323360 rs700635 chr2 202153225 C A 0.0000334 post-traumatic stress disorder ALS2CR12 UTR-3 22869035 rs700635 chr2 202153225 C A 3.34E-05 Schizophrenia ALS2CR12 UTR-3 22883433 rs6714430 chr2 202153684 C T 0.00000158 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs6714430 chr2 202153684 C T 0.0000334 post-traumatic stress disorder ALS2CR12 intron 22869035 rs6714430 chr2 202153684 C T 3.34E-05 Schizophrenia ALS2CR12 intron 22883433 rs11674814 chr2 202153846 G A 1.71E-04 Telomere length ALS2CR12 intron 23900074 rs6743068 chr2 202153920 A G 0.00000156 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs6715284 chr2 202154397 C G 2.00E-09 Rheumatoid arthritis ALS2CR12 intron 24390342 rs6715284 chr2 202154397 C G 3.00E-09 Rheumatoid arthritis ALS2CR12 intron 24390342 rs13009885 chr2 202161636 G A 2.52E-04 Telomere length ALS2CR12 intron 23900074 rs11679181 chr2 202162338 C T 2.10E-04 Telomere length ALS2CR12 intron 23900074 rs13016963 chr2 202162811 A G 9.00E-10 Melanoma ALS2CR12 intron 21983787 rs13016963 chr2 202162811 A G 7.63E-10 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs9288316 chr2 202163483 G A 0.00000102 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs7560328 chr2 202164837 A C 0.00000101 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs6719014 chr2 202176024 T C 0.000000974 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs7582362 chr2 202176294 A G 0.000000973 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs12986657 chr2 202178089 G A 1.79E-04 Telomere length ALS2CR12 intron 23900074 rs10931940 chr2 202178672 C T 2.04E-04 Telomere length ALS2CR12 intron 23900074 rs6731171 chr2 202179011 T A 0.000000964 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs6735641 chr2 202180491 T C 0.000000955 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs2110690 chr2 202185132 A G 0.000000843 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs7570324 chr2 202185604 G T 1.93E-04 Telomere length ALS2CR12 intron 23900074 rs2080304 chr2 202186422 G C 0.000000815 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs2349073 chr2 202186986 C A 0.000000808 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs11688692 chr2 202189451 T C 1.35E-04 Telomere length ALS2CR12 intron 23900074 rs9288318 chr2 202196063 C A 6.40E-04 Alcohol dependence ALS2CR12 intron 20201924 rs9288318 chr2 202196063 C A 1.35E-09 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs11898821 chr2 202199688 T C 0.000000205 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs6757783 chr2 202199824 C T 0.000000203 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs6435079 chr2 202200331 C G 0.000000363 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs7579792 chr2 202200450 A G 0.000000195 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs10186527 chr2 202200575 C T 0.000000193 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs10171829 chr2 202201189 C T 4.84E-04 Insulin resistance ALS2CR12 intron 21901158 rs6745435 chr2 202202563 G A 0.000000169 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs10201587 chr2 202202791 A G 8.71E-10 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs7597617 chr2 202203235 G A 0.000000171 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs10197246 chr2 202204741 T C 0.000000182 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs10454127 chr2 202212374 G A 0.00000047 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs6711127 chr2 202213515 C T 5.13E-04 Alzheimer's disease ALS2CR12 intron 22005930 rs6714736 chr2 202214148 C T 0.00000076 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs6715380 chr2 202214505 G A 4.99E-04 Alzheimer's disease ALS2CR12 intron 22005930 rs13014235 chr2 202215492 C G 0.00000489 Esophageal cancer (squamous cell) ALS2CR12 missense 22323360 rs6435081 chr2 202220623 T C 0.00000866 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs6737085 chr2 202221441 T A 0.0000021 Esophageal cancer (squamous cell) ALS2CR12 intron 22323360 rs2349075 chr2 202223566 A G 0.00000732 Esophageal cancer (squamous cell) / / 22323360 rs6761514 chr2 202227549 T C 0.00000236 Esophageal cancer (squamous cell) / / 22323360 rs10178982 chr2 202227640 G C 0.00000236 Esophageal cancer (squamous cell) / / 22323360 rs11691602 chr2 202227699 A C 0.00000833 Esophageal cancer (squamous cell) / / 22323360 rs72937111 chr2 202227922 A G 0.00000239 Esophageal cancer (squamous cell) / / 22323360 rs10206231 chr2 202229225 A C 0.00000911 Esophageal cancer (squamous cell) / / 22323360 rs7578456 chr2 202235348 A G 0.000000016 Esophageal cancer (squamous cell) / / 22323360 rs10202963 chr2 202241907 T G 8.60E-04 Alcohol dependence / / 20201924 rs1914265 chr2 202417023 C T 3.52E-04 Multiple complex diseases ALS2CR11 intron 17554300 rs12693941 chr2 202423436 G A 1.15E-04 Multiple complex diseases ALS2CR11 intron 17554300 rs1208082 chr2 202497586 A C 8.49E-05 Pulmonary function in asthmatics TMEM237 intron 23541324 rs11894115 chr2 202512449 C T 7.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MPP4 missense 20877124 rs17384314 chr2 202531136 G C 5.10E-05 Cytomegalovirus antibody response MPP4 intron 21993531 rs17469010 chr2 202555755 T C 8.94E-04 Type 2 diabetes MPP4 intron 17463246 rs6731583 chr2 202560854 T C 2.09E-04 Type 2 diabetes MPP4 intron 17463246 rs6731583 chr2 202560854 T C 2.91E-04 Gallstones MPP4 intron 17632509 rs7598082 chr2 202569654 C A 6.89E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ALS2 intron 20031582 rs3731704 chr2 202603147 A G 1.91E-05 Type 2 diabetes ALS2 intron 17463246 rs7597686 chr2 202657193 A G 7.12E-04 Heart Failure / / pha002884 rs9784022 chr2 202657818 G A 1.47E-04 Lymphocyte counts / / 22286170 rs7582228 chr2 202659709 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4673210 chr2 202682736 T A 2.82E-04 Body mass index CDK15 intron 23669352 rs2072504 chr2 202741064 G A 9.00E-06 Urinary metabolites CDK15 intron 21572414 rs6708814 chr2 202742455 A C 8.79E-05 Blood Pressure CDK15 intron pha002903 rs759419 chr2 202766647 G A 1.50E-05 Urinary metabolites / / 21572414 rs6722501 chr2 202793266 G A 6.05E-05 Glucose levels / / pha003061 rs17385675 chr2 202807196 C T 3.00E-06 Response to antipsychotic treatment / / 20195266 rs7562987 chr2 202815530 G A 9.70E-05 Personality dimensions / / 18957941 rs12693955 chr2 202841545 G A 0.000385 Salmonella-induced pyroptosis / / 22837397 rs4321346 chr2 202852216 A G 8.20E-06 Urinary metabolites / / 21572414 rs13410775 chr2 202852739 T G 8.73E-06 Response to amphetamines / / 22952603 rs62193867 chr2 202854721 C T 7.84E-06 Response to amphetamines / / 22952603 rs4675242 chr2 202855194 A G 1.10E-04 Response to antidepressants / / 19736353 rs17476956 chr2 202857337 T C 9.67E-06 Response to amphetamines / / 22952603 rs6754521 chr2 202859617 G A 5.00E-06 Response to amphetamines / / 22952603 rs13402103 chr2 202869881 T C 3.14E-05 Body Composition / / pha003012 rs12185569 chr2 202875552 G A 1.54E-05 Body Composition / / pha003012 rs12185569 chr2 202875552 G A 9.69E-05 Body Mass Index / / pha003021 rs12185569 chr2 202875552 G A 8.18E-05 Insulin-related traits / / pha003063 rs12185569 chr2 202875552 G A 8.94E-05 HDL cholesterol / / pha003074 rs1477032 chr2 202875696 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10490083 chr2 202877944 C T 1.54E-05 Body Composition / / pha003012 rs10490083 chr2 202877944 C T 9.69E-05 Body Mass Index / / pha003021 rs10490083 chr2 202877944 C T 8.18E-05 Insulin-related traits / / pha003063 rs10490083 chr2 202877944 C T 8.94E-05 HDL cholesterol / / pha003074 rs7566288 chr2 202928940 G T 8.90E-05 Alcoholism (heaviness of drinking) / / 21529783 rs1521882 chr2 202949851 G A 8.00E-06 Attention deficit hyperactivity disorder and conduct disorder LOC100652824 intron 18951430 rs2177083 chr2 202961665 G A 1.01E-05 Amyotrophic lateral sclerosis LOC100652824 intron 20801717 rs2177083 chr2 202961665 G A 0.00000618 Amyotrophic lateral sclerosis LOC100652824 intron 23587638 rs2177083 chr2 202961665 G A 0.0000112 Amyotrophic lateral sclerosis LOC100652824 intron 23587638 rs4675268 chr2 203014746 G C 2.10E-05 Urinary metabolites FLJ39061 intron 21572414 rs13015146 chr2 203062103 T C 9.49E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs16838988 chr2 203142338 T C 4.74E-04 Multiple complex diseases NOP58 intron 17554300 rs1105047 chr2 203202958 A G 1.88E-05 Serum metabolites / / 19043545 rs4516412 chr2 203203865 G A 8.00E-04 Amyotrophic lateral sclerosis / / 17671248 rs12473579 chr2 203204567 G A 8.00E-04 Amyotrophic lateral sclerosis / / 17671248 rs7589059 chr2 203313638 T C 7.75E-05 Serum metabolites BMPR2 intron 19043545 rs6747756 chr2 203315612 T C 8.37E-05 Serum metabolites BMPR2 intron 19043545 rs12468226 chr2 203337001 A G 3.00E-06 Urate levels BMPR2 intron 23263486 rs12621870 chr2 203358214 T C 9.74E-05 Monocyte counts BMPR2 intron pha003089 rs12467409 chr2 203394348 G T 2.65E-06 Lipid levels BMPR2 intron 19913121 rs10200587 chr2 203419284 A G 2.00E-11 HDL cholesterol BMPR2 intron 23063622 rs17386813 chr2 203458494 T C 5.98E-05 Alzheimer's disease (late onset) / / 21379329 rs13432396 chr2 203469588 C A 8.70E-04 Alcohol dependence / / 20201924 rs13432396 chr2 203469588 C A 5.26E-04 Smoking cessation / / 24665060 rs11694172 chr2 203532304 A G 2.00E-09 Cholesterol,total FAM117B intron 24097068 rs7577225 chr2 203550741 T C 7.10E-04 Iris characteristics FAM117B intron 21835309 rs7571219 chr2 203583254 G A 8.70E-04 Alcohol dependence FAM117B intron 20201924 rs7602496 chr2 203602207 C A 8.20E-04 Alcohol dependence FAM117B intron 20201924 rs7581854 chr2 203606754 T C 4.00E-04 Alcohol dependence FAM117B intron 20201924 rs7581854 chr2 203606754 T C 8.40E-04 Alcohol dependence FAM117B intron 20201924 rs6435163 chr2 203608742 T C 4.20E-04 Alcohol dependence FAM117B intron 20201924 rs6435163 chr2 203608742 T C 7.20E-04 Alcohol dependence FAM117B intron 20201924 rs2351116 chr2 203627311 G A 4.00E-04 Alcohol dependence FAM117B intron 20201924 rs2351116 chr2 203627311 G A 6.10E-04 Alcohol dependence FAM117B intron 20201924 rs2351117 chr2 203627412 C T 5.30E-04 Alcohol dependence FAM117B intron 20201924 rs11685819 chr2 203628757 G A 4.60E-04 Alcohol dependence FAM117B intron 20201924 rs11685819 chr2 203628757 G A 7.40E-04 Alcohol dependence FAM117B intron 20201924 rs17807135 chr2 203633245 A C 8.11E-04 Smoking cessation FAM117B UTR-3 24665060 rs6733972 chr2 203652838 T C 2.20E-11 Butyrylcholinesterase levels ICA1L intron 21862451 rs6705330 chr2 203662197 A G 5.70E-05 White matter hyperintensity burden ICA1L intron 21681796 rs11694728 chr2 203666319 T G 4.50E-11 Butyrylcholinesterase levels ICA1L intron 21862451 rs17594321 chr2 203695265 A T 2.30E-11 Butyrylcholinesterase levels ICA1L intron 21862451 rs1866423 chr2 203697790 G A 2.90E-11 Butyrylcholinesterase levels ICA1L intron 21862451 rs12053074 chr2 203699740 G C 4.30E-04 Iris characteristics ICA1L intron 21835309 rs4673238 chr2 203723989 A T 4.90E-10 Butyrylcholinesterase levels ICA1L intron 21862451 rs3845802 chr2 203740672 T G 3.30E-11 Butyrylcholinesterase levels / / 21862451 rs6725887 chr2 203745885 T C 1.00E-08 Myocardial infarction (early onset) WDR12 intron 19198609 rs6725887 chr2 203745885 T C 3.36E-05 Cardiovascular disease risk factors WDR12 intron 21239051 rs6725887 chr2 203745885 T C 1.00E-08 Coronary heart disease WDR12 intron 21347282 rs6725887 chr2 203745885 T C 1.00E-09 Coronary heart disease WDR12 intron 21378990 rs6725887 chr2 203745885 T C 1.12E-09 Pericardial fat WDR12 intron 22589742 rs6725887 chr2 203745885 T C 0.000000148 Coronary artery disease (CAD) age >50 WDR12 intron 23202125 rs6725887 chr2 203745885 T C 0.000000188 Coronary artery disease (CAD) (males) WDR12 intron 23202125 rs6725887 chr2 203745885 T C 0.00017 Coronary artery disease (CAD) age <=50 WDR12 intron 23202125 rs6725887 chr2 203745885 T C 5.51E-10 Coronary artery disease with myocardial infarction WDR12 intron 23202125 rs6725887 chr2 203745885 T C 6.55E-08 Coronary artery disease (CAD) (females) WDR12 intron 23202125 rs6725887 chr2 203745885 T C 2.00E-08 Coronary artery disease WDR12 intron 24262325 rs7582720 chr2 203753072 T C 3.00E-08 Coronary artery disease or large artery stroke WDR12 intron 24262325 rs7582720 chr2 203753072 T C 4.00E-09 Coronary artery disease or ischemic stroke WDR12 intron 24262325 rs3933629 chr2 203766367 T C 3.30E-11 Butyrylcholinesterase levels WDR12 intron 21862451 rs6719001 chr2 203777903 G A 8.80E-05 White matter hyperintensity burden ALS2CR8 intron 21681796 rs17406900 chr2 203784202 A G 1.20E-09 Butyrylcholinesterase levels ALS2CR8 intron 21862451 rs3731695 chr2 203820275 T C 4.00E-12 Butyrylcholinesterase levels ALS2CR8 intron 21862451 rs11691351 chr2 203873912 A G 4.40E-12 Butyrylcholinesterase levels / / 21862451 rs4675310 chr2 203880834 G A 1.85E-06 Coronary heart disease NBEAL1 intron 22319020 rs2351524 chr2 203880992 T C 0.000451 Cholesterol,total NBEAL1 UTR-5 23202125 rs1947983 chr2 203882593 A C 4.40E-12 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs6715752 chr2 203913552 A G 2.20E-10 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs13396160 chr2 203913942 C T 2.20E-10 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs10439267 chr2 203923447 C T 5.70E-11 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs7573079 chr2 203927551 G A 2.90E-12 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs7593917 chr2 203931012 A G 2.90E-12 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs11690927 chr2 203944028 A G 1.30E-12 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs1545885 chr2 203962030 A G 9.70E-13 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs17473735 chr2 203962146 T C 4.20E-12 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs7574314 chr2 203964137 T C 3.10E-10 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs10497870 chr2 203970283 A G 3.10E-10 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs17474056 chr2 203987554 C T 4.85E-04 Multiple complex diseases NBEAL1 intron 17554300 rs17474056 chr2 203987554 C T 9.70E-13 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs6748898 chr2 203996870 A G 1.39E-04 Multiple complex diseases NBEAL1 intron 17554300 rs17408550 chr2 203998336 C G 9.70E-13 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs10180815 chr2 204002809 A C 1.00E-04 Multiple complex diseases NBEAL1 intron 17554300 rs6751448 chr2 204006637 T G 7.70E-13 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs7564679 chr2 204012790 A G 7.70E-13 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs6435173 chr2 204013112 A G 3.64E-04 Multiple complex diseases NBEAL1 intron 17554300 rs6725247 chr2 204021436 A G 3.11E-04 Multiple complex diseases NBEAL1 intron 17554300 rs2043446 chr2 204045539 T C 2.26E-04 Multiple complex diseases NBEAL1 intron 17554300 rs2043448 chr2 204046526 A G 8.20E-13 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs10182274 chr2 204051009 G A 5.20E-04 Alcohol dependence NBEAL1 intron 20201924 rs10182274 chr2 204051009 G A 9.90E-05 Alcohol dependence NBEAL1 intron 20201924 rs10182274 chr2 204051009 G A 9.90E-05 Alcoholism NBEAL1 intron pha002893 rs6733725 chr2 204051070 G A 5.70E-06 Obesity-related traits NBEAL1 intron 23251661 rs11675464 chr2 204053742 A G 8.20E-13 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs2117266 chr2 204060148 G T 1.60E-04 Alcohol dependence NBEAL1 intron 20201924 rs6714802 chr2 204062329 T C 8.20E-13 Butyrylcholinesterase levels NBEAL1 intron 21862451 rs2060388 chr2 204067268 A G 8.69E-04 Multiple complex diseases NBEAL1 intron 17554300 rs12693982 chr2 204085635 C T 2.30E-10 Butyrylcholinesterase levels / / 21862451 rs6704959 chr2 204088522 G A 8.20E-13 Butyrylcholinesterase levels / / 21862451 rs16839626 chr2 204089730 G A 2.00E-07 Obesity-related traits / / 23251661 rs16839626 chr2 204089730 G A 3.00E-06 Obesity-related traits / / 23251661 rs16839626 chr2 204089730 G A 4.00E-07 Obesity-related traits / / 23251661 rs7581515 chr2 204093040 A C 1.60E-12 Butyrylcholinesterase levels / / 21862451 rs2351774 chr2 204099222 A G 2.70E-13 Butyrylcholinesterase levels LOC100507265 intron 21862451 rs4675324 chr2 204107025 G A 9.60E-11 Butyrylcholinesterase levels CYP20A1 intron 21862451 rs182035689 chr2 204111603 C A 0.00007 Breast cancer(er negative) CYP20A1 missense 23555315 rs4675326 chr2 204114965 C T 1.75E-04 Multiple complex diseases CYP20A1 intron 17554300 rs11693128 chr2 204115901 A G 2.40E-13 Butyrylcholinesterase levels CYP20A1 intron 21862451 rs3731694 chr2 204116660 A T 2.40E-13 Butyrylcholinesterase levels CYP20A1 intron 21862451 rs10211196 chr2 204129896 G A 8.50E-11 Butyrylcholinesterase levels CYP20A1 intron 21862451 rs7606820 chr2 204135270 A G 8.50E-11 Butyrylcholinesterase levels CYP20A1 intron 21862451 rs2043444 chr2 204143126 T C 4.80E-11 Butyrylcholinesterase levels CYP20A1 intron 21862451 rs12693984 chr2 204152533 C T 8.00E-11 Butyrylcholinesterase levels CYP20A1 intron 21862451 rs11888559 chr2 204165171 T C 2.00E-06 Height CYP20A1 UTR-3 20966902 rs6435185 chr2 204213503 T C 1.10E-04 Multiple complex diseases ABI2 intron 17554300 rs12474416 chr2 204226003 G T 3.80E-08 Butyrylcholinesterase levels ABI2 intron 21862451 rs12466364 chr2 204226331 A G 3.80E-08 Butyrylcholinesterase levels ABI2 intron 21862451 rs11686036 chr2 204241639 A G 9.10E-18 Butyrylcholinesterase levels ABI2 intron 21862451 rs11675251 chr2 204249399 A G 4.00E-18 Butyrylcholinesterase levels ABI2 intron 21862451 rs3769676 chr2 204266343 T C 3.70E-15 Butyrylcholinesterase levels ABI2 intron 21862451 rs1376877 chr2 204272090 C T 4.00E-07 Subclinical atherosclerosis ABI2 intron 17903303 rs1376877 chr2 204272090 C T 1.50E-17 Butyrylcholinesterase levels ABI2 intron 21862451 rs3769678 chr2 204276327 T C 1.50E-17 Butyrylcholinesterase levels ABI2 intron 21862451 rs2255047 chr2 204287133 G A 4.90E-04 Type 2 diabetes ABI2 intron 17463246 rs2469954 chr2 204292517 T C 2.80E-15 Butyrylcholinesterase levels ABI2 UTR-3 21862451 rs2250522 chr2 204301296 G A 1.60E-15 Butyrylcholinesterase levels RAPH1 UTR-3 21862451 rs2247197 chr2 204306433 T C 1.94E-04 Multiple complex diseases RAPH1 UTR-3 17554300 rs2247097 chr2 204307003 G A 2.76E-04 Multiple complex diseases RAPH1 intron 17554300 rs2246849 chr2 204309325 G A 1.80E-14 Butyrylcholinesterase levels RAPH1 intron 21862451 rs11679740 chr2 204315394 G A 3.40E-17 Butyrylcholinesterase levels RAPH1 intron 21862451 rs2352079 chr2 204316532 C T 3.40E-17 Butyrylcholinesterase levels RAPH1 intron 21862451 rs11687186 chr2 204319839 C G 2.60E-17 Butyrylcholinesterase levels RAPH1 intron 21862451 rs2469953 chr2 204322298 T C 1.80E-14 Butyrylcholinesterase levels RAPH1 cds-synon 21862451 rs2246118 chr2 204327639 T C 2.00E-13 Butyrylcholinesterase levels RAPH1 intron 21862451 rs2469949 chr2 204336700 C T 3.29E-04 Multiple complex diseases RAPH1 intron 17554300 rs2251317 chr2 204354823 C T 2.44E-05 Multiple complex diseases RAPH1 intron 17554300 rs2469962 chr2 204355822 G A 1.80E-14 Butyrylcholinesterase levels RAPH1 intron 21862451 rs2305417 chr2 204360201 A G 1.50E-17 Butyrylcholinesterase levels RAPH1 intron 21862451 rs2247380 chr2 204364721 C T 1.10E-14 Butyrylcholinesterase levels RAPH1 intron 21862451 rs2012774 chr2 204370203 A G 1.10E-14 Butyrylcholinesterase levels RAPH1 intron 21862451 rs11683935 chr2 204377871 C G 1.50E-17 Butyrylcholinesterase levels RAPH1 intron 21862451 rs1174604 chr2 204421284 T C 1.50E-16 Butyrylcholinesterase levels / / 21862451 rs1174605 chr2 204421504 T C 1.30E-09 Butyrylcholinesterase levels / / 21862451 rs1174606 chr2 204424549 T C 6.00E-10 Butyrylcholinesterase levels / / 21862451 rs2443796 chr2 204425613 C T 6.00E-10 Butyrylcholinesterase levels / / 21862451 rs727361 chr2 204427247 T C 1.90E-10 Butyrylcholinesterase levels / / 21862451 rs4675344 chr2 204429558 C T 3.60E-10 Butyrylcholinesterase levels / / 21862451 rs11887555 chr2 204430093 T C 2.70E-10 Butyrylcholinesterase levels / / 21862451 rs6730171 chr2 204432604 T C 3.60E-10 Butyrylcholinesterase levels / / 21862451 rs2030552 chr2 204433184 C T 2.70E-10 Butyrylcholinesterase levels / / 21862451 rs1403239 chr2 204438198 A G 4.20E-10 Butyrylcholinesterase levels / / 21862451 rs7592180 chr2 204439623 C A 6.30E-10 Butyrylcholinesterase levels / / 21862451 rs7594831 chr2 204439701 C T 8.30E-10 Butyrylcholinesterase levels / / 21862451 rs7568353 chr2 204439759 A G 2.00E-09 Butyrylcholinesterase levels / / 21862451 rs7609267 chr2 204439982 T C 1.50E-09 Butyrylcholinesterase levels / / 21862451 rs7595502 chr2 204440081 G A 1.50E-09 Butyrylcholinesterase levels / / 21862451 rs16839922 chr2 204440345 T G 1.10E-09 Butyrylcholinesterase levels / / 21862451 rs13032082 chr2 204441505 A T 3.20E-09 Butyrylcholinesterase levels / / 21862451 rs13032680 chr2 204441557 G T 3.20E-09 Butyrylcholinesterase levels / / 21862451 rs4675348 chr2 204442447 A G 3.20E-09 Butyrylcholinesterase levels / / 21862451 rs12989998 chr2 204442556 G C 3.20E-09 Butyrylcholinesterase levels / / 21862451 rs7572405 chr2 204444331 G A 6.70E-09 Butyrylcholinesterase levels / / 21862451 rs17419055 chr2 204454414 G T 7.97E-05 Cognitive test performance / / 20125193 rs12618748 chr2 204455171 G A 2.54E-05 Multiple complex diseases / / 17554300 rs12618748 chr2 204455171 G A 1.02E-04 Myocardial Infarction / / pha002883 rs10191601 chr2 204455370 C T 1.02E-05 Multiple sclerosis / / 19525953 rs17478537 chr2 204459179 T C 7.55E-04 Alcohol dependence / / 21314694 rs4675350 chr2 204459206 C T 1.76E-04 Cholesterol / / 17255346 rs10207814 chr2 204459961 C T 1.30E-04 Celiac disease / / 22057235 rs10207814 chr2 204459961 C T 0.00013 Celiac disease / / 23143596 rs1879878 chr2 204465119 A G 1.82E-04 Cholesterol / / 17255346 rs7422945 chr2 204494698 A G 3.46E-05 Cholesterol / / 17255346 rs6435197 chr2 204497336 T C 4.86E-07 Cholesterol / / 17255346 rs3115961 chr2 204529949 G A 3.72E-05 Acne (severe) / / 24927181 rs4675357 chr2 204539973 G A 4.32E-05 Cognitive test performance / / 20125193 rs3181096 chr2 204570092 C T 7.12E-05 Asthma CD28 nearGene-5 20159242 rs3769683 chr2 204578797 A G 4.77E-05 Type 2 diabetes CD28 intron 17463246 rs55686954 chr2 204586515 G A 0.00000012 Rheumatoid arthritis CD28 intron 23143596 rs3181107 chr2 204593726 G A 4.57E-05 Type 2 diabetes CD28 intron 17463246 rs3181108 chr2 204593862 C T 8.76E-05 Type 2 diabetes CD28 intron 17463246 rs3116496 chr2 204594512 T C 2.07E-06 Celiac disease and Rheumatoid arthritis CD28 intron 21383967 rs4673260 chr2 204605487 C T 1.33E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs1980422 chr2 204610396 C T 1.40E-15 Celiac disease / / 22057235 rs1980422 chr2 204610396 C T 1.80E-08 Multiple sclerosis / / 22190364 rs1980422 chr2 204610396 C T 7.40E-05 Rheumatoid arthritis / / 22446963 rs1980422 chr2 204610396 C T 0.000000257 Rheumatoid arthritis (CCP positive) / / 23143596 rs1980422 chr2 204610396 C T 1.40E-15 Celiac disease / / 23143596 rs1980422 chr2 204610396 C T 2.77E-12 Rheumatoid arthritis / / 23143596 rs1980422 chr2 204610396 C T 2.00E-13 Rheumatoid arthritis / / 24390342 rs1980422 chr2 204610396 C T 3.00E-14 Rheumatoid arthritis / / 24390342 rs1980422 chr2 204610396 C T 1.75E-04 Rheumatoid arthritis / / 24449572 rs6435203 chr2 204611195 G A 7.20E-05 Immunoglobulin A / / 20694011 rs6435203 chr2 204611195 G A 1.52E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs7426056 chr2 204612058 A G 1.89E-20 Primary sclerosing cholangitis / / 23603763 rs4675366 chr2 204627793 T C 5.88E-05 Cognitive test performance / / 20125193 rs10932019 chr2 204628810 G A 6.64E-07 Celiac disease and Rheumatoid arthritis / / 21383967 rs4675367 chr2 204630692 T G 5.88E-05 Cognitive test performance / / 20125193 rs11689629 chr2 204633075 C T 5.33E-04 Type 2 diabetes / / 17463246 rs34322855 chr2 204633075 C CT 5.33E-04 Type 2 diabetes / / 17463246 rs7599230 chr2 204648661 T C 3.20E-05 Lung adenocarcinoma / / 22797724 rs3116507 chr2 204661524 G A 2.52E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs6749204 chr2 204662268 G A 1.28E-05 Cytomegalovirus antibody response / / 21993531 rs231814 chr2 204670195 G C 2.27E-04 Smoking quantity / / 24665060 rs231735 chr2 204693876 G T 6.00E-09 Rheumatoid arthritis / / 19503088 rs231790 chr2 204700574 G T 3.13E-05 Multiple complex diseases / / 17554300 rs231797 chr2 204706107 A G 4.44E-05 Multiple complex diseases / / 17554300 rs231802 chr2 204708279 T C 1.55E-05 Tuberculosis / / 24057671 rs231804 chr2 204708646 C T 8.15E-06 Rheumatoid arthritis / / 19503088 rs231804 chr2 204708646 C T 1.79E-10 Celiac disease and Rheumatoid arthritis / / 21383967 rs231804 chr2 204708646 C T 2.12E-11 Graves' disease / / 21841780 rs11571304 chr2 204708776 T A 4.35E-05 Multiple complex diseases / / 17554300 rs11571293 chr2 204717713 G T 1.56E-06 Multiple complex diseases / / 17554300 rs11571292 chr2 204720139 G A 4.51E-05 Multiple complex diseases / / 17554300 rs1024161 chr2 204721752 T C 4.00E-13 Alopecia areata / / 20596022 rs1024161 chr2 204721752 T C 2.00E-17 Graves' disease / / 21841780 rs926169 chr2 204722752 G T 8.48E-08 Graves' disease / / 21841780 rs11571316 chr2 204731089 G A 2.44E-15 Type 1 diabetes CTLA4 nearGene-5 21980299 rs16840252 chr2 204731519 C T 8.00E-04 Acute lymphoblastic leukemia (childhood) CTLA4 nearGene-5 20189245 rs16840252 chr2 204731519 C T 1.28E-05 Antineutrophil cytoplasmic antibody-associated vasculitis CTLA4 nearGene-5 22808956 rs231774 chr2 204732223 T A 0.000000913 Cholesterol,total CTLA4 nearGene-5 23063622 rs5742909 chr2 204732347 C T 8.00E-04 Acute lymphoblastic leukemia (childhood) CTLA4 nearGene-5 20189245 rs231775 chr2 204732714 A G 1 Drug response to Cyclosporine CTLA4 missense 18021981 rs231775 chr2 204732714 A G 9.40E-06 Hypothyroidism CTLA4 missense 22493691 rs231779 chr2 204734487 C T 7.00E-06 Hypothyroidism CTLA4 intron 22493691 rs3087243 chr2 204738919 G A 2.07E-07 Multiple complex diseases CTLA4 nearGene-3 17554300 rs3087243 chr2 204738919 G A 8.00E-11 Type 1 diabetes CTLA4 nearGene-3 18978792 rs3087243 chr2 204738919 G A 1.00E-15 Type 1 diabetes CTLA4 nearGene-3 19430480 rs3087243 chr2 204738919 G A 1.00E-08 Rheumatoid arthritis CTLA4 nearGene-3 20453842 rs3087243 chr2 204738919 G A 1.20E-08 Celiac disease and Rheumatoid arthritis CTLA4 nearGene-3 21383967 rs3087243 chr2 204738919 G A 2.00E-17 Type 1 diabetes autoantibodies CTLA4 nearGene-3 21829393 rs3087243 chr2 204738919 G A 8.00E-11 Multiple sclerosis CTLA4 nearGene-3 22190364 rs3087243 chr2 204738919 G A 2.20E-08 Rheumatoid arthritis CTLA4 nearGene-3 22446963 rs3087243 chr2 204738919 G A 6.80E-05 Hypothyroidism CTLA4 nearGene-3 22493691 rs3087243 chr2 204738919 G A 1.42E-11 Rheumatoid arthritis CTLA4 nearGene-3 23143596 rs3087243 chr2 204738919 G A 3.88E-11 Rheumatoid arthritis (CCP positive) CTLA4 nearGene-3 23143596 rs3087243 chr2 204738919 G A 1.00E-04 Rheumatoid arthritis CTLA4 nearGene-3 24390342 rs3087243 chr2 204738919 G A 3.00E-25 Rheumatoid arthritis CTLA4 nearGene-3 24390342 rs3087243 chr2 204738919 G A 4.00E-22 Rheumatoid arthritis CTLA4 nearGene-3 24390342 rs231726 chr2 204740866 C T 1.40E-06 Multiple complex diseases / / 17554300 rs231726 chr2 204740866 C T 1.16E-13 Graves' disease / / 21841780 rs1427676 chr2 204741166 C T 1.37E-06 Multiple complex diseases / / 17554300 rs11571302 chr2 204742934 G T 0.000000045 Rheumatoid arthritis / / 23143596 rs11571302 chr2 204742934 G T 4.49E-08 Rheumatoid arthritis (CCP positive) / / 23143596 rs11571297 chr2 204745003 T C 2.09E-23 Graves' disease and Hashimoto's thyroiditis / / 22922229 rs11571297 chr2 204745003 T C 2.81E-23 Graves' disease / / 22922229 rs231757 chr2 204753487 T G 5.57E-05 Personality dimensions / / 18957941 rs231757 chr2 204753487 T G 5.07E-04 Celiac disease / / 23936387 rs6748358 chr2 204756905 C A 4.05E-05 Multiple complex diseases / / 17554300 rs6748358 chr2 204756905 C A 3.04E-06 Rheumatoid arthritis / / 19503088 rs16840307 chr2 204756999 C T 6.20E-04 Multiple complex diseases / / 17554300 rs859839 chr2 204757804 C T 2.49E-05 Personality dimensions / / 18957941 rs859839 chr2 204757804 C T 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs13421616 chr2 204758695 C T 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs10197319 chr2 204763044 G A 2.87E-08 Graves' disease / / 21841780 rs10197319 chr2 204763044 G A 6.20E-05 Celiac disease / / 23936387 rs3096851 chr2 204763882 A C 3.69E-05 Graves' disease / / 21841780 rs7607760 chr2 204765194 G T 6.34E-05 Celiac disease / / 23936387 rs3116504 chr2 204769054 A G 3.57E-05 Graves' disease / / 21841780 rs34037980 chr2 204770054 A G 1.60E-05 Celiac disease / / 22057235 rs34037980 chr2 204770054 A G 0.000016 Celiac disease / / 23143596 rs12616245 chr2 204770803 A G 9.16E-05 Celiac disease / / 23936387 rs11890284 chr2 204777404 C T 5.66E-04 Celiac disease / / 23936387 rs6752680 chr2 204779005 T A 7.65E-05 Personality dimensions / / 18957941 rs6752680 chr2 204779005 T A 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs3096866 chr2 204794952 A G 4.20E-05 Monocyte counts / / pha003089 rs3923093 chr2 204798020 T C 5.22E-05 Personality dimensions / / 18957941 rs4675374 chr2 204802578 T C 3.87E-05 Personality dimensions ICOS intron 18957941 rs4675374 chr2 204802578 T C 6.00E-09 Celiac disease ICOS intron 20190752 rs4675374 chr2 204802578 T C 6.00E-09 Asthma ICOS intron 21150878 rs4675374 chr2 204802578 T C 5.79E-09 Celiac disease and Rheumatoid arthritis ICOS intron 21383967 rs4675374 chr2 204802578 T C 5.79E-09 Multiple sclerosis ICOS intron 22190364 rs10932034 chr2 204812993 A G 1.80E-05 Urinary metabolites ICOS intron 21572414 rs1896286 chr2 204832438 G T 7.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3116534 chr2 204833769 C T 7.99E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1427363 chr2 204837629 T C 7.99E-05 Triglycerides / / pha003081 rs1427363 chr2 204837629 T C 4.77E-05 Lipid levels / / pha003082 rs6754914 chr2 204859514 A G 2.05E-04 Type 2 diabetes / / 17463246 rs4675397 chr2 204875234 T C 8.09E-04 Type 2 diabetes / / 17463246 rs13383369 chr2 204876709 T C 7.85E-05 Glycosylated haemoglobin levels / / 17255346 rs4675399 chr2 204877120 A G 5.00E-04 Type 2 diabetes / / 17463246 rs11884257 chr2 204886474 C T 5.27E-04 Type 2 diabetes / / 17463246 rs16840552 chr2 204888602 C T 3.51E-04 Type 2 diabetes / / 17463246 rs4675401 chr2 204889068 G A 1.58E-04 Type 2 diabetes / / 17463246 rs16824662 chr2 204895415 A G 3.11E-04 Type 2 diabetes / / 17463246 rs10206295 chr2 204918905 C T 1.59E-04 Glycosylated haemoglobin levels / / 17255346 rs961738 chr2 204951268 G A 3.49E-05 Multiple complex diseases / / 17554300 rs7588516 chr2 204967832 C G 9.01E-04 Alzheimer's disease / / 22005930 rs7562030 chr2 204967907 A G 8.48E-04 Alzheimer's disease / / 22005930 rs7588715 chr2 204967966 C G 8.74E-04 Alzheimer's disease / / 22005930 rs12465161 chr2 204969670 A C 5.85E-04 Type 2 diabetes / / 17463246 rs17214199 chr2 204969905 A C 5.85E-04 Type 2 diabetes / / 17463246 rs13419001 chr2 204981908 G A 2.52E-04 Glycosylated haemoglobin levels / / 17255346 rs16840760 chr2 204983554 T C 1.00E-06 Obesity-related traits / / 23251661 rs11673985 chr2 204986334 C T 2.49E-05 Triglycerides / / pha003081 rs11673985 chr2 204986334 C T 6.05E-05 Lipid levels / / pha003082 rs13414989 chr2 204991338 G A 1.35E-04 Glycosylated haemoglobin levels / / 17255346 rs6747093 chr2 204999862 C A 3.80E-05 Temporomandibular joint disorders / / 23746317 rs6747746 chr2 205000176 G A 2.70E-05 Temporomandibular joint disorders / / 23746317 rs10932047 chr2 205004122 T G 6.79E-04 Type 2 diabetes / / 17463246 rs10189390 chr2 205008681 C T 2.35E-05 Smoking behavior / / 19188921 rs219224 chr2 205011169 G T 1.10E-05 Temporomandibular joint disorders / / 23746317 rs7580465 chr2 205022291 T C 6.28E-05 Psoriasis / / 18364390 rs2042580 chr2 205027279 G A 2.70E-05 Temporomandibular joint disorders / / 23746317 rs6730424 chr2 205031069 G T 2.53E-05 Cognitive performance / / 19734545 rs16840880 chr2 205053197 C T 1.20E-06 Thyroid function / / 20826269 rs13401647 chr2 205057668 T C 9.60E-07 Thyroid function / / 20826269 rs6714929 chr2 205062633 G A 6.87E-05 Socioeconomic Factors / / pha003066 rs6714893 chr2 205116824 G A 1.73E-04 IgE levels / / 17255346 rs7421114 chr2 205118574 G C 9.89E-05 Age-related macular degeneration / / pha000002 rs6738181 chr2 205128021 G A 5.00E-06 Alzheimer's disease (late onset) / / 22881374 rs9288351 chr2 205131349 T C 2.63E-04 Smoking initiation / / 24665060 rs16841113 chr2 205153827 C A 4.07E-04 Alzheimer's disease (late onset) / / 21379329 rs13397660 chr2 205166492 C T 3.87E-05 Erythrocyte counts / / pha003090 rs1981913 chr2 205169149 T C 9.14E-05 Orofacial clefts / / 22419666 rs7603542 chr2 205177698 C T 9.73E-05 Erythrocyte counts / / pha003090 rs16841178 chr2 205186475 C T 3.27E-04 Alzheimer's disease (late onset) / / 21379329 rs6760579 chr2 205209449 G A 4.48E-06 Post-operative nausea and vomiting / / 21694509 rs7599719 chr2 205212629 C T 5.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6750362 chr2 205219203 A G 6.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7608404 chr2 205232597 A G 6.41E-05 AIDS / / 19754311 rs16824671 chr2 205344693 A C 8.50E-04 Multiple complex diseases / / 17554300 rs2121681 chr2 205355892 T C 2.22E-04 Multiple complex diseases / / 17554300 rs4556959 chr2 205366339 A G 1.70E-05 Partial epilepsies / / 20522523 rs4673301 chr2 205368458 T C 3.25E-04 Lung function (forced vital capacity) / / 24023788 rs4673301 chr2 205368458 T C 4.00E-06 Lung function (forced expiratory volume in 1 second) / / 24023788 rs9288354 chr2 205378570 A G 3.35E-04 Type 2 diabetes / / 17463246 rs7581786 chr2 205385338 A G 7.78E-04 Type 2 diabetes / / 17463246 rs12622755 chr2 205438485 A G 8.56E-04 Multiple complex diseases PARD3B intron 17554300 rs7565043 chr2 205448791 T A 3.93E-04 Multiple complex diseases PARD3B intron 17554300 rs11903539 chr2 205461753 G A 1.52E-04 Multiple complex diseases PARD3B intron 17554300 rs1978368 chr2 205501337 T G 5.88E-05 Multiple complex diseases PARD3B intron 17554300 rs13432594 chr2 205523721 T C 5.84E-04 Multiple complex diseases PARD3B intron 17554300 rs41482445 chr2 205578015 C T 2.19E-05 Multiple sclerosis PARD3B intron 17660530 rs1477179 chr2 205582870 A T 5.80E-04 Type 2 diabetes PARD3B intron 17463246 rs17113 chr2 205627933 C G 1.56E-05 Multiple sclerosis PARD3B intron 17660530 rs17638223 chr2 205643248 T C 4.77E-05 Multiple complex diseases PARD3B intron 17554300 rs17595547 chr2 205646304 T A 1.13E-04 Multiple complex diseases PARD3B intron 17554300 rs2058988 chr2 205650440 A T 1.77E-04 Multiple complex diseases PARD3B intron 17554300 rs6435252 chr2 205658016 G A 0.000510575 Hypertension (early onset hypertension) PARD3B intron 22479346 rs7580648 chr2 205668052 G A 4.39E-05 Aging (time to event) PARD3B intron 21782286 rs7580648 chr2 205668052 G A 0.000755917 Hypertension (early onset hypertension) PARD3B intron 22479346 rs7591697 chr2 205694022 A C 8.06E-05 Multiple complex diseases PARD3B intron 17554300 rs16836655 chr2 205697151 A C 7.25E-04 Multiple complex diseases PARD3B intron 17554300 rs6735981 chr2 205700834 T C 7.21E-04 Multiple complex diseases PARD3B intron 17554300 rs6747533 chr2 205744282 T G 7.54E-04 Multiple complex diseases PARD3B intron 17554300 rs7589114 chr2 205775783 C T 5.13E-05 Alcohol consumption PARD3B intron 23743675 rs7590088 chr2 205776549 G A 6.62E-05 Smoking initiation PARD3B intron 24665060 rs7572649 chr2 205783828 A C 5.74E-04 Smoking initiation PARD3B intron 24665060 rs1510775 chr2 205790839 T C 8.56E-05 Alzheimer's disease (age of onset) PARD3B intron 22005931 rs1510775 chr2 205790839 T C 1.00E-04 Smoking initiation PARD3B intron 24665060 rs2216852 chr2 205794074 C T 1.27E-04 Smoking initiation PARD3B intron 24665060 rs17535696 chr2 205799134 A T 9.08E-04 Response to cytidine analogues (gemcitabine) PARD3B intron 24483146 rs2194513 chr2 205803372 A G 4.50E-05 Glaucoma (primary open-angle) PARD3B intron 20835238 rs13390761 chr2 205809938 T G 2.73E-05 Tuberculosis PARD3B intron 20694014 rs13399116 chr2 205822633 T G 2.90E-06 Iron levels PARD3B intron 21208937 rs6731648 chr2 205853136 T C 1.74E-05 C-Reactive Protein PARD3B intron pha003070 rs2335705 chr2 205864532 C A 4.59E-06 Tuberculosis PARD3B intron 20694014 rs2335704 chr2 205864832 C A 2.00E-06 Tuberculosis PARD3B intron 20694014 rs11896055 chr2 205883547 A G 1.00E-04 Prostate cancer PARD3B intron 21743057 rs2082622 chr2 205904133 C G 4.89E-04 Nicotine smoking PARD3B intron 19268276 rs2289025 chr2 205969220 G A 3.17E-06 Smoking cessation PARD3B missense 18519826 rs2289025 chr2 205969220 G A 5.36E-04 Premature ovarian failure PARD3B missense 19508998 rs4675499 chr2 205973568 A G 3.52E-04 Type 2 diabetes PARD3B intron 17463246 rs6715145 chr2 205974111 T C 8.80E-05 Vaspin levels PARD3B intron 22907691 rs6715145 chr2 205974111 T C 0.000088 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit PARD3B intron 22907730 rs6715145 chr2 205974111 T C 0.0002364 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit PARD3B intron 22907730 rs1434160 chr2 205987805 G C 1.88E-04 Smoking cessation PARD3B intron 18519826 rs10497881 chr2 205992964 C T 8.61E-04 Premature ovarian failure PARD3B intron 19508998 rs16837019 chr2 206002808 A T 6.59E-04 Type 2 diabetes PARD3B intron 17463246 rs849107 chr2 206009266 T C 6.38E-04 Type 2 diabetes PARD3B intron 17463246 rs6738364 chr2 206024264 G A 1.20E-04 Smoking cessation PARD3B intron 18519826 rs849118 chr2 206025174 G A 5.32E-04 Alcohol dependence PARD3B intron 21314694 rs13422432 chr2 206031987 A T 4.28E-04 Multiple complex diseases PARD3B intron 17554300 rs1368943 chr2 206033222 G T 5.01E-04 Multiple complex diseases PARD3B intron 17554300 rs1368944 chr2 206033290 G T 5.37E-04 Multiple complex diseases PARD3B intron 17554300 rs13415503 chr2 206037412 C T 7.04E-04 Multiple complex diseases PARD3B intron 17554300 rs17248501 chr2 206039045 A C 1.40E-05 Type 2 diabetes PARD3B intron 17463249 rs17248501 chr2 206039045 A C 1.37E-05 Multiple complex diseases PARD3B intron 17554300 rs7587983 chr2 206039704 T C 9.98E-06 Multiple complex diseases PARD3B intron 17554300 rs10170188 chr2 206048814 G A 3.30E-05 Melanoma PARD3B intron 21983785 rs10153620 chr2 206060637 G C 6.00E-06 Attention deficit hyperactivity disorder (combined symptoms) PARD3B intron 23527680 rs11681930 chr2 206063298 G A 5.00E-06 Attention deficit hyperactivity disorder (combined symptoms) PARD3B intron 23527680 rs4675502 chr2 206086171 G A 4.00E-07 Autism PARD3B intron 22843504 rs4675506 chr2 206086520 C A 5.97E-04 Multiple complex diseases PARD3B intron 17554300 rs1921797 chr2 206087119 T C 5.47E-04 Multiple complex diseases PARD3B intron 17554300 rs6730457 chr2 206087477 C T 1.76E-04 Multiple complex diseases PARD3B intron 17554300 rs6435278 chr2 206087758 A G 1.37E-04 Multiple complex diseases PARD3B intron 17554300 rs1921796 chr2 206087912 G C 1.25E-04 Multiple complex diseases PARD3B intron 17554300 rs1921795 chr2 206088079 A G 4.47E-04 Multiple complex diseases PARD3B intron 17554300 rs10182802 chr2 206088211 G A 6.30E-05 Glioma (high-grade) PARD3B intron 19578366 rs7593566 chr2 206095820 G A 1.83E-04 Smoking cessation PARD3B intron 18519826 rs11888554 chr2 206096536 C A 3.07E-04 Nicotine smoking PARD3B intron 19268276 rs2336413 chr2 206131317 A G 6.65E-05 Vaspin levels PARD3B intron 22907691 rs2336413 chr2 206131317 A G 0.0000665 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit PARD3B intron 22907730 rs1540364 chr2 206132248 T C 6.82E-04 Suicide attempts in bipolar disorder PARD3B intron 21423239 rs10197562 chr2 206138074 G A 3.48E-04 Suicide attempts in bipolar disorder PARD3B intron 21423239 rs10490296 chr2 206141889 G C 2.71E-04 Prostate cancer mortality PARD3B intron 20978177 rs7606468 chr2 206144833 G A 3.78E-05 Prostate cancer mortality PARD3B intron 20978177 rs1207421 chr2 206150594 A G 6.00E-06 Knee osteoarthritis PARD3B intron 18471798 rs1211319 chr2 206156161 C T 4.95E-04 Suicide attempts in bipolar disorder PARD3B intron 21423239 rs1207433 chr2 206161433 C A 5.77E-04 Suicide attempts in bipolar disorder PARD3B intron 21423239 rs1207430 chr2 206163817 G C 5.47E-04 Suicide attempts in bipolar disorder PARD3B intron 21423239 rs2878692 chr2 206164173 G A 4.59E-04 Suicide attempts in bipolar disorder PARD3B intron 21423239 rs1207411 chr2 206173703 A T 8.75E-04 Suicide attempts in bipolar disorder PARD3B intron 21423239 rs2704643 chr2 206176140 G A 7.87E-04 Suicide attempts in bipolar disorder PARD3B intron 21423239 rs7567356 chr2 206184135 C G 5.02E-04 Depression (quantitative trait) PARD3B intron 20800221 rs12476682 chr2 206203291 A C 7.26E-05 Cognitive impairment induced by topiramate PARD3B intron 22091778 rs10490290 chr2 206227173 A G 7.46E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) PARD3B intron 17982456 rs10490290 chr2 206227173 A G 1.00E-04 Cognitive impairment induced by topiramate PARD3B intron 22091778 rs964356 chr2 206250241 G A 7.78E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) PARD3B intron 17982456 rs6711300 chr2 206260544 A G 8.47E-05 Depression (quantitative trait) PARD3B intron 20800221 rs849230 chr2 206261029 G A 6.86E-06 Type 2 diabetes PARD3B intron 21647700 rs849248 chr2 206264876 T C 5.00E-04 Gamma gluatamyl transferase levels (interaction with age) PARD3B intron 22010049 rs10185378 chr2 206305156 C T 1.80E-05 Platelet counts PARD3B missense pha003100 rs11884476 chr2 206318593 C G 3.00E-09 AIDS progression PARD3B intron 21502085 rs6705488 chr2 206342846 T C 4.32E-05 Platelet counts PARD3B intron pha003100 rs10206532 chr2 206416848 G A 4.90E-04 Smoking cessation PARD3B intron 24665060 rs16837439 chr2 206432930 T C 2.04E-04 Type 2 diabetes PARD3B intron 17463246 rs17626122 chr2 206474012 T C 0.0000595 5-fluorouracil and oxaliplatin combined induced haematologic in response to colorectal cancer treatment PARD3B intron 22310351 rs17626122 chr2 206474012 T C 0.0000595 Oxaliplatin induced haematologic in response to colorectal cancer treatment PARD3B intron 22310351 rs17626201 chr2 206476386 C T 4.71E-05 Multiple complex diseases PARD3B intron 17554300 rs17626309 chr2 206478258 G A 7.03E-04 Multiple complex diseases PARD3B intron 17554300 rs6739327 chr2 206495714 G A 4.07E-04 Multiple complex diseases / / 17554300 rs6757529 chr2 206510949 G A 8.70E-05 Serum metabolites / / 19043545 rs849515 chr2 206512573 C G 3.88E-04 Testicular dysgenesis syndrome / / 22140272 rs3856510 chr2 206512921 C G 8.48E-05 Serum metabolites / / 19043545 rs10490287 chr2 206522975 G C 5.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs2160327 chr2 206536329 A G 1.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6756429 chr2 206541927 T C 8.76E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs10207599 chr2 206543736 T A 3.25E-04 Type 2 diabetes / / 17463246 rs10171821 chr2 206544094 A G 9.43E-04 Type 2 diabetes / / 17463246 rs2192884 chr2 206545465 G A 4.13E-04 Smoking initiation NRP2 nearGene-5 24665060 rs849557 chr2 206563023 G A 7.63E-04 Insulin resistance NRP2 intron 21901158 rs3771038 chr2 206586412 G A 8.05E-04 Type 2 diabetes NRP2 intron 17463246 rs849537 chr2 206588114 T G 4.00E-04 Multiple complex diseases NRP2 intron 17554300 rs849527 chr2 206592525 A G 1.70E-05 Urinary metabolites NRP2 intron 21572414 rs849526 chr2 206592695 T C 6.20E-06 Urinary metabolites NRP2 cds-synon 21572414 rs849525 chr2 206593241 T A,C,G 2.60E-05 Urinary metabolites NRP2 intron 21572414 rs868196 chr2 206594141 G T 9.10E-06 Urinary metabolites NRP2 intron 21572414 rs849581 chr2 206602765 C T 0.00005212 Sarcoidosis NRP2 intron 22952805 rs13026243 chr2 206614091 T G 5.70E-04 Alzheimer's disease NRP2 intron 17998437 rs13026243 chr2 206614091 T G 1.79E-04 Osteoarthritis (knee and hip) NRP2 intron 21177295 rs13026243 chr2 206614091 T G 3.18E-04 Osteoarthritis (knee and hip) NRP2 intron 21177295 rs13026243 chr2 206614091 T G 3.37E-05 Osteoarthritis (knee and hip) NRP2 intron 21177295 rs849560 chr2 206614160 A G 2.48E-04 Smoking cessation NRP2 intron 24665060 rs870068 chr2 206625266 C G 1.67E-04 Multiple complex diseases NRP2 intron 17554300 rs3755233 chr2 206639831 G A 2.13E-05 Alcohol and nictotine co-dependence NRP2 intron 20158304 rs4675542 chr2 206645247 G C 5.03E-05 Serum metabolites NRP2 intron 19043545 rs10932125 chr2 206652300 C G 1 Drug response to Daunorubicin NRP2 intron 18451141 rs3770990 chr2 206656185 C G 6.79E-04 Type 2 diabetes NRP2 intron 17463246 rs2041915 chr2 206669214 A G 2.79E-04 Lung function (forced vital capacity) / / 24023788 rs10182735 chr2 206690019 C T 5.45E-05 Lung adenocarcinoma / / 19836008 rs10185592 chr2 206694181 A C 3.15E-07 Autism / / 22843504 rs960705 chr2 206696300 A G 3.59E-05 Lung adenocarcinoma / / 19836008 rs955395 chr2 206718710 G A 1.40E-04 Primary sclerosing cholangitis / / 19944697 rs6745633 chr2 206719553 T C 5.70E-06 Intraocular pressure / / 22570627 rs2193227 chr2 206729306 A C 4.31E-04 Lung function (forced vital capacity) / / 24023788 rs6435307 chr2 206735656 T C 5.79E-04 Multiple complex diseases / / 17554300 rs7592297 chr2 206773502 C A 6.36E-05 Lung adenocarcinoma / / 19836008 rs7592297 chr2 206773502 C A 3.58E-04 Coronary heart disease / / 21971053 rs1420786 chr2 206776113 G A 8.69E-05 Multiple complex diseases / / 17554300 rs1861719 chr2 206779987 C T 6.56E-05 Orofacial clefts / / 22419666 rs10490682 chr2 206792412 G A 1.70E-05 Urinary metabolites / / 21572414 rs6760400 chr2 206795210 A G 7.37E-05 Lung adenocarcinoma / / 19836008 rs13384308 chr2 206795827 A G 1.30E-05 Urinary metabolites / / 21572414 rs17308259 chr2 206828161 C T 1.64E-04 Type 2 diabetes / / 17463246 rs17308259 chr2 206828161 C T 9.85E-05 Multiple complex diseases / / 17554300 rs7603514 chr2 206836612 G A 8.00E-06 Obesity (extreme) / / 19553259 rs12618490 chr2 206847296 T C 6.20E-04 Lymphocyte counts / / 22286170 rs16837908 chr2 206850155 A G 5.75E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs10192718 chr2 206862015 G A 1.07E-04 Alzheimer's disease (late onset) INO80D UTR-3 21379329 rs818026 chr2 206863874 C T 3.38E-04 Multiple complex diseases INO80D UTR-3 17554300 rs818017 chr2 206902233 A G 5.34E-04 Multiple complex diseases INO80D intron 17554300 rs17286674 chr2 206927850 G A 1.18E-04 Alzheimer's disease (late onset) INO80D intron 21379329 rs6718656 chr2 206965837 T G 6.30E-04 Iris characteristics / / 21835309 rs4147713 chr2 207015772 A C 9.24E-05 Type 1 diabetes NDUFS1 intron 18978792 rs3755227 chr2 207041933 T C 9.43E-05 Adipocyte fatty acid-binding protein concentration,in serum GPR1 cds-synon 21863005 rs16838023 chr2 207053416 G T 3.66E-05 Response to taxane treatment (placlitaxel) GPR1 intron 23006423 rs13410751 chr2 207086752 C T 4.51E-04 Menopause (age at onset) / / 22267201 rs2058710 chr2 207121782 A G 9.00E-06 Bipolar disorder and schizophrenia / / 22688191 rs146428765 chr2 207172889 C T 0.000087 Breast cancer(er negative) ZDBF2 missense 23555315 rs144699200 chr2 207173160 C T 0.00024 Breast cancer (ER positive) ZDBF2 missense 23555315 rs1031293 chr2 207229821 T C 6.65E-06 Rheumatoid arthritis / / 19503088 rs6751830 chr2 207260970 T G 1.58E-05 Serum metabolites / / 19043545 rs4675609 chr2 207267616 C T 4.97E-06 Hodgkin's lymphoma / / 24149102 rs41344245 chr2 207347917 A G 8.07E-04 Multiple complex diseases ADAM23 intron 17554300 rs2113379 chr2 207351674 C T 1.40E-05 Kidney function and endocine traits ADAM23 intron 17903292 rs2269183 chr2 207355354 G T 4.65E-04 Prostate cancer mortality ADAM23 intron 20978177 rs16838306 chr2 207393829 T C 2.82E-04 Blood pressure (response to calcium channel blocker) ADAM23 intron 24192120 rs16838318 chr2 207399907 T C 2.64E-05 Blood pressure (response to calcium channel blocker) ADAM23 intron 24192120 rs3770977 chr2 207418899 C T 1.28E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) ADAM23 intron 23648065 rs3770978 chr2 207441588 C G 8.28E-04 Prostate cancer mortality ADAM23 intron 20978177 rs3821170 chr2 207453310 C T 7.01E-06 Meningococcal disease ADAM23 intron 20694013 rs13420297 chr2 207457265 T C 2.88E-05 Cholesterol ADAM23 intron pha003073 rs13420297 chr2 207457265 T C 2.91E-05 Cholesterol ADAM23 intron pha003078 rs6435342 chr2 207465830 A G 2.21E-04 Type 2 diabetes ADAM23 intron 17463246 rs10490745 chr2 207466560 C T 9.51E-05 Corneal structure ADAM23 intron 22003120 rs3755226 chr2 207478649 T C 3.32E-04 Multiple complex diseases ADAM23 intron 17554300 rs3755226 chr2 207478649 T C 5.67E-04 Smoking quantity ADAM23 intron 24665060 rs13396148 chr2 207484372 G A 3.08E-06 Corneal structure / / 22003120 rs13396148 chr2 207484372 G A 1.77E-05 Cholesterol / / pha003073 rs13396148 chr2 207484372 G A 2.00E-05 Cholesterol / / pha003078 rs10186957 chr2 207486889 C T 5.87E-04 Prostate cancer mortality / / 20978177 rs10490747 chr2 207572396 C A 8.67E-04 Parkinson's disease DYTN intron 17052657 rs16838677 chr2 207581835 T C 8.35E-04 Multiple complex diseases DYTN intron 17554300 rs3828294 chr2 207629904 G A 4.64E-07 Facial morphology MDH1B intron 22341974 rs147727753 chr2 207631446 G C 0.00047 Prostate cancer FASTKD2 missense 23555315 rs3815686 chr2 207633002 A G 8.30E-05 Information processing speed FASTKD2 intron 21130836 rs2277912 chr2 207634236 T G 5.00E-06 Height FASTKD2 intron 20966902 rs12475891 chr2 207637397 C T 0.000402 Common carotid artery thickness (average of near and far wall measures) FASTKD2 intron 23487405 rs879472 chr2 207651782 G A 0.000275 Common carotid artery thickness (average of near and far wall measures) FASTKD2 intron 23487405 rs3791984 chr2 207654106 A G 0.000663 Common carotid artery thickness (average of near and far wall measures) FASTKD2 intron 23487405 rs1048783 chr2 207657153 T C 8.55E-05 Information processing speed FASTKD2 UTR-3 21130836 rs6435351 chr2 207659014 T C 9.40E-05 Personality dimensions FASTKD2 UTR-3 18957941 rs17280449 chr2 207686461 G T 9.19E-04 Type 2 diabetes / / 17463246 rs35342955 chr2 207696262 G A 8.39E-04 Type 2 diabetes / / 17463246 rs6755560 chr2 207717783 T C 2.00E-06 QT interval (interaction) / / 23459443 rs2042135 chr2 207726297 G A 8.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4673364 chr2 207733111 C T 3.72E-04 Hearing function / / 17255346 rs6705071 chr2 207733838 G A 2.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12694063 chr2 207737751 T C 0.000135 Salmonella-induced pyroptosis / / 22837397 rs1453175 chr2 207747657 C T 5.43E-05 Hematocrit / / pha003097 rs6720430 chr2 207798923 T G 2.92E-05 Orofacial clefts / / 22419666 rs10932173 chr2 207802126 T C 0.000643 Salmonella-induced pyroptosis / / 22837397 rs17639570 chr2 207828958 C G 3.49E-05 Schizophrenia(age at onset) CPO intron 21688384 rs7582092 chr2 207833848 A G 5.20E-05 Cholesterol CPO intron pha003073 rs7582092 chr2 207833848 A G 1.96E-05 Cholesterol CPO intron pha003078 rs4675644 chr2 207840332 G C 9.00E-06 Pulmonary function decline / / 22424883 rs13391185 chr2 207841680 C A 7.02E-04 Alzheimer's disease / / 17998437 rs11695049 chr2 207851374 A G 4.14E-04 Parkinson's disease / / 17052657 rs1453160 chr2 207877465 G A 4.00E-06 Subcutaneous adipose tissue / / 22589738 rs6732038 chr2 207890135 T C 8.80E-04 Coronary heart disease / / 21971053 rs11902322 chr2 207915477 A G 4.04E-07 Rheumatoid arthritis / / 19503088 rs6734537 chr2 207925963 T C 2.57E-06 Rheumatoid arthritis / / 19503088 rs10490478 chr2 207928063 T C 3.13E-05 Type 2 diabetes / / 17846125 rs1263600 chr2 207930673 G T 5.99E-04 Parkinson's disease / / 17052657 rs2287505 chr2 207947086 G T 3.28E-05 Blood Pressure KLF7 intron pha003043 rs13012163 chr2 207960996 C T 9.80E-04 Response to cytidine analogues (gemcitabine) KLF7 intron 24483146 rs6759901 chr2 207962456 C T 9.80E-04 Response to cytidine analogues (gemcitabine) KLF7 intron 24483146 rs1263627 chr2 207977253 A T 1.66E-04 Type 2 diabetes KLF7 intron 22238593 rs10170608 chr2 207983805 A G 6.90E-04 Breast cancer (survival) KLF7 intron 22232737 rs6727168 chr2 207989470 T C 4.73E-04 Coronary heart disease KLF7 intron 21606135 rs6743779 chr2 207990038 A C 2.40E-05 Lipid traits KLF7 intron 17903299 rs10168999 chr2 208005994 G C 2.80E-05 Urinary metabolites KLF7 intron 21572414 rs10181757 chr2 208006413 T C 9.40E-06 Urinary metabolites KLF7 intron 21572414 rs10195536 chr2 208006820 A T 1.00E-06 Urinary metabolites KLF7 intron 21572414 rs10932180 chr2 208026913 T C 5.55E-05 Major depressive disorder KLF7 intron 21621269 rs2111593 chr2 208046998 C T 5.18E-05 Major depressive disorder / / 21621269 rs7582312 chr2 208105518 C T 3.45E-04 Coronary heart disease / / 21606135 rs1012264 chr2 208115003 G A 1.99E-04 Sarcoidosis / / 19165924 rs4673368 chr2 208126719 T C 1.40E-06 Urinary metabolites / / 21572414 rs7577873 chr2 208133793 G A 2.60E-05 Tooth agenesis (maxillary third molar) / / 24172245 rs7577873 chr2 208133793 G A 8.80E-05 Tooth agenesis (third molar) / / 24172245 rs10173558 chr2 208133995 T C 4.60E-06 Urinary metabolites / / 21572414 rs4303702 chr2 208141493 C G 4.70E-08 Urinary metabolites / / 21572414 rs10932186 chr2 208142194 C T 9.30E-07 Urinary metabolites / / 21572414 rs4675658 chr2 208145220 C T 9.20E-05 Tooth agenesis (maxillary third molar) / / 24172245 rs16839535 chr2 208149684 G A 4.70E-08 Urinary metabolites / / 21572414 rs4673369 chr2 208155834 G T 1.10E-09 Urinary metabolites / / 21572414 rs16839580 chr2 208169592 G T 1.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9288382 chr2 208178532 C T 7.70E-04 Depression (quantitative trait) / / 20800221 rs11898976 chr2 208196098 G T 1.64E-05 Serum metabolites / / 19043545 rs2113383 chr2 208221168 G A 5.47E-04 Multiple complex diseases / / 17554300 rs2161767 chr2 208222261 A G 2.46E-04 Type 2 diabetes / / 17463246 rs2113385 chr2 208223028 A T 4.30E-04 Multiple complex diseases / / 17554300 rs11695858 chr2 208229699 C T 6.30E-07 Urinary metabolites / / 21572414 rs11684690 chr2 208230091 A C 5.50E-07 Urinary metabolites / / 21572414 rs17202778 chr2 208234786 T C 0.00000862 Cytarabine sensitivity / / 23538338 rs10932191 chr2 208236250 C T 5.00E-07 Urinary metabolites / / 21572414 rs7561038 chr2 208236850 A G 3.36E-05 Serum metabolites / / 19043545 rs7561038 chr2 208236850 A G 9.32E-05 Bipolar disorder and schizophrenia / / 20889312 rs13426173 chr2 208251443 A T 4.20E-06 Urinary metabolites / / 21572414 rs11692326 chr2 208263279 C T 8.58E-04 Coronary heart disease / / 21971053 rs11682446 chr2 208263699 A C 2.70E-05 Urinary metabolites / / 21572414 rs17203403 chr2 208263990 A G 1.10E-05 Urinary metabolites / / 21572414 rs17203578 chr2 208270827 T C 7.13E-05 Hemoglobin / / pha003098 rs4510210 chr2 208298672 T C 6.99E-04 Coronary heart disease / / 21971053 rs10172070 chr2 208307761 C T 8.35E-04 Coronary heart disease / / 21971053 rs722760 chr2 208345241 T C 9.11E-04 Tuberculosis / / 22239941 rs722761 chr2 208345380 C T 9.11E-04 Tuberculosis / / 22239941 rs722761 chr2 208345380 C T 7.48E-05 Hemoglobin / / pha003098 rs10490595 chr2 208346410 C T 9.11E-04 Tuberculosis / / 22239941 rs2254137 chr2 208444028 C A 1.12E-05 Opioid sensitivity CREB1 intron 23183491 rs1806584 chr2 208466270 A G 2.00E-04 Type 2 diabetes and 6 quantitative traits CREB1 UTR-3 17848626 rs7569963 chr2 208473184 G A 1 Drug response to Citalopram / / 17548750 rs2709416 chr2 208477956 C T 9.16E-04 Insulin resistance METTL21A cds-synon 21901158 rs4234080 chr2 208489101 C A 2.00E-07 Amyotrophic lateral sclerosis (sporadic) METTL21A UTR-5 24529757 rs2952768 chr2 208494234 T C 8.00E-07 Opioid sensitivity / / 23183491 rs2709386 chr2 208497034 G A 1.14E-06 Opioid sensitivity / / 23183491 rs12998817 chr2 208500945 C T 9.98E-04 Multiple complex diseases / / 17554300 rs7591784 chr2 208501730 A G 1.06E-06 Opioid sensitivity / / 23183491 rs7595131 chr2 208506396 T C 7.30E-04 Multiple complex diseases / / 17554300 rs4675690 chr2 208507807 C T 1 Drug response to Citalopram / / 17548750 rs2551968 chr2 208536536 C A 0.0000498 Carotid intima media thickness / / 23152477 rs2432726 chr2 208544582 A G 4.74E-04 Gallstones / / 17632509 rs2663887 chr2 208566869 G A 9.07E-07 Calcium levels / / pha003085 rs10176319 chr2 208569590 C T 2.50E-06 Calcium levels / / pha003085 rs7582078 chr2 208646851 C A 4.91E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2127685 chr2 208712855 A G 9.04E-04 Type 2 diabetes PLEKHM3 intron 17463246 rs2127685 chr2 208712855 A G 3.68E-04 Lymphocyte counts PLEKHM3 intron 22286170 rs7584910 chr2 208713027 G A 6.38E-04 Type 2 diabetes PLEKHM3 intron 17463246 rs6435396 chr2 208715314 G A 3.65E-04 Myocardial Infarction PLEKHM3 intron pha002873 rs2621469 chr2 208765698 T C 1.42E-04 Myocardial Infarction PLEKHM3 intron pha002873 rs200816436 chr2 208773279 G C 0.00031 Breast cancer PLEKHM3 missense 23555315 rs2718663 chr2 208809569 C G 1.10E-05 Urinary metabolites PLEKHM3 intron 21572414 rs6705199 chr2 208820252 G A 2.79E-04 Myocardial Infarction PLEKHM3 intron pha002873 rs71418661 chr2 208842154 G A 0.00027 Breast cancer PLEKHM3 missense 23555315 rs10497890 chr2 208853299 T C 2.10E-05 Urinary metabolites PLEKHM3 intron 21572414 rs12464255 chr2 208926542 G A 9.64E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10497895 chr2 208927293 C T 9.80E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10932231 chr2 208929312 G C 9.67E-04 Prostate cancer mortality / / 20978177 rs896637 chr2 208957750 A G 8.11E-05 Body Mass Index / / pha003014 rs6713275 chr2 208961424 C A 7.32E-04 Multiple complex diseases / / 17554300 rs2242073 chr2 208994045 T G 8.00E-06 Attention deficit hyperactivity disorder CRYGC intron 18839057 rs796283 chr2 209011127 T C 7.84E-04 Multiple complex diseases LOC100507443 intron 17554300 rs2362790 chr2 209012367 A G 6.58E-05 Body Mass Index LOC100507443 intron pha003020 rs12468216 chr2 209023201 A G 6.91E-04 Multiple complex diseases / / 17554300 rs796280 chr2 209028191 C T 5.50E-04 Major depressive disorder CRYGA intron 21042317 rs2123291 chr2 209029192 A C 6.20E-04 Major depressive disorder CRYGA nearGene-5 21042317 rs6722000 chr2 209075957 A G 2.50E-05 Urinary metabolites / / 21572414 rs7593466 chr2 209099479 G T 5.89E-05 Cytomegalovirus antibody response / / 21993531 rs6746926 chr2 209135339 G A 4.57E-05 Brain lesion load PIKFYVE intron 19010793 rs11678092 chr2 209149617 T G 0.0000374 Polycystic ovary syndrome PIKFYVE intron 22951595 rs11678092 chr2 209149617 T G 3.74E-05 Intracranial aneurysm PIKFYVE intron 22961961 rs2289171 chr2 209204714 G A 1.17E-05 Brain lesion load PIKFYVE intron 19010793 rs4673402 chr2 209235373 G A 6.92E-05 Brain lesion load / / 19010793 rs4675764 chr2 209239742 G A 3.98E-05 Brain lesion load / / 19010793 rs1347664 chr2 209295729 C T 8.71E-04 Multiple complex diseases PTH2R intron 17554300 rs2924790 chr2 209330031 T A 4.50E-06 Urinary metabolites PTH2R intron 21572414 rs2576810 chr2 209332455 T C 7.90E-06 Urinary metabolites PTH2R intron 21572414 rs879707 chr2 209334978 A G 8.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTH2R intron 20877124 rs199930708 chr2 209339913 A ATG 3.55E-04 Stroke PTH2R intron pha002886 rs897082 chr2 209339913 A G 3.55E-04 Stroke PTH2R intron pha002886 rs897083 chr2 209342094 A G 9.60E-06 Urinary metabolites PTH2R intron 21572414 rs897083 chr2 209342094 A G 4.09E-04 Stroke PTH2R intron pha002886 rs3820902 chr2 209350128 G A 7.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTH2R intron 20877124 rs1057392 chr2 209359062 T C 1.50E-05 Urinary metabolites PTH2R UTR-3 21572414 rs10932263 chr2 209412884 G A 7.91E-05 Height / / 17255346 rs10932263 chr2 209412884 G A 1.86E-05 Brain lesion load / / 19010793 rs1429882 chr2 209455032 G A 2.74E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6722486 chr2 209455766 T C 3.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7580611 chr2 209467044 C T 3.66E-04 Stroke / / pha002886 rs13394305 chr2 209496949 T C 1.20E-05 Job-related exhaustion / / 23620144 rs1429879 chr2 209500802 A G 4.26E-05 Job-related exhaustion / / 23620144 rs2099159 chr2 209511062 C T 1.91E-04 Multiple complex diseases / / 17554300 rs2048920 chr2 209517915 T G 1.90E-05 Job-related exhaustion / / 23620144 rs17664733 chr2 209521984 A G 6.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs16841676 chr2 209575924 C T 1.97E-05 Multiple complex diseases / / 17554300 rs13383928 chr2 209578600 T G 2.00E-06 Lung cancer-asbestos exposure interaction / / 22637743 rs13028604 chr2 209599808 T C 2.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs7593239 chr2 209605944 G A 3.77E-04 Multiple complex diseases / / 17554300 rs1356378 chr2 209622265 A T 3.45E-04 Multiple complex diseases / / 17554300 rs11897307 chr2 209635009 A G 2.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs11896599 chr2 209643445 T A 3.36E-04 Multiple complex diseases / / 17554300 rs11896599 chr2 209643445 T A 3.70E-05 Panic disorder / / 19165232 rs6414172 chr2 209748356 A G 3.84E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs3851939 chr2 209757798 C T 6.73E-05 Hepatitis B vaccine response / / 21764829 rs1533807 chr2 209868471 T A 3.20E-06 Hearing function / / 21493956 rs2364820 chr2 209873988 A G 8.67E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13387460 chr2 209878841 C A 1.09E-05 Primary biliary cirrhosis / / 23000144 rs10804172 chr2 209881980 A G 5.30E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs4520973 chr2 209912108 G A 3.17E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1439736 chr2 209950995 G T 1.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs12468520 chr2 209962629 G A 1.10E-04 Multiple complex diseases / / 17554300 rs1439724 chr2 209976271 G A 1.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs939850 chr2 209993085 G C 3.58E-04 IgE levels / / 17255346 rs939850 chr2 209993085 G C 5.83E-05 Multiple complex diseases / / 17554300 rs1371436 chr2 210016186 T C 9.77E-05 Height / / 17255346 rs1371436 chr2 210016186 T C 2.93E-05 Multiple complex diseases / / 17554300 rs1371437 chr2 210016281 G A 3.37E-04 Height / / 17255346 rs4075133 chr2 210017298 C G 3.59E-04 IgE levels / / 17255346 rs4075133 chr2 210017298 C G 1.79E-05 Multiple complex diseases / / 17554300 rs3890028 chr2 210017891 G A 1.31E-04 Height / / 17255346 rs1079125 chr2 210017945 A C 9.79E-06 Multiple complex diseases / / 17554300 rs13392114 chr2 210026471 C T 9.12E-06 Serum metabolites / / 19043545 rs16824899 chr2 210034790 A G 4.36E-05 Serum metabolites / / 19043545 rs7560269 chr2 210037293 C G 8.66E-06 Serum metabolites / / 19043545 rs17738962 chr2 210058068 C T 1.09E-04 Height / / 17255346 rs17738962 chr2 210058068 C T 1.49E-04 Multiple complex diseases / / 17554300 rs7581212 chr2 210058383 G A 5.40E-05 Serum metabolites / / 19043545 rs1583758 chr2 210060812 T C 7.90E-05 Serum metabolites / / 19043545 rs12995006 chr2 210066993 A G 6.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs1446607 chr2 210114896 A G 9.77E-05 Cytomegalovirus antibody response / / 21993531 rs2100078 chr2 210116243 C A 7.52E-05 Multiple complex diseases / / 17554300 rs2100078 chr2 210116243 C A 5.80E-05 Lipid levels / / 18193043 rs12465726 chr2 210122097 T A 2.03E-04 Multiple complex diseases / / 17554300 rs17740667 chr2 210122477 C T 2.91E-04 Multiple complex diseases / / 17554300 rs2028894 chr2 210138573 A T 4.39E-04 Multiple complex diseases / / 17554300 rs16842765 chr2 210156850 G A 4.86E-05 IgE levels / / 17255346 rs10176569 chr2 210175008 A G 4.33E-04 IgE levels / / 17255346 rs17674248 chr2 210204057 G A 3.48E-04 Height / / 17255346 rs17674248 chr2 210204057 G A 7.46E-06 Multiple complex diseases / / 17554300 rs17725929 chr2 210222441 G C 7.09E-07 Multiple complex diseases / / 17554300 rs17675086 chr2 210223378 C T 2.67E-04 Height / / 17255346 rs975719 chr2 210232466 T C 2.58E-05 IgE levels / / 17255346 rs975719 chr2 210232466 T C 3.47E-04 Body mass index / / 21701565 rs975719 chr2 210232466 T C 4.52E-04 Body mass index / / 21701565 rs6726105 chr2 210234774 A C 2.48E-04 Body mass index / / 21701565 rs6726105 chr2 210234774 A C 3.87E-04 Body mass index / / 21701565 rs11892351 chr2 210235426 C A 6.06E-04 Multiple complex diseases / / 17554300 rs16842863 chr2 210244181 T C 7.53E-05 IgE levels / / 17255346 rs12475149 chr2 210244866 C A 3.21E-04 Body mass index / / 21701565 rs12475149 chr2 210244866 C A 4.47E-04 Body mass index / / 21701565 rs7606091 chr2 210245922 G A 2.79E-04 Height / / 17255346 rs7606091 chr2 210245922 G A 5.63E-05 Multiple complex diseases / / 17554300 rs13017199 chr2 210246064 C G 2.01E-04 IgE levels / / 17255346 rs13017199 chr2 210246064 C G 1.90E-04 Body mass index / / 21701565 rs13017199 chr2 210246064 C G 2.30E-04 Body mass index / / 21701565 rs7355281 chr2 210248192 G T 3.16E-04 Type 2 diabetes / / 17846125 rs1446597 chr2 210250705 T G 7.11E-05 IgE levels / / 17255346 rs11676603 chr2 210261491 G C 1.55E-04 IgE levels / / 17255346 rs11677905 chr2 210261858 G T 9.64E-05 IgE levels / / 17255346 rs11677905 chr2 210261858 G T 2.14E-04 Body mass index / / 21701565 rs11677905 chr2 210261858 G T 7.66E-04 Body mass index / / 21701565 rs11889366 chr2 210263288 G A 9.00E-05 Prostate cancer / / 21743057 rs718647 chr2 210265247 C T 9.59E-05 IgE levels / / 17255346 rs12471015 chr2 210265916 G C 9.80E-05 IgE levels / / 17255346 rs12471015 chr2 210265916 G C 6.20E-04 Body mass index / / 21701565 rs11896886 chr2 210268142 G A 1.08E-04 Body mass index / / 21701565 rs11896886 chr2 210268142 G A 5.52E-04 Body mass index / / 21701565 rs10445803 chr2 210271767 C A 2.25E-04 Body mass index / / 21701565 rs10445803 chr2 210271767 C A 7.93E-04 Body mass index / / 21701565 rs10196056 chr2 210274200 C T 3.33E-04 Body mass index / / 21701565 rs1080278 chr2 210275709 G A 9.74E-05 IgE levels / / 17255346 rs1900308 chr2 210277526 A C 7.87E-05 IgE levels / / 17255346 rs1446596 chr2 210285528 C T 1.99E-04 Body mass index / / 21701565 rs6435527 chr2 210291373 A G 1.73E-04 IgE levels MAP2 intron 17255346 rs16842900 chr2 210312533 A G 6.82E-05 Multiple complex diseases MAP2 intron 17554300 rs17236116 chr2 210312769 A G 5.34E-04 Body mass index MAP2 intron 21701565 rs17236116 chr2 210312769 A G 8.19E-04 Body mass index MAP2 intron 21701565 rs16842904 chr2 210312788 C T 8.69E-04 Multiple complex diseases MAP2 intron 17554300 rs10737940 chr2 210330754 G A 1.08E-04 IgE levels MAP2 intron 17255346 rs7601095 chr2 210344871 G A 4.15E-04 IgE levels MAP2 intron 17255346 rs6728378 chr2 210346084 A G 4.38E-05 IgE levels MAP2 intron 17255346 rs7594825 chr2 210398232 G A 2.81E-05 Heart Rate MAP2 intron pha003053 rs288095 chr2 210403912 A C 2.00E-05 Prostate cancer MAP2 intron 21743057 rs6733319 chr2 210465558 G A 8.31E-04 Response to taxane treatment (placlitaxel) MAP2 intron 23006423 rs906831 chr2 210498057 G A 9.50E-04 Response to taxane treatment (placlitaxel) MAP2 intron 23006423 rs9288410 chr2 210498261 G A 5.64E-07 Age-related macular degeneration MAP2 intron pha000001 rs9288410 chr2 210498261 G A 3.28E-05 Age-related macular degeneration MAP2 intron pha000002 rs9288410 chr2 210498261 G A 2.71E-05 Age-related macular degeneration MAP2 intron pha002856 rs2663652 chr2 210508524 G A 0.000784115 Hypertension (early onset hypertension) MAP2 intron 22479346 rs16843390 chr2 210519833 A G 6.83E-04 Type 2 diabetes MAP2 intron 17463246 rs3768812 chr2 210555776 C T 9.37E-06 Taste perception MAP2 intron 22132133 rs35927101 chr2 210559865 G A 0.00027 Prostate cancer MAP2 missense 23555315 rs2191912 chr2 210606243 A G 7.87E-04 Type 2 diabetes / / 17463246 rs10932308 chr2 210642473 A T 1.90E-05 Urinary metabolites UNC80 intron 21572414 rs11692338 chr2 210643881 T C 2.80E-05 Urinary metabolites UNC80 intron 21572414 rs11680007 chr2 210646814 A C 8.70E-04 Type 2 diabetes UNC80 intron 17463246 rs11680964 chr2 210652613 A C 8.70E-04 Type 2 diabetes UNC80 intron 17463246 rs10932310 chr2 210672638 T C 2.10E-05 Urinary metabolites UNC80 intron 21572414 rs6761179 chr2 210701101 A G 9.13E-04 Myopia (pathological) UNC80 intron 21095009 rs9288414 chr2 210704200 C A 2.60E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10178425 chr2 210704893 G T 2.64E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10178425 chr2 210704893 G T 0.0000098 Amygdala reactivity UNC80 intron 22856363 rs10178431 chr2 210704907 G T 6.24E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10178675 chr2 210705348 C G 2.81E-04 Suicide attempts in bipolar disorder UNC80 cds-synon 21041247 rs10490024 chr2 210707361 G A 2.80E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10188289 chr2 210707767 G A 2.78E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs16843780 chr2 210709033 G C 2.77E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs12386218 chr2 210709793 C G 2.65E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs13028068 chr2 210710406 T G 2.61E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs6752217 chr2 210711426 G T 2.49E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10194322 chr2 210715174 G A 6.11E-04 Multiple complex diseases UNC80 intron 17554300 rs10194322 chr2 210715174 G A 5.40E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10194322 chr2 210715174 G A 6.10E-06 Urinary metabolites UNC80 intron 21572414 rs10194333 chr2 210715307 C A 5.43E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10170708 chr2 210715357 A T 1.77E-04 Multiple complex diseases UNC80 intron 17554300 rs13013030 chr2 210716930 C G 5.58E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs7584039 chr2 210717526 T C 5.60E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs2191909 chr2 210718772 C G 5.64E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs2159747 chr2 210718897 T C 5.75E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs7579121 chr2 210721446 T C 5.87E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs13010864 chr2 210722025 A G 4.24E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs9631001 chr2 210725694 C T 6.13E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs9973787 chr2 210728999 A G 6.30E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs7595063 chr2 210729517 C A,G 3.05E-04 Multiple complex diseases UNC80 intron 17554300 rs7595063 chr2 210729517 C A,G 6.45E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs7598071 chr2 210729711 G C 6.51E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs9973848 chr2 210730560 A G 6.58E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs9973317 chr2 210731012 C T 6.48E-04 Multiple complex diseases UNC80 intron 17554300 rs9973317 chr2 210731012 C T 6.63E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs13414802 chr2 210732686 A G 1.41E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10490025 chr2 210733400 A T 3.98E-04 Multiple complex diseases UNC80 intron 17554300 rs10490025 chr2 210733400 A T 1.27E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10490026 chr2 210733445 G A 4.03E-04 Multiple complex diseases UNC80 intron 17554300 rs10490026 chr2 210733445 G A 1.27E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs7593426 chr2 210733835 G A 5.57E-04 Multiple complex diseases UNC80 intron 17554300 rs7593426 chr2 210733835 G A 5.40E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs7566741 chr2 210733952 A G 5.67E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10490027 chr2 210734462 T A 5.80E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs12328328 chr2 210734843 C T 6.29E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs12329111 chr2 210734855 A C 6.34E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs12328346 chr2 210735086 G A 6.40E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10490028 chr2 210735160 C T 6.55E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs12328869 chr2 210736168 T A 6.61E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs12328884 chr2 210736388 T C 6.62E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs12329303 chr2 210736612 A G 6.64E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs7581628 chr2 210737831 A G 6.72E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs7581974 chr2 210738089 A G 6.78E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs17748674 chr2 210738851 T C 6.84E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs17748692 chr2 210738874 T C 6.93E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs1558474 chr2 210739353 C T 7.00E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs16843893 chr2 210741592 C T 7.09E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs11682914 chr2 210742033 G A 1.58E-04 Multiple complex diseases UNC80 intron 17554300 rs11682914 chr2 210742033 G A 7.12E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs2109970 chr2 210742253 A G 7.17E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs17748818 chr2 210745855 C T 7.35E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs7608462 chr2 210748646 G A 9.19E-04 Myopia (pathological) UNC80 intron 21095009 rs11688226 chr2 210770527 C T 8.68E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs11694132 chr2 210772283 A G 9.15E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs6739769 chr2 210773300 C T 9.23E-05 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs10166445 chr2 210773693 A C 1.00E-05 Urinary metabolites UNC80 intron 21572414 rs2192027 chr2 210776629 T A 2.10E-05 Urinary metabolites UNC80 intron 21572414 rs10200921 chr2 210799863 G A 5.29E-04 Suicide attempts in bipolar disorder UNC80 intron 21041247 rs7584375 chr2 210808905 A G 5.09E-04 Multiple complex diseases UNC80 intron 17554300 rs16843977 chr2 210818971 G A 9.10E-04 Response to cytadine analogues (cytosine arabinoside) UNC80 cds-synon 24483146 rs16843990 chr2 210838759 A G 1.32E-04 Multiple complex diseases UNC80 intron 17554300 rs3738934 chr2 210874246 T C 1.00E-134 Blood metabolite levels RPE intron 24816252 rs10490029 chr2 210941899 T C 1.50E-04 Type 2 diabetes and 6 quantitative traits KANSL1L intron 17848626 rs2160020 chr2 211001813 T C 7.82E-04 Suicide attempts in bipolar disorder KANSL1L intron 21041247 rs12613036 chr2 211007521 T C 5.34E-14 Metabolite levels KANSL1L intron 23281178 rs10932320 chr2 211009107 T C 0.0000993 Menopause (age at onset) KANSL1L intron 23424626 rs4673501 chr2 211024197 A G 2.47E-05 Osteoarthritis (knee and hip) KANSL1L intron 21177295 rs4673501 chr2 211024197 A G 4.49E-05 Osteoarthritis (knee and hip) KANSL1L intron 21177295 rs4673501 chr2 211024197 A G 6.29E-05 Osteoarthritis (knee and hip) KANSL1L intron 21177295 rs263675 chr2 211037204 A G 2.75E-04 Suicide attempts in bipolar disorder / / 21041247 rs7584317 chr2 211043102 A G 9.14E-16 Metabolite levels / / 23281178 rs1396828 chr2 211045482 T C 3.11E-04 Multiple complex diseases / / 17554300 rs1396828 chr2 211045482 T C 1.60E-11 Metabolite levels / / 23281178 rs1155845 chr2 211054599 C T 2.36E-04 Suicide attempts in bipolar disorder ACADL intron 21041247 rs7601356 chr2 211056657 T C 1.40E-15 Metabolite levels ACADL intron 23281178 rs2286963 chr2 211060050 T G 3.09E-05 Serum metabolites ACADL missense 19043545 rs2286963 chr2 211060050 T G 3.00E-60 Metabolite levels ACADL missense 20037589 rs2286963 chr2 211060050 T G 1.04E-15 Metabolite levels ACADL missense 23281178 rs6739874 chr2 211061670 G T 0.000000288 Cholesterol,total ACADL intron 23236364 rs263681 chr2 211063352 G C 2.28E-04 Suicide attempts in bipolar disorder ACADL intron 21041247 rs263680 chr2 211067401 G A 2.27E-04 Suicide attempts in bipolar disorder ACADL intron 21041247 rs1509568 chr2 211069011 T C 2.24E-04 Suicide attempts in bipolar disorder ACADL intron 21041247 rs1509572 chr2 211073337 A T 2.23E-04 Suicide attempts in bipolar disorder ACADL intron 21041247 rs1509571 chr2 211073548 C T 2.21E-04 Suicide attempts in bipolar disorder ACADL intron 21041247 rs3764913 chr2 211074909 T C 6.03E-05 Serum metabolites ACADL intron 19043545 rs3764913 chr2 211074909 T C 4.00E-29 Metabolite levels ACADL intron 23281178 rs16844213 chr2 211079166 C T 2.18E-04 Suicide attempts in bipolar disorder ACADL intron 21041247 rs13415601 chr2 211080124 T A 2.19E-04 Suicide attempts in bipolar disorder ACADL intron 21041247 rs13009758 chr2 211101839 T C 2.19E-04 Suicide attempts in bipolar disorder / / 21041247 rs7558218 chr2 211103445 G T 2.10E-15 Metabolite levels / / 23281178 rs263666 chr2 211107802 A G 2.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs12476559 chr2 211112436 G A 1.54E-11 Metabolite levels / / 23281178 rs6716836 chr2 211118337 A G 2.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs6760874 chr2 211118510 T C 2.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs1509569 chr2 211132415 A G 4.49E-14 Metabolite levels / / 23281178 rs1509569 chr2 211132415 A G 3.00E-18 Urinary metabolites (H-NMR features) / / 24586186 rs7557847 chr2 211133150 G A 9.82E-15 Metabolite levels / / 23281178 rs4558528 chr2 211134546 A T 2.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs1396830 chr2 211136612 G A 2.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs1396831 chr2 211136678 A T 2.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs7563494 chr2 211141267 T C 2.36E-08 Metabolite levels / / 23281178 rs13001183 chr2 211146773 A T 7.75E-10 Metabolite levels / / 23281178 rs7582804 chr2 211149820 G A 7.75E-10 Metabolite levels / / 23281178 rs7596691 chr2 211149926 T C 4.35E-05 Bipolar disorder / / 22925353 rs7583039 chr2 211150016 G C 2.92E-08 Metabolite levels / / 23281178 rs12999760 chr2 211150037 T C 7.75E-10 Metabolite levels / / 23281178 rs2048274 chr2 211151626 C T 7.75E-10 Metabolite levels / / 23281178 rs2048275 chr2 211151668 T C 7.75E-10 Metabolite levels / / 23281178 rs2048276 chr2 211151691 T C 7.75E-10 Metabolite levels / / 23281178 rs6734950 chr2 211151969 T G 7.75E-10 Metabolite levels / / 23281178 rs867342 chr2 211152705 A G 7.75E-10 Metabolite levels / / 23281178 rs11889646 chr2 211154128 G A 7.75E-10 Metabolite levels / / 23281178 rs6736750 chr2 211156528 G A 2.18E-09 Metabolite levels MYL1 intron 23281178 rs2136457 chr2 211157449 T C 7.75E-10 Metabolite levels MYL1 intron 23281178 rs1995836 chr2 211159671 G A,T 7.75E-10 Metabolite levels MYL1 intron 23281178 rs6735154 chr2 211161154 G C 1.75E-09 Metabolite levels MYL1 intron 23281178 rs2063311 chr2 211163574 C A,T 7.75E-10 Metabolite levels MYL1 intron 23281178 rs12469767 chr2 211168346 A C 7.75E-10 Metabolite levels MYL1 intron 23281178 rs1472955 chr2 211168638 A G 3.24E-05 Bipolar disorder MYL1 intron 22925353 rs6725084 chr2 211170972 A G 7.75E-10 Metabolite levels MYL1 intron 23281178 rs1074158 chr2 211175043 A G 9.31E-05 Height MYL1 intron pha003010 rs1074158 chr2 211175043 A G 3.52E-05 Height MYL1 intron pha003011 rs6435569 chr2 211289689 G A 8.12E-04 Multiple complex diseases / / 17554300 rs3821136 chr2 211299687 G A 1.68E-04 Multiple complex diseases LANCL1 intron 17554300 rs3770699 chr2 211304138 G T 4.13E-04 Multiple complex diseases LANCL1 intron 17554300 rs2287432 chr2 211319824 T C 1.95E-04 Amyotrophic lateral sclerosis (sporadic) LANCL1 intron 24529757 rs2042049 chr2 211320374 G C 7.74E-04 Multiple complex diseases LANCL1 intron 17554300 rs4640325 chr2 211448624 G A 9.12E-04 Type 2 diabetes CPS1 intron 17463246 rs2371002 chr2 211471071 G A 6.00E-05 Prostate cancer CPS1 intron 21743057 rs12468557 chr2 211495587 C T 9.00E-06 Body mass index (asthmatics) CPS1 intron 23517042 rs2302909 chr2 211503556 G T 5.88E-06 Carotenoid and tocopherol levels CPS1 intron 19185284 rs2371007 chr2 211508194 C G 9.34E-04 Multiple complex diseases CPS1 intron 17554300 rs6435580 chr2 211523457 C T 1.06E-04 Lung function (forced expiratory volume in 1 second) CPS1 intron 24023788 rs6435580 chr2 211523457 C T 2.54E-04 Lung function (forced vital capacity) CPS1 intron 24023788 rs6726148 chr2 211526922 A T 1.00E-05 Prostate cancer CPS1 intron 21743057 rs12997383 chr2 211529850 C T 1.00E-05 Prostate cancer CPS1 intron 21743057 rs12997383 chr2 211529850 C T 2.35E-05 Brain structure CPS1 intron 22504417 rs16844777 chr2 211535278 C T 1.00E-05 Prostate cancer CPS1 intron 21743057 rs1047891 chr2 211540507 C A 9.00E-09 Fibrinogen CPS1 missense 20031577 rs1047891 chr2 211540507 C A 5.00E-09 Homocysteine levels CPS1 missense 20154341 rs1047891 chr2 211540507 C A 1.00E-15 Chronic kidney disease CPS1 missense 20383146 rs1047891 chr2 211540507 C A 1.35E-10 Chronic kidney disease CPS1 missense 22479191 rs1047891 chr2 211540507 C A 5.00E-27 Homocysteine levels CPS1 missense 23824729 rs1047891 chr2 211540507 C A 9.00E-10 HDL cholesterol CPS1 missense 24097068 rs1047891 chr2 211540507 C A 9.00E-13 Plasma homocysteine levels (post-methionine load test) CPS1 missense 24651765 rs1047891 chr2 211540507 C A 9.00E-09 Fibrinogen CPS1 missense 20031577 rs1047891 chr2 211540507 C A 5.00E-09 Homocysteine levels CPS1 missense 20154341 rs1047891 chr2 211540507 C A 1.00E-15 Chronic kidney disease CPS1 missense 20383146 rs1047891 chr2 211540507 C A 5.00E-27 Homocysteine levels CPS1 missense 23824729 rs1047891 chr2 211540507 C A 3.55E-17 Homoarginine levels CPS1 missense 24047826 rs1047891 chr2 211540507 C A 4.00E-12 Metabolite levels CPS1 missense 24625756 rs715 chr2 211543055 T C 3.00E-50 Metabolite levels (Glycine metabolism) CPS1 UTR-3 23378610 rs715 chr2 211543055 T C 2.00E-11 Fibrinogen CPS1 UTR-3 23969696 rs715 chr2 211543055 T C 1.00E-24 Blood metabolite levels CPS1 UTR-3 24816252 rs715 chr2 211543055 T C 2.00E-147 Blood metabolite levels CPS1 UTR-3 24816252 rs715 chr2 211543055 T C 2.00E-16 Blood metabolite levels CPS1 UTR-3 24816252 rs715 chr2 211543055 T C 2.00E-19 Blood metabolite levels CPS1 UTR-3 24816252 rs715 chr2 211543055 T C 3.00E-21 Blood metabolite levels CPS1 UTR-3 24816252 rs715 chr2 211543055 T C 4.00E-16 Blood metabolite levels CPS1 UTR-3 24816252 rs715 chr2 211543055 T C 7.00E-35 Blood metabolite levels CPS1 UTR-3 24816252 rs715 chr2 211543055 T C 7.00E-58 Blood metabolite levels CPS1 UTR-3 24816252 rs2887915 chr2 211554574 C T 9.09E-08 Chronic kidney disease / / 21931561 rs2371030 chr2 211569722 G A 3.00E-06 Non-small cell lung cancer / / 23144319 rs1160096 chr2 211578483 C T 8.73E-05 Orofacial clefts / / 22419666 rs10490322 chr2 211583022 C T 6.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10490323 chr2 211583253 G A 6.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2216405 chr2 211616894 A G 1.90E-30 Serum metabolites / / 20037589 rs2216405 chr2 211616894 A G 2.00E-27 Metabolic traits / / 21886157 rs2371079 chr2 211638554 A G 1.59E-04 Aortic root size / / 21223598 rs764637 chr2 211641003 G A 3.30E-04 Diabetic retinopathy / / 20871662 rs16844916 chr2 211647290 A G 2.08E-04 Tourette syndrome / / 22889924 rs4673558 chr2 211661897 C T 4.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12998006 chr2 211669006 T C 7.60E-07 Bipolar disorder / / 19416921 rs16824978 chr2 211672061 C T 7.77E-06 Ankle-brachial index / / 22199011 rs986293 chr2 211672261 A G 9.98E-04 Stroke / / pha002886 rs12478788 chr2 211681243 G A 2.75E-05 Serum metabolites / / 19043545 rs12464940 chr2 211682987 G T 6.63E-05 Monocyte chemoattractant protein-1 / / pha003071 rs2719969 chr2 211683144 G C 2.20E-04 Spine bone size / / 23207799 rs7608489 chr2 211699011 G A 5.26E-04 Parkinson's disease / / 17052657 rs7608489 chr2 211699011 G A 3.07E-04 Hearing function / / 17255346 rs13019409 chr2 211701811 A G 1.29E-04 Stroke / / pha002886 rs7580498 chr2 211703869 A C 8.74E-04 Multiple complex diseases / / 17554300 rs2542929 chr2 211711593 T G 0.0000147 LDL cholesterol particle diameter / / 23263444 rs13013804 chr2 211761578 A G 1.94E-04 Osteoarthritis / / 19508968 rs4327185 chr2 211764584 C T 2.55E-06 Glycemic traits (pregnancy) / / 23903356 rs4327185 chr2 211764584 C T 7.29E-06 Glycemic traits (pregnancy) / / 23903356 rs4362497 chr2 211772578 T A 2.84E-06 Glycemic traits (pregnancy) / / 23903356 rs4362497 chr2 211772578 T A 7.71E-06 Glycemic traits (pregnancy) / / 23903356 rs7420853 chr2 211778201 G A 2.50E-05 Urinary metabolites / / 21572414 rs7420853 chr2 211778201 G A 6.16E-06 Glycemic traits (pregnancy) / / 23903356 rs4505460 chr2 211778272 C A 8.91E-06 Glycemic traits (pregnancy) / / 23903356 rs4438425 chr2 211781209 C T 2.63E-06 Glycemic traits (pregnancy) / / 23903356 rs4438425 chr2 211781209 C T 8.23E-06 Glycemic traits (pregnancy) / / 23903356 rs4635463 chr2 211781238 C T 2.79E-06 Glycemic traits (pregnancy) / / 23903356 rs4635463 chr2 211781238 C T 8.89E-06 Glycemic traits (pregnancy) / / 23903356 rs4505461 chr2 211781269 G C 3.39E-06 Glycemic traits (pregnancy) / / 23903356 rs7566803 chr2 211782674 G A 3.31E-06 Glycemic traits (pregnancy) / / 23903356 rs7580725 chr2 211782699 T C 3.58E-06 Glycemic traits (pregnancy) / / 23903356 rs4611592 chr2 211786679 G A 2.18E-06 Glycemic traits (pregnancy) / / 23903356 rs4611592 chr2 211786679 G A 6.33E-06 Glycemic traits (pregnancy) / / 23903356 rs4425028 chr2 211799738 A G 7.02E-06 Glycemic traits (pregnancy) / / 23903356 rs4580326 chr2 211804851 C T 4.96E-06 Glycemic traits (pregnancy) / / 23903356 rs4580326 chr2 211804851 C T 8.25E-06 Glycemic traits (pregnancy) / / 23903356 rs4455102 chr2 211808697 A G 6.35E-04 Stroke / / pha002886 rs13006521 chr2 211813132 A G 4.96E-06 Glycemic traits (pregnancy) / / 23903356 rs13006521 chr2 211813132 A G 7.85E-06 Glycemic traits (pregnancy) / / 23903356 rs809949 chr2 211830196 C T 6.53E-06 Glycemic traits (pregnancy) / / 23903356 rs809949 chr2 211830196 C T 7.93E-06 Glycemic traits (pregnancy) / / 23903356 rs920212 chr2 211874950 A G 1.70E-05 Urinary metabolites / / 21572414 rs920211 chr2 211874991 T C 4.60E-06 Urinary metabolites / / 21572414 rs11688017 chr2 211880639 T C 1.70E-05 Urinary metabolites / / 21572414 rs167650 chr2 211895267 A G 4.40E-06 Urinary metabolites / / 21572414 rs1821825 chr2 211914804 C T 2.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1821825 chr2 211914804 C T 4.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13016652 chr2 211927188 G A 1.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13016652 chr2 211927188 G A 3.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12464316 chr2 211935990 C T 2.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12464316 chr2 211935990 C T 4.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs697663 chr2 211943622 A C 3.86E-04 Type 2 diabetes / / 17846124 rs17737064 chr2 211981461 T A 5.54E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs16845357 chr2 211989141 A G 7.02E-04 Multiple complex diseases / / 17554300 rs11679051 chr2 212029656 T C 7.78E-05 Cardiovascular disease / / pha003064 rs35082087 chr2 212063805 T C 1.20E-05 Urinary metabolites / / 21572414 rs16845632 chr2 212080318 G C 6.87E-05 Multiple complex diseases / / 17554300 rs4632271 chr2 212157104 T C 5.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4632271 chr2 212157104 T C 7.43E-04 Rheumatoid arthritis / / 21452313 rs4632271 chr2 212157104 T C 8.49E-04 Gallbladder cancer / / 22318345 rs7557116 chr2 212158670 C T 4.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7557116 chr2 212158670 C T 9.33E-04 Rheumatoid arthritis / / 21452313 rs1595063 chr2 212167904 A G 9.48E-04 Rheumatoid arthritis / / 21452313 rs6728697 chr2 212169952 C A 4.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12694232 chr2 212194222 T C 6.52E-04 Insulin resistance / / 21901158 rs11901831 chr2 212225520 T C 1.20E-05 Melanoma / / 24980573 rs1821659 chr2 212238982 T C 5.53E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1595066 chr2 212241725 C T 9.47E-05 Monocyte chemoattractant protein-1 ERBB4 UTR-3 pha003071 rs10932374 chr2 212244403 G A 2.58E-05 Paclitaxel-induced neuropathy ERBB4 UTR-3 23776197 rs10932374 chr2 212244403 G A 9.42E-05 HDL cholesterol ERBB4 UTR-3 pha003075 rs17744862 chr2 212244520 A G 2.12E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ERBB4 UTR-3 24023788 rs3791682 chr2 212249706 T C 8.60E-04 Myopia (pathological) ERBB4 intron 21095009 rs3791682 chr2 212249706 T C 9.56E-05 HDL cholesterol ERBB4 intron pha003074 rs3791682 chr2 212249706 T C 2.61E-05 HDL cholesterol ERBB4 intron pha003075 rs1595062 chr2 212251070 A G 2.76E-04 Taste perception ERBB4 intron 22132133 rs149419131 chr2 212331808 C G 0.0000461 Nonsyndromic striae distensae (stretch marks) ERBB4 intron 23633020 rs13021324 chr2 212350245 T C 1.59E-04 Epilepsy ERBB4 intron 22116939 rs9941626 chr2 212351667 T G 1.23E-04 Epilepsy ERBB4 intron 22116939 rs4500888 chr2 212368188 G T 8.15E-05 Multiple complex diseases ERBB4 intron 17554300 rs6435632 chr2 212378524 G A 2.82E-05 Multiple complex diseases ERBB4 intron 17554300 rs7603778 chr2 212384650 T C 9.80E-06 Urinary metabolites ERBB4 intron 21572414 rs7597024 chr2 212386461 C T 7.60E-06 Urinary metabolites ERBB4 intron 21572414 rs11887047 chr2 212409199 G C 0.0000776 Placental abruption ERBB4 intron 23205182 rs13014132 chr2 212415917 C G 5.08E-04 Multiple complex diseases ERBB4 intron 17554300 rs13421680 chr2 212416029 A G 4.42E-04 Alcohol dependence ERBB4 intron 21314694 rs11885579 chr2 212431529 A G 9.38E-04 Alcohol dependence ERBB4 intron 21314694 rs12694242 chr2 212438861 T C 5.10E-05 HIV-1 control ERBB4 intron 20041166 rs1879532 chr2 212439312 T C,G 1.66E-07 Autism ERBB4 intron 22843504 rs4672619 chr2 212457195 C A 3.63E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ERBB4 intron 24023788 rs1851196 chr2 212470620 G A 2.14E-06 Schizophrenia ERBB4 intron 19571809 rs1851196 chr2 212470620 G A 5.11E-06 Schizophrenia ERBB4 intron pha002859 rs41382849 chr2 212471471 G A 6.93E-04 Multiple complex diseases ERBB4 intron 17554300 rs12616462 chr2 212490272 A C 3.65E-05 Tuberculosis ERBB4 intron 20694014 rs10180037 chr2 212508067 T C 5.50E-04 Taste perception ERBB4 intron 22132133 rs6706854 chr2 212508134 A G 2.57E-04 Type 2 diabetes ERBB4 intron 17463246 rs17335518 chr2 212526025 A G 3.10E-06 Urinary metabolites ERBB4 intron 21572414 rs10173674 chr2 212545533 C T 8.56E-04 Amyotrophic Lateral Sclerosis ERBB4 intron 17362836 rs7588792 chr2 212626917 A C 6.02E-04 Type 2 diabetes ERBB4 intron 17463246 rs1371200 chr2 212691392 G T 7.51E-04 Taste perception ERBB4 intron 22132133 rs16846917 chr2 212697542 G T 1.54E-05 Multiple sclerosis (brain glutamate levels) ERBB4 intron 20802204 rs6435678 chr2 212710468 G C 6.01E-04 Multiple complex diseases ERBB4 intron 17554300 rs6435678 chr2 212710468 G C 3.06E-04 Nicotine smoking ERBB4 intron 19268276 rs1159709 chr2 212715410 T C 1.17E-05 Multiple sclerosis (brain glutamate levels) ERBB4 intron 20802204 rs16847102 chr2 212722988 G A 7.59E-04 Multiple complex diseases ERBB4 intron 17554300 rs11679499 chr2 212729377 A T 8.50E-04 Acute lung injury ERBB4 intron 22295056 rs16847152 chr2 212736394 T C 7.92E-05 Cognitive impairment induced by topiramate ERBB4 intron 22091778 rs13390226 chr2 212739861 G A 4.24E-05 Multiple complex diseases ERBB4 intron 17554300 rs7603039 chr2 212788895 G A 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ERBB4 intron 22628534 rs16847207 chr2 212791249 A G 0.000738 Height (Pygmy height) ERBB4 intron 22570615 rs839533 chr2 212808107 A G 0.000159 Oxaliplatin induced mucositis in response to colorectal cancer treatment ERBB4 intron 22310351 rs839511 chr2 212822242 C T 4.69E-04 Alzheimer's disease ERBB4 intron 17998437 rs839511 chr2 212822242 C T 2.58E-04 Alzheimer's disease ERBB4 intron pha002879 rs10205607 chr2 212845461 T C 0.000849 Salmonella-induced pyroptosis ERBB4 intron 22837397 rs17415079 chr2 212856363 T C 5.73E-04 Smoking initiation ERBB4 intron 24665060 rs4673646 chr2 212860841 G A 0.000708 Salmonella-induced pyroptosis ERBB4 intron 22837397 rs13020474 chr2 212866473 C T 0.000369 Salmonella-induced pyroptosis ERBB4 intron 22837397 rs1879637 chr2 212868624 C T 4.00E-06 Personality dimensions ERBB4 intron 23903073 rs1521537 chr2 212885510 T C 0.0000657 Circulating PCSK9 levels ERBB4 intron 22460556 rs2139938 chr2 212891137 C A 4.90E-06 Urinary metabolites ERBB4 intron 21572414 rs1546717 chr2 212902339 A G 2.60E-05 Urinary metabolites ERBB4 intron 21572414 rs1464443 chr2 212914726 C A 1.00E-06 Amyotrophic lateral sclerosis (sporadic) ERBB4 intron 24529757 rs41422148 chr2 212967009 T C 1.98E-04 Multiple complex diseases ERBB4 intron 17554300 rs16847757 chr2 212994669 T C 2.53E-04 Multiple complex diseases ERBB4 intron 17554300 rs4673651 chr2 213004603 G A,T 0.00000608 Aging ERBB4 intron 22445811 rs13035998 chr2 213029668 T C 2.31E-05 Serum metabolites ERBB4 intron 19043545 rs6751662 chr2 213033118 T C 1.77E-05 Serum metabolites ERBB4 intron 19043545 rs1402766 chr2 213033301 A C 7.74E-06 Rheumatoid arthritis ERBB4 intron 19503088 rs12621602 chr2 213036190 A C 1.88E-07 Fibrinogen ERBB4 intron pha003068 rs939664 chr2 213038087 C G 7.85E-05 Serum metabolites ERBB4 intron 19043545 rs10497963 chr2 213065329 C T 5.42E-05 Bilirubin levels,in serum ERBB4 intron 19389676 rs1402769 chr2 213081443 T G 4.46E-05 Chronic obstructive pulmonary disease ERBB4 intron 19300482 rs1402769 chr2 213081443 T G 4.46E-05 Response to statin treatment (atorvastatin),change in cholesterol levels ERBB4 intron 20031582 rs9288446 chr2 213082027 G C 2.30E-05 Volumetric brain MRI ERBB4 intron 17903297 rs9288449 chr2 213085996 T C 1.44E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ERBB4 intron 20031582 rs10497966 chr2 213113079 C A 9.90E-05 Psoriasis ERBB4 intron 18364390 rs1021916 chr2 213132822 A G 2.20E-05 Renal function-related traits (urea) ERBB4 intron 22797727 rs10170838 chr2 213164466 C T 9.76E-07 Type 1 diabetes nephropathy ERBB4 intron 23028342 rs1857795 chr2 213164907 A C 3.00E-05 Prostate cancer ERBB4 intron 21743057 rs17346933 chr2 213165193 A G 5.77E-05 Left ventricular hypertrophy ERBB4 intron pha003052 rs7588550 chr2 213168768 G A 2.00E-07 Type 1 diabetes nephropathy ERBB4 intron 23028342 rs7559911 chr2 213186351 C A 2.02E-04 Response to taxane treatment (placlitaxel) ERBB4 intron 23006423 rs10164675 chr2 213187034 G T 8.71E-04 Response to taxane treatment (placlitaxel) ERBB4 intron 23006423 rs12993440 chr2 213188013 A G 2.06E-04 Response to taxane treatment (placlitaxel) ERBB4 intron 23006423 rs905883 chr2 213188470 C A,G,T 2.00E-04 Breast cancer and prostate cancer ERBB4 intron 17903305 rs16775 chr2 213189297 G A 9.06E-05 Schizophrenia ERBB4 intron 24253340 rs4673659 chr2 213189729 A C 9.00E-07 Asthma (sex interaction) ERBB4 intron 24824216 rs6719811 chr2 213194405 G A 8.27E-04 Response to taxane treatment (placlitaxel) ERBB4 intron 23006423 rs1394782 chr2 213200920 G A 8.30E-05 Pericardial fat ERBB4 intron 22589742 rs1505356 chr2 213205001 C A 8.70E-05 Pericardial fat ERBB4 intron 22589742 rs1876048 chr2 213205849 G A 9.40E-05 Pericardial fat ERBB4 intron 22589742 rs1995567 chr2 213206165 T C 6.43E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ERBB4 intron 20031582 rs2135157 chr2 213206302 C T 9.40E-05 Pericardial fat ERBB4 intron 22589742 rs4630710 chr2 213211617 G A 2.66E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ERBB4 intron 20031582 rs2888089 chr2 213219281 C A 6.40E-05 Pericardial fat ERBB4 intron 22589742 rs1948877 chr2 213219641 G A 5.09E-04 Type 2 diabetes ERBB4 intron 17463246 rs11892564 chr2 213226544 A G 8.08E-04 Alzheimer's disease ERBB4 intron 24755620 rs1394799 chr2 213230879 A G 7.42E-04 Response to taxane treatment (placlitaxel) ERBB4 intron 23006423 rs4511675 chr2 213233739 G T 9.30E-05 Alzheimer's disease (late onset) ERBB4 intron 21379329 rs13383860 chr2 213253930 T C 6.11E-06 Alzheimer's disease (late onset) ERBB4 intron 21379329 rs16848495 chr2 213273682 C T 3.45E-04 Type 2 diabetes ERBB4 intron 17463246 rs1283310 chr2 213273891 A G 7.64E-06 Serum dimethylarginine levels (symmetric) ERBB4 intron 24159190 rs10197836 chr2 213274278 T C 7.76E-06 Serum dimethylarginine levels (symmetric) ERBB4 intron 24159190 rs4673664 chr2 213277649 T C 8.30E-06 Serum dimethylarginine levels (symmetric) ERBB4 intron 24159190 rs10167244 chr2 213281310 A G 6.17E-06 Serum dimethylarginine levels (symmetric) ERBB4 intron 24159190 rs10197535 chr2 213282922 G A 9.33E-06 Serum dimethylarginine levels (symmetric) ERBB4 intron 24159190 rs6435701 chr2 213283512 A G 7.33E-06 Serum dimethylarginine levels (symmetric) ERBB4 intron 24159190 rs10201067 chr2 213284411 C T 8.50E-06 Serum dimethylarginine levels (symmetric) ERBB4 intron 24159190 rs13413590 chr2 213292329 C T 3.18E-06 Serum dimethylarginine levels (symmetric) ERBB4 intron 24159190 rs7569142 chr2 213294557 C T 2.83E-06 Serum dimethylarginine levels (symmetric) ERBB4 intron 24159190 rs13393577 chr2 213296863 T C 9.00E-14 Breast cancer ERBB4 intron 22452962 rs1505368 chr2 213297253 G A 1.00E-06 Serum dimethylarginine levels (symmetric) ERBB4 intron 24159190 rs1505376 chr2 213303947 T C 2.09E-04 Parkinson's disease ERBB4 intron 17052657 rs17259208 chr2 213316586 T C 3.00E-05 Kawasaki disease ERBB4 intron 22446962 rs6711080 chr2 213317329 C T 9.00E-04 Nicotine smoking ERBB4 intron 19268276 rs10168850 chr2 213334523 C T 4.90E-05 Kawasaki disease ERBB4 intron 22446962 rs16848847 chr2 213434347 A G 6.72E-04 Type 2 diabetes / / 17463246 rs984455 chr2 213453046 G C 7.54E-04 Multiple complex diseases / / 17554300 rs11693009 chr2 213486117 C T 6.57E-05 Relative hand skill / / 24068947 rs931217 chr2 213496450 C G 6.22E-05 Relative hand skill / / 24068947 rs956558 chr2 213497090 G A 6.20E-05 Relative hand skill / / 24068947 rs10179457 chr2 213500670 A G 8.30E-04 Type 2 diabetes / / 17463246 rs17331220 chr2 213510571 A G 2.95E-05 Relative hand skill / / 24068947 rs11683491 chr2 213515027 C A 3.52E-05 Relative hand skill / / 24068947 rs17331933 chr2 213545335 A C 8.75E-04 Multiple complex diseases / / 17554300 rs2371713 chr2 213547267 C G 3.37E-05 Relative hand skill / / 24068947 rs11674822 chr2 213555564 T C 3.85E-05 Sodium levels / / pha003093 rs10932444 chr2 213584688 C A 8.44E-05 Serum metabolites / / 19043545 rs7565158 chr2 213593970 G T 8.82E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs16849204 chr2 213606762 T C 3.22E-05 Neuroblastoma / / pha002895 rs10497985 chr2 213609252 C T 4.00E-06 Cognitive decline (age-related) / / 24468470 rs16849209 chr2 213611221 G T 5.00E-04 Alcohol dependence / / 20201924 rs9288457 chr2 213676322 A C 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs7604632 chr2 213680645 C T 5.97E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4673693 chr2 213680973 T C 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs4673694 chr2 213690991 G T 2.40E-05 Urinary metabolites / / 21572414 rs4131363 chr2 213707759 A G 6.91E-04 Multiple complex diseases / / 17554300 rs7600221 chr2 213738972 G A 6.53E-05 Diabetic nephropathy / / pha002852 rs10189511 chr2 213782542 G A 0.000012 Pancreatic cancer and survival / / 22665904 rs4673710 chr2 213820871 C T 8.79E-04 Multiple complex diseases / / 17554300 rs12619285 chr2 213824045 A G 5.00E-10 Eosinophil counts / / 19198610 rs12619285 chr2 213824045 A G 4.50E-05 Information processing speed / / 21130836 rs4673714 chr2 213858157 G A 6.50E-05 Coronary heart disease / / pha003035 rs12328640 chr2 213859185 G T 5.01E-05 IgE levels / / 22075330 rs1871946 chr2 213879407 T C 3.62E-05 Response to hepatitis C treatment IKZF2 intron 19684573 rs1871946 chr2 213879407 T C 2.00E-04 Information processing speed IKZF2 intron 21130836 rs13397204 chr2 213902295 C A 1.13E-04 Self-reported allergy IKZF2 intron 23817569 rs1564612 chr2 213904322 A T 8.39E-05 Self-reported allergy IKZF2 intron 23817569 rs2220038 chr2 213905274 A G 8.95E-05 Self-reported allergy IKZF2 intron 23817569 rs10207031 chr2 213906692 T C 4.67E-04 Self-reported allergy IKZF2 intron 23817569 rs10207031 chr2 213906692 T C 4.40E-04 Smoking initiation IKZF2 intron 24665060 rs2069267 chr2 213908722 C T 1.30E-04 Self-reported allergy IKZF2 intron 23817569 rs2069266 chr2 213908979 G T 1.48E-04 Self-reported allergy IKZF2 intron 23817569 rs12622499 chr2 213910104 G A 8.93E-05 Self-reported allergy IKZF2 intron 23817569 rs1482579 chr2 213911042 G A 8.56E-05 Self-reported allergy IKZF2 intron 23817569 rs4458156 chr2 213911107 G A 8.29E-05 Self-reported allergy IKZF2 intron 23817569 rs13019839 chr2 213915104 C A 1.03E-04 Self-reported allergy IKZF2 intron 23817569 rs2035426 chr2 213915748 C G 1.10E-05 Urinary metabolites IKZF2 intron 21572414 rs2035426 chr2 213915748 C G 2.87E-04 Self-reported allergy IKZF2 intron 23817569 rs9288462 chr2 213919289 G T 1.05E-04 Self-reported allergy IKZF2 intron 23817569 rs4672669 chr2 213922773 A T 6.64E-05 Lipoprotein-associated phospholipase A2 activity and mass IKZF2 intron 20442857 rs4672670 chr2 213923059 A C 6.27E-04 Smoking initiation IKZF2 intron 24665060 rs10497990 chr2 213926508 A G 6.28E-04 Self-reported allergy IKZF2 intron 23817569 rs10186029 chr2 213929286 C T 1.92E-05 Response to hepatitis C treatment IKZF2 intron 19684573 rs16849708 chr2 213946569 G C 1.65E-04 Type 2 diabetes IKZF2 intron 17463246 rs4672676 chr2 214001948 C T 3.59E-04 Smoking initiation IKZF2 intron 24665060 rs6709554 chr2 214012508 C T 2.51E-04 Self-reported allergy IKZF2 cds-synon 23817569 rs935092 chr2 214021325 G A 2.62E-04 Multiple complex diseases / / 17554300 rs935092 chr2 214021325 G A 3.39E-05 Sudden cardiac arrest / / 21658281 rs12471471 chr2 214023052 A G 3.00E-04 Amyotrophic lateral sclerosis / / 17671248 rs10932472 chr2 214038302 A G 3.49E-04 Multiple complex diseases / / 17554300 rs4567882 chr2 214039733 T C 2.50E-05 Urinary metabolites / / 21572414 rs16849921 chr2 214061022 C A,G,T 2.82E-05 Multiple complex diseases / / 17554300 rs2099799 chr2 214073968 G A 1.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1372140 chr2 214099810 G T 1.52E-04 Alzheimer's disease (late onset) / / 21379329 rs10497997 chr2 214103779 C T 1.20E-06 Fasting plasma glucose / / 19060907 rs10168433 chr2 214110416 T G 8.70E-05 Diabetic retinopathy / / 21441570 rs10181294 chr2 214115898 A G 5.56E-05 Fasting insulin (interaction) / / 24204828 rs10181294 chr2 214115898 A G 7.71E-05 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs10185045 chr2 214117303 A G 4.40E-05 Diabetic retinopathy / / 21441570 rs10208952 chr2 214117454 G A 4.40E-05 Diabetic retinopathy / / 21441570 rs16850049 chr2 214118025 G T 1.38E-07 Multiple complex diseases / / 17554300 rs17362900 chr2 214118473 C G 4.40E-05 Diabetic retinopathy / / 21441570 rs17362920 chr2 214118499 T G 5.10E-05 Diabetic retinopathy / / 21441570 rs17362983 chr2 214118592 G A 4.30E-05 Diabetic retinopathy / / 21441570 rs16850055 chr2 214118734 A G 4.30E-05 Diabetic retinopathy / / 21441570 rs10184123 chr2 214120412 T C 6.00E-05 Diabetic retinopathy / / 21441570 rs17363242 chr2 214123685 C G 3.20E-05 Diabetic retinopathy / / 21441570 rs1219984 chr2 214133382 T C 3.30E-05 Diabetic retinopathy / / 21441570 rs10198138 chr2 214134615 T C 4.30E-05 Diabetic retinopathy / / 21441570 rs10169033 chr2 214137152 A G 4.20E-05 Diabetic retinopathy / / 21441570 rs1219973 chr2 214138425 T G 3.60E-05 Diabetic retinopathy / / 21441570 rs13416683 chr2 214138559 C T 4.10E-05 Diabetic retinopathy / / 21441570 rs13393868 chr2 214138770 A G 3.50E-05 Diabetic retinopathy / / 21441570 rs7581685 chr2 214138789 T C 1.75E-05 Fasting insulin (interaction) / / 24204828 rs7581685 chr2 214138789 T C 3.04E-05 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs1219972 chr2 214139065 A G 3.50E-05 Diabetic retinopathy / / 21441570 rs1219970 chr2 214139258 T C 3.50E-05 Diabetic retinopathy / / 21441570 rs13428264 chr2 214151720 G A 2.90E-05 Diabetic retinopathy SPAG16 intron 21441570 rs17298252 chr2 214153802 G T 2.80E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13401350 chr2 214154634 T C 3.30E-05 Diabetic retinopathy SPAG16 intron 21441570 rs9653340 chr2 214154726 C T 2.90E-05 Diabetic retinopathy SPAG16 intron 21441570 rs1488987 chr2 214158151 A G 2.70E-05 Diabetic retinopathy SPAG16 intron 21441570 rs975956 chr2 214161773 C T 2.40E-05 Diabetic retinopathy SPAG16 intron 21441570 rs1488988 chr2 214161849 C T 2.40E-05 Diabetic retinopathy SPAG16 intron 21441570 rs1219987 chr2 214162730 T G 3.78E-13 Multiple complex diseases SPAG16 intron 17554300 rs13422754 chr2 214169642 C T 2.40E-05 Diabetic retinopathy SPAG16 intron 21441570 rs11695933 chr2 214170625 A T 2.40E-05 Diabetic retinopathy SPAG16 intron 21441570 rs10203794 chr2 214171778 T C 2.40E-05 Diabetic retinopathy SPAG16 intron 21441570 rs2371890 chr2 214173451 G A 2.40E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13389980 chr2 214173563 A G 2.30E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13418276 chr2 214173587 G A 2.20E-05 Diabetic retinopathy SPAG16 intron 21441570 rs11678617 chr2 214174298 A G 2.10E-05 Diabetic retinopathy SPAG16 intron 21441570 rs7425349 chr2 214174519 C T 2.10E-05 Diabetic retinopathy SPAG16 intron 21441570 rs10498003 chr2 214174767 C T 2.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs10498004 chr2 214175270 C T 2.10E-05 Diabetic retinopathy SPAG16 intron 21441570 rs766258 chr2 214176980 G A 2.10E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13424627 chr2 214180831 G A 2.10E-05 Diabetic retinopathy SPAG16 intron 21441570 rs1043646 chr2 214182321 T G 2.10E-05 Diabetic retinopathy SPAG16 UTR-3 21441570 rs10210603 chr2 214183098 C A 2.10E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13384459 chr2 214183769 G A 3.60E-05 Diabetic retinopathy SPAG16 intron 21441570 rs11677851 chr2 214185900 C T 1.00E-05 Diabetic retinopathy SPAG16 intron 21441570 rs1012556 chr2 214189591 C A 1.40E-05 Diabetic retinopathy SPAG16 intron 21441570 rs10206666 chr2 214192212 C T 1.10E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13395064 chr2 214197366 G A 1.10E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13395079 chr2 214197488 C G 1.10E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13400851 chr2 214204084 G T 1.20E-05 Diabetic retinopathy SPAG16 intron 21441570 rs11688212 chr2 214208290 C A 4.00E-05 Diabetic retinopathy SPAG16 intron 21441570 rs7355430 chr2 214221925 G A 4.20E-05 Diabetic retinopathy SPAG16 intron 21441570 rs7355432 chr2 214222167 C T 4.20E-05 Diabetic retinopathy SPAG16 intron 21441570 rs10172140 chr2 214225606 C T 4.40E-05 Diabetic retinopathy SPAG16 intron 21441570 rs1488982 chr2 214227945 A G 4.30E-05 Diabetic retinopathy SPAG16 intron 21441570 rs1488981 chr2 214228020 T C 4.30E-05 Diabetic retinopathy SPAG16 intron 21441570 rs7589864 chr2 214231045 G T 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13414104 chr2 214234050 T C 4.30E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13411979 chr2 214237404 G A 4.20E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13411988 chr2 214237420 G T 4.20E-05 Diabetic retinopathy SPAG16 intron 21441570 rs4672679 chr2 214238530 G A 4.20E-05 Diabetic retinopathy SPAG16 intron 21441570 rs1387209 chr2 214241939 G A 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs10191191 chr2 214242433 G A 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs1844227 chr2 214244304 A G 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs11692490 chr2 214246268 G A 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs11682739 chr2 214247115 A G 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs1488978 chr2 214248686 G A 3.40E-05 Diabetic retinopathy SPAG16 intron 21441570 rs2130056 chr2 214255693 T A 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs17750222 chr2 214256618 T G 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs11682093 chr2 214258901 C T 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs11690986 chr2 214269693 C T 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs17694142 chr2 214269942 A G 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs11691151 chr2 214270027 C T 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs2634482 chr2 214271199 A G 4.50E-05 Diabetic retinopathy SPAG16 intron 21441570 rs16850304 chr2 214280525 A G 4.60E-05 Diabetic retinopathy SPAG16 intron 21441570 rs17750805 chr2 214280634 T G 4.60E-05 Diabetic retinopathy SPAG16 intron 21441570 rs2035694 chr2 214282132 T A 4.60E-05 Diabetic retinopathy SPAG16 intron 21441570 rs17750895 chr2 214284096 G A 4.70E-05 Diabetic retinopathy SPAG16 intron 21441570 rs13390905 chr2 214392651 T C 5.03E-04 Multiple complex diseases SPAG16 intron 17554300 rs12466426 chr2 214426720 G A 6.55E-05 Response to cytidine analogues (gemcitabine) SPAG16 intron 24483146 rs1400015 chr2 214462816 T G 5.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPAG16 intron 20877124 rs11683006 chr2 214483528 A C 1.11E-05 Fasting insulin (interaction) SPAG16 intron 24204828 rs11683006 chr2 214483528 A C 2.03E-05 Homeostasis model assessment of insulin resistance (interaction) SPAG16 intron 24204828 rs1515915 chr2 214527841 G A 8.39E-04 White matter integrity SPAG16 intron 22425255 rs2013922 chr2 214531723 C T 6.23E-06 Fasting insulin (interaction) SPAG16 intron 24204828 rs1028137 chr2 214535540 C G 3.43E-06 Fasting insulin (interaction) SPAG16 intron 24204828 rs1028137 chr2 214535540 C G 7.33E-06 Homeostasis model assessment of insulin resistance (interaction) SPAG16 intron 24204828 rs6707387 chr2 214548537 G A 1.00E-06 Homeostasis model assessment of insulin resistance (interaction) SPAG16 intron 24204828 rs6707387 chr2 214548537 G A 6.00E-07 Fasting insulin (interaction) SPAG16 intron 24204828 rs10165804 chr2 214575924 T G 1.11E-05 Fasting insulin (interaction) SPAG16 intron 24204828 rs10165804 chr2 214575924 T G 1.98E-05 Homeostasis model assessment of insulin resistance (interaction) SPAG16 intron 24204828 rs7597928 chr2 214592382 A G 1.44E-04 Alcohol dependence SPAG16 intron 21314694 rs2457183 chr2 214635332 G C 3.70E-04 Type 2 diabetes SPAG16 intron 17463246 rs2662683 chr2 214639706 T A 3.01E-04 Type 2 diabetes SPAG16 intron 17463246 rs11893486 chr2 214672291 C A 1.12E-04 Type 2 diabetes SPAG16 intron 17463246 rs6705746 chr2 214678340 G A 2.42E-04 Type 2 diabetes SPAG16 intron 17463246 rs1582839 chr2 214683214 G A 7.21E-04 Type 2 diabetes SPAG16 intron 17463246 rs10932501 chr2 214700768 C A 2.60E-04 Type 2 diabetes SPAG16 intron 17463246 rs11674163 chr2 214713451 A C 3.35E-04 Type 2 diabetes SPAG16 intron 17463246 rs4503943 chr2 214714975 G A 2.01E-04 Type 2 diabetes SPAG16 intron 17463246 rs10498015 chr2 214717579 C A 1.19E-04 Type 2 diabetes SPAG16 intron 17463246 rs10179905 chr2 214726239 T A 2.11E-04 Type 2 diabetes SPAG16 intron 17463246 rs2662676 chr2 214727997 G T 1.31E-05 Multiple complex diseases SPAG16 intron 17554300 rs16851125 chr2 214789988 C T 6.61E-04 Type 2 diabetes SPAG16 intron 17463246 rs4427965 chr2 214802528 C T 3.59E-04 Type 2 diabetes SPAG16 intron 17463246 rs11678221 chr2 214803693 A T 6.89E-04 Type 2 diabetes SPAG16 intron 17463246 rs9789347 chr2 214838513 G T 8.00E-06 Obesity-related traits SPAG16 intron 23251661 rs10498012 chr2 214861233 C T 1.80E-06 Urinary metabolites SPAG16 intron 21572414 rs4673801 chr2 214862848 G A 1.90E-06 Urinary metabolites SPAG16 intron 21572414 rs1397351 chr2 214867132 A G 5.16E-04 Amyotrophic Lateral Sclerosis SPAG16 intron 17362836 rs71428314 chr2 214904957 G T 2.37E-06 Contrast sensitivity SPAG16 intron 24152035 rs9288484 chr2 214907853 C G 4.07E-06 Contrast sensitivity SPAG16 intron 24152035 rs737690 chr2 214907914 T C 4.07E-06 Contrast sensitivity SPAG16 intron 24152035 rs17207375 chr2 214914721 C T 2.22E-06 Contrast sensitivity SPAG16 intron 24152035 rs1510552 chr2 214917402 A C 1.00E-06 Contrast sensitivity SPAG16 intron 24152035 rs2058991 chr2 214932580 A G 1.37E-04 Response to taxane treatment (placlitaxel) SPAG16 intron 23006423 rs6715771 chr2 214940734 T C 2.02E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) SPAG16 intron 23648065 rs6715771 chr2 214940734 T C 6.46E-06 Contrast sensitivity SPAG16 intron 24152035 rs2080776 chr2 214956523 C T 9.03E-04 Response to cytadine analogues (cytosine arabinoside) SPAG16 intron 24483146 rs10514628 chr2 214966973 G C 5.10E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SPAG16 intron 21844884 rs4541202 chr2 214969001 C T 5.04E-04 Response to cytadine analogues (cytosine arabinoside) SPAG16 intron 24483146 rs2161022 chr2 214993997 G A 1.46E-04 Type 2 diabetes SPAG16 intron 17463246 rs7597126 chr2 215009358 T C 5.12E-05 Blood Pressure SPAG16 intron pha003039 rs7597126 chr2 215009358 T C 4.35E-05 Blood Pressure SPAG16 intron pha003045 rs16851532 chr2 215018724 A C 4.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPAG16 intron 20877124 rs16851554 chr2 215024392 T G 2.46E-05 Response to acetaminophen (hepatotoxicity) SPAG16 intron 21177773 rs2372227 chr2 215034435 C A 5.34E-04 Stroke SPAG16 intron pha002887 rs2161082 chr2 215046533 A G 4.07E-05 Cytomegalovirus antibody response SPAG16 intron 21993531 rs10190431 chr2 215048212 T C 1.66E-05 Cytomegalovirus antibody response SPAG16 intron 21993531 rs1912196 chr2 215050520 G T 6.23E-05 Cognitive test performance SPAG16 intron 20125193 rs11887857 chr2 215052524 G A 1.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPAG16 intron 20877124 rs12617276 chr2 215061093 G T 6.80E-05 Cytomegalovirus antibody response SPAG16 intron 21993531 rs16851611 chr2 215081910 C T 4.03E-04 Coronary Artery Disease SPAG16 intron 17634449 rs13404035 chr2 215121966 T C 2.00E-05 Melanoma SPAG16 intron 24980573 rs10932529 chr2 215144720 G A 2.02E-04 Myocardial Infarction SPAG16 intron pha002873 rs6731110 chr2 215179277 C A 4.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPAG16 intron 20877124 rs6731110 chr2 215179277 C A 9.24E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) SPAG16 intron 23648065 rs1912169 chr2 215181488 T G 1.00E-04 Cognitive impairment induced by topiramate SPAG16 intron 22091778 rs2216544 chr2 215182877 G A 6.29E-04 Myocardial Infarction SPAG16 intron pha002873 rs16851771 chr2 215188619 A G 2.00E-06 Obesity-related traits SPAG16 intron 23251661 rs1912185 chr2 215194668 T G 4.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPAG16 intron 20877124 rs4673821 chr2 215243815 T C 4.45E-04 Schizophrenia(treatment response to risperidone) SPAG16 intron 19850283 rs4286276 chr2 215264826 T C 5.11E-04 Tourette syndrome SPAG16 intron 22889924 rs13428663 chr2 215285651 A G 2.86E-05 Dilated cardiomyopathy VWC2L intron 23853074 rs7563874 chr2 215325694 T C 6.24E-04 Response to taxane treatment (placlitaxel) VWC2L intron 23006423 rs4673828 chr2 215330568 C T 6.83E-05 Coronary Artery Disease VWC2L intron 17634449 rs11897844 chr2 215334760 G A 7.66E-04 Tourette syndrome VWC2L intron 22889924 rs7604827 chr2 215341890 C T 5.00E-06 PR interval VWC2L intron 23534349 rs7604827 chr2 215341890 C T 2.62E-04 Celiac disease VWC2L intron 23936387 rs13425618 chr2 215350167 A G 8.80E-04 Alcohol dependence VWC2L intron 20201924 rs4629153 chr2 215356938 C T 3.80E-04 Alcohol dependence VWC2L intron 20201924 rs4629153 chr2 215356938 C T 3.80E-04 Alcohol dependence VWC2L intron 20201924 rs9288497 chr2 215370052 A G 3.20E-04 Alcohol dependence VWC2L intron 20201924 rs9288497 chr2 215370052 A G 5.80E-04 Alcohol dependence VWC2L intron 20201924 rs11886252 chr2 215382534 C T 5.77E-04 Multiple complex diseases VWC2L intron 17554300 rs6435833 chr2 215433565 A T 1.24E-05 Biliary atresia VWC2L intron 20460270 rs7425848 chr2 215458633 T C 1.98E-05 Biliary atresia / / 20460270 rs13009173 chr2 215515382 T C 0.000103 Salmonella-induced pyroptosis / / 22837397 rs12615863 chr2 215561552 C T 6.67E-05 Alzheimer's disease / / 17998437 rs12615863 chr2 215561552 C T 4.46E-05 Alzheimer's disease / / pha002879 rs1914516 chr2 215561933 T C 3.61E-05 Alzheimer's disease / / 17998437 rs1914516 chr2 215561933 T C 1.42E-05 Alzheimer's disease / / pha002879 rs1517796 chr2 215564323 G A 5.06E-04 Alzheimer's disease / / 17998437 rs1979028 chr2 215592906 T A 1.16E-04 Multiple complex diseases BARD1 nearGene-3 17554300 rs12614960 chr2 215595512 C T 1.07E-04 Multiple complex diseases BARD1 intron 17554300 rs16852600 chr2 215595645 C T 1.92E-04 Multiple complex diseases BARD1 intron 17554300 rs16852600 chr2 215595645 C T 1.40E-07 Neuroblastoma (high-risk) BARD1 intron 19412175 rs16852600 chr2 215595645 C T 6.83E-05 Neuroblastoma BARD1 intron pha002895 rs16852600 chr2 215595645 C T 3.64E-05 Coronary heart disease BARD1 intron pha003030 rs16852600 chr2 215595645 C T 5.87E-05 Coronary heart disease BARD1 intron pha003031 rs895459 chr2 215600257 G A 7.82E-07 Neuroblastoma (high-risk) BARD1 intron 19412175 rs895459 chr2 215600257 G A 1.11E-05 Neuroblastoma BARD1 intron pha002895 rs10183009 chr2 215602074 G T 3.57E-04 Multiple complex diseases BARD1 intron 17554300 rs2053710 chr2 215616708 C T 5.77E-04 Amyotrophic Lateral Sclerosis BARD1 intron 17362836 rs2053710 chr2 215616708 C T 2.56E-07 Neuroblastoma (high-risk) BARD1 intron 19412175 rs2053710 chr2 215616708 C T 1.62E-06 Neuroblastoma BARD1 intron pha002895 rs1374230 chr2 215618779 A G 1.34E-04 Multiple complex diseases BARD1 intron 17554300 rs1374230 chr2 215618779 A G 1.10E-07 Neuroblastoma (high-risk) BARD1 intron 19412175 rs1374230 chr2 215618779 A G 1.62E-05 Neuroblastoma BARD1 intron pha002895 rs10221582 chr2 215623390 C T 2.36E-05 Multiple complex diseases BARD1 intron 17554300 rs10932572 chr2 215627397 A G 1.20E-04 Amyotrophic Lateral Sclerosis BARD1 intron 17362836 rs10932572 chr2 215627397 A G 2.80E-09 Neuroblastoma (high-risk) BARD1 intron 19412175 rs10932572 chr2 215627397 A G 2.84E-05 Neuroblastoma BARD1 intron pha002895 rs7584646 chr2 215629322 A G 2.50E-10 Neuroblastoma (high-risk) BARD1 intron 19412175 rs7584646 chr2 215629322 A G 3.73E-05 Neuroblastoma BARD1 intron pha002895 rs6706777 chr2 215629543 G C 1.48E-05 Multiple complex diseases BARD1 intron 17554300 rs7599060 chr2 215631302 G A 3.79E-05 Multiple complex diseases BARD1 intron 17554300 rs11685215 chr2 215633624 C T 4.63E-04 Amyotrophic lateral sclerosis (sporadic) BARD1 intron 24529757 rs7557557 chr2 215634627 C T 2.79E-08 Neuroblastoma (high-risk) BARD1 intron 19412175 rs7557557 chr2 215634627 C T 1.42E-06 Neuroblastoma BARD1 intron pha002895 rs3768716 chr2 215635794 T C 1.62E-14 Neuroblastoma (high-risk) BARD1 intron 19412175 rs3768716 chr2 215635794 T C 5.00E-13 Neuroblastoma BARD1 intron 21124317 rs3768716 chr2 215635794 T C 7.25E-13 Neuroblastoma BARD1 intron pha002895 rs17487792 chr2 215643500 C T 1.82E-14 Neuroblastoma (high-risk) BARD1 intron 19412175 rs17487792 chr2 215643500 C T 1.35E-12 Neuroblastoma BARD1 intron pha002895 rs7587476 chr2 215653887 T C 8.61E-13 Neuroblastoma (high-risk) BARD1 intron 19412175 rs7587476 chr2 215653887 T C 4.00E-14 Neuroblastoma BARD1 intron 22941191 rs7587476 chr2 215653887 T C 3.05E-13 Neuroblastoma BARD1 intron pha002895 rs6712055 chr2 215666904 T C 5.17E-12 Neuroblastoma (high-risk) BARD1 intron 19412175 rs6712055 chr2 215666904 T C 2.17E-09 Neuroblastoma BARD1 intron pha002895 rs16852802 chr2 215672041 T C 8.50E-04 Multiple complex diseases BARD1 intron 17554300 rs6435862 chr2 215672546 G T 9.00E-18 Neuroblastoma (high-risk) BARD1 intron 19412175 rs6435862 chr2 215672546 G T 9.00E-18 Nasopharyngeal carcinoma BARD1 intron 20512145 rs6435862 chr2 215672546 G T 2.93E-09 Neuroblastoma BARD1 intron pha002895 rs6715570 chr2 215673440 T C 1.02E-12 Neuroblastoma (high-risk) BARD1 intron 19412175 rs6715570 chr2 215673440 T C 1.21E-09 Neuroblastoma BARD1 intron pha002895 rs6744811 chr2 215677308 A C 1.30E-09 Neuroblastoma (high-risk) / / 19412175 rs6744811 chr2 215677308 A C 4.72E-07 Neuroblastoma / / pha002895 rs2121283 chr2 215710338 C T 4.19E-06 Neuroblastoma / / pha002895 rs1026020 chr2 215715707 A G,T 4.74E-05 Serum metabolites / / 19043545 rs11677798 chr2 215724550 C T 2.38E-06 Neuroblastoma / / pha002895 rs2592232 chr2 215725751 G A 8.87E-10 Neuroblastoma / / pha002895 rs10498025 chr2 215749256 A G 5.45E-11 Neuroblastoma / / pha002895 rs10498026 chr2 215749350 G A 9.69E-09 Neuroblastoma / / pha002895 rs7560809 chr2 215758159 A C 4.21E-04 Multiple complex diseases / / 17554300 rs1952224 chr2 215772412 G A 1.77E-05 Neuroblastoma / / pha002895 rs6737675 chr2 215780700 A G 3.20E-04 Multiple complex diseases / / 17554300 rs10204986 chr2 215790001 T G 8.07E-05 Meningococcal disease / / 20694013 rs7578759 chr2 215798408 A G 9.43E-05 Personality dimensions ABCA12 intron 18957941 rs1409612 chr2 215800710 G A 8.70E-04 Multiple complex diseases ABCA12 intron 17554300 rs1409612 chr2 215800710 G A 2.80E-05 Urinary metabolites ABCA12 intron 21572414 rs10498027 chr2 215820013 G A 1.99E-04 Multiple complex diseases ABCA12 cds-synon 17554300 rs4673925 chr2 215833415 A G 3.50E-04 Alcohol dependence ABCA12 intron 20201924 rs6756540 chr2 215833622 G T 6.10E-04 Alcohol dependence ABCA12 intron 20201924 rs1464678 chr2 215834466 A G 2.50E-04 Alcohol dependence ABCA12 intron 20201924 rs3795857 chr2 215834676 A G 3.10E-04 Alcohol dependence ABCA12 intron 20201924 rs3795857 chr2 215834676 A G 5.80E-06 Neuroblastoma ABCA12 intron pha002895 rs17493319 chr2 215840414 C A 6.95E-04 Multiple complex diseases ABCA12 intron 17554300 rs7579031 chr2 215843954 C T 7.70E-04 Response to cytidine analogues (gemcitabine) ABCA12 intron 24483146 rs13385378 chr2 215883362 A G 9.15E-06 PR interval in Tripanosoma cruzi seropositivity ABCA12 intron 24324551 rs10210200 chr2 215929125 G A 2.00E-06 PR interval in Tripanosoma cruzi seropositivity ABCA12 intron 24324551 rs2372479 chr2 215942490 T G 1.98E-04 Response to cytidine analogues (gemcitabine) ABCA12 intron 24483146 rs1880130 chr2 215947252 A G 2.38E-04 Response to cytidine analogues (gemcitabine) ABCA12 intron 24483146 rs13014763 chr2 216009353 C A 1.90E-05 Urinary metabolites / / 21572414 rs7557923 chr2 216009374 T C 2.20E-05 Urinary metabolites / / 21572414 rs1004301 chr2 216010390 C T 1.30E-05 Urinary metabolites / / 21572414 rs4673965 chr2 216106637 G A 1.34E-04 Age-related macular degeneration / / 22125219 rs16853680 chr2 216137978 A C 3.56E-04 Smoking quantity / / 24665060 rs2372536 chr2 216190020 C G 1 Drug response to Methotrexate ATIC missense 15457444 rs2372536 chr2 216190020 C G 1 Drug response to Methotrexate ATIC missense 15677700 rs2372536 chr2 216190020 C G 1 Drug response to Folic Acid ATIC missense 19016697 rs2372536 chr2 216190020 C G 1 Drug response to Methotrexate ATIC missense 19016697 rs6757920 chr2 216205267 A G 9.60E-05 Height ATIC intron pha003011 rs6728999 chr2 216235046 C T 3.43E-10 Triglycerides FN1 missense 23063622 rs13414859 chr2 216243342 A C 0.000012 HDL cholesterol FN1 intron 23063622 rs1561302 chr2 216260298 A G 0.0000046 HDL cholesterol FN1 intron 23063622 rs17457029 chr2 216272514 G A 0.0000124 HDL cholesterol FN1 intron 23063622 rs17458018 chr2 216285375 T C 7.00E-06 Coronary heart disease FN1 intron 22319020 rs1250248 chr2 216287093 A G 1.70E-05 Endometriosis FN1 intron 21151130 rs13423742 chr2 216287796 C G 0.0000164 Nonsyndromic striae distensae (stretch marks) FN1 intron 23633020 rs1837121 chr2 216292331 G A 0.00000919 Nonsyndromic striae distensae (stretch marks) FN1 intron 23633020 rs7609476 chr2 216294016 C A 0.0000131 Nonsyndromic striae distensae (stretch marks) FN1 intron 23633020 rs1250239 chr2 216294957 C G 0.00000852 Nonsyndromic striae distensae (stretch marks) FN1 intron 23633020 rs1250240 chr2 216295014 A G 0.0000118 Nonsyndromic striae distensae (stretch marks) FN1 intron 23633020 rs1250241 chr2 216295312 T A 0.0000183 Nonsyndromic striae distensae (stretch marks) FN1 intron 23633020 rs7586990 chr2 216295337 A G 0.0000275 HDL cholesterol FN1 intron 23063622 rs1250242 chr2 216296257 G C 0.00000923 Nonsyndromic striae distensae (stretch marks) FN1 intron 23633020 rs1250247 chr2 216299629 C G 0.00000745 Nonsyndromic striae distensae (stretch marks) FN1 intron 23633020 rs1250258 chr2 216300185 C T 0.00000151 Nonsyndromic striae distensae (stretch marks) FN1 intron 23633020 rs1250259 chr2 216300482 T A 0.000000901 Nonsyndromic striae distensae (stretch marks) FN1 missense 23633020 rs4473378 chr2 216303005 T C 0.0000937 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs3910516 chr2 216303053 A G 0.000000267 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1250229 chr2 216304384 T C 0.000000502 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1250229 chr2 216304384 T C 3.00E-08 LDL cholesterol / / 24097068 rs1250231 chr2 216305834 G A 0.000000498 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1250232 chr2 216306635 C T 0.000000485 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1250234 chr2 216308148 C T 0.00000353 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7423688 chr2 216308221 C T 0.0000258 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1250255 chr2 216316487 C T 0.00000685 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1250255 chr2 216316487 C T 3.21E-05 Breast cancer / / pha002853 rs1437787 chr2 216318237 T C 2.67E-06 Esophageal cancer (squamous cell) / / 22960999 rs10498039 chr2 216325768 C T 3.20E-04 Asthma / / 20698975 rs1561299 chr2 216339259 T C 9.43E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1561299 chr2 216339259 T C 4.15E-05 Relative hand skill / / 24068947 rs1437793 chr2 216364035 T C 1.84E-04 Heart Failure / / pha002885 rs1898716 chr2 216465787 C T 7.59E-04 Type 2 diabetes / / 17463246 rs10932621 chr2 216476038 G C 2.26E-04 Multiple complex diseases / / 17554300 rs11891673 chr2 216477172 G A 2.70E-06 Urinary metabolites / / 21572414 rs2579013 chr2 216517083 A G 9.72E-05 Socioeconomic Factors LOC646324 intron pha003067 rs10932623 chr2 216517945 G T 2.40E-05 Urinary metabolites LOC646324 intron 21572414 rs2678286 chr2 216526011 A G 2.40E-05 Urinary metabolites LOC646324 intron 21572414 rs869141 chr2 216534383 C G 7.17E-04 Multiple complex diseases LOC646324 intron 17554300 rs4672777 chr2 216555565 C G 5.88E-04 Type 2 diabetes LOC646324 intron 17463246 rs10932626 chr2 216627933 G T 2.93E-06 Smoking initiation LOC646324 intron 24665060 rs4674024 chr2 216631366 C T 1.52E-06 Smoking initiation LOC646324 intron 24665060 rs4674024 chr2 216631366 C T 2.00E-06 Smoking initiation LOC646324 intron 24665060 rs4257398 chr2 216758854 A G 3.99E-04 Myocardial Infarction / / pha002873 rs934152 chr2 216831098 T A 4.11E-04 Insulin resistance MREG intron 21901158 rs3770535 chr2 216838699 T C 2.07E-04 Cognitive decline MREG intron 23732972 rs3770542 chr2 216847151 A T 5.89E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MREG intron 22566498 rs3770549 chr2 216860550 A T 3.00E-06 Blood trace element (Se levels) MREG intron 23720494 rs3770560 chr2 216866439 G A 1.75E-04 Alzheimer's disease (late onset) MREG intron 21379329 rs13410982 chr2 216868598 C G 1.05E-05 Aging (time to event) MREG intron 21782286 rs4672790 chr2 216892446 C T 1.41E-04 Breast cancer / / 21060860 rs1344694 chr2 216893637 T G 1.47E-05 Alcohol dependence / / 19581569 rs1344694 chr2 216893637 T G 5.00E-06 Alcohol dependence / / 22004471 rs7590720 chr2 216898658 G A 1.00E-08 Alcohol dependence / / 19581569 rs934154 chr2 216901933 C T 4.20E-05 Eating disorders (purging via substances) / / 23568457 rs705648 chr2 216933792 C T 6.17E-05 Alcohol dependence PECR intron 19581569 rs17548312 chr2 216951247 A G 5.98E-05 Coronary heart disease TMEM169 intron pha003055 rs10166817 chr2 216982691 T C 7.78E-05 Cognitive test performance XRCC5 intron 20125193 rs828704 chr2 216993611 C A 6.40E-05 Coronary heart disease XRCC5 intron pha003055 rs13006837 chr2 217059254 G A 2.00E-06 Urinary metabolites XRCC5 intron 21572414 rs16855635 chr2 217067347 G T 5.71E-04 Multiple complex diseases XRCC5 intron 17554300 rs380919 chr2 217153080 C T 1.50E-05 Urinary metabolites MARCH4 intron 21572414 rs440866 chr2 217153197 G A 2.60E-05 Urinary metabolites MARCH4 intron 21572414 rs6705793 chr2 217155206 C T 4.18E-04 Type 2 diabetes MARCH4 intron 17463246 rs955816 chr2 217199624 A G 2.34E-05 Anxiety in major depressive disorder MARCH4 intron 24047446 rs6756590 chr2 217208571 C T 1.00E-06 Migraine MARCH4 intron 22683712 rs907171 chr2 217237803 A T 7.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs705657 chr2 217241528 G C 8.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs11687270 chr2 217246055 G A 4.20E-05 Iron levels / / 21208937 rs2243956 chr2 217252118 G T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs925540 chr2 217252898 A G 8.46E-04 Multiple complex diseases / / 17554300 rs12615939 chr2 217258369 T A 1.48E-06 Multiple complex diseases / / 17554300 rs11888959 chr2 217326879 T C 4.54E-05 Serum metabolites SMARCAL1 intron 19043545 rs284531 chr2 217333174 C G 9.54E-05 Serum metabolites SMARCAL1 intron 19043545 rs3755140 chr2 217363049 C T 0.00064509 Hypertension (early onset hypertension) LOC100507554 intron 22479346 rs3755140 chr2 217363049 C T 7.14E-04 Smoking initiation LOC100507554 intron 24665060 rs2272243 chr2 217364764 G T 0.000782021 Hypertension (early onset hypertension) RPL37A intron 22479346 rs922987 chr2 217411246 T C 2.40E-04 Iris characteristics / / 21835309 rs1949872 chr2 217443802 C T 9.80E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs940794 chr2 217456567 T G 6.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7590938 chr2 217463442 A G 2.47E-05 Schizophrenia / / 19571809 rs10932667 chr2 217469796 A G 4.96E-05 Coronary heart disease / / pha003032 rs9288520 chr2 217481271 G A 4.00E-11 Esophageal cancer (alcohol interaction) / / 22960999 rs6733115 chr2 217488954 T C 5.30E-04 Multiple complex diseases / / 17554300 rs6733115 chr2 217488954 T C 2.43E-06 Asthma (childhood onset) / / 23829686 rs9341145 chr2 217511100 C T 3.99E-07 Glaucoma-related traits / / 22058429 rs7422089 chr2 217532139 C T 9.32E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2241193 chr2 217554213 T C 1.00E-07 Visceral fat IGFBP5 intron 22589738 rs888185 chr2 217570723 T G 3.88E-04 Alzheimer's disease / / 22005930 rs888184 chr2 217570766 A G 3.83E-04 Alzheimer's disease / / 22005930 rs2372865 chr2 217570995 T C 3.87E-04 Alzheimer's disease / / 22005930 rs888182 chr2 217571845 T G 4.38E-04 Alzheimer's disease / / 22005930 rs12473011 chr2 217573408 T G 7.12E-04 Alzheimer's disease / / 22005930 rs16856529 chr2 217573692 A C 6.43E-04 Alzheimer's disease / / 22005930 rs7557921 chr2 217574217 A G 7.15E-04 Alzheimer's disease / / 22005930 rs6757568 chr2 217575726 T C 7.10E-04 Alzheimer's disease / / 22005930 rs11676402 chr2 217596250 T C 6.81E-04 Aortic root size / / 21223598 rs2712170 chr2 217619858 G A,T 4.46E-04 Multiple complex diseases / / 17554300 rs13015993 chr2 217625523 G A 2.00E-07 Thyroid hormone levels / / 23408906 rs13015993 chr2 217625523 G A 3.00E-15 Thyroid hormone levels / / 23408906 rs13015993 chr2 217625523 G A 8.00E-11 Thyroid hormone levels / / 23408906 rs4674113 chr2 217638521 T C 1.14E-04 Schizophrenia / / 20832056 rs7421283 chr2 217640818 C T 2.90E-04 Alcohol dependence / / 21314694 rs16856673 chr2 217714625 T C 8.18E-04 Multiple complex diseases / / 17554300 rs10178069 chr2 217720468 A G 1.20E-05 Urinary metabolites / / 21572414 rs1179688 chr2 217749691 T G 2.80E-05 Urinary metabolites / / 21572414 rs1179683 chr2 217751546 A G 7.26E-04 Alzheimer's disease / / 17998437 rs41509447 chr2 217753980 T C 3.23E-06 Alzheimer's disease / / 17998437 rs1179697 chr2 217759516 T C 7.90E-06 Urinary metabolites / / 21572414 rs1179692 chr2 217761884 A G 3.97E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7589256 chr2 217775937 C T 2.30E-05 Urinary metabolites / / 21572414 rs1179669 chr2 217780457 G T 8.41E-04 Multiple complex diseases / / 17554300 rs10932682 chr2 217787536 C T 4.29E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17776232 chr2 217826219 T C 3.45E-04 Taste perception / / 22132133 rs2372928 chr2 217827849 A G 5.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs10932688 chr2 217863481 C G 2.90E-04 Primary tooth development (time to first tooth eruption) / / 23704328 rs10932688 chr2 217863481 C G 3.00E-08 Primary tooth development (number of teeth) / / 23704328 rs6435957 chr2 217878209 T C 4.00E-07 Primary tooth development (number of teeth) / / 20195514 rs6435957 chr2 217878209 T C 4.66E-09 Permanent tooth development / / 21931568 rs4491709 chr2 217894756 T C 2.00E-14 Permanent tooth development / / 21931568 rs6435958 chr2 217896612 A G 1.34E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7564605 chr2 217898088 T C 2.29E-04 Response to TNF antagonist treatment / / 21061259 rs6735174 chr2 217900280 A C 4.33E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13387042 chr2 217905832 A G 1.00E-13 Breast cancer / / 17529974 rs13387042 chr2 217905832 A G 2.00E-08 Breast cancer / / 19330030 rs13387042 chr2 217905832 A G 2.00E-10 Breast cancer / / 20453838 rs13387042 chr2 217905832 A G 1.00E-13 Nasopharyngeal carcinoma / / 20512145 rs13387042 chr2 217905832 A G 9.00E-06 Breast cancer / / 20872241 rs13387042 chr2 217905832 A G 2.00E-10 Breast cancer / / 21263130 rs13387042 chr2 217905832 A G 5.49E-04 Permanent tooth development / / 21931568 rs13387042 chr2 217905832 A G 2.00E-57 Breast cancer / / 23535729 rs4621152 chr2 217908985 T C 4.58E-05 Schizophrenia / / 19571811 rs13000023 chr2 217924394 G A 3.36E-04 Type 2 diabetes / / 17463246 rs13011060 chr2 217938177 G A 1.50E-04 Breast cancer / / pha002853 rs6739040 chr2 217951726 A G 1.39E-06 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs2372965 chr2 217967717 C A 6.72E-05 Serum selenium levels / / 23698163 rs2372967 chr2 217967913 T C 6.72E-05 Serum selenium levels / / 23698163 rs3843337 chr2 217969435 A G 6.04E-05 Serum selenium levels / / 23698163 rs2372972 chr2 217971141 T C 8.94E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs2372972 chr2 217971141 T C 3.58E-05 Serum selenium levels / / 23698163 rs9677455 chr2 217972252 A C 3.73E-05 Serum selenium levels / / 23698163 rs13015994 chr2 217974444 A C 2.08E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs12466929 chr2 217980433 G A 1.50E-04 Premature ovarian failure / / 19508998 rs12466929 chr2 217980433 G A 1.45E-04 Vaspin levels / / 22907691 rs12466929 chr2 217980433 G A 0.0001454 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs12466929 chr2 217980433 G A 1.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs1344723 chr2 218050827 A C 4.07E-04 Smoking cessation / / 24665060 rs1583111 chr2 218065917 G A 5.16E-04 Smoking cessation / / 24665060 rs12623903 chr2 218073392 T C 3.83E-04 Smoking cessation / / 24665060 rs13012936 chr2 218074070 A G 5.63E-04 Smoking cessation / / 24665060 rs13013676 chr2 218074128 G C 1.08E-04 Smoking cessation / / 24665060 rs12477810 chr2 218081443 G A 5.06E-05 Smoking cessation / / 24665060 rs2553038 chr2 218090609 C T 1.20E-05 Urinary metabolites / / 21572414 rs2115862 chr2 218095054 G C 7.00E-06 Height / / 21998595 rs2553034 chr2 218097054 G A 8.62E-05 Smoking cessation / / 24665060 rs1609871 chr2 218108789 G A 1.94E-04 Acute lung injury / / 22295056 rs2565689 chr2 218110548 T A 6.20E-06 Height / / 21998595 rs2113827 chr2 218111310 C T 9.10E-08 Height / / 21998595 rs2565688 chr2 218111701 T A 3.70E-07 Height / / 21998595 rs2553028 chr2 218117956 C G 7.30E-07 Height / / 21998595 rs1549738 chr2 218118722 G A 4.88E-05 Nicotine smoking / / 19268276 rs2553027 chr2 218121610 C T 2.60E-07 Height / / 21998595 rs11684828 chr2 218122764 A G 2.22E-04 Smoking cessation / / 24665060 rs2553026 chr2 218123648 G A 6.00E-08 Height / / 21998595 rs10490757 chr2 218126236 T C 2.77E-04 Smoking cessation / / 24665060 rs1863190 chr2 218128152 A T 1.60E-07 Height / / 21998595 rs10490758 chr2 218139894 C G 1.80E-04 Smoking cessation / / 24665060 rs2888479 chr2 218139904 G A 2.62E-04 Coronary Artery Disease / / 17634449 rs4356643 chr2 218145931 C G 9.82E-05 Coronary Artery Disease / / 17634449 rs13412710 chr2 218149159 A G 5.43E-05 Smoking cessation / / 24665060 rs1863189 chr2 218153015 C T 6.06E-04 Smoking cessation DIRC3 intron 24665060 rs2888481 chr2 218161392 G A 7.83E-04 Alzheimer's disease DIRC3 intron 22005930 rs13425869 chr2 218171660 T C 5.27E-04 Alzheimer's disease DIRC3 intron 22005930 rs4674159 chr2 218223023 T C 6.97E-04 Type 2 diabetes DIRC3 intron 17463246 rs6724073 chr2 218236786 T C 9.00E-04 Multiple complex diseases DIRC3 intron 17554300 rs16857473 chr2 218258530 T C 9.38E-04 Multiple complex diseases DIRC3 intron 17554300 rs10932715 chr2 218259783 T C 3.86E-04 Aortic root size DIRC3 intron 21223598 rs6759952 chr2 218271719 T C 6.00E-10 Thyroid cancer DIRC3 intron 23894154 rs1351164 chr2 218271898 T C 2.00E-14 Height DIRC3 intron 20881960 rs12694415 chr2 218289357 G A 7.84E-04 Multiple complex diseases DIRC3 intron 17554300 rs1478579 chr2 218291524 C T 5.89E-04 Aortic root size DIRC3 intron 21223598 rs1478581 chr2 218292652 G A 1.83E-04 Aortic root size DIRC3 intron 21223598 rs13388294 chr2 218295406 G A 4.13E-05 Thyroid cancer DIRC3 intron 23894154 rs1382435 chr2 218296003 T C 7.16E-06 Thyroid cancer DIRC3 intron 23894154 rs13004333 chr2 218296141 C G 2.72E-04 Multiple complex diseases DIRC3 intron 17554300 rs16857609 chr2 218296508 C T 1.00E-15 Breast cancer DIRC3 intron 23535729 rs16857609 chr2 218296508 C T 1.00E-04 Breast cancer DIRC3 intron 23535733 rs966423 chr2 218310340 C T 1.00E-09 Thyroid cancer DIRC3 intron 22267200 rs11689435 chr2 218314253 C T 4.00E-06 Metabolite levels (MHPG) DIRC3 intron 23319000 rs370140661 chr2 218314253 CGT C 4.00E-06 Metabolite levels (MHPG) DIRC3 intron 23319000 rs874840 chr2 218354130 C T 3.92E-04 Disc degeneration (lumbar) DIRC3 intron 24216480 rs12472818 chr2 218358312 T C 1.93E-04 Amyotrophic lateral sclerosis (sporadic) DIRC3 intron 24529757 rs4674189 chr2 218413982 C T 9.28E-05 Diabetes Mellitus DIRC3 intron pha003059 rs16857851 chr2 218418350 A G 4.91E-05 Taste perception DIRC3 intron 22132133 rs7585421 chr2 218421136 T C 7.69E-04 Aortic root size DIRC3 intron 21223598 rs4674192 chr2 218429292 C T 5.61E-04 Aortic root size DIRC3 intron 21223598 rs6714500 chr2 218438843 C T 3.25E-05 Cognitive test performance DIRC3 intron 20125193 rs6714500 chr2 218438843 C T 1.10E-05 Urinary metabolites DIRC3 intron 21572414 rs6733585 chr2 218512598 A G 5.48E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) DIRC3 intron 23648065 rs7578283 chr2 218517719 C T 3.20E-06 Height DIRC3 intron 21998595 rs6435999 chr2 218523162 A G 7.00E-07 Height DIRC3 intron 21998595 rs6761086 chr2 218543430 T C 1.90E-06 Height DIRC3 intron 21998595 rs934241 chr2 218563466 G A 8.40E-05 Calcium levels DIRC3 intron pha003085 rs2373146 chr2 218638176 T C 7.22E-04 Insulin resistance / / 21901158 rs11676172 chr2 218647122 T C 1.18E-04 Coronary heart disease / / 21606135 rs768921 chr2 218663979 G A 9.88E-05 Glucose levels / / pha003058 rs768921 chr2 218663979 G A 2.99E-05 Diabetes Mellitus / / pha003060 rs76043829 chr2 218677586 G A 6.00E-07 Asthma and hay fever TNS1 intron 24388013 rs2571445 chr2 218683154 A G 1.00E-12 Pulmonary function TNS1 missense 20010834 rs2571445 chr2 218683154 A G 0.0000339 Coronary artery disease TNS1 missense 23202125 rs2571445 chr2 218683154 A G 8.00E-09 Pulmonary function (interaction) TNS1 missense 23284291 rs2571445 chr2 218683154 A G 3.38E-04 Heart Failure TNS1 missense pha002885 rs11897815 chr2 218690487 T C 8.26E-04 Coronary Artery Disease TNS1 intron 17634449 rs2571440 chr2 218695686 T C 7.59E-05 Blood Pressure TNS1 intron pha003039 rs11677276 chr2 218696949 G A 3.97E-04 Blood pressure (response to calcium channel blocker) TNS1 intron 24192120 rs2059409 chr2 218720042 C T 1.08E-04 Age-related macular degeneration TNS1 intron 22125219 rs3791966 chr2 218720268 G A 2.73E-04 Age-related macular degeneration TNS1 intron 22125219 rs3791950 chr2 218729865 C A 2.00E-06 Height TNS1 intron 21998595 rs1863133 chr2 218732208 T C 4.90E-06 Height TNS1 intron 21998595 rs2042542 chr2 218736292 A G 9.25E-05 HIV-1 viral setpoint TNS1 intron 22174851 rs1424916 chr2 218739300 T C 2.60E-05 Height TNS1 intron 21998595 rs11898107 chr2 218744803 C T 3.61E-04 Multiple complex diseases TNS1 intron 17554300 rs7421896 chr2 218745862 A G 3.59E-05 Age-related macular degeneration TNS1 intron 22125219 rs10174633 chr2 218754326 T C 1.57E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) TNS1 intron 23648065 rs16858462 chr2 218783532 G C 1.36E-04 Multiple complex diseases TNS1 intron 17554300 rs3791919 chr2 218783751 A G 8.10E-06 Urinary metabolites TNS1 intron 21572414 rs16858496 chr2 218824450 G A 1.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs11892423 chr2 218824573 C T 1.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs11904083 chr2 218824711 A G 1.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs16858509 chr2 218825607 G C 1.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs11688938 chr2 218827778 G A 3.07E-04 Multiple complex diseases / / 17554300 rs16858515 chr2 218828035 G T 1.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs881745 chr2 218846455 C G 3.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs934039 chr2 218853391 G A 3.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs1001098 chr2 218862241 C T 7.33E-04 Alcohol dependence / / 20201924 rs6712327 chr2 218864319 T C 2.75E-04 Multiple complex diseases / / 17554300 rs13389420 chr2 218866036 T C 9.73E-04 Multiple complex diseases / / 17554300 rs934036 chr2 218869388 A G 6.23E-05 Major depressive disorder (broad) / / 20038947 rs876961 chr2 218880952 A G 9.06E-05 Soluble levels of adhesion molecules / / pha003072 rs7580997 chr2 218883186 C T 1.24E-05 Colorectal cancer / / 21242260 rs1427667 chr2 218894127 C T 7.57E-07 Colorectal cancer / / 21242260 rs4672870 chr2 218941916 C T 6.57E-05 Colorectal cancer RUFY4 intron 23266556 rs12694425 chr2 218942313 C T 6.58E-05 Colorectal cancer RUFY4 intron 23266556 rs12694426 chr2 218942351 T G 6.67E-05 Colorectal cancer RUFY4 intron 23266556 rs6436025 chr2 218942848 G A 6.59E-05 Attention deficit hyperactivity disorder RUFY4 intron 22420046 rs10932745 chr2 218942976 T C 4.94E-05 Colorectal cancer RUFY4 intron 23266556 rs11687200 chr2 218944615 A G 5.60E-05 Colorectal cancer RUFY4 intron 23266556 rs11676275 chr2 218944808 G A 5.07E-05 Colorectal cancer RUFY4 intron 23266556 rs12694427 chr2 218945045 G A 5.43E-05 Colorectal cancer RUFY4 intron 23266556 rs6737563 chr2 218945674 T C 6.75E-04 Acute lung injury RUFY4 intron 22295056 rs6737563 chr2 218945674 T C 1.04E-05 Colorectal cancer RUFY4 intron 23266556 rs13013361 chr2 218947515 A T 6.97E-04 Acute lung injury RUFY4 intron 22295056 rs13013361 chr2 218947515 A T 8.94E-06 Colorectal cancer RUFY4 intron 23266556 rs4133195 chr2 218951245 C T 4.68E-04 Acute lung injury RUFY4 intron 22295056 rs4133195 chr2 218951245 C T 6.47E-06 Colorectal cancer RUFY4 intron 23266556 rs6726126 chr2 218952233 G A 4.68E-04 Acute lung injury RUFY4 intron 22295056 rs6726126 chr2 218952233 G A 9.71E-06 Colorectal cancer RUFY4 intron 23266556 rs7422358 chr2 218952778 G A 7.42E-05 Colorectal cancer RUFY4 intron 23266556 rs10804264 chr2 218955809 T C 3.77E-05 Colorectal cancer / / 23266556 rs12694428 chr2 218958820 G A 1.91E-04 Colorectal cancer / / 23266556 rs13035513 chr2 218960680 C T 1.11E-05 Colorectal cancer / / 23266556 rs13007992 chr2 218964051 G T 5.87E-05 Colorectal cancer / / 23266556 rs7426289 chr2 218966315 C T 1.56E-05 Colorectal cancer / / 23266556 rs4674250 chr2 218977531 G A 2.93E-04 Colorectal cancer / / 23266556 rs6436032 chr2 218982862 T C 9.66E-05 Colorectal cancer / / 23266556 rs4674257 chr2 218988774 A G 1.14E-05 Colorectal cancer / / 23266556 rs4674258 chr2 218990586 C T 6.92E-05 Colorectal cancer CXCR2 intron 23266556 rs4674259 chr2 218991005 G A 1.12E-05 Colorectal cancer CXCR2 UTR-5 23266556 rs6761387 chr2 218996553 C T 3.06E-05 Blood Pressure CXCR2 intron pha002903 rs6723449 chr2 218997580 T C 1.03E-05 Colorectal cancer CXCR2 intron 23266556 rs1126579 chr2 219000734 T C 1.04E-05 Colorectal cancer CXCR2 UTR-3 23266556 rs1126580 chr2 219000966 G A 2.05E-04 Colorectal cancer CXCR2 UTR-3 23266556 rs4674261 chr2 219005009 G C 2.86E-04 Colorectal cancer / / 23266556 rs11677534 chr2 219007060 T C 8.49E-06 Colorectal cancer / / 23266556 rs13009946 chr2 219007752 T G 9.97E-06 Colorectal cancer / / 23266556 rs7594532 chr2 219008000 T C 1.19E-05 Colorectal cancer / / 23266556 rs7607437 chr2 219008392 A G 1.14E-05 Colorectal cancer / / 23266556 rs11676348 chr2 219010146 C T 1.00E-10 Ulcerative colitis / / 21297633 rs11676348 chr2 219010146 C T 7.35E-05 Colorectal cancer / / 23266556 rs11676348 chr2 219010146 C T 0.000000492 Primary sclerosing cholangitis / / 23603763 rs13027120 chr2 219020914 T C 1.06E-05 Colorectal cancer / / 23266556 rs16858717 chr2 219021226 C T 8.55E-05 Bipolar disorder,affective / / 20528957 rs1008563 chr2 219026888 G A 6.39E-04 Colorectal cancer / / 23266556 rs1008562 chr2 219026972 G C 1.82E-04 Colorectal cancer / / 23266556 rs3138060 chr2 219031500 G C 8.37E-05 Bipolar disorder,affective CXCR1 intron 20528957 rs16858856 chr2 219032781 T C 8.36E-04 Multiple complex diseases CXCR1 nearGene-5 17554300 rs4674267 chr2 219046437 T C 7.29E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs13397673 chr2 219047782 G A 8.42E-05 Insulin resistance / / 21901158 rs13026485 chr2 219057984 T C 6.91E-04 Multiple complex diseases / / 17554300 rs11695623 chr2 219068115 G A 3.92E-05 Attention deficit hyperactivity disorder / / 22420046 rs6720449 chr2 219080978 G A 5.73E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs13403276 chr2 219081297 T C 3.00E-06 Obesity-related traits / / 23251661 rs13403276 chr2 219081297 T C 7.00E-06 Obesity-related traits / / 23251661 rs6733051 chr2 219084533 C T 2.00E-06 Obesity-related traits ARPC2 intron 23251661 rs7605980 chr2 219100869 C G 1.40E-04 Multiple complex diseases ARPC2 intron 17554300 rs6436047 chr2 219108913 C A 8.96E-05 Multiple complex diseases ARPC2 intron 17554300 rs6436048 chr2 219109033 A G 1.50E-04 Multiple complex diseases ARPC2 intron 17554300 rs1079204 chr2 219130514 G A 2.00E-06 Smooth-surface caries AAMP intron 23470693 rs2382817 chr2 219151218 A C 4.00E-12 Inflammatory bowel disease PNKD intron 23128233 rs1017697 chr2 219170462 G A 5.22E-05 Coronary Artery Disease PNKD intron 17634449 rs1017698 chr2 219170525 G A 8.44E-04 Multiple complex diseases PNKD intron 17554300 rs2014615 chr2 219171191 T C 6.17E-04 Multiple complex diseases PNKD intron 17554300 rs10932775 chr2 219195799 G A 2.00E-04 Information processing speed PNKD intron 21130836 rs11899020 chr2 219235224 C T 4.03E-04 Insulin resistance / / 21901158 rs11904786 chr2 219238738 G A 3.01E-04 Insulin resistance / / 21901158 rs3731863 chr2 219252208 C T 6.56E-04 Schizophrenia SLC11A1 intron 19197363 rs7580808 chr2 219271804 A C 5.16E-05 Multiple complex diseases / / 17554300 rs7607369 chr2 219279097 A G 6.08E-05 Hepatitis B vaccine response / / 21764829 rs7607369 chr2 219279097 A G 7.00E-06 Amyotrophic lateral sclerosis / / 22959728 rs6717434 chr2 219288137 A G 1.41E-09 Triglycerides VIL1 intron 23063622 rs6720403 chr2 219294258 A C 6.89E-04 Suicide attempts in bipolar disorder VIL1 intron 21041247 rs3821031 chr2 219295249 C T 6.96E-04 Suicide attempts in bipolar disorder VIL1 intron 21041247 rs17572485 chr2 219296545 G A 7.55E-04 Suicide attempts in bipolar disorder VIL1 intron 21041247 rs17572485 chr2 219296545 G A 6.43E-06 Kawasaki disease VIL1 intron 21221998 rs6726798 chr2 219300855 A C 2.07E-22 HDL cholesterol VIL1 intron 23063622 rs6726798 chr2 219300855 A C 6.14E-14 Triglycerides VIL1 intron 23063622 rs1000879 chr2 219304130 G A 0.00000121 LDL cholesterol VIL1 intron 23063622 rs1000879 chr2 219304130 G A 2.04E-23 HDL cholesterol VIL1 intron 23063622 rs1000879 chr2 219304130 G A 5.41E-15 Triglycerides VIL1 intron 23063622 rs4674308 chr2 219310483 A C 7.40E-04 Suicide attempts in bipolar disorder VIL1 intron 21041247 rs3755042 chr2 219317248 T C 7.44E-04 Suicide attempts in bipolar disorder USP37 UTR-3 21041247 rs7601872 chr2 219319885 C G 7.45E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs10189064 chr2 219327500 G A 1.01E-08 Corneal structure USP37 intron 23291589 rs664514 chr2 219329819 A G 7.34E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs10200507 chr2 219335944 C A 7.49E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs3845835 chr2 219342284 T C 7.51E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs7571743 chr2 219352572 C T 6.24E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs10932782 chr2 219353195 C T 6.24E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs6710383 chr2 219359685 T G 6.24E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs634590 chr2 219372768 C A 6.11E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs636723 chr2 219373197 A G 7.55E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs662250 chr2 219374117 T A 7.56E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs6717433 chr2 219375711 G C 7.56E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs599973 chr2 219387273 C G 7.60E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs7603816 chr2 219396255 C T 7.44E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs687747 chr2 219399627 T C 7.62E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs578450 chr2 219401237 C T 8.50E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs523305 chr2 219402691 T C 7.64E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs7583449 chr2 219403022 A C 7.64E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs630858 chr2 219409689 C A 7.65E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs12619347 chr2 219419935 T C 7.66E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs4674314 chr2 219423520 T C 7.20E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs576901 chr2 219424364 A G 7.68E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs490483 chr2 219429052 A T 7.71E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs496674 chr2 219432569 G A 7.75E-04 Suicide attempts in bipolar disorder USP37 intron 21041247 rs526897 chr2 219433597 G A 7.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs523937 chr2 219437596 G C 7.83E-04 Suicide attempts in bipolar disorder RQCD1 intron 21041247 rs647990 chr2 219441428 T C 8.40E-04 Suicide attempts in bipolar disorder RQCD1 intron 21041247 rs3755041 chr2 219442499 A T 7.84E-04 Suicide attempts in bipolar disorder RQCD1 intron 21041247 rs562510 chr2 219443001 A C 7.83E-04 Suicide attempts in bipolar disorder RQCD1 intron 21041247 rs3770216 chr2 219443717 A G 7.83E-04 Suicide attempts in bipolar disorder RQCD1 intron 21041247 rs585185 chr2 219457741 G A 6.12E-04 Suicide attempts in bipolar disorder RQCD1 intron 21041247 rs620596 chr2 219462419 G A 7.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs832798 chr2 219464810 G A 6.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs611203 chr2 219472325 G A 1.20E-04 Height / / 21194676 rs611203 chr2 219472325 G A 1.20E-05 Height / / 21194676 rs611203 chr2 219472325 G A 5.80E-09 Height / / 21194676 rs3731867 chr2 219472734 G A 6.12E-04 Suicide attempts in bipolar disorder PLCD4 UTR-5 21041247 rs7574429 chr2 219498759 T G 6.07E-04 Suicide attempts in bipolar disorder PLCD4 intron 21041247 rs6710896 chr2 219500879 T C 9.02E-09 HDL cholesterol PLCD4 intron 23063622 rs3770213 chr2 219508372 A T 7.04E-04 Suicide attempts in bipolar disorder ZNF142 missense 21041247 rs3770214 chr2 219508988 T C 6.13E-04 Suicide attempts in bipolar disorder ZNF142 missense 21041247 rs10187066 chr2 219514759 A G 2.00E-07 Height ZNF142 intron 20881960 rs41272683 chr2 219530662 G A 0.00025 Prostate cancer (non-advanced prostate cancer) RNF25 missense 23555315 rs41272683 chr2 219530662 G A 0.00071 Prostate cancer RNF25 missense 23555315 rs2710246 chr2 219533894 T C 5.05E-04 Suicide attempts in bipolar disorder RNF25 intron 21041247 rs2241527 chr2 219537224 G A 4.10E-04 Suicide attempts in bipolar disorder STK36 intron 21041247 rs2241527 chr2 219537224 G A 1.27E-06 Statin-induced myopathy STK36 intron 21826682 rs7604319 chr2 219538799 A C 3.83E-04 Suicide attempts in bipolar disorder STK36 intron 21041247 rs2303565 chr2 219545309 T C 6.00E-07 Amyotrophic lateral sclerosis STK36 intron 22959728 rs1863704 chr2 219562675 G A 3.01E-04 Suicide attempts in bipolar disorder STK36 missense 21041247 rs10178538 chr2 219615968 T C 1.57E-06 Corneal structure TTLL4 intron 23291589 rs7603709 chr2 219642601 G A 0.0000735 Triglycerides / / 23063622 rs4674338 chr2 219647487 G A 2.60E-05 Urinary metabolites CYP27A1 intron 21572414 rs17470271 chr2 219651995 A T 2.00E-05 Urinary metabolites CYP27A1 intron 21572414 rs691960 chr2 219674004 G T 1.17E-15 HDL cholesterol CYP27A1 intron 23063622 rs691960 chr2 219674004 G T 6.88E-10 Triglycerides CYP27A1 intron 23063622 rs9973579 chr2 219697061 G C 9.29E-06 Age-related macular degeneration PRKAG3 nearGene-5 pha000001 rs10197074 chr2 219706535 C T 1.70E-05 Height / / 21998595 rs11695967 chr2 219721190 C T 7.30E-06 Urinary metabolites / / 21572414 rs10193725 chr2 219726498 T C 7.90E-06 Urinary metabolites WNT6 intron 21572414 rs6754599 chr2 219732142 C G 3.60E-04 Type 2 diabetes WNT6 intron 17463246 rs10177996 chr2 219746561 T C 3.55E-09 Common traits (Other) WNT10A intron 20585627 rs7349332 chr2 219756383 C T 1.00E-06 Hair morphology WNT10A intron 19896111 rs7349332 chr2 219756383 C T 3.00E-14 Common traits (Other) WNT10A intron 20585627 rs4674347 chr2 219759079 C G 8.48E-06 Hair morphology WNT10A nearGene-3 19896111 rs6723140 chr2 219774700 T C 1.62E-09 Common traits (Other) / / 20585627 rs6723140 chr2 219774700 T C 4.01E-05 Heart Rate / / pha003054 rs4672907 chr2 219821169 G A 5.75E-09 Common traits (Other) / / 20585627 rs359983 chr2 219823497 G A 0.0000423 Panic disorder / / 23149450 rs359983 chr2 219823497 G A 4.23E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs359980 chr2 219829206 T C 4.54E-04 Coronary Artery Disease / / 17634449 rs359980 chr2 219829206 T C 7.00E-06 Obesity-related traits / / 23251661 rs359965 chr2 219840891 G A 2.00E-06 Immune response to smallpox vaccine (IL-6) / / 22542470 rs359965 chr2 219840891 G A 0.0000494 Panic disorder / / 23149450 rs359965 chr2 219840891 G A 4.94E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs9967806 chr2 219878756 G A 8.69E-05 Amyotrophic lateral sclerosis (sporadic) CCDC108 missense 24529757 rs10932793 chr2 219896981 C A 9.06E-04 Type 2 diabetes CCDC108 intron 17463246 rs16859493 chr2 219898496 T C 7.81E-04 Type 2 diabetes CCDC108 UTR-3 17463246 rs6736922 chr2 219903258 T G 9.45E-04 Heart Failure CCDC108 missense pha002885 rs12470505 chr2 219908369 T G 9.00E-12 Height / / 20881960 rs1052483 chr2 219934348 G T 1.00E-06 Height / / 18391951 rs33967926 chr2 219936589 T C 4.22E-04 Multiple complex diseases / / 17554300 rs41398145 chr2 219943828 T A 9.50E-05 Multiple complex diseases NHEJ1 intron 17554300 rs6724465 chr2 219943846 G A 2.00E-08 Height NHEJ1 intron 18391952 rs7559667 chr2 219947184 A G 2.82E-04 Multiple complex diseases NHEJ1 intron 17554300 rs16859517 chr2 219949184 C T 5.00E-06 Height NHEJ1 intron 20189936 rs13419740 chr2 219969097 A G 3.83E-05 Multiple complex diseases NHEJ1 intron 17554300 rs6729662 chr2 219969798 G A 9.25E-04 Multiple complex diseases NHEJ1 intron 17554300 rs2272019 chr2 220002534 C A 3.52E-04 Multiple complex diseases NHEJ1 intron 17554300 rs6735637 chr2 220003241 T A 3.00E-04 Multiple complex diseases NHEJ1 intron 17554300 rs6761113 chr2 220006172 A G 5.58E-04 Multiple complex diseases NHEJ1 intron 17554300 rs10168553 chr2 220007414 C T 2.77E-04 Multiple complex diseases NHEJ1 intron 17554300 rs17655123 chr2 220037444 G A,C,T 1.29E-04 Amyotrophic lateral sclerosis (sporadic) CNPPD1 missense 24529757 rs73074979 chr2 220038094 G A 0.000037 Breast cancer(er negative) CNPPD1 missense 23555315 rs1127101 chr2 220040330 A G 1.57E-04 Multiple complex diseases CNPPD1 cds-synon 17554300 rs2293072 chr2 220045454 G A 4.57E-06 White blood cell count FAM134A cds-synon 21738479 rs2385394 chr2 220049290 C T 1.93E-04 Fibrinogen FAM134A UTR-3 17255346 rs2385394 chr2 220049290 C T 3.23E-04 Multiple complex diseases FAM134A UTR-3 17554300 rs6710315 chr2 220137991 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6728330 chr2 220218007 A G 2.48E-04 Multiple complex diseases / / 17554300 rs6757398 chr2 220218199 G A 2.76E-04 Multiple complex diseases / / 17554300 rs7586419 chr2 220220503 A G 1.87E-29 Narcolepsy / / 19629137 rs6717249 chr2 220243295 G A 2.00E-05 Urinary metabolites DNPEP intron 21572414 rs1132736 chr2 220250800 C T 2.27E-04 Smoking initiation DNPEP cds-synon 24665060 rs1512692 chr2 220267327 C A 8.10E-05 Height / / 21998595 rs1512693 chr2 220267512 T C 1.40E-04 Height / / 21998595 rs12466021 chr2 220268765 G A 2.90E-04 Height / / 21998595 rs4674397 chr2 220302549 C T 1.58E-04 Heart rate SPEG intron 23583979 rs748515 chr2 220311039 C A 8.89E-05 stroke (ischemic) SPEG intron 17434096 rs753974 chr2 220441067 C T 2.87E-04 Multiple complex diseases / / 17554300 rs659266 chr2 220512823 C T 2.03E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs628917 chr2 220521602 G T 2.30E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13416781 chr2 220523837 T A 8.25E-05 Multiple complex diseases / / 17554300 rs661039 chr2 220526923 A G 2.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4674417 chr2 220535148 G A 1.04E-05 Reading and spelling / / 23738518 rs639259 chr2 220556378 A G 2.06E-05 Reading and spelling / / 23738518 rs682699 chr2 220564839 C T 2.12E-05 Reading and spelling / / 23738518 rs605017 chr2 220566980 C T 2.12E-05 Reading and spelling / / 23738518 rs2891824 chr2 220569420 C T 6.14E-04 Multiple complex diseases / / 17554300 rs471443 chr2 220570313 G A 2.12E-05 Reading and spelling / / 23738518 rs539166 chr2 220575527 C T 2.02E-05 Reading and spelling / / 23738518 rs645999 chr2 220575854 A G 2.02E-05 Reading and spelling / / 23738518 rs674301 chr2 220577576 T C 2.02E-05 Reading and spelling / / 23738518 rs11901529 chr2 220590182 G A 2.18E-04 Multiple complex diseases / / 17554300 rs7569439 chr2 220590633 T C 2.52E-05 Reading and spelling / / 23738518 rs16860222 chr2 220592494 A G 1.20E-05 Urinary metabolites / / 21572414 rs1425029 chr2 220594539 C T 3.08E-04 Multiple complex diseases / / 17554300 rs6414197 chr2 220598195 G C 2.48E-05 Reading and spelling / / 23738518 rs6436163 chr2 220603899 C T 1.51E-05 Orofacial clefts / / 22863734 rs13389204 chr2 220606009 T A 3.72E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4674424 chr2 220607936 A G 1.18E-04 Amyotrophic lateral sclerosis / / 20801718 rs1477511 chr2 220621838 T G 7.42E-05 Telomere length / / 21573004 rs4674431 chr2 220632013 G A 9.73E-05 Amyotrophic lateral sclerosis / / 20801718 rs12464951 chr2 220632540 A T 2.07E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1035680 chr2 220634509 C T 1.86E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12476246 chr2 220635070 C T 1.54E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1364701 chr2 220657836 C T 8.33E-05 Orofacial clefts / / 22863734 rs982693 chr2 220659638 T G 6.54E-05 Orofacial clefts / / 22863734 rs1549380 chr2 220667582 G A 6.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs958548 chr2 220667880 C T 5.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs719325 chr2 220667933 C T 5.00E-05 Orofacial clefts / / 22863734 rs1549379 chr2 220668099 T G 5.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs3815854 chr2 220668738 C T 2.87E-05 Cleft lip / / 20436469 rs3815854 chr2 220668738 C T 7.00E-06 Orofacial clefts / / 22863734 rs2113855 chr2 220672168 C T 2.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs10932827 chr2 220675717 T G 2.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs2385619 chr2 220677432 G A 3.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs7595045 chr2 220677682 T C 3.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs7595519 chr2 220678105 T G 3.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs2162017 chr2 220686765 A G 3.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs4674451 chr2 220687535 C T 4.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs890087 chr2 220689022 G A 4.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs992871 chr2 220689584 C T 1.29E-05 Orofacial clefts / / 22863734 rs10932828 chr2 220691684 A G 3.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs4674452 chr2 220694084 A T 3.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs6719949 chr2 220696298 T C 1.20E-05 Urinary metabolites / / 21572414 rs6719949 chr2 220696298 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11686815 chr2 220697170 C G 4.30E-05 Bilirubin levels / / 19414484 rs11686846 chr2 220697212 C T 3.50E-05 Bilirubin levels / / 19414484 rs11688142 chr2 220697602 C T 3.50E-05 Bilirubin levels / / 19414484 rs10498070 chr2 220698125 A C 2.00E-07 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs4439946 chr2 220700665 A G 3.20E-05 Bilirubin levels / / 19414484 rs13000695 chr2 220703292 C A 2.06E-04 Alzheimer's disease (late onset) / / 21379329 rs2253615 chr2 220768879 C A 4.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs2253615 chr2 220768879 C A 1.82E-04 Sudden cardiac arrest / / 21658281 rs7587562 chr2 220772757 A G 6.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs10804284 chr2 220773549 G T 5.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs750764 chr2 220781006 C T 2.34E-05 Pulmonary function in asthmatics / / 23541324 rs4672960 chr2 220783322 C T 7.45E-06 Triglycerides / / pha002904 rs731412 chr2 220789370 C T 1.30E-05 Urinary metabolites / / 21572414 rs1007684 chr2 220790637 A G 2.52E-05 Pulmonary function in asthmatics / / 23541324 rs7584117 chr2 220830207 T G 2.71E-05 Coronary heart disease / / pha003031 rs7584117 chr2 220830207 T G 6.82E-05 Coronary heart disease / / pha003033 rs10221578 chr2 220833222 G A 4.68E-06 Coronary heart disease / / pha003031 rs7608541 chr2 220848941 G A 3.89E-05 Multiple sclerosis (age of onset) / / 19010793 rs13414052 chr2 220851174 G A 2.15E-05 Triglycerides / / pha002904 rs17290560 chr2 220862496 C G 2.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs10198756 chr2 220864654 A C 3.00E-06 IgG glycosylation / / 23382691 rs2664226 chr2 220873544 A G 2.96E-04 Height / / 17255346 rs965203 chr2 220876652 T G 9.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs11690874 chr2 220877631 C T 6.64E-05 Personality dimensions / / 18957941 rs1991107 chr2 220903603 C A 1.65E-04 Height / / 17255346 rs2971617 chr2 220919581 A G 9.60E-06 Coffee consumption / / 21357676 rs2911653 chr2 220921082 A C 1.17E-04 Cognitive function / / 24684796 rs17226763 chr2 220921801 C T 8.94E-05 Serum metabolites / / 19043545 rs4674493 chr2 220926429 C T 9.28E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs2911657 chr2 220937247 A G 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer / / 21245432 rs6728048 chr2 220971641 G A 2.20E-05 Urinary metabolites / / 21572414 rs13383613 chr2 220978325 T C 4.63E-04 Alzheimer's disease (late onset) / / 21379329 rs3935261 chr2 220981041 G T 6.78E-05 Schizophrenia / / pha002859 rs4073777 chr2 220997227 G A 5.93E-04 Smoking quantity / / 24665060 rs12614221 chr2 221000018 G T 3.42E-05 Major depressive disorder / / 22472876 rs12614221 chr2 221000018 G T 3.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs10932834 chr2 221003489 C G 6.30E-04 Smoking quantity / / 24665060 rs7577412 chr2 221031183 G A 1.41E-04 Multiple complex diseases / / 17554300 rs4572586 chr2 221035381 G A 1.93E-04 Multiple complex diseases / / 17554300 rs4517963 chr2 221062914 A G 4.75E-04 Multiple complex diseases / / 17554300 rs6714889 chr2 221062958 G A 6.29E-04 Multiple complex diseases / / 17554300 rs4430944 chr2 221063063 T C 4.76E-04 Multiple complex diseases / / 17554300 rs6718891 chr2 221063851 G A 3.81E-04 Multiple complex diseases / / 17554300 rs10932840 chr2 221064094 T C 3.57E-04 Multiple complex diseases / / 17554300 rs10932841 chr2 221064147 A G 7.03E-04 Multiple complex diseases / / 17554300 rs6436191 chr2 221065795 T G 4.25E-04 Multiple complex diseases / / 17554300 rs7594438 chr2 221075841 C T 7.55E-04 Multiple complex diseases / / 17554300 rs4340499 chr2 221077011 C G 2.97E-04 Multiple complex diseases / / 17554300 rs17610108 chr2 221080067 A C 4.10E-04 Fibrinogen / / 17255346 rs17610130 chr2 221081421 T C 7.78E-05 Fibrinogen / / 17255346 rs17610130 chr2 221081421 T C 1.46E-06 Glucose levels / / pha003061 rs10498072 chr2 221094454 T C 2.50E-05 Urinary metabolites / / 21572414 rs1466241 chr2 221103085 G A 1.96E-04 Multiple complex diseases / / 17554300 rs17656411 chr2 221109732 C T 2.50E-05 Urinary metabolites / / 21572414 rs1551385 chr2 221110435 G A 1.50E-05 Urinary metabolites / / 21572414 rs1993313 chr2 221110780 T G 6.50E-06 Urinary metabolites / / 21572414 rs17472512 chr2 221112306 G A 1.13E-04 Fibrinogen / / 17255346 rs17472512 chr2 221112306 G A 2.65E-07 Glucose levels / / pha003061 rs10498073 chr2 221124116 C T 5.06E-04 Multiple complex diseases / / 17554300 rs16860976 chr2 221125397 G A 9.60E-04 Multiple complex diseases / / 17554300 rs2034755 chr2 221139346 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs17656530 chr2 221139537 G A 1.55E-04 Multiple complex diseases / / 17554300 rs17610425 chr2 221140247 C T 7.40E-06 Urinary metabolites / / 21572414 rs10804287 chr2 221146465 G A 3.64E-05 Breast cancer / / pha002853 rs17610460 chr2 221148833 A G 1.60E-06 Urinary metabolites / / 21572414 rs6757239 chr2 221149105 G A 1.50E-06 Urinary metabolites / / 21572414 rs12468264 chr2 221166863 G A 5.50E-06 Urinary metabolites / / 21572414 rs4674516 chr2 221166925 T G 8.70E-04 Multiple complex diseases / / 17554300 rs10498076 chr2 221172135 A G 5.50E-06 Urinary metabolites / / 21572414 rs6757742 chr2 221179591 G A 1.20E-05 Urinary metabolites / / 21572414 rs6414198 chr2 221181167 T C 1.20E-05 Urinary metabolites / / 21572414 rs17657062 chr2 221183617 C A 1.60E-05 Urinary metabolites / / 21572414 rs897144 chr2 221186275 C A 2.13E-04 Breast cancer / / pha002853 rs1454552 chr2 221187549 C T 3.15E-05 Statin-induced myopathy / / 21826682 rs724158 chr2 221187667 G A 4.30E-06 Urinary metabolites / / 21572414 rs4672976 chr2 221189253 C T 1.20E-05 Urinary metabolites / / 21572414 rs12477337 chr2 221200915 G C 8.10E-06 Urinary metabolites / / 21572414 rs897141 chr2 221212147 G A 4.84E-04 Cognition,early reading ability / / 17684495 rs1378013 chr2 221221043 C T 3.50E-06 Urinary metabolites / / 21572414 rs897138 chr2 221229692 G C 2.50E-06 Urinary metabolites / / 21572414 rs6741459 chr2 221229840 G A 1.00E-05 Urinary metabolites / / 21572414 rs10498077 chr2 221238914 T C 2.75E-20 Varicose Veins / / pha001412 rs10180439 chr2 221307881 G A 5.34E-04 Type 2 diabetes / / 17463246 rs4362550 chr2 221312732 G A 3.52E-04 Type 2 diabetes / / 17463246 rs7592124 chr2 221326873 T C 6.81E-04 Multiple complex diseases / / 17554300 rs4350737 chr2 221327051 G A 1.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4350737 chr2 221327051 G A 6.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12613270 chr2 221329785 G A 4.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1922772 chr2 221364518 C T 4.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1955401 chr2 221400478 G T 4.55E-04 Taste perception / / 22132133 rs4674541 chr2 221412389 G A 1.41E-04 Taste perception / / 22132133 rs2708144 chr2 221440560 T C 3.86E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1796432 chr2 221447084 C T 6.00E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12613990 chr2 221454349 A C 6.07E-04 Obesity (extreme) / / 21935397 rs1796427 chr2 221457064 G C 3.87E-04 Type 2 diabetes / / 17463246 rs10932873 chr2 221457624 T C 5.55E-04 Obesity (extreme) / / 21935397 rs1850490 chr2 221458773 A T 5.42E-04 Obesity (extreme) / / 21935397 rs6716476 chr2 221460840 T C 9.56E-04 Obesity (extreme) / / 21935397 rs6730649 chr2 221461430 A G 5.18E-04 Obesity (extreme) / / 21935397 rs1517441 chr2 221461957 T A 9.10E-04 Obesity (extreme) / / 21935397 rs1589097 chr2 221464470 C G 8.80E-04 Obesity (extreme) / / 21935397 rs1589098 chr2 221464504 C T 8.72E-04 Obesity (extreme) / / 21935397 rs1607212 chr2 221464710 A C 8.48E-04 Obesity (extreme) / / 21935397 rs1607213 chr2 221465057 A G 8.26E-04 Obesity (extreme) / / 21935397 rs10169304 chr2 221465182 C T 6.80E-04 Obesity (extreme) / / 21935397 rs12619185 chr2 221465555 A C 7.38E-04 Obesity (extreme) / / 21935397 rs1796433 chr2 221466813 T A 2.21E-04 Type 2 diabetes / / 17463246 rs1850492 chr2 221471181 C T 3.94E-04 Obesity (extreme) / / 21935397 rs1356397 chr2 221473858 T C 7.01E-04 Obesity (extreme) / / 21935397 rs2392718 chr2 221475085 G A 3.79E-04 Obesity (extreme) / / 21935397 rs1949415 chr2 221478093 A C 6.74E-04 Obesity (extreme) / / 21935397 rs10207622 chr2 221478235 T G 6.68E-04 Obesity (extreme) / / 21935397 rs7558221 chr2 221486767 G A 6.00E-04 Obesity (extreme) / / 21935397 rs6719602 chr2 221490435 G A 6.54E-04 Obesity (extreme) / / 21935397 rs1568179 chr2 221492759 A G 3.74E-04 Obesity (extreme) / / 21935397 rs12471834 chr2 221498729 A C 6.50E-04 Obesity (extreme) / / 21935397 rs13407859 chr2 221503828 A G 7.49E-04 Multiple complex diseases / / 17554300 rs11684111 chr2 221521161 G C 4.51E-04 Obesity (extreme) / / 21935397 rs11896343 chr2 221529878 A G 2.53E-04 Obesity (extreme) / / 21935397 rs11896343 chr2 221529878 A G 7.10E-04 Alzheimer's disease / / 22005930 rs7582123 chr2 221533933 C G 2.51E-04 Obesity (extreme) / / 21935397 rs7582123 chr2 221533933 C G 6.90E-04 Alzheimer's disease / / 22005930 rs10932878 chr2 221535030 C T 2.50E-04 Obesity (extreme) / / 21935397 rs10932878 chr2 221535030 C T 5.81E-04 Alzheimer's disease / / 22005930 rs10932879 chr2 221535247 T C 2.48E-04 Obesity (extreme) / / 21935397 rs10932879 chr2 221535247 T C 7.59E-04 Alzheimer's disease / / 22005930 rs7558655 chr2 221538442 T C 2.78E-04 Obesity (extreme) / / 21935397 rs7558655 chr2 221538442 T C 4.87E-04 Alzheimer's disease / / 22005930 rs1517449 chr2 221539821 A G 2.90E-04 Obesity (extreme) / / 21935397 rs7600191 chr2 221549153 C T 3.73E-05 Hypertension / / pha003041 rs7606753 chr2 221556078 G A 2.16E-04 Kawasaki disease / / 21326860 rs7606753 chr2 221556078 G A 3.22E-05 Alzheimer's disease / / 22005930 rs1517443 chr2 221559762 T C 6.00E-05 Alzheimer's disease / / 22005930 rs1517445 chr2 221560164 A G 4.24E-05 Alzheimer's disease / / 22005930 rs12694533 chr2 221570900 C T 2.80E-06 Urinary metabolites / / 21572414 rs2893610 chr2 221571162 A G 1.04E-04 Alzheimer's disease / / 22005930 rs17578449 chr2 221574105 T C 1.20E-04 Alzheimer's disease / / 22005930 rs11690540 chr2 221576490 T C 2.23E-05 Alzheimer's disease / / 22005930 rs12694534 chr2 221576851 G T 2.42E-05 Alzheimer's disease / / 22005930 rs6705773 chr2 221578398 T C 3.04E-05 Alzheimer's disease / / 22005930 rs1996407 chr2 221579238 G A 8.69E-05 Alzheimer's disease / / 22005930 rs7599725 chr2 221584571 G A 6.17E-05 Alzheimer's disease / / 22005930 rs12694536 chr2 221585681 C T 8.63E-05 Alzheimer's disease / / 22005930 rs6712787 chr2 221594497 C T 8.90E-05 Alzheimer's disease / / 22005930 rs16861701 chr2 221596539 G A 6.98E-04 Depression (quantitative trait) / / 20800221 rs13036102 chr2 221604489 C T 1.21E-04 Alzheimer's disease / / 22005930 rs6742961 chr2 221606739 C A 1.22E-04 Alzheimer's disease / / 22005930 rs6713453 chr2 221610016 T C 1.33E-04 Alzheimer's disease / / 22005930 rs12694545 chr2 221626806 G C 1.84E-04 Alzheimer's disease / / 22005930 rs11675742 chr2 221630579 G A 1.18E-04 Alzheimer's disease / / 22005930 rs10183570 chr2 221632617 A G 1.85E-04 Alzheimer's disease / / 22005930 rs17396049 chr2 221632812 G A 6.97E-05 Alzheimer's disease / / 22005930 rs1876832 chr2 221638280 C A 4.23E-04 Myopia (pathological) / / 21095009 rs16861747 chr2 221643240 G A 2.14E-05 Cognitive test performance / / 20125193 rs7598755 chr2 221648888 C T 8.81E-06 Kawasaki disease / / 22446961 rs10804291 chr2 221651555 C T 9.71E-05 Kawasaki disease / / 22446961 rs7562441 chr2 221654925 T C 6.39E-04 Alzheimer's disease / / 22005930 rs10205272 chr2 221678075 T C 4.46E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1463990 chr2 221704514 G A 2.28E-04 Longevity / / 22279548 rs2136492 chr2 221704949 A C 1.97E-05 Cognitive performance / / 19734545 rs10932886 chr2 221720088 G A 1.00E-06 Brain imaging / / 20100581 rs2444838 chr2 221724838 A G 5.97E-04 Multiple complex diseases / / 17554300 rs7568936 chr2 221731360 C T 9.46E-04 Type 2 diabetes / / 17463246 rs11885719 chr2 221736049 C G 4.95E-04 Multiple complex diseases / / 17554300 rs17398519 chr2 221744435 A G 5.64E-04 Multiple complex diseases / / 17554300 rs830747 chr2 221762952 G A 1.59E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs17339993 chr2 221773296 A G 1.60E-04 Multiple complex diseases / / 17554300 rs749635 chr2 221786860 A C 2.79E-04 Alzheimer's disease / / 24755620 rs630054 chr2 221788172 T C 2.33E-05 Glycosylated haemoglobin levels / / 17255346 rs582085 chr2 221792364 T C 4.77E-05 Glycosylated haemoglobin levels / / 17255346 rs666274 chr2 221794326 G A 2.87E-04 Alzheimer's disease / / 24755620 rs630592 chr2 221794898 G C 7.64E-05 Glycosylated haemoglobin levels / / 17255346 rs11682003 chr2 221820913 A G 9.87E-04 Type 2 diabetes / / 17463246 rs7579067 chr2 221847734 T G 1.66E-05 Schizophrenia / / 19197363 rs897124 chr2 221862562 C T 8.95E-04 Schizophrenia / / 19197363 rs11678670 chr2 221882584 T C 2.97E-04 Smoking initiation / / 24665060 rs10498091 chr2 221899444 C T 6.00E-06 Echocardiographic traits / / 17903301 rs9808155 chr2 221927852 G T 3.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs10804294 chr2 221928569 G A 2.20E-06 Schizophrenia / / 21795503 rs1991966 chr2 221938126 T C 8.49E-06 Schizophrenia / / 21795503 rs7581869 chr2 221950948 A T 1.72E-05 Personality dimensions / / 22628180 rs143917964 chr2 221951747 G A 9.78E-06 Contrast sensitivity / / 24152035 rs10498101 chr2 221954500 A G 9.70E-06 Contrast sensitivity / / 24152035 rs16862154 chr2 221954950 G A 1.41E-05 Orofacial clefts / / 22419666 rs17412073 chr2 221962096 G A 9.73E-06 Contrast sensitivity / / 24152035 rs6709919 chr2 221964881 A C 8.34E-06 Contrast sensitivity / / 24152035 rs7604236 chr2 221987040 A G 4.19E-04 Smoking initiation / / 24665060 rs4536641 chr2 222013644 A G 2.34E-04 Smoking initiation / / 24665060 rs2019083 chr2 222027666 T C 8.11E-05 Colorectal cancer / / 19723657 rs12477147 chr2 222067150 T G 7.33E-05 Orofacial clefts / / 22863734 rs17348202 chr2 222072178 T C 1.00E-06 Paclitaxel-induced neuropathy / / 23776197 rs13029409 chr2 222105363 A G 3.91E-05 Cholesterol / / pha003073 rs13029409 chr2 222105363 A G 3.76E-05 Cholesterol / / pha003078 rs1002827 chr2 222130384 A G 4.57E-05 Cholesterol / / pha003073 rs1002827 chr2 222130384 A G 4.14E-05 Cholesterol / / pha003078 rs982757 chr2 222153932 A G 3.06E-05 Triglycerides / / pha003080 rs10498105 chr2 222157677 G T 2.60E-04 White matter integrity / / 22425255 rs10188163 chr2 222166280 C G 8.19E-04 Type 2 diabetes / / 17463246 rs10188163 chr2 222166280 C G 6.63E-04 Multiple complex diseases / / 17554300 rs1430246 chr2 222178867 A G 2.00E-07 Immune response to measles-mumps-rubella vaccine / / 24811271 rs1346801 chr2 222180661 A G 6.91E-05 Cholesterol / / pha003073 rs1346800 chr2 222180677 G T 6.91E-05 Cholesterol / / pha003073 rs17431881 chr2 222193919 G C 1.75E-04 Attention deficit hyperactivity disorder / / pha002875 rs1897119 chr2 222208451 G C 5.05E-06 Stroke (ischemic) / / 22941190 rs1025369 chr2 222211083 T C 3.59E-05 Premature ovarian failure / / 19508998 rs1025369 chr2 222211083 T C 3.59E-05 Other erythrocyte phenotypes / / 19862010 rs4674596 chr2 222280806 C G 2.60E-04 Iris characteristics / / 21835309 rs3770205 chr2 222295760 C A 2.01E-04 Premature ovarian failure EPHA4 intron 19508998 rs1430216 chr2 222330970 T C 6.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) EPHA4 intron 23648065 rs10498114 chr2 222358909 A G 6.58E-04 Parkinson's disease EPHA4 intron 17052657 rs2710507 chr2 222380800 G A 5.62E-04 Smoking cessation EPHA4 intron 24665060 rs4302206 chr2 222394305 A G 1.44E-04 Smoking cessation EPHA4 intron 24665060 rs2250204 chr2 222400223 G A 1.78E-04 Smoking cessation EPHA4 intron 24665060 rs16862811 chr2 222401086 G T 2.65E-05 Type 2 diabetes EPHA4 intron 21647700 rs2680856 chr2 222410331 A C 4.62E-04 Smoking cessation EPHA4 intron 24665060 rs7340471 chr2 222432320 T C 2.20E-05 Urinary metabolites EPHA4 intron 21572414 rs2946558 chr2 222450800 A T 3.80E-04 Multiple complex diseases / / 17554300 rs2680837 chr2 222471516 A G 7.12E-04 Parkinson's disease / / 17052657 rs872217 chr2 222482917 A G 6.83E-04 Type 2 diabetes / / 17463246 rs13030635 chr2 222524442 G A 1.11E-04 Multiple complex diseases / / 17554300 rs10498121 chr2 222527540 G A 7.53E-04 Multiple complex diseases / / 17554300 rs12477986 chr2 222536261 A G 6.22E-04 Multiple complex diseases / / 17554300 rs1364387 chr2 222620133 G A 6.57E-04 Alzheimer's disease / / 17998437 rs2161765 chr2 222685565 A G 4.23E-06 Schizophrenia / / 21795503 rs4674616 chr2 222717778 C T 6.32E-05 HIV-1 viral setpoint / / 22174851 rs4099423 chr2 222766109 A G 7.04E-04 Multiple complex diseases / / 17554300 rs4099423 chr2 222766109 A G 9.01E-05 Insulin resistance / / 21901158 rs4085528 chr2 222771911 T C 8.81E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs824931 chr2 222801699 C T 3.00E-06 Body mass index / / 19851299 rs1834134 chr2 222857113 G A 2.25E-04 Type 2 diabetes / / 17463246 rs1559473 chr2 222881518 T G 1.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4673008 chr2 222883193 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs889837 chr2 222917491 T C 2.20E-05 Urinary metabolites / / 21572414 rs1007119 chr2 222922524 T G 9.83E-05 Cognitive impairment induced by topiramate / / 22091778 rs348964 chr2 222933684 T C 4.63E-05 Lipoproteins / / pha003079 rs348967 chr2 222943096 T C 9.08E-04 Parkinson's disease / / 17052657 rs348970 chr2 222943945 C T 1.75E-05 Parkinson's disease / / 17052657 rs348970 chr2 222943945 C T 8.80E-05 Lipoproteins / / pha003079 rs348998 chr2 222950677 G A 4.95E-05 Lipoproteins / / pha003079 rs1424356 chr2 222957916 C T 5.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs349016 chr2 222962444 T C 1.36E-05 Lipoproteins / / pha003079 rs349020 chr2 222965299 G A 8.05E-05 Lipoproteins / / pha003079 rs9941713 chr2 222968278 C T 5.82E-04 Multiple complex diseases / / 17554300 rs2894449 chr2 222968617 C T 3.02E-05 Lipoproteins / / pha003079 rs4673012 chr2 222976013 C T 6.62E-05 Cognitive test performance / / 20125193 rs4674634 chr2 222977035 G A 7.34E-05 Cognitive test performance / / 20125193 rs4673013 chr2 222977078 C T 8.85E-05 Cognitive test performance / / 20125193 rs6757456 chr2 222986828 T C 2.75E-07 Facial morphology / / 22341974 rs16863422 chr2 222990015 A G 2.06E-08 Primary biliary cirrhosis / / 23000144 rs16863422 chr2 222990015 A G 2.06E-08 Facial morphology / / 23028347 rs11886961 chr2 222991918 C G 2.03E-07 Facial morphology / / 22341974 rs12694574 chr2 222993733 T C 2.55E-08 Primary biliary cirrhosis / / 23000144 rs12694574 chr2 222993733 T C 2.55E-08 Facial morphology / / 23028347 rs6749789 chr2 222994221 G A 1.88E-07 Facial morphology / / 22341974 rs2894450 chr2 222997104 G A 3.93E-07 Facial morphology / / 22341974 rs2894450 chr2 222997104 G A 1.55E-07 Primary biliary cirrhosis / / 23000144 rs2894450 chr2 222997104 G A 0.000000155 Facial morphology / / 23028347 rs10932943 chr2 223001061 G A 1.72E-07 Facial morphology / / 22341974 rs13385121 chr2 223002705 A G 1.62E-07 Facial morphology / / 22341974 rs974448 chr2 223005314 A G 1.57E-08 Primary biliary cirrhosis / / 23000144 rs974448 chr2 223005314 A G 1.56E-08 Facial morphology / / 23028347 rs7608778 chr2 223023579 T C 1.27E-07 Facial morphology / / 22341974 rs1370926 chr2 223030502 C G 1.88E-06 Biliary atresia / / 20460270 rs1370926 chr2 223030502 C G 1.40E-05 Urinary metabolites / / 21572414 rs1370926 chr2 223030502 C G 1.68E-09 Facial morphology / / 22341974 rs7607981 chr2 223032002 C T 1.24E-07 Facial morphology / / 22341974 rs986429 chr2 223032399 T A 1.65E-09 Facial morphology / / 22341974 rs986430 chr2 223032642 G T 1.65E-09 Facial morphology / / 22341974 rs10210971 chr2 223038895 C T 1.12E-07 Facial morphology / / 22341974 rs10176525 chr2 223039052 T A 1.37E-09 Facial morphology / / 22341974 rs10211404 chr2 223039180 G A 8.99E-08 Facial morphology / / 22341974 rs1438605 chr2 223043337 A G 1.80E-06 Urinary metabolites / / 21572414 rs1438605 chr2 223043337 A G 8.23E-08 Facial morphology / / 22341974 rs6730714 chr2 223049021 G A 9.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10169326 chr2 223051502 G A 3.59E-08 Facial morphology / / 22341974 rs11677206 chr2 223051983 C T 6.07E-10 Facial morphology / / 22341974 rs6728938 chr2 223053757 C T 3.38E-08 Facial morphology / / 22341974 rs10178871 chr2 223054001 G A 5.75E-10 Facial morphology / / 22341974 rs13023573 chr2 223055226 A C 4.86E-07 Facial morphology / / 22341974 rs10498131 chr2 223055805 G A 3.92E-07 Facial morphology / / 22341974 rs10208761 chr2 223055976 A C 3.92E-07 Facial morphology / / 22341974 rs10209141 chr2 223056368 A C 2.55E-10 Facial morphology / / 22341974 rs10209300 chr2 223056500 A G 1.07E-08 Facial morphology / / 22341974 rs6741414 chr2 223057138 C G 2.42E-10 Facial morphology / / 22341974 rs7597751 chr2 223058905 C T 9.81E-09 Facial morphology / / 22341974 rs1438607 chr2 223059951 A G 3.77E-07 Facial morphology / / 22341974 rs2855268 chr2 223066919 C G 8.77E-09 Facial morphology PAX3 intron 22341974 rs7559271 chr2 223068286 G A 4.00E-16 Facial morphology PAX3 intron 22341974 rs7588554 chr2 223074651 A G 3.72E-07 Facial morphology PAX3 intron 22341974 rs6730989 chr2 223079344 G A 8.05E-09 Facial morphology PAX3 intron 22341974 rs2578449 chr2 223080192 G A 8.07E-09 Facial morphology PAX3 intron 22341974 rs1978859 chr2 223082331 C T 3.61E-07 Primary biliary cirrhosis PAX3 intron 23000144 rs1978859 chr2 223082331 C T 0.000000361 Facial morphology PAX3 intron 23028347 rs2234675 chr2 223085955 G T 0.0001 Prostate cancer PAX3 missense 23555315 rs7590866 chr2 223087329 G A 1.11E-08 Facial morphology PAX3 intron 22341974 rs17401668 chr2 223089739 A G 1.40E-08 Facial morphology PAX3 intron 22341974 rs1013262 chr2 223090779 T G 4.67E-07 Facial morphology PAX3 intron 22341974 rs1549773 chr2 223095968 C T 1.71E-08 Facial morphology PAX3 intron 22341974 rs13410020 chr2 223102937 G A 1.22E-08 Facial morphology PAX3 intron 22341974 rs1430655 chr2 223103548 G A 3.57E-08 Facial morphology PAX3 intron 22341974 rs13388386 chr2 223104418 A G 9.08E-08 Facial morphology PAX3 intron 22341974 rs10498134 chr2 223104980 T C 3.27E-04 Tourette syndrome PAX3 intron 22889924 rs1367413 chr2 223106018 G T 3.16E-05 Asthma PAX3 intron pha003127 rs10932951 chr2 223131962 G C 8.31E-04 Multiple complex diseases PAX3 intron 17554300 rs10498137 chr2 223141438 C T 2.23E-05 Pulmonary function PAX3 intron 17903307 rs6436310 chr2 223167710 A G 7.60E-05 Asthma CCDC140 intron pha003128 rs1430666 chr2 223235543 C A 1.30E-05 Urinary metabolites / / 21572414 rs6716300 chr2 223246297 G A 2.60E-05 Urinary metabolites / / 21572414 rs1430654 chr2 223276366 T C 4.60E-05 Serum albumin level / / pha003084 rs7604173 chr2 223331920 C T 2.48E-04 Amyotrophic Lateral Sclerosis SGPP2 intron 17362836 rs735678 chr2 223339582 C A 9.50E-04 White matter integrity SGPP2 intron 22425255 rs17496827 chr2 223353446 A C 7.00E-06 Anorexia nervosa SGPP2 intron 23568457 rs1436786 chr2 223353778 T C 8.10E-05 Major depressive disorder SGPP2 intron 19107115 rs1436788 chr2 223411493 C T 7.97E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SGPP2 intron 20031582 rs1436788 chr2 223411493 C T 9.96E-06 Lymphocyte counts SGPP2 intron 22286170 rs11883877 chr2 223415918 C T 8.97E-04 Suicide attempts in bipolar disorder SGPP2 intron 21423239 rs4674663 chr2 223416670 C G 6.15E-04 Type 2 diabetes SGPP2 intron 17463246 rs12614577 chr2 223419529 G C 6.32E-07 Personality dimensions SGPP2 intron 21173776 rs6751616 chr2 223422407 T G 2.61E-04 Type 2 diabetes SGPP2 intron 17463246 rs3754672 chr2 223422680 C T 7.19E-04 Suicide attempts in bipolar disorder SGPP2 intron 21423239 rs5016700 chr2 223422720 C T 5.81E-04 Suicide attempts in bipolar disorder SGPP2 intron 21423239 rs1347630 chr2 223427854 A G 3.32E-06 Cognitive test performance / / 20125193 rs11896566 chr2 223431383 T A 3.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs11899318 chr2 223432967 T C 4.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs7185 chr2 223436607 C T 5.25E-06 Cognitive test performance FARSB missense 20125193 rs3768976 chr2 223436860 A G 8.96E-05 Tunica Media FARSB intron pha003038 rs13030452 chr2 223474697 G A 6.27E-04 Suicide attempts in bipolar disorder FARSB intron 21423239 rs2028953 chr2 223477160 A G 5.56E-04 Suicide attempts in bipolar disorder FARSB intron 21423239 rs2028953 chr2 223477160 A G 2.18E-05 Tunica Media FARSB intron pha003038 rs13009500 chr2 223497633 T C 4.69E-04 Suicide attempts in bipolar disorder FARSB intron 21423239 rs13410038 chr2 223499077 C T 5.22E-04 Suicide attempts in bipolar disorder FARSB intron 21423239 rs921121 chr2 223505872 T C 5.32E-04 Suicide attempts in bipolar disorder FARSB intron 21423239 rs1447111 chr2 223510142 A G 5.18E-04 Suicide attempts in bipolar disorder FARSB intron 21423239 rs868392 chr2 223517259 C T 2.79E-05 Tunica Media FARSB intron pha003038 rs6740452 chr2 223518452 C T 1.16E-06 Personality dimensions FARSB intron 21173776 rs10180632 chr2 223526384 G A 1.03E-06 Personality dimensions / / 21173776 rs11684328 chr2 223528317 C A 1.60E-05 Cognitive test performance / / 20125193 rs4674677 chr2 223529658 G A 1.82E-06 Personality dimensions / / 21173776 rs10932966 chr2 223531739 C A 4.80E-07 Personality dimensions / / 21173776 rs1447108 chr2 223542231 A G 6.62E-06 Personality dimensions MOGAT1 intron 21173776 rs12614976 chr2 223542896 A T 6.71E-06 Personality dimensions MOGAT1 intron 21173776 rs11692810 chr2 223544096 C A 6.64E-06 Personality dimensions MOGAT1 intron 21173776 rs951997 chr2 223567016 A G 2.00E-05 Partial epilepsies MOGAT1 intron 20522523 rs951997 chr2 223567016 A G 4.53E-05 Epilepsy MOGAT1 intron 22116939 rs7562188 chr2 223588587 A G 3.92E-05 Fibrinogen / / 17255346 rs1374538 chr2 223600805 T C 3.52E-06 Fibrinogen / / 17255346 rs1374538 chr2 223600805 T C 4.20E-04 Myopia (pathological) / / 21095009 rs4312478 chr2 223616610 T C 5.01E-04 Multiple complex diseases / / 17554300 rs7589928 chr2 223655115 T C 9.63E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs13408246 chr2 223664488 G A 9.32E-05 Bipolar disorder / / 19488044 rs1867802 chr2 223667882 G A 5.86E-05 Coronary heart disease / / pha003031 rs6436346 chr2 223674322 G A 2.90E-05 Adiposity / / 19461586 rs6718498 chr2 223677951 C G 4.58E-12 Multiple complex diseases / / 17554300 rs2053717 chr2 223715899 C T 3.41E-06 Coronary heart disease / / pha003031 rs795887 chr2 223758070 C T 5.69E-05 Leukocyte Counts ACSL3 intron pha003091 rs6722420 chr2 223766830 A G 7.81E-05 Leukocyte Counts ACSL3 intron pha003091 rs6756323 chr2 223785740 A G 2.49E-05 Coronary heart disease ACSL3 intron pha003031 rs6756107 chr2 223798501 G A 3.25E-06 Coronary heart disease ACSL3 intron pha003031 rs10932980 chr2 223802386 C G 9.29E-05 Serum metabolites ACSL3 intron 19043545 rs6734103 chr2 223805495 A G 2.49E-05 Coronary heart disease ACSL3 intron pha003031 rs10755042 chr2 223808401 A C 9.35E-05 Leukocyte Counts / / pha003091 rs4330101 chr2 223817023 A G 8.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2028383 chr2 223823132 T C 6.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1465882 chr2 223823654 G C 9.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13393781 chr2 223838190 G T 4.73E-04 Alzheimer's disease / / 22005930 rs6717772 chr2 223838450 G A 2.40E-05 Urinary metabolites / / 21572414 rs6717772 chr2 223838450 G A 9.55E-04 Alzheimer's disease / / 22005930 rs6717855 chr2 223838477 G A 9.53E-04 Alzheimer's disease / / 22005930 rs13022307 chr2 223839835 G A 7.81E-04 Alzheimer's disease / / 22005930 rs13013147 chr2 223843829 C A 7.41E-04 Alzheimer's disease / / 22005930 rs13025241 chr2 223849170 T C 5.95E-04 Alzheimer's disease / / 22005930 rs1440065 chr2 223849610 G A 1.58E-290 Multiple complex diseases / / 17554300 rs10498146 chr2 223852036 A G 7.41E-10 Schizophrenia / / 21795503 rs1440063 chr2 223852353 G A 0.00084912 Hypertension (early onset hypertension) / / 22479346 rs13033186 chr2 223852436 C T 6.58E-04 Depression (quantitative trait) / / 20800221 rs11687274 chr2 223854254 G T 6.50E-04 Depression (quantitative trait) / / 20800221 rs935028 chr2 223857554 A G 4.69E-04 Depression (quantitative trait) / / 20800221 rs1371647 chr2 223872737 G A 1.06E-05 Gallbladder cancer / / 22318345 rs1371647 chr2 223872737 G A 2.77E-06 Coronary arterial lesions in patients with Kawasaki disease / / 23677057 rs1961637 chr2 223905108 G T 2.23E-05 Serum metabolites / / 19043545 rs12621643 chr2 223917983 T G 3.00E-06 Acute lymphoblastic leukemia (childhood) KCNE4 missense 19684603 rs12621643 chr2 223917983 T G 3.00E-06 Nasopharyngeal carcinoma KCNE4 missense 20512145 rs9283536 chr2 223930506 C T 7.10E-04 Crohn's disease / / 17684544 rs1440072 chr2 223936738 C T 1.30E-04 Glycosylated haemoglobin levels / / 17255346 rs1440072 chr2 223936738 C T 4.00E-06 Body mass index / / 20966902 rs1440072 chr2 223936738 C T 8.00E-07 Waist circumference / / 20966902 rs960246 chr2 223937559 T G 1.00E-09 C-reactive protein and white blood cell count / / 22788528 rs12617270 chr2 223946634 G A 3.41E-04 Hemoglobin concentration / / 20534544 rs75419782 chr2 223946834 T C 4.17E-05 Acne (severe) / / 24927181 rs921190 chr2 223947404 G T 1.60E-04 Glycosylated haemoglobin levels / / 17255346 rs10200800 chr2 223952836 T C 1.42E-30 Narcolepsy / / 19629137 rs11884475 chr2 224006491 C T 4.05E-04 Obesity (extreme) / / 21935397 rs11894487 chr2 224010921 A T 3.21E-04 Obesity (extreme) / / 21935397 rs16864483 chr2 224012136 A G 3.20E-04 Obesity (extreme) / / 21935397 rs16864484 chr2 224012318 A C,G 3.20E-04 Obesity (extreme) / / 21935397 rs10202577 chr2 224015538 A G 7.00E-06 Urinary metabolites / / 21572414 rs1448310 chr2 224018296 T C 1.60E-05 Urinary metabolites / / 21572414 rs10432545 chr2 224018650 C T 4.94E-04 Multiple complex diseases / / 17554300 rs16864505 chr2 224018770 C T 8.26E-06 Fibrinogen / / 17255346 rs1448288 chr2 224021048 A G 5.60E-04 Multiple complex diseases / / 17554300 rs1448293 chr2 224021310 C A 1.60E-05 Urinary metabolites / / 21572414 rs11899732 chr2 224023217 T C 3.17E-04 Obesity (extreme) / / 21935397 rs895767 chr2 224023296 A C 7.00E-06 Cognitive decline (age-related) / / 24468470 rs6739367 chr2 224025078 A G 1.40E-05 Immunoglobulin A / / 20694011 rs12694596 chr2 224025984 C G 7.10E-05 Coffee consumption / / 21357676 rs10204910 chr2 224028510 G A 1.12E-06 Blood Pressure / / pha003039 rs10204910 chr2 224028510 G A 3.91E-05 Blood Pressure / / pha003045 rs11902770 chr2 224028633 C T 3.17E-04 Obesity (extreme) / / 21935397 rs10209741 chr2 224034735 G A 5.29E-04 Type 2 diabetes / / 17463246 rs6734400 chr2 224036411 C T 7.90E-04 Type 2 diabetes / / 17463246 rs2218665 chr2 224036759 G C 2.00E-05 Urinary metabolites / / 21572414 rs10172933 chr2 224038175 C A 3.63E-04 Type 2 diabetes / / 17463246 rs6713755 chr2 224038435 A C 0.0000317 5-fluorouracil induced diarrhoea in response to colorectal cancer treatment / / 22310351 rs1375084 chr2 224042628 C G 2.10E-05 Urinary metabolites / / 21572414 rs1597167 chr2 224044250 A G 3.69E-07 Asthma / / 21790008 rs6745131 chr2 224079263 C T 9.96E-04 Type 2 diabetes / / 17463246 rs1400796 chr2 224084303 C A 2.17E-04 Fibrinogen / / 17255346 rs4673054 chr2 224087862 A T 6.49E-04 Type 2 diabetes / / 17463246 rs2203733 chr2 224093101 A G 5.59E-04 Type 2 diabetes / / 17463246 rs10933000 chr2 224093410 G A 6.81E-04 Type 2 diabetes / / 17463246 rs969494 chr2 224095058 G A 4.01E-04 Type 2 diabetes / / 17463246 rs970816 chr2 224097340 G A 4.16E-04 Type 2 diabetes / / 17463246 rs1517650 chr2 224105676 A T 5.81E-04 Multiple complex diseases / / 17554300 rs2395967 chr2 224111323 T C 5.05E-04 Response to alcohol consumption (flushing response) / / 24277619 rs10183888 chr2 224116596 G A 1.80E-05 Urinary metabolites / / 21572414 rs13424509 chr2 224151518 A G 4.20E-05 Response to statin therapy / / 20339536 rs13412714 chr2 224151579 T C 3.80E-05 Response to statin therapy / / 20339536 rs2090504 chr2 224164448 C T 3.60E-05 Response to statin therapy / / 20339536 rs6709028 chr2 224165404 G T 3.30E-05 Response to statin therapy / / 20339536 rs10168471 chr2 224167273 C G 3.60E-05 Response to statin therapy / / 20339536 rs13414858 chr2 224167716 A C 3.60E-05 Response to statin therapy / / 20339536 rs1517645 chr2 224172750 G C 7.20E-04 Type 2 diabetes / / 17846124 rs1517628 chr2 224175831 A G 4.96E-05 Coronary heart disease / / 21971053 rs1517635 chr2 224203115 T A 1.32E-05 Educational attainment / / 21694764 rs12151816 chr2 224204815 C T 3.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs10176350 chr2 224214759 G A 2.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs1517641 chr2 224227452 T C 8.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs1250915 chr2 224228758 T A 5.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs1250920 chr2 224230626 G C 4.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs990296 chr2 224232297 G A 4.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs990297 chr2 224232396 C A 8.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs1250924 chr2 224232527 A G 8.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs1250939 chr2 224244634 A G 5.15E-04 Insulin resistance / / 21901158 rs6727591 chr2 224262876 A T 5.79E-04 Insulin resistance / / 21901158 rs16864755 chr2 224274622 G A 4.00E-06 Osteoporosis-related phenotypes / / 20200953 rs16864788 chr2 224300897 G A 5.77E-04 Depression (quantitative trait) / / 20800221 rs7601486 chr2 224344833 A G 9.54E-06 Obesity-related traits / / 23251661 rs2395987 chr2 224349558 C A 6.84E-04 Type 2 diabetes / / 17463246 rs755187 chr2 224350339 A G 5.00E-04 Type 2 diabetes / / 17463246 rs6731710 chr2 224351752 C T 7.28E-04 Type 2 diabetes / / 17463246 rs6436408 chr2 224352075 G C 3.62E-04 Type 2 diabetes / / 17463246 rs17230683 chr2 224406462 C T 1.83E-04 Gallstones / / 17632509 rs11675944 chr2 224408490 G T 0.000607 Salmonella-induced pyroptosis / / 22837397 rs10498152 chr2 224439486 A G 7.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs16864968 chr2 224459683 A G 3.00E-06 Response to hepatitis C treatment / / 22095909 rs2230168 chr2 224462056 G A,C,T 1.49E-04 Stroke SCG2 UTR-3 pha002886 rs4673067 chr2 224472252 G A 1.17E-04 Hearing function / / 17255346 rs13402129 chr2 224473767 T G 4.01E-04 Schizophrenia / / 19197363 rs13402129 chr2 224473767 T G 8.56E-05 Erythrocyte counts / / pha003099 rs13385650 chr2 224508025 G A 8.00E-05 Cholesterol / / pha003073 rs7585595 chr2 224531242 A C,T 1.98E-04 Multiple complex diseases / / 17554300 rs734556 chr2 224561329 C T 4.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4674808 chr2 224562525 A G 2.59E-04 Multiple complex diseases / / 17554300 rs625588 chr2 224602647 T C 7.90E-06 Major depressive disorder / / 21042317 rs4673075 chr2 224610232 C T 8.00E-05 Prostate cancer / / 21743057 rs7603262 chr2 224636490 A C 9.55E-05 Blood Pressure AP1S3 intron pha003048 rs12623921 chr2 224637079 C T 9.55E-05 Blood Pressure AP1S3 intron pha003048 rs7604002 chr2 224658733 C A 1.20E-05 Urinary metabolites AP1S3 intron 21572414 rs603848 chr2 224679310 C T 6.86E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines AP1S3 intron 21844884 rs16865241 chr2 224689660 C A 2.60E-05 Urinary metabolites AP1S3 intron 21572414 rs7558186 chr2 224696267 G T 6.50E-04 Glaucoma (primary open-angle) AP1S3 intron 22419738 rs625289 chr2 224731744 G A 3.32E-04 Myocardial Infarction / / pha002883 rs1438832 chr2 224811952 T C 4.69E-04 Smoking initiation / / 24665060 rs7608941 chr2 224854068 C A 2.81E-04 Multiple complex diseases SERPINE2 intron 17554300 rs6436459 chr2 224880336 C T 4.20E-05 Bone mineral density (BMD),in women SERPINE2 intron 20164292 rs6436459 chr2 224880336 C T 3.37E-05 Myopia (pathological) SERPINE2 intron 21095009 rs13022548 chr2 224884090 G C 8.59E-04 Suicide attempts in bipolar disorder SERPINE2 intron 21423239 rs13013387 chr2 224886238 T C 7.13E-04 Suicide attempts in bipolar disorder SERPINE2 intron 21423239 rs13008520 chr2 224889383 G A 7.02E-04 Suicide attempts in bipolar disorder SERPINE2 intron 21423239 rs13027940 chr2 224895301 C T 8.65E-04 Suicide attempts in bipolar disorder SERPINE2 intron 21423239 rs6436462 chr2 224898155 C T 9.38E-04 Suicide attempts in bipolar disorder SERPINE2 intron 21423239 rs13012418 chr2 224905555 G A 7.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs282265 chr2 224917560 G A 7.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs13016241 chr2 224918221 G T 6.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs6740660 chr2 224943685 G A 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs896899 chr2 224961762 T C 0.000504431 Hypertension (early onset hypertension) / / 22479346 rs6754790 chr2 224965458 A G 0.000582293 Hypertension (early onset hypertension) / / 22479346 rs12477352 chr2 224970482 T G 0.000790666 Hypertension (early onset hypertension) / / 22479346 rs6436465 chr2 224976957 A G 7.64E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2396057 chr2 224977216 G C 3.65E-04 Acute lung injury / / 22295056 rs958380 chr2 224999824 C T 3.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7607972 chr2 225005316 T C 8.30E-06 Urinary metabolites / / 21572414 rs4264554 chr2 225007071 T C 1.89E-05 Common variable immunodeficiency / / 21497890 rs13019329 chr2 225015584 T C 3.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13019329 chr2 225015584 T C 6.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13019329 chr2 225015584 T C 0.0002 Migraine / / 22678113 rs6436469 chr2 225017062 T C 9.07E-05 Epilepsy (remission after treatment) / / 23962720 rs1476205 chr2 225024332 G A 4.24E-04 Acute lung injury / / 22295056 rs1453672 chr2 225025120 A G 4.23E-04 Acute lung injury / / 22295056 rs6761041 chr2 225030129 T C 2.82E-04 Smoking initiation / / 24665060 rs2602675 chr2 225042531 T C 5.46E-04 Smoking initiation / / 24665060 rs2629046 chr2 225047744 T C 8.00E-12 Height / / 20881960 rs2602681 chr2 225070767 C T 5.96E-04 Smoking initiation / / 24665060 rs12477529 chr2 225084764 G A 9.54E-04 Multiple complex diseases / / 17554300 rs7578029 chr2 225122467 T A 4.71E-04 Multiple complex diseases / / 17554300 rs1008415 chr2 225151655 T C 9.44E-05 Cholesterol / / pha003083 rs6755111 chr2 225178583 C T 7.21E-05 Cholesterol / / pha003083 rs13024765 chr2 225180219 C T 8.11E-05 Cholesterol / / pha003083 rs2098533 chr2 225182419 T C 8.04E-05 Cholesterol / / pha003083 rs6708010 chr2 225186069 C T 2.88E-05 Cholesterol / / pha003083 rs2042086 chr2 225222900 T C 8.71E-06 Longevity,exceptional / / 20595579 rs16865908 chr2 225245151 A G 5.09E-04 Tourette syndrome FAM124B intron 22889924 rs2216460 chr2 225247487 C A 5.74E-04 Parkinson's disease FAM124B intron 17052657 rs741533 chr2 225260618 C T 2.21E-04 Myocardial Infarction FAM124B intron pha002883 rs4673104 chr2 225285539 C G 3.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs12694637 chr2 225300505 A G 7.16E-04 Multiple complex diseases / / 17554300 rs12328241 chr2 225302513 T C 6.70E-04 Multiple complex diseases / / 17554300 rs1642922 chr2 225305832 C T 5.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1523921 chr2 225308978 T C 2.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1523921 chr2 225308978 T C 5.95E-05 Anorexia nervosa / / 24514567 rs2710598 chr2 225309374 A G 1.14E-08 Metabolite levels / / 23281178 rs2462140 chr2 225310582 A G 1.14E-08 Metabolite levels / / 23281178 rs2462140 chr2 225310582 A G 4.72E-04 Myocardial Infarction / / pha002883 rs2710603 chr2 225311923 T C 3.00E-08 Metabolite levels / / 23281178 rs1721279 chr2 225314761 A G 1.14E-08 Metabolite levels / / 23281178 rs1721279 chr2 225314761 A G 4.91E-04 Myocardial Infarction / / pha002883 rs6436488 chr2 225317949 A G 1.11E-08 Metabolite levels / / 23281178 rs6733771 chr2 225318816 T G 1.11E-08 Metabolite levels / / 23281178 rs11901496 chr2 225320132 C T 1.24E-08 Metabolite levels / / 23281178 rs11677844 chr2 225323473 A T 1.11E-08 Metabolite levels / / 23281178 rs1568752 chr2 225324758 G C 1.92E-08 Metabolite levels / / 23281178 rs6436490 chr2 225326693 A C 1.11E-08 Metabolite levels / / 23281178 rs16865992 chr2 225327572 C T 1.20E-05 Urinary metabolites / / 21572414 rs16866061 chr2 225439844 A G 9.74E-04 Multiple complex diseases CUL3 intron 17554300 rs16866061 chr2 225439844 A G 8.70E-06 Serum metabolites CUL3 intron 19043545 rs10498164 chr2 225478729 C T 8.64E-04 Depression (quantitative trait) / / 20800221 rs16866105 chr2 225515527 T C 3.71E-04 Multiple complex diseases / / 17554300 rs397871951 chr2 225543748 TG T,TTG 3.12E-11 Metabolite levels / / 22286219 rs1843834 chr2 225558042 A G 4.00E-06 IgE levels in asthmatics (D.p. specific) / / 23967269 rs1843834 chr2 225558042 A G 9.31E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs10197382 chr2 225574650 T C 5.72E-06 IgE levels in asthmatics (D.p. specific) / / 23967269 rs1565073 chr2 225634693 T G 6.52E-04 Multiple complex diseases DOCK10 intron 17554300 rs1565073 chr2 225634693 T G 3.31E-05 IgE levels in asthmatics (D.p. specific) DOCK10 intron 23967269 rs17271511 chr2 225643831 A G 2.40E-05 Urinary metabolites DOCK10 intron 21572414 rs6717059 chr2 225665193 C T 1.81E-05 Cognitive performance DOCK10 intron 19734545 rs6717059 chr2 225665193 C T 4.54E-05 IgE levels in asthmatics (D.p. specific) DOCK10 intron 23967269 rs4674941 chr2 225670901 G C 0.00029 Prostate cancer DOCK10 missense 23555315 rs13024433 chr2 225774612 A C 2.49E-05 Attention deficit hyperactivity disorder DOCK10 intron 22420046 rs11694713 chr2 225787887 G A 2.85E-04 Lymphocyte counts DOCK10 intron 22286170 rs11686538 chr2 225818564 A G 1.27E-05 Attention deficit hyperactivity disorder DOCK10 intron 22420046 rs4674953 chr2 225826811 T C 3.86E-05 Attention deficit hyperactivity disorder DOCK10 intron 22420046 rs9967872 chr2 225845136 C G 7.45E-04 Response to taxane treatment (placlitaxel) DOCK10 intron 23006423 rs4674958 chr2 225845489 C A 7.45E-04 Response to taxane treatment (placlitaxel) DOCK10 intron 23006423 rs7566475 chr2 225847668 C A 7.45E-04 Response to taxane treatment (placlitaxel) DOCK10 intron 23006423 rs281526 chr2 225853618 C T 1.42E-04 Response to taxane treatment (placlitaxel) DOCK10 intron 23006423 rs4674964 chr2 225921137 G A 2.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs4674965 chr2 225921569 C G 2.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs7586721 chr2 225923843 C T 2.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs6721066 chr2 225927090 A G 2.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs7598761 chr2 225927422 G A 1.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs7574966 chr2 225927736 A G 1.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs13418232 chr2 225928691 T C 1.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs6748196 chr2 225931905 C T 2.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs6760820 chr2 225935261 C G 2.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs6741439 chr2 225952702 A G 3.53E-05 Bipolar disorder and schizophrenia / / 20889312 rs6717227 chr2 226013860 G A 5.05E-04 Hemoglobin concentration / / 20534544 rs728654 chr2 226030132 T G 5.05E-04 Hemoglobin concentration / / 20534544 rs3845841 chr2 226031280 T A 1.60E-05 Urinary metabolites / / 21572414 rs1443668 chr2 226032426 T C 7.73E-04 Multiple complex diseases / / 17554300 rs1443668 chr2 226032426 T C 1.50E-05 Urinary metabolites / / 21572414 rs1443667 chr2 226032555 T C 1.60E-05 Urinary metabolites / / 21572414 rs1596395 chr2 226035953 C T 1.30E-05 Urinary metabolites / / 21572414 rs10190539 chr2 226036157 C T 1.50E-05 Urinary metabolites / / 21572414 rs10165442 chr2 226038842 T C 1.30E-05 Urinary metabolites / / 21572414 rs13387555 chr2 226040421 T G 1.50E-05 Urinary metabolites / / 21572414 rs9288601 chr2 226045748 C A 8.44E-04 Multiple complex diseases / / 17554300 rs1348430 chr2 226047177 T C 1.30E-05 Urinary metabolites / / 21572414 rs1470328 chr2 226051978 A G 1.30E-05 Urinary metabolites / / 21572414 rs1348422 chr2 226067358 A G 7.98E-04 Alzheimer's disease / / 22005930 rs6736537 chr2 226082156 A G 8.49E-04 Alzheimer's disease / / 22005930 rs4674980 chr2 226112612 T C 7.74E-05 Serum metabolites / / 19043545 rs12694665 chr2 226148202 A G 3.75E-04 Multiple complex diseases / / 17554300 rs2044235 chr2 226157767 C A 2.70E-05 Urinary metabolites / / 21572414 rs2044236 chr2 226157800 C A 7.85E-05 Alzheimer's disease / / 17998437 rs6436551 chr2 226183487 G A 2.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4673141 chr2 226191730 G A 5.60E-06 Urinary metabolites / / 21572414 rs1473307 chr2 226225623 C T 3.00E-07 Menopause (age at onset) / / 23307926 rs1517484 chr2 226237910 C T 5.00E-07 Attention deficit hyperactivity disorder (time to onset) / / 18937294 rs9973944 chr2 226244129 T C 8.33E-04 Sarcoidosis / / 19165924 rs2030199 chr2 226261607 G A 2.82E-05 Suicide attempts in depression or bipolar disorder / / 24964207 rs11692499 chr2 226364402 A G 4.55E-05 Serum metabolites NYAP2 intron 19043545 rs11692499 chr2 226364402 A G 1.43E-05 Attention deficit hyperactivity disorder NYAP2 intron 23728934 rs6706295 chr2 226364934 A C 5.87E-05 Serum metabolites NYAP2 intron 19043545 rs6706295 chr2 226364934 A C 2.05E-05 Attention deficit hyperactivity disorder NYAP2 intron 23728934 rs6713607 chr2 226372129 A G 4.55E-05 Serum metabolites NYAP2 intron 19043545 rs6713607 chr2 226372129 A G 3.88E-05 Attention deficit hyperactivity disorder NYAP2 intron 23728934 rs12466468 chr2 226382951 T C 8.05E-05 Serum metabolites NYAP2 intron 19043545 rs12466468 chr2 226382951 T C 1.11E-05 Attention deficit hyperactivity disorder NYAP2 intron 23728934 rs11695839 chr2 226393981 G A 7.20E-05 Serum metabolites NYAP2 intron 19043545 rs12053018 chr2 226395276 A C,G,T 1.85E-05 Attention deficit hyperactivity disorder NYAP2 intron 23728934 rs891585 chr2 226400416 A T 7.67E-05 Serum metabolites NYAP2 intron 19043545 rs891585 chr2 226400416 A T 3.26E-05 Attention deficit hyperactivity disorder NYAP2 intron 23728934 rs1431082 chr2 226451269 T G 5.25E-05 Coronary heart disease NYAP2 intron 21971053 rs1993323 chr2 226456461 C A 2.89E-04 Alcohol dependence NYAP2 intron 20201924 rs1993323 chr2 226456461 C A 8.29E-05 Coronary heart disease NYAP2 intron 21971053 rs715678 chr2 226465409 T C 9.80E-05 Response to statin therapy NYAP2 intron 20339536 rs10498192 chr2 226482621 T A 7.91E-04 Type 2 diabetes NYAP2 intron 17463246 rs936070 chr2 226501136 G A 3.22E-04 Coronary heart disease NYAP2 intron 21971053 rs16866682 chr2 226504486 A C 7.00E-05 Schizophrenia NYAP2 intron 19571809 rs13400632 chr2 226504838 C T 3.84E-04 Multiple complex diseases NYAP2 intron 17554300 rs13407844 chr2 226506851 C A 3.50E-05 Response to statin therapy NYAP2 intron 20339536 rs12994235 chr2 226507838 G A 4.80E-04 Multiple complex diseases NYAP2 intron 17554300 rs12694674 chr2 226510293 G C 4.22E-04 Multiple complex diseases NYAP2 intron 17554300 rs12694674 chr2 226510293 G C 8.10E-05 Schizophrenia NYAP2 intron 19571809 rs7595617 chr2 226515698 A G 8.17E-04 Alcohol dependence NYAP2 intron 20201924 rs6736992 chr2 226538647 A G 1.42E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs7558384 chr2 226568924 T C 7.75E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs2017444 chr2 226596497 A G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs16866733 chr2 226749371 T C 4.34E-04 Multiple complex diseases / / 17554300 rs13018599 chr2 226902562 T G 3.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10168777 chr2 226914836 G C 9.38E-04 Multiple complex diseases / / 17554300 rs13393056 chr2 226921917 G C 9.51E-04 Multiple complex diseases / / 17554300 rs16866798 chr2 226922612 G A 9.20E-04 Multiple complex diseases / / 17554300 rs6436593 chr2 226939141 T A 9.99E-04 Multiple complex diseases / / 17554300 rs1949717 chr2 226951194 C G 2.78E-04 Multiple complex diseases / / 17554300 rs4675047 chr2 226957178 G A 3.35E-04 Multiple complex diseases / / 17554300 rs1522804 chr2 226989156 A C 4.04E-04 Multiple complex diseases / / 17554300 rs10498197 chr2 226993313 A G 5.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs6758183 chr2 227000986 G A 3.00E-06 Corneal astigmatism / / 22144915 rs2948556 chr2 227009627 G A 1.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC646736 intron 20877124 rs2948560 chr2 227014062 A C 3.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC646736 intron 20877124 rs114455893 chr2 227018516 C T 0.00005295 Sarcoidosis LOC646736 intron 22952805 rs13404263 chr2 227020399 G A 2.27E-04 IgE levels LOC646736 intron 17255346 rs1522802 chr2 227020494 A C 7.05E-05 Information processing speed LOC646736 intron 21130836 rs7578326 chr2 227020653 A G 5.00E-20 Type 2 diabetes LOC646736 intron 20581827 rs7578326 chr2 227020653 A G 3.80E-10 Type 2 diabetes LOC646736 intron 22885922 rs7578326 chr2 227020653 A G 5.00E-20 Type 2 diabetes LOC646736 intron 23300278 rs952227 chr2 227062080 A G 1.05E-06 Coronary heart disease / / 22319020 rs2943634 chr2 227068080 A C,G 7.49E-06 Multiple complex diseases / / 17554300 rs2943634 chr2 227068080 A C,G 2.00E-07 Coronary heart disease / / 17634449 rs2943634 chr2 227068080 A C,G 2.00E-07 Coronary heart disease / / 21347282 rs2943634 chr2 227068080 A C,G 5.00E-05 Coronary heart disease / / 21966275 rs2943634 chr2 227068080 A C,G 0.000000432 Type 2 diabetes / / 22325160 rs2943634 chr2 227068080 A C,G 2.00E-14 Fasting insulin-related traits (interaction with BMI) / / 22581228 rs2943634 chr2 227068080 A C,G 0.00000134 Triglycerides / / 23063622 rs2943634 chr2 227068080 A C,G 2.36E-09 HDL cholesterol / / 23063622 rs2943636 chr2 227087284 G A 2.00E-07 Sexual dimorphism in anthropometric traits / / 23754948 rs2943640 chr2 227093585 A C 5.10E-04 Multiple complex diseases / / 17554300 rs2943640 chr2 227093585 A C 4.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs2943640 chr2 227093585 A C 0.00000003 Type 2 diabetes (males) / / 22885922 rs2943640 chr2 227093585 A C 0.00000014 Fasting insulin-related traits / / 22885922 rs2943640 chr2 227093585 A C 1.30E-09 Type 2 diabetes (females) / / 22885922 rs2943640 chr2 227093585 A C 2.70E-14 Type 2 diabetes / / 22885922 rs2943640 chr2 227093585 A C 7.00E-09 Type 2 diabetes / / 24509480 rs2943641 chr2 227093745 T C 9.00E-12 Type 2 diabetes and other traits / / 19734900 rs2943641 chr2 227093745 T C 9.00E-12 Coronary heart disease / / 21347282 rs2943641 chr2 227093745 T C 9.00E-12 Type 2 diabetes / / 21647700 rs2943641 chr2 227093745 T C 9.28E-12 Type 2 diabetes / / 23300278 rs1515114 chr2 227098387 A G 8.13E-04 Parkinson's disease / / 17052657 rs2943645 chr2 227099180 C T 2.26E-19 Fasting insulin-related traits / / 22885924 rs2943646 chr2 227099534 A G 3.58E-04 Multiple complex diseases / / 17554300 rs2972147 chr2 227099854 T C 3.89E-04 Multiple complex diseases / / 17554300 rs2972146 chr2 227100698 G T 2.00E-08 Triglycerides / / 20686565 rs2972146 chr2 227100698 G T 2.00E-09 HDL cholesterol / / 20686565 rs2972146 chr2 227100698 G T 2.00E-17 HDL cholesterol / / 24097068 rs2972146 chr2 227100698 G T 3.00E-15 Triglycerides / / 24097068 rs2972144 chr2 227101411 A G 3.56E-04 Multiple complex diseases / / 17554300 rs2943650 chr2 227105921 C T 4.00E-11 Adiposity / / 21706003 rs2972143 chr2 227116365 A G 3.21E-19 Fasting insulin-related traits / / 22885924 rs2943656 chr2 227121918 A G 6.62E-04 Multiple complex diseases / / 17554300 rs1515110 chr2 227122216 G T 2.00E-07 Adiponectin levels / / 22479202 rs2943657 chr2 227123439 C T 7.69E-04 Multiple complex diseases / / 17554300 rs2943658 chr2 227123584 A G 7.45E-04 Multiple complex diseases / / 17554300 rs1515099 chr2 227128899 G A 7.66E-04 Multiple complex diseases / / 17554300 rs41504645 chr2 227131174 T C 9.37E-04 Multiple complex diseases / / 17554300 rs964818 chr2 227131780 C A 2.50E-04 Alcohol dependence / / 20201924 rs964818 chr2 227131780 C A 4.40E-05 Alcohol dependence / / 20201924 rs964818 chr2 227131780 C A 5.63E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs964818 chr2 227131780 C A 4.37E-05 Alcoholism / / pha002893 rs186397905 chr2 227134138 C G 0.0000221 Menopause (age at onset) / / 23424626 rs2713541 chr2 227141768 A T 8.07E-04 Multiple complex diseases / / 17554300 rs4510219 chr2 227148722 A C 2.40E-04 Alcohol dependence / / 20201924 rs4510219 chr2 227148722 A C 4.90E-05 Alcohol dependence / / 20201924 rs4510219 chr2 227148722 A C 4.86E-05 Alcoholism / / pha002893 rs189110944 chr2 227149196 C A 0.0000472 Menopause (age at onset) / / 23424626 rs35660230 chr2 227149196 C CA 0.0000472 Menopause (age at onset) / / 23424626 rs567779929 chr2 227149196 C CA 0.0000472 Menopause (age at onset) / / 23424626 rs71410385 chr2 227149196 C CA 0.0000472 Menopause (age at onset) / / 23424626 rs117258126 chr2 227172342 C T 0.0000218 Menopause (age at onset) / / 23424626 rs3914466 chr2 227174846 G A 8.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3914465 chr2 227174909 A G 1.60E-04 Alcohol dependence / / 20201924 rs3914465 chr2 227174909 A G 1.90E-05 Alcohol dependence / / 20201924 rs3914465 chr2 227174909 A G 1.85E-05 Alcoholism / / pha002893 rs2673148 chr2 227174983 A C 8.81E-05 Multiple complex diseases / / 17554300 rs925735 chr2 227179630 C G 2.00E-08 Adiponectin levels / / 22479202 rs10933137 chr2 227184631 C T 7.33E-04 Multiple complex diseases / / 17554300 rs2894592 chr2 227226621 T G 2.07E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs2396341 chr2 227253414 C T 1.60E-05 Urinary metabolites / / 21572414 rs2396342 chr2 227253518 T C 1.50E-05 Urinary metabolites / / 21572414 rs2894604 chr2 227259267 C T 4.87E-05 Coronary Artery Disease / / 17634449 rs12185566 chr2 227263777 A G 1.87E-04 IgE levels / / 17255346 rs7599722 chr2 227265046 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs13032261 chr2 227268591 C A 4.53E-05 Parkinson's disease / / 17052657 rs12991594 chr2 227270422 G A 4.42E-04 IgE levels / / 17255346 rs6749681 chr2 227277006 A G 1.05E-04 IgE levels / / 17255346 rs6749681 chr2 227277006 A G 9.73E-04 Alzheimer's disease / / 17998437 rs4281890 chr2 227284206 A G 4.75E-04 Parkinson's disease / / 17052657 rs4390759 chr2 227288763 A G 5.60E-06 Urinary metabolites / / 21572414 rs4392250 chr2 227289084 T C 1.80E-05 Urinary metabolites / / 21572414 rs4129068 chr2 227294482 C T 1.27E-04 Parkinson's disease / / 17052657 rs12694698 chr2 227296072 G A 2.14E-04 IgE levels / / 17255346 rs4446065 chr2 227308257 T A 1.80E-05 Urinary metabolites / / 21572414 rs6436625 chr2 227308645 T G 1.70E-05 Urinary metabolites / / 21572414 rs4675080 chr2 227309616 C T 2.20E-05 Urinary metabolites / / 21572414 rs10186065 chr2 227339408 A G 2.80E-05 Urinary metabolites / / 21572414 rs6757297 chr2 227342038 G C 7.71E-05 Coronary Artery Disease / / 17634449 rs13425767 chr2 227342966 C T 2.90E-05 Urinary metabolites / / 21572414 rs1392841 chr2 227345365 C A 4.24E-04 Parkinson's disease / / 17052657 rs13392647 chr2 227353550 G A 0.000773446 Hypertension (early onset hypertension) / / 22479346 rs11903929 chr2 227360446 T C 4.37E-05 Attention deficit hyperactivity disorder / / pha002875 rs10933150 chr2 227361185 T A 3.50E-06 White blood cell count / / 21738479 rs7581080 chr2 227376088 T A 8.73E-04 Alzheimer's disease / / 17998437 rs6436630 chr2 227379856 C T 9.97E-04 Alzheimer's disease / / 17998437 rs11899501 chr2 227387524 T C 5.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs11899345 chr2 227393893 A G 3.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs12467492 chr2 227418826 C T 4.08E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs12467492 chr2 227418826 C T 1.08E-05 Platelet counts / / pha003100 rs16867090 chr2 227428810 T C 5.62E-04 Insulin resistance / / 21901158 rs16867099 chr2 227447917 A C 9.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs12185555 chr2 227559317 A G 8.25E-04 HIV-1 viral setpoint / / 17641165 rs12185555 chr2 227559317 A G 9.99E-07 HIV-1 control / / 20041166 rs12185555 chr2 227559317 A G 9.69E-06 HIV-1 viral setpoint / / 21490045 rs12185556 chr2 227559414 A G 1.10E-05 Urinary metabolites / / 21572414 rs7558386 chr2 227562139 A G 1.00E-07 P-tau181p levels / / 20932310 rs1882577 chr2 227574207 C T 6.64E-04 Type 2 diabetes / / 17463246 rs2288587 chr2 227596512 T C 8.36E-04 Multiple complex diseases IRS1 UTR-3 17554300 rs16822570 chr2 227599533 T G 5.16E-04 Multiple complex diseases IRS1 UTR-3 17554300 rs10182336 chr2 227608811 A G 0.000053 Coronary artery calcification IRS1 intron 23727086 rs13431179 chr2 227610241 G A 6.14E-04 Multiple complex diseases IRS1 intron 17554300 rs13431179 chr2 227610241 G A 4.29E-04 Sudden cardiac arrest IRS1 intron 21658281 rs10205233 chr2 227614005 C T 5.73E-04 Multiple complex diseases IRS1 intron 17554300 rs10181778 chr2 227614237 A T 7.44E-04 Multiple complex diseases IRS1 intron 17554300 rs10498210 chr2 227619946 G A 1.28E-15 Varicose Veins IRS1 intron pha001416 rs12052364 chr2 227635208 A G 9.20E-05 Multiple complex diseases IRS1 intron 17554300 rs1560251 chr2 227653948 C A 2.39E-04 Lymphocyte counts IRS1 intron 22286170 rs2288586 chr2 227655390 G C 2.19E-04 Multiple complex diseases IRS1 intron 17554300 rs2229613 chr2 227660689 C T 8.20E-09 LDL cholesterol IRS1 cds-synon 23063622 rs2229613 chr2 227660689 C T 9.37E-11 Cholesterol,total IRS1 cds-synon 23063622 rs6725556 chr2 227666992 A G 9.89E-05 Monocyte chemoattractant protein-1 / / pha003071 rs13015698 chr2 227700818 C T 8.01E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs13015698 chr2 227700818 C T 6.66E-04 Response to cytadine analogues (cytosine arabinoside) RHBDD1 intron 24483146 rs16822834 chr2 227739823 A G 1.20E-06 Urinary metabolites RHBDD1 intron 21572414 rs6734566 chr2 227757492 C A 2.30E-06 Urinary metabolites RHBDD1 intron 21572414 rs2396432 chr2 227765891 C T 9.06E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs3820928 chr2 227773466 T C 5.00E-06 Pulmonary function RHBDD1 intron 17903307 rs1864271 chr2 227780266 G C 9.90E-05 White matter hyperintensity burden RHBDD1 intron 21681796 rs7560867 chr2 227780945 C A,G 9.92E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs1114562 chr2 227788592 T C 4.43E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs2115597 chr2 227791218 T C 9.22E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs7582251 chr2 227791703 G T 4.42E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs10167086 chr2 227792729 A T 4.41E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs10195072 chr2 227794452 G A 4.40E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs10174073 chr2 227794944 A G 4.54E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs10169717 chr2 227796911 T G 4.45E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs11685983 chr2 227799853 A G 4.40E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs4675123 chr2 227800205 T C 4.40E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs6718767 chr2 227800776 A G 9.36E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs4673174 chr2 227801316 A T 3.75E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs13384342 chr2 227805010 G A 3.76E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs7562776 chr2 227806550 G A 3.76E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs4675128 chr2 227814757 T C 3.75E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs10439363 chr2 227815065 C T 3.75E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs4234062 chr2 227819050 C A 3.77E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs10210963 chr2 227821845 A G 4.41E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs10197773 chr2 227824835 G A 3.75E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs4234063 chr2 227828335 A T 4.29E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs2177593 chr2 227833869 G A 7.36E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs6718057 chr2 227834349 T G 4.38E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs1917122 chr2 227835681 C T 5.01E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs2177594 chr2 227836239 C G 4.77E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs7421491 chr2 227839278 C A 4.79E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs1996998 chr2 227840294 C A 5.48E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs1917126 chr2 227840923 G T 5.60E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs4675132 chr2 227841792 A C 5.31E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs4675133 chr2 227843010 C T 5.23E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs4675134 chr2 227843489 C T 5.84E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs4461255 chr2 227846524 A G 5.91E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs6707265 chr2 227849255 T A 8.65E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs6706802 chr2 227850776 A G 5.42E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs6728239 chr2 227856552 A G 7.87E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs4234064 chr2 227857497 G T 7.44E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs10210997 chr2 227859108 C T 8.73E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs12151848 chr2 227859326 G A 7.38E-04 Suicide attempts in bipolar disorder RHBDD1 intron 21423239 rs10933164 chr2 227860671 G A 4.42E-04 Suicide attempts in bipolar disorder RHBDD1 UTR-3 21423239 rs10189579 chr2 227864876 A G 8.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs1320407 chr2 227867385 G T 7.33E-04 Suicide attempts in bipolar disorder COL4A4 nearGene-3 21423239 rs1054413 chr2 227867719 G A 7.35E-04 Suicide attempts in bipolar disorder COL4A4 UTR-3 21423239 rs2228557 chr2 227872182 G A 7.33E-04 Suicide attempts in bipolar disorder COL4A4 cds-synon 21423239 rs9288618 chr2 227872617 A G 7.32E-04 Suicide attempts in bipolar disorder COL4A4 intron 21423239 rs13419076 chr2 227873028 A G 8.61E-04 Suicide attempts in bipolar disorder COL4A4 intron 21423239 rs4423583 chr2 227874957 C T 6.24E-04 Suicide attempts in bipolar disorder COL4A4 intron 21423239 rs10182307 chr2 227875360 G A 8.08E-04 Suicide attempts in bipolar disorder COL4A4 intron 21423239 rs10188770 chr2 227877037 G A 8.64E-04 Suicide attempts in bipolar disorder COL4A4 intron 21423239 rs6740108 chr2 227889559 A C 7.29E-04 Suicide attempts in bipolar disorder COL4A4 intron 21423239 rs2272205 chr2 227915924 T C 3.00E-09 Immune reponse to smallpox (secreted IFN-alpha) COL4A4 intron 22610502 rs4566357 chr2 227922015 A G 0.0000247 Coronary artery disease COL4A4 intron 23202125 rs11898094 chr2 227924774 C T 1.62E-05 Brain structure COL4A4 intron 22504417 rs13015629 chr2 227938880 A G 6.24E-04 Alzheimer's disease COL4A4 intron 17998437 rs7574757 chr2 227943480 C T 2.43E-05 Brain structure COL4A4 intron 22504417 rs6743614 chr2 227977893 C A 8.02E-04 Response to taxane treatment (placlitaxel) COL4A4 intron 23006423 rs6743614 chr2 227977893 C A 3.64E-04 Smoking quantity COL4A4 intron 24665060 rs2396463 chr2 228044992 C A 1.50E-06 Creatinine levels COL4A3 intron 20222955 rs2204862 chr2 228052600 A G 4.80E-05 Creatinine levels COL4A3 intron 20222955 rs4278919 chr2 228058027 G A 6.12E-04 Acute lung injury COL4A3 intron 22295056 rs17367956 chr2 228064828 A G 3.95E-05 Parent of origin effect on language impairment (maternal) COL4A3 intron 24571439 rs6739977 chr2 228065095 A G 7.60E-05 Parent of origin effect on language impairment (maternal) COL4A3 intron 24571439 rs2141831 chr2 228087689 C T 6.51E-05 Myopia (pathological) COL4A3 intron 21095009 rs13021572 chr2 228090768 G A 7.48E-05 Telomere length COL4A3 intron 21573004 rs13028299 chr2 228091661 G A 2.24E-06 White blood cell count COL4A3 intron 21738479 rs35212277 chr2 228092035 G A 9.00E-06 Metabolite levels (5-HIAA/ MHPG Ratio) COL4A3 intron 23319000 rs13424243 chr2 228102723 G C 1.80E-05 Urinary metabolites COL4A3 missense 21572414 rs10933172 chr2 228121147 T G 9.83E-05 Non-alcoholic fatty liver disease histology (other) COL4A3 intron 20708005 rs7606754 chr2 228135180 A G 1.00E-09 Corneal structure COL4A3 intron 23291589 rs4073904 chr2 228161915 A G 1.99E-05 Monocyte chemoattractant protein-1 COL4A3 intron pha003071 rs10451555 chr2 228167560 G A 2.10E-05 Monocyte chemoattractant protein-1 COL4A3 intron pha003071 rs7582023 chr2 228267108 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4344925 chr2 228271651 G A 9.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs4344925 chr2 228271651 G A 1.20E-05 Urinary metabolites / / 21572414 rs76113735 chr2 228308820 C T 0.0006664 Sarcoidosis / / 22952805 rs4485561 chr2 228373683 G T 1.15E-05 Airway hyperresponsiveness AGFG1 intron 23984888 rs77827358 chr2 228378545 T C 0.0005882 Sarcoidosis AGFG1 intron 22952805 rs10189795 chr2 228378861 C T 2.97E-06 Airway hyperresponsiveness AGFG1 intron 23984888 rs4972983 chr2 228393168 C A 8.62E-06 Airway hyperresponsiveness AGFG1 intron 23984888 rs6731443 chr2 228397566 T G 2.00E-06 Airway hyperresponsiveness AGFG1 intron 23984888 rs13382948 chr2 228418957 A G 2.75E-06 Airway hyperresponsiveness AGFG1 intron 23984888 rs4129709 chr2 228438549 G A 2.27E-05 Airway hyperresponsiveness / / 23984888 rs11674314 chr2 228442208 C T 2.27E-05 Airway hyperresponsiveness / / 23984888 rs7595130 chr2 228443552 A G 2.24E-05 Airway hyperresponsiveness / / 23984888 rs7579157 chr2 228445730 C T 2.23E-05 Airway hyperresponsiveness / / 23984888 rs11683662 chr2 228448028 G A 2.21E-05 Airway hyperresponsiveness / / 23984888 rs7592613 chr2 228451190 T C 2.25E-05 Airway hyperresponsiveness / / 23984888 rs7581631 chr2 228458944 A T 5.15E-04 Coronary heart disease / / 21606135 rs6714320 chr2 228466832 G A 2.26E-05 Serum metabolites / / 19043545 rs16823699 chr2 228474106 A C 2.03E-04 IgE levels / / 17255346 rs2138402 chr2 228476253 C G 4.60E-04 Suicide attempts in bipolar disorder C2orf83 missense 21423239 rs16823709 chr2 228479171 T C 1.33E-04 IgE levels C2orf83 intron 17255346 rs16823719 chr2 228481316 T C 1.16E-05 IgE levels C2orf83 intron 17255346 rs11889798 chr2 228481419 C T 4.00E-07 Immune reponse to smallpox (secreted TNF-alpha) C2orf83 intron 22610502 rs12616684 chr2 228489694 A G 2.28E-04 Multiple complex diseases C2orf83 intron 17554300 rs12616684 chr2 228489694 A G 1.60E-05 Urinary metabolites C2orf83 intron 21572414 rs10179572 chr2 228504503 A G 8.99E-04 Multiple complex diseases / / 17554300 rs10179572 chr2 228504503 A G 1.31E-05 Mathematical ability / / 24801482 rs2396468 chr2 228506119 C A 1.47E-04 Bulimia nervosa / / 23568457 rs7593751 chr2 228506427 T C 6.50E-06 Urinary metabolites / / 21572414 rs997363 chr2 228509458 C T 1.00E-06 Cervical cancer / / 24700089 rs17371490 chr2 228527799 C T 9.39E-04 Type 2 diabetes / / 17463246 rs145288025 chr2 228560632 C T 0.00062 Prostate cancer (non-advanced prostate cancer) SLC19A3 missense 23555315 rs7567984 chr2 228567967 C T 3.54E-05 Response to hepatitis C treatment SLC19A3 intron 19684573 rs11691652 chr2 228584898 T G 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11691652 chr2 228584898 T G 8.00E-06 Obesity-related traits / / 23251661 rs7557339 chr2 228595557 C T 4.88E-04 Parkinson's disease / / 16252231 rs10208046 chr2 228602577 T C 7.87E-06 Type 2 diabetes / / 17463246 rs10198436 chr2 228610384 A C 9.13E-04 Parkinson's disease / / 16252231 rs7595272 chr2 228615752 C T 4.02E-04 Hemoglobin concentration / / 20534544 rs9288627 chr2 228655101 G T 3.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9288627 chr2 228655101 G T 5.73E-05 Sodium levels / / pha003093 rs7556897 chr2 228660112 C T 0.000000324 Primary sclerosing cholangitis / / 23603763 rs13385901 chr2 228668322 C A 4.00E-06 Eating disorders (purging via substances) / / 23568457 rs367819358 chr2 228668322 CTT CAA 4.00E-06 Eating disorders (purging via substances) / / 23568457 rs13389224 chr2 228669035 C T 3.50E-04 Colorectal cancer / / 24737748 rs10175070 chr2 228670575 G A 2.00E-06 Eating disorders (purging via substances) / / 23568457 rs41397446 chr2 228692124 A G 8.01E-04 Multiple complex diseases / / 17554300 rs7591163 chr2 228715375 C T 3.00E-07 Blood pressure / / 17903302 rs13400894 chr2 228723220 G A 7.21E-04 Coronary heart disease / / 21971053 rs4973445 chr2 228750239 G T 9.06E-04 Alzheimer's disease WDR69 intron 24755620 rs1721359 chr2 228751874 G A 1.00E-05 Blood Pressure and Arterial Stiffness WDR69 intron 17903302 rs1721341 chr2 228768484 A G 0.00027599 Hypertension (early onset hypertension) WDR69 intron 22479346 rs7578514 chr2 228772961 T C 9.76E-04 Multiple complex diseases WDR69 intron 17554300 rs17197476 chr2 228773146 C T 7.77E-04 Multiple complex diseases WDR69 intron 17554300 rs11680252 chr2 228773287 T C 4.08E-04 Coronary heart disease WDR69 intron 21971053 rs10188509 chr2 228776385 T C 7.96E-04 Multiple complex diseases WDR69 intron 17554300 rs1721355 chr2 228782976 C T 0.000202413 Hypertension (early onset hypertension) WDR69 intron 22479346 rs10498224 chr2 228789581 T C 4.34E-04 Coronary heart disease / / 21971053 rs7608896 chr2 228790328 G A 2.33E-04 Coronary heart disease / / 21971053 rs11690643 chr2 228792481 C T 2.55E-04 Coronary heart disease / / 21971053 rs1916804 chr2 228808696 G T 9.98E-05 Asthma / / 20159242 rs10200894 chr2 228817132 C G 1.70E-05 Parkinson's disease / / 16252231 rs4438469 chr2 228923045 G T 3.55E-05 Neuroblastoma SPHKAP intron pha002895 rs6760875 chr2 228925898 A G 2.73E-05 Neuroblastoma SPHKAP intron pha002895 rs7561798 chr2 228973660 A G 7.86E-06 Rheumatoid arthritis SPHKAP intron 21452313 rs12615089 chr2 228989962 G A 5.12E-05 Serum metabolites SPHKAP intron 19043545 rs7577229 chr2 228991638 T C 1.62E-04 Sudden cardiac arrest SPHKAP intron 21658281 rs6436758 chr2 229000048 A G 2.06E-04 Smoking quantity SPHKAP intron 24665060 rs10171038 chr2 229028291 G A 9.04E-05 Post-operative nausea and vomiting SPHKAP intron 21694509 rs4641922 chr2 229031147 C T 2.87E-04 Stroke SPHKAP intron pha002886 rs4450587 chr2 229033765 T G 3.73E-04 Multiple complex diseases SPHKAP intron 17554300 rs6436768 chr2 229082019 C T 4.93E-04 Multiple complex diseases / / 17554300 rs7569857 chr2 229087980 C T 8.12E-04 Depression (quantitative trait) / / 20800221 rs7596305 chr2 229088071 A G 7.73E-04 Depression (quantitative trait) / / 20800221 rs7570056 chr2 229088182 C A 7.45E-04 Depression (quantitative trait) / / 20800221 rs6734910 chr2 229088564 T C 7.48E-04 Depression (quantitative trait) / / 20800221 rs4973623 chr2 229088999 A C 7.52E-04 Depression (quantitative trait) / / 20800221 rs4973077 chr2 229089087 T C 7.52E-04 Depression (quantitative trait) / / 20800221 rs7577217 chr2 229089667 G A 7.49E-04 Depression (quantitative trait) / / 20800221 rs6756442 chr2 229090591 A G 7.48E-04 Depression (quantitative trait) / / 20800221 rs11687136 chr2 229090681 C T 7.45E-04 Depression (quantitative trait) / / 20800221 rs6738921 chr2 229091495 A T 7.44E-04 Depression (quantitative trait) / / 20800221 rs6710405 chr2 229091508 C T 7.44E-04 Depression (quantitative trait) / / 20800221 rs7565432 chr2 229092221 G A 7.43E-04 Depression (quantitative trait) / / 20800221 rs12467514 chr2 229093362 A G 7.28E-04 Depression (quantitative trait) / / 20800221 rs7591756 chr2 229099320 G A 7.22E-04 Depression (quantitative trait) / / 20800221 rs7591756 chr2 229099320 G A 1.66E-04 Stroke / / pha002886 rs13394977 chr2 229100109 C A 7.31E-04 Depression (quantitative trait) / / 20800221 rs13395080 chr2 229100197 C T 7.33E-04 Depression (quantitative trait) / / 20800221 rs9989832 chr2 229100407 T C 7.42E-04 Depression (quantitative trait) / / 20800221 rs6752284 chr2 229103185 T C 7.02E-04 Depression (quantitative trait) / / 20800221 rs7593752 chr2 229104720 G A 9.16E-04 Depression (quantitative trait) / / 20800221 rs7607608 chr2 229104755 T G 9.21E-04 Depression (quantitative trait) / / 20800221 rs10804339 chr2 229106949 T C 9.23E-04 Depression (quantitative trait) / / 20800221 rs6753687 chr2 229107336 G T 8.84E-04 Depression (quantitative trait) / / 20800221 rs6711657 chr2 229107495 T C 8.90E-04 Depression (quantitative trait) / / 20800221 rs6711657 chr2 229107495 T C 2.09E-05 Stroke / / pha002886 rs1316628 chr2 229115093 T C 8.96E-04 Depression (quantitative trait) / / 20800221 rs4973079 chr2 229186057 G T 1.95E-04 Stroke / / pha002886 rs12052730 chr2 229188012 T C 2.10E-04 Sudden cardiac arrest / / 21658281 rs7582313 chr2 229193646 T C 4.77E-04 Stroke / / pha002886 rs4973082 chr2 229201398 T A 9.94E-05 Multiple complex diseases / / 17554300 rs16824782 chr2 229244723 G A 7.99E-04 Insulin resistance / / 21901158 rs7608014 chr2 229297173 A G 1.70E-05 Urinary metabolites / / 21572414 rs2216873 chr2 229297199 A G 2.00E-05 Urinary metabolites / / 21572414 rs2059390 chr2 229332491 A G 3.02E-05 Osteoarthritis (knee and hip) / / 21177295 rs2059390 chr2 229332491 A G 3.22E-05 Osteoarthritis (knee and hip) / / 21177295 rs1019599 chr2 229355615 C G 2.30E-05 Urinary metabolites / / 21572414 rs7419568 chr2 229355672 G A 1.80E-05 Urinary metabolites / / 21572414 rs7609102 chr2 229380037 C T 8.63E-04 Multiple complex diseases / / 17554300 rs16825109 chr2 229404774 T C 7.05E-04 Multiple complex diseases / / 17554300 rs16825116 chr2 229406685 G T 1.30E-05 Urinary metabolites / / 21572414 rs1435850 chr2 229430921 T C 5.88E-04 Type 2 diabetes / / 17463246 rs6752685 chr2 229478347 G A 6.82E-04 Multiple complex diseases / / 17554300 rs12616353 chr2 229485782 A T 2.20E-05 Urinary metabolites / / 21572414 rs1469837 chr2 229490307 G A 6.85E-06 Pulmonary function / / 20010835 rs16825200 chr2 229501745 A T 7.24E-08 Pulmonary function / / 20010835 rs10498230 chr2 229502503 C T 3.87E-08 Pulmonary function / / 20010835 rs1435867 chr2 229510929 T C 3.74E-08 Pulmonary function / / 20010835 rs1435867 chr2 229510929 T C 2.00E-09 Pulmonary function (interaction) / / 23284291 rs4143199 chr2 229512901 C T 4.01E-08 Pulmonary function / / 20010835 rs16825247 chr2 229524141 A G 4.38E-08 Pulmonary function / / 20010835 rs16825251 chr2 229524638 G A 4.45E-08 Pulmonary function / / 20010835 rs7574134 chr2 229531165 C A 4.76E-08 Pulmonary function / / 20010835 rs1881204 chr2 229533885 C T 9.96E-08 Pulmonary function / / 20010835 rs12613830 chr2 229548445 A G 4.54E-05 Pulmonary function / / 20010835 rs6757803 chr2 229554943 C A 5.79E-08 Pulmonary function / / 20010835 rs16825267 chr2 229569919 C G 9.40E-08 Pulmonary function / / 20010835 rs12614274 chr2 229583850 A G 1.08E-07 Pulmonary function / / 20010835 rs4973115 chr2 229590717 G A 1.10E-07 Pulmonary function / / 20010835 rs3732192 chr2 229592304 T C 6.88E-08 Pulmonary function / / 20010835 rs9631013 chr2 229611986 C A 9.75E-04 Multiple complex diseases / / 17554300 rs10181531 chr2 229626575 A G 7.02E-04 Multiple complex diseases / / 17554300 rs11679180 chr2 229642422 G A 1.44E-05 Endometrial cancer / / 24096698 rs11679180 chr2 229642422 G A 2.37E-05 Endometrial cancer / / 24096698 rs11679180 chr2 229642422 G A 3.00E-06 Endometrial cancer / / 24096698 rs1527669 chr2 229652463 G A 3.83E-06 Basophils / / pha003087 rs1527671 chr2 229684700 C T 7.30E-04 Type 2 diabetes / / 17463246 rs4487082 chr2 229723961 A G 5.70E-06 Schizophrenia / / 19197363 rs10490037 chr2 229741332 T C 2.84E-05 Bipolar disorder and schizophrenia / / 20889312 rs12472073 chr2 229742593 T C 6.89E-05 Bipolar disorder and schizophrenia / / 20889312 rs7578485 chr2 229743009 G A 7.57E-05 Bipolar disorder and schizophrenia / / 20889312 rs809616 chr2 229763919 G A 1.18E-04 IgE levels / / 17255346 rs7571792 chr2 229766101 C T 4.49E-05 Bipolar disorder and schizophrenia / / 20889312 rs7593561 chr2 229828458 T G 5.55E-04 Type 2 diabetes / / 17463246 rs16825544 chr2 229851713 T C 3.88E-05 Personality dimensions / / 22628180 rs13410077 chr2 229866471 G A 6.58E-04 Type 2 diabetes / / 17463246 rs13419855 chr2 229902479 A T 7.72E-04 Type 2 diabetes PID1 intron 17463246 rs2215598 chr2 229908245 C T 2.13E-04 Multiple complex diseases PID1 intron 17554300 rs6739369 chr2 229912852 A C 8.22E-05 Multiple complex diseases PID1 intron 17554300 rs6739369 chr2 229912852 A C 1.20E-05 Cognitive function PID1 intron 24684796 rs16825626 chr2 229918641 T C 3.00E-05 Cognitive function PID1 intron 24684796 rs31276 chr2 229920520 C T 2.50E-05 Cognitive function PID1 intron 24684796 rs17475974 chr2 229956007 G T 9.65E-05 Cognitive impairment induced by topiramate PID1 intron 22091778 rs10200706 chr2 229965638 T C 2.00E-04 Information processing speed PID1 intron 21130836 rs6436839 chr2 229969798 A G 3.00E-06 Response to antipsychotic treatment in schizophrenia (reasoning) PID1 intron 21107309 rs17676106 chr2 229983205 G A 0.000778 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PID1 intron 23233654 rs17676106 chr2 229983205 G A 7.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) PID1 intron 23233662 rs1419950 chr2 229993089 T C 9.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) PID1 intron 23233662 rs12467995 chr2 229994369 T C 2.13E-04 Stroke PID1 intron pha002887 rs1419951 chr2 229999602 C T 8.57E-04 Nicotine smoking PID1 intron 19268276 rs7561332 chr2 230012894 G A 9.79E-04 Type 2 diabetes PID1 intron 17463246 rs7561470 chr2 230013020 G A 9.79E-04 Type 2 diabetes PID1 intron 17463246 rs7575420 chr2 230013055 T A 9.79E-04 Type 2 diabetes PID1 intron 17463246 rs10804349 chr2 230032129 G T 6.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PID1 intron 20877124 rs1419958 chr2 230033560 T G 2.17E-05 Cognitive performance PID1 intron 19734545 rs12623151 chr2 230077532 G A 6.01E-05 Lipoprotein-associated phospholipase A2 activity and mass PID1 intron 20442857 rs10498234 chr2 230083143 G T 5.98E-05 Cognitive test performance PID1 intron 20125193 rs1235203 chr2 230095897 G A 9.56E-04 Suicide attempts in bipolar disorder PID1 intron 21423239 rs974251 chr2 230097911 C G 7.18E-05 Lipoprotein-associated phospholipase A2 activity and mass PID1 intron 20442857 rs6747101 chr2 230103371 C T 1.07E-04 Suicide attempts in bipolar disorder PID1 intron 21423239 rs1226994 chr2 230104110 C T 4.91E-05 Orofacial clefts PID1 intron 22419666 rs1226997 chr2 230109580 C T 1.67E-05 Suicide attempts in bipolar disorder PID1 intron 21423239 rs1226998 chr2 230109673 T C 3.69E-05 Orofacial clefts PID1 intron 22419666 rs10933284 chr2 230115370 C T 2.22E-04 Suicide attempts in bipolar disorder PID1 intron 21423239 rs6724020 chr2 230122247 G A 6.76E-05 Serum metabolites PID1 intron 19043545 rs10498236 chr2 230127085 T C 5.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) PID1 intron 17982456 rs4321351 chr2 230129493 A G 6.76E-06 Lipoproteins PID1 intron pha003079 rs6754229 chr2 230131445 T C 5.97E-04 Suicide attempts in bipolar disorder PID1 intron 21041247 rs10185903 chr2 230132158 T C 5.81E-04 Suicide attempts in bipolar disorder PID1 intron 21041247 rs13026191 chr2 230135172 C T 5.14E-05 Lipoproteins PID1 intron pha003079 rs10498237 chr2 230141849 A G 3.39E-05 Anxiety in major depressive disorder / / 24047446 rs12988652 chr2 230142079 G A 1.46E-05 Orofacial clefts / / 22419666 rs7579884 chr2 230146591 A G 4.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs1226946 chr2 230148538 C T 4.79E-04 Suicide attempts in bipolar disorder / / 21041247 rs1226936 chr2 230155126 T G 4.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs11676521 chr2 230155626 G T 5.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs11678426 chr2 230157108 G A 6.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs1922458 chr2 230159931 A G 6.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs35134249 chr2 230159931 A AT 6.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs1419948 chr2 230160162 A C 6.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs1419947 chr2 230160233 A G 6.37E-04 Suicide attempts in bipolar disorder / / 21041247 rs1226973 chr2 230163047 C A 7.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs10498238 chr2 230166564 C T 4.74E-07 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs17257436 chr2 230166970 A G 8.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs16825971 chr2 230167323 C T 8.43E-04 Suicide attempts in bipolar disorder / / 21041247 rs1226959 chr2 230169199 C A 8.20E-04 Suicide attempts in bipolar disorder / / 21041247 rs1226954 chr2 230172176 T C 7.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs6436859 chr2 230197262 A G 7.46E-05 Lipoproteins / / pha003079 rs6728087 chr2 230211261 A C 4.29E-04 Coronary heart disease / / 21606135 rs4973190 chr2 230211434 T C 7.37E-05 Cognitive impairment induced by topiramate / / 22091778 rs9288645 chr2 230214932 T C 2.89E-04 Glaucoma (primary open-angle) / / 22419738 rs7594321 chr2 230224031 T C 3.00E-09 Pulmonary function (interaction) DNER intron 23284291 rs7594321 chr2 230224031 T C 5.00E-11 Pulmonary function (interaction) DNER intron 23284291 rs10933295 chr2 230271297 T C 2.94E-05 Blood Pressure DNER intron pha003043 rs6731881 chr2 230276998 A G 1.40E-05 Blood Pressure DNER intron pha003043 rs2396663 chr2 230284815 T C 9.36E-04 Parkinson's disease DNER intron 17052657 rs6718937 chr2 230307418 T C 5.39E-04 Type 2 diabetes DNER intron 17463246 rs4973205 chr2 230321488 C T 5.05E-05 Coronary heart disease DNER intron pha003035 rs6733371 chr2 230325123 C T 5.79E-05 Femoral neck bone geometry DNER intron 22087292 rs11675728 chr2 230326068 C T 7.22E-05 Pulmonary function in asthmatics DNER intron 23541324 rs9967719 chr2 230327643 G T 7.41E-05 Femoral neck bone geometry DNER intron 22087292 rs6750269 chr2 230341132 T C 9.79E-04 Multiple complex diseases DNER intron 17554300 rs11890081 chr2 230349989 T C 8.00E-06 IgG glycosylation DNER intron 23382691 rs12620995 chr2 230351558 G A 9.39E-05 Information processing speed DNER intron 21130836 rs7570424 chr2 230352718 T C 4.82E-04 Multiple complex diseases DNER intron 17554300 rs7556846 chr2 230352851 G A 8.00E-04 Multiple complex diseases DNER intron 17554300 rs7570739 chr2 230352976 T C 5.02E-04 Multiple complex diseases DNER intron 17554300 rs2216531 chr2 230383471 A C 2.88E-04 Lung function (forced vital capacity) DNER intron 24023788 rs11695348 chr2 230436865 A G 9.03E-04 Amyotrophic lateral sclerosis (sporadic) DNER intron 24529757 rs888177 chr2 230461323 G A 4.60E-05 Glycosylated haemoglobin levels DNER intron 17255346 rs2052303 chr2 230461850 C T 4.66E-05 Glycosylated haemoglobin levels DNER intron 17255346 rs1861616 chr2 230462275 G A 4.18E-04 Body mass index DNER intron 17255346 rs759538 chr2 230463394 C T 4.31E-04 Body mass index DNER intron 17255346 rs6743564 chr2 230468618 C A 1.16E-04 Glycosylated haemoglobin levels DNER intron 17255346 rs6727393 chr2 230485415 T G 4.88E-04 Smoking initiation DNER intron 24665060 rs12986692 chr2 230485450 C T 2.89E-04 Parkinson's disease DNER intron 17052657 rs7605496 chr2 230506712 G T 7.04E-05 Response to cholinesterase inhibitors in Alzheimer's disease DNER intron 23374588 rs6752370 chr2 230518233 A G 8.53E-07 Autism DNER intron 22843504 rs1861612 chr2 230522398 G A 7.00E-08 Type 2 diabetes DNER intron 24101674 rs6712401 chr2 230532751 A G 4.96E-04 Multiple complex diseases DNER intron 17554300 rs6712401 chr2 230532751 A G 0.00037 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DNER intron 23233654 rs6712401 chr2 230532751 A G 3.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) DNER intron 23233662 rs6756438 chr2 230532819 T C 0.0003106 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DNER intron 23233654 rs6756438 chr2 230532819 T C 3.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) DNER intron 23233662 rs6741523 chr2 230532873 G C 0.0002448 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DNER intron 23233654 rs6741523 chr2 230532873 G C 2.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) DNER intron 23233662 rs2216249 chr2 230545356 T C 6.00E-04 Alcohol dependence DNER intron 20201924 rs7558924 chr2 230545657 T C 6.11E-05 C-Reactive Protein DNER intron pha003070 rs2761119 chr2 230555225 A T 3.11E-05 Serum metabolites DNER intron 19043545 rs208785 chr2 230562456 G C 7.89E-04 Response to cytidine analogues (gemcitabine) DNER intron 24483146 rs6707272 chr2 230609149 C T 4.95E-18 Breast cancer (Postmenopausal women) / / 23423446 rs10432554 chr2 230666898 A G 9.27E-04 Parkinson's disease TRIP12 intron 17052657 rs1035833 chr2 230709198 A G 2.30E-04 Type 2 diabetes TRIP12 intron 19184112 rs13014061 chr2 230759699 C A 1.70E-16 Breast cancer (Postmenopausal women) TRIP12 intron 23423446 rs7607428 chr2 230796237 A C 7.35E-04 Myopia (pathological) FBXO36 intron 21095009 rs7558844 chr2 230814685 C T 0.000719 Salmonella-induced pyroptosis FBXO36 intron 22837397 rs6757156 chr2 230820600 A G 4.65E-04 Multiple complex diseases FBXO36 intron 17554300 rs560304 chr2 230822296 C T 5.66E-16 Breast cancer (Postmenopausal women) FBXO36 intron 23423446 rs12694823 chr2 230952046 G A 1.55E-05 Parkinson's disease / / 21738487 rs12162384 chr2 230959532 C A 4.68E-04 Smoking quantity / / 24665060 rs1365773 chr2 231009554 C A 7.57E-04 Alcohol dependence / / 20201924 rs4973275 chr2 231014505 C T 9.84E-05 Parkinson's disease / / 21738487 rs7424288 chr2 231018169 C T 4.05E-05 Parkinson's disease / / 21738487 rs6735555 chr2 231021064 C A 2.37E-05 Parkinson's disease / / 21738487 rs6742762 chr2 231029682 A G 2.43E-05 Personality dimensions / / 22628180 rs6436915 chr2 231034524 G T 0.0000068 Autism spectrum disorders SP110 intron 22412387 rs13004065 chr2 231035100 A G 3.63E-04 Multiple complex diseases SP110 intron 17554300 rs9784019 chr2 231035575 A G 9.72E-06 Obesity-related traits SP110 intron 23251661 rs13010639 chr2 231035745 C T 6.00E-06 Obesity-related traits SP110 intron 23251661 rs13018234 chr2 231036866 G A 9.72E-06 Obesity-related traits SP110 cds-synon 23251661 rs10498244 chr2 231037833 T C 6.24E-04 Bipolar disorder SP110 intron 19259986 rs13025520 chr2 231038029 G A 9.72E-06 Obesity-related traits SP110 intron 23251661 rs4973285 chr2 231045943 G C 8.05E-05 Schizophrenia SP110 intron 20832056 rs10804364 chr2 231047303 G A 3.54E-05 Schizophrenia SP110 intron 20832056 rs10755048 chr2 231047645 T C 4.88E-05 Schizophrenia SP110 intron 20832056 rs10755048 chr2 231047645 T C 1.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SP110 intron 20877124 rs6752361 chr2 231053318 A G 4.04E-04 Schizophrenia SP110 intron 20832056 rs1896259 chr2 231058869 C A 4.04E-04 Schizophrenia SP110 intron 20832056 rs1896258 chr2 231058954 C T 4.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SP110 intron 20877124 rs4973298 chr2 231060003 A G 4.04E-04 Schizophrenia SP110 intron 20832056 rs41345344 chr2 231064928 G C 4.04E-04 Schizophrenia SP110 intron 20832056 rs41423848 chr2 231065083 C A 4.04E-04 Schizophrenia SP110 intron 20832056 rs2114592 chr2 231075206 G A 2.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SP110 intron 20877124 rs7601299 chr2 231077994 A G 5.08E-04 Multiple complex diseases SP110 intron 17554300 rs13389060 chr2 231082124 G T 4.60E-06 Urinary metabolites SP110 intron 21572414 rs11695193 chr2 231090015 T A 1.49E-04 Multiple complex diseases SP110 intron 17554300 rs13397985 chr2 231091223 T G 7.40E-05 Multiple complex diseases SP140 intron 17554300 rs13397985 chr2 231091223 T G 9.04E-06 Crohn's disease SP140 intron 18587394 rs13397985 chr2 231091223 T G 6.00E-10 Chronic lymphocytic leukemia SP140 intron 18758461 rs13397985 chr2 231091223 T G 6.00E-10 Nasopharyngeal carcinoma SP140 intron 20512145 rs13397985 chr2 231091223 T G 3.55E-04 Lymphocyte counts SP140 intron 22286170 rs13397985 chr2 231091223 T G 2.00E-07 Chronic lymphocytic leukemia SP140 intron 22700719 rs13397985 chr2 231091223 T G 1.75E-07 Erectile dysfunction SP140 intron 22704111 rs13397985 chr2 231091223 T G 1.00E-22 Chronic lymphocytic leukemia SP140 intron 23770605 rs13397985 chr2 231091223 T G 5.00E-13 Chronic lymphocytic leukemia SP140 intron 24292274 rs13397985 chr2 231091223 T G 7.51E-06 Waist Circumference SP140 intron pha003023 rs6716753 chr2 231097129 T C 1.00E-16 Crohn's disease SP140 intron 23128233 rs10201872 chr2 231106724 C T 2.00E-10 Multiple sclerosis SP140 intron 21833088 rs10201872 chr2 231106724 C T 5.60E-04 Multiple sclerosis SP140 intron 24234648 rs10201872 chr2 231106724 C T 3.10E-06 Waist Circumference SP140 intron pha003023 rs6743984 chr2 231109329 T C 3.52E-05 Multiple complex diseases SP140 intron 17554300 rs6743984 chr2 231109329 T C 2.48E-06 Crohn's disease SP140 intron 18587394 rs6743984 chr2 231109329 T C 7.26E-04 Lymphocyte counts SP140 intron 22286170 rs10498245 chr2 231111422 A G 9.50E-04 Amyotrophic lateral sclerosis (sporadic) SP140 intron 24529757 rs9989899 chr2 231114131 G A 5.97E-06 Waist Circumference SP140 intron pha003023 rs9989808 chr2 231114180 A G 1.70E-05 Urinary metabolites SP140 intron 21572414 rs2114590 chr2 231114593 C G 1.10E-05 Urinary metabolites SP140 intron 21572414 rs2114590 chr2 231114593 C G 1.47E-04 Response to taxane treatment (placlitaxel) SP140 intron 23006423 rs9989792 chr2 231115603 T C 4.67E-04 Response to taxane treatment (placlitaxel) SP140 intron 23006423 rs7423615 chr2 231116874 C T 3.00E-13 Crohn's disease SP140 intron 21102463 rs3820975 chr2 231118041 A C 1.60E-06 Urinary metabolites SP140 missense 21572414 rs4973305 chr2 231139382 C A,T 7.30E-06 Urinary metabolites SP140 intron 21572414 rs4973306 chr2 231139777 T C 7.52E-05 Cognitive performance SP140 intron 19734545 rs11689231 chr2 231148009 A G 6.72E-05 Platelet counts SP140 intron pha003100 rs6710297 chr2 231157512 A G 1.95E-04 Multiple complex diseases SP140 intron 17554300 rs3769846 chr2 231159410 T A 4.10E-06 Urinary metabolites SP140 intron 21572414 rs16827035 chr2 231174138 G C 5.90E-05 Response to statin therapy SP140 intron 20339536 rs6707578 chr2 231174420 G A 2.20E-05 Urinary metabolites SP140 intron 21572414 rs4973310 chr2 231180915 A G 8.90E-05 Response to statin therapy / / 20339536 rs4973310 chr2 231180915 A G 7.32E-05 Kawasaki disease / / 22081228 rs4973311 chr2 231180966 A G 8.10E-05 Response to statin therapy / / 20339536 rs4973311 chr2 231180966 A G 3.20E-07 Urinary metabolites / / 21572414 rs4973312 chr2 231181285 C T 8.20E-05 Response to statin therapy / / 20339536 rs4973312 chr2 231181285 C T 1.30E-06 Urinary metabolites / / 21572414 rs12464193 chr2 231181428 G A 8.00E-05 Response to statin therapy / / 20339536 rs12464229 chr2 231181554 G A 7.40E-05 Response to statin therapy / / 20339536 rs11886029 chr2 231182472 G C 6.40E-05 Response to statin therapy / / 20339536 rs10498248 chr2 231182505 C T 5.50E-05 Response to statin therapy / / 20339536 rs10498248 chr2 231182505 C T 5.70E-07 Urinary metabolites / / 21572414 rs11887130 chr2 231182682 C T 6.60E-05 Response to statin therapy / / 20339536 rs10498249 chr2 231182893 C T 4.50E-05 Response to statin therapy / / 20339536 rs12466273 chr2 231183091 G A 4.10E-05 Response to statin therapy / / 20339536 rs720977 chr2 231183321 G A 7.54E-05 Cognitive test performance / / 20125193 rs6726527 chr2 231184106 G T 2.60E-05 Response to statin therapy / / 20339536 rs6726527 chr2 231184106 G T 6.30E-06 Urinary metabolites / / 21572414 rs16827136 chr2 231196132 C A 2.26E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SP140L intron 24023788 rs4973316 chr2 231221928 C T 3.47E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SP140L intron 24023788 rs11678791 chr2 231223975 C T 3.44E-05 Platelet counts SP140L intron pha003100 rs16827171 chr2 231224255 A G 1.00E-06 Urinary metabolites SP140L intron 21572414 rs6712333 chr2 231230171 C T 5.00E-06 Nicotine use SP140L intron 23942779 rs6712333 chr2 231230171 C T 6.10E-05 Alcohol dependence SP140L intron 23942779 rs6712333 chr2 231230171 C T 8.30E-04 Illicit drug use SP140L intron 23942779 rs12694866 chr2 231284556 T C 8.78E-04 Tourette syndrome SP100 intron 22889924 rs7595408 chr2 231320960 T G 4.49E-05 Response to mTOR inhibitor (rapamycin) SP100 intron 24009623 rs1649866 chr2 231329517 G A 2.03E-05 Bone mineral traits,in men SP100 intron 21427758 rs1649890 chr2 231337546 A C 2.00E-05 Urinary metabolites SP100 intron 21572414 rs1678211 chr2 231349111 C T 2.90E-05 Urinary metabolites SP100 intron 21572414 rs1678189 chr2 231411995 A T 4.83E-04 Multiple complex diseases / / 17554300 rs17275498 chr2 231420401 A C 8.00E-06 Cognitive performance / / 20125193 rs6759540 chr2 231428531 G A 2.60E-05 Urinary metabolites / / 21572414 rs17354508 chr2 231429977 G A 9.86E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10933342 chr2 231442359 A T 3.12E-04 Type 2 diabetes / / 17463246 rs7562389 chr2 231442496 T C 7.13E-04 Alzheimer's disease / / 17998437 rs11691070 chr2 231442959 G A 8.09E-05 Epilepsy (remission after treatment) / / 23962720 rs11674767 chr2 231443143 T C 8.14E-05 Epilepsy (remission after treatment) / / 23962720 rs73992446 chr2 231443209 T C 8.14E-05 Epilepsy (remission after treatment) / / 23962720 rs10498252 chr2 231443428 G T 4.21E-04 Type 2 diabetes / / 17463246 rs2241534 chr2 231443615 C T 8.10E-05 Epilepsy (remission after treatment) / / 23962720 rs2241536 chr2 231443924 T C 8.99E-05 Epilepsy (remission after treatment) / / 23962720 rs2241537 chr2 231444292 T C 8.06E-05 Epilepsy (remission after treatment) / / 23962720 rs56199999 chr2 231444470 C T 8.02E-05 Epilepsy (remission after treatment) / / 23962720 rs11692958 chr2 231444526 G T 8.03E-05 Epilepsy (remission after treatment) / / 23962720 rs11681649 chr2 231444531 A T 8.03E-05 Epilepsy (remission after treatment) / / 23962720 rs11694266 chr2 231444896 C T 8.05E-05 Epilepsy (remission after treatment) / / 23962720 rs11694317 chr2 231445045 C G 8.02E-05 Epilepsy (remission after treatment) / / 23962720 rs73992447 chr2 231445247 C T 7.99E-05 Epilepsy (remission after treatment) / / 23962720 rs113951959 chr2 231446036 C T 9.21E-05 Epilepsy (remission after treatment) / / 23962720 rs11676418 chr2 231447589 C G 9.46E-05 Epilepsy (remission after treatment) / / 23962720 rs11682332 chr2 231447604 T C 9.44E-05 Epilepsy (remission after treatment) / / 23962720 rs11687550 chr2 231447739 A G 9.46E-05 Epilepsy (remission after treatment) / / 23962720 rs11682484 chr2 231447937 T C 6.82E-05 Epilepsy (remission after treatment) / / 23962720 rs80252298 chr2 231448572 C T 3.44E-05 Epilepsy (remission after treatment) / / 23962720 rs79961618 chr2 231448590 G A 3.49E-05 Epilepsy (remission after treatment) / / 23962720 rs77776156 chr2 231448703 A G 3.51E-05 Epilepsy (remission after treatment) / / 23962720 rs80339554 chr2 231448713 T C 3.51E-05 Epilepsy (remission after treatment) / / 23962720 rs76024850 chr2 231448773 G A 3.51E-05 Epilepsy (remission after treatment) / / 23962720 rs77816227 chr2 231448842 C A 3.51E-05 Epilepsy (remission after treatment) / / 23962720 rs79209263 chr2 231448987 A G 3.50E-05 Epilepsy (remission after treatment) / / 23962720 rs78397825 chr2 231449008 C T 5.21E-05 Epilepsy (remission after treatment) / / 23962720 rs75634989 chr2 231449009 A G 5.21E-05 Epilepsy (remission after treatment) / / 23962720 rs4972965 chr2 231477415 G A 6.65E-05 HIV-1 viral setpoint / / 22174851 rs10168790 chr2 231492965 C A 7.57E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7584576 chr2 231508389 T C 5.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9973459 chr2 231525099 C A 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs16827514 chr2 231546750 T C 5.12E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs938906 chr2 231555684 T C 4.23E-05 Cognitive performance / / 19734545 rs9973480 chr2 231573384 A C 2.90E-04 Alcohol dependence / / 20201924 rs9973480 chr2 231573384 A C 5.30E-04 Alcohol dependence / / 20201924 rs11682404 chr2 231574896 A G 2.70E-04 Alcohol dependence / / 20201924 rs11682404 chr2 231574896 A G 3.10E-04 Alcohol dependence / / 20201924 rs10933355 chr2 231582196 G A 3.10E-04 Alcohol dependence CAB39 intron 20201924 rs10933355 chr2 231582196 G A 3.70E-04 Alcohol dependence CAB39 intron 20201924 rs6436971 chr2 231582797 T C 2.00E-05 Urinary metabolites CAB39 intron 21572414 rs13411251 chr2 231586340 T G 2.40E-04 Alcohol dependence CAB39 intron 20201924 rs13411251 chr2 231586340 T G 3.10E-04 Alcohol dependence CAB39 intron 20201924 rs6711453 chr2 231594089 A G 3.00E-04 Alcohol dependence CAB39 intron 20201924 rs6711453 chr2 231594089 A G 3.70E-04 Alcohol dependence CAB39 intron 20201924 rs6717266 chr2 231613141 G A 3.00E-04 Alcohol dependence CAB39 intron 20201924 rs6717266 chr2 231613141 G A 3.70E-04 Alcohol dependence CAB39 intron 20201924 rs2438296 chr2 231651832 G T 5.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAB39 intron 20877124 rs3792068 chr2 231673225 A G 3.40E-04 Alcohol dependence CAB39 intron 20201924 rs3792068 chr2 231673225 A G 4.00E-04 Alcohol dependence CAB39 intron 20201924 rs6436975 chr2 231701319 G A 3.62E-04 Multiple complex diseases / / 17554300 rs10182071 chr2 231709953 A G 5.14E-05 Orofacial clefts / / 19270707 rs2466149 chr2 231722128 T C 2.82E-05 Bipolar disorder / / 22925353 rs10201627 chr2 231774377 C A 0.000441 Rate of forced expiratory volume in 1 second (FEV1) decline (young adult women) GPR55 UTR-3 23527081 rs3749073 chr2 231775094 C A 0.000536 Rate of forced expiratory volume in 1 second (FEV1) decline (young adult women) GPR55 missense 23527081 rs3111780 chr2 231790097 T C 3.21E-04 Stroke (pediatric) / / 22990015 rs2175149 chr2 231877207 T C 1.66E-04 Bipolar disorder,schizoaffective / / 19567891 rs2136477 chr2 231877319 G A 5.20E-05 Malaria / / 19465909 rs2136477 chr2 231877319 G A 9.40E-05 Bipolar disorder,schizoaffective / / 19567891 rs4973362 chr2 231877952 G T 9.54E-05 Bipolar disorder,schizoaffective / / 19567891 rs1543061 chr2 231878496 C T 9.60E-07 Malaria / / 19465909 rs1543061 chr2 231878496 C T 9.21E-05 Bipolar disorder,schizoaffective / / 19567891 rs10192428 chr2 231878740 G A 5.10E-07 Malaria / / 19465909 rs10192428 chr2 231878740 G A 1.01E-04 Bipolar disorder,schizoaffective / / 19567891 rs6750230 chr2 231880112 G A 1.60E-05 Malaria / / 19465909 rs6750277 chr2 231880308 C T 6.60E-05 Malaria / / 19465909 rs6750277 chr2 231880308 C T 6.25E-05 Bipolar disorder,schizoaffective / / 19567891 rs4973370 chr2 231882118 G A 1.74E-04 Bipolar disorder,schizoaffective / / 19567891 rs4973371 chr2 231882293 A G 2.41E-04 Bipolar disorder,schizoaffective / / 19567891 rs4973374 chr2 231885415 T C 1.15E-05 HIV-1 progression to AIDS and death / / 21811574 rs4973374 chr2 231885415 T C 1.15E-05 HIV-1 progression to AIDS and death / / 21811574 rs4973374 chr2 231885415 T C 1.80E-04 HIV-1 progression to AIDS and death / / 21811574 rs1472959 chr2 231940960 A G 9.81E-04 Alzheimer's disease PSMD1 intron 17998437 rs6736017 chr2 231973416 T C 0.000000137 LDL cholesterol HTR2B missense 23063622 rs6736017 chr2 231973416 T C 7.39E-16 Triglycerides HTR2B missense 23063622 rs6437001 chr2 232013304 G T 5.24E-05 Multiple complex diseases PSMD1 intron 17554300 rs6437002 chr2 232025284 G A 6.86E-05 HDL particle features PSMD1 intron pha002900 rs6755467 chr2 232044684 A C 1.01E-04 Multiple complex diseases / / 17554300 rs753855 chr2 232066651 T C 9.82E-06 Alzheimer's disease (age of onset) ARMC9 intron 22005931 rs5018532 chr2 232077075 A G 1.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) ARMC9 intron 23648065 rs5018532 chr2 232077075 A G 6.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) ARMC9 intron 23648065 rs16827863 chr2 232077670 T C 1.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) ARMC9 intron 23648065 rs16827863 chr2 232077670 T C 6.89E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) ARMC9 intron 23648065 rs3731776 chr2 232091479 C T 4.53E-04 Multiple complex diseases ARMC9 intron 17554300 rs6437008 chr2 232091948 C G 0.000096 Panic disorder ARMC9 intron 23149450 rs6437008 chr2 232091948 C G 9.60E-05 Serum tamsulosin hydrochloride concentration ARMC9 intron 23151678 rs9677476 chr2 232126290 A G 2.40E-05 Urinary metabolites ARMC9 intron 21572414 rs745962 chr2 232159212 T C 7.00E-06 Follicle stimulating hormone ARMC9 intron 24049095 rs11894854 chr2 232171968 A G 9.75E-04 Suicide attempts in bipolar disorder ARMC9 intron 21423239 rs7580717 chr2 232176541 G A 5.00E-06 Multiple myeloma ARMC9 intron 23955597 rs1868929 chr2 232183591 C T 7.67E-05 Systemic sclerosis ARMC9 intron 21779181 rs6753112 chr2 232187155 C T 5.00E-06 Multiple myeloma ARMC9 intron 23955597 rs10498225 chr2 232190985 C A 9.29E-04 Celiac disease ARMC9 intron 23936387 rs1669070 chr2 232192305 C T 4.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients ARMC9 intron 23400010 rs1729086 chr2 232208056 C T 4.72E-04 Smoking cessation ARMC9 intron 24665060 rs1729085 chr2 232208941 C G 6.15E-04 Smoking cessation ARMC9 intron 24665060 rs2595503 chr2 232252322 T G 2.60E-04 Smoking cessation / / 24665060 rs13030174 chr2 232271284 A C 1.00E-10 Heart rate / / 23583979 rs12475512 chr2 232298076 G A 7.00E-07 Eating disorders (purging via substances) / / 23568457 rs13017932 chr2 232298812 C T 9.67E-04 Acute lung injury / / 22295056 rs7563453 chr2 232301670 G A 1.90E-05 Urinary metabolites / / 21572414 rs7563453 chr2 232301670 G A 9.31E-04 Acute lung injury / / 22295056 rs16828074 chr2 232318754 C G,T 4.31E-04 Multiple complex diseases / / 17554300 rs16828074 chr2 232318754 C G,T 6.00E-09 Attention deficit hyperactivity disorder / / 23728934 rs4449121 chr2 232370059 A C 5.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs6750795 chr2 232378231 T C 2.00E-08 Height LINC00471 intron 23563607 rs1797395 chr2 232401503 T C 1.60E-05 Serum metabolites / / 19043545 rs1667305 chr2 232403829 T C 2.32E-05 Blood Pressure / / pha003043 rs1797396 chr2 232403863 G A 8.78E-04 Type 2 diabetes / / 17463246 rs1797397 chr2 232404469 A G 1.75E-05 Serum metabolites / / 19043545 rs1667313 chr2 232408018 A C 2.32E-05 Blood Pressure / / pha003043 rs1667314 chr2 232408269 A T 1.83E-05 Serum metabolites / / 19043545 rs2595506 chr2 232408841 G A 3.51E-05 Serum metabolites / / 19043545 rs2595506 chr2 232408841 G A 1.46E-07 Lymphocyte counts / / 22286170 rs1797386 chr2 232414338 C T 7.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs1667320 chr2 232418314 G T 2.00E-04 Dietary macronutrient intake / / 23636237 rs10165533 chr2 232419666 A C 1.92E-05 Coronary heart disease / / pha003031 rs1797392 chr2 232422257 C T 6.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs1667301 chr2 232423717 A G 6.78E-05 Cardiovascular disease / / pha003065 rs6733018 chr2 232425276 A G 6.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs12993888 chr2 232425763 A G 6.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs4340504 chr2 232432298 A C 5.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs10460338 chr2 232434661 C T 4.63E-04 Suicide attempts in bipolar disorder / / 21041247 rs6727830 chr2 232436364 G A 4.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs10498258 chr2 232437359 A G 3.37E-04 Type 2 diabetes / / 17463246 rs10498258 chr2 232437359 A G 4.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs10182727 chr2 232440737 A T 4.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs13025854 chr2 232441175 C A 4.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs4973009 chr2 232461115 A G 2.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs4973462 chr2 232491289 C T 9.40E-06 Urinary metabolites / / 21572414 rs13007920 chr2 232491355 C T 2.87E-05 Body Mass Index / / pha003015 rs13007920 chr2 232491355 C T 4.10E-05 Waist Circumference / / pha003025 rs4530357 chr2 232540702 T C 5.04E-05 Hypertension / / 22384028 rs3856531 chr2 232544906 C T 2.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs4973472 chr2 232550160 T A 2.87E-05 Serum metabolites / / 19043545 rs4973475 chr2 232553362 C T 4.11E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13398149 chr2 232564881 A C 2.15E-05 Response to methylphenidate treatment / / 21130132 rs13398149 chr2 232564881 A C 6.50E-05 Major depressive disorder / / 22472876 rs6737601 chr2 232572381 A G 1.35E-05 Major depressive disorder / / 22472876 rs6755895 chr2 232579795 T C 3.17E-05 Major depressive disorder / / 22472876 rs11695646 chr2 232584807 A G 2.02E-05 Major depressive disorder / / 22472876 rs838423 chr2 232598197 G A 1.41E-04 Fibrinogen PDE6D intron 17255346 rs4973479 chr2 232624863 C T 0.000000315 Total IFN-gamma response to smallpox vaccine PDE6D intron 22661280 rs10195385 chr2 232720739 A G 4.74E-04 Multiple complex diseases / / 17554300 rs1866599 chr2 232726300 C T 6.07E-04 Major depressive disorder / / 22472876 rs2119063 chr2 232751057 T G 7.78E-04 Coronary Artery Disease / / 17634449 rs2119061 chr2 232751260 G A 8.63E-04 Coronary Artery Disease / / 17634449 rs2679180 chr2 232756528 C T 8.16E-05 Serum metabolites / / 19043545 rs3107179 chr2 232788325 C T 9.60E-10 Height NPPC intron 21194676 rs749052 chr2 232796610 T C 1.00E-06 Height / / 18391951 rs749052 chr2 232796610 T C 5.04E-05 Bipolar disorder and schizophrenia / / 20889312 rs2679178 chr2 232797861 C T 5.73E-05 Bipolar disorder and schizophrenia / / 20889312 rs2679178 chr2 232797861 C T 1.60E-09 Height / / 21194676 rs2679178 chr2 232797861 C T 3.80E-06 Height / / 21194676 rs2679178 chr2 232797861 C T 4.40E-14 Height / / 21194676 rs2580816 chr2 232797966 C T 6.00E-22 Height / / 20881960 rs2580817 chr2 232798723 G A 1.20E-04 Attention deficit hyperactivity disorder / / 22012869 rs2580823 chr2 232806319 G A 1.59E-05 Recombination rate / / 21698098 rs12473319 chr2 232880971 G C 2.91E-05 Multiple complex diseases DIS3L2 intron 17554300 rs3100624 chr2 232938583 C T 9.00E-04 Bipolar disorder DIS3L2 intron 17486107 rs3100584 chr2 232946290 C T 8.49E-05 Bipolar disorder and schizophrenia DIS3L2 intron 20889312 rs3116158 chr2 232955363 G A 6.62E-05 Bipolar disorder and schizophrenia DIS3L2 intron 20889312 rs3103267 chr2 232988582 A C 3.00E-08 Height DIS3L2 intron 23563607 rs3103296 chr2 233034495 T C 3.10E-05 Height DIS3L2 intron 21194676 rs3103296 chr2 233034495 T C 4.80E-09 Height DIS3L2 intron 21194676 rs3103296 chr2 233034495 T C 5.60E-05 Height DIS3L2 intron 21194676 rs4973508 chr2 233067832 T A 1.00E-05 Malaria DIS3L2 intron 19465909 rs7571816 chr2 233077064 A G 9.00E-09 Height DIS3L2 intron 20189936 rs13020779 chr2 233149600 A G 8.00E-05 Lung cancer DIS3L2 intron 18978790 rs6717918 chr2 233155110 T C 3.00E-09 Height DIS3L2 intron 19570815 rs12617170 chr2 233161765 A G 4.93E-04 Alzheimer's disease (late onset) DIS3L2 intron 21379329 rs2741311 chr2 233239743 T C 4.31E-04 Myopia (pathological) / / 21095009 rs7599982 chr2 233247873 G A 4.52E-05 Type 2 diabetes ALPP nearGene-3 22158537 rs7573222 chr2 233247934 A C 3.97E-05 Type 2 diabetes ALPP nearGene-3 22158537 rs11687072 chr2 233259466 A G 7.25E-06 Type 2 diabetes / / 17463246 rs11687072 chr2 233259466 A G 2.38E-05 Type 2 diabetes / / 22158537 rs2741321 chr2 233280239 C T 2.48E-04 Type 2 diabetes / / 17463246 rs2741321 chr2 233280239 C T 2.04E-05 Type 2 diabetes / / 22158537 rs744873 chr2 233280565 A G 1.76E-04 Type 2 diabetes / / 17463246 rs744874 chr2 233280822 G T 1.76E-04 Type 2 diabetes / / 17463246 rs2573219 chr2 233288667 A C 1.97E-05 Type 2 diabetes / / 22158537 rs2853392 chr2 233293773 A G 1.94E-05 Type 2 diabetes / / 22158537 rs2573232 chr2 233300046 T C 8.85E-05 Type 2 diabetes / / 22158537 rs790025 chr2 233303133 C A 4.49E-05 Parkinson's disease / / 17052657 rs790039 chr2 233309026 G C 3.82E-04 Type 2 diabetes / / 22158537 rs2678505 chr2 233309066 A G 3.76E-04 Type 2 diabetes / / 17463246 rs2678505 chr2 233309066 A G 1.60E-04 Type 2 diabetes / / 22158537 rs2853407 chr2 233310094 C T 1.47E-04 Type 2 diabetes / / 22158537 rs6721457 chr2 233319977 G C 6.60E-05 Aortic root size / / 21223598 rs2003780 chr2 233323177 T C 4.06E-05 Waist-Hip Ratio ALPI intron pha003013 rs2003780 chr2 233323177 T C 4.12E-05 Waist-Hip Ratio ALPI intron pha003028 rs11693163 chr2 233326446 C T 5.10E-05 Waist-Hip Ratio / / pha003013 rs11693163 chr2 233326446 C T 6.10E-05 Waist-Hip Ratio / / pha003028 rs2853425 chr2 233343228 G A 5.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1190468 chr2 233353904 G A 0.00023 Coronary artery calcification / / 23727086 rs2573223 chr2 233372850 A G 8.26E-06 Sleep duration / / 22105623 rs1656404 chr2 233379941 G A 8.00E-11 Refractive error / / 23396134 rs2697804 chr2 233380020 G A 4.46E-06 Sleep duration / / 22105623 rs2697800 chr2 233383416 C T 1.97E-05 Sleep duration PRSS56 nearGene-5 22105623 rs2697800 chr2 233383416 C T 1.30E-04 Smoking quantity PRSS56 nearGene-5 24665060 rs1550094 chr2 233385396 G A 1.30E-15 Myopia (Age of onset) PRSS56 missense 23468642 rs2245601 chr2 233390937 A G 4.13E-06 Sleep duration CHRND cds-synon 22105623 rs12466358 chr2 233397525 T G 1.03E-05 Arthritis (juvenile idiopathic) CHRND intron 22354554 rs1881492 chr2 233406998 T G 6.96E-04 Multiple complex diseases CHRNG intron 17554300 rs1881492 chr2 233406998 T G 5.00E-11 Refractive error CHRNG intron 23396134 rs2853462 chr2 233407120 C T 7.61E-05 Cytomegalovirus antibody response CHRNG intron 21993531 rs1190449 chr2 233418920 G T 4.07E-04 Smoking quantity EIF4E2 intron 24665060 rs1656402 chr2 233426526 C T 8.00E-08 Non-small cell lung cancer (survival) EIF4E2 intron 21079520 rs2276560 chr2 233450919 C T 9.67E-05 Femoral neck bone geometry / / 22087292 rs2140773 chr2 233513175 C A 1.00E-09 Liver enzyme levels (gamma-glutamyl transferase) EFHD1 intron 22001757 rs7578760 chr2 233533202 C T 1.03E-06 Schizophrenia EFHD1 intron 21795503 rs10207739 chr2 233684097 T C 9.19E-04 Rheumatoid arthritis GIGYF2 intron 21452313 rs6731064 chr2 233721684 A C 7.35E-04 Aortic root size GIGYF2 UTR-3 21223598 rs2675968 chr2 233736244 C T 2.58E-06 Schizophrenia C2orf82 intron 21926974 rs2675968 chr2 233736244 C T 5.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) C2orf82 intron 23453885 rs2675968 chr2 233736244 C T 0.0000564 Schizophrenia C2orf82 intron 23637625 rs778371 chr2 233743109 A G 2.00E-08 Schizophrenia / / 23974872 rs895431 chr2 233759362 G C 1.33E-04 Sudden cardiac arrest NGEF intron 21658281 rs7355380 chr2 233772300 C T 5.63E-05 Soluble levels of adhesion molecules NGEF intron pha003072 rs809017 chr2 233774183 G A 7.72E-05 Intracranial aneurysm NGEF intron 22286173 rs778362 chr2 233780186 C T 4.19E-04 Sudden cardiac arrest NGEF intron 21658281 rs7602554 chr2 233820737 G A 7.10E-06 Urinary metabolites NGEF intron 21572414 rs7583124 chr2 233835654 C T 4.95E-04 Obesity (extreme) NGEF intron 21935397 rs11678495 chr2 233838447 A G 5.13E-04 Obesity (extreme) NGEF intron 21935397 rs6437079 chr2 233839174 G A 5.68E-04 Obesity (extreme) NGEF intron 21935397 rs954526 chr2 233840063 A G 4.55E-04 Obesity (extreme) NGEF intron 21935397 rs938572 chr2 233841300 G A 2.00E-04 Obesity (extreme) NGEF intron 21935397 rs938573 chr2 233841366 A G 1.82E-04 Obesity (extreme) NGEF intron 21935397 rs6745724 chr2 233854241 A G 2.00E-04 Adiposity NGEF intron 19461586 rs11885626 chr2 233854397 G A 6.00E-05 Prostate cancer NGEF intron 21743057 rs6437080 chr2 233855461 G A 9.14E-04 Alzheimer's disease NGEF intron 17998437 rs4973062 chr2 233858636 C T 1.30E-04 Adiposity NGEF intron 19461586 rs1104953 chr2 233870366 G C 4.59E-04 Obesity (extreme) NGEF intron 21935397 rs10169320 chr2 233871619 A G 4.54E-04 Obesity (extreme) NGEF intron 21935397 rs10169752 chr2 233872049 A G 4.83E-04 Obesity (extreme) NGEF intron 21935397 rs13383577 chr2 233874399 T C 5.00E-04 Adiposity NGEF intron 19461586 rs3811588 chr2 233875975 G A 1.66E-05 Sudden cardiac arrest NGEF intron 21658281 rs13396115 chr2 233882712 T C 6.99E-04 Obesity (extreme) / / 21935397 rs6437086 chr2 233893807 A G 2.00E-05 Lupus / / 17911428 rs4511711 chr2 233895666 A C 9.19E-05 Lung function (forced vital capacity) / / pha003104 rs2233375 chr2 233896498 C T 4.00E-06 Contrast sensitivity / / 24152035 rs2233382 chr2 233897161 A C 7.79E-04 Multiple complex diseases / / 17554300 rs11695991 chr2 233900089 A C 8.16E-06 Contrast sensitivity / / 24152035 rs62191860 chr2 233904259 C T 8.31E-06 Contrast sensitivity / / 24152035 rs4246649 chr2 233925491 A G 2.67E-07 Contrast sensitivity / / 24152035 rs11674347 chr2 233941388 A G 3.25E-04 Smoking quantity / / 24665060 rs4356648 chr2 233950265 C A 5.12E-05 Type 2 diabetes / / 17463246 rs6756729 chr2 233957253 A T 1.97E-04 Type 2 diabetes / / 17463246 rs6437090 chr2 233962551 G A 6.61E-06 Contrast sensitivity / / 24152035 rs9288685 chr2 233987114 T C 7.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10200271 chr2 233997057 A C 7.51E-04 Multiple complex diseases / / 17554300 rs10933434 chr2 233998108 G T 2.20E-05 Urinary metabolites / / 21572414 rs10933436 chr2 233998481 C A 7.00E-06 Coronary heart disease / / 21378990 rs35349669 chr2 234068476 C T 3.00E-08 Alzheimer's disease (late onset) / / 24162737 rs11673739 chr2 234072738 A G 9.55E-04 Obesity (extreme) / / 21935397 rs10929180 chr2 234073523 G C 9.67E-04 Obesity (extreme) / / 21935397 rs4436949 chr2 234092392 A G 6.58E-05 Obesity (extreme) / / 21935397 rs4663834 chr2 234118583 T G 1.90E-05 Urinary metabolites / / 21572414 rs12471808 chr2 234138324 A T 1.90E-05 Urinary metabolites / / 21572414 rs2083575 chr2 234145080 T C 1.78E-04 Multiple complex diseases / / 17554300 rs2083575 chr2 234145080 T C 1.00E-07 Bilirubin levels / / 19414484 rs10210302 chr2 234158839 C T 5.00E-14 Crohn's disease ATG16L1 nearGene-5 17554300 rs6752107 chr2 234161448 G A 3.80E-05 Multiple complex diseases ATG16L1 intron 17554300 rs6431654 chr2 234161769 C T 1.39E-16 Multiple complex diseases ATG16L1 intron 17554300 rs6737398 chr2 234170397 G A 1.23E-06 Multiple complex diseases ATG16L1 intron 17554300 rs12994997 chr2 234173503 G A 4.00E-70 Crohn's disease ATG16L1 intron 23128233 rs3828309 chr2 234180410 A G 7.98E-05 Multiple complex diseases ATG16L1 intron 17554300 rs3828309 chr2 234180410 A G 2.00E-32 Crohn's disease ATG16L1 intron 18587394 rs3828309 chr2 234180410 A G 2.00E-32 Asthma ATG16L1 intron 21150878 rs3828309 chr2 234180410 A G 2.36E-32 Multiple sclerosis ATG16L1 intron 22190364 rs2289473 chr2 234182025 C A,G,T 1.20E-07 Bilirubin levels ATG16L1 intron 19414484 rs2241880 chr2 234183368 A G 1.00E-13 Crohn's disease ATG16L1 missense 17435756 rs2241880 chr2 234183368 A G 8.68E-07 Crohn's disease ATG16L1 missense 17684544 rs2241880 chr2 234183368 A G 4.61E-25 Crohn's disease ATG16L1 missense 18587394 rs2241880 chr2 234183368 A G 3.00E-06 Crohn's disease ATG16L1 missense 20570966 rs2241880 chr2 234183368 A G 1.00E-12 Crohn's disease ATG16L1 missense 22412388 rs3792109 chr2 234184417 G A 7.00E-41 Crohn's disease ATG16L1 intron 21102463 rs3792109 chr2 234184417 G A 5.00E-09 Crohn's disease ATG16L1 intron 22936669 rs3792106 chr2 234190740 T C 2.60E-13 Multiple complex diseases ATG16L1 intron 17554300 rs4663396 chr2 234192251 C T 7.58E-08 Multiple complex diseases ATG16L1 intron 17554300 rs7587051 chr2 234194755 G C 3.60E-10 Bilirubin levels ATG16L1 intron 19414484 rs11890449 chr2 234199401 C T 6.13E-04 Multiple complex diseases ATG16L1 intron 17554300 rs6431262 chr2 234199537 G T 6.28E-05 Multiple complex diseases ATG16L1 intron 17554300 rs4663421 chr2 234201700 G C 1.30E-04 Multiple complex diseases ATG16L1 intron 17554300 rs4663147 chr2 234210681 G A 6.05E-05 Crohn's disease / / 23850713 rs6759896 chr2 234210972 G A 2.10E-07 Bilirubin levels / / 19414484 rs6759896 chr2 234210972 G A 1.70E-04 Eating disorders / / 23568457 rs3792104 chr2 234221935 G T 1.68E-04 Response to cytadine analogues (cytosine arabinoside) SAG intron 24483146 rs11891546 chr2 234232722 T G 2.60E-10 Bilirubin levels SAG intron 19414484 rs2304773 chr2 234235820 C T 6.26E-04 Response to cytadine analogues (cytosine arabinoside) SAG cds-synon 24483146 rs880116 chr2 234246264 C T 4.00E-05 Bilirubin levels SAG intron 19414484 rs880114 chr2 234246458 T C 3.90E-05 Bilirubin levels SAG intron 19414484 rs3828305 chr2 234246994 A G 3.90E-05 Bilirubin levels SAG intron 19414484 rs13427703 chr2 234247508 C G 1.42E-04 Response to cytadine analogues (cytosine arabinoside) SAG intron 24483146 rs13427703 chr2 234247508 C G 4.27E-04 Smoking initiation SAG intron 24665060 rs2241874 chr2 234247627 T C 1.87E-04 Multiple complex diseases SAG intron 17554300 rs2241873 chr2 234247924 G A 2.08E-04 Multiple complex diseases SAG intron 17554300 rs3792091 chr2 234251322 T G 2.30E-06 Bilirubin levels SAG intron 19414484 rs1046974 chr2 234255547 G A 3.80E-08 Bilirubin levels SAG missense 19414484 rs13014016 chr2 234257454 A G 3.50E-06 Bilirubin levels / / 19414484 rs11679046 chr2 234258101 C T 4.30E-06 Bilirubin levels / / 19414484 rs1550532 chr2 234264848 C G 2.40E-14 Bilirubin levels DGKD intron 19414484 rs1550532 chr2 234264848 C G 1.20E-07 Bilirubin levels DGKD intron 19419973 rs1550532 chr2 234264848 C G 3.08E-19 Bilirubin levels,in serum DGKD intron 20639394 rs1550532 chr2 234264848 C G 8.00E-11 Calcium levels DGKD intron 24068962 rs1441093 chr2 234272484 A G 1.50E-07 Bilirubin levels DGKD intron 19414484 rs838705 chr2 234273242 G A 3.30E-13 Bilirubin levels DGKD intron 19414484 rs838705 chr2 234273242 G A 9.00E-06 Calcium levels DGKD intron 20705733 rs838705 chr2 234273242 G A 0.00047 Prostate cancer (non-advanced prostate cancer) DGKD intron 23555315 rs7573866 chr2 234276216 T C 1.40E-14 Bilirubin levels DGKD intron 19414484 rs7576633 chr2 234279252 C G 2.30E-09 Bilirubin levels DGKD intron 19414484 rs7566221 chr2 234279295 G C 2.50E-04 Multiple complex diseases DGKD intron 17554300 rs7566221 chr2 234279295 G C 2.30E-09 Bilirubin levels DGKD intron 19414484 rs6759246 chr2 234281439 G C 2.30E-09 Bilirubin levels DGKD intron 19414484 rs6722763 chr2 234282210 A G 1.60E-09 Bilirubin levels DGKD intron 19414484 rs7580412 chr2 234283288 T C 2.30E-09 Bilirubin levels DGKD intron 19414484 rs838708 chr2 234284399 G A 1.80E-15 Bilirubin levels DGKD intron 19414484 rs838708 chr2 234284399 G A 4.35E-08 Bilirubin levels DGKD intron 19419973 rs838708 chr2 234284399 G A 6.37E-18 Bilirubin levels,in serum DGKD intron 20639394 rs838709 chr2 234284744 C A 9.80E-15 Bilirubin levels DGKD intron 19414484 rs838709 chr2 234284744 C A 6.85E-18 Bilirubin levels,in serum DGKD intron 20639394 rs6726046 chr2 234287221 G A 2.50E-05 Bilirubin levels DGKD intron 19414484 rs7598771 chr2 234288048 T C 2.40E-14 Bilirubin levels DGKD intron 19414484 rs838716 chr2 234294791 G C 1.40E-15 Bilirubin levels DGKD intron 19414484 rs838717 chr2 234296444 G A 8.30E-16 Bilirubin levels DGKD intron 19414484 rs838718 chr2 234296650 G A 1.80E-16 Bilirubin levels DGKD intron 19414484 rs706848 chr2 234299919 G A 3.00E-16 Bilirubin levels DGKD intron 19414484 rs706848 chr2 234299919 G A 1.26E-08 Bilirubin levels,in serum DGKD intron 20639394 rs7584554 chr2 234308782 T G 1.60E-18 Bilirubin levels DGKD intron 19414484 rs13414407 chr2 234313158 A G 6.55E-04 Smoking initiation DGKD intron 24665060 rs838730 chr2 234314479 A T 1.80E-05 Bilirubin levels DGKD intron 19414484 rs7568534 chr2 234315079 G C 1.10E-08 Bilirubin levels DGKD intron 19414484 rs838731 chr2 234315363 C T 1.80E-05 Bilirubin levels DGKD intron 19414484 rs7422734 chr2 234315792 C T 5.79E-04 Smoking initiation DGKD intron 24665060 rs7587876 chr2 234316032 A G 9.40E-15 Bilirubin levels DGKD intron 19414484 rs838732 chr2 234321752 T C 1.70E-05 Bilirubin levels DGKD intron 19414484 rs838733 chr2 234323261 A G 1.70E-05 Bilirubin levels DGKD intron 19414484 rs838733 chr2 234323261 A G 2.48E-04 Lymphocyte counts DGKD intron 22286170 rs838734 chr2 234323564 G A 1.70E-05 Bilirubin levels DGKD intron 19414484 rs838735 chr2 234324192 G C 1.70E-05 Bilirubin levels DGKD intron 19414484 rs838736 chr2 234324232 G A 1.20E-17 Bilirubin levels DGKD intron 19414484 rs6753242 chr2 234329419 G T 7.00E-15 Bilirubin levels DGKD intron 19414484 rs2971868 chr2 234329549 T C 1.30E-05 Bilirubin levels DGKD intron 19414484 rs2924808 chr2 234329816 G C 4.90E-18 Bilirubin levels DGKD intron 19414484 rs11694406 chr2 234331810 G A 4.50E-17 Bilirubin levels DGKD intron 19414484 rs11694406 chr2 234331810 G A 5.45E-08 Metabolite levels DGKD intron 23281178 rs11689634 chr2 234338179 T C 1.70E-13 Bilirubin levels DGKD intron 19414484 rs11681604 chr2 234338227 G A 4.10E-08 Bilirubin levels DGKD intron 19414484 rs11892545 chr2 234338935 G A 6.77E-05 Multiple complex diseases DGKD intron 17554300 rs6714168 chr2 234339999 A G 3.50E-08 Bilirubin levels DGKD intron 19414484 rs2924815 chr2 234340446 A C 2.60E-05 Bilirubin levels DGKD intron 19414484 rs2305542 chr2 234354245 G A 3.40E-09 Bilirubin levels DGKD intron 19414484 rs2971859 chr2 234355898 G C 6.30E-06 Bilirubin levels DGKD intron 19414484 rs2242100 chr2 234358286 C T 2.30E-10 Bilirubin levels DGKD intron 19414484 rs3820744 chr2 234361548 T C 4.90E-15 Bilirubin levels DGKD intron 19414484 rs13391864 chr2 234362816 C T 2.40E-04 Smoking initiation DGKD intron 24665060 rs11675254 chr2 234364047 G A 3.30E-15 Bilirubin levels DGKD intron 19414484 rs2034762 chr2 234364237 T A 5.20E-15 Bilirubin levels DGKD intron 19414484 rs2290464 chr2 234368821 T C 6.30E-08 Bilirubin levels DGKD intron 19414484 rs3754595 chr2 234370425 A G 2.00E-15 Bilirubin levels DGKD intron 19414484 rs1053895 chr2 234378902 T C 8.70E-07 Bilirubin levels DGKD UTR-3 19414484 rs2026 chr2 234380666 C T 9.80E-06 Bilirubin levels DGKD UTR-3 19414484 rs2971869 chr2 234380988 G T 8.12E-04 Multiple complex diseases DGKD nearGene-3 17554300 rs10175828 chr2 234381817 G T 7.81E-08 Bilirubin levels / / 19419973 rs745155 chr2 234386803 T G 7.61E-05 Partial epilepsies USP40 intron 20522523 rs2971865 chr2 234388689 G A 8.39E-04 Multiple complex diseases USP40 intron 17554300 rs3796092 chr2 234390469 C A 1.40E-19 Bilirubin levels USP40 intron 19414484 rs3796090 chr2 234390602 T C 1.80E-18 Bilirubin levels USP40 intron 19414484 rs10929178 chr2 234396566 G C 1.20E-19 Bilirubin levels USP40 intron 19414484 rs10929178 chr2 234396566 G C 5.29E-04 Rheumatoid arthritis (ACPA-negative) USP40 intron 24532677 rs11683101 chr2 234398725 T C 7.60E-15 Bilirubin levels USP40 intron 19414484 rs6704644 chr2 234406655 G T 3.20E-20 Bilirubin levels USP40 intron 19414484 rs6704644 chr2 234406655 G T 8.00E-08 Bilirubin levels USP40 intron 21646302 rs2603545 chr2 234425051 C T 9.10E-04 Multiple complex diseases USP40 intron 17554300 rs6746234 chr2 234433081 G A 5.20E-20 Bilirubin levels USP40 intron 19414484 rs11675858 chr2 234440053 G A 5.30E-20 Bilirubin levels USP40 intron 19414484 rs4047189 chr2 234442949 G T 6.00E-23 Bilirubin levels USP40 intron 19414484 rs1597940 chr2 234446511 C T 5.70E-04 Multiple complex diseases USP40 intron 17554300 rs1453321 chr2 234446594 A T 4.83E-04 Multiple complex diseases USP40 intron 17554300 rs2167884 chr2 234449316 G A 3.72E-04 Smoking initiation USP40 cds-synon 24665060 rs1901812 chr2 234450822 T C 6.90E-04 Multiple complex diseases USP40 intron 17554300 rs10929208 chr2 234451486 C T 8.28E-04 Multiple complex diseases USP40 intron 17554300 rs11686188 chr2 234451630 G A 4.30E-20 Bilirubin levels USP40 intron 19414484 rs4047198 chr2 234454900 C G 3.90E-09 Bilirubin levels USP40 intron 19414484 rs6756068 chr2 234455898 A G 1.77E-04 Multiple complex diseases USP40 intron 17554300 rs13385018 chr2 234456256 C T 1.50E-07 Bilirubin levels USP40 intron 19414484 rs1542325 chr2 234456752 C G 9.58E-04 Multiple complex diseases USP40 intron 17554300 rs11676524 chr2 234460968 A T 3.90E-20 Bilirubin levels USP40 intron 19414484 rs12472244 chr2 234466843 A G 2.20E-14 Bilirubin levels USP40 intron 19414484 rs6720619 chr2 234468148 C A 1.43E-04 Smoking initiation USP40 intron 24665060 rs13401703 chr2 234477460 T C 2.30E-04 Multiple complex diseases / / 17554300 rs12467878 chr2 234477504 G A 8.10E-04 Multiple complex diseases / / 17554300 rs13387539 chr2 234482610 C T 1.50E-07 Bilirubin levels / / 19414484 rs4129945 chr2 234493048 A G 2.90E-08 Bilirubin levels / / 19414484 rs4129945 chr2 234493048 A G 3.40E-06 HIV-1 control / / 20041166 rs4132954 chr2 234493876 T A 2.10E-08 Bilirubin levels / / 19414484 rs13417719 chr2 234494173 G A 5.80E-08 Bilirubin levels / / 19414484 rs13430633 chr2 234494513 C A 1.70E-08 Bilirubin levels / / 19414484 rs13383300 chr2 234495469 C G 5.90E-08 Bilirubin levels / / 19414484 rs17864661 chr2 234495742 C T 1.10E-26 Bilirubin levels / / 19414484 rs17864661 chr2 234495742 C T 5.71E-08 Metabolite levels / / 23281178 rs17864662 chr2 234496534 C T 1.70E-07 Bilirubin levels / / 19414484 rs1002846 chr2 234496945 A G 7.70E-06 Bilirubin levels / / 19414484 rs17868296 chr2 234497246 A G 1.70E-08 Bilirubin levels / / 19414484 rs6757739 chr2 234498128 C T 1.90E-08 Bilirubin levels / / 19414484 rs6757739 chr2 234498128 C T 5.13E-11 Bilirubin levels,in serum / / 20639394 rs17863751 chr2 234498485 A T 2.00E-05 Bilirubin levels / / 19414484 rs17868297 chr2 234498651 C A,G,T 6.90E-09 Bilirubin levels / / 19414484 rs17868297 chr2 234498651 C A,G,T 7.20E-06 HIV-1 control / / 20041166 rs17868297 chr2 234498651 C A,G,T 2.10E-08 Bilirubin levels,in serum / / 20639394 rs13394291 chr2 234501740 T C 8.00E-09 Bilirubin levels / / 19414484 rs13394291 chr2 234501740 T C 2.10E-08 Bilirubin levels,in serum / / 20639394 rs13394720 chr2 234502121 T C 7.70E-09 Bilirubin levels / / 19414484 rs13394720 chr2 234502121 T C 5.00E-07 HIV-1 control / / 20041166 rs13394720 chr2 234502121 T C 2.10E-08 Bilirubin levels,in serum / / 20639394 rs1597944 chr2 234504098 C T 4.00E-06 Brain lesion load / / 19010793 rs1597944 chr2 234504098 C T 4.00E-06 Normalized brain volume / / 19010793 rs1115381 chr2 234505285 T C 1.90E-23 Bilirubin levels / / 19414484 rs1115381 chr2 234505285 T C 4.53E-73 Bilirubin levels,in serum / / 20639394 rs17868298 chr2 234505915 C T 5.00E-14 Bilirubin levels / / 19414484 rs17868299 chr2 234506808 C T 5.00E-14 Bilirubin levels / / 19414484 rs12618259 chr2 234506921 A T 6.00E-36 Bilirubin levels / / 19414484 rs2602385 chr2 234508075 T C 4.80E-20 Bilirubin levels / / 19414484 rs6728792 chr2 234508692 A C 8.20E-21 Bilirubin levels / / 19414484 rs1901813 chr2 234508768 A G 7.00E-37 Bilirubin levels / / 19414484 rs2741012 chr2 234508963 C T 1.87E-12 Metabolite levels / / 23281178 rs17864666 chr2 234509857 T C 5.00E-14 Bilirubin levels / / 19414484 rs2741013 chr2 234509911 C T 1.87E-12 Metabolite levels / / 23281178 rs7563478 chr2 234510446 A G 5.00E-14 Bilirubin levels / / 19414484 rs2741019 chr2 234510688 C G 4.70E-217 Bilirubin levels / / 19414484 rs2741019 chr2 234510688 C G 1.87E-12 Metabolite levels / / 23281178 rs6713902 chr2 234511864 C A 2.30E-21 Bilirubin levels / / 19414484 rs2741021 chr2 234511883 C T 1.40E-216 Bilirubin levels / / 19414484 rs2741021 chr2 234511883 C T 1.87E-12 Metabolite levels / / 23281178 rs2219067 chr2 234512005 C G 5.60E-36 Bilirubin levels / / 19414484 rs2219067 chr2 234512005 C G 6.54E-104 Bilirubin levels,in serum / / 20639394 rs2219067 chr2 234512005 C G 1.16E-10 Bilirubin levels / / 23371916 rs2269352 chr2 234512976 T C 4.70E-34 Bilirubin levels / / 19414484 rs2269352 chr2 234512976 T C 1.10E-07 Bilirubin levels / / 19419973 rs2269352 chr2 234512976 T C 4.15E-103 Bilirubin levels,in serum / / 20639394 rs2269352 chr2 234512976 T C 2.26E-10 Bilirubin levels / / 23371916 rs6707134 chr2 234513372 G A 2.30E-21 Bilirubin levels / / 19414484 rs4663754 chr2 234513720 A C 4.10E-34 Bilirubin levels / / 19414484 rs17863756 chr2 234513980 T C 6.60E-20 Bilirubin levels / / 19414484 rs2741022 chr2 234514273 C T 1.87E-12 Metabolite levels / / 23281178 rs17862835 chr2 234514513 C T 5.20E-14 Bilirubin levels / / 19414484 rs17862836 chr2 234514763 A C 2.20E-21 Bilirubin levels / / 19414484 rs1551286 chr2 234515155 C T 5.30E-14 Bilirubin levels / / 19414484 rs4402757 chr2 234516455 G C 1.40E-10 Bilirubin levels / / 19414484 rs2602362 chr2 234516548 A C 1.40E-215 Bilirubin levels / / 19414484 rs2602362 chr2 234516548 A C 1.87E-12 Metabolite levels / / 23281178 rs2741023 chr2 234516714 G A 1.01E-25 Bilirubin levels / / 19419973 rs2741023 chr2 234516714 G A 1.64E-19 Bilirubin levels,in serum / / 20639394 rs2741023 chr2 234516714 G A 1.67E-09 Bilirubin levels / / 23642732 rs2741023 chr2 234516714 G A 2.55E-10 Bilirubin levels / / 23642732 rs2741023 chr2 234516714 G A 5.00E-04 Bilirubin levels / / 23642732 rs2741023 chr2 234516714 G A 6.00E-04 Bilirubin levels / / 23642732 rs17862837 chr2 234516799 T A 5.30E-37 Bilirubin levels / / 19414484 rs17868303 chr2 234517082 C T 1.50E-23 Bilirubin levels / / 19414484 rs2741027 chr2 234518011 G A 2.40E-215 Bilirubin levels / / 19414484 rs2741027 chr2 234518011 G A 1.87E-12 Metabolite levels / / 23281178 rs17864668 chr2 234518422 T G 1.60E-23 Bilirubin levels / / 19414484 rs17864669 chr2 234518514 T C 5.70E-14 Bilirubin levels / / 19414484 rs2741028 chr2 234518914 G A 2.40E-215 Bilirubin levels / / 19414484 rs2741028 chr2 234518914 G A 1.87E-12 Metabolite levels / / 23281178 rs17868306 chr2 234519337 A G 6.10E-14 Bilirubin levels / / 19414484 rs2602363 chr2 234520525 T C 1.40E-215 Bilirubin levels / / 19414484 rs2602363 chr2 234520525 T C 1.87E-12 Metabolite levels / / 23281178 rs4281899 chr2 234520669 T G 3.20E-34 Bilirubin levels / / 19414484 rs4281899 chr2 234520669 T G 1.15E-113 Bilirubin levels,in serum / / 20639394 rs2602364 chr2 234524229 G A 4.90E-215 Bilirubin levels / / 19414484 rs2602364 chr2 234524229 G A 3.35E-11 Metabolite levels / / 23281178 rs10210058 chr2 234525355 C T 3.00E-34 Bilirubin levels / / 19414484 rs10210058 chr2 234525355 C T 1.15E-113 Bilirubin levels,in serum / / 20639394 rs4114768 chr2 234525824 G A 1.50E-23 Bilirubin levels / / 19414484 rs1042590 chr2 234526785 G A 3.60E-11 Bilirubin levels UGT1A8 cds-synon 19414484 rs1042590 chr2 234526785 G A 6.73E-09 Bilirubin levels,in serum UGT1A8 cds-synon 20639394 rs1042597 chr2 234526871 C G,T 2.80E-34 Bilirubin levels UGT1A8 missense 19414484 rs1042597 chr2 234526871 C G,T 1 Drug response to Cyclosporine UGT1A8 missense 19890249 rs1042597 chr2 234526871 C G,T 1 Drug response to Mycophenolate Mofetil UGT1A8 missense 19890249 rs1042597 chr2 234526871 C G,T 1 Drug response to Mycophenolic Acid UGT1A8 missense 19890249 rs1126806 chr2 234527073 A G 6.70E-06 Bilirubin levels UGT1A8 cds-synon 19414484 rs17863762 chr2 234527183 G A 3.90E-10 Bilirubin levels UGT1A8 missense 19414484 rs13027376 chr2 234527397 G A 2.70E-34 Bilirubin levels UGT1A8 intron 19414484 rs17864670 chr2 234527398 G T 6.60E-14 Bilirubin levels UGT1A8 intron 19414484 rs10221563 chr2 234528798 G A 1.30E-05 Bilirubin levels UGT1A8 intron 19414484 rs13400017 chr2 234529391 A G 2.50E-34 Bilirubin levels UGT1A8 intron 19414484 rs13400017 chr2 234529391 A G 4.79E-107 Bilirubin levels,in serum UGT1A8 intron 20639394 rs6431558 chr2 234529643 C T 8.60E-111 Bilirubin levels UGT1A8 intron 19414484 rs2741029 chr2 234530160 T G 4.40E-216 Bilirubin levels UGT1A8 intron 19414484 rs2741029 chr2 234530160 T G 1.87E-12 Metabolite levels UGT1A8 intron 23281178 rs2741029 chr2 234530160 T G 1.16E-08 Bilirubin levels UGT1A8 intron 23642732 rs2741029 chr2 234530160 T G 2.18E-09 Bilirubin levels UGT1A8 intron 23642732 rs17862846 chr2 234534625 T C 6.50E-14 Bilirubin levels UGT1A8 intron 19414484 rs1597941 chr2 234534648 G A 2.30E-34 Bilirubin levels UGT1A8 intron 19414484 rs17863766 chr2 234535189 G A 1.00E-23 Bilirubin levels UGT1A8 intron 19414484 rs2741030 chr2 234536152 C T 1.87E-12 Metabolite levels UGT1A8 intron 23281178 rs1377460 chr2 234536637 A G 3.90E-11 Bilirubin levels UGT1A8 intron 19414484 rs1377460 chr2 234536637 A G 1.25E-69 Bilirubin levels,in serum UGT1A8 intron 20639394 rs13394704 chr2 234537447 G T 2.20E-34 Bilirubin levels UGT1A8 intron 19414484 rs17864675 chr2 234538491 C A 6.50E-14 Bilirubin levels UGT1A8 intron 19414484 rs2741031 chr2 234538716 T C 3.80E-11 Bilirubin levels UGT1A8 intron 19414484 rs2741031 chr2 234538716 T C 4.53E-73 Bilirubin levels,in serum UGT1A8 intron 20639394 rs1823803 chr2 234539111 T C 2.80E-60 Bilirubin levels UGT1A8 intron 19414484 rs1823803 chr2 234539111 T C 2.60E-09 Bilirubin levels UGT1A8 intron 23371916 rs28969975 chr2 234539381 T A 1.80E-34 Bilirubin levels UGT1A8 intron 19414484 rs17864678 chr2 234544610 T A 1.70E-15 Bilirubin levels UGT1A8 intron 19414484 rs11683356 chr2 234545294 G A 5.30E-43 Bilirubin levels UGT1A10 cds-synon 19414484 rs10929251 chr2 234546229 A G 1.10E-23 Bilirubin levels UGT1A10 intron 19414484 rs10929252 chr2 234546321 G C 1.10E-23 Bilirubin levels UGT1A10 intron 19414484 rs6738678 chr2 234548334 C T 1.60E-34 Bilirubin levels UGT1A10 intron 19414484 rs6738678 chr2 234548334 C T 1.19E-106 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6738678 chr2 234548334 C T 2.54E-10 Bilirubin levels UGT1A10 intron 23371916 rs17868314 chr2 234548474 T G 3.00E-11 Bilirubin levels UGT1A10 intron 19414484 rs2018609 chr2 234548576 T C 1.50E-34 Bilirubin levels UGT1A10 intron 19414484 rs2018609 chr2 234548576 T C 1.19E-106 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2741034 chr2 234548814 A G 8.20E-217 Bilirubin levels UGT1A10 intron 19414484 rs2741034 chr2 234548814 A G 1.32E-40 Bilirubin levels UGT1A10 intron 19419973 rs2741034 chr2 234548814 A G 1.16E-12 Metabolite levels UGT1A10 intron 23281178 rs2741034 chr2 234548814 A G 1.49E-09 Bilirubin levels UGT1A10 intron 23642732 rs2741034 chr2 234548814 A G 2.00E-04 Bilirubin levels UGT1A10 intron 23642732 rs2741034 chr2 234548814 A G 3.75E-09 Bilirubin levels UGT1A10 intron 23642732 rs2741034 chr2 234548814 A G 4.00E-04 Bilirubin levels UGT1A10 intron 23642732 rs17862847 chr2 234549011 T A 1.00E-23 Bilirubin levels UGT1A10 intron 19414484 rs2602372 chr2 234553314 A C 2.70E-20 Bilirubin levels UGT1A10 intron 19414484 rs2741035 chr2 234555809 G A 6.87E-70 Bilirubin levels,in serum UGT1A10 intron 20639394 rs17862848 chr2 234556070 C G 6.40E-14 Bilirubin levels UGT1A10 intron 19414484 rs12327959 chr2 234556326 C G 1.30E-34 Bilirubin levels UGT1A10 intron 19414484 rs1964501 chr2 234557274 T A 4.00E-28 Bilirubin levels UGT1A10 intron 19414484 rs2741036 chr2 234558802 G A 4.70E-217 Bilirubin levels UGT1A10 intron 19414484 rs2741036 chr2 234558802 G A 1.48E-12 Metabolite levels UGT1A10 intron 23281178 rs1817154 chr2 234560591 C A 4.30E-11 Bilirubin levels UGT1A10 intron 19414484 rs1817154 chr2 234560591 C A 1.10E-69 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2602373 chr2 234561953 T C 4.70E-217 Bilirubin levels UGT1A10 intron 19414484 rs2602373 chr2 234561953 T C 1.48E-12 Metabolite levels UGT1A10 intron 23281178 rs2741038 chr2 234563998 G A 2.70E-217 Bilirubin levels UGT1A10 intron 19414484 rs2741038 chr2 234563998 G A 1.48E-12 Metabolite levels UGT1A10 intron 23281178 rs17864679 chr2 234564068 G A 4.30E-43 Bilirubin levels UGT1A10 intron 19414484 rs2924450 chr2 234564405 C G 4.50E-11 Bilirubin levels UGT1A10 intron 19414484 rs2924450 chr2 234564405 C G 4.53E-73 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2248733 chr2 234564737 A T 9.70E-24 Bilirubin levels UGT1A10 intron 19414484 rs11893247 chr2 234565254 T G 2.10E-10 Bilirubin levels UGT1A10 intron 19414484 rs11892031 chr2 234565283 A C 2.10E-10 Bilirubin levels UGT1A10 intron 19414484 rs11892031 chr2 234565283 A C 1.00E-07 Bladder cancer UGT1A10 intron 20972438 rs11892031 chr2 234565283 A C 1.00E-07 Bladder cancer UGT1A10 intron 24163127 rs1453322 chr2 234565438 C T 8.90E-35 Bilirubin levels UGT1A10 intron 19414484 rs1453322 chr2 234565438 C T 5.04E-09 Bilirubin levels UGT1A10 intron 19419973 rs1453322 chr2 234565438 C T 5.91E-107 Bilirubin levels,in serum UGT1A10 intron 20639394 rs1453322 chr2 234565438 C T 3.94E-10 Bilirubin levels UGT1A10 intron 23371916 rs2741042 chr2 234565917 C T 1.50E-217 Bilirubin levels UGT1A10 intron 19414484 rs2741042 chr2 234565917 C T 1.48E-12 Metabolite levels UGT1A10 intron 23281178 rs7571337 chr2 234566418 T C 1.70E-112 Bilirubin levels UGT1A10 intron 19414484 rs7608713 chr2 234567051 G A 6.70E-37 Bilirubin levels UGT1A10 intron 19414484 rs2741043 chr2 234567601 G A 4.80E-11 Bilirubin levels UGT1A10 intron 19414484 rs2741043 chr2 234567601 G A 6.87E-70 Bilirubin levels,in serum UGT1A10 intron 20639394 rs1112310 chr2 234567916 G T 6.70E-104 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2602374 chr2 234568964 C T 6.99E-14 Metabolite levels UGT1A10 intron 23281178 rs1113193 chr2 234569137 G A 1.38E-08 Bilirubin levels,in serum UGT1A10 intron 19389676 rs1113193 chr2 234569137 G A 1.50E-43 Bilirubin levels UGT1A10 intron 19414484 rs1113193 chr2 234569137 G A 6.30E-16 Bilirubin levels UGT1A10 intron 19419973 rs17868318 chr2 234569185 C T 7.30E-14 Bilirubin levels UGT1A10 intron 19414484 rs17862851 chr2 234570474 G A 7.40E-14 Bilirubin levels UGT1A10 intron 19414484 rs12479240 chr2 234570829 C T 3.90E-29 Bilirubin levels UGT1A10 intron 19414484 rs7585521 chr2 234571072 G A 7.60E-14 Bilirubin levels UGT1A10 intron 19414484 rs1901815 chr2 234571814 A G 7.50E-16 Bilirubin levels UGT1A10 intron 19414484 rs6760588 chr2 234572783 A C 1.70E-36 Bilirubin levels UGT1A10 intron 19414484 rs6706988 chr2 234573623 A G 1.40E-25 Bilirubin levels UGT1A10 intron 19414484 rs17863773 chr2 234573896 T C 3.50E-24 Bilirubin levels UGT1A10 intron 19414484 rs6731242 chr2 234578693 T A,G 1.70E-24 Bilirubin levels UGT1A10 intron 19414484 rs13418420 chr2 234578762 T C 6.80E-40 Bilirubin levels UGT1A10 intron 19414484 rs17864683 chr2 234579209 A C 6.20E-230 Bilirubin levels UGT1A10 intron 19414484 rs17864683 chr2 234579209 A C 1.02E-12 Metabolite levels UGT1A10 intron 23281178 rs17864684 chr2 234579363 G A 1.70E-24 Bilirubin levels UGT1A10 intron 19414484 rs17864684 chr2 234579363 G A 2.38E-05 Follicle stimulating hormone UGT1A10 intron 24049095 rs2741044 chr2 234579368 G A 3.39E-17 Metabolite levels UGT1A10 intron 23281178 rs10176426 chr2 234579915 C T 2.20E-20 Bilirubin levels UGT1A10 intron 19414484 rs2741045 chr2 234580140 C T 1.50E-300 Bilirubin levels UGT1A10 intron 19414484 rs2741045 chr2 234580140 C T 3.32E-53 Bilirubin levels UGT1A10 intron 19419973 rs2741045 chr2 234580140 C T 3.01E-24 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2741045 chr2 234580140 C T 3.39E-17 Metabolite levels UGT1A10 intron 23281178 rs2741045 chr2 234580140 C T 2.02E-14 Bilirubin levels UGT1A10 intron 23642732 rs2741045 chr2 234580140 C T 4.00E-04 Bilirubin levels UGT1A10 intron 23642732 rs2741045 chr2 234580140 C T 4.81E-13 Bilirubin levels UGT1A10 intron 23642732 rs2741046 chr2 234580249 T C 7.70E-301 Bilirubin levels UGT1A10 intron 19414484 rs2741046 chr2 234580249 T C 3.39E-17 Metabolite levels UGT1A10 intron 23281178 rs6714486 chr2 234580305 T A 4.70E-13 Bilirubin levels UGT1A10 intron 19414484 rs17868322 chr2 234580494 G A 1.00E-44 Bilirubin levels UGT1A10 intron 19414484 rs58597806 chr2 234581346 G A 1 Drug response to Propofol UGT1A9 missense 18816295 rs4663871 chr2 234581587 G A 5.20E-34 Bilirubin levels UGT1A10 intron 19414484 rs2741047 chr2 234581654 A T 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs2741048 chr2 234581748 C A 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs2741048 chr2 234581748 C A 1.87E-100 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2741049 chr2 234581834 T C 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs2741049 chr2 234581834 T C 2.83E-102 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7349250 chr2 234581920 A G 5.30E-08 Bilirubin levels UGT1A10 intron 19414484 rs7349250 chr2 234581920 A G 1.40E-06 Bilirubin levels UGT1A10 intron 22085899 rs2602376 chr2 234582051 C T 1.50E-300 Bilirubin levels UGT1A10 intron 19414484 rs2602376 chr2 234582051 C T 3.39E-17 Metabolite levels UGT1A10 intron 23281178 rs17862857 chr2 234582084 C T 7.00E-34 Bilirubin levels UGT1A10 intron 19414484 rs2602377 chr2 234582212 G A 6.90E-96 Bilirubin levels UGT1A10 intron 19414484 rs2602378 chr2 234582504 A T 6.90E-96 Bilirubin levels UGT1A10 intron 19414484 rs2602378 chr2 234582504 A T 2.83E-102 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2602379 chr2 234583062 G A 6.90E-96 Bilirubin levels UGT1A10 intron 19414484 rs2602379 chr2 234583062 G A 2.83E-102 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2602379 chr2 234583062 G A 7.53E-18 Bilirubin levels UGT1A10 intron 23371916 rs10189426 chr2 234583490 C T 1.40E-25 Bilirubin levels UGT1A10 intron 19414484 rs10189426 chr2 234583490 C T 1.94E-100 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10189426 chr2 234583490 C T 6.92E-07 Bilirubin levels UGT1A10 intron 22085899 rs10189426 chr2 234583490 C T 1.46E-08 Bilirubin levels UGT1A10 intron 23371916 rs12615708 chr2 234583846 G A 4.90E-08 Bilirubin levels UGT1A10 intron 19414484 rs12615708 chr2 234583846 G A 1.11E-98 Bilirubin levels,in serum UGT1A10 intron 20639394 rs12615708 chr2 234583846 G A 6.09E-07 Bilirubin levels UGT1A10 intron 22085899 rs2602380 chr2 234584306 T C 1.00E-95 Bilirubin levels UGT1A10 intron 19414484 rs2602380 chr2 234584306 T C 7.32E-19 Bilirubin levels UGT1A10 intron 19419973 rs2602380 chr2 234584306 T C 2.53E-100 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2602380 chr2 234584306 T C 5.88E-19 Bilirubin levels UGT1A10 intron 23371916 rs2602381 chr2 234584324 T C 5.60E-111 Bilirubin levels UGT1A10 intron 19414484 rs2602381 chr2 234584324 T C 1.02E-29 Bilirubin levels UGT1A10 intron 19419973 rs2602381 chr2 234584324 T C 4.00E-06 Attention deficit hyperactivity disorder UGT1A10 intron 20732626 rs2602381 chr2 234584324 T C 3.10E-07 Bilirubin levels UGT1A10 intron 23371916 rs28948388 chr2 234586518 A T 2.40E-14 Bilirubin levels UGT1A10 intron 19414484 rs7571915 chr2 234586574 G A 9.71E-107 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7571915 chr2 234586574 G A 4.25E-06 Bilirubin levels UGT1A10 intron 22085899 rs4663877 chr2 234586671 G A 6.93E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7587916 chr2 234586814 A G 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs7587916 chr2 234586814 A G 1.54E-18 Bilirubin levels UGT1A10 intron 19419973 rs7587916 chr2 234586814 A G 6.17E-96 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7587916 chr2 234586814 A G 4.70E-19 Bilirubin levels UGT1A10 intron 23371916 rs10190976 chr2 234587442 G T 2.09E-102 Bilirubin levels,in serum UGT1A10 intron 20639394 rs12053462 chr2 234587639 A G 9.10E-34 Bilirubin levels UGT1A10 intron 19414484 rs12053462 chr2 234587639 A G 6.93E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10202865 chr2 234587707 C T 9.71E-107 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10202865 chr2 234587707 C T 4.07E-06 Bilirubin levels UGT1A10 intron 22085899 rs10202865 chr2 234587707 C T 6.92E-19 Metabolite levels UGT1A10 intron 23281178 rs7595138 chr2 234588045 T C 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs7595138 chr2 234588045 T C 2.09E-102 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7579530 chr2 234588585 G A 2.50E-87 Bilirubin levels UGT1A10 intron 19414484 rs7579530 chr2 234588585 G A 2.09E-102 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10197460 chr2 234589190 G T 1.30E-230 Bilirubin levels UGT1A10 intron 19414484 rs10197460 chr2 234589190 G T 9.47E-30 Bilirubin levels UGT1A10 intron 19419973 rs10197460 chr2 234589190 G T 2.46E-100 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10197460 chr2 234589190 G T 4.04E-06 Bilirubin levels UGT1A10 intron 22085899 rs10197460 chr2 234589190 G T 6.30E-16 Metabolite levels UGT1A10 intron 23281178 rs10197460 chr2 234589190 G T 7.70E-12 Bilirubin levels UGT1A10 intron 23371916 rs10197460 chr2 234589190 G T 3.70E-13 Bilirubin levels UGT1A10 intron 23642732 rs10197460 chr2 234589190 G T 7.64E-12 Bilirubin levels UGT1A10 intron 23642732 rs10167119 chr2 234589312 T C 1.30E-230 Bilirubin levels UGT1A10 intron 19414484 rs10167119 chr2 234589312 T C 9.71E-107 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10167119 chr2 234589312 T C 4.07E-06 Bilirubin levels UGT1A10 intron 22085899 rs10167119 chr2 234589312 T C 6.30E-16 Metabolite levels UGT1A10 intron 23281178 rs10199293 chr2 234589504 T C 1.50E-91 Bilirubin levels UGT1A10 intron 19414484 rs10199293 chr2 234589504 T C 2.09E-102 Bilirubin levels,in serum UGT1A10 intron 20639394 rs12474215 chr2 234589560 A T 8.90E-34 Bilirubin levels UGT1A10 intron 19414484 rs12474215 chr2 234589560 A T 6.93E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs12472689 chr2 234589616 C T 9.60E-34 Bilirubin levels UGT1A10 intron 19414484 rs12472689 chr2 234589616 C T 6.93E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4530361 chr2 234590041 A G 1.30E-230 Bilirubin levels UGT1A10 intron 19414484 rs4530361 chr2 234590041 A G 6.30E-16 Metabolite levels UGT1A10 intron 23281178 rs28946877 chr2 234590243 C T 1.10E-33 Bilirubin levels UGT1A10 intron 19414484 rs28946877 chr2 234590243 C T 6.93E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7586110 chr2 234590527 T G 1 Drug response to Irinotecan UGT1A10 intron 18349289 rs7586110 chr2 234590527 T G 2.40E-230 Bilirubin levels UGT1A10 intron 19414484 rs7586110 chr2 234590527 T G 5.10E-29 Bilirubin levels UGT1A10 intron 19419973 rs7586110 chr2 234590527 T G 9.71E-107 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7586110 chr2 234590527 T G 2.43E-06 Bilirubin levels UGT1A10 intron 22085899 rs7586110 chr2 234590527 T G 6.30E-16 Metabolite levels UGT1A10 intron 23281178 rs7577677 chr2 234590616 C A 1.30E-230 Bilirubin levels UGT1A7 cds-synon 19414484 rs7577677 chr2 234590616 C A 9.71E-107 Bilirubin levels,in serum UGT1A7 cds-synon 20639394 rs7577677 chr2 234590616 C A 2.43E-06 Bilirubin levels UGT1A7 cds-synon 22085899 rs7577677 chr2 234590616 C A 6.30E-16 Metabolite levels UGT1A7 cds-synon 23281178 rs17868323 chr2 234590970 T G 1 Drug response to Irinotecan UGT1A7 missense 18349289 rs17864686 chr2 234591339 G A 1.30E-33 Bilirubin levels UGT1A7 cds-synon 19414484 rs17864686 chr2 234591339 G A 6.93E-09 Bilirubin levels,in serum UGT1A7 cds-synon 20639394 rs4663888 chr2 234591987 G A 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs4663888 chr2 234591987 G A 2.09E-102 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4433994 chr2 234592635 G T 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs6724485 chr2 234592816 G A 8.50E-229 Bilirubin levels UGT1A10 intron 19414484 rs6724485 chr2 234592816 G A 7.82E-08 Bilirubin levels UGT1A10 intron 22085899 rs6724485 chr2 234592816 G A 2.68E-16 Metabolite levels UGT1A10 intron 23281178 rs4347832 chr2 234593041 T C 8.50E-229 Bilirubin levels UGT1A10 intron 19414484 rs4347832 chr2 234593041 T C 4.25E-111 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4347832 chr2 234593041 T C 7.82E-08 Bilirubin levels UGT1A10 intron 22085899 rs4347832 chr2 234593041 T C 4.86E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs4347832 chr2 234593041 T C 2.68E-16 Metabolite levels UGT1A10 intron 23281178 rs4261716 chr2 234593117 G T 1.60E-228 Bilirubin levels UGT1A10 intron 19414484 rs4261716 chr2 234593117 G T 9.71E-107 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4261716 chr2 234593117 G T 7.82E-08 Bilirubin levels UGT1A10 intron 22085899 rs4261716 chr2 234593117 G T 4.85E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs4261716 chr2 234593117 G T 2.68E-16 Metabolite levels UGT1A10 intron 23281178 rs4583459 chr2 234593374 G T 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs4583459 chr2 234593374 G T 2.09E-102 Bilirubin levels,in serum UGT1A10 intron 20639394 rs13002774 chr2 234593706 G A 1.60E-228 Bilirubin levels UGT1A10 intron 19414484 rs13002774 chr2 234593706 G A 9.71E-107 Bilirubin levels,in serum UGT1A10 intron 20639394 rs13002774 chr2 234593706 G A 7.80E-08 Bilirubin levels UGT1A10 intron 22085899 rs13002774 chr2 234593706 G A 4.84E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs13002774 chr2 234593706 G A 2.68E-16 Metabolite levels UGT1A10 intron 23281178 rs4553819 chr2 234594083 A G 1.60E-228 Bilirubin levels UGT1A10 intron 19414484 rs4553819 chr2 234594083 A G 9.71E-107 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4553819 chr2 234594083 A G 8.01E-08 Bilirubin levels UGT1A10 intron 22085899 rs4553819 chr2 234594083 A G 4.83E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs4553819 chr2 234594083 A G 2.68E-16 Metabolite levels UGT1A10 intron 23281178 rs17864689 chr2 234594234 G T 1.80E-13 Bilirubin levels UGT1A10 intron 19414484 rs11902131 chr2 234594269 C T 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs11902131 chr2 234594269 C T 9.71E-107 Bilirubin levels,in serum UGT1A10 intron 20639394 rs11902131 chr2 234594269 C T 8.01E-08 Bilirubin levels UGT1A10 intron 22085899 rs11902131 chr2 234594269 C T 4.82E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs11902131 chr2 234594269 C T 1.42E-16 Metabolite levels UGT1A10 intron 23281178 rs17868325 chr2 234594387 T G 3.00E-33 Bilirubin levels UGT1A10 intron 19414484 rs17868325 chr2 234594387 T G 6.93E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6753317 chr2 234594979 T A 3.10E-33 Bilirubin levels UGT1A10 intron 19414484 rs6753317 chr2 234594979 T A 6.93E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6753320 chr2 234595615 A C 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs6753320 chr2 234595615 A C 8.30E-19 Bilirubin levels UGT1A10 intron 19419973 rs6753320 chr2 234595615 A C 4.46E-109 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6753320 chr2 234595615 A C 1.56E-09 Bilirubin levels UGT1A10 intron 22085899 rs6753320 chr2 234595615 A C 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs6753320 chr2 234595615 A C 4.52E-16 Metabolite levels UGT1A10 intron 23281178 rs6753320 chr2 234595615 A C 5.32E-13 Bilirubin levels UGT1A10 intron 23371916 rs6736508 chr2 234595747 G A 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs6736508 chr2 234595747 G A 2.39E-21 Bilirubin levels UGT1A10 intron 19419973 rs6736508 chr2 234595747 G A 3.67E-110 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6736508 chr2 234595747 G A 1.47E-09 Bilirubin levels UGT1A10 intron 22085899 rs6736508 chr2 234595747 G A 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs6736508 chr2 234595747 G A 2.07E-16 Metabolite levels UGT1A10 intron 23281178 rs6736508 chr2 234595747 G A 3.72E-13 Bilirubin levels UGT1A10 intron 23371916 rs6736508 chr2 234595747 G A 1.22E-11 Bilirubin levels UGT1A10 intron 23642732 rs6736508 chr2 234595747 G A 4.71E-13 Bilirubin levels UGT1A10 intron 23642732 rs6753569 chr2 234595817 A C 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs6753569 chr2 234595817 A C 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6753569 chr2 234595817 A C 1.47E-09 Bilirubin levels UGT1A10 intron 22085899 rs6753569 chr2 234595817 A C 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs6753569 chr2 234595817 A C 8.12E-17 Metabolite levels UGT1A10 intron 23281178 rs6736743 chr2 234595950 G A 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs6736743 chr2 234595950 G A 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6736743 chr2 234595950 G A 1.47E-09 Bilirubin levels UGT1A10 intron 22085899 rs6736743 chr2 234595950 G A 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs6736743 chr2 234595950 G A 8.12E-17 Metabolite levels UGT1A10 intron 23281178 rs6737107 chr2 234596195 G A 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs6737107 chr2 234596195 G A 1.47E-103 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6754100 chr2 234596214 A C 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs6754100 chr2 234596214 A C 4.85E-17 Bilirubin levels UGT1A10 intron 19419973 rs6754100 chr2 234596214 A C 3.41E-101 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6754100 chr2 234596214 A C 4.85E-18 Bilirubin levels UGT1A10 intron 23371916 rs17863781 chr2 234596515 C G 7.40E-20 Bilirubin levels UGT1A10 intron 19414484 rs10168155 chr2 234596836 C T 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs10168155 chr2 234596836 C T 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10168155 chr2 234596836 C T 1.47E-09 Bilirubin levels UGT1A10 intron 22085899 rs10168155 chr2 234596836 C T 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs10168155 chr2 234596836 C T 8.12E-17 Metabolite levels UGT1A10 intron 23281178 rs10175809 chr2 234596865 T A 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs10175809 chr2 234596865 T A 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10175809 chr2 234596865 T A 6.39E-08 Bilirubin levels UGT1A10 intron 22085899 rs10175809 chr2 234596865 T A 4.85E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs10175809 chr2 234596865 T A 8.12E-17 Metabolite levels UGT1A10 intron 23281178 rs10168333 chr2 234596988 C T 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs10168333 chr2 234596988 C T 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10168333 chr2 234596988 C T 6.39E-08 Bilirubin levels UGT1A10 intron 22085899 rs10168333 chr2 234596988 C T 4.87E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs10168333 chr2 234596988 C T 8.12E-17 Metabolite levels UGT1A10 intron 23281178 rs10168416 chr2 234597087 C G 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10168416 chr2 234597087 C G 1.46E-06 Bilirubin levels UGT1A10 intron 22085899 rs10168416 chr2 234597087 C G 0.00058 fMRI brain tests in schizophrenia UGT1A10 intron 22440650 rs10168416 chr2 234597087 C G 1.46E-19 Metabolite levels UGT1A10 intron 23281178 rs10173355 chr2 234597321 A T 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10173355 chr2 234597321 A T 2.11E-06 Bilirubin levels UGT1A10 intron 22085899 rs10173355 chr2 234597321 A T 1.46E-19 Metabolite levels UGT1A10 intron 23281178 rs11680450 chr2 234597483 T C 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs11680450 chr2 234597483 T C 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs11680450 chr2 234597483 T C 3.05E-09 Bilirubin levels UGT1A10 intron 22085899 rs11680450 chr2 234597483 T C 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs11680450 chr2 234597483 T C 8.12E-17 Metabolite levels UGT1A10 intron 23281178 rs4485562 chr2 234597566 G A 4.40E-33 Bilirubin levels UGT1A10 intron 19414484 rs4485562 chr2 234597566 G A 2.32E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10171367 chr2 234597667 C G 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs10171367 chr2 234597667 C G 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10171367 chr2 234597667 C G 3.05E-09 Bilirubin levels UGT1A10 intron 22085899 rs10171367 chr2 234597667 C G 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs10171367 chr2 234597667 C G 8.12E-17 Metabolite levels UGT1A10 intron 23281178 rs10179094 chr2 234597825 T A 7.00E-231 Bilirubin levels UGT1A10 intron 19414484 rs10179094 chr2 234597825 T A 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10179094 chr2 234597825 T A 2.11E-06 Bilirubin levels UGT1A10 intron 22085899 rs10179094 chr2 234597825 T A 3.55E-16 Metabolite levels UGT1A10 intron 23281178 rs17862859 chr2 234597842 G A 1.70E-14 Bilirubin levels UGT1A10 intron 19414484 rs6707947 chr2 234597915 T C 4.70E-96 Bilirubin levels UGT1A10 intron 19414484 rs6707947 chr2 234597915 T C 1.62E-103 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7563561 chr2 234598991 T G 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs7563561 chr2 234598991 T G 1.69E-20 Bilirubin levels UGT1A10 intron 19419973 rs7563561 chr2 234598991 T G 6.18E-115 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7563561 chr2 234598991 T G 2.83E-09 Bilirubin levels UGT1A10 intron 22085899 rs7563561 chr2 234598991 T G 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs7563561 chr2 234598991 T G 1.87E-16 Metabolite levels UGT1A10 intron 23281178 rs7563561 chr2 234598991 T G 1.10E-12 Bilirubin levels UGT1A10 intron 23371916 rs7563561 chr2 234598991 T G 2.47E-11 Bilirubin levels UGT1A10 intron 23642732 rs7563561 chr2 234598991 T G 7.18E-13 Bilirubin levels UGT1A10 intron 23642732 rs7608175 chr2 234599089 C G 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs7608175 chr2 234599089 C G 1.96E-21 Bilirubin levels UGT1A10 intron 19419973 rs7608175 chr2 234599089 C G 3.23E-110 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7608175 chr2 234599089 C G 1.42E-07 Bilirubin levels UGT1A10 intron 22085899 rs7608175 chr2 234599089 C G 4.96E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs7608175 chr2 234599089 C G 2.36E-16 Metabolite levels UGT1A10 intron 23281178 rs7608175 chr2 234599089 C G 3.91E-13 Bilirubin levels UGT1A10 intron 23371916 rs7608175 chr2 234599089 C G 2.20E-11 Bilirubin levels UGT1A10 intron 23642732 rs7608175 chr2 234599089 C G 7.45E-13 Bilirubin levels UGT1A10 intron 23642732 rs12623271 chr2 234599941 C G 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs12623271 chr2 234599941 C G 3.05E-09 Bilirubin levels UGT1A10 intron 22085899 rs12623271 chr2 234599941 C G 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs12623271 chr2 234599941 C G 8.12E-17 Metabolite levels UGT1A10 intron 23281178 rs12474980 chr2 234600116 G A 3.10E-33 Bilirubin levels UGT1A10 intron 19414484 rs12474980 chr2 234600116 G A 2.32E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10445704 chr2 234600274 G A 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs10445704 chr2 234600274 G A 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10445704 chr2 234600274 G A 2.16E-09 Bilirubin levels UGT1A10 intron 22085899 rs10445704 chr2 234600274 G A 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs10445704 chr2 234600274 G A 8.12E-17 Metabolite levels UGT1A10 intron 23281178 rs13015720 chr2 234600999 G A 3.00E-228 Bilirubin levels UGT1A10 intron 19414484 rs13015720 chr2 234600999 G A 4.98E-99 Bilirubin levels,in serum UGT1A10 intron 20639394 rs13015720 chr2 234600999 G A 1.98E-09 Bilirubin levels UGT1A10 intron 22085899 rs13015720 chr2 234600999 G A 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A10 intron 22566498 rs13015720 chr2 234600999 G A 8.12E-17 Metabolite levels UGT1A10 intron 23281178 rs12476197 chr2 234601224 G C 3.10E-33 Bilirubin levels UGT1A10 intron 19414484 rs12476197 chr2 234601224 G C 2.32E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6759892 chr2 234601669 T G 5.70E-228 Bilirubin levels UGT1A6 missense 19414484 rs6759892 chr2 234601669 T G 1.47E-21 Bilirubin levels UGT1A6 missense 19419973 rs6759892 chr2 234601669 T G 1.79E-110 Bilirubin levels,in serum UGT1A6 missense 20639394 rs6759892 chr2 234601669 T G 1.98E-09 Bilirubin levels UGT1A6 missense 22085899 rs6759892 chr2 234601669 T G 3.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) UGT1A6 missense 22566498 rs6759892 chr2 234601669 T G 8.12E-17 Metabolite levels UGT1A6 missense 23281178 rs6759892 chr2 234601669 T G 3.91E-13 Bilirubin levels UGT1A6 missense 23371916 rs6759892 chr2 234601669 T G 2.51E-11 Bilirubin levels UGT1A6 missense 23642732 rs6759892 chr2 234601669 T G 7.93E-13 Bilirubin levels UGT1A6 missense 23642732 rs1105880 chr2 234601965 A G 4.98E-99 Bilirubin levels,in serum UGT1A6 cds-synon 20639394 rs1105880 chr2 234601965 A G 1.98E-09 Bilirubin levels UGT1A6 cds-synon 22085899 rs1105880 chr2 234601965 A G 0.000261 fMRI brain tests in schizophrenia UGT1A6 cds-synon 22440650 rs1105880 chr2 234601965 A G 5.50E-13 Bilirubin levels UGT1A6 cds-synon 23371916 rs2070959 chr2 234602191 A G 4.98E-99 Bilirubin levels,in serum UGT1A6 missense 20639394 rs2070959 chr2 234602191 A G 2.11E-06 Bilirubin levels UGT1A6 missense 22085899 rs2070959 chr2 234602191 A G 0.00058 fMRI brain tests in schizophrenia UGT1A6 missense 22440650 rs2070959 chr2 234602191 A G 2.33E-19 Metabolite levels UGT1A6 missense 23281178 rs2070959 chr2 234602191 A G 1.52E-12 Bilirubin levels UGT1A6 missense 23642732 rs2070959 chr2 234602191 A G 2.48E-14 Bilirubin levels UGT1A6 missense 23642732 rs1105879 chr2 234602202 A C 4.98E-99 Bilirubin levels,in serum UGT1A6 missense 20639394 rs1105879 chr2 234602202 A C 4.12E-08 Bilirubin levels UGT1A6 missense 22085899 rs1105879 chr2 234602202 A C 0.000212 fMRI brain tests in schizophrenia UGT1A6 missense 22440650 rs1105879 chr2 234602202 A C 1.21E-14 Bilirubin levels UGT1A6 missense 23642732 rs1105879 chr2 234602202 A C 1.30E-12 Bilirubin levels UGT1A6 missense 23642732 rs7592281 chr2 234602641 G T 2.70E-08 Bilirubin levels UGT1A10 intron 19414484 rs7592624 chr2 234602906 G A 2.50E-131 Bilirubin levels UGT1A10 intron 19414484 rs7592624 chr2 234602906 G A 1.03E-103 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6761246 chr2 234603439 A C 1.00E-96 Bilirubin levels UGT1A10 intron 19414484 rs6761246 chr2 234603439 A C 5.82E-18 Bilirubin levels UGT1A10 intron 19419973 rs6761246 chr2 234603439 A C 2.69E-101 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6761246 chr2 234603439 A C 1.05E-18 Bilirubin levels UGT1A10 intron 23371916 rs28899170 chr2 234604230 C A 8.40E-19 Metabolite levels UGT1A10 intron 23281178 rs6751673 chr2 234604903 G A 5.80E-53 Bilirubin levels UGT1A10 intron 19414484 rs17864692 chr2 234605486 G A 1.80E-11 Bilirubin levels UGT1A10 intron 19414484 rs1604144 chr2 234605835 C T 1.30E-49 Bilirubin levels UGT1A10 intron 19414484 rs1604144 chr2 234605835 C T 8.93E-08 Metabolite levels UGT1A10 intron 23281178 rs1604144 chr2 234605835 C T 4.75E-05 Neuroblastoma UGT1A10 intron pha002895 rs6715829 chr2 234606162 A T 1.50E-291 Bilirubin levels UGT1A10 intron 19414484 rs6715829 chr2 234606162 A T 2.44E-16 Metabolite levels UGT1A10 intron 23281178 rs28898578 chr2 234606528 A T 6.34E-13 Bilirubin levels,in serum UGT1A10 intron 20639394 rs12466747 chr2 234606787 G C 2.90E-34 Bilirubin levels UGT1A10 intron 19414484 rs12466747 chr2 234606787 G C 2.32E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs12988520 chr2 234607394 A C 4.70E-130 Bilirubin levels UGT1A10 intron 19414484 rs12988520 chr2 234607394 A C 1.07E-06 Bilirubin levels UGT1A10 intron 22085899 rs12471030 chr2 234607560 C T 4.70E-35 Bilirubin levels UGT1A10 intron 19414484 rs12471030 chr2 234607560 C T 2.32E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs35982104 chr2 234607560 C CT 4.70E-35 Bilirubin levels UGT1A10 intron 19414484 rs35982104 chr2 234607560 C CT 2.32E-09 Bilirubin levels,in serum UGT1A10 intron 20639394 rs17862866 chr2 234610912 A G 6.10E-210 Bilirubin levels UGT1A10 intron 19414484 rs17862866 chr2 234610912 A G 1.35E-82 Bilirubin levels,in serum UGT1A10 intron 20639394 rs17862866 chr2 234610912 A G 2.96E-11 Metabolite levels UGT1A10 intron 23281178 rs17863787 chr2 234611094 T G 9.27E-09 Bilirubin levels UGT1A10 intron 22085899 rs17863787 chr2 234611094 T G 3.71E-19 Metabolite levels UGT1A10 intron 23281178 rs7420193 chr2 234611523 C G 6.50E-07 Bilirubin levels UGT1A10 intron 19414484 rs11683974 chr2 234613000 C T 2.80E-40 Bilirubin levels UGT1A10 intron 19414484 rs6722836 chr2 234613196 A C 4.42E-10 Bilirubin levels,in serum UGT1A10 intron 20639394 rs17863788 chr2 234614499 T C 5.00E-06 Bilirubin levels UGT1A10 intron 19414484 rs6725478 chr2 234615400 C T 4.50E-273 Bilirubin levels UGT1A10 intron 19414484 rs6725478 chr2 234615400 C T 9.02E-17 Metabolite levels UGT1A10 intron 23281178 rs4663325 chr2 234616357 C T 6.60E-07 Bilirubin levels UGT1A10 intron 19414484 rs4663326 chr2 234616571 A G 6.50E-07 Bilirubin levels UGT1A10 intron 19414484 rs7572563 chr2 234617236 G A 1.80E-210 Bilirubin levels UGT1A10 intron 19414484 rs7572563 chr2 234617236 G A 1.35E-82 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7572563 chr2 234617236 G A 2.03E-11 Metabolite levels UGT1A10 intron 23281178 rs7583278 chr2 234617407 C T 2.90E-274 Bilirubin levels UGT1A10 intron 19414484 rs7583278 chr2 234617407 C T 9.02E-17 Metabolite levels UGT1A10 intron 23281178 rs4663327 chr2 234617632 G A 6.40E-07 Bilirubin levels UGT1A10 intron 19414484 rs28898589 chr2 234617750 A G 4.42E-10 Bilirubin levels,in serum UGT1A10 intron 20639394 rs28898590 chr2 234619422 G T 2.20E-16 Bilirubin levels UGT1A10 intron 19414484 rs2885295 chr2 234619866 T A 6.30E-07 Bilirubin levels UGT1A10 intron 19414484 rs4233633 chr2 234619937 G C 3.86E-08 Bilirubin levels UGT1A10 intron 23371916 rs28898593 chr2 234620171 A G 1.77E-06 Bilirubin levels UGT1A10 intron 22085899 rs28898596 chr2 234620640 G A 2.50E-07 Bilirubin levels UGT1A10 intron 19414484 rs3893334 chr2 234620917 C T 2.40E-07 Bilirubin levels UGT1A10 intron 19414484 rs2013030 chr2 234621040 A G 1.80E-09 Bilirubin levels UGT1A10 intron 19414484 rs2013021 chr2 234621086 C T 1.70E-07 Bilirubin levels UGT1A10 intron 19414484 rs2013018 chr2 234621157 T C 1.60E-07 Bilirubin levels UGT1A10 intron 19414484 rs5020121 chr2 234621269 C T 1.50E-07 Bilirubin levels UGT1A10 intron 19414484 rs4556969 chr2 234621404 C T 1.40E-07 Bilirubin levels UGT1A10 intron 19414484 rs28898600 chr2 234621436 T G 1.77E-06 Bilirubin levels UGT1A10 intron 22085899 rs11689628 chr2 234621488 C T 1.50E-40 Bilirubin levels UGT1A10 intron 19414484 rs3755321 chr2 234621825 T C 1.40E-07 Bilirubin levels UGT1A5 missense 19414484 rs28946885 chr2 234622067 A T 1.20E-07 Bilirubin levels UGT1A5 missense 19414484 rs12475068 chr2 234622110 C G 1.20E-07 Bilirubin levels UGT1A5 missense 19414484 rs3892170 chr2 234622412 G C 1.20E-07 Bilirubin levels UGT1A5 missense 19414484 rs17862870 chr2 234622742 G A 1.20E-07 Bilirubin levels UGT1A10 intron 19414484 rs4663945 chr2 234623117 G A 1.20E-07 Bilirubin levels UGT1A10 intron 19414484 rs12477216 chr2 234623667 C T 1.20E-07 Bilirubin levels UGT1A10 intron 19414484 rs17868334 chr2 234624817 A G 1.20E-07 Bilirubin levels UGT1A10 intron 19414484 rs17863791 chr2 234624884 T C 1.20E-07 Bilirubin levels UGT1A10 intron 19414484 rs17863792 chr2 234625126 G A 1.20E-07 Bilirubin levels UGT1A10 intron 19414484 rs17874943 chr2 234625239 A G 1.20E-07 Bilirubin levels UGT1A10 intron 19414484 rs6744284 chr2 234625297 C T 1.56E-40 Bilirubin levels UGT1A10 intron 19419973 rs6744284 chr2 234625297 C T 1.55E-153 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6744284 chr2 234625297 C T 5.82E-14 Metabolite levels UGT1A10 intron 23281178 rs6744284 chr2 234625297 C T 7.71E-20 Bilirubin levels UGT1A10 intron 23371916 rs6744284 chr2 234625297 C T 3.26E-16 Bilirubin levels UGT1A10 intron 23642732 rs6744284 chr2 234625297 C T 3.85E-19 Bilirubin levels UGT1A10 intron 23642732 rs28898605 chr2 234625494 A G 1.20E-07 Bilirubin levels UGT1A10 intron 19414484 rs1875263 chr2 234625622 C T 3.60E-218 Bilirubin levels UGT1A10 intron 19414484 rs1875263 chr2 234625622 C T 1.66E-149 Bilirubin levels,in serum UGT1A10 intron 20639394 rs1875263 chr2 234625622 C T 6.11E-07 Bilirubin levels UGT1A10 intron 22085899 rs1875263 chr2 234625622 C T 1.88E-12 Metabolite levels UGT1A10 intron 23281178 rs3806595 chr2 234625718 T A 1.20E-07 Bilirubin levels UGT1A10 intron 19414484 rs3806594 chr2 234625890 T C 1.20E-07 Bilirubin levels UGT1A10 intron 19414484 rs3806593 chr2 234625919 A G 1.10E-07 Bilirubin levels UGT1A10 intron 19414484 rs11676072 chr2 234625983 A G 1.60E-40 Bilirubin levels UGT1A10 intron 19414484 rs3806591 chr2 234626199 T C 1.10E-07 Bilirubin levels UGT1A10 intron 19414484 rs869283 chr2 234626287 G A 1.30E-279 Bilirubin levels UGT1A10 intron 19414484 rs869283 chr2 234626287 G A 1.66E-149 Bilirubin levels,in serum UGT1A10 intron 20639394 rs869283 chr2 234626287 G A 4.57E-06 Bilirubin levels UGT1A10 intron 22085899 rs869283 chr2 234626287 G A 3.10E-16 Metabolite levels UGT1A10 intron 23281178 rs3732221 chr2 234627010 C T 1.10E-07 Bilirubin levels UGT1A10 intron 19414484 rs3732220 chr2 234627048 G A 1.10E-07 Bilirubin levels UGT1A10 intron 19414484 rs3732218 chr2 234627304 G A 2.10E-07 Bilirubin levels UGT1A10 intron 19414484 rs6755571 chr2 234627536 C A 9.60E-19 Bilirubin levels UGT1A4 missense 19414484 rs2011404 chr2 234627937 T C 5.60E-50 Bilirubin levels UGT1A4 cds-synon 19414484 rs28898611 chr2 234628526 G C 3.54E-06 Bilirubin levels UGT1A10 intron 22085899 rs871514 chr2 234628529 T C 6.94E-04 Multiple complex diseases UGT1A10 intron 17554300 rs871514 chr2 234628529 T C 7.50E-262 Bilirubin levels UGT1A10 intron 19414484 rs871514 chr2 234628529 T C 7.62E-38 Bilirubin levels UGT1A10 intron 19419973 rs871514 chr2 234628529 T C 3.01E-82 Bilirubin levels,in serum UGT1A10 intron 20639394 rs871514 chr2 234628529 T C 2.85E-12 Metabolite levels UGT1A10 intron 23281178 rs7597496 chr2 234630443 A G 1.90E-262 Bilirubin levels UGT1A10 intron 19414484 rs7597496 chr2 234630443 A G 1.04E-84 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7597496 chr2 234630443 A G 2.85E-12 Metabolite levels UGT1A10 intron 23281178 rs6715325 chr2 234635241 T C 2.90E-201 Bilirubin levels UGT1A10 intron 19414484 rs6715325 chr2 234635241 T C 1.04E-84 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6715325 chr2 234635241 T C 5.02E-09 Bilirubin levels UGT1A10 intron 22085899 rs6715325 chr2 234635241 T C 1.35E-08 Metabolite levels UGT1A10 intron 23281178 rs6715325 chr2 234635241 T C 1.20E-21 Bilirubin levels UGT1A10 intron 23371916 rs4294999 chr2 234635467 A G 1.90E-262 Bilirubin levels UGT1A10 intron 19414484 rs4294999 chr2 234635467 A G 1.04E-84 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4294999 chr2 234635467 A G 2.85E-12 Metabolite levels UGT1A10 intron 23281178 rs4294999 chr2 234635467 A G 1.88E-21 Bilirubin levels UGT1A10 intron 23371916 rs1983023 chr2 234637022 T C 2.80E-307 Bilirubin levels UGT1A10 intron 19414484 rs1983023 chr2 234637022 T C 3.99E-15 Metabolite levels UGT1A10 intron 23281178 rs2008595 chr2 234637192 C T 1.90E-262 Bilirubin levels UGT1A10 intron 19414484 rs2008595 chr2 234637192 C T 1.04E-84 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2008595 chr2 234637192 C T 2.85E-12 Metabolite levels UGT1A10 intron 23281178 rs3806597 chr2 234637569 A G 1.90E-262 Bilirubin levels UGT1A10 intron 19414484 rs3806597 chr2 234637569 A G 1.04E-84 Bilirubin levels,in serum UGT1A10 intron 20639394 rs3806597 chr2 234637569 A G 2.85E-12 Metabolite levels UGT1A10 intron 23281178 rs3806597 chr2 234637569 A G 3.40E-21 Bilirubin levels UGT1A10 intron 23371916 rs3806596 chr2 234637707 T C 9.80E-263 Bilirubin levels UGT1A10 intron 19414484 rs3806596 chr2 234637707 T C 1.04E-84 Bilirubin levels,in serum UGT1A10 intron 20639394 rs3806596 chr2 234637707 T C 2.85E-12 Metabolite levels UGT1A10 intron 23281178 rs3806596 chr2 234637707 T C 3.51E-21 Bilirubin levels UGT1A10 intron 23371916 rs17868336 chr2 234638006 A G 8.00E-14 Bilirubin levels UGT1A3 cds-synon 19414484 rs7574296 chr2 234638249 A G 9.80E-263 Bilirubin levels UGT1A3 cds-synon 19414484 rs7574296 chr2 234638249 A G 1.04E-84 Bilirubin levels,in serum UGT1A3 cds-synon 20639394 rs7574296 chr2 234638249 A G 2.85E-12 Metabolite levels UGT1A3 cds-synon 23281178 rs11891311 chr2 234639310 G A 1.40E-235 Bilirubin levels UGT1A10 intron 19414484 rs11891311 chr2 234639310 G A 1.66E-25 Bilirubin levels UGT1A10 intron 19419973 rs11891311 chr2 234639310 G A 8.68E-157 Height UGT1A10 intron 20400458 rs11891311 chr2 234639310 G A 8.68E-157 Bilirubin levels,in serum UGT1A10 intron 20639394 rs11891311 chr2 234639310 G A 9.85E-11 Metabolite levels UGT1A10 intron 23281178 rs11891311 chr2 234639310 G A 1.00E-41 Bilirubin levels UGT1A10 intron 23371916 rs11891311 chr2 234639310 G A 2.06E-14 Bilirubin levels UGT1A10 intron 23642732 rs11891311 chr2 234639310 G A 6.71E-17 Bilirubin levels UGT1A10 intron 23642732 rs17868337 chr2 234639656 G A 2.10E-09 Bilirubin levels UGT1A10 intron 19414484 rs7564935 chr2 234645186 G T 7.50E-236 Bilirubin levels UGT1A10 intron 19414484 rs7564935 chr2 234645186 G T 1.16E-156 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7564935 chr2 234645186 G T 1.95E-15 Bilirubin levels UGT1A10 intron 22085899 rs7564935 chr2 234645186 G T 3.43E-10 Metabolite levels UGT1A10 intron 23281178 rs7564935 chr2 234645186 G T 1.76E-21 Bilirubin levels UGT1A10 intron 23371916 rs11902624 chr2 234646664 T C 7.90E-07 Bilirubin levels UGT1A10 intron 19414484 rs28899194 chr2 234646682 C T 5.00E-40 Bilirubin levels UGT1A10 intron 19414484 rs6722076 chr2 234647317 G A 1.16E-156 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6431628 chr2 234647478 A G 1.30E-263 Bilirubin levels UGT1A10 intron 19414484 rs6431628 chr2 234647478 A G 2.57E-12 Metabolite levels UGT1A10 intron 23281178 rs6740653 chr2 234648708 C A 5.30E-40 Bilirubin levels UGT1A10 intron 19414484 rs17862874 chr2 234648746 A G 6.40E-19 Bilirubin levels UGT1A10 intron 19414484 rs2018985 chr2 234648860 A G 2.80E-307 Bilirubin levels UGT1A10 intron 19414484 rs2018985 chr2 234648860 A G 2.90E-06 Bilirubin levels UGT1A10 intron 22085899 rs2018985 chr2 234648860 A G 3.16E-15 Metabolite levels UGT1A10 intron 23281178 rs17862875 chr2 234649302 G A 1.16E-156 Bilirubin levels,in serum UGT1A10 intron 20639394 rs17862875 chr2 234649302 G A 1.52E-09 Bilirubin levels UGT1A10 intron 22085899 rs17862875 chr2 234649302 G A 8.26E-14 Metabolite levels UGT1A10 intron 23281178 rs4663963 chr2 234650193 T G 1.30E-263 Bilirubin levels UGT1A10 intron 19414484 rs4663963 chr2 234650193 T G 1.02E-84 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4663963 chr2 234650193 T G 2.57E-12 Metabolite levels UGT1A10 intron 23281178 rs28900371 chr2 234650208 G A 5.80E-40 Bilirubin levels UGT1A10 intron 19414484 rs4663965 chr2 234650604 T C 6.40E-264 Bilirubin levels UGT1A10 intron 19414484 rs4663965 chr2 234650604 T C 1.09E-37 Bilirubin levels UGT1A10 intron 19419973 rs4663965 chr2 234650604 T C 3.13E-85 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4663965 chr2 234650604 T C 5.02E-12 Metabolite levels UGT1A10 intron 23281178 rs4663965 chr2 234650604 T C 4.18E-21 Bilirubin levels UGT1A10 intron 23371916 rs4663965 chr2 234650604 T C 1.05E-14 Bilirubin levels UGT1A10 intron 23642732 rs4663965 chr2 234650604 T C 3.90E-13 Bilirubin levels UGT1A10 intron 23642732 rs28900373 chr2 234651223 G T 5.90E-40 Bilirubin levels UGT1A10 intron 19414484 rs17863795 chr2 234651369 T C 6.40E-19 Bilirubin levels UGT1A10 intron 19414484 rs13009407 chr2 234652347 C G 7.07E-12 Metabolite levels D/JB3 cds-synon 23281178 rs17864701 chr2 234652717 C T 7.86E-14 Metabolite levels UGT1A10 intron 23281178 rs6741543 chr2 234653107 A T 6.20E-40 Bilirubin levels UGT1A10 intron 19414484 rs4663967 chr2 234653184 A C 8.30E-265 Bilirubin levels UGT1A10 intron 19414484 rs4663967 chr2 234653184 A C 2.57E-12 Metabolite levels UGT1A10 intron 23281178 rs6741669 chr2 234653192 A G 4.20E-265 Bilirubin levels UGT1A10 intron 19414484 rs6741669 chr2 234653192 A G 2.57E-12 Metabolite levels UGT1A10 intron 23281178 rs28899468 chr2 234653292 T C 2.10E-38 Bilirubin levels UGT1A10 intron 19414484 rs28900379 chr2 234654322 C T 6.40E-40 Bilirubin levels UGT1A10 intron 19414484 rs11695484 chr2 234654449 A G 4.82E-11 Bilirubin levels UGT1A10 intron 22085899 rs11695484 chr2 234654449 A G 1.12E-21 Bilirubin levels UGT1A10 intron 23371916 rs4663333 chr2 234655303 G T 4.20E-265 Bilirubin levels UGT1A10 intron 19414484 rs4663333 chr2 234655303 G T 1.46E-86 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4663333 chr2 234655303 G T 2.57E-12 Metabolite levels UGT1A10 intron 23281178 rs4663969 chr2 234655313 C A 1.50E-203 Bilirubin levels UGT1A10 intron 19414484 rs4663969 chr2 234655313 C A 3.19E-89 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4663969 chr2 234655313 C A 5.32E-10 Bilirubin levels UGT1A10 intron 22085899 rs12466997 chr2 234656517 T C 3.95E-11 Bilirubin levels UGT1A10 intron 22085899 rs11888459 chr2 234656640 T C 2.80E-238 Bilirubin levels UGT1A10 intron 19414484 rs11888459 chr2 234656640 T C 8.40E-16 Bilirubin levels UGT1A10 intron 22085899 rs11888459 chr2 234656640 T C 3.55E-10 Metabolite levels UGT1A10 intron 23281178 rs17862876 chr2 234657512 G T 5.20E-54 Bilirubin levels UGT1A10 intron 19414484 rs10178992 chr2 234657877 T A 5.30E-238 Bilirubin levels UGT1A10 intron 19414484 rs10178992 chr2 234657877 T A 1.09E-16 Bilirubin levels UGT1A10 intron 22085899 rs10178992 chr2 234657877 T A 3.55E-10 Metabolite levels UGT1A10 intron 23281178 rs28900384 chr2 234657937 C G 7.20E-40 Bilirubin levels UGT1A10 intron 19414484 rs10179091 chr2 234657983 T C 4.20E-265 Bilirubin levels UGT1A10 intron 19414484 rs10179091 chr2 234657983 T C 2.93E-30 Bilirubin levels UGT1A10 intron 19419973 rs10179091 chr2 234657983 T C 1.17E-87 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10179091 chr2 234657983 T C 2.46E-14 Bilirubin levels UGT1A10 intron 22085899 rs10179091 chr2 234657983 T C 2.57E-12 Metabolite levels UGT1A10 intron 23281178 rs10179091 chr2 234657983 T C 7.73E-21 Bilirubin levels UGT1A10 intron 23371916 rs7604115 chr2 234658116 C T 2.80E-238 Bilirubin levels UGT1A10 intron 19414484 rs7604115 chr2 234658116 C T 8.84E-17 Bilirubin levels UGT1A10 intron 22085899 rs7604115 chr2 234658116 C T 3.55E-10 Metabolite levels UGT1A10 intron 23281178 rs7556676 chr2 234658250 A G 2.70E-203 Bilirubin levels UGT1A10 intron 19414484 rs7556676 chr2 234658250 A G 7.39E-87 Bilirubin levels,in serum UGT1A10 intron 20639394 rs7556676 chr2 234658250 A G 2.45E-10 Bilirubin levels UGT1A10 intron 22085899 rs2221198 chr2 234658623 G A 9.00E-196 Bilirubin levels UGT1A10 intron 19414484 rs2221198 chr2 234658623 G A 7.39E-87 Bilirubin levels,in serum UGT1A10 intron 20639394 rs2221198 chr2 234658623 G A 2.07E-10 Bilirubin levels UGT1A10 intron 22085899 rs2221198 chr2 234658623 G A 3.87E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) UGT1A10 intron 24023788 rs28900385 chr2 234661136 T C 7.70E-40 Bilirubin levels UGT1A10 intron 19414484 rs17862878 chr2 234661948 G A 6.38E-06 Bilirubin levels UGT1A10 intron 22085899 rs28900387 chr2 234662173 T C 1.27E-06 Bilirubin levels UGT1A10 intron 22085899 rs7608038 chr2 234662263 T C 8.85E-06 Bilirubin levels UGT1A10 intron 22085899 rs1054804 chr2 234663045 C T 8.10E-40 Bilirubin levels UGT1A10 intron 19414484 rs10929301 chr2 234663649 C G 2.10E-265 Bilirubin levels UGT1A10 intron 19414484 rs10929301 chr2 234663649 C G 7.39E-87 Bilirubin levels,in serum UGT1A10 intron 20639394 rs10929301 chr2 234663649 C G 3.66E-10 Bilirubin levels UGT1A10 intron 22085899 rs10929301 chr2 234663649 C G 3.01E-12 Metabolite levels UGT1A10 intron 23281178 rs11673726 chr2 234664060 G T 4.40E-239 Bilirubin levels UGT1A10 intron 19414484 rs11673726 chr2 234664060 G T 2.66E-18 Bilirubin levels UGT1A10 intron 22085899 rs11673726 chr2 234664060 G T 2.05E-10 Metabolite levels UGT1A10 intron 23281178 rs6747843 chr2 234664354 G A 3.26E-11 Metabolite levels UGT1A10 intron 23281178 rs11675168 chr2 234664679 G A 8.50E-40 Bilirubin levels UGT1A10 intron 19414484 rs6714634 chr2 234664765 T C 8.15E-13 Bilirubin levels UGT1A10 intron 22085899 rs6714634 chr2 234664765 T C 1.74E-13 Metabolite levels UGT1A10 intron 23281178 rs6714634 chr2 234664765 T C 4.01E-21 Bilirubin levels UGT1A10 intron 23371916 rs17874945 chr2 234664826 C T 3.90E-19 Bilirubin levels UGT1A10 intron 19414484 rs17863800 chr2 234664881 C G 3.80E-19 Bilirubin levels UGT1A10 intron 19414484 rs11568318 chr2 234665498 C A 3.80E-19 Bilirubin levels UGT1A10 intron 19414484 rs4124874 chr2 234665659 T G 6.90E-267 Bilirubin levels UGT1A10 intron 19414484 rs4124874 chr2 234665659 T G 7.39E-87 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4124874 chr2 234665659 T G 2.97E-12 Metabolite levels UGT1A10 intron 23281178 rs10929302 chr2 234665782 G A 1 Drug response to Irinotecan UGT1A10 intron 15007088 rs10929302 chr2 234665782 G A 1 Drug response to Irinotecan UGT1A10 intron 17510208 rs10929302 chr2 234665782 G A 1 Drug response to Irinotecan UGT1A10 intron 19125129 rs10929302 chr2 234665782 G A 1.37E-11 Bilirubin levels UGT1A10 intron 22085899 rs10929302 chr2 234665782 G A 1.74E-13 Metabolite levels UGT1A10 intron 23281178 rs4399719 chr2 234666461 T G 6.90E-267 Bilirubin levels UGT1A10 intron 19414484 rs4399719 chr2 234666461 T G 7.39E-87 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4399719 chr2 234666461 T G 2.97E-12 Metabolite levels UGT1A10 intron 23281178 rs3755319 chr2 234667582 A C 8.57E-04 Type 2 diabetes UGT1A10 intron 17463246 rs3755319 chr2 234667582 A C 1.40E-266 Bilirubin levels UGT1A10 intron 19414484 rs3755319 chr2 234667582 A C 5.95E-42 Bilirubin levels UGT1A10 intron 19419973 rs3755319 chr2 234667582 A C 6.99E-87 Bilirubin levels,in serum UGT1A10 intron 20639394 rs3755319 chr2 234667582 A C 4.11E-11 Bilirubin levels UGT1A10 intron 22085899 rs3755319 chr2 234667582 A C 1.16E-12 Metabolite levels UGT1A10 intron 23281178 rs3755319 chr2 234667582 A C 1.83E-21 Bilirubin levels UGT1A10 intron 23371916 rs3755319 chr2 234667582 A C 3.53E-14 Bilirubin levels UGT1A10 intron 23642732 rs3755319 chr2 234667582 A C 8.09E-16 Bilirubin levels UGT1A10 intron 23642732 rs28899472 chr2 234667809 C T 1.00E-39 Bilirubin levels UGT1A10 intron 19414484 rs2003569 chr2 234667937 G A 1.80E-18 Bilirubin levels UGT1A10 intron 19414484 rs2003569 chr2 234667937 G A 9.00E-06 Bilirubin levels UGT1A10 intron 22085899 rs6723506 chr2 234668025 A G 4.94E-22 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6723506 chr2 234668025 A G 5.50E-07 Bilirubin levels UGT1A10 intron 23371916 rs887829 chr2 234668570 C T 5.59E-04 Multiple complex diseases UGT1A10 intron 17554300 rs887829 chr2 234668570 C T 1.00E-69 Bilirubin levels UGT1A10 intron 19419973 rs887829 chr2 234668570 C T 1.46E-158 Bilirubin levels,in serum UGT1A10 intron 20639394 rs887829 chr2 234668570 C T 3.00E-74 Metabolic traits UGT1A10 intron 21886157 rs887829 chr2 234668570 C T 2.00E-22 Bilirubin levels UGT1A10 intron 22085899 rs887829 chr2 234668570 C T 5.00E-25 Cholelithiasis-related traits in sickle cell anemia UGT1A10 intron 22558097 rs887829 chr2 234668570 C T 9.00E-25 Metabolite levels UGT1A10 intron 23281178 rs887829 chr2 234668570 C T 2.50E-20 Bilirubin levels UGT1A10 intron 23371916 rs887829 chr2 234668570 C T 6.37E-18 Bilirubin levels UGT1A10 intron 23642732 rs887829 chr2 234668570 C T 9.00E-20 Bilirubin levels UGT1A10 intron 23642732 rs887829 chr2 234668570 C T 1.00E-17 Metabolite levels UGT1A10 intron 24625756 rs887829 chr2 234668570 C T 6.00E-13 Metabolite levels UGT1A10 intron 24625756 rs887829 chr2 234668570 C T 8.00E-23 Metabolite levels UGT1A10 intron 24625756 rs887829 chr2 234668570 C T 2.00E-140 Blood metabolite levels UGT1A10 intron 24816252 rs887829 chr2 234668570 C T 2.00E-152 Blood metabolite levels UGT1A10 intron 24816252 rs887829 chr2 234668570 C T 2.00E-56 Blood metabolite levels UGT1A10 intron 24816252 rs887829 chr2 234668570 C T 3.00E-114 Blood metabolite levels UGT1A10 intron 24816252 rs887829 chr2 234668570 C T 3.00E-168 Blood metabolite levels UGT1A10 intron 24816252 rs887829 chr2 234668570 C T 4.00E-95 Blood metabolite levels UGT1A10 intron 24816252 rs873478 chr2 234668870 G C 5.86E-14 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4148323 chr2 234669144 G A 2.64E-05 Hirschsprung's disease UGT1A1 missense 19196962 rs4148323 chr2 234669144 G A 3.08E-139 Height UGT1A1 missense 20400458 rs4148323 chr2 234669144 G A 3.08E-139 Bilirubin levels,in serum UGT1A1 missense 20639394 rs4148323 chr2 234669144 G A 2.00E-62 Bilirubin levels UGT1A1 missense 23371916 rs4148323 chr2 234669144 G A 5.00E-69 Bilirubin levels UGT1A1 missense 23371916 rs4148323 chr2 234669144 G A 7.00E-30 Bilirubin levels UGT1A1 missense 23371916 rs4148323 chr2 234669144 G A 9.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) UGT1A1 missense 23648065 rs17868341 chr2 234669886 C T 3.50E-19 Bilirubin levels UGT1A10 intron 19414484 rs28900396 chr2 234670560 T C 1.05E-07 Bilirubin levels UGT1A10 intron 22085899 rs28900396 chr2 234670560 T C 5.14E-14 Triglycerides UGT1A10 intron 23063622 rs28946889 chr2 234671462 G T 2.80E-69 Bilirubin levels UGT1A10 intron 19414484 rs17864704 chr2 234672172 C T 9.80E-39 Bilirubin levels UGT1A10 intron 19414484 rs28900398 chr2 234672338 T G 1.27E-06 Bilirubin levels UGT1A10 intron 22085899 rs6742078 chr2 234672639 G T 5E-324 Bilirubin levels UGT1A10 intron 19414484 rs6742078 chr2 234672639 G T 1.18E-158 Bilirubin levels,in serum UGT1A10 intron 20639394 rs6742078 chr2 234672639 G T 8.23E-18 Bilirubin levels UGT1A10 intron 22085899 rs6742078 chr2 234672639 G T 2.00E-23 Circulating cell-free DNA UGT1A10 intron 22511988 rs6742078 chr2 234672639 G T 4.17E-18 Metabolite levels UGT1A10 intron 23281178 rs6742078 chr2 234672639 G T 1.00E-89 Bilirubin levels UGT1A10 intron 23371916 rs6742078 chr2 234672639 G T 2.00E-78 Bilirubin levels UGT1A10 intron 23371916 rs6742078 chr2 234672639 G T 6.00E-40 Bilirubin levels UGT1A10 intron 23371916 rs6742078 chr2 234672639 G T 3.22E-18 Bilirubin levels UGT1A10 intron 23642732 rs6742078 chr2 234672639 G T 4.44E-20 Bilirubin levels UGT1A10 intron 23642732 rs6742078 chr2 234672639 G T 2.89E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) UGT1A10 intron 24023788 rs3771342 chr2 234672663 G T 1.80E-18 Bilirubin levels UGT1A10 intron 19414484 rs4148324 chr2 234672722 T G 1.72E-158 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4148324 chr2 234672722 T G 1.04E-16 Bilirubin levels UGT1A10 intron 22085899 rs4148324 chr2 234672722 T G 4.17E-18 Metabolite levels UGT1A10 intron 23281178 rs4148324 chr2 234672722 T G 2.00E-116 Blood metabolite levels UGT1A10 intron 24816252 rs4148324 chr2 234672722 T G 5.00E-117 Blood metabolite levels UGT1A10 intron 24816252 rs3771341 chr2 234673239 G A,T 1.74E-13 Metabolite levels UGT1A10 intron 23281178 rs4148325 chr2 234673309 C T 1.72E-158 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4148325 chr2 234673309 C T 5.00E-62 Bilirubin levels UGT1A10 intron 21646302 rs4148325 chr2 234673309 C T 3.06E-22 Bilirubin levels UGT1A10 intron 22085899 rs4148325 chr2 234673309 C T 4.17E-18 Metabolite levels UGT1A10 intron 23281178 rs4148325 chr2 234673309 C T 3.22E-18 Bilirubin levels UGT1A10 intron 23642732 rs4148325 chr2 234673309 C T 4.44E-20 Bilirubin levels UGT1A10 intron 23642732 rs4148325 chr2 234673309 C T 2.89E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) UGT1A10 intron 24023788 rs4148326 chr2 234673462 T C 1.80E-267 Bilirubin levels UGT1A10 intron 19414484 rs4148326 chr2 234673462 T C 2.98E-13 Bilirubin levels UGT1A10 intron 22085899 rs4148326 chr2 234673462 T C 2.97E-12 Metabolite levels UGT1A10 intron 23281178 rs4148326 chr2 234673462 T C 3.98E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) UGT1A10 intron 24023788 rs4663971 chr2 234674252 C G 3.50E-267 Bilirubin levels UGT1A10 intron 19414484 rs4663971 chr2 234674252 C G 5.22E-87 Bilirubin levels,in serum UGT1A10 intron 20639394 rs4663971 chr2 234674252 C G 4.96E-12 Bilirubin levels UGT1A10 intron 22085899 rs4663971 chr2 234674252 C G 2.97E-12 Metabolite levels UGT1A10 intron 23281178 rs929596 chr2 234674476 A G 1.72E-158 Bilirubin levels,in serum UGT1A10 intron 20639394 rs929596 chr2 234674476 A G 7.42E-14 Bilirubin levels UGT1A10 intron 22085899 rs929596 chr2 234674476 A G 2.18E-11 Metabolite levels UGT1A10 intron 23281178 rs11679312 chr2 234675036 C T 2.80E-39 Bilirubin levels UGT1A10 intron 19414484 rs6708136 chr2 234675567 C T 1.50E-38 Bilirubin levels UGT1A10 intron 19414484 rs28900402 chr2 234676412 C T 2.39E-09 Triglycerides UGT1A10 intron 23063622 rs12471326 chr2 234676458 T C 1.80E-34 Bilirubin levels UGT1A10 intron 19414484 rs10445705 chr2 234676787 G A 4.05E-06 Bilirubin levels UGT1A10 intron 22085899 rs6431630 chr2 234677386 G A 1.20E-15 Bilirubin levels UGT1A10 intron 19414484 rs4148328 chr2 234677659 C T 3.50E-61 Bilirubin levels UGT1A10 intron 19414484 rs4148328 chr2 234677659 C T 1.42E-06 Bilirubin levels UGT1A10 intron 23371916 rs11563251 chr2 234679384 C T 9.60E-15 Bilirubin levels UGT1A10 intron 19414484 rs11563251 chr2 234679384 C T 2.50E-09 Cholesterol,total UGT1A10 intron 23063622 rs11563251 chr2 234679384 C T 1.00E-09 Cholesterol,total UGT1A10 intron 24097068 rs11563251 chr2 234679384 C T 5.00E-08 LDL cholesterol UGT1A10 intron 24097068 rs11888492 chr2 234679974 C G 2.90E-14 Bilirubin levels UGT1A10 intron 19414484 rs10929303 chr2 234681416 T C 2.00E-21 Bilirubin levels UGT1A10 UTR-3 19414484 rs1042640 chr2 234681544 G C 4.90E-21 Bilirubin levels UGT1A10 UTR-3 19414484 rs8330 chr2 234681645 G C 3.20E-19 Bilirubin levels UGT1A10 UTR-3 19414484 rs4148329 chr2 234682062 C T 9.20E-10 Bilirubin levels / / 19414484 rs4148329 chr2 234682062 C T 7.49E-05 Response to hepatitis C treatment / / 19684573 rs6717546 chr2 234682119 A G 1.00E-25 Bilirubin levels / / 19414484 rs6717546 chr2 234682119 A G 7.14E-05 Response to hepatitis C treatment / / 19684573 rs1500482 chr2 234683038 C T 3.20E-15 Bilirubin levels / / 19414484 rs11563250 chr2 234683350 A G 3.70E-08 Bilirubin levels / / 19414484 rs6719561 chr2 234683763 C T 6.90E-54 Bilirubin levels / / 19414484 rs28900408 chr2 234683826 G A 5.68E-06 Bilirubin levels / / 22085899 rs4663972 chr2 234683892 C T 2.30E-17 Bilirubin levels / / 19414484 rs10199882 chr2 234685264 T C 3.90E-08 Bilirubin levels HEATR7B1 intron 19414484 rs7586006 chr2 234685527 T G 3.90E-08 Bilirubin levels HEATR7B1 intron 19414484 rs10203853 chr2 234687418 A T 3.70E-79 Bilirubin levels HEATR7B1 intron 19414484 rs10209214 chr2 234687583 T C 3.90E-54 Bilirubin levels HEATR7B1 intron 19414484 rs6431631 chr2 234688036 C A 3.10E-15 Bilirubin levels HEATR7B1 missense 19414484 rs17868345 chr2 234688360 C T 2.60E-11 Bilirubin levels HEATR7B1 cds-synon 19414484 rs4663335 chr2 234689090 G A 1.10E-09 Bilirubin levels HEATR7B1 intron 19414484 rs6728940 chr2 234689164 G A 8.40E-54 Bilirubin levels HEATR7B1 intron 19414484 rs4663973 chr2 234689189 G T 1.10E-09 Bilirubin levels HEATR7B1 intron 19414484 rs6746002 chr2 234689421 A G 8.60E-54 Bilirubin levels HEATR7B1 intron 19414484 rs1587493 chr2 234689751 G A 3.80E-36 Bilirubin levels HEATR7B1 intron 19414484 rs9287649 chr2 234689830 C G 1.10E-09 Bilirubin levels HEATR7B1 intron 19414484 rs6728520 chr2 234690093 A G 6.10E-54 Bilirubin levels HEATR7B1 intron 19414484 rs6431632 chr2 234690545 A G 1.20E-14 Bilirubin levels HEATR7B1 intron 19414484 rs7583811 chr2 234692539 C T 1.50E-14 Bilirubin levels HEATR7B1 intron 19414484 rs11690786 chr2 234692617 C T 8.00E-184 Bilirubin levels HEATR7B1 intron 19414484 rs6723936 chr2 234693382 G A 4.60E-30 Bilirubin levels HEATR7B1 intron 19414484 rs11903524 chr2 234693769 A G 1.50E-14 Bilirubin levels HEATR7B1 intron 19414484 rs7596785 chr2 234694177 T C 1.80E-14 Bilirubin levels HEATR7B1 intron 19414484 rs17868346 chr2 234695087 A G 1.60E-30 Bilirubin levels HEATR7B1 intron 19414484 rs17863806 chr2 234695150 C A 3.70E-45 Bilirubin levels HEATR7B1 intron 19414484 rs10929304 chr2 234695224 T G 1.40E-14 Bilirubin levels HEATR7B1 intron 19414484 rs17862885 chr2 234695549 A G 9.50E-10 Bilirubin levels HEATR7B1 intron 19414484 rs12468017 chr2 234698097 T C 2.40E-11 Bilirubin levels HEATR7B1 intron 19414484 rs2361502 chr2 234698790 T C 7.80E-178 Bilirubin levels HEATR7B1 intron 19414484 rs2361502 chr2 234698790 T C 7.00E-23 Bilirubin levels HEATR7B1 intron 21646302 rs12986677 chr2 234698976 G A 1.00E-171 Bilirubin levels HEATR7B1 intron 19414484 rs13022508 chr2 234699086 T C 1.60E-176 Bilirubin levels HEATR7B1 intron 19414484 rs10207194 chr2 234700385 C A 3.50E-16 Bilirubin levels HEATR7B1 intron 19414484 rs10170160 chr2 234700578 T C 3.70E-19 Bilirubin levels HEATR7B1 intron 19414484 rs28948069 chr2 234700865 C G 5.40E-06 Bilirubin levels HEATR7B1 intron 19414484 rs12622156 chr2 234701686 G A 5.70E-08 Bilirubin levels HEATR7B1 intron 19414484 rs6755193 chr2 234701822 A G 9.49E-05 Response to mTOR inhibitor (everolimus) HEATR7B1 intron 24009623 rs17864714 chr2 234704076 G A 1.30E-20 Bilirubin levels HEATR7B1 intron 19414484 rs2885297 chr2 234704150 T C 2.40E-13 Bilirubin levels HEATR7B1 intron 19414484 rs1076454 chr2 234704607 C T 6.20E-16 Bilirubin levels HEATR7B1 intron 19414484 rs741160 chr2 234705389 A G 3.42E-08 Schizophrenia HEATR7B1 intron 21795503 rs741159 chr2 234706167 A G 4.20E-06 Bilirubin levels HEATR7B1 intron 19414484 rs741159 chr2 234706167 A G 1.00E-05 Urinary metabolites HEATR7B1 intron 21572414 rs9808308 chr2 234707921 A G 2.90E-05 Bilirubin levels HEATR7B1 intron 19414484 rs9808231 chr2 234708152 C T 6.80E-09 Bilirubin levels HEATR7B1 intron 19414484 rs13013882 chr2 234708428 G A 5.90E-13 Bilirubin levels HEATR7B1 cds-synon 19414484 rs11563069 chr2 234708570 G A 5.80E-13 Bilirubin levels HEATR7B1 intron 19414484 rs11563245 chr2 234709000 C T 2.50E-05 Bilirubin levels HEATR7B1 intron 19414484 rs11678741 chr2 234709831 C G 2.70E-11 Bilirubin levels HEATR7B1 intron 19414484 rs17862891 chr2 234710283 G A 6.30E-13 Bilirubin levels HEATR7B1 intron 19414484 rs730673 chr2 234711677 G C 6.90E-15 Bilirubin levels HEATR7B1 intron 19414484 rs10175949 chr2 234712921 G A 6.70E-17 Bilirubin levels HEATR7B1 intron 19414484 rs6716168 chr2 234713429 C T 5.00E-15 Bilirubin levels HEATR7B1 intron 19414484 rs2041651 chr2 234713812 G T 5.80E-17 Bilirubin levels HEATR7B1 intron 19414484 rs10929307 chr2 234717239 A G 1.60E-05 Urinary metabolites HEATR7B1 intron 21572414 rs10803663 chr2 234717669 A G 1.70E-05 Urinary metabolites HEATR7B1 intron 21572414 rs11674078 chr2 234718524 T C 1.30E-11 Bilirubin levels HEATR7B1 intron 19414484 rs11674078 chr2 234718524 T C 5.49E-05 Major depressive disorder HEATR7B1 intron pha002850 rs988344 chr2 234720734 A C 1.40E-16 Bilirubin levels HEATR7B1 intron 19414484 rs10929308 chr2 234722065 T C 8.10E-06 Bilirubin levels HEATR7B1 intron 19414484 rs1580834 chr2 234724048 G A 2.22E-04 Smoking cessation HEATR7B1 intron 24665060 rs726016 chr2 234725502 T C 7.40E-06 Bilirubin levels HEATR7B1 missense 19414484 rs726017 chr2 234725819 A G 4.30E-06 Bilirubin levels HEATR7B1 intron 19414484 rs13015369 chr2 234726058 G T 4.02E-05 Nephrolithiasis HEATR7B1 intron 22396660 rs1500480 chr2 234728078 T C 1.60E-06 Bilirubin levels HEATR7B1 missense 19414484 rs6734083 chr2 234730807 G A 4.26E-04 Alzheimer's disease HEATR7B1 missense 24755620 rs17868361 chr2 234732311 G A 1.10E-05 Bilirubin levels HEATR7B1 missense 19414484 rs7557532 chr2 234733064 T G 5.29E-05 Orofacial clefts HEATR7B1 intron 22419666 rs17862900 chr2 234736311 A G 1.40E-05 Bilirubin levels HEATR7B1 intron 19414484 rs2361507 chr2 234739810 T G 3.30E-08 Bilirubin levels HEATR7B1 intron 19414484 rs879665 chr2 234740136 G A 2.80E-07 Bilirubin levels HEATR7B1 missense 19414484 rs10185631 chr2 234740490 T G 1.10E-06 Bilirubin levels HEATR7B1 intron 19414484 rs213548 chr2 234741443 G A 3.60E-05 Bilirubin levels HEATR7B1 intron 19414484 rs2270856 chr2 234741808 C T 3.10E-10 Bilirubin levels HEATR7B1 missense 19414484 rs13416326 chr2 234744661 A G 4.80E-10 Bilirubin levels / / 19414484 rs213551 chr2 234745389 A G 5.58E-04 Multiple complex diseases / / 17554300 rs213553 chr2 234745975 A C 8.50E-04 Parkinson's disease HJURP UTR-3 17052657 rs685139 chr2 234758539 T C 6.90E-04 Suicide attempts in bipolar disorder HJURP intron 21423239 rs2286430 chr2 234761225 C A,G,T 9.98E-04 Multiple complex diseases HJURP missense 17554300 rs10204079 chr2 234762099 G A 1.30E-06 Bilirubin levels HJURP intron 19414484 rs511387 chr2 234772911 G C 3.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs566985 chr2 234772983 G A 3.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs568906 chr2 234773193 C T 3.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs570800 chr2 234773403 A G 3.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs186159 chr2 234773876 G C 2.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs213543 chr2 234774025 C T 2.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs188492 chr2 234774076 A G 2.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs13384181 chr2 234775346 G A 4.80E-07 Bilirubin levels / / 19414484 rs213544 chr2 234775675 G T 4.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs13390675 chr2 234776752 G C 4.00E-07 Bilirubin levels MSL3P1 intron 19414484 rs213541 chr2 234779644 C T 2.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs11890203 chr2 234780131 A G 4.60E-07 Bilirubin levels / / 19414484 rs6727154 chr2 234788734 G A 2.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs28900731 chr2 234790111 A G 2.90E-09 Bilirubin levels / / 19414484 rs17862910 chr2 234790181 G A 2.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs17862913 chr2 234793402 G T 5.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs17863831 chr2 234796001 T G 2.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs11563065 chr2 234796385 C T 5.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs17868375 chr2 234799231 G A 3.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs17864734 chr2 234800159 G A 5.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs17864735 chr2 234801252 A C 3.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs10164928 chr2 234801785 C T 5.60E-07 Bilirubin levels / / 19414484 rs17864737 chr2 234802187 A T 4.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs765900 chr2 234806833 G A 4.08E-04 Smoking initiation / / 24665060 rs17868378 chr2 234808378 A C 4.70E-07 Bilirubin levels / / 19414484 rs10929317 chr2 234811911 G T 2.55E-04 Smoking initiation / / 24665060 rs10187654 chr2 234814059 C T 9.00E-06 Pulmonary function decline / / 22424883 rs11562941 chr2 234815167 G A 2.71E-04 Smoking initiation / / 24665060 rs7577262 chr2 234818869 G A 3.00E-08 Blood pressure measurement (cold pressor test) / / 24165912 rs7577262 chr2 234818869 G A 1.95E-04 Smoking initiation / / 24665060 rs10166942 chr2 234825093 T C 6.00E-12 Migraine / / 21666692 rs10166942 chr2 234825093 T C 1.00E-12 Migraine / / 22683712 rs10166942 chr2 234825093 T C 1.21E-10 Migraine without aura / / 23793025 rs10166942 chr2 234825093 T C 1.69E-06 Migraine with aura / / 23793025 rs10166942 chr2 234825093 T C 2.91E-12 Migraine / / 23793025 rs10166942 chr2 234825093 T C 6.39E-09 Migraine - clinic-based / / 23793025 rs6741751 chr2 234827661 G A 1.00E-07 Migraine with aura TRPM8 intron 23793025 rs6741751 chr2 234827661 G A 1.00E-08 Migraine - clinic-based TRPM8 intron 23793025 rs6741751 chr2 234827661 G A 9.00E-11 Migraine without aura TRPM8 intron 23793025 rs6741751 chr2 234827661 G A 9.00E-14 Migraine TRPM8 intron 23793025 rs17862920 chr2 234827995 C T 1.26E-05 Migraine TRPM8 intron 20802479 rs17862920 chr2 234827995 C T 6.00E-09 Migraine TRPM8 intron 22683712 rs17862920 chr2 234827995 C T 1.96E-04 Smoking initiation TRPM8 intron 24665060 rs10803666 chr2 234838947 G C 8.70E-04 Blood pressure TRPM8 intron 21572416 rs12472151 chr2 234852692 G A 2.00E-06 Alcohol consumption TRPM8 intron 23942779 rs12992084 chr2 234855354 T C 2.40E-06 Alcohol consumption TRPM8 intron 23942779 rs4663989 chr2 234859056 G T 9.71E-04 Multiple complex diseases TRPM8 intron 17554300 rs10929321 chr2 234871343 G A 4.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRPM8 intron 20877124 rs10207672 chr2 234888161 T C 7.09E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) TRPM8 intron 23648065 rs2362294 chr2 234900513 G A 1.81E-04 Smoking initiation TRPM8 intron 24665060 rs3732214 chr2 234923124 A C 1.00E-04 Cognitive impairment induced by topiramate TRPM8 intron 22091778 rs11563054 chr2 234924941 T C 1.50E-04 Multiple complex diseases TRPM8 intron 17554300 rs11563199 chr2 234925521 C T 5.34E-05 Cognitive performance TRPM8 intron 19734545 rs17869077 chr2 234925758 C T 5.34E-05 Cognitive performance TRPM8 intron 19734545 rs11901004 chr2 234927260 G T 4.89E-06 Hippocampal volume in schizophrenia TRPM8 UTR-3 23805179 rs1987842 chr2 234928517 G A 4.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17866592 chr2 234929686 T C 2.31E-06 Hippocampal volume in schizophrenia / / 23805179 rs603217 chr2 234931522 G C 3.05E-04 Nicotine smoking / / 19268276 rs622060 chr2 234948684 G A 1.50E-05 Urinary metabolites / / 21572414 rs620654 chr2 234949004 G A 3.68E-04 Alzheimer's disease (late onset) / / 21379329 rs7593927 chr2 234953978 T G 0.0000917 Panic disorder / / 23149450 rs7593927 chr2 234953978 T G 9.17E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs634613 chr2 234954619 G A 1.40E-05 Urinary metabolites / / 21572414 rs11563197 chr2 234960021 C T 0.000596 Salmonella-induced pyroptosis SPP2 intron 22837397 rs2267903 chr2 234962651 G A 9.20E-05 Glioma (high-grade) SPP2 intron 19578366 rs2267903 chr2 234962651 G A 2.94E-05 Alzheimer's disease (late onset) SPP2 intron 21379329 rs7603271 chr2 234964316 C A 6.04E-05 Bipolar disorder and schizophrenia SPP2 intron 20889312 rs7603271 chr2 234964316 C A 2.49E-05 Alzheimer's disease (late onset) SPP2 intron 21379329 rs11563194 chr2 234966165 T C 7.37E-05 Bipolar disorder and schizophrenia SPP2 intron 20889312 rs11563194 chr2 234966165 T C 3.60E-05 Alzheimer's disease (late onset) SPP2 intron 21379329 rs13396164 chr2 234966238 C T 2.98E-05 Alzheimer's disease (late onset) SPP2 intron 21379329 rs17865706 chr2 234966486 C T 3.60E-05 Alzheimer's disease (late onset) SPP2 intron 21379329 rs17865708 chr2 234967410 G A 0.000378 Salmonella-induced pyroptosis SPP2 intron 22837397 rs2239536 chr2 234968051 C T 2.98E-05 Alzheimer's disease (late onset) SPP2 intron 21379329 rs10803669 chr2 234968786 G T 2.40E-05 Urinary metabolites SPP2 intron 21572414 rs250977 chr2 234978363 G A 4.20E-05 HIV-1 control SPP2 intron 20041166 rs250975 chr2 234981061 C T 2.90E-05 HIV-1 control SPP2 intron 20041166 rs250973 chr2 234983001 G A 9.98E-04 Alzheimer's disease SPP2 intron 24755620 rs13017720 chr2 234984758 G A 4.67E-04 Alzheimer's disease (late onset) SPP2 intron 21379329 rs250962 chr2 234991336 T C 4.22E-04 Rheumatoid arthritis / / 21452313 rs250958 chr2 234992912 T C 3.51E-04 Rheumatoid arthritis / / 21452313 rs7581053 chr2 234993308 C A 3.41E-04 Alzheimer's disease (late onset) / / 21379329 rs250944 chr2 234997218 G A 0.0000218 Oxaliplatin induced diarrhea in response to colorectal cancer treatment / / 22310351 rs250938 chr2 235002822 G A 6.45E-04 Rheumatoid arthritis / / 21452313 rs250928 chr2 235008881 G A 7.67E-04 Rheumatoid arthritis / / 21452313 rs6731887 chr2 235020980 T G 3.88E-05 Cholesterol / / 17255346 rs6710850 chr2 235036470 A T 2.20E-04 Cholesterol / / 17255346 rs16850525 chr2 235055333 A G 7.98E-05 Asthma / / pha003128 rs11884879 chr2 235078194 G A 1.11E-04 Celiac disease / / 23936387 rs2049026 chr2 235192719 G A 7.66E-05 Body mass index / / 17255346 rs6716674 chr2 235194783 G C 4.20E-05 Cognitive function / / 24684796 rs11894176 chr2 235195326 G A 5.71E-05 Cognitive test performance / / 20125193 rs12467783 chr2 235204421 C T 6.84E-05 Blood pressure / / 17255346 rs12151790 chr2 235210727 G A 5.00E-07 Osteoporosis / / 20548944 rs4663384 chr2 235216752 G T 7.90E-05 Serum metabolites / / 19043545 rs2885958 chr2 235229127 C T 3.44E-04 Prostate cancer mortality / / 20978177 rs772781 chr2 235242143 T C 7.44E-04 Type 2 diabetes / / 17463246 rs772781 chr2 235242143 T C 1.00E-05 Urinary metabolites / / 21572414 rs772780 chr2 235242416 C T 2.23E-04 Type 2 diabetes / / 17463246 rs772780 chr2 235242416 C T 4.70E-06 Urinary metabolites / / 21572414 rs1401504 chr2 235262862 A G 7.60E-05 Glioma (high-grade) / / 19578366 rs7572928 chr2 235284355 C T 8.19E-05 Vascular dementia / / 22116812 rs10205735 chr2 235288471 C T 7.60E-07 Urinary metabolites / / 21572414 rs10165917 chr2 235292064 A G 2.60E-06 Urinary metabolites / / 21572414 rs11887188 chr2 235302810 C T 1.00E-06 Blood pressure measurement (high sodium and potassium intervention) / / 24165912 rs11887188 chr2 235302810 C T 2.00E-08 Blood pressure measurement (high sodium and potassium intervention) / / 24165912 rs11886562 chr2 235315413 G A 1.20E-05 Urinary metabolites / / 21572414 rs6743014 chr2 235350736 A G 8.99E-04 Multiple complex diseases / / 17554300 rs1876715 chr2 235364851 C T 8.10E-04 Multiple complex diseases / / 17554300 rs7584396 chr2 235383267 T C 2.38E-04 Coronary heart disease / / 21606135 rs7594052 chr2 235390834 T G 6.35E-04 Type 2 diabetes / / 17463246 rs10177805 chr2 235425433 T C 2.49E-05 Behcet's disease / / 23291587 rs4663425 chr2 235430409 G A 1.07E-04 Blood pressure / / 17255346 rs7592582 chr2 235446253 A C 1.00E-05 Crohn's disease / / 20570966 rs10803621 chr2 235458755 A C 3.95E-04 Type 2 diabetes / / 17463246 rs12469734 chr2 235469549 G A 1.45E-04 Taste perception / / 22132133 rs6738554 chr2 235481565 G A 1.48E-04 Multiple complex diseases / / 17554300 rs950834 chr2 235492499 T G 2.39E-05 Eosinophil counts / / pha003088 rs7594340 chr2 235501150 C T 4.95E-07 Eosinophil counts / / pha003088 rs4663445 chr2 235503852 T C 7.73E-04 Obesity (extreme) / / 21935397 rs4663447 chr2 235504056 T C 2.33E-06 Eosinophil counts / / pha003088 rs13013073 chr2 235505424 G C 6.73E-05 Depression (quantitative trait) / / 23290196 rs10190832 chr2 235509738 T C 7.67E-05 Glucose levels / / pha003058 rs10190832 chr2 235509738 T C 8.12E-05 Glucose levels / / pha003061 rs1917946 chr2 235517079 A C 3.30E-06 Urinary metabolites / / 21572414 rs7561154 chr2 235518737 G A 1.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs7605520 chr2 235519242 T G 4.00E-06 Urinary metabolites / / 21572414 rs940943 chr2 235525096 G C 1.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs2386503 chr2 235525262 A T 1.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs2386502 chr2 235525579 A G 1.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs2386501 chr2 235525599 G A 1.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs2030841 chr2 235526784 G A 2.80E-05 Suicide attempts in bipolar disorder / / 21423239 rs6711637 chr2 235527499 T C 3.40E-06 Urinary metabolites / / 21572414 rs4663448 chr2 235529903 T C 8.79E-05 Suicide attempts in bipolar disorder / / 21423239 rs10176169 chr2 235531098 A G 6.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs4467334 chr2 235531268 G C,T 8.30E-06 Urinary metabolites / / 21572414 rs10167927 chr2 235550321 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10167927 chr2 235550321 G A 8.69E-05 Pancreatic cancer / / pha002889 rs2119659 chr2 235593473 T C 8.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2119659 chr2 235593473 T C 6.61E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4663471 chr2 235594798 T A 1.97E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11677044 chr2 235599903 A C 1.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9287580 chr2 235600076 G A 7.99E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4663476 chr2 235601064 T G 8.00E-06 Response to angiotensin II receptor blocker therapy / / 22566498 rs4663477 chr2 235601211 C G 4.43E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4663478 chr2 235601276 G C 1.57E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1358069 chr2 235603435 G A 8.61E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1358070 chr2 235603599 C G 5.40E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6736997 chr2 235615197 A C 6.00E-06 Pancreatic cancer / / 20686608 rs4663163 chr2 235626160 A G 2.76E-05 Major depressive disorder / / 20516156 rs2218249 chr2 235628051 C T 3.20E-05 Tooth agenesis (third molar) / / 24172245 rs6730767 chr2 235635006 G A 2.10E-05 Tooth agenesis (third molar) / / 24172245 rs7586477 chr2 235639080 T C 1.77E-06 Schizophrenia / / 21795503 rs2380261 chr2 235641180 C A 2.00E-04 Diabetic retinopathy / / 23562823 rs2380261 chr2 235641180 C A 4.70E-06 Diabetic retinopathy / / 23562823 rs1441605 chr2 235647366 C G 7.50E-06 Diabetic retinopathy / / 23562823 rs13016879 chr2 235693788 G A 3.75E-04 Depression (quantitative trait) / / 20800221 rs894188 chr2 235699767 C T 1.59E-04 Depression (quantitative trait) / / 20800221 rs10201498 chr2 235706129 G A 1.31E-04 Multiple complex diseases / / 17554300 rs10929056 chr2 235714013 C A 8.17E-06 Coronary heart disease / / pha003030 rs13022629 chr2 235720850 A G 7.94E-04 Depression (quantitative trait) / / 20800221 rs1441612 chr2 235721740 G T 3.58E-05 Coronary heart disease / / pha003030 rs13016685 chr2 235723806 G T 8.52E-05 Smoking initiation / / 24665060 rs961818 chr2 235726745 A G 5.75E-05 Coronary heart disease / / pha003030 rs11681769 chr2 235730405 G A 1.17E-06 Coronary heart disease / / pha003030 rs10929060 chr2 235733155 C A 3.46E-06 Coronary heart disease / / pha003030 rs1427696 chr2 235735930 T C 9.62E-05 Sodium levels / / pha003093 rs1529413 chr2 235775041 A G 1.60E-06 Schizophrenia / / 21795503 rs1863815 chr2 235779262 G C 4.02E-04 Multiple complex diseases / / 17554300 rs6723979 chr2 235803863 G C 8.91E-04 Aortic root size / / 21223598 rs10803629 chr2 235891645 A G 3.74E-05 Type 2 diabetes SH3BP4 intron 17463246 rs11676855 chr2 235900171 T C 9.00E-06 Dialysis-related mortality SH3BP4 intron 21546767 rs12471688 chr2 235932581 G A 2.30E-05 Response to statin therapy SH3BP4 intron 20339536 rs10199034 chr2 235935809 G C 3.10E-05 Response to statin therapy SH3BP4 intron 20339536 rs2195195 chr2 235938690 T C 2.40E-05 Response to statin therapy SH3BP4 intron 20339536 rs2195195 chr2 235938690 T C 2.56E-05 Blood Pressure SH3BP4 intron pha003046 rs11898961 chr2 235938976 A G 5.61E-04 Multiple complex diseases SH3BP4 intron 17554300 rs6739712 chr2 235945879 T A 2.20E-05 Urinary metabolites SH3BP4 intron 21572414 rs3731644 chr2 235949877 T C 0.000873929 Hypertension (early onset hypertension) SH3BP4 missense 22479346 rs3731646 chr2 235950002 G A 0.000873929 Hypertension (early onset hypertension) SH3BP4 missense 22479346 rs3731648 chr2 235950284 A C 0.000873929 Hypertension (early onset hypertension) SH3BP4 cds-synon 22479346 rs1559986 chr2 235957657 T C 2.57E-04 Cholesterol SH3BP4 intron 17255346 rs4505466 chr2 235960824 C T 8.31E-05 Longevity SH3BP4 intron 21612516 rs4505466 chr2 235960824 C T 3.13E-06 Orofacial clefts SH3BP4 intron 22419666 rs10174126 chr2 235960893 T C 7.00E-07 Orofacial clefts SH3BP4 intron 22419666 rs4334446 chr2 235965403 T C 6.70E-05 Orofacial clefts / / 22419666 rs4528714 chr2 235969515 G T 4.34E-05 Magnesium levels / / pha003092 rs13407724 chr2 235985354 C T 8.61E-04 Tourette syndrome / / 22889924 rs12692159 chr2 235990320 C A 8.10E-05 Heart Rate / / pha003053 rs12692159 chr2 235990320 C A 7.84E-05 Heart Rate / / pha003054 rs7560067 chr2 235997858 T C 1.85E-04 Tourette syndrome / / 22889924 rs11680191 chr2 236030089 G A 5.93E-05 Glucose levels / / pha003058 rs6746703 chr2 236063063 C T 2.78E-05 Myopia (severe) / / 23933737 rs10221738 chr2 236085432 G A 2.50E-04 Intracranial aneurysm / / 20613766 rs4663553 chr2 236100852 A C 5.10E-04 Tourette syndrome / / 22889924 rs6741541 chr2 236104693 T C 9.55E-04 Multiple complex diseases / / 17554300 rs6724006 chr2 236104861 C G 9.81E-04 Multiple complex diseases / / 17554300 rs10929105 chr2 236104982 C T 1.10E-05 Urinary metabolites / / 21572414 rs6727347 chr2 236111180 C A 9.55E-04 Multiple complex diseases / / 17554300 rs1991705 chr2 236128951 A G 7.00E-06 Obesity-related traits / / 23251661 rs1367878 chr2 236133216 A G 1.24E-04 Intracranial aneurysm / / 20613766 rs6710111 chr2 236144476 G A 2.44E-04 Acute lung injury / / 22295056 rs7599884 chr2 236147276 C T 3.06E-04 Acute lung injury / / 22295056 rs8179638 chr2 236161371 A C 5.97E-04 Acute lung injury / / 22295056 rs13432658 chr2 236165791 T G 4.66E-04 Acute lung injury / / 22295056 rs7595069 chr2 236166480 T C 2.20E-05 Urinary metabolites / / 21572414 rs13420609 chr2 236166928 C A 2.82E-04 Acute lung injury / / 22295056 rs12052405 chr2 236167636 T G 2.80E-04 Acute lung injury / / 22295056 rs12052406 chr2 236167696 T C 5.50E-04 Acute lung injury / / 22295056 rs12052330 chr2 236167826 A G 5.32E-04 Acute lung injury / / 22295056 rs4663191 chr2 236174758 A G 3.79E-05 Height / / pha003010 rs10929115 chr2 236179761 A C 6.93E-04 Multiple complex diseases / / 17554300 rs2043194 chr2 236180672 A G 9.99E-04 Multiple complex diseases / / 17554300 rs6431360 chr2 236180811 T G 1.59E-04 Multiple complex diseases / / 17554300 rs6431360 chr2 236180811 T G 1.45E-29 Narcolepsy / / 19629137 rs4663563 chr2 236194197 C T 3.30E-04 Height / / 17255346 rs13412315 chr2 236195931 A G 2.00E-06 Urinary metabolites / / 21572414 rs4663564 chr2 236197807 C T 7.67E-04 Smoking quantity / / 24665060 rs13422090 chr2 236197888 T C 8.20E-07 Urinary metabolites / / 21572414 rs1367876 chr2 236212004 A G 9.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs13020554 chr2 236214007 G A 8.47E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs13020554 chr2 236214007 G A 3.48E-05 Cognitive test performance / / 20125193 rs2163566 chr2 236228143 A G 9.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs13428584 chr2 236265539 A G 7.62E-04 Coronary Artery Disease / / 17634449 rs11691626 chr2 236267980 C T 7.60E-05 Prostate cancer / / 22923026 rs2090418 chr2 236272767 C T 7.68E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs10803639 chr2 236282912 G A 7.47E-06 Personality dimensions / / 23658558 rs11691754 chr2 236340067 A C 9.51E-04 Parkinson's disease / / 17052657 rs12474898 chr2 236367367 C T 1.80E-05 Urinary metabolites / / 21572414 rs10929133 chr2 236369719 C A 1.80E-05 Urinary metabolites / / 21572414 rs2316431 chr2 236407716 T C 7.77E-04 Suicide attempts in bipolar disorder AGAP1 intron 21041247 rs7599284 chr2 236410952 G A 8.28E-04 Suicide attempts in bipolar disorder AGAP1 intron 21041247 rs1865951 chr2 236415339 G A 8.27E-04 Suicide attempts in bipolar disorder AGAP1 intron 21041247 rs7595159 chr2 236478388 A G 0.0006816 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) AGAP1 intron 23233654 rs7595159 chr2 236478388 A G 6.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) AGAP1 intron 23233662 rs12151399 chr2 236478656 A G 7.03E-04 Multiple complex diseases AGAP1 intron 17554300 rs11676226 chr2 236514769 A G 7.63E-04 Response to taxane treatment (placlitaxel) AGAP1 intron 23006423 rs11676226 chr2 236514769 A G 3.66E-06 Coronary heart disease AGAP1 intron pha003032 rs7564374 chr2 236516480 G A 7.16E-04 Response to taxane treatment (placlitaxel) AGAP1 intron 23006423 rs7564374 chr2 236516480 G A 8.40E-07 Coronary heart disease AGAP1 intron pha003032 rs6431393 chr2 236539307 A G 4.00E-06 Menarche (age at onset) AGAP1 intron 23667675 rs6750322 chr2 236589977 A G 3.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) AGAP1 intron 23648065 rs12992033 chr2 236605782 G A 3.56E-04 Lung function (forced expiratory volume in 1 second) AGAP1 intron 17255346 rs3754670 chr2 236617595 T C 6.31E-04 Multiple complex diseases AGAP1 intron 17554300 rs3754669 chr2 236617736 C T 8.79E-05 Lung function (forced expiratory volume in 1 second) AGAP1 intron 17255346 rs1568069 chr2 236618642 G T 1.24E-05 Parkinson's disease AGAP1 intron 21738487 rs2675124 chr2 236631040 G A 7.39E-05 Hypertension (essential hypertension) AGAP1 intron 22184326 rs2675144 chr2 236641479 C T 4.17E-04 Alzheimer's disease AGAP1 intron 22005930 rs6711814 chr2 236646486 G T 4.19E-04 Multiple complex diseases AGAP1 intron 17554300 rs3738996 chr2 236655526 G A 1.90E-05 Cognitive test performance AGAP1 intron 20125193 rs1728286 chr2 236658058 A G 4.07E-04 Alzheimer's disease AGAP1 intron 22005930 rs6760477 chr2 236709123 G A 1.74E-05 Cognitive test performance AGAP1 intron 20125193 rs7565206 chr2 236717001 G T 6.44E-05 Cognitive test performance AGAP1 intron 20125193 rs12616076 chr2 236719302 A G 1.61E-04 Type 2 diabetes AGAP1 intron 17463246 rs12616076 chr2 236719302 A G 2.60E-05 Urinary metabolites AGAP1 intron 21572414 rs12478435 chr2 236737133 T C 3.96E-04 Amyotrophic lateral sclerosis (sporadic) AGAP1 intron 24529757 rs3820776 chr2 236780457 A G 8.48E-05 Schizophrenia AGAP1 intron 19571809 rs67755945 chr2 236792769 AC AAC,ACA 2.00E-04 Cognitive impairment induced by topiramate AGAP1 intron 22091778 rs7426112 chr2 236792769 A C,T 2.00E-04 Cognitive impairment induced by topiramate AGAP1 intron 22091778 rs13025591 chr2 236795343 A C 4.59E-07 Schizophrenia AGAP1 intron 19571809 rs13025591 chr2 236795343 A C 6.00E-06 Schizophrenia AGAP1 intron 21926974 rs13025591 chr2 236795343 A C 8.00E-08 Schizophrenia AGAP1 intron 22688191 rs11688841 chr2 236795801 G A 9.89E-04 Alcohol dependence AGAP1 intron 21314694 rs4663627 chr2 236796548 C T 0.000131 Schizophrenia AGAP1 intron 23637625 rs6747286 chr2 236813557 T C 9.91E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) AGAP1 intron 23648065 rs1962550 chr2 236822569 C G 1.15E-06 Schizophrenia AGAP1 intron 19571809 rs7571708 chr2 236832573 A G 2.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) AGAP1 intron 23648065 rs1962299 chr2 236834160 A G 2.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) AGAP1 intron 23648065 rs7583139 chr2 236835657 A G 1.13E-04 Insulin resistance AGAP1 intron 21901158 rs10200514 chr2 236849630 C A 4.20E-06 Urinary metabolites AGAP1 intron 21572414 rs11902362 chr2 236858701 G A 6.80E-06 Urinary metabolites AGAP1 intron 21572414 rs6431414 chr2 236862139 A G 1.50E-06 Urinary metabolites AGAP1 intron 21572414 rs4261675 chr2 236864057 A C,G,T 1.60E-06 Urinary metabolites AGAP1 intron 21572414 rs7601459 chr2 236890713 T C 8.00E-06 Urinary metabolites AGAP1 intron 21572414 rs1530940 chr2 236905308 C A 2.63E-05 Hemoglobin AGAP1 intron pha003096 rs10206890 chr2 236922324 C A 6.94E-04 Amyotrophic Lateral Sclerosis AGAP1 intron 17362836 rs6739594 chr2 236951982 C T 2.44E-04 Multiple complex diseases AGAP1 intron 17554300 rs3768945 chr2 236972635 G A 8.01E-05 Amyotrophic lateral sclerosis AGAP1 intron 23624525 rs3768940 chr2 236980678 A T 6.26E-04 Acute lung injury AGAP1 intron 22295056 rs1530933 chr2 236988413 C A 6.26E-04 Acute lung injury AGAP1 intron 22295056 rs1530932 chr2 236988590 T A 6.26E-04 Acute lung injury AGAP1 intron 22295056 rs11889753 chr2 236988903 A C 6.26E-04 Acute lung injury AGAP1 intron 22295056 rs3768939 chr2 236990057 G A 2.00E-04 Information processing speed AGAP1 intron 21130836 rs3768939 chr2 236990057 G A 4.20E-05 Myopia (pathological) AGAP1 intron 23049088 rs3768939 chr2 236990057 G A 8.70E-05 Cardiovascular disease AGAP1 intron pha003064 rs6709778 chr2 236999752 T C 7.40E-04 Coronary heart disease AGAP1 intron 21971053 rs7557498 chr2 237019256 A G 2.80E-05 Urinary metabolites AGAP1 intron 21572414 rs6742722 chr2 237040797 G A 1.63E-05 Body Mass Index / / pha002896 rs11687170 chr2 237058144 T A,C 3.00E-08 Educational attainment / / 23722424 rs13386897 chr2 237099410 A G 2.47E-06 Body Mass Index / / pha002896 rs13398522 chr2 237099438 G T 4.16E-04 Multiple complex diseases / / 17554300 rs10177957 chr2 237103697 G T 5.23E-06 Body Mass Index ASB18 missense pha002896 rs13401104 chr2 237105518 G A 5.00E-09 Educational attainment ASB18 intron 23722424 rs1530952 chr2 237131159 C A 2.57E-05 Body Mass Index ASB18 intron pha002896 rs13390159 chr2 237156549 G A 2.00E-07 Response to statin therapy ASB18 intron 20339536 rs10198281 chr2 237194279 A G 4.09E-04 Smoking quantity / / 24665060 rs7586359 chr2 237195419 T G 3.00E-06 Personality dimensions / / 18957941 rs7607774 chr2 237429154 G A 4.00E-07 Alcohol dependence / / 21956439 rs7577417 chr2 237450912 G A 3.30E-04 Primary sclerosing cholangitis / / 19944697 rs6431472 chr2 237451035 C G 4.40E-04 Primary sclerosing cholangitis / / 19944697 rs4571012 chr2 237453806 G T 6.10E-04 Primary sclerosing cholangitis / / 19944697 rs7585641 chr2 237488429 G C 2.45E-04 Type 2 diabetes CXCR7 intron 17463246 rs7585641 chr2 237488429 G C 2.83E-04 Multiple complex diseases CXCR7 intron 17554300 rs896543 chr2 237509207 G A 0.00000435 Alcohol dependence / / 23089632 rs896543 chr2 237509207 G A 4.75E-07 Alcohol dependence / / 23089632 rs896543 chr2 237509207 G A 1.00E-06 Alcohol dependence (age at onset) / / 24962325 rs7565777 chr2 237516294 A G 3.60E-06 Alcohol dependence (age at onset) / / 24962325 rs6431476 chr2 237517937 T C 0.00000114 Alcohol dependence / / 23089632 rs6431476 chr2 237517937 T C 0.00000392 Alcohol dependence / / 23089632 rs7607316 chr2 237521842 C A 3.00E-06 Airflow obstruction / / 22837378 rs7588302 chr2 237531788 T C 1.78E-04 Epilepsy / / 22116939 rs7594454 chr2 237537935 C T 0.0000305 Alcohol dependence / / 23089632 rs7594454 chr2 237537935 C T 2.60E-06 Alcohol dependence / / 23089632 rs2464850 chr2 237545512 A C 9.46E-05 Serum metabolites / / 19043545 rs2600737 chr2 237561751 C A 3.26E-05 Serum metabolites / / 19043545 rs2600731 chr2 237567361 G T 8.01E-05 Serum metabolites / / 19043545 rs2720094 chr2 237629858 G C 6.75E-05 Bipolar disorder / / 18317468 rs7556982 chr2 237644199 A G 1.55E-05 Odorant perception / / 23910658 rs10207770 chr2 237703303 T C 2.48E-04 IgE levels / / 17255346 rs1344766 chr2 237704004 G T 2.08E-04 IgE levels / / 17255346 rs7598243 chr2 237705892 A C 2.95E-04 IgE levels / / 17255346 rs934397 chr2 237706939 A G 1.23E-04 IgE levels / / 17255346 rs934396 chr2 237707002 C T 3.23E-04 IgE levels / / 17255346 rs10929194 chr2 237720634 G A 3.94E-04 IgE levels / / 17255346 rs7584906 chr2 237736216 C T 0.000897 Salmonella-induced pyroptosis / / 22837397 rs11676193 chr2 237750619 C T 0.0009 Salmonella-induced pyroptosis / / 22837397 rs1000007 chr2 237752054 T C 0.0000669 Salmonella-induced pyroptosis / / 22837397 rs12991682 chr2 237757355 C T 2.03E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2164397 chr2 237791011 G C 5.26E-04 Alzheimer's disease / / 17998437 rs1435843 chr2 237798803 G A 5.39E-08 Metabolite levels / / 23281178 rs10192201 chr2 237803408 C G 4.44E-04 Type 2 diabetes / / 21647700 rs7599706 chr2 237805687 T G 4.65E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2573730 chr2 237866135 C T 1.60E-05 Urinary metabolites / / 21572414 rs10803652 chr2 237876320 C T 8.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9646715 chr2 237895397 A T 7.46E-04 Type 2 diabetes / / 17463246 rs9287614 chr2 237901609 G A 8.50E-04 Alzheimer's disease / / 17998437 rs7597880 chr2 237958171 G A 4.54E-05 Platelet counts / / pha003100 rs13404290 chr2 237991777 T C 1.50E-05 Tooth agenesis (third molar) / / 24172245 rs7577630 chr2 237992613 G A 3.80E-05 Tooth agenesis (third molar) / / 24172245 rs10172321 chr2 238065463 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6711456 chr2 238114043 C T 8.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs13023077 chr2 238117179 A G 5.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs11694263 chr2 238190389 G A 6.69E-04 Parkinson's disease / / 17052657 rs4274551 chr2 238195820 G A 5.41E-06 Height / / pha003010 rs4274551 chr2 238195820 G A 2.70E-05 Height / / pha003011 rs11676186 chr2 238205060 C T 2.04E-04 Blood pressure / / 17255346 rs11897292 chr2 238210640 G C 8.30E-04 Diabetic nephropathy / / 20347642 rs12052878 chr2 238227594 G A 1.84E-05 Blood pressure / / 21909110 rs11690358 chr2 238244781 T C 3.43E-04 Type 2 diabetes COL6A3 missense 17463246 rs6725567 chr2 238253518 C T 7.66E-04 Insulin resistance COL6A3 intron 21901158 rs7586225 chr2 238255686 C A 9.88E-05 Insulin resistance COL6A3 intron 21901158 rs7586225 chr2 238255686 C A 2.64E-05 Height COL6A3 intron pha003011 rs2646265 chr2 238257013 G A 5.87E-04 Parkinson's disease COL6A3 cds-synon 17052657 rs2646262 chr2 238258280 C T 3.16E-05 Height COL6A3 intron pha003011 rs2646254 chr2 238267717 C T 3.30E-04 Blood pressure COL6A3 cds-synon 17255346 rs10202497 chr2 238270894 C A 8.00E-06 Aging (time to event) COL6A3 intron 21782286 rs2645770 chr2 238274828 C A 1.50E-05 Urinary metabolites COL6A3 intron 21572414 rs13407339 chr2 238316137 C T 1.14E-04 Acute lung injury COL6A3 intron 22295056 rs6717825 chr2 238334279 G A 2.72E-05 Femoral neck bone geometry / / 22087292 rs937387 chr2 238348503 T C 9.94E-05 Femoral neck bone geometry / / 22087292 rs7600317 chr2 238353513 G A 2.23E-04 Smoking initiation / / 24665060 rs7598589 chr2 238355639 A T 1.30E-04 Multiple complex diseases / / 17554300 rs7595979 chr2 238364492 C A 6.38E-06 Smoking cessation / / 18519826 rs9287620 chr2 238368730 C A,T 3.33E-04 Smoking initiation / / 24665060 rs1497129 chr2 238369184 C T 2.08E-05 Smoking cessation / / 18519826 rs13398506 chr2 238374824 A G 4.33E-04 Smoking initiation / / 24665060 rs6431541 chr2 238376190 A T 1.96E-04 Smoking cessation / / 18519826 rs7584330 chr2 238387228 A G 3.00E-09 Prostate cancer / / 21743467 rs12469812 chr2 238415117 C T 7.00E-05 Prostate cancer MLPH intron 21743057 rs2292884 chr2 238443226 A G 4.00E-08 Prostate cancer MLPH missense 21743057 rs2292884 chr2 238443226 A G 7.71E-04 Alzheimer's disease MLPH missense 22005930 rs3817362 chr2 238449007 T C 4.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) MLPH missense 21239504 rs6760287 chr2 238498996 A G 1.51E-05 Response to taxane treatment (placlitaxel) RAB17 intron 23006423 rs2292873 chr2 238499444 C T 8.00E-06 Obesity-related traits RAB17 UTR-5 23251661 rs34832187 chr2 238499444 C CG 8.00E-06 Obesity-related traits RAB17 UTR-5 23251661 rs6755617 chr2 238499727 G A 1.37E-04 Response to taxane treatment (placlitaxel) RAB17 UTR-5 23006423 rs6709393 chr2 238505625 A G 3.73E-05 Cognitive impairment induced by topiramate / / 22091778 rs1316476 chr2 238508099 T C 8.75E-04 Obesity (extreme) / / 21935397 rs7585075 chr2 238509273 G A 2.00E-04 Information processing speed / / 21130836 rs11894280 chr2 238509759 G A 1.81E-05 Arthritis (juvenile idiopathic) / / 22354554 rs10929238 chr2 238509820 G A 2.40E-06 Urinary metabolites / / 21572414 rs13000086 chr2 238515227 A T 7.70E-06 Urinary metabolites / / 21572414 rs4278886 chr2 238522744 C T 3.34E-07 Schizophrenia / / 21795503 rs13414926 chr2 238524267 C T 7.73E-04 Obesity (extreme) / / 21935397 rs57673119 chr2 238524267 C CGAGT 7.73E-04 Obesity (extreme) / / 21935397 rs12464145 chr2 238526411 A C 2.80E-06 Urinary metabolites / / 21572414 rs12464145 chr2 238526411 A C 1.39E-04 Arthritis (juvenile idiopathic) / / 22354554 rs12464181 chr2 238526498 A G 9.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs12464181 chr2 238526498 A G 4.40E-07 Urinary metabolites / / 21572414 rs12464181 chr2 238526498 A G 2.57E-05 Arthritis (juvenile idiopathic) / / 22354554 rs6715815 chr2 238541938 T C 4.04E-08 Schizophrenia LRRFIP1 intron 21795503 rs12052937 chr2 238546572 C T 1.22E-11 Schizophrenia LRRFIP1 intron 21795503 rs13408642 chr2 238564791 G A 4.29E-06 Schizophrenia LRRFIP1 intron 21795503 rs6725315 chr2 238569285 T C 2.83E-06 Schizophrenia LRRFIP1 intron 21795503 rs4663779 chr2 238576444 G A 1.90E-04 Arthritis (juvenile idiopathic) LRRFIP1 intron 22354554 rs4663780 chr2 238578365 T C 2.39E-04 Response to cytidine analogues (gemcitabine) LRRFIP1 intron 24483146 rs7588573 chr2 238590702 G A 2.55E-04 Amyotrophic Lateral Sclerosis LRRFIP1 intron 17827064 rs10211393 chr2 238594788 T C 1.31E-04 Response to cytidine analogues (gemcitabine) LRRFIP1 intron 24483146 rs10211393 chr2 238594788 T C 1.44E-05 Response to cytadine analogues (cytosine arabinoside) LRRFIP1 intron 24483146 rs3213869 chr2 238668783 A G 3.30E-04 Multiple complex diseases LRRFIP1 missense 17554300 rs11680012 chr2 238672425 G C 4.00E-06 Adiposity LRRFIP1 missense 23505185 rs2289094 chr2 238680442 T C 1.60E-05 Urinary metabolites LRRFIP1 intron 21572414 rs3769047 chr2 238769892 A G 8.73E-04 Multiple complex diseases RAMP1 intron 17554300 rs12465864 chr2 238773705 A G 2.15E-04 Alzheimer's disease (late onset) RAMP1 intron 21379329 rs6728476 chr2 238792133 A G 1.54E-06 Systemic lupus erythematosus and Systemic sclerosis RAMP1 intron 23740937 rs6741923 chr2 238799206 C G 3.87E-04 Lymphocyte counts RAMP1 intron 22286170 rs11692472 chr2 238803386 C G 5.21E-04 Obesity (extreme) RAMP1 intron 21935397 rs11675972 chr2 238803478 A G 5.20E-04 Obesity (extreme) RAMP1 intron 21935397 rs4663269 chr2 238806370 T C 7.48E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) RAMP1 intron 23648065 rs10185142 chr2 238822331 C T 8.00E-06 Obesity-related traits / / 23251661 rs6729271 chr2 238825809 C T 0.0003 Migraine / / 22678113 rs6729271 chr2 238825809 C T 1.10E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6729271 chr2 238825809 C T 1.31E-05 Waist-Hip Ratio / / pha003029 rs6719401 chr2 238836195 G A 1.96E-05 Myopia (pathological) / / 21640322 rs1446930 chr2 238870879 C T 1.27E-04 Alcohol consumption / / 23743675 rs10167252 chr2 238872246 T C 1.29E-04 Alcohol consumption / / 23743675 rs1446924 chr2 238877740 A G 1.33E-04 Alcohol consumption UBE2F intron 23743675 rs10929255 chr2 238879302 G A 1.34E-04 Alcohol consumption UBE2F intron 23743675 rs7567199 chr2 238880530 G A 1.41E-04 Alcohol consumption UBE2F intron 23743675 rs6711485 chr2 238882675 A G 1.45E-04 Alcohol consumption UBE2F intron 23743675 rs6754093 chr2 238882735 C A 1.39E-04 Alcohol consumption UBE2F intron 23743675 rs4461215 chr2 238883966 G A 1.52E-04 Alcohol consumption UBE2F intron 23743675 rs2121472 chr2 238884837 C T 1.41E-04 Alcohol consumption UBE2F intron 23743675 rs10187736 chr2 238887575 C T 6.41E-04 Aortic root size UBE2F intron 21223598 rs10187736 chr2 238887575 C T 1.41E-04 Alcohol consumption UBE2F intron 23743675 rs7572717 chr2 238890316 T A 1.50E-04 Alcohol consumption UBE2F intron 23743675 rs6726393 chr2 238891591 A G 1.47E-04 Alcohol consumption UBE2F intron 23743675 rs7422865 chr2 238892692 T C 1.47E-04 Alcohol consumption UBE2F intron 23743675 rs6755573 chr2 238895612 G A 1.38E-04 Alcohol consumption UBE2F intron 23743675 rs11690668 chr2 238896958 C T 1.43E-04 Alcohol consumption UBE2F intron 23743675 rs4663819 chr2 238897374 G A 1.38E-04 Alcohol consumption UBE2F intron 23743675 rs11692064 chr2 238897587 C G 1.41E-04 Alcohol consumption UBE2F intron 23743675 rs11692068 chr2 238897606 C T 1.41E-04 Alcohol consumption UBE2F intron 23743675 rs10048814 chr2 238897755 C T 1.46E-04 Alcohol consumption UBE2F intron 23743675 rs10048643 chr2 238897934 A G 1.48E-04 Alcohol consumption UBE2F intron 23743675 rs4663276 chr2 238898809 G A 1.46E-04 Alcohol consumption UBE2F intron 23743675 rs10203101 chr2 238903310 C T 1.48E-04 Alcohol consumption UBE2F intron 23743675 rs10469607 chr2 238904792 G A 1.49E-04 Alcohol consumption UBE2F intron 23743675 rs9751676 chr2 238906315 G C 4.30E-05 Cognitive decline UBE2F intron 23732972 rs10166061 chr2 238906511 C T 1.49E-04 Alcohol consumption UBE2F intron 23743675 rs7594965 chr2 238911101 C A 1.43E-04 Alcohol consumption UBE2F intron 23743675 rs6431570 chr2 238924568 G A 1.53E-04 Alcohol consumption UBE2F intron 23743675 rs821509 chr2 238946583 C G 4.86E-04 Aortic root size UBE2F intron 21223598 rs821501 chr2 238950886 T C 4.60E-04 Aortic root size UBE2F UTR-3 21223598 rs821497 chr2 238952547 G A 3.17E-04 Aortic root size UBE2F-SCLY intron 21223598 rs843977 chr2 238958166 T C 4.85E-04 Aortic root size UBE2F-SCLY intron 21223598 rs821490 chr2 238960572 G A 1.41E-04 Alcohol consumption UBE2F-SCLY intron 23743675 rs821488 chr2 238963756 T C 1.28E-04 Alcohol consumption UBE2F-SCLY intron 23743675 rs865380 chr2 238963998 C G 1.10E-04 Alcohol consumption UBE2F-SCLY intron 23743675 rs2264165 chr2 238966048 G A 6.66E-05 Alcohol consumption UBE2F-SCLY intron 23743675 rs821486 chr2 238966691 T C 6.91E-05 Alcohol consumption UBE2F-SCLY intron 23743675 rs821485 chr2 238966807 A G 6.82E-05 Alcohol consumption UBE2F-SCLY intron 23743675 rs843975 chr2 238967565 A C 6.66E-05 Alcohol consumption UBE2F-SCLY intron 23743675 rs821484 chr2 238967652 A T 6.30E-05 Alcohol consumption UBE2F-SCLY intron 23743675 rs1374479 chr2 238968025 C G 6.23E-05 Alcohol consumption UBE2F-SCLY intron 23743675 rs2243545 chr2 238969150 C T 6.15E-05 Alcohol consumption UBE2F-SCLY intron 23743675 rs2250045 chr2 238970862 C T 7.04E-05 Alcohol consumption SCLY intron 23743675 rs2250039 chr2 238970937 G A 6.23E-05 Alcohol consumption SCLY intron 23743675 rs2250038 chr2 238970943 G T 6.15E-05 Alcohol consumption SCLY intron 23743675 rs821482 chr2 238971111 T C 6.22E-05 Alcohol consumption SCLY intron 23743675 rs821480 chr2 238972827 T C 7.43E-05 Alcohol consumption SCLY intron 23743675 rs2249543 chr2 238974811 A G 6.73E-05 Alcohol consumption SCLY intron 23743675 rs2249434 chr2 238975753 G C 9.10E-05 Type 2 diabetes SCLY intron 17463248 rs2592585 chr2 238979621 C T 9.57E-05 Alcohol consumption SCLY intron 23743675 rs2264166 chr2 238981301 C A 1.04E-04 Alcohol consumption SCLY intron 23743675 rs7601010 chr2 238982773 C T 1.44E-04 Alcohol consumption SCLY intron 23743675 rs2252822 chr2 238983267 A G 1.32E-04 Alcohol consumption SCLY intron 23743675 rs2262425 chr2 238984129 A G 8.08E-05 Bipolar disorder SCLY intron 17486107 rs2262425 chr2 238984129 A G 8.67E-04 Aortic root size SCLY intron 21223598 rs2262425 chr2 238984129 A G 7.76E-04 Response to taxane treatment (placlitaxel) SCLY intron 23006423 rs2262425 chr2 238984129 A G 1.35E-04 Alcohol consumption SCLY intron 23743675 rs2262426 chr2 238984497 G A 1.33E-04 Alcohol consumption SCLY intron 23743675 rs4663836 chr2 238987185 A T 9.60E-05 Alcohol consumption SCLY intron 23743675 rs3210400 chr2 238990388 G A 0.0008744 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SCLY missense 23233654 rs3210400 chr2 238990388 G A 8.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) SCLY missense 23233662 rs2249077 chr2 238990985 T C 9.20E-05 Alcohol consumption SCLY intron 23743675 rs2249067 chr2 238991187 G A 6.89E-05 Alcohol consumption SCLY intron 23743675 rs2278742 chr2 238991796 C T 8.01E-05 Alcohol consumption SCLY intron 23953852 rs2248825 chr2 238993045 G A 6.80E-05 Alcohol consumption SCLY intron 23743675 rs2248824 chr2 238993104 T C 6.97E-05 Alcohol consumption SCLY intron 23743675 rs2326009 chr2 238993857 C A 8.90E-05 Alcohol consumption SCLY intron 23743675 rs2264132 chr2 238994676 T C 5.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SCLY intron 20877124 rs2248623 chr2 238994828 T G 1.41E-04 Alcohol consumption SCLY intron 23743675 rs2592583 chr2 238995760 G T 1.43E-04 Alcohol consumption SCLY intron 23743675 rs34049050 chr2 238998581 A G 1.27E-04 Alcohol consumption SCLY intron 23743675 rs7591078 chr2 239005014 C G 3.71E-04 Aortic root size SCLY intron 21223598 rs7591078 chr2 239005014 C G 1.06E-04 Alcohol consumption SCLY intron 23743675 rs13033964 chr2 239005586 G A 1.10E-04 Alcohol consumption SCLY intron 23743675 rs62196004 chr2 239006314 G A 1.07E-04 Alcohol consumption SCLY intron 23743675 rs41264151 chr2 239007635 G A 1.21E-04 Alcohol consumption SCLY UTR-3 23743675 rs1562337 chr2 239008203 T C 3.72E-04 Parkinson's disease / / 17052657 rs13006807 chr2 239008542 C T 1.31E-04 Alcohol consumption / / 23743675 rs62196014 chr2 239010167 C G 1.15E-04 Alcohol consumption ESPNL intron 23743675 rs34878344 chr2 239010690 C A 1.27E-04 Alcohol consumption ESPNL cds-synon 23743675 rs7565244 chr2 239013662 A G 7.61E-04 Premature ovarian failure ESPNL intron 19508998 rs4663837 chr2 239013841 C A,G,T 1.31E-04 Alcohol consumption ESPNL intron 23743675 rs62196019 chr2 239014715 G A 1.47E-04 Alcohol consumption ESPNL intron 23743675 rs4663285 chr2 239014834 G A 1.39E-04 Alcohol consumption ESPNL intron 23743675 rs878134 chr2 239016640 G T 1.28E-04 Alcohol consumption ESPNL intron 23743675 rs878133 chr2 239016933 G A 1.28E-04 Alcohol consumption ESPNL intron 23743675 rs13025510 chr2 239017140 G A 1.33E-04 Alcohol consumption ESPNL intron 23743675 rs62197363 chr2 239028740 T C 9.99E-05 Alcohol consumption ESPNL intron 23743675 rs199604026 chr2 239049718 G A 1.70E-09 Prostate cancer (advanced) KLHL30 missense 23555315 rs2880132 chr2 239082976 G A 3.11E-04 Lung function (forced expiratory volume in 1 second) ILKAP intron 24023788 rs6431587 chr2 239090042 G A 4.38E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ILKAP intron 24023788 rs12472274 chr2 239095422 G A 2.00E-08 Phospholipid levels (plasma) ILKAP intron 22359512 rs6722019 chr2 239128117 T C 5.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6722019 chr2 239128117 T C 0.000182 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs934945 chr2 239155053 C T 9.83E-05 Cognitive performance PER2 missense 19734545 rs2304674 chr2 239181904 A G 2.20E-06 Urinary metabolites PER2 intron 21572414 rs7598777 chr2 239230657 C T 7.00E-04 Gamma gluatamyl transferase levels (interaction with age) TRAF3IP1 intron 22010049 rs13402781 chr2 239231518 T A 7.56E-04 Type 2 diabetes TRAF3IP1 intron 17463246 rs6714098 chr2 239236301 C G 5.77E-04 Type 2 diabetes TRAF3IP1 intron 17463246 rs10205543 chr2 239243117 T C 6.13E-04 Type 2 diabetes TRAF3IP1 intron 17463246 rs3739070 chr2 239306268 A C 2.00E-12 Iris characteristics TRAF3IP1 missense 21835309 rs3739070 chr2 239306268 A C 6.00E-06 Iris characteristics TRAF3IP1 missense 21835309 rs541864 chr2 239314634 T C 7.16E-04 Type 2 diabetes / / 17463246 rs541013 chr2 239336492 G A 3.76E-04 Tourette syndrome ASB1 intron 22889924 rs579861 chr2 239348995 G T 5.73E-04 Substance dependence ASB1 intron 21818250 rs3769124 chr2 239349362 G A 7.00E-08 Pulmonary function ASB1 intron 21946350 rs472357 chr2 239355454 C T 4.70E-04 Tourette syndrome ASB1 UTR-3 22889924 rs103718 chr2 239398488 G A 1.00E-04 Prostate cancer / / 21743057 rs523437 chr2 239398809 C T 1.00E-04 Prostate cancer / / 21743057 rs2878083 chr2 239416791 C A 4.67E-05 Schizophrenia / / 19571809 rs2878083 chr2 239416791 C A 4.21E-05 Schizophrenia / / pha002859 rs303037 chr2 239425904 C A,G 5.75E-04 Suicide attempts in bipolar disorder LOC151171 intron 21423239 rs752123 chr2 239427379 C T 6.78E-04 Multiple complex diseases LOC151171 intron 17554300 rs2334004 chr2 239427579 A G 5.63E-04 Multiple complex diseases LOC151171 intron 17554300 rs10203243 chr2 239442908 T G 6.32E-04 Suicide attempts in bipolar disorder LOC151171 intron 21423239 rs2166855 chr2 239455842 T C 7.61E-04 Suicide attempts in bipolar disorder LOC151171 intron 21423239 rs1027928 chr2 239524082 G A 1.30E-04 Endometriosis / / 21151130 rs12614869 chr2 239554884 T C 4.69E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11690021 chr2 239637228 T C 3.52E-05 Esophageal cancer (squamous cell) / / 22960999 rs11690021 chr2 239637228 T C 8.77E-05 Serum albumin level / / pha003084 rs6716943 chr2 239638153 C A 9.95E-06 Carotenoid and tocopherol levels / / 19185284 rs4545955 chr2 239638300 T C 6.67E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12692245 chr2 239655737 G A 6.66E-05 Bipolar disorder / / 19488044 rs12692245 chr2 239655737 G A 6.85E-05 Bipolar disorder and schizophrenia / / 20889312 rs12692245 chr2 239655737 G A 4.48E-05 Bipolar Disorder / / pha002858 rs4075846 chr2 239692909 A T 3.61E-09 Male-pattern baldness / / 22693459 rs9287638 chr2 239694631 C A 1.00E-12 Male-pattern baldness / / 22693459 rs9711321 chr2 239697444 T C 6.05E-11 Male-pattern baldness / / 22693459 rs11683401 chr2 239697605 T C 6.02E-11 Male-pattern baldness / / 22693459 rs10929296 chr2 239710123 A G 6.11E-04 Multiple complex diseases / / 17554300 rs9798281 chr2 239720326 T C 3.87E-05 Behcet's disease / / pha002888 rs9710693 chr2 239722254 T C 9.36E-04 Type 2 diabetes / / 17463246 rs9287645 chr2 239722506 T C 1.10E-08 Male-pattern baldness / / 22693459 rs9751357 chr2 239733773 A G 2.08E-09 Schizophrenia / / 21795503 rs9751357 chr2 239733773 A G 2.42E-04 Smoking initiation / / 24665060 rs9752491 chr2 239734678 G A 3.78E-08 Male-pattern baldness / / 22693459 rs9751918 chr2 239735812 A G 1.71E-08 Male-pattern baldness / / 22693459 rs9750952 chr2 239736364 C T 2.21E-08 Male-pattern baldness / / 22693459 rs12613833 chr2 239749411 T C 2.84E-08 Male-pattern baldness / / 22693459 rs4078407 chr2 239835244 T C 5.56E-05 Acute lung injury / / 22295056 rs7602841 chr2 239847486 C T 9.44E-04 Multiple complex diseases FLJ43879 intron 17554300 rs12477314 chr2 239877148 C T 1.00E-07 Pulmonary function / / 21946350 rs12477314 chr2 239877148 C T 2.00E-12 Pulmonary function / / 21946350 rs12477314 chr2 239877148 C T 2.00E-07 Pulmonary function (interaction) / / 23284291 rs12467854 chr2 239888758 C G 6.66E-05 Pulmonary function / / 20010835 rs4852066 chr2 239890696 G A 9.21E-04 Depression (quantitative trait) / / 20800221 rs4851977 chr2 239891296 G A 9.58E-04 Depression (quantitative trait) / / 20800221 rs6543542 chr2 239891644 T C 9.65E-04 Depression (quantitative trait) / / 20800221 rs11679161 chr2 239893009 C T 7.80E-05 Pulmonary function / / 20010835 rs4852079 chr2 239899327 A G 8.52E-04 Depression (quantitative trait) / / 20800221 rs3922831 chr2 239935543 T C 6.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4075018 chr2 239949681 G A 8.47E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs3752755 chr2 240004245 C T 5.40E-04 Coronary heart disease HDAC4 intron 21966275 rs3791398 chr2 240025666 G A 1.80E-05 Carotid intima media thickness HDAC4 intron 19679847 rs3791399 chr2 240025761 G A 3.70E-06 Urinary metabolites HDAC4 intron 21572414 rs747787 chr2 240032319 G A 4.80E-04 Myocardial infarction HDAC4 intron 21107343 rs3791426 chr2 240039401 A G 0.000506 Salmonella-induced pyroptosis HDAC4 intron 22837397 rs3791446 chr2 240045350 T C 3.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HDAC4 intron 20877124 rs3791461 chr2 240051965 G A 3.78E-04 Multiple complex diseases HDAC4 intron 17554300 rs3791461 chr2 240051965 G A 1.40E-05 Urinary metabolites HDAC4 intron 21572414 rs12469994 chr2 240053966 G A 5.41E-04 Alzheimer's disease HDAC4 intron 24755620 rs2121980 chr2 240055553 T C 7.10E-05 Dental caries HDAC4 intron 21940522 rs2121980 chr2 240055553 T C 0.0000346 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) HDAC4 intron 23233654 rs2121980 chr2 240055553 T C 3.46E-05 Methotrexate clearance (acute lymphoblastic leukemia) HDAC4 intron 23233662 rs3791511 chr2 240080540 G A 6.43E-05 Melanoma HDAC4 intron 21926416 rs7599555 chr2 240086580 C T 5.15E-04 Multiple complex diseases HDAC4 intron 17554300 rs1448430 chr2 240092739 G A 8.10E-05 Bipolar disorder HDAC4 intron 22925353 rs489806 chr2 240099456 C A 3.06E-04 Hemoglobin concentration HDAC4 intron 20534544 rs3791549 chr2 240109024 G A 4.17E-05 Multiple complex diseases HDAC4 intron 17554300 rs3828222 chr2 240109568 C T 4.55E-05 Multiple complex diseases HDAC4 intron 17554300 rs3791556 chr2 240112972 G A 2.80E-05 Diabetic retinopathy HDAC4 intron 21441570 rs3791556 chr2 240112972 G A 8.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) HDAC4 intron 23453885 rs753302 chr2 240114137 A G 7.04E-04 Amyotrophic Lateral Sclerosis HDAC4 intron 17827064 rs6735945 chr2 240115818 G C 6.28E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines HDAC4 intron 21844884 rs496316 chr2 240155231 T C 1.80E-05 Urinary metabolites HDAC4 intron 21572414 rs12151485 chr2 240176736 G A 1.62E-04 IgE levels HDAC4 intron 17255346 rs7595357 chr2 240180336 C A 1.29E-05 IgE levels HDAC4 intron 17255346 rs7595357 chr2 240180336 C A 7.04E-05 Weight HDAC4 intron pha003027 rs1403608 chr2 240181872 G A 5.86E-04 Type 2 diabetes HDAC4 intron 17463246 rs7587786 chr2 240186518 G A 6.73E-06 Body mass index HDAC4 intron 19557197 rs6742576 chr2 240187632 G A 6.56E-06 Body mass index HDAC4 intron 19557197 rs10208713 chr2 240188918 C T 4.94E-04 Hemoglobin concentration HDAC4 intron 20534544 rs6745266 chr2 240193575 G A 6.15E-06 Body mass index HDAC4 intron 19557197 rs6737742 chr2 240216021 G A 8.58E-05 Hemoglobin concentration HDAC4 intron 20534544 rs6737742 chr2 240216021 G A 5.53E-05 Response to acetaminophen (hepatotoxicity) HDAC4 intron 21177773 rs908262 chr2 240217522 C A 8.58E-05 Hemoglobin concentration HDAC4 intron 20534544 rs908262 chr2 240217522 C A 3.71E-05 Response to acetaminophen (hepatotoxicity) HDAC4 intron 21177773 rs925738 chr2 240241255 C T 4.76E-04 Hemoglobin concentration HDAC4 intron 20534544 rs950225 chr2 240258244 C T 7.90E-04 Myocardial infarction HDAC4 intron 21107343 rs908265 chr2 240262287 T C 9.27E-05 Triglycerides HDAC4 intron pha002904 rs11686104 chr2 240286146 G A 1.03E-04 Hemoglobin concentration HDAC4 intron 20534544 rs11124194 chr2 240290494 C T 5.22E-05 Response to cytadine analogues (cytosine arabinoside) HDAC4 intron 24483146 rs11124194 chr2 240290494 C T 6.62E-04 Response to cytidine analogues (gemcitabine) HDAC4 intron 24483146 rs2411843 chr2 240294969 A C 5.47E-05 Bladder cancer (smoking interaction) HDAC4 intron 24662972 rs843453 chr2 240333093 G A 1.50E-05 Urinary metabolites / / 21572414 rs6726998 chr2 240399614 A G 3.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs11894982 chr2 240401778 A G 8.40E-05 Multiple complex diseases / / 17554300 rs6743931 chr2 240418660 G A 2.00E-06 Response to antipsychotic therapy (extrapyramidal side effects) / / 19875103 rs2630755 chr2 240426236 T C 2.00E-05 Urinary metabolites / / 21572414 rs6709029 chr2 240439835 G A 3.46E-05 Serum metabolites / / 19043545 rs12612849 chr2 240442702 C T 1.11E-05 Conotruncal heart defects / / 24800985 rs6706785 chr2 240444053 G T 6.00E-06 Conotruncal heart defects / / 24800985 rs4852088 chr2 240456946 T C 8.04E-05 Alzheimer's disease (age of onset) / / 22005931 rs731154 chr2 240457989 T G 8.73E-05 Alzheimer's disease (age of onset) / / 22005931 rs62180959 chr2 240463182 T C 9.18E-05 Atopic dermatitis / / 23042114 rs7571310 chr2 240467250 T A 8.35E-05 Atopic dermatitis / / 23042114 rs62183061 chr2 240468521 G A 8.33E-05 Atopic dermatitis / / 23042114 rs62183062 chr2 240468671 A T 8.44E-05 Atopic dermatitis / / 23042114 rs55814338 chr2 240469892 G A 9.82E-05 Atopic dermatitis / / 23042114 rs10206786 chr2 240471992 G A 2.57E-04 Alzheimer's disease (late onset) / / 21379329 rs11679505 chr2 240499376 C T 4.61E-04 Obesity (extreme) / / 21935397 rs11684324 chr2 240510908 G A 8.29E-04 Obesity (extreme) / / 21935397 rs4852097 chr2 240530881 G T 4.75E-05 Tunica Media / / pha003037 rs7604209 chr2 240537244 G A 9.23E-05 Tunica Media / / pha003037 rs1030891 chr2 240539765 A G 2.10E-04 Alcohol dependence / / 20201924 rs1030891 chr2 240539765 A G 7.40E-04 Alcohol dependence / / 20201924 rs3916020 chr2 240562386 A C 9.46E-05 Diabetes Mellitus / / pha003059 rs4852100 chr2 240571827 A G 3.80E-05 Celiac disease / / 17558408 rs10165876 chr2 240574731 G A 3.62E-05 Leukocyte Counts / / pha003091 rs7598519 chr2 240651354 A C 6.20E-08 Iron levels / / 21208937 rs4852118 chr2 240660209 G A 2.95E-04 Coronary heart disease / / 21971053 rs4852124 chr2 240680022 T C 7.41E-06 Obesity-related traits / / 23251661 rs6748389 chr2 240685573 T G 2.64E-04 Alcohol dependence LOC150935 intron 20201924 rs10207060 chr2 240687289 T G 6.00E-06 Obesity-related traits LOC150935 intron 23251661 rs11904223 chr2 240688338 T C 4.15E-04 Parkinson's disease LOC150935 intron 17052657 rs1316932 chr2 240695187 A G 4.76E-04 Parkinson's disease LOC150935 intron 17052657 rs11674512 chr2 240695511 A G 1.59E-05 Alcohol dependence LOC150935 intron 20201924 rs11674512 chr2 240695511 A G 1.59E-05 Alcoholism LOC150935 intron pha002891 rs6543581 chr2 240702308 A G 6.42E-05 Aortic root size LOC150935 intron 21223598 rs2412042 chr2 240722820 C T 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11695034 chr2 240728640 G A 1.06E-04 Attention deficit hyperactivity disorder / / pha002875 rs4241236 chr2 240740612 C T 8.35E-04 White matter integrity / / 22425255 rs1996511 chr2 240741278 T C 4.66E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs4852140 chr2 240745718 A G 8.00E-06 Obesity-related traits / / 23251661 rs12618573 chr2 240843638 G A 8.00E-06 Response to amphetamines / / 22952603 rs11900622 chr2 240862048 T C 3.08E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4853981 chr2 240871893 T C 7.54E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs4996007 chr2 240874059 T C 4.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4996007 chr2 240874059 T C 1.95E-04 Smoking initiation / / 24665060 rs4854071 chr2 240885050 C T 5.67E-04 Breast cancer / / 20852631 rs13424612 chr2 240900121 C T 6.00E-10 Odorant perception NDUFA10 UTR-3 23910658 rs6748327 chr2 240902511 G A 4.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NDUFA10 intron 20877124 rs4149556 chr2 240915307 C T 9.75E-04 Breast cancer NDUFA10 intron 20852631 rs4149556 chr2 240915307 C T 6.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NDUFA10 intron 20877124 rs13848 chr2 240946766 T C 6.30E-04 Breast cancer NDUFA10 cds-synon 20852631 rs3792085 chr2 240948789 G A 5.02E-04 Coronary heart disease NDUFA10 intron 21606135 rs2289407 chr2 240954110 A G 9.78E-04 Breast cancer NDUFA10 intron 20852631 rs3792083 chr2 240954904 G A 8.65E-04 Coronary heart disease NDUFA10 intron 21606135 rs6735806 chr2 240954972 C A 3.33E-04 Hearing function NDUFA10 intron 17255346 rs4149541 chr2 240957734 G A 4.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NDUFA10 intron 20877124 rs10933552 chr2 240971519 T C 8.73E-05 Serum metabolites / / 19043545 rs13415895 chr2 240976581 A C 9.83E-05 Interstitial lung disease / / 23583980 rs2099727 chr2 240979959 T C 5.76E-04 Menopause (age at onset) / / 22267201 rs6731916 chr2 240981179 T C 4.06E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6741800 chr2 241008898 T C 7.33E-05 Hypertension / / 19609347 rs4292120 chr2 241066280 C T 8.65E-04 Response to taxane treatment (placlitaxel) MYEOV2 cds-synon 23006423 rs1866646 chr2 241070240 A G 7.82E-04 Response to taxane treatment (placlitaxel) MYEOV2 intron 23006423 rs3749078 chr2 241073450 C T 1.76E-04 IgE levels MYEOV2 intron 17255346 rs12621732 chr2 241073496 A G 2.60E-05 Iron levels MYEOV2 intron 21208937 rs4854022 chr2 241080654 C G 1.34E-05 Age-related macular degeneration / / 23577725 rs2368498 chr2 241091482 C T 8.30E-06 Urinary metabolites / / 21572414 rs6719685 chr2 241108454 G A 6.70E-06 Urinary metabolites / / 21572414 rs6719685 chr2 241108454 G A 2.92E-05 Erythrocyte counts / / pha003101 rs4853996 chr2 241109747 C T 9.72E-04 Multiple complex diseases / / 17554300 rs4854090 chr2 241168633 T C 6.80E-07 Multiple complex diseases / / 17554300 rs4854078 chr2 241182744 C A 5.15E-06 Retinopathy in non-diabetics / / 23393555 rs10170009 chr2 241213217 T G 4.29E-04 Alzheimer's disease (late onset) / / 21379329 rs7562354 chr2 241228985 C T 0.0000966 Migraine / / 22678113 rs7562354 chr2 241228985 C T 9.66E-05 Migraine / / 22683712 rs1106154 chr2 241231989 G A 3.45E-05 Triglycerides / / pha003081 rs1106154 chr2 241231989 G A 2.30E-05 Lipid levels / / pha003082 rs1105760 chr2 241232298 C G 2.95E-04 Telomere length / / 23900074 rs4854033 chr2 241233933 T C 2.46E-04 Telomere length / / 23900074 rs3935911 chr2 241247757 C T 1.70E-06 Thyroid function / / 20826269 rs12695016 chr2 241250109 A G 1.50E-06 Thyroid function / / 20826269 rs13383344 chr2 241252648 A G 1.10E-06 Thyroid function / / 20826269 rs2352816 chr2 241256135 A G 2.40E-06 Thyroid function / / 20826269 rs2352817 chr2 241256453 G A 3.40E-06 Thyroid function / / 20826269 rs4676361 chr2 241259159 C A 2.80E-06 Thyroid function / / 20826269 rs2352821 chr2 241261657 C T 1.20E-06 Thyroid function / / 20826269 rs2352821 chr2 241261657 C T 6.61E-05 Triglycerides / / pha003080 rs2352821 chr2 241261657 C T 7.20E-05 Triglycerides / / pha003081 rs2352821 chr2 241261657 C T 4.05E-05 Lipid levels / / pha003082 rs1320123 chr2 241293064 G T 8.50E-05 Bipolar disorder and schizophrenia / / 20889312 rs1574192 chr2 241308505 G A 4.00E-06 Brain imaging in schizophrenia (interaction) / / 19023125 rs28443480 chr2 241437820 G T 5.25E-04 Alzheimer's disease ANKMY1 intron 24755620 rs4676354 chr2 241456250 G A 7.74E-04 Multiple complex diseases ANKMY1 intron 17554300 rs4676432 chr2 241456297 C T 7.50E-04 Multiple complex diseases ANKMY1 intron 17554300 rs4676428 chr2 241492255 G T 4.75E-04 Insulin resistance ANKMY1 intron 21901158 rs4305276 chr2 241495013 C G 2.00E-11 Mean platelet volume ANKMY1 intron 22139419 rs11683693 chr2 241506669 C A 4.80E-06 Age-related macular degeneration / / 20861866 rs2953146 chr2 241515252 G A 2.08E-06 Multiple complex diseases RNPEPL1 intron 17554300 rs2953145 chr2 241515596 G C 7.00E-06 Bipolar disorder RNPEPL1 intron 17554300 rs2975752 chr2 241521327 T C 2.10E-04 Multiple complex diseases / / 17554300 rs1133352 chr2 241522252 C T 3.77E-05 Multiple complex diseases / / 17554300 rs1133353 chr2 241522267 A T 3.94E-06 Multiple complex diseases / / 17554300 rs1133353 chr2 241522267 A T 6.00E-06 Bipolar disorder / / 21254220 rs1133353 chr2 241522267 A T 6.00E-06 Bipolar disorder / / 21254220 rs1133354 chr2 241522450 T C 3.15E-05 Multiple complex diseases / / 17554300 rs4676420 chr2 241527673 G A 2.95E-05 HIV-1 control CAPN10 intron 20041166 rs2975760 chr2 241531163 T C 5.31E-04 Multiple complex diseases CAPN10 intron 17554300 rs3828345 chr2 241536819 C A 2.19E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CAPN10 intron 24023788 rs4234123 chr2 241541640 C T 2.72E-05 Multiple complex diseases / / 17554300 rs5030952 chr2 241542703 C T 1 Drug response to Tacrolimus / / 19752882 rs4676348 chr2 241544190 C T 1.02E-04 Multiple complex diseases / / 17554300 rs4676410 chr2 241563739 G A 2.00E-09 Sclerosing cholangitis and ulcerative colitis (combined) GPR35 intron 22821403 rs3749171 chr2 241569692 C T 3.00E-21 Inflammatory bowel disease GPR35 missense 23128233 rs4676406 chr2 241579108 G T 8.00E-11 Ulcerative colitis / / 21297633 rs2011743 chr2 241580725 C T 0.00005 Primary sclerosing cholangitis / / 23603763 rs1864879 chr2 241581451 C G 4.20E-04 Type 2 diabetes / / 17463246 rs4676403 chr2 241583676 A G 4.34E-05 Blood Pressure / / pha003043 rs6724516 chr2 241586810 G A 0.0000595 Primary sclerosing cholangitis / / 23603763 rs6744241 chr2 241592778 A G 2.40E-05 Erythrocyte counts / / pha003099 rs2060188 chr2 241593944 T G 3.80E-04 Type 2 diabetes / / 17463246 rs2060188 chr2 241593944 T G 2.77E-04 Lymphocyte counts / / 22286170 rs10933628 chr2 241594645 G C 3.65E-04 Type 2 diabetes / / 17463246 rs6437358 chr2 241597150 G C 5.90E-07 Ulcerative colitis / / 19915572 rs1003972 chr2 241627836 G C 3.74E-05 Type 2 diabetes / / 17463246 rs7576602 chr2 241684692 C T 7.15E-04 Depression (quantitative trait) KIF1A intron 20800221 rs2288751 chr2 241713429 T C 8.93E-04 Suicide attempts in bipolar disorder KIF1A intron 21423239 rs6708456 chr2 241729993 C T 3.45E-05 Prostate cancer KIF1A intron pha002878 rs12329123 chr2 241765872 G A 1.28E-05 Multiple complex diseases / / 17554300 rs4234121 chr2 241769281 T G 2.00E-05 Pericardial fat / / 22589742 rs4234121 chr2 241769281 T G 3.25E-05 Pulmonary function in asthmatics / / 23541324 rs4234121 chr2 241769281 T G 5.32E-05 Pulmonary function in asthmatics / / 23541324 rs4676347 chr2 241770943 A T 3.90E-05 Pericardial fat / / 22589742 rs6718518 chr2 241777882 C T 3.90E-05 Pericardial fat / / 22589742 rs11680616 chr2 241792959 T G 5.89E-04 Type 2 diabetes / / 17463246 rs11679258 chr2 241793061 A G 6.02E-04 Type 2 diabetes / / 17463246 rs11679258 chr2 241793061 A G 3.43E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs11686679 chr2 241803100 A G 6.96E-04 Type 2 diabetes / / 17463246 rs115014558 chr2 241808308 C A 0.00052 Breast cancer AGXT missense 23555315 rs4344931 chr2 241818527 A C 8.10E-05 Pericardial fat AGXT UTR-3 22589742 rs4675792 chr2 241819526 C T 3.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs4675874 chr2 241819796 G A 3.00E-20 Blood metabolite levels / / 24816252 rs4311055 chr2 241821017 T C 9.60E-05 Pericardial fat / / 22589742 rs3936203 chr2 241834654 A G 9.50E-05 Pericardial fat C2orf54 intron 22589742 rs10206101 chr2 241835543 A C 2.03E-04 Gallbladder cancer C2orf54 UTR-5 22318345 rs4630763 chr2 241838504 G A,T 3.46E-05 Gallbladder cancer / / 22318345 rs4675847 chr2 241865156 T C 2.98E-04 Type 2 diabetes / / 17463246 rs13405273 chr2 241882747 C T 4.70E-04 Smoking initiation LOC728763 intron 24665060 rs4521036 chr2 241927477 G A 8.24E-04 Type 2 diabetes / / 17463246 rs4676003 chr2 241960749 G A 6.85E-06 Odorant perception SNED1 intron 23910658 rs4234102 chr2 241968979 A G 7.50E-05 Celiac disease SNED1 intron 23936387 rs185349960 chr2 241969887 G A 0.00035 Prostate cancer SNED1 missense 23555315 rs185349960 chr2 241969887 G A 0.00056 Prostate cancer (non-advanced prostate cancer) SNED1 missense 23555315 rs7571117 chr2 241979550 T C 7.18E-04 Type 2 diabetes SNED1 cds-synon 17463246 rs7609450 chr2 241990727 C T 1.40E-06 Urinary metabolites SNED1 intron 21572414 rs2286321 chr2 242004866 A G 0.000012 Skin 1-naphthyl-keratin adduct (1NKA) levels in workers exposed to naphthalene SNED1 cds-synon 22391508 rs2286321 chr2 242004866 A G 0.0000419 Skin naphthyl-keratin adduct (NKA) levels in workers exposed to naphthalene SNED1 cds-synon 22391508 rs2286321 chr2 242004866 A G 9.53E-05 Mammographic density SNED1 cds-synon 22532574 rs2074843 chr2 242007839 G A 6.90E-06 Urinary metabolites SNED1 intron 21572414 rs6721345 chr2 242012729 G A 3.00E-06 Sex hormone-binding globulin levels SNED1 missense 22675492 rs12694993 chr2 242014364 C T 1.97E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SNED1 intron 20031582 rs13411510 chr2 242015650 T C 3.01E-04 Mammographic density SNED1 intron 22532574 rs13411556 chr2 242026649 A G 8.88E-04 Amyotrophic lateral sclerosis (sporadic) SNED1 intron 24529757 rs16843242 chr2 242031281 C T 8.52E-04 Suicide attempts in bipolar disorder SNED1 UTR-3 21423239 rs16843242 chr2 242031281 C T 1.26E-04 Insulin resistance SNED1 UTR-3 21901158 rs2240538 chr2 242035146 G T 8.90E-05 Lymphocyte counts MTERFD2 UTR-3 22286170 rs17382723 chr2 242053546 C G 3.00E-07 Height PASK UTR-3 23456168 rs2270044 chr2 242056924 T C 5.70E-04 Aortic root size PASK intron 21223598 rs141663644 chr2 242065754 C T 0.00048 Prostate cancer PASK missense 23555315 rs2058062 chr2 242068968 G A 4.00E-07 Urinary metabolites PASK intron 21572414 rs2240547 chr2 242069342 C T 9.40E-07 Urinary metabolites PASK intron 21572414 rs2120853 chr2 242080418 C T 0.000724019 Hypertension (early onset hypertension) PASK intron 22479346 rs758072 chr2 242083872 G T 9.79E-05 Alzheimer's disease (late onset) PASK intron 21379329 rs12052982 chr2 242111332 A G 4.21E-04 Alzheimer's disease (late onset) PPP1R7 intron 21379329 rs12052982 chr2 242111332 A G 0.000560685 Hypertension (early onset hypertension) PPP1R7 intron 22479346 rs6710177 chr2 242113054 A G 3.86E-05 Cognitive performance PPP1R7 intron 19734545 rs7562408 chr2 242113819 A G 0.000498847 Hypertension (early onset hypertension) PPP1R7 intron 22479346 rs1540528 chr2 242118686 C T 8.96E-05 Lung function (forced vital capacity) PPP1R7 intron pha003104 rs16843438 chr2 242137702 C T 3.44E-05 Cholesterol ANO7 intron 17255346 rs16843440 chr2 242138065 G A 8.55E-04 Multiple complex diseases ANO7 intron 17554300 rs2011792 chr2 242140427 C A 8.74E-04 Suicide attempts in bipolar disorder ANO7 intron 21423239 rs13028587 chr2 242141245 C A 8.83E-04 Suicide attempts in bipolar disorder ANO7 intron 21423239 rs7590653 chr2 242163359 G A 5.68E-04 Tourette syndrome ANO7 missense 22889924 rs7355565 chr2 242165048 T C 5.70E-04 Multiple complex diseases ANO7 nearGene-3 17554300 rs11674695 chr2 242165701 G A 7.95E-04 Multiple complex diseases / / 17554300 rs7578199 chr2 242192848 T C 1.15E-04 Tourette syndrome HDLBP missense 22889924 rs7578199 chr2 242192848 T C 5.39E-07 Chronic lymphocytic leukemia HDLBP missense 23770605 rs11693230 chr2 242212917 G A 0.0000631 Nonsyndromic striae distensae (stretch marks) HDLBP intron 23633020 rs6704615 chr2 242228733 G A 3.67E-04 Multiple complex diseases HDLBP intron 17554300 rs6752050 chr2 242228780 T C 1.20E-06 Fibrinogen HDLBP intron 20978265 rs11680983 chr2 242247994 T C 2.78E-04 Multiple complex diseases HDLBP intron 17554300 rs7599888 chr2 242248033 C G,T 3.48E-05 Multiple complex diseases HDLBP intron 17554300 rs7599888 chr2 242248033 C G,T 6.82E-05 Serum metabolites HDLBP intron 19043545 rs12694997 chr2 242262986 G A 1.00E-08 Height SEPT2 intron 20881960 rs12694997 chr2 242262986 G A 5.72E-04 Tourette syndrome SEPT2 intron 22889924 rs14351 chr2 242292378 G A,C,T 5.32E-04 Acute lung injury SEPT2 UTR-3 22295056 rs1476698 chr2 242296449 A G 9.33E-05 Coronary heart disease FARP2 intron 21971053 rs1476698 chr2 242296449 A G 2.00E-09 Fibrinogen FARP2 intron 23969696 rs11684105 chr2 242310174 T C 1.64E-04 Multiple complex diseases FARP2 intron 17554300 rs6761444 chr2 242321358 C T 1.42E-04 Multiple complex diseases FARP2 intron 17554300 rs3771561 chr2 242353704 G A 3.00E-04 Diabetic nephropathy FARP2 intron 19252134 rs757978 chr2 242371101 C T 2.00E-09 Chronic lymphocytic leukemia FARP2 missense 20062064 rs757978 chr2 242371101 C T 2.00E-09 Nasopharyngeal carcinoma FARP2 missense 20512145 rs757978 chr2 242371101 C T 3.00E-06 Chronic lymphocytic leukemia FARP2 missense 22700719 rs757978 chr2 242371101 C T 3.21E-06 Erectile dysfunction FARP2 missense 22704111 rs757978 chr2 242371101 C T 1.00E-07 Chronic lymphocytic leukemia FARP2 missense 23770605 rs757978 chr2 242371101 C T 3.47E-04 Chronic lymphocytic leukemia FARP2 missense 24292274 rs11679955 chr2 242382133 C T 2.43E-04 Multiple complex diseases FARP2 intron 17554300 rs3771570 chr2 242382864 C T 5.00E-09 Prostate cancer FARP2 intron 23535732 rs10192057 chr2 242387984 A G 2.86E-05 Multiple complex diseases FARP2 intron 17554300 rs10192057 chr2 242387984 A G 8.89E-05 Tourette syndrome FARP2 intron 22889924 rs2302013 chr2 242393658 A C 8.36E-04 Tourette syndrome FARP2 intron 22889924 rs17387035 chr2 242394003 T C 7.54E-04 Multiple complex diseases FARP2 intron 17554300 rs4675812 chr2 242395674 G A 2.51E-04 Coronary heart disease FARP2 intron 21971053 rs7597299 chr2 242398074 T C 6.31E-04 Multiple complex diseases FARP2 intron 17554300 rs62190407 chr2 242405772 G A 0.000713 Sarcoidosis FARP2 intron 22952805 rs10933558 chr2 242407478 A G 8.31E-04 Multiple complex diseases FARP2 intron 17554300 rs10933559 chr2 242407746 A G 8.50E-04 Multiple complex diseases FARP2 cds-synon 17554300 rs2240480 chr2 242408219 G A 9.49E-04 Acute lung injury FARP2 intron 22295056 rs2286277 chr2 242418362 C T 1.84E-04 Tourette syndrome FARP2 intron 22889924 rs740314 chr2 242418618 T C 8.12E-04 Acute lung injury FARP2 intron 22295056 rs13408032 chr2 242490658 C T 8.62E-04 Response to taxane treatment (placlitaxel) BOK-AS1 intron 23006423 rs12479254 chr2 242502956 C T 6.00E-07 Brain structure BOK intron 20171287 rs13004470 chr2 242511083 C T 0.0000469 Ankle-brachial index BOK intron 22361517 rs1106639 chr2 242690675 G A 0.00063 Breast cancer D2HGDH missense 23555315 rs4973677 chr2 242934578 C A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12478415 chr2 242976461 G A 8.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12468297 chr2 242996474 T C 0.0007183 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12468297 chr2 242996474 T C 7.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7573042 chr2 242996589 T C 0.0006979 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7573042 chr2 242996589 T C 6.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12719765 chr2 242997202 C G 0.0007936 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12719765 chr2 242997202 C G 7.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13412492 chr2 243000583 T G 0.0006474 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13412492 chr2 243000583 T G 6.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6746311 chr2 243001279 A G 0.0006438 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6746311 chr2 243001279 A G 6.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7421576 chr2 243007944 G A 0.0007322 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7421576 chr2 243007944 G A 7.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11899408 chr2 243014630 A G 9.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs749924 chr2 243026495 C T 1.00E-07 Coronary artery calcification / / 23870195 rs12478296 chr2 243048760 C T 8.00E-06 Obesity-related traits LOC728323 intron 23251661 rs9682794 chr3 70895 T C 1.16E-04 Scoliosis / / 21216876 rs6801472 chr3 73912 A G 6.17E-05 Scoliosis / / 21216876 rs1400174 chr3 77174 A G 6.17E-05 Scoliosis / / 21216876 rs2176251 chr3 94149 T G 8.08E-05 Scoliosis / / 21216876 rs17075507 chr3 94150 A G 8.08E-05 Scoliosis / / 21216876 rs6800996 chr3 96855 G C,T 8.62E-04 Type 2 diabetes / / 17463246 rs12487203 chr3 99083 A G 1.38E-04 Scoliosis / / 21216876 rs7630409 chr3 101192 T A 4.23E-05 Coronary heart disease / / 21606135 rs990284 chr3 104972 A G 8.20E-04 Coronary heart disease / / 21606135 rs17042708 chr3 108226 A G 6.20E-04 Alcohol dependence / / 20201924 rs6775203 chr3 108804 G A 6.70E-04 Scoliosis / / 21216876 rs9841287 chr3 108993 A G 7.00E-09 Fasting insulin-related traits (interaction with BMI) / / 22581228 rs9852028 chr3 113534 G T 5.79E-04 Scoliosis / / 21216876 rs954824 chr3 114133 T C 5.79E-04 Scoliosis / / 21216876 rs9867864 chr3 116498 G A 5.79E-04 Scoliosis / / 21216876 rs4685781 chr3 117152 C A 5.79E-04 Scoliosis / / 21216876 rs1568095 chr3 120220 G A 5.79E-04 Scoliosis / / 21216876 rs9861004 chr3 120401 G C 5.79E-04 Scoliosis / / 21216876 rs9311804 chr3 121226 C T 5.79E-04 Scoliosis / / 21216876 rs6778252 chr3 126158 C A 5.73E-05 Orofacial clefts / / 22419666 rs2138518 chr3 126456 T G 5.49E-04 Scoliosis / / 21216876 rs2176253 chr3 126629 C T 5.79E-04 Scoliosis / / 21216876 rs9865039 chr3 127804 C G 5.79E-04 Scoliosis / / 21216876 rs17047384 chr3 127933 C A 8.88E-05 Coronary heart disease / / 21606135 rs17047384 chr3 127933 C A 4.79E-05 Recombination rate / / 21698098 rs6443038 chr3 133412 G A 2.10E-04 Alcohol dependence / / 20201924 rs1516316 chr3 142131 C G 7.19E-04 Type 2 diabetes / / 17463246 rs1516316 chr3 142131 C G 6.07E-04 Scoliosis / / 21216876 rs1016162 chr3 143982 C T 5.70E-05 Scoliosis / / 21216876 rs9856879 chr3 148725 T C 2.01E-04 Alcohol dependence / / 20201924 rs17050452 chr3 149179 T G 7.45E-05 Scoliosis / / 21216876 rs12485321 chr3 149986 G A 3.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs7629216 chr3 152005 G T 2.48E-04 Coronary heart disease / / 21606135 rs9857814 chr3 152047 A G 7.24E-05 Coronary heart disease / / 21606135 rs6786696 chr3 152592 G A 1.52E-04 Coronary heart disease / / 21606135 rs11131185 chr3 157445 T C 2.51E-05 Scoliosis / / 21216876 rs1996305 chr3 158340 C T 2.70E-05 Scoliosis / / 21216876 rs1568087 chr3 160100 A G 2.51E-05 Scoliosis / / 21216876 rs1878169 chr3 165112 A T 2.92E-07 Scoliosis / / 21216876 rs9819101 chr3 166507 G A 2.92E-07 Scoliosis / / 21216876 rs965084 chr3 167098 G C 2.92E-07 Scoliosis / / 21216876 rs13070820 chr3 168827 T C 7.32E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1400182 chr3 170611 C G 1.81E-07 Scoliosis / / 21216876 rs1400181 chr3 170798 C G 1.44E-06 Scoliosis / / 21216876 rs1400180 chr3 170968 T G 7.91E-08 Scoliosis / / 21216876 rs6795349 chr3 172477 A G 2.00E-06 Response to antidepressant treatment / / 22041458 rs7639674 chr3 172520 A T 1.55E-07 Scoliosis / / 21216876 rs17326792 chr3 172756 A G 4.63E-07 Scoliosis / / 21216876 rs6790856 chr3 172808 C A 1.44E-06 Scoliosis / / 21216876 rs1516342 chr3 172906 G A 6.72E-04 Alzheimer's disease / / 17998437 rs1516342 chr3 172906 G A 4.23E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17326898 chr3 173374 T C 1.28E-06 Scoliosis / / 21216876 rs9310378 chr3 173714 G A 8.63E-04 Scoliosis / / 21216876 rs2102777 chr3 174816 A G 2.68E-05 Scoliosis / / 21216876 rs2386564 chr3 177882 A G 4.75E-04 Scoliosis / / 21216876 rs4684051 chr3 178525 A G 1.12E-07 Scoliosis / / 21216876 rs1568096 chr3 179950 A G 1.28E-06 Scoliosis / / 21216876 rs1568097 chr3 180151 T C 6.25E-07 Scoliosis / / 21216876 rs1588962 chr3 184035 T C 4.01E-07 Scoliosis / / 21216876 rs7619069 chr3 184365 T G 2.23E-04 Scoliosis / / 21216876 rs9878349 chr3 185281 C T 2.23E-04 Scoliosis / / 21216876 rs2048629 chr3 186790 C A 6.31E-04 Scoliosis / / 21216876 rs6780087 chr3 187697 A G 2.64E-04 Scoliosis / / 21216876 rs4684083 chr3 188865 T C 9.73E-06 Alzheimer's disease / / 17998437 rs17038327 chr3 190200 T A 2.19E-06 Scoliosis / / 21216876 rs9754850 chr3 190290 T C 3.01E-04 Scoliosis / / 21216876 rs9754552 chr3 190411 A G 3.01E-04 Scoliosis / / 21216876 rs10510181 chr3 191047 G A 8.00E-07 Adolescent idiopathic scoliosis / / 21216876 rs10510182 chr3 191914 G A 2.88E-05 Scoliosis / / 21216876 rs1516348 chr3 202034 T C 3.78E-04 Alzheimer's disease / / 17998437 rs6442427 chr3 211745 C T 2.00E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17262485 chr3 217541 G A 6.49E-04 Coronary Artery Disease / / 17634449 rs17262485 chr3 217541 G A 4.83E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9809528 chr3 250758 A G 2.39E-05 Femoral neck bone geometry CHL1 intron 22087292 rs11917787 chr3 253919 A G 9.00E-06 QT interval in Tripanosoma cruzi seropositivity CHL1 intron 24324551 rs459362 chr3 261442 A G 7.40E-05 Hypothyroidism CHL1 intron 22493691 rs11707773 chr3 262775 A T 6.70E-05 White matter hyperintensity burden CHL1 intron 21681796 rs11709854 chr3 268981 G C 2.60E-05 White matter hyperintensity burden CHL1 intron 21681796 rs17264626 chr3 272256 T C 9.93E-05 Type 2 diabetes CHL1 intron 17463246 rs17264828 chr3 277219 T C 7.50E-05 White matter hyperintensity burden CHL1 intron 21681796 rs13091217 chr3 277778 T C 2.88E-04 Type 2 diabetes CHL1 intron 17463246 rs13091420 chr3 277889 T C 6.45E-05 Type 2 diabetes CHL1 intron 17463246 rs17273893 chr3 309363 C T 4.31E-04 Common variable immunodeficiency CHL1 intron 21497890 rs17016845 chr3 309858 G A 4.78E-05 Acute lung injury CHL1 intron 22295056 rs17016917 chr3 310747 C T 8.94E-04 Acute lung injury CHL1 intron 22295056 rs17017010 chr3 311851 G T 1.22E-04 Acute lung injury CHL1 intron 22295056 rs6795631 chr3 312177 G A 9.58E-05 Pulmonary function CHL1 intron 19300500 rs6764363 chr3 312349 T C 6.00E-06 Sudden cardiac arrest CHL1 intron 21658281 rs9830226 chr3 318812 T C 4.70E-06 Urinary metabolites CHL1 intron 21572414 rs4541385 chr3 329970 G C 2.00E-05 Urinary metabolites CHL1 intron 21572414 rs17021268 chr3 336454 G C 7.99E-05 Brain derived neurotrophic factor levels,in serum CHL1 intron 22047184 rs11928134 chr3 353520 G T 4.69E-05 Multiple complex diseases CHL1 intron 17554300 rs144055818 chr3 367705 A G 0.000025 Breast cancer CHL1 missense 23555315 rs4685598 chr3 373693 A C 1.60E-05 Urinary metabolites CHL1 intron 21572414 rs12494297 chr3 377792 C T 8.65E-04 Multiple complex diseases CHL1 intron 17554300 rs892295 chr3 397553 A G 1.00E-06 Obesity-related traits CHL1 intron 23251661 rs892295 chr3 397553 A G 4.00E-06 Obesity-related traits CHL1 intron 23251661 rs12637802 chr3 409221 C G 1.54E-04 Blood pressure CHL1 intron 17255346 rs3773383 chr3 416943 G A 7.44E-05 Cognitive decline CHL1 intron 23732972 rs3773379 chr3 418585 A G 2.10E-05 Urinary metabolites CHL1 intron 21572414 rs4685668 chr3 430682 T C 3.84E-04 Hearing function CHL1 intron 17255346 rs1065035 chr3 448979 A T 2.25E-04 Hearing function CHL1 UTR-3 17255346 rs1065035 chr3 448979 A T 2.02E-04 Alzheimer's disease CHL1 UTR-3 17998437 rs9819810 chr3 454777 C T 8.26E-05 Cognitive impairment induced by topiramate / / 22091778 rs6788648 chr3 457164 C T 7.57E-05 Cognitive impairment induced by topiramate / / 22091778 rs6805861 chr3 465476 T C 1.22E-04 Multiple complex diseases / / 17554300 rs6442890 chr3 527223 A G 9.08E-05 Diabetic nephropathy / / pha002852 rs1865160 chr3 535673 C T 9.44E-06 Glycemic traits (pregnancy) / / 23903356 rs9837987 chr3 598777 C T 6.71E-04 Multiple complex diseases / / 17554300 rs2729207 chr3 604868 T A,C 1.30E-04 Multiple complex diseases / / 17554300 rs9848984 chr3 668914 T C 0.0000352 Colorectal cancer vs. adenoma controls / / 22532847 rs1484543 chr3 671006 G C 2.65E-04 Multiple complex diseases / / 17554300 rs9846843 chr3 674171 A G 3.82E-04 Multiple complex diseases / / 17554300 rs1905605 chr3 703725 T C 7.04E-04 Aortic root size / / 21223598 rs2627963 chr3 724380 A G 7.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs2627943 chr3 732778 T C 5.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs2729166 chr3 733281 A T 7.87E-05 Multiple complex diseases / / 17554300 rs2729093 chr3 776321 T C 5.22E-04 Type 2 diabetes / / 17463246 rs17047538 chr3 800606 A G 8.54E-05 Neuroblastoma / / pha002895 rs11714239 chr3 809720 G T 4.10E-05 Neuroblastoma / / pha002895 rs11131099 chr3 848802 C A 2.22E-04 Alzheimer's disease (late onset) / / 20885792 rs2177444 chr3 877011 G T 3.70E-05 Response to statin therapy / / 20339536 rs1568748 chr3 877235 A G 4.00E-05 Response to statin therapy / / 20339536 rs13066217 chr3 877912 C T 3.50E-05 Response to statin therapy / / 20339536 rs13066227 chr3 877925 C A 3.60E-05 Response to statin therapy / / 20339536 rs12494851 chr3 878192 A G 3.60E-05 Response to statin therapy / / 20339536 rs13084891 chr3 878370 T C 3.30E-05 Response to statin therapy / / 20339536 rs12495737 chr3 878511 T C 4.00E-05 Response to statin therapy / / 20339536 rs17048862 chr3 878547 T C 4.00E-05 Response to statin therapy / / 20339536 rs4684585 chr3 883851 G A 9.00E-07 Response to statin therapy / / 20339536 rs6764632 chr3 887059 C T 3.50E-05 Response to statin therapy / / 20339536 rs4686247 chr3 892951 C A 2.30E-06 Response to statin therapy / / 20339536 rs7619975 chr3 894729 C T 7.20E-05 Response to statin therapy / / 20339536 rs35964523 chr3 898661 C T 8.00E-06 Response to statin therapy / / 20339536 rs11131168 chr3 998513 G A 9.87E-05 Neuroblastoma / / pha002895 rs6803398 chr3 1007443 A G 6.18E-04 Multiple complex diseases / / 17554300 rs11927325 chr3 1015397 A G 5.45E-04 Multiple complex diseases / / 17554300 rs4390915 chr3 1018544 C T 8.67E-05 Coronary Artery Disease / / 17634449 rs4367044 chr3 1029987 C G 3.12E-04 Coronary Artery Disease / / 17634449 rs6443262 chr3 1040562 A T 7.98E-04 Coronary Artery Disease / / 17634449 rs6764623 chr3 1046038 A C 2.00E-06 Venous thromboembolism / / 23650146 rs10212227 chr3 1090485 G A 0.0000022 Amygdala reactivity / / 22856363 rs1504058 chr3 1090602 A G 3.10E-05 Response to statin therapy / / 20339536 rs11719195 chr3 1122000 C A 4.01E-05 Glucose levels / / pha003061 rs2313543 chr3 1122369 A G 5.84E-04 Iron levels / / pha002876 rs2729130 chr3 1125605 A G 7.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs76090503 chr3 1129819 G A 4.00E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs6442221 chr3 1171860 G A 7.90E-04 Type 2 diabetes and 6 quantitative traits CNTN6 intron 17848626 rs13326242 chr3 1187861 C T 2.93E-05 Orofacial clefts CNTN6 intron 22419666 rs9823028 chr3 1190111 G A 1.30E-06 Carotid intima media thickness CNTN6 intron 21909108 rs7625601 chr3 1191340 C G 2.61E-04 IgE levels CNTN6 intron 17255346 rs17034364 chr3 1191638 A C 2.10E-04 IgE levels CNTN6 intron 17255346 rs1846466 chr3 1192829 T G 1.87E-04 IgE levels CNTN6 intron 17255346 rs3772371 chr3 1204591 A C 0.0000232 Tuberculosis with late age of onset CNTN6 intron 22551897 rs6806307 chr3 1222180 G A 2.61E-04 IgE levels CNTN6 intron 17255346 rs1499097 chr3 1227382 G A 2.10E-05 Urinary metabolites CNTN6 intron 21572414 rs1353821 chr3 1238287 T C 2.21E-05 Cognitive impairment induced by topiramate CNTN6 intron 22091778 rs9850313 chr3 1255731 G C 3.55E-04 Multiple complex diseases CNTN6 intron 17554300 rs7644569 chr3 1257668 C T 6.03E-05 Multiple sclerosis (age of onset) CNTN6 intron 19010793 rs9844484 chr3 1272373 T C 5.84E-04 Multiple complex diseases CNTN6 intron 17554300 rs9844484 chr3 1272373 T C 8.02E-05 Blood Pressure CNTN6 intron pha003046 rs11925058 chr3 1276092 A C 8.94E-04 Amyotrophic Lateral Sclerosis CNTN6 intron 17362836 rs3902530 chr3 1299185 A G 4.31E-06 PR interval in Tripanosoma cruzi seropositivity CNTN6 intron 24324551 rs9815195 chr3 1301130 C A 7.00E-07 PR interval in Tripanosoma cruzi seropositivity CNTN6 intron 24324551 rs9834544 chr3 1301197 A G 7.03E-06 PR interval in Tripanosoma cruzi seropositivity CNTN6 intron 24324551 rs3872629 chr3 1304868 A C 5.29E-06 PR interval in Tripanosoma cruzi seropositivity CNTN6 intron 24324551 rs17036851 chr3 1305415 G A 5.90E-04 Nicotine dependence CNTN6 intron 17407593 rs6766488 chr3 1312979 C T 9.20E-06 Urinary metabolites CNTN6 intron 21572414 rs3772325 chr3 1313419 C G 5.47E-04 Response to cytidine analogues (gemcitabine) CNTN6 intron 24483146 rs3772324 chr3 1313477 C T 7.26E-04 Response to cytidine analogues (gemcitabine) CNTN6 intron 24483146 rs10510189 chr3 1316884 A G 8.65E-04 Myocardial Infarction CNTN6 intron pha002883 rs6442316 chr3 1319698 T C 9.49E-04 Response to cytidine analogues (gemcitabine) CNTN6 intron 24483146 rs6442316 chr3 1319698 T C 1.14E-05 Magnesium levels CNTN6 intron pha003092 rs7638616 chr3 1321018 C T 9.13E-05 Myocardial Infarction CNTN6 intron pha002883 rs17037155 chr3 1327426 C G 5.84E-07 Multiple complex diseases CNTN6 intron 17554300 rs17271519 chr3 1336397 A G 2.72E-04 Height CNTN6 intron 17255346 rs9861887 chr3 1345425 C T 9.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio CNTN6 intron 22589738 rs4684880 chr3 1348362 T C 2.53E-04 Smoking initiation CNTN6 intron 24665060 rs155230 chr3 1357380 G A 9.39E-04 Myopia (pathological) CNTN6 intron 21095009 rs10510170 chr3 1374976 A G 5.00E-06 Alcohol dependence CNTN6 intron 21956439 rs155403 chr3 1377266 G A 9.41E-05 Gallstones CNTN6 intron 17632509 rs155399 chr3 1386467 T C 5.50E-04 Rheumatoid arthritis CNTN6 intron 22446963 rs17038032 chr3 1389117 C T 8.11E-04 Alcohol dependence CNTN6 intron 21314694 rs7653048 chr3 1396176 T C 5.11E-05 Bone mineral density CNTN6 intron 19181680 rs1499215 chr3 1397069 T C 9.82E-04 Type 2 diabetes CNTN6 intron 17463246 rs1479530 chr3 1400419 C G 4.07E-04 Type 2 diabetes CNTN6 intron 17463246 rs13063912 chr3 1408344 C T 6.32E-04 Multiple complex diseases CNTN6 intron 17554300 rs429922 chr3 1408503 A G 2.10E-05 Urinary metabolites CNTN6 intron 21572414 rs155390 chr3 1421673 C A 1.76E-05 Type 1 diabetes CNTN6 intron 18978792 rs155390 chr3 1421673 C A 2.48E-05 Bipolar disorder (mania) CNTN6 intron 23326512 rs3772274 chr3 1421885 G A 2.50E-07 Urinary metabolites CNTN6 intron 21572414 rs155391 chr3 1421900 G A 2.30E-05 Urinary metabolites CNTN6 intron 21572414 rs155391 chr3 1421900 G A 2.44E-05 Bipolar disorder (mania) CNTN6 intron 23326512 rs2291101 chr3 1424718 G A 2.00E-05 Urinary metabolites CNTN6 cds-synon 21572414 rs2291101 chr3 1424718 G A 6.14E-04 Response to cytidine analogues (gemcitabine) CNTN6 cds-synon 24483146 rs4684146 chr3 1424745 C T 3.82E-04 Multiple complex diseases CNTN6 cds-synon 17554300 rs2291100 chr3 1424850 T G 5.47E-06 Bipolar disorder (mania) CNTN6 cds-synon 23326512 rs3845158 chr3 1425506 G A 1.20E-06 Urinary metabolites CNTN6 intron 21572414 rs1532552 chr3 1462739 T C 5.82E-04 Multiple complex diseases / / 17554300 rs2167471 chr3 1469092 C T 5.35E-04 Multiple complex diseases / / 17554300 rs1037386 chr3 1478453 T C 3.00E-06 Type 2 diabetes / / 17293876 rs1037386 chr3 1478453 T C 3.00E-06 Type 2 diabetes / / 19184112 rs12488675 chr3 1492235 G T 9.57E-06 Post-operative nausea and vomiting / / 21694509 rs17039471 chr3 1494264 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12489351 chr3 1495993 T G 2.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17039498 chr3 1496493 A G 1.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17786098 chr3 1496821 T C 7.10E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17193526 chr3 1500657 T G 4.90E-05 Post-operative nausea and vomiting / / 21694509 rs11919047 chr3 1510310 C A 2.77E-04 Coronary heart disease / / 21971053 rs6799147 chr3 1510822 G A 1.54E-04 Coronary heart disease / / 21971053 rs9856251 chr3 1511108 A G 1.42E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6763848 chr3 1512587 C A 4.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs6795018 chr3 1515094 G A 5.39E-04 Coronary heart disease / / 21971053 rs6786404 chr3 1515274 A G 7.34E-04 Coronary heart disease / / 21971053 rs10212138 chr3 1517822 A G 9.06E-04 Coronary heart disease / / 21971053 rs12107552 chr3 1529992 T C 2.06E-04 Alzheimer's disease / / 17998437 rs7613331 chr3 1533549 T A 1.14E-06 Asthma (childhood onset) / / 23829686 rs9876109 chr3 1550301 A G 6.27E-06 Non-obstructive azoospermia / / 22541561 rs12487870 chr3 1551708 G A 3.85E-05 Major depressive disorder / / pha002850 rs11128726 chr3 1557413 G A 3.61E-04 Alzheimer's disease (late onset) / / 21379329 rs17193610 chr3 1563944 T G 7.77E-04 Multiple complex diseases / / 17554300 rs17193610 chr3 1563944 T G 9.33E-04 Alzheimer's disease / / 17998437 rs17193610 chr3 1563944 T G 9.30E-06 Urinary metabolites / / 21572414 rs9829889 chr3 1565113 T C 3.91E-04 Multiple complex diseases / / 17554300 rs9829889 chr3 1565113 T C 8.63E-05 Lung cancer / / 18978787 rs9829889 chr3 1565113 T C 9.30E-06 Urinary metabolites / / 21572414 rs400048 chr3 1587860 T C 8.10E-05 Major depressive disorder / / 21621269 rs443052 chr3 1588919 G A 2.20E-05 Urinary metabolites / / 21572414 rs450994 chr3 1589120 G T 1.90E-05 Urinary metabolites / / 21572414 rs11712183 chr3 1597057 T C 6.06E-05 Major depressive disorder / / pha002850 rs403961 chr3 1600422 A G 3.08E-04 Height / / 17255346 rs437161 chr3 1620644 C G 7.90E-04 Testosterone levels / / 22675492 rs402675 chr3 1623393 T A 6.00E-06 Estradiol levels / / 22675492 rs13320862 chr3 1631265 G A 6.35E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs4684256 chr3 1632353 C T 1.00E-07 Systemic lupus erythematosus / / 24871463 rs9310485 chr3 1641389 A G 4.36E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs417975 chr3 1655984 T C 2.09E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs4143127 chr3 1670301 T C 8.60E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs4524263 chr3 1673354 G A 4.60E-05 Receptive language ability / / 24687471 rs7645123 chr3 1704667 C T 1.81E-05 Triglycerides / / pha003080 rs1316461 chr3 1710334 G A 9.65E-06 Metabolite levels (MHPG) / / 23319000 rs6798827 chr3 1716268 G A 8.51E-04 Acne (severe) / / 24927181 rs6442607 chr3 1718156 C T 3.02E-06 Response to amphetamines / / 22952603 rs9815216 chr3 1720667 G A 4.11E-06 Response to amphetamines / / 22952603 rs9854279 chr3 1720834 C G 4.12E-06 Response to amphetamines / / 22952603 rs6798098 chr3 1721618 G A 8.72E-06 Response to amphetamines / / 22952603 rs13084459 chr3 1723221 C G 3.42E-06 Response to amphetamines / / 22952603 rs11128802 chr3 1723272 G A 3.17E-06 Response to amphetamines / / 22952603 rs113043097 chr3 1723661 A G 4.94E-06 Response to amphetamines / / 22952603 rs111902843 chr3 1724225 G C 3.19E-06 Response to amphetamines / / 22952603 rs6800665 chr3 1725469 A G 3.11E-06 Response to amphetamines / / 22952603 rs9831634 chr3 1731173 T C 8.05E-06 Response to amphetamines / / 22952603 rs4376023 chr3 1731450 G A 9.95E-06 Response to amphetamines / / 22952603 rs4557143 chr3 1734749 C G 1.58E-06 Response to amphetamines / / 22952603 rs73001814 chr3 1738844 G A 1.79E-06 Response to amphetamines / / 22952603 rs73001827 chr3 1741765 G C 1.00E-06 Response to amphetamines / / 22952603 rs73001862 chr3 1754948 T A 1.28E-06 Response to amphetamines / / 22952603 rs6804104 chr3 1756711 A G 2.01E-06 Response to amphetamines / / 22952603 rs73013208 chr3 1762743 C A 7.12E-06 Response to amphetamines / / 22952603 rs9848738 chr3 1775892 A T 7.55E-04 Multiple complex diseases / / 17554300 rs17029209 chr3 1781625 T C 6.21E-05 Alcohol withdrawal symptoms / / 22072270 rs4594600 chr3 1791072 C G 7.48E-04 Type 2 diabetes / / 17463246 rs12633977 chr3 1808553 C T 5.62E-06 Triglycerides / / pha003080 rs9848095 chr3 1814351 C A 3.20E-05 Cognitive impairment induced by topiramate / / 22091778 rs9883145 chr3 1816980 T C 6.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7624354 chr3 1818056 C T 3.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9875417 chr3 1819843 C T 3.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4603939 chr3 1826067 A G 5.46E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9832637 chr3 1826892 T C 5.46E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11128846 chr3 1827768 C T 4.18E-05 Glaucoma (primary open-angle) / / 22605921 rs9310530 chr3 1827967 C T 8.93E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10510216 chr3 1834534 G A 6.05E-05 Cognitive test performance / / 20125193 rs10510217 chr3 1839693 G A 7.70E-05 Multiple complex diseases / / 17554300 rs10510217 chr3 1839693 G A 3.00E-06 Total ventricular volume / / 21116278 rs11927576 chr3 1839723 T C 6.19E-05 Serum metabolites / / 19043545 rs6809401 chr3 1843129 C T 1.68E-04 Amyotrophic lateral sclerosis / / 20801718 rs4234543 chr3 1854320 T C 1.23E-05 Serum metabolites / / 19043545 rs12106926 chr3 1854867 T G 2.95E-05 Waist-Hip Ratio / / pha003013 rs12106926 chr3 1854867 T G 9.24E-05 Waist-Hip Ratio / / pha003028 rs7648375 chr3 1861769 T C 7.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9838423 chr3 1865505 G A 4.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7621478 chr3 1882958 T A 2.46E-04 Multiple complex diseases / / 17554300 rs7625240 chr3 1884889 A G 7.87E-04 Coronary heart disease / / 21971053 rs2727943 chr3 1897973 T C 3.00E-08 Bipolar disorder / / 22205951 rs9878659 chr3 1908074 G A 1.10E-04 Bipolar disorder / / 17486107 rs17044559 chr3 1912443 A G 6.61E-05 Triglycerides / / pha003081 rs7631764 chr3 1913585 G T 5.07E-05 Triglycerides / / pha003081 rs13097461 chr3 1926105 G A 3.23E-04 Type 2 diabetes / / 17463246 rs11713534 chr3 1929666 T C 3.78E-04 Multiple complex diseases / / 17554300 rs6800691 chr3 1931258 A C 9.72E-06 Kawasaki disease / / 22446961 rs4424753 chr3 1938484 A T 8.64E-04 Multiple complex diseases / / 17554300 rs7431184 chr3 1947477 T C 3.47E-05 Multiple complex diseases / / 17554300 rs6783551 chr3 1985238 T C 3.64E-04 Alcohol dependence / / 24277619 rs6763575 chr3 1996786 G A 9.93E-04 Coronary heart disease / / 21971053 rs1488745 chr3 2001802 G T 2.72E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs116110883 chr3 2002783 T C 9.46E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs11128917 chr3 2007438 C A 7.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs1387092 chr3 2011341 T C 7.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs2729313 chr3 2034355 C T 8.00E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs2727952 chr3 2038356 C A 9.79E-04 Multiple complex diseases / / 17554300 rs2600056 chr3 2044132 A T 5.34E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6793275 chr3 2053707 T G 1.61E-04 Multiple complex diseases / / 17554300 rs17786584 chr3 2057749 T C 2.81E-04 Multiple complex diseases / / 17554300 rs4593008 chr3 2059893 T G 1.26E-04 Multiple complex diseases / / 17554300 rs2729317 chr3 2063776 T C 1.39E-04 Smoking quantity / / 24665060 rs4434131 chr3 2078499 T C 9.59E-04 Multiple complex diseases / / 17554300 rs6767146 chr3 2080561 G T 5.11E-04 Aortic root size / / 21223598 rs4685480 chr3 2088751 T C 5.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs9826632 chr3 2120011 A T 3.60E-06 Urinary metabolites / / 21572414 rs2729277 chr3 2128834 A G 1.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4129976 chr3 2169803 T C 1.00E-05 Urinary metabolites CNTN4 intron 21572414 rs4129976 chr3 2169803 T C 0.00000712 Panic disorder CNTN4 intron 23149450 rs4129976 chr3 2169803 T C 7.12E-06 Serum tamsulosin hydrochloride concentration CNTN4 intron 23151678 rs2729017 chr3 2194392 C A,T 0.0000343 Panic disorder CNTN4 intron 23149450 rs2729017 chr3 2194392 C A,T 3.43E-05 Serum tamsulosin hydrochloride concentration CNTN4 intron 23151678 rs2727925 chr3 2195364 C T 4.08E-05 IgE levels CNTN4 intron 17255346 rs9849406 chr3 2198715 C T 4.81E-04 Insulin resistance CNTN4 intron 21901158 rs17194161 chr3 2206173 A G 1.22E-04 Insulin resistance CNTN4 intron 21901158 rs2727927 chr3 2206373 G A 1.93E-04 IgE levels CNTN4 intron 17255346 rs2728524 chr3 2212318 A G 2.61E-04 Multiple complex diseases CNTN4 intron 17554300 rs7613165 chr3 2223722 T C 2.02E-04 Response to taxane treatment (placlitaxel) CNTN4 intron 23006423 rs17009194 chr3 2227373 G A 8.69E-04 Response to taxane treatment (placlitaxel) CNTN4 intron 23006423 rs9968167 chr3 2229166 C T 8.60E-05 Hypothyroidism CNTN4 intron 22493691 rs9968229 chr3 2229445 T C 4.85E-05 Multiple complex diseases CNTN4 intron 17554300 rs13324989 chr3 2230964 G A 3.25E-04 Response to taxane treatment (placlitaxel) CNTN4 intron 23006423 rs7641285 chr3 2247857 C T 9.22E-04 Bone mineral density CNTN4 intron 19181680 rs12633359 chr3 2263432 A G 2.00E-05 Urinary metabolites CNTN4 intron 21572414 rs7613221 chr3 2270812 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CNTN4 intron 22628534 rs1153495 chr3 2310591 A T 8.14E-04 Response to TNF antagonist treatment CNTN4 intron 21061259 rs1014805 chr3 2335471 A G 8.49E-05 Blood Pressure CNTN4 intron pha003047 rs1145050 chr3 2354512 T C 8.26E-05 Cognitive performance CNTN4 intron 19734545 rs4684343 chr3 2391098 G A 1.80E-04 Lipid traits CNTN4 intron 17903299 rs11129117 chr3 2395843 A T 1.29E-05 Personality dimensions CNTN4 intron 22628180 rs6785626 chr3 2400967 A G 1.70E-05 Personality dimensions CNTN4 intron 22628180 rs9862494 chr3 2402673 T C 1.10E-05 Celiac disease CNTN4 intron 17558408 rs6792956 chr3 2412847 T C 1.55E-04 Nicotine smoking CNTN4 intron 19268276 rs13064317 chr3 2413859 A G 1.09E-06 Response to tocilizumab in rheumatoid arthritis CNTN4 intron 22491018 rs17013514 chr3 2421975 A G 6.59E-06 Bipolar disorder,affective CNTN4 intron 20528957 rs17013524 chr3 2423127 T G 1.51E-05 Vitiligo CNTN4 intron 22951725 rs17013524 chr3 2423127 T G 8.59E-06 Smooth-surface caries CNTN4 intron 24556642 rs1393484 chr3 2429767 T C 4.85E-05 Cognitive test performance CNTN4 intron 20125193 rs13068208 chr3 2435741 C T 3.99E-05 Cognitive test performance CNTN4 intron 20125193 rs2653492 chr3 2480438 A G 3.32E-05 Smoking initiation CNTN4 intron 24665060 rs11129148 chr3 2486763 C T 4.00E-06 Urinary metabolites CNTN4 intron 21572414 rs2221294 chr3 2487197 A G 5.25E-05 Serum metabolites CNTN4 intron 19043545 rs2174018 chr3 2487697 A G 7.62E-04 Type 2 diabetes CNTN4 intron 17463246 rs1551997 chr3 2534772 G A 1.40E-05 Urinary metabolites CNTN4 intron 21572414 rs17620999 chr3 2561556 A G 2.11E-05 Renal cell carcinoma CNTN4 intron 23184150 rs6793017 chr3 2579127 A G 6.60E-04 Suicidal ideation CNTN4 intron 22030708 rs899540 chr3 2609580 C G 3.43E-04 Multiple complex diseases CNTN4 intron 17554300 rs899540 chr3 2609580 C G 2.15E-04 Smoking initiation CNTN4 intron 24665060 rs11707897 chr3 2614626 T C 0.0000278 Nicotine dependence (smoking) CNTN4 intron 22377092 rs11707897 chr3 2614626 T C 0.0000241 Alcohol craving with or without dependence CNTN4 intron 22481050 rs11707897 chr3 2614626 T C 3.11E-05 Alcohol consumption CNTN4 intron 23953852 rs2728055 chr3 2616290 C T 1.70E-04 Alcohol dependence CNTN4 intron 20201924 rs1466459 chr3 2621687 A G 8.62E-04 Multiple complex diseases CNTN4 intron 17554300 rs2619566 chr3 2624938 G A 4.26E-05 Hirschsprung's disease CNTN4 intron 19196962 rs2619566 chr3 2624938 G A 7.00E-06 Amyotrophic lateral sclerosis CNTN4 intron 19451621 rs1479540 chr3 2629477 A G 1.74E-04 Nicotine smoking CNTN4 intron 19268276 rs1020997 chr3 2653577 C T 3.37E-04 Common variable immunodeficiency CNTN4 intron 21497890 rs4370013 chr3 2654691 A T 4.00E-06 Blood pressure CNTN4 intron 17903302 rs2600318 chr3 2670624 G A 3.85E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CNTN4 intron 24023788 rs9849237 chr3 2675189 C T 5.11E-04 Oral cancers (chewing tobacco related) CNTN4 intron 22503698 rs1600359 chr3 2690405 G A 9.44E-05 Height CNTN4 intron pha003010 rs6442743 chr3 2701863 G T 1.71E-04 Schizophrenia CNTN4 intron 19197363 rs6442743 chr3 2701863 G T 9.86E-05 Body Mass Index CNTN4 intron pha003019 rs6442743 chr3 2701863 G T 5.45E-05 Body Mass Index CNTN4 intron pha003022 rs2600274 chr3 2716743 G A 8.22E-04 Schizophrenia CNTN4 intron 19197363 rs2600274 chr3 2716743 G A 9.63E-06 Glucose levels CNTN4 intron pha003057 rs1914011 chr3 2717559 A C 7.54E-04 Insulin resistance CNTN4 intron 21901158 rs2675307 chr3 2725060 T C 6.45E-04 Schizophrenia CNTN4 intron 19197363 rs1516390 chr3 2728391 A G 9.52E-05 Alzheimer's disease CNTN4 intron 17998437 rs7646667 chr3 2731319 C T 2.77E-04 Schizophrenia CNTN4 intron 19197363 rs2675304 chr3 2733172 C T 6.66E-04 Myopia (pathological) CNTN4 intron 21095009 rs2728024 chr3 2735354 G A 7.98E-04 Myopia (pathological) CNTN4 intron 21095009 rs1949344 chr3 2738520 G A 7.50E-06 Urinary metabolites CNTN4 intron 21572414 rs7652776 chr3 2741024 G A,C 3.19E-04 Type 2 diabetes CNTN4 intron 17463246 rs7652776 chr3 2741024 G A,C 6.19E-04 Alzheimer's disease CNTN4 intron 17998437 rs7635049 chr3 2743571 A G 1.48E-04 Type 2 diabetes CNTN4 intron 17463246 rs7623658 chr3 2743593 C G 1.32E-04 Type 2 diabetes CNTN4 intron 17463246 rs7645216 chr3 2743688 G A 1.20E-04 Type 2 diabetes CNTN4 intron 17463246 rs2600294 chr3 2752024 G C 6.37E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs9837487 chr3 2753872 T C 9.21E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs9852788 chr3 2756368 T G 5.65E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs13324651 chr3 2756816 G A 1.98E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs11714965 chr3 2757213 A C 1.98E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs9845036 chr3 2759106 C A 4.23E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs9868328 chr3 2759118 T G 2.43E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs11129249 chr3 2759551 T C 9.53E-05 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs9310831 chr3 2760139 C G 1.47E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs9310832 chr3 2760177 A G 1.64E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs9832509 chr3 2760298 G C 1.66E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs13077493 chr3 2761667 T G 9.15E-05 Platelet counts CNTN4 intron pha003100 rs2675283 chr3 2761728 T G 1.34E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs7434142 chr3 2763405 C T 1.80E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs17019466 chr3 2770509 G A 4.00E-04 Response to taxane treatment (placlitaxel) CNTN4 intron 23006423 rs11129265 chr3 2772862 A G 1.91E-04 Alzheimer's disease CNTN4 intron 22005930 rs2320957 chr3 2780675 T C 7.40E-05 Lung adenocarcinoma CNTN4 intron 19836008 rs9880202 chr3 2782210 T C 5.26E-04 Multiple complex diseases CNTN4 intron 17554300 rs3897737 chr3 2796414 G A 8.04E-04 Tourette syndrome CNTN4 intron 22889924 rs3897737 chr3 2796414 G A 1.06E-05 Prostate cancer CNTN4 intron 22923026 rs12494784 chr3 2799942 A C 2.04E-04 Tourette syndrome CNTN4 intron 22889924 rs2320960 chr3 2802443 G C 7.34E-04 Suicide attempts in bipolar disorder CNTN4 intron 21423239 rs11129291 chr3 2812755 C G 4.06E-04 IgE levels CNTN4 intron 17255346 rs3935671 chr3 2815150 C T 8.76E-05 IgE levels CNTN4 intron 17255346 rs3935673 chr3 2815263 C T 5.07E-05 IgE levels CNTN4 intron 17255346 rs955340 chr3 2821345 C T 7.35E-05 IgE levels CNTN4 intron 17255346 rs7652782 chr3 2821616 G A 7.00E-07 Serum uric acid levels CNTN4 intron 24379826 rs6786387 chr3 2822150 C A 1.77E-04 IgE levels CNTN4 intron 17255346 rs6786387 chr3 2822150 C A 7.60E-07 Serum uric acid levels CNTN4 intron 24379826 rs954882 chr3 2826545 G A 7.67E-04 Alzheimer's disease CNTN4 intron 17998437 rs954882 chr3 2826545 G A 2.70E-05 Urinary metabolites CNTN4 intron 21572414 rs7636727 chr3 2830717 G A 8.10E-06 Urinary metabolites CNTN4 intron 21572414 rs2728090 chr3 2831511 A G 2.45E-04 Type 2 diabetes CNTN4 intron 17463246 rs41521446 chr3 2833324 C G 5.22E-05 Response to metformin CNTN4 intron 21186350 rs9847255 chr3 2835174 C T 5.16E-04 Type 2 diabetes CNTN4 intron 17463246 rs7635582 chr3 2835473 G C 6.29E-04 Type 2 diabetes CNTN4 intron 17463246 rs7628425 chr3 2836270 A G 3.20E-06 Urinary metabolites CNTN4 intron 21572414 rs1400211 chr3 2842906 G A 8.51E-04 HIV-1 viral setpoint CNTN4 intron 17641165 rs2728089 chr3 2845843 T C 2.60E-04 Amyotrophic Lateral Sclerosis CNTN4 intron 17362836 rs2728089 chr3 2845843 T C 9.61E-04 HIV-1 viral setpoint CNTN4 intron 17641165 rs975334 chr3 2846316 G A 9.00E-07 Gallbladder cancer CNTN4 intron 22318345 rs4685564 chr3 2851955 G T 6.98E-04 Coronary heart disease CNTN4 intron 21606135 rs9841434 chr3 2854988 T C 4.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CNTN4 intron 20877124 rs9861814 chr3 2878116 C T 7.29E-04 Multiple complex diseases CNTN4 intron 17554300 rs7642309 chr3 2880210 T C 5.90E-05 Personality dimensions CNTN4 intron 18957941 rs6781149 chr3 2881575 A G 1.00E-07 Intelligence CNTN4 intron 22449649 rs17021399 chr3 2893696 A G 2.48E-05 Type 2 diabetes CNTN4 intron 17463246 rs11713158 chr3 2895684 T C 9.00E-07 Intelligence CNTN4 intron 22449649 rs7636197 chr3 2901065 G A 7.54E-04 Type 2 diabetes CNTN4 intron 17463246 rs7636197 chr3 2901065 G A 3.43E-04 Response to taxane treatment (placlitaxel) CNTN4 intron 23006423 rs17584923 chr3 2902492 A G 2.09E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CNTN4 intron 22566498 rs13324783 chr3 2902809 G C 1.06E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CNTN4 intron 22566498 rs17021457 chr3 2902945 T C 2.66E-05 Bipolar disorder and schizophrenia CNTN4 intron 20889312 rs9872038 chr3 2903408 G T 1.80E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CNTN4 intron 22566498 rs9872038 chr3 2903408 G T 8.10E-05 Erythrocyte counts CNTN4 intron pha003099 rs7631834 chr3 2904908 G A 2.84E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CNTN4 intron 22566498 rs9869344 chr3 2905353 T C 2.92E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CNTN4 intron 22566498 rs7639356 chr3 2909402 T A 2.33E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CNTN4 intron 22566498 rs12494869 chr3 2910980 A G 2.30E-04 Multiple complex diseases CNTN4 intron 17554300 rs4608676 chr3 2912864 C T 4.47E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CNTN4 intron 24023788 rs7611373 chr3 2917437 G A 2.64E-05 Alcohol consumption CNTN4 intron 23743675 rs9882169 chr3 2917622 C G 2.03E-05 Bipolar disorder CNTN4 intron 22925353 rs7641289 chr3 2921404 A G 4.79E-04 Coronary heart disease CNTN4 intron 21971053 rs17646346 chr3 2925030 A G 6.62E-05 Intelligence CNTN4 intron 21826061 rs17022006 chr3 2938734 G A 1.38E-04 Nicotine smoking CNTN4 intron 19268276 rs17586876 chr3 2964182 A G 1.56E-05 Systolic blood pressure in sickle cell anemia CNTN4 intron 24058526 rs17586876 chr3 2964182 A G 2.00E-06 Serum uric acid levels CNTN4 intron 24379826 rs6786174 chr3 2982630 T G 1.20E-06 Serum uric acid levels CNTN4 intron 24379826 rs427502 chr3 2999019 C T 2.71E-04 Multiple complex diseases CNTN4 intron 17554300 rs751056 chr3 3000908 A G 9.92E-05 Panic disorder CNTN4 intron 19165232 rs751056 chr3 3000908 A G 0.0000527 Panic disorder CNTN4 intron 23149450 rs751056 chr3 3000908 A G 5.27E-05 Serum tamsulosin hydrochloride concentration CNTN4 intron 23151678 rs13079652 chr3 3002447 G A 2.30E-05 Urinary metabolites CNTN4 intron 21572414 rs12715157 chr3 3006381 T C 1.21E-05 HDL cholesterol CNTN4 intron pha003075 rs12715157 chr3 3006381 T C 7.77E-05 Lipid levels CNTN4 intron pha003082 rs10510243 chr3 3006444 A G 2.94E-05 Blood Pressure CNTN4 intron pha003049 rs17595878 chr3 3027090 G A 8.84E-04 Multiple complex diseases CNTN4 intron 17554300 rs7613278 chr3 3031308 T C 4.43E-05 Type 2 diabetes CNTN4 intron 17463246 rs1499126 chr3 3035593 A G 1.17E-04 Multiple complex diseases CNTN4 intron 17554300 rs17024684 chr3 3055247 C T 2.00E-09 Brain connectivity CNTN4 intron 23471985 rs12497768 chr3 3071742 T C 2.60E-04 Primary sclerosing cholangitis CNTN4 intron 19944697 rs1039255 chr3 3073509 G A 3.40E-04 Primary sclerosing cholangitis CNTN4 intron 19944697 rs9845519 chr3 3076218 G A 6.95E-04 Taste perception CNTN4 intron 22132133 rs9820464 chr3 3078840 C T 7.99E-04 Response to taxane treatment (placlitaxel) CNTN4 intron 23006423 rs7617493 chr3 3080200 T C 7.44E-04 Amyotrophic Lateral Sclerosis CNTN4 intron 17362836 rs339286 chr3 3081544 C T 6.81E-04 Smoking quantity CNTN4 intron 24665060 rs95866 chr3 3082778 C A 5.82E-04 Smoking quantity CNTN4 intron 24665060 rs7649378 chr3 3091331 C A 1.13E-05 Coronary restenosis CNTN4 intron 21878436 rs7649378 chr3 3091331 C A 8.90E-05 Hypothyroidism CNTN4 intron 22493691 rs163574 chr3 3096927 A G 6.77E-05 Chronic obstructive pulmonary disease CNTN4 intron 19300482 rs163574 chr3 3096927 A G 6.77E-05 Response to statin treatment (atorvastatin),change in cholesterol levels CNTN4 intron 20031582 rs163579 chr3 3101065 C T 3.07E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs163582 chr3 3103110 A C 0.000426861 Hypertension (early onset hypertension) / / 22479346 rs340826 chr3 3104758 A G 2.19E-05 Hypertension (early onset hypertension) / / 22479346 rs3792424 chr3 3117700 A G 2.12E-05 Parkinson's disease IL5RA intron 21738487 rs4322988 chr3 3120571 G T 4.60E-04 Coronary heart disease IL5RA intron 21966275 rs17026370 chr3 3125441 G T 3.67E-05 Parkinson's disease IL5RA intron 21738487 rs334809 chr3 3130221 A T 1.00E-06 Oleic acid (18:1n-9) plasma levels IL5RA intron 23362303 rs3804795 chr3 3130645 T C 1.00E-06 Immune response to smallpox vaccine (IL-6) IL5RA intron 22542470 rs3856848 chr3 3147676 C T 1.84E-05 Cognitive impairment induced by topiramate IL5RA intron 22091778 rs17879755 chr3 3147981 G A 2.00E-06 QT interval IL5RA intron 23166209 rs334782 chr3 3148458 T C 2.77E-06 Cognitive impairment induced by topiramate IL5RA intron 22091778 rs334782 chr3 3148458 T C 5.42E-06 Cognitive impairment induced by topiramate IL5RA intron 22091778 rs17878749 chr3 3150573 A C 3.13E-06 QT interval IL5RA intron 23166209 rs3806680 chr3 3152384 A G 6.24E-04 Obesity (extreme) IL5RA nearGene-5 21935397 rs9814648 chr3 3155229 G A 8.45E-04 Obesity (extreme) / / 21935397 rs1153459 chr3 3158485 T C 5.40E-04 Alcohol dependence / / 20201924 rs1278150 chr3 3165907 C T 2.91E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs3762760 chr3 3188016 A G 0.000013 Endometrial cancer TRNT1 intron 22426144 rs1669342 chr3 3193676 A G 8.14E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) CRBN intron 23648065 rs17027638 chr3 3197918 A G 2.18E-04 Birth weight CRBN cds-synon 17255346 rs1669338 chr3 3199635 A C 6.00E-06 White matter integrity CRBN intron 23218918 rs698204 chr3 3205432 G C 9.04E-05 Serum metabolites CRBN intron 19043545 rs1669325 chr3 3213262 A G 1.84E-05 Word reading CRBN intron 23738518 rs9828825 chr3 3228123 G A 9.72E-06 White blood cell count / / 21738479 rs1672743 chr3 3231838 A T 6.00E-06 IgG glycosylation / / 23382691 rs967963 chr3 3236900 T C 8.70E-06 Urinary metabolites / / 21572414 rs4109078 chr3 3240356 T C 0.00038 Breast cancer / / 23555315 rs3856858 chr3 3260833 G T 2.97E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3856858 chr3 3260833 G T 6.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13065779 chr3 3261377 T C 1.00E-05 Urinary metabolites / / 21572414 rs13080820 chr3 3261438 G A 1.50E-05 Urinary metabolites / / 21572414 rs6799305 chr3 3262363 G C 2.70E-05 Urinary metabolites / / 21572414 rs4376017 chr3 3262478 C T 1.20E-05 Urinary metabolites / / 21572414 rs3914759 chr3 3265099 G A 2.50E-05 Urinary metabolites / / 21572414 rs13068305 chr3 3271778 C T 3.00E-06 Urinary metabolites / / 21572414 rs9832310 chr3 3274815 G C 3.00E-06 Urinary metabolites / / 21572414 rs12497635 chr3 3276490 C T 7.60E-06 Urinary metabolites / / 21572414 rs3843388 chr3 3280819 A C 7.48E-04 Schizophrenia / / 19197363 rs12490364 chr3 3283626 T C 4.50E-06 Urinary metabolites / / 21572414 rs7615479 chr3 3286100 T C 2.55E-15 Multiple complex diseases / / 17554300 rs11129510 chr3 3287422 T C 1.60E-05 Urinary metabolites / / 21572414 rs3914770 chr3 3288998 A C 7.90E-06 Urinary metabolites / / 21572414 rs9854706 chr3 3301678 C T 3.35E-05 Cognitive test performance / / 20125193 rs3846145 chr3 3307984 A G 3.75E-05 Cognitive test performance / / 20125193 rs771000 chr3 3342533 A G 7.52E-05 Coronary heart disease / / 21606135 rs17029949 chr3 3346910 C T 6.93E-04 Multiple complex diseases / / 17554300 rs770996 chr3 3355544 C T 6.39E-06 Pancreatic cancer / / 23180869 rs9874556 chr3 3356174 A G 4.00E-06 Pancreatic cancer / / 23180869 rs9874556 chr3 3356174 A G 9.00E-06 Alcohol dependence (age at onset) / / 24962325 rs9835812 chr3 3375784 G T 8.00E-07 Immune response to smallpox vaccine (IL-6) / / 22542470 rs1499088 chr3 3376689 T C 3.49E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1499085 chr3 3378900 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1812967 chr3 3385383 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1812967 chr3 3385383 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1812967 chr3 3385383 A G 6.84E-05 Cognitive impairment induced by topiramate / / 22091778 rs7619998 chr3 3387384 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1396429 chr3 3399310 A C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1396429 chr3 3399310 A C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1396429 chr3 3399310 A C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1396429 chr3 3399310 A C 8.32E-05 Cognitive impairment induced by topiramate / / 22091778 rs1508738 chr3 3414001 C T 1.20E-05 Urinary metabolites / / 21572414 rs2279977 chr3 3414586 A C 9.50E-06 Urinary metabolites / / 21572414 rs13322888 chr3 3423218 A G 6.52E-05 Coronary Artery Disease / / 17634449 rs1396433 chr3 3463376 T C 6.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7624675 chr3 3494748 T G 1.58E-04 Intracranial aneurysm / / 22286173 rs12492635 chr3 3501945 C T 4.11E-04 Alzheimer's disease / / 17998437 rs12486658 chr3 3502091 G A 2.91E-04 Alzheimer's disease / / 17998437 rs2220186 chr3 3505049 T A 2.72E-04 Alzheimer's disease / / 17998437 rs10212196 chr3 3545416 C T 4.01E-04 Alzheimer's disease / / 17998437 rs9876298 chr3 3556810 T C 7.63E-04 Alzheimer's disease / / 17998437 rs330243 chr3 3572242 G A 2.49E-04 Myopia (pathological) / / 21095009 rs7652928 chr3 3577113 G A 7.83E-06 Acne (severe teenage) / / 24114350 rs723168 chr3 3583063 T G 1.07E-05 Acne (severe teenage) / / 24114350 rs17684824 chr3 3588042 A C 4.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7650676 chr3 3593290 C G 8.31E-04 Depression (quantitative trait) / / 20800221 rs9811783 chr3 3599937 A C 6.09E-04 Acute lung injury / / 22295056 rs1072848 chr3 3600161 A G 7.28E-04 Depression (quantitative trait) / / 20800221 rs7626957 chr3 3602046 A G 6.82E-05 Post-operative nausea and vomiting / / 21694509 rs4684396 chr3 3614418 T C 7.00E-06 Personality dimensions / / 18957941 rs9815663 chr3 3614887 C T 5.00E-06 Personality dimensions / / 18957941 rs9815663 chr3 3614887 C T 2.00E-08 Asthma (childhood onset) / / 22560479 rs1584573 chr3 3617016 A G 1.40E-05 Personality dimensions / / 18957941 rs9829721 chr3 3622611 C T 6.83E-05 Pancreatic cancer / / pha002874 rs10865864 chr3 3628981 A G 4.00E-06 Callous-unemotional behaviour / / 23874384 rs11711298 chr3 3641794 G C 2.30E-04 Depression (quantitative trait) / / 20800221 rs9837561 chr3 3650239 A C 2.68E-04 Depression (quantitative trait) / / 20800221 rs9837561 chr3 3650239 A C 3.00E-06 Response to amphetamines / / 22952603 rs1601875 chr3 3658840 A G 1.93E-05 Bipolar disorder / / 18317468 rs1601875 chr3 3658840 A G 7.00E-06 Bipolar disorder / / 18711365 rs1488407 chr3 3659566 G C 1.30E-05 Urinary metabolites / / 21572414 rs1386948 chr3 3659605 A C 5.02E-04 Iron levels / / pha002876 rs901859 chr3 3671849 A G 9.17E-04 Depression (quantitative trait) / / 20800221 rs11129700 chr3 3672111 G T 4.32E-04 Depression (quantitative trait) / / 20800221 rs17034687 chr3 3679852 C G 2.00E-09 Disc degeneration (lumbar) / / 22993228 rs7613060 chr3 3720820 C T 2.80E-06 Urinary metabolites / / 21572414 rs711567 chr3 3725595 G T 9.76E-04 Self-reported allergy / / 23817569 rs6796108 chr3 3741831 A G 7.11E-04 Alzheimer's disease / / 22005930 rs6796414 chr3 3742077 A G 3.05E-05 Neutrophil count / / pha003095 rs1596152 chr3 3749436 A G 3.12E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs769784 chr3 3756970 C T 4.10E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7628234 chr3 3773131 A G 6.45E-05 Prostate cancer / / pha002877 rs1073657 chr3 3792945 C T 8.32E-05 Tunica Media / / pha003037 rs711548 chr3 3794591 A G 7.00E-05 Nicotine dependence / / 17407593 rs1661532 chr3 3805368 T C 4.67E-04 Multiple complex diseases / / 17554300 rs769626 chr3 3818605 T G 3.56E-05 Cervical cancer / / 24700089 rs812750 chr3 3828840 G C 1.76E-04 Coronary Artery Disease / / 17634449 rs1442211 chr3 3848714 C T 2.03E-05 Hearing function LRRN1 intron 17255346 rs1825912 chr3 3866316 A G 1.00E-04 Cognitive impairment induced by topiramate LRRN1 intron 22091778 rs1488455 chr3 3869513 A T 9.46E-08 Narcolepsy LRRN1 intron 19629137 rs10510280 chr3 3965910 G C 3.99E-05 Bipolar disorder and schizophrenia / / 20889312 rs9311205 chr3 3966355 T G 0.000529 Salmonella-induced pyroptosis / / 22837397 rs1385464 chr3 3967467 T C 0.000657 Salmonella-induced pyroptosis / / 22837397 rs9860821 chr3 3970428 T A 3.57E-05 Serum metabolites / / 19043545 rs1385457 chr3 3971379 T A 1.96E-05 Serum metabolites / / 19043545 rs1825503 chr3 3971502 G A 3.51E-05 Serum metabolites / / 19043545 rs2322357 chr3 3971538 C T 2.50E-05 Serum metabolites / / 19043545 rs2034162 chr3 3971603 C T 2.50E-05 Serum metabolites / / 19043545 rs7614075 chr3 3972228 C G 2.19E-05 Serum metabolites / / 19043545 rs1244000 chr3 3973674 G A 2.04E-05 Serum metabolites / / 19043545 rs1244001 chr3 3973807 C T 2.01E-05 Serum metabolites / / 19043545 rs1116189 chr3 3974718 G T 2.50E-05 Serum metabolites / / 19043545 rs11716390 chr3 3999670 C T 8.36E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs317544 chr3 4041690 T C 2.60E-05 Urinary metabolites / / 21572414 rs317542 chr3 4043018 T C 8.63E-05 Femoral neck bone geometry / / 22087292 rs317593 chr3 4052274 G A 8.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs317599 chr3 4056652 C A 3.40E-04 Multiple complex diseases / / 17554300 rs317614 chr3 4061316 T C 2.39E-04 Multiple complex diseases / / 17554300 rs317608 chr3 4075936 G A 2.22E-04 Multiple complex diseases / / 17554300 rs17039868 chr3 4136564 C T 2.48E-05 Multiple complex diseases / / 17554300 rs7612596 chr3 4139899 C A,T 1.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10510288 chr3 4157417 G C 9.73E-05 Suicide attempts in bipolar disorder / / 21423239 rs13084851 chr3 4157503 T C 5.49E-05 Suicide attempts in bipolar disorder / / 21423239 rs17702174 chr3 4158345 C T 6.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs1400167 chr3 4159402 A G 1.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs1596472 chr3 4163562 G A 8.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs1373341 chr3 4168251 G C 4.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs17702647 chr3 4168600 A C 1.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs952644 chr3 4181750 G A 4.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs1843303 chr3 4185124 T C 0.0000002 Myopia (Age of onset) / / 23468642 rs17591501 chr3 4212684 A G 4.30E-04 Multiple complex diseases / / 17554300 rs1403124 chr3 4213033 C A 2.75E-05 Blood Pressure / / pha003039 rs1403124 chr3 4213033 C A 6.70E-05 Blood Pressure / / pha003045 rs2587949 chr3 4223616 C G 8.00E-06 Periodontitis (DPAL) / / 24024966 rs2600116 chr3 4224731 G A 7.93E-05 Blood Pressure / / pha003039 rs1485247 chr3 4238196 C T 7.02E-05 Blood Pressure / / pha003039 rs1444056 chr3 4239953 A C 4.37E-05 Blood Pressure / / pha003039 rs1444056 chr3 4239953 A C 7.18E-05 Blood Pressure / / pha003045 rs1153572 chr3 4275803 C T 5.66E-04 Taste perception / / 22132133 rs314416 chr3 4317445 C T 3.78E-04 Smoking quantity / / 24665060 rs310727 chr3 4336589 T C 6.22E-04 Taste perception / / 22132133 rs314439 chr3 4344303 C G 2.83E-04 Multiple complex diseases / / 17554300 rs17040374 chr3 4376778 A G 3.64E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2582349 chr3 4393415 A G 6.25E-05 Cognitive impairment induced by topiramate / / 22091778 rs9811531 chr3 4400806 A T 2.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs9867526 chr3 4400904 C G 3.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs1688416 chr3 4402649 A C 2.30E-04 Suicide attempts in bipolar disorder SUMF1 nearGene-3 21423239 rs964403 chr3 4432033 G T 9.36E-04 Bipolar disorder SUMF1 intron 19259986 rs964403 chr3 4432033 G T 4.91E-05 Longevity SUMF1 intron 21612516 rs3864051 chr3 4432116 C T 5.49E-05 Longevity SUMF1 intron 21612516 rs794185 chr3 4437358 T C 6.00E-07 Multiple sclerosis (brain glutamate levels) SUMF1 intron 20802204 rs17040638 chr3 4451420 G A 3.16E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SUMF1 intron 24023788 rs1625605 chr3 4456185 G T 5.29E-04 Type 2 diabetes SUMF1 intron 17463246 rs711667 chr3 4461569 G A 0.000339279 Hypertension (early onset hypertension) SUMF1 intron 22479346 rs2582343 chr3 4467253 A G 0.000299496 Hypertension (early onset hypertension) SUMF1 intron 22479346 rs6442884 chr3 4469949 C G 1.59E-04 Aortic root size SUMF1 intron 21223598 rs17516078 chr3 4479914 A C 1.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SUMF1 intron 20877124 rs12634249 chr3 4486303 C A 6.86E-04 Longevity SUMF1 intron 22279548 rs17040698 chr3 4489562 T C 5.08E-05 Cognitive performance SUMF1 intron 19734545 rs2259801 chr3 4513543 A G 8.63E-05 Testicular dysgenesis syndrome / / 22140272 rs304082 chr3 4527619 A C 4.99E-05 Cholesterol / / pha003073 rs2291597 chr3 4536403 G A 8.81E-04 Type 2 diabetes ITPR1 intron 17463246 rs2291597 chr3 4536403 G A 4.54E-04 Multiple complex diseases ITPR1 intron 17554300 rs11130036 chr3 4543463 A G 2.44E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ITPR1 intron 21844884 rs17757503 chr3 4543995 T C 3.90E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ITPR1 intron 21844884 rs7639802 chr3 4565559 C T 2.05E-05 Schizophrenia ITPR1 intron 20185149 rs11708874 chr3 4567628 T G 9.65E-05 Response to citalopram treatment ITPR1 intron 19846067 rs11708874 chr3 4567628 T G 1.27E-05 Schizophrenia ITPR1 intron 20185149 rs184231 chr3 4583026 G A 4.36E-05 Body Mass Index ITPR1 intron pha003021 rs10510294 chr3 4593482 T C 4.85E-04 Multiple complex diseases ITPR1 intron 17554300 rs4685758 chr3 4602498 C T 2.68E-05 Insulin Resistance ITPR1 intron pha003062 rs4685758 chr3 4602498 C T 2.42E-05 Insulin-related traits ITPR1 intron pha003063 rs4685765 chr3 4607133 C T 3.41E-04 Heart Failure ITPR1 intron pha002885 rs6774037 chr3 4615243 A G 2.18E-04 Multiple complex diseases ITPR1 intron 17554300 rs2322734 chr3 4633492 C A 8.00E-06 Airflow obstruction ITPR1 intron 22837378 rs4684427 chr3 4645916 C A 1.00E-04 Cognitive impairment induced by topiramate ITPR1 intron 22091778 rs902985 chr3 4671393 C G 7.56E-05 Aortic root size ITPR1 intron 21223598 rs4074087 chr3 4681908 C A 1.20E-05 Urinary metabolites ITPR1 intron 21572414 rs4073665 chr3 4682229 G A 3.05E-05 Depression (quantitative trait) ITPR1 intron 23290196 rs4073664 chr3 4682456 A T 1.10E-05 Urinary metabolites ITPR1 intron 21572414 rs2306870 chr3 4699776 T C 5.92E-06 Obesity-related traits ITPR1 intron 23251661 rs2306868 chr3 4699967 C G 5.92E-06 Obesity-related traits ITPR1 intron 23251661 rs7632000 chr3 4703937 C T 7.00E-07 Obesity-related traits ITPR1 intron 23251661 rs17041165 chr3 4720206 G T 2.61E-04 Response to cytidine analogues (gemcitabine) ITPR1 intron 24483146 rs3804987 chr3 4721624 C T 1.70E-05 Urinary metabolites ITPR1 intron 21572414 rs4685803 chr3 4740592 A G 8.81E-04 Type 2 diabetes ITPR1 intron 17463246 rs4685804 chr3 4740646 G A 7.54E-04 Type 2 diabetes ITPR1 intron 17463246 rs6762558 chr3 4742251 A G 4.94E-06 Systemic lupus erythematosus and Systemic sclerosis ITPR1 intron 23740937 rs6762644 chr3 4742276 A G 2.00E-12 Breast cancer ITPR1 intron 23535729 rs6802366 chr3 4743418 C G 9.05E-04 Response to cytadine analogues (cytosine arabinoside) ITPR1 intron 24483146 rs2322830 chr3 4745230 T C 4.28E-04 Type 2 diabetes ITPR1 intron 17463246 rs3804995 chr3 4751010 C T 6.89E-05 Gallstones ITPR1 intron 17632509 rs7613447 chr3 4767262 T C 2.79E-04 Aortic root size ITPR1 cds-synon 21223598 rs11920001 chr3 4776784 A G 4.39E-05 Response to cytadine analogues (cytosine arabinoside) ITPR1 intron 24483146 rs931389 chr3 4777544 T C 5.23E-04 Schizophrenia ITPR1 intron 19197363 rs13092274 chr3 4781349 T C 1.68E-04 Age-related macular degeneration ITPR1 intron 22125219 rs142774343 chr3 4783001 G T 0.00004453 Sarcoidosis ITPR1 intron 22952805 rs1866997 chr3 4794099 T C 3.79E-04 Lung function (forced vital capacity) ITPR1 intron 24023788 rs13068994 chr3 4794128 C A 8.21E-05 Height ITPR1 intron pha003011 rs3805006 chr3 4800769 T C 5.39E-86 Multiple complex diseases ITPR1 intron 17554300 rs2291863 chr3 4808703 G A 2.57E-04 HIV-1 viral setpoint ITPR1 intron 17641165 rs13060980 chr3 4826452 A G 7.74E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs1018107 chr3 4827309 A G 5.34E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs1018108 chr3 4827514 A T 6.18E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs1018109 chr3 4827533 A G 8.39E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs3805017 chr3 4828136 A G 6.13E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs6801569 chr3 4828703 T C 6.41E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs6809847 chr3 4828764 G C 5.28E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs2633718 chr3 4828806 G A 6.40E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs2633760 chr3 4829010 A G 6.35E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs7611657 chr3 4829198 G C 6.33E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs4685820 chr3 4829412 A G 4.02E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs7649642 chr3 4830995 A T 2.97E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs7637819 chr3 4831225 T C 2.76E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs2165624 chr3 4832534 T A 5.46E-04 Multiple complex diseases ITPR1 intron 17554300 rs11917686 chr3 4834409 A T 5.00E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs2270748 chr3 4836462 C T 9.74E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs11713160 chr3 4837269 T G 7.00E-05 Epilepsy (remission after treatment) ITPR1 intron 23962720 rs7612703 chr3 4852446 C T 1.05E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ITPR1 intron 24023788 rs3792511 chr3 4866320 T G 9.32E-05 Alzheimer's disease ITPR1 intron 22832961 rs13096481 chr3 4874498 C T 1.79E-04 Blood pressure ITPR1 intron 17255346 rs6768569 chr3 4879350 A G 4.51E-05 Psoriasis ITPR1 intron 20953190 rs876349 chr3 4928098 G T 9.38E-04 Type 2 diabetes / / 17463246 rs3856883 chr3 4928159 C T 8.39E-04 Type 2 diabetes / / 17463246 rs9836040 chr3 4941141 T C 1.19E-04 Obesity (extreme) LOC100507582 intron 21935397 rs12497445 chr3 4969763 C T 4.59E-06 Schizophrenia / / 22037555 rs7641083 chr3 4977383 C T 1.20E-05 Urinary metabolites / / 21572414 rs6442925 chr3 5013876 T C 2.00E-06 Corneal structure / / 21979947 rs1110261 chr3 5019936 G A 6.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs908078 chr3 5024771 T C 4.00E-06 Smoking behavior BHLHE40 cds-synon 20418888 rs2616521 chr3 5055578 T C 3.49E-05 Systemic lupus erythematosus / / pha002867 rs9858342 chr3 5078255 C T 3.10E-04 Multiple complex diseases / / 17554300 rs744230 chr3 5126013 G A 1.57E-05 Cognitive test performance / / 20125193 rs2671766 chr3 5129126 A G 2.20E-05 Urinary metabolites / / 21572414 rs2671766 chr3 5129126 A G 8.48E-04 Alzheimer's disease / / 22005930 rs2606783 chr3 5129238 A G 7.98E-04 Alzheimer's disease / / 22005930 rs3864053 chr3 5131363 T C 4.77E-05 Cognitive test performance / / 20125193 rs17735361 chr3 5131396 A G 6.84E-04 Alzheimer's disease / / 22005930 rs3930716 chr3 5132540 T C 2.46E-04 Myopia (pathological) / / 21095009 rs11918654 chr3 5188246 T C 7.00E-06 Disc degeneration (lumbar) ARL8B intron 22993228 rs459289 chr3 5225773 G T 1.47E-05 Type 2 diabetes / / 17463246 rs341974 chr3 5234726 A G 7.20E-04 Type 2 diabetes EDEM1 intron 17463246 rs341981 chr3 5245146 T G 4.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EDEM1 intron 20877124 rs341988 chr3 5254685 A G 7.03E-04 Type 2 diabetes EDEM1 intron 17463246 rs3846158 chr3 5273528 G A 9.40E-04 HIV-1 viral setpoint / / 17641165 rs9872393 chr3 5299769 G A 4.85E-04 Lymphocyte counts / / 22286170 rs7638397 chr3 5316622 A G 5.11E-06 Multiple complex diseases / / 17554300 rs1874971 chr3 5319518 A G 0.000531 Salmonella-induced pyroptosis / / 22837397 rs9311480 chr3 5332265 G T 3.20E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs407334 chr3 5351214 C T 2.03E-26 Multiple complex diseases / / 17554300 rs407334 chr3 5351214 C T 4.63E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1319054 chr3 5359930 A C 4.91E-04 Type 2 diabetes / / 17463246 rs9831553 chr3 5365266 A G 9.25E-04 Type 2 diabetes / / 17463246 rs11130339 chr3 5365353 A T 9.53E-04 Type 2 diabetes / / 17463246 rs343427 chr3 5365682 C T 9.53E-04 Type 2 diabetes / / 17463246 rs4485702 chr3 5389179 C T 4.72E-05 Longevity / / 20304771 rs4485702 chr3 5389179 C T 5.70E-06 Urinary metabolites / / 21572414 rs4367043 chr3 5390506 A T 4.71E-05 Longevity / / 20304771 rs4367043 chr3 5390506 A T 3.50E-06 Urinary metabolites / / 21572414 rs4234565 chr3 5400168 G A 9.60E-06 Urinary metabolites / / 21572414 rs4143244 chr3 5410364 C T 7.05E-07 Bone mass and geometry / / 17903296 rs4143244 chr3 5410364 C T 1.40E-04 Statin-induced myopathy / / 21826682 rs10510303 chr3 5410409 C T 3.72E-05 Longevity / / 20304771 rs17042380 chr3 5420067 A C 3.62E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6799552 chr3 5427290 C T 2.22E-04 Vaspin levels / / 22907691 rs6799552 chr3 5427290 C T 0.0002223 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs9842582 chr3 5427679 A G 3.18E-05 Lymphocyte counts / / pha003094 rs9842582 chr3 5427679 A G 5.56E-05 Neutrophil count / / pha003095 rs6781429 chr3 5429527 G A 8.23E-05 Serum metabolites / / 19043545 rs4685921 chr3 5434536 A G 8.01E-04 Multiple complex diseases / / 17554300 rs2323142 chr3 5464641 T A 9.02E-04 Multiple complex diseases / / 17554300 rs2323142 chr3 5464641 T A 0.000123 Breast cancer early age of onset / / 18463975 rs2323142 chr3 5464641 T A 4.07E-05 Bipolar disorder / / 19488044 rs2323141 chr3 5465805 A G 8.68E-05 Bipolar disorder / / 19488044 rs6793307 chr3 5478372 G A 8.73E-04 Alzheimer's disease / / 17998437 rs10510307 chr3 5478616 T A 6.28E-04 Alzheimer's disease / / 22005930 rs17030987 chr3 5483616 G C 9.39E-04 Alzheimer's disease / / 22005930 rs17803386 chr3 5492216 T A 5.37E-04 Alzheimer's disease / / 17998437 rs7627551 chr3 5507957 T G 3.53E-04 Rheumatoid arthritis / / 21452313 rs2565612 chr3 5522945 G A 6.70E-05 Response to statin therapy / / 20339536 rs2565611 chr3 5524641 A G 1.81E-04 Body mass index / / 21701565 rs2565611 chr3 5524641 A G 3.84E-04 Body mass index / / 21701565 rs2686534 chr3 5525968 G A 2.53E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1991578 chr3 5534360 C G 7.86E-05 Bipolar disorder and schizophrenia / / 20889312 rs11710159 chr3 5534417 C A 4.67E-04 Alzheimer's disease / / 22005930 rs11719822 chr3 5536052 G A 5.58E-04 Alzheimer's disease / / 22005930 rs2163210 chr3 5536975 G A 6.38E-04 Alzheimer's disease / / 22005930 rs17042723 chr3 5537714 C A 7.79E-04 Alzheimer's disease / / 22005930 rs9874195 chr3 5543950 T G 6.34E-04 Type 2 diabetes / / 17463246 rs9823228 chr3 5564422 A G 9.30E-06 Urinary metabolites / / 21572414 rs7635047 chr3 5592056 A G 2.20E-05 Urinary metabolites / / 21572414 rs7615007 chr3 5631528 G A 4.36E-05 Intelligence / / 21826061 rs1864428 chr3 5632123 G C 8.35E-05 Alzheimer's disease / / 17998437 rs2218972 chr3 5681597 A G 5.44E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6442967 chr3 5688304 T G 6.96E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11710433 chr3 5705052 C T 1.00E-06 Bipolar disorder (mood-incongruent) / / 23092984 rs9873292 chr3 5711897 G A 8.75E-05 Cognitive test performance / / 20125193 rs13100888 chr3 5713757 G A 1.30E-05 Urinary metabolites / / 21572414 rs4283565 chr3 5714159 C T 3.96E-05 Prostate cancer / / 22923026 rs17043278 chr3 5714934 A C 0.000621 Salmonella-induced pyroptosis / / 22837397 rs6791910 chr3 5716365 T C 6.13E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6791910 chr3 5716365 T C 1.10E-05 Prostate cancer / / 22923026 rs7428299 chr3 5730884 T C 5.47E-04 Type 2 diabetes / / 17463246 rs11713590 chr3 5731142 G A 3.73E-05 Bipolar disorder and schizophrenia / / 20889312 rs10212309 chr3 5741743 C T 1.69E-05 Personality dimensions / / 22628180 rs6776169 chr3 5752152 C T 1.62E-05 Personality dimensions / / 22628180 rs2123370 chr3 5754294 G T 8.73E-04 Type 2 diabetes / / 17463246 rs4143284 chr3 5760140 G A 5.83E-04 Multiple complex diseases / / 17554300 rs17043388 chr3 5760703 T A 3.89E-06 Personality dimensions / / 22628180 rs6782143 chr3 5768262 T A 1.19E-06 Personality dimensions / / 22628180 rs41322746 chr3 5772947 T C 7.41E-04 Multiple complex diseases / / 17554300 rs1811510 chr3 5775231 G T 4.06E-06 Personality dimensions / / 22628180 rs2470646 chr3 5775765 T C 2.91E-06 Personality dimensions / / 22628180 rs7621135 chr3 5776564 T A 3.07E-06 Personality dimensions / / 22628180 rs7618793 chr3 5776587 A G 5.27E-06 Personality dimensions / / 22628180 rs2470644 chr3 5776857 T C 3.37E-06 Personality dimensions / / 22628180 rs1452713 chr3 5777222 C T 5.70E-06 Personality dimensions / / 22628180 rs7632506 chr3 5785451 T G 5.25E-15 Multiple complex diseases / / 17554300 rs2444218 chr3 5796661 G T 3.28E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11130597 chr3 5821999 C T 3.40E-04 Parkinson's disease / / 17052657 rs6805513 chr3 5830561 C T 3.06E-06 Coronary heart disease / / pha003056 rs1897964 chr3 5831955 G C 5.28E-04 Body mass index / / 21701565 rs1836581 chr3 5832156 T C 2.38E-04 Body mass index / / 21701565 rs1836581 chr3 5832156 T C 5.51E-04 Body mass index / / 21701565 rs2437216 chr3 5835060 T C 4.81E-04 Body mass index / / 21701565 rs2437221 chr3 5840111 C T 4.55E-04 Body mass index / / 21701565 rs2437221 chr3 5840111 C T 8.09E-04 Body mass index / / 21701565 rs6785659 chr3 5842729 G A 8.68E-05 Type 2 diabetes and other traits / / 19734900 rs920063 chr3 5847660 A G 8.40E-04 Body mass index / / 21701565 rs1529860 chr3 5856373 A G 1.36E-04 Body mass index / / 17255346 rs17043640 chr3 5857133 G C 1.85E-04 Body mass index / / 17255346 rs17043640 chr3 5857133 G C 5.59E-04 Alzheimer's disease / / 17998437 rs1836583 chr3 5861205 G T 8.83E-08 Metabolite levels / / 23281178 rs4685988 chr3 5866407 G A 3.80E-08 Metabolite levels / / 23281178 rs4685989 chr3 5867227 C A 5.14E-08 Metabolite levels / / 23281178 rs1541971 chr3 5868533 A C 3.80E-08 Metabolite levels / / 23281178 rs2470649 chr3 5869470 G A 5.76E-04 Multiple complex diseases / / 17554300 rs11130617 chr3 5874245 C A 3.80E-08 Metabolite levels / / 23281178 rs2730302 chr3 5876448 C A 3.80E-08 Metabolite levels / / 23281178 rs1836574 chr3 5878521 G A 4.49E-08 Metabolite levels / / 23281178 rs4684510 chr3 5881625 T C 8.15E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1946692 chr3 5882386 G A 3.34E-08 Metabolite levels / / 23281178 rs2572641 chr3 5883768 G A 2.96E-08 Metabolite levels / / 23281178 rs2730303 chr3 5890516 T C 6.35E-04 Multiple complex diseases / / 17554300 rs1435372 chr3 5891539 G A 3.98E-04 Multiple complex diseases / / 17554300 rs2572690 chr3 5891648 T C 5.91E-04 Common variable immunodeficiency / / 21497890 rs2730306 chr3 5891856 A G 5.11E-04 Multiple complex diseases / / 17554300 rs4685993 chr3 5895027 C T 0.00056418 Hypertension (early onset hypertension) / / 22479346 rs7427632 chr3 5897751 G T 1.75E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs1961394 chr3 5900250 T A 6.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs2730313 chr3 5904553 T G 2.64E-04 Coronary heart disease / / 21606135 rs1435366 chr3 5925183 G C 1.81E-04 Type 2 diabetes / / 17463246 rs11130673 chr3 5936245 A G 0.000655 Salmonella-induced pyroptosis / / 22837397 rs12233495 chr3 5938105 C T 1.19E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs2090350 chr3 5950921 G A 0.000356 Salmonella-induced pyroptosis / / 22837397 rs11495886 chr3 5953419 C T 0.000604 Salmonella-induced pyroptosis / / 22837397 rs1568170 chr3 5965594 C G 1.00E-04 Coronary heart disease / / 21606135 rs2222098 chr3 5986390 C A 3.35E-05 Serum metabolites / / 19043545 rs6767324 chr3 6002693 G A 1.89E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs6807385 chr3 6002768 T C 1.89E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs6768819 chr3 6005401 T C 2.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs17043997 chr3 6006004 A G 6.16E-05 Stroke (ischemic) / / 22941190 rs2048923 chr3 6010772 T G 2.66E-04 Hearing function / / 17255346 rs953402 chr3 6011639 A G 2.10E-05 Hearing function / / 17255346 rs953402 chr3 6011639 A G 9.10E-06 Biomarkers / / 17903293 rs10084653 chr3 6020439 G C 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs7615497 chr3 6080593 G A 3.75E-04 Acute lung injury / / 22295056 rs1033251 chr3 6081827 G A 6.13E-04 Acute lung injury / / 22295056 rs9814750 chr3 6081942 T C 6.13E-04 Acute lung injury / / 22295056 rs9858176 chr3 6092918 G C 6.70E-06 Urinary metabolites / / 21572414 rs925852 chr3 6119146 A G 7.75E-05 Magnesium levels / / pha003092 rs868243 chr3 6120442 G A 8.96E-05 Serum metabolites / / 19043545 rs10510325 chr3 6134806 G A 7.71E-05 Elbow pain / / pha003008 rs1504035 chr3 6135268 C A 6.20E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs13078896 chr3 6141469 G C 1.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs17215895 chr3 6179757 A G 7.49E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10510328 chr3 6194317 G A 3.22E-08 Pure-tone audiometry / / pha001964 rs17215933 chr3 6199813 G A 8.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs17215939 chr3 6201267 C T 8.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs4547687 chr3 6216211 C T 9.86E-05 Cleft lip / / 20436469 rs12374158 chr3 6230553 G T 1.85E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs9839456 chr3 6231998 C T 1.72E-04 Vaspin levels / / 22907691 rs9839456 chr3 6231998 C T 0.0001724 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs6788599 chr3 6239264 C T 6.56E-04 Multiple complex diseases / / 17554300 rs6774280 chr3 6255997 T C 9.00E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs6796959 chr3 6287176 C T 8.00E-06 Smoking behavior / / 20418888 rs6767746 chr3 6291637 G A 6.09E-04 Multiple complex diseases / / 17554300 rs7620588 chr3 6296931 A G 2.70E-05 Urinary metabolites / / 21572414 rs7629918 chr3 6302110 G A 4.24E-04 Body mass index / / 17255346 rs17044468 chr3 6302155 T C 4.82E-04 Multiple complex diseases / / 17554300 rs4686037 chr3 6317058 C G 2.24E-05 Alzheimer's disease (age of onset) / / 22005931 rs17044542 chr3 6341499 A C 2.02E-29 Narcolepsy / / 19629137 rs17044542 chr3 6341499 A C 0.0000181 HDL cholesterol particle diameter / / 23263444 rs17044643 chr3 6364098 A G 2.24E-05 Multiple complex diseases / / 17554300 rs157462 chr3 6364784 C G 4.65E-05 Coronary heart disease / / 21606135 rs157544 chr3 6376084 C T 9.11E-05 Alzheimer's disease (age of onset) / / 22005931 rs271066 chr3 6377695 A T 3.00E-06 Alzheimer's disease (age of onset) / / 22005931 rs157296 chr3 6378688 A G 1.48E-05 Alzheimer's disease (age of onset) / / 22005931 rs157297 chr3 6379792 G A 3.59E-06 Alzheimer's disease (age of onset) / / 22005931 rs6806982 chr3 6391939 T C 6.16E-04 Tourette syndrome / / 22889924 rs1435719 chr3 6421284 A G 1.42E-04 Alzheimer's disease (late onset) / / 21379329 rs7625304 chr3 6458550 A G 0.000009 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) / / 23080225 rs2124811 chr3 6478949 A G 1.11E-04 Osteoarthritis / / 19508968 rs17234606 chr3 6481461 A C 4.33E-05 Multiple complex diseases / / 17554300 rs17216035 chr3 6481625 C A 3.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs266415 chr3 6488648 T C 8.93E-05 Gallstones / / 17632509 rs9847060 chr3 6516654 G A 9.88E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9834048 chr3 6546891 T G 3.99E-04 Smoking initiation / / 24665060 rs6765007 chr3 6548800 T C 5.21E-04 Smoking initiation / / 24665060 rs9809045 chr3 6551706 C G 1.30E-05 Diabetic retinopathy / / 21441570 rs17045225 chr3 6553454 G A 8.11E-05 Blood pressure / / 17255346 rs17045232 chr3 6554226 C G 2.38E-04 Blood pressure / / 17255346 rs12639375 chr3 6558517 G A 1.30E-05 Diabetic retinopathy / / 21441570 rs12639378 chr3 6558567 G A 1.30E-05 Diabetic retinopathy / / 21441570 rs155206 chr3 6562331 A G 2.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs2034871 chr3 6563099 G A 6.60E-05 Diabetic retinopathy / / 21441570 rs1456935 chr3 6564662 G T 3.99E-04 Type 2 diabetes / / 17463246 rs1456935 chr3 6564662 G T 1.40E-05 Diabetic retinopathy / / 21441570 rs17045248 chr3 6565409 A T 9.34E-05 Blood pressure / / 17255346 rs10510338 chr3 6565877 A G 3.06E-04 Blood pressure / / 17255346 rs4686069 chr3 6566412 C G 1.60E-05 Diabetic retinopathy / / 21441570 rs9880678 chr3 6568221 G A 2.20E-05 Diabetic retinopathy / / 21441570 rs12330764 chr3 6574839 A G 2.50E-05 Diabetic retinopathy / / 21441570 rs6783239 chr3 6584177 C T 6.09E-04 Smoking initiation / / 24665060 rs729008 chr3 6590865 A G 2.60E-05 Diabetic retinopathy / / 21441570 rs12633898 chr3 6591750 G T 3.10E-05 Diabetic retinopathy / / 21441570 rs9831858 chr3 6592515 A G 3.10E-05 Diabetic retinopathy / / 21441570 rs11714080 chr3 6592700 G A 3.10E-05 Diabetic retinopathy / / 21441570 rs10510340 chr3 6594461 A G 3.70E-05 Diabetic retinopathy / / 21441570 rs13321931 chr3 6595783 T G 3.70E-05 Diabetic retinopathy / / 21441570 rs11714361 chr3 6601031 A T 4.30E-05 Diabetic retinopathy / / 21441570 rs4686070 chr3 6603915 T C 4.30E-05 Diabetic retinopathy / / 21441570 rs9864053 chr3 6607460 C G 4.30E-05 Diabetic retinopathy / / 21441570 rs9311949 chr3 6615658 A G 4.20E-05 Diabetic retinopathy / / 21441570 rs17216174 chr3 6625081 A G 4.10E-05 Diabetic retinopathy / / 21441570 rs352748 chr3 6640700 C G 8.58E-04 Multiple complex diseases / / 17554300 rs7430827 chr3 6642993 A C 5.19E-05 Postoperative ventricular dysfunction / / 21980348 rs7637316 chr3 6643607 A C 2.36E-05 Postoperative ventricular dysfunction / / 21980348 rs17045412 chr3 6660474 C A 1.35E-04 Blood pressure / / 17255346 rs352283 chr3 6666083 T C 0.00002203 Sarcoidosis / / 22952805 rs352281 chr3 6666458 A G 0.00001717 Sarcoidosis / / 22952805 rs675803 chr3 6671011 G T 0.00001668 Sarcoidosis / / 22952805 rs631985 chr3 6673897 A G 0.00003048 Sarcoidosis / / 22952805 rs6766507 chr3 6674723 C T 0.00001668 Sarcoidosis / / 22952805 rs616244 chr3 6675168 T A 0.00001668 Sarcoidosis / / 22952805 rs13326304 chr3 6675541 T C 1.95E-05 HIV-1 viral setpoint / / 22174851 rs602939 chr3 6675838 T G 0.00001629 Sarcoidosis / / 22952805 rs589846 chr3 6676453 A G 0.00001629 Sarcoidosis / / 22952805 rs635098 chr3 6678415 C A 0.00001629 Sarcoidosis / / 22952805 rs632436 chr3 6679059 G A 0.00001629 Sarcoidosis / / 22952805 rs1718564 chr3 6679250 T C 0.00001629 Sarcoidosis / / 22952805 rs1698361 chr3 6679315 A G 0.00001629 Sarcoidosis / / 22952805 rs618657 chr3 6679838 C T 0.00001629 Sarcoidosis / / 22952805 rs621329 chr3 6680288 C T 0.00006677 Sarcoidosis / / 22952805 rs352275 chr3 6685140 C T 0.00001742 Sarcoidosis / / 22952805 rs9843107 chr3 6686203 G A 8.21E-05 HIV-1 viral setpoint / / 22174851 rs9843107 chr3 6686203 G A 9.92E-07 Telomere length / / 23001564 rs168460 chr3 6686606 C A 0.00001742 Sarcoidosis / / 22952805 rs624782 chr3 6687479 A G 0.00003295 Sarcoidosis / / 22952805 rs349894 chr3 6693581 G A 0.00009939 Sarcoidosis / / 22952805 rs371167 chr3 6699156 C T 0.0000761 Sarcoidosis / / 22952805 rs349898 chr3 6713095 C T 0.00009843 Sarcoidosis / / 22952805 rs349900 chr3 6716209 T G 0.00009291 Sarcoidosis / / 22952805 rs401572 chr3 6718604 A G 0.00006052 Sarcoidosis / / 22952805 rs6787150 chr3 6728385 G A 1.10E-05 Urinary metabolites / / 21572414 rs9990237 chr3 6748069 G A 8.06E-04 Alzheimer's disease / / 17998437 rs9817032 chr3 6748343 C T 3.87E-04 Alzheimer's disease / / 17998437 rs9829452 chr3 6752294 A G 3.05E-05 Telomere length / / 23001564 rs164336 chr3 6762242 T C 9.40E-04 Coronary heart disease / / 21606135 rs345244 chr3 6767906 G C 4.09E-04 Coronary heart disease / / 21606135 rs345233 chr3 6770752 T C 4.56E-04 Schizophrenia / / 19197363 rs6781770 chr3 6814988 C T 3.58E-04 Type 2 diabetes / / 17463246 rs17046124 chr3 6861866 T C 4.62E-05 Height / / 22021425 rs17288435 chr3 6863813 A C 8.13E-05 Coronary heart disease / / 21606135 rs11131055 chr3 6867518 A G 5.99E-05 Coronary heart disease / / pha003055 rs17046143 chr3 6873446 A G 1.77E-10 Multiple complex diseases / / 17554300 rs342016 chr3 6882212 G A 7.55E-05 Socioeconomic Factors / / pha003066 rs3749380 chr3 6903297 C T 2.00E-06 Panic disorder GRM7 cds-synon 19165232 rs6783840 chr3 6915723 C G 1.40E-05 Urinary metabolites GRM7 intron 21572414 rs114246623 chr3 6935066 G A 7.70E-07 Prostate cancer GRM7 intron 24185611 rs3846161 chr3 6939834 A G 8.13E-05 Serum metabolites GRM7 intron 19043545 rs339020 chr3 6973116 G T 8.43E-06 Post-operative nausea and vomiting GRM7 intron 21694509 rs802646 chr3 6978547 C T 0.0000876 Sarcoidosis GRM7 intron 22952805 rs1667850 chr3 7003531 G A 8.93E-04 Myopia (pathological) GRM7 intron 21095009 rs480409 chr3 7010081 C T 9.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) GRM7 intron 23648065 rs6796324 chr3 7012842 G A 2.86E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) GRM7 intron 23648065 rs13317247 chr3 7026535 C T 3.93E-05 Attention deficit hyperactivity disorder GRM7 intron 23728934 rs1391950 chr3 7058417 T C 0.000027 Migraine GRM7 intron 22678113 rs1391950 chr3 7058417 T C 2.70E-05 Migraine GRM7 intron 22683712 rs11713183 chr3 7078179 T C 0.0000726 Migraine GRM7 intron 22678113 rs11713183 chr3 7078179 T C 7.26E-05 Migraine GRM7 intron 22683712 rs1353832 chr3 7083814 C T 5.06E-04 Aortic root size GRM7 intron 21223598 rs1353832 chr3 7083814 C T 3.99E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) GRM7 intron 23648065 rs6771606 chr3 7085713 T C 1.97E-04 Aortic root size GRM7 intron 21223598 rs6771606 chr3 7085713 T C 4.49E-04 Smoking initiation GRM7 intron 24665060 rs6785425 chr3 7125901 A G 6.90E-04 Schizophrenia GRM7 intron 19197363 rs6788201 chr3 7126102 T C 9.32E-05 HIV-1 viral setpoint GRM7 intron 17641165 rs9876724 chr3 7152640 G A 4.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) GRM7 intron 23648065 rs11928865 chr3 7155702 T A 8.67E-04 Alzheimer's disease GRM7 intron 17998437 rs9872427 chr3 7164223 T A 2.57E-04 Multiple complex diseases GRM7 intron 17554300 rs11131063 chr3 7167701 G A 1.83E-05 Iron levels GRM7 intron 19880490 rs11131063 chr3 7167701 G A 1.83E-05 Iron levels GRM7 intron pha002876 rs6443090 chr3 7168009 C G 4.10E-04 Multiple complex diseases GRM7 intron 17554300 rs6443090 chr3 7168009 C G 7.67E-04 Alzheimer's disease GRM7 intron 17998437 rs6765482 chr3 7168677 T C 7.40E-06 Urinary metabolites GRM7 intron 21572414 rs1353828 chr3 7169453 A C 1.85E-05 Iron levels GRM7 intron 19880490 rs1353828 chr3 7169453 A C 1.85E-05 Iron levels GRM7 intron pha002876 rs6766686 chr3 7170011 A G 6.90E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) GRM7 intron 23648065 rs9814809 chr3 7170741 G C 6.68E-04 Multiple complex diseases GRM7 intron 17554300 rs1874981 chr3 7172721 C T 2.29E-04 Multiple complex diseases GRM7 intron 17554300 rs1878164 chr3 7173002 G A 7.50E-06 Urinary metabolites GRM7 intron 21572414 rs9880404 chr3 7175878 C T 3.99E-05 Iron levels GRM7 intron 19880490 rs9880404 chr3 7175878 C T 3.99E-05 Iron levels GRM7 intron pha002876 rs17824908 chr3 7176252 A G 1.06E-04 Iron levels GRM7 intron pha002876 rs4441639 chr3 7179682 G A 9.25E-04 Alzheimer's disease GRM7 intron 17998437 rs3749448 chr3 7188116 G A 2.24E-04 Multiple complex diseases GRM7 intron 17554300 rs3749448 chr3 7188116 G A 3.46E-04 Alzheimer's disease GRM7 intron 17998437 rs17234983 chr3 7189058 A C 8.62E-04 Response to taxane treatment (placlitaxel) GRM7 intron 23006423 rs7650218 chr3 7191923 C T 3.09E-04 Multiple complex diseases GRM7 intron 17554300 rs17234990 chr3 7195141 T C 4.90E-04 Response to taxane treatment (placlitaxel) GRM7 intron 23006423 rs7621420 chr3 7196728 C T 7.70E-04 Multiple complex diseases GRM7 intron 17554300 rs9814881 chr3 7198602 A G 7.46E-04 Alzheimer's disease GRM7 intron 17998437 rs12497688 chr3 7201316 T C 8.03E-04 Multiple complex diseases GRM7 intron 17554300 rs1818033 chr3 7202533 C G 5.05E-04 Multiple complex diseases GRM7 intron 17554300 rs9864350 chr3 7202909 C T 8.00E-06 Brain size GRM7 intron 22156575 rs965170 chr3 7214563 C T 6.14E-05 Iron levels GRM7 intron 19880490 rs965170 chr3 7214563 C T 6.14E-05 Iron levels GRM7 intron pha002876 rs10866078 chr3 7215759 T C 2.74E-05 Iron levels GRM7 intron 19880490 rs10866078 chr3 7215759 T C 2.74E-05 Iron levels GRM7 intron pha002876 rs1400166 chr3 7218175 G A 5.84E-04 Iron levels GRM7 intron pha002876 rs10510351 chr3 7219432 T C 3.30E-04 Iron levels GRM7 intron pha002876 rs11715681 chr3 7222094 A G 6.17E-04 Iron levels GRM7 intron pha002876 rs6784317 chr3 7222236 G T 5.91E-04 Iron levels GRM7 intron pha002876 rs2063880 chr3 7228869 G A 2.40E-05 Urinary metabolites GRM7 intron 21572414 rs6797852 chr3 7262014 G A 3.00E-06 Breast cancer GRM7 intron 23468962 rs951557 chr3 7269035 C T 9.29E-04 Multiple complex diseases GRM7 intron 17554300 rs951557 chr3 7269035 C T 5.82E-04 Bipolar disorder,schizoaffective GRM7 intron 19567891 rs4686119 chr3 7282739 T C 6.69E-04 Type 2 diabetes GRM7 intron 17463246 rs4686119 chr3 7282739 T C 4.34E-05 Telomere length GRM7 intron 23001564 rs908465 chr3 7283715 T G 6.76E-04 Type 2 diabetes GRM7 intron 17463246 rs1605705 chr3 7290044 G A 2.18E-05 Multiple complex diseases GRM7 intron 17554300 rs4095095 chr3 7309658 G A 4.00E-04 Lung function (forced expiratory volume in 1 second) GRM7 intron 24023788 rs1876614 chr3 7321289 A G 9.74E-04 Multiple complex diseases GRM7 intron 17554300 rs7632044 chr3 7335947 C G 2.76E-04 Multiple complex diseases GRM7 intron 17554300 rs9846024 chr3 7350891 A G 8.52E-04 Multiple complex diseases GRM7 intron 17554300 rs17697853 chr3 7366195 C T 8.86E-04 Multiple complex diseases GRM7 intron 17554300 rs9990013 chr3 7366352 G T 7.96E-04 Multiple complex diseases GRM7 intron 17554300 rs6810141 chr3 7383890 T C 4.30E-04 Body mass index GRM7 intron 17255346 rs12491592 chr3 7394287 C A 2.96E-04 Common variable immunodeficiency GRM7 intron 21497890 rs13080594 chr3 7403646 C T 8.00E-07 Personality dimensions GRM7 intron 21368711 rs1499209 chr3 7418725 C T 1.90E-05 Urinary metabolites GRM7 intron 21572414 rs1499204 chr3 7437037 C G 6.30E-05 Diabetic retinopathy GRM7 intron 21441570 rs12489041 chr3 7437599 A G 5.00E-05 Diabetic retinopathy GRM7 intron 21441570 rs13066750 chr3 7438708 G A 4.70E-05 Diabetic retinopathy GRM7 intron 21441570 rs17047288 chr3 7455576 C G 4.56E-04 Alzheimer's disease GRM7 intron 17998437 rs712773 chr3 7456558 T C 4.98E-05 Longevity GRM7 intron 21612516 rs978826 chr3 7478305 C T 1.63E-04 Aortic root size GRM7 intron 21223598 rs1868616 chr3 7505487 A G 3.68E-04 Nicotine smoking GRM7 intron 19268276 rs1868616 chr3 7505487 A G 7.77E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) GRM7 intron 23648065 rs7623046 chr3 7510856 G A 3.55E-04 Amyotrophic Lateral Sclerosis GRM7 intron 17362836 rs779708 chr3 7512728 G A 1.56E-04 Parkinson's disease GRM7 intron 16252231 rs1391901 chr3 7517340 G A 9.51E-05 Coronary heart disease GRM7 intron pha003033 rs752300 chr3 7520084 C T 6.33E-05 Coronary heart disease GRM7 intron pha003033 rs17047422 chr3 7522152 A G 2.15E-04 Multiple complex diseases GRM7 intron 17554300 rs17047426 chr3 7522463 G A 1.85E-04 Multiple complex diseases GRM7 intron 17554300 rs9870680 chr3 7529555 C T 1.00E-06 Major depressive disorder (broad) GRM7 intron 20038947 rs9870680 chr3 7529555 C T 4.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRM7 intron 20877124 rs9870680 chr3 7529555 C T 0.0000837 Major depressive disorder GRM7 intron 23149448 rs9815274 chr3 7529849 A T 2.01E-06 Major depressive disorder (broad) GRM7 intron 20038947 rs9815274 chr3 7529849 A T 6.43E-05 Major depressive disorder GRM7 intron 22472876 rs12494654 chr3 7533393 C T 2.12E-04 Multiple complex diseases GRM7 intron 17554300 rs1450100 chr3 7538202 T G 8.00E-06 Orofacial clefts GRM7 intron 22419666 rs3804945 chr3 7539974 A G 5.45E-04 Multiple complex diseases GRM7 intron 17554300 rs3804945 chr3 7539974 A G 1.93E-05 Multiple sclerosis GRM7 intron 17660530 rs1375923 chr3 7542268 C T 4.29E-06 Major depressive disorder (broad) GRM7 intron 20038947 rs3804936 chr3 7553165 C T 6.90E-05 Orofacial clefts GRM7 intron 22419666 rs1531940 chr3 7555709 T A 1.37E-05 Major depressive disorder (broad) GRM7 intron 20038947 rs6778646 chr3 7558907 C T 1.18E-05 Major depressive disorder (broad) GRM7 intron 20038947 rs1106485 chr3 7562685 C G 2.25E-05 Major depressive disorder (broad) GRM7 intron 20038947 rs779749 chr3 7576541 C T 3.51E-04 Lung function (forced expiratory volume in 1 second) GRM7 intron 17255346 rs7651961 chr3 7578273 T C 2.25E-05 Major depressive disorder (broad) GRM7 intron 20038947 rs779746 chr3 7578531 T C 2.00E-04 Cognitive impairment induced by topiramate GRM7 intron 22091778 rs7652246 chr3 7578563 T G 1.99E-05 Major depressive disorder (broad) GRM7 intron 20038947 rs6443114 chr3 7578602 A T 1.95E-05 Major depressive disorder (broad) GRM7 intron 20038947 rs3804925 chr3 7580979 G A 2.00E-04 Cognitive impairment induced by topiramate GRM7 intron 22091778 rs3804925 chr3 7580979 G A 2.00E-04 Cognitive impairment induced by topiramate GRM7 intron 22091778 rs779742 chr3 7583058 A G 9.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) GRM7 intron 17982456 rs17664833 chr3 7583314 C G 1.31E-05 Major depressive disorder (broad) GRM7 intron 20038947 rs17664833 chr3 7583314 C G 8.12E-05 Major depressive disorder GRM7 intron 21621269 rs779741 chr3 7583602 C A 1.35E-05 Major depressive disorder (broad) GRM7 intron 20038947 rs1143740 chr3 7602077 T C 3.76E-04 Lung function (forced expiratory volume in 1 second) GRM7 intron 17255346 rs1485179 chr3 7603708 C T 6.73E-04 Alcohol dependence GRM7 intron 21314694 rs1485179 chr3 7603708 C T 7.18E-04 Smoking initiation GRM7 intron 24665060 rs17666140 chr3 7634675 G T 3.96E-05 Hypertension (early onset hypertension) GRM7 intron 22479346 rs1485171 chr3 7651185 C A 9.73E-05 Multiple complex diseases GRM7 intron 17554300 rs3792452 chr3 7666784 C T 0.000871166 Hypertension (early onset hypertension) GRM7 intron 22479346 rs3804867 chr3 7667909 C T 8.00E-04 Tourette syndrome GRM7 intron 22889924 rs1872396 chr3 7680452 A G 4.65E-05 Melanoma GRM7 intron 21926416 rs3912449 chr3 7683162 G A 6.99E-05 Melanoma GRM7 intron 21926416 rs4686148 chr3 7688662 G T 9.11E-05 Serum metabolites GRM7 intron 19043545 rs3804850 chr3 7688702 C T 2.50E-05 Urinary metabolites GRM7 intron 21572414 rs3804850 chr3 7688702 C T 4.38E-04 Non-small cell lung cancer (recurrence rate) GRM7 intron 24737549 rs9838647 chr3 7690439 A G 9.10E-04 Suicide attempts in bipolar disorder GRM7 intron 21423239 rs4686151 chr3 7693806 G C 9.65E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines GRM7 intron 21844884 rs9881908 chr3 7695065 G A 3.80E-04 Suicide attempts in bipolar disorder GRM7 intron 21423239 rs3792439 chr3 7695640 T C 5.49E-04 Suicide attempts in bipolar disorder GRM7 intron 21423239 rs6782528 chr3 7721032 T A 1.37E-05 Serum metabolites GRM7 intron 19043545 rs924806 chr3 7743541 G C 1.65E-04 Multiple complex diseases GRM7 intron 17554300 rs10510371 chr3 7745206 C T 1.32E-05 Cognitive performance GRM7 intron 19734545 rs9860560 chr3 7748736 T G 5.51E-05 Stroke (ischemic) GRM7 intron 22941190 rs1504047 chr3 7748843 T G 5.51E-05 Stroke (ischemic) GRM7 intron 22941190 rs1354407 chr3 7758042 A G 5.55E-05 Stroke (ischemic) GRM7 intron 22941190 rs161885 chr3 7797492 A G 3.35E-05 Erythrocyte counts / / pha003099 rs9841316 chr3 7820659 T G 9.10E-06 Urinary metabolites / / 21572414 rs11708896 chr3 7837624 A G 6.00E-26 PR interval / / 20062060 rs6780542 chr3 7850284 T C 0.0007272 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6780542 chr3 7850284 T C 7.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6443126 chr3 7851708 T G 4.00E-05 Bone mineral density (BMD),in women / / 20164292 rs161898 chr3 7856288 C A 9.44E-05 Cognitive test performance / / 20125193 rs161899 chr3 7856946 G A 7.86E-05 Body Mass Index / / pha003009 rs162216 chr3 7858048 G A 2.03E-04 Parkinson's disease / / 17052657 rs162216 chr3 7858048 G A 1.57E-06 Insulin-related traits / / 19902172 rs4686162 chr3 7858150 T C 8.80E-05 Bone mineral density (BMD),in women / / 20164292 rs162712 chr3 7865719 C T 4.15E-04 Parkinson's disease / / 17052657 rs9883082 chr3 7883963 C A 1.75E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs17048056 chr3 7884798 G T 9.80E-07 Urinary metabolites / / 21572414 rs453488 chr3 7886169 C A 1.27E-05 Personality dimensions / / 22628180 rs2324413 chr3 7886455 T C 5.93E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2160954 chr3 7886502 A G 8.22E-04 Multiple complex diseases / / 17554300 rs2160954 chr3 7886502 A G 3.06E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2875342 chr3 7888645 T C 9.20E-07 Urinary metabolites / / 21572414 rs2875342 chr3 7888645 T C 8.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs373953 chr3 7890279 T C 1.27E-05 Personality dimensions / / 22628180 rs397592 chr3 7890939 G A 1.27E-05 Personality dimensions / / 22628180 rs399150 chr3 7891227 T G 7.19E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs370017 chr3 7891245 A G 1.10E-06 Urinary metabolites / / 21572414 rs7629975 chr3 7895111 G A 7.31E-05 Body Mass Index / / pha003022 rs326419 chr3 7895790 G A 8.68E-06 Personality dimensions / / 22628180 rs326417 chr3 7896492 C T 8.97E-06 Personality dimensions / / 22628180 rs326416 chr3 7897016 A G 8.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13323237 chr3 7898720 C T 9.94E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs17740513 chr3 7902712 G A 2.20E-05 Urinary metabolites / / 21572414 rs326414 chr3 7903040 T C 4.70E-06 Urinary metabolites / / 21572414 rs1386987 chr3 7905067 G T 9.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9867817 chr3 7905524 C T 2.20E-06 Urinary metabolites / / 21572414 rs9867817 chr3 7905524 C T 7.92E-05 Body Mass Index / / pha003022 rs9829153 chr3 7905601 G A 2.10E-06 Urinary metabolites / / 21572414 rs9829153 chr3 7905601 G A 3.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs326410 chr3 7905802 A G 1.60E-05 Urinary metabolites / / 21572414 rs227 chr3 7906607 G A 2.88E-05 Acute lung injury / / 22295056 rs11720252 chr3 7907748 C T 2.40E-05 Urinary metabolites / / 21572414 rs17741012 chr3 7909163 T G 1.43E-05 Personality dimensions / / 22628180 rs10510373 chr3 7911027 G C 0.0000303 Lumbar spine bone mineral density (males) / / 22692763 rs10510373 chr3 7911027 G C 3.41E-08 Lumbar spine bone mineral density / / 22692763 rs7653216 chr3 7912970 G C 1.08E-05 Personality dimensions / / 22628180 rs438386 chr3 7913516 C T 5.59E-04 Sarcoidosis / / 19165924 rs1001254 chr3 7934333 C G 2.00E-05 Blood Phenotypes / / 17903294 rs13088386 chr3 7950430 A G 2.35E-05 Personality dimensions / / 22628180 rs10510375 chr3 7952250 C T 1.70E-14 Multiple complex diseases / / 17554300 rs10510376 chr3 7952593 A T 2.03E-05 Personality dimensions / / 22628180 rs1825924 chr3 7962284 C T 2.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6803927 chr3 7966137 G T 2.61E-05 Serum metabolites / / 19043545 rs6782967 chr3 7966315 C T 9.38E-04 Alzheimer's disease / / 17998437 rs17048378 chr3 7971351 A G 6.11E-04 Acute lung injury / / 22295056 rs9810651 chr3 7975633 A G 8.89E-04 Acute lung injury / / 22295056 rs2324442 chr3 7977880 A C 3.04E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4591494 chr3 7982827 T C 9.00E-06 Factor VII / / 17903294 rs4591494 chr3 7982827 T C 1.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9824002 chr3 7983000 A G 6.67E-04 Acute lung injury / / 22295056 rs3916089 chr3 7986755 C G 7.46E-04 Acute lung injury / / 22295056 rs1385437 chr3 7990493 T G 4.78E-04 Alzheimer's disease (late onset) / / 21379329 rs10510382 chr3 7997953 T C 7.96E-05 Cytomegalovirus antibody response / / 21993531 rs17048455 chr3 8017430 G C 2.04E-05 Cytomegalovirus antibody response / / 21993531 rs6769352 chr3 8018694 A G 5.05E-05 Cytomegalovirus antibody response / / 21993531 rs6780683 chr3 8018918 G A 5.04E-05 Cytomegalovirus antibody response / / 21993531 rs9985243 chr3 8020574 C T 7.24E-04 Type 2 diabetes / / 17463246 rs17048464 chr3 8022506 C T 4.30E-05 Cytomegalovirus antibody response / / 21993531 rs1385436 chr3 8024019 T G 4.29E-05 Cytomegalovirus antibody response / / 21993531 rs9859247 chr3 8030809 A G 8.45E-05 Cortisol secretion,in saliva / / 21316860 rs1485160 chr3 8031257 C T 7.51E-04 Taste perception / / 22132133 rs9834849 chr3 8039210 T C 5.36E-05 Cytomegalovirus antibody response / / 21993531 rs527498 chr3 8139779 G A 6.45E-06 Cardiovascular disease / / 18179892 rs13317787 chr3 8141952 C A 2.13E-04 Type 2 diabetes / / 17463246 rs9844587 chr3 8144234 C A 2.13E-04 Type 2 diabetes / / 17463246 rs11925840 chr3 8144902 A T 2.11E-04 Type 2 diabetes / / 17463246 rs13097609 chr3 8147718 A G 2.86E-04 Multiple complex diseases / / 17554300 rs6779176 chr3 8148696 C A 6.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2675247 chr3 8163253 C T 8.26E-04 Acute lung injury / / 22295056 rs1878175 chr3 8164718 G A 1.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs466663 chr3 8188766 G A 9.55E-04 Acute lung injury / / 22295056 rs320067 chr3 8194599 G A 9.26E-04 Acute lung injury / / 22295056 rs6796806 chr3 8195676 A G 3.10E-09 Platelet aggregation(pre- and post-aspirin) / / 20529293 rs178597 chr3 8196941 C T 7.57E-04 Acute lung injury / / 22295056 rs6764798 chr3 8200271 A G 1.30E-08 Platelet aggregation(pre- and post-aspirin) / / 20529293 rs13088606 chr3 8230904 C T 6.10E-06 Stroke (ischemic) / / 22384361 rs390783 chr3 8233002 T C 3.90E-06 Stroke (ischemic) / / 22384361 rs4684589 chr3 8239386 G A 9.80E-06 Stroke (ischemic) / / 22384361 rs6780741 chr3 8240179 A G 9.10E-06 Stroke (ischemic) / / 22384361 rs6443171 chr3 8244910 T C 2.86E-05 Basophils / / pha003087 rs9866825 chr3 8250790 A C 8.00E-06 QT interval / / 23166209 rs11131119 chr3 8256964 T C 0.000243 Salmonella-induced pyroptosis / / 22837397 rs9312006 chr3 8259491 A C,G,T 1.64E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs1873029 chr3 8266451 G A 9.80E-05 Response to lithium treatment in bipolar disorder LOC100288428 intron 19448189 rs984475 chr3 8272008 C T 1.68E-04 Multiple complex diseases LOC100288428 intron 17554300 rs2046745 chr3 8272716 C A 2.48E-04 Multiple complex diseases LOC100288428 intron 17554300 rs1545998 chr3 8273661 G T 2.07E-04 Multiple complex diseases LOC100288428 intron 17554300 rs1545997 chr3 8273987 T C 1.97E-04 Multiple complex diseases LOC100288428 intron 17554300 rs6762549 chr3 8274906 T C 2.61E-04 Multiple complex diseases LOC100288428 intron 17554300 rs9882964 chr3 8297505 C T 2.00E-05 Urinary metabolites LOC100288428 intron 21572414 rs2324475 chr3 8313219 G C 5.27E-04 Multiple complex diseases LOC100288428 intron 17554300 rs923381 chr3 8314924 T C 7.85E-04 Response to cytidine analogues (gemcitabine) LOC100288428 intron 24483146 rs17763297 chr3 8316110 G A 4.70E-05 Blood pressure LOC100288428 intron 21572416 rs6799462 chr3 8327085 A G 4.12E-04 Suicide attempts in bipolar disorder LOC100288428 intron 21423239 rs17048945 chr3 8330426 C T 4.20E-06 Urinary metabolites LOC100288428 intron 21572414 rs6763794 chr3 8330534 A G 4.95E-05 Serum metabolites LOC100288428 intron 19043545 rs9819127 chr3 8330829 T A 2.70E-05 Urinary metabolites LOC100288428 intron 21572414 rs4470491 chr3 8332283 C G 1.55E-05 Femoral neck bone geometry LOC100288428 intron 22087292 rs4470491 chr3 8332283 C G 9.90E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100288428 intron 23233662 rs10514664 chr3 8360701 G C 8.30E-04 Type 2 diabetes and 6 quantitative traits LOC100288428 intron 17848626 rs10514664 chr3 8360701 G C 1.30E-05 Urinary metabolites LOC100288428 intron 21572414 rs11712836 chr3 8375136 T C 9.62E-05 Serum metabolites LOC100288428 intron 19043545 rs359030 chr3 8403739 T C 3.51E-04 Common variable immunodeficiency LOC100288428 intron 21497890 rs2875366 chr3 8406253 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC100288428 intron 22628534 rs358989 chr3 8410210 G A,T 6.57E-05 Schizophrenia LOC100288428 intron 19571811 rs9824143 chr3 8426682 T C 2.70E-05 Urinary metabolites LOC100288428 intron 21572414 rs358996 chr3 8429631 C T 7.00E-04 Multiple complex diseases LOC100288428 intron 17554300 rs1391988 chr3 8430919 G C 7.30E-04 Multiple complex diseases LOC100288428 intron 17554300 rs359040 chr3 8438577 A G 1.60E-05 Urinary metabolites LOC100288428 intron 21572414 rs1161171 chr3 8442494 C T 7.60E-04 Type 2 diabetes and 6 quantitative traits LOC100288428 intron 17848626 rs359033 chr3 8456789 A G 8.43E-04 Type 2 diabetes LOC100288428 intron 17846125 rs1562688 chr3 8500321 G T 4.93E-05 Longevity LOC100288428 intron 21612516 rs17049174 chr3 8509497 G A 3.04E-05 Progressive supranuclear palsy LOC100288428 intron 21685912 rs7611030 chr3 8511921 A G 1.30E-05 Urinary metabolites LOC100288428 intron 21572414 rs7611030 chr3 8511921 A G 9.00E-04 Coronary heart disease LOC100288428 intron 21606135 rs11720160 chr3 8517932 T A 1.50E-05 Urinary metabolites LOC100288428 intron 21572414 rs11720160 chr3 8517932 T A 4.27E-04 Coronary heart disease LOC100288428 intron 21606135 rs17049179 chr3 8521841 T C 9.19E-04 Multiple complex diseases LOC100288428 intron 17554300 rs9882165 chr3 8548048 T A 2.60E-05 Urinary metabolites LMCD1 intron 21572414 rs6798584 chr3 8548827 G T 1.20E-05 Urinary metabolites LMCD1 intron 21572414 rs931685 chr3 8548850 G A 1.60E-05 Urinary metabolites LMCD1 intron 21572414 rs931686 chr3 8548885 T C 2.40E-05 Urinary metabolites LMCD1 intron 21572414 rs7637683 chr3 8555507 A C 1.60E-05 Urinary metabolites LMCD1 intron 21572414 rs12715650 chr3 8556784 A C 1.50E-05 Urinary metabolites LMCD1 intron 21572414 rs9312024 chr3 8561732 T C 4.40E-06 Urinary metabolites LMCD1 intron 21572414 rs1947220 chr3 8562637 A G 1.10E-05 Urinary metabolites LMCD1 intron 21572414 rs1947220 chr3 8562637 A G 5.95E-04 Smoking initiation LMCD1 intron 24665060 rs9810512 chr3 8570874 A G 2.73E-04 Smoking initiation LMCD1 intron 24665060 rs9831647 chr3 8571110 G A 1.10E-05 Urinary metabolites LMCD1 intron 21572414 rs9831647 chr3 8571110 G A 0.00000936 Preeclampsia LMCD1 intron 22748001 rs41378247 chr3 8575845 G A 7.82E-05 Type 2 diabetes LMCD1 intron 17463246 rs1027327 chr3 8606839 A G 0.00000868 Narcolepsy (non-HLA narcolepsy) LMCD1 intron 23459209 rs355136 chr3 8620012 C T 8.41E-04 Multiple complex diseases / / 17554300 rs355137 chr3 8620174 G A 7.90E-04 Multiple complex diseases / / 17554300 rs355142 chr3 8623429 C T 3.42E-04 Multiple complex diseases / / 17554300 rs3774210 chr3 8676204 A G 7.30E-05 Heart Rate C3orf32 intron pha003051 rs17049383 chr3 8680116 C T 7.08E-04 Multiple complex diseases C3orf32 intron 17554300 rs164956 chr3 8684764 A G 0.000000859 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes C3orf32 intron 22628534 rs412508 chr3 8702963 A G 2.00E-05 Lung adenocarcinoma / / 19836008 rs2172557 chr3 8709205 C T 1.12E-04 Taste perception / / 22132133 rs164466 chr3 8749171 T C 7.47E-05 ldl cholesterol / / pha003076 rs12497498 chr3 8751490 G A 5.36E-04 Multiple complex diseases / / 17554300 rs1471970 chr3 8765024 A G 1.18E-04 Multiple complex diseases / / 17554300 rs237872 chr3 8780438 C T 2.50E-04 HDL particle features CAV3 intron 21283740 rs11706648 chr3 8796547 A C 6.60E-04 Asthma OXTR intron 20698975 rs2268490 chr3 8797085 C T 4.95E-05 Coronary heart disease OXTR intron pha003033 rs2268492 chr3 8800672 C T 6.42E-05 Cholesterol OXTR intron pha003078 rs2268495 chr3 8807535 G A 5.10E-06 Urinary metabolites OXTR intron 21572414 rs237899 chr3 8808515 G A 2.20E-04 Alcohol dependence OXTR intron 20201924 rs237899 chr3 8808515 G A 2.00E-06 Depression and alcohol dependence OXTR intron 22064162 rs17049528 chr3 8812862 G A 8.40E-05 Cholesterol OXTR nearGene-5 17255346 rs1488467 chr3 8813231 G C 9.97E-05 Cholesterol OXTR nearGene-5 17255346 rs6790467 chr3 8826023 A G 8.66E-05 Asthma / / pha003127 rs6793234 chr3 8826396 A G 6.86E-06 Osteoarthritis / / 22763110 rs9844525 chr3 8834445 G A 1.00E-04 Information processing speed / / 21130836 rs2544163 chr3 8854367 T C 2.76E-05 Alzheimer's disease (late onset) / / 21379329 rs2544163 chr3 8854367 T C 1.21E-05 Coronary heart disease / / pha003031 rs345069 chr3 8856126 T C 4.96E-04 Coronary heart disease / / 21606135 rs345067 chr3 8856500 T C 7.36E-04 Type 2 diabetes / / 17463246 rs173182 chr3 8858201 T C 8.85E-04 Type 2 diabetes / / 17463246 rs345065 chr3 8862925 T C 3.52E-05 Asthma / / pha003128 rs124844 chr3 8881649 A G 3.30E-06 Alzheimer's disease (late onset) / / 21379329 rs83622 chr3 8881713 T G 1.88E-04 Alzheimer's disease (late onset) / / 21379329 rs2270474 chr3 8883040 T C 4.11E-04 Coronary Artery Disease / / 17634449 rs9867782 chr3 8884204 G A 3.26E-05 Alzheimer's disease (late onset) / / 21379329 rs7632085 chr3 8890021 A G 6.27E-06 Alzheimer's disease (late onset) / / 21379329 rs11706378 chr3 8905524 C T 1.58E-04 Multiple complex diseases / / 17554300 rs11706378 chr3 8905524 C T 3.53E-04 Depression (quantitative trait) / / 20800221 rs9816708 chr3 8906295 C T 6.90E-04 Multiple complex diseases / / 17554300 rs11715042 chr3 8906866 G A 1.99E-04 Depression (quantitative trait) / / 20800221 rs17734025 chr3 8911347 T G 1.98E-04 Depression (quantitative trait) / / 20800221 rs658339 chr3 8932353 A G 7.68E-04 Suicide attempts in bipolar disorder RAD18 intron 21041247 rs250411 chr3 8942437 C G 9.00E-06 Personality dimensions RAD18 intron 18957941 rs373090 chr3 8942606 G T 7.00E-06 Personality dimensions RAD18 intron 18957941 rs11707481 chr3 8954385 G A 6.80E-05 Height RAD18 intron 21998595 rs7622068 chr3 8970377 T G 1.54E-04 Response to cytadine analogues (cytosine arabinoside) RAD18 intron 24483146 rs583509 chr3 9032897 T A 2.60E-05 Urinary metabolites SRGAP3 intron 21572414 rs413789 chr3 9034145 T G 3.42E-04 Amyotrophic Lateral Sclerosis SRGAP3 intron 17362836 rs487865 chr3 9041094 G C 1.90E-05 Urinary metabolites SRGAP3 intron 21572414 rs487865 chr3 9041094 G C 7.00E-04 Breast cancer (survival) SRGAP3 intron 22232737 rs486012 chr3 9041299 T C 9.90E-06 Urinary metabolites SRGAP3 intron 21572414 rs486012 chr3 9041299 T C 9.14E-05 Smoking quantity SRGAP3 intron 24665060 rs666743 chr3 9041346 T C 8.20E-04 Coronary heart disease SRGAP3 intron 21606135 rs571701 chr3 9041687 T C 1.70E-05 Urinary metabolites SRGAP3 intron 21572414 rs341795 chr3 9046906 T A 2.10E-05 Urinary metabolites SRGAP3 intron 21572414 rs1161765 chr3 9048152 A G 7.31E-04 Coronary heart disease SRGAP3 intron 21606135 rs341789 chr3 9050155 C G 8.18E-04 Multiple complex diseases SRGAP3 intron 17554300 rs341788 chr3 9050659 C T 9.31E-04 Coronary heart disease SRGAP3 intron 21606135 rs383563 chr3 9052494 A G 1.70E-05 Urinary metabolites SRGAP3 intron 21572414 rs399747 chr3 9052506 G T 1.30E-05 Urinary metabolites SRGAP3 intron 21572414 rs17798894 chr3 9061714 T G 9.23E-04 Multiple complex diseases SRGAP3 intron 17554300 rs1513315 chr3 9072286 T C 3.55E-04 Insulin resistance SRGAP3 intron 21901158 rs7617156 chr3 9072878 T C 6.26E-05 Triglycerides SRGAP3 intron pha003080 rs884237 chr3 9079896 T C 2.44E-04 Fibrinogen SRGAP3 intron 17255346 rs639952 chr3 9080714 T C 6.15E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SRGAP3 intron 20031582 rs2662090 chr3 9091946 T G 3.00E-04 Suicidal ideation SRGAP3 intron 22030708 rs2662090 chr3 9091946 T G 9.95E-05 Glucose levels SRGAP3 intron pha002899 rs2664095 chr3 9099653 T C 4.50E-07 Urinary metabolites SRGAP3 intron 21572414 rs2669989 chr3 9120004 T C 1.75E-04 Tourette syndrome SRGAP3 intron 22889924 rs17050039 chr3 9157737 A C 8.42E-04 Taste perception SRGAP3 intron 22132133 rs17050048 chr3 9160213 G A 7.39E-05 Cognitive impairment induced by topiramate SRGAP3 intron 22091778 rs12634676 chr3 9164440 G C 3.88E-05 Odorant perception SRGAP3 intron 23910658 rs2675187 chr3 9179971 C A 5.00E-04 Stroke SRGAP3 intron pha002886 rs2675186 chr3 9193324 T C 6.08E-04 Multiple complex diseases SRGAP3 intron 17554300 rs2543499 chr3 9194156 A G 5.82E-04 Multiple complex diseases SRGAP3 intron 17554300 rs17530358 chr3 9200375 G A 3.80E-04 Alcohol dependence SRGAP3 intron 24277619 rs17530358 chr3 9200375 G A 5.79E-05 Coronary heart disease SRGAP3 intron pha003031 rs2664108 chr3 9207125 A G 1.07E-04 Lung function (forced vital capacity) SRGAP3 intron 24023788 rs386011 chr3 9214397 A T 2.97E-05 Serum metabolites SRGAP3 intron 19043545 rs446975 chr3 9217383 G T 1.72E-04 Premature ovarian failure SRGAP3 intron 19508998 rs446975 chr3 9217383 G T 7.38E-05 Cognitive impairment induced by topiramate SRGAP3 intron 22091778 rs10490820 chr3 9230006 G A 1.66E-04 Insulin resistance SRGAP3 intron 21901158 rs6765880 chr3 9232109 T C 2.00E-05 Urinary metabolites SRGAP3 intron 21572414 rs1145153 chr3 9234763 C T 8.04E-05 Coronary heart disease SRGAP3 intron pha003031 rs9819189 chr3 9251198 T C 6.27E-04 Myopia (pathological) SRGAP3 intron 21095009 rs9819189 chr3 9251198 T C 1.25E-04 Lung function (forced expiratory volume in 1 second) SRGAP3 intron 24023788 rs9819189 chr3 9251198 T C 1.54E-04 Lung function (forced vital capacity) SRGAP3 intron 24023788 rs12638703 chr3 9252998 C T 3.53E-06 Interstitial lung disease SRGAP3 intron 23583980 rs4684627 chr3 9256398 T C 1.45E-05 Amyotrophic lateral sclerosis SRGAP3 intron 20801717 rs4684627 chr3 9256398 T C 0.000038 Amyotrophic lateral sclerosis SRGAP3 intron 23587638 rs1154398 chr3 9258218 A G 1.00E-04 Cognitive impairment induced by topiramate SRGAP3 intron 22091778 rs9853725 chr3 9273196 T C 8.81E-04 Myopia (pathological) SRGAP3 intron 21095009 rs1186291 chr3 9274570 A T 3.55E-04 Multiple complex diseases SRGAP3 intron 17554300 rs4684630 chr3 9287144 C A 3.48E-04 Nicotine smoking SRGAP3 intron 19268276 rs2137216 chr3 9288545 T C 9.80E-05 Major depressive disorder SRGAP3 intron 21042317 rs11131163 chr3 9291861 A G 3.76E-05 Amyotrophic lateral sclerosis / / 20801717 rs2600175 chr3 9294880 C T 0.000593 Salmonella-induced pyroptosis / / 22837397 rs4686337 chr3 9311215 A T 1.90E-04 Multiple complex diseases / / 17554300 rs2600163 chr3 9312283 G A 6.49E-05 Smoking initiation / / 24665060 rs4686340 chr3 9345218 A C 1.00E-06 Hypertension / / 22384028 rs17050220 chr3 9350167 C A 8.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs17802092 chr3 9359037 G T 9.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs3930151 chr3 9373721 T C 5.25E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10510398 chr3 9374170 T C 8.35E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4053784 chr3 9374648 C G 9.76E-05 Cytomegalovirus antibody response / / 21993531 rs2600169 chr3 9375147 C T 9.38E-05 Alzheimer's disease (late onset) / / 21379329 rs2728945 chr3 9418510 A G 8.42E-04 Body mass index THUMPD3 intron 21701565 rs2596917 chr3 9421024 C T 9.73E-05 Alzheimer's disease (late onset) THUMPD3 intron 21379329 rs2600193 chr3 9425743 A G 9.97E-05 Alzheimer's disease (late onset) THUMPD3 intron 21379329 rs6443238 chr3 9449055 C T 5.10E-08 Alcohol dependence SETD5 intron 22096494 rs11915826 chr3 9451377 T A 2.60E-05 Response to statin therapy SETD5 intron 20339536 rs4258956 chr3 9455051 T A 2.70E-05 Response to statin therapy SETD5 intron 20339536 rs11922615 chr3 9458307 A G 2.60E-08 Alcohol dependence SETD5 intron 22096494 rs4078527 chr3 9463688 A G 3.00E-05 Response to statin therapy SETD5 intron 20339536 rs3872706 chr3 9464092 A G 3.20E-05 Response to statin therapy SETD5 intron 20339536 rs7613389 chr3 9473202 A C 2.72E-04 Coronary Artery Disease SETD5 intron 17634449 rs7613389 chr3 9473202 A C 7.10E-05 Response to statin therapy SETD5 intron 20339536 rs3912330 chr3 9474061 A G 7.20E-05 Response to statin therapy SETD5 intron 20339536 rs17050346 chr3 9481593 A G 7.40E-05 Response to statin therapy SETD5 intron 20339536 rs6803966 chr3 9486503 G A 7.70E-05 Response to statin therapy SETD5 intron 20339536 rs2290164 chr3 9487148 T C 9.10E-05 Response to statin therapy SETD5 intron 20339536 rs7617427 chr3 9499448 A G 4.14E-04 Coronary Artery Disease SETD5 intron 17634449 rs7628780 chr3 9635563 G A 3.40E-04 Multiple complex diseases / / 17554300 rs6809387 chr3 9702755 A G 5.85E-04 Multiple complex diseases MTMR14 intron 17554300 rs3868041 chr3 9706177 A G 1.07E-04 Multiple complex diseases MTMR14 intron 17554300 rs12493353 chr3 9710307 T C 2.34E-04 Multiple complex diseases MTMR14 intron 17554300 rs10510414 chr3 9716403 A T 9.62E-05 Multiple complex diseases MTMR14 intron 17554300 rs4686369 chr3 9722566 G A 3.84E-04 Multiple complex diseases MTMR14 intron 17554300 rs159142 chr3 9730868 G C 5.11E-04 Suicide attempts in bipolar disorder MTMR14 intron 21423239 rs11131183 chr3 9735683 G A 2.60E-04 Multiple complex diseases MTMR14 intron 17554300 rs12490544 chr3 9736452 C G 6.83E-04 Multiple complex diseases MTMR14 intron 17554300 rs468056 chr3 9748636 A G 3.03E-05 Cytomegalovirus antibody response CPNE9 intron 21993531 rs293782 chr3 9819922 A C 2.80E-04 Coronary heart disease / / 21966275 rs11711241 chr3 9831970 T G 4.31E-04 Multiple complex diseases TADA3 intron 17554300 rs9879307 chr3 9870065 C T 0.0000012 Child behavior checklist/1.5-5 total problems TTLL3 intron 23049896 rs4686377 chr3 9877452 G A 6.40E-04 Type 2 diabetes TTLL3 UTR-3 17463246 rs279565 chr3 9898280 A C 3.74E-04 Stroke (pediatric) / / 22990015 rs1053239 chr3 9908749 G C 4.50E-06 Speech perception in dyslexia CIDEC UTR-3 19786962 rs17222564 chr3 9910334 T C 6.72E-04 Multiple complex diseases CIDEC intron 17554300 rs279553 chr3 9934605 T C 3.00E-05 Suicidal ideation JAGN1 cds-synon 22030708 rs279542 chr3 9935773 C G 3.00E-05 Suicidal ideation JAGN1 UTR-3 22030708 rs12053867 chr3 9939828 G A 2.86E-04 Schizophrenia / / 20832056 rs279545 chr3 9972493 G A 1.10E-04 Endometriosis IL17RC intron 21151130 rs279545 chr3 9972493 G A 2.98E-04 Alzheimer's disease IL17RC intron 24755620 rs34233937 chr3 9989107 C T 1.16E-05 Orofacial clefts PRRT3 missense 22419666 rs17050660 chr3 10001772 C T 1.33E-05 Alzheimer's disease / / 24755620 rs13063929 chr3 10010308 T C 1.55E-05 Alzheimer's disease TMEM111 intron 24755620 rs3732968 chr3 10013273 A G 1.55E-05 Alzheimer's disease TMEM111 intron 24755620 rs3732967 chr3 10015437 T C 1.54E-05 Alzheimer's disease TMEM111 intron 24755620 rs3732966 chr3 10015740 C T 7.23E-06 Alzheimer's disease TMEM111 intron 24755620 rs7633769 chr3 10020622 C T 1.72E-05 Alzheimer's disease TMEM111 intron 24755620 rs3755783 chr3 10029289 A G 9.79E-06 Alzheimer's disease LOC442075 intron 24755620 rs13089863 chr3 10032259 T G 2.19E-05 Alzheimer's disease LOC442075 intron 24755620 rs13066757 chr3 10045030 C A 2.19E-05 Alzheimer's disease / / 24755620 rs6804473 chr3 10060425 C T 9.63E-05 Alzheimer's disease (late onset) CIDECP intron 21379329 rs6804473 chr3 10060425 C T 6.45E-06 Alzheimer's disease CIDECP intron 24755620 rs7611218 chr3 10063960 T C 5.12E-06 Alzheimer's disease CIDECP intron 24755620 rs3846177 chr3 10068572 G T 6.03E-06 Alzheimer's disease FANCD2 intron 24755620 rs7648104 chr3 10073311 C A 6.41E-06 Alzheimer's disease FANCD2 intron 24755620 rs17032278 chr3 10077955 A G 6.41E-06 Alzheimer's disease FANCD2 intron 24755620 rs6442147 chr3 10078247 A G 4.73E-06 Alzheimer's disease FANCD2 intron 24755620 rs7631678 chr3 10078816 T G 6.61E-06 Alzheimer's disease FANCD2 intron 24755620 rs7637888 chr3 10080722 T C 6.61E-06 Alzheimer's disease FANCD2 intron 24755620 rs17032283 chr3 10081545 G C 7.51E-06 Alzheimer's disease FANCD2 intron 24755620 rs9875081 chr3 10083935 G A 2.96E-04 Alzheimer's disease (late onset) FANCD2 intron 21379329 rs9875081 chr3 10083935 G A 1.03E-05 Alzheimer's disease FANCD2 intron 24755620 rs35625434 chr3 10084828 G A 0.00036 Prostate cancer FANCD2 missense 23555315 rs17032295 chr3 10086680 G A 1.81E-04 Alzheimer's disease (late onset) FANCD2 intron 21379329 rs17032295 chr3 10086680 G A 7.24E-06 Alzheimer's disease FANCD2 intron 24755620 rs17032299 chr3 10087638 C T 7.03E-06 Alzheimer's disease FANCD2 intron 24755620 rs35782247 chr3 10089689 T G 2.39E-09 LDL cholesterol FANCD2 missense 23063622 rs7615646 chr3 10089773 A C,G 3.18E-04 Alzheimer's disease (late onset) FANCD2 intron 21379329 rs7615646 chr3 10089773 A C,G 7.08E-06 Alzheimer's disease FANCD2 intron 24755620 rs6781811 chr3 10121922 C T 4.62E-06 Alzheimer's disease FANCD2 intron 24755620 rs6442150 chr3 10122575 T C 5.40E-06 Alzheimer's disease FANCD2 intron 24755620 rs6789156 chr3 10124120 G A 5.77E-06 Alzheimer's disease FANCD2 intron 24755620 rs6791810 chr3 10124444 C T 5.18E-06 Alzheimer's disease FANCD2 intron 24755620 rs13319597 chr3 10126312 G T 5.42E-06 Alzheimer's disease FANCD2 intron 24755620 rs34632086 chr3 10133478 T C 3.00E-04 Alzheimer's disease (late onset) FANCD2 intron 21379329 rs34632086 chr3 10133478 T C 1.95E-06 Alzheimer's disease FANCD2 intron 24755620 rs9849434 chr3 10133710 G A 1.88E-06 Alzheimer's disease FANCD2 intron 24755620 rs9811771 chr3 10133949 A G 1.88E-06 Alzheimer's disease FANCD2 intron 24755620 rs12374115 chr3 10134766 C T 2.22E-06 Alzheimer's disease FANCD2 intron 24755620 rs1552244 chr3 10135577 A G 4.37E-04 Alzheimer's disease (late onset) FANCD2 intron 21379329 rs1552244 chr3 10135577 A G 2.00E-06 Alzheimer's disease FANCD2 intron 24755620 rs2272125 chr3 10138069 T G 4.44E-06 Alzheimer's disease FANCD2 cds-synon 24755620 rs2272124 chr3 10138189 T C 4.44E-06 Alzheimer's disease FANCD2 intron 24755620 rs2272123 chr3 10140115 G A 4.35E-06 Alzheimer's disease FANCD2 intron 24755620 rs7626117 chr3 10140671 G A 7.17E-05 Alzheimer's disease FANCD2 UTR-3 24755620 rs7647987 chr3 10140696 A G 4.60E-06 Alzheimer's disease FANCD2 UTR-3 24755620 rs12152512 chr3 10143770 C T 5.13E-06 Alzheimer's disease C3orf24 intron 24755620 rs7652935 chr3 10151138 T C 5.32E-06 Alzheimer's disease / / 24755620 rs41520445 chr3 10153141 G T 5.32E-06 Alzheimer's disease / / 24755620 rs17032396 chr3 10153559 G A 5.86E-06 Alzheimer's disease / / 24755620 rs6764068 chr3 10153842 A G 6.04E-06 Alzheimer's disease / / 24755620 rs17032414 chr3 10158302 C G 6.26E-06 Alzheimer's disease BRK1 intron 24755620 rs3774208 chr3 10164722 T G 9.57E-04 Alzheimer's disease BRK1 intron 24755620 rs713024 chr3 10181240 A G 2.30E-04 Lymphocyte counts / / 22286170 rs779803 chr3 10182562 G A 1.10E-05 Urinary metabolites VHL nearGene-5 21572414 rs457414 chr3 10202884 C A 1.83E-20 Lymphocyte counts / / 22286170 rs6779158 chr3 10203562 A G 4.31E-09 HDL cholesterol / / 23063622 rs3844278 chr3 10211918 C T 9.46E-05 Cognitive impairment induced by topiramate IRAK2 intron 22091778 rs11465886 chr3 10250783 A G 0.00041 Coronary artery calcification IRAK2 intron 23727086 rs2302862 chr3 10258493 T C 1.12E-04 Attention deficit hyperactivity disorder IRAK2 intron 22420046 rs2302862 chr3 10258493 T C 3.42E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) IRAK2 intron 23648065 rs778041 chr3 10272181 T G 3.99E-05 Lymphocyte counts IRAK2 intron 22286170 rs11926277 chr3 10277463 G A 4.33E-05 Bipolar disorder IRAK2 intron 22925353 rs11706450 chr3 10277866 T C 7.86E-05 Systemic sclerosis IRAK2 intron 21750679 rs11711184 chr3 10278980 A C 5.50E-05 Bipolar disorder IRAK2 intron 22925353 rs11707074 chr3 10292643 C T 7.12E-04 Alcohol dependence TATDN2 intron 21314694 rs2241312 chr3 10301300 A G 3.57E-04 Alcohol dependence TATDN2 intron 21314694 rs3732950 chr3 10334981 G A 0.000000559 Triglycerides / / 23063622 rs2619507 chr3 10335786 A G 3.83E-04 Type 2 diabetes GHRL nearGene-5 17463246 rs1629816 chr3 10336291 G A 2.20E-05 Urinary metabolites GHRL nearGene-5 21572414 rs696220 chr3 10344111 G A 1.10E-05 Urinary metabolites SEC13 intron 21572414 rs35668 chr3 10351830 G A 7.06E-05 Prion diseases SEC13 intron 22210626 rs154238 chr3 10355584 C G 7.26E-05 Serum metabolites SEC13 intron 19043545 rs1719571 chr3 10369180 A G 5.05E-04 Coronary heart disease ATP2B2 UTR-3 21606135 rs697973 chr3 10388902 G A 6.43E-05 Blood Pressure ATP2B2 intron pha003050 rs775018 chr3 10400145 A G 9.63E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ATP2B2 intron 22566498 rs28113 chr3 10400643 G A 6.26E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ATP2B2 intron 22566498 rs775022 chr3 10404739 C A 3.29E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ATP2B2 intron 22566498 rs1658704 chr3 10407045 G C 1.93E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ATP2B2 intron 22566498 rs4684684 chr3 10411344 C T 4.19E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ATP2B2 intron 22566498 rs1473183 chr3 10411827 G A 7.85E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ATP2B2 intron 22566498 rs2289272 chr3 10413526 G A 3.46E-04 Type 2 diabetes ATP2B2 cds-synon 17463246 rs2289273 chr3 10413601 G A 1.60E-05 Schizophrenia(treatment response to risperidone) ATP2B2 cds-synon 19850283 rs6442165 chr3 10415108 T G 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ATP2B2 intron 22566498 rs26796 chr3 10415314 G A 1.99E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ATP2B2 intron 22566498 rs1438168 chr3 10437280 T C 5.57E-04 Smoking initiation ATP2B2 intron 24665060 rs1438168 chr3 10437280 T C 2.82E-06 Body mass index ATP2B2 intron 24827717 rs17032820 chr3 10442539 A G 6.19E-04 Alzheimer's disease ATP2B2 intron 24755620 rs759692 chr3 10443000 C T 1.58E-04 Response to taxane treatment (placlitaxel) ATP2B2 intron 23006423 rs11710165 chr3 10443090 A C 4.77E-05 Cholesterol ATP2B2 intron pha003073 rs11710165 chr3 10443090 A C 7.43E-05 Cholesterol ATP2B2 intron pha003078 rs9839685 chr3 10448340 T C 9.53E-04 Multiple complex diseases ATP2B2 intron 17554300 rs6786239 chr3 10448772 C T 1.42E-04 Cocaine dependence ATP2B2 intron 23958962 rs6786239 chr3 10448772 C T 3.30E-06 Cocaine dependence ATP2B2 intron 23958962 rs34907 chr3 10452231 G A 2.51E-04 Taste perception ATP2B2 intron 22132133 rs34918 chr3 10460174 G A 4.21E-05 Cholesterol ATP2B2 intron pha003073 rs34918 chr3 10460174 G A 4.46E-05 Cholesterol ATP2B2 intron pha003078 rs11707511 chr3 10463507 G A 9.47E-05 Response to taxane treatment (placlitaxel) ATP2B2 intron 23006423 rs523180 chr3 10470828 C T 7.96E-05 Cholesterol ATP2B2 intron pha003073 rs523180 chr3 10470828 C T 6.78E-05 Cholesterol ATP2B2 intron pha003078 rs17032876 chr3 10470911 G A 8.83E-04 Multiple complex diseases ATP2B2 intron 17554300 rs929707 chr3 10477026 T C 8.62E-04 Stroke ATP2B2 intron pha002887 rs17603886 chr3 10484726 C T 7.00E-06 Amyotrophic lateral sclerosis (sporadic) ATP2B2 intron 24529757 rs3774135 chr3 10489487 C T 7.20E-04 Multiple complex diseases ATP2B2 intron 17554300 rs34872 chr3 10508495 T C 4.65E-05 Alzheimer's disease (age of onset) ATP2B2 intron 22005931 rs17032984 chr3 10529069 G T 0.0000459 Salmonella-induced pyroptosis ATP2B2 intron 22837397 rs799320 chr3 10533302 G T 7.70E-04 Smoking initiation ATP2B2 intron 24665060 rs6807064 chr3 10535771 C T 1.00E-07 Metabolite levels ATP2B2 intron 19043545 rs6442177 chr3 10573967 A G 2.80E-04 Multiple complex diseases / / 17554300 rs6442180 chr3 10588012 T C 9.32E-04 Multiple complex diseases / / 17554300 rs6796050 chr3 10602685 C T 4.17E-04 Acute lung injury / / 22295056 rs17509502 chr3 10605733 C T 6.51E-04 Acute lung injury / / 22295056 rs4572750 chr3 10605861 C A 6.09E-04 Acute lung injury / / 22295056 rs7629483 chr3 10611507 A G 3.29E-04 Acute lung injury / / 22295056 rs4684713 chr3 10617557 A T 5.32E-04 Acute lung injury / / 22295056 rs6803992 chr3 10622941 A C 8.07E-04 Multiple complex diseases / / 17554300 rs11920105 chr3 10627684 G T 6.80E-06 Type 2 diabetes / / 21573907 rs17033143 chr3 10630258 G A 9.20E-05 Tunica Media / / pha003037 rs4234503 chr3 10632679 C T 0.000000509 Brain activation patterns in response to human facial expressions-for the positive faces task / / 22828495 rs4234503 chr3 10632679 C T 1.95E-08 Brain activation patterns in response to human facial expressions-for the negative faces task / / 22828495 rs4234503 chr3 10632679 C T 1.95E-08 Airflow obstruction / / 22837378 rs9822272 chr3 10642523 A G 7.66E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs9822272 chr3 10642523 A G 4.98E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17033198 chr3 10645143 T C 2.45E-04 Multiple complex diseases / / 17554300 rs6772499 chr3 10658014 A G 4.82E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17033245 chr3 10661289 C T 1.86E-06 Erythrocyte counts / / pha003090 rs9880149 chr3 10686437 G A 2.51E-09 Narcolepsy / / 19629137 rs892601 chr3 10732548 A C 3.77E-05 Cognitive impairment induced by topiramate / / 22091778 rs1682825 chr3 10774759 C T 4.00E-06 Economic and political preferences (feminism/equality) / / 22566634 rs171239 chr3 10780817 T C 1.02E-06 Cognitive impairment induced by topiramate / / 22091778 rs13059249 chr3 10780904 A G 2.40E-05 Urinary metabolites / / 21572414 rs9830378 chr3 10784877 A G 2.34E-04 Multiple complex diseases / / 17554300 rs350665 chr3 10785012 C T 4.86E-04 Coronary heart disease / / 21971053 rs7627250 chr3 10785091 T C 1.44E-04 Multiple complex diseases / / 17554300 rs3900076 chr3 10801251 C T 5.99E-04 Multiple complex diseases / / 17554300 rs13078886 chr3 10801693 C A 4.54E-04 Multiple complex diseases / / 17554300 rs2581204 chr3 10815485 C T 8.90E-04 Stroke / / pha002886 rs2596834 chr3 10820067 C T 9.03E-04 Response to TNF antagonist treatment / / 21061259 rs2596834 chr3 10820067 C T 4.48E-04 Coronary heart disease / / 21971053 rs9835411 chr3 10873434 C T 1.42E-04 Multiple complex diseases SLC6A11 intron 17554300 rs1809529 chr3 10877611 C T 3.00E-07 Response to tocilizumab in rheumatoid arthritis SLC6A11 intron 22491018 rs999448 chr3 10902353 G A 3.83E-04 Tourette syndrome SLC6A11 intron 22889924 rs3774084 chr3 10958276 T C 6.50E-06 Alcohol dependence SLC6A11 intron 22096494 rs4684746 chr3 10966588 A G 1.94E-04 Substance dependence SLC6A11 intron 21818250 rs1881370 chr3 10974156 C T 9.66E-05 Multiple complex diseases SLC6A11 intron 17554300 rs751960 chr3 11016323 A G 7.90E-04 Multiple complex diseases / / 17554300 rs2930149 chr3 11021097 C T 9.06E-05 Cognitive impairment induced by topiramate / / 22091778 rs1710885 chr3 11038807 T C 3.19E-05 Major depressive disorder SLC6A1 intron 19107115 rs1710887 chr3 11039960 T G 6.70E-04 Coronary heart disease SLC6A1 intron 21606135 rs9990174 chr3 11040439 G T 6.00E-06 Conduct disorder (interaction) SLC6A1 intron 18846501 rs1919075 chr3 11043019 G A 7.13E-04 Response to TNF antagonist treatment SLC6A1 intron 21061259 rs1710891 chr3 11049133 C T 1.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC6A1 intron 20877124 rs6778281 chr3 11053517 C A 7.52E-05 Attention deficit hyperactivity disorder SLC6A1 intron 20732625 rs2928079 chr3 11055114 A T 6.62E-04 Alzheimer's disease SLC6A1 intron 17998437 rs1170695 chr3 11055338 A G 5.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC6A1 intron 20877124 rs2950798 chr3 11062934 G A 6.83E-04 Schizophrenia SLC6A1 intron 19197363 rs17033829 chr3 11065807 A C 5.53E-04 Amyotrophic Lateral Sclerosis SLC6A1 intron 17362836 rs17033829 chr3 11065807 A C 9.76E-05 Cognitive test performance SLC6A1 intron 20125193 rs9879137 chr3 11066388 T C 3.31E-04 Multiple complex diseases SLC6A1 intron 17554300 rs2675163 chr3 11075014 C T 6.00E-06 Response to Vitamin E supplementation SLC6A1 intron 22437554 rs2675163 chr3 11075014 C T 6.58E-05 Platelet counts SLC6A1 intron pha003100 rs11128537 chr3 11092828 C T 7.21E-04 Schizophrenia / / 21747397 rs7615791 chr3 11124925 T C 3.53E-05 Prion diseases / / 22210626 rs4684758 chr3 11139579 G A 0.00039 Breast cancer early age of onset / / 18463975 rs4593010 chr3 11164415 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs17034071 chr3 11211338 C T 1.50E-05 Urinary metabolites HRH1 intron 21572414 rs4684059 chr3 11232779 G C 8.00E-06 IgG glycosylation HRH1 intron 23382691 rs9822871 chr3 11239366 C T 6.31E-05 Alcohol dependence HRH1 intron 21703634 rs12493961 chr3 11244825 A G 4.49E-04 Suicide attempts in bipolar disorder HRH1 intron 21041247 rs433303 chr3 11244906 C T 1.72E-06 Alcohol dependence HRH1 intron 20202923 rs433303 chr3 11244906 C T 6.90E-04 Alcohol dependence HRH1 intron 21956439 rs443137 chr3 11253721 G A 1.80E-05 Alcohol dependence HRH1 intron 21703634 rs55748939 chr3 11257378 C T 0.00007801 Sarcoidosis HRH1 intron 22952805 rs440646 chr3 11291171 G T 4.40E-05 Type 2 diabetes HRH1 intron 17463249 rs440646 chr3 11291171 G T 4.42E-05 Multiple complex diseases HRH1 intron 17554300 rs346078 chr3 11327840 G C 1.20E-04 Multiple complex diseases ATG7 intron 17554300 rs2594995 chr3 11369117 G A 4.06E-04 Nicotine dependence ATG7 intron 17158188 rs2606747 chr3 11374955 T C,G 6.67E-04 Nicotine dependence ATG7 intron 17158188 rs2594978 chr3 11383347 C A 4.13E-04 Nicotine dependence ATG7 intron 17158188 rs2606742 chr3 11391717 G A 5.80E-04 Nicotine dependence ATG7 intron 17158188 rs2606736 chr3 11400249 C T 5.00E-08 HDL cholesterol ATG7 intron 24097068 rs7621218 chr3 11442013 C T 3.27E-04 Type 2 diabetes ATG7 intron 17463246 rs9874535 chr3 11463730 A G 5.47E-04 Type 2 diabetes ATG7 intron 17463246 rs7623889 chr3 11477387 C T 8.57E-04 Suicide attempts in bipolar disorder ATG7 intron 21041247 rs9818393 chr3 11509668 C T 1.52E-04 Obesity (extreme) ATG7 intron 21935397 rs4684782 chr3 11518755 T C 6.26E-04 Type 2 diabetes ATG7 intron 17463246 rs17536147 chr3 11559102 G C 4.91E-04 Multiple complex diseases ATG7 intron 17554300 rs6442260 chr3 11590751 G A 8.69E-04 Type 2 diabetes ATG7 intron 17463246 rs7617620 chr3 11600563 C T 1.59E-05 Coronary heart disease VGLL4 intron pha003030 rs7617187 chr3 11605944 G C 1.46E-04 Obesity (extreme) VGLL4 intron 21935397 rs2574706 chr3 11615207 T C 3.00E-04 Cognitive decline VGLL4 intron 23732972 rs2004837 chr3 11617308 A G 5.56E-04 Type 2 diabetes VGLL4 intron 17463246 rs2077507 chr3 11618468 A G 7.24E-04 Type 2 diabetes VGLL4 intron 17463246 rs892932 chr3 11624211 C A 1.18E-04 Type 2 diabetes VGLL4 intron 17463246 rs892932 chr3 11624211 C A 2.92E-05 Bipolar disorder VGLL4 intron 19488044 rs892932 chr3 11624211 C A 6.66E-05 Bipolar Disorder VGLL4 intron pha002863 rs6802119 chr3 11625414 C T 2.00E-06 Metabolite levels (HVA) VGLL4 intron 23319000 rs6802119 chr3 11625414 C T 8.00E-06 Metabolite levels (HVA-5-HIAA Factor score) VGLL4 intron 23319000 rs2574726 chr3 11627978 G A 2.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VGLL4 intron 20877124 rs17776482 chr3 11633951 G A 3.04E-04 Alzheimer's disease VGLL4 intron 17998437 rs6780175 chr3 11638519 G C,T 1.70E-07 Urinary metabolites VGLL4 intron 21572414 rs6772112 chr3 11641535 C T 8.30E-07 Urinary metabolites VGLL4 intron 21572414 rs2574704 chr3 11655381 T C 7.22E-04 Schizophrenia VGLL4 intron 19197363 rs2574720 chr3 11660412 A C 9.88E-04 Multiple complex diseases VGLL4 intron 17554300 rs2574717 chr3 11661280 G T 8.31E-04 Multiple complex diseases VGLL4 intron 17554300 rs9871522 chr3 11663976 A G 5.00E-05 Information processing speed VGLL4 intron 21130836 rs6766610 chr3 11664859 C A 5.20E-04 Multiple complex diseases VGLL4 intron 17554300 rs6766610 chr3 11664859 C A 7.60E-05 Serum metabolites VGLL4 intron 19043545 rs2574713 chr3 11666874 G A 3.25E-05 Serum metabolites VGLL4 intron 19043545 rs6807423 chr3 11669548 A G 2.50E-06 Urinary metabolites VGLL4 intron 21572414 rs2447613 chr3 11670573 A G 2.36E-05 Serum metabolites VGLL4 intron 19043545 rs6781822 chr3 11675632 T C 2.92E-04 Obesity (extreme) VGLL4 intron 21935397 rs6782029 chr3 11675789 T C 9.00E-06 Anorexia nervosa VGLL4 intron 21079607 rs6782029 chr3 11675789 T C 3.30E-04 Alzheimer's disease (late onset) VGLL4 intron 21379329 rs13075818 chr3 11686389 G C 6.91E-04 Multiple complex diseases VGLL4 intron 17554300 rs17034986 chr3 11693869 A C 9.87E-05 Parent of origin effect on language impairment (maternal) VGLL4 intron 24571439 rs4684792 chr3 11694467 T C 9.00E-06 Relative hand skill in reading disability VGLL4 intron 24068947 rs12374138 chr3 11698796 G A 2.64E-04 Multiple complex diseases VGLL4 intron 17554300 rs11715990 chr3 11703635 G A 4.32E-05 Relative hand skill in reading disability VGLL4 intron 24068947 rs4444693 chr3 11704885 T A 4.01E-05 Relative hand skill in reading disability VGLL4 intron 24068947 rs3846116 chr3 11706197 G C 3.09E-05 Relative hand skill in reading disability VGLL4 intron 24068947 rs7644580 chr3 11721793 T C 6.28E-05 Serum metabolites VGLL4 intron 19043545 rs9854973 chr3 11727998 C T 3.77E-04 Response to taxane treatment (placlitaxel) VGLL4 intron 23006423 rs1039200 chr3 11730846 C A 8.76E-04 Response to taxane treatment (placlitaxel) VGLL4 intron 23006423 rs9835698 chr3 11736267 A G 5.26E-04 Response to taxane treatment (placlitaxel) VGLL4 intron 23006423 rs7619252 chr3 11737145 C T 2.18E-04 Multiple complex diseases VGLL4 intron 17554300 rs7619252 chr3 11737145 C T 8.16E-05 Type 1 diabetes VGLL4 intron 18978792 rs370234 chr3 11785147 T C 2.25E-05 Insulin Resistance / / pha003062 rs370234 chr3 11785147 T C 2.31E-05 Insulin-related traits / / pha003063 rs392621 chr3 11886365 T C 6.77E-04 Type 2 diabetes TAMM41 intron 17463246 rs392621 chr3 11886365 T C 5.44E-04 Multiple complex diseases TAMM41 intron 17554300 rs392621 chr3 11886365 T C 1.57E-09 Lymphocyte counts TAMM41 intron 22286170 rs392621 chr3 11886365 T C 1.02E-04 Smoking quantity TAMM41 intron 24665060 rs440746 chr3 11888556 G T 2.97E-04 Type 2 diabetes / / 17463246 rs440746 chr3 11888556 G T 8.23E-04 Multiple complex diseases / / 17554300 rs430373 chr3 11889365 G A 1.23E-05 Smoking quantity / / 24665060 rs4684823 chr3 11889787 C T 2.50E-05 Urinary metabolites / / 21572414 rs4684823 chr3 11889787 C T 3.38E-05 Smoking quantity / / 24665060 rs732096 chr3 11893950 T C 2.28E-05 Smoking quantity / / 24665060 rs303850 chr3 11896347 A G 1.31E-04 Smoking quantity / / 24665060 rs6777876 chr3 11956598 A G 4.00E-07 Alcohol dependence / / 21314694 rs438129 chr3 12007910 T C 7.40E-05 Aging (time to event) / / 21782286 rs305506 chr3 12026709 G T 7.67E-04 Multiple complex diseases / / 17554300 rs7615580 chr3 12027240 T C 1.97E-05 White matter integrity / / 22425255 rs2618405 chr3 12038264 C A 2.03E-05 Anorexia nervosa / / 24514567 rs308971 chr3 12116620 G A 2.00E-07 Fasting insulin-related traits (interaction with BMI) SYN2 intron 22581228 rs308971 chr3 12116620 G A 2.97E-11 Body mass index SYN2 intron 22885924 rs11720130 chr3 12156316 G A 1.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SYN2 intron 20877124 rs4488811 chr3 12182028 C T 1.70E-05 White matter integrity SYN2 intron 22425255 rs4488811 chr3 12182028 C T 9.63E-05 Waist-Hip Ratio SYN2 intron pha003029 rs310746 chr3 12259616 C T 6.15E-05 Systemic sclerosis / / 21750679 rs7616006 chr3 12267648 A G 5.00E-08 Platelet counts / / 22139419 rs17036101 chr3 12277845 G A 2.00E-07 Type 2 diabetes / / 18372903 rs17036101 chr3 12277845 G A 2.00E-07 Coronary heart disease / / 21347282 rs17036101 chr3 12277845 G A 2.00E-07 Type 2 diabetes / / 21647700 rs13081389 chr3 12289800 A G 2.00E-07 Type 2 diabetes / / 20581827 rs13081389 chr3 12289800 A G 0.00000082 Type 2 diabetes / / 22885922 rs13081389 chr3 12289800 A G 2.00E-07 Type 2 diabetes / / 23300278 rs7641345 chr3 12296540 A G 3.10E-05 Response to statin therapy / / 20339536 rs13089415 chr3 12301360 G T 6.22E-04 White matter integrity / / 22425255 rs13089415 chr3 12301360 G T 7.79E-05 Waist-Hip Ratio / / pha003029 rs12330874 chr3 12302242 G A 7.85E-04 Alzheimer's disease / / 17998437 rs17036160 chr3 12329783 C T 0.00000787 Type 2 diabetes PPARG intron 22325160 rs17036170 chr3 12330411 G A 2.00E-08 Drug-induced liver injury PPARG intron 22968431 rs2972164 chr3 12334416 T C 0.00003 Coronary artery calcification PPARG intron 23727086 rs11709077 chr3 12336507 G A 5.10E-04 Multiple complex diseases PPARG intron 17554300 rs11709077 chr3 12336507 G A 6.98E-04 Alzheimer's disease PPARG intron 17998437 rs11709077 chr3 12336507 G A 0.000000011 Type 2 diabetes (females) PPARG intron 22885922 rs11709077 chr3 12336507 G A 0.00000015 Type 2 diabetes (males) PPARG intron 22885922 rs4684846 chr3 12338849 A G 0.00037 Coronary artery calcification PPARG intron 23727086 rs12631819 chr3 12342861 G T 0.00000835 HDL cholesterol PPARG intron 23063622 rs11128596 chr3 12343117 A C 0.00027 Coronary artery calcification PPARG intron 23727086 rs12485478 chr3 12351223 A G 0.0000359 HDL cholesterol PPARG intron 23063622 rs12496505 chr3 12356158 G A 0.00029 Coronary artery calcification PPARG intron 23727086 rs13433696 chr3 12358492 G A 0.00029 Coronary artery calcification PPARG intron 23727086 rs7646510 chr3 12363358 A G 2.05E-08 LDL cholesterol PPARG intron 23063622 rs3892175 chr3 12368038 G A 9.96E-04 Alzheimer's disease PPARG intron 22005930 rs12496005 chr3 12371082 G C 0.00021 Coronary artery calcification PPARG intron 23727086 rs12490265 chr3 12384542 G A 2.10E-05 Urinary metabolites PPARG intron 21572414 rs17036321 chr3 12384599 T C 7.44E-08 LDL cholesterol PPARG intron 23063622 rs11128603 chr3 12385828 A G 9.00E-08 Plasminogen activator inhibitor type 1 levels (PAI-1) PPARG intron 22990020 rs17036328 chr3 12390484 T C 3.46E-04 Multiple complex diseases PPARG intron 17554300 rs17036328 chr3 12390484 T C 3.59E-12 Fasting insulin-related traits PPARG intron 22885924 rs7649970 chr3 12392272 C T 0.00000454 Type 2 diabetes PPARG intron 22325160 rs1801282 chr3 12393125 C G 2.00E-06 Type 2 diabetes PPARG missense 17463246 rs1801282 chr3 12393125 C G 2.00E-06 Type 2 diabetes PPARG missense 17463248 rs1801282 chr3 12393125 C G 2.00E-06 Type 2 diabetes PPARG missense 17463249 rs1801282 chr3 12393125 C G 2.31E-04 Alzheimer's disease PPARG missense 17998437 rs1801282 chr3 12393125 C G 2.00E-06 Coronary heart disease PPARG missense 21347282 rs1801282 chr3 12393125 C G 2.00E-06 Type 2 diabetes PPARG missense 21647700 rs1801282 chr3 12393125 C G 0.0000215 Type 2 diabetes PPARG missense 22325160 rs1801282 chr3 12393125 C G 2.00E-07 Fasting insulin-related traits (interaction with BMI) PPARG missense 22581228 rs1801282 chr3 12393125 C G 0.00033 Fasting insulin-related traits PPARG missense 22885922 rs1801282 chr3 12393125 C G 1.10E-12 Type 2 diabetes PPARG missense 22885922 rs1801282 chr3 12393125 C G 1.40E-07 Plasminogen activator inhibitor type 1 levels (PAI-1) PPARG missense 22990020 rs1801282 chr3 12393125 C G 1.70E-06 Type 2 diabetes PPARG missense 23300278 rs1801282 chr3 12393125 C G 6.00E-10 Type 2 diabetes PPARG missense 24509480 rs1899951 chr3 12394840 C T 0.00000037 Type 2 diabetes PPARG intron 22885922 rs2938397 chr3 12408278 A G 8.30E-05 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy PPARG intron 23118302 rs73025249 chr3 12410290 G A 0.0000217 Menopause (age at onset) PPARG intron 23424626 rs13306745 chr3 12421056 G T 3.50E-17 HDL cholesterol PPARG intron 23063622 rs4135268 chr3 12437237 C G 9.20E-06 Memory performance PPARG intron 22105620 rs4135275 chr3 12443844 A G 1.35E-04 Alcohol dependence PPARG intron 20201924 rs73027210 chr3 12447268 G A 0.0000217 Menopause (age at onset) PPARG intron 23424626 rs114451007 chr3 12454621 A T 0.0000093 Menopause (age at onset) PPARG intron 23424626 rs17036700 chr3 12468627 G T 2.44E-04 Multiple complex diseases PPARG intron 17554300 rs1797912 chr3 12470239 A C 0.0000548 Type 2 diabetes PPARG intron 22325160 rs4135361 chr3 12470663 G A 5.22E-11 LDL cholesterol PPARG intron 23063622 rs7626560 chr3 12475088 C T 2.40E-05 Urinary metabolites PPARG intron 21572414 rs7650895 chr3 12475162 A C 2.40E-05 Urinary metabolites PPARG intron 21572414 rs9833097 chr3 12478817 G A 5.57E-05 Major depressive disorder / / 21621269 rs9833097 chr3 12478817 G A 6.72E-05 Major depressive disorder / / pha002850 rs4498025 chr3 12481375 C T 9.22E-04 Multiple complex diseases / / 17554300 rs13088214 chr3 12487827 T C 6.11E-05 Tunica Media / / pha003036 rs4684854 chr3 12488882 G C 4.00E-06 Sexual dimorphism in anthropometric traits / / 23754948 rs9855622 chr3 12493347 C T 3.48E-06 Systemic sclerosis / / 21750679 rs1185784 chr3 12494278 C T 0.000645 Salmonella-induced pyroptosis / / 22837397 rs1185784 chr3 12494278 C T 7.87E-04 Smoking quantity / / 24665060 rs11917039 chr3 12506675 G C 7.30E-05 Iron levels / / 21208937 rs17036788 chr3 12507401 T C 1.30E-04 Smoking quantity / / 24665060 rs709165 chr3 12514124 A G 4.97E-05 Multiple complex diseases / / 17554300 rs17036821 chr3 12533148 G T 4.42E-08 Lymphocyte counts TSEN2 intron 22286170 rs17036841 chr3 12537924 T C 4.23E-04 Smoking quantity TSEN2 intron 24665060 rs299651 chr3 12537955 T A 1.66E-04 Multiple complex diseases TSEN2 intron 17554300 rs2596827 chr3 12546172 T G 9.26E-04 Multiple complex diseases TSEN2 intron 17554300 rs299653 chr3 12548943 G C 2.28E-04 Multiple complex diseases TSEN2 intron 17554300 rs299653 chr3 12548943 G C 2.31E-04 Lymphocyte counts TSEN2 intron 22286170 rs299655 chr3 12550235 A G 3.30E-04 Multiple complex diseases TSEN2 intron 17554300 rs6766510 chr3 12551807 T C 2.00E-06 Prostate cancer (gene x gene interaction) TSEN2 intron 22219177 rs17036870 chr3 12553933 C T 3.53E-04 Multiple complex diseases TSEN2 intron 17554300 rs17036872 chr3 12559188 G A 1.92E-28 Metabolite levels TSEN2 intron 22286219 rs1618545 chr3 12560763 A T 3.18E-04 Multiple complex diseases TSEN2 intron 17554300 rs796173 chr3 12564302 A G 3.17E-04 Multiple complex diseases TSEN2 intron 17554300 rs299630 chr3 12568425 T G 3.27E-04 Multiple complex diseases TSEN2 intron 17554300 rs1552484 chr3 12580246 G C 1.34E-04 Arthritis (juvenile idiopathic) / / 22354554 rs2596822 chr3 12596844 T C 9.26E-05 Arthritis (juvenile idiopathic) / / 22354554 rs2454422 chr3 12603900 G A 8.08E-04 Multiple complex diseases MKRN2 intron 17554300 rs2454422 chr3 12603900 G A 6.22E-05 Arthritis (juvenile idiopathic) MKRN2 intron 22354554 rs2633442 chr3 12609937 G A 3.35E-04 Multiple complex diseases MKRN2 intron 17554300 rs15997 chr3 12624070 C T 5.54E-04 Multiple complex diseases MKRN2 UTR-3 17554300 rs5746255 chr3 12624321 A G 5.85E-05 Multiple complex diseases MKRN2 UTR-3 17554300 rs13106 chr3 12624580 G A 7.96E-04 Alcohol dependence MKRN2 UTR-3 20201924 rs7956 chr3 12624763 T C 1.46E-04 Multiple complex diseases MKRN2 UTR-3 17554300 rs3729931 chr3 12626516 G A 7.00E-07 Cardiac hypertrophy RAF1 intron 21348951 rs2290159 chr3 12628920 G C 4.00E-09 Cholesterol,total RAF1 intron 20686565 rs2290159 chr3 12628920 G C 2.00E-09 Cholesterol,total RAF1 intron 24097068 rs1532533 chr3 12635706 G A 8.55E-05 Arthritis (juvenile idiopathic) RAF1 intron 22354554 rs2442809 chr3 12637675 T G 2.94E-04 Multiple complex diseases RAF1 intron 17554300 rs11705805 chr3 12662370 A G 2.62E-04 Suicide attempts in bipolar disorder RAF1 intron 21423239 rs2055312 chr3 12663250 C T 2.59E-04 Suicide attempts in bipolar disorder RAF1 intron 21423239 rs6766666 chr3 12690855 G T 8.15E-04 Multiple complex diseases RAF1 intron 17554300 rs9874315 chr3 12727962 C A 6.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs9818046 chr3 12736530 C G 7.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs4444694 chr3 12741219 T A 8.18E-04 Type 2 diabetes / / 17463246 rs4399872 chr3 12741345 T A 8.24E-04 Type 2 diabetes / / 17463246 rs6442325 chr3 12763841 A C 7.94E-05 Orofacial clefts / / 19270707 rs17037220 chr3 12818103 T C 7.20E-04 Type 2 diabetes / / 17463246 rs6791647 chr3 12826425 A G 7.40E-04 Type 2 diabetes / / 17463246 rs9874893 chr3 12833079 C G 2.54E-04 Type 2 diabetes / / 17463246 rs4034942 chr3 12836792 C T 2.54E-04 Type 2 diabetes / / 17463246 rs2305397 chr3 12857493 C T 2.54E-04 Type 2 diabetes CAND2 missense 17463246 rs200149446 chr3 12857896 C T 0.00004 Breast cancer CAND2 missense 23555315 rs536280133 chr3 12874937 G GT 1.53E-04 Acute lung injury CAND2 intron 22295056 rs7622555 chr3 12874937 G T 1.53E-04 Acute lung injury CAND2 intron 22295056 rs7628715 chr3 12907090 C T 6.97E-05 Acute lung injury / / 22295056 rs2600228 chr3 12908510 A C 7.44E-06 Lung function (forced expiratory volume in 1 second) / / pha003102 rs434460 chr3 12917207 A G 6.08E-06 Multiple complex diseases / / 17554300 rs2569991 chr3 12923197 C A 1.00E-06 Periodontitis (DPAL) / / 24024966 rs11128623 chr3 12939829 T C 2.29E-05 Vaspin levels IQSEC1 UTR-3 22907691 rs2600322 chr3 12954868 A G 8.22E-06 Periodontitis (DPAL) IQSEC1 intron 24024966 rs2600221 chr3 12963216 C T 8.77E-06 Periodontitis (DPAL) IQSEC1 intron 24024966 rs2252275 chr3 12963445 T A 8.54E-06 Periodontitis (DPAL) IQSEC1 intron 24024966 rs2600328 chr3 12998180 T C 7.97E-05 Partial epilepsies IQSEC1 intron 20522523 rs3816058 chr3 13004851 T C 9.37E-04 Multiple complex diseases IQSEC1 intron 17554300 rs360834 chr3 13047002 T C 9.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) IQSEC1 intron 22566498 rs360833 chr3 13047602 A G 9.43E-04 Type 2 diabetes IQSEC1 intron 17463246 rs165571 chr3 13050094 T C 5.72E-05 Fibrinogen IQSEC1 intron pha003068 rs11712537 chr3 13052644 C T 0.000214 Salmonella-induced pyroptosis IQSEC1 intron 22837397 rs11715824 chr3 13055495 G A 0.000857 Salmonella-induced pyroptosis IQSEC1 intron 22837397 rs361052 chr3 13070799 A G 3.00E-04 Pancreatic cancer IQSEC1 intron 23180869 rs444944 chr3 13117999 G A 1.30E-05 Schizophrenia / / pha002857 rs181721 chr3 13129241 C T 6.72E-06 Glycemic traits (pregnancy) / / 23903356 rs6801338 chr3 13130396 G A 8.56E-04 Multiple complex diseases / / 17554300 rs4684119 chr3 13131195 A G 7.39E-06 Glycemic traits (pregnancy) / / 23903356 rs80136581 chr3 13133587 G A 0.00008642 Sarcoidosis / / 22952805 rs2600203 chr3 13136829 C T 5.78E-06 Glycemic traits (pregnancy) / / 23903356 rs3856816 chr3 13137229 C T 6.36E-04 Multiple complex diseases / / 17554300 rs3856816 chr3 13137229 C T 9.30E-04 Response to TNF antagonist treatment / / 21061259 rs360751 chr3 13139038 T C 4.07E-06 Glycemic traits (pregnancy) / / 23903356 rs165567 chr3 13140732 A G 3.12E-06 Glycemic traits (pregnancy) / / 23903356 rs17833070 chr3 13150039 T C 1.60E-05 Urinary metabolites / / 21572414 rs9864101 chr3 13190384 C T 2.55E-07 Intracranial aneurysm / / 20613766 rs9864101 chr3 13190384 C T 5.69E-05 Post-operative nausea and vomiting / / 21694509 rs4684121 chr3 13217692 G T 3.13E-04 Multiple complex diseases / / 17554300 rs357118 chr3 13232489 G A 4.03E-05 Mammographic density / / 22532574 rs357119 chr3 13233451 G A 2.45E-04 Mammographic density / / 22532574 rs2166856 chr3 13268998 A G 9.83E-04 Multiple complex diseases / / 17554300 rs2166856 chr3 13268998 A G 1.40E-06 Urinary metabolites / / 21572414 rs9869761 chr3 13286504 G C 7.01E-05 Multiple complex diseases / / 17554300 rs357159 chr3 13308740 G C 6.33E-04 Alcohol dependence / / 21314694 rs357116 chr3 13321852 A G 2.80E-05 Urinary metabolites / / 21572414 rs749574 chr3 13330721 C T 1.05E-04 Smoking initiation / / 24665060 rs3852032 chr3 13339060 G A 6.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs3852032 chr3 13339060 G A 6.20E-04 Smoking initiation / / 24665060 rs17038082 chr3 13400275 G A 2.30E-15 Progranulin levels NUP210 intron 21087763 rs17038082 chr3 13400275 G A 2.30E-15 Myocardial infarction NUP210 intron 21211798 rs2046190 chr3 13404761 G A 3.71E-06 Lymphocyte counts NUP210 intron 22286170 rs6771144 chr3 13423110 G A 4.69E-05 Schizophrenia (cytomegalovirus infection interaction) NUP210 intron 23358160 rs9874760 chr3 13463133 C T 2.78E-04 Multiple complex diseases / / 17554300 rs4283554 chr3 13466117 C G 1.26E-04 Multiple complex diseases / / 17554300 rs365691 chr3 13478434 T C 8.27E-04 Multiple complex diseases / / 17554300 rs468113 chr3 13499551 G A 9.52E-04 Multiple complex diseases / / 17554300 rs59585 chr3 13501254 T C 8.33E-04 Multiple complex diseases / / 17554300 rs3846119 chr3 13505180 C T 1.45E-05 Multiple complex diseases / / 17554300 rs12635063 chr3 13508455 G A 4.24E-04 Multiple complex diseases / / 17554300 rs17029076 chr3 13508915 A C 1.34E-04 Multiple complex diseases / / 17554300 rs2675234 chr3 13517751 C T 1.36E-04 Self-reported allergy / / 23817569 rs2655215 chr3 13517761 T C 1.41E-04 Self-reported allergy / / 23817569 rs2675233 chr3 13518034 C T 1.64E-04 Self-reported allergy / / 23817569 rs2597510 chr3 13523338 C G 1.96E-04 Self-reported allergy HDAC11 intron 23817569 rs2597515 chr3 13527134 A G 1.69E-04 Self-reported allergy HDAC11 intron 23817569 rs2655222 chr3 13537240 A G 1.63E-04 Myopia (pathological) HDAC11 intron 21095009 rs1116048 chr3 13537336 T C 1.63E-04 Myopia (pathological) HDAC11 intron 21095009 rs34210830 chr3 13555017 C G 0.000023 Mean arterial pressure / / 22510845 rs2597513 chr3 13555836 C T 7.00E-10 Height / / 20881960 rs896056 chr3 13583528 G A 1.29E-05 Myopia (pathological) / / 23049088 rs4684960 chr3 13607746 C G 2.46E-04 Height FBLN2 intron 17255346 rs908813 chr3 13608182 G C 3.73E-04 Height FBLN2 intron 17255346 rs908811 chr3 13610577 T G 3.90E-04 Height FBLN2 UTR-5 17255346 rs3773283 chr3 13626592 T C 2.92E-05 Partial epilepsies FBLN2 intron 20522523 rs3773282 chr3 13630307 T C 1.08E-05 Partial epilepsies FBLN2 intron 20522523 rs1878173 chr3 13642946 A G 3.63E-04 Schizophrenia FBLN2 intron 19197363 rs3773271 chr3 13646818 T C 2.47E-04 Schizophrenia FBLN2 intron 19197363 rs17793957 chr3 13649920 C G 2.90E-04 Multiple complex diseases FBLN2 intron 17554300 rs17793957 chr3 13649920 C G 1.85E-04 Alzheimer's disease FBLN2 intron pha002879 rs1562808 chr3 13665148 T C 9.61E-05 Hemoglobin FBLN2 intron pha003096 rs6795255 chr3 13665926 C G 1.41E-05 Bipolar disorder,schizoaffective FBLN2 intron 19567891 rs3773250 chr3 13676094 C T 9.65E-05 Bipolar disorder and schizophrenia FBLN2 intron 20889312 rs7610284 chr3 13680861 C T 2.77E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4603942 chr3 13704113 T C 9.53E-04 Obesity (extreme) LOC285375 intron 21935397 rs6793679 chr3 13705345 C T 2.08E-05 HIV-1 viral setpoint LOC285375 intron 21490045 rs6792244 chr3 13717199 A G 6.86E-04 Obesity (extreme) LOC285375 intron 21935397 rs12495328 chr3 13717252 C T 9.57E-04 Amyotrophic lateral sclerosis (sporadic) LOC285375 intron 24529757 rs11128653 chr3 13717663 A G 6.61E-04 Obesity (extreme) LOC285375 intron 21935397 rs6775581 chr3 13720097 C T 6.41E-04 Obesity (extreme) LOC285375 intron 21935397 rs6775581 chr3 13720097 C T 8.27E-05 Taste perception LOC285375 intron 22132133 rs4557142 chr3 13722407 A C 9.97E-04 Obesity (extreme) LOC285375 intron 21935397 rs9849455 chr3 13726270 A G 4.05E-04 Obesity (extreme) LOC285375 intron 21935397 rs9849613 chr3 13726334 A G 8.28E-04 Obesity (extreme) LOC285375 intron 21935397 rs6781368 chr3 13726840 G A 9.16E-04 Obesity (extreme) LOC285375 intron 21935397 rs6794344 chr3 13726888 T C 8.54E-04 Obesity (extreme) LOC285375 intron 21935397 rs6781488 chr3 13727086 C G 8.67E-04 Obesity (extreme) LOC285375 intron 21935397 rs6795216 chr3 13730682 G T 9.23E-04 Obesity (extreme) LOC285375 intron 21935397 rs9826161 chr3 13730960 T G 8.56E-04 Obesity (extreme) LOC285375 intron 21935397 rs9830904 chr3 13731645 T C 8.95E-04 Obesity (extreme) LOC285375 intron 21935397 rs9811516 chr3 13731786 G A 3.39E-04 Multiple complex diseases LOC285375 intron 17554300 rs9848869 chr3 13731856 A G 5.65E-04 Obesity (extreme) LOC285375 intron 21935397 rs4234514 chr3 13736633 G A 2.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC285375 intron 20877124 rs4450798 chr3 13737000 G T 2.00E-06 Bipolar disorder (mood-incongruent) LOC285375 intron 23092984 rs12490834 chr3 13742435 G C 9.23E-04 Suicide attempts in bipolar disorder LOC285375 intron 21423239 rs9846232 chr3 13743132 G T 1.00E-08 Personality dimensions LOC285375 intron 21368711 rs4684993 chr3 13757482 G A 2.88E-04 Suicide attempts in bipolar disorder LOC285375 intron 21423239 rs4684995 chr3 13758474 A G 4.12E-04 Suicide attempts in bipolar disorder LOC285375 intron 21423239 rs7631252 chr3 13803506 G A 9.64E-05 Femoral neck bone geometry / / 22087292 rs4684157 chr3 13807781 G A 9.68E-05 Femoral neck bone geometry / / 22087292 rs4685016 chr3 13808010 C T 5.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs9866343 chr3 13808439 T C 4.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs9284832 chr3 13810540 G C 3.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs4525847 chr3 13810670 C A 3.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs4498020 chr3 13810820 C A 3.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs9872360 chr3 13811824 A G 2.32E-05 Suicide attempts in bipolar disorder / / 21423239 rs4234519 chr3 13812873 G A 4.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs12630573 chr3 13824605 T A 3.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs13097641 chr3 13825666 A G 4.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs13079210 chr3 13829565 G A 8.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs12629061 chr3 13831614 C T 8.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs1124480 chr3 13857969 T C 9.00E-06 Chronic obstructive pulmonary disease-related biomarkers / / 23144326 rs4685039 chr3 13866499 G A 6.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) WNT7A intron 23648065 rs12634816 chr3 13872270 A G 2.67E-05 Blood Pressure WNT7A intron pha003049 rs10510424 chr3 13875328 C G 5.00E-04 Type 2 diabetes and 6 quantitative traits WNT7A intron 17848626 rs13321422 chr3 13884815 G A 3.90E-04 Multiple complex diseases WNT7A intron 17554300 rs1368576 chr3 13889848 G A 2.50E-04 Response to ximelagatran treatment WNT7A intron 17505501 rs9878521 chr3 13895187 C A 6.83E-04 Multiple complex diseases WNT7A intron 17554300 rs7653849 chr3 13899147 A G 3.40E-06 Schizophrenia WNT7A intron 20185149 rs1433357 chr3 13944838 C T 6.46E-04 Alzheimer's disease / / 17998437 rs9875589 chr3 13961157 T G 4.00E-06 Ovarian reserve / / 22116950 rs2731306 chr3 14080189 T C 1.03E-05 Alzheimer's disease TPRXL intron 21627779 rs2731334 chr3 14107387 C T 9.70E-04 Coronary heart disease / / 21606135 rs2731334 chr3 14107387 C T 1.03E-05 Alzheimer's disease / / 21627779 rs2607741 chr3 14147892 T C 1.03E-05 Alzheimer's disease / / 21627779 rs139590716 chr3 14180693 G C 0.00026 Breast cancer (ER positive) TMEM43 missense 23555315 rs1043953 chr3 14183758 A G 6.88E-04 Smoking initiation TMEM43 UTR-3 24665060 rs8516 chr3 14184669 T C 2.08E-04 Alcohol dependence TMEM43 UTR-3 21314694 rs8516 chr3 14184669 T C 5.68E-04 Smoking initiation TMEM43 UTR-3 24665060 rs2470458 chr3 14186823 T C 7.42E-04 Smoking initiation XPC UTR-3 24665060 rs2228001 chr3 14187449 G T 1 Drug response to Cisplatin XPC missense 19434073 rs2733533 chr3 14188700 C A 4.56E-05 Smoking initiation XPC intron 24665060 rs2733534 chr3 14188762 G C 4.83E-05 Smoking initiation XPC intron 24665060 rs2607737 chr3 14193168 C T 1.56E-04 Smoking initiation XPC intron 24665060 rs1350344 chr3 14217576 G A 1.35E-05 Smoking initiation XPC intron 24665060 rs2607744 chr3 14235285 C G 7.89E-05 Smoking initiation LSM3 intron 24665060 rs2733551 chr3 14238743 T G 2.01E-04 Smoking initiation LSM3 intron 24665060 rs4685080 chr3 14253947 C A 4.62E-04 Alzheimer's disease (late onset) / / 21379329 rs12639212 chr3 14267211 A G 2.10E-05 Urinary metabolites / / 21572414 rs6442433 chr3 14275759 C G 7.22E-04 Alcohol dependence / / 21314694 rs12493406 chr3 14280171 C T 6.08E-04 Smoking initiation / / 24665060 rs6802240 chr3 14285238 A G 5.98E-05 Body Fat Distribution / / pha003016 rs6802240 chr3 14285238 A G 5.29E-06 Body Fat Distribution / / pha003017 rs6802240 chr3 14285238 A G 3.31E-06 Body Fat Distribution / / pha003018 rs10510427 chr3 14287703 G A 5.86E-05 Smoking initiation / / 24665060 rs1871856 chr3 14290893 A G 4.76E-04 Schizophrenia / / 19197363 rs2341654 chr3 14298116 T A 8.30E-05 Personality dimensions / / 18957941 rs2341654 chr3 14298116 T A 9.20E-05 Serum metabolites / / 19043545 rs9881693 chr3 14311273 T C 9.88E-05 Multiple complex diseases / / 17554300 rs9883639 chr3 14345707 C T 6.96E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs9837707 chr3 14347085 T C 2.50E-05 Response to alcohol consumption (flushing response) / / 24277619 rs9844272 chr3 14357848 C T 1.95E-04 Hearing function / / 17255346 rs4684207 chr3 14374615 T C 3.39E-05 Cognitive impairment induced by topiramate / / 22091778 rs900176 chr3 14377925 A G 7.59E-05 Schizophrenia / / 19571809 rs6794796 chr3 14383632 A G 6.89E-05 Cognitive impairment induced by topiramate / / 22091778 rs749855 chr3 14387154 T C 2.15E-05 Cognitive impairment induced by topiramate / / 22091778 rs4684208 chr3 14389483 C T 4.53E-04 Type 2 diabetes / / 17463246 rs9878149 chr3 14402491 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1550158 chr3 14406623 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs721377 chr3 14435063 C T 5.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs17308574 chr3 14455958 G A 9.96E-05 Kawasaki disease SLC6A6 intron 22446961 rs4331657 chr3 14459473 G A 5.74E-05 Glucose levels SLC6A6 intron pha003061 rs12638941 chr3 14460915 C T 7.05E-04 Nicotine smoking SLC6A6 intron 19268276 rs6801669 chr3 14473278 G A 4.02E-05 Response to taxane treatment (placlitaxel) SLC6A6 intron 23006423 rs4402920 chr3 14478231 C G 2.60E-05 Response to taxane treatment (placlitaxel) SLC6A6 intron 23006423 rs6790433 chr3 14480778 T C 1.00E-06 Response to taxane treatment (docetaxel) SLC6A6 intron 23006423 rs6766142 chr3 14482659 G A 8.38E-05 Body Mass Index SLC6A6 intron pha003022 rs11128699 chr3 14496162 G A 4.47E-05 Brain lesion load SLC6A6 intron 19010793 rs17237132 chr3 14499020 C T 3.61E-04 Nicotine smoking SLC6A6 intron 19268276 rs12489456 chr3 14501174 G A 4.00E-07 Alcohol dependence SLC6A6 intron 21956439 rs2289129 chr3 14508311 C T 2.02E-05 Basophils SLC6A6 intron pha003087 rs3773175 chr3 14510761 T C 4.55E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs3773174 chr3 14510861 T C 1.79E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs3773173 chr3 14510886 T C 4.48E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs3773172 chr3 14511699 G A 1.80E-04 Alcohol dependence SLC6A6 intron 20201924 rs3773172 chr3 14511699 G A 5.30E-04 Alcohol dependence SLC6A6 intron 20201924 rs3773172 chr3 14511699 G A 4.48E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs3773171 chr3 14512093 C T 3.20E-04 Alcohol dependence SLC6A6 intron 20201924 rs3773171 chr3 14512093 C T 4.80E-04 Alcohol dependence SLC6A6 intron 20201924 rs3773171 chr3 14512093 C T 4.48E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs9826660 chr3 14512731 A C 4.47E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs9868733 chr3 14513180 C T 4.46E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs2289128 chr3 14513695 G A 2.20E-04 Alcohol dependence SLC6A6 intron 20201924 rs2289128 chr3 14513695 G A 4.00E-04 Alcohol dependence SLC6A6 intron 20201924 rs2289128 chr3 14513695 G A 5.88E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs9834678 chr3 14517115 T C 2.50E-04 Alcohol dependence SLC6A6 intron 20201924 rs9834678 chr3 14517115 T C 5.60E-05 Alcohol dependence SLC6A6 intron 20201924 rs9834678 chr3 14517115 T C 2.73E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs9834678 chr3 14517115 T C 5.65E-05 Alcoholism SLC6A6 intron pha002893 rs3773167 chr3 14517282 G A 1.93E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs9820113 chr3 14517999 G T 6.41E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs9845444 chr3 14519102 T C 7.41E-04 Depression (quantitative trait) SLC6A6 intron 20800221 rs3773165 chr3 14524270 G A 1.00E-06 Alcohol dependence SLC6A6 intron 21956439 rs9036 chr3 14530721 A G 3.00E-06 Cognitive performance SLC6A6 UTR-3 19734545 rs2276756 chr3 14548208 G A 9.82E-04 Alzheimer's disease GRIP2 intron 22005930 rs4516597 chr3 14554476 T C 9.58E-04 Alzheimer's disease GRIP2 intron 22005930 rs11128703 chr3 14554608 C T 5.82E-04 Alzheimer's disease GRIP2 intron 22005930 rs11128703 chr3 14554608 C T 8.37E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GRIP2 intron 22566498 rs4685169 chr3 14554845 T A 5.53E-04 Alzheimer's disease GRIP2 intron 22005930 rs4685170 chr3 14555009 C T 8.76E-04 Alzheimer's disease GRIP2 intron 22005930 rs4685170 chr3 14555009 C T 8.14E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GRIP2 intron 22566498 rs4685171 chr3 14555216 T C 9.81E-04 Alzheimer's disease GRIP2 cds-synon 22005930 rs4685172 chr3 14555367 T C 7.35E-04 Alzheimer's disease GRIP2 intron 22005930 rs4361268 chr3 14555739 G A 5.11E-04 Alzheimer's disease GRIP2 intron 22005930 rs4613440 chr3 14555811 A G 9.92E-05 Cognitive test performance GRIP2 cds-synon 20125193 rs4613440 chr3 14555811 A G 9.26E-04 Alzheimer's disease GRIP2 cds-synon 22005930 rs4684229 chr3 14556198 T A,C,G 4.34E-04 Alzheimer's disease GRIP2 intron 22005930 rs872526 chr3 14560840 A C 3.08E-04 Nicotine smoking GRIP2 intron 19268276 rs872526 chr3 14560840 A C 8.05E-04 Alzheimer's disease GRIP2 intron 22005930 rs4234526 chr3 14563258 A G 5.90E-04 Alzheimer's disease GRIP2 cds-synon 22005930 rs200550670 chr3 14570887 CCATTTA C 6.11E-04 Alzheimer's disease GRIP2 intron 22005930 rs4685180 chr3 14570887 C T 6.11E-04 Alzheimer's disease GRIP2 intron 22005930 rs4684231 chr3 14571310 G A 6.02E-04 Alzheimer's disease GRIP2 intron 22005930 rs4684232 chr3 14571669 C T 5.58E-04 Alzheimer's disease GRIP2 intron 22005930 rs4685188 chr3 14571892 A G 5.50E-04 Alzheimer's disease GRIP2 intron 22005930 rs4685189 chr3 14571956 T C 5.45E-04 Alzheimer's disease GRIP2 intron 22005930 rs2139505 chr3 14572596 G A 5.29E-04 Alzheimer's disease GRIP2 intron 22005930 rs2139507 chr3 14572643 C G 5.37E-04 Alzheimer's disease GRIP2 intron 22005930 rs9310449 chr3 14591346 C A 9.90E-05 Cognitive performance / / 19734545 rs4449299 chr3 14598965 C A 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer / / 21245432 rs1533671 chr3 14603343 T G 7.70E-05 Mammographic density / / 22532574 rs13090178 chr3 14609299 C T 9.01E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9829645 chr3 14613390 A G 2.71E-04 Type 2 diabetes / / 17463246 rs17318350 chr3 14635048 T C 2.81E-04 Type 2 diabetes / / 17463246 rs17039949 chr3 14672637 T C 8.82E-05 Multiple complex diseases / / 17554300 rs4684236 chr3 14700046 T C 1.00E-04 Prostate cancer C3orf19 intron 21743057 rs9830735 chr3 14701635 G A 1.00E-04 Prostate cancer C3orf19 intron 21743057 rs3773487 chr3 14706848 G A 1.00E-04 Prostate cancer C3orf19 intron 21743057 rs3773489 chr3 14707132 A C 1.00E-04 Prostate cancer C3orf19 intron 21743057 rs7633011 chr3 14710679 T C 3.36E-04 Lymphocyte counts C3orf19 intron 22286170 rs3773491 chr3 14712042 A G 1.00E-04 Prostate cancer C3orf19 intron 21743057 rs11709673 chr3 14713306 A G 1.00E-04 Prostate cancer C3orf19 UTR-3 21743057 rs1432601 chr3 14731808 C T 9.66E-04 Amyotrophic Lateral Sclerosis C3orf20 intron 17362836 rs7640439 chr3 14732694 C T 6.63E-04 Suicide attempts in bipolar disorder C3orf20 intron 21423239 rs11712257 chr3 14733230 G T 7.05E-04 Suicide attempts in bipolar disorder C3orf20 intron 21423239 rs10470604 chr3 14737182 G T 9.06E-04 Suicide attempts in bipolar disorder C3orf20 intron 21423239 rs7622324 chr3 14751296 G A 9.15E-04 Suicide attempts in bipolar disorder C3orf20 intron 21423239 rs141714657 chr3 14755667 G C 0.0000093 Breast cancer C3orf20 splice-5 23555315 rs141714657 chr3 14755667 G C 0.000016 Prostate cancer C3orf20 splice-5 23555315 rs141714657 chr3 14755667 G C 0.00033 Breast cancer (ER positive) C3orf20 splice-5 23555315 rs13075489 chr3 14758055 T C 7.65E-04 Suicide attempts in bipolar disorder C3orf20 intron 21423239 rs6442472 chr3 14765262 C T 4.19E-04 Suicide attempts in bipolar disorder C3orf20 intron 21423239 rs2195918 chr3 14770495 A G 7.22E-04 Suicide attempts in bipolar disorder C3orf20 intron 21423239 rs9834046 chr3 14772357 G T 9.39E-04 Suicide attempts in bipolar disorder C3orf20 intron 21423239 rs12496846 chr3 14773267 A G 3.24E-05 Opioid sensitivity C3orf20 intron 23183491 rs17040258 chr3 14796144 C T 8.71E-04 Type 2 diabetes C3orf20 intron 17463246 rs17040258 chr3 14796144 C T 1.84E-06 White blood cell count C3orf20 intron 21738479 rs17040258 chr3 14796144 C T 4.96E-05 Lung function (forced vital capacity) C3orf20 intron 24023788 rs1347104 chr3 14800419 A C 5.15E-04 Alzheimer's disease C3orf20 intron 22005930 rs7651825 chr3 14812118 G A 3.91E-05 Parkinson's disease C3orf20 intron 19915575 rs7651825 chr3 14812118 G A 2.20E-05 Parkinson's disease C3orf20 intron pha002868 rs853334 chr3 14817654 G A 3.66E-05 Body mass (lean) / / 19268274 rs3899614 chr3 14817727 G A 2.87E-04 Alzheimer's disease / / 24755620 rs13074606 chr3 14830469 A G 9.66E-05 Type 2 diabetes / / 17463246 rs1689549 chr3 14837473 T C 1.10E-05 Urinary metabolites / / 21572414 rs10510432 chr3 14865367 A C 2.32E-07 Paclitaxel sensitivity in NCI60 cancer cell lines FGD5 intron 21314952 rs9837816 chr3 14873640 C T 6.01E-07 Red blood cell traits FGD5 intron 23222517 rs7653784 chr3 14873794 T C 8.29E-04 Parkinson's disease FGD5 intron 17052657 rs1689581 chr3 14882551 T C 2.56E-04 Fibrinogen FGD5 intron 17255346 rs3887276 chr3 14886362 T C 9.22E-04 Type 2 diabetes FGD5 intron 17463246 rs1389300 chr3 14886796 A G 3.31E-04 Fibrinogen FGD5 intron 17255346 rs1389300 chr3 14886796 A G 4.90E-04 Myasthenia gravis FGD5 intron 23055271 rs1389301 chr3 14887029 G A 3.06E-04 Fibrinogen FGD5 intron 17255346 rs1826215 chr3 14887182 T C,G 4.04E-04 Suicide attempts in bipolar disorder FGD5 intron 21423239 rs1826215 chr3 14887182 T C,G 2.99E-07 Red blood cell traits FGD5 intron 23222517 rs1687295 chr3 14889756 T C 6.37E-08 Blood pressure FGD5 intron 21909110 rs4685217 chr3 14894121 G A 1.98E-04 Suicide attempts in bipolar disorder FGD5 intron 21423239 rs4685219 chr3 14894188 A G 2.82E-04 Suicide attempts in bipolar disorder FGD5 intron 21423239 rs1687320 chr3 14894634 C G 1.28E-04 Nicotine smoking FGD5 intron 19268276 rs294634 chr3 14900551 T G 1.90E-04 Smoking cessation FGD5 intron 24665060 rs294634 chr3 14900551 T G 9.23E-05 Serum albumin level FGD5 intron pha003084 rs17040409 chr3 14904727 G C 3.44E-04 Suicide attempts in bipolar disorder FGD5 intron 21423239 rs17040409 chr3 14904727 G C 4.30E-08 Red blood cell traits FGD5 intron 23222517 rs13084708 chr3 14909380 G A 4.17E-04 Suicide attempts in bipolar disorder FGD5 intron 21423239 rs13064931 chr3 14911568 C T 9.13E-08 Red blood cell traits FGD5 intron 23222517 rs1602300 chr3 14914699 A G 9.55E-06 Coronary artery calcification FGD5 intron 23870195 rs6804922 chr3 14923396 A G 5.84E-08 Red blood cell traits FGD5 intron 23222517 rs4684243 chr3 14931118 T A 8.06E-04 Multiple complex diseases FGD5 intron 17554300 rs903061 chr3 14958074 T G 9.71E-05 Type 2 diabetes FGD5 intron 17463246 rs13097792 chr3 14999621 G A 7.10E-06 Elbow pain NR2C2 intron pha003008 rs13097792 chr3 14999621 G A 8.64E-05 Weight NR2C2 intron pha003026 rs10510434 chr3 15020349 A G 2.57E-04 Suicide attempts in bipolar disorder NR2C2 intron 21041247 rs17040623 chr3 15028478 A G 2.43E-04 Suicide attempts in bipolar disorder NR2C2 intron 21041247 rs9839660 chr3 15030545 T A 2.38E-04 Suicide attempts in bipolar disorder NR2C2 intron 21041247 rs2164358 chr3 15051128 G A 9.57E-04 HIV-1 viral setpoint NR2C2 intron 17641165 rs11128731 chr3 15059330 T C 3.18E-04 Suicide attempts in bipolar disorder NR2C2 intron 21041247 rs612051 chr3 15075360 A G 2.25E-05 Response to taxane treatment (placlitaxel) NR2C2 intron 23006423 rs6442494 chr3 15081352 T C 7.24E-05 Serum albumin level NR2C2 intron pha003084 rs9820676 chr3 15083784 C G 2.92E-04 Suicide attempts in bipolar disorder NR2C2 intron 21041247 rs9825022 chr3 15084014 C T 2.89E-04 Suicide attempts in bipolar disorder NR2C2 intron 21041247 rs3773478 chr3 15113042 C T 1.74E-04 Suicide attempts in bipolar disorder ZFYVE20 UTR-3 21041247 rs9830744 chr3 15115478 C T 2.22E-04 Suicide attempts in bipolar disorder ZFYVE20 missense 21041247 rs9851219 chr3 15115723 T C 1.68E-04 Suicide attempts in bipolar disorder ZFYVE20 missense 21041247 rs9868848 chr3 15115872 A G 1.68E-04 Suicide attempts in bipolar disorder ZFYVE20 missense 21041247 rs746665 chr3 15118733 A T 1.68E-04 Suicide attempts in bipolar disorder ZFYVE20 intron 21041247 rs2306854 chr3 15119720 A C 1.70E-04 Suicide attempts in bipolar disorder ZFYVE20 intron 21041247 rs2306855 chr3 15119804 T C 1.70E-04 Suicide attempts in bipolar disorder ZFYVE20 intron 21041247 rs13326820 chr3 15122978 A G 1.47E-04 Suicide attempts in bipolar disorder ZFYVE20 intron 21041247 rs17040729 chr3 15129537 T G 1.34E-04 Suicide attempts in bipolar disorder ZFYVE20 intron 21041247 rs17040733 chr3 15134320 C G 1.11E-04 Suicide attempts in bipolar disorder ZFYVE20 intron 21041247 rs9839836 chr3 15143428 T G 1.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs13318013 chr3 15145487 G A 1.81E-04 Suicide attempts in bipolar disorder / / 21041247 rs9867224 chr3 15150797 A G 1.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs9867224 chr3 15150797 A G 7.30E-05 Cognitive function / / 24684796 rs7625117 chr3 15162577 T C 3.60E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs7639618 chr3 15216429 C T 7.30E-11 Osteoarthritis (knee) / / 18622395 rs353093 chr3 15224983 C T 6.20E-05 Osteoarthritis (knee) COL6A4P1 intron 18622395 rs9864422 chr3 15227252 C T 2.40E-08 Osteoarthritis (knee) COL6A4P1 intron 18622395 rs1287464 chr3 15247796 A G 6.70E-05 Osteoarthritis (knee) CAPN7 UTR-5 18622395 rs3773475 chr3 15264563 T C 2.40E-05 Osteoarthritis (knee) CAPN7 intron 18622395 rs10510438 chr3 15273386 T C 4.94E-06 Age-related macular degeneration CAPN7 intron pha000001 rs11713836 chr3 15294811 G A 2.10E-04 Osteoarthritis (knee) / / 18622395 rs1318937 chr3 15295364 A G 1.44E-04 Substance dependence / / 21818250 rs1318937 chr3 15295364 A G 3.00E-06 Alcohol dependence / / 21956439 rs1318937 chr3 15295364 A G 4.00E-07 Alcohol and nictotine co-dependence / / 22488850 rs3732728 chr3 15297954 G C 1.53E-04 Aortic root size SH3BP5 intron 21223598 rs3773474 chr3 15299028 G C 0.00000476 HDL cholesterol particle diameter SH3BP5 intron 23263444 rs6771876 chr3 15299227 G A 0.00000546 HDL cholesterol particle diameter SH3BP5 intron 23263444 rs9818506 chr3 15299437 T C 1.04E-04 Glycosylated haemoglobin levels SH3BP5 intron 17255346 rs9813606 chr3 15300655 A G 0.00000859 HDL cholesterol particle diameter SH3BP5 intron 23263444 rs9817868 chr3 15301052 A T 0.00000859 HDL cholesterol particle diameter SH3BP5 intron 23263444 rs2291853 chr3 15301363 G A 6.86E-04 Multiple complex diseases SH3BP5 intron 17554300 rs3773472 chr3 15302753 G C 6.50E-07 Osteoarthritis (knee) SH3BP5 intron 18622395 rs6442508 chr3 15304741 C G 1.96E-04 Glycosylated haemoglobin levels SH3BP5 intron 17255346 rs6442508 chr3 15304741 C G 0.0000084 HDL cholesterol particle diameter SH3BP5 intron 23263444 rs9310472 chr3 15306599 C T 1.88E-04 Glycosylated haemoglobin levels SH3BP5 intron 17255346 rs9310472 chr3 15306599 C T 0.00000596 HDL cholesterol particle diameter SH3BP5 intron 23263444 rs3773469 chr3 15308240 A G 5.40E-04 Osteoarthritis (knee) SH3BP5 intron 18622395 rs6788936 chr3 15309925 G T 0.00000889 HDL cholesterol particle diameter SH3BP5 intron 23263444 rs6808313 chr3 15314024 A G 0.00000828 HDL cholesterol particle diameter SH3BP5 intron 23263444 rs851848 chr3 15317938 T C 3.80E-04 Response to taxane treatment (placlitaxel) SH3BP5 intron 23006423 rs7340679 chr3 15346700 C T 1.04E-05 Attention deficit hyperactivity disorder SH3BP5 intron 20732625 rs9837421 chr3 15347293 C T 1.99E-05 Waist Circumference SH3BP5 intron pha003023 rs9837421 chr3 15347293 C T 8.20E-05 Waist-Hip Ratio SH3BP5 intron pha003029 rs9990297 chr3 15348130 T C 8.57E-05 Waist Circumference SH3BP5 intron pha003023 rs10510436 chr3 15349125 T C 2.40E-04 Multiple complex diseases SH3BP5 intron 17554300 rs2688665 chr3 15354907 G C 2.80E-05 Urinary metabolites SH3BP5 intron 21572414 rs17041032 chr3 15375822 G A 8.26E-04 Type 2 diabetes SH3BP5 intron 17463246 rs3844287 chr3 15379981 T C 0.0006 Salmonella-induced pyroptosis SH3BP5 intron 22837397 rs11926124 chr3 15398047 G A 3.62E-04 Myocardial Infarction / / pha002883 rs6442522 chr3 15440556 C T 5.00E-06 Uric acid levels / / 18759275 rs2290536 chr3 15469001 A C 9.12E-04 Multiple complex diseases METTL6 UTR-5 17554300 rs9855575 chr3 15514063 A C 4.67E-04 Multiple complex diseases COLQ intron 17554300 rs17041248 chr3 15545475 C G 1.69E-04 Multiple complex diseases COLQ intron 17554300 rs76909367 chr3 15552751 C T 0.0000689 Menopause (age at onset) COLQ intron 23424626 rs12495710 chr3 15559228 C T 4.38E-05 Alcohol dependence COLQ intron 20201924 rs12495710 chr3 15559228 C T 4.38E-05 Alcoholism COLQ intron pha002891 rs17041264 chr3 15562831 C T 3.81E-04 Iron levels COLQ intron pha002876 rs905648 chr3 15565322 C T 4.58E-06 Cardiovascular disease / / 18179892 rs4685252 chr3 15568863 C T 5.61E-05 Height / / pha003010 rs4685252 chr3 15568863 C T 1.65E-05 Height / / pha003011 rs4305404 chr3 15577567 G A 5.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs11707889 chr3 15579892 C A 6.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs7651039 chr3 15648004 T C 2.00E-06 Coronary heart disease BTD intron 21378990 rs9830528 chr3 15662606 G A 2.31E-04 Multiple complex diseases BTD intron 17554300 rs2455853 chr3 15690025 G A 1.51E-04 Multiple complex diseases / / 17554300 rs2455800 chr3 15701589 T G 6.15E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs2455801 chr3 15701857 G A 5.76E-04 Aortic root size / / 21223598 rs17041442 chr3 15719279 T C 7.50E-04 Type 2 diabetes ANKRD28 intron 17463246 rs35755845 chr3 15719279 T TG 7.50E-04 Type 2 diabetes ANKRD28 intron 17463246 rs6796083 chr3 15723586 G A 3.49E-04 Suicide attempts in bipolar disorder ANKRD28 intron 21423239 rs2455848 chr3 15771372 T C 1.92E-04 Multiple complex diseases ANKRD28 intron 17554300 rs10865735 chr3 15802131 A T 4.08E-04 Multiple complex diseases ANKRD28 intron 17554300 rs10865735 chr3 15802131 A T 1.70E-05 Urinary metabolites ANKRD28 intron 21572414 rs6789076 chr3 15807725 T A 6.34E-04 Aortic root size ANKRD28 intron 21223598 rs1447650 chr3 15808707 C T 6.57E-04 Suicide attempts in bipolar disorder ANKRD28 intron 21423239 rs6442550 chr3 15810309 A G 5.32E-04 Aortic root size ANKRD28 intron 21223598 rs7630373 chr3 15812085 T C 1.29E-08 Adiponectin levels ANKRD28 intron 20887962 rs1348981 chr3 15828811 G T 1.70E-04 Multiple complex diseases ANKRD28 intron 17554300 rs10510443 chr3 15829127 A G 5.72E-04 Aortic root size ANKRD28 intron 21223598 rs6762442 chr3 15833903 C G 1.57E-04 Multiple complex diseases ANKRD28 intron 17554300 rs13078999 chr3 15834746 G A 3.06E-04 Multiple complex diseases ANKRD28 intron 17554300 rs1447649 chr3 15837784 C T 1.63E-04 Multiple complex diseases ANKRD28 intron 17554300 rs11128758 chr3 15849330 G A 7.54E-04 Multiple complex diseases ANKRD28 intron 17554300 rs7610596 chr3 15849456 T C 4.29E-04 Suicide attempts in bipolar disorder ANKRD28 intron 21423239 rs17041542 chr3 15854043 A G 4.14E-04 Suicide attempts in bipolar disorder ANKRD28 intron 21423239 rs2166759 chr3 15856285 G A 7.42E-04 Aortic root size ANKRD28 intron 21223598 rs2166760 chr3 15857465 A G 6.96E-04 Multiple complex diseases ANKRD28 intron 17554300 rs12493140 chr3 15857590 G A 8.28E-04 Multiple complex diseases ANKRD28 intron 17554300 rs17041564 chr3 15861637 T C 2.54E-04 Multiple complex diseases ANKRD28 intron 17554300 rs17041564 chr3 15861637 T C 4.27E-04 Suicide attempts in bipolar disorder ANKRD28 intron 21423239 rs1345161 chr3 15863426 A G 9.61E-04 Suicide attempts in bipolar disorder ANKRD28 intron 21423239 rs11713820 chr3 15866590 C T 1.19E-04 Aortic root size ANKRD28 intron 21223598 rs9815283 chr3 15867375 A G 1.35E-04 Multiple complex diseases ANKRD28 intron 17554300 rs9864353 chr3 15869766 C T 2.38E-04 Multiple complex diseases ANKRD28 intron 17554300 rs11128760 chr3 15873407 A G 3.62E-04 Aortic root size ANKRD28 intron 21223598 rs11128762 chr3 15883439 G A 2.94E-04 Aortic root size ANKRD28 intron 21223598 rs2121737 chr3 15907946 G C 5.20E-04 Multiple complex diseases / / 17554300 rs4685266 chr3 15908766 A G 2.72E-04 Alcohol dependence / / 20201924 rs9813577 chr3 15909323 G A 7.30E-04 Multiple complex diseases / / 17554300 rs9813577 chr3 15909323 G A 4.90E-05 Cognitive function / / 24684796 rs1869627 chr3 16004488 C A 0.0008276 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1869627 chr3 16004488 C A 8.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7639184 chr3 16006626 A T 0.0003376 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7639184 chr3 16006626 A T 3.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1454776 chr3 16009044 G T 0.0003248 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1454776 chr3 16009044 G T 3.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9811682 chr3 16009368 C T 0.0003232 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9811682 chr3 16009368 C T 3.23E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4685286 chr3 16009804 C G 0.0003213 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4685286 chr3 16009804 C G 3.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10510444 chr3 16010476 C T 6.60E-05 Bone mineral density / / 19181680 rs10510444 chr3 16010476 C T 0.0003197 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10510444 chr3 16010476 C T 3.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1378169 chr3 16010612 C G 3.55E-05 Brain structure / / 22504417 rs13079584 chr3 16010715 G T 0.0003165 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13079584 chr3 16010715 G T 3.17E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1563229 chr3 16011202 G T 0.0003167 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1563229 chr3 16011202 G T 3.17E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9869915 chr3 16011708 C T 0.0003151 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9869915 chr3 16011708 C T 3.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2085149 chr3 16012131 A G 0.0003136 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2085149 chr3 16012131 A G 3.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2085151 chr3 16012191 G A 0.0003124 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2085151 chr3 16012191 G A 3.12E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1902115 chr3 16014620 G A 0.0003125 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1902115 chr3 16014620 G A 3.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1902116 chr3 16014736 G T 0.0003101 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1902116 chr3 16014736 G T 3.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1902117 chr3 16014769 A C 0.0003089 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1902117 chr3 16014769 A C 3.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6442563 chr3 16014859 T C 0.0002512 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6442563 chr3 16014859 T C 2.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11717117 chr3 16017665 A T 0.0002941 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11717117 chr3 16017665 A T 2.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4685294 chr3 16017905 T C 0.0002931 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4685294 chr3 16017905 T C 2.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6442565 chr3 16018470 A G 4.08E-05 Bone mineral density / / 19181680 rs10510445 chr3 16022885 G T 8.32E-04 Age-related macular degeneration / / 22125219 rs1378168 chr3 16024923 G A 3.11E-05 Brain structure / / 22504417 rs7625628 chr3 16035590 T C 3.30E-05 Brain structure / / 22504417 rs6770617 chr3 16036830 G A 3.26E-05 Brain structure / / 22504417 rs17041715 chr3 16042244 A G 6.34E-04 Age-related macular degeneration / / 22125219 rs4685304 chr3 16066211 C G 0.0000488 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4685304 chr3 16066211 C G 4.88E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9815997 chr3 16068354 C T 0.0000481 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9815997 chr3 16068354 C T 4.81E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9874065 chr3 16070506 C T 0.0000347 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9874065 chr3 16070506 C T 3.47E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs987858 chr3 16090920 T A 5.77E-04 Body mass index / / 21701565 rs1454768 chr3 16101186 T C 6.70E-04 Parkinson's disease / / 17052657 rs1454765 chr3 16110666 T G 2.67E-05 Brain structure / / 22504417 rs12497859 chr3 16114461 A G 6.20E-05 Orofacial clefts / / 22419666 rs9830122 chr3 16127222 T C 7.09E-05 Orofacial clefts / / 22419666 rs10865738 chr3 16133383 T C 1.41E-05 Orofacial clefts / / 22419666 rs6776952 chr3 16148056 T C 3.73E-04 Type 2 diabetes / / 17463246 rs6772516 chr3 16152118 T A 3.73E-04 Type 2 diabetes / / 17463246 rs4685307 chr3 16165418 G T 1.51E-07 Blood pressure / / 21996601 rs7624406 chr3 16169491 A G 7.47E-05 Serum metabolites / / 19043545 rs7624406 chr3 16169491 A G 2.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs2657606 chr3 16176298 C T 2.52E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12497461 chr3 16184030 A C 8.16E-05 Serum metabolites / / 19043545 rs6771632 chr3 16192143 T C 9.00E-06 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs6775152 chr3 16196224 G A 2.21E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs6775152 chr3 16196224 G A 4.36E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs4685319 chr3 16207275 A G 7.62E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2047975 chr3 16222989 G A 7.95E-04 Amyotrophic Lateral Sclerosis GALNTL2 intron 17827064 rs11128786 chr3 16233242 T C 1.84E-05 Leprosy GALNTL2 intron 22019778 rs6807124 chr3 16251995 G A 9.85E-05 Triglycerides GALNTL2 intron pha003081 rs7642905 chr3 16259904 T A 9.22E-04 Multiple complex diseases GALNTL2 intron 17554300 rs2271077 chr3 16261420 C T 7.58E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GALNTL2 missense 20031582 rs14576 chr3 16268986 C A 6.54E-05 Aging (time to event) GALNTL2 cds-synon 21782286 rs842264 chr3 16285262 T A 4.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs842263 chr3 16285414 T A 8.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs842262 chr3 16285927 G C 5.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs842261 chr3 16285941 G A 6.68E-04 Depression (quantitative trait) / / 20800221 rs842247 chr3 16291822 T C 9.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs842246 chr3 16293425 T C 6.53E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2292612 chr3 16300996 C T 2.28E-04 Multiple complex diseases DPH3 UTR-3 17554300 rs483682 chr3 16365223 G A 2.71E-04 Response to taxane treatment (placlitaxel) RFTN1 intron 23006423 rs542591 chr3 16391908 C A 1.00E-04 Cognitive impairment induced by topiramate RFTN1 intron 22091778 rs542591 chr3 16391908 C A 1.00E-04 Cognitive impairment induced by topiramate RFTN1 intron 22091778 rs542591 chr3 16391908 C A 2.00E-04 Cognitive impairment induced by topiramate RFTN1 intron 22091778 rs690037 chr3 16395668 C T 6.00E-07 optic disc size (cup) RFTN1 intron 20395239 rs7634895 chr3 16397878 T C 8.88E-04 Response to taxane treatment (placlitaxel) RFTN1 intron 23006423 rs17200269 chr3 16398797 G C 3.59E-04 Response to taxane treatment (placlitaxel) RFTN1 intron 23006423 rs12635698 chr3 16408489 T C 5.00E-06 Obesity (extreme) RFTN1 intron 19553259 rs9310496 chr3 16422989 A G 1.02E-04 Atopy RFTN1 intron 21625490 rs12629276 chr3 16428481 C T 1.40E-05 Type 2 diabetes RFTN1 intron 17293876 rs12629276 chr3 16428481 C T 1.40E-05 Type 2 diabetes RFTN1 intron 19184112 rs690403 chr3 16432477 C T 2.22E-05 Major depressive disorder RFTN1 intron 19107115 rs842495 chr3 16439969 G C 3.72E-04 Type 2 diabetes RFTN1 intron 17463246 rs842496 chr3 16440244 G A 3.88E-04 Type 2 diabetes RFTN1 intron 17463246 rs6442600 chr3 16441428 T C 3.98E-04 Type 2 diabetes RFTN1 intron 17463246 rs2860052 chr3 16441518 G C 5.17E-04 Type 2 diabetes RFTN1 intron 17463246 rs4685335 chr3 16448636 C T 3.28E-04 Type 2 diabetes RFTN1 intron 17463246 rs6776854 chr3 16457973 C T 7.03E-04 Body mass index RFTN1 intron 21701565 rs9817739 chr3 16480827 G A 7.32E-04 Multiple complex diseases RFTN1 intron 17554300 rs9817739 chr3 16480827 G A 3.47E-05 Bipolar disorder RFTN1 intron 18317468 rs9867980 chr3 16491898 T C 1.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RFTN1 intron 20877124 rs7621664 chr3 16518270 T C 5.80E-06 Urinary metabolites RFTN1 intron 21572414 rs11128791 chr3 16520435 T C 2.14E-04 Vaspin levels RFTN1 intron 22907691 rs11128791 chr3 16520435 T C 0.0002136 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit RFTN1 intron 22907730 rs2881512 chr3 16543983 A G 7.81E-05 Body Mass Index RFTN1 intron pha003021 rs3856834 chr3 16581660 T C 5.28E-13 Leprosy / / 22019778 rs6797084 chr3 16584850 C T 0.000496 Salmonella-induced pyroptosis / / 22837397 rs2042826 chr3 16585132 T C 0.000276 Salmonella-induced pyroptosis / / 22837397 rs6799971 chr3 16585193 G A 0.000194 Salmonella-induced pyroptosis / / 22837397 rs6442608 chr3 16588273 T C 0.000038 Coronary artery calcification / / 23727086 rs17042395 chr3 16593431 G A 1.09E-13 Gender / / 22362730 rs4685345 chr3 16610448 C G 6.16E-10 Gender / / 22362730 rs6803924 chr3 16617065 C G 1.51E-09 Gender / / 22362730 rs10510452 chr3 16625048 A G 4.54E-05 Cognitive test performance / / 20125193 rs10510452 chr3 16625048 A G 1.00E-08 Testicular germ cell tumor / / 23666240 rs4685366 chr3 16656331 A G 6.09E-05 Lipoproteins / / pha003079 rs1469372 chr3 16664509 A G 1.01E-05 Serum metabolites / / 19043545 rs17200411 chr3 16670655 C T 2.44E-04 Substance dependence / / 21818250 rs7631231 chr3 16673075 T C 4.59E-04 Body mass index / / 21701565 rs12107998 chr3 16693232 T C 3.90E-04 Body mass index / / 21701565 rs12106804 chr3 16693266 A T 3.90E-04 Body mass index / / 21701565 rs12494691 chr3 16700334 G A 6.61E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs9860475 chr3 16749024 C T 4.05E-04 Alcohol dependence / / 20201924 rs7618461 chr3 16762185 C T 9.58E-06 Serum metabolites / / 19043545 rs13322151 chr3 16763573 G T 7.27E-05 Serum metabolites / / 19043545 rs17272677 chr3 16783341 A C 2.77E-05 Serum metabolites / / 19043545 rs1449531 chr3 16840813 C T 2.39E-04 Schizophrenia / / 21674006 rs7625233 chr3 16852736 A G 5.56E-06 Hirschsprung's disease / / 19196962 rs6778524 chr3 16855953 T C 9.00E-08 Alcohol dependence / / 21956439 rs6796955 chr3 16885602 C T 4.14E-05 Major depressive disorder / / 22472876 rs6797038 chr3 16885685 C A 8.33E-05 Major depressive disorder / / 22472876 rs13081010 chr3 16899947 T C 2.10E-05 Urinary metabolites / / 21572414 rs2252086 chr3 16924645 T C 8.00E-06 Urinary metabolites / / 21572414 rs10510468 chr3 16938623 G T 6.68E-04 Type 2 diabetes PLCL2 intron 17463246 rs11917952 chr3 16943878 C T 8.89E-04 Type 2 diabetes PLCL2 intron 17463246 rs1372072 chr3 16955259 G A 2.00E-08 Primary biliary cirrhosis PLCL2 intron 21399635 rs11928330 chr3 16958367 C T 4.07E-05 Primary biliary cirrhosis PLCL2 intron 21399635 rs1025818 chr3 16965021 T C 0.0000353 Primary biliary cirrhosis PLCL2 intron 22936693 rs1025818 chr3 16965021 T C 0.0000406 Primary biliary cirrhosis in females PLCL2 intron 22936693 rs1025818 chr3 16965021 T C 0.000106 Primary biliary cirrhosis (anti-mitochondrial antibody positive) PLCL2 intron 22936693 rs1025818 chr3 16965021 T C 0.000189 Primary biliary cirrhosis PLCL2 intron 22961000 rs7637568 chr3 16965216 T C 0.0000614 Primary biliary cirrhosis PLCL2 intron 22936693 rs9821630 chr3 16970938 A G 4.00E-06 Multiple sclerosis PLCL2 intron 21833088 rs17042882 chr3 16971876 C A,T 2.51E-177 Multiple complex diseases PLCL2 intron 17554300 rs4684305 chr3 17001165 T G 2.80E-05 Urinary metabolites PLCL2 intron 21572414 rs6769249 chr3 17002619 G A 3.75E-05 Intelligence PLCL2 intron 21826061 rs6769249 chr3 17002619 G A 9.35E-04 Heart Failure PLCL2 intron pha002884 rs6769249 chr3 17002619 G A 3.55E-05 Neutrophil count PLCL2 intron pha003095 rs4452313 chr3 17047032 A T 2.00E-10 Rheumatoid arthritis PLCL2 intron 24390342 rs4452313 chr3 17047032 A T 5.00E-11 Rheumatoid arthritis PLCL2 intron 24390342 rs9876768 chr3 17049965 T C 5.05E-04 Alcohol dependence PLCL2 intron 20201924 rs9876768 chr3 17049965 T C 9.41E-05 Response to taxane treatment (placlitaxel) PLCL2 intron 23006423 rs7653834 chr3 17051328 T C 0.000438 Salmonella-induced pyroptosis PLCL2 cds-synon 22837397 rs4383507 chr3 17073032 T C 2.40E-05 Urinary metabolites PLCL2 intron 21572414 rs12108065 chr3 17074871 A G 0.000655 Salmonella-induced pyroptosis PLCL2 intron 22837397 rs7648912 chr3 17076560 C G 0.000863 Salmonella-induced pyroptosis PLCL2 intron 22837397 rs3796299 chr3 17109339 C T 9.70E-06 Urinary metabolites PLCL2 intron 21572414 rs4685424 chr3 17117747 A T 1.50E-05 Urinary metabolites PLCL2 intron 21572414 rs4618210 chr3 17124384 A G 3.00E-09 Myocardial infarction PLCL2 intron 24916648 rs4618210 chr3 17124384 A G 5.62E-04 Heart Failure PLCL2 intron pha002884 rs4077616 chr3 17173415 A G 2.20E-05 Urinary metabolites / / 21572414 rs4234541 chr3 17182697 T C 8.28E-04 Multiple complex diseases / / 17554300 rs4685442 chr3 17213357 A G 9.71E-04 Heart Failure TBC1D5 intron pha002884 rs2470584 chr3 17214070 A G 4.97E-04 Amyotrophic lateral sclerosis (sporadic) TBC1D5 intron 24529757 rs2733500 chr3 17276149 G A 8.74E-05 Type 2 diabetes TBC1D5 intron 17846125 rs2733499 chr3 17276334 C T 6.41E-04 Type 2 diabetes TBC1D5 intron 17846125 rs2596638 chr3 17287018 C T 6.96E-04 Type 2 diabetes TBC1D5 intron 17846125 rs283917 chr3 17328509 A G 6.11E-04 Type 2 diabetes TBC1D5 intron 17846125 rs283929 chr3 17359916 C T 7.06E-04 Type 2 diabetes TBC1D5 intron 17846125 rs1374197 chr3 17394615 A G 5.91E-04 Alcohol dependence TBC1D5 intron 20201924 rs7647905 chr3 17433383 T C 6.47E-04 Alcohol dependence TBC1D5 intron 20201924 rs9823767 chr3 17615737 A G 8.17E-04 Alcohol dependence TBC1D5 intron 20201924 rs6792422 chr3 17701005 G T 6.09E-04 Type 2 diabetes TBC1D5 intron 17846125 rs10510478 chr3 17730282 A G 5.99E-04 Type 2 diabetes TBC1D5 intron 17846125 rs4128509 chr3 17731099 T C 6.04E-04 Type 2 diabetes TBC1D5 intron 17846125 rs4908967 chr3 17774944 C A 7.30E-04 Alcohol dependence TBC1D5 intron 20201924 rs7627732 chr3 17784818 T C 7.82E-04 Alcohol dependence LOC100505786 intron 20201924 rs4349529 chr3 17792118 A G 5.68E-04 Alcohol dependence / / 20201924 rs4611850 chr3 17798649 T G 6.50E-04 Alcohol dependence / / 20201924 rs11921152 chr3 17812688 C A 3.99E-05 Schizophrenia / / 20185149 rs11929066 chr3 17895208 C T 1.96E-05 Multiple complex diseases / / 17554300 rs13087154 chr3 17909190 T A 3.46E-04 Type 2 diabetes / / 17463246 rs1367522 chr3 17968408 C T 6.17E-04 Myopia (pathological) / / 21095009 rs7432256 chr3 18031212 A G 1.00E-04 Prostate cancer LOC339862 intron 21743057 rs7645289 chr3 18072808 A G 1.40E-04 Suicidal ideation LOC339862 intron 22030708 rs13079656 chr3 18093080 A G 6.16E-04 Coronary Artery Disease LOC339862 intron 17634449 rs13092967 chr3 18125502 G A 3.49E-06 Paget's disease LOC339862 intron 20436471 rs4688911 chr3 18129219 T C 8.00E-05 Prostate cancer LOC339862 intron 21743057 rs938180 chr3 18133207 A C 8.00E-05 Prostate cancer LOC339862 intron 21743057 rs4688903 chr3 18160060 G A 2.48E-06 Paget's disease LOC339862 intron 20436471 rs13060927 chr3 18190493 G A 8.27E-04 Suicide attempts in bipolar disorder LOC339862 intron 21041247 rs13071948 chr3 18192240 A G 8.79E-04 Suicide attempts in bipolar disorder LOC339862 intron 21041247 rs2102623 chr3 18206165 C T 4.84E-04 Type 2 diabetes LOC339862 intron 17463246 rs13078687 chr3 18223442 G A 7.26E-04 Multiple complex diseases LOC339862 intron 17554300 rs7641175 chr3 18311412 G A 3.00E-11 Platelet counts / / 22139419 rs6577641 chr3 18397849 C T 4.00E-06 Chronic mucus hypersecretion SATB1 intron 24714607 rs7621961 chr3 18399864 G A 2.83E-05 Suicide attempts in bipolar disorder SATB1 intron 21041247 rs11927883 chr3 18401567 A G 2.71E-05 Suicide attempts in bipolar disorder SATB1 intron 21041247 rs3922895 chr3 18402591 T A 2.68E-05 Suicide attempts in bipolar disorder SATB1 intron 21041247 rs9713190 chr3 18408096 T C 9.60E-06 Intraocular pressure SATB1 intron 22570627 rs9837588 chr3 18408930 A G 9.40E-06 Intraocular pressure SATB1 intron 22570627 rs9879688 chr3 18409067 G A 9.20E-06 Intraocular pressure SATB1 intron 22570627 rs9841621 chr3 18409077 A G 1.00E-04 Intraocular pressure SATB1 intron 22570627 rs9879573 chr3 18409169 C T 9.20E-06 Intraocular pressure SATB1 intron 22570627 rs6762753 chr3 18465443 A G 3.66E-04 Alzheimer's disease SATB1 UTR-5 22005930 rs6550850 chr3 18507382 C T 0.0000688 Salmonella-induced pyroptosis / / 22837397 rs6550850 chr3 18507382 C T 3.80E-08 Metabolite levels / / 23281178 rs2304763 chr3 18512879 C T 4.35E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1553995 chr3 18516620 A T 6.40E-06 Urinary metabolites / / 21572414 rs7633075 chr3 18581848 G T 1.53E-05 Cognitive test performance / / 20125193 rs7633075 chr3 18581848 G T 6.00E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs17044638 chr3 18609712 A G 3.45E-04 Type 2 diabetes / / 17463246 rs334960 chr3 18610877 C T 4.30E-04 Alcohol dependence / / 20201924 rs12714959 chr3 18621091 C T 6.14E-14 Multiple complex diseases / / 17554300 rs11707806 chr3 18623123 C G 8.51E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs400432 chr3 18623278 A G 2.73E-04 Type 2 diabetes / / 17463246 rs17044664 chr3 18643821 A C 7.95E-04 Multiple complex diseases / / 17554300 rs7651512 chr3 18647513 G A 5.26E-05 Eosinophil counts / / pha003088 rs2165399 chr3 18648481 C A 1.34E-04 Multiple complex diseases / / 17554300 rs336605 chr3 18656350 G T 4.10E-04 Alcohol dependence / / 20201924 rs4280655 chr3 18674920 C T 8.40E-06 Urinary metabolites / / 21572414 rs7638294 chr3 18675418 C T 2.45E-04 Obesity (extreme) / / 21935397 rs11128892 chr3 18684046 A G 9.30E-04 Obesity (extreme) / / 21935397 rs10780005 chr3 18693179 C T 9.28E-04 Obesity (extreme) / / 21935397 rs9855153 chr3 18693223 A G 2.00E-04 Alcohol dependence / / 20201924 rs9855153 chr3 18693223 A G 8.15E-05 Coronary heart disease / / pha003035 rs11714395 chr3 18699977 G T 3.84E-05 Insulin Resistance / / pha003062 rs11914608 chr3 18704299 A G 1.40E-05 Alcohol dependence / / 20201924 rs11914608 chr3 18704299 A G 2.30E-04 Alcohol dependence / / 20201924 rs11914608 chr3 18704299 A G 1.42E-05 Alcoholism / / pha002892 rs13073817 chr3 18706858 G A 7.00E-09 Crohn's disease / / 21102463 rs13073817 chr3 18706858 G A 8.40E-04 Obesity (extreme) / / 21935397 rs11918322 chr3 18716133 T A 0.000562392 Primary sclerosing cholangitis / / 23603763 rs9845140 chr3 18728878 C A 1.70E-04 Alcohol dependence / / 20201924 rs9826966 chr3 18737796 A G 1.90E-04 Alcohol dependence / / 20201924 rs9826966 chr3 18737796 A G 6.66E-05 Coronary heart disease / / pha003035 rs13098781 chr3 18758419 A G 6.58E-05 Insulin Resistance / / pha003062 rs11711641 chr3 18760244 A G 6.58E-05 Insulin Resistance / / pha003062 rs6778301 chr3 18765029 A G 1.26E-04 Alzheimer's disease (late onset) / / 21379329 rs11713774 chr3 18765978 T C 1.59E-05 Insulin Resistance / / pha003062 rs11713774 chr3 18765978 T C 4.14E-05 Insulin-related traits / / pha003063 rs4256159 chr3 18767404 C T 9.00E-15 Inflammatory bowel disease / / 23128233 rs4256159 chr3 18767404 C T 2.71E-05 Insulin Resistance / / pha003062 rs4256159 chr3 18767404 C T 5.70E-05 Insulin-related traits / / pha003063 rs6809854 chr3 18784423 A G 1.00E-07 Psoriasis / / 20953190 rs9284846 chr3 18790702 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9824781 chr3 18800046 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9847248 chr3 18804655 G A 1.30E-04 Alcohol dependence / / 20201924 rs7644430 chr3 18812072 A G 1.35E-04 Alzheimer's disease (late onset) / / 21379329 rs4280657 chr3 18814977 C T 5.82E-04 Multiple complex diseases / / 17554300 rs4482682 chr3 18817257 A G 1.30E-04 Alzheimer's disease (late onset) / / 21379329 rs11926588 chr3 18838880 G T 2.10E-05 Urinary metabolites / / 21572414 rs7640928 chr3 18840933 A T 8.40E-04 Type 2 diabetes / / 17463246 rs4973706 chr3 18921772 T C 0.0000531 Gains in maximal O2 uptake response / / 21183627 rs9860501 chr3 18928109 T G 2.04E-04 Blood pressure / / 17255346 rs4401379 chr3 18930125 C T 2.94E-04 Blood pressure / / 17255346 rs11710762 chr3 18939227 A G 9.98E-05 Cognitive impairment induced by topiramate / / 22091778 rs12714975 chr3 19085374 C G 8.90E-05 Adiponectin levels / / 24105470 rs7612947 chr3 19117118 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6791995 chr3 19129843 A G 3.40E-05 Multiple complex diseases / / 17554300 rs997384 chr3 19224498 G A 9.29E-05 Pancreatic cancer KCNH8 intron pha002874 rs17005751 chr3 19242993 C G 3.39E-04 Multiple complex diseases KCNH8 intron 17554300 rs1389538 chr3 19266335 A G 1.00E-04 Cognitive impairment induced by topiramate KCNH8 intron 22091778 rs1389538 chr3 19266335 A G 0.000079 Coronary artery calcification KCNH8 intron 23727086 rs2034007 chr3 19371858 A G 5.98E-04 Smoking cessation KCNH8 intron 24665060 rs2053506 chr3 19375791 G A 4.00E-06 Hip geometry KCNH8 intron 17903296 rs13316471 chr3 19384526 C T 5.50E-04 Atrial fibrillation KCNH8 intron 21846873 rs12488588 chr3 19385436 G A 7.34E-05 Multiple complex diseases KCNH8 intron 17554300 rs9310595 chr3 19410169 C T 5.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNH8 intron 20877124 rs10470605 chr3 19436270 A G 9.90E-04 Multiple complex diseases KCNH8 intron 17554300 rs1348232 chr3 19441126 G A 5.12E-06 Serum metabolites KCNH8 intron 19043545 rs9826227 chr3 19441363 T C 0.0000009 Internal carotid artery thickness (near walls) KCNH8 intron 23487405 rs7630677 chr3 19467040 A G 8.76E-04 Type 2 diabetes KCNH8 intron 17463246 rs9809140 chr3 19519043 A G 3.43E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) KCNH8 intron 24023788 rs4858318 chr3 19547184 C T 4.83E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) KCNH8 intron 24023788 rs33915638 chr3 19574945 A G 8.72E-05 Lipoprotein A [Lp(a)] levels in plasma KCNH8 missense 21592478 rs12108194 chr3 19582423 C A 2.54E-04 Smoking cessation / / 24665060 rs949665 chr3 19613756 T G 1.64E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10510494 chr3 19614045 A G 5.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs17543807 chr3 19614280 A G 1.64E-05 Serum metabolites / / 19043545 rs2203428 chr3 19680408 C T 9.11E-05 Blood Pressure / / pha003046 rs17006139 chr3 19716075 T C 2.67E-04 Multiple complex diseases / / 17554300 rs10510489 chr3 19774292 T G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs17006217 chr3 19783277 T C 4.52E-07 Cardiovascular disease / / 18179892 rs10510491 chr3 19788213 A G 5.46E-06 Kawasaki disease / / 21221998 rs10510492 chr3 19792397 C T 7.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7431008 chr3 19854531 C A 9.05E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4858725 chr3 19888048 A G 6.01E-04 Aortic root size / / 21223598 rs2929344 chr3 19980160 C G 1.44E-05 Serum metabolites / / 19043545 rs2929343 chr3 19981414 A T 7.52E-04 Coronary heart disease / / 21606135 rs2364515 chr3 19981555 G C 6.38E-04 Coronary heart disease / / 21606135 rs2170342 chr3 19982135 C T 7.48E-05 Hemoglobin concentration / / 20534544 rs2170342 chr3 19982135 C T 1.34E-04 Attention deficit hyperactivity disorder / / 22420046 rs4858660 chr3 19994475 G A 3.12E-05 Osteoarthritis (knee and hip) RAB5A intron 21177295 rs13070718 chr3 20003228 G A 1.56E-04 Type 2 diabetes RAB5A intron 17463246 rs11128930 chr3 20022050 G A 6.77E-04 Type 2 diabetes RAB5A intron 17463246 rs4103004 chr3 20042834 C T 8.32E-05 Alzheimer's disease (late onset) PP2D1 missense 21379329 rs1915919 chr3 20083881 C T 8.00E-06 Post-traumatic stress disorder KAT2B intron 24677629 rs6773122 chr3 20087221 G A 9.47E-05 Femoral neck bone geometry KAT2B intron 22087292 rs2929404 chr3 20094566 T C 2.20E-05 Response to statin therapy KAT2B intron 20339536 rs2948085 chr3 20098119 T C 5.10E-05 Response to statin therapy KAT2B intron 20339536 rs9874923 chr3 20101563 C T 4.00E-07 Mean arterial pressure (alcohol consumption interaction) KAT2B intron 24376456 rs1124376 chr3 20108546 C T 5.00E-06 Bipolar disorder and schizophrenia KAT2B intron 20889312 rs11714225 chr3 20121828 C T 9.20E-04 Parkinson's disease KAT2B intron 17052657 rs12636856 chr3 20136959 A G 2.30E-05 Urinary metabolites KAT2B intron 21572414 rs12636856 chr3 20136959 A G 7.00E-06 Response to mTOR inhibitor (rapamycin) KAT2B intron 24009623 rs9819628 chr3 20140837 C T 1.52E-05 Bipolar disorder and schizophrenia KAT2B intron 20889312 rs4241546 chr3 20147562 A G 8.98E-05 Asthma KAT2B intron 23181788 rs12488369 chr3 20154059 A C 1.68E-05 Bipolar disorder and schizophrenia KAT2B intron 20889312 rs17678713 chr3 20192769 G A 5.81E-04 Alcohol dependence KAT2B intron 20201924 rs9849205 chr3 20207136 T C 5.50E-05 Temperament (bipolar disorder) SGOL1 intron 22365631 rs1052930 chr3 20212189 A G 1.30E-05 Temperament (bipolar disorder) SGOL1 UTR-3 22365631 rs3852067 chr3 20219477 A G 7.50E-04 Multiple complex diseases SGOL1 intron 17554300 rs3852067 chr3 20219477 A G 2.60E-06 Temperament (bipolar disorder) SGOL1 intron 22365631 rs6767049 chr3 20220712 G T 2.00E-06 Temperament (bipolar disorder) SGOL1 intron 22365631 rs4858166 chr3 20292978 T C 5.99E-04 Taste perception / / 22132133 rs12489472 chr3 20301354 A C 2.24E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs12386343 chr3 20306777 G T 8.68E-05 Coronary Artery Disease / / 17634449 rs9862603 chr3 20324715 C T 3.93E-07 Glaucoma-related traits / / 22058429 rs9820730 chr3 20348723 A G 3.42E-04 Coronary Artery Disease / / 17634449 rs9871864 chr3 20352766 T C 4.40E-04 Behavioural disinhibition (generation interaction) / / 23942779 rs9871864 chr3 20352766 T C 6.00E-06 Behavioural disinhibition (generation interaction) / / 23942779 rs6809146 chr3 20362439 T C 1.71E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7619947 chr3 20371453 T C 3.04E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6550498 chr3 20372799 G A 4.10E-06 Urinary metabolites / / 21572414 rs11128951 chr3 20375546 A G 4.27E-08 Alcohol consumption / / 23953852 rs1356792 chr3 20378153 A G 3.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12489904 chr3 20384627 G A 4.98E-04 Gallstones / / 17632509 rs9854943 chr3 20414230 T G 4.47E-04 Tourette syndrome / / 22889924 rs9854943 chr3 20414230 T G 9.15E-05 Coronary heart disease / / pha003030 rs6763225 chr3 20415512 G A 1.78E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs6768597 chr3 20419583 T C 5.30E-05 Coronary heart disease / / pha003031 rs11128953 chr3 20433212 C T 2.36E-04 Tourette syndrome / / 22889924 rs1401921 chr3 20436493 C T 6.55E-04 Tourette syndrome / / 22889924 rs4858191 chr3 20437608 C G 3.94E-04 Alzheimer's disease / / 17998437 rs4858191 chr3 20437608 C G 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs17805724 chr3 20451350 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6793327 chr3 20465208 T A 3.06E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs13070421 chr3 20476362 C T 1.43E-05 Monocyte chemoattractant protein-1 / / pha003071 rs7629464 chr3 20493568 A G 5.26E-05 Monocyte chemoattractant protein-1 / / pha003071 rs1520050 chr3 20500104 G A 8.39E-05 Multiple complex diseases / / 17554300 rs1523347 chr3 20512768 A C 9.66E-05 Bipolar disorder and schizophrenia / / 20889312 rs599845 chr3 20515745 G A 6.39E-05 Bipolar disorder and schizophrenia / / 20889312 rs1520043 chr3 20518701 T G 0.0000149 Schizophrenia / / 22440650 rs648238 chr3 20527133 A G 9.63E-05 Monocyte chemoattractant protein-1 / / pha003071 rs582714 chr3 20527630 C A 4.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1523351 chr3 20577473 C T 6.18E-07 Coronary heart disease / / pha003031 rs10440098 chr3 20578998 T C 6.53E-07 Coronary heart disease / / pha003031 rs4292253 chr3 20605302 T C 3.04E-06 Coronary heart disease / / pha003031 rs1395103 chr3 20615273 G A 9.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs9841080 chr3 20707404 T G 8.93E-06 Bipolar disorder and schizophrenia / / 20889312 rs75430906 chr3 20717929 G A 1.00E-07 Acne (severe) / / 24927181 rs1500422 chr3 20720138 G A 6.31E-04 Alcohol dependence / / 20201924 rs7638430 chr3 20731953 A G 4.69E-04 Multiple complex diseases / / 17554300 rs931717 chr3 20736153 T G 2.08E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2173734 chr3 20736506 C T 8.81E-04 Alzheimer's disease / / 22005930 rs17809565 chr3 20738089 A G 5.24E-04 Alcohol dependence / / 20201924 rs9990219 chr3 20809206 T C 6.00E-06 Multiple complex diseases / / 17554300 rs1500415 chr3 20819623 C T 8.60E-04 Type 2 diabetes / / 17846125 rs13071397 chr3 20830711 C T 3.79E-05 Type 2 diabetes and other traits / / 19734900 rs4858270 chr3 20856539 A G 8.92E-05 Serum metabolites / / 19043545 rs6773660 chr3 20865519 C A 2.98E-04 Alzheimer's disease / / 22005930 rs2366536 chr3 20868825 A G 9.71E-04 Alzheimer's disease / / 22005930 rs375137468 chr3 20868825 A AC 9.71E-04 Alzheimer's disease / / 22005930 rs4498065 chr3 20869043 A G 4.57E-04 Alzheimer's disease / / 22005930 rs1499004 chr3 20880872 G C 7.72E-05 Multiple complex diseases / / 17554300 rs12486758 chr3 20907259 C T 3.81E-04 Alzheimer's disease / / 22005930 rs12490794 chr3 20922300 C G 2.98E-04 Alzheimer's disease / / 22005930 rs1498996 chr3 20925380 T A 6.63E-05 Serum metabolites / / 19043545 rs17811911 chr3 20931562 A G 2.43E-05 Alzheimer's disease / / 22005930 rs1580800 chr3 20939291 G A 3.94E-04 Alzheimer's disease / / 22005930 rs7427261 chr3 20939370 A G 1.37E-05 Alzheimer's disease / / 22005930 rs6787231 chr3 20957810 G C 5.00E-06 IgG glycosylation / / 23382691 rs2201910 chr3 20995849 T C 7.08E-04 Obesity (extreme) / / 21935397 rs4858283 chr3 20996215 A G 2.74E-04 Obesity (extreme) / / 21935397 rs6791186 chr3 20996399 T C 3.35E-04 Obesity (extreme) / / 21935397 rs2366681 chr3 20997613 C A 4.75E-05 Blood Pressure / / pha003048 rs13072255 chr3 21038260 A C 9.84E-05 Type 2 diabetes / / 17463246 rs2173233 chr3 21058911 A G 2.65E-04 Type 2 diabetes / / 17463246 rs2132889 chr3 21076341 G A 2.05E-04 Coronary Artery Disease / / 17634449 rs13086092 chr3 21077375 T G 8.74E-04 Type 2 diabetes / / 17463246 rs7622116 chr3 21078939 G A 5.48E-04 Type 2 diabetes / / 17463246 rs9825481 chr3 21097113 G T 2.37E-04 Type 2 diabetes / / 17463246 rs1391139 chr3 21118255 T C 3.71E-04 Birth weight / / 17255346 rs1391139 chr3 21118255 T C 2.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs17008182 chr3 21135162 T C 6.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs9864927 chr3 21136309 T A 4.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs9883374 chr3 21136757 A G 3.53E-04 Birth weight / / 17255346 rs9883374 chr3 21136757 A G 2.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs9845916 chr3 21136818 C A 3.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs7648119 chr3 21140240 C T 5.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs9310636 chr3 21149605 C G 4.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs1391136 chr3 21161388 C T 7.50E-05 Type 2 diabetes / / 17463248 rs13064120 chr3 21165513 C T 8.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs1497502 chr3 21165530 A C 8.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs12185976 chr3 21165908 T C 8.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs10780008 chr3 21166410 C G 9.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs6798717 chr3 21174797 T C 5.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs6763489 chr3 21178623 T A 4.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs4857979 chr3 21179332 A G 9.67E-05 Type 1 diabetes / / 18978792 rs4857979 chr3 21179332 A G 2.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs6800727 chr3 21179734 C T 3.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs1550171 chr3 21180323 C A 2.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs6767979 chr3 21180789 A T 3.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs13060855 chr3 21182719 G A 4.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs11720452 chr3 21248642 C T 5.00E-06 Bipolar disorder / / 18711365 rs1347636 chr3 21271043 A T 1.69E-04 Type 2 diabetes / / 17846125 rs6785004 chr3 21290055 T C 1.15E-04 Lung function (forced vital capacity) / / 24023788 rs6785004 chr3 21290055 T C 4.66E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs9815041 chr3 21301170 C A 1.60E-05 Triglycerides / / 19074352 rs9815041 chr3 21301170 C A 1.60E-05 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs1344870 chr3 21307401 T G 5.32E-04 Type 2 diabetes / / 17846125 rs9310639 chr3 21308534 G T 2.30E-04 Type 2 diabetes / / 17846125 rs10514675 chr3 21308756 G T 3.56E-04 Type 2 diabetes / / 17846125 rs10514676 chr3 21309839 C G 2.47E-04 Type 2 diabetes / / 17846125 rs1344868 chr3 21311150 C G 1.29E-04 Type 2 diabetes / / 17846125 rs9876170 chr3 21353382 G A 6.87E-05 Self-reported allergy / / 23817569 rs9816785 chr3 21356372 G A 6.83E-05 Self-reported allergy / / 23817569 rs13059346 chr3 21361784 T C 2.59E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs1395993 chr3 21369586 T C 3.49E-05 Parkinson's disease / / pha002868 rs1605524 chr3 21376648 G A 9.16E-04 Type 2 diabetes / / 17463246 rs1605524 chr3 21376648 G A 2.65E-04 Type 2 diabetes / / 17846125 rs2731943 chr3 21380677 C T 2.63E-05 Major depressive disorder / / 20516156 rs7650051 chr3 21383764 A G 9.91E-05 Schizophrenia / / 19571809 rs6770065 chr3 21392307 A G 6.17E-06 Longevity,exceptional / / 20595579 rs341859 chr3 21433365 T C 2.31E-05 HDL cholesterol / / pha003074 rs423879 chr3 21442468 G C 4.24E-05 Serum metabolites / / 19043545 rs409974 chr3 21447336 G A 9.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs440905 chr3 21447834 C T 5.57E-05 Serum metabolites / / 19043545 rs341865 chr3 21449227 G C 1.01E-04 Multiple complex diseases / / 17554300 rs341865 chr3 21449227 G C 1.76E-05 Serum metabolites / / 19043545 rs376703 chr3 21456170 C T 6.40E-05 HDL cholesterol / / pha003074 rs3849537 chr3 21479454 C T 1.25E-04 Attention deficit hyperactivity disorder ZNF385D intron 22420046 rs17008734 chr3 21480984 C T 2.67E-04 Multiple complex diseases ZNF385D intron 17554300 rs424695 chr3 21490145 A G 5.74E-04 Multiple complex diseases ZNF385D intron 17554300 rs424695 chr3 21490145 A G 2.60E-04 Type 2 diabetes ZNF385D intron 17846125 rs365392 chr3 21490868 G A 1.38E-04 Type 2 diabetes ZNF385D intron 17846125 rs800621 chr3 21499213 T C 5.51E-04 Multiple complex diseases ZNF385D intron 17554300 rs388647 chr3 21500623 G A 5.06E-06 Bicuspid aortic valve ZNF385D intron 20098615 rs7629679 chr3 21509376 A G 8.43E-04 Type 2 diabetes ZNF385D intron 17463246 rs1457590 chr3 21555974 C T 2.07E-04 Bipolar disorder,schizoaffective ZNF385D intron 19567891 rs1978516 chr3 21556404 C T 2.96E-04 Bipolar disorder,schizoaffective ZNF385D intron 19567891 rs13317601 chr3 21559129 C A 3.39E-04 Bipolar disorder,schizoaffective ZNF385D intron 19567891 rs9829496 chr3 21559633 C T 4.26E-04 Bipolar disorder,schizoaffective ZNF385D intron 19567891 rs17008992 chr3 21582201 A C 5.74E-05 Cognitive impairment induced by topiramate ZNF385D intron 22091778 rs7650823 chr3 21601844 T A 6.01E-05 Relative hand skill ZNF385D intron 24068947 rs11919873 chr3 21602714 T G 6.05E-05 Relative hand skill ZNF385D intron 24068947 rs13072036 chr3 21603251 C T 6.26E-05 Relative hand skill ZNF385D intron 24068947 rs10460951 chr3 21603613 A G 6.27E-05 Relative hand skill ZNF385D intron 24068947 rs7626779 chr3 21613034 T C 6.59E-05 Relative hand skill ZNF385D intron 24068947 rs3860581 chr3 21616429 G C 2.75E-05 Relative hand skill ZNF385D intron 24068947 rs7637584 chr3 21617814 A T 9.04E-05 Relative hand skill ZNF385D intron 24068947 rs1457582 chr3 21618520 A G 2.53E-05 Relative hand skill ZNF385D intron 24068947 rs1841914 chr3 21623631 T C 2.85E-04 Multiple complex diseases ZNF385D intron 17554300 rs9879945 chr3 21630297 C T 6.36E-05 Tunica Media ZNF385D intron pha003034 rs6780177 chr3 21647818 C T 1.31E-05 Heart Rate ZNF385D intron pha003054 rs13316093 chr3 21654425 T C 2.35E-05 Brain structure ZNF385D intron 22504417 rs17029417 chr3 21658582 C T 3.00E-05 Prostate cancer ZNF385D intron 21743057 rs17009164 chr3 21662929 G A 3.09E-05 Multiple complex diseases ZNF385D intron 17554300 rs3860583 chr3 21670520 T C 5.41E-04 Acute lung injury ZNF385D intron 22295056 rs7649561 chr3 21670879 C T 6.53E-05 Acute lung injury ZNF385D intron 22295056 rs7649561 chr3 21670879 C T 2.40E-05 Heart Rate ZNF385D intron pha003054 rs7619318 chr3 21673600 G A 4.59E-05 Acute lung injury ZNF385D intron 22295056 rs7619318 chr3 21673600 G A 3.71E-05 Heart Rate ZNF385D intron pha003054 rs7619318 chr3 21673600 G A 4.39E-05 Lipoproteins ZNF385D intron pha003079 rs3849544 chr3 21675069 C G 7.92E-04 Acute lung injury ZNF385D intron 22295056 rs11919688 chr3 21681969 G T 6.77E-04 Type 2 diabetes ZNF385D intron 17463246 rs11919688 chr3 21681969 G T 2.23E-04 Acute lung injury ZNF385D intron 22295056 rs3936575 chr3 21682494 A G 3.07E-05 Acute lung injury ZNF385D intron 22295056 rs1387822 chr3 21686466 G A 2.92E-05 Partial epilepsies ZNF385D intron 20522523 rs1387822 chr3 21686466 G A 2.51E-05 Epilepsy ZNF385D intron 22116939 rs1387822 chr3 21686466 G A 5.23E-04 Acute lung injury ZNF385D intron 22295056 rs1021351 chr3 21689194 G A 6.47E-05 Acute lung injury ZNF385D intron 22295056 rs2335811 chr3 21689398 G T 1.79E-04 Acute lung injury ZNF385D intron 22295056 rs2335812 chr3 21689628 T C 3.03E-05 Acute lung injury ZNF385D intron 22295056 rs1352646 chr3 21689964 T G 9.20E-05 Acute lung injury ZNF385D intron 22295056 rs2335813 chr3 21694884 A G 4.27E-04 Acute lung injury ZNF385D intron 22295056 rs9881055 chr3 21695821 G A 1.04E-04 Acute lung injury ZNF385D intron 22295056 rs11129014 chr3 21696848 G T 1.56E-04 Acute lung injury ZNF385D intron 22295056 rs2054942 chr3 21698394 A C 1.38E-04 Acute lung injury ZNF385D intron 22295056 rs6762678 chr3 21698690 A G 7.59E-05 Multiple complex diseases ZNF385D intron 17554300 rs17553605 chr3 21700102 T C 4.11E-04 Acute lung injury ZNF385D intron 22295056 rs12497214 chr3 21700282 G A 1.94E-04 Acute lung injury ZNF385D intron 22295056 rs12491669 chr3 21701236 A G 7.96E-05 Acute lung injury ZNF385D intron 22295056 rs1320292 chr3 21701712 A G 1.61E-05 Partial epilepsies ZNF385D intron 20522523 rs1320292 chr3 21701712 A G 1.82E-05 Epilepsy ZNF385D intron 22116939 rs1320292 chr3 21701712 A G 1.13E-04 Acute lung injury ZNF385D intron 22295056 rs3821396 chr3 21706369 G A 5.00E-06 Bipolar disorder ZNF385D intron 18711365 rs3821396 chr3 21706369 G A 8.20E-05 Bipolar disorder and major depressive disorder (combined) ZNF385D intron 20351715 rs9839129 chr3 21712555 C T 4.33E-05 Acute lung injury ZNF385D intron 22295056 rs12491351 chr3 21713210 G C 4.23E-05 Acute lung injury ZNF385D intron 22295056 rs986503 chr3 21714103 A G 4.31E-05 Partial epilepsies ZNF385D intron 20522523 rs986503 chr3 21714103 A G 4.80E-05 Acute lung injury ZNF385D intron 22295056 rs9816269 chr3 21718841 T C 5.00E-06 Palmitic acid (16:0) plasma levels ZNF385D intron 23362303 rs1490157 chr3 21719246 C T 5.00E-06 Partial epilepsies ZNF385D intron 20522523 rs1490157 chr3 21719246 C T 2.36E-05 Epilepsy ZNF385D intron 22116939 rs1490157 chr3 21719246 C T 4.85E-05 Acute lung injury ZNF385D intron 22295056 rs1490157 chr3 21719246 C T 0.00089 Prostate cancer ZNF385D intron 23555315 rs4298061 chr3 21726363 G T 3.14E-05 Partial epilepsies ZNF385D intron 20522523 rs4298061 chr3 21726363 G T 3.45E-05 Acute lung injury ZNF385D intron 22295056 rs2054945 chr3 21731567 C T 8.54E-04 Acute lung injury ZNF385D intron 22295056 rs11710743 chr3 21732114 T C 6.40E-06 Acute lung injury ZNF385D intron 22295056 rs6800607 chr3 21734116 C G 3.28E-04 Acute lung injury ZNF385D intron 22295056 rs7644742 chr3 21734234 C T 3.67E-05 Acute lung injury ZNF385D intron 22295056 rs7628221 chr3 21736303 G C 1.68E-04 Acute lung injury ZNF385D intron 22295056 rs4488861 chr3 21736573 G A 6.90E-04 Alcohol dependence ZNF385D intron 20201924 rs4488861 chr3 21736573 G A 1.22E-04 Acute lung injury ZNF385D intron 22295056 rs6781372 chr3 21738714 T G 3.41E-04 Acute lung injury ZNF385D intron 22295056 rs6790087 chr3 21738751 G A 9.09E-05 Acute lung injury ZNF385D intron 22295056 rs6550619 chr3 21742649 G T 6.00E-06 Acute lung injury ZNF385D intron 22295056 rs2336038 chr3 21745040 C A 8.82E-05 Acute lung injury ZNF385D intron 22295056 rs4858344 chr3 21745418 G A 8.82E-05 Acute lung injury ZNF385D intron 22295056 rs4858345 chr3 21745505 T C 8.82E-05 Acute lung injury ZNF385D intron 22295056 rs6784935 chr3 21745877 A C,G,T 3.01E-05 Acute lung injury ZNF385D intron 22295056 rs12106696 chr3 21756553 G A 2.24E-05 Serum metabolites ZNF385D intron 19043545 rs13318017 chr3 21763896 A G 8.78E-04 Taste perception ZNF385D intron 22132133 rs9882615 chr3 21771422 G A 8.04E-04 Acute lung injury ZNF385D intron 22295056 rs11712735 chr3 21774269 T A 2.26E-04 Nicotine smoking ZNF385D intron 19268276 rs13062599 chr3 21779621 C T 2.39E-04 Sarcoidosis ZNF385D intron 19165924 rs13340131 chr3 21794174 A G 1.60E-05 HIV-1 control / / 20041166 rs6805992 chr3 21796865 T C 7.91E-04 Smoking cessation / / 24665060 rs7641603 chr3 21798340 C T 2.09E-29 Narcolepsy / / 19629137 rs4538394 chr3 21799709 A T 3.67E-05 Male fertility / / 22633400 rs4588386 chr3 21799771 A C 1.80E-06 Coronary heart disease / / pha003030 rs7637596 chr3 21802251 C T 3.00E-04 Smoking cessation / / 24665060 rs1320288 chr3 21802296 T C 9.35E-05 Coronary heart disease / / pha003030 rs12633231 chr3 21807679 C T 2.70E-04 Orofacial clefts / / 22419666 rs11129021 chr3 21816466 T G 6.72E-05 Coronary heart disease / / pha003030 rs6798138 chr3 21816589 G A 1.60E-05 HIV-1 control / / 20041166 rs3111745 chr3 21827159 G T 2.50E-05 Urinary metabolites / / 21572414 rs1606851 chr3 21837427 G A 9.21E-05 Alcohol withdrawal symptoms / / 22072270 rs1606852 chr3 21837676 C A 5.40E-05 Coronary heart disease / / pha003030 rs13083531 chr3 21844883 T G 1.98E-04 Alzheimer's disease (late onset) / / 21379329 rs1878012 chr3 21847618 C G 4.40E-05 Anger / / 24489884 rs13098512 chr3 21871752 G C 8.24E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11129025 chr3 21872193 A G 3.39E-04 Type 2 diabetes / / 17463246 rs2630787 chr3 21872335 C T 2.21E-06 Type 2 diabetes / / 17463246 rs2630787 chr3 21872335 C T 5.59E-04 Multiple complex diseases / / 17554300 rs9810237 chr3 21879418 A G 8.55E-04 Type 2 diabetes / / 17463246 rs3912513 chr3 21882659 T C 5.20E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs2673522 chr3 21882969 G T 2.15E-06 Type 2 diabetes / / 17463246 rs2673522 chr3 21882969 G T 6.28E-04 Multiple complex diseases / / 17554300 rs9836784 chr3 21882991 G A 7.48E-05 Alcohol dependence / / 19581569 rs3860587 chr3 21886008 T C 6.49E-04 Type 2 diabetes / / 17463246 rs3843879 chr3 21886287 A G 3.39E-04 Type 2 diabetes / / 17463246 rs2630801 chr3 21887264 G C 8.05E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17009800 chr3 21887582 G A 7.41E-04 Multiple complex diseases / / 17554300 rs1515452 chr3 21888146 G C 2.00E-05 Type 2 diabetes / / 17463246 rs12489919 chr3 21889995 A C 6.49E-04 Type 2 diabetes / / 17463246 rs2673515 chr3 21894748 C T 3.27E-05 Type 2 diabetes / / 17463246 rs2336055 chr3 21895087 C T 4.91E-04 Parkinson's disease / / 17052657 rs2336055 chr3 21895087 C T 5.36E-05 Alcohol dependence / / 19581569 rs9310661 chr3 21897140 G A 1.59E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9855717 chr3 21898859 A C 6.49E-04 Type 2 diabetes / / 17463246 rs2673513 chr3 21898877 C T 4.79E-04 Multiple complex diseases / / 17554300 rs9838038 chr3 21898931 T C 6.49E-04 Type 2 diabetes / / 17463246 rs9822486 chr3 21899128 G A 8.55E-04 Type 2 diabetes / / 17463246 rs12487689 chr3 21899332 G A 8.82E-04 Type 2 diabetes / / 17463246 rs12487689 chr3 21899332 G A 8.36E-04 Alzheimer's disease / / 17998437 rs12494075 chr3 21899355 A G 8.74E-04 Alzheimer's disease / / 17998437 rs1621132 chr3 21909164 A G 1.61E-05 Type 2 diabetes / / 23945395 rs259498 chr3 21936532 G A 5.58E-05 Orofacial clefts LOC100505836 intron 20023658 rs1479975 chr3 21936641 G A,C 5.56E-05 Magnesium levels LOC100505836 intron pha003092 rs17010025 chr3 21941353 G C 4.64E-04 Multiple complex diseases LOC100505836 intron 17554300 rs17010054 chr3 21947772 G A 4.16E-04 Multiple complex diseases LOC100505836 intron 17554300 rs17010081 chr3 21951883 T A 4.44E-04 Multiple complex diseases LOC100505836 intron 17554300 rs10510519 chr3 21952110 G A 8.79E-04 Multiple complex diseases LOC100505836 intron 17554300 rs11719664 chr3 21955198 C T 2.00E-06 Attention deficit hyperactivity disorder LOC100505836 intron 18821565 rs1352135 chr3 21960467 G A 8.78E-06 Parkinson's disease LOC100505836 intron 21812969 rs1684524 chr3 21961267 T G 7.74E-06 Parkinson's disease LOC100505836 intron 21812969 rs1694037 chr3 21966110 T C 1.02E-05 Parkinson's disease LOC100505836 intron 21812969 rs259521 chr3 21967150 C T 1.12E-04 Bipolar disorder LOC100505836 intron 18317468 rs259521 chr3 21967150 C T 2.42E-06 Reading disability and language impairment LOC100505836 intron 24024963 rs9814232 chr3 21973175 G A 1.30E-06 Reading disability and language impairment LOC100505836 intron 24024963 rs519051 chr3 21985417 C T 8.00E-06 Urinary metabolites LOC100505836 intron 21572414 rs12489570 chr3 22003365 T C 4.97E-04 Obesity (extreme) LOC100505836 intron 21935397 rs7619247 chr3 22004458 G C 9.36E-04 Obesity (extreme) LOC100505836 intron 21935397 rs7642008 chr3 22004547 C A 9.35E-04 Obesity (extreme) LOC100505836 intron 21935397 rs17583756 chr3 22004875 G T 4.63E-05 Parkinson's disease LOC100505836 intron 21812969 rs12487974 chr3 22005305 C T 9.06E-04 Obesity (extreme) LOC100505836 intron 21935397 rs6765798 chr3 22009022 C T 3.53E-04 Obesity (extreme) LOC100505836 intron 21935397 rs9871168 chr3 22012285 A G 5.92E-05 Parkinson's disease LOC100505836 intron 21812969 rs1585863 chr3 22012418 A G 8.11E-04 Obesity (extreme) LOC100505836 intron 21935397 rs9815743 chr3 22019395 T C 2.60E-06 Urinary metabolites LOC100505836 intron 21572414 rs2291818 chr3 22019794 A G 7.95E-04 Obesity (extreme) LOC100505836 intron 21935397 rs12638192 chr3 22021630 T A 7.98E-04 Obesity (extreme) LOC100505836 intron 21935397 rs6789283 chr3 22021947 T C 1.34E-07 Femoral neck bone geometry LOC100505836 intron 22087292 rs1679255 chr3 22047934 C T 6.87E-07 Reading disability and language impairment LOC100505836 intron 24024963 rs259432 chr3 22057218 T C 8.16E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LOC100505836 intron 20031582 rs779098 chr3 22061945 T A 5.60E-06 Urinary metabolites LOC100505836 intron 21572414 rs12636438 chr3 22063277 A G 5.45E-07 Reading disability and language impairment LOC100505836 intron 24024963 rs711688 chr3 22080819 G T 3.96E-05 Parent of origin effect on language impairment (paternal) LOC100505836 intron 24571439 rs166315 chr3 22083587 A G 7.83E-05 Parent of origin effect on language impairment (paternal) LOC100505836 intron 24571439 rs259456 chr3 22084139 T C 7.76E-05 Parent of origin effect on language impairment (paternal) LOC100505836 intron 24571439 rs259458 chr3 22085607 A C 8.44E-05 Parent of origin effect on language impairment (paternal) LOC100505836 intron 24571439 rs259463 chr3 22088181 G A 6.67E-05 Parent of origin effect on language impairment (paternal) LOC100505836 intron 24571439 rs941350 chr3 22103918 T A 3.00E-07 Urinary metabolites LOC100505836 intron 21572414 rs779167 chr3 22105044 A C 5.87E-05 Tunica Media LOC100505836 intron pha003037 rs11717259 chr3 22106222 G A 6.57E-05 Tunica Media LOC100505836 intron pha003037 rs17010728 chr3 22116971 C T 4.88E-04 Response to cytadine analogues (cytosine arabinoside) LOC100505836 intron 24483146 rs2593321 chr3 22122396 C T 8.00E-06 HIV-1 viral setpoint LOC100505836 intron 20205591 rs13069223 chr3 22129501 G C 6.04E-04 Multiple complex diseases LOC100505836 intron 17554300 rs2695642 chr3 22130392 G A 4.10E-07 Urinary metabolites LOC100505836 intron 21572414 rs779170 chr3 22137440 A G 4.78E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100505836 intron 20877124 rs17010793 chr3 22144069 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC100505836 intron 22628534 rs6797769 chr3 22171297 A T 3.00E-06 IgG glycosylation LOC100505836 intron 23382691 rs4858389 chr3 22191086 A G 8.53E-04 Diabetic retinopathy LOC100505836 intron 20871662 rs1965306 chr3 22205505 C T 5.68E-04 Acute lung injury LOC100505836 intron 22295056 rs6769268 chr3 22206832 T C 7.25E-04 Acute lung injury LOC100505836 intron 22295056 rs9310685 chr3 22207033 G A 3.99E-05 Smoking quantity LOC100505836 intron 24665060 rs9868641 chr3 22207459 G A 6.57E-04 Type 2 diabetes LOC100505836 intron 17463246 rs9868641 chr3 22207459 G A 1.92E-04 Smoking quantity LOC100505836 intron 24665060 rs6782722 chr3 22212943 G A 5.58E-04 Acute lung injury LOC100505836 intron 22295056 rs6775362 chr3 22214274 A C 3.41E-04 Smoking quantity LOC100505836 intron 24665060 rs17010983 chr3 22229748 C A 3.67E-04 Alcohol dependence LOC100505836 intron 20201924 rs17029476 chr3 22231873 G C 9.58E-04 Type 2 diabetes LOC100505836 intron 17463246 rs1994727 chr3 22231931 T A 6.79E-04 Suicide attempts in bipolar disorder LOC100505836 intron 21041247 rs1405829 chr3 22235890 A G 7.56E-04 Type 2 diabetes LOC100505836 intron 17463246 rs6779779 chr3 22259851 C T 7.17E-04 Acute lung injury LOC100505836 intron 22295056 rs2638136 chr3 22261353 A G 5.81E-04 Acute lung injury LOC100505836 intron 22295056 rs2638143 chr3 22266934 C T 6.34E-04 Acute lung injury LOC100505836 intron 22295056 rs2035848 chr3 22278497 A G 1.76E-04 Multiple complex diseases LOC100505836 intron 17554300 rs2728954 chr3 22283291 C T 5.37E-04 Acute lung injury LOC100505836 intron 22295056 rs2728955 chr3 22284122 A G 3.67E-04 Acute lung injury LOC100505836 intron 22295056 rs729286 chr3 22285562 T G 7.59E-05 Acute lung injury LOC100505836 intron 22295056 rs2638150 chr3 22286262 C T 1.24E-04 Acute lung injury LOC100505836 intron 22295056 rs2638151 chr3 22287995 G C 1.32E-04 Acute lung injury LOC100505836 intron 22295056 rs1388550 chr3 22292516 C T 4.08E-04 Acute lung injury LOC100505836 intron 22295056 rs1388551 chr3 22292571 G A 2.00E-06 Waist-to-hip circumference ratio (interaction) LOC100505836 intron 23192594 rs2728958 chr3 22293609 T C 1.54E-04 Acute lung injury LOC100505836 intron 22295056 rs2728988 chr3 22300883 T C 5.66E-05 Acute lung injury LOC100505836 intron 22295056 rs2638159 chr3 22305788 C T 5.25E-04 Acute lung injury LOC100505836 intron 22295056 rs2638162 chr3 22314030 G A 8.48E-04 Acute lung injury LOC100505836 intron 22295056 rs2256818 chr3 22314463 T A 7.64E-04 Acute lung injury LOC100505836 intron 22295056 rs2638145 chr3 22318273 C A 5.64E-04 Acute lung injury LOC100505836 intron 22295056 rs1352869 chr3 22337031 T C 2.57E-04 Acute lung injury LOC100505836 intron 22295056 rs7621773 chr3 22339463 A T 1.07E-04 Acute lung injury LOC100505836 intron 22295056 rs9859862 chr3 22341338 G A 9.76E-05 Height LOC100505836 intron 17255346 rs9809134 chr3 22351154 C T 0.000679 Salmonella-induced pyroptosis LOC100505836 intron 22837397 rs9813743 chr3 22362562 C T 0.000257 Salmonella-induced pyroptosis LOC100505836 intron 22837397 rs1389661 chr3 22393482 C T 9.09E-04 Multiple complex diseases LOC100505836 intron 17554300 rs1494219 chr3 22395279 C T 2.91E-04 Response to cytidine analogues (gemcitabine) LOC100505836 intron 24483146 rs4858402 chr3 22428845 T G 2.39E-05 Schizophrenia / / 20832056 rs9852024 chr3 22471746 T A 5.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs9861611 chr3 22473092 T C 5.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs17011371 chr3 22473729 A G 6.00E-06 Periodontitis (PAL4Q3) / / 24024966 rs11716879 chr3 22473843 T A 5.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs10510530 chr3 22484605 T A 1.79E-04 Alzheimer's disease / / 17998437 rs1450348 chr3 22504135 G A 7.23E-04 Multiple complex diseases / / 17554300 rs1450349 chr3 22504332 A G 9.11E-05 Multiple complex diseases / / 17554300 rs1901103 chr3 22513807 G T 9.12E-04 Myocardial Infarction / / pha002883 rs17011474 chr3 22535867 A G 8.46E-04 Multiple complex diseases / / 17554300 rs17011480 chr3 22535891 C G 6.92E-04 Multiple complex diseases / / 17554300 rs17011503 chr3 22545276 T C 3.42E-04 Type 2 diabetes / / 17463246 rs1597395 chr3 22552457 T C 2.21E-04 Type 2 diabetes / / 17463246 rs6550696 chr3 22562175 T A 6.30E-04 Type 2 diabetes / / 17463246 rs4392438 chr3 22562237 C T 2.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs4392438 chr3 22562237 C T 3.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs4580581 chr3 22566324 C T 4.51E-04 Type 2 diabetes / / 17463246 rs1466123 chr3 22571896 G A 9.15E-04 Rheumatoid arthritis / / 21452313 rs1868577 chr3 22577278 T C 1.13E-05 Multiple complex diseases / / 17554300 rs6791874 chr3 22592585 C T 9.55E-06 Personality dimensions / / 23903073 rs13071252 chr3 22594055 C T 7.14E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6775609 chr3 22597882 T A 5.98E-04 Schizophrenia / / 21674006 rs6778123 chr3 22597952 T G 4.70E-05 Body Mass Index / / pha003007 rs6778123 chr3 22597952 T G 5.10E-05 Body Fat Distribution / / pha003016 rs6778123 chr3 22597952 T G 9.00E-05 Body Fat Distribution / / pha003017 rs1026527 chr3 22609529 C T 6.95E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1375823 chr3 22618061 T A,C 8.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1531160 chr3 22623604 C T 1.60E-04 IgE levels in asthmatics / / 23967269 rs7612139 chr3 22624379 T C 8.28E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13070085 chr3 22627609 T C 2.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1349281 chr3 22647701 C T 4.32E-04 Multiple complex diseases / / 17554300 rs6781670 chr3 22654835 C A 6.55E-04 Alzheimer's disease / / 22005930 rs6763517 chr3 22656900 G A 8.49E-04 Alzheimer's disease / / 24755620 rs17011741 chr3 22659186 A G 1.67E-04 Multiple complex diseases / / 17554300 rs3911109 chr3 22660100 T C 2.15E-04 Alzheimer's disease / / 22005930 rs1524309 chr3 22671737 C T 9.22E-05 Multiple complex diseases / / 17554300 rs9819972 chr3 22686023 T G 6.78E-04 Alzheimer's disease / / 22005930 rs1466352 chr3 22708802 T C 1.68E-04 Iron levels / / pha002876 rs9310704 chr3 22711446 G A 2.08E-04 Iron levels / / pha002876 rs3915080 chr3 22711509 A G 1.63E-04 Iron levels / / pha002876 rs11129085 chr3 22741464 A G 3.87E-04 Iron levels / / pha002876 rs11717343 chr3 22759348 T C 1.15E-05 Alzheimer's disease / / 21627779 rs6805037 chr3 22763202 A C 1.15E-05 Alzheimer's disease / / 21627779 rs17395135 chr3 22767397 A G 8.83E-06 Alzheimer's disease / / 21627779 rs7615445 chr3 22770593 C G 1.94E-04 Multiple complex diseases / / 17554300 rs11715788 chr3 22807079 C T 1.33E-05 Alzheimer's disease / / 21627779 rs11707636 chr3 22815982 T C 1.14E-05 Alzheimer's disease / / 21627779 rs17396388 chr3 22838756 C A 1.04E-05 Alzheimer's disease / / 21627779 rs33115 chr3 22840407 G A 3.57E-05 Multiple complex diseases / / 17554300 rs11718398 chr3 22860611 G A 9.20E-06 Alzheimer's disease / / 21627779 rs11718398 chr3 22860611 G A 8.25E-04 Alzheimer's disease / / 24755620 rs17337351 chr3 22865395 T C 9.13E-06 Alzheimer's disease / / 21627779 rs620918 chr3 22889452 T C 7.28E-07 Bipolar disorder / / 19488044 rs620918 chr3 22889452 T C 7.25E-06 Bipolar Disorder / / pha002858 rs299070 chr3 22905895 G A 0.0000108 Major depressive disorder / / 23149448 rs580227 chr3 22931734 T C 4.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs822759 chr3 22973112 G T 3.36E-05 Multiple complex diseases / / 17554300 rs711702 chr3 22981276 G A 4.00E-05 Obesity-related traits / / 17903300 rs711704 chr3 22983152 T C 5.69E-06 Hemoglobin / / pha003096 rs711704 chr3 22983152 T C 4.46E-05 Hematocrit / / pha003097 rs822780 chr3 22989819 A G 1.67E-04 Multiple complex diseases / / 17554300 rs822786 chr3 22994301 C T 8.37E-06 Hemoglobin / / pha003096 rs822786 chr3 22994301 C T 6.64E-05 Hematocrit / / pha003097 rs822789 chr3 22994602 G A 4.00E-05 Hemoglobin / / pha003096 rs711711 chr3 22998753 C T 5.42E-04 Multiple complex diseases / / 17554300 rs711714 chr3 23005150 T C 2.38E-04 Multiple complex diseases / / 17554300 rs711715 chr3 23010390 A G 5.25E-05 Multiple complex diseases / / 17554300 rs711716 chr3 23010422 C G 7.24E-05 Multiple complex diseases / / 17554300 rs680110 chr3 23032225 A G 6.88E-04 Iron levels / / pha002876 rs497387 chr3 23032340 A G 7.40E-04 Iron levels / / pha002876 rs9310709 chr3 23093574 T C 2.00E-06 Chronic kidney disease and serum creatinine levels / / 20686651 rs3860593 chr3 23102368 A G 5.95E-04 Body mass index / / 21701565 rs1485385 chr3 23123846 C G 8.89E-04 Body mass index / / 21701565 rs4591517 chr3 23143047 C T 3.00E-06 Colorectal cancer / / 23300701 rs9826624 chr3 23150308 C A 4.82E-05 Progressive supranuclear palsy / / 21685912 rs9827163 chr3 23150473 G C 8.01E-05 Progressive supranuclear palsy / / 21685912 rs4858477 chr3 23155165 G C 2.70E-06 Urinary metabolites / / 21572414 rs13317243 chr3 23185162 G C 5.25E-04 Substance dependence / / 21818250 rs9863600 chr3 23190832 A G 6.71E-10 Type 2 diabetes / / 22158537 rs9830468 chr3 23191098 G T 4.82E-11 Type 2 diabetes / / 22158537 rs4858060 chr3 23192695 T C 5.85E-04 Substance dependence / / 21818250 rs6762856 chr3 23193007 G A 2.85E-11 Type 2 diabetes / / 22158537 rs4619807 chr3 23193928 G A 2.00E-06 Psychosis (atypical) / / 24132900 rs6780569 chr3 23198484 G A 6.76E-09 Type 2 diabetes / / 20818381 rs6780569 chr3 23198484 G A 1.58E-11 Type 2 diabetes / / 22158537 rs6780569 chr3 23198484 G A 6.76E-09 Type 2 diabetes / / 23300278 rs6780569 chr3 23198484 G A 4.00E-07 Type 2 diabetes / / 23945395 rs9855620 chr3 23201290 C G 3.55E-08 Type 2 diabetes / / 22158537 rs7374732 chr3 23203454 C T 2.33E-08 Type 2 diabetes / / 22158537 rs9812056 chr3 23204024 T C 6.18E-08 Type 2 diabetes / / 20818381 rs9812056 chr3 23204024 T C 1.20E-10 Type 2 diabetes / / 22158537 rs9812056 chr3 23204024 T C 1.83E-08 Type 2 diabetes / / 23300278 rs7619223 chr3 23208008 C A 3.11E-05 Bipolar disorder / / 21771265 rs4311238 chr3 23209677 G T 4.42E-05 Multiple complex diseases / / 17554300 rs13314285 chr3 23212575 C A 1.76E-09 Type 2 diabetes / / 22158537 rs11927173 chr3 23225194 T C 9.99E-10 Type 2 diabetes / / 22158537 rs2014132 chr3 23234339 C T 2.64E-09 Type 2 diabetes / / 22158537 rs2291720 chr3 23237189 A G 2.36E-09 Type 2 diabetes LOC100505877 intron 22158537 rs1495130 chr3 23241009 C G 4.01E-09 Type 2 diabetes LOC100505877 intron 22158537 rs1552931 chr3 23248486 A G 1.88E-07 Type 2 diabetes UBE2E2 intron 22158537 rs17012823 chr3 23259724 C G 2.06E-09 Type 2 diabetes UBE2E2 intron 22158537 rs2055156 chr3 23262197 G A 2.70E-05 Urinary metabolites UBE2E2 intron 21572414 rs17012834 chr3 23262290 C T 1.54E-08 Type 2 diabetes UBE2E2 intron 22158537 rs1908475 chr3 23268156 G A 1.33E-09 Type 2 diabetes UBE2E2 intron 22158537 rs17012844 chr3 23269591 A G 1.27E-08 Type 2 diabetes UBE2E2 intron 22158537 rs10510536 chr3 23269770 T C 1.41E-09 Type 2 diabetes UBE2E2 intron 22158537 rs1495134 chr3 23270047 C A 3.66E-07 Type 2 diabetes UBE2E2 intron 22158537 rs17012852 chr3 23270561 G A 1.19E-08 Type 2 diabetes UBE2E2 intron 22158537 rs17012861 chr3 23275053 A G 1.31E-08 Type 2 diabetes UBE2E2 intron 22158537 rs11715035 chr3 23278691 A T 1.80E-05 Urinary metabolites UBE2E2 intron 21572414 rs13087234 chr3 23283132 T C 5.20E-09 Type 2 diabetes UBE2E2 intron 22158537 rs13083654 chr3 23286684 A C 9.71E-09 Type 2 diabetes UBE2E2 intron 22158537 rs6792370 chr3 23289892 C T 6.52E-07 Type 2 diabetes UBE2E2 intron 20818381 rs6792370 chr3 23289892 C T 1.22E-09 Type 2 diabetes UBE2E2 intron 22158537 rs1390083 chr3 23299166 T A 1.57E-07 Type 2 diabetes UBE2E2 intron 22158537 rs2132145 chr3 23302649 G A 8.81E-08 Type 2 diabetes UBE2E2 intron 22158537 rs9846398 chr3 23312158 A G 4.10E-05 Lung cancer UBE2E2 intron 18385738 rs7630344 chr3 23317542 C T 1.84E-07 Red blood cell traits UBE2E2 intron 23222517 rs17012943 chr3 23317924 T A 6.38E-09 Type 2 diabetes UBE2E2 intron 22158537 rs10510537 chr3 23321920 C A 6.47E-09 Type 2 diabetes UBE2E2 intron 22158537 rs1495133 chr3 23322679 A G 7.19E-07 Type 2 diabetes UBE2E2 intron 22158537 rs17012959 chr3 23332784 T G 1.50E-05 Type 2 diabetes UBE2E2 intron 22158537 rs7612463 chr3 23336450 C A 3.19E-08 Type 2 diabetes UBE2E2 intron 20818381 rs7612463 chr3 23336450 C A 4.50E-09 Type 2 diabetes UBE2E2 intron 22158537 rs7612463 chr3 23336450 C A 2.27E-09 Type 2 diabetes UBE2E2 intron 23300278 rs7612463 chr3 23336450 C A 7.00E-09 Type 2 diabetes UBE2E2 intron 24509480 rs2055155 chr3 23343192 A G 2.29E-06 Type 2 diabetes UBE2E2 intron 22158537 rs17012969 chr3 23344383 C T 2.58E-09 Type 2 diabetes UBE2E2 intron 22158537 rs7648425 chr3 23346407 G C 6.40E-07 Type 2 diabetes UBE2E2 intron 22158537 rs7627380 chr3 23346795 C T 4.26E-09 Type 2 diabetes UBE2E2 intron 22158537 rs17012988 chr3 23349775 A G 6.28E-09 Type 2 diabetes UBE2E2 intron 22158537 rs6790185 chr3 23352223 G A 1.23E-06 Type 2 diabetes UBE2E2 intron 22158537 rs17012998 chr3 23360627 T G 1.65E-08 Type 2 diabetes UBE2E2 intron 22158537 rs17013003 chr3 23361463 T C 3.33E-07 Type 2 diabetes UBE2E2 intron 22158537 rs9844558 chr3 23364883 G A 1.27E-04 Type 2 diabetes UBE2E2 intron 22158537 rs6806387 chr3 23369029 C G 2.59E-05 Type 2 diabetes UBE2E2 intron 22158537 rs952134 chr3 23374559 A G 1.57E-07 Red blood cell traits UBE2E2 intron 23222517 rs17013026 chr3 23375083 A G 3.50E-05 Type 2 diabetes UBE2E2 intron 22158537 rs4858505 chr3 23377366 C T 7.05E-07 Red blood cell traits UBE2E2 intron 23222517 rs17013029 chr3 23378027 A G 1.61E-05 Type 2 diabetes UBE2E2 intron 22158537 rs716456 chr3 23380290 C G 3.58E-07 Red blood cell traits UBE2E2 intron 23222517 rs17013035 chr3 23383068 C G 2.00E-06 Type 2 diabetes UBE2E2 intron 22158537 rs17013049 chr3 23385942 G T 2.78E-06 Type 2 diabetes UBE2E2 intron 22158537 rs17013104 chr3 23398680 A G 2.26E-06 Type 2 diabetes UBE2E2 intron 22158537 rs17013116 chr3 23400417 T G 2.16E-06 Type 2 diabetes UBE2E2 intron 22158537 rs17013125 chr3 23401528 C G 1.90E-06 Type 2 diabetes UBE2E2 intron 22158537 rs17013128 chr3 23401596 G T 2.08E-06 Type 2 diabetes UBE2E2 intron 22158537 rs2047340 chr3 23402038 G A 9.48E-05 Type 2 diabetes UBE2E2 intron 22158537 rs13063986 chr3 23404705 T C 3.71E-05 Type 2 diabetes UBE2E2 intron 22158537 rs13084327 chr3 23405023 A G 4.58E-06 Type 2 diabetes UBE2E2 intron 22158537 rs13098494 chr3 23415697 T G 7.56E-07 Type 2 diabetes UBE2E2 intron 22158537 rs6795968 chr3 23417027 A C 3.45E-07 Red blood cell traits UBE2E2 intron 23222517 rs17345745 chr3 23418527 C T 9.00E-07 Type 2 diabetes UBE2E2 intron 22158537 rs17013152 chr3 23419945 C G 1.47E-04 Type 2 diabetes UBE2E2 intron 22158537 rs12715048 chr3 23425959 A T 1.12E-07 Red blood cell traits UBE2E2 intron 23222517 rs1496653 chr3 23454790 A G 2.30E-08 Type 2 diabetes UBE2E2 intron 22158537 rs1496653 chr3 23454790 A G 0.00000044 Type 2 diabetes (males) UBE2E2 intron 22885922 rs1496653 chr3 23454790 A G 0.000017 Fasting insulin-related traits UBE2E2 intron 22885922 rs1496653 chr3 23454790 A G 3.60E-09 Type 2 diabetes UBE2E2 intron 22885922 rs7613185 chr3 23455464 T C 3.89E-07 Type 2 diabetes UBE2E2 intron 22158537 rs13094957 chr3 23457080 T C 6.24E-07 Type 2 diabetes UBE2E2 intron 22158537 rs1692619 chr3 23460232 G A 2.80E-05 Urinary metabolites UBE2E2 intron 21572414 rs13090303 chr3 23463647 A G 2.25E-06 Type 2 diabetes UBE2E2 intron 22158537 rs1692617 chr3 23463814 A G 8.25E-05 Alopecia areata UBE2E2 intron 22027810 rs1692617 chr3 23463814 A G 1.92E-05 Vitiligo UBE2E2 intron 22561518 rs13095736 chr3 23464320 A C 2.52E-06 Type 2 diabetes UBE2E2 intron 22158537 rs778493 chr3 23466101 G T 1.68E-05 Type 2 diabetes UBE2E2 intron 22158537 rs7628372 chr3 23466255 A C 4.67E-07 Type 2 diabetes UBE2E2 intron 22158537 rs9873329 chr3 23467026 T C 5.55E-09 Type 2 diabetes UBE2E2 intron 22158537 rs2359765 chr3 23467773 G A 3.69E-07 Type 2 diabetes UBE2E2 intron 22158537 rs17013216 chr3 23476008 C T 1.24E-06 Type 2 diabetes UBE2E2 intron 22158537 rs17013223 chr3 23476407 A G 7.52E-07 Type 2 diabetes UBE2E2 intron 22158537 rs17013241 chr3 23482110 T C 9.22E-07 Type 2 diabetes UBE2E2 intron 22158537 rs17013245 chr3 23482375 A G 7.50E-07 Type 2 diabetes UBE2E2 intron 22158537 rs9836574 chr3 23493521 G C 2.54E-07 Red blood cell traits UBE2E2 intron 23222517 rs17013286 chr3 23496134 C T 2.90E-09 Type 2 diabetes UBE2E2 intron 22158537 rs17013320 chr3 23513056 T G 3.04E-09 Type 2 diabetes UBE2E2 intron 22158537 rs17013322 chr3 23517847 T C 2.25E-09 Type 2 diabetes UBE2E2 intron 22158537 rs1695192 chr3 23522003 G C 7.38E-06 Type 2 diabetes UBE2E2 intron 22158537 rs2173461 chr3 23522217 A C 8.79E-06 Vitiligo UBE2E2 intron 22561518 rs1692647 chr3 23522809 A C 6.34E-06 Type 2 diabetes UBE2E2 intron 22158537 rs17013333 chr3 23523106 G T 1.15E-09 Type 2 diabetes UBE2E2 intron 22158537 rs17013344 chr3 23525461 G A 1.16E-09 Type 2 diabetes UBE2E2 intron 22158537 rs17013348 chr3 23525997 G A 1.35E-09 Type 2 diabetes UBE2E2 intron 22158537 rs801277 chr3 23529021 T C 8.68E-08 Type 2 diabetes UBE2E2 intron 22158537 rs9631541 chr3 23539779 A G 7.15E-08 Type 2 diabetes UBE2E2 intron 22158537 rs1011754 chr3 23541057 A G 2.15E-09 Type 2 diabetes UBE2E2 intron 22158537 rs17013383 chr3 23547371 A T 9.57E-10 Type 2 diabetes UBE2E2 intron 22158537 rs2133331 chr3 23549075 C T 6.50E-07 Red blood cell traits UBE2E2 intron 23222517 rs6770091 chr3 23554807 G A 4.69E-08 Red blood cell traits UBE2E2 intron 23222517 rs17013390 chr3 23556924 T C 1.24E-09 Type 2 diabetes UBE2E2 intron 22158537 rs7632814 chr3 23567289 T G 9.11E-07 Red blood cell traits UBE2E2 intron 23222517 rs17013429 chr3 23577554 T C 1.21E-08 Type 2 diabetes UBE2E2 intron 22158537 rs17013433 chr3 23578594 G A 6.22E-10 Type 2 diabetes UBE2E2 intron 22158537 rs12637722 chr3 23605325 G A 6.39E-04 Oral cancers (chewing tobacco related) UBE2E2 intron 22503698 rs6550767 chr3 23639400 T G 4.58E-07 Red blood cell traits / / 23222517 rs4389424 chr3 23677525 C T 2.73E-05 Blood Pressure / / pha003048 rs4596094 chr3 23680901 C T 4.01E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6793612 chr3 23684312 C T 9.10E-05 White matter hyperintensity burden / / 21681796 rs6793612 chr3 23684312 C T 7.36E-05 Alcohol consumption / / 23953852 rs4516558 chr3 23692695 G A 0.000847 Salmonella-induced pyroptosis / / 22837397 rs4858524 chr3 23695943 G T 0.00013 Salmonella-induced pyroptosis / / 22837397 rs4858524 chr3 23695943 G T 8.10E-05 Heart Rate / / pha003051 rs11129122 chr3 23712616 A G 4.97E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs9812786 chr3 23735174 T C 9.04E-04 Acute lung injury / / 22295056 rs6807249 chr3 23739829 A G 1.28E-04 Acute lung injury / / 22295056 rs73048609 chr3 23746535 C T 4.25E-04 Tuberculosis / / 22306650 rs7620545 chr3 23748920 T C 3.82E-04 Smoking cessation / / 24665060 rs6550784 chr3 23753135 T C 7.36E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs751481 chr3 23768866 A G 2.39E-04 Longevity / / 22279548 rs4510335 chr3 23770133 C T 1.16E-04 Hearing function / / 17255346 rs17013700 chr3 23785623 G A 7.35E-05 Suicide attempts in bipolar disorder / / 21423239 rs6774017 chr3 23789836 A G 1.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs6791919 chr3 23804744 T C 7.01E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9825869 chr3 23822247 G A 1.15E-04 Blood pressure / / 17255346 rs9825869 chr3 23822247 G A 1.34E-04 Rheumatoid arthritis / / 21452313 rs6774787 chr3 23859061 T C 8.68E-04 Lymphocyte counts UBE2E1 intron 22286170 rs1037635 chr3 23882465 G C 7.34E-04 Aortic root size UBE2E1 intron 21223598 rs28405582 chr3 23904762 T C 1.00E-06 Acne (severe) UBE2E1 intron 24927181 rs9809225 chr3 23941023 T C 3.37E-05 Aortic root size NKIRAS1 intron 21223598 rs13317815 chr3 23988685 C T 6.69E-04 Aortic root size NR1D2 intron 21223598 rs3935253 chr3 23999756 C T 7.04E-05 Aortic root size NR1D2 intron 21223598 rs4321479 chr3 24001078 C T 3.86E-04 Insulin resistance NR1D2 intron 21901158 rs6550825 chr3 24034969 G A 0.00000229 Cytarabine sensitivity / / 23538338 rs6550826 chr3 24034988 G C 0.0000054 Cytarabine sensitivity / / 23538338 rs1567582 chr3 24036167 A C 0.00000368 Cytarabine sensitivity / / 23538338 rs1533140 chr3 24039380 G A 0.00000481 Cytarabine sensitivity / / 23538338 rs9883101 chr3 24044400 C A 0.00000426 Cytarabine sensitivity / / 23538338 rs4568061 chr3 24049520 C A 4.55E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4356765 chr3 24052025 C T 4.47E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7612158 chr3 24109112 G A 1.65E-05 Type 2 diabetes / / 21799836 rs6800768 chr3 24113252 T C 6.00E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs6781758 chr3 24119857 G A 9.10E-05 Type 2 diabetes / / 21799836 rs7630879 chr3 24128336 T C 9.56E-04 Type 2 diabetes / / 17463246 rs2360959 chr3 24143200 C A 2.97E-05 Type 2 diabetes LOC152024 intron 21799836 rs2360958 chr3 24143273 T C 1.79E-05 Type 2 diabetes LOC152024 intron 21799836 rs2063481 chr3 24143301 T G 5.02E-08 Narcolepsy LOC152024 intron 19629137 rs1511540 chr3 24152386 C T 3.44E-05 Type 2 diabetes / / 21799836 rs6782978 chr3 24165541 G A 2.78E-05 Type 2 diabetes THRB intron 21799836 rs1868573 chr3 24169493 C T 4.90E-05 Temporomandibular joint disorders THRB intron 23746317 rs826379 chr3 24172777 A C 9.94E-05 Body Fat Distribution THRB intron pha003016 rs1705734 chr3 24173744 A G 8.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) THRB intron 23648065 rs826385 chr3 24187084 A G 1.90E-04 Acute lung injury THRB intron 22295056 rs9844739 chr3 24190184 G A 7.73E-05 Body Fat Distribution THRB intron pha003016 rs2683545 chr3 24192584 C T 9.51E-05 Cognitive test performance THRB intron 20125193 rs2596623 chr3 24204984 C T 4.92E-05 Intelligence THRB intron 21826061 rs2683530 chr3 24211739 T C 6.32E-05 stroke (ischemic) THRB intron 17434096 rs2683540 chr3 24221947 G T 1.00E-04 Information processing speed THRB intron 21130836 rs2683540 chr3 24221947 G T 7.41E-05 Cognitive decline THRB intron 23732972 rs1667739 chr3 24230196 G A 3.53E-04 Multiple complex diseases THRB intron 17554300 rs6800891 chr3 24251816 G A 4.81E-04 Lung function (forced expiratory volume in 1 second) THRB intron 24023788 rs7632417 chr3 24254517 C T 8.20E-04 Bipolar disorder THRB intron 19259986 rs17014338 chr3 24255079 C T 1.00E-04 Lung function (forced expiratory volume in 1 second) THRB intron 24023788 rs826223 chr3 24267140 A G 4.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) THRB intron 23648065 rs826221 chr3 24268436 A G 7.00E-06 Systolic blood pressure in sickle cell anemia THRB intron 24058526 rs826218 chr3 24269690 A G 3.48E-04 Multiple complex diseases THRB intron 17554300 rs1466122 chr3 24270796 A G 5.40E-04 Multiple complex diseases THRB intron 17554300 rs4858593 chr3 24270970 C A 2.40E-06 Urinary metabolites THRB intron 21572414 rs7619754 chr3 24271599 A G 2.40E-04 Multiple complex diseases THRB intron 17554300 rs9874037 chr3 24271657 C T 1.76E-05 Parent of origin effect on language impairment (child trend) THRB intron 24571439 rs9874037 chr3 24271657 C T 7.65E-05 Parent of origin effect on language impairment (maternal) THRB intron 24571439 rs1449874 chr3 24271828 C T 5.90E-04 Multiple complex diseases THRB intron 17554300 rs4858594 chr3 24273854 G A 4.02E-05 Multiple complex diseases THRB intron 17554300 rs9829876 chr3 24277179 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes THRB intron 22628534 rs12386345 chr3 24281488 G A 0.000326 Salmonella-induced pyroptosis THRB intron 22837397 rs1505298 chr3 24284794 G T 8.92E-08 Metabolite levels THRB intron 23281178 rs826230 chr3 24306302 G A 1.89E-09 Metabolite levels THRB intron 23281178 rs826231 chr3 24306831 T G 1.89E-09 Metabolite levels THRB intron 23281178 rs862247 chr3 24307693 T C 1.89E-09 Metabolite levels THRB intron 23281178 rs826236 chr3 24314612 A C 1.62E-09 Metabolite levels THRB intron 23281178 rs826238 chr3 24316463 T C 6.38E-09 Metabolite levels THRB intron 23281178 rs826240 chr3 24317591 A G 6.38E-09 Metabolite levels THRB intron 23281178 rs1827736 chr3 24328678 G C 3.57E-04 Multiple complex diseases THRB intron 17554300 rs1868575 chr3 24330283 G A 3.09E-10 Red blood cell traits THRB intron 23222517 rs1158265 chr3 24336162 T C 1.49E-08 Red blood cell traits THRB intron 23222517 rs9830674 chr3 24337914 C T 1.88E-11 Red blood cell traits THRB intron 23222517 rs2167115 chr3 24339734 A G 5.15E-09 Red blood cell traits THRB intron 23222517 rs4858603 chr3 24340817 A G 8.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) THRB intron 20877124 rs1505307 chr3 24343330 T C 1.81E-12 Red blood cell traits THRB intron 23222517 rs1505283 chr3 24345776 A G 2.67E-11 Red blood cell traits THRB intron 23222517 rs12485694 chr3 24346109 A G 1.98E-11 Red blood cell traits THRB intron 23222517 rs9850879 chr3 24346981 G A 1.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) THRB intron 20877124 rs9310736 chr3 24350811 A G 3.33E-08 Blood cell counts and other traits THRB intron 20139978 rs9310736 chr3 24350811 A G 3.52E-10 Blood cell counts and other traits THRB intron 20139978 rs9310736 chr3 24350811 A G 4.00E-10 Blood cell counts and other traits THRB intron 20139978 rs9310736 chr3 24350811 A G 0.000000006 Mean corpuscular volume THRB intron 22560525 rs9310736 chr3 24350811 A G 6.00E-16 Red blood cell traits THRB intron 23222517 rs10510543 chr3 24351642 T C 5.32E-05 Type 2 diabetes THRB intron 17846125 rs7622481 chr3 24351871 C T 2.32E-07 Red blood cell traits THRB intron 23222517 rs1505297 chr3 24355634 T C 8.42E-13 Red blood cell traits THRB intron 23222517 rs7610039 chr3 24357082 T C 5.23E-09 Red blood cell traits THRB intron 23222517 rs7640580 chr3 24357243 C A 3.46E-09 Red blood cell traits THRB intron 23222517 rs7610222 chr3 24357286 T C 1.00E-05 Cognitive performance THRB intron 19734545 rs7610222 chr3 24357286 T C 3.12E-11 Red blood cell traits THRB intron 23222517 rs12639035 chr3 24357332 G C 3.96E-04 Type 2 diabetes THRB intron 17463246 rs17014539 chr3 24369366 A G 3.93E-04 Alzheimer's disease THRB intron 22005930 rs9812034 chr3 24370875 T G 1.57E-05 Acne (severe teenage) THRB intron 24114350 rs7609823 chr3 24379744 G A 1.00E-04 Cognitive impairment induced by topiramate THRB intron 22091778 rs9833191 chr3 24384005 C T 4.39E-05 Malignant pleural mesothelioma THRB intron 23626673 rs9833191 chr3 24384005 C T 7.67E-06 Malignant pleural mesothelioma THRB intron 23626673 rs7619474 chr3 24390258 T C 5.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) THRB intron 20877124 rs7619474 chr3 24390258 T C 6.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) THRB intron 20877124 rs6781111 chr3 24403210 T C 4.47E-04 Parkinson's disease THRB intron 16252231 rs6550859 chr3 24410415 G A 5.72E-05 Male-pattern baldness THRB intron 18849994 rs11919155 chr3 24413479 C A 3.66E-04 Myopia (pathological) THRB intron 21095009 rs12638970 chr3 24419005 T C 2.90E-05 Urinary metabolites THRB intron 21572414 rs3903470 chr3 24508021 T C 1.20E-04 Parkinson's disease THRB intron 17052657 rs3903470 chr3 24508021 T C 1.00E-04 Cognitive impairment induced by topiramate THRB intron 22091778 rs982952 chr3 24511270 G A 2.10E-05 Urinary metabolites THRB intron 21572414 rs4353759 chr3 24512956 A C 1.90E-04 Parkinson's disease THRB intron 17052657 rs892941 chr3 24573805 T C 2.69E-04 Coronary heart disease / / 21971053 rs9838720 chr3 24590744 G A 9.19E-04 Type 2 diabetes / / 17463246 rs9838616 chr3 24590841 C T 8.27E-04 Type 2 diabetes / / 17463246 rs17014812 chr3 24597454 G A 9.91E-05 Multiple complex diseases / / 17554300 rs12496683 chr3 24627561 G A 6.65E-04 Coronary heart disease / / 21971053 rs6795607 chr3 24631165 T C 2.40E-05 Alcohol dependence / / 20201924 rs6795607 chr3 24631165 T C 3.00E-05 Coronary restenosis / / 21878436 rs6795607 chr3 24631165 T C 2.36E-05 Alcoholism / / pha002893 rs10490837 chr3 24632124 A C 7.60E-04 Multiple complex diseases / / 17554300 rs10490837 chr3 24632124 A C 3.12E-04 Alzheimer's disease / / 17998437 rs9819865 chr3 24636524 G A 3.10E-06 Coronary restenosis / / 21878436 rs9819865 chr3 24636524 G A 6.81E-05 Alcoholism / / pha002893 rs12631757 chr3 24643573 C T 2.09E-05 Celiac disease / / 23936387 rs10490835 chr3 24646108 G A 9.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17014951 chr3 24652813 A G 7.70E-04 Suicide attempts in bipolar disorder / / 21041247 rs11129156 chr3 24660864 A G 2.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs12495477 chr3 24666286 G A 7.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2362758 chr3 24669959 A C 9.90E-04 Multiple complex diseases / / 17554300 rs9861176 chr3 24670141 C G 5.75E-04 Multiple complex diseases / / 17554300 rs9817530 chr3 24681883 G A 1.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs9843745 chr3 24686548 G A,T 1.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs9843745 chr3 24686548 G A,T 1.90E-04 Myasthenia gravis / / 23055271 rs7610415 chr3 24691022 C T 4.60E-04 Myasthenia gravis / / 23055271 rs4452272 chr3 24691209 T C 1.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs4131483 chr3 24691492 A T 2.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs6793060 chr3 24696284 A G 3.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs2362754 chr3 24700277 G C 1.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs11928551 chr3 24703899 G T 1.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs9812637 chr3 24705221 G A 1.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs9812637 chr3 24705221 G A 1.90E-04 Myasthenia gravis / / 23055271 rs7643926 chr3 24707093 C T 3.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs7643926 chr3 24707093 C T 6.99E-04 Obesity (extreme) / / 21935397 rs7644196 chr3 24707364 C G 2.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs17787397 chr3 24708074 C T 2.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs6767967 chr3 24708874 A G 3.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs6770162 chr3 24711013 G A 2.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs1984874 chr3 24715105 C T 3.91E-05 Suicide attempts in bipolar disorder / / 21041247 rs1984870 chr3 24715135 G T 3.87E-05 Suicide attempts in bipolar disorder / / 21041247 rs2362755 chr3 24716668 G T 5.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs2362756 chr3 24716764 G T 4.87E-05 Suicide attempts in bipolar disorder / / 21041247 rs6550889 chr3 24718439 G T 2.50E-04 Myasthenia gravis / / 23055271 rs4241531 chr3 24767611 T C 2.24E-04 Hearing function / / 17255346 rs4241531 chr3 24767611 T C 6.64E-04 Multiple complex diseases / / 17554300 rs4375990 chr3 24774912 T C 1.12E-06 Multiple complex diseases / / 17554300 rs12486584 chr3 24776203 G T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12486584 chr3 24776203 G T 1.58E-04 Taste perception / / 22132133 rs6766822 chr3 24778690 A G 1.51E-04 Self-reported allergy / / 23817569 rs6772760 chr3 24779648 T C 9.01E-04 Multiple complex diseases / / 17554300 rs4075988 chr3 24780266 A G 2.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs7616736 chr3 24781645 G C 9.15E-04 Aortic root size / / 21223598 rs13433781 chr3 24782701 C T 1.16E-04 Celiac disease / / 23936387 rs13072480 chr3 24782825 G C 2.98E-04 Taste perception / / 22132133 rs9853202 chr3 24788904 G T 6.86E-05 Serum metabolites / / 19043545 rs10154915 chr3 24791059 C G 4.62E-05 Odorant perception / / 23910658 rs4858647 chr3 24791375 C A 7.58E-04 Taste perception / / 22132133 rs9856194 chr3 24794547 C T 2.10E-05 Urinary metabolites / / 21572414 rs11129165 chr3 24813614 C T 3.59E-04 Cognitive decline / / 23732972 rs2362772 chr3 24918232 C A 0.0005692 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2362772 chr3 24918232 C A 5.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12493197 chr3 24919200 C G 3.33E-04 Aortic root size / / 21223598 rs10865799 chr3 24921468 C T 0.0004473 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10865799 chr3 24921468 C T 4.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10865800 chr3 24921483 C A 0.0004487 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10865800 chr3 24921483 C A 4.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6550923 chr3 24924495 G A 0.000000917 Joint damage severity in rheumatoid arthritis / / 23696630 rs10510551 chr3 24927203 T C 9.60E-06 Endometriosis / / 23104006 rs10865801 chr3 24929802 C A 5.34E-04 Aortic root size / / 21223598 rs2363518 chr3 24942213 G A 4.81E-04 Acute lung injury / / 22295056 rs9808989 chr3 24956222 T C 1.45E-04 Acute lung injury / / 22295056 rs9827612 chr3 24956953 A G 8.09E-05 Acute lung injury / / 22295056 rs9827612 chr3 24956953 A G 1.26E-04 Tourette syndrome / / 22889924 rs9827642 chr3 24957017 A G 1.96E-04 Acute lung injury / / 22295056 rs6772273 chr3 24961039 A G 2.18E-04 Acute lung injury / / 22295056 rs6772493 chr3 24961293 A G 1.46E-04 Acute lung injury / / 22295056 rs13326208 chr3 24961849 A G 3.34E-04 Smoking cessation / / 24665060 rs6779838 chr3 24963711 A G 2.19E-04 Acute lung injury / / 22295056 rs2363525 chr3 24971843 G A 4.87E-04 Tourette syndrome / / 22889924 rs12637240 chr3 24972398 C T 1.06E-04 Aortic root size / / 21223598 rs2363526 chr3 24972416 C A 5.84E-04 Acute lung injury / / 22295056 rs2363527 chr3 24972792 T C 1.40E-05 Urinary metabolites / / 21572414 rs2363527 chr3 24972792 T C 1.60E-10 Non-obstructive azoospermia / / 22197933 rs2363528 chr3 24972894 T A 4.36E-04 Acute lung injury / / 22295056 rs9878781 chr3 24974882 G A 5.19E-04 Tourette syndrome / / 22889924 rs9883836 chr3 24975890 C T 4.45E-04 Acute lung injury / / 22295056 rs2363529 chr3 24977639 T C 4.76E-04 Multiple complex diseases / / 17554300 rs2363529 chr3 24977639 T C 6.30E-06 Urinary metabolites / / 21572414 rs13070123 chr3 24977884 A G 9.20E-07 Urinary metabolites / / 21572414 rs2363530 chr3 24979142 C T 8.32E-04 Acute lung injury / / 22295056 rs11710017 chr3 24979746 C A 3.07E-04 Multiple complex diseases / / 17554300 rs11710017 chr3 24979746 C A 2.00E-06 Urinary metabolites / / 21572414 rs11710017 chr3 24979746 C A 8.44E-04 Acute lung injury / / 22295056 rs11710017 chr3 24979746 C A 7.98E-04 Smoking cessation / / 24665060 rs9882350 chr3 24980763 G A 4.64E-04 Multiple complex diseases / / 17554300 rs9882350 chr3 24980763 G A 5.05E-04 Coronary Artery Disease / / 17634449 rs9882350 chr3 24980763 G A 3.60E-04 Tourette syndrome / / 22889924 rs12629369 chr3 24981362 C T 6.91E-05 Multiple complex diseases / / 17554300 rs7648839 chr3 24981622 A T 1.50E-05 Urinary metabolites / / 21572414 rs7614855 chr3 24981701 G A 4.60E-05 Multiple complex diseases / / 17554300 rs7614855 chr3 24981701 G A 2.85E-04 Tourette syndrome / / 22889924 rs7614855 chr3 24981701 G A 3.06E-04 Lung function (forced vital capacity) / / 24023788 rs6798808 chr3 24990630 G C 3.25E-04 Multiple complex diseases / / 17554300 rs6798808 chr3 24990630 G C 1.80E-06 Urinary metabolites / / 21572414 rs13325698 chr3 24994235 T C 7.19E-04 Smoking cessation / / 24665060 rs6780762 chr3 24997512 C A 2.10E-05 Urinary metabolites / / 21572414 rs17195108 chr3 25001225 C T 2.40E-05 Urinary metabolites / / 21572414 rs4858671 chr3 25008333 G C 2.40E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs9849459 chr3 25009827 T C 5.55E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs6779328 chr3 25017218 T C 2.92E-06 Schizophrenia / / 19571811 rs11928745 chr3 25029366 G A 1.50E-05 Urinary metabolites / / 21572414 rs9826014 chr3 25040502 T A 5.25E-05 Serum metabolites / / 19043545 rs6550933 chr3 25043105 G A 3.00E-06 Urinary metabolites / / 21572414 rs9842801 chr3 25047228 C G 5.70E-06 Urinary metabolites / / 21572414 rs9842936 chr3 25047254 C A 3.80E-06 Urinary metabolites / / 21572414 rs9868031 chr3 25050175 A T 1.82E-04 Type 2 diabetes / / 17463246 rs4858681 chr3 25052109 C T 8.00E-07 Urinary metabolites / / 21572414 rs6550934 chr3 25052333 G A 1.00E-05 Urinary metabolites / / 21572414 rs4241541 chr3 25052548 G C 1.40E-06 Urinary metabolites / / 21572414 rs4241542 chr3 25052754 C T 6.04E-06 Eosinophil counts / / pha003088 rs4280597 chr3 25053482 G A 1.50E-07 Urinary metabolites / / 21572414 rs4298013 chr3 25053643 A C 5.79E-05 Type 2 diabetes / / 17463246 rs4298013 chr3 25053643 A C 5.70E-06 Urinary metabolites / / 21572414 rs1875062 chr3 25055926 G C 1.00E-05 Urinary metabolites / / 21572414 rs1021702 chr3 25059227 A G 1.20E-05 Eosinophil counts / / pha003088 rs1909520 chr3 25063701 G C 1.45E-04 Type 2 diabetes / / 17463246 rs1909520 chr3 25063701 G C 5.80E-06 Urinary metabolites / / 21572414 rs1604006 chr3 25064354 C T 5.02E-04 Multiple complex diseases / / 17554300 rs1604006 chr3 25064354 C T 6.64E-05 Serum metabolites / / 19043545 rs10865802 chr3 25064898 C G 1.31E-04 Multiple complex diseases / / 17554300 rs10865802 chr3 25064898 C G 6.73E-06 Schizophrenia / / 19571809 rs10865802 chr3 25064898 C G 1.32E-05 Schizophrenia / / pha002859 rs873429 chr3 25065129 G A 8.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6806291 chr3 25068162 G A 2.10E-05 Urinary metabolites / / 21572414 rs4858692 chr3 25075167 C T 2.70E-05 Endometriosis / / 21151130 rs4858692 chr3 25075167 C T 1.30E-06 Endometriosis / / 23104006 rs1603995 chr3 25075530 C T 1.60E-06 Endometriosis / / 23104006 rs9310769 chr3 25092767 T A 7.78E-06 Bipolar disorder and schizophrenia / / 20889312 rs4858695 chr3 25097838 T C 9.50E-06 Urinary metabolites / / 21572414 rs993803 chr3 25112118 C T 2.30E-05 Urinary metabolites / / 21572414 rs993804 chr3 25112171 C T 1.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs993804 chr3 25112171 C T 1.40E-05 Urinary metabolites / / 21572414 rs993804 chr3 25112171 C T 4.39E-05 Schizophrenia / / pha002857 rs9827724 chr3 25127498 C T 2.10E-05 Urinary metabolites / / 21572414 rs4858700 chr3 25127689 T A 2.00E-05 Urinary metabolites / / 21572414 rs13072262 chr3 25131570 A G 8.00E-06 Urinary metabolites / / 21572414 rs13072262 chr3 25131570 A G 2.01E-05 Asthma / / 23181788 rs17516267 chr3 25141279 G A 3.95E-04 Depression (quantitative trait) / / 20800221 rs17575546 chr3 25141612 T C 1.90E-04 Depression (quantitative trait) / / 20800221 rs4858142 chr3 25143427 T C 7.93E-04 Parkinson's disease / / 17052657 rs41530749 chr3 25155871 A C 8.40E-04 Multiple complex diseases / / 17554300 rs41441147 chr3 25158418 A G 6.77E-04 Multiple complex diseases / / 17554300 rs11129182 chr3 25171297 T C 3.52E-07 Cataracts in type 2 diabetes / / 20664687 rs11129184 chr3 25172600 A G 3.88E-05 Serum metabolites / / 19043545 rs11129187 chr3 25172786 G C 4.07E-05 Serum metabolites / / 19043545 rs6804502 chr3 25173349 G A 1.37E-05 Serum metabolites / / 19043545 rs4542987 chr3 25174769 T C 3.37E-05 Serum metabolites / / 19043545 rs9840225 chr3 25181030 G A 6.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs7611139 chr3 25183414 T C 1.91E-04 Fibrinogen / / 17255346 rs17576864 chr3 25192389 A G 6.86E-04 Multiple complex diseases / / 17554300 rs2885836 chr3 25195123 A G 5.40E-05 Calcium levels / / 24068962 rs17517875 chr3 25208270 C G 9.91E-04 Multiple complex diseases / / 17554300 rs12152294 chr3 25215670 A G 5.54E-04 Multiple complex diseases / / 17554300 rs11924843 chr3 25272108 A G 6.49E-05 Serum metabolites / / 19043545 rs322668 chr3 25343615 G A 4.00E-06 IgG glycosylation / / 23382691 rs322695 chr3 25349538 G A 7.28E-04 Acute lung injury / / 22295056 rs9867006 chr3 25361852 C G 5.00E-07 Urinary metabolites / / 21572414 rs17016187 chr3 25364289 A G 4.40E-07 Urinary metabolites / / 21572414 rs11720675 chr3 25376779 A G 5.10E-07 Urinary metabolites / / 21572414 rs322684 chr3 25377223 G A 8.71E-06 Primary biliary cirrhosis / / 21399635 rs6799363 chr3 25379134 C G 2.80E-05 Urinary metabolites / / 21572414 rs4681047 chr3 25383258 A G 5.06E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs1483831 chr3 25383666 G A 8.34E-06 Primary biliary cirrhosis / / 21399635 rs6550966 chr3 25388856 G C 1.80E-07 Urinary metabolites / / 21572414 rs729236 chr3 25390429 C G 1.00E-05 Urinary metabolites / / 21572414 rs11709732 chr3 25391348 A C 2.10E-07 Urinary metabolites / / 21572414 rs17016260 chr3 25392580 A G 1.40E-08 Urinary metabolites / / 21572414 rs11718836 chr3 25392772 G A 5.20E-08 Osteoarthritis (knee) / / 18622395 rs6550967 chr3 25396760 G T 7.72E-05 Erythrocyte counts / / pha003101 rs17588596 chr3 25396865 C T 2.20E-06 Urinary metabolites / / 21572414 rs12631631 chr3 25398175 G A 5.02E-05 Bipolar disorder and schizophrenia / / 20889312 rs1016787 chr3 25406510 T C 9.92E-05 Bipolar disorder and schizophrenia / / 20889312 rs922943 chr3 25408748 G A 4.79E-04 Longevity / / 22279548 rs7622538 chr3 25414937 G C 5.03E-05 Bipolar disorder / / 18317468 rs1864911 chr3 25418008 G A 1.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4681053 chr3 25418646 T C 4.02E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7628541 chr3 25422696 G A 1.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7618590 chr3 25422776 A G 1.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9839276 chr3 25423766 A G 4.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1159899 chr3 25424428 G A 7.28E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2306624 chr3 25424561 T C 1.63E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6786765 chr3 25431234 T C 8.41E-04 Multiple complex diseases / / 17554300 rs6550974 chr3 25450943 G A 2.83E-05 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs6805482 chr3 25460596 A G 1.78E-05 Alzheimer's disease / / 17998437 rs6550976 chr3 25480678 C T 4.66E-05 Body Composition RARB intron pha003012 rs6550976 chr3 25480678 C T 8.75E-05 Body Mass Index RARB intron pha003021 rs6550976 chr3 25480678 C T 2.52E-05 Basophils RARB intron pha003087 rs1529672 chr3 25520582 C A 1.42E-06 Pulmonary function RARB intron 20010835 rs1529672 chr3 25520582 C A 4.00E-14 Pulmonary function RARB intron 21946350 rs1529672 chr3 25520582 C A 7.00E-11 Pulmonary function (interaction) RARB intron 23284291 rs1286664 chr3 25529280 C T 3.26E-06 Pulmonary function RARB intron 20010835 rs1286654 chr3 25531265 C A 6.01E-05 Pulmonary function RARB intron 20010835 rs1997352 chr3 25538317 C A,T 9.00E-07 Airflow obstruction RARB intron 22837378 rs2056777 chr3 25540391 T C 1.97E-05 Pulmonary function RARB intron 20010835 rs1406575 chr3 25541371 A G 8.45E-05 Pulmonary function RARB intron 20010835 rs1153582 chr3 25543275 C T 1.16E-06 Pulmonary function RARB intron 20010835 rs1286641 chr3 25543870 A T 7.34E-05 Pulmonary function RARB intron 20010835 rs17016566 chr3 25546219 C G 3.05E-04 Multiple complex diseases RARB intron 17554300 rs1560633 chr3 25548555 T C 0.00006142 Sarcoidosis RARB intron 22952805 rs17016570 chr3 25550039 A G 0.00003451 Sarcoidosis RARB intron 22952805 rs17016584 chr3 25551807 C G 0.000006682 Sarcoidosis RARB intron 22952805 rs1286750 chr3 25553292 A C 7.60E-05 Pulmonary function RARB intron 20010835 rs1435703 chr3 25560231 G T 4.00E-06 Obesity (extreme) RARB intron 19553259 rs1347459 chr3 25561156 T G 1.56E-04 Multiple complex diseases RARB intron 17554300 rs1286756 chr3 25567080 G A 7.44E-05 Cognitive test performance RARB intron 20125193 rs13099641 chr3 25568512 T A 0.0000187 Sarcoidosis RARB intron 22952805 rs1286665 chr3 25575675 C T 4.34E-05 Alcohol withdrawal symptoms RARB intron 22072270 rs7631979 chr3 25578938 T C 0.0000629 Sarcoidosis RARB intron 22952805 rs1286772 chr3 25580776 C G 0.00008274 Sarcoidosis RARB intron 22952805 rs1290443 chr3 25601835 T C 5.29E-04 Smoking initiation RARB intron 24665060 rs55684655 chr3 25614943 G A 0.00008834 Sarcoidosis RARB intron 22952805 rs868368 chr3 25623740 T C 2.11E-04 Smoking initiation RARB intron 24665060 rs1058378 chr3 25639394 T G 1.50E-05 Urinary metabolites RARB UTR-3 21572414 rs41453046 chr3 25746240 A G 1.59E-08 Multiple complex diseases / / 17554300 rs6762659 chr3 25777072 C T 4.42E-04 Multiple complex diseases NGLY1 intron 17554300 rs4681079 chr3 25872276 T G 1.00E-04 Personality dimensions / / 23903073 rs11928013 chr3 25919933 C G 1.80E-04 Obesity,menopause / / 21424828 rs7644516 chr3 25922285 G A 4.00E-06 DNA methylation (variation) / / 23725790 rs2052760 chr3 25924698 C A 3.40E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2052760 chr3 25924698 C A 1.45E-05 Waist Circumference / / pha003025 rs9310784 chr3 25930204 T C 4.77E-05 Waist Circumference / / pha003025 rs41406647 chr3 25938577 G A 7.97E-04 Type 2 diabetes / / 17463246 rs13101095 chr3 26011005 T C 4.90E-04 Aortic root size / / 21223598 rs11928334 chr3 26256357 A G 1.25E-04 Multiple complex diseases / / 17554300 rs2188635 chr3 26257541 G A 3.36E-04 Taste perception / / 22132133 rs10510573 chr3 26410029 A G 6.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1532719 chr3 26418818 T G 7.50E-08 Urinary metabolites / / 21572414 rs1502380 chr3 26419124 G A 1.30E-07 Urinary metabolites / / 21572414 rs17017980 chr3 26446285 T C 6.70E-07 Urinary metabolites / / 21572414 rs17017986 chr3 26446840 T C 2.60E-05 Urinary metabolites / / 21572414 rs9869163 chr3 26455761 A C 5.10E-07 Urinary metabolites / / 21572414 rs9851714 chr3 26455832 T G 8.00E-07 Urinary metabolites / / 21572414 rs7619880 chr3 26471474 T C 1.10E-06 Urinary metabolites / / 21572414 rs7621238 chr3 26481898 C T 7.67E-04 Multiple complex diseases / / 17554300 rs12631272 chr3 26485461 T C 1.70E-05 Urinary metabolites / / 21572414 rs1393398 chr3 26523122 T C 8.80E-07 Urinary metabolites / / 21572414 rs17018180 chr3 26539793 C T 1.90E-06 Urinary metabolites / / 21572414 rs12633182 chr3 26539885 A G 4.80E-06 Urinary metabolites / / 21572414 rs2202157 chr3 26543420 C T 8.00E-07 Tuberculosis / / 24057671 rs4973735 chr3 26556776 G A 4.92E-04 Lung function (forced vital capacity) / / 24023788 rs7638812 chr3 26557594 C T 4.97E-04 Lung function (forced vital capacity) / / 24023788 rs12715100 chr3 26567893 T C 5.52E-04 Multiple complex diseases / / 17554300 rs1907183 chr3 26577066 C T 6.54E-04 Multiple complex diseases / / 17554300 rs7611530 chr3 26588657 T C 1.02E-04 Multiple complex diseases / / 17554300 rs9817533 chr3 26623453 G A 3.86E-04 Multiple complex diseases / / 17554300 rs1826223 chr3 26647422 G T 2.00E-05 Personality dimensions / / 18957941 rs1586716 chr3 26668383 G T 9.67E-05 Cholesterol LRRC3B intron pha003078 rs1599923 chr3 26676314 G A 4.14E-04 Alzheimer's disease (late onset) LRRC3B intron 21379329 rs17018450 chr3 26685101 G A 8.88E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LRRC3B intron 20031582 rs12496948 chr3 26685539 G A 4.00E-05 Asthma (bronchodilator response) LRRC3B intron 22792082 rs4496439 chr3 26688971 T C 9.37E-04 Response to taxane treatment (placlitaxel) LRRC3B intron 23006423 rs6551125 chr3 26698628 A G 3.58E-05 Cholesterol LRRC3B intron pha003073 rs6551125 chr3 26698628 A G 4.48E-05 Cholesterol LRRC3B intron pha003078 rs4973738 chr3 26702391 G A 9.08E-04 Suicide attempts in bipolar disorder LRRC3B intron 21423239 rs4973800 chr3 26702980 A G 7.97E-06 Cholesterol LRRC3B intron pha003073 rs4973800 chr3 26702980 A G 4.93E-05 ldl cholesterol LRRC3B intron pha003076 rs4973800 chr3 26702980 A G 1.12E-05 Cholesterol LRRC3B intron pha003078 rs7616728 chr3 26705637 C T 5.17E-04 Alzheimer's disease LRRC3B intron 17998437 rs4973801 chr3 26706382 A G 5.10E-05 Cholesterol LRRC3B intron pha003073 rs4973801 chr3 26706382 A G 7.31E-05 Cholesterol LRRC3B intron pha003078 rs923593 chr3 26710645 G A 4.31E-04 Alzheimer's disease LRRC3B intron 17998437 rs11916104 chr3 26718724 C G 4.65E-04 Alzheimer's disease LRRC3B intron 17998437 rs715642 chr3 26720690 A G 5.41E-04 Alzheimer's disease LRRC3B intron 17998437 rs6551130 chr3 26722139 T C 2.02E-04 Alzheimer's disease LRRC3B intron 17998437 rs6776559 chr3 26725121 G A 2.07E-04 Alzheimer's disease LRRC3B intron 17998437 rs7616110 chr3 26735083 C T 7.23E-04 Alzheimer's disease LRRC3B intron 17998437 rs17018559 chr3 26739650 G A 1.70E-05 Iron levels LRRC3B intron 21208937 rs4395366 chr3 26742691 T C 5.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LRRC3B intron 20877124 rs1386886 chr3 26775763 C T 2.14E-06 Diabetes (gestational) / / 22233651 rs1488233 chr3 26777472 A G 4.09E-04 Alzheimer's disease / / 17998437 rs9866020 chr3 26778370 G A 5.27E-06 Diabetes (gestational) / / 22233651 rs9872064 chr3 26802920 A G 7.52E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1160339 chr3 26809950 G A 1.60E-05 Psoriasis / / 19169255 rs1160339 chr3 26809950 G A 2.46E-05 Dengue shock syndrome / / 22001756 rs1488219 chr3 26838752 G A 2.02E-06 Dengue shock syndrome / / 22001756 rs1155107 chr3 26843377 A G 5.71E-04 Coronary Artery Disease / / 17634449 rs1155107 chr3 26843377 A G 6.37E-05 Diabetes (gestational) / / 22233651 rs4267616 chr3 26846174 C T 3.36E-07 Dengue shock syndrome / / 22001756 rs9848111 chr3 26847785 A G 2.47E-05 Diabetes (gestational) / / 22233651 rs9877107 chr3 26891510 C G 2.00E-05 Urinary metabolites / / 21572414 rs9839380 chr3 26891616 A G 1.40E-05 Urinary metabolites / / 21572414 rs4973823 chr3 26897595 G A 1.10E-05 Urinary metabolites / / 21572414 rs4973824 chr3 26897667 G C 1.50E-05 Urinary metabolites / / 21572414 rs955027 chr3 26947415 A C 5.10E-04 Pulmonary function / / 20010834 rs955027 chr3 26947415 A C 2.01E-05 Calcium levels / / pha003085 rs12486501 chr3 26950415 T A 5.71E-04 Insulin resistance / / 21901158 rs4493387 chr3 26958669 C T 8.10E-05 Serum metabolites / / 19043545 rs17019022 chr3 26979984 T C 3.87E-04 Multiple complex diseases / / 17554300 rs9851229 chr3 27002945 T G 8.01E-05 Serum metabolites / / 19043545 rs2044573 chr3 27024947 T C 4.91E-04 Type 2 diabetes / / 17463246 rs2044573 chr3 27024947 T C 5.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs17019085 chr3 27024977 G C 4.91E-04 Type 2 diabetes / / 17463246 rs17019085 chr3 27024977 G C 6.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs7340535 chr3 27025575 T C 5.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs9841676 chr3 27025777 T C 3.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs9822018 chr3 27026032 C T 2.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs1348979 chr3 27027497 G C 5.90E-04 Type 2 diabetes / / 17463246 rs10510586 chr3 27028661 C T 1.90E-04 Type 2 diabetes / / 17463246 rs13093597 chr3 27037728 T C 0.0000584 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1402991 chr3 27053802 A G 1.00E-04 Prostate cancer / / 21743057 rs939838 chr3 27054896 A C 1.00E-04 Prostate cancer / / 21743057 rs6766181 chr3 27100290 C T 6.64E-04 Type 2 diabetes / / 17463246 rs6766181 chr3 27100290 C T 2.40E-05 Alcoholism (heaviness of drinking) / / 21529783 rs6766181 chr3 27100290 C T 3.06E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs9881362 chr3 27105502 G C 1.16E-04 Insulin resistance / / 21901158 rs17019325 chr3 27118517 A G 1.46E-07 Multiple complex diseases / / 17554300 rs6551174 chr3 27150110 C T 2.12E-04 Insulin resistance / / 21901158 rs1522153 chr3 27170777 G A 6.43E-04 Insulin resistance / / 21901158 rs1522153 chr3 27170777 G A 3.00E-06 Alcohol dependence / / 21956439 rs10510590 chr3 27180143 T C 4.69E-04 Hemoglobin concentration / / 20534544 rs10510590 chr3 27180143 T C 7.37E-05 Insulin resistance / / 21901158 rs1357245 chr3 27186602 C T 1.90E-07 Breast cancer / / 19330027 rs12487340 chr3 27208975 C T 3.88E-11 Breast cancer (early onset) / / 24493630 rs7653795 chr3 27217080 G A 8.96E-11 Breast cancer (early onset) / / 24493630 rs7653480 chr3 27229286 C T 1.86E-04 Type 2 diabetes / / 17463246 rs7634878 chr3 27241219 G A 1.13E-09 Breast cancer (early onset) / / 24493630 rs10049490 chr3 27241776 G T 2.93E-10 Breast cancer (early onset) / / 24493630 rs1445111 chr3 27253971 C T 1.32E-10 Breast cancer (early onset) / / 24493630 rs11129270 chr3 27257943 A G 1.42E-10 Breast cancer (early onset) NEK10 intron 24493630 rs2370946 chr3 27260283 G A 1.14E-10 Breast cancer (early onset) NEK10 intron 24493630 rs2100006 chr3 27273415 G A 1.13E-11 Breast cancer (early onset) NEK10 intron 24493630 rs2034190 chr3 27292557 T C 1.23E-11 Breast cancer (early onset) NEK10 intron 24493630 rs487930 chr3 27330335 C A 5.04E-12 Breast cancer (early onset) NEK10 intron 24493630 rs653465 chr3 27343644 C T 5.00E-12 Breast cancer (early onset) NEK10 intron 24493630 rs552647 chr3 27353716 C A 5.28E-12 Breast cancer (early onset) NEK10 intron 24493630 rs1603051 chr3 27378511 A C 3.95E-04 Suicide attempts in bipolar disorder NEK10 intron 21423239 rs9847010 chr3 27382214 A G 9.51E-04 Type 2 diabetes NEK10 intron 17463246 rs7611368 chr3 27395970 T C 2.77E-04 Suicide attempts in bipolar disorder NEK10 intron 21423239 rs12715121 chr3 27413246 T C 0.0000734 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4973768 chr3 27416013 C T 4.10E-23 Breast cancer SLC4A7 UTR-3 19330027 rs4973768 chr3 27416013 C T 6.00E-07 Breast cancer SLC4A7 UTR-3 20453838 rs4973768 chr3 27416013 C T 2.00E-08 Breast cancer SLC4A7 UTR-3 21263130 rs4973768 chr3 27416013 C T 2.00E-30 Breast cancer SLC4A7 UTR-3 23535729 rs9856538 chr3 27417601 T C 0.0000679 Nonsyndromic striae distensae (stretch marks) SLC4A7 UTR-3 23633020 rs1472256 chr3 27424718 A G 2.51E-04 Iron levels SLC4A7 cds-synon pha002876 rs1472254 chr3 27427225 A G 5.76E-10 Breast cancer (early onset) SLC4A7 intron 24493630 rs2172297 chr3 27428423 G A 1.60E-04 Multiple complex diseases SLC4A7 intron 17554300 rs2131205 chr3 27428501 A G 1.97E-04 Multiple complex diseases SLC4A7 intron 17554300 rs2307033 chr3 27433163 T C 0.0000585 Nonsyndromic striae distensae (stretch marks) SLC4A7 intron 23633020 rs2307034 chr3 27433360 G A 0.0000562 Nonsyndromic striae distensae (stretch marks) SLC4A7 intron 23633020 rs9810587 chr3 27433911 T C 0.0000541 Nonsyndromic striae distensae (stretch marks) SLC4A7 intron 23633020 rs9826281 chr3 27436776 T A 0.0000573 Nonsyndromic striae distensae (stretch marks) SLC4A7 intron 23633020 rs13318924 chr3 27440096 A G 0.0000464 Nonsyndromic striae distensae (stretch marks) SLC4A7 intron 23633020 rs9823798 chr3 27441221 T C 0.0000593 Nonsyndromic striae distensae (stretch marks) SLC4A7 intron 23633020 rs35700247 chr3 27443161 A G 0.0000513 Nonsyndromic striae distensae (stretch marks) SLC4A7 intron 23633020 rs10510595 chr3 27443488 T C 1.20E-04 Multiple complex diseases SLC4A7 intron 17554300 rs13078798 chr3 27445971 G A 1.42E-04 Multiple complex diseases SLC4A7 intron 17554300 rs7610114 chr3 27458622 C T 4.14E-04 Iron levels SLC4A7 intron pha002876 rs3755652 chr3 27472936 C T 2.54E-04 Multiple complex diseases SLC4A7 missense 17554300 rs13077400 chr3 27473066 A G 1.65E-04 Multiple complex diseases SLC4A7 cds-synon 17554300 rs2029618 chr3 27478899 A G 4.57E-04 Hemoglobin concentration SLC4A7 cds-synon 20534544 rs17682751 chr3 27497027 T C 2.56E-04 Multiple complex diseases SLC4A7 intron 17554300 rs2643813 chr3 27537746 A G 7.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs13082711 chr3 27537909 T C 5.00E-09 Blood pressure / / 21909110 rs13082711 chr3 27537909 T C 2.00E-06 Systolic blood pressure / / 21909115 rs13082711 chr3 27537909 T C 4.00E-09 Diastolic blood pressure / / 21909115 rs629462 chr3 27553839 G A 6.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs13091026 chr3 27563686 C T 0.0000916 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1495566 chr3 27566810 T A 0.0000776 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs66893799 chr3 27617913 G A 0.0000838 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13092204 chr3 27618343 G A 0.0000855 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7625865 chr3 27619708 T C 0.0000791 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13073304 chr3 27620947 G A 0.0000733 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2642905 chr3 27638500 A G 1.23E-04 Multiple complex diseases / / 17554300 rs6551218 chr3 27665791 A C 1.20E-05 Urinary metabolites / / 21572414 rs6769210 chr3 27666131 C T 2.50E-05 Urinary metabolites / / 21572414 rs6551219 chr3 27666362 T C 2.70E-05 Urinary metabolites / / 21572414 rs2370990 chr3 27690531 C T 4.74E-05 Magnesium levels / / pha003092 rs4461380 chr3 27697129 G T 1.45E-04 Multiple complex diseases / / 17554300 rs3856677 chr3 27697503 A G 7.61E-04 Multiple complex diseases / / 17554300 rs17020218 chr3 27723197 A G 5.68E-05 Multiple complex diseases / / 17554300 rs2724509 chr3 27724852 G A 4.76E-04 Hemoglobin concentration / / 20534544 rs9846205 chr3 27725605 G A 6.37E-04 Premature ovarian failure / / 19508998 rs2642935 chr3 27726951 A G 4.76E-04 Hemoglobin concentration / / 20534544 rs1494835 chr3 27729109 A G 4.76E-04 Hemoglobin concentration / / 20534544 rs9848796 chr3 27738395 A G 4.23E-04 Hemoglobin concentration / / 20534544 rs3806624 chr3 27764623 A G 1.00E-12 Hodgkin's lymphoma / / 24149102 rs3806624 chr3 27764623 A G 1.04E-06 Hodgkin's lymphoma / / 24149102 rs3806624 chr3 27764623 A G 3.00E-08 Rheumatoid arthritis / / 24390342 rs3806624 chr3 27764623 A G 9.00E-09 Rheumatoid arthritis / / 24390342 rs3806624 chr3 27764623 A G 2.26E-04 Hodgkin's lymphoma / / 24920014 rs9878516 chr3 27782360 G A 5.54E-06 Inflammation / / pha002897 rs11129295 chr3 27788780 C T 1.00E-09 Multiple sclerosis / / 21833088 rs11129295 chr3 27788780 C T 2.19E-04 Hodgkin's lymphoma / / 24149102 rs12493245 chr3 27797810 G A 1.26E-05 Hodgkin's lymphoma / / 24149102 rs9817112 chr3 27827733 A G 3.35E-04 Gallstones / / 17632509 rs9817112 chr3 27827733 A G 3.88E-05 Hodgkin's lymphoma / / 24149102 rs730510 chr3 27833251 T C 5.11E-04 Hodgkin's lymphoma / / 24149102 rs6770352 chr3 27847279 T G 1.97E-04 Multiple complex diseases / / 17554300 rs2371121 chr3 27850725 G T 1.32E-05 Multiple complex diseases / / 17554300 rs10510597 chr3 27850945 C T 2.66E-04 Bipolar disorder / / 19259986 rs2887957 chr3 27901738 C A 1.46E-04 Multiple complex diseases / / 17554300 rs7623233 chr3 27922474 G A 2.21E-04 Multiple complex diseases / / 17554300 rs2581194 chr3 27927730 T C 9.51E-05 Post-operative nausea and vomiting / / 21694509 rs2581186 chr3 27930639 A G 2.22E-05 Post-operative nausea and vomiting / / 21694509 rs993668 chr3 27931338 C G 8.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs2618115 chr3 27943158 G A 7.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs9816729 chr3 27945306 C T 8.09E-04 Multiple complex diseases / / 17554300 rs17020592 chr3 27950570 C T 1.22E-04 Multiple complex diseases / / 17554300 rs9830403 chr3 27963608 C G 1.50E-05 Urinary metabolites / / 21572414 rs1842033 chr3 27968947 A G 9.84E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs10510599 chr3 27975263 T C 1.40E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2169820 chr3 27976288 A G 3.86E-04 Multiple complex diseases / / 17554300 rs4680886 chr3 28007973 G A 2.31E-05 Brain structure / / 22504417 rs17020708 chr3 28017802 C T 8.15E-05 Suicide attempts in bipolar disorder / / 21423239 rs17020710 chr3 28017987 G A 5.49E-05 Suicide attempts in bipolar disorder / / 21423239 rs12632457 chr3 28020552 T C 1.40E-05 Amyotrophic Lateral Sclerosis / / 17362836 rs12632457 chr3 28020552 T C 6.53E-05 Coronary heart disease / / pha003032 rs12639500 chr3 28026396 A G 4.44E-05 Brain structure / / 22504417 rs6790513 chr3 28034296 T C 5.82E-04 Insulin resistance / / 21901158 rs9825129 chr3 28043715 T C 1.26E-04 Multiple complex diseases / / 17554300 rs669607 chr3 28071444 A C 2.00E-15 Multiple sclerosis / / 21833088 rs669607 chr3 28071444 A C 2.50E-05 Multiple sclerosis / / 24234648 rs170934 chr3 28079085 C T 2.00E-08 Multiple sclerosis / / 22190364 rs17020950 chr3 28119946 T C 4.11E-04 Multiple complex diseases / / 17554300 rs10510605 chr3 28123769 T G 8.40E-06 Urinary metabolites / / 21572414 rs17688561 chr3 28124209 G A 1.50E-05 Urinary metabolites / / 21572414 rs879871 chr3 28124899 A G 8.30E-06 Urinary metabolites / / 21572414 rs368524 chr3 28130759 A T 6.38E-04 Coronary Artery Disease / / 17634449 rs647616 chr3 28143749 A G 7.62E-04 Coronary Artery Disease / / 17634449 rs380560 chr3 28146941 T C 2.18E-04 Coronary Artery Disease / / 17634449 rs384620 chr3 28147286 T C 2.14E-04 Coronary Artery Disease / / 17634449 rs1395409 chr3 28148832 A G 3.83E-04 Coronary Artery Disease / / 17634449 rs440254 chr3 28149666 T C 3.82E-04 Coronary Artery Disease / / 17634449 rs401387 chr3 28149683 G C 3.13E-04 Coronary Artery Disease / / 17634449 rs6764680 chr3 28154465 G C 1.73E-04 Coronary Artery Disease / / 17634449 rs6806119 chr3 28164921 C T 1.85E-04 Coronary Artery Disease / / 17634449 rs1389155 chr3 28165662 G A 6.55E-04 Myopia (pathological) / / 21095009 rs17021139 chr3 28171237 G C 8.48E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs13094235 chr3 28178694 G C 4.17E-04 Coronary Artery Disease / / 17634449 rs7646845 chr3 28181591 G A 4.38E-04 Coronary Artery Disease / / 17634449 rs7636966 chr3 28181761 A G 5.86E-04 Coronary Artery Disease / / 17634449 rs6803625 chr3 28188749 C G 5.62E-04 Alcohol dependence / / 21314694 rs6788643 chr3 28204584 T C 2.50E-04 Behavioural disinhibition (generation interaction) / / 23942779 rs6788643 chr3 28204584 T C 4.10E-06 Behavioural disinhibition (generation interaction) / / 23942779 rs9310862 chr3 28206877 G A 2.30E-04 Behavioural disinhibition (generation interaction) / / 23942779 rs9310862 chr3 28206877 G A 4.00E-06 Behavioural disinhibition (generation interaction) / / 23942779 rs17710733 chr3 28211713 G A 5.07E-04 Multiple complex diseases / / 17554300 rs6800659 chr3 28270669 G A 1.68E-04 Heart Failure / / pha002885 rs4680748 chr3 28293360 G C 2.39E-05 Serum metabolites CMC1 intron 19043545 rs17021306 chr3 28304126 T G 1.17E-04 Coronary Artery Disease CMC1 intron 17634449 rs10510608 chr3 28305152 T C 2.20E-04 Multiple complex diseases CMC1 intron 17554300 rs11706542 chr3 28328583 C T 8.17E-04 Coronary Artery Disease CMC1 intron 17634449 rs11706542 chr3 28328583 C T 9.43E-05 Alcohol dependence CMC1 intron 19581569 rs17638991 chr3 28350969 G C 6.70E-04 Coronary Artery Disease CMC1 intron 17634449 rs4552313 chr3 28355386 G A 2.00E-06 Height CMC1 intron 17767157 rs11706332 chr3 28358057 C T 5.89E-04 Coronary Artery Disease CMC1 intron 17634449 rs7612033 chr3 28426978 C T 7.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs13095628 chr3 28467123 G A 6.24E-04 Coronary Artery Disease ZCWPW2 intron 17634449 rs11720107 chr3 28472728 C T 6.51E-04 Coronary Artery Disease ZCWPW2 intron 17634449 rs1598846 chr3 28510453 A G 7.98E-04 Coronary Artery Disease ZCWPW2 intron 17634449 rs17696783 chr3 28537611 G A 6.49E-04 Coronary Artery Disease ZCWPW2 intron 17634449 rs4361241 chr3 28607548 C G 4.80E-04 Coronary Artery Disease / / 17634449 rs4133027 chr3 28624327 T C 6.97E-05 Coronary Artery Disease LOC645206 intron 17634449 rs4521182 chr3 28631124 T C 3.32E-05 Glucose levels LOC645206 intron pha003058 rs4521182 chr3 28631124 T C 4.33E-05 Glucose levels LOC645206 intron pha003061 rs4680765 chr3 28648364 C G 2.89E-04 Multiple complex diseases LOC645206 intron 17554300 rs13327669 chr3 28651451 A G 7.20E-06 Urinary metabolites LOC645206 intron 21572414 rs6776912 chr3 28652496 A G 3.78E-05 Gaucher disease severity LOC645206 intron 22388998 rs4306817 chr3 28660626 A G 3.80E-06 Urinary metabolites LOC645206 intron 21572414 rs1599489 chr3 28681632 T C 8.20E-06 Urinary metabolites LOC645206 intron 21572414 rs970624 chr3 28682296 A C 3.02E-04 Age-related macular degeneration LOC645206 intron 22125219 rs9310867 chr3 28690589 A G 7.57E-04 Parkinson's disease LOC645206 intron 21044948 rs9310867 chr3 28690589 A G 2.78E-05 Parkinson's disease LOC645206 intron 22438815 rs9310867 chr3 28690589 A G 6.15E-04 Stroke LOC645206 intron pha002886 rs6549869 chr3 28701496 C T 2.49E-05 HIV-1 viral setpoint LOC645206 intron 22174851 rs4399848 chr3 28704463 A G 9.94E-05 Multiple complex diseases LOC645206 intron 17554300 rs7617877 chr3 28705764 A G 3.00E-06 Parkinson's disease LOC645206 intron 21044948 rs13075697 chr3 28712239 G A 1.51E-05 HIV-1 viral setpoint LOC645206 intron 22174851 rs6780486 chr3 28713787 A G 1.80E-05 Urinary metabolites LOC645206 intron 21572414 rs4680773 chr3 28714733 A G 8.07E-04 Multiple complex diseases LOC645206 intron 17554300 rs6762880 chr3 28715369 G C 3.77E-04 Type 2 diabetes LOC645206 intron 17463246 rs9861037 chr3 28719312 C G 4.74E-20 Metabolite levels LOC645206 intron 22286219 rs17651822 chr3 28720126 C T 1.14E-04 Type 2 diabetes LOC645206 intron 17463246 rs1156965 chr3 28723446 C G 1.80E-06 Urinary metabolites LOC645206 intron 21572414 rs4398388 chr3 28736622 G A 1.48E-04 Alcohol dependence LOC645206 intron 20201924 rs1381392 chr3 28749314 G A 9.33E-04 Myocardial Infarction LOC645206 intron pha002883 rs1011417 chr3 28796482 T C 2.00E-06 Urinary metabolites LOC645206 intron 21572414 rs1903586 chr3 28803094 C T 3.22E-05 Serum metabolites / / 19043545 rs1461802 chr3 28819123 C T 7.36E-04 Type 2 diabetes / / 17463246 rs17021958 chr3 28827335 C T 1.97E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs7633531 chr3 28828525 G T 1.30E-07 Response to statin therapy / / 20339536 rs4680784 chr3 28832119 G A 1.60E-07 Response to statin therapy / / 20339536 rs3902030 chr3 28840724 G A 2.10E-05 Response to statin therapy / / 20339536 rs11922379 chr3 28843983 T A 4.20E-04 Type 2 diabetes / / 17463246 rs7631590 chr3 28845890 A G 2.20E-05 Response to statin therapy / / 20339536 rs1392311 chr3 28846545 C T 2.20E-05 Response to statin therapy / / 20339536 rs6768567 chr3 28847358 G A 2.30E-05 Response to statin therapy / / 20339536 rs9883412 chr3 28862422 A G 2.30E-05 Response to statin therapy / / 20339536 rs9857300 chr3 28864888 C T 4.32E-04 Alzheimer's disease / / 22005930 rs11926073 chr3 28871595 G A 1.74E-05 Nephrolithiasis / / 22396660 rs12490883 chr3 28877081 T C 8.60E-05 Response to statin therapy / / 20339536 rs6770726 chr3 28879089 T A 1.84E-04 Blood pressure / / 17255346 rs6770726 chr3 28879089 T A 5.31E-04 Type 2 diabetes / / 17463246 rs11129333 chr3 28879197 C A 6.35E-04 Alzheimer's disease / / 22005930 rs7623722 chr3 28882980 A G 8.78E-04 Alzheimer's disease / / 22005930 rs13077892 chr3 28883279 C T 9.07E-04 Alzheimer's disease / / 22005930 rs1125186 chr3 28885804 C G 9.02E-04 Alzheimer's disease / / 22005930 rs2221154 chr3 28928860 T G 3.00E-06 Alzheimer's disease / / 22159054 rs4680793 chr3 28929230 G A 0.000438 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs9816337 chr3 28936109 G T 6.76E-04 Schizophrenia / / 19197363 rs9817531 chr3 28936836 G A 7.89E-04 Schizophrenia / / 19197363 rs4016429 chr3 28964801 C G 2.00E-06 Smooth-surface caries / / 24556642 rs7641837 chr3 29019592 A G 8.37E-05 Parkinson's disease / / 21248740 rs2167089 chr3 29034403 T G 6.00E-06 White matter hyperintensity burden / / 21681796 rs2167089 chr3 29034403 T G 0.000638 white matter hyperintensity burden / / 23674528 rs9828929 chr3 29044226 C T 3.29E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1449692 chr3 29051853 T C 2.20E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1979113 chr3 29057186 A G 1.16E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6772740 chr3 29059651 G C 7.24E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs619656 chr3 29105651 A G 2.60E-06 Urinary metabolites / / 21572414 rs512613 chr3 29142926 G C 8.62E-05 Serum metabolites / / 19043545 rs613516 chr3 29154358 A G 8.26E-05 Disc degeneration (lumbar) / / 24216480 rs9859945 chr3 29169954 T C 6.19E-05 Waist Circumference / / pha003023 rs13097297 chr3 29175398 C T 0.00000008 Brain microstructure and intellectual performance / / 22723713 rs6549915 chr3 29209151 T C 9.00E-06 Breast size / / 22747683 rs12496180 chr3 29212935 T A 8.77E-04 Multiple complex diseases / / 17554300 rs6780332 chr3 29218259 T C 4.02E-04 Parkinson's disease / / 17052657 rs41356346 chr3 29247332 T C 5.68E-04 Multiple complex diseases / / 17554300 rs7616684 chr3 29251992 A G 8.85E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2196554 chr3 29258751 T C 5.67E-04 Smoking initiation / / 24665060 rs13098112 chr3 29263650 C A 1.59E-05 Blood Pressure / / pha003050 rs768303 chr3 29265952 T C 2.39E-04 Smoking initiation / / 24665060 rs4680719 chr3 29275646 G A 3.00E-06 Metabolite levels (HVA) / / 23319000 rs2196556 chr3 29277986 G A 9.81E-04 Alzheimer's disease / / 17998437 rs7646464 chr3 29279486 C G 5.81E-04 Multiple complex diseases / / 17554300 rs6778464 chr3 29279779 A G 1.22E-06 Age-related macular degeneration / / pha000001 rs984462 chr3 29284286 T C 7.83E-04 Myocardial Infarction / / pha002873 rs9877517 chr3 29287651 G A 6.53E-05 Alcohol dependence / / 20201924 rs9877517 chr3 29287651 G A 6.53E-05 Alcoholism / / pha002891 rs1004644 chr3 29291048 G A 8.47E-04 Myocardial Infarction / / pha002873 rs11129357 chr3 29319887 G A 7.30E-06 Urinary metabolites / / 21572414 rs2888099 chr3 29322297 A C 6.15E-05 Pulmonary function / / 20010835 rs9832625 chr3 29329020 C A 3.00E-06 Response to radiotherapy in cancer (late toxicity) RBMS3 intron 24785509 rs9832625 chr3 29329020 C A 7.78E-05 Response to radiotherapy in cancer (late toxicity) RBMS3 intron 24785509 rs9878305 chr3 29335426 A G 1.84E-05 Nonalcoholic fatty liver disease RBMS3 intron 21423719 rs6549924 chr3 29357063 C T 2.54E-06 Stroke RBMS3 intron pha002887 rs6549924 chr3 29357063 C T 3.58E-06 Left ventricular hypertrophy RBMS3 intron pha003052 rs7349464 chr3 29357140 G A 9.64E-04 Type 2 diabetes RBMS3 intron 17463246 rs7349464 chr3 29357140 G A 4.76E-04 Alzheimer's disease (late onset) RBMS3 intron 21379329 rs6804900 chr3 29373424 A G 3.39E-05 Bipolar disorder and schizophrenia RBMS3 intron 20889312 rs7431530 chr3 29382541 C T 2.00E-06 Upper aerodigestive tract cancers RBMS3 intron 21437268 rs7644260 chr3 29384227 C T 7.16E-04 Response to statin treatment (atorvastatin),change in cholesterol levels RBMS3 intron 20031582 rs7610043 chr3 29387631 G A 8.00E-04 Bipolar disorder RBMS3 intron 17486107 rs4574243 chr3 29420132 T C 4.38E-04 Suicide attempts in bipolar disorder RBMS3 intron 21423239 rs11713209 chr3 29427676 T G 1.15E-04 Suicide attempts in bipolar disorder RBMS3 intron 21423239 rs4377455 chr3 29428187 C T 5.39E-07 Bipolar disorder RBMS3 intron 20451256 rs4377455 chr3 29428187 C T 1.53E-04 Suicide attempts in bipolar disorder RBMS3 intron 21423239 rs7636503 chr3 29436928 G A 6.93E-04 Suicide attempts in bipolar disorder RBMS3 intron 21423239 rs7642033 chr3 29438500 C T 5.77E-04 Type 2 diabetes RBMS3 intron 17463246 rs4130687 chr3 29444111 A G 8.82E-04 Nicotine smoking RBMS3 intron 19268276 rs13079920 chr3 29445931 G A 8.58E-05 Left ventricular hypertrophy RBMS3 intron pha003052 rs1561374 chr3 29458092 A G 7.71E-05 Coronary restenosis RBMS3 intron 21878436 rs7634956 chr3 29463968 C T 1.54E-05 Blood Pressure RBMS3 intron pha002903 rs1438339 chr3 29482046 C T 5.56E-04 Alcohol dependence RBMS3 intron 24277619 rs17023487 chr3 29482712 G A 7.77E-07 Cholesterol RBMS3 intron pha003073 rs17023487 chr3 29482712 G A 3.35E-06 ldl cholesterol RBMS3 intron pha003076 rs17023487 chr3 29482712 G A 2.15E-05 ldl cholesterol RBMS3 intron pha003077 rs17023487 chr3 29482712 G A 4.55E-06 Cholesterol RBMS3 intron pha003078 rs17023487 chr3 29482712 G A 2.47E-05 Cholesterol RBMS3 intron pha003083 rs4146794 chr3 29484045 A G 1.01E-04 Alzheimer's disease (late onset) RBMS3 intron 21379329 rs4146794 chr3 29484045 A G 5.84E-05 Prion diseases RBMS3 intron 22210626 rs4146794 chr3 29484045 A G 5.61E-05 Diabetes Mellitus RBMS3 intron pha003059 rs7632290 chr3 29484510 T G 8.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBMS3 intron 20877124 rs17023578 chr3 29496026 C T 1.41E-04 Multiple complex diseases RBMS3 intron 17554300 rs4452286 chr3 29500962 C G 3.91E-04 Multiple complex diseases RBMS3 intron 17554300 rs1370788 chr3 29512221 A T 2.37E-05 Multiple complex diseases RBMS3 intron 17554300 rs10510621 chr3 29516639 G A 1.32E-04 Myopia (pathological) RBMS3 intron 21095009 rs17023679 chr3 29518548 C T 6.04E-05 Multiple complex diseases RBMS3 intron 17554300 rs17023697 chr3 29522455 C G 8.39E-05 Multiple complex diseases RBMS3 intron 17554300 rs3773047 chr3 29545182 A G 2.95E-04 Multiple complex diseases RBMS3 intron 17554300 rs9867172 chr3 29551939 C T 9.01E-04 Multiple complex diseases RBMS3 intron 17554300 rs1530057 chr3 29575463 G T 3.00E-06 Lung cancer RBMS3 intron 19654303 rs1530057 chr3 29575463 G T 3.00E-06 Nasopharyngeal carcinoma RBMS3 intron 20512145 rs35883 chr3 29597791 A G 6.67E-06 Parkinson's disease RBMS3 intron 21738487 rs35883 chr3 29597791 A G 8.60E-05 Systemic sclerosis RBMS3 intron 21750679 rs35881 chr3 29599663 C T 5.73E-05 Parkinson's disease RBMS3 intron 21738487 rs13323338 chr3 29620604 C T 1.64E-05 Parkinson's disease RBMS3 intron 21738487 rs13323338 chr3 29620604 C T 2.06E-05 Systemic sclerosis RBMS3 intron 21750679 rs2168765 chr3 29663099 C T 6.05E-04 Multiple complex diseases RBMS3 intron 17554300 rs9829357 chr3 29665461 T G 1.47E-04 Prion diseases RBMS3 intron 22210626 rs9877765 chr3 29690385 T C 4.08E-04 Multiple complex diseases RBMS3 intron 17554300 rs9862854 chr3 29691197 C G 7.23E-04 Multiple complex diseases RBMS3 intron 17554300 rs10510622 chr3 29695588 T C 9.40E-04 Type 2 diabetes and 6 quantitative traits RBMS3 intron 17848626 rs4630899 chr3 29699586 T C 3.92E-04 Multiple complex diseases RBMS3 intron 17554300 rs9831584 chr3 29700014 G T 3.29E-04 Multiple complex diseases RBMS3 intron 17554300 rs9882829 chr3 29700225 G A 2.01E-04 Prion diseases RBMS3 intron 22210626 rs9883185 chr3 29738025 A G 1.74E-25 Narcolepsy RBMS3 intron 19629137 rs17550007 chr3 29759336 G T 8.58E-04 Suicide attempts in bipolar disorder RBMS3 intron 21041247 rs1440524 chr3 29760507 T C 5.48E-04 Suicide attempts in bipolar disorder RBMS3 intron 21041247 rs1371844 chr3 29761506 C T 6.23E-04 Suicide attempts in bipolar disorder RBMS3 intron 21041247 rs1371846 chr3 29761649 A C 6.26E-04 Suicide attempts in bipolar disorder RBMS3 intron 21041247 rs6779932 chr3 29761943 G T 8.86E-04 Suicide attempts in bipolar disorder RBMS3 intron 21041247 rs6780134 chr3 29762129 G A 6.31E-04 Suicide attempts in bipolar disorder RBMS3 intron 21041247 rs6783723 chr3 29763238 G A 6.42E-04 Suicide attempts in bipolar disorder RBMS3 intron 21041247 rs12374076 chr3 29764315 A G 4.20E-04 Smoking initiation RBMS3 intron 24665060 rs6549953 chr3 29764850 C T 6.00E-04 Acute lymphoblastic leukemia (childhood) RBMS3 intron 20189245 rs1866773 chr3 29778243 T C 5.92E-04 Suicide attempts in bipolar disorder RBMS3 intron 21041247 rs17024316 chr3 29782718 C G 5.99E-04 Suicide attempts in bipolar disorder RBMS3 intron 21041247 rs1371837 chr3 29789588 A C 8.82E-04 Multiple complex diseases RBMS3 intron 17554300 rs7623158 chr3 29791640 C G 3.14E-04 Multiple complex diseases RBMS3 intron 17554300 rs7623178 chr3 29791698 C A 5.47E-04 Multiple complex diseases RBMS3 intron 17554300 rs2577120 chr3 29798434 C G 5.87E-04 Coronary heart disease RBMS3 intron 21606135 rs17551079 chr3 29800270 G A 1.20E-05 Urinary metabolites RBMS3 intron 21572414 rs9821929 chr3 29803505 C T 7.62E-05 Multiple complex diseases RBMS3 intron 17554300 rs9852393 chr3 29805345 T G 1.70E-04 Multiple complex diseases RBMS3 intron 17554300 rs10510628 chr3 29853403 G A 3.00E-06 Bone mineral density RBMS3 intron 17903296 rs2218724 chr3 29925518 A G 3.77E-05 Prostate cancer RBMS3 intron pha002878 rs17838728 chr3 29942006 A G 4.75E-04 Multiple complex diseases RBMS3 intron 17554300 rs7610139 chr3 29949712 A G 5.27E-04 Depression (quantitative trait) RBMS3 intron 20800221 rs17024608 chr3 29954690 A G 7.47E-08 Bisphosphonate-induced osteonecrosis of the jaw RBMS3 intron 22267851 rs1816996 chr3 30007105 G C 5.53E-04 Type 2 diabetes RBMS3 intron 17463246 rs3773127 chr3 30033043 A C 9.88E-04 Type 2 diabetes RBMS3 intron 17463246 rs6768053 chr3 30054818 C T 8.87E-04 Type 2 diabetes / / 17463246 rs13077725 chr3 30059761 C A 8.62E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7427882 chr3 30085222 C A 9.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs9867656 chr3 30100084 A G 3.74E-04 Type 2 diabetes / / 17463246 rs7649490 chr3 30111359 G A 1.86E-04 Response to alcohol consumption (flushing response) / / 24277619 rs6549973 chr3 30118857 C T 7.10E-04 Multiple complex diseases / / 17554300 rs7639172 chr3 30118918 T G 2.95E-04 Multiple complex diseases / / 17554300 rs1434012 chr3 30124229 G A 6.30E-04 Multiple complex diseases / / 17554300 rs17555240 chr3 30124257 A G 7.58E-04 Multiple complex diseases / / 17554300 rs13079874 chr3 30124940 A C 2.80E-06 Urinary metabolites / / 21572414 rs11919248 chr3 30125732 G A 1.54E-04 Parkinson's disease / / 16252231 rs9840784 chr3 30132198 C T 2.10E-06 Urinary metabolites / / 21572414 rs4680872 chr3 30151116 G A 3.77E-04 Blood pressure / / 17255346 rs4680872 chr3 30151116 G A 1.80E-06 Urinary metabolites / / 21572414 rs1434019 chr3 30188747 T C 7.51E-04 Multiple complex diseases / / 17554300 rs4680878 chr3 30193543 T G 8.71E-05 Parkinson's disease / / 16252231 rs2371997 chr3 30211106 T C 2.80E-05 Myocardial Infarction / / pha002873 rs12488511 chr3 30220012 G T 1.69E-04 Height / / 17255346 rs1036308 chr3 30235221 G A 4.45E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1433991 chr3 30236309 G T 3.77E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs72853527 chr3 30237298 C T 0.0000999 Sarcoidosis / / 22952805 rs968896 chr3 30240425 T C 4.55E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1560848 chr3 30245137 T C 1.40E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9824898 chr3 30254185 G T 4.55E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6779483 chr3 30258522 G A 4.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6549977 chr3 30259240 G A 6.08E-06 Calcium levels / / pha003085 rs7644703 chr3 30271646 T C 9.24E-05 Schizophrenia / / 19571811 rs11926889 chr3 30278290 G A 6.10E-05 Type 2 diabetes / / 17463248 rs17564364 chr3 30285495 C A 8.27E-05 Body Mass Index / / pha003020 rs1434006 chr3 30293504 C T 4.40E-05 Type 2 diabetes / / 17463248 rs13075234 chr3 30294430 C T 5.80E-05 Type 2 diabetes / / 17463248 rs10440137 chr3 30295974 G T 4.40E-05 Type 2 diabetes / / 17463248 rs999853 chr3 30298849 C A 5.45E-04 Insulin resistance / / 21901158 rs9870410 chr3 30308759 C T 3.80E-05 Type 2 diabetes / / 17463248 rs13092602 chr3 30309945 G A 8.20E-06 Type 2 diabetes / / 17463248 rs1495586 chr3 30327788 G A 8.20E-06 Type 2 diabetes / / 17463248 rs2077164 chr3 30332349 A G 3.86E-04 Alcohol dependence / / 20201924 rs17081352 chr3 30332847 C A 5.50E-06 Type 2 diabetes / / 17463248 rs9843153 chr3 30333248 G T 8.40E-06 Type 2 diabetes / / 17463248 rs1390298 chr3 30344776 C T 4.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs10510634 chr3 30346968 A G 4.72E-06 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10510634 chr3 30346968 A G 5.00E-06 Fasting plasma glucose / / 17903298 rs1495579 chr3 30347354 G T 3.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs1495578 chr3 30347455 G A 3.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs6549981 chr3 30348760 C T 3.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs6809482 chr3 30353412 G A 3.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs11129397 chr3 30354360 C T 3.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs6780847 chr3 30355530 T C 2.95E-04 Suicide attempts in bipolar disorder / / 21041247 rs6781057 chr3 30355787 T G 2.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs9876671 chr3 30360636 G A 2.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs9876727 chr3 30360854 C A 2.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs7653488 chr3 30368930 T C 7.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs7634533 chr3 30372053 C A 5.00E-06 Dental caries / / 23259602 rs9841664 chr3 30373341 C T 8.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs17623569 chr3 30377485 G A 2.30E-05 Urinary metabolites / / 21572414 rs6778682 chr3 30381927 A G 3.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs6778682 chr3 30381927 A G 1.90E-05 Urinary metabolites / / 21572414 rs11925190 chr3 30382639 C T 1.30E-05 Urinary metabolites / / 21572414 rs7629687 chr3 30386542 T A 4.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs9875447 chr3 30390204 C T 2.60E-05 Urinary metabolites / / 21572414 rs9826631 chr3 30395073 C G 2.20E-05 Urinary metabolites / / 21572414 rs2132298 chr3 30402863 G A 7.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2101835 chr3 30437075 T A 6.41E-04 Insulin resistance / / 21901158 rs7653262 chr3 30443869 G A 4.31E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs7640543 chr3 30462403 G A 1.00E-09 Migraine / / 22683712 rs7640543 chr3 30462403 G A 1.05E-05 Migraine without aura / / 23793025 rs7640543 chr3 30462403 G A 1.32E-05 Migraine / / 23793025 rs7640543 chr3 30462403 G A 1.54E-06 Migraine - clinic-based / / 23793025 rs1117751 chr3 30467155 G A 4.96E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4955308 chr3 30470027 C T 7.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs4075749 chr3 30478897 A G 6.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs6790925 chr3 30480085 C T 9.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs6790925 chr3 30480085 C T 2.00E-08 Migraine - clinic-based / / 23793025 rs6790925 chr3 30480085 C T 8.35E-05 Migraine without aura / / 23793025 rs6790925 chr3 30480085 C T 8.74E-05 Migraine / / 23793025 rs6783265 chr3 30483304 G A 2.06E-04 Multiple complex diseases / / 17554300 rs9825365 chr3 30486148 T C 3.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs13062325 chr3 30488000 C G 3.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs4325953 chr3 30488348 T C 2.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs11129406 chr3 30493494 G C 2.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs9310936 chr3 30499437 T G 3.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs4613502 chr3 30503020 A G 1.65E-04 Pancreatic cancer / / pha002874 rs4955307 chr3 30506137 A G 2.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs4312687 chr3 30509720 T A 7.22E-05 Suicide attempts in bipolar disorder / / 21423239 rs12635464 chr3 30511330 G A 6.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs9874162 chr3 30511372 T C 6.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs4461455 chr3 30519860 C T 7.21E-04 Prostate cancer mortality / / 20978177 rs4461455 chr3 30519860 C T 2.90E-05 Urinary metabolites / / 21572414 rs11917602 chr3 30530899 G T 8.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9818535 chr3 30564369 C T 6.46E-04 Type 2 diabetes / / 17463246 rs9815023 chr3 30618711 C G 7.45E-04 Multiple complex diseases / / 17554300 rs2116137 chr3 30626098 G A 8.89E-04 Multiple complex diseases / / 17554300 rs2129842 chr3 30626595 C T 3.61E-04 Multiple complex diseases / / 17554300 rs6798752 chr3 30651546 A C 6.54E-04 Multiple complex diseases TGFBR2 intron 17554300 rs1991657 chr3 30658031 C T 4.84E-04 Multiple complex diseases TGFBR2 intron 17554300 rs11129420 chr3 30658541 T A 1.53E-04 Multiple complex diseases TGFBR2 intron 17554300 rs4522809 chr3 30668684 A G 7.15E-04 Alzheimer's disease TGFBR2 intron 22005930 rs10212320 chr3 30673865 C T 0.000000989 LDL cholesterol TGFBR2 intron 23063622 rs11466491 chr3 30675151 C T 0.000066 Cholesterol,total TGFBR2 intron 23063622 rs3863057 chr3 30680370 T C 8.16E-04 Acute lung injury TGFBR2 intron 22295056 rs12493607 chr3 30682939 G C 2.00E-08 Breast cancer TGFBR2 intron 23535729 rs9838771 chr3 30698782 G A 0.000000226 Triglycerides TGFBR2 intron 23063622 rs9838771 chr3 30698782 G A 1.27E-09 LDL cholesterol TGFBR2 intron 23063622 rs3773640 chr3 30709511 A T 7.58E-04 Multiple complex diseases TGFBR2 intron 17554300 rs3773643 chr3 30710243 A G 2.00E-07 Tonometry TGFBR2 intron 17903302 rs3773646 chr3 30714757 C T 0.00019 Coronary artery calcification TGFBR2 intron 23727086 rs3773651 chr3 30718532 A G 0.0000417 HDL cholesterol TGFBR2 intron 23063622 rs3773652 chr3 30718942 G A 8.01E-04 Smoking initiation TGFBR2 intron 24665060 rs2043136 chr3 30720304 G A 9.09E-05 Pancreatic cancer TGFBR2 intron pha002889 rs6804368 chr3 30753573 A G 8.00E-21 Blood metabolite levels / / 24816252 rs6550010 chr3 30772165 A G 7.22E-04 Response to cholinesterase inhibitors in Alzheimer's disease GADL1 intron 23374588 rs795448 chr3 30800620 G T 1.20E-05 Urinary metabolites GADL1 intron 21572414 rs795446 chr3 30801088 A G 4.15E-05 Varicose Veins GADL1 intron pha001411 rs797054 chr3 30801175 T C 2.23E-05 Varicose Veins GADL1 intron pha001411 rs6805561 chr3 30801713 C A 5.16E-04 Multiple complex diseases GADL1 intron 17554300 rs7649779 chr3 30817218 T C 8.60E-05 Response to statin therapy GADL1 intron 20339536 rs9882060 chr3 30817996 C A 8.70E-05 Response to statin therapy GADL1 intron 20339536 rs11129424 chr3 30848253 G A 6.45E-04 Response to cytadine analogues (cytosine arabinoside) GADL1 intron 24483146 rs11129425 chr3 30870256 C T 9.01E-05 Response to cytadine analogues (cytosine arabinoside) GADL1 intron 24483146 rs10510640 chr3 30882031 C A 3.60E-06 Urinary metabolites GADL1 intron 21572414 rs12636066 chr3 30913645 C A 5.45E-05 Cognitive test performance GADL1 intron 20125193 rs12636066 chr3 30913645 C A 8.60E-05 Endometriosis GADL1 intron 21151130 rs1494736 chr3 30981986 A G 5.82E-04 Multiple complex diseases / / 17554300 rs9821361 chr3 30992726 T C 1.12E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955351 chr3 30995589 A T 1.40E-05 Suicide attempts in bipolar disorder / / 21423239 rs1494741 chr3 30995986 A C 1.57E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955352 chr3 30996395 G C 1.83E-05 Suicide attempts in bipolar disorder / / 21423239 rs17026829 chr3 30996531 C G 9.98E-06 Suicide attempts in bipolar disorder / / 21423239 rs9860804 chr3 30996999 A G 1.88E-05 Suicide attempts in bipolar disorder / / 21423239 rs17026833 chr3 31000622 A T 1.24E-05 Suicide attempts in bipolar disorder / / 21423239 rs1494742 chr3 31001640 T G 8.87E-06 Suicide attempts in bipolar disorder / / 21423239 rs4955355 chr3 31002590 C A 3.75E-05 Suicide attempts in bipolar disorder / / 21423239 rs17026835 chr3 31005429 G C 1.63E-05 Suicide attempts in bipolar disorder / / 21423239 rs6788647 chr3 31007847 T C 1.64E-05 Suicide attempts in bipolar disorder / / 21423239 rs6550032 chr3 31008073 G A 1.67E-05 Suicide attempts in bipolar disorder / / 21423239 rs6550033 chr3 31008204 C A 1.27E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955356 chr3 31009886 C A 2.69E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955173 chr3 31010785 A G 8.62E-06 Suicide attempts in bipolar disorder / / 21423239 rs17433029 chr3 31012087 G A 7.80E-06 Suicide attempts in bipolar disorder / / 21423239 rs17026839 chr3 31012135 T C 1.63E-05 Suicide attempts in bipolar disorder / / 21423239 rs1565881 chr3 31014526 A G 7.95E-06 Suicide attempts in bipolar disorder / / 21423239 rs1112792 chr3 31015186 C T 1.27E-05 Suicide attempts in bipolar disorder / / 21423239 rs17026845 chr3 31016294 G A 1.16E-05 Suicide attempts in bipolar disorder / / 21423239 rs6550034 chr3 31016445 C A 1.53E-05 Suicide attempts in bipolar disorder / / 21423239 rs6791315 chr3 31016950 G A 1.47E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955357 chr3 31018158 C A 1.19E-05 Suicide attempts in bipolar disorder / / 21423239 rs6807602 chr3 31018512 T C 1.24E-05 Suicide attempts in bipolar disorder / / 21423239 rs2201438 chr3 31019238 G C 1.48E-05 Suicide attempts in bipolar disorder / / 21423239 rs2201439 chr3 31019269 G A 1.19E-05 Suicide attempts in bipolar disorder / / 21423239 rs6787451 chr3 31021894 C T 1.41E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955358 chr3 31022013 G A 1.48E-05 Suicide attempts in bipolar disorder / / 21423239 rs6779686 chr3 31026401 A G 1.88E-05 Suicide attempts in bipolar disorder / / 21423239 rs6804483 chr3 31026667 G C 1.98E-05 Suicide attempts in bipolar disorder / / 21423239 rs11129431 chr3 31026886 A G 1.84E-05 Suicide attempts in bipolar disorder / / 21423239 rs6772140 chr3 31027764 T G 1.10E-05 Suicide attempts in bipolar disorder / / 21423239 rs6808005 chr3 31027867 G A 1.54E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955174 chr3 31028079 T C 1.81E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955175 chr3 31028378 C T 2.72E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955176 chr3 31028401 G A 2.86E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955177 chr3 31028426 T G 2.84E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955361 chr3 31028533 A G 2.82E-05 Suicide attempts in bipolar disorder / / 21423239 rs6765969 chr3 31029542 C T 2.80E-05 Suicide attempts in bipolar disorder / / 21423239 rs6790372 chr3 31029600 A G 2.85E-05 Suicide attempts in bipolar disorder / / 21423239 rs6793134 chr3 31029935 A T 2.80E-05 Suicide attempts in bipolar disorder / / 21423239 rs9820757 chr3 31031572 C T 4.23E-05 Suicide attempts in bipolar disorder / / 21423239 rs17026882 chr3 31031841 C T 3.45E-05 Suicide attempts in bipolar disorder / / 21423239 rs12054010 chr3 31033280 G T 3.54E-05 Suicide attempts in bipolar disorder / / 21423239 rs9831434 chr3 31033407 G T 7.49E-05 Suicide attempts in bipolar disorder / / 21423239 rs4368536 chr3 31034632 C G 3.97E-05 Suicide attempts in bipolar disorder / / 21423239 rs17026902 chr3 31040041 A G 8.31E-05 Suicide attempts in bipolar disorder / / 21423239 rs1506206 chr3 31040377 T C 4.36E-04 Type 2 diabetes / / 17463246 rs1506205 chr3 31040399 C T 6.00E-05 Suicide attempts in bipolar disorder / / 21423239 rs1506204 chr3 31040494 T G 5.98E-05 Suicide attempts in bipolar disorder / / 21423239 rs1506203 chr3 31040503 G T 6.00E-05 Suicide attempts in bipolar disorder / / 21423239 rs1506203 chr3 31040503 G T 8.00E-06 Eating disorders (purging via substances) / / 23568457 rs1567026 chr3 31042356 C T 5.75E-05 Suicide attempts in bipolar disorder / / 21423239 rs9790023 chr3 31047830 T G 6.70E-05 Suicide attempts in bipolar disorder / / 21423239 rs9883843 chr3 31048958 C A 7.03E-05 Suicide attempts in bipolar disorder / / 21423239 rs17026930 chr3 31056398 T C 5.77E-05 Suicide attempts in bipolar disorder / / 21423239 rs10512719 chr3 31058249 T A 6.49E-05 Suicide attempts in bipolar disorder / / 21423239 rs9858387 chr3 31059661 T C 6.67E-05 Suicide attempts in bipolar disorder / / 21423239 rs9844634 chr3 31060089 T C 7.39E-05 Suicide attempts in bipolar disorder / / 21423239 rs4955366 chr3 31060338 G A 7.09E-05 Suicide attempts in bipolar disorder / / 21423239 rs294314 chr3 31067452 C T 8.77E-05 Coronary heart disease / / 24778558 rs1683753 chr3 31073011 A G 4.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs1119709 chr3 31073762 A G 6.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs1683768 chr3 31074131 C T 7.21E-04 Multiple complex diseases / / 17554300 rs1385828 chr3 31074175 T A 3.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs839589 chr3 31076044 T C 7.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs839590 chr3 31076965 T G 7.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs865735 chr3 31078350 C T 8.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs4308316 chr3 31079105 A C 9.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs294309 chr3 31079270 C T 9.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs294308 chr3 31079320 A G 9.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs294307 chr3 31079443 G A 4.97E-04 Multiple complex diseases / / 17554300 rs294305 chr3 31079959 T C 9.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs1701423 chr3 31086976 A G 7.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs1701428 chr3 31088615 T C 9.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs981985 chr3 31089142 T A 3.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs1683760 chr3 31089530 A G 9.75E-04 Multiple complex diseases / / 17554300 rs1485915 chr3 31089689 T C 6.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs1683759 chr3 31089788 T C 6.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs6810010 chr3 31091438 A G 6.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs1395162 chr3 31092371 C A 7.74E-04 Multiple complex diseases / / 17554300 rs839585 chr3 31092929 G C 7.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs711685 chr3 31093900 C T 5.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs839588 chr3 31096879 A G 9.60E-06 Left ventricular mass / / 21212386 rs839588 chr3 31096879 A G 4.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs1098080 chr3 31100532 C T 3.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs9828280 chr3 31103466 A G 3.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs4955369 chr3 31112187 T G 0.0000665 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1683772 chr3 31118448 T C 4.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs294284 chr3 31126912 A C 4.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs7620843 chr3 31137630 G A 1.40E-05 Urinary metabolites / / 21572414 rs1857876 chr3 31149368 T C 1.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs1701443 chr3 31158864 G T 1.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs1683766 chr3 31159149 G T 6.48E-05 Suicide attempts in bipolar disorder / / 21423239 rs9848246 chr3 31161057 T G 2.50E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs839581 chr3 31163822 T G 2.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs4955372 chr3 31171437 T C 2.96E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs7625163 chr3 31175501 T C 3.30E-04 Asperger disorder / / 21182207 rs1485916 chr3 31179339 C A 1.79E-04 Type 2 diabetes / / 22158537 rs9838192 chr3 31263782 C T 5.79E-04 Myopia (pathological) / / 21095009 rs7628394 chr3 31314100 C T 3.11E-04 Depression (quantitative trait) / / 20800221 rs6798661 chr3 31316585 A C 3.20E-04 Depression (quantitative trait) / / 20800221 rs6804612 chr3 31321856 T C 3.16E-04 Depression (quantitative trait) / / 20800221 rs9844475 chr3 31322654 C T 3.17E-04 Depression (quantitative trait) / / 20800221 rs9865155 chr3 31323210 T C 3.17E-04 Depression (quantitative trait) / / 20800221 rs9822344 chr3 31324186 C G 3.18E-04 Depression (quantitative trait) / / 20800221 rs9826665 chr3 31324352 G A 3.18E-04 Depression (quantitative trait) / / 20800221 rs9310965 chr3 31327951 C T 3.20E-04 Depression (quantitative trait) / / 20800221 rs9811300 chr3 31329185 A G 3.21E-04 Depression (quantitative trait) / / 20800221 rs9873949 chr3 31330024 T C 3.23E-04 Depression (quantitative trait) / / 20800221 rs9859166 chr3 31330858 C T 3.30E-04 Depression (quantitative trait) / / 20800221 rs9879457 chr3 31331119 T G 3.34E-04 Depression (quantitative trait) / / 20800221 rs9825803 chr3 31331273 A T 3.36E-04 Depression (quantitative trait) / / 20800221 rs9870170 chr3 31332995 G T 3.41E-04 Depression (quantitative trait) / / 20800221 rs9865912 chr3 31333290 T C 3.42E-04 Depression (quantitative trait) / / 20800221 rs6764036 chr3 31334622 T G 3.46E-04 Depression (quantitative trait) / / 20800221 rs9859409 chr3 31351988 T A 5.61E-04 Multiple complex diseases / / 17554300 rs17841960 chr3 31360453 A G 1.19E-04 Multiple complex diseases / / 17554300 rs9310966 chr3 31364686 G A 7.49E-04 Type 2 diabetes / / 17463246 rs1006965 chr3 31383105 C T 9.24E-04 Multiple complex diseases / / 17554300 rs9862255 chr3 31392328 T C 1.06E-05 Type 2 diabetes / / 17463246 rs6805533 chr3 31406542 C A 1.87E-05 Eosinophil counts / / pha003088 rs7642575 chr3 31425161 T C 1.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10510650 chr3 31433240 C T 3.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs931567 chr3 31435577 G A 6.72E-04 Multiple complex diseases / / 17554300 rs931567 chr3 31435577 G A 1.80E-05 Type 2 diabetes / / 17903298 rs931567 chr3 31435577 G A 9.76E-06 Eosinophil counts / / pha003088 rs9310968 chr3 31439256 C T 3.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17027625 chr3 31445580 T C 4.00E-06 HIV-1 control / / 20041166 rs9843322 chr3 31452963 G T 5.74E-05 Orofacial clefts / / 22419666 rs4955190 chr3 31454973 A C 1.93E-04 Follicle stimulating hormone / / 24049095 rs9831111 chr3 31456161 C T 6.85E-05 Orofacial clefts / / 22419666 rs6771464 chr3 31494000 C A 6.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6794150 chr3 31528413 A G 7.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs7639313 chr3 31529089 A G 8.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs9810171 chr3 31532258 T G 4.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs6800262 chr3 31533626 T C 7.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs4611854 chr3 31537830 T C 9.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs1902334 chr3 31726314 G A 8.93E-05 IgE levels OSBPL10 intron 17255346 rs9819360 chr3 31754338 C A 9.15E-04 Aortic root size OSBPL10 intron 21223598 rs9819360 chr3 31754338 C A 1.59E-04 Obesity (early onset extreme) OSBPL10 intron 23563609 rs2085311 chr3 31778395 A G 6.29E-04 Smoking quantity OSBPL10 intron 24665060 rs11129461 chr3 31779692 T C 4.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OSBPL10 intron 20877124 rs11129461 chr3 31779692 T C 4.43E-04 Smoking cessation OSBPL10 intron 24665060 rs17028180 chr3 31787449 A G 2.62E-05 Multiple complex diseases OSBPL10 intron 17554300 rs11714423 chr3 31793857 A G 2.56E-05 Coronary heart disease OSBPL10 intron 21606135 rs11710822 chr3 31793871 T C 6.26E-05 Coronary heart disease OSBPL10 intron 21606135 rs1902341 chr3 31795570 C T 5.00E-07 Peripheral artery disease OSBPL10 intron 20610895 rs2045298 chr3 31799254 T C 2.87E-04 Alzheimer's disease OSBPL10 intron 17998437 rs2168422 chr3 31804842 G T 7.80E-04 Alcohol dependence OSBPL10 intron 20201924 rs7631385 chr3 31806071 T C 3.91E-04 Alzheimer's disease OSBPL10 intron 17998437 rs7621973 chr3 31806188 C T 5.21E-05 Alzheimer's disease OSBPL10 intron 17998437 rs7612780 chr3 31810558 A G 8.10E-04 Alcohol dependence OSBPL10 intron 20201924 rs936160 chr3 31812585 C T 1.93E-04 Alzheimer's disease OSBPL10 intron 17998437 rs936160 chr3 31812585 C T 2.16E-04 Coronary heart disease OSBPL10 intron 21606135 rs936160 chr3 31812585 C T 1.94E-04 Alzheimer's disease OSBPL10 intron pha002879 rs2219250 chr3 31817544 T C 5.03E-04 Alzheimer's disease OSBPL10 intron 17998437 rs2219250 chr3 31817544 T C 3.80E-04 Alcohol dependence OSBPL10 intron 20201924 rs2219250 chr3 31817544 T C 5.70E-04 Alcohol dependence OSBPL10 intron 20201924 rs2219250 chr3 31817544 T C 4.65E-04 Coronary heart disease OSBPL10 intron 21606135 rs2068100 chr3 31837204 A T 4.65E-04 Coronary heart disease OSBPL10 intron 21606135 rs7628972 chr3 31839097 C T 3.70E-04 Coronary heart disease OSBPL10 intron 21606135 rs7643025 chr3 31839242 T C 5.32E-04 Coronary heart disease OSBPL10 intron 21606135 rs6550070 chr3 31842635 C A 8.84E-04 Coronary heart disease OSBPL10 intron 21606135 rs4611855 chr3 31847360 T C 1.97E-04 Barrett's esophagus OSBPL10 intron 24121790 rs4611855 chr3 31847360 T C 2.57E-04 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) OSBPL10 intron 24121790 rs6808708 chr3 31847977 T A 7.71E-05 Coronary heart disease OSBPL10 intron 21606135 rs7649767 chr3 31850663 G A 1.47E-04 Alzheimer's disease (late onset) OSBPL10 intron 21379329 rs6773772 chr3 31851726 T C 3.41E-04 Epilepsy OSBPL10 intron 22116939 rs13087711 chr3 31857836 C T 3.90E-04 Major depressive disorder OSBPL10 intron 21042317 rs4349533 chr3 31893789 G A 8.80E-06 Response to cholinesterase inhibitors in Alzheimer's disease OSBPL10 intron 23374588 rs6776254 chr3 31901848 C T 1.42E-05 Recombination rate OSBPL10 intron 21698098 rs7629505 chr3 31921624 A G 6.91E-04 Type 2 diabetes OSBPL10 intron 17463246 rs7644177 chr3 31964898 G A 8.64E-04 Parkinson's disease OSBPL10 intron 17052657 rs7644177 chr3 31964898 G A 5.23E-04 Tourette syndrome OSBPL10 intron 22889924 rs6810295 chr3 31967967 G A 6.56E-04 Multiple complex diseases OSBPL10 intron 17554300 rs6810295 chr3 31967967 G A 7.00E-06 Body mass index (education interaction) OSBPL10 intron 24281739 rs11713199 chr3 31975321 C G 6.90E-06 Periodontal disease-related phenotypes OSBPL10 intron 24347629 rs12630254 chr3 31981227 T C 6.70E-06 Periodontal disease-related phenotypes OSBPL10 intron 24347629 rs12630931 chr3 31981767 T C 6.00E-06 Periodontal disease-related phenotypes OSBPL10 intron 24347629 rs9847964 chr3 32001194 C T 2.30E-05 Urinary metabolites OSBPL10 intron 21572414 rs7643045 chr3 32125010 G A 1.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs1159444 chr3 32146188 G T 8.88E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GPD1L nearGene-5 20031582 rs17028882 chr3 32153391 T A 3.14E-04 Multiple complex diseases GPD1L intron 17554300 rs17028885 chr3 32155048 C T 3.03E-04 Cognitive decline GPD1L intron 23732972 rs11710089 chr3 32180635 C G 2.10E-05 Urinary metabolites GPD1L intron 21572414 rs1451523 chr3 32218812 G C 7.64E-04 Smoking initiation / / 24665060 rs11922715 chr3 32219726 G A 1.31E-06 Intelligence / / 21826061 rs9842565 chr3 32223481 G A 0.000257605 Hypertension (early onset hypertension) / / 22479346 rs11922502 chr3 32225203 C T 1.90E-07 Intelligence / / 21826061 rs7644491 chr3 32225326 C T 2.60E-05 Smoking initiation / / 24665060 rs9867908 chr3 32233643 G A 4.18E-04 Smoking initiation / / 24665060 rs11720070 chr3 32235481 C T 7.00E-06 Urinary metabolites / / 21572414 rs11720070 chr3 32235481 C T 3.04E-06 Heart Rate / / pha003054 rs4440157 chr3 32236058 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9825310 chr3 32240119 G A 8.00E-06 Alcohol dependence / / 22004471 rs4955256 chr3 32257143 T C 2.16E-04 Multiple complex diseases / / 17554300 rs4376071 chr3 32264991 C T 8.00E-06 IgG glycosylation / / 23382691 rs4955265 chr3 32267947 G A 3.58E-04 IgE levels / / 17255346 rs9813563 chr3 32272498 C G 8.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs4075566 chr3 32282686 G A 1.11E-06 Hemoglobin CMTM8 intron pha003096 rs4075566 chr3 32282686 G A 4.67E-06 Hematocrit CMTM8 intron pha003097 rs7621429 chr3 32302529 C T 5.66E-05 Alzheimer's disease CMTM8 intron 21098978 rs4245886 chr3 32304103 C A 9.03E-04 Multiple complex diseases CMTM8 intron 17554300 rs4245886 chr3 32304103 C A 2.31E-04 Bipolar disorder,schizoaffective CMTM8 intron 19567891 rs4245886 chr3 32304103 C A 5.52E-05 Alzheimer's disease CMTM8 intron 21098978 rs7636660 chr3 32312914 G A 1.82E-05 Alzheimer's disease CMTM8 intron 21098978 rs4132830 chr3 32315383 T C 8.23E-04 Stroke CMTM8 intron pha002886 rs4572808 chr3 32317714 G C 1.82E-05 Alzheimer's disease CMTM8 intron 21098978 rs7644602 chr3 32320408 G T 2.28E-05 Alzheimer's disease CMTM8 intron 21098978 rs11708149 chr3 32321599 A T 2.47E-05 Alzheimer's disease CMTM8 intron 21098978 rs6783478 chr3 32322975 A T 5.11E-04 Multiple complex diseases CMTM8 intron 17554300 rs6783478 chr3 32322975 A T 2.46E-05 Alzheimer's disease CMTM8 intron 21098978 rs6783478 chr3 32322975 A T 3.61E-05 Schizophrenia(age at onset) CMTM8 intron 21688384 rs12637074 chr3 32324460 T C 6.44E-05 Femoral neck bone geometry CMTM8 intron 22087292 rs4955274 chr3 32327421 A G 1.02E-05 Alzheimer's disease CMTM8 intron 21098978 rs4380451 chr3 32329497 C T 4.00E-06 Bipolar disorder CMTM8 intron 18711365 rs4276227 chr3 32330686 C T 4.57E-06 Multiple complex diseases CMTM8 intron 17554300 rs6793780 chr3 32339493 T G 6.53E-05 Cognitive test performance CMTM8 intron 20125193 rs1398101 chr3 32345699 T G 5.49E-05 Multiple complex diseases CMTM8 intron 17554300 rs17029181 chr3 32346116 A G 2.51E-05 Fibrinogen CMTM8 intron 17255346 rs4627791 chr3 32347824 A G 2.37E-06 Multiple complex diseases CMTM8 intron 17554300 rs4627791 chr3 32347824 A G 2.00E-06 Bipolar disorder CMTM8 intron 21254220 rs9875310 chr3 32348195 A G 5.40E-06 Fibrinogen CMTM8 intron 17255346 rs9875310 chr3 32348195 A G 9.70E-05 Cognitive performance CMTM8 intron 19734545 rs9875310 chr3 32348195 A G 1.71E-04 Parkinson's disease CMTM8 intron 21248740 rs1370718 chr3 32353131 C A 9.06E-04 Type 2 diabetes CMTM8 intron 17463246 rs1438182 chr3 32365788 C T 4.92E-04 Stroke CMTM8 intron pha002887 rs6776297 chr3 32378271 G A 5.00E-06 HIV-1 viral setpoint CMTM8 intron 22174851 rs17029245 chr3 32389053 A G 2.64E-06 Personality dimensions CMTM8 intron 23658558 rs4955144 chr3 32395216 C A 2.53E-05 Body Composition CMTM8 intron pha003012 rs4955144 chr3 32395216 C A 9.34E-05 Body Mass Index CMTM8 intron pha003021 rs2289244 chr3 32399181 G A 8.08E-06 Body Composition CMTM8 intron pha003012 rs2289244 chr3 32399181 G A 3.14E-05 Body Mass Index CMTM8 intron pha003021 rs4955281 chr3 32399859 T A 6.91E-34 Metabolite levels CMTM8 intron 22286219 rs4266227 chr3 32402435 T C 6.54E-05 Smoking initiation CMTM8 intron 24665060 rs11924535 chr3 32423251 T C 7.24E-05 Blood Pressure / / pha003048 rs2343849 chr3 32446152 C A 2.97E-06 Multiple complex diseases CMTM7 intron 17554300 rs9853991 chr3 32466797 C T 9.53E-06 Hypertension CMTM7 intron 21082022 rs17804246 chr3 32473512 C T 2.58E-04 Type 2 diabetes CMTM7 intron 17463246 rs17804246 chr3 32473512 C T 6.65E-05 Erythrocyte counts CMTM7 intron pha003101 rs12638540 chr3 32488534 A G 3.00E-07 Heart failure CMTM7 intron 20400778 rs3888882 chr3 32497574 G T 2.98E-05 Hypertension / / 21082022 rs164214 chr3 32498154 T C 1.44E-04 Parkinson's disease / / 21248740 rs9854574 chr3 32527218 G A 2.47E-05 Information processing speed CMTM6 intron 21130836 rs7640978 chr3 32533010 C T 1.00E-08 LDL cholesterol CMTM6 intron 24097068 rs7640978 chr3 32533010 C T 2.00E-08 Cholesterol,total CMTM6 intron 24097068 rs12488997 chr3 32535028 A T 6.84E-04 Suicide attempts in bipolar disorder CMTM6 intron 21423239 rs342763 chr3 32537791 C T 6.74E-04 Multiple complex diseases CMTM6 intron 17554300 rs6782149 chr3 32569096 C T 6.18E-04 Smoking initiation DYNC1LI1 intron 24665060 rs6550135 chr3 32592852 A G 4.48E-04 Smoking initiation DYNC1LI1 intron 24665060 rs9868569 chr3 32599939 G A 1.30E-05 Multiple complex diseases DYNC1LI1 intron 17554300 rs17029747 chr3 32644001 T C 2.06E-04 Blood pressure / / 17255346 rs6550146 chr3 32704743 A G 2.63E-04 Schizophrenia / / 20832056 rs6790023 chr3 32706557 G C 3.40E-04 Schizophrenia / / 20832056 rs9845475 chr3 32842101 T G 4.00E-06 Attention deficit hyperactivity disorder (time to onset) / / 18937294 rs12629685 chr3 32880078 G A 0.0001982 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRIM71 intron 23233654 rs12629685 chr3 32880078 G A 1.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRIM71 intron 23233662 rs13075951 chr3 32882007 G A 0.0001987 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRIM71 intron 23233654 rs13075951 chr3 32882007 G A 1.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRIM71 intron 23233662 rs7610310 chr3 32883189 G A 2.52E-06 Schizophrenia TRIM71 intron 22037555 rs997520 chr3 32883581 G A 2.74E-06 Schizophrenia TRIM71 intron 22037555 rs9310995 chr3 32929115 T C 4.00E-06 Pulmonary function TRIM71 intron 21946350 rs7648704 chr3 32941852 G T 1.00E-09 Venous thromboembolism (gene x gene interaction) / / 23509962 rs13071058 chr3 32958723 G A 5.01E-04 Multiple complex diseases / / 17554300 rs9310996 chr3 32999260 C T 8.04E-04 Multiple complex diseases / / 17554300 rs13314993 chr3 33015469 G T 3.00E-09 Celiac disease / / 20190752 rs13314993 chr3 33015469 G T 3.00E-09 Asthma / / 21150878 rs13314993 chr3 33015469 G T 3.27E-09 Celiac disease and Rheumatoid arthritis / / 21383967 rs13314993 chr3 33015469 G T 3.00E-09 Asthma / / 21907864 rs13314993 chr3 33015469 G T 3.27E-09 Multiple sclerosis / / 22190364 rs4678649 chr3 33017224 A G 8.54E-05 Parkinson's disease / / 21812969 rs4678680 chr3 33020035 G T 2.00E-07 Hepatocellular carcinoma / / 21105107 rs4678680 chr3 33020035 G T 2.00E-07 Hepatocellular carcinoma (hepatitis B virus related) / / 23242368 rs6778706 chr3 33024069 G A 0.000156644 Primary sclerosing cholangitis / / 23603763 rs4678523 chr3 33037721 T C 2.40E-07 Celiac disease GLB1 nearGene-3 22057235 rs9828592 chr3 33044339 T C 3.09E-04 Self-reported allergy GLB1 intron 23817569 rs4402881 chr3 33054331 T C 0.000000495 Triglycerides GLB1 intron 23063622 rs4402881 chr3 33054331 T C 0.00000155 LDL cholesterol GLB1 intron 23063622 rs4402881 chr3 33054331 T C 2.11E-10 Cholesterol,total GLB1 intron 23063622 rs12635761 chr3 33059101 G A 9.46E-04 White matter integrity GLB1 intron 22425255 rs7613051 chr3 33065339 G A 6.00E-21 Atopic dermatitis GLB1 intron 23042114 rs4679074 chr3 33082656 A G 9.13E-04 White matter integrity GLB1 intron 22425255 rs6550204 chr3 33107645 C T 1.90E-04 Smoking initiation GLB1 intron 24665060 rs4320035 chr3 33113697 G C 7.51E-05 Smoking initiation GLB1 intron 24665060 rs9827863 chr3 33118951 A G 1.40E-04 Smoking initiation GLB1 intron 24665060 rs9883177 chr3 33123354 T C 7.81E-05 Smoking initiation GLB1 intron 24665060 rs9868526 chr3 33124269 G A 1.47E-04 Smoking initiation GLB1 intron 24665060 rs73043340 chr3 33126972 C T 3.76E-07 Prostate cancer GLB1 intron 24185611 rs9810375 chr3 33127867 G T 2.57E-04 Type 2 diabetes GLB1 intron 17463246 rs4578976 chr3 33146189 C T 3.01E-04 Smoking initiation / / 24665060 rs4678681 chr3 33150829 G A 8.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4074418 chr3 33161165 G T 2.00E-04 Cognitive impairment induced by topiramate CRTAP intron 22091778 rs4234239 chr3 33175793 C A 0.0005188 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CRTAP intron 23233654 rs4234239 chr3 33175793 C A 5.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) CRTAP intron 23233662 rs7652193 chr3 33176824 A G 0.000519 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CRTAP intron 23233654 rs7652193 chr3 33176824 A G 5.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) CRTAP intron 23233662 rs7623768 chr3 33182052 A C 5.36E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CRTAP intron 24578207 rs7623768 chr3 33182052 A C 5.36E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CRTAP intron 24578207 rs7623768 chr3 33182052 A C 9.51E-05 Tunica Media CRTAP intron pha003034 rs9854123 chr3 33211327 G A 3.69E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SUSD5 intron 21844884 rs4678732 chr3 33212485 G A 3.32E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SUSD5 intron 21844884 rs4678497 chr3 33213119 T C 4.12E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SUSD5 intron 21844884 rs12632512 chr3 33225343 A C 6.14E-05 Tunica Media SUSD5 intron pha003034 rs4384906 chr3 33240314 T G 4.70E-04 Response to taxane treatment (placlitaxel) SUSD5 intron 23006423 rs4389431 chr3 33243386 C T 5.63E-04 Alcohol dependence SUSD5 intron 21314694 rs4535176 chr3 33248370 T C 2.04E-04 Coronary heart disease SUSD5 intron 21971053 rs6800399 chr3 33281293 G A 5.61E-05 HIV-1 viral setpoint / / 22174851 rs7653239 chr3 33289596 G A 2.04E-04 Alcohol dependence / / 21314694 rs13323402 chr3 33293350 C G 5.27E-05 Type 2 diabetes / / 17463246 rs9880596 chr3 33293758 T C 8.54E-04 Type 2 diabetes / / 17463246 rs7628482 chr3 33336370 C T 0.0005823 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FBXL2 intron 23233654 rs7628482 chr3 33336370 C T 5.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) FBXL2 intron 23233662 rs6769005 chr3 33388184 T A 8.13E-04 Multiple complex diseases FBXL2 intron 17554300 rs4678929 chr3 33413263 T G 1.73E-05 Behcet's disease FBXL2 intron 23291587 rs2291897 chr3 33419422 C T 1.47E-05 Behcet's disease FBXL2 intron 23291587 rs2291897 chr3 33419422 C T 1.82E-05 Behcet's disease FBXL2 intron pha002888 rs4045539 chr3 33421178 A C 1.56E-05 Behcet's disease FBXL2 intron 23291587 rs17029983 chr3 33442890 A G 5.44E-04 Type 2 diabetes UBP1 intron 17463246 rs1807844 chr3 33472937 T C 2.13E-05 Behcet's disease UBP1 intron 23291587 rs1807844 chr3 33472937 T C 5.56E-05 Behcet's disease UBP1 intron pha002888 rs1357540 chr3 33479982 T C 2.13E-05 Behcet's disease UBP1 intron 23291587 rs1357540 chr3 33479982 T C 2.69E-05 Behcet's disease UBP1 intron pha002888 rs6550222 chr3 33534885 T C 7.88E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6781484 chr3 33545785 T C 1.05E-04 Arthritis (juvenile idiopathic) CLASP2 intron 22354554 rs6781484 chr3 33545785 T C 4.66E-06 Behcet's disease CLASP2 intron 23291587 rs9862261 chr3 33562114 A G 6.89E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CLASP2 intron 21844884 rs12487660 chr3 33592572 T G 2.90E-05 Behcet's disease CLASP2 intron 23291587 rs12487660 chr3 33592572 T G 2.70E-05 Behcet's disease CLASP2 intron pha002888 rs4504126 chr3 33600582 A C 3.54E-04 Multiple complex diseases CLASP2 intron 17554300 rs8179967 chr3 33609330 T C 6.04E-05 Arthritis (juvenile idiopathic) CLASP2 intron 22354554 rs6807542 chr3 33653622 T G 9.56E-05 Arthritis (juvenile idiopathic) CLASP2 intron 22354554 rs7374396 chr3 33670344 C A 4.45E-04 HIV-1 progression to AIDS and death CLASP2 intron 21811574 rs7374396 chr3 33670344 C A 6.59E-05 HIV-1 progression to AIDS and death CLASP2 intron 21811574 rs7374396 chr3 33670344 C A 8.32E-06 HIV-1 progression to AIDS and death CLASP2 intron 21811574 rs4679073 chr3 33689633 C T 9.13E-04 Multiple complex diseases CLASP2 intron 17554300 rs9876025 chr3 33698172 G A 4.69E-04 Alcohol dependence CLASP2 intron 21314694 rs9844608 chr3 33774574 A G 9.31E-06 Attention deficit hyperactivity disorder / / 22012869 rs9843488 chr3 33838124 T G 1.71E-04 Vaspin levels / / 22907691 rs9843488 chr3 33838124 T G 0.0001714 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs7626555 chr3 33865612 G A 1.85E-04 Vaspin levels PDCD6IP intron 22907691 rs7626555 chr3 33865612 G A 0.0001851 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit PDCD6IP intron 22907730 rs3792594 chr3 33877626 G A 2.35E-04 Vaspin levels PDCD6IP missense 22907691 rs3792594 chr3 33877626 G A 0.0002346 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit PDCD6IP missense 22907730 rs10865850 chr3 33900980 G A 2.17E-04 Vaspin levels PDCD6IP intron 22907691 rs10865850 chr3 33900980 G A 0.0002171 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit PDCD6IP intron 22907730 rs6764014 chr3 33980449 C T 1.89E-05 Post-operative nausea and vomiting / / 21694509 rs9881576 chr3 33991181 T A 3.36E-05 Bipolar disorder and schizophrenia / / 20889312 rs12629322 chr3 33991854 T C 2.23E-04 Alzheimer's disease / / 22005930 rs4678623 chr3 33997849 T C 8.98E-05 Body Fat Distribution / / pha003017 rs4350875 chr3 34001134 T C 7.54E-04 Type 2 diabetes / / 17463246 rs4350875 chr3 34001134 T C 4.17E-04 Alzheimer's disease / / 22005930 rs4380367 chr3 34002063 G A 4.47E-04 Alzheimer's disease / / 22005930 rs7620363 chr3 34013205 C T 4.60E-04 Nicotine use / / 23942779 rs7620363 chr3 34013205 C T 7.10E-04 Alcohol consumption / / 23942779 rs7620363 chr3 34013205 C T 9.00E-06 Non-substance related behavioral disinhibition / / 23942779 rs13098651 chr3 34014094 T C 2.46E-04 Alzheimer's disease / / 22005930 rs13097841 chr3 34020900 T G 4.73E-04 Alzheimer's disease / / 22005930 rs9866710 chr3 34021986 G A 8.81E-05 Type 2 diabetes / / 17463246 rs4132587 chr3 34023066 A G 4.79E-04 Alzheimer's disease / / 22005930 rs4258910 chr3 34023225 C T 4.78E-04 Alzheimer's disease / / 22005930 rs12634235 chr3 34042955 C T 5.54E-04 Alzheimer's disease / / 22005930 rs4438609 chr3 34044652 A C 5.04E-04 Alzheimer's disease / / 22005930 rs11709925 chr3 34044916 G A 5.00E-05 Body Fat Distribution / / pha003017 rs11709925 chr3 34044916 G A 9.51E-05 Body Fat Distribution / / pha003018 rs4045199 chr3 34047586 G A 3.55E-06 Type 2 diabetes / / 17463246 rs9845173 chr3 34047877 G T 2.23E-04 Type 2 diabetes / / 17463246 rs4566485 chr3 34052641 T C 5.57E-04 Alzheimer's disease / / 22005930 rs11714011 chr3 34053980 G A 4.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4072315 chr3 34060079 G A 4.13E-04 Alzheimer's disease / / 22005930 rs4234232 chr3 34076846 T G 6.22E-05 Alzheimer's disease (late onset) / / 20885792 rs4373023 chr3 34077223 T C 2.33E-04 Type 2 diabetes / / 17463246 rs9852942 chr3 34120142 A G 7.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs4044970 chr3 34120978 G T 7.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs1595878 chr3 34135180 G A 9.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs10049124 chr3 34149458 T C 8.60E-05 HIV-1 control / / 20041166 rs7641622 chr3 34168020 T C 7.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs9863160 chr3 34170395 T A 7.11E-04 Multiple complex diseases / / 17554300 rs11705728 chr3 34176277 A C 6.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs2336117 chr3 34179261 T C 4.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs12638888 chr3 34182565 C T 8.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs6770257 chr3 34184505 T C 2.95E-06 Longevity,exceptional / / 20595579 rs7614971 chr3 34187468 G A 8.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs7653017 chr3 34192975 A C 8.47E-05 Suicide attempts in bipolar disorder / / 21423239 rs4678459 chr3 34194392 A G 3.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs6801432 chr3 34195620 A T 4.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs1440387 chr3 34196788 C A 4.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs6781182 chr3 34212166 T C 3.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs145744974 chr3 34260092 A G 4.00E-06 Periodontitis (Mean PAL) / / 24024966 rs2139172 chr3 34288960 G A 1.20E-05 Urinary metabolites / / 21572414 rs939021 chr3 34298029 G A 1.41E-04 Type 2 diabetes / / 17463246 rs1529075 chr3 34427945 T G 5.69E-04 Alcohol dependence / / 20201924 rs17031657 chr3 34446738 A C 7.55E-04 Alcohol dependence / / 20201924 rs11714343 chr3 34462869 C T 9.60E-05 Type 2 diabetes / / 17463248 rs1529079 chr3 34544260 G A 5.46E-04 Stroke / / pha002887 rs921265 chr3 34546747 T C 5.56E-04 Type 2 diabetes / / 17463246 rs2122231 chr3 34562070 A T 7.31E-05 Multiple complex diseases / / 17554300 rs6808710 chr3 34574455 C T 3.71E-04 Type 2 diabetes / / 17463246 rs6787412 chr3 34587868 G A 4.47E-04 Type 2 diabetes / / 17463246 rs1402246 chr3 34589121 G A 6.23E-04 Type 2 diabetes / / 17463246 rs9881586 chr3 34589478 G C 5.87E-04 Type 2 diabetes / / 17463246 rs11924179 chr3 34600734 T C 1.74E-04 Type 2 diabetes / / 17463246 rs1002486 chr3 34622921 A C 5.70E-04 Stroke / / pha002887 rs13075567 chr3 34665118 T C 2.56E-05 ldl cholesterol / / pha003077 rs2358503 chr3 34744752 T C 4.50E-05 Stroke / / pha002887 rs11129615 chr3 34814789 T C 8.95E-05 Blood Pressure / / pha003044 rs655228 chr3 34817239 C T 9.35E-04 Coronary Artery Disease / / 17634449 rs13095300 chr3 34833827 T C 7.26E-04 Multiple complex diseases / / 17554300 rs7646181 chr3 34846024 A G 9.50E-04 Multiple complex diseases / / 17554300 rs6798946 chr3 34852103 C T 7.10E-04 Multiple complex diseases / / 17554300 rs2200675 chr3 34860208 C T 2.97E-04 Multiple complex diseases / / 17554300 rs559356 chr3 34865597 T C 3.00E-06 Cognitive function / / 24684796 rs479394 chr3 34875841 G T 5.02E-06 Cognitive function / / 24684796 rs1403441 chr3 34876028 G A 8.92E-04 Alzheimer's disease / / 22005930 rs613192 chr3 34876582 G T 2.10E-05 Urinary metabolites / / 21572414 rs659668 chr3 34880031 A T 3.26E-06 Cognitive function / / 24684796 rs940048 chr3 34887468 G C 1.03E-04 Birth weight / / 17255346 rs2358748 chr3 34887681 C A,G,T 1.14E-04 Birth weight / / 17255346 rs7652586 chr3 34905662 C A 1.50E-05 Urinary metabolites / / 21572414 rs7632967 chr3 34906302 A G 3.87E-04 Lung function (forced vital capacity) / / 24023788 rs1522978 chr3 34926622 C A 6.84E-05 Birth weight / / 17255346 rs41321847 chr3 34927004 A G 2.42E-05 Postoperative ventricular dysfunction / / 21980348 rs6550308 chr3 34936569 A G 2.20E-05 Cognitive function / / 24684796 rs11129625 chr3 34939893 A G 2.75E-05 Postoperative ventricular dysfunction / / 21980348 rs885314 chr3 34940732 T C 2.55E-05 Postoperative ventricular dysfunction / / 21980348 rs885315 chr3 34940818 C T 5.67E-06 Cognitive function / / 24684796 rs1403442 chr3 34941006 G A 5.84E-04 Multiple complex diseases / / 17554300 rs10514688 chr3 34962669 T C 6.00E-06 Tonometry / / 17903302 rs17691914 chr3 34962803 A G 3.42E-08 Postoperative ventricular dysfunction / / 21980348 rs9835451 chr3 34971564 G A 5.55E-06 Postoperative ventricular dysfunction / / 21980348 rs11129626 chr3 34975045 G A 1.81E-05 Postoperative ventricular dysfunction / / 21980348 rs4678726 chr3 34976020 G A 1.63E-05 Postoperative ventricular dysfunction / / 21980348 rs4678496 chr3 34993312 C T 5.50E-06 Total ventricular volume / / 21116278 rs13071005 chr3 35019950 T G 8.42E-06 Total ventricular volume / / 21116278 rs1979406 chr3 35039322 T C 4.55E-07 Postoperative ventricular dysfunction / / 21980348 rs17032625 chr3 35077009 C T 2.50E-07 Postoperative ventricular dysfunction / / 21980348 rs2035260 chr3 35089305 C A 4.50E-06 Urinary metabolites / / 21572414 rs7641653 chr3 35118418 T C 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1382544 chr3 35127769 G A 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs11129640 chr3 35142511 G T 6.00E-08 Entorhinal cortical thickness / / 21116278 rs2127120 chr3 35142682 C T 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2127119 chr3 35142699 T C 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1376021 chr3 35278091 A G 9.98E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9811203 chr3 35282759 T C 2.29E-04 Parkinson's disease / / 17052657 rs4678766 chr3 35368128 G A 8.07E-05 Atopic dermatitis / / 23042114 rs11705929 chr3 35392137 C T 7.20E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1455327 chr3 35448187 T G 9.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1378394 chr3 35475083 T C 8.03E-04 Pemphigus vulgaris / / 22437316 rs17033265 chr3 35505374 G A 7.20E-06 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs7650296 chr3 35536237 C T 0.00016 Prostate cancer / / 23555315 rs7650296 chr3 35536237 C T 0.00052 Breast cancer / / 23555315 rs940070 chr3 35539957 C G 4.30E-04 Crohn's disease / / 17684544 rs6801949 chr3 35565537 T C 3.20E-04 IgE levels / / 17255346 rs17033506 chr3 35639826 G T 4.00E-07 Asthma (childhood onset) / / 23829686 rs13061600 chr3 35645818 C T 8.54E-04 Obesity (extreme) / / 21935397 rs9881157 chr3 35651949 C A 1.92E-11 Gender / / 22362730 rs1470558 chr3 35670051 T C 0.00077 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines / / 23204130 rs6799641 chr3 35686732 A T 9.42E-04 Multiple complex diseases ARPP21 intron 17554300 rs17201627 chr3 35695010 C T 8.06E-04 Multiple complex diseases ARPP21 intron 17554300 rs4678789 chr3 35695512 T C 7.68E-04 Multiple complex diseases ARPP21 intron 17554300 rs11129660 chr3 35695961 C T 1.47E-04 Smoking cessation ARPP21 intron 18519826 rs7349512 chr3 35743058 G A 4.60E-05 Kawasaki disease ARPP21 intron 22446962 rs1963934 chr3 35767788 G C 8.11E-04 Type 2 diabetes ARPP21 intron 17463246 rs35102908 chr3 35774989 G A 4.02E-04 Type 2 diabetes ARPP21 intron 17463246 rs9865772 chr3 35794900 C T 1.80E-06 Smoking cessation ARPP21 intron 18519826 rs9865772 chr3 35794900 C T 6.13E-05 Diabetes (gestational) ARPP21 intron 22233651 rs1455496 chr3 35948642 A G 6.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs9845811 chr3 35970883 G A 1.11E-04 Fibrinogen / / 17255346 rs12491195 chr3 35980407 C T 9.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs6799705 chr3 35982130 C T 2.00E-07 Cognitive performance / / 19734545 rs12486302 chr3 35987444 A G 1.29E-04 Parkinson's disease / / 21248740 rs12486302 chr3 35987444 A G 8.80E-06 Urinary metabolites / / 21572414 rs4234249 chr3 35988262 G T 3.32E-04 Multiple complex diseases / / 17554300 rs4234249 chr3 35988262 G T 2.50E-05 Urinary metabolites / / 21572414 rs3996 chr3 35995866 A G 1.60E-04 Alzheimer's disease / / 17998437 rs3996 chr3 35995866 A G 6.12E-05 Alzheimer's disease / / pha002879 rs1488092 chr3 35996873 A G 1.25E-05 Cognitive test performance / / 20125193 rs6550379 chr3 36007114 G A 1.50E-05 Urinary metabolites / / 21572414 rs17827807 chr3 36008561 T C 7.34E-12 Adiponectin levels / / 20887962 rs6550380 chr3 36021077 C T 1.50E-05 Urinary metabolites / / 21572414 rs6550381 chr3 36021293 C A 6.30E-06 Urinary metabolites / / 21572414 rs986277 chr3 36027917 G A 4.40E-06 Urinary metabolites / / 21572414 rs1451799 chr3 36062609 C A 5.92E-04 Multiple complex diseases / / 17554300 rs2359957 chr3 36095941 T G 6.86E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9877548 chr3 36137084 T C 1.44E-04 Multiple complex diseases / / 17554300 rs11916736 chr3 36186144 T A 7.80E-06 Urinary metabolites / / 21572414 rs4678850 chr3 36189216 T C 2.60E-06 Urinary metabolites / / 21572414 rs10510677 chr3 36193066 A G 3.80E-06 Urinary metabolites / / 21572414 rs2044769 chr3 36194506 A T 2.50E-06 Urinary metabolites / / 21572414 rs7647206 chr3 36215009 T C 6.56E-05 Bipolar disorder / / 17486107 rs6550407 chr3 36222649 T C 1.25E-05 Bipolar disorder / / 17486107 rs6793640 chr3 36238545 A G 3.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs285322 chr3 36249481 A G 4.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs285321 chr3 36250041 C A 2.26E-04 Type 2 diabetes / / 17463246 rs1479151 chr3 36344479 G A 7.81E-04 Multiple complex diseases / / 17554300 rs1479151 chr3 36344479 G A 4.75E-08 Narcolepsy / / 19629137 rs11706900 chr3 36348968 G A 7.10E-06 Type 2 diabetes / / 17463246 rs2046000 chr3 36352364 A C 9.42E-06 Celiac disease / / 23936387 rs1871352 chr3 36354537 A C 1.66E-05 Celiac disease / / 23936387 rs1479146 chr3 36360999 A G 2.58E-04 Celiac disease / / 23936387 rs10510683 chr3 36361555 G A 1.20E-05 Type 2 diabetes / / 17463246 rs1871350 chr3 36373765 C T 8.49E-06 Celiac disease / / 23936387 rs1842149 chr3 36391710 T G 1.91E-05 Celiac disease / / 23936387 rs1155010 chr3 36395598 T C 1.20E-05 Type 2 diabetes / / 17463246 rs1378784 chr3 36396158 C T 1.20E-05 Type 2 diabetes / / 17463246 rs1993923 chr3 36403951 C T 2.83E-05 Celiac disease / / 23936387 rs2605393 chr3 36409601 T G 6.00E-06 Celiac disease / / 23936387 rs6550422 chr3 36420628 A G 1.05E-04 Type 2 diabetes / / 17463246 rs9870425 chr3 36428232 A T 8.46E-05 Type 2 diabetes STAC intron 17463246 rs4505641 chr3 36432081 C T 2.17E-05 Blood Pressure STAC intron pha003050 rs4678878 chr3 36470307 T C 9.30E-04 Type 2 diabetes STAC intron 17463246 rs4678878 chr3 36470307 T C 7.65E-05 Blood Pressure STAC intron pha003050 rs11129714 chr3 36473840 T C 5.71E-05 Blood Pressure STAC intron pha003050 rs936154 chr3 36487492 G A 0.0006497 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) STAC intron 23233654 rs936154 chr3 36487492 G A 6.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) STAC intron 23233662 rs936156 chr3 36487696 C T 0.000791 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) STAC intron 23233654 rs936156 chr3 36487696 C T 7.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) STAC intron 23233662 rs6767011 chr3 36504281 A G 5.44E-05 Multiple complex diseases STAC intron 17554300 rs1350146 chr3 36516326 G A 4.30E-05 Malaria STAC intron 19465909 rs9881075 chr3 36517935 C A 6.39E-05 Graves' disease STAC intron 21841780 rs1456074 chr3 36524206 C T 2.10E-04 Amyotrophic Lateral Sclerosis STAC intron 17362836 rs1456074 chr3 36524206 C T 6.41E-05 Blood Pressure STAC intron pha003039 rs867840 chr3 36622550 C T 3.30E-06 Urinary metabolites / / 21572414 rs6780039 chr3 36655637 C G 1.10E-05 Urinary metabolites / / 21572414 rs9854871 chr3 36662503 C T 3.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs6550429 chr3 36674940 C T 2.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs13323950 chr3 36679558 C T 2.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs950146 chr3 36680099 G T 4.00E-06 Erectile dysfunction / / 22704111 rs5009838 chr3 36681026 C T 2.22E-04 Type 2 diabetes / / 17463246 rs4678541 chr3 36689524 G A 1.48E-04 Alzheimer's disease (late onset) / / 21379329 rs11707751 chr3 36690903 G A 1.30E-04 Alzheimer's disease (late onset) / / 21379329 rs1396029 chr3 36703758 C T 3.60E-04 Alzheimer's disease (late onset) / / 21379329 rs2174855 chr3 36731104 A G 2.13E-05 Smoking initiation / / 24665060 rs7625360 chr3 36748860 A C 9.78E-05 Dietary macronutrient intake / / 23636237 rs17197692 chr3 36775946 A C 1.54E-04 Multiple complex diseases DCLK3 intron 17554300 rs17197692 chr3 36775946 A C 1.76E-07 Glaucoma-related traits DCLK3 intron 22058429 rs4678550 chr3 36803994 T C 6.40E-06 Parkinson's disease / / 20711177 rs9838964 chr3 36812510 A C 5.59E-04 Smoking initiation / / 24665060 rs9838964 chr3 36812510 A C 9.34E-05 ldl cholesterol / / pha003076 rs17035576 chr3 36817025 T C 2.60E-05 Urinary metabolites / / 21572414 rs11927951 chr3 36817611 C G 3.30E-06 Urinary metabolites / / 21572414 rs13072940 chr3 36842623 T A 9.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs13072940 chr3 36842623 T A 0.0000127 Schizophrenia / / 23637625 rs13072940 chr3 36842623 T A 4.95E-05 Bipolar disorder / / 24618891 rs931913 chr3 36843149 G A 2.74E-07 Bipolar disorder / / 24618891 rs9882879 chr3 36844071 C T 2.38E-07 Bipolar disorder / / 24618891 rs9876421 chr3 36848316 C T 1.89E-07 Bipolar disorder / / 24618891 rs11707149 chr3 36850490 C T 3.52E-05 Bipolar disorder / / 24618891 rs925135 chr3 36854253 G A 3.69E-05 Bipolar disorder / / 24618891 rs9834970 chr3 36856030 T C 1.21E-06 Multiple complex diseases / / 17554300 rs9834970 chr3 36856030 T C 1.00E-12 Bipolar disorder / / 22182935 rs9834970 chr3 36856030 T C 5.41E-06 Major depressive disorder / / 22472876 rs9834970 chr3 36856030 T C 0.00000304 Bipolar disorder / / 23070075 rs9834970 chr3 36856030 T C 1.00E-07 Bipolar disorder (mood-incongruent) / / 23092984 rs9834970 chr3 36856030 T C 2.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs9834970 chr3 36856030 T C 0.00052 Bipolar disorder / / 23637625 rs9834970 chr3 36856030 T C 1.00E-10 Bipolar disorder and schizophrenia / / 24280982 rs9834970 chr3 36856030 T C 4.00E-07 Bipolar disorder and schizophrenia / / 24280982 rs9834970 chr3 36856030 T C 7.18E-05 Bipolar disorder and schizophrenia / / 24280982 rs9834970 chr3 36856030 T C 4.81E-08 Bipolar disorder / / 24618891 rs906482 chr3 36856328 G A 1.10E-04 Multiple complex diseases / / 17554300 rs906482 chr3 36856328 G A 8.41E-04 Schizophrenia / / 19197363 rs1553656 chr3 36859705 T C 2.10E-05 Type 2 diabetes / / 23209189 rs1553656 chr3 36859705 T C 2.40E-07 Bipolar disorder / / 24618891 rs1532965 chr3 36861196 T G 2.73E-08 Bipolar disorder / / 24618891 rs4072458 chr3 36862680 T C 2.10E-07 Bipolar disorder / / 24618891 rs4624519 chr3 36862980 C T 4.04E-04 Multiple complex diseases / / 17554300 rs4624519 chr3 36862980 C T 2.00E-07 Schizophrenia / / 21926974 rs4624519 chr3 36862980 C T 2.61E-08 Bipolar disorder / / 24618891 rs9917659 chr3 36864160 A G 5.00E-04 Multiple complex diseases / / 17554300 rs6550435 chr3 36864489 T G 9.00E-06 Bipolar disorder / / 21926972 rs6550435 chr3 36864489 T G 0.0000454 Bipolar disorder / / 23070075 rs6550435 chr3 36864489 T G 6.00E-08 Schizophrenia / / 23974872 rs6550435 chr3 36864489 T G 2.00E-08 Bipolar disorder / / 24618891 rs4789 chr3 36869439 T C 4.32E-07 Bipolar disorder TRANK1 UTR-3 22182935 rs4789 chr3 36869439 T C 4.53E-05 Major depressive disorder TRANK1 UTR-3 22472876 rs4789 chr3 36869439 T C 3.33E-07 Bipolar disorder TRANK1 UTR-3 24618891 rs11129735 chr3 36870230 A G 2.56E-07 Bipolar disorder TRANK1 intron 24618891 rs7652637 chr3 36871507 T C 3.41E-08 Bipolar disorder TRANK1 intron 24618891 rs12637912 chr3 36871894 C A 4.81E-08 Bipolar disorder TRANK1 intron 24618891 rs3732386 chr3 36871993 C T 3.12E-08 Bipolar disorder TRANK1 intron 24618891 rs9811916 chr3 36878086 A G 2.88E-08 Bipolar disorder TRANK1 intron 24618891 rs4678909 chr3 36878563 A G 3.12E-08 Bipolar disorder TRANK1 intron 24618891 rs4234258 chr3 36878970 A G 2.45E-08 Bipolar disorder TRANK1 intron 24618891 rs9821223 chr3 36883369 T C 2.43E-08 Bipolar disorder TRANK1 intron 24618891 rs9882911 chr3 36885392 T C 4.37E-04 Multiple complex diseases TRANK1 intron 17554300 rs9882911 chr3 36885392 T C 2.09E-08 Bipolar disorder TRANK1 intron 24618891 rs4678910 chr3 36887973 C G 2.35E-08 Bipolar disorder TRANK1 intron 24618891 rs9985296 chr3 36889621 T C 1.08E-05 Bipolar disorder TRANK1 intron 24618891 rs4441609 chr3 36892717 T C 2.40E-07 Bipolar disorder TRANK1 intron 22182935 rs4441609 chr3 36892717 T C 1.30E-05 Bipolar disorder TRANK1 intron 24618891 rs17807744 chr3 36894048 C T 4.07E-08 Bipolar disorder TRANK1 intron 24618891 rs11706780 chr3 36896235 C T 5.04E-08 Bipolar disorder TRANK1 intron 24618891 rs4327336 chr3 36896270 C T 1.19E-07 Bipolar disorder TRANK1 intron 22182935 rs17201603 chr3 36898973 G A 8.75E-04 Aortic root size TRANK1 missense 21223598 rs4642070 chr3 36900944 C T 2.39E-05 Bipolar disorder TRANK1 intron 24618891 rs111687462 chr3 36903246 G C 0.0000449 Nonsyndromic striae distensae (stretch marks) TRANK1 intron 23633020 rs6808230 chr3 36911597 T C 2.31E-05 Multiple complex diseases TRANK1 intron 17554300 rs7649846 chr3 36914958 C T 2.32E-05 Multiple complex diseases TRANK1 intron 17554300 rs4296548 chr3 36915814 T G 9.04E-06 Bipolar disorder TRANK1 intron 24618891 rs9810132 chr3 36920050 G A 3.51E-05 Multiple complex diseases TRANK1 intron 17554300 rs11129740 chr3 36925194 C A 2.34E-05 Multiple complex diseases TRANK1 intron 17554300 rs6765624 chr3 36927546 G A 2.40E-05 Multiple complex diseases TRANK1 intron 17554300 rs4328757 chr3 36938180 C T 2.79E-04 Multiple complex diseases TRANK1 intron 17554300 rs4328757 chr3 36938180 C T 7.84E-06 Bipolar disorder TRANK1 intron 24618891 rs6550440 chr3 36939286 G A 2.07E-05 Multiple complex diseases TRANK1 intron 17554300 rs9864910 chr3 36940741 G T 5.42E-05 Multiple complex diseases TRANK1 cds-synon 17554300 rs4425211 chr3 36951898 A G 4.62E-05 Bipolar disorder TRANK1 intron 24618891 rs6769189 chr3 36958773 G A 3.39E-04 Multiple complex diseases TRANK1 intron 17554300 rs6769400 chr3 36958995 G A 9.47E-04 Multiple complex diseases TRANK1 intron 17554300 rs6769400 chr3 36958995 G A 1.99E-05 Longevity TRANK1 intron 21612516 rs13314421 chr3 36962388 A G 1.75E-05 Bipolar disorder TRANK1 intron 24618891 rs4678915 chr3 36964583 G A 2.38E-05 Bipolar disorder TRANK1 intron 24618891 rs4678917 chr3 36965158 T C 1.51E-04 Alzheimer's disease TRANK1 intron 22005930 rs1800734 chr3 37034946 G A 1 Drug response to Dacarbazine MLH1 UTR-5 17959715 rs1800734 chr3 37034946 G A 1 Drug response to Procarbazine MLH1 UTR-5 17959715 rs1053006 chr3 37224099 G A 3.06E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs1053006 chr3 37224099 G A 2.90E-05 Alzheimer's disease / / 22005930 rs7631605 chr3 37234589 C T 1.00E-06 P-tau181p levels / / 20932310 rs6809976 chr3 37270341 A C 2.69E-04 Birth weight / / 17255346 rs169188 chr3 37507449 G A 3.16E-07 Nasopharyngeal carcinoma ITGA9 intron 19478819 rs197721 chr3 37510036 C A 1.45E-06 Nasopharyngeal carcinoma ITGA9 intron 19478819 rs149816 chr3 37510766 G C 1.45E-06 Nasopharyngeal carcinoma ITGA9 intron 19478819 rs169111 chr3 37515533 C T 8.98E-07 Nasopharyngeal carcinoma ITGA9 intron 19478819 rs197770 chr3 37515827 A G 1.10E-06 Nasopharyngeal carcinoma ITGA9 intron 19478819 rs197770 chr3 37515827 A G 2.00E-08 Phospholipid levels (plasma) ITGA9 intron 22359512 rs2212020 chr3 37517462 C T 8.27E-07 Nasopharyngeal carcinoma ITGA9 intron 19478819 rs2212020 chr3 37517462 C T 3.29E-05 White matter integrity ITGA9 intron 22425255 rs189897 chr3 37518545 T A 7.00E-08 Nasopharyngeal carcinoma ITGA9 intron 19478819 rs189897 chr3 37518545 T A 7.00E-08 Nasopharyngeal carcinoma ITGA9 intron 20512145 rs197757 chr3 37522828 G A 1.04E-07 Nasopharyngeal carcinoma ITGA9 intron 19478819 rs7611844 chr3 37542325 C T 1.84E-04 Glycosylated haemoglobin levels ITGA9 intron 17255346 rs9809662 chr3 37545107 G A 1.76E-04 Glycosylated haemoglobin levels ITGA9 intron 17255346 rs928799 chr3 37550382 G A 8.84E-05 Glycosylated haemoglobin levels ITGA9 intron 17255346 rs267567 chr3 37574024 G A 3.03E-06 Crohn's disease ITGA9 intron 18587394 rs267567 chr3 37574024 G A 4.00E-11 PR interval ITGA9 intron 23139255 rs267564 chr3 37574437 A C 8.51E-04 Aortic root size ITGA9 intron 21223598 rs267554 chr3 37576985 T C 4.98E-04 Aortic root size ITGA9 intron 21223598 rs2559894 chr3 37582867 C T 3.63E-04 Coronary heart disease ITGA9 intron 21971053 rs3016003 chr3 37587444 C T 5.38E-04 Fibrinogen ITGA9 intron 17255346 rs17828003 chr3 37593585 A G 9.25E-05 Glycosylated haemoglobin levels ITGA9 intron 17255346 rs17828003 chr3 37593585 A G 3.03E-04 Type 2 diabetes ITGA9 intron 17463246 rs919113 chr3 37600470 A G 4.95E-04 Nicotine smoking ITGA9 intron 19268276 rs9825420 chr3 37604012 T G 3.00E-08 Amyotrophic lateral sclerosis (sporadic) ITGA9 intron 24529757 rs7649363 chr3 37604726 G T 0.0000499 Salmonella-induced pyroptosis ITGA9 intron 22837397 rs17828523 chr3 37606770 T C 0.000191 Salmonella-induced pyroptosis ITGA9 intron 22837397 rs7642079 chr3 37607725 G A 0.000214 Salmonella-induced pyroptosis ITGA9 intron 22837397 rs2844363 chr3 37611860 C T 5.90E-06 Lung cancer ITGA9 intron 19654303 rs6550481 chr3 37614710 T G 2.68E-04 Nicotine smoking ITGA9 intron 19268276 rs6419832 chr3 37618097 T C 1.34E-04 Smoking cessation ITGA9 intron 18519826 rs6419832 chr3 37618097 T C 7.23E-06 Smoking cessation ITGA9 intron 18519826 rs2212035 chr3 37624245 T C 2.15E-05 Smoking cessation ITGA9 intron 18519826 rs2212035 chr3 37624245 T C 5.33E-05 Smoking cessation ITGA9 intron 18519826 rs9857453 chr3 37625750 T G 2.44E-04 Smoking cessation ITGA9 intron 18519826 rs9857453 chr3 37625750 T G 3.69E-05 Smoking cessation ITGA9 intron 18519826 rs1155741 chr3 37627112 T C 1.60E-04 Smoking cessation ITGA9 intron 18519826 rs6550486 chr3 37628954 G A 1.63E-05 Smoking cessation ITGA9 intron 18519826 rs6550486 chr3 37628954 G A 4.05E-05 Smoking cessation ITGA9 intron 18519826 rs7641625 chr3 37667634 C G 1.35E-04 Acute lung injury ITGA9 intron 22295056 rs2070482 chr3 37693145 G A 6.08E-05 Heart rate ITGA9 intron 23583979 rs17036765 chr3 37705356 A G 2.00E-05 Urinary metabolites ITGA9 intron 21572414 rs6770747 chr3 37726832 A G 8.30E-06 Urinary metabolites ITGA9 intron 21572414 rs743393 chr3 37743968 T C 7.40E-04 Psychosis ITGA9 intron 23871474 rs11717973 chr3 37762014 C T 4.76E-04 Nicotine smoking ITGA9 intron 19268276 rs11129773 chr3 37855114 C T 8.00E-06 Illicit drug use ITGA9 intron 23942779 rs6780036 chr3 37858410 G A 7.04E-04 Alzheimer's disease ITGA9 intron 24755620 rs6782856 chr3 37858771 G A 5.85E-04 Alzheimer's disease ITGA9 intron 24755620 rs6794868 chr3 37887360 G A 4.35E-05 Bone mineral density / / 19181680 rs9877943 chr3 37914922 G A 5.68E-05 Bone mineral density CTDSPL intron 19181680 rs9877943 chr3 37914922 G A 3.07E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CTDSPL intron 24023788 rs9822761 chr3 37969439 T C 7.53E-05 Bone mineral density CTDSPL intron 19181680 rs9311168 chr3 37977417 G T 4.90E-05 Volumetric brain MRI CTDSPL intron 17903297 rs9311171 chr3 37996477 T G 4.03E-05 Blood Pressure and Arterial Stiffness CTDSPL intron 17903302 rs9311171 chr3 37996477 T G 2.00E-06 Prostate cancer CTDSPL intron 17903305 rs9311171 chr3 37996477 T G 2.00E-06 Nasopharyngeal carcinoma CTDSPL intron 20512145 rs10095 chr3 38023553 A G 3.49E-04 Tourette syndrome CTDSPL UTR-3 22889924 rs11711286 chr3 38026652 C T 5.56E-04 Tourette syndrome / / 22889924 rs6809649 chr3 38038982 T C 2.44E-04 Bulimia nervosa VILL cds-synon 23568457 rs928807 chr3 38042182 T G 5.53E-04 Tourette syndrome VILL intron 22889924 rs1123569 chr3 38140721 G T 5.45E-04 Multiple complex diseases DLEC1 intron 17554300 rs9847922 chr3 38142082 G C 4.76E-04 Multiple complex diseases DLEC1 intron 17554300 rs9847922 chr3 38142082 G C 1.80E-05 Urinary metabolites DLEC1 intron 21572414 rs6599263 chr3 38144875 G T 3.50E-06 Urinary metabolites DLEC1 intron 21572414 rs6767684 chr3 38185174 G A 7.07E-04 Multiple complex diseases / / 17554300 rs9881120 chr3 38186417 A T 8.08E-04 Multiple complex diseases / / 17554300 rs72542450 chr3 38307398 G A 0.00055 Prostate cancer (non-advanced prostate cancer) SLC22A13 missense 23555315 rs1979845 chr3 38311953 C T 8.50E-04 Myopia (pathological) SLC22A13 intron 21095009 rs116741759 chr3 38355325 G A 0.00031 Breast cancer (ER positive) SLC22A14 missense 23555315 rs696256 chr3 38375557 G A 2.97E-04 Multiple complex diseases / / 17554300 rs820296 chr3 38396543 T C 2.05E-04 Multiple complex diseases XYLB intron 17554300 rs818838 chr3 38405785 C T 1.33E-04 Multiple complex diseases XYLB intron 17554300 rs1093685 chr3 38406277 T C 1.99E-04 Multiple complex diseases XYLB intron 17554300 rs2234608 chr3 38406793 T G 3.20E-04 Multiple complex diseases XYLB intron 17554300 rs704946 chr3 38408248 G A 9.47E-05 Multiple complex diseases XYLB intron 17554300 rs2234617 chr3 38408459 A G 2.58E-04 Multiple complex diseases XYLB intron 17554300 rs818836 chr3 38410509 T C 2.28E-04 Multiple complex diseases XYLB intron 17554300 rs818833 chr3 38410632 A G 1.27E-04 Multiple complex diseases XYLB intron 17554300 rs704952 chr3 38413880 T C 7.74E-04 Multiple complex diseases XYLB intron 17554300 rs2070988 chr3 38437835 A G 2.00E-05 Electrocardiographic conduction measures XYLB intron 19389651 rs2169552 chr3 38437968 G A 4.70E-04 Multiple complex diseases XYLB intron 17554300 rs2067082 chr3 38438182 G C 6.70E-06 Electrocardiographic conduction measures XYLB intron 19389651 rs2070488 chr3 38442490 G A 4.00E-06 Electrocardiographic conduction measures XYLB intron 19389651 rs2234628 chr3 38442504 G A 4.00E-10 P wave duration XYLB intron 24850809 rs1002676 chr3 38444932 G T 5.10E-06 Electrocardiographic conduction measures XYLB intron 19389651 rs12636358 chr3 38455901 G A 4.66E-10 P wave duration XYLB UTR-3 24850809 rs2268757 chr3 38505853 C T 4.60E-06 Electrocardiographic conduction measures ACVR2B intron 19389651 rs2284816 chr3 38510346 T C 3.36E-10 P wave duration ACVR2B intron 24850809 rs12637034 chr3 38512619 T C 2.27E-10 P wave duration ACVR2B intron 24850809 rs7373828 chr3 38524311 A G 6.70E-06 Electrocardiographic conduction measures ACVR2B intron 19389651 rs12636077 chr3 38525588 G A 2.51E-10 P wave duration ACVR2B UTR-3 24850809 rs1058945 chr3 38532511 G A 4.70E-06 Electrocardiographic conduction measures ACVR2B UTR-3 19389651 rs11706270 chr3 38548658 A G 7.73E-05 Body Fat Distribution EXOG intron pha003016 rs11706270 chr3 38548658 A G 3.34E-05 Body Fat Distribution EXOG intron pha003017 rs2051215 chr3 38560345 A G 5.50E-06 Electrocardiographic conduction measures EXOG intron 19389651 rs17037809 chr3 38561079 G A 2.32E-12 P wave duration EXOG intron 24850809 rs2284820 chr3 38562579 C T 4.40E-06 Electrocardiographic conduction measures EXOG intron 19389651 rs1065800 chr3 38566480 G A 4.60E-06 Electrocardiographic conduction measures EXOG UTR-3 19389651 rs12631864 chr3 38569764 G A 2.62E-12 P wave duration / / 24850809 rs11711260 chr3 38571289 C T 1.11E-04 Smoking quantity / / 24665060 rs11129795 chr3 38589163 G A 5.00E-14 QT interval SCN5A nearGene-3 19305409 rs11129795 chr3 38589163 G A 5.00E-10 Electrocardiographic traits SCN5A nearGene-3 20062063 rs7429945 chr3 38591689 T C 4.27E-14 P wave duration SCN5A UTR-3 24850809 rs1805126 chr3 38592406 A G 2.80E-06 Urinary metabolites SCN5A cds-synon 21572414 rs1805126 chr3 38592406 A G 3.00E-20 Electrocardiographic conduction measures SCN5A cds-synon 23463857 rs12053903 chr3 38593393 T C 1.00E-14 QT interval SCN5A intron 19305408 rs12053903 chr3 38593393 T C 6.88E-08 QT interval SCN5A intron 19305409 rs12053903 chr3 38593393 T C 1.00E-07 Electrocardiographic traits SCN5A intron 20062063 rs12053903 chr3 38593393 T C 2.38E-12 P wave duration SCN5A intron 24850809 rs7638909 chr3 38594973 T G 2.00E-06 Electrocardiographic conduction measures SCN5A intron 19389651 rs7638909 chr3 38594973 T G 2.91E-14 P wave duration SCN5A intron 24850809 rs6793245 chr3 38599037 G A 9.90E-05 Electrocardiographic conduction measures SCN5A intron 19389651 rs6793245 chr3 38599037 G A 1.40E-11 P wave duration SCN5A intron 24850809 rs6799868 chr3 38601556 T C 4.69E-12 P wave duration SCN5A intron 24850809 rs3935472 chr3 38602855 G A 4.80E-05 Electrocardiographic conduction measures SCN5A intron 19389651 rs3935472 chr3 38602855 G A 2.37E-14 P wave duration SCN5A intron 24850809 rs7374138 chr3 38605732 G C 1.38E-18 P wave duration SCN5A intron 24850809 rs9812912 chr3 38607229 C T 3.11E-18 P wave duration SCN5A intron 24850809 rs9861242 chr3 38609334 A G 9.60E-12 P wave duration SCN5A intron 24850809 rs4130467 chr3 38611704 C T 1.48E-12 P wave duration SCN5A intron 24850809 rs3922844 chr3 38624253 T C 3.00E-23 PR interval SCN5A intron 21347284 rs3922844 chr3 38624253 T C 5.00E-43 PR interval SCN5A intron 23139255 rs3922844 chr3 38624253 T C 2.83E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SCN5A intron 24023788 rs3922844 chr3 38624253 T C 1.78E-08 P wave duration SCN5A intron 24850809 rs3922843 chr3 38624343 A G 1.88E-08 P wave duration SCN5A intron 24850809 rs6599214 chr3 38629814 G A 3.02E-08 P wave duration SCN5A intron 24850809 rs7374040 chr3 38632047 C G 1.70E-16 P wave duration SCN5A intron 24850809 rs10154914 chr3 38632630 T A 8.88E-13 P wave duration SCN5A intron 24850809 rs9311191 chr3 38633110 T C 1.19E-12 P wave duration SCN5A intron 24850809 rs11708996 chr3 38633923 G C 6.00E-26 PR interval SCN5A intron 20062060 rs11708996 chr3 38633923 G C 1.00E-16 QRS duration SCN5A intron 21076409 rs11708996 chr3 38633923 G C 7.00E-06 Ventricular conduction SCN5A intron 21076409 rs11708996 chr3 38633923 G C 1.00E-14 Brugada syndrome SCN5A intron 23872634 rs11708996 chr3 38633923 G C 3.63E-11 P wave duration SCN5A intron 24850809 rs7374540 chr3 38634142 C A 3.40E-14 P wave duration SCN5A intron 24850809 rs7373862 chr3 38634343 G A 4.04E-13 P wave duration SCN5A intron 24850809 rs9311194 chr3 38635072 G A 6.43E-13 P wave duration SCN5A intron 24850809 rs3935184 chr3 38638202 C G 2.28E-13 P wave duration SCN5A intron 24850809 rs10212202 chr3 38638390 G C 9.05E-13 P wave duration SCN5A intron 24850809 rs9833775 chr3 38641084 C T 4.18E-11 P wave duration SCN5A intron 24850809 rs11714074 chr3 38643785 C T 1.15E-10 P wave duration SCN5A intron 24850809 rs1805124 chr3 38645420 T C 9.89E-13 P wave duration SCN5A missense 24850809 rs7428779 chr3 38646423 C T 5.17E-11 P wave duration SCN5A intron 24850809 rs11711602 chr3 38647047 C T 5.43E-11 P wave duration SCN5A intron 24850809 rs6599222 chr3 38648062 C T 2.26E-08 PR interval SCN5A intron 21347284 rs6599222 chr3 38648062 C T 3.19E-04 Brugada syndrome SCN5A intron 23872634 rs11710077 chr3 38657899 A T 1.00E-06 Ventricular conduction SCN5A intron 21076409 rs11710077 chr3 38657899 A T 6.00E-22 QRS duration SCN5A intron 21076409 rs186437034 chr3 38658508 T C 0.0000245 Menopause (age at onset) SCN5A intron 23424626 rs7637849 chr3 38659275 G A 3.95E-04 Response to taxane treatment (placlitaxel) SCN5A intron 23006423 rs9832895 chr3 38661533 T C 2.29E-06 QT interval SCN5A intron 19305409 rs9832895 chr3 38661533 T C 1.73E-06 Personality dimensions SCN5A intron 23658558 rs6781731 chr3 38663707 C T 2.80E-05 Electrocardiographic conduction measures SCN5A intron 19389651 rs13073578 chr3 38679364 A G 8.30E-05 Non-alcoholic fatty liver disease histology (other) SCN5A intron 20708005 rs6763048 chr3 38681394 A G 4.00E-12 PR interval SCN5A intron 23139255 rs6768664 chr3 38684466 C A 1.90E-08 PR segment SCN5A intron 24850809 rs7373934 chr3 38695708 A G 0.000306661 Hypertension (early onset hypertension) / / 22479346 rs13061927 chr3 38707352 G T 4.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9851710 chr3 38719901 C A 6.52E-20 P wave duration / / 24850809 rs9851710 chr3 38719901 C A 7.81E-10 PR segment / / 24850809 rs9851724 chr3 38719935 C T 2.00E-20 QRS duration / / 21076409 rs9851724 chr3 38719935 C T 6.00E-16 Ventricular conduction / / 21076409 rs9851724 chr3 38719935 C T 1.56E-04 Brugada syndrome / / 23872634 rs7373154 chr3 38721308 T C 4.49E-08 P wave duration / / 24850809 rs11717818 chr3 38722696 C T 8.28E-04 Multiple complex diseases / / 17554300 rs7633988 chr3 38723217 T A 2.79E-12 PR segment / / 24850809 rs7633988 chr3 38723217 T A 7.93E-23 P wave duration / / 24850809 rs7374165 chr3 38726685 A C 1.10E-08 PR segment / / 24850809 rs7374165 chr3 38726685 A C 1.41E-09 P wave duration / / 24850809 rs12639182 chr3 38736230 C T 6.65E-05 Major depressive disorder (broad) / / 20038947 rs6599239 chr3 38737984 G A 4.41E-08 PR segment / / 24850809 rs6599240 chr3 38738717 G A 1.20E-13 Brugada syndrome SCN10A nearGene-3 23872634 rs6599240 chr3 38738717 G A 4.53E-27 PR segment SCN10A nearGene-3 24850809 rs6599240 chr3 38738717 G A 7.17E-19 P wave duration SCN10A nearGene-3 24850809 rs6599242 chr3 38739845 A G 2.96E-08 PR segment SCN10A cds-synon 24850809 rs11129799 chr3 38742229 T C 1.78E-11 PR segment SCN10A intron 24850809 rs11129800 chr3 38744370 C T 2.95E-15 PR segment SCN10A intron 24850809 rs6599243 chr3 38747277 C T 1.14E-09 PR segment SCN10A intron 24850809 rs6599247 chr3 38747872 T C 1.02E-09 PR segment SCN10A intron 24850809 rs6599248 chr3 38749026 T A 1.14E-11 PR segment SCN10A intron 24850809 rs11129801 chr3 38750375 A G 8.17E-10 Multiple complex diseases SCN10A intron 17554300 rs11129801 chr3 38750375 A G 2.77E-08 Brugada syndrome SCN10A intron 23872634 rs11129801 chr3 38750375 A G 6.03E-12 PR segment SCN10A intron 24850809 rs11129802 chr3 38750436 T C 7.13E-05 Cognitive performance SCN10A intron 19734545 rs11129802 chr3 38750436 T C 8.92E-10 PR segment SCN10A intron 24850809 rs11710006 chr3 38752790 A T 1.89E-08 PR segment SCN10A intron 24850809 rs11710006 chr3 38752790 A T 3.51E-10 P wave duration SCN10A intron 24850809 rs6783110 chr3 38752935 A G 1.28E-24 P wave duration SCN10A intron 24850809 rs6783110 chr3 38752935 A G 8.75E-38 PR segment SCN10A intron 24850809 rs11129803 chr3 38752968 T C 4.56E-11 PR segment SCN10A intron 24850809 rs11928905 chr3 38756498 T C 1.87E-11 PR segment SCN10A intron 24850809 rs11924846 chr3 38756566 C T 3.72E-25 P wave duration SCN10A intron 24850809 rs11924846 chr3 38756566 C T 9.69E-39 PR segment SCN10A intron 24850809 rs6794914 chr3 38757235 C T 1.39E-12 PR segment SCN10A intron 24850809 rs6794914 chr3 38757235 C T 4.43E-08 P wave duration SCN10A intron 24850809 rs9990137 chr3 38759465 A G 1.03E-14 PR segment SCN10A intron 24850809 rs9990137 chr3 38759465 A G 3.61E-13 P wave duration SCN10A intron 24850809 rs6805187 chr3 38760506 C A 7.67E-11 P wave duration SCN10A intron 24850809 rs6805187 chr3 38760506 C A 9.24E-15 PR segment SCN10A intron 24850809 rs7617547 chr3 38763500 G C 4.05E-18 PR segment SCN10A intron 24850809 rs6771157 chr3 38763863 G C 2.76E-09 P wave duration SCN10A cds-synon 24850809 rs6771157 chr3 38763863 G C 6.20E-11 PR segment SCN10A cds-synon 24850809 rs4076737 chr3 38764782 G T 1.50E-09 PR interval SCN10A intron 21347284 rs4076737 chr3 38764782 G T 1.22E-39 PR segment SCN10A intron 24850809 rs4076737 chr3 38764782 G T 1.32E-25 P wave duration SCN10A intron 24850809 rs12632942 chr3 38764998 A G 2.27E-11 P wave duration SCN10A missense 24850809 rs12632942 chr3 38764998 A G 4.78E-10 PR segment SCN10A missense 24850809 rs7430477 chr3 38765490 C T 4.38E-30 PR segment SCN10A intron 24850809 rs7430477 chr3 38765490 C T 9.56E-24 P wave duration SCN10A intron 24850809 rs9825762 chr3 38766338 T C 2.66E-11 PR segment SCN10A intron 24850809 rs6795970 chr3 38766675 A G 3.00E-15 Electrocardiographic traits SCN10A missense 20062061 rs6795970 chr3 38766675 A G 1.00E-58 Electrocardiographic traits SCN10A missense 20062063 rs6795970 chr3 38766675 A G 4.00E-09 Electrocardiographic traits SCN10A missense 20062063 rs6795970 chr3 38766675 A G 1.45E-09 PR interval SCN10A missense 21347284 rs6795970 chr3 38766675 A G 2.20E-05 Atrial fibrillation SCN10A missense 22544366 rs6795970 chr3 38766675 A G 9.80E-04 Orofacial clefts SCN10A missense 22863734 rs6795970 chr3 38766675 A G 5.00E-27 Electrocardiographic conduction measures SCN10A missense 23463857 rs6795970 chr3 38766675 A G 1.11E-27 Brugada syndrome SCN10A missense 23872634 rs6795970 chr3 38766675 A G 4.79E-40 PR segment SCN10A missense 24850809 rs6795970 chr3 38766675 A G 8.79E-26 P wave duration SCN10A missense 24850809 rs6791171 chr3 38766701 C T 2.66E-11 PR segment SCN10A cds-synon 24850809 rs6801957 chr3 38767315 T C 1.00E-28 QRS duration SCN10A intron 21076409 rs6801957 chr3 38767315 T C 3.00E-14 Ventricular conduction SCN10A intron 21076409 rs6801957 chr3 38767315 T C 5.37E-12 PR interval SCN10A intron 21347284 rs6801957 chr3 38767315 T C 9.00E-09 PR interval SCN10A intron 23139255 rs6801957 chr3 38767315 T C 7.00E-41 PR segment SCN10A intron 24850809 rs6801957 chr3 38767315 T C 8.00E-27 P wave duration SCN10A intron 24850809 rs7433306 chr3 38770639 C G 3.00E-09 PR interval SCN10A intron 21347284 rs7433306 chr3 38770639 C G 2.47E-04 Heart rate SCN10A intron 23583979 rs7433306 chr3 38770639 C G 1.21E-39 PR segment SCN10A intron 24850809 rs7433306 chr3 38770639 C G 5.17E-26 P wave duration SCN10A intron 24850809 rs6780103 chr3 38771464 G A 1.20E-06 Urinary metabolites SCN10A intron 21572414 rs6780103 chr3 38771464 G A 1.29E-15 PR segment SCN10A intron 24850809 rs6780103 chr3 38771464 G A 2.26E-08 P wave duration SCN10A intron 24850809 rs6790396 chr3 38771925 C G 2.18E-08 PR interval SCN10A intron 21347284 rs6790396 chr3 38771925 C G 4.31E-26 P wave duration SCN10A intron 24850809 rs6790396 chr3 38771925 C G 4.84E-39 PR segment SCN10A intron 24850809 rs9874633 chr3 38771994 A G 1.66E-13 Brugada syndrome SCN10A intron 23872634 rs13096893 chr3 38772864 G A 5.96E-12 PR segment SCN10A intron 24850809 rs6800541 chr3 38774832 C T 2.00E-74 PR interval SCN10A intron 20062060 rs6800541 chr3 38774832 C T 9.70E-17 Electrocardiographic traits SCN10A intron 20062061 rs6800541 chr3 38774832 C T 5.00E-07 Atrioventricular conduction SCN10A intron 21041692 rs6800541 chr3 38774832 C T 3.37E-09 PR interval SCN10A intron 21347284 rs6800541 chr3 38774832 C T 2.80E-06 Atrial fibrillation SCN10A intron 22544366 rs6800541 chr3 38774832 C T 2.74E-39 PR segment SCN10A intron 24850809 rs6800541 chr3 38774832 C T 8.35E-26 P wave duration SCN10A intron 24850809 rs10428132 chr3 38777554 T G 1.00E-68 Brugada syndrome SCN10A intron 23872634 rs7428167 chr3 38778191 T C 1.22E-22 Brugada syndrome SCN10A intron 23872634 rs6776034 chr3 38779189 T A 3.02E-25 PR segment SCN10A intron 24850809 rs6776034 chr3 38779189 T A 4.22E-20 P wave duration SCN10A intron 24850809 rs10428168 chr3 38780059 T C 2.36E-15 Brugada syndrome SCN10A intron 23872634 rs7615140 chr3 38782026 T C 2.96E-13 PR segment SCN10A intron 24850809 rs7615140 chr3 38782026 T C 6.54E-09 P wave duration SCN10A intron 24850809 rs6599250 chr3 38784029 T C 3.56E-09 PR interval SCN10A intron 21347284 rs6599250 chr3 38784029 T C 1.47E-40 PR segment SCN10A intron 24850809 rs6599250 chr3 38784029 T C 1.90E-26 P wave duration SCN10A intron 24850809 rs7433723 chr3 38784957 G A 8.89E-12 PR interval SCN10A intron 21347284 rs7433723 chr3 38784957 G A 1.79E-26 P wave duration SCN10A intron 24850809 rs7433723 chr3 38784957 G A 2.60E-40 PR segment SCN10A intron 24850809 rs6599251 chr3 38785809 G T 6.45E-26 P wave duration SCN10A intron 24850809 rs6599251 chr3 38785809 G T 8.46E-37 PR segment SCN10A intron 24850809 rs12638572 chr3 38787797 A G 2.48E-10 Brugada syndrome SCN10A intron 23872634 rs9844265 chr3 38788506 C T 2.07E-12 PR segment SCN10A intron 24850809 rs9844265 chr3 38788506 C T 3.19E-08 P wave duration SCN10A intron 24850809 rs9844577 chr3 38788728 C A 1.89E-26 P wave duration SCN10A intron 24850809 rs6599252 chr3 38789691 T A 3.67E-09 P wave duration SCN10A intron 24850809 rs7430451 chr3 38795495 C G 9.90E-13 P wave duration SCN10A intron 24850809 rs6599254 chr3 38795555 A G 3.81E-09 PR interval SCN10A intron 21347284 rs6599254 chr3 38795555 A G 3.30E-25 P wave duration SCN10A intron 24850809 rs6599255 chr3 38796415 A C 3.31E-12 PR interval SCN10A intron 21347284 rs6599255 chr3 38796415 A C 1.06E-25 P wave duration SCN10A intron 24850809 rs12630795 chr3 38796985 A G 1.85E-09 P wave duration SCN10A intron 24850809 rs6798015 chr3 38798836 C T 2.10E-12 PR interval SCN10A intron 21347284 rs6798015 chr3 38798836 C T 4.21E-05 Orofacial clefts SCN10A intron 22863734 rs6798015 chr3 38798836 C T 3.53E-26 Brugada syndrome SCN10A intron 23872634 rs6798015 chr3 38798836 C T 3.83E-25 P wave duration SCN10A intron 24850809 rs6763876 chr3 38800747 T C 4.88E-08 P wave duration SCN10A intron 24850809 rs6599256 chr3 38801225 G T 5.09E-10 P wave duration SCN10A intron 24850809 rs7641844 chr3 38802251 A G 3.80E-08 Brugada syndrome SCN10A intron 23872634 rs7641844 chr3 38802251 A G 6.76E-10 P wave duration SCN10A intron 24850809 rs7432804 chr3 38803509 A G 8.10E-10 P wave duration SCN10A intron 24850809 rs7430438 chr3 38803618 G A 2.30E-05 Urinary metabolites SCN10A intron 21572414 rs7430438 chr3 38803618 G A 2.69E-17 P wave duration SCN10A intron 24850809 rs7430439 chr3 38803639 G A 1.10E-08 Brugada syndrome SCN10A intron 23872634 rs7430439 chr3 38803639 G A 7.67E-17 P wave duration SCN10A intron 24850809 rs7651106 chr3 38804341 T C 9.92E-16 P wave duration SCN10A intron 24850809 rs6599257 chr3 38804588 C T 8.20E-14 Electrocardiographic traits SCN10A intron 20062061 rs6599257 chr3 38804588 C T 1.01E-14 Brugada syndrome SCN10A intron 23872634 rs6599257 chr3 38804588 C T 8.93E-15 P wave duration SCN10A intron 24850809 rs7610489 chr3 38806478 A G 8.37E-15 P wave duration SCN10A intron 24850809 rs7650384 chr3 38806511 C T 8.49E-15 P wave duration SCN10A intron 24850809 rs10212338 chr3 38812650 G A 2.20E-14 P wave duration SCN10A intron 24850809 rs11717455 chr3 38843647 T C 7.00E-06 Systemic lupus erythematosus / / 23273568 rs11717588 chr3 38853160 C T 7.74E-04 Type 2 diabetes / / 17463246 rs4453791 chr3 38882519 T C 9.00E-09 Social communication problems / / 24564958 rs3923518 chr3 38886413 C A 8.00E-06 Migraine / / 23793025 rs6776510 chr3 38887253 C T 6.41E-04 Smoking initiation / / 24665060 rs4481097 chr3 38909570 T C 4.58E-04 Type 2 diabetes SCN11A intron 17463246 rs4676588 chr3 38940741 C T 4.31E-04 Multiple complex diseases SCN11A intron 17554300 rs4676588 chr3 38940741 C T 9.55E-06 Left ventricular hypertrophy SCN11A intron pha003052 rs11716902 chr3 38958010 G T 6.09E-06 Left ventricular hypertrophy SCN11A intron pha003052 rs7636049 chr3 38972592 C T 8.01E-05 Cognitive performance SCN11A intron 19734545 rs4491835 chr3 39005889 T C 4.78E-04 Ankylosing spondylitis / / 22138694 rs883565 chr3 39055317 C T 3.00E-07 Handedness / / 24065183 rs144954527 chr3 39118649 C T 0.00087 Prostate cancer WDR48 missense 23555315 rs2370860 chr3 39127685 T C 8.96E-30 Narcolepsy WDR48 intron 19629137 rs784490 chr3 39173530 A G 2.80E-05 Kidney function and endocine traits TTC21A intron 17903292 rs784498 chr3 39180099 T C 1.04E-11 Lymphocyte counts TTC21A cds-synon 22286170 rs17735402 chr3 39205176 C T 2.26E-05 Diabetes Mellitus / / pha003059 rs4676609 chr3 39214256 C T 8.90E-05 Cognitive test performance / / 20125193 rs11129816 chr3 39229044 C T 5.25E-04 Amyotrophic lateral sclerosis (sporadic) XIRP1 cds-synon 24529757 rs17729892 chr3 39234170 G A 6.43E-05 Diabetes Mellitus / / pha003059 rs7622284 chr3 39240559 T C 2.67E-05 Multiple complex diseases / / 17554300 rs2137581 chr3 39246142 T G 6.09E-04 Obesity (extreme) LOC729454 intron 21935397 rs12637451 chr3 39247658 G C 1.90E-04 Alzheimer's disease LOC729454 intron 22005930 rs12632771 chr3 39248852 A G 2.43E-05 Celiac disease LOC729454 intron 23936387 rs9809830 chr3 39251141 C G 1.45E-04 Alzheimer's disease LOC729454 intron 22005930 rs12636775 chr3 39254384 A G 2.17E-04 Alzheimer's disease LOC729454 intron 22005930 rs11720021 chr3 39254755 G A 7.82E-04 Obesity (extreme) LOC729454 intron 21935397 rs11707681 chr3 39257892 C T 8.38E-04 Obesity (extreme) / / 21935397 rs4314106 chr3 39265616 C T 3.56E-04 Alzheimer's disease / / 22005930 rs1913242 chr3 39265933 G T 2.84E-04 Alzheimer's disease / / 22005930 rs1344220 chr3 39266121 C T 1.50E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9833185 chr3 39266199 C T 5.64E-04 Alzheimer's disease / / 22005930 rs4676487 chr3 39303147 T C 4.16E-05 Tunica Media / / pha003038 rs17038645 chr3 39304570 G A 5.16E-04 Multiple complex diseases CX3CR1 nearGene-3 17554300 rs13088991 chr3 39310269 T C 2.12E-05 Tunica Media CX3CR1 intron pha003038 rs2853711 chr3 39318797 G T 0.00048 Coronary artery calcification CX3CR1 intron 23727086 rs9825782 chr3 39334720 C T 2.50E-05 Orofacial clefts / / 22419666 rs12107527 chr3 39369682 C T 2.37E-05 Osteoarthritis (knee and hip) / / 21177295 rs12107527 chr3 39369682 C T 5.83E-06 Osteoarthritis (knee and hip) / / 21177295 rs2201965 chr3 39388280 G A 4.48E-04 Iron levels / / pha002876 rs4464383 chr3 39444870 C G 7.86E-05 Multiple complex diseases / / 17554300 rs6806372 chr3 39445780 C T 6.05E-05 Multiple complex diseases / / 17554300 rs12638378 chr3 39455315 G A 1.01E-04 Multiple complex diseases / / 17554300 rs12638341 chr3 39455354 C T 1.04E-04 Multiple complex diseases / / 17554300 rs4676495 chr3 39457861 G T 8.41E-04 Alzheimer's disease / / 24755620 rs2039845 chr3 39463986 A G 3.69E-05 Multiple complex diseases / / 17554300 rs953275 chr3 39465777 A T 2.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10510701 chr3 39466445 C T 3.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1009966 chr3 39473591 A G 2.13E-04 Multiple complex diseases / / 17554300 rs17038828 chr3 39475342 C T 8.00E-06 IgG glycosylation / / 23382691 rs9820623 chr3 39493858 G T 8.98E-04 Multiple complex diseases / / 17554300 rs13092508 chr3 39507945 A G 7.18E-04 Alzheimer's disease / / 17998437 rs538867 chr3 39513278 C T 1.00E-07 Alzheimer's disease (cognitive decline) MOBP intron 23535033 rs1768208 chr3 39523003 T C 5.00E-17 Progressive supranuclear palsy MOBP intron 21685912 rs1707957 chr3 39523491 C A 1.16E-09 Non-obstructive azoospermia MOBP intron 22197933 rs1609647 chr3 39533071 C T 9.79E-04 Multiple complex diseases MOBP intron 17554300 rs526446 chr3 39545772 G A 5.64E-06 Cognitive performance MOBP intron 19734545 rs666534 chr3 39545934 G T 3.85E-04 Multiple complex diseases MOBP intron 17554300 rs816488 chr3 39553788 C T 4.00E-06 Cognitive performance MOBP intron 19734545 rs864643 chr3 39555580 A G 1.00E-08 Attention deficit hyperactivity disorder MOBP UTR-3 18839057 rs1768172 chr3 39640587 G T 8.73E-04 Aortic root size / / 21223598 rs4296532 chr3 39707198 A G 2.05E-04 Multiple complex diseases / / 17554300 rs9832461 chr3 39749593 A G 3.72E-06 Temporal lobe volumes / / 20197096 rs9832461 chr3 39749593 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1527566 chr3 39772451 A G 2.32E-06 Temporal lobe volumes / / 20197096 rs1527566 chr3 39772451 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs376566053 chr3 39796726 GCTTCA G 2.90E-06 Temporal lobe volumes / / 20197096 rs376566053 chr3 39796726 GCTTCA G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9878556 chr3 39796726 G T 2.90E-06 Temporal lobe volumes / / 20197096 rs9878556 chr3 39796726 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4676517 chr3 39812292 C T 2.40E-05 Urinary metabolites / / 21572414 rs13086503 chr3 39837709 G T 5.68E-04 Acute lung injury / / 22295056 rs17079534 chr3 39847072 G A 2.00E-07 Acute lymphoblastic leukemia (childhood) / / 23007406 rs1599903 chr3 39955066 A C 5.42E-05 Nicotine smoking MYRIP intron 19268276 rs9831761 chr3 39967902 G A 3.81E-05 Coronary Artery Disease MYRIP intron 17634449 rs1598994 chr3 39975762 T G 1.03E-04 Nicotine smoking MYRIP intron 19268276 rs1304138 chr3 40004366 G A 2.40E-05 Urinary metabolites MYRIP intron 21572414 rs9985399 chr3 40008634 T C 9.00E-06 Information processing speed MYRIP intron 21130836 rs13085835 chr3 40020555 A G 3.90E-05 Kawasaki disease MYRIP intron 22446962 rs4676548 chr3 40025296 C T 3.80E-05 Kawasaki disease MYRIP intron 22446962 rs6791790 chr3 40050275 G A 4.66E-05 Hemoglobin concentration MYRIP intron 20534544 rs6791790 chr3 40050275 G A 9.82E-06 Information processing speed MYRIP intron 21130836 rs2067773 chr3 40058331 C T 3.60E-05 Kawasaki disease MYRIP intron 22446962 rs7632391 chr3 40080544 A G 4.42E-04 Hemoglobin concentration MYRIP intron 20534544 rs6599077 chr3 40096618 G A 1.00E-07 Sleep duration MYRIP intron 17903308 rs2679824 chr3 40168322 G C 1.21E-06 Schizophrenia MYRIP intron 22037555 rs9878321 chr3 40174858 A G 7.15E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) MYRIP intron 23648065 rs4132209 chr3 40185635 C T 4.14E-04 Multiple complex diseases MYRIP intron 17554300 rs1799428 chr3 40188011 C T 5.38E-06 Schizophrenia MYRIP intron 22037555 rs2679807 chr3 40195206 G T 7.59E-04 Multiple complex diseases MYRIP intron 17554300 rs1714414 chr3 40204178 T C 7.04E-04 Multiple complex diseases MYRIP intron 17554300 rs11714144 chr3 40219170 A G 5.76E-04 Type 2 diabetes MYRIP intron 17463246 rs2371176 chr3 40226685 C A 8.95E-05 Body Composition MYRIP intron pha003012 rs2371176 chr3 40226685 C A 8.72E-05 Body Mass Index MYRIP intron pha003021 rs1574138 chr3 40232469 G T 1.75E-05 Body Composition MYRIP intron pha003012 rs1574138 chr3 40232469 G T 2.73E-05 Body Mass Index MYRIP intron pha003021 rs2261542 chr3 40234083 A G 1.26E-05 Body Composition MYRIP intron pha003012 rs2261542 chr3 40234083 A G 1.94E-05 Body Mass Index MYRIP intron pha003021 rs2679813 chr3 40234623 G A 1.70E-05 Body Composition MYRIP intron pha003012 rs2679813 chr3 40234623 G A 2.64E-05 Body Mass Index MYRIP intron pha003021 rs2679814 chr3 40235264 T C 1.26E-05 Body Composition MYRIP intron pha003012 rs2679814 chr3 40235264 T C 1.94E-05 Body Mass Index MYRIP intron pha003021 rs2887962 chr3 40235522 C T 7.93E-05 Body Composition MYRIP intron pha003012 rs17076767 chr3 40248826 G A 6.91E-04 Multiple complex diseases MYRIP intron 17554300 rs2679798 chr3 40251282 G A 9.29E-04 Insulin resistance MYRIP intron 21901158 rs2679822 chr3 40267321 T C 6.76E-05 Epilepsy MYRIP intron 22116939 rs6599081 chr3 40273500 A G 1.28E-04 Hemoglobin concentration MYRIP intron 20534544 rs6599081 chr3 40273500 A G 1.29E-05 Epilepsy MYRIP intron 22116939 rs2371136 chr3 40275655 C T 1.28E-04 Hemoglobin concentration MYRIP intron 20534544 rs2371136 chr3 40275655 C T 1.29E-05 Epilepsy MYRIP intron 22116939 rs7639223 chr3 40285160 G A 1.16E-04 Amyotrophic lateral sclerosis (sporadic) MYRIP intron 24529757 rs11129874 chr3 40326165 C T 8.30E-05 Age-related macular degeneration FLJ33065 intron 20861866 rs7644643 chr3 40350209 A G 7.98E-04 Type 2 diabetes FLJ33065 intron 17463246 rs6805026 chr3 40366460 T C 3.35E-05 Multiple complex diseases / / 17554300 rs4974067 chr3 40374551 C T 2.80E-05 Urinary metabolites / / 21572414 rs10865895 chr3 40378677 C T 2.70E-05 Urinary metabolites / / 21572414 rs6599094 chr3 40399593 T C 2.40E-05 Urinary metabolites / / 21572414 rs11129876 chr3 40401636 A G 1.90E-05 Urinary metabolites / / 21572414 rs9842564 chr3 40405810 C T 9.24E-05 Serum metabolites / / 19043545 rs7615540 chr3 40411129 A G 9.93E-06 Multiple complex diseases / / 17554300 rs7631893 chr3 40440869 T C 4.34E-05 Serum metabolites ENTPD3 intron 19043545 rs1037516 chr3 40441280 T G 3.99E-04 Amyotrophic lateral sclerosis (sporadic) ENTPD3 intron 24529757 rs7625736 chr3 40441345 G C 6.13E-05 Serum metabolites ENTPD3 intron 19043545 rs17078914 chr3 40445118 A G 9.42E-05 Hemoglobin concentration ENTPD3 intron 20534544 rs6599101 chr3 40447548 G A 3.09E-04 Multiple complex diseases ENTPD3 intron 17554300 rs17078941 chr3 40450888 C T 1.50E-05 Urinary metabolites ENTPD3 intron 21572414 rs17078941 chr3 40450888 C T 2.58E-24 Lymphocyte counts ENTPD3 intron 22286170 rs7648952 chr3 40457038 T C 2.90E-05 Urinary metabolites ENTPD3 intron 21572414 rs9822909 chr3 40457084 C A 1.80E-05 Urinary metabolites ENTPD3 intron 21572414 rs9332450 chr3 40458041 T C 2.90E-05 Urinary metabolites ENTPD3 intron 21572414 rs4973898 chr3 40459532 A G 3.49E-05 Serum metabolites ENTPD3 intron 19043545 rs1047855 chr3 40468896 C T 2.30E-05 Urinary metabolites ENTPD3 missense 21572414 rs11707278 chr3 40487075 T A 9.87E-05 Serum metabolites ENTPD3-AS1 intron 19043545 rs11707278 chr3 40487075 T A 2.40E-05 Urinary metabolites ENTPD3-AS1 intron 21572414 rs6801859 chr3 40493218 G T 2.84E-05 Serum metabolites / / 19043545 rs9968170 chr3 40494274 T C 1.78E-05 Serum metabolites ENTPD3-AS1 intron 19043545 rs2276871 chr3 40499273 A G 3.44E-05 Serum metabolites RPL14 intron 19043545 rs4974031 chr3 40562981 C T 7.07E-04 Smoking cessation / / 24665060 rs3924444 chr3 40576061 T C 6.55E-04 Smoking cessation ZNF621 UTR-3 24665060 rs9844316 chr3 40597520 T C 3.91E-04 Hemoglobin concentration / / 20534544 rs12491211 chr3 40613519 A G 9.57E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6774841 chr3 40617539 C T 4.91E-04 Smoking initiation / / 24665060 rs6599111 chr3 40631348 A G 7.53E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4974049 chr3 40807501 A G 7.08E-05 Type 2 diabetes / / 17463246 rs586287 chr3 40892119 C A 7.90E-04 Alzheimer's disease / / 17998437 rs17051601 chr3 40911348 G A 9.12E-04 Depression (quantitative trait) / / 20800221 rs9311253 chr3 40920689 C T 1.18E-05 Cognitive performance / / 19734545 rs7629386 chr3 40966907 C T 2.28E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs11721013 chr3 41025765 C T 7.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs6802072 chr3 41027680 T C 1.01E-04 Type 2 diabetes / / 17463246 rs11708803 chr3 41029087 G A 7.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs4130762 chr3 41037669 C T 3.30E-04 Schizophrenia / / 19197363 rs4459874 chr3 41066221 G A 2.63E-04 Multiple complex diseases / / 17554300 rs1544887 chr3 41066528 G A 7.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1544887 chr3 41066528 G A 8.16E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs408499 chr3 41093575 A G 0.000617387 Hypertension (early onset hypertension) / / 22479346 rs6788984 chr3 41107173 A G 5.84E-05 Cognitive test performance / / 20125193 rs416183 chr3 41113201 T C 7.61E-04 Type 2 diabetes / / 17463246 rs416183 chr3 41113201 T C 7.55E-05 Lymphocyte counts / / 22286170 rs10490823 chr3 41123735 C T 9.00E-06 Bone mineral density (hip) / / 19079262 rs12634519 chr3 41127360 G A 9.90E-04 Multiple complex diseases / / 17554300 rs430727 chr3 41128564 T C 4.00E-25 Bone mineral density / / 22504420 rs430727 chr3 41128564 T C 3.15E-04 Bone mineral density / / 24249740 rs430727 chr3 41128564 T C 6.53E-04 Bone mineral density (paediatric,total body less head) / / 24945404 rs450615 chr3 41133610 G A 2.10E-05 Bone mineral density (spine) / / 19079262 rs87938 chr3 41137672 A G 8.00E-10 Bone mineral density (hip) / / 19801982 rs13314643 chr3 41139829 C T 7.18E-05 Multiple complex diseases / / 17554300 rs4437116 chr3 41161343 C T 2.39E-04 Bone mineral density / / 24249740 rs433879 chr3 41163296 C G 5.82E-04 Multiple complex diseases / / 17554300 rs7648547 chr3 41188000 A C 4.45E-05 Serum metabolites / / 19043545 rs2691678 chr3 41230323 A G 2.77E-04 Alcohol dependence / / 20201924 rs13072632 chr3 41262444 T C 8.85E-04 Multiple complex diseases CTNNB1 intron 17554300 rs10510717 chr3 41332490 T C 5.00E-05 Volumetric brain MRI ULK4 intron 17903297 rs1487569 chr3 41368428 C T 9.44E-05 Coronary Artery Disease ULK4 intron 17634449 rs9311269 chr3 41374621 T C 2.19E-04 Coronary Artery Disease ULK4 intron 17634449 rs9311269 chr3 41374621 T C 2.62E-05 Statin-induced myopathy ULK4 intron 21826682 rs11915888 chr3 41453936 A G 9.50E-04 Coronary heart disease ULK4 intron 21606135 rs9872216 chr3 41458638 T C 4.39E-04 Coronary heart disease ULK4 intron 21606135 rs17057270 chr3 41477890 T C 1.10E-05 Eosinophil counts ULK4 intron pha003088 rs10446425 chr3 41484831 C A 3.40E-06 Alcohol dependence ULK4 intron 22096494 rs10446425 chr3 41484831 C A 8.30E-06 Alcohol and nictotine co-dependence ULK4 intron 22488850 rs1495692 chr3 41485477 T C 4.32E-05 Substance dependence ULK4 intron 21818250 rs2643976 chr3 41541841 A G 8.39E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs2643977 chr3 41541987 C T 7.98E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs1691983 chr3 41542342 G A 7.95E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs4258937 chr3 41544423 G A 7.88E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs9831248 chr3 41549933 C G 7.72E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs1256396 chr3 41551051 A T 7.70E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs2017454 chr3 41555563 A G 7.67E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs1631168 chr3 41559614 A C 7.55E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs1495693 chr3 41560092 C T 7.54E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs1795312 chr3 41560382 A T 7.53E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs1565960 chr3 41567692 A G 7.48E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs7624356 chr3 41570772 A G 2.61E-05 Intelligence ULK4 intron 21826061 rs4580521 chr3 41576183 A C 6.51E-05 Intelligence ULK4 intron 21826061 rs1629284 chr3 41586308 C G 4.89E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs3897976 chr3 41606692 G A 8.24E-05 Body mass index ULK4 intron 22446040 rs3897976 chr3 41606692 G A 1.62E-05 Tunica Media ULK4 intron pha003038 rs7627367 chr3 41611228 T G 8.38E-07 Intelligence ULK4 intron 21826061 rs1256388 chr3 41613317 T C 3.19E-04 Gallstones ULK4 intron 17632509 rs17058895 chr3 41615845 T G 2.30E-05 Urinary metabolites ULK4 intron 21572414 rs17059208 chr3 41636664 C G 1.24E-04 Suicide attempts in bipolar disorder ULK4 intron 21041247 rs9941986 chr3 41638274 T C 4.00E-05 Temporomandibular joint disorders ULK4 intron 23746317 rs6599167 chr3 41750260 A G 5.27E-08 Multiple myeloma ULK4 intron 22120009 rs6599168 chr3 41750323 T C 5.26E-08 Multiple myeloma ULK4 intron 22120009 rs6771928 chr3 41750973 G A 5.31E-08 Multiple myeloma ULK4 intron 22120009 rs6763508 chr3 41750989 T C 5.32E-08 Multiple myeloma ULK4 intron 22120009 rs6809328 chr3 41751005 A C 5.29E-08 Multiple myeloma ULK4 intron 22120009 rs6794074 chr3 41751147 A G 5.27E-08 Multiple myeloma ULK4 intron 22120009 rs6794211 chr3 41751324 A T 5.32E-08 Multiple myeloma ULK4 intron 22120009 rs6781529 chr3 41751333 C T 5.33E-08 Multiple myeloma ULK4 intron 22120009 rs73069356 chr3 41752845 G A 1.20E-07 Multiple myeloma ULK4 intron 22120009 rs73069357 chr3 41753319 T G 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs9848754 chr3 41753647 C T 5.47E-08 Multiple myeloma ULK4 intron 22120009 rs4616614 chr3 41753648 T G 5.46E-08 Multiple myeloma ULK4 intron 22120009 rs4408846 chr3 41753679 A G 5.46E-08 Multiple myeloma ULK4 intron 22120009 rs1025646 chr3 41754422 A T 5.54E-08 Multiple myeloma ULK4 intron 22120009 rs6807015 chr3 41754514 T C 5.54E-08 Multiple myeloma ULK4 intron 22120009 rs9847006 chr3 41755359 T C 3.15E-08 Multiple myeloma ULK4 intron 22120009 rs9869282 chr3 41756064 A G 5.66E-08 Multiple myeloma ULK4 intron 22120009 rs61744388 chr3 41756965 C T 5.72E-08 Multiple myeloma ULK4 missense 22120009 rs61744385 chr3 41756986 A T 5.73E-08 Multiple myeloma ULK4 missense 22120009 rs9866759 chr3 41758418 T C 5.78E-08 Multiple myeloma ULK4 intron 22120009 rs17060938 chr3 41759191 T C 5.85E-08 Multiple myeloma ULK4 intron 22120009 rs9852303 chr3 41759525 C T 4.79E-08 Multiple myeloma ULK4 intron 22120009 rs11923562 chr3 41760331 G T 5.88E-08 Multiple myeloma ULK4 intron 22120009 rs3890604 chr3 41760625 C T 4.91E-08 Multiple myeloma ULK4 intron 22120009 rs1125203 chr3 41760895 T C 1.27E-07 Multiple myeloma ULK4 intron 22120009 rs1125203 chr3 41760895 T C 6.00E-10 Multiple myeloma ULK4 intron 23955597 rs2371623 chr3 41761083 T C 5.92E-08 Multiple myeloma ULK4 intron 22120009 rs9825741 chr3 41761828 A T 5.01E-08 Multiple myeloma ULK4 intron 22120009 rs9863915 chr3 41762002 G A 5.92E-08 Multiple myeloma ULK4 intron 22120009 rs9826058 chr3 41762062 A G 5.89E-08 Multiple myeloma ULK4 intron 22120009 rs9864217 chr3 41762206 G A 5.92E-08 Multiple myeloma ULK4 intron 22120009 rs9864331 chr3 41762217 G A 5.92E-08 Multiple myeloma ULK4 intron 22120009 rs9830469 chr3 41762535 A G 5.93E-08 Multiple myeloma ULK4 intron 22120009 rs55835726 chr3 41763049 C A,G,T 5.95E-08 Multiple myeloma ULK4 intron 22120009 rs9869440 chr3 41763155 G C 5.96E-08 Multiple myeloma ULK4 intron 22120009 rs9874975 chr3 41764300 G A 5.41E-08 Multiple myeloma ULK4 intron 22120009 rs7651190 chr3 41765955 A G 6.23E-08 Multiple myeloma ULK4 intron 22120009 rs9882329 chr3 41767154 T C 6.24E-08 Multiple myeloma ULK4 intron 22120009 rs6801343 chr3 41767234 C T 6.24E-08 Multiple myeloma ULK4 intron 22120009 rs6778699 chr3 41770835 T C 2.86E-04 Multiple complex diseases ULK4 intron 17554300 rs73069380 chr3 41771177 C T 3.35E-04 Multiple myeloma ULK4 intron 22120009 rs6599170 chr3 41772718 C G 6.28E-08 Multiple myeloma ULK4 intron 22120009 rs28755797 chr3 41774446 C T 6.44E-08 Multiple myeloma ULK4 intron 22120009 rs9854833 chr3 41775577 C T 5.92E-08 Multiple myeloma ULK4 intron 22120009 rs9875083 chr3 41775786 T A 6.84E-08 Multiple myeloma ULK4 intron 22120009 rs6789260 chr3 41776350 G C 7.77E-08 Multiple myeloma ULK4 intron 22120009 rs6781326 chr3 41777028 T C 7.76E-08 Multiple myeloma ULK4 intron 22120009 rs73069390 chr3 41785513 C T 1.09E-07 Multiple myeloma ULK4 intron 22120009 rs6599175 chr3 41786009 T C 8.85E-08 Multiple myeloma ULK4 intron 22120009 rs6599175 chr3 41786009 T C 1.00E-09 Multiple myeloma (hyperdiploidy) ULK4 intron 23502783 rs6599175 chr3 41786009 T C 3.00E-10 Multiple myeloma ULK4 intron 23955597 rs9847975 chr3 41786904 A G 8.08E-08 Multiple myeloma ULK4 intron 22120009 rs73069392 chr3 41787009 C T 8.07E-08 Multiple myeloma ULK4 intron 22120009 rs73069394 chr3 41787233 G A 8.00E-08 Multiple myeloma ULK4 intron 22120009 rs73069396 chr3 41787236 A T 8.00E-08 Multiple myeloma ULK4 intron 22120009 rs6599176 chr3 41788492 T G 7.73E-08 Multiple myeloma ULK4 intron 22120009 rs17061431 chr3 41792655 T C 6.89E-08 Multiple myeloma ULK4 intron 22120009 rs9868066 chr3 41794161 T A 6.62E-08 Multiple myeloma ULK4 intron 22120009 rs7650227 chr3 41794937 T G 6.49E-08 Multiple myeloma ULK4 intron 22120009 rs9867627 chr3 41795841 A C,G,T 7.73E-08 Multiple myeloma ULK4 intron 22120009 rs73071304 chr3 41797504 G C 8.22E-08 Multiple myeloma ULK4 intron 22120009 rs57479675 chr3 41798038 C T 5.98E-08 Multiple myeloma ULK4 intron 22120009 rs73071307 chr3 41798699 T C 8.00E-08 Multiple myeloma ULK4 intron 22120009 rs7616123 chr3 41798941 A G 7.96E-08 Multiple myeloma ULK4 intron 22120009 rs76471037 chr3 41799414 T C 5.80E-08 Multiple myeloma ULK4 intron 22120009 rs9311288 chr3 41804581 C G 5.10E-08 Multiple myeloma ULK4 intron 22120009 rs55748698 chr3 41805233 G A 6.92E-08 Multiple myeloma ULK4 intron 22120009 rs9854838 chr3 41805670 C A 4.97E-08 Multiple myeloma ULK4 intron 22120009 rs73071315 chr3 41805887 T C 6.83E-08 Multiple myeloma ULK4 intron 22120009 rs17280777 chr3 41806167 C T 6.79E-08 Multiple myeloma ULK4 intron 22120009 rs111304140 chr3 41806492 G A 6.75E-08 Multiple myeloma ULK4 intron 22120009 rs113874002 chr3 41806714 A G 6.71E-08 Multiple myeloma ULK4 intron 22120009 rs201957963 chr3 41807448 C CAT 4.77E-08 Multiple myeloma ULK4 intron 22120009 rs9865127 chr3 41807448 C T 4.77E-08 Multiple myeloma ULK4 intron 22120009 rs17214945 chr3 41808660 T G 2.83E-08 Multiple myeloma ULK4 intron 22120009 rs59583650 chr3 41809063 A G 6.40E-08 Multiple myeloma ULK4 intron 22120009 rs57638657 chr3 41809238 G C 7.04E-08 Multiple myeloma ULK4 intron 22120009 rs111708447 chr3 41809583 G A 6.32E-08 Multiple myeloma ULK4 intron 22120009 rs73071325 chr3 41809989 T G 6.28E-08 Multiple myeloma ULK4 intron 22120009 rs73071328 chr3 41810055 A C 6.27E-08 Multiple myeloma ULK4 intron 22120009 rs73828254 chr3 41810180 T A 6.26E-08 Multiple myeloma ULK4 intron 22120009 rs17062109 chr3 41810364 C A,T 2.97E-08 Multiple myeloma ULK4 intron 22120009 rs17214987 chr3 41810481 A G 6.22E-08 Multiple myeloma ULK4 intron 22120009 rs73071329 chr3 41810539 G A 4.45E-08 Multiple myeloma ULK4 intron 22120009 rs73071330 chr3 41810553 T G 6.22E-08 Multiple myeloma ULK4 intron 22120009 rs17280952 chr3 41810834 T C 6.19E-08 Multiple myeloma ULK4 intron 22120009 rs17280980 chr3 41810949 A T 6.18E-08 Multiple myeloma ULK4 intron 22120009 rs9832037 chr3 41812032 T C 4.35E-08 Multiple myeloma ULK4 intron 22120009 rs55744136 chr3 41812293 A C 7.00E-07 Multiple myeloma ULK4 intron 22120009 rs59432762 chr3 41812294 G C 7.00E-07 Multiple myeloma ULK4 intron 22120009 rs17215183 chr3 41812334 T C 2.87E-08 Multiple myeloma ULK4 intron 22120009 rs60764195 chr3 41812522 G C 6.06E-08 Multiple myeloma ULK4 intron 22120009 rs9837273 chr3 41813104 T C 4.30E-08 Multiple myeloma ULK4 intron 22120009 rs9817510 chr3 41813108 C T 4.30E-08 Multiple myeloma ULK4 intron 22120009 rs7631914 chr3 41813557 T C 4.27E-08 Multiple myeloma ULK4 intron 22120009 rs10452020 chr3 41815951 A C 4.15E-08 Multiple myeloma ULK4 intron 22120009 rs10452022 chr3 41816042 G A 4.61E-07 Multiple myeloma ULK4 intron 22120009 rs113722150 chr3 41816541 A T 6.33E-08 Multiple myeloma ULK4 intron 22120009 rs111877184 chr3 41816673 G C 4.12E-08 Multiple myeloma ULK4 intron 22120009 rs17281182 chr3 41817263 C T 5.68E-08 Multiple myeloma ULK4 intron 22120009 rs73071337 chr3 41822518 G C 5.91E-08 Multiple myeloma ULK4 intron 22120009 rs114034165 chr3 41823297 G A 5.30E-08 Multiple myeloma ULK4 intron 22120009 rs112071272 chr3 41823363 G A 5.86E-08 Multiple myeloma ULK4 intron 22120009 rs73071338 chr3 41824328 G A 5.25E-08 Multiple myeloma ULK4 intron 22120009 rs6803652 chr3 41824556 A G 3.18E-08 Multiple myeloma ULK4 intron 22120009 rs73071341 chr3 41826211 C T 4.71E-08 Multiple myeloma ULK4 intron 22120009 rs10212536 chr3 41827026 A G 3.57E-08 Multiple myeloma ULK4 intron 22120009 rs73071344 chr3 41827062 C T 4.55E-08 Multiple myeloma ULK4 intron 22120009 rs58442057 chr3 41827209 G A 4.58E-08 Multiple myeloma ULK4 intron 22120009 rs9840037 chr3 41827522 C T 3.39E-08 Multiple myeloma ULK4 intron 22120009 rs73071352 chr3 41828300 A G 4.82E-08 Multiple myeloma ULK4 intron 22120009 rs73071354 chr3 41829186 C A 5.42E-08 Multiple myeloma ULK4 intron 22120009 rs73071356 chr3 41829486 C T 6.12E-08 Multiple myeloma ULK4 intron 22120009 rs17215498 chr3 41829679 G C 6.72E-08 Multiple myeloma ULK4 intron 22120009 rs9852020 chr3 41830206 G A,T 4.78E-08 Multiple myeloma ULK4 intron 22120009 rs73071358 chr3 41830487 G A 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs17215589 chr3 41831203 C T 1.39E-07 Multiple myeloma ULK4 missense 22120009 rs17215589 chr3 41831203 C T 2.00E-09 Multiple myeloma ULK4 missense 23955597 rs10510729 chr3 41831998 G A 7.36E-08 Multiple myeloma ULK4 intron 22120009 rs17281609 chr3 41833432 G A 7.36E-08 Multiple myeloma ULK4 intron 22120009 rs9834098 chr3 41833493 A G 5.01E-08 Multiple myeloma ULK4 intron 22120009 rs73828280 chr3 41833907 A T 7.35E-08 Multiple myeloma ULK4 intron 22120009 rs73073323 chr3 41834051 C T 7.35E-08 Multiple myeloma ULK4 intron 22120009 rs73073326 chr3 41834195 G T 7.35E-08 Multiple myeloma ULK4 intron 22120009 rs12185908 chr3 41834492 A C 8.29E-08 Multiple myeloma ULK4 intron 22120009 rs12186076 chr3 41834639 T C 5.01E-08 Multiple myeloma ULK4 intron 22120009 rs73828283 chr3 41835099 T C 7.36E-08 Multiple myeloma ULK4 intron 22120009 rs112265441 chr3 41836068 G A 7.36E-08 Multiple myeloma ULK4 intron 22120009 rs12185934 chr3 41836558 A C 7.35E-08 Multiple myeloma ULK4 intron 22120009 rs12186050 chr3 41836879 G C 7.35E-08 Multiple myeloma ULK4 intron 22120009 rs12186051 chr3 41836919 G A 7.35E-08 Multiple myeloma ULK4 intron 22120009 rs12186109 chr3 41836920 T C 7.35E-08 Multiple myeloma ULK4 intron 22120009 rs73073337 chr3 41837497 T C 7.35E-08 Multiple myeloma ULK4 intron 22120009 rs766286 chr3 41838329 G A 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs11129932 chr3 41838767 C A 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs2371627 chr3 41839219 A G 5.05E-08 Multiple myeloma ULK4 intron 22120009 rs4621303 chr3 41839370 T A 5.05E-08 Multiple myeloma ULK4 intron 22120009 rs73073342 chr3 41839455 A C 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs58360908 chr3 41839837 A G 8.29E-08 Multiple myeloma ULK4 intron 22120009 rs57809229 chr3 41840162 G A 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs6776724 chr3 41841270 A G 5.06E-08 Multiple myeloma ULK4 intron 22120009 rs17215883 chr3 41841873 C T 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs6599178 chr3 41842129 C T 5.06E-08 Multiple myeloma ULK4 intron 22120009 rs73073352 chr3 41842184 T C 7.33E-08 Multiple myeloma ULK4 intron 22120009 rs73073355 chr3 41842332 G A 7.33E-08 Multiple myeloma ULK4 intron 22120009 rs7626217 chr3 41842415 A G 5.07E-08 Multiple myeloma ULK4 intron 22120009 rs73073358 chr3 41842527 G A 8.28E-08 Multiple myeloma ULK4 intron 22120009 rs73073361 chr3 41842926 C G 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs73073364 chr3 41843058 T C 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs73073368 chr3 41843391 A G 5.08E-08 Multiple myeloma ULK4 intron 22120009 rs73073371 chr3 41843443 A G 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs57525756 chr3 41843591 A C 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs56194645 chr3 41843593 T C 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs55788971 chr3 41843965 T A 7.34E-08 Multiple myeloma ULK4 intron 22120009 rs60927633 chr3 41844010 C T 7.33E-08 Multiple myeloma ULK4 intron 22120009 rs111520733 chr3 41844612 A G 3.78E-06 Multiple myeloma ULK4 intron 22120009 rs6793567 chr3 41845547 T A,C 7.32E-08 Multiple myeloma ULK4 intron 22120009 rs78863838 chr3 41845597 C G 1.74E-04 Multiple myeloma ULK4 intron 22120009 rs56183581 chr3 41848492 C T 7.32E-08 Multiple myeloma ULK4 intron 22120009 rs55682201 chr3 41848497 A G 7.32E-08 Multiple myeloma ULK4 intron 22120009 rs7647561 chr3 41848627 T A 7.32E-08 Multiple myeloma ULK4 intron 22120009 rs10510730 chr3 41849013 C G 2.99E-06 Multiple myeloma ULK4 intron 22120009 rs55916959 chr3 41849130 G A 7.31E-08 Multiple myeloma ULK4 intron 22120009 rs7648357 chr3 41849670 A G 5.14E-08 Multiple myeloma ULK4 intron 22120009 rs73077358 chr3 41850005 C T 7.29E-08 Multiple myeloma ULK4 intron 22120009 rs73077359 chr3 41850016 G A 7.29E-08 Multiple myeloma ULK4 intron 22120009 rs73077360 chr3 41850054 C T 7.28E-08 Multiple myeloma ULK4 intron 22120009 rs73077361 chr3 41850146 G A 7.28E-08 Multiple myeloma ULK4 intron 22120009 rs113683976 chr3 41850685 A C 7.16E-07 Multiple myeloma ULK4 intron 22120009 rs17215988 chr3 41851320 A C 7.21E-08 Multiple myeloma ULK4 intron 22120009 rs17063297 chr3 41851509 C G 8.49E-04 Multiple complex diseases ULK4 intron 17554300 rs73077365 chr3 41851559 T C 7.11E-08 Multiple myeloma ULK4 intron 22120009 rs6796210 chr3 41851718 T C 7.70E-08 Multiple myeloma ULK4 intron 22120009 rs73077367 chr3 41851959 G A 6.62E-08 Multiple myeloma ULK4 intron 22120009 rs60943892 chr3 41852307 T C 7.04E-08 Multiple myeloma ULK4 intron 22120009 rs73077373 chr3 41852887 C T 7.03E-08 Multiple myeloma ULK4 intron 22120009 rs73077375 chr3 41853058 C T 7.80E-08 Multiple myeloma ULK4 intron 22120009 rs7646144 chr3 41853125 T A 6.79E-08 Multiple myeloma ULK4 intron 22120009 rs7632387 chr3 41853161 C T 6.80E-08 Multiple myeloma ULK4 intron 22120009 rs10510731 chr3 41853310 C T 7.02E-08 Multiple myeloma ULK4 intron 22120009 rs61283393 chr3 41854135 T G 7.03E-08 Multiple myeloma ULK4 intron 22120009 rs57209010 chr3 41854743 A T 7.02E-08 Multiple myeloma ULK4 intron 22120009 rs6599179 chr3 41855284 C T 6.90E-08 Multiple myeloma ULK4 intron 22120009 rs73077386 chr3 41857652 A G 7.02E-08 Multiple myeloma ULK4 intron 22120009 rs7648578 chr3 41858731 C T 7.82E-08 Multiple myeloma ULK4 intron 22120009 rs73077390 chr3 41860255 T C 7.00E-08 Multiple myeloma ULK4 intron 22120009 rs9856088 chr3 41860482 G T 7.10E-08 Multiple myeloma ULK4 intron 22120009 rs9855965 chr3 41860508 C T 7.10E-08 Multiple myeloma ULK4 intron 22120009 rs9818169 chr3 41860599 A G 7.09E-08 Multiple myeloma ULK4 intron 22120009 rs12639255 chr3 41861738 T C 7.10E-08 Multiple myeloma ULK4 intron 22120009 rs6783001 chr3 41862232 C A 7.14E-08 Multiple myeloma ULK4 intron 22120009 rs6795797 chr3 41862250 A G 7.14E-08 Multiple myeloma ULK4 intron 22120009 rs73079307 chr3 41862273 A C 6.84E-08 Multiple myeloma ULK4 intron 22120009 rs1564716 chr3 41862613 A G 7.14E-08 Multiple myeloma ULK4 intron 22120009 rs2128834 chr3 41862645 A G 6.23E-08 Multiple myeloma ULK4 intron 22120009 rs2128834 chr3 41862645 A G 0.0000277 Adenoma (female) ULK4 intron 22532847 rs2128835 chr3 41862873 A G 5.79E-08 Multiple myeloma ULK4 intron 22120009 rs2128835 chr3 41862873 A G 2.00E-10 Multiple myeloma ULK4 intron 23955597 rs17063649 chr3 41863406 C T 7.14E-08 Multiple myeloma ULK4 intron 22120009 rs28733681 chr3 41863444 C A 7.14E-08 Multiple myeloma ULK4 intron 22120009 rs17063653 chr3 41863817 A G 7.14E-08 Multiple myeloma ULK4 intron 22120009 rs73079316 chr3 41863859 G A 7.14E-08 Multiple myeloma ULK4 intron 22120009 rs73079321 chr3 41863910 C T 7.14E-08 Multiple myeloma ULK4 intron 22120009 rs74482513 chr3 41864097 G C 7.14E-08 Multiple myeloma ULK4 intron 22120009 rs112059754 chr3 41864125 C A 7.14E-08 Multiple myeloma ULK4 intron 22120009 rs111465678 chr3 41864405 C A 6.81E-08 Multiple myeloma ULK4 intron 22120009 rs73079324 chr3 41864564 T C 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs73079325 chr3 41864565 G A 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs73830511 chr3 41864643 G T 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs73079327 chr3 41864697 A T 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs6790732 chr3 41864872 C T 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs6768128 chr3 41865080 G A 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs6793520 chr3 41865289 C G 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs6768438 chr3 41865355 G A 7.16E-08 Multiple myeloma ULK4 intron 22120009 rs6805880 chr3 41865397 A G 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs6768542 chr3 41865474 G A 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs6768563 chr3 41865541 G A 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs7649989 chr3 41865843 A C 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs7652541 chr3 41866093 A G 7.58E-08 Multiple myeloma ULK4 intron 22120009 rs59553563 chr3 41866599 T A 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs59248949 chr3 41866657 C T 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs59849553 chr3 41866786 G A 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs56776628 chr3 41866856 A G 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs7432737 chr3 41867859 C T 5.29E-06 Multiple myeloma ULK4 intron 22120009 rs111821658 chr3 41870466 C G 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs111634789 chr3 41871356 T C 7.18E-08 Multiple myeloma ULK4 intron 22120009 rs28642910 chr3 41871391 A G 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs28581706 chr3 41871397 A C 7.18E-08 Multiple myeloma ULK4 intron 22120009 rs113416896 chr3 41871443 G C 1.82E-04 Multiple myeloma ULK4 intron 22120009 rs28652776 chr3 41871520 A C 5.27E-06 Multiple myeloma ULK4 intron 22120009 rs9831404 chr3 41871825 T G 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs77717550 chr3 41872504 T A 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs9816560 chr3 41872527 G T 7.18E-08 Multiple myeloma ULK4 intron 22120009 rs9816772 chr3 41872877 C T 7.18E-08 Multiple myeloma ULK4 intron 22120009 rs113213296 chr3 41873097 G A 9.71E-08 Multiple myeloma ULK4 intron 22120009 rs111967505 chr3 41873157 C T 6.71E-08 Multiple myeloma ULK4 intron 22120009 rs6803198 chr3 41873778 C G 7.18E-08 Multiple myeloma ULK4 intron 22120009 rs7616844 chr3 41874343 A G 7.18E-08 Multiple myeloma ULK4 intron 22120009 rs9849393 chr3 41875369 G C 7.18E-08 Multiple myeloma ULK4 intron 22120009 rs9852991 chr3 41875455 C A 7.18E-08 Multiple myeloma ULK4 intron 22120009 rs73830516 chr3 41876056 A C,G 6.67E-08 Multiple myeloma ULK4 intron 22120009 rs73079350 chr3 41876310 C T 7.53E-08 Multiple myeloma ULK4 intron 22120009 rs967619 chr3 41876710 C G 7.53E-08 Multiple myeloma ULK4 intron 22120009 rs3774372 chr3 41877414 T C 8.00E-07 Blood pressure ULK4 missense 21909110 rs3774372 chr3 41877414 T C 9.02E-14 Systolic blood pressure ULK4 missense 21909115 rs3774372 chr3 41877414 T C 2.57E-07 Multiple myeloma ULK4 missense 22120009 rs3774372 chr3 41877414 T C 9.00E-10 Multiple myeloma ULK4 missense 23955597 rs56104136 chr3 41877853 C T 6.66E-08 Multiple myeloma ULK4 intron 22120009 rs9869207 chr3 41878661 C G 7.18E-08 Multiple myeloma ULK4 intron 22120009 rs79817383 chr3 41880766 A T 6.65E-08 Multiple myeloma ULK4 intron 22120009 rs7624372 chr3 41881107 T A 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs7622259 chr3 41881351 A T 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs9830064 chr3 41881801 T C 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs9810731 chr3 41882101 C T 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs9810865 chr3 41882147 C T 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs114960066 chr3 41882323 A G 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs113341165 chr3 41882716 C A 6.65E-08 Multiple myeloma ULK4 intron 22120009 rs114714860 chr3 41882905 G C 2.86E-06 Multiple myeloma ULK4 intron 22120009 rs113449797 chr3 41883019 A G 6.65E-08 Multiple myeloma ULK4 intron 22120009 rs113471865 chr3 41883101 C A 7.16E-08 Multiple myeloma ULK4 intron 22120009 rs55941479 chr3 41883501 A G 7.17E-08 Multiple myeloma ULK4 intron 22120009 rs58940436 chr3 41883682 T A,G 7.16E-08 Multiple myeloma ULK4 intron 22120009 rs60248638 chr3 41883692 G A 6.65E-08 Multiple myeloma ULK4 intron 22120009 rs56121764 chr3 41883975 T C 7.16E-08 Multiple myeloma ULK4 intron 22120009 rs9873207 chr3 41884750 C T 7.78E-08 Multiple myeloma ULK4 intron 22120009 rs112736802 chr3 41884867 C T 6.64E-08 Multiple myeloma ULK4 intron 22120009 rs7642083 chr3 41884899 G A 7.16E-08 Multiple myeloma ULK4 intron 22120009 rs56081180 chr3 41885239 C T 7.16E-08 Multiple myeloma ULK4 intron 22120009 rs56036624 chr3 41885339 G A 7.16E-08 Multiple myeloma ULK4 intron 22120009 rs56158380 chr3 41885588 G A 7.16E-08 Multiple myeloma ULK4 intron 22120009 rs9823027 chr3 41885655 T C 7.16E-08 Multiple myeloma ULK4 intron 22120009 rs9840532 chr3 41885697 A G 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs11928580 chr3 41885722 C T 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs11917248 chr3 41885723 T C 7.15E-08 Multiple myeloma ULK4 intron 22120009 rs17282671 chr3 41887455 T C 6.62E-08 Multiple myeloma ULK4 intron 22120009 rs6797165 chr3 41887777 A G 6.91E-08 Multiple myeloma ULK4 intron 22120009 rs73079360 chr3 41888372 T A 6.22E-08 Multiple myeloma ULK4 intron 22120009 rs17216919 chr3 41888938 G C 6.12E-08 Multiple myeloma ULK4 intron 22120009 rs9820192 chr3 41889281 G A 6.40E-08 Multiple myeloma ULK4 intron 22120009 rs9824731 chr3 41889698 G T 6.40E-08 Multiple myeloma ULK4 intron 22120009 rs28702390 chr3 41889920 C A 6.40E-08 Multiple myeloma ULK4 intron 22120009 rs6791806 chr3 41889995 C T 6.59E-08 Multiple myeloma ULK4 intron 22120009 rs73081321 chr3 41890231 G A 6.12E-08 Multiple myeloma ULK4 intron 22120009 rs17064124 chr3 41890803 A G 6.40E-08 Multiple myeloma ULK4 intron 22120009 rs9850310 chr3 41891098 T C 6.40E-08 Multiple myeloma ULK4 intron 22120009 rs9854954 chr3 41891660 T C 6.40E-08 Multiple myeloma ULK4 intron 22120009 rs12107693 chr3 41892456 T C 6.40E-08 Multiple myeloma ULK4 intron 22120009 rs12107296 chr3 41892503 C G 6.39E-08 Multiple myeloma ULK4 intron 22120009 rs58212289 chr3 41892643 T A 6.16E-07 Multiple myeloma ULK4 intron 22120009 rs56134026 chr3 41892644 G T 6.16E-07 Multiple myeloma ULK4 intron 22120009 rs57653201 chr3 41892693 T C 6.39E-08 Multiple myeloma ULK4 intron 22120009 rs9883369 chr3 41893771 A T 6.39E-08 Multiple myeloma ULK4 intron 22120009 rs6802340 chr3 41894034 T C 6.39E-08 Multiple myeloma ULK4 intron 22120009 rs9846634 chr3 41894049 G A 6.39E-08 Multiple myeloma ULK4 intron 22120009 rs1016669 chr3 41894440 T C 6.57E-08 Multiple myeloma ULK4 intron 22120009 rs9823254 chr3 41894768 G C 6.39E-08 Multiple myeloma ULK4 intron 22120009 rs73081335 chr3 41895177 A G 6.11E-08 Multiple myeloma ULK4 intron 22120009 rs9865780 chr3 41895802 A G 6.38E-08 Multiple myeloma ULK4 intron 22120009 rs1994157 chr3 41897482 G A 1.14E-07 Multiple myeloma ULK4 intron 22120009 rs1994157 chr3 41897482 G A 7.00E-10 Multiple myeloma ULK4 intron 23955597 rs376773321 chr3 41898004 AATATAT A 6.95E-08 Multiple myeloma ULK4 intron 22120009 rs577040336 chr3 41898004 A AAT 6.95E-08 Multiple myeloma ULK4 intron 22120009 rs7426868 chr3 41898004 A T 6.95E-08 Multiple myeloma ULK4 intron 22120009 rs2888133 chr3 41898054 C T 6.37E-08 Multiple myeloma ULK4 intron 22120009 rs35167597 chr3 41898108 C T 6.10E-08 Multiple myeloma ULK4 intron 22120009 rs73830532 chr3 41898814 T C 6.09E-08 Multiple myeloma ULK4 intron 22120009 rs73081341 chr3 41900335 A T 6.95E-08 Multiple myeloma ULK4 intron 22120009 rs2625667 chr3 41900951 C A 6.36E-08 Multiple myeloma ULK4 intron 22120009 rs1717028 chr3 41902964 C T 6.10E-08 Multiple myeloma ULK4 intron 22120009 rs1716674 chr3 41902972 G C 6.10E-08 Multiple myeloma ULK4 intron 22120009 rs1716676 chr3 41903208 T C 6.07E-08 Multiple myeloma ULK4 intron 22120009 rs9832548 chr3 41903491 A T 6.04E-08 Multiple myeloma ULK4 intron 22120009 rs73081347 chr3 41903582 T C 5.85E-08 Multiple myeloma ULK4 intron 22120009 rs1607908 chr3 41905196 T G 5.92E-08 Multiple myeloma ULK4 intron 22120009 rs1716679 chr3 41905339 T C 5.91E-08 Multiple myeloma ULK4 intron 22120009 rs1717031 chr3 41905791 G T 5.88E-08 Multiple myeloma ULK4 intron 22120009 rs2625668 chr3 41905930 T C 5.87E-08 Multiple myeloma ULK4 intron 22120009 rs1613759 chr3 41906183 G A 5.85E-08 Multiple myeloma ULK4 intron 22120009 rs1615543 chr3 41906404 C T 5.84E-08 Multiple myeloma ULK4 intron 22120009 rs73081353 chr3 41906448 T A 5.84E-08 Multiple myeloma ULK4 intron 22120009 rs1716668 chr3 41907850 T C 5.75E-08 Multiple myeloma ULK4 intron 22120009 rs116202370 chr3 41908273 T G 5.74E-08 Multiple myeloma ULK4 intron 22120009 rs59138513 chr3 41908611 T G 5.63E-08 Multiple myeloma ULK4 intron 22120009 rs60796012 chr3 41908668 T C 5.63E-08 Multiple myeloma ULK4 intron 22120009 rs1716669 chr3 41908681 A G 5.74E-08 Multiple myeloma ULK4 intron 22120009 rs9874513 chr3 41909508 G A 5.73E-08 Multiple myeloma ULK4 intron 22120009 rs1717033 chr3 41910216 C T 5.73E-08 Multiple myeloma ULK4 intron 22120009 rs1716670 chr3 41910571 T C 6.70E-05 Prion diseases ULK4 intron 22210626 rs73081361 chr3 41912535 G A 6.47E-08 Multiple myeloma ULK4 intron 22120009 rs9815354 chr3 41912651 G A 3.00E-09 Diastolic blood pressure ULK4 intron 19430479 rs9815354 chr3 41912651 G A 3.00E-09 Coronary heart disease ULK4 intron 21347282 rs9815354 chr3 41912651 G A 6.63E-06 Blood pressure ULK4 intron 21909110 rs9815354 chr3 41912651 G A 5.73E-08 Multiple myeloma ULK4 intron 22120009 rs73081363 chr3 41913478 C T 1.73E-04 Multiple myeloma ULK4 intron 22120009 rs73081364 chr3 41913616 G C 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs1717018 chr3 41913617 G A 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs1617271 chr3 41914000 G T 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs1619558 chr3 41914213 C G 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs6599185 chr3 41914730 T A 6.46E-08 Multiple myeloma ULK4 intron 22120009 rs17283243 chr3 41914792 C T 5.62E-08 Multiple myeloma ULK4 intron 22120009 rs2683696 chr3 41914898 T C 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs2683695 chr3 41914928 C T 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs13325965 chr3 41914942 G T 5.65E-08 Multiple myeloma ULK4 intron 22120009 rs2683694 chr3 41915374 T G 5.62E-08 Multiple myeloma ULK4 intron 22120009 rs1717017 chr3 41915616 A C 5.65E-08 Multiple myeloma ULK4 intron 22120009 rs73081370 chr3 41916258 G C 5.62E-08 Multiple myeloma ULK4 intron 22120009 rs1717015 chr3 41917204 G T 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs1717014 chr3 41917395 C T 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs73081372 chr3 41917993 C T 5.62E-08 Multiple myeloma ULK4 intron 22120009 rs1716657 chr3 41918456 C T 5.71E-08 Multiple myeloma ULK4 intron 22120009 rs1716655 chr3 41918706 A G 5.71E-08 Multiple myeloma ULK4 intron 22120009 rs9839213 chr3 41918992 T C 5.71E-08 Multiple myeloma ULK4 intron 22120009 rs10865914 chr3 41919499 C T 5.71E-08 Multiple myeloma ULK4 intron 22120009 rs73081378 chr3 41920189 G A 6.46E-08 Multiple myeloma ULK4 intron 22120009 rs6794477 chr3 41920401 C T 5.71E-08 Multiple myeloma ULK4 intron 22120009 rs73081383 chr3 41920614 A G 6.46E-08 Multiple myeloma ULK4 intron 22120009 rs1716641 chr3 41921681 C T 4.35E-08 Multiple myeloma ULK4 intron 22120009 rs1716683 chr3 41923074 A G 5.71E-08 Multiple myeloma ULK4 intron 22120009 rs17217536 chr3 41923300 A C 5.61E-08 Multiple myeloma ULK4 intron 22120009 rs17283481 chr3 41924015 T C 5.61E-08 Multiple myeloma ULK4 intron 22120009 rs1716996 chr3 41924294 C T 5.71E-08 Multiple myeloma ULK4 intron 22120009 rs1716997 chr3 41924333 A G 5.71E-08 Multiple myeloma ULK4 intron 22120009 rs1716685 chr3 41925301 T C 5.63E-08 Multiple myeloma ULK4 intron 22120009 rs1052501 chr3 41925398 C T 2.00E-08 Multiple myeloma ULK4 missense 22120009 rs1052501 chr3 41925398 C T 2.00E-10 Multiple myeloma ULK4 missense 23955597 rs17217746 chr3 41926021 A G 5.62E-08 Multiple myeloma ULK4 intron 22120009 rs17283677 chr3 41926148 A G 5.62E-08 Multiple myeloma ULK4 intron 22120009 rs1716688 chr3 41926546 G A 5.71E-08 Multiple myeloma ULK4 intron 22120009 rs73083326 chr3 41927150 G T 5.63E-08 Multiple myeloma ULK4 intron 22120009 rs73083329 chr3 41927151 C T 5.63E-08 Multiple myeloma ULK4 intron 22120009 rs4973991 chr3 41927273 C T 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs1629460 chr3 41927449 T G 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs1629462 chr3 41927452 G C 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs73083333 chr3 41927505 G A 6.47E-08 Multiple myeloma ULK4 intron 22120009 rs9838965 chr3 41927938 C T 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs9839399 chr3 41928044 G A 5.64E-08 Multiple myeloma ULK4 intron 22120009 rs9839491 chr3 41928301 C T 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs56167033 chr3 41928317 C T 6.47E-08 Multiple myeloma ULK4 intron 22120009 rs59873855 chr3 41929538 T C 5.64E-08 Multiple myeloma ULK4 intron 22120009 rs1716660 chr3 41929960 G A 5.73E-08 Multiple myeloma ULK4 intron 22120009 rs1716999 chr3 41930041 C G 5.73E-08 Multiple myeloma ULK4 intron 22120009 rs1717000 chr3 41930219 A C 5.64E-08 Multiple myeloma ULK4 intron 22120009 rs73087368 chr3 41930379 A G 5.64E-08 Multiple myeloma ULK4 intron 22120009 rs4973995 chr3 41931473 T C 5.73E-08 Multiple myeloma ULK4 intron 22120009 rs76313799 chr3 41931751 A C 8.41E-08 Multiple myeloma ULK4 intron 22120009 rs76276404 chr3 41931770 A G 8.41E-08 Multiple myeloma ULK4 intron 22120009 rs113941228 chr3 41932076 G A 5.65E-08 Multiple myeloma ULK4 intron 22120009 rs62258655 chr3 41932330 G A 5.73E-08 Multiple myeloma ULK4 intron 22120009 rs113059632 chr3 41932858 G A 5.65E-08 Multiple myeloma ULK4 intron 22120009 rs11717540 chr3 41932938 G A 5.74E-08 Multiple myeloma ULK4 intron 22120009 rs113772069 chr3 41933389 T C 5.66E-08 Multiple myeloma ULK4 intron 22120009 rs1717001 chr3 41934949 G A 5.75E-08 Multiple myeloma ULK4 intron 22120009 rs1716696 chr3 41935811 C T 5.75E-08 Multiple myeloma ULK4 intron 22120009 rs1717002 chr3 41936668 G A 5.75E-08 Multiple myeloma ULK4 intron 22120009 rs73087378 chr3 41936827 G A 5.67E-08 Multiple myeloma ULK4 intron 22120009 rs1717003 chr3 41937000 C T 5.75E-08 Multiple myeloma ULK4 intron 22120009 rs74371586 chr3 41937890 G A 5.68E-08 Multiple myeloma ULK4 intron 22120009 rs77572508 chr3 41938044 C A 6.53E-08 Multiple myeloma ULK4 intron 22120009 rs73069203 chr3 41938767 T C 6.53E-08 Multiple myeloma ULK4 intron 22120009 rs73069208 chr3 41939198 C T 5.68E-08 Multiple myeloma ULK4 intron 22120009 rs73069209 chr3 41939781 G A 5.68E-08 Multiple myeloma ULK4 intron 22120009 rs4615050 chr3 41942498 T A 5.77E-08 Multiple myeloma ULK4 intron 22120009 rs201425733 chr3 41942664 CTTTTTTTTTTT C 5.69E-08 Multiple myeloma ULK4 intron 22120009 rs60664243 chr3 41942664 C T 5.69E-08 Multiple myeloma ULK4 intron 22120009 rs17218103 chr3 41943724 A G 4.09E-08 Multiple myeloma ULK4 intron 22120009 rs111671485 chr3 41944080 G A 2.82E-05 Multiple myeloma ULK4 intron 22120009 rs537842940 chr3 41944080 GA G 2.82E-05 Multiple myeloma ULK4 intron 22120009 rs1613233 chr3 41945144 A G 5.79E-08 Multiple myeloma ULK4 intron 22120009 rs77778906 chr3 41945612 A C 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs77732985 chr3 41945872 G A 5.72E-08 Multiple myeloma ULK4 intron 22120009 rs1717009 chr3 41946308 T C 5.80E-08 Multiple myeloma ULK4 intron 22120009 rs59476821 chr3 41946481 A G 5.73E-08 Multiple myeloma ULK4 intron 22120009 rs1717010 chr3 41946903 G A 5.80E-08 Multiple myeloma ULK4 intron 22120009 rs11705749 chr3 41947294 C A,T 5.81E-08 Multiple myeloma ULK4 intron 22120009 rs79741604 chr3 41947321 C T 6.60E-08 Multiple myeloma ULK4 intron 22120009 rs13063523 chr3 41947437 C T 1.92E-04 Multiple myeloma ULK4 intron 22120009 rs1717012 chr3 41948255 G A 5.81E-08 Multiple myeloma ULK4 intron 22120009 rs1716664 chr3 41948378 G A 5.81E-08 Multiple myeloma ULK4 intron 22120009 rs78342280 chr3 41948810 G A 5.75E-08 Multiple myeloma ULK4 intron 22120009 rs59146151 chr3 41949301 T C 5.75E-08 Multiple myeloma ULK4 intron 22120009 rs60659106 chr3 41949569 G C 5.75E-08 Multiple myeloma ULK4 intron 22120009 rs13076952 chr3 41950033 G A 5.82E-08 Multiple myeloma ULK4 intron 22120009 rs112245154 chr3 41950520 G T 6.63E-08 Multiple myeloma ULK4 intron 22120009 rs73069240 chr3 41950973 A T 5.77E-08 Multiple myeloma ULK4 intron 22120009 rs12330363 chr3 41951186 G A 5.83E-08 Multiple myeloma ULK4 intron 22120009 rs73069245 chr3 41951452 G A 5.77E-08 Multiple myeloma ULK4 intron 22120009 rs113528686 chr3 41951547 T C 5.77E-08 Multiple myeloma ULK4 intron 22120009 rs13087719 chr3 41951576 C T 5.83E-08 Multiple myeloma ULK4 intron 22120009 rs13088394 chr3 41951715 G A 5.83E-08 Multiple myeloma ULK4 intron 22120009 rs11711210 chr3 41951952 G C 6.22E-08 Multiple myeloma ULK4 intron 22120009 rs4547673 chr3 41952303 A C 7.24E-08 Multiple myeloma ULK4 intron 22120009 rs4299460 chr3 41952445 A C 7.68E-08 Multiple myeloma ULK4 intron 22120009 rs4264702 chr3 41952539 T A 7.73E-08 Multiple myeloma ULK4 intron 22120009 rs4577439 chr3 41952540 T A 7.73E-08 Multiple myeloma ULK4 intron 22120009 rs35263917 chr3 41952852 T C 7.86E-08 Multiple myeloma ULK4 missense 22120009 rs75651509 chr3 41953564 A G 7.88E-08 Multiple myeloma ULK4 intron 22120009 rs9822598 chr3 41954587 G A 7.41E-08 Multiple myeloma ULK4 intron 22120009 rs9822288 chr3 41954588 C T 7.41E-08 Multiple myeloma ULK4 intron 22120009 rs1628874 chr3 41955714 G A 7.43E-08 Multiple myeloma ULK4 intron 22120009 rs1717034 chr3 41955913 A G 7.44E-08 Multiple myeloma ULK4 intron 22120009 rs1716698 chr3 41957466 T G 7.70E-08 Multiple myeloma ULK4 intron 22120009 rs77047799 chr3 41958895 T C 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs7617397 chr3 41959037 T C 9.07E-08 Multiple myeloma ULK4 intron 22120009 rs55899232 chr3 41959357 T C 1.07E-07 Multiple myeloma ULK4 intron 22120009 rs13321282 chr3 41959452 C T 9.51E-08 Multiple myeloma ULK4 intron 22120009 rs1716975 chr3 41960006 T C 1.49E-06 Multiple myeloma ULK4 missense 22120009 rs1716975 chr3 41960006 T C 6.00E-09 Multiple myeloma ULK4 missense 23955597 rs1716981 chr3 41962662 G T 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716661 chr3 41962818 C T 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs55820810 chr3 41962832 G A 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs1716982 chr3 41962963 C T 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716983 chr3 41964128 G A 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs76319026 chr3 41964542 T C 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs9809833 chr3 41964648 A G 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1615243 chr3 41965234 C T 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716984 chr3 41965532 G A 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716642 chr3 41965865 A C 7.83E-08 Multiple myeloma ULK4 intron 22120009 rs1716643 chr3 41967192 C T 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs73069277 chr3 41967521 C T 6.33E-06 Multiple myeloma ULK4 intron 22120009 rs1612124 chr3 41967893 C A 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716644 chr3 41968028 A G 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716985 chr3 41968894 T G 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716645 chr3 41970480 T C 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716987 chr3 41970516 A G 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs7622665 chr3 41970743 T C 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs7616780 chr3 41971559 G A 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716989 chr3 41972186 C T 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716990 chr3 41972209 C T 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716648 chr3 41972849 G A 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs73069292 chr3 41973963 T C 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs1716993 chr3 41974556 G C 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716651 chr3 41975099 A T 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716652 chr3 41975535 A T 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1716653 chr3 41975598 C A 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs17218264 chr3 41975847 T C 6.28E-08 Multiple myeloma ULK4 intron 22120009 rs939558 chr3 41976040 C A 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs56207540 chr3 41976627 G C 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs34121549 chr3 41976773 C T 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs111419796 chr3 41976968 G A 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs3934103 chr3 41977214 C T 7.83E-08 Multiple myeloma ULK4 intron 22120009 rs73071203 chr3 41977464 A C 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs73071208 chr3 41978738 A T 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs1717011 chr3 41980199 T C 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1717020 chr3 41981490 C A 9.79E-08 Multiple myeloma ULK4 intron 22120009 rs73071212 chr3 41981856 C A 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs113611706 chr3 41983242 T C 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs1716691 chr3 41983615 G C 2.98E-04 Multiple complex diseases ULK4 intron 17554300 rs1716692 chr3 41983786 G A 1.02E-07 Multiple myeloma ULK4 intron 22120009 rs1717021 chr3 41983860 A T 1.01E-07 Multiple myeloma ULK4 intron 22120009 rs1717023 chr3 41984213 G A 1.01E-07 Multiple myeloma ULK4 intron 22120009 rs113300894 chr3 41984243 G C 4.80E-06 Multiple myeloma ULK4 intron 22120009 rs199568018 chr3 41984775 G T 1.01E-07 Multiple myeloma ULK4 intron 22120009 rs1624519 chr3 41984800 G A 1.01E-07 Multiple myeloma ULK4 intron 22120009 rs1717024 chr3 41984888 C A 9.68E-08 Multiple myeloma ULK4 intron 22120009 rs11129935 chr3 41985203 A C 1.18E-07 Multiple myeloma ULK4 intron 22120009 rs1716693 chr3 41985600 C T 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs9876960 chr3 41985812 C T 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs1716694 chr3 41986399 G T 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs17284313 chr3 41986787 A C 8.82E-08 Multiple myeloma ULK4 intron 22120009 rs73071222 chr3 41986896 C T 1.20E-07 Multiple myeloma ULK4 intron 22120009 rs17218441 chr3 41987044 A G 1.20E-07 Multiple myeloma ULK4 intron 22120009 rs17218504 chr3 41987278 A G 1.46E-07 Multiple myeloma ULK4 intron 22120009 rs1717027 chr3 41987920 T C 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs1717027 chr3 41987920 T C 5.00E-13 Blood pressure ULK4 intron 23972371 rs1716695 chr3 41988695 C T 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs113803925 chr3 41989859 C T 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs7372217 chr3 41990122 G A 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs12330747 chr3 41990829 A C 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs73071236 chr3 41992042 A G 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs73071238 chr3 41992243 A G 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs6599192 chr3 41992408 G A 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs112787664 chr3 41992441 C T 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs73071239 chr3 41992610 C A 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs73071242 chr3 41993011 T C 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs56983571 chr3 41994473 T C 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs11712394 chr3 41994779 T C 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs113923306 chr3 41994948 C T 1.91E-07 Multiple myeloma ULK4 intron 22120009 rs6807562 chr3 41995655 T C 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs6805140 chr3 41995791 A G 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs2272007 chr3 41996136 T C 7.93E-08 Multiple myeloma ULK4 missense 22120009 rs2272007 chr3 41996136 T C 2.00E-09 Multiple myeloma (hyperdiploidy) ULK4 missense 23502783 rs2272007 chr3 41996136 T C 4.00E-10 Multiple myeloma ULK4 missense 23955597 rs17284472 chr3 41996304 G A 8.87E-08 Multiple myeloma ULK4 intron 22120009 rs73830583 chr3 41996948 C T 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs2272006 chr3 41997059 C T 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs60690674 chr3 41997811 G C 1.47E-07 Multiple myeloma ULK4 intron 22120009 rs9842305 chr3 41998412 G A 1.00E-07 Multiple myeloma ULK4 intron 22120009 rs112490357 chr3 41998940 C CAA 8.04E-06 Multiple myeloma ULK4 intron 22120009 rs11455719 chr3 41998940 C CAAA,CAAAAA 8.04E-06 Multiple myeloma ULK4 intron 22120009 rs549551862 chr3 41998940 CAAAAA C 8.04E-06 Multiple myeloma ULK4 intron 22120009 rs71939903 chr3 41998940 C CAAA 8.04E-06 Multiple myeloma ULK4 intron 22120009 rs56728371 chr3 41999381 T A 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs80066790 chr3 42000843 A G 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs1474219 chr3 42000913 G A 1.01E-07 Multiple myeloma ULK4 intron 22120009 rs79323474 chr3 42000973 C T 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs73071259 chr3 42001847 G A 1.26E-06 Multiple myeloma ULK4 intron 22120009 rs7639859 chr3 42001987 C T 1.21E-07 Multiple myeloma ULK4 intron 22120009 rs55916855 chr3 42002761 A G 1.22E-07 Multiple myeloma ULK4 intron 22120009 rs11717170 chr3 42002811 G C 1.01E-07 Multiple myeloma ULK4 intron 22120009 rs73071261 chr3 42003369 C A 1.22E-07 Multiple myeloma ULK4 intron 22120009 rs73830585 chr3 42003698 T A 1.47E-07 Multiple myeloma LOC100287063 missense 22120009 rs56201224 chr3 42004427 A C 1.47E-07 Multiple myeloma LOC100287063 intron 22120009 rs55953604 chr3 42004428 A G 1.47E-07 Multiple myeloma LOC100287063 intron 22120009 rs4434125 chr3 42004681 A G 1.22E-07 Multiple myeloma LOC100287063 intron 22120009 rs56290987 chr3 42004882 T C 1.22E-07 Multiple myeloma LOC100287063 intron 22120009 rs60966614 chr3 42005166 A G 1.25E-06 Multiple myeloma LOC100287063 intron 22120009 rs12492599 chr3 42005734 C A 1.01E-07 Multiple myeloma LOC100287063 intron 22120009 rs73073226 chr3 42005838 T C 1.22E-07 Multiple myeloma LOC100287063 intron 22120009 rs74947509 chr3 42006323 T C 1.22E-07 Multiple myeloma LOC100287063 intron 22120009 rs10510732 chr3 42007339 G A 8.90E-08 Multiple myeloma LOC100287063 intron 22120009 rs1915482 chr3 42007734 G C 9.59E-04 Multiple complex diseases LOC100287063 intron 17554300 rs73073229 chr3 42007850 T C 1.22E-07 Multiple myeloma LOC100287063 intron 22120009 rs113379006 chr3 42008186 C T 1.22E-07 Multiple myeloma LOC100287063 intron 22120009 rs73073230 chr3 42008263 G A 1.22E-07 Multiple myeloma LOC100287063 intron 22120009 rs113144620 chr3 42008312 A G 1.22E-07 Multiple myeloma LOC100287063 intron 22120009 rs78629637 chr3 42008781 C T 1.22E-07 Multiple myeloma LOC100287063 intron 22120009 rs10510733 chr3 42009192 T C 1.22E-07 Multiple myeloma LOC100287063 intron 22120009 rs9835059 chr3 42009726 A G 1.01E-07 Multiple myeloma LOC100287063 intron 22120009 rs73073233 chr3 42010550 A G 1.23E-07 Multiple myeloma LOC100287063 intron 22120009 rs73073234 chr3 42012071 C T 1.24E-07 Multiple myeloma LOC100287063 intron 22120009 rs73073235 chr3 42012693 C A 1.02E-07 Multiple myeloma LOC100287063 intron 22120009 rs56332587 chr3 42012714 T C 1.25E-07 Multiple myeloma LOC100287063 intron 22120009 rs7373694 chr3 42012719 G A 1.02E-07 Multiple myeloma LOC100287063 intron 22120009 rs58916656 chr3 42012781 C G 1.25E-07 Multiple myeloma LOC100287063 intron 22120009 rs9856633 chr3 42013850 A G 9.87E-08 Multiple myeloma LOC100287063 intron 22120009 rs73073238 chr3 42014325 G C 1.33E-07 Multiple myeloma LOC100287063 intron 22120009 rs73073239 chr3 42014597 G C 7.27E-06 Multiple myeloma LOC100287063 intron 22120009 rs13087502 chr3 42015110 C T 6.79E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073242 chr3 42015335 G A 8.37E-06 Multiple myeloma LOC100287063 intron 22120009 rs12108064 chr3 42016217 C T 6.24E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073250 chr3 42016559 G T 8.48E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073252 chr3 42016891 C T 6.28E-06 Multiple myeloma LOC100287063 intron 22120009 rs115754309 chr3 42017246 A G 8.55E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073253 chr3 42017494 T A 8.56E-06 Multiple myeloma LOC100287063 intron 22120009 rs13084436 chr3 42017537 T A 6.31E-06 Multiple myeloma LOC100287063 intron 22120009 rs17218866 chr3 42017634 T C 8.58E-06 Multiple myeloma LOC100287063 intron 22120009 rs6796078 chr3 42017820 A T 6.33E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073258 chr3 42017894 G A 1.09E-05 Multiple myeloma LOC100287063 intron 22120009 rs6801339 chr3 42018233 T A 6.34E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073262 chr3 42018443 G T 8.63E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073263 chr3 42018666 C A 8.65E-06 Multiple myeloma LOC100287063 intron 22120009 rs17218936 chr3 42019392 C T 5.68E-06 Multiple myeloma LOC100287063 intron 22120009 rs7634985 chr3 42019565 C T 6.39E-06 Multiple myeloma LOC100287063 intron 22120009 rs7634985 chr3 42019565 C T 2.00E-07 Multiple myeloma LOC100287063 intron 23955597 rs7652369 chr3 42020973 T G 6.50E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073266 chr3 42021116 A G 8.84E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073267 chr3 42021163 A T 8.84E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073268 chr3 42021403 C A 8.86E-06 Multiple myeloma LOC100287063 intron 22120009 rs1851149 chr3 42021708 T C 6.54E-06 Multiple myeloma LOC100287063 intron 22120009 rs80120812 chr3 42021760 C T 8.89E-06 Multiple myeloma LOC100287063 intron 22120009 rs111788014 chr3 42021796 C T 8.89E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073272 chr3 42022446 G A 8.93E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073274 chr3 42022810 T C 8.96E-06 Multiple myeloma LOC100287063 intron 22120009 rs6798152 chr3 42023558 A T 6.65E-06 Multiple myeloma LOC100287063 intron 22120009 rs79626430 chr3 42023786 A G 9.04E-06 Multiple myeloma LOC100287063 intron 22120009 rs2683692 chr3 42024527 A G 6.70E-06 Multiple myeloma LOC100287063 intron 22120009 rs112310714 chr3 42024797 A C 9.13E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073276 chr3 42025354 G A 4.00E-05 Multiple myeloma LOC100287063 intron 22120009 rs78662667 chr3 42025579 G A 9.20E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073280 chr3 42025772 T C 9.20E-06 Multiple myeloma LOC100287063 intron 22120009 rs794902 chr3 42025939 T C 6.79E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073281 chr3 42026366 C T 1.17E-05 Multiple myeloma LOC100287063 intron 22120009 rs56008529 chr3 42026755 A T 1.17E-05 Multiple myeloma LOC100287063 intron 22120009 rs552804358 chr3 42027247 TA T 9.34E-06 Multiple myeloma LOC100287063 intron 22120009 rs56865718 chr3 42027247 T C 9.34E-06 Multiple myeloma LOC100287063 intron 22120009 rs1087599 chr3 42027363 G A 6.89E-06 Multiple myeloma LOC100287063 intron 22120009 rs116717051 chr3 42027411 G C 7.14E-05 Multiple myeloma LOC100287063 intron 22120009 rs73073285 chr3 42027566 T G 9.37E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073288 chr3 42027637 G C 9.37E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073290 chr3 42027684 T G 9.38E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073291 chr3 42028004 G C 9.41E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073292 chr3 42028023 C A 9.41E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073294 chr3 42028053 A G 9.41E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073296 chr3 42028074 G A 9.42E-06 Multiple myeloma LOC100287063 intron 22120009 rs73830596 chr3 42028223 G A 9.43E-06 Multiple myeloma LOC100287063 intron 22120009 rs78402272 chr3 42028425 G C 9.45E-06 Multiple myeloma LOC100287063 intron 22120009 rs113496706 chr3 42028574 G T 9.46E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073298 chr3 42028657 G A 6.98E-06 Multiple myeloma LOC100287063 intron 22120009 rs794899 chr3 42028722 T C 6.98E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073301 chr3 42028777 T C 9.48E-06 Multiple myeloma LOC100287063 intron 22120009 rs61646756 chr3 42029352 A C 9.58E-06 Multiple myeloma LOC100287063 intron 22120009 rs17284933 chr3 42029835 T C 7.44E-06 Multiple myeloma LOC100287063 intron 22120009 rs73073302 chr3 42029879 T C 9.67E-06 Multiple myeloma LOC100287063 intron 22120009 rs113027442 chr3 42030029 G A 5.81E-06 Multiple myeloma LOC100287063 intron 22120009 rs79239400 chr3 42030249 C A 1.23E-05 Multiple myeloma LOC100287063 intron 22120009 rs73075204 chr3 42030392 G A 9.82E-06 Multiple myeloma LOC100287063 intron 22120009 rs115135603 chr3 42031622 T C 1.02E-05 Multiple myeloma LOC100287063 intron 22120009 rs794897 chr3 42031865 T C 7.59E-06 Multiple myeloma LOC100287063 intron 22120009 rs75308766 chr3 42031894 G A 1.03E-05 Multiple myeloma LOC100287063 intron 22120009 rs794896 chr3 42031902 C T 7.60E-06 Multiple myeloma LOC100287063 intron 22120009 rs794895 chr3 42031974 A C 7.62E-06 Multiple myeloma LOC100287063 intron 22120009 rs794894 chr3 42032483 C T 5.89E-06 Multiple myeloma LOC100287063 intron 22120009 rs794894 chr3 42032483 C T 2.00E-07 Multiple myeloma LOC100287063 intron 23955597 rs61182696 chr3 42032511 C T 1.05E-05 Multiple myeloma LOC100287063 intron 22120009 rs73075211 chr3 42033424 G T 1.09E-05 Multiple myeloma LOC100287063 intron 22120009 rs75047809 chr3 42033437 T C 1.09E-05 Multiple myeloma LOC100287063 intron 22120009 rs76127736 chr3 42033645 A G 1.38E-05 Multiple myeloma LOC100287063 intron 22120009 rs11926737 chr3 42034007 C T 8.24E-06 Multiple myeloma LOC100287063 intron 22120009 rs794905 chr3 42034730 C T 8.50E-06 Multiple myeloma LOC100287063 intron 22120009 rs794904 chr3 42035157 G A 8.63E-06 Multiple myeloma LOC100287063 intron 22120009 rs77014899 chr3 42037880 T C 1.63E-05 Multiple myeloma LOC100287063 intron 22120009 rs73075219 chr3 42038429 A C 1.33E-05 Multiple myeloma LOC100287063 intron 22120009 rs57945879 chr3 42038842 C G 1.35E-05 Multiple myeloma LOC100287063 intron 22120009 rs73828505 chr3 42042714 C T 1.11E-05 Multiple myeloma LOC100287063 intron 22120009 rs7629767 chr3 42043509 T G 1.65E-05 Multiple myeloma LOC100287063 intron 22120009 rs7629767 chr3 42043509 T G 6.00E-07 Multiple myeloma LOC100287063 intron 23955597 rs60525434 chr3 42044286 T G 1.26E-05 Multiple myeloma LOC100287063 intron 22120009 rs75687617 chr3 42044664 C T 2.13E-05 Multiple myeloma LOC100287063 intron 22120009 rs113956045 chr3 42045303 G A 2.15E-05 Multiple myeloma LOC100287063 intron 22120009 rs56212772 chr3 42046780 T G 1.89E-05 Multiple myeloma LOC100287063 intron 22120009 rs73075224 chr3 42048248 G A 1.88E-05 Multiple myeloma LOC100287063 intron 22120009 rs73075228 chr3 42049629 T G 2.31E-05 Multiple myeloma LOC100287063 intron 22120009 rs73075231 chr3 42051694 T C 2.06E-05 Multiple myeloma LOC100287063 intron 22120009 rs73075234 chr3 42051801 G A 2.42E-05 Multiple myeloma LOC100287063 intron 22120009 rs12635286 chr3 42051836 T C 2.86E-05 Multiple myeloma LOC100287063 intron 22120009 rs17219090 chr3 42051952 G C 2.45E-05 Multiple myeloma LOC100287063 intron 22120009 rs794892 chr3 42052932 G T 2.67E-05 Multiple myeloma LOC100287063 intron 22120009 rs704964 chr3 42053899 G A 2.92E-05 Multiple myeloma LOC100287063 intron 22120009 rs112912733 chr3 42054910 C A 2.28E-05 Multiple myeloma LOC100287063 cds-synon 22120009 rs939561 chr3 42057101 G A 4.00E-06 Multiple myeloma LOC100287063 intron 23955597 rs73075241 chr3 42058045 C T 2.46E-05 Multiple myeloma LOC100287063 intron 22120009 rs115702638 chr3 42058594 C T 3.98E-05 Multiple myeloma LOC100287063 intron 22120009 rs7652506 chr3 42060235 C T 4.38E-05 Multiple myeloma LOC100287063 intron 22120009 rs12152489 chr3 42060402 T C 2.43E-05 Multiple myeloma LOC100287063 intron 22120009 rs56994465 chr3 42061606 A G 3.96E-05 Multiple myeloma LOC100287063 intron 22120009 rs794890 chr3 42062339 G T 3.94E-05 Multiple myeloma LOC100287063 intron 22120009 rs73075250 chr3 42063734 A G 3.80E-05 Multiple myeloma LOC100287063 intron 22120009 rs809930 chr3 42065005 G A 5.26E-05 Multiple myeloma LOC100287063 intron 22120009 rs12106811 chr3 42076970 G T 5.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100287063 intron 20877124 rs1498095 chr3 42093422 T C 8.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio LOC100287063 intron 22589738 rs73066375 chr3 42173947 G A 0.000008435 Sarcoidosis TRAK1 intron 22952805 rs73066377 chr3 42174148 C T 0.000004058 Sarcoidosis TRAK1 intron 22952805 rs2371797 chr3 42175099 C T 0.000006553 Sarcoidosis TRAK1 intron 22952805 rs113518061 chr3 42175887 A G 0.00002181 Sarcoidosis TRAK1 intron 22952805 rs17220629 chr3 42177180 T C 0.00002029 Sarcoidosis TRAK1 intron 22952805 rs1979789 chr3 42177407 C T 0.00002741 Sarcoidosis TRAK1 intron 22952805 rs11709083 chr3 42178461 G A 0.0000226 Sarcoidosis TRAK1 intron 22952805 rs2133072 chr3 42178759 G A 0.00002516 Sarcoidosis TRAK1 intron 22952805 rs2133073 chr3 42178898 C T 0.00002219 Sarcoidosis TRAK1 intron 22952805 rs9311297 chr3 42179870 G A 0.00001571 Sarcoidosis TRAK1 intron 22952805 rs2055285 chr3 42180651 T C 0.00007907 Sarcoidosis TRAK1 intron 22952805 rs1874756 chr3 42181039 A G 0.0000969 Sarcoidosis TRAK1 intron 22952805 rs9851827 chr3 42183692 C G 0.000009875 Sarcoidosis TRAK1 intron 22952805 rs9852262 chr3 42183776 G C 0.00002037 Sarcoidosis TRAK1 intron 22952805 rs9284877 chr3 42185135 C T 1.50E-06 Iron levels TRAK1 intron 21208937 rs4234445 chr3 42226151 T C 9.39E-04 Alcohol dependence TRAK1 intron 24277619 rs2290135 chr3 42230743 G A 6.04E-04 Smoking initiation TRAK1 intron 24665060 rs2290137 chr3 42234740 G A 4.96E-04 Smoking initiation TRAK1 intron 24665060 rs2290134 chr3 42251263 C T 3.37E-05 Cognitive impairment induced by topiramate TRAK1 cds-synon 22091778 rs3196165 chr3 42252141 A G 4.70E-04 Tourette syndrome TRAK1 UTR-3 22889924 rs11928109 chr3 42259299 G A 5.86E-04 Alcohol consumption (maxi-drinks) TRAK1 intron 24277619 rs3774391 chr3 42265369 C T 8.70E-04 Alcohol dependence TRAK1 UTR-3 20201924 rs9879040 chr3 42272118 A G 2.24E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs9311317 chr3 42295806 A G 6.77E-05 Insulin-related traits / / pha002901 rs8192472 chr3 42299870 C T 1.00E-06 Body mass index CCK intron 24348519 rs4377469 chr3 42303074 G T 2.00E-07 Body mass index CCK intron 22344221 rs2029127 chr3 42311742 G A 7.70E-04 Multiple complex diseases / / 17554300 rs11129950 chr3 42314587 A G 8.83E-06 Bipolar disorder / / 21771265 rs9839267 chr3 42332624 T G 0.0000305 Alcohol consumption (Heavy) / / 23422394 rs9683362 chr3 42343321 A G 2.34E-05 Intelligence / / 21826061 rs9311322 chr3 42347749 T C 6.42E-05 Cognitive test performance / / 20125193 rs1442265 chr3 42355010 G A 1.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1442265 chr3 42355010 G A 7.02E-05 Intelligence / / 21826061 rs17073237 chr3 42368424 T A 1.31E-04 Multiple complex diseases / / 17554300 rs1019188 chr3 42378179 G A 9.99E-05 Lipoproteins / / pha003079 rs17073898 chr3 42388026 A G 5.32E-04 Multiple complex diseases / / 17554300 rs33457 chr3 42403380 A G 3.27E-06 Multiple complex diseases / / 17554300 rs33460 chr3 42404564 A G 2.44E-04 Type 2 diabetes / / 17463246 rs33460 chr3 42404564 A G 9.56E-05 Multiple complex diseases / / 17554300 rs33470 chr3 42408243 G A 1.24E-05 Multiple complex diseases / / 17554300 rs33527 chr3 42408422 T C 7.71E-04 Multiple complex diseases / / 17554300 rs33528 chr3 42409748 T C 4.37E-04 Multiple complex diseases / / 17554300 rs33528 chr3 42409748 T C 9.92E-04 Lymphocyte counts / / 22286170 rs12636553 chr3 42427036 G A 8.06E-05 Alzheimer's disease (late onset) / / 21460841 rs11718659 chr3 42428487 C T 1.60E-05 Alzheimer's disease (late onset) / / 21460841 rs17074351 chr3 42433305 T C 2.90E-05 Urinary metabolites / / 21572414 rs17074351 chr3 42433305 T C 8.27E-05 Left ventricular hypertrophy / / pha003052 rs2286720 chr3 42448471 G A 1.00E-06 Response to antipsychotic treatment in schizophrenia (reasoning) LYZL4 cds-synon 21107309 rs704966 chr3 42472986 G A 4.41E-04 Multiple complex diseases / / 17554300 rs4682961 chr3 42483911 T A 3.50E-06 Urinary metabolites / / 21572414 rs621966 chr3 42495350 T G 1.48E-04 Autism spectrum disorders (language delay) / / 21519539 rs7613206 chr3 42550294 G A 6.16E-04 Multiple complex diseases VIPR1 intron 17554300 rs12493291 chr3 42550651 G A 7.40E-04 Multiple complex diseases VIPR1 intron 17554300 rs4467424 chr3 42553262 G T 2.26E-04 Multiple complex diseases VIPR1 intron 17554300 rs14380 chr3 42578579 A T 2.29E-05 Bipolar disorder VIPR1 UTR-3 19488044 rs14380 chr3 42578579 A T 1.78E-05 Bipolar disorder and schizophrenia VIPR1 UTR-3 20889312 rs14380 chr3 42578579 A T 1.21E-05 Bipolar Disorder VIPR1 UTR-3 pha002858 rs342525 chr3 42585461 G A 1.70E-05 Urinary metabolites / / 21572414 rs339707 chr3 42723827 G T 1.40E-05 Urinary metabolites / / 21572414 rs4371488 chr3 42724452 G A 7.80E-05 Diabetic retinopathy / / 21441570 rs6805421 chr3 42728144 A G 2.94E-04 Schizophrenia(treatment response to risperidone) KBTBD5 missense 19850283 rs6773675 chr3 42774783 C T 8.83E-04 Multiple complex diseases CCDC13 intron 17554300 rs339678 chr3 42799858 T A 8.59E-06 Periodontitis (DPAL) CCDC13 intron 24024966 rs11915803 chr3 42800291 T C 8.68E-04 Alcohol dependence CCDC13 intron 20201924 rs339676 chr3 42800778 G A 6.67E-05 Schizophrenia CCDC13 intron 19571809 rs339676 chr3 42800778 G A 5.84E-05 Schizophrenia CCDC13 intron pha002859 rs339665 chr3 42808071 C T 6.00E-06 Periodontitis (DPAL) CCDC13 intron 24024966 rs339664 chr3 42808493 A G 8.73E-06 Obesity-related traits CCDC13 intron 23251661 rs11717346 chr3 42828546 G A 9.38E-06 Obesity-related traits HIGD1A intron 23251661 rs11129979 chr3 42890731 T C 4.07E-06 Obesity-related traits CCBP2 intron 23251661 rs9815043 chr3 42896639 A G 7.54E-07 Obesity-related traits CCBP2 intron 23251661 rs2228467 chr3 42906116 T C 1.89E-06 Obesity-related traits CCBP2 missense 23251661 rs2228467 chr3 42906116 T C 2.00E-07 Monocyte counts CCBP2 missense 23314186 rs2228468 chr3 42907112 A C,T 2.44E-07 Obesity-related traits CCBP2 missense 23251661 rs2228468 chr3 42907112 A C,T 5.00E-07 Monocyte counts CCBP2 missense 23314186 rs1366046 chr3 42908775 A C 2.44E-07 Obesity-related traits CCBP2 UTR-3 23251661 rs3919627 chr3 42909160 G A 2.00E-07 Obesity-related traits / / 23251661 rs11715464 chr3 42909687 A G 9.14E-07 Obesity-related traits / / 23251661 rs7612912 chr3 42910621 T C 3.73E-07 Obesity-related traits / / 23251661 rs760193 chr3 42918297 C T 7.21E-05 Serum metabolites CYP8B1 nearGene-5 19043545 rs11919400 chr3 43005979 A G 8.83E-06 Obesity-related traits / / 23251661 rs4146792 chr3 43038237 T G 1.99E-04 Amyotrophic lateral sclerosis (sporadic) FAM198A intron 24529757 rs536119 chr3 43095101 A G 6.33E-05 Weight loss (gastric bypass surgery) FAM198A missense 23643386 rs2867 chr3 43120835 T G 3.75E-04 Type 2 diabetes C3orf39 UTR-3 17463246 rs2936818 chr3 43122966 G A,C,T 1.85E-04 Smoking initiation C3orf39 UTR-5 24665060 rs488069 chr3 43132444 C T 7.60E-07 Malaria C3orf39 intron 19465909 rs12639294 chr3 43150736 C G 2.15E-04 Glycosylated haemoglobin levels / / 17255346 rs7648947 chr3 43174229 G A 4.13E-04 Smoking initiation / / 24665060 rs12629249 chr3 43191899 C A 8.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs938922 chr3 43214678 A C 6.15E-04 Acute lung injury / / 22295056 rs17075286 chr3 43230723 C G 8.00E-07 Bipolar disorder and schizophrenia / / 21057379 rs6800874 chr3 43234782 C G 9.18E-04 Insulin resistance / / 21901158 rs6808396 chr3 43294971 T C 1.62E-05 Orofacial clefts / / 22419666 rs6767019 chr3 43297689 A C 9.00E-06 Obesity-related traits / / 23251661 rs7646966 chr3 43300871 C A 2.08E-04 Parkinson's disease / / 21044948 rs1320163 chr3 43303296 A G 2.46E-04 Parkinson's disease / / 21044948 rs1320163 chr3 43303296 A G 8.94E-05 Orofacial clefts / / 22419666 rs7621298 chr3 43383641 A G 6.03E-04 Type 2 diabetes SNRK intron 17463246 rs17075600 chr3 43401268 G A 5.06E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1848069 chr3 43417349 T C 1.48E-04 Response to taxane treatment (placlitaxel) ANO10 intron 23006423 rs17075630 chr3 43417495 T C 0.000147553 Hypertension (early onset hypertension) ANO10 intron 22479346 rs17075630 chr3 43417495 T C 2.57E-04 Response to taxane treatment (placlitaxel) ANO10 intron 23006423 rs17473118 chr3 43443534 G A 2.33E-07 Obesity-related traits ANO10 intron 23251661 rs1105263 chr3 43445129 G A 6.77E-04 Response to taxane treatment (placlitaxel) ANO10 intron 23006423 rs7650267 chr3 43467895 T C 2.00E-07 Obesity-related traits ANO10 intron 23251661 rs11710107 chr3 43473914 A C 7.50E-05 Alcoholism (heaviness of drinking) ANO10 intron 21529783 rs2888312 chr3 43484967 G A 7.70E-05 Alcoholism (heaviness of drinking) ANO10 intron 21529783 rs6802567 chr3 43537085 T C 1.34E-05 Stroke ANO10 intron pha002886 rs17075780 chr3 43575362 T C 5.28E-04 Multiple complex diseases ANO10 intron 17554300 rs17409162 chr3 43591327 G A 2.17E-05 Self-reported allergy ANO10 missense 23817569 rs1013758 chr3 43626375 G A 0.000807718 Hypertension (early onset hypertension) ANO10 intron 22479346 rs6800306 chr3 43658845 G A 7.35E-04 Type 2 diabetes ANO10 intron 17463246 rs4432612 chr3 43700292 T C 5.04E-05 Post-operative nausea and vomiting / / 21694509 rs9831161 chr3 43768018 G A 9.61E-04 Alzheimer's disease / / 24755620 rs740836 chr3 43794560 A G 6.12E-04 Tourette syndrome / / 22889924 rs1076413 chr3 43795310 T C 9.97E-04 Multiple complex diseases / / 17554300 rs4073774 chr3 43836717 A G 3.44E-04 Type 2 diabetes / / 17463246 rs4535201 chr3 43880640 A G 1.96E-04 Heart Failure / / pha002885 rs6790122 chr3 43909699 T A 2.93E-05 Chronic obstructive pulmonary disease / / 19300482 rs6790122 chr3 43909699 T A 7.00E-06 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6785433 chr3 43964265 A G 6.81E-04 Type 2 diabetes / / 22158537 rs9836268 chr3 43965755 T G 6.92E-06 Type 2 diabetes / / 22158537 rs11708363 chr3 43966585 G A 9.78E-04 Type 2 diabetes / / 22158537 rs6801252 chr3 43967803 T C 6.46E-06 Type 2 diabetes / / 22158537 rs6809522 chr3 43967899 G T 6.65E-06 Type 2 diabetes / / 22158537 rs7634369 chr3 43968636 C T 1.01E-06 Type 2 diabetes / / 22158537 rs6441805 chr3 43968796 G A 6.49E-06 Type 2 diabetes / / 22158537 rs6441806 chr3 43968819 T C 9.39E-07 Type 2 diabetes / / 22158537 rs6804956 chr3 43969244 T C 6.75E-06 Type 2 diabetes / / 22158537 rs7641395 chr3 43972203 T C 1.67E-05 Type 2 diabetes / / 22158537 rs9861276 chr3 43989595 C T 9.47E-04 Type 2 diabetes / / 22158537 rs6782500 chr3 43990260 G A 2.41E-04 Type 2 diabetes / / 22158537 rs4682924 chr3 43992760 G A 6.97E-04 Type 2 diabetes / / 22158537 rs11917885 chr3 44008013 C T 7.15E-04 Multiple complex diseases / / 17554300 rs11917885 chr3 44008013 C T 8.46E-04 Type 2 diabetes / / 22158537 rs1524887 chr3 44016371 C T 1.79E-05 Type 2 diabetes / / 22158537 rs9858826 chr3 44031412 A G 9.76E-04 Multiple complex diseases / / 17554300 rs2372580 chr3 44049945 A G 3.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11718455 chr3 44056898 C T 0.000122 Coronary artery disease / / 23202125 rs7635417 chr3 44074449 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7635417 chr3 44074449 C T 7.72E-05 Cognitive impairment induced by topiramate / / 22091778 rs7635417 chr3 44074449 C T 9.21E-05 Cognitive impairment induced by topiramate / / 22091778 rs9881814 chr3 44111902 C A 9.58E-05 Eosinophil counts / / pha003088 rs7626631 chr3 44197258 C T 8.70E-07 Urinary metabolites / / 21572414 rs1110330 chr3 44222317 G A 6.42E-05 Glucose levels / / pha003057 rs1105023 chr3 44222351 T G 3.46E-05 Glucose levels / / pha003058 rs4682718 chr3 44226332 A G 1.16E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6808448 chr3 44243607 G T 6.19E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4682949 chr3 44245155 T C 3.01E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10510740 chr3 44254630 T C 8.81E-04 Lymphocyte counts / / 22286170 rs10510741 chr3 44264194 G A 3.68E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4392391 chr3 44272966 G A 4.44E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4392391 chr3 44272966 G A 5.78E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs967285 chr3 44275276 C T 1.48E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs967285 chr3 44275276 C T 8.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9852733 chr3 44277339 C T 4.59E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9846155 chr3 44282840 A G 6.33E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9809107 chr3 44282934 G A 1.46E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9809107 chr3 44282934 G A 5.18E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9284879 chr3 44284584 G A 1.10E-04 Statin-induced myopathy C3orf77 missense 21826682 rs9284879 chr3 44284584 G A 8.41E-04 Obesity (extreme) C3orf77 missense 21935397 rs9284879 chr3 44284584 G A 9.43E-04 Response to cytidine analogues (gemcitabine) C3orf77 missense 24483146 rs1488623 chr3 44291850 C T 8.30E-04 Obesity (extreme) C3orf77 intron 21935397 rs2171569 chr3 44292399 A G 8.25E-04 Obesity (extreme) C3orf77 intron 21935397 rs13067367 chr3 44293275 T C 9.30E-04 Obesity (extreme) C3orf77 intron 21935397 rs9311352 chr3 44293839 C G 8.22E-04 Obesity (extreme) C3orf77 intron 21935397 rs4682735 chr3 44295184 T C 8.18E-04 Obesity (extreme) C3orf77 intron 21935397 rs4682960 chr3 44296403 T C 8.15E-04 Obesity (extreme) C3orf77 intron 21935397 rs7631790 chr3 44299205 C T 8.10E-04 Obesity (extreme) C3orf77 intron 21935397 rs7631790 chr3 44299205 C T 9.43E-04 Response to cytidine analogues (gemcitabine) C3orf77 intron 24483146 rs1124124 chr3 44302545 A T 8.07E-04 Obesity (extreme) C3orf77 intron 21935397 rs9821268 chr3 44303124 A G 8.06E-04 Obesity (extreme) C3orf77 intron 21935397 rs9821268 chr3 44303124 A G 2.43E-04 Response to cytidine analogues (gemcitabine) C3orf77 intron 24483146 rs11130023 chr3 44307888 A G 8.02E-04 Obesity (extreme) C3orf77 intron 21935397 rs12631341 chr3 44309268 A G 8.01E-04 Obesity (extreme) C3orf77 intron 21935397 rs12631341 chr3 44309268 A G 9.43E-04 Response to cytidine analogues (gemcitabine) C3orf77 intron 24483146 rs6768749 chr3 44309620 G T 7.98E-04 Obesity (extreme) C3orf77 intron 21935397 rs7349467 chr3 44314778 C T 7.95E-04 Obesity (extreme) C3orf77 intron 21935397 rs1387046 chr3 44324114 C G 7.94E-04 Obesity (extreme) C3orf77 intron 21935397 rs12486452 chr3 44324565 G A 7.91E-04 Obesity (extreme) C3orf77 intron 21935397 rs12486452 chr3 44324565 G A 9.43E-04 Response to cytidine analogues (gemcitabine) C3orf77 intron 24483146 rs7649004 chr3 44325471 G C 7.89E-04 Obesity (extreme) C3orf77 intron 21935397 rs6803491 chr3 44333153 T A 7.79E-04 Obesity (extreme) C3orf77 intron 21935397 rs13323323 chr3 44333324 G T 4.00E-06 IgG glycosylation C3orf77 intron 23382691 rs1565215 chr3 44334099 T C 7.70E-04 Obesity (extreme) C3orf77 intron 21935397 rs1565215 chr3 44334099 T C 2.64E-04 Response to cytidine analogues (gemcitabine) C3orf77 intron 24483146 rs1565215 chr3 44334099 T C 7.67E-04 Response to cytadine analogues (cytosine arabinoside) C3orf77 intron 24483146 rs1565214 chr3 44334299 C A 7.69E-04 Obesity (extreme) C3orf77 intron 21935397 rs1565214 chr3 44334299 C A 1.35E-04 Response to cytidine analogues (gemcitabine) C3orf77 intron 24483146 rs1565214 chr3 44334299 C A 6.62E-04 Response to cytadine analogues (cytosine arabinoside) C3orf77 intron 24483146 rs6780605 chr3 44338242 G A 7.65E-04 Obesity (extreme) C3orf77 intron 21935397 rs1488638 chr3 44342654 A C 7.62E-04 Obesity (extreme) C3orf77 intron 21935397 rs2372598 chr3 44343362 T C 7.60E-04 Obesity (extreme) C3orf77 intron 21935397 rs7630980 chr3 44348123 A G 7.45E-04 Obesity (extreme) C3orf77 intron 21935397 rs9853705 chr3 44353145 T G 7.03E-04 Obesity (extreme) C3orf77 intron 21935397 rs12386385 chr3 44457540 A G 7.98E-04 Obesity (extreme) / / 21935397 rs12108134 chr3 44543030 C T 6.80E-06 Urinary metabolites ZNF852 intron 21572414 rs1402751 chr3 44594030 C A 8.53E-04 Obesity (extreme) / / 21935397 rs149108320 chr3 44635975 G A 0.000014 Breast cancer(er negative) ZNF660 missense 23555315 rs1402752 chr3 44687300 G A 6.63E-04 Alzheimer's disease ZNF197 intron 21059989 rs1402752 chr3 44687300 G A 8.69E-06 Alzheimer's disease ZNF197 intron 21059989 rs4429669 chr3 44775325 A G 1.96E-05 Lymphocyte counts ZNF501 intron 22286170 rs9849390 chr3 44868381 G T 5.00E-06 Urinary metabolites KIF15 intron 21572414 rs7621143 chr3 44915992 T G 5.40E-06 Urinary metabolites / / 21572414 rs1532898 chr3 44922141 A C 7.37E-05 Interstitial lung disease TGM4 intron 23583980 rs9816639 chr3 44934381 A G 2.70E-05 Urinary metabolites TGM4 intron 21572414 rs6765789 chr3 44938586 A C 2.58E-11 Metabolite levels TGM4 intron 22286219 rs6768893 chr3 44939120 T C 2.66E-05 Height TGM4 intron pha003011 rs1995641 chr3 44943389 G A 8.70E-04 Coronary heart disease TGM4 missense 21971053 rs142655195 chr3 44943399 C A 0.00077 Breast cancer TGM4 missense 23555315 rs3749189 chr3 44986836 T C 6.60E-05 Memory performance ZDHHC3 intron 22105620 rs9835136 chr3 45036175 G A 1.41E-06 Lymphocyte counts EXOSC7 intron 22286170 rs6805138 chr3 45071538 A G 6.20E-05 HIV-1 control CLEC3B intron 20041166 rs2372851 chr3 45076308 A T 6.30E-11 Metabolite levels CLEC3B intron 22286219 rs4683029 chr3 45076823 A G 3.50E-05 Lipid levels CLEC3B intron 18193043 rs11924100 chr3 45083741 T C 4.36E-04 Smoking initiation / / 24665060 rs10514712 chr3 45083928 T C 8.07E-05 Alcohol and nictotine co-dependence / / 20158304 rs2372856 chr3 45111448 C A 6.80E-04 Urinary metabolites / / 21572414 rs6773576 chr3 45117173 A G 5.25E-04 White matter integrity / / 22425255 rs4682765 chr3 45125566 C T 0.00013 fMRI brain tests in schizophrenia CDCP1 UTR-3 22440650 rs7618923 chr3 45130725 C T 2.38E-04 Hemoglobin concentration CDCP1 intron 20534544 rs3749191 chr3 45134822 T C 7.45E-04 Coronary heart disease CDCP1 missense 21971053 rs3749191 chr3 45134822 T C 0.000021 Erectile dysfunction after radiotherapy for prostate cancer CDCP1 missense 23021708 rs2037358 chr3 45137087 T G 6.98E-05 Attention deficit hyperactivity disorder CDCP1 intron 22420046 rs4579052 chr3 45145019 G T 0.0000557 Panic disorder CDCP1 intron 23149450 rs4579052 chr3 45145019 G T 5.57E-05 Serum tamsulosin hydrochloride concentration CDCP1 intron 23151678 rs5007171 chr3 45149708 A G 2.17E-07 Multiple complex diseases CDCP1 intron 17554300 rs5007171 chr3 45149708 A G 3.10E-04 Urinary metabolites CDCP1 intron 21572414 rs12494480 chr3 45154357 G A 5.84E-04 Smoking quantity CDCP1 intron 24665060 rs4683049 chr3 45160335 G C 7.79E-05 Femoral neck bone geometry CDCP1 intron 22087292 rs6794913 chr3 45163449 A G 2.50E-04 Urinary metabolites CDCP1 intron 21572414 rs4683077 chr3 45210212 G A 8.49E-04 Multiple complex diseases / / 17554300 rs12330287 chr3 45212132 C T 1.30E-04 Urinary metabolites / / 21572414 rs4524316 chr3 45212443 T G 1.90E-04 Urinary metabolites / / 21572414 rs9850250 chr3 45213371 T A 6.79E-04 Suicide attempts in bipolar disorder / / 21041247 rs9850250 chr3 45213371 T A 7.30E-05 Urinary metabolites / / 21572414 rs9817295 chr3 45215803 G A 4.30E-04 Urinary metabolites / / 21572414 rs4683079 chr3 45215992 C G 1.90E-05 Urinary metabolites / / 21572414 rs4683081 chr3 45216880 A G 2.60E-04 Urinary metabolites / / 21572414 rs6767173 chr3 45220085 T C 8.47E-05 Response to citalopram treatment / / 19846067 rs17077435 chr3 45227101 G A 7.00E-04 Multiple complex diseases / / 17554300 rs17077435 chr3 45227101 G A 7.11E-04 Aortic root size / / 21223598 rs17077435 chr3 45227101 G A 2.20E-04 Smoking initiation / / 24665060 rs33731 chr3 45249923 T C 1.98E-06 Serum metabolites / / 19043545 rs28294 chr3 45256191 C G 8.46E-06 Serum metabolites / / 19043545 rs33741 chr3 45257947 T C 4.27E-04 Smoking initiation / / 24665060 rs6773435 chr3 45268654 G A,T 2.15E-04 Smoking initiation / / 24665060 rs33762 chr3 45278332 A C 1.76E-04 Type 2 diabetes / / 17463246 rs33767 chr3 45281604 G A 1.28E-05 Serum metabolites / / 19043545 rs33769 chr3 45282000 C T 9.00E-04 Urinary metabolites / / 21572414 rs33773 chr3 45284315 G A 1.12E-05 Serum metabolites / / 19043545 rs33773 chr3 45284315 G A 2.71E-05 Lung Function (Forced Expiratory Volume in 1 second) / / 25044411 rs28288 chr3 45290007 G A 8.66E-06 Serum metabolites / / 19043545 rs28288 chr3 45290007 G A 2.77E-05 Lung Function (Forced Expiratory Volume in 1 second) / / 25044411 rs33786 chr3 45293379 G A 8.55E-04 Alcohol dependence / / 20201924 rs33794 chr3 45300605 A G 5.82E-06 Serum metabolites / / 19043545 rs33794 chr3 45300605 A G 6.00E-06 Lung Function (Forced Expiratory Volume in 1 second) / / 25044411 rs33798 chr3 45303313 G A 2.02E-04 Multiple complex diseases / / 17554300 rs12633044 chr3 45307445 A C 3.05E-05 Body Mass Index / / pha003019 rs2215708 chr3 45311618 G A 5.55E-04 Alzheimer's disease / / 17998437 rs33801 chr3 45314894 T G 4.20E-04 Multiple complex diseases / / 17554300 rs7650391 chr3 45325521 A G 3.02E-05 Body Mass Index / / pha003019 rs7650391 chr3 45325521 A G 5.32E-05 Body Mass Index / / pha003022 rs33805 chr3 45327512 C T 3.80E-05 Body Mass Index / / pha003019 rs33805 chr3 45327512 C T 6.05E-05 Body Mass Index / / pha003022 rs4464495 chr3 45328423 C G 4.53E-04 Multiple complex diseases / / 17554300 rs33807 chr3 45334692 G A 2.80E-07 Urinary metabolites / / 21572414 rs9861198 chr3 45335390 C T 9.07E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9809772 chr3 45335495 T C 2.01E-06 C-reactive protein / / 22492993 rs854195 chr3 45342242 C T 5.90E-04 Urinary metabolites / / 21572414 rs9816196 chr3 45346378 C T 6.70E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6441911 chr3 45347519 C A 6.20E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9878275 chr3 45356039 A C 8.31E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9846284 chr3 45356966 G A 6.20E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9850725 chr3 45357427 G A 6.20E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9867344 chr3 45360872 G C 1.70E-06 C-reactive protein / / 22492993 rs854213 chr3 45374553 C T 3.97E-04 Multiple complex diseases / / 17554300 rs17077682 chr3 45375070 C G 6.10E-04 Multiple complex diseases / / 17554300 rs854215 chr3 45379597 G A 2.17E-06 C-reactive protein / / 22492993 rs146692665 chr3 45384683 G T 3.00E-06 Acne (severe) / / 24927181 rs11711985 chr3 45396036 C G 2.40E-04 Urinary metabolites / / 21572414 rs17077726 chr3 45397582 A G 7.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs17637580 chr3 45436473 G A 2.82E-04 Cholesterol LARS2 intron 17255346 rs11707177 chr3 45441280 C G 5.70E-04 Urinary metabolites LARS2 intron 21572414 rs13084381 chr3 45444155 A C 5.99E-04 Smoking initiation LARS2 intron 24665060 rs17576051 chr3 45449980 A G 8.20E-09 Urinary metabolites LARS2 intron 21572414 rs17576051 chr3 45449980 A G 0.0000284 Migraine LARS2 intron 22678113 rs17576051 chr3 45449980 A G 2.84E-05 Migraine LARS2 intron 22683712 rs41480152 chr3 45451623 C T 4.56E-04 Smoking initiation LARS2 intron 24665060 rs62244094 chr3 45470723 G T 5.40E-09 Urinary metabolites LARS2 intron 21572414 rs2014378 chr3 45476486 A G 1.71E-04 Smoking initiation LARS2 intron 24665060 rs4682785 chr3 45479698 T C 7.39E-04 Smoking initiation LARS2 intron 24665060 rs2063810 chr3 45483897 G A 6.08E-05 Multiple complex diseases LARS2 intron 17554300 rs1877960 chr3 45496144 G A 5.35E-05 Cognitive impairment induced by topiramate LARS2 intron 22091778 rs965238 chr3 45497671 G A 7.00E-04 Gamma gluatamyl transferase levels (interaction with age) LARS2 intron 22010049 rs3774692 chr3 45507305 T A 5.88E-05 Serum metabolites LARS2 intron 19043545 rs3774692 chr3 45507305 T A 1.52E-04 Smoking initiation LARS2 intron 24665060 rs4683118 chr3 45528134 T A 7.17E-05 Bipolar disorder and schizophrenia LARS2 intron 20889312 rs17639812 chr3 45536988 T C 2.80E-05 Urinary metabolites LARS2 intron 21572414 rs62243387 chr3 45543950 C A 5.70E-04 Urinary metabolites LARS2 intron 21572414 rs2128358 chr3 45549028 T C 9.24E-04 Amyotrophic lateral sclerosis (sporadic) LARS2 intron 24529757 rs17260680 chr3 45596445 C T 1.70E-07 Urinary metabolites / / 21572414 rs267241 chr3 45618309 G A 1.10E-05 Urinary metabolites / / 21572414 rs13084796 chr3 45619988 C T 8.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs1021124 chr3 45623774 G A 6.47E-04 White matter integrity / / 22425255 rs1021124 chr3 45623774 G A 7.26E-05 Lymphocyte counts / / pha003094 rs1021124 chr3 45623774 G A 3.41E-05 Neutrophil count / / pha003095 rs267216 chr3 45632221 A G 1.65E-04 Multiple complex diseases / / 17554300 rs267235 chr3 45640227 A C 1.20E-04 Urinary metabolites LIMD1 intron 21572414 rs267234 chr3 45640732 G A 8.00E-04 Urinary metabolites LIMD1 intron 21572414 rs267233 chr3 45642223 C G 6.50E-04 Urinary metabolites LIMD1 intron 21572414 rs267232 chr3 45644183 G A 7.50E-05 Urinary metabolites LIMD1 intron 21572414 rs13097531 chr3 45645082 C T 5.70E-04 Urinary metabolites LIMD1 intron 21572414 rs13094545 chr3 45647523 T A 3.60E-04 Urinary metabolites LIMD1 intron 21572414 rs12630731 chr3 45648015 C T 5.50E-04 Urinary metabolites LIMD1 intron 21572414 rs12330308 chr3 45648926 G C 4.00E-04 Urinary metabolites LIMD1 intron 21572414 rs13085281 chr3 45650380 C G 5.40E-04 Urinary metabolites LIMD1 intron 21572414 rs267208 chr3 45652046 G A 2.80E-06 Urinary metabolites LIMD1 intron 21572414 rs187884 chr3 45652055 G T 5.40E-04 Urinary metabolites LIMD1 intron 21572414 rs267209 chr3 45652161 G A 5.40E-04 Urinary metabolites LIMD1 intron 21572414 rs267210 chr3 45652275 C T 5.10E-04 Urinary metabolites LIMD1 intron 21572414 rs267211 chr3 45652393 A G 5.40E-04 Urinary metabolites LIMD1 intron 21572414 rs267212 chr3 45652734 A G 5.30E-04 Urinary metabolites LIMD1 intron 21572414 rs267213 chr3 45653283 G A 5.30E-04 Urinary metabolites LIMD1 intron 21572414 rs267228 chr3 45656723 G A 1.00E-04 Urinary metabolites LIMD1 intron 21572414 rs267230 chr3 45659356 T C 5.20E-04 Urinary metabolites LIMD1 intron 21572414 rs34996077 chr3 45662650 C T 1.10E-04 Urinary metabolites LIMD1 intron 21572414 rs3774675 chr3 45667387 T C 2.70E-04 Urinary metabolites LIMD1 intron 21572414 rs4683131 chr3 45667989 G A 4.45E-05 Cognitive impairment induced by topiramate LIMD1 intron 22091778 rs58879887 chr3 45668729 A T 1.10E-04 Urinary metabolites LIMD1 intron 21572414 rs62242172 chr3 45671204 C T 1.10E-04 Urinary metabolites LIMD1 intron 21572414 rs893563 chr3 45672210 G A 1.10E-04 Urinary metabolites LIMD1 intron 21572414 rs9311374 chr3 45672925 C T 3.18E-04 Multiple complex diseases LIMD1 intron 17554300 rs3774670 chr3 45673090 C T 1.30E-04 Urinary metabolites LIMD1 intron 21572414 rs7648681 chr3 45677398 G A 5.40E-04 Urinary metabolites LIMD1 intron 21572414 rs36136468 chr3 45677782 G A 7.50E-05 Urinary metabolites LIMD1 intron 21572414 rs13082607 chr3 45680581 T C 8.50E-04 Urinary metabolites LIMD1 intron 21572414 rs36002900 chr3 45682685 G A 7.10E-04 Urinary metabolites LIMD1 intron 21572414 rs34355059 chr3 45682897 C T 7.10E-04 Urinary metabolites LIMD1 intron 21572414 rs7648441 chr3 45683107 G A 4.56E-04 Suicide attempts in bipolar disorder LIMD1 intron 21423239 rs62242182 chr3 45683363 G A 2.70E-04 Urinary metabolites LIMD1 intron 21572414 rs1866402 chr3 45684955 C T 2.80E-04 Urinary metabolites LIMD1 intron 21572414 rs13094441 chr3 45688319 T A 3.10E-04 Urinary metabolites LIMD1 intron 21572414 rs34448158 chr3 45689473 T G 7.90E-04 Urinary metabolites LIMD1 intron 21572414 rs11710266 chr3 45690222 C T 1.40E-04 Urinary metabolites LIMD1 intron 21572414 rs35321098 chr3 45692006 G A 3.10E-04 Urinary metabolites LIMD1 intron 21572414 rs11709753 chr3 45694685 C T 1.70E-04 Urinary metabolites LIMD1 intron 21572414 rs2742408 chr3 45697817 A G 9.68E-04 Suicide attempts in bipolar disorder LIMD1 intron 21423239 rs2118752 chr3 45700125 A G 6.90E-04 Urinary metabolites LIMD1 intron 21572414 rs2578694 chr3 45701455 T C 1.70E-04 Urinary metabolites LIMD1 intron 21572414 rs12493946 chr3 45706167 C T 9.30E-04 Alzheimer's disease LIMD1 intron 17998437 rs2673023 chr3 45711367 T C 3.30E-04 Urinary metabolites LIMD1 intron 21572414 rs1318992 chr3 45711735 T C 3.30E-04 Urinary metabolites LIMD1 intron 21572414 rs2016681 chr3 45712280 G C 3.20E-04 Urinary metabolites LIMD1 intron 21572414 rs1962892 chr3 45712301 C T 3.20E-04 Urinary metabolites LIMD1 intron 21572414 rs2578679 chr3 45715688 G A 5.10E-04 Urinary metabolites LIMD1 intron 21572414 rs2742417 chr3 45731451 C T 5.00E-07 Response to antidepressant treatment SACM1L intron 22041458 rs3774666 chr3 45731732 A C 7.00E-08 Urinary metabolites SACM1L intron 21572414 rs2673051 chr3 45732409 G T 9.77E-04 White matter integrity SACM1L intron 22425255 rs11707239 chr3 45735152 A G 1.81E-04 Multiple complex diseases SACM1L intron 17554300 rs2742424 chr3 45735218 G A 5.26E-04 Alzheimer's disease SACM1L intron 17998437 rs2742424 chr3 45735218 G A 9.56E-05 Serum metabolites SACM1L intron 19043545 rs56331328 chr3 45737844 C T 3.70E-09 Urinary metabolites SACM1L intron 21572414 rs2742369 chr3 45754487 C A 9.77E-04 White matter integrity SACM1L intron 22425255 rs13086080 chr3 45762725 C T 9.70E-08 Urinary metabolites SACM1L intron 21572414 rs62242217 chr3 45767174 C T 1.50E-05 Urinary metabolites SACM1L intron 21572414 rs17078258 chr3 45773963 A G 7.16E-05 Multiple complex diseases SACM1L intron 17554300 rs2742461 chr3 45774501 C G 6.59E-04 Multiple complex diseases SACM1L intron 17554300 rs12490575 chr3 45792209 C T 4.35E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12495593 chr3 45795498 A G 2.50E-05 Urinary metabolites / / 21572414 rs4683139 chr3 45796429 A G 7.73E-04 Alzheimer's disease / / 17998437 rs9864354 chr3 45801912 C T 6.00E-12 Urinary metabolites SLC6A20 intron 21572414 rs2286489 chr3 45804069 C T 6.50E-04 Urinary metabolites SLC6A20 intron 21572414 rs6770261 chr3 45804734 C T 8.30E-06 Urinary metabolites SLC6A20 intron 21572414 rs9857669 chr3 45806066 C T 5.30E-09 Urinary metabolites SLC6A20 intron 21572414 rs9867918 chr3 45807699 G C 2.50E-11 Urinary metabolites SLC6A20 intron 21572414 rs4327428 chr3 45809329 C A 6.40E-12 Urinary metabolites SLC6A20 intron 21572414 rs4327428 chr3 45809329 C A 3.00E-12 Blood metabolite levels SLC6A20 intron 24816252 rs2108918 chr3 45809829 A G 2.00E-04 Urinary metabolites SLC6A20 intron 21572414 rs2108917 chr3 45809843 A G 2.00E-04 Urinary metabolites SLC6A20 intron 21572414 rs6768156 chr3 45810604 A T 4.20E-05 Urinary metabolites SLC6A20 intron 21572414 rs9818982 chr3 45812514 G A 1.40E-10 Urinary metabolites SLC6A20 intron 21572414 rs17279437 chr3 45814094 G A 3.00E-19 Urinary metabolites SLC6A20 missense 21572414 rs17279437 chr3 45814094 G A 1.00E-20 Blood metabolite levels SLC6A20 missense 24816252 rs17279437 chr3 45814094 G A 2.00E-35 Blood metabolite ratios SLC6A20 missense 24816252 rs17279465 chr3 45814748 A G 2.20E-04 Blood pressure SLC6A20 intron 21228793 rs758386 chr3 45817418 A G 2.00E-07 Immune reponse to smallpox (secreted TNF-alpha) SLC6A20 cds-synon 22610502 rs17078335 chr3 45818419 A G 0.00067 Salmonella-induced pyroptosis SLC6A20 intron 22837397 rs2742396 chr3 45819701 C T 2.70E-04 Urinary metabolites SLC6A20 intron 21572414 rs2531748 chr3 45819837 A G 7.00E-04 Urinary metabolites SLC6A20 intron 21572414 rs2252547 chr3 45821624 T C 3.00E-04 Urinary metabolites SLC6A20 intron 21572414 rs1860263 chr3 45832052 A T 1.31E-04 Type 2 diabetes SLC6A20 intron 17463246 rs13064991 chr3 45834811 G T 4.60E-05 Type 2 diabetes SLC6A20 intron 17293876 rs17763742 chr3 45846769 A G 3.38E-04 Multiple complex diseases / / 17554300 rs2531757 chr3 45850520 C A 8.00E-04 Urinary metabolites / / 21572414 rs11130076 chr3 45853072 C T 9.36E-06 Uric acid levels / / 21294900 rs17713054 chr3 45859651 G A 2.57E-04 Multiple complex diseases / / 17554300 rs7614952 chr3 45900621 A G 2.34E-05 Monocyte chemoattractant protein-1 / / pha003071 rs1024626 chr3 45902844 G A 7.60E-04 Coronary Artery Disease / / 17634449 rs12639224 chr3 45916222 C T 7.43E-05 Behcet's disease / / pha002888 rs9842595 chr3 45922691 G A,T 1.90E-05 Hepatitis B vaccine response / / 21764829 rs12633699 chr3 45922735 G A 2.89E-04 Insulin resistance / / 21901158 rs12638201 chr3 45934279 G A 1.14E-05 Depression (quantitative trait) CCR9 intron 20800221 rs3774642 chr3 45937782 C G 3.37E-05 Depression (quantitative trait) CCR9 intron 20800221 rs17765088 chr3 45943595 C G 1.80E-05 Urinary metabolites CCR9 UTR-3 21572414 rs1471962 chr3 45949187 G C 4.40E-05 Urinary metabolites / / 21572414 rs12493471 chr3 45951678 T C 1.80E-04 Depression (quantitative trait) / / 20800221 rs9810934 chr3 45954352 A G 4.73E-04 Depression (quantitative trait) / / 20800221 rs7652331 chr3 45962752 T C 4.47E-05 Prostate cancer FYCO1 UTR-3 18073375 rs7652331 chr3 45962752 T C 4.97E-04 Depression (quantitative trait) FYCO1 UTR-3 20800221 rs11130079 chr3 45978473 A G 1.05E-04 HIV-1 viral setpoint FYCO1 intron 21490045 rs2234358 chr3 45989044 T G 9.70E-10 HIV-1 non-progression CXCR6 UTR-3 20704485 rs2234358 chr3 45989044 T G 9.71E-05 Monocyte chemoattractant protein-1 CXCR6 UTR-3 pha003071 rs4388012 chr3 45996501 A G 3.56E-04 Multiple complex diseases FYCO1 intron 17554300 rs1545985 chr3 46005478 G A 6.61E-06 Prostate cancer FYCO1 intron 18073375 rs1545985 chr3 46005478 G A 5.83E-04 Depression (quantitative trait) FYCO1 intron 20800221 rs13078739 chr3 46007488 G A 2.87E-05 Multiple complex diseases FYCO1 intron 17554300 rs4683159 chr3 46025013 A G 9.39E-04 Depression (quantitative trait) FYCO1 intron 20800221 rs13075758 chr3 46025048 G A 0.0000168 Primary sclerosing cholangitis FYCO1 intron 23603763 rs11130082 chr3 46025518 T C 9.44E-04 Depression (quantitative trait) FYCO1 intron 20800221 rs13086858 chr3 46026699 C A 9.51E-04 Depression (quantitative trait) FYCO1 intron 20800221 rs13086858 chr3 46026699 C A 5.57E-04 Smoking cessation FYCO1 intron 24665060 rs7653682 chr3 46029271 A G 6.96E-04 Suicide attempts in bipolar disorder FYCO1 intron 21423239 rs1873000 chr3 46029458 G C 9.57E-04 Depression (quantitative trait) FYCO1 intron 20800221 rs7628447 chr3 46030003 C T 9.58E-04 Depression (quantitative trait) FYCO1 intron 20800221 rs2133660 chr3 46031957 C T 8.02E-05 Behcet's disease FYCO1 intron pha002888 rs4683166 chr3 46089341 G C 3.12E-05 Telomere length / / 20139977 rs1500005 chr3 46102620 G A 8.28E-07 Inflammatory biomarkers / / 22291609 rs1388608 chr3 46118749 T G 4.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs9990063 chr3 46123839 T G 4.48E-04 Parkinson's disease / / 17052657 rs17078589 chr3 46124511 G C 3.35E-04 Multiple complex diseases / / 17554300 rs4683177 chr3 46126467 T C 2.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs6767559 chr3 46127642 G C 3.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs902760 chr3 46127987 T C 2.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs751625 chr3 46128080 A G 5.90E-04 Multiple complex diseases / / 17554300 rs6808712 chr3 46131231 G C 2.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs1491952 chr3 46141902 T C 7.16E-04 Multiple complex diseases / / 17554300 rs1873616 chr3 46143602 T C 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs1392296 chr3 46143930 A G 5.35E-04 Depression (quantitative trait) / / 20800221 rs2888512 chr3 46145295 T G 0.000862752 Hypertension (early onset hypertension) / / 22479346 rs1546076 chr3 46150517 A G 3.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs1500004 chr3 46150937 G A 8.60E-06 Urinary metabolites / / 21572414 rs1500004 chr3 46150937 G A 9.33E-09 Macrophage inflammatory protein-1b / / 23696881 rs2087727 chr3 46153768 G C 2.10E-04 Urinary metabolites / / 21572414 rs1809733 chr3 46154473 G A 3.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs9820016 chr3 46154841 A C 3.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs1388606 chr3 46158434 T C 3.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs9879257 chr3 46158717 G A 6.37E-04 Multiple complex diseases / / 17554300 rs6807578 chr3 46163873 A G 3.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs4682811 chr3 46164795 A G 2.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs1388605 chr3 46166734 T C 2.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs2373152 chr3 46170086 G A 3.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs2373155 chr3 46172072 T C 9.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs6774742 chr3 46173446 A C 0.00000195 Lumbar spine bone mineral density (premenopausal) / / 23074152 rs4683182 chr3 46173936 A G 4.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs7634822 chr3 46174936 G C 1.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs1873618 chr3 46175976 C T 1.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs1873617 chr3 46175980 T C 1.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs10510749 chr3 46180416 C T 2.63E-05 Behcet's disease / / 23291587 rs10510749 chr3 46180416 C T 4.22E-05 Behcet's disease / / pha002888 rs7631551 chr3 46186310 C A 9.40E-05 Response to statin therapy / / 20339536 rs7631551 chr3 46186310 C A 7.95E-05 Behcet's disease / / pha002888 rs7616215 chr3 46205686 C T 3.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs7616215 chr3 46205686 C T 8.60E-09 Celiac disease / / 22057235 rs7616215 chr3 46205686 C T 4.00E-13 Behcet's disease / / 23291587 rs13098911 chr3 46235201 C T 3.00E-17 Celiac disease / / 20190752 rs13098911 chr3 46235201 C T 3.00E-17 Asthma / / 21150878 rs13098911 chr3 46235201 C T 3.26E-17 Celiac disease and Rheumatoid arthritis / / 21383967 rs13098911 chr3 46235201 C T 3.26E-17 Multiple sclerosis / / 22190364 rs3176953 chr3 46243718 T A 8.80E-04 Urinary metabolites CCR1 UTR-3 21572414 rs79893749 chr3 46253650 C T 0.000000188 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs79893749 chr3 46253650 C T 0.000000939 Oligoarticular juvenile idiopathic arthritis / / 23603761 rs2373156 chr3 46266379 A T 1.70E-05 Urinary metabolites / / 21572414 rs11919943 chr3 46266726 T C 5.15E-04 Multiple complex diseases / / 17554300 rs11919943 chr3 46266726 T C 2.70E-05 Urinary metabolites / / 21572414 rs7651539 chr3 46268079 C T 1.70E-05 Urinary metabolites / / 21572414 rs13067058 chr3 46273766 G A 6.65E-05 Lymphocyte counts / / 22286170 rs58697594 chr3 46275570 G A 1.00E-04 Urinary metabolites / / 21572414 rs13096142 chr3 46281744 C T 2.35E-05 Multiple complex diseases / / 17554300 rs13096142 chr3 46281744 C T 4.52E-04 Celiac disease / / 23936387 rs13096142 chr3 46281744 C T 4.00E-08 Celiac disease / / 24999842 rs12636651 chr3 46282391 T C 7.00E-09 Monocyte chemoattractant protein-1 / / 23017229 rs12636651 chr3 46282391 T C 7.00E-09 Obesity-related traits / / 23251661 rs201395642 chr3 46284093 G GTAA 8.29E-05 Monocyte chemoattractant protein-1 CCR3 intron pha003071 rs9853223 chr3 46284093 G A 8.29E-05 Monocyte chemoattractant protein-1 CCR3 intron pha003071 rs7652290 chr3 46299765 A G 3.25E-07 Obesity-related traits CCR3 intron 23251661 rs4413345 chr3 46310921 T C 1.86E-06 Obesity-related traits / / 23251661 rs13100243 chr3 46317898 A T 9.38E-04 Multiple complex diseases / / 17554300 rs7371987 chr3 46318508 A G 1.80E-04 Multiple complex diseases / / 17554300 rs4383561 chr3 46320462 T C 9.82E-05 Cognitive performance / / 19734545 rs4383561 chr3 46320462 T C 8.65E-06 Lung adenocarcinoma / / 19836008 rs9839623 chr3 46323859 A G 3.47E-05 Multiple complex diseases / / 17554300 rs9839623 chr3 46323859 A G 7.50E-05 Response to antidepressants / / 19736353 rs7645716 chr3 46336781 G A 9.56E-08 Obesity-related traits / / 23251661 rs9990343 chr3 46339812 A G 4.00E-07 Brain structure / / 20171287 rs9990343 chr3 46339812 A G 1.87E-05 Behcet's disease / / 23291587 rs9990343 chr3 46339812 A G 2.76E-05 Behcet's disease / / pha002888 rs6441958 chr3 46341335 C A 1.32E-05 Multiple complex diseases / / 17554300 rs6441959 chr3 46342429 A G 1.30E-05 Multiple complex diseases / / 17554300 rs11711054 chr3 46345611 G A 6.41E-04 Celiac disease / / 23936387 rs11711054 chr3 46345611 G A 8.80E-08 Celiac disease / / 24999842 rs10510751 chr3 46346025 T G 3.74E-06 Obesity-related traits / / 23251661 rs12494200 chr3 46350538 C T 0.0003602 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12494200 chr3 46350538 C T 3.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs57093591 chr3 46350716 T C 7.30E-05 Urinary metabolites / / 21572414 rs6441960 chr3 46351874 C T 1.72E-04 Multiple complex diseases / / 17554300 rs6441961 chr3 46352384 T C 4.50E-07 Multiple complex diseases / / 17554300 rs6441961 chr3 46352384 T C 3.00E-07 Celiac disease / / 18311140 rs6441961 chr3 46352384 T C 1.66E-05 Type 1 diabetes / / 18978792 rs6441961 chr3 46352384 T C 8.99E-04 Celiac disease / / 23936387 rs6441961 chr3 46352384 T C 6.63E-08 Celiac disease / / 24999842 rs2157057 chr3 46366269 A G 1.33E-06 Multiple complex diseases / / 17554300 rs2157057 chr3 46366269 A G 7.05E-05 Type 1 diabetes / / 18978792 rs2157058 chr3 46366324 C T 3.20E-05 Multiple complex diseases / / 17554300 rs2097282 chr3 46378025 C T 1.10E-20 Celiac disease / / 22057235 rs6441970 chr3 46384169 A G 3.92E-06 Multiple complex diseases / / 17554300 rs113341849 chr3 46384204 G A 1.37E-11 Macrophage inflammatory protein-1b / / 23696881 rs6441971 chr3 46391071 C T 4.33E-06 Multiple complex diseases / / 17554300 rs3918357 chr3 46393970 C A 8.49E-08 Inflammatory biomarkers CCR2 nearGene-5 22291609 rs3092962 chr3 46397039 G A 4.54E-06 Multiple complex diseases CCR2 intron 17554300 rs1799864 chr3 46399208 G A 2.82E-06 Obesity-related traits CCR2 missense 23251661 rs1799865 chr3 46399798 T C 5.99E-07 Multiple complex diseases CCR2 cds-synon 17554300 rs743660 chr3 46402018 G A 5.61E-06 Multiple complex diseases CCR2 UTR-3 17554300 rs3092957 chr3 46403961 G A 2.36E-04 Multiple complex diseases / / 17554300 rs3136536 chr3 46409636 C T 1.52E-04 Birth weight CCR5 nearGene-5 17255346 rs11575821 chr3 46422355 G A 7.29E-04 Multiple complex diseases / / 17554300 rs11575821 chr3 46422355 G A 1.40E-04 Urinary metabolites / / 21572414 rs7652037 chr3 46423063 A C 7.32E-04 Multiple complex diseases / / 17554300 rs7652037 chr3 46423063 A C 2.34E-05 HIV-1 control / / 20041166 rs7652037 chr3 46423063 A C 1.50E-04 Urinary metabolites / / 21572414 rs6441975 chr3 46428190 A C 5.00E-06 AIDS progression / / 21502085 rs17782636 chr3 46440072 T G 6.17E-04 Multiple complex diseases / / 17554300 rs916093 chr3 46444794 T C 2.60E-04 Urinary metabolites / / 21572414 rs11574428 chr3 46446721 T A 1.60E-04 Urinary metabolites / / 21572414 rs11574428 chr3 46446721 T A 0.000387 Salmonella-induced pyroptosis / / 22837397 rs6808835 chr3 46449864 G T 6.73E-05 HIV-1 control CCRL2 cds-synon 20041166 rs6808835 chr3 46449864 G T 2.80E-04 Urinary metabolites CCRL2 cds-synon 21572414 rs6441977 chr3 46450072 G A 2.07E-05 HIV-1 control CCRL2 missense 20041166 rs6441977 chr3 46450072 G A 9.80E-05 Urinary metabolites CCRL2 missense 21572414 rs6441977 chr3 46450072 G A 0.000258 Salmonella-induced pyroptosis CCRL2 missense 22837397 rs2157062 chr3 46451647 C T 3.40E-04 Urinary metabolites / / 21572414 rs1015164 chr3 46451680 A G 9.00E-06 AIDS progression / / 21502085 rs6762266 chr3 46452863 T C 9.50E-04 Multiple complex diseases / / 17554300 rs6762266 chr3 46452863 T C 1.80E-04 Urinary metabolites / / 21572414 rs6762266 chr3 46452863 T C 0.000703 Salmonella-induced pyroptosis / / 22837397 rs6791599 chr3 46458942 G A 1.70E-04 Urinary metabolites / / 21572414 rs7613132 chr3 46460163 A G 8.26E-05 Hearing function / / 17255346 rs7623238 chr3 46460351 G A 9.21E-05 Hearing function / / 17255346 rs4630979 chr3 46460718 G C 1.19E-04 Hearing function / / 17255346 rs2097276 chr3 46460794 G T 9.11E-05 Hearing function / / 17255346 rs7624805 chr3 46463424 A G 6.56E-05 Cervical cancer / / 24700089 rs6441991 chr3 46484283 T A 1.36E-04 Multiple complex diseases LTF intron 17554300 rs6441991 chr3 46484283 T A 4.80E-05 Celiac disease LTF intron 22057235 rs17141154 chr3 46491267 G A 6.21E-04 Femoral neck bone geometry LTF intron 20175129 rs11707471 chr3 46498865 T G 4.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LTF intron 20877124 rs11707471 chr3 46498865 T G 1.73E-04 Arthritis (juvenile idiopathic) LTF intron 22354554 rs141854619 chr3 46501168 A T 0.0004 Breast cancer LTF missense 23555315 rs1126478 chr3 46501213 T C 3.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LTF missense 20877124 rs1520483 chr3 46510209 C T 1.81E-04 Femoral neck bone geometry / / 20175129 rs1520483 chr3 46510209 C T 7.14E-04 Femoral neck bone geometry / / 20175129 rs7641783 chr3 46514272 T C 4.06E-04 Femoral neck bone geometry / / 20175129 rs7641783 chr3 46514272 T C 6.56E-05 Femoral neck bone geometry / / 20175129 rs7644995 chr3 46530169 C T 9.81E-06 Lung adenocarcinoma / / 19836008 rs883739 chr3 46538018 G T 4.99E-05 Femoral neck bone geometry / / 20175129 rs883739 chr3 46538018 G T 8.87E-05 Femoral neck bone geometry / / 20175129 rs7430431 chr3 46541147 T C 1.61E-07 Femoral neck bone geometry RTP3 intron 20175129 rs7430431 chr3 46541147 T C 1.92E-06 Femoral neck bone geometry RTP3 intron 20175129 rs11130094 chr3 46541503 G A 2.49E-04 Femoral neck bone geometry RTP3 intron 20175129 rs10514713 chr3 46543617 C A 2.68E-04 Femoral neck bone geometry / / 20175129 rs10514713 chr3 46543617 C A 3.09E-04 Femoral neck bone geometry / / 20175129 rs17030627 chr3 46556948 T G 1.89E-04 HIV-1 viral setpoint LRRC2 UTR-3 17641165 rs6791703 chr3 46569721 G T 2.93E-04 Multiple complex diseases LRRC2 intron 17554300 rs6791703 chr3 46569721 G T 1.80E-04 Femoral neck bone geometry LRRC2 intron 20175129 rs6791703 chr3 46569721 G T 8.69E-07 Femoral neck bone geometry LRRC2 intron 20175129 rs9810340 chr3 46584172 A T 1.12E-04 Multiple complex diseases LRRC2 intron 17554300 rs9810340 chr3 46584172 A T 5.33E-07 Femoral neck bone geometry LRRC2 intron 20175129 rs9810340 chr3 46584172 A T 7.70E-05 Femoral neck bone geometry LRRC2 intron 20175129 rs7648827 chr3 46586179 C T 9.67E-05 Non-alcoholic fatty liver disease histology (other) LRRC2 intron 20708005 rs11710224 chr3 46586278 C G 0.0000782 Coronary artery disease LRRC2 intron 23202125 rs1879325 chr3 46593147 A G 3.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LRRC2 intron 20877124 rs13321616 chr3 46595169 G A 3.10E-04 Urinary metabolites LRRC2 intron 21572414 rs2280410 chr3 46599937 T C 5.74E-07 Non-albumin protein levels LRRC2 intron 22558069 rs2280411 chr3 46599984 A G 1.20E-04 Urinary metabolites LRRC2 intron 21572414 rs2280412 chr3 46600068 A G 7.00E-04 Urinary metabolites LRRC2 intron 21572414 rs17078953 chr3 46601753 C T 6.50E-04 Urinary metabolites LRRC2 intron 21572414 rs3827494 chr3 46602231 A G 8.60E-05 Urinary metabolites LRRC2 intron 21572414 rs2139633 chr3 46602736 A G 7.50E-05 Urinary metabolites LRRC2 intron 21572414 rs9822457 chr3 46603951 C T 7.80E-05 Urinary metabolites LRRC2 intron 21572414 rs9822459 chr3 46603955 C T 4.60E-04 Urinary metabolites LRRC2 intron 21572414 rs2385855 chr3 46604586 A G 1.10E-04 Urinary metabolites LRRC2 intron 21572414 rs871636 chr3 46605091 C T 7.10E-05 Urinary metabolites LRRC2 intron 21572414 rs3806700 chr3 46617311 A C 8.30E-04 Multiple complex diseases TDGF1 intron 17554300 rs17078977 chr3 46636530 C T 4.03E-04 Type 1 diabetes / / 21980299 rs17287638 chr3 46637687 A G 3.40E-04 Urinary metabolites / / 21572414 rs1520485 chr3 46644094 G A 1.40E-04 Urinary metabolites / / 21572414 rs6799581 chr3 46644909 T G 5.35E-05 Systemic sclerosis / / 21750679 rs9817966 chr3 46650540 A G 3.40E-05 Urinary metabolites / / 21572414 rs2176862 chr3 46650993 C T 4.00E-06 Plasma amyloid beta peptide concentrations (ABx-42) / / 24535457 rs1520489 chr3 46677519 G A 9.99E-05 Body Fat Distribution / / pha003016 rs1520489 chr3 46677519 G A 4.23E-05 Body Fat Distribution / / pha003017 rs1520489 chr3 46677519 G A 1.83E-05 Body Fat Distribution / / pha003018 rs12491236 chr3 46688481 C T 3.77E-05 Body Fat Distribution / / pha003017 rs12491236 chr3 46688481 C T 1.62E-05 Body Fat Distribution / / pha003018 rs7633770 chr3 46688562 G A 6.42E-05 Lung adenocarcinoma / / 19836008 rs9861101 chr3 46692379 C T 5.66E-04 Depression (quantitative trait) / / 20800221 rs17079097 chr3 46696797 T C 4.60E-04 Depression (quantitative trait) / / 20800221 rs6442013 chr3 46700713 C T 4.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7373994 chr3 46701114 G C 1.80E-05 Urinary metabolites / / 21572414 rs7633016 chr3 46728659 G A 3.19E-06 Leprosy ALS2CL intron pha002872 rs7642448 chr3 46729757 C G 8.74E-04 Birth weight ALS2CL missense 17255346 rs4076927 chr3 46730749 A G 2.53E-06 Leprosy ALS2CL intron pha002872 rs7639979 chr3 46774776 A G 3.17E-04 Alcohol dependence PRSS46 intron 20201924 rs6808303 chr3 46777885 T C 2.23E-04 Alcohol dependence PRSS46 UTR-5 20201924 rs6793661 chr3 46778008 C T 2.23E-04 Alcohol dependence / / 20201924 rs1077216 chr3 46892161 C T 2.00E-04 Iris characteristics / / 21835309 rs6778660 chr3 46895300 A G 5.99E-04 Smoking quantity / / 24665060 rs6781266 chr3 46895333 T C 2.48E-04 Smoking quantity / / 24665060 rs6442037 chr3 46929546 G A 4.70E-06 Type 2 diabetes PTH1R intron 21647700 rs4683301 chr3 46931478 A T 6.60E-06 Urinary metabolites PTH1R intron 21572414 rs17079313 chr3 46975317 G A 4.05E-10 Multiple complex diseases CCDC12 intron 17554300 rs4683295 chr3 46978923 A G 6.71E-04 Tourette syndrome CCDC12 intron 22889924 rs2061197 chr3 47001350 C T 8.10E-04 Multiple complex diseases CCDC12 intron 17554300 rs2305634 chr3 47043538 C T 6.29E-05 Serum metabolites NBEAL2 cds-synon 19043545 rs181413143 chr3 47047500 G A 0.0001 Breast cancer NBEAL2 missense 23555315 rs2290547 chr3 47061183 G A,C,T 6.86E-04 Type 2 diabetes SETD2 intron 17846125 rs2290547 chr3 47061183 G A,C,T 4.00E-09 HDL cholesterol SETD2 intron 24097068 rs11917361 chr3 47070497 C A 8.40E-04 Multiple complex diseases SETD2 intron 17554300 rs9828473 chr3 47159688 G A 6.84E-04 Alcohol dependence SETD2 intron 20201924 rs7639121 chr3 47303170 G T 2.04E-04 Multiple complex diseases KIF9 intron 17554300 rs295442 chr3 47335881 A C 2.59E-05 Serum metabolites KLHL18 intron 19043545 rs8180040 chr3 47388947 T A 2.59E-05 Serum metabolites / / 19043545 rs8180040 chr3 47388947 T A 2.00E-06 Colorectal cancer / / 23350875 rs4858888 chr3 47405305 C T 2.19E-05 Serum metabolites / / 19043545 rs2062278 chr3 47416761 A G 7.84E-06 Serum metabolites / / 19043545 rs138320436 chr3 47447473 C A 0.00021 Breast cancer PTPN23 missense 23555315 rs12636851 chr3 47463567 T C 8.79E-06 Serum metabolites SCAP intron 19043545 rs6800271 chr3 47470787 T A 2.19E-05 Serum metabolites SCAP intron 19043545 rs11130137 chr3 47578838 G A 2.68E-05 Serum metabolites / / 19043545 rs17303478 chr3 47897367 G C 7.90E-04 Multiple complex diseases MAP4 intron 17554300 rs34675858 chr3 47902247 C T 6.60E-04 Alcohol dependence MAP4 intron 20201924 rs17729010 chr3 47912703 G A 1.47E-04 Multiple complex diseases MAP4 intron 17554300 rs319690 chr3 47927484 T C 3.00E-08 Blood pressure MAP4 intron 21909110 rs2053767 chr3 47999674 A G 3.07E-04 Parkinson's disease MAP4 intron 17052657 rs7642590 chr3 48099750 G A 0.000073 Coronary artery disease MAP4 intron 23202125 rs10446426 chr3 48170521 C G 2.10E-04 Iris characteristics / / 21835309 rs9832957 chr3 48185266 A G 4.60E-05 Personality dimensions / / 18957941 rs3731544 chr3 48207997 C A,G,T 1.01E-04 Multiple complex diseases CDC25A intron 17554300 rs3731539 chr3 48209486 C T 6.12E-04 Alcohol dependence CDC25A intron 20201924 rs11130161 chr3 48259631 G A 4.61E-04 Coronary heart disease / / 21971053 rs6442112 chr3 48316034 A G 6.90E-05 Personality dimensions / / 18957941 rs11706277 chr3 48360433 A G 1.20E-04 Lymphocyte counts SPINK8 intron 22286170 rs11716371 chr3 48362750 C T 2.84E-05 Post-operative nausea and vomiting SPINK8 intron 21694509 rs6779517 chr3 48384388 C T 5.70E-05 Post-operative nausea and vomiting / / 21694509 rs6779517 chr3 48384388 C T 4.92E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7610524 chr3 48395372 A G 9.87E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs986739 chr3 48395539 G C 5.84E-04 Multiple complex diseases / / 17554300 rs4558783 chr3 48407462 C T 3.75E-07 Post-operative nausea and vomiting / / 21694509 rs9826195 chr3 48433635 A C 4.53E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FBXW12 intron 24023788 rs4858818 chr3 48450082 T C 8.68E-04 Alcohol dependence PLXNB1 intron 20201924 rs730566 chr3 48487048 C A 7.00E-06 Prion diseases / / 22210626 rs9876781 chr3 48487338 G A 1.00E-06 Longevity / / 20834067 rs3135940 chr3 48507575 G A 6.00E-06 Obesity-related traits TREX1 UTR-5 23251661 rs11710798 chr3 48570686 A C 7.63E-04 Depression (quantitative trait) PFKFB4 intron 20800221 rs9839959 chr3 48599898 G A 0.000000793 LDL cholesterol UCN2 UTR-3 23063622 rs2255532 chr3 48624611 C T 5.02E-04 Amyotrophic Lateral Sclerosis COL7A1 intron 17362836 rs139999010 chr3 48637143 C T 0.00054 Breast cancer UQCRC1 missense 23555315 rs13063312 chr3 48661985 G A 4.95E-05 Psoriasis / / 20953190 rs13063312 chr3 48661985 G A 4.30E-05 Blood Pressure / / pha003045 rs13063312 chr3 48661985 G A 2.32E-05 Blood Pressure / / pha003046 rs13063312 chr3 48661985 G A 1.62E-05 Blood Pressure / / pha003047 rs13063312 chr3 48661985 G A 2.71E-05 Blood Pressure / / pha003048 rs2276852 chr3 48666923 A G 6.65E-05 Blood Pressure SLC26A6 intron pha003047 rs13324142 chr3 48669447 C T 5.45E-05 Psoriasis SLC26A6 missense 20953190 rs13324142 chr3 48669447 C T 2.52E-05 Blood Pressure SLC26A6 missense pha003045 rs13324142 chr3 48669447 C T 2.30E-05 Blood Pressure SLC26A6 missense pha003046 rs13324142 chr3 48669447 C T 9.41E-06 Blood Pressure SLC26A6 missense pha003047 rs13324142 chr3 48669447 C T 2.57E-05 Blood Pressure SLC26A6 missense pha003048 rs7633840 chr3 48719638 T C 2.95E-04 Heart rate NCKIPSD intron 23583979 rs3172494 chr3 48731487 G T 6.10E-05 Lung adenocarcinoma IP6K2 UTR-3 19836008 rs9882443 chr3 48749064 G A 4.37E-04 Heart rate IP6K2 intron 23583979 rs11708786 chr3 48752654 C T 3.53E-04 Multiple complex diseases IP6K2 intron 17554300 rs3923913 chr3 48842864 G A 3.86E-09 HDL cholesterol PRKAR2A intron 23063622 rs7621226 chr3 48928759 T C 8.43E-04 Heart rate SLC25A20 intron 23583979 rs4974078 chr3 49009386 C T 2.20E-05 Urinary metabolites ARIH2 intron 21572414 rs4974078 chr3 49009386 C T 9.84E-04 Response to cytadine analogues (cytosine arabinoside) ARIH2 intron 24483146 rs13324117 chr3 49012672 C T 8.43E-04 Amyotrophic lateral sclerosis (sporadic) ARIH2 intron 24529757 rs11706052 chr3 49064110 A G 1 Drug response to Mycophenolic Acid IMPDH2 intron 19770842 rs4955420 chr3 49208865 T C 8.08E-04 Lymphocyte counts KLHDC8B nearGene-5 22286170 rs7617480 chr3 49210732 A C 3.00E-08 Menarche (age at onset) KLHDC8B intron 21102462 rs2117938 chr3 49263850 G A 5.71E-04 Type 2 diabetes CCDC36 intron 17463246 rs2304442 chr3 49322027 T A 5.07E-05 Multiple complex diseases USP4 intron 17554300 rs9874474 chr3 49326178 A G 1.31E-06 Crohn's disease USP4 intron 17804789 rs4410472 chr3 49329090 A T 1.75E-05 Multiple complex diseases USP4 intron 17554300 rs4410472 chr3 49329090 A T 1.53E-06 Crohn's disease USP4 intron 17804789 rs2230929 chr3 49343175 G A,C,T 1.38E-06 Crohn's disease USP4 missense 17804789 rs9864406 chr3 49352619 T C 4.57E-05 Multiple complex diseases USP4 intron 17554300 rs9873994 chr3 49359943 T C 1.63E-06 Crohn's disease USP4 intron 17804789 rs9863142 chr3 49366741 G C 6.89E-05 Multiple complex diseases USP4 intron 17554300 rs9863142 chr3 49366741 G C 1.32E-06 Crohn's disease USP4 intron 17804789 rs17080528 chr3 49389842 C T 8.75E-05 Crohn's disease LOC100289130 intron 17804789 rs8179169 chr3 49395698 C G 1.22E-14 Cholesterol,total GPX1 missense 23063622 rs8179169 chr3 49395698 C G 2.63E-23 LDL cholesterol GPX1 missense 23063622 rs2878298 chr3 49406080 T C 4.62E-06 Crohn's disease RHOA intron 17804789 rs11716445 chr3 49406095 G A 7.95E-04 Tourette syndrome RHOA intron 22889924 rs7621003 chr3 49411404 T C 4.76E-06 Crohn's disease RHOA intron 17804789 rs7648841 chr3 49416825 G A 3.63E-07 Crohn's disease RHOA intron 17804789 rs6784820 chr3 49450864 A G 1.44E-05 Multiple complex diseases TCTA intron 17554300 rs6784820 chr3 49450864 A G 1.20E-07 Crohn's disease TCTA intron 18587394 rs6997 chr3 49453834 C T 4.28E-07 Multiple complex diseases TCTA UTR-3 17554300 rs6997 chr3 49453834 C T 3.16E-07 Crohn's disease TCTA UTR-3 17804789 rs9814873 chr3 49454112 A G 2.39E-09 Multiple complex diseases AMT nearGene-3 17554300 rs11715915 chr3 49455330 C T 2.14E-09 Multiple complex diseases AMT cds-synon 17554300 rs11715915 chr3 49455330 C T 0.000000049 Fasting blood glucose AMT cds-synon 22885924 rs4855873 chr3 49459114 A C 3.25E-15 Crohn's disease AMT intron 17804789 rs1464567 chr3 49459252 C G 9.53E-06 Multiple complex diseases AMT intron 17554300 rs6446272 chr3 49463287 G A 4.17E-07 Crohn's disease NICN1 intron 17804789 rs7646366 chr3 49470668 G A 5.82E-07 Crohn's disease / / 17804789 rs885592 chr3 49497883 T G 1.61E-06 Crohn's disease / / 17804789 rs10865955 chr3 49499829 G A 2.81E-06 Crohn's disease / / 17804789 rs1568661 chr3 49520958 A G 1.92E-06 Crohn's disease DAG1 intron 17804789 rs4855864 chr3 49521974 C T 2.03E-06 Crohn's disease DAG1 intron 17804789 rs3924462 chr3 49524236 T G 3.56E-08 Crohn's disease DAG1 intron 18587394 rs3924462 chr3 49524236 T G 5.38E-04 Premature ovarian failure DAG1 intron 19508998 rs4855861 chr3 49525962 G T 1.53E-06 Crohn's disease DAG1 intron 17804789 rs7637999 chr3 49535115 C T 1.41E-06 Crohn's disease DAG1 intron 17804789 rs11130199 chr3 49538799 T C 1.85E-06 Crohn's disease DAG1 intron 17804789 rs11130199 chr3 49538799 T C 5.38E-04 Premature ovarian failure DAG1 intron 19508998 rs3870338 chr3 49557051 A G 8.11E-06 Multiple complex diseases DAG1 intron 17554300 rs3870338 chr3 49557051 A G 1.45E-06 Crohn's disease DAG1 intron 17804789 rs1801143 chr3 49570200 C T 2.21E-07 Multiple complex diseases DAG1 cds-synon 17554300 rs1801143 chr3 49570200 C T 6.45E-04 Bipolar disorder,schizoaffective DAG1 cds-synon 19567891 rs1050088 chr3 49570882 T C 1.24E-05 Multiple complex diseases DAG1 UTR-3 17554300 rs1050088 chr3 49570882 T C 1.40E-06 Crohn's disease DAG1 UTR-3 17804789 rs1050088 chr3 49570882 T C 2.62E-05 Lymphocyte counts DAG1 UTR-3 22286170 rs11720264 chr3 49580347 C T 1.79E-06 Crohn's disease / / 17804789 rs3870341 chr3 49584745 A G 4.64E-04 Heart rate / / 23583979 rs3811697 chr3 49590770 C T 3.19E-06 Crohn's disease BSN-AS2 intron 17804789 rs9858280 chr3 49597737 T C 9.76E-04 Tourette syndrome BSN intron 22889924 rs2312462 chr3 49601255 T C 2.51E-04 Sarcoidosis BSN intron 19165924 rs6446285 chr3 49626306 G A 1.97E-04 Crohn's disease BSN intron 17804789 rs9875617 chr3 49634696 G A 1.95E-07 Crohn's disease BSN intron 17804789 rs9827708 chr3 49649989 C G 1.28E-07 Multiple complex diseases BSN intron 17554300 rs9827708 chr3 49649989 C G 6.61E-08 Crohn's disease BSN intron 17804789 rs9827708 chr3 49649989 C G 9.43E-05 Personality dimensions BSN intron 18957941 rs9827708 chr3 49649989 C G 4.66E-04 Bipolar disorder,schizoaffective BSN intron 19567891 rs1352889 chr3 49652148 T C 7.74E-05 Lung adenocarcinoma BSN intron 19836008 rs11919311 chr3 49656789 G T 6.66E-06 Multiple complex diseases BSN intron 17554300 rs6803222 chr3 49665976 T G 0.000811 Height (Pygmy height) BSN intron 22570615 rs1873625 chr3 49666964 C A 6.61E-08 Crohn's disease BSN intron 17804789 rs1873626 chr3 49675142 T A 1.92E-05 Crohn's disease BSN intron 17804789 rs2329021 chr3 49679072 G A 2.69E-09 Crohn's disease BSN intron 17804789 rs9812791 chr3 49682311 G A 1.61E-08 Crohn's disease BSN intron 17804789 rs2329020 chr3 49685073 G A 5.33E-06 Multiple complex diseases BSN intron 17554300 rs2329020 chr3 49685073 G A 5.01E-04 Tourette syndrome BSN intron 22889924 rs34762726 chr3 49689210 G A 9.52E-25 Primary sclerosing cholangitis BSN missense 23603763 rs2131104 chr3 49696633 C G 1.63E-04 Multiple complex diseases BSN intron 17554300 rs11718165 chr3 49696797 A G 1.83E-08 Multiple complex diseases BSN intron 17554300 rs11718165 chr3 49696797 A G 1.48E-08 Crohn's disease BSN intron 17804789 rs9858542 chr3 49701983 G A 5.00E-08 Crohn's disease BSN cds-synon 17554261 rs9858542 chr3 49701983 G A 4.00E-08 Crohn's disease BSN cds-synon 17554300 rs9858542 chr3 49701983 G A 3.55E-12 Crohn's disease BSN cds-synon 18587394 rs9858542 chr3 49701983 G A 5.63E-05 Personality dimensions BSN cds-synon 18957941 rs9858542 chr3 49701983 G A 1.34E-04 Bipolar disorder,schizoaffective BSN cds-synon 19567891 rs9858542 chr3 49701983 G A 7.00E-09 Ulcerative colitis BSN cds-synon 19915572 rs2131109 chr3 49704987 T C 3.35E-04 Tourette syndrome BSN intron 22889924 rs1131095 chr3 49714225 T C 1.99E-06 Crohn's disease APEH cds-synon 17804789 rs4855882 chr3 49715354 G T 6.00E-06 Plasminogen activator inhibitor-1 (PAI1) levels,in plasma APEH intron 20558613 rs4855881 chr3 49715446 G A 2.85E-06 Multiple complex diseases APEH intron 17554300 rs4855881 chr3 49715446 G A 1.09E-05 Crohn's disease APEH intron 17804789 rs4855881 chr3 49715446 G A 0.000184 Rate of forced expiratory volume in 1 second (FEV1) decline (young adult women) APEH intron 23527081 rs9822268 chr3 49719729 G A 1.26E-08 Crohn's disease APEH intron 17804789 rs9822268 chr3 49719729 G A 2.00E-17 Ulcerative colitis APEH intron 21297633 rs3197999 chr3 49721532 G A 1.00E-12 Crohn's disease MST1 missense 18587394 rs3197999 chr3 49721532 G A 4.00E-09 Ulcerative colitis MST1 missense 20228799 rs3197999 chr3 49721532 G A 6.00E-17 Crohn's disease MST1 missense 21102463 rs3197999 chr3 49721532 G A 1.00E-12 Asthma MST1 missense 21150878 rs3197999 chr3 49721532 G A 1.00E-16 Primary sclerosing cholangitis MST1 missense 21151127 rs3197999 chr3 49721532 G A 1.15E-12 Multiple sclerosis MST1 missense 22190364 rs3197999 chr3 49721532 G A 1.00E-47 Inflammatory bowel disease MST1 missense 23128233 rs3197999 chr3 49721532 G A 2.45E-26 Primary sclerosing cholangitis MST1 missense 23603763 rs11130214 chr3 49735746 C G 6.74E-05 Multiple complex diseases RNF123 intron 17554300 rs11130214 chr3 49735746 C G 8.10E-04 Bipolar disorder,schizoaffective RNF123 intron 19567891 rs6804655 chr3 49738945 C T 3.80E-04 Coronary heart disease RNF123 cds-synon 21966275 rs2291542 chr3 49751585 C T 5.32E-05 Multiple complex diseases RNF123 cds-synon 17554300 rs3749237 chr3 49770032 G A 4.45E-05 Multiple complex diseases IP6K1 intron 17554300 rs7649348 chr3 49772375 G A 2.09E-05 Crohn's disease IP6K1 intron 17804789 rs7372966 chr3 49788969 T C 2.36E-05 Crohn's disease IP6K1 intron 17804789 rs7372725 chr3 49790544 C A 1.52E-05 Crohn's disease IP6K1 intron 17804789 rs9859153 chr3 49807085 G T 2.62E-05 Crohn's disease IP6K1 intron 17804789 rs11130221 chr3 49819102 C G 2.33E-05 Crohn's disease IP6K1 intron 17804789 rs6802890 chr3 49832261 A G 0.000103 Height (Pygmy height) CDHR4 intron 22570615 rs7629936 chr3 49836707 G A 3.36E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CDHR4 cds-synon 24023788 rs2234391 chr3 49842625 A G 1.35E-05 Crohn's disease / / 17804789 rs6775384 chr3 49853073 G A 0.000103 Height (Pygmy height) / / 22570615 rs695238 chr3 49869158 A C 1.09E-05 Crohn's disease TRAIP intron 17804789 rs2271960 chr3 49878078 T C 1.96E-05 Multiple complex diseases TRAIP intron 17554300 rs2271961 chr3 49878113 T C 5.62E-05 Multiple complex diseases TRAIP intron 17554300 rs2271961 chr3 49878113 T C 2.49E-06 Bipolar disorder,schizoaffective TRAIP intron 19567891 rs2247036 chr3 49882349 C T 1.16E-05 Crohn's disease TRAIP intron 17804789 rs2352974 chr3 49890613 C T 3.48E-05 Multiple complex diseases TRAIP intron 17554300 rs2352974 chr3 49890613 C T 2.02E-05 Crohn's disease TRAIP intron 17804789 rs2352974 chr3 49890613 C T 8.27E-07 Bipolar disorder,schizoaffective TRAIP intron 19567891 rs2352974 chr3 49890613 C T 0.000103 Height (Pygmy height) TRAIP intron 22570615 rs2777888 chr3 49898000 A G 1.32E-05 Crohn's disease CAMKV intron 17804789 rs9821675 chr3 49902544 A G 2.57E-04 Crohn's disease CAMKV intron 17804789 rs11713193 chr3 49924424 G A 2.57E-05 Crohn's disease MST1R nearGene-3 17804789 rs2230590 chr3 49936102 T C 3.91E-05 Crohn's disease MST1R missense 17804789 rs7616171 chr3 49938758 A T 1.54E-04 Multiple complex diseases MST1R intron 17554300 rs7634084 chr3 49949834 A T 3.20E-05 Crohn's disease MON1A intron 17804789 rs148635727 chr3 50006026 G A 0.00012 Breast cancer RBM6 missense 23555315 rs2681779 chr3 50011021 T C 6.15E-05 Alcohol dependence RBM6 intron 20201924 rs2681779 chr3 50011021 T C 6.15E-05 Alcoholism RBM6 intron pha002891 rs2624821 chr3 50014114 G A 6.07E-05 Alcohol dependence RBM6 intron 20201924 rs2624821 chr3 50014114 G A 6.07E-05 Alcoholism RBM6 intron pha002891 rs11130237 chr3 50039303 A G 8.73E-04 Lymphocyte counts RBM6 intron 22286170 rs6762477 chr3 50093209 G A 2.00E-08 Menarche (age at onset) RBM6 intron 21102462 rs2240328 chr3 50113004 T C 6.81E-04 Alcohol dependence RBM6 intron 20201924 rs2240327 chr3 50113034 A G 1.25E-05 Lymphocyte counts RBM6 intron 22286170 rs2013208 chr3 50129399 C T 9.00E-12 HDL cholesterol RBM5 intron 24097068 rs2624834 chr3 50132131 G T 4.44E-05 Alcohol dependence RBM5 intron 20201924 rs2624834 chr3 50132131 G T 4.44E-05 Alcoholism RBM5 intron pha002891 rs2526391 chr3 50169266 A T 5.07E-04 Multiple complex diseases LOC100129060 intron 17554300 rs13100903 chr3 50174572 C T 8.50E-04 Acute lung injury LOC100129060 intron 22295056 rs2188151 chr3 50201924 G T 7.75E-04 Multiple complex diseases SEMA3F intron 17554300 rs2518796 chr3 50207075 T C 7.21E-04 Multiple complex diseases SEMA3F intron 17554300 rs2518796 chr3 50207075 T C 9.49E-04 Acute lung injury SEMA3F intron 22295056 rs1005678 chr3 50210289 C G 9.95E-05 Crohn's disease SEMA3F intron 17804789 rs2624833 chr3 50212512 G T 5.45E-05 Crohn's disease SEMA3F intron 17804789 rs12632110 chr3 50224225 A G 1.10E-09 Progranulin levels SEMA3F intron 21087763 rs12632110 chr3 50224225 A G 4.90E-04 Lymphocyte counts SEMA3F intron 22286170 rs2236941 chr3 50247824 C T 9.38E-05 Potassium levels SLC38A3 intron pha003086 rs4688682 chr3 50267128 C A,G,T 2.15E-05 Smoking quantity / / 24665060 rs9826676 chr3 50281080 G C 3.96E-10 HDL cholesterol G/I2 intron 23063622 rs2282751 chr3 50291785 G A 7.20E-06 Esophageal cancer (squamous cell) G/I2 intron 22960999 rs1283 chr3 50337422 G A 4.50E-06 Plasminogen activator inhibitor-1 (PAI1) levels,in plasma HYAL1 UTR-3 20558613 rs11130248 chr3 50352200 A G 5.00E-07 Keloid / / 20711176 rs7644782 chr3 50424814 A G 2.54E-04 Alcohol dependence CAC/2D2 intron 20201924 rs7612641 chr3 50430478 G A 3.56E-04 Alcohol dependence CAC/2D2 intron 20201924 rs2282755 chr3 50442800 G T 5.64E-05 Tourette syndrome CAC/2D2 intron 22889924 rs7647409 chr3 50457599 G A 0.0000205 Primary sclerosing cholangitis CAC/2D2 intron 23603763 rs2236989 chr3 50505395 C T 3.70E-04 Tourette syndrome CAC/2D2 intron 22889924 rs1467913 chr3 50525017 C A 5.19E-06 F-cell distribution CAC/2D2 intron 21326311 rs12487817 chr3 50562566 T C 4.33E-04 Alcohol dependence / / 20201924 rs399484 chr3 50589455 T C 6.21E-04 Multiple complex diseases / / 17554300 rs2232248 chr3 50609624 T A,C,G 9.99E-04 Alzheimer's disease HEMK1 cds-synon 17998437 rs2232248 chr3 50609624 T A,C,G 2.04E-05 Multiple sclerosis (brain glutamate levels) HEMK1 cds-synon 20802204 rs417592 chr3 50610696 A G 0.000339 Height (Pygmy height) HEMK1 intron 22570615 rs2232251 chr3 50614990 T G 7.61E-04 Alcohol dependence HEMK1 missense 20201924 rs17787569 chr3 50616646 G A 7.14E-04 Alzheimer's disease HEMK1 intron 17998437 rs201198 chr3 50636111 G A 3.63E-04 Alzheimer's disease / / 17998437 rs453570 chr3 50637469 G C 3.10E-04 Alzheimer's disease / / 17998437 rs175634 chr3 50644134 C T 0.000422 Height (Pygmy height) CISH UTR-3 22570615 rs873985 chr3 50651751 A G 1.80E-05 Blood pressure MAPKAPK3 intron 21060006 rs873985 chr3 50651751 A G 6.70E-05 Blood pressure MAPKAPK3 intron 21060006 rs873985 chr3 50651751 A G 5.80E-04 Coronary heart disease MAPKAPK3 intron 21966275 rs6779819 chr3 50719345 A G 0.0000299 Height (Pygmy height) DOCK3 intron 22570615 rs6796769 chr3 50723927 A G 0.0000299 Height (Pygmy height) DOCK3 intron 22570615 rs7615703 chr3 50732402 G A 0.0000299 Height (Pygmy height) DOCK3 intron 22570615 rs7611428 chr3 50748598 C T 0.000606 Height (Pygmy height) DOCK3 intron 22570615 rs6446213 chr3 50749265 G A 0.0000299 Height (Pygmy height) DOCK3 intron 22570615 rs17051404 chr3 50751850 A C 7.44E-04 Alcohol dependence DOCK3 intron 20201924 rs7652715 chr3 50763034 A C 0.000606 Height (Pygmy height) DOCK3 intron 22570615 rs11712367 chr3 50775446 C T 0.0000299 Height (Pygmy height) DOCK3 intron 22570615 rs4485709 chr3 50776497 G T 0.000487 Height (Pygmy height) DOCK3 intron 22570615 rs6446222 chr3 50837083 A C 0.0000299 Height (Pygmy height) DOCK3 intron 22570615 rs9869945 chr3 50849368 A G 0.0000299 Height (Pygmy height) DOCK3 intron 22570615 rs10510754 chr3 50861611 A G 7.05E-04 Bipolar disorder DOCK3 intron 19259986 rs7638082 chr3 50880677 G A 0.000179 Height (Pygmy height) DOCK3 intron 22570615 rs6795573 chr3 50921261 T C 0.000487 Height (Pygmy height) DOCK3 intron 22570615 rs7627266 chr3 50962368 C T 0.000714 Height (Pygmy height) DOCK3 intron 22570615 rs9868870 chr3 50977139 G A 0.000606 Height (Pygmy height) DOCK3 intron 22570615 rs7433217 chr3 50987194 G A 0.0000299 Height (Pygmy height) DOCK3 intron 22570615 rs11130267 chr3 51024903 A G 0.000324 Height (Pygmy height) DOCK3 intron 22570615 rs6446245 chr3 51037258 T G 0.000268 Height (Pygmy height) DOCK3 intron 22570615 rs7614881 chr3 51038375 C T 0.000227 Height (Pygmy height) DOCK3 intron 22570615 rs4443210 chr3 51067562 G A 0.000179 Height (Pygmy height) DOCK3 intron 22570615 rs13088462 chr3 51071713 T C 4.00E-10 Height DOCK3 intron 20881960 rs7638732 chr3 51075876 A G 0.000227 Height (Pygmy height) DOCK3 intron 22570615 rs6795272 chr3 51107870 T C 0.000227 Height (Pygmy height) DOCK3 intron 22570615 rs12494165 chr3 51136572 A G 0.000227 Height (Pygmy height) DOCK3 intron 22570615 rs4356848 chr3 51137089 C T 0.000179 Height (Pygmy height) DOCK3 intron 22570615 rs4286453 chr3 51142359 C T 5.55E-04 Multiple complex diseases DOCK3 intron 17554300 rs9865532 chr3 51144316 G A 0.000211 Height (Pygmy height) DOCK3 intron 22570615 rs6772197 chr3 51151799 G A 0.000211 Height (Pygmy height) DOCK3 intron 22570615 rs4560329 chr3 51193805 C A 0.000179 Height (Pygmy height) DOCK3 intron 22570615 rs6787805 chr3 51204788 A G 0.000179 Height (Pygmy height) DOCK3 intron 22570615 rs1480360 chr3 51311849 G A 0.000179 Height (Pygmy height) DOCK3 intron 22570615 rs1318649 chr3 51341471 C T 0.000179 Height (Pygmy height) DOCK3 intron 22570615 rs7630259 chr3 51378548 G A 8.13E-04 Alcohol dependence DOCK3 intron 20201924 rs1031925 chr3 51379274 T C 8.00E-06 Melanoma DOCK3 intron 24980573 rs7642077 chr3 51382601 T C 8.94E-04 Alcohol dependence DOCK3 intron 20201924 rs7635095 chr3 51382652 C T 8.94E-04 Alcohol dependence DOCK3 intron 20201924 rs17051755 chr3 51387047 T C 8.13E-04 Alcohol dependence DOCK3 intron 20201924 rs12487468 chr3 51389570 A G 3.90E-06 Schizophrenia DOCK3 intron 19571808 rs4974096 chr3 51393046 G A 2.30E-06 Schizophrenia DOCK3 intron 19571808 rs4974096 chr3 51393046 G A 8.18E-04 Alcohol dependence DOCK3 intron 20201924 rs2306431 chr3 51393457 C T 8.18E-04 Alcohol dependence DOCK3 intron 20201924 rs3828395 chr3 51411797 T C 7.40E-06 Schizophrenia DOCK3 intron 19571808 rs2241785 chr3 51418135 C T 3.40E-06 Schizophrenia DOCK3 intron 19571808 rs1370124 chr3 51422188 A G 1.30E-04 Alcohol dependence MANF nearGene-5 20201924 rs2304512 chr3 51425481 T C 1.26E-04 Alcohol dependence MANF intron 20201924 rs2217938 chr3 51425674 A G 1.30E-04 Alcohol dependence MANF intron 20201924 rs3804766 chr3 51430657 A C 2.40E-06 Schizophrenia RBM15B cds-synon 19571808 rs3804766 chr3 51430657 A C 1.27E-04 Alcohol dependence RBM15B cds-synon 20201924 rs3792408 chr3 51437597 A G 1.42E-04 Alcohol dependence VPRBP intron 20201924 rs10510758 chr3 51441667 C A 2.28E-04 Alcohol dependence VPRBP intron 20201924 rs2356261 chr3 51445146 C A 1.27E-04 Alcohol dependence VPRBP intron 20201924 rs3749317 chr3 51457035 T C 2.01E-04 Alcohol dependence VPRBP intron 20201924 rs17712228 chr3 51474182 G A 1.37E-04 Alcohol dependence VPRBP intron 20201924 rs4687610 chr3 51483210 T C 1.27E-04 Alcohol dependence VPRBP intron 20201924 rs3762714 chr3 51517653 G A 1.40E-04 Alcohol dependence VPRBP intron 20201924 rs4687605 chr3 51554042 T C 8.45E-04 Alcohol dependence / / 20201924 rs11720298 chr3 51581509 A G 9.92E-05 Serum metabolites RAD54L2 intron 19043545 rs4687721 chr3 51598254 G A 9.97E-04 Depression (quantitative trait) RAD54L2 intron 20800221 rs6809155 chr3 51623216 A G 8.07E-04 Depression (quantitative trait) RAD54L2 intron 20800221 rs6787312 chr3 51650510 G A 6.88E-04 Depression (quantitative trait) RAD54L2 intron 20800221 rs4687592 chr3 51655856 C T 6.30E-06 Schizophrenia RAD54L2 intron 19571808 rs9864693 chr3 51656370 G C 6.85E-04 Depression (quantitative trait) RAD54L2 intron 20800221 rs11917683 chr3 51668409 G A 6.83E-04 Depression (quantitative trait) RAD54L2 intron 20800221 rs4494918 chr3 51683248 G C 6.66E-04 Depression (quantitative trait) RAD54L2 intron 20800221 rs4234644 chr3 51695865 G C 6.52E-04 Depression (quantitative trait) RAD54L2 intron 20800221 rs6445959 chr3 51772347 A G 4.49E-05 Glucose levels / / pha002899 rs6445959 chr3 51772347 A G 6.59E-05 Coronary heart disease / / pha003032 rs6445959 chr3 51772347 A G 1.40E-05 Coronary heart disease / / pha003033 rs6796373 chr3 51824167 G C 2.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9836804 chr3 51837850 T C 1.28E-05 Multiple complex diseases / / 17554300 rs12639503 chr3 51860817 G A 5.73E-05 Multiple complex diseases / / 17554300 rs12639503 chr3 51860817 G A 3.20E-05 Anger / / 24489884 rs9866552 chr3 51864849 A G 7.93E-05 Multiple complex diseases IQCF3 UTR-3 17554300 rs6762371 chr3 51871405 C T 6.20E-05 Multiple complex diseases / / 17554300 rs16943 chr3 51874679 C T 1.19E-05 Acute lung injury / / 22295056 rs710 chr3 51874679 CGGG CC,CG,CT 1.19E-05 Acute lung injury / / 22295056 rs7635409 chr3 51907736 A G 2.16E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1605070 chr3 51917015 C A 2.00E-09 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs379462 chr3 52004317 G A 1.98E-04 Multiple complex diseases ABHD14B intron 17554300 rs9851576 chr3 52091254 A G 2.78E-04 Alzheimer's disease (late onset) / / 21379329 rs164637 chr3 52265215 G A 3.46E-06 Waist-hip ratio TWF2 cds-synon 20935629 rs7618915 chr3 52279594 G A 3.00E-10 Bipolar disorder / / 22182935 rs7614727 chr3 52295895 C T 2.08E-05 Glaucoma (primary open-angle) WDR82 intron 22605921 rs9844183 chr3 52315192 A G 0.0002616 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9844183 chr3 52315192 A G 2.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17052058 chr3 52344680 A G 0.0001989 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17052058 chr3 52344680 A G 1.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17052061 chr3 52346240 T G 0.0001837 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17052061 chr3 52346240 T G 1.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6445386 chr3 52350212 A G 0.0001384 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6445386 chr3 52350212 A G 1.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17052068 chr3 52352864 C T 0.0002359 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) D/H1 intron 23233654 rs17052068 chr3 52352864 C T 2.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) D/H1 intron 23233662 rs11711934 chr3 52358117 T C 0.0002253 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) D/H1 intron 23233654 rs11711934 chr3 52358117 T C 2.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) D/H1 intron 23233662 rs11707931 chr3 52358417 C G 0.0002595 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) D/H1 intron 23233654 rs11707931 chr3 52358417 C G 2.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) D/H1 intron 23233662 rs6796333 chr3 52359678 T C 0.0001926 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) D/H1 intron 23233654 rs6796333 chr3 52359678 T C 1.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) D/H1 intron 23233662 rs13059674 chr3 52371789 T G 0.0004045 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) D/H1 intron 23233654 rs13059674 chr3 52371789 T G 4.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) D/H1 intron 23233662 rs11714402 chr3 52391735 A C 9.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) D/H1 cds-synon 23233662 rs1077142 chr3 52403526 A G 9.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) D/H1 intron 23233662 rs149319231 chr3 52409393 A C 0.00001 Breast cancer(er negative) D/H1 missense 23555315 rs390802 chr3 52431671 G A 0.0008707 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) D/H1 intron 23233654 rs390802 chr3 52431671 G A 8.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) D/H1 intron 23233662 rs13094687 chr3 52450043 A G 4.48E-07 Bipolar disorder PHF7 intron 22182935 rs13094687 chr3 52450043 A G 1.47E-04 Major depressive disorder PHF7 intron 22472876 rs2272088 chr3 52456973 A G 1.47E-04 Major depressive disorder PHF7 intron 22472876 rs82825 chr3 52471942 G A 0.0006614 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SEMA3G intron 23233654 rs82825 chr3 52471942 G A 6.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) SEMA3G intron 23233662 rs2016575 chr3 52477080 T C 0.0006579 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SEMA3G intron 23233654 rs2016575 chr3 52477080 T C 6.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) SEMA3G intron 23233662 rs634382 chr3 52482851 A G 0.0006625 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs634382 chr3 52482851 A G 6.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2159607 chr3 52501451 G T 0.0005515 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NISCH intron 23233654 rs2159607 chr3 52501451 G T 5.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) NISCH intron 23233662 rs6784615 chr3 52506426 C T 4.00E-10 Waist-hip ratio NISCH intron 20935629 rs7620015 chr3 52510697 G A 5.66E-04 Alzheimer's disease NISCH intron 24755620 rs2109559 chr3 52512318 A G 5.62E-04 Alzheimer's disease NISCH intron 24755620 rs6800707 chr3 52516293 C G 0.0006352 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NISCH intron 23233654 rs6800707 chr3 52516293 C G 6.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) NISCH intron 23233662 rs728408 chr3 52517206 G A 5.44E-04 Alzheimer's disease NISCH intron 24755620 rs887515 chr3 52523405 C T 0.0006672 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NISCH missense 23233654 rs887515 chr3 52523405 C T 6.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) NISCH missense 23233662 rs13326165 chr3 52532118 A G 7.92E-05 Response to acetaminophen (hepatotoxicity) STAB1 intron 21177773 rs13326165 chr3 52532118 A G 9.00E-11 HDL cholesterol STAB1 intron 24097068 rs758801 chr3 52536308 A C 2.68E-06 Waist-hip ratio STAB1 intron 20935629 rs758801 chr3 52536308 A C 0.0001205 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) STAB1 intron 23233654 rs758801 chr3 52536308 A C 1.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) STAB1 intron 23233662 rs731831 chr3 52536514 G A 1.89E-05 Major depressive disorder STAB1 intron 22472876 rs1010553 chr3 52540773 T C 4.45E-06 Waist-hip ratio STAB1 cds-synon 20935629 rs1010554 chr3 52542919 T C 8.00E-04 Bipolar disorder STAB1 intron 17486107 rs6445528 chr3 52572447 A G 1.63E-08 Lymphocyte counts C3orf78 intron 22286170 rs2878628 chr3 52584715 A G 4.46E-04 Multiple complex diseases PBRM1 intron 17554300 rs2878628 chr3 52584715 A G 3.56E-07 Bipolar disorder PBRM1 intron 22182935 rs2878628 chr3 52584715 A G 6.90E-08 Major depressive disorder PBRM1 intron 22472876 rs2251219 chr3 52584787 T C 3.44E-04 Multiple complex diseases PBRM1 cds-synon 17554300 rs2251219 chr3 52584787 T C 2.00E-09 Major mood disorders PBRM1 cds-synon 20081856 rs2251219 chr3 52584787 T C 6.35E-07 Bipolar disorder PBRM1 cds-synon 22182935 rs2251219 chr3 52584787 T C 1.91E-08 Major depressive disorder PBRM1 cds-synon 22472876 rs1961958 chr3 52585990 A G 5.11E-04 Multiple complex diseases PBRM1 intron 17554300 rs1961958 chr3 52585990 A G 3.94E-07 Bipolar disorder PBRM1 intron 22182935 rs1961958 chr3 52585990 A G 6.98E-08 Major depressive disorder PBRM1 intron 22472876 rs17052256 chr3 52593119 A G 5.80E-08 Major depressive disorder PBRM1 intron 22472876 rs3796353 chr3 52593230 C T 2.56E-07 Bipolar disorder PBRM1 intron 22182935 rs3796353 chr3 52593230 C T 6.56E-08 Major depressive disorder PBRM1 intron 22472876 rs6778844 chr3 52596398 T C 3.63E-04 Multiple complex diseases PBRM1 intron 17554300 rs6778844 chr3 52596398 T C 4.01E-07 Bipolar disorder PBRM1 intron 22182935 rs6778844 chr3 52596398 T C 6.98E-08 Major depressive disorder PBRM1 intron 22472876 rs2289249 chr3 52597664 G A 9.02E-08 Major depressive disorder PBRM1 intron 22472876 rs6786919 chr3 52599789 A G 7.32E-08 Major depressive disorder PBRM1 intron 22472876 rs13063160 chr3 52602274 T C 7.65E-08 Major depressive disorder PBRM1 intron 22472876 rs6786043 chr3 52604861 A G 6.61E-08 Major depressive disorder PBRM1 intron 22472876 rs11714565 chr3 52606292 C T 2.38E-07 Bipolar disorder PBRM1 intron 22182935 rs11714565 chr3 52606292 C T 6.51E-08 Major depressive disorder PBRM1 intron 22472876 rs7652191 chr3 52610415 T C 1.93E-07 Bipolar disorder PBRM1 intron 22182935 rs7652191 chr3 52610415 T C 5.65E-08 Major depressive disorder PBRM1 intron 22472876 rs11720243 chr3 52618018 T C 2.05E-07 Bipolar disorder PBRM1 intron 22182935 rs11720243 chr3 52618018 T C 5.65E-08 Major depressive disorder PBRM1 intron 22472876 rs12487445 chr3 52618319 A C 2.65E-07 Bipolar disorder PBRM1 intron 22182935 rs12487445 chr3 52618319 A C 7.93E-08 Major depressive disorder PBRM1 intron 22472876 rs3852066 chr3 52621839 C T 7.88E-08 Major depressive disorder PBRM1 intron 22472876 rs2590838 chr3 52622086 G A 9.06E-05 Major depressive disorder PBRM1 intron 22472876 rs2590838 chr3 52622086 G A 2.00E-13 Adiponectin levels PBRM1 intron 22479202 rs2336146 chr3 52626646 A G 3.13E-07 Bipolar disorder PBRM1 intron 22182935 rs2336146 chr3 52626646 A G 7.38E-08 Major depressive disorder PBRM1 intron 22472876 rs2577831 chr3 52628056 C A 5.11E-05 Major depressive disorder PBRM1 intron 22472876 rs11714419 chr3 52628816 A G 8.79E-08 Major depressive disorder PBRM1 intron 22472876 rs3774366 chr3 52641255 T C 3.13E-07 Bipolar disorder PBRM1 intron 22182935 rs3774366 chr3 52641255 T C 6.48E-08 Major depressive disorder PBRM1 intron 22472876 rs12487591 chr3 52642936 A T 4.23E-04 Multiple complex diseases PBRM1 intron 17554300 rs12487591 chr3 52642936 A T 3.46E-07 Bipolar disorder PBRM1 intron 22182935 rs12487591 chr3 52642936 A T 3.09E-08 Major depressive disorder PBRM1 intron 22472876 rs3733045 chr3 52643307 A G 7.04E-04 Multiple complex diseases PBRM1 intron 17554300 rs3733045 chr3 52643307 A G 3.99E-07 Bipolar disorder PBRM1 intron 22182935 rs3733045 chr3 52643307 A G 6.20E-08 Major depressive disorder PBRM1 intron 22472876 rs3755806 chr3 52643685 T C 3.60E-04 Multiple complex diseases PBRM1 cds-synon 17554300 rs3755806 chr3 52643685 T C 9.90E-07 Bipolar disorder PBRM1 cds-synon 22182935 rs3755806 chr3 52643685 T C 3.09E-08 Major depressive disorder PBRM1 cds-synon 22472876 rs3755806 chr3 52643685 T C 0.000000421 Bipolar disorder PBRM1 cds-synon 23070075 rs13083798 chr3 52649748 A G 5.83E-05 Major depressive disorder PBRM1 intron 22472876 rs10510760 chr3 52650348 G A 1.14E-05 Major depressive disorder PBRM1 intron 22472876 rs4687638 chr3 52651966 A C 7.75E-08 Major depressive disorder PBRM1 intron 22472876 rs13064064 chr3 52657002 T C 3.57E-07 Bipolar disorder PBRM1 intron 22182935 rs13064064 chr3 52657002 T C 3.09E-08 Major depressive disorder PBRM1 intron 22472876 rs1561337 chr3 52659963 G A 3.60E-04 Multiple complex diseases PBRM1 intron 17554300 rs1561337 chr3 52659963 G A 3.26E-07 Bipolar disorder PBRM1 intron 22182935 rs1561337 chr3 52659963 G A 2.83E-08 Major depressive disorder PBRM1 intron 22472876 rs7622694 chr3 52663882 G A 6.05E-08 Major depressive disorder PBRM1 intron 22472876 rs2083180 chr3 52668119 G T 5.04E-08 Major depressive disorder PBRM1 intron 22472876 rs13068293 chr3 52672167 C A 3.34E-07 Bipolar disorder PBRM1 intron 22182935 rs13068293 chr3 52672167 C A 2.90E-08 Major depressive disorder PBRM1 intron 22472876 rs11130310 chr3 52674667 C T 5.43E-08 Major depressive disorder PBRM1 intron 22472876 rs2028216 chr3 52680823 C T 8.14E-08 Major depressive disorder PBRM1 intron 22472876 rs2289250 chr3 52682946 C A 4.05E-04 Multiple complex diseases PBRM1 intron 17554300 rs2289250 chr3 52682946 C A 3.48E-07 Bipolar disorder PBRM1 intron 22182935 rs2289250 chr3 52682946 C A 2.89E-08 Major depressive disorder PBRM1 intron 22472876 rs33967311 chr3 52683864 C A 3.40E-04 Multiple complex diseases PBRM1 intron 17554300 rs33967311 chr3 52683864 C A 2.79E-08 Major depressive disorder PBRM1 intron 22472876 rs2336149 chr3 52692124 G A 3.43E-07 Bipolar disorder PBRM1 intron 22182935 rs2336149 chr3 52692124 G A 4.85E-08 Major depressive disorder PBRM1 intron 22472876 rs7611731 chr3 52692721 T C 4.61E-07 Bipolar disorder PBRM1 intron 22182935 rs7611731 chr3 52692721 T C 5.00E-08 Major depressive disorder PBRM1 intron 22472876 rs6804145 chr3 52694198 C T 3.43E-07 Bipolar disorder PBRM1 intron 22182935 rs6804145 chr3 52694198 C T 5.04E-08 Major depressive disorder PBRM1 intron 22472876 rs11715796 chr3 52695650 A C 7.61E-04 Nicotine smoking PBRM1 intron 19268276 rs11130315 chr3 52697163 A G 3.02E-08 Major depressive disorder PBRM1 intron 22472876 rs12488461 chr3 52698417 T C 9.12E-08 Major depressive disorder PBRM1 intron 22472876 rs12496634 chr3 52709259 A C 3.44E-08 Major depressive disorder PBRM1 intron 22472876 rs10865974 chr3 52718280 G T 7.57E-04 Multiple complex diseases PBRM1 intron 17554300 rs10865974 chr3 52718280 G T 4.46E-07 Bipolar disorder PBRM1 intron 22182935 rs10865974 chr3 52718280 G T 8.48E-08 Major depressive disorder PBRM1 intron 22472876 rs10865974 chr3 52718280 G T 2.00E-06 Bipolar disorder (mood-incongruent) PBRM1 intron 23092984 rs3733039 chr3 52719088 C T 6.05E-08 Major depressive disorder PBRM1 intron 22472876 rs1866268 chr3 52719398 C A 4.04E-07 Bipolar disorder PBRM1 intron 22182935 rs1866268 chr3 52719398 C A 6.51E-08 Major depressive disorder PBRM1 intron 22472876 rs1108842 chr3 52720080 A C 1.13E-04 Major depressive disorder GNL3 UTR-5 22472876 rs1108842 chr3 52720080 A C 1.00E-13 Adiponectin levels GNL3 UTR-5 22479202 rs11554256 chr3 52720080 A AA,AC 1.13E-04 Major depressive disorder GNL3 UTR-5 22472876 rs11554256 chr3 52720080 A AA,AC 1.00E-13 Adiponectin levels GNL3 UTR-5 22479202 rs11177 chr3 52721305 G A 1.11E-07 Major depressive disorder GNL3 missense 22472876 rs11177 chr3 52721305 G A 5.00E-09 Osteoarthritis GNL3 missense 22763110 rs11177 chr3 52721305 G A 5.00E-09 Cortical thickness GNL3 missense 22792071 rs6762813 chr3 52726695 C T 3.48E-07 Bipolar disorder GNL3 intron 22182935 rs6762813 chr3 52726695 C T 1.01E-07 Major depressive disorder GNL3 intron 22472876 rs2289247 chr3 52727257 G A 6.02E-04 Multiple complex diseases GNL3 missense 17554300 rs2289247 chr3 52727257 G A 3.23E-07 Bipolar disorder GNL3 missense 22182935 rs2289247 chr3 52727257 G A 6.46E-08 Major depressive disorder GNL3 missense 22472876 rs6976 chr3 52728804 C T 1.45E-07 Major depressive disorder GLT8D1 UTR-3 22472876 rs6976 chr3 52728804 C T 2.27E-10 Osteoarthritis GLT8D1 UTR-3 22763110 rs2164885 chr3 52731269 T C 7.18E-08 Major depressive disorder GLT8D1 intron 22472876 rs11130317 chr3 52731483 C T 4.83E-08 Major depressive disorder GLT8D1 intron 22472876 rs3733041 chr3 52731598 T C 3.16E-07 Bipolar disorder GLT8D1 intron 22182935 rs3733041 chr3 52731598 T C 7.72E-08 Major depressive disorder GLT8D1 intron 22472876 rs115960994 chr3 52731828 C T 0.00000101 Alcohol consumption GLT8D1 missense 23555315 rs6765687 chr3 52733106 C T 5.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) GLT8D1 intron 23453885 rs12635140 chr3 52738165 T C 4.34E-04 Multiple complex diseases GLT8D1 intron 17554300 rs12635140 chr3 52738165 T C 3.22E-07 Bipolar disorder GLT8D1 intron 22182935 rs12635140 chr3 52738165 T C 1.19E-07 Major depressive disorder GLT8D1 intron 22472876 rs8906 chr3 52739520 T C 1.24E-07 Major depressive disorder GLT8D1 UTR-5 22472876 rs3755798 chr3 52741160 G A 3.15E-07 Bipolar disorder SPCS1 intron 22182935 rs3755798 chr3 52741160 G A 9.87E-08 Major depressive disorder SPCS1 intron 22472876 rs34017441 chr3 52742413 T C 6.28E-08 Major depressive disorder / / 22472876 rs11716747 chr3 52748857 C T 8.61E-08 Major depressive disorder NEK4 intron 22472876 rs35526119 chr3 52749334 C T 8.63E-08 Major depressive disorder NEK4 intron 22472876 rs7624716 chr3 52751534 T C 7.51E-08 Major depressive disorder NEK4 intron 22472876 rs10780035 chr3 52764624 C T 1.39E-07 Major depressive disorder NEK4 intron 22472876 rs2079929 chr3 52765646 C T 8.17E-08 Major depressive disorder NEK4 intron 22472876 rs767418 chr3 52767427 C T 8.03E-08 Major depressive disorder NEK4 intron 22472876 rs6445535 chr3 52771468 T C 7.51E-08 Major depressive disorder NEK4 intron 22472876 rs2159644 chr3 52774530 C T 7.05E-08 Major depressive disorder NEK4 intron 22472876 rs2268026 chr3 52778347 T C 4.77E-07 Bipolar disorder NEK4 intron 22182935 rs2268026 chr3 52778347 T C 3.41E-08 Major depressive disorder NEK4 intron 22472876 rs2072390 chr3 52780509 A T 5.01E-04 Multiple complex diseases NEK4 intron 17554300 rs2072390 chr3 52780509 A T 4.36E-07 Bipolar disorder NEK4 intron 22182935 rs2072390 chr3 52780509 A T 8.00E-08 Major depressive disorder NEK4 intron 22472876 rs2336545 chr3 52787603 T C 4.38E-04 Multiple complex diseases NEK4 intron 17554300 rs2336545 chr3 52787603 T C 5.26E-07 Bipolar disorder NEK4 intron 22182935 rs2336545 chr3 52787603 T C 5.95E-08 Major depressive disorder NEK4 intron 22472876 rs12497998 chr3 52793602 C T 5.53E-07 Bipolar disorder NEK4 intron 22182935 rs12497998 chr3 52793602 C T 9.23E-08 Major depressive disorder NEK4 intron 22472876 rs2230535 chr3 52800284 T C 9.43E-07 Bipolar disorder NEK4 cds-synon 22182935 rs2230535 chr3 52800284 T C 6.89E-08 Major depressive disorder NEK4 cds-synon 22472876 rs2230534 chr3 52802402 A C 6.89E-08 Major depressive disorder NEK4 cds-synon 22472876 rs13071584 chr3 52804487 T C 1.05E-07 Major depressive disorder NEK4 intron 22472876 rs1014969 chr3 52808341 G A 5.55E-08 Major depressive disorder / / 22472876 rs3755799 chr3 52809193 G A 1.08E-07 Major depressive disorder / / 22472876 rs2019065 chr3 52809525 T C 5.46E-08 Major depressive disorder / / 22472876 rs2710323 chr3 52815905 T C 1.02E-04 Major depressive disorder ITIH1 intron 22472876 rs2710323 chr3 52815905 T C 3.00E-08 Schizophrenia,schizoaffective disorder or bipolar disorder ITIH1 intron 24166486 rs3774354 chr3 52817675 G A 5.19E-07 Major depressive disorder ITIH1 intron 22472876 rs3774356 chr3 52817891 A C 1.20E-05 Myocardial infarction ITIH1 intron 17211523 rs2239551 chr3 52818579 G A 3.49E-07 Major depressive disorder ITIH1 intron 22472876 rs1042779 chr3 52821011 A G 2.00E-07 Bipolar disorder ITIH1 missense 19416921 rs1042779 chr3 52821011 A G 1.02E-07 Major depressive disorder ITIH1 missense 22472876 rs2286798 chr3 52821177 A C 7.01E-07 Major depressive disorder ITIH1 intron 22472876 rs2300149 chr3 52822921 C T 6.27E-07 Major depressive disorder ITIH1 intron 22472876 rs2239549 chr3 52823126 G A 4.33E-07 Major depressive disorder ITIH1 intron 22472876 rs4687551 chr3 52823448 T C 4.04E-06 Major depressive disorder ITIH1 intron 22472876 rs1076425 chr3 52825462 A G 3.24E-06 Major depressive disorder ITIH1 intron 22472876 rs1075653 chr3 52825528 T C 3.38E-06 Major depressive disorder ITIH1 intron 22472876 rs9324 chr3 52825585 T C 4.17E-06 Major depressive disorder ITIH1 cds-synon 22472876 rs7549 chr3 52825912 C A 8.76E-06 Leukocyte Counts ITIH1 cds-synon pha003091 rs2071506 chr3 52826276 T C 3.24E-06 Major depressive disorder ITIH1 nearGene-3 22472876 rs2071508 chr3 52826846 G A 3.18E-05 Multiple complex diseases / / 17554300 rs2071508 chr3 52826846 G A 4.56E-06 Major depressive disorder / / 22472876 rs9881468 chr3 52828628 C T 3.68E-06 Major depressive disorder / / 22472876 rs2286797 chr3 52829633 G A 6.10E-07 Myocardial infarction ITIH3 cds-synon 17211523 rs115714636 chr3 52830527 A G 0.000000291 Alcohol consumption ITIH3 missense 23555315 rs9816589 chr3 52830547 C T 9.37E-05 HIV-1 viral setpoint ITIH3 cds-synon 22174851 rs2240920 chr3 52831009 C T 1 Drug response to Etoposide ITIH3 intron 17537913 rs2240920 chr3 52831009 C T 2.38E-04 Multiple complex diseases ITIH3 intron 17554300 rs2535629 chr3 52833219 G A 5.88E-09 Major depressive disorder ITIH3 intron 22472876 rs2535629 chr3 52833219 G A 3.00E-12 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) ITIH3 intron 23453885 rs2535629 chr3 52833219 G A 0.0000129 Bipolar disorder ITIH3 intron 23637625 rs3617 chr3 52833805 C A 1.12E-05 Major depressive disorder ITIH3 missense 22472876 rs736408 chr3 52835354 C T 2.00E-06 Bipolar disorder ITIH3 intron 21926972 rs736408 chr3 52835354 C T 0.000000503 Bipolar disorder ITIH3 intron 23070075 rs4687552 chr3 52838402 T C 1.00E-08 Schizophrenia ITIH3 intron 23974872 rs9858074 chr3 52843613 G C 1.18E-04 Multiple complex diseases / / 17554300 rs17331151 chr3 52844534 C T 2.00E-09 Immune reponse to smallpox (secreted IL-2) / / 22610502 rs2071044 chr3 52847601 C T 1.32E-05 Major depressive disorder ITIH4 intron 22472876 rs4687657 chr3 52852538 G T 1.79E-05 Major depressive disorder ITIH4 missense 22472876 rs4687657 chr3 52852538 G T 0.00027 Prostate cancer ITIH4 missense 23555315 rs4687657 chr3 52852538 G T 0.000156 Schizophrenia ITIH4 missense 23637625 rs9831977 chr3 52854140 T G 5.48E-04 Suicide attempts in bipolar disorder ITIH4 intron 21423239 rs2239547 chr3 52855229 T C 6.00E-08 Schizophrenia ITIH4 intron 21926974 rs2239547 chr3 52855229 T C 1.96E-05 Major depressive disorder ITIH4 intron 22472876 rs2535633 chr3 52859630 C G 2.00E-10 Body mass index ITIH4 intron 24861553 rs2276817 chr3 52860936 C T 3.12E-04 Major depressive disorder ITIH4 cds-synon 22472876 rs13072536 chr3 52861211 A T 0.00021 Prostate cancer ITIH4 missense 23555315 rs4687554 chr3 52864135 T C 2.74E-04 Major depressive disorder ITIH4 intron 22472876 rs13083728 chr3 52868445 G A 3.40E-04 Major depressive disorder MUSTN1 intron 22472876 rs1573815 chr3 52870132 G A 3.25E-04 Major depressive disorder TMEM110-MUSTN1 intron 22472876 rs1139106 chr3 52871101 G A 0.0000198 Body mass index TMEM110-MUSTN1 intron 22885924 rs3733047 chr3 52871929 G A 3.30E-04 Major depressive disorder TMEM110-MUSTN1 intron 22472876 rs6445538 chr3 52874288 T C 3.08E-04 Major depressive disorder TMEM110-MUSTN1 intron 22472876 rs6445538 chr3 52874288 T C 0.00025 Prostate cancer TMEM110-MUSTN1 intron 23555315 rs6445539 chr3 52874296 G A 3.17E-04 Major depressive disorder TMEM110-MUSTN1 intron 22472876 rs11720228 chr3 52877270 G A 3.88E-04 Suicide attempts in bipolar disorder TMEM110-MUSTN1 intron 21423239 rs6803519 chr3 52889771 C T 6.04E-04 Lymphocyte counts TMEM110-MUSTN1 intron 22286170 rs6803519 chr3 52889771 C T 3.25E-04 Major depressive disorder TMEM110-MUSTN1 intron 22472876 rs13076033 chr3 52898427 T C 7.02E-04 Suicide attempts in bipolar disorder TMEM110-MUSTN1 intron 21423239 rs3796352 chr3 52913279 C T 5.00E-07 Immune reponse to smallpox (secreted IL-2) TMEM110-MUSTN1 intron 22610502 rs2581824 chr3 53022408 C A 0.000485485 Hypertension (early onset hypertension) SFMBT1 intron 22479346 rs2581824 chr3 53022408 C A 8.35E-16 Urate levels SFMBT1 intron 23263486 rs2564934 chr3 53024580 G A 2.67E-15 Urate levels SFMBT1 intron 23263486 rs6771610 chr3 53026104 T C 6.72E-04 Acute lung injury SFMBT1 intron 22295056 rs2564938 chr3 53026384 C T 8.73E-11 Urate levels SFMBT1 intron 23263486 rs2246556 chr3 53027983 T C 6.96E-04 Acute lung injury SFMBT1 intron 22295056 rs11708675 chr3 53031912 G C 9.24E-11 Urate levels SFMBT1 intron 23263486 rs2564919 chr3 53033295 A G 5.92E-11 Urate levels SFMBT1 intron 23263486 rs12635298 chr3 53033796 T C 7.54E-11 Urate levels SFMBT1 intron 23263486 rs2581792 chr3 53035044 T C 3.65E-08 Urate levels SFMBT1 intron 23263486 rs2564917 chr3 53037695 C T 2.92E-11 Urate levels SFMBT1 intron 23263486 rs2581795 chr3 53038786 A G 1.52E-11 Urate levels SFMBT1 intron 23263486 rs1529544 chr3 53039455 G A 2.01E-11 Urate levels SFMBT1 intron 23263486 rs2564947 chr3 53046216 C T 4.27E-04 Acute lung injury SFMBT1 intron 22295056 rs17304694 chr3 53051577 G A 1.49E-08 Urate levels SFMBT1 intron 23263486 rs2581777 chr3 53054727 T C 7.35E-10 Urate levels SFMBT1 intron 23263486 rs2244552 chr3 53055522 A G 2.08E-15 Urate levels SFMBT1 intron 23263486 rs2244461 chr3 53055842 G A 1.09E-09 Urate levels SFMBT1 intron 23263486 rs2581780 chr3 53058960 C T 4.27E-04 Acute lung injury SFMBT1 intron 22295056 rs2255107 chr3 53060637 C T 8.56E-05 Coronary restenosis SFMBT1 intron 21878436 rs2255107 chr3 53060637 C T 4.29E-04 Major depressive disorder SFMBT1 intron 22472876 rs9847710 chr3 53062661 T C 0.000587353 Hypertension (early onset hypertension) SFMBT1 intron 22479346 rs9847710 chr3 53062661 T C 1.00E-08 Ulcerative colitis SFMBT1 intron 23128233 rs9847710 chr3 53062661 T C 6.42E-16 Urate levels SFMBT1 intron 23263486 rs2581806 chr3 53063360 A G 8.52E-10 Urate levels SFMBT1 intron 23263486 rs2564956 chr3 53070462 C T 1.00E-15 Urate levels SFMBT1 intron 23263486 rs17304995 chr3 53070755 A G 8.09E-04 Multiple complex diseases SFMBT1 intron 17554300 rs2581818 chr3 53071652 C A 4.24E-10 Urate levels SFMBT1 intron 23263486 rs9756317 chr3 53088815 T C 2.27E-06 Waist-hip ratio / / 20935629 rs9870898 chr3 53092375 A G 9.73E-05 Acute lung injury / / 22295056 rs6770152 chr3 53100214 G T 3.00E-16 Urate levels / / 23263486 rs2581790 chr3 53101780 T C 3.29E-09 Urate levels / / 23263486 rs2336725 chr3 53118739 C T 1.00E-12 Height / / 20881960 rs2564921 chr3 53125585 T C 2.00E-12 Height RFT1 UTR-3 23563607 rs13088281 chr3 53147576 C A 3.00E-11 Immune reponse to smallpox (secreted IL-2) RFT1 intron 22610502 rs1560332 chr3 53164803 C T 8.77E-04 Multiple complex diseases RFT1 nearGene-5 17554300 rs7615501 chr3 53175557 G A 8.23E-04 Alcohol dependence / / 20201924 rs3736151 chr3 53259608 C T 8.86E-05 Waist Circumference TKT UTR-3 pha003023 rs3163 chr3 53259850 C T 1.40E-04 Smoking initiation TKT cds-synon 24665060 rs7650103 chr3 53260325 A G 2.48E-05 Orofacial clefts TKT intron 22419666 rs735940 chr3 53266531 C T 4.31E-05 Waist Circumference TKT intron pha003023 rs2242302 chr3 53267296 G A 4.12E-04 Smoking initiation TKT intron 24665060 rs7628245 chr3 53272944 C T 3.73E-95 Multiple complex diseases TKT intron 17554300 rs12493802 chr3 53278241 C T 1.81E-05 Relative hand skill TKT intron 24068947 rs4687717 chr3 53282188 T C 1.00E-13 Blood metabolite levels TKT intron 24816252 rs4687717 chr3 53282188 T C 9.00E-23 Blood metabolite ratios TKT intron 24816252 rs4687718 chr3 53282303 A G 6.00E-09 Ventricular conduction TKT intron 21076409 rs7648309 chr3 53291982 G A 1.57E-04 Multiple complex diseases TKT nearGene-5 17554300 rs7649323 chr3 53332706 G C 1.19E-04 Multiple complex diseases DCP1A intron 17554300 rs7649323 chr3 53332706 G C 0.00000742 Fear (ARBQ) in children DCP1A intron 23565138 rs2029213 chr3 53378245 C T 7.00E-06 Heart rate DCP1A intron 23583979 rs9873674 chr3 53435726 G T 6.66E-04 Multiple complex diseases / / 17554300 rs13080668 chr3 53443354 T C 4.56E-04 Multiple complex diseases / / 17554300 rs13080668 chr3 53443354 T C 1.87E-07 Heart rate / / 23583979 rs674628 chr3 53445957 G A 6.90E-05 Endometriosis / / 21151130 rs555480 chr3 53495847 G T 1.79E-04 Hemoglobin concentration / / 20534544 rs562331 chr3 53509316 T C 8.52E-04 Multiple complex diseases / / 17554300 rs17053107 chr3 53519922 C A 8.95E-04 Multiple complex diseases / / 17554300 rs312483 chr3 53524051 G A 6.89E-04 Multiple complex diseases / / 17554300 rs6763768 chr3 53537879 T C 1.97E-04 Cognition,early reading ability CAC/1D intron 17684495 rs979220 chr3 53556223 T C 3.72E-04 Multiple complex diseases CAC/1D intron 17554300 rs10049492 chr3 53596532 A G 8.46E-06 Cardiovascular disease CAC/1D intron pha003064 rs10490772 chr3 53605845 C T 1.46E-04 Alzheimer's disease CAC/1D intron 24755620 rs6445588 chr3 53630679 C T 3.26E-04 Nicotine smoking CAC/1D intron 19268276 rs6445588 chr3 53630679 C T 8.81E-04 Nicotine smoking CAC/1D intron 19268276 rs6445588 chr3 53630679 C T 1.97E-07 Delayed encephalopathy in acute carbon monoxide poisoning CAC/1D intron 24265751 rs6445588 chr3 53630679 C T 6.29E-07 Delayed encephalopathy in acute carbon monoxide poisoning CAC/1D intron 24265751 rs936450 chr3 53634426 A G 1.70E-05 Urinary metabolites CAC/1D intron 21572414 rs898414 chr3 53651291 A G 3.62E-04 Multiple complex diseases CAC/1D intron 17554300 rs3774490 chr3 53663648 C T 2.64E-04 Amyotrophic lateral sclerosis (sporadic) CAC/1D intron 24529757 rs1401492 chr3 53680124 C T 3.00E-06 Insulin resistance CAC/1D intron 21901158 rs1401492 chr3 53680124 C T 5.00E-06 Insulin resistance CAC/1D intron 21901158 rs3774519 chr3 53695242 T G 9.85E-04 Insulin resistance CAC/1D intron 21901158 rs2612017 chr3 53730773 G A 4.77E-04 Multiple complex diseases CAC/1D intron 17554300 rs3774541 chr3 53741132 G A 8.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/1D intron 20877124 rs2169143 chr3 53750681 C G 9.90E-04 Type 2 diabetes and 6 quantitative traits CAC/1D intron 17848626 rs2253795 chr3 53778875 G T 5.18E-04 Major depressive disorder CAC/1D intron 22472876 rs3774560 chr3 53785403 T C 4.21E-04 Smoking initiation CAC/1D intron 24665060 rs17053472 chr3 53788732 A C 3.01E-05 Major depressive disorder CAC/1D intron 22472876 rs719260 chr3 53789172 T C 3.27E-04 Major depressive disorder CAC/1D intron 22472876 rs1573818 chr3 53800238 T C 1.62E-04 Smoking initiation CAC/1D intron 24665060 rs3774581 chr3 53802748 A G 9.49E-04 Type 2 diabetes CAC/1D intron 17463246 rs3774581 chr3 53802748 A G 2.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/1D intron 20877124 rs3774581 chr3 53802748 A G 1.31E-05 Orofacial clefts CAC/1D intron 22419666 rs3774601 chr3 53822893 G A 2.98E-04 Major depressive disorder CAC/1D intron 22472876 rs3774604 chr3 53824136 C T 3.61E-04 Major depressive disorder CAC/1D intron 22472876 rs3774608 chr3 53832712 G A 2.21E-04 Major depressive disorder CAC/1D intron 22472876 rs3774609 chr3 53832903 T G 1.14E-05 Bipolar disorder CAC/1D intron 21926972 rs3774609 chr3 53832903 T G 2.16E-04 Major depressive disorder CAC/1D intron 22472876 rs2359133 chr3 53836742 G C 3.77E-04 Type 2 diabetes CAC/1D intron 17463246 rs877483 chr3 53846741 T C 7.46E-06 Major depressive disorder / / 22472876 rs893363 chr3 53847062 G A 1.33E-05 Major depressive disorder / / 22472876 rs893363 chr3 53847062 G A 8.00E-06 Axial length / / 24144296 rs14165 chr3 53847408 A G 2.00E-08 Refractive error / / 23396134 rs4687587 chr3 53849510 A G 8.90E-06 Axial length / / 24144296 rs4687747 chr3 53865433 G T 8.77E-04 Response to taxane treatment (placlitaxel) CHDH intron 23006423 rs13317328 chr3 53870840 A C 1.87E-05 Coronary heart disease CHDH intron pha003031 rs920253 chr3 53872753 G A,C,T 7.90E-04 Type 2 diabetes CHDH intron 17463246 rs3821869 chr3 53893840 C A 1.03E-04 Lung function (forced expiratory volume in 1 second) IL17RB intron 24023788 rs3821869 chr3 53893840 C A 4.42E-05 Lung function (forced vital capacity) IL17RB intron 24023788 rs6766099 chr3 53894412 C T 4.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IL17RB intron 20877124 rs2232350 chr3 53899178 T C 0.000000259 HDL cholesterol IL17RB missense 23063622 rs1043261 chr3 53899276 C T 1.54E-04 Intracranial aneurysm IL17RB STOP-GAIN 22286173 rs2241806 chr3 53901611 A G 2.83E-04 Lung function (forced vital capacity) ACTR8 UTR-3 24023788 rs2241806 chr3 53901611 A G 3.69E-04 Lung function (forced expiratory volume in 1 second) ACTR8 UTR-3 24023788 rs893367 chr3 53909731 C A 2.65E-04 Lung function (forced vital capacity) ACTR8 intron 24023788 rs7636856 chr3 53934171 A G 1.29E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7636856 chr3 53934171 A G 4.75E-05 Lung function (forced vital capacity) / / 24023788 rs6803364 chr3 54036698 T G 0.00000027 Mean arterial pressure / / 22510845 rs17053682 chr3 54077334 A G 2.16E-04 Multiple complex diseases / / 17554300 rs1992965 chr3 54077726 G A 0.000000522 Femoral neck bone mineral density (premenopausal) / / 23074152 rs7637998 chr3 54086583 T C 3.63E-05 AIDS progression / / 19115949 rs750379 chr3 54111877 T C 3.60E-05 Alcoholism (heaviness of drinking) / / 21529783 rs1349205 chr3 54118117 G C 1.42E-05 Bone mass and geometry / / 17903296 rs9841694 chr3 54120245 C T 4.35E-04 Type 2 diabetes / / 17463246 rs9841694 chr3 54120245 C T 6.82E-04 Insulin resistance / / 21901158 rs13322861 chr3 54122673 G A 2.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4472075 chr3 54123011 G T 2.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17801638 chr3 54128575 T C 7.95E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs4320084 chr3 54149801 G A 1.34E-05 Heart Failure / / pha002885 rs2034444 chr3 54165888 A G 1.20E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs6765381 chr3 54173258 T C 1.53E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs9880023 chr3 54178199 G T 4.43E-04 Type 2 diabetes CAC/2D3 intron 17463246 rs9880023 chr3 54178199 G T 3.54E-05 ldl cholesterol CAC/2D3 intron pha003076 rs6796475 chr3 54188188 T C 1.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D3 intron 20877124 rs2359784 chr3 54200456 T C 4.18E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs4345101 chr3 54221986 T C 1.53E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs4077974 chr3 54226000 G A 9.54E-04 Obesity (extreme) CAC/2D3 intron 21935397 rs12630117 chr3 54228291 A T 0.0004874 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CAC/2D3 intron 23233654 rs12630117 chr3 54228291 A T 4.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) CAC/2D3 intron 23233662 rs11717167 chr3 54229726 C T 1.36E-08 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D3 intron 20877124 rs6445633 chr3 54230638 A C 0.0002 Common carotid artery thickness (average of near and far wall measures) CAC/2D3 intron 23487405 rs11714003 chr3 54234467 A G 0.0003 Migraine CAC/2D3 intron 22678113 rs9839121 chr3 54240680 T C 3.62E-05 Waist Circumference CAC/2D3 intron pha003023 rs9840694 chr3 54244778 C T 3.00E-06 Prostate cancer CAC/2D3 intron 21743057 rs9828664 chr3 54247916 C T 1.00E-04 Prostate cancer CAC/2D3 intron 21743057 rs11130399 chr3 54249650 G T 5.55E-04 Intracranial aneurysm CAC/2D3 intron 20613766 rs11130399 chr3 54249650 G T 4.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D3 intron 20877124 rs11130399 chr3 54249650 G T 1.42E-04 Type 2 diabetes CAC/2D3 intron 22158537 rs11130401 chr3 54250278 A C 6.00E-04 Type 2 diabetes CAC/2D3 intron 22158537 rs9840489 chr3 54250489 G A 8.00E-06 Prostate cancer CAC/2D3 intron 21743057 rs6806229 chr3 54253658 G A 6.08E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs6806229 chr3 54253658 G A 8.00E-06 Prostate cancer CAC/2D3 intron 21743057 rs3923436 chr3 54254041 T G 8.00E-06 Prostate cancer CAC/2D3 intron 21743057 rs6763602 chr3 54258383 A G 5.70E-04 Type 2 diabetes CAC/2D3 intron 22158537 rs6763602 chr3 54258383 A G 0.000856958 Hypertension (early onset hypertension) CAC/2D3 intron 22479346 rs6763602 chr3 54258383 A G 9.19E-05 Lipoproteins CAC/2D3 intron pha003079 rs9878916 chr3 54267797 G A 3.11E-04 Alzheimer's disease (late onset) CAC/2D3 intron 21379329 rs4928020 chr3 54273364 A G 5.11E-04 Smoking initiation CAC/2D3 intron 24665060 rs4927995 chr3 54275323 T C 6.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D3 intron 20877124 rs11130407 chr3 54285030 C T 7.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D3 intron 20877124 rs9846140 chr3 54286459 G A 7.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D3 intron 20877124 rs7615792 chr3 54305670 A G 6.72E-04 Iron levels CAC/2D3 intron pha002876 rs6792199 chr3 54326491 C T 6.55E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs3934631 chr3 54330455 A G 4.08E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs4078006 chr3 54338062 C G 5.03E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs7431577 chr3 54339912 G T 1.16E-04 Amyotrophic lateral sclerosis (sporadic) CAC/2D3 intron 24529757 rs7431992 chr3 54353240 T A 2.62E-04 Nicotine smoking CAC/2D3 intron 19268276 rs11708620 chr3 54371791 C T 5.37E-04 Alcohol dependence CAC/2D3 intron 21314694 rs11711956 chr3 54378600 A G 2.00E-06 Musician's dystonia CAC/2D3 intron 24375517 rs2359790 chr3 54387169 T C 4.49E-05 Body mass index CAC/2D3 intron 17255346 rs2359793 chr3 54406659 A G 1.60E-04 Body mass index CAC/2D3 intron 17255346 rs2359793 chr3 54406659 A G 8.00E-04 Acute lymphoblastic leukemia (childhood) CAC/2D3 intron 20189245 rs1449330 chr3 54409526 A G 9.40E-05 Body mass index CAC/2D3 intron 17255346 rs9862718 chr3 54424701 G A 2.39E-04 Body mass index CAC/2D3 intron 17255346 rs9851130 chr3 54435589 A G 3.75E-04 Insulin resistance CAC/2D3 intron 21901158 rs12632768 chr3 54450047 C A 1.92E-04 Body mass index CAC/2D3 intron 17255346 rs6803199 chr3 54450193 T C 2.04E-04 Bipolar disorder CAC/2D3 intron 19259986 rs9816445 chr3 54470968 G A 6.31E-04 Insulin resistance CAC/2D3 intron 21901158 rs6768189 chr3 54471010 A G 8.19E-04 Intracranial aneurysm CAC/2D3 intron 20613766 rs6768189 chr3 54471010 A G 0.0000357 Antithrombin CAC/2D3 intron 23705025 rs6796049 chr3 54503574 C G 5.27E-04 Acute lung injury CAC/2D3 intron 22295056 rs17747001 chr3 54511119 A G 5.65E-04 Acute lung injury CAC/2D3 intron 22295056 rs6773944 chr3 54516884 C A 1.99E-04 Smoking initiation CAC/2D3 intron 24665060 rs17747054 chr3 54517051 G A 5.94E-04 Acute lung injury CAC/2D3 intron 22295056 rs11708855 chr3 54525443 A T 4.62E-04 Acute lung injury CAC/2D3 intron 22295056 rs7614229 chr3 54529944 T C 4.91E-04 Acute lung injury CAC/2D3 intron 22295056 rs11706275 chr3 54535284 C T 4.92E-04 Acute lung injury CAC/2D3 intron 22295056 rs7432776 chr3 54555192 T G 8.10E-04 Acute lung injury CAC/2D3 intron 22295056 rs7372026 chr3 54592177 G A 5.65E-04 Smoking initiation CAC/2D3 intron 24665060 rs17054142 chr3 54599814 T C 3.46E-04 Type 2 diabetes CAC/2D3 intron 17463246 rs1543208 chr3 54609024 A G 1.48E-05 Alzheimer's disease (late onset) CAC/2D3 intron 21379329 rs4955861 chr3 54611163 C T 1.56E-04 Smoking cessation CAC/2D3 intron 18519826 rs4955861 chr3 54611163 C T 4.37E-04 Smoking cessation CAC/2D3 intron 18519826 rs4955866 chr3 54611753 A G 1.46E-05 Smoking cessation CAC/2D3 intron 18519826 rs6445700 chr3 54613359 G A 2.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D3 intron 20877124 rs6445700 chr3 54613359 G A 3.53E-04 Alzheimer's disease (late onset) CAC/2D3 intron 21379329 rs6782115 chr3 54615971 A G 5.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D3 intron 20877124 rs1356895 chr3 54625797 C T 1.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D3 intron 20877124 rs13064588 chr3 54632547 T A 4.00E-06 Bipolar disorder and schizophrenia CAC/2D3 intron 20889312 rs616788 chr3 54639209 A G 3.52E-04 Amyotrophic Lateral Sclerosis CAC/2D3 intron 17362836 rs12497334 chr3 54655054 T C 5.31E-05 Smoking cessation CAC/2D3 intron 24665060 rs496625 chr3 54663005 A G 2.52E-04 Alzheimer's disease CAC/2D3 intron 24755620 rs1965072 chr3 54679831 C T 9.70E-04 Myocardial Infarction CAC/2D3 intron pha002873 rs578032 chr3 54687361 T C 1.23E-04 Type 2 diabetes CAC/2D3 intron 17463246 rs838022 chr3 54689649 A G 2.06E-04 Type 2 diabetes CAC/2D3 intron 17463246 rs517729 chr3 54708376 G A 5.77E-04 Suicide attempts in bipolar disorder CAC/2D3 intron 21041247 rs666071 chr3 54709721 T C 1.05E-06 Smoking cessation CAC/2D3 intron 18519826 rs515920 chr3 54718721 T C 7.18E-04 Suicide attempts in bipolar disorder CAC/2D3 intron 21041247 rs515920 chr3 54718721 T C 5.42E-04 Alzheimer's disease CAC/2D3 intron 24755620 rs583190 chr3 54727077 C A 7.49E-04 Alzheimer's disease CAC/2D3 intron 24755620 rs652424 chr3 54745555 C T 7.74E-04 Suicide attempts in bipolar disorder CAC/2D3 intron 21041247 rs589281 chr3 54747244 C T 7.75E-04 Suicide attempts in bipolar disorder CAC/2D3 intron 21041247 rs589281 chr3 54747244 C T 6.05E-04 Alzheimer's disease CAC/2D3 intron 24755620 rs604132 chr3 54748234 T A 4.58E-04 Suicide attempts in bipolar disorder CAC/2D3 intron 21041247 rs934083 chr3 54790379 C T 7.37E-05 Alzheimer's disease CAC/2D3 intron 24755620 rs7636321 chr3 54793450 T C 5.24E-04 Alzheimer's disease CAC/2D3 intron 24755620 rs3732748 chr3 54798258 G A 9.47E-04 Alzheimer's disease CAC/2D3 cds-synon 24755620 rs1820616 chr3 54800316 T C 1.27E-05 Fractional exhaled nitric oxide (childhood) CAC/2D3 intron 24315451 rs1820616 chr3 54800316 T C 3.00E-06 Fractional exhaled nitric oxide (childhood) CAC/2D3 intron 24315451 rs1997463 chr3 54807240 A G 3.80E-05 Subclinical atherosclerosis CAC/2D3 intron 17903303 rs9849795 chr3 54885173 T G 5.00E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs6810058 chr3 54891599 G T 6.40E-04 Alcohol dependence CAC/2D3 intron 20201924 rs17253119 chr3 54930773 A G 3.36E-04 Response to TNF antagonist treatment CAC/2D3 intron 21061259 rs9808962 chr3 54941441 G T 9.08E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs1918070 chr3 54941578 C T 9.92E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs4245919 chr3 54948936 G A 2.53E-05 Tunica Media CAC/2D3 intron pha003034 rs1515955 chr3 54984197 A G 9.64E-05 Personality dimensions CAC/2D3 intron 18957941 rs2048809 chr3 54990157 T G 6.82E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer CAC/2D3 intron 21483023 rs4955912 chr3 54996448 C T 9.16E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs3773586 chr3 55008746 C A 5.38E-04 Nicotine smoking CAC/2D3 intron 19268276 rs3773582 chr3 55017749 A G 1.78E-04 Endometrial cancer CAC/2D3 intron 24096698 rs3773582 chr3 55017749 A G 8.00E-06 Endometrial cancer CAC/2D3 intron 24096698 rs2360667 chr3 55031354 A G 5.84E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs4423737 chr3 55032038 C T 4.48E-04 Multiple complex diseases CAC/2D3 intron 17554300 rs4955826 chr3 55035874 C T 5.00E-06 Immune response to smallpox vaccine (IL-6) CAC/2D3 intron 22542470 rs17054685 chr3 55039611 G C 8.98E-04 Suicide attempts in bipolar disorder CAC/2D3 intron 21423239 rs1982862 chr3 55064740 C A 1.82E-08 Facial morphology CAC/2D3 intron 22341974 rs3773555 chr3 55065684 C T 5.36E-04 Iron levels CAC/2D3 intron pha002876 rs358493 chr3 55072187 C T 4.00E-05 Serum metabolites CAC/2D3 intron 19043545 rs358070 chr3 55105390 C A 6.88E-05 Leukocyte Counts CAC/2D3 intron pha003091 rs17323097 chr3 55107944 A G 4.31E-04 Alzheimer's disease CAC/2D3 intron 17998437 rs358077 chr3 55108358 A G 4.19E-04 Alzheimer's disease CAC/2D3 UTR-3 17998437 rs1458977 chr3 55136997 A G 2.41E-04 Iron levels / / pha002876 rs7651413 chr3 55139336 G T 3.60E-04 Primary sclerosing cholangitis / / 19944697 rs709330 chr3 55142430 G A 9.22E-04 Type 2 diabetes / / 17463246 rs6782380 chr3 55184213 C G 8.00E-06 Coronary artery calcification / / 23870195 rs11706236 chr3 55188273 A G 4.00E-06 Insomnia (caffeine-induced) / / 22754043 rs4955832 chr3 55188479 T G 5.77E-05 IgE levels / / 17255346 rs4955937 chr3 55194254 A G 0.000842 Salmonella-induced pyroptosis / / 22837397 rs753294 chr3 55194956 A G 8.40E-05 Ankylosing spondylitis / / 20062062 rs9311552 chr3 55216779 C T 5.60E-06 Cognitive impairment induced by topiramate / / 22091778 rs9311552 chr3 55216779 C T 7.40E-06 Endometriosis / / 23104006 rs6770519 chr3 55221542 A C 8.19E-04 Myocardial Infarction / / pha002873 rs1461796 chr3 55224080 T C 3.85E-04 Type 2 diabetes / / 17463246 rs1461796 chr3 55224080 T C 3.45E-05 Relative hand skill / / 24068947 rs6782687 chr3 55229775 T C 5.39E-04 Insulin resistance / / 21901158 rs1381389 chr3 55231799 G A 8.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs12491607 chr3 55236699 C A,G,T 5.10E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs10510777 chr3 55237738 C T 3.06E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs9860541 chr3 55237880 A T 4.70E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs6802697 chr3 55241137 T C 5.14E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs374563 chr3 55256432 C A 4.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs373532 chr3 55263106 C T 2.70E-05 Information processing speed / / 21130836 rs535157 chr3 55263442 A C 2.73E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs6801136 chr3 55265321 C T 9.97E-06 Information processing speed / / 21130836 rs6801136 chr3 55265321 C T 2.50E-05 Urinary metabolites / / 21572414 rs393836 chr3 55265674 A C 8.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs747030 chr3 55271653 T A 7.76E-04 Multiple complex diseases / / 17554300 rs4955965 chr3 55291294 T C 7.28E-04 Multiple complex diseases / / 17554300 rs1122341 chr3 55294422 T C 4.36E-04 Multiple complex diseases / / 17554300 rs459737 chr3 55305884 A G 3.99E-04 Alcohol dependence / / 20201924 rs358806 chr3 55313400 A C 3.00E-06 Type 2 diabetes / / 17554300 rs358806 chr3 55313400 A C 3.00E-06 Coronary heart disease / / 21347282 rs358806 chr3 55313400 A C 3.00E-06 Type 2 diabetes / / 21647700 rs17055095 chr3 55315152 C T 5.53E-04 Parkinson's disease / / 16252231 rs749152 chr3 55332449 C T 2.39E-05 Blood pressure / / 17255346 rs358810 chr3 55349432 T C 3.56E-05 Coronary heart disease / / pha003030 rs1000408 chr3 55356725 C T 1.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs358792 chr3 55360261 T G 3.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs358793 chr3 55361433 T C 1.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9839808 chr3 55377935 T C 4.63E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4955848 chr3 55392281 G A 7.75E-04 Multiple complex diseases / / 17554300 rs9683127 chr3 55406338 A G 2.07E-05 Serum metabolites / / 19043545 rs6763470 chr3 55424943 T G 6.05E-07 Blood pressure / / 21909110 rs17327860 chr3 55462573 G A 4.89E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2362199 chr3 55464381 A G 0.0007895 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2362199 chr3 55464381 A G 7.90E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17327979 chr3 55465656 C T 3.46E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1520703 chr3 55469813 A C 1.08E-05 Multiple complex diseases / / 17554300 rs1392224 chr3 55474073 A G 6.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs544704 chr3 55480723 T C 5.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3913369 chr3 55481075 G T 4.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs751193 chr3 55487317 T A 2.96E-04 Multiple complex diseases / / 17554300 rs751193 chr3 55487317 T A 2.59E-04 Insulin resistance / / 21901158 rs751194 chr3 55487428 G A 2.27E-04 Multiple complex diseases / / 17554300 rs751194 chr3 55487428 G A 3.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11706227 chr3 55496260 C T 1.61E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11710229 chr3 55497953 A T 6.00E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12497254 chr3 55499664 G A 1.19E-04 Multiple complex diseases WNT5A nearGene-3 17554300 rs10865994 chr3 55500408 T A 5.72E-04 Multiple complex diseases WNT5A UTR-3 17554300 rs570374 chr3 55551064 C T 4.98E-04 Smoking cessation ERC2 intron 24665060 rs528574 chr3 55556129 A G 4.70E-05 Cognitive impairment induced by topiramate ERC2 intron 22091778 rs1875110 chr3 55563344 T C 4.00E-06 Periodontitis (Mean PAL) ERC2 intron 24024966 rs1795648 chr3 55571760 G A 6.00E-06 Bipolar disorder and schizophrenia ERC2 intron 21057379 rs17263248 chr3 55574820 A G 6.10E-06 Parkinson's disease (familial) ERC2 intron 18985386 rs17263248 chr3 55574820 A G 4.60E-05 Iron levels ERC2 intron 21208937 rs1167242 chr3 55575785 G A 7.42E-04 Myocardial Infarction ERC2 intron pha002873 rs11720559 chr3 55586557 T C 4.38E-04 White matter integrity ERC2 intron 22425255 rs4538346 chr3 55607629 G A 8.52E-04 Multiple complex diseases ERC2 intron 17554300 rs904622 chr3 55625184 A G 1.00E-04 Prostate cancer ERC2 intron 21743057 rs17055623 chr3 55679808 C G 5.00E-04 Acute lymphoblastic leukemia (childhood) ERC2 intron 20189245 rs17055647 chr3 55681358 C A 0.000305 Height (Pygmy height) ERC2 intron 22570615 rs17055741 chr3 55717324 C T 5.05E-06 Kawasaki disease ERC2 intron 21221998 rs2270583 chr3 55733717 A G 2.80E-06 Urinary metabolites ERC2 intron 21572414 rs815440 chr3 55738747 T C 1.03E-04 Response to cytidine analogues (gemcitabine) ERC2 intron 24483146 rs815437 chr3 55739360 C T 1.10E-04 Response to cytidine analogues (gemcitabine) ERC2 intron 24483146 rs815425 chr3 55741141 G A 1.17E-04 Response to cytidine analogues (gemcitabine) ERC2 intron 24483146 rs709339 chr3 55741894 T A 5.42E-04 Response to cytidine analogues (gemcitabine) ERC2 intron 24483146 rs815422 chr3 55742066 T G 1.33E-04 Response to cytidine analogues (gemcitabine) ERC2 intron 24483146 rs1179376 chr3 55743058 C T 8.14E-04 Response to cytidine analogues (gemcitabine) ERC2 intron 24483146 rs1179375 chr3 55743198 T C 7.13E-06 Uric acid levels ERC2 intron 21294900 rs1179375 chr3 55743198 T C 9.27E-04 Response to cytidine analogues (gemcitabine) ERC2 intron 24483146 rs1495360 chr3 55760165 G A 5.99E-04 Type 2 diabetes ERC2 intron 17463246 rs815453 chr3 55767988 C T 7.57E-04 Type 2 diabetes ERC2 intron 17463246 rs815452 chr3 55768130 T C 8.37E-04 Type 2 diabetes ERC2 intron 17463246 rs815451 chr3 55768688 G C 8.14E-04 Type 2 diabetes ERC2 intron 17463246 rs1495365 chr3 55802668 G T 5.30E-04 Rheumatoid arthritis ERC2 intron 21452313 rs9852746 chr3 55803332 A G 9.15E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs9852888 chr3 55803435 A T 2.48E-05 Esophageal cancer (squamous cell) ERC2 intron 22960999 rs4955878 chr3 55805447 C T 4.42E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs4974144 chr3 55805996 G A 6.60E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs6445754 chr3 55807255 C T 7.72E-05 Sarcoidosis ERC2 intron 19165924 rs6445754 chr3 55807255 C T 1.31E-04 Acute lymphoblastic leukemia (childhood) ERC2 intron 22076464 rs6445754 chr3 55807255 C T 8.49E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs7641474 chr3 55821111 C T 1.00E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs4572738 chr3 55824412 T C 7.31E-04 Rheumatoid arthritis ERC2 intron 21452313 rs4572738 chr3 55824412 T C 4.45E-05 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs4459870 chr3 55829060 C T 2.88E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs12488085 chr3 55834871 G A 7.38E-04 Rheumatoid arthritis ERC2 intron 21452313 rs12488085 chr3 55834871 G A 4.64E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs4129822 chr3 55839410 A G 7.49E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs4260395 chr3 55846469 C A 4.96E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs9860951 chr3 55846998 C T 2.10E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs7615473 chr3 55849978 G T 3.72E-04 Rheumatoid arthritis ERC2 intron 21452313 rs7615473 chr3 55849978 G T 2.08E-04 Response to cytadine analogues (cytosine arabinoside) ERC2 intron 24483146 rs6782906 chr3 55881520 C T 2.26E-04 Alcohol dependence ERC2 intron 20201924 rs7631846 chr3 55883396 T C 3.10E-04 Alcohol dependence ERC2 intron 20201924 rs13098621 chr3 55914171 G A 0.000171952 Primary sclerosing cholangitis ERC2 intron 23603763 rs1156513 chr3 55929848 A G 6.98E-05 Eosinophil counts ERC2 intron pha003088 rs13080171 chr3 55941438 A C 6.40E-04 Insulin resistance ERC2 intron 21901158 rs4541375 chr3 55942547 G C 8.76E-04 Alzheimer's disease ERC2 intron 24755620 rs13072547 chr3 55943591 T C 8.57E-05 Alzheimer's disease ERC2 intron 24755620 rs1110225 chr3 55945666 C T 9.87E-04 Alzheimer's disease ERC2 intron 24755620 rs6794124 chr3 55946297 A C 8.24E-05 Alzheimer's disease ERC2 intron 24755620 rs11712729 chr3 55949485 G C 4.65E-04 Multiple complex diseases ERC2 intron 17554300 rs11917617 chr3 55952782 A G 4.13E-04 Alzheimer's disease ERC2 intron 24755620 rs17288603 chr3 55955214 G A 7.82E-04 Alcohol dependence ERC2 intron 20201924 rs724333 chr3 55958059 T G 1.55E-04 Diabetic retinopathy ERC2 intron 20871662 rs724334 chr3 55958082 T C 8.57E-05 Alzheimer's disease ERC2 intron 24755620 rs11712398 chr3 55969663 T C 7.28E-04 Alzheimer's disease ERC2 intron 24755620 rs4974153 chr3 55969858 G T 9.55E-05 Chronic obstructive pulmonary disease ERC2 intron 19300482 rs4974153 chr3 55969858 G T 1.28E-05 Post-operative nausea and vomiting ERC2 intron 21694509 rs9311590 chr3 55989518 C G 6.29E-04 Multiple complex diseases ERC2 intron 17554300 rs12495172 chr3 55993656 G A 2.79E-05 Chronic obstructive pulmonary disease ERC2 intron 19300482 rs17056288 chr3 55993951 C T 7.76E-04 Smoking cessation ERC2 intron 24665060 rs732255 chr3 56016672 C T 8.10E-04 Alzheimer's disease ERC2 intron 24755620 rs1379720 chr3 56023942 A C,G,T 0.000454 Salmonella-induced pyroptosis ERC2 intron 22837397 rs7641427 chr3 56026877 C T 0.00043 Salmonella-induced pyroptosis ERC2 intron 22837397 rs1379717 chr3 56037999 G A 2.27E-04 Alzheimer's disease ERC2 intron 24755620 rs13061634 chr3 56054077 T C 2.76E-05 Chronic obstructive pulmonary disease ERC2 intron 19300482 rs11130493 chr3 56055557 G C 0.00088 Salmonella-induced pyroptosis ERC2 intron 22837397 rs9862661 chr3 56070758 A C 1.57E-05 Chronic obstructive pulmonary disease ERC2 intron 19300482 rs7623143 chr3 56088978 T C 4.73E-05 Cognitive test performance ERC2 intron 20125193 rs1485674 chr3 56105313 G A 1.23E-04 Multiple complex diseases ERC2 intron 17554300 rs1352008 chr3 56142860 T C 1.56E-04 Multiple complex diseases ERC2 intron 17554300 rs9873343 chr3 56189053 C T 2.25E-04 Coronary Artery Disease ERC2 intron 17634449 rs1452206 chr3 56233022 G A 5.82E-05 Varicose Veins ERC2 intron pha001413 rs9851360 chr3 56434975 C T 8.68E-04 Suicide attempts in bipolar disorder ERC2 intron 21041247 rs1491158 chr3 56436161 G A 8.21E-04 Suicide attempts in bipolar disorder ERC2 intron 21041247 rs6763636 chr3 56440429 T G 8.71E-04 Suicide attempts in bipolar disorder ERC2 intron 21041247 rs9817231 chr3 56440977 A T 8.67E-04 Suicide attempts in bipolar disorder ERC2 intron 21041247 rs11130520 chr3 56441119 T G 8.65E-04 Suicide attempts in bipolar disorder ERC2 intron 21041247 rs885211 chr3 56447869 C T 3.10E-04 Aortic root size ERC2 intron 21223598 rs885211 chr3 56447869 C T 3.93E-04 Insulin resistance ERC2 intron 21901158 rs885211 chr3 56447869 C T 7.80E-04 Heart Failure ERC2 intron pha002884 rs9814545 chr3 56458160 G A 2.25E-04 Multiple complex diseases ERC2 intron 17554300 rs9855289 chr3 56471160 C T 9.33E-05 Multiple complex diseases ERC2 intron 17554300 rs1878270 chr3 56487580 C G 7.11E-05 Schizophrenia(age at onset) ERC2 intron 21688384 rs9873381 chr3 56489776 G A 2.51E-05 Schizophrenia(age at onset) ERC2 intron 21688384 rs9881216 chr3 56516645 C T 4.62E-04 Multiple complex diseases / / 17554300 rs9881216 chr3 56516645 C T 6.38E-05 Schizophrenia(age at onset) / / 21688384 rs7633140 chr3 56521164 G A 4.94E-04 Multiple complex diseases / / 17554300 rs2054989 chr3 56530709 A G 6.00E-07 Hip geometry / / 17903296 rs978979 chr3 56533016 A G 9.05E-04 Multiple complex diseases / / 17554300 rs12054450 chr3 56576503 C T 5.78E-04 Myopia (pathological) / / 21095009 rs6791987 chr3 56579538 C T 2.82E-05 Creatinine levels / / pha003069 rs13093662 chr3 56581983 T C 5.78E-04 Myopia (pathological) / / 21095009 rs17288810 chr3 56582589 G A 8.41E-04 Multiple complex diseases / / 17554300 rs7637449 chr3 56628031 G A 1.80E-06 Height CCDC66 missense 21998595 rs2317134 chr3 56648363 T C 1.04E-04 Multiple complex diseases CCDC66 intron 17554300 rs9833926 chr3 56650178 A G 7.00E-06 Height CCDC66 intron 21998595 rs9835332 chr3 56667682 G C 5.00E-13 Height FAM208A missense 20881960 rs3732513 chr3 56674303 T C 1.70E-04 Nonalcoholic fatty liver disease FAM208A intron 21423719 rs11719707 chr3 56691393 G A 5.60E-05 Lymphocyte counts FAM208A intron 22286170 rs958755 chr3 56716922 T G 9.60E-06 Height FAM208A missense 21998595 rs6773931 chr3 56735180 C A 8.00E-08 Height / / 21998595 rs6445815 chr3 56740101 A G 3.50E-07 Height / / 21998595 rs6805864 chr3 56754839 C G 2.10E-05 Urinary metabolites / / 21572414 rs13319627 chr3 56769446 C T 1.20E-05 Urinary metabolites ARHGEF3 intron 21572414 rs3732509 chr3 56784848 C G 2.00E-05 Urinary metabolites ARHGEF3 intron 21572414 rs13100723 chr3 56798495 C T 1.00E-06 Obesity-related traits ARHGEF3 intron 23251661 rs2171858 chr3 56798704 C G 2.84E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs2171857 chr3 56798749 A G 2.94E-05 Multiple complex diseases ARHGEF3 intron 17554300 rs1039384 chr3 56849189 A G 1.76E-05 Personality dimensions ARHGEF3 intron 22628180 rs1354034 chr3 56849749 T C 3.00E-54 Platelet counts ARHGEF3 intron 22139419 rs1354034 chr3 56849749 T C 3.00E-69 Mean platelet volume ARHGEF3 intron 22139419 rs1354034 chr3 56849749 T C 1.00E-19 Platelet counts ARHGEF3 intron 23263863 rs1354034 chr3 56849749 T C 4.00E-09 Platelet counts ARHGEF3 intron 23263863 rs1354034 chr3 56849749 T C 9.00E-13 Platelet counts ARHGEF3 intron 23263863 rs1354034 chr3 56849749 T C 6.00E-24 Platelet counts ARHGEF3 intron 24026423 rs1354034 chr3 56849749 T C 9.00E-34 Mean platelet volume ARHGEF3 intron 24026423 rs4681908 chr3 56865752 C T 7.44E-06 Body Mass Index ARHGEF3 intron pha003020 rs12485738 chr3 56865776 A G 4.00E-27 Mean platelet volume ARHGEF3 intron 19110211 rs12485738 chr3 56865776 A G 6.00E-31 Mean platelet volume ARHGEF3 intron 19820697 rs12485738 chr3 56865776 A G 6.60E-14 Mean platelet volume ARHGEF3 intron 22423221 rs9881237 chr3 56870534 A G 6.73E-05 Body Mass Index ARHGEF3 intron pha003020 rs10510789 chr3 56877788 C T 1.45E-05 F-cell distribution ARHGEF3 intron 21326311 rs9845092 chr3 56893125 A G 8.23E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs1500710 chr3 56914065 C A 5.20E-05 Multiple sclerosis ARHGEF3 intron 21833088 rs6445834 chr3 56915719 T C 9.72E-05 Calcium intake levels and metabolic syndrome ARHGEF3 intron 22170361 rs9823870 chr3 56917254 T C 2.31E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs4681927 chr3 56919435 C T 5.01E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs950155 chr3 56920880 G C 6.31E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs950154 chr3 56920909 G A 2.78E-04 Type 2 diabetes ARHGEF3 intron 17463246 rs11916112 chr3 56924711 G A 7.29E-04 Alcohol dependence ARHGEF3 intron 20201924 rs4681929 chr3 56927023 G A 3.86E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ARHGEF3 intron 24023788 rs13070800 chr3 56942973 C T 2.26E-04 Blood pressure ARHGEF3 intron 17255346 rs9882574 chr3 56944019 T C 5.73E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs9828029 chr3 56949707 A C 6.75E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs17825630 chr3 56950055 G A 6.78E-04 Amyotrophic Lateral Sclerosis ARHGEF3 intron 17362836 rs1354035 chr3 56953624 C T 1.00E-04 Blood pressure ARHGEF3 intron 17255346 rs6792170 chr3 56958358 G A 2.64E-04 Type 2 diabetes ARHGEF3 intron 17463246 rs41433248 chr3 56962393 T C 3.76E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs41425945 chr3 56962422 G A 6.49E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs1021734 chr3 56963344 C T 4.74E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs11130557 chr3 56964674 T C 6.97E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs2062583 chr3 56966246 G T 2.00E-06 Rheumatoid arthritis ARHGEF3 intron 21452313 rs7650541 chr3 56990550 C T 3.89E-04 Type 2 diabetes ARHGEF3 intron 17463246 rs11925114 chr3 57014082 G A 6.19E-04 Obesity (extreme) ARHGEF3 intron 21935397 rs3924042 chr3 57020736 C T 2.36E-05 Heart Rate ARHGEF3 intron pha003054 rs11130559 chr3 57046092 G A 5.16E-04 Alzheimer's disease ARHGEF3 intron 24755620 rs11130567 chr3 57074119 C T 2.11E-04 Multiple complex diseases ARHGEF3 intron 17554300 rs11130567 chr3 57074119 C T 2.00E-04 Cognitive impairment induced by topiramate ARHGEF3 intron 22091778 rs755871 chr3 57080938 C T 6.95E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ARHGEF3 intron 21844884 rs2291462 chr3 57132200 A G 0.000491045 Hypertension (early onset hypertension) IL17RD cds-synon 22479346 rs6445853 chr3 57134115 A G 0.000227043 Hypertension (early onset hypertension) IL17RD intron 22479346 rs2247656 chr3 57137090 A G 8.57E-04 Insulin resistance IL17RD intron 21901158 rs1545981 chr3 57139972 A G 0.000510901 Hypertension (early onset hypertension) IL17RD cds-synon 22479346 rs747089 chr3 57153869 C T 1.82E-04 Lymphocyte counts IL17RD intron 22286170 rs12495640 chr3 57160312 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes IL17RD intron 22628534 rs4535195 chr3 57186035 A C 1.00E-05 F-cell distribution IL17RD intron 17767159 rs1352343 chr3 57195276 C G 8.98E-04 Multiple complex diseases IL17RD intron 17554300 rs4283545 chr3 57200758 C A 2.16E-04 Celiac disease / / 23936387 rs11130575 chr3 57204419 A G 9.14E-04 Heart Failure / / pha002885 rs11544593 chr3 57303684 A G 8.28E-05 Orofacial clefts APPL1 missense 20023658 rs571879 chr3 57347878 C T 1.38E-04 Celiac disease D/H12 intron 23936387 rs7648819 chr3 57351327 G A 1.13E-04 Multiple complex diseases D/H12 intron 17554300 rs1916284 chr3 57394766 T C 7.87E-04 Multiple complex diseases D/H12 intron 17554300 rs1916284 chr3 57394766 T C 1.00E-06 Prostate cancer (gene x gene interaction) D/H12 intron 22219177 rs11915740 chr3 57414330 C A 9.99E-04 Stroke D/H12 intron pha002887 rs2121743 chr3 57431985 G A 1.56E-05 Pulmonary function in asthmatics D/H12 cds-synon 23541324 rs9855748 chr3 57432609 C A 7.26E-04 Multiple complex diseases D/H12 intron 17554300 rs10510793 chr3 57473750 G A 4.49E-04 Renal cell carcinoma D/H12 intron 22010048 rs4681992 chr3 57489591 C A 4.01E-05 Pulmonary function in asthmatics D/H12 intron 23541324 rs4681993 chr3 57497715 C T 2.07E-04 Alzheimer's disease D/H12 intron 22005930 rs6445905 chr3 57499769 A G 2.55E-04 Alzheimer's disease D/H12 intron 22005930 rs6768058 chr3 57501031 G A 2.02E-04 Alzheimer's disease D/H12 intron 22005930 rs7612786 chr3 57508012 T C 1.95E-04 Alzheimer's disease D/H12 intron 22005930 rs3816365 chr3 57508538 C A 4.13E-04 Multiple complex diseases D/H12 intron 17554300 rs1470552 chr3 57510660 G A 1.88E-04 Alzheimer's disease D/H12 intron 22005930 rs6786181 chr3 57516548 G A 1.62E-04 Alzheimer's disease D/H12 intron 22005930 rs6769578 chr3 57518766 C T 1.60E-04 Alzheimer's disease D/H12 intron 22005930 rs9870678 chr3 57522950 A G 3.67E-05 Multiple complex diseases D/H12 intron 17554300 rs9311651 chr3 57528503 A G 2.86E-04 Birth weight D/H12 missense 17255346 rs12488539 chr3 57586825 G T 2.49E-04 Alzheimer's disease / / 22005930 rs6762914 chr3 57612623 T C 1.86E-04 Alzheimer's disease FAM116A UTR-3 22005930 rs11130595 chr3 57640001 T A 1.88E-04 Alzheimer's disease FAM116A intron 22005930 rs2361345 chr3 57666571 T C 7.81E-05 HIV-1 control FAM116A intron 20041166 rs12638616 chr3 57672353 G C 9.93E-04 Multiple complex diseases FAM116A intron 17554300 rs9873544 chr3 57708022 T C 3.41E-04 Alzheimer's disease / / 22005930 rs4530498 chr3 57724602 A G 1.21E-04 Alzheimer's disease (late onset) / / 21379329 rs6445927 chr3 57741346 A G 3.70E-04 Alzheimer's disease (late onset) / / 21379329 rs2061573 chr3 57763642 G A 4.93E-04 Alzheimer's disease (late onset) SLMAP intron 21379329 rs6768930 chr3 57779836 T C 5.00E-06 Obesity-related traits SLMAP intron 23251661 rs17745496 chr3 57902639 G A 6.32E-05 HIV-1 control SLMAP cds-synon 20041166 rs1098018 chr3 57979767 G T 1.10E-04 Height / / 19039035 rs9828717 chr3 57998986 C T 1.63E-04 Myocardial Infarction FLNB intron pha002883 rs1718460 chr3 58006413 A G 1.04E-05 Height FLNB intron 19039035 rs1658342 chr3 58009259 G A,C 1.09E-05 Height FLNB intron 19039035 rs865726 chr3 58018879 C T 3.76E-05 Height FLNB intron 19039035 rs839232 chr3 58020826 T A 1.49E-05 Height FLNB intron 19039035 rs1718481 chr3 58025903 C T 1.67E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) FLNB intron 23648065 rs1718481 chr3 58025903 C T 7.53E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) FLNB intron 23648065 rs1623879 chr3 58027197 A G 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) FLNB intron 23648065 rs839230 chr3 58036792 C T 2.42E-04 Multiple complex diseases FLNB intron 17554300 rs839230 chr3 58036792 C T 2.60E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) FLNB intron 23648065 rs839230 chr3 58036792 C T 5.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) FLNB intron 23648065 rs732527 chr3 58036935 T C 3.20E-04 Multiple complex diseases FLNB intron 17554300 rs732526 chr3 58036962 C T 3.84E-04 Multiple complex diseases FLNB intron 17554300 rs1249968 chr3 58045538 C T 2.37E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) FLNB intron 23648065 rs1249968 chr3 58045538 C T 6.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) FLNB intron 23648065 rs9809315 chr3 58050265 C T 2.84E-05 Eye color FLNB intron 23118974 rs4681659 chr3 58059661 G C 6.62E-05 Lymphocyte counts FLNB intron 22286170 rs2033739 chr3 58063819 G A 8.43E-04 Myocardial Infarction FLNB intron pha002883 rs4681784 chr3 58071644 C A 3.94E-04 Height FLNB intron 19039035 rs13315037 chr3 58072471 T G 8.96E-04 Suicide attempts in bipolar disorder FLNB intron 21041247 rs9834312 chr3 58082709 G A 7.30E-06 Height FLNB intron 19039035 rs7615893 chr3 58098444 T C 6.97E-04 Alcohol dependence FLNB intron 21314694 rs13077017 chr3 58105776 C T 1.00E-06 Eating disorders (purging via substances) FLNB intron 23568457 rs4681800 chr3 58109748 T A 8.12E-04 Alcohol dependence FLNB intron 21314694 rs2362904 chr3 58112488 C T 2.44E-04 Alcohol dependence FLNB cds-synon 20201924 rs3772993 chr3 58114884 C T 5.94E-04 Height FLNB intron 19039035 rs200297468 chr3 58116540 G C 0.000061 Breast cancer FLNB missense 23555315 rs4681795 chr3 58136429 T C 1.70E-05 Alcohol dependence FLNB intron 20201924 rs4681795 chr3 58136429 T C 1.70E-05 Alcoholism FLNB intron pha002891 rs35677470 chr3 58183636 G A 0.00000017 Rheumatoid arthritis D/SE1L3 missense 23143596 rs35677470 chr3 58183636 G A 0.00000109 Rheumatoid arthritis (CCP positive) D/SE1L3 missense 23143596 rs4681824 chr3 58199669 T G 6.88E-04 Alcohol dependence D/SE1L3 intron 21314694 rs9986 chr3 58280406 A G 5.81E-06 Esophageal cancer (squamous cell) ABHD6 UTR-3 22960999 rs2363688 chr3 58282128 A G 7.69E-04 Multiple complex diseases / / 17554300 rs17059150 chr3 58292131 C A 7.36E-04 Multiple complex diseases RPP14 UTR-5 17554300 rs73081554 chr3 58302935 C T 4.60E-08 Rheumatoid arthritis RPP14 intron 24390342 rs73081554 chr3 58302935 C T 5.00E-08 Rheumatoid arthritis RPP14 intron 24390342 rs2176082 chr3 58331186 G A 5.00E-11 Systemic lupus erythematosus and Systemic sclerosis PXK intron 23740937 rs11715445 chr3 58343888 T C 1.46E-04 Multiple complex diseases PXK intron 17554300 rs6445975 chr3 58370177 G T 7.00E-09 Systemic lupus erythematosus PXK intron 18204446 rs6445975 chr3 58370177 G T 7.10E-09 Multiple sclerosis PXK intron 22190364 rs6772228 chr3 58376019 T A 3.91E-10 Telomere length PXK intron 23900074 rs11923253 chr3 58376992 G A 5.35E-04 Smoking initiation PXK intron 24665060 rs13315871 chr3 58381287 G A 4.00E-08 Cholesterol,total PXK intron 24097068 rs4681851 chr3 58395891 C G 1.87E-07 Telomere length PXK intron 23900074 rs2070662 chr3 58415590 C A 2.46E-06 Telomere length PDHB intron 23900074 rs6768547 chr3 58434969 T C 1.99E-06 Telomere length / / 23900074 rs7633553 chr3 58440236 T C 1.10E-04 Telomere length / / 23900074 rs4681861 chr3 58495739 A T 1.81E-04 Telomere length ACOX2 intron 23900074 rs4317122 chr3 58498843 C T 1.40E-04 Telomere length ACOX2 intron 23900074 rs2120577 chr3 58551800 T C 3.30E-05 HIV-1 control FAM107A UTR-3 20041166 rs11539086 chr3 58552329 C G 1.35E-04 Type 2 diabetes FAM107A missense 17463246 rs11539086 chr3 58552329 C G 5.24E-10 Adiponectin levels FAM107A missense 20887962 rs9813011 chr3 58555895 T C 2.63E-06 Telomere length FAM107A intron 23900074 rs13315591 chr3 58556841 T C 8.43E-05 Type 2 diabetes FAM107A intron 17463246 rs13315591 chr3 58556841 T C 5.00E-08 Rheumatoid arthritis FAM107A intron 20453842 rs13315591 chr3 58556841 T C 4.60E-08 Celiac disease and Rheumatoid arthritis FAM107A intron 21383967 rs13315591 chr3 58556841 T C 4.60E-08 Multiple sclerosis FAM107A intron 22190364 rs13315591 chr3 58556841 T C 6.30E-07 Rheumatoid arthritis FAM107A intron 22446963 rs13315591 chr3 58556841 T C 0.000000046 Rheumatoid arthritis FAM107A intron 23143596 rs1444189 chr3 58566057 C T 3.42E-05 Type 2 diabetes / / 17463246 rs6445991 chr3 58575110 A G 9.41E-04 Alzheimer's disease / / 17998437 rs17059467 chr3 58590414 T C 3.11E-05 Multiple complex diseases / / 17554300 rs2306667 chr3 58594655 T C 6.05E-05 Response to diuretic therapy in hypertension / / 23753411 rs900871 chr3 58595376 G A 3.44E-05 Telomere length LOC100506924 intron 23900074 rs4681875 chr3 58595823 T C 5.57E-05 Telomere length LOC100506924 intron 23900074 rs11710358 chr3 58614016 C T 7.52E-04 Type 2 diabetes / / 17463246 rs1373407 chr3 58614195 G A 5.66E-04 Tourette syndrome / / 22889924 rs753819 chr3 58614393 A G 8.39E-04 Type 2 diabetes / / 17463246 rs753821 chr3 58614420 G A 6.18E-04 Type 2 diabetes / / 17463246 rs753821 chr3 58614420 G A 7.35E-05 Multiple sclerosis / / 17660530 rs3860562 chr3 58619522 C T 6.92E-05 Coronary restenosis / / 21878436 rs11130665 chr3 58622620 G T 9.90E-04 Type 2 diabetes FAM3D intron 17463246 rs2364305 chr3 58653904 C G 1.70E-05 Urinary metabolites / / 21572414 rs2364306 chr3 58654095 T C 1.90E-06 Urinary metabolites / / 21572414 rs900878 chr3 58654265 T C 9.10E-06 Urinary metabolites / / 21572414 rs13075889 chr3 58655038 G A 1.10E-05 Urinary metabolites / / 21572414 rs6802213 chr3 58655999 T A 1.90E-05 Urinary metabolites / / 21572414 rs11130671 chr3 58754163 C T 1.10E-04 HIV-1 viral setpoint C3orf67 intron 17641165 rs17360960 chr3 58854266 T C 3.34E-04 Birth weight C3orf67 intron 17255346 rs6783793 chr3 59012177 A G 8.66E-04 Multiple complex diseases C3orf67 intron 17554300 rs2137457 chr3 59105913 G A 6.48E-04 Alcohol dependence / / 21314694 rs9824833 chr3 59126777 G T 8.59E-04 HIV-1 viral setpoint / / 17641165 rs1512823 chr3 59144273 G A 5.75E-04 Smoking initiation / / 24665060 rs4274771 chr3 59182023 T G 1.94E-04 HIV-1 viral setpoint / / 17641165 rs9838009 chr3 59265315 G T 8.40E-05 Asthma (bronchodilator response) / / 22792082 rs13321256 chr3 59295141 A G 3.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11130695 chr3 59305064 A C 7.00E-06 Asthma / / 21790008 rs9842553 chr3 59306653 G A 2.51E-04 Endometrial cancer / / 24096698 rs9842553 chr3 59306653 G A 5.80E-04 Endometrial cancer / / 24096698 rs6414594 chr3 59308131 A G 5.63E-05 Multiple complex diseases / / 17554300 rs6446030 chr3 59312883 T C 1.81E-05 Multiple complex diseases / / 17554300 rs6414595 chr3 59316581 T C 2.60E-05 Multiple complex diseases / / 17554300 rs4679621 chr3 59324733 C T 6.13E-04 Multiple complex diseases / / 17554300 rs9811499 chr3 59325384 C T 9.88E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6771019 chr3 59354158 G A 2.00E-06 Capecitabine sensitivity / / 22864933 rs6446043 chr3 59356425 T A 7.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs6446043 chr3 59356425 T A 7.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs2366434 chr3 59357436 A G 7.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs11130703 chr3 59358190 T C 4.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs11130703 chr3 59358190 T C 9.37E-06 Suicide attempts in bipolar disorder / / 21041247 rs2034127 chr3 59368074 A G 8.54E-08 Primary biliary cirrhosis / / 23000144 rs2034127 chr3 59368074 A G 8.54E-08 Facial morphology / / 23028347 rs2034128 chr3 59368259 A G 9.55E-08 Primary biliary cirrhosis / / 23000144 rs2034128 chr3 59368259 A G 9.55E-08 Facial morphology / / 23028347 rs2034129 chr3 59368293 C A 9.25E-08 Primary biliary cirrhosis / / 23000144 rs2034129 chr3 59368293 C A 9.25E-08 Facial morphology / / 23028347 rs7628370 chr3 59370600 A C 2.27E-07 Primary biliary cirrhosis / / 23000144 rs7628370 chr3 59370600 A C 0.000000227 Facial morphology / / 23028347 rs7617069 chr3 59370695 C A 2.47E-07 Primary biliary cirrhosis / / 23000144 rs7617069 chr3 59370695 C A 0.000000247 Facial morphology / / 23028347 rs717463 chr3 59372700 T C 4.74E-07 Primary biliary cirrhosis / / 23000144 rs717463 chr3 59372700 T C 0.000000474 Facial morphology / / 23028347 rs894883 chr3 59373255 A G 1.34E-07 Primary biliary cirrhosis / / 23000144 rs894883 chr3 59373255 A G 0.000000134 Facial morphology / / 23028347 rs755314 chr3 59373505 C T 7.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2886671 chr3 59373745 C T 2.06E-08 Narcolepsy / / 19629137 rs7640340 chr3 59380011 A G 3.07E-07 Primary biliary cirrhosis / / 23000144 rs7640340 chr3 59380011 A G 0.000000307 Facial morphology / / 23028347 rs875143 chr3 59380371 C T 4.21E-07 Primary biliary cirrhosis / / 23000144 rs875143 chr3 59380371 C T 0.000000421 Facial morphology / / 23028347 rs6795519 chr3 59388206 C T 4.58E-07 Primary biliary cirrhosis / / 23000144 rs6795519 chr3 59388206 C T 0.000000458 Facial morphology / / 23028347 rs4679485 chr3 59405125 T C 7.95E-05 Heart Rate / / pha003054 rs1021813 chr3 59413060 T C 8.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9849137 chr3 59413111 G A 6.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2062751 chr3 59413947 G A 6.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs962791 chr3 59417186 A G 4.94E-04 Rheumatoid arthritis / / 21452313 rs6783485 chr3 59427797 G A 4.68E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1910236 chr3 59434420 G A 9.37E-06 Response to gemcitabine in pancreatic cancer / / 22142827 rs6795120 chr3 59439285 A G 0.000312 Salmonella-induced pyroptosis / / 22837397 rs12492703 chr3 59439794 T G 0.0008439 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12492703 chr3 59439794 T G 8.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17060744 chr3 59445755 A G 0.0008319 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17060744 chr3 59445755 A G 8.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6803293 chr3 59452332 A G 2.67E-04 Multiple complex diseases / / 17554300 rs9883195 chr3 59460320 C A 0.0006968 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9883195 chr3 59460320 C A 6.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12498091 chr3 59460477 G A 0.0005832 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12498091 chr3 59460477 G A 5.83E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4679576 chr3 59470877 A T 8.15E-05 Serum metabolites / / 19043545 rs6772601 chr3 59472325 T G 2.93E-05 Serum metabolites / / 19043545 rs1502618 chr3 59474415 C G 2.20E-05 Serum metabolites / / 19043545 rs7626018 chr3 59474911 T C 3.87E-05 Serum metabolites / / 19043545 rs6780771 chr3 59475736 A G 3.88E-05 Serum metabolites / / 19043545 rs10510812 chr3 59481606 A G 1.05E-04 Multiple complex diseases / / 17554300 rs11130713 chr3 59481821 G A 1.39E-04 Multiple complex diseases / / 17554300 rs7620213 chr3 59482405 C T 4.06E-05 Serum metabolites / / 19043545 rs17333781 chr3 59487381 G T 2.34E-04 Multiple complex diseases / / 17554300 rs11925209 chr3 59491084 G A 1.60E-04 Multiple complex diseases / / 17554300 rs9862576 chr3 59491566 C T 2.51E-05 Serum metabolites / / 19043545 rs11130715 chr3 59492701 C G 3.54E-05 Serum metabolites / / 19043545 rs9848067 chr3 59504497 T A 7.39E-04 Multiple complex diseases / / 17554300 rs9832635 chr3 59504894 G A 3.58E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9855650 chr3 59519764 C T 7.41E-04 Schizophrenia / / 19197363 rs6768376 chr3 59523538 G A 9.90E-05 Insulin-related traits / / pha002901 rs1502616 chr3 59530321 A G 3.92E-04 Type 2 diabetes / / 17463246 rs10510813 chr3 59535975 G A 2.06E-04 Multiple complex diseases / / 17554300 rs734185 chr3 59555122 C T 1.82E-04 Multiple complex diseases / / 17554300 rs2886745 chr3 59560769 T C 3.38E-04 Multiple complex diseases / / 17554300 rs1504915 chr3 59566484 A G 6.56E-04 Coronary heart disease / / 21606135 rs6809606 chr3 59568658 C G 7.16E-04 Coronary Artery Disease / / 17634449 rs7615380 chr3 59570968 C T 5.13E-04 Coronary heart disease / / 21971053 rs4679496 chr3 59580150 T G 8.92E-04 Multiple complex diseases / / 17554300 rs1504912 chr3 59598180 T G 4.43E-05 White matter integrity / / 22425255 rs1281444 chr3 59619214 G A 1.09E-04 White matter integrity / / 22425255 rs12493940 chr3 59620667 G A 1.44E-04 Multiple complex diseases / / 17554300 rs732514 chr3 59623920 C T 8.13E-05 White matter integrity / / 22425255 rs2121794 chr3 59644233 G A 1.13E-04 Alzheimer's disease / / 17998437 rs2121794 chr3 59644233 G A 2.14E-04 Alzheimer's disease / / pha002879 rs1447807 chr3 59648681 A G 2.56E-06 Conotruncal heart defects / / 24800985 rs6763159 chr3 59649521 T C 1.00E-06 Conotruncal heart defects / / 24800985 rs10510816 chr3 59655530 C A 5.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10510816 chr3 59655530 C A 2.34E-06 Osteoarthritis / / 22763110 rs10510818 chr3 59659240 C T 4.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1550922 chr3 59659658 G A 4.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs6774996 chr3 59674664 A G 5.01E-05 Multiple complex diseases / / 17554300 rs7634315 chr3 59675336 G A 8.96E-05 Monocyte counts / / pha003089 rs17358517 chr3 59685732 C T 2.04E-05 Postoperative ventricular dysfunction / / 21980348 rs17292696 chr3 59686286 G A 2.23E-05 Postoperative ventricular dysfunction / / 21980348 rs11924953 chr3 59686425 G C 3.21E-05 Postoperative ventricular dysfunction / / 21980348 rs10510819 chr3 59691572 C G 5.73E-05 Multiple complex diseases / / 17554300 rs6766124 chr3 59693397 G A 9.60E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4679599 chr3 59695594 A C 5.20E-04 Insomnia / / 23728906 rs2366846 chr3 59705894 C A 4.53E-04 Sudden cardiac arrest / / 21658281 rs7373248 chr3 59711017 C T 3.97E-04 Response to alcohol consumption (flushing response) / / 24277619 rs7373248 chr3 59711017 C T 9.37E-04 Stroke / / pha002886 rs1155530 chr3 59727802 A G 0.0000497 Carotid intima media thickness / / 23152477 rs812965 chr3 59736299 T C 4.80E-04 Crohn's disease FHIT intron 17684544 rs13075135 chr3 59739630 G C 5.86E-04 Suicide attempts in bipolar disorder FHIT intron 21423239 rs6803403 chr3 59739919 G A 8.19E-04 Suicide attempts in bipolar disorder FHIT intron 21423239 rs1385715 chr3 59741515 A C 3.99E-04 Suicide attempts in bipolar disorder FHIT intron 21423239 rs1385715 chr3 59741515 A C 9.65E-06 Tuberculosis FHIT intron 24057671 rs13313901 chr3 59748732 A G 9.64E-05 Bipolar disorder FHIT intron 22925353 rs12152416 chr3 59750069 G A 8.95E-05 Bipolar disorder FHIT intron 22925353 rs17061182 chr3 59757136 C A 4.51E-05 Multiple complex diseases FHIT intron 17554300 rs812964 chr3 59757883 G A 2.85E-04 Multiple complex diseases FHIT intron 17554300 rs780358 chr3 59759119 A G 5.77E-04 Multiple complex diseases FHIT intron 17554300 rs517711 chr3 59762008 G A 1.73E-05 Personality dimensions FHIT intron 22628180 rs780346 chr3 59766184 A T 9.06E-06 Personality dimensions FHIT intron 22628180 rs780347 chr3 59767118 G A 8.74E-06 Personality dimensions FHIT intron 22628180 rs673870 chr3 59770221 C T 1.52E-05 Personality dimensions FHIT intron 22628180 rs17361780 chr3 59772328 A G 2.50E-04 Multiple complex diseases FHIT intron 17554300 rs780354 chr3 59772460 A C 2.00E-04 Gamma gluatamyl transferase levels (interaction with age) FHIT intron 22010049 rs780354 chr3 59772460 A C 3.49E-04 Response to taxane treatment (placlitaxel) FHIT intron 23006423 rs2629877 chr3 59793062 C T 8.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FHIT intron 20877124 rs2171077 chr3 59797400 C A,G,T 0.00006 Nonsyndromic striae distensae (stretch marks) FHIT intron 23633020 rs2605441 chr3 59797584 G C 0.0000619 Nonsyndromic striae distensae (stretch marks) FHIT intron 23633020 rs2629899 chr3 59800539 T G 0.0000608 Nonsyndromic striae distensae (stretch marks) FHIT intron 23633020 rs1079196 chr3 59806778 G A 8.00E-08 Personality dimensions FHIT intron 22628180 rs1079196 chr3 59806778 G A 0.00000568 Nonsyndromic striae distensae (stretch marks) FHIT intron 23633020 rs4679614 chr3 59810867 C T 1.32E-06 Personality dimensions FHIT intron 22628180 rs4679615 chr3 59811024 T C 2.75E-06 Personality dimensions FHIT intron 22628180 rs689497 chr3 59811462 G T 6.35E-04 Alzheimer's disease FHIT intron 24755620 rs17061239 chr3 59811605 T C 3.75E-04 Smoking initiation FHIT intron 24665060 rs1872495 chr3 59811637 A G 2.76E-06 Personality dimensions FHIT intron 22628180 rs10428174 chr3 59814048 G A 4.49E-05 Cleft lip FHIT intron 20436469 rs10428174 chr3 59814048 G A 5.33E-07 Personality dimensions FHIT intron 22628180 rs639244 chr3 59839235 G C 5.77E-04 Multiple complex diseases FHIT intron 17554300 rs598678 chr3 59844944 C T 2.53E-05 Personality dimensions FHIT intron 22628180 rs620113 chr3 59869370 G A 9.65E-04 Insulin resistance FHIT intron 21901158 rs11915344 chr3 59877910 G A 9.03E-04 Multiple complex diseases FHIT intron 17554300 rs11715245 chr3 59891227 C T 2.48E-04 Alzheimer's disease (late onset) FHIT intron 21379329 rs11715245 chr3 59891227 C T 4.51E-05 Serum albumin level FHIT intron pha003084 rs294459 chr3 59898057 T C 4.35E-05 Osteoarthritis (knee and hip) FHIT intron 21177295 rs294457 chr3 59899215 A G 2.09E-05 Hepatitis B vaccine response FHIT intron 21764829 rs294454 chr3 59900739 T C 3.92E-05 Waist Circumference FHIT intron pha003025 rs294453 chr3 59900929 G T 5.03E-05 Aortic root size FHIT intron 21223598 rs1825630 chr3 59902801 C T 8.00E-06 Aortic root size FHIT intron 21223598 rs1038516 chr3 59917928 A G 6.22E-04 Multiple complex diseases FHIT intron 17554300 rs4502542 chr3 59921020 T C 2.00E-06 Response to citalopram treatment FHIT intron 22760553 rs17302202 chr3 59922638 T C 4.04E-04 Type 2 diabetes FHIT intron 17463246 rs17061517 chr3 59924843 A G 9.42E-04 Major depressive disorder FHIT intron 22472876 rs931317 chr3 59928851 A G 1.44E-05 Nicotine smoking FHIT intron 19268276 rs931317 chr3 59928851 A G 3.00E-06 Myopia (pathological) FHIT intron 23049088 rs11707783 chr3 59946384 A G 5.11E-05 Orofacial clefts FHIT intron 22419666 rs9863289 chr3 59957814 C T 3.24E-04 Aortic root size FHIT intron 21223598 rs212034 chr3 59961536 G A 5.84E-05 Orofacial clefts FHIT intron 22419666 rs802775 chr3 59968353 C T 5.30E-04 Amyotrophic Lateral Sclerosis FHIT intron 17362836 rs2630190 chr3 59970997 T C 2.60E-05 Urinary metabolites FHIT intron 21572414 rs2630167 chr3 59974515 T C 8.39E-04 Aortic root size FHIT intron 21223598 rs3772503 chr3 59980424 T C 7.89E-05 Body Composition FHIT intron pha003012 rs212016 chr3 59981525 T C 7.00E-06 Orofacial clefts FHIT intron 22419666 rs212016 chr3 59981525 T C 0.0000166 Tuberculosis with late age of onset FHIT intron 22551897 rs13086424 chr3 59982062 C T 0.0000236 Tuberculosis with late age of onset FHIT intron 22551897 rs212017 chr3 59984501 A C 5.87E-04 Alzheimer's disease FHIT intron 22005930 rs212018 chr3 59985179 G A 2.23E-04 Alzheimer's disease FHIT intron 22005930 rs9311744 chr3 59991006 C G 5.70E-04 Aortic root size FHIT intron 21223598 rs802777 chr3 59991863 G A 3.55E-04 Alzheimer's disease FHIT intron 22005930 rs802779 chr3 59993222 T C 3.48E-04 Alzheimer's disease FHIT intron 22005930 rs17061792 chr3 60000052 C T 4.17E-05 Blood Pressure FHIT intron pha003045 rs17061792 chr3 60000052 C T 3.93E-05 Blood Pressure FHIT intron pha003047 rs3845970 chr3 60000536 C A 6.38E-05 Lipoproteins FHIT intron pha003079 rs3845971 chr3 60000672 T C 1.00E-04 Type 2 diabetes FHIT intron 17846126 rs9311745 chr3 60001825 T C 5.00E-06 Pit-and-Fissure caries FHIT intron 23470693 rs3912494 chr3 60007657 C G,T 7.44E-05 Schizophrenia FHIT intron 19571809 rs3912494 chr3 60007657 C G,T 9.80E-05 Schizophrenia FHIT intron pha002859 rs9817995 chr3 60009521 C A 8.22E-04 Multiple complex diseases FHIT intron 17554300 rs9874888 chr3 60016317 T A 2.40E-04 Multiple complex diseases FHIT intron 17554300 rs9874888 chr3 60016317 T A 1.36E-09 Narcolepsy FHIT intron 19629137 rs2630161 chr3 60019926 G A 2.32E-04 Type 2 diabetes FHIT intron 17463246 rs182418 chr3 60020000 G A 2.60E-05 Urinary metabolites FHIT intron 21572414 rs212063 chr3 60022161 C T 3.56E-05 Type 2 diabetes FHIT intron 17463246 rs212062 chr3 60022470 A G 1.71E-04 Type 2 diabetes FHIT intron 17463246 rs212062 chr3 60022470 A G 3.94E-04 Myocardial Infarction FHIT intron pha002873 rs212059 chr3 60024883 T C 1.20E-05 Urinary metabolites FHIT intron 21572414 rs17257269 chr3 60025505 T C 9.79E-26 Narcolepsy FHIT intron 19629137 rs17257269 chr3 60025505 T C 1.80E-05 Bipolar disorder and schizophrenia FHIT intron 20889312 rs3845972 chr3 60027834 G A 4.60E-05 Bone mineral density (BMD),in women FHIT intron 20164292 rs3856662 chr3 60028556 A G 4.35E-05 Bipolar disorder and schizophrenia FHIT intron 20889312 rs212057 chr3 60028591 T C 1.25E-04 Type 2 diabetes FHIT intron 17463246 rs212051 chr3 60034455 T C 1.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FHIT intron 20877124 rs212049 chr3 60035129 C T 9.05E-05 Coronary heart disease FHIT intron pha003030 rs212046 chr3 60036213 T C 5.77E-05 Body Mass Index FHIT intron pha003014 rs212041 chr3 60038278 G T 3.94E-04 Suicide attempts in bipolar disorder FHIT intron 21041247 rs212039 chr3 60038581 C T 3.84E-04 Suicide attempts in bipolar disorder FHIT intron 21041247 rs9860107 chr3 60040105 A G 5.70E-05 Endometriosis FHIT intron 21151130 rs9860107 chr3 60040105 A G 9.96E-05 Erythrocyte counts FHIT intron pha003101 rs7638558 chr3 60045801 T C 0.000036 Primary sclerosing cholangitis FHIT intron 22521342 rs2630165 chr3 60051898 G T 9.35E-04 Type 2 diabetes FHIT intron 17463246 rs2630194 chr3 60056524 C T 9.90E-06 Urinary metabolites FHIT intron 21572414 rs2630197 chr3 60057008 C T 1.19E-04 Type 2 diabetes FHIT intron 17463246 rs2630200 chr3 60057160 G A 1.44E-04 Type 2 diabetes FHIT intron 17463246 rs2736821 chr3 60059610 G A 1.54E-04 Type 2 diabetes FHIT intron 17463246 rs17062101 chr3 60062654 A G 5.86E-05 Bipolar disorder and schizophrenia FHIT intron 20889312 rs6446109 chr3 60076989 G C 3.83E-05 Multiple complex diseases FHIT intron 17554300 rs6772047 chr3 60087728 A G 2.40E-05 Urinary metabolites FHIT intron 21572414 rs6766789 chr3 60090013 C A 7.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FHIT intron 20877124 rs4679636 chr3 60103026 C G 8.02E-04 Coronary Artery Disease FHIT intron 17634449 rs4679636 chr3 60103026 C G 3.48E-05 Recombination rate FHIT intron 21698098 rs722070 chr3 60112295 G A 6.15E-05 Cytomegalovirus antibody response FHIT intron 21993531 rs41355450 chr3 60115462 T G 4.56E-05 Parkinson's disease FHIT intron 23793441 rs10510828 chr3 60120243 A G 3.12E-04 Longevity FHIT intron 22279548 rs10510829 chr3 60123522 A G 7.00E-07 Adverse response to lamotrigine and phenytoin FHIT intron 22379998 rs2064020 chr3 60138099 C A 2.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FHIT intron 20877124 rs9876685 chr3 60171660 T C 6.29E-05 Multiple sclerosis (OCB status) FHIT intron 23785401 rs1566057 chr3 60182144 C T 8.94E-04 Body mass index FHIT intron 21701565 rs213307 chr3 60188605 T C 7.44E-04 Amyotrophic Lateral Sclerosis FHIT intron 17362836 rs11130760 chr3 60196537 G T 2.50E-04 Oral cancers (chewing tobacco related) FHIT intron 22503698 rs11717164 chr3 60218337 G T 0.0000796 Tuberculosis with early age of onset FHIT intron 22551897 rs7628950 chr3 60220307 T A 4.70E-04 Suicide attempts in bipolar disorder FHIT intron 21041247 rs10510834 chr3 60221516 A G 2.05E-04 Bipolar disorder FHIT intron 19259986 rs10510834 chr3 60221516 A G 4.27E-04 Suicide attempts in bipolar disorder FHIT intron 21041247 rs9311754 chr3 60221953 C G 6.10E-04 Bipolar disorder FHIT intron 19259986 rs13082004 chr3 60222035 T C 3.84E-04 Suicide attempts in bipolar disorder FHIT intron 21041247 rs17062579 chr3 60224011 A G 6.20E-04 Insulin resistance FHIT intron 21901158 rs17062609 chr3 60235256 G A 6.29E-04 Insulin resistance FHIT intron 21901158 rs143018 chr3 60246190 G A 1.91E-04 Lung function (forced expiratory volume in 1 second) FHIT intron 17255346 rs10510835 chr3 60247121 G T 1.90E-05 Sleep and circadian phenotypes FHIT intron 17903308 rs10510835 chr3 60247121 G T 9.42E-05 Cognitive test performance FHIT intron 20125193 rs213333 chr3 60252827 C T 2.86E-04 Lung function (forced expiratory volume in 1 second) FHIT intron 17255346 rs213344 chr3 60258799 A G 7.60E-04 Type 2 diabetes and 6 quantitative traits FHIT intron 17848626 rs9879860 chr3 60272317 T C 2.79E-05 Coronary restenosis FHIT intron 21878436 rs6768755 chr3 60286486 T C 9.40E-04 Height FHIT intron 21998595 rs9829607 chr3 60289140 A G 3.50E-05 Coronary restenosis FHIT intron 21878436 rs10510837 chr3 60289842 G A 4.00E-06 Asperger disorder FHIT intron 21182207 rs1353546 chr3 60291875 T C 5.04E-05 Coronary restenosis FHIT intron 21878436 rs6776005 chr3 60295081 A G 4.40E-05 Kawasaki disease FHIT intron 22446962 rs7631389 chr3 60297746 A G 4.51E-05 Coronary restenosis FHIT intron 21878436 rs7647196 chr3 60311682 C T 7.28E-05 Multiple complex diseases FHIT intron 17554300 rs963685 chr3 60321572 A C 9.10E-05 Suicide attempts in bipolar disorder FHIT intron 21423239 rs11708562 chr3 60330356 C A 6.27E-05 Smoking quantity FHIT intron 24665060 rs17062850 chr3 60357382 T C 2.85E-04 Response to cytidine analogues (gemcitabine) FHIT intron 24483146 rs1057504 chr3 60357956 C T 1.00E-04 Cognitive impairment induced by topiramate FHIT intron 22091778 rs11130770 chr3 60364046 C T 2.69E-05 Aortic root size FHIT intron 21223598 rs4679533 chr3 60367530 G C 2.21E-04 Aortic root size FHIT intron 21223598 rs9848065 chr3 60370637 C T 2.70E-05 Urinary metabolites FHIT intron 21572414 rs17062963 chr3 60379864 C G 1.60E-05 Urinary metabolites FHIT intron 21572414 rs13098396 chr3 60382828 T C 2.40E-05 Urinary metabolites FHIT intron 21572414 rs242201 chr3 60395260 A G 6.53E-06 Kawasaki disease FHIT intron 22081228 rs242201 chr3 60395260 A G 2.50E-05 Lipid levels FHIT intron pha003082 rs2687194 chr3 60417130 C G 3.20E-06 Glycemic traits (pregnancy) FHIT intron 23903356 rs2687194 chr3 60417130 C G 5.67E-06 Glycemic traits (pregnancy) FHIT intron 23903356 rs409484 chr3 60420417 G A 1.30E-05 Urinary metabolites FHIT intron 21572414 rs4566489 chr3 60439567 C T 4.05E-04 Lung function (forced expiratory volume in 1 second) FHIT intron 17255346 rs12629710 chr3 60441487 A C 7.48E-04 Type 2 diabetes FHIT intron 22158537 rs12638086 chr3 60445573 C T 7.62E-04 Type 2 diabetes FHIT intron 22158537 rs12638610 chr3 60445806 C T 6.95E-04 Type 2 diabetes FHIT intron 22158537 rs1579912 chr3 60447340 T G 7.87E-04 Type 2 diabetes FHIT intron 22158537 rs424675 chr3 60448261 C T 4.78E-04 Type 2 diabetes FHIT intron 22158537 rs378346 chr3 60448591 G A 4.67E-04 Type 2 diabetes FHIT intron 22158537 rs2594239 chr3 60449009 C G 9.91E-04 Multiple complex diseases FHIT intron 17554300 rs1447971 chr3 60465279 G A 1.02E-04 Sleep time FHIT intron 23728906 rs2205042 chr3 60471104 T C 1.19E-04 Sleep latency FHIT intron 23728906 rs2594266 chr3 60487739 C T 3.52E-04 Multiple complex diseases FHIT intron 17554300 rs9985430 chr3 60488758 C T 9.00E-06 Urinary metabolites FHIT intron 21572414 rs6789538 chr3 60491103 G A 4.42E-04 Lung function (forced vital capacity) FHIT intron 24023788 rs10212340 chr3 60504260 G A,C 4.77E-04 Multiple complex diseases FHIT intron 17554300 rs10212340 chr3 60504260 G A,C 8.60E-06 Urinary metabolites FHIT intron 21572414 rs80171647 chr3 60508340 G T 2.00E-06 Response to amphetamines FHIT intron 22952603 rs12492175 chr3 60510909 C A 7.78E-04 White matter integrity FHIT intron 22425255 rs12492175 chr3 60510909 C A 3.52E-04 Alzheimer's disease FHIT intron 24755620 rs241704 chr3 60512889 A G 3.95E-05 Prostate cancer FHIT intron pha002878 rs7426703 chr3 60516181 T C 5.30E-06 Response to amphetamines FHIT intron 22952603 rs17063477 chr3 60518998 A G 7.29E-06 Response to amphetamines FHIT intron 22952603 rs11130772 chr3 60535731 G T 3.49E-04 Lung function (forced expiratory volume in 1 second) FHIT intron 17255346 rs241684 chr3 60536669 C G 8.99E-05 Bipolar disorder and schizophrenia FHIT intron 20889312 rs76200451 chr3 60538853 G C 5.54E-06 Response to amphetamines FHIT intron 22952603 rs151737 chr3 60540745 A G 8.40E-05 White matter integrity FHIT intron 22425255 rs2856045 chr3 60545429 A G 6.31E-05 Bipolar disorder and schizophrenia FHIT intron 20889312 rs180998 chr3 60545602 G A 2.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FHIT intron 20877124 rs17063532 chr3 60562327 G A 1.16E-04 Vaspin levels FHIT intron 22907691 rs17063532 chr3 60562327 G A 0.0001157 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks FHIT intron 22907730 rs2734365 chr3 60565903 T C 0.0001779 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FHIT intron 23233654 rs2734365 chr3 60565903 T C 1.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) FHIT intron 23233662 rs10510850 chr3 60567102 C T 4.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FHIT intron 20877124 rs9833533 chr3 60568253 G A 5.00E-04 Response to cytadine analogues (cytosine arabinoside) FHIT intron 24483146 rs7651468 chr3 60572073 G A 1.99E-05 Response to cytadine analogues (cytosine arabinoside) FHIT intron 24483146 rs2252742 chr3 60580713 G C 8.09E-04 Type 2 diabetes FHIT intron 17463246 rs7617530 chr3 60585756 G A 1.00E-05 Anxiety spectrum disorders FHIT intron 20368705 rs2856030 chr3 60591219 C G 1.50E-05 Urinary metabolites FHIT intron 21572414 rs11720214 chr3 60592348 C T 1.60E-04 Alzheimer's disease (late onset) FHIT intron 21379329 rs11720214 chr3 60592348 C T 4.52E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FHIT intron 24023788 rs17624325 chr3 60595986 C T 5.99E-04 Smoking cessation FHIT intron 24665060 rs2885865 chr3 60610341 G A 7.26E-04 Prostate cancer mortality FHIT intron 20978177 rs11926787 chr3 60615310 G A 5.51E-04 Smoking initiation FHIT intron 24665060 rs6762641 chr3 60616153 T C 2.30E-05 Urinary metabolites FHIT intron 21572414 rs10510852 chr3 60616790 G A 1.79E-05 Rheumatoid arthritis FHIT intron 17804836 rs10510853 chr3 60625286 C G 6.86E-07 Paclitaxel sensitivity in NCI60 cancer cell lines FHIT intron 21314952 rs1623091 chr3 60654169 C G 2.93E-04 Body mass index FHIT intron 21701565 rs1735444 chr3 60664075 G T 1.86E-04 Parkinson's disease FHIT intron 17052657 rs1735457 chr3 60683737 G A 6.50E-04 Alcohol dependence FHIT intron 20201924 rs1735460 chr3 60691605 T C 3.40E-05 Alcohol dependence FHIT intron 20201924 rs1735460 chr3 60691605 T C 3.70E-05 Alcohol dependence FHIT intron 20201924 rs1735460 chr3 60691605 T C 3.67E-05 Alcoholism FHIT intron pha002892 rs1735460 chr3 60691605 T C 3.40E-05 Alcoholism FHIT intron pha002893 rs1716744 chr3 60705150 G C 6.41E-04 Aortic root size FHIT intron 21223598 rs12493219 chr3 60725603 A G 4.43E-05 Erythrocyte counts FHIT intron pha003101 rs12631593 chr3 60726844 G A 3.49E-04 Alzheimer's disease (late onset) FHIT intron 21379329 rs4974227 chr3 60748726 A G 8.34E-04 Alzheimer's disease FHIT intron 24755620 rs1569346 chr3 60750062 A G 3.31E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FHIT intron 24023788 rs13073028 chr3 60761472 G A 2.47E-05 Cognitive test performance FHIT intron 20125193 rs11919041 chr3 60763256 G T 2.00E-06 Breast size FHIT intron 22747683 rs12492901 chr3 60767452 G T 9.24E-04 Alzheimer's disease FHIT intron 22005930 rs6791644 chr3 60771108 A G 8.00E-06 Attention deficit hyperactivity disorder FHIT intron 18821565 rs4974230 chr3 60780913 T C 9.90E-05 Pericardial fat FHIT intron 22589742 rs1447927 chr3 60787599 T C 5.79E-04 Alzheimer's disease FHIT intron 22005930 rs17064028 chr3 60793400 G A 2.90E-05 Urinary metabolites FHIT intron 21572414 rs2142296 chr3 60794217 G A 1.50E-05 Urinary metabolites FHIT intron 21572414 rs17064029 chr3 60799235 A G 2.09E-04 Fibrinogen FHIT intron 17255346 rs2364295 chr3 60800699 G C 2.60E-05 Urinary metabolites FHIT intron 21572414 rs2205353 chr3 60807828 C G 7.06E-04 Response to cytidine analogues (gemcitabine) FHIT intron 24483146 rs2594135 chr3 60812574 G C 1.54E-04 Multiple complex diseases FHIT intron 17554300 rs2594135 chr3 60812574 G C 4.50E-06 Urinary metabolites FHIT intron 21572414 rs17064083 chr3 60852438 C G 1.13E-04 Alcohol dependence FHIT intron 21314694 rs17064094 chr3 60856466 G A 1.54E-04 Multiple complex diseases FHIT intron 17554300 rs7613542 chr3 60872879 C T 0.0000182 Sarcoidosis FHIT intron 22952805 rs2121845 chr3 60907899 A G 1.80E-05 Urinary metabolites FHIT intron 21572414 rs1562524 chr3 60933749 G A 3.20E-05 Response to statin therapy FHIT intron 20339536 rs6792544 chr3 60974088 G C 2.70E-05 Urinary metabolites FHIT intron 21572414 rs6782531 chr3 60995600 G C 8.00E-07 Blood pressure FHIT intron 24954895 rs6786392 chr3 61004199 T C 3.71E-05 Height FHIT intron 22021425 rs2365045 chr3 61021239 G A 8.21E-06 Multiple sclerosis FHIT intron 17660530 rs1898748 chr3 61021337 G C 8.12E-04 Multiple complex diseases FHIT intron 17554300 rs17064337 chr3 61027076 G A 4.77E-05 Multiple complex diseases FHIT intron 17554300 rs11715589 chr3 61043939 G C 4.31E-04 Multiple complex diseases FHIT intron 17554300 rs11715589 chr3 61043939 G C 3.62E-04 Alzheimer's disease FHIT intron 17998437 rs17064395 chr3 61045092 A G 5.94E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FHIT intron 24023788 rs7650123 chr3 61045899 T C 2.09E-04 Alzheimer's disease FHIT intron 17998437 rs9850713 chr3 61048581 C T 3.04E-04 Alzheimer's disease FHIT intron 17998437 rs1965143 chr3 61048665 T C 2.42E-04 Alzheimer's disease FHIT intron 17998437 rs10222378 chr3 61048979 A G 2.54E-04 Alzheimer's disease FHIT intron 17998437 rs9855931 chr3 61049559 C G 2.66E-04 Alzheimer's disease FHIT intron 17998437 rs7631974 chr3 61051617 G A 2.54E-04 Alzheimer's disease FHIT intron 17998437 rs11919495 chr3 61052499 A T 5.27E-04 Alzheimer's disease FHIT intron 17998437 rs9871875 chr3 61052520 C A 2.95E-04 Alzheimer's disease FHIT intron 17998437 rs9834182 chr3 61052642 A G 8.63E-04 Alzheimer's disease FHIT intron 17998437 rs9876579 chr3 61052979 G T 6.30E-05 Alzheimer's disease FHIT intron 17998437 rs9845837 chr3 61071811 G A 5.12E-05 Major depressive disorder FHIT intron 22472876 rs17687542 chr3 61077258 T C 3.66E-04 Coronary heart disease FHIT intron 21971053 rs1347852 chr3 61080782 G A,C,T 5.59E-05 Major depressive disorder FHIT intron 22472876 rs11921290 chr3 61081768 A G 8.53E-04 Coronary heart disease FHIT intron 21971053 rs9825823 chr3 61082153 T C 2.13E-05 Alcohol dependence FHIT intron 20201924 rs9825823 chr3 61082153 T C 4.08E-06 Major depressive disorder FHIT intron 22472876 rs9825823 chr3 61082153 T C 2.13E-05 Alcoholism FHIT intron pha002891 rs7626688 chr3 61106321 T G 6.42E-04 Multiple complex diseases FHIT intron 17554300 rs7626688 chr3 61106321 T G 8.47E-06 Major depressive disorder FHIT intron 22472876 rs6445194 chr3 61111195 G T 1.28E-04 Alcohol dependence FHIT intron 20201924 rs6445194 chr3 61111195 G T 6.04E-06 Major depressive disorder FHIT intron 22472876 rs6445194 chr3 61111195 G T 4.61E-05 Depression (quantitative trait) FHIT intron 23290196 rs1821942 chr3 61116009 C T 6.84E-04 Heart Failure FHIT intron pha002885 rs9830950 chr3 61122318 C T 1.24E-06 Major depressive disorder FHIT intron 22472876 rs2886261 chr3 61126821 A G 0.000863 Salmonella-induced pyroptosis FHIT intron 22837397 rs9877396 chr3 61127205 T C 3.00E-06 Bronchopulmonary dysplasia FHIT intron 23897914 rs4309721 chr3 61132698 C T 1.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FHIT intron 20877124 rs4309721 chr3 61132698 C T 2.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FHIT intron 20877124 rs4309721 chr3 61132698 C T 8.14E-05 Major depressive disorder FHIT intron 22472876 rs6807748 chr3 61149967 T C 1.27E-05 Major depressive disorder FHIT intron 22472876 rs11707984 chr3 61150158 C T 1.26E-05 Major depressive disorder FHIT intron 22472876 rs1966136 chr3 61153578 A C 1.37E-05 Major depressive disorder FHIT intron 22472876 rs4020068 chr3 61153578 A AA,AC 1.37E-05 Major depressive disorder FHIT intron 22472876 rs9851485 chr3 61155891 C G 1.46E-05 Major depressive disorder FHIT intron 22472876 rs9871451 chr3 61155929 T C 1.84E-05 Major depressive disorder FHIT intron 22472876 rs1969420 chr3 61156905 T G 1.11E-05 Major depressive disorder FHIT intron 22472876 rs1550343 chr3 61159488 A C 1.87E-05 Major depressive disorder FHIT intron 22472876 rs7631246 chr3 61162404 G T 5.42E-05 Major depressive disorder FHIT intron 22472876 rs9875365 chr3 61171057 G A 1.38E-05 Suicidal ideation FHIT intron 20877300 rs9875228 chr3 61171102 C T 8.73E-04 Multiple complex diseases FHIT intron 17554300 rs1001788 chr3 61171806 G A 7.97E-04 Tourette syndrome FHIT intron 22889924 rs9846073 chr3 61186550 T G 5.13E-05 Major depressive disorder FHIT intron 22472876 rs1916800 chr3 61187197 C T 5.46E-05 Major depressive disorder FHIT intron 22472876 rs9843007 chr3 61207077 A T 9.68E-05 Major depressive disorder FHIT intron 22472876 rs6802718 chr3 61227198 G A 9.76E-05 Left ventricular hypertrophy FHIT intron pha003052 rs9817853 chr3 61240793 T C 6.16E-04 Major depressive disorder / / 22472876 rs6445200 chr3 61241048 T C 7.36E-05 Major depressive disorder / / 22472876 rs6785875 chr3 61243611 T C 8.22E-05 Major depressive disorder / / 22472876 rs7629340 chr3 61246997 G A 4.94E-05 Major depressive disorder / / 22472876 rs815718 chr3 61253888 A G 6.71E-04 Smoking cessation / / 24665060 rs815710 chr3 61262149 A G 6.26E-05 Major depressive disorder / / 22472876 rs815710 chr3 61262149 A G 9.28E-04 Tourette syndrome / / 22889924 rs704471 chr3 61268160 G A 5.11E-04 Type 2 diabetes / / 17463246 rs7651321 chr3 61281841 A G 3.08E-05 Odorant perception / / 23910658 rs9877709 chr3 61282140 C A 3.81E-04 Multiple complex diseases / / 17554300 rs7637487 chr3 61282503 A C 8.02E-04 Multiple complex diseases / / 17554300 rs7637487 chr3 61282503 A C 3.48E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7615788 chr3 61282721 G T 6.69E-06 ldl cholesterol / / pha003077 rs7615788 chr3 61282721 G T 5.49E-05 Cholesterol / / pha003078 rs7615788 chr3 61282721 G T 5.61E-05 Cholesterol / / pha003083 rs7652939 chr3 61287140 A G 7.51E-04 Multiple complex diseases / / 17554300 rs7652939 chr3 61287140 A G 2.24E-05 Aging (time to event) / / 21782286 rs17064749 chr3 61292646 G C 2.64E-15 Multiple complex diseases / / 17554300 rs1901892 chr3 61318721 A G 8.58E-04 Multiple complex diseases / / 17554300 rs6445205 chr3 61335812 G A,C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6414548 chr3 61337690 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17697347 chr3 61370879 T C 4.10E-04 Smoking initiation / / 24665060 rs10514718 chr3 61413814 C G 4.00E-06 Major depressive disorder / / 20125088 rs10514718 chr3 61413814 C G 0.00024 Breast cancer / / 23555315 rs4432637 chr3 61452146 C T 7.36E-04 Heart Failure / / pha002884 rs2365953 chr3 61516927 T C 8.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9808938 chr3 61549568 G T 7.28E-05 Multiple complex diseases PTPRG intron 17554300 rs938959 chr3 61559771 A G 9.82E-04 Multiple complex diseases PTPRG intron 17554300 rs4447759 chr3 61580912 C T 2.42E-04 Multiple complex diseases PTPRG intron 17554300 rs4580548 chr3 61581049 C G 2.22E-04 Multiple complex diseases PTPRG intron 17554300 rs4580548 chr3 61581049 C G 9.96E-04 Alcohol dependence PTPRG intron 21314694 rs13326767 chr3 61583077 C T 3.33E-04 Multiple complex diseases PTPRG intron 17554300 rs12715571 chr3 61583134 G T 2.72E-05 Multiple complex diseases PTPRG intron 17554300 rs13074575 chr3 61583283 T G 3.49E-05 Multiple complex diseases PTPRG intron 17554300 rs12715572 chr3 61586124 G A 1.58E-04 Multiple complex diseases PTPRG intron 17554300 rs2886526 chr3 61599000 G A 2.28E-04 Multiple complex diseases PTPRG intron 17554300 rs36051446 chr3 61603665 T C 1.72E-05 Attention deficit hyperactivity disorder PTPRG intron 20732625 rs4419372 chr3 61605791 T C 1.79E-05 Multiple complex diseases PTPRG intron 17554300 rs1320234 chr3 61615565 C T 4.02E-05 Prostate cancer PTPRG intron 22923026 rs17624623 chr3 61620466 T C 0.0000202 Otitis media (children 3 years old or younger) PTPRG intron 23133572 rs2365936 chr3 61648636 T C 3.81E-05 Soluble levels of adhesion molecules PTPRG intron pha003072 rs6784338 chr3 61663778 G A 8.45E-05 Cognitive performance PTPRG intron 19734545 rs4688268 chr3 61670137 T C 9.57E-05 Glucose levels PTPRG intron pha003061 rs6763976 chr3 61682383 C G 4.77E-04 Multiple complex diseases PTPRG intron 17554300 rs4688658 chr3 61696032 C T 4.95E-04 Multiple complex diseases PTPRG intron 17554300 rs12491760 chr3 61749709 A G 8.00E-05 Fibrinogen PTPRG intron 17255346 rs12629194 chr3 61750276 G A 1.93E-04 Smoking cessation PTPRG intron 24665060 rs665974 chr3 61755838 C A 3.47E-06 Waist Circumference PTPRG intron pha003023 rs660323 chr3 61762630 T C 9.81E-05 Waist Circumference PTPRG intron pha003023 rs658432 chr3 61770307 A G 2.80E-05 Urinary metabolites PTPRG intron 21572414 rs4622897 chr3 61774076 C G 5.39E-05 Fibrinogen PTPRG intron 17255346 rs666403 chr3 61775808 A T 4.80E-08 Metabolite levels PTPRG intron 23281178 rs1713534 chr3 61778264 T G 4.81E-08 Metabolite levels PTPRG intron 23281178 rs652889 chr3 61794054 C A 8.00E-07 QT interval PTPRG intron 20031603 rs1522549 chr3 61812690 A G 6.09E-05 Bipolar disorder,schizoaffective PTPRG intron 19567891 rs11130855 chr3 61814181 T G 2.82E-04 Bipolar disorder,schizoaffective PTPRG intron 19567891 rs11130857 chr3 61814338 C T 3.73E-04 Bipolar disorder,schizoaffective PTPRG intron 19567891 rs11130858 chr3 61814372 T C 6.96E-04 Multiple complex diseases PTPRG intron 17554300 rs11130858 chr3 61814372 T C 1.07E-04 Bipolar disorder,schizoaffective PTPRG intron 19567891 rs686518 chr3 61824692 C G 9.87E-05 IgE levels PTPRG intron 22075330 rs686553 chr3 61824707 T G 9.83E-05 IgE levels PTPRG intron 22075330 rs592179 chr3 61825441 G T 9.74E-05 IgE levels PTPRG intron 22075330 rs605580 chr3 61826068 C T 9.08E-05 IgE levels PTPRG intron 22075330 rs622358 chr3 61827555 A T 9.25E-05 IgE levels PTPRG intron 22075330 rs607882 chr3 61827694 T A 9.16E-05 IgE levels PTPRG intron 22075330 rs689236 chr3 61839880 C T 7.03E-05 IgE levels PTPRG intron 22075330 rs625177 chr3 61840295 G A 7.08E-05 IgE levels PTPRG intron 22075330 rs868925 chr3 61848017 G A 8.02E-05 IgE levels PTPRG intron 22075330 rs677654 chr3 61849133 G T 8.07E-05 IgE levels PTPRG intron 22075330 rs17065527 chr3 61850090 G A 0.000000036 Mean arterial pressure PTPRG intron 22510845 rs6445243 chr3 61884868 C G 8.58E-05 IgE levels PTPRG intron 22075330 rs4234692 chr3 61904945 A G 6.99E-04 Multiple complex diseases PTPRG intron 17554300 rs2366461 chr3 61907965 G A 3.10E-05 Coronary heart disease PTPRG intron pha003031 rs1871393 chr3 61953317 A G 5.85E-05 Iron status biomarkers PTPRG intron 19084217 rs4447756 chr3 61964956 A C 1.42E-05 Follicular lymphoma PTPRG intron 21533074 rs7647959 chr3 61967036 T C 5.81E-06 Hearing function PTPRG intron 21493956 rs2189693 chr3 61968443 G C 4.50E-06 Hearing function PTPRG intron 21493956 rs6785475 chr3 61989945 C T 2.30E-06 Urinary metabolites PTPRG intron 21572414 rs739984 chr3 62000317 G A 7.20E-05 Type 2 diabetes PTPRG intron 17463248 rs9860802 chr3 62011210 G T 3.22E-04 Nonalcoholic fatty liver disease PTPRG intron 21423719 rs10490779 chr3 62011294 C T 5.50E-06 Urinary metabolites PTPRG intron 21572414 rs2366421 chr3 62019400 A T 9.94E-05 Type 2 diabetes PTPRG intron 17463246 rs7647422 chr3 62026588 T G 1.00E-06 Urinary metabolites PTPRG intron 21572414 rs7637898 chr3 62032584 C T 3.26E-05 Type 2 diabetes PTPRG intron 17463246 rs7638067 chr3 62032616 G A 3.26E-05 Type 2 diabetes PTPRG intron 17463246 rs10490775 chr3 62036724 C T 1.00E-06 Fuchs's corneal dystrophy PTPRG intron 20825314 rs6774478 chr3 62037499 T C 8.82E-04 Type 2 diabetes PTPRG intron 17463246 rs17065828 chr3 62042825 T C 3.90E-05 Melanoma PTPRG intron 21983785 rs349171 chr3 62051711 T C 9.58E-05 Schizophrenia PTPRG intron 19571811 rs11130874 chr3 62064769 A G 2.00E-06 Schizophrenia PTPRG intron 21926974 rs11130874 chr3 62064769 A G 0.00000945 Schizophrenia PTPRG intron 23637625 rs349158 chr3 62079245 T C 5.49E-04 Smoking cessation PTPRG intron 24665060 rs349153 chr3 62081495 T C 7.77E-05 Smoking initiation PTPRG intron 24665060 rs1911746 chr3 62100840 T C 8.54E-04 Oral cancers (chewing tobacco related) PTPRG intron 22503698 rs35593266 chr3 62112141 G A 5.00E-06 Metabolite levels (HVA/5-HIAA ratio) PTPRG intron 23319000 rs17066182 chr3 62116228 C T 3.98E-04 Suicide attempts in bipolar disorder PTPRG intron 21041247 rs17066200 chr3 62133088 G T 9.29E-04 Multiple complex diseases PTPRG intron 17554300 rs7632091 chr3 62134802 T C 2.52E-05 Inflammation PTPRG intron pha002897 rs11711888 chr3 62157211 A G 3.50E-06 Bipolar disorder PTPRG intron 19416921 rs11130879 chr3 62157497 A G 5.93E-04 Coronary heart disease PTPRG intron 21606135 rs1508401 chr3 62158372 T C 6.12E-04 Coronary heart disease PTPRG intron 21606135 rs17066234 chr3 62159745 C T 2.89E-04 Coronary heart disease PTPRG intron 21606135 rs7641268 chr3 62174532 A G 9.64E-05 Body Mass Index PTPRG intron pha002896 rs7631948 chr3 62178521 G A 9.22E-05 Multiple complex diseases PTPRG intron 17554300 rs6792421 chr3 62185364 C T 1.12E-04 Multiple complex diseases PTPRG intron 17554300 rs6805070 chr3 62185405 T C 5.84E-04 Response to cytadine analogues (cytosine arabinoside) PTPRG intron 24483146 rs17066275 chr3 62188720 A G 6.72E-04 Taste perception PTPRG intron 22132133 rs10510873 chr3 62206239 T C 7.20E-06 Urinary metabolites PTPRG intron 21572414 rs4560291 chr3 62212162 T A,C,G 8.17E-04 Taste perception PTPRG intron 22132133 rs6785764 chr3 62221041 A G 1.70E-05 Urinary metabolites PTPRG intron 21572414 rs1388612 chr3 62244444 G A 6.76E-04 Taste perception PTPRG intron 22132133 rs1388613 chr3 62244570 T C 7.36E-04 Taste perception PTPRG intron 22132133 rs2291540 chr3 62263047 T C 5.01E-06 Substance dependence phenotypes PTPRG intron 24832863 rs9813294 chr3 62270556 G A 8.63E-04 Type 2 diabetes PTPRG intron 17463246 rs9813294 chr3 62270556 G A 1.10E-05 Urinary metabolites PTPRG intron 21572414 rs785164 chr3 62314820 A T 1.80E-05 Urinary metabolites C3orf14 intron 21572414 rs3774700 chr3 62316394 T G 3.23E-06 Taste perception C3orf14 intron 22132133 rs6777784 chr3 62376645 G T 3.17E-05 Prion diseases / / 22210626 rs9844504 chr3 62421793 C T 5.33E-04 Suicide attempts in bipolar disorder CADPS intron 21423239 rs1997366 chr3 62439586 T C 8.79E-04 Suicide attempts in bipolar disorder CADPS intron 21423239 rs7635279 chr3 62473481 A T 0.000285 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CADPS intron 23233654 rs7635279 chr3 62473481 A T 2.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) CADPS intron 23233662 rs7631150 chr3 62475455 T G 0.0000416 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CADPS intron 23233654 rs7631150 chr3 62475455 T G 4.16E-05 Methotrexate clearance (acute lymphoblastic leukemia) CADPS intron 23233662 rs2367089 chr3 62476790 G A 7.66E-04 Amyotrophic lateral sclerosis (sporadic) CADPS intron 24529757 rs9871763 chr3 62477699 C A 3.34E-06 Glaucoma (primary open-angle) CADPS intron 22605921 rs13325751 chr3 62478194 C T 6.00E-06 Economic and political preferences (environmentalism) CADPS intron 22566634 rs1376917 chr3 62498378 G A 7.61E-04 Multiple complex diseases CADPS intron 17554300 rs6445276 chr3 62505260 T C 2.44E-04 Nicotine smoking CADPS intron 19268276 rs6445276 chr3 62505260 T C 2.60E-05 Urinary metabolites CADPS intron 21572414 rs855586 chr3 62525450 C A 9.93E-04 Response to taxane treatment (placlitaxel) CADPS intron 23006423 rs2600859 chr3 62534165 T A 9.03E-04 Insulin resistance CADPS intron 21901158 rs755358 chr3 62534469 T C 5.81E-09 Metabolite levels CADPS intron 23281178 rs2251423 chr3 62539736 A G 9.60E-05 Blood Pressure CADPS intron pha003046 rs4447757 chr3 62544840 T A 8.48E-04 Lymphocyte counts CADPS intron 22286170 rs833661 chr3 62553061 C G 2.66E-04 Suicide attempts in bipolar disorder CADPS intron 21423239 rs11130888 chr3 62562709 C A,G,T 6.96E-07 Glaucoma (primary open-angle) CADPS intron 22605921 rs833651 chr3 62563888 G A 9.05E-04 Iron levels CADPS intron pha002876 rs833637 chr3 62583180 G C 4.14E-05 Sudden cardiac arrest CADPS intron 21658281 rs1231831 chr3 62601366 T C 2.00E-06 Metabolite levels (X-11787) CADPS intron 23934736 rs833668 chr3 62615298 A G 1.50E-05 Urinary metabolites CADPS intron 21572414 rs17066711 chr3 62620842 C A 9.16E-05 Multiple complex diseases CADPS intron 17554300 rs9861841 chr3 62622267 T C 3.92E-04 Type 2 diabetes CADPS intron 17463246 rs10510883 chr3 62656259 C A 1.53E-05 Caffeine consumption CADPS intron 21490707 rs4688306 chr3 62657282 T A 2.20E-05 Serum metabolites CADPS intron 19043545 rs6445283 chr3 62658282 T C 3.09E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CADPS intron 24023788 rs1858385 chr3 62659658 T C 3.05E-05 Vaspin levels CADPS intron 22907691 rs17066793 chr3 62660566 A G 1.24E-06 Kawasaki disease CADPS intron 21221998 rs17066793 chr3 62660566 A G 1.07E-07 Cognitive impairment induced by topiramate CADPS intron 22091778 rs17066793 chr3 62660566 A G 2.32E-06 Cognitive impairment induced by topiramate CADPS intron 22091778 rs17066793 chr3 62660566 A G 6.78E-06 Cognitive impairment induced by topiramate CADPS intron 22091778 rs17066793 chr3 62660566 A G 8.42E-07 Cognitive impairment induced by topiramate CADPS intron 22091778 rs17066811 chr3 62673292 T C 7.61E-06 Kawasaki disease CADPS intron 21221998 rs4688308 chr3 62674434 C A 3.60E-07 Urinary metabolites CADPS intron 21572414 rs4429621 chr3 62676804 T C 9.69E-06 Kawasaki disease CADPS intron 21221998 rs1948926 chr3 62678071 A C 7.47E-04 Response to cytadine analogues (cytosine arabinoside) CADPS intron 24483146 rs13090570 chr3 62686403 G T 3.47E-05 Response to taxane treatment (placlitaxel) CADPS intron 23006423 rs1344072 chr3 62688923 A G 2.70E-05 Response to taxane treatment (placlitaxel) CADPS intron 23006423 rs6445290 chr3 62691870 T C 1.04E-04 Smoking initiation CADPS intron 24665060 rs6774997 chr3 62694321 A C 7.61E-06 Kawasaki disease CADPS intron 21221998 rs6774997 chr3 62694321 A C 1.89E-06 Cognitive impairment induced by topiramate CADPS intron 22091778 rs6774997 chr3 62694321 A C 3.63E-07 Cognitive impairment induced by topiramate CADPS intron 22091778 rs6774997 chr3 62694321 A C 7.87E-07 Cognitive impairment induced by topiramate CADPS intron 22091778 rs6774997 chr3 62694321 A C 9.53E-07 Cognitive impairment induced by topiramate CADPS intron 22091778 rs17357323 chr3 62696567 A G 1.86E-07 Cognitive impairment induced by topiramate CADPS intron 22091778 rs17357323 chr3 62696567 A G 4.22E-07 Cognitive impairment induced by topiramate CADPS intron 22091778 rs17357323 chr3 62696567 A G 6.41E-06 Cognitive impairment induced by topiramate CADPS intron 22091778 rs17357323 chr3 62696567 A G 7.55E-07 Cognitive impairment induced by topiramate CADPS intron 22091778 rs10510886 chr3 62697211 T G 2.34E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CADPS intron 24023788 rs952040 chr3 62698892 G A 3.66E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CADPS intron 24023788 rs504987 chr3 62705064 A G 9.28E-06 Kawasaki disease CADPS intron 21221998 rs493639 chr3 62705919 C T 9.28E-06 Kawasaki disease CADPS intron 21221998 rs581316 chr3 62715890 G C 3.16E-04 Multiple complex diseases CADPS intron 17554300 rs2886894 chr3 62716076 T A 6.66E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CADPS intron 20031582 rs569079 chr3 62720047 C G 1.76E-04 Hearing function CADPS intron 17255346 rs569079 chr3 62720047 C G 4.45E-04 Multiple complex diseases CADPS intron 17554300 rs17067111 chr3 62721971 A G 3.23E-05 Sudden cardiac arrest CADPS intron 21658281 rs564720 chr3 62729934 A G 7.50E-04 Type 2 diabetes and 6 quantitative traits CADPS intron 17848626 rs531700 chr3 62731267 G A 6.62E-05 Multiple complex diseases CADPS intron 17554300 rs526005 chr3 62731323 A G 1.83E-04 Multiple complex diseases CADPS intron 17554300 rs3843397 chr3 62733212 T C 7.25E-04 Schizophrenia CADPS intron 19197363 rs580384 chr3 62733366 C T 4.00E-06 Breast size CADPS intron 22747683 rs304170 chr3 62780639 A G 8.69E-05 Monocyte counts CADPS intron pha003089 rs304172 chr3 62782468 G A 8.00E-06 IgG glycosylation CADPS intron 23382691 rs2063621 chr3 62786855 G T 2.27E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CADPS intron 24023788 rs304230 chr3 62801073 G A 1.30E-04 Alzheimer's disease CADPS intron 17998437 rs304230 chr3 62801073 G A 1.40E-04 Alzheimer's disease CADPS intron pha002879 rs17280557 chr3 62802839 C A 2.16E-04 Alzheimer's disease CADPS intron 17998437 rs11707381 chr3 62808969 T C 4.73E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CADPS intron 24023788 rs581190 chr3 62846109 G A 4.30E-05 Major depressive disorder CADPS intron 21042317 rs581190 chr3 62846109 G A 0.0000514 Major depressive disorder CADPS intron 23149448 rs1812677 chr3 62853439 G A 8.02E-04 Alzheimer's disease CADPS intron 22005930 rs304233 chr3 62863316 G A 6.73E-04 Alzheimer's disease / / 22005930 rs304234 chr3 62863469 G A 3.56E-05 Post-operative nausea and vomiting / / 21694509 rs6775597 chr3 62868539 T G 5.65E-06 Blood Pressure / / pha003040 rs6775597 chr3 62868539 T G 1.09E-05 Blood Pressure / / pha003048 rs526163 chr3 62871502 A G 6.23E-04 Alzheimer's disease / / 22005930 rs11130901 chr3 62873406 G A 3.54E-04 Alzheimer's disease / / 22005930 rs9854059 chr3 62876133 T A 4.38E-04 Alzheimer's disease / / 22005930 rs9825965 chr3 62880928 T C 3.08E-05 Blood Pressure / / pha003040 rs6445299 chr3 62881664 A C 6.57E-04 Alzheimer's disease / / 22005930 rs1992192 chr3 62883380 C T 3.04E-05 Blood Pressure / / pha002898 rs2886966 chr3 62933534 C T 1.24E-04 Multiple complex diseases / / 17554300 rs1031246 chr3 63028072 G A 2.25E-05 Orofacial clefts / / 22419666 rs6445310 chr3 63039589 T C 4.57E-04 Insulin resistance / / 21901158 rs11711402 chr3 63040149 A C 5.52E-04 Type 2 diabetes / / 17463246 rs7644552 chr3 63050227 G A 5.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs1374682 chr3 63050385 C G 8.09E-04 Insulin resistance / / 21901158 rs1868065 chr3 63063240 C T 3.59E-05 Orofacial clefts / / 22419666 rs2053759 chr3 63073352 C T 4.39E-05 Orofacial clefts / / 22419666 rs2034318 chr3 63078242 G A 6.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs982678 chr3 63088315 A C 6.36E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2367607 chr3 63101614 T C 6.78E-04 Suicide attempts in bipolar disorder LOC285401 intron 21423239 rs6445318 chr3 63133304 A C 6.88E-05 Intelligence / / 21826061 rs1838990 chr3 63167851 A G 5.64E-04 Rheumatoid arthritis / / 21452313 rs17365274 chr3 63177345 A G 8.91E-04 Multiple complex diseases / / 17554300 rs41470345 chr3 63204420 G C 5.16E-04 Multiple complex diseases / / 17554300 rs9311860 chr3 63214900 T C 8.11E-04 Smoking quantity / / 24665060 rs17300316 chr3 63218397 G A 2.36E-04 Multiple complex diseases / / 17554300 rs2887078 chr3 63248575 C T 6.88E-04 Type 2 diabetes / / 17463246 rs7433582 chr3 63261972 T G 1.64E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7433582 chr3 63261972 T G 2.97E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs6792395 chr3 63271485 G A 2.36E-04 Obesity (extreme) SYNPR intron 21935397 rs6792508 chr3 63271746 C T 4.82E-04 Obesity (extreme) SYNPR intron 21935397 rs6792896 chr3 63271968 G A 2.10E-05 Urinary metabolites SYNPR intron 21572414 rs6792896 chr3 63271968 G A 4.77E-04 Obesity (extreme) SYNPR intron 21935397 rs6792744 chr3 63272034 C T 4.75E-04 Obesity (extreme) SYNPR intron 21935397 rs6768281 chr3 63272058 A C 4.73E-04 Obesity (extreme) SYNPR intron 21935397 rs6801595 chr3 63272468 A G 4.70E-04 Obesity (extreme) SYNPR intron 21935397 rs6790463 chr3 63272557 T C 4.68E-04 Obesity (extreme) SYNPR intron 21935397 rs9867170 chr3 63272826 T A 4.67E-04 Obesity (extreme) SYNPR intron 21935397 rs6777885 chr3 63273068 C T 4.66E-04 Obesity (extreme) SYNPR intron 21935397 rs6793545 chr3 63273274 T A 4.65E-04 Obesity (extreme) SYNPR intron 21935397 rs9873263 chr3 63274302 T C 4.60E-04 Obesity (extreme) SYNPR intron 21935397 rs9815672 chr3 63274436 A T 4.59E-04 Obesity (extreme) SYNPR intron 21935397 rs9853765 chr3 63274579 C G 4.55E-04 Obesity (extreme) SYNPR intron 21935397 rs2367783 chr3 63275271 C T 4.54E-04 Obesity (extreme) SYNPR intron 21935397 rs4688390 chr3 63275851 C T 4.54E-04 Obesity (extreme) SYNPR intron 21935397 rs4688391 chr3 63275929 C T 4.53E-04 Obesity (extreme) SYNPR intron 21935397 rs6767034 chr3 63276836 A G 5.38E-05 Bipolar disorder SYNPR intron 21771265 rs6767034 chr3 63276836 A G 3.42E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SYNPR intron 24023788 rs6767034 chr3 63276836 A G 8.71E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SYNPR intron 24023788 rs9857192 chr3 63277968 A G 4.42E-04 Obesity (extreme) SYNPR intron 21935397 rs9311870 chr3 63278311 C T 4.38E-04 Obesity (extreme) SYNPR intron 21935397 rs2887081 chr3 63278809 T C 4.37E-04 Obesity (extreme) SYNPR intron 21935397 rs2367788 chr3 63281427 C T 4.16E-04 Obesity (extreme) SYNPR intron 21935397 rs1403703 chr3 63282650 C T 4.24E-04 Obesity (extreme) SYNPR intron 21935397 rs2056546 chr3 63283665 C T 4.27E-04 Obesity (extreme) SYNPR intron 21935397 rs2056545 chr3 63283701 C T 4.28E-04 Obesity (extreme) SYNPR intron 21935397 rs10510893 chr3 63285628 C T 4.47E-04 Obesity (extreme) SYNPR intron 21935397 rs11130920 chr3 63285738 A T 3.98E-04 Obesity (extreme) SYNPR intron 21935397 rs870364 chr3 63286254 C G 4.44E-04 Obesity (extreme) SYNPR intron 21935397 rs1608452 chr3 63294690 T A 4.32E-04 Obesity (extreme) SYNPR intron 21935397 rs7626955 chr3 63294802 T A 4.32E-04 Obesity (extreme) SYNPR intron 21935397 rs1523436 chr3 63297904 T C 4.03E-04 Obesity (extreme) SYNPR intron 21935397 rs12489378 chr3 63298608 A G 3.57E-05 Bipolar disorder SYNPR intron 21771265 rs4688393 chr3 63299052 C A 4.02E-04 Obesity (extreme) SYNPR intron 21935397 rs1851666 chr3 63299949 G A 4.02E-04 Obesity (extreme) SYNPR intron 21935397 rs7636388 chr3 63306819 G A 4.07E-04 Obesity (extreme) SYNPR intron 21935397 rs1451312 chr3 63307868 A T 4.09E-04 Obesity (extreme) SYNPR intron 21935397 rs11130924 chr3 63308160 T C 4.09E-04 Obesity (extreme) SYNPR intron 21935397 rs1376481 chr3 63309050 A G 3.57E-05 Bipolar disorder SYNPR intron 21771265 rs1376481 chr3 63309050 A G 2.36E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SYNPR intron 24023788 rs1349478 chr3 63311967 A C 4.15E-04 Obesity (extreme) SYNPR intron 21935397 rs2037571 chr3 63312698 T C 7.14E-04 Obesity (extreme) SYNPR intron 21935397 rs2037570 chr3 63313144 A G 2.80E-05 Urinary metabolites SYNPR intron 21572414 rs2037570 chr3 63313144 A G 4.21E-04 Obesity (extreme) SYNPR intron 21935397 rs11714718 chr3 63314568 G T 4.27E-04 Obesity (extreme) SYNPR intron 21935397 rs935786 chr3 63342866 G A 9.15E-05 Magnesium levels SYNPR intron pha003092 rs13068980 chr3 63350469 A G 0.000000772 Cytarabine sensitivity SYNPR intron 23538338 rs17068377 chr3 63352539 G T 0.000000652 Cytarabine sensitivity SYNPR intron 23538338 rs12638620 chr3 63354550 C G 0.000000717 Cytarabine sensitivity SYNPR intron 23538338 rs10510896 chr3 63355092 G A 0.00000076 Cytarabine sensitivity SYNPR intron 23538338 rs17068392 chr3 63355984 T C 0.000000717 Cytarabine sensitivity SYNPR intron 23538338 rs2167353 chr3 63361571 T C 2.13E-04 Multiple complex diseases SYNPR intron 17554300 rs17068421 chr3 63369620 A C 2.17E-04 Multiple complex diseases SYNPR intron 17554300 rs17068439 chr3 63375979 C T 4.78E-04 Multiple complex diseases SYNPR intron 17554300 rs17313993 chr3 63378419 T C 2.76E-09 Breast cancer SYNPR intron 20852631 rs1996918 chr3 63380775 T C 9.86E-05 Magnesium levels SYNPR intron pha003092 rs9856132 chr3 63385383 G C 1.09E-04 Lipid traits SYNPR intron 22028671 rs727777 chr3 63405972 T C 1.20E-05 Asthma SYNPR intron pha003127 rs17031729 chr3 63412569 A C 8.66E-04 Multiple complex diseases SYNPR intron 17554300 rs1403700 chr3 63415195 A G 6.40E-05 Serum metabolites SYNPR intron 19043545 rs1545458 chr3 63417340 A G 8.00E-07 Urinary metabolites SYNPR intron 21572414 rs1545458 chr3 63417340 A G 8.55E-05 Tourette syndrome SYNPR intron 22889924 rs12374033 chr3 63430538 T C 7.89E-05 Smoking cessation SYNPR intron 18519826 rs6766009 chr3 63437107 A G 2.37E-04 Tourette syndrome SYNPR intron 22889924 rs57891639 chr3 63449855 T C 2.22E-04 Acne (severe) SYNPR intron 24927181 rs59460117 chr3 63449954 T C 4.66E-05 Acne (severe) SYNPR intron 24927181 rs7629131 chr3 63456132 T C 9.29E-12 Metabolite levels SYNPR intron 22286219 rs13088837 chr3 63459125 A G 8.85E-04 Taste perception SYNPR intron 22132133 rs9841251 chr3 63460373 A C 8.50E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs6765895 chr3 63464370 G A 9.01E-04 Coronary heart disease SYNPR intron 21606135 rs6772726 chr3 63466382 G T 4.85E-04 Coronary heart disease SYNPR intron 21606135 rs6783555 chr3 63469983 C T 5.64E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs6799191 chr3 63470203 T C 5.64E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs6799373 chr3 63470356 T C 5.65E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs1901303 chr3 63471314 A G 5.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs9838946 chr3 63472023 G A 5.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs4688402 chr3 63472192 A G 5.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs4688403 chr3 63472310 A C 5.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs4688404 chr3 63472534 G T 5.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs7621849 chr3 63472842 C G 5.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs935792 chr3 63473375 G A 5.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs6803417 chr3 63474104 A C 5.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs6781972 chr3 63474250 G A 5.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs17068808 chr3 63475294 A G 5.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs4688412 chr3 63491925 A C 5.65E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs1158186 chr3 63495185 T C 3.72E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs6769577 chr3 63495805 G A 4.56E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs13086578 chr3 63496778 T C 4.54E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNPR intron 22566498 rs17397636 chr3 63501455 C G 2.79E-05 Smoking cessation SYNPR intron 18519826 rs17338206 chr3 63501532 T C 1.97E-04 Smoking cessation SYNPR intron 18519826 rs11918416 chr3 63505191 C T 6.94E-04 Multiple complex diseases SYNPR intron 17554300 rs7614676 chr3 63507244 A G 1.36E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs7614676 chr3 63507244 A G 4.25E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs2221476 chr3 63507544 A G 1.08E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs2221476 chr3 63507544 A G 4.11E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs2202492 chr3 63507662 T C 1.12E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs2202492 chr3 63507662 T C 4.09E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs13067087 chr3 63508251 A T 4.08E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs13067087 chr3 63508251 A T 9.86E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs6775133 chr3 63509964 A G 3.95E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs6775133 chr3 63509964 A G 9.44E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs17068905 chr3 63510844 C T 3.74E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs17068905 chr3 63510844 C T 8.89E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs7617487 chr3 63512021 T G 3.49E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs7617487 chr3 63512021 T G 8.67E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs11928896 chr3 63512762 A G 3.34E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs11928896 chr3 63512762 A G 7.46E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs6770081 chr3 63513405 A G 3.26E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs6770081 chr3 63513405 A G 8.90E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs11921529 chr3 63513585 G A 3.17E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs11921529 chr3 63513585 G A 8.61E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs9848074 chr3 63513985 C G 3.13E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs9848074 chr3 63513985 C G 8.67E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs7641936 chr3 63514176 C T 3.08E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs7641936 chr3 63514176 C T 8.67E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs6766087 chr3 63515740 T C 3.47E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs6766087 chr3 63515740 T C 7.74E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs6777474 chr3 63515886 A G 3.51E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs6777474 chr3 63515886 A G 7.28E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs11130939 chr3 63518063 G T 1.43E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs11130939 chr3 63518063 G T 4.77E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1505600 chr3 63518842 G C 1.05E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1505600 chr3 63518842 G C 7.70E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1394902 chr3 63519693 C T 2.62E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1394902 chr3 63519693 C T 7.71E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1394901 chr3 63519727 T C 2.58E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1394901 chr3 63519727 T C 7.74E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs4392412 chr3 63520037 T G 2.58E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs4392412 chr3 63520037 T G 7.74E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs985370 chr3 63520117 A G 2.62E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs985370 chr3 63520117 A G 7.75E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs985368 chr3 63520390 C T 2.62E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs985368 chr3 63520390 C T 7.78E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs985367 chr3 63520475 G T 2.40E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs985367 chr3 63520475 G T 7.81E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs11926493 chr3 63523311 C T 2.86E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs11926493 chr3 63523311 C T 6.99E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs12054371 chr3 63524098 C T 5.03E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs12054371 chr3 63524098 C T 6.16E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1505599 chr3 63524793 A C 2.11E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1505599 chr3 63524793 A C 7.87E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1505598 chr3 63524880 C G 1.21E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1505598 chr3 63524880 C G 7.90E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs4616634 chr3 63525003 A G 7.91E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs4616634 chr3 63525003 A G 8.62E-05 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1505597 chr3 63526806 A G 1.03E-04 Alzheimer's disease SYNPR intron 17998437 rs1039631 chr3 63528049 G A 9.64E-04 Suicide attempts in bipolar disorder SYNPR intron 21423239 rs1039631 chr3 63528049 G A 2.00E-04 Cognitive impairment induced by topiramate SYNPR intron 22091778 rs11130944 chr3 63528914 T C 1.53E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs11130944 chr3 63528914 T C 6.53E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1027764 chr3 63529614 T G 1.64E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1027764 chr3 63529614 T G 6.42E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1505595 chr3 63530277 C T 2.69E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs1505595 chr3 63530277 C T 6.30E-04 Suicide attempts in bipolar disorder SYNPR intron 21041247 rs17399296 chr3 63535676 T C 0.000737 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SYNPR intron 23233654 rs17399296 chr3 63535676 T C 7.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) SYNPR intron 23233662 rs17399554 chr3 63567354 G A 3.49E-05 Smoking cessation SYNPR intron 18519826 rs9877629 chr3 63588304 A T 4.59E-05 Height SYNPR intron 22021425 rs10510900 chr3 63609030 C A 3.29E-04 Multiple complex diseases / / 17554300 rs7646765 chr3 63612431 T C 6.12E-04 Stroke / / pha002887 rs7609960 chr3 63618827 C T 7.47E-05 Blood Pressure / / pha003044 rs11130951 chr3 63623361 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs73111385 chr3 63645410 A G 0.000016 Breast cancer (ER positive) SNTN missense 23555315 rs6784922 chr3 63660258 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11707243 chr3 63663240 G A 6.27E-04 Multiple complex diseases / / 17554300 rs9680958 chr3 63697487 C T 2.90E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs10510911 chr3 63703641 C G 1.65E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs7623146 chr3 63703985 G A 6.58E-07 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs17069314 chr3 63713245 A C 0.000746 Salmonella-induced pyroptosis / / 22837397 rs35059906 chr3 63738355 G A 4.60E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs10510910 chr3 63739175 A C 4.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs35330798 chr3 63744332 C T 6.30E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs6799578 chr3 63745668 C A 6.30E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs9842724 chr3 63804761 T C 6.35E-06 Type 2 diabetes / / 22158537 rs7614311 chr3 63813654 A C 1.00E-06 Lung function (forced vital capacity) C3orf49 intron 24023788 rs7614311 chr3 63813654 A C 6.00E-06 Lung function (forced expiratory volume in 1 second) C3orf49 intron 24023788 rs6801346 chr3 63947128 G A 2.18E-05 Bipolar disorder and schizophrenia ATXN7 intron 20889312 rs13434089 chr3 63948566 T C 2.57E-05 Type 2 diabetes ATXN7 intron 22158537 rs13433909 chr3 63948609 C G 3.80E-05 Type 2 diabetes ATXN7 intron 22158537 rs62252368 chr3 63959465 C T 0.0000226 Colorectal adenoma (excluding hyperplasic) ATXN7 intron 23677573 rs62252368 chr3 63959465 C T 0.0000226 Colorectal adenoma (including hyperplasic) ATXN7 intron 23677573 rs10510903 chr3 63970192 C G 5.61E-05 Bipolar disorder and schizophrenia ATXN7 intron 20889312 rs17069612 chr3 63977676 G A 2.51E-05 Multiple complex diseases ATXN7 intron 17554300 rs3733127 chr3 63988174 C T 0.0000333 Colorectal adenoma (excluding hyperplasic) ATXN7 UTR-3 23677573 rs3733127 chr3 63988174 C T 0.0000333 Colorectal adenoma (including hyperplasic) ATXN7 UTR-3 23677573 rs35836 chr3 64009102 G T 9.56E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs40610 chr3 64009508 T C 4.91E-04 Stroke / / pha002887 rs35837 chr3 64013249 T C 4.38E-05 Type 2 diabetes / / 22158537 rs35840 chr3 64014904 C A 7.45E-06 Type 2 diabetes / / 22158537 rs13093232 chr3 64019642 G A 6.33E-04 Obesity (extreme) / / 21935397 rs6764606 chr3 64020447 C T 4.93E-06 Brain structure / / 22504417 rs6808752 chr3 64024529 G A 4.80E-05 Brain structure / / 22504417 rs831574 chr3 64029383 A G 1.26E-05 Cognitive test performance / / 20125193 rs831574 chr3 64029383 A G 8.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) / / 23934736 rs1376338 chr3 64031906 T C 2.25E-05 Brain structure / / 22504417 rs831571 chr3 64048297 T C 8.00E-11 Type 2 diabetes / / 22158537 rs831571 chr3 64048297 T C 8.41E-11 Type 2 diabetes / / 23300278 rs831571 chr3 64048297 T C 3.70E-04 Type 2 diabetes / / 24509480 rs166230 chr3 64053207 T C 2.89E-05 Type 2 diabetes / / 22158537 rs11707025 chr3 64055501 T G 3.37E-05 Brain structure LOC100652759 intron 22504417 rs1450985 chr3 64060128 G A 3.92E-05 Brain structure LOC100652759 intron 22504417 rs153734 chr3 64078009 C T 7.00E-06 Folate pathway vitamin levels LOC100652759 intron 19303062 rs153712 chr3 64096122 C T 4.87E-05 Magnesium levels PRICKLE2 intron pha003092 rs11130957 chr3 64097856 T G 2.64E-05 Magnesium levels PRICKLE2 intron pha003092 rs1096170 chr3 64104388 C T 0.0000518 Nicotine dependence (smoking) PRICKLE2 intron 22377092 rs1096170 chr3 64104388 C T 2.53E-05 Schizophrenia PRICKLE2 intron 24253340 rs11130958 chr3 64105279 T C 5.70E-05 Response to statin therapy PRICKLE2 intron 20339536 rs830010 chr3 64108737 C A 0.0000979 Nicotine dependence (smoking) PRICKLE2 intron 22377092 rs985280 chr3 64108853 C G 2.61E-05 Neuroticism PRICKLE2 intron 23229837 rs1024895 chr3 64111658 T C 0.0000025 Nicotine dependence (smoking) PRICKLE2 intron 22377092 rs201013261 chr3 64111658 T TAC 0.0000025 Nicotine dependence (smoking) PRICKLE2 intron 22377092 rs696009 chr3 64111719 T C 7.21E-05 Schizophrenia PRICKLE2 intron 24253340 rs696010 chr3 64111897 G A 6.16E-05 Schizophrenia PRICKLE2 intron 24253340 rs696011 chr3 64125385 T C 1.92E-05 Adipocyte fatty acid-binding protein concentration,in serum PRICKLE2 intron 21863005 rs697266 chr3 64125639 G C 2.46E-05 Adipocyte fatty acid-binding protein concentration,in serum PRICKLE2 intron 21863005 rs1432583 chr3 64127012 C T 1.10E-04 Multiple complex diseases PRICKLE2 intron 17554300 rs6445392 chr3 64135500 T C 6.79E-05 Cognitive impairment induced by topiramate PRICKLE2 intron 22091778 rs17664296 chr3 64148288 C T 9.55E-04 Multiple complex diseases PRICKLE2 intron 17554300 rs7637364 chr3 64157235 G T 6.43E-04 Tourette syndrome PRICKLE2 intron 22889924 rs697277 chr3 64166741 C T 5.46E-05 Blood pressure (response to angiotensin II receptor blocker) PRICKLE2 intron 24192120 rs1035275 chr3 64173901 T C 9.00E-06 IgG glycosylation PRICKLE2 intron 23382691 rs696018 chr3 64184956 G A 1.15E-04 Glycosylated haemoglobin levels PRICKLE2 intron 17255346 rs7610343 chr3 64199364 T C 1.80E-04 Glycosylated haemoglobin levels PRICKLE2 intron 17255346 rs17666009 chr3 64205332 C T 4.12E-05 Cognitive impairment induced by topiramate PRICKLE2 intron 22091778 rs1963348 chr3 64215255 G A 8.94E-05 Response to metformin / / 21186350 rs3911778 chr3 64230433 C A 8.03E-05 Response to metformin / / 21186350 rs41325347 chr3 64240985 T C 4.09E-04 Multiple complex diseases / / 17554300 rs704409 chr3 64246829 C A 9.48E-05 Colorectal cancer / / 19723657 rs1471377 chr3 64252968 A G 7.92E-05 Stroke (ischemic) / / 22941190 rs704422 chr3 64256270 G A 6.41E-05 Alzheimer's disease / / 17998437 rs862500 chr3 64272649 A T 5.07E-04 Multiple complex diseases / / 17554300 rs17404667 chr3 64274552 C G 9.55E-07 Coronary artery calcification / / 23870195 rs1102918 chr3 64283477 G A 4.02E-04 Multiple complex diseases / / 17554300 rs1102918 chr3 64283477 G A 8.58E-04 Alzheimer's disease / / 17998437 rs4688441 chr3 64285015 C A 3.11E-04 Alzheimer's disease / / 17998437 rs17070340 chr3 64289354 A C 3.85E-04 Alzheimer's disease / / 17998437 rs9874230 chr3 64289732 C T 1.84E-04 Multiple complex diseases / / 17554300 rs853284 chr3 64290587 T C 2.22E-04 Alzheimer's disease / / 17998437 rs741013 chr3 64292637 A T 5.00E-07 Coronary artery calcification / / 23870195 rs853275 chr3 64294523 C A 7.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs853260 chr3 64314552 G A 4.40E-04 Volumetric brain MRI / / 17903297 rs853256 chr3 64315464 A G 7.50E-04 Volumetric brain MRI / / 17903297 rs6762476 chr3 64326232 A G 4.61E-04 Insulin resistance / / 21901158 rs6791551 chr3 64328025 G T 8.64E-05 Hemoglobin / / pha003096 rs6791551 chr3 64328025 G T 6.24E-05 Hematocrit / / pha003097 rs17070461 chr3 64329989 T C 2.87E-05 Cognitive test performance / / 20125193 rs7653442 chr3 64370063 T G 6.91E-05 Lipoproteins / / pha003079 rs4688187 chr3 64372607 G A 4.02E-04 Alzheimer's disease / / 17998437 rs4688187 chr3 64372607 G A 1.93E-04 Alzheimer's disease / / pha002879 rs13065232 chr3 64373715 T A 1.20E-06 Urinary metabolites / / 21572414 rs17070662 chr3 64377302 T C 0.0000027 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) / / 23080225 rs719775 chr3 64391453 T A 1.80E-05 Volumetric brain MRI / / 17903297 rs9830368 chr3 64396264 G A 9.66E-06 Sleep quality / / 23728906 rs6445401 chr3 64396762 A G 4.40E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7611296 chr3 64415110 G A 7.94E-04 Multiple complex diseases / / 17554300 rs6787902 chr3 64439166 A C 7.38E-04 Insulin resistance / / 21901158 rs11917164 chr3 64451058 T C 0.000219494 Hypertension (early onset hypertension) / / 22479346 rs7612038 chr3 64467869 A C 0.000436372 Hypertension (early onset hypertension) / / 22479346 rs11714687 chr3 64470812 C T 1.20E-05 Urinary metabolites / / 21572414 rs6787443 chr3 64472243 C A 9.57E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4688470 chr3 64497351 A C 5.04E-04 Alcohol dependence / / 20201924 rs4688470 chr3 64497351 A C 2.81E-04 Hodgkin's lymphoma / / 24149102 rs2888015 chr3 64499343 G A 1.52E-04 Hodgkin's lymphoma / / 24149102 rs11718026 chr3 64505376 T C 0.0006589 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ADAMTS9 intron 23233654 rs11718026 chr3 64505376 T C 6.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) ADAMTS9 intron 23233662 rs11713906 chr3 64505542 C T 1.83E-04 Hodgkin's lymphoma ADAMTS9 intron 24149102 rs11717554 chr3 64519156 C T 5.62E-05 Hodgkin's lymphoma ADAMTS9 intron 24149102 rs1373163 chr3 64527321 T C 4.43E-05 Hodgkin's lymphoma ADAMTS9 intron 24149102 rs1036918 chr3 64527378 G A 8.87E-04 Myopia (pathological) ADAMTS9 intron 21095009 rs9311895 chr3 64532254 A G 4.35E-04 Myopia (pathological) ADAMTS9 intron 21095009 rs80311637 chr3 64536648 C T 2.00E-06 Liver enzyme levels (aspartate transaminase) ADAMTS9 missense 24124411 rs80311637 chr3 64536648 C T 7.00E-06 Liver enzyme levels (alanine transaminase) ADAMTS9 missense 24124411 rs9311896 chr3 64539775 C T 1.24E-04 Hodgkin's lymphoma ADAMTS9 intron 24149102 rs1014640 chr3 64543615 T C 8.89E-05 Alcohol withdrawal symptoms ADAMTS9 intron 22072270 rs4405909 chr3 64575629 G A 2.90E-06 Urinary metabolites ADAMTS9 intron 21572414 rs7652817 chr3 64614313 G A 5.02E-05 Type 1 diabetes nephropathy ADAMTS9 intron 23028342 rs6445420 chr3 64617070 C T 0.0000967 post-traumatic stress disorder ADAMTS9 intron 22869035 rs6445420 chr3 64617070 C T 9.67E-05 Schizophrenia ADAMTS9 intron 22883433 rs11719363 chr3 64620801 G T 4.66E-05 Type 1 diabetes nephropathy ADAMTS9 intron 23028342 rs7632980 chr3 64627817 G A 1.03E-04 Telomere length ADAMTS9 intron 21573004 rs9861153 chr3 64634411 T C 8.47E-05 Blood Pressure ADAMTS9 intron pha003039 rs9855230 chr3 64642056 G A 1.30E-05 Alzheimer's disease (late onset) ADAMTS9 intron 21379329 rs4688495 chr3 64643533 A T 9.68E-04 Prostate cancer mortality ADAMTS9 intron 20978177 rs13085005 chr3 64650290 C T 0.00074 Endometrial cancer ADAMTS9 intron 22426144 rs9820318 chr3 64654679 G A 1.17E-04 Amyotrophic lateral sclerosis (sporadic) ADAMTS9 intron 24529757 rs6793277 chr3 64655357 T G 1.94E-04 Alzheimer's disease (late onset) ADAMTS9 intron 21379329 rs12488554 chr3 64692746 T C 1.59E-04 Alzheimer's disease ADAMTS9-AS2 intron 24755620 rs9828674 chr3 64693100 T G 6.55E-05 Alzheimer's disease ADAMTS9-AS2 intron 24755620 rs9850029 chr3 64697088 T C 7.07E-04 Alzheimer's disease ADAMTS9-AS2 intron 17998437 rs4611812 chr3 64699445 C T 0.00000033 Type 2 diabetes (females) ADAMTS9-AS2 intron 22885922 rs4611812 chr3 64699445 C T 0.0000011 Type 2 diabetes (males) ADAMTS9-AS2 intron 22885922 rs9860730 chr3 64701146 A G 4.46E-04 Multiple complex diseases ADAMTS9-AS2 intron 17554300 rs6795735 chr3 64705365 C T 2.00E-16 Waist-hip ratio ADAMTS9-AS2 intron 20935629 rs6795735 chr3 64705365 C T 7.40E-11 Type 2 diabetes ADAMTS9-AS2 intron 22885922 rs6795735 chr3 64705365 C T 8.40E-05 Type 2 diabetes ADAMTS9-AS2 intron 23300278 rs6795735 chr3 64705365 C T 5.00E-09 Age-related macular degeneration ADAMTS9-AS2 intron 23455636 rs6795735 chr3 64705365 C T 2.10E-04 Type 2 diabetes ADAMTS9-AS2 intron 24509480 rs11720604 chr3 64710089 A G 2.05E-04 Multiple complex diseases ADAMTS9-AS2 intron 17554300 rs918466 chr3 64710253 G A 4.68E-04 Type 2 diabetes ADAMTS9-AS2 intron 17463246 rs13060013 chr3 64710709 C A 3.80E-05 Waist-hip ratio ADAMTS9-AS2 intron 23966867 rs4607103 chr3 64711904 C T 1.00E-08 Type 2 diabetes ADAMTS9-AS2 intron 18372903 rs4607103 chr3 64711904 C T 1.00E-08 Coronary heart disease ADAMTS9-AS2 intron 21347282 rs4607103 chr3 64711904 C T 1.00E-08 Type 2 diabetes ADAMTS9-AS2 intron 21647700 rs4607103 chr3 64711904 C T 1.00E-08 Type 2 diabetes ADAMTS9-AS2 intron 23300278 rs17676096 chr3 64715467 G A 6.70E-06 Aortic stiffness ADAMTS9-AS2 intron 22068335 rs2371767 chr3 64718258 G C 2.00E-06 Sexual dimorphism in anthropometric traits ADAMTS9-AS2 intron 23754948 rs7433808 chr3 64727086 A T 2.00E-07 Visceral adipose tissue/subcutaneous adipose tissue ratio ADAMTS9-AS2 intron 22589738 rs7638389 chr3 64729892 G A 8.00E-06 Visceral adipose tissue adjusted for BMI ADAMTS9-AS2 intron 22589738 rs2371765 chr3 64736577 G A 8.88E-04 Multiple complex diseases ADAMTS9-AS2 intron 17554300 rs9856731 chr3 64782724 C T 1.70E-05 HIV-1 control ADAMTS9-AS2 intron 20041166 rs10510925 chr3 64789061 G A 6.56E-04 Multiple complex diseases ADAMTS9-AS2 intron 17554300 rs399322 chr3 64793523 T C 2.02E-04 Insulin resistance ADAMTS9-AS2 intron 21901158 rs384441 chr3 64793541 A G 9.39E-05 Insulin resistance ADAMTS9-AS2 intron 21901158 rs4142325 chr3 64794743 T C 1.70E-05 HIV-1 control ADAMTS9-AS2 intron 20041166 rs11923135 chr3 64842029 G T 5.91E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ADAMTS9-AS2 intron 20031582 rs11923135 chr3 64842029 G T 4.99E-04 Alzheimer's disease (late onset) ADAMTS9-AS2 intron 21379329 rs2583718 chr3 64845735 G A 1.11E-05 Bleomycin sensitivity ADAMTS9-AS2 intron 21106707 rs1036797 chr3 64886110 A G 2.00E-06 White matter integrity (interaction) ADAMTS9-AS2 intron 23218918 rs704447 chr3 64891099 G T 1.32E-04 Type 2 diabetes ADAMTS9-AS2 intron 17463246 rs17071750 chr3 64895544 T G 4.84E-04 Multiple complex diseases ADAMTS9-AS2 intron 17554300 rs793290 chr3 64906434 A T 4.47E-04 Type 2 diabetes ADAMTS9-AS2 intron 17463246 rs2280585 chr3 64907284 A G 1.10E-04 Longevity and age-related phenotypes ADAMTS9-AS2 intron 17903295 rs793291 chr3 64907649 A G 4.89E-05 Height ADAMTS9-AS2 intron pha003011 rs704454 chr3 64927025 C T 3.00E-06 Alzheimer's disease (age of onset) ADAMTS9-AS2 intron 22005931 rs704454 chr3 64927025 C T 6.94E-05 Height ADAMTS9-AS2 intron pha003011 rs704457 chr3 64930075 G A 3.05E-06 Alzheimer's disease (age of onset) ADAMTS9-AS2 intron 22005931 rs1357523 chr3 64938050 A G 3.50E-04 Myocardial Infarction ADAMTS9-AS2 intron pha002873 rs116309954 chr3 64956369 T C 0.00000958 Nonsyndromic striae distensae (stretch marks) ADAMTS9-AS2 intron 23633020 rs7625481 chr3 64987245 T C 0.0000988 Nonsyndromic striae distensae (stretch marks) ADAMTS9-AS2 intron 23633020 rs6785581 chr3 65010837 A C 5.63E-04 Insulin resistance / / 21901158 rs17072107 chr3 65013180 T A,C,G 8.36E-04 Depression (quantitative trait) / / 20800221 rs1517931 chr3 65018403 A G 7.64E-05 Cognitive impairment induced by topiramate / / 22091778 rs13071619 chr3 65019442 C T 9.02E-04 Alzheimer's disease / / 22005930 rs9873203 chr3 65021946 C T 1.33E-04 Alzheimer's disease (late onset) / / 21379329 rs6445445 chr3 65037485 G T 2.73E-05 Receptive language ability / / 24687471 rs9875970 chr3 65047603 G A 7.44E-05 Hemoglobin / / pha003098 rs6767418 chr3 65048037 G C 3.01E-04 Multiple complex diseases / / 17554300 rs12636227 chr3 65065491 T C 9.90E-04 Alzheimer's disease / / 17998437 rs17342237 chr3 65072366 G A 1.33E-04 Depression (quantitative trait) / / 20800221 rs6773617 chr3 65077900 G A 2.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17072306 chr3 65082367 C T 1.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9818174 chr3 65083725 G C 6.05E-04 Depression (quantitative trait) / / 20800221 rs6809503 chr3 65086196 A G 7.58E-04 Smoking quantity / / 24665060 rs9842777 chr3 65090427 T C 1.37E-04 Smoking quantity / / 24665060 rs2128405 chr3 65100060 A C 7.27E-05 Depression (quantitative trait) / / 20800221 rs2128404 chr3 65100158 T C 4.42E-07 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs9790242 chr3 65103850 C A 5.84E-04 Smoking quantity / / 24665060 rs17403629 chr3 65104040 A G 6.87E-05 Depression (quantitative trait) / / 20800221 rs17403692 chr3 65104083 C T 4.57E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs559397185 chr3 65104083 CG C 4.57E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9831020 chr3 65104234 A G 2.89E-05 Hemoglobin / / pha003098 rs9833943 chr3 65116677 G A 1.63E-04 Coronary Artery Disease / / 17634449 rs1482610 chr3 65121636 G C 1.68E-04 Coronary Artery Disease / / 17634449 rs9311934 chr3 65122103 G C 1.08E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs7613923 chr3 65127044 T C,G 7.98E-05 Hemoglobin / / pha003098 rs6445466 chr3 65132291 C T 6.40E-05 Creatinine levels / / pha003069 rs7626309 chr3 65133021 A G 4.94E-04 Multiple complex diseases / / 17554300 rs6807775 chr3 65133697 C T 4.74E-05 Erythrocyte counts / / pha003099 rs10510933 chr3 65148621 G A 3.46E-05 Behcet's disease / / pha002888 rs17072468 chr3 65152166 G A 3.53E-05 Receptive language ability / / 24687471 rs9311935 chr3 65153699 C T 5.39E-04 Multiple complex diseases / / 17554300 rs6786533 chr3 65175093 A G 9.51E-04 Aortic root size / / 21223598 rs7634969 chr3 65176116 A G 4.97E-04 Multiple complex diseases / / 17554300 rs7634969 chr3 65176116 A G 1.03E-04 Age-related macular degeneration / / 22125219 rs11131006 chr3 65179919 G A 2.16E-04 Age-related macular degeneration / / 22125219 rs2620525 chr3 65218668 A G 4.51E-04 Type 2 diabetes / / 17463246 rs2620525 chr3 65218668 A G 1.51E-04 Age-related macular degeneration / / 22125219 rs900371 chr3 65219673 G T 1.95E-04 Age-related macular degeneration / / 22125219 rs1384409 chr3 65222061 G T 2.29E-05 Tunica Media / / pha003036 rs17349171 chr3 65226990 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17349380 chr3 65231027 C A 8.58E-05 Cholesterol / / pha003073 rs4557104 chr3 65232772 G A 1.35E-05 Brain structure / / 22504417 rs781304 chr3 65237921 C T 6.83E-05 Height / / pha003011 rs6780864 chr3 65245294 C G 9.64E-04 Multiple complex diseases / / 17554300 rs7431862 chr3 65250132 G A 2.73E-06 Stroke (ischemic) / / 21957438 rs1531643 chr3 65262951 T C 3.50E-04 Multiple complex diseases / / 17554300 rs17072701 chr3 65271855 T C 7.51E-04 Insulin resistance / / 21901158 rs13100540 chr3 65295327 A G 3.53E-04 Rheumatoid arthritis (ACPA-negative) / / 24532677 rs17072783 chr3 65326224 G A 4.73E-07 Diabetes Mellitus / / pha003059 rs6764388 chr3 65326882 T C 6.00E-06 Corneal astigmatism / / 23322567 rs11720037 chr3 65368011 T G 0.0000686 Tuberculosis with early age of onset MAGI1 intron 22551897 rs1319134 chr3 65370493 A G 4.43E-04 Type 2 diabetes MAGI1 intron 17463246 rs9847394 chr3 65373365 A C 3.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAGI1 intron 20877124 rs1016553 chr3 65379294 A G 1.46E-04 Multiple complex diseases MAGI1 intron 17554300 rs1016553 chr3 65379294 A G 1.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAGI1 intron 20877124 rs1016553 chr3 65379294 A G 6.00E-06 Homeostasis model assessment of beta-cell function (interaction) MAGI1 intron 24204828 rs2127522 chr3 65381652 C T 9.61E-04 Insulin resistance MAGI1 intron 21901158 rs2127521 chr3 65382140 T C 4.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAGI1 intron 20877124 rs2127521 chr3 65382140 T C 6.28E-06 Homeostasis model assessment of beta-cell function (interaction) MAGI1 intron 24204828 rs7649739 chr3 65398898 G A 6.00E-06 IgG glycosylation MAGI1 intron 23382691 rs13078969 chr3 65404650 C A 0.00087 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MAGI1 intron 23233654 rs13078969 chr3 65404650 C A 8.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI1 intron 23233662 rs4396824 chr3 65405078 A G 1.70E-04 Body mass index MAGI1 intron 21701565 rs4396824 chr3 65405078 A G 0.0007357 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MAGI1 intron 23233654 rs4396824 chr3 65405078 A G 7.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI1 intron 23233662 rs6766260 chr3 65406444 C T 6.39E-04 Multiple complex diseases MAGI1 intron 17554300 rs7428806 chr3 65409511 C T 0.000272 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MAGI1 intron 23233654 rs7428806 chr3 65409511 C T 2.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI1 intron 23233662 rs12485896 chr3 65410395 T A 3.66E-28 Narcolepsy MAGI1 intron 19629137 rs11131020 chr3 65411716 A G 8.23E-05 Heart Rate MAGI1 intron pha003053 rs11710619 chr3 65473862 T C 9.47E-05 Multiple complex diseases MAGI1 intron 17554300 rs1524968 chr3 65480973 T C 1.95E-04 Multiple complex diseases MAGI1 intron 17554300 rs1524976 chr3 65486388 A G 1.00E-04 Prostate cancer MAGI1 intron 21743057 rs1524976 chr3 65486388 A G 8.00E-06 PR interval MAGI1 intron 23534349 rs9864728 chr3 65486793 A C 2.00E-05 Prostate cancer MAGI1 intron 21743057 rs1404550 chr3 65487427 G C 2.00E-05 Prostate cancer MAGI1 intron 21743057 rs1554664 chr3 65501649 A G 5.00E-05 Prostate cancer MAGI1 intron 21743057 rs2177686 chr3 65510177 T A 6.72E-05 Multiple complex diseases MAGI1 intron 17554300 rs17073046 chr3 65510244 A G 7.30E-05 Multiple complex diseases MAGI1 intron 17554300 rs17073049 chr3 65511404 A C 5.76E-04 Multiple complex diseases MAGI1 intron 17554300 rs2091244 chr3 65517919 A G 8.21E-05 Multiple complex diseases MAGI1 intron 17554300 rs2037671 chr3 65540670 A C,T 1.38E-04 Response to platinum-based chemotherapy in small-cell lung cancer MAGI1 intron 20463552 rs2888232 chr3 65543934 T C 4.30E-04 Multiple complex diseases MAGI1 intron 17554300 rs6787045 chr3 65544252 T G 4.35E-05 Intelligence MAGI1 intron 21826061 rs4688585 chr3 65567691 G A 7.21E-04 Insulin resistance MAGI1 intron 21901158 rs1880521 chr3 65568609 T C 2.65E-04 Alzheimer's disease (late onset) MAGI1 intron 21379329 rs12635482 chr3 65575360 A C 2.56E-04 Multiple complex diseases MAGI1 intron 17554300 rs1917527 chr3 65580498 G T 9.87E-04 Multiple complex diseases MAGI1 intron 17554300 rs4407359 chr3 65597953 C A 1.01E-04 Endometrial cancer MAGI1 intron 24096698 rs11926742 chr3 65611042 G A 1.46E-04 Alzheimer's disease (late onset) MAGI1 intron 21379329 rs9311947 chr3 65620088 G A 1.57E-05 Heart Rate MAGI1 intron pha003053 rs77162136 chr3 65620208 G C 0.00006349 Sarcoidosis MAGI1 intron 22952805 rs7618480 chr3 65691280 A T 7.37E-04 Multiple complex diseases MAGI1 intron 17554300 rs1499508 chr3 65692063 G A 3.16E-04 Alzheimer's disease MAGI1 intron 22005930 rs2372184 chr3 65698154 C A 2.50E-06 Biomarkers MAGI1 intron 17903293 rs13082646 chr3 65732113 T C 2.01E-05 Coronary heart disease MAGI1 intron 21606135 rs264096 chr3 65745435 G A 5.62E-04 Schizophrenia MAGI1 intron 19197363 rs814756 chr3 65753414 T C 9.37E-04 Coronary heart disease MAGI1 intron 21606135 rs11924265 chr3 65760342 T C 3.73E-04 Smoking quantity MAGI1 intron 24665060 rs984038 chr3 65762252 C T 4.95E-04 Coronary heart disease MAGI1 intron 21606135 rs1495453 chr3 65762547 G A 1.15E-05 Coronary heart disease MAGI1 intron 21606135 rs880167 chr3 65794968 A G 6.63E-05 Tuberculosis MAGI1 intron 24057671 rs1909492 chr3 65797540 T C 6.38E-05 Relative hand skill MAGI1 intron 24068947 rs1909492 chr3 65797540 T C 9.52E-06 Height MAGI1 intron pha003010 rs1909492 chr3 65797540 T C 1.66E-07 Height MAGI1 intron pha003011 rs17295791 chr3 65801606 T C 0.000006 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) MAGI1 intron 23080225 rs17361892 chr3 65806838 T C 6.09E-04 Type 2 diabetes MAGI1 intron 17463246 rs17073902 chr3 65813197 A G 9.33E-05 Multiple complex diseases MAGI1 intron 17554300 rs1495451 chr3 65833959 T C 3.90E-06 Triglycerides MAGI1 intron pha003081 rs1495451 chr3 65833959 T C 6.07E-06 Lipid levels MAGI1 intron pha003082 rs1021534 chr3 65837994 C T 3.62E-04 Multiple complex diseases MAGI1 intron 17554300 rs9876471 chr3 65873106 G A 6.20E-06 Insulin-related traits MAGI1 intron 19902172 rs9876471 chr3 65873106 G A 4.48E-05 Cataracts in type 2 diabetes MAGI1 intron 20664687 rs264668 chr3 65879245 C T 2.79E-05 Cataracts in type 2 diabetes MAGI1 intron 20664687 rs9864600 chr3 65881273 C T 6.17E-04 Smoking quantity MAGI1 intron 24665060 rs1390245 chr3 65893577 T C 6.49E-04 Multiple complex diseases MAGI1 intron 17554300 rs264692 chr3 65904425 G A 3.89E-05 Amyotrophic lateral sclerosis (sporadic) MAGI1 intron 24529757 rs174653 chr3 65908488 T A 3.78E-04 Multiple complex diseases MAGI1 intron 17554300 rs9880270 chr3 65944066 G A 5.55E-05 Erythrocyte counts MAGI1 intron pha003099 rs1430415 chr3 65951661 T C 1.70E-05 Urinary metabolites MAGI1 intron 21572414 rs1430416 chr3 65951752 G A 5.50E-06 Urinary metabolites MAGI1 intron 21572414 rs9823801 chr3 65952671 C T 4.77E-05 Erythrocyte counts MAGI1 intron pha003099 rs7637355 chr3 65952898 T C 2.80E-05 Urinary metabolites MAGI1 intron 21572414 rs6795228 chr3 65963727 T C 6.37E-06 Bipolar disorder MAGI1 intron 21771265 rs17074219 chr3 65965425 G T 4.77E-04 Multiple complex diseases MAGI1 intron 17554300 rs6445523 chr3 65966296 T G 1.47E-05 Brain structure MAGI1 intron 22504417 rs6445523 chr3 65966296 T G 9.84E-05 Mammographic density MAGI1 intron 22532574 rs17074228 chr3 65967673 C T 3.53E-05 Mammographic density MAGI1 intron 22532574 rs17031811 chr3 65970610 G A 6.94E-04 Multiple complex diseases MAGI1 intron 17554300 rs7620106 chr3 65971499 T C 9.10E-06 Coronary heart disease (incident CHD) MAGI1 intron 21880673 rs6763833 chr3 65978092 C T 8.18E-05 Blood Pressure and Arterial Stiffness MAGI1 intron 17903302 rs6445524 chr3 65979643 T G 3.70E-04 Tourette syndrome MAGI1 intron 22889924 rs1541855 chr3 65991856 C T 2.83E-04 Multiple complex diseases MAGI1 intron 17554300 rs6445525 chr3 65993104 C G 4.45E-04 Multiple complex diseases MAGI1 intron 17554300 rs6762527 chr3 66003745 T C 7.15E-04 Depression (quantitative trait) MAGI1 intron 20800221 rs13081023 chr3 66317480 G T 7.11E-04 Alzheimer's disease SLC25A26 intron 17998437 rs11128157 chr3 66330608 G T 7.43E-04 Multiple complex diseases SLC25A26 intron 17554300 rs6793050 chr3 66385769 C A 3.58E-05 Vaspin levels SLC25A26 intron 22907691 rs6793050 chr3 66385769 C A 0.0000358 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks SLC25A26 intron 22907730 rs332354 chr3 66396845 G A 2.43E-04 Amyotrophic Lateral Sclerosis SLC25A26 intron 17362836 rs9829376 chr3 66410397 A G 1.63E-04 Amyotrophic Lateral Sclerosis SLC25A26 intron 17362836 rs332389 chr3 66411214 G A 1.30E-05 Amyotrophic Lateral Sclerosis SLC25A26 intron 17362836 rs2242285 chr3 66431602 A G 1.00E-08 QRS duration LRIG1 intron 21076409 rs9827908 chr3 66445601 A G 6.00E-08 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) LRIG1 intron 24554482 rs12633819 chr3 66448307 A G 2.86E-04 Amyotrophic Lateral Sclerosis LRIG1 intron 17362836 rs12633819 chr3 66448307 A G 0.000122 Salmonella-induced pyroptosis LRIG1 intron 22837397 rs12494912 chr3 66451907 T C 8.74E-05 Triglycerides LRIG1 intron pha003080 rs7651129 chr3 66474954 A G 2.00E-05 Urinary metabolites LRIG1 intron 21572414 rs12487264 chr3 66475637 C T 9.03E-04 Alzheimer's disease LRIG1 intron 22005930 rs12487264 chr3 66475637 C T 1.39E-05 Mammographic density LRIG1 intron 22532574 rs13078828 chr3 66479487 G A 5.13E-04 White matter integrity LRIG1 intron 22425255 rs13078828 chr3 66479487 G A 1.49E-05 Mammographic density LRIG1 intron 22532574 rs13078828 chr3 66479487 G A 4.00E-07 Antibody status in Tripanosoma cruzi seropositivity LRIG1 intron 24324551 rs17832271 chr3 66486380 C G 3.80E-06 Urinary metabolites LRIG1 intron 21572414 rs13096446 chr3 66488134 G T 9.42E-06 Mammographic density LRIG1 intron 22532574 rs13323717 chr3 66488656 C T 1.13E-04 Multiple complex diseases LRIG1 intron 17554300 rs6419763 chr3 66495755 T C 3.47E-04 Multiple complex diseases LRIG1 intron 17554300 rs13325263 chr3 66503207 T C 8.27E-04 Multiple complex diseases LRIG1 intron 17554300 rs3845903 chr3 66517670 C T 1.14E-14 Multiple complex diseases LRIG1 intron 17554300 rs3845905 chr3 66525963 T C 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) LRIG1 intron 23648065 rs3845905 chr3 66525963 T C 6.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LRIG1 intron 23648065 rs17044781 chr3 66570660 G T 4.43E-07 Multiple complex diseases / / 17554300 rs4241442 chr3 66580551 A G 2.66E-04 Lung function (forced vital capacity) / / 24023788 rs11918414 chr3 66618030 C T 7.48E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs11918414 chr3 66618030 C T 2.81E-06 Coronary heart disease / / pha003030 rs17044826 chr3 66620523 C A 2.55E-04 Type 2 diabetes / / 17463246 rs4547637 chr3 66627521 C T 3.40E-05 Coronary heart disease / / pha003030 rs4856952 chr3 66635873 G A 7.33E-05 Coronary heart disease / / pha003030 rs17044857 chr3 66637182 A G 1.89E-04 Multiple complex diseases / / 17554300 rs7612441 chr3 66648162 C T 2.75E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11128158 chr3 66668365 A G 2.32E-04 Insulin resistance / / 21901158 rs9870520 chr3 66706240 C T 0.000694 Salmonella-induced pyroptosis / / 22837397 rs1563541 chr3 66709318 A G 0.000378 Salmonella-induced pyroptosis / / 22837397 rs11717412 chr3 66713592 G A 2.60E-05 Urinary metabolites / / 21572414 rs12488407 chr3 66745365 T C 8.63E-05 Socioeconomic Factors / / pha003066 rs11710109 chr3 66753674 C T 2.18E-05 Socioeconomic Factors / / pha003066 rs1379186 chr3 66760417 A T 3.25E-04 Depression (quantitative trait) / / 20800221 rs11128202 chr3 66768059 T C 5.78E-04 Type 2 diabetes / / 17463246 rs17045031 chr3 66768364 G A 4.00E-07 Carotid intima media thickness / / 21909108 rs6549373 chr3 66769884 C T 2.01E-06 Uric acid levels / / 21294900 rs2120503 chr3 66779891 C T 2.23E-05 Multiple complex diseases / / 17554300 rs2034151 chr3 66782263 C T 4.52E-04 Type 2 diabetes / / 17463246 rs9845175 chr3 66797032 C T 3.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13069000 chr3 66798950 C G 1.00E-19 Renal function-related traits (BUN) / / 22797727 rs17045066 chr3 66799169 C T 3.61E-05 Height / / 17255346 rs13080378 chr3 66804200 A G 8.61E-04 Response to alcohol consumption (flushing response) / / 24277619 rs6796957 chr3 66807194 A G 2.07E-04 Prostate cancer / / 23023329 rs13069049 chr3 66809942 A T 3.00E-18 Metabolite levels / / 21909109 rs11709625 chr3 66823157 C A 1.00E-10 Blood cell counts and other traits / / 20139978 rs11709625 chr3 66823157 C A 1.46E-10 Blood cell counts and other traits / / 20139978 rs1001689 chr3 66843365 G T 2.15E-04 IgE levels / / 17255346 rs10049466 chr3 66868609 C T 9.66E-05 Diabetes (gestational) / / 22233651 rs10049470 chr3 66868827 C T 1.36E-04 IgE levels / / 17255346 rs3884663 chr3 66869791 G A 1.47E-04 IgE levels / / 17255346 rs3884663 chr3 66869791 G A 7.47E-04 Heart Failure / / pha002884 rs11719970 chr3 66890737 T A,C 1.30E-06 Urinary metabolites / / 21572414 rs4411828 chr3 66912679 T C 4.46E-04 Alzheimer's disease / / 24755620 rs6794835 chr3 66916783 G A 9.68E-05 Alzheimer's disease (late onset) / / 21379329 rs6794835 chr3 66916783 G A 3.09E-05 Alzheimer's disease / / 24755620 rs1563441 chr3 66921142 G A 2.02E-04 Alzheimer's disease (late onset) / / 21379329 rs1563441 chr3 66921142 G A 2.36E-05 Alzheimer's disease / / 24755620 rs12496807 chr3 66931388 A G 9.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs9681451 chr3 66940463 T A 7.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs2219265 chr3 66942668 C T 6.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs2219265 chr3 66942668 C T 2.60E-05 Urinary metabolites / / 21572414 rs1350164 chr3 66942979 T C 8.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs6778915 chr3 66956170 T C 8.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs6778915 chr3 66956170 T C 1.90E-05 Urinary metabolites / / 21572414 rs10446399 chr3 66957796 G C 5.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs9836258 chr3 66995981 C G 8.51E-08 Metabolite levels / / 23281178 rs9816008 chr3 67016686 C T 3.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1869900 chr3 67023150 C T 2.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs12714803 chr3 67032138 T C 8.02E-08 Metabolite levels / / 23281178 rs12486952 chr3 67040146 A C 9.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs9875436 chr3 67046187 G T 1.82E-08 Metabolite levels / / 23281178 rs2364281 chr3 67050203 T G 4.23E-04 Suicide attempts in bipolar disorder KBTBD8 intron 21423239 rs4074707 chr3 67072952 A G 1.83E-04 Alzheimer's disease (late onset) / / 21379329 rs7653502 chr3 67079104 C T 2.37E-05 Alzheimer's disease (late onset) / / 21379329 rs7641944 chr3 67132470 T C 0.0006558 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7641944 chr3 67132470 T C 6.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4392363 chr3 67143838 T A 1.00E-06 Migraine - clinic-based / / 23793025 rs4392363 chr3 67143838 T A 1.70E-04 Migraine / / 23793025 rs4417811 chr3 67145427 T C 1.52E-05 Schizophrenia / / pha002857 rs13089748 chr3 67148307 T C 1.68E-04 Alzheimer's disease (late onset) / / 21379329 rs7618179 chr3 67150373 A T 0.0005789 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7618179 chr3 67150373 A T 5.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9867793 chr3 67160633 A G 1.45E-05 Alzheimer's disease (late onset) / / 21379329 rs6762402 chr3 67172100 T C 1.17E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6766797 chr3 67183628 T A 1.36E-05 Postoperative ventricular dysfunction / / 21980348 rs17804294 chr3 67294182 G C 1.80E-05 Urinary metabolites / / 21572414 rs872101 chr3 67298578 G C 3.71E-06 Asthma (childhood onset) / / 23829686 rs1490244 chr3 67317284 A G 1.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1387862 chr3 67317393 G C 2.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4396908 chr3 67336441 G C 4.23E-04 Type 2 diabetes / / 17463246 rs1490270 chr3 67340025 A C 9.54E-04 Type 2 diabetes / / 17463246 rs9856163 chr3 67346041 G A 1.23E-04 Type 2 diabetes / / 17463246 rs9860348 chr3 67346325 G T 1.89E-05 Type 2 diabetes / / 17463246 rs10510963 chr3 67352876 A C 1.40E-05 Urinary metabolites / / 21572414 rs6548450 chr3 67354022 A G 5.44E-05 Type 2 diabetes / / 17463246 rs9863572 chr3 67355643 A G 2.77E-05 Type 2 diabetes / / 17463246 rs931437 chr3 67364804 G A 7.81E-04 Myocardial Infarction / / pha002883 rs79075676 chr3 67366908 C T 1.96E-06 Response to amphetamines / / 22952603 rs17805868 chr3 67366936 T C 2.50E-05 Urinary metabolites / / 21572414 rs6548463 chr3 67367341 C T 3.64E-04 Myocardial Infarction / / pha002883 rs977102 chr3 67373977 A G 2.00E-06 Response to amphetamines / / 22952603 rs7639918 chr3 67386369 G C 6.52E-04 Type 2 diabetes / / 17463246 rs1586671 chr3 67388815 A C 5.75E-04 Type 2 diabetes / / 17463246 rs17806805 chr3 67415904 G T 2.20E-05 Type 2 diabetes SUCLG2 intron 17463246 rs17806888 chr3 67416322 T C 2.00E-09 Height SUCLG2 intron 20881960 rs17806888 chr3 67416322 T C 4.14E-06 Response to amphetamines SUCLG2 intron 22952603 rs17806888 chr3 67416322 T C 7.00E-11 Blood metabolite levels SUCLG2 intron 24816252 rs2363709 chr3 67417105 G A 5.00E-06 IgE levels SUCLG2 intron 23146381 rs3952322 chr3 67421818 C A 1.40E-06 Urinary metabolites SUCLG2 intron 21572414 rs115560420 chr3 67425963 G T 5.38E-06 Response to amphetamines SUCLG2 UTR-3 22952603 rs35494829 chr3 67426281 T C 5.38E-06 Response to amphetamines SUCLG2 missense 22952603 rs11923377 chr3 67427443 C T 1.08E-04 Lung function (forced expiratory volume in 1 second) SUCLG2 intron 24023788 rs6791324 chr3 67437836 C A 4.84E-04 Tourette syndrome SUCLG2 intron 22889924 rs41356347 chr3 67440712 T A 4.65E-26 Multiple complex diseases SUCLG2 intron 17554300 rs4856782 chr3 67463065 C T 6.24E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SUCLG2 intron 22566498 rs4856863 chr3 67470690 G A 6.62E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SUCLG2 intron 22566498 rs6792584 chr3 67531388 G A 5.00E-06 Corneal astigmatism SUCLG2 intron 22144915 rs1888089 chr3 67605629 C T 1.57E-04 Multiple complex diseases SUCLG2 intron 17554300 rs2634737 chr3 67608349 C G 8.29E-04 Multiple complex diseases SUCLG2 intron 17554300 rs2634743 chr3 67612285 C T 4.40E-04 Multiple complex diseases SUCLG2 intron 17554300 rs2250952 chr3 67628283 A C 7.62E-04 Response to cytidine analogues (gemcitabine) SUCLG2 intron 24483146 rs6794298 chr3 67635506 A C 5.13E-04 Response to cytidine analogues (gemcitabine) SUCLG2 intron 24483146 rs2076913 chr3 67649769 A C 6.22E-04 Type 2 diabetes SUCLG2 intron 17463246 rs1868674 chr3 67667800 T C 1.79E-05 Smoking quantity SUCLG2 intron 24665060 rs7646094 chr3 67672171 T C 2.48E-04 Obesity (extreme) SUCLG2 intron 21935397 rs10510965 chr3 67679557 C T 2.48E-04 Type 2 diabetes SUCLG2 intron 17463246 rs144647865 chr3 67795556 T TC 2.32E-05 Glucose levels / / pha003061 rs17046946 chr3 67795556 T C 2.32E-05 Glucose levels / / pha003061 rs4856894 chr3 67833293 G T 2.32E-05 Cognitive test performance / / 20125193 rs41375847 chr3 67950420 G C 8.67E-05 Smoking initiation / / 24665060 rs6795684 chr3 67964947 G C 4.35E-04 Alzheimer's disease / / 17998437 rs9857691 chr3 68065895 C G 6.32E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) FAM19A1 intron 24236485 rs11920675 chr3 68069643 G T 4.64E-04 Multiple complex diseases FAM19A1 intron 17554300 rs1447756 chr3 68069731 G A 5.16E-04 Multiple complex diseases FAM19A1 intron 17554300 rs1447756 chr3 68069731 G A 8.27E-04 Suicide attempts in bipolar disorder FAM19A1 intron 21423239 rs9865881 chr3 68087505 T C 3.59E-04 Tourette syndrome FAM19A1 intron 22889924 rs6792324 chr3 68096404 T A 1.61E-05 Aging (time to event) FAM19A1 intron 21782286 rs7433199 chr3 68115348 T C 0.000571 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FAM19A1 intron 23233654 rs7433199 chr3 68115348 T C 5.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) FAM19A1 intron 23233662 rs6548964 chr3 68122404 G A 9.91E-04 Multiple complex diseases FAM19A1 intron 17554300 rs7610023 chr3 68123731 A C 8.26E-05 Caffeine consumption FAM19A1 intron 21490707 rs9990002 chr3 68165772 G T 3.52E-04 Alcohol dependence FAM19A1 intron 20201924 rs7617812 chr3 68177942 G A 0.0000291 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FAM19A1 intron 23233654 rs7617812 chr3 68177942 G A 2.91E-05 Methotrexate clearance (acute lymphoblastic leukemia) FAM19A1 intron 23233662 rs7624036 chr3 68179836 G A 0.0000289 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FAM19A1 intron 23233654 rs7624036 chr3 68179836 G A 2.89E-05 Methotrexate clearance (acute lymphoblastic leukemia) FAM19A1 intron 23233662 rs1595493 chr3 68194293 G A 6.00E-04 Multiple complex diseases FAM19A1 intron 17554300 rs1595491 chr3 68196810 T A 0.0000195 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FAM19A1 intron 23233654 rs1595491 chr3 68196810 T A 1.95E-05 Methotrexate clearance (acute lymphoblastic leukemia) FAM19A1 intron 23233662 rs1595490 chr3 68196836 G A 5.64E-05 Multiple complex diseases FAM19A1 intron 17554300 rs17047216 chr3 68200366 A G 9.49E-04 Multiple complex diseases FAM19A1 intron 17554300 rs7650009 chr3 68252679 A G 3.17E-04 Alcohol dependence FAM19A1 intron 20201924 rs12053924 chr3 68261646 G A 4.70E-04 Alzheimer's disease FAM19A1 intron 17998437 rs12494944 chr3 68268104 C T 7.80E-06 Urinary metabolites FAM19A1 intron 21572414 rs1032376 chr3 68317975 T C 1.01E-06 Cognitive test performance FAM19A1 intron 20125193 rs902719 chr3 68331611 G T 2.07E-05 Multiple complex diseases FAM19A1 intron 17554300 rs1491758 chr3 68365879 C A 6.51E-04 Suicide attempts in bipolar disorder FAM19A1 intron 21423239 rs4568137 chr3 68372690 C T 9.13E-04 Multiple complex diseases FAM19A1 intron 17554300 rs1388505 chr3 68373086 G A 5.90E-04 Type 2 diabetes FAM19A1 intron 17463246 rs9809500 chr3 68377212 G C 0.00000999 Nonsyndromic striae distensae (stretch marks) FAM19A1 intron 23633020 rs9848233 chr3 68377214 C T 0.00000998 Nonsyndromic striae distensae (stretch marks) FAM19A1 intron 23633020 rs1491745 chr3 68379169 G A 9.04E-04 Coronary heart disease FAM19A1 intron 21971053 rs6792971 chr3 68385527 T C 2.59E-05 Reading disability and language impairment FAM19A1 intron 24024963 rs17047573 chr3 68411119 T G 8.35E-08 Cataracts in type 2 diabetes FAM19A1 intron 20664687 rs17047586 chr3 68412874 A G 7.65E-08 Cataracts in type 2 diabetes FAM19A1 intron 20664687 rs4855469 chr3 68458440 C T 3.00E-04 Response to interferon beta in multiple sclerosis FAM19A1 intron 18195134 rs9822547 chr3 68459113 A G 6.61E-04 Amyotrophic Lateral Sclerosis FAM19A1 intron 17362836 rs4277695 chr3 68462634 T C 4.07E-04 Bipolar disorder FAM19A1 intron 19259986 rs17047650 chr3 68464413 C T 0.0000319 Aging FAM19A1 intron 22445811 rs9850187 chr3 68468152 T C 3.73E-04 Amyotrophic Lateral Sclerosis FAM19A1 intron 17362836 rs876610 chr3 68470376 C A 5.83E-04 Amyotrophic Lateral Sclerosis FAM19A1 intron 17362836 rs4855475 chr3 68484388 A G 3.79E-05 Type 2 diabetes FAM19A1 intron 17463246 rs7634101 chr3 68485443 A G 0.0000872 Nonsyndromic striae distensae (stretch marks) FAM19A1 intron 23633020 rs73111013 chr3 68486196 G A 0.0000863 Nonsyndromic striae distensae (stretch marks) FAM19A1 intron 23633020 rs10433502 chr3 68487102 C T 0.0000349 Aging FAM19A1 intron 22445811 rs1858243 chr3 68545254 T C 8.00E-06 Urinary metabolites FAM19A1 intron 21572414 rs17245086 chr3 68583049 C A 9.73E-04 Multiple complex diseases FAM19A1 intron 17554300 rs17047811 chr3 68583643 T C 7.05E-04 HIV-1 viral setpoint FAM19A1 intron 17641165 rs1398072 chr3 68643676 A G 9.76E-04 Tourette syndrome / / 22889924 rs11721243 chr3 68650788 T C 9.17E-04 Tourette syndrome / / 22889924 rs4305427 chr3 68667357 A C 6.38E-04 Tourette syndrome / / 22889924 rs1504294 chr3 68749138 T G 5.50E-04 Obesity-related traits / / 17903300 rs6771218 chr3 68767391 G A 1.80E-04 Aortic root size / / 21223598 rs9856483 chr3 68776817 A G 8.64E-04 Tourette syndrome / / 22889924 rs6786379 chr3 68785967 A G 7.97E-04 Tourette syndrome FAM19A4 intron 22889924 rs12629919 chr3 68828723 A G 9.52E-04 Type 2 diabetes FAM19A4 intron 17463246 rs9851941 chr3 68837555 G A 1.16E-04 Amyotrophic lateral sclerosis FAM19A4 intron 20801718 rs1873264 chr3 68844213 A G 2.35E-05 Amyotrophic lateral sclerosis FAM19A4 intron 20801718 rs2171870 chr3 68905151 C G 9.90E-04 Multiple complex diseases FAM19A4 intron 17554300 rs6765918 chr3 68906466 G A 5.71E-04 Multiple complex diseases FAM19A4 intron 17554300 rs923512 chr3 68912531 A G 4.04E-05 Glucose levels FAM19A4 intron pha002899 rs11128100 chr3 68915052 T C 3.40E-04 Acute lung injury FAM19A4 intron 22295056 rs11128102 chr3 68918580 T C 3.47E-04 Acute lung injury FAM19A4 intron 22295056 rs13096541 chr3 68921682 A G 1.19E-04 Amyotrophic lateral sclerosis FAM19A4 intron 20801718 rs17048089 chr3 68923779 A G 3.84E-04 Acute lung injury FAM19A4 intron 22295056 rs17048091 chr3 68925778 A G 4.31E-04 Multiple complex diseases FAM19A4 intron 17554300 rs4855535 chr3 68934434 T G 5.71E-05 Glucose levels FAM19A4 UTR-5 pha002899 rs17048119 chr3 68940944 C G,T 5.86E-04 Suicide attempts in bipolar disorder FAM19A4 intron 21423239 rs6770678 chr3 68961010 C T 5.29E-04 Alcohol dependence FAM19A4 intron 21314694 rs9835177 chr3 68963038 A T 4.44E-05 Multiple complex diseases FAM19A4 intron 17554300 rs6787753 chr3 68995937 C A 2.25E-05 Lymphocyte counts / / pha003094 rs6787753 chr3 68995937 C A 2.55E-05 Neutrophil count / / pha003095 rs6785239 chr3 69001402 A G 2.63E-05 Lymphocyte counts / / pha003094 rs6785239 chr3 69001402 A G 2.96E-05 Neutrophil count / / pha003095 rs2033773 chr3 69034385 G T 7.42E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) C3orf64 intron 23648065 rs4411889 chr3 69045948 C T 3.12E-04 Type 2 diabetes C3orf64 intron 17463246 rs12488463 chr3 69063936 G A 1.81E-04 Type 2 diabetes / / 17463246 rs1745 chr3 69070457 G A 7.73E-05 Type 2 diabetes TMF1 UTR-3 17463246 rs9862298 chr3 69072761 T C 2.13E-04 Type 2 diabetes TMF1 intron 17463246 rs7375020 chr3 69073917 A G 3.90E-04 Type 2 diabetes TMF1 intron 17463246 rs937858 chr3 69082873 G T 2.25E-04 Type 2 diabetes TMF1 intron 17463246 rs2271121 chr3 69084161 C A 7.55E-05 Type 2 diabetes TMF1 intron 17463246 rs9809889 chr3 69087412 T G 4.18E-04 Type 2 diabetes TMF1 intron 17463246 rs2271118 chr3 69093598 T C 4.93E-06 Lymphocyte counts TMF1 intron 22286170 rs3853157 chr3 69126628 C T 6.01E-04 Coronary heart disease UBA3 intron 21606135 rs3772979 chr3 69127133 T C 9.38E-04 Coronary heart disease UBA3 intron 21606135 rs3853158 chr3 69137219 C T 5.47E-04 Age-related macular degeneration ARL6IP5 intron 22125219 rs6549184 chr3 69150277 G A 1.10E-04 Alcohol dependence ARL6IP5 intron 20201924 rs9824846 chr3 69166895 A G 4.53E-04 HIV-1 viral setpoint LMOD3 intron 17641165 rs7638995 chr3 69173375 C A 2.00E-06 Alzheimer's disease (late onset) / / 22881374 rs4525874 chr3 69197709 G C 5.67E-04 Multiple complex diseases / / 17554300 rs9310139 chr3 69217344 G C 2.23E-04 Multiple complex diseases / / 17554300 rs9831516 chr3 69230061 G A 5.67E-07 Multiple complex diseases FRMD4B missense 17554300 rs6772387 chr3 69252261 T C 7.60E-05 Diabetic retinopathy FRMD4B intron 21441570 rs4376041 chr3 69252443 A T 7.60E-05 Diabetic retinopathy FRMD4B intron 21441570 rs6781505 chr3 69252824 G A 7.90E-05 Diabetic retinopathy FRMD4B intron 21441570 rs6806528 chr3 69252899 C T 2.00E-07 Celiac disease FRMD4B intron 20190752 rs6806528 chr3 69252899 C T 8.00E-05 Diabetic retinopathy FRMD4B intron 21441570 rs6776027 chr3 69253455 T C 5.60E-05 Diabetic retinopathy FRMD4B intron 21441570 rs6784841 chr3 69253632 G A 5.60E-05 Diabetic retinopathy FRMD4B intron 21441570 rs4075188 chr3 69254120 G A 6.70E-05 Diabetic retinopathy FRMD4B intron 21441570 rs11128120 chr3 69266821 G A 7.75E-05 Potassium levels FRMD4B intron pha003086 rs13073189 chr3 69273132 T A 3.20E-05 Diabetic retinopathy FRMD4B intron 21441570 rs9849591 chr3 69274066 G A 2.27E-04 Amyotrophic lateral sclerosis (sporadic) FRMD4B intron 24529757 rs9840469 chr3 69274314 T C 7.83E-05 Potassium levels FRMD4B intron pha003086 rs4447768 chr3 69280903 C T 2.33E-04 Multiple complex diseases FRMD4B intron 17554300 rs1483892 chr3 69302563 A G 0.0007011 Sarcoidosis FRMD4B intron 22952805 rs6549198 chr3 69362959 A G 5.82E-05 Orofacial clefts FRMD4B intron 22419666 rs13066342 chr3 69369296 C A 5.28E-04 Nicotine smoking FRMD4B intron 19268276 rs12629229 chr3 69411222 T C 1.07E-05 Mathematical ability FRMD4B intron 24801482 rs17005675 chr3 69413674 G A 5.81E-04 Multiple complex diseases FRMD4B intron 17554300 rs6792404 chr3 69432044 C T 5.14E-05 Multiple complex diseases FRMD4B intron 17554300 rs12330712 chr3 69432555 A C 9.18E-04 Suicide attempts in bipolar disorder FRMD4B intron 21423239 rs13099017 chr3 69434145 A C 9.47E-04 Suicide attempts in bipolar disorder FRMD4B intron 21423239 rs17005789 chr3 69434867 T G 3.70E-04 Major depressive disorder FRMD4B intron 21042317 rs981053 chr3 69437217 C G 9.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs922948 chr3 69442637 G A 2.00E-06 Hip geometry / / 17903296 rs11128129 chr3 69454010 C T 7.20E-05 Body Mass Index / / pha003009 rs4855311 chr3 69456914 A G 2.02E-05 Body Mass Index / / pha003009 rs9846189 chr3 69459393 A G 1.81E-05 Body Mass Index / / pha003009 rs4855312 chr3 69463211 C T 1.81E-05 Body Mass Index / / pha003009 rs4855403 chr3 69463560 T C 1.70E-05 Body Mass Index / / pha003009 rs7625432 chr3 69477220 C T 7.35E-05 Body Mass Index / / pha003009 rs6795389 chr3 69483946 A G 9.58E-05 Body Mass Index / / pha003009 rs7631421 chr3 69507299 G C 0.0000226 Adenoma (female) / / 22532847 rs9843168 chr3 69513198 C T 1.26E-05 Prostate cancer / / 22923026 rs1498839 chr3 69516937 C T 5.02E-05 Cognitive performance / / 19734545 rs374977094 chr3 69516937 C CG 5.02E-05 Cognitive performance / / 19734545 rs10510980 chr3 69520888 T C 6.50E-04 Type 2 diabetes / / 17460697 rs9834457 chr3 69521568 T C 6.10E-05 Neuroticism / / 23229837 rs9869412 chr3 69523979 C T 9.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7647186 chr3 69540495 C T 2.77E-04 Smoking initiation / / 24665060 rs9822785 chr3 69554953 T C 4.19E-04 Depression (quantitative trait) / / 20800221 rs2133343 chr3 69555087 T G 4.21E-04 Depression (quantitative trait) / / 20800221 rs3947355 chr3 69555159 C A 5.28E-04 Depression (quantitative trait) / / 20800221 rs1498854 chr3 69560235 C G 6.06E-04 Depression (quantitative trait) / / 20800221 rs9843182 chr3 69564625 A G 6.10E-04 Depression (quantitative trait) / / 20800221 rs1391774 chr3 69566966 C T 6.91E-04 Depression (quantitative trait) / / 20800221 rs1391769 chr3 69573402 T C 6.42E-04 Depression (quantitative trait) / / 20800221 rs17006074 chr3 69582315 G A 9.10E-05 Cognitive impairment induced by topiramate / / 22091778 rs995829 chr3 69601480 A G 4.35E-04 Insulin resistance / / 21901158 rs904418 chr3 69616814 T C 7.29E-04 Smoking quantity / / 24665060 rs7647307 chr3 69623188 G A,T 0.000341142 Hypertension (early onset hypertension) / / 22479346 rs7623679 chr3 69640802 G T 3.30E-04 Response to antidepressants / / 19736353 rs10510985 chr3 69663871 C T 2.00E-04 Chronic fatigue syndrome / / 21912186 rs13086517 chr3 69694728 C A 2.00E-05 Urinary metabolites / / 21572414 rs17006293 chr3 69694906 C T 9.38E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs1559941 chr3 69700787 G T 2.72E-05 Alzheimer's disease / / 17998437 rs6549245 chr3 69705616 T C 9.90E-05 Myopia (pathological) / / 21640322 rs890595 chr3 69708931 C T 1.51E-04 Multiple complex diseases / / 17554300 rs9821048 chr3 69750087 T C 4.20E-05 Aortic root size / / 21223598 rs7613991 chr3 69762586 G T 4.72E-05 Response to metformin / / 21186350 rs6794315 chr3 69783567 T C 4.71E-05 Serum albumin level / / pha003084 rs12489786 chr3 69788068 T C 5.17E-04 Multiple complex diseases MITF nearGene-5 17554300 rs13073599 chr3 69808638 A G 5.51E-05 Glucose levels MITF intron pha003057 rs78356356 chr3 69824093 A G 5.00E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity MITF intron 24324551 rs6805563 chr3 69879323 G A 4.68E-05 Glucose levels MITF intron pha003057 rs17006615 chr3 70000216 T C 2.44E-04 Multiple complex diseases MITF intron 17554300 rs17006637 chr3 70036761 T C 8.66E-04 Type 2 diabetes / / 17463246 rs9863457 chr3 70037117 G C 0.000441 Breast cancer early age of onset / / 18463975 rs765015 chr3 70135943 G T 2.35E-04 Alzheimer's disease (late onset) / / 21379329 rs4855460 chr3 70146574 G T 4.57E-04 Schizophrenia / / 19197363 rs7639059 chr3 70161591 A C 2.18E-04 Celiac disease / / 23936387 rs7633462 chr3 70186696 G T 1.00E-04 Information processing speed / / 21130836 rs6549282 chr3 70204843 C A 2.22E-05 Cognitive impairment induced by topiramate / / 22091778 rs6549289 chr3 70224360 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4334612 chr3 70224889 C T 7.07E-05 Cognitive impairment induced by topiramate / / 22091778 rs7431876 chr3 70246225 C T 5.25E-05 Coronary heart disease / / pha003032 rs7623693 chr3 70248282 G T 1.05E-05 Body Mass Index / / pha003007 rs7623693 chr3 70248282 G T 7.24E-05 Weight / / pha003027 rs17006842 chr3 70259702 C T 2.82E-04 Multiple complex diseases / / 17554300 rs1546734 chr3 70286279 A G 4.76E-05 Cognitive impairment induced by topiramate / / 22091778 rs6549321 chr3 70320787 A T 1.50E-05 Urinary metabolites / / 21572414 rs6549322 chr3 70320864 T G 2.70E-05 Urinary metabolites / / 21572414 rs12634491 chr3 70329538 C T 1.44E-04 Sudden cardiac arrest / / 21658281 rs1111622 chr3 70330389 C T 3.99E-04 Type 2 diabetes / / 17463246 rs1105032 chr3 70330440 A C 1.61E-04 Type 2 diabetes / / 17463246 rs1105033 chr3 70330465 G A 1.99E-04 Type 2 diabetes / / 17463246 rs7646775 chr3 70348796 G A 1.70E-04 Type 2 diabetes / / 17463246 rs1403076 chr3 70348881 G A 1.70E-04 Type 2 diabetes / / 17463246 rs2030526 chr3 70352489 C T 4.37E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1403072 chr3 70373502 C T 8.27E-05 Body Fat Distribution / / pha003016 rs1403072 chr3 70373502 C T 4.20E-05 Body Fat Distribution / / pha003017 rs1403072 chr3 70373502 C T 2.35E-05 Body Fat Distribution / / pha003018 rs805469 chr3 70391905 T C 4.94E-04 Multiple complex diseases / / 17554300 rs1090502 chr3 70394223 A G 3.29E-05 Major depressive disorder / / 21621269 rs1090502 chr3 70394223 A G 8.12E-05 Major depressive disorder / / pha002850 rs805492 chr3 70406133 C A 2.38E-05 Creatinine levels / / pha003069 rs810912 chr3 70410209 G A 4.50E-06 Urinary metabolites / / 21572414 rs7643940 chr3 70413176 G T 5.00E-05 Sudden cardiac arrest / / 21658281 rs13314351 chr3 70417993 C T 1.60E-05 Hypothyroidism / / 22493691 rs805476 chr3 70426862 A G 3.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs805478 chr3 70427067 G T 3.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs1008411 chr3 70445977 T C 1.74E-04 Coronary heart disease / / 21971053 rs1024889 chr3 70463330 A G 6.00E-06 Body mass index / / 19851299 rs9820110 chr3 70469958 T G 2.03E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2874359 chr3 70482549 G C 4.25E-04 Multiple complex diseases / / 17554300 rs4974292 chr3 70516683 T C 2.77E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17789963 chr3 70517534 G C 7.11E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs7610220 chr3 70522017 G C 6.16E-04 Spine bone size / / 23207799 rs4638930 chr3 70528833 A G 1.90E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9830720 chr3 70543096 A G 6.82E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1491609 chr3 70550462 C A 5.95E-05 Cardiovascular disease / / 22029572 rs17790790 chr3 70565820 G A 9.91E-04 Common variable immunodeficiency / / 21497890 rs11128181 chr3 70608205 A C 4.85E-04 Amyotrophic lateral sclerosis / / 23624525 rs7628219 chr3 70626360 C T 2.00E-06 Insomnia (caffeine-induced) / / 22754043 rs4974301 chr3 70639463 G A 1.30E-04 Multiple complex diseases / / 17554300 rs725611 chr3 70671050 C A 8.29E-05 Multiple complex diseases / / 17554300 rs12631500 chr3 70671498 T C 8.15E-05 Multiple complex diseases / / 17554300 rs17792804 chr3 70673153 G C 1.64E-04 Multiple complex diseases / / 17554300 rs9828127 chr3 70674911 G C 8.11E-05 Multiple complex diseases / / 17554300 rs9864594 chr3 70681401 G A 2.10E-04 Multiple complex diseases / / 17554300 rs11915836 chr3 70684565 C T 1.00E-04 Prostate cancer / / 21743057 rs1907559 chr3 70693650 A T 1.87E-04 Multiple complex diseases / / 17554300 rs7626132 chr3 70698286 G C 1.96E-04 Multiple complex diseases / / 17554300 rs11128186 chr3 70704970 C T 6.96E-04 Multiple complex diseases / / 17554300 rs6549348 chr3 70730524 G A 6.00E-05 Prostate cancer / / 21743057 rs11918019 chr3 70784994 A G 3.51E-05 Multiple complex diseases / / 17554300 rs7633132 chr3 70791669 A C 1.51E-04 Multiple complex diseases / / 17554300 rs17007780 chr3 70807623 C T 9.12E-24 Narcolepsy / / 19629137 rs6763648 chr3 70807661 C T 6.83E-05 Multiple complex diseases / / 17554300 rs2117760 chr3 70850461 C A 5.50E-04 Intraocular pressure / / 22570627 rs10865656 chr3 70857460 T C 6.92E-05 Multiple complex diseases / / 17554300 rs7618715 chr3 70873278 G A 7.59E-04 Multiple complex diseases / / 17554300 rs1522552 chr3 70907252 A G 6.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2597301 chr3 70909494 C G 4.02E-04 Multiple complex diseases / / 17554300 rs1018340 chr3 70918127 G A 3.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2687201 chr3 70928930 A C 3.11E-04 Multiple complex diseases / / 17554300 rs2687201 chr3 70928930 A C 2.00E-06 Barrett's esophagus / / 24121790 rs2687201 chr3 70928930 A C 5.00E-09 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs2687201 chr3 70928930 A C 6.00E-07 Esophageal adenocarcinoma / / 24121790 rs2597312 chr3 70938609 C T 7.52E-04 Multiple complex diseases / / 17554300 rs17007999 chr3 70958673 A G 8.13E-04 Depression (quantitative trait) / / 20800221 rs9837992 chr3 70959438 G A 1.00E-04 Barrett's esophagus / / 24121790 rs9837992 chr3 70959438 G A 2.26E-06 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs9837992 chr3 70959438 G A 3.63E-05 Esophageal adenocarcinoma / / 24121790 rs6789153 chr3 71001255 C G 9.20E-06 Hepatitis B / / 21750111 rs17651978 chr3 71020490 G A 6.00E-06 Attention deficit hyperactivity disorder FOXP1 intron 18821565 rs17652341 chr3 71051352 T C 9.99E-04 Coronary Artery Disease FOXP1 intron 17634449 rs13093086 chr3 71055162 G A 5.00E-06 Intraocular pressure FOXP1 intron 24002674 rs9858444 chr3 71077031 T C 7.00E-05 Response to statin therapy FOXP1 intron 20339536 rs7653129 chr3 71079420 A G 6.20E-05 Response to statin therapy FOXP1 intron 20339536 rs6549371 chr3 71080759 G C 6.50E-05 Response to statin therapy FOXP1 intron 20339536 rs9861326 chr3 71081836 C A,T 6.70E-05 Response to statin therapy FOXP1 intron 20339536 rs9880715 chr3 71081865 A G 6.42E-04 Multiple complex diseases FOXP1 intron 17554300 rs9880715 chr3 71081865 A G 6.40E-05 Response to statin therapy FOXP1 intron 20339536 rs1288979 chr3 71103136 T C 5.90E-05 Response to statin therapy FOXP1 intron 20339536 rs1288980 chr3 71105863 A G 5.90E-05 Response to statin therapy FOXP1 intron 20339536 rs7616330 chr3 71115751 C A 6.00E-06 QT interval FOXP1 intron 23166209 rs10212561 chr3 71125604 T C 5.35E-05 Response to mTOR inhibitor (rapamycin) FOXP1 intron 24009623 rs2686268 chr3 71145830 A C 9.64E-04 Depression (quantitative trait) FOXP1 intron 20800221 rs831439 chr3 71154818 G A 7.98E-04 Aortic root size FOXP1 intron 21223598 rs3846029 chr3 71155119 T C 7.58E-04 Body mass index FOXP1 intron 21701565 rs3846028 chr3 71155250 T C 2.56E-04 Depression (quantitative trait) FOXP1 intron 20800221 rs831444 chr3 71158354 T C 3.97E-04 Depression (quantitative trait) FOXP1 intron 20800221 rs2121783 chr3 71174475 C T 8.86E-05 Schizophrenia (cytomegalovirus infection interaction) FOXP1 intron 23358160 rs11719587 chr3 71185630 T C 1.90E-04 HDL particle features FOXP1 intron 21283740 rs6800929 chr3 71199187 G A 1.01E-04 Acute lymphoblastic leukemia (childhood) FOXP1 intron 22076464 rs13097125 chr3 71199338 T G 2.35E-04 Smoking initiation FOXP1 intron 24665060 rs9829152 chr3 71200872 C T 3.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FOXP1 intron 20877124 rs7653672 chr3 71201454 G A 3.45E-05 Serum alpha1-antitrypsin levels FOXP1 intron 23990791 rs11923661 chr3 71202106 A C 2.34E-05 Serum alpha1-antitrypsin levels FOXP1 intron 23990791 rs1402994 chr3 71203369 G T 1.67E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FOXP1 intron 20877124 rs1402994 chr3 71203369 G T 1.70E-05 Hodgkin's lymphoma FOXP1 intron 24149102 rs1522178 chr3 71204263 C G 2.63E-05 Serum alpha1-antitrypsin levels FOXP1 intron 23990791 rs7623157 chr3 71225021 A G 8.64E-04 Obesity (extreme) FOXP1 intron 21935397 rs6549381 chr3 71256462 A C 5.98E-05 Relative hand skill in reading disability FOXP1 intron 24068947 rs6549382 chr3 71257082 T C 7.21E-05 Relative hand skill in reading disability FOXP1 intron 24068947 rs939840 chr3 71258187 C T 8.27E-05 Relative hand skill in reading disability FOXP1 intron 24068947 rs939841 chr3 71258386 T C 8.43E-05 Relative hand skill in reading disability FOXP1 intron 24068947 rs12714772 chr3 71260194 A G 6.95E-05 Relative hand skill in reading disability FOXP1 intron 24068947 rs17008389 chr3 71283516 A T 4.26E-04 Major depressive disorder FOXP1 intron 22472876 rs4055824 chr3 71292039 A G 3.08E-04 Coronary Artery Disease FOXP1 intron 17634449 rs17008402 chr3 71300567 A G 2.00E-06 Subcutaneous adipose tissue FOXP1 intron 22589738 rs17008404 chr3 71302616 T C 3.68E-05 Coronary Artery Disease FOXP1 intron 17634449 rs1541903 chr3 71324328 C T 5.20E-04 Rheumatoid arthritis FOXP1 intron 21452313 rs1288694 chr3 71324580 T C 1.10E-05 Urinary metabolites FOXP1 intron 21572414 rs1288825 chr3 71330949 C T 6.40E-05 Brain derived neurotrophic factor levels,in serum FOXP1 intron 22047184 rs6780738 chr3 71365496 G A 1.22E-04 Rheumatoid arthritis FOXP1 intron 21452313 rs4677035 chr3 71371734 A C 0.0000596 Follicular lymphoma FOXP1 intron 23025665 rs4677602 chr3 71379806 T C 0.0000181 Follicular lymphoma FOXP1 intron 23025665 rs7638193 chr3 71387060 C A,G,T 0.0000392 Follicular lymphoma FOXP1 intron 23025665 rs9859586 chr3 71396478 A G 0.0000377 Follicular lymphoma FOXP1 intron 23025665 rs4327353 chr3 71403694 T C 7.76E-04 Body mass index FOXP1 intron 21701565 rs4327353 chr3 71403694 T C 5.59E-05 Femoral neck bone geometry FOXP1 intron 22087292 rs17008544 chr3 71408319 C T 5.68E-05 Eosinophil counts FOXP1 UTR-5 pha003088 rs10511017 chr3 71410012 T C 0.0000189 Follicular lymphoma FOXP1 intron 23025665 rs13072512 chr3 71414045 A G 6.00E-06 IgG glycosylation FOXP1 intron 23382691 rs17717911 chr3 71417200 C T 7.15E-04 Multiple complex diseases FOXP1 intron 17554300 rs864386 chr3 71425370 G C 6.46E-05 Serum metabolites FOXP1 intron 19043545 rs831072 chr3 71427707 T C 3.29E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FOXP1 intron 24023788 rs9815974 chr3 71439472 G A 9.66E-06 Anxiety and major depressive disorder FOXP1 intron 24047446 rs13063872 chr3 71464335 G A 3.62E-05 Migraine with aura FOXP1 intron 23793025 rs13063872 chr3 71464335 G A 9.00E-06 Migraine - clinic-based FOXP1 intron 23793025 rs4369992 chr3 71479212 G A 1.70E-05 Immunoglobulin A FOXP1 intron 20694011 rs6803690 chr3 71501077 C T 1.17E-04 Multiple complex diseases FOXP1 intron 17554300 rs2135548 chr3 71501895 G A 1.46E-04 Hearing function FOXP1 intron 17255346 rs11706279 chr3 71517643 T C 9.30E-06 Behcet's disease FOXP1 intron 23291587 rs9819066 chr3 71523110 C T 6.82E-05 Vaspin levels FOXP1 intron 22907691 rs9819066 chr3 71523110 C T 0.0000682 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit FOXP1 intron 22907730 rs9819066 chr3 71523110 C T 7.07E-06 Behcet's disease FOXP1 intron 23291587 rs9819066 chr3 71523110 C T 0.00000415 Primary sclerosing cholangitis FOXP1 intron 23603763 rs9819066 chr3 71523110 C T 4.55E-06 Behcet's disease FOXP1 intron pha002888 rs6549391 chr3 71529915 A C 1.02E-04 Vaspin levels FOXP1 intron 22907691 rs6549391 chr3 71529915 A C 0.0001017 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit FOXP1 intron 22907730 rs6549391 chr3 71529915 A C 1.32E-05 Behcet's disease FOXP1 intron 23291587 rs9828629 chr3 71530346 C T 6.36E-05 Vaspin levels FOXP1 intron 22907691 rs9828629 chr3 71530346 C T 0.0000636 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit FOXP1 intron 22907730 rs9828629 chr3 71530346 C T 1.42E-05 Behcet's disease FOXP1 intron 23291587 rs9828629 chr3 71530346 C T 8.89E-06 Behcet's disease FOXP1 intron pha002888 rs6549392 chr3 71538696 G T 7.35E-05 Vaspin levels FOXP1 intron 22907691 rs6549392 chr3 71538696 G T 0.0000735 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit FOXP1 intron 22907730 rs6549392 chr3 71538696 G T 2.33E-05 Behcet's disease FOXP1 intron pha002888 rs11720523 chr3 71545170 C A 2.09E-05 Behcet's disease FOXP1 intron pha002888 rs6789751 chr3 71546744 T C 1.15E-05 Behcet's disease FOXP1 intron 23291587 rs6779258 chr3 71549639 T C 1.11E-05 Behcet's disease FOXP1 intron pha002888 rs17718783 chr3 71555553 C T 1.47E-04 Bipolar disorder FOXP1 intron 18317468 rs13071862 chr3 71562157 A G 9.48E-05 Hearing function FOXP1 intron 17255346 rs17008713 chr3 71566417 C T 3.70E-06 Vitiligo FOXP1 intron 21326295 rs17008723 chr3 71573135 T G 4.81E-08 Vitiligo FOXP1 intron 22561518 rs830604 chr3 71590347 C T 1.00E-05 Type 2 diabetes and 6 quantitative traits FOXP1 intron 17848626 rs11720121 chr3 71595258 T C 2.76E-05 Behcet's disease FOXP1 intron 23291587 rs11720121 chr3 71595258 T C 1.28E-05 Behcet's disease FOXP1 intron pha002888 rs6549400 chr3 71606466 T G 1.85E-05 Behcet's disease FOXP1 intron 23291587 rs6549400 chr3 71606466 T G 8.46E-06 Behcet's disease FOXP1 intron pha002888 rs878172 chr3 71622449 A G 3.35E-04 Multiple complex diseases FOXP1 intron 17554300 rs7643734 chr3 71652888 G A 9.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs9846001 chr3 71660196 A G 6.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs830637 chr3 71670465 T C 1.17E-06 Post-operative nausea and vomiting / / 21694509 rs10460943 chr3 71672306 C T 7.33E-05 Behcet's disease / / pha002888 rs830622 chr3 71677817 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs830611 chr3 71683947 G A 1.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs830609 chr3 71684904 A G 7.74E-05 Suicide attempts in bipolar disorder / / 21423239 rs830609 chr3 71684904 A G 6.75E-04 Response to alcohol consumption (flushing response) / / 24277619 rs830608 chr3 71685189 A G 1.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs12492625 chr3 71687846 G C 4.62E-04 Lymphocyte counts / / 22286170 rs704279 chr3 71711979 A G 5.75E-06 Scoliosis / / 21216876 rs704292 chr3 71726259 T C 1.75E-05 Tunica Media / / pha003034 rs3796226 chr3 71737107 A G 4.64E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) EIF4E3 intron 23648065 rs3796226 chr3 71737107 A G 1.55E-05 Tunica Media EIF4E3 intron pha003034 rs17008934 chr3 71745012 A G 8.66E-04 Depression (quantitative trait) EIF4E3 intron 20800221 rs4387935 chr3 71747831 A C 6.96E-04 Response to statin treatment (atorvastatin),change in cholesterol levels EIF4E3 intron 20031582 rs1447905 chr3 71748643 T C 3.36E-06 Waist circumference EIF4E3 intron 19557197 rs9790104 chr3 71750728 G C 7.64E-06 Waist circumference EIF4E3 intron 19557197 rs17664691 chr3 71753742 G T 0.0007449 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) EIF4E3 intron 23233654 rs17664691 chr3 71753742 G T 7.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) EIF4E3 intron 23233662 rs13098806 chr3 71753949 T C 1.67E-04 Depression (quantitative trait) EIF4E3 intron 20800221 rs13070781 chr3 71753986 G A 2.82E-05 Personality dimensions EIF4E3 intron 18957941 rs13070781 chr3 71753986 G A 2.80E-05 Personality dimensions EIF4E3 intron 21173776 rs17008958 chr3 71755488 G A 4.45E-06 Waist circumference EIF4E3 intron 19557197 rs9823269 chr3 71756375 A C 0.0001549 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) EIF4E3 intron 23233654 rs9823269 chr3 71756375 A C 1.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) EIF4E3 intron 23233662 rs4677039 chr3 71756765 C T 0.0002439 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) EIF4E3 intron 23233654 rs4677039 chr3 71756765 C T 2.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) EIF4E3 intron 23233662 rs13085841 chr3 71757540 T C 0.0002246 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) EIF4E3 intron 23233654 rs13085841 chr3 71757540 T C 2.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) EIF4E3 intron 23233662 rs13091306 chr3 71758197 T C 9.44E-04 Depression (quantitative trait) EIF4E3 intron 20800221 rs6775276 chr3 71768473 T A 4.59E-04 Gallstones EIF4E3 intron 17632509 rs4677042 chr3 71781701 C G 9.23E-04 Multiple complex diseases EIF4E3 intron 17554300 rs12629971 chr3 71783318 C T 2.19E-06 Longevity,exceptional EIF4E3 intron 20595579 rs12629971 chr3 71783318 C T 3.70E-04 Coronary heart disease EIF4E3 intron 21966275 rs12629971 chr3 71783318 C T 1.90E-06 Longevity EIF4E3 intron 22279548 rs11927001 chr3 71795224 A G 3.62E-05 Depression (quantitative trait) EIF4E3 intron 23290196 rs6801173 chr3 71795743 C T 7.94E-06 Rheumatoid arthritis EIF4E3 intron 19503088 rs6801173 chr3 71795743 C T 9.33E-06 Longevity,exceptional EIF4E3 intron 20595579 rs6801173 chr3 71795743 C T 8.16E-06 Longevity EIF4E3 intron 22279548 rs7635127 chr3 71832941 C A 1.25E-11 Cholesterol,total PROK2 intron 23063622 rs7635127 chr3 71832941 C A 1.58E-10 Triglycerides PROK2 intron 23063622 rs17665418 chr3 71849165 T A 2.57E-04 Type 2 diabetes / / 17463246 rs17665418 chr3 71849165 T A 1.24E-48 Multiple complex diseases / / 17554300 rs17721983 chr3 71855936 C T 2.98E-05 Type 2 diabetes / / 17463246 rs17665544 chr3 71858990 A G 9.69E-05 Type 2 diabetes / / 17463246 rs35535279 chr3 71871180 T C 7.82E-04 Multiple complex diseases / / 17554300 rs9812198 chr3 71879327 A G 1.33E-04 Height / / 17255346 rs9841733 chr3 71889603 T G 8.57E-08 Metabolite levels / / 23281178 rs7631578 chr3 71913071 A C 4.60E-04 Tourette syndrome / / 22889924 rs2322168 chr3 71930159 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17009073 chr3 71939885 G A 9.90E-04 Tourette syndrome / / 22889924 rs17009077 chr3 71941154 A G 3.50E-04 Tourette syndrome / / 22889924 rs1995453 chr3 71948799 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7616034 chr3 71951781 C T 2.69E-05 Brain structure / / 22504417 rs2874710 chr3 71956442 C T 4.70E-06 Urinary metabolites / / 21572414 rs6801579 chr3 71956808 T A 2.90E-05 Urinary metabolites / / 21572414 rs9841665 chr3 71956987 G A 2.90E-05 Urinary metabolites / / 21572414 rs6790891 chr3 71959310 T C 3.21E-05 Telomere length / / 23001564 rs9832640 chr3 71962547 C T 9.77E-04 Depression (quantitative trait) / / 20800221 rs7648163 chr3 71969532 A C 1.11E-06 Common variable immunodeficiency / / 21497890 rs7648163 chr3 71969532 A C 7.02E-04 Heart Failure / / pha002884 rs11718781 chr3 71971643 A G 9.35E-04 Tourette syndrome / / 22889924 rs7631897 chr3 71980643 G A 3.39E-05 Celiac disease / / 23936387 rs6808405 chr3 71995328 A C 3.66E-05 Aging (time to event) / / 21782286 rs12491110 chr3 72022752 G A 9.50E-06 Cognitive test performance / / 20125193 rs2135320 chr3 72023674 G A 6.42E-06 Bilirubin levels / / 22085899 rs2135319 chr3 72023700 G A 4.00E-06 Bilirubin levels / / 22085899 rs13080489 chr3 72035087 A C 4.37E-04 Multiple complex diseases / / 17554300 rs9860628 chr3 72043000 C T 7.90E-04 Alcohol dependence / / 20201924 rs9860628 chr3 72043000 C T 4.06E-04 Insulin resistance / / 21901158 rs4677073 chr3 72044909 T C 6.24E-04 Insulin resistance / / 21901158 rs9871415 chr3 72045130 C T 2.25E-05 Insulin resistance / / 21901158 rs1532870 chr3 72046220 T G 3.92E-05 Glucose levels / / pha003058 rs1532870 chr3 72046220 T G 4.94E-05 Diabetes Mellitus / / pha003059 rs9879563 chr3 72048692 A G 3.50E-05 Glucose levels / / pha003058 rs2174546 chr3 72050088 G A 8.43E-05 Attention deficit hyperactivity disorder / / 22420046 rs1547458 chr3 72128884 A C 4.62E-05 HIV-1 viral setpoint LOC285286 intron 22174851 rs6771316 chr3 72140532 G A 5.00E-09 Venous thromboembolism (gene x gene interaction) LOC285286 intron 23509962 rs11707080 chr3 72141723 G A 9.76E-04 Alzheimer's disease LOC285286 intron 24755620 rs1580953 chr3 72154835 T A 8.42E-05 Alcohol consumption / / 23743675 rs4677086 chr3 72158332 C G 8.72E-05 Alcohol consumption / / 23743675 rs9832693 chr3 72158910 A G 1.04E-05 Alcohol consumption / / 23743675 rs9836943 chr3 72159035 T G 1.11E-05 Alcohol consumption / / 23743675 rs6549438 chr3 72161233 T A 4.00E-06 Migraine - clinic-based / / 23793025 rs4677093 chr3 72167049 A T 6.53E-04 Type 2 diabetes / / 17846124 rs17009412 chr3 72171883 T C 4.45E-05 Diabetes Mellitus / / pha003059 rs17009412 chr3 72171883 T C 5.47E-06 Diabetes Mellitus / / pha003060 rs1505975 chr3 72177083 A G 1.25E-04 Smoking initiation / / 24665060 rs7618650 chr3 72177754 C T 7.90E-04 Alzheimer's disease / / 22005930 rs4676859 chr3 72181956 T C 9.80E-04 Multiple complex diseases / / 17554300 rs9863047 chr3 72199906 A C 7.59E-04 Multiple complex diseases / / 17554300 rs7629597 chr3 72207426 A C 5.97E-04 Multiple complex diseases LOC201617 intron 17554300 rs9816781 chr3 72217198 G A 6.08E-06 Glaucoma (primary open-angle) LOC201617 intron 22605921 rs6808099 chr3 72219675 C T 6.83E-05 Orofacial clefts LOC201617 intron 22419666 rs9829428 chr3 72227587 T C 1.82E-05 Hemoglobin / / pha003098 rs7644006 chr3 72227868 A G 8.14E-04 Multiple complex diseases / / 17554300 rs7632787 chr3 72228716 T C 1.54E-04 Insulin resistance / / 21901158 rs9917700 chr3 72238235 C G 7.20E-04 Insulin resistance / / 21901158 rs13327342 chr3 72275215 G T 6.21E-05 Schizophrenia / / 19571809 rs13327342 chr3 72275215 G T 3.68E-05 Schizophrenia / / pha002859 rs13074688 chr3 72278900 G A 6.37E-05 Schizophrenia / / 19571809 rs13074688 chr3 72278900 G A 3.73E-05 Schizophrenia / / pha002859 rs11128255 chr3 72286089 T C 3.99E-04 Alzheimer's disease / / 17998437 rs4525828 chr3 72294743 C T 4.48E-04 Rheumatoid arthritis / / 21452313 rs4532099 chr3 72315956 T C 2.20E-05 Personality dimensions / / 18957941 rs11715226 chr3 72326800 A T 1.80E-05 Urinary metabolites / / 21572414 rs4677135 chr3 72334859 T C 4.91E-04 Type 2 diabetes / / 17463246 rs4677135 chr3 72334859 T C 1.85E-05 ldl cholesterol / / pha003077 rs4677135 chr3 72334859 T C 7.37E-05 Cholesterol / / pha003083 rs9847707 chr3 72344971 A G 3.01E-06 Monocyte chemoattractant protein-1 / / pha003071 rs4128691 chr3 72349863 C T 8.44E-04 Type 2 diabetes / / 17463246 rs4128691 chr3 72349863 C T 8.40E-05 Male fertility / / 22633400 rs4128691 chr3 72349863 C T 9.57E-05 Monocyte chemoattractant protein-1 / / pha003071 rs9809213 chr3 72353932 G A 9.45E-05 Tunica Media / / pha003038 rs9682388 chr3 72354566 C A 1.18E-06 Amyotrophic lateral sclerosis / / 19193627 rs4073919 chr3 72361466 G A 7.83E-04 Type 2 diabetes / / 17463246 rs9820604 chr3 72363674 T C 3.79E-04 Smoking cessation / / 24665060 rs4676870 chr3 72365204 T C 7.85E-05 Monocyte chemoattractant protein-1 / / pha003071 rs9820851 chr3 72366285 G A 9.63E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11708375 chr3 72366790 G C 5.15E-05 Smoking cessation / / 24665060 rs9811454 chr3 72371525 C T 4.53E-05 Cholesterol / / pha003073 rs9811454 chr3 72371525 C T 8.49E-05 Cholesterol / / pha003078 rs13094012 chr3 72372395 T C 5.07E-04 Smoking cessation / / 24665060 rs2322431 chr3 72375939 A T 2.56E-04 Smoking cessation / / 24665060 rs9832740 chr3 72393141 G C 5.00E-13 Height / / 23563607 rs4677150 chr3 72393982 C G 9.01E-04 Type 2 diabetes / / 17463246 rs4677156 chr3 72417857 A T 4.77E-05 Serum metabolites / / 19043545 rs9863706 chr3 72437413 C T 4.00E-13 Height RYBP intron 20881960 rs10511023 chr3 72455447 G A 2.40E-04 Type 2 diabetes and 6 quantitative traits RYBP intron 17848626 rs6776427 chr3 72455707 G A 1.97E-04 Age-related macular degeneration RYBP intron 22125219 rs12493016 chr3 72481461 A C 8.28E-05 Soluble levels of adhesion molecules RYBP intron pha003072 rs11128271 chr3 72509271 T C 6.00E-06 IgG glycosylation / / 23382691 rs11128271 chr3 72509271 T C 6.00E-07 IgG glycosylation / / 23382691 rs10049211 chr3 72514676 T C 5.11E-06 Behcet's disease / / 23291587 rs10049211 chr3 72514676 T C 5.35E-06 Behcet's disease / / pha002888 rs11128275 chr3 72515960 G A 3.80E-05 Behcet's disease / / pha002888 rs934841 chr3 72516206 C T 5.91E-04 Multiple complex diseases / / 17554300 rs934841 chr3 72516206 C T 7.01E-04 Alzheimer's disease / / 17998437 rs9832314 chr3 72518040 A G 9.00E-06 IgG glycosylation / / 23382691 rs10222493 chr3 72523385 C T 1.70E-05 Urinary metabolites / / 21572414 rs7613906 chr3 72525387 T C 8.42E-05 Height / / pha003011 rs6775777 chr3 72533244 T C 5.86E-05 Bipolar disorder / / 19488044 rs6775777 chr3 72533244 T C 6.72E-05 Bipolar disorder and schizophrenia / / 20889312 rs6775777 chr3 72533244 T C 2.36E-05 Bipolar Disorder / / pha002858 rs10511022 chr3 72544196 C T 2.24E-05 Alcohol and nictotine co-dependence / / 20158304 rs10511022 chr3 72544196 C T 9.40E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9836156 chr3 72572216 T A 6.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs4677181 chr3 72576888 A G 2.00E-04 Vaspin levels / / 22907691 rs4677181 chr3 72576888 A G 0.0001999 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs11924047 chr3 72622532 A G 9.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs17010000 chr3 72648022 G A 7.54E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10049135 chr3 72648980 A G 4.65E-05 Nicotine dependence / / 17158188 rs1490504 chr3 72650355 G C 5.99E-04 Nicotine dependence / / 17158188 rs1873350 chr3 72650886 C T 3.09E-05 Body Mass Index / / pha003007 rs1873350 chr3 72650886 C T 3.34E-05 Waist Circumference / / pha003025 rs13076653 chr3 72655715 C T 0.00000416 Major depressive disorder / / 23149448 rs12714788 chr3 72657113 A C 2.60E-05 Major depressive disorder / / 21042317 rs12714788 chr3 72657113 A C 1.97E-05 Major depressive disorder / / 22472876 rs17678033 chr3 72657311 T C 2.31E-05 Major depressive disorder / / 22472876 rs4677197 chr3 72667611 G A 5.74E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4676887 chr3 72673025 G A 5.27E-04 Multiple complex diseases / / 17554300 rs7637028 chr3 72674925 A G 5.32E-05 Major depressive disorder / / 22472876 rs7639455 chr3 72675032 T C 6.34E-05 Major depressive disorder / / 22472876 rs4676888 chr3 72686090 G A 1.20E-05 Urinary metabolites / / 21572414 rs923572 chr3 72697011 G A 8.50E-05 Alcohol consumption (maxi-drinks) / / 24277619 rs1123121 chr3 72697160 G A 9.14E-05 Tunica Media / / pha003037 rs17010083 chr3 72707853 T A 2.14E-04 Cholesterol / / 17255346 rs6781545 chr3 72736603 A C 0.00009895 Sarcoidosis / / 22952805 rs17043990 chr3 72880470 T C 1.58E-06 Hypothyroidism SHQ1 intron 21981779 rs6808341 chr3 72914847 T C 4.77E-04 Multiple complex diseases / / 17554300 rs6808341 chr3 72914847 T C 3.51E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs13090900 chr3 72946560 C A 3.64E-04 Amyotrophic Lateral Sclerosis GXYLT2 intron 17362836 rs13089190 chr3 72958877 C T 6.10E-05 Coronary heart disease GXYLT2 intron 21606135 rs17010249 chr3 72959232 G A 7.78E-05 Coronary heart disease GXYLT2 intron 21606135 rs17010250 chr3 72959472 C G 8.90E-05 Coronary heart disease GXYLT2 intron 21606135 rs7649077 chr3 72964057 C T 2.00E-05 Coronary heart disease GXYLT2 intron 21606135 rs9876619 chr3 72971749 C T 1.20E-05 Urinary metabolites GXYLT2 intron 21572414 rs9876619 chr3 72971749 C T 2.75E-05 Coronary heart disease GXYLT2 intron 21606135 rs7640661 chr3 72973732 G A 3.83E-04 Coronary heart disease GXYLT2 intron 21606135 rs2134426 chr3 72973781 G C 2.49E-07 Multiple complex diseases GXYLT2 intron 17554300 rs2322692 chr3 72980177 G A 9.81E-05 Height GXYLT2 intron pha003011 rs2322693 chr3 72982575 A G 9.06E-05 Height GXYLT2 intron pha003011 rs17742733 chr3 73004580 T A 3.10E-04 Coronary heart disease GXYLT2 intron 21606135 rs17691949 chr3 73010363 A G 1.77E-04 Coronary heart disease GXYLT2 intron 21606135 rs6793043 chr3 73020764 T C 8.13E-05 Serum metabolites GXYLT2 intron 19043545 rs9862032 chr3 73022032 G A 2.40E-06 Coronary heart disease GXYLT2 intron 22319020 rs1052278 chr3 73024350 C A 2.40E-05 Height GXYLT2 UTR-3 pha003011 rs12638019 chr3 73091447 T G 7.65E-05 Cognitive performance PPP4R2 intron 19734545 rs9824246 chr3 73102725 A G 9.95E-05 Nicotine smoking PPP4R2 intron 19268276 rs902652 chr3 73131351 G A 1.50E-06 Coronary spasm / / 18075462 rs6766673 chr3 73157288 T C 2.61E-04 Alzheimer's disease (late onset) / / 21379329 rs9835056 chr3 73179320 T C 9.00E-04 Alcohol dependence / / 20201924 rs10460946 chr3 73180606 T G 7.36E-04 Coronary Artery Disease / / 17634449 rs7636585 chr3 73251964 A G 8.40E-05 Primary sclerosing cholangitis / / 19944697 rs11128317 chr3 73252141 T A,C 4.50E-05 Primary sclerosing cholangitis / / 19944697 rs9826629 chr3 73252662 C T 3.28E-04 Multiple complex diseases / / 17554300 rs17751397 chr3 73261224 C T 6.65E-05 Cholesterol / / pha003073 rs4676908 chr3 73274994 G A 3.45E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs11128319 chr3 73275553 G C 1.53E-04 Multiple complex diseases / / 17554300 rs12486903 chr3 73276952 T C 8.93E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs574715 chr3 73305809 G A 2.30E-05 Urinary metabolites / / 21572414 rs574715 chr3 73305809 G A 6.93E-06 Parent of origin effect on language impairment (child trend) / / 24571439 rs671986 chr3 73308948 G A 1.02E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs656016 chr3 73310251 T G 1.30E-05 Urinary metabolites / / 21572414 rs13099495 chr3 73370625 A G 0.00000478 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs4677261 chr3 73374442 T C 5.03E-05 Response to citalopram treatment / / 19846067 rs7612030 chr3 73375196 T C 2.00E-05 Urinary metabolites / / 21572414 rs966163 chr3 73375302 G A 6.54E-05 Response to citalopram treatment / / 19846067 rs6764873 chr3 73375371 T C 2.00E-05 Urinary metabolites / / 21572414 rs4677262 chr3 73376013 C T 4.69E-05 Response to citalopram treatment / / 19846067 rs7647234 chr3 73378844 A G 7.88E-04 Type 2 diabetes / / 17463246 rs7647311 chr3 73378879 A G 6.49E-04 Type 2 diabetes / / 17463246 rs11710982 chr3 73398839 A G 1.80E-04 Primary sclerosing cholangitis / / 19944697 rs11710982 chr3 73398839 A G 2.20E-05 Urinary metabolites / / 21572414 rs13070556 chr3 73399384 C T 3.76E-04 Taste perception / / 22132133 rs9866906 chr3 73405263 A C 1.20E-04 Primary sclerosing cholangitis / / 19944697 rs11128329 chr3 73411670 C T 8.48E-05 Hypertension (essential hypertension) / / 22184326 rs3912601 chr3 73411687 C T 5.94E-06 Taste perception / / 22132133 rs12638564 chr3 73413820 G A 1.00E-04 Information processing speed / / 21130836 rs3816831 chr3 73450198 G A 3.79E-04 Alcohol dependence PDZRN3 intron 21314694 rs13063715 chr3 73476665 T C 1.00E-04 Prostate cancer PDZRN3 intron 21743057 rs9883532 chr3 73489259 A G 3.31E-04 Multiple complex diseases PDZRN3 intron 17554300 rs6549543 chr3 73520059 A G 7.80E-06 Urinary metabolites PDZRN3 intron 21572414 rs4557101 chr3 73540618 T C 4.00E-06 QT interval PDZRN3 intron 23166209 rs12632755 chr3 73548335 C T 4.20E-04 Alcohol dependence PDZRN3 intron 20201924 rs12632755 chr3 73548335 C T 5.60E-04 Alcohol dependence PDZRN3 intron 20201924 rs12632755 chr3 73548335 C T 7.97E-04 Myocardial Infarction PDZRN3 intron pha002873 rs12632758 chr3 73548400 C T 4.90E-04 Alcohol dependence PDZRN3 intron 20201924 rs12632758 chr3 73548400 C T 6.50E-04 Alcohol dependence PDZRN3 intron 20201924 rs9842067 chr3 73601210 A G 9.43E-04 Multiple complex diseases PDZRN3 intron 17554300 rs11128347 chr3 73619561 G C 6.00E-07 Dialysis-related mortality PDZRN3 intron 21546767 rs9830956 chr3 73636020 G A 5.11E-04 Prostate cancer mortality PDZRN3 intron 20978177 rs1022170 chr3 73705297 A C 3.46E-06 Pulmonary function / / 19300500 rs1022170 chr3 73705297 A C 3.10E-06 Pulmonary function / / 20010835 rs2036893 chr3 73706022 G A 3.47E-06 Pulmonary function / / 19300500 rs2036893 chr3 73706022 G A 3.10E-06 Pulmonary function / / 20010835 rs11128357 chr3 73708530 A C 1.01E-05 Pulmonary function / / 19300500 rs11128357 chr3 73708530 A C 2.23E-05 Pulmonary function / / 20010835 rs1858325 chr3 73710372 G A 1.48E-05 Pulmonary function / / 19300500 rs1858325 chr3 73710372 G A 2.85E-05 Pulmonary function / / 20010835 rs4677325 chr3 73710707 A G 1.49E-05 Pulmonary function / / 19300500 rs4677325 chr3 73710707 A G 2.84E-05 Pulmonary function / / 20010835 rs4677326 chr3 73710752 C G 1.49E-05 Pulmonary function / / 19300500 rs4677326 chr3 73710752 C G 2.83E-05 Pulmonary function / / 20010835 rs9310279 chr3 73710945 T C 1.50E-05 Pulmonary function / / 19300500 rs9310279 chr3 73710945 T C 2.90E-05 Pulmonary function / / 20010835 rs9847694 chr3 73711625 T A 1.77E-05 Pulmonary function / / 19300500 rs9847694 chr3 73711625 T A 2.83E-05 Pulmonary function / / 20010835 rs9824294 chr3 73711635 C T 1.51E-05 Pulmonary function / / 19300500 rs9824294 chr3 73711635 C T 2.75E-05 Pulmonary function / / 20010835 rs1511521 chr3 73711863 C T 1.52E-05 Pulmonary function / / 19300500 rs1511521 chr3 73711863 C T 2.74E-05 Pulmonary function / / 20010835 rs1355467 chr3 73714140 T C 2.02E-05 Pulmonary function / / 19300500 rs1355467 chr3 73714140 T C 5.58E-05 Pulmonary function / / 20010835 rs1039956 chr3 73714843 T A 1.72E-05 Pulmonary function / / 19300500 rs1039956 chr3 73714843 T A 4.74E-05 Pulmonary function / / 20010835 rs1912769 chr3 73715891 G T 4.63E-04 Alzheimer's disease (late onset) / / 21379329 rs1039955 chr3 73716064 T C 2.35E-05 Pulmonary function / / 19300500 rs1039955 chr3 73716064 T C 5.55E-05 Pulmonary function / / 20010835 rs2875192 chr3 73716503 C T 2.96E-04 Alzheimer's disease (late onset) / / 21379329 rs12493615 chr3 73719148 T C 3.50E-04 Alzheimer's disease (late onset) / / 21379329 rs4677328 chr3 73719944 A T 7.67E-06 Pulmonary function / / 19300500 rs4677328 chr3 73719944 A T 2.32E-05 Pulmonary function / / 20010835 rs1877252 chr3 73727540 T C 6.98E-06 Pulmonary function / / 19300500 rs1877252 chr3 73727540 T C 1.54E-05 Pulmonary function / / 20010835 rs9790264 chr3 73731306 C T 5.04E-06 Pulmonary function / / 19300500 rs9790264 chr3 73731306 C T 1.63E-05 Pulmonary function / / 20010835 rs9790092 chr3 73731538 G A 4.63E-06 Pulmonary function / / 19300500 rs9790092 chr3 73731538 G A 1.40E-05 Pulmonary function / / 20010835 rs994960 chr3 73731916 G A 4.53E-06 Pulmonary function / / 19300500 rs994960 chr3 73731916 G A 1.45E-05 Pulmonary function / / 20010835 rs6777769 chr3 73735358 C G 5.21E-06 Pulmonary function / / 19300500 rs6777769 chr3 73735358 C G 1.57E-05 Pulmonary function / / 20010835 rs11918578 chr3 73736121 G A 6.04E-06 Pulmonary function / / 19300500 rs11918578 chr3 73736121 G A 1.66E-05 Pulmonary function / / 20010835 rs1567573 chr3 73737353 G T 7.13E-05 Pulmonary function / / 19300500 rs1567574 chr3 73737467 T C 6.63E-06 Pulmonary function / / 19300500 rs1567574 chr3 73737467 T C 1.96E-05 Pulmonary function / / 20010835 rs1543070 chr3 73749237 T C 1.82E-05 Pulmonary function / / 19300500 rs1543070 chr3 73749237 T C 4.56E-05 Pulmonary function / / 20010835 rs2137064 chr3 73750993 A G 1.01E-05 Pulmonary function / / 19300500 rs2137064 chr3 73750993 A G 1.82E-05 Pulmonary function / / 20010835 rs9868151 chr3 73751432 A C 1.02E-05 Pulmonary function / / 19300500 rs9868151 chr3 73751432 A C 1.74E-05 Pulmonary function / / 20010835 rs4494867 chr3 73755403 C T 1.64E-05 Pulmonary function / / 19300500 rs4494867 chr3 73755403 C T 1.73E-05 Pulmonary function / / 20010835 rs13096120 chr3 73756085 G A 5.12E-05 Pulmonary function / / 19300500 rs13096120 chr3 73756085 G A 6.23E-05 Pulmonary function / / 20010835 rs6787034 chr3 73764542 A G 3.94E-05 Pulmonary function / / 20010835 rs952708 chr3 73767193 C T 3.28E-05 Pulmonary function / / 20010835 rs1511531 chr3 73767504 C T 3.29E-05 Pulmonary function / / 20010835 rs1877256 chr3 73769502 G A 8.55E-05 Pulmonary function / / 20010835 rs4676946 chr3 73778404 T C 2.04E-04 Type 2 diabetes / / 17463246 rs10865679 chr3 73781217 T C 1.97E-05 Type 2 diabetes / / 17463246 rs10865679 chr3 73781217 T C 1.60E-05 Urinary metabolites / / 21572414 rs2874965 chr3 73786144 T C 6.22E-05 Type 2 diabetes / / 17463246 rs2874965 chr3 73786144 T C 2.30E-05 Urinary metabolites / / 21572414 rs291475 chr3 73800888 C G 6.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs291479 chr3 73809294 G A 8.25E-04 Type 2 diabetes / / 17463246 rs6780964 chr3 73854671 G A 3.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs291533 chr3 73861878 C T 2.29E-04 Taste perception / / 22132133 rs9848344 chr3 73869793 G A 8.00E-05 Malaria / / 19465909 rs4627704 chr3 73871925 C T 0.0007549 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4627704 chr3 73871925 C T 7.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs907336 chr3 73877100 G A 3.90E-05 Taste perception / / 22132133 rs291484 chr3 73877349 G A 3.43E-04 Type 2 diabetes / / 17463246 rs291484 chr3 73877349 G A 7.46E-04 Taste perception / / 22132133 rs4676955 chr3 73899756 G C 4.91E-04 Multiple complex diseases / / 17554300 rs1372248 chr3 73918067 C T 4.85E-04 Smoking initiation / / 24665060 rs10460948 chr3 73946281 A G 1.23E-04 Prion diseases / / 22210626 rs5012667 chr3 73958469 T C 1.62E-04 Celiac disease / / 23936387 rs1405402 chr3 73971120 G A,C,T 1.90E-04 Myopia (pathological) / / 21095009 rs13098784 chr3 73971723 T G 3.04E-05 Serum metabolites / / 19043545 rs941068 chr3 73974792 C T 1.00E-04 Prostate cancer / / 21743057 rs1918101 chr3 73976238 G T 2.32E-04 Myopia (pathological) / / 21095009 rs6770247 chr3 73976514 G A 1.00E-04 Prostate cancer / / 21743057 rs10048995 chr3 73976539 C G,T 1.00E-04 Prostate cancer / / 21743057 rs1526717 chr3 73980833 C T 9.59E-05 Type 2 diabetes / / 17463246 rs9865110 chr3 73981773 A C 1.80E-05 Endometriosis / / 21151130 rs9865110 chr3 73981773 A C 9.03E-05 Cognitive impairment induced by topiramate / / 22091778 rs11718192 chr3 73987905 A G 5.60E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13325429 chr3 73991897 C T 5.21E-04 Multiple complex diseases / / 17554300 rs12494782 chr3 74060951 C T 2.32E-05 Coronary heart disease / / pha003032 rs6783757 chr3 74094657 A G 6.50E-07 Urinary metabolites / / 21572414 rs1526727 chr3 74095314 C T 5.20E-07 Urinary metabolites / / 21572414 rs1526728 chr3 74095484 T C 6.10E-07 Urinary metabolites / / 21572414 rs4677373 chr3 74097623 G A 2.95E-04 Smoking initiation / / 24665060 rs2197713 chr3 74169348 A G 3.48E-04 Diabetic retinopathy / / 20871662 rs17762788 chr3 74175656 G T 4.86E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs278392 chr3 74177720 T A 5.70E-05 Parkinson's disease (age of onset) / / 19772629 rs278405 chr3 74191690 G A 9.05E-06 Job-related exhaustion / / 23620144 rs278466 chr3 74218884 A G 5.23E-04 Smoking initiation / / 24665060 rs7627251 chr3 74219054 C T 4.13E-04 Smoking initiation / / 24665060 rs1005940 chr3 74221493 A G 4.48E-04 Smoking initiation / / 24665060 rs278468 chr3 74222026 T G 2.79E-04 Smoking initiation / / 24665060 rs278472 chr3 74226790 G T 5.01E-04 Smoking initiation / / 24665060 rs664864 chr3 74305127 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs541653 chr3 74321141 C T 2.93E-05 Tunica Media CNTN3 intron pha003036 rs668645 chr3 74324790 C A 6.60E-04 Multiple complex diseases CNTN3 intron 17554300 rs6779469 chr3 74343804 G A 1.91E-05 Weight CNTN3 intron pha003026 rs10490832 chr3 74344356 T G 5.20E-04 Suicidal ideation CNTN3 cds-synon 22030708 rs10490832 chr3 74344356 T G 6.85E-05 Bipolar disorder CNTN3 cds-synon 22925353 rs502114 chr3 74345242 A T 2.60E-05 Urinary metabolites CNTN3 intron 21572414 rs1545384 chr3 74352261 C A 5.20E-04 Suicidal ideation CNTN3 intron 22030708 rs487087 chr3 74379786 G C 1.70E-05 Urinary metabolites CNTN3 intron 21572414 rs503058 chr3 74383222 C T 1.60E-05 Urinary metabolites CNTN3 intron 21572414 rs12634243 chr3 74383419 G C 9.90E-06 Urinary metabolites CNTN3 intron 21572414 rs554676 chr3 74385011 C G 2.30E-06 Urinary metabolites CNTN3 intron 21572414 rs7613439 chr3 74442523 T C 4.54E-06 Insulin resistance CNTN3 intron 21901158 rs7613439 chr3 74442523 T C 2.67E-04 Response to cytadine analogues (cytosine arabinoside) CNTN3 intron 24483146 rs6780510 chr3 74447090 T C 3.50E-05 Coronary heart disease CNTN3 intron pha003030 rs4677395 chr3 74471410 T C 1.23E-05 Height CNTN3 intron 22021425 rs6549604 chr3 74545777 T C 3.20E-04 Cholesterol CNTN3 intron 17255346 rs9876789 chr3 74545880 G A 5.41E-04 Multiple complex diseases CNTN3 intron 17554300 rs7430259 chr3 74563488 C T 2.20E-05 Obesity-related traits CNTN3 intron 17658951 rs7430822 chr3 74564816 C A 4.25E-04 Multiple complex diseases CNTN3 intron 17554300 rs4676973 chr3 74565355 C A 6.33E-04 Myopia (pathological) CNTN3 intron 21095009 rs9814206 chr3 74573227 G T 4.47E-04 Smoking quantity / / 24665060 rs6767471 chr3 74577921 C T 3.21E-05 Orofacial clefts / / 19270707 rs9831609 chr3 74584605 A C 4.50E-06 Orofacial clefts / / 19270707 rs9836097 chr3 74591012 A G 7.74E-06 Asthma (childhood onset) / / 23829686 rs4677414 chr3 74607020 A G 1.43E-05 Orofacial clefts / / 19270707 rs2323570 chr3 74608373 C T 5.17E-04 Smoking quantity / / 24665060 rs11928037 chr3 74616253 G T 0.00000827 Asthma / / 22694930 rs7630534 chr3 74625123 A G 0.00000122 Asthma / / 22694930 rs13073838 chr3 74627703 T C 7.96E-05 Alzheimer's disease (late onset) / / 21379329 rs13073838 chr3 74627703 T C 3.00E-06 Economic and political preferences / / 22566634 rs1579905 chr3 74628590 T C 7.83E-04 Multiple complex diseases / / 17554300 rs1374879 chr3 74635097 T C 8.00E-06 Smoking quantity / / 24665060 rs6792938 chr3 74661433 T A 2.65E-04 Smoking initiation / / 24665060 rs17012697 chr3 74672571 C T 0.0000597 Asthma / / 22694930 rs6775796 chr3 74703689 G A 7.93E-05 Cognitive impairment induced by topiramate / / 22091778 rs935523 chr3 74710819 C A 4.80E-05 Tooth agenesis (mandibular third molar) / / 24172245 rs1447826 chr3 74718758 T C 1.10E-16 Pancreatic cancer / / 21849791 rs6762970 chr3 74742625 T A 1.90E-05 Urinary metabolites / / 21572414 rs6762970 chr3 74742625 T A 0.0000174 Adenoma / / 22532847 rs9879684 chr3 74753994 C T 1.00E-06 Urinary metabolites / / 21572414 rs7642555 chr3 74769420 A G 8.60E-07 Urinary metabolites / / 21572414 rs9861122 chr3 74770447 T C 7.50E-07 Urinary metabolites / / 21572414 rs9837543 chr3 74770492 C T 2.20E-06 Urinary metabolites / / 21572414 rs11924855 chr3 74775136 C T 2.20E-06 Urinary metabolites / / 21572414 rs4131575 chr3 74775497 C T 2.20E-06 Urinary metabolites / / 21572414 rs7635818 chr3 74783476 G C 4.10E-04 Abdominal aortic aneurysm / / 19497516 rs13061773 chr3 74787022 A G 2.90E-06 Urinary metabolites / / 21572414 rs6549652 chr3 74790990 C A 1.70E-06 Urinary metabolites / / 21572414 rs6549654 chr3 74791125 A G 7.80E-06 Urinary metabolites / / 21572414 rs1918399 chr3 74812194 A T 8.80E-04 Multiple complex diseases / / 17554300 rs12714812 chr3 74813002 A G 1.20E-05 Urinary metabolites / / 21572414 rs9859437 chr3 74816460 A G 9.70E-06 Urinary metabolites / / 21572414 rs9827925 chr3 74834053 C T 3.00E-06 Urinary metabolites / / 21572414 rs7651319 chr3 74836374 T C 4.40E-06 Urinary metabolites / / 21572414 rs1527527 chr3 74836946 G T 3.00E-06 Urinary metabolites / / 21572414 rs1918392 chr3 74880857 A G 5.22E-04 Alcohol dependence / / 20201924 rs941304 chr3 74887781 C T 6.24E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs1918394 chr3 74903904 T C 2.30E-05 Urinary metabolites / / 21572414 rs4417905 chr3 74916063 A G 6.60E-06 Urinary metabolites / / 21572414 rs12630469 chr3 74955581 G A 6.41E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs4420916 chr3 74989983 A G 7.11E-05 Postoperative ventricular dysfunction / / 21980348 rs7618969 chr3 75003489 G A 8.60E-05 Endometriosis / / 21151130 rs7618969 chr3 75003489 G A 7.33E-04 Taste perception / / 22132133 rs4428227 chr3 75063638 C T 7.42E-04 Multiple complex diseases / / 17554300 rs4676989 chr3 75064460 C T 3.91E-04 Multiple complex diseases / / 17554300 rs9863767 chr3 75081957 C A 4.19E-05 Postoperative ventricular dysfunction / / 21980348 rs4635750 chr3 75097869 G A 4.63E-05 Postoperative ventricular dysfunction / / 21980348 rs12486094 chr3 75127552 T C 8.11E-05 Postoperative ventricular dysfunction / / 21980348 rs9310315 chr3 75166496 C T 5.26E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs12636203 chr3 75186326 C T 4.54E-04 Endometrial cancer / / 24096698 rs7430216 chr3 75201030 C T 7.41E-04 Acute lung injury / / 22295056 rs12186094 chr3 75217530 G A 8.83E-04 Taste perception / / 22132133 rs6803834 chr3 75221611 C T 3.20E-05 Type 2 diabetes / / 17463246 rs9810161 chr3 75222937 A G 3.94E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs9828201 chr3 75245774 C T 9.86E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs4677485 chr3 75257002 C T 6.86E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs4072316 chr3 75269488 C G 1.06E-04 Acute lung injury / / 22295056 rs12495867 chr3 75275099 A G 1.06E-04 Acute lung injury / / 22295056 rs12491189 chr3 75278358 C T 1.06E-04 Acute lung injury / / 22295056 rs7430900 chr3 75292707 T G 7.23E-04 Acute lung injury / / 22295056 rs6768580 chr3 75374095 C T 1.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4677496 chr3 75377715 C T 2.77E-04 Multiple complex diseases / / 17554300 rs4677496 chr3 75377715 C T 0.000134 Salmonella-induced pyroptosis / / 22837397 rs2091870 chr3 75382434 C T 5.27E-04 Heart Failure / / pha002885 rs145339139 chr3 75641711 T G 8.51E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs352398 chr3 75727056 A C,G,T 2.81E-06 Coronary arterial lesions in patients with Kawasaki disease LOC401074 intron 23677057 rs76875512 chr3 75754704 G A 3.08E-06 Coronary arterial lesions in patients with Kawasaki disease / / 23677057 rs9865038 chr3 75754704 G A 3.08E-06 Coronary arterial lesions in patients with Kawasaki disease / / 23677057 rs200986341 chr3 75787540 T C 2.81E-06 Coronary arterial lesions in patients with Kawasaki disease ZNF717 missense 23677057 rs138304140 chr3 75789971 G A 3.99E-05 Bilirubin levels,in serum ZNF717 intron 19389676 rs3887345 chr3 75803471 T C 5.12E-05 Myopia (pathological) ZNF717 intron 21640322 rs7429112 chr3 75913502 C A 4.77E-04 Multiple complex diseases / / 17554300 rs7429112 chr3 75913502 C A 4.21E-05 Aortic root size / / 21223598 rs2220458 chr3 76110145 C A 5.52E-04 Parkinson's disease ROBO2 intron 17052657 rs1489092 chr3 76121506 T C 1.00E-04 Type 2 diabetes ROBO2 intron 17903298 rs1489091 chr3 76121631 C T 1.10E-04 Type 2 diabetes and 6 quantitative traits ROBO2 intron 17848626 rs1489100 chr3 76132564 C T 7.00E-04 Type 2 diabetes and 6 quantitative traits ROBO2 intron 17848626 rs6806589 chr3 76148360 C T 7.02E-05 Lung adenocarcinoma ROBO2 intron 19836008 rs17577450 chr3 76153036 G A 6.88E-04 Type 2 diabetes ROBO2 intron 17463246 rs1400237 chr3 76172232 T G 5.37E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ROBO2 intron 24023788 rs17013887 chr3 76206413 A C 6.61E-04 Multiple complex diseases ROBO2 intron 17554300 rs4856011 chr3 76225482 T C 2.70E-05 Soluble levels of adhesion molecules ROBO2 intron pha003072 rs1516459 chr3 76261820 T C 3.00E-06 Eating disorders (purging via substances) ROBO2 intron 23568457 rs4855973 chr3 76262385 T C 4.95E-04 Multiple complex diseases ROBO2 intron 17554300 rs17140566 chr3 76296672 A T 8.00E-04 Acute lymphoblastic leukemia (childhood) ROBO2 intron 20189245 rs7613428 chr3 76301369 T C 8.00E-04 Acute lymphoblastic leukemia (childhood) ROBO2 intron 20189245 rs4855978 chr3 76358868 G T 5.00E-04 Acute lymphoblastic leukemia (childhood) ROBO2 intron 20189245 rs3860545 chr3 76406576 A C 8.00E-04 Acute lymphoblastic leukemia (childhood) ROBO2 intron 20189245 rs7611506 chr3 76413820 T C 1.00E-04 Acute lymphoblastic leukemia (childhood) ROBO2 intron 20189245 rs10511047 chr3 76455579 C G 4.10E-04 Type 2 diabetes and 6 quantitative traits ROBO2 intron 17848626 rs3849487 chr3 76464458 C G 8.34E-04 Multiple complex diseases ROBO2 intron 17554300 rs3849487 chr3 76464458 C G 6.34E-05 Serum metabolites ROBO2 intron 19043545 rs3849488 chr3 76464685 G A 7.74E-06 Asthma (childhood onset) ROBO2 intron 23829686 rs7616894 chr3 76464816 G C 5.00E-04 Acute lymphoblastic leukemia (childhood) ROBO2 intron 20189245 rs9875646 chr3 76469652 C T 7.01E-04 Multiple complex diseases ROBO2 intron 17554300 rs13072871 chr3 76473371 G A 5.80E-04 Smoking cessation ROBO2 intron 24665060 rs10514733 chr3 76483391 G A 2.58E-04 Insulin resistance ROBO2 intron 21901158 rs3849491 chr3 76484183 T C 6.00E-06 Sex hormone-binding globulin levels ROBO2 intron 22675492 rs7612860 chr3 76489848 T C 5.28E-04 Coronary heart disease ROBO2 intron 21971053 rs3913578 chr3 76515427 A G 2.40E-05 Urinary metabolites ROBO2 intron 21572414 rs9883120 chr3 76516505 C G 8.03E-05 Acute lymphoblastic leukemia (childhood) ROBO2 intron 19684603 rs3849498 chr3 76526866 C T 2.90E-05 Personality dimensions ROBO2 intron 22628180 rs3849499 chr3 76533656 T C 2.69E-05 Personality dimensions ROBO2 intron 22628180 rs9878750 chr3 76546187 C A 6.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ROBO2 intron 20877124 rs7431017 chr3 76551403 C A 1.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ROBO2 intron 20877124 rs12497354 chr3 76570616 G A 3.45E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ROBO2 intron 24023788 rs3913574 chr3 76575853 A G 7.25E-04 Obesity (extreme) ROBO2 intron 21935397 rs11127548 chr3 76598690 T C 5.35E-04 Obesity (extreme) ROBO2 intron 21935397 rs1447793 chr3 76620047 G A 5.10E-05 Eosinophil counts ROBO2 intron pha003088 rs6793784 chr3 76653139 C T 1.20E-04 Amyotrophic lateral sclerosis (sporadic) ROBO2 intron 24529757 rs9867514 chr3 76689925 T C 1.49E-04 Endometrial cancer ROBO2 intron 24096698 rs9867514 chr3 76689925 T C 5.37E-04 Endometrial cancer ROBO2 intron 24096698 rs1349008 chr3 76721413 T G 4.90E-05 Subclinical atherosclerosis ROBO2 intron 17903303 rs197097 chr3 76722454 G A 2.66E-06 Periodontitis (PAL4Q3) ROBO2 intron 24024966 rs264537 chr3 76722766 C G 3.00E-06 Periodontitis (PAL4Q3) ROBO2 intron 24024966 rs10511052 chr3 76725903 G A 7.72E-04 Response to taxane treatment (placlitaxel) ROBO2 intron 23006423 rs10511052 chr3 76725903 G A 6.00E-06 IgG glycosylation ROBO2 intron 23382691 rs3849508 chr3 76739295 A C 1.26E-04 Response to taxane treatment (placlitaxel) ROBO2 intron 23006423 rs7630682 chr3 76741635 T A 2.27E-05 Response to taxane treatment (placlitaxel) ROBO2 intron 23006423 rs264553 chr3 76759892 G A 3.85E-04 Coronary heart disease ROBO2 intron 21971053 rs267122 chr3 76775169 T A 8.52E-05 Multiple sclerosis ROBO2 intron 17660530 rs267120 chr3 76775597 G T 6.10E-05 Multiple sclerosis ROBO2 intron 17660530 rs6808931 chr3 76780491 A G 8.32E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ROBO2 intron 20877124 rs774610 chr3 76780594 C T 2.90E-04 Coronary heart disease ROBO2 intron 21971053 rs810184 chr3 76783510 C T 1.36E-05 Blood Pressure ROBO2 intron pha003050 rs174812 chr3 76786877 A G 6.02E-04 Response to cytadine analogues (cytosine arabinoside) ROBO2 intron 24483146 rs7630234 chr3 76787711 A G 6.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ROBO2 intron 20877124 rs1375963 chr3 76792468 A G 8.22E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ROBO2 intron 20877124 rs6797550 chr3 76796645 A G 5.00E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ROBO2 intron 20877124 rs3884314 chr3 76802905 C T 8.22E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ROBO2 intron 20877124 rs7609557 chr3 76806018 A G 8.15E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) ROBO2 intron 23648065 rs11127559 chr3 76809834 G T 1.96E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ROBO2 intron 24023788 rs2608157 chr3 76810615 G T 6.53E-04 Response to cytadine analogues (cytosine arabinoside) ROBO2 intron 24483146 rs774588 chr3 76821848 A G 3.74E-05 Blood Pressure ROBO2 intron pha003050 rs267103 chr3 76825682 T C 3.32E-05 Blood Pressure ROBO2 intron pha003050 rs2608131 chr3 76849447 A G 2.95E-04 Response to cytadine analogues (cytosine arabinoside) ROBO2 intron 24483146 rs1167035 chr3 76850916 C T 4.48E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) ROBO2 intron 23648065 rs2608132 chr3 76852241 G T 2.12E-04 Response to cytadine analogues (cytosine arabinoside) ROBO2 intron 24483146 rs1166940 chr3 76882785 G T 8.35E-04 Coronary Artery Disease ROBO2 intron 17634449 rs1166974 chr3 76919042 T G 1.26E-04 Coronary Artery Disease ROBO2 intron 17634449 rs6792260 chr3 76919232 T C 2.66E-04 Multiple complex diseases ROBO2 intron 17554300 rs1166980 chr3 76928990 A G 5.53E-04 Smoking cessation ROBO2 intron 24665060 rs4855965 chr3 76929347 G T 2.15E-04 Height ROBO2 intron 17255346 rs11127566 chr3 76930358 C T 1.10E-05 Urinary metabolites ROBO2 intron 21572414 rs11127568 chr3 76933219 A G 4.20E-05 Height ROBO2 intron 17255346 rs12630815 chr3 76947105 T C 1.91E-04 Height ROBO2 intron 17255346 rs1166994 chr3 76954766 A C 5.02E-05 Left ventricular hypertrophy ROBO2 intron pha003052 rs17819911 chr3 76982025 G A 7.00E-05 Parkinson's disease (age of onset) ROBO2 intron 19772629 rs7643047 chr3 77018252 A G 1.20E-05 Urinary metabolites ROBO2 intron 21572414 rs6786589 chr3 77046740 G A 2.52E-04 Alzheimer's disease (late onset) ROBO2 intron 21379329 rs6773575 chr3 77060574 A C 5.98E-05 Fibrinogen ROBO2 intron pha003068 rs4557199 chr3 77069266 T C 1.55E-04 Major depressive disorder ROBO2 intron 22472876 rs4521284 chr3 77081899 T C 7.08E-04 Multiple complex diseases ROBO2 intron 17554300 rs11127575 chr3 77086844 T G 1.03E-05 Fibrinogen ROBO2 intron pha003068 rs7612655 chr3 77195530 C T 8.13E-04 Amyotrophic lateral sclerosis ROBO2 intron 23624525 rs9852548 chr3 77238070 G A 3.84E-04 Alzheimer's disease (late onset) ROBO2 intron 21460841 rs9857299 chr3 77238881 C T 3.81E-04 Alzheimer's disease (late onset) ROBO2 intron 21460841 rs9877746 chr3 77239172 T C 3.82E-04 Alzheimer's disease (late onset) ROBO2 intron 21460841 rs17015072 chr3 77244218 T C 0.00000421 HDL cholesterol particle diameter ROBO2 intron 23263444 rs17820446 chr3 77244589 T C 2.99E-04 Alzheimer's disease (late onset) ROBO2 intron 21460841 rs4684030 chr3 77273602 A G 5.19E-04 Rheumatoid arthritis ROBO2 intron 21452313 rs6768395 chr3 77288105 T C 3.03E-04 Fibrinogen ROBO2 intron 17255346 rs12633766 chr3 77291050 G A 2.71E-04 Amyotrophic Lateral Sclerosis ROBO2 intron 17362836 rs12491865 chr3 77291314 G C 7.95E-04 Suicide attempts in bipolar disorder ROBO2 intron 21423239 rs6764366 chr3 77295470 G C 0.00023 Endometrial cancer ROBO2 intron 22426144 rs6764328 chr3 77295661 C T 8.13E-04 Suicide attempts in bipolar disorder ROBO2 intron 21423239 rs9882239 chr3 77322334 T C 9.20E-06 Urinary metabolites ROBO2 intron 21572414 rs1992449 chr3 77329004 G A 2.63E-04 Lung function (forced expiratory volume in 1 second) ROBO2 intron 24023788 rs998037 chr3 77346963 G A 5.54E-05 Blood Pressure ROBO2 intron pha003039 rs998037 chr3 77346963 G A 9.95E-05 Blood Pressure ROBO2 intron pha003045 rs1899373 chr3 77353410 G A 9.91E-05 Blood Pressure ROBO2 intron pha003039 rs9309766 chr3 77358965 G T 4.28E-04 Alzheimer's disease ROBO2 intron 17998437 rs10084692 chr3 77378207 C T 3.47E-04 Alzheimer's disease ROBO2 intron 17998437 rs9818075 chr3 77386855 A G 1.14E-04 Alzheimer's disease ROBO2 intron 17998437 rs6548506 chr3 77439564 A G 0.000878 Salmonella-induced pyroptosis ROBO2 intron 22837397 rs6548507 chr3 77444366 A G 8.20E-05 Height ROBO2 intron pha003010 rs6548507 chr3 77444366 A G 8.93E-05 Height ROBO2 intron pha003011 rs11127593 chr3 77474818 C T 3.10E-05 Parkinson's disease (age of onset) ROBO2 intron 19772629 rs34557441 chr3 77525616 A C 8.49E-05 Bipolar disorder and schizophrenia ROBO2 intron 20889312 rs34557441 chr3 77525616 A C 6.68E-05 Femoral neck bone geometry ROBO2 intron 22087292 rs7610881 chr3 77536346 A G 1.17E-04 Hearing function ROBO2 intron 17255346 rs13081032 chr3 77541547 A G 3.64E-04 Smoking initiation ROBO2 intron 24665060 rs6797725 chr3 77544822 C T 8.36E-05 Hearing function ROBO2 intron 17255346 rs6797725 chr3 77544822 C T 2.30E-05 Femoral neck bone geometry ROBO2 intron 22087292 rs13077150 chr3 77558385 G A 4.24E-04 Smoking initiation ROBO2 intron 24665060 rs935526 chr3 77560017 C T 5.63E-05 Aging (time to event) ROBO2 intron 21782286 rs9309770 chr3 77564310 C G 5.50E-04 Obesity-related traits ROBO2 intron 17903300 rs775775 chr3 77570375 T C 1.50E-05 Sarcoidosis ROBO2 intron 19165924 rs2218647 chr3 77570419 G A 3.12E-07 Multiple complex diseases ROBO2 intron 17554300 rs775748 chr3 77596460 T A 4.80E-04 Obesity-related traits ROBO2 intron 17903300 rs1666130 chr3 77598943 C T 1.72E-04 Sarcoidosis ROBO2 intron 19165924 rs17015351 chr3 77614088 T G 8.79E-04 Multiple complex diseases ROBO2 intron 17554300 rs775713 chr3 77617219 C G 1.49E-04 Lipid traits ROBO2 intron 22028671 rs1523769 chr3 77639342 A G 6.53E-05 Sarcoidosis ROBO2 intron 19165924 rs775723 chr3 77643174 G T 6.94E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) ROBO2 intron 23648065 rs73114594 chr3 77652742 G A 7.00E-06 Metabolite levels (5-HIAA/ MHPG Ratio) ROBO2 intron 23319000 rs9848106 chr3 77668346 A G 2.10E-04 Myocardial Infarction ROBO2 intron pha002883 rs876675 chr3 77675638 C T 3.96E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) ROBO2 intron 23648065 rs876675 chr3 77675638 C T 4.86E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) ROBO2 intron 23648065 rs3821735 chr3 77684222 C T 2.27E-04 Myocardial Infarction ROBO2 intron pha002883 rs13061961 chr3 77717622 T C 1.15E-04 Multiple complex diseases / / 17554300 rs1721179 chr3 77724063 G A 1.87E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs990249 chr3 77725925 A C 5.42E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1880140 chr3 77735235 T C 6.37E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6548519 chr3 77735324 T C 5.23E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs776125 chr3 77735945 G C 4.51E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs776106 chr3 77742551 C A 5.63E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs776107 chr3 77742903 A G 7.44E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs776108 chr3 77743786 A G 3.46E-04 Multiple complex diseases / / 17554300 rs10511058 chr3 77769689 A G 9.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs7630397 chr3 77771603 G A 9.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs6794930 chr3 77804193 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6798119 chr3 77836956 T C 8.57E-05 Cognitive impairment induced by topiramate / / 22091778 rs7618756 chr3 77989402 T C 4.58E-05 Brain imaging in schizophrenia (interaction) / / 19023125 rs17775669 chr3 78012759 C T 4.30E-05 HIV-1 control / / 20041166 rs6548539 chr3 78019050 A G 9.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs9836484 chr3 78044689 G A 4.00E-06 Brain imaging in schizophrenia (interaction) / / 19023125 rs9836484 chr3 78044689 G A 8.39E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7610746 chr3 78055947 C T 7.56E-06 Brain imaging in schizophrenia (interaction) / / 19023125 rs17832529 chr3 78056120 A G 0.000515 Salmonella-induced pyroptosis / / 22837397 rs1390308 chr3 78087465 T C 0.000393 Salmonella-induced pyroptosis / / 22837397 rs7614879 chr3 78132623 C T 5.20E-05 Tooth agenesis (mandibular third molar) / / 24172245 rs2177573 chr3 78183513 T C 0.000775 Salmonella-induced pyroptosis / / 22837397 rs1917084 chr3 78184798 G T 0.000142 Salmonella-induced pyroptosis / / 22837397 rs10511131 chr3 78192927 A G 0.000162 Salmonella-induced pyroptosis / / 22837397 rs17015805 chr3 78231381 G A 8.03E-05 Fibrinogen / / 17255346 rs9882906 chr3 78234456 C T 6.08E-04 Coronary heart disease / / 21971053 rs7433616 chr3 78276135 T G 5.72E-04 Type 2 diabetes / / 17463246 rs7433616 chr3 78276135 T G 2.34E-05 Bipolar disorder and schizophrenia / / 20889312 rs7623262 chr3 78288690 A G 2.20E-04 Multiple complex diseases / / 17554300 rs1398330 chr3 78322882 C A 6.20E-05 Bone mineral density (spine) / / 19079262 rs1512486 chr3 78325071 A G 7.42E-05 Partial epilepsies / / 20522523 rs9831754 chr3 78353591 T G 8.00E-06 Calcium levels / / 20705733 rs9831754 chr3 78353591 T G 1.12E-05 Postoperative ventricular dysfunction / / 21980348 rs6765243 chr3 78387430 A G 6.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs6791610 chr3 78398761 C T 9.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs9840973 chr3 78399857 C T 6.07E-05 Cognitive test performance / / 20125193 rs11921066 chr3 78400215 C A 7.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs9837024 chr3 78451637 A G 2.52E-05 Postoperative ventricular dysfunction / / 21980348 rs13322524 chr3 78495720 A G 2.98E-05 Postoperative ventricular dysfunction / / 21980348 rs9834373 chr3 78498997 G T 4.00E-06 Protein quantitative trait loci / / 18464913 rs4680933 chr3 78552995 G A 2.40E-05 Urinary metabolites / / 21572414 rs11721300 chr3 78553501 G T 1.42E-04 Parkinson's disease / / 17052657 rs41377648 chr3 78564700 G T 7.77E-04 Type 2 diabetes / / 17463246 rs41377648 chr3 78564700 G T 7.08E-04 Multiple complex diseases / / 17554300 rs10511127 chr3 78594711 C A 1.10E-06 Urinary metabolites / / 21572414 rs9876636 chr3 78594819 A G 6.30E-07 Urinary metabolites / / 21572414 rs1470377 chr3 78595575 T C 6.30E-07 Urinary metabolites / / 21572414 rs1444478 chr3 78596039 A C 6.30E-07 Urinary metabolites / / 21572414 rs1373524 chr3 78598282 G T 1.40E-06 Urinary metabolites / / 21572414 rs9682630 chr3 78604287 G A 5.20E-07 Urinary metabolites / / 21572414 rs6801989 chr3 78615037 A G 8.03E-04 Stroke / / pha002887 rs6807667 chr3 78640492 T C 2.85E-05 Male fertility / / 22633400 rs1507417 chr3 78650645 A G 2.41E-05 Male fertility ROBO1 intron 22633400 rs12496962 chr3 78652831 C T 1.85E-04 Alzheimer's disease ROBO1 intron 24755620 rs2660739 chr3 78693840 T C 9.64E-04 Response to alcohol consumption (flushing response) ROBO1 intron 24277619 rs1032966 chr3 78698388 T C 1.20E-06 Paclitaxel sensitivity in NCI60 cancer cell lines ROBO1 intron 21314952 rs9851228 chr3 78702439 C T 8.88E-05 Bipolar disorder ROBO1 intron 19488044 rs1865863 chr3 78803784 G A 1.61E-04 Schizophrenia ROBO1 intron 21674006 rs1865862 chr3 78803850 G T 8.58E-04 Myocardial Infarction ROBO1 intron pha002883 rs333473 chr3 78825048 C A,G,T 5.78E-04 Multiple complex diseases ROBO1 intron 17554300 rs1383407 chr3 78908171 T C 7.63E-05 Stroke (ischemic) ROBO1 intron 21940970 rs983513 chr3 79195157 G A 0.000025 Primary sclerosing cholangitis ROBO1 intron 22521342 rs1455825 chr3 79253857 G A 2.98E-05 Multiple complex diseases ROBO1 intron 17554300 rs11920171 chr3 79272194 G T 4.81E-04 Multiple complex diseases ROBO1 intron 17554300 rs9880736 chr3 79318988 C A 9.47E-05 Non-alcoholic fatty liver disease histology (other) ROBO1 intron 20708005 rs6548616 chr3 79399575 T C 8.83E-06 Kawasaki disease ROBO1 intron 21221998 rs7617893 chr3 79419101 G C 3.14E-04 Multiple complex diseases ROBO1 intron 17554300 rs6773975 chr3 79440654 T C 2.41E-04 Multiple complex diseases ROBO1 intron 17554300 rs17396958 chr3 79443051 A G 2.65E-04 Multiple complex diseases ROBO1 intron 17554300 rs4550794 chr3 79443746 T C 2.87E-04 Multiple complex diseases ROBO1 intron 17554300 rs12497294 chr3 79449194 C A 3.39E-04 Multiple complex diseases ROBO1 intron 17554300 rs9876243 chr3 79599467 T C 3.35E-04 Acute lung injury ROBO1 intron 22295056 rs7611200 chr3 79601895 G T 3.35E-04 Acute lung injury ROBO1 intron 22295056 rs7617400 chr3 79604064 C T 6.00E-06 Liver enzyme levels (aspartate transaminase) ROBO1 intron 24124411 rs9882958 chr3 79604494 C T 3.35E-04 Acute lung injury ROBO1 intron 22295056 rs9828140 chr3 79604842 T C 3.35E-04 Acute lung injury ROBO1 intron 22295056 rs9834080 chr3 79605705 C T 3.35E-04 Acute lung injury ROBO1 intron 22295056 rs11924965 chr3 79610625 C T 3.35E-04 Acute lung injury ROBO1 intron 22295056 rs11924965 chr3 79610625 C T 6.16E-06 Liver enzyme levels (aspartate transaminase) ROBO1 intron 24124411 rs12714481 chr3 79621993 C T 3.35E-04 Acute lung injury ROBO1 intron 22295056 rs7644918 chr3 79646157 A C 6.97E-06 Liver enzyme levels (aspartate transaminase) ROBO1 intron 24124411 rs7433360 chr3 79685538 T C 5.50E-04 Amyotrophic lateral sclerosis (sporadic) ROBO1 intron 24529757 rs9870957 chr3 79695551 A C 5.96E-04 Smoking initiation ROBO1 intron 24665060 rs4856447 chr3 79707357 G T 9.97E-04 Multiple complex diseases ROBO1 intron 17554300 rs9849596 chr3 79756484 A G 1.50E-05 Age-related macular degeneration ROBO1 intron pha002890 rs9309828 chr3 79760774 G A 3.79E-05 Age-related macular degeneration ROBO1 intron pha002890 rs6548651 chr3 79784416 G A 4.43E-04 Lymphocyte counts ROBO1 intron 22286170 rs2055451 chr3 79842129 G T 2.70E-05 Age-related macular degeneration / / 20861866 rs2055451 chr3 79842129 G T 9.34E-06 Age-related macular degeneration / / 21197116 rs2055451 chr3 79842129 G T 2.72E-06 Age-related macular degeneration / / pha000001 rs2055451 chr3 79842129 G T 2.98E-07 Age-related macular degeneration / / pha002856 rs7429136 chr3 79848404 T C 7.32E-04 Stroke / / pha002886 rs1502305 chr3 79858493 A T 2.20E-05 Age-related macular degeneration / / 20861866 rs1502305 chr3 79858493 A T 1.98E-06 Age-related macular degeneration / / pha000002 rs1502304 chr3 79858750 C T 2.50E-05 Age-related macular degeneration / / 20861866 rs1502304 chr3 79858750 C T 2.36E-06 Age-related macular degeneration / / pha000002 rs9848056 chr3 79884675 T C 4.67E-05 Pulmonary function in asthmatics / / 23541324 rs4856360 chr3 79888401 A G 4.07E-05 Pulmonary function in asthmatics / / 23541324 rs2055459 chr3 79909421 C G 5.43E-04 Type 2 diabetes / / 17463246 rs17815382 chr3 80081183 T G 3.06E-04 Alzheimer's disease (late onset) / / 21379329 rs12629494 chr3 80122427 C T 4.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs2197383 chr3 80131214 G A 2.99E-04 Type 2 diabetes / / 17463246 rs4856497 chr3 80132645 A G 9.35E-04 Sarcoidosis / / 21540310 rs1373509 chr3 80136989 T A 3.90E-04 Type 2 diabetes / / 17463246 rs12489982 chr3 80137908 C A 4.66E-04 Type 2 diabetes / / 17463246 rs10511116 chr3 80171159 A G 6.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs6774541 chr3 80200082 A G 1.90E-05 Telomere length / / 21573004 rs7645008 chr3 80270541 G A 9.26E-04 Type 2 diabetes / / 17463246 rs950570 chr3 80302512 C T 9.50E-05 Response to alcohol consumption (flushing response) / / 24277619 rs17451453 chr3 80353541 G C 8.48E-05 Pulmonary function / / 19300500 rs1876089 chr3 80355773 T C 3.97E-05 Pulmonary function / / 19300500 rs2340392 chr3 80358300 G A 1.70E-04 Longevity and age-related phenotypes / / 17903295 rs2340392 chr3 80358300 G A 6.71E-05 Pulmonary function / / 19300500 rs10511112 chr3 80368463 T C 5.00E-06 Migraine / / 23793025 rs7641536 chr3 80403233 T C 4.04E-05 Neuroblastoma / / pha002895 rs2340388 chr3 80410159 T G 2.82E-05 Neuroblastoma / / pha002895 rs949455 chr3 80426568 A C 7.12E-05 Neuroblastoma / / pha002895 rs9862709 chr3 80467009 G C 8.51E-04 Alzheimer's disease / / 17998437 rs6795503 chr3 80478208 T A 5.68E-04 Alzheimer's disease / / 17998437 rs12634573 chr3 80489310 G A 2.30E-05 Urinary metabolites / / 21572414 rs11918372 chr3 80545136 C T 1.31E-04 Alzheimer's disease / / 17998437 rs11914812 chr3 80547244 G A 7.16E-04 Alzheimer's disease / / 17998437 rs1515002 chr3 80549257 G A 3.64E-04 Alzheimer's disease / / 17998437 rs1971568 chr3 80551182 T C 1.99E-04 Alzheimer's disease / / 17998437 rs8180054 chr3 80553618 G C 6.81E-04 Alzheimer's disease / / 17998437 rs6548709 chr3 80560408 A G 1.64E-04 Alzheimer's disease / / 17998437 rs6780379 chr3 80560525 A G 1.39E-04 Alzheimer's disease / / 17998437 rs1406784 chr3 80563194 A G 2.99E-04 Alzheimer's disease / / 17998437 rs1399556 chr3 80564338 C A 2.26E-04 Alzheimer's disease / / 17998437 rs1406780 chr3 80570997 G A 4.35E-04 Alzheimer's disease / / 17998437 rs13084778 chr3 80571946 T C 2.43E-04 Alzheimer's disease / / 17998437 rs1516584 chr3 80584747 G C 3.27E-04 Alzheimer's disease / / 17998437 rs6548713 chr3 80596593 G A 5.10E-04 Alzheimer's disease / / 17998437 rs1370205 chr3 80628901 G C 9.27E-04 Alzheimer's disease / / 17998437 rs664100 chr3 80700658 T C 7.07E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs485487 chr3 80711889 G A 8.60E-04 Alzheimer's disease / / 17998437 rs1402203 chr3 80720427 G A 5.33E-05 Multiple complex diseases / / 17554300 rs527157 chr3 80723865 T C 5.65E-04 Aortic root size / / 21223598 rs1437042 chr3 80748093 G A,C,T 1.30E-05 Urinary metabolites / / 21572414 rs2139685 chr3 80787263 G A 9.67E-04 Alzheimer's disease / / 17998437 rs17018312 chr3 80836506 A G 4.60E-06 Urinary metabolites / / 21572414 rs9850225 chr3 80865764 G C 5.00E-08 Erectile dysfunction / / 22704111 rs17018320 chr3 80875679 G C 8.10E-06 Urinary metabolites / / 21572414 rs12487279 chr3 80914409 C G 5.52E-05 Bipolar disorder and schizophrenia / / 20889312 rs13060424 chr3 80933596 T C 2.00E-05 Urinary metabolites / / 21572414 rs6790313 chr3 80948443 T C 2.20E-05 Urinary metabolites / / 21572414 rs4856305 chr3 80951289 T A 2.00E-05 Urinary metabolites / / 21572414 rs2372749 chr3 80966773 C G 2.20E-05 Urinary metabolites / / 21572414 rs4298011 chr3 80984958 A G 2.86E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4603923 chr3 80997120 G A 1.42E-05 Alzheimer's disease / / 17998437 rs12637623 chr3 81027695 A G 6.20E-06 Urinary metabolites / / 21572414 rs2578305 chr3 81043111 C T 9.40E-04 Multiple complex diseases / / 17554300 rs2639277 chr3 81092688 A G 2.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9882538 chr3 81135791 A G 1.52E-04 Multiple complex diseases / / 17554300 rs1583673 chr3 81161078 C T 5.22E-04 Circulating vasoactive peptide levels / / 23381795 rs7612339 chr3 81270797 C T 1.07E-05 Brain structure / / 22504417 rs7614137 chr3 81283747 A T 4.14E-05 Brain structure / / 22504417 rs7628478 chr3 81293381 A C 4.82E-05 Brain structure / / 22504417 rs1487111 chr3 81296550 A G 2.38E-05 Brain structure / / 22504417 rs1487111 chr3 81296550 A G 5.48E-04 Myocardial Infarction / / pha002873 rs7630516 chr3 81297288 T A 4.51E-05 Brain structure / / 22504417 rs1982627 chr3 81318989 A G 4.23E-04 Myocardial Infarction / / pha002873 rs763855 chr3 81331298 C T 3.37E-05 Brain structure / / 22504417 rs1382261 chr3 81373838 C A 4.69E-04 Aortic root size / / 21223598 rs1871126 chr3 81385347 C T 1.71E-04 Myocardial Infarction / / pha002873 rs6796620 chr3 81385955 A G 1.40E-04 Multiple complex diseases / / 17554300 rs6780018 chr3 81405815 A T 3.18E-04 Multiple complex diseases / / 17554300 rs9877021 chr3 81406155 C T 5.90E-06 Urinary metabolites / / 21572414 rs275365 chr3 81413725 C T 5.30E-05 Endometriosis / / 21151130 rs4856343 chr3 81429555 G A 7.32E-04 Aortic root size / / 21223598 rs276105 chr3 81433234 T G 8.18E-06 Post-operative nausea and vomiting / / 21694509 rs17018881 chr3 81439098 C A 5.83E-04 Aortic root size / / 21223598 rs2372905 chr3 81504592 G C 1.93E-04 Multiple complex diseases / / 17554300 rs9874464 chr3 81505488 G C 2.31E-04 Multiple complex diseases / / 17554300 rs6783132 chr3 81534944 G A 1.35E-04 Glycosylated haemoglobin levels / / 17255346 rs843940 chr3 81547122 T A 9.22E-04 Multiple complex diseases GBE1 intron 17554300 rs17019039 chr3 81552859 G A 2.38E-04 Glycosylated haemoglobin levels GBE1 intron 17255346 rs17019042 chr3 81559500 C T 1.57E-04 Glycosylated haemoglobin levels GBE1 intron 17255346 rs2372908 chr3 81590296 G C 3.54E-04 Multiple complex diseases GBE1 intron 17554300 rs11922101 chr3 81604779 C T 1.41E-04 Multiple complex diseases GBE1 intron 17554300 rs9309872 chr3 81611837 T C 3.34E-04 Multiple complex diseases GBE1 intron 17554300 rs13082939 chr3 81612216 A G 1.51E-04 Glycosylated haemoglobin levels GBE1 intron 17255346 rs7618973 chr3 81619588 A G 4.57E-04 Multiple complex diseases GBE1 intron 17554300 rs2172397 chr3 81643167 T C 5.03E-04 Glycosylated haemoglobin levels / / 17255346 rs6800135 chr3 81650488 C T 4.12E-04 Multiple complex diseases GBE1 intron 17554300 rs9814053 chr3 81660022 T C 4.78E-04 Multiple complex diseases GBE1 intron 17554300 rs2229519 chr3 81698130 T A,C,G 0.0000549 Body mass index GBE1 missense 23001569 rs13320194 chr3 81720076 G A 8.63E-05 Coronary heart disease GBE1 cds-synon 21606135 rs3821548 chr3 81758728 G C 1.90E-04 Multiple complex diseases GBE1 intron 17554300 rs3821548 chr3 81758728 G C 6.95E-05 Serum metabolites GBE1 intron 19043545 rs13072957 chr3 81776242 C T 5.34E-04 Multiple complex diseases GBE1 intron 17554300 rs3772891 chr3 81776760 C T 5.37E-05 Multiple complex diseases GBE1 intron 17554300 rs3772884 chr3 81802720 C A 3.67E-04 Multiple complex diseases GBE1 intron 17554300 rs3755713 chr3 81811224 A G 4.38E-04 Multiple complex diseases GBE1 nearGene-5 17554300 rs3860595 chr3 81811784 T C 8.88E-04 Multiple complex diseases GBE1 nearGene-5 17554300 rs11711331 chr3 81819040 G A 1.62E-04 Multiple complex diseases / / 17554300 rs11711331 chr3 81819040 G A 7.95E-05 Serum metabolites / / 19043545 rs6548773 chr3 81840222 T C 1.14E-04 Multiple complex diseases / / 17554300 rs6548773 chr3 81840222 T C 9.04E-05 Serum metabolites / / 19043545 rs7646435 chr3 81846607 G C 8.16E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1464790 chr3 81852923 T A 3.31E-04 Multiple complex diseases / / 17554300 rs1524557 chr3 81892031 T C 2.77E-04 Multiple complex diseases / / 17554300 rs1464791 chr3 81893929 G T 9.55E-05 Multiple complex diseases / / 17554300 rs1464791 chr3 81893929 G T 8.48E-05 Serum metabolites / / 19043545 rs1973804 chr3 81962522 C T 0.000764 Salmonella-induced pyroptosis / / 22837397 rs9814843 chr3 81994505 G A 2.20E-05 Urinary metabolites / / 21572414 rs7644264 chr3 82011680 C T 6.00E-05 Asthma (bronchodilator response) / / 22792082 rs7431326 chr3 82019603 G A 6.49E-04 Alcohol dependence / / 20201924 rs9875387 chr3 82050284 A G 4.24E-05 Body Mass Index / / pha002896 rs17784061 chr3 82074024 G A 3.45E-05 Multiple complex diseases / / 17554300 rs1113444 chr3 82100377 C T 3.39E-04 Multiple complex diseases / / 17554300 rs9309886 chr3 82143651 G T 9.03E-05 Body Mass Index / / pha002896 rs17728526 chr3 82147289 T A 3.16E-05 Multiple complex diseases / / 17554300 rs4618241 chr3 82184158 A T 9.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs1534671 chr3 82198467 G A 9.66E-04 Coronary heart disease / / 21971053 rs4856210 chr3 82213185 C T 5.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs17114 chr3 82213636 C T 9.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs6779875 chr3 82223946 A G 6.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs6783449 chr3 82446513 T A 7.83E-04 Multiple complex diseases / / 17554300 rs1992984 chr3 82448822 A C 8.70E-06 Intelligence / / 21826061 rs17019771 chr3 82458130 A G 7.08E-06 Alcohol and nictotine co-dependence / / 20158304 rs1375799 chr3 82469264 A G 9.20E-04 Multiple complex diseases / / 17554300 rs9875783 chr3 82477805 T G 5.78E-05 Cognitive decline / / 22054870 rs4856389 chr3 82507996 A T 4.24E-04 Multiple complex diseases / / 17554300 rs7645265 chr3 82541672 G A 9.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs6548822 chr3 82551142 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9814570 chr3 82589732 C T 6.95E-04 Multiple complex diseases / / 17554300 rs13079811 chr3 82614903 C A 2.69E-06 Major depressive disorder / / 20516156 rs13079811 chr3 82614903 C A 0.0000034 Major depressive disorder age at onset<30 / / 22915352 rs13079811 chr3 82614903 C A 3.49E-05 Anxiety and major depressive disorder / / 24047446 rs716764 chr3 82646519 T C 6.18E-05 Multiple complex diseases / / 17554300 rs834858 chr3 82660035 T C 6.52E-05 Multiple complex diseases / / 17554300 rs834864 chr3 82663150 T C 8.28E-05 Multiple complex diseases / / 17554300 rs834873 chr3 82667244 A T 2.58E-05 Multiple complex diseases / / 17554300 rs834849 chr3 82687133 C T 9.91E-04 Type 2 diabetes / / 17463246 rs17019986 chr3 82689239 T A 2.50E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11127782 chr3 82691819 T C 7.88E-06 Cognitive test performance / / 20125193 rs1097157 chr3 82697313 C T 1.94E-04 Multiple complex diseases / / 17554300 rs2873392 chr3 82697984 C T 3.05E-04 Multiple complex diseases / / 17554300 rs834843 chr3 82706368 A G 7.32E-05 Multiple complex diseases / / 17554300 rs1580295 chr3 82715343 A G 5.28E-05 Multiple complex diseases / / 17554300 rs1600058 chr3 82732832 A G 6.18E-05 Multiple complex diseases / / 17554300 rs6548843 chr3 82758743 T C 6.97E-04 Multiple complex diseases / / 17554300 rs11712238 chr3 82775843 G T 1.03E-04 Tourette syndrome / / 22889924 rs9880341 chr3 82850096 T G 2.13E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12493332 chr3 82896772 A C 0.00000274 VLDL cholesterol particle diameter / / 23263444 rs17020227 chr3 82906400 T C 0.0000027 VLDL cholesterol particle diameter / / 23263444 rs17020233 chr3 82922579 G A 0.00000177 VLDL cholesterol particle diameter / / 23263444 rs13075335 chr3 82923361 T C 0.00000174 VLDL cholesterol particle diameter / / 23263444 rs9309915 chr3 82925724 C A 0.00000169 VLDL cholesterol particle diameter / / 23263444 rs9867035 chr3 82926370 G C 9.00E-04 Multiple complex diseases / / 17554300 rs12486708 chr3 82936617 G C 0.00000179 VLDL cholesterol particle diameter / / 23263444 rs13091263 chr3 82937049 T A 0.00000178 VLDL cholesterol particle diameter / / 23263444 rs13094197 chr3 82958776 A C 0.00000145 VLDL cholesterol particle diameter / / 23263444 rs2047333 chr3 82959022 T G 9.12E-04 Parkinson's disease / / 17052657 rs13063170 chr3 82960559 A G 0.00000143 VLDL cholesterol particle diameter / / 23263444 rs9309919 chr3 82960892 G A 1.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs13092936 chr3 82962078 T C 0.0000118 VLDL cholesterol particle diameter / / 23263444 rs975488 chr3 82992714 A C 8.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs4856423 chr3 83004185 G A 7.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs2317601 chr3 83019201 A T 8.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs17020418 chr3 83034644 A G 8.11E-04 Type 2 diabetes / / 17463246 rs35216186 chr3 83038704 C T 1.24E-06 Asthma (childhood onset) / / 23829686 rs41514251 chr3 83054736 G A 9.52E-04 Multiple complex diseases / / 17554300 rs7618878 chr3 83089596 C T 9.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs1080728 chr3 83107505 G A 8.23E-04 Multiple complex diseases / / 17554300 rs1473624 chr3 83169976 A G 7.18E-04 Parkinson's disease / / 17052657 rs1376967 chr3 83501948 T G 9.69E-04 Parkinson's disease / / 17052657 rs17780040 chr3 83502697 C T 2.40E-06 Urinary metabolites / / 21572414 rs6800558 chr3 83523168 T A 4.73E-04 Multiple complex diseases / / 17554300 rs8180101 chr3 83547435 A G 8.16E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs8180101 chr3 83547435 A G 1.57E-05 Magnesium levels / / pha003092 rs4856462 chr3 83609341 T G 5.68E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11710892 chr3 83617489 A G 5.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1357797 chr3 83775078 A G 1.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1357797 chr3 83775078 A G 6.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11715563 chr3 83791220 T C 3.91E-04 Parkinson's disease / / 17052657 rs1917372 chr3 83793414 A G 2.64E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1524783 chr3 83800798 A C 1.88E-04 Parkinson's disease / / 17052657 rs4856472 chr3 83838977 C T 2.46E-04 Parkinson's disease / / 17052657 rs17021121 chr3 83843079 T C 3.34E-05 Heart Failure / / pha002884 rs4274767 chr3 83877497 A G 6.20E-05 Serum metabolites / / 19043545 rs4413325 chr3 83877684 T G 9.27E-04 Parkinson's disease / / 17052657 rs4574309 chr3 83905418 C T 4.62E-05 Parkinson's disease / / 17052657 rs4264742 chr3 83906468 C G 1.39E-05 Serum metabolites / / 19043545 rs4396907 chr3 83906804 G A 3.40E-05 Parkinson's disease / / 17052657 rs7649903 chr3 83907751 A G 3.14E-04 Parkinson's disease / / 17052657 rs9879027 chr3 83914442 G T 5.23E-04 Parkinson's disease / / 17052657 rs11127827 chr3 83914758 A G 1.29E-04 Parkinson's disease / / 17052657 rs4260455 chr3 83921894 T A 2.36E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs6777459 chr3 83937348 T C 1.00E-04 Spine bone size / / 21947420 rs6777545 chr3 83937394 T C 1.00E-04 Spine bone size / / 21947420 rs6548921 chr3 83938414 T C 6.20E-06 Urinary metabolites / / 21572414 rs6548923 chr3 83939565 A G 5.90E-06 Urinary metabolites / / 21572414 rs4128523 chr3 83940448 G A 2.11E-04 Parkinson's disease / / 17052657 rs5010174 chr3 83943663 C T 7.69E-04 Parkinson's disease / / 17052657 rs4276197 chr3 83945963 A G 6.14E-04 Premature ovarian failure / / 19508998 rs9865049 chr3 84008488 T C 1.63E-04 Parkinson's disease / / 17052657 rs4856477 chr3 84017630 C T 3.58E-05 Tunica Media / / pha003038 rs17178354 chr3 84076514 C T 2.30E-06 Urinary metabolites / / 21572414 rs4856242 chr3 84127821 G A 1.40E-06 Urinary metabolites / / 21572414 rs4856490 chr3 84147884 T C 6.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4856244 chr3 84184134 T C 1.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4522784 chr3 84202203 T G 7.00E-06 Obesity-related traits / / 23251661 rs6772122 chr3 84205939 C T 8.12E-04 Smoking cessation / / 24665060 rs9818995 chr3 84224057 C A 1.24E-04 Parkinson's disease / / 17052657 rs4279116 chr3 84253609 T C 1.50E-04 Multiple complex diseases / / 17554300 rs7617594 chr3 84296569 T C 8.36E-04 Heart Failure / / pha002884 rs4320067 chr3 84303380 A G 1.83E-04 Multiple complex diseases / / 17554300 rs7636111 chr3 84304241 A T 1.57E-04 Multiple complex diseases / / 17554300 rs11915176 chr3 84332255 T A 1.92E-05 Multiple complex diseases / / 17554300 rs1384300 chr3 84356646 T C 5.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1384301 chr3 84357128 A G 5.54E-04 Multiple complex diseases / / 17554300 rs4856502 chr3 84357635 G A 7.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11929542 chr3 84394801 C T 6.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12633731 chr3 84403117 T A 7.36E-04 Multiple complex diseases / / 17554300 rs7653393 chr3 84403239 A T 5.87E-04 Multiple complex diseases / / 17554300 rs1384307 chr3 84425895 C T 5.61E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12714597 chr3 84443114 G A 2.86E-04 Parkinson's disease / / 17052657 rs10511089 chr3 84481068 G T 7.00E-07 Brain structure / / 20171287 rs1471804 chr3 84616264 T C 4.88E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs4373074 chr3 84688248 T C 5.98E-04 Multiple complex diseases / / 17554300 rs7642488 chr3 84688723 C T 6.72E-04 Multiple complex diseases LOC440970 intron 17554300 rs4374542 chr3 84716208 A G 4.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6783281 chr3 84791851 A G 1.70E-04 Type 2 diabetes LOC440970 intron 17463246 rs9869020 chr3 84798458 C T 2.42E-04 Multiple complex diseases LOC440970 intron 17554300 rs9818956 chr3 84819147 G T 1.13E-05 Platelet counts LOC440970 intron 21507922 rs1248845 chr3 84871763 T A 9.26E-05 Schizophrenia LOC440970 intron 19571809 rs10440084 chr3 84872804 A G 3.00E-06 Urinary metabolites LOC440970 intron 21572414 rs1248821 chr3 84930747 T C 5.59E-05 Schizophrenia / / 19571809 rs1248820 chr3 84931323 T C 5.80E-05 Alcoholism (heaviness of drinking) / / 21529783 rs9882516 chr3 84941806 C G 1.35E-04 Multiple complex diseases / / 17554300 rs2132183 chr3 84966867 C T 1.26E-04 Multiple complex diseases / / 17554300 rs9683309 chr3 84977191 C T 1.42E-04 Multiple complex diseases / / 17554300 rs11127866 chr3 84978010 C A 1.20E-04 Multiple complex diseases / / 17554300 rs7614596 chr3 84986027 T G 1.22E-04 Multiple complex diseases / / 17554300 rs4856554 chr3 85022821 G A 7.46E-05 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs6768455 chr3 85040649 C T 4.38E-05 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs17022259 chr3 85051839 G A 3.33E-04 Insulin resistance CADM2 intron 21901158 rs17022281 chr3 85059619 G A 4.36E-04 Insulin resistance CADM2 intron 21901158 rs1994316 chr3 85069287 T G 1.00E-04 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs1016305 chr3 85082924 G A 2.10E-05 Serum metabolites CADM2 intron 19043545 rs2171143 chr3 85084508 C T 1.00E-04 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs2062430 chr3 85095081 A G 8.59E-04 Multiple complex diseases CADM2 intron 17554300 rs9814835 chr3 85099943 T C 5.06E-05 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs11127876 chr3 85124697 C T 1.00E-04 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs9820587 chr3 85138172 A G 2.00E-04 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs13061527 chr3 85151828 T G 1.66E-05 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs13061527 chr3 85151828 T G 2.00E-04 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs13061527 chr3 85151828 T G 3.15E-05 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs4516626 chr3 85152987 C T 5.76E-05 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs9875381 chr3 85158733 A G 1.66E-05 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs9875381 chr3 85158733 A G 2.00E-04 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs9875381 chr3 85158733 A G 3.15E-05 Cognitive impairment induced by topiramate CADM2 intron 22091778 rs2034619 chr3 85281802 G A 2.92E-04 Premature ovarian failure CADM2 intron 19508998 rs818215 chr3 85371400 A C 1.46E-05 Serum metabolites CADM2 intron 19043545 rs818215 chr3 85371400 A C 0.0000044 Femoral neck bone mineral density (premenopausal) CADM2 intron 23074152 rs9822731 chr3 85405501 T C 2.14E-04 Amyotrophic Lateral Sclerosis CADM2 intron 17827064 rs7627971 chr3 85414291 T C 3.80E-04 Amyotrophic Lateral Sclerosis CADM2 intron 17827064 rs1821349 chr3 85438564 A G 3.94E-04 Amyotrophic Lateral Sclerosis CADM2 intron 17827064 rs1549979 chr3 85460131 C T 2.39E-07 Bipolar disorder CADM2 intron 22182935 rs2053108 chr3 85467972 C A 2.90E-05 Urinary metabolites CADM2 intron 21572414 rs2053108 chr3 85467972 C A 2.41E-07 Bipolar disorder CADM2 intron 22182935 rs6780968 chr3 85469041 C G 1.60E-05 Urinary metabolites CADM2 intron 21572414 rs2196096 chr3 85470642 T C 1.89E-04 Amyotrophic Lateral Sclerosis CADM2 intron 17827064 rs2326309 chr3 85477017 T G 6.08E-07 Bipolar disorder CADM2 intron 22182935 rs7609594 chr3 85482595 G A 1.90E-05 Urinary metabolites CADM2 intron 21572414 rs7609594 chr3 85482595 G A 1.68E-07 Bipolar disorder CADM2 intron 22182935 rs35827242 chr3 85482661 G A 2.10E-05 Urinary metabolites CADM2 intron 21572414 rs1865252 chr3 85488740 A G 2.20E-05 Urinary metabolites CADM2 intron 21572414 rs2082556 chr3 85490947 G A 2.15E-07 Bipolar disorder CADM2 intron 22182935 rs993137 chr3 85499035 C T 1.40E-05 Urinary metabolites CADM2 intron 21572414 rs993137 chr3 85499035 C T 2.79E-07 Bipolar disorder CADM2 intron 22182935 rs993136 chr3 85499333 T C 2.20E-05 Urinary metabolites CADM2 intron 21572414 rs993136 chr3 85499333 T C 2.72E-07 Bipolar disorder CADM2 intron 22182935 rs11920711 chr3 85502556 G A 1.39E-04 Multiple complex diseases CADM2 intron 17554300 rs13323436 chr3 85502845 T A 3.00E-06 Visceral fat CADM2 intron 22589738 rs2117153 chr3 85504452 G A 4.91E-05 Intelligence CADM2 intron 21826061 rs2117153 chr3 85504452 G A 1.95E-07 Bipolar disorder CADM2 intron 22182935 rs2875907 chr3 85518580 A G 7.44E-08 Bipolar disorder CADM2 intron 22182935 rs12637791 chr3 85525323 T G 1.00E-04 Prostate cancer CADM2 intron 21743057 rs1542248 chr3 85527334 G A 9.65E-07 Bipolar disorder CADM2 intron 22182935 rs726610 chr3 85551403 C T 1.49E-07 Bipolar disorder CADM2 intron 22182935 rs12638798 chr3 85551820 T C 1.42E-07 Bipolar disorder CADM2 intron 22182935 rs1449391 chr3 85554582 G T 7.10E-07 Bipolar disorder CADM2 intron 22182935 rs6804845 chr3 85563846 A C 1.51E-04 Amyotrophic Lateral Sclerosis CADM2 intron 17827064 rs6804845 chr3 85563846 A C 7.07E-07 Bipolar disorder CADM2 intron 22182935 rs10511083 chr3 85570959 A G 1.75E-04 Amyotrophic Lateral Sclerosis CADM2 intron 17827064 rs10511083 chr3 85570959 A G 9.08E-07 Bipolar disorder CADM2 intron 22182935 rs4856582 chr3 85577197 G A 6.77E-04 Type 2 diabetes CADM2 intron 17463246 rs4856584 chr3 85580328 A T 8.00E-05 Prostate cancer CADM2 intron 21743057 rs11127898 chr3 85587729 C G 8.00E-05 Prostate cancer CADM2 intron 21743057 rs17517121 chr3 85591108 G A 8.89E-07 Bipolar disorder CADM2 intron 22182935 rs2326319 chr3 85597135 G A 1.33E-04 Amyotrophic Lateral Sclerosis CADM2 intron 17827064 rs2326319 chr3 85597135 G A 1.09E-07 Bipolar disorder CADM2 intron 22182935 rs7652808 chr3 85603643 T G 1.20E-07 Bipolar disorder CADM2 intron 22182935 rs17518584 chr3 85604923 C T 9.85E-07 Bipolar disorder CADM2 intron 22182935 rs1375547 chr3 85608137 G A 2.20E-04 Amyotrophic Lateral Sclerosis CADM2 intron 17827064 rs17023019 chr3 85614272 A G 8.37E-08 Bipolar disorder CADM2 intron 22182935 rs1900916 chr3 85646426 T G 4.40E-07 Bipolar disorder CADM2 intron 22182935 rs12637027 chr3 85658601 C G 5.94E-07 Bipolar disorder CADM2 intron 22182935 rs7632056 chr3 85659025 A G 7.21E-07 Bipolar disorder CADM2 intron 22182935 rs6779752 chr3 85663849 G A 1.82E-04 Amyotrophic Lateral Sclerosis CADM2 intron 17827064 rs6779752 chr3 85663849 G A 8.30E-07 Bipolar disorder CADM2 intron 22182935 rs1449395 chr3 85667683 C A 3.78E-04 Amyotrophic Lateral Sclerosis CADM2 intron 17827064 rs9829032 chr3 85683600 A G 9.68E-07 Bipolar disorder CADM2 intron 22182935 rs4302392 chr3 85689076 A G 1.14E-05 Serum metabolites CADM2 intron 19043545 rs9844720 chr3 85719890 C T 5.48E-04 Response to alcohol consumption (flushing response) CADM2 intron 24277619 rs7612090 chr3 85729502 G A 3.71E-04 Response to alcohol consumption (flushing response) CADM2 intron 24277619 rs10514735 chr3 85798950 A G 3.76E-04 Multiple complex diseases CADM2 intron 17554300 rs9864042 chr3 85823561 G A 3.19E-06 Esophageal cancer (squamous cell) CADM2 intron 22960999 rs9852859 chr3 85842341 T C 5.30E-04 Type 2 diabetes CADM2 intron 17463246 rs12494658 chr3 85874476 T C 5.00E-06 Temperament CADM2 intron 22832960 rs13078807 chr3 85884150 A G 4.00E-11 Body mass index CADM2 intron 20935630 rs13078807 chr3 85884150 A G 3.94E-11 Body mass index CADM2 intron 23001569 rs13078807 chr3 85884150 A G 3.00E-11 Obesity CADM2 intron 23563607 rs9861174 chr3 85989000 G T 8.51E-05 Multiple sclerosis (age of onset) CADM2 intron 19010793 rs9829960 chr3 86065598 A G 4.37E-05 Multiple sclerosis (age of onset) CADM2 intron 19010793 rs2324999 chr3 86158885 C T 2.00E-06 Subcutaneous adipose tissue / / 22589738 rs2324999 chr3 86158885 C T 4.00E-06 Subcutaneous adipose tissue / / 22589738 rs6796873 chr3 86168194 A G 8.55E-04 Multiple complex diseases / / 17554300 rs6549077 chr3 86196341 C T 2.13E-05 Suicide attempts in bipolar disorder / / 21423239 rs11127920 chr3 86196664 T C 1.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs11127920 chr3 86196664 T C 7.61E-05 Coronary heart disease / / pha003030 rs6549078 chr3 86197342 A G 3.65E-05 Suicide attempts in bipolar disorder / / 21423239 rs7432587 chr3 86199354 A G 2.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs7428811 chr3 86199798 G C 1.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs11127922 chr3 86203314 A G 6.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs11127924 chr3 86203406 C G 2.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs6790538 chr3 86203821 G C 2.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs12493043 chr3 86204275 T C 3.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs13093222 chr3 86204867 G A 4.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs12636212 chr3 86205223 T C 9.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs12636212 chr3 86205223 T C 4.00E-05 Body Mass Index / / pha002896 rs12485540 chr3 86206285 T C 2.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs12633890 chr3 86209277 A G 5.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs10865615 chr3 86214243 G T 2.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs4688888 chr3 86221347 T C 3.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs12486352 chr3 86223273 A T 1.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs12638689 chr3 86225928 A G 2.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs12634090 chr3 86226739 G C 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs11127925 chr3 86226925 T C 3.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs11707021 chr3 86246160 C A 4.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs13072339 chr3 86247275 G A 2.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs7636401 chr3 86249401 G A 9.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs1512914 chr3 86251199 G T 4.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs6773947 chr3 86251656 A T 5.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs12487215 chr3 86254241 A G 6.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs12487215 chr3 86254241 A G 4.32E-05 Fibrinogen / / pha003068 rs7428796 chr3 86255672 T C 2.00E-18 Myopia (pathological) / / 23049088 rs7428796 chr3 86255672 T C 4.21E-05 Fibrinogen / / pha003068 rs4073109 chr3 86256530 T C 8.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs4688890 chr3 86260728 C G 4.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs4396896 chr3 86261800 A T 3.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs2175671 chr3 86264283 T C 1.94E-06 Suicide attempts in bipolar disorder / / 21423239 rs1512929 chr3 86265219 C T 2.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs2137492 chr3 86266408 A G 3.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs2137492 chr3 86266408 A G 4.88E-05 Prion diseases / / 22210626 rs2048589 chr3 86268100 T C 2.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs1949197 chr3 86273850 A G 3.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs13077697 chr3 86278209 A G 3.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs17026843 chr3 86282294 T C 3.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs12487935 chr3 86284649 A G 4.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs4263293 chr3 86286959 A G 3.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs1512934 chr3 86288495 T C 2.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs12636329 chr3 86289542 C G,T 2.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs932058 chr3 86292844 T A 2.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs1512922 chr3 86296208 C A,T 1.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs11127927 chr3 86300035 A G 3.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs2175673 chr3 86301073 A T 2.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs6788794 chr3 86303453 C T 3.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs11127928 chr3 86303487 A G 6.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs11127929 chr3 86305485 G A 3.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs6774344 chr3 86306259 A C 6.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs6763450 chr3 86306651 T G 7.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs1355686 chr3 86345140 G A 9.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs6801738 chr3 86357790 T C 7.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs11127934 chr3 86362700 A G 7.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs11127935 chr3 86364123 C T 9.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs11707281 chr3 86372407 A C 8.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs12495441 chr3 86376976 T C 9.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs1170215 chr3 86381727 G C 6.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs1170214 chr3 86381883 T C 9.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs2669408 chr3 86385475 G C 7.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs979471 chr3 86385687 A G 7.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs13316811 chr3 86391789 G T 7.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs9829587 chr3 86392751 C T 5.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs7616481 chr3 86394337 A G 5.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs1495888 chr3 86411414 G A 2.08E-05 Personality dimensions / / 18957941 rs7643206 chr3 86441163 G A 9.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs9820995 chr3 86457535 T C 5.87E-05 Suicide attempts in bipolar disorder / / 21423239 rs6786876 chr3 86462805 G A 5.52E-05 Suicide attempts in bipolar disorder / / 21423239 rs884026 chr3 86467434 T G 8.06E-05 Suicide attempts in bipolar disorder / / 21423239 rs291956 chr3 86500544 G A 8.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs1603320 chr3 86526422 T G 5.22E-05 Orofacial clefts / / 22419666 rs188655146 chr3 86544386 T G 9.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2035985 chr3 86555969 C T 3.22E-04 Alcohol dependence / / 24277619 rs7640494 chr3 86565981 C G 4.34E-04 Multiple complex diseases / / 17554300 rs6763219 chr3 86693588 A T 3.73E-04 Parkinson's disease / / 16252231 rs7649866 chr3 86717004 A T 8.32E-04 Parkinson's disease / / 16252231 rs1370209 chr3 86749427 A G 9.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6796925 chr3 86757306 T C 9.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9850360 chr3 86761070 A T 9.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11919691 chr3 86782582 A G 9.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9827403 chr3 86790149 T C 1.33E-04 Body mass index / / 21701565 rs9827403 chr3 86790149 T C 1.97E-05 Body mass index / / 21701565 rs9827403 chr3 86790149 T C 5.37E-04 Body mass index / / 21701565 rs4530527 chr3 86800085 A C 1.28E-04 Body mass index / / 21701565 rs9866309 chr3 86821558 G A 2.96E-04 Body mass index / / 21701565 rs9866309 chr3 86821558 G A 7.26E-05 Body mass index / / 21701565 rs11127958 chr3 86825600 A T 1.53E-06 Body mass index / / 21701565 rs11127958 chr3 86825600 A T 2.64E-05 Body mass index / / 21701565 rs7628864 chr3 86850618 A G 3.00E-09 Pubertal anthropometrics / / 23449627 rs2118188 chr3 86868436 C T 3.14E-04 Body mass index / / 21701565 rs2118188 chr3 86868436 C T 8.60E-05 Body mass index / / 21701565 rs9683166 chr3 86874663 T G 1.64E-04 Body mass index / / 21701565 rs9683166 chr3 86874663 T G 5.95E-04 Body mass index / / 21701565 rs9310023 chr3 86875458 A G 1.66E-04 Body mass index / / 21701565 rs9310023 chr3 86875458 A G 5.95E-04 Body mass index / / 21701565 rs9683172 chr3 86883956 C A 3.10E-04 Body mass index / / 21701565 rs9757252 chr3 86894478 T C 5.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs9310043 chr3 86911330 T A 2.89E-04 Body mass index / / 21701565 rs9310043 chr3 86911330 T A 5.28E-05 Body mass index / / 21701565 rs9682134 chr3 86913288 C T 1.65E-04 Body mass index / / 21701565 rs9682134 chr3 86913288 C T 5.95E-04 Body mass index / / 21701565 rs7642134 chr3 86916882 A G 4.00E-10 Menarche (age at onset) / / 21102462 rs7642134 chr3 86916882 A G 0.00062 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs9842925 chr3 86917446 C T 2.81E-04 Body mass index / / 21701565 rs4859048 chr3 86952516 C T 7.87E-05 Blood Pressure / / pha003040 rs6419888 chr3 86961118 A G 1.64E-04 Body mass index / / 21701565 rs6419888 chr3 86961118 A G 5.95E-04 Body mass index / / 21701565 rs4859060 chr3 86962760 G A 1.80E-04 Body mass index / / 21701565 rs4859060 chr3 86962760 G A 5.79E-04 Body mass index / / 21701565 rs6551477 chr3 86963417 C T 2.57E-04 Body mass index / / 21701565 rs6551477 chr3 86963417 C T 8.89E-04 Body mass index / / 21701565 rs7649306 chr3 86964922 A G 4.02E-04 Body mass index / / 21701565 rs7649306 chr3 86964922 A G 4.19E-05 Body mass index / / 21701565 rs7649317 chr3 86964949 A G 1.29E-04 Body mass index / / 21701565 rs13074417 chr3 86968492 A G 7.63E-05 Blood Pressure / / pha003040 rs17023661 chr3 86968509 C T 7.49E-04 Body mass index / / 21701565 rs17023661 chr3 86968509 C T 2.00E-06 Obesity-related traits / / 23251661 rs1370036 chr3 86969519 T C 5.05E-04 Body mass index / / 21701565 rs1370036 chr3 86969519 T C 5.50E-05 Body mass index / / 21701565 rs7614681 chr3 86975072 T C 7.92E-04 Body mass index / / 21701565 rs7614681 chr3 86975072 T C 7.98E-05 Body mass index / / 21701565 rs1370032 chr3 86975853 T C 7.22E-05 Blood Pressure / / pha003040 rs1898274 chr3 87050997 G A 0.00033 Endometrial cancer / / 22426144 rs2118079 chr3 87063871 C T 8.19E-04 Aortic root size / / 21223598 rs1370042 chr3 87084332 G A 0.00025 Endometrial cancer / / 22426144 rs9836203 chr3 87097872 T C 4.41E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17023854 chr3 87104899 T C 1.50E-05 Urinary metabolites / / 21572414 rs2660753 chr3 87110674 T C 3.00E-08 Prostate cancer / / 18264097 rs2660753 chr3 87110674 T C 3.00E-08 Nasopharyngeal carcinoma / / 20512145 rs17023900 chr3 87134800 A G 3.10E-07 Prostate cancer / / 18264097 rs17023900 chr3 87134800 A G 6.00E-08 Prostate cancer / / 22923026 rs9284813 chr3 87152169 A G 5.00E-09 Prostate cancer / / 20676098 rs9284813 chr3 87152169 A G 0.00001 Prostate cancer / / 23555315 rs17181079 chr3 87162301 G A 2.00E-04 Multiple complex diseases / / 17554300 rs9836404 chr3 87172005 G A 1.05E-04 Prostate cancer / / 23023329 rs17181170 chr3 87173324 G A 3.00E-08 Prostate cancer / / 19767753 rs17181170 chr3 87173324 G A 3.00E-08 Nasopharyngeal carcinoma / / 20512145 rs17181170 chr3 87173324 G A 0.00011 Prostate cancer / / 23555315 rs17181170 chr3 87173324 G A 8.62E-05 Cardiovascular disease / / pha003065 rs7639047 chr3 87173731 C T 6.58E-05 Cardiovascular disease / / pha003065 rs17023969 chr3 87189024 C T 2.04E-05 Cardiovascular disease / / pha003065 rs12633313 chr3 87212726 C T 2.70E-06 Urinary metabolites / / 21572414 rs1825896 chr3 87219009 G A 8.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1825896 chr3 87219009 G A 2.50E-05 Urinary metabolites / / 21572414 rs963622 chr3 87223646 A G 0.000684 Height (Pygmy height) / / 22570615 rs7629490 chr3 87241497 C T 1.20E-05 Urinary metabolites / / 21572414 rs7629490 chr3 87241497 C T 1.00E-07 Prostate cancer / / 21743057 rs7629490 chr3 87241497 C T 0.00004 Prostate cancer / / 23555315 rs7629490 chr3 87241497 C T 0.000061 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs17024019 chr3 87257423 A G 0.00000957 Preeclampsia / / 22432041 rs17024024 chr3 87258681 T A 6.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs1994487 chr3 87262998 A G 4.80E-06 Stroke (ischemic) / / 22384361 rs17024046 chr3 87263497 C T 2.40E-05 Urinary metabolites / / 21572414 rs6773746 chr3 87265821 T G 6.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs12488607 chr3 87267240 T C 6.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs904115 chr3 87274437 T G 5.93E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) CHMP2B nearGene-5 23648065 rs2279720 chr3 87276699 C T 0.00000866 Preeclampsia CHMP2B cds-synon 22432041 rs13061754 chr3 87280088 C T 1.52E-05 Cardiovascular disease CHMP2B intron pha003065 rs10511133 chr3 87284401 C T 0.000338 Height (Pygmy height) CHMP2B intron 22570615 rs9858626 chr3 87287120 G A 0.000567 Height (Pygmy height) CHMP2B intron 22570615 rs6768771 chr3 87290389 A G 1.50E-05 Cardiovascular disease CHMP2B intron pha003065 rs2879985 chr3 87293542 G A 2.84E-04 Suicide attempts in bipolar disorder CHMP2B intron 21423239 rs1044499 chr3 87299075 A C 0.00000866 Preeclampsia CHMP2B cds-synon 22432041 rs3804602 chr3 87301263 T C 3.75E-04 Suicide attempts in bipolar disorder CHMP2B intron 21423239 rs1060241 chr3 87304561 G A 2.87E-04 Suicide attempts in bipolar disorder CHMP2B UTR-3 21423239 rs7428816 chr3 87307547 G A 4.15E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3804605 chr3 87308553 C G 2.63E-04 Suicide attempts in bipolar disorder POU1F1 nearGene-3 21423239 rs12486159 chr3 87311893 T A 3.30E-04 Suicide attempts in bipolar disorder POU1F1 intron 21423239 rs9837195 chr3 87313147 A G 7.12E-06 Cardiovascular disease POU1F1 intron pha003065 rs9837195 chr3 87313147 A G 9.22E-05 HDL cholesterol POU1F1 intron pha003075 rs9822911 chr3 87318758 T C 3.00E-05 Cardiovascular disease POU1F1 intron pha003065 rs9822911 chr3 87318758 T C 3.48E-05 HDL cholesterol POU1F1 intron pha003075 rs17189466 chr3 87321022 T C 1.40E-05 Urinary metabolites POU1F1 intron 21572414 rs17024118 chr3 87321757 A G 3.24E-05 Cardiovascular disease POU1F1 intron pha003065 rs300978 chr3 87323334 G T 1.41E-05 Cardiovascular disease POU1F1 intron pha003065 rs300978 chr3 87323334 G T 3.40E-05 HDL cholesterol POU1F1 intron pha003075 rs2633674 chr3 87328365 G A 1.10E-05 Urinary metabolites / / 21572414 rs2172685 chr3 87342944 C T 4.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs300989 chr3 87344797 A G 8.34E-06 Cardiovascular disease / / pha003065 rs2642318 chr3 87347466 T C 8.68E-06 Cardiovascular disease / / pha003065 rs1497411 chr3 87349897 C T 0.0000771 Placental abruption / / 23205182 rs12492392 chr3 87350420 A G 6.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs903292 chr3 87351380 C T 8.68E-06 Cardiovascular disease / / pha003065 rs4345069 chr3 87352633 G A 1.50E-05 Urinary metabolites / / 21572414 rs1845427 chr3 87357589 C T 7.49E-06 Cardiovascular disease / / pha003065 rs2646229 chr3 87363580 T C 6.20E-05 Cardiovascular disease / / pha003065 rs2646229 chr3 87363580 T C 8.96E-05 HDL cholesterol / / pha003075 rs7629275 chr3 87369511 T G 7.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs2642349 chr3 87370697 G A 1.10E-05 Urinary metabolites / / 21572414 rs6551471 chr3 87371282 G T 1.06E-05 Cardiovascular disease / / pha003065 rs6551471 chr3 87371282 G T 4.74E-05 Fibrinogen / / pha003068 rs4859055 chr3 87373894 C T 4.91E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs4859055 chr3 87373894 C T 7.24E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs11709932 chr3 87383582 G A 3.83E-04 Multiple complex diseases / / 17554300 rs11709932 chr3 87383582 G A 8.80E-06 Urinary metabolites / / 21572414 rs11127978 chr3 87386029 A T 4.61E-04 Multiple complex diseases / / 17554300 rs2342158 chr3 87386369 A G 5.25E-04 Multiple complex diseases / / 17554300 rs2342158 chr3 87386369 A G 8.20E-06 Urinary metabolites / / 21572414 rs17024255 chr3 87397099 A G 6.27E-04 Multiple complex diseases / / 17554300 rs17024255 chr3 87397099 A G 8.20E-06 Urinary metabolites / / 21572414 rs12634320 chr3 87397470 G A 1.40E-05 Urinary metabolites / / 21572414 rs12637307 chr3 87397841 T C 5.70E-05 Multiple complex diseases / / 17554300 rs12637307 chr3 87397841 T C 8.70E-06 Urinary metabolites / / 21572414 rs7626102 chr3 87398577 T C 9.50E-06 Urinary metabolites / / 21572414 rs9882711 chr3 87400383 T C 3.20E-06 Urinary metabolites / / 21572414 rs1011609 chr3 87401121 A G 7.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs6789301 chr3 87406236 T C 1.50E-04 Smoking initiation / / 24665060 rs1494259 chr3 87417983 T A 1.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs983717 chr3 87419255 A T 1.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs1389679 chr3 87421298 G A 1.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs9848337 chr3 87424037 T G 1.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs9863213 chr3 87428317 A G 1.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs13076266 chr3 87431686 T C 2.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs6769149 chr3 87436327 A T 9.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs4858959 chr3 87436489 T C 5.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs1494250 chr3 87438076 A T 4.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs6776212 chr3 87438524 A C 5.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs1494252 chr3 87439974 T C 7.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs7430556 chr3 87445713 T C 8.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs17024472 chr3 87447949 A G 3.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs1494255 chr3 87448376 A G 4.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs12486356 chr3 87456495 C T 4.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs12630755 chr3 87457926 G A 1.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs11917983 chr3 87458840 G A 2.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs7619499 chr3 87461795 A T 3.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs7622319 chr3 87461843 T C 3.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs9846842 chr3 87462333 C G 5.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs9873569 chr3 87466305 A G 9.60E-06 Urinary metabolites / / 21572414 rs9815149 chr3 87486475 G C 5.10E-05 Serum metabolites / / 19043545 rs9834692 chr3 87495550 C T 3.00E-09 Brain connectivity / / 23471985 rs9883474 chr3 87525449 C A 3.00E-09 Brain connectivity / / 23471985 rs17465479 chr3 87528969 C A 8.19E-05 Glycosylated haemoglobin levels / / 17255346 rs17465479 chr3 87528969 C A 9.10E-05 Lung adenocarcinoma / / 22797724 rs17525168 chr3 87532267 A T 8.19E-05 Glycosylated haemoglobin levels / / 17255346 rs1106145 chr3 87548405 G T 3.42E-04 Parkinson's disease / / 17052657 rs17525351 chr3 87548544 T C 4.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs2175180 chr3 87566304 C T 2.55E-04 Multiple complex diseases / / 17554300 rs2048291 chr3 87618918 A C 3.48E-04 Dental caries / / 21940522 rs4561856 chr3 87660121 G T 0.0000179 Alcohol craving with or without dependence / / 22481050 rs9860340 chr3 87783976 A G 4.00E-06 Electroencephalographic traits in alcoholism / / 22554406 rs2880695 chr3 87833897 C T 4.66E-05 Post-operative nausea and vomiting / / 21694509 rs959132 chr3 87854277 T C 1.10E-04 Osteoarthritis / / 19508968 rs959132 chr3 87854277 T C 6.72E-05 Coronary heart disease / / pha003032 rs17025015 chr3 87875813 C T 5.16E-05 Serum metabolites / / 19043545 rs1847313 chr3 87909084 T A 1.00E-05 Urinary metabolites / / 21572414 rs12491283 chr3 87909248 C G 6.60E-06 Urinary metabolites / / 21572414 rs17025082 chr3 87909882 G A 2.60E-05 Urinary metabolites / / 21572414 rs1503434 chr3 87910388 T C 3.83E-04 Longevity / / 22279548 rs2932286 chr3 87910931 G A 2.83E-04 Smoking initiation / / 24665060 rs12497315 chr3 87920980 G A 2.60E-05 Urinary metabolites / / 21572414 rs1864617 chr3 87948318 T C 2.83E-04 Coronary heart disease / / 21971053 rs2915287 chr3 87957076 G A 4.68E-05 HIV-1 control / / 20041166 rs17025178 chr3 87978091 A G 1.90E-05 Urinary metabolites / / 21572414 rs10511135 chr3 87983962 C A 1.90E-05 Urinary metabolites / / 21572414 rs4858927 chr3 88030689 A G 4.68E-05 HIV-1 control / / 20041166 rs9863076 chr3 88033939 T G 3.43E-05 Lymphocyte counts HTR1F intron 22286170 rs1503433 chr3 88037200 C A 0.00036 Coronary artery calcification HTR1F intron 23727086 rs4858970 chr3 88048652 C T 4.68E-05 HIV-1 control / / 20041166 rs1431154 chr3 88074793 G A 4.68E-05 HIV-1 control / / 20041166 rs73144035 chr3 88077379 C T 0.0000996 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4616669 chr3 88086823 G A 4.73E-05 HIV-1 control / / 20041166 rs12629581 chr3 88171228 A C 9.80E-04 Alcohol consumption (maxi-drinks) CGGBP1 intron 24277619 rs4414876 chr3 88183068 A C 5.91E-07 Lymphocyte counts CGGBP1 intron 22286170 rs7432826 chr3 88190768 C A 7.44E-05 Information processing speed CGGBP1 intron 21130836 rs11916151 chr3 88280676 T A 0.00000554 Coronary artery disease / / 23202125 rs6551304 chr3 88306596 A G 7.35E-04 Schizophrenia / / 19197363 rs2061372 chr3 88336413 G A 6.95E-04 Schizophrenia / / 19197363 rs2168809 chr3 88377746 T C 3.60E-07 Primary biliary cirrhosis / / 23000144 rs2168809 chr3 88377746 T C 0.00000036 Facial morphology / / 23028347 rs9858909 chr3 88378348 A G 2.89E-07 Primary biliary cirrhosis / / 23000144 rs9858909 chr3 88378348 A G 0.000000289 Facial morphology / / 23028347 rs9874952 chr3 88381469 A C 8.13E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12494959 chr3 88414986 A G 1.00E-04 Major depressive disorder LOC100506944 intron 21042317 rs9816432 chr3 88442421 G A 6.55E-04 Response to taxane treatment (placlitaxel) LOC100506944 intron 23006423 rs1463473 chr3 88455499 G A 5.91E-05 Schizophrenia (cytomegalovirus infection interaction) LOC100506944 intron 23358160 rs1463473 chr3 88455499 G A 5.46E-06 Socioeconomic Factors LOC100506944 intron pha003067 rs1458005 chr3 88462605 A C 7.32E-06 Socioeconomic Factors LOC100506944 intron pha003067 rs7645228 chr3 88467206 C A 1.48E-05 Socioeconomic Factors LOC100506944 intron pha003067 rs4859028 chr3 88478666 A G 2.71E-05 Monocyte chemoattractant protein-1 LOC100506944 intron pha003071 rs4563418 chr3 88479786 G A 3.87E-05 Response to acetaminophen (hepatotoxicity) LOC100506944 intron 21177773 rs998268 chr3 88511685 A G 3.42E-04 Multiple complex diseases LOC100506944 intron 17554300 rs11713321 chr3 88514766 T A 7.15E-04 Multiple complex diseases / / 17554300 rs7640178 chr3 88514808 C T 8.72E-04 Type 2 diabetes / / 17463246 rs7638511 chr3 88520988 A T 6.57E-04 Type 2 diabetes / / 17463246 rs2880961 chr3 88524175 C T 2.00E-07 Response to acetaminophen (hepatotoxicity) / / 21177773 rs7617735 chr3 88533115 T A 1.67E-04 Multiple complex diseases / / 17554300 rs6803234 chr3 88589247 A G 2.54E-08 Metabolite levels / / 23281178 rs7614273 chr3 88591827 T C 2.54E-08 Metabolite levels / / 23281178 rs9878827 chr3 88597239 T G 2.54E-08 Metabolite levels / / 23281178 rs6419877 chr3 88609467 A G 2.54E-08 Metabolite levels / / 23281178 rs7432027 chr3 88611423 T G 5.09E-08 Metabolite levels / / 23281178 rs7432026 chr3 88611597 A C 2.54E-08 Metabolite levels / / 23281178 rs6551346 chr3 88613505 T C 2.54E-08 Metabolite levels / / 23281178 rs7372825 chr3 88620182 C A 2.54E-08 Metabolite levels / / 23281178 rs6551361 chr3 88750857 T C 6.87E-05 Depression (quantitative trait) / / 23290196 rs11927424 chr3 88757831 A G 3.02E-05 Depression (quantitative trait) / / 23290196 rs7641985 chr3 88758307 A C,T 3.14E-05 Depression (quantitative trait) / / 23290196 rs1587150 chr3 88763195 T A 3.27E-05 Depression (quantitative trait) / / 23290196 rs1353416 chr3 88775481 G A 2.97E-05 Depression (quantitative trait) / / 23290196 rs6551366 chr3 88786963 G C 3.66E-05 Depression (quantitative trait) / / 23290196 rs17026230 chr3 88790882 G A 5.86E-06 Depression (quantitative trait) / / 23290196 rs11914750 chr3 88793424 T C 5.58E-06 Depression (quantitative trait) / / 23290196 rs2046327 chr3 88793982 C T 1.29E-05 Major depressive disorder / / 19107115 rs2046327 chr3 88793982 C T 8.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10511142 chr3 88863054 A G 4.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1384771 chr3 88872504 G A 3.28E-05 Cognitive decline / / 23732972 rs6551374 chr3 88873356 C T 1.35E-06 Basophils / / pha003087 rs1384778 chr3 88891990 T C 4.37E-04 Insulin resistance / / 21901158 rs4552364 chr3 88974863 C T 1.77E-07 Primary biliary cirrhosis / / 23000144 rs4552364 chr3 88974863 C T 0.000000177 Facial morphology / / 23028347 rs12497795 chr3 88977897 C T 2.00E-06 Periodontitis (Mean PAL) / / 24024966 rs4353811 chr3 88981207 T C 2.20E-07 Primary biliary cirrhosis / / 23000144 rs4353811 chr3 88981207 T C 0.00000022 Facial morphology / / 23028347 rs4325924 chr3 88989209 T C 4.69E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs958144 chr3 88994672 C T 4.31E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7650924 chr3 89018866 T C 3.59E-04 Multiple complex diseases / / 17554300 rs17026569 chr3 89048023 C T 1.20E-04 Type 2 diabetes / / 17463246 rs4555526 chr3 89075886 A G 7.00E-04 Polycystic ovary syndrome / / 22178785 rs12486049 chr3 89241280 T G 3.50E-05 Type 2 diabetes EPHA3 intron 17460697 rs1040017 chr3 89329632 T G 8.63E-04 Orofacial clefts EPHA3 intron 22863734 rs1015126 chr3 89364451 A G 4.38E-04 Multiple complex diseases EPHA3 intron 17554300 rs35968370 chr3 89466339 A T 8.43E-04 Orofacial clefts EPHA3 intron 22863734 rs6771054 chr3 89489529 T C 3.63E-04 Orofacial clefts EPHA3 intron 22863734 rs7637670 chr3 89493167 G A 3.22E-04 Orofacial clefts EPHA3 intron 22863734 rs987748 chr3 89494030 C A 2.12E-04 Orofacial clefts EPHA3 intron 22863734 rs7633500 chr3 89497082 G A 7.35E-05 Orofacial clefts EPHA3 intron 22863734 rs7626735 chr3 89506958 C A 9.83E-05 Triglycerides EPHA3 intron pha003080 rs35124509 chr3 89521693 T C 9.68E-06 Orofacial clefts EPHA3 missense 22863734 rs12636275 chr3 89523038 C A 7.62E-06 Orofacial clefts EPHA3 intron 22863734 rs2117137 chr3 89525505 A G 7.76E-06 Orofacial clefts EPHA3 intron 22863734 rs7650184 chr3 89530057 C A 9.08E-07 Orofacial clefts EPHA3 UTR-3 22863734 rs7632427 chr3 89534377 T C 5.36E-07 Cleft lip / / 20436469 rs7632427 chr3 89534377 T C 4.00E-08 Orofacial clefts / / 22863734 rs11706497 chr3 89538366 C T 5.75E-04 Obesity (extreme) / / 21935397 rs11918555 chr3 89541934 C T 2.06E-07 Orofacial clefts / / 22863734 rs6774870 chr3 89564891 C T 8.24E-06 Orofacial clefts / / 22863734 rs907548 chr3 89574852 C T 9.84E-06 Orofacial clefts / / 22863734 rs724972 chr3 89581408 A T 4.66E-04 Alzheimer's disease / / 17998437 rs724972 chr3 89581408 A T 3.26E-06 Orofacial clefts / / 22863734 rs7652296 chr3 89587262 A G 2.39E-06 Orofacial clefts / / 22863734 rs7621573 chr3 89595252 C T 3.05E-07 Orofacial clefts / / 22863734 rs10511145 chr3 89597679 C A 7.30E-06 Cleft lip / / 20436469 rs10511145 chr3 89597679 C A 3.59E-07 Orofacial clefts / / 22863734 rs17027018 chr3 89604774 C T 2.96E-07 Orofacial clefts / / 22863734 rs541455490 chr3 89612941 C CA 1.20E-06 Orofacial clefts / / 22863734 rs55747880 chr3 89612941 C A 1.20E-06 Orofacial clefts / / 22863734 rs7635916 chr3 89633140 G A 5.16E-07 Orofacial clefts / / 22863734 rs7618160 chr3 89635631 A C 1.71E-04 Lung function (forced vital capacity) / / 24023788 rs6551413 chr3 89640350 C G 5.82E-07 Orofacial clefts / / 22863734 rs6795325 chr3 89642054 T C 9.03E-07 Orofacial clefts / / 22863734 rs1520596 chr3 89645542 T C 1.45E-06 Orofacial clefts / / 22863734 rs60243237 chr3 89694053 C T 4.99E-06 Orofacial clefts / / 22863734 rs59381722 chr3 89701482 T G 9.36E-06 Orofacial clefts / / 22863734 rs6551415 chr3 89705161 G T 2.39E-06 Orofacial clefts / / 22863734 rs11925143 chr3 89723684 G A 4.47E-06 Orofacial clefts / / 22863734 rs7613412 chr3 89724217 A T 4.47E-06 Orofacial clefts / / 22863734 rs7628116 chr3 89730653 G C 8.23E-05 Depression (quantitative trait) / / 23290196 rs2049103 chr3 89731393 A G 7.68E-05 Depression (quantitative trait) / / 23290196 rs7631883 chr3 89732392 G A 9.27E-05 Depression (quantitative trait) / / 23290196 rs2139686 chr3 89733298 A C 9.53E-05 Depression (quantitative trait) / / 23290196 rs7620638 chr3 89737061 A G 8.70E-05 Depression (quantitative trait) / / 23290196 rs11923274 chr3 89739704 A G 7.73E-05 Depression (quantitative trait) / / 23290196 rs2881577 chr3 89759790 A G 7.94E-05 Depression (quantitative trait) / / 23290196 rs7651475 chr3 89761271 C T 7.93E-05 Depression (quantitative trait) / / 23290196 rs11917572 chr3 89768052 T C 6.42E-05 Depression (quantitative trait) / / 23290196 rs12106694 chr3 89952298 A T 2.60E-05 Urinary metabolites / / 21572414 rs6551454 chr3 90194352 G T 6.62E-05 Cognitive impairment induced by topiramate / / 22091778 rs13059313 chr3 90194622 C A 7.17E-05 Cytomegalovirus antibody response / / 21993531 rs76877671 chr3 93598157 A G 0.00073 Prostate cancer PROS1 cds-synon 23555315 rs4857037 chr3 93627812 G A 6.60E-05 HDL particle features PROS1 intron 21283740 rs7428007 chr3 93638017 A G 4.77E-04 Alcohol dependence PROS1 intron 21314694 rs8178591 chr3 93681489 C T 4.60E-05 Carotid intima media thickness PROS1 intron 19679847 rs13062355 chr3 93688511 G A 3.64E-06 Carotenoid and tocopherol levels PROS1 intron 19185284 rs921728 chr3 93833575 A G 3.54E-04 Parkinson's disease NSUN3 intron 17052657 rs9844341 chr3 93936708 A G 1.40E-05 Urinary metabolites / / 21572414 rs13100852 chr3 93946101 G A 0.000728 Salmonella-induced pyroptosis / / 22837397 rs7640233 chr3 93973213 T C 4.95E-04 Alzheimer's disease (late onset) / / 21379329 rs9815406 chr3 93974279 T C 4.70E-04 Alzheimer's disease (late onset) / / 21379329 rs10511147 chr3 94030669 A C 7.29E-04 Schizophrenia / / 19197363 rs17749495 chr3 94183112 A C 5.30E-05 Type 1 diabetes / / 18978792 rs35679394 chr3 94185767 T C 6.56E-04 Smoking initiation / / 24665060 rs472026 chr3 94205951 T C 7.75E-04 Smoking quantity / / 24665060 rs522161 chr3 94206032 A C 7.14E-04 Smoking quantity / / 24665060 rs13067306 chr3 94243713 G A 4.00E-07 Blood pressure measurement (high sodium intervention) / / 24165912 rs13067306 chr3 94243713 G A 5.00E-06 Blood pressure measurement (high sodium intervention) / / 24165912 rs9850669 chr3 94245163 C T 8.08E-04 Multiple complex diseases / / 17554300 rs9809680 chr3 94335547 G A 1.00E-04 Prostate cancer / / 21743057 rs6791440 chr3 94342853 T C 1.00E-04 Prostate cancer / / 21743057 rs9290624 chr3 94343965 T A 1.00E-04 Prostate cancer / / 21743057 rs6791218 chr3 94345578 C G 1.00E-04 Prostate cancer / / 21743057 rs1873072 chr3 94345961 T C 1.00E-04 Prostate cancer / / 21743057 rs1374901 chr3 94522270 C T 1.15E-06 Multiple complex diseases / / 17554300 rs6765666 chr3 94541813 G A 5.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs4629334 chr3 94581146 G A 4.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs4642127 chr3 94601417 C T 1.30E-04 Multiple complex diseases / / 17554300 rs7630043 chr3 94614746 G A 2.00E-04 Information processing speed / / 21130836 rs12492825 chr3 94623600 C T 2.66E-04 Response to alcohol consumption (flushing response) / / 24277619 rs9790140 chr3 94675697 G T 4.10E-05 Melanoma LOC255025 intron 21926416 rs9790140 chr3 94675697 G T 8.36E-04 Response to alcohol consumption (flushing response) LOC255025 intron 24277619 rs9817636 chr3 94833030 A G 8.63E-05 Multiple complex diseases / / 17554300 rs6802456 chr3 94913312 C T 7.33E-04 Multiple complex diseases / / 17554300 rs7615904 chr3 94913348 T G 6.47E-05 Bipolar disorder / / 19488044 rs1114509 chr3 95034322 T C 1.90E-04 Multiple complex diseases / / 17554300 rs569216 chr3 95094716 A G 1.53E-04 Body mass index / / 21701565 rs16857046 chr3 95115832 A G 4.48E-04 Body mass index / / 21701565 rs490783 chr3 95130274 A G 8.56E-05 Multiple complex diseases / / 17554300 rs551192 chr3 95131358 C G 1.74E-04 Multiple complex diseases / / 17554300 rs7620512 chr3 95146114 A C 1.07E-04 Multiple complex diseases / / 17554300 rs9288907 chr3 95146462 A C 5.36E-06 Body mass index / / 19584900 rs9288907 chr3 95146462 A C 6.88E-05 Body mass index / / 19584900 rs2311291 chr3 95148975 G A 2.65E-04 Smoking initiation / / 24665060 rs6784642 chr3 95151467 G T 1.14E-04 Body mass index / / 21701565 rs6784642 chr3 95151467 G T 8.39E-04 Body mass index / / 21701565 rs6776804 chr3 95152427 A G 1.18E-04 Body mass index / / 21701565 rs6776804 chr3 95152427 A G 8.40E-04 Body mass index / / 21701565 rs41450548 chr3 95152892 G A 2.77E-04 Body mass index / / 21701565 rs13077133 chr3 95155263 G C 4.54E-04 Body mass index / / 21701565 rs1914881 chr3 95155374 G A 2.43E-04 Body mass index / / 21701565 rs10511152 chr3 95156018 G A 2.45E-04 Body mass index / / 21701565 rs13090887 chr3 95157543 C T 1.16E-04 Body mass index / / 21701565 rs13090887 chr3 95157543 C T 8.43E-04 Body mass index / / 21701565 rs4371519 chr3 95176370 C T 1.01E-04 Body mass index / / 21701565 rs4371519 chr3 95176370 C T 5.92E-04 Body mass index / / 21701565 rs7652786 chr3 95181382 C T 2.49E-04 Body mass index / / 21701565 rs5000487 chr3 95181602 T G 1.45E-04 Body mass index / / 21701565 rs5000487 chr3 95181602 T G 5.35E-04 Body mass index / / 21701565 rs7628662 chr3 95183629 T A 2.30E-05 Urinary metabolites / / 21572414 rs7628662 chr3 95183629 T A 3.41E-04 Body mass index / / 21701565 rs7629169 chr3 95184353 A G 3.79E-04 Body mass index / / 21701565 rs7629169 chr3 95184353 A G 5.12E-05 Body mass index / / 21701565 rs5011739 chr3 95184490 A G 1.15E-04 Body mass index / / 21701565 rs5011739 chr3 95184490 A G 8.40E-04 Body mass index / / 21701565 rs9850286 chr3 95205522 C T 3.94E-04 Body mass index / / 21701565 rs11919338 chr3 95209823 G T 6.48E-04 Type 2 diabetes / / 17463246 rs11919338 chr3 95209823 G T 2.66E-04 Body mass index / / 21701565 rs4574293 chr3 95211175 C G 4.20E-04 Body mass index / / 21701565 rs4574293 chr3 95211175 C G 7.30E-05 Body mass index / / 21701565 rs12374087 chr3 95219791 T C 3.31E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7631830 chr3 95225762 A G 2.52E-04 Body mass index / / 21701565 rs7631830 chr3 95225762 A G 5.16E-05 Body mass index / / 21701565 rs6786347 chr3 95234331 C G 2.19E-04 Body mass index / / 21701565 rs6801582 chr3 95234379 T A 3.59E-04 Body mass index / / 21701565 rs6801582 chr3 95234379 T A 5.42E-04 Body mass index / / 21701565 rs6790116 chr3 95253096 G A 1.78E-04 Body mass index / / 21701565 rs6787987 chr3 95277621 G A 4.51E-04 Body mass index / / 21701565 rs6787987 chr3 95277621 G A 8.19E-05 Body mass index / / 21701565 rs6437927 chr3 95288786 T C 1.84E-04 Body mass index / / 21701565 rs13091676 chr3 95291185 A G 2.86E-04 Body mass index / / 21701565 rs4073617 chr3 95298427 C T 1.83E-04 Body mass index / / 21701565 rs11710879 chr3 95318618 A G 4.18E-04 Body mass index / / 21701565 rs11710879 chr3 95318618 A G 7.21E-05 Body mass index / / 21701565 rs7431311 chr3 95324170 G C 3.02E-04 Body mass index / / 21701565 rs6803348 chr3 95334933 T G 8.89E-04 Myopia (pathological) / / 21095009 rs6437963 chr3 95335260 T C 4.19E-04 Body mass index / / 21701565 rs6437963 chr3 95335260 T C 7.24E-05 Body mass index / / 21701565 rs6437968 chr3 95337468 G A 8.31E-04 Type 2 diabetes / / 17463246 rs12486609 chr3 95344899 A C 7.37E-05 Lipid levels / / pha003082 rs12497437 chr3 95371394 C A 9.47E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6767658 chr3 95374182 T C 3.82E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1511731 chr3 95516022 C T 4.85E-04 Multiple complex diseases / / 17554300 rs1511730 chr3 95516190 T C 9.01E-04 Multiple complex diseases / / 17554300 rs1368515 chr3 95549039 T C 8.85E-05 Multiple complex diseases / / 17554300 rs10934261 chr3 95557085 T C 1.33E-04 Multiple complex diseases / / 17554300 rs13059492 chr3 95606270 C A 4.57E-05 Multiple complex diseases / / 17554300 rs980856 chr3 95617191 A G 3.85E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs1433247 chr3 95648883 A G 4.97E-04 Multiple complex diseases / / 17554300 rs9837738 chr3 95654115 G C 5.98E-04 Multiple complex diseases / / 17554300 rs6777564 chr3 95671292 T C 6.47E-04 Multiple complex diseases / / 17554300 rs9814870 chr3 95688843 A G 7.00E-07 Male infertility / / 19478329 rs12633936 chr3 95693066 T C 2.40E-05 Urinary metabolites / / 21572414 rs4589952 chr3 95702105 C T 2.96E-05 Type 2 diabetes / / 17463246 rs6773783 chr3 95711037 A G 1.32E-04 Type 2 diabetes / / 17463246 rs4404462 chr3 95731858 T C 2.94E-04 Parkinson's disease / / 17052657 rs11713687 chr3 95745701 A G 7.84E-04 Acute lung injury / / 22295056 rs6438267 chr3 95767088 A T 9.23E-04 Parkinson's disease / / 17052657 rs4256148 chr3 95769703 A G 3.34E-04 Parkinson's disease / / 17052657 rs4462982 chr3 95778099 T C 8.55E-04 Body mass index / / 21701565 rs7647183 chr3 95825679 A G 3.96E-04 Multiple complex diseases / / 17554300 rs9866011 chr3 95849132 A C 2.85E-04 Type 2 diabetes / / 17463246 rs111325002 chr3 95853632 A G 4.00E-07 Cocaine dependence / / 23958962 rs11716789 chr3 95875551 G C 7.75E-04 Body mass index / / 21701565 rs7636345 chr3 95908799 G T 8.43E-04 Body mass index / / 21701565 rs9861020 chr3 95915498 G T 8.94E-04 Body mass index / / 21701565 rs7619022 chr3 95935906 A G 2.68E-04 Multiple complex diseases / / 17554300 rs1020612 chr3 95995099 T C 6.20E-04 Type 2 diabetes / / 17463246 rs35430887 chr3 95997959 T A 0.00007946 Sarcoidosis / / 22952805 rs35772335 chr3 95998046 T C 0.00007946 Sarcoidosis / / 22952805 rs2167937 chr3 95999354 T C 8.81E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs13076095 chr3 96000435 G C 0.00007562 Sarcoidosis / / 22952805 rs6765296 chr3 96000890 G C 0.00007562 Sarcoidosis / / 22952805 rs67641371 chr3 96001651 C T 0.00007311 Sarcoidosis / / 22952805 rs7611281 chr3 96002983 T A 0.000087 Sarcoidosis / / 22952805 rs7641736 chr3 96003204 C A 0.00009167 Sarcoidosis / / 22952805 rs12497163 chr3 96003706 G A 8.81E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs13088064 chr3 96020322 T A 8.81E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs6763181 chr3 96037804 C T 8.81E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs16830554 chr3 96042675 C T 8.77E-04 Type 2 diabetes / / 17463246 rs9839551 chr3 96043188 C G 8.81E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs12695385 chr3 96053691 G A 8.81E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs1877807 chr3 96085680 A G 9.81E-05 Major depressive disorder / / 21621269 rs13073413 chr3 96090309 T C 9.46E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2875764 chr3 96112179 C T 3.75E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6797214 chr3 96121386 G A 3.75E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs980031 chr3 96140650 A G 6.25E-05 Coronary heart disease / / pha003030 rs326296 chr3 96161227 G C 8.09E-11 Multiple complex diseases / / 17554300 rs12634381 chr3 96168115 G A 1.48E-05 Coronary heart disease / / pha003030 rs34658433 chr3 96182315 G A 6.37E-04 Type 2 diabetes / / 17463246 rs326293 chr3 96187781 T C 9.03E-05 Multiple complex diseases / / 17554300 rs690994 chr3 96244775 G A 3.55E-05 Lipoproteins / / pha003079 rs7631577 chr3 96308055 G T 6.02E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs7631577 chr3 96308055 G T 3.59E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs6796026 chr3 96328827 C T 8.00E-06 Obesity-related traits / / 23251661 rs1825828 chr3 96390960 C T 6.98E-07 Bipolar disorder / / 19488044 rs1825828 chr3 96390960 C T 1.82E-07 Bipolar Disorder / / pha002858 rs6793516 chr3 96400599 G A 5.00E-06 Blood trace element (Zn levels) / / 23720494 rs6764705 chr3 96432294 G T 8.61E-05 Multiple complex diseases / / 17554300 rs9826636 chr3 96547856 G A 7.13E-06 Coronary heart disease EPHA6 intron pha003030 rs2318152 chr3 96563889 A C,G,T 5.18E-05 Multiple complex diseases EPHA6 intron 17554300 rs10511159 chr3 96634492 A G 3.20E-05 Iron levels EPHA6 intron 21208937 rs1806558 chr3 96675504 G A 6.00E-06 Urinary metabolites EPHA6 intron 21572414 rs7650621 chr3 96682262 A C 2.00E-06 Obesity-related traits EPHA6 intron 23251661 rs2027815 chr3 96719929 C T 5.46E-04 Multiple complex diseases EPHA6 intron 17554300 rs2213260 chr3 96746928 G A 1.61E-05 LDL lipoproteins EPHA6 intron pha002902 rs7612669 chr3 96779326 A G 4.98E-05 LDL lipoproteins EPHA6 intron pha002902 rs7640007 chr3 96789865 G A 9.81E-05 LDL lipoproteins EPHA6 intron pha002902 rs11915818 chr3 96814320 T A 1.30E-05 Urinary metabolites EPHA6 intron 21572414 rs1500704 chr3 96827817 G A 8.48E-04 Multiple complex diseases EPHA6 intron 17554300 rs1598915 chr3 97105552 C T 9.15E-04 Alcohol consumption (maxi-drinks) EPHA6 intron 24277619 rs1458303 chr3 97168740 A T 3.00E-07 Blood trace element (Cu levels) EPHA6 intron 23720494 rs9825788 chr3 97185056 G A 6.81E-05 Multiple complex diseases EPHA6 intron 17554300 rs6784670 chr3 97188153 G A 5.27E-04 Smoking cessation EPHA6 intron 24665060 rs6801975 chr3 97191339 C T 4.79E-04 Smoking cessation EPHA6 intron 24665060 rs2305893 chr3 97194317 T G 6.18E-04 Smoking cessation EPHA6 intron 24665060 rs2034941 chr3 97200108 T C 5.59E-04 Smoking cessation EPHA6 intron 24665060 rs1379842 chr3 97201750 C A 9.15E-04 Alcohol consumption (maxi-drinks) EPHA6 intron 24277619 rs6795420 chr3 97215583 A G 7.89E-04 Alcohol consumption (maxi-drinks) EPHA6 intron 24277619 rs4857268 chr3 97240654 G A 7.91E-04 Smoking cessation EPHA6 intron 24665060 rs2053246 chr3 97300717 G A 4.80E-04 Smoking cessation EPHA6 intron 24665060 rs301927 chr3 97346618 G A 3.44E-05 Paclitaxel-induced neuropathy EPHA6 intron 23776197 rs10222570 chr3 97355029 C T 3.01E-04 Multiple sclerosis (OCB status) EPHA6 intron 23785401 rs167306 chr3 97384488 T C 7.79E-05 Serum metabolites EPHA6 intron 19043545 rs1009521 chr3 97386798 C T 9.09E-04 Type 2 diabetes EPHA6 intron 17463246 rs1658146 chr3 97388193 G A 6.31E-05 Multiple sclerosis (age of onset) EPHA6 intron 19010793 rs301923 chr3 97411617 A G 7.41E-05 Multiple sclerosis (age of onset) EPHA6 intron 19010793 rs4257593 chr3 97443050 C T 2.61E-04 Response to taxane treatment (placlitaxel) EPHA6 intron 23006423 rs6439361 chr3 97472556 G A 4.37E-04 Alcohol dependence / / 20201924 rs3856571 chr3 97549049 G T 3.74E-04 Multiple complex diseases CRYBG3 intron 17554300 rs1354728 chr3 97558176 A G 3.96E-04 Multiple complex diseases CRYBG3 intron 17554300 rs699300 chr3 97566573 G A 8.74E-04 Alcohol dependence CRYBG3 intron 21314694 rs3856567 chr3 97583676 A G 5.38E-04 Alcohol dependence CRYBG3 intron 20201924 rs6786354 chr3 97595379 G A 6.04E-04 Alcohol dependence CRYBG3 missense 20201924 rs1498652 chr3 97620528 A C 4.88E-04 Alcohol dependence CRYBG3 intron 20201924 rs4857068 chr3 97622697 C A 8.07E-04 Alcohol dependence CRYBG3 intron 20201924 rs1391665 chr3 97633737 T C 7.65E-04 Alcohol dependence CRYBG3 intron 20201924 rs17302656 chr3 97650715 A G 5.97E-04 Multiple complex diseases CRYBG3 intron 17554300 rs6796047 chr3 97698818 C T 4.59E-05 Multiple complex diseases / / 17554300 rs6780855 chr3 97704434 C A 9.70E-05 Endometriosis / / 21151130 rs1688377 chr3 97721745 T C 9.37E-04 Suicide attempts in bipolar disorder GABRR3 intron 21423239 rs6769842 chr3 97752197 A G 4.77E-05 Major depressive disorder GABRR3 intron 22472876 rs832067 chr3 97754170 A G 5.03E-05 Major depressive disorder / / 22472876 rs1694834 chr3 97759649 A T 9.00E-05 Major depressive disorder / / 22472876 rs832052 chr3 97766185 A G 9.22E-05 Major depressive disorder / / 22472876 rs7643404 chr3 97771603 A G 5.63E-05 Major depressive disorder / / 22472876 rs861271 chr3 97771736 T G 2.13E-05 Major depressive disorder / / 22472876 rs832095 chr3 97772007 A G 5.41E-05 Major depressive disorder / / 22472876 rs1352891 chr3 97784175 C A 7.09E-04 Smoking initiation / / 24665060 rs4130110 chr3 97873430 A G 3.15E-07 Odorant perception / / 23910658 rs7644271 chr3 97920897 C T 7.20E-05 Parkinson's disease (age of onset) / / 19772629 rs1497536 chr3 97955056 T C 5.05E-05 Multiple complex diseases / / 17554300 rs2316277 chr3 97991044 G T 2.15E-04 Self-reported allergy / / 23817569 rs1566167 chr3 97993889 C T 2.12E-04 Self-reported allergy / / 23817569 rs6796881 chr3 97995163 T C 2.16E-04 Self-reported allergy / / 23817569 rs2316276 chr3 98001332 T C 3.99E-04 Self-reported allergy / / 23817569 rs16839610 chr3 98001676 T C 4.00E-04 Self-reported allergy / / 23817569 rs16839214 chr3 98002419 A G 4.09E-04 Self-reported allergy OR5H2 missense 23817569 rs16839628 chr3 98003806 A T 4.51E-04 Self-reported allergy / / 23817569 rs6777938 chr3 98004783 C A 3.61E-04 Self-reported allergy / / 23817569 rs2316275 chr3 98006007 G T 3.00E-04 Self-reported allergy / / 23817569 rs6769731 chr3 98009479 G A 2.25E-04 Self-reported allergy / / 23817569 rs1603605 chr3 98015837 G A 3.12E-06 Drug-induced liver injury (flucloxacillin) / / 19483685 rs1472413 chr3 98025676 T G 3.12E-06 Drug-induced liver injury (flucloxacillin) / / 19483685 rs7634235 chr3 98033400 T C 3.12E-06 Drug-induced liver injury (flucloxacillin) / / 19483685 rs1497546 chr3 98034526 G A 2.00E-07 Drug-induced liver injury (flucloxacillin) / / 19483685 rs16839655 chr3 98037282 C G 6.96E-04 Self-reported allergy / / 23817569 rs11928290 chr3 98039620 A G 3.12E-06 Drug-induced liver injury (flucloxacillin) / / 19483685 rs1391149 chr3 98057496 A T 3.06E-04 Self-reported allergy / / 23817569 rs12630857 chr3 98057660 C T 3.20E-06 Drug-induced liver injury (flucloxacillin) / / 19483685 rs955716 chr3 98059188 C T 3.09E-04 Self-reported allergy / / 23817569 rs7637695 chr3 98102195 G A 4.66E-04 Insulin resistance / / 21901158 rs4290839 chr3 98105216 T C 9.44E-04 Self-reported allergy / / 23817569 rs9289587 chr3 98108370 A G 4.93E-04 Coronary heart disease / / 21606135 rs75457563 chr3 98169442 A G 0.00014 Prostate cancer (advanced) / / 23555315 rs1461155 chr3 98248732 T C 7.00E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs3749260 chr3 98250862 C A 1.26E-08 Corneal structure / / 23291589 rs1529047 chr3 98252027 G A 7.94E-04 Insulin resistance / / 21901158 rs1870717 chr3 98268670 A C 1.14E-06 Corneal structure / / 23291589 rs13069468 chr3 98272751 T C 3.35E-06 Corneal structure / / 23291589 rs1675505 chr3 98285043 G A 2.85E-04 Birth weight / / 17255346 rs1675505 chr3 98285043 G A 1.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4857097 chr3 98286775 T C 8.29E-05 Birth weight / / 17255346 rs4857097 chr3 98286775 T C 3.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1350791 chr3 98296446 A T 3.40E-04 Birth weight / / 17255346 rs1729963 chr3 98297057 A G 2.90E-05 Urinary metabolites / / 21572414 rs828588 chr3 98433611 T C 3.12E-05 Hodgkin's lymphoma / / 24149102 rs3755573 chr3 98489011 C T 3.37E-04 Response to cytadine analogues (cytosine arabinoside) ST3GAL6 intron 24483146 rs7431448 chr3 98493644 G A 1.45E-04 Lung function (forced expiratory volume in 1 second) ST3GAL6 intron 24023788 rs7431448 chr3 98493644 G A 2.92E-04 Lung function (forced vital capacity) ST3GAL6 intron 24023788 rs13091236 chr3 98500511 A C 9.34E-05 Cognitive performance ST3GAL6 intron 19734545 rs4425201 chr3 98504628 G A 1.19E-04 Lung function (forced vital capacity) ST3GAL6 intron 24023788 rs4425201 chr3 98504628 G A 8.48E-05 Lung function (forced expiratory volume in 1 second) ST3GAL6 intron 24023788 rs6785935 chr3 98525983 G A 1.43E-04 Lung function (forced vital capacity) DCBLD2 intron 24023788 rs6785935 chr3 98525983 G A 8.40E-05 Lung function (forced expiratory volume in 1 second) DCBLD2 intron 24023788 rs828616 chr3 98541116 G A 2.00E-06 Asthma (aspirin-intolerant) DCBLD2 cds-synon 21072201 rs2119187 chr3 98594499 G A 1.59E-04 Lung function (forced expiratory volume in 1 second) DCBLD2 intron 24023788 rs2119187 chr3 98594499 G A 1.98E-04 Lung function (forced vital capacity) DCBLD2 intron 24023788 rs1524228 chr3 98736952 A G 8.85E-04 Type 2 diabetes / / 17463246 rs2449066 chr3 98737270 G A 1.36E-04 Progressive supranuclear palsy / / 21685912 rs2462239 chr3 98738839 G A 0.000061 Endometrial cancer / / 22426144 rs2462242 chr3 98740728 T C 8.90E-04 Type 2 diabetes / / 17463246 rs2470765 chr3 98742958 A T 8.95E-04 Type 2 diabetes / / 17463246 rs2449054 chr3 98744654 A C 8.74E-04 Type 2 diabetes / / 17463246 rs2462199 chr3 98751421 G C 8.72E-04 Type 2 diabetes / / 17463246 rs2449007 chr3 98768040 C T 8.27E-04 Type 2 diabetes / / 17463246 rs2449073 chr3 98770189 A G 7.69E-04 Type 2 diabetes / / 17463246 rs704588 chr3 98849672 T C 7.99E-04 Type 2 diabetes / / 17846125 rs704592 chr3 98850962 A G 3.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs774951 chr3 98919134 G A 6.78E-04 Smoking quantity / / 24665060 rs6803675 chr3 98934512 A G 7.99E-04 Multiple complex diseases / / 17554300 rs6807964 chr3 98969437 C G 7.53E-04 Smoking quantity / / 24665060 rs1481517 chr3 99005053 T G 9.56E-04 Myopia (pathological) / / 21095009 rs4417903 chr3 99020533 T C 8.12E-04 Schizophrenia / / 21674006 rs1871791 chr3 99051153 C T 0.000235 Salmonella-induced pyroptosis / / 22837397 rs750858 chr3 99060832 A C 0.000111 Salmonella-induced pyroptosis / / 22837397 rs1481532 chr3 99078711 G T 3.38E-04 Multiple complex diseases / / 17554300 rs1871793 chr3 99083437 A G 0.000061 Salmonella-induced pyroptosis / / 22837397 rs2700667 chr3 99085806 G A 4.00E-04 Alcohol dependence / / 20201924 rs2700667 chr3 99085806 G A 3.31E-05 Monocyte chemoattractant protein-1 / / pha003071 rs10935768 chr3 99088011 C A 1.39E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2700586 chr3 99094790 C T 3.50E-04 Alcohol dependence / / 20201924 rs2700586 chr3 99094790 C T 3.31E-05 Monocyte chemoattractant protein-1 / / pha003071 rs2200019 chr3 99095896 C T 4.10E-04 Alcohol dependence / / 20201924 rs2200019 chr3 99095896 C T 5.58E-05 Monocyte chemoattractant protein-1 / / pha003071 rs2700648 chr3 99107683 G A 8.20E-04 Alcohol dependence / / 20201924 rs1481544 chr3 99113228 T C 2.37E-05 Monocyte chemoattractant protein-1 / / pha003071 rs9990265 chr3 99113500 G A 5.28E-05 Monocyte chemoattractant protein-1 / / pha003071 rs1383852 chr3 99116207 G A 5.06E-05 Monocyte chemoattractant protein-1 / / pha003071 rs2700592 chr3 99131409 T G 3.60E-05 Monocyte chemoattractant protein-1 / / pha003071 rs2929435 chr3 99132512 C T 3.82E-05 Monocyte chemoattractant protein-1 / / pha003071 rs980842 chr3 99138140 G A 3.82E-05 Monocyte chemoattractant protein-1 / / pha003071 rs9835548 chr3 99142668 A C 3.82E-05 Monocyte chemoattractant protein-1 / / pha003071 rs2670321 chr3 99167107 A C 2.00E-06 RR interval (heart rate) / / 20031603 rs9289822 chr3 99189574 T C 6.93E-05 Hemoglobin / / pha003098 rs1398741 chr3 99238606 T G 5.60E-04 Acute lung injury / / 22295056 rs1014514 chr3 99249301 T A 6.79E-04 Acute lung injury / / 22295056 rs1014515 chr3 99249640 G C 6.79E-04 Acute lung injury / / 22295056 rs4928200 chr3 99258202 G A 2.69E-04 Smoking initiation / / 24665060 rs10514745 chr3 99266122 C T 1.52E-04 Lung function (forced vital capacity) / / 24023788 rs13070584 chr3 99266337 C T 2.00E-06 Chronic kidney disease and serum creatinine levels / / 20686651 rs6772110 chr3 99307461 G A 1.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1355765 chr3 99320707 A C 8.59E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1849496 chr3 99328145 C A 9.11E-05 Triglycerides / / pha003081 rs16841441 chr3 99340297 G A 7.00E-05 Lupus / / 17911428 rs1567784 chr3 99342155 G A 3.72E-05 Triglycerides / / pha003081 rs1567784 chr3 99342155 G A 8.11E-05 Lipid levels / / pha003082 rs1361822 chr3 99354350 T C 0.00019 Coronary artery calcification / / 23727086 rs7645305 chr3 99363985 T G 0.000079 Coronary artery calcification COL8A1 intron 23727086 rs7613565 chr3 99367869 T C 7.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL8A1 intron 20877124 rs4928213 chr3 99371781 G A 6.52E-04 Multiple complex diseases COL8A1 intron 17554300 rs596300 chr3 99383030 C G 0.0002 Coronary artery calcification COL8A1 intron 23727086 rs13095226 chr3 99396272 T C 3.00E-06 Age-related macular degeneration COL8A1 intron 20385826 rs13095226 chr3 99396272 T C 9.70E-07 Age-related macular degeneration COL8A1 intron 21665990 rs629120 chr3 99425767 A T 9.69E-04 Multiple complex diseases COL8A1 intron 17554300 rs668668 chr3 99436424 C T 9.52E-05 Cleft lip COL8A1 intron 20436469 rs668668 chr3 99436424 C T 2.65E-06 Orofacial clefts COL8A1 intron 22863734 rs694429 chr3 99459669 C T 2.23E-05 Orofacial clefts COL8A1 intron 22863734 rs792829 chr3 99462647 G A 5.67E-06 Orofacial clefts COL8A1 intron 22863734 rs792841 chr3 99471308 G T 2.92E-06 Cleft lip COL8A1 intron 20436469 rs792841 chr3 99471308 G T 3.69E-05 Orofacial clefts COL8A1 intron 22863734 rs792833 chr3 99475268 C T 6.01E-06 Blood Pressure and Arterial Stiffness COL8A1 intron 17903302 rs792835 chr3 99476295 C T 1.59E-06 Cleft lip COL8A1 intron 20436469 rs792835 chr3 99476295 C T 2.82E-06 Orofacial clefts COL8A1 intron 22863734 rs704570 chr3 99477142 A G 2.97E-06 Cleft lip COL8A1 intron 20436469 rs704570 chr3 99477142 A G 1.70E-06 Orofacial clefts COL8A1 intron 22863734 rs13081855 chr3 99481539 G T 4.00E-13 Age-related macular degeneration COL8A1 intron 23455636 rs704574 chr3 99483773 A G 1.46E-06 Cleft lip COL8A1 intron 20436469 rs704574 chr3 99483773 A G 2.56E-06 Orofacial clefts COL8A1 intron 22863734 rs1038294 chr3 99503728 A G 1.35E-05 Cleft lip COL8A1 intron 20436469 rs1038294 chr3 99503728 A G 2.17E-05 Orofacial clefts COL8A1 intron 22863734 rs793494 chr3 99508768 T C 3.56E-05 Cleft lip COL8A1 intron 20436469 rs793494 chr3 99508768 T C 2.33E-05 Orofacial clefts COL8A1 intron 22863734 rs1287283 chr3 99515750 A G 7.56E-05 Orofacial clefts / / 22863734 rs41432451 chr3 99520888 T C 8.74E-04 Multiple complex diseases / / 17554300 rs793475 chr3 99543764 A G 1.24E-06 Axial length C3orf26 intron 24144296 rs793470 chr3 99548274 A G 2.00E-06 Axial length C3orf26 intron 24144296 rs7626245 chr3 99570761 G C 6.80E-06 Age-related macular degeneration FILIP1L intron 21665990 rs704582 chr3 99571926 C T 3.58E-05 Cleft lip FILIP1L intron 20436469 rs793443 chr3 99573547 G A 1.16E-06 Axial length FILIP1L intron 24144296 rs793445 chr3 99576644 T A 8.49E-07 Axial length FILIP1L intron 24144296 rs793446 chr3 99578114 A T 1.54E-06 Axial length FILIP1L intron 24144296 rs813218 chr3 99592596 C T 1.97E-06 Cleft lip FILIP1L intron 20436469 rs813218 chr3 99592596 C T 1.00E-06 Orofacial clefts FILIP1L intron 22863734 rs1384062 chr3 99597928 A C 1.80E-05 Cleft lip FILIP1L intron 20436469 rs1384062 chr3 99597928 A C 6.80E-05 Podoconiosis FILIP1L intron 22455414 rs1384062 chr3 99597928 A C 2.82E-06 Orofacial clefts FILIP1L intron 22863734 rs1384062 chr3 99597928 A C 9.65E-07 Axial length FILIP1L intron 24144296 rs796976 chr3 99621002 G A 8.03E-07 Axial length FILIP1L intron 24144296 rs793464 chr3 99626028 G A 8.74E-07 Axial length FILIP1L intron 24144296 rs793465 chr3 99627750 A G 2.88E-06 Axial length FILIP1L intron 24144296 rs1688782 chr3 99630527 G C 2.86E-06 Axial length FILIP1L intron 24144296 rs117859753 chr3 99632575 G A 5.42E-07 Coronary heart disease FILIP1L intron 22751097 rs7626310 chr3 99636625 T C 1.30E-04 Smoking cessation FILIP1L intron 24665060 rs1016914 chr3 99640121 C T 2.70E-06 Axial length FILIP1L intron 24144296 rs793440 chr3 99643176 C T 3.12E-05 Cleft lip FILIP1L missense 20436469 rs793440 chr3 99643176 C T 3.91E-05 Orofacial clefts FILIP1L missense 22863734 rs793440 chr3 99643176 C T 3.54E-06 Axial length FILIP1L missense 24144296 rs704583 chr3 99643693 A G 2.75E-06 Axial length FILIP1L intron 24144296 rs2452320 chr3 99645216 G A 2.76E-06 Axial length FILIP1L intron 24144296 rs6440938 chr3 99652092 T C 2.77E-06 Axial length FILIP1L intron 24144296 rs7629426 chr3 99652577 C G 2.69E-06 Axial length FILIP1L intron 24144296 rs4479633 chr3 99654510 G A 2.78E-06 Axial length FILIP1L intron 24144296 rs6809988 chr3 99656615 A G 2.76E-06 Axial length FILIP1L intron 24144296 rs4577503 chr3 99657922 G A 8.54E-07 Axial length FILIP1L intron 24144296 rs9872871 chr3 99658702 C G 2.70E-06 Axial length FILIP1L intron 24144296 rs4928230 chr3 99661963 T C 3.25E-06 Axial length FILIP1L intron 24144296 rs13317017 chr3 99665521 A C 1.36E-05 Cleft lip FILIP1L intron 20436469 rs13317017 chr3 99665521 A C 2.39E-05 Orofacial clefts FILIP1L intron 22863734 rs7638900 chr3 99670773 T C 1.87E-06 Axial length FILIP1L intron 24144296 rs11719468 chr3 99671848 G C 2.01E-06 Axial length FILIP1L intron 24144296 rs10936005 chr3 99674093 G A 1.50E-06 Axial length FILIP1L intron 24144296 rs13059754 chr3 99678490 C A,G 4.06E-07 Axial length FILIP1L intron 24144296 rs4244713 chr3 99679584 T G 1.82E-05 Cleft lip FILIP1L intron 20436469 rs4244713 chr3 99679584 T G 3.00E-05 Orofacial clefts FILIP1L intron 22863734 rs4244713 chr3 99679584 T G 2.80E-06 Axial length FILIP1L intron 24144296 rs4075038 chr3 99680086 A G 3.10E-05 Cleft lip FILIP1L intron 20436469 rs4928150 chr3 99685991 G T 3.53E-07 Axial length FILIP1L intron 24144296 rs10936008 chr3 99686665 A G 1.26E-06 Axial length FILIP1L intron 24144296 rs16841874 chr3 99720564 A C 9.50E-07 Axial length FILIP1L intron 24144296 rs6440967 chr3 99722396 A C 3.03E-07 Axial length FILIP1L intron 24144296 rs6806323 chr3 99722564 G C 3.07E-07 Axial length FILIP1L intron 24144296 rs7649349 chr3 99725629 A G 3.08E-07 Axial length FILIP1L intron 24144296 rs4928237 chr3 99731330 A T 3.10E-07 Axial length FILIP1L intron 24144296 rs902159 chr3 99747445 C T 3.05E-07 Axial length FILIP1L intron 24144296 rs766778 chr3 99751480 C T 1.73E-05 Cleft lip FILIP1L intron 20436469 rs766778 chr3 99751480 C T 1.92E-06 Orofacial clefts FILIP1L intron 22863734 rs766778 chr3 99751480 C T 3.66E-07 Axial length FILIP1L intron 24144296 rs923472 chr3 99758029 A T 2.45E-07 Axial length FILIP1L intron 24144296 rs4928151 chr3 99767553 A C 2.13E-07 Axial length FILIP1L intron 24144296 rs6802817 chr3 99779264 A G 1.88E-07 Axial length FILIP1L intron 24144296 rs4928153 chr3 99808445 G A 1.72E-07 Axial length FILIP1L intron 24144296 rs1387647 chr3 99826942 T G 9.70E-08 Axial length FILIP1L intron 24144296 rs12488245 chr3 99835254 T C 1.68E-08 Axial length C3orf26 intron 24144296 rs9811920 chr3 99844293 G A 5.00E-11 Axial length C3orf26 intron 24144296 rs17315194 chr3 99848340 T G 8.64E-04 Suicide attempts in bipolar disorder C3orf26 intron 21041247 rs9837131 chr3 99854514 G A 1.03E-08 Axial length C3orf26 intron 24144296 rs7629487 chr3 99860401 G A 1.09E-08 Axial length C3orf26 intron 24144296 rs10222474 chr3 99862551 T C 1.46E-08 Axial length C3orf26 intron 24144296 rs6767441 chr3 99863183 T C 1.22E-08 Axial length C3orf26 intron 24144296 rs9289981 chr3 99868104 A T 1.48E-08 Axial length C3orf26 intron 24144296 rs2130369 chr3 99873317 C T 1.20E-07 Axial length C3orf26 intron 24144296 rs9814549 chr3 99892190 C A 3.72E-07 Axial length C3orf26 intron 24144296 rs6798114 chr3 99892825 C T 2.97E-07 Axial length C3orf26 intron 24144296 rs2316263 chr3 99900096 G A 3.01E-07 Axial length / / 24144296 rs12629505 chr3 99904783 G A 1.97E-04 IgE levels TMEM30C intron 17255346 rs12629505 chr3 99904783 G A 9.23E-05 Orofacial clefts TMEM30C intron 22863734 rs1017967 chr3 99905803 C A 6.13E-07 Axial length TMEM30C intron 24144296 rs6810262 chr3 99906342 C G 5.58E-07 Axial length TMEM30C intron 24144296 rs1872609 chr3 99906579 T C 1.25E-06 Axial length TMEM30C intron 24144296 rs7623587 chr3 99906751 T C 1.67E-07 Axial length TMEM30C intron 24144296 rs9290003 chr3 99906993 T C 3.85E-07 Axial length TMEM30C intron 24144296 rs9847283 chr3 99910320 A T 2.74E-07 Axial length TMEM30C intron 24144296 rs7631174 chr3 99913902 T C 4.84E-07 Axial length / / 24144296 rs9868170 chr3 99914139 A G 4.83E-07 Axial length / / 24144296 rs9850382 chr3 99915939 A G 4.32E-06 Axial length / / 24144296 rs7619048 chr3 99927237 G A 3.00E-05 Height / / 21998595 rs12486865 chr3 99956556 G C 7.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs17395659 chr3 100014606 G A 6.01E-05 Body Mass Index TBC1D23 intron pha003009 rs277630 chr3 100054160 A G 7.39E-04 Alzheimer's disease NIT2 intron 22005930 rs277638 chr3 100079447 G T 9.26E-04 Alzheimer's disease / / 22005930 rs12591 chr3 100082857 C G 2.20E-05 Urinary metabolites TOMM70A UTR-3 21572414 rs277633 chr3 100096419 G A 7.64E-04 Alzheimer's disease TOMM70A intron 22005930 rs10936180 chr3 100107095 A C 7.66E-04 Alzheimer's disease TOMM70A intron 22005930 rs7616634 chr3 100109150 C T 7.70E-04 Alzheimer's disease TOMM70A intron 22005930 rs6794955 chr3 100117696 T C 9.27E-04 Alzheimer's disease TOMM70A intron 22005930 rs7641630 chr3 100124112 A C 9.26E-04 Alzheimer's disease LNP1 intron 22005930 rs6780662 chr3 100130270 G A 9.28E-04 Alzheimer's disease LNP1 intron 22005930 rs7641299 chr3 100170553 G A 7.45E-05 Cognitive test performance LNP1 intron 20125193 rs7641299 chr3 100170553 G A 8.20E-06 Urinary metabolites LNP1 intron 21572414 rs4928050 chr3 100178459 G A 0.0000347 Antisocial behavior / / 23077488 rs9857793 chr3 100186962 C T 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4928088 chr3 100204958 G A 2.40E-05 Urinary metabolites / / 21572414 rs4928088 chr3 100204958 G A 3.43E-05 Glucose levels / / pha003061 rs4075020 chr3 100239024 T A 6.39E-04 Type 2 diabetes TMEM45A intron 17463246 rs6780654 chr3 100244677 A G 9.85E-05 Type 2 diabetes TMEM45A intron 17463246 rs6792014 chr3 100244825 G A 1.31E-04 Type 2 diabetes TMEM45A intron 17463246 rs3924054 chr3 100247165 G A 6.00E-05 Iris characteristics TMEM45A intron 21835309 rs4928110 chr3 100251674 A G 9.94E-05 Type 2 diabetes TMEM45A intron 17463246 rs4928112 chr3 100263559 G A 2.24E-04 Alcohol dependence TMEM45A intron 20201924 rs9874401 chr3 100305890 C T 3.64E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs9290097 chr3 100308825 T C 2.99E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1144125 chr3 100350745 C T 2.73E-04 Aortic root size GPR128 intron 21223598 rs2046227 chr3 100377943 A G 5.33E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GPR128 intron 20877124 rs2046227 chr3 100377943 A G 7.89E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GPR128 intron 20877124 rs905604 chr3 100472848 T C 5.84E-05 Glucose levels ABI3BP intron pha003058 rs9823506 chr3 100476713 C T 6.00E-08 Asthma (childhood onset) ABI3BP intron 23829686 rs544500 chr3 100485451 A G 1.28E-18 Lymphocyte counts ABI3BP intron 22286170 rs900234 chr3 100493062 C T 1.49E-04 Body mass index ABI3BP intron 21701565 rs900234 chr3 100493062 C T 4.77E-06 Body mass index ABI3BP intron 21701565 rs16842822 chr3 100495178 G C 1.68E-04 Smoking initiation ABI3BP intron 24665060 rs6441552 chr3 100496615 C T 3.66E-06 Body mass index ABI3BP intron 21701565 rs6441552 chr3 100496615 C T 9.94E-05 Body mass index ABI3BP intron 21701565 rs1394076 chr3 100499690 T C 6.18E-04 Myocardial Infarction ABI3BP intron pha002873 rs17217760 chr3 100512794 G A 7.40E-05 Femoral neck bone geometry ABI3BP intron 22087292 rs17337512 chr3 100525973 C T 6.31E-05 Femoral neck bone geometry ABI3BP intron 22087292 rs17337645 chr3 100527785 C T 5.18E-05 Femoral neck bone geometry ABI3BP intron 22087292 rs17338068 chr3 100537601 G A 6.68E-05 Femoral neck bone geometry ABI3BP intron 22087292 rs9840549 chr3 100550650 G A 1.41E-05 Paget's disease ABI3BP intron 20436471 rs9841585 chr3 100558416 T C 6.09E-05 Coronary heart disease ABI3BP intron pha003031 rs1354374 chr3 100558905 A G 6.96E-05 Tunica Media ABI3BP intron pha003034 rs4928089 chr3 100571493 G A 1.35E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) ABI3BP intron 24236485 rs4928089 chr3 100571493 G A 2.12E-06 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) ABI3BP intron 24236485 rs12330531 chr3 100588943 T A 2.90E-06 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) ABI3BP intron 24236485 rs12330531 chr3 100588943 T A 9.38E-07 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) ABI3BP intron 24236485 rs1116931 chr3 100589330 C A 3.07E-06 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) ABI3BP intron 24236485 rs1116931 chr3 100589330 C A 8.39E-07 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) ABI3BP intron 24236485 rs9833094 chr3 100590925 C T 2.00E-06 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) ABI3BP intron 24236485 rs9833094 chr3 100590925 C T 5.00E-07 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) ABI3BP intron 24236485 rs6778625 chr3 100596371 G A 0.0004341 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ABI3BP intron 23233654 rs6778625 chr3 100596371 G A 4.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) ABI3BP intron 23233662 rs1821794 chr3 100597517 T C 0.0004335 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ABI3BP intron 23233654 rs1821794 chr3 100597517 T C 4.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) ABI3BP intron 23233662 rs1816567 chr3 100597678 C G 0.0004335 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ABI3BP intron 23233654 rs1816567 chr3 100597678 C G 4.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) ABI3BP intron 23233662 rs9878937 chr3 100597989 G T 0.0006319 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ABI3BP intron 23233654 rs9878937 chr3 100597989 G T 6.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) ABI3BP intron 23233662 rs17338506 chr3 100607281 T C 1.61E-04 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs9290245 chr3 100612453 C A 0.0003487 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ABI3BP intron 23233654 rs9290245 chr3 100612453 C A 3.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) ABI3BP intron 23233662 rs2245556 chr3 100615550 T C 8.31E-08 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs2245473 chr3 100616136 G A 8.21E-08 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs2576369 chr3 100618155 G A 7.93E-08 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs2245266 chr3 100618773 T C 7.88E-08 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs2713793 chr3 100619174 A G 7.77E-08 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs4928096 chr3 100619760 G A 7.05E-08 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs2576365 chr3 100621426 C A 7.05E-08 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs9832195 chr3 100622392 A C 7.05E-08 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs2713787 chr3 100624438 G C 7.05E-08 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs4060963 chr3 100624561 A G 7.06E-08 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs17398137 chr3 100625703 G A 7.72E-04 Myopia (pathological) ABI3BP intron 21095009 rs13072000 chr3 100625822 A G 6.56E-08 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs2713782 chr3 100629304 G A 6.56E-08 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs13079002 chr3 100630141 C T 6.47E-08 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs7431835 chr3 100642723 T A 8.56E-08 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs1036467 chr3 100642804 C T 8.58E-08 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs17284842 chr3 100644947 T C 8.74E-08 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs2576377 chr3 100647749 C T 2.55E-08 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs13060137 chr3 100647927 A G 8.96E-08 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs13077353 chr3 100650307 T G 9.04E-08 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs7355920 chr3 100663543 A T 1.01E-04 Type 2 diabetes ABI3BP intron 17463246 rs2576382 chr3 100667829 T A 1.10E-07 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs17398421 chr3 100672907 T G 1.56E-07 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs2576390 chr3 100672975 T C 6.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ABI3BP intron 20877124 rs2576391 chr3 100677010 C G 1.56E-07 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs7641631 chr3 100677661 C T 0.000356 Common carotid artery thickness (average of near and far wall measures) ABI3BP intron 23487405 rs2595893 chr3 100677842 C T 1.55E-07 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs2595894 chr3 100677882 G C 1.54E-07 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs13088524 chr3 100688082 A C 1.53E-07 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs10511181 chr3 100689862 T G 1.53E-07 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs17398684 chr3 100695342 G A 1.53E-07 Suicide attempts in bipolar disorder ABI3BP intron 21041247 rs6774218 chr3 100695682 C T 0.000356 Common carotid artery thickness (average of near and far wall measures) ABI3BP intron 23487405 rs10511180 chr3 100697500 G C 1.07E-04 Type 2 diabetes ABI3BP intron 17463246 rs2595899 chr3 100698454 T C 5.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ABI3BP intron 20877124 rs2595899 chr3 100698454 T C 5.46E-05 Orofacial clefts ABI3BP intron 22419666 rs7651634 chr3 100698675 G A 4.05E-05 Type 2 diabetes ABI3BP intron 17463246 rs1449308 chr3 100708996 C T 5.86E-04 Type 2 diabetes ABI3BP intron 17463246 rs3732895 chr3 100712249 T C 6.56E-05 Major depressive disorder ABI3BP missense 19107115 rs13060756 chr3 100736117 A C 1.60E-05 Brain structure / / 22504417 rs17399603 chr3 100736139 A G 2.71E-07 Suicide attempts in bipolar disorder / / 21041247 rs13085823 chr3 100737036 G T 5.35E-04 Suicide attempts in bipolar disorder / / 21041247 rs2713777 chr3 100737101 T G 1.97E-05 Cognitive performance / / 19734545 rs13091963 chr3 100738011 G A 8.21E-05 Suicide attempts in bipolar disorder / / 21041247 rs2713775 chr3 100738327 T A 8.30E-05 Suicide attempts in bipolar disorder / / 21041247 rs35064087 chr3 100740363 G A 4.80E-12 Urinary metabolites / / 21572414 rs9839647 chr3 100753381 T C 4.53E-04 Lung function (forced vital capacity) / / 24023788 rs13074729 chr3 100765584 G T 2.64E-07 Suicide attempts in bipolar disorder / / 21041247 rs13099753 chr3 100769324 C G 4.19E-07 Suicide attempts in bipolar disorder / / 21041247 rs1375513 chr3 100771291 T G 1.13E-06 Suicide attempts in bipolar disorder / / 21041247 rs1375513 chr3 100771291 T G 3.35E-05 Brain structure / / 22504417 rs10511182 chr3 100772835 C G 2.00E-05 Type 2 diabetes / / 17903298 rs10511182 chr3 100772835 C G 1.93E-06 Suicide attempts in bipolar disorder / / 21041247 rs13060849 chr3 100773483 A C 1.85E-06 Suicide attempts in bipolar disorder / / 21041247 rs13065684 chr3 100773738 T C 1.81E-06 Suicide attempts in bipolar disorder / / 21041247 rs16843198 chr3 100783075 G T 9.63E-04 Multiple complex diseases / / 17554300 rs16843198 chr3 100783075 G T 1.66E-06 Suicide attempts in bipolar disorder / / 21041247 rs16843205 chr3 100789979 C T 6.84E-04 Multiple complex diseases / / 17554300 rs13081830 chr3 100791262 G A 9.15E-07 Suicide attempts in bipolar disorder / / 21041247 rs16843216 chr3 100796879 C T 8.54E-07 Suicide attempts in bipolar disorder / / 21041247 rs17219986 chr3 100799670 G A 8.03E-07 Suicide attempts in bipolar disorder / / 21041247 rs16843225 chr3 100801257 T G 7.81E-07 Suicide attempts in bipolar disorder / / 21041247 rs13096071 chr3 100801643 T A,C,G 4.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs13096071 chr3 100801643 T A,C,G 5.40E-07 Schizophrenia / / 21926974 rs16843229 chr3 100802220 G A 7.44E-07 Suicide attempts in bipolar disorder / / 21041247 rs12636874 chr3 100834291 A T 1.00E-04 Prostate cancer / / 21743057 rs6784790 chr3 100844373 C T 5.21E-05 Taste perception / / 22132133 rs10433355 chr3 100845845 A G 4.74E-04 Type 2 diabetes / / 17463246 rs6790241 chr3 100850928 C T 1.01E-05 Taste perception / / 22132133 rs2317412 chr3 100852812 G T 4.74E-04 Type 2 diabetes / / 17463246 rs7611779 chr3 100853831 T C 5.38E-04 Type 2 diabetes / / 17463246 rs6441582 chr3 100854588 C T 2.20E-04 Type 2 diabetes / / 17463246 rs9812448 chr3 100858010 C T 5.35E-04 Type 2 diabetes / / 17463246 rs9854892 chr3 100859412 G A 4.08E-04 Type 2 diabetes / / 17463246 rs9879324 chr3 100869029 G A 4.61E-04 Type 2 diabetes / / 17463246 rs13099833 chr3 100878496 A G 5.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1857975 chr3 100890246 G C 5.00E-06 Urinary metabolites / / 21572414 rs2317582 chr3 100914154 G C 0.0000128 Panic disorder / / 23149450 rs2317582 chr3 100914154 G C 1.28E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs1471738 chr3 100915962 G A 8.60E-06 Parkinson's disease / / 21738487 rs1471738 chr3 100915962 G A 4.51E-04 Taste perception / / 22132133 rs4683877 chr3 100921280 G A 1.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4683877 chr3 100921280 G A 2.02E-05 Parkinson's disease / / 21738487 rs348867 chr3 100949842 G A 9.25E-06 Psoriasis IMPG2 cds-synon 18364390 rs513154 chr3 100953212 T G 2.14E-06 Longevity IMPG2 intron 21612516 rs571391 chr3 100963154 G A 1.39E-05 Longevity IMPG2 missense 21612516 rs9870114 chr3 100970240 T C 6.26E-05 Parkinson's disease IMPG2 intron 21738487 rs3732893 chr3 100972858 A G 3.92E-05 Pancreatic cancer IMPG2 intron pha002874 rs6441595 chr3 101001759 A G 9.46E-04 Type 2 diabetes IMPG2 intron 17463246 rs473702 chr3 101045977 A G 1.31E-04 Multiple complex diseases SENP7 intron 17554300 rs5009801 chr3 101058775 A G 9.99E-04 Multiple complex diseases SENP7 intron 17554300 rs5009801 chr3 101058775 A G 5.92E-05 Schizophrenia SENP7 intron 20832056 rs3846085 chr3 101059816 G A 6.97E-04 Smoking quantity SENP7 intron 24665060 rs2553419 chr3 101068620 C T 5.92E-05 Schizophrenia SENP7 intron 20832056 rs2682386 chr3 101068873 C T 1.73E-04 Multiple complex diseases SENP7 intron 17554300 rs9877228 chr3 101069852 G C 8.87E-05 Schizophrenia SENP7 intron 20832056 rs9875156 chr3 101072258 A C 4.92E-05 Schizophrenia SENP7 intron 20832056 rs2553427 chr3 101106527 A G 2.50E-04 Multiple complex diseases SENP7 intron 17554300 rs2553427 chr3 101106527 A G 4.35E-05 Parkinson's disease SENP7 intron 21738487 rs9857723 chr3 101109166 A T 4.65E-05 Schizophrenia SENP7 intron 20832056 rs1520653 chr3 101113177 C T 7.03E-05 Schizophrenia SENP7 intron 20832056 rs12497154 chr3 101114990 G A 4.10E-05 Schizophrenia SENP7 intron 20832056 rs2317749 chr3 101121980 A G 1.14E-04 Multiple complex diseases SENP7 intron 17554300 rs2317750 chr3 101122120 C A 5.92E-05 Schizophrenia SENP7 intron 20832056 rs9822356 chr3 101136340 C T 7.54E-05 Schizophrenia SENP7 intron 20832056 rs9859077 chr3 101136402 G C 2.68E-04 Multiple complex diseases SENP7 intron 17554300 rs9814840 chr3 101155038 T C 9.01E-04 White matter integrity SENP7 intron 22425255 rs10936631 chr3 101165959 A G 9.07E-04 Multiple complex diseases SENP7 intron 17554300 rs10936631 chr3 101165959 A G 2.49E-05 Schizophrenia SENP7 intron 20832056 rs12496159 chr3 101177644 A C 4.85E-05 Schizophrenia SENP7 intron 20832056 rs2141180 chr3 101179057 T C 1.82E-04 Multiple complex diseases SENP7 intron 17554300 rs6441608 chr3 101181028 G A 5.58E-05 Parkinson's disease SENP7 intron 21738487 rs2317703 chr3 101181890 T C 5.92E-05 Schizophrenia SENP7 intron 20832056 rs3846087 chr3 101211487 A G 1.38E-04 Schizophrenia SENP7 intron 20832056 rs6791803 chr3 101212855 T C 3.83E-05 Tourette syndrome SENP7 intron 22889924 rs3846092 chr3 101220400 C T 1.66E-04 Tourette syndrome SENP7 intron 22889924 rs2317704 chr3 101230304 C G 8.78E-04 Multiple complex diseases SENP7 intron 17554300 rs2317704 chr3 101230304 C G 4.26E-05 Schizophrenia SENP7 intron 20832056 rs16843947 chr3 101238259 A G 8.03E-04 Multiple complex diseases FAM172BP intron 17554300 rs7631506 chr3 101242614 A C 0.0008559 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7631506 chr3 101242614 A C 8.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13088318 chr3 101242751 A G 0.0007111 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13088318 chr3 101242751 A G 7.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4287896 chr3 101261559 A G 0.0007743 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4287896 chr3 101261559 A G 7.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4618204 chr3 101281534 T C 0.0002926 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RG9MTD1 intron 23233654 rs4618204 chr3 101281534 T C 2.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) RG9MTD1 intron 23233662 rs13072301 chr3 101281665 T C 0.0000151 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RG9MTD1 intron 23233654 rs13072301 chr3 101281665 T C 1.51E-05 Methotrexate clearance (acute lymphoblastic leukemia) RG9MTD1 intron 23233662 rs6769049 chr3 101291872 A G 0.0000123 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6769049 chr3 101291872 A G 1.23E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3804777 chr3 101294659 G A 0.000023 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PCNP intron 23233654 rs3804777 chr3 101294659 G A 2.30E-05 Methotrexate clearance (acute lymphoblastic leukemia) PCNP intron 23233662 rs16844076 chr3 101296067 A G 7.25E-04 Amyotrophic lateral sclerosis (sporadic) PCNP intron 24529757 rs1365319 chr3 101299572 A T 0.0000257 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PCNP intron 23233654 rs1365319 chr3 101299572 A T 2.57E-05 Methotrexate clearance (acute lymphoblastic leukemia) PCNP intron 23233662 rs3804775 chr3 101306507 C T 2.40E-04 Gastric cancer (diffuse-type gastric cancer) PCNP intron 18488030 rs6791392 chr3 101313542 T G 0.0000281 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6791392 chr3 101313542 T G 2.81E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6782404 chr3 101315030 C G 0.0000293 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6782404 chr3 101315030 C G 2.93E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7651917 chr3 101321101 G C 0.0000303 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7651917 chr3 101321101 G C 3.03E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6771590 chr3 101332729 T A 0.0000354 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6771590 chr3 101332729 T A 3.54E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6779153 chr3 101335471 A G 0.0000374 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6779153 chr3 101335471 A G 3.74E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2303474 chr3 101371899 G T 5.40E-04 Gastric cancer (diffuse-type gastric cancer) ZBTB11 intron 18488030 rs2288273 chr3 101378927 G A 1.60E-05 Urinary metabolites ZBTB11 intron 21572414 rs17411983 chr3 101399126 G A 6.44E-04 Lymphocyte counts / / 22286170 rs112553552 chr3 101411978 C A 3.00E-06 Response to amphetamines / / 22952603 rs145072852 chr3 101476645 C T 0.00029 Breast cancer (ER positive) CEP97 missense 23555315 rs145072852 chr3 101476645 C T 0.00075 Breast cancer CEP97 missense 23555315 rs2722166 chr3 101489702 C T 1.01E-04 Tourette syndrome / / 22889924 rs11718446 chr3 101552553 G A 1.33E-04 Lymphocyte counts NFKBIZ intron 22286170 rs7644388 chr3 101556546 C T 7.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NFKBIZ intron 20877124 rs76884309 chr3 101576143 A G 0.00031 Prostate cancer (non-advanced prostate cancer) NFKBIZ missense 23555315 rs16844402 chr3 101623260 T C 2.64E-05 Postoperative ventricular dysfunction / / 21980348 rs1707574 chr3 101671755 A G 2.92E-04 Type 2 diabetes LOC152225 intron 17463246 rs771828 chr3 101692131 T C 5.72E-04 Type 2 diabetes LOC152225 intron 17463246 rs1514471 chr3 101697208 A G 8.94E-04 Schizophrenia LOC152225 intron 19197363 rs708233 chr3 101705550 C T 9.58E-05 Intelligence LOC152225 intron 21826061 rs771785 chr3 101705809 G A 5.73E-05 Psoriasis LOC152225 intron 20953190 rs771787 chr3 101710357 A G 3.57E-04 Type 2 diabetes LOC152225 intron 17463246 rs771795 chr3 101718657 T A 1.45E-04 Arthritis (juvenile idiopathic) / / 22354554 rs771797 chr3 101719299 A T 1.79E-04 Arthritis (juvenile idiopathic) / / 22354554 rs771798 chr3 101719377 A C 1.25E-04 Arthritis (juvenile idiopathic) / / 22354554 rs7625376 chr3 101721602 G A 5.25E-04 Taste perception / / 22132133 rs4683863 chr3 101735205 A G 1.42E-04 Arthritis (juvenile idiopathic) / / 22354554 rs1828668 chr3 101746730 C T 6.01E-04 White matter integrity / / 22425255 rs771767 chr3 101748638 A G 9.00E-09 Multiple sclerosis / / 21833088 rs1398607 chr3 101755738 C A 3.65E-04 White matter integrity / / 22425255 rs10804863 chr3 101756221 C T 3.65E-04 White matter integrity / / 22425255 rs991258 chr3 101774043 G C 5.00E-07 Hip geometry / / 17903296 rs10212363 chr3 101848561 G A 2.00E-06 Waist-to-hip circumference ratio (interaction) / / 23192594 rs2679234 chr3 101884795 C T 2.59E-04 Longevity / / 22279548 rs2619283 chr3 101890895 G A 8.77E-04 Multiple complex diseases / / 17554300 rs13075312 chr3 101909291 C A 3.99E-04 Schizophrenia / / 19197363 rs13075312 chr3 101909291 C A 2.63E-05 Cognitive performance / / 19734545 rs9838540 chr3 101986003 A C 9.94E-04 Response to TNF antagonist treatment / / 21061259 rs1479371 chr3 102017934 C G 9.22E-04 Multiple complex diseases / / 17554300 rs7636808 chr3 102043743 C T 6.73E-04 Multiple complex diseases / / 17554300 rs7616427 chr3 102044044 G T 6.79E-04 Multiple complex diseases / / 17554300 rs16844949 chr3 102045882 C G 6.30E-04 Multiple complex diseases / / 17554300 rs7623736 chr3 102054274 T C 4.78E-04 Multiple complex diseases / / 17554300 rs16844969 chr3 102055038 T C 6.32E-04 Multiple complex diseases / / 17554300 rs6781453 chr3 102055738 T C 5.56E-04 Multiple complex diseases / / 17554300 rs985375 chr3 102067246 G A 7.00E-08 Metabolite levels / / 23281178 rs6784362 chr3 102157365 A T 0.000021 Breast cancer ZPLD1 missense 23555315 rs6784389 chr3 102157417 A G 0.000019 Breast cancer ZPLD1 missense 23555315 rs16845038 chr3 102173174 G A 4.32E-05 Multiple complex diseases ZPLD1 intron 17554300 rs12054046 chr3 102181131 A G 0.000032 Breast cancer ZPLD1 missense 23555315 rs2063640 chr3 102203045 C A 3.00E-06 Type 2 diabetes / / 21490949 rs2063640 chr3 102203045 C A 2.00E-06 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs1296064 chr3 102360190 C T 7.48E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10212345 chr3 102406978 C T 2.92E-04 Alcohol dependence / / 20201924 rs9873502 chr3 102436522 G T 6.00E-04 Alcohol dependence / / 20201924 rs9860789 chr3 102467051 A G 2.23E-04 Alcohol dependence / / 20201924 rs1498075 chr3 102533446 G A 4.65E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6441684 chr3 102587024 G T 7.10E-04 Alzheimer's disease / / 17998437 rs1241287 chr3 102598113 C T 8.05E-05 Coronary heart disease / / pha003031 rs12374017 chr3 102797451 A G 8.25E-05 Serum metabolites / / 19043545 rs9832587 chr3 102834800 T C 5.65E-04 Alcohol dependence / / 20201924 rs3849514 chr3 102840677 T C 6.08E-04 Stroke / / pha002886 rs17781533 chr3 102862014 G A 1.70E-05 Urinary metabolites / / 21572414 rs11918929 chr3 102863976 T A 4.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6791223 chr3 102924004 T C 7.20E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13071097 chr3 102938744 A C 3.94E-04 Breast cancer / / 21060860 rs13063401 chr3 102946216 G A 6.15E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9869251 chr3 102988379 A G 1.70E-05 Urinary metabolites / / 21572414 rs9873831 chr3 102988684 T C 0.000000013 Mean arterial pressure / / 22510845 rs1304118 chr3 102990250 C T 1.80E-05 Urinary metabolites / / 21572414 rs1907878 chr3 103004472 A G 1.80E-05 Urinary metabolites / / 21572414 rs17511442 chr3 103005775 G A 1.70E-05 Urinary metabolites / / 21572414 rs6788848 chr3 103028245 C T 4.99E-05 Pulmonary function in asthmatics / / 23541324 rs10511210 chr3 103055872 T C 6.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs6803269 chr3 103158770 T C 8.87E-04 Myocardial Infarction / / pha002883 rs1397924 chr3 103245092 C T 1.00E-06 Economic and political preferences (environmentalism) / / 22566634 rs4856162 chr3 103292226 G A 1.00E-06 Economic and political preferences (environmentalism) / / 22566634 rs7612581 chr3 103307642 T G 2.00E-06 Economic and political preferences (environmentalism) / / 22566634 rs9820695 chr3 103331483 G A 9.00E-07 Economic and political preferences (environmentalism) / / 22566634 rs9821642 chr3 103345439 A G 7.00E-07 Economic and political preferences (environmentalism) / / 22566634 rs2063485 chr3 103348699 T C 1.34E-05 Pulmonary function in asthmatics / / 23541324 rs2063485 chr3 103348699 T C 7.18E-05 Pulmonary function in asthmatics / / 23541324 rs10937540 chr3 103359218 C T 4.00E-07 Economic and political preferences (environmentalism) / / 22566634 rs10937544 chr3 103363061 A C 6.00E-06 Economic and political preferences (environmentalism) / / 22566634 rs6775909 chr3 103380852 T C 6.00E-07 Economic and political preferences (environmentalism) / / 22566634 rs1511639 chr3 103395889 T G 9.92E-05 Cytomegalovirus antibody response / / 21993531 rs12485744 chr3 103397769 T C 2.00E-06 Economic and political preferences (environmentalism) / / 22566634 rs12485744 chr3 103397769 T C 7.63E-06 Personality dimensions / / 22628180 rs7628767 chr3 103400082 G A 1.00E-06 Economic and political preferences (environmentalism) / / 22566634 rs10511217 chr3 103403514 C T 2.00E-06 Economic and political preferences (environmentalism) / / 22566634 rs16846607 chr3 103404111 T C 2.48E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs4370037 chr3 103422112 G A 1.26E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs7643412 chr3 103427950 T C 7.16E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7643412 chr3 103427950 T C 9.32E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7629646 chr3 103428035 C T 6.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9291039 chr3 103430322 C T 7.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4493441 chr3 103438874 G A 1.00E-06 Economic and political preferences (environmentalism) / / 22566634 rs9835108 chr3 103447896 A T 5.81E-06 Type 2 diabetes / / 17463246 rs2677247 chr3 103450591 A C 9.00E-06 IgG glycosylation / / 23382691 rs995470 chr3 103453964 T G 9.90E-04 Type 2 diabetes / / 17463246 rs995470 chr3 103453964 T G 2.92E-04 Bipolar disorder,schizoaffective / / 19567891 rs12635765 chr3 103482015 A G 1.29E-04 Type 2 diabetes / / 17463246 rs2045483 chr3 103482085 A G 2.07E-05 Smoking cessation / / 24665060 rs1673866 chr3 103513436 C T 7.00E-06 IgG glycosylation / / 23382691 rs2608486 chr3 103599833 G T 7.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs4132806 chr3 103635435 C T 1.05E-04 Alcohol dependence / / 24277619 rs6797644 chr3 103643745 A G 6.65E-04 Multiple complex diseases / / 17554300 rs6765661 chr3 103648320 A G 5.14E-04 Alcohol dependence / / 24277619 rs35184949 chr3 103673938 C G 9.14E-04 Multiple complex diseases / / 17554300 rs7634768 chr3 103678133 C T 5.19E-04 Multiple complex diseases / / 17554300 rs9853755 chr3 103685086 G T 5.46E-04 Multiple complex diseases / / 17554300 rs6791670 chr3 103696692 A G 5.44E-04 Multiple complex diseases / / 17554300 rs7628112 chr3 103716354 G A 2.88E-04 Myocardial Infarction / / pha002883 rs7628112 chr3 103716354 G A 7.51E-04 Heart Failure / / pha002885 rs6808622 chr3 103722343 A G 1.81E-04 Heart Failure / / pha002885 rs1666533 chr3 103757541 A G 7.03E-04 Multiple complex diseases / / 17554300 rs1666533 chr3 103757541 A G 2.92E-04 Alzheimer's disease / / 17998437 rs1165915 chr3 103759372 G T 1.50E-05 Urinary metabolites / / 21572414 rs13324427 chr3 103782849 G A 2.97E-05 Serum metabolites / / 19043545 rs1666547 chr3 103798598 C T 2.30E-05 Urinary metabolites / / 21572414 rs1731645 chr3 103806985 G A 2.20E-05 Urinary metabolites / / 21572414 rs1345189 chr3 103811702 A G 1.10E-04 Pemphigus vulgaris / / 22437316 rs1447967 chr3 103846834 G T 2.90E-05 Urinary metabolites / / 21572414 rs6796440 chr3 103861164 G T 2.40E-05 Urinary metabolites / / 21572414 rs1920325 chr3 103866190 T C 1.60E-05 Urinary metabolites / / 21572414 rs13060684 chr3 103897106 C A 7.01E-04 Multiple complex diseases / / 17554300 rs17535407 chr3 103899073 C G 1.80E-05 Anger / / 24489884 rs11921067 chr3 103899423 T C 5.23E-04 Multiple complex diseases / / 17554300 rs10804426 chr3 103980017 C T 6.88E-04 Smoking initiation / / 24665060 rs9809062 chr3 104053028 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2713694 chr3 104057728 G C 6.52E-04 Multiple complex diseases / / 17554300 rs2895285 chr3 104082176 G A 4.03E-04 Lung function (forced vital capacity) / / 24023788 rs17435554 chr3 104106742 C T 5.50E-05 Schizophrenia / / 24253340 rs6806731 chr3 104135255 G A 6.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2953134 chr3 104191041 C G 1.80E-05 Urinary metabolites / / 21572414 rs6790921 chr3 104213388 A G 0.000142391 Hypertension (early onset hypertension) / / 22479346 rs2961221 chr3 104231441 A G 5.95E-04 Type 2 diabetes / / 17463246 rs10049449 chr3 104231516 G A 1.00E-04 Spine bone size / / 21947420 rs1599765 chr3 104231982 T C 9.07E-04 Type 2 diabetes / / 17463246 rs2961359 chr3 104238052 C G 6.37E-04 Type 2 diabetes / / 17463246 rs2961318 chr3 104239654 G A 5.71E-04 Type 2 diabetes / / 17463246 rs12491455 chr3 104246695 T C 6.25E-05 Coronary heart disease / / pha003035 rs1610247 chr3 104259387 T G 5.26E-04 Type 2 diabetes / / 17463246 rs7643516 chr3 104263821 G A 7.54E-05 Coronary heart disease / / pha003035 rs9288786 chr3 104274472 T G 4.15E-04 Lung function (forced vital capacity) / / 24023788 rs6437523 chr3 104289464 C T 1.67E-05 Blood Pressure / / pha002898 rs12637047 chr3 104289715 C T 9.90E-06 Urinary metabolites / / 21572414 rs12637047 chr3 104289715 C T 2.00E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs9870668 chr3 104290380 G T 2.11E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2961214 chr3 104296634 A G 3.03E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4414882 chr3 104300275 G A 3.07E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs9835784 chr3 104303223 C T 3.29E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2961330 chr3 104303507 C T 3.42E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs9834974 chr3 104306303 A G 3.50E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11926262 chr3 104312420 A G 4.10E-06 Urinary metabolites / / 21572414 rs7648727 chr3 104326725 T C 9.72E-04 Myocardial Infarction / / pha002873 rs13093544 chr3 104336857 A G 9.30E-07 Urinary metabolites / / 21572414 rs2685033 chr3 104342857 G A 3.60E-07 Urinary metabolites / / 21572414 rs777904 chr3 104377890 G C 2.50E-05 Urinary metabolites / / 21572414 rs2685056 chr3 104418573 G A 4.00E-08 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1521615 chr3 104421626 G T 9.73E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2947786 chr3 104439114 C T 2.10E-04 Myocardial Infarction / / pha002873 rs777952 chr3 104446688 C T 5.73E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs777952 chr3 104446688 C T 1.26E-04 Myocardial Infarction / / pha002873 rs10511227 chr3 104464640 C T 2.69E-04 Multiple complex diseases / / 17554300 rs4895102 chr3 104486791 T A 5.00E-04 Spine bone size / / 21947420 rs16850410 chr3 104502301 A G 3.44E-04 Multiple complex diseases / / 17554300 rs4144913 chr3 104518665 C G 7.00E-04 Spine bone size / / 21947420 rs3947974 chr3 104524769 A C 7.00E-04 Spine bone size / / 21947420 rs9868935 chr3 104531106 A G 3.40E-06 Urinary metabolites / / 21572414 rs10446267 chr3 104536448 G A 2.91E-04 Acute lung injury / / 22295056 rs9878252 chr3 104538180 A C 2.91E-04 Acute lung injury / / 22295056 rs1836862 chr3 104542237 A C 1.20E-06 Urinary metabolites / / 21572414 rs6437543 chr3 104542522 A G 2.08E-05 Serum metabolites / / 19043545 rs13321530 chr3 104545336 C T 5.06E-05 Serum metabolites / / 19043545 rs6783422 chr3 104548890 G A 7.05E-05 Serum metabolites / / 19043545 rs1436335 chr3 104552789 G A 4.70E-05 Serum metabolites / / 19043545 rs1436330 chr3 104558505 A T 7.24E-05 Serum metabolites / / 19043545 rs1975269 chr3 104562324 G T 3.31E-04 Acute lung injury / / 22295056 rs6782803 chr3 104575425 T C 4.76E-04 Acute lung injury / / 22295056 rs12635480 chr3 104575864 C A 8.60E-06 Endometriosis / / 23104006 rs1541993 chr3 104582144 A C 4.16E-04 Type 2 diabetes / / 17463246 rs9826514 chr3 104590454 C T 7.20E-05 basal cell carcinoma / / 21700618 rs1436339 chr3 104595269 G A 9.70E-05 Orofacial clefts / / 22419666 rs11926023 chr3 104599330 T C 4.60E-05 basal cell carcinoma / / 21700618 rs1344861 chr3 104604813 A C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs9874718 chr3 104620103 C A 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7616848 chr3 104620951 A C 9.55E-04 Multiple complex diseases / / 17554300 rs4894891 chr3 104626013 C T 4.03E-04 Smoking initiation / / 24665060 rs10511235 chr3 104813322 A C 9.85E-06 Lipid levels / / 19016617 rs9830827 chr3 104828356 T G 9.17E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9818246 chr3 104877718 A G 1.82E-06 Post-operative nausea and vomiting / / 21694509 rs884477 chr3 104885104 G A 6.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs884477 chr3 104885104 G A 3.76E-04 Alzheimer's disease / / 24755620 rs16850936 chr3 104892984 A G 3.72E-04 Alzheimer's disease / / 24755620 rs16850937 chr3 104895676 T C 3.62E-04 Alzheimer's disease / / 24755620 rs6776849 chr3 104896082 C A 1.72E-04 Alzheimer's disease / / 24755620 rs1568421 chr3 104917227 G T 4.65E-04 Rheumatoid arthritis / / 21452313 rs1568420 chr3 104917398 T C 1.79E-04 Suicide attempts in bipolar disorder / / 21041247 rs1007679 chr3 104917626 A G 3.43E-04 Alzheimer's disease / / 24755620 rs6794974 chr3 104922030 G A 1.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs9846852 chr3 104928448 A G 2.77E-04 Alzheimer's disease / / 24755620 rs10933810 chr3 104933158 C T 2.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs10933810 chr3 104933158 C T 2.17E-04 Alzheimer's disease / / 24755620 rs12639365 chr3 104940342 A T 2.69E-04 Suicide attempts in bipolar disorder / / 21041247 rs10511240 chr3 104972487 A G 2.21E-04 Acute lung injury / / 22295056 rs10511241 chr3 104972931 A G 2.21E-04 Acute lung injury / / 22295056 rs9683082 chr3 104986735 C A 8.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9683082 chr3 104986735 C A 3.79E-06 Tunica Media / / pha003036 rs1259383 chr3 104995109 G A 8.80E-05 Multiple complex diseases / / 17554300 rs1259444 chr3 104996918 C A,G 8.41E-04 Multiple complex diseases / / 17554300 rs16851027 chr3 105005089 T C 1.38E-04 Multiple complex diseases / / 17554300 rs9810233 chr3 105010890 A G 7.00E-07 Erectile dysfunction / / 22704111 rs1438545 chr3 105052404 A G 3.69E-04 Type 2 diabetes / / 17463246 rs4894919 chr3 105058348 A G 2.10E-05 Urinary metabolites / / 21572414 rs9869867 chr3 105068356 A C 2.70E-05 Urinary metabolites / / 21572414 rs4894924 chr3 105113237 T A,C 9.81E-05 Cortisol secretion,in saliva ALCAM intron 21316860 rs13070790 chr3 105135987 C T 5.00E-08 Meningococcal disease ALCAM intron 20694013 rs2252459 chr3 105246772 G A 8.75E-06 Cortisol secretion,in saliva ALCAM intron 21316860 rs3772556 chr3 105249211 C T 3.60E-04 Multiple complex diseases ALCAM intron 17554300 rs503321 chr3 105261887 C G 2.50E-05 Urinary metabolites ALCAM intron 21572414 rs485922 chr3 105263624 A G 8.93E-04 Multiple complex diseases ALCAM intron 17554300 rs519016 chr3 105264953 G A 4.33E-04 Multiple complex diseases ALCAM intron 17554300 rs10933821 chr3 105266536 T C 7.34E-04 Multiple complex diseases ALCAM intron 17554300 rs13317567 chr3 105267906 G A 4.06E-05 Lipoproteins ALCAM intron pha003079 rs7610031 chr3 105270596 A G 2.79E-04 Multiple complex diseases ALCAM intron 17554300 rs2030515 chr3 105276595 G A 3.80E-06 Odorant perception ALCAM intron 23910658 rs11559013 chr3 105294502 G A 4.06E-05 Lipoproteins ALCAM UTR-3 pha003079 rs620165 chr3 105300908 C T 4.02E-04 Tourette syndrome / / 22889924 rs12633734 chr3 105316769 G A 8.63E-05 Post-operative nausea and vomiting / / 21694509 rs894934 chr3 105338152 G A 5.18E-05 Relative hand skill in reading disability / / 24068947 rs894932 chr3 105338346 A G 5.45E-05 Relative hand skill in reading disability / / 24068947 rs2305037 chr3 105422844 C T 2.54E-04 Celiac disease CBLB cds-synon 23936387 rs1867189 chr3 105447746 G A 2.30E-04 Celiac disease CBLB intron 23936387 rs9876767 chr3 105449793 T G 1.95E-04 Celiac disease CBLB intron 23936387 rs9880861 chr3 105449986 T C 2.71E-04 Celiac disease CBLB intron 23936387 rs3772513 chr3 105488572 A G 9.31E-04 Lymphocyte counts CBLB intron 22286170 rs7638504 chr3 105499373 T C 6.18E-04 Multiple complex diseases CBLB intron 17554300 rs2028597 chr3 105558837 G A 7.20E-04 Multiple sclerosis CBLB intron 21833088 rs6767627 chr3 105560638 G A 3.17E-04 Alzheimer's disease CBLB intron 22005930 rs7641825 chr3 105567658 A T 5.99E-05 Alzheimer's disease CBLB intron 22005930 rs2197209 chr3 105568165 C A 5.78E-04 Alzheimer's disease CBLB intron 22005930 rs1867192 chr3 105568246 T C 2.94E-04 Alzheimer's disease CBLB intron 22005930 rs16851673 chr3 105573413 G A 2.80E-04 Gallstones CBLB intron 17632509 rs9657904 chr3 105586714 T C 2.00E-10 Multiple sclerosis CBLB intron 20453840 rs7649466 chr3 105587845 C G 3.13E-04 Alzheimer's disease CBLB UTR-5 22005930 rs6437625 chr3 105599119 C T 4.50E-06 Multiple complex diseases / / 17554300 rs6437626 chr3 105599207 T C 2.43E-04 Alzheimer's disease / / 22005930 rs13062596 chr3 105691565 G T 8.57E-05 Common variable immunodeficiency / / 21497890 rs2455879 chr3 105698149 G A 4.49E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2618321 chr3 105699113 C T 6.45E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1478786 chr3 105760373 C T 4.51E-06 Brachial circumference / / 22479309 rs2399060 chr3 105762360 T C 5.95E-06 Brachial circumference / / 22479309 rs767150 chr3 105807750 G A 5.18E-04 Acute lung injury / / 22295056 rs767151 chr3 105808038 G C 7.68E-04 Acute lung injury / / 22295056 rs7641450 chr3 105808727 C A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2035254 chr3 105809730 G A 2.20E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs931081 chr3 105833043 A G 4.93E-04 Acute lung injury / / 22295056 rs4894981 chr3 105840871 T G 4.75E-05 Cognitive impairment induced by topiramate / / 22091778 rs1545340 chr3 105841928 A G 4.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16852066 chr3 105843309 A G 4.89E-04 Acute lung injury / / 22295056 rs17201890 chr3 105846933 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17201890 chr3 105846933 G A 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17201989 chr3 105850165 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17201989 chr3 105850165 C T 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6809315 chr3 105877465 C T 7.58E-06 Schizophrenia / / 19571809 rs1871274 chr3 105902476 G A 1.98E-05 Schizophrenia / / 19571809 rs7633167 chr3 105911539 C A 1.49E-05 Attention deficit hyperactivity disorder / / 20732627 rs12487066 chr3 105912130 T C 4.09E-05 Multiple sclerosis / / 17660530 rs12487092 chr3 105912175 T G 4.35E-05 Multiple sclerosis / / 17660530 rs12695132 chr3 105913278 G C,T 4.78E-05 Multiple sclerosis / / 17660530 rs12489296 chr3 105925276 T C 8.12E-04 Longevity / / 22279548 rs6414233 chr3 105952383 T G 2.02E-05 Schizophrenia / / 19571809 rs10433374 chr3 105953778 T C 5.04E-04 Multiple complex diseases / / 17554300 rs9866721 chr3 106007364 T C 2.23E-04 Type 2 diabetes / / 17463246 rs13314006 chr3 106007760 A T 5.82E-04 Type 2 diabetes / / 17463246 rs16852308 chr3 106008997 C T 7.17E-04 Multiple complex diseases / / 17554300 rs4243429 chr3 106009067 C G 2.38E-04 Type 2 diabetes / / 17463246 rs4429664 chr3 106016673 C T 6.85E-05 Basophils / / pha003087 rs6437659 chr3 106026883 G A 7.83E-04 Type 2 diabetes / / 17463246 rs4626130 chr3 106029482 C G 7.68E-04 Multiple complex diseases / / 17554300 rs11927143 chr3 106047014 G A 8.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs13094374 chr3 106048760 G A 1.40E-05 Parkinson's disease (age of onset) / / 19772629 rs6777583 chr3 106063694 C T 4.06E-06 Statin-induced myopathy / / 21826682 rs9831569 chr3 106089227 C T 5.35E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs16852418 chr3 106090073 C G 2.00E-05 Urinary metabolites / / 21572414 rs6773325 chr3 106126869 C A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10933849 chr3 106139801 C T 5.87E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs1031170 chr3 106160503 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12637864 chr3 106172302 G C 5.68E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12330872 chr3 106191567 A G 2.33E-04 Insulin resistance / / 21901158 rs9845337 chr3 106197762 C A 3.75E-04 Alzheimer's disease / / 22005930 rs2712475 chr3 106208882 G A 5.23E-04 Taste perception / / 22132133 rs2712457 chr3 106210457 T C 6.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2712457 chr3 106210457 T C 2.69E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2712473 chr3 106218553 T G 2.40E-06 Urinary metabolites / / 21572414 rs2953040 chr3 106220714 T C 1.70E-06 Urinary metabolites / / 21572414 rs2590195 chr3 106240290 T C 8.92E-05 Cognitive test performance / / 20125193 rs2084037 chr3 106260773 C T 6.33E-05 Cognitive test performance / / 20125193 rs920937 chr3 106288013 C A 3.04E-05 Cognitive test performance / / 20125193 rs12491921 chr3 106288950 T C 1.00E-06 Cannabis dependence / / 21668797 rs2590187 chr3 106327107 A G 2.03E-04 Alzheimer's disease (late onset) / / 21379329 rs4515089 chr3 106336790 A C 8.38E-06 Personality dimensions / / 21173776 rs7651154 chr3 106348442 G T 7.41E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2399116 chr3 106354003 C T 7.41E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7612369 chr3 106355471 G A 4.79E-04 Type 2 diabetes / / 17463246 rs9853790 chr3 106364551 C T 7.02E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6794293 chr3 106402592 A C 5.39E-04 Type 2 diabetes / / 17463246 rs16852873 chr3 106408871 G C 2.50E-05 Urinary metabolites / / 21572414 rs16852873 chr3 106408871 G C 4.88E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9867153 chr3 106412711 C T 3.90E-05 Bipolar disorder / / 21771265 rs2895316 chr3 106446981 T C 3.79E-05 Creatinine levels / / pha003069 rs1520710 chr3 106493345 C T 5.39E-04 Multiple complex diseases / / 17554300 rs1356933 chr3 106494004 G A 5.24E-04 Multiple complex diseases / / 17554300 rs9852248 chr3 106494685 C T 5.40E-04 Multiple complex diseases / / 17554300 rs1402304 chr3 106495324 A G 7.52E-04 Multiple complex diseases / / 17554300 rs1520717 chr3 106528644 C T 8.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1517605 chr3 106624294 T C 1.98E-04 Crohn's disease and Celiac disease / / 21298027 rs1568206 chr3 106639719 C G 9.66E-04 Multiple complex diseases / / 17554300 rs1568206 chr3 106639719 C G 2.90E-04 Crohn's disease and Celiac disease / / 21298027 rs1712549 chr3 106689615 A G 9.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs1712548 chr3 106689869 T C 9.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs1709961 chr3 106692933 G A 9.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs1517606 chr3 106693263 T C 9.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs1709962 chr3 106694227 T G 9.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs6762185 chr3 106708686 C T 9.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs4437182 chr3 106710952 T A 8.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs1112207 chr3 106711476 A G 9.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs1709969 chr3 106716721 C T 8.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs1913697 chr3 106725717 A G 6.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs6792401 chr3 106769904 A G 7.45E-04 Multiple complex diseases / / 17554300 rs4345063 chr3 106770054 T C 7.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs12493716 chr3 106777359 A G 1.37E-04 Acne (severe) / / 24927181 rs4374528 chr3 106777569 G A 9.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs9821348 chr3 106777677 G A 1.38E-04 Multiple complex diseases / / 17554300 rs12494766 chr3 106778761 A G 1.69E-04 Acne (severe) / / 24927181 rs9856141 chr3 106780110 T G 8.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs9816953 chr3 106792426 T C 1.02E-04 Smoking quantity / / 24665060 rs9288843 chr3 106807621 C A 9.60E-04 Type 2 diabetes / / 17463246 rs28475802 chr3 106830128 G A 4.32E-04 Multiple complex diseases LOC100302640 intron 17554300 rs9863794 chr3 106836240 C T 6.55E-04 Obesity (extreme) LOC100302640 intron 21935397 rs9863794 chr3 106836240 C T 3.29E-05 Neuroblastoma LOC100302640 intron pha002895 rs7631112 chr3 106926845 G A 1.50E-05 Urinary metabolites LOC100302640 intron 21572414 rs11915523 chr3 106928929 A G 1.36E-05 Parkinson's disease LOC100302640 intron 21248740 rs11915523 chr3 106928929 A G 1.36E-04 Epilepsy LOC100302640 intron 22116939 rs793616 chr3 106974523 A G 2.03E-06 Multiple complex diseases LOC344595 intron 17554300 rs7645377 chr3 106987474 T G 3.99E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LOC344595 intron 20031582 rs16853338 chr3 107003691 G A 3.90E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) LOC344595 intron 23648065 rs809421 chr3 107019713 A G 8.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) LOC344595 intron 23648065 rs12629430 chr3 107041230 G A 5.51E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LOC344595 intron 20031582 rs12633568 chr3 107044905 A G 4.71E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LOC344595 intron 20031582 rs6782559 chr3 107091046 C T 2.80E-05 Urinary metabolites / / 21572414 rs2248981 chr3 107091102 A T 1.60E-05 Urinary metabolites / / 21572414 rs793551 chr3 107105237 A C 1.77E-04 Multiple complex diseases / / 17554300 rs7610766 chr3 107115317 C T 7.10E-04 Insulin resistance / / 21901158 rs7610766 chr3 107115317 C T 7.23E-05 Schizophrenia / / pha002859 rs11709763 chr3 107116139 T C 7.96E-04 Premature ovarian failure / / 19508998 rs2673644 chr3 107117408 T C 2.87E-04 Smoking initiation / / 24665060 rs793541 chr3 107136246 G A 9.49E-04 Multiple complex diseases / / 17554300 rs17808412 chr3 107139310 G C 0.00000463 Cytarabine sensitivity / / 23538338 rs2676371 chr3 107144292 C A 4.68E-04 Multiple complex diseases / / 17554300 rs7630522 chr3 107153088 T C 6.08E-04 Multiple complex diseases / / 17554300 rs7627215 chr3 107168315 A G 1.73E-05 Multiple complex diseases / / 17554300 rs7627215 chr3 107168315 A G 9.63E-04 Coronary Artery Disease / / 17634449 rs41517052 chr3 107174600 G A 1.82E-04 Multiple complex diseases / / 17554300 rs1850344 chr3 107185073 A G 4.70E-05 Alcohol dependence / / 20201924 rs1850344 chr3 107185073 A G 0.00000816 Alcohol dependence / / 23691058 rs1850344 chr3 107185073 A G 4.72E-05 Alcoholism / / pha002892 rs1429 chr3 107187344 C T 3.60E-04 Alcohol dependence / / 20201924 rs17808847 chr3 107197288 C A 2.00E-05 Urinary metabolites / / 21572414 rs10511261 chr3 107202624 C A 2.70E-04 Alcohol dependence / / 20201924 rs1299704 chr3 107205742 C T 1.43E-04 Coronary Artery Disease / / 17634449 rs1820527 chr3 107225146 G A 5.68E-04 Schizophrenia / / 21674006 rs10513196 chr3 107225678 G A 6.87E-04 Schizophrenia / / 21674006 rs10511260 chr3 107233097 T G 3.40E-06 Alcohol dependence / / 20201924 rs10511260 chr3 107233097 T G 4.70E-04 Alcohol dependence / / 20201924 rs10511260 chr3 107233097 T G 6.33E-05 Schizophrenia / / 21674006 rs10511260 chr3 107233097 T G 3.41E-06 Alcoholism / / pha002892 rs513007 chr3 107238607 C T 4.10E-06 Urinary metabolites / / 21572414 rs9877739 chr3 107266759 T G 5.59E-05 Coronary heart disease BBX intron pha003032 rs9851055 chr3 107295008 C T 0.000244998 Primary sclerosing cholangitis BBX intron 23603763 rs9851055 chr3 107295008 C T 2.18E-07 Waist Circumference BBX intron pha003025 rs606028 chr3 107308977 C T 2.13E-05 Weight BBX intron pha003026 rs709529 chr3 107314192 G A 2.02E-05 Weight BBX intron pha003026 rs9288851 chr3 107316938 A G 3.24E-05 Coronary heart disease BBX intron pha003032 rs9868167 chr3 107333473 G A 3.24E-05 Coronary heart disease BBX intron pha003032 rs6779452 chr3 107398611 A G 3.34E-06 Colorectal cancer BBX intron 21242260 rs6782394 chr3 107399129 A G 1.64E-05 Colorectal cancer BBX intron 21242260 rs9848674 chr3 107401883 A C 7.58E-06 Colorectal cancer BBX intron 21242260 rs9848674 chr3 107401883 A C 8.73E-05 Body Mass Index BBX intron pha003007 rs9848674 chr3 107401883 A C 2.48E-05 Body Mass Index BBX intron pha003015 rs9848674 chr3 107401883 A C 1.09E-06 Waist Circumference BBX intron pha003025 rs9848674 chr3 107401883 A C 5.07E-05 Weight BBX intron pha003027 rs6789529 chr3 107404701 C T 1.68E-05 Colorectal cancer BBX intron 21242260 rs9875732 chr3 107461731 T C 4.35E-06 Colorectal cancer BBX intron 21242260 rs11710737 chr3 107464170 A G 2.04E-05 Colorectal cancer BBX intron 21242260 rs11710737 chr3 107464170 A G 3.12E-05 Body Mass Index BBX intron pha003006 rs11710737 chr3 107464170 A G 1.20E-06 Body Mass Index BBX intron pha003007 rs11710737 chr3 107464170 A G 2.34E-05 Waist-Hip Ratio BBX intron pha003013 rs11710737 chr3 107464170 A G 2.82E-06 Body Mass Index BBX intron pha003015 rs11710737 chr3 107464170 A G 1.14E-05 Body Fat Distribution BBX intron pha003016 rs11710737 chr3 107464170 A G 2.75E-05 Body Fat Distribution BBX intron pha003018 rs11710737 chr3 107464170 A G 1.02E-06 Waist Circumference BBX intron pha003024 rs11710737 chr3 107464170 A G 8.65E-10 Waist Circumference BBX intron pha003025 rs11710737 chr3 107464170 A G 3.59E-06 Weight BBX intron pha003026 rs11710737 chr3 107464170 A G 3.67E-07 Weight BBX intron pha003027 rs11710737 chr3 107464170 A G 2.23E-05 Waist-Hip Ratio BBX intron pha003028 rs6437740 chr3 107465817 T C 2.00E-07 Smoking behavior BBX intron 19247474 rs6437740 chr3 107465817 T C 4.08E-06 Waist Circumference BBX intron pha003025 rs6437740 chr3 107465817 T C 5.20E-05 Weight BBX intron pha003027 rs6437740 chr3 107465817 T C 4.23E-05 Waist-Hip Ratio BBX intron pha003029 rs2049339 chr3 107471699 T G 2.92E-06 Colorectal cancer BBX intron 21242260 rs1403774 chr3 107479754 T G 1.13E-05 Colorectal cancer BBX intron 21242260 rs1403774 chr3 107479754 T G 7.36E-05 Waist Circumference BBX intron pha003025 rs10212337 chr3 107483187 G C 6.66E-04 Multiple complex diseases BBX intron 17554300 rs9839514 chr3 107488492 G A 6.96E-04 Multiple complex diseases BBX intron 17554300 rs9871235 chr3 107494345 G A 9.56E-04 Type 2 diabetes BBX intron 17463246 rs17812907 chr3 107508317 A G 2.74E-05 Waist Circumference BBX intron pha003025 rs12330842 chr3 107513866 T C 3.96E-04 Multiple complex diseases BBX intron 17554300 rs7634587 chr3 107516847 A G 7.99E-05 Body Mass Index BBX intron pha003007 rs7634587 chr3 107516847 A G 8.92E-05 Waist Circumference BBX intron pha003024 rs7634587 chr3 107516847 A G 6.82E-06 Waist Circumference BBX intron pha003025 rs9813554 chr3 107536562 C A 1.22E-05 Smoking quantity / / 24665060 rs9849845 chr3 107548789 G T 4.92E-05 Hypertension (essential hypertension) / / 22184326 rs10933916 chr3 107555466 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs13070401 chr3 107561983 C T 7.29E-05 Body Mass Index LOC151658 intron pha003009 rs9852257 chr3 107575074 T G 7.69E-04 Alzheimer's disease LOC151658 intron 17998437 rs4392414 chr3 107588992 T C 8.69E-05 Body Fat Distribution LOC151658 intron pha003016 rs4392414 chr3 107588992 T C 1.27E-05 Waist Circumference LOC151658 intron pha003025 rs4392414 chr3 107588992 T C 2.02E-05 Weight LOC151658 intron pha003027 rs4392414 chr3 107588992 T C 6.90E-05 Insulin Resistance LOC151658 intron pha003062 rs4392414 chr3 107588992 T C 8.91E-05 Insulin-related traits LOC151658 intron pha003063 rs6789170 chr3 107589551 G T 3.63E-05 Response to acetaminophen (hepatotoxicity) LOC151658 intron 21177773 rs9879639 chr3 107589681 C T 1.60E-05 Urinary metabolites LOC151658 intron 21572414 rs709514 chr3 107620896 G A 9.30E-05 Response to statin therapy LOC285205 intron 20339536 rs1700452 chr3 107626777 A C 8.00E-05 Response to statin therapy LOC285205 intron 20339536 rs1432595 chr3 107626808 A G 8.60E-05 Response to statin therapy LOC285205 intron 20339536 rs1437235 chr3 107627378 C G 8.70E-05 Response to statin therapy LOC285205 intron 20339536 rs1437234 chr3 107627532 C T 8.90E-05 Response to statin therapy LOC285205 intron 20339536 rs1437233 chr3 107627569 C T 8.50E-05 Response to statin therapy LOC285205 intron 20339536 rs1437232 chr3 107627644 C T 8.40E-05 Response to statin therapy LOC285205 intron 20339536 rs1700456 chr3 107629427 C T 8.30E-05 Response to statin therapy LOC285205 intron 20339536 rs1653907 chr3 107629549 A C 8.00E-05 Response to statin therapy LOC285205 intron 20339536 rs1700457 chr3 107630178 T C 7.70E-05 Response to statin therapy LOC285205 intron 20339536 rs1347651 chr3 107630289 G C 7.60E-05 Response to statin therapy LOC285205 intron 20339536 rs1370283 chr3 107630310 T G 7.50E-05 Response to statin therapy LOC285205 intron 20339536 rs1368255 chr3 107630420 C T 7.40E-05 Response to statin therapy LOC285205 intron 20339536 rs13086279 chr3 107640533 G A 0.0000929 post-traumatic stress disorder LOC285205 intron 22869035 rs13086279 chr3 107640533 G A 9.29E-05 Schizophrenia LOC285205 intron 22883433 rs9868359 chr3 107645193 A C 2.61E-04 Alzheimer's disease LOC285205 intron 17998437 rs6774951 chr3 107667951 G A 7.33E-05 Orofacial clefts / / 22419666 rs709477 chr3 107703656 C T 6.27E-06 Common variable immunodeficiency / / 21497890 rs697957 chr3 107707753 T G 5.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs709465 chr3 107708877 G T 7.77E-04 Coronary heart disease / / 21606135 rs7638293 chr3 107709857 T A 1.65E-04 Coronary heart disease / / 21606135 rs877859 chr3 107714075 G A 9.14E-05 Coronary heart disease / / 21606135 rs6798831 chr3 107722134 T C 2.40E-06 Multiple sclerosis / / 21833088 rs9835822 chr3 107731924 T C 0.0000183 Skin naphthyl-keratin adduct (NKA) levels in workers exposed to naphthalene / / 22391508 rs696375 chr3 107732083 A G 3.89E-05 Sudden cardiac arrest / / 21658281 rs10933931 chr3 107787525 C T 8.65E-04 Alzheimer's disease CD47 intron 24755620 rs3762681 chr3 107811787 G A 2.68E-05 Blood Pressure / / pha003043 rs7635063 chr3 107818777 G A 2.70E-05 Urinary metabolites / / 21572414 rs17828045 chr3 107821546 T G 2.50E-05 Urinary metabolites / / 21572414 rs17232226 chr3 107848221 C T 1.96E-05 Insulin Resistance / / pha003062 rs16854283 chr3 107912815 G T 3.93E-04 Lymphocyte counts IFT57 intron 22286170 rs7636464 chr3 107970160 T C 9.56E-04 Type 2 diabetes / / 17463246 rs7622810 chr3 107971021 T C 9.56E-04 Type 2 diabetes / / 17463246 rs1870007 chr3 107975332 A G 1.32E-05 Bone mass and geometry / / 17903296 rs768342 chr3 108015247 G T 9.56E-04 Type 2 diabetes / / 17463246 rs2016469 chr3 108023965 G A 2.20E-06 Insulin Resistance HHLA2 intron pha003062 rs2016469 chr3 108023965 G A 1.66E-06 Insulin-related traits HHLA2 intron pha003063 rs6768207 chr3 108024901 A C 7.00E-04 Stroke HHLA2 intron pha002886 rs16854447 chr3 108037843 A G 7.28E-04 Multiple complex diseases HHLA2 intron 17554300 rs16854451 chr3 108039513 C T 3.80E-04 Multiple complex diseases HHLA2 intron 17554300 rs2061245 chr3 108046671 G A 6.64E-05 Post-operative nausea and vomiting HHLA2 intron 21694509 rs2085408 chr3 108086031 C T 2.13E-05 Word reading HHLA2 intron 23738518 rs6799532 chr3 108118700 T C 3.81E-05 Body Composition MYH15 intron pha003012 rs6768511 chr3 108120250 A G 2.59E-04 Type 2 diabetes MYH15 intron 17463246 rs7630352 chr3 108123001 G A 0.000711402 Hypertension (early onset hypertension) MYH15 intron 22479346 rs3957543 chr3 108126872 T C 5.03E-04 Bipolar disorder MYH15 intron 19259986 rs3957559 chr3 108184858 T C 7.96E-08 Metabolite levels MYH15 intron 23281178 rs2688252 chr3 108227197 A G 0.000817892 Hypertension (early onset hypertension) MYH15 intron 22479346 rs3843872 chr3 108229122 C G 3.91E-04 Type 2 diabetes MYH15 intron 17463246 rs2603127 chr3 108243551 G A 5.00E-06 Hemostatic factors and hematological phenotypes MYH15 intron 22443383 rs2603127 chr3 108243551 G A 9.52E-05 Body Composition MYH15 intron pha003012 rs2603127 chr3 108243551 G A 8.81E-05 Body Mass Index MYH15 intron pha003021 rs2290444 chr3 108329761 G A 5.99E-04 Myopia (pathological) DZIP3 intron 21095009 rs1377843 chr3 108382760 A G 4.14E-04 Longevity DZIP3 intron 22279548 rs3902849 chr3 108443335 T C 2.96E-04 Type 2 diabetes / / 17463246 rs41454852 chr3 108592615 C T 2.19E-04 Alzheimer's disease / / 17998437 rs4499605 chr3 108594185 T C 4.19E-04 Type 2 diabetes / / 17463246 rs6437804 chr3 108606743 T C 3.31E-04 Type 2 diabetes / / 17463246 rs10933971 chr3 108623388 C T 1.71E-05 Hepatocellular carcinoma / / 22807686 rs6791490 chr3 108630221 T G 2.09E-04 Type 2 diabetes GUCA1C intron 17463246 rs2715689 chr3 108637430 G T 4.91E-05 Alcohol and nictotine co-dependence GUCA1C intron 20158304 rs751298 chr3 108656151 T C 2.40E-04 Iris characteristics GUCA1C intron 21835309 rs2715719 chr3 108660691 G C 1.70E-05 Urinary metabolites GUCA1C intron 21572414 rs9842454 chr3 108663080 C T 9.65E-05 Bipolar disorder,affective GUCA1C intron 20528957 rs10490845 chr3 108681891 G A 1.66E-05 Prion diseases MORC1 intron 22210626 rs2922138 chr3 108694040 G A 3.71E-08 Metabolite levels MORC1 intron 23281178 rs2593957 chr3 108703025 T C 2.00E-06 Colorectal cancer (diet interaction) MORC1 intron 24743840 rs2593970 chr3 108710199 T A 1.10E-05 Urinary metabolites MORC1 intron 21572414 rs2715701 chr3 108714592 C T 3.54E-04 Gallstones MORC1 intron 17632509 rs2044590 chr3 108725984 G C 9.33E-04 Alcohol dependence MORC1 intron 21314694 rs13322246 chr3 108746084 G A 5.29E-05 Serum metabolites MORC1 intron 19043545 rs2290060 chr3 108774124 A T 2.40E-05 Urinary metabolites MORC1 intron 21572414 rs13086910 chr3 108774266 C A 2.70E-06 Homeostasis model assessment of beta-cell function (interaction) MORC1 intron 24204828 rs16855331 chr3 108780310 A C 1.70E-05 Urinary metabolites MORC1 intron 21572414 rs4855687 chr3 108789873 G A 2.63E-06 Homeostasis model assessment of beta-cell function (interaction) MORC1 intron 24204828 rs4413319 chr3 108790856 C T 3.33E-06 Homeostasis model assessment of beta-cell function (interaction) MORC1 intron 24204828 rs4585204 chr3 108791087 T C 6.29E-06 Left ventricular mass MORC1 intron 21212386 rs4585204 chr3 108791087 T C 2.63E-06 Homeostasis model assessment of beta-cell function (interaction) MORC1 intron 24204828 rs4555525 chr3 108810524 C T 7.52E-04 Type 2 diabetes MORC1 intron 17463246 rs4075512 chr3 108810568 C T 2.60E-05 Urinary metabolites MORC1 intron 21572414 rs11715192 chr3 108811639 G C 1.50E-05 Urinary metabolites MORC1 intron 21572414 rs4855695 chr3 108851484 T C 2.00E-06 Colorectal cancer (diet interaction) / / 24743840 rs4441659 chr3 108851791 A G 5.20E-06 Urinary metabolites / / 21572414 rs4441659 chr3 108851791 A G 3.00E-07 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs10049362 chr3 108861404 A G 5.02E-07 Homeostasis model assessment of beta-cell function (interaction) FLJ22763 intron 24204828 rs1606830 chr3 108871461 T C 1.90E-05 Urinary metabolites / / 21572414 rs6801594 chr3 108905914 A G 1.39E-04 Smoking initiation / / 24665060 rs1163404 chr3 108910376 C T 1.19E-04 Prion diseases / / 22210626 rs1163400 chr3 108914650 T C 1.04E-04 Prion diseases / / 22210626 rs1163397 chr3 108918239 C T 1.78E-04 Cardiovascular disease / / 17903304 rs1163397 chr3 108918239 C T 7.49E-05 Prion diseases / / 22210626 rs11712428 chr3 109034120 G T 2.00E-05 Multiple sclerosis (age of onset) DPPA2 intron 19010793 rs2699985 chr3 109037160 A G 2.42E-04 Type 2 diabetes / / 17463246 rs3804621 chr3 109047191 G A 7.68E-04 Type 2 diabetes DPPA4 intron 17463246 rs3762648 chr3 109052732 T C 4.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DPPA4 missense 20877124 rs1163447 chr3 109056751 C A 3.33E-04 Fibrinogen / / 17255346 rs16855573 chr3 109070168 G A 2.86E-05 Intracerebral hemorrhage / / 24656865 rs16855581 chr3 109072016 A T 2.52E-05 Intracerebral hemorrhage / / 24656865 rs13069030 chr3 109072323 C T 7.54E-05 Cognitive test performance / / 20125193 rs12497535 chr3 109073022 T A 2.61E-05 Intracerebral hemorrhage / / 24656865 rs12495109 chr3 109074136 G C 1.67E-05 Intracerebral hemorrhage / / 24656865 rs12495109 chr3 109074136 G C 4.04E-05 Intracerebral hemorrhage / / 24656865 rs17193050 chr3 109106911 G A 5.30E-05 Heart Rate / / pha003051 rs6778096 chr3 109142424 G A 4.20E-05 Socioeconomic Factors FLJ25363 intron pha003067 rs13314017 chr3 109174537 T C 8.25E-04 Depression (quantitative trait) FLJ25363 intron 20800221 rs769529 chr3 109182586 A G 8.21E-04 Depression (quantitative trait) FLJ25363 intron 20800221 rs769528 chr3 109183295 C G 8.84E-04 Depression (quantitative trait) FLJ25363 intron 20800221 rs1081119 chr3 109193224 A G 7.20E-04 Depression (quantitative trait) FLJ25363 intron 20800221 rs769570 chr3 109194595 A G 7.31E-04 Depression (quantitative trait) FLJ25363 intron 20800221 rs769566 chr3 109195259 A G 7.15E-04 Depression (quantitative trait) FLJ25363 intron 20800221 rs769556 chr3 109203399 A G 3.57E-04 Smoking initiation FLJ25363 intron 24665060 rs769554 chr3 109204413 C T 3.00E-06 Cardiac hypertrophy FLJ25363 intron 21348951 rs769548 chr3 109207140 A G 5.10E-04 Smoking initiation FLJ25363 intron 24665060 rs769543 chr3 109211394 A C 6.81E-05 Smoking initiation FLJ25363 intron 24665060 rs769537 chr3 109218681 A T 9.52E-05 Smoking initiation / / 24665060 rs13063502 chr3 109224312 C T 8.96E-06 Tourette syndrome / / 22889924 rs10933993 chr3 109249961 C T 2.05E-04 Smoking initiation / / 24665060 rs11717790 chr3 109250510 C T 4.26E-04 Smoking initiation / / 24665060 rs1612794 chr3 109338852 C T 2.05E-04 Smoking initiation / / 24665060 rs1534630 chr3 109363105 T C 2.66E-05 Height / / 22021425 rs2222787 chr3 109381428 G A 8.74E-05 Cognitive test performance / / 20125193 rs12491990 chr3 109447463 G A 8.02E-05 Cognitive test performance / / 20125193 rs1164064 chr3 109462400 G A 2.00E-06 Corneal astigmatism / / 23761726 rs1164067 chr3 109466019 G A 4.57E-05 Schizophrenia / / 19571811 rs938545 chr3 109468540 A C 7.19E-06 Uric acid levels / / 21294900 rs679711 chr3 109529550 T C 1.00E-06 Sleep depth / / 23728906 rs1881949 chr3 109555870 G A 8.14E-04 Schizophrenia / / 19197363 rs1164194 chr3 109604806 C T 7.29E-05 Serum metabolites / / 19043545 rs9647326 chr3 109699459 A G 2.91E-05 Cognitive test performance / / 20125193 rs17722374 chr3 109739262 C T 0.00000715 Antisocial behavior / / 23077488 rs6414241 chr3 109744638 G C 8.65E-04 Multiple complex diseases / / 17554300 rs2692657 chr3 109780311 A T 1.32E-05 Multiple complex diseases / / 17554300 rs10934011 chr3 109789570 A G 1.00E-09 DNA methylation (parent-of-origin) / / 23725790 rs1358018 chr3 109799304 G A 5.46E-05 Cognitive test performance / / 20125193 rs7642520 chr3 109829416 T C 3.92E-05 Bipolar disorder and schizophrenia / / 20889312 rs9288904 chr3 109840388 A T 1.18E-04 Multiple complex diseases / / 17554300 rs10755068 chr3 109875668 C T 4.22E-04 Multiple complex diseases / / 17554300 rs13323983 chr3 109927376 A G 5.00E-06 Neutrophil count / / 21507922 rs2895366 chr3 109933826 C T 1.80E-04 Multiple complex diseases / / 17554300 rs716534 chr3 109942107 G A 5.27E-04 Multiple complex diseases / / 17554300 rs716534 chr3 109942107 G A 1.13E-04 Telomere length / / 21573004 rs4682566 chr3 109959743 C G 5.15E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9883805 chr3 109961194 A G 2.81E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs6799277 chr3 109974076 C T 7.03E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs1461762 chr3 109983269 T G 7.57E-04 Alzheimer's disease / / 22005930 rs2713001 chr3 110000728 T C 6.32E-04 Heart Failure / / pha002885 rs6802410 chr3 110015748 C T 8.38E-04 Heart Failure / / pha002885 rs9861768 chr3 110034660 G A 1.63E-05 Cognitive test performance / / 20125193 rs12185907 chr3 110044601 C T 3.87E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12634736 chr3 110083045 T C 2.71E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2712964 chr3 110108236 C T 1.08E-04 Body mass index / / 21701565 rs2669100 chr3 110133332 C T 1.43E-04 Body mass index / / 21701565 rs6773922 chr3 110192254 C T 1.78E-04 Body mass index / / 21701565 rs963345 chr3 110206030 C T 4.96E-04 Multiple complex diseases / / 17554300 rs41509750 chr3 110223092 C T 6.95E-04 Body mass index / / 21701565 rs41509750 chr3 110223092 C T 8.19E-05 Body mass index / / 21701565 rs11919628 chr3 110330282 G T 7.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs1512530 chr3 110340886 T A 7.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs11919437 chr3 110380923 T C 7.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs11917622 chr3 110383041 G T 7.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs11720760 chr3 110455048 G A 7.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs9288916 chr3 110493206 C T 2.01E-04 Multiple complex diseases / / 17554300 rs1462307 chr3 110501848 T C 4.76E-04 Alcohol dependence / / 20201924 rs2399367 chr3 110641021 G A 3.64E-05 Intracerebral hemorrhage / / 24656865 rs2399368 chr3 110642384 G C 3.60E-05 Intracerebral hemorrhage / / 24656865 rs4682215 chr3 110642634 T G 3.60E-05 Intracerebral hemorrhage / / 24656865 rs6787921 chr3 110643763 A G 3.00E-05 Intracerebral hemorrhage / / 24656865 rs1462807 chr3 110645112 C A 2.97E-05 Intracerebral hemorrhage / / 24656865 rs992130 chr3 110676677 A G 1.08E-04 Multiple complex diseases / / 17554300 rs4682240 chr3 110892394 A G 1.57E-06 Intracerebral hemorrhage PVRL3 intron 24656865 rs4682240 chr3 110892394 A G 4.12E-06 Intracerebral hemorrhage PVRL3 intron 24656865 rs6437958 chr3 110935466 G A 5.78E-04 Alzheimer's disease / / 22005930 rs6437959 chr3 110936853 A C 5.74E-04 Alzheimer's disease / / 22005930 rs6437960 chr3 110937558 T C 3.09E-04 Alzheimer's disease / / 22005930 rs6437962 chr3 110940332 T C 3.63E-04 Alzheimer's disease / / 22005930 rs4410442 chr3 110951810 T C 2.00E-04 Type 2 diabetes / / 17846126 rs16857932 chr3 111030592 C T 3.00E-04 Multiple complex diseases / / 17554300 rs13099027 chr3 111035942 T G 7.83E-04 Alzheimer's disease / / 22005930 rs13077161 chr3 111036206 G T 7.80E-04 Alzheimer's disease / / 22005930 rs7648318 chr3 111037011 C G 7.77E-04 Alzheimer's disease / / 22005930 rs10934082 chr3 111038422 A C 6.70E-04 Alzheimer's disease / / 22005930 rs1352499 chr3 111039431 T A 7.78E-04 Alzheimer's disease / / 22005930 rs10804486 chr3 111039820 G T 7.72E-04 Alzheimer's disease / / 22005930 rs7625666 chr3 111040512 T C 7.73E-04 Alzheimer's disease / / 22005930 rs1844239 chr3 111040667 G C 9.81E-04 Alzheimer's disease / / 22005930 rs13070202 chr3 111072117 G A 6.61E-05 Multiple complex diseases / / 17554300 rs4611815 chr3 111079230 A G 9.02E-04 Depression (quantitative trait) / / 20800221 rs973209 chr3 111080674 G A 5.78E-04 Multiple complex diseases / / 17554300 rs973208 chr3 111080687 T C 2.78E-04 Depression (quantitative trait) / / 20800221 rs4145123 chr3 111081318 C T 7.60E-04 Depression (quantitative trait) / / 20800221 rs4145122 chr3 111081455 T C 7.60E-04 Depression (quantitative trait) / / 20800221 rs2958074 chr3 111081538 G C 6.17E-04 Depression (quantitative trait) / / 20800221 rs1529058 chr3 111086040 C T 2.83E-04 Depression (quantitative trait) / / 20800221 rs6785820 chr3 111086732 G A 6.31E-04 Depression (quantitative trait) / / 20800221 rs7645369 chr3 111087191 T C 6.31E-04 Depression (quantitative trait) / / 20800221 rs7633973 chr3 111087564 C T 6.32E-04 Depression (quantitative trait) / / 20800221 rs9843462 chr3 111087800 C T 7.77E-04 Depression (quantitative trait) / / 20800221 rs7618272 chr3 111089831 A G 6.31E-04 Depression (quantitative trait) / / 20800221 rs7646572 chr3 111102893 T C 8.80E-04 Multiple complex diseases / / 17554300 rs7612956 chr3 111110278 C A 7.18E-04 Multiple complex diseases / / 17554300 rs1601964 chr3 111110391 T C 2.86E-04 Depression (quantitative trait) / / 20800221 rs6778463 chr3 111119350 C T 2.87E-04 Depression (quantitative trait) / / 20800221 rs2646991 chr3 111120319 T C 7.19E-04 Multiple complex diseases / / 17554300 rs2646992 chr3 111120382 T C 7.98E-04 Multiple complex diseases / / 17554300 rs7623819 chr3 111124619 C T 6.82E-04 Depression (quantitative trait) / / 20800221 rs1406562 chr3 111124985 T C 2.95E-04 Depression (quantitative trait) / / 20800221 rs4682264 chr3 111125434 C T 3.37E-04 Depression (quantitative trait) / / 20800221 rs13095499 chr3 111127330 C T 3.00E-04 Depression (quantitative trait) / / 20800221 rs1391353 chr3 111131512 C A 7.46E-04 Depression (quantitative trait) / / 20800221 rs1529057 chr3 111134809 A T 3.63E-04 Depression (quantitative trait) / / 20800221 rs1391354 chr3 111137009 G T 3.24E-04 Depression (quantitative trait) / / 20800221 rs6799452 chr3 111141002 G A 2.65E-04 Depression (quantitative trait) / / 20800221 rs3902555 chr3 111144002 C A 2.61E-04 Depression (quantitative trait) / / 20800221 rs2698363 chr3 111146775 G T 8.60E-04 Depression (quantitative trait) / / 20800221 rs1609394 chr3 111153487 C A 6.91E-04 Multiple complex diseases / / 17554300 rs1909095 chr3 111153501 T C 8.99E-04 Depression (quantitative trait) / / 20800221 rs1498004 chr3 111157674 C G 4.49E-04 Depression (quantitative trait) / / 20800221 rs1529054 chr3 111157773 A G 3.41E-04 Depression (quantitative trait) / / 20800221 rs2698370 chr3 111159353 T C 3.26E-05 Epilepsy (remission after treatment) / / 23962720 rs2935905 chr3 111161969 G A 3.24E-05 Epilepsy (remission after treatment) / / 23962720 rs9834882 chr3 111163081 A G 9.40E-05 Epilepsy (remission after treatment) / / 23962720 rs2698374 chr3 111165054 G T 4.62E-05 Epilepsy (remission after treatment) / / 23962720 rs80184502 chr3 111167381 A C 4.12E-05 Epilepsy (remission after treatment) / / 23962720 rs72937591 chr3 111167783 T G 3.89E-05 Epilepsy (remission after treatment) / / 23962720 rs35655617 chr3 111171372 CA C 7.12E-04 Depression (quantitative trait) / / 20800221 rs7643569 chr3 111171372 C A 7.12E-04 Depression (quantitative trait) / / 20800221 rs2698357 chr3 111173131 G A 8.51E-04 Depression (quantitative trait) / / 20800221 rs2646977 chr3 111175311 G A,C,T 8.24E-04 Depression (quantitative trait) / / 20800221 rs1391366 chr3 111184140 C A 9.94E-04 Depression (quantitative trait) / / 20800221 rs1113850 chr3 111197213 A G 7.79E-04 Depression (quantitative trait) / / 20800221 rs76884941 chr3 111201785 T G 1.00E-07 Chronic obstructive pulmonary disease / / 21685187 rs2133031 chr3 111208529 C T 9.09E-04 Depression (quantitative trait) / / 20800221 rs13075227 chr3 111215119 T A 9.66E-04 Depression (quantitative trait) / / 20800221 rs56238310 chr3 111233239 C A,T 1.00E-07 Chronic obstructive pulmonary disease / / 21685187 rs1282090 chr3 111297114 A G 4.00E-04 Type 2 diabetes CD96 intron 17846126 rs1282090 chr3 111297114 A G 3.19E-04 Myopia (pathological) CD96 intron 21095009 rs1398750 chr3 111300465 G T 1.23E-04 Smoking initiation CD96 intron 24665060 rs16858329 chr3 111330061 G T 4.29E-06 Lipid traits CD96 intron 21777205 rs4450776 chr3 111423129 G C 5.00E-06 Cognitive performance PLCXD2 intron 20125193 rs11922220 chr3 111429532 G A 2.00E-04 Cognitive impairment induced by topiramate PLCXD2 intron 22091778 rs16858448 chr3 111430969 G C 9.42E-05 Pulmonary function PLCXD2 intron 20010835 rs2137595 chr3 111431818 G A 3.82E-05 Telomere length PLCXD2 intron 23001564 rs2399395 chr3 111433494 T C 1.45E-04 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) PLCXD2 intron 23103227 rs951338 chr3 111433815 C T 9.70E-04 Rheumatoid arthritis PLCXD2 intron 21452313 rs9877859 chr3 111440689 C T 1.20E-04 Suicidal ideation PLCXD2 intron 22030708 rs13074817 chr3 111467155 A G 7.13E-05 Orofacial clefts PHLDB2 intron 22419666 rs4284954 chr3 111468099 T C 4.84E-05 Orofacial clefts PHLDB2 intron 22419666 rs9834030 chr3 111469374 A G 5.19E-05 Orofacial clefts PHLDB2 intron 22419666 rs7616638 chr3 111514405 T A 9.61E-04 Suicide attempts in bipolar disorder PHLDB2 intron 21423239 rs6769535 chr3 111544295 T C 7.37E-05 Body Fat Distribution PHLDB2 intron pha003016 rs6769535 chr3 111544295 T C 3.41E-05 Body Fat Distribution PHLDB2 intron pha003017 rs6769535 chr3 111544295 T C 9.73E-05 Body Fat Distribution PHLDB2 intron pha003018 rs3925081 chr3 111556141 C T 6.44E-04 Response to taxane treatment (placlitaxel) PHLDB2 intron 23006423 rs1282970 chr3 111567238 A C 6.20E-04 Response to taxane treatment (placlitaxel) PHLDB2 intron 23006423 rs17424938 chr3 111585933 A G 7.08E-04 Alzheimer's disease PHLDB2 intron 22005930 rs17490701 chr3 111587879 G A 6.49E-04 Alzheimer's disease PHLDB2 intron 22005930 rs1282948 chr3 111631564 G A 7.51E-04 Body mass index PHLDB2 intron 21701565 rs951660 chr3 111638132 A C 5.19E-04 Multiple complex diseases PHLDB2 intron 17554300 rs2137897 chr3 111643561 C T 3.94E-04 Type 2 diabetes PHLDB2 intron 17463246 rs13091880 chr3 111646052 C T 4.36E-05 Vitiligo PHLDB2 intron 19890347 rs6804475 chr3 111669631 A G 3.22E-05 Male-pattern baldness PHLDB2 intron 18849994 rs17492619 chr3 111671794 G A 8.55E-04 Type 2 diabetes PHLDB2 intron 17463246 rs766745 chr3 111673636 T A 2.20E-05 Urinary metabolites PHLDB2 intron 21572414 rs11713044 chr3 111677526 G A 2.00E-05 Urinary metabolites PHLDB2 intron 21572414 rs16858950 chr3 111683753 A C 6.50E-05 Coronary heart disease PHLDB2 intron pha003030 rs774861 chr3 111684866 A G 6.49E-05 Coronary heart disease PHLDB2 intron pha003030 rs774855 chr3 111686073 C T 5.78E-04 Multiple complex diseases PHLDB2 intron 17554300 rs799570 chr3 111686738 G A 8.56E-04 Multiple complex diseases PHLDB2 intron 17554300 rs16858964 chr3 111687328 T C 9.50E-05 Response to statin therapy PHLDB2 intron 20339536 rs16858964 chr3 111687328 T C 2.03E-05 Coronary heart disease PHLDB2 intron pha003030 rs774854 chr3 111688578 C T 1.80E-05 Response to statin therapy PHLDB2 cds-synon 20339536 rs774854 chr3 111688578 C T 6.48E-04 Rheumatoid arthritis PHLDB2 cds-synon 21452313 rs581126 chr3 111689915 C G 2.10E-05 Response to statin therapy PHLDB2 intron 20339536 rs529159 chr3 111690620 G A 2.10E-05 Response to statin therapy PHLDB2 intron 20339536 rs1994731 chr3 111690768 A G 8.87E-04 Parkinson's disease PHLDB2 intron 17052657 rs774852 chr3 111692829 C T 1.77E-04 Suicide attempts in bipolar disorder PHLDB2 intron 21423239 rs703271 chr3 111696893 C G 5.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs510549 chr3 111700305 A G 8.46E-04 Suicide attempts in bipolar disorder ABHD10 intron 21423239 rs2289597 chr3 111701010 G A 6.93E-04 Suicide attempts in bipolar disorder ABHD10 intron 21423239 rs774745 chr3 111701870 T C 8.14E-04 Suicide attempts in bipolar disorder ABHD10 intron 21423239 rs774745 chr3 111701870 T C 9.91E-04 Rheumatoid arthritis ABHD10 intron 21452313 rs774751 chr3 111706266 G C 9.78E-04 Suicide attempts in bipolar disorder ABHD10 intron 21423239 rs17429033 chr3 111710398 A G 3.27E-07 Lymphocyte counts ABHD10 missense 22286170 rs1058062 chr3 111717906 G C 8.43E-04 Suicide attempts in bipolar disorder TAGLN3 UTR-5 21423239 rs11929538 chr3 111721092 T C 8.35E-04 Alzheimer's disease TAGLN3 intron 22005930 rs774760 chr3 111721929 G A 8.42E-04 Alzheimer's disease TAGLN3 intron 22005930 rs774758 chr3 111722196 G A 9.45E-04 Alzheimer's disease TAGLN3 intron 22005930 rs8070 chr3 111732608 G A 4.06E-04 Type 2 diabetes TAGLN3 UTR-3 17463246 rs2218325 chr3 111758207 G C 6.76E-04 Type 2 diabetes / / 17463246 rs7625219 chr3 111762451 A C 8.54E-05 IgE levels TMPRSS7 intron 17255346 rs4682349 chr3 111762752 C T 7.96E-05 IgE levels TMPRSS7 intron 17255346 rs774778 chr3 111763779 T C 7.48E-05 IgE levels TMPRSS7 intron 17255346 rs1561911 chr3 111765834 G A 4.83E-05 IgE levels TMPRSS7 intron 17255346 rs774770 chr3 111771444 A G 7.97E-05 IgE levels TMPRSS7 intron 17255346 rs16859140 chr3 111792594 T C 5.00E-06 Telomere length TMPRSS7 intron 24478790 rs13066495 chr3 111800753 T C 1.90E-05 Urinary metabolites / / 21572414 rs4682355 chr3 111807719 G A 9.40E-05 Cleft lip C3orf52 intron 20436469 rs16859207 chr3 111824279 A G 9.99E-06 Cleft lip C3orf52 intron 20436469 rs1492483 chr3 111847985 A G 4.68E-04 Response to taxane treatment (placlitaxel) GCET2 intron 23006423 rs950528 chr3 111851817 C T 7.23E-04 Response to taxane treatment (placlitaxel) GCET2 intron 23006423 rs201680751 chr3 111923150 T C 0.000087 Breast cancer(er negative) SLC9A10 missense 23555315 rs2399413 chr3 112042969 A C 9.92E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1317243 chr3 112053246 T C 9.21E-05 Parkinson's disease CD200 intron 21812969 rs10511311 chr3 112055839 A T 4.45E-05 Cardiovascular disease CD200 intron 17903304 rs16859476 chr3 112060256 A C 6.07E-04 Multiple complex diseases CD200 intron 17554300 rs1050572 chr3 112066562 G A 9.53E-04 Myocardial Infarction CD200 cds-synon pha002883 rs2399417 chr3 112067241 C T 5.65E-04 Multiple complex diseases CD200 intron 17554300 rs2399418 chr3 112067438 C G 5.50E-04 Multiple complex diseases CD200 intron 17554300 rs9867544 chr3 112079277 T C 3.08E-05 Parkinson's disease CD200 intron 21812969 rs6794784 chr3 112085536 G C 2.51E-04 Multiple complex diseases / / 17554300 rs10934170 chr3 112090292 G T 7.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs7641311 chr3 112091696 C T 8.17E-06 Parkinson's disease / / 21812969 rs17513880 chr3 112093413 G A 9.60E-07 Urinary metabolites / / 21572414 rs1879512 chr3 112093900 C T 3.04E-06 Parkinson's disease / / 21812969 rs16859530 chr3 112113143 T C 4.92E-04 Multiple complex diseases / / 17554300 rs999802 chr3 112127280 A G 1.18E-05 ldl cholesterol / / pha003077 rs999802 chr3 112127280 A G 8.44E-05 Cholesterol / / pha003083 rs7609904 chr3 112130589 G A 4.27E-05 ldl cholesterol / / pha003077 rs13090873 chr3 112165339 C T 9.74E-05 Coronary heart disease / / pha003035 rs546779181 chr3 112207075 C CT 9.43E-06 Stroke (ischemic) BTLA intron 21957438 rs71134837 chr3 112207075 C CT 9.43E-06 Stroke (ischemic) BTLA intron 21957438 rs76802195 chr3 112207075 C T 9.43E-06 Stroke (ischemic) BTLA intron 21957438 rs2633580 chr3 112219753 C G 3.66E-05 Schizophrenia / / pha002857 rs2633578 chr3 112220781 A G 3.53E-05 Schizophrenia / / pha002857 rs4682413 chr3 112235371 A C 1.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs2933142 chr3 112237656 T C 2.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs9848054 chr3 112246081 T C 2.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs2638037 chr3 112252390 A G 2.01E-04 Suicide attempts in bipolar disorder ATG3 intron 21423239 rs4682110 chr3 112253756 G A 8.25E-04 Lymphocyte counts ATG3 intron 22286170 rs2638016 chr3 112258243 G A 2.48E-04 Suicide attempts in bipolar disorder ATG3 intron 21423239 rs2638017 chr3 112259158 T C 1.53E-04 Suicide attempts in bipolar disorder ATG3 intron 21423239 rs1873571 chr3 112259388 T G 1.46E-04 Suicide attempts in bipolar disorder ATG3 intron 21423239 rs2952327 chr3 112261672 G A 1.68E-04 Suicide attempts in bipolar disorder ATG3 intron 21423239 rs2952326 chr3 112261768 A G 1.59E-04 Suicide attempts in bipolar disorder ATG3 intron 21423239 rs2705559 chr3 112263955 C A 1.32E-04 Suicide attempts in bipolar disorder ATG3 intron 21423239 rs2638022 chr3 112265776 T C 1.09E-04 Suicide attempts in bipolar disorder ATG3 intron 21423239 rs2705520 chr3 112269287 A G 2.00E-06 Asthma (childhood onset) ATG3 intron 23829686 rs16859787 chr3 112274613 A G 5.53E-04 Multiple complex diseases ATG3 intron 17554300 rs7652377 chr3 112282892 A C 3.72E-04 Suicide attempts in bipolar disorder SLC35A5 intron 21423239 rs2638031 chr3 112287760 T C 5.79E-05 Suicide attempts in bipolar disorder SLC35A5 intron 21423239 rs766968 chr3 112291878 T C 1.45E-04 Suicide attempts in bipolar disorder SLC35A5 intron 21423239 rs766968 chr3 112291878 T C 2.64E-05 Schizophrenia SLC35A5 intron pha002857 rs2638039 chr3 112294120 G A 8.36E-05 Suicide attempts in bipolar disorder SLC35A5 intron 21423239 rs1877363 chr3 112303184 G A 3.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs1512006 chr3 112304805 A C 4.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs367978275 chr3 112304805 AT A 4.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs9866734 chr3 112311790 A G 4.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs2172196 chr3 112317291 A G 4.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs2705517 chr3 112319683 C G 6.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs11711357 chr3 112330798 A T 0.0007347 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CCDC80 intron 23233654 rs11711357 chr3 112330798 A T 7.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) CCDC80 intron 23233662 rs3846050 chr3 112338424 T G 7.08E-04 Suicide attempts in bipolar disorder CCDC80 intron 21423239 rs16859847 chr3 112338722 A G 0.0004542 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CCDC80 intron 23233654 rs16859847 chr3 112338722 A G 4.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) CCDC80 intron 23233662 rs12634229 chr3 112376308 T C 2.00E-19 Atopic dermatitis / / 23042114 rs9818848 chr3 112394340 C T 2.70E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1154270 chr3 112397186 A G 1.74E-05 Multiple complex diseases / / 17554300 rs17457593 chr3 112407697 G A 6.63E-05 Cognitive test performance / / 20125193 rs56084816 chr3 112423332 A C 0.0000872 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7627205 chr3 112434931 A C 3.91E-04 Multiple complex diseases / / 17554300 rs4682115 chr3 112441098 A G 2.82E-36 Narcolepsy / / 19629137 rs820553 chr3 112470586 C T 4.77E-04 Coronary heart disease / / 21971053 rs4682421 chr3 112478591 G A 4.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs1002979 chr3 112497880 T C 3.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs6775807 chr3 112512819 T C 1.00E-04 Iris characteristics / / 21835309 rs1352425 chr3 112519276 T C 0.000015 Mean arterial pressure / / 22510845 rs1387024 chr3 112547601 G A 3.70E-05 Anger CD200R1L intron 24489884 rs4682438 chr3 112564663 G C 8.46E-04 Obesity (extreme) CD200R1L UTR-5 21935397 rs4234417 chr3 112566924 G A 9.14E-05 Hemoglobin / / pha003098 rs4234417 chr3 112566924 G A 6.86E-05 Erythrocyte counts / / pha003099 rs4682442 chr3 112574745 T A 3.00E-04 Type 2 diabetes / / 17463246 rs4682123 chr3 112597706 A G 8.11E-04 Obesity (extreme) / / 21935397 rs4682124 chr3 112597844 C G 8.16E-04 Obesity (extreme) / / 21935397 rs9876981 chr3 112604252 G T 8.18E-04 Alcohol dependence / / 21314694 rs9870568 chr3 112643560 C A 7.08E-05 Erythrocyte counts CD200R1 intron pha003099 rs7622812 chr3 112650420 T C 7.08E-05 Erythrocyte counts CD200R1 intron pha003099 rs7646849 chr3 112665298 A C 3.85E-05 Hemoglobin CD200R1 intron pha003098 rs7646849 chr3 112665298 A C 6.99E-06 Erythrocyte counts CD200R1 intron pha003099 rs1488193 chr3 112681585 A G 6.00E-06 Economic and political preferences CD200R1 intron 22566634 rs7630531 chr3 112707676 C T 5.92E-04 Multiple complex diseases / / 17554300 rs41270443 chr3 112710194 T G 0.0000815 Nonsyndromic striae distensae (stretch marks) GTPBP8 intron 23633020 rs76863923 chr3 112710552 T G 0.0000731 Nonsyndromic striae distensae (stretch marks) GTPBP8 intron 23633020 rs78453530 chr3 112710844 C G 0.0000602 Nonsyndromic striae distensae (stretch marks) GTPBP8 intron 23633020 rs76755033 chr3 112717725 G A 0.0000338 Nonsyndromic striae distensae (stretch marks) GTPBP8 intron 23633020 rs1054263 chr3 112718352 G T 2.25E-04 Hearing function GTPBP8 missense 17255346 rs76664669 chr3 112721198 G A 0.0000619 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs3732814 chr3 112724336 G A 0.0000991 Nonsyndromic striae distensae (stretch marks) C3orf17 UTR-3 23633020 rs3864002 chr3 112726411 G A 9.35E-05 Lymphocyte counts C3orf17 intron 22286170 rs7650483 chr3 112754626 C T 7.97E-04 Coronary Artery Disease / / 17634449 rs3872612 chr3 112782186 T G 2.43E-04 Alzheimer's disease / / 22005930 rs12106863 chr3 112783847 G A 2.70E-05 Urinary metabolites / / 21572414 rs7651227 chr3 112807215 A G 3.27E-05 Height / / 22021425 rs7647147 chr3 112811208 A G 2.05E-04 Multiple complex diseases / / 17554300 rs7625411 chr3 112811428 G A 0.00000384 Attention deficit-hyperactivity disorder (ADHD) DSM-IV scale,preschool edition / / 23049896 rs12695286 chr3 112816746 T C 2.09E-04 Alzheimer's disease / / 22005930 rs12695286 chr3 112816746 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6782826 chr3 112819811 A G 4.19E-05 Alzheimer's disease / / 22005930 rs9811423 chr3 112822322 C G 4.00E-06 Alzheimer's disease / / 22005930 rs11706492 chr3 112822841 G C 8.85E-04 Alzheimer's disease / / 22005930 rs2700227 chr3 112824212 G A 9.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs1797616 chr3 112836389 A G 8.65E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1795161 chr3 112837075 T C 2.25E-04 IgE levels / / 17255346 rs7650532 chr3 112840604 T C 3.84E-04 Sarcoidosis / / 19165924 rs1881942 chr3 112852051 T C 4.81E-05 Nicotine dependence / / 17158188 rs2700230 chr3 112854339 T G 3.86E-05 Acne (severe) / / 24927181 rs9822730 chr3 112854675 G A 1.26E-05 Alzheimer's disease / / 22005930 rs9822730 chr3 112854675 G A 7.83E-06 Personality dimensions / / 23658558 rs73223903 chr3 112855401 A G 3.89E-05 Acne (severe) / / 24927181 rs12486305 chr3 112858184 C A 5.91E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2613964 chr3 112860780 A G 5.99E-04 Parkinson's disease / / 17052657 rs7619876 chr3 112864351 G A 1.47E-04 IgE levels / / 17255346 rs7619876 chr3 112864351 G A 7.27E-04 Alzheimer's disease / / 22005930 rs13086237 chr3 112879711 A G 4.56E-05 Platelet counts / / pha003100 rs1124502 chr3 112886577 G A 4.83E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9682694 chr3 112895679 A G 3.78E-05 Suicidal ideation / / 20877300 rs1846594 chr3 112916203 G A 8.58E-37 Lung cancer / / 21725308 rs9831167 chr3 112919344 A G 0.0000762 Salmonella-induced pyroptosis / / 22837397 rs4682475 chr3 112921268 T C 0.000288 Salmonella-induced pyroptosis / / 22837397 rs9816033 chr3 112923814 G T 0.0000522 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs3814399 chr3 112991492 C A,G,T 8.95E-07 Asthma (childhood onset) BOC cds-synon 23829686 rs775227 chr3 112995074 A C 2.00E-06 Dental caries BOC intron 23259602 rs4682484 chr3 113022870 T C 1.70E-07 Fasting plasma glucose WDR52 missense 19060907 rs16860868 chr3 113079949 G C 0.0000362 Colorectal cancer vs. adenoma controls (females) WDR52 intron 22532847 rs11919031 chr3 113097654 C A 9.31E-04 Myocardial Infarction WDR52 intron pha002883 rs1392284 chr3 113101410 G A 6.39E-06 ECG dimensions,brachial artery endothelial function,treadmill exercise responses WDR52 intron 17903301 rs1513287 chr3 113272208 G A 9.30E-04 Crohn's disease SIDT1 intron 17684544 rs1513287 chr3 113272208 G A 2.00E-04 Type 2 diabetes SIDT1 intron 17846126 rs7611694 chr3 113275624 A C 4.00E-13 Prostate cancer SIDT1 intron 23535732 rs11929640 chr3 113288430 G A 5.08E-04 Smoking initiation SIDT1 intron 24665060 rs13092825 chr3 113290468 T C 2.00E-06 Dental caries SIDT1 intron 23259602 rs4682499 chr3 113313194 C T 2.66E-04 Alzheimer's disease (late onset) SIDT1 intron 21379329 rs3773684 chr3 113334488 A T 0.000755304 Primary sclerosing cholangitis SIDT1 intron 23603763 rs16861260 chr3 113366113 G A 5.72E-04 Taste perception / / 22132133 rs1026364 chr3 113370010 G T 4.00E-10 Bone mineral density KIAA2018 UTR-3 22504420 rs12636240 chr3 113391282 A G 6.20E-05 Hypertension KIAA2018 intron 21082022 rs9881563 chr3 113414031 T C 5.00E-05 Hypertension KIAA2018 intron 21082022 rs11711311 chr3 113430599 T G 4.00E-07 IgG glycosylation / / 23382691 rs9865965 chr3 113450495 C T 4.25E-05 Hypertension /A50 intron 21082022 rs2566970 chr3 113462123 C T 5.67E-05 Serum metabolites /A50 intron 19043545 rs12695295 chr3 113474866 A G 4.46E-05 Serum metabolites ATP6V1A intron 19043545 rs16861312 chr3 113492402 G T 4.07E-05 Serum metabolites ATP6V1A intron 19043545 rs9851731 chr3 113502651 G A 8.78E-05 Serum metabolites ATP6V1A intron 19043545 rs13061150 chr3 113506734 G A 7.18E-05 Serum metabolites ATP6V1A intron 19043545 rs13061150 chr3 113506734 G A 6.90E-05 Hypertension ATP6V1A intron 21082022 rs9828099 chr3 113518402 T C 7.59E-05 Hypertension ATP6V1A intron 21082022 rs1043132 chr3 113528689 T G 6.16E-05 Serum metabolites ATP6V1A UTR-3 19043545 rs4362695 chr3 113534856 G A 8.13E-05 Serum metabolites / / 19043545 rs2566980 chr3 113560020 A C 3.46E-04 Alcohol dependence GRAMD1C intron 24277619 rs2566977 chr3 113596992 C A 9.04E-05 Ankle-brachial index GRAMD1C intron 22199011 rs2245830 chr3 113600970 G T 6.62E-05 Ankle-brachial index GRAMD1C intron 22199011 rs2566973 chr3 113605375 T C 6.99E-05 Ankle-brachial index GRAMD1C intron 22199011 rs4682143 chr3 113606970 T G 6.64E-05 Ankle-brachial index GRAMD1C intron 22199011 rs6438172 chr3 113608975 A G 6.56E-05 Ankle-brachial index GRAMD1C intron 22199011 rs6794522 chr3 113637424 G A 6.84E-05 Response to taxane treatment (placlitaxel) GRAMD1C intron 23006423 rs11921691 chr3 113673125 A G 2.38E-04 Amyotrophic Lateral Sclerosis ZDHHC23 missense 17362836 rs9866271 chr3 113675662 G A 1.04E-04 Amyotrophic Lateral Sclerosis ZDHHC23 intron 17362836 rs1386478 chr3 113680951 A G 7.00E-06 Crohn's disease and psoriasis ZDHHC23 UTR-3 22482804 rs722927 chr3 113681175 C G 2.40E-04 Coronary heart disease ZDHHC23 UTR-3 21606135 rs3903132 chr3 113700726 T C 5.87E-05 Cognitive performance KIAA1407 intron 19734545 rs3903132 chr3 113700726 T C 1.12E-05 Alcohol withdrawal symptoms KIAA1407 intron 22072270 rs12492484 chr3 113723144 T A 1.30E-05 Urinary metabolites KIAA1407 intron 21572414 rs324556 chr3 113731287 G T 3.16E-05 Alcohol withdrawal symptoms KIAA1407 intron 22072270 rs2087017 chr3 113842013 G A 6.00E-06 Personality dimensions / / 23903073 rs167771 chr3 113876275 G A 1 Drug response to Risperidone DRD3 intron 19506579 rs1486008 chr3 113888441 C T 2.41E-04 Alzheimer's disease DRD3 intron 22005930 rs16822416 chr3 113890310 G A 2.87E-04 Alzheimer's disease DRD3 intron 22005930 rs3732783 chr3 113890789 T C 7.04E-04 Alzheimer's disease DRD3 cds-synon 22005930 rs3732783 chr3 113890789 T C 9.00E-06 Smooth-surface caries DRD3 cds-synon 24556642 rs6280 chr3 113890815 C T 1 Drug response to Olanzapine DRD3 missense 18320559 rs6280 chr3 113890815 C T 1 Drug response to Pramipexole DRD3 missense 19396436 rs6280 chr3 113890815 C T 1 Drug response to Risperidone DRD3 missense 19997080 rs6280 chr3 113890815 C T 1 Drug response to Clozapine DRD3 missense 20029384 rs9846423 chr3 113937335 G A 6.43E-04 Iron levels / / pha002876 rs7616367 chr3 113937999 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7620754 chr3 113947975 T C 2.50E-05 Urinary metabolites / / 21572414 rs712531 chr3 113958972 A G 2.09E-04 Multiple complex diseases / / 17554300 rs1065639 chr3 113959074 C G 1.90E-04 Multiple complex diseases / / 17554300 rs10511329 chr3 113970270 T C 3.56E-05 Iron status biomarkers / / 19084217 rs2683780 chr3 113993518 C T 3.23E-07 Multiple complex diseases / / 17554300 rs1039524 chr3 114012274 T C 1.29E-04 Myocardial Infarction / / pha002873 rs17614981 chr3 114109544 C A 5.95E-06 Pulmonary function ZBTB20 intron 19300500 rs17615035 chr3 114110200 C T 2.30E-05 Urinary metabolites ZBTB20 intron 21572414 rs9859157 chr3 114110546 C A 6.06E-06 Pulmonary function ZBTB20 intron 19300500 rs9859304 chr3 114110629 C T 6.15E-06 Pulmonary function ZBTB20 intron 19300500 rs3957585 chr3 114112056 G A 5.74E-04 Type 2 diabetes ZBTB20 intron 17463246 rs2718419 chr3 114136969 T G 5.19E-04 Common variable immunodeficiency ZBTB20 intron 21497890 rs7647708 chr3 114182433 G A 5.34E-08 Metabolite levels ZBTB20 intron 23281178 rs10511334 chr3 114191863 T C 2.38E-05 Iron status biomarkers ZBTB20 intron 19084217 rs2718425 chr3 114205687 G A 3.55E-04 Myopia (pathological) ZBTB20 intron 21095009 rs7643975 chr3 114221822 C T 8.34E-05 Polycystic ovary syndrome ZBTB20 intron 22178785 rs2669897 chr3 114257956 C T 3.93E-04 Smoking initiation ZBTB20 intron 24665060 rs9831254 chr3 114280956 T C 2.00E-05 Urinary metabolites ZBTB20 intron 21572414 rs7637678 chr3 114305702 T C 4.69E-04 Multiple complex diseases ZBTB20 intron 17554300 rs7637678 chr3 114305702 T C 1.15E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ZBTB20 intron 24023788 rs1402558 chr3 114318854 T C 4.59E-04 Multiple complex diseases ZBTB20 intron 17554300 rs950992 chr3 114319046 G A 1.43E-04 Multiple complex diseases ZBTB20 intron 17554300 rs2947483 chr3 114325385 A G 1.77E-04 Lung function (forced vital capacity) ZBTB20 intron 24023788 rs2947483 chr3 114325385 A G 6.79E-05 Lung function (forced expiratory volume in 1 second) ZBTB20 intron 24023788 rs6438213 chr3 114329961 A G 8.73E-04 Multiple complex diseases ZBTB20 intron 17554300 rs6438213 chr3 114329961 A G 2.63E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ZBTB20 intron 24023788 rs10511335 chr3 114332963 T C 1.52E-04 Multiple complex diseases ZBTB20 intron 17554300 rs2669892 chr3 114335023 T C 1.13E-04 Lung function (forced expiratory volume in 1 second) ZBTB20 intron 24023788 rs2669892 chr3 114335023 T C 3.48E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ZBTB20 intron 24023788 rs1274267 chr3 114340473 C T 4.81E-04 Multiple complex diseases ZBTB20 intron 17554300 rs9860965 chr3 114341550 C T 7.90E-04 Amyotrophic Lateral Sclerosis ZBTB20 intron 17362836 rs11717204 chr3 114347164 G A 1.27E-04 Lung function (forced vital capacity) ZBTB20 intron 24023788 rs9841504 chr3 114362764 C G 2.00E-09 Gastric cancer ZBTB20 intron 22037551 rs9841504 chr3 114362764 C G 2.33E-08 Schizophrenia ZBTB20 intron 22037555 rs1290892 chr3 114364462 C T 7.38E-05 Lung function (forced vital capacity) ZBTB20 intron 24023788 rs1274261 chr3 114368193 T A 2.60E-04 Multiple complex diseases ZBTB20 intron 17554300 rs2669904 chr3 114368695 C T 4.75E-04 Multiple complex diseases ZBTB20 intron 17554300 rs17681475 chr3 114401208 C G 0.0007702 Sarcoidosis ZBTB20 intron 22952805 rs10934276 chr3 114417343 G T 2.52E-04 Glycosylated haemoglobin levels ZBTB20 intron 17255346 rs6762934 chr3 114419948 C T 6.82E-04 Multiple complex diseases ZBTB20 intron 17554300 rs2056533 chr3 114485145 C T 2.52E-04 Glycosylated haemoglobin levels ZBTB20 intron 17255346 rs7631872 chr3 114513019 G A 1.28E-04 Lung function (forced expiratory volume in 1 second) ZBTB20 intron 24023788 rs6804032 chr3 114548471 C T 8.70E-04 Lipid traits ZBTB20 intron 17903299 rs688357 chr3 114556835 C T 3.81E-05 Multiple complex diseases ZBTB20 intron 17554300 rs1354056 chr3 114593970 G A 3.37E-04 Response to cytadine analogues (cytosine arabinoside) ZBTB20 intron 24483146 rs7635846 chr3 114599103 G A 3.71E-04 Type 2 diabetes ZBTB20 intron 17463246 rs4682165 chr3 114622323 C T 2.20E-04 Height ZBTB20 intron 17255346 rs11923714 chr3 114671715 A G 1.19E-04 Birth weight ZBTB20 intron 17255346 rs10804515 chr3 114702057 A G 1.11E-06 Type 2 diabetes ZBTB20 intron 17463246 rs10804515 chr3 114702057 A G 1.00E-06 Height ZBTB20 intron 17767157 rs7648400 chr3 114793620 T C 2.11E-06 Birth weight ZBTB20 intron 17255346 rs6768251 chr3 114812777 T C 1.34E-05 Birth weight ZBTB20 intron 17255346 rs9289008 chr3 114820006 A G 4.93E-06 Type 2 diabetes ZBTB20 intron 17463246 rs2177041 chr3 114821299 A C 4.58E-05 Multiple sclerosis (brain glutamate levels) ZBTB20 intron 20802204 rs6793973 chr3 114855021 T C 4.45E-04 Type 2 diabetes ZBTB20 intron 17463246 rs6793973 chr3 114855021 T C 1.24E-04 Multiple complex diseases ZBTB20 intron 17554300 rs2139950 chr3 114871127 G A 1.30E-05 Parkinson's disease / / 21738487 rs7621209 chr3 114883647 G C 7.58E-05 Birth weight / / 17255346 rs6438234 chr3 114913508 A G 1.18E-04 Type 2 diabetes / / 17463246 rs6786991 chr3 114926956 G A 5.68E-06 Type 2 diabetes / / 17463246 rs6786991 chr3 114926956 G A 1.73E-04 Multiple complex diseases / / 17554300 rs6786991 chr3 114926956 G A 4.59E-05 Type 1 diabetes / / 18978792 rs980944 chr3 114929512 T G 7.61E-04 Multiple complex diseases / / 17554300 rs980944 chr3 114929512 T G 2.74E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs2085700 chr3 114934339 A C 4.00E-05 Type 2 diabetes / / 17463246 rs2085700 chr3 114934339 A C 3.10E-04 Multiple complex diseases / / 17554300 rs2085700 chr3 114934339 A C 5.97E-05 Type 1 diabetes / / 18978792 rs17755786 chr3 114940210 C T 3.03E-04 Tourette syndrome / / 22889924 rs9831948 chr3 114971759 T C 9.95E-04 Type 2 diabetes / / 17463246 rs1459515 chr3 114984256 G A 6.92E-04 Multiple complex diseases / / 17554300 rs6805459 chr3 115000949 A G 4.70E-04 Multiple complex diseases / / 17554300 rs16823659 chr3 115011917 T C 6.03E-04 Multiple complex diseases / / 17554300 rs17705602 chr3 115012080 T A 4.33E-06 Multiple complex diseases / / 17554300 rs1031678 chr3 115026041 G A 9.45E-04 Tourette syndrome / / 22889924 rs6438246 chr3 115079383 C T 2.68E-04 Birth weight / / 17255346 rs9839522 chr3 115082129 C A,G 6.65E-04 Type 2 diabetes / / 17463246 rs13327867 chr3 115097587 T C 1.31E-04 Multiple complex diseases / / 17554300 rs9879234 chr3 115100216 C T 2.12E-04 Breast cancer / / 21060860 rs4075930 chr3 115122663 C A 3.69E-05 Blood Pressure / / pha003046 rs6781222 chr3 115125869 G A 9.54E-07 C-reactive protein / / 22492993 rs13090809 chr3 115134513 G A 1.75E-06 C-reactive protein / / 22492993 rs1909574 chr3 115143941 C T 1.07E-06 C-reactive protein / / 22492993 rs1392261 chr3 115144685 G T 1.07E-06 C-reactive protein / / 22492993 rs9826938 chr3 115155648 G A 3.70E-04 Type 2 diabetes / / 17463246 rs1463869 chr3 115157029 C T 1.82E-04 Type 2 diabetes / / 17463246 rs1463869 chr3 115157029 C T 2.70E-05 Urinary metabolites / / 21572414 rs12636063 chr3 115161400 G A 9.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs1499952 chr3 115167177 A T 4.69E-05 Type 2 diabetes / / 17463246 rs1499952 chr3 115167177 A T 9.01E-05 Serum metabolites / / 19043545 rs9811128 chr3 115241953 C G 2.50E-05 Urinary metabolites / / 21572414 rs7635642 chr3 115280281 T C 6.57E-04 Smoking cessation / / 24665060 rs3827496 chr3 115340900 C A,G,T 2.10E-05 Urinary metabolites / / 21572414 rs6803101 chr3 115355964 A G 1.00E-04 Information processing speed GAP43 intron 21130836 rs9289026 chr3 115356176 C G 1.50E-04 Type 2 diabetes and 6 quantitative traits GAP43 intron 17848626 rs6795687 chr3 115366350 C T 1.00E-04 Information processing speed GAP43 intron 21130836 rs12488667 chr3 115386571 G T 7.88E-04 Type 2 diabetes GAP43 intron 17463246 rs4831199 chr3 115387010 T C 1.07E-04 Diabetic nephropathy GAP43 intron pha002866 rs11926976 chr3 115394293 C T 7.10E-05 Diabetic nephropathy GAP43 intron pha002866 rs283374 chr3 115406086 T C 2.91E-04 Multiple complex diseases GAP43 intron 17554300 rs9858175 chr3 115407784 G A 8.72E-04 Heart Failure GAP43 intron pha002884 rs2918239 chr3 115481562 A C 4.03E-04 Type 2 diabetes / / 17463246 rs2918231 chr3 115490010 A G 4.04E-04 Type 2 diabetes / / 17463246 rs2972491 chr3 115502481 A G 2.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs1062118 chr3 115522560 A G 2.96E-04 Epilepsy LSAMP UTR-3 22116939 rs2918217 chr3 115546380 C T 1.92E-04 Suicide attempts in bipolar disorder LSAMP intron 21041247 rs2944404 chr3 115552170 G A 3.82E-04 Suicide attempts in bipolar disorder LSAMP intron 21041247 rs2972481 chr3 115565706 G A 4.53E-04 Suicide attempts in bipolar disorder LSAMP intron 21041247 rs2972481 chr3 115565706 G A 0.0000207 Carotid intima media thickness LSAMP intron 23152477 rs2972479 chr3 115566027 T C 8.80E-04 Suicide attempts in bipolar disorder LSAMP intron 21041247 rs10511351 chr3 115594175 G A 3.06E-04 Suicide,with and without major depression LSAMP intron 22059935 rs10511351 chr3 115594175 G A 6.53E-05 Suicide,with and without major depression LSAMP intron 22059935 rs4831119 chr3 115624440 C T 2.98E-04 Response to taxane treatment (placlitaxel) LSAMP intron 23006423 rs9853758 chr3 115624856 G C 3.92E-04 Response to taxane treatment (placlitaxel) LSAMP intron 23006423 rs9827155 chr3 115627355 A G 4.14E-04 Response to taxane treatment (placlitaxel) LSAMP intron 23006423 rs4378954 chr3 115650448 T C 5.81E-05 Multiple complex diseases LSAMP intron 17554300 rs6438291 chr3 115671985 C G 2.47E-04 Multiple complex diseases LSAMP intron 17554300 rs9849995 chr3 115679228 C T 1.17E-04 Acute lung injury LSAMP intron 22295056 rs11918028 chr3 115722224 A T 1.80E-05 Urinary metabolites LSAMP intron 21572414 rs16824395 chr3 115740719 A G 6.00E-06 Alcohol dependence (age at onset) LSAMP intron 24962325 rs62271282 chr3 115758068 T G 9.16E-06 Alcohol dependence (age at onset) LSAMP intron 24962325 rs6438298 chr3 115841684 T C 8.00E-05 HIV-1 control LSAMP intron 20041166 rs4511899 chr3 115850594 C T 2.86E-04 Suicide attempts in bipolar disorder LSAMP intron 21423239 rs17698500 chr3 115853857 T C 2.58E-04 Suicide attempts in bipolar disorder LSAMP intron 21423239 rs4146782 chr3 115857314 T C 4.88E-04 Suicide attempts in bipolar disorder LSAMP intron 21423239 rs1920363 chr3 115864422 A G 5.39E-04 Suicide attempts in bipolar disorder LSAMP intron 21423239 rs1461137 chr3 115901390 A G 1.30E-05 Urinary metabolites LSAMP intron 21572414 rs1870709 chr3 115952799 T C 2.41E-05 Coronary heart disease LSAMP intron pha003035 rs957783 chr3 116017931 C T 2.95E-05 Post-operative nausea and vomiting LSAMP intron 21694509 rs17646070 chr3 116031472 G T 5.87E-05 Intelligence LSAMP intron 21826061 rs1346944 chr3 116034589 T C 6.74E-04 Alzheimer's disease LSAMP intron 17998437 rs11928524 chr3 116096600 G A 9.22E-04 Multiple complex diseases LSAMP intron 17554300 rs17647091 chr3 116104521 T G 3.96E-04 Multiple complex diseases LSAMP intron 17554300 rs1920184 chr3 116126476 A T 6.99E-04 Multiple complex diseases LSAMP intron 17554300 rs4831136 chr3 116128090 G A 6.59E-04 Multiple complex diseases LSAMP intron 17554300 rs1712999 chr3 116131936 A G 7.63E-05 HDL cholesterol LSAMP intron pha003075 rs16824930 chr3 116166626 A G 1.00E-05 Urinary metabolites / / 21572414 rs16824957 chr3 116181025 A C 7.00E-06 Political ideology / / 24569950 rs4831100 chr3 116185514 G A 4.89E-04 Multiple complex diseases / / 17554300 rs10934349 chr3 116229655 G A 2.10E-05 Urinary metabolites / / 21572414 rs17706256 chr3 116235856 T C 8.17E-04 Multiple complex diseases / / 17554300 rs6809127 chr3 116236364 G A 2.22E-05 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia / / 24039173 rs1401069 chr3 116279888 T G 6.65E-05 HDL cholesterol / / pha003075 rs4305418 chr3 116281408 G A 9.30E-06 Urinary metabolites / / 21572414 rs1518325 chr3 116313644 A G 1.30E-04 Type 2 diabetes / / 17463246 rs938913 chr3 116337995 A G 1.40E-04 Prion diseases / / 22210626 rs7649435 chr3 116353532 A G 2.58E-05 Alcohol withdrawal symptoms / / 22072270 rs1401083 chr3 116373807 A G 7.80E-05 Alcohol withdrawal symptoms / / 22072270 rs2867833 chr3 116378627 A G 4.44E-04 Alzheimer's disease (late onset) / / 21379329 rs10934362 chr3 116381899 C T 4.00E-05 Prostate cancer / / 21743057 rs1543175 chr3 116386909 G A 3.00E-07 Prostate cancer / / 21743057 rs6795004 chr3 116387052 C T 4.98E-04 Multiple complex diseases / / 17554300 rs13325108 chr3 116390670 C G 1.00E-06 Prostate cancer / / 21743057 rs11711002 chr3 116394204 T C 6.00E-06 Prostate cancer / / 21743057 rs7647681 chr3 116394860 C G 6.00E-06 Prostate cancer / / 21743057 rs4429629 chr3 116395890 C G 6.00E-06 Prostate cancer / / 21743057 rs13087427 chr3 116396116 A G 1.00E-04 Prostate cancer / / 21743057 rs7432616 chr3 116425434 T C 6.07E-05 Response to methylphenidate treatment / / 21130132 rs7640361 chr3 116440045 A C 7.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1432364 chr3 116445324 T G 4.00E-06 Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure) / / 21130132 rs1030631 chr3 116475496 A C 9.80E-04 Multiple complex diseases / / 17554300 rs9858874 chr3 116500860 A C 4.64E-07 White blood cell count / / 21738479 rs13090380 chr3 116507763 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs16825624 chr3 116514356 T C 2.71E-05 Triglycerides / / 19074352 rs16825624 chr3 116514356 T C 2.71E-05 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs4075379 chr3 116552604 T G 4.92E-04 Multiple complex diseases / / 17554300 rs6438347 chr3 116558335 A G 9.52E-06 Lung cancer / / 19654303 rs2373 chr3 116579622 C A 0.000394 Salmonella-induced pyroptosis / / 22837397 rs6772580 chr3 116581536 G C 0.000399 Salmonella-induced pyroptosis / / 22837397 rs7643014 chr3 116585281 T C 1.55E-04 Age-related macular degeneration / / 22125219 rs6438359 chr3 116589267 T C 0.000601 Salmonella-induced pyroptosis / / 22837397 rs7430708 chr3 116614189 C G 6.64E-04 Body mass index / / 21701565 rs9875005 chr3 116620127 G A 8.72E-04 Coronary heart disease / / 21606135 rs6777242 chr3 116630343 G A 6.31E-04 Coronary heart disease / / 21606135 rs9289064 chr3 116649860 G A 8.90E-04 Body mass index / / 21701565 rs7626684 chr3 116654520 A G 9.20E-04 Alzheimer's disease / / 22005930 rs1568700 chr3 116673804 C G 6.24E-04 Multiple complex diseases / / 17554300 rs35258147 chr3 116729273 C T 7.85E-04 Taste perception / / 22132133 rs10511363 chr3 116735107 C T 8.69E-05 Orofacial clefts / / 20023658 rs10511363 chr3 116735107 C T 1.44E-04 Taste perception / / 22132133 rs871216 chr3 116735288 C T 8.69E-05 Orofacial clefts / / 20023658 rs1521418 chr3 116761660 G C 8.00E-06 Cognitive function / / 24684796 rs644454 chr3 116764315 G T 4.99E-04 Aortic root size / / 21223598 rs9820102 chr3 116784852 G A 8.28E-04 Type 2 diabetes / / 17463246 rs9820102 chr3 116784852 G A 5.74E-04 Smoking initiation / / 24665060 rs12634401 chr3 116791023 T C 4.79E-06 Asthma / / 23181788 rs1357099 chr3 116813492 T G 2.17E-05 Asthma / / pha003128 rs9810432 chr3 116827967 C T 7.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1357103 chr3 116839289 C T 1.42E-04 Celiac disease / / 23936387 rs6806238 chr3 116885358 G A 6.76E-05 Cholesterol / / pha003073 rs6806238 chr3 116885358 G A 5.21E-05 Cholesterol / / pha003078 rs16826237 chr3 116890198 G T 2.49E-04 Smoking initiation / / 24665060 rs9862920 chr3 116945080 T A 3.34E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12494616 chr3 116961821 A G 2.15E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs3900989 chr3 116970253 T C 5.55E-05 Cognitive impairment induced by topiramate / / 22091778 rs1237325 chr3 116972030 C A 3.10E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1513168 chr3 117004941 C T 1.30E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1513168 chr3 117004941 C T 6.98E-05 Lung function (forced vital capacity) / / 24023788 rs4855941 chr3 117014065 A G 8.55E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs9815346 chr3 117017795 A G 9.59E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs7632070 chr3 117027512 A G 8.00E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1877544 chr3 117053613 G C 1.90E-05 Urinary metabolites / / 21572414 rs1849474 chr3 117102416 C T 1.32E-04 IgE levels / / 17255346 rs4632551 chr3 117148573 G C 4.81E-04 Type 2 diabetes / / 17463246 rs4128236 chr3 117152384 C T 6.60E-05 Systemic sclerosis / / 21750679 rs9870146 chr3 117156255 C T 9.00E-06 Obesity-related traits / / 23251661 rs16826930 chr3 117157296 A G 7.60E-06 Urinary metabolites / / 21572414 rs16849236 chr3 117157814 G A 2.30E-04 Multiple complex diseases / / 17554300 rs16849236 chr3 117157814 G A 1.50E-05 Urinary metabolites / / 21572414 rs11708237 chr3 117160955 C T 1.90E-05 Urinary metabolites / / 21572414 rs4075039 chr3 117162784 C T 8.88E-04 Premature ovarian failure / / 19508998 rs11715287 chr3 117177909 G T 8.00E-05 Age-related macular degeneration / / 20861866 rs7652799 chr3 117186995 C T 8.62E-04 Obesity (extreme) / / 21935397 rs1350967 chr3 117187330 G A 8.68E-04 Obesity (extreme) / / 21935397 rs1676230 chr3 117198185 T G 5.80E-05 Age-related macular degeneration / / 20861866 rs2927279 chr3 117200934 A G 4.44E-05 Meningococcal disease / / 20694013 rs2055426 chr3 117220344 C T 5.63E-05 Cognitive impairment induced by topiramate / / 22091778 rs12629904 chr3 117230623 C T 0.000125 Prostate cancer / / 22532847 rs1676232 chr3 117234839 G A 4.22E-04 IgE levels / / 17255346 rs1381801 chr3 117240895 A T 7.48E-04 Multiple complex diseases / / 17554300 rs78926777 chr3 117242427 C G 9.84E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs16827097 chr3 117243036 A G 9.09E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs72951640 chr3 117243796 C T 5.00E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs6763855 chr3 117258570 C T 8.61E-05 Multiple complex diseases / / 17554300 rs6803377 chr3 117280721 G C 6.20E-06 Urinary metabolites / / 21572414 rs16827196 chr3 117285470 C A 8.09E-05 Bipolar disorder and schizophrenia / / 20889312 rs16827220 chr3 117290322 A G 6.35E-05 Bipolar disorder and schizophrenia / / 20889312 rs1903736 chr3 117292748 T G 3.78E-16 Multiple complex diseases / / 17554300 rs9867372 chr3 117292978 A G 0.000747 Salmonella-induced pyroptosis / / 22837397 rs1875517 chr3 117307567 G A 2.00E-06 Waist circumference / / 17903300 rs2869787 chr3 117308818 T C 6.95E-06 Lipoproteins / / pha003079 rs872593 chr3 117319832 C T 3.10E-05 Bone mineral density (spine) / / 19079262 rs7645105 chr3 117325451 C T 9.27E-05 Cognitive test performance / / 20125193 rs11707363 chr3 117327243 T C 8.22E-04 Smoking cessation / / 24665060 rs1354147 chr3 117330255 C T 9.00E-06 Urinary metabolites / / 21572414 rs1501871 chr3 117330716 G A 9.00E-06 Urinary metabolites / / 21572414 rs12485703 chr3 117335320 C T 1.40E-05 Urinary metabolites / / 21572414 rs1354151 chr3 117335421 C T 8.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1354151 chr3 117335421 C T 2.00E-05 Urinary metabolites / / 21572414 rs2904196 chr3 117346618 T C 3.54E-04 Osteoarthritis / / 19508968 rs4234649 chr3 117413844 T C 3.67E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs4234649 chr3 117413844 T C 7.29E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs4234649 chr3 117413844 T C 8.72E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs4496520 chr3 117416967 C A,T 1.13E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs4496520 chr3 117416967 C A,T 1.13E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs4496520 chr3 117416967 C A,T 4.80E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs6806811 chr3 117427559 C T 1.73E-04 Blood pressure / / 17255346 rs4687866 chr3 117488858 A G 5.71E-05 Glycosylated haemoglobin levels / / 17255346 rs6438424 chr3 117574822 A C 1.00E-13 Menarche (age at onset) / / 21102462 rs9812067 chr3 117594641 T C 7.33E-04 Obesity (extreme) / / 21935397 rs6805565 chr3 117640199 C A 1.40E-04 Myasthenia gravis / / 23055271 rs9849010 chr3 117690978 G A 0.000026 Endometrial cancer / / 22426144 rs817515 chr3 117740707 G A 0.00019 Breast cancer / / 23555315 rs13066366 chr3 117762458 C T 0.000293 Salmonella-induced pyroptosis / / 22837397 rs1499976 chr3 117801330 T C 6.14E-04 Multiple complex diseases / / 17554300 rs9828285 chr3 117803574 T C 6.50E-05 Memory performance / / 22105620 rs4688077 chr3 117831093 A G 4.31E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16827961 chr3 117833398 C A 4.37E-04 Type 2 diabetes / / 17463246 rs2101367 chr3 117877410 G A 9.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2865313 chr3 117909752 A C 5.15E-04 Type 2 diabetes / / 17463246 rs17281325 chr3 117995184 A G 4.75E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4688094 chr3 118003477 G C 1.20E-05 Biliary atresia / / 20460270 rs6779441 chr3 118016233 A G 1.35E-04 Amyotrophic Lateral Sclerosis / / 18057069 rs500097 chr3 118114690 C T 7.69E-04 Parkinson's disease / / 16252231 rs488628 chr3 118121335 G A 6.00E-07 White matter integrity (interaction) / / 23218918 rs4688104 chr3 118154526 T C 4.46E-04 Smoking initiation / / 24665060 rs577196 chr3 118157897 C T 2.70E-04 Alcohol dependence / / 20201924 rs516560 chr3 118161497 C T 6.61E-04 Smoking initiation / / 24665060 rs10511378 chr3 118162623 T C 1.00E-06 Obesity-related traits / / 23251661 rs499789 chr3 118163149 T C 2.78E-04 Smoking initiation / / 24665060 rs524245 chr3 118163503 C T 7.85E-04 Parkinson's disease / / 17052657 rs1949542 chr3 118183783 A G 1.84E-04 Type 2 diabetes / / 17463246 rs17676122 chr3 118193612 G A 7.37E-04 Type 2 diabetes / / 17463246 rs7618451 chr3 118202086 G A 5.99E-05 Age-related macular degeneration / / 22125219 rs6438452 chr3 118274925 A C 7.84E-06 Carotenoid and tocopherol levels / / 19185284 rs6438466 chr3 118364455 G A 1.42E-04 Multiple complex diseases / / 17554300 rs16828751 chr3 118380279 C G 9.03E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6438471 chr3 118402543 A G 6.94E-04 Smoking quantity / / 24665060 rs6438472 chr3 118402562 C A 9.12E-04 Alzheimer's disease / / 17998437 rs4687935 chr3 118413478 G A 0.0000802 Nicotine dependence (smoking) / / 22377092 rs16828784 chr3 118418924 T C 7.90E-04 Alzheimer's disease / / 24755620 rs1566414 chr3 118425462 T G 8.37E-04 Body mass index / / 21701565 rs10934459 chr3 118425484 T C 2.30E-04 Schizophrenia / / 19197363 rs7610551 chr3 118525556 G A 5.58E-05 Cognitive impairment induced by topiramate / / 22091778 rs7610551 chr3 118525556 G A 9.85E-05 Glucose levels / / pha003058 rs17465252 chr3 118537079 G A 7.32E-04 Multiple complex diseases / / 17554300 rs1081894 chr3 118548921 A G 2.32E-04 Multiple complex diseases / / 17554300 rs1081897 chr3 118549617 G C 1.14E-04 Multiple complex diseases / / 17554300 rs1272707 chr3 118550190 A T 9.45E-04 Multiple complex diseases / / 17554300 rs1499906 chr3 118554429 A G 7.21E-05 Erythrocyte counts / / pha003099 rs962115 chr3 118600075 A C 4.15E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6438476 chr3 118618860 A C 9.99E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17491031 chr3 118639523 C G 6.76E-04 Multiple complex diseases IGSF11 intron 17554300 rs2110365 chr3 118640168 T C 6.77E-04 Multiple complex diseases IGSF11 intron 17554300 rs9878706 chr3 118659679 T G 5.12E-05 Orofacial clefts IGSF11 intron 22419666 rs4687833 chr3 118676492 T C 4.00E-06 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) IGSF11 intron 24023788 rs35874 chr3 118700783 T C 8.65E-04 Response to taxane treatment (placlitaxel) IGSF11 intron 23006423 rs2160050 chr3 118745936 T C 9.00E-06 Response to amphetamines IGSF11 intron 22952603 rs4449310 chr3 118799682 T C 7.38E-05 Cognitive impairment induced by topiramate IGSF11 intron 22091778 rs1369574 chr3 118803278 T C 4.90E-04 Response to taxane treatment (placlitaxel) IGSF11 intron 23006423 rs6784018 chr3 118820510 C T 6.61E-04 Multiple complex diseases IGSF11 intron 17554300 rs11550908 chr3 118865332 A G 0.000597 Salmonella-induced pyroptosis C3orf30 missense 22837397 rs11926466 chr3 118874044 A C 0.000612 Salmonella-induced pyroptosis / / 22837397 rs6438498 chr3 118883265 A G 5.23E-05 Smoking initiation / / 24665060 rs16829389 chr3 118891680 C T 0.000663 Salmonella-induced pyroptosis / / 22837397 rs7613994 chr3 118899855 C A 1.75E-04 Response to taxane treatment (placlitaxel) UPK1B intron 23006423 rs13098659 chr3 118915012 C A 1.92E-04 Follicle stimulating hormone UPK1B intron 24049095 rs13315549 chr3 118917422 G A 2.67E-06 Systemic lupus erythematosus and Systemic sclerosis UPK1B intron 23740937 rs6774 chr3 118930884 G A 1.82E-05 Multiple complex diseases B4GALT4 UTR-3 17554300 rs4234656 chr3 118948155 C T 5.77E-04 Multiple complex diseases B4GALT4 intron 17554300 rs12695382 chr3 118948171 A G 1.00E-06 Lipid levels B4GALT4 intron 18193043 rs7622994 chr3 119023971 C T 4.93E-07 Post-operative nausea and vomiting ARHGAP31 intron 21694509 rs7610546 chr3 119027344 A G 3.22E-04 Lung function (forced expiratory volume in 1 second) ARHGAP31 intron 17255346 rs10511386 chr3 119030889 G A 2.60E-04 Lung function (forced expiratory volume in 1 second) ARHGAP31 intron 17255346 rs6786522 chr3 119032360 C G 1.94E-04 Lung function (forced expiratory volume in 1 second) ARHGAP31 intron 17255346 rs7649930 chr3 119034510 T G 2.24E-04 Lung function (forced expiratory volume in 1 second) ARHGAP31 intron 17255346 rs1448434 chr3 119043011 C G 1.60E-04 Lung function (forced expiratory volume in 1 second) ARHGAP31 intron 17255346 rs6438523 chr3 119045123 G A 1.47E-04 Lung function (forced expiratory volume in 1 second) ARHGAP31 intron 17255346 rs16829720 chr3 119065339 T C 1.50E-06 Urinary metabolites ARHGAP31 intron 21572414 rs935617 chr3 119071876 G T 6.30E-06 Urinary metabolites ARHGAP31 intron 21572414 rs9713311 chr3 119075768 T C 3.57E-04 Alzheimer's disease (late onset) ARHGAP31 intron 21379329 rs9713311 chr3 119075768 T C 0.000697263 Hypertension (early onset hypertension) ARHGAP31 intron 22479346 rs16829757 chr3 119080910 G A 5.36E-04 Insulin resistance ARHGAP31 intron 21901158 rs17203055 chr3 119084331 A G 5.00E-06 Schizophrenia ARHGAP31 intron 23894747 rs9837853 chr3 119099049 A G 7.75E-05 IgE levels ARHGAP31 intron 17255346 rs9837853 chr3 119099049 A G 1.28E-05 Psoriasis ARHGAP31 intron 18364390 rs13078855 chr3 119107277 C T 2.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARHGAP31 intron 20877124 rs13078855 chr3 119107277 C T 7.88E-04 Obesity (extreme) ARHGAP31 intron 21935397 rs11712165 chr3 119118796 T G 8.00E-09 Celiac disease ARHGAP31 intron 20190752 rs11712165 chr3 119118796 T G 8.00E-09 Asthma ARHGAP31 intron 21150878 rs11712165 chr3 119118796 T G 8.03E-09 Celiac disease and Rheumatoid arthritis ARHGAP31 intron 21383967 rs11712165 chr3 119118796 T G 8.03E-09 Multiple sclerosis ARHGAP31 intron 22190364 rs12494314 chr3 119122820 T C 2.08E-10 Primary biliary cirrhosis ARHGAP31 intron 21399635 rs61579022 chr3 119123278 G A 9.90E-09 Celiac disease ARHGAP31 intron 22057235 rs9855065 chr3 119130141 G A 1.88E-04 Insulin resistance ARHGAP31 intron 21901158 rs16829840 chr3 119147958 C T 3.00E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs3732421 chr3 119150089 A G 2.37E-10 Primary biliary cirrhosis TMEM39A UTR-3 21399635 rs1132200 chr3 119150836 C T 5.05E-04 Multiple complex diseases TMEM39A missense 17554300 rs1132200 chr3 119150836 C T 7.00E-07 Multiple sclerosis TMEM39A missense 21833088 rs1132200 chr3 119150836 C T 0.0000012 Primary biliary cirrhosis TMEM39A missense 22936693 rs1132200 chr3 119150836 C T 5.76E-12 Primary biliary cirrhosis TMEM39A missense 22961000 rs1132200 chr3 119150836 C T 2.52E-04 Systemic lupus erythematosus and Systemic sclerosis TMEM39A missense 23740937 rs2282171 chr3 119182598 C T 1.04E-04 Type 2 diabetes / / 17463246 rs2282171 chr3 119182598 C T 0.000039 Primary biliary cirrhosis / / 22936693 rs3732419 chr3 119196334 G T 4.59E-04 Obesity (extreme) POGLUT1 intron 21935397 rs6799691 chr3 119196781 G A 4.61E-04 Obesity (extreme) POGLUT1 intron 21935397 rs3755579 chr3 119214549 T C 2.20E-05 Urinary metabolites / / 21572414 rs3755579 chr3 119214549 T C 1.40E-04 Arthritis (juvenile idiopathic) / / 22354554 rs2280670 chr3 119217312 C T 5.05E-05 IgE levels / / 22075330 rs6438535 chr3 119218714 T C 6.99E-04 Response to taxane treatment (placlitaxel) TIMMDC1 intron 23006423 rs2293370 chr3 119219934 G A 3.00E-11 Primary biliary cirrhosis TIMMDC1 intron 21399635 rs2293370 chr3 119219934 G A 3.00E-09 Multiple sclerosis TIMMDC1 intron 21833088 rs2293370 chr3 119219934 G A 0.000000137 Primary biliary cirrhosis TIMMDC1 intron 22936693 rs2293370 chr3 119219934 G A 6.84E-16 Primary biliary cirrhosis TIMMDC1 intron 22961000 rs2293370 chr3 119219934 G A 3.00E-09 Primary biliary cirrhosis TIMMDC1 intron 23000144 rs11714843 chr3 119221064 T A 0.000000364 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) TIMMDC1 intron 23603761 rs1131265 chr3 119222456 G C 0.00000582 Primary biliary cirrhosis in females TIMMDC1 cds-synon 22936693 rs1131265 chr3 119222456 G C 4.40E-09 Primary biliary cirrhosis (anti-mitochondrial antibody positive) TIMMDC1 cds-synon 22936693 rs1131265 chr3 119222456 G C 4.49E-09 Primary biliary cirrhosis TIMMDC1 cds-synon 22936693 rs4688011 chr3 119227247 G A 9.37E-04 Type 2 diabetes TIMMDC1 intron 17463246 rs4688011 chr3 119227247 G A 5.11E-05 IgE levels TIMMDC1 intron 22075330 rs4688011 chr3 119227247 G A 1.00E-07 Arthritis (juvenile idiopathic) TIMMDC1 intron 22354554 rs4688013 chr3 119229486 G A 5.13E-05 IgE levels TIMMDC1 intron 22075330 rs4688013 chr3 119229486 G A 0.00000063 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) TIMMDC1 intron 23603761 rs4688013 chr3 119229486 G A 0.00000706 Oligoarticular juvenile idiopathic arthritis TIMMDC1 intron 23603761 rs11719448 chr3 119234594 C T 5.20E-05 IgE levels TIMMDC1 intron 22075330 rs4447803 chr3 119235977 C A 1.80E-05 Urinary metabolites TIMMDC1 intron 21572414 rs4447803 chr3 119235977 C A 9.54E-05 Arthritis (juvenile idiopathic) TIMMDC1 intron 22354554 rs4461452 chr3 119236017 G T 5.01E-04 Insulin resistance TIMMDC1 intron 21901158 rs4461452 chr3 119236017 G T 9.92E-05 Arthritis (juvenile idiopathic) TIMMDC1 intron 22354554 rs1599795 chr3 119243855 T A 5.15E-05 IgE levels CD80 UTR-3 22075330 rs1599796 chr3 119243934 G A 5.14E-05 IgE levels CD80 UTR-3 22075330 rs7628626 chr3 119244421 A C 6.85E-04 Response to taxane treatment (placlitaxel) CD80 UTR-3 23006423 rs6804441 chr3 119260944 A G 3.00E-16 Systemic lupus erythematosus CD80 intron 23273568 rs7648642 chr3 119261375 A C 5.00E-06 Lobular breast cancer (menopausal hormone therapy interaction) CD80 intron 24080446 rs2222630 chr3 119277309 T C 4.67E-04 Type 2 diabetes CD80 intron 17463246 rs59374417 chr3 119288414 A C 4.00E-10 Vitiligo / / 22561518 rs4330287 chr3 119288848 C A 2.58E-04 Vitiligo / / 22561518 rs4407429 chr3 119288897 G A 9.12E-04 Type 2 diabetes / / 17463246 rs10511393 chr3 119290051 G C 2.06E-04 Type 2 diabetes / / 17463246 rs16830002 chr3 119290708 G A 3.39E-04 Type 2 diabetes / / 17463246 rs16830004 chr3 119290823 C T 2.47E-04 Type 2 diabetes / / 17463246 rs529650 chr3 119295128 C T 8.91E-05 Suicide attempts in bipolar disorder / / 21423239 rs1485331 chr3 119300655 G A 1.50E-05 Urinary metabolites ADPRH intron 21572414 rs4688018 chr3 119305724 C A 7.80E-06 Urinary metabolites ADPRH intron 21572414 rs2272266 chr3 119337198 C T 2.43E-06 Asthma (childhood onset) PLA1A intron 23829686 rs657079 chr3 119345950 T C 3.29E-04 Alzheimer's disease (late onset) PLA1A intron 21379329 rs571352 chr3 119359045 C T 5.53E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4327424 chr3 119390844 T C 9.25E-04 Response to taxane treatment (placlitaxel) COX17 intron 23006423 rs4234663 chr3 119424206 T C 1.40E-04 Multiple complex diseases C3orf15 intron 17554300 rs7644545 chr3 119425349 A G 7.90E-04 Lipid levels C3orf15 intron 18193043 rs12053990 chr3 119433508 A G 1.68E-04 Obesity (extreme) C3orf15 intron 21935397 rs1523129 chr3 119499608 A G 8.34E-05 Cognitive impairment induced by topiramate NR1I2 UTR-5 22091778 rs12721602 chr3 119499856 G A 3.60E-04 Coronary heart disease NR1I2 UTR-5 21966275 rs2472669 chr3 119501960 T C 2.17E-06 Asthma (childhood onset) NR1I2 intron 23829686 rs11712211 chr3 119504140 T C 6.80E-06 Malaria NR1I2 intron 19465909 rs2472677 chr3 119518417 C T 1 Drug response to Rifampin NR1I2 intron 17925385 rs1879997 chr3 119521228 T C 0.000000977 HDL cholesterol NR1I2 intron 23063622 rs12721613 chr3 119526176 C T 0.0000011 HDL cholesterol NR1I2 missense 23063622 rs12721613 chr3 119526176 C T 0.00000175 Cholesterol,total NR1I2 missense 23063622 rs12721613 chr3 119526176 C T 3.13E-21 LDL cholesterol NR1I2 missense 23063622 rs16830551 chr3 119552878 C T 1.43E-08 HDL cholesterol GSK3B intron 23063622 rs16830551 chr3 119552878 C T 1.56E-19 LDL cholesterol GSK3B intron 23063622 rs6808874 chr3 119557851 A T 1 Drug response to Citalopram GSK3B intron 18195730 rs6808874 chr3 119557851 A T 1 Drug response to Fluoxetine GSK3B intron 18195730 rs6805251 chr3 119560606 T C 1.00E-08 HDL cholesterol GSK3B intron 24097068 rs2319398 chr3 119612942 C A 1 Drug response to Citalopram GSK3B intron 18195730 rs2319398 chr3 119612942 C A 1 Drug response to Fluoxetine GSK3B intron 18195730 rs13321783 chr3 119615375 T C 1 Drug response to Citalopram GSK3B intron 18195730 rs13321783 chr3 119615375 T C 1 Drug response to Fluoxetine GSK3B intron 18195730 rs10934504 chr3 119756947 T C 5.46E-05 IgE levels GSK3B intron 22075330 rs334558 chr3 119813282 A G 1 Drug response to Citalopram GSK3B nearGene-5 16315267 rs334558 chr3 119813282 A G 1 Drug response to Fluoxetine GSK3B nearGene-5 16315267 rs334558 chr3 119813282 A G 1 Drug response to Citalopram GSK3B nearGene-5 18195729 rs334558 chr3 119813282 A G 1 Drug response to Fluoxetine GSK3B nearGene-5 18195729 rs334538 chr3 119825211 G A 8.90E-07 Urinary metabolites / / 21572414 rs7644268 chr3 119844713 A G 6.27E-05 Cytomegalovirus antibody response / / 21993531 rs6438558 chr3 119847792 C T 6.20E-05 Cytomegalovirus antibody response / / 21993531 rs6781470 chr3 119851394 C A 6.16E-05 Cytomegalovirus antibody response / / 21993531 rs923380 chr3 119855410 T C 6.02E-05 Cytomegalovirus antibody response / / 21993531 rs2035674 chr3 119862702 C G 5.54E-05 Cytomegalovirus antibody response / / 21993531 rs902795 chr3 119865700 A G 5.22E-05 Cytomegalovirus antibody response / / 21993531 rs6438559 chr3 119867015 A G 5.19E-05 Cytomegalovirus antibody response / / 21993531 rs6769988 chr3 119867624 G A 5.16E-05 Cytomegalovirus antibody response / / 21993531 rs6794478 chr3 119867803 A G 4.07E-05 Cytomegalovirus antibody response / / 21993531 rs10934511 chr3 119867927 T C 1.20E-05 Urinary metabolites / / 21572414 rs4488869 chr3 119869509 A G 4.49E-05 Cytomegalovirus antibody response / / 21993531 rs6438564 chr3 119870476 A T 4.36E-05 Cytomegalovirus antibody response / / 21993531 rs6438566 chr3 119870789 T C 3.13E-05 Cytomegalovirus antibody response / / 21993531 rs2035671 chr3 119875948 C T 4.22E-05 Cytomegalovirus antibody response / / 21993531 rs12152218 chr3 119878877 A G 4.23E-05 Cytomegalovirus antibody response / / 21993531 rs13079094 chr3 119882088 C T 3.99E-05 Stroke / / pha002887 rs1488763 chr3 119884663 G T 3.84E-04 Stroke GPR156 UTR-3 pha002887 rs9853082 chr3 119885430 G C 4.23E-05 Cytomegalovirus antibody response GPR156 UTR-3 21993531 rs9858566 chr3 119886548 G C 4.23E-05 Cytomegalovirus antibody response GPR156 cds-synon 21993531 rs902790 chr3 119886776 T A 4.23E-05 Cytomegalovirus antibody response GPR156 missense 21993531 rs10934512 chr3 119887646 C A 4.23E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs9841122 chr3 119890064 A G 4.23E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs9841303 chr3 119890181 A G 4.23E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs7653263 chr3 119890883 T C 4.23E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs7653396 chr3 119891039 T C 4.23E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs7642171 chr3 119891781 C T 3.15E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs9289142 chr3 119892779 T G 4.23E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs9857123 chr3 119893063 A C 3.13E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs1488762 chr3 119893257 G A 5.62E-04 Suicide attempts in bipolar disorder GPR156 intron 21423239 rs1488761 chr3 119893503 C T 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs9813834 chr3 119897778 C T 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs6776122 chr3 119898985 G C 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs979682 chr3 119899523 C T 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs6438567 chr3 119899628 G T 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs1488764 chr3 119900260 T C 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs2319541 chr3 119903369 A C 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs1907681 chr3 119903742 C G 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs902791 chr3 119904125 A G 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs2319542 chr3 119905641 G A 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs1352458 chr3 119906510 C A 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs4676809 chr3 119907244 T C 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs7637828 chr3 119907510 A G 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs7630226 chr3 119908128 T A 2.96E-04 Multiple complex diseases GPR156 intron 17554300 rs2130000 chr3 119910524 G A 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs6764549 chr3 119911603 C T 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs2319543 chr3 119911667 G A 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs902794 chr3 119912406 A G 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs4676822 chr3 119913188 G T 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs4676822 chr3 119913188 G T 1.07E-04 Eating disorders (purging via substances) GPR156 intron 23568457 rs2874022 chr3 119913520 T C 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs2035669 chr3 119915437 T C 6.48E-04 Type 2 diabetes GPR156 intron 17463246 rs923726 chr3 119917879 T C 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs923727 chr3 119918124 G A 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs923728 chr3 119918149 T C 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs9842302 chr3 119918358 C T 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs9289143 chr3 119918661 C A 2.72E-05 Parkinson's disease GPR156 intron 17052657 rs9289143 chr3 119918661 C A 4.24E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs2874023 chr3 119919544 T C 4.25E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs10049256 chr3 119920683 G T 4.26E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs4676832 chr3 119935080 T C 4.65E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs11929146 chr3 119943453 A C 9.74E-05 Cognitive impairment induced by topiramate GPR156 intron 22091778 rs6787458 chr3 119944395 T C 4.65E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs1388755 chr3 119947711 T C 4.65E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs6438569 chr3 119953272 C T 4.68E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs1492271 chr3 119961596 G A 4.69E-05 Cytomegalovirus antibody response GPR156 intron 21993531 rs6803611 chr3 119963432 G C 5.27E-05 Cytomegalovirus antibody response / / 21993531 rs1907680 chr3 119976017 C T 5.46E-05 Cytomegalovirus antibody response / / 21993531 rs1352932 chr3 119979146 C T 5.51E-05 Cytomegalovirus antibody response / / 21993531 rs1352931 chr3 119979305 C T 5.53E-05 Cytomegalovirus antibody response / / 21993531 rs980839 chr3 119980196 T A 5.54E-05 Cytomegalovirus antibody response / / 21993531 rs9637364 chr3 119981494 T C 3.86E-05 Cytomegalovirus antibody response / / 21993531 rs9878591 chr3 119981798 T C 1.50E-04 Cognitive impairment induced by topiramate / / 22091778 rs813697 chr3 119989611 G T 5.76E-05 Cytomegalovirus antibody response / / 21993531 rs787185 chr3 119990987 T C 4.00E-05 Cytomegalovirus antibody response / / 21993531 rs787211 chr3 120005723 A C 6.54E-05 Cytomegalovirus antibody response / / 21993531 rs1085625 chr3 120008050 G T 7.79E-05 HIV-1 viral setpoint / / 22174851 rs796825 chr3 120017480 G A 8.00E-06 HIV-1 susceptibility / / 22174851 rs7632516 chr3 120039375 T C 2.01E-05 Multiple complex diseases / / 17554300 rs10511400 chr3 120043836 C T 8.00E-06 Economic and political preferences (feminism/equality) LRRC58 UTR-3 22566634 rs6803428 chr3 120051323 A T 5.86E-04 Multiple complex diseases LRRC58 intron 17554300 rs950649 chr3 120084375 C G 2.00E-05 Bone mass and geometry / / 17903296 rs2943754 chr3 120088887 G A 1.60E-08 Narcolepsy / / 19629137 rs4676776 chr3 120106539 T C 2.06E-07 Smoking cessation / / 18519826 rs1733329 chr3 120106820 T C 3.81E-05 Smoking cessation / / 18519826 rs1733329 chr3 120106820 T C 0.000141 Prostate cancer / / 22532847 rs4676698 chr3 120107213 T C 1.71E-04 Smoking cessation / / 18519826 rs1700 chr3 120114637 C T 1.02E-04 Smoking cessation FSTL1 UTR-3 18519826 rs1147695 chr3 120119446 C T 2.07E-06 Smoking cessation FSTL1 intron 18519826 rs1147695 chr3 120119446 C T 2.42E-04 Smoking cessation FSTL1 intron 18519826 rs9880550 chr3 120122624 T C 4.95E-05 Smoking cessation FSTL1 intron 18519826 rs1147702 chr3 120126377 T C 9.58E-04 Suicide attempts in bipolar disorder FSTL1 intron 21423239 rs6764364 chr3 120154643 A G 5.76E-04 Multiple complex diseases FSTL1 intron 17554300 rs6791913 chr3 120155043 G A 6.56E-04 Multiple complex diseases FSTL1 intron 17554300 rs1123897 chr3 120157034 A T 2.18E-04 Multiple complex diseases FSTL1 intron 17554300 rs1259337 chr3 120165394 C T 6.86E-05 Sudden cardiac arrest FSTL1 intron 21658281 rs1259312 chr3 120186012 T C 8.11E-04 Multiple complex diseases / / 17554300 rs1147720 chr3 120206372 C T 4.49E-04 Response to TNF antagonist treatment / / 21061259 rs1259321 chr3 120208332 C T 9.87E-05 HIV-1 viral setpoint / / 22174851 rs9289146 chr3 120236329 C T 7.00E-06 Obesity-related traits / / 23251661 rs804987 chr3 120315044 G A 2.60E-05 Urinary metabolites / / 21572414 rs804980 chr3 120343766 G A 1.21E-11 Multiple complex diseases / / 17554300 rs7613732 chr3 120350505 A G 3.82E-04 Alcohol dependence HGD intron 21314694 rs804974 chr3 120351791 C T 1.91E-05 Multiple complex diseases HGD intron 17554300 rs16849176 chr3 120362321 C G 4.55E-04 Sudden cardiac arrest HGD intron 21658281 rs10511396 chr3 120363773 T G 3.25E-04 Type 2 diabetes HGD intron 17463246 rs1862942 chr3 120365010 G A 1.90E-05 Urinary metabolites HGD intron 21572414 rs13077101 chr3 120425331 T C 1.00E-06 Obesity-related traits RABL3 intron 23251661 rs13077101 chr3 120425331 T C 2.00E-07 Obesity-related traits RABL3 intron 23251661 rs447978 chr3 120491086 G A 0.000135 Oxaliplatin induced neuropathy in response to colorectal cancer treatment GTF2E1 intron 22310351 rs1505700 chr3 120492916 G A 8.40E-04 Type 2 diabetes and 6 quantitative traits GTF2E1 intron 17848626 rs624496 chr3 120506737 T C 9.18E-04 Alzheimer's disease / / 17998437 rs373188 chr3 120511490 G T 4.92E-06 Obesity-related traits / / 23251661 rs11718363 chr3 120513409 C T 7.77E-04 Alzheimer's disease / / 17998437 rs11718363 chr3 120513409 C T 1.60E-05 Urinary metabolites / / 21572414 rs10511404 chr3 120518357 G A 3.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs322463 chr3 120528283 C T 1.07E-04 Cholesterol / / 17255346 rs399491 chr3 120531127 T G 3.74E-05 Cholesterol / / 17255346 rs391361 chr3 120531523 A G 3.53E-05 Cholesterol / / 17255346 rs412962 chr3 120533884 A G 1.63E-04 Cholesterol / / 17255346 rs2971384 chr3 120542949 G C 9.28E-04 Multiple complex diseases / / 17554300 rs2971381 chr3 120553956 G C 9.67E-04 Multiple complex diseases / / 17554300 rs413401 chr3 120568391 C A 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs408378 chr3 120573295 C T 7.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs322458 chr3 120585315 C T 2.00E-08 Aging (facial) / / 23223146 rs657578 chr3 120657777 A C 6.87E-05 Serum metabolites STXBP5L intron 19043545 rs1683984 chr3 120663037 C T 7.08E-04 Alzheimer's disease STXBP5L intron 22005930 rs12491742 chr3 120690203 T G 6.40E-04 Alcohol dependence STXBP5L intron 21314694 rs11707293 chr3 121084467 C T 5.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy) STXBP5L intron 24554482 rs17740066 chr3 121100283 G A 6.00E-09 Aging (facial) STXBP5L missense 23223146 rs17740072 chr3 121100414 A G 6.81E-04 Response to cytadine analogues (cytosine arabinoside) STXBP5L intron 24483146 rs7650658 chr3 121131376 G A 2.70E-05 Urinary metabolites STXBP5L intron 21572414 rs9849118 chr3 121132268 T A 2.70E-05 Urinary metabolites STXBP5L intron 21572414 rs6782025 chr3 121137976 C T 4.00E-09 Aging (facial) STXBP5L UTR-3 23223146 rs6787048 chr3 121141036 T G 2.20E-05 Urinary metabolites STXBP5L UTR-3 21572414 rs7632907 chr3 121141718 T C 2.00E-05 Urinary metabolites STXBP5L UTR-3 21572414 rs6800901 chr3 121154193 C T 1.70E-05 Parkinson's disease (age of onset) POLQ intron 19772629 rs6800901 chr3 121154193 C T 2.00E-06 Multiple myeloma (IgH translocation) POLQ intron 23502783 rs12485719 chr3 121289499 C T 1.70E-05 Urinary metabolites ARGFX intron 21572414 rs13065635 chr3 121302410 G T 6.50E-06 Dietary macronutrient intake ARGFX intron 23372041 rs61750878 chr3 121305086 C T 0.000093 Stroke ARGFX missense 23422753 rs6775899 chr3 121319824 A G 8.85E-04 Coronary Artery Disease FBXO40 intron 17634449 rs6775899 chr3 121319824 A G 4.91E-04 Alzheimer's disease (late onset) FBXO40 intron 21379329 rs6775899 chr3 121319824 A G 1.00E-09 Aging (facial) FBXO40 intron 23223146 rs3845864 chr3 121323360 T C 8.39E-05 Coronary Artery Disease FBXO40 intron 17634449 rs1464099 chr3 121324643 T C 1.12E-05 Amyotrophic lateral sclerosis (sporadic) FBXO40 intron 24529757 rs6773252 chr3 121327184 T G 1.62E-04 Alzheimer's disease (late onset) FBXO40 intron 21379329 rs3772130 chr3 121344140 A G 6.00E-06 Cognitive performance FBXO40 intron 19734545 rs9810952 chr3 121346930 A C 5.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FBXO40 UTR-3 20877124 rs3732410 chr3 121415720 T C 0.000093 Stroke GOLGB1 missense 23422753 rs1919555 chr3 121446900 G A 6.70E-05 Bone mineral density (BMD),in women GOLGB1 intron 20164292 rs9849087 chr3 121465220 A G 5.44E-25 Lymphocyte counts GOLGB1 intron 22286170 rs4413346 chr3 121486310 T C 9.68E-04 Alcohol dependence / / 21314694 rs1135750 chr3 121488995 C G 2.24E-04 Multiple complex diseases IQCB1 UTR-3 17554300 rs1135750 chr3 121488995 C G 2.07E-07 Lymphocyte counts IQCB1 UTR-3 22286170 rs7623901 chr3 121529011 T C 6.41E-06 Body mass index IQCB1 intron 24827717 rs4482697 chr3 121536497 C T 0.0000366 Primary sclerosing cholangitis IQCB1 intron 23603763 rs6802715 chr3 121538798 A T 3.75E-04 Multiple complex diseases IQCB1 intron 17554300 rs6802715 chr3 121538798 A T 2.60E-05 Urinary metabolites IQCB1 intron 21572414 rs2331964 chr3 121542898 T C 5.48E-04 Multiple complex diseases IQCB1 intron 17554300 rs2331964 chr3 121542898 T C 1.14E-08 Lymphocyte counts IQCB1 intron 22286170 rs12695416 chr3 121551570 A G 6.31E-06 Crohn's disease IQCB1 intron 17804789 rs9826473 chr3 121556219 C T 7.75E-04 Alcohol dependence EAF2 intron 21314694 rs1920321 chr3 121557251 A T 3.16E-04 Multiple complex diseases EAF2 intron 17554300 rs1920322 chr3 121557533 G T 2.11E-04 Multiple complex diseases EAF2 intron 17554300 rs1920322 chr3 121557533 G T 5.74E-06 Lymphocyte counts EAF2 intron 22286170 rs12496318 chr3 121561500 T G 7.26E-06 Body mass index EAF2 intron 24827717 rs2332056 chr3 121598297 A G 2.33E-07 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines EAF2 intron 21483694 rs1881997 chr3 121614489 T C 8.50E-04 Depression (quantitative trait) SLC15A2 intron 20800221 rs4285028 chr3 121660664 A C 9.86E-05 Non-alcoholic fatty liver disease histology (other) SLC15A2 UTR-3 20708005 rs4285028 chr3 121660664 A C 2.00E-08 Multiple sclerosis SLC15A2 UTR-3 21833088 rs11718322 chr3 121710086 G A 8.23E-05 Behcet's disease ILDR1 intron pha002888 rs9824120 chr3 121717577 T C 7.46E-04 Parkinson's disease ILDR1 intron 16252231 rs12489988 chr3 121723700 G A 4.40E-05 Creatinine levels ILDR1 intron 20222955 rs1523517 chr3 121726991 G C 5.53E-04 Coronary heart disease ILDR1 intron 21606135 rs13080516 chr3 121757123 A G 7.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs12106790 chr3 121767054 A C 1.74E-06 Carotenoid and tocopherol levels / / 19185284 rs2681424 chr3 121769522 T C 2.00E-07 Multiple sclerosis / / 22190364 rs2255214 chr3 121770539 G T 4.33E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs13082681 chr3 121775134 C T 5.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CD86 intron 20877124 rs13095010 chr3 121784531 A G 5.15E-04 Suicide attempts in bipolar disorder CD86 intron 21423239 rs2681411 chr3 121785631 G A 4.20E-05 Alzheimer's disease (late onset) CD86 intron 21460841 rs4308217 chr3 121793187 C A,T 6.00E-08 Multiple sclerosis CD86 intron 21833088 rs2715260 chr3 121793490 G A 1.07E-05 Smoking behavior CD86 intron 19188921 rs9282641 chr3 121796768 G A 1.00E-11 Multiple sclerosis CD86 UTR-5 21833088 rs9831894 chr3 121800487 A C 2.10E-05 Immunoglobulin A CD86 intron 20694011 rs13090103 chr3 121811585 G A 8.03E-04 Suicide attempts in bipolar disorder CD86 intron 21423239 rs2332096 chr3 121821143 T G 9.95E-05 Erythrocyte counts CD86 intron pha003101 rs6780593 chr3 121927927 G A 2.10E-04 Smoking cessation CASR intron 24665060 rs9866419 chr3 121940209 G A 3.30E-06 Calcium levels CASR intron 20705733 rs9811123 chr3 121949292 G A 3.20E-06 Calcium levels CASR intron 20705733 rs7618100 chr3 121950120 G C 2.90E-06 Calcium levels CASR intron 20705733 rs4336054 chr3 121951055 G A 1.21E-05 Acute lymphoblastic leukemia (childhood) CASR intron 19684603 rs2134221 chr3 121962246 G A 2.10E-06 Calcium levels CASR intron 20705733 rs12493480 chr3 121962963 G A 2.00E-06 Calcium levels CASR intron 20705733 rs1979869 chr3 121963285 T C 2.00E-06 Calcium levels CASR intron 20705733 rs3863977 chr3 121964262 T C 2.40E-06 Calcium levels CASR intron 20705733 rs13326577 chr3 121965246 A T 2.50E-06 Calcium levels CASR intron 20705733 rs7635354 chr3 121966638 C A 2.50E-06 Calcium levels CASR intron 20705733 rs9875101 chr3 121968090 T C 2.45E-05 Type 2 diabetes CASR intron 17463246 rs9875101 chr3 121968090 T C 2.50E-06 Calcium levels CASR intron 20705733 rs2173961 chr3 121968847 T G 4.91E-06 Type 2 diabetes CASR intron 17463246 rs2173961 chr3 121968847 T G 2.70E-06 Calcium levels CASR intron 20705733 rs1965358 chr3 121970301 G A 2.70E-06 Calcium levels CASR intron 20705733 rs1463892 chr3 121970386 A G 3.50E-05 Type 2 diabetes CASR intron 17463246 rs1463892 chr3 121970386 A G 2.70E-06 Calcium levels CASR intron 20705733 rs937626 chr3 121971802 G A 2.10E-06 Calcium levels CASR intron 20705733 rs3749203 chr3 121976494 C T 3.20E-12 Calcium levels CASR intron 20705733 rs10222633 chr3 121976926 G A 9.70E-13 Calcium levels CASR intron 20705733 rs10934578 chr3 121977282 G T 2.90E-09 Calcium levels CASR intron 20705733 rs10934578 chr3 121977282 G T 1.20E-05 Urinary metabolites CASR intron 21572414 rs10934578 chr3 121977282 G T 5.80E-04 Coronary heart disease CASR intron 21966275 rs3804590 chr3 121978073 G T 3.00E-09 Calcium levels CASR intron 20705733 rs6768471 chr3 121979704 G A 1.40E-06 Calcium levels CASR intron 20705733 rs3749208 chr3 121980284 C T 2.80E-09 Calcium levels CASR intron 20705733 rs11711910 chr3 121985882 T G 1.40E-06 Calcium levels CASR intron 20705733 rs11716910 chr3 121987619 A G 1.40E-06 Calcium levels CASR intron 20705733 rs2202127 chr3 121988355 G A 3.43E-04 Smoking initiation CASR intron 24665060 rs7644390 chr3 121990228 T A 1.60E-06 Calcium levels CASR intron 20705733 rs13095172 chr3 121990257 C T 1.40E-09 Calcium levels CASR intron 20705733 rs4678173 chr3 121991139 C A 1.60E-06 Calcium levels CASR intron 20705733 rs17251221 chr3 121993247 A G 2.00E-22 Calcium levels CASR intron 20705733 rs17251221 chr3 121993247 A G 1.40E-05 IgE levels CASR intron 22075330 rs3792289 chr3 121993600 A G 1.50E-09 Calcium levels CASR intron 20705733 rs3792289 chr3 121993600 A G 2.00E-05 Urinary metabolites CASR intron 21572414 rs11922857 chr3 121997388 G A 1.50E-06 Calcium levels CASR intron 20705733 rs7652858 chr3 121998105 T C 4.05E-05 Multiple complex diseases CASR intron 17554300 rs4678174 chr3 122000871 C T 2.93E-04 Smoking initiation CASR intron 24665060 rs2036400 chr3 122003045 G C 6.42E-05 Multiple complex diseases / / 17554300 rs1801725 chr3 122003757 G T 6.00E-37 Calcium levels CASR missense 20661308 rs1801725 chr3 122003757 G T 3.00E-22 Calcium levels CASR missense 20705733 rs1801725 chr3 122003757 G T 1.33E-05 IgE levels CASR missense 22075330 rs1801725 chr3 122003757 G T 9.00E-86 Calcium levels CASR missense 24068962 rs1042636 chr3 122003769 A G 8.00E-04 Coronary heart disease CASR missense 21966275 rs9740 chr3 122005053 A G 7.40E-06 Calcium levels CASR UTR-3 20705733 rs7646147 chr3 122006527 T C 7.20E-06 Calcium levels / / 20705733 rs12635478 chr3 122008553 C A 2.80E-08 Calcium levels / / 20705733 rs4678176 chr3 122009175 A G 6.40E-07 Urinary metabolites / / 21572414 rs7614328 chr3 122010340 T C 3.59E-04 Smoking initiation / / 24665060 rs10934581 chr3 122011154 C T 7.90E-06 Calcium levels / / 20705733 rs13085674 chr3 122011351 G A 2.90E-09 Calcium levels / / 20705733 rs13085674 chr3 122011351 G A 7.30E-06 Urinary metabolites / / 21572414 rs13085498 chr3 122011363 C T 2.80E-09 Calcium levels / / 20705733 rs7633800 chr3 122011665 G A 8.40E-06 Calcium levels / / 20705733 rs7633667 chr3 122011726 C G 7.90E-06 Calcium levels / / 20705733 rs1472621 chr3 122012726 A G 4.70E-09 Calcium levels / / 20705733 rs10934582 chr3 122013354 G A 4.50E-09 Calcium levels / / 20705733 rs13083990 chr3 122014566 T C 3.60E-05 Parkinson's disease (familial) / / 18985386 rs13083990 chr3 122014566 T C 6.31E-05 Serum metabolites / / 19043545 rs13083990 chr3 122014566 T C 5.40E-08 Calcium levels / / 20705733 rs13083990 chr3 122014566 T C 8.10E-06 Urinary metabolites / / 21572414 rs13083990 chr3 122014566 T C 4.00E-06 Cardiac Troponin-T levels / / 23247143 rs6438720 chr3 122017232 A C 1.00E-07 Calcium levels / / 20705733 rs16832956 chr3 122017508 C G 1.70E-16 Calcium levels / / 20705733 rs9851884 chr3 122020194 A G 2.80E-08 Calcium levels / / 20705733 rs1402200 chr3 122022417 G C 2.10E-07 Calcium levels / / 20705733 rs5008830 chr3 122030462 G A 3.70E-18 Calcium levels / / 20705733 rs5008830 chr3 122030462 G A 3.54E-05 IgE levels / / 22075330 rs2001548 chr3 122032789 G A 4.70E-18 Calcium levels / / 20705733 rs2001548 chr3 122032789 G A 3.94E-05 IgE levels / / 22075330 rs2001548 chr3 122032789 G A 6.86E-06 Lymphocyte counts / / 22286170 rs4678180 chr3 122037797 T C 2.80E-09 Calcium levels / / 20705733 rs9864290 chr3 122040062 C T 2.60E-09 Calcium levels / / 20705733 rs6803098 chr3 122040610 C T 2.60E-09 Calcium levels / / 20705733 rs17265703 chr3 122048644 A G 4.00E-09 Phosphorus levels CSTA intron 20558539 rs17265703 chr3 122048644 A G 1.80E-18 Calcium levels CSTA intron 20705733 rs17265703 chr3 122048644 A G 3.18E-05 IgE levels CSTA intron 22075330 rs9817571 chr3 122055980 C T 2.90E-06 Calcium levels CSTA intron 20705733 rs17589 chr3 122056432 C T 7.77E-04 Multiple complex diseases CSTA cds-synon 17554300 rs4491840 chr3 122080747 G A 1.70E-12 Calcium levels CCDC58 intron 20705733 rs4491840 chr3 122080747 G A 4.36E-05 Calcium levels CCDC58 intron pha003085 rs6438725 chr3 122088106 T C 2.30E-12 Calcium levels CCDC58 intron 20705733 rs9834317 chr3 122089359 G T 2.30E-12 Calcium levels CCDC58 intron 20705733 rs16833078 chr3 122099594 A G 2.50E-12 Calcium levels CCDC58 intron 20705733 rs16833080 chr3 122100907 C T 2.80E-12 Calcium levels CCDC58 intron 20705733 rs6791616 chr3 122107235 C T 3.70E-11 Calcium levels FAM162A intron 20705733 rs6791616 chr3 122107235 C T 4.56E-05 IgE levels FAM162A intron 22075330 rs11924963 chr3 122122133 A G 5.70E-05 Smoking initiation FAM162A intron 24665060 rs12107092 chr3 122123848 C T 4.40E-11 Calcium levels FAM162A intron 20705733 rs12107092 chr3 122123848 C T 4.97E-05 IgE levels FAM162A intron 22075330 rs6768280 chr3 122125052 G A 5.40E-06 Calcium levels FAM162A intron 20705733 rs7615930 chr3 122125750 G T 8.00E-04 Acute lymphoblastic leukemia (childhood) FAM162A intron 20189245 rs4678192 chr3 122127592 A G 8.39E-05 IgE levels FAM162A intron 22075330 rs1127343 chr3 122128394 G A 5.48E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) FAM162A intron 23648065 rs1127343 chr3 122128394 G A 8.30E-05 Tooth agenesis (maxillary third molar) FAM162A intron 24172245 rs4306808 chr3 122128466 G C 1.20E-10 Calcium levels FAM162A intron 20705733 rs17266816 chr3 122128874 G A 2.10E-10 Calcium levels FAM162A UTR-3 20705733 rs17200894 chr3 122130141 C G 1.10E-09 Calcium levels / / 20705733 rs1067 chr3 122132965 G A 2.50E-08 Calcium levels WDR5B UTR-3 20705733 rs11932 chr3 122141135 C T 8.67E-04 Type 2 diabetes KP/1 UTR-3 17463246 rs11932 chr3 122141135 C T 6.00E-04 Acute lymphoblastic leukemia (childhood) KP/1 UTR-3 20189245 rs17201246 chr3 122145470 C A 1.30E-09 Calcium levels KP/1 UTR-3 20705733 rs12487598 chr3 122178602 T C 3.70E-06 Calcium levels KP/1 intron 20705733 rs9789994 chr3 122217851 T A 2.10E-09 Calcium levels KP/1 intron 20705733 rs9789994 chr3 122217851 T A 9.36E-05 IgE levels KP/1 intron 22075330 rs7645862 chr3 122221139 C T 7.00E-04 Acute lymphoblastic leukemia (childhood) KP/1 intron 20189245 rs10934602 chr3 122223182 G T 9.37E-04 Type 2 diabetes KP/1 intron 17463246 rs10934602 chr3 122223182 G T 6.00E-04 Acute lymphoblastic leukemia (childhood) KP/1 intron 20189245 rs6438737 chr3 122228974 C T 6.70E-06 Calcium levels KP/1 intron 20705733 rs16833168 chr3 122254647 C T 2.00E-09 Calcium levels PARP9 UTR-3 20705733 rs16833168 chr3 122254647 C T 6.98E-05 IgE levels PARP9 UTR-3 22075330 rs2270859 chr3 122255708 G A 1.80E-09 Calcium levels PARP9 intron 20705733 rs2270859 chr3 122255708 G A 6.47E-05 IgE levels PARP9 intron 22075330 rs7629285 chr3 122265739 C T 6.00E-04 Acute lymphoblastic leukemia (childhood) PARP9 intron 20189245 rs17267388 chr3 122267546 G A 9.70E-10 Calcium levels PARP9 intron 20705733 rs17267388 chr3 122267546 G A 7.69E-05 IgE levels PARP9 intron 22075330 rs11929034 chr3 122279049 G A 1.50E-09 Calcium levels PARP9 intron 20705733 rs9839782 chr3 122287289 T C 5.40E-05 Tooth agenesis (maxillary third molar) DTX3L intron 24172245 rs2036342 chr3 122290579 C T 3.85E-04 Hemoglobin concentration DTX3L cds-synon 20534544 rs6785609 chr3 122302815 T C 9.09E-04 Multiple complex diseases PARP15 intron 17554300 rs4678202 chr3 122314374 T G 5.78E-04 Insulin resistance PARP15 intron 21901158 rs9882797 chr3 122315893 T C 3.28E-04 Parkinson's disease PARP15 intron 17052657 rs9882797 chr3 122315893 T C 8.52E-04 Insulin resistance PARP15 intron 21901158 rs9823535 chr3 122327950 G A 7.12E-04 Multiple complex diseases PARP15 intron 17554300 rs2173763 chr3 122329160 A G 6.00E-06 Major depressive disorder PARP15 intron 22472876 rs9827225 chr3 122341401 A G 5.57E-04 Insulin resistance PARP15 intron 21901158 rs78411303 chr3 122356451 G A 3.00E-06 Periodontitis (CDC/AAP) / / 24024966 rs80157733 chr3 122366381 C G 6.35E-06 Periodontitis (CDC/AAP) / / 24024966 rs2650951 chr3 122368347 C T 1.00E-06 QT interval / / 20031603 rs16834903 chr3 122379614 G A 2.57E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs790116 chr3 122380923 G C 2.00E-07 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs790115 chr3 122381117 C T 1.09E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2650950 chr3 122382048 G A 8.45E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs790125 chr3 122388464 A G 5.75E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs790123 chr3 122388993 T C 6.00E-06 Response to angiotensin II receptor blocker therapy / / 22566498 rs41341249 chr3 122407599 T C 1.00E-04 Multiple complex diseases PARP14 intron 17554300 rs13086236 chr3 122460470 G C 1.78E-07 Lymphocyte counts HSPBAP1 intron 22286170 rs9859701 chr3 122601270 A G 1.15E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11721287 chr3 122605009 T C 4.45E-04 Alzheimer's disease / / 24755620 rs12638324 chr3 122607098 G A 3.92E-04 Alzheimer's disease / / 24755620 rs7640146 chr3 122610629 A G 7.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9813853 chr3 122636148 T G 2.67E-04 Multiple complex diseases SEMA5B intron 17554300 rs4378918 chr3 122639009 A G 9.75E-05 Non-alcoholic fatty liver disease histology (other) SEMA5B intron 20708005 rs2276775 chr3 122646734 C T 3.57E-05 Brain structure SEMA5B cds-synon 22504417 rs13099843 chr3 122650890 A C 4.18E-05 Angioedema in response to angiotensin-converting enzyme inhibitor SEMA5B intron 23838604 rs11711303 chr3 122679716 G A 2.00E-04 Acute lymphoblastic leukemia (childhood) SEMA5B intron 20189245 rs17171 chr3 122681930 T C 9.75E-04 Coronary heart disease SEMA5B intron 21971053 rs7432970 chr3 122695288 G A 3.91E-04 Type 2 diabetes SEMA5B intron 17463246 rs16833750 chr3 122714241 C T 8.34E-06 Telomere length SEMA5B intron 23001564 rs9868873 chr3 122730910 G A 1.00E-07 Esophageal cancer SEMA5B intron 21642993 rs12492773 chr3 122788006 C G 4.64E-04 Multiple complex diseases PDIA5 intron 17554300 rs13434289 chr3 122792686 G T 0.000327 Breast cancer early age of onset PDIA5 intron 18463975 rs4677994 chr3 122814053 C T 9.35E-06 Gallstones PDIA5 intron 17632509 rs3792366 chr3 122839876 G A 4.00E-09 Platelet counts PDIA5 intron 22139419 rs836832 chr3 122853805 A G 0.00051 Endometrial cancer PDIA5 intron 22426144 rs1533394 chr3 122862779 A G 0.00023 Endometrial cancer PDIA5 intron 22426144 rs12487554 chr3 122942782 G A 8.50E-05 Myasthenia gravis SEC22A intron 23055271 rs7626920 chr3 122949656 G A 9.11E-04 Alzheimer's disease SEC22A intron 22005930 rs13317079 chr3 123003298 C A 2.00E-06 Obesity-related traits ADCY5 UTR-3 23251661 rs3934729 chr3 123019763 T C 2.80E-04 Myasthenia gravis ADCY5 intron 23055271 rs9850375 chr3 123023615 C T 5.72E-05 Serum metabolites ADCY5 intron 19043545 rs11708067 chr3 123065778 A G 3.00E-12 Fasting glucose-related traits ADCY5 intron 20081858 rs11708067 chr3 123065778 A G 7.00E-22 Fasting insulin-related traits ADCY5 intron 20081858 rs11708067 chr3 123065778 A G 3.00E-10 Fasting glucose-related traits (interaction with BMI) ADCY5 intron 22581228 rs11708067 chr3 123065778 A G 6.00E-08 Type 2 diabetes ADCY5 intron 22693455 rs11708067 chr3 123065778 A G 0.00000041 Type 2 diabetes (males) ADCY5 intron 22885922 rs11708067 chr3 123065778 A G 1.30E-18 Type 2 diabetes ADCY5 intron 22885922 rs11708067 chr3 123065778 A G 1.70E-10 Type 2 diabetes (females) ADCY5 intron 22885922 rs11708067 chr3 123065778 A G 0.00000069 Fasting insulin-related traits ADCY5 intron 22885924 rs11708067 chr3 123065778 A G 0.0005046 Glycated hemoglobin levels ADCY5 intron 22885924 rs11708067 chr3 123065778 A G 1.30E-18 Fasting blood glucose ADCY5 intron 22885924 rs11708067 chr3 123065778 A G 5.92E-13 2-hour glucose tolerance test ADCY5 intron 22885924 rs11708067 chr3 123065778 A G 4.99E-04 Type 2 diabetes ADCY5 intron 24390345 rs11708903 chr3 123066010 A G 8.93E-04 Amyotrophic lateral sclerosis (sporadic) ADCY5 intron 24529757 rs11717195 chr3 123082398 T C 0.000018 Fasting insulin-related traits ADCY5 intron 22885922 rs11717195 chr3 123082398 T C 0.000027 HOMA-B ADCY5 intron 22885922 rs11717195 chr3 123082398 T C 1.70E-17 Fasting blood glucose ADCY5 intron 22885922 rs11717195 chr3 123082398 T C 6.50E-14 Type 2 diabetes ADCY5 intron 22885922 rs11717195 chr3 123082398 T C 0.00000198 Fasting insulin-related traits ADCY5 intron 22885924 rs11717195 chr3 123082398 T C 1.65E-17 Fasting blood glucose ADCY5 intron 22885924 rs11717195 chr3 123082398 T C 4.05E-13 2-hour glucose tolerance test ADCY5 intron 22885924 rs11717195 chr3 123082398 T C 2.00E-08 Type 2 diabetes ADCY5 intron 24509480 rs2877716 chr3 123094451 T C 7.00E-16 Two-hour glucose challenge ADCY5 intron 20081857 rs2877716 chr3 123094451 T C 0.000202 Fasting insulin-related traits ADCY5 intron 22885924 rs2877716 chr3 123094451 T C 2.82E-09 2-hour glucose tolerance test ADCY5 intron 22885924 rs2877716 chr3 123094451 T C 3.95E-13 Fasting blood glucose ADCY5 intron 22885924 rs9883204 chr3 123096820 T C 7.00E-15 Birth weight ADCY5 intron 20372150 rs9883204 chr3 123096820 T C 6.00E-20 Birth weight ADCY5 intron 23202124 rs6764842 chr3 123106287 T A 3.33E-05 Height ADCY5 intron 22021425 rs4677889 chr3 123143272 G A 1.00E-04 Cognitive impairment induced by topiramate ADCY5 intron 22091778 rs12665 chr3 123210978 T C 8.41E-11 Multiple complex diseases / / 17554300 rs1055137 chr3 123212563 A G 5.91E-04 Multiple complex diseases / / 17554300 rs1965290 chr3 123287806 T C 4.39E-05 Bipolar disorder and schizophrenia PTPLB intron 20889312 rs1268623 chr3 123312228 T G 6.54E-04 Suicide attempts in bipolar disorder MYLK-AS1 intron 21041247 rs6765680 chr3 123315936 G T 1.59E-04 Lymphocyte counts MYLK-AS1 intron 22286170 rs861890 chr3 123318520 A G 8.45E-04 Suicide attempts in bipolar disorder MYLK-AS1 intron 21041247 rs820479 chr3 123323164 A G 8.36E-04 Suicide attempts in bipolar disorder MYLK-AS1 intron 21041247 rs848146 chr3 123323767 G C 8.27E-04 Suicide attempts in bipolar disorder MYLK-AS1 intron 21041247 rs4530474 chr3 123327675 T C 8.22E-04 Suicide attempts in bipolar disorder MYLK-AS1 intron 21041247 rs2626028 chr3 123329932 T C 8.31E-04 Suicide attempts in bipolar disorder MYLK-AS1 intron 21041247 rs848145 chr3 123336982 G A 1.23E-04 Suicide attempts in bipolar disorder MYLK intron 21041247 rs860224 chr3 123337414 C G 8.55E-04 Suicide attempts in bipolar disorder MYLK intron 21041247 rs820459 chr3 123337938 A G 1.23E-04 Suicide attempts in bipolar disorder MYLK intron 21041247 rs820458 chr3 123338457 T C 8.68E-04 Suicide attempts in bipolar disorder MYLK intron 21041247 rs820455 chr3 123340878 A G 1.23E-04 Suicide attempts in bipolar disorder MYLK intron 21041247 rs820446 chr3 123348776 T C 1.21E-04 Suicide attempts in bipolar disorder MYLK intron 21041247 rs1254397 chr3 123351288 C T 1.19E-04 Suicide attempts in bipolar disorder MYLK intron 21041247 rs1254401 chr3 123353741 G C 1.19E-04 Suicide attempts in bipolar disorder MYLK intron 21041247 rs820460 chr3 123355193 T C 1.19E-04 Suicide attempts in bipolar disorder MYLK intron 21041247 rs820463 chr3 123357037 A G 1.19E-04 Suicide attempts in bipolar disorder MYLK cds-synon 21041247 rs820464 chr3 123357062 G C 1.19E-04 Suicide attempts in bipolar disorder MYLK intron 21041247 rs1254403 chr3 123358278 A C 1.19E-04 Suicide attempts in bipolar disorder MYLK intron 21041247 rs1254403 chr3 123358278 A C 7.76E-04 Suicide attempts in bipolar disorder MYLK intron 21041247 rs820470 chr3 123362856 T C 1.19E-04 Suicide attempts in bipolar disorder MYLK intron 21041247 rs820472 chr3 123364313 T C 1.20E-04 Suicide attempts in bipolar disorder MYLK intron 21041247 rs1254389 chr3 123369728 T A 1.29E-04 Suicide attempts in bipolar disorder MYLK intron 21041247 rs33261 chr3 123413742 T C 5.28E-05 Multiple complex diseases MYLK intron 17554300 rs3732487 chr3 123419573 G T 6.86E-04 Smoking initiation MYLK missense 24665060 rs820343 chr3 123432512 T C 3.20E-04 Multiple complex diseases MYLK intron 17554300 rs2332589 chr3 123438187 G C 4.60E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MYLK intron 21844884 rs11718105 chr3 123463708 C T 1.66E-05 Psoriasis MYLK intron 18364390 rs1463390 chr3 123509929 C T 4.17E-04 Alzheimer's disease MYLK intron 17998437 rs17125 chr3 123511983 A G 6.08E-06 Post-operative nausea and vomiting MYLK intron 21694509 rs1947510 chr3 123514927 T C 5.34E-05 Multiple complex diseases MYLK intron 17554300 rs10511417 chr3 123535336 T C 5.21E-18 Alcohol consumption MYLK intron pha001400 rs9289225 chr3 123536043 T C 1.85E-04 Bicuspid aortic valve MYLK intron 20098615 rs4461370 chr3 123566172 C T 7.59E-04 Type 2 diabetes MYLK intron 22158537 rs7646900 chr3 123568458 C T 3.93E-04 Type 2 diabetes MYLK intron 22158537 rs1343700 chr3 123571754 G A 3.20E-05 Asthma MYLK intron 22561531 rs9682818 chr3 123582450 C T 8.31E-04 Type 2 diabetes MYLK intron 22158537 rs2682218 chr3 123583879 A G 2.32E-04 Type 2 diabetes MYLK intron 22158537 rs2700405 chr3 123590573 T C 6.83E-04 Bicuspid aortic valve MYLK intron 20098615 rs2700388 chr3 123642636 C T 7.93E-04 Obesity (extreme) CCDC14 intron 21935397 rs4678073 chr3 123667524 A C 3.18E-12 Alcohol consumption CCDC14 intron pha001400 rs2332715 chr3 123691011 C G 1.03E-04 Body mass index ROPN1 intron 21701565 rs2332715 chr3 123691011 C G 4.75E-04 Body mass index ROPN1 intron 21701565 rs2280422 chr3 123696930 A G 2.19E-04 Prion diseases ROPN1 intron 22210626 rs7644284 chr3 123699502 A G 1.41E-04 Body mass index ROPN1 intron 21701565 rs17310770 chr3 123699823 A C 6.65E-05 Chronic obstructive pulmonary disease ROPN1 intron 19300482 rs4678074 chr3 123713532 C G 6.80E-04 Obesity (extreme) / / 21935397 rs7429448 chr3 123715852 G A 4.04E-04 Obesity (extreme) / / 21935397 rs2877780 chr3 123723448 C T 4.13E-04 Obesity (extreme) / / 21935397 rs12634530 chr3 123744470 C T 8.14E-05 Waist Circumference / / pha003025 rs9289231 chr3 123774078 T G 2.91E-06 Cardiovascular disease / / 18179892 rs4527323 chr3 123776152 T C 3.57E-05 Body Fat Distribution / / pha003016 rs4527323 chr3 123776152 T C 4.22E-05 Insulin-related traits / / pha003063 rs7640139 chr3 123791201 C T 8.40E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2332737 chr3 123791464 G A 8.76E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs6438827 chr3 123796759 G A 9.58E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs1320186 chr3 123804254 G T 5.14E-04 Body mass index / / 21701565 rs11721323 chr3 123807012 C T 4.57E-05 Body Mass Index / / pha003007 rs11721323 chr3 123807012 C T 5.02E-05 Body Fat Distribution / / pha003016 rs11721323 chr3 123807012 C T 1.01E-05 Waist Circumference / / pha003025 rs11721323 chr3 123807012 C T 2.43E-05 Insulin-related traits / / pha003063 rs4678082 chr3 123810460 A G 3.04E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs1920616 chr3 123819583 G A 2.58E-06 PR interval in Tripanosoma cruzi seropositivity KALRN intron 24324551 rs6794106 chr3 123820597 G C 2.85E-06 PR interval in Tripanosoma cruzi seropositivity KALRN intron 24324551 rs13087591 chr3 123824460 G A 3.54E-06 PR interval in Tripanosoma cruzi seropositivity KALRN intron 24324551 rs13067260 chr3 123824461 T G 2.00E-06 PR interval in Tripanosoma cruzi seropositivity KALRN intron 24324551 rs11714061 chr3 123825522 G A 1.66E-04 Amyotrophic lateral sclerosis KALRN intron 20801718 rs11714061 chr3 123825522 G A 4.57E-05 Body Mass Index KALRN intron pha003007 rs11714061 chr3 123825522 G A 5.02E-05 Body Fat Distribution KALRN intron pha003016 rs11714061 chr3 123825522 G A 1.01E-05 Waist Circumference KALRN intron pha003025 rs11714061 chr3 123825522 G A 2.43E-05 Insulin-related traits KALRN intron pha003063 rs1920625 chr3 123827286 C T 2.48E-06 PR interval in Tripanosoma cruzi seropositivity KALRN intron 24324551 rs9811597 chr3 123832697 G A 6.61E-04 Type 2 diabetes KALRN intron 17463246 rs1316375 chr3 123833614 G A 2.60E-04 Obesity (extreme) KALRN intron 21935397 rs10512620 chr3 123858749 C T 4.30E-04 Type 2 diabetes and 6 quantitative traits KALRN intron 17848626 rs1444767 chr3 123924803 T G 3.02E-04 Obesity (extreme) KALRN intron 21935397 rs1822791 chr3 123925295 A G 3.03E-04 Obesity (extreme) KALRN intron 21935397 rs2084017 chr3 123927948 T G 3.95E-04 Obesity (extreme) KALRN intron 21935397 rs6789134 chr3 123942339 A G 6.78E-10 Narcolepsy KALRN intron 19629137 rs1373609 chr3 123949529 C T 7.55E-05 Multiple complex diseases KALRN intron 17554300 rs1031156 chr3 123956712 G A 9.27E-05 Hypertension KALRN intron pha003041 rs13321072 chr3 123970864 T C 6.63E-04 Aortic root size KALRN intron 21223598 rs9880957 chr3 123979651 A G 3.34E-04 Schizophrenia KALRN intron 20832056 rs13078438 chr3 123982972 G A 2.51E-04 Obesity (extreme) KALRN intron 21935397 rs2276739 chr3 123983604 C T 2.56E-04 Obesity (extreme) KALRN intron 21935397 rs7636024 chr3 123985016 G T 5.18E-04 Schizophrenia KALRN intron 20832056 rs13064819 chr3 123986115 G C 2.80E-04 Obesity (extreme) KALRN intron 21935397 rs9868324 chr3 123989444 G A 2.85E-04 Obesity (extreme) KALRN intron 21935397 rs9812928 chr3 123989465 T G 2.85E-04 Obesity (extreme) KALRN intron 21935397 rs4420813 chr3 123990232 G A 4.93E-06 Multiple complex diseases KALRN intron 17554300 rs12695435 chr3 123990763 C T 2.88E-04 Obesity (extreme) KALRN intron 21935397 rs13100913 chr3 123992247 C A 2.90E-04 Obesity (extreme) KALRN intron 21935397 rs9819643 chr3 123994564 C G 2.92E-04 Obesity (extreme) KALRN intron 21935397 rs7610173 chr3 123996623 G A 2.03E-04 Obesity (extreme) KALRN intron 21935397 rs9813330 chr3 123998735 G T 3.04E-04 Obesity (extreme) KALRN intron 21935397 rs4634050 chr3 123999430 C A 3.05E-04 Obesity (extreme) KALRN intron 21935397 rs7628367 chr3 124005821 A G 3.26E-04 Obesity (extreme) KALRN intron 21935397 rs13076923 chr3 124015999 A G 3.62E-04 Obesity (extreme) KALRN intron 21935397 rs7623994 chr3 124016583 C A 3.65E-04 Obesity (extreme) KALRN intron 21935397 rs12695436 chr3 124017996 C T 3.67E-04 Obesity (extreme) KALRN intron 21935397 rs976634 chr3 124018422 T C 3.71E-04 Obesity (extreme) KALRN intron 21935397 rs4678107 chr3 124019387 T C 3.73E-04 Obesity (extreme) KALRN intron 21935397 rs9818967 chr3 124021862 A C 3.80E-04 Obesity (extreme) KALRN intron 21935397 rs9790193 chr3 124022223 G C 3.81E-04 Multiple complex diseases KALRN intron 17554300 rs4280578 chr3 124022742 G A 3.84E-04 Obesity (extreme) KALRN intron 21935397 rs1444752 chr3 124026558 T A 3.84E-04 Obesity (extreme) KALRN intron 21935397 rs6797486 chr3 124027499 C T 3.85E-04 Obesity (extreme) KALRN intron 21935397 rs6797788 chr3 124027773 C A 3.85E-04 Obesity (extreme) KALRN intron 21935397 rs9861401 chr3 124028225 G A 3.87E-04 Obesity (extreme) KALRN intron 21935397 rs13082414 chr3 124029662 G A 3.85E-04 Obesity (extreme) KALRN intron 21935397 rs6793443 chr3 124031727 G A 3.84E-04 Obesity (extreme) KALRN intron 21935397 rs3755659 chr3 124054964 C T 4.72E-05 Serum metabolites KALRN intron 19043545 rs7614068 chr3 124073040 G T 3.62E-04 Multiple complex diseases KALRN intron 17554300 rs492270 chr3 124084974 T A 9.23E-05 Serum metabolites KALRN intron 19043545 rs627830 chr3 124088009 A G 5.87E-05 Serum metabolites KALRN intron 19043545 rs1154799 chr3 124102176 C T 3.55E-05 Asthma KALRN intron 20920776 rs9832203 chr3 124102317 G T 9.88E-05 Asthma KALRN intron 20920776 rs17288804 chr3 124110560 A C 8.49E-05 Type 2 diabetes KALRN intron 17463246 rs3772744 chr3 124120819 T G 8.42E-05 Orofacial clefts KALRN intron 22419666 rs9289235 chr3 124154160 G C 9.31E-05 Serum metabolites KALRN intron 19043545 rs7653717 chr3 124154372 A G 9.31E-05 Serum metabolites KALRN intron 19043545 rs555540 chr3 124166965 G T 1.70E-04 Alcohol consumption (maxi-drinks) KALRN intron 24277619 rs1445637 chr3 124219712 C T 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes KALRN intron 22628534 rs16835545 chr3 124244479 G A 9.94E-04 Type 2 diabetes KALRN intron 17463246 rs2256831 chr3 124281980 T C 7.70E-04 Amyotrophic lateral sclerosis (sporadic) KALRN intron 24529757 rs986909 chr3 124283901 A G 0.0004992 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KALRN intron 23233654 rs986909 chr3 124283901 A G 4.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) KALRN intron 23233662 rs986911 chr3 124283993 A C 0.0005003 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KALRN intron 23233654 rs986911 chr3 124283993 A C 5.00E-04 Methotrexate clearance (acute lymphoblastic leukemia) KALRN intron 23233662 rs986912 chr3 124284055 G A 0.0004725 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KALRN intron 23233654 rs986912 chr3 124284055 G A 4.73E-04 Methotrexate clearance (acute lymphoblastic leukemia) KALRN intron 23233662 rs2651625 chr3 124284325 T C 1.84E-05 Body Mass Index KALRN intron pha003015 rs1995322 chr3 124284649 C T 0.0004668 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KALRN intron 23233654 rs1995322 chr3 124284649 C T 4.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) KALRN intron 23233662 rs7633134 chr3 124285048 C T 0.0004702 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KALRN intron 23233654 rs7633134 chr3 124285048 C T 4.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) KALRN intron 23233662 rs7633543 chr3 124285457 C T 0.000778 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KALRN intron 23233654 rs7633543 chr3 124285457 C T 7.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) KALRN intron 23233662 rs16835606 chr3 124288962 T C 0.0004692 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KALRN intron 23233654 rs16835606 chr3 124288962 T C 4.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) KALRN intron 23233662 rs13077090 chr3 124289287 A G 7.10E-05 Orofacial clefts KALRN intron 22419666 rs1501190 chr3 124289413 A T 0.0005361 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KALRN intron 23233654 rs1501190 chr3 124289413 A T 5.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) KALRN intron 23233662 rs1021748 chr3 124289574 C T 0.0005065 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KALRN intron 23233654 rs1021748 chr3 124289574 C T 5.07E-04 Methotrexate clearance (acute lymphoblastic leukemia) KALRN intron 23233662 rs1021749 chr3 124289632 A T 0.0005098 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KALRN intron 23233654 rs1021749 chr3 124289632 A T 5.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) KALRN intron 23233662 rs1532668 chr3 124290306 T C 0.0005039 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KALRN intron 23233654 rs1532668 chr3 124290306 T C 5.04E-04 Methotrexate clearance (acute lymphoblastic leukemia) KALRN intron 23233662 rs1021750 chr3 124290320 C G 0.000524 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KALRN intron 23233654 rs1021750 chr3 124290320 C G 5.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) KALRN intron 23233662 rs6438847 chr3 124297645 A C 3.02E-04 Alcohol dependence KALRN intron 24277619 rs6772598 chr3 124299968 C T 9.60E-04 Multiple complex diseases KALRN intron 17554300 rs2010099 chr3 124300257 C T 3.00E-08 Thyroid peroxidase antibody levels KALRN intron 24586183 rs4678137 chr3 124300765 G A 9.23E-04 Multiple complex diseases KALRN intron 17554300 rs6797559 chr3 124318900 T G 2.85E-05 Orofacial clefts KALRN intron 22419666 rs13066544 chr3 124322816 G A 8.46E-05 Orofacial clefts KALRN intron 22419666 rs333243 chr3 124323168 A G 9.30E-06 Body Mass Index KALRN intron pha003015 rs12493681 chr3 124323326 G C 3.53E-04 Multiple complex diseases KALRN intron 17554300 rs7626419 chr3 124323346 C T 9.30E-06 Body Mass Index KALRN intron pha003015 rs333338 chr3 124326801 G T 3.64E-05 Body Mass Index KALRN intron pha003015 rs1561579 chr3 124328633 A T 2.39E-04 Glycosylated haemoglobin levels KALRN intron 17255346 rs10934675 chr3 124330316 A G 6.36E-04 Multiple complex diseases KALRN intron 17554300 rs10934675 chr3 124330316 A G 9.66E-06 Body Mass Index KALRN intron pha003015 rs16835717 chr3 124330415 A T 6.24E-04 Multiple complex diseases KALRN intron 17554300 rs10512627 chr3 124340222 G C 5.00E-10 Mean platelet volume KALRN intron 22139419 rs10512627 chr3 124340222 G C 9.00E-05 Mean platelet volume KALRN intron 24026423 rs1708303 chr3 124351316 G A 9.38E-05 Multiple complex diseases KALRN cds-synon 17554300 rs1660038 chr3 124351424 T A,C,G 7.44E-05 Multiple complex diseases KALRN cds-synon 17554300 rs652046 chr3 124352573 A G 6.12E-05 Multiple complex diseases KALRN intron 17554300 rs686507 chr3 124354607 A G 6.39E-05 Multiple complex diseases KALRN intron 17554300 rs686412 chr3 124354684 T C 8.93E-05 Multiple complex diseases KALRN intron 17554300 rs640766 chr3 124357902 C G 6.05E-04 Acute lung injury KALRN intron 22295056 rs2651604 chr3 124369211 A G 7.08E-04 Acute lung injury KALRN intron 22295056 rs1440146 chr3 124372103 T C 6.24E-04 Multiple complex diseases KALRN intron 17554300 rs333301 chr3 124377049 G C 1.02E-04 Multiple complex diseases KALRN intron 17554300 rs10804562 chr3 124377196 G A 2.16E-04 Breast cancer KALRN intron 21060860 rs333297 chr3 124378386 C G 2.14E-04 Multiple complex diseases KALRN intron 17554300 rs231601 chr3 124382676 A G 9.62E-05 Multiple complex diseases KALRN intron 17554300 rs231601 chr3 124382676 A G 9.60E-05 Myasthenia gravis KALRN intron 23055271 rs333354 chr3 124393610 A G 4.96E-05 Multiple complex diseases KALRN intron 17554300 rs821366 chr3 124404696 G A 8.61E-04 Type 2 diabetes KALRN intron 17463246 rs821366 chr3 124404696 G A 8.07E-04 Multiple complex diseases KALRN intron 17554300 rs17308266 chr3 124406098 C A 8.26E-05 Type 2 diabetes KALRN intron 17463246 rs333284 chr3 124412153 T C 1.57E-04 Graves' disease KALRN intron 21841780 rs3736388 chr3 124443522 T C 5.87E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs10934683 chr3 124453383 C T 7.79E-04 Type 2 diabetes UMPS intron 17463246 rs1801019 chr3 124456742 G C 1 Drug response to Fluorouracil UMPS missense 16818689 rs694897 chr3 124458816 C G 1.30E-05 Urinary metabolites UMPS intron 21572414 rs3772809 chr3 124462824 A G 0.00081 Prostate cancer UMPS missense 23555315 rs10934685 chr3 124466520 C T 8.25E-04 Type 2 diabetes UMPS UTR-3 17463246 rs614664 chr3 124486993 C A 6.73E-05 Airway hyperresponsiveness ITGB5 intron 23984888 rs3772827 chr3 124499685 C T 4.05E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) ITGB5 intron 23648065 rs702037 chr3 124500541 C G 5.48E-04 Type 2 diabetes ITGB5 intron 17463246 rs702036 chr3 124501072 A G 7.58E-05 Airway hyperresponsiveness ITGB5 intron 23984888 rs2291086 chr3 124515395 G A 6.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) ITGB5 cds-synon 23648065 rs2291089 chr3 124515636 C T 3.18E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) ITGB5 missense 23648065 rs848788 chr3 124528424 T C 1.30E-05 Airway hyperresponsiveness ITGB5 intron 23984888 rs6771896 chr3 124545750 G A 4.21E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) ITGB5 intron 23648065 rs6771896 chr3 124545750 G A 3.63E-04 Alcohol dependence ITGB5 intron 24277619 rs4677946 chr3 124546047 A G 6.17E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) ITGB5 intron 23648065 rs3772840 chr3 124550364 C T 8.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) ITGB5 intron 23648065 rs4141663 chr3 124551967 C T 2.80E-05 Urinary metabolites ITGB5 intron 21572414 rs4141663 chr3 124551967 C T 0.00000456 Major depressive disorder ITGB5 intron 22915352 rs3772853 chr3 124572219 G A 2.60E-05 Urinary metabolites ITGB5 intron 21572414 rs11928651 chr3 124577555 T C 2.50E-05 Urinary metabolites ITGB5 intron 21572414 rs6778643 chr3 124577826 C T 2.00E-05 Urinary metabolites ITGB5 intron 21572414 rs9813129 chr3 124587917 G T 1.00E-05 Urinary metabolites ITGB5 intron 21572414 rs1265646 chr3 124592700 A G 0.00039 Coronary artery calcification ITGB5 intron 23727086 rs10804563 chr3 124598499 T C 8.60E-06 Urinary metabolites ITGB5 intron 21572414 rs10804564 chr3 124598526 A G 2.20E-05 Urinary metabolites ITGB5 intron 21572414 rs4422355 chr3 124602882 G C 3.80E-06 Urinary metabolites ITGB5 intron 21572414 rs1007856 chr3 124604858 A G 2.40E-05 Urinary metabolites ITGB5 intron 21572414 rs7373878 chr3 124610238 G T 6.49E-08 Major depressive disorder / / 22915352 rs7373878 chr3 124610238 G T 1.50E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs7373878 chr3 124610238 G T 9.70E-04 Alcohol dependence / / 24277619 rs2270780 chr3 124632127 A G 3.33E-04 Smoking initiation MUC13 intron 24665060 rs16836194 chr3 124632279 G A 5.81E-04 Multiple complex diseases MUC13 intron 17554300 rs10804566 chr3 124649519 C T 2.00E-04 Cognitive impairment induced by topiramate MUC13 intron 22091778 rs9880945 chr3 124664036 A G 6.69E-04 Multiple complex diseases / / 17554300 rs7629502 chr3 124672813 G A 3.95E-04 Tourette syndrome / / 22889924 rs17237607 chr3 124687432 G A 2.73E-04 Smoking cessation HEG1 UTR-3 24665060 rs16836316 chr3 124688269 T C 5.16E-04 Body mass index HEG1 UTR-3 21701565 rs6790780 chr3 124695684 T C 6.79E-04 Body mass index HEG1 intron 21701565 rs6763492 chr3 124702008 C A 7.80E-04 Body mass index HEG1 intron 21701565 rs7629166 chr3 124713340 G T 3.64E-04 Body mass index HEG1 intron 21701565 rs6795558 chr3 124721503 C T 3.79E-04 Body mass index HEG1 intron 21701565 rs6795558 chr3 124721503 C T 4.33E-05 Body mass index HEG1 intron 21701565 rs6796048 chr3 124721791 G A 8.22E-04 Multiple complex diseases HEG1 intron 17554300 rs6796048 chr3 124721791 G A 1.02E-04 Body mass index HEG1 intron 21701565 rs6796048 chr3 124721791 G A 3.48E-05 Body mass index HEG1 intron 21701565 rs4679232 chr3 124730132 T C 7.22E-05 Lung cancer HEG1 intron 18978787 rs7611514 chr3 124756667 G C 4.02E-05 Kawasaki disease HEG1 intron 22446961 rs4679258 chr3 124756771 C T 0.0003658 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) HEG1 intron 23233654 rs4679258 chr3 124756771 C T 3.66E-04 Methotrexate clearance (acute lymphoblastic leukemia) HEG1 intron 23233662 rs1574733 chr3 124757318 T C 9.52E-05 Sudden cardiac arrest HEG1 intron 21658281 rs1574733 chr3 124757318 T C 7.52E-04 Taste perception HEG1 intron 22132133 rs2981534 chr3 124764110 A G 3.26E-04 Premature ovarian failure HEG1 intron 19508998 rs2981496 chr3 124788013 G A 1.94E-05 Eosinophil counts / / pha003088 rs2981493 chr3 124789658 A C 1.71E-05 Eosinophil counts / / pha003088 rs2948821 chr3 124792303 T C 2.53E-05 Eosinophil counts / / pha003088 rs2981486 chr3 124801799 G A 2.35E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC12A8 UTR-3 20877124 rs2688992 chr3 124805610 A C 8.21E-04 Body mass index SLC12A8 intron 21701565 rs2688994 chr3 124818093 G A 9.69E-04 Tourette syndrome SLC12A8 intron 22889924 rs2948798 chr3 124820822 C T 5.75E-06 Triglycerides SLC12A8 intron pha003080 rs2945118 chr3 124843489 C T 4.09E-05 Bipolar disorder SLC12A8 intron 21771265 rs2981514 chr3 124844922 T G 4.09E-05 Bipolar disorder SLC12A8 intron 21771265 rs2981503 chr3 124854636 A T 2.00E-04 Cardiovascular disease adverse events in renal patients treated with calcineurin inhibitors SLC12A8 intron 16155738 rs2981503 chr3 124854636 A T 3.92E-05 Pulmonary function SLC12A8 intron 20010835 rs673693 chr3 124859482 C T 7.14E-04 Alzheimer's disease SLC12A8 intron 17998437 rs6764841 chr3 124869548 A G 8.86E-05 Blood pressure SLC12A8 intron 17255346 rs679990 chr3 124869928 C T 4.47E-04 Amyotrophic lateral sclerosis (sporadic) SLC12A8 intron 24529757 rs16836571 chr3 124876757 T G 6.74E-04 Type 2 diabetes SLC12A8 intron 17463246 rs587926 chr3 124883086 C A,T 5.46E-04 Type 2 diabetes SLC12A8 intron 17463246 rs587926 chr3 124883086 C A,T 2.11E-04 Multiple complex diseases SLC12A8 intron 17554300 rs6763338 chr3 124887233 C A 6.73E-04 Nicotine dependence SLC12A8 intron 17158188 rs545103 chr3 124896861 C G 1.63E-05 Alzheimer's disease SLC12A8 intron 17998437 rs1708332 chr3 124904631 T C 2.84E-05 Type 2 diabetes SLC12A8 intron 17463246 rs13101034 chr3 124923381 A C 2.50E-05 Urinary metabolites SLC12A8 intron 21572414 rs560015 chr3 124923586 G A 2.00E-05 Urinary metabolites SLC12A8 intron 21572414 rs1712468 chr3 124928422 A T 8.50E-06 Urinary metabolites SLC12A8 intron 21572414 rs9832863 chr3 124929748 T C 7.90E-06 Urinary metabolites SLC12A8 intron 21572414 rs6438885 chr3 124960842 C T 5.20E-04 Multiple complex diseases ZNF148 intron 17554300 rs6438885 chr3 124960842 C T 3.84E-07 Lymphocyte counts ZNF148 intron 22286170 rs6772299 chr3 124990027 C A 7.35E-04 Multiple complex diseases ZNF148 intron 17554300 rs1999919 chr3 124990545 G T 4.41E-04 Multiple complex diseases ZNF148 intron 17554300 rs6781706 chr3 124990888 A G 7.26E-04 Multiple complex diseases ZNF148 intron 17554300 rs2039718 chr3 125003517 C A 5.95E-04 Multiple complex diseases ZNF148 intron 17554300 rs1869673 chr3 125006520 T C 5.43E-04 Multiple complex diseases ZNF148 intron 17554300 rs9850300 chr3 125008177 T C 4.97E-04 Multiple complex diseases ZNF148 intron 17554300 rs1817183 chr3 125027314 G A 8.38E-04 Multiple complex diseases ZNF148 intron 17554300 rs7612285 chr3 125028360 C A 6.67E-04 Multiple complex diseases ZNF148 intron 17554300 rs4679382 chr3 125028649 C T 6.55E-04 Multiple complex diseases ZNF148 intron 17554300 rs1975760 chr3 125030381 T C 4.94E-04 Multiple complex diseases ZNF148 intron 17554300 rs7642600 chr3 125036353 A C 6.84E-04 Multiple complex diseases ZNF148 intron 17554300 rs7620790 chr3 125036369 G A 1.88E-04 Multiple complex diseases ZNF148 intron 17554300 rs11711167 chr3 125039019 C T 6.00E-04 Type 2 diabetes ZNF148 intron 21874001 rs9289250 chr3 125067174 G C 9.65E-04 Multiple complex diseases ZNF148 intron 17554300 rs9809356 chr3 125129489 C T 3.44E-04 Type 2 diabetes / / 17463246 rs4679393 chr3 125154388 C T 9.56E-05 Cognitive impairment induced by topiramate / / 22091778 rs2333223 chr3 125166035 G C 9.47E-04 Suicide attempts in bipolar disorder SNX4 UTR-3 21423239 rs16836828 chr3 125169672 C T 6.28E-05 Major depressive disorder (broad) SNX4 intron 20038947 rs9841525 chr3 125246363 C T 3.98E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs16836892 chr3 125309954 T C 8.52E-05 Major depressive disorder (broad) OSBPL11 intron 20038947 rs16836899 chr3 125312100 C T 9.07E-05 Major depressive disorder (broad) OSBPL11 intron 20038947 rs146199292 chr3 125313552 G T 1.16E-10 Body mass index OSBPL11 missense 23555315 rs1055419 chr3 125313832 G A 9.76E-05 Major depressive disorder (broad) OSBPL11 UTR-5 20038947 rs9830176 chr3 125338880 G A 3.02E-06 Serum metabolites / / 19043545 rs4328760 chr3 125376108 G A 3.22E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11717181 chr3 125376982 T G 2.45E-04 Type 2 diabetes / / 17463246 rs2979342 chr3 125407689 T A 1.75E-04 Type 2 diabetes / / 17463246 rs2979375 chr3 125414766 A G 2.94E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2979359 chr3 125419772 G A 2.61E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2735247 chr3 125477762 A G 8.89E-06 Type 2 diabetes / / 17463246 rs4422259 chr3 125545831 C T 3.43E-04 Multiple complex diseases / / 17554300 rs71327718 chr3 125592857 C G 7.00E-06 Metabolite levels (HVA/5-HIAA ratio) LOC100131679 intron 23319000 rs6804367 chr3 125639911 C T 1.91E-04 Cocaine dependence LOC100125556 intron 23958962 rs3828357 chr3 125648356 T C 0.00013 Stroke ALG1L missense 23422753 rs7630575 chr3 125682330 A G 3.51E-04 Heart Failure / / pha002884 rs2003334 chr3 125822003 C T 4.80E-16 Progranulin levels ALDH1L1 nearGene-3 21087763 rs2003334 chr3 125822003 C T 4.80E-16 Myocardial infarction ALDH1L1 nearGene-3 21211798 rs4646759 chr3 125822946 G C 4.10E-04 Alzheimer's disease (late onset) ALDH1L1 intron 21379329 rs1127717 chr3 125826059 T C 4.65E-04 Alzheimer's disease (late onset) ALDH1L1 missense 21379329 rs1127717 chr3 125826059 T C 0.0000808 Type 2 diabetes ALDH1L1 missense 22325160 rs4646748 chr3 125826329 G A 1.50E-04 Alzheimer's disease (late onset) ALDH1L1 intron 21379329 rs2886059 chr3 125865766 C A 1.23E-04 Arthritis (juvenile idiopathic) ALDH1L1 missense 22354554 rs3821450 chr3 125870708 C T 7.76E-04 Suicide attempts in bipolar disorder ALDH1L1 intron 21423239 rs4521172 chr3 125883511 C T 2.40E-04 Response to alcohol consumption (flushing response) ALDH1L1 intron 24277619 rs7617733 chr3 125890744 G A 3.47E-04 Alcohol consumption (maxi-drinks) ALDH1L1 intron 24277619 rs9842910 chr3 125896572 G A 5.89E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ALDH1L1 intron 20031582 rs114542799 chr3 125900953 G A 5.00E-06 PR interval in Tripanosoma cruzi seropositivity ALDH1L1-AS2 intron 24324551 rs9874508 chr3 125902417 G A 2.37E-04 Alcohol consumption (maxi-drinks) ALDH1L1-AS2 intron 24277619 rs1107366 chr3 125904165 A G 2.00E-06 Metabolite levels (Glycine metabolism) ALDH1L1-AS2 intron 23378610 rs10934753 chr3 125906179 G A 7.00E-13 Plasma homocysteine levels (post-methionine load test) ALDH1L1-AS2 intron 24651765 rs13082246 chr3 125910955 G A 7.62E-04 Alcohol consumption (maxi-drinks) ALDH1L1-AS2 intron 24277619 rs4459845 chr3 125917628 A C 2.30E-05 Lipid traits ALDH1L1-AS2 intron 17903299 rs6793040 chr3 125919839 A C 0.000727 Salmonella-induced pyroptosis ALDH1L1-AS2 intron 22837397 rs4374483 chr3 125920064 G A 3.57E-05 Attention deficit hyperactivity disorder ALDH1L1-AS2 intron 20732627 rs16837262 chr3 125923783 C G 9.32E-04 Type 2 diabetes ALDH1L1-AS2 intron 17463246 rs9822040 chr3 125927761 G A 1.50E-04 Parkinson's disease / / 17052657 rs11924509 chr3 125934221 G A 1.56E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs16837293 chr3 125935921 T G 0.0000029 Dependent (behavior influenced) stressful life events / / 23237013 rs10470318 chr3 125983084 A G 1.80E-05 Lung adenocarcinoma / / 22797724 rs10470321 chr3 125983428 A G 0.000455 Salmonella-induced pyroptosis / / 22837397 rs10470322 chr3 125983610 A C 0.000655 Salmonella-induced pyroptosis / / 22837397 rs9825772 chr3 125987924 G A 0.000177942 Hypertension (early onset hypertension) LOC644662 intron 22479346 rs6809287 chr3 125990463 A G 5.00E-05 Lung adenocarcinoma LOC644662 intron 22797724 rs4679115 chr3 125997198 C T 8.07E-05 Schizophrenia LOC644662 intron 24253340 rs2280158 chr3 126010000 T C 5.17E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC644662 UTR-3 20877124 rs9821733 chr3 126015667 A G 3.16E-05 Cognitive impairment induced by topiramate / / 22091778 rs7614306 chr3 126025195 G A 9.52E-04 Type 2 diabetes / / 17463246 rs11916543 chr3 126027431 G T 2.30E-05 Urinary metabolites / / 21572414 rs9851868 chr3 126033522 G A 8.95E-05 Schizophrenia / / 19571809 rs9851868 chr3 126033522 G A 2.63E-05 Schizophrenia / / pha002859 rs6802920 chr3 126037221 T C 4.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9854816 chr3 126039033 G A 8.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs938389 chr3 126058762 G A 8.75E-04 Multiple complex diseases / / 17554300 rs6791445 chr3 126142871 G A 5.93E-05 Insulin-related traits CCDC37 intron pha003063 rs13099144 chr3 126153361 T C 2.56E-05 Insulin-related traits CCDC37 intron pha003063 rs1799404 chr3 126158622 A C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ZXDC intron 22628534 rs777498 chr3 126189000 C A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ZXDC intron 22628534 rs9844797 chr3 126220539 A G 4.49E-05 F-cell distribution UROC1 intron 21326311 rs3108333 chr3 126222207 G C 5.69E-04 Response to taxane treatment (placlitaxel) UROC1 intron 23006423 rs16837531 chr3 126227185 G A 0.0000302 Panic disorder UROC1 intron 23149450 rs16837531 chr3 126227185 G A 3.02E-05 Serum tamsulosin hydrochloride concentration UROC1 intron 23151678 rs1873388 chr3 126228953 G A 1.63E-04 Celiac disease UROC1 intron 23936387 rs777488 chr3 126230388 T C 2.09E-04 Celiac disease UROC1 intron 23936387 rs1873392 chr3 126269316 A C 2.58E-04 Amyotrophic lateral sclerosis (sporadic) C3orf22 intron 24529757 rs2363947 chr3 126287440 G A 8.46E-05 Cognitive test performance / / 20125193 rs777217 chr3 126298935 C T 6.38E-05 Major depressive disorder (broad) TXNRD3NB intron 20038947 rs777230 chr3 126304038 C T 9.99E-05 Major depressive disorder (broad) TXNRD3NB intron 20038947 rs708908 chr3 126321546 C T 3.71E-05 Major depressive disorder (broad) TXNRD3NB intron 20038947 rs777228 chr3 126323221 G T 7.23E-05 Major depressive disorder (broad) TXNRD3NB intron 20038947 rs777241 chr3 126329910 A G 1.41E-06 Esophageal cancer (squamous cell) / / 22960999 rs777240 chr3 126330242 A G 7.48E-05 Major depressive disorder (broad) TXNRD3 intron 20038947 rs796574 chr3 126330765 A G 7.59E-05 Major depressive disorder (broad) TXNRD3 intron 20038947 rs4147483 chr3 126334860 G A 7.82E-04 Alzheimer's disease TXNRD3 intron 24755620 rs1716617 chr3 126334872 A G 7.95E-05 Major depressive disorder (broad) TXNRD3 intron 20038947 rs951739 chr3 126425661 C T 1.84E-04 Blood pressure CHCHD6 intron 17255346 rs4679286 chr3 126440014 G A 1.02E-04 Blood pressure CHCHD6 intron 17255346 rs13313873 chr3 126451229 G T 8.74E-05 Blood pressure CHCHD6 intron 17255346 rs2272487 chr3 126451937 G T 5.40E-05 Blood pressure CHCHD6 missense 17255346 rs999215 chr3 126453835 G A 1.13E-04 Blood pressure CHCHD6 intron 17255346 rs11718344 chr3 126466465 A G 1.47E-04 Iron levels CHCHD6 intron pha002876 rs4679131 chr3 126501279 T C 3.15E-04 Blood pressure CHCHD6 intron 17255346 rs4679293 chr3 126504141 G A 2.75E-04 Blood pressure CHCHD6 intron 17255346 rs16837750 chr3 126595001 A G 5.64E-04 Multiple complex diseases CHCHD6 intron 17554300 rs9872353 chr3 126623316 T C 2.16E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CHCHD6 intron 24023788 rs16837814 chr3 126634254 G A 1.59E-04 Multiple complex diseases CHCHD6 intron 17554300 rs4679316 chr3 126685000 A G 4.26E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs17751931 chr3 126756490 G A 7.74E-04 Iron levels / / pha002876 rs919662 chr3 126772366 A G 8.85E-04 Type 2 diabetes / / 17463246 rs6775019 chr3 126782635 C T 7.60E-04 Alzheimer's disease / / 24755620 rs11921451 chr3 126787159 G T 5.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9843758 chr3 126787276 G A 4.00E-05 Prostate cancer / / 21743057 rs9848844 chr3 126788323 C T 4.00E-05 Prostate cancer / / 21743057 rs9848844 chr3 126788323 C T 4.87E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs13318335 chr3 126792461 A T 4.00E-05 Prostate cancer / / 21743057 rs16837992 chr3 126816310 A G 4.38E-04 Coronary heart disease / / 21971053 rs4679336 chr3 126817583 T C 5.18E-04 Multiple complex diseases / / 17554300 rs12490229 chr3 126841978 T C 1.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12492133 chr3 126844168 T C 1.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9681359 chr3 126899748 T C 6.31E-05 Femoral neck bone geometry / / 22087292 rs9827714 chr3 126900492 T C 6.90E-06 Bone mineral density (BMD),in women / / 20164292 rs11710590 chr3 126901114 T C 7.87E-05 Post-operative nausea and vomiting / / 21694509 rs11915684 chr3 126917430 C T 3.50E-05 Diabetic nephropathy / / 20347642 rs11915684 chr3 126917430 C T 3.50E-05 Diabetic nephropathy / / pha002864 rs11716691 chr3 126931173 G A 8.16E-04 Multiple complex diseases / / 17554300 rs4679351 chr3 126933242 G A 2.42E-04 Alzheimer's disease / / 17998437 rs4679351 chr3 126933242 G A 1.81E-04 Alzheimer's disease / / pha002879 rs7616053 chr3 126934437 A G 3.52E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6809319 chr3 126935129 T G 3.63E-04 Alzheimer's disease / / 17998437 rs6809319 chr3 126935129 T G 2.64E-04 Alzheimer's disease / / pha002879 rs13095826 chr3 126942965 T G 4.49E-06 Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel) / / 24025145 rs1994128 chr3 126945750 T C 4.43E-06 Total ventricular volume / / 21116278 rs4679354 chr3 126947703 G A 9.40E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11925520 chr3 126949354 A G 4.89E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4234284 chr3 126950126 G A 1.52E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4234284 chr3 126950126 G A 3.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel) / / 24025145 rs959035 chr3 126956698 C A 6.63E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs13075436 chr3 126961148 C T 6.00E-06 Response to angiotensin II receptor blocker therapy / / 22566498 rs9871760 chr3 126993099 C A 4.00E-06 MRI atrophy measures / / 21116278 rs9871760 chr3 126993099 C A 4.12E-05 Glucose levels / / pha002899 rs9826609 chr3 127003972 C T 0.0000116 Major depressive disorder / / 23149448 rs6439066 chr3 127081929 G A 3.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs11710178 chr3 127097896 A G 4.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs4679364 chr3 127116269 C T 6.73E-05 Type 2 diabetes / / 17463246 rs9876080 chr3 127122272 A G 2.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs2594228 chr3 127125439 G A 1.00E-04 Prostate cancer / / 21743057 rs10804580 chr3 127125589 C T 4.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs6800029 chr3 127171794 C G 3.40E-05 Serum metabolites / / 19043545 rs9858161 chr3 127191375 C T 8.39E-05 Cognitive test performance / / 20125193 rs2720240 chr3 127247374 G A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2594207 chr3 127258150 G T 8.50E-04 Type 2 diabetes / / 17463246 rs4974444 chr3 127280969 G A 7.16E-04 Type 2 diabetes / / 17463246 rs3087452 chr3 127318358 T G 1.80E-27 Health and aging,CVD and cancer age of onset MCM2 missense 22174011 rs3087452 chr3 127318358 T G 2.60E-17 Health and aging,CVD and cancer age of onset MCM2 missense 22174011 rs3087452 chr3 127318358 T G 2.80E-09 Health and aging,CVD and cancer age of onset MCM2 missense 22174011 rs3087452 chr3 127318358 T G 6.80E-46 Health and aging,CVD and cancer age of onset MCM2 missense 22174011 rs7609914 chr3 127416243 C A 2.30E-05 Urinary metabolites MGLL intron 21572414 rs484061 chr3 127435561 G A 9.78E-04 Amyotrophic Lateral Sclerosis MGLL intron 17362836 rs3773159 chr3 127438938 C T 2.64E-07 Type 2 diabetes MGLL intron 21799836 rs796701 chr3 127452273 T C 1.99E-04 Body mass index MGLL intron 21701565 rs796701 chr3 127452273 T C 7.27E-04 Body mass index MGLL intron 21701565 rs7651814 chr3 127470166 C T 8.88E-05 C-Reactive Protein MGLL intron pha003070 rs664910 chr3 127474030 G A 1.27E-04 Amyotrophic Lateral Sclerosis MGLL intron 17827064 rs664910 chr3 127474030 G A 7.00E-09 Venous thromboembolism (gene x gene interaction) MGLL intron 23509962 rs7653663 chr3 127475626 G A 2.39E-05 Amyotrophic Lateral Sclerosis MGLL intron 17827064 rs9832418 chr3 127478666 T C 3.69E-05 Response to cytidine analogues (gemcitabine) MGLL intron 24483146 rs664954 chr3 127481318 T C 8.80E-04 Response to taxane treatment (placlitaxel) MGLL intron 23006423 rs664095 chr3 127481508 G C 2.70E-05 Urinary metabolites MGLL intron 21572414 rs541042 chr3 127484431 C T 2.10E-05 Urinary metabolites MGLL intron 21572414 rs541042 chr3 127484431 C T 7.98E-05 Arthritis (juvenile idiopathic) MGLL intron 22354554 rs9869280 chr3 127494587 C A,T 4.41E-04 Multiple complex diseases MGLL intron 17554300 rs9836225 chr3 127516394 C T 4.03E-09 HDL cholesterol MGLL intron 23063622 rs9836225 chr3 127516394 C T 9.20E-10 Cholesterol,total MGLL intron 23063622 rs16835913 chr3 127522132 G A 2.09E-04 Bipolar disorder MGLL intron 18317468 rs1525855 chr3 127548479 G A 8.29E-05 Alcohol dependence / / 21314694 rs11716997 chr3 127551630 G T 4.44E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6763775 chr3 127576515 C G 7.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs7633928 chr3 127577328 A G 7.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs10934830 chr3 127612826 G T 0.00001912 Sarcoidosis / / 22952805 rs7640916 chr3 127616295 T C 5.77E-05 Hemoglobin / / pha003098 rs6783960 chr3 127616342 G A 8.20E-05 Major depressive disorder / / 21042317 rs6783960 chr3 127616342 G A 4.79E-05 Hemoglobin / / pha003098 rs13086734 chr3 127643953 T C 6.34E-05 Cognitive test performance KBTBD12 intron 20125193 rs2053016 chr3 127645188 T C 2.40E-05 Endometriosis KBTBD12 intron 21151130 rs2195914 chr3 127674313 T C 5.92E-05 Cognitive impairment induced by topiramate KBTBD12 intron 22091778 rs16839633 chr3 127693417 C T 1.00E-04 Cognitive impairment induced by topiramate KBTBD12 intron 22091778 rs16839675 chr3 127694583 C T 1.54E-04 Type 2 diabetes KBTBD12 intron 17463246 rs11712112 chr3 127742365 G A 8.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs9849210 chr3 127779633 G T 6.33E-04 Amyotrophic lateral sclerosis (sporadic) SEC61A1 intron 24529757 rs11714256 chr3 127804368 G A 8.85E-04 Amyotrophic lateral sclerosis (sporadic) RUVBL1 intron 24529757 rs11716941 chr3 127875374 A G 5.24E-04 Alzheimer's disease EEFSEC intron 17998437 rs2687729 chr3 127895226 A G 1.00E-07 Menarche (age at onset) EEFSEC intron 21102462 rs2999090 chr3 127931340 G A 3.88E-04 Alcohol dependence EEFSEC intron 21314694 rs2999081 chr3 127956272 A G 8.61E-04 Depression (quantitative trait) EEFSEC intron 20800221 rs17343355 chr3 127966791 C T 0.00062 Endometrial cancer EEFSEC intron 22426144 rs2955095 chr3 127977665 A T 9.67E-04 Alzheimer's disease EEFSEC intron 17998437 rs10934853 chr3 128038373 C A 5.23E-05 Schizophrenia EEFSEC intron 19197363 rs10934853 chr3 128038373 C A 3.00E-10 Prostate cancer EEFSEC intron 19767754 rs10934853 chr3 128038373 C A 3.00E-10 Nasopharyngeal carcinoma EEFSEC intron 20512145 rs4857879 chr3 128064118 A C 0.00071 Endometrial cancer EEFSEC intron 22426144 rs1735538 chr3 128092102 A G 1.50E-04 Breast cancer (survival) EEFSEC intron 22232737 rs3021461 chr3 128095652 T C 3.18E-05 Schizophrenia EEFSEC intron 19197363 rs2293947 chr3 128097496 A C 5.45E-04 Schizophrenia EEFSEC intron 19197363 rs1735537 chr3 128122820 T C 2.18E-04 Schizophrenia EEFSEC intron 19197363 rs7612413 chr3 128127805 T C 0.00084 Prostate cancer / / 23555315 rs2981030 chr3 128149590 A G 3.69E-04 Heart Failure / / pha002884 rs12491486 chr3 128162235 A C 7.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs9855048 chr3 128163890 A G 2.80E-05 Diabetic retinopathy / / 21441570 rs4857894 chr3 128168037 G C 4.82E-05 Intracerebral hemorrhage / / 24656865 rs2659703 chr3 128169862 G A 3.00E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2953128 chr3 128189572 C T 9.64E-05 Serum metabolites D/JB8-AS1 intron 19043545 rs7431368 chr3 128190941 C A 3.86E-05 Parkinson's disease (motor and cognition) / / 22658654 rs7431368 chr3 128190941 C A 3.86E-05 Immune response to anthrax vaccine / / 22658931 rs2713590 chr3 128192796 C A 7.32E-05 Parkinson's disease (motor and cognition) / / 22658654 rs2713590 chr3 128192796 C A 7.32E-05 Immune response to anthrax vaccine / / 22658931 rs11718692 chr3 128195814 G T 0.000452527 Hypertension (early onset hypertension) / / 22479346 rs2713594 chr3 128196500 G A 5.97E-05 Body Mass Index / / pha003009 rs3803 chr3 128199380 G A 0.000480305 Hypertension (early onset hypertension) GATA2 UTR-3 22479346 rs2713604 chr3 128200459 T C 3.50E-05 Elbow pain GATA2 intron pha003008 rs2335052 chr3 128204951 C T 3.40E-05 Prostate cancer GATA2 missense 23023329 rs2335052 chr3 128204951 C T 2.37E-04 Stroke GATA2 missense pha002887 rs2860228 chr3 128209667 C T 6.92E-05 Information processing speed GATA2 intron 21130836 rs6789646 chr3 128215775 T C 7.33E-05 Information processing speed LOC100506995 intron 21130836 rs2659695 chr3 128229571 G A 4.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs6769565 chr3 128243631 G A 9.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs4857855 chr3 128260550 C T 9.00E-17 Eosinophil counts / / 19198610 rs4857855 chr3 128260550 C T 0.00027 Prostate cancer / / 23555315 rs4857855 chr3 128260550 C T 0.00048 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs9850534 chr3 128272081 T C 9.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6806253 chr3 128282697 A G 6.00E-06 Pit-and-Fissure caries / / 23470693 rs9880192 chr3 128297569 G C 6.00E-13 White blood cell count / / 21738480 rs4328821 chr3 128316435 A G 3.00E-17 White blood cell types / / 21738478 rs4328821 chr3 128316435 A G 5.00E-40 White blood cell types / / 21738478 rs4328821 chr3 128316435 A G 4.00E-13 White blood cell count / / 21738480 rs2253144 chr3 128329920 A G 1.00E-04 Prostate cancer / / 21743057 rs13325747 chr3 128336023 G A 5.56E-04 Heart Failure / / pha002885 rs2712381 chr3 128338600 A C 2.00E-16 Monocyte counts / / 23314186 rs11712115 chr3 128404269 G A 5.99E-05 Eosinophil counts / / pha003088 rs9831813 chr3 128478542 G A 5.45E-05 Neutrophil count RAB7A intron pha003095 rs13081864 chr3 128490273 C T 8.88E-06 Erythrocyte counts RAB7A intron pha003101 rs3772158 chr3 128516142 A C 7.66E-05 Neutrophil count RAB7A intron pha003095 rs1994312 chr3 128527929 C T 7.54E-04 Multiple complex diseases RAB7A intron 17554300 rs9853945 chr3 128528630 A G 6.76E-05 Neutrophil count RAB7A intron pha003095 rs789254 chr3 128574593 C T 5.40E-05 Primary sclerosing cholangitis / / 19944697 rs789214 chr3 128594995 A G 9.59E-05 Leukocyte Counts / / pha003091 rs789233 chr3 128603150 G T 5.40E-05 Primary sclerosing cholangitis ACAD9 intron 19944697 rs1683787 chr3 128627021 A G 5.40E-05 Primary sclerosing cholangitis ACAD9 intron 19944697 rs9810890 chr3 128652553 C T 6.00E-06 Dental caries LOC100132731 intron 23064961 rs2933343 chr3 128658492 G A 8.00E-06 IgG glycosylation LOC100132731 intron 23382691 rs6771574 chr3 128703702 G A 6.59E-05 Information processing speed KIAA1257 intron 21130836 rs3732430 chr3 128755953 G A 9.66E-05 Information processing speed CCDC48 missense 21130836 rs6439154 chr3 128762833 G A 2.00E-04 Information processing speed / / 21130836 rs6439158 chr3 128959313 T C 7.29E-04 Multiple complex diseases / / 17554300 rs4927941 chr3 128983224 C T 6.51E-04 Multiple complex diseases COPG1 intron 17554300 rs10934876 chr3 128987899 T A 6.87E-04 Multiple complex diseases COPG1 intron 17554300 rs10934878 chr3 129012744 A G 7.08E-05 Parkinson's disease C3orf37 intron 21738487 rs7646150 chr3 129019245 G A 1.07E-04 Multiple complex diseases C3orf37 intron 17554300 rs4076437 chr3 129035969 T C 4.22E-05 Parkinson's disease / / 21738487 rs6439167 chr3 129050756 T C 9.00E-15 Height / / 20881960 rs6791509 chr3 129096909 T C 2.19E-04 Depression (quantitative trait) / / 20800221 rs6764325 chr3 129099871 A G 2.83E-04 Depression (quantitative trait) / / 20800221 rs12632105 chr3 129108435 G C 1.50E-05 Urinary metabolites RPL32P3 intron 21572414 rs16859047 chr3 129108935 C T 1.90E-05 Urinary metabolites RPL32P3 intron 21572414 rs16859134 chr3 129118583 T C 2.52E-04 Depression (quantitative trait) / / 20800221 rs7622524 chr3 129118922 A G 2.55E-04 Depression (quantitative trait) / / 20800221 rs7615711 chr3 129122292 A G 9.53E-04 Depression (quantitative trait) C3orf25 intron 20800221 rs4429625 chr3 129139320 A G 1.60E-05 Urinary metabolites C3orf25 intron 21572414 rs4128190 chr3 129142951 C G 2.67E-04 Depression (quantitative trait) C3orf25 intron 20800221 rs3138360 chr3 129151170 C T 2.02E-04 Depression (quantitative trait) MBD4 intron 20800221 rs2301570 chr3 129195663 C T 3.91E-05 Depression (quantitative trait) IFT122 intron 20800221 rs2285353 chr3 129210867 C A 3.27E-05 Depression (quantitative trait) IFT122 intron 20800221 rs2285354 chr3 129210977 G C 9.72E-04 Depression (quantitative trait) IFT122 intron 20800221 rs3774769 chr3 129212271 G A 3.84E-05 Depression (quantitative trait) IFT122 intron 20800221 rs6803484 chr3 129250326 G A 9.21E-05 Depression (quantitative trait) RHO intron 20800221 rs1078507 chr3 129262580 G T 9.65E-05 Depression (quantitative trait) H1FOO intron 20800221 rs1872111 chr3 129263140 A G 2.39E-05 Soluble levels of adhesion molecules H1FOO intron pha003072 rs6794108 chr3 129265192 A G 3.42E-04 Depression (quantitative trait) H1FOO intron 20800221 rs10934885 chr3 129298994 G T 2.10E-05 Homocysteine levels,in plasma PLXND1 intron 19525478 rs2301573 chr3 129305919 T C 3.68E-06 Waist-hip ratio PLXND1 intron 20935629 rs4688807 chr3 129309263 T C 5.34E-05 Multiple complex diseases PLXND1 intron 17554300 rs6792344 chr3 129317304 G C 4.23E-05 Multiple complex diseases PLXND1 intron 17554300 rs2626005 chr3 129321610 A G 7.41E-04 Multiple complex diseases PLXND1 intron 17554300 rs2811435 chr3 129339470 A G 1.14E-04 Multiple complex diseases / / 17554300 rs2811434 chr3 129339615 T G 1.06E-04 Multiple complex diseases / / 17554300 rs729208 chr3 129339642 G C 1.13E-04 Multiple complex diseases / / 17554300 rs2811332 chr3 129515128 G C 4.28E-06 Response to lithium treatment in bipolar disorder TMCC1 intron 21961650 rs6439200 chr3 129521807 G A 5.86E-04 Alzheimer's disease TMCC1 intron 17998437 rs6439200 chr3 129521807 G A 2.80E-05 Urinary metabolites TMCC1 intron 21572414 rs6439200 chr3 129521807 G A 6.88E-05 Lymphocyte counts TMCC1 intron 22286170 rs6439200 chr3 129521807 G A 9.88E-05 Esophageal cancer (squamous cell) TMCC1 intron 22960999 rs784734 chr3 129653682 G A 4.39E-05 Multiple complex diseases / / 17554300 rs784731 chr3 129654115 T A 4.84E-04 Multiple complex diseases / / 17554300 rs72628507 chr3 129690222 G A 0.00002482 Sarcoidosis / / 22952805 rs11921179 chr3 129695038 G A 9.53E-04 Multiple complex diseases TRH intron 17554300 rs11921179 chr3 129695038 G A 0.000000202 HDL cholesterol TRH intron 23063622 rs11921179 chr3 129695038 G A 3.22E-14 LDL cholesterol TRH intron 23063622 rs11921179 chr3 129695038 G A 5.47E-09 Cholesterol,total TRH intron 23063622 rs7355998 chr3 129766327 G A 4.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs57804141 chr3 129962512 C T 2.30E-06 Response to amphetamines COL6A4P2 intron 22952603 rs9864582 chr3 129970462 G A 2.43E-06 Response to amphetamines COL6A4P2 intron 22952603 rs9813712 chr3 129971101 T A 2.00E-06 Response to amphetamines COL6A4P2 intron 22952603 rs6439222 chr3 129975141 A C 4.65E-06 Response to amphetamines COL6A4P2 intron 22952603 rs6804874 chr3 129976048 C A 2.38E-06 Response to amphetamines COL6A4P2 intron 22952603 rs7619208 chr3 129977006 T G 9.34E-06 Response to amphetamines COL6A4P2 intron 22952603 rs10934930 chr3 129978407 T G 4.65E-06 Response to amphetamines COL6A4P2 intron 22952603 rs9883455 chr3 129978931 G A 3.41E-06 Response to amphetamines COL6A4P2 intron 22952603 rs10934931 chr3 129980208 C T 8.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL6A4P2 intron 20877124 rs9822192 chr3 129986907 C G 6.25E-04 Multiple complex diseases / / 17554300 rs4688871 chr3 129990413 A C 7.85E-04 Multiple complex diseases / / 17554300 rs13093343 chr3 129990672 A C 4.00E-04 Multiple complex diseases / / 17554300 rs9861868 chr3 130015554 G A 5.33E-06 Response to amphetamines / / 22952603 rs6790445 chr3 130019326 A G 7.33E-06 Response to amphetamines / / 22952603 rs7649424 chr3 130028717 A G 6.73E-04 Multiple complex diseases / / 17554300 rs7609940 chr3 130048207 C T 1.60E-05 Urinary metabolites / / 21572414 rs13314616 chr3 130050582 C A 1.98E-04 Type 2 diabetes / / 17463246 rs13095825 chr3 130066557 C T 4.55E-04 Multiple complex diseases COL6A5 intron 17554300 rs10934938 chr3 130113635 T G 1.59E-04 Lung function (forced expiratory volume in 1 second) COL6A5 intron 17255346 rs1353613 chr3 130114082 C G 4.62E-04 Response to cytidine analogues (gemcitabine) COL6A5 missense 24483146 rs1391056 chr3 130125350 A C 0.000734 Salmonella-induced pyroptosis COL6A5 intron 22837397 rs2219026 chr3 130132509 A G 3.44E-04 Lung function (forced expiratory volume in 1 second) COL6A5 intron 17255346 rs1391053 chr3 130132631 G C 3.44E-04 Lung function (forced expiratory volume in 1 second) COL6A5 intron 17255346 rs7628563 chr3 130134563 G A 2.48E-05 Height COL6A5 intron pha003011 rs1542829 chr3 130137471 G A 4.35E-09 Body mass index COL6A5 intron 24348519 rs12637622 chr3 130146963 G C 6.19E-05 Cognitive decline COL6A5 intron 22054870 rs1497305 chr3 130147388 G A 9.94E-04 Response to cytadine analogues (cytosine arabinoside) COL6A5 intron 24483146 rs11927775 chr3 130147914 C G,T 2.40E-04 Multiple complex diseases COL6A5 intron 17554300 rs11927775 chr3 130147914 C G,T 3.08E-04 Obesity (extreme) COL6A5 intron 21935397 rs7629719 chr3 130159934 G T 1.20E-07 Atopy COL6A5 intron 19961619 rs7629719 chr3 130159934 G T 9.96E-05 Height COL6A5 intron pha003011 rs1846030 chr3 130160461 A G 9.72E-06 Cognitive decline COL6A5 intron 22054870 rs9883988 chr3 130162395 A G 3.74E-05 Height COL6A5 missense pha003011 rs819085 chr3 130174334 G A 6.86E-05 Elbow pain COL6A5 missense pha003008 rs819085 chr3 130174334 G A 3.66E-05 Height COL6A5 missense pha003011 rs819079 chr3 130178066 A C 9.10E-06 Urinary metabolites COL6A5 intron 21572414 rs11719898 chr3 130203727 C T 6.72E-05 Cognitive decline COL6A5 nearGene-3 22054870 rs1391054 chr3 130207777 G A 7.10E-04 Coronary heart disease / / 21971053 rs16828872 chr3 130231509 T C 4.44E-04 Obesity (extreme) / / 21935397 rs16828872 chr3 130231509 T C 1.28E-05 Cognitive impairment induced by topiramate / / 22091778 rs11923817 chr3 130233917 G C 4.52E-04 Obesity (extreme) / / 21935397 rs6794690 chr3 130234550 T C 4.55E-04 Obesity (extreme) / / 21935397 rs4525833 chr3 130249728 T C 1.30E-05 Urinary metabolites / / 21572414 rs1396328 chr3 130255866 T A 1.90E-05 Urinary metabolites / / 21572414 rs4682618 chr3 130273269 C T 2.00E-05 Urinary metabolites / / 21572414 rs2174944 chr3 130277221 C T 1.70E-05 Urinary metabolites / / 21572414 rs9838052 chr3 130296680 C T 2.40E-04 Suicide attempts in bipolar disorder COL6A6 intron 21423239 rs6781724 chr3 130322553 A G 3.66E-05 Cognitive test performance COL6A6 intron 20125193 rs9823913 chr3 130346579 A G 3.47E-04 Multiple complex diseases COL6A6 intron 17554300 rs1396332 chr3 130346995 G A 4.70E-04 Multiple complex diseases COL6A6 intron 17554300 rs9849240 chr3 130354824 T C 6.60E-04 Multiple complex diseases COL6A6 intron 17554300 rs12489013 chr3 130356238 T A 9.12E-04 Multiple complex diseases COL6A6 intron 17554300 rs965122 chr3 130360904 A G 5.28E-04 Coronary Artery Disease COL6A6 intron 17634449 rs16830494 chr3 130361856 G A 9.50E-06 Urinary metabolites COL6A6 missense 21572414 rs1022033 chr3 130364523 T C 1.40E-05 Urinary metabolites COL6A6 intron 21572414 rs17748304 chr3 130370748 A G 7.40E-06 Urinary metabolites COL6A6 intron 21572414 rs16830716 chr3 130378213 A G 2.40E-05 Urinary metabolites COL6A6 intron 21572414 rs16845869 chr3 130477566 T G 1.85E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2090994 chr3 130481527 A G 6.90E-07 Urinary metabolites / / 21572414 rs1554513 chr3 130504256 A G 3.26E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs712984 chr3 130648798 A G 1.74E-04 Multiple complex diseases ATP2C1 intron 17554300 rs218498 chr3 130686917 C T 2.01E-04 Multiple complex diseases ATP2C1 intron 17554300 rs13076493 chr3 130730517 C T 3.34E-05 Anorexia nervosa ATP2C1 intron 23568457 rs7641006 chr3 130734061 C T 9.46E-04 Type 2 diabetes ATP2C1 intron 17463246 rs17330404 chr3 130742687 T C 6.51E-04 Type 2 diabetes ASTE1 intron 17463246 rs1389271 chr3 130785106 G T 2.90E-04 Multiple complex diseases NEK11 intron 17554300 rs9844721 chr3 130878640 T C 8.57E-06 Multiple complex diseases NEK11 intron 17554300 rs9842019 chr3 130899418 A G 8.54E-06 Multiple complex diseases NEK11 intron 17554300 rs10512802 chr3 130948009 G T 9.72E-04 Bipolar disorder NEK11 intron 19259986 rs16836269 chr3 131005070 C A 7.13E-04 Response to cytidine analogues (gemcitabine) NEK11 intron 24483146 rs2336820 chr3 131006658 G A 7.12E-04 Response to cytidine analogues (gemcitabine) NEK11 intron 24483146 rs748157 chr3 131041284 A G 1.13E-04 Multiple complex diseases NEK11 intron 17554300 rs9861674 chr3 131060915 G A 9.09E-05 Premature ovarian failure NEK11 intron 19508998 rs9861674 chr3 131060915 G A 9.09E-05 Other erythrocyte phenotypes NEK11 intron 19862010 rs16836493 chr3 131082104 T C 8.48E-04 Response to cytidine analogues (gemcitabine) NUDT16P1 intron 24483146 rs13091744 chr3 131199837 G A 4.23E-04 Iron levels MRPL3 intron pha002876 rs1843604 chr3 131237247 G A 4.40E-05 Parkinson's disease (age of onset) LOC100507134 intron 19772629 rs1054473 chr3 131239666 T C 5.34E-04 Smoking quantity / / 24665060 rs12639456 chr3 131276719 G A 1.71E-05 Myocardial Infarction CPNE4 intron pha002883 rs16837140 chr3 131290631 C T 8.48E-04 Iron levels CPNE4 intron pha002876 rs6439313 chr3 131372762 T A 5.80E-04 Alzheimer's disease CPNE4 intron 17998437 rs7613777 chr3 131389020 A G 9.03E-05 Triglycerides CPNE4 intron pha003080 rs9813969 chr3 131390490 A G 9.03E-05 Triglycerides CPNE4 intron pha003080 rs7627915 chr3 131401811 G A 9.72E-04 Multiple complex diseases CPNE4 intron 17554300 rs4854829 chr3 131406051 C A 7.39E-05 Multiple complex diseases CPNE4 intron 17554300 rs1393560 chr3 131408143 C T 1.15E-04 Multiple complex diseases CPNE4 intron 17554300 rs6769500 chr3 131414045 T C 6.63E-05 Cognitive impairment induced by topiramate CPNE4 intron 22091778 rs11714960 chr3 131427185 T G 5.00E-05 Cognitive impairment induced by topiramate CPNE4 intron 22091778 rs7636346 chr3 131430841 T C 5.29E-04 Type 2 diabetes CPNE4 intron 17463246 rs995540 chr3 131433077 C T 3.70E-04 HIV-1 viral setpoint CPNE4 intron 17641165 rs995540 chr3 131433077 C T 4.64E-05 Multiple sclerosis CPNE4 intron 17660530 rs9826951 chr3 131438446 A G 2.54E-04 Multiple complex diseases CPNE4 intron 17554300 rs6806286 chr3 131460188 T C 7.04E-04 Schizophrenia CPNE4 intron 19197363 rs9871139 chr3 131464259 C A 7.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CPNE4 intron 20877124 rs1398764 chr3 131481185 G C 9.59E-04 Multiple complex diseases CPNE4 intron 17554300 rs1913290 chr3 131481440 A T 8.74E-04 Bipolar disorder CPNE4 intron 19259986 rs1877587 chr3 131482204 T G 1.90E-06 Urinary metabolites CPNE4 intron 21572414 rs16837796 chr3 131482288 A C 1.06E-04 Smoking quantity CPNE4 intron 24665060 rs10512824 chr3 131484558 T C 2.95E-04 Smoking quantity CPNE4 intron 24665060 rs9828720 chr3 131486468 C A,T 3.93E-04 Amyotrophic lateral sclerosis (sporadic) CPNE4 intron 24529757 rs1355782 chr3 131487666 T C 3.83E-07 Osteoarthritis CPNE4 intron 22763110 rs1513382 chr3 131492106 A G 2.00E-06 Urinary metabolites CPNE4 intron 21572414 rs9810650 chr3 131493432 T C 2.20E-06 Urinary metabolites CPNE4 intron 21572414 rs9866365 chr3 131493730 C T 2.30E-06 Urinary metabolites CPNE4 intron 21572414 rs1355785 chr3 131503372 T C 0.000745075 Hypertension (early onset hypertension) CPNE4 intron 22479346 rs938241 chr3 131514365 A G 5.12E-04 Coronary Artery Disease CPNE4 intron 17634449 rs1543099 chr3 131519641 T C 5.18E-04 Response to taxane treatment (placlitaxel) CPNE4 intron 23006423 rs16837866 chr3 131535978 G A 4.40E-04 Smoking quantity CPNE4 intron 24665060 rs9855524 chr3 131537034 A T 1.30E-05 Urinary metabolites CPNE4 intron 21572414 rs9839168 chr3 131541029 C A 7.13E-04 Response to taxane treatment (placlitaxel) CPNE4 intron 23006423 rs4574338 chr3 131578501 G C 4.19E-04 Response to taxane treatment (placlitaxel) CPNE4 intron 23006423 rs1513378 chr3 131578561 C T 5.20E-04 Response to taxane treatment (placlitaxel) CPNE4 intron 23006423 rs1005996 chr3 131585137 C T 4.56E-04 Response to taxane treatment (placlitaxel) CPNE4 intron 23006423 rs1513376 chr3 131586635 G A 6.66E-04 Type 2 diabetes CPNE4 intron 17463246 rs1513376 chr3 131586635 G A 8.00E-04 Response to taxane treatment (placlitaxel) CPNE4 intron 23006423 rs1463518 chr3 131587773 C T 5.88E-04 Type 2 diabetes CPNE4 intron 17463246 rs1463518 chr3 131587773 C T 9.08E-04 Response to taxane treatment (placlitaxel) CPNE4 intron 23006423 rs6801798 chr3 131589085 T G 2.00E-05 Urinary metabolites CPNE4 intron 21572414 rs4107954 chr3 131592696 C A 3.83E-04 Response to taxane treatment (placlitaxel) CPNE4 intron 23006423 rs11921795 chr3 131593461 T C 5.12E-04 Response to taxane treatment (placlitaxel) CPNE4 intron 23006423 rs4345110 chr3 131595809 G A 5.35E-04 Type 2 diabetes CPNE4 intron 17463246 rs4345110 chr3 131595809 G A 6.84E-04 Response to taxane treatment (placlitaxel) CPNE4 intron 23006423 rs2199351 chr3 131607539 G A 9.44E-04 Response to taxane treatment (placlitaxel) CPNE4 intron 23006423 rs9837417 chr3 131610928 C G 2.70E-05 Urinary metabolites CPNE4 intron 21572414 rs1381074 chr3 131621088 G A 3.91E-04 Response to taxane treatment (placlitaxel) CPNE4 intron 23006423 rs1381073 chr3 131621309 A G 3.92E-04 Response to taxane treatment (placlitaxel) CPNE4 intron 23006423 rs11925138 chr3 131626048 G A 9.40E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CPNE4 intron 22566498 rs957919 chr3 131629716 C T 8.00E-04 Schizophrenia CPNE4 intron 19197363 rs6787286 chr3 131652142 C T 1.20E-04 Type 2 diabetes and 6 quantitative traits CPNE4 intron 17848626 rs1870712 chr3 131674718 C T 3.75E-04 Multiple complex diseases CPNE4 intron 17554300 rs748731 chr3 131693006 A G 1.29E-04 Taste perception CPNE4 intron 22132133 rs7617481 chr3 131706617 G C 5.78E-04 Type 2 diabetes CPNE4 intron 17463246 rs1320900 chr3 131713566 G T 7.00E-06 Amyotrophic lateral sclerosis CPNE4 intron 22959728 rs10512839 chr3 131730242 G A 5.00E-04 Type 2 diabetes and 6 quantitative traits CPNE4 intron 17848626 rs1122856 chr3 131733286 G A 2.30E-05 Angioedema in response to angiotensin-converting enzyme inhibitor CPNE4 intron 23838604 rs7623216 chr3 131744131 G C 5.95E-04 Multiple complex diseases CPNE4 intron 17554300 rs7623216 chr3 131744131 G C 2.50E-05 Urinary metabolites CPNE4 intron 21572414 rs1406773 chr3 131744779 G A 3.12E-04 Type 2 diabetes CPNE4 intron 17846124 rs1406773 chr3 131744779 G A 8.24E-05 Parkinson's disease CPNE4 intron 21738487 rs6790962 chr3 131748098 G A 3.32E-05 Asthma CPNE4 intron pha003128 rs1919986 chr3 131755360 C T 1.27E-04 Schizophrenia / / 20832056 rs16838395 chr3 131755693 G A 5.50E-05 Personality dimensions / / 18957941 rs3009511 chr3 131759457 C T 2.69E-05 Asthma / / pha003128 rs12634678 chr3 131775316 T G 1.19E-04 Alcohol dependence / / 21314694 rs9840453 chr3 131777465 G T 1.20E-05 Type 2 diabetes / / 24509480 rs1569280 chr3 131778754 C T 1.32E-04 Type 2 diabetes / / 17846124 rs10470437 chr3 131782733 A T 7.73E-04 Multiple complex diseases / / 17554300 rs11924777 chr3 131786302 C T 9.23E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2951398 chr3 131786594 C A 8.97E-04 Type 2 diabetes / / 17846124 rs9842509 chr3 131789864 A G 9.73E-04 Multiple complex diseases / / 17554300 rs9289415 chr3 131793628 G A 5.29E-04 Type 2 diabetes / / 17846124 rs6775745 chr3 131813900 G A 2.00E-07 Neutrophil count / / 21507922 rs1533747 chr3 131845893 A G 2.26E-06 Body mass index / / 19584900 rs1533747 chr3 131845893 A G 4.24E-05 Body mass index / / 19584900 rs11714053 chr3 131849410 C T 7.98E-05 Parkinson's disease / / 21812969 rs1521286 chr3 131854840 C T 3.65E-05 Cognitive impairment induced by topiramate / / 22091778 rs9864518 chr3 131882129 C T 4.98E-04 Multiple complex diseases / / 17554300 rs1505799 chr3 131907899 A C,G,T 9.92E-04 Multiple complex diseases / / 17554300 rs11710455 chr3 131916272 G T 7.45E-04 Type 2 diabetes / / 17463246 rs11710455 chr3 131916272 G T 2.14E-04 Multiple complex diseases / / 17554300 rs1316655 chr3 131921956 C A 7.45E-04 Type 2 diabetes / / 17463246 rs1316655 chr3 131921956 C A 2.10E-04 Multiple complex diseases / / 17554300 rs1827816 chr3 131924008 T G 2.38E-04 Multiple complex diseases / / 17554300 rs1847830 chr3 131931711 G T 8.57E-05 Fibrinogen / / pha003068 rs1505819 chr3 131938082 G A 9.50E-06 Urinary metabolites / / 21572414 rs10934991 chr3 131938708 C A 9.47E-04 Multiple complex diseases / / 17554300 rs10934992 chr3 131938895 C T 4.61E-04 Multiple complex diseases / / 17554300 rs1505825 chr3 131942935 A G 9.09E-04 Multiple complex diseases / / 17554300 rs11714139 chr3 131944637 G A 1.14E-05 Hypertension / / 19609347 rs9878957 chr3 131947937 A G 7.70E-04 Multiple complex diseases / / 17554300 rs6766469 chr3 131984240 A G 8.71E-04 Acute lung injury / / 22295056 rs924949 chr3 131984388 G A 5.33E-05 Alcohol dependence / / 21314694 rs3931393 chr3 132000576 T C 8.93E-04 Acute lung injury / / 22295056 rs1505829 chr3 132006118 A G 1.56E-04 Age-related macular degeneration / / 22125219 rs7611943 chr3 132006294 C T 7.45E-04 Type 2 diabetes / / 17463246 rs3905934 chr3 132007117 G A 9.68E-04 Acute lung injury / / 22295056 rs11706024 chr3 132007210 G A 9.57E-04 Acute lung injury / / 22295056 rs1910955 chr3 132010325 G A 1.30E-04 Age-related macular degeneration / / 22125219 rs2670104 chr3 132012079 A G 2.98E-05 Longevity / / 21612516 rs2887519 chr3 132015809 G A 7.71E-04 Acute lung injury / / 22295056 rs1100396 chr3 132021906 T C 1.30E-04 Amyotrophic lateral sclerosis / / 20801718 rs309987 chr3 132034647 C T 1.99E-05 Multiple complex diseases / / 17554300 rs111913500 chr3 132035291 G T 0.00009097 Sarcoidosis / / 22952805 rs309988 chr3 132036992 G A 8.28E-04 Multiple complex diseases ACPP intron 17554300 rs10935002 chr3 132052269 A G 1.45E-04 Age-related macular degeneration ACPP intron 22125219 rs17182582 chr3 132072419 G C 5.94E-04 Multiple complex diseases ACPP intron 17554300 rs9790142 chr3 132074036 G A 1.24E-05 Smoking behavior ACPP intron 19188921 rs16839247 chr3 132149352 A T 4.85E-05 Hypertension D/JC13 intron 19609347 rs10490862 chr3 132160713 A G 1.70E-05 Coronary heart disease D/JC13 intron pha003031 rs17404153 chr3 132163200 G T 2.00E-09 LDL cholesterol D/JC13 intron 24097068 rs17404153 chr3 132163200 G T 5.00E-09 HDL cholesterol D/JC13 intron 24097068 rs9829140 chr3 132192129 T C 6.21E-05 Crohn's disease D/JC13 intron 18587394 rs11709339 chr3 132237119 T C 1.60E-05 Urinary metabolites D/JC13 intron 21572414 rs12633010 chr3 132248681 G T 2.20E-05 Urinary metabolites D/JC13 intron 21572414 rs1378810 chr3 132254090 A T 7.00E-04 General cognitive ability D/JC13 intron 18067574 rs10512861 chr3 132257961 G T 5.43E-05 Coronary heart disease / / pha003031 rs12496278 chr3 132260487 G C 1.90E-05 Urinary metabolites / / 21572414 rs7619350 chr3 132269435 G A 2.20E-05 Urinary metabolites / / 21572414 rs6800166 chr3 132270181 A G 0.0000141 Tuberculosis with early age of onset / / 22551897 rs10935019 chr3 132283715 A G 3.70E-06 Urinary metabolites ACAD11 intron 21572414 rs9818117 chr3 132294075 C T 0.0000509 Tuberculosis with early age of onset ACAD11 intron 22551897 rs3762678 chr3 132298558 T C 1.30E-21 Multiple complex diseases ACAD11 intron 17554300 rs6794496 chr3 132401600 C T 1.58E-05 Brain lesion load NPHP3 cds-synon 19010793 rs6805662 chr3 132459904 C A 3.04E-05 Multiple complex diseases NPHP3-AS1 intron 17554300 rs4017724 chr3 132478233 G A 3.60E-05 Vaspin levels NPHP3-AS1 intron 22907691 rs9879204 chr3 132488754 T C 5.74E-05 Vaspin levels NPHP3-AS1 intron 22907691 rs10512862 chr3 132492942 A G 2.42E-05 Multiple complex diseases NPHP3-AS1 intron 17554300 rs7613434 chr3 132538452 G A 2.69E-04 Multiple complex diseases NPHP3-AS1 intron 17554300 rs7652595 chr3 132548805 A C 1.79E-04 Multiple complex diseases NPHP3-AS1 intron 17554300 rs7632744 chr3 132554855 G T 5.99E-04 Multiple complex diseases NPHP3-AS1 intron 17554300 rs1869155 chr3 132606028 G A 3.34E-04 Type 2 diabetes / / 17463246 rs6439371 chr3 132610752 G A 1.00E-08 Menarche (age at onset) / / 21102462 rs2369949 chr3 132642871 C T 3.00E-04 Body mass index / / 24827717 rs4538372 chr3 132646367 G A 2.78E-04 Birth weight / / 17255346 rs13079107 chr3 132660274 C T 1.89E-04 Birth weight / / 17255346 rs4634112 chr3 132661290 T A 6.15E-05 Birth weight / / 17255346 rs13077501 chr3 132672668 A G 3.06E-04 Birth weight / / 17255346 rs17353336 chr3 132672981 T C 3.06E-04 Birth weight / / 17255346 rs2369950 chr3 132685161 C T 4.10E-05 Endometriosis / / 21151130 rs9876198 chr3 132685783 C T 4.10E-05 Endometriosis / / 21151130 rs6439372 chr3 132687517 T C 3.73E-04 Birth weight / / 17255346 rs6763720 chr3 132690957 G A 5.10E-05 Endometriosis / / 21151130 rs2369955 chr3 132693588 A C 2.00E-06 Alcoholism (heaviness of drinking) / / 21529783 rs9873398 chr3 132724912 C T 1.50E-05 Urinary metabolites / / 21572414 rs1013391 chr3 132725363 A C 1.50E-05 Urinary metabolites / / 21572414 rs6763815 chr3 132725875 G C 1.40E-05 Urinary metabolites / / 21572414 rs4280636 chr3 132727357 G A 2.56E-05 Post-operative nausea and vomiting / / 21694509 rs7617456 chr3 132727903 G A 3.00E-06 IgE grass sensitization / / 22036096 rs6439381 chr3 132736382 T G 7.00E-06 Urinary metabolites / / 21572414 rs9869948 chr3 132740125 T A 2.00E-05 Urinary metabolites / / 21572414 rs939572 chr3 132742844 T C 8.90E-06 Urinary metabolites / / 21572414 rs1464403 chr3 132751699 C T 4.40E-06 Urinary metabolites / / 21572414 rs2331 chr3 132760219 G A 9.88E-05 Major depressive disorder TMEM108 intron 22472876 rs1568478 chr3 132760427 C T 6.70E-06 Urinary metabolites TMEM108 intron 21572414 rs1568478 chr3 132760427 C T 4.88E-05 Major depressive disorder TMEM108 intron 22472876 rs2030444 chr3 132761684 A G 5.50E-06 Urinary metabolites TMEM108 intron 21572414 rs2030443 chr3 132761698 C T 7.00E-06 Urinary metabolites TMEM108 intron 21572414 rs4854680 chr3 132763170 C A 7.10E-06 Urinary metabolites TMEM108 intron 21572414 rs4854680 chr3 132763170 C A 4.97E-05 Major depressive disorder TMEM108 intron 22472876 rs2049149 chr3 132776901 C T 3.67E-05 Major depressive disorder TMEM108 intron 22472876 rs9879280 chr3 132777314 T C 4.10E-05 Major depressive disorder TMEM108 intron 22472876 rs9817813 chr3 132784951 T C 1.74E-05 Major depressive disorder TMEM108 intron 22472876 rs9836009 chr3 132785380 A G 1.70E-06 Urinary metabolites TMEM108 intron 21572414 rs4496483 chr3 132790686 T G 1.10E-06 Urinary metabolites TMEM108 intron 21572414 rs4496483 chr3 132790686 T G 3.30E-05 Major depressive disorder TMEM108 intron 22472876 rs4487238 chr3 132790857 C G 1.97E-05 Major depressive disorder TMEM108 intron 22472876 rs9835480 chr3 132792209 C A 1.86E-05 Major depressive disorder TMEM108 intron 22472876 rs9860508 chr3 132794953 A G 6.90E-07 Urinary metabolites TMEM108 intron 21572414 rs9860508 chr3 132794953 A G 1.99E-05 Major depressive disorder TMEM108 intron 22472876 rs9839858 chr3 132798639 C T 3.40E-06 Urinary metabolites TMEM108 intron 21572414 rs10935045 chr3 132800146 C A 1.70E-06 Alcoholism (heaviness of drinking) TMEM108 intron 21529783 rs11712701 chr3 132805572 T C 5.91E-04 Type 2 diabetes TMEM108 intron 17463246 rs41520845 chr3 132807261 T C 4.81E-04 Type 2 diabetes TMEM108 intron 17463246 rs9859356 chr3 132812204 C G 3.30E-07 Urinary metabolites TMEM108 intron 21572414 rs9859356 chr3 132812204 C G 9.40E-05 Cognitive function TMEM108 intron 24684796 rs6807522 chr3 132815704 T G 7.23E-05 Major depressive disorder TMEM108 intron 22472876 rs6797320 chr3 132821475 G A 6.65E-04 Type 2 diabetes TMEM108 intron 17463246 rs16839984 chr3 132837238 T C 1.48E-05 Major depressive disorder TMEM108 intron 22472876 rs3752770 chr3 132839956 A G 1.90E-07 Urinary metabolites TMEM108 intron 21572414 rs7636123 chr3 132841417 T C 1.96E-05 Major depressive disorder TMEM108 intron 22472876 rs9864890 chr3 132843338 G A 1.99E-05 Major depressive disorder TMEM108 intron 22472876 rs9854387 chr3 132862516 T G 1.10E-05 Urinary metabolites TMEM108 intron 21572414 rs13079918 chr3 132866503 C T 7.00E-06 Urinary metabolites TMEM108 intron 21572414 rs6784028 chr3 132879712 A G 3.63E-04 Multiple complex diseases TMEM108 intron 17554300 rs12493846 chr3 132902053 G A 7.62E-05 Brain derived neurotrophic factor levels,in serum TMEM108 intron 22047184 rs10460836 chr3 132905078 G T 7.86E-05 Brain derived neurotrophic factor levels,in serum TMEM108 intron 22047184 rs12490128 chr3 132908793 C A 1.10E-05 Type 2 diabetes TMEM108 intron 17463248 rs1450050 chr3 132911040 A G 5.85E-30 Narcolepsy TMEM108 intron 19629137 rs6439388 chr3 132915474 G C 3.39E-05 Serum metabolites TMEM108 intron 19043545 rs6439388 chr3 132915474 G C 2.23E-04 Smoking initiation TMEM108 intron 24665060 rs6439389 chr3 132916612 G A 3.02E-04 Multiple complex diseases TMEM108 intron 17554300 rs7628842 chr3 132933495 T G 4.26E-05 Serum metabolites TMEM108 intron 19043545 rs7628842 chr3 132933495 T G 4.09E-04 Smoking initiation TMEM108 intron 24665060 rs9968156 chr3 132936976 T C 9.53E-06 Serum metabolites TMEM108 intron 19043545 rs9968156 chr3 132936976 T C 3.52E-04 Smoking initiation TMEM108 intron 24665060 rs4854701 chr3 132938130 G A 2.84E-04 Smoking initiation TMEM108 intron 24665060 rs4854702 chr3 132938378 G A 2.78E-04 Smoking initiation TMEM108 intron 24665060 rs1901039 chr3 132941928 G A 2.43E-04 Smoking initiation TMEM108 intron 24665060 rs13072106 chr3 132942753 C T 8.70E-05 Type 2 diabetes TMEM108 intron 17463248 rs10512891 chr3 132948859 T A 8.30E-05 Type 2 diabetes TMEM108 intron 17463248 rs7650741 chr3 132949579 C T 8.20E-05 Type 2 diabetes TMEM108 intron 17463248 rs9820056 chr3 132956092 T C 1.29E-05 Serum metabolites TMEM108 intron 19043545 rs7612595 chr3 132957293 C T 7.50E-05 Type 2 diabetes TMEM108 intron 17463248 rs7648973 chr3 132980711 T A 2.75E-04 Multiple complex diseases TMEM108 intron 17554300 rs7648973 chr3 132980711 T A 2.30E-05 Urinary metabolites TMEM108 intron 21572414 rs7648973 chr3 132980711 T A 6.81E-04 Smoking cessation TMEM108 intron 24665060 rs769097 chr3 132981813 C A 7.31E-05 Multiple complex diseases TMEM108 intron 17554300 rs7624858 chr3 132984117 A G 1.52E-04 Multiple complex diseases TMEM108 intron 17554300 rs7639076 chr3 132993565 A G 2.01E-04 Multiple complex diseases TMEM108 intron 17554300 rs16840161 chr3 132995726 G A 3.10E-05 Type 2 diabetes TMEM108 intron 17463248 rs17297332 chr3 132998084 C G 2.90E-05 Type 2 diabetes TMEM108 intron 17463248 rs11922891 chr3 133011204 C T 5.21E-04 Smoking cessation TMEM108 intron 24665060 rs7625110 chr3 133011779 G T 2.90E-05 Type 2 diabetes TMEM108 intron 17463248 rs4854579 chr3 133014772 C T 3.11E-04 Multiple complex diseases TMEM108 intron 17554300 rs10512895 chr3 133015904 C T 4.33E-04 Multiple complex diseases TMEM108 intron 17554300 rs10512896 chr3 133016759 C G 2.70E-05 Type 2 diabetes TMEM108 intron 17463248 rs11717365 chr3 133019280 C T 8.26E-05 Waist-Hip Ratio TMEM108 intron pha003013 rs1708373 chr3 133019327 G A 2.50E-05 Type 2 diabetes TMEM108 intron 17463248 rs16840202 chr3 133020950 A G 8.43E-06 Serum metabolites TMEM108 intron 19043545 rs4600815 chr3 133020968 A T 6.75E-05 Multiple complex diseases TMEM108 intron 17554300 rs4507250 chr3 133024577 C T 2.91E-04 Multiple complex diseases TMEM108 intron 17554300 rs2699869 chr3 133032892 A C 6.68E-04 Multiple complex diseases TMEM108 intron 17554300 rs2699869 chr3 133032892 A C 5.71E-05 Serum metabolites TMEM108 intron 19043545 rs9838338 chr3 133035173 T C 2.70E-05 Serum metabolites TMEM108 intron 19043545 rs17298063 chr3 133036810 C G 2.75E-04 Multiple complex diseases TMEM108 intron 17554300 rs1197316 chr3 133039585 G A 2.30E-05 Type 2 diabetes TMEM108 intron 17463248 rs9876399 chr3 133051572 G A 1.20E-05 Serum metabolites TMEM108 intron 19043545 rs1920021 chr3 133071425 C T 3.10E-05 Type 2 diabetes TMEM108 intron 17463248 rs11706381 chr3 133074787 T C 8.26E-05 Waist-Hip Ratio TMEM108 intron pha003013 rs938238 chr3 133081026 G A 8.90E-04 Type 2 diabetes TMEM108 intron 17463246 rs938229 chr3 133088362 G A 4.47E-04 Multiple complex diseases TMEM108 intron 17554300 rs938229 chr3 133088362 G A 1.90E-04 Type 2 diabetes and 6 quantitative traits TMEM108 intron 17848626 rs938229 chr3 133088362 G A 6.80E-05 Bipolar disorder TMEM108 intron 19259986 rs1795101 chr3 133090106 C T 4.03E-04 Bipolar disorder TMEM108 intron 19259986 rs4479595 chr3 133090973 A C 1.90E-05 Urinary metabolites TMEM108 intron 21572414 rs954658 chr3 133091120 C T 3.60E-06 Urinary metabolites TMEM108 intron 21572414 rs1197313 chr3 133100452 G A 8.95E-05 Parkinson's disease TMEM108 intron pha002865 rs9821742 chr3 133105849 C A 3.62E-04 Response to cytadine analogues (cytosine arabinoside) TMEM108 intron 24483146 rs16840309 chr3 133109606 T C 5.32E-06 Hepatitis C induced liver cirrhosis TMEM108 intron 23321320 rs1197310 chr3 133128224 T A 6.30E-04 Type 2 diabetes and 6 quantitative traits BFSP2 intron 17848626 rs11708694 chr3 133130924 C A 9.50E-05 Major depressive disorder BFSP2 intron 21042317 rs11708694 chr3 133130924 C A 1.80E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) BFSP2 intron 24023788 rs9853365 chr3 133147720 C G 4.00E-04 Smoking initiation BFSP2 intron 24665060 rs6762405 chr3 133156692 C T 0.0004291 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BFSP2 intron 23233654 rs6762405 chr3 133156692 C T 4.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) BFSP2 intron 23233662 rs2078262 chr3 133172374 C A 6.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BFSP2 intron 20877124 rs2737717 chr3 133185834 T C 1.70E-05 Urinary metabolites BFSP2 intron 21572414 rs7628262 chr3 133189192 T C 2.36E-05 Varicose Veins BFSP2 intron pha001415 rs13069027 chr3 133190190 C A 3.90E-06 Urinary metabolites BFSP2 intron 21572414 rs9828692 chr3 133192169 C T 2.56E-05 Personality dimensions BFSP2 intron 18957941 rs7637878 chr3 133194456 A G 1.85E-05 Personality dimensions BFSP2 nearGene-3 18957941 rs7637878 chr3 133194456 A G 1.90E-05 Personality dimensions BFSP2 nearGene-3 21173776 rs9825996 chr3 133244619 A G 6.34E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12630919 chr3 133252369 T C 8.01E-05 Blood Pressure / / pha003039 rs4854723 chr3 133254258 A C 2.78E-08 Alcohol consumption / / 21665994 rs4854727 chr3 133257885 A G 8.08E-07 Alcohol consumption / / 21665994 rs4017074 chr3 133260427 T C 7.76E-07 Alcohol consumption / / 21665994 rs3860498 chr3 133260516 T C 9.11E-07 Alcohol consumption / / 21665994 rs11708304 chr3 133260874 C T 6.00E-06 Bulimia nervosa / / 23568457 rs6785365 chr3 133262445 A G 4.64E-07 Alcohol consumption / / 21665994 rs6763627 chr3 133262567 C G 4.71E-07 Alcohol consumption / / 21665994 rs10935068 chr3 133262807 T A 4.61E-07 Alcohol consumption / / 21665994 rs7614812 chr3 133264251 C A 1.26E-08 Alcohol consumption / / 21665994 rs872134 chr3 133265532 G T 1.27E-08 Alcohol consumption / / 21665994 rs6778062 chr3 133267153 G C 1.28E-08 Alcohol consumption / / 21665994 rs10433415 chr3 133285530 G T 2.13E-08 Alcohol consumption / / 21665994 rs4854733 chr3 133287065 A G 2.11E-08 Alcohol consumption / / 21665994 rs1444600 chr3 133288506 C T 6.62E-08 Alcohol consumption / / 21665994 rs6781238 chr3 133298120 C T 7.30E-09 Iron levels CDV3 intron 21208937 rs10935070 chr3 133341988 T C 1.10E-08 Alcohol consumption TOPBP1 missense 21665994 rs2718812 chr3 133399702 C T 1.00E-06 Iron status biomarkers / / 19084217 rs1867504 chr3 133410661 A G 2.00E-06 Iron status biomarkers / / 19084217 rs6802154 chr3 133419805 C T 2.92E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9830001 chr3 133433470 G A 6.31E-11 Alcohol consumption / / 21665994 rs11715340 chr3 133434817 T A 3.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs4525863 chr3 133436136 C A 4.60E-08 Iron status biomarkers / / 19084217 rs4525863 chr3 133436136 C A 8.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4525863 chr3 133436136 C A 3.99E-12 Alcohol consumption / / 21665994 rs16840699 chr3 133437601 C T 4.69E-04 Suicide attempts in bipolar disorder / / 21041247 rs4287912 chr3 133437778 A G 3.31E-05 Calcium levels / / pha003085 rs4582061 chr3 133438026 G A 4.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs11717407 chr3 133438264 A G 4.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs9847885 chr3 133438344 T C 4.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs6782523 chr3 133438917 C T 2.74E-12 Alcohol consumption / / 21665994 rs10935073 chr3 133439184 T C 2.72E-12 Alcohol consumption / / 21665994 rs11921527 chr3 133441167 G A 3.89E-12 Alcohol consumption / / 21665994 rs12639304 chr3 133441594 A T 3.81E-12 Alcohol consumption / / 21665994 rs6774822 chr3 133442012 G T 3.84E-12 Alcohol consumption / / 21665994 rs6775042 chr3 133442245 G T 3.85E-12 Alcohol consumption / / 21665994 rs6439431 chr3 133448109 A C 3.78E-12 Alcohol consumption / / 21665994 rs7646118 chr3 133450039 C T 3.78E-12 Alcohol consumption / / 21665994 rs6439434 chr3 133450371 T G 5.30E-05 Calcium levels / / pha003085 rs16840751 chr3 133450433 G A 3.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs6787177 chr3 133450720 C T 1.29E-12 Alcohol consumption / / 21665994 rs10935083 chr3 133453827 T C 3.63E-04 Suicide attempts in bipolar disorder / / 21041247 rs16840812 chr3 133462807 T C 8.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs8177178 chr3 133463272 G A 4.02E-12 Alcohol consumption TF nearGene-5 21665994 rs8177181 chr3 133463798 T A 8.43E-04 Suicide attempts in bipolar disorder TF nearGene-5 21041247 rs8177313 chr3 133464102 T G 1.65E-13 Alcohol consumption TF nearGene-5 21665994 rs8177184 chr3 133464496 A G 8.06E-04 Suicide attempts in bipolar disorder TF nearGene-5 21041247 rs8177184 chr3 133464496 A G 3.33E-04 Smoking cessation TF nearGene-5 24665060 rs8177185 chr3 133464618 G A 7.91E-05 Suicide attempts in bipolar disorder TF nearGene-5 21041247 rs8177186 chr3 133465201 G T 7.66E-05 Suicide attempts in bipolar disorder TF UTR-5 21041247 rs8177186 chr3 133465201 G T 7.33E-04 Smoking cessation TF UTR-5 24665060 rs4459901 chr3 133465699 T C 3.18E-12 Alcohol consumption TF intron 21665994 rs1800277 chr3 133466155 C T 1.60E-14 Alcohol consumption TF intron 21665994 rs6796795 chr3 133466222 A G 1.69E-15 Alcohol consumption TF intron 21665994 rs6785596 chr3 133466457 T A 1.53E-15 Alcohol consumption TF intron 21665994 rs4532136 chr3 133466885 G A 7.25E-05 Suicide attempts in bipolar disorder TF intron 21041247 rs8177318 chr3 133467377 T A 6.14E-08 LDL cholesterol TF missense 23063622 rs8177191 chr3 133468139 G A 1.76E-18 Alcohol consumption TF intron 21665994 rs8177191 chr3 133468139 G A 2.40E-04 Coronary heart disease TF intron 21966275 rs8177197 chr3 133469530 G A 5.24E-12 Alcohol consumption TF intron 21665994 rs8177203 chr3 133470025 A G 6.66E-05 Suicide attempts in bipolar disorder TF intron 21041247 rs8177213 chr3 133472227 A C 2.92E-07 Alcohol consumption TF intron 21665994 rs8177220 chr3 133473625 G T 4.54E-04 Type 2 diabetes TF intron 17463246 rs8177220 chr3 133473625 G T 1.33E-15 Alcohol consumption TF intron 21665994 rs1799852 chr3 133475722 C T 5.00E-06 Iron status biomarkers TF cds-synon 19084217 rs1799852 chr3 133475722 C T 6.28E-14 Alcohol consumption TF cds-synon 21665994 rs1799899 chr3 133475812 G A 1.00E-09 Alcohol consumption (transferrin glycosylation) TF missense 21665994 rs8177233 chr3 133475961 A G 1.02E-26 Narcolepsy TF intron 19629137 rs8177235 chr3 133476083 G A 5.70E-06 Urinary metabolites TF intron 21572414 rs8177240 chr3 133477701 T G 3.12E-13 Alcohol consumption TF intron 21665994 rs8177248 chr3 133479626 C T 5.60E-06 Urinary metabolites TF intron 21572414 rs8177252 chr3 133480174 C A 2.56E-13 Alcohol consumption TF intron 21665994 rs8177253 chr3 133480192 C T 6.70E-06 Urinary metabolites TF intron 21572414 rs8177262 chr3 133480652 G A 1.10E-05 Urinary metabolites TF intron 21572414 rs8177272 chr3 133482870 G A 1.30E-05 Urinary metabolites TF intron 21572414 rs8177272 chr3 133482870 G A 2.13E-13 Alcohol consumption TF intron 21665994 rs3811647 chr3 133484029 G A 3.00E-15 Iron status biomarkers TF intron 19084217 rs3811647 chr3 133484029 G A 1.21E-05 Hypertension TF intron 21082022 rs3811647 chr3 133484029 G A 3.00E-47 Iron levels TF intron 21208937 rs3811647 chr3 133484029 G A 5.00E-10 Iron status biomarkers TF intron 21483845 rs3811647 chr3 133484029 G A 8.00E-06 Iron status biomarkers TF intron 21483845 rs3811647 chr3 133484029 G A 1.00E-35 Alcohol consumption (transferrin glycosylation) TF intron 21665994 rs3811647 chr3 133484029 G A 2.00E-16 Hepcidin levels TF intron 21785125 rs1358024 chr3 133484188 C T 3.61E-10 Iron status biomarkers TF intron 19084217 rs1358024 chr3 133484188 C T 1.09E-07 Alcohol consumption TF intron 21665994 rs1525892 chr3 133484712 G A 1.20E-05 Urinary metabolites TF intron 21572414 rs1525892 chr3 133484712 G A 2.05E-13 Alcohol consumption TF intron 21665994 rs41295800 chr3 133484712 GT G 1.20E-05 Urinary metabolites TF intron 21572414 rs41295800 chr3 133484712 GT G 2.05E-13 Alcohol consumption TF intron 21665994 rs8177277 chr3 133484830 T C 2.40E-05 Urinary metabolites TF intron 21572414 rs2692695 chr3 133485454 A G 4.70E-29 Alcohol consumption TF intron 21665994 rs1525889 chr3 133490033 A C 8.21E-13 Alcohol consumption TF intron 21665994 rs1049296 chr3 133494354 C T 5.00E-43 Alcohol consumption (transferrin glycosylation) TF missense 21665994 rs1049296 chr3 133494354 C T 0.000097 Endometrial cancer TF missense 22426144 rs7638018 chr3 133495461 A G 1.10E-05 Urinary metabolites TF intron 21572414 rs7638018 chr3 133495461 A G 1.16E-12 Alcohol consumption TF intron 21665994 rs4854760 chr3 133498741 A G 7.80E-06 Urinary metabolites / / 21572414 rs4854760 chr3 133498741 A G 1.14E-12 Alcohol consumption / / 21665994 rs4854761 chr3 133498789 G A 8.00E-06 Urinary metabolites / / 21572414 rs4854761 chr3 133498789 G A 2.00E-12 Alcohol consumption / / 21665994 rs4854762 chr3 133499063 G A 1.07E-13 Alcohol consumption / / 21665994 rs9843728 chr3 133501407 C T 2.09E-12 Alcohol consumption / / 21665994 rs1830084 chr3 133508464 A T 1.00E-09 Iron status biomarkers SRPRB intron 19084217 rs1830084 chr3 133508464 A T 1.93E-12 Alcohol consumption SRPRB intron 21665994 rs9881405 chr3 133518198 G T 3.71E-13 Alcohol consumption SRPRB intron 21665994 rs6794945 chr3 133518463 C T 4.96E-15 Iron status biomarkers SRPRB intron 19084217 rs6794945 chr3 133518463 C T 6.09E-05 Hypertension SRPRB intron 21082022 rs6794945 chr3 133518463 C T 1.00E-05 Urinary metabolites SRPRB intron 21572414 rs6794945 chr3 133518463 C T 6.06E-13 Alcohol consumption SRPRB intron 21665994 rs9853615 chr3 133519981 A G 6.85E-06 Response to metformin SRPRB intron 21186350 rs9853615 chr3 133519981 A G 6.28E-29 Alcohol consumption SRPRB intron 21665994 rs9853615 chr3 133519981 A G 1.90E-05 Inflammation SRPRB intron pha002897 rs12490148 chr3 133523973 C T 1.98E-12 Alcohol consumption SRPRB intron 21665994 rs1107413 chr3 133524717 G C 1.13E-12 Alcohol consumption SRPRB missense 21665994 rs3817524 chr3 133526403 C T 1.18E-28 Alcohol consumption SRPRB intron 21665994 rs7650925 chr3 133527169 G T 2.74E-11 Alcohol consumption SRPRB intron 21665994 rs6439441 chr3 133529594 A G 4.69E-11 Alcohol consumption SRPRB intron 21665994 rs1464937 chr3 133536655 G C 4.99E-05 Response to metformin SRPRB intron 21186350 rs1464937 chr3 133536655 G C 6.15E-26 Alcohol consumption SRPRB intron 21665994 rs1534165 chr3 133536917 T C 1.15E-07 Alcohol consumption SRPRB intron 21665994 rs1534166 chr3 133537067 A G 2.00E-17 Alcohol consumption (transferrin glycosylation) SRPRB intron 21665994 rs6439442 chr3 133540359 A C 2.62E-07 Alcohol consumption / / 21665994 rs17376019 chr3 133540883 C T 8.05E-24 Alcohol consumption / / 21665994 rs6439443 chr3 133540915 T C 6.52E-07 Alcohol consumption / / 21665994 rs6786236 chr3 133541701 T C 2.15E-04 White matter integrity / / 22425255 rs6773354 chr3 133541774 C T 3.21E-05 Iron status biomarkers / / 19084217 rs6773354 chr3 133541774 C T 2.29E-09 Alcohol consumption / / 21665994 rs17310413 chr3 133541961 T G 3.25E-20 Alcohol consumption / / 21665994 rs12637730 chr3 133546297 C T 2.10E-17 Iron levels RAB6B UTR-3 21208937 rs12637730 chr3 133546297 C T 7.32E-09 Alcohol consumption RAB6B UTR-3 21665994 rs2293374 chr3 133547245 G A 1.03E-08 Alcohol consumption RAB6B UTR-3 21665994 rs11921187 chr3 133551642 T C 5.22E-18 Alcohol consumption RAB6B intron 21665994 rs6793673 chr3 133553272 C T 8.61E-21 Alcohol consumption RAB6B intron 21665994 rs6793673 chr3 133553272 C T 1.17E-05 Diabetes Mellitus RAB6B intron pha003059 rs2692672 chr3 133555500 T G 1.22E-08 Alcohol consumption RAB6B intron 21665994 rs2280673 chr3 133558154 A C 6.35E-05 Diabetes Mellitus RAB6B intron pha003059 rs17310798 chr3 133562939 T C 1.98E-17 Alcohol consumption RAB6B intron 21665994 rs7644124 chr3 133575865 T C 2.90E-04 Crohn's disease RAB6B intron 17684544 rs1880663 chr3 133581459 A G 3.79E-09 Alcohol consumption RAB6B intron 21665994 rs3811646 chr3 133583577 C T 9.27E-05 Blood Pressure RAB6B intron pha003046 rs9835973 chr3 133589324 C T 7.00E-08 Immune reponse to smallpox (secreted IL-1beta) RAB6B intron 22610502 rs9835973 chr3 133589324 C T 2.02E-05 Blood Pressure RAB6B intron pha003046 rs2692681 chr3 133595618 G A 1.28E-04 Type 2 diabetes RAB6B intron 17463246 rs2692685 chr3 133629362 A G 3.56E-04 Type 2 diabetes / / 17463246 rs2692685 chr3 133629362 A G 5.69E-04 Multiple complex diseases / / 17554300 rs6772354 chr3 133631211 C T 7.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs6439447 chr3 133637933 G A 4.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs4854766 chr3 133643283 T A 5.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs7623757 chr3 133644893 A G 6.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs7340717 chr3 133674895 G T 7.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLCO2A1 intron 20877124 rs7428024 chr3 133725592 C T 1.00E-04 Cognitive impairment induced by topiramate SLCO2A1 intron 22091778 rs4528941 chr3 133760537 G A 5.97E-18 Metabolite levels / / 22286219 rs9812483 chr3 133780030 C T 2.18E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7653175 chr3 133823275 G A 8.54E-04 Type 2 diabetes / / 17463246 rs7611109 chr3 133823507 C T 8.92E-04 Type 2 diabetes / / 17463246 rs6800143 chr3 133844946 G A 3.24E-05 Cognitive decline / / 23732972 rs10804625 chr3 133854624 G T 5.31E-05 Type 2 diabetes / / 17463246 rs4450813 chr3 133874113 T C 3.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1131262 chr3 133941320 C T 1.93E-04 Cognitive decline RYK missense 23732972 rs9856298 chr3 133957265 A G 2.30E-04 Cognitive decline RYK intron 23732972 rs9820182 chr3 134003345 T G 1.10E-04 Endometriosis / / 21151130 rs4343599 chr3 134004200 A G 6.47E-05 Type 2 diabetes / / 17463246 rs6439477 chr3 134071042 C T 0.000531 Salmonella-induced pyroptosis / / 22837397 rs1353778 chr3 134088443 A T 9.23E-04 Type 2 diabetes AMOTL2 intron 17463246 rs11919447 chr3 134090703 G A 7.09E-04 Type 2 diabetes AMOTL2 intron 17463246 rs11923513 chr3 134090793 T G 7.43E-04 Type 2 diabetes AMOTL2 intron 17463246 rs17312996 chr3 134094894 G A 9.76E-04 Type 2 diabetes / / 17463246 rs17313003 chr3 134095168 G C 7.91E-04 Type 2 diabetes / / 17463246 rs9682157 chr3 134108539 C T 1.04E-05 Lung function (forced vital capacity) / / pha003104 rs4974500 chr3 134109630 T C 6.94E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs4974500 chr3 134109630 T C 2.58E-05 Lung function (forced vital capacity) / / pha003104 rs11715463 chr3 134109877 C T 2.63E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs11715463 chr3 134109877 C T 1.43E-05 Lung function (forced vital capacity) / / pha003104 rs10433423 chr3 134134236 G A 4.03E-05 Lung function (forced vital capacity) / / pha003104 rs4974505 chr3 134135590 A G 8.31E-05 Lung function (forced vital capacity) / / pha003104 rs13094395 chr3 134137137 C T 1.02E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs9841212 chr3 134191938 C T 7.28E-05 Elbow pain / / pha003008 rs9866359 chr3 134198838 T C 1.44E-04 Height A/PC13 intron 22216288 rs6806417 chr3 134211446 A G 9.31E-04 Lymphocyte counts CEP63 intron 22286170 rs10935116 chr3 134217904 A G 9.52E-05 Hemoglobin CEP63 intron pha003098 rs10935120 chr3 134233092 A G 7.00E-08 Height CEP63 intron 18391952 rs4634170 chr3 134335471 T C 8.00E-05 Cognitive test performance KY intron 20125193 rs1982353 chr3 134381229 G A 3.87E-05 Insulin resistance / / 21901158 rs9818188 chr3 134382955 C T 3.59E-05 Insulin resistance / / 21901158 rs2895695 chr3 134392298 G T 5.84E-04 Smoking cessation / / 24665060 rs6802668 chr3 134395361 A G 7.08E-04 Smoking cessation / / 24665060 rs6763799 chr3 134397858 A G 5.59E-04 Smoking cessation / / 24665060 rs7632935 chr3 134401030 A G 0.000129228 Hypertension (early onset hypertension) / / 22479346 rs1562489 chr3 134405873 T C 6.03E-04 Smoking cessation / / 24665060 rs1447690 chr3 134419118 G A 0.0002057 Hypertension (early onset hypertension) / / 22479346 rs4955479 chr3 134431409 G T 7.75E-06 Lung cancer / / 19654303 rs6439515 chr3 134438659 C T 6.61E-04 Smoking cessation / / 24665060 rs13092177 chr3 134455794 G T 4.80E-04 Alzheimer's disease / / 22005930 rs17694881 chr3 134459997 C G 7.26E-04 Multiple complex diseases / / 17554300 rs17694881 chr3 134459997 C G 9.77E-04 Alzheimer's disease / / 22005930 rs10935129 chr3 134469531 T A 7.59E-04 Alcohol dependence / / 21314694 rs1877962 chr3 134476223 A C 3.20E-06 Panic disorder / / 19165232 rs6804153 chr3 134478439 G A 1.90E-05 Urinary metabolites / / 21572414 rs16842007 chr3 134479281 G A 2.60E-05 Urinary metabolites / / 21572414 rs11712035 chr3 134526235 C T 2.40E-05 Urinary metabolites EPHB1 intron 21572414 rs6439522 chr3 134530843 T C 9.30E-06 Urinary metabolites EPHB1 intron 21572414 rs6439524 chr3 134537888 A T 9.40E-06 Urinary metabolites EPHB1 intron 21572414 rs12489463 chr3 134562095 A G 4.80E-05 Temperament (bipolar disorder) EPHB1 intron 22365631 rs13072597 chr3 134565134 A C 3.40E-05 Temperament (bipolar disorder) EPHB1 intron 22365631 rs13073658 chr3 134565434 G A 4.19E-04 Response to alcohol consumption (flushing response) EPHB1 intron 24277619 rs13079457 chr3 134573484 G A 3.00E-05 Temperament (bipolar disorder) EPHB1 intron 22365631 rs938382 chr3 134589067 C T 5.10E-04 Schizophrenia EPHB1 intron 20832056 rs7646638 chr3 134599236 T C 1.42E-04 Barrett's esophagus EPHB1 intron 24121790 rs7639843 chr3 134604237 C T 2.60E-04 Schizophrenia EPHB1 intron 20832056 rs16842236 chr3 134619642 A G 1.44E-13 Narcolepsy EPHB1 intron 19629137 rs187586 chr3 134624187 T C 2.07E-05 Alzheimer's disease (late onset) EPHB1 intron 21379329 rs187586 chr3 134624187 T C 8.09E-04 Obesity (extreme) EPHB1 intron 21935397 rs36167 chr3 134652757 T C 5.60E-04 Response to cytadine analogues (cytosine arabinoside) EPHB1 intron 24483146 rs36161 chr3 134656289 A G 8.34E-04 Response to cytadine analogues (cytosine arabinoside) EPHB1 intron 24483146 rs1350350 chr3 134699523 G T 5.42E-04 Multiple complex diseases EPHB1 intron 17554300 rs7644618 chr3 134756760 T A 1.30E-04 Multiple complex diseases EPHB1 intron 17554300 rs12639432 chr3 134770520 C T 7.10E-05 Diabetic retinopathy EPHB1 intron 21441570 rs6439553 chr3 134805581 A C 0.000488 Salmonella-induced pyroptosis EPHB1 intron 22837397 rs6764345 chr3 134815392 C T 1.00E-04 Cognitive impairment induced by topiramate EPHB1 intron 22091778 rs7373984 chr3 134820091 T C 5.50E-04 Coronary Artery Disease EPHB1 intron 17634449 rs7374822 chr3 134820184 A G 4.47E-04 Coronary Artery Disease EPHB1 intron 17634449 rs11711351 chr3 134821129 G A 9.66E-04 Stroke EPHB1 intron pha002886 rs10935154 chr3 134830532 T C 5.83E-05 Vascular dementia EPHB1 intron 22116812 rs9864760 chr3 134837039 G A 8.50E-04 Response to statin treatment (atorvastatin),change in cholesterol levels EPHB1 intron 20031582 rs9864760 chr3 134837039 G A 4.21E-05 Smoking quantity EPHB1 intron 24665060 rs11706256 chr3 134841452 C T 7.28E-05 Vascular dementia EPHB1 intron 22116812 rs7627183 chr3 134843240 A G 3.76E-04 Sudden cardiac arrest EPHB1 intron 21658281 rs7625747 chr3 134845693 T G 9.30E-06 Urinary metabolites EPHB1 intron 21572414 rs6762543 chr3 134857076 A C 9.95E-06 Smoking cessation EPHB1 intron 18519826 rs7373413 chr3 134861679 G A 1.45E-05 Coronary heart disease EPHB1 intron pha003031 rs3772646 chr3 134867952 C T 3.31E-05 Coronary heart disease EPHB1 intron pha003033 rs12492126 chr3 134871575 A G 8.90E-05 Elbow pain EPHB1 intron pha003008 rs7611233 chr3 134874869 G C 6.85E-04 Suicide attempts in bipolar disorder EPHB1 intron 21423239 rs6439559 chr3 134875103 G A 7.88E-04 Suicide attempts in bipolar disorder EPHB1 intron 21423239 rs7620133 chr3 134877681 C A,T 2.49E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) EPHB1 intron 25044411 rs10804635 chr3 134879076 C A 2.02E-04 Smoking cessation EPHB1 intron 18519826 rs10804635 chr3 134879076 C A 7.94E-05 Smoking cessation EPHB1 intron 18519826 rs12636613 chr3 134879121 A G 2.29E-04 Smoking cessation EPHB1 intron 18519826 rs12636613 chr3 134879121 A G 2.56E-04 Smoking cessation EPHB1 intron 18519826 rs4243398 chr3 134968574 T A 6.69E-04 Body mass index EPHB1 intron 21701565 rs13085606 chr3 134977164 T A,C,G 2.24E-06 White blood cell count EPHB1 intron 21738479 rs13067639 chr3 135018070 G A 8.60E-05 HIV-1 control / / 20041166 rs10935162 chr3 135018895 G A 6.20E-05 HIV-1 control / / 20041166 rs977026 chr3 135028442 C T 4.99E-04 Depression (quantitative trait) / / 20800221 rs1445217 chr3 135033871 T C 4.21E-04 Depression (quantitative trait) / / 20800221 rs823959 chr3 135049723 T C 4.66E-04 Lung function (forced vital capacity) / / 24023788 rs823968 chr3 135060057 C T 6.70E-05 Type 2 diabetes / / 17463248 rs711947 chr3 135112479 A G 4.02E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11712655 chr3 135225249 T G 1.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs1502172 chr3 135235358 A G 3.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs4894260 chr3 135245762 C G 8.85E-05 Serum metabolites / / 19043545 rs11926571 chr3 135260047 T G 7.00E-05 Coronary heart disease / / pha003031 rs972869 chr3 135265399 G A 7.00E-05 Coronary heart disease / / pha003031 rs6439573 chr3 135273799 C T 8.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6439578 chr3 135280770 A G 6.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9833932 chr3 135282024 C T 4.70E-05 Malaria / / 19465909 rs6808137 chr3 135310068 G A 1.50E-04 Myasthenia gravis / / 23055271 rs1447598 chr3 135345493 G A 1.57E-04 Amyotrophic lateral sclerosis / / 20801718 rs6799786 chr3 135430476 A G 9.42E-05 Multiple complex diseases / / 17554300 rs11719713 chr3 135441431 C A 7.22E-05 Chronic obstructive pulmonary disease / / 19300482 rs11922097 chr3 135447944 A G 0.0000255 Menopause (age at onset) / / 23424626 rs12632633 chr3 135458294 G C 9.18E-04 Alzheimer's disease / / 17998437 rs1401543 chr3 135587811 T C 4.02E-04 Alcohol dependence / / 21314694 rs1401543 chr3 135587811 T C 8.00E-06 Anticoagulant levels / / 22216198 rs6776731 chr3 135609461 G A 3.22E-04 Alzheimer's disease / / 24755620 rs9877722 chr3 135635468 G C 5.84E-05 Schizophrenia / / 19571809 rs9819440 chr3 135663482 C T 9.06E-05 Schizophrenia / / 19571809 rs9814557 chr3 135720540 A G 7.87E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PPP2R3A missense 20031582 rs940229 chr3 135784478 G A 5.11E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PPP2R3A intron 20031582 rs6439623 chr3 135787529 C A 7.75E-05 Lung function (forced vital capacity) PPP2R3A intron pha003104 rs1393786 chr3 135854035 C A 0.0000452 Coronary artery disease PPP2R3A intron 23202125 rs1154988 chr3 135925191 T A 1.20E-05 Urinary metabolites / / 21572414 rs1154988 chr3 135925191 T A 1.00E-16 Fibrinogen / / 23969696 rs645040 chr3 135926622 G T 3.00E-08 Triglycerides / / 20686565 rs645040 chr3 135926622 G T 8.50E-06 Urinary metabolites / / 21572414 rs645040 chr3 135926622 G T 2.00E-12 Triglycerides / / 24097068 rs511154 chr3 135950921 A G 6.00E-10 Fibrinogen / / 20031576 rs684773 chr3 135956305 A C 9.20E-06 Urinary metabolites / / 21572414 rs548288 chr3 135969755 T C 2.00E-05 Urinary metabolites PCCB intron 21572414 rs9844666 chr3 135974216 G A 4.00E-09 Height PCCB intron 20881960 rs9844666 chr3 135974216 G A 3.80E-05 Height PCCB intron 21194676 rs9844666 chr3 135974216 G A 5.50E-04 Height PCCB intron 21194676 rs9844666 chr3 135974216 G A 8.90E-08 Height PCCB intron 21194676 rs4678428 chr3 135988412 G A 1.40E-05 Urinary metabolites PCCB intron 21572414 rs3821445 chr3 136002809 T C 1.19E-06 Fibrinogen PCCB intron 20978265 rs9853387 chr3 136038988 A G 6.50E-04 Coronary heart disease PCCB intron 21966275 rs13068119 chr3 136206369 T C 2.10E-05 Urinary metabolites STAG1 intron 21572414 rs6794351 chr3 136292279 C T 2.40E-05 Urinary metabolites STAG1 intron 21572414 rs12635723 chr3 136300732 A G 1.10E-05 Urinary metabolites STAG1 intron 21572414 rs3856637 chr3 136391195 A G 1.10E-09 Lipid levels STAG1 intron 19936222 rs3856637 chr3 136391195 A G 3.00E-05 Lipid levels STAG1 intron 19936222 rs9826828 chr3 136402060 G A 8.60E-10 Rheumatoid arthritis STAG1 intron 24390342 rs9826828 chr3 136402060 G A 9.00E-10 Rheumatoid arthritis STAG1 intron 24390342 rs6789329 chr3 136476862 T C 3.48E-04 Dental caries / / 21940522 rs17374749 chr3 136768010 G A 7.00E-06 Anxiety in major depressive disorder / / 24047446 rs2053439 chr3 136844600 A C 1.30E-05 Urinary metabolites / / 21572414 rs7624691 chr3 136863079 T C 8.83E-06 Longevity / / 20304771 rs7647718 chr3 136867313 A G 8.58E-04 Rheumatoid arthritis / / 21452313 rs10513028 chr3 136905916 A C 3.39E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4678297 chr3 136907111 C T 7.93E-04 Multiple complex diseases / / 17554300 rs4678297 chr3 136907111 C T 3.15E-05 Coronary heart disease / / pha003031 rs2880857 chr3 136921564 A G 4.73E-06 Serum metabolites / / 19043545 rs1461511 chr3 136936116 G A 8.98E-06 Serum metabolites / / 19043545 rs1351114 chr3 137015273 G C 5.28E-04 Body mass index / / 21701565 rs12488660 chr3 137108175 C T 8.98E-04 Body mass index / / 21701565 rs1382269 chr3 137108482 T C 5.00E-07 Metabolite levels / / 19043545 rs1382269 chr3 137108482 T C 8.97E-04 Body mass index / / 21701565 rs13064915 chr3 137121243 T C 0.00005 Endoxifen sentivity (7 uM) / / 23508821 rs4505635 chr3 137124702 A G 8.85E-05 Serum metabolites / / 19043545 rs7375035 chr3 137156951 G A 9.19E-04 Type 2 diabetes / / 17463246 rs9878890 chr3 137158170 G A 9.19E-04 Type 2 diabetes / / 17463246 rs4510336 chr3 137180913 C T 8.73E-04 Type 2 diabetes / / 17463246 rs3922442 chr3 137214174 T C 8.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4342060 chr3 137215820 C T 7.60E-04 Pulmonary function / / 23932459 rs11922179 chr3 137224838 A C 8.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12631816 chr3 137233814 C T 3.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs981626 chr3 137250044 T C 3.11E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs981626 chr3 137250044 T C 2.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6797178 chr3 137253713 G A 7.46E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9813034 chr3 137281630 T G 3.10E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12630965 chr3 137282985 T C 8.15E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2345270 chr3 137325390 A G 4.19E-04 Obesity (extreme) / / 21935397 rs4568062 chr3 137330127 C A 4.63E-05 Serum metabolites / / 19043545 rs4597662 chr3 137330205 A T 5.15E-05 Serum metabolites / / 19043545 rs9289544 chr3 137334960 G T 1.15E-05 Serum metabolites / / 19043545 rs6777144 chr3 137367809 C T 1.90E-06 Urinary metabolites / / 21572414 rs4678363 chr3 137368142 T C 3.70E-06 Urinary metabolites / / 21572414 rs9830526 chr3 137369181 G C 5.70E-06 Urinary metabolites / / 21572414 rs1442608 chr3 137370076 A G 9.80E-06 Urinary metabolites / / 21572414 rs12637203 chr3 137409366 A G 4.37E-04 Common variable immunodeficiency / / 21497890 rs917937 chr3 137411336 T C 6.70E-04 Type 2 diabetes / / 17463246 rs17547056 chr3 137427679 G A 2.75E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs10935268 chr3 137447485 G A 8.00E-07 Acenocoumarol maintenance dosage / / 19578179 rs16847433 chr3 137481342 C T 7.24E-04 Multiple complex diseases / / 17554300 rs6798439 chr3 137512736 A C 5.35E-04 Multiple complex diseases / / 17554300 rs2024370 chr3 137524754 T C 2.64E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12488404 chr3 137526940 C T 1.94E-04 Parkinson's disease / / 17052657 rs11708430 chr3 137533273 A G 6.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17282551 chr3 137653568 G A 6.78E-04 Type 2 diabetes / / 17463246 rs6439772 chr3 137681448 A G 4.26E-04 Alcohol dependence / / 21314694 rs151311746 chr3 137702328 G A 0.00003168 Sarcoidosis / / 22952805 rs149331339 chr3 137703222 T C 0.00001297 Sarcoidosis / / 22952805 rs138073103 chr3 137703889 C T 0.00001203 Sarcoidosis / / 22952805 rs35928468 chr3 137704360 G A 0.00001203 Sarcoidosis / / 22952805 rs2724722 chr3 137778660 G A 3.10E-05 Odorant perception / / 23910658 rs774806 chr3 137896924 A G 0.0004612 Sarcoidosis / / 22952805 rs774813 chr3 137899898 G A 0.0005957 Sarcoidosis / / 22952805 rs9846722 chr3 137997835 C T 5.21E-07 Carotenoid and tocopherol levels ARMC8 intron 19185284 rs6796663 chr3 138001553 A G 5.00E-05 Prostate cancer ARMC8 intron 21743057 rs6797207 chr3 138002064 A G 5.00E-05 Prostate cancer ARMC8 intron 21743057 rs3886726 chr3 138009184 A G 1.00E-04 Prostate cancer ARMC8 intron 21743057 rs3856636 chr3 138025136 T G 5.22E-04 Parkinson's disease NME9 intron 16252231 rs9846480 chr3 138025396 A G 8.00E-06 MRI atrophy measures NME9 intron 21116278 rs9289556 chr3 138033181 C T 1.75E-04 Parkinson's disease NME9 cds-synon 16252231 rs6802211 chr3 138051423 G A 8.99E-05 Parkinson's disease / / 16252231 rs811332 chr3 138078348 T C 0.0000304 Colorectal adenoma (excluding hyperplasic) MRAS intron 23677573 rs811332 chr3 138078348 T C 0.0000304 Colorectal adenoma (including hyperplasic) MRAS intron 23677573 rs1199338 chr3 138087467 A C 9.06E-06 PR interval in Tripanosoma cruzi seropositivity MRAS intron 24324551 rs1199337 chr3 138088064 G C 9.16E-06 PR interval in Tripanosoma cruzi seropositivity MRAS intron 24324551 rs4678260 chr3 138089513 C T 1.22E-04 Parkinson's disease MRAS intron 16252231 rs1199335 chr3 138089824 A G 8.33E-04 Alcohol dependence MRAS intron 21314694 rs1199334 chr3 138091140 A G 7.37E-05 Platelet counts MRAS intron pha003100 rs1199333 chr3 138091701 G T 0.000044 Colorectal adenoma (excluding hyperplasic) MRAS intron 23677573 rs1199333 chr3 138091701 G T 0.000044 Colorectal adenoma (including hyperplasic) MRAS intron 23677573 rs1199333 chr3 138091701 G T 3.00E-06 Amyotrophic lateral sclerosis (sporadic) MRAS intron 24529757 rs1199333 chr3 138091701 G T 6.81E-05 Platelet counts MRAS intron pha003100 rs185244 chr3 138092889 C T 8.94E-06 PR interval in Tripanosoma cruzi seropositivity MRAS intron 24324551 rs181877 chr3 138094898 A G 8.06E-06 PR interval in Tripanosoma cruzi seropositivity MRAS intron 24324551 rs1199340 chr3 138096252 G A 1.51E-06 PR interval in Tripanosoma cruzi seropositivity MRAS intron 24324551 rs253662 chr3 138097313 T C 5.59E-05 Platelet counts MRAS intron pha003100 rs1678443 chr3 138097534 C A 1.00E-06 PR interval in Tripanosoma cruzi seropositivity MRAS intron 24324551 rs774009 chr3 138104780 G A 4.70E-06 PR interval in Tripanosoma cruzi seropositivity MRAS intron 24324551 rs1209710 chr3 138106698 C T 3.71E-23 Narcolepsy MRAS intron 19629137 rs13082471 chr3 138107880 T C 6.94E-04 Acute lung injury MRAS intron 22295056 rs2306374 chr3 138119952 T C 3.00E-08 Coronary heart disease MRAS intron 21378990 rs2306374 chr3 138119952 T C 3.34E-08 Pericardial fat MRAS intron 22589742 rs2306374 chr3 138119952 T C 5.22E-10 Coronary artery disease MRAS intron 23202125 rs2306374 chr3 138119952 T C 0.000027 Coronary artery calcification MRAS intron 23394302 rs9818870 chr3 138122122 C T 7.00E-13 Coronary heart disease MRAS UTR-3 19198612 rs9818870 chr3 138122122 C T 7.00E-13 Coronary heart disease MRAS UTR-3 21347282 rs9818870 chr3 138122122 C T 0.000000297 Coronary artery disease (CAD) (males) MRAS UTR-3 23202125 rs9818870 chr3 138122122 C T 0.000000326 Coronary artery disease (CAD) age >50 MRAS UTR-3 23202125 rs9818870 chr3 138122122 C T 0.0000106 Coronary artery disease (CAD) age <=50 MRAS UTR-3 23202125 rs9818870 chr3 138122122 C T 6.44E-11 Coronary artery disease with myocardial infarction MRAS UTR-3 23202125 rs9818870 chr3 138122122 C T 1.00E-07 Coronary artery disease MRAS UTR-3 24262325 rs774015 chr3 138170116 G A 1.11E-04 Response to cytidine analogues (gemcitabine) ESYT3 intron 24483146 rs529615 chr3 138313834 C T 2.82E-04 Alcohol dependence / / 21314694 rs361057 chr3 138355606 T C 8.72E-04 Suicide attempts in bipolar disorder LOC256374 intron 21423239 rs2607796 chr3 138356417 G A 8.82E-04 Suicide attempts in bipolar disorder LOC256374 intron 21423239 rs1068685 chr3 138365552 C A 9.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs624099 chr3 138371699 C T 9.80E-04 Suicide attempts in bipolar disorder PIK3CB UTR-3 21423239 rs635592 chr3 138372052 A G 9.91E-04 Suicide attempts in bipolar disorder PIK3CB UTR-3 21423239 rs2305268 chr3 138384073 C T 4.62E-04 Smoking initiation PIK3CB intron 24665060 rs12493155 chr3 138400332 C T 7.31E-04 Alcohol dependence PIK3CB intron 21314694 rs531577 chr3 138401299 A C 1.37E-04 Bone mineral traits,in men PIK3CB intron 21427758 rs531577 chr3 138401299 A C 2.89E-05 Bone mineral traits,in men PIK3CB intron 21427758 rs531577 chr3 138401299 A C 4.34E-04 Bone mineral traits,in men PIK3CB intron 21427758 rs7612106 chr3 138525773 G A 9.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs11705762 chr3 138527094 A G 9.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs11720178 chr3 138532887 C T 9.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs9879784 chr3 138533503 G C 8.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs6784610 chr3 138537022 G C 6.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs2881900 chr3 138549009 A G 6.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs9647336 chr3 138552705 G A 5.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs9647337 chr3 138552809 G A 4.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs11716652 chr3 138565389 C T 5.79E-04 HIV-1 viral setpoint / / 17641165 rs7650967 chr3 138579015 G A 7.05E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9851887 chr3 138588081 C T 5.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs2046288 chr3 138592606 G T 4.37E-04 Multiple complex diseases / / 17554300 rs7617334 chr3 138592974 G T 3.88E-04 Multiple complex diseases / / 17554300 rs2348384 chr3 138602342 G C 5.98E-05 Multiple complex diseases / / 17554300 rs9820131 chr3 138608009 T G 7.79E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs1021135 chr3 138620638 G A 9.46E-04 Multiple complex diseases / / 17554300 rs4894332 chr3 138650742 A C 9.15E-05 Alzheimer's disease / / 22005930 rs12107422 chr3 138652077 C T 1.15E-04 Alzheimer's disease / / 22005930 rs12107433 chr3 138652273 G T 1.15E-04 Alzheimer's disease / / 22005930 rs11924939 chr3 138665796 C T 8.64E-04 Suicide attempts in bipolar disorder FOXL2 UTR-5 21423239 rs7626152 chr3 138675066 T C 1.89E-04 Cognitive decline / / 23732972 rs1511412 chr3 138713704 A G 2.00E-13 Keloid / / 20711176 rs2348394 chr3 138716500 A T 1.97E-04 Cognitive decline / / 23732972 rs614535 chr3 138804170 G C 0.000191 Salmonella-induced pyroptosis / / 22837397 rs2246671 chr3 138821205 A G 0.000212 Salmonella-induced pyroptosis / / 22837397 rs581530 chr3 138825892 G T 0.000003 Salmonella-induced pyroptosis BPESC1 intron 22837397 rs13101018 chr3 138861711 T C 1.51E-04 Cognitive decline / / 23732972 rs11915859 chr3 138867882 T A 3.00E-04 Cognitive decline / / 23732972 rs9836163 chr3 138877031 T C 9.83E-04 Multiple complex diseases / / 17554300 rs7638110 chr3 138903985 G T 2.00E-06 Obesity and blood pressure / / 22013104 rs7638110 chr3 138903985 G T 5.00E-08 Obesity and blood pressure / / 22013104 rs11706018 chr3 138916393 C T 4.04E-05 Caffeine consumption / / 21490707 rs11706018 chr3 138916393 C T 7.00E-06 IgG glycosylation / / 23382691 rs11706018 chr3 138916393 C T 9.00E-06 IgG glycosylation / / 23382691 rs10513059 chr3 138992418 C T 2.07E-06 Crohn's disease / / 17684544 rs10513061 chr3 138999031 G C 7.10E-05 Bipolar Disorder / / pha002863 rs10460842 chr3 139020433 C A 6.90E-05 Body mass index / / 24827717 rs4894345 chr3 139034049 C T 4.27E-04 Myopia (pathological) / / 21095009 rs1873666 chr3 139040661 A G 1.23E-04 Kawasaki disease / / 21326860 rs9814754 chr3 139041889 G T 2.33E-05 Serum metabolites / / 19043545 rs4894410 chr3 139043236 C G 1.03E-04 Kawasaki disease / / 21326860 rs4894410 chr3 139043236 C G 8.00E-06 Kawasaki disease / / 22446961 rs9826331 chr3 139044466 G C 2.50E-05 Urinary metabolites / / 21572414 rs1873668 chr3 139045061 T G 9.52E-05 Kawasaki disease / / 21326860 rs1873668 chr3 139045061 T G 4.38E-05 Kawasaki disease / / 22446961 rs4243399 chr3 139050910 G A 9.93E-05 Kawasaki disease / / 21326860 rs4243399 chr3 139050910 G A 4.67E-05 Kawasaki disease / / 22446961 rs1586861 chr3 139058496 T C 6.98E-04 Multiple complex diseases / / 17554300 rs1044826 chr3 139073011 C T 8.00E-06 Obesity-related traits MRPS22 intron 23251661 rs1044826 chr3 139073011 C T 9.00E-06 Obesity-related traits MRPS22 intron 23251661 rs9859864 chr3 139091219 G T 6.13E-05 Schizophrenia(age at onset) COPB2 intron 21688384 rs1599744 chr3 139116581 C T 4.24E-05 Kawasaki disease LOC100507291 intron 22446961 rs1580642 chr3 139132203 T G 8.87E-05 Schizophrenia(age at onset) LOC100507291 intron 21688384 rs16849065 chr3 139161352 A G 2.43E-04 Kawasaki disease LOC100507291 intron 21326860 rs2289345 chr3 139169964 G A 3.84E-04 Type 2 diabetes / / 17463246 rs6439860 chr3 139175797 T C 7.46E-05 Schizophrenia(age at onset) RBP2 intron 21688384 rs6439863 chr3 139175972 G T 2.85E-04 Type 2 diabetes RBP2 intron 17463246 rs6771831 chr3 139177585 G A 6.10E-05 Schizophrenia(age at onset) RBP2 intron 21688384 rs16849083 chr3 139184279 C T 2.19E-05 Kawasaki disease RBP2 intron 21326860 rs3772875 chr3 139188118 A G 2.78E-04 Type 2 diabetes RBP2 intron 17463246 rs2278577 chr3 139194921 C T 2.85E-04 Type 2 diabetes RBP2 intron 17463246 rs4683464 chr3 139196961 C T 6.21E-05 Schizophrenia(age at onset) / / 21688384 rs7651618 chr3 139199262 C T 2.75E-04 Type 2 diabetes / / 17463246 rs295470 chr3 139213903 A G 5.47E-05 Multiple complex diseases / / 17554300 rs295470 chr3 139213903 A G 7.75E-05 Schizophrenia(age at onset) / / 21688384 rs295484 chr3 139231782 T C 6.93E-05 Schizophrenia(age at onset) / / 21688384 rs188421 chr3 139234066 A C 6.03E-05 Schizophrenia(age at onset) / / 21688384 rs167187 chr3 139237008 G A 6.21E-05 Schizophrenia(age at onset) RBP1 intron 21688384 rs295490 chr3 139241371 C T 8.00E-06 PR interval in Tripanosoma cruzi seropositivity RBP1 intron 24324551 rs9826668 chr3 139271591 T C 7.02E-05 HIV-1 control / / 20041166 rs6439866 chr3 139295952 T C 7.73E-04 Aortic root size NM/T3 intron 21223598 rs10935337 chr3 139298199 C T 7.97E-04 Type 2 diabetes NM/T3 intron 17463246 rs47442 chr3 139307160 G A 9.37E-05 Serum metabolites NM/T3 intron 19043545 rs2201713 chr3 139320637 G A 8.81E-04 Aortic root size NM/T3 intron 21223598 rs4516568 chr3 139322348 C G 4.96E-04 Aortic root size NM/T3 intron 21223598 rs2292412 chr3 139353664 A G 0.000395 Salmonella-induced pyroptosis NM/T3 intron 22837397 rs7639511 chr3 139392368 T C 6.60E-06 Urinary metabolites NM/T3 intron 21572414 rs10935342 chr3 139405342 T C 6.70E-05 Alcoholism (heaviness of drinking) / / 21529783 rs12632145 chr3 139427206 C A 9.74E-05 Major depressive disorder / / 21621269 rs10935348 chr3 139447500 C A 2.80E-05 Alcoholism (heaviness of drinking) / / 21529783 rs4399852 chr3 139449250 G C 1.91E-06 Lymphocyte counts / / 22286170 rs4683698 chr3 139485456 G A 1.36E-12 Narcolepsy / / 19629137 rs1868172 chr3 139493701 C T 8.23E-04 Multiple complex diseases / / 17554300 rs6772801 chr3 139496471 A G 0.0003 Prostate cancer / / 22367438 rs13098819 chr3 139505788 A G 7.85E-04 Taste perception / / 22132133 rs2028994 chr3 139506968 G A 2.10E-05 Urinary metabolites / / 21572414 rs11707795 chr3 139549939 A G 8.44E-05 Taste perception / / 22132133 rs1447722 chr3 139554453 C G 0.000003741 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1447722 chr3 139554453 C G 5.46E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1374825 chr3 139565057 T C 2.60E-06 Taste perception / / 22132133 rs1374825 chr3 139565057 T C 0.0004857 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1374825 chr3 139565057 T C 4.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs16849528 chr3 139585439 G A 7.93E-04 Schizophrenia / / 19197363 rs2554152 chr3 139606794 G T 7.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs17336463 chr3 139622829 C T 5.93E-05 Cognitive test performance / / 20125193 rs2059572 chr3 139634355 C T 6.04E-05 Type 2 diabetes / / 17463246 rs4613415 chr3 139636462 T C 3.99E-05 Type 2 diabetes / / 17463246 rs1834502 chr3 139650242 A G 6.78E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2330 chr3 139655773 A C 7.26E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CLSTN2 intron 21844884 rs966866 chr3 139682048 T C 3.28E-04 Alzheimer's disease CLSTN2 intron 22005930 rs6439886 chr3 139682495 A G 6.99E-04 Alzheimer's disease CLSTN2 intron 22005930 rs11927306 chr3 139683731 C G 6.82E-04 Alzheimer's disease CLSTN2 intron 22005930 rs11927384 chr3 139683783 G A 6.82E-04 Alzheimer's disease CLSTN2 intron 22005930 rs7637853 chr3 139684407 G C 6.80E-04 Alzheimer's disease CLSTN2 intron 22005930 rs7617850 chr3 139684636 A G 6.20E-04 Alzheimer's disease CLSTN2 intron 22005930 rs9859388 chr3 139686208 G A 6.29E-04 Alzheimer's disease CLSTN2 intron 22005930 rs9821561 chr3 139686400 A C 6.63E-04 Alzheimer's disease CLSTN2 intron 22005930 rs6439887 chr3 139688912 A G 5.13E-04 Multiple complex diseases CLSTN2 intron 17554300 rs11707973 chr3 139689253 T C 2.89E-04 Alzheimer's disease CLSTN2 intron 22005930 rs9810814 chr3 139691236 G C 7.59E-04 Alzheimer's disease CLSTN2 intron 22005930 rs9810814 chr3 139691236 G C 2.43E-05 Personality dimensions CLSTN2 intron 22628180 rs1834498 chr3 139693440 A G 5.23E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CLSTN2 intron 21844884 rs10935363 chr3 139695735 T A 7.12E-04 Alzheimer's disease CLSTN2 intron 22005930 rs6791621 chr3 139696209 A G 4.64E-04 Parkinson's disease CLSTN2 intron 17052657 rs6791736 chr3 139696324 A G 6.78E-04 Multiple complex diseases CLSTN2 intron 17554300 rs16849613 chr3 139698588 T A 1.50E-04 Nicotine smoking CLSTN2 intron 19268276 rs1426036 chr3 139702991 C G 7.83E-05 Multiple complex diseases CLSTN2 intron 17554300 rs1426034 chr3 139707965 C T 9.99E-04 Multiple complex diseases CLSTN2 intron 17554300 rs16849682 chr3 139728959 C T 2.72E-04 Suicide attempts in bipolar disorder CLSTN2 intron 21041247 rs16849682 chr3 139728959 C T 5.15E-04 Suicide attempts in bipolar disorder CLSTN2 intron 21041247 rs1157820 chr3 139769880 G A 2.10E-07 Rheumatoid arthritis CLSTN2 intron 19503088 rs2350491 chr3 139782336 C T 1.22E-04 Response to taxane treatment (placlitaxel) CLSTN2 intron 23006423 rs2350488 chr3 139784874 A G 2.20E-04 Substance dependence CLSTN2 intron 21818250 rs2280336 chr3 139796544 A C 6.83E-05 Hemoglobin CLSTN2 intron pha003096 rs1316806 chr3 139805080 A T 9.32E-04 Multiple complex diseases CLSTN2 intron 17554300 rs7652623 chr3 139817289 A G 1.16E-04 Lung function (forced expiratory volume in 1 second) CLSTN2 intron 17255346 rs4683798 chr3 139818305 G A 5.67E-04 Multiple complex diseases CLSTN2 intron 17554300 rs2350500 chr3 139838877 C T 8.40E-04 Multiple complex diseases CLSTN2 intron 17554300 rs2350502 chr3 139839519 A C 6.74E-06 Hearing function CLSTN2 intron 21493956 rs2350278 chr3 139843181 A G 7.63E-04 Multiple complex diseases CLSTN2 intron 17554300 rs4683806 chr3 139844670 A G 1.29E-05 Hypertension (early onset hypertension) CLSTN2 intron 22479346 rs1317898 chr3 139850272 G A 1.77E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CLSTN2 intron 20031582 rs9868890 chr3 139853644 G A 6.27E-04 Response to cytidine analogues (gemcitabine) CLSTN2 intron 24483146 rs4596106 chr3 139854253 G C 8.62E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CLSTN2 intron 20031582 rs12637089 chr3 139887968 C T 7.30E-05 Response to metformin CLSTN2 intron 21186350 rs17402510 chr3 139938947 C A 8.43E-04 Type 2 diabetes CLSTN2 intron 17463246 rs2350510 chr3 139942147 C T 5.56E-04 Aortic root size CLSTN2 intron 21223598 rs4538338 chr3 139953635 G T 3.83E-06 Multiple complex diseases CLSTN2 intron 17554300 rs9853327 chr3 139993059 A G 0.0002127 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CLSTN2 intron 23233654 rs9853327 chr3 139993059 A G 2.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) CLSTN2 intron 23233662 rs7626587 chr3 139993694 A G 8.08E-04 Alcohol dependence CLSTN2 intron 20201924 rs7626587 chr3 139993694 A G 3.57E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CLSTN2 intron 24023788 rs4077501 chr3 139997148 T C 1.53E-04 Alcohol dependence CLSTN2 intron 20201924 rs6439914 chr3 140009220 A G 7.96E-04 Alcohol dependence CLSTN2 intron 20201924 rs1001518 chr3 140010660 C T 0.000537 Salmonella-induced pyroptosis CLSTN2 intron 22837397 rs1351313 chr3 140014763 A C 7.62E-04 Tourette syndrome CLSTN2 intron 22889924 rs1011757 chr3 140022990 A G 7.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CLSTN2 intron 20877124 rs12634849 chr3 140038091 A G 0.000724 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CLSTN2 intron 23233654 rs12634849 chr3 140038091 A G 7.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) CLSTN2 intron 23233662 rs987486 chr3 140049319 C T 0.000424 Salmonella-induced pyroptosis CLSTN2 intron 22837397 rs879716 chr3 140052260 T C 9.82E-05 Socioeconomic Factors CLSTN2 intron pha003066 rs1006877 chr3 140053766 G A 4.77E-05 Schizophrenia (cytomegalovirus infection interaction) CLSTN2 intron 23358160 rs9810564 chr3 140080015 A G 7.56E-06 Alzheimer's disease (late onset) CLSTN2 intron 21379329 rs9864332 chr3 140083060 C A 1.10E-05 Urinary metabolites CLSTN2 intron 21572414 rs1026773 chr3 140084268 G T 9.52E-05 Schizophrenia (cytomegalovirus infection interaction) CLSTN2 intron 23358160 rs6770610 chr3 140086027 A G 5.45E-04 Schizophrenia (cytomegalovirus infection interaction) CLSTN2 intron 23358160 rs11719890 chr3 140086874 T C 6.78E-04 Schizophrenia (cytomegalovirus infection interaction) CLSTN2 intron 23358160 rs1026778 chr3 140088610 T C 3.98E-05 Schizophrenia (cytomegalovirus infection interaction) CLSTN2 intron 23358160 rs899622 chr3 140089611 A G 0.000492 Salmonella-induced pyroptosis CLSTN2 intron 22837397 rs1383016 chr3 140090936 G A 6.18E-05 Schizophrenia (cytomegalovirus infection interaction) CLSTN2 intron 23358160 rs1479852 chr3 140093954 G A 0.000209 Salmonella-induced pyroptosis CLSTN2 intron 22837397 rs7618673 chr3 140094984 T G 0.000381 Salmonella-induced pyroptosis CLSTN2 intron 22837397 rs13099847 chr3 140097318 A G 0.00033 Salmonella-induced pyroptosis CLSTN2 intron 22837397 rs17411949 chr3 140099693 C T 8.00E-07 Multiple sclerosis (OCB status) CLSTN2 intron 23472185 rs6793803 chr3 140101406 C T 0.0000499 Salmonella-induced pyroptosis CLSTN2 intron 22837397 rs6771702 chr3 140101504 A G 0.000283 Salmonella-induced pyroptosis CLSTN2 intron 22837397 rs1479863 chr3 140112407 G A 2.09E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CLSTN2 intron 20031582 rs4683831 chr3 140114278 G T 2.94E-05 Smoking cessation CLSTN2 intron 18519826 rs4683831 chr3 140114278 G T 8.48E-04 Aortic root size CLSTN2 intron 21223598 rs6439919 chr3 140165322 G A 8.11E-05 Smoking cessation CLSTN2 intron 18519826 rs6810310 chr3 140166125 G C 4.65E-07 Smoking cessation CLSTN2 intron 18519826 rs2162652 chr3 140168977 A C 8.68E-05 HIV-1 viral setpoint CLSTN2 intron 22174851 rs6439924 chr3 140169657 A C 6.00E-05 Crohn's disease CLSTN2 intron 17435756 rs6439924 chr3 140169657 A C 8.00E-07 Hodgkin's lymphoma CLSTN2 intron 24920014 rs11708189 chr3 140175360 G A 2.00E-06 Sudden cardiac arrest CLSTN2 intron 21658281 rs6439926 chr3 140176642 A G 1.30E-05 Urinary metabolites CLSTN2 intron 21572414 rs9836487 chr3 140178279 G A 7.67E-05 Multiple complex diseases CLSTN2 intron 17554300 rs563342 chr3 140190809 G T 2.20E-05 Urinary metabolites CLSTN2 intron 21572414 rs546655 chr3 140198492 T C 8.86E-05 Cognitive test performance CLSTN2 intron 20125193 rs9862730 chr3 140223794 G A 3.00E-06 Fasting insulin (interaction) CLSTN2 intron 24204828 rs9862730 chr3 140223794 G A 4.00E-06 Homeostasis model assessment of insulin resistance (interaction) CLSTN2 intron 24204828 rs349569 chr3 140242181 A G 5.47E-06 Fasting insulin (interaction) CLSTN2 intron 24204828 rs349569 chr3 140242181 A G 7.62E-06 Homeostasis model assessment of insulin resistance (interaction) CLSTN2 intron 24204828 rs4683505 chr3 140247177 C T 4.00E-07 Myopia (pathological) CLSTN2 intron 23049088 rs349543 chr3 140255693 A G 2.10E-05 Urinary metabolites CLSTN2 intron 21572414 rs349549 chr3 140258520 T C 6.21E-05 Progressive supranuclear palsy CLSTN2 intron 21685912 rs9876855 chr3 140278895 A G 2.52E-05 Reading and spelling CLSTN2 intron 23738518 rs9839670 chr3 140278952 G A 3.06E-05 Reading and spelling CLSTN2 intron 23738518 rs16846209 chr3 140288049 A G 2.00E-05 Urinary metabolites / / 21572414 rs347975 chr3 140291413 A G 6.70E-05 Memory performance / / 22105620 rs347970 chr3 140294985 G A 6.41E-04 Bipolar disorder,schizoaffective / / 19567891 rs17350780 chr3 140298563 G A 6.73E-04 Multiple complex diseases / / 17554300 rs1834869 chr3 140298808 G A 5.84E-04 Multiple complex diseases / / 17554300 rs164346 chr3 140306700 G T 7.10E-06 Urinary metabolites / / 21572414 rs347964 chr3 140307406 A G 5.38E-04 Alcohol dependence / / 21314694 rs347965 chr3 140307929 C T 0.0000117 LDL cholesterol particle diameter / / 23263444 rs16850633 chr3 140315715 A G 5.01E-05 Serum metabolites / / 19043545 rs1499876 chr3 140330785 C T 4.50E-05 Serum metabolites / / 19043545 rs1696201 chr3 140353233 C T 1.36E-05 Serum metabolites / / 19043545 rs182827559 chr3 140357428 T C 7.31E-09 Bipolar disorder (body mass index interaction) / / 24322204 rs2649851 chr3 140362036 T G 1.64E-05 Serum metabolites / / 19043545 rs72977016 chr3 140370012 C T 7.00E-09 Bipolar disorder (body mass index interaction) / / 24322204 rs60035994 chr3 140392076 G A 2.53E-08 Bipolar disorder (body mass index interaction) / / 24322204 rs7651388 chr3 140396022 C A 4.61E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs698666 chr3 140399077 G T 4.50E-05 Serum metabolites TRIM42 intron 19043545 rs698675 chr3 140405654 C T 8.36E-05 Lipoproteins TRIM42 intron pha003079 rs79436609 chr3 140417446 T C 3.00E-08 Bipolar disorder (body mass index interaction) TRIM42 intron 24322204 rs1899356 chr3 140456679 C T 4.93E-04 Parkinson's disease / / 16252231 rs7645792 chr3 140476691 A G 7.86E-05 Blood Pressure / / pha003046 rs7630239 chr3 140479023 C A 6.32E-04 Parkinson's disease / / 16252231 rs4437117 chr3 140493471 A G 5.44E-04 Type 2 diabetes / / 17463246 rs2139266 chr3 140526480 C T 9.98E-04 Alzheimer's disease / / 22005930 rs11711439 chr3 140537685 G A 8.99E-04 Parkinson's disease / / 17052657 rs908821 chr3 140540718 A G 3.00E-06 Multiple sclerosis / / 19010793 rs6808549 chr3 140542380 C T 7.11E-05 Bladder cancer / / 19648920 rs9849881 chr3 140566130 T C 5.05E-04 Type 2 diabetes / / 17463246 rs878117 chr3 140642161 G C 4.47E-04 Type 2 diabetes / / 17463246 rs878117 chr3 140642161 G C 4.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs1109284 chr3 140643038 A G 4.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs13100471 chr3 140663931 G A 3.74E-04 Suicide attempts in bipolar disorder SLC25A36 intron 21423239 rs13099216 chr3 140669440 A G 4.63E-04 Suicide attempts in bipolar disorder SLC25A36 intron 21423239 rs7638025 chr3 140669988 C G 4.88E-04 Suicide attempts in bipolar disorder SLC25A36 intron 21423239 rs16850921 chr3 140670142 T C 8.17E-04 Multiple complex diseases SLC25A36 intron 17554300 rs3773837 chr3 140675313 A G 3.15E-04 Multiple complex diseases SLC25A36 intron 17554300 rs141220432 chr3 140676800 C T 4.00E-06 Bipolar disorder (body mass index interaction) SLC25A36 intron 24322204 rs150888153 chr3 140681913 T A 4.00E-06 Bipolar disorder (body mass index interaction) SLC25A36 intron 24322204 rs6439962 chr3 140715552 G A 3.87E-04 Multiple complex diseases / / 17554300 rs11919476 chr3 140723237 T C 9.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs13100444 chr3 140751864 C T 3.33E-05 Hypertension / / 19609347 rs2310868 chr3 140752790 G A 5.05E-05 Hypertension / / 19609347 rs2310869 chr3 140752934 A G 3.79E-05 Hypertension / / 19609347 rs2114514 chr3 140766806 A G 3.59E-04 HIV-1 viral setpoint / / 17641165 rs16851055 chr3 140799213 G A 6.00E-07 Stroke (ischemic) SPSB4 intron 23041239 rs16851055 chr3 140799213 G A 7.00E-07 Stroke (ischemic) SPSB4 intron 24262325 rs16851055 chr3 140799213 G A 8.00E-04 Large artery stroke SPSB4 intron 24262325 rs6788334 chr3 140809235 G T 2.47E-04 Smoking cessation SPSB4 intron 24665060 rs4683553 chr3 140809531 T C 1.73E-04 Smoking cessation SPSB4 intron 24665060 rs6791826 chr3 140810146 G A 3.42E-04 Smoking cessation SPSB4 intron 24665060 rs16851066 chr3 140842821 G A 5.37E-06 Osteoarthritis SPSB4 intron 22763110 rs9841889 chr3 140869794 C T 6.76E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1010717 chr3 140902128 C T 3.78E-05 Orofacial clefts / / 22419666 rs1010717 chr3 140902128 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs17282759 chr3 140905562 T C 4.58E-05 Diabetes Mellitus / / pha003059 rs9859339 chr3 140909061 T C 8.10E-05 Bone mineral density (BMD),in women / / 20164292 rs9289625 chr3 140911204 G A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2086182 chr3 140914251 T C 2.79E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2292400 chr3 140953898 T C 2.60E-06 Asthma ACPL2 intron 21790008 rs16851185 chr3 140960769 T C 4.46E-04 Multiple complex diseases ACPL2 intron 17554300 rs1877219 chr3 140965583 T C 2.33E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ACPL2 intron 24023788 rs4683588 chr3 140969254 C T 2.33E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ACPL2 intron 24023788 rs11713226 chr3 140970556 C T 3.18E-05 HIV-1 control ACPL2 intron 20041166 rs3796259 chr3 140978921 C T 3.14E-06 Asthma ACPL2 intron 21790008 rs3796259 chr3 140978921 C T 6.74E-06 Asthma ACPL2 intron 21790008 rs3796259 chr3 140978921 C T 9.76E-06 Asthma ACPL2 intron 21790008 rs16851254 chr3 140979411 A G 8.00E-06 Cognitive performance ACPL2 intron 19734545 rs6775902 chr3 140995801 C T 6.56E-06 Asthma ACPL2 intron 21790008 rs10935427 chr3 141002564 T C 0.000018 Transmission distortion ACPL2 intron 22377632 rs3210458 chr3 141011630 C G,T 0.0000152 Aging ACPL2 missense 22445811 rs3210458 chr3 141011630 C G,T 5.61E-05 Myopia (pathological) ACPL2 missense 23049088 rs2871887 chr3 141054579 C T 5.81E-04 Multiple complex diseases ZBTB38 intron 17554300 rs4683602 chr3 141058687 G A 6.00E-05 Amyotrophic Lateral Sclerosis ZBTB38 intron 17827064 rs1346408 chr3 141072289 C T 4.05E-08 Metabolite levels ZBTB38 intron 23281178 rs726838 chr3 141072666 A T 8.26E-07 Red blood cell traits ZBTB38 intron 23222517 rs6784404 chr3 141073675 G A 1.52E-08 Metabolite levels ZBTB38 intron 23281178 rs9866391 chr3 141076084 T C 1.48E-08 Metabolite levels ZBTB38 intron 23281178 rs9857275 chr3 141078188 C A 2.00E-06 Prion diseases ZBTB38 intron 22210626 rs7613516 chr3 141079309 T G 7.03E-08 Metabolite levels ZBTB38 intron 23281178 rs6440001 chr3 141085972 T C 7.48E-08 Metabolite levels ZBTB38 intron 23281178 rs7624084 chr3 141093285 T C 5.72E-08 Metabolite levels ZBTB38 intron 23281178 rs6440003 chr3 141094209 G A 2.00E-24 Height ZBTB38 intron 18391952 rs6440003 chr3 141094209 G A 2.40E-07 Height ZBTB38 intron 19396169 rs6440003 chr3 141094209 G A 1.81E-05 Height ZBTB38 intron 19570815 rs6440003 chr3 141094209 G A 4.51E-07 Height ZBTB38 intron 19893584 rs6440003 chr3 141094209 G A 2.00E-10 Height ZBTB38 intron 21998595 rs6440003 chr3 141094209 G A 7.15E-04 Self-reported allergy ZBTB38 intron 23817569 rs9821337 chr3 141096185 C G 9.13E-04 Self-reported allergy ZBTB38 intron 23817569 rs6764769 chr3 141100280 A G 5.40E-10 Height ZBTB38 UTR-5 21998595 rs6764769 chr3 141100280 A G 7.29E-04 Self-reported allergy ZBTB38 UTR-5 23817569 rs6763931 chr3 141102833 G A 1.00E-27 Height ZBTB38 intron 18391951 rs6763931 chr3 141102833 G A 3.00E-12 Height ZBTB38 intron 19343178 rs6763931 chr3 141102833 G A 5.02E-06 Rheumatoid arthritis ZBTB38 intron 19503088 rs6763931 chr3 141102833 G A 2.21E-05 Height ZBTB38 intron 19570815 rs6763931 chr3 141102833 G A 2.00E-08 Prostate cancer ZBTB38 intron 21743467 rs6763931 chr3 141102833 G A 5.20E-10 Height ZBTB38 intron 21998595 rs6763931 chr3 141102833 G A 5.88E-04 Self-reported allergy ZBTB38 intron 23817569 rs724016 chr3 141105570 A G 1.00E-06 Height ZBTB38 intron 18193045 rs724016 chr3 141105570 A G 8.00E-22 Height ZBTB38 intron 18391950 rs724016 chr3 141105570 A G 2.22E-05 Height ZBTB38 intron 19570815 rs724016 chr3 141105570 A G 3.00E-86 Height ZBTB38 intron 20881960 rs724016 chr3 141105570 A G 2.90E-08 Height ZBTB38 intron 21998595 rs724016 chr3 141105570 A G 5.10E-04 Self-reported allergy ZBTB38 intron 23817569 rs7632381 chr3 141106063 T C 5.09E-04 Self-reported allergy ZBTB38 intron 23817569 rs6808936 chr3 141109321 A G 9.74E-07 Red blood cell traits ZBTB38 intron 23222517 rs6808936 chr3 141109321 A G 6.19E-04 Self-reported allergy ZBTB38 intron 23817569 rs1582874 chr3 141115219 T C 9.56E-07 Red blood cell traits ZBTB38 UTR-5 23222517 rs1582874 chr3 141115219 T C 4.79E-04 Self-reported allergy ZBTB38 UTR-5 23817569 rs2871960 chr3 141121814 A C 5.70E-10 Height ZBTB38 intron 21998595 rs2871960 chr3 141121814 A C 9.26E-07 Red blood cell traits ZBTB38 intron 23222517 rs2871960 chr3 141121814 A C 4.86E-04 Self-reported allergy ZBTB38 intron 23817569 rs1344674 chr3 141125186 A G 1.40E-09 Height ZBTB38 intron 21998595 rs1344674 chr3 141125186 A G 9.64E-07 Red blood cell traits ZBTB38 intron 23222517 rs1344674 chr3 141125186 A G 3.91E-04 Self-reported allergy ZBTB38 intron 23817569 rs1344672 chr3 141125705 C G 5.45E-04 Self-reported allergy ZBTB38 intron 23817569 rs1991431 chr3 141133450 G A 9.57E-07 Red blood cell traits ZBTB38 intron 23222517 rs1991431 chr3 141133450 G A 4.00E-47 Height ZBTB38 intron 23563607 rs1991431 chr3 141133450 G A 7.84E-04 Self-reported allergy ZBTB38 intron 23817569 rs13091182 chr3 141133960 G A 9.00E-10 Myopia (Age of onset) ZBTB38 intron 23468642 rs16851397 chr3 141134818 A G 3.80E-05 Type 2 diabetes ZBTB38 intron 17463246 rs9825379 chr3 141137035 G A 6.00E-09 Height ZBTB38 intron 20189936 rs6785073 chr3 141139330 G A 4.38E-05 Prion diseases ZBTB38 intron 22210626 rs6763927 chr3 141140366 A T 5.79E-07 Red blood cell traits ZBTB38 intron 23222517 rs6763927 chr3 141140366 A T 8.90E-04 Self-reported allergy ZBTB38 intron 23817569 rs9846396 chr3 141140968 C T 6.91E-07 Red blood cell traits ZBTB38 intron 23222517 rs9846396 chr3 141140968 C T 7.62E-04 Self-reported allergy ZBTB38 intron 23817569 rs6440006 chr3 141142691 G A 7.45E-04 Self-reported allergy ZBTB38 intron 23817569 rs10513137 chr3 141143430 G A 3.57E-04 Multiple complex diseases ZBTB38 intron 17554300 rs10513137 chr3 141143430 G A 6.00E-12 Height ZBTB38 intron 19396169 rs10513137 chr3 141143430 G A 8.00E-08 Height ZBTB38 intron 19893584 rs6789653 chr3 141150990 G A,C,T 4.12E-04 Self-reported allergy ZBTB38 intron 23817569 rs7612543 chr3 141158212 G T 3.46E-04 Self-reported allergy ZBTB38 intron 23817569 rs7636914 chr3 141158614 A G 6.54E-04 Self-reported allergy ZBTB38 intron 23817569 rs13059128 chr3 141171190 G A 3.77E-07 Red blood cell traits / / 23222517 rs1077181 chr3 141174956 C A 1.80E-06 Urinary metabolites / / 21572414 rs1077181 chr3 141174956 C A 4.02E-07 Red blood cell traits / / 23222517 rs9289629 chr3 141178347 A G 2.30E-06 Urinary metabolites / / 21572414 rs9289629 chr3 141178347 A G 7.89E-07 Red blood cell traits / / 23222517 rs11709875 chr3 141180511 A G 3.10E-06 Urinary metabolites / / 21572414 rs13088429 chr3 141181790 G A 9.73E-07 Red blood cell traits / / 23222517 rs13083593 chr3 141198568 A G 8.80E-06 Urinary metabolites / / 21572414 rs11917587 chr3 141207575 G A 2.58E-07 Red blood cell traits RASA2 intron 23222517 rs9289634 chr3 141251655 A G 5.00E-07 Red blood cell traits RASA2 intron 23222517 rs6776003 chr3 141266493 G A 4.00E-11 Red blood cell traits RASA2 intron 23222517 rs9850416 chr3 141272216 G A 3.00E-06 Urinary metabolites RASA2 intron 21572414 rs13084444 chr3 141277651 T G 5.30E-06 Urinary metabolites RASA2 intron 21572414 rs11714208 chr3 141295050 A G 1.70E-05 Urinary metabolites RASA2 intron 21572414 rs11714208 chr3 141295050 A G 6.82E-07 Red blood cell traits RASA2 intron 23222517 rs9833121 chr3 141309304 G A 3.00E-06 Urinary metabolites RASA2 intron 21572414 rs295320 chr3 141324556 A G 4.88E-05 Height RASA2 intron 22021425 rs11557453 chr3 141333835 C T 9.77E-04 Self-reported allergy / / 23817569 rs295301 chr3 141338641 G A 3.73E-06 Prion diseases / / 22210626 rs1568173 chr3 141346019 A G 3.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs2640013 chr3 141350123 G A 6.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs2030186 chr3 141350903 C T 9.65E-04 Type 2 diabetes / / 17463246 rs11921014 chr3 141376140 C A 8.00E-06 Coronary artery calcification / / 23870195 rs2640002 chr3 141376570 T C 3.76E-04 Depression (quantitative trait) / / 20800221 rs868767 chr3 141377330 A G 3.26E-04 Multiple complex diseases / / 17554300 rs868768 chr3 141377532 C T 8.51E-04 Multiple complex diseases / / 17554300 rs12485563 chr3 141405708 C T 2.02E-04 Response to cytidine analogues (gemcitabine) LOC646730 intron 24483146 rs9855944 chr3 141418907 G A 1.71E-04 White matter integrity LOC646730 intron 22425255 rs9876068 chr3 141419203 T G 2.94E-05 Type 2 diabetes and other traits LOC646730 intron 19734900 rs7630533 chr3 141440311 G A 7.99E-04 Type 2 diabetes / / 17463246 rs10433346 chr3 141444530 T C 6.48E-04 Type 2 diabetes / / 17463246 rs1105082 chr3 141448766 A G 2.06E-04 Type 2 diabetes / / 17463246 rs16851704 chr3 141452359 C T 1.87E-04 Aortic root size / / 21223598 rs16851720 chr3 141463298 A C 9.00E-09 Hepatitis C induced liver fibrosis RNF7 intron 22841784 rs17195449 chr3 141463803 G T 1.58E-04 Suicide attempts in bipolar disorder RNF7 intron 21423239 rs13078635 chr3 141572495 T C 4.02E-05 Post-operative nausea and vomiting / / 21694509 rs138560542 chr3 141603979 C T 0.0000174 Nonsyndromic striae distensae (stretch marks) ATP1B3 intron 23633020 rs147092892 chr3 141606792 G A 0.0000178 Nonsyndromic striae distensae (stretch marks) ATP1B3 intron 23633020 rs148201066 chr3 141611410 A G 0.0000156 Nonsyndromic striae distensae (stretch marks) ATP1B3 intron 23633020 rs9942 chr3 141663752 A G 3.57E-05 Hearing impairment TFDP2 UTR-3 19047183 rs11569177 chr3 141732321 A G 1.00E-04 Cognitive impairment induced by topiramate TFDP2 intron 22091778 rs11569177 chr3 141732321 A G 2.00E-04 Cognitive impairment induced by topiramate TFDP2 intron 22091778 rs202217285 chr3 141732321 AT A 1.00E-04 Cognitive impairment induced by topiramate TFDP2 intron 22091778 rs202217285 chr3 141732321 AT A 2.00E-04 Cognitive impairment induced by topiramate TFDP2 intron 22091778 rs6781340 chr3 141733417 G T 2.10E-04 Chronic kidney disease TFDP2 intron 21931561 rs4683659 chr3 141735532 C T 2.00E-04 Cognitive impairment induced by topiramate TFDP2 intron 22091778 rs4683659 chr3 141735532 C T 2.00E-04 Cognitive impairment induced by topiramate TFDP2 intron 22091778 rs9848817 chr3 141752804 T C 4.72E-04 Multiple complex diseases TFDP2 intron 17554300 rs9848817 chr3 141752804 T C 8.00E-05 Electrocardiographic conduction measures TFDP2 intron 19389651 rs347689 chr3 141781890 G T 3.06E-04 Multiple complex diseases TFDP2 intron 17554300 rs347682 chr3 141805388 G A 5.18E-04 Multiple complex diseases TFDP2 intron 17554300 rs347684 chr3 141806655 T C 3.41E-04 Multiple complex diseases TFDP2 intron 17554300 rs347685 chr3 141807137 C A 8.55E-04 Type 2 diabetes TFDP2 intron 17463246 rs347685 chr3 141807137 C A 3.00E-11 Chronic kidney disease TFDP2 intron 20383146 rs347685 chr3 141807137 C A 4.96E-09 Chronic kidney disease TFDP2 intron 22479191 rs347685 chr3 141807137 C A 5.60E-04 Glomerular filtration rate TFDP2 intron 23535967 rs347685 chr3 141807137 C A 6.80E-04 Glomerular filtration rate TFDP2 intron 23535967 rs347685 chr3 141807137 C A 7.30E-04 Glomerular filtration rate TFDP2 intron 23535967 rs347685 chr3 141807137 C A 9.70E-04 Glomerular filtration rate TFDP2 intron 23535967 rs9877817 chr3 141812759 G A 8.09E-06 Lung cancer TFDP2 intron 19654303 rs1397763 chr3 141817436 G A 4.14E-04 Multiple complex diseases TFDP2 intron 17554300 rs11705932 chr3 141818850 C T 6.38E-06 Lung cancer TFDP2 intron 19654303 rs6766782 chr3 141853926 C T 9.78E-04 Multiple complex diseases TFDP2 intron 17554300 rs4624580 chr3 141925404 T C 1.16E-04 Multiple complex diseases GK5 intron 17554300 rs7653823 chr3 141929862 A G 7.85E-07 Red blood cell traits GK5 intron 23222517 rs9882537 chr3 141931635 A T 9.72E-07 Red blood cell traits GK5 intron 23222517 rs6774637 chr3 141952543 T C 8.49E-04 Endometrial cancer / / 24096698 rs6769004 chr3 141954700 G A,T 3.16E-04 Type 2 diabetes / / 17463246 rs6769004 chr3 141954700 G A,T 2.29E-09 Red blood cell traits / / 23222517 rs7644451 chr3 141957076 A G 3.04E-04 Type 2 diabetes / / 17463246 rs7644451 chr3 141957076 A G 3.51E-10 Red blood cell traits / / 23222517 rs13067734 chr3 141963015 C A 1.98E-09 Red blood cell traits / / 23222517 rs11713316 chr3 141979119 A C 9.01E-11 Red blood cell traits / / 23222517 rs13070171 chr3 141981059 G A 2.92E-08 Red blood cell traits / / 23222517 rs13081882 chr3 141982959 C G 1.01E-10 Red blood cell traits / / 23222517 rs7627347 chr3 141984638 T C 1.95E-08 Red blood cell traits / / 23222517 rs11710559 chr3 141985348 T C 3.50E-10 Red blood cell traits / / 23222517 rs7625539 chr3 141988243 C A 1.30E-08 Red blood cell traits / / 23222517 rs11711821 chr3 141989926 G A 1.93E-10 Red blood cell traits / / 23222517 rs7621485 chr3 141992053 G A 1.66E-10 Red blood cell traits / / 23222517 rs7621757 chr3 141992282 G A 1.39E-10 Red blood cell traits / / 23222517 rs6791161 chr3 141992672 T A 9.69E-11 Red blood cell traits / / 23222517 rs6440074 chr3 141996887 A C 8.34E-12 Red blood cell traits / / 23222517 rs36075013 chr3 142000210 C CG 5.80E-07 Red blood cell traits / / 23222517 rs6802667 chr3 142000210 C G 5.80E-07 Red blood cell traits / / 23222517 rs10935459 chr3 142001287 G A 7.35E-11 Red blood cell traits / / 23222517 rs2086932 chr3 142002207 C T 3.19E-08 Red blood cell traits / / 23222517 rs1552340 chr3 142015590 G A 4.13E-04 Body mass index / / 17255346 rs6440077 chr3 142017527 A G 3.76E-08 Red blood cell traits / / 23222517 rs9289647 chr3 142032483 G A 2.50E-07 Red blood cell traits XRN1 intron 23222517 rs9821271 chr3 142034522 A C 2.84E-09 Red blood cell traits XRN1 intron 23222517 rs6440078 chr3 142070495 C T 3.79E-08 Red blood cell traits XRN1 intron 23222517 rs2862745 chr3 142071932 A G 7.66E-08 Red blood cell traits XRN1 intron 23222517 rs3816805 chr3 142076059 A G 4.01E-08 Red blood cell traits XRN1 intron 23222517 rs6802631 chr3 142080583 G T 4.27E-08 Red blood cell traits XRN1 intron 23222517 rs9859834 chr3 142106351 T A 1.31E-04 Body mass index XRN1 intron 17255346 rs6440082 chr3 142114406 G A 6.84E-07 Red blood cell traits XRN1 intron 23222517 rs7643377 chr3 142114694 C T 5.70E-05 Staphylococcus aureus infection XRN1 intron 24847357 rs13061823 chr3 142120786 C T 3.85E-08 Red blood cell traits XRN1 intron 23222517 rs7652687 chr3 142123276 G A 7.38E-07 Red blood cell traits XRN1 intron 23222517 rs1351965 chr3 142123384 A G 1.20E-04 Endometrial cancer XRN1 intron 24096698 rs1351965 chr3 142123384 A G 1.95E-04 Endometrial cancer XRN1 intron 24096698 rs9867210 chr3 142132749 T C 6.17E-05 Staphylococcus aureus infection XRN1 intron 24847357 rs4441672 chr3 142149212 C T 1.35E-07 Red blood cell traits XRN1 intron 23222517 rs9816736 chr3 142172780 T C 1.89E-07 Red blood cell traits ATR intron 23222517 rs6780250 chr3 142179497 T C 2.25E-07 Red blood cell traits ATR intron 23222517 rs3922730 chr3 142202857 A T 4.11E-08 Red blood cell traits ATR intron 23222517 rs7630115 chr3 142210801 G A 1.75E-05 Body mass index ATR intron 17255346 rs4273389 chr3 142213930 A G 1.58E-08 Red blood cell traits ATR intron 23222517 rs531114901 chr3 142215178 A ATC 1.21E-07 Red blood cell traits ATR intron 23222517 rs7620648 chr3 142215178 A C 1.21E-07 Red blood cell traits ATR intron 23222517 rs4256152 chr3 142219542 G A 1.69E-05 Body mass index ATR intron 17255346 rs7634158 chr3 142227902 T C 1.09E-08 Red blood cell traits ATR intron 23222517 rs6791816 chr3 142233990 T C 6.41E-08 Red blood cell traits ATR intron 23222517 rs9855919 chr3 142234589 C A 6.22E-08 Red blood cell traits ATR intron 23222517 rs9808914 chr3 142241058 T G 5.17E-08 Red blood cell traits ATR intron 23222517 rs9808943 chr3 142241123 T C 5.16E-08 Red blood cell traits ATR intron 23222517 rs13085261 chr3 142242287 G A 1.26E-05 Body mass index ATR intron 17255346 rs7651071 chr3 142243850 T A 5.12E-08 Red blood cell traits ATR intron 23222517 rs9683085 chr3 142248498 G A 4.82E-08 Red blood cell traits ATR intron 23222517 rs7647573 chr3 142251583 C T 4.03E-08 Red blood cell traits ATR intron 23222517 rs13065800 chr3 142251714 G A 1.32E-05 Body mass index ATR intron 17255346 rs7636909 chr3 142260562 A G 2.69E-05 Alcohol and nictotine co-dependence ATR intron 20158304 rs13085998 chr3 142263812 T C 3.32E-08 Red blood cell traits ATR intron 23222517 rs13067795 chr3 142263858 C A 3.41E-08 Red blood cell traits ATR intron 23222517 rs13065075 chr3 142265166 T C 6.05E-08 Red blood cell traits ATR intron 23222517 rs9869842 chr3 142272314 G A 8.23E-08 Red blood cell traits ATR intron 23222517 rs2227929 chr3 142277536 A G 1.11E-05 Body mass index ATR cds-synon 17255346 rs2227930 chr3 142277575 A T 8.24E-09 Red blood cell traits ATR cds-synon 23222517 rs2227928 chr3 142281612 A G 1.87E-08 Red blood cell traits ATR missense 23222517 rs12639363 chr3 142292518 A G 1.52E-05 Body mass index ATR intron 17255346 rs6782400 chr3 142295368 C A 2.35E-08 Red blood cell traits ATR intron 23222517 rs6792259 chr3 142301439 A T 1.61E-08 Red blood cell traits / / 23222517 rs7641330 chr3 142305638 T C 1.47E-08 Red blood cell traits / / 23222517 rs9846960 chr3 142308070 G A 3.00E-08 Red blood cell traits / / 23222517 rs6799752 chr3 142311712 T C 7.75E-09 Red blood cell traits / / 23222517 rs7610557 chr3 142312371 A G 1.85E-08 Red blood cell traits / / 23222517 rs6440094 chr3 142316443 C T 1.96E-08 Red blood cell traits PLS1 intron 23222517 rs7647212 chr3 142322055 G A 6.73E-06 QRS duration in Tripanosoma cruzi seropositivity PLS1 intron 24324551 rs7647497 chr3 142322333 G A 7.07E-06 QRS duration in Tripanosoma cruzi seropositivity PLS1 intron 24324551 rs9844137 chr3 142323770 T A 4.53E-06 QRS duration in Tripanosoma cruzi seropositivity PLS1 intron 24324551 rs9816128 chr3 142327107 C T 4.53E-06 QRS duration in Tripanosoma cruzi seropositivity PLS1 intron 24324551 rs9816275 chr3 142327240 C G 4.53E-06 QRS duration in Tripanosoma cruzi seropositivity PLS1 intron 24324551 rs7633021 chr3 142327824 T C 4.38E-06 QRS duration in Tripanosoma cruzi seropositivity PLS1 intron 24324551 rs9826463 chr3 142328919 C G 4.00E-06 QRS duration in Tripanosoma cruzi seropositivity PLS1 intron 24324551 rs56383228 chr3 142330863 T C 4.60E-06 QRS duration in Tripanosoma cruzi seropositivity PLS1 intron 24324551 rs6440097 chr3 142331719 G C 4.42E-06 QRS duration in Tripanosoma cruzi seropositivity PLS1 intron 24324551 rs28709617 chr3 142332635 C G 4.41E-06 QRS duration in Tripanosoma cruzi seropositivity PLS1 intron 24324551 rs4413348 chr3 142333025 G A 1.27E-08 Red blood cell traits PLS1 intron 23222517 rs28378300 chr3 142333064 T C 4.40E-06 QRS duration in Tripanosoma cruzi seropositivity PLS1 intron 24324551 rs28647471 chr3 142333164 A C 4.40E-06 QRS duration in Tripanosoma cruzi seropositivity PLS1 intron 24324551 rs4398471 chr3 142333969 A G 4.39E-06 QRS duration in Tripanosoma cruzi seropositivity PLS1 intron 24324551 rs9868309 chr3 142335332 A G 4.37E-06 QRS duration in Tripanosoma cruzi seropositivity PLS1 intron 24324551 rs2049325 chr3 142337430 A G 1.56E-07 Red blood cell traits PLS1 intron 23222517 rs9866958 chr3 142338441 T C 1.10E-08 Red blood cell traits PLS1 intron 23222517 rs9862919 chr3 142341146 G A 4.44E-10 Red blood cell traits PLS1 intron 23222517 rs2030613 chr3 142343391 G A 1.75E-08 Red blood cell traits PLS1 intron 23222517 rs2140432 chr3 142343552 C T 1.83E-08 Red blood cell traits PLS1 intron 23222517 rs2140433 chr3 142343691 C G 4.85E-06 QRS duration in Tripanosoma cruzi seropositivity PLS1 intron 24324551 rs6775813 chr3 142345623 A C 3.25E-08 Red blood cell traits PLS1 intron 23222517 rs1983434 chr3 142347757 A G 4.91E-08 Red blood cell traits PLS1 intron 23222517 rs1357530 chr3 142350756 C T 4.19E-08 Red blood cell traits PLS1 intron 23222517 rs1357529 chr3 142351097 T G 5.57E-08 Red blood cell traits PLS1 intron 23222517 rs6809448 chr3 142353730 C T 7.27E-04 Insulin resistance PLS1 intron 21901158 rs7631313 chr3 142354408 A G 6.90E-07 Red blood cell traits PLS1 intron 23222517 rs6440098 chr3 142355410 G T 4.00E-08 Red blood cell traits PLS1 intron 23222517 rs7615316 chr3 142355926 G A 6.77E-09 Red blood cell traits PLS1 intron 23222517 rs13079246 chr3 142359427 A G 2.24E-09 Red blood cell traits PLS1 intron 23222517 rs9832606 chr3 142360373 G A 1.47E-09 Red blood cell traits PLS1 intron 23222517 rs2883380 chr3 142362402 C T 9.74E-08 Red blood cell traits PLS1 intron 23222517 rs6808205 chr3 142365769 A G 8.14E-08 Red blood cell traits PLS1 intron 23222517 rs4683690 chr3 142366626 T C 2.45E-09 Red blood cell traits PLS1 intron 23222517 rs6798232 chr3 142369839 G A 3.65E-04 Type 2 diabetes PLS1 intron 17463246 rs6798232 chr3 142369839 G A 7.70E-10 Red blood cell traits PLS1 intron 23222517 rs7430429 chr3 142372156 C G 2.88E-04 Type 2 diabetes PLS1 intron 17463246 rs7430429 chr3 142372156 C G 5.93E-09 Red blood cell traits PLS1 intron 23222517 rs11715610 chr3 142375817 G A 2.90E-07 Red blood cell traits PLS1 UTR-5 23222517 rs7648354 chr3 142394620 A G 1.92E-07 Red blood cell traits PLS1 intron 23222517 rs6793735 chr3 142408606 G A 2.78E-09 Red blood cell traits PLS1 cds-synon 23222517 rs9823492 chr3 142411287 A G 2.98E-05 Tuberculosis PLS1 intron 20694014 rs1916638 chr3 142412224 C T 3.28E-04 Dental caries PLS1 intron 21940522 rs1916638 chr3 142412224 C T 0.0007659 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PLS1 intron 23233654 rs1916638 chr3 142412224 C T 7.66E-04 Methotrexate clearance (acute lymphoblastic leukemia) PLS1 intron 23233662 rs11929069 chr3 142420213 C G 0.0007348 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PLS1 intron 23233654 rs11929069 chr3 142420213 C G 7.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) PLS1 intron 23233662 rs3773506 chr3 142431000 G C 9.00E-06 Type 2 diabetes PLS1 UTR-3 21490949 rs9849265 chr3 142435388 T C 1.27E-04 Type 2 diabetes / / 17463246 rs1403725 chr3 142444133 G A 2.20E-04 Intelligence (childhood) TRPC1 intron 23358156 rs13094259 chr3 142444625 G T 6.44E-04 Alcohol dependence TRPC1 intron 20201924 rs953239 chr3 142446205 A C 2.27E-05 Type 2 diabetes TRPC1 intron 17463246 rs9815607 chr3 142510348 G A 7.95E-04 Alcohol dependence TRPC1 intron 20201924 rs7637053 chr3 142514310 G C 4.57E-04 Multiple complex diseases TRPC1 intron 17554300 rs16852615 chr3 142516826 G A 5.91E-04 HIV-1 viral setpoint TRPC1 intron 17641165 rs4627 chr3 142526594 T C 1.18E-05 Response to tocilizumab in rheumatoid arthritis TRPC1 UTR-3 22491018 rs116465281 chr3 142535266 C T 4.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs16852641 chr3 142541514 A C 1.47E-05 Intracerebral hemorrhage PCOLCE2 intron 24656865 rs9841007 chr3 142541687 T C 1.52E-04 Alcohol dependence PCOLCE2 intron 20201924 rs9681405 chr3 142547417 C T 4.60E-05 Bipolar disorder and schizophrenia PCOLCE2 intron 20889312 rs7624656 chr3 142585802 T C 1.70E-05 HIV-1 control PCOLCE2 intron 20041166 rs2707985 chr3 142599820 C T 2.70E-05 Urinary metabolites PCOLCE2 intron 21572414 rs16852815 chr3 142633319 T C 6.00E-07 Personality dimensions / / 18957941 rs893885 chr3 142634888 T A 4.34E-04 Smoking quantity / / 24665060 rs9832727 chr3 142649110 C G 6.00E-29 Phospholipid levels (plasma) LOC100507389 intron 22359512 rs9844683 chr3 142672769 T C 6.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs4683457 chr3 142865170 T C 2.10E-05 Multiple complex diseases / / 17554300 rs6805378 chr3 142866513 G T 5.20E-06 Urinary metabolites / / 21572414 rs1449866 chr3 142876633 G T 1.80E-05 Lipid traits / / 17903299 rs1449866 chr3 142876633 G T 4.07E-05 Bone mineral density / / 19181680 rs1449867 chr3 142887460 A C 5.78E-04 Multiple complex diseases / / 17554300 rs17572584 chr3 142888043 C T 9.70E-07 Asthma / / 20698975 rs10935483 chr3 142890392 T C 2.89E-05 Bone mineral density / / 19181680 rs894177 chr3 142894411 G A 3.00E-06 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1372288 chr3 142901537 T C 3.43E-08 N-glycan levels,in plasma / / 21908519 rs1372288 chr3 142901537 T C 3.60E-13 N-glycan levels,in plasma / / 21908519 rs54520 chr3 142904112 C G 4.28E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs6786129 chr3 142913697 A G 6.79E-04 Substance dependence / / 21818250 rs4839637 chr3 142939948 A G 9.62E-04 Type 2 diabetes / / 17463246 rs4839604 chr3 142960273 C T 3.50E-13 N-glycan levels,in plasma / / 21908519 rs4839604 chr3 142960273 C T 3.57E-08 N-glycan levels,in plasma / / 21908519 rs11921088 chr3 142964147 A G 5.19E-04 Insulin resistance / / 21901158 rs9289659 chr3 142971279 A C 4.57E-05 Blood Pressure / / pha003040 rs7625382 chr3 142979264 C T 6.62E-06 Blood Pressure / / pha003040 rs7625382 chr3 142979264 C T 9.00E-05 Diabetes Mellitus / / pha003059 rs9857832 chr3 142980880 T C 7.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9810857 chr3 142982899 A G 6.00E-06 Attention deficit hyperactivity disorder / / 20732626 rs9810857 chr3 142982899 A G 7.14E-05 Information processing speed / / 21130836 rs2289492 chr3 142987912 C T 4.18E-04 Premature ovarian failure SLC9A9 intron 19508998 rs7641350 chr3 142991226 T C 3.31E-04 Premature ovarian failure SLC9A9 intron 19508998 rs7639109 chr3 142994194 C T 7.92E-04 Alcohol dependence SLC9A9 intron 21314694 rs1501626 chr3 142994822 G A 8.87E-05 Coronary heart disease SLC9A9 intron pha003031 rs17636071 chr3 143005029 T C 4.19E-04 Type 2 diabetes SLC9A9 intron 17463246 rs17636071 chr3 143005029 T C 2.00E-06 Response to cholinesterase inhibitors in Alzheimer's disease SLC9A9 intron 23374588 rs6806500 chr3 143013203 G A 3.81E-04 Premature ovarian failure SLC9A9 intron 19508998 rs986376 chr3 143017187 T C 8.46E-04 QT interval SLC9A9 intron 22726844 rs6440162 chr3 143020269 T C 9.61E-04 Amyotrophic lateral sclerosis (sporadic) SLC9A9 intron 24529757 rs1393072 chr3 143020870 T C 3.38E-05 Lipoproteins SLC9A9 intron pha003079 rs1112189 chr3 143029589 G A 9.42E-05 Non-alcoholic fatty liver disease histology (other) SLC9A9 intron 20708005 rs17574671 chr3 143029792 G A 3.75E-04 Depression (quantitative trait) SLC9A9 intron 20800221 rs17574746 chr3 143032500 C T 2.09E-04 Depression (quantitative trait) SLC9A9 intron 20800221 rs17636943 chr3 143037998 C T 6.90E-04 Depression (quantitative trait) SLC9A9 intron 20800221 rs1501630 chr3 143044216 C T 7.13E-06 Personality dimensions SLC9A9 intron 23658558 rs12488603 chr3 143044440 G T 9.21E-04 Depression (quantitative trait) SLC9A9 intron 20800221 rs7431637 chr3 143049769 T C 0.00000758 Alcohol dependence SLC9A9 intron 23089632 rs7431637 chr3 143049769 T C 0.00036 Alcohol dependence SLC9A9 intron 23089632 rs729511 chr3 143055707 G A 1.65E-04 Type 2 diabetes SLC9A9 intron 17463246 rs7632299 chr3 143056467 G A 4.00E-06 Non-alcoholic fatty liver disease histology (lobular) SLC9A9 intron 20708005 rs16853457 chr3 143059497 C A 2.06E-04 Alzheimer's disease (late onset) SLC9A9 intron 21379329 rs10446322 chr3 143068250 A G 0.00000173 Alcohol dependence SLC9A9 intron 23089632 rs10446322 chr3 143068250 A G 0.0000577 Alcohol dependence SLC9A9 intron 23089632 rs6775025 chr3 143069304 T C 6.08E-04 Nicotine smoking SLC9A9 intron 19268276 rs16853475 chr3 143074614 C T 5.30E-04 QT interval SLC9A9 intron 22726844 rs868702 chr3 143085345 G A 0.0000258 Alcohol dependence SLC9A9 intron 23089632 rs868702 chr3 143085345 G A 1.73E-06 Alcohol dependence SLC9A9 intron 23089632 rs4839627 chr3 143086243 A G 9.10E-07 Major depressive disorder SLC9A9 intron 19065144 rs7619769 chr3 143090003 A G 4.47E-04 Substance dependence phenotypes SLC9A9 intron 24832863 rs7619769 chr3 143090003 A G 4.78E-06 Substance dependence phenotypes SLC9A9 intron 24832863 rs11715693 chr3 143090698 C T 8.79E-06 Substance dependence phenotypes SLC9A9 intron 24832863 rs6440165 chr3 143097448 G A 2.57E-05 Recombination rate SLC9A9 intron 21698098 rs13099124 chr3 143100626 C A 2.90E-05 Major depressive disorder SLC9A9 intron 21621269 rs11711068 chr3 143126720 G A 5.66E-05 Major depressive disorder SLC9A9 intron 21621269 rs10513201 chr3 143138382 G A 8.62E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SLC9A9 intron 24023788 rs11923950 chr3 143160538 G T 7.61E-05 Response to taxane treatment (placlitaxel) SLC9A9 intron 23006423 rs4839595 chr3 143163169 G A 1.95E-04 Lung function (forced expiratory volume in 1 second) SLC9A9 intron 24023788 rs4839595 chr3 143163169 G A 3.73E-04 Lung function (forced vital capacity) SLC9A9 intron 24023788 rs1875463 chr3 143165502 T C 0.00000151 Rheumatoid arthritis SLC9A9 intron 23143596 rs1875463 chr3 143165502 T C 0.0000475 Rheumatoid arthritis (CCP negative) SLC9A9 intron 23143596 rs1875463 chr3 143165502 T C 0.000288 Rheumatoid arthritis (CCP positive) SLC9A9 intron 23143596 rs2582354 chr3 143171885 G A 7.27E-04 Response to cytadine analogues (cytosine arabinoside) SLC9A9 intron 24483146 rs61385953 chr3 143176066 C T 1.58E-41 Metabolite levels SLC9A9 intron 22286219 rs1723034 chr3 143177248 C T 4.77E-04 Alcohol dependence SLC9A9 intron 20201924 rs1723034 chr3 143177248 C T 7.27E-04 Response to cytadine analogues (cytosine arabinoside) SLC9A9 intron 24483146 rs838610 chr3 143178526 A C 4.23E-04 Alcohol dependence SLC9A9 intron 20201924 rs838610 chr3 143178526 A C 7.27E-04 Response to cytadine analogues (cytosine arabinoside) SLC9A9 intron 24483146 rs838610 chr3 143178526 A C 7.49E-04 Smoking initiation SLC9A9 intron 24665060 rs838612 chr3 143178775 C G 4.47E-04 Response to cytadine analogues (cytosine arabinoside) SLC9A9 intron 24483146 rs1525011 chr3 143180612 A G 2.53E-05 Socioeconomic Factors SLC9A9 intron pha003066 rs838621 chr3 143188053 C T 4.64E-04 Alcohol dependence SLC9A9 intron 20201924 rs838621 chr3 143188053 C T 5.02E-04 Response to cytadine analogues (cytosine arabinoside) SLC9A9 intron 24483146 rs10513205 chr3 143200129 C T 2.00E-04 Cognitive impairment induced by topiramate SLC9A9 intron 22091778 rs838601 chr3 143216783 G A 7.23E-05 Arthritis (juvenile idiopathic) SLC9A9 intron 22354554 rs9289666 chr3 143244982 A G 3.00E-04 Nicotine dependence SLC9A9 intron 17158188 rs9289666 chr3 143244982 A G 4.13E-05 Alzheimer's disease SLC9A9 intron 22005930 rs1371924 chr3 143250070 T C 4.00E-06 Tonometry SLC9A9 intron 17903302 rs13099818 chr3 143253814 C T 9.60E-05 Waist Circumference SLC9A9 intron pha003023 rs16853767 chr3 143254045 G A 1.00E-06 Urinary metabolites SLC9A9 intron 21572414 rs7642430 chr3 143257069 T C 1.58E-04 Smoking initiation SLC9A9 intron 24665060 rs6791556 chr3 143264183 C T 1.98E-05 Waist Circumference SLC9A9 intron pha003023 rs10513209 chr3 143269658 C T 2.24E-05 Osteoarthritis SLC9A9 intron 19508968 rs4839641 chr3 143271854 T G 4.67E-05 Waist Circumference SLC9A9 intron pha003023 rs12633124 chr3 143281983 G A 9.80E-06 Urinary metabolites SLC9A9 intron 21572414 rs1025813 chr3 143283337 C T 4.79E-05 Waist Circumference SLC9A9 intron pha003023 rs1440730 chr3 143286344 C T 4.58E-05 Waist Circumference SLC9A9 intron pha003023 rs6784124 chr3 143291957 C T 2.80E-05 Urinary metabolites SLC9A9 intron 21572414 rs12494880 chr3 143292831 G A 2.32E-04 Smoking initiation SLC9A9 intron 24665060 rs13076949 chr3 143297591 A C 7.79E-04 Smoking initiation SLC9A9 intron 24665060 rs4024563 chr3 143304507 C A,G,T 5.30E-06 Urinary metabolites SLC9A9 intron 21572414 rs17582102 chr3 143311453 T C 3.61E-04 Osteoarthritis SLC9A9 intron 19508968 rs10513212 chr3 143314564 G C 8.40E-04 Type 2 diabetes and 6 quantitative traits SLC9A9 intron 17848626 rs9811274 chr3 143347484 G A 8.37E-05 HDL cholesterol SLC9A9 intron pha003075 rs1534162 chr3 143356977 C T 3.82E-05 Diabetes Mellitus SLC9A9 intron pha003059 rs1320916 chr3 143373319 A G 7.33E-04 Alzheimer's disease SLC9A9 intron 24755620 rs1242058 chr3 143377573 C A 1.00E-04 Prostate cancer SLC9A9 intron 21743057 rs1992864 chr3 143406442 C T 7.48E-04 Nicotine smoking SLC9A9 intron 19268276 rs1597081 chr3 143421239 A C 8.51E-05 Non-alcoholic fatty liver disease histology (other) SLC9A9 intron 20708005 rs2801 chr3 143424787 C T 5.13E-05 Serum metabolites SLC9A9 intron 19043545 rs2800 chr3 143424822 C T 3.00E-06 Non-alcoholic fatty liver disease histology (other) SLC9A9 intron 20708005 rs4240552 chr3 143424849 G C 4.76E-05 Serum metabolites SLC9A9 intron 19043545 rs1122452 chr3 143427340 C G 5.09E-05 Serum metabolites SLC9A9 intron 19043545 rs1124329 chr3 143427439 T G 3.40E-04 Type 2 diabetes SLC9A9 intron 17463246 rs16854155 chr3 143431103 T C 3.85E-04 Multiple complex diseases SLC9A9 intron 17554300 rs9289667 chr3 143431923 T C 2.05E-04 Body mass index SLC9A9 intron 17255346 rs9819844 chr3 143440367 T C 3.00E-05 Response to statin therapy SLC9A9 intron 20339536 rs6807319 chr3 143440698 T G 3.00E-05 Response to statin therapy SLC9A9 intron 20339536 rs4330252 chr3 143442860 C T 7.80E-04 Smoking cessation SLC9A9 intron 24665060 rs7645841 chr3 143443103 C A 5.00E-06 QT interval in Tripanosoma cruzi seropositivity SLC9A9 intron 24324551 rs9829503 chr3 143447722 T C 5.20E-05 Diabetic retinopathy SLC9A9 intron 21441570 rs7616384 chr3 143453195 C A 1.18E-06 Diabetes Mellitus SLC9A9 intron pha003059 rs7616384 chr3 143453195 C A 6.37E-05 Glucose levels SLC9A9 intron pha003061 rs16854224 chr3 143455010 A G 2.10E-06 Diabetes Mellitus SLC9A9 intron pha003059 rs16854224 chr3 143455010 A G 6.68E-05 Glucose levels SLC9A9 intron pha003061 rs4839608 chr3 143497630 C T 2.30E-05 Urinary metabolites SLC9A9 intron 21572414 rs6805483 chr3 143498566 C T 3.38E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLC9A9 intron 22566498 rs13059339 chr3 143498642 T G 3.30E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLC9A9 intron 22566498 rs13091085 chr3 143500272 G T 3.30E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLC9A9 intron 22566498 rs12491888 chr3 143502226 A G 3.29E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLC9A9 intron 22566498 rs746351 chr3 143503070 A G 3.29E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLC9A9 intron 22566498 rs2166774 chr3 143504153 C G 3.29E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLC9A9 intron 22566498 rs2166775 chr3 143504533 G A 3.00E-06 Response to angiotensin II receptor blocker therapy SLC9A9 intron 22566498 rs1868179 chr3 143505568 G A 3.28E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLC9A9 intron 22566498 rs16854336 chr3 143510312 C T 3.66E-04 Suicide attempts in bipolar disorder SLC9A9 intron 21041247 rs2361198 chr3 143510847 C T 7.94E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLC9A9 intron 22566498 rs12233446 chr3 143511130 C T 3.84E-04 Suicide attempts in bipolar disorder SLC9A9 intron 21041247 rs2121775 chr3 143512152 A G 3.58E-04 Suicide attempts in bipolar disorder SLC9A9 intron 21041247 rs6800578 chr3 143512737 C T 3.51E-04 Suicide attempts in bipolar disorder SLC9A9 intron 21041247 rs11706302 chr3 143514237 A G 3.42E-04 Suicide attempts in bipolar disorder SLC9A9 intron 21041247 rs11706302 chr3 143514237 A G 4.62E-04 Suicide attempts in bipolar disorder SLC9A9 intron 21041247 rs6807571 chr3 143514942 G A 3.37E-04 Suicide attempts in bipolar disorder SLC9A9 intron 21041247 rs4839610 chr3 143526250 T C 8.25E-06 Glycemic traits (pregnancy) SLC9A9 intron 23903356 rs1868183 chr3 143526685 C G 6.88E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLC9A9 intron 22566498 rs9817066 chr3 143537964 G A 5.24E-04 Type 2 diabetes SLC9A9 intron 22158537 rs9817066 chr3 143537964 G A 2.92E-04 Lung function (forced expiratory volume in 1 second) SLC9A9 intron 24023788 rs12637090 chr3 143540594 A C 3.33E-04 Lung function (forced expiratory volume in 1 second) SLC9A9 intron 24023788 rs4839668 chr3 143541237 C G 2.33E-04 Type 2 diabetes SLC9A9 intron 22158537 rs4839611 chr3 143541467 G C 4.52E-04 Type 2 diabetes SLC9A9 intron 22158537 rs4839669 chr3 143541943 G C 1.23E-04 Nicotine smoking SLC9A9 intron 19268276 rs4839669 chr3 143541943 G C 9.96E-05 Type 2 diabetes SLC9A9 intron 22158537 rs2361204 chr3 143553693 T G 4.36E-06 Blood Pressure SLC9A9 intron pha003039 rs2361204 chr3 143553693 T G 5.40E-05 Blood Pressure SLC9A9 intron pha003045 rs6764661 chr3 143572786 T C 6.07E-06 Blood Pressure / / pha003039 rs6768702 chr3 143574439 T C 3.80E-05 Intelligence (childhood) / / 23358156 rs4839614 chr3 143576347 G A 7.56E-06 Blood Pressure / / pha003039 rs4839614 chr3 143576347 G A 5.80E-06 Blood Pressure / / pha003045 rs4839614 chr3 143576347 G A 5.22E-05 Blood Pressure / / pha003047 rs17275413 chr3 143604632 G C 0.00000449 Behcet's disease / / 23041938 rs9847681 chr3 143704516 C T 2.21E-05 Parent of origin effect on language impairment (paternal) C3orf58 cds-synon 24571439 rs9879081 chr3 143706302 G A 4.46E-05 Parent of origin effect on language impairment (paternal) C3orf58 intron 24571439 rs10935504 chr3 143707802 C T 9.24E-04 Type 2 diabetes C3orf58 intron 17463246 rs16854819 chr3 143736126 A G 8.07E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6767236 chr3 143758399 T G 3.30E-05 Psychosis (methamphetamine induced) / / 23594818 rs11706025 chr3 143762420 C T 9.19E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs13068298 chr3 143772247 T C 8.00E-06 Economic and political preferences (feminism/equality) / / 22566634 rs16854874 chr3 143774531 G A 9.17E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs16854884 chr3 143778708 A C 7.00E-06 Economic and political preferences (feminism/equality) / / 22566634 rs17668478 chr3 143794370 G A 1.96E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9809103 chr3 143825439 A G 9.17E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs9862771 chr3 143828430 C G 5.52E-08 Metabolite levels / / 23281178 rs9825324 chr3 143828642 A G 9.17E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs1445420 chr3 143840744 G A 1.06E-04 Type 2 diabetes / / 17846125 rs12152433 chr3 143848820 T C 7.22E-05 Hypertension / / 19609347 rs11717074 chr3 143853187 C T 9.34E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs4839680 chr3 143902027 T C 1.00E-15 Myopia (pathological) / / 23049088 rs10212266 chr3 143908518 T C 1.60E-04 Intelligence (childhood) / / 23358156 rs9289674 chr3 143962410 C T 4.34E-05 Type 2 diabetes / / 17846125 rs10490849 chr3 144079222 A G 0.0002 Migraine / / 22678113 rs7649937 chr3 144110578 G A 4.83E-04 Multiple complex diseases / / 17554300 rs708475 chr3 144112161 T A 8.70E-04 Multiple complex diseases / / 17554300 rs9289675 chr3 144126032 G A 8.00E-05 Post-operative nausea and vomiting / / 21694509 rs10804694 chr3 144138070 G C 9.90E-04 Multiple complex diseases / / 17554300 rs2569944 chr3 144144945 C T 7.83E-05 Amyotrophic lateral sclerosis / / 20801717 rs2717385 chr3 144261726 G T 8.85E-05 Post-operative nausea and vomiting / / 21694509 rs2575185 chr3 144264442 C T 7.37E-05 Bipolar disorder and schizophrenia / / 20889312 rs12631899 chr3 144268855 T C 2.98E-05 Attention deficit hyperactivity disorder / / 20732627 rs16855622 chr3 144269422 C T 6.73E-04 Multiple complex diseases / / 17554300 rs10490827 chr3 144271458 C T 4.48E-06 Attention deficit hyperactivity disorder / / 20732627 rs16855649 chr3 144283642 A G 5.26E-17 Multiple complex diseases / / 17554300 rs16855649 chr3 144283642 A G 5.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12633370 chr3 144285575 G A 5.03E-06 Attention deficit hyperactivity disorder / / 20732627 rs1989624 chr3 144286112 A G 6.25E-05 Post-operative nausea and vomiting / / 21694509 rs12631326 chr3 144298314 T C 1.14E-05 Attention deficit hyperactivity disorder / / 20732627 rs35172169 chr3 144298450 T C 2.46E-04 Multiple complex diseases / / 17554300 rs16855659 chr3 144301659 C T 1.26E-04 Type 2 diabetes / / 17463246 rs16855659 chr3 144301659 C T 1.28E-05 Attention deficit hyperactivity disorder / / 20732627 rs16855707 chr3 144318425 T C 4.32E-04 Multiple complex diseases / / 17554300 rs7640226 chr3 144320575 A C 3.93E-04 Multiple complex diseases / / 17554300 rs800082 chr3 144340205 C T 3.00E-06 Smoking behavior / / 19247474 rs800086 chr3 144342672 T C 5.19E-04 Myopia (pathological) / / 21095009 rs183670238 chr3 144430822 T C 7.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs7340591 chr3 144473747 T C 2.77E-04 Type 2 diabetes / / 17463246 rs6791012 chr3 144492294 G A 1.17E-05 Cognitive test performance / / 20125193 rs7615606 chr3 144496334 T G 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7651550 chr3 144497412 G A 1.53E-04 Type 2 diabetes / / 17463246 rs6805089 chr3 144511555 C T 9.86E-05 Post-operative nausea and vomiting / / 21694509 rs6440268 chr3 144549968 C T 4.82E-04 Body mass index / / 21701565 rs12630923 chr3 144551335 T C 7.43E-04 Body mass index / / 21701565 rs1401033 chr3 144559115 C T 3.59E-05 Lymphocyte counts / / pha003094 rs1401033 chr3 144559115 C T 8.41E-05 Neutrophil count / / pha003095 rs7644156 chr3 144618021 C G 3.96E-04 Type 2 diabetes / / 17463246 rs57941817 chr3 144631299 G A 0.0000908 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6794760 chr3 144664456 A G 6.56E-04 Smoking initiation / / 24665060 rs7431736 chr3 144773442 T C 0.00000452 LDL cholesterol particle diameter / / 23263444 rs6762817 chr3 144786831 G T 1.00E-04 Prostate cancer / / 21743057 rs13082097 chr3 144792528 A G 0.00000456 LDL cholesterol particle diameter / / 23263444 rs10470456 chr3 144861392 C G 3.25E-04 Multiple complex diseases / / 17554300 rs6763427 chr3 145028224 C T 6.78E-04 Type 2 diabetes / / 17463246 rs10935547 chr3 145030556 C T 4.11E-04 Type 2 diabetes / / 17463246 rs12634033 chr3 145041839 C T 1.80E-05 Reading disability and language impairment / / 24024963 rs1829146 chr3 145059356 T G 3.60E-04 Type 2 diabetes / / 17463246 rs1114002 chr3 145071574 G A 7.35E-04 Type 2 diabetes / / 17463246 rs13072906 chr3 145079739 C T 9.53E-04 Type 2 diabetes / / 17463246 rs1842547 chr3 145081128 A T 9.10E-06 Urinary metabolites / / 21572414 rs1481073 chr3 145105533 G C 9.67E-04 Type 2 diabetes / / 17463246 rs1481073 chr3 145105533 G C 9.10E-06 Urinary metabolites / / 21572414 rs2166819 chr3 145106442 T C 9.68E-04 Type 2 diabetes / / 17463246 rs9681852 chr3 145110301 G C 9.10E-06 Urinary metabolites / / 21572414 rs12631962 chr3 145121567 A G 3.60E-06 Urinary metabolites / / 21572414 rs35631275 chr3 145122223 A G 3.69E-04 Type 2 diabetes / / 17463246 rs35631275 chr3 145122223 A G 1.20E-05 Urinary metabolites / / 21572414 rs344978 chr3 145134188 C T 1.75E-04 Coronary Artery Disease / / 17634449 rs2199940 chr3 145134776 G A 4.20E-06 Urinary metabolites / / 21572414 rs344985 chr3 145136777 C A 2.10E-05 Breast cancer and prostate cancer / / 17903305 rs1564488 chr3 145145521 A C 0.0006489 Sarcoidosis / / 22952805 rs10935555 chr3 145151554 G A 6.00E-06 Urinary metabolites / / 21572414 rs1516545 chr3 145152484 C A 5.20E-06 Urinary metabolites / / 21572414 rs6800998 chr3 145155399 G T 8.90E-04 Type 2 diabetes / / 17463246 rs6800998 chr3 145155399 G T 4.80E-06 Urinary metabolites / / 21572414 rs10513259 chr3 145170449 C G 2.12E-05 Type 2 diabetes / / 17463246 rs345013 chr3 145173788 A G 5.00E-06 Prostate cancer / / 17903305 rs345013 chr3 145173788 A G 5.00E-06 Nasopharyngeal carcinoma / / 20512145 rs345020 chr3 145189041 T C 2.47E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs345020 chr3 145189041 T C 4.99E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7622747 chr3 145213242 C G 9.04E-04 Type 2 diabetes / / 17463246 rs13064850 chr3 145213484 C A 0.000842 Salmonella-induced pyroptosis / / 22837397 rs1481071 chr3 145217859 T C 9.08E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs522711 chr3 145228080 C T 6.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs13091557 chr3 145228614 A G 4.69E-04 Type 2 diabetes / / 17463246 rs624226 chr3 145232366 T G 1.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs624226 chr3 145232366 T G 4.71E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs612188 chr3 145238544 T G 1.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs612188 chr3 145238544 T G 4.65E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2101091 chr3 145245467 C T 0.000822 Salmonella-induced pyroptosis / / 22837397 rs10513261 chr3 145253739 T C 0.000564 Salmonella-induced pyroptosis / / 22837397 rs2695775 chr3 145287372 C A 2.33E-05 F-cell distribution / / 21326311 rs1523023 chr3 145321967 A C 2.95E-04 Lung function (forced vital capacity) / / 24023788 rs1523074 chr3 145355433 G A 8.19E-04 Multiple complex diseases / / 17554300 rs3844271 chr3 145420382 A G 4.19E-04 Suicide attempts in bipolar disorder / / 21041247 rs2459136 chr3 145425046 T G 5.11E-04 Type 2 diabetes / / 17463246 rs2687861 chr3 145443409 C G 9.75E-04 Type 2 diabetes / / 17463246 rs9845771 chr3 145506189 G C 1.50E-05 Urinary metabolites / / 21572414 rs9866001 chr3 145506580 T C 7.41E-04 Coronary Artery Disease / / 17634449 rs9866001 chr3 145506580 T C 1.20E-05 Urinary metabolites / / 21572414 rs6770379 chr3 145506849 C G 6.29E-04 Coronary Artery Disease / / 17634449 rs6770379 chr3 145506849 C G 1.20E-05 Urinary metabolites / / 21572414 rs6440373 chr3 145508776 A G 2.82E-61 Multiple complex diseases / / 17554300 rs9845121 chr3 145513255 A G 1.10E-05 Urinary metabolites / / 21572414 rs7630694 chr3 145542558 T G 3.30E-05 Type 2 diabetes / / 17460697 rs10935586 chr3 145559423 G A 1.20E-05 Urinary metabolites / / 21572414 rs523993 chr3 145614317 T C 1.57E-04 Age-related macular degeneration / / 22125219 rs655679 chr3 145618422 C A 1.50E-04 Age-related macular degeneration / / 22125219 rs6440401 chr3 145623801 A G 4.70E-05 Response to hepatitis C treatment / / 19684573 rs6440401 chr3 145623801 A G 2.55E-04 Age-related macular degeneration / / 22125219 rs1913293 chr3 145626368 G A 4.89E-05 Response to hepatitis C treatment / / 19684573 rs1913293 chr3 145626368 G A 2.56E-04 Age-related macular degeneration / / 22125219 rs13092361 chr3 145665253 G A 1.40E-05 Urinary metabolites / / 21572414 rs9821424 chr3 145734131 A T 4.14E-04 Insulin resistance / / 21901158 rs1449440 chr3 145819723 G T 4.42E-05 Type 1 diabetes PLOD2 intron 18978792 rs6780480 chr3 145825043 T C 5.41E-04 Suicide attempts in bipolar disorder PLOD2 intron 21423239 rs4681295 chr3 145832664 G A 9.76E-04 Suicide attempts in bipolar disorder PLOD2 intron 21423239 rs12632001 chr3 145849908 T C 4.75E-06 Obesity-related traits PLOD2 intron 23251661 rs1913185 chr3 145888457 T G 2.00E-07 Obesity-related traits / / 23251661 rs1398525 chr3 145894098 T C 6.69E-04 Type 2 diabetes / / 17463246 rs6793582 chr3 145894415 T C 5.21E-04 Type 2 diabetes / / 17463246 rs11928424 chr3 145903426 G T 3.22E-05 HDL particle features / / pha002900 rs1828652 chr3 145915013 C T 7.08E-05 Cognitive test performance PLSCR4 intron 20125193 rs16858040 chr3 145919398 T G 2.29E-23 Multiple complex diseases PLSCR4 intron 17554300 rs9839874 chr3 145921954 T C 9.58E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) PLSCR4 intron 23648065 rs17349248 chr3 145925572 T C 2.96E-05 Sudden cardiac arrest PLSCR4 intron 21658281 rs3762685 chr3 145938619 T C 7.50E-05 Bipolar disorder PLSCR4 missense 17486107 rs9836580 chr3 146027000 T G 7.89E-04 Parkinson's disease / / 17052657 rs9836580 chr3 146027000 T G 5.26E-04 Heart Failure / / pha002885 rs1606264 chr3 146032307 T C 2.87E-05 Serum metabolites / / 19043545 rs1160641 chr3 146033145 G A 7.89E-04 Parkinson's disease / / 17052657 rs1160641 chr3 146033145 G A 5.74E-04 Heart Failure / / pha002885 rs12495688 chr3 146042845 C T 4.13E-04 Parkinson's disease / / 17052657 rs1912892 chr3 146049601 C T 7.13E-04 Multiple complex diseases / / 17554300 rs7642687 chr3 146062738 A G 4.10E-04 Multiple complex diseases / / 17554300 rs9842818 chr3 146067740 C T 5.41E-04 Parkinson's disease / / 17052657 rs6803636 chr3 146117041 C T 5.16E-05 Cognitive impairment induced by topiramate LOC440981 intron 22091778 rs6803636 chr3 146117041 C T 3.89E-05 Amyotrophic lateral sclerosis (sporadic) LOC440981 intron 24529757 rs1403641 chr3 146178101 T C 1.50E-04 Type 2 diabetes and 6 quantitative traits PLSCR2 intron 17848626 rs1870424 chr3 146231988 T C 9.90E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs3773521 chr3 146257359 G A 1.10E-05 Urinary metabolites PLSCR1 intron 21572414 rs2587012 chr3 146258670 C A 4.00E-04 Type 2 diabetes PLSCR1 intron 17846126 rs342931 chr3 146295559 C T 7.20E-05 Serum metabolites / / 19043545 rs17367522 chr3 146312160 T A 3.00E-04 Multiple complex diseases PLSCR5 intron 17554300 rs342912 chr3 146339790 A C 7.38E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs10513283 chr3 146345928 A G 2.23E-04 Multiple complex diseases / / 17554300 rs17434589 chr3 146346195 T C 2.42E-04 Multiple complex diseases / / 17554300 rs17368986 chr3 146352140 G A 4.14E-04 Multiple complex diseases / / 17554300 rs2868452 chr3 146391374 T C 7.41E-05 Major depressive disorder / / 21621269 rs2868452 chr3 146391374 T C 3.18E-05 Major depressive disorder / / pha002850 rs10935638 chr3 146394094 C T 1.75E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs1912785 chr3 146402171 G A 8.00E-06 Barrett's esophagus / / 22961001 rs1912785 chr3 146402171 G A 8.00E-06 Body mass index / / 22982992 rs114774257 chr3 146409183 T C 5.00E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs6440448 chr3 146412213 T C 6.92E-05 Multiple complex diseases / / 17554300 rs9872768 chr3 146414212 C T 0.000324532 Hypertension (early onset hypertension) / / 22479346 rs1521580 chr3 146521978 G A 9.98E-05 Elbow pain / / pha003008 rs1431969 chr3 146541654 T C 7.33E-04 Type 2 diabetes / / 17463246 rs1431969 chr3 146541654 T C 6.49E-05 Elbow pain / / pha003008 rs1431969 chr3 146541654 T C 4.26E-05 Weight / / pha003026 rs7636940 chr3 146544813 C T 2.01E-04 Type 2 diabetes / / 17463246 rs1978683 chr3 146570867 T C 0.000347199 Hypertension (early onset hypertension) / / 22479346 rs1521588 chr3 146572777 G C 2.11E-04 Type 2 diabetes / / 17463246 rs9816683 chr3 146601714 G T 1.86E-05 Acne (severe teenage) / / 24114350 rs6792682 chr3 146618768 T C 1.07E-04 Bipolar disorder,schizoaffective / / 19567891 rs6792682 chr3 146618768 T C 1.08E-05 Acne (severe teenage) / / 24114350 rs12629805 chr3 146632164 T C 9.44E-04 Alzheimer's disease / / 22005930 rs12629805 chr3 146632164 T C 3.00E-06 Subcutaneous adipose tissue / / 22589738 rs4643673 chr3 146647304 C T 5.55E-05 Melanoma / / 21926416 rs4610191 chr3 146650887 G A 4.05E-04 Multiple complex diseases / / 17554300 rs7624556 chr3 146683672 G A 7.02E-04 Multiple complex diseases / / 17554300 rs7624556 chr3 146683672 G A 9.19E-04 Coronary heart disease / / 21606135 rs1354197 chr3 146709009 C T 2.54E-04 Fibrinogen / / 17255346 rs6809481 chr3 146713537 C A 4.23E-04 Fibrinogen / / 17255346 rs6774215 chr3 146713828 T C 5.09E-05 Height / / pha003011 rs1995392 chr3 146719217 C T 7.16E-04 Multiple complex diseases / / 17554300 rs6798430 chr3 146729939 C T 4.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs2047764 chr3 146750925 C T 8.18E-05 Suicide attempts in bipolar disorder / / 21423239 rs1910100 chr3 146758581 C G 5.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs16859029 chr3 146759515 G A 4.65E-04 Type 2 diabetes / / 17463246 rs11717721 chr3 146797378 G A 8.26E-04 HIV-1 viral setpoint / / 17641165 rs1502106 chr3 146804159 C A 5.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs9289736 chr3 146809521 G A 1.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs9809259 chr3 146815969 C T 2.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs4681346 chr3 146816711 A C 3.00E-06 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia / / 24039173 rs1604498 chr3 146821538 G A 2.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs7635583 chr3 146827987 G T 0.0000662 Height (Pygmy height) / / 22570615 rs2047763 chr3 146858410 A G 2.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs9875931 chr3 146860445 T G 1.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs7642421 chr3 146861521 T A 9.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs9865951 chr3 146867800 G T 6.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs11719030 chr3 146881054 A C 5.90E-06 Urinary metabolites / / 21572414 rs1393295 chr3 146883452 C T 1.96E-04 Body mass index / / 21701565 rs1827419 chr3 146883647 G A 2.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs7625438 chr3 146884607 C T 3.70E-06 Urinary metabolites / / 21572414 rs7625438 chr3 146884607 C T 3.80E-04 Heart Failure / / pha002884 rs7609658 chr3 146886758 A T 3.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs9871116 chr3 146893003 C T 2.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs867828 chr3 146897134 T C 1.69E-04 Body mass index / / 21701565 rs6773881 chr3 146905640 A C 5.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs9289742 chr3 146907198 C T 5.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs2202054 chr3 146922987 C A 1.16E-04 Body mass index / / 21701565 rs16859245 chr3 146934275 G C 1.09E-04 Multiple complex diseases / / 17554300 rs11715829 chr3 146957166 T C 0.00000868 Gains in maximal O2 uptake response / / 21183627 rs12695835 chr3 146960644 C T 1.23E-04 Body mass index / / 21701565 rs1996711 chr3 146980646 T C 1.47E-04 Body mass index / / 21701565 rs7623067 chr3 147000441 T A 7.01E-04 Body mass index / / 21701565 rs6768571 chr3 147016796 G A 7.02E-04 Body mass index / / 21701565 rs2651314 chr3 147063796 A G 4.01E-04 Body mass index / / 21701565 rs1394041 chr3 147096847 C A 5.60E-05 Lipid traits / / 17903299 rs7614043 chr3 147122182 G A 7.43E-04 Smoking initiation ZIC4 intron 24665060 rs2202285 chr3 147135736 C A,G,T 5.03E-04 Smoking initiation / / 24665060 rs7640258 chr3 147141379 C A 5.96E-04 Smoking initiation / / 24665060 rs9840229 chr3 147179404 T A 5.63E-04 Smoking initiation / / 24665060 rs9836676 chr3 147182707 C A 6.27E-04 Smoking initiation / / 24665060 rs9876193 chr3 147200492 G A 8.58E-04 Type 2 diabetes / / 17463246 rs62273834 chr3 147259703 T A 4.89E-05 Epilepsy (remission after treatment) / / 23962720 rs11917877 chr3 147268583 A G 5.01E-06 Pancreatic cancer / / 22158540 rs115602621 chr3 147283295 G A 2.49E-05 Intracerebral hemorrhage / / 24656865 rs115591632 chr3 147287710 T C 2.97E-05 Intracerebral hemorrhage / / 24656865 rs13063052 chr3 147339776 T G 3.25E-05 Response to hepatitis C treatment / / 19684573 rs2319336 chr3 147362266 T C 4.97E-04 Parkinson's disease / / 17052657 rs12633893 chr3 147377500 A G 2.97E-04 Obesity (extreme) / / 21935397 rs13068216 chr3 147379632 C A,G,T 6.67E-04 Alzheimer's disease / / 22005930 rs13094504 chr3 147385216 T C 4.11E-04 Alzheimer's disease / / 22005930 rs13084164 chr3 147387379 C T 4.74E-04 Alzheimer's disease / / 22005930 rs13096069 chr3 147389299 A G 9.75E-04 Multiple complex diseases / / 17554300 rs7622746 chr3 147390505 G A 3.90E-06 Coffee consumption / / 21357676 rs16859648 chr3 147394647 G T 1.90E-05 Urinary metabolites / / 21572414 rs13324393 chr3 147395072 T A 2.60E-05 Urinary metabolites / / 21572414 rs9864940 chr3 147435803 T C 9.16E-05 Post-operative nausea and vomiting / / 21694509 rs7642279 chr3 147455409 A G 3.87E-06 Esophageal cancer (squamous cell) / / 22960999 rs10513320 chr3 147472375 G A 1.30E-04 Lipid traits / / 17903299 rs10428219 chr3 147494219 G A 5.00E-06 Body mass index / / 20818722 rs9682099 chr3 147495559 G A 3.53E-05 Neuroblastoma / / pha002895 rs1116439 chr3 147599246 C T 8.80E-06 Urinary metabolites / / 21572414 rs10935679 chr3 147602431 G A 2.80E-06 Urinary metabolites / / 21572414 rs11925068 chr3 147602793 T A 1.20E-05 Urinary metabolites / / 21572414 rs11710688 chr3 147607449 T C 1.20E-05 Urinary metabolites / / 21572414 rs10935681 chr3 147611441 T C 2.20E-06 Urinary metabolites / / 21572414 rs6775904 chr3 147631763 A G 5.77E-04 Smoking quantity / / 24665060 rs10513324 chr3 147693471 T C 1.77E-04 Type 2 diabetes / / 17846124 rs16859998 chr3 147702510 C G 3.32E-04 Multiple complex diseases / / 17554300 rs2061668 chr3 147712979 C A 1.60E-05 Alcohol dependence / / 20201924 rs2061668 chr3 147712979 C A 3.40E-05 Alcohol dependence / / 20201924 rs2061668 chr3 147712979 C A 1.64E-05 Alcoholism / / pha002892 rs2061668 chr3 147712979 C A 3.39E-05 Alcoholism / / pha002893 rs17589187 chr3 147745545 G A 2.05E-04 Multiple complex diseases / / 17554300 rs16860030 chr3 147746622 G A 3.34E-05 Multiple complex diseases / / 17554300 rs1462651 chr3 147753556 C T 8.42E-05 Multiple complex diseases / / 17554300 rs1841770 chr3 147756686 G T 8.00E-06 Multiple sclerosis / / 19010793 rs16860055 chr3 147774140 C T 4.40E-05 Multiple complex diseases / / 17554300 rs9848851 chr3 147774712 G T 3.06E-04 Multiple complex diseases / / 17554300 rs6440527 chr3 147775869 A G 7.02E-04 Multiple complex diseases / / 17554300 rs9833366 chr3 147789187 A G 4.69E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs15606 chr3 147805662 T C 5.64E-04 Longevity / / 22279548 rs9879001 chr3 147827080 T C 1.51E-05 Odorant perception / / 23910658 rs16860117 chr3 147827984 A C 2.18E-05 Multiple complex diseases / / 17554300 rs7645488 chr3 147927668 C T 3.93E-04 Schizophrenia / / 21674006 rs1456669 chr3 147935635 C A 3.55E-06 Longevity,exceptional / / 20595579 rs1456669 chr3 147935635 C A 4.05E-06 Longevity / / 22279548 rs202007557 chr3 147952147 A AG 1.80E-04 Endometriosis / / 21151130 rs9821034 chr3 147952147 A G 1.80E-04 Endometriosis / / 21151130 rs6769088 chr3 147960665 A G 2.92E-04 Multiple complex diseases / / 17554300 rs6769088 chr3 147960665 A G 8.16E-05 Orofacial clefts / / 22419666 rs9813855 chr3 147963123 C G 2.50E-05 Urinary metabolites / / 21572414 rs16860271 chr3 147982777 A G 0.000882 Common carotid artery thickness (average of near and far wall measures) / / 23487405 rs16860271 chr3 147982777 A G 2.27E-04 Myocardial Infarction / / pha002873 rs10804724 chr3 147989624 T C 8.86E-04 Myocardial Infarction / / pha002873 rs16860281 chr3 147995347 T C 7.34E-06 Nicotine smoking / / 19268276 rs11929120 chr3 148037176 G T 5.92E-05 Erythrocyte counts / / pha003090 rs7612531 chr3 148037315 C A,G,T 1.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7612531 chr3 148037315 C A,G,T 7.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6763183 chr3 148048706 A C 8.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9874354 chr3 148102948 A G 4.30E-04 Insulin resistance / / 21901158 rs6440539 chr3 148124129 C T 8.06E-06 Erythrocyte counts / / pha003090 rs4484161 chr3 148160093 C T 1.07E-05 Erythrocyte counts / / pha003090 rs2172347 chr3 148321254 C A 1.21E-05 Weight / / pha003027 rs13077378 chr3 148324342 A G 1.14E-05 Weight / / pha003027 rs6803324 chr3 148335030 C T 9.99E-05 Multiple complex diseases / / 17554300 rs188019 chr3 148336197 G A 6.05E-05 Weight / / pha003027 rs4306816 chr3 148337463 A G 8.35E-06 Weight / / pha003027 rs1879976 chr3 148343517 G A 8.91E-06 Type 2 diabetes / / 21647700 rs9825391 chr3 148346933 G A 1.41E-05 Cognitive test performance / / 20125193 rs6440562 chr3 148358705 C T 4.75E-04 Aortic root size / / 21223598 rs6440565 chr3 148358932 T C 2.40E-05 Parkinson's disease (age of onset) / / 19772629 rs812196 chr3 148369654 C T 5.86E-05 Orofacial clefts / / 22419666 rs421791 chr3 148370256 A G 9.68E-05 Orofacial clefts / / 22419666 rs7617587 chr3 148375111 C T 7.85E-10 Type 2 diabetes / / 23300278 rs17762633 chr3 148383072 A C 6.42E-04 Smoking cessation / / 24665060 rs12721308 chr3 148423081 A G 0.00000495 HDL cholesterol AGTR1 intron 23236364 rs2131127 chr3 148424143 G A 2.62E-04 Scoliosis AGTR1 intron 21216876 rs4681444 chr3 148432574 A C 2.47E-04 Sarcoidosis AGTR1 intron 19165924 rs4524238 chr3 148439788 G A 8.83E-05 Sarcoidosis AGTR1 intron 19165924 rs12721235 chr3 148440374 C A 1.77E-10 Cholesterol,total AGTR1 intron 23063622 rs12721235 chr3 148440374 C A 4.52E-15 LDL cholesterol AGTR1 intron 23063622 rs12721235 chr3 148440374 C A 5.04E-08 Triglycerides AGTR1 intron 23063622 rs12695894 chr3 148442640 A G 1.48E-26 Narcolepsy AGTR1 intron 19629137 rs1826361 chr3 148444728 A C 9.07E-08 LDL cholesterol AGTR1 intron 23063622 rs5182 chr3 148459395 C T 1 Drug response to Captopril AGTR1 cds-synon 18347611 rs5182 chr3 148459395 C T 1 Drug response to Enalapril AGTR1 cds-synon 18347611 rs5182 chr3 148459395 C T 1 Drug response to Fosinopril AGTR1 cds-synon 18347611 rs5182 chr3 148459395 C T 1 Drug response to Imidapril AGTR1 cds-synon 18347611 rs5182 chr3 148459395 C T 1 Drug response to Lisinopril AGTR1 cds-synon 18347611 rs5185 chr3 148459972 T G 0.00000012 Triglycerides AGTR1 UTR-3 23063622 rs5185 chr3 148459972 T G 0.000000131 Cholesterol,total AGTR1 UTR-3 23063622 rs5185 chr3 148459972 T G 1.14E-11 LDL cholesterol AGTR1 UTR-3 23063622 rs5186 chr3 148459988 A C 1 Drug response to Pravastatin AGTR1 UTR-3 11250978 rs5186 chr3 148459988 A C 1 Drug response to Atenolol AGTR1 UTR-3 11593098 rs5186 chr3 148459988 A C 1 Drug response to Losartan AGTR1 UTR-3 11593098 rs2933260 chr3 148517373 A G 7.52E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16861027 chr3 148550124 T G 2.71E-05 Multiple complex diseases CPB1 intron 17554300 rs3772601 chr3 148554759 T C 4.67E-06 Glaucoma (primary open-angle) CPB1 intron 22605921 rs149931188 chr3 148575278 C T 0.0001 Breast cancer CPB1 missense 23555315 rs3772574 chr3 148609672 T G 9.67E-04 Multiple complex diseases CPA3 intron 17554300 rs12163649 chr3 148652620 C T 2.80E-04 Multiple complex diseases / / 17554300 rs2874129 chr3 148652879 T C 2.00E-05 Urinary metabolites / / 21572414 rs12492507 chr3 148675937 G A 2.66E-05 Multiple complex diseases / / 17554300 rs4681471 chr3 148677435 A G 5.33E-05 Cytomegalovirus antibody response / / 21993531 rs6780596 chr3 148679329 A C 0.0000137 Tuberculosis with early age of onset / / 22551897 rs6807987 chr3 148679896 G A 3.16E-04 Multiple complex diseases / / 17554300 rs6440578 chr3 148681703 T C 1.60E-04 Multiple complex diseases / / 17554300 rs16861232 chr3 148682436 T G 9.66E-04 Acute lung injury / / 22295056 rs2029756 chr3 148683203 A G 4.34E-06 Glycemic traits (pregnancy) / / 23903356 rs6803641 chr3 148683977 C T 3.00E-04 Multiple complex diseases / / 17554300 rs6764973 chr3 148686636 C T 0.000000618 Tuberculosis with early age of onset / / 22551897 rs4681164 chr3 148688304 A G 0.0000654 Tuberculosis with early age of onset / / 22551897 rs893980 chr3 148690107 T A 3.13E-04 Multiple complex diseases / / 17554300 rs893979 chr3 148690841 T G 6.23E-04 Multiple complex diseases / / 17554300 rs4681166 chr3 148696479 C G 3.86E-04 Multiple complex diseases / / 17554300 rs4681476 chr3 148718395 G A 6.09E-04 Smoking cessation GYG1 intron 24665060 rs4938 chr3 148727133 G A 3.87E-04 Type 2 diabetes GYG1 cds-synon 17463246 rs4938 chr3 148727133 G A 1.83E-04 Smoking cessation GYG1 cds-synon 24665060 rs3772570 chr3 148736214 C G 9.59E-04 Suicide attempts in bipolar disorder GYG1 intron 21423239 rs7644579 chr3 148741070 A G 6.81E-04 Smoking cessation GYG1 intron 24665060 rs4681478 chr3 148743690 G A 4.80E-04 Smoking cessation GYG1 intron 24665060 rs3182285 chr3 148748380 T C 5.49E-04 Smoking cessation HLTF UTR-3 24665060 rs10513348 chr3 148755861 G A 6.00E-04 Type 2 diabetes HLTF intron 17463246 rs10513348 chr3 148755861 G A 5.15E-04 Smoking cessation HLTF intron 24665060 rs13090196 chr3 148755934 C G 5.15E-04 Smoking cessation HLTF intron 24665060 rs2229361 chr3 148757864 C T 7.67E-04 Glycosylated haemoglobin levels HLTF missense 17255346 rs2290725 chr3 148759325 T C 5.15E-04 Smoking cessation HLTF cds-synon 24665060 rs3816570 chr3 148760285 C G 5.15E-04 Smoking cessation HLTF intron 24665060 rs1017489 chr3 148764090 C T 9.94E-04 Suicide attempts in bipolar disorder HLTF intron 21423239 rs12488819 chr3 148767116 C T 4.84E-04 Type 2 diabetes HLTF intron 17463246 rs12488819 chr3 148767116 C T 5.15E-04 Smoking cessation HLTF intron 24665060 rs12488889 chr3 148767157 G T 5.15E-04 Type 2 diabetes HLTF intron 17463246 rs11715474 chr3 148801915 G T 9.41E-04 Suicide attempts in bipolar disorder HLTF intron 21423239 rs6440583 chr3 148805199 C T 2.81E-04 Smoking cessation / / 24665060 rs7628248 chr3 148807559 C A 6.16E-04 Smoking cessation / / 24665060 rs4681482 chr3 148809472 T A 9.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs12491456 chr3 148810176 G A 2.52E-04 Smoking cessation / / 24665060 rs4280589 chr3 148811983 A G 8.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs13068491 chr3 148812260 C A 8.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs6788799 chr3 148835753 T C 2.33E-05 Smoking cessation / / 24665060 rs9855625 chr3 148842644 C T 1.09E-04 Smoking cessation / / 24665060 rs6805170 chr3 148846090 T G 6.62E-04 Smoking cessation HPS3 nearGene-5 24665060 rs16861598 chr3 148900046 C T 4.07E-04 Multiple complex diseases CP intron 17554300 rs13072552 chr3 148913126 G T 2.00E-11 Serum ceruloplasmin levels CP intron 22075249 rs9834971 chr3 148921003 A C 2.37E-05 Cognitive impairment induced by topiramate CP intron 22091778 rs1879169 chr3 148938346 T C 2.00E-05 Urinary metabolites CP intron 21572414 rs3755641 chr3 148941898 G A 2.10E-05 Urinary metabolites / / 21572414 rs7624706 chr3 148967335 C T 2.08E-05 Height / / pha003010 rs13072463 chr3 148973465 A G 9.93E-04 Tourette syndrome / / 22889924 rs951776 chr3 148974301 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7617219 chr3 148977314 A G 1.00E-06 Subcutaneous adipose tissue / / 22589738 rs11919380 chr3 148993158 G T 5.03E-04 Acute lung injury / / 22295056 rs3845984 chr3 148993743 A T 2.82E-04 Acute lung injury / / 22295056 rs6781013 chr3 148994188 T C 2.52E-04 Acute lung injury / / 22295056 rs903015 chr3 148997630 G A 3.72E-04 Acute lung injury / / 22295056 rs12152496 chr3 148998726 A G 4.10E-04 Acute lung injury / / 22295056 rs6440593 chr3 148999224 G A 6.90E-04 Acute lung injury / / 22295056 rs6440594 chr3 148999343 A G 4.41E-04 Acute lung injury / / 22295056 rs6763649 chr3 148999547 A C 4.19E-04 Acute lung injury / / 22295056 rs1574958 chr3 148999788 T C 4.47E-04 Acute lung injury / / 22295056 rs6801533 chr3 149000041 T C 4.65E-04 Acute lung injury / / 22295056 rs1403724 chr3 149017394 T G 1.74E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1403724 chr3 149017394 T G 8.03E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs9831865 chr3 149033096 G A 2.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9851035 chr3 149038691 T C 4.57E-05 Cognitive decline TM4SF18 UTR-3 22054870 rs9869587 chr3 149056149 C G 1.59E-04 Multiple complex diseases / / 17554300 rs7618084 chr3 149060020 C T 2.54E-04 Multiple complex diseases / / 17554300 rs6786289 chr3 149074545 G A 1.59E-04 Multiple complex diseases / / 17554300 rs6440602 chr3 149075359 C G 4.86E-04 Coronary heart disease / / 21606135 rs9865279 chr3 149079931 C T 3.48E-04 Multiple complex diseases / / 17554300 rs11718592 chr3 149081194 C A 3.03E-05 Multiple complex diseases / / 17554300 rs6440605 chr3 149090907 G T 2.30E-05 Smoking cessation TM4SF1 intron 18519826 rs6440605 chr3 149090907 G T 4.33E-05 Smoking cessation TM4SF1 intron 18519826 rs6808255 chr3 149091756 G T 1.16E-04 Smoking cessation TM4SF1 intron 18519826 rs10935749 chr3 149099575 G A 5.45E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4404386 chr3 149115592 A G 6.87E-05 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs9832360 chr3 149151571 A G 5.51E-05 Serum metabolites / / 19043545 rs4681173 chr3 149177380 A G 2.43E-04 Stroke / / pha002887 rs9880421 chr3 149183359 C T 1.35E-04 Lung function (forced vital capacity) / / 24023788 rs11919764 chr3 149187235 A G 2.94E-04 Lung function (forced vital capacity) / / 24023788 rs9824906 chr3 149192432 C A,G,T 7.30E-05 Response to statin therapy TM4SF4 UTR-5 20339536 rs11920457 chr3 149199869 G A 2.00E-04 Cognitive impairment induced by topiramate TM4SF4 intron 22091778 rs12633863 chr3 149211512 G A 1.87E-04 Lung function (forced vital capacity) TM4SF4 intron 24023788 rs12633863 chr3 149211512 G A 4.80E-04 Lung function (forced expiratory volume in 1 second) TM4SF4 intron 24023788 rs9858201 chr3 149219668 C T 8.34E-05 Body Composition TM4SF4 intron pha003012 rs9858201 chr3 149219668 C T 9.81E-05 Body Mass Index TM4SF4 intron pha003021 rs9823078 chr3 149225023 A T 1.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs6779672 chr3 149225882 A G 1.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs6779678 chr3 149225903 A G 2.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs6440618 chr3 149226255 C T 2.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs7652887 chr3 149232489 C T 8.51E-04 Multiple complex diseases / / 17554300 rs10513354 chr3 149250284 A C 4.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WWTR1 intron 20877124 rs17787940 chr3 149250589 T C 3.00E-06 Preeclampsia WWTR1 intron 23551011 rs10513355 chr3 149251359 A G 4.66E-05 Behcet's disease WWTR1 intron pha002888 rs16861952 chr3 149252824 C A 8.28E-06 Serum alpha1-antitrypsin levels WWTR1 intron 23990791 rs1865604 chr3 149259169 C T 9.45E-05 Intelligence WWTR1 intron 21826061 rs713372 chr3 149277773 C A 1.36E-05 Intelligence WWTR1 intron 21826061 rs16861999 chr3 149279595 T G 5.46E-05 Panic disorder WWTR1 intron 19165232 rs16862007 chr3 149293316 T C 9.67E-04 Type 2 diabetes WWTR1 intron 17463246 rs16862007 chr3 149293316 T C 3.45E-04 Gallstones WWTR1 intron 17632509 rs1344817 chr3 149302530 C T 2.69E-04 Aortic root size WWTR1 intron 21223598 rs1344815 chr3 149340813 A G 7.50E-04 Alcohol dependence WWTR1 intron 20201924 rs9857773 chr3 149344615 C A 4.70E-04 Alcohol dependence WWTR1 intron 20201924 rs6790596 chr3 149347047 G A 4.10E-04 Alcohol dependence WWTR1 intron 20201924 rs6790596 chr3 149347047 G A 4.70E-04 Alcohol dependence WWTR1 intron 20201924 rs7638140 chr3 149347571 G A 3.00E-04 Alcohol dependence WWTR1 intron 20201924 rs7638140 chr3 149347571 G A 4.60E-04 Alcohol dependence WWTR1 intron 20201924 rs10513356 chr3 149384287 T A 4.58E-04 Multiple complex diseases WWTR1 intron 17554300 rs1946704 chr3 149397793 T C 2.03E-04 Multiple complex diseases WWTR1 intron 17554300 rs1435622 chr3 149404001 C G 1.00E-05 Urinary metabolites WWTR1 intron 21572414 rs12107159 chr3 149466594 T G 0.000563754 Hypertension (early onset hypertension) COMMD2 intron 22479346 rs6796427 chr3 149472100 A G 4.11E-11 Lymphocyte counts / / 22286170 rs6796427 chr3 149472100 A G 0.000326413 Hypertension (early onset hypertension) / / 22479346 rs954715 chr3 149479256 A G 0.000771124 Hypertension (early onset hypertension) ANKUB1 UTR-3 22479346 rs6764359 chr3 149531177 T G 2.31E-05 Non-word repetition RNF13 intron 23738518 rs3772200 chr3 149544358 A C 4.11E-05 Waist-Hip Ratio RNF13 intron pha003029 rs12152387 chr3 149582066 T C 7.83E-04 Suicide attempts in bipolar disorder RNF13 intron 21423239 rs9851265 chr3 149667426 C A 7.84E-04 Response to cytadine analogues (cytosine arabinoside) RNF13 intron 24483146 rs3911489 chr3 149672139 A G 0.00000784 HDL cholesterol particle diameter RNF13 intron 23263444 rs9860302 chr3 149681694 A G 3.52E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2219387 chr3 149682156 C T 7.03E-04 Type 2 diabetes / / 17463246 rs2306372 chr3 149696358 A G 6.71E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2007869 chr3 149737330 G A 6.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs16862394 chr3 149754956 C T 5.10E-09 Brain activation patterns in response to human facial expressions-for the negative faces task / / 22828495 rs16862394 chr3 149754956 C T 5.10E-09 Airflow obstruction / / 22837378 rs9874505 chr3 149777163 G A 4.09E-05 Intracerebral hemorrhage / / 24656865 rs4681564 chr3 149777272 C T 1.79E-05 Intracerebral hemorrhage / / 24656865 rs7632916 chr3 149777563 A C 1.71E-05 Intracerebral hemorrhage / / 24656865 rs9846753 chr3 149778944 A T 1.77E-05 Intracerebral hemorrhage / / 24656865 rs4681569 chr3 149814751 C G 2.15E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs4681574 chr3 149823327 T C 3.27E-04 Smoking cessation / / 24665060 rs9834782 chr3 149824179 C A 5.60E-04 Suicide attempts in bipolar disorder / / 21041247 rs6440648 chr3 149829915 T C 9.47E-04 Coronary heart disease / / 21971053 rs12485454 chr3 149844435 C T 8.13E-04 Suicide attempts in bipolar disorder / / 21041247 rs6440651 chr3 149850328 G A 4.93E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2867840 chr3 149871159 G A 8.96E-04 Schizophrenia / / 19197363 rs7617738 chr3 149881712 T C 3.01E-05 Cognitive test performance / / 20125193 rs7634136 chr3 149883483 A G 2.21E-05 Cognitive test performance / / 20125193 rs16862540 chr3 149887788 C G 5.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs1486796 chr3 149888992 T C 5.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs1386291 chr3 149894219 C T 5.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs6802313 chr3 149900094 C G 8.95E-04 Type 2 diabetes / / 17463246 rs4681593 chr3 149917021 A G 4.99E-04 Smoking cessation / / 24665060 rs4681593 chr3 149917021 A G 5.57E-05 Smoking initiation / / 24665060 rs7629819 chr3 149926130 T C 5.70E-04 Taste perception / / 22132133 rs7629819 chr3 149926130 T C 1.61E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7432940 chr3 149980548 G T 8.80E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4301033 chr3 150042618 G A 6.00E-07 Adiponectin levels / / 22479202 rs4301033 chr3 150042618 G A 0.00014 Coronary artery disease / / 23202125 rs2167178 chr3 150065289 A G 1.80E-05 Urinary metabolites / / 21572414 rs1562788 chr3 150065903 A T 1.75E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1012583 chr3 150087008 G A 4.00E-06 IgG glycosylation / / 23382691 rs12639090 chr3 150114504 C T 1.00E-04 Prostate cancer / / 21743057 rs12639090 chr3 150114504 C T 4.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1463229 chr3 150167912 A G 1.68E-05 Esophageal cancer (squamous cell) TSC22D2 intron 22960999 rs6767155 chr3 150173434 A G 7.60E-05 Response to cytadine analogues (cytosine arabinoside) TSC22D2 intron 24483146 rs4681620 chr3 150181413 A G 4.86E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6440677 chr3 150188234 C A 5.50E-06 Lymphocyte counts / / 22286170 rs4586836 chr3 150222435 T A 4.73E-04 Type 2 diabetes / / 17463246 rs9289815 chr3 150229958 G A 3.01E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7638277 chr3 150243878 G A 7.16E-05 Melanoma / / 21926416 rs8180104 chr3 150244772 T G 2.17E-04 Taste perception / / 22132133 rs16862734 chr3 150267585 A T 0.000000494 HDL cholesterol EIF2A intron 23063622 rs9873729 chr3 150315244 T C 7.83E-06 Lymphocyte counts / / 22286170 rs2116691 chr3 150444673 G A 2.89E-05 Personality dimensions / / 22628180 rs6795266 chr3 150445101 G A 2.83E-05 Personality dimensions / / 22628180 rs6788895 chr3 150467808 G T 9.00E-08 Breast cancer SIAH2 intron 22951594 rs935223 chr3 150487531 G A 8.12E-05 Multiple complex diseases / / 17554300 rs7617507 chr3 150499595 A G 6.87E-04 Smoking initiation / / 24665060 rs1220472 chr3 150510292 A C 8.76E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4679980 chr3 150530740 T C 3.88E-06 Kawasaki disease / / 21221998 rs4680005 chr3 150585344 T C 3.41E-04 Alzheimer's disease (late onset) / / 21379329 rs13322091 chr3 150614600 T C 5.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs936189 chr3 150636224 C T 8.61E-05 Multiple complex diseases / / 17554300 rs936189 chr3 150636224 C T 3.50E-05 Major depressive disorder (broad) / / 20038947 rs732289 chr3 150636345 A G 1.58E-04 Multiple complex diseases / / 17554300 rs1456139 chr3 150641304 G A 1.23E-05 Major depressive disorder (broad) / / 20038947 rs9840380 chr3 150647396 T G 5.60E-04 Multiple complex diseases CLRN1 intron 17554300 rs7612632 chr3 150692298 A G 7.43E-04 Coronary heart disease CLRN1-AS1 intron 21971053 rs16863118 chr3 150697208 C T 7.00E-07 IgG glycosylation CLRN1-AS1 intron 23382691 rs16863118 chr3 150697208 C T 8.00E-06 IgG glycosylation CLRN1-AS1 intron 23382691 rs9837084 chr3 150738755 A C 5.93E-04 Response to taxane treatment (placlitaxel) CLRN1-AS1 intron 23006423 rs571170 chr3 150758083 C T 1.10E-05 Urinary metabolites CLRN1-AS1 intron 21572414 rs358954 chr3 150768607 C T 4.50E-06 Urinary metabolites CLRN1-AS1 intron 21572414 rs358958 chr3 150770614 C A 2.92E-04 Parkinson's disease CLRN1-AS1 intron 17052657 rs358958 chr3 150770614 C A 7.87E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CLRN1-AS1 intron 20031582 rs7634663 chr3 150778251 T C 3.18E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CLRN1-AS1 intron 24023788 rs7634663 chr3 150778251 T C 3.30E-04 Lung function (forced expiratory volume in 1 second) CLRN1-AS1 intron 24023788 rs906766 chr3 150811294 C T 1.44E-05 Multiple complex diseases MED12L intron 17554300 rs2048229 chr3 150812674 T C 1.50E-05 Parkinson's disease (familial) MED12L intron 18985386 rs891666 chr3 150827190 A T 2.20E-05 Parkinson's disease (familial) MED12L intron 18985386 rs2567325 chr3 150842234 A G 6.51E-05 Hypertension MED12L intron pha003041 rs1431496 chr3 150891702 C T 8.49E-04 Alzheimer's disease MED12L intron 17998437 rs1882013 chr3 150967269 T C 9.82E-04 Tourette syndrome P2RY14 intron 22889924 rs1920395 chr3 150970686 G A 4.40E-04 Type 2 diabetes P2RY14 intron 17463246 rs10513391 chr3 150984427 T G 9.49E-04 Suicide attempts in bipolar disorder P2RY14 intron 21423239 rs10935833 chr3 150988281 C T 8.19E-04 Suicide attempts in bipolar disorder P2RY14 intron 21423239 rs3773621 chr3 150996434 A C 9.62E-04 Suicide attempts in bipolar disorder MED12L intron 21423239 rs10935835 chr3 150998157 A G 7.09E-04 Prostate cancer mortality MED12L intron 20978177 rs10935835 chr3 150998157 A G 9.53E-04 Suicide attempts in bipolar disorder MED12L intron 21423239 rs4680307 chr3 151000939 T A 8.31E-04 Suicide attempts in bipolar disorder MED12L intron 21423239 rs10513392 chr3 151015241 G A 2.50E-04 Type 2 diabetes and 6 quantitative traits GPR87 intron 17848626 rs11926145 chr3 151019928 A C 9.32E-04 Suicide attempts in bipolar disorder GPR87 intron 21423239 rs6784934 chr3 151039018 A T 7.68E-04 Suicide attempts in bipolar disorder MED12L intron 21423239 rs12107539 chr3 151042464 A G 3.32E-04 Tourette syndrome MED12L intron 22889924 rs12107539 chr3 151042464 A G 4.00E-06 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) MED12L intron 24023788 rs3971192 chr3 151047828 A G 4.00E-05 Parkinson's disease (familial) MED12L intron 18985386 rs10513393 chr3 151054115 G A 6.60E-04 Type 2 diabetes and 6 quantitative traits MED12L intron 17848626 rs6785930 chr3 151056616 G A 9.83E-04 Suicide attempts in bipolar disorder P2RY12 cds-synon 21423239 rs2046934 chr3 151057642 G A 1 Drug response to Aspirin P2RY12 intron 12912815 rs2046934 chr3 151057642 G A 1 Drug response to Clopidogrel P2RY12 intron 12912815 rs2046934 chr3 151057642 G A 1 Drug response to Aspirin P2RY12 intron 14662702 rs2046934 chr3 151057642 G A 1 Drug response to Clopidogrel P2RY12 intron 14662702 rs2046934 chr3 151057642 G A 1 Drug response to Aspirin P2RY12 intron 16181985 rs2046934 chr3 151057642 G A 1 Drug response to Clopidogrel P2RY12 intron 16181985 rs2046934 chr3 151057642 G A 1 Drug response to Aspirin P2RY12 intron 16405973 rs2046934 chr3 151057642 G A 1 Drug response to Clopidogrel P2RY12 intron 16405973 rs2046934 chr3 151057642 G A 1 Drug response to Aspirin P2RY12 intron 16581111 rs2046934 chr3 151057642 G A 1 Drug response to Clopidogrel P2RY12 intron 16581111 rs2046934 chr3 151057642 G A 1 Drug response to Aspirin P2RY12 intron 16769602 rs2046934 chr3 151057642 G A 1 Drug response to Clopidogrel P2RY12 intron 16769602 rs2046934 chr3 151057642 G A 1 Drug response to Aspirin P2RY12 intron 16961627 rs2046934 chr3 151057642 G A 1 Drug response to Clopidogrel P2RY12 intron 16961627 rs2046934 chr3 151057642 G A 1 Drug response to Aspirin P2RY12 intron 17337040 rs2046934 chr3 151057642 G A 1 Drug response to Clopidogrel P2RY12 intron 17337040 rs2046934 chr3 151057642 G A 1 Drug response to Aspirin P2RY12 intron 17803810 rs2046934 chr3 151057642 G A 1 Drug response to Clopidogrel P2RY12 intron 17803810 rs6790448 chr3 151075674 A G 6.96E-05 Partial epilepsies P2RY12 intron 20522523 rs11925037 chr3 151079041 A G 9.22E-04 Suicide attempts in bipolar disorder P2RY12 intron 21423239 rs6787801 chr3 151099741 A G 1.46E-04 Multiple complex diseases P2RY12 intron 17554300 rs10935840 chr3 151101083 A G 6.23E-04 Multiple complex diseases P2RY12 intron 17554300 rs7429509 chr3 151101167 C T 5.96E-05 Postoperative ventricular dysfunction P2RY12 intron 21980348 rs1491974 chr3 151102452 A G 5.11E-04 Multiple complex diseases P2RY12 intron 17554300 rs16863355 chr3 151105407 G T 0.000000344 Triglycerides MED12L intron 23063622 rs12490051 chr3 151118042 T C 2.99E-04 Multiple complex diseases MED12L intron 17554300 rs11708767 chr3 151119726 G A 3.28E-04 Multiple complex diseases MED12L intron 17554300 rs11709550 chr3 151119862 C G 2.79E-04 Multiple complex diseases MED12L intron 17554300 rs10935844 chr3 151128895 T G 6.17E-04 Multiple complex diseases MED12L intron 17554300 rs6781302 chr3 151155620 G A 9.57E-05 Neutrophil count IGSF10 cds-synon pha003095 rs6440747 chr3 151192856 G A 8.20E-04 Alzheimer's disease / / 22005930 rs6440747 chr3 151192856 G A 8.10E-04 Smoking cessation / / 24665060 rs6792286 chr3 151200601 T C 2.05E-05 Height / / 22021425 rs4680474 chr3 151207768 T C 4.35E-05 Schizophrenia / / 20832056 rs6768085 chr3 151208119 T C 3.64E-05 Schizophrenia / / 20832056 rs4679848 chr3 151220186 A G 7.13E-04 Coronary Artery Disease / / 17634449 rs6440770 chr3 151280014 C T 9.18E-04 Alzheimer's disease / / 17998437 rs9289851 chr3 151320010 C T 2.79E-04 Alzheimer's disease / / 17998437 rs4679873 chr3 151335498 G C 9.84E-04 Alzheimer's disease / / 22005930 rs6764062 chr3 151363844 A G 4.28E-04 Type 2 diabetes / / 17463246 rs4679898 chr3 151375575 T C 9.18E-06 Stroke (ischemic) / / 22941190 rs7624285 chr3 151381828 T C 2.19E-05 Creatinine levels / / pha003069 rs2049168 chr3 151396728 C T 4.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1474251 chr3 151436104 G A 2.14E-05 Heart Failure / / pha002885 rs16846748 chr3 151438247 T G 7.96E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16846748 chr3 151438247 T G 1.80E-05 Glucose levels / / pha003057 rs12152279 chr3 151493391 A G 8.69E-04 Taste perception LOC201651 intron 22132133 rs1401970 chr3 151507750 C T 1.95E-05 HDL particle features / / pha002900 rs9874357 chr3 151514705 T C 3.60E-04 Alcohol dependence / / 20201924 rs2120982 chr3 151530121 T C 7.72E-05 Orofacial clefts / / 20023658 rs1803155 chr3 151545601 G A 6.31E-05 Post-operative nausea and vomiting AADAC missense 21694509 rs1881988 chr3 151561598 T C 0.000215 Salmonella-induced pyroptosis / / 22837397 rs6798928 chr3 151579873 A T 3.00E-06 Immunoglobulin A / / 20694011 rs6806340 chr3 151627988 C T 3.85E-05 Hemoglobin / / pha003098 rs6806340 chr3 151627988 C T 9.87E-05 Erythrocyte counts / / pha003099 rs2590705 chr3 151674675 C T 3.37E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs10513403 chr3 151678505 C G 5.11E-05 Bipolar disorder / / 19259986 rs9863347 chr3 151727164 G A 6.86E-05 Heart Rate / / pha003054 rs842522 chr3 151761349 T C 1.67E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs1351267 chr3 151763701 C T 7.00E-06 Schizophrenia / / 23212062 rs13091544 chr3 151784582 A G 1.42E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs13091724 chr3 151784685 A G 1.55E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs4679963 chr3 151784951 G A 1.48E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs4679965 chr3 151785114 A G 1.50E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs4679966 chr3 151785146 T C 1.50E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs71306578 chr3 151786752 T G 1.56E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs34258508 chr3 151787167 A C 1.57E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs13099974 chr3 151787285 T G 1.58E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs13078000 chr3 151787693 C G 1.59E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs17204830 chr3 151787890 A T 1.59E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs71306579 chr3 151788298 G C 1.60E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs4679967 chr3 151788532 A G 1.60E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs74669765 chr3 151788742 C T 2.43E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs74669765 chr3 151788742 C T 2.19E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs4679968 chr3 151788754 G T 2.00E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs4679969 chr3 151788767 T A 8.31E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs71306580 chr3 151790028 C T 1.63E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs4679970 chr3 151790345 C A 1.64E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs4679971 chr3 151790687 A C 1.65E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs4679972 chr3 151790845 A C 1.66E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs35133564 chr3 151792157 T A 1.70E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs4679973 chr3 151792707 T C 1.71E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs4679974 chr3 151792982 G A 1.73E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs13094219 chr3 151793672 T C 1.75E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs17283374 chr3 151793915 G A 1.77E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs71306581 chr3 151794789 C G 1.81E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs17283381 chr3 151795116 A G 1.82E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs34947246 chr3 151795222 C A 1.83E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs17283395 chr3 151795256 T C 1.83E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs71306582 chr3 151795379 A G 1.84E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs17204851 chr3 151795584 T C 1.85E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs17204858 chr3 151796020 G T 1.87E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs17204865 chr3 151796727 G C 1.87E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs11710723 chr3 151797571 T C 1.87E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs114519281 chr3 151797604 C A 1.20E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs34757926 chr3 151798217 A T 1.87E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs35873186 chr3 151798370 G A 1.87E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs13069494 chr3 151798659 A G 1.87E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs13074144 chr3 151798919 A T 1.87E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs13098573 chr3 151799739 T G 1.87E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs13060417 chr3 151799862 T C 1.87E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs13080856 chr3 151799971 G A 1.87E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs13080568 chr3 151800017 C T 1.87E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs13081215 chr3 151800191 G A 1.87E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs13080934 chr3 151800199 C T 1.87E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs13081237 chr3 151800240 G C 1.87E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs13061845 chr3 151800693 T G 1.87E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs10513415 chr3 151800977 C T 1.87E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs13087268 chr3 151801497 A G 1.87E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs71306584 chr3 151801839 A T 1.88E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs556925 chr3 151803306 A G 7.45E-05 Monocyte counts / / pha003089 rs71306585 chr3 151804140 T C 1.94E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs17283423 chr3 151805729 T C 2.01E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs4679976 chr3 151807118 C T 2.04E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs71306586 chr3 151812652 T C 2.27E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs13077931 chr3 151813425 T A 2.31E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs13078008 chr3 151815152 G A 2.63E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs1993937 chr3 151818217 C A 2.59E-04 Myopia (pathological) / / 21095009 rs17204886 chr3 151822139 T G 2.86E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs202037736 chr3 151824298 T TG 1.17E-09 Infantile hypertrophic pyloric stenosis / / 22306654 rs78498091 chr3 151824298 T G 1.17E-09 Infantile hypertrophic pyloric stenosis / / 22306654 rs4679979 chr3 151828456 T C 3.18E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs473170 chr3 151830017 C T 5.76E-05 Monocyte counts / / pha003089 rs4679681 chr3 151830144 G A 3.28E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs11712066 chr3 151830309 A G 2.00E-17 Infantile hypertrophic pyloric stenosis / / 22306654 rs11712066 chr3 151830309 A G 3.00E-21 Infantile hypertrophic pyloric stenosis / / 23989729 rs34534745 chr3 151831603 T G 3.14E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs10513411 chr3 151831998 G A 3.11E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs13063262 chr3 151832313 C T 2.97E-04 Type 2 diabetes / / 17463246 rs13063262 chr3 151832313 C T 3.00E-04 Type 2 diabetes / / 17846124 rs13063262 chr3 151832313 C T 3.07E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs17283444 chr3 151833373 G A 2.99E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs10513410 chr3 151833458 G C 2.98E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs35929413 chr3 151833540 A G 2.95E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs13067441 chr3 151838387 A G 2.66E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs13079834 chr3 151840312 G C 2.58E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs17204907 chr3 151840752 C T 4.94E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs325748 chr3 151841511 A G 1.03E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325747 chr3 151841614 G A 1.03E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs17204928 chr3 151842129 C T 4.77E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs325745 chr3 151842359 T C 1.07E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs11711811 chr3 151842487 G A 4.78E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs325741 chr3 151842974 G A 1.02E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325740 chr3 151843610 C T 1.02E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325738 chr3 151846308 G A 1.01E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325734 chr3 151849275 T C 1.01E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325733 chr3 151849411 A T 1.01E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs167810 chr3 151849502 G T 1.01E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325731 chr3 151850421 C T 1.00E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs226750 chr3 151850483 T G 3.79E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs226749 chr3 151851201 T C 1.00E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325719 chr3 151851509 T A 9.98E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs325721 chr3 151853117 T C 9.96E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs188981 chr3 151854115 A G 9.94E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs325722 chr3 151854485 C T 9.93E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs671935 chr3 151855029 C A 9.93E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs13064084 chr3 151855620 C T 5.03E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs688263 chr3 151856324 G A 9.90E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs325723 chr3 151856675 T C 2.91E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs76663203 chr3 151857207 G A 5.12E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs325725 chr3 151858942 C T 1.00E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325726 chr3 151859117 T C 1.01E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs79805599 chr3 151861601 T C 2.49E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs191758 chr3 151862947 A G 1.24E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs178983 chr3 151863024 T A 1.24E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs35918469 chr3 151863201 T A 7.14E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs325728 chr3 151863457 A T 1.24E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325730 chr3 151864957 T C 1.26E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs11711754 chr3 151865428 A T 1.53E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs11711755 chr3 151865429 A T 2.03E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs11711757 chr3 151865441 A G 1.26E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs34532091 chr3 151865630 T G 1.27E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs1628487 chr3 151865694 T C 1.27E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs600922 chr3 151866403 A C 1.27E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs601007 chr3 151866461 T C 1.27E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs556598 chr3 151866491 C T 1.27E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs601790 chr3 151866606 T C 1.27E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs553904 chr3 151866800 A T 1.28E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs71306587 chr3 151866825 T C 7.86E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs79579178 chr3 151867485 C A 7.97E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs74461807 chr3 151868232 T C 1.31E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs6774740 chr3 151868629 C G 8.14E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs2724677 chr3 151869647 T C 1.30E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs647388 chr3 151869971 T C 1.30E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs11709524 chr3 151870202 G C 8.53E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs661220 chr3 151870686 A C 3.32E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs532659 chr3 151870701 A C 3.54E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs661302 chr3 151870754 A G 2.92E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs2642007 chr3 151871285 C T 1.30E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs675098 chr3 151871493 G A 1.31E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs71306588 chr3 151871513 C G,T 1.03E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs675621 chr3 151871647 C A 1.24E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs478729 chr3 151872225 T C 1.31E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs34320614 chr3 151872952 T A 8.83E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs17204956 chr3 151873058 G A 1.31E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325794 chr3 151873982 G A 1.32E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325793 chr3 151874714 G A 1.32E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325790 chr3 151876214 T C 1.33E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325789 chr3 151877129 T C 1.34E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325788 chr3 151877608 A C 1.34E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs13059913 chr3 151879813 A G 6.70E-04 Type 2 diabetes / / 17463246 rs13059913 chr3 151879813 A G 9.56E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs325785 chr3 151881244 A C 1.32E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs484118 chr3 151881753 G T 1.32E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs650351 chr3 151881914 A G 3.37E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs77006815 chr3 151882732 A G 1.09E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs325784 chr3 151883396 A G 1.42E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs1494014 chr3 151883510 C T 2.60E-04 Type 2 diabetes / / 17463246 rs1494014 chr3 151883510 C T 5.80E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325783 chr3 151883621 A G 1.42E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325782 chr3 151883677 T C 1.41E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325781 chr3 151883726 C A 5.43E-05 Monocyte counts / / pha003089 rs325780 chr3 151885050 T C 6.54E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325775 chr3 151885987 G A 3.41E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325772 chr3 151887185 A G 1.29E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325771 chr3 151887832 A T 1.28E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325770 chr3 151888275 G A 1.27E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs2098930 chr3 151888934 C A 5.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs325768 chr3 151889648 G A 1.15E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325767 chr3 151889737 T G 1.14E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325765 chr3 151889786 T G 1.93E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs13094097 chr3 151890663 A G 5.64E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs325764 chr3 151892364 C T 8.76E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs325763 chr3 151892503 G T 8.66E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs9854676 chr3 151892847 A G 8.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs325762 chr3 151893028 A G 8.85E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs7627592 chr3 151893739 A C 4.27E-04 Type 2 diabetes / / 17463246 rs7627592 chr3 151893739 A C 4.49E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs7627663 chr3 151893780 A T 4.55E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs325761 chr3 151894165 A C 1.02E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs11917315 chr3 151894512 C T 8.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs325760 chr3 151894921 C A,G,T 1.05E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325759 chr3 151895813 T G 1.03E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs325758 chr3 151895859 C T 1.03E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs13084564 chr3 151897838 T C 5.02E-13 Infantile hypertrophic pyloric stenosis / / 22306654 rs323615 chr3 151898400 T A,G 9.92E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs161792 chr3 151899704 T A 9.84E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs641025 chr3 151900225 C G 9.74E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs325712 chr3 151900673 C G 9.65E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs325713 chr3 151900719 C A 9.65E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs75526922 chr3 151901500 A G 2.31E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs16863993 chr3 151901510 G A 4.81E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs323610 chr3 151904190 T G 6.24E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs78008608 chr3 151905505 G A 9.71E-09 Infantile hypertrophic pyloric stenosis / / 22306654 rs1402008 chr3 151920995 C T 4.01E-04 Coronary Artery Disease / / 17634449 rs323628 chr3 151929429 G A 1.34E-04 Stroke / / pha002886 rs755763 chr3 151999929 A G 9.84E-04 Multiple complex diseases MBNL1 intron 17554300 rs12492498 chr3 152008390 A G 2.48E-05 Alzheimer's disease MBNL1 intron 24755620 rs1426383 chr3 152016969 C T 3.09E-05 Alzheimer's disease MBNL1 intron 24755620 rs2681437 chr3 152039322 A G 2.52E-04 Type 2 diabetes MBNL1 intron 17846125 rs3842879 chr3 152044418 C T 3.67E-06 Lipid levels MBNL1 intron 19016617 rs6440796 chr3 152054222 A G 1.35E-04 Alzheimer's disease (late onset) MBNL1 intron 21379329 rs6440796 chr3 152054222 A G 1.79E-05 Alzheimer's disease MBNL1 intron 24755620 rs1382 chr3 152064520 C G 1.78E-05 Alzheimer's disease MBNL1 intron 24755620 rs2036291 chr3 152066793 A G 3.38E-04 Alzheimer's disease (late onset) MBNL1 intron 21379329 rs3920075 chr3 152073055 T C 1.11E-04 Alzheimer's disease (late onset) MBNL1 intron 21379329 rs3920075 chr3 152073055 T C 1.38E-04 Alzheimer's disease MBNL1 intron 24755620 rs2055355 chr3 152077625 A G 1.34E-04 Alzheimer's disease (late onset) MBNL1 intron 21379329 rs2055355 chr3 152077625 A G 1.52E-04 Alzheimer's disease MBNL1 intron 24755620 rs17370519 chr3 152108562 A C 1.37E-13 Lymphocyte counts MBNL1 intron 22286170 rs17370867 chr3 152122752 T C 4.32E-04 Smoking initiation MBNL1 intron 24665060 rs9822902 chr3 152191809 T G 2.63E-04 Smoking initiation / / 24665060 rs1946671 chr3 152193063 A G 2.80E-05 Urinary metabolites / / 21572414 rs9990017 chr3 152206062 T G 4.52E-04 Insulin resistance / / 21901158 rs1434792 chr3 152225685 A G 2.32E-11 Multiple complex diseases / / 17554300 rs6771654 chr3 152256744 A G 2.68E-05 Serum metabolites / / 19043545 rs6784379 chr3 152265596 A C 6.49E-04 Multiple complex diseases / / 17554300 rs2141601 chr3 152324110 T G 2.66E-04 Type 2 diabetes / / 17463246 rs2141601 chr3 152324110 T G 5.02E-04 Major depressive disorder / / 22472876 rs11923297 chr3 152327018 C T 9.43E-04 Type 2 diabetes / / 17463246 rs7613502 chr3 152328725 T G 7.24E-04 Major depressive disorder / / 22472876 rs7646341 chr3 152329006 G A 4.58E-04 Type 2 diabetes / / 17463246 rs11919979 chr3 152331312 A G 4.43E-04 Major depressive disorder / / 22472876 rs6766179 chr3 152337618 G T 2.00E-05 Urinary metabolites / / 21572414 rs1540774 chr3 152360283 T C 7.25E-04 Major depressive disorder / / 22472876 rs4679989 chr3 152364694 T G 6.77E-04 Major depressive disorder / / 22472876 rs9842903 chr3 152385748 C G 5.83E-04 Type 2 diabetes / / 17463246 rs9842903 chr3 152385748 C G 7.55E-04 Major depressive disorder / / 22472876 rs12233485 chr3 152385842 C T 4.12E-04 Type 2 diabetes / / 17463246 rs12695977 chr3 152389757 A G 2.64E-04 Type 2 diabetes / / 17463246 rs9878891 chr3 152392008 C A,G,T 9.54E-04 Type 2 diabetes / / 17463246 rs9878891 chr3 152392008 C A,G,T 6.77E-04 Major depressive disorder / / 22472876 rs4679689 chr3 152404607 C T 8.95E-05 Height / / pha003010 rs9852240 chr3 152427651 G A 9.24E-04 Type 2 diabetes / / 17463246 rs16864534 chr3 152441723 G A 4.96E-04 Multiple complex diseases / / 17554300 rs1381094 chr3 152473776 C T 1.78E-15 Schizophrenia / / 22037552 rs10513432 chr3 152535365 T C 2.67E-05 Brain structure / / 22504417 rs10513432 chr3 152535365 T C 4.00E-07 Immune reponse to smallpox (secreted IL-2) / / 22610502 rs16864605 chr3 152551071 T C 7.10E-04 Coronary heart disease / / 21966275 rs1371097 chr3 152552190 C T 6.60E-05 Coronary heart disease / / 21966275 rs16864613 chr3 152555452 C G 9.07E-04 Type 2 diabetes P2RY1 UTR-3 17463246 rs9847124 chr3 152590762 T G 3.20E-04 Coronary Artery Disease / / 17634449 rs7649494 chr3 152611465 A G 1.60E-04 Asperger disorder / / 21182207 rs2872090 chr3 152613883 C T 1.70E-04 Asperger disorder / / 21182207 rs10935907 chr3 152630713 T C 6.00E-05 Asperger disorder / / 21182207 rs11718068 chr3 152631729 A G 1.37E-05 Alzheimer's disease (late onset) / / 21460841 rs1371102 chr3 152633486 A G 2.14E-05 Alzheimer's disease (late onset) / / 21460841 rs1371102 chr3 152633486 A G 2.84E-05 Eosinophil counts / / pha003088 rs1371103 chr3 152633843 C T 3.93E-05 Alzheimer's disease (late onset) / / 21460841 rs17452880 chr3 152652737 A G 9.85E-04 Type 2 diabetes / / 17463246 rs6785504 chr3 152672779 G T 7.00E-06 Response to antineoplastic agents / / 21659360 rs6440836 chr3 152679420 G A 8.78E-04 Type 2 diabetes / / 17463246 rs7635777 chr3 152711260 T C 5.34E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs16864783 chr3 152712586 T A 6.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs9883654 chr3 152721975 C T 2.00E-06 Response to antineoplastic agents / / 21659360 rs2687880 chr3 152775129 T A 1.40E-05 Urinary metabolites / / 21572414 rs521627 chr3 152777949 T C 1.40E-05 Urinary metabolites / / 21572414 rs701248 chr3 152803599 C A 9.46E-05 Monocyte counts / / pha003089 rs2120369 chr3 152814472 G A 6.48E-04 Smoking quantity / / 24665060 rs9830448 chr3 152867288 C A 0.0000479 Ankle-brachial index / / 22361517 rs16822398 chr3 152868698 G A 1.17E-04 Multiple complex diseases / / 17554300 rs17789039 chr3 152921620 C A 1.20E-05 Urinary metabolites / / 21572414 rs6800715 chr3 152935967 A G 6.08E-05 Monocyte counts / / pha003089 rs6440853 chr3 152937218 G A 8.28E-05 Body Fat Distribution / / pha003016 rs6440853 chr3 152937218 G A 2.15E-05 Body Fat Distribution / / pha003017 rs6799941 chr3 152999379 T G 7.60E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs9824588 chr3 153022780 T C 2.19E-04 Prostate cancer / / 23023329 rs9822442 chr3 153027489 T C 4.61E-04 Alcohol dependence / / 20201924 rs7612570 chr3 153033177 C T 7.30E-04 Multiple complex diseases / / 17554300 rs10513440 chr3 153040824 G A 7.92E-05 Multiple complex diseases / / 17554300 rs16822557 chr3 153080714 A T 4.70E-04 Multiple complex diseases / / 17554300 rs6440876 chr3 153117271 A G 1.89E-05 Coronary restenosis / / 21878436 rs4680060 chr3 153118913 A T 1.19E-04 Sarcoidosis / / 19165924 rs12695988 chr3 153122300 C A 9.00E-04 Amyotrophic lateral sclerosis / / 17671248 rs7617173 chr3 153125480 T C 8.08E-05 Coronary restenosis / / 21878436 rs7622540 chr3 153132547 T C 1.89E-05 Coronary restenosis / / 21878436 rs4680062 chr3 153132716 C T 6.72E-05 Hypertension (essential hypertension) / / 22184326 rs4680062 chr3 153132716 C T 2.60E-05 Cognitive function / / 24684796 rs6440881 chr3 153145382 C A 6.40E-05 Cognitive function / / 24684796 rs2902334 chr3 153179301 A C 0.000433 Salmonella-induced pyroptosis / / 22837397 rs6778194 chr3 153184656 A C 2.00E-09 Immune reponse to smallpox (secreted IFN-alpha) / / 22610502 rs6440892 chr3 153252942 G A 1.72E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4680074 chr3 153286204 C T 0.000883612 Hypertension (early onset hypertension) / / 22479346 rs3961460 chr3 153316224 T C 1.20E-05 Alcoholism (heaviness of drinking) / / 21529783 rs6808058 chr3 153318171 T C 4.51E-04 Type 2 diabetes / / 17463246 rs6771021 chr3 153318351 A C 1.83E-04 Type 2 diabetes / / 17463246 rs6773964 chr3 153318840 A G 3.60E-04 Type 2 diabetes / / 17463246 rs1880034 chr3 153320256 C A 2.43E-04 Type 2 diabetes / / 17463246 rs6769589 chr3 153329877 G A 3.85E-04 Type 2 diabetes / / 17463246 rs6799174 chr3 153342357 A C 1.90E-05 Response to statin therapy / / 20339536 rs7623788 chr3 153350116 A G 5.00E-06 IgG glycosylation / / 23382691 rs6806502 chr3 153352722 T C 2.50E-05 Response to statin therapy / / 20339536 rs13321012 chr3 153354747 A G 2.74E-04 Fibrinogen / / 17255346 rs13321012 chr3 153354747 A G 4.26E-05 Gallbladder cancer / / 22318345 rs11711889 chr3 153370666 G A 1.75E-04 Alzheimer's disease / / 21059989 rs11711889 chr3 153370666 G A 6.95E-06 Alzheimer's disease / / 21059989 rs1006979 chr3 153376620 C G 1.16E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs1006979 chr3 153376620 C G 1.16E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs1006979 chr3 153376620 C G 1.16E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs6778630 chr3 153388774 T C 8.34E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs952124 chr3 153408795 C T 1.32E-04 Bipolar disorder / / 19259986 rs2863756 chr3 153430095 G C 7.01E-05 Formal thought disorder in schizophrenia / / 22648509 rs1532796 chr3 153461235 C T 5.50E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs519073 chr3 153463040 G A 5.51E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs543037 chr3 153463381 G A 5.51E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs575068 chr3 153464529 C T 5.52E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs580122 chr3 153469301 T C 7.01E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs483795 chr3 153469302 A G 3.90E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs544280 chr3 153471221 G C 5.21E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs531369 chr3 153471379 T A 5.20E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs567326 chr3 153471461 T C 5.20E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs569147 chr3 153471636 C T 5.18E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs558023 chr3 153472037 C T 5.17E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs573872 chr3 153472163 T G 4.00E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs573872 chr3 153472163 T G 5.00E-14 Infantile hypertrophic pyloric stenosis / / 23989729 rs565329 chr3 153472823 T C 5.19E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs9851769 chr3 153473013 C T 1.40E-05 Infantile hypertrophic pyloric stenosis / / 22306654 rs493799 chr3 153473192 T G 5.17E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs518339 chr3 153473540 C T 5.04E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs1699525 chr3 153473796 G A 4.96E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs581425 chr3 153473875 G C 4.94E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs510173 chr3 153474220 T C 4.89E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs524862 chr3 153474279 A G 4.59E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs547578 chr3 153474414 C T 4.85E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs568454135 chr3 153474414 CT C 4.85E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs512603 chr3 153474458 A C 4.85E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs686753 chr3 153474473 C A 4.84E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs659379 chr3 153474644 T A 4.81E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs514646 chr3 153474732 A C 4.31E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs657652 chr3 153474992 A C 4.22E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs539376 chr3 153475113 A G 4.17E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs578077 chr3 153475491 T C 4.09E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs578788 chr3 153475533 G A 4.08E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs578897 chr3 153475576 T A 4.07E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs6794649 chr3 153478423 G C 1.00E-06 IgG glycosylation / / 23382691 rs6794649 chr3 153478423 G C 2.00E-06 IgG glycosylation / / 23382691 rs6781197 chr3 153492010 A G 6.93E-05 Waist Circumference / / pha003024 rs1524548 chr3 153495291 T G 1.05E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1524548 chr3 153495291 T G 3.28E-05 Asthma / / pha003127 rs9851119 chr3 153499535 T C 6.93E-05 Asthma / / pha003127 rs924825 chr3 153508217 C T 5.73E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs17745935 chr3 153508546 C T 5.73E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12487439 chr3 153509149 A G 3.45E-05 Serum metabolites / / 19043545 rs12487439 chr3 153509149 A G 4.14E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs16823180 chr3 153509489 C A 9.05E-05 Serum metabolites / / 19043545 rs7622338 chr3 153513139 G A 4.14E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7634167 chr3 153513378 T G 4.14E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs10935950 chr3 153522080 G A 4.14E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1910590 chr3 153523601 T C 9.61E-04 Alzheimer's disease / / 24755620 rs10935951 chr3 153524432 A C 6.42E-04 Alzheimer's disease / / 24755620 rs10935952 chr3 153525308 G A 6.38E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9810882 chr3 153544403 C T 9.66E-05 Schizophrenia / / 19571809 rs6803060 chr3 153573828 A C 5.16E-05 Post-operative nausea and vomiting / / 21694509 rs4314134 chr3 153581251 G A 1.85E-05 Post-operative nausea and vomiting / / 21694509 rs701263 chr3 153627929 C T 2.21E-05 Post-operative nausea and vomiting / / 21694509 rs1521302 chr3 153670538 A G 6.96E-05 Type 2 diabetes / / 17463246 rs4680113 chr3 153727337 C T 9.86E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6766612 chr3 153751223 T C 5.88E-04 Type 2 diabetes ARHGEF26-AS1 intron 17463246 rs17817202 chr3 153764585 G T 8.02E-04 Depression (quantitative trait) ARHGEF26-AS1 intron 20800221 rs1949634 chr3 153769557 G T 4.96E-05 Bipolar disorder and schizophrenia ARHGEF26-AS1 intron 20889312 rs17817774 chr3 153779868 A G 9.92E-05 Orofacial clefts ARHGEF26-AS1 intron 22419666 rs938989 chr3 153788222 A G 4.42E-05 Panic disorder ARHGEF26-AS1 intron 19165232 rs1727936 chr3 153827681 A T 5.99E-04 Type 2 diabetes ARHGEF26-AS1 intron 17463246 rs12493885 chr3 153839866 G C 0.0000429 Coronary artery calcification ARHGEF26 missense 23394302 rs12488999 chr3 153955907 T A 2.93E-05 Multiple complex diseases ARHGEF26 intron 17554300 rs789384 chr3 154082787 T C 1.92E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines GPR149 intron 21844884 rs12488867 chr3 154095778 C T 3.78E-04 Osteosarcoma GPR149 intron 23727862 rs16824046 chr3 154158724 G C 1.81E-04 Type 2 diabetes / / 17463246 rs1356122 chr3 154183562 G C 5.39E-16 Multiple sclerosis / / 17660530 rs11916232 chr3 154253163 C G 6.20E-05 Response to statin therapy / / 20339536 rs1160335 chr3 154258918 G T 6.83E-05 Body Mass Index / / pha003014 rs9809000 chr3 154268934 A G 6.52E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs980023 chr3 154275492 T C 8.00E-05 Response to statin therapy / / 20339536 rs980026 chr3 154275967 G T 8.00E-05 Response to statin therapy / / 20339536 rs2314058 chr3 154277932 G T 6.30E-05 Response to statin therapy / / 20339536 rs2314058 chr3 154277932 G T 3.31E-05 Body Mass Index / / pha003014 rs2313950 chr3 154279750 T C 5.72E-04 Multiple complex diseases / / 17554300 rs2313950 chr3 154279750 T C 6.20E-05 Response to statin therapy / / 20339536 rs11928294 chr3 154279947 C T 6.20E-05 Response to statin therapy / / 20339536 rs10513461 chr3 154281430 G A 6.00E-05 Response to statin therapy / / 20339536 rs11921298 chr3 154289811 T C 6.40E-05 Response to statin therapy / / 20339536 rs11921298 chr3 154289811 T C 3.31E-05 Body Mass Index / / pha003014 rs7633033 chr3 154290631 A G 7.60E-05 Response to statin therapy / / 20339536 rs7611470 chr3 154290828 G A 7.70E-05 Response to statin therapy / / 20339536 rs7633236 chr3 154290854 A G 8.00E-05 Response to statin therapy / / 20339536 rs7623517 chr3 154291363 T C 6.50E-05 Response to statin therapy / / 20339536 rs7612082 chr3 154291456 G C 5.60E-05 Response to statin therapy / / 20339536 rs7614327 chr3 154291478 G A 5.60E-05 Response to statin therapy / / 20339536 rs7626254 chr3 154291973 T C 6.00E-05 Response to statin therapy / / 20339536 rs7626254 chr3 154291973 T C 3.46E-05 Body Mass Index / / pha003014 rs6440946 chr3 154292075 G T 3.70E-05 Response to statin therapy / / 20339536 rs7614819 chr3 154292183 C T 3.60E-05 Response to statin therapy / / 20339536 rs7626504 chr3 154292249 T C 3.30E-05 Response to statin therapy / / 20339536 rs7626506 chr3 154292259 T A 2.90E-05 Response to statin therapy / / 20339536 rs6770742 chr3 154292676 G A 3.50E-05 Response to statin therapy / / 20339536 rs11928416 chr3 154301325 T C 2.20E-05 Response to statin therapy / / 20339536 rs6777121 chr3 154305151 C G 2.20E-05 Response to statin therapy / / 20339536 rs17372655 chr3 154309977 T C 2.10E-05 Response to statin therapy / / 20339536 rs7620094 chr3 154325046 T C 2.20E-05 Response to statin therapy / / 20339536 rs4132402 chr3 154337156 A G 1.40E-05 Response to statin therapy / / 20339536 rs11915900 chr3 154353017 G A 2.70E-05 Response to statin therapy / / 20339536 rs7652824 chr3 154354998 G T 3.60E-05 Response to statin therapy / / 20339536 rs7610698 chr3 154361091 C A 3.00E-05 Response to statin therapy / / 20339536 rs7610714 chr3 154361137 C T 2.50E-05 Response to statin therapy / / 20339536 rs7610905 chr3 154361357 C A,G,T 3.00E-04 Multiple complex diseases / / 17554300 rs12493149 chr3 154376514 C T 8.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12493149 chr3 154376514 C T 8.46E-06 Asthma / / 23181788 rs4533608 chr3 154398140 G T 1.99E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12632386 chr3 154437381 C A 1.30E-05 Urinary metabolites / / 21572414 rs7629959 chr3 154449684 A C 1.90E-06 Cognitive test performance / / 20125193 rs11927211 chr3 154491978 A G 4.00E-05 Prostate cancer / / 21743057 rs11927211 chr3 154491978 A G 8.42E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6789924 chr3 154492161 A C 4.01E-05 Intracerebral hemorrhage / / 24656865 rs10935990 chr3 154493381 G T 4.00E-05 Prostate cancer / / 21743057 rs10935990 chr3 154493381 G T 8.42E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6440957 chr3 154494952 C T 1.00E-05 Urinary metabolites / / 21572414 rs6440957 chr3 154494952 C T 7.42E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs6440958 chr3 154497361 A T 3.45E-05 Intracerebral hemorrhage / / 24656865 rs12633900 chr3 154499514 C T 3.24E-05 Intracerebral hemorrhage / / 24656865 rs34174758 chr3 154500154 C T 2.84E-05 Intracerebral hemorrhage / / 24656865 rs55927312 chr3 154500310 C A 1.25E-05 Intracerebral hemorrhage / / 24656865 rs55811364 chr3 154500441 C T 1.25E-05 Intracerebral hemorrhage / / 24656865 rs1402731 chr3 154501571 T C 3.46E-05 Intracerebral hemorrhage / / 24656865 rs7636681 chr3 154502582 A T 1.40E-05 Intracerebral hemorrhage / / 24656865 rs12629156 chr3 154503522 T A 1.29E-05 Intracerebral hemorrhage / / 24656865 rs16824293 chr3 154508800 C A 4.43E-05 Intracerebral hemorrhage / / 24656865 rs997183 chr3 154511264 G A 1.54E-05 Intracerebral hemorrhage / / 24656865 rs7645606 chr3 154518276 C T 4.17E-05 Intracerebral hemorrhage / / 24656865 rs7651145 chr3 154519470 C T 4.48E-05 Intracerebral hemorrhage / / 24656865 rs6440959 chr3 154522673 T C 4.71E-05 Intracerebral hemorrhage / / 24656865 rs1852217 chr3 154532079 A G 4.44E-05 Intracerebral hemorrhage / / 24656865 rs12629856 chr3 154532713 T A 3.77E-05 Intracerebral hemorrhage / / 24656865 rs34758654 chr3 154536231 G A 4.46E-05 Intracerebral hemorrhage / / 24656865 rs58859735 chr3 154536725 C A 4.46E-05 Intracerebral hemorrhage / / 24656865 rs7652581 chr3 154537891 A G 4.47E-05 Intracerebral hemorrhage / / 24656865 rs7635271 chr3 154541218 T A 4.72E-05 Intracerebral hemorrhage / / 24656865 rs6783876 chr3 154542763 C A,T 4.47E-05 Intracerebral hemorrhage / / 24656865 rs13090520 chr3 154563232 C T 2.40E-05 Urinary metabolites / / 21572414 rs1608001 chr3 154676122 T C 2.88E-04 Smoking initiation / / 24665060 rs940894 chr3 154687338 C T 7.63E-04 Smoking initiation / / 24665060 rs7635887 chr3 154715596 A G 2.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10513467 chr3 154749792 C G 3.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs968628 chr3 154816911 G A 7.46E-04 Alzheimer's disease MME intron 22005930 rs968628 chr3 154816911 G A 8.19E-04 Smoking initiation MME intron 24665060 rs1436634 chr3 154819781 G A 8.90E-09 Platelet aggregation(pre- and post-aspirin) MME intron 20529293 rs1025192 chr3 154827787 C T 1.94E-05 Serum metabolites MME intron 19043545 rs10513469 chr3 154835722 C A 2.90E-05 Serum metabolites MME intron 19043545 rs6797911 chr3 154862390 T A 2.38E-05 Serum metabolites MME intron 19043545 rs6665 chr3 154901205 C A 2.77E-05 Hodgkin's lymphoma MME UTR-3 24149102 rs9851460 chr3 154902256 A G 1.24E-05 Male fertility / / 22633400 rs4345034 chr3 154902795 C G 5.08E-05 Serum metabolites / / 19043545 rs13081581 chr3 154908281 C A,G 6.10E-05 Serum metabolites / / 19043545 rs17386464 chr3 154920664 A G 1.69E-04 Alzheimer's disease (late onset) / / 21379329 rs7624578 chr3 154949850 G A 9.30E-06 Urinary metabolites / / 21572414 rs9289952 chr3 155003301 T G 3.10E-05 Cognitive performance / / 19734545 rs6440972 chr3 155045430 C A 4.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs6440972 chr3 155045430 C A 8.00E-07 Response to inhaled corticosteroid treatment in asthma (percentage change of FEV1) / / 24792382 rs9817455 chr3 155061124 A G 1.30E-05 Alzheimer's disease (late onset) / / 21460841 rs6440974 chr3 155070465 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9821888 chr3 155074529 G C 6.54E-04 Multiple complex diseases / / 17554300 rs4455360 chr3 155078062 A C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4680172 chr3 155117112 C T 1.90E-04 Type 2 diabetes / / 17463246 rs12493778 chr3 155128631 T C 9.81E-04 Type 2 diabetes / / 17463246 rs13066178 chr3 155136645 C T 2.33E-04 Type 2 diabetes / / 17463246 rs13083852 chr3 155139253 G A 2.33E-04 Type 2 diabetes / / 17463246 rs4680175 chr3 155141729 A C 5.36E-04 Type 2 diabetes / / 17463246 rs4680176 chr3 155141789 C T 5.36E-04 Type 2 diabetes / / 17463246 rs13081656 chr3 155142297 T C 2.33E-04 Type 2 diabetes / / 17463246 rs4680177 chr3 155145375 A G 2.33E-04 Type 2 diabetes / / 17463246 rs7615026 chr3 155152505 C T 9.11E-04 Type 2 diabetes / / 17463246 rs12696031 chr3 155158484 C T 5.84E-04 Type 2 diabetes / / 17463246 rs16825042 chr3 155217347 A G 7.79E-04 Suicide attempts in bipolar disorder PLCH1 intron 21423239 rs592982 chr3 155259656 G A 5.52E-05 Cognitive test performance PLCH1 intron 20125193 rs16825084 chr3 155267180 A G 3.56E-04 Suicide attempts in bipolar disorder PLCH1 intron 21423239 rs3851357 chr3 155267440 G A 9.00E-06 IgG glycosylation PLCH1 intron 23382691 rs3851357 chr3 155267440 G A 9.15E-05 Blood Pressure PLCH1 intron pha003044 rs11915975 chr3 155270504 T C 4.00E-05 Cognitive performance PLCH1 intron 19734545 rs3914781 chr3 155270553 T A 6.24E-04 Suicide attempts in bipolar disorder PLCH1 intron 21423239 rs7633176 chr3 155279983 T G 4.70E-04 Suicide attempts in bipolar disorder PLCH1 intron 21423239 rs4389522 chr3 155285327 T C 5.05E-04 Suicide attempts in bipolar disorder PLCH1 intron 21423239 rs1610251 chr3 155286530 A G 9.20E-04 Suicide attempts in bipolar disorder PLCH1 intron 21423239 rs2320186 chr3 155286621 A T 9.04E-04 Suicide attempts in bipolar disorder PLCH1 intron 21423239 rs7630469 chr3 155288429 G A 8.96E-04 Suicide attempts in bipolar disorder PLCH1 intron 21423239 rs359570 chr3 155314296 A G 7.96E-05 Blood Pressure PLCH1 intron pha003044 rs359571 chr3 155315059 A G 3.52E-05 Fibrinogen PLCH1 intron pha003068 rs9811329 chr3 155373483 C T 5.09E-04 Multiple complex diseases PLCH1 intron 17554300 rs17348181 chr3 155394761 T C 3.67E-04 Suicide attempts in bipolar disorder PLCH1 intron 21423239 rs17414074 chr3 155398278 C T 4.97E-04 Suicide attempts in bipolar disorder PLCH1 intron 21423239 rs7636687 chr3 155405923 C G 6.30E-04 Suicide attempts in bipolar disorder PLCH1 intron 21423239 rs16825274 chr3 155408234 C T 6.17E-04 Suicide attempts in bipolar disorder PLCH1 intron 21423239 rs446716 chr3 155409181 C T 8.77E-04 Suicide attempts in bipolar disorder PLCH1 intron 21423239 rs17414810 chr3 155418611 A C 2.74E-04 Suicide attempts in bipolar disorder PLCH1 intron 21423239 rs12628990 chr3 155418827 C A 1.76E-04 Suicide attempts in bipolar disorder PLCH1 intron 21423239 rs6441010 chr3 155422972 G A 4.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs16825341 chr3 155426023 T C 9.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs9811107 chr3 155474879 T C 2.00E-05 Urinary metabolites / / 21572414 rs11716272 chr3 155599263 A T 3.41E-04 Suicide attempts in bipolar disorder GMPS intron 21423239 rs6441023 chr3 155605597 G A 6.70E-05 Parkinson's disease (familial) GMPS intron 18985386 rs7633168 chr3 155609343 T C 4.73E-04 Lung function (forced expiratory volume in 1 second) GMPS intron 17255346 rs9825321 chr3 155615475 C T 8.35E-04 Multiple complex diseases GMPS intron 17554300 rs819838 chr3 155677475 T C 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs819834 chr3 155682770 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1516500 chr3 155685093 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs819856 chr3 155688027 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs11927605 chr3 155830578 C T 6.02E-05 HIV-1 viral setpoint / / 22174851 rs9882449 chr3 155837381 C T 1.56E-05 HIV-1 viral setpoint / / 22174851 rs6441041 chr3 155891027 G A 6.06E-04 Suicide attempts in bipolar disorder KC/B1 intron 21423239 rs6799888 chr3 155903204 C A 7.71E-04 Suicide attempts in bipolar disorder KC/B1 intron 21423239 rs1353812 chr3 155907740 A C 5.55E-04 Nicotine smoking KC/B1 intron 19268276 rs6764861 chr3 155958216 T C 3.47E-05 Post-operative nausea and vomiting KC/B1 intron 21694509 rs7623436 chr3 155966912 T C 5.71E-04 Suicide attempts in bipolar disorder KC/B1 intron 21423239 rs13081735 chr3 155983937 C A 5.30E-04 Depression (quantitative trait) KC/B1 intron 20800221 rs2167144 chr3 155994762 G A 5.48E-04 Depression (quantitative trait) KC/B1 intron 20800221 rs1551066 chr3 156009925 C T 4.36E-05 Schizophrenia (cytomegalovirus infection interaction) KC/B1 intron 23358160 rs9843163 chr3 156062666 A G 4.23E-04 Smoking initiation KC/B1 intron 24665060 rs9824778 chr3 156071120 G A 1.35E-05 Smoking initiation KC/B1 intron 24665060 rs9855009 chr3 156073089 T G 3.55E-04 Smoking initiation KC/B1 intron 24665060 rs16826030 chr3 156082851 A G 2.02E-04 Smoking initiation KC/B1 intron 24665060 rs3772255 chr3 156102734 C T 8.00E-06 Aging traits KC/B1 intron 17903295 rs940050 chr3 156102890 T C 4.30E-04 Myasthenia gravis KC/B1 intron 23055271 rs7615568 chr3 156105084 T G 1.00E-08 Age-related nuclear cataracts KC/B1 intron 24951543 rs3772262 chr3 156132937 A G 7.94E-04 Smoking initiation KC/B1 intron 24665060 rs816546 chr3 156147368 G C 2.84E-05 Tuberculosis KC/B1 intron 24057671 rs12053933 chr3 156176714 G C 2.96E-04 Smoking initiation KC/B1 intron 24665060 rs13315136 chr3 156182208 A C 6.84E-04 Myopia (pathological) KC/B1 intron 21095009 rs11915422 chr3 156194565 C T 3.37E-04 Type 2 diabetes KC/B1 intron 17463246 rs1879977 chr3 156202517 G A 1.28E-05 Type 2 diabetes KC/B1 intron 17463246 rs2679596 chr3 156203216 G A 1.28E-05 Type 2 diabetes KC/B1 intron 17463246 rs7644005 chr3 156204177 C T 3.10E-05 Type 2 diabetes KC/B1 intron 17463246 rs11918294 chr3 156205797 A G 5.28E-04 Suicide attempts in bipolar disorder KC/B1 intron 21423239 rs13095723 chr3 156211203 T G 9.45E-04 Suicide attempts in bipolar disorder KC/B1 intron 21423239 rs16826325 chr3 156218007 C T 1.45E-05 Waist-Hip Ratio KC/B1 intron pha003029 rs13084354 chr3 156218823 C T 3.56E-04 Suicide attempts in bipolar disorder KC/B1 intron 21423239 rs7644368 chr3 156228514 G A 1.01E-04 Type 2 diabetes KC/B1 intron 17463246 rs4302336 chr3 156235116 G C 1.72E-05 Type 2 diabetes KC/B1 intron 17463246 rs13092077 chr3 156237352 G A 2.60E-06 Sleep duration KC/B1 intron 22105623 rs13097501 chr3 156237978 G C 3.34E-04 Multiple complex diseases KC/B1 intron 17554300 rs6441075 chr3 156241306 G A 7.20E-04 Parkinson's disease KC/B1 intron 17052657 rs2280299 chr3 156241965 A G 9.27E-04 Suicide attempts in bipolar disorder KC/B1 intron 21423239 rs2280298 chr3 156242091 G A 7.43E-04 Suicide attempts in bipolar disorder KC/B1 intron 21423239 rs4680276 chr3 156244447 A G 3.95E-04 Multiple complex diseases KC/B1 intron 17554300 rs9830714 chr3 156248426 C T 8.11E-05 Birth weight KC/B1 intron 17255346 rs2280031 chr3 156249214 T C 7.26E-05 Birth weight KC/B1 cds-synon 17255346 rs3821686 chr3 156265940 C T 1.44E-05 Birth weight SSR3 intron 17255346 rs9820091 chr3 156267397 T C 4.88E-04 Alzheimer's disease (late onset) SSR3 intron 21379329 rs2292340 chr3 156271926 C T 1.09E-04 Birth weight SSR3 intron 17255346 rs1510271 chr3 156290855 C T 9.59E-04 Multiple complex diseases / / 17554300 rs6650896 chr3 156298457 T C 0.000448 Salmonella-induced pyroptosis / / 22837397 rs7615297 chr3 156299313 C G 0.00041 Salmonella-induced pyroptosis / / 22837397 rs1983205 chr3 156300190 T G 0.000118 Salmonella-induced pyroptosis / / 22837397 rs16826603 chr3 156319934 A T 1.14E-04 Multiple complex diseases / / 17554300 rs7651778 chr3 156336555 C T 5.00E-06 Corneal astigmatism / / 23761726 rs13092225 chr3 156355404 G A 1.69E-05 Type 2 diabetes / / 22158537 rs13092225 chr3 156355404 G A 3.58E-05 Corneal structure / / 23291589 rs4680295 chr3 156358487 A G 8.70E-05 Personality dimensions / / 18957941 rs12485328 chr3 156360259 T G 1.89E-05 Type 2 diabetes / / 22158537 rs985855 chr3 156362664 G C 2.69E-05 Type 2 diabetes / / 22158537 rs2136690 chr3 156363242 A G 2.63E-05 Type 2 diabetes / / 22158537 rs1510279 chr3 156365470 C T 6.55E-06 Type 2 diabetes / / 22158537 rs1510280 chr3 156366613 A C 6.20E-06 Type 2 diabetes / / 22158537 rs7628802 chr3 156369933 T G 4.00E-06 Personality dimensions / / 18957941 rs7628802 chr3 156369933 T G 1.26E-04 Type 2 diabetes / / 22158537 rs7617108 chr3 156369955 C T 1.90E-05 Personality dimensions / / 18957941 rs7617108 chr3 156369955 C T 1.13E-05 Type 2 diabetes / / 22158537 rs7617108 chr3 156369955 C T 3.03E-06 Corneal structure / / 23291589 rs7639306 chr3 156370088 A G 9.72E-06 Type 2 diabetes / / 22158537 rs9852504 chr3 156370713 A T 2.67E-06 Type 2 diabetes / / 22158537 rs9852504 chr3 156370713 A T 3.90E-04 Corneal structure / / 23291589 rs1510276 chr3 156371356 G A 9.78E-06 Type 2 diabetes / / 22158537 rs6807248 chr3 156371743 C T 2.25E-06 Type 2 diabetes / / 22158537 rs16826679 chr3 156372110 C T 4.86E-04 Type 2 diabetes / / 22158537 rs6807894 chr3 156372177 G T 9.54E-06 Type 2 diabetes / / 22158537 rs6807894 chr3 156372177 G T 3.88E-06 Corneal structure / / 23291589 rs6772236 chr3 156372336 T C 9.78E-06 Type 2 diabetes / / 22158537 rs6441091 chr3 156373580 C T 9.78E-06 Type 2 diabetes / / 22158537 rs6441091 chr3 156373580 C T 5.39E-06 Corneal structure / / 23291589 rs6766154 chr3 156374010 G T 1.16E-05 Type 2 diabetes / / 22158537 rs6790457 chr3 156374086 A G 1.67E-05 Type 2 diabetes / / 22158537 rs6778962 chr3 156374101 T C 1.39E-05 Type 2 diabetes / / 22158537 rs12696042 chr3 156376036 C G 1.45E-05 Type 2 diabetes / / 22158537 rs9289971 chr3 156389947 T C 5.39E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2665390 chr3 156397749 C T 3.00E-07 Ovarian cancer TIPARP intron 20852632 rs2665390 chr3 156397749 C T 7.00E-06 Ovarian cancer in BRCA1 mutation carriers TIPARP intron 23544013 rs3851992 chr3 156399180 G A 1.10E-05 Urinary metabolites TIPARP intron 21572414 rs7651446 chr3 156406997 G T 2.00E-29 Ovarian cancer TIPARP intron 23535730 rs7651446 chr3 156406997 G T 2.00E-34 Ovarian cancer TIPARP intron 23535730 rs1367311 chr3 156418756 C T 6.25E-04 Amyotrophic Lateral Sclerosis TIPARP intron 17362836 rs1367312 chr3 156418908 T C 5.89E-07 Red blood cell traits TIPARP intron 23222517 rs17373227 chr3 156431045 A T 4.54E-07 Red blood cell traits / / 23222517 rs891463 chr3 156442304 C T 2.89E-07 Red blood cell traits / / 23222517 rs344001 chr3 156453407 G T 1.83E-04 Type 2 diabetes / / 22158537 rs13095806 chr3 156456060 G C 2.90E-05 Urinary metabolites / / 21572414 rs344030 chr3 156464729 A C 9.40E-05 Pericardial fat / / 22589742 rs8792 chr3 156465428 A C 2.80E-05 Urinary metabolites / / 21572414 rs9822953 chr3 156472071 C T 2.70E-08 Corneal structure LOC730091 intron 23291589 rs41366145 chr3 156489722 C T 3.16E-04 Type 2 diabetes LOC730091 intron 17463246 rs12497777 chr3 156495781 T A 2.30E-05 Urinary metabolites LOC730091 intron 21572414 rs17380954 chr3 156505106 G A 1.35E-05 Height LOC730091 intron pha003010 rs17380954 chr3 156505106 G A 5.01E-05 Height LOC730091 intron pha003011 rs1430412 chr3 156521121 T C 2.59E-04 Type 2 diabetes LOC730091 intron 22158537 rs343992 chr3 156530170 T C 2.33E-04 Type 2 diabetes LOC730091 intron 22158537 rs9847692 chr3 156531322 T C 2.48E-04 Type 2 diabetes LOC730091 intron 22158537 rs11717138 chr3 156534628 T C 2.24E-04 Type 2 diabetes LOC730091 intron 22158537 rs919520 chr3 156537119 T A 3.15E-08 Red blood cell traits / / 23222517 rs2653817 chr3 156547846 G A 1.67E-04 Type 2 diabetes LEKR1 intron 17463246 rs344074 chr3 156548657 A G 3.62E-04 Bone mineral density LEKR1 intron 24249740 rs344074 chr3 156548657 A G 4.83E-04 Bone mineral density LEKR1 intron 24249740 rs344076 chr3 156552785 G A 2.28E-04 Type 2 diabetes LEKR1 intron 22158537 rs344078 chr3 156554568 C T 3.82E-04 Type 2 diabetes LEKR1 intron 22158537 rs171080 chr3 156555500 A G 4.68E-04 Type 2 diabetes LEKR1 intron 22158537 rs344081 chr3 156555984 T C 4.22E-04 Type 2 diabetes LEKR1 intron 22158537 rs344081 chr3 156555984 T C 4.00E-12 Bone mineral density LEKR1 intron 22504420 rs344081 chr3 156555984 T C 0.000131 Femoral neck bone mineral density LEKR1 intron 22692763 rs344081 chr3 156555984 T C 1.09E-04 Bone mineral density LEKR1 intron 24249740 rs344081 chr3 156555984 T C 2.50E-04 Bone mineral density LEKR1 intron 24249740 rs344081 chr3 156555984 T C 5.87E-04 Bone mineral density LEKR1 intron 24249740 rs344081 chr3 156555984 T C 4.71E-04 Bone mineral density (paediatric,skull) LEKR1 intron 24945404 rs344085 chr3 156558120 C T 3.07E-04 Type 2 diabetes LEKR1 intron 22158537 rs344086 chr3 156559445 G A 3.26E-04 Type 2 diabetes LEKR1 intron 22158537 rs344088 chr3 156561361 C T 2.89E-04 Type 2 diabetes LEKR1 intron 22158537 rs344091 chr3 156564107 C T 4.50E-05 Type 2 diabetes LEKR1 intron 22158537 rs344092 chr3 156564320 T G 2.88E-04 Type 2 diabetes LEKR1 intron 22158537 rs414683 chr3 156570703 A G 4.02E-04 Type 2 diabetes LEKR1 cds-synon 22158537 rs2633815 chr3 156573214 A G 3.40E-04 Type 2 diabetes LEKR1 intron 22158537 rs491423 chr3 156574076 C T 5.01E-04 Type 2 diabetes LEKR1 intron 22158537 rs9861359 chr3 156578046 C G 3.46E-04 Type 2 diabetes LEKR1 intron 22158537 rs16826858 chr3 156578398 A T 8.18E-04 Type 2 diabetes LEKR1 intron 17463246 rs16826858 chr3 156578398 A T 1.38E-04 Type 2 diabetes LEKR1 intron 22158537 rs16826864 chr3 156580033 A G 3.94E-04 Type 2 diabetes LEKR1 intron 22158537 rs16826869 chr3 156580766 G A 6.62E-04 Tourette syndrome LEKR1 intron 22889924 rs11927500 chr3 156580796 C T 3.68E-04 Type 2 diabetes LEKR1 intron 22158537 rs7630909 chr3 156581583 T A 3.75E-04 Type 2 diabetes LEKR1 intron 22158537 rs9878709 chr3 156581778 G A 5.31E-04 Type 2 diabetes LEKR1 intron 22158537 rs6441099 chr3 156583855 T G 5.21E-04 Type 2 diabetes LEKR1 intron 22158537 rs6441100 chr3 156586131 C T 6.10E-04 Type 2 diabetes LEKR1 intron 22158537 rs6786167 chr3 156591290 C T 6.07E-04 Type 2 diabetes LEKR1 intron 22158537 rs6787535 chr3 156608966 G A 4.46E-04 Type 2 diabetes LEKR1 intron 22158537 rs17382119 chr3 156609102 G T 6.26E-04 Suicide attempts in bipolar disorder LEKR1 intron 21423239 rs6787952 chr3 156609375 G A 4.97E-04 Type 2 diabetes LEKR1 intron 22158537 rs16826899 chr3 156610667 G A 1.53E-04 Type 2 diabetes LEKR1 intron 22158537 rs13321802 chr3 156611328 G A 6.49E-04 Type 2 diabetes LEKR1 intron 22158537 rs6792917 chr3 156621393 G A 6.37E-04 Type 2 diabetes LEKR1 intron 22158537 rs6795327 chr3 156621548 C A 4.94E-04 Type 2 diabetes LEKR1 intron 22158537 rs6795516 chr3 156621679 C T 4.51E-04 Type 2 diabetes LEKR1 intron 22158537 rs6802042 chr3 156623465 C T 3.21E-04 Type 2 diabetes LEKR1 intron 22158537 rs12638253 chr3 156626091 C T 2.00E-06 Multiple sclerosis (severity) LEKR1 intron 19010793 rs12638253 chr3 156626091 C T 8.31E-05 Parkinson's disease LEKR1 intron pha002865 rs16826906 chr3 156632439 C G 4.84E-04 Type 2 diabetes LEKR1 intron 22158537 rs2874490 chr3 156635513 C T 9.50E-05 Type 2 diabetes LEKR1 intron 22158537 rs7609851 chr3 156638503 A G 3.24E-04 Type 2 diabetes LEKR1 intron 22158537 rs7635521 chr3 156639710 G A 5.21E-04 Type 2 diabetes LEKR1 intron 22158537 rs7650127 chr3 156642634 A G 3.66E-04 Type 2 diabetes LEKR1 UTR-3 22158537 rs6441103 chr3 156643385 T A,C 2.74E-04 Type 2 diabetes LEKR1 intron 22158537 rs2874491 chr3 156649111 T G 3.51E-04 Type 2 diabetes LEKR1 intron 22158537 rs6802511 chr3 156653922 G C 7.18E-04 Type 2 diabetes LEKR1 intron 17463246 rs6802511 chr3 156653922 G C 1.59E-04 Type 2 diabetes LEKR1 intron 22158537 rs10513503 chr3 156680577 A G 6.70E-04 Tourette syndrome LEKR1 intron 22889924 rs6441104 chr3 156681441 G A 2.80E-04 Type 2 diabetes LEKR1 intron 22158537 rs16826948 chr3 156681774 T C 2.75E-04 Type 2 diabetes LEKR1 intron 22158537 rs6763233 chr3 156683111 T C 2.82E-04 Type 2 diabetes LEKR1 intron 22158537 rs1384538 chr3 156695609 T A 8.21E-04 Multiple complex diseases LEKR1 intron 17554300 rs7635876 chr3 156700416 C T 4.12E-05 Hypertension LEKR1 intron 21082022 rs10513502 chr3 156701861 C T 9.05E-04 Tourette syndrome LEKR1 intron 22889924 rs1032044 chr3 156707330 C A 3.99E-05 Tuberculosis LEKR1 intron 24057671 rs10513500 chr3 156716041 T G 1.85E-04 Tourette syndrome LEKR1 intron 22889924 rs6799034 chr3 156717880 C T 1.81E-05 Bone mineral traits,in men LEKR1 intron 21427758 rs1842840 chr3 156728057 T G 4.16E-05 Hypertension LEKR1 intron 21082022 rs1842840 chr3 156728057 T G 1.00E-04 Cognitive impairment induced by topiramate LEKR1 intron 22091778 rs11715321 chr3 156742775 C T 3.37E-05 Hypertension LEKR1 intron 21082022 rs11715321 chr3 156742775 C T 2.00E-04 Cognitive impairment induced by topiramate LEKR1 intron 22091778 rs2046273 chr3 156777127 T C 4.71E-04 Iron levels / / pha002876 rs11719102 chr3 156786544 G A 5.48E-04 Iron levels / / pha002876 rs2128535 chr3 156789192 C T 4.16E-05 Vitiligo / / 19890347 rs17451107 chr3 156797609 T C 1.00E-06 Adiposity in newborns / / 23575227 rs17451107 chr3 156797609 T C 1.20E-05 Adiposity in newborns / / 23575227 rs17451107 chr3 156797609 T C 1.39E-07 Adiposity in newborns / / 23575227 rs17451107 chr3 156797609 T C 1.42E-08 Adiposity in newborns / / 23575227 rs17451107 chr3 156797609 T C 1.52E-14 Adiposity in newborns / / 23575227 rs17451107 chr3 156797609 T C 1.90E-13 Adiposity in newborns / / 23575227 rs17451107 chr3 156797609 T C 2.93E-06 Adiposity in newborns / / 23575227 rs17451107 chr3 156797609 T C 5.72E-07 Adiposity in newborns / / 23575227 rs17451107 chr3 156797609 T C 6.08E-07 Adiposity in newborns / / 23575227 rs17451107 chr3 156797609 T C 7.09E-08 Adiposity in newborns / / 23575227 rs17451107 chr3 156797609 T C 7.92E-09 Adiposity in newborns / / 23575227 rs17451107 chr3 156797609 T C 9.35E-06 Adiposity in newborns / / 23575227 rs10049088 chr3 156797648 C T 1.04E-06 Adiposity in newborns / / 23575227 rs10049088 chr3 156797648 C T 1.18E-08 Adiposity in newborns / / 23575227 rs10049088 chr3 156797648 C T 1.19E-05 Adiposity in newborns / / 23575227 rs10049088 chr3 156797648 C T 1.88E-05 Adiposity in newborns / / 23575227 rs10049088 chr3 156797648 C T 2.68E-12 Adiposity in newborns / / 23575227 rs10049088 chr3 156797648 C T 3.27E-08 Adiposity in newborns / / 23575227 rs10049088 chr3 156797648 C T 3.46E-13 Adiposity in newborns / / 23575227 rs10049088 chr3 156797648 C T 4.39E-08 Adiposity in newborns / / 23575227 rs10049088 chr3 156797648 C T 4.88E-06 Adiposity in newborns / / 23575227 rs10049088 chr3 156797648 C T 5.22E-07 Adiposity in newborns / / 23575227 rs10049088 chr3 156797648 C T 6.12E-07 Adiposity in newborns / / 23575227 rs10049088 chr3 156797648 C T 9.29E-06 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 1.01E-07 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 1.20E-07 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 1.27E-05 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 1.39E-06 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 1.54E-08 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 1.59E-04 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 1.59E-08 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 1.61E-05 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 1.63E-04 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 1.85E-06 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 2.03E-13 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 2.29E-05 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 2.59E-06 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 3.00E-13 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 3.10E-08 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 3.92E-09 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 4.09E-12 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 4.88E-07 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 5.02E-13 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 5.84E-08 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 5.85E-06 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 6.00E-21 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 6.08E-13 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 7.00E-08 Adiposity in newborns / / 23575227 rs1482853 chr3 156798473 C A 8.34E-07 Adiposity in newborns / / 23575227 rs900400 chr3 156798775 T C 2.00E-35 Birth weight / / 20372150 rs900400 chr3 156798775 T C 4.00E-38 Birth weight / / 23202124 rs900400 chr3 156798775 T C 1.40E-05 Adiposity in newborns / / 23575227 rs900400 chr3 156798775 T C 1.43E-05 Adiposity in newborns / / 23575227 rs900400 chr3 156798775 T C 1.48E-06 Adiposity in newborns / / 23575227 rs900400 chr3 156798775 T C 1.81E-05 Adiposity in newborns / / 23575227 rs900400 chr3 156798775 T C 2.90E-08 Adiposity in newborns / / 23575227 rs900400 chr3 156798775 T C 3.38E-08 Adiposity in newborns / / 23575227 rs900400 chr3 156798775 T C 3.44E-12 Adiposity in newborns / / 23575227 rs900400 chr3 156798775 T C 3.46E-06 Adiposity in newborns / / 23575227 rs900400 chr3 156798775 T C 4.08E-13 Adiposity in newborns / / 23575227 rs900400 chr3 156798775 T C 4.57E-07 Adiposity in newborns / / 23575227 rs900400 chr3 156798775 T C 8.55E-09 Adiposity in newborns / / 23575227 rs900400 chr3 156798775 T C 8.89E-07 Adiposity in newborns / / 23575227 rs11719286 chr3 156802256 T C 1.30E-05 Urinary metabolites LOC339894 intron 21572414 rs13094970 chr3 156815280 A G 8.96E-04 Multiple complex diseases LOC339894 intron 17554300 rs35942312 chr3 156815558 C T 5.96E-05 Epilepsy (remission after treatment) LOC339894 intron 23962720 rs6441111 chr3 156821808 C T 5.58E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) LOC339894 intron 23648065 rs7624327 chr3 156836906 G A 3.00E-06 Eating disorders LOC339894 intron 22911880 rs13064954 chr3 156854742 G A 7.00E-07 Diabetic retinopathy / / 21441570 rs6809003 chr3 156861750 C G 2.47E-04 Bipolar disorder,schizoaffective / / 19567891 rs10936063 chr3 156880883 C T 4.78E-04 Bipolar disorder,schizoaffective / / 19567891 rs10936066 chr3 156881002 T C 4.78E-04 Bipolar disorder,schizoaffective / / 19567891 rs9827476 chr3 156883141 T C 1.30E-06 Diabetic retinopathy / / 21441570 rs6781682 chr3 156891102 A C 4.46E-04 Bipolar disorder,schizoaffective / / 19567891 rs13091531 chr3 156894096 A G 1.40E-06 Diabetic retinopathy / / 21441570 rs9830661 chr3 156897868 C T 1.40E-06 Diabetic retinopathy / / 21441570 rs2133952 chr3 156915650 C T 9.60E-04 Iris characteristics / / 21835309 rs41342446 chr3 156936159 G A 3.14E-04 Multiple complex diseases / / 17554300 rs9812766 chr3 156947754 A G 1.70E-06 Diabetic retinopathy / / 21441570 rs9866141 chr3 156950579 C T 9.00E-07 Diabetic retinopathy / / 21441570 rs13081038 chr3 156950732 A G 3.33E-04 Bipolar disorder,schizoaffective / / 19567891 rs16827322 chr3 156950878 G A 8.77E-05 Bipolar disorder,schizoaffective / / 19567891 rs6764639 chr3 156951188 A G 1.90E-06 Diabetic retinopathy / / 21441570 rs10451916 chr3 156952194 A T 2.57E-04 Bipolar disorder,schizoaffective / / 19567891 rs4679788 chr3 156954391 T C 2.93E-07 Lipid traits / / 22028671 rs9814609 chr3 156956584 T C 2.00E-06 Diabetic retinopathy / / 21441570 rs13319093 chr3 156957264 A G 2.00E-06 Diabetic retinopathy / / 21441570 rs13326278 chr3 156957471 G A 4.60E-06 Diabetic retinopathy / / 21441570 rs13060940 chr3 156959711 C T 2.20E-06 Diabetic retinopathy / / 21441570 rs1587534 chr3 156962761 A C 9.60E-04 Iris characteristics / / 21835309 rs9868982 chr3 156963404 A C 2.30E-06 Diabetic retinopathy / / 21441570 rs9831830 chr3 156963598 C T 4.48E-04 Bipolar disorder,schizoaffective / / 19567891 rs7613866 chr3 156964032 C T 2.40E-06 Diabetic retinopathy / / 21441570 rs13090731 chr3 156964347 G A 2.40E-06 Diabetic retinopathy / / 21441570 rs7642179 chr3 156966235 A G 2.52E-04 Bipolar disorder,schizoaffective / / 19567891 rs11917697 chr3 156967568 G A 2.60E-06 Diabetic retinopathy / / 21441570 rs1500925 chr3 156973804 A G 2.41E-04 Bipolar disorder,schizoaffective / / 19567891 rs9289980 chr3 156974431 A G 2.21E-04 Bipolar disorder,schizoaffective / / 19567891 rs12696046 chr3 156981267 C T 2.60E-06 Diabetic retinopathy VEPH1 intron 21441570 rs924517 chr3 156981485 C G 1.42E-04 Bipolar disorder,schizoaffective VEPH1 intron 19567891 rs12634613 chr3 156984216 A G 2.80E-06 Diabetic retinopathy VEPH1 intron 21441570 rs13319063 chr3 156987271 A G 4.20E-06 Diabetic retinopathy VEPH1 intron 21441570 rs13326287 chr3 156987632 G A 4.30E-06 Diabetic retinopathy VEPH1 intron 21441570 rs12633429 chr3 156991392 T C 7.58E-04 Bipolar disorder,schizoaffective VEPH1 intron 19567891 rs12637932 chr3 156998998 A G 6.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VEPH1 intron 20877124 rs12637932 chr3 156998998 A G 7.87E-04 Insulin resistance VEPH1 intron 21901158 rs10440022 chr3 157001472 T C 4.80E-06 Diabetic retinopathy VEPH1 intron 21441570 rs13321401 chr3 157011913 G C 4.40E-06 Diabetic retinopathy VEPH1 intron 21441570 rs1581413 chr3 157050165 T C 2.20E-05 Subclinical atherosclerosis VEPH1 intron 17903303 rs13325320 chr3 157051818 G A 5.30E-06 Diabetic retinopathy VEPH1 intron 21441570 rs988587 chr3 157054271 T G 1.79E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) VEPH1 intron 23648065 rs988587 chr3 157054271 T G 6.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) VEPH1 intron 23648065 rs9817490 chr3 157066161 G A 3.50E-06 Diabetic retinopathy VEPH1 intron 21441570 rs13316165 chr3 157079625 A G 3.50E-06 Diabetic retinopathy VEPH1 intron 21441570 rs73873651 chr3 157081214 C T 0.00038 Breast cancer (ER positive) VEPH1 cds-synon 23555315 rs9883103 chr3 157088982 C T 8.25E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) VEPH1 intron 23648065 rs9883103 chr3 157088982 C T 6.47E-04 Response to alcohol consumption (flushing response) VEPH1 intron 24277619 rs12637261 chr3 157093360 A G 8.91E-04 Type 2 diabetes VEPH1 intron 17463246 rs4680360 chr3 157094479 T C 4.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) VEPH1 intron 23648065 rs16827563 chr3 157098978 C T 4.67E-09 Multiple complex diseases VEPH1 missense 17554300 rs13083863 chr3 157101998 T G 4.50E-06 Diabetic retinopathy VEPH1 intron 21441570 rs12486427 chr3 157113276 A C 2.64E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) VEPH1 intron 23648065 rs1563420 chr3 157119326 A G 8.10E-04 Bipolar disorder VEPH1 intron 19259986 rs6803628 chr3 157125584 G A 2.85E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) VEPH1 intron 23648065 rs2120243 chr3 157147568 A C 1.78E-04 Blood pressure (response to calcium channel blocker) VEPH1 intron 24192120 rs1840680 chr3 157156029 A G 8.11E-05 Blood pressure (response to calcium channel blocker) PTX3 intron 24192120 rs4680367 chr3 157166123 G A 1.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) VEPH1 intron 23648065 rs12634412 chr3 157172112 G T 6.50E-06 Urinary metabolites VEPH1 intron 21572414 rs12634385 chr3 157172163 C T 7.30E-06 Urinary metabolites VEPH1 intron 21572414 rs16827688 chr3 157183136 A C 6.90E-06 Urinary metabolites VEPH1 intron 21572414 rs12494965 chr3 157185986 C T 6.90E-06 Urinary metabolites VEPH1 intron 21572414 rs4679797 chr3 157186712 G C 5.40E-06 Urinary metabolites VEPH1 intron 21572414 rs9845279 chr3 157312442 G C 8.63E-06 Brachial circumference C3orf55 intron 22479309 rs9817096 chr3 157314066 A G 8.97E-04 Type 2 diabetes C3orf55 intron 17463246 rs9838074 chr3 157316437 G A 8.60E-04 Type 2 diabetes C3orf55 intron 17463246 rs9837954 chr3 157316461 C T 2.41E-04 Type 2 diabetes C3orf55 intron 17463246 rs7610823 chr3 157319765 T C 8.01E-04 Type 2 diabetes / / 17463246 rs4502543 chr3 157324023 A C 2.73E-04 Type 2 diabetes / / 17463246 rs11709879 chr3 157339389 G A 4.07E-04 Fibrinogen / / 17255346 rs1499782 chr3 157339925 G A 3.13E-04 Type 2 diabetes / / 17463246 rs9876844 chr3 157341407 A G 3.47E-04 Fibrinogen / / 17255346 rs1015389 chr3 157359662 G A 1.44E-04 Fibrinogen / / 17255346 rs1909551 chr3 157365023 T C 3.88E-04 Type 2 diabetes / / 17463246 rs1392187 chr3 157365321 G A 4.01E-04 Type 2 diabetes / / 17463246 rs9871401 chr3 157370438 A G 3.21E-04 Fibrinogen / / 17255346 rs1027083 chr3 157378340 C T 6.20E-05 Fibrinogen / / 17255346 rs1553187 chr3 157378711 T A 7.48E-06 Sleep duration / / 22105623 rs6807691 chr3 157387481 C A,T 1.79E-04 Fibrinogen / / 17255346 rs963354 chr3 157393770 C A 8.41E-07 Sleep duration / / 22105623 rs16828142 chr3 157419554 G C 7.63E-04 Multiple complex diseases / / 17554300 rs13064628 chr3 157449239 C T 6.03E-05 Fibrinogen / / 17255346 rs16828327 chr3 157514666 C T 6.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16828327 chr3 157514666 C T 2.53E-04 Iron levels / / pha002876 rs16828352 chr3 157536183 C T 1.47E-04 Iron levels / / pha002876 rs6794184 chr3 157542303 A G 2.32E-04 Multiple complex diseases / / 17554300 rs1515474 chr3 157553508 A G 1.33E-27 Narcolepsy / / 19629137 rs16828379 chr3 157558463 T G 3.70E-04 Multiple complex diseases / / 17554300 rs16828478 chr3 157591239 C T 2.10E-05 Height / / 19396169 rs9290008 chr3 157639491 A C 3.86E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9290008 chr3 157639491 A C 5.30E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3925065 chr3 157667114 G A 1.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3925065 chr3 157667114 G A 1.40E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9825122 chr3 157672947 T C 2.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9825122 chr3 157672947 T C 4.13E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6441171 chr3 157808875 T G 3.66E-05 Personality dimensions / / 18957941 rs1879803 chr3 157819584 C T 8.33E-05 Personality dimensions SHOX2 intron 18957941 rs7624303 chr3 157851223 A G 6.79E-05 Neuroblastoma RSRC1 intron pha002895 rs9857883 chr3 157887272 A C 3.34E-04 Response to alcohol consumption (flushing response) RSRC1 intron 24277619 rs9857883 chr3 157887272 A C 7.19E-05 Neuroblastoma RSRC1 intron pha002895 rs1918000 chr3 158017687 A G 2.00E-05 Personality dimensions RSRC1 intron 18957941 rs1193510 chr3 158030216 A G 9.86E-05 Neuroblastoma RSRC1 intron pha002895 rs17683861 chr3 158036690 G T 4.41E-05 Job-related exhaustion RSRC1 intron 23620144 rs9827781 chr3 158050196 T C 1.95E-05 Neuroblastoma RSRC1 intron pha002895 rs6441188 chr3 158069107 C A 7.47E-06 Neuroblastoma RSRC1 intron pha002895 rs10936131 chr3 158070858 C T 8.61E-05 Neuroblastoma RSRC1 intron pha002895 rs6778370 chr3 158094422 C T 7.84E-06 Neuroblastoma RSRC1 intron pha002895 rs7639867 chr3 158099176 C A 8.50E-06 Neuroblastoma RSRC1 intron pha002895 rs2362965 chr3 158109379 T A 2.00E-09 Height RSRC1 intron 23563607 rs939114 chr3 158115253 C A 1.66E-05 Neuroblastoma RSRC1 intron pha002895 rs11716327 chr3 158115915 G T 9.71E-05 Neuroblastoma RSRC1 intron pha002895 rs7632059 chr3 158133307 T G 7.21E-06 Neuroblastoma RSRC1 intron pha002895 rs10936142 chr3 158172405 T C 1.06E-05 Neuroblastoma RSRC1 intron pha002895 rs6441201 chr3 158178324 G A 3.43E-07 Neuroblastoma RSRC1 intron pha002895 rs2885663 chr3 158184263 G A 4.77E-06 Neuroblastoma RSRC1 intron pha002895 rs7649463 chr3 158190313 A G 8.31E-04 Response to alcohol consumption (flushing response) RSRC1 intron 24277619 rs10936146 chr3 158203468 T C 8.31E-04 Response to alcohol consumption (flushing response) RSRC1 intron 24277619 rs1714518 chr3 158213423 C T 5.71E-07 Neuroblastoma RSRC1 intron pha002895 rs1595027 chr3 158243086 A T 3.32E-04 Multiple complex diseases RSRC1 intron 17554300 rs1714524 chr3 158273096 C T 8.07E-04 Parkinson's disease / / 17052657 rs1714524 chr3 158273096 C T 1.36E-05 Neuroblastoma / / pha002895 rs1656376 chr3 158284681 G C 9.31E-04 Parkinson's disease / / 17052657 rs1656377 chr3 158285280 T C 4.94E-05 Neuroblastoma / / pha002895 rs6441208 chr3 158299555 T A 5.39E-04 Multiple complex diseases MLF1 intron 17554300 rs10513527 chr3 158301682 C A 8.11E-04 Suicide attempts in bipolar disorder MLF1 intron 21423239 rs2304408 chr3 158320880 G C 1.99E-05 Serum alpha1-antitrypsin levels MLF1 intron 23990791 rs13315529 chr3 158328274 G A 8.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs7624771 chr3 158335409 C T 2.28E-05 Serum alpha1-antitrypsin levels / / 23990791 rs6776901 chr3 158360592 T C 2.55E-05 Serum alpha1-antitrypsin levels GFM1 nearGene-5 23990791 rs6777231 chr3 158360944 T C 2.56E-05 Serum alpha1-antitrypsin levels GFM1 nearGene-5 23990791 rs1367313 chr3 158365538 A G 3.00E-04 Type 2 diabetes GFM1 intron 17846126 rs17697458 chr3 158376354 C G 2.62E-05 Serum alpha1-antitrypsin levels GFM1 intron 23990791 rs1492908 chr3 158386507 A G 2.00E-04 Type 2 diabetes LXN intron 17846126 rs17630607 chr3 158389860 C T 2.67E-05 Serum alpha1-antitrypsin levels LXN intron 23990791 rs9832803 chr3 158391124 C G 2.07E-05 Lymphocyte counts GFM1 intron 22286170 rs17698494 chr3 158405873 G A 2.57E-05 Serum alpha1-antitrypsin levels GFM1 intron 23990791 rs17698754 chr3 158411704 G A 2.46E-05 Serum alpha1-antitrypsin levels / / 23990791 rs539104674 chr3 158411704 G GC 2.46E-05 Serum alpha1-antitrypsin levels / / 23990791 rs3867391 chr3 158415840 T G 2.44E-05 Serum alpha1-antitrypsin levels RARRES1 intron 23990791 rs17699103 chr3 158419789 A G 2.41E-05 Serum alpha1-antitrypsin levels RARRES1 intron 23990791 rs7610009 chr3 158420369 C A 2.41E-05 Serum alpha1-antitrypsin levels RARRES1 intron 23990791 rs16847130 chr3 158423574 T A 7.02E-04 Suicide attempts in bipolar disorder RARRES1 intron 21423239 rs16847135 chr3 158423853 T C 9.16E-04 Suicide attempts in bipolar disorder RARRES1 intron 21423239 rs17699324 chr3 158424561 T C 2.40E-05 Serum alpha1-antitrypsin levels RARRES1 intron 23990791 rs17699478 chr3 158426243 C T 6.52E-04 Multiple complex diseases RARRES1 intron 17554300 rs2307064 chr3 158428642 G A 5.64E-05 Cognitive test performance RARRES1 cds-synon 20125193 rs9864589 chr3 158430706 A G 7.40E-04 Tourette syndrome RARRES1 intron 22889924 rs9864589 chr3 158430706 A G 1.71E-06 Tetralogy of Fallot RARRES1 intron 23297363 rs9864589 chr3 158430706 A G 1.71E-06 Type 2 diabetes RARRES1 intron 23300278 rs17700122 chr3 158444491 A G 6.02E-04 Multiple complex diseases RARRES1 intron 17554300 rs7646881 chr3 158453279 C A 2.00E-06 Tetralogy of Fallot / / 23297363 rs12489730 chr3 158457914 T G 3.94E-05 Serum alpha1-antitrypsin levels / / 23990791 rs7635704 chr3 158459720 T C 5.84E-08 Metabolite levels LOC100287290 intron 23281178 rs7624161 chr3 158459914 C G 5.84E-08 Metabolite levels LOC100287290 UTR-5 23281178 rs7617304 chr3 158463101 G A 7.00E-04 Thyroid cancer / / 23894154 rs17700475 chr3 158484933 A G 1.25E-06 Serum alpha1-antitrypsin levels / / 23990791 rs17643860 chr3 158485260 G A 1.24E-06 Serum alpha1-antitrypsin levels / / 23990791 rs17643917 chr3 158485739 A G 1.23E-06 Serum alpha1-antitrypsin levels / / 23990791 rs3863076 chr3 158486700 A G 1.69E-06 Serum alpha1-antitrypsin levels / / 23990791 rs1560418 chr3 158489641 A G 1.11E-07 Serum alpha1-antitrypsin levels / / 23990791 rs1560417 chr3 158489782 G A 1.11E-07 Serum alpha1-antitrypsin levels / / 23990791 rs2566347 chr3 158491377 C A 7.88E-08 Serum alpha1-antitrypsin levels / / 23990791 rs6761989 chr3 158500559 C T 1.14E-06 Serum alpha1-antitrypsin levels / / 23990791 rs1430414 chr3 158505003 G T 9.26E-07 Serum alpha1-antitrypsin levels / / 23990791 rs7615751 chr3 158509830 A C 1.94E-06 Periodontitis (CDC/AAP) / / 24024966 rs7624420 chr3 158510674 C A 4.43E-05 Serum alpha1-antitrypsin levels / / 23990791 rs9822005 chr3 158512381 G A 2.17E-06 Periodontitis (CDC/AAP) / / 24024966 rs9822005 chr3 158512381 G A 3.65E-06 Periodontitis (CDC/AAP) / / 24024966 rs6802315 chr3 158514360 T A 3.00E-07 Periodontitis (CDC/AAP) / / 24024966 rs41434057 chr3 158526120 C T 3.82E-04 Type 2 diabetes MFSD1 intron 17463246 rs10936160 chr3 158535951 T C 8.72E-06 Hearing function MFSD1 intron 21493956 rs340304 chr3 158572245 C A 3.06E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs340315 chr3 158575589 T C 6.02E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs340280 chr3 158585531 T C 3.79E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs340268 chr3 158594656 C T 8.20E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11917732 chr3 158613381 C T 9.17E-04 Multiple complex diseases / / 17554300 rs17646246 chr3 158622785 A G 9.85E-05 Coronary heart disease / / pha003032 rs340231 chr3 158627486 T C 5.37E-04 Type 2 diabetes / / 17463246 rs340229 chr3 158627645 C T 4.41E-04 Sudden cardiac arrest / / 21658281 rs12496761 chr3 158633726 C T 5.98E-05 Acute lung injury / / 22295056 rs340258 chr3 158634099 A G 1.28E-04 Type 2 diabetes / / 17463246 rs340260 chr3 158634689 C T 5.46E-04 Type 2 diabetes / / 17463246 rs340297 chr3 158646151 T C 6.84E-04 Type 2 diabetes / / 17463246 rs1604643 chr3 158653634 A G 8.78E-04 Multiple complex diseases / / 17554300 rs11707952 chr3 158665225 A G 8.70E-06 Personality dimensions / / 21173776 rs12696090 chr3 158669688 G T 2.72E-05 Staphylococcus aureus infection / / 24847357 rs13059184 chr3 158670454 A C 2.38E-04 Multiple complex diseases / / 17554300 rs7618072 chr3 158681562 C T 2.40E-06 Atrial fibrillation / / 19597491 rs992089 chr3 158684240 C T 7.06E-04 Endometrial cancer / / 24096698 rs992089 chr3 158684240 C T 7.84E-04 Endometrial cancer / / 24096698 rs6798734 chr3 158790222 G A 8.23E-04 Amyotrophic Lateral Sclerosis IQCJ intron 17362836 rs7615992 chr3 158828643 A G 1.31E-04 Amyotrophic Lateral Sclerosis IQCJ intron 17362836 rs12496828 chr3 158830545 T C 8.28E-04 Insulin resistance IQCJ intron 21901158 rs6785766 chr3 158831718 C T 1.55E-04 Amyotrophic Lateral Sclerosis IQCJ intron 17362836 rs9816422 chr3 158833189 T G 9.20E-05 Body mass index IQCJ intron 17255346 rs7615549 chr3 158834092 A G 1.54E-04 Body mass index IQCJ intron 17255346 rs1566548 chr3 158839647 A C 1.12E-04 Body mass index IQCJ intron 17255346 rs885342 chr3 158842166 G A 1.36E-04 Body mass index IQCJ intron 17255346 rs7634829 chr3 158928265 G A 9.00E-05 Prostate cancer IQCJ intron 21743057 rs2595258 chr3 158934353 T C 8.02E-04 Type 2 diabetes IQCJ intron 17463246 rs2595260 chr3 158937938 T C 4.10E-04 Type 2 diabetes IQCJ intron 17463246 rs2595233 chr3 158962830 C A 2.09E-04 Cholesterol IQCJ intron 17255346 rs2595233 chr3 158962830 C A 6.36E-04 Rheumatoid arthritis IQCJ intron 21452313 rs2621306 chr3 158977434 T G 2.66E-05 Type 2 diabetes IQCJ intron 17463246 rs1449009 chr3 158977883 G A 1.48E-04 Cholesterol IQCJ intron 17255346 rs1449009 chr3 158977883 G A 6.29E-04 Rheumatoid arthritis IQCJ intron 21452313 rs2595240 chr3 158988594 C T 6.32E-04 Rheumatoid arthritis IQCJ-SCHIP1 intron 21452313 rs2595244 chr3 159007035 A G 6.26E-04 Type 2 diabetes SCHIP1 intron 17463246 rs2595248 chr3 159018527 T C 0.0000929 Nicotine dependence (smoking) SCHIP1 intron 22377092 rs2621312 chr3 159027205 T C 3.18E-04 Type 2 diabetes SCHIP1 intron 17463246 rs1900860 chr3 159031722 G A 4.84E-04 Rheumatoid arthritis SCHIP1 intron 21452313 rs9290036 chr3 159056759 C T 0.0000216 Panic disorder SCHIP1 intron 23149450 rs9290036 chr3 159056759 C T 2.16E-05 Serum tamsulosin hydrochloride concentration SCHIP1 intron 23151678 rs9823822 chr3 159074327 G A 0.0000239 Panic disorder SCHIP1 intron 23149450 rs9823822 chr3 159074327 G A 2.39E-05 Serum tamsulosin hydrochloride concentration SCHIP1 intron 23151678 rs2084507 chr3 159079542 A G 8.86E-04 Type 2 diabetes SCHIP1 intron 17463246 rs1449004 chr3 159081357 G A 8.98E-05 AIDS SCHIP1 intron 19754311 rs6787941 chr3 159087665 G T 8.97E-04 Type 2 diabetes SCHIP1 intron 17463246 rs1868415 chr3 159094569 C T 8.00E-05 Prostate cancer SCHIP1 intron 21743057 rs4440163 chr3 159098080 G A 7.80E-04 Taste perception SCHIP1 intron 22132133 rs7640445 chr3 159105475 C T 2.06E-04 Taste perception SCHIP1 intron 22132133 rs9290042 chr3 159140615 A C 6.84E-04 Taste perception SCHIP1 intron 22132133 rs1554141 chr3 159155074 A G 9.20E-06 Urinary metabolites SCHIP1 intron 21572414 rs4142769 chr3 159173074 C T 7.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SCHIP1 intron 20877124 rs9824310 chr3 159192743 A G 1.31E-04 Type 2 diabetes SCHIP1 intron 17463246 rs1017970 chr3 159201944 A G 7.82E-04 Type 2 diabetes SCHIP1 intron 17463246 rs1017970 chr3 159201944 A G 8.89E-05 Prion diseases SCHIP1 intron 22210626 rs1565352 chr3 159217153 C T 7.21E-05 Prion diseases SCHIP1 intron 22210626 rs1489912 chr3 159220116 T C 2.58E-04 Type 2 diabetes SCHIP1 intron 17463246 rs10470336 chr3 159221461 C T 8.48E-05 Prion diseases SCHIP1 intron 22210626 rs7627201 chr3 159231807 C T 6.20E-04 Type 2 diabetes SCHIP1 intron 17463246 rs2222328 chr3 159259291 T C 8.00E-07 Quantitative traits SCHIP1 intron 19197348 rs9872731 chr3 159428329 A G 5.40E-06 Urinary metabolites SCHIP1 intron 21572414 rs9865997 chr3 159439565 C T 1.40E-05 Urinary metabolites SCHIP1 intron 21572414 rs11705997 chr3 159448225 G A 5.40E-06 Urinary metabolites SCHIP1 intron 21572414 rs4602438 chr3 159454827 A G 8.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SCHIP1 intron 20877124 rs12487057 chr3 159455394 C T 3.01E-05 Eosinophil counts SCHIP1 intron pha003088 rs4679863 chr3 159490286 A G 7.77E-05 Serum metabolites SCHIP1 intron 19043545 rs4513503 chr3 159502420 T C 9.81E-04 Parkinson's disease SCHIP1 intron 17052657 rs10513546 chr3 159551651 G A 4.12E-04 Type 2 diabetes SCHIP1 intron 17463246 rs13088856 chr3 159554958 T G 6.44E-04 Type 2 diabetes SCHIP1 intron 17463246 rs3888010 chr3 159559868 G A 6.76E-04 Multiple complex diseases SCHIP1 intron 17554300 rs7648959 chr3 159562497 A G 5.45E-04 Type 2 diabetes SCHIP1 intron 17463246 rs1109156 chr3 159572120 C T 1.44E-04 Multiple complex diseases SCHIP1 intron 17554300 rs1675497 chr3 159582382 A G 1.40E-05 Urinary metabolites SCHIP1 intron 21572414 rs1353248 chr3 159623559 C T 9.80E-09 Celiac disease / / 22057235 rs17809756 chr3 159630084 G A 1.20E-05 Behcet's disease / / 23291587 rs76830965 chr3 159637678 C A 2.60E-27 Celiac disease / / 22057235 rs2047173 chr3 159640518 G A 2.49E-04 Multiple complex diseases / / 17554300 rs13086980 chr3 159641399 A G 5.80E-06 Urinary metabolites / / 21572414 rs6799788 chr3 159644297 A G 1.00E-06 Major depressive disorder / / 23377640 rs1366302 chr3 159661275 A G 2.43E-04 Alzheimer's disease / / 17998437 rs17810546 chr3 159665050 A G 1.00E-09 Celiac disease / / 18311140 rs17810546 chr3 159665050 A G 4.00E-28 Celiac disease / / 20190752 rs17810546 chr3 159665050 A G 4.00E-28 Asthma / / 21150878 rs17810546 chr3 159665050 A G 3.98E-28 Celiac disease and Rheumatoid arthritis / / 21383967 rs17810546 chr3 159665050 A G 3.98E-28 Multiple sclerosis / / 22190364 rs17810546 chr3 159665050 A G 6.00E-07 Behcet's disease / / 23291587 rs17810546 chr3 159665050 A G 1.49E-05 Behcet's disease / / pha002888 rs627865 chr3 159667232 G C 1.37E-05 Alzheimer's disease / / 17998437 rs480350 chr3 159668291 A G 1.32E-05 Alzheimer's disease / / 17998437 rs11918254 chr3 159669994 C T 6.29E-05 Pulmonary function in asthmatics / / 23541324 rs2561288 chr3 159674928 T C 8.10E-08 Celiac disease / / 22057235 rs10513548 chr3 159675391 A C 5.30E-04 Alzheimer's disease / / 22005930 rs501636 chr3 159678183 A C 9.79E-05 Type 2 diabetes / / 17463246 rs7611965 chr3 159678255 A G 9.40E-06 Urinary metabolites / / 21572414 rs7636840 chr3 159678641 G T 9.40E-06 Urinary metabolites / / 21572414 rs7636840 chr3 159678641 G T 3.58E-05 Pulmonary function in asthmatics / / 23541324 rs6808024 chr3 159681666 A T 2.38E-11 Primary biliary cirrhosis / / 22961000 rs7372767 chr3 159698866 G A 1.08E-05 Alzheimer's disease / / 17998437 rs4680534 chr3 159698945 T C 6.00E-06 Multiple sclerosis / / 19525953 rs4680534 chr3 159698945 T C 3.60E-05 Multiple sclerosis / / 21833088 rs4680534 chr3 159698945 T C 3.28E-05 Multiple sclerosis / / 22190364 rs6800657 chr3 159699372 A G 6.25E-04 Type 2 diabetes / / 17463246 rs755004 chr3 159700325 G A 3.91E-04 Type 2 diabetes / / 17463246 rs662959 chr3 159701231 G A 7.97E-05 Cognitive test performance / / 20125193 rs2243112 chr3 159705669 G C 2.15E-09 Cholesterol,total / / 23063622 rs2243112 chr3 159705669 G C 7.67E-09 LDL cholesterol / / 23063622 rs647801 chr3 159707519 A G 9.06E-14 Primary biliary cirrhosis IL12A intron 22961000 rs2243123 chr3 159709651 T C 7.00E-06 Multiple sclerosis IL12A intron 21833088 rs2243123 chr3 159709651 T C 4.71E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) IL12A intron 24023788 rs582054 chr3 159710001 A T 3.83E-14 Primary biliary cirrhosis IL12A intron 22961000 rs582537 chr3 159710098 A C 3.13E-14 Primary biliary cirrhosis IL12A intron 22961000 rs2243131 chr3 159712058 A C 2.62E-05 Waist-Hip Ratio IL12A intron pha003029 rs2243143 chr3 159714802 G A 6.19E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs6441284 chr3 159718268 A G 6.19E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs629209 chr3 159728713 C G 5.21E-22 Primary biliary cirrhosis / / 22961000 rs6441286 chr3 159728878 T G 2.00E-14 Primary biliary cirrhosis / / 19458352 rs6441286 chr3 159728878 T G 8.00E-12 Primary biliary cirrhosis / / 20639880 rs564799 chr3 159728987 C T 8.19E-16 Primary biliary cirrhosis / / 21399635 rs480134 chr3 159729532 C T 4.69E-22 Primary biliary cirrhosis / / 22961000 rs586094 chr3 159729548 T G 4.69E-22 Primary biliary cirrhosis / / 22961000 rs480913 chr3 159729580 T G 4.91E-22 Primary biliary cirrhosis / / 22961000 rs1874886 chr3 159729655 G A 4.80E-22 Primary biliary cirrhosis / / 22961000 rs587422 chr3 159729805 G C 4.42E-22 Primary biliary cirrhosis / / 22961000 rs483714 chr3 159729877 T C 4.62E-22 Primary biliary cirrhosis / / 22961000 rs484600 chr3 159729961 A C 4.55E-22 Primary biliary cirrhosis / / 22961000 rs485789 chr3 159730148 G T 4.38E-22 Primary biliary cirrhosis / / 22961000 rs600519 chr3 159730417 G A 4.42E-22 Primary biliary cirrhosis / / 22961000 rs9877910 chr3 159730819 C T 1.02E-17 Primary biliary cirrhosis / / 22936693 rs9877910 chr3 159730819 C T 4.00E-17 Primary biliary cirrhosis (anti-mitochondrial antibody positive) / / 22936693 rs9877910 chr3 159730819 C T 8.53E-15 Primary biliary cirrhosis in females / / 22936693 rs669003 chr3 159731885 A G 4.22E-22 Primary biliary cirrhosis / / 22961000 rs545143 chr3 159731995 C T 1.18E-14 Primary biliary cirrhosis / / 22936693 rs545143 chr3 159731995 C T 4.09E-22 Primary biliary cirrhosis / / 22961000 rs545232 chr3 159732031 C T 5.20E-22 Primary biliary cirrhosis / / 22961000 rs1651081 chr3 159732502 A T 6.14E-22 Primary biliary cirrhosis / / 22961000 rs571099 chr3 159732564 T G 3.49E-22 Primary biliary cirrhosis / / 22961000 rs6441288 chr3 159732840 C T 1.03E-21 Primary biliary cirrhosis / / 22961000 rs2366643 chr3 159736485 T C 3.92E-22 Primary biliary cirrhosis / / 22961000 rs9816860 chr3 159738608 G A 2.83E-05 Cognitive impairment induced by topiramate / / 22091778 rs9968095 chr3 159739966 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9968095 chr3 159739966 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9968095 chr3 159739966 G A 9.85E-06 Cognitive impairment induced by topiramate / / 22091778 rs485499 chr3 159745863 T C 2.00E-16 Primary biliary cirrhosis / / 21399635 rs485499 chr3 159745863 T C 5.36E-22 Primary biliary cirrhosis / / 22961000 rs6795264 chr3 159800890 C T 8.76E-04 Parkinson's disease / / 16252231 rs9880666 chr3 159803697 A C 4.82E-04 Taste perception / / 22132133 rs867885 chr3 159811970 T G 4.60E-04 Multiple complex diseases / / 17554300 rs9866988 chr3 159814546 T C 7.29E-04 Parkinson's disease / / 16252231 rs7622728 chr3 159845146 C A 4.55E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6441299 chr3 159850606 G C 6.33E-04 Type 2 diabetes / / 17463246 rs10936198 chr3 159877652 A G 4.86E-04 Fibrinogen / / 17255346 rs11918142 chr3 159907085 T C 1.14E-07 Non-obstructive azoospermia / / 22197933 rs884254 chr3 159913837 G A 9.17E-04 Multiple complex diseases / / 17554300 rs9812738 chr3 159929106 T C 6.90E-06 Urinary metabolites / / 21572414 rs6441306 chr3 159952278 A G 9.73E-05 Atopy / / 21625490 rs6441306 chr3 159952278 A G 3.52E-05 Behcet's disease / / pha002888 rs10513552 chr3 159952941 C T 3.88E-04 Stroke / / pha002886 rs10513552 chr3 159952941 C T 1.45E-05 Tunica Media / / pha003036 rs6797926 chr3 159956559 C T 1.94E-05 Tunica Media / / pha003036 rs4679881 chr3 160028014 T C 4.70E-05 Bone mineral density IFT80 intron 21927923 rs10513551 chr3 160086055 G T 6.30E-04 Type 2 diabetes and 6 quantitative traits IFT80 intron 17848626 rs4680580 chr3 160115004 C T 4.70E-05 Bone mineral density IFT80 intron 21927923 rs4680588 chr3 160192518 T G 1.40E-04 Bone mineral density / / 21927923 rs2029361 chr3 160209895 C A,T 1.20E-05 Urinary metabolites / / 21572414 rs721022 chr3 160223032 C T 1.00E-05 Anxiety spectrum disorders KP/4 intron 20368705 rs17236529 chr3 160226307 C T 2.03E-09 Smooth-surface caries KP/4 intron 24556642 rs17236529 chr3 160226307 C T 3.00E-06 Smooth-surface caries KP/4 intron 24556642 rs17236537 chr3 160275031 G A 1.70E-08 Smooth-surface caries KP/4 intron 24556642 rs17236537 chr3 160275031 G A 3.52E-06 Smooth-surface caries KP/4 intron 24556642 rs9862595 chr3 160279879 T A 8.75E-05 Serum metabolites KP/4 intron 19043545 rs3806629 chr3 160283815 C A 3.71E-05 Partial epilepsies / / 20522523 rs1920644 chr3 160313354 C T 8.03E-04 Smoking initiation / / 24665060 rs4679903 chr3 160328568 C A 3.71E-04 Smoking initiation / / 24665060 rs1920650 chr3 160335588 T C 5.27E-05 Parkinson's disease / / 21738487 rs4679904 chr3 160340896 C T 1.00E-06 Primary biliary cirrhosis / / 19458352 rs2141671 chr3 160358415 A G 1.27E-05 Post-operative nausea and vomiting / / 21694509 rs1378659 chr3 160406325 T C 6.07E-05 Bipolar disorder / / 22925353 rs1378661 chr3 160424299 C T 7.44E-05 Bipolar disorder / / 22925353 rs7646957 chr3 160429700 G A 8.91E-05 Bipolar disorder / / 22925353 rs7624766 chr3 160429869 A G 4.00E-07 Response to methotrexate in rheumatoid arthritis / / 24583629 rs6772563 chr3 160451248 G A 1.20E-04 Coronary heart disease / / 21606135 rs9849216 chr3 160457351 C T 4.10E-04 Coronary heart disease / / 21606135 rs12487861 chr3 160535721 G T 9.69E-05 Erythrocyte counts PPM1L intron pha003101 rs1839017 chr3 160577670 C T 4.60E-06 Parkinson's disease (familial) PPM1L intron 18985386 rs16831552 chr3 160589400 T C 8.03E-04 Multiple complex diseases PPM1L intron 17554300 rs10513557 chr3 160594496 C T 7.20E-04 Multiple complex diseases PPM1L intron 17554300 rs11716265 chr3 160602111 G A 8.00E-06 Urinary metabolites PPM1L intron 21572414 rs1348977 chr3 160621195 T C 1.10E-05 Urinary metabolites PPM1L intron 21572414 rs9790132 chr3 160627289 A T 5.10E-06 Urinary metabolites PPM1L intron 21572414 rs6789195 chr3 160630325 T C 1.30E-05 Urinary metabolites PPM1L intron 21572414 rs6809177 chr3 160630477 G T 4.40E-06 Urinary metabolites PPM1L intron 21572414 rs16831611 chr3 160631123 C T 9.70E-04 Multiple complex diseases PPM1L intron 17554300 rs13064176 chr3 160644181 T A 1.30E-05 Urinary metabolites PPM1L intron 21572414 rs2121721 chr3 160685788 T C 0.0000905 Panic disorder PPM1L intron 23149450 rs2121721 chr3 160685788 T C 9.05E-05 Serum tamsulosin hydrochloride concentration PPM1L intron 23151678 rs10513560 chr3 160710798 G A 7.15E-04 Type 2 diabetes PPM1L intron 17463246 rs17392097 chr3 160717708 G A 7.12E-04 Multiple complex diseases PPM1L intron 17554300 rs9290065 chr3 160776964 C T 4.10E-04 Obesity-related traits PPM1L intron 17903300 rs9290065 chr3 160776964 C T 9.00E-06 Kawasaki disease PPM1L intron 22446961 rs9861850 chr3 160803242 C T 6.73E-04 Smoking cessation B3GALNT1 UTR-3 24665060 rs2231252 chr3 160805352 T C 4.31E-04 Smoking cessation B3GALNT1 intron 24665060 rs6795977 chr3 160816935 C T 5.63E-04 Smoking cessation B3GALNT1 intron 24665060 rs4557202 chr3 160820524 G C 2.00E-06 Menarche (age at onset) B3GALNT1 intron 23599027 rs6441354 chr3 160826404 T C 1.67E-04 Smoking cessation / / 24665060 rs1599389 chr3 160836006 G A 1.42E-04 Smoking cessation / / 24665060 rs9860738 chr3 160843290 G A 9.76E-05 Smoking cessation / / 24665060 rs731363 chr3 160849094 G T 9.16E-05 Smoking cessation / / 24665060 rs9290067 chr3 160852662 T C 2.61E-04 Smoking cessation / / 24665060 rs9810737 chr3 160853401 G A 2.11E-04 Smoking cessation / / 24665060 rs6789244 chr3 160866230 T G 1.01E-04 Smoking cessation / / 24665060 rs12494844 chr3 160870529 T C 6.98E-05 Smoking cessation / / 24665060 rs9879687 chr3 160874938 A G 7.90E-04 Smoking cessation / / 24665060 rs9858399 chr3 160877937 G A 1.87E-04 Smoking cessation / / 24665060 rs9878365 chr3 160878126 T G 1.65E-04 Smoking cessation / / 24665060 rs12631850 chr3 160883062 T C 1.74E-04 Smoking cessation / / 24665060 rs34016896 chr3 160992864 C T 3.00E-07 Parkinson's disease / / 22451204 rs9290075 chr3 161020136 G T 6.96E-05 Type 2 diabetes / / 17846125 rs7652447 chr3 161062331 C T 6.04E-05 Smoking cessation / / 24665060 rs336583 chr3 161081981 T A 3.90E-04 Obesity-related traits SPTSSB intron 17903300 rs12634006 chr3 161083709 A G 0.0005007 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPTSSB intron 23233654 rs12634006 chr3 161083709 A G 5.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) SPTSSB intron 23233662 rs464766 chr3 161087592 C G 6.10E-05 Obesity-related traits SPTSSB intron 17903300 rs16832246 chr3 161109916 G A 6.64E-05 Longevity / / 20304771 rs11713185 chr3 161111357 C G 6.47E-05 Longevity / / 20304771 rs16832279 chr3 161120483 C T 7.25E-05 Longevity / / 20304771 rs16832279 chr3 161120483 C T 1.33E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs11710086 chr3 161125858 A T 6.87E-05 Longevity / / 20304771 rs11710916 chr3 161130070 T C 6.88E-05 Longevity / / 20304771 rs1811483 chr3 161130900 A G 5.35E-05 Longevity / / 20304771 rs1811483 chr3 161130900 A G 1.22E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs16832548 chr3 161219005 G T 0.0001731 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) OTOL1 intron 23233654 rs16832548 chr3 161219005 G T 1.73E-04 Methotrexate clearance (acute lymphoblastic leukemia) OTOL1 intron 23233662 rs7644500 chr3 161224538 G A 9.51E-06 Alcohol and nictotine co-dependence / / 20158304 rs4287919 chr3 161226185 C T 5.93E-05 Longevity / / 20304771 rs17479823 chr3 161229214 C T 2.67E-05 Alcohol dependence / / 21703634 rs9883089 chr3 161229396 G A 8.43E-05 Longevity / / 20304771 rs9831924 chr3 161238856 G A 5.73E-05 Longevity / / 20304771 rs4856642 chr3 161248326 T A 7.60E-05 Longevity / / 20304771 rs13324941 chr3 161251252 G C 6.83E-04 Alzheimer's disease / / 17998437 rs9831040 chr3 161251781 A G 6.93E-05 Longevity / / 20304771 rs17420696 chr3 161252370 A G 0.0007049 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17420696 chr3 161252370 A G 7.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2221517 chr3 161260281 C T 7.19E-05 Longevity / / 20304771 rs2221516 chr3 161263939 T C 8.34E-05 Longevity / / 20304771 rs1506473 chr3 161264661 A C 4.28E-05 Colorectal cancer / / 24448986 rs17421292 chr3 161265567 G A 0.0006449 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17421292 chr3 161265567 G A 6.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7621711 chr3 161267127 G A 8.69E-05 Longevity / / 20304771 rs6781716 chr3 161268611 G A 7.62E-05 Longevity / / 20304771 rs9868834 chr3 161272774 T C 7.73E-05 Longevity / / 20304771 rs6793693 chr3 161290167 A G 3.28E-05 Longevity / / 20304771 rs7620901 chr3 161307316 C T 2.97E-05 Longevity / / 20304771 rs16832858 chr3 161336354 G A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs16832858 chr3 161336354 G A 3.18E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6441391 chr3 161339031 T G 5.82E-05 Longevity / / 20304771 rs2048801 chr3 161339936 C A 9.72E-05 Longevity / / 20304771 rs1588907 chr3 161342964 G A 7.88E-05 Longevity / / 20304771 rs9290087 chr3 161343916 C G 7.91E-05 Longevity / / 20304771 rs1399904 chr3 161347871 G A 6.72E-05 Longevity / / 20304771 rs9813121 chr3 161348551 A G 6.65E-05 Longevity / / 20304771 rs1399910 chr3 161349373 A C 6.34E-05 Longevity / / 20304771 rs1878064 chr3 161349630 T C 6.34E-05 Longevity / / 20304771 rs1399906 chr3 161351226 C T 6.05E-05 Longevity / / 20304771 rs9871565 chr3 161352205 C T 5.84E-05 Longevity / / 20304771 rs9876608 chr3 161352859 G A 4.54E-05 Longevity / / 20304771 rs9876363 chr3 161352907 C G 5.62E-05 Longevity / / 20304771 rs9877938 chr3 161353644 G A 5.51E-05 Longevity / / 20304771 rs1515741 chr3 161355207 A C 4.05E-05 Longevity / / 20304771 rs1850000 chr3 161357044 C T 4.40E-05 Longevity / / 20304771 rs1399916 chr3 161359375 C T 4.34E-05 Longevity / / 20304771 rs1399916 chr3 161359375 C T 2.55E-05 Height / / 22021425 rs1515743 chr3 161360807 T C 4.25E-05 Longevity / / 20304771 rs1568020 chr3 161364319 A T 3.87E-05 Longevity / / 20304771 rs4305435 chr3 161366641 T G 3.80E-05 Longevity / / 20304771 rs4305435 chr3 161366641 T G 2.32E-05 Height / / 22021425 rs2203490 chr3 161367689 C T 3.77E-05 Longevity / / 20304771 rs1515724 chr3 161369987 T C 3.18E-05 Longevity / / 20304771 rs1399915 chr3 161375350 C T 2.65E-05 Longevity / / 20304771 rs4389491 chr3 161389515 C A 7.04E-04 Smoking initiation / / 24665060 rs908351 chr3 161389636 C T 5.20E-04 Breast cancer / / 21060860 rs6808138 chr3 161392576 C G 5.00E-06 Hyperactive-impulsive symptoms / / 18821565 rs6808138 chr3 161392576 C G 8.00E-06 Hyperactive-impulsive symptoms / / 18821565 rs2404571 chr3 161392969 G A 2.81E-07 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs4635724 chr3 161394052 C T 5.45E-05 Attention deficit hyperactivity disorder / / 23728934 rs1399903 chr3 161394104 T C 3.08E-04 Type 2 diabetes / / 17463246 rs1104702 chr3 161394234 A G 1.47E-04 Type 2 diabetes / / 17846125 rs12486357 chr3 161396686 C G 2.41E-05 Type 2 diabetes / / 17463246 rs6797942 chr3 161396753 A G 9.62E-05 Type 2 diabetes / / 17463246 rs6773928 chr3 161396942 G A 2.94E-04 Type 2 diabetes / / 17463246 rs11916521 chr3 161397139 G A 3.88E-04 Multiple complex diseases / / 17554300 rs1515721 chr3 161397284 C T 1.71E-04 Type 2 diabetes / / 17463246 rs9857552 chr3 161397466 A C 6.86E-05 Type 2 diabetes / / 17463246 rs1399898 chr3 161416296 C G 2.31E-04 Multiple complex diseases / / 17554300 rs2063836 chr3 161423967 A G 4.50E-05 Schizophrenia / / 21791550 rs2063836 chr3 161423967 A G 0.0000018 Psychosis / / 23164818 rs1399900 chr3 161446446 A T 9.19E-04 Type 2 diabetes / / 17463246 rs523441 chr3 161450141 C T 1.96E-04 Multiple complex diseases / / 17554300 rs16833312 chr3 161460016 C T 2.00E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs498051 chr3 161460507 G C 3.21E-05 Multiple complex diseases / / 17554300 rs308698 chr3 161488348 A T 2.46E-04 Multiple complex diseases / / 17554300 rs1515730 chr3 161490079 G A 3.57E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs1515738 chr3 161501787 C T 9.97E-04 Type 2 diabetes / / 17846125 rs4856728 chr3 161520610 A G 5.86E-04 Response to TNF antagonist treatment / / 21061259 rs1436740 chr3 161522742 T C 6.24E-05 Lung adenocarcinoma / / 19836008 rs1017437 chr3 161529448 C T 0.00000712 Alpha-2-adrenoceptor-mediated vasoconstriction / / 23337848 rs13061797 chr3 161544997 T C 1.28E-06 Sickle cell anemia (severity) / / 20029952 rs5029866 chr3 161576835 T C 1.20E-05 Urinary metabolites / / 21572414 rs12696123 chr3 161616372 C G 1.30E-04 Weight loss (gastric bypass surgery) / / 23643386 rs6441417 chr3 161649352 G A 3.32E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs6441418 chr3 161649516 A C 2.91E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs6778365 chr3 161657384 C A 1.99E-04 Hearing function / / 17255346 rs13433983 chr3 161660646 C T 5.01E-04 Alzheimer's disease / / 22005930 rs12330759 chr3 161661354 T C 5.13E-04 Alzheimer's disease / / 22005930 rs10513576 chr3 161667800 T C 3.59E-04 Body mass index / / 21701565 rs6441421 chr3 161669809 G A 4.71E-04 Alzheimer's disease / / 22005930 rs9830696 chr3 161687983 C A 7.71E-04 Multiple complex diseases / / 17554300 rs4856666 chr3 161747143 C T 7.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs951475 chr3 161760549 T C 7.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs28688125 chr3 161782354 G A 1.70E-05 Urinary metabolites / / 21572414 rs1581057 chr3 161821524 A C 6.00E-06 Social communication problems / / 24564958 rs4539953 chr3 161826690 G A 8.70E-04 Multiple complex diseases / / 17554300 rs2175263 chr3 161841018 A T 6.27E-05 Cognitive decline / / 23732972 rs1510328 chr3 161847016 T G 5.44E-04 Alzheimer's disease / / 22005930 rs2221756 chr3 161854718 T C 3.75E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2405282 chr3 161867079 T G 2.90E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs79408325 chr3 161886186 T C 0.0000644 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1397220 chr3 161886323 T C 0.0000693 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs75579764 chr3 161887594 G T 0.0000506 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs79784056 chr3 161888543 T C 0.0000438 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs78825750 chr3 161891713 T G 0.0000299 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1976600 chr3 161892106 G A 0.0000719 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10513579 chr3 161892530 T C 0.0000278 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs76094653 chr3 161892718 T C 0.000028 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs982053 chr3 161894154 T C 0.0000349 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs16850784 chr3 161895538 A G 7.25E-04 Multiple complex diseases / / 17554300 rs4134190 chr3 161910591 T C 6.54E-04 Multiple complex diseases / / 17554300 rs7624830 chr3 161921368 A C 4.36E-04 Multiple complex diseases / / 17554300 rs10513580 chr3 161939907 T C 4.38E-05 Major depressive disorder / / 20516156 rs1488583 chr3 161949284 G A 1.32E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs13083821 chr3 161979926 T A 1.86E-06 Reading and spelling / / 23738518 rs13083821 chr3 161979926 T A 2.60E-05 Word reading / / 23738518 rs1109921 chr3 161980275 T C 2.22E-05 Hearing function / / 17255346 rs9833288 chr3 161984517 C T 1.42E-04 Hearing function / / 17255346 rs13072299 chr3 161994639 C T 1.84E-04 Coronary heart disease / / 21606135 rs6441441 chr3 162003027 G C 3.33E-05 Hearing function / / 17255346 rs9883161 chr3 162004273 C A 7.51E-05 Hearing function / / 17255346 rs7651936 chr3 162022959 C A 3.30E-05 Type 2 diabetes / / 17293876 rs7651936 chr3 162022959 C A 3.30E-05 Type 2 diabetes / / 19184112 rs9833336 chr3 162055990 T C 3.41E-05 Hearing function / / 17255346 rs12493123 chr3 162069009 G A 1.65E-05 Word reading / / 23738518 rs12493123 chr3 162069009 G A 2.00E-06 Reading and spelling / / 23738518 rs2405749 chr3 162084947 C T 7.98E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12488754 chr3 162085820 T C 1.90E-04 Schizophrenia / / 19197363 rs2897223 chr3 162109383 C T 4.68E-04 Multiple complex diseases / / 17554300 rs6780978 chr3 162117350 A G 6.17E-05 Tuberculosis / / 20694014 rs2405755 chr3 162117467 C T 2.06E-06 Cognitive impairment induced by topiramate / / 22091778 rs4856685 chr3 162130691 A G 7.40E-05 Glucose levels / / pha003061 rs12636148 chr3 162131408 T C 5.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs6805705 chr3 162134690 A G 7.40E-05 Glucose levels / / pha003061 rs11924705 chr3 162161616 T C 6.37E-05 Multiple complex diseases / / 17554300 rs11924705 chr3 162161616 T C 4.00E-14 Coronary heart disease / / 21626137 rs6789378 chr3 162167396 G A 4.00E-14 Coronary heart disease / / 21626137 rs1031838 chr3 162236534 C T 5.77E-04 Multiple complex diseases / / 17554300 rs1478149 chr3 162236954 T C 4.42E-04 Multiple complex diseases / / 17554300 rs1478148 chr3 162237128 A G 5.94E-04 Multiple complex diseases / / 17554300 rs3933789 chr3 162237888 G A 4.85E-04 Multiple complex diseases / / 17554300 rs2061739 chr3 162238020 G A 3.53E-04 Multiple complex diseases / / 17554300 rs1478146 chr3 162243751 C T 4.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1478146 chr3 162243751 C T 4.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10936294 chr3 162251934 C T 7.56E-04 Multiple complex diseases / / 17554300 rs1542531 chr3 162256364 C T 6.64E-04 Multiple complex diseases / / 17554300 rs1968824 chr3 162261021 A G 1.66E-05 Multiple complex diseases / / 17554300 rs1600094 chr3 162266475 G A 8.15E-05 Body Fat Distribution / / pha003016 rs13083177 chr3 162286357 T C 9.62E-05 Aging (time to event) / / 21782286 rs9836512 chr3 162290890 G A 2.43E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs7643623 chr3 162337011 T A 1.50E-04 Type 2 diabetes / / 17463246 rs17758217 chr3 162359891 C G 7.83E-04 Multiple complex diseases / / 17554300 rs766810 chr3 162360950 G A 1.16E-04 Type 2 diabetes / / 17463246 rs924154 chr3 162361568 A C 7.64E-05 Type 2 diabetes / / 17463246 rs4858919 chr3 162362878 T C 5.03E-04 Alzheimer's disease / / 22005930 rs1496741 chr3 162363057 G A 1.16E-04 Type 2 diabetes / / 17463246 rs2132621 chr3 162363141 A T 7.64E-05 Type 2 diabetes / / 17463246 rs17707861 chr3 162376931 A G 5.11E-04 Type 2 diabetes / / 17463246 rs9290132 chr3 162400620 G A 4.23E-05 Intracerebral hemorrhage / / 24656865 rs11926645 chr3 162439725 T C 5.15E-04 Type 2 diabetes / / 17463246 rs11926645 chr3 162439725 T C 6.98E-04 Body mass index / / 21701565 rs9681374 chr3 162489466 C T 4.80E-04 Multiple complex diseases / / 17554300 rs206316 chr3 162490482 C T 4.93E-04 Multiple complex diseases / / 17554300 rs150219 chr3 162490957 A C 4.85E-04 Multiple complex diseases / / 17554300 rs206313 chr3 162491873 G A 5.18E-04 Multiple complex diseases / / 17554300 rs206310 chr3 162492971 G A 6.04E-04 Multiple complex diseases / / 17554300 rs206303 chr3 162494772 A G 5.39E-05 Waist Circumference / / pha003023 rs9851876 chr3 162496237 T C 4.76E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4140866 chr3 162498022 A G 4.25E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs206276 chr3 162626585 T C 4.81E-05 Waist Circumference / / pha003023 rs206868 chr3 162632001 G A 7.07E-04 Body mass index / / 21701565 rs12632433 chr3 162632020 A G 5.50E-04 Body mass index / / 21701565 rs12630083 chr3 162632090 T C 6.86E-04 Body mass index / / 21701565 rs12630065 chr3 162662110 T C 6.39E-04 Body mass index / / 21701565 rs1844080 chr3 162681813 T C 1.83E-04 Body mass index / / 21701565 rs1844080 chr3 162681813 T C 7.81E-04 Body mass index / / 21701565 rs1425609 chr3 162681995 G A 1.00E-06 Aging (time to death) / / 21782286 rs1386856 chr3 162689869 A G 4.17E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs9860284 chr3 162695483 G A 4.24E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs10513598 chr3 162704020 G A 5.10E-06 Urinary metabolites / / 21572414 rs901816 chr3 162727247 C A 4.39E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs12497312 chr3 162729979 T C 4.24E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs9798973 chr3 162744813 C T 8.12E-05 Diabetic nephropathy / / 21150874 rs9798973 chr3 162744813 C T 2.13E-04 Type 2 diabetes / / 22238593 rs9290197 chr3 162745208 T C 1.80E-04 Multiple complex diseases / / 17554300 rs9647385 chr3 162747142 T C 3.07E-04 Type 2 diabetes / / 22238593 rs4260465 chr3 162748352 C G 4.31E-04 Type 2 diabetes / / 22238593 rs41435944 chr3 162750809 T C 6.90E-06 Urinary metabolites / / 21572414 rs6796209 chr3 162781486 C T 5.10E-06 Urinary metabolites / / 21572414 rs9839688 chr3 162808992 A T 7.17E-04 Alzheimer's disease / / 22005930 rs9827926 chr3 162810274 T C 7.11E-04 Alzheimer's disease / / 22005930 rs9290200 chr3 162820525 T C 5.49E-05 Femoral neck bone geometry / / 22087292 rs9864056 chr3 162831457 G A 5.91E-04 Alzheimer's disease / / 22005930 rs9864056 chr3 162831457 G A 4.87E-05 Femoral neck bone geometry / / 22087292 rs9824150 chr3 162834301 T A 7.00E-06 Capecitabine sensitivity / / 22864933 rs11706407 chr3 162837351 T C 7.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs4387974 chr3 162856358 C T 8.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs13075153 chr3 162873191 A T 1.83E-05 Aging (time to event) / / 21782286 rs13075153 chr3 162873191 A T 4.36E-08 Metabolite levels / / 23281178 rs11718187 chr3 162885471 A G 7.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs16845642 chr3 162899930 T C 2.81E-05 Type 2 diabetes LOC647107 intron 17463246 rs2291554 chr3 162917440 G A 8.46E-04 Multiple complex diseases / / 17554300 rs3843871 chr3 162949985 T C 8.11E-04 Multiple complex diseases LOC647107 intron 17554300 rs16846689 chr3 162971818 T C 1.80E-05 Type 2 diabetes LOC647107 intron 17463246 rs16846689 chr3 162971818 T C 1.16E-04 Body mass index LOC647107 intron 21701565 rs16846689 chr3 162971818 T C 3.35E-04 Body mass index LOC647107 intron 21701565 rs843055 chr3 162975100 C A 3.75E-05 Waist Circumference LOC647107 intron pha003023 rs843044 chr3 162986427 G A 3.65E-05 Waist Circumference LOC647107 intron pha003023 rs10936348 chr3 162991229 A T 4.81E-04 Type 2 diabetes LOC647107 intron 17463246 rs6809795 chr3 163034658 G A 6.34E-04 Multiple complex diseases / / 17554300 rs1841355 chr3 163142162 G A 6.45E-04 Alzheimer's disease / / 22005930 rs2711775 chr3 163180280 G A 2.33E-05 Waist Circumference / / pha003023 rs1599271 chr3 163223847 T G 2.14E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs9811637 chr3 163242030 G T 8.83E-05 Aging (time to event) / / 21782286 rs9841414 chr3 163258818 C T 2.46E-05 Osteoarthritis (knee and hip) / / 21177295 rs9841414 chr3 163258818 C T 3.13E-04 Osteoarthritis (knee and hip) / / 21177295 rs13071293 chr3 163278972 A G 6.03E-04 Alzheimer's disease / / 22005930 rs10513599 chr3 163282204 C G 6.23E-05 Multiple complex diseases / / 17554300 rs9866619 chr3 163283930 T C 9.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs9841034 chr3 163288530 G A 9.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs9862149 chr3 163292376 G A 8.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs722352 chr3 163317819 G A 8.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs11720215 chr3 163323631 A G 7.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs1491291 chr3 163334806 C T 8.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs16847040 chr3 163338289 G A 1.81E-04 Multiple complex diseases / / 17554300 rs9989989 chr3 163342892 G T 7.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs4855275 chr3 163344654 T C 7.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs7628212 chr3 163349378 C A 7.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs7622802 chr3 163350517 G A 6.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs9834858 chr3 163351983 G A 6.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs12488490 chr3 163355963 C T 7.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs17478859 chr3 163367109 T C 6.29E-04 Alzheimer's disease / / 22005930 rs12330396 chr3 163378461 T C 9.95E-04 Alzheimer's disease / / 22005930 rs11918683 chr3 163402435 T C 5.81E-04 Alzheimer's disease / / 22005930 rs13085094 chr3 163427533 A G 9.05E-04 Alzheimer's disease / / 22005930 rs10513601 chr3 163442156 T C 7.15E-04 Type 2 diabetes / / 17846125 rs9839386 chr3 163476673 A C 4.59E-04 Alzheimer's disease / / 22005930 rs9826390 chr3 163486271 C A 4.87E-04 Alzheimer's disease / / 22005930 rs16847256 chr3 163494059 G A 9.53E-05 Coronary restenosis / / 21878436 rs9877213 chr3 163497626 T A 4.74E-04 Alzheimer's disease / / 22005930 rs11914827 chr3 163498917 T C 4.52E-04 Alzheimer's disease / / 22005930 rs1602724 chr3 163500280 A G 4.67E-04 Alzheimer's disease / / 22005930 rs1602726 chr3 163504147 C G 3.93E-04 Alzheimer's disease / / 22005930 rs10936362 chr3 163510195 G T 4.24E-04 Alzheimer's disease / / 22005930 rs11706994 chr3 163529040 T C 9.77E-05 Alzheimer's disease / / 22005930 rs11713450 chr3 163579773 C A 1.16E-04 Multiple complex diseases / / 17554300 rs6794999 chr3 163589650 T G 5.04E-04 Multiple complex diseases / / 17554300 rs6548299 chr3 163590984 A T 1.45E-05 Esophageal cancer (squamous cell) / / 22960999 rs10513603 chr3 163595897 C T 3.39E-04 Bipolar disorder / / 19259986 rs1907861 chr3 163606756 C G 4.52E-04 Multiple complex diseases / / 17554300 rs1150433 chr3 163653210 C A,G,T 8.33E-04 Multiple complex diseases / / 17554300 rs1150433 chr3 163653210 C A,G,T 2.82E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1176943 chr3 163658583 G A 6.31E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6548311 chr3 163662424 C T 6.95E-04 Type 2 diabetes / / 17463246 rs7619158 chr3 163662721 T C 7.92E-05 Type 2 diabetes / / 17463246 rs7626252 chr3 163686247 A G 5.25E-04 Multiple complex diseases / / 17554300 rs16847436 chr3 163699131 T A 4.95E-05 Multiple complex diseases / / 17554300 rs2181198 chr3 163705731 C T 8.54E-04 Multiple complex diseases / / 17554300 rs9828272 chr3 163711497 C T 5.73E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6780079 chr3 163715862 T C 5.61E-05 Type 2 diabetes / / 17463246 rs7614697 chr3 163723996 G T 8.02E-04 Type 2 diabetes / / 17463246 rs16847509 chr3 163730700 T C 7.13E-04 Type 2 diabetes / / 17463246 rs16847533 chr3 163733492 C G 9.84E-04 Type 2 diabetes / / 17463246 rs6775072 chr3 163733836 T C 4.91E-04 Type 2 diabetes / / 17463246 rs6772582 chr3 163733946 A G 9.05E-04 Type 2 diabetes / / 17463246 rs6775165 chr3 163734101 A G 9.84E-04 Type 2 diabetes / / 17463246 rs6762784 chr3 163734218 C A 4.41E-04 Type 2 diabetes / / 17463246 rs6778024 chr3 163734383 T C 6.15E-04 Type 2 diabetes / / 17463246 rs6786739 chr3 163734551 G A 6.15E-04 Type 2 diabetes / / 17463246 rs6775703 chr3 163734688 A G 4.91E-04 Type 2 diabetes / / 17463246 rs6775795 chr3 163734747 A G 8.02E-04 Type 2 diabetes / / 17463246 rs16847564 chr3 163734819 G C 8.02E-04 Type 2 diabetes / / 17463246 rs4530528 chr3 163736622 G A 9.47E-04 Type 2 diabetes / / 17463246 rs16833934 chr3 163737250 A G 1.00E-08 Blood pressure / / 24954895 rs16833934 chr3 163737250 A G 7.00E-07 Blood pressure / / 24954895 rs11709545 chr3 163737754 T G 4.08E-04 Multiple complex diseases / / 17554300 rs11710379 chr3 163746974 G T 9.35E-05 Multiple complex diseases / / 17554300 rs1376959 chr3 163753113 G A 8.94E-05 Multiple complex diseases / / 17554300 rs7427021 chr3 163761964 A G 5.00E-06 Bipolar disorder / / 19416921 rs1349608 chr3 163790566 C A 1.07E-04 Multiple complex diseases / / 17554300 rs1580039 chr3 163791884 C T 5.74E-04 Multiple complex diseases / / 17554300 rs7626385 chr3 163811528 A C 1.24E-04 Multiple complex diseases / / 17554300 rs6548331 chr3 163834154 C T 8.97E-04 Multiple complex diseases / / 17554300 rs1817116 chr3 163834254 T C 1.34E-05 Multiple complex diseases / / 17554300 rs78661745 chr3 163855069 C T 7.00E-06 Bulimia nervosa / / 23568457 rs1947243 chr3 163861651 A G 5.27E-04 Multiple complex diseases / / 17554300 rs10936410 chr3 163884507 T C 5.64E-05 Multiple complex diseases / / 17554300 rs9863717 chr3 163989075 G A 2.00E-05 Coronary heart disease / / pha003030 rs7623391 chr3 164046501 A G 3.90E-08 Butyrylcholinesterase levels / / 21862451 rs7622507 chr3 164062356 G A 2.80E-04 Multiple complex diseases / / 17554300 rs78633285 chr3 164062563 G A 0.0000844 Sarcoidosis / / 22952805 rs71300589 chr3 164064149 G A 0.00004303 Sarcoidosis / / 22952805 rs13064650 chr3 164064470 G A 0.0000844 Sarcoidosis / / 22952805 rs12106930 chr3 164067781 T A 0.00004964 Sarcoidosis / / 22952805 rs1124227 chr3 164068589 T G 0.00005431 Sarcoidosis / / 22952805 rs73157115 chr3 164071965 G A 0.00006737 Sarcoidosis / / 22952805 rs55803242 chr3 164077463 A T 0.00007978 Sarcoidosis / / 22952805 rs73157124 chr3 164078581 C T 0.00003847 Sarcoidosis / / 22952805 rs11715582 chr3 164079114 T C 0.00004015 Sarcoidosis / / 22952805 rs11719327 chr3 164079270 A C 0.00006693 Sarcoidosis / / 22952805 rs11711672 chr3 164079761 C G 0.00004641 Sarcoidosis / / 22952805 rs73157129 chr3 164082344 T C 0.00005141 Sarcoidosis / / 22952805 rs13071561 chr3 164083080 C A 0.00008076 Sarcoidosis / / 22952805 rs7617240 chr3 164088333 C T 1.40E-04 Multiple complex diseases / / 17554300 rs7617240 chr3 164088333 C T 7.40E-05 Pericardial fat / / 22589742 rs4855220 chr3 164094009 C T 7.40E-05 Pericardial fat / / 22589742 rs6762010 chr3 164098723 G T 5.80E-05 Pericardial fat / / 22589742 rs721975 chr3 164101145 G T 5.80E-05 Pericardial fat / / 22589742 rs892764 chr3 164101779 A C 6.10E-05 Pericardial fat / / 22589742 rs1821575 chr3 164102274 G A 6.20E-05 Pericardial fat / / 22589742 rs892762 chr3 164102653 C T 5.30E-05 Pericardial fat / / 22589742 rs7623591 chr3 164111756 A G 5.50E-05 Pericardial fat / / 22589742 rs67458848 chr3 164112464 C G 0.00009796 Sarcoidosis / / 22952805 rs35739005 chr3 164114281 G T 0.00009796 Sarcoidosis / / 22952805 rs13093079 chr3 164115963 T A 0.00009796 Sarcoidosis / / 22952805 rs9824997 chr3 164117065 G A 5.70E-05 Pericardial fat / / 22589742 rs6767488 chr3 164117862 C T 5.70E-05 Pericardial fat / / 22589742 rs34592962 chr3 164118910 G A 0.00009796 Sarcoidosis / / 22952805 rs7638502 chr3 164121974 A G 5.80E-05 Pericardial fat / / 22589742 rs16848141 chr3 164123367 G A 8.19E-05 Multiple complex diseases / / 17554300 rs16848141 chr3 164123367 G A 6.10E-05 Pericardial fat / / 22589742 rs10513613 chr3 164123862 T C 5.90E-05 Pericardial fat / / 22589742 rs9290232 chr3 164125223 C T 6.00E-05 Pericardial fat / / 22589742 rs9840047 chr3 164125572 G T 6.10E-05 Pericardial fat / / 22589742 rs73157169 chr3 164126108 C T 0.00009796 Sarcoidosis / / 22952805 rs7637477 chr3 164126802 A G 6.20E-05 Pericardial fat / / 22589742 rs7614257 chr3 164132635 T C 6.40E-05 Pericardial fat / / 22589742 rs34849632 chr3 164132818 G A 0.00008081 Sarcoidosis / / 22952805 rs10212606 chr3 164133176 C T 6.80E-05 Pericardial fat / / 22589742 rs7618193 chr3 164134783 A G 6.80E-05 Pericardial fat / / 22589742 rs3816090 chr3 164135957 C T 7.40E-05 Pericardial fat / / 22589742 rs2304377 chr3 164136172 A G 7.50E-05 Pericardial fat / / 22589742 rs9849665 chr3 164156963 G A 4.39E-05 Cortisol secretion,in saliva / / 21316860 rs783586 chr3 164171479 A G 7.90E-05 Pericardial fat / / 22589742 rs810692 chr3 164172830 A G 2.50E-05 Pericardial fat / / 22589742 rs1708471 chr3 164180991 G A 7.50E-05 Pericardial fat / / 22589742 rs35295912 chr3 164187697 G A 0.00005191 Sarcoidosis / / 22952805 rs13084073 chr3 164194049 T C 0.00008833 Sarcoidosis / / 22952805 rs4855247 chr3 164197039 T C 9.10E-06 Pericardial fat / / 22589742 rs298760 chr3 164197756 G A 9.20E-06 Pericardial fat / / 22589742 rs298759 chr3 164197863 G C 9.20E-06 Pericardial fat / / 22589742 rs298758 chr3 164198166 T C 9.20E-06 Pericardial fat / / 22589742 rs298757 chr3 164198750 G A 8.88E-05 Multiple complex diseases / / 17554300 rs298757 chr3 164198750 G A 1.30E-05 Pericardial fat / / 22589742 rs298756 chr3 164199329 A G 2.10E-06 Pericardial fat / / 22589742 rs298755 chr3 164199354 G A 1.60E-06 Pericardial fat / / 22589742 rs4855182 chr3 164200220 G A 2.63E-05 Coronary heart disease / / pha003030 rs298751 chr3 164207720 A T 9.20E-07 Pericardial fat / / 22589742 rs298750 chr3 164209389 C T 1.90E-05 Pericardial fat / / 22589742 rs298749 chr3 164210422 C G 1.90E-05 Pericardial fat / / 22589742 rs1351067 chr3 164212378 A G 9.22E-05 Body Mass Index / / pha003019 rs6785268 chr3 164213117 T G 1.60E-08 Butyrylcholinesterase levels / / 21862451 rs13074881 chr3 164217297 A G 1.60E-08 Butyrylcholinesterase levels / / 21862451 rs13079677 chr3 164221641 T A 1.50E-08 Butyrylcholinesterase levels / / 21862451 rs13067630 chr3 164222860 A G 1.60E-08 Butyrylcholinesterase levels / / 21862451 rs2840057 chr3 164247760 G A 7.20E-09 Butyrylcholinesterase levels / / 21862451 rs6548357 chr3 164269186 G A 1.80E-08 Butyrylcholinesterase levels / / 21862451 rs1478011 chr3 164272311 A C 1.80E-08 Butyrylcholinesterase levels / / 21862451 rs12633984 chr3 164272414 T C 1.80E-08 Butyrylcholinesterase levels / / 21862451 rs9290240 chr3 164297552 C T 7.90E-06 Type 2 diabetes / / 17293876 rs9290240 chr3 164297552 C T 7.90E-06 Type 2 diabetes / / 19184112 rs11708948 chr3 164330094 A G 6.72E-05 HDL cholesterol / / pha003074 rs11917341 chr3 164335502 A G 3.14E-05 Height / / pha003010 rs11917341 chr3 164335502 A G 1.05E-05 Height / / pha003011 rs11917341 chr3 164335502 A G 4.66E-05 Lung function (forced vital capacity) / / pha003104 rs7647084 chr3 164335815 A G 5.09E-04 Multiple complex diseases / / 17554300 rs17445697 chr3 164359759 G T 3.46E-05 Height / / pha003011 rs2643191 chr3 164378693 C G,T 5.20E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs9881897 chr3 164399225 C T 1.25E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs16847459 chr3 164412364 A G 9.96E-05 Cognitive impairment induced by topiramate / / 22091778 rs7626880 chr3 164413730 A T 1.36E-06 Phospholipid levels (plasma) / / 21829377 rs6548369 chr3 164435533 C T 1.31E-05 Osteoarthritis (knee and hip) / / 21177295 rs6548369 chr3 164435533 C T 5.51E-05 Osteoarthritis (knee and hip) / / 21177295 rs9853751 chr3 164485161 T C 9.12E-04 Myopia (pathological) / / 21095009 rs57350471 chr3 164520763 T A 2.11E-08 Alcohol dependence (age at onset) / / 24962325 rs9871275 chr3 164520783 C T 2.11E-08 Alcohol dependence (age at onset) / / 24962325 rs9875364 chr3 164520853 G C 2.06E-08 Alcohol dependence (age at onset) / / 24962325 rs12637513 chr3 164525133 G A 4.52E-04 Myopia (pathological) / / 21095009 rs9862987 chr3 164531227 A C 4.31E-08 Alcohol dependence (age at onset) / / 24962325 rs10936425 chr3 164534026 A G 6.06E-08 Alcohol dependence (age at onset) / / 24962325 rs9838822 chr3 164535514 T C 6.06E-08 Alcohol dependence (age at onset) / / 24962325 rs10433463 chr3 164540649 G A 6.06E-08 Alcohol dependence (age at onset) / / 24962325 rs9876205 chr3 164542525 T C 6.06E-08 Alcohol dependence (age at onset) / / 24962325 rs9824015 chr3 164543628 A G 6.06E-08 Alcohol dependence (age at onset) / / 24962325 rs9849299 chr3 164546258 G A 6.06E-08 Alcohol dependence (age at onset) / / 24962325 rs57369046 chr3 164549686 T C 6.06E-08 Alcohol dependence (age at onset) / / 24962325 rs7633723 chr3 164551044 T C 6.06E-08 Alcohol dependence (age at onset) / / 24962325 rs9825394 chr3 164552132 T C 8.06E-08 Alcohol dependence (age at onset) / / 24962325 rs9831395 chr3 164553575 T C 5.55E-08 Alcohol dependence (age at onset) / / 24962325 rs9816120 chr3 164554023 G T 8.06E-08 Alcohol dependence (age at onset) / / 24962325 rs9817317 chr3 164554801 G A 9.29E-09 Alcohol dependence (age at onset) / / 24962325 rs7630142 chr3 164555706 A G 2.07E-08 Alcohol dependence (age at onset) / / 24962325 rs9874932 chr3 164556648 G A 2.07E-08 Alcohol dependence (age at onset) / / 24962325 rs9824625 chr3 164557575 T C 2.07E-08 Alcohol dependence (age at onset) / / 24962325 rs9880338 chr3 164557652 G A 2.07E-08 Alcohol dependence (age at onset) / / 24962325 rs4541411 chr3 164557917 T C 2.07E-08 Alcohol dependence (age at onset) / / 24962325 rs9847462 chr3 164558595 A G 6.65E-07 Alcohol dependence / / 23089632 rs9847462 chr3 164558595 A G 2.64E-06 Substance dependence phenotypes / / 24832863 rs9847462 chr3 164558595 A G 8.38E-05 Substance dependence phenotypes / / 24832863 rs9847462 chr3 164558595 A G 2.07E-08 Alcohol dependence (age at onset) / / 24962325 rs28821642 chr3 164559430 C T 2.07E-08 Alcohol dependence (age at onset) / / 24962325 rs7645282 chr3 164560182 A G 2.07E-08 Alcohol dependence (age at onset) / / 24962325 rs7647704 chr3 164560194 T A 2.07E-08 Alcohol dependence (age at onset) / / 24962325 rs7640074 chr3 164562164 C T 2.07E-08 Alcohol dependence (age at onset) / / 24962325 rs9855885 chr3 164563201 T C 2.07E-08 Alcohol dependence (age at onset) / / 24962325 rs9873722 chr3 164563390 A G 2.07E-08 Alcohol dependence (age at onset) / / 24962325 rs9819217 chr3 164565763 C T 2.07E-08 Alcohol dependence (age at onset) / / 24962325 rs79139973 chr3 164567759 G GTAAA 2.91E-08 Alcohol dependence (age at onset) / / 24962325 rs9830200 chr3 164567759 G A 2.91E-08 Alcohol dependence (age at onset) / / 24962325 rs9290244 chr3 164568563 T G 2.07E-08 Alcohol dependence (age at onset) / / 24962325 rs7628882 chr3 164571138 G A 2.07E-08 Alcohol dependence (age at onset) / / 24962325 rs9881091 chr3 164573311 T G 2.07E-08 Alcohol dependence (age at onset) / / 24962325 rs4602392 chr3 164578266 C T 2.07E-08 Alcohol dependence (age at onset) / / 24962325 rs9865078 chr3 164579310 G A 9.71E-09 Alcohol dependence (age at onset) / / 24962325 rs7619524 chr3 164580672 C T 9.71E-09 Alcohol dependence (age at onset) / / 24962325 rs6791103 chr3 164585575 A C 8.85E-09 Alcohol dependence (age at onset) / / 24962325 rs5023277 chr3 164586715 C G 4.99E-09 Alcohol dependence (age at onset) / / 24962325 rs9879548 chr3 164587302 G T 4.99E-09 Alcohol dependence (age at onset) / / 24962325 rs7641732 chr3 164587350 A T 4.99E-09 Alcohol dependence (age at onset) / / 24962325 rs6808582 chr3 164587559 G A 4.99E-09 Alcohol dependence (age at onset) / / 24962325 rs6763281 chr3 164588205 G T 9.02E-09 Alcohol dependence (age at onset) / / 24962325 rs6788557 chr3 164588388 C G 4.99E-09 Alcohol dependence (age at onset) / / 24962325 rs9810313 chr3 164588702 G T 4.14E-06 Alcohol dependence / / 23089632 rs9810313 chr3 164588702 G T 6.95E-09 Alcohol dependence (age at onset) / / 24962325 rs56303997 chr3 164589150 G A 9.02E-09 Alcohol dependence (age at onset) / / 24962325 rs2168784 chr3 164589939 C T 5.00E-09 Alcohol dependence (age at onset) / / 24962325 rs9838256 chr3 164734273 G C 5.40E-07 Urinary metabolites SI intron 21572414 rs12696219 chr3 164736048 C T 7.00E-07 Urinary metabolites SI intron 21572414 rs11916446 chr3 164836372 G T 9.10E-05 Alcoholism (heaviness of drinking) / / 21529783 rs9867979 chr3 164863010 A G 3.06E-06 Osteoarthritis / / 22763110 rs11929631 chr3 164980538 T A 5.40E-09 Butyrylcholinesterase levels / / 21862451 rs16849002 chr3 164998397 C T 5.55E-04 Alzheimer's disease / / 17998437 rs9815979 chr3 165006471 C T 6.85E-04 Alzheimer's disease / / 17998437 rs13315478 chr3 165031357 G C 3.53E-06 Alzheimer's disease / / 17998437 rs6791864 chr3 165040564 T G 2.62E-04 Alzheimer's disease / / 17998437 rs6784190 chr3 165040863 C T 3.70E-04 Alzheimer's disease / / 17998437 rs9841819 chr3 165041116 C A 7.38E-04 Alzheimer's disease / / 17998437 rs11924073 chr3 165048951 G T 5.73E-04 Alzheimer's disease / / 17998437 rs6769881 chr3 165054003 T A 4.49E-05 Alzheimer's disease / / 17998437 rs7619601 chr3 165054691 T C 5.57E-04 Alzheimer's disease / / 17998437 rs1595781 chr3 165055469 C T 6.70E-05 Cognitive decline / / 22054870 rs9878522 chr3 165125159 T C 6.00E-06 Response to amphetamines / / 22952603 rs9859645 chr3 165125655 G A 6.71E-06 Response to amphetamines / / 22952603 rs9864667 chr3 165126682 C T 7.90E-06 Response to amphetamines / / 22952603 rs9869260 chr3 165127088 G A 6.79E-06 Response to amphetamines / / 22952603 rs9874980 chr3 165128475 C G 6.42E-06 Response to amphetamines / / 22952603 rs10936444 chr3 165129566 T A 7.73E-06 Response to amphetamines / / 22952603 rs2312406 chr3 165132797 C T 5.03E-04 Multiple complex diseases / / 17554300 rs1525373 chr3 165153120 A G 1.70E-08 Butyrylcholinesterase levels / / 21862451 rs10513615 chr3 165160646 G A 8.14E-04 Heart Failure / / pha002884 rs10513615 chr3 165160646 G A 2.48E-05 Blood Pressure / / pha003040 rs1525379 chr3 165162827 C T 2.10E-05 Blood Pressure / / pha003040 rs1525380 chr3 165163087 A G 2.10E-05 Blood Pressure / / pha003040 rs4593053 chr3 165182446 T C 8.68E-05 Bladder cancer / / 19648920 rs4593053 chr3 165182446 T C 7.29E-05 Blood Pressure / / pha003040 rs1523288 chr3 165280209 C T 6.00E-06 Heart failure / / 20445134 rs694664 chr3 165330411 C G 3.10E-46 Butyrylcholinesterase levels / / 21862451 rs17654379 chr3 165333124 T C 6.10E-45 Butyrylcholinesterase levels / / 21862451 rs13083055 chr3 165336308 T C 2.70E-16 Butyrylcholinesterase levels / / 21862451 rs524217 chr3 165336842 C A 1.90E-45 Butyrylcholinesterase levels / / 21862451 rs656339 chr3 165338832 A C 6.10E-46 Butyrylcholinesterase levels / / 21862451 rs7624915 chr3 165339010 A C 7.40E-47 Butyrylcholinesterase levels / / 21862451 rs7620921 chr3 165339415 C T 4.70E-05 Multiple complex diseases / / 17554300 rs3106448 chr3 165343107 C T 2.20E-08 Butyrylcholinesterase levels / / 21862451 rs683789 chr3 165350395 A G 1.20E-45 Butyrylcholinesterase levels / / 21862451 rs525537 chr3 165355602 G C 1.50E-46 Butyrylcholinesterase levels / / 21862451 rs17706019 chr3 165357405 G C 1.10E-31 Butyrylcholinesterase levels / / 21862451 rs3106442 chr3 165363821 T C 9.40E-48 Butyrylcholinesterase levels / / 21862451 rs17706250 chr3 165374980 A C 1.50E-44 Butyrylcholinesterase levels / / 21862451 rs3863088 chr3 165376373 T C 1.50E-44 Butyrylcholinesterase levels / / 21862451 rs2669572 chr3 165378644 C T 2.40E-05 Urinary metabolites / / 21572414 rs41360444 chr3 165383607 C T 6.02E-04 Multiple complex diseases / / 17554300 rs17706650 chr3 165389132 T C 2.40E-45 Butyrylcholinesterase levels / / 21862451 rs17706693 chr3 165392256 G A 1.00E-45 Butyrylcholinesterase levels / / 21862451 rs541614 chr3 165396507 A G 2.20E-45 Butyrylcholinesterase levels / / 21862451 rs7349596 chr3 165397955 T G 1.60E-45 Butyrylcholinesterase levels / / 21862451 rs694955 chr3 165403192 G A 2.20E-45 Butyrylcholinesterase levels / / 21862451 rs687453 chr3 165406756 A G,T 2.20E-45 Butyrylcholinesterase levels / / 21862451 rs659854 chr3 165407086 A G 2.20E-45 Butyrylcholinesterase levels / / 21862451 rs10513619 chr3 165414837 G A 1.60E-45 Butyrylcholinesterase levels / / 21862451 rs613996 chr3 165428606 G A 2.20E-45 Butyrylcholinesterase levels / / 21862451 rs697355 chr3 165435642 G A 4.80E-77 Butyrylcholinesterase levels / / 21862451 rs11928838 chr3 165435695 G A 8.70E-20 Butyrylcholinesterase levels / / 21862451 rs11921875 chr3 165435919 A C 1.10E-32 Butyrylcholinesterase levels / / 21862451 rs6771420 chr3 165436169 G A 8.70E-127 Butyrylcholinesterase levels / / 21862451 rs13058994 chr3 165436253 G C 1.80E-57 Butyrylcholinesterase levels / / 21862451 rs697357 chr3 165436272 A G 1.60E-147 Butyrylcholinesterase levels / / 21862451 rs3863079 chr3 165436647 C G 3.20E-46 Butyrylcholinesterase levels / / 21862451 rs11711013 chr3 165437567 T G 8.20E-179 Butyrylcholinesterase levels / / 21862451 rs1707705 chr3 165437847 G A 2.90E-122 Butyrylcholinesterase levels / / 21862451 rs9824100 chr3 165438881 C G 4.30E-08 Butyrylcholinesterase levels / / 21862451 rs1706441 chr3 165439071 A G 5.70E-156 Butyrylcholinesterase levels / / 21862451 rs17459269 chr3 165439372 T C 1.60E-88 Butyrylcholinesterase levels / / 21862451 rs1707709 chr3 165439533 T G 8.10E-54 Butyrylcholinesterase levels / / 21862451 rs9825443 chr3 165439721 C T 4.30E-08 Butyrylcholinesterase levels / / 21862451 rs9829513 chr3 165439953 C G 4.30E-08 Butyrylcholinesterase levels / / 21862451 rs1007845 chr3 165440096 C T 5.70E-156 Butyrylcholinesterase levels / / 21862451 rs1707713 chr3 165441595 C T 4.00E-151 Butyrylcholinesterase levels / / 21862451 rs1707714 chr3 165442455 G A 8.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1707714 chr3 165442455 G A 2.90E-122 Butyrylcholinesterase levels / / 21862451 rs9841594 chr3 165442697 G A 4.30E-08 Butyrylcholinesterase levels / / 21862451 rs1398616 chr3 165442806 C T 5.70E-156 Butyrylcholinesterase levels / / 21862451 rs1613764 chr3 165442857 C T 5.70E-129 Butyrylcholinesterase levels / / 21862451 rs705016 chr3 165443782 C T 2.90E-122 Butyrylcholinesterase levels / / 21862451 rs16849491 chr3 165443810 C T 4.60E-08 Butyrylcholinesterase levels / / 21862451 rs864908 chr3 165444075 C A 2.40E-89 Butyrylcholinesterase levels / / 21862451 rs705017 chr3 165444701 G A 5.70E-156 Butyrylcholinesterase levels / / 21862451 rs9848129 chr3 165445086 T G 4.30E-08 Butyrylcholinesterase levels / / 21862451 rs17519507 chr3 165445557 G A 1.60E-88 Butyrylcholinesterase levels / / 21862451 rs9834008 chr3 165446301 G A 4.30E-08 Butyrylcholinesterase levels / / 21862451 rs17519564 chr3 165446373 A G 3.20E-63 Butyrylcholinesterase levels / / 21862451 rs829506 chr3 165446643 G A 8.10E-54 Butyrylcholinesterase levels / / 21862451 rs1707648 chr3 165447907 G C 4.00E-151 Butyrylcholinesterase levels / / 21862451 rs13098460 chr3 165447997 A G 3.20E-63 Butyrylcholinesterase levels / / 21862451 rs9864985 chr3 165448710 T C 4.30E-08 Butyrylcholinesterase levels / / 21862451 rs1706417 chr3 165448909 A G 4.00E-151 Butyrylcholinesterase levels / / 21862451 rs1707647 chr3 165449105 C A,G,T 8.10E-54 Butyrylcholinesterase levels / / 21862451 rs1706418 chr3 165449733 C T 5.70E-156 Butyrylcholinesterase levels / / 21862451 rs1706419 chr3 165449915 A G 2.90E-122 Butyrylcholinesterase levels / / 21862451 rs1706420 chr3 165450469 T C 4.80E-141 Butyrylcholinesterase levels / / 21862451 rs9875785 chr3 165450743 T C 4.30E-08 Butyrylcholinesterase levels / / 21862451 rs1707638 chr3 165450872 A G 3.50E-122 Butyrylcholinesterase levels / / 21862451 rs1706421 chr3 165450913 A T 6.90E-156 Butyrylcholinesterase levels / / 21862451 rs1706429 chr3 165457743 C T 1.20E-179 Butyrylcholinesterase levels / / 21862451 rs3908218 chr3 165462643 A G 2.70E-192 Butyrylcholinesterase levels / / 21862451 rs10513616 chr3 165467037 A G 5.00E-08 Butyrylcholinesterase levels / / 21862451 rs1403015 chr3 165468999 G T 5.00E-134 Butyrylcholinesterase levels / / 21862451 rs3898601 chr3 165469024 A G 4.30E-08 Butyrylcholinesterase levels / / 21862451 rs3894957 chr3 165469909 C T 5.00E-134 Butyrylcholinesterase levels / / 21862451 rs4632584 chr3 165470804 T C 4.30E-08 Butyrylcholinesterase levels / / 21862451 rs844200 chr3 165472248 A G 5.30E-167 Butyrylcholinesterase levels / / 21862451 rs829783 chr3 165474409 G A 1.30E-138 Butyrylcholinesterase levels / / 21862451 rs829785 chr3 165474831 A G 4.00E-137 Butyrylcholinesterase levels / / 21862451 rs4113819 chr3 165476026 A G 4.30E-08 Butyrylcholinesterase levels / / 21862451 rs1707691 chr3 165477373 A G 4.50E-167 Butyrylcholinesterase levels / / 21862451 rs1707690 chr3 165477855 A T 4.60E-187 Butyrylcholinesterase levels / / 21862451 rs1626881 chr3 165478486 C A 4.50E-167 Butyrylcholinesterase levels / / 21862451 rs1707652 chr3 165478799 C T 4.10E-201 Butyrylcholinesterase levels / / 21862451 rs1398617 chr3 165479756 G T 4.50E-167 Butyrylcholinesterase levels / / 21862451 rs6445035 chr3 165480100 G A 2.90E-259 Butyrylcholinesterase levels / / 21862451 rs6445035 chr3 165480100 G A 9.00E-17 Aspirin hydrolysis (plasma) / / 23508960 rs4680604 chr3 165480900 G C 4.90E-200 Butyrylcholinesterase levels / / 21862451 rs7650626 chr3 165481928 T G 4.30E-08 Butyrylcholinesterase levels / / 21862451 rs11720167 chr3 165486145 T G 2.90E-259 Butyrylcholinesterase levels / / 21862451 rs11925572 chr3 165486970 G A 5.00E-08 Butyrylcholinesterase levels / / 21862451 rs9864714 chr3 165487621 G A 1.08E-05 Multiple complex diseases / / 17554300 rs9864714 chr3 165487621 G A 4.30E-08 Butyrylcholinesterase levels / / 21862451 rs2686401 chr3 165488865 T C 4.90E-200 Butyrylcholinesterase levels / / 21862451 rs10049434 chr3 165489033 G C 4.30E-08 Butyrylcholinesterase levels / / 21862451 rs10049436 chr3 165489266 C T 2.39E-22 Narcolepsy / / 19629137 rs10049436 chr3 165489266 C T 4.30E-08 Butyrylcholinesterase levels / / 21862451 rs10049010 chr3 165489497 T C 4.30E-08 Butyrylcholinesterase levels / / 21862451 rs3863085 chr3 165489550 C T 1.90E-93 Butyrylcholinesterase levels / / 21862451 rs2668202 chr3 165490468 A G 7.40E-203 Butyrylcholinesterase levels BCHE nearGene-3 21862451 rs1803274 chr3 165491280 C T 1 Drug response to Succinylcholine BCHE missense 11749053 rs1803274 chr3 165491280 C T 1 Drug response to Succinylcholine BCHE missense 12724618 rs1803274 chr3 165491280 C T 1 Drug response to Succinylcholine BCHE missense 12881446 rs1803274 chr3 165491280 C T 1 Drug response to Succinylcholine BCHE missense 1570838 rs1803274 chr3 165491280 C T 6.00E-262 Butyrylcholinesterase levels BCHE missense 21862451 rs1803274 chr3 165491280 C T 6.00E-92 Cardiovascular disease risk factors BCHE missense 21943158 rs2686405 chr3 165491765 G C 9.40E-169 Butyrylcholinesterase levels BCHE intron 21862451 rs2668203 chr3 165491796 A G 3.10E-168 Butyrylcholinesterase levels BCHE intron 21862451 rs9840730 chr3 165493420 T C 2.50E-08 Butyrylcholinesterase levels BCHE intron 21862451 rs2668206 chr3 165493454 A C 3.10E-202 Butyrylcholinesterase levels BCHE intron 21862451 rs2668207 chr3 165493724 C T 3.10E-202 Butyrylcholinesterase levels BCHE intron 21862451 rs2668208 chr3 165493819 A G 3.10E-168 Butyrylcholinesterase levels BCHE intron 21862451 rs2668209 chr3 165494567 G A 4.50E-169 Butyrylcholinesterase levels BCHE intron 21862451 rs2686409 chr3 165495400 G A 3.10E-168 Butyrylcholinesterase levels BCHE intron 21862451 rs2686410 chr3 165495420 G C 3.10E-202 Butyrylcholinesterase levels BCHE intron 21862451 rs12107166 chr3 165497293 T G 1.90E-93 Butyrylcholinesterase levels BCHE intron 21862451 rs829502 chr3 165499257 A G 3.80E-159 Butyrylcholinesterase levels BCHE intron 21862451 rs6798514 chr3 165500054 G A 1.90E-08 Butyrylcholinesterase levels BCHE intron 21862451 rs16849623 chr3 165500160 G T 2.50E-08 Butyrylcholinesterase levels BCHE intron 21862451 rs829500 chr3 165500409 T C 4.80E-66 Butyrylcholinesterase levels BCHE intron 21862451 rs3863086 chr3 165500685 C T 2.50E-08 Butyrylcholinesterase levels BCHE intron 21862451 rs2668196 chr3 165502709 A T 7.00E-103 Butyrylcholinesterase levels BCHE intron 21862451 rs829508 chr3 165502724 C T 4.80E-66 Butyrylcholinesterase levels BCHE intron 21862451 rs9883728 chr3 165503635 A T 2.50E-08 Butyrylcholinesterase levels BCHE intron 21862451 rs1355538 chr3 165505177 A G 3.50E-150 Butyrylcholinesterase levels BCHE intron 21862451 rs1355535 chr3 165505759 T G 6.80E-64 Butyrylcholinesterase levels BCHE intron 21862451 rs1355535 chr3 165505759 T G 6.37E-04 Spine bone size BCHE intron 23207799 rs7616975 chr3 165505886 G C 2.00E-09 Butyrylcholinesterase levels BCHE intron 21862451 rs9843853 chr3 165506467 C T 2.00E-09 Butyrylcholinesterase levels BCHE intron 21862451 rs9873779 chr3 165508102 T G 6.80E-64 Butyrylcholinesterase levels BCHE intron 21862451 rs2089885 chr3 165509241 G A 6.80E-64 Butyrylcholinesterase levels BCHE intron 21862451 rs6779207 chr3 165513574 G C 2.00E-09 Butyrylcholinesterase levels BCHE intron 21862451 rs4680662 chr3 165516550 A G 6.80E-64 Butyrylcholinesterase levels BCHE intron 21862451 rs12186091 chr3 165517590 C A 1.40E-08 Butyrylcholinesterase levels BCHE intron 21862451 rs12487357 chr3 165521816 G C 1.40E-08 Butyrylcholinesterase levels BCHE intron 21862451 rs6796307 chr3 165524239 G T 6.80E-64 Butyrylcholinesterase levels BCHE intron 21862451 rs9836347 chr3 165524683 C T 8.30E-63 Butyrylcholinesterase levels BCHE intron 21862451 rs9823473 chr3 165527034 G A 2.00E-09 Butyrylcholinesterase levels BCHE intron 21862451 rs16849671 chr3 165527379 C A 1.40E-08 Butyrylcholinesterase levels BCHE intron 21862451 rs6808121 chr3 165527573 T C 6.80E-64 Butyrylcholinesterase levels BCHE intron 21862451 rs9878990 chr3 165539122 T C 2.10E-173 Butyrylcholinesterase levels BCHE intron 21862451 rs4465985 chr3 165539942 A T 2.10E-92 Butyrylcholinesterase levels BCHE intron 21862451 rs2048493 chr3 165544302 G C 2.10E-173 Butyrylcholinesterase levels BCHE intron 21862451 rs28933390 chr3 165547569 C A 1 Drug response to Pseudocholinesterase Deficiency BCHE missense 12856264 rs28933390 chr3 165547569 C A 1 Drug response to Pseudocholinesterase Deficiency BCHE missense 12881446 rs28933390 chr3 165547569 C A 1 Drug response to Dibucaine BCHE missense 1415224 rs28933390 chr3 165547569 C A 1 Drug response to Succinylcholine BCHE missense 1415224 rs28933389 chr3 165548010 G A 1 Drug response to Pseudocholinesterase Deficiency BCHE missense 12856264 rs28933389 chr3 165548010 G A 1 Drug response to Pseudocholinesterase Deficiency BCHE missense 12881446 rs28933389 chr3 165548010 G A 1 Drug response to Dibucaine BCHE missense 1415224 rs28933389 chr3 165548010 G A 1 Drug response to Succinylcholine BCHE missense 1415224 rs1799807 chr3 165548529 T C 1 Drug response to Succinylcholine BCHE missense 11749053 rs1799807 chr3 165548529 T C 1 Drug response to Succinylcholine BCHE missense 12724618 rs1799807 chr3 165548529 T C 1 Drug response to Pseudocholinesterase Deficiency BCHE missense 12856264 rs1799807 chr3 165548529 T C 1 Drug response to Pseudocholinesterase Deficiency BCHE missense 12881446 rs1799807 chr3 165548529 T C 1 Drug response to Succinylcholine BCHE missense 12881446 rs1799807 chr3 165548529 T C 1 Drug response to Succinylcholine BCHE missense 1570838 rs1799807 chr3 165548529 T C 1 Drug response to Dibucaine BCHE missense 2915989 rs1799807 chr3 165548529 T C 1 Drug response to Succinylcholine BCHE missense 2915989 rs4635756 chr3 165550036 C G 6.00E-174 Butyrylcholinesterase levels BCHE intron 21862451 rs12053876 chr3 165550383 G A 1.10E-35 Butyrylcholinesterase levels BCHE intron 21862451 rs4639017 chr3 165551084 T C 6.20E-135 Butyrylcholinesterase levels BCHE intron 21862451 rs4563443 chr3 165552837 C A 2.00E-152 Butyrylcholinesterase levels BCHE intron 21862451 rs5012260 chr3 165552965 A T 2.00E-152 Butyrylcholinesterase levels BCHE intron 21862451 rs4680606 chr3 165553274 C T 1.10E-35 Butyrylcholinesterase levels BCHE intron 21862451 rs4680664 chr3 165553318 A G 1.10E-35 Butyrylcholinesterase levels BCHE intron 21862451 rs4680665 chr3 165553334 T G 1.10E-35 Butyrylcholinesterase levels BCHE intron 21862451 rs4680607 chr3 165553587 G T 1.10E-35 Butyrylcholinesterase levels BCHE intron 21862451 rs4680608 chr3 165553646 C T 1.10E-35 Butyrylcholinesterase levels BCHE intron 21862451 rs4680666 chr3 165553664 A T 1.10E-35 Butyrylcholinesterase levels BCHE intron 21862451 rs7653294 chr3 165553860 A G 1.10E-35 Butyrylcholinesterase levels BCHE intron 21862451 rs4599347 chr3 165554221 A G 3.40E-09 Butyrylcholinesterase levels BCHE intron 21862451 rs3806650 chr3 165555811 G A 3.50E-04 Blood pressure BCHE nearGene-5 21228793 rs3806650 chr3 165555811 G A 1.50E-160 Butyrylcholinesterase levels BCHE nearGene-5 21862451 rs567732903 chr3 165556567 TA T 3.20E-173 Butyrylcholinesterase levels BCHE nearGene-5 21862451 rs9838443 chr3 165556567 T C 3.20E-173 Butyrylcholinesterase levels BCHE nearGene-5 21862451 rs9860697 chr3 165557079 A T 2.50E-08 Butyrylcholinesterase levels BCHE nearGene-5 21862451 rs1511973 chr3 165558472 C T 3.10E-151 Butyrylcholinesterase levels / / 21862451 rs1511974 chr3 165558481 A G 1.50E-151 Butyrylcholinesterase levels / / 21862451 rs893522 chr3 165560618 A C 3.10E-151 Butyrylcholinesterase levels / / 21862451 rs893521 chr3 165560664 G A 3.10E-151 Butyrylcholinesterase levels / / 21862451 rs893519 chr3 165560959 T A 3.10E-151 Butyrylcholinesterase levels / / 21862451 rs4362765 chr3 165561549 C T 6.10E-30 Butyrylcholinesterase levels / / 21862451 rs6788406 chr3 165567382 A G 2.50E-68 Butyrylcholinesterase levels / / 21862451 rs6773027 chr3 165567905 A G 2.90E-162 Butyrylcholinesterase levels / / 21862451 rs9864022 chr3 165570008 C T 2.90E-162 Butyrylcholinesterase levels / / 21862451 rs966224 chr3 165572009 T C 2.50E-68 Butyrylcholinesterase levels / / 21862451 rs17658319 chr3 165578444 A G 3.40E-79 Butyrylcholinesterase levels / / 21862451 rs2118657 chr3 165582511 T C 4.11E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2118657 chr3 165582511 T C 2.90E-162 Butyrylcholinesterase levels / / 21862451 rs7645596 chr3 165582870 C T 2.90E-162 Butyrylcholinesterase levels / / 21862451 rs10936458 chr3 165585255 C T 1.40E-105 Butyrylcholinesterase levels / / 21862451 rs7610733 chr3 165585820 C T 1.10E-47 Butyrylcholinesterase levels / / 21862451 rs4602440 chr3 165586274 A C 5.40E-67 Butyrylcholinesterase levels / / 21862451 rs9850874 chr3 165592717 G A 1.80E-67 Butyrylcholinesterase levels / / 21862451 rs9837190 chr3 165594875 G C 1.80E-67 Butyrylcholinesterase levels / / 21862451 rs6770809 chr3 165596381 T A 1.50E-158 Butyrylcholinesterase levels / / 21862451 rs10936462 chr3 165597419 A G 7.15E-04 Coronary Artery Disease / / 17634449 rs1511979 chr3 165601421 T C 1.30E-171 Butyrylcholinesterase levels / / 21862451 rs2048492 chr3 165602805 A G 3.30E-174 Butyrylcholinesterase levels / / 21862451 rs9847379 chr3 165603990 A T 1.50E-70 Butyrylcholinesterase levels / / 21862451 rs9879188 chr3 165606177 A G 1.50E-163 Butyrylcholinesterase levels / / 21862451 rs17658995 chr3 165607500 T C 1.60E-78 Butyrylcholinesterase levels / / 21862451 rs17715654 chr3 165608868 C G 1.60E-78 Butyrylcholinesterase levels / / 21862451 rs17659116 chr3 165610499 T G 1.60E-78 Butyrylcholinesterase levels / / 21862451 rs1370899 chr3 165611151 T C 1.50E-70 Butyrylcholinesterase levels / / 21862451 rs1868530 chr3 165612909 A C 1.60E-78 Butyrylcholinesterase levels / / 21862451 rs17659206 chr3 165613562 T G 1.60E-78 Butyrylcholinesterase levels / / 21862451 rs282185 chr3 165614859 T G 3.30E-174 Butyrylcholinesterase levels / / 21862451 rs1036584 chr3 165615141 C G 1.30E-12 Butyrylcholinesterase levels / / 21862451 rs16849858 chr3 165617478 A G 1.70E-12 Butyrylcholinesterase levels / / 21862451 rs16849861 chr3 165617929 A T 1.70E-12 Butyrylcholinesterase levels / / 21862451 rs1036585 chr3 165623834 A G 2.10E-08 Butyrylcholinesterase levels / / 21862451 rs1036585 chr3 165623834 A G 6.48E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs282188 chr3 165627690 G A 9.40E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs282188 chr3 165627690 G A 2.30E-168 Butyrylcholinesterase levels / / 21862451 rs1370895 chr3 165629972 A G 5.10E-158 Butyrylcholinesterase levels / / 21862451 rs7644298 chr3 165630641 G T 2.10E-08 Butyrylcholinesterase levels / / 21862451 rs7615933 chr3 165630653 T C 2.50E-56 Butyrylcholinesterase levels / / 21862451 rs2901954 chr3 165631184 A G 2.50E-11 Butyrylcholinesterase levels / / 21862451 rs4496529 chr3 165631381 G A 5.13E-04 Coronary Artery Disease / / 17634449 rs4496529 chr3 165631381 G A 1.60E-11 Butyrylcholinesterase levels / / 21862451 rs1837232 chr3 165631805 G A 1.00E-76 Butyrylcholinesterase levels / / 21862451 rs6773030 chr3 165632240 T A 1.60E-11 Butyrylcholinesterase levels / / 21862451 rs6804445 chr3 165632531 G A 1.60E-11 Butyrylcholinesterase levels / / 21862451 rs1545163 chr3 165633598 C T 1.60E-11 Butyrylcholinesterase levels / / 21862451 rs1545164 chr3 165633695 G A 1.60E-11 Butyrylcholinesterase levels / / 21862451 rs1545165 chr3 165633729 A C 4.99E-04 Coronary Artery Disease / / 17634449 rs1545165 chr3 165633729 A C 1.60E-11 Butyrylcholinesterase levels / / 21862451 rs1545166 chr3 165633784 C T 5.29E-04 Coronary Artery Disease / / 17634449 rs1545166 chr3 165633784 C T 1.60E-11 Butyrylcholinesterase levels / / 21862451 rs4365667 chr3 165637529 C A 7.70E-13 Butyrylcholinesterase levels / / 21862451 rs4365667 chr3 165637529 C A 5.00E-06 Smoking quantity / / 24665060 rs6445115 chr3 165640992 G A 7.70E-13 Butyrylcholinesterase levels / / 21862451 rs282194 chr3 165642569 A G 1.10E-119 Butyrylcholinesterase levels / / 21862451 rs17659724 chr3 165642641 C T 1.40E-132 Butyrylcholinesterase levels / / 21862451 rs282195 chr3 165644311 T G 1.10E-119 Butyrylcholinesterase levels / / 21862451 rs6802425 chr3 165645661 T A 4.80E-122 Butyrylcholinesterase levels / / 21862451 rs282196 chr3 165645820 T C 1.10E-119 Butyrylcholinesterase levels / / 21862451 rs282198 chr3 165648229 G A 1.10E-119 Butyrylcholinesterase levels / / 21862451 rs12490216 chr3 165651200 T G 4.80E-11 Butyrylcholinesterase levels / / 21862451 rs12496013 chr3 165654438 A G 2.50E-11 Butyrylcholinesterase levels / / 21862451 rs16849898 chr3 165655877 G A 4.80E-11 Butyrylcholinesterase levels / / 21862451 rs282219 chr3 165658522 G C 9.80E-119 Butyrylcholinesterase levels / / 21862451 rs9869715 chr3 165659225 A G 3.50E-08 Butyrylcholinesterase levels / / 21862451 rs7616229 chr3 165661735 A T 3.50E-08 Butyrylcholinesterase levels / / 21862451 rs9847966 chr3 165662040 C T 2.10E-121 Butyrylcholinesterase levels / / 21862451 rs9873540 chr3 165663234 T A 1.50E-08 Butyrylcholinesterase levels / / 21862451 rs282220 chr3 165663642 T A 2.90E-119 Butyrylcholinesterase levels / / 21862451 rs282221 chr3 165664248 T A 6.10E-107 Butyrylcholinesterase levels / / 21862451 rs7627395 chr3 165666554 C T 2.40E-131 Butyrylcholinesterase levels / / 21862451 rs9819444 chr3 165669181 A C 3.50E-08 Butyrylcholinesterase levels / / 21862451 rs1438577 chr3 165674663 C T 3.50E-08 Butyrylcholinesterase levels / / 21862451 rs9829437 chr3 165683741 G A 5.10E-121 Butyrylcholinesterase levels / / 21862451 rs830205 chr3 165684692 A G 1.40E-118 Butyrylcholinesterase levels / / 21862451 rs9865215 chr3 165688760 A G 3.50E-08 Butyrylcholinesterase levels / / 21862451 rs1096215 chr3 165689651 T C 1.40E-118 Butyrylcholinesterase levels / / 21862451 rs830207 chr3 165690853 T C 1.40E-118 Butyrylcholinesterase levels / / 21862451 rs6797161 chr3 165694915 G A 1.70E-121 Butyrylcholinesterase levels / / 21862451 rs2197905 chr3 165695438 A G 1.40E-118 Butyrylcholinesterase levels / / 21862451 rs13083341 chr3 165701524 C T 3.50E-08 Butyrylcholinesterase levels / / 21862451 rs12493215 chr3 165705694 T G 1.00E-125 Butyrylcholinesterase levels / / 21862451 rs12491503 chr3 165706855 G A 2.50E-177 Butyrylcholinesterase levels / / 21862451 rs1900912 chr3 165711873 T C 1.10E-90 Butyrylcholinesterase levels / / 21862451 rs1900912 chr3 165711873 T C 6.69E-05 Monocyte chemoattractant protein-1 / / pha003071 rs1839308 chr3 165717417 G C 1.20E-08 Butyrylcholinesterase levels / / 21862451 rs1839308 chr3 165717417 G C 3.60E-05 Type 1 diabetes / / 21980299 rs1584483 chr3 165717956 A T 8.10E-108 Butyrylcholinesterase levels / / 21862451 rs6776751 chr3 165719378 G A 8.10E-108 Butyrylcholinesterase levels / / 21862451 rs7634582 chr3 165720102 C T 2.00E-55 Butyrylcholinesterase levels / / 21862451 rs1349212 chr3 165721590 G A 2.00E-55 Butyrylcholinesterase levels / / 21862451 rs1349213 chr3 165721773 A G 1.20E-116 Butyrylcholinesterase levels / / 21862451 rs2218730 chr3 165723243 T C 2.30E-107 Butyrylcholinesterase levels / / 21862451 rs10513621 chr3 165727119 T G 3.20E-132 Butyrylcholinesterase levels / / 21862451 rs10513622 chr3 165727249 G C 5.00E-107 Butyrylcholinesterase levels / / 21862451 rs16849947 chr3 165727429 A G 1.70E-08 Butyrylcholinesterase levels / / 21862451 rs7647059 chr3 165727682 A C 6.20E-59 Butyrylcholinesterase levels / / 21862451 rs6799419 chr3 165728468 C T 2.00E-106 Butyrylcholinesterase levels / / 21862451 rs12494359 chr3 165731478 T C 1.10E-107 Butyrylcholinesterase levels / / 21862451 rs9883928 chr3 165732008 A C 2.20E-55 Butyrylcholinesterase levels / / 21862451 rs7617676 chr3 165737888 A G 7.10E-107 Butyrylcholinesterase levels / / 21862451 rs6784032 chr3 165745768 G A 1.70E-08 Butyrylcholinesterase levels / / 21862451 rs6801576 chr3 165745880 T G 1.10E-107 Butyrylcholinesterase levels / / 21862451 rs1584485 chr3 165747302 G A,C 3.00E-55 Butyrylcholinesterase levels / / 21862451 rs7627855 chr3 165747683 C T 1.70E-08 Butyrylcholinesterase levels / / 21862451 rs1449369 chr3 165748218 A G 2.20E-55 Butyrylcholinesterase levels / / 21862451 rs9876147 chr3 165748631 C T 2.20E-55 Butyrylcholinesterase levels / / 21862451 rs9810931 chr3 165750168 C T 2.20E-55 Butyrylcholinesterase levels / / 21862451 rs9854178 chr3 165751527 A C 2.20E-55 Butyrylcholinesterase levels / / 21862451 rs2872066 chr3 165753921 G A 2.20E-55 Butyrylcholinesterase levels / / 21862451 rs9808916 chr3 165754881 C T 1.40E-104 Butyrylcholinesterase levels / / 21862451 rs721192 chr3 165755453 T C 2.20E-55 Butyrylcholinesterase levels / / 21862451 rs17717669 chr3 165755916 A G 5.50E-93 Butyrylcholinesterase levels / / 21862451 rs13315074 chr3 165756533 C G 1.20E-58 Butyrylcholinesterase levels / / 21862451 rs6805902 chr3 165757606 T C 8.90E-81 Butyrylcholinesterase levels / / 21862451 rs10936468 chr3 165758908 A G 8.90E-81 Butyrylcholinesterase levels / / 21862451 rs6445180 chr3 165760706 T G 3.40E-81 Butyrylcholinesterase levels / / 21862451 rs2034445 chr3 165761055 T G 3.10E-85 Butyrylcholinesterase levels / / 21862451 rs1868531 chr3 165761918 G A 8.90E-81 Butyrylcholinesterase levels / / 21862451 rs2312530 chr3 165763419 T A 2.60E-28 Butyrylcholinesterase levels / / 21862451 rs11916666 chr3 165764752 A G 3.00E-22 Butyrylcholinesterase levels / / 21862451 rs6777981 chr3 165766451 C T 4.00E-58 Butyrylcholinesterase levels / / 21862451 rs13080144 chr3 165767509 T C 3.20E-22 Butyrylcholinesterase levels / / 21862451 rs16849971 chr3 165767741 T C 3.00E-22 Butyrylcholinesterase levels / / 21862451 rs11715356 chr3 165769158 C G 8.90E-81 Butyrylcholinesterase levels / / 21862451 rs13069682 chr3 165769683 A G 8.90E-81 Butyrylcholinesterase levels / / 21862451 rs17717909 chr3 165772299 A G 7.65E-04 Coronary Artery Disease / / 17634449 rs17717909 chr3 165772299 A G 1.60E-10 Butyrylcholinesterase levels / / 21862451 rs9834427 chr3 165772627 A G 2.20E-80 Butyrylcholinesterase levels / / 21862451 rs11928507 chr3 165773794 G T 1.20E-67 Butyrylcholinesterase levels / / 21862451 rs7634954 chr3 165774722 C A 2.00E-29 Butyrylcholinesterase levels / / 21862451 rs12233613 chr3 165775434 T C 1.30E-99 Butyrylcholinesterase levels / / 21862451 rs12494123 chr3 165775650 G A 4.30E-81 Butyrylcholinesterase levels / / 21862451 rs7632669 chr3 165778330 A G 3.80E-80 Butyrylcholinesterase levels / / 21862451 rs13067211 chr3 165781282 G A 2.30E-74 Butyrylcholinesterase levels / / 21862451 rs7613317 chr3 165785410 T C 2.70E-42 Butyrylcholinesterase levels / / 21862451 rs7613317 chr3 165785410 T C 9.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1551041 chr3 165786026 T C 5.30E-50 Butyrylcholinesterase levels / / 21862451 rs9862986 chr3 165788382 A C 5.50E-12 Butyrylcholinesterase levels / / 21862451 rs2084526 chr3 165789914 T C 5.30E-61 Butyrylcholinesterase levels / / 21862451 rs2084525 chr3 165790002 A G 1.10E-57 Butyrylcholinesterase levels / / 21862451 rs1597314 chr3 165790342 A G 7.96E-05 Multiple complex diseases / / 17554300 rs1597314 chr3 165790342 A G 1.10E-57 Butyrylcholinesterase levels / / 21862451 rs7429483 chr3 165793899 A G 7.80E-61 Butyrylcholinesterase levels / / 21862451 rs9856615 chr3 165793928 C T 4.00E-76 Butyrylcholinesterase levels / / 21862451 rs6781105 chr3 165794197 A T 4.10E-76 Butyrylcholinesterase levels / / 21862451 rs6781216 chr3 165794317 A G 5.00E-12 Butyrylcholinesterase levels / / 21862451 rs7635888 chr3 165796468 T C 3.10E-61 Butyrylcholinesterase levels / / 21862451 rs9883028 chr3 165797626 A C 5.00E-12 Butyrylcholinesterase levels / / 21862451 rs9883330 chr3 165797754 A G 1.50E-61 Butyrylcholinesterase levels / / 21862451 rs6779983 chr3 165799044 A G 7.60E-85 Butyrylcholinesterase levels / / 21862451 rs6767888 chr3 165799452 C T 7.60E-85 Butyrylcholinesterase levels / / 21862451 rs6794226 chr3 165799663 G A 7.60E-85 Butyrylcholinesterase levels / / 21862451 rs7431693 chr3 165800175 G T 7.60E-85 Butyrylcholinesterase levels / / 21862451 rs6797530 chr3 165800605 G A 2.60E-12 Butyrylcholinesterase levels / / 21862451 rs7642230 chr3 165801175 G A 7.60E-85 Butyrylcholinesterase levels / / 21862451 rs7431014 chr3 165802319 A G 2.60E-12 Butyrylcholinesterase levels / / 21862451 rs6443293 chr3 165803609 A T 2.20E-77 Butyrylcholinesterase levels / / 21862451 rs6443295 chr3 165806432 C G 7.60E-85 Butyrylcholinesterase levels / / 21862451 rs7427342 chr3 165814600 A G 7.50E-12 Butyrylcholinesterase levels / / 21862451 rs9810061 chr3 165820640 C T 1.70E-56 Butyrylcholinesterase levels / / 21862451 rs11922912 chr3 165824337 T C 7.50E-43 Butyrylcholinesterase levels / / 21862451 rs4632505 chr3 165827721 A G 4.20E-35 Butyrylcholinesterase levels / / 21862451 rs4642076 chr3 165828596 A G 4.20E-35 Butyrylcholinesterase levels / / 21862451 rs4603915 chr3 165828608 A G 4.20E-35 Butyrylcholinesterase levels / / 21862451 rs4440084 chr3 165832341 C G 3.30E-04 Multiple complex diseases / / 17554300 rs4440084 chr3 165832341 C G 5.80E-56 Butyrylcholinesterase levels / / 21862451 rs11706636 chr3 165833637 A G 7.50E-43 Butyrylcholinesterase levels / / 21862451 rs4376001 chr3 165839267 A G 2.70E-35 Butyrylcholinesterase levels / / 21862451 rs6801661 chr3 165839562 T G 2.70E-35 Butyrylcholinesterase levels / / 21862451 rs6802874 chr3 165841020 A G 2.70E-35 Butyrylcholinesterase levels / / 21862451 rs4325882 chr3 165842306 A C 2.70E-56 Butyrylcholinesterase levels / / 21862451 rs4441616 chr3 165844211 A T 2.70E-35 Butyrylcholinesterase levels / / 21862451 rs4504133 chr3 165845302 C G 2.70E-35 Butyrylcholinesterase levels / / 21862451 rs4419345 chr3 165845837 T C 4.20E-35 Butyrylcholinesterase levels / / 21862451 rs7651964 chr3 165847833 A G 1.24E-04 Type 2 diabetes / / 17463246 rs7651964 chr3 165847833 A G 6.60E-35 Butyrylcholinesterase levels / / 21862451 rs7640480 chr3 165847875 C A 4.20E-35 Butyrylcholinesterase levels / / 21862451 rs7640759 chr3 165848219 C T 4.20E-35 Butyrylcholinesterase levels / / 21862451 rs7640841 chr3 165848328 C T 4.20E-35 Butyrylcholinesterase levels / / 21862451 rs7653493 chr3 165852207 C T 4.20E-35 Butyrylcholinesterase levels / / 21862451 rs9917747 chr3 165854420 T C 1.79E-04 Type 2 diabetes / / 17463246 rs9917689 chr3 165854648 G A 4.20E-35 Butyrylcholinesterase levels / / 21862451 rs6795406 chr3 165854956 G A 4.20E-35 Butyrylcholinesterase levels / / 21862451 rs6786880 chr3 165855100 T C 1.50E-30 Butyrylcholinesterase levels / / 21862451 rs6763923 chr3 165858176 C G 4.90E-35 Butyrylcholinesterase levels / / 21862451 rs6779201 chr3 165858241 T A 4.90E-35 Butyrylcholinesterase levels / / 21862451 rs6776635 chr3 165858427 A C 4.90E-35 Butyrylcholinesterase levels / / 21862451 rs13061243 chr3 165859107 T C 4.90E-31 Butyrylcholinesterase levels / / 21862451 rs17661858 chr3 165861028 A T 4.90E-35 Butyrylcholinesterase levels / / 21862451 rs9876868 chr3 165861111 A G 4.90E-31 Butyrylcholinesterase levels / / 21862451 rs4353770 chr3 165869371 A G 1.30E-36 Butyrylcholinesterase levels / / 21862451 rs17662040 chr3 165869830 C G 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs1440676 chr3 165871128 A T 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs1440675 chr3 165871221 A C 5.30E-58 Butyrylcholinesterase levels / / 21862451 rs1440674 chr3 165871264 C T 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs3887050 chr3 165875913 C T 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs4680679 chr3 165876088 A G 4.30E-34 Butyrylcholinesterase levels / / 21862451 rs12374202 chr3 165880011 C T 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs1961187 chr3 165880527 T C 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs3886295 chr3 165880715 C G 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs4680682 chr3 165881881 A G 7.00E-35 Butyrylcholinesterase levels / / 21862451 rs9862382 chr3 165883074 A G 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs1157199 chr3 165883856 G A 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs1157198 chr3 165883999 G T 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs2024539 chr3 165885052 A C 3.17E-04 Type 2 diabetes / / 17463246 rs2024539 chr3 165885052 A C 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs2024537 chr3 165887034 A C 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs2024536 chr3 165887076 T A 3.00E-33 Butyrylcholinesterase levels / / 21862451 rs2024535 chr3 165887199 A G 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs7639801 chr3 165887994 C T 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs1371898 chr3 165889022 A G 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs1158519 chr3 165889118 T C 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs996053 chr3 165889857 T C 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs1440653 chr3 165891291 C G 1.20E-34 Butyrylcholinesterase levels / / 21862451 rs1899169 chr3 165894868 G A 1.80E-19 Butyrylcholinesterase levels / / 21862451 rs7617559 chr3 165895105 C A 1.80E-19 Butyrylcholinesterase levels / / 21862451 rs17730227 chr3 165903693 A G 1.20E-33 Butyrylcholinesterase levels / / 21862451 rs17662627 chr3 165903730 G C 1.30E-16 Butyrylcholinesterase levels / / 21862451 rs4680683 chr3 165907209 C T 2.10E-30 Butyrylcholinesterase levels / / 21862451 rs1348070 chr3 165908521 G C 1.30E-36 Butyrylcholinesterase levels / / 21862451 rs12638042 chr3 165909425 T C 1.20E-19 Butyrylcholinesterase levels / / 21862451 rs1440647 chr3 165910050 G C 9.60E-23 Butyrylcholinesterase levels / / 21862451 rs1440650 chr3 165914538 C T 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs6776482 chr3 165917057 T C 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs9872308 chr3 165918236 C T 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs9851453 chr3 165921816 A C 8.20E-20 Butyrylcholinesterase levels / / 21862451 rs1899171 chr3 165923729 A G 4.60E-33 Butyrylcholinesterase levels / / 21862451 rs10936474 chr3 165925527 G T 1.30E-36 Butyrylcholinesterase levels / / 21862451 rs1440652 chr3 165925772 A G 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs11924406 chr3 165931222 T C 9.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6789103 chr3 165931957 A T 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs6776859 chr3 165932378 C A 1.00E-29 Butyrylcholinesterase levels / / 21862451 rs13083464 chr3 165933096 T G 0.0003684 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13083464 chr3 165933096 T G 3.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6803823 chr3 165933307 G A 3.10E-34 Butyrylcholinesterase levels / / 21862451 rs9857044 chr3 165936570 T G 6.63E-05 Cognitive performance / / 19734545 rs17663143 chr3 165937710 G A 1.00E-09 Butyrylcholinesterase levels / / 21862451 rs6443374 chr3 165959791 A G 4.90E-10 Butyrylcholinesterase levels / / 21862451 rs1371901 chr3 165961111 A G 5.34E-05 Waist-Hip Ratio / / pha003013 rs1371901 chr3 165961111 A G 2.03E-05 Waist Circumference / / pha003023 rs1371901 chr3 165961111 A G 7.09E-05 Waist-Hip Ratio / / pha003028 rs1371901 chr3 165961111 A G 9.46E-06 Waist-Hip Ratio / / pha003029 rs509208 chr3 166014469 G C 3.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs509208 chr3 166014469 G C 3.00E-08 Alzheimer's disease biomarkers / / 23419831 rs526992 chr3 166028706 T C 4.00E-06 Alcohol dependence / / 21956439 rs2863389 chr3 166148892 C T 4.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12490625 chr3 166155183 A G 6.00E-09 Butyrylcholinesterase levels / / 21862451 rs9819099 chr3 166179549 T C 5.51E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12497520 chr3 166180790 G A 6.00E-09 Butyrylcholinesterase levels / / 21862451 rs13314077 chr3 166181528 G A 3.50E-11 Butyrylcholinesterase levels / / 21862451 rs17469768 chr3 166282475 A T 3.00E-08 Butyrylcholinesterase levels / / 21862451 rs522409 chr3 166284157 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12696252 chr3 166298513 G A 3.00E-08 Butyrylcholinesterase levels / / 21862451 rs13325962 chr3 166304191 C T 1.40E-08 Butyrylcholinesterase levels / / 21862451 rs651776 chr3 166354412 T C 1.00E-08 Butyrylcholinesterase levels / / 21862451 rs1517057 chr3 166444013 C T 8.10E-05 Major depressive disorder (broad) / / 20038947 rs2900668 chr3 166608790 G A 5.58E-04 Multiple complex diseases / / 17554300 rs6791684 chr3 166634791 A G 7.05E-04 Multiple complex diseases / / 17554300 rs1949532 chr3 166743282 T A 9.88E-04 Prostate cancer mortality / / 20978177 rs10460872 chr3 166749739 T C 2.30E-04 Myasthenia gravis / / 23055271 rs4549272 chr3 166869208 T G 7.93E-04 Type 2 diabetes / / 17463246 rs4955621 chr3 167076982 G A 6.12E-04 Depression (quantitative trait) ZBBX intron 20800221 rs13070237 chr3 167078870 C T 3.10E-05 Response to statin therapy ZBBX intron 20339536 rs12493595 chr3 167079380 A G 2.00E-05 Response to statin therapy ZBBX intron 20339536 rs12491610 chr3 167080569 T C 2.90E-05 Response to statin therapy ZBBX intron 20339536 rs13094759 chr3 167082954 C T 2.90E-05 Response to statin therapy ZBBX intron 20339536 rs7642707 chr3 167083028 G A 3.60E-05 Response to statin therapy ZBBX intron 20339536 rs10936534 chr3 167086796 A G 2.90E-05 Response to statin therapy ZBBX intron 20339536 rs13100414 chr3 167089620 G A 2.90E-05 Response to statin therapy ZBBX intron 20339536 rs13073265 chr3 167097421 C T 3.00E-05 Response to statin therapy ZBBX intron 20339536 rs2140366 chr3 167101478 T C 3.60E-05 Response to statin therapy / / 20339536 rs13074970 chr3 167119945 C T 6.63E-04 Alcohol dependence / / 21314694 rs4955672 chr3 167175247 C G 9.56E-04 Alcohol dependence SERPINI2 intron 21314694 rs9881165 chr3 167208012 T C 5.75E-04 Smoking quantity WDR49 intron 24665060 rs6807215 chr3 167289471 C T 6.60E-04 Multiple complex diseases WDR49 intron 17554300 rs13318752 chr3 167300830 A G 2.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WDR49 intron 20877124 rs13318752 chr3 167300830 A G 8.93E-05 Coronary heart disease WDR49 intron pha003031 rs7627289 chr3 167348838 G A 2.00E-06 Visceral fat WDR49 intron 22589738 rs6769769 chr3 167443156 T C 5.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDCD10 intron 20877124 rs9856551 chr3 167480664 A G 1.13E-05 Coronary heart disease SERPINI1 intron pha003033 rs9815034 chr3 167497444 A G 7.26E-06 Heart rate SERPINI1 intron 23534349 rs1473511 chr3 167500763 T G 7.26E-06 Heart rate SERPINI1 intron 23534349 rs13090836 chr3 167508062 T C 7.00E-06 Heart rate SERPINI1 intron 23534349 rs1553221 chr3 167525326 A G 9.09E-05 Coronary heart disease SERPINI1 intron pha003033 rs6783981 chr3 167528129 T C 3.94E-06 Coronary artery calcification SERPINI1 intron 22144573 rs2055027 chr3 167530444 C T 8.17E-04 Premature ovarian failure SERPINI1 intron 19508998 rs9843721 chr3 167631012 A G 2.70E-05 Urinary metabolites LOC646168 intron 21572414 rs6444751 chr3 167663718 A G 4.44E-05 Duodenal ulcer / / 22387998 rs9845178 chr3 167675629 T A 7.02E-04 Acute lung injury / / 22295056 rs6780067 chr3 167681966 T A 6.08E-04 Acute lung injury / / 22295056 rs9683345 chr3 167682686 T C 6.08E-04 Acute lung injury / / 22295056 rs9683345 chr3 167682686 T C 6.47E-06 Duodenal ulcer / / 22387998 rs9683106 chr3 167686232 T C 6.08E-04 Acute lung injury / / 22295056 rs7628231 chr3 167687369 C T 6.08E-04 Acute lung injury / / 22295056 rs7619300 chr3 167690296 T C 6.45E-06 Duodenal ulcer / / 22387998 rs12630921 chr3 167694177 G T 1.26E-05 Duodenal ulcer / / 22387998 rs4431164 chr3 167696174 C A 8.90E-06 Duodenal ulcer / / 22387998 rs4431164 chr3 167696174 C A 7.71E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7631039 chr3 167699702 A C 1.24E-05 Duodenal ulcer / / 22387998 rs7632500 chr3 167725349 A G 1.00E-06 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs7632500 chr3 167725349 A G 2.70E-04 Esophageal adenocarcinoma / / 24121790 rs7632500 chr3 167725349 A G 3.18E-05 Barrett's esophagus / / 24121790 rs11914431 chr3 167737813 C T 2.53E-05 Amyotrophic lateral sclerosis (sporadic) GOLIM4 intron 24529757 rs7639014 chr3 167766491 C A 6.91E-04 Rheumatoid arthritis GOLIM4 intron 21452313 rs1522380 chr3 167783178 A G 9.07E-04 Rheumatoid arthritis GOLIM4 intron 21452313 rs4955785 chr3 167796581 G A 8.56E-04 Rheumatoid arthritis GOLIM4 intron 21452313 rs7647200 chr3 167796646 C T 8.24E-04 Rheumatoid arthritis GOLIM4 intron 21452313 rs877439 chr3 167799902 T C 3.99E-04 Multiple complex diseases GOLIM4 intron 17554300 rs1522378 chr3 167800537 A G 2.25E-04 Multiple complex diseases GOLIM4 intron 17554300 rs1357282 chr3 167821883 G A 3.62E-04 Obesity (extreme) / / 21935397 rs4345115 chr3 167837748 T C 7.00E-06 Height / / 18391951 rs1608124 chr3 167869432 A C 9.88E-04 Obesity (extreme) / / 21935397 rs2253178 chr3 167890718 A C 9.26E-07 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs2593422 chr3 167897555 T G 3.02E-07 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs2249516 chr3 167897774 A G 3.05E-07 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs2686586 chr3 167897821 T C 6.00E-08 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs2249391 chr3 167898790 A G 3.00E-07 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs2593423 chr3 167899270 T G 3.41E-07 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs2593426 chr3 167903833 T A 2.75E-07 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs9830585 chr3 167968421 T A 1.01E-04 Multiple complex diseases EGFEM1P intron 17554300 rs1605389 chr3 167974061 T C 5.67E-04 Coronary heart disease EGFEM1P intron 21606135 rs9832762 chr3 167989930 A T 3.52E-04 Multiple complex diseases EGFEM1P intron 17554300 rs16852120 chr3 167992842 A C 3.18E-04 Multiple complex diseases EGFEM1P intron 17554300 rs3904606 chr3 168093442 A G 2.90E-05 Urinary metabolites EGFEM1P intron 21572414 rs6777018 chr3 168166186 A G 4.78E-04 Alcohol consumption (maxi-drinks) EGFEM1P intron 24277619 rs1365540 chr3 168181974 T C 8.34E-04 Parkinson's disease EGFEM1P intron 17052657 rs329083 chr3 168222980 G A 5.92E-04 Parkinson's disease EGFEM1P intron 17052657 rs7642311 chr3 168223132 A G 1.80E-05 Urinary metabolites EGFEM1P intron 21572414 rs16852382 chr3 168246224 A G 2.04E-06 PR interval in Tripanosoma cruzi seropositivity EGFEM1P intron 24324551 rs6782264 chr3 168252304 C T 2.00E-06 PR interval in Tripanosoma cruzi seropositivity EGFEM1P intron 24324551 rs73878922 chr3 168267918 C T 2.08E-06 PR interval in Tripanosoma cruzi seropositivity EGFEM1P intron 24324551 rs10936559 chr3 168299193 A C 8.01E-04 Schizophrenia EGFEM1P intron 19197363 rs7647208 chr3 168309257 C T 7.61E-04 Schizophrenia EGFEM1P intron 19197363 rs6766202 chr3 168338128 T C 1.70E-05 Urinary metabolites EGFEM1P intron 21572414 rs16852525 chr3 168363205 A G 6.76E-04 Type 2 diabetes EGFEM1P intron 17463246 rs16852525 chr3 168363205 A G 2.51E-05 Coronary heart disease EGFEM1P intron pha003055 rs4955612 chr3 168364224 A G 7.79E-04 Multiple complex diseases EGFEM1P intron 17554300 rs6807896 chr3 168383288 G A 4.93E-05 Coronary heart disease EGFEM1P intron pha003055 rs10049401 chr3 168413945 A G 2.14E-04 Hearing function EGFEM1P intron 17255346 rs475749 chr3 168456385 A G 2.88E-04 Hearing function EGFEM1P intron 17255346 rs475749 chr3 168456385 A G 2.60E-06 Lipid levels EGFEM1P intron 18193043 rs6763367 chr3 168463089 A C 3.22E-04 Amyotrophic lateral sclerosis (sporadic) EGFEM1P intron 24529757 rs1514150 chr3 168560268 T C 3.16E-04 Hearing function / / 17255346 rs1877268 chr3 168622049 G A 8.18E-04 Response to taxane treatment (placlitaxel) LOC100507661 intron 23006423 rs6768780 chr3 168644514 C A 5.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs1498444 chr3 168645035 T G 9.14E-05 Heart Failure / / pha002884 rs2201862 chr3 168648039 T C 3.10E-06 Urinary metabolites / / 21572414 rs13066712 chr3 168659599 G A 0.0004521 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13066712 chr3 168659599 G A 4.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9871556 chr3 168671733 T C 1.61E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs16852880 chr3 168673332 G A 9.90E-05 Diabetic nephropathy / / pha002866 rs16852912 chr3 168686676 C T 6.60E-04 Multiple complex diseases / / 17554300 rs16852912 chr3 168686676 C T 3.00E-06 Aging (time to event) / / 21782286 rs3851374 chr3 168701648 A G 4.42E-04 Type 2 diabetes / / 17463246 rs3851374 chr3 168701648 A G 7.00E-04 Pulmonary function / / 23932459 rs1420469 chr3 168742461 T C 2.37E-04 Alcohol dependence / / 24277619 rs16853070 chr3 168773344 C T 7.58E-04 Multiple complex diseases / / 17554300 rs7615880 chr3 168823078 T C 3.85E-04 Suicide attempts in bipolar disorder MECOM intron 21423239 rs4092655 chr3 168826901 C T 4.92E-04 Multiple complex diseases MECOM intron 17554300 rs3863097 chr3 168827022 G A 4.85E-04 Suicide attempts in bipolar disorder MECOM intron 21423239 rs3889027 chr3 168836505 G T 7.50E-06 Urinary metabolites MECOM intron 21572414 rs3851378 chr3 168837949 C A 3.95E-04 Suicide attempts in bipolar disorder MECOM intron 21423239 rs4407439 chr3 168842549 G C 4.95E-04 Suicide attempts in bipolar disorder MECOM intron 21423239 rs3851383 chr3 168842593 C G 5.40E-04 Suicide attempts in bipolar disorder MECOM intron 21423239 rs9826358 chr3 168844587 A T 2.75E-04 Suicide attempts in bipolar disorder MECOM intron 21423239 rs6773653 chr3 168851934 G A 1.40E-05 Urinary metabolites MECOM intron 21572414 rs1488106 chr3 168859006 T C 2.22E-04 Heart Failure MECOM intron pha002884 rs10936575 chr3 168865151 C T 7.70E-04 Heart Failure MECOM UTR-5 pha002884 rs7625096 chr3 168871003 C T 7.65E-04 Suicide attempts in bipolar disorder MECOM intron 21423239 rs9809990 chr3 168871394 A G 1.17E-05 Colorectal cancer MECOM intron 21242260 rs16853262 chr3 168871942 G A 7.59E-04 Suicide attempts in bipolar disorder MECOM intron 21423239 rs1516498 chr3 168884367 A G 5.51E-04 Suicide attempts in bipolar disorder MECOM intron 21423239 rs9809961 chr3 168885028 T C 9.82E-04 Alzheimer's disease MECOM intron 17998437 rs9809961 chr3 168885028 T C 1.49E-05 Alzheimer's disease MECOM intron 24755620 rs6444847 chr3 168904516 A G 5.06E-05 Response to hepatitis C treatment MECOM intron 19684573 rs9866086 chr3 168911333 T C 3.52E-04 Multiple complex diseases MECOM intron 17554300 rs2220393 chr3 168915658 C A 1.70E-05 Urinary metabolites MECOM intron 21572414 rs9864370 chr3 168916240 T C 9.00E-06 Multiple myeloma (hyperdiploidy) MECOM intron 23502783 rs4441704 chr3 168924612 G A 8.24E-04 Heart Failure MECOM intron pha002884 rs2220392 chr3 168932039 G A 7.34E-04 Response to statin treatment (atorvastatin),change in cholesterol levels MECOM intron 20031582 rs1568098 chr3 168943180 G T 5.24E-04 Alzheimer's disease MECOM intron 24755620 rs784288 chr3 168971231 A G 4.00E-08 Osteoporosis MECOM intron 23349225 rs12633242 chr3 168975395 G A 2.58E-04 Heart Failure MECOM intron pha002884 rs6444848 chr3 168982572 C A 1.91E-04 Type 2 diabetes MECOM intron 17463246 rs6790035 chr3 168987080 G A 0.00000232 VLDL cholesterol particle diameter MECOM intron 23263444 rs6799444 chr3 168989217 A G 3.68E-04 Fibrinogen MECOM intron 17255346 rs6799444 chr3 168989217 A G 5.37E-05 HDL cholesterol MECOM intron pha003075 rs11915511 chr3 168989910 C T 0.00000038 VLDL cholesterol particle diameter MECOM intron 23263444 rs9681698 chr3 168994926 T C 0.00000027 VLDL cholesterol particle diameter MECOM intron 23263444 rs16853491 chr3 169033294 C T 2.04E-07 Multiple complex diseases MECOM intron 17554300 rs16853509 chr3 169040952 T A 4.60E-06 Insulin-related traits MECOM intron 22791750 rs16853540 chr3 169061067 G A 1.73E-08 Cholesterol,total MECOM intron 23063622 rs16853540 chr3 169061067 G A 5.64E-09 LDL cholesterol MECOM intron 23063622 rs1879796 chr3 169063121 C T 5.65E-05 Cognitive impairment induced by topiramate MECOM intron 22091778 rs1430438 chr3 169067599 A G 5.65E-05 Cognitive impairment induced by topiramate MECOM intron 22091778 rs13324208 chr3 169071370 T C 0.000679027 Hypertension (early onset hypertension) MECOM intron 22479346 rs16853574 chr3 169079763 T C 5.10E-06 Blood pressure MECOM intron 21378095 rs9883650 chr3 169080185 T G 4.00E-07 Immune reponse to smallpox (secreted IL-1beta) MECOM intron 22610502 rs6774494 chr3 169082633 G A 1.00E-08 Nasopharyngeal carcinoma MECOM intron 20512145 rs6774494 chr3 169082633 G A 4.39E-05 Nasopharyngeal carcinoma MECOM intron 23209447 rs756644 chr3 169084827 C A 5.77E-04 Multiple complex diseases MECOM intron 17554300 rs756644 chr3 169084827 C A 0.00089496 Hypertension (early onset hypertension) MECOM intron 22479346 rs419076 chr3 169100886 T C 8.00E-13 Blood pressure MECOM intron 21909110 rs419076 chr3 169100886 T C 2.00E-12 Diastolic blood pressure MECOM intron 21909115 rs419076 chr3 169100886 T C 2.00E-13 Systolic blood pressure MECOM intron 21909115 rs448378 chr3 169100899 G A 1.00E-07 Systolic blood pressure MECOM intron 19430479 rs448378 chr3 169100899 G A 1.00E-08 Magnesium levels MECOM intron 20700443 rs448378 chr3 169100899 G A 1.00E-07 Coronary heart disease MECOM intron 21347282 rs1835374 chr3 169103185 C A 7.30E-04 Multiple complex diseases MECOM intron 17554300 rs9858375 chr3 169106928 A G 2.16E-04 Height MECOM intron 17255346 rs9814713 chr3 169118660 A G 2.16E-04 Height MECOM intron 17255346 rs1918966 chr3 169128274 A G 1.42E-05 Cognitive performance MECOM intron 19734545 rs16853722 chr3 169150632 T C 3.00E-14 Renal function-related traits (BUN) MECOM intron 22797727 rs1918974 chr3 169165888 C T 8.00E-08 Diastolic blood pressure MECOM intron 19430483 rs1918974 chr3 169165888 C T 8.00E-08 Coronary heart disease MECOM intron 21347282 rs4245909 chr3 169172788 A G 6.63E-05 Cognitive performance MECOM intron 19734545 rs1343040 chr3 169186293 G A 1.22E-11 Blood pressure MECOM intron 21909110 rs7613341 chr3 169190907 G A 2.76E-05 Cognitive performance MECOM intron 19734545 rs2178175 chr3 169195349 C T 1.27E-05 Parkinson's disease (motor and cognition) MECOM intron 22658654 rs2178175 chr3 169195349 C T 1.27E-05 Immune response to anthrax vaccine MECOM intron 22658931 rs6788901 chr3 169202548 G T 7.79E-04 Smoking initiation MECOM intron 24665060 rs6782346 chr3 169213490 C T 5.30E-05 Hemoglobin MECOM intron pha003096 rs6782346 chr3 169213490 C T 7.67E-05 Hematocrit MECOM intron pha003097 rs3863105 chr3 169283495 T C 9.55E-05 Brain lesion load MECOM intron 19010793 rs3863105 chr3 169283495 T C 2.13E-04 Response to cytadine analogues (cytosine arabinoside) MECOM intron 24483146 rs1344555 chr3 169300219 C T 3.00E-08 Pulmonary function MECOM intron 21946350 rs1344555 chr3 169300219 C T 4.00E-06 Pulmonary function (interaction) MECOM intron 23284291 rs6771699 chr3 169322889 G C 7.26E-04 Aortic root size MECOM intron 21223598 rs9290370 chr3 169325013 T G 4.66E-05 Aortic root size MECOM intron 21223598 rs9290370 chr3 169325013 T G 3.97E-07 Blood pressure MECOM intron 21909110 rs10513679 chr3 169353184 C T 0.000553253 Hypertension (early onset hypertension) MECOM intron 22479346 rs6444870 chr3 169358974 A C 3.63E-05 Parkinson's disease (motor and cognition) MECOM intron 22658654 rs1477192 chr3 169365939 A G 5.74E-06 Multiple complex diseases MECOM intron 17554300 rs10936590 chr3 169406484 C T 4.32E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10936590 chr3 169406484 C T 9.66E-04 Telomere length / / 23900074 rs1421018 chr3 169411792 A G 4.32E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7637639 chr3 169422522 C T 0.000877 Salmonella-induced pyroptosis / / 22837397 rs11718668 chr3 169458199 C T 8.08E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1881984 chr3 169464459 A G 1.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1881984 chr3 169464459 A G 3.60E-06 Interstitial lung disease / / 23583980 rs13097028 chr3 169464942 C T 7.00E-07 Melanoma / / 24980573 rs12638862 chr3 169477506 A G 2.00E-06 Multiple myeloma (IgH translocation) / / 23502783 rs12638862 chr3 169477506 A G 8.68E-09 Interstitial lung disease / / 23583980 rs12638862 chr3 169477506 A G 3.00E-09 Multiple myeloma / / 23955597 rs12630450 chr3 169480204 A G 3.29E-09 Interstitial lung disease / / 23583980 rs12630450 chr3 169480204 A G 1.11E-14 Telomere length / / 23900074 rs12630450 chr3 169480204 A G 2.00E-08 Multiple myeloma / / 23955597 rs12696304 chr3 169481271 C G 4.00E-14 Telomere length / / 20139977 rs12696304 chr3 169481271 C G 2.00E-14 Telomere length / / 21573004 rs12696304 chr3 169481271 C G 1.00E-09 Interstitial lung disease / / 23583980 rs12696304 chr3 169481271 C G 1.02E-09 Interstitial lung disease / / 23583980 rs9860874 chr3 169486271 C A 2.00E-09 Interstitial lung disease ARPM1 intron 23583980 rs9860874 chr3 169486271 C A 2.02E-09 Interstitial lung disease ARPM1 intron 23583980 rs3821383 chr3 169489946 A C,G,T 2.66E-09 Interstitial lung disease / / 23583980 rs3821383 chr3 169489946 A C,G,T 4.00E-08 Multiple myeloma / / 23955597 rs10936599 chr3 169492101 C T 5.00E-07 Celiac disease MYNN cds-synon 20190752 rs10936599 chr3 169492101 C T 3.00E-08 Colorectal cancer MYNN cds-synon 20972440 rs10936599 chr3 169492101 C T 7.00E-07 Multiple sclerosis MYNN cds-synon 21833088 rs10936599 chr3 169492101 C T 3.00E-31 Telomere length MYNN cds-synon 23535734 rs10936599 chr3 169492101 C T 1.52E-08 Interstitial lung disease MYNN cds-synon 23583980 rs10936599 chr3 169492101 C T 3.90E-07 Interstitial lung disease MYNN cds-synon 23583980 rs10936599 chr3 169492101 C T 9.00E-14 Multiple myeloma MYNN cds-synon 23955597 rs10936599 chr3 169492101 C T 5.00E-09 Bladder cancer MYNN cds-synon 24163127 rs10936599 chr3 169492101 C T 2.00E-09 Chronic lymphocytic leukemia MYNN cds-synon 24292274 rs1317082 chr3 169497585 A G 1.00E-08 Telomere length MYNN intron 23001564 rs1317082 chr3 169497585 A G 2.40E-08 Interstitial lung disease MYNN intron 23583980 rs1317082 chr3 169497585 A G 1.33E-19 Telomere length MYNN intron 23900074 rs1317082 chr3 169497585 A G 1.00E-09 Multiple myeloma MYNN intron 23955597 rs1920120 chr3 169502180 T C 3.11E-09 Interstitial lung disease MYNN intron 23583980 rs2141595 chr3 169503432 C T 1.86E-09 Interstitial lung disease MYNN intron 23583980 rs13069553 chr3 169508272 A G 3.00E-09 Multiple myeloma / / 23955597 rs7625734 chr3 169508915 T C 1.25E-05 Telomere length / / 20139977 rs7625734 chr3 169508915 T C 8.48E-09 Interstitial lung disease / / 23583980 rs7633750 chr3 169509244 G A 4.88E-09 Interstitial lung disease / / 23583980 rs7633750 chr3 169509244 G A 3.00E-08 Multiple myeloma / / 23955597 rs1997392 chr3 169509652 C T 1.00E-08 Interstitial lung disease / / 23583980 rs1997392 chr3 169509652 C T 3.71E-07 Interstitial lung disease / / 23583980 rs1997392 chr3 169509652 C T 9.99E-09 Interstitial lung disease / / 23583980 rs7621631 chr3 169512145 C A 2.00E-09 Multiple myeloma LRRC34 intron 23955597 rs6793295 chr3 169518455 T C 3.20E-07 Interstitial lung disease LRRC34 missense 23583980 rs6793295 chr3 169518455 T C 8.00E-13 Interstitial lung disease LRRC34 missense 23583980 rs6793295 chr3 169518455 T C 8.23E-09 Interstitial lung disease LRRC34 missense 23583980 rs10936601 chr3 169528449 C T 1.43E-05 Telomere length LRRC34 intron 20139977 rs10936601 chr3 169528449 C T 4.41E-09 Interstitial lung disease LRRC34 intron 23583980 rs10936601 chr3 169528449 C T 4.00E-15 Telomere length LRRC34 intron 23900074 rs10936601 chr3 169528449 C T 4.00E-08 Multiple myeloma LRRC34 intron 23955597 rs9831661 chr3 169528523 G T 1.38E-05 Telomere length LRRC34 intron 20139977 rs9831661 chr3 169528523 G T 4.48E-09 Interstitial lung disease LRRC34 intron 23583980 rs10936602 chr3 169536637 T C 3.00E-09 Multiple myeloma / / 23955597 rs1920119 chr3 169540397 T C 9.00E-07 Multiple myeloma LRRIQ4 cds-synon 23955597 rs10936603 chr3 169545652 G T 4.00E-08 Multiple myeloma LRRIQ4 intron 23955597 rs9833035 chr3 169553498 G T 8.00E-09 Multiple myeloma LRRIQ4 intron 23955597 rs16854445 chr3 169557842 C T 5.25E-05 Body Mass Index LRRC31 cds-synon pha003014 rs3732451 chr3 169558025 C T 6.12E-05 Intelligence LRRC31 cds-synon 21826061 rs3732451 chr3 169558025 C T 4.00E-06 Multiple myeloma LRRC31 cds-synon 23955597 rs16854453 chr3 169559234 G A 8.00E-09 Multiple myeloma LRRC31 intron 23955597 rs116674307 chr3 169562965 T C 6.40E-05 Colorectal cancer LRRC31 intron 24737748 rs13074500 chr3 169565571 T C 8.00E-09 Multiple myeloma LRRC31 intron 23955597 rs9290375 chr3 169566090 A G 6.27E-05 Intelligence LRRC31 intron 21826061 rs16847897 chr3 169568116 G C 1.03E-05 Telomere length LRRC31 intron 20139977 rs4955677 chr3 169568510 T C 1.65E-14 Telomere length LRRC31 intron 23900074 rs11709840 chr3 169570241 A C 6.54E-14 Telomere length LRRC31 intron 23900074 rs11709840 chr3 169570241 A C 5.00E-07 Multiple myeloma LRRC31 intron 23955597 rs11919269 chr3 169574465 T G 6.00E-07 Multiple myeloma LRRC31 intron 23955597 rs1920116 chr3 169579971 G A 1.00E-05 Bladder cancer LRRC31 intron 24163127 rs1920116 chr3 169579971 G A 8.00E-09 Glioma (high-grade) LRRC31 intron 24908248 rs41399944 chr3 169581202 A C 8.57E-05 Multiple complex diseases LRRC31 intron 17554300 rs7628292 chr3 169597186 G T 8.95E-05 Prostate cancer / / 22923026 rs13098597 chr3 169599567 T A 5.59E-06 Telomere length / / 23900074 rs6796010 chr3 169613751 T A,G 4.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16854522 chr3 169617405 T C 4.84E-04 Premature ovarian failure / / 19508998 rs16854531 chr3 169617880 A G 2.61E-04 Alzheimer's disease / / 17998437 rs1290666 chr3 169621681 G T 1.30E-12 Health and aging,CVD and cancer age of onset / / 22174011 rs1290666 chr3 169621681 G T 1.90E-12 Health and aging,CVD and cancer age of onset / / 22174011 rs1014702 chr3 169642073 G A 5.61E-05 Depression (quantitative trait) SAMD7 intron 20800221 rs1290670 chr3 169643955 C T 3.61E-05 Depression (quantitative trait) SAMD7 intron 20800221 rs960353 chr3 169659270 C T 1.50E-05 Urinary metabolites / / 21572414 rs9812475 chr3 169662086 A C 2.94E-04 Multiple complex diseases / / 17554300 rs7652524 chr3 169733428 C A 1.10E-05 Blood Pressure / / pha003043 rs9868633 chr3 169741291 C T 4.80E-04 Premature ovarian failure / / 19508998 rs2287482 chr3 169765795 T G 1.10E-05 Urinary metabolites GPR160 intron 21572414 rs6804193 chr3 169782204 T C 8.20E-09 Progranulin levels GPR160 intron 21087763 rs6804193 chr3 169782204 T C 8.20E-09 Myocardial infarction GPR160 intron 21211798 rs1684883 chr3 169921407 A G 6.74E-05 Cognitive test performance / / 20125193 rs481781 chr3 169940045 T C 2.16E-05 Cognitive test performance / / 20125193 rs546950 chr3 169944100 C T 6.91E-05 Cognitive test performance PRKCI intron 20125193 rs2140825 chr3 169990410 T C 1.76E-06 Multiple complex diseases PRKCI intron 17554300 rs2140825 chr3 169990410 T C 8.84E-05 Pulmonary function PRKCI intron 19300500 rs12493973 chr3 170027997 A G 4.61E-05 Pulmonary function / / 19300500 rs6444914 chr3 170061756 A G 5.29E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9841852 chr3 170067049 C G 1.28E-04 Cholesterol / / 17255346 rs7643085 chr3 170070371 A G 1.99E-04 Cholesterol / / 17255346 rs13101192 chr3 170080752 C G 3.80E-05 Eating disorders (purging via substances) SKIL intron 23568457 rs11917147 chr3 170088448 C T 5.49E-05 Response to hepatitis C treatment SKIL intron 19684573 rs4292231 chr3 170117518 C G 2.45E-04 Eating disorders / / 23568457 rs10936632 chr3 170130102 C A 7.00E-22 Prostate cancer / / 21743467 rs10513681 chr3 170141308 T C 7.80E-07 Breast cancer and prostate cancer CLDN11 intron 17903305 rs6794467 chr3 170147991 C A 6.13E-04 Type 2 diabetes CLDN11 intron 17463246 rs10936633 chr3 170158128 A G 7.42E-04 Type 2 diabetes / / 17463246 rs10936633 chr3 170158128 A G 2.00E-05 Urinary metabolites / / 21572414 rs6444931 chr3 170163474 G A 6.00E-07 Bipolar disorder and schizophrenia / / 20889312 rs6444931 chr3 170163474 G A 1.96E-05 Schizophrenia / / pha002857 rs6764438 chr3 170166091 G A 6.02E-06 Bipolar disorder and schizophrenia / / 20889312 rs6789806 chr3 170166274 C T 5.75E-06 Bipolar disorder and schizophrenia / / 20889312 rs7647823 chr3 170171835 A G 1.07E-04 Osteoarthritis (knee and hip) / / 21177295 rs7647823 chr3 170171835 A G 1.12E-04 Osteoarthritis (knee and hip) / / 21177295 rs7632718 chr3 170232408 A G 3.71E-06 Malignant pleural mesothelioma SLC7A14 intron 23626673 rs7632718 chr3 170232408 A G 9.07E-06 Malignant pleural mesothelioma SLC7A14 intron 23626673 rs17236879 chr3 170322647 A T 7.80E-05 Cognitive function / / 24684796 rs17826561 chr3 170341683 G A 6.98E-06 Calcium levels / / pha003085 rs531404 chr3 170419712 A G 5.27E-05 Left ventricular hypertrophy / / pha003052 rs534024 chr3 170422887 A C 5.98E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs474432 chr3 170433931 A T 6.90E-06 Urinary metabolites / / 21572414 rs502233 chr3 170442722 C T 1.80E-06 Urinary metabolites / / 21572414 rs17289605 chr3 170448037 T C 1.15E-04 Stroke / / pha002887 rs575242 chr3 170452081 G A 5.64E-04 Schizophrenia / / 19197363 rs564598 chr3 170457337 A C 5.30E-04 Schizophrenia / / 19197363 rs474588 chr3 170462589 A C 3.58E-04 Schizophrenia / / 19197363 rs517315 chr3 170465372 G A 3.89E-04 Schizophrenia / / 19197363 rs4955755 chr3 170494409 G A 7.00E-07 Menopause (age at onset) / / 19448619 rs12485248 chr3 170522227 A G 2.41E-04 Glycosylated haemoglobin levels / / 17255346 rs12485248 chr3 170522227 A G 5.10E-04 Multiple complex diseases / / 17554300 rs7632259 chr3 170526632 T C 5.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4955761 chr3 170580505 T C 1.50E-05 Urinary metabolites / / 21572414 rs11919564 chr3 170585408 C T 4.48E-04 Smoking initiation RPL22L1 intron 24665060 rs3821747 chr3 170585617 A G 6.80E-04 Multiple complex diseases RPL22L1 intron 17554300 rs3821747 chr3 170585617 A G 1.61E-46 Lymphocyte counts RPL22L1 intron 22286170 rs12486780 chr3 170589304 A C 3.03E-05 Erythrocyte counts / / pha003090 rs6444952 chr3 170628770 T C 2.17E-04 Vaspin levels / / 22907691 rs6444952 chr3 170628770 T C 0.0002168 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs10936665 chr3 170659019 T G 3.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs10936665 chr3 170659019 T G 1.10E-04 Myasthenia gravis / / 23055271 rs9875793 chr3 170686573 A G 0.0008 Delusions of guilt / / 23010768 rs9875793 chr3 170686573 A G 4.65E-08 Bipolar disorder (Negative mood delusions) / / 23010768 rs1280 chr3 170713290 T C 0.0004823 Glycated hemoglobin levels / / 22885924 rs1280 chr3 170713290 T C 1.98E-21 Fasting blood glucose / / 22885924 rs11920090 chr3 170717521 T A 5.00E-06 Fasting glucose-related traits SLC2A2 intron 20081858 rs11920090 chr3 170717521 T A 8.00E-13 Fasting insulin-related traits SLC2A2 intron 20081858 rs11920090 chr3 170717521 T A 8.00E-11 Fasting glucose-related traits (interaction with BMI) SLC2A2 intron 22581228 rs11920090 chr3 170717521 T A 2.20E-09 Fasting blood glucose SLC2A2 intron 22885924 rs73169713 chr3 170718937 C T 2.46E-04 Acne (severe) SLC2A2 intron 24927181 rs61791073 chr3 170721810 T A 0.0007149 Sarcoidosis SLC2A2 intron 22952805 rs1499821 chr3 170724729 C T 0.000000058 Bipolar disorder (Negative mood delusions) SLC2A2 intron 23010768 rs10513686 chr3 170725542 G A 6.00E-11 Liver enzyme levels (gamma-glutamyl transferase) SLC2A2 intron 22001757 rs3138708 chr3 170727703 T G 1.10E-09 Fasting blood glucose SLC2A2 intron 22885924 rs11924032 chr3 170735099 G A 0.0000026 Type 2 diabetes SLC2A2 intron 22325160 rs11924032 chr3 170735099 G A 0.00017 Bipolar disorder (Negative mood delusions) SLC2A2 intron 23010768 rs5394 chr3 170744893 G A 2.00E-10 Fasting blood glucose SLC2A2 nearGene-5 22885924 rs4133045 chr3 170769171 T C 3.50E-05 Pulmonary function in asthmatics / / 23541324 rs16855688 chr3 170772678 A G 6.60E-06 Urinary metabolites / / 21572414 rs16855724 chr3 170778342 T C 1.31E-04 Multiple complex diseases / / 17554300 rs16855724 chr3 170778342 T C 6.10E-06 Urinary metabolites / / 21572414 rs17826584 chr3 170787301 T C 5.90E-06 Urinary metabolites TNIK intron 21572414 rs12494349 chr3 170787528 T G 2.05E-04 Multiple complex diseases TNIK intron 17554300 rs12494349 chr3 170787528 T G 5.70E-06 Urinary metabolites TNIK intron 21572414 rs10513691 chr3 170797252 G A 7.10E-07 Urinary metabolites TNIK intron 21572414 rs16855778 chr3 170798794 T G 1.20E-06 Urinary metabolites TNIK intron 21572414 rs6781167 chr3 170798924 C A 1.20E-06 Urinary metabolites TNIK intron 21572414 rs16855789 chr3 170811667 G A 1.10E-06 Urinary metabolites TNIK cds-synon 21572414 rs12486611 chr3 170812288 C T 6.90E-07 Urinary metabolites TNIK intron 21572414 rs4955765 chr3 170831072 G A 4.05E-04 Alcohol dependence TNIK intron 21314694 rs11920719 chr3 170834559 A C 4.00E-06 Coronary heart disease TNIK intron 21347282 rs6782845 chr3 170842217 G T 2.22E-04 Smoking quantity TNIK intron 24665060 rs9814699 chr3 170877110 G A 3.04E-04 Type 2 diabetes TNIK intron 17463246 rs6768132 chr3 170905996 A G 9.55E-04 Type 2 diabetes TNIK intron 17463246 rs1875446 chr3 170950924 A C 3.25E-04 Schizophrenia TNIK intron 19197363 rs9857839 chr3 170957052 T C 3.40E-04 Suicide attempts in bipolar disorder TNIK intron 21041247 rs2088885 chr3 170971291 C A 6.00E-06 Brain imaging in schizophrenia (interaction) TNIK intron 19023125 rs16856054 chr3 170974549 T C 9.75E-04 Type 2 diabetes TNIK intron 17463246 rs7627954 chr3 170979975 T C 6.24E-06 Brain imaging in schizophrenia (interaction) TNIK intron 19023125 rs4894643 chr3 170981057 G A 2.14E-04 Hearing function TNIK intron 17255346 rs4894643 chr3 170981057 G A 4.58E-04 Myopia (pathological) TNIK intron 21095009 rs4894672 chr3 170984808 A G 5.44E-05 Soluble levels of adhesion molecules TNIK intron pha003072 rs13065441 chr3 170995335 C T 1.94E-05 Schizophrenia TNIK intron 19571809 rs13065441 chr3 170995335 C T 3.16E-05 Schizophrenia TNIK intron pha002859 rs16856118 chr3 171003804 A C 7.14E-04 Amyotrophic Lateral Sclerosis TNIK intron 17362836 rs13082302 chr3 171008371 C A 6.29E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines TNIK intron 21844884 rs7615681 chr3 171011079 T C 2.15E-05 Brain imaging in schizophrenia (interaction) TNIK intron 19023125 rs16856134 chr3 171020308 T C 4.30E-04 Multiple complex diseases TNIK intron 17554300 rs6444980 chr3 171048165 T C 2.79E-04 Scoliosis TNIK intron 21216876 rs6763184 chr3 171064766 A G 6.45E-04 Alzheimer's disease TNIK intron 24755620 rs6768644 chr3 171071204 T C 8.05E-05 Cognitive test performance TNIK intron 20125193 rs9865569 chr3 171080777 A G 1.57E-05 Cognitive performance TNIK intron 19734545 rs902952 chr3 171088709 A G 1.57E-05 Cognitive performance TNIK intron 19734545 rs11926949 chr3 171095094 T C 6.20E-04 Alcohol dependence TNIK intron 20201924 rs16856229 chr3 171097020 A G 5.81E-04 Multiple complex diseases TNIK intron 17554300 rs9290412 chr3 171108599 A G 5.18E-04 Multiple complex diseases TNIK intron 17554300 rs2010887 chr3 171131457 T G 6.86E-05 Hemoglobin TNIK intron pha003098 rs10936685 chr3 171135807 T C 8.35E-04 Amyotrophic Lateral Sclerosis TNIK intron 17362836 rs12634193 chr3 171180685 T C 6.05E-05 Alcohol and nictotine co-dependence / / 20158304 rs9844740 chr3 171188929 C A 8.39E-05 Suicide attempts in bipolar disorder / / 21423239 rs9844925 chr3 171189031 C T 2.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs11916004 chr3 171196599 A G 3.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs6777074 chr3 171199203 C T 5.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs10490809 chr3 171216755 G A 8.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs2131017 chr3 171217561 C T 3.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs9844361 chr3 171220350 T C 3.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs9290419 chr3 171223959 A G 3.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs1565567 chr3 171224161 A T 3.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs260789 chr3 171225136 A G 2.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs7651813 chr3 171226045 G A 6.79E-04 Suicide attempts in bipolar disorder / / 21041247 rs7651813 chr3 171226045 G A 5.17E-05 Suicide attempts in bipolar disorder / / 21423239 rs2075360 chr3 171227112 C T 4.80E-04 Asperger disorder / / 21182207 rs260774 chr3 171245526 T C 4.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs9870268 chr3 171264065 G A 8.81E-04 Multiple complex diseases / / 17554300 rs360464 chr3 171264604 C T 1.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs16856450 chr3 171264618 C T 6.77E-05 Multiple complex diseases / / 17554300 rs360463 chr3 171265330 C G 5.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs360459 chr3 171269939 G A 2.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs360457 chr3 171270483 G T 3.73E-05 Personality dimensions / / 18957941 rs360457 chr3 171270483 G T 3.02E-06 Diabetes (gestational) / / 22233651 rs360435 chr3 171277333 T C 3.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs360434 chr3 171277471 G A 4.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs360424 chr3 171279210 G A 5.33E-05 Odorant perception / / 23910658 rs918313 chr3 171284445 C T 7.40E-04 Type 2 diabetes / / 17463246 rs387048 chr3 171292911 C A 7.26E-04 Epilepsy / / 22116939 rs626270 chr3 171301434 T C 1.62E-04 Epilepsy / / 22116939 rs372623 chr3 171304058 C T 6.40E-04 Epilepsy / / 22116939 rs3774039 chr3 171380174 G A 6.30E-04 Multiple complex diseases PLD1 intron 17554300 rs3774033 chr3 171389976 A G 2.59E-04 Multiple complex diseases PLD1 intron 17554300 rs7649974 chr3 171409603 A G 1.25E-04 Multiple complex diseases PLD1 intron 17554300 rs1563261 chr3 171410889 C T 8.91E-04 Multiple complex diseases PLD1 intron 17554300 rs16856569 chr3 171414895 C G 5.77E-04 Multiple complex diseases PLD1 intron 17554300 rs2168205 chr3 171419179 C T 8.24E-04 Multiple complex diseases PLD1 intron 17554300 rs2168205 chr3 171419179 C T 8.21E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PLD1 intron 20031582 rs1921344 chr3 171450180 G T 9.07E-08 Metabolite levels PLD1 intron 23281178 rs4256166 chr3 171454877 C T 6.10E-05 Serum metabolites PLD1 intron 19043545 rs6794454 chr3 171455188 T C 7.45E-05 Bipolar disorder and schizophrenia PLD1 intron 20889312 rs7626674 chr3 171501314 C G 1.48E-04 Multiple complex diseases PLD1 intron 17554300 rs10936700 chr3 171506698 C T 4.38E-04 Response to cytadine analogues (cytosine arabinoside) PLD1 intron 24483146 rs6767600 chr3 171506951 T G 1.42E-04 Multiple complex diseases PLD1 intron 17554300 rs4243419 chr3 171507381 G A 1.28E-04 Multiple complex diseases PLD1 intron 17554300 rs9839909 chr3 171508463 T C 4.92E-05 Tunica Media PLD1 intron pha003034 rs9872465 chr3 171514831 T C 3.64E-04 Multiple complex diseases PLD1 intron 17554300 rs4894769 chr3 171516306 T A 8.89E-05 Serum metabolites PLD1 intron 19043545 rs6787821 chr3 171520989 G A 6.56E-05 Bipolar disorder PLD1 intron 17486107 rs9860739 chr3 171521120 G C 6.84E-04 Type 2 diabetes PLD1 intron 17463246 rs111355755 chr3 171550648 G A 7.70E-12 Mean platelet volume / / 22423221 rs7620616 chr3 171553796 C T 4.63E-04 Multiple complex diseases / / 17554300 rs6794092 chr3 171558344 G A 2.00E-06 Basal cell carcinoma / / 21700618 rs6794092 chr3 171558344 G A 2.00E-06 Body mass index / / 21701570 rs3914272 chr3 171558536 G A 3.54E-04 Multiple complex diseases / / 17554300 rs3929518 chr3 171562199 T C 4.50E-04 Multiple complex diseases TMEM212 intron 17554300 rs7627958 chr3 171616571 T C 1.10E-05 Urinary metabolites / / 21572414 rs9865258 chr3 171622717 G A 7.53E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12485367 chr3 171631672 C G 0.00000294 Brain activation patterns in response to human facial expressions-for the positive faces task / / 22828495 rs12485367 chr3 171631672 C G 0.0000029 Brain activation patterns in response to human facial expressions-with the fusiform gyrus for the positive faces task / / 22828495 rs12485367 chr3 171631672 C G 1.53E-09 Brain activation patterns in response to human facial expressions-for the negative faces task / / 22828495 rs12485367 chr3 171631672 C G 1.53E-09 Airflow obstruction / / 22837378 rs4894785 chr3 171632051 C G 7.25E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4894786 chr3 171645174 G A 3.38E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs13064045 chr3 171652849 T G 6.23E-07 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs3913363 chr3 171653903 C T 4.00E-07 Response to angiotensin II receptor blocker therapy / / 22566498 rs9862319 chr3 171656847 G A 2.50E-05 Urinary metabolites / / 21572414 rs6787381 chr3 171658880 T A 1.07E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs817797 chr3 171731061 T C 2.00E-05 Urinary metabolites / / 21572414 rs472728 chr3 171738987 G A 5.74E-04 Iron levels / / pha002876 rs575444 chr3 171746395 G A 1.11E-04 Hearing function / / 17255346 rs9647379 chr3 171785168 G C 1.00E-09 Heart rate FNDC3B intron 23583979 rs6792418 chr3 171835568 G A 8.80E-04 Multiple complex diseases FNDC3B intron 17554300 rs11718188 chr3 171855599 T C 2.00E-04 Response to cytadine analogues (cytosine arabinoside) FNDC3B intron 24483146 rs6445040 chr3 171858523 G A 6.61E-04 Type 2 diabetes FNDC3B intron 17463246 rs9825202 chr3 171870344 C T 8.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FNDC3B intron 20877124 rs75835198 chr3 171891476 T G 0.0000885 Nonsyndromic striae distensae (stretch marks) FNDC3B intron 23633020 rs7653441 chr3 171891732 G A 3.41E-43 Multiple complex diseases FNDC3B intron 17554300 rs56293326 chr3 171893547 A G 0.0000151 Nonsyndromic striae distensae (stretch marks) FNDC3B intron 23633020 rs62283844 chr3 171894947 A T 0.0000179 Nonsyndromic striae distensae (stretch marks) FNDC3B intron 23633020 rs61629847 chr3 171898246 T C 0.0000151 Nonsyndromic striae distensae (stretch marks) FNDC3B intron 23633020 rs4894819 chr3 171898476 A G 1.00E-04 Cognitive impairment induced by topiramate FNDC3B intron 22091778 rs12633433 chr3 171903075 G A 9.00E-06 Smoking behavior FNDC3B intron 20418888 rs7643363 chr3 171915776 T C 1.40E-07 Central corneal thickness FNDC3B intron 20485516 rs6414541 chr3 171920637 C T 2.05E-05 Alopecia areata FNDC3B intron 22027810 rs12493901 chr3 171922055 G A 5.41E-05 Alopecia areata FNDC3B intron 22027810 rs4535251 chr3 171926373 T C 4.00E-16 Height FNDC3B intron 23563607 rs6445047 chr3 171937014 T C 3.30E-05 Leukocyte Counts FNDC3B intron pha003091 rs7625948 chr3 171937813 G C 2.60E-05 Urinary metabolites FNDC3B intron 21572414 rs34770855 chr3 171940305 A G 6.94E-06 Stroke (ischemic) FNDC3B intron 21957438 rs79676570 chr3 171942911 T G 7.87E-06 Stroke (ischemic) FNDC3B intron 21957438 rs7428410 chr3 171943473 C T 2.01E-05 Leukocyte Counts FNDC3B intron pha003091 rs13073573 chr3 171945349 C T 2.83E-05 Leukocyte Counts FNDC3B intron pha003091 rs11712833 chr3 171949208 G A 8.08E-06 Stroke (ischemic) FNDC3B intron 21957438 rs35898760 chr3 171950181 C T 8.19E-06 Stroke (ischemic) FNDC3B intron 21957438 rs4364195 chr3 171951160 A G 8.18E-05 Leukocyte Counts FNDC3B intron pha003091 rs6445051 chr3 171954098 A G 8.19E-06 Stroke (ischemic) FNDC3B intron 21957438 rs34718992 chr3 171956029 A G 8.19E-06 Stroke (ischemic) FNDC3B intron 21957438 rs7652177 chr3 171969077 C G 7.00E-11 Height FNDC3B missense 20881960 rs6445055 chr3 171992387 G A 9.50E-08 Corneal structure FNDC3B intron 23291589 rs10513699 chr3 171992912 G T 7.60E-04 Renal function-related traits (urea) FNDC3B intron 22797727 rs4894535 chr3 171995605 C T 2.20E-06 Central corneal thickness FNDC3B intron 20485516 rs4894535 chr3 171995605 C T 5.00E-12 Corneal structure FNDC3B intron 23291589 rs7630681 chr3 172006714 T C 6.40E-06 Tunica Media FNDC3B intron pha003038 rs7610481 chr3 172055807 A G 9.52E-05 Coronary heart disease FNDC3B intron pha003031 rs593739 chr3 172061303 T C 4.84E-06 Suicide attempts in bipolar disorder FNDC3B intron 21423239 rs6776935 chr3 172062333 G A 5.02E-06 Suicide attempts in bipolar disorder FNDC3B intron 21423239 rs9821137 chr3 172069865 G A 2.04E-05 Suicide attempts in bipolar disorder FNDC3B intron 21423239 rs6804183 chr3 172083214 T C 9.76E-06 Suicide attempts in bipolar disorder FNDC3B intron 21423239 rs4894544 chr3 172091717 G A 1.93E-04 Premature ovarian failure FNDC3B intron 19508998 rs4894544 chr3 172091717 G A 7.26E-04 Depression (quantitative trait) FNDC3B intron 20800221 rs200926122 chr3 172106261 A AT 7.07E-04 Suicide attempts in bipolar disorder FNDC3B intron 21423239 rs2293236 chr3 172106261 A T 7.07E-04 Suicide attempts in bipolar disorder FNDC3B intron 21423239 rs4626122 chr3 172121012 G A 1.30E-05 Urinary metabolites / / 21572414 rs582780 chr3 172121443 A G 2.75E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10936722 chr3 172130237 C T 8.09E-04 Multiple complex diseases / / 17554300 rs522101 chr3 172132236 A G 1.09E-04 Lung function (forced vital capacity) / / 24023788 rs522101 chr3 172132236 A G 1.88E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2593858 chr3 172133487 A G 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1403637 chr3 172158397 T C 5.39E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs565105 chr3 172162117 G T 8.38E-05 Vitiligo GHSR UTR-3 22951725 rs509035 chr3 172163449 G A 8.50E-06 Height GHSR intron 18391952 rs2948694 chr3 172165163 A G 1 Drug response to Ethanol GHSR intron 18828808 rs572169 chr3 172165727 C T 3.00E-18 Height GHSR cds-synon 20881960 rs572169 chr3 172165727 C T 3.40E-06 Height GHSR cds-synon 21194676 rs572169 chr3 172165727 C T 4.70E-08 Height GHSR cds-synon 21194676 rs572169 chr3 172165727 C T 8.30E-13 Height GHSR cds-synon 21194676 rs572169 chr3 172165727 C T 1.00E-12 Height GHSR cds-synon 23563607 rs2232165 chr3 172166144 G A 1 Drug response to Ethanol GHSR cds-synon 18828808 rs2922126 chr3 172167261 T A 5.20E-04 Atrial fibrillation GHSR nearGene-5 21846873 rs9881097 chr3 172185376 A G 6.36E-04 Multiple complex diseases / / 17554300 rs10513702 chr3 172186953 T C 9.35E-04 Multiple complex diseases / / 17554300 rs10513702 chr3 172186953 T C 4.53E-05 Longevity / / 21612516 rs6445063 chr3 172193632 T C 1.70E-04 Osteoarthritis (hip) / / 21760914 rs6445063 chr3 172193632 T C 6.54E-05 Bipolar disorder / / 22925353 rs6777318 chr3 172205950 A G 4.06E-05 Alzheimer's disease (late onset) / / 21379329 rs6445065 chr3 172208177 T C 2.90E-06 Urinary metabolites / / 21572414 rs6445065 chr3 172208177 T C 9.24E-05 Bipolar disorder / / 22925353 rs2041693 chr3 172215575 C T 1.50E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs2041692 chr3 172215637 T C 7.67E-04 Alcohol dependence / / 20201924 rs2041692 chr3 172215637 T C 4.76E-05 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs3821821 chr3 172231610 C T 8.66E-04 Body mass index TNFSF10 intron 21701565 rs3774315 chr3 172231986 A G 7.34E-05 Prostate cancer(aggressive) TNFSF10 intron 21467234 rs143353036 chr3 172232682 A G 0.000034 Breast cancer (ER positive) TNFSF10 missense 23555315 rs143353036 chr3 172232682 A G 0.00008 Breast cancer TNFSF10 missense 23555315 rs11925997 chr3 172247790 A G 2.44E-04 Alzheimer's disease (late onset) / / 21379329 rs13316580 chr3 172262053 T C 3.92E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9833915 chr3 172266021 A G 9.13E-04 Type 2 diabetes / / 17463246 rs231994 chr3 172273873 C T 5.98E-04 Acute lung injury / / 22295056 rs4894422 chr3 172274516 G C 2.40E-04 Alzheimer's disease / / 17998437 rs2286983 chr3 172292484 G A 5.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs6804138 chr3 172308659 C A 1.72E-04 Multiple complex diseases / / 17554300 rs11914753 chr3 172309040 C T 3.13E-05 Triglycerides / / 19074352 rs11914753 chr3 172309040 C T 3.13E-05 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs6779133 chr3 172321159 C T 2.25E-04 Age-related macular degeneration / / 22125219 rs17524400 chr3 172321768 C T 2.07E-04 Age-related macular degeneration / / 22125219 rs234006 chr3 172357499 A C 1.50E-05 Urinary metabolites NCEH1 intron 21572414 rs1522354 chr3 172367873 C T 8.98E-04 Suicide attempts in bipolar disorder NCEH1 intron 21423239 rs6779265 chr3 172368980 G A 1.90E-05 Urinary metabolites NCEH1 intron 21572414 rs11712263 chr3 172385693 C T 8.00E-06 Obesity-related traits NCEH1 intron 23251661 rs9881902 chr3 172389700 T C 2.58E-05 Heart Rate NCEH1 intron pha003051 rs645253 chr3 172418184 T G 3.97E-04 Alzheimer's disease NCEH1 intron 22005930 rs1105152 chr3 172421968 C T 1.40E-05 Urinary metabolites NCEH1 intron 21572414 rs10936730 chr3 172426069 A C 3.83E-04 Alzheimer's disease NCEH1 intron 22005930 rs10936731 chr3 172427426 G A 3.50E-04 Alzheimer's disease NCEH1 intron 22005930 rs10936731 chr3 172427426 G A 9.40E-04 Response to cytadine analogues (cytosine arabinoside) NCEH1 intron 24483146 rs7629698 chr3 172428508 C T 3.47E-04 Alzheimer's disease NCEH1 intron 22005930 rs4894580 chr3 172438835 T C 3.95E-04 Alzheimer's disease LOC100505528 intron 22005930 rs4894582 chr3 172445186 G C 3.52E-04 Alzheimer's disease / / 22005930 rs4894585 chr3 172448455 T G 4.70E-04 Alzheimer's disease / / 22005930 rs9860467 chr3 172450560 T C 4.54E-04 Alzheimer's disease / / 22005930 rs4894589 chr3 172450607 C G 4.56E-04 Alzheimer's disease / / 22005930 rs9863121 chr3 172455843 T C 3.78E-04 Alzheimer's disease / / 22005930 rs9874197 chr3 172458175 T C 6.52E-04 Alzheimer's disease / / 22005930 rs9790224 chr3 172459863 C G 1.92E-04 Alzheimer's disease / / 22005930 rs7646507 chr3 172476419 G A 8.00E-06 Obesity-related traits ECT2 intron 23251661 rs7636100 chr3 172573325 G A 1.09E-04 Multiple complex diseases / / 17554300 rs17758354 chr3 172594446 C G 5.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs1353868 chr3 172661239 G T 2.60E-05 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) SPATA16 intron 24325915 rs12630349 chr3 172684081 C T 4.23E-04 Type 2 diabetes SPATA16 intron 17463246 rs12639277 chr3 172687161 C T 6.15E-04 Type 2 diabetes SPATA16 intron 17463246 rs16846345 chr3 172687693 A G 1.19E-04 Multiple complex diseases SPATA16 intron 17554300 rs13084672 chr3 172704529 G C 2.67E-04 Suicide attempts in bipolar disorder SPATA16 intron 21423239 rs16846377 chr3 172706118 A T 2.94E-04 Suicide attempts in bipolar disorder SPATA16 intron 21423239 rs7632999 chr3 172715828 A C 0.0000445 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity SPATA16 intron 22945461 rs1878006 chr3 172722507 C T 0.0000742 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity SPATA16 intron 22945461 rs2669178 chr3 172730694 A G 3.34E-04 Multiple complex diseases SPATA16 intron 17554300 rs791824 chr3 172732486 C A 2.76E-04 Multiple complex diseases SPATA16 intron 17554300 rs2673504 chr3 172732605 C T 2.35E-04 Multiple complex diseases SPATA16 intron 17554300 rs575511 chr3 172735766 A G 4.89E-04 Multiple complex diseases SPATA16 intron 17554300 rs506433 chr3 172755861 G A 9.54E-04 Amyotrophic Lateral Sclerosis SPATA16 intron 17827064 rs6445094 chr3 172770280 A G 6.73E-04 Prostate cancer mortality SPATA16 intron 20978177 rs1878007 chr3 172798800 G A 9.00E-06 Preschool internalizing problems SPATA16 intron 24839885 rs9823188 chr3 172813481 A G 2.82E-06 Glycemic traits (pregnancy) SPATA16 intron 23903356 rs7653527 chr3 172815740 A G 2.96E-05 Cognitive impairment induced by topiramate SPATA16 intron 22091778 rs9822041 chr3 172818799 A G 2.83E-06 Glycemic traits (pregnancy) SPATA16 intron 23903356 rs9809764 chr3 172819653 T C 2.61E-06 Glycemic traits (pregnancy) SPATA16 intron 23903356 rs16846616 chr3 172835082 C T 0.000011 Breast cancer (ER positive) SPATA16 missense 23555315 rs11720607 chr3 172843277 T G 5.00E-06 Prostate cancer (gene x gene interaction) SPATA16 intron 22219177 rs1512747 chr3 172851177 T C 5.18E-04 Smoking quantity SPATA16 intron 24665060 rs1606394 chr3 172861708 C T 5.45E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1512745 chr3 172881415 A G 5.92E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1512744 chr3 172881577 C T 5.91E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4588392 chr3 172884480 C A 5.92E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs792128 chr3 172973907 T C 0.00005412 Sarcoidosis / / 22952805 rs11927298 chr3 172986536 G A 5.86E-04 Multiple complex diseases / / 17554300 rs1879370 chr3 173002125 A T 7.83E-05 Personality dimensions / / 18957941 rs2030398 chr3 173005973 G A 0.000132 Gains in maximal O2 uptake response / / 21183627 rs12489095 chr3 173008491 G A 6.07E-05 Cognitive impairment induced by topiramate / / 22091778 rs488029 chr3 173119378 G A 4.92E-05 Type 2 diabetes NLGN1 intron 22158537 rs536445 chr3 173120103 C T 1.02E-04 Type 2 diabetes NLGN1 intron 22158537 rs548757 chr3 173133322 C T 1.00E-04 Cognitive impairment induced by topiramate NLGN1 intron 22091778 rs247978 chr3 173152748 G A 0.000771 Salmonella-induced pyroptosis NLGN1 intron 22837397 rs187448 chr3 173152783 A T 0.000167 Salmonella-induced pyroptosis NLGN1 intron 22837397 rs11721044 chr3 173155123 T C 3.00E-05 Cognitive performance NLGN1 intron 19734545 rs11718137 chr3 173156488 G A 3.80E-06 Urinary metabolites NLGN1 intron 21572414 rs11926626 chr3 173156682 C T 1.30E-05 Urinary metabolites NLGN1 intron 21572414 rs583173 chr3 173161912 A G 3.37E-04 Response to cytadine analogues (cytosine arabinoside) NLGN1 intron 24483146 rs11709498 chr3 173180633 A C 9.69E-04 Type 2 diabetes NLGN1 intron 17463246 rs11709498 chr3 173180633 A C 6.00E-06 Periodontitis (DPAL) NLGN1 intron 24024966 rs580219 chr3 173184667 A G 6.64E-04 Multiple complex diseases NLGN1 intron 17554300 rs6771377 chr3 173185376 A G 1.60E-04 Multiple complex diseases NLGN1 intron 17554300 rs721729 chr3 173189273 T C 2.00E-04 Type 2 diabetes NLGN1 intron 17846126 rs483487 chr3 173197712 A C 3.24E-05 Cardiovascular disease NLGN1 intron 22029572 rs1023738 chr3 173203230 G A 2.00E-04 Type 2 diabetes NLGN1 intron 17846126 rs13098458 chr3 173225367 T C 4.35E-05 Type 2 diabetes NLGN1 intron 17463246 rs9838752 chr3 173227868 A G 6.63E-04 Type 2 diabetes NLGN1 intron 17463246 rs9838752 chr3 173227868 A G 7.93E-05 Multiple complex diseases NLGN1 intron 17554300 rs17254553 chr3 173228796 T C 7.75E-04 Multiple complex diseases NLGN1 intron 17554300 rs1523344 chr3 173229774 C T 6.75E-04 Premature ovarian failure NLGN1 intron 19508998 rs9823727 chr3 173253447 T A 1.48E-04 Type 2 diabetes NLGN1 intron 17463246 rs6787959 chr3 173270074 T G 6.56E-04 Multiple complex diseases NLGN1 intron 17554300 rs1080310 chr3 173281266 A C 6.84E-04 Premature ovarian failure NLGN1 intron 19508998 rs9883143 chr3 173289599 G C 9.08E-04 Type 2 diabetes NLGN1 intron 17463246 rs16828127 chr3 173317852 T C 1.22E-05 Osteoarthritis (knee and hip) NLGN1 intron 21177295 rs16828127 chr3 173317852 T C 2.26E-04 Osteoarthritis (knee and hip) NLGN1 intron 21177295 rs16828127 chr3 173317852 T C 3.48E-05 Osteoarthritis (knee and hip) NLGN1 intron 21177295 rs16828127 chr3 173317852 T C 6.92E-04 Osteoarthritis (knee and hip) NLGN1 intron 21177295 rs9833711 chr3 173322076 A G 9.25E-04 Multiple complex diseases NLGN1 UTR-5 17554300 rs3844523 chr3 173322248 T C 4.77E-04 Myocardial Infarction NLGN1 UTR-5 pha002873 rs10513715 chr3 173323726 C T 6.09E-05 Orofacial clefts NLGN1 intron 22419666 rs9868927 chr3 173339777 A G 1.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NLGN1 intron 20877124 rs9868927 chr3 173339777 A G 9.49E-04 Response to taxane treatment (placlitaxel) NLGN1 intron 23006423 rs1393450 chr3 173402170 T G 8.15E-04 Parkinson's disease NLGN1 intron 16252231 rs9815508 chr3 173431705 G A 2.07E-08 Metabolite levels NLGN1 intron 23281178 rs9856236 chr3 173437476 A G 5.00E-08 Metabolite levels NLGN1 intron 23281178 rs10460881 chr3 173439059 G C 6.72E-08 Metabolite levels NLGN1 intron 23281178 rs9877840 chr3 173441676 A G 2.57E-08 Metabolite levels NLGN1 intron 23281178 rs1488564 chr3 173453868 A G 6.90E-08 Metabolite levels NLGN1 intron 23281178 rs1352416 chr3 173480707 G C 3.40E-05 Breast cancer and prostate cancer NLGN1 intron 17903305 rs6779246 chr3 173488175 C G 1.37E-04 Blood pressure (response to angiotensin II receptor blocker) NLGN1 intron 24192120 rs9879266 chr3 173489454 C T 2.00E-04 Cognitive impairment induced by topiramate NLGN1 intron 22091778 rs9879266 chr3 173489454 C T 1.25E-04 Blood pressure (response to angiotensin II receptor blocker) NLGN1 intron 24192120 rs9868353 chr3 173494682 A G 4.26E-04 Blood pressure (response to angiotensin II receptor blocker) NLGN1 intron 24192120 rs1873038 chr3 173537641 C T 1.80E-05 Breast cancer and prostate cancer NLGN1 intron 17903305 rs9878343 chr3 173543235 C A 1.43E-04 Blood pressure (response to angiotensin II receptor blocker) NLGN1 intron 24192120 rs1077344 chr3 173559551 G C 7.80E-06 Urinary metabolites NLGN1 intron 21572414 rs1077344 chr3 173559551 G C 2.92E-04 Blood pressure (response to angiotensin II receptor blocker) NLGN1 intron 24192120 rs16831160 chr3 173575416 C T 0.000000707 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment NLGN1 intron 23392654 rs16831160 chr3 173575416 C T 7.07E-07 Thiazide-induced adverse metabolic effects in hypertensive patients NLGN1 intron 23400010 rs12630744 chr3 173615136 A C 4.08E-05 Height NLGN1 intron pha003011 rs2172212 chr3 173619257 T C 4.97E-05 Height NLGN1 intron pha003010 rs2172212 chr3 173619257 T C 1.38E-05 Height NLGN1 intron pha003011 rs4280663 chr3 173623133 G A 7.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NLGN1 intron 20877124 rs9290488 chr3 173689779 C T 7.60E-05 Aging (time to event) NLGN1 intron 21782286 rs13078193 chr3 173716814 A G 2.20E-05 Schizophrenia NLGN1 intron 21791550 rs13078193 chr3 173716814 A G 0.000022 Psychosis NLGN1 intron 23164818 rs291928 chr3 173727983 A G 6.90E-05 Rheumatoid arthritis NLGN1 intron 22446963 rs9290489 chr3 173757884 C G 2.25E-04 Multiple complex diseases NLGN1 intron 17554300 rs11922785 chr3 173786367 A G 3.10E-04 Multiple complex diseases NLGN1 intron 17554300 rs7638337 chr3 173798922 G A 3.80E-04 Multiple complex diseases NLGN1 intron 17554300 rs7612490 chr3 173877136 C A 1.57E-04 Osteoarthritis (knee and hip) NLGN1 intron 21177295 rs7612490 chr3 173877136 C A 3.64E-06 Osteoarthritis (knee and hip) NLGN1 intron 21177295 rs7612490 chr3 173877136 C A 6.57E-04 Osteoarthritis (knee and hip) NLGN1 intron 21177295 rs9844610 chr3 173880309 A G 3.50E-06 Urinary metabolites NLGN1 intron 21572414 rs7618997 chr3 173899890 C A 4.58E-04 Multiple complex diseases NLGN1 intron 17554300 rs16857540 chr3 173900575 C G 6.26E-04 Multiple complex diseases NLGN1 intron 17554300 rs16857540 chr3 173900575 C G 0.000513 5-fluorouracil induced mucositis in response to colorectal cancer treatment NLGN1 intron 22310351 rs16857557 chr3 173900788 T G 4.93E-04 Multiple complex diseases NLGN1 intron 17554300 rs16857562 chr3 173900969 C A 4.15E-04 Multiple complex diseases NLGN1 intron 17554300 rs9880810 chr3 173920165 C T 2.82E-04 Multiple complex diseases NLGN1 intron 17554300 rs4404456 chr3 173921099 T G 2.47E-04 Multiple complex diseases NLGN1 intron 17554300 rs9848355 chr3 173921149 A G 2.56E-04 Multiple complex diseases NLGN1 intron 17554300 rs17788364 chr3 173925594 A G 5.56E-04 Multiple complex diseases NLGN1 intron 17554300 rs2861668 chr3 173927196 G A 3.51E-04 Multiple complex diseases NLGN1 intron 17554300 rs13064752 chr3 173934318 A C 5.01E-05 Body Mass Index NLGN1 intron pha003009 rs17184565 chr3 173937157 T C 7.16E-04 Multiple complex diseases NLGN1 intron 17554300 rs16858344 chr3 173958362 G A 1.43E-05 Cognitive impairment induced by topiramate NLGN1 intron 22091778 rs16858344 chr3 173958362 G A 8.24E-05 Orofacial clefts NLGN1 intron 22419666 rs16858417 chr3 173967286 T C 1.00E-04 Cognitive impairment induced by topiramate NLGN1 intron 22091778 rs16858428 chr3 173968508 T C 3.04E-05 Cognitive impairment induced by topiramate NLGN1 intron 22091778 rs808079 chr3 173976450 A G 6.51E-04 Multiple complex diseases NLGN1 intron 17554300 rs692486 chr3 174015110 T C 8.99E-04 Multiple complex diseases / / 17554300 rs6445164 chr3 174025863 C T 5.41E-05 Body Mass Index / / pha003009 rs16859116 chr3 174027501 T C 5.41E-05 Body Mass Index / / pha003009 rs13074924 chr3 174029045 A G 9.00E-06 Major depressive disorder / / 20516156 rs13074924 chr3 174029045 A G 0.0001 Prostate cancer / / 23555315 rs13098004 chr3 174038312 C A 2.90E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs11714539 chr3 174139845 C A 7.42E-04 Heart Failure / / pha002884 rs9830993 chr3 174166224 G A 0.000155885 Hypertension (early onset hypertension) / / 22479346 rs10936797 chr3 174194243 T G 2.00E-06 Obesity-related traits / / 23251661 rs1588892 chr3 174217522 C A 3.40E-06 Urinary metabolites / / 21572414 rs12632844 chr3 174225345 A G 6.51E-04 Stroke / / pha002886 rs9827557 chr3 174278640 A G 1.12E-05 Pulmonary function in asthmatics / / 23541324 rs17330411 chr3 174280930 T C 4.19E-04 Smoking initiation / / 24665060 rs950636 chr3 174300045 T C 2.32E-05 Pulmonary function in asthmatics / / 23541324 rs9875462 chr3 174338087 A T 7.98E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs3928247 chr3 174365638 G C 5.26E-06 Body mass index / / 19557197 rs508094 chr3 174370818 G A 4.95E-04 Smoking initiation / / 24665060 rs9810363 chr3 174382744 G A 5.82E-04 Multiple complex diseases / / 17554300 rs531838 chr3 174383077 C A 4.14E-04 Smoking initiation / / 24665060 rs489683 chr3 174383389 G A 6.15E-04 Smoking initiation / / 24665060 rs491606 chr3 174383624 G C 1.90E-04 Smoking initiation / / 24665060 rs484879 chr3 174413951 C T 1.10E-05 Urinary metabolites / / 21572414 rs6783729 chr3 174425811 A G 4.49E-05 Cholesterol / / pha003083 rs13325005 chr3 174444171 G A 6.70E-05 Information processing speed / / 21130836 rs572786 chr3 174450031 A G 3.78E-04 Type 2 diabetes / / 17463246 rs572786 chr3 174450031 A G 3.44E-04 Myocardial Infarction / / pha002873 rs6809168 chr3 174452796 C T 0.0007668 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6809168 chr3 174452796 C T 7.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9846937 chr3 174461025 T C 8.70E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs519642 chr3 174491067 G A 0.0006571 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1515618 chr3 174525732 C G 2.40E-05 Urinary metabolites / / 21572414 rs9861204 chr3 174536444 G T 1.64E-05 Cognitive test performance / / 20125193 rs6801807 chr3 174667446 A G 2.78E-04 Stroke /ALADL2 intron pha002887 rs10513729 chr3 174681247 T G 5.77E-04 Alcohol consumption (maxi-drinks) /ALADL2 intron 24277619 rs6445188 chr3 174717183 T C 2.74E-05 Cleft lip /ALADL2 intron 20436469 rs9868994 chr3 174733081 C T 5.95E-04 Response to taxane treatment (placlitaxel) /ALADL2 intron 23006423 rs9845338 chr3 174744836 T C 0.000738344 Hypertension (early onset hypertension) /ALADL2 intron 22479346 rs9831769 chr3 174756151 C A 2.16E-04 Multiple complex diseases /ALADL2 intron 17554300 rs12633726 chr3 174758302 G T 7.50E-06 Urinary metabolites /ALADL2 intron 21572414 rs12636705 chr3 174758639 T A 2.00E-05 Urinary metabolites /ALADL2 intron 21572414 rs12636747 chr3 174758763 T A 5.10E-06 Urinary metabolites /ALADL2 intron 21572414 rs10212390 chr3 174759377 G A 7.10E-06 Urinary metabolites /ALADL2 intron 21572414 rs4367078 chr3 174764067 G T 1.80E-05 Urinary metabolites /ALADL2 intron 21572414 rs4261887 chr3 174764228 A G 1.90E-05 Urinary metabolites /ALADL2 intron 21572414 rs6788065 chr3 174767354 C T 1.00E-05 Urinary metabolites /ALADL2 intron 21572414 rs9873308 chr3 174769315 G A 0.000755233 Hypertension (early onset hypertension) /ALADL2 intron 22479346 rs9854799 chr3 174778214 A G 1.57E-04 HIV-1 viral setpoint /ALADL2 intron 17641165 rs6797728 chr3 174790418 A G 2.30E-05 Urinary metabolites /ALADL2 intron 21572414 rs1381130 chr3 174816927 C T 1.48E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs9848123 chr3 174817169 A G 1.48E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs1461255 chr3 174818156 G A 4.46E-04 HIV-1 viral setpoint /ALADL2 intron 17641165 rs7627996 chr3 174819027 T C 5.39E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs9859106 chr3 174819434 A T 2.64E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs6443283 chr3 174820195 C T 3.44E-04 Osteoarthritis /ALADL2 intron 19508968 rs9869809 chr3 174821539 A T 4.07E-05 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs936475 chr3 174822148 G T 5.22E-05 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs936474 chr3 174822729 A G 5.22E-05 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs17588796 chr3 174823698 G A 5.25E-05 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs9290531 chr3 174823729 G A 8.07E-05 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs17588879 chr3 174823758 T A 5.14E-05 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs10049218 chr3 174824444 G A 1.59E-04 Amyotrophic Lateral Sclerosis /ALADL2 intron 17362836 rs10049218 chr3 174824444 G A 1.21E-04 HIV-1 viral setpoint /ALADL2 intron 17641165 rs4894477 chr3 174824539 G A 3.37E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs11710345 chr3 174826589 G A 9.66E-05 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs6797428 chr3 174827233 G A 9.64E-05 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs6797510 chr3 174827266 G A 9.60E-05 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs6782155 chr3 174827794 G A 9.46E-05 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs6782183 chr3 174827967 C T 6.01E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs4505709 chr3 174828317 G A 9.40E-05 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs4355289 chr3 174828460 G A 1.40E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs9847129 chr3 174829687 C T 1.40E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs7646135 chr3 174830294 T A 8.47E-05 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs9877212 chr3 174831434 T C 1.38E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs6796537 chr3 174832383 C T 1.38E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs6809009 chr3 174832420 T G 1.38E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs6774509 chr3 174832617 A T 1.38E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs6763592 chr3 174832948 T G 5.77E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs6773961 chr3 174836057 T A 1.38E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs6809556 chr3 174836132 C T 1.38E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs6774272 chr3 174836393 T C 1.36E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs2862042 chr3 174836848 C T 1.35E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21041247 rs1461272 chr3 174880072 A G 4.65E-04 Smoking initiation /ALADL2 intron 24665060 rs17531088 chr3 174893775 C T 1.00E-06 Kawasaki disease /ALADL2 intron 19132087 rs17531088 chr3 174893775 C T 3.89E-05 Response to platinum-based chemotherapy in small-cell lung cancer /ALADL2 intron 20463552 rs7642577 chr3 174924018 T C 8.03E-04 Self-reported allergy /ALADL2 intron 23817569 rs1471306 chr3 174924711 T A 6.12E-04 Self-reported allergy /ALADL2 intron 23817569 rs4243408 chr3 174926485 G A 4.02E-04 Self-reported allergy /ALADL2 intron 23817569 rs4312664 chr3 174926597 A G 3.93E-04 Self-reported allergy /ALADL2 intron 23817569 rs6804034 chr3 174930740 T G 5.25E-04 Self-reported allergy /ALADL2 intron 23817569 rs11915650 chr3 174942871 G A 2.69E-04 Taste perception /ALADL2 intron 22132133 rs4371530 chr3 174951756 T C 5.16E-05 Prostate cancer /ALADL2 missense 22923026 rs6795495 chr3 174953393 T C 8.79E-05 Prostate cancer /ALADL2 intron 22923026 rs1463525 chr3 174961387 T C 8.00E-06 Systemic lupus erythematosus /ALADL2 intron 21408207 rs1580258 chr3 174971225 A T 5.66E-05 Epilepsy (remission after treatment) /ALADL2 intron 23962720 rs12633712 chr3 174971516 A C 3.86E-05 Epilepsy (remission after treatment) /ALADL2 intron 23962720 rs4555531 chr3 174997538 C A 5.20E-05 Body Mass Index /ALADL2 intron pha003022 rs6801137 chr3 175004221 G A 9.60E-06 Urinary metabolites /ALADL2 intron 21572414 rs7630477 chr3 175015466 T C 1.60E-05 Urinary metabolites /ALADL2 intron 21572414 rs4894713 chr3 175042776 G A 4.26E-05 Platelet counts /ALADL2 intron pha003100 rs2042126 chr3 175055759 T G 3.00E-06 Sleep duration /ALADL2 intron 23728906 rs16825471 chr3 175057188 G T 2.53E-05 Glucose levels /ALADL2 intron pha003061 rs16825520 chr3 175067264 C T 6.31E-04 Obesity (extreme) /ALADL2 intron 21935397 rs16825529 chr3 175068218 A C 1.22E-04 Coronary heart disease /ALADL2 intron 21971053 rs10936847 chr3 175070188 G A 8.80E-06 Urinary metabolites /ALADL2 intron 21572414 rs10936847 chr3 175070188 G A 1.50E-04 Coronary heart disease /ALADL2 intron 21971053 rs9818703 chr3 175070839 T C 1.32E-04 Coronary heart disease /ALADL2 intron 21971053 rs17205180 chr3 175071295 C T 3.80E-05 Coronary heart disease /ALADL2 intron 21971053 rs6771725 chr3 175075109 G T 2.62E-04 Coronary heart disease /ALADL2 intron 21971053 rs6771725 chr3 175075109 G T 9.00E-09 Venous thromboembolism (gene x gene interaction) /ALADL2 intron 23509962 rs4894485 chr3 175077686 T C 1.29E-05 Schizophrenia /ALADL2 intron 19197363 rs4894485 chr3 175077686 T C 7.05E-05 Coronary heart disease /ALADL2 intron 21971053 rs12634318 chr3 175086544 T C 4.05E-04 Coronary heart disease /ALADL2 intron 21971053 rs9869663 chr3 175094357 G A 9.21E-04 HIV-1 viral setpoint /ALADL2 intron 17641165 rs9869663 chr3 175094357 G A 7.34E-05 Coronary heart disease /ALADL2 intron 21971053 rs6793266 chr3 175102338 C T 1.23E-04 Follicular lymphoma /ALADL2 intron 21533074 rs6793266 chr3 175102338 C T 1.58E-04 Coronary heart disease /ALADL2 intron 21971053 rs62287976 chr3 175103614 G T 1.00E-06 Metabolite levels (MHPG) /ALADL2 intron 23319000 rs7613835 chr3 175149368 G A 2.77E-05 Follicular lymphoma /ALADL2 intron 21533074 rs10490876 chr3 175151789 C T 3.10E-04 Crohn's disease /ALADL2 intron 17684544 rs1549108 chr3 175171066 G A 7.66E-04 Multiple complex diseases /ALADL2 intron 17554300 rs41482845 chr3 175212106 C G 4.71E-04 Multiple complex diseases /ALADL2 intron 17554300 rs6773476 chr3 175216396 G T 4.63E-04 Multiple complex diseases /ALADL2 intron 17554300 rs74619861 chr3 175223896 G A 3.00E-06 Bipolar disorder (body mass index interaction) /ALADL2 intron 24322204 rs4894721 chr3 175240642 T C 7.90E-04 Multiple complex diseases /ALADL2 intron 17554300 rs4340713 chr3 175242215 A G 9.35E-05 Blood Pressure /ALADL2 intron pha003050 rs4243411 chr3 175262419 A G 4.57E-04 Multiple complex diseases /ALADL2 intron 17554300 rs7638295 chr3 175267563 G T 0.0005148 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) /ALADL2 intron 23233654 rs7638295 chr3 175267563 G T 5.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) /ALADL2 intron 23233662 rs6798499 chr3 175351938 A G 2.50E-05 Urinary metabolites /ALADL2 intron 21572414 rs9868563 chr3 175370599 C T 2.25E-05 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction) /ALADL2 intron 24280104 rs10470504 chr3 175372903 T C 5.10E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21423239 rs7636207 chr3 175386962 C T 8.91E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21423239 rs12107747 chr3 175389857 T C 7.77E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21423239 rs7636981 chr3 175399120 T C,G 7.53E-04 Suicide attempts in bipolar disorder /ALADL2 intron 21423239 rs1889261 chr3 175410177 G A 2.66E-05 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction) /ALADL2 intron 24280104 rs17276578 chr3 175456634 C T 8.14E-04 Acute lung injury /ALADL2 intron 22295056 rs17355228 chr3 175457527 A T 8.72E-04 Acute lung injury /ALADL2 intron 22295056 rs7621879 chr3 175457885 G A 8.72E-04 Acute lung injury /ALADL2 intron 22295056 rs7637270 chr3 175462774 C T 8.09E-04 Acute lung injury /ALADL2 intron 22295056 rs9869315 chr3 175555304 T C 5.84E-04 Parkinson's disease / / 17052657 rs12493932 chr3 175586997 C A 4.55E-04 Parkinson's disease / / 17052657 rs6772209 chr3 175647165 G A 3.00E-07 Esophageal cancer / / 21642993 rs9823496 chr3 175669896 C A 8.61E-06 Cleft lip / / 20436469 rs9823496 chr3 175669896 C A 7.90E-05 Parkinson's disease / / 21248740 rs9882167 chr3 175767376 G A 9.62E-04 HIV-1 viral setpoint / / 17641165 rs7653056 chr3 175790003 A G 5.37E-05 Bipolar disorder / / 21771265 rs9869872 chr3 175802031 A G 4.78E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs9875122 chr3 175806373 C T 9.58E-05 Ulcerative colitis / / 19915573 rs9875122 chr3 175806373 C T 7.26E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs9820268 chr3 175806735 T C 6.86E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs9847632 chr3 175808125 A G 9.33E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs4428195 chr3 175809188 A G 7.14E-05 Serum metabolites / / 19043545 rs6788471 chr3 175850699 C T 2.11E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs7614108 chr3 175864210 G C 3.00E-04 Multiple complex diseases / / 17554300 rs4894505 chr3 175920884 G T 8.00E-04 Chronic fatigue syndrome / / 21912186 rs16848186 chr3 175925416 A G 5.94E-05 Cognitive impairment induced by topiramate / / 22091778 rs11923600 chr3 175927451 G A 8.00E-06 Height / / 23456168 rs11923600 chr3 175927451 G A 3.41E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1921476 chr3 175929674 C A 8.70E-05 Cognitive impairment induced by topiramate / / 22091778 rs7615573 chr3 175934613 C T 5.75E-05 Cognitive impairment induced by topiramate / / 22091778 rs7609918 chr3 175954186 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12498113 chr3 175998525 C G 4.30E-06 Urinary metabolites / / 21572414 rs1483622 chr3 176007583 C A 2.86E-05 Cognitive impairment induced by topiramate / / 22091778 rs9812934 chr3 176009517 G A 7.85E-05 Cognitive impairment induced by topiramate / / 22091778 rs1483623 chr3 176011073 A G 2.40E-05 Urinary metabolites / / 21572414 rs2046351 chr3 176014391 T G 3.50E-06 Urinary metabolites / / 21572414 rs2046352 chr3 176014495 C T 9.80E-06 Urinary metabolites / / 21572414 rs1483628 chr3 176027779 T C 3.40E-06 Response to antidepressants / / 19736353 rs6799767 chr3 176030096 G T 8.80E-05 Response to hepatitis C treatment / / 19684573 rs6799767 chr3 176030096 G T 4.00E-07 Eosinophilic esophagitis (pediatric) / / 20208534 rs9835842 chr3 176031687 A G 1.90E-04 Alcohol dependence / / 20201924 rs2170749 chr3 176032695 T A 6.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs2062245 chr3 176032963 T A 5.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs1483630 chr3 176033450 G A 5.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs1156636 chr3 176035490 C A 4.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs900576 chr3 176039079 T C 7.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs2220099 chr3 176045736 G T 7.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs7612779 chr3 176051881 A G 8.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs2128850 chr3 176055539 C G,T 6.10E-05 Major depressive disorder / / 21621269 rs13100596 chr3 176055995 C T 8.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs13100792 chr3 176056198 A C 8.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs9813690 chr3 176057222 A G 5.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs13065195 chr3 176057800 A G 7.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs1601122 chr3 176061082 T C 4.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs2625695 chr3 176062264 G T 7.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs2625697 chr3 176063223 G A 7.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs1483615 chr3 176063682 G A 7.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs954586 chr3 176065174 G C 7.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs2128985 chr3 176065368 G T 6.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs2626473 chr3 176065445 C T 7.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs1905480 chr3 176066387 G T 9.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs9877234 chr3 176067474 G A 6.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs2626477 chr3 176068870 T C 8.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs2626479 chr3 176070509 G A 8.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs2626479 chr3 176070509 G A 5.64E-05 Major depressive disorder / / 21621269 rs2626480 chr3 176071072 G T 6.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs900673 chr3 176071640 G A 8.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs2626481 chr3 176072526 G T 7.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs9853201 chr3 176082414 C T 8.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs301177 chr3 176132164 C T 0.000440449 Hypertension (early onset hypertension) / / 22479346 rs301191 chr3 176138839 G A 8.90E-04 Suicidal ideation / / 22030708 rs301193 chr3 176139525 T C 8.90E-04 Suicidal ideation / / 22030708 rs962256 chr3 176183377 A C 2.10E-05 Urinary metabolites / / 21572414 rs1586185 chr3 176190210 G A 2.10E-05 Urinary metabolites / / 21572414 rs9812654 chr3 176215079 G A 9.45E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs486054 chr3 176225042 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2198526 chr3 176226619 G T 2.40E-05 Urinary metabolites / / 21572414 rs1377828 chr3 176245042 G T 6.00E-04 Chronic fatigue syndrome / / 21912186 rs838209 chr3 176352763 A G 4.14E-05 Obsessive-compulsive disorder LOC100505547 intron 24821223 rs1027185 chr3 176406924 G A 1.51E-05 Acne (severe teenage) / / 24114350 rs6779279 chr3 176411271 T G 2.00E-04 Statin-induced myopathy / / 21826682 rs1490075 chr3 176422652 C T 2.00E-06 Response to amphetamines / / 22952603 rs1906995 chr3 176438209 G T 0.0001508 Sarcoidosis / / 22952805 rs12489251 chr3 176444421 C T 0.0001365 Sarcoidosis / / 22952805 rs1027175 chr3 176450118 G A 2.14E-04 Type 2 diabetes / / 17463246 rs7621575 chr3 176456273 A C 2.14E-04 Type 2 diabetes / / 17463246 rs10936905 chr3 176457319 G A 0.0001069 Sarcoidosis / / 22952805 rs62285735 chr3 176461256 T C 0.0001006 Sarcoidosis / / 22952805 rs62285737 chr3 176464651 G A 0.00001095 Sarcoidosis / / 22952805 rs6771463 chr3 176488398 G A 3.03E-05 Multiple complex diseases / / 17554300 rs1490047 chr3 176501869 A G 8.54E-04 Rheumatoid arthritis / / 21452313 rs6775468 chr3 176505053 T C 7.03E-04 Rheumatoid arthritis / / 21452313 rs6443373 chr3 176505197 A G 8.54E-04 Rheumatoid arthritis / / 21452313 rs6762836 chr3 176535400 C G 2.80E-05 Urinary metabolites / / 21572414 rs9874964 chr3 176556670 G A 8.67E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12636660 chr3 176561143 A G 1.90E-05 Urinary metabolites / / 21572414 rs1488895 chr3 176577830 A G 2.55E-04 Sudden cardiac arrest / / 21658281 rs1488897 chr3 176577979 T C 7.78E-04 Multiple complex diseases / / 17554300 rs6771042 chr3 176613174 G A 1.40E-05 Urinary metabolites / / 21572414 rs2130014 chr3 176616271 C T 4.30E-05 Temporomandibular joint disorders / / 23746317 rs4857661 chr3 176618251 A G 8.20E-04 Multiple complex diseases / / 17554300 rs1387161 chr3 176623079 T C 2.70E-05 Temporomandibular joint disorders / / 23746317 rs1906660 chr3 176631854 C T 2.70E-05 Urinary metabolites / / 21572414 rs7642777 chr3 176644316 A G 2.70E-05 Urinary metabolites / / 21572414 rs9879251 chr3 176645087 A G 2.70E-05 Urinary metabolites / / 21572414 rs10936919 chr3 176645435 G T 2.70E-05 Urinary metabolites / / 21572414 rs6784900 chr3 176647385 C T 8.51E-05 Major depressive disorder / / 19107115 rs9869671 chr3 176650834 G A 2.70E-05 Urinary metabolites / / 21572414 rs9817921 chr3 176650849 T C 2.70E-05 Urinary metabolites / / 21572414 rs6803282 chr3 176691008 A G 1.60E-05 Urinary metabolites / / 21572414 rs11916879 chr3 176703201 A G 1.30E-05 Urinary metabolites / / 21572414 rs13072667 chr3 176706602 C A 5.22E-04 Smoking initiation / / 24665060 rs6792256 chr3 176730199 G A 8.87E-05 Schizophrenia / / 20185149 rs6768711 chr3 176778098 G A 3.63E-05 Schizophrenia TBL1XR1 intron 20185149 rs1201284 chr3 176807314 G A 1.76E-05 Alcohol dependence TBL1XR1 intron 19581569 rs1201292 chr3 176820705 A G 3.80E-05 Lung cancer TBL1XR1 intron 18385738 rs1209035 chr3 176827927 T C 3.96E-05 Alcohol dependence TBL1XR1 intron 19581569 rs1201296 chr3 176830302 G A 2.40E-05 Lung cancer TBL1XR1 intron 18385738 rs1950081 chr3 176837749 G A 2.90E-05 Lung cancer TBL1XR1 intron 18385738 rs2141599 chr3 176842475 T C 3.41E-04 Smoking initiation TBL1XR1 intron 24665060 rs7426456 chr3 176859444 C T 6.02E-04 Smoking initiation TBL1XR1 intron 24665060 rs7632766 chr3 176868053 T C 9.73E-04 Alcohol dependence TBL1XR1 intron 21314694 rs6443429 chr3 176869498 A C 2.52E-04 Longevity TBL1XR1 intron 22279548 rs7426956 chr3 176894837 C T 6.61E-11 Narcolepsy TBL1XR1 intron 19629137 rs6780461 chr3 176947302 A C 1.59E-04 Multiple complex diseases / / 17554300 rs2862647 chr3 176948789 T C 6.65E-04 Rheumatoid arthritis / / 21452313 rs12629106 chr3 177095072 C T 4.00E-06 Systemic lupus erythematosus / / 21408207 rs9850957 chr3 177113056 C T 4.48E-04 Alcohol dependence / / 20201924 rs9850957 chr3 177113056 C T 7.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9877175 chr3 177170859 A G 3.68E-04 Multiple complex diseases LINC00578 intron 17554300 rs4539982 chr3 177171101 G A 7.51E-04 Multiple complex diseases LINC00578 intron 17554300 rs7632844 chr3 177177991 G A 8.73E-05 Cognitive test performance LINC00578 intron 20125193 rs9835831 chr3 177191841 T C 1.00E-04 Prostate cancer LINC00578 intron 21743057 rs1995242 chr3 177196081 C T 5.26E-05 Coronary heart disease LINC00578 intron pha003030 rs1995241 chr3 177196292 T C 1.00E-04 Prostate cancer LINC00578 intron 21743057 rs12696443 chr3 177197754 C T 1.00E-04 Prostate cancer LINC00578 intron 21743057 rs17631673 chr3 177198248 T G 1.80E-05 Urinary metabolites LINC00578 intron 21572414 rs10513754 chr3 177199160 A G 2.80E-05 Breast cancer and prostate cancer LINC00578 intron 17903305 rs6794095 chr3 177211328 T G 3.94E-04 Depression (quantitative trait) LINC00578 intron 20800221 rs1392219 chr3 177222429 C T 5.00E-06 Alcohol consumption LINC00578 intron 23743675 rs7615202 chr3 177223067 T C 8.67E-05 Depression (quantitative trait) LINC00578 intron 20800221 rs7615202 chr3 177223067 T C 1.20E-04 Alcohol consumption LINC00578 intron 23743675 rs13095990 chr3 177223930 C T 2.23E-04 Depression (quantitative trait) LINC00578 intron 20800221 rs6793094 chr3 177226809 A T 2.25E-04 Depression (quantitative trait) LINC00578 intron 20800221 rs59539624 chr3 177227517 G T 1.42E-05 Alcohol consumption LINC00578 intron 23743675 rs4857700 chr3 177228494 A G 3.69E-04 Rheumatoid arthritis LINC00578 intron 21452313 rs1353899 chr3 177228979 T G 4.00E-06 Alcohol consumption LINC00578 intron 23743675 rs6776893 chr3 177230565 T C 3.09E-04 Depression (quantitative trait) LINC00578 intron 20800221 rs16828059 chr3 177241232 T C 5.34E-05 Bipolar disorder LINC00578 intron 22925353 rs2863009 chr3 177254210 G A 7.80E-04 Suicide attempts in bipolar disorder LINC00578 intron 21423239 rs2863009 chr3 177254210 G A 4.83E-04 Rheumatoid arthritis LINC00578 intron 21452313 rs3913367 chr3 177262427 G T 9.80E-05 Insulin resistance LINC00578 intron 21901158 rs11715199 chr3 177274479 C G 4.89E-06 Ankle-brachial index LINC00578 intron 22199011 rs7653765 chr3 177277803 A G 7.86E-08 White blood cell count LINC00578 intron 21738479 rs644695 chr3 177291697 A G 5.00E-06 Major depressive disorder (broad) LINC00578 intron 20038947 rs6763998 chr3 177301513 C A 3.78E-06 White blood cell count LINC00578 intron 21738479 rs7620503 chr3 177304298 C T 1.00E-08 Corneal structure LINC00578 intron 23291589 rs539967 chr3 177305797 A C 4.85E-04 Suicide attempts in bipolar disorder LINC00578 intron 21041247 rs4857716 chr3 177312876 C T 2.31E-05 Suicide attempts in bipolar disorder LINC00578 intron 21041247 rs4241484 chr3 177316085 C A 2.12E-05 Suicide attempts in bipolar disorder LINC00578 intron 21041247 rs11716881 chr3 177321475 G A 2.11E-05 Suicide attempts in bipolar disorder LINC00578 intron 21041247 rs6766914 chr3 177322867 T C 2.13E-05 Suicide attempts in bipolar disorder LINC00578 intron 21041247 rs9855198 chr3 177324996 G A 8.82E-04 Suicide attempts in bipolar disorder LINC00578 intron 21041247 rs1466846 chr3 177333006 A G 1.98E-06 Suicide attempts in bipolar disorder LINC00578 intron 21041247 rs9825151 chr3 177335249 T C 9.37E-06 Suicide attempts in bipolar disorder LINC00578 intron 21041247 rs9880740 chr3 177335305 G A 1.23E-05 Suicide attempts in bipolar disorder LINC00578 intron 21041247 rs16828300 chr3 177337534 G A 0.000489 Breast cancer early age of onset LINC00578 intron 18463975 rs1875102 chr3 177342468 T C 1.55E-05 Suicide attempts in bipolar disorder LINC00578 intron 21041247 rs17633881 chr3 177346889 T C 9.24E-05 Hemoglobin LINC00578 intron pha003098 rs2133591 chr3 177347042 A G 3.27E-04 Smoking quantity LINC00578 intron 24665060 rs10513752 chr3 177359599 A G 9.24E-05 Hemoglobin LINC00578 intron pha003098 rs4857724 chr3 177364745 T C 1.39E-04 Multiple complex diseases LINC00578 intron 17554300 rs4857616 chr3 177368489 A G 8.82E-04 Type 2 diabetes LINC00578 intron 17463246 rs4857616 chr3 177368489 A G 5.75E-04 Multiple complex diseases LINC00578 intron 17554300 rs570687536 chr3 177368489 A ATATG 8.82E-04 Type 2 diabetes LINC00578 intron 17463246 rs570687536 chr3 177368489 A ATATG 5.75E-04 Multiple complex diseases LINC00578 intron 17554300 rs1500048 chr3 177420809 T A 5.16E-04 Smoking initiation LINC00578 intron 24665060 rs6788878 chr3 177443968 C A 3.17E-05 Odorant perception LINC00578 intron 23910658 rs6443486 chr3 177449828 A C 2.09E-04 Glycosylated haemoglobin levels LINC00578 intron 17255346 rs7426990 chr3 177461731 G A 7.77E-05 Glycosylated haemoglobin levels LINC00578 intron 17255346 rs7430873 chr3 177461858 A T 6.06E-05 Glycosylated haemoglobin levels LINC00578 intron 17255346 rs9815071 chr3 177462041 C A 2.39E-04 Glycosylated haemoglobin levels LINC00578 intron 17255346 rs1984961 chr3 177510103 C T 1.37E-06 Potassium levels / / pha003086 rs9861373 chr3 177527363 A G 7.57E-06 Potassium levels / / pha003086 rs16828677 chr3 177556896 G C 1.52E-04 Aortic root size / / 21223598 rs10936959 chr3 177591074 A G 6.19E-05 Cognitive performance / / 19734545 rs10936959 chr3 177591074 A G 4.85E-05 Cortisol secretion,in saliva / / 21316860 rs10936959 chr3 177591074 A G 7.95E-05 Height / / pha003010 rs7612209 chr3 177596989 G A 4.00E-06 Cognitive performance / / 19734545 rs11922170 chr3 177667289 G T 1.96E-05 Post-operative nausea and vomiting / / 21694509 rs6443523 chr3 177705068 G A 3.66E-05 Alcohol and nictotine co-dependence / / 20158304 rs6443530 chr3 177764782 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7634528 chr3 177766464 T G 1.00E-06 Myopia (pathological) / / 23049088 rs2902414 chr3 177767236 A C 1.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10212387 chr3 177779943 A C 2.83E-06 White blood cell count / / 21738479 rs1982821 chr3 177793107 G T 4.00E-06 Uric acid levels / / 21294900 rs13101116 chr3 177816610 T C 3.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs13096683 chr3 177819411 G A 6.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs1489625 chr3 177822378 C T 2.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs9883878 chr3 177855632 G A 1.00E-06 Asthma (childhood onset) / / 23829686 rs6782817 chr3 177856521 C A 2.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs6781544 chr3 177861254 C G 8.84E-05 Suicide attempts in bipolar disorder / / 21423239 rs6805875 chr3 177861507 A T 1.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs1489626 chr3 177861884 A G 1.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs6800711 chr3 177862628 T C 2.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs2863110 chr3 177864536 C A 1.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs1844389 chr3 177864660 A T 1.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs16829147 chr3 177865602 C T 2.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs16829162 chr3 177869073 T C 9.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs4603971 chr3 177902467 G A 7.57E-06 Hearing function / / 21493956 rs7653036 chr3 177920208 G A 6.15E-05 Creatinine levels / / pha003069 rs62282665 chr3 177926294 C T 0.0000504 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62282669 chr3 177929293 T C 0.0000898 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62282670 chr3 177929294 A G 0.0000902 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62282671 chr3 177929711 C G 0.0000244 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6793822 chr3 177931471 T A 0.0000415 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4566554 chr3 177934259 G C 0.0000187 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6772577 chr3 177935554 A G 0.0000259 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6810087 chr3 177944933 G A 0.0000268 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9817039 chr3 177948377 T G 0.000024 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9866767 chr3 177954491 A T 0.0000309 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4857761 chr3 177957401 T C 0.0000325 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7622819 chr3 177959697 G C,T 0.0000702 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13068026 chr3 177964796 C G 0.0000987 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9862444 chr3 177967690 T C 0.0000973 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9848064 chr3 177968730 G A 0.0000953 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4241486 chr3 177969396 C T 0.000092 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4635726 chr3 177969526 C A 0.0000915 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6808703 chr3 177970694 T C 5.19E-05 Creatinine levels / / pha003069 rs6808802 chr3 177970767 T G 0.0000992 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9823729 chr3 177974321 T C 0.0001 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6443539 chr3 177976063 C G 0.0000299 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9811836 chr3 177977475 T G 0.0000262 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35980113 chr3 177984839 A G 0.0000237 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs371232344 chr3 177984839 AGAGT A 0.0000237 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4857763 chr3 177985395 T C 0.0000244 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4857640 chr3 177987724 T C 0.0000191 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7629595 chr3 177990186 A G 0.0000238 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9857322 chr3 177990968 T C 0.0000281 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11712746 chr3 177991895 G A 0.0000281 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9879640 chr3 177997568 A G 7.29E-05 Osteoarthritis / / 19508968 rs9879640 chr3 177997568 A G 0.0000373 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2863129 chr3 178005783 T C 0.0000428 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4857765 chr3 178008970 G T 0.0000274 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6808737 chr3 178014562 G C 4.26E-05 Intracerebral hemorrhage / / 24656865 rs6808895 chr3 178014909 C T 4.37E-05 Intracerebral hemorrhage / / 24656865 rs2863125 chr3 178017473 C T 2.48E-05 Intracerebral hemorrhage / / 24656865 rs2575992 chr3 178030432 A T 1.47E-05 Intracerebral hemorrhage / / 24656865 rs2583480 chr3 178030492 C G 1.95E-05 Intracerebral hemorrhage / / 24656865 rs1961019 chr3 178052017 G A 9.09E-05 Personality dimensions / / 18957941 rs2583482 chr3 178083676 G T 4.95E-05 Intracerebral hemorrhage / / 24656865 rs16829380 chr3 178096195 A G 5.64E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7650856 chr3 178097463 A G 7.68E-04 Multiple complex diseases / / 17554300 rs17647871 chr3 178164238 G A 3.27E-05 Multiple complex diseases / / 17554300 rs1441886 chr3 178168544 G A 2.36E-04 Multiple complex diseases / / 17554300 rs1387129 chr3 178183370 T C 4.16E-05 Cognitive performance / / 19734545 rs1016911 chr3 178196694 G A 8.44E-05 Multiple complex diseases / / 17554300 rs1551850 chr3 178197021 G A 1.31E-05 Serum metabolites / / 19043545 rs6797870 chr3 178199837 A G 1.31E-05 Serum metabolites / / 19043545 rs9832697 chr3 178261186 C T 1.13E-05 C-reactive protein KCNMB2 intron 22492993 rs1382041 chr3 178291630 G A 3.25E-05 Bipolar disorder,affective KCNMB2 intron 20528957 rs6443547 chr3 178291847 T G 6.54E-05 Bipolar disorder,affective KCNMB2 intron 20528957 rs9290656 chr3 178292353 T C 3.34E-06 Bipolar disorder KCNMB2 intron 19259986 rs2054399 chr3 178341582 G A 1.00E-06 Bipolar disorder and schizophrenia KCNMB2 intron 22688191 rs9290659 chr3 178344908 T C 4.71E-06 C-reactive protein KCNMB2 intron 22492993 rs9847335 chr3 178357197 A G 1.86E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) KCNMB2 intron 23648065 rs1600052 chr3 178360978 C G 6.04E-04 Multiple complex diseases KCNMB2 intron 17554300 rs7615444 chr3 178365840 A C 4.79E-04 Multiple complex diseases KCNMB2 intron 17554300 rs7615444 chr3 178365840 A C 5.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) KCNMB2 intron 23648065 rs6775196 chr3 178392199 T C 2.54E-05 Odorant perception KCNMB2 intron 23910658 rs13100616 chr3 178399551 A G 9.00E-07 Amyotrophic lateral sclerosis (sporadic) KCNMB2 intron 24529757 rs7427433 chr3 178429263 C T 6.41E-04 Taste perception KCNMB2 intron 22132133 rs9290663 chr3 178429939 A T 6.00E-06 Acute lymphoblastic leukemia (childhood) KCNMB2 intron 19684603 rs9290663 chr3 178429939 A T 6.00E-06 Nasopharyngeal carcinoma KCNMB2 intron 20512145 rs9825087 chr3 178430670 C G 2.34E-04 Response to radiotherapy in cancer (late toxicity) KCNMB2 intron 24785509 rs6443571 chr3 178449906 G A 1.89E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) KCNMB2 intron 23648065 rs4260410 chr3 178469932 C T 2.26E-05 Serum metabolites KCNMB2 intron 19043545 rs6798237 chr3 178473222 G C 1.21E-04 Multiple complex diseases KCNMB2 intron 17554300 rs11924694 chr3 178502029 C T 1.96E-05 Multiple complex diseases KCNMB2 intron 17554300 rs4513434 chr3 178524747 G A 5.09E-04 Multiple complex diseases KCNMB2 intron 17554300 rs4624543 chr3 178544317 T C 4.33E-04 Smoking initiation KCNMB2 intron 24665060 rs4549252 chr3 178563170 G T 3.14E-05 Smoking initiation / / 24665060 rs6443599 chr3 178590769 G A 1.97E-04 Heart Failure / / pha002884 rs12495431 chr3 178597521 C T 3.07E-04 Obesity (extreme) / / 21935397 rs6804849 chr3 178620709 G A 4.60E-04 Obesity (extreme) / / 21935397 rs9882284 chr3 178631131 T C 5.27E-04 Tourette syndrome / / 22889924 rs9872496 chr3 178638752 C T 4.73E-04 Obesity (extreme) / / 21935397 rs4362766 chr3 178680442 T C 7.15E-05 Body Mass Index / / pha003014 rs6797848 chr3 178686039 A G 2.15E-04 Type 2 diabetes / / 17463246 rs6794279 chr3 178688208 G A 3.00E-04 Type 2 diabetes / / 17463246 rs6794279 chr3 178688208 G A 8.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs7611854 chr3 178689595 T C 9.56E-04 Type 2 diabetes / / 17463246 rs11918186 chr3 178700766 T C 3.00E-04 Type 2 diabetes / / 17463246 rs11918186 chr3 178700766 T C 8.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs11716079 chr3 178706028 C T 6.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs10936987 chr3 178709464 C T 3.00E-04 Type 2 diabetes / / 17463246 rs10936988 chr3 178712559 G T 3.00E-04 Type 2 diabetes / / 17463246 rs4955793 chr3 178782021 C T 2.00E-06 Post-traumatic stress disorder (asjusted for relatedness) ZMAT3 intron 23726511 rs9861291 chr3 178791678 C G 0.0000747 5-fluorouracil induced haematologic in response to colorectal cancer treatment / / 22310351 rs17592582 chr3 178910350 T C 1.90E-04 Alcohol dependence PIK3CA intron 20201924 rs3729693 chr3 178948196 A G 3.27E-09 Triglycerides PIK3CA intron 23063622 rs3729693 chr3 178948196 A G 8.40E-13 HDL cholesterol PIK3CA intron 23063622 rs10804876 chr3 178975408 T C 7.24E-04 Amyotrophic Lateral Sclerosis KCNMB3 intron 17362836 rs10804876 chr3 178975408 T C 2.00E-05 Urinary metabolites KCNMB3 intron 21572414 rs1468922 chr3 178982819 T G 2.10E-05 Urinary metabolites KCNMB3 intron 21572414 rs1468924 chr3 178982969 G T 7.01E-04 Parkinson's disease KCNMB3 intron 17052657 rs1468924 chr3 178982969 G T 7.48E-04 Amyotrophic Lateral Sclerosis KCNMB3 intron 17362836 rs115965187 chr3 178983060 C T 6.00E-06 PR interval in Tripanosoma cruzi seropositivity KCNMB3 intron 24324551 rs6781173 chr3 178988564 T C 8.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9290675 chr3 179006633 T C 7.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs6762743 chr3 179012000 C T 8.10E-07 Celiac disease / / 17558408 rs9290676 chr3 179012129 T G 2.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9290678 chr3 179017020 A G 1.10E-06 Celiac disease / / 17558408 rs6794192 chr3 179027813 T C 4.37E-05 HIV-1 viral setpoint / / 22174851 rs3806685 chr3 179039751 A G 8.75E-04 Multiple complex diseases / / 17554300 rs3806685 chr3 179039751 A G 2.70E-05 Urinary metabolites / / 21572414 rs3806685 chr3 179039751 A G 2.40E-06 Breast cancer / / 22452962 rs6786409 chr3 179045493 T C 3.90E-05 HIV-1 viral setpoint ZNF639 intron 22174851 rs12491673 chr3 179050721 T C 4.32E-06 Blood Pressure ZNF639 intron pha003048 rs10460887 chr3 179056135 A G 2.00E-05 Insulin response / / 19430760 rs2111534 chr3 179090772 G A 2.46E-04 Alzheimer's disease (late onset) MFN1 intron 21379329 rs7618348 chr3 179144739 C T 1.16E-04 Alzheimer's disease (late onset) GNB4 intron 21379329 rs1344538 chr3 179163520 G A 2.50E-05 Urinary metabolites GNB4 intron 21572414 rs7612445 chr3 179172979 G T 1.76E-04 Alzheimer's disease (late onset) / / 21379329 rs7612445 chr3 179172979 G T 2.00E-14 Heart rate / / 23583979 rs2339802 chr3 179228364 C T 8.83E-04 White matter integrity / / 22425255 rs9816801 chr3 179279381 G C 3.45E-07 Facial morphology / / 22341974 rs7650126 chr3 179286954 T C 7.84E-04 Insulin resistance ACTL6A intron 21901158 rs12632721 chr3 179288086 C T 4.31E-04 Smoking initiation ACTL6A intron 24665060 rs10513761 chr3 179288279 G A 7.77E-04 Smoking initiation ACTL6A intron 24665060 rs4855090 chr3 179288496 A G 7.77E-04 Smoking initiation ACTL6A intron 24665060 rs6790272 chr3 179289429 A C 3.34E-07 Facial morphology ACTL6A intron 22341974 rs4855092 chr3 179290093 G A 7.77E-04 Smoking initiation ACTL6A intron 24665060 rs2292907 chr3 179294352 C A 7.77E-04 Smoking initiation ACTL6A intron 24665060 rs3774260 chr3 179308309 C T 7.10E-04 Smoking initiation MRPL47 intron 24665060 rs2339843 chr3 179311981 T A 9.01E-04 Type 2 diabetes MRPL47 intron 17463246 rs2339843 chr3 179311981 T A 1.45E-04 Multiple complex diseases MRPL47 intron 17554300 rs9831673 chr3 179313562 T C 8.93E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MRPL47 intron 21844884 rs9831673 chr3 179313562 T C 3.32E-07 Facial morphology MRPL47 intron 22341974 rs4855096 chr3 179315767 T G 3.32E-07 Facial morphology MRPL47 intron 22341974 rs2339844 chr3 179322385 A C 8.30E-04 Smoking initiation MRPL47 missense 24665060 rs7630170 chr3 179329595 G A 3.34E-07 Facial morphology NDUFB5 intron 22341974 rs9883607 chr3 179330692 A G 3.35E-07 Facial morphology NDUFB5 intron 22341974 rs6775695 chr3 179352174 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6443664 chr3 179385000 C T 1.99E-05 Calcium levels USP13 intron pha003085 rs4854942 chr3 179388406 C T 7.88E-04 Type 2 diabetes USP13 intron 17463246 rs12636924 chr3 179390043 T C 5.20E-06 Urinary metabolites USP13 intron 21572414 rs4854945 chr3 179391320 T G 8.38E-05 Non-alcoholic fatty liver disease histology (other) USP13 intron 20708005 rs4855104 chr3 179394123 T G 8.76E-05 Non-alcoholic fatty liver disease histology (other) USP13 intron 20708005 rs6807974 chr3 179399946 A G 2.22E-12 Lymphocyte counts USP13 intron 22286170 rs9816744 chr3 179404673 C T 6.26E-04 Smoking quantity USP13 intron 24665060 rs61760203 chr3 179408054 C T 0.0000663 Nonsyndromic striae distensae (stretch marks) USP13 missense 23633020 rs2284887 chr3 179425147 A G 2.52E-05 Mammographic density USP13 intron 22532574 rs2268939 chr3 179425959 A G 3.30E-05 Mammographic density USP13 intron 22532574 rs4854951 chr3 179436298 C T 9.98E-05 Non-alcoholic fatty liver disease histology (other) USP13 intron 20708005 rs116049736 chr3 179438464 C T 0.00000573 Nonsyndromic striae distensae (stretch marks) USP13 intron 23633020 rs2268937 chr3 179448869 C G 8.47E-05 Mammographic density USP13 intron 22532574 rs17195948 chr3 179455796 G A 1.02E-06 Vascular dementia USP13 intron 22116812 rs3732992 chr3 179474767 A G 5.13E-04 Type 2 diabetes USP13 intron 17463246 rs1024852 chr3 179482482 T C 6.91E-06 Vascular dementia USP13 intron 22116812 rs13327135 chr3 179495657 A G 1.07E-04 Smoking initiation USP13 intron 24665060 rs759596 chr3 179498965 C A 7.90E-05 Smoking initiation USP13 intron 24665060 rs17195983 chr3 179499215 G T 2.59E-04 Smoking initiation USP13 intron 24665060 rs12107867 chr3 179499960 G A 5.32E-04 Smoking initiation USP13 intron 24665060 rs16848333 chr3 179500901 A C 2.89E-05 Smoking initiation USP13 intron 24665060 rs9814513 chr3 179504309 C T 2.23E-04 Smoking initiation USP13 UTR-3 24665060 rs3774227 chr3 179517671 C T 4.97E-04 Type 2 diabetes PEX5L UTR-3 17463246 rs1442495 chr3 179521935 C T 2.64E-04 Type 2 diabetes PEX5L intron 17463246 rs9845643 chr3 179531062 A G 8.58E-05 Obsessive-compulsive disorder PEX5L intron 24821223 rs6443673 chr3 179566283 C T 5.19E-05 Alcohol consumption PEX5L intron 23743675 rs7640024 chr3 179568940 G A 4.54E-05 Alcohol consumption PEX5L intron 23743675 rs9823402 chr3 179569548 G A 4.73E-05 Alcohol consumption PEX5L intron 23743675 rs9290684 chr3 179606442 G T 2.95E-05 Duodenal ulcer PEX5L intron 22387998 rs3774247 chr3 179607186 G C 7.14E-04 Type 2 diabetes PEX5L intron 17463246 rs9842394 chr3 179613236 C T 2.68E-05 Attention deficit hyperactivity disorder PEX5L intron 22420046 rs11708154 chr3 179635808 T C 3.33E-05 Attention deficit hyperactivity disorder PEX5L intron 22420046 rs3821798 chr3 179639199 T C 3.00E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PEX5L intron 20031582 rs7630877 chr3 179661318 G A 7.00E-06 Type 2 diabetes PEX5L intron 21490949 rs7630877 chr3 179661318 G A 5.22E-05 Attention deficit hyperactivity disorder PEX5L intron 22420046 rs9842133 chr3 179664102 T C 4.20E-05 Prostate cancer PEX5L intron 22923026 rs9842133 chr3 179664102 T C 4.00E-12 Blood metabolite levels PEX5L intron 24816252 rs7623941 chr3 179666018 A C 7.50E-05 Prostate cancer PEX5L intron 22923026 rs1524516 chr3 179666298 A G 6.47E-05 Prostate cancer PEX5L intron 22923026 rs9825224 chr3 179675554 C A 8.99E-05 Hypertension PEX5L intron 19609347 rs13096920 chr3 179703343 G C 1.53E-04 Insulin resistance PEX5L intron 21901158 rs1522116 chr3 179706448 C T 3.69E-05 Depression (quantitative trait) PEX5L intron 23290196 rs1522115 chr3 179706629 A C 2.48E-04 Type 2 diabetes PEX5L intron 17463246 rs940522 chr3 179712132 C A 3.60E-04 Type 2 diabetes PEX5L intron 17463246 rs7645574 chr3 179736342 C T 8.84E-04 Acute lymphoblastic leukemia (childhood) PEX5L intron 22076464 rs7618538 chr3 179776782 C G 4.54E-04 Type 2 diabetes / / 17463246 rs6781524 chr3 179777942 A G 7.64E-04 Type 2 diabetes / / 17463246 rs10513767 chr3 179815191 G A 5.80E-04 Multiple complex diseases / / 17554300 rs17693325 chr3 179819447 T C 7.33E-04 Multiple complex diseases / / 17554300 rs4855140 chr3 179826491 C A 9.61E-05 Blood Pressure / / pha003050 rs1522118 chr3 179827381 A G 9.37E-05 Blood Pressure / / pha003050 rs1522122 chr3 179829075 A C 4.43E-05 Blood Pressure / / pha003050 rs1525270 chr3 179934679 T C 4.03E-05 Multiple complex diseases / / 17554300 rs3914869 chr3 180017244 T G 3.68E-05 Multiple complex diseases / / 17554300 rs3849426 chr3 180023747 A G 1.47E-06 Multiple complex diseases / / 17554300 rs11705819 chr3 180038514 C T 1.40E-06 Urinary metabolites / / 21572414 rs11921783 chr3 180041532 T C 1.30E-06 Urinary metabolites / / 21572414 rs1402225 chr3 180066018 C T 2.46E-04 Multiple complex diseases / / 17554300 rs7611300 chr3 180108963 C A,T 0.00000163 Colorectal cancer / / 22532847 rs7611300 chr3 180108963 C A,T 0.00000174 Colorectal cancer (males) / / 22532847 rs16831570 chr3 180152340 A C 1.29E-04 Multiple complex diseases / / 17554300 rs7615390 chr3 180193022 A C 4.94E-04 Multiple complex diseases / / 17554300 rs904241 chr3 180264743 A C 8.19E-04 Multiple complex diseases / / 17554300 rs6443702 chr3 180307628 C T 2.10E-04 Multiple complex diseases / / 17554300 rs1532485 chr3 180319981 G T 2.32E-04 Multiple complex diseases TTC14 UTR-5 17554300 rs145653627 chr3 180321090 T G 0.00043 Breast cancer TTC14 missense 23555315 rs9865325 chr3 180514892 T C 2.43E-05 Height / / 17255346 rs6443721 chr3 180521624 A G 1.68E-05 Height / / 17255346 rs16832027 chr3 180523951 C A 1.83E-06 Cognitive impairment induced by topiramate / / 22091778 rs7640601 chr3 180524764 G C 7.30E-07 Schizophrenia (treatment refractory) / / 22479419 rs9869882 chr3 180531941 A G 3.80E-07 Schizophrenia (treatment refractory) / / 22479419 rs9838229 chr3 180533251 C A 2.10E-07 Schizophrenia (treatment refractory) / / 22479419 rs9838229 chr3 180533251 C A 0.0000289 Schizophrenia / / 23637625 rs4488266 chr3 180535405 C T 3.80E-07 Schizophrenia (treatment refractory) / / 22479419 rs2139551 chr3 180536365 A G 1.80E-07 Schizophrenia (treatment refractory) / / 22479419 rs10937048 chr3 180539392 A G 3.90E-07 Schizophrenia (treatment refractory) / / 22479419 rs6782299 chr3 180550702 G T 1.00E-07 Schizophrenia / / 19571811 rs6782299 chr3 180550702 G T 2.00E-04 Asthma (childhood onset) / / 21359210 rs6782299 chr3 180550702 G T 1.40E-07 Schizophrenia (treatment refractory) / / 22479419 rs1879248 chr3 180551214 C T 7.00E-06 Schizophrenia / / 21926974 rs1879248 chr3 180551214 C T 1.50E-07 Schizophrenia (treatment refractory) / / 22479419 rs1915104 chr3 180556904 C A 1.50E-07 Schizophrenia (treatment refractory) / / 22479419 rs6767560 chr3 180566221 G T 4.00E-07 Schizophrenia (treatment refractory) / / 22479419 rs6763026 chr3 180570320 C T 1.81E-05 Alzheimer's disease (late onset) / / 21379329 rs2337743 chr3 180576673 T A 1.60E-07 Schizophrenia (treatment refractory) / / 22479419 rs9827910 chr3 180582496 T A 9.76E-04 Obesity (extreme) / / 21935397 rs1607678 chr3 180584718 C T 1.70E-07 Schizophrenia (treatment refractory) / / 22479419 rs1011927 chr3 180636744 A G 1.88E-06 Schizophrenia FXR1 intron 19571809 rs1805572 chr3 180647263 T C 5.03E-06 Schizophrenia FXR1 intron 19571809 rs1805614 chr3 180673421 T C 4.92E-04 Obesity (extreme) FXR1 intron 21935397 rs1010471 chr3 180691092 G A 3.20E-06 Schizophrenia FXR1 intron 21791550 rs1010471 chr3 180691092 G A 6.50E-07 Schizophrenia (treatment refractory) FXR1 intron 22479419 rs1010471 chr3 180691092 G A 0.0000032 Psychosis FXR1 intron 23164818 rs1010471 chr3 180691092 G A 8.11E-05 Gallbladder disease FXR1 intron pha001403 rs9810292 chr3 180714307 T G 1.80E-05 Urinary metabolites / / 21572414 rs1805610 chr3 180772241 C T 5.95E-05 Schizophrenia / / 19571809 rs1806190 chr3 180778763 T C 6.06E-05 Schizophrenia / / 19571809 rs9873522 chr3 180786749 C A 1.70E-04 Insulin resistance / / 21901158 rs2718767 chr3 180910040 T G 4.24E-05 Heart rate / / 23583979 rs13316409 chr3 180949215 A G 6.15E-04 Multiple complex diseases / / 17554300 rs7619173 chr3 180996959 C T 2.00E-05 Bipolar I disorder / / 24444492 rs4608697 chr3 181011601 T C 9.10E-06 Urinary metabolites / / 21572414 rs7651261 chr3 181023400 C T 1.80E-04 Bipolar I disorder / / 24444492 rs13081180 chr3 181098717 C T 9.78E-04 Obesity (extreme) / / 21935397 rs11718683 chr3 181099673 A T 9.30E-04 Obesity (extreme) / / 21935397 rs12636303 chr3 181104283 G A 8.60E-04 Obesity (extreme) / / 21935397 rs1518932 chr3 181119272 G C 6.74E-04 Obesity (extreme) / / 21935397 rs9821187 chr3 181137068 G T 6.02E-04 Obesity (extreme) / / 21935397 rs9820920 chr3 181137091 C T 5.97E-04 Obesity (extreme) / / 21935397 rs10937057 chr3 181150062 G A 7.90E-04 Obesity (extreme) / / 21935397 rs16832504 chr3 181168699 G A 7.48E-04 Obesity (extreme) / / 21935397 rs11717567 chr3 181186359 C T 7.02E-04 Obesity (extreme) / / 21935397 rs2199718 chr3 181204102 G T 1.10E-04 Iron levels / / pha002876 rs12485391 chr3 181205593 C A 5.74E-06 Schizophrenia / / 21926974 rs766743 chr3 181247797 T C 4.95E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6779474 chr3 181255808 T C 9.90E-05 Asthma / / 20159242 rs16832543 chr3 181272496 C G 6.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs16832544 chr3 181277708 G A 3.43E-04 Substance dependence / / 21818250 rs6763311 chr3 181277913 A G 5.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs6443745 chr3 181278376 T G 8.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs6443746 chr3 181278496 C T 6.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs9839776 chr3 181311567 C T 3.00E-07 Anorexia nervosa / / 24514567 rs13086529 chr3 181340141 A G 4.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SOX2-OT intron 20877124 rs13086529 chr3 181340141 A G 6.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) SOX2-OT intron 23648065 rs12491867 chr3 181448558 G A 2.52E-04 Celiac disease SOX2-OT intron 23936387 rs6765739 chr3 181457601 T C 4.06E-05 Body Mass Index / / pha003009 rs6765739 chr3 181457601 T C 5.54E-05 Body Mass Index / / pha003014 rs6765739 chr3 181457601 T C 8.32E-05 Weight / / pha003026 rs1345415 chr3 181477410 T C 4.19E-04 Rheumatoid arthritis / / 21452313 rs9840545 chr3 181484270 A C 4.70E-05 Lung cancer / / 18385738 rs2339460 chr3 181524517 T C 2.61E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1420639 chr3 181533482 A G 5.10E-04 Multiple complex diseases / / 17554300 rs11922688 chr3 181573945 A G 6.78E-05 Lipoproteins / / pha003079 rs833292 chr3 181581183 A T 9.19E-04 Multiple complex diseases / / 17554300 rs833283 chr3 181590598 G C 9.33E-05 Serum metabolites / / 19043545 rs12486193 chr3 181592172 A G 1.90E-05 Urinary metabolites / / 21572414 rs864420 chr3 181614307 A G 6.44E-05 Bipolar disorder,affective / / 20528957 rs9290731 chr3 181619312 C G 1.19E-04 Bipolar disorder,affective / / 20528957 rs1392340 chr3 181659359 C T 7.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6773663 chr3 181676929 A G 6.70E-05 Bipolar disorder,affective / / 20528957 rs13065735 chr3 181680609 A G 1.04E-04 Fibrinogen / / 17255346 rs2339521 chr3 181691296 G A 5.44E-04 Multiple complex diseases / / 17554300 rs3844288 chr3 181706602 G A 1.67E-04 Bipolar disorder,affective / / 20528957 rs11917584 chr3 181715549 A T 7.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs1561072 chr3 181752619 A G 5.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11926120 chr3 181775922 C T 1.44E-05 Age-related macular degeneration / / pha000001 rs16832889 chr3 181851284 A C 1.00E-06 Estradiol plasma levels (breast cancer) / / 23518928 rs377443148 chr3 181969352 G GA 3.29E-05 Systemic lupus erythematosus / / pha002867 rs559996376 chr3 181969352 G GA 3.29E-05 Systemic lupus erythematosus / / pha002867 rs6791663 chr3 181969352 G A 3.29E-05 Systemic lupus erythematosus / / pha002867 rs2129824 chr3 181991496 C T 7.59E-04 Smoking initiation / / 24665060 rs2129824 chr3 181991496 C T 4.20E-05 Cognitive function / / 24684796 rs16832987 chr3 181993707 C T 2.83E-04 Smoking initiation / / 24665060 rs7651164 chr3 182005354 T G 7.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs12631861 chr3 182024376 C A 8.70E-04 Coronary Artery Disease / / 17634449 rs4859215 chr3 182038330 T C 7.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs10513787 chr3 182045590 G C 3.48E-04 Coronary Artery Disease / / 17634449 rs10513787 chr3 182045590 G C 2.42E-05 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia / / 24039173 rs7650249 chr3 182049514 G A 5.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs6788702 chr3 182051041 A G 5.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs11916493 chr3 182052794 C T 3.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs7632661 chr3 182053973 T G 5.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs7624385 chr3 182055057 G A 3.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs6443799 chr3 182059278 T C 6.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs1006048 chr3 182070444 C T 4.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs4859219 chr3 182073903 T C 4.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs2879539 chr3 182077798 G A 5.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs6803006 chr3 182078464 C T 6.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs7613345 chr3 182088108 T C 5.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs10513788 chr3 182121573 A T 5.00E-06 Cognitive function / / 24684796 rs6773839 chr3 182124101 G A 4.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs1906508 chr3 182124501 T C 4.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs17826716 chr3 182132052 T C 3.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs16833118 chr3 182132383 C T 7.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs1488135 chr3 182133422 G A 3.30E-05 Cognitive function / / 24684796 rs4859223 chr3 182138481 T A 7.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs1457578 chr3 182222315 T C 8.62E-04 Multiple complex diseases / / 17554300 rs12486463 chr3 182243381 T A 0.0000218 Panic disorder / / 23149450 rs12486463 chr3 182243381 T A 2.18E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs9833934 chr3 182243833 A G 3.92E-05 Cognitive impairment induced by topiramate / / 22091778 rs1457567 chr3 182245072 G A 0.0000141 Panic disorder / / 23149450 rs1457567 chr3 182245072 G A 1.41E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs7613189 chr3 182252137 G A 0.0000107 Panic disorder / / 23149450 rs7613189 chr3 182252137 G A 1.07E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs7615678 chr3 182252604 G T 0.00001 Panic disorder / / 23149450 rs7615678 chr3 182252604 G T 1.00E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs7622673 chr3 182255337 G A 0.0000174 Panic disorder / / 23149450 rs7622673 chr3 182255337 G A 1.74E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs1580194 chr3 182291291 G A 9.50E-04 Multiple complex diseases / / 17554300 rs3922915 chr3 182336422 G A 2.10E-05 Urinary metabolites / / 21572414 rs9862173 chr3 182347019 G A 2.24E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7649624 chr3 182349694 G A 8.52E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6766049 chr3 182370476 A T 3.40E-05 Multiple complex diseases / / 17554300 rs2717298 chr3 182398290 G C 3.15E-06 Phospholipid levels (plasma) / / 21829377 rs3109398 chr3 182402101 A C 3.77E-04 Alzheimer's disease / / 17998437 rs2717320 chr3 182410264 A T 6.77E-04 Type 2 diabetes / / 17463246 rs2700868 chr3 182440135 C T 6.56E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1523059 chr3 182453304 A G 8.01E-04 Type 2 diabetes / / 17463246 rs16833439 chr3 182454115 G T 4.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2700842 chr3 182456918 A G 6.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4384980 chr3 182459069 A C 3.20E-04 Alcohol dependence / / 20201924 rs4384980 chr3 182459069 A C 0.000000578 Alcohol dependence / / 23691058 rs9870317 chr3 182514636 A C 1.28E-04 Multiple complex diseases ATP11B intron 17554300 rs529155 chr3 182557989 T C 2.31E-04 Multiple complex diseases ATP11B intron 17554300 rs521829 chr3 182563768 C T 3.06E-04 Multiple complex diseases ATP11B intron 17554300 rs584074 chr3 182573482 A G 2.20E-04 Multiple complex diseases ATP11B intron 17554300 rs6800358 chr3 182586116 A G 4.57E-06 Insulin-related traits ATP11B intron 22791750 rs9870669 chr3 182625519 A C 7.80E-05 HIV-1 control ATP11B intron 20041166 rs2136331 chr3 182652017 G A 7.61E-04 Acute lung injury / / 22295056 rs2175065 chr3 182652077 G T 6.24E-04 Acute lung injury / / 22295056 rs2036711 chr3 182652845 G A 7.38E-04 Acute lung injury / / 22295056 rs1002767 chr3 182655858 T C 8.03E-04 Acute lung injury / / 22295056 rs9878775 chr3 182659953 T C 1.00E-06 Parkinson's disease / / 21738487 rs4859259 chr3 182664547 G A 1.96E-04 IgE levels DCUN1D1 intron 17255346 rs6786608 chr3 182669780 G A 7.46E-04 Acute lung injury DCUN1D1 intron 22295056 rs10937104 chr3 182670993 A T 3.72E-04 Acute lung injury DCUN1D1 intron 22295056 rs9814216 chr3 182671158 C T 1.07E-06 Parkinson's disease DCUN1D1 intron 21738487 rs7641401 chr3 182673196 C T 7.18E-04 Type 2 diabetes DCUN1D1 intron 17463246 rs13093344 chr3 182681074 G C 7.19E-04 Acute lung injury DCUN1D1 intron 22295056 rs4859147 chr3 182681853 T C 3.54E-04 Acute lung injury DCUN1D1 intron 22295056 rs4859148 chr3 182685440 G A 2.85E-05 Parkinson's disease DCUN1D1 intron 21738487 rs4859148 chr3 182685440 G A 6.41E-04 Acute lung injury DCUN1D1 intron 22295056 rs13099939 chr3 182710230 C A 5.39E-05 Parkinson's disease / / 21738487 rs13099939 chr3 182710230 C A 8.54E-04 Acute lung injury / / 22295056 rs9841498 chr3 182727097 C T 3.78E-07 Parkinson's disease / / 21738487 rs4074110 chr3 182728669 G A 7.58E-06 Parkinson's disease / / 21738487 rs9290751 chr3 182732230 A G 3.55E-04 Parkinson's disease / / 24842889 rs7640612 chr3 182743267 C A 1.21E-08 Parkinson's disease MCCC1 intron 21738487 rs7640612 chr3 182743267 C A 6.30E-04 Smoking initiation MCCC1 intron 24665060 rs2270968 chr3 182755209 T G 1.00E-16 Blood metabolite levels MCCC1 missense 24816252 rs10513789 chr3 182760073 T G 3.00E-10 Parkinson's disease MCCC1 intron 21738487 rs1502762 chr3 182763580 G A 2.47E-04 Multiple complex diseases MCCC1 intron 17554300 rs1502762 chr3 182763580 G A 4.39E-06 Parkinson's disease MCCC1 intron 21738487 rs13078931 chr3 182778941 G A 1.54E-05 Parkinson's disease MCCC1 intron 21738487 rs12638619 chr3 182799242 C T 9.83E-08 Parkinson's disease MCCC1 intron 21738487 rs9882050 chr3 182800039 C T 1.54E-06 Parkinson's disease MCCC1 intron 21738487 rs9822789 chr3 182802874 G T 1.72E-07 Parkinson's disease MCCC1 intron 21738487 rs12495806 chr3 182807992 G T 3.84E-05 Cognitive performance MCCC1 intron 19734545 rs11711441 chr3 182821275 G A 8.00E-12 Parkinson's disease / / 21292315 rs11711441 chr3 182821275 G A 6.92E-05 Prion diseases / / 22210626 rs11711441 chr3 182821275 G A 2.45E-10 Parkinson's disease / / 22438815 rs11711441 chr3 182821275 G A 2.10E-08 Parkinson's disease / / 22451204 rs7618830 chr3 182826316 A G 1.60E-05 Urinary metabolites / / 21572414 rs11716740 chr3 182831688 C T 1.93E-06 Parkinson's disease / / 21738487 rs500193 chr3 182846387 C T 1.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LAMP3 intron 20877124 rs3772715 chr3 182849564 C T 4.65E-07 Parkinson's disease LAMP3 intron 21738487 rs633725 chr3 182850258 C T 2.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LAMP3 intron 20877124 rs482912 chr3 182853670 T C 5.17E-07 Parkinson's disease LAMP3 missense 21738487 rs675924 chr3 182859401 G T 6.76E-05 Postoperative ventricular dysfunction LAMP3 intron 21980348 rs7639990 chr3 182861174 G T 2.99E-07 Schizophrenia LAMP3 intron 21926974 rs12493050 chr3 182865073 G A 6.78E-05 Parkinson's disease LAMP3 intron 21738487 rs589445 chr3 182868995 G A 3.66E-06 Multiple complex diseases LAMP3 intron 17554300 rs589445 chr3 182868995 G A 5.94E-04 Bipolar disorder,schizoaffective LAMP3 intron 19567891 rs683395 chr3 182869818 G A 5.00E-06 Bipolar disorder LAMP3 intron 17554300 rs683395 chr3 182869818 G A 6.00E-04 Bipolar disorder,schizoaffective LAMP3 intron 19567891 rs514636 chr3 182870436 G A 2.49E-06 Multiple complex diseases LAMP3 intron 17554300 rs514636 chr3 182870436 G A 7.00E-07 Bipolar disorder LAMP3 intron 21254220 rs6414498 chr3 182871214 T G 3.80E-06 Multiple complex diseases LAMP3 intron 17554300 rs6414500 chr3 182871299 T G 2.89E-06 Multiple complex diseases LAMP3 intron 17554300 rs6414500 chr3 182871299 T G 6.78E-04 Bipolar disorder,schizoaffective LAMP3 intron 19567891 rs580116 chr3 182872446 T C 4.91E-05 Parkinson's disease LAMP3 intron 21738487 rs658672 chr3 182877292 T C 6.60E-04 Alzheimer's disease LAMP3 intron 17998437 rs13088121 chr3 182877413 T C 6.85E-04 Multiple complex diseases LAMP3 intron 17554300 rs500910 chr3 182878032 A T 4.01E-05 Postoperative ventricular dysfunction LAMP3 intron 21980348 rs1464574 chr3 182878838 T C 2.88E-06 Postoperative ventricular dysfunction LAMP3 intron 21980348 rs1965484 chr3 182878897 T G 9.71E-05 Postoperative ventricular dysfunction LAMP3 intron 21980348 rs6443856 chr3 182880111 A G 1.19E-04 Multiple complex diseases LAMP3 intron 17554300 rs6771207 chr3 182896412 A G 2.00E-05 Response to statin therapy MCF2L2 UTR-3 20339536 rs11708313 chr3 182903072 G A 2.90E-05 Response to statin therapy MCF2L2 intron 20339536 rs11707756 chr3 182909201 T A 4.40E-05 Response to statin therapy MCF2L2 intron 20339536 rs2103062 chr3 182924298 G A 6.17E-05 Multiple complex diseases MCF2L2 intron 17554300 rs10937118 chr3 182931845 A G 1.26E-04 Multiple complex diseases MCF2L2 intron 17554300 rs6809709 chr3 182940548 C A 1.31E-05 Multiple complex diseases MCF2L2 intron 17554300 rs6793163 chr3 182973255 A C 6.53E-04 Rheumatoid arthritis MCF2L2 intron 21452313 rs7634425 chr3 183020592 T C 2.63E-05 Behcet's disease MCF2L2 intron 23291587 rs7634425 chr3 183020592 T C 2.97E-05 Behcet's disease MCF2L2 intron pha002888 rs1010769 chr3 183024519 T G 2.26E-05 Behcet's disease MCF2L2 intron 23291587 rs3732593 chr3 183036166 G T 2.96E-04 Suicide attempts in bipolar disorder MCF2L2 intron 21423239 rs13434301 chr3 183036526 T C 3.24E-04 Suicide attempts in bipolar disorder MCF2L2 intron 21423239 rs6767909 chr3 183043365 C T 5.78E-04 Suicide attempts in bipolar disorder MCF2L2 intron 21423239 rs6770912 chr3 183043851 G A 7.35E-04 Suicide attempts in bipolar disorder MCF2L2 intron 21423239 rs12630205 chr3 183048627 C G 7.89E-04 Suicide attempts in bipolar disorder MCF2L2 intron 21423239 rs9838217 chr3 183052242 G A 1.58E-04 Multiple complex diseases MCF2L2 intron 17554300 rs2314349 chr3 183091098 G T 4.67E-07 Multiple complex diseases MCF2L2 intron 17554300 rs12635655 chr3 183095982 C T 5.80E-04 Alcohol dependence MCF2L2 intron 20201924 rs4859178 chr3 183099294 C T 3.58E-04 Taste perception MCF2L2 intron 22132133 rs12491399 chr3 183125354 T G 3.65E-04 Parkinson's disease MCF2L2 intron 17052657 rs6808204 chr3 183162227 T C 3.59E-06 Multiple complex diseases / / 17554300 rs6793484 chr3 183197823 T G 2.30E-05 Urinary metabolites / / 21572414 rs1979983 chr3 183210991 G T 6.38E-04 Alzheimer's disease KLHL6 intron 17998437 rs16857726 chr3 183278844 C T 5.71E-04 Multiple complex diseases / / 17554300 rs9824873 chr3 183301774 T C 7.71E-04 Multiple complex diseases / / 17554300 rs9290762 chr3 183306844 G T 5.42E-04 Multiple complex diseases / / 17554300 rs6776812 chr3 183312675 T C 6.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4473579 chr3 183319054 A T 5.44E-04 Multiple complex diseases / / 17554300 rs6807489 chr3 183394462 A G 1.13E-04 Alcohol consumption (maxi-drinks) KLHL24 intron 24277619 rs9826007 chr3 183420976 G T 2.29E-04 Multiple complex diseases YEATS2 intron 17554300 rs7612556 chr3 183425850 A G 4.97E-05 Epilepsy YEATS2 intron 22116939 rs262977 chr3 183455153 A G 2.72E-04 Epilepsy YEATS2 intron 22116939 rs262993 chr3 183476685 G A 4.62E-04 Epilepsy YEATS2 missense 22116939 rs6443904 chr3 183481246 A G 4.91E-04 Atopy YEATS2 intron 21625490 rs262959 chr3 183492617 G A 4.67E-04 Multiple complex diseases YEATS2 intron 17554300 rs79808533 chr3 183508590 A G 0.00029 Breast cancer YEATS2 cds-synon 23555315 rs74496163 chr3 183508714 G A 0.000087 Breast cancer YEATS2 missense 23555315 rs263044 chr3 183517999 A G 5.58E-04 Schizophrenia YEATS2 intron 19197363 rs263044 chr3 183517999 A G 3.52E-04 Epilepsy YEATS2 intron 22116939 rs263035 chr3 183523657 A G 2.26E-07 Autism YEATS2 intron 22843504 rs263030 chr3 183525121 A G 2.76E-07 Autism YEATS2 intron 22843504 rs263025 chr3 183527618 T C 6.62E-04 Schizophrenia YEATS2 intron 19197363 rs263025 chr3 183527618 T C 4.76E-04 Epilepsy YEATS2 intron 22116939 rs263025 chr3 183527618 T C 1.58E-07 Autism YEATS2 intron 22843504 rs2255015 chr3 183534976 G A 8.90E-05 Immunoglobulin A MAP6D1 UTR-3 20694011 rs7349550 chr3 183545282 A G 6.90E-06 Urinary metabolites / / 21572414 rs1378909 chr3 183545750 G A 9.70E-06 Urinary metabolites / / 21572414 rs2305666 chr3 183551733 A C 5.70E-06 Urinary metabolites PARL intron 21572414 rs3732581 chr3 183558402 C G 3.84E-04 Lung function (forced expiratory volume in 1 second) PARL missense 17255346 rs12634358 chr3 183562662 A G 7.69E-04 Taste perception PARL intron 22132133 rs9844777 chr3 183566942 A G 2.29E-04 Parkinson's disease PARL intron 17052657 rs6809370 chr3 183577904 G A 5.23E-04 Smoking initiation PARL intron 24665060 rs1554397 chr3 183580750 A G 1.52E-04 Parkinson's disease PARL intron 17052657 rs9290776 chr3 183597998 A C 5.13E-04 Smoking initiation PARL intron 24665060 rs2056332 chr3 183601498 T C 2.80E-04 Iris characteristics PARL intron 21835309 rs6775950 chr3 183618707 T C 3.01E-04 Multiple complex diseases / / 17554300 rs10470523 chr3 183623778 A G 6.87E-05 Weight / / pha003027 rs11716770 chr3 183628585 C T 1.41E-04 Smoking initiation / / 24665060 rs2176825 chr3 183634592 A G 4.62E-05 Waist Circumference / / pha003025 rs1533682 chr3 183634879 T C 7.97E-04 Multiple complex diseases / / 17554300 rs1000002 chr3 183635768 C T 4.49E-04 Multiple complex diseases / / 17554300 rs1000002 chr3 183635768 C T 9.78E-04 Alcohol dependence / / 21314694 rs4148594 chr3 183640384 T C 2.33E-04 Insulin resistance ABCC5 intron 21901158 rs7646621 chr3 183640865 G T 3.95E-04 Multiple complex diseases ABCC5 intron 17554300 rs8180093 chr3 183642303 G A 3.03E-05 Weight ABCC5 intron pha003027 rs1402001 chr3 183642751 A G 4.40E-04 Multiple complex diseases ABCC5 intron 17554300 rs3805112 chr3 183645662 C T 4.71E-04 Multiple complex diseases ABCC5 intron 17554300 rs4912515 chr3 183653718 A G 1.00E-04 Prostate cancer ABCC5 intron 21743057 rs3749441 chr3 183660806 C G 3.95E-04 Multiple complex diseases ABCC5 intron 17554300 rs1401999 chr3 183678342 C G 8.00E-09 Anterior chamber depth ABCC5 intron 24603532 rs3792583 chr3 183683938 G A 9.10E-06 Urinary metabolites ABCC5 intron 21572414 rs3792582 chr3 183694602 A G 3.56E-04 Multiple complex diseases ABCC5 intron 17554300 rs6775518 chr3 183698219 G A 7.20E-06 Urinary metabolites ABCC5 intron 21572414 rs9290779 chr3 183721975 C A 9.16E-09 HDL cholesterol ABCC5 intron 23063622 rs7620457 chr3 183747266 G A 7.50E-06 Urinary metabolites / / 21572414 rs7621975 chr3 183758506 G A 1.39E-05 Bipolar disorder / / 21771265 rs7638896 chr3 183776022 A G 5.33E-04 Multiple complex diseases HTR3C intron 17554300 rs11706269 chr3 183793499 C T 1.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs9874060 chr3 183796081 G A 3.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs11720399 chr3 183797063 G C 3.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs9290781 chr3 183829733 C A 5.76E-06 Lung cancer / / 19414679 rs11718245 chr3 183830393 G A 1.14E-04 Lung cancer / / 19414679 rs6806377 chr3 183843135 A G 1.00E-06 Obesity-related traits / / 23251661 rs865808 chr3 183858939 A C 6.91E-05 Major depressive disorder EIF2B5 intron 22472876 rs844540 chr3 183863813 A T 5.83E-05 Coronary Artery Disease / / 17634449 rs863615 chr3 183864863 G A 6.30E-06 Urinary metabolites / / 21572414 rs863615 chr3 183864863 G A 8.61E-05 Major depressive disorder / / 22472876 rs1969253 chr3 183876512 A C 5.00E-06 Major depressive disorder DVL3 intron 22472876 rs13262 chr3 183901389 T C 3.42E-04 Alcohol dependence AP2M1 cds-synon 20201924 rs9882147 chr3 183938418 G A 8.95E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs843350 chr3 183946274 T C 8.00E-04 Lymphocyte counts / / 22286170 rs199885492 chr3 183957291 G A 0.00019 Breast cancer VWA5B2 missense 23555315 rs1709621 chr3 183976906 G A 7.25E-04 Multiple complex diseases ECE2 intron 17554300 rs35637422 chr3 184009586 A G 2.09E-04 Smoking cessation ECE2 intron 24665060 rs3914188 chr3 184010048 G C 3.00E-07 Menarche (age at onset) ECE2 UTR-3 21102462 rs2230571 chr3 184046470 C T 6.33E-05 Scoliosis EIF4G1 cds-synon 21216876 rs4912540 chr3 184069654 G A 3.17E-05 Serum metabolites CLCN2 intron 19043545 rs6141 chr3 184090266 C T 5.00E-11 Blood cell counts and other traits THPO UTR-3 20139978 rs6141 chr3 184090266 C T 5.38E-11 Blood cell counts and other traits THPO UTR-3 20139978 rs6141 chr3 184090266 C T 5.38E-11 Hepatitis B THPO UTR-3 21750111 rs6141 chr3 184090266 C T 6.00E-08 Platelet counts THPO UTR-3 22139419 rs6141 chr3 184090266 C T 5.38E-11 Mean platelet volume THPO UTR-3 22423221 rs6141 chr3 184090266 C T 1.21E-05 Platelet counts THPO UTR-3 23263863 rs6141 chr3 184090266 C T 2.00E-04 Platelet counts THPO UTR-3 24026423 rs885838 chr3 184096578 A G 8.00E-04 Coronary heart disease THPO nearGene-5 21966275 rs12493455 chr3 184141428 A G 8.33E-04 Tourette syndrome / / 22889924 rs11927393 chr3 184157976 T G 5.64E-04 Intracranial aneurysm / / 20613766 rs9844738 chr3 184181808 C T 4.99E-05 Interstitial lung disease / / 23583980 rs6777514 chr3 184188338 G A 1.40E-06 Urinary metabolites / / 21572414 rs9822959 chr3 184198443 T G 4.79E-04 IgE levels / / 17255346 rs6443976 chr3 184202412 G C 1.80E-05 Urinary metabolites / / 21572414 rs11709926 chr3 184213807 G A 3.88E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3930234 chr3 184216130 T C 8.00E-06 Alcoholism (alcohol use disorder factor score) / / 21529783 rs4912575 chr3 184223930 G A 5.69E-26 Narcolepsy / / 19629137 rs7618102 chr3 184241262 G T 5.29E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs4074869 chr3 184331242 G A 1.10E-05 Urinary metabolites / / 21572414 rs13098099 chr3 184339667 G A 1.92E-07 Primary biliary cirrhosis / / 23000144 rs13098099 chr3 184339667 G A 0.000000192 Facial morphology / / 23028347 rs13097965 chr3 184339757 C T 2.18E-07 Primary biliary cirrhosis / / 23000144 rs13097965 chr3 184339757 C T 0.000000218 Facial morphology / / 23028347 rs10937181 chr3 184341513 G A 3.59E-05 Coronary heart disease / / 21971053 rs7646910 chr3 184355688 G A 1.15E-04 Arthritis (juvenile idiopathic) / / 22354554 rs4686705 chr3 184356355 C T 1.86E-04 Arthritis (juvenile idiopathic) / / 22354554 rs4635684 chr3 184363909 T C 0.0000155 Panic disorder / / 23149450 rs4635684 chr3 184363909 T C 1.55E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs10937184 chr3 184366735 C T 0.0000173 Panic disorder / / 23149450 rs10937184 chr3 184366735 C T 1.73E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs9855937 chr3 184380746 T A 0.0000283 Panic disorder / / 23149450 rs9855937 chr3 184380746 T A 2.83E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs4234607 chr3 184384129 C G 0.0000592 Panic disorder / / 23149450 rs4234607 chr3 184384129 C G 5.92E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs3934720 chr3 184406682 A C 7.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4686690 chr3 184452573 T G 2.32E-08 Metabolite levels LOC100505710 intron 23281178 rs2278761 chr3 184455373 A G 2.61E-08 Metabolite levels / / 23281178 rs747877 chr3 184457078 A G 7.55E-04 Alzheimer's disease / / 17998437 rs747877 chr3 184457078 A G 5.84E-09 Metabolite levels / / 23281178 rs2377104 chr3 184459876 T G 1.94E-04 Multiple complex diseases / / 17554300 rs6766579 chr3 184465325 C T 8.03E-04 Intracranial aneurysm / / 20613766 rs4381915 chr3 184468603 G A 2.50E-05 Urinary metabolites / / 21572414 rs4309706 chr3 184474826 G A 4.60E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs9883278 chr3 184475833 G A 8.86E-04 Alcohol dependence / / 21314694 rs2377102 chr3 184485548 G A 9.87E-05 White matter integrity / / 22425255 rs12496472 chr3 184493051 G A 1.80E-04 Tourette syndrome / / 22889924 rs4686407 chr3 184499277 A C 6.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4686760 chr3 184514613 G A 1.00E-06 vWF and FVIII levels / / 21810271 rs7625123 chr3 184532028 A G 3.96E-04 Multiple complex diseases VPS8 intron 17554300 rs9830734 chr3 184550501 A G 4.10E-06 Urinary metabolites VPS8 missense 21572414 rs6443999 chr3 184573555 C T 1.17E-04 Schizophrenia(treatment response to risperidone) VPS8 cds-synon 19850283 rs16859357 chr3 184575434 A G 2.00E-05 Urinary metabolites VPS8 intron 21572414 rs7618180 chr3 184630294 A G 1.60E-05 Urinary metabolites VPS8 intron 21572414 rs9821657 chr3 184631103 G A 1.40E-05 Urinary metabolites VPS8 intron 21572414 rs10937194 chr3 184718718 G T 5.90E-05 Parkinson's disease VPS8 intron pha002865 rs10937197 chr3 184769455 A G 3.10E-06 Urinary metabolites VPS8 intron 21572414 rs10937202 chr3 184793756 G A 1.30E-06 Urinary metabolites / / 21572414 rs2132240 chr3 184816323 T C 0.00059 Prostate cancer (non-advanced prostate cancer) C3orf70 intron 23555315 rs13069476 chr3 184831158 G C 2.40E-05 Urinary metabolites C3orf70 intron 21572414 rs7619914 chr3 184838045 C T 4.23E-05 Major depressive disorder C3orf70 intron 22472876 rs7619914 chr3 184838045 C T 0.000614 Salmonella-induced pyroptosis C3orf70 intron 22837397 rs7629390 chr3 184841184 C G 1.50E-05 Urinary metabolites C3orf70 intron 21572414 rs9841506 chr3 184853342 A G 9.70E-06 Major depressive disorder C3orf70 intron 22472876 rs11714089 chr3 184872794 C T 5.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6797705 chr3 184875106 G C 5.36E-04 Type 2 diabetes / / 17463246 rs6797705 chr3 184875106 G C 3.20E-06 Malaria / / 19465909 rs4419361 chr3 184875154 A G 2.25E-04 Major depressive disorder / / 22472876 rs6800626 chr3 184875746 C T 9.45E-05 Blood Pressure / / pha003047 rs7647854 chr3 184876783 G A 5.00E-06 Major depressive disorder / / 21042317 rs7647854 chr3 184876783 G A 6.51E-07 Major depressive disorder / / 22472876 rs7647854 chr3 184876783 G A 4.60E-06 Depression (quantitative trait) / / 23290196 rs16859737 chr3 184890501 G A 9.36E-04 Multiple complex diseases LOC339926 intron 17554300 rs16859737 chr3 184890501 G A 2.51E-04 Insulin resistance LOC339926 intron 21901158 rs1039829 chr3 184892886 A G 8.53E-04 Insulin resistance LOC339926 intron 21901158 rs6783938 chr3 184906201 C T 5.20E-08 Metabolite levels LOC339926 intron 23281178 rs11919970 chr3 184910133 G T 5.15E-08 Metabolite levels EHHADH missense 23281178 rs7374394 chr3 184945849 C T 2.00E-06 Cognitive performance EHHADH intron 19734545 rs9858538 chr3 185055476 C T 8.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP3K13 intron 20877124 rs7428983 chr3 185097580 A G 8.97E-04 Myopia (pathological) MAP3K13 intron 21095009 rs4687296 chr3 185112300 T C 3.90E-05 Type 2 diabetes MAP3K13 intron 17463248 rs4687299 chr3 185112659 A G 3.90E-05 Type 2 diabetes MAP3K13 intron 17463248 rs7629245 chr3 185141857 C T 9.00E-06 Airflow obstruction MAP3K13 intron 22837378 rs6444074 chr3 185223193 G T 2.86E-05 Post-operative nausea and vomiting / / 21694509 rs497680 chr3 185242212 G A 6.52E-04 Smoking cessation LIPH intron 24665060 rs4626118 chr3 185258933 T C 8.34E-04 Smoking cessation LIPH intron 24665060 rs4362741 chr3 185259843 C A 3.45E-04 Smoking cessation LIPH intron 24665060 rs11917863 chr3 185290346 T G 4.18E-04 Multiple complex diseases / / 17554300 rs9878208 chr3 185356176 T G 9.84E-04 Multiple complex diseases / / 17554300 rs9864104 chr3 185357531 C T 4.87E-04 Alcohol dependence / / 21314694 rs6780808 chr3 185442119 G A 8.80E-05 Heart Failure IGF2BP2 intron pha002884 rs6784185 chr3 185473065 G A 3.10E-05 Type 2 diabetes IGF2BP2 intron 22158537 rs6784050 chr3 185473132 C T 6.48E-05 Type 2 diabetes IGF2BP2 intron 22158537 rs6789741 chr3 185479733 G T 7.72E-04 Type 2 diabetes IGF2BP2 intron 22158537 rs6763887 chr3 185482618 T C 9.02E-05 Blood Pressure IGF2BP2 intron pha003043 rs4376068 chr3 185497635 A C 4.31E-05 Multiple complex diseases IGF2BP2 intron 17554300 rs4376068 chr3 185497635 A C 1.79E-06 Type 2 diabetes IGF2BP2 intron 22158537 rs4376068 chr3 185497635 A C 6.37E-06 Diabetes (gestational) IGF2BP2 intron 22233651 rs6801848 chr3 185499057 C G 8.82E-05 Multiple complex diseases IGF2BP2 intron 17554300 rs6801848 chr3 185499057 C G 2.61E-11 Type 2 diabetes IGF2BP2 intron 22158537 rs6801848 chr3 185499057 C G 1.00E-05 Diabetes (gestational) IGF2BP2 intron 22233651 rs4481184 chr3 185505787 C T 5.23E-13 Type 2 diabetes IGF2BP2 intron 22158537 rs11705729 chr3 185507299 A T 2.93E-13 Type 2 diabetes IGF2BP2 intron 22158537 rs11929397 chr3 185510190 T C 2.85E-12 Type 2 diabetes IGF2BP2 intron 22158537 rs7633675 chr3 185510613 T G 1.05E-13 Type 2 diabetes IGF2BP2 intron 22158537 rs16860234 chr3 185510884 A C 4.25E-08 Type 2 diabetes IGF2BP2 intron 22158537 rs4402960 chr3 185511687 G T 2.00E-09 Type 2 diabetes IGF2BP2 intron 17463246 rs4402960 chr3 185511687 G T 9.00E-16 Type 2 diabetes IGF2BP2 intron 17463248 rs4402960 chr3 185511687 G T 9.00E-16 Type 2 diabetes IGF2BP2 intron 17463249 rs4402960 chr3 185511687 G T 2.91E-05 Multiple complex diseases IGF2BP2 intron 17554300 rs4402960 chr3 185511687 G T 8.00E-08 Type 2 diabetes IGF2BP2 intron 18372903 rs4402960 chr3 185511687 G T 1.00E-06 Type 2 diabetes IGF2BP2 intron 19401414 rs4402960 chr3 185511687 G T 9.00E-16 Coronary heart disease IGF2BP2 intron 21347282 rs4402960 chr3 185511687 G T 9.00E-16 Type 2 diabetes IGF2BP2 intron 21647700 rs4402960 chr3 185511687 G T 1.77E-07 Type 2 diabetes IGF2BP2 intron 22158537 rs4402960 chr3 185511687 G T 7.72E-06 Diabetes (gestational) IGF2BP2 intron 22233651 rs4402960 chr3 185511687 G T 3.00E-09 Type 2 diabetes IGF2BP2 intron 22693455 rs4402960 chr3 185511687 G T 0.000000044 Fasting blood glucose IGF2BP2 intron 22885922 rs4402960 chr3 185511687 G T 2.40E-23 Type 2 diabetes IGF2BP2 intron 22885922 rs4402960 chr3 185511687 G T 0.000001002 2-hour glucose tolerance test IGF2BP2 intron 22885924 rs4402960 chr3 185511687 G T 8.90E-16 Type 2 diabetes IGF2BP2 intron 23300278 rs4402960 chr3 185511687 G T 1.00E-17 Type 2 diabetes IGF2BP2 intron 24509480 rs7640539 chr3 185513296 T A 1.41E-12 Type 2 diabetes IGF2BP2 intron 22158537 rs7640539 chr3 185513296 T A 1.50E-17 Type 2 diabetes (males) IGF2BP2 intron 22885922 rs7640539 chr3 185513296 T A 1.80E-09 Type 2 diabetes (females) IGF2BP2 intron 22885922 rs7651090 chr3 185513392 A G 2.63E-05 Multiple complex diseases IGF2BP2 intron 17554300 rs7651090 chr3 185513392 A G 2.24E-07 Type 2 diabetes IGF2BP2 intron 22158537 rs7651090 chr3 185513392 A G 2.47E-05 Diabetes (gestational) IGF2BP2 intron 22233651 rs7651090 chr3 185513392 A G 3.40E-23 Type 2 diabetes IGF2BP2 intron 22885922 rs7651090 chr3 185513392 A G 2.02E-10 Fasting blood glucose IGF2BP2 intron 22885924 rs7651090 chr3 185513392 A G 4.47E-08 2-hour glucose tolerance test IGF2BP2 intron 22885924 rs6444081 chr3 185514393 T C 1.35E-12 Type 2 diabetes IGF2BP2 intron 22158537 rs7646518 chr3 185514931 T C 2.10E-12 Type 2 diabetes IGF2BP2 intron 22158537 rs7637773 chr3 185515635 G A 1.51E-12 Type 2 diabetes IGF2BP2 intron 22158537 rs4686696 chr3 185516520 G A 2.05E-12 Type 2 diabetes IGF2BP2 intron 22158537 rs6767484 chr3 185520578 A G 2.34E-12 Type 2 diabetes IGF2BP2 intron 22158537 rs6767577 chr3 185520732 A C 1.98E-07 Type 2 diabetes IGF2BP2 intron 22158537 rs34782298 chr3 185520996 G A 5.10E-05 Urinary metabolites IGF2BP2 intron 21572414 rs7640744 chr3 185522447 G A 5.42E-08 Type 2 diabetes IGF2BP2 intron 22158537 rs13060777 chr3 185525199 A G 2.17E-07 Type 2 diabetes IGF2BP2 intron 22158537 rs11711477 chr3 185526690 T A 3.34E-08 Type 2 diabetes IGF2BP2 intron 22158537 rs1470579 chr3 185529080 A C 1.30E-09 Type 2 diabetes IGF2BP2 intron 17463246 rs1470579 chr3 185529080 A C 4.41E-05 Multiple complex diseases IGF2BP2 intron 17554300 rs1470579 chr3 185529080 A C 2.00E-09 Type 2 diabetes IGF2BP2 intron 20581827 rs1470579 chr3 185529080 A C 5.20E-08 Type 2 diabetes IGF2BP2 intron 20818381 rs1470579 chr3 185529080 A C 1.80E-14 Type 2 diabetes IGF2BP2 intron 21874001 rs1470579 chr3 185529080 A C 2.90E-13 Type 2 diabetes IGF2BP2 intron 22158537 rs1470579 chr3 185529080 A C 2.00E-07 Diabetes (gestational) IGF2BP2 intron 22233651 rs1470579 chr3 185529080 A C 9.19E-16 Type 2 diabetes IGF2BP2 intron 22325160 rs1470579 chr3 185529080 A C 6.00E-07 Fasting glucose-related traits (interaction with BMI) IGF2BP2 intron 22581228 rs1470579 chr3 185529080 A C 7.50E-11 Type 2 diabetes IGF2BP2 intron 22885922 rs1470579 chr3 185529080 A C 2.00E-13 Type 2 diabetes IGF2BP2 intron 23300278 rs1470579 chr3 185529080 A C 2.00E-19 Type 2 diabetes IGF2BP2 intron 23300278 rs1470579 chr3 185529080 A C 4.00E-07 Type 2 diabetes IGF2BP2 intron 23300278 rs1470579 chr3 185529080 A C 4.00E-09 Type 2 diabetes IGF2BP2 intron 23300278 rs1470579 chr3 185529080 A C 5.00E-06 Type 2 diabetes IGF2BP2 intron 23300278 rs1470579 chr3 185529080 A C 5.00E-14 Type 2 diabetes IGF2BP2 intron 23945395 rs1470580 chr3 185529174 T A 5.76E-13 Type 2 diabetes IGF2BP2 intron 22158537 rs1470581 chr3 185529327 A G 3.84E-08 Type 2 diabetes IGF2BP2 intron 22158537 rs6769511 chr3 185530290 T C 1.00E-09 Type 2 diabetes IGF2BP2 intron 18711366 rs6769511 chr3 185530290 T C 1.00E-09 Coronary heart disease IGF2BP2 intron 21347282 rs6769511 chr3 185530290 T C 1.93E-13 Type 2 diabetes IGF2BP2 intron 22158537 rs6769511 chr3 185530290 T C 2.00E-21 Type 2 diabetes IGF2BP2 intron 22885922 rs9837654 chr3 185530322 G A 4.10E-08 Type 2 diabetes IGF2BP2 intron 22158537 rs1374910 chr3 185531661 C T 1.00E-07 Type 2 diabetes IGF2BP2 intron 21573907 rs9859406 chr3 185534482 G A 2.99E-13 Type 2 diabetes IGF2BP2 intron 22158537 rs6444082 chr3 185536223 G T 3.22E-10 Type 2 diabetes IGF2BP2 intron 22158537 rs764129 chr3 185547917 C T 2.56E-05 Type 2 diabetes / / 20818381 rs764129 chr3 185547917 C T 4.59E-06 Type 2 diabetes / / 22158537 rs720390 chr3 185548683 G A 2.00E-14 Height / / 20881960 rs2098771 chr3 185563274 G A 9.29E-05 Major depressive disorder / / 21621269 rs741604 chr3 185592046 C T 8.36E-05 Diabetes Mellitus / / pha003059 rs4686399 chr3 185618266 G A 2.33E-05 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction) / / 24280104 rs6444087 chr3 185621829 G A 9.00E-06 Smoking behavior / / 19247474 rs56173229 chr3 185626747 T G 0.0000948 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2002675 chr3 185629568 A G 1.00E-09 Menarche (age at onset) / / 21102462 rs9830552 chr3 185659252 G A 0.0000666 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1862906 chr3 185675973 G A 0.00000591 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10937232 chr3 185676165 A G 0.0000376 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6444089 chr3 185676350 G A 0.0000354 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs56136116 chr3 185676917 A G 0.0000333 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6793264 chr3 185677564 T C 0.000076 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12497588 chr3 185679423 G T 0.0000161 Nonsyndromic striae distensae (stretch marks) LOC344887 intron 23633020 rs55681808 chr3 185680547 G A 0.00000501 Nonsyndromic striae distensae (stretch marks) LOC344887 intron 23633020 rs6803442 chr3 185680586 T C 0.0000747 Nonsyndromic striae distensae (stretch marks) LOC344887 intron 23633020 rs6766856 chr3 185681210 A T 0.0000897 Nonsyndromic striae distensae (stretch marks) LOC344887 intron 23633020 rs62290872 chr3 185681400 C G 0.00000625 Nonsyndromic striae distensae (stretch marks) LOC344887 intron 23633020 rs55913389 chr3 185681457 G A 0.0000507 Nonsyndromic striae distensae (stretch marks) LOC344887 intron 23633020 rs10049246 chr3 185686741 A G 8.00E-06 Attention deficit hyperactivity disorder symptoms (interaction) LOC344887 intron 18846501 rs10049246 chr3 185686741 A G 0.00000438 Nonsyndromic striae distensae (stretch marks) LOC344887 intron 23633020 rs60144468 chr3 185687347 A G 0.0000031 Nonsyndromic striae distensae (stretch marks) LOC344887 intron 23633020 rs6779456 chr3 185687565 C G 0.00000212 Nonsyndromic striae distensae (stretch marks) LOC344887 intron 23633020 rs6779654 chr3 185687737 C G 0.00000309 Nonsyndromic striae distensae (stretch marks) LOC344887 intron 23633020 rs4686716 chr3 185688482 T G 0.00000351 Nonsyndromic striae distensae (stretch marks) LOC344887 intron 23633020 rs9290827 chr3 185689050 A G 0.00000441 Nonsyndromic striae distensae (stretch marks) LOC344887 intron 23633020 rs9867660 chr3 185689242 A G 0.0000036 Nonsyndromic striae distensae (stretch marks) LOC344887 intron 23633020 rs9845879 chr3 185692061 C T 6.65E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines LOC344887 intron 21844884 rs4686719 chr3 185704236 C A 2.30E-04 Parkinson's disease / / 17052657 rs11710503 chr3 185704891 C T 0.00000229 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6763587 chr3 185707966 C T 3.97E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs3885392 chr3 185709201 C A,G,T 0.0000273 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs182857216 chr3 185789194 T G 0.0000217 Menopause (age at onset) ETV5 intron 23424626 rs6777779 chr3 185794946 G T 3.20E-04 Multiple complex diseases ETV5 intron 17554300 rs4686728 chr3 185795333 T C 6.45E-05 IgE levels ETV5 intron 17255346 rs7433760 chr3 185801628 A G 8.12E-06 Major depressive disorder ETV5 intron 20516156 rs4686730 chr3 185805993 C T 1.82E-04 IgE levels ETV5 intron 17255346 rs6444106 chr3 185811495 G A 2.27E-04 IgE levels ETV5 intron 17255346 rs10513801 chr3 185822353 T G 5.43E-05 Body mass index ETV5 intron 24861553 rs1516725 chr3 185824004 T C 3.00E-09 Obesity ETV5 intron 23563607 rs1516725 chr3 185824004 T C 4.00E-08 Body mass index ETV5 intron 23563607 rs1516728 chr3 185829891 T A 1.19E-04 IgE levels / / 17255346 rs4686733 chr3 185830514 G A 7.88E-04 Multiple complex diseases / / 17554300 rs7635103 chr3 185833759 C A 3.60E-05 IgE levels / / 17255346 rs7647305 chr3 185834290 T C 7.90E-05 IgE levels / / 17255346 rs7647305 chr3 185834290 T C 4.00E-09 Weight / / 19079260 rs7647305 chr3 185834290 T C 7.00E-11 Body mass index / / 19079260 rs7647305 chr3 185834290 T C 3.10E-06 Smoking behavior / / 20418888 rs9816226 chr3 185834499 A T 2.00E-18 Body mass index / / 20935630 rs9816226 chr3 185834499 A T 1.69E-18 Body mass index / / 23001569 rs9816226 chr3 185834499 A T 2.00E-13 Obesity / / 23563607 rs9816226 chr3 185834499 A T 2.00E-14 Obesity / / 23563607 rs16860529 chr3 185900369 C G 7.87E-05 Personality dimensions DGKG intron 18957941 rs759678 chr3 185902030 T C 9.80E-05 Personality dimensions DGKG intron 18957941 rs2268844 chr3 185920603 T G 2.90E-04 Celiac disease DGKG intron 23936387 rs7648336 chr3 185949248 C A 3.66E-04 Orofacial clefts DGKG intron 22419666 rs2239625 chr3 186002740 G T 1.44E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) DGKG intron 24023788 rs2239625 chr3 186002740 G T 2.08E-04 Lung function (forced expiratory volume in 1 second) DGKG intron 24023788 rs1004589 chr3 186006307 C T 4.89E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) DGKG intron 24023788 rs41527249 chr3 186026428 A G 9.91E-04 Type 2 diabetes DGKG intron 17463246 rs1981783 chr3 186054149 A G 4.58E-04 Schizophrenia DGKG intron 19197363 rs12233555 chr3 186063184 T G 6.37E-04 Schizophrenia DGKG intron 19197363 rs4583642 chr3 186126310 T C 9.23E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs6777345 chr3 186148622 A G 9.07E-04 Type 2 diabetes / / 17463246 rs11916012 chr3 186158483 G A 0.000436 Salmonella-induced pyroptosis / / 22837397 rs6782743 chr3 186159130 T A 0.000732 Salmonella-induced pyroptosis / / 22837397 rs6765480 chr3 186177529 G T 7.08E-05 Alzheimer's disease LOC253573 intron 22005930 rs6764306 chr3 186182489 C A 9.70E-05 Parkinson's disease (age of onset) LOC253573 intron 19772629 rs6771063 chr3 186184328 G A 3.05E-06 Intelligence LOC253573 intron 21826061 rs7610178 chr3 186191696 C T 8.91E-05 Brain lesion load LOC253573 intron 19010793 rs6767055 chr3 186193436 G A 5.37E-04 Alzheimer's disease LOC253573 intron 22005930 rs12107740 chr3 186201861 C A 8.14E-04 Alzheimer's disease LOC253573 intron 22005930 rs9681406 chr3 186205356 C T 8.75E-05 Blood Pressure LOC253573 intron pha003044 rs11918665 chr3 186213784 A G 1.10E-07 Illicit drug use / / 23942779 rs11918665 chr3 186213784 A G 2.20E-04 Non-substance related behavioral disinhibition / / 23942779 rs11918665 chr3 186213784 A G 4.20E-04 Nicotine use / / 23942779 rs11918665 chr3 186213784 A G 5.50E-04 Alcohol consumption / / 23942779 rs1868152 chr3 186220063 A G 2.20E-04 Nicotine use / / 23942779 rs1868152 chr3 186220063 A G 3.50E-05 Non-substance related behavioral disinhibition / / 23942779 rs1868152 chr3 186220063 A G 5.00E-08 Illicit drug use / / 23942779 rs1868152 chr3 186220063 A G 7.00E-04 Alcohol consumption / / 23942779 rs2889756 chr3 186252771 A G 7.77E-04 Lymphocyte counts / / 22286170 rs2280391 chr3 186293588 A G 8.33E-05 Multiple sclerosis D/JB11 intron 17660530 rs2280390 chr3 186293820 T G 5.33E-04 Alcohol dependence D/JB11 intron 21314694 rs9840074 chr3 186298381 G A 2.07E-06 Multiple sclerosis D/JB11 intron 17660530 rs3846211 chr3 186306541 T C 7.69E-05 Alzheimer's disease / / 17998437 rs6787877 chr3 186310301 G C 4.14E-05 Alzheimer's disease / / 17998437 rs3936433 chr3 186311744 A G 2.14E-04 Alzheimer's disease / / 17998437 rs16860926 chr3 186327771 T C 0.000000441 LDL cholesterol / / 23063622 rs16860926 chr3 186327771 T C 1.41E-08 HDL cholesterol / / 23063622 rs6785067 chr3 186364046 G A 1.55E-05 Multiple complex diseases FETUB missense 17554300 rs6801438 chr3 186365309 T C 6.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FETUB intron 20877124 rs9898 chr3 186390627 C T 1.00E-11 Activated partial thromboplastin time HRG missense 20303064 rs9898 chr3 186390627 C T 1.00E-111 Activated partial thromboplastin time HRG missense 22703881 rs9898 chr3 186390627 C T 0.000000261 Activated partial thromboplastin time HRG missense 23188048 rs9898 chr3 186390627 C T 5.26E-11 Activated protein C resistance HRG missense 23188048 rs16860992 chr3 186394038 G C 2.29E-15 Activated protein C resistance HRG intron 23188048 rs16860992 chr3 186394038 G C 4.37E-17 Activated partial thromboplastin time HRG intron 23188048 rs2228243 chr3 186395113 A G 1.35E-17 Activated partial thromboplastin time HRG missense 23188048 rs2228243 chr3 186395113 A G 9.55E-15 Activated protein C resistance HRG missense 23188048 rs1042445 chr3 186395436 C T 2.27E-08 Activated partial thromboplastin time HRG missense 23188048 rs13315296 chr3 186429001 C T 1.59E-04 Lymphocyte counts / / 22286170 rs11924390 chr3 186433099 T C 2.00E-09 Adiponectin levels KNG1 nearGene-5 20876611 rs1624230 chr3 186438935 C A 9.47E-14 Activated partial thromboplastin time KNG1 intron 23188048 rs1621816 chr3 186439173 T C 2.33E-14 Activated partial thromboplastin time KNG1 intron 23188048 rs5030023 chr3 186444644 G A 4.16E-14 Activated partial thromboplastin time KNG1 intron 23188048 rs2304456 chr3 186445052 T G 0.000486 Plasma factor XI level and activated partial thromboplastin time KNG1 missense 22701019 rs5030028 chr3 186445754 C T 3.78E-14 Activated partial thromboplastin time KNG1 intron 23188048 rs266723 chr3 186447047 A C 3.31E-10 Activated partial thromboplastin time KNG1 intron 23188048 rs1624569 chr3 186450069 T C 5.15E-08 Activated partial thromboplastin time KNG1 intron 23188048 rs4686799 chr3 186451236 T C 1 Drug response to Hydrochlorothiazide KNG1 intron 19584173 rs4686799 chr3 186451236 T C 0.000000167 Plasma factor XI level and activated partial thromboplastin time KNG1 intron 22701019 rs5030062 chr3 186454180 A C 1 Drug response to Candesartan KNG1 intron 19584173 rs5030062 chr3 186454180 A C 1 Drug response to Hydrochlorothiazide KNG1 intron 19584173 rs5030062 chr3 186454180 A C 2.19E-09 Plasma factor XI level and activated partial thromboplastin time KNG1 intron 22701019 rs5030062 chr3 186454180 A C 3.55E-15 Activated partial thromboplastin time KNG1 intron 23188048 rs5030062 chr3 186454180 A C 6.00E-13 Blood metabolite levels KNG1 intron 24816252 rs5030072 chr3 186455546 T C 0.000188 Plasma factor XI level and activated partial thromboplastin time KNG1 intron 22701019 rs3856930 chr3 186458322 C T 6.90E-14 Activated partial thromboplastin time KNG1 intron 23188048 rs698078 chr3 186459227 A G 1 Drug response to Candesartan KNG1 intron 19584173 rs698078 chr3 186459227 A G 1 Drug response to Hydrochlorothiazide KNG1 intron 19584173 rs698078 chr3 186459227 A G 0.000155 Plasma factor XI level and activated partial thromboplastin time KNG1 intron 22701019 rs710446 chr3 186459927 T C 1.00E-21 Activated partial thromboplastin time KNG1 missense 20303064 rs710446 chr3 186459927 T C 7.98E-10 Plasma factor XI level and activated partial thromboplastin time KNG1 missense 22701019 rs710446 chr3 186459927 T C 2.00E-203 Activated partial thromboplastin time KNG1 missense 22703881 rs710446 chr3 186459927 T C 2.68E-19 Activated partial thromboplastin time KNG1 missense 23188048 rs5030091 chr3 186460877 T C 3.83E-04 Suicide attempts in bipolar disorder KNG1 intron 21423239 rs5030091 chr3 186460877 T C 0.000000729 Activated partial thromboplastin time KNG1 intron 23188048 rs2062632 chr3 186461181 T C 0.000000104 Activated partial thromboplastin time KNG1 intron 23188048 rs1656966 chr3 186466252 G A 4.00E-21 Myopia (pathological) / / 23049088 rs822373 chr3 186471186 A G 9.65E-05 Height / / pha003011 rs822354 chr3 186480206 A G 4.00E-08 Adiponectin levels / / 21700879 rs266733 chr3 186493313 T G 2.08E-06 Adiponectin levels / / 20887962 rs266719 chr3 186501648 T C 7.00E-07 Adiponectin levels EIF4A2 intron 24105470 rs1047148 chr3 186507757 G A 7.51E-04 Type 2 diabetes RFC4 UTR-3 17463246 rs1648703 chr3 186519136 A C 1.10E-05 Body mass index (asthmatics) RFC4 intron 23517042 rs1648703 chr3 186519136 A C 7.83E-05 Pulmonary function in asthmatics RFC4 intron 23541324 rs71528570 chr3 186519136 A AC 1.10E-05 Body mass index (asthmatics) RFC4 intron 23517042 rs71528570 chr3 186519136 A AC 7.83E-05 Pulmonary function in asthmatics RFC4 intron 23541324 rs1656941 chr3 186519141 A C 1.20E-05 Body mass index (asthmatics) RFC4 intron 23517042 rs1656941 chr3 186519141 A C 7.44E-05 Pulmonary function in asthmatics RFC4 intron 23541324 rs266717 chr3 186530484 T C 5.10E-04 Schizophrenia / / 19197363 rs266717 chr3 186530484 T C 9.00E-19 Adiponectin levels / / 20011104 rs6810075 chr3 186548565 T C 2.00E-42 Adiponectin levels / / 22479202 rs10937273 chr3 186549695 G A 2.00E-22 Adiponectin levels / / 24105470 rs1648707 chr3 186551711 A C 3.00E-12 Adiponectin levels / / 20011104 rs1656930 chr3 186552857 A G 3.88E-06 Type 2 diabetes / / 17463246 rs1656930 chr3 186552857 A G 1.31E-07 Adiponectin levels / / 20887962 rs864265 chr3 186554292 T G 1.32E-05 Type 2 diabetes / / 17463246 rs864265 chr3 186554292 T G 1.00E-19 Adiponectin levels / / 20876611 rs864265 chr3 186554292 T G 5.58E-08 Adiponectin levels / / 20887962 rs17300539 chr3 186559460 G A 3.56E-04 Alzheimer's disease (late onset) ADIPOQ nearGene-5 21379329 rs182052 chr3 186560782 G A 5.00E-44 Adiponectin levels ADIPOQ intron 22479202 rs822394 chr3 186566728 A C 4.09E-04 Alzheimer's disease (late onset) ADIPOQ intron 21379329 rs822396 chr3 186566877 G A 0.00000028 Confectionary intake ADIPOQ intron 23408455 rs17366568 chr3 186570453 G A 1.00E-41 Adiponectin levels ADIPOQ intron 20018283 rs2241767 chr3 186571196 A G 3.29E-08 Adiponectin levels ADIPOQ intron 20887962 rs2241767 chr3 186571196 A G 3.44E-04 Aortic root size ADIPOQ intron 21223598 rs6773957 chr3 186573705 A G 5.00E-08 Adiponectin levels ADIPOQ UTR-3 19165155 rs6444175 chr3 186579744 G A 9.64E-04 Heart Failure / / pha002885 rs7610498 chr3 186610838 A G 1.13E-05 Aortic root size / / 21223598 rs9853553 chr3 186612489 A T 8.22E-06 Aortic root size / / 21223598 rs11716002 chr3 186613364 A G 5.89E-05 Psoriasis / / 18364390 rs12632385 chr3 186633439 A G 8.00E-05 Aortic root size / / 21223598 rs7627293 chr3 186633775 G A,C,T 6.89E-06 HDL cholesterol / / 21589926 rs9876387 chr3 186634074 G A 2.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4686814 chr3 186642865 T C 7.40E-04 Type 2 diabetes / / 21874001 rs7356053 chr3 186644343 G C 6.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10937275 chr3 186650790 A G 1.00E-08 Drug-induced liver injury (flucloxacillin) ST6GAL1 intron 19483685 rs12493118 chr3 186650942 T C 8.51E-04 Type 2 diabetes ST6GAL1 intron 17463246 rs12493118 chr3 186650942 T C 6.33E-04 Multiple complex diseases ST6GAL1 intron 17554300 rs16861317 chr3 186664728 G A 1.90E-05 Type 2 diabetes ST6GAL1 intron 21874001 rs3852060 chr3 186665539 C G 7.90E-06 Type 2 diabetes ST6GAL1 intron 21874001 rs3887925 chr3 186665645 C T 2.90E-05 Type 2 diabetes ST6GAL1 intron 21874001 rs16861329 chr3 186666461 C T 3.00E-08 Type 2 diabetes ST6GAL1 intron 21874001 rs16861329 chr3 186666461 C T 3.40E-08 Type 2 diabetes ST6GAL1 intron 23300278 rs16861329 chr3 186666461 C T 9.00E-06 Type 2 diabetes ST6GAL1 intron 24509480 rs12632862 chr3 186669214 A G 1.10E-05 Type 2 diabetes ST6GAL1 intron 21874001 rs6444187 chr3 186674138 C G 1.10E-05 Type 2 diabetes ST6GAL1 intron 21874001 rs6444188 chr3 186677936 G T 2.30E-04 Type 2 diabetes ST6GAL1 intron 21874001 rs6444188 chr3 186677936 G T 4.18E-05 Response to tocilizumab in rheumatoid arthritis ST6GAL1 intron 22491018 rs4686819 chr3 186681207 G C 5.90E-04 Type 2 diabetes ST6GAL1 intron 21874001 rs6809750 chr3 186682612 C T 1.30E-04 Blood pressure ST6GAL1 intron 17255346 rs6778436 chr3 186684364 T A 5.00E-06 Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure) ST6GAL1 intron 21130132 rs16861384 chr3 186684511 C T 1.91E-04 Blood pressure ST6GAL1 intron 17255346 rs16861384 chr3 186684511 C T 2.10E-07 Adiponectin levels ST6GAL1 intron 20887962 rs16861384 chr3 186684511 C T 3.60E-04 Alzheimer's disease (late onset) ST6GAL1 intron 21379329 rs12495023 chr3 186685299 A G 1.71E-04 Common variable immunodeficiency ST6GAL1 intron 21497890 rs6795614 chr3 186688608 C G 7.10E-04 Response to cytadine analogues (cytosine arabinoside) ST6GAL1 intron 24483146 rs17374323 chr3 186690716 G A 3.90E-08 Metabolite levels ST6GAL1 intron 23281178 rs6444190 chr3 186691605 C T 1.30E-08 Metabolite levels ST6GAL1 intron 23281178 rs6444191 chr3 186699610 A G 5.31E-04 Smoking initiation ST6GAL1 intron 24665060 rs7652995 chr3 186722944 G A 2.00E-20 IgG glycosylation ST6GAL1 intron 23382691 rs7652995 chr3 186722944 G A 3.00E-40 IgG glycosylation ST6GAL1 intron 23382691 rs7652995 chr3 186722944 G A 4.00E-07 IgG glycosylation ST6GAL1 intron 23382691 rs7652995 chr3 186722944 G A 4.00E-16 IgG glycosylation ST6GAL1 intron 23382691 rs7652995 chr3 186722944 G A 5.00E-08 IgG glycosylation ST6GAL1 intron 23382691 rs7652995 chr3 186722944 G A 5.00E-08 IgG glycosylation ST6GAL1 intron 23382691 rs7652995 chr3 186722944 G A 5.00E-19 IgG glycosylation ST6GAL1 intron 23382691 rs7652995 chr3 186722944 G A 7.00E-17 IgG glycosylation ST6GAL1 intron 23382691 rs7652995 chr3 186722944 G A 9.00E-15 IgG glycosylation ST6GAL1 intron 23382691 rs11710456 chr3 186725887 G A 1.00E-08 IgG glycosylation ST6GAL1 intron 23382691 rs11710456 chr3 186725887 G A 2.00E-06 IgG glycosylation ST6GAL1 intron 23382691 rs11710456 chr3 186725887 G A 2.00E-13 IgG glycosylation ST6GAL1 intron 23382691 rs11710456 chr3 186725887 G A 2.00E-45 IgG glycosylation ST6GAL1 intron 23382691 rs11710456 chr3 186725887 G A 3.00E-06 IgG glycosylation ST6GAL1 intron 23382691 rs11710456 chr3 186725887 G A 3.00E-37 IgG glycosylation ST6GAL1 intron 23382691 rs11710456 chr3 186725887 G A 4.00E-31 IgG glycosylation ST6GAL1 intron 23382691 rs11710456 chr3 186725887 G A 5.00E-06 IgG glycosylation ST6GAL1 intron 23382691 rs11710456 chr3 186725887 G A 5.00E-06 IgG glycosylation ST6GAL1 intron 23382691 rs11710456 chr3 186725887 G A 5.00E-17 IgG glycosylation ST6GAL1 intron 23382691 rs11710456 chr3 186725887 G A 5.00E-44 IgG glycosylation ST6GAL1 intron 23382691 rs11710456 chr3 186725887 G A 6.00E-11 IgG glycosylation ST6GAL1 intron 23382691 rs11710456 chr3 186725887 G A 6.00E-17 IgG glycosylation ST6GAL1 intron 23382691 rs11710456 chr3 186725887 G A 6.00E-75 IgG glycosylation ST6GAL1 intron 23382691 rs11710456 chr3 186725887 G A 8.00E-07 IgG glycosylation ST6GAL1 intron 23382691 rs11710456 chr3 186725887 G A 8.00E-17 IgG glycosylation ST6GAL1 intron 23382691 rs11710456 chr3 186725887 G A 9.00E-07 IgG glycosylation ST6GAL1 intron 23382691 rs11710456 chr3 186725887 G A 9.00E-07 IgG glycosylation ST6GAL1 intron 23382691 rs11710456 chr3 186725887 G A 9.00E-37 IgG glycosylation ST6GAL1 intron 23382691 rs7619989 chr3 186731749 G C 7.83E-05 Alzheimer's disease (late onset) ST6GAL1 intron 21460841 rs17776120 chr3 186732679 C A 2.00E-06 IgG glycosylation ST6GAL1 intron 23382691 rs3821819 chr3 186732725 G A 3.00E-06 IgG glycosylation ST6GAL1 intron 23382691 rs4686837 chr3 186739677 G A 0.000046 Aging ST6GAL1 UTR-5 22445811 rs4012249 chr3 186779864 G A 8.73E-04 Obesity (extreme) ST6GAL1 intron 21935397 rs2239612 chr3 186793242 G A 6.00E-14 Esophageal cancer (squamous cell) ST6GAL1 intron 22960999 rs270161 chr3 186830661 G T 1.57E-04 Alzheimer's disease (late onset) / / 21379329 rs9817493 chr3 186836148 A G 7.80E-06 Urinary metabolites / / 21572414 rs16861630 chr3 186840304 G C 3.64E-04 Multiple complex diseases RPL39L intron 17554300 rs6444209 chr3 186902640 A G 1.17E-05 Alzheimer's disease (late onset) / / 21379329 rs10513812 chr3 186905494 T C 4.32E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs13097373 chr3 186911335 A G 6.87E-04 Alzheimer's disease / / 17998437 rs4621318 chr3 186921468 G A 8.00E-04 Alzheimer's disease / / 17998437 rs3908206 chr3 186928756 G A 1.25E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3852053 chr3 186937200 T G 2.00E-07 Amyotrophic lateral sclerosis (sporadic) MASP1 UTR-3 24529757 rs3821801 chr3 186937221 T C 3.86E-04 Alzheimer's disease (late onset) MASP1 UTR-3 21379329 rs3914010 chr3 186939573 A G 1.35E-04 Depression (quantitative trait) MASP1 intron 20800221 rs3864097 chr3 186950635 G A 6.03E-04 Multiple complex diseases MASP1 intron 17554300 rs696405 chr3 186956223 T G 5.73E-04 Response to statin treatment (atorvastatin),change in cholesterol levels MASP1 intron 20031582 rs3815623 chr3 186959042 G A 3.33E-04 Schizophrenia MASP1 intron 19197363 rs3105782 chr3 186971296 A G 3.85E-05 Alcohol and nictotine co-dependence MASP1 intron 20158304 rs698103 chr3 186993633 C T 4.40E-04 Type 2 diabetes MASP1 intron 21874001 rs698084 chr3 186997648 C T 1.05E-04 Response to cytadine analogues (cytosine arabinoside) MASP1 intron 24483146 rs13086064 chr3 187082029 A G 1.82E-04 HIV-1 viral setpoint / / 17641165 rs3821812 chr3 187088812 C T 2.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RTP4 missense 20877124 rs2102860 chr3 187110983 G A 3.50E-07 Primary nonsyndromic vesicoureteric reflex / / 19959718 rs7637064 chr3 187158529 T C 4.27E-05 Cleft lip / / 20436469 rs9815313 chr3 187175707 T C 9.45E-04 Alzheimer's disease / / 17998437 rs2687929 chr3 187198594 T C 0.00006789 Sarcoidosis / / 22952805 rs3096554 chr3 187212929 G A 0.0000447 Sarcoidosis / / 22952805 rs2553985 chr3 187214953 C T 0.0000447 Sarcoidosis / / 22952805 rs1452186 chr3 187217907 T C 0.00003759 Sarcoidosis / / 22952805 rs9846911 chr3 187218336 A G 0.0000045 Chronic kidney disease / / 23539754 rs9846911 chr3 187218336 A G 0.000018 Chronic kidney disease in individuals with hypertension / / 23539754 rs9846911 chr3 187218336 A G 0.0007 Glomerular filtration rate / / 23539754 rs3096555 chr3 187220117 C T 0.00009022 Sarcoidosis / / 22952805 rs9867503 chr3 187221936 A C 6.31E-05 Insulin resistance / / 21901158 rs6792062 chr3 187223152 T C 7.34E-04 Insulin resistance / / 21901158 rs7627908 chr3 187223750 G A 5.77E-04 Insulin resistance / / 21901158 rs10937304 chr3 187233157 A G 2.56E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs11922608 chr3 187236486 G A 5.40E-04 Pulmonary function / / 23932459 rs2653294 chr3 187242051 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2653295 chr3 187242776 A C 6.02E-04 Type 2 diabetes / / 17463246 rs2123174 chr3 187251280 A C 8.53E-04 Bipolar disorder / / 19259986 rs2653312 chr3 187264516 A G 3.61E-04 Multiple complex diseases / / 17554300 rs12491596 chr3 187290759 C A 8.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs6444238 chr3 187293669 T C 1.46E-04 Cholesterol / / 17255346 rs4472044 chr3 187294550 C T 9.00E-05 Prostate cancer / / 21743057 rs7635068 chr3 187331590 C T 7.93E-05 Recombination rate / / 21698098 rs13094242 chr3 187347603 A G 5.66E-05 Bipolar disorder / / 17486107 rs12638067 chr3 187391918 T C 1.50E-10 Coronary heart disease / / 21971053 rs6802392 chr3 187401981 T C 4.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs6765587 chr3 187402515 A T 5.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs12330172 chr3 187404538 C T 4.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs9852013 chr3 187404569 A T 3.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs3915052 chr3 187407916 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12635770 chr3 187408532 C A 3.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs9861141 chr3 187408853 G A 2.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs955305 chr3 187409112 A C 4.49E-04 Multiple complex diseases / / 17554300 rs6774111 chr3 187409817 A G 2.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs7616340 chr3 187411599 T C 3.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs4686898 chr3 187411830 C T 3.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs954470 chr3 187412271 C T 5.17E-04 Multiple complex diseases / / 17554300 rs6808829 chr3 187412783 G A 2.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs10937316 chr3 187413688 C T 9.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs6764050 chr3 187413991 G A 9.00E-07 Response to citalopram treatment / / 22760553 rs9878204 chr3 187435688 A G 7.85E-04 Multiple complex diseases LOC100131635 intron 17554300 rs9865102 chr3 187436167 T C 5.81E-04 Multiple complex diseases LOC100131635 intron 17554300 rs4686904 chr3 187438522 C T 9.96E-04 Suicide attempts in bipolar disorder LOC100131635 intron 21423239 rs1056932 chr3 187447032 G A 3.66E-04 Suicide attempts in bipolar disorder BCL6 cds-synon 21423239 rs6762932 chr3 187448997 G A 9.63E-04 Multiple complex diseases BCL6 intron 17554300 rs1880100 chr3 187451701 T C 7.04E-04 Suicide attempts in bipolar disorder BCL6 intron 21423239 rs3774304 chr3 187454731 C G 8.30E-04 Suicide attempts in bipolar disorder BCL6 intron 21423239 rs3733017 chr3 187456709 T G 6.00E-06 PR interval BCL6 intron 23534349 rs3172469 chr3 187459088 T G 3.38E-04 Amyotrophic Lateral Sclerosis BCL6 intron 17362836 rs1523474 chr3 187459497 T C 5.36E-04 Suicide attempts in bipolar disorder BCL6 intron 21423239 rs1980301 chr3 187494790 A G 4.52E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10446290 chr3 187536139 C T 3.88E-04 Self-reported allergy / / 23817569 rs2713721 chr3 187541227 A G 8.43E-05 Cognitive test performance / / 20125193 rs10513821 chr3 187543342 A G 5.00E-07 Pulmonary function (interaction) / / 23284291 rs2611624 chr3 187547134 C T 7.00E-05 Self-reported allergy / / 23817569 rs878447 chr3 187547250 T C 7.00E-05 Self-reported allergy / / 23817569 rs512178 chr3 187549526 G T 6.59E-05 Self-reported allergy / / 23817569 rs2713717 chr3 187550417 T A 6.64E-05 Self-reported allergy / / 23817569 rs1975515 chr3 187551861 A C 6.60E-05 Self-reported allergy / / 23817569 rs2679538 chr3 187553580 G A 6.21E-05 Self-reported allergy / / 23817569 rs577790 chr3 187554959 T C 6.59E-05 Self-reported allergy / / 23817569 rs718952 chr3 187555952 G C 7.27E-05 Self-reported allergy / / 23817569 rs2611611 chr3 187556692 G C 5.65E-05 Self-reported allergy / / 23817569 rs503787 chr3 187562959 A G 7.64E-05 Self-reported allergy / / 23817569 rs9847913 chr3 187567641 A G 1.59E-04 Self-reported allergy / / 23817569 rs2713725 chr3 187569084 C G 9.66E-05 Self-reported allergy / / 23817569 rs16862659 chr3 187573501 T C 0.0000072 Mean arterial pressure / / 22510845 rs507205 chr3 187574871 G A 9.33E-05 Self-reported allergy / / 23817569 rs508925 chr3 187575052 G A 9.32E-05 Self-reported allergy / / 23817569 rs10049107 chr3 187592796 T C 4.15E-05 Self-reported allergy / / 23817569 rs6444260 chr3 187593594 A G 4.59E-05 Self-reported allergy / / 23817569 rs6444261 chr3 187593709 T A 4.20E-05 Self-reported allergy / / 23817569 rs6444262 chr3 187593922 C G 4.33E-05 Self-reported allergy / / 23817569 rs6778044 chr3 187594092 C T 1.06E-04 Self-reported allergy / / 23817569 rs9290865 chr3 187594772 A C 1.06E-04 Self-reported allergy / / 23817569 rs6805813 chr3 187595294 A G 1.86E-04 Self-reported allergy / / 23817569 rs7630284 chr3 187595977 C T 4.72E-05 Self-reported allergy / / 23817569 rs6785112 chr3 187596036 G A 5.63E-05 Self-reported allergy / / 23817569 rs6798156 chr3 187596315 T G 5.63E-05 Self-reported allergy / / 23817569 rs6788294 chr3 187596744 G T 6.69E-05 Self-reported allergy / / 23817569 rs6788131 chr3 187596829 C A 6.69E-05 Self-reported allergy / / 23817569 rs6788231 chr3 187596865 C G 6.70E-05 Self-reported allergy / / 23817569 rs6788563 chr3 187597020 G A 7.09E-05 Self-reported allergy / / 23817569 rs10937325 chr3 187600070 T G 2.57E-04 Self-reported allergy / / 23817569 rs2009621 chr3 187600435 T C 3.80E-04 Self-reported allergy / / 23817569 rs2590442 chr3 187621807 G C 1.45E-04 Smoking cessation / / 24665060 rs11718528 chr3 187624205 G A 1.23E-04 Alzheimer's disease (late onset) / / 21379329 rs11718528 chr3 187624205 G A 2.82E-05 Platelet counts / / pha003100 rs1903216 chr3 187629503 A G 5.04E-05 Paclitaxel-induced neuropathy / / 23776197 rs11711595 chr3 187630727 A G 7.26E-04 Smoking quantity / / 24665060 rs9810106 chr3 187632238 G C 3.32E-04 Depression (quantitative trait) / / 20800221 rs507595 chr3 187642421 A G 2.70E-04 Multiple complex diseases / / 17554300 rs6773854 chr3 187649419 T C 3.00E-13 B cell non-Hodgkin lymphoma / / 23749188 rs542887 chr3 187650907 C T 1.00E-05 Urinary metabolites / / 21572414 rs16862729 chr3 187652724 A T 5.03E-04 Multiple complex diseases / / 17554300 rs563275 chr3 187658376 G A 1.26E-05 Soluble levels of adhesion molecules / / pha003072 rs2590453 chr3 187667808 A G 1.45E-05 Soluble levels of adhesion molecules / / pha003072 rs2292893 chr3 187684310 A G 4.88E-05 Type 2 diabetes / / 22158537 rs9820070 chr3 187687074 A C 1.00E-11 Blood cell counts and other traits LOC100505844 intron 20139978 rs9820070 chr3 187687074 A C 1.24E-11 Blood cell counts and other traits LOC100505844 intron 20139978 rs16862782 chr3 187687890 C A 5.00E-07 Myopia (pathological) LOC100505844 intron 23049088 rs16862782 chr3 187687890 C A 4.79E-05 HDL particle features LOC100505844 intron pha002900 rs1348637 chr3 187688669 A G 3.10E-05 Immunoglobulin A LOC100505844 intron 20694011 rs13084873 chr3 187689617 G A 4.83E-04 Smoking initiation LOC100505844 intron 24665060 rs16862801 chr3 187694384 C A 7.30E-05 Multiple complex diseases / / 17554300 rs13095186 chr3 187694767 T A 3.65E-05 Schizophrenia / / 19571809 rs17807098 chr3 187696291 C T 3.15E-04 Prostate cancer mortality / / 20978177 rs182181457 chr3 187698127 G A,T 1.78E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs182181457 chr3 187698127 G A,T 4.01E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs183664191 chr3 187700110 G A 1.70E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs183664191 chr3 187700110 G A 3.76E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs13086642 chr3 187705040 G A 6.02E-04 Smoking initiation / / 24665060 rs13086642 chr3 187705040 G A 5.85E-04 Alzheimer's disease / / 24755620 rs184662298 chr3 187705887 G A 2.00E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs184662298 chr3 187705887 G A 3.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs9860469 chr3 187710426 A G 5.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs57649868 chr3 187711072 C T 7.77E-06 Stroke (ischemic) / / 21957438 rs10937329 chr3 187713718 T A 9.00E-30 Renal function-related traits (BUN) / / 22797727 rs1553091 chr3 187716886 A G 7.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs4686914 chr3 187717540 C T 3.00E-21 Metabolite levels / / 21909109 rs35198260 chr3 187718139 G A 7.45E-06 Stroke (ischemic) / / 21957438 rs9843063 chr3 187719473 G A 5.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs16848771 chr3 187721355 T C 4.86E-04 Alzheimer's disease / / 24755620 rs11924318 chr3 187727515 G A 7.12E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs9816541 chr3 187735687 T C 3.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6808574 chr3 187740523 T C 6.00E-09 Type 2 diabetes / / 24509480 rs2378357 chr3 187743661 T C 8.66E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10937331 chr3 187748077 A G 0.00000271 Sasang constitution (Taeum) / / 22394158 rs11710227 chr3 187753995 A G 1.08E-04 Colorectal cancer / / 24448986 rs9856948 chr3 187757401 C T 2.51E-05 Male-pattern baldness / / 18849994 rs6789987 chr3 187763398 C T 3.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs6789987 chr3 187763398 C T 9.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs6773107 chr3 187783035 C A 8.92E-04 Multiple complex diseases / / 17554300 rs6773107 chr3 187783035 C A 2.60E-05 Urinary metabolites / / 21572414 rs16862964 chr3 187792711 T C 7.00E-06 Type 2 diabetes (young onset) and obesity / / 24465431 rs147069939 chr3 187792953 A G 3.88E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs147069939 chr3 187792953 A G 9.35E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs9833256 chr3 187793410 T C 3.27E-05 Eosinophil counts / / pha003088 rs2037184 chr3 187795657 T C 3.64E-04 Multiple complex diseases / / 17554300 rs9821867 chr3 187799940 G T 3.86E-05 Intelligence / / 21826061 rs7640617 chr3 187814402 T C 1.76E-04 Multiple complex diseases / / 17554300 rs189372 chr3 187839070 T C 2.98E-05 Paclitaxel-induced neuropathy / / 23776197 rs13322880 chr3 187845477 A G 1.91E-05 HDL cholesterol / / pha003074 rs4686935 chr3 187856109 A C 1.19E-04 Tourette syndrome / / 22889924 rs844106 chr3 187874933 C A 6.81E-05 Bipolar disorder LPP intron 22925353 rs10937342 chr3 187876908 A C 5.40E-06 Urinary metabolites LPP intron 21572414 rs1711001 chr3 187879004 C T 4.00E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LPP intron 20031582 rs1711001 chr3 187879004 C T 3.92E-04 Hodgkin's lymphoma LPP intron 24149102 rs9863441 chr3 187901252 A G 2.35E-04 Multiple complex diseases LPP intron 17554300 rs1710997 chr3 187908259 T C 2.39E-05 Hodgkin's lymphoma LPP intron 24149102 rs13091770 chr3 187931652 G C,T 2.90E-05 Urinary metabolites LPP intron 21572414 rs1975991 chr3 187944924 A G 6.00E-06 White matter integrity (interaction) LPP intron 23218918 rs7637251 chr3 187947144 G A 6.48E-05 Multiple complex diseases LPP intron 17554300 rs12629148 chr3 187963313 C G 5.40E-05 Depression (quantitative trait) LPP intron 20800221 rs6782041 chr3 187965184 T C 1.73E-04 QT interval LPP intron 22726844 rs9844029 chr3 187971048 T C 2.53E-04 Hearing function LPP intron 17255346 rs9844029 chr3 187971048 T C 2.30E-05 Depression (quantitative trait) LPP intron 20800221 rs9838939 chr3 187979323 G T 2.86E-04 Depression (quantitative trait) LPP intron 20800221 rs715790 chr3 187985004 C T 6.07E-04 Multiple complex diseases LPP intron 17554300 rs715790 chr3 187985004 C T 2.24E-04 Depression (quantitative trait) LPP intron 20800221 rs6807582 chr3 187986617 C T 4.44E-04 Depression (quantitative trait) LPP intron 20800221 rs13066827 chr3 187987726 A G 1.00E-04 Depression (quantitative trait) LPP intron 20800221 rs16848776 chr3 187988025 C T 4.22E-04 Depression (quantitative trait) LPP intron 20800221 rs6444273 chr3 187989520 T A 4.06E-04 Depression (quantitative trait) LPP intron 20800221 rs6444274 chr3 187989686 A G 3.39E-04 Depression (quantitative trait) LPP intron 20800221 rs6762523 chr3 187991205 A G 3.37E-04 Depression (quantitative trait) LPP intron 20800221 rs6779331 chr3 187995779 A G 4.25E-04 Depression (quantitative trait) LPP intron 20800221 rs6792835 chr3 187998081 C G 1.16E-05 Large artery stroke LPP intron 24262325 rs9839229 chr3 188000625 T C 1.27E-04 Depression (quantitative trait) LPP intron 20800221 rs11713973 chr3 188001875 T C 1.07E-04 Depression (quantitative trait) LPP intron 20800221 rs4461411 chr3 188016822 G C 9.23E-04 Acute lung injury LPP intron 22295056 rs13061167 chr3 188021469 G A 5.69E-04 Self-reported allergy LPP intron 23817569 rs9818529 chr3 188031813 T C 5.67E-04 Self-reported allergy LPP intron 23817569 rs9823591 chr3 188032635 T C 6.00E-04 Self-reported allergy LPP intron 23817569 rs9828858 chr3 188035619 A G 5.02E-04 Self-reported allergy LPP intron 23817569 rs9865818 chr3 188072513 A G 2.29E-07 Self-reported allergy LPP intron 23817569 rs9865818 chr3 188072513 A G 3.00E-10 Allergic sensitization LPP intron 23817571 rs9865818 chr3 188072513 A G 1.77E-04 Celiac disease LPP intron 23936387 rs7629708 chr3 188075185 C A,T 5.11E-04 Type 2 diabetes LPP intron 17463246 rs7629708 chr3 188075185 C A,T 1.40E-05 Urinary metabolites LPP intron 21572414 rs11709472 chr3 188077586 C T 3.10E-08 Self-reported allergy LPP intron 23817569 rs9842232 chr3 188080163 C G 1.79E-08 Self-reported allergy LPP intron 23817569 rs7640550 chr3 188080248 T C 3.22E-07 Self-reported allergy LPP intron 23817569 rs9851967 chr3 188087628 C T 9.00E-08 Vitiligo LPP intron 22951725 rs9851967 chr3 188087628 C T 4.62E-09 Self-reported allergy LPP intron 23817569 rs9851967 chr3 188087628 C T 7.94E-04 Celiac disease LPP intron 23936387 rs11715716 chr3 188088640 C G 3.67E-09 Self-reported allergy LPP intron 23817569 rs13076312 chr3 188089254 C T 9.92E-07 Vitiligo LPP intron 20410501 rs13076312 chr3 188089254 C T 9.37E-06 Vitiligo LPP intron 22951725 rs13076312 chr3 188089254 C T 9.54E-07 Self-reported allergy LPP intron 23817569 rs11709294 chr3 188098035 T A 4.22E-09 Self-reported allergy LPP intron 23817569 rs1474275 chr3 188099420 T G 2.14E-07 Self-reported allergy LPP intron 23817569 rs1915930 chr3 188100256 G T 9.29E-09 Self-reported allergy LPP intron 23817569 rs2030517 chr3 188101703 A C 3.07E-08 Self-reported allergy LPP intron 23817569 rs2030516 chr3 188101739 T C 3.82E-09 Self-reported allergy LPP intron 23817569 rs13079741 chr3 188101861 G C 2.48E-07 Self-reported allergy LPP intron 23817569 rs2889896 chr3 188102716 C T 6.01E-07 Self-reported allergy LPP intron 23817569 rs9864529 chr3 188105056 G A 9.75E-08 Self-reported allergy LPP intron 23817569 rs4686955 chr3 188106379 A G 3.15E-09 Self-reported allergy LPP intron 23817569 rs12485704 chr3 188109766 C T 2.36E-07 Self-reported allergy LPP intron 23817569 rs7613192 chr3 188109833 G C 1.83E-09 Self-reported allergy LPP intron 23817569 rs1464510 chr3 188112554 C A,G,T 9.00E-05 Celiac disease LPP intron 17558408 rs1464510 chr3 188112554 C A,G,T 5.00E-09 Celiac disease LPP intron 18311140 rs1464510 chr3 188112554 C A,G,T 3.00E-40 Celiac disease LPP intron 20190752 rs1464510 chr3 188112554 C A,G,T 1.00E-11 Vitiligo LPP intron 20410501 rs1464510 chr3 188112554 C A,G,T 3.00E-40 Asthma LPP intron 21150878 rs1464510 chr3 188112554 C A,G,T 6.45E-09 Vitiligo LPP intron 21326295 rs1464510 chr3 188112554 C A,G,T 2.98E-40 Celiac disease and Rheumatoid arthritis LPP intron 21383967 rs1464510 chr3 188112554 C A,G,T 3.00E-40 Asthma LPP intron 21907864 rs1464510 chr3 188112554 C A,G,T 2.98E-40 Multiple sclerosis LPP intron 22190364 rs1464510 chr3 188112554 C A,G,T 8.83E-20 Vitiligo LPP intron 22561518 rs1464510 chr3 188112554 C A,G,T 8.37E-08 Self-reported allergy LPP intron 23817569 rs13091753 chr3 188114589 G T 3.61E-07 Vitiligo LPP intron 20410501 rs13091753 chr3 188114589 G T 7.27E-08 Self-reported allergy LPP intron 23817569 rs9834115 chr3 188115142 T C 3.05E-08 Self-reported allergy LPP intron 23817569 rs9834159 chr3 188115232 T A 6.48E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LPP intron 22566498 rs9834159 chr3 188115232 T A 6.00E-09 Self-reported allergy LPP intron 23817569 rs2030520 chr3 188119582 C T 7.77E-09 Self-reported allergy LPP intron 23817569 rs2030519 chr3 188119901 G A 3.00E-49 Celiac disease LPP intron 22057235 rs6785284 chr3 188120643 C T 5.68E-08 Self-reported allergy LPP intron 23817569 rs1035766 chr3 188120740 G A 5.65E-08 Self-reported allergy LPP intron 23817569 rs1035765 chr3 188120783 A T 6.14E-08 Self-reported allergy LPP intron 23817569 rs12639588 chr3 188121263 A G 2.24E-09 Self-reported allergy LPP intron 23817569 rs2049218 chr3 188122978 C T 1.39E-09 Self-reported allergy LPP intron 23817569 rs1559810 chr3 188124354 C A 4.37E-07 Vitiligo LPP intron 20410501 rs1559810 chr3 188124354 C A 6.32E-08 Self-reported allergy LPP intron 23817569 rs13093110 chr3 188125120 C T 0.000000817 Graves' disease LPP intron 22922229 rs13093110 chr3 188125120 C T 3.69E-08 Graves' disease and Hashimoto's thyroiditis LPP intron 22922229 rs13093110 chr3 188125120 C T 8.04E-08 Self-reported allergy LPP intron 23817569 rs9860547 chr3 188128979 G A 1.00E-09 Self-reported allergy LPP intron 23817569 rs6780858 chr3 188132110 A G 1.47E-08 Self-reported allergy LPP intron 23817569 rs13098877 chr3 188133163 C T 1.15E-07 Self-reported allergy LPP intron 23817569 rs6808893 chr3 188133439 C T 4.89E-08 Self-reported allergy LPP intron 23817569 rs13099273 chr3 188133518 A T 1.83E-08 Self-reported allergy LPP intron 23817569 rs12485444 chr3 188135783 T A 1.78E-08 Self-reported allergy LPP intron 23817569 rs4122385 chr3 188140653 G A 6.81E-05 Hypertension LPP intron 19609347 rs6444295 chr3 188192294 G A 2.33E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) LPP intron 24023788 rs1426270 chr3 188213695 C T 9.36E-05 Erythrocyte counts LPP intron pha003090 rs1426267 chr3 188223849 A G 1.10E-05 Urinary metabolites LPP intron 21572414 rs7428265 chr3 188224549 A G 2.53E-05 Triglycerides LPP intron pha003080 rs6807897 chr3 188233404 G A 7.15E-04 Nicotine smoking LPP intron 19268276 rs6806091 chr3 188237765 C G 1.82E-04 Blood pressure (response to calcium channel blocker) LPP intron 24192120 rs6782121 chr3 188238011 A G 6.52E-04 Type 2 diabetes LPP intron 17463246 rs6782121 chr3 188238011 A G 1.82E-04 Blood pressure (response to calcium channel blocker) LPP intron 24192120 rs16863413 chr3 188261073 A G 7.52E-05 Insulin resistance LPP intron 21901158 rs10937355 chr3 188289697 C T 9.00E-06 Obesity-related traits LPP intron 23251661 rs7629059 chr3 188290842 G C 2.54E-04 Gallstones LPP intron 17632509 rs4686980 chr3 188302851 T C 1.49E-04 Lung function (forced expiratory volume in 1 second) LPP intron 24023788 rs4686980 chr3 188302851 T C 1.98E-04 Lung function (forced vital capacity) LPP intron 24023788 rs4407399 chr3 188304448 T C 2.63E-04 Body mass index LPP intron 17255346 rs4407399 chr3 188304448 T C 3.36E-04 Lung function (forced expiratory volume in 1 second) LPP intron 24023788 rs4407399 chr3 188304448 T C 4.18E-04 Lung function (forced vital capacity) LPP intron 24023788 rs6444307 chr3 188307518 A G 7.20E-05 Lipid traits LPP intron 24386095 rs6777758 chr3 188314294 C T 2.24E-04 Alzheimer's disease LPP intron 22005930 rs6807988 chr3 188315629 A G 3.89E-04 Alzheimer's disease LPP intron 22005930 rs6807988 chr3 188315629 A G 3.61E-04 Self-reported allergy LPP intron 23817569 rs11711393 chr3 188316361 T C 2.28E-04 Alzheimer's disease LPP intron 22005930 rs9837401 chr3 188320064 G A 2.53E-04 Alzheimer's disease LPP intron 22005930 rs9837401 chr3 188320064 G A 0.0000039 Follicular lymphoma LPP intron 23025665 rs6780491 chr3 188320409 G A 2.93E-04 Alzheimer's disease LPP intron 22005930 rs7615767 chr3 188323593 A G 2.00E-05 Urinary metabolites LPP intron 21572414 rs9877898 chr3 188338763 C T 8.23E-04 Tourette syndrome LPP intron 22889924 rs17669928 chr3 188360043 A G 7.00E-05 Hypertension LPP intron pha003041 rs938413 chr3 188364613 C T 1.27E-11 Alcohol consumption LPP intron pha001402 rs1818553 chr3 188367252 G A 1.95E-04 Response to cytidine analogues (gemcitabine) LPP intron 24483146 rs9815785 chr3 188375952 G T 3.53E-04 Response to cytidine analogues (gemcitabine) LPP intron 24483146 rs6796000 chr3 188391519 T A 1.10E-04 Blood Pressure and Arterial Stiffness LPP intron 17903302 rs17670280 chr3 188400239 G C 4.07E-04 Multiple complex diseases LPP intron 17554300 rs17607619 chr3 188403035 A G 5.60E-04 Multiple complex diseases LPP intron 17554300 rs11916786 chr3 188408718 T C 5.53E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines LPP intron 21844884 rs7651859 chr3 188409366 G A 7.85E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines LPP intron 21844884 rs1254774 chr3 188419526 G A 3.72E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines LPP intron 21844884 rs1152846 chr3 188420897 T C 3.00E-06 Body mass index LPP intron 19851299 rs1152846 chr3 188420897 T C 6.00E-06 Weight LPP intron 19851299 rs4686492 chr3 188436575 T C 1.24E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines LPP intron 21844884 rs9810196 chr3 188439936 C G 6.63E-05 IgE levels LPP intron 22075330 rs9848114 chr3 188440176 A G 6.57E-05 IgE levels LPP intron 22075330 rs9815874 chr3 188441161 C T 6.33E-05 IgE levels LPP intron 22075330 rs9290877 chr3 188442480 T C 2.00E-06 IgE levels LPP intron 22075330 rs2889906 chr3 188445385 C G 6.21E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines LPP intron 21844884 rs2378442 chr3 188445634 T A 3.24E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines LPP intron 21844884 rs9877870 chr3 188456755 A C 1.28E-05 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia LPP intron 24039173 rs16848791 chr3 188470563 T G 1.55E-04 Type 2 diabetes LPP intron 17463246 rs10513829 chr3 188488333 A G 8.94E-04 Schizophrenia LPP intron 21674006 rs6808275 chr3 188491558 A G 2.94E-05 Multiple sclerosis LPP intron 20598377 rs1546736 chr3 188495948 G A 6.11E-05 Multiple sclerosis LPP intron 20598377 rs12487595 chr3 188518434 A C 8.80E-06 Breast cancer LPP intron 22452962 rs6801602 chr3 188519594 A G 1.13E-05 Fibrinogen LPP intron pha003068 rs4686997 chr3 188539861 G A 1.60E-05 Fibrinogen LPP intron pha003068 rs3856921 chr3 188550579 T C 9.71E-04 Parkinson's disease LPP intron 16252231 rs9861473 chr3 188566306 A G 0.0000588 Panic disorder LPP intron 23149450 rs9861473 chr3 188566306 A G 5.88E-05 Serum tamsulosin hydrochloride concentration LPP intron 23151678 rs1513181 chr3 188574996 G A 7.93E-05 Fibrinogen LPP intron pha003068 rs13067593 chr3 188584679 A G 8.00E-08 Immune reponse to smallpox (secreted IFN-alpha) LPP intron 22610502 rs6793523 chr3 188600300 G A 8.84E-05 Body Mass Index LPP UTR-3 pha003015 rs16863691 chr3 188609999 G T 5.70E-05 Body Mass Index / / pha003015 rs16863700 chr3 188638526 G C 4.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs17283813 chr3 188639695 G A 1.62E-05 Celiac disease / / 23936387 rs16863715 chr3 188640763 C G 6.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs16863750 chr3 188655545 C T 2.38E-05 Multiple complex diseases / / 17554300 rs6778275 chr3 188662678 A G 6.02E-04 Multiple complex diseases / / 17554300 rs10490882 chr3 188695971 G A 9.24E-04 Multiple complex diseases / / 17554300 rs6784681 chr3 188705022 A G 1.09E-05 Smoking cessation / / 24665060 rs1879903 chr3 188711067 G A 3.11E-05 Celiac disease / / 23936387 rs849006 chr3 188753635 G A 1.02E-04 Multiple complex diseases / / 17554300 rs2378464 chr3 188822577 G C 4.50E-04 Type 2 diabetes and 6 quantitative traits LOC100505861 intron 17848626 rs9815495 chr3 188860551 C T 8.10E-05 Response to alcohol consumption (flushing response) LOC100505861 intron 24277619 rs9836375 chr3 188864388 C T 8.82E-05 Monocyte chemoattractant protein-1 LOC100505861 intron pha003071 rs12494229 chr3 188873939 G A 5.77E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17479382 chr3 188878729 G A 9.20E-04 Multiple complex diseases / / 17554300 rs16864075 chr3 188917022 A G 3.23E-04 Smoking cessation TPRG1 intron 24665060 rs1450118 chr3 188936758 A G 2.69E-05 Serum metabolites TPRG1 intron 19043545 rs1375938 chr3 188939209 C G 6.06E-05 Serum metabolites TPRG1 intron 19043545 rs9833300 chr3 188939343 C A 6.06E-05 Serum metabolites TPRG1 intron 19043545 rs16864103 chr3 188939541 G A 5.03E-04 Suicide attempts in bipolar disorder TPRG1 intron 21423239 rs1562762 chr3 188940206 T G 6.42E-05 Suicide attempts in bipolar disorder TPRG1 intron 21423239 rs16864111 chr3 188941449 G A 1.96E-04 Suicide attempts in bipolar disorder TPRG1 intron 21423239 rs10513833 chr3 188989795 G A,C 3.46E-04 IgE levels TPRG1 intron 17255346 rs2176038 chr3 189000601 C G 6.93E-04 Multiple complex diseases TPRG1 intron 17554300 rs9682650 chr3 189004818 C T 2.54E-04 IgE levels TPRG1 intron 17255346 rs9682650 chr3 189004818 C T 7.58E-04 Premature ovarian failure TPRG1 intron 19508998 rs9682650 chr3 189004818 C T 9.72E-05 Non-alcoholic fatty liver disease histology (other) TPRG1 intron 20708005 rs1515078 chr3 189012573 A C 5.66E-04 Type 2 diabetes TPRG1 intron 17463246 rs1515078 chr3 189012573 A C 5.59E-06 Lipid traits TPRG1 intron 24023261 rs7640138 chr3 189019953 C T 2.87E-05 Lipid traits TPRG1 intron 24023261 rs17422816 chr3 189021709 C T 6.59E-04 Response to statin treatment (atorvastatin),change in cholesterol levels TPRG1 intron 20031582 rs17422816 chr3 189021709 C T 1.67E-05 Lipid traits TPRG1 intron 24023261 rs17422816 chr3 189021709 C T 4.70E-05 Lipid traits TPRG1 intron 24023261 rs9848261 chr3 189033565 T C 1.53E-05 Coronary heart disease TPRG1 intron pha003056 rs142095888 chr3 189055932 A G 2.33E-04 Acne (severe) / / 24927181 rs1399614 chr3 189067066 C G 5.83E-04 Type 2 diabetes / / 17846124 rs6775310 chr3 189075833 A C 1.90E-05 Urinary metabolites / / 21572414 rs4282052 chr3 189083242 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs260555 chr3 189107451 C A 1.84E-04 Rheumatoid arthritis / / 21452313 rs6778546 chr3 189110132 C T 6.18E-04 Rheumatoid arthritis / / 21452313 rs6789327 chr3 189113261 G A 3.00E-07 Axial length / / 24144296 rs13085813 chr3 189121959 C A 2.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs13084980 chr3 189127455 C T 9.05E-07 Coronary Artery Disease / / 17634449 rs13084980 chr3 189127455 C T 3.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs11712618 chr3 189129249 A T 3.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs11707115 chr3 189131433 C T 3.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs7619107 chr3 189132881 G A 2.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs6775595 chr3 189133577 G A 4.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs13101021 chr3 189135308 C T 6.85E-07 Coronary Artery Disease / / 17634449 rs13101021 chr3 189135308 C T 5.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs17491280 chr3 189142602 T C 6.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs260578 chr3 189149516 C G 8.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs6771859 chr3 189159352 T C 4.23E-06 Coronary Artery Disease / / 17634449 rs3891799 chr3 189161056 A G 1.38E-05 Coronary Artery Disease / / 17634449 rs3891798 chr3 189161117 A G 1.50E-05 Coronary Artery Disease / / 17634449 rs11706039 chr3 189190614 C A 3.47E-04 Obesity (extreme) / / 21935397 rs9290892 chr3 189206491 C T 1.45E-05 Bilirubin levels,in serum / / 19389676 rs1152862 chr3 189209220 C T 2.21E-04 Aortic root size / / 21223598 rs6444381 chr3 189231017 C G 5.92E-04 Depression (quantitative trait) / / 20800221 rs1895664 chr3 189239766 G A 7.20E-04 Depression (quantitative trait) / / 20800221 rs1424824 chr3 189256981 G T 9.42E-04 Multiple complex diseases / / 17554300 rs1424824 chr3 189256981 G T 0.000131057 Primary sclerosing cholangitis / / 23603763 rs4425233 chr3 189268798 T C 1.73E-04 Coronary heart disease / / 21606135 rs4687067 chr3 189284718 G A 7.80E-04 Multiple complex diseases / / 17554300 rs7610017 chr3 189343424 A G 3.09E-05 Age-related macular degeneration / / 22125219 rs4488809 chr3 189356261 T C 7.00E-26 Lung cancer TP63 intron 21725308 rs4488809 chr3 189356261 T C 4.00E-09 Lung cancer TP63 intron 23143601 rs7636839 chr3 189356941 A G 2.60E-06 Lung cancer TP63 intron 21725308 rs7636839 chr3 189356941 A G 1.08E-04 Acne (severe) TP63 intron 24399259 rs13314271 chr3 189357602 T C 1.82E-05 Lung cancer TP63 intron 24880342 rs13314271 chr3 189357602 T C 7.00E-10 Lung cancer TP63 intron 24880342 rs10937405 chr3 189383183 C T 7.00E-12 Lung adenocarcinoma TP63 intron 20871597 rs10937405 chr3 189383183 C T 7.00E-17 Lung adenocarcinoma TP63 intron 22797724 rs17505102 chr3 189401776 G C 2.00E-08 Acute lymphoblastic leukemia (childhood) TP63 intron 22076464 rs17505102 chr3 189401776 G C 9.00E-09 Acute lymphoblastic leukemia (childhood) TP63 intron 22076464 rs7622471 chr3 189404837 G A 1.25E-04 Cholesterol TP63 intron 17255346 rs4450788 chr3 189422355 G A 1.09E-04 Cholesterol TP63 intron 17255346 rs4687091 chr3 189448545 G A 8.34E-05 Height TP63 intron pha003011 rs9876702 chr3 189454340 G A 2.07E-04 Type 2 diabetes TP63 intron 17463246 rs6800495 chr3 189457674 G T 1.80E-05 Hypertension TP63 intron 22384028 rs4456839 chr3 189471289 C T 0.0007056 Sarcoidosis TP63 intron 22952805 rs6780467 chr3 189484028 A T 1.09E-04 Hearing function TP63 intron 17255346 rs1515496 chr3 189508566 T C 8.68E-05 Pancreatic cancer TP63 intron pha002889 rs1515495 chr3 189514047 A G 6.06E-05 ldl cholesterol TP63 intron pha003077 rs7619549 chr3 189522258 A G 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes TP63 intron 22628534 rs7624774 chr3 189527177 T A,C 5.24E-04 Amyotrophic lateral sclerosis (sporadic) TP63 intron 24529757 rs4687094 chr3 189528852 C A 5.46E-05 Orofacial clefts TP63 intron 20023658 rs9881595 chr3 189536660 A G 2.86E-05 Relative hand skill TP63 intron 24068947 rs17447439 chr3 189549423 A G 3.99E-05 Cleft lip TP63 intron 20436469 rs17447439 chr3 189549423 A G 4.44E-08 Primary biliary cirrhosis TP63 intron 23000144 rs17447439 chr3 189549423 A G 4.44E-08 Facial morphology TP63 intron 23028347 rs9817981 chr3 189563530 A G 6.21E-07 Nonalcoholic fatty liver disease TP63 intron 21423719 rs2176085 chr3 189570356 T G 9.01E-05 Cognitive decline TP63 intron 22054870 rs12106692 chr3 189574086 C T 1.42E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) TP63 intron 24023788 rs2378526 chr3 189574447 C G 7.06E-05 Cognitive decline TP63 intron 22054870 rs16864872 chr3 189581392 A G 8.45E-04 Type 2 diabetes TP63 intron 17463246 rs7653848 chr3 189585852 C T 4.64E-04 Type 2 diabetes TP63 intron 17463246 rs6789961 chr3 189587091 A G 2.52E-04 Amyotrophic Lateral Sclerosis TP63 intron 17827064 rs12107036 chr3 189600160 A G 3.03E-06 Osteoarthritis TP63 intron 22763110 rs148076109 chr3 189607152 C A 0.00068 Prostate cancer TP63 missense 23555315 rs9681004 chr3 189611194 T C 1.70E-05 Urinary metabolites TP63 intron 21572414 rs4687103 chr3 189632664 A G 7.08E-04 Response to TNF antagonist treatment / / 21061259 rs710521 chr3 189645933 T C 1.00E-07 Urinary bladder cancer / / 18794855 rs710521 chr3 189645933 T C 6.00E-08 Urinary bladder cancer / / 20348956 rs710521 chr3 189645933 T C 1.00E-07 Nasopharyngeal carcinoma / / 20512145 rs710521 chr3 189645933 T C 2.00E-10 Bladder cancer / / 20972438 rs710521 chr3 189645933 T C 0.00016 Breast cancer / / 23555315 rs710521 chr3 189645933 T C 2.00E-11 Bladder cancer / / 24163127 rs696065 chr3 189672384 A G 3.44E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs9290911 chr3 189674483 A G 2.08E-04 Multiple complex diseases LEPREL1 nearGene-3 17554300 rs837678 chr3 189685881 G A 3.80E-05 Kidney function and endocine traits LEPREL1 intron 17903292 rs710558 chr3 189702200 T C 9.68E-05 Calcium levels LEPREL1 intron pha003085 rs1349033 chr3 189748701 C T 8.16E-04 Multiple complex diseases LEPREL1 intron 17554300 rs1719625 chr3 189749583 T C 6.18E-05 Serum metabolites LEPREL1 intron 19043545 rs1447947 chr3 189750238 T G 3.61E-05 Serum metabolites LEPREL1 intron 19043545 rs1666484 chr3 189753608 C T 5.25E-04 Type 2 diabetes LEPREL1 intron 17846124 rs1719615 chr3 189753707 A C 8.61E-05 Serum metabolites LEPREL1 intron 19043545 rs1719615 chr3 189753707 A C 4.50E-04 Coronary heart disease LEPREL1 intron 21606135 rs9290916 chr3 189754057 C A 6.20E-05 Serum metabolites LEPREL1 intron 19043545 rs1666486 chr3 189754413 A C 6.15E-05 Serum metabolites LEPREL1 intron 19043545 rs2693032 chr3 189759206 C T 2.85E-04 Alzheimer's disease LEPREL1 intron 17998437 rs1447934 chr3 189760111 A G 2.62E-04 Alzheimer's disease LEPREL1 intron 17998437 rs765711 chr3 189761864 T G 2.57E-04 Alzheimer's disease LEPREL1 intron 17998437 rs7632740 chr3 189770598 T C 6.66E-04 Multiple complex diseases LEPREL1 intron 17554300 rs13073092 chr3 189775156 A G 9.72E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines LEPREL1 intron 21844884 rs16865025 chr3 189789545 T C 2.00E-05 Urinary metabolites LEPREL1 intron 21572414 rs1403414 chr3 189791147 T C 6.31E-04 Multiple complex diseases LEPREL1 intron 17554300 rs6789122 chr3 189794491 T C 3.85E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines LEPREL1 intron 21844884 rs838268 chr3 189849198 C T 5.07E-04 Acute lung injury / / 22295056 rs838267 chr3 189849381 T C 2.09E-04 Acute lung injury / / 22295056 rs1949130 chr3 189850413 T G 6.71E-04 Acute lung injury / / 22295056 rs2667690 chr3 189851382 G C 2.02E-04 Acute lung injury / / 22295056 rs2675424 chr3 189855182 C G 5.18E-04 Acute lung injury / / 22295056 rs2969262 chr3 189855359 A G 5.43E-04 Acute lung injury / / 22295056 rs2944389 chr3 189855650 A G 6.21E-04 Acute lung injury / / 22295056 rs2944388 chr3 189855681 C A 5.46E-04 Acute lung injury / / 22295056 rs2675420 chr3 189856669 A G 2.50E-04 Acute lung injury / / 22295056 rs2667699 chr3 189857218 A G 5.22E-04 Acute lung injury / / 22295056 rs2675418 chr3 189857237 T C 5.22E-04 Acute lung injury / / 22295056 rs2675417 chr3 189857276 A G 5.22E-04 Acute lung injury / / 22295056 rs2667698 chr3 189857444 A C 6.76E-04 Acute lung injury / / 22295056 rs2675416 chr3 189857644 A T 2.67E-04 Acute lung injury / / 22295056 rs2667697 chr3 189857794 A G 2.67E-04 Acute lung injury / / 22295056 rs2667696 chr3 189858440 A G 2.67E-04 Acute lung injury / / 22295056 rs551223 chr3 189858693 A G 6.42E-04 Acute lung injury / / 22295056 rs501443 chr3 189858976 T C 2.32E-04 Acute lung injury / / 22295056 rs547432 chr3 189859123 T G 2.32E-04 Acute lung injury / / 22295056 rs477215 chr3 189859307 A C 2.59E-04 Acute lung injury / / 22295056 rs3106810 chr3 189861107 G T 1.10E-04 Acute lung injury / / 22295056 rs2944385 chr3 189861477 C T 1.03E-04 Acute lung injury / / 22295056 rs692909 chr3 189873465 A G 1.13E-04 Acute lung injury / / 22295056 rs2667711 chr3 189874037 A G 2.43E-04 Acute lung injury / / 22295056 rs2667710 chr3 189874063 A G 2.18E-04 Acute lung injury / / 22295056 rs2667709 chr3 189874137 C T 1.68E-04 Acute lung injury / / 22295056 rs893054 chr3 189874202 A G 1.93E-04 Acute lung injury / / 22295056 rs526335 chr3 189874990 A C 2.34E-04 Acute lung injury / / 22295056 rs488930 chr3 189875392 T G 2.42E-04 Acute lung injury / / 22295056 rs488811 chr3 189875427 A G 2.59E-04 Acute lung injury / / 22295056 rs487737 chr3 189875574 G A 2.59E-04 Acute lung injury / / 22295056 rs2575820 chr3 189875642 A G 2.74E-04 Acute lung injury / / 22295056 rs2675435 chr3 189875706 G A 2.64E-04 Acute lung injury / / 22295056 rs573533 chr3 189875918 T C 2.64E-04 Acute lung injury / / 22295056 rs572605 chr3 189876025 T C 2.64E-04 Acute lung injury / / 22295056 rs572569 chr3 189876033 A G 2.64E-04 Acute lung injury / / 22295056 rs2969254 chr3 189876118 G A 2.64E-04 Acute lung injury / / 22295056 rs2969255 chr3 189876130 A G 2.64E-04 Acute lung injury / / 22295056 rs2969256 chr3 189876156 A G 2.64E-04 Acute lung injury / / 22295056 rs569722 chr3 189876367 T G 2.64E-04 Acute lung injury / / 22295056 rs17491071 chr3 189880471 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17491071 chr3 189880471 T C 7.10E-04 Smoking cessation / / 24665060 rs9882745 chr3 189884967 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6798531 chr3 189886875 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs491944 chr3 189890232 G C 7.36E-05 Acute lung injury / / 22295056 rs16865151 chr3 189900082 T C 1.71E-04 Alzheimer's disease / / pha002879 rs977265 chr3 189914180 C T 5.05E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16865153 chr3 189914330 C T 3.30E-04 Smoking cessation / / 24665060 rs719205 chr3 189916935 C T 8.52E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1436649 chr3 189946318 A G 4.23E-04 Type 2 diabetes / / 17463246 rs1436656 chr3 189948689 A G 5.69E-04 Type 2 diabetes / / 17463246 rs484004 chr3 189954665 C A 3.60E-04 Alzheimer's disease (late onset) / / 21379329 rs16865258 chr3 189997396 C T 2.00E-06 Response to antipsychotic treatment in schizophrenia (working memory) / / 21107309 rs6793070 chr3 190034970 C T 7.15E-04 Multiple complex diseases CLDN1 intron 17554300 rs41472149 chr3 190036971 C T 9.26E-04 Multiple complex diseases CLDN1 intron 17554300 rs1465494 chr3 190081601 G A 3.01E-04 Multiple complex diseases / / 17554300 rs17504169 chr3 190102869 G A 1.44E-04 Obesity (extreme) / / 21935397 rs13080849 chr3 190105451 C T 5.10E-05 ldl cholesterol CLDN16 nearGene-5 pha003076 rs1425116 chr3 190110425 A C 1.28E-04 Obesity (extreme) CLDN16 intron 21935397 rs3774007 chr3 190115611 A G 7.70E-05 ldl cholesterol CLDN16 intron pha003076 rs6776775 chr3 190143045 A G 9.70E-04 Parkinson's disease / / 17052657 rs1024935 chr3 190175151 T G 7.38E-04 Multiple complex diseases / / 17554300 rs10490818 chr3 190180740 A C 4.81E-05 ldl cholesterol / / pha003076 rs1008800 chr3 190194568 T C 1.56E-04 Multiple complex diseases / / 17554300 rs9859989 chr3 190201381 G A 1.62E-05 Coronary heart disease / / pha003031 rs9290936 chr3 190252635 G T 4.00E-06 Waist circumference IL1RAP intron 20966902 rs3773989 chr3 190265429 G A 2.80E-04 Atrial fibrillation IL1RAP intron 21846873 rs3773986 chr3 190278915 G A 2.79E-07 Kawasaki disease IL1RAP intron 21221998 rs3773986 chr3 190278915 G A 0.000717397 Hypertension (early onset hypertension) IL1RAP intron 22479346 rs3773983 chr3 190279866 G A 1.38E-06 Kawasaki disease IL1RAP intron 21221998 rs3773976 chr3 190287285 T G 9.61E-04 Myocardial Infarction IL1RAP intron pha002873 rs12152223 chr3 190294365 A C 2.84E-05 Lipoproteins IL1RAP intron pha003079 rs1559017 chr3 190297036 C G 5.87E-04 Response to taxane treatment (placlitaxel) IL1RAP intron 23006423 rs1559018 chr3 190297083 A G 7.35E-04 Response to taxane treatment (placlitaxel) IL1RAP intron 23006423 rs3773959 chr3 190309356 G A 1.61E-04 Multiple complex diseases IL1RAP intron 17554300 rs3773958 chr3 190309603 A C 1.26E-04 Prion diseases IL1RAP intron 22210626 rs6767500 chr3 190310701 A C 6.50E-04 Suicide attempts in bipolar disorder IL1RAP intron 21423239 rs6796131 chr3 190312132 G C 0.00023 Coronary artery calcification IL1RAP intron 23727086 rs7652346 chr3 190312433 T C 6.01E-04 Suicide attempts in bipolar disorder IL1RAP intron 21423239 rs7642899 chr3 190312715 C G 6.53E-04 Suicide attempts in bipolar disorder IL1RAP intron 21423239 rs2193873 chr3 190313507 G A 2.80E-05 Urinary metabolites IL1RAP intron 21572414 rs2193873 chr3 190313507 G A 8.44E-04 Alzheimer's disease IL1RAP intron 22005930 rs3773949 chr3 190323256 C G 9.77E-04 Suicide attempts in bipolar disorder IL1RAP intron 21423239 rs716984 chr3 190323875 G A 9.45E-04 Suicide attempts in bipolar disorder IL1RAP intron 21423239 rs4571225 chr3 190324454 T C 1.26E-05 Type 2 diabetes and other traits IL1RAP intron 19734900 rs1469007 chr3 190324570 G T 6.76E-04 Suicide attempts in bipolar disorder IL1RAP intron 21423239 rs11719416 chr3 190325242 G A 5.37E-04 Suicide attempts in bipolar disorder IL1RAP intron 21423239 rs6781037 chr3 190327521 G A 6.89E-04 Suicide attempts in bipolar disorder IL1RAP intron 21423239 rs6765375 chr3 190327752 C A 5.47E-04 Suicide attempts in bipolar disorder IL1RAP intron 21423239 rs4687156 chr3 190328242 T C 4.81E-04 Suicide attempts in bipolar disorder IL1RAP intron 21423239 rs10937443 chr3 190328669 C T 4.87E-04 Suicide attempts in bipolar disorder IL1RAP intron 21423239 rs6793204 chr3 190328808 A G 6.09E-04 Suicide attempts in bipolar disorder IL1RAP intron 21423239 rs12636004 chr3 190329191 A G 7.51E-04 Suicide attempts in bipolar disorder IL1RAP intron 21423239 rs3796293 chr3 190332093 G A 5.78E-04 Suicide attempts in bipolar disorder IL1RAP intron 21423239 rs1015704 chr3 190338412 G A 5.92E-04 Suicide attempts in bipolar disorder IL1RAP intron 21423239 rs4687161 chr3 190341292 C T 8.82E-04 Suicide attempts in bipolar disorder IL1RAP intron 21423239 rs4687161 chr3 190341292 C T 2.69E-05 Coronary heart disease IL1RAP intron pha003030 rs7626795 chr3 190350461 A G 8.00E-06 Lung cancer IL1RAP intron 18385676 rs7626795 chr3 190350461 A G 8.00E-06 Nasopharyngeal carcinoma IL1RAP intron 20512145 rs7626795 chr3 190350461 A G 1.57E-04 Osteoarthritis (knee and hip) IL1RAP intron 21177295 rs7626795 chr3 190350461 A G 1.73E-04 Osteoarthritis (knee and hip) IL1RAP intron 21177295 rs7626795 chr3 190350461 A G 4.45E-05 Osteoarthritis (knee and hip) IL1RAP intron 21177295 rs7626795 chr3 190350461 A G 3.63E-06 Esophageal cancer (squamous cell) IL1RAP intron 22960999 rs7628357 chr3 190362979 C G 2.90E-05 Urinary metabolites IL1RAP intron 21572414 rs10433493 chr3 190365600 G C 0.00000176 Cholesterol,total IL1RAP intron 23063622 rs10433493 chr3 190365600 G C 2.21E-09 LDL cholesterol IL1RAP intron 23063622 rs6791374 chr3 190431993 T C 7.85E-04 Multiple complex diseases / / 17554300 rs9810034 chr3 190527863 A G 3.46E-04 Multiple complex diseases / / 17554300 rs9290953 chr3 190546144 T C 4.76E-05 Serum metabolites / / 19043545 rs1393061 chr3 190607235 C T 3.76E-04 Tourette syndrome / / 22889924 rs6778263 chr3 190637833 C A 2.52E-04 Alcohol dependence / / 24277619 rs1316356 chr3 190657163 T C 1.96E-07 Alzheimer's disease biomarkers / / 23562540 rs1316356 chr3 190657163 T C 2.80E-07 Alzheimer's disease biomarkers / / 23562540 rs9877502 chr3 190669518 G A 5.00E-09 Alzheimer's disease biomarkers / / 23562540 rs9860559 chr3 190687002 T C 4.59E-04 Stroke / / pha002886 rs13314338 chr3 190700869 C T 9.54E-04 Multiple complex diseases / / 17554300 rs951704 chr3 190714258 A G 5.49E-04 Multiple complex diseases / / 17554300 rs9864764 chr3 190714587 A C 8.67E-04 Alcohol dependence / / 24277619 rs7626377 chr3 190746035 A C 2.00E-05 Urinary metabolites / / 21572414 rs6444482 chr3 190751609 T C 2.00E-05 Urinary metabolites / / 21572414 rs9290963 chr3 190754184 G C 1.70E-05 Urinary metabolites / / 21572414 rs11708492 chr3 190766811 A G 9.70E-05 Triglycerides / / pha003081 rs1355367 chr3 190790951 C T 2.30E-05 Urinary metabolites / / 21572414 rs6444495 chr3 190792562 C T 2.00E-05 Urinary metabolites / / 21572414 rs2063421 chr3 190801723 G A 6.77E-05 Cognitive test performance / / 20125193 rs6444501 chr3 190820242 G T 1.96E-04 Coronary heart disease / / 21606135 rs2666367 chr3 190826979 C T 5.82E-05 Triglycerides / / pha003081 rs10755145 chr3 190842124 A G 1.73E-05 Triglycerides / / pha003081 rs9855788 chr3 190848369 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6793890 chr3 190881904 T C 4.97E-04 Obesity (extreme) / / 21935397 rs7638730 chr3 190896030 G C 2.70E-05 Urinary metabolites / / 21572414 rs7628727 chr3 190898482 C A 2.30E-05 Urinary metabolites / / 21572414 rs6797951 chr3 190920432 A T 2.90E-05 Urinary metabolites / / 21572414 rs6773838 chr3 190920536 G A 2.70E-05 Urinary metabolites / / 21572414 rs16866328 chr3 190921176 C T 2.70E-05 Urinary metabolites / / 21572414 rs6444530 chr3 190982425 T C 7.05E-04 Parkinson's disease / / 17052657 rs10937470 chr3 191000808 C T 9.00E-06 Total ventricular volume UTS2D intron 21116278 rs1435066 chr3 191014928 T C 2.42E-04 Myocardial Infarction UTS2D intron pha002873 rs6796119 chr3 191019603 A G 3.74E-04 Myocardial Infarction UTS2D intron pha002873 rs78204017 chr3 191039246 T C 0.0000336 Nonsyndromic striae distensae (stretch marks) UTS2D intron 23633020 rs293871 chr3 191043302 A T 7.04E-04 Type 2 diabetes UTS2D intron 17463246 rs4687210 chr3 191046770 G A 4.57E-04 Type 2 diabetes UTS2D intron 17463246 rs4247190 chr3 191065921 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CCDC50 intron 22628534 rs16866504 chr3 191084653 T C 5.43E-04 Multiple complex diseases CCDC50 intron 17554300 rs293806 chr3 191093434 A C,G,T 4.05E-04 Multiple complex diseases CCDC50 intron 17554300 rs432085 chr3 191099468 T C 1.74E-04 IgE levels CCDC50 intron 23661040 rs293820 chr3 191150836 A G 8.51E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs167149 chr3 191169024 T C 5.94E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs430271 chr3 191186292 C T 7.04E-05 Heart Rate / / pha003054 rs2886242 chr3 191189965 A G 4.91E-05 Job-related exhaustion / / 23620144 rs430388 chr3 191191370 T G 8.54E-05 Heart Rate / / pha003054 rs433617 chr3 191191560 A G 8.54E-05 Heart Rate / / pha003054 rs16822582 chr3 191196592 A G 8.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs16822582 chr3 191196592 A G 1.60E-05 Urinary metabolites / / 21572414 rs4234621 chr3 191207636 C T 1.14E-04 HIV(mother-to-child transmission) / / 20487506 rs4234621 chr3 191207636 C T 4.58E-05 HIV(mother-to-child transmission) / / 20487506 rs7642724 chr3 191216000 A G 2.21E-05 Intelligence / / 21826061 rs7632529 chr3 191216111 T C 7.45E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12633186 chr3 191223664 G T 9.78E-06 Intelligence / / 21826061 rs10937486 chr3 191239571 T G 5.90E-06 Multiple sclerosis / / 21833088 rs1405037 chr3 191267203 C T 4.97E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6444558 chr3 191275499 C A 1.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6444558 chr3 191275499 C A 5.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6444558 chr3 191275499 C A 1.54E-04 Pancreatic cancer / / pha002874 rs10937502 chr3 191291423 T C 1.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10937502 chr3 191291423 T C 2.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10937502 chr3 191291423 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4686582 chr3 191314079 C T 4.26E-05 IgE levels / / 22075330 rs10446354 chr3 191315051 A G 4.27E-05 IgE levels / / 22075330 rs1949751 chr3 191317215 A G 4.26E-05 IgE levels / / 22075330 rs6444578 chr3 191317792 G A 4.26E-05 IgE levels / / 22075330 rs10937504 chr3 191331505 A G 1.30E-05 Urinary metabolites / / 21572414 rs9810936 chr3 191343042 C A 1.20E-05 Urinary metabolites / / 21572414 rs13100016 chr3 191360075 G A 7.76E-04 Smoking quantity / / 24665060 rs9850168 chr3 191360971 C A 1.20E-05 Urinary metabolites / / 21572414 rs1916631 chr3 191362353 A G 7.30E-04 Smoking quantity / / 24665060 rs1806335 chr3 191367296 G A 3.63E-04 Smoking quantity / / 24665060 rs6780520 chr3 191398966 C G 7.67E-04 Type 2 diabetes / / 17463246 rs779506 chr3 191412597 G A 7.01E-05 Meningococcal disease / / 20694013 rs779503 chr3 191418993 A G 2.69E-04 Stroke / / pha002887 rs709086 chr3 191456220 T C 0.0001 Migraine / / 22678113 rs709086 chr3 191456220 T C 7.81E-04 Stroke / / pha002887 rs709087 chr3 191456299 C T 0.0001 Migraine / / 22678113 rs9844345 chr3 191460727 C T 1.54E-04 Multiple complex diseases / / 17554300 rs709094 chr3 191463845 A C 0.0001 Migraine / / 22678113 rs709102 chr3 191470965 A G 2.27E-04 Multiple complex diseases / / 17554300 rs1083670 chr3 191489973 T C 4.19E-04 Multiple complex diseases / / 17554300 rs1400245 chr3 191499816 C T 2.67E-04 Multiple complex diseases / / 17554300 rs810471 chr3 191513295 G T 3.52E-04 Multiple complex diseases / / 17554300 rs1516489 chr3 191521852 A C 8.00E-08 Immune response to smallpox vaccine (IL-6) / / 22610502 rs779279 chr3 191543927 G T 0.0002 Migraine / / 22678113 rs2138537 chr3 191551479 G C 8.50E-04 Type 2 diabetes / / 17463246 rs2138537 chr3 191551479 G C 2.29E-04 Multiple complex diseases / / 17554300 rs4019795 chr3 191563357 T C 6.05E-05 Multiple complex diseases / / 17554300 rs10937515 chr3 191569634 G A 1.48E-05 Multiple complex diseases / / 17554300 rs779331 chr3 191570663 G T 2.62E-04 Multiple complex diseases / / 17554300 rs779331 chr3 191570663 G T 0.000068 Migraine / / 22678113 rs779331 chr3 191570663 G T 6.80E-05 Migraine / / 22683712 rs7609639 chr3 191656413 A G 3.67E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7635839 chr3 191667777 G A 3.00E-06 Response to antipsychotic treatment / / 19721433 rs10470540 chr3 191670086 C T 5.44E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2649820 chr3 191690287 C T 7.14E-05 Multiple complex diseases / / 17554300 rs6444602 chr3 191691994 G A 7.02E-04 Multiple complex diseases / / 17554300 rs2669961 chr3 191693878 A G 6.75E-05 Multiple complex diseases / / 17554300 rs2669960 chr3 191693913 C A 7.14E-05 Multiple complex diseases / / 17554300 rs2173612 chr3 191694424 T C 2.18E-05 Multiple complex diseases / / 17554300 rs1392203 chr3 191699597 A G 7.77E-05 Multiple complex diseases / / 17554300 rs1392203 chr3 191699597 A G 1.00E-04 Prostate cancer / / 21743057 rs1472509 chr3 191700435 C T 6.34E-05 Multiple complex diseases / / 17554300 rs2458487 chr3 191700654 C T 4.07E-05 Multiple complex diseases / / 17554300 rs2649828 chr3 191701277 A G 9.39E-05 Multiple complex diseases / / 17554300 rs6797647 chr3 191701454 T C 7.80E-05 Multiple complex diseases / / 17554300 rs2669971 chr3 191701671 G A 5.76E-05 Multiple complex diseases / / 17554300 rs9809714 chr3 191704258 A G 1.35E-04 Multiple complex diseases / / 17554300 rs2649836 chr3 191707834 A G 1.19E-04 Multiple complex diseases / / 17554300 rs2649834 chr3 191708539 A T 1.84E-04 Multiple complex diseases / / 17554300 rs6764161 chr3 191710630 T C 1.11E-04 Multiple complex diseases / / 17554300 rs6764696 chr3 191711064 T C 4.51E-04 Multiple complex diseases / / 17554300 rs2649832 chr3 191713147 C T 1.00E-04 Prostate cancer / / 21743057 rs6773818 chr3 191718973 T C 1.25E-04 Multiple complex diseases / / 17554300 rs2087698 chr3 191738026 G A 5.34E-05 Cholesterol / / pha003073 rs6773170 chr3 191757620 C T 9.81E-04 Multiple complex diseases / / 17554300 rs1491520 chr3 191760451 G A 1.77E-05 Pulmonary function / / 17903307 rs10440063 chr3 191777754 A T 1.02E-04 Multiple complex diseases / / 17554300 rs1602518 chr3 191804762 G A 3.97E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs1602517 chr3 191805160 T C 2.39E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs4585146 chr3 191818642 G A 3.00E-07 Major depressive disorder / / 23377640 rs4585146 chr3 191818642 G A 6.00E-06 Major depressive disorder / / 23377640 rs6779599 chr3 191847799 C A 1.98E-04 Alcohol dependence / / 21314694 rs975121 chr3 191897218 G A 7.00E-06 Ileal carcinoids FGF12 intron 21139019 rs11707231 chr3 191909300 C A 6.00E-07 Urinary metabolites FGF12 intron 21572414 rs9836672 chr3 191912870 C T 5.00E-06 Sleep quality FGF12 intron 23728906 rs2126071 chr3 191956119 G A 2.60E-05 Urinary metabolites FGF12 intron 21572414 rs2126071 chr3 191956119 G A 4.96E-04 Antineutrophil cytoplasmic antibody-associated vasculitis FGF12 intron 22808956 rs940901 chr3 191966701 C T 0.00048 Breast cancer early age of onset FGF12 intron 18463975 rs1522264 chr3 191987899 C T 1.90E-05 Urinary metabolites FGF12 intron 21572414 rs4686602 chr3 191988845 A G 4.00E-05 Prostate cancer FGF12 intron 21743057 rs1464941 chr3 192009516 C A 1.00E-05 Urinary metabolites FGF12 intron 21572414 rs9850123 chr3 192042183 T C 1.89E-04 Multiple complex diseases FGF12 intron 17554300 rs9850123 chr3 192042183 T C 4.23E-05 Job-related exhaustion FGF12 intron 23620144 rs4438608 chr3 192043478 G A 2.82E-04 Multiple complex diseases FGF12 intron 17554300 rs4687319 chr3 192043849 C T 4.60E-05 Alzheimer's disease FGF12 intron 17998437 rs4686605 chr3 192060611 C T 4.96E-04 Multiple complex diseases FGF12 intron 17554300 rs923820 chr3 192066029 G A 6.30E-04 Multiple complex diseases FGF12 intron 17554300 rs4602335 chr3 192070587 T G 7.13E-05 Soluble levels of adhesion molecules FGF12 intron pha003072 rs6784434 chr3 192079832 G A 1 Drug response to Etoposide FGF12 intron 17537913 rs6788148 chr3 192081098 G A 1 Drug response to Etoposide FGF12 intron 17537913 rs1574091 chr3 192082082 T C 1 Drug response to Etoposide FGF12 intron 17537913 rs9859577 chr3 192088525 G T 9.87E-05 Parkinson's disease FGF12 intron pha002865 rs4453795 chr3 192093975 A G 4.00E-07 Metabolite levels FGF12 intron 19043545 rs4381887 chr3 192094033 T C 5.18E-05 Serum metabolites FGF12 intron 19043545 rs1525910 chr3 192105055 T G 2.02E-04 Amyotrophic Lateral Sclerosis FGF12 intron 17827064 rs4687336 chr3 192223737 G A 7.06E-04 Epilepsy FGF12 intron 22116939 rs11705857 chr3 192251697 A G 1.48E-04 Progressive supranuclear palsy FGF12 intron 21685912 rs3845944 chr3 192263633 G T 4.58E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FGF12 intron 20877124 rs9853605 chr3 192270281 A C 5.03E-05 Multiple complex diseases FGF12 intron 17554300 rs1875732 chr3 192313035 A G 1.51E-05 Serum metabolites FGF12 intron 19043545 rs1875731 chr3 192313057 G T 2.01E-04 Type 2 diabetes FGF12 intron 17463246 rs1875730 chr3 192313238 G A 5.64E-04 Type 2 diabetes FGF12 intron 17463246 rs2174178 chr3 192315165 A G 8.81E-04 Type 2 diabetes FGF12 intron 17463246 rs2654689 chr3 192315399 C G 6.13E-04 Type 2 diabetes FGF12 intron 17463246 rs2654689 chr3 192315399 C G 4.11E-06 Serum metabolites FGF12 intron 19043545 rs905566 chr3 192320179 C T 7.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FGF12 intron 20877124 rs6444652 chr3 192325595 C T 2.20E-05 Urinary metabolites FGF12 intron 21572414 rs4687347 chr3 192326678 A T 8.22E-05 Blood pressure FGF12 intron 17255346 rs1922910 chr3 192338861 A G 8.18E-05 Alcohol withdrawal symptoms FGF12 intron 22072270 rs2062832 chr3 192341051 T C 5.92E-05 Alcohol withdrawal symptoms FGF12 intron 22072270 rs2886785 chr3 192371402 A G 9.60E-05 Diabetic nephropathy FGF12 intron pha002864 rs9873551 chr3 192374485 A T 5.37E-05 Diabetic nephropathy FGF12 intron pha002864 rs1605083 chr3 192407268 G A 2.60E-05 Height FGF12 intron pha003010 rs1605083 chr3 192407268 G A 5.34E-06 Height FGF12 intron pha003011 rs9859403 chr3 192424298 C T 7.23E-05 Height FGF12 intron pha003011 rs7614462 chr3 192440779 G A 9.97E-04 Parkinson's disease FGF12 intron 17052657 rs13088552 chr3 192444742 G C 2.30E-05 Urinary metabolites FGF12 intron 21572414 rs879772 chr3 192446063 A C 2.70E-05 Urinary metabolites / / 21572414 rs11917199 chr3 192447707 G T 2.40E-05 Urinary metabolites / / 21572414 rs2367016 chr3 192450732 G T 8.70E-06 Urinary metabolites / / 21572414 rs2135189 chr3 192450906 C A 9.15E-05 Type 2 diabetes / / 17463246 rs2135190 chr3 192451041 A C 9.58E-05 Type 2 diabetes / / 17463246 rs869696 chr3 192489132 G A 3.67E-04 HIV-1 viral setpoint / / 17641165 rs12481 chr3 192515050 A G 1.50E-05 Urinary metabolites MB21D2 UTR-3 21572414 rs12636637 chr3 192548545 G C 2.10E-05 Urinary metabolites MB21D2 intron 21572414 rs7637984 chr3 192554450 C T 1.90E-05 Urinary metabolites MB21D2 intron 21572414 rs9870592 chr3 192554933 G C 1.50E-05 Urinary metabolites MB21D2 intron 21572414 rs9837912 chr3 192555960 A C 9.50E-06 Urinary metabolites MB21D2 intron 21572414 rs6803445 chr3 192557171 G A 1.70E-05 Urinary metabolites MB21D2 intron 21572414 rs9870609 chr3 192562429 A G 3.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) MB21D2 intron 23648065 rs1500609 chr3 192585608 A G 9.46E-04 Alzheimer's disease MB21D2 intron 17998437 rs1553257 chr3 192593148 G A 9.98E-04 Alzheimer's disease MB21D2 intron 17998437 rs2367129 chr3 192595307 A C 1.90E-04 Crohn's disease MB21D2 intron 17684544 rs7621131 chr3 192596365 A G 5.54E-05 Cognitive test performance MB21D2 intron 20125193 rs4455277 chr3 192614308 T C 1.90E-05 Alcohol dependence MB21D2 intron 20201924 rs4455277 chr3 192614308 T C 1.94E-05 Alcoholism MB21D2 intron pha002892 rs3952738 chr3 192614483 T C 1.90E-05 Alcohol dependence MB21D2 intron 20201924 rs3952738 chr3 192614483 T C 1.94E-05 Alcoholism MB21D2 intron pha002892 rs11716375 chr3 192618263 C G 1.20E-07 Lymphocyte counts MB21D2 intron 22286170 rs7643379 chr3 192619383 A G 5.20E-06 Alcohol dependence MB21D2 intron 20201924 rs7643379 chr3 192619383 A G 5.25E-06 Alcoholism MB21D2 intron pha002892 rs9869202 chr3 192625190 C T 2.20E-04 Alcohol dependence MB21D2 intron 20201924 rs6444683 chr3 192737761 T C 9.60E-04 Multiple complex diseases / / 17554300 rs9283662 chr3 192758191 T C 1.99E-04 Celiac disease / / 23936387 rs9855714 chr3 192765819 A G 1.51E-05 Body Mass Index / / pha003006 rs9855714 chr3 192765819 A G 7.54E-05 Body Mass Index / / pha003020 rs9855714 chr3 192765819 A G 8.31E-06 Waist Circumference / / pha003024 rs9855714 chr3 192765819 A G 5.82E-06 Weight / / pha003026 rs13068101 chr3 192772295 G A 2.00E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs13068101 chr3 192772295 G A 7.00E-06 Sleep time / / 23728906 rs9852198 chr3 192784094 A G 2.80E-05 Urinary metabolites / / 21572414 rs11716239 chr3 192803283 C A 8.70E-04 Bipolar disorder,schizoaffective / / 19567891 rs1075458 chr3 192842282 C T 9.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs1075458 chr3 192842282 C T 7.43E-04 Smoking quantity / / 24665060 rs1462478 chr3 192848914 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12493738 chr3 192896299 A C 8.33E-04 Parkinson's disease / / 17052657 rs12493236 chr3 193043636 C A 1.14E-06 Triglycerides ATP13A5 intron pha002904 rs6806913 chr3 193052630 G A 1.39E-06 Multiple complex diseases ATP13A5 intron 17554300 rs10804953 chr3 193060677 A G 5.44E-04 Type 2 diabetes ATP13A5 intron 17463246 rs6802760 chr3 193064199 A G 4.78E-04 Type 2 diabetes ATP13A5 intron 17463246 rs11919228 chr3 193065575 T A 4.30E-04 Type 2 diabetes ATP13A5 intron 17463246 rs12633921 chr3 193071307 C T 5.89E-04 Type 2 diabetes ATP13A5 intron 17463246 rs7648423 chr3 193076940 C T 5.69E-04 Type 2 diabetes ATP13A5 intron 17463246 rs7630292 chr3 193136476 G A 1.57E-04 Pancreatic cancer ATP13A4 intron pha002874 rs7613433 chr3 193143488 A G 4.72E-04 Type 2 diabetes ATP13A4 intron 17463246 rs13077551 chr3 193150569 G C 1.81E-04 Type 2 diabetes ATP13A4 intron 17463246 rs11916762 chr3 193292035 G A 9.97E-04 Type 2 diabetes / / 17463246 rs145565705 chr3 193332564 C G 0.000045 Breast cancer(er negative) OPA1 missense 23555315 rs7646250 chr3 193334593 A T 8.59E-04 Type 2 diabetes OPA1 intron 17463246 rs7616162 chr3 193428567 T C 2.48E-11 Multiple complex diseases / / 17554300 rs11717055 chr3 193451757 G A 7.36E-05 Serum metabolites / / 19043545 rs11709874 chr3 193487588 A T 2.50E-05 Urinary metabolites / / 21572414 rs476927 chr3 193513016 A G 5.80E-05 Waist-Hip Ratio / / pha003028 rs9879015 chr3 193517969 C T 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10933707 chr3 193532008 C A 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1392705 chr3 193533201 A G 3.22E-04 Major depressive disorder / / 22472876 rs1165640 chr3 193537991 C T 3.99E-04 Bipolar disorder / / 19259986 rs9878109 chr3 193576832 G T 2.32E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs604222 chr3 193583710 G A 7.00E-06 Major depressive disorder / / 23377640 rs4687470 chr3 193651300 T C 9.04E-04 Depression (quantitative trait) / / 20800221 rs2636914 chr3 193653537 T C 9.64E-04 Depression (quantitative trait) / / 20800221 rs2636909 chr3 193667833 A G 4.95E-04 Multiple complex diseases / / 17554300 rs6771223 chr3 193669436 G A 6.40E-06 Retinopathy in non-diabetics / / 23393555 rs11914434 chr3 193674581 C T 7.00E-07 Bone mineral density (BMD),in women / / 20164292 rs2367937 chr3 193697644 G A 0.0000297 Panic disorder LOC647323 intron 23149450 rs2367937 chr3 193697644 G A 2.97E-05 Serum tamsulosin hydrochloride concentration LOC647323 intron 23151678 rs7649230 chr3 193699775 G T 5.69E-05 Multiple complex diseases LOC647323 intron 17554300 rs4687479 chr3 193705455 G T 4.51E-04 Multiple complex diseases LOC647323 intron 17554300 rs4687480 chr3 193706181 G A 3.14E-04 Multiple complex diseases LOC647323 intron 17554300 rs724767 chr3 193722330 C T 4.01E-05 Bipolar disorder / / 19259986 rs724767 chr3 193722330 C T 2.00E-06 Estradiol plasma levels (breast cancer) / / 23518928 rs4686659 chr3 193729048 G A 2.00E-05 Urinary metabolites LOC100505902 intron 21572414 rs9851309 chr3 193747276 T C 7.00E-07 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100505902 intron 20877124 rs7628226 chr3 193748075 C T 1.90E-05 Urinary metabolites LOC100505902 intron 21572414 rs4687500 chr3 193752149 G A 3.18E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100505902 intron 20877124 rs4687500 chr3 193752149 G A 2.30E-05 Urinary metabolites LOC100505902 intron 21572414 rs4686667 chr3 193757098 C T 6.44E-05 Cognitive performance LOC100505902 intron 19734545 rs7643259 chr3 193810848 G A 3.98E-04 Hearing function / / 17255346 rs6767127 chr3 193851390 G A 3.75E-04 Multiple complex diseases / / 17554300 rs4380361 chr3 193875909 G T 5.74E-04 Acute lung injury / / 22295056 rs2368046 chr3 193876042 G A 8.03E-04 Acute lung injury / / 22295056 rs9872836 chr3 193876706 G A 8.03E-04 Acute lung injury / / 22295056 rs6444774 chr3 193887194 G A 2.42E-04 Alzheimer's disease / / 17998437 rs9819097 chr3 193887662 C T 6.60E-07 Urinary metabolites / / 21572414 rs9819097 chr3 193887662 C T 7.91E-04 Body mass index / / 21701565 rs11709923 chr3 193889252 C T 3.05E-04 Body mass index / / 21701565 rs11711981 chr3 193891012 C T 3.08E-04 Body mass index / / 21701565 rs11711981 chr3 193891012 C T 2.19E-05 Asthma / / 22561531 rs4441603 chr3 193913088 C T 3.92E-05 Schizophrenia / / 19571811 rs9858096 chr3 193918902 T C 4.62E-04 Hemoglobin concentration / / 20534544 rs4349452 chr3 193955440 G A 2.32E-05 Major depressive disorder LOC100505920 intron 21621269 rs4547644 chr3 193963483 G A 1.50E-05 Urinary metabolites LOC100505920 intron 21572414 rs9862745 chr3 194000979 C T 5.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs4686685 chr3 194028647 A G 1.60E-05 Non-small cell lung cancer LOC100131551 intron 21866343 rs11711157 chr3 194061826 C T 9.20E-05 Bone mineral density (spine) CPN2 missense 19079262 rs3732477 chr3 194062519 C T 9.20E-05 Bone mineral density (spine) CPN2 missense 19079262 rs7618186 chr3 194063951 C T 2.40E-04 Multiple complex diseases CPN2 intron 17554300 rs7618278 chr3 194064075 G T 2.27E-04 Multiple complex diseases CPN2 intron 17554300 rs11925396 chr3 194112351 A G 1.01E-09 Triglycerides / / 23063622 rs11925396 chr3 194112351 A G 1.12E-27 LDL cholesterol / / 23063622 rs2185479 chr3 194119180 C T 6.01E-05 Acute lung injury GP5 intron 21257790 rs1572840 chr3 194119583 G A 4.60E-04 Alcohol dependence GP5 intron 20201924 rs10933656 chr3 194226486 C A 4.07E-04 Multiple complex diseases / / 17554300 rs10933657 chr3 194226525 T C 6.43E-04 Multiple complex diseases / / 17554300 rs10933658 chr3 194226576 A G 6.92E-04 Multiple complex diseases / / 17554300 rs7627066 chr3 194232753 T G 8.79E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs4493370 chr3 194245931 G T 6.53E-04 Aortic root size / / 21223598 rs1706017 chr3 194319490 C T 4.58E-04 Multiple complex diseases TMEM44 intron 17554300 rs1706016 chr3 194319882 C T 3.66E-04 Multiple complex diseases TMEM44 intron 17554300 rs789852 chr3 194327098 T C 7.00E-07 QT interval TMEM44 intron 20031603 rs789999 chr3 194328298 G A 5.63E-04 Sarcoidosis TMEM44 intron 19165924 rs789997 chr3 194328524 A G 6.44E-06 Renal cell carcinoma TMEM44 intron 23184150 rs7642318 chr3 194329285 G T 0.00022 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines TMEM44 intron 23204130 rs10933663 chr3 194337708 T G 0.0004 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines TMEM44 intron 23204130 rs1320623 chr3 194381272 T C 0.0000564 Menopause (age at onset) LSG1 intron 23424626 rs1706011 chr3 194398333 A C 3.87E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1773225 chr3 194403578 A G 1.20E-06 Intracerebral hemorrhage / / 24656865 rs789862 chr3 194404522 A G 5.73E-06 Intracerebral hemorrhage / / 24656865 rs789860 chr3 194405630 A T 3.34E-06 Intracerebral hemorrhage / / 24656865 rs789859 chr3 194405888 G T 3.25E-06 Intracerebral hemorrhage / / 24656865 rs789859 chr3 194405888 G T 4.57E-06 Mathematical ability / / 24801482 rs789858 chr3 194405966 C T 3.25E-06 Intracerebral hemorrhage / / 24656865 rs812583 chr3 194406505 C G 2.77E-06 Intracerebral hemorrhage / / 24656865 rs2035138 chr3 194420000 C T 9.47E-04 Multiple complex diseases / / 17554300 rs6437407 chr3 194435039 G C 8.21E-04 Multiple complex diseases LOC100507391 intron 17554300 rs9854809 chr3 194448231 A G 9.53E-04 Multiple complex diseases LOC100507391 intron 17554300 rs4234200 chr3 194475474 T G 0.0007973 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100507391 intron 23233654 rs4234200 chr3 194475474 T G 7.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100507391 intron 23233662 rs4311168 chr3 194476401 C T 0.0007925 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100507391 intron 23233654 rs4311168 chr3 194476401 C T 7.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100507391 intron 23233662 rs4458311 chr3 194482164 G C 0.0007914 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100507391 intron 23233654 rs4458311 chr3 194482164 G C 7.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100507391 intron 23233662 rs4677740 chr3 194483962 G A 0.0005584 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100507391 intron 23233654 rs4677740 chr3 194483962 G A 5.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100507391 intron 23233662 rs4677742 chr3 194487957 T C 9.94E-05 Multiple complex diseases LOC100507391 intron 17554300 rs4677742 chr3 194487957 T C 0.0008018 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100507391 intron 23233654 rs4677742 chr3 194487957 T C 8.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100507391 intron 23233662 rs7632151 chr3 194491496 G T 7.37E-04 Taste perception LOC100507391 intron 22132133 rs6437415 chr3 194500357 A G 2.60E-05 Urinary metabolites / / 21572414 rs7632686 chr3 194517499 A T 1.70E-05 Urinary metabolites / / 21572414 rs7631413 chr3 194520717 G T 1.66E-04 Smoking cessation / / 24665060 rs9837804 chr3 194539121 T C 4.23E-04 Parkinson's disease / / 17052657 rs9837804 chr3 194539121 T C 2.08E-04 Celiac disease / / 23936387 rs11717356 chr3 194570134 G A 4.13E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2043264 chr3 194628050 C T 6.67E-05 Monocyte chemoattractant protein-1 / / pha003071 rs4677776 chr3 194629709 T C 6.06E-04 Type 2 diabetes / / 17463246 rs4677776 chr3 194629709 T C 2.32E-04 Multiple complex diseases / / 17554300 rs2082377 chr3 194667767 C T 2.09E-05 Acne (severe teenage) / / 24114350 rs11927349 chr3 194668776 C A 2.23E-05 Acne (severe teenage) / / 24114350 rs6770825 chr3 194687331 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs823026 chr3 194692585 G C 2.33E-05 Hearing function / / 17255346 rs4677652 chr3 194695307 T C 7.49E-04 Type 2 diabetes / / 17463246 rs823036 chr3 194697091 A G 5.55E-05 Hearing function / / 17255346 rs1878428 chr3 194709026 T G 6.70E-05 Response to statin therapy / / 20339536 rs2720939 chr3 194711047 T A,C,G 3.21E-05 Hearing function / / 17255346 rs2676914 chr3 194713365 G A 2.60E-05 Response to statin therapy / / 20339536 rs2676914 chr3 194713365 G A 5.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7629991 chr3 194721311 G C 2.01E-04 Type 2 diabetes / / 17463246 rs4677791 chr3 194731991 C T 9.90E-06 Urinary metabolites / / 21572414 rs2676917 chr3 194737873 T G 7.00E-06 Metabolite levels (Pyroglutamine) / / 23934736 rs2676917 chr3 194737873 T G 5.73E-06 Serum albumin level / / pha003084 rs2676874 chr3 194751316 G C 7.50E-06 Urinary metabolites / / 21572414 rs3892715 chr3 194758010 C T 6.00E-06 Attention deficit hyperactivity disorder (time to onset) / / 18937294 rs2720955 chr3 194770850 C T 4.80E-06 Urinary metabolites / / 21572414 rs4677797 chr3 194771964 G T 6.20E-05 Type 2 diabetes / / 17463246 rs7645177 chr3 194785565 T C 6.60E-04 Type 2 diabetes / / 17463246 rs2720948 chr3 194791657 T C 6.80E-06 Type 2 diabetes XXYLT1 intron 17463246 rs1389726 chr3 194799002 A G 1.95E-04 Type 2 diabetes XXYLT1 intron 17463246 rs4677803 chr3 194814686 G C 7.53E-04 Suicide attempts in bipolar disorder XXYLT1 intron 21423239 rs903307 chr3 194834171 T G 1.74E-05 Bilirubin levels,in serum XXYLT1 intron 19389676 rs1494327 chr3 194837732 G A 1.40E-05 Urinary metabolites XXYLT1 intron 21572414 rs2131879 chr3 194838916 G A 2.67E-05 Longevity XXYLT1 intron 20304771 rs6797160 chr3 194850659 A G 2.26E-05 Amyotrophic lateral sclerosis (sporadic) XXYLT1 intron 24529757 rs7628775 chr3 194851177 G A 1.08E-04 Type 2 diabetes XXYLT1 intron 17463246 rs2410845 chr3 194854022 A C 5.54E-05 Longevity XXYLT1 intron 20304771 rs2131877 chr3 194858374 G A 2.00E-08 Non-small cell lung cancer XXYLT1 intron 20876614 rs12633566 chr3 194880989 T C 1.20E-05 Urinary metabolites XXYLT1 intron 21572414 rs7653427 chr3 194894248 T C 7.25E-04 Multiple complex diseases XXYLT1 intron 17554300 rs3796161 chr3 194930028 C T 1.88E-04 Multiple complex diseases XXYLT1 intron 17554300 rs9825185 chr3 194934634 C A 2.48E-06 Longevity XXYLT1 intron 20304771 rs1538767 chr3 195007852 T C 8.07E-04 Smoking initiation ACAP2 intron 24665060 rs13079866 chr3 195160252 A G 2.84E-05 Male-pattern baldness ACAP2 intron 18849994 rs10933645 chr3 195174420 A G 2.43E-05 Cortisol secretion,in saliva / / 21316860 rs2550233 chr3 195453064 T G 1.64E-04 Taste perception MUC20 cds-synon 22132133 rs3103934 chr3 195477088 A G 3.64E-05 Taste perception MUC4 intron 22132133 rs842225 chr3 195479748 G A 8.32E-04 Type 2 diabetes MUC4 intron 17463246 rs2688513 chr3 195505664 G A 1.80E-04 Taste perception MUC4 missense 22132133 rs3103954 chr3 195516630 G T 4.43E-04 Taste perception MUC4 cds-synon 22132133 rs2177336 chr3 195516878 T C 7.99E-04 Taste perception MUC4 missense 22132133 rs1106502 chr3 195517258 G A 7.99E-04 Taste perception MUC4 missense 22132133 rs1104760 chr3 195517321 G A 7.99E-04 Taste perception MUC4 missense 22132133 rs882605 chr3 195517553 A C 7.99E-04 Taste perception MUC4 missense 22132133 rs2688515 chr3 195527471 C T 3.90E-04 Birth weight MUC4 intron 17255346 rs2641773 chr3 195528226 C A 2.01E-04 Birth weight MUC4 intron 17255346 rs9858622 chr3 195577630 A G 1.60E-05 Type 2 diabetes / / 17460697 rs112384084 chr3 195594494 C T 0.00041 Prostate cancer TNK2 missense 23555315 rs2278034 chr3 195596907 T C 5.00E-06 Bronchopulmonary dysplasia TNK2 intron 23897914 rs9818146 chr3 195641908 C T 2.86E-04 Obesity (extreme) / / 21935397 rs9866616 chr3 195719885 A G 3.29E-05 Obesity (extreme) / / 21935397 rs6797622 chr3 195734915 C T 7.10E-04 Obesity (extreme) / / 21935397 rs6797622 chr3 195734915 C T 6.47E-04 Stroke (pediatric) / / 22990015 rs9837977 chr3 195746112 C T 6.41E-04 Obesity (extreme) / / 21935397 rs4927850 chr3 195751630 T C 2.00E-07 Pancreatic cancer / / 22158540 rs406271 chr3 195776976 T C 1.11E-12 Red blood cell traits TFRC UTR-3 23222517 rs557527 chr3 195780709 G A 6.40E-04 Blood cell counts and traits,in red and white blood cells TFRC intron 21153663 rs557527 chr3 195780709 G A 9.89E-10 Red blood cell traits TFRC intron 23222517 rs3326 chr3 195781506 G A 5.95E-09 Other erythrocyte phenotypes TFRC intron 19862010 rs3326 chr3 195781506 G A 2.48E-13 Red blood cell traits TFRC intron 23222517 rs3933 chr3 195784997 G A 5.70E-07 Red blood cell traits TFRC intron 23222517 rs9846149 chr3 195787308 C G 1.74E-09 Other erythrocyte phenotypes TFRC intron 19862010 rs9846149 chr3 195787308 C G 3.44E-15 Red blood cell traits TFRC intron 23222517 rs2284890 chr3 195788147 T C 1.75E-09 Other erythrocyte phenotypes TFRC intron 19862010 rs2284890 chr3 195788147 T C 4.74E-16 Red blood cell traits TFRC intron 23222517 rs2284889 chr3 195788247 G A 1.75E-09 Other erythrocyte phenotypes TFRC intron 19862010 rs2284889 chr3 195788247 G A 2.46E-11 Red blood cell traits TFRC intron 23222517 rs2300780 chr3 195790291 T C 4.17E-14 Red blood cell traits TFRC intron 23222517 rs454516 chr3 195793395 G C 6.72E-10 Red blood cell traits TFRC intron 23222517 rs2300774 chr3 195793712 G A 3.95E-10 Other erythrocyte phenotypes TFRC intron 19862010 rs2300774 chr3 195793712 G A 1.38E-15 Red blood cell traits TFRC intron 23222517 rs714602 chr3 195793979 T C 4.51E-14 Red blood cell traits TFRC intron 23222517 rs9858727 chr3 195794241 A T 1.79E-09 Other erythrocyte phenotypes TFRC intron 19862010 rs9858727 chr3 195794241 A T 3.04E-11 Red blood cell traits TFRC intron 23222517 rs4927866 chr3 195796049 G T 1.76E-12 Red blood cell traits TFRC intron 23222517 rs11185506 chr3 195797576 G C 3.26E-10 Other erythrocyte phenotypes TFRC intron 19862010 rs11185506 chr3 195797576 G C 2.51E-16 Red blood cell traits TFRC intron 23222517 rs3761717 chr3 195797947 G C 3.25E-10 Other erythrocyte phenotypes TFRC intron 19862010 rs3761717 chr3 195797947 G C 2.23E-16 Red blood cell traits TFRC intron 23222517 rs13072608 chr3 195800267 C T 4.12E-10 Other erythrocyte phenotypes TFRC intron 19862010 rs13072608 chr3 195800267 C T 8.32E-15 Red blood cell traits TFRC intron 23222517 rs9859260 chr3 195800547 C T 8.00E-14 Mean corpuscular volume TFRC intron 19862010 rs9859260 chr3 195800547 C T 2.11E-13 Red blood cell traits TFRC intron 23222517 rs9859401 chr3 195800603 C A 1.77E-09 Other erythrocyte phenotypes TFRC intron 19862010 rs9859401 chr3 195800603 C A 2.08E-11 Red blood cell traits TFRC intron 23222517 rs3817672 chr3 195800811 C T 5.81E-10 Red blood cell traits TFRC missense 23222517 rs4927868 chr3 195804763 C T 6.44E-05 Type 2 diabetes TFRC intron 22158537 rs3804139 chr3 195807625 T C 2.07E-09 Other erythrocyte phenotypes TFRC intron 19862010 rs3804139 chr3 195807625 T C 7.55E-18 Red blood cell traits TFRC intron 23222517 rs11915082 chr3 195809139 G A 8.00E-13 Mean corpuscular hemoglobin / / 19862010 rs11915082 chr3 195809139 G A 2.91E-13 Red blood cell traits / / 23222517 rs6583288 chr3 195809564 A G 8.14E-11 Red blood cell traits / / 23222517 rs12632706 chr3 195815594 C T 5.99E-09 Other erythrocyte phenotypes / / 19862010 rs12632706 chr3 195815594 C T 3.29E-08 Red blood cell traits / / 23222517 rs12490036 chr3 195816195 C T 8.16E-14 Red blood cell traits / / 23222517 rs12490036 chr3 195816195 C T 1.38E-05 Platelet counts / / 23263863 rs7617509 chr3 195820446 A G 1.02E-11 Red blood cell traits / / 23222517 rs12631246 chr3 195821584 G T 2.28E-08 Other erythrocyte phenotypes / / 19862010 rs12631246 chr3 195821584 G T 4.92E-10 Red blood cell traits / / 23222517 rs9990333 chr3 195827205 C T 1.33E-10 Red blood cell traits / / 23222517 rs11717368 chr3 195834357 G C 7.00E-19 Red blood cell traits / / 23222517 rs6799597 chr3 195835519 C T 2.98E-11 Red blood cell traits / / 23222517 rs7432894 chr3 195841644 C T 2.58E-07 Red blood cell traits / / 23222517 rs4927717 chr3 195847490 G C 1.06E-08 Red blood cell traits / / 23222517 rs9834962 chr3 195851223 C A 4.45E-05 Fibrinogen / / 17255346 rs7625441 chr3 195854279 C T 4.21E-08 Red blood cell traits / / 23222517 rs7634650 chr3 195865387 G A 7.92E-07 Red blood cell traits / / 23222517 rs9325432 chr3 195874107 T C 2.46E-08 Red blood cell traits LOC401109 intron 23222517 rs4927880 chr3 195877558 T C 5.53E-08 Red blood cell traits LOC401109 intron 23222517 rs4927879 chr3 195877603 T C 8.73E-04 Type 2 diabetes LOC401109 intron 17463246 rs9816881 chr3 195905946 A G 1.60E-09 Red blood cell traits / / 23222517 rs9869983 chr3 195905971 G C 2.64E-12 Red blood cell traits / / 23222517 rs4916483 chr3 195907653 T C 4.73E-05 Type 2 diabetes / / 17463246 rs4916483 chr3 195907653 T C 1.66E-08 Blood cell counts and other traits / / 20139978 rs4916483 chr3 195907653 T C 4.00E-11 Blood cell counts and other traits / / 20139978 rs4916483 chr3 195907653 T C 4.46E-11 Blood cell counts and other traits / / 20139978 rs4916483 chr3 195907653 T C 1.12E-11 Red blood cell traits / / 23222517 rs4916483 chr3 195907653 T C 1.01E-05 Platelet counts / / 23263863 rs4916491 chr3 195910628 A G 3.62E-09 Red blood cell traits / / 23222517 rs9812813 chr3 195911634 C T 7.30E-09 Red blood cell traits / / 23222517 rs3893275 chr3 195918956 A C 4.40E-11 Red blood cell traits / / 23222517 rs9325434 chr3 195921311 G A 4.41E-07 Red blood cell traits / / 23222517 rs4916478 chr3 195922570 C G 1.55E-11 Red blood cell traits / / 23222517 rs1106479 chr3 195925355 C T 1.39E-07 Red blood cell traits ZDHHC19 intron 23222517 rs1106480 chr3 195925458 A C 9.10E-07 Red blood cell traits ZDHHC19 intron 23222517 rs939892 chr3 195926234 T C 7.44E-05 Cholesterol ZDHHC19 intron 17255346 rs11924930 chr3 195928854 G A 7.00E-06 HIV-1 susceptibility ZDHHC19 intron 21160409 rs9812036 chr3 195929268 A G 6.38E-05 Glycosylated haemoglobin levels ZDHHC19 intron 17255346 rs7642243 chr3 195941216 C G 8.00E-16 Blood metabolite levels / / 24816252 rs1476332 chr3 195952731 C G 6.00E-06 Prostate cancer OSTalpha intron 21743057 rs7625886 chr3 195952900 T C 3.00E-05 Prostate cancer OSTalpha intron 21743057 rs1044988 chr3 195961685 A G 9.38E-05 Hypertension (essential hypertension) / / 22184326 rs884534 chr3 195964298 A G 7.56E-04 Smoking initiation / / 24665060 rs1580820 chr3 195966258 G A 1.69E-04 Cholesterol PCYT1A intron 17255346 rs1580820 chr3 195966258 G A 6.90E-04 Smoking initiation PCYT1A intron 24665060 rs7639752 chr3 195973244 G A 3.84E-04 Insulin resistance PCYT1A intron 21901158 rs2047550 chr3 196057616 G T 8.33E-05 Serum metabolites TM4SF19 intron 19043545 rs6774852 chr3 196078427 C T 7.00E-06 Obesity-related traits / / 23251661 rs6764533 chr3 196088464 G A 0.0002 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 UBXN7 intron 21873659 rs11920918 chr3 196095560 G A 4.26E-10 Cholesterol,total UBXN7 intron 23063622 rs11920918 chr3 196095560 G A 8.70E-23 LDL cholesterol UBXN7 intron 23063622 rs6583305 chr3 196118621 A T 0.0002 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 UBXN7 intron 21873659 rs12631706 chr3 196167930 T C 5.51E-05 Dengue shock syndrome / / 22001756 rs2342371 chr3 196187608 G A 4.40E-06 Subcutaneous adipose tissue volume in HIV-infected men / / 21897333 rs7433483 chr3 196217038 G A 4.87E-05 Response to mTOR inhibitor (everolimus) RNF168 intron 24009623 rs9858020 chr3 196219794 A G 6.05E-05 Response to mTOR inhibitor (everolimus) RNF168 intron 24009623 rs9858020 chr3 196219794 A G 6.32E-05 Response to mTOR inhibitor (rapamycin) RNF168 intron 24009623 rs7633212 chr3 196271808 G A 7.73E-04 Rheumatoid arthritis / / 21452313 rs11707537 chr3 196286536 G A 4.58E-04 Amyotrophic lateral sclerosis (sporadic) WDR53 intron 24529757 rs1355533 chr3 196286655 T C 4.80E-06 Urinary metabolites WDR53 intron 21572414 rs11711139 chr3 196315260 T C 1.91E-04 Lymphocyte counts FBXO45 UTR-3 22286170 rs1385331 chr3 196351215 C T 1.70E-04 Parkinson's disease / / 17052657 rs1385331 chr3 196351215 C T 7.78E-05 Celiac disease / / 23936387 rs1973265 chr3 196355432 A G 2.20E-05 Odorant perception / / 23910658 rs1798624 chr3 196365765 A G 3.38E-04 Type 2 diabetes / / 17463246 rs1718407 chr3 196365919 T G 1.80E-05 Serum metabolites / / 19043545 rs7636495 chr3 196367936 G A 0.0000367 Primary sclerosing cholangitis LRRC33 intron 23603763 rs12152276 chr3 196368501 A G 2.82E-05 Self-reported allergy LRRC33 intron 23817569 rs76036994 chr3 196369163 GA G 5.04E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) LRRC33 intron 23648065 rs843522 chr3 196369163 G A 5.04E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) LRRC33 intron 23648065 rs6766451 chr3 196375140 T G 5.39E-04 Celiac disease LRRC33 intron 23936387 rs6805151 chr3 196394518 T C 9.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs843511 chr3 196414159 C T 4.31E-04 Alcohol dependence / / 21314694 rs1684470 chr3 196467603 T G 2.19E-05 Personality dimensions PAK2 intron 22628180 rs1798619 chr3 196485851 G T 1.28E-05 Personality dimensions PAK2 intron 22628180 rs2084385 chr3 196553867 A G 5.00E-06 Total ventricular volume PAK2 intron 21116278 rs6789365 chr3 196554952 C A 9.30E-06 Prostate cancer (early onset) PAK2 intron 24740154 rs746037 chr3 196676487 A G 6.30E-04 Smoking quantity PIGZ intron 24665060 rs556043 chr3 196684793 T C 3.68E-06 Obesity and osteoporosis PIGZ intron 19714249 rs3821716 chr3 196738953 C T 6.76E-05 Multiple complex diseases MFI2 intron 17554300 rs6779362 chr3 196743130 T C 6.61E-05 Stroke MFI2 cds-synon pha002886 rs13321237 chr3 196766967 A G 2.20E-05 Urinary metabolites / / 21572414 rs17597256 chr3 196767854 C T 3.64E-05 Postoperative ventricular dysfunction / / 21980348 rs3773843 chr3 196809656 G T 6.39E-05 Erythrocyte counts DLG1 intron pha003101 rs3843376 chr3 196814424 T C 7.85E-05 Orofacial clefts DLG1 intron 22863734 rs12632536 chr3 196833650 T C 5.84E-05 Orofacial clefts DLG1 intron 22863734 rs1134986 chr3 196865242 C T 7.42E-05 Orofacial clefts DLG1 missense 22863734 rs10489880 chr3 196961186 A G 6.41E-05 Orofacial clefts DLG1 intron 22863734 rs338186 chr3 196963612 G A 4.06E-05 Orofacial clefts DLG1 intron 22863734 rs373889 chr3 196974183 C T 4.54E-04 Response to cytadine analogues (cytosine arabinoside) DLG1 intron 24483146 rs404377 chr3 196974757 T C 9.49E-04 Response to cytadine analogues (cytosine arabinoside) DLG1 intron 24483146 rs13059981 chr3 197043066 A G 1.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs17129333 chr3 197064879 C T 1.19E-04 Multiple complex diseases / / 17554300 rs768858 chr3 197075721 G A 0.0004567 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs768858 chr3 197075721 G A 4.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6583204 chr3 197079826 G T 7.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6792258 chr3 197124134 A G 1.74E-05 Prion diseases / / 22210626 rs7645524 chr3 197126303 A C 6.60E-05 Diabetes Mellitus / / pha003060 rs9821349 chr3 197127523 A G 4.13E-05 HDL cholesterol / / pha003074 rs7630584 chr3 197130874 C T 1.45E-05 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs9843268 chr3 197134110 G A 9.60E-05 HDL cholesterol / / pha003074 rs7620033 chr3 197147144 C A 7.55E-05 Prion diseases / / 22210626 rs1431499 chr3 197166491 C T 3.17E-04 Age-related macular degeneration / / 22125219 rs13083034 chr3 197174028 G T 1.87E-04 Age-related macular degeneration / / 22125219 rs1431500 chr3 197191912 A C 5.82E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs1431500 chr3 197191912 A C 5.82E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs11712523 chr3 197211398 T C 1.91E-04 Type 2 diabetes / / 17463246 rs4857607 chr3 197212660 C T 9.15E-04 Type 2 diabetes / / 17463246 rs2567357 chr3 197219237 C G 5.20E-05 IgE levels / / 22075330 rs2686084 chr3 197222523 C T 5.07E-05 IgE levels / / 22075330 rs7642375 chr3 197252834 G A 4.56E-04 Suicide attempts in bipolar disorder BDH1 intron 21423239 rs13095317 chr3 197254231 T C 3.22E-04 Suicide attempts in bipolar disorder BDH1 intron 21423239 rs13058936 chr3 197255522 A G 3.81E-04 Suicide attempts in bipolar disorder BDH1 intron 21423239 rs1549830 chr3 197269980 A C 2.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BDH1 intron 20877124 rs13097456 chr3 197272457 A T 3.57E-06 Brachial circumference BDH1 intron 22479309 rs1966617 chr3 197281093 A G 5.70E-04 Suicide attempts in bipolar disorder BDH1 intron 21423239 rs1966618 chr3 197281338 C A 5.75E-04 Suicide attempts in bipolar disorder BDH1 intron 21423239 rs2686107 chr3 197295958 T G 7.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BDH1 intron 20877124 rs11709808 chr3 197314132 C T 3.58E-04 Multiple complex diseases / / 17554300 rs7622678 chr3 197314448 A G 0.0000193 Aging / / 22445811 rs4857506 chr3 197332150 C T 4.77E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3749249 chr3 197445211 C T 1.90E-04 Prion diseases KIAA0226 intron 22210626 rs3749249 chr3 197445211 C T 3.47E-04 Response to cytidine analogues (gemcitabine) KIAA0226 intron 24483146 rs6788048 chr3 197646145 A G 3.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IQCG intron 20877124 rs9819156 chr3 197646762 A G 2.60E-05 Urinary metabolites IQCG intron 21572414 rs11919221 chr3 197653899 T C 2.60E-05 Urinary metabolites IQCG intron 21572414 rs9880989 chr3 197665599 G T 3.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IQCG missense 20877124 rs9884834 chr4 102571 T C 8.26E-04 Multiple complex diseases / / 17554300 rs11727494 chr4 110646 G A 3.46E-04 Multiple complex diseases / / 17554300 rs17745701 chr4 116981 C G 7.00E-05 Asthma / / 23181788 rs6830247 chr4 150683 G A 7.23E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6830247 chr4 150683 G A 8.47E-04 Coronary heart disease / / 21971053 rs6837818 chr4 178112 T A 5.21E-06 Waist circumference / / 19557197 rs7665922 chr4 181476 T C 2.84E-04 Coronary heart disease / / 21971053 rs6817633 chr4 181832 A G 5.84E-06 Waist circumference / / 19557197 rs6599313 chr4 195709 A C 5.42E-04 Coronary heart disease / / 21971053 rs11723261 chr4 282499 A G 4.00E-06 Immune response to smallpox vaccine (IL-6) ZNF732 intron 22542470 rs17719492 chr4 354051 C G 9.12E-05 Parkinson's disease ZNF141 intron 16252231 rs2280249 chr4 421086 C T 4.51E-05 Lymphocyte counts ABCA11P intron 22286170 rs960015 chr4 428311 C G 5.80E-04 Parkinson's disease ABCA11P intron 16252231 rs894534 chr4 429720 T C 6.54E-04 Alzheimer's disease ABCA11P intron 24755620 rs1045887 chr4 434079 G A 6.83E-04 Alzheimer's disease ZNF721 UTR-3 24755620 rs12644335 chr4 496594 G C 3.41E-04 Parkinson's disease PIGG intron 16252231 rs7678962 chr4 517198 G A 2.21E-04 Alcohol dependence PIGG intron 21314694 rs4624610 chr4 521480 T C 1.81E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) PIGG intron 24023788 rs6857009 chr4 691026 G A 4.20E-11 Triglycerides / / 23063622 rs12646225 chr4 696848 C T 2.21E-05 Multiple complex diseases / / 17554300 rs4690187 chr4 703813 C T 1.00E-04 Cognitive impairment induced by topiramate PCGF3 intron 22091778 rs4690187 chr4 703813 C T 7.08E-06 Hemostatic factors and hematological phenotypes PCGF3 intron 22443383 rs4690187 chr4 703813 C T 3.64E-05 Body Mass Index PCGF3 intron pha003015 rs4690296 chr4 732261 A G 2.52E-04 Parkinson's disease PCGF3 intron 21248740 rs4234853 chr4 735150 G A 6.00E-06 Hemostatic factors and hematological phenotypes PCGF3 intron 22443383 rs2242235 chr4 755210 A G 7.49E-05 Parkinson's disease PCGF3 intron 21248740 rs6816483 chr4 759733 T C 7.00E-04 Eating disorders PCGF3 intron 23568457 rs17165022 chr4 796405 C A,T 7.32E-04 Multiple complex diseases CPLX1 intron 17554300 rs28504502 chr4 803637 C T 5.58E-04 Major depressive disorder CPLX1 intron 22472876 rs936551 chr4 821490 A G 1.11E-07 Behcet's disease / / 23291587 rs936551 chr4 821490 A G 5.29E-08 Behcet's disease / / pha002888 rs1134921 chr4 843508 C T 7.78E-05 Psoriasis GAK missense 18364390 rs1564282 chr4 852313 C T 7.00E-07 Parkinson's disease (familial) GAK intron 18985386 rs1564282 chr4 852313 C T 3.97E-08 Parkinson's disease GAK intron 21258085 rs1564282 chr4 852313 C T 2.56E-06 Parkinson's disease GAK intron 21738487 rs1564282 chr4 852313 C T 2.22E-09 Parkinson's disease GAK intron 22438815 rs1564282 chr4 852313 C T 5.99E-06 Parkinson's disease GAK intron pha002865 rs11248051 chr4 858332 C T 3.00E-09 Parkinson's disease GAK intron 20711177 rs11248051 chr4 858332 C T 3.05E-06 Parkinson's disease GAK intron 22438815 rs11248051 chr4 858332 C T 3.00E-04 Parkinson's disease GAK intron 24511991 rs11248051 chr4 858332 C T 8.00E-05 Parkinson's disease GAK intron 24511991 rs11248051 chr4 858332 C T 5.25E-06 Parkinson's disease GAK intron pha002865 rs2279186 chr4 875887 G A 6.87E-05 Parkinson's disease GAK intron 21738487 rs11726508 chr4 888937 C T 3.86E-06 Parkinson's disease GAK intron 21738487 rs3775121 chr4 893520 G A 8.65E-11 Lymphocyte counts GAK intron 22286170 rs3755963 chr4 894255 A G 7.57E-05 Parkinson's disease GAK intron 21738487 rs873785 chr4 925149 T C 5.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GAK intron 20877124 rs873785 chr4 925149 T C 3.53E-05 Parkinson's disease GAK intron 21738487 rs6599388 chr4 939087 C T 4.00E-12 Parkinson's disease TMEM175 intron 21292315 rs6599388 chr4 939087 C T 9.54E-11 Parkinson's disease TMEM175 intron 22438815 rs6599389 chr4 939113 G A 4.00E-08 Parkinson's disease TMEM175 intron 21738487 rs2290403 chr4 942006 G A 1.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM175 intron 20877124 rs2290403 chr4 942006 G A 4.58E-05 Parkinson's disease TMEM175 intron 21738487 rs2290405 chr4 946974 G A 1.78E-04 Breast cancer TMEM175 intron pha002853 rs11248060 chr4 964359 C T 2.00E-06 Parkinson's disease DGKQ intron 20070850 rs11248060 chr4 964359 C T 1.16E-05 Paget's disease DGKQ intron 20436471 rs11248060 chr4 964359 C T 1.91E-06 Parkinson's disease DGKQ intron 21738487 rs11248060 chr4 964359 C T 3.00E-12 Parkinson's disease DGKQ intron 22438815 rs11248060 chr4 964359 C T 3.00E-09 Parkinson's disease DGKQ intron 22451204 rs11248060 chr4 964359 C T 3.39E-06 Parkinson's disease DGKQ intron pha002865 rs11724804 chr4 965779 G A 2.43E-07 Parkinson's disease DGKQ intron 21738487 rs11724804 chr4 965779 G A 1.99E-05 Systemic sclerosis DGKQ intron 21779181 rs6856425 chr4 976918 T C 0.00000053 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 SLC26A1 intron 21873659 rs6856425 chr4 976918 T C 0.000029 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 SLC26A1 intron 21873659 rs4690221 chr4 983809 C T 0.000367 Salmonella-induced pyroptosis SLC26A1 cds-synon 22837397 rs3755955 chr4 994414 G A 1.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IDUA missense 20877124 rs3755955 chr4 994414 G A 5.00E-15 Bone mineral density IDUA missense 22504420 rs3755955 chr4 994414 G A 0.000605 Femoral neck bone mineral density (premenopausal) IDUA missense 23074152 rs3755955 chr4 994414 G A 1.80E-06 Bone mineral density IDUA missense 24249740 rs3755955 chr4 994414 G A 7.82E-05 Bone mineral density IDUA missense 24249740 rs6815946 chr4 995305 T C 5.66E-04 Smoking cessation IDUA cds-synon 24665060 rs6831280 chr4 996165 G A 6.39E-04 Smoking cessation IDUA missense 24665060 rs6827815 chr4 999445 C G 5.00E-12 Bone mineral density / / 24249740 rs6827815 chr4 999445 C G 6.01E-07 Bone mineral density / / 24249740 rs62296075 chr4 1039215 A G 4.00E-06 Obesity-related traits / / 23251661 rs62294688 chr4 1043718 T G 6.98E-06 Obesity-related traits / / 23251661 rs935970 chr4 1045323 C G 2.46E-04 Type 2 diabetes / / 17463246 rs2045065 chr4 1052488 A G 3.30E-19 Recombination rate / / 18239089 rs6839931 chr4 1053172 T C 2.09E-05 Asthma / / 11022011 rs6839931 chr4 1053172 T C 7.37E-04 Type 2 diabetes / / 17463246 rs10084890 chr4 1053934 G C 4.44E-04 Type 2 diabetes / / 17463246 rs13137782 chr4 1058358 C T 7.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7669622 chr4 1058659 T C 4.53E-05 Asthma / / 11022011 rs7669622 chr4 1058659 T C 6.12E-04 Type 2 diabetes / / 17463246 rs6599278 chr4 1058798 C T 6.54E-04 Type 2 diabetes / / 17463246 rs6827357 chr4 1059202 A C 5.15E-05 Asthma / / 11022011 rs6827357 chr4 1059202 A C 7.54E-04 Type 2 diabetes / / 17463246 rs2290409 chr4 1067249 T C 1.45E-04 Glycosylated haemoglobin levels RNF212 intron 17255346 rs2290409 chr4 1067249 T C 1.50E-05 Urinary metabolites RNF212 intron 21572414 rs2290408 chr4 1067267 G T 4.53E-04 Type 2 diabetes RNF212 intron 17463246 rs2014318 chr4 1068778 A G 8.95E-04 Type 2 diabetes RNF212 intron 17463246 rs1010342 chr4 1068819 G A 6.65E-04 Type 2 diabetes RNF212 intron 17463246 rs1010342 chr4 1068819 G A 5.23E-04 Multiple complex diseases RNF212 intron 17554300 rs1010342 chr4 1068819 G A 2.27E-04 Recombination rate RNF212 intron 21698098 rs1670533 chr4 1078187 G A 2.00E-12 Recombination rate (females) RNF212 intron 18239089 rs11939380 chr4 1086871 T C 2.05E-04 Glycosylated haemoglobin levels RNF212 intron 17255346 rs11939380 chr4 1086871 T C 1.50E-05 Urinary metabolites RNF212 intron 21572414 rs11939380 chr4 1086871 T C 4.45E-16 Recombination rate RNF212 intron 21698098 rs4045481 chr4 1090625 G A 1.68E-04 Glycosylated haemoglobin levels RNF212 cds-synon 17255346 rs4045481 chr4 1090625 G A 1.60E-05 Urinary metabolites RNF212 cds-synon 21572414 rs4045481 chr4 1090625 G A 1.47E-04 Lymphocyte counts RNF212 cds-synon 22286170 rs3796619 chr4 1095281 A G 3.00E-24 Recombination rate (males) RNF212 intron 18239089 rs11937228 chr4 1147407 G A 6.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17802266 chr4 1158991 C A 9.86E-05 Cleft lip / / 20436469 rs2291199 chr4 1244267 A G 7.10E-04 Multiple complex diseases / / 17554300 rs7656416 chr4 1254535 C T 1.00E-08 Type 2 diabetes / / 22456796 rs11247983 chr4 1281951 C G 5.41E-06 Obesity-related traits / / 23251661 rs11727167 chr4 1285521 A G 5.41E-06 Obesity-related traits MAEA intron 23251661 rs13108904 chr4 1291113 G T 2.00E-06 Obesity-related traits MAEA intron 23251661 rs2293635 chr4 1291791 A G 5.41E-06 Obesity-related traits MAEA intron 23251661 rs7672093 chr4 1304743 C A 3.18E-06 Type 2 diabetes MAEA intron 22158537 rs6599299 chr4 1305018 T C 3.11E-07 Type 2 diabetes MAEA intron 22158537 rs6599300 chr4 1305269 G A 3.48E-07 Type 2 diabetes MAEA intron 22158537 rs17164638 chr4 1306595 C G 3.16E-07 Type 2 diabetes MAEA intron 22158537 rs11247989 chr4 1308337 A G 3.97E-06 Type 2 diabetes MAEA intron 22158537 rs11247990 chr4 1308536 G C 2.79E-07 Type 2 diabetes MAEA intron 22158537 rs11247991 chr4 1308564 A G 2.06E-05 Type 2 diabetes MAEA intron 22158537 rs6815464 chr4 1309901 C G 2.00E-20 Type 2 diabetes MAEA intron 22158537 rs6815464 chr4 1309901 C G 2.00E-07 Type 2 diabetes MAEA intron 23945395 rs6815464 chr4 1309901 C G 1.21E-05 Type 2 diabetes MAEA intron 24390345 rs11933854 chr4 1315172 G A 1.19E-04 Type 2 diabetes MAEA intron 22158537 rs11933855 chr4 1315183 G A 7.20E-06 Obesity-related traits MAEA intron 23251661 rs4333131 chr4 1323789 A G 6.68E-07 Type 2 diabetes MAEA intron 22158537 rs3856982 chr4 1328863 T C 6.76E-07 Type 2 diabetes MAEA intron 22158537 rs3856982 chr4 1328863 T C 2.54E-04 Lymphocyte counts MAEA intron 22286170 rs10006789 chr4 1330333 T C 1.91E-06 Type 2 diabetes MAEA intron 22158537 rs3749456 chr4 1344228 C G 3.44E-07 Type 2 diabetes KIAA1530 intron 22158537 rs17164682 chr4 1346796 A G 1.50E-04 Type 2 diabetes KIAA1530 intron 22158537 rs13142085 chr4 1348020 C T 1.02E-04 Fibrinogen KIAA1530 intron 17255346 rs1882099 chr4 1352685 A G 8.14E-06 Type 2 diabetes KIAA1530 intron 22158537 rs1882099 chr4 1352685 A G 3.96E-04 Lung function (forced vital capacity) KIAA1530 intron 24023788 rs11247998 chr4 1363602 T C 9.05E-06 Obesity-related traits KIAA1530 intron 23251661 rs13118159 chr4 1365127 T C 1.00E-06 Longevity KIAA1530 intron 20834067 rs6826415 chr4 1365623 A G 2.47E-04 Response to cytadine analogues (cytosine arabinoside) KIAA1530 intron 24483146 rs4974613 chr4 1367552 A G 2.11E-05 Aging (time to event) KIAA1530 intron 21782286 rs4974559 chr4 1380848 A G 8.53E-06 Obesity-related traits KIAA1530 UTR-3 23251661 rs4130791 chr4 1414684 G A 6.78E-06 Alopecia areata / / 22027810 rs10029689 chr4 1533976 T C 5.88E-05 Rheumatoid arthritis / / 17804836 rs6852065 chr4 1684409 C T 1.46E-05 Response to taxane treatment (placlitaxel) FAM53A intron 23006423 rs3958122 chr4 1693931 C T 2.82E-04 Suicide attempts in bipolar disorder / / 21041247 rs8051 chr4 1694809 T C 1.86E-04 Suicide attempts in bipolar disorder SLBP UTR-3 21041247 rs8051 chr4 1694809 T C 2.97E-04 Suicide attempts in bipolar disorder SLBP UTR-3 21041247 rs2247341 chr4 1701317 G A 2.00E-11 Height SLBP cds-synon 20881960 rs2247341 chr4 1701317 G A 2.75E-04 Suicide attempts in bipolar disorder SLBP cds-synon 21041247 rs743569 chr4 1719620 T G 2.08E-04 Suicide attempts in bipolar disorder TMEM129 intron 21041247 rs2854917 chr4 1720550 T C 2.01E-04 Suicide attempts in bipolar disorder TMEM129 intron 21041247 rs798754 chr4 1720757 A G 7.33E-11 Lymphocyte counts TMEM129 intron 22286170 rs2854916 chr4 1721348 G A 2.04E-04 Suicide attempts in bipolar disorder TMEM129 intron 21041247 rs145470576 chr4 1725159 A G 0.00073 Breast cancer TACC3 missense 23555315 rs798761 chr4 1731126 G A 1.98E-04 Suicide attempts in bipolar disorder TACC3 intron 21041247 rs798766 chr4 1734239 T C 1.00E-11 Urinary bladder cancer TACC3 intron 20348956 rs798766 chr4 1734239 T C 4.00E-13 Bladder cancer TACC3 intron 20972438 rs798766 chr4 1734239 T C 7.00E-25 Bladder cancer TACC3 intron 24163127 rs11248073 chr4 1737502 C T 1.86E-04 Suicide attempts in bipolar disorder TACC3 cds-synon 21041247 rs1530588 chr4 1742779 G A 1.88E-04 Suicide attempts in bipolar disorder TACC3 intron 21041247 rs487903 chr4 1901909 T C 2.70E-05 Urinary metabolites WHSC1 intron 21572414 rs439275 chr4 2046747 A G 4.34E-04 Multiple complex diseases / / 17554300 rs1923775 chr4 2103096 C T 6.00E-06 Alzheimer's disease POLN intron 22159054 rs554399 chr4 2139047 G A 8.49E-05 Celiac disease POLN intron 23936387 rs472972 chr4 2139886 A G 0.000462 Salmonella-induced pyroptosis POLN intron 22837397 rs11725880 chr4 2195009 G A 0.00015 Breast cancer POLN missense 23555315 rs202206471 chr4 2210057 T G 0.00058 Breast cancer POLN missense 23555315 rs2282764 chr4 2255063 A G 5.36E-04 Type 2 diabetes MXD4 intron 17463246 rs17132392 chr4 2277731 G T 4.37E-05 Brain structure ZFYVE28 intron 22504417 rs17818992 chr4 2283623 A G 4.43E-06 Phospholipid levels (plasma) ZFYVE28 intron 21829377 rs4974669 chr4 2286850 C G 8.57E-06 Antibody status in Tripanosoma cruzi seropositivity ZFYVE28 intron 24324551 rs11737692 chr4 2287421 A C 3.90E-04 Alzheimer's disease ZFYVE28 intron 22005930 rs11722299 chr4 2288238 A G 8.73E-06 Antibody status in Tripanosoma cruzi seropositivity ZFYVE28 intron 24324551 rs11723429 chr4 2288626 T G 4.12E-06 Antibody status in Tripanosoma cruzi seropositivity ZFYVE28 intron 24324551 rs4602560 chr4 2292921 A G 2.00E-06 Antibody status in Tripanosoma cruzi seropositivity ZFYVE28 intron 24324551 rs7694083 chr4 2294578 G A 1.76E-04 Alzheimer's disease ZFYVE28 intron 22005930 rs7666177 chr4 2294633 C G 4.18E-06 Phospholipid levels (plasma) ZFYVE28 intron 21829377 rs7681318 chr4 2294746 T C 4.69E-04 Alzheimer's disease ZFYVE28 intron 22005930 rs7693437 chr4 2296245 T C 4.85E-04 Alzheimer's disease ZFYVE28 intron 22005930 rs7660280 chr4 2296372 G C 5.00E-06 Phospholipid levels (plasma) ZFYVE28 intron 21829377 rs13105288 chr4 2297550 T C 7.67E-04 Alzheimer's disease ZFYVE28 intron 22005930 rs6599426 chr4 2300841 A G 6.03E-04 White matter integrity ZFYVE28 intron 22425255 rs612973 chr4 2304770 C A 1.78E-04 Alzheimer's disease ZFYVE28 intron 22005930 rs17132455 chr4 2320937 C T 5.15E-04 Response to taxane treatment (placlitaxel) ZFYVE28 intron 23006423 rs2148777 chr4 2324656 C A 1.40E-05 Urinary metabolites ZFYVE28 intron 21572414 rs654207 chr4 2324865 C T 3.62E-04 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs612243 chr4 2325910 C T 2.58E-04 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs3135115 chr4 2332319 C G 2.45E-04 Suicide attempts in bipolar disorder ZFYVE28 UTR-3 21423239 rs599642 chr4 2337603 G T 6.85E-04 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs663871 chr4 2340389 T C 1.16E-04 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs3118617 chr4 2340417 C T 5.00E-04 Type 2 diabetes ZFYVE28 intron 17463249 rs3118617 chr4 2340417 C T 5.03E-04 Multiple complex diseases ZFYVE28 intron 17554300 rs3118617 chr4 2340417 C T 8.29E-04 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs2071680 chr4 2341194 T C 1.59E-04 Suicide attempts in bipolar disorder ZFYVE28 cds-synon 21423239 rs2071678 chr4 2343851 G A 3.62E-04 Blood pressure ZFYVE28 intron 17255346 rs3135127 chr4 2359802 G A 6.85E-05 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs3135144 chr4 2365541 G A 3.33E-04 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs3128826 chr4 2366445 A G 5.30E-05 Suicide attempts in bipolar disorder ZFYVE28 UTR-5 21423239 rs3128823 chr4 2368222 C T 1.56E-04 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs1894433 chr4 2369253 G A 1.40E-04 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs3128816 chr4 2370341 G T 1.58E-04 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs3128814 chr4 2370829 C T 7.33E-05 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs3128813 chr4 2371109 G T 1.46E-04 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs3135137 chr4 2371174 T C 6.68E-05 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs3128809 chr4 2371930 A G 7.20E-05 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs3128808 chr4 2372183 G A 9.78E-05 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs3128806 chr4 2372263 C A 9.45E-05 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs2239722 chr4 2372496 G A 9.29E-05 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs2239721 chr4 2372929 G A 8.63E-05 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs2239719 chr4 2373307 A G 1.00E-04 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs2239718 chr4 2373418 C G 5.90E-05 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs2239717 chr4 2373437 T C 5.97E-05 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs3135459 chr4 2374646 C T 5.87E-05 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs3128801 chr4 2374659 A C 7.27E-05 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs13139003 chr4 2375250 A G 6.90E-05 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs7665067 chr4 2375942 A G 7.84E-05 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs4132858 chr4 2376423 A G 8.08E-05 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs9990556 chr4 2376576 T C 8.75E-05 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs4974680 chr4 2377083 G C 7.20E-05 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs13104914 chr4 2377413 C T 1.42E-04 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs10014641 chr4 2377460 C T 1.34E-04 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs2354519 chr4 2385312 T C 7.23E-05 Serum metabolites ZFYVE28 intron 19043545 rs2354519 chr4 2385312 T C 8.53E-05 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs3135095 chr4 2389800 A G 2.25E-04 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs10488837 chr4 2390058 A G 1.51E-04 Multiple complex diseases ZFYVE28 intron 17554300 rs3135093 chr4 2390303 G A 9.17E-05 Serum metabolites ZFYVE28 intron 19043545 rs3135093 chr4 2390303 G A 1.37E-04 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs2354522 chr4 2392155 G A 1.40E-04 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs959770 chr4 2395297 A G 4.85E-04 Multiple complex diseases ZFYVE28 intron 17554300 rs959770 chr4 2395297 A G 9.00E-06 Schizophrenia ZFYVE28 intron 23212062 rs3135085 chr4 2396435 A G 7.94E-05 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs2071674 chr4 2397084 C T 2.33E-04 Multiple complex diseases ZFYVE28 intron 17554300 rs2071674 chr4 2397084 C T 1.90E-06 Reading disability and language impairment ZFYVE28 intron 24024963 rs875130 chr4 2402706 A G 2.95E-04 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs3128775 chr4 2404150 T C 7.98E-04 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs3128768 chr4 2405197 C T 5.80E-04 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs12644662 chr4 2405338 C A 3.83E-04 Suicide attempts in bipolar disorder ZFYVE28 intron 21423239 rs12644638 chr4 2413461 G A 3.34E-05 Body Fat Distribution ZFYVE28 intron pha003017 rs1203790 chr4 2424197 C G 7.01E-04 Alzheimer's disease LOC402160 intron 17998437 rs2178136 chr4 2427127 C T 2.58E-04 Multiple complex diseases LOC402160 intron 17554300 rs7669749 chr4 2436042 C A 6.41E-05 Body Fat Distribution LOC402160 intron pha003016 rs7669749 chr4 2436042 C A 2.58E-05 Body Fat Distribution LOC402160 intron pha003017 rs7669749 chr4 2436042 C A 9.56E-05 Body Fat Distribution LOC402160 intron pha003018 rs846253 chr4 2463064 G A 1.34E-04 Sarcoidosis LOC402160 intron 19165924 rs846252 chr4 2465304 G A 9.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs11248108 chr4 2481490 G A 1.74E-22 Huntington's disease RNF4 intron 22387017 rs704352 chr4 2486486 C T 5.25E-17 Huntington's disease RNF4 intron 22387017 rs17825119 chr4 2674271 G T 2.95E-04 Age-related macular degeneration FAM193A intron 22125219 rs17825119 chr4 2674271 G T 0.0000632 Huntington's disease FAM193A intron 22387017 rs139214890 chr4 2695585 C T 0.000063 Prostate cancer (advanced) FAM193A missense 23555315 rs2295499 chr4 2717690 C T 0.0000105 Huntington's disease FAM193A intron 22387017 rs8426 chr4 2734175 G A 0.000436 Salmonella-induced pyroptosis FAM193A UTR-3 22837397 rs2269495 chr4 2744087 G A 1.80E-05 Urinary metabolites TNIP2 missense 21572414 rs9683949 chr4 2744480 C T 1.40E-04 Age-related macular degeneration TNIP2 intron 22125219 rs3733223 chr4 2745508 C A 1 Drug response to Etoposide TNIP2 intron 17537913 rs57277452 chr4 2774458 T TC,TCT 2.16E-12 Metabolite levels / / 22286219 rs1751848 chr4 2804476 A G 7.30E-05 Rheumatoid arthritis SH3BP2 intron 17804836 rs1751848 chr4 2804476 A G 0.0000357 Huntington's disease SH3BP2 intron 22387017 rs433030 chr4 2815632 G A 0.00000943 Huntington's disease SH3BP2 intron 22387017 rs189139 chr4 2832727 C T 1.97E-09 Huntington's disease SH3BP2 intron 22387017 rs624833 chr4 2881256 T G 8.88E-04 Stroke ADD1 intron pha002886 rs10488838 chr4 2881335 A G 2.33E-12 Alcohol consumption ADD1 intron pha001400 rs3775068 chr4 2888441 A G 5.40E-04 Coronary heart disease ADD1 intron 21966275 rs3775068 chr4 2888441 A G 1.00E-04 Cognitive impairment induced by topiramate ADD1 intron 22091778 rs17777307 chr4 2903285 A G 1.97E-04 Multiple complex diseases ADD1 intron 17554300 rs2285084 chr4 2906285 A G 9.77E-05 Birth weight ADD1 intron 17255346 rs2285084 chr4 2906285 A G 8.07E-04 Tourette syndrome ADD1 intron 22889924 rs2239728 chr4 2906453 T G 3.36E-04 Birth weight ADD1 intron 17255346 rs4961 chr4 2906707 G T 1 Drug response to Hydrochlorothiazide ADD1 missense 12623934 rs4961 chr4 2906707 G T 1 Drug response to Benazepril ADD1 missense 15773232 rs17834108 chr4 2910702 A C 1.11E-04 Multiple complex diseases ADD1 intron 17554300 rs762847 chr4 2912063 A G 7.07E-09 Huntington's disease ADD1 intron 22387017 rs16843589 chr4 2916931 G A 3.86E-04 Lung function (forced expiratory volume in 1 second) ADD1 intron 24023788 rs16843596 chr4 2925576 G T 5.29E-04 Type 2 diabetes ADD1 intron 17463246 rs16843629 chr4 2946481 A G 0.0000958 Huntington's disease NOP14 intron 22387017 rs7665452 chr4 2949878 A G 3.23E-04 Multiple complex diseases NOP14 intron 17554300 rs7667661 chr4 2954717 G A 2.50E-05 IgE levels in asthmatics NOP14 intron 23967269 rs2105380 chr4 2982929 C T 5.80E-04 Volumetric brain MRI GRK4 intron 17903297 rs1419046 chr4 2986049 T A 0.000000551 Huntington's disease GRK4 intron 22387017 rs2051556 chr4 2990338 G T 0.0000011 Huntington's disease GRK4 intron 22387017 rs2960308 chr4 2991040 G A 0.000000319 Huntington's disease GRK4 intron 22387017 rs2471340 chr4 2992341 G T 0.0000011 Huntington's disease GRK4 intron 22387017 rs2471336 chr4 2997611 T C 0.00000094 Huntington's disease GRK4 intron 22387017 rs34163500 chr4 2998674 C T 4.87E-05 Intracerebral hemorrhage GRK4 intron 24656865 rs1891710 chr4 3024723 A G 0.0000027 Huntington's disease GRK4 intron 22387017 rs2515943 chr4 3025015 T C 0.00000886 Huntington's disease GRK4 intron 22387017 rs2471327 chr4 3026173 G A 0.00000198 Huntington's disease GRK4 intron 22387017 rs2471327 chr4 3026173 G A 2.00E-06 Systemic lupus erythematosus and Systemic sclerosis GRK4 intron 23740937 rs2342295 chr4 3027493 G A 0.00000251 Huntington's disease GRK4 intron 22387017 rs2515933 chr4 3027897 T C 2.80E-05 Urinary metabolites GRK4 intron 21572414 rs2515933 chr4 3027897 T C 0.00000102 Huntington's disease GRK4 intron 22387017 rs2857845 chr4 3028113 A T 3.60E-04 Alcohol dependence GRK4 intron 21314694 rs2857845 chr4 3028113 A T 2.01E-20 Huntington's disease GRK4 intron 22387017 rs1419043 chr4 3029128 C G 5.91E-04 Sleep depth GRK4 intron 23728906 rs2857839 chr4 3036630 T C 2.50E-04 Alcohol dependence GRK4 intron 20201924 rs2857839 chr4 3036630 T C 0.0000066 Alcohol dependence GRK4 intron 23691058 rs1801058 chr4 3039150 T C 2.20E-04 Alcohol dependence GRK4 missense 20201924 rs1801058 chr4 3039150 T C 9.00E-04 Alcohol dependence GRK4 missense 20201924 rs1801058 chr4 3039150 T C 0.00000648 Alcohol dependence GRK4 missense 23691058 rs2798303 chr4 3040587 T C 1.50E-04 Alcohol dependence GRK4 intron 20201924 rs2798303 chr4 3040587 T C 2.40E-04 Alcohol dependence GRK4 intron 20201924 rs2798303 chr4 3040587 T C 0.00000128 Alcohol dependence GRK4 intron 23691058 rs16843773 chr4 3042258 C T 1.52E-04 Multiple complex diseases GRK4 intron 17554300 rs2471347 chr4 3044435 G A 7.05E-10 Huntington's disease / / 22387017 rs2798296 chr4 3062165 A G 7.57E-12 Huntington's disease / / 22387017 rs7694687 chr4 3063817 C T 1.70E-04 IgE levels in asthmatics / / 23967269 rs9291159 chr4 3066932 T C 1.55E-06 Statin-induced myopathy HTT-AS1 intron 21826682 rs3856973 chr4 3080173 G A 1.87E-14 Huntington's disease HTT intron 22387017 rs2285086 chr4 3089259 A G 4.01E-16 Huntington's disease HTT intron 22387017 rs10015979 chr4 3109442 A G 6.69E-13 Huntington's disease HTT intron 22387017 rs2071655 chr4 3118116 T G 7.42E-15 Huntington's disease HTT intron 22387017 rs363082 chr4 3132713 T C 2.67E-04 Type 2 diabetes HTT intron 17463246 rs363082 chr4 3132713 T C 0.000269 Huntington's disease HTT intron 22387017 rs363080 chr4 3133911 C T 4.29E-05 Prion diseases HTT intron 22210626 rs363066 chr4 3135953 T G 2.08E-14 Huntington's disease HTT intron 22387017 rs6855981 chr4 3148276 G A 4.84E-16 Huntington's disease HTT intron 22387017 rs363102 chr4 3149016 A C,G,T 2.52E-05 Prion diseases HTT intron 22210626 rs11731237 chr4 3151813 C T 1.13E-18 Huntington's disease HTT intron 22387017 rs11731237 chr4 3151813 C T 6.25E-05 Prostate cancer HTT intron pha002878 rs363146 chr4 3160477 A G 1.19E-04 Multiple complex diseases HTT intron 17554300 rs363096 chr4 3180021 T C 6.74E-09 Huntington's disease HTT intron 22387017 rs2298969 chr4 3186244 A G 4.64E-18 Huntington's disease HTT intron 22387017 rs16844026 chr4 3190533 C T 8.75E-05 HDL cholesterol HTT intron pha003074 rs363092 chr4 3196029 A C 2.82E-15 Huntington's disease HTT intron 22387017 rs3025830 chr4 3197648 C T 3.00E-08 Multiple complex diseases HTT intron 17554300 rs916171 chr4 3216815 C G 4.39E-14 Huntington's disease HTT intron 22387017 rs82333 chr4 3225389 A G 7.32E-17 Huntington's disease HTT intron 22387017 rs110501 chr4 3225478 T C 5.07E-16 Huntington's disease HTT intron 22387017 rs362272 chr4 3234980 G A 9.37E-12 Huntington's disease HTT missense 22387017 rs362313 chr4 3235589 C T 2.74E-04 Smoking quantity HTT intron 24665060 rs2269499 chr4 3239702 C T 4.42E-12 Huntington's disease HTT intron 22387017 rs3129322 chr4 3252852 T C 2.35E-04 Major depressive disorder MSANTD1 intron 22472876 rs362266 chr4 3259632 G C 1.50E-05 Urinary metabolites / / 21572414 rs3095073 chr4 3263138 G A 1.30E-05 Urinary metabolites / / 21572414 rs3095073 chr4 3263138 G A 1.11E-10 Huntington's disease / / 22387017 rs3095081 chr4 3263776 C T 1.10E-05 Urinary metabolites / / 21572414 rs3129319 chr4 3265381 A G 8.50E-06 Urinary metabolites / / 21572414 rs3129319 chr4 3265381 A G 1.78E-10 Huntington's disease / / 22387017 rs3095079 chr4 3265414 C T 8.50E-06 Urinary metabolites / / 21572414 rs3095079 chr4 3265414 C T 2.59E-10 Huntington's disease / / 22387017 rs3095077 chr4 3265710 C T 1.10E-05 Urinary metabolites / / 21572414 rs2798224 chr4 3267668 G A 1.40E-05 Urinary metabolites / / 21572414 rs2798224 chr4 3267668 G A 6.04E-14 Huntington's disease / / 22387017 rs2858087 chr4 3268892 T A 9.90E-06 Urinary metabolites / / 21572414 rs10937921 chr4 3276491 C T 6.69E-14 Huntington's disease / / 22387017 rs7658462 chr4 3283422 C T 7.45E-41 Huntington's disease / / 22387017 rs7658462 chr4 3283422 C T 0.0008406 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7658462 chr4 3283422 C T 8.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1138690 chr4 3291401 G T 8.20E-52 Huntington's disease / / 22387017 rs3135146 chr4 3307638 C G 1.99E-09 Huntington's disease / / 22387017 rs16844136 chr4 3307759 G A 3.29E-04 Multiple complex diseases / / 17554300 rs3129308 chr4 3309272 G A 1.41E-09 Huntington's disease / / 22387017 rs2236052 chr4 3318413 A G 4.50E-08 Progranulin levels RGS12 cds-synon 21087763 rs2236052 chr4 3318413 A G 4.50E-08 Myocardial infarction RGS12 cds-synon 21211798 rs2281470 chr4 3319553 C T 2.34E-05 Brain structure RGS12 cds-synon 22504417 rs2857861 chr4 3323767 C T 3.62E-12 Huntington's disease RGS12 intron 22387017 rs2749782 chr4 3339761 T C 5.73E-09 Huntington's disease RGS12 intron 22387017 rs7435601 chr4 3369645 T C 0.000000012 Huntington's disease RGS12 intron 22387017 rs11732375 chr4 3396963 G A 6.48E-04 Alcohol dependence RGS12 intron 20201924 rs16844280 chr4 3409024 C T 2.68E-04 Alcohol dependence RGS12 intron 20201924 rs1730768 chr4 3409359 A G 7.84E-17 Huntington's disease RGS12 intron 22387017 rs6446740 chr4 3409383 G A 1.05E-09 Huntington's disease RGS12 intron 22387017 rs13109976 chr4 3411058 A G 0.00000203 Huntington's disease RGS12 intron 22387017 rs16844307 chr4 3418165 C T 0.00000118 Huntington's disease RGS12 intron 22387017 rs16844309 chr4 3418266 G A 0.000000645 Huntington's disease RGS12 intron 22387017 rs12641989 chr4 3419840 G A 1.73E-64 Huntington's disease RGS12 intron 22387017 rs16844383 chr4 3447243 C T 6.90E-04 Response to cytidine analogues (gemcitabine) HGFAC intron 24483146 rs16844401 chr4 3449652 G A 2.00E-08 Fibrinogen HGFAC missense 23969696 rs2091626 chr4 3461900 G T 7.80E-04 Tourette syndrome / / 22889924 rs6831256 chr4 3473139 A G 1.00E-10 Cholesterol,total DOK7 intron 24097068 rs6831256 chr4 3473139 A G 2.00E-08 LDL cholesterol DOK7 intron 24097068 rs6831256 chr4 3473139 A G 2.00E-12 Triglycerides DOK7 intron 24097068 rs9993029 chr4 3473639 A C 3.77E-04 Response to cytidine analogues (gemcitabine) DOK7 intron 24483146 rs1794429 chr4 3533066 C T 3.60E-24 Progranulin levels LRPAP1 intron 21087763 rs1794429 chr4 3533066 C T 3.60E-24 Myocardial infarction LRPAP1 intron 21211798 rs2073503 chr4 3536176 C G 3.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs6817919 chr4 3582651 T C 6.17E-05 Vaspin levels FLJ35424 intron 22907691 rs2880892 chr4 3683269 G A 8.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16844797 chr4 3713599 C T 8.39E-05 Body Mass Index / / pha003014 rs202121184 chr4 3768805 G A 0.00038 Breast cancer ADRA2C missense 23555315 rs7678463 chr4 3770952 C G 8.60E-04 Atrial fibrillation / / 21846873 rs3889790 chr4 3923728 A G 3.76E-05 Cytomegalovirus antibody response / / 21993531 rs9291063 chr4 4015443 C T 2.31E-04 Multiple complex diseases / / 17554300 rs4974760 chr4 4160063 A G 1.23E-04 Multiple complex diseases / / 17554300 rs2028584 chr4 4190182 A G 6.60E-06 Urinary metabolites / / 21572414 rs2916408 chr4 4193060 T C 1.80E-05 Urinary metabolites OTOP1 intron 21572414 rs2920185 chr4 4203890 T C 1.60E-05 Urinary metabolites OTOP1 intron 21572414 rs1991915 chr4 4208861 T C 8.10E-04 Type 2 diabetes OTOP1 intron 17463246 rs1991914 chr4 4209113 C A 7.25E-04 Coronary heart disease OTOP1 intron 21971053 rs2294107 chr4 4238062 G C 3.81E-15 Lymphocyte counts TMEM128 intron 22286170 rs3846232 chr4 4247059 T C 1.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM128 intron 20877124 rs2916468 chr4 4249300 T C 7.10E-04 Alcohol dependence TMEM128 intron 20201924 rs2916464 chr4 4249620 T C 8.20E-04 Alcohol dependence TMEM128 UTR-5 20201924 rs2980098 chr4 4252956 A G 1.22E-04 Chronic kidney disease / / 24351856 rs2980098 chr4 4252956 A G 2.16E-06 Glomerular filtration rate / / 24351856 rs2916457 chr4 4253074 T C 1.39E-04 Multiple complex diseases / / 17554300 rs2920228 chr4 4263579 A C 1.12E-06 Parkinson's disease / / 17052657 rs2920228 chr4 4263579 A C 5.23E-04 Multiple complex diseases / / 17554300 rs2980089 chr4 4267298 G A 1.00E-04 Prostate cancer / / 21743057 rs16835397 chr4 4268642 C T 6.36E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2916438 chr4 4285865 A G 1.92E-04 Sudden cardiac arrest LYAR intron 21658281 rs12642617 chr4 4309280 C T 2.00E-04 Cognitive impairment induced by topiramate ZBTB49 intron 22091778 rs6855893 chr4 4333387 T C 6.13E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs4689316 chr4 4347505 C T 4.46E-04 White matter integrity / / 22425255 rs6446632 chr4 4355380 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7674400 chr4 4360381 A G 2.63E-04 Alzheimer's disease (late onset) / / 21379329 rs12511804 chr4 4369224 C A 4.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3792686 chr4 4393068 T C 5.80E-07 Alcohol dependence D4S234E intron 22096494 rs11729131 chr4 4460925 G T 9.41E-04 Multiple complex diseases STX18 intron 17554300 rs11729131 chr4 4460925 G T 7.21E-05 Bipolar disorder and schizophrenia STX18 intron 20889312 rs10017573 chr4 4463064 T C 6.51E-05 Multiple complex diseases STX18 intron 17554300 rs10516164 chr4 4497011 G C 2.10E-04 Lung function (forced expiratory volume in 1 second) STX18 intron 17255346 rs6838568 chr4 4498594 C T 1.82E-04 Lung function (forced expiratory volume in 1 second) STX18 intron 17255346 rs6853914 chr4 4499020 A G 1.79E-05 Bipolar disorder and schizophrenia STX18 intron 20889312 rs8180115 chr4 4521915 T C 1 Drug response to Etoposide STX18 intron 17537913 rs16835830 chr4 4523198 A G 8.44E-04 Body mass index STX18 intron 21701565 rs16835910 chr4 4570057 A G 3.61E-04 Multiple complex diseases LOC100507266 intron 17554300 rs4689896 chr4 4597420 G A 1.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100507266 intron 20877124 rs11935567 chr4 4611123 C T 7.01E-04 Suicide attempts in bipolar disorder LOC100507266 intron 21423239 rs16835941 chr4 4611819 G A 9.70E-07 Urinary metabolites LOC100507266 intron 21572414 rs6824295 chr4 4614280 C T 9.73E-10 Congenital heart disease LOC100507266 intron 23708191 rs1837711 chr4 4615708 A G 2.30E-06 Urinary metabolites LOC100507266 intron 21572414 rs6831607 chr4 4617756 G A 1.00E-06 Urinary metabolites LOC100507266 intron 21572414 rs2102528 chr4 4631235 T C 3.19E-04 Aortic root size LOC100507266 intron 21223598 rs16835979 chr4 4635276 C A 2.94E-10 Congenital heart disease LOC100507266 intron 23708191 rs870142 chr4 4648047 C T 3.00E-10 Congenital heart disease LOC100507266 intron 23708191 rs6830734 chr4 4653004 T C 3.49E-05 Orofacial clefts LOC100507266 intron 22863734 rs2063413 chr4 4654357 T C 2.64E-05 Multiple sclerosis (brain glutamate levels) LOC100507266 intron 20802204 rs4689915 chr4 4666330 A G 3.53E-06 Multiple complex diseases LOC100507266 intron 17554300 rs7675915 chr4 4678907 A G 0.0000595 Schizophrenia LOC100507266 intron 22440650 rs11730104 chr4 4682267 T G 5.54E-05 Orofacial clefts LOC100507266 intron 22419666 rs13149758 chr4 4682289 A G 1.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100507266 intron 20877124 rs2019908 chr4 4682768 A G 1.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100507266 intron 20877124 rs2136844 chr4 4685142 A T 7.13E-04 Type 2 diabetes LOC100507266 intron 17463246 rs2136843 chr4 4685195 A G 8.69E-04 Type 2 diabetes LOC100507266 intron 17463246 rs2369289 chr4 4685587 G A 7.58E-04 Type 2 diabetes LOC100507266 intron 17463246 rs2887447 chr4 4692728 A G 6.14E-04 White matter integrity LOC100507266 intron 22425255 rs2887447 chr4 4692728 A G 3.26E-06 Hypertension LOC100507266 intron pha003042 rs2887447 chr4 4692728 A G 8.83E-05 Blood Pressure LOC100507266 intron pha003046 rs2887447 chr4 4692728 A G 1.08E-06 Blood Pressure LOC100507266 intron pha003048 rs4476553 chr4 4704014 C T 3.00E-06 Response to amphetamines LOC100507266 intron 22952603 rs1022135 chr4 4707192 G T 7.80E-05 Parkinson's disease (familial) LOC100507266 intron 18985386 rs12696704 chr4 4711210 C T 8.97E-06 Response to amphetamines LOC100507266 intron 22952603 rs1022133 chr4 4712140 C T 7.58E-06 Response to amphetamines / / 22952603 rs1000579 chr4 4719494 A G 4.00E-07 Alcohol dependence / / 22004471 rs13130037 chr4 4724676 A C 1.13E-04 White matter integrity / / 22425255 rs13130037 chr4 4724676 A C 9.62E-05 Hypertension / / pha003042 rs10516168 chr4 4744037 C A 4.26E-05 Blood Pressure / / pha003048 rs7679624 chr4 4751272 T G 7.00E-06 Pancreatic cancer / / pha002889 rs6830371 chr4 4767695 C T 5.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12186237 chr4 4774402 G A 9.60E-05 Response to statin therapy / / 20339536 rs41473944 chr4 4778394 G A 1.15E-04 Multiple complex diseases / / 17554300 rs6835562 chr4 4781109 C A 3.00E-06 Urinary metabolites / / 21572414 rs2933568 chr4 4784580 T C 4.21E-05 Hypertension / / pha003042 rs10937891 chr4 4792249 C T 3.64E-04 Multiple complex diseases / / 17554300 rs12507605 chr4 4795402 A G 1.40E-05 Hypertension / / pha003042 rs12507605 chr4 4795402 A G 6.73E-05 Blood Pressure / / pha003046 rs2933572 chr4 4799692 G A 2.79E-05 Prostate cancer / / pha002878 rs2933572 chr4 4799692 G A 3.05E-05 Hypertension / / pha003042 rs2087865 chr4 4803675 A G 1.46E-07 Hypertension / / pha003042 rs16836297 chr4 4807342 G T 2.80E-05 Urinary metabolites / / 21572414 rs4689941 chr4 4809353 A C 1.60E-04 IgE levels in asthmatics / / 23967269 rs4689941 chr4 4809353 A C 1.29E-06 Hypertension / / pha003042 rs1907989 chr4 4818925 A G 7.66E-05 Orofacial clefts / / 22863734 rs1907987 chr4 4819240 G A 7.40E-06 Urinary metabolites / / 21572414 rs1907986 chr4 4819408 G A 7.30E-06 Urinary metabolites / / 21572414 rs17716572 chr4 4819835 A G 1.70E-05 Urinary metabolites / / 21572414 rs10212960 chr4 4822309 C T 6.30E-06 Urinary metabolites / / 21572414 rs6852205 chr4 4824151 C T 1.60E-05 Urinary metabolites / / 21572414 rs6833060 chr4 4826875 A G 2.15E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7666443 chr4 4837058 T C 3.64E-06 Hypertension / / pha003042 rs12500028 chr4 4883409 A C 2.77E-05 Type 2 diabetes / / 17463246 rs6817411 chr4 4891148 C T 2.98E-06 Neuroblastoma / / pha002895 rs4689186 chr4 4895065 C G 5.05E-04 Insulin resistance / / 21901158 rs4566595 chr4 4905782 C A 7.88E-06 Neuroblastoma / / pha002895 rs6446700 chr4 4911642 A G 7.63E-05 Neuroblastoma / / pha002895 rs4234840 chr4 4917511 A G 4.56E-06 Neuroblastoma / / pha002895 rs736405 chr4 4923296 C T 7.66E-05 Cognitive impairment induced by topiramate / / 22091778 rs13139027 chr4 4926166 G A 1.75E-05 Parkinson's disease / / pha002868 rs4689963 chr4 4935205 G A 8.76E-07 Neuroblastoma / / pha002895 rs6831989 chr4 4941687 G T 9.51E-04 Multiple complex diseases / / 17554300 rs6831989 chr4 4941687 G T 1.11E-06 Alzheimer's disease / / 17998437 rs1010776 chr4 4942150 C T 5.69E-04 Alzheimer's disease / / 17998437 rs10025128 chr4 4944596 T G 4.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs7681839 chr4 4950184 G C 8.85E-04 Multiple complex diseases / / 17554300 rs2968680 chr4 4950210 T C 1.05E-06 Alzheimer's disease / / 17998437 rs11728854 chr4 4952425 G A 7.55E-04 Type 2 diabetes / / 17463246 rs16836497 chr4 4952677 T C 0.0000746 Alcohol consumption / / 22613542 rs2968673 chr4 4969745 T A 1.51E-06 Alzheimer's disease / / 17998437 rs4491964 chr4 5019651 C T 5.49E-04 Multiple complex diseases CYTL1 intron 17554300 rs10937616 chr4 5025923 G C 7.61E-05 Femoral neck bone geometry / / 22087292 rs6446313 chr4 5032174 C G 2.45E-05 Femoral neck bone geometry / / 22087292 rs9799796 chr4 5055774 C T 9.82E-05 LDL lipoproteins STK32B intron pha002902 rs10009026 chr4 5057311 G A 4.17E-05 Bipolar disorder and schizophrenia STK32B intron 20889312 rs7655852 chr4 5058979 C A 1.19E-04 Progressive supranuclear palsy STK32B intron 21685912 rs16836590 chr4 5063297 A G 0.000299 Salmonella-induced pyroptosis STK32B intron 22837397 rs6811343 chr4 5081995 G A 3.43E-05 Alcohol and nictotine co-dependence STK32B intron 20158304 rs7693293 chr4 5093523 G A 6.77E-05 Serum metabolites STK32B intron 19043545 rs6833812 chr4 5110140 G A 7.00E-06 Sensory disturbances after bilateral sagittal split ramus osteotomy STK32B intron 23834954 rs12509816 chr4 5116247 A G 3.34E-05 Schizophrenia STK32B intron 20185149 rs1374621 chr4 5125724 T C 2.36E-04 Alzheimer's disease (late onset) STK32B intron 21379329 rs16836697 chr4 5139124 C T 6.15E-30 Metabolite levels STK32B intron 22286219 rs9291071 chr4 5152981 T C 3.26E-05 Bilirubin levels,in serum STK32B intron 19389676 rs7672067 chr4 5154673 G A 2.79E-05 Bilirubin levels,in serum STK32B intron 19389676 rs7683724 chr4 5159654 A G 6.06E-05 Stroke (ischemic) STK32B intron 22941190 rs13128441 chr4 5162389 C T 8.00E-06 Celiac disease STK32B intron 23936387 rs1530609 chr4 5163447 G A 4.82E-05 Aging (time to event) STK32B intron 21782286 rs1077366 chr4 5165075 A T 9.46E-05 Serum metabolites STK32B intron 19043545 rs10022435 chr4 5170549 A G 6.10E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) STK32B intron 20877124 rs2008242 chr4 5221538 G C 3.00E-06 Electrocardiographic conduction measures STK32B intron 19389651 rs11728216 chr4 5231006 A G 1.06E-04 Aortic root size STK32B intron 21223598 rs78647349 chr4 5237153 G A 5.00E-07 Alzheimer's disease (cognitive decline) STK32B intron 23535033 rs6817353 chr4 5241571 A G 7.13E-04 Alzheimer's disease STK32B intron 17998437 rs6817353 chr4 5241571 A G 2.17E-04 Sarcoidosis STK32B intron 19165924 rs6817353 chr4 5241571 A G 9.30E-08 Metabolite levels STK32B intron 23281178 rs4479644 chr4 5254800 A T 8.82E-04 Alzheimer's disease STK32B intron 17998437 rs16837040 chr4 5343287 G C 1.46E-04 Type 2 diabetes STK32B intron 17463246 rs1393867 chr4 5345949 T C 5.83E-04 Alzheimer's disease STK32B intron 17998437 rs7697839 chr4 5367985 A G 2.00E-11 Coronary heart disease STK32B intron 21626137 rs7673097 chr4 5368224 G T 2.00E-11 Coronary heart disease STK32B intron 21626137 rs12651236 chr4 5384476 T C 2.80E-05 Urinary metabolites STK32B intron 21572414 rs10010358 chr4 5405805 C A 1.08E-05 Vascular dementia STK32B intron 22116812 rs195113 chr4 5413525 C T 6.97E-05 Vascular dementia STK32B intron 22116812 rs195112 chr4 5413699 G A 3.61E-04 Parkinson's disease STK32B intron 16252231 rs195112 chr4 5413699 G A 6.49E-04 Multiple complex diseases STK32B intron 17554300 rs3774846 chr4 5414131 T C 2.00E-04 Cognitive impairment induced by topiramate STK32B intron 22091778 rs2301857 chr4 5418485 C T 5.94E-04 Multiple complex diseases STK32B intron 17554300 rs2654505 chr4 5426327 A G 2.78E-04 Multiple complex diseases STK32B intron 17554300 rs3774830 chr4 5440083 C T 4.00E-05 Bone mineral density (BMD),in women STK32B intron 20164292 rs6827240 chr4 5440224 G T 7.90E-05 Bone mineral density (BMD),in women STK32B intron 20164292 rs10433660 chr4 5449048 G A 8.56E-04 Insulin resistance STK32B intron 21901158 rs16837323 chr4 5469466 G C 2.23E-04 Multiple complex diseases STK32B intron 17554300 rs16837352 chr4 5504274 G T 3.78E-06 Osteoarthritis / / 22763110 rs16837352 chr4 5504274 G T 1.22E-05 Word reading / / 23738518 rs11729670 chr4 5507518 C A 6.79E-04 Type 2 diabetes / / 17463246 rs2267654 chr4 5527249 A G 8.50E-05 Malaria C4orf6 intron 19465909 rs3846230 chr4 5543143 A G 2.48E-04 HIV-1 viral setpoint / / 17641165 rs4688940 chr4 5557569 A G 9.91E-04 HIV-1 viral setpoint / / 17641165 rs4629382 chr4 5559671 T C 9.59E-04 HIV-1 viral setpoint / / 17641165 rs13113867 chr4 5563196 A G 9.83E-04 HIV-1 viral setpoint / / 17641165 rs6853237 chr4 5564860 G T 7.35E-04 Multiple complex diseases EVC2 intron 17554300 rs6818363 chr4 5579370 C A 7.54E-04 Multiple complex diseases EVC2 intron 17554300 rs4450870 chr4 5580774 T G 9.16E-04 HIV-1 viral setpoint EVC2 intron 17641165 rs4333126 chr4 5594969 C T 4.24E-04 Coronary Artery Disease EVC2 intron 17634449 rs11929929 chr4 5618000 G A 5.80E-04 Multiple complex diseases EVC2 intron 17554300 rs4321576 chr4 5619562 C T 2.52E-04 Multiple complex diseases EVC2 intron 17554300 rs28379106 chr4 5620515 C T 7.18E-04 Multiple complex diseases EVC2 intron 17554300 rs12640355 chr4 5621820 A G 4.67E-04 Response to cytidine analogues (gemcitabine) EVC2 intron 24483146 rs7688985 chr4 5631628 G A 3.87E-04 Multiple complex diseases EVC2 intron 17554300 rs6849773 chr4 5640348 A G 4.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EVC2 intron 20877124 rs6830983 chr4 5652712 A G 2.50E-05 Urinary metabolites EVC2 intron 21572414 rs4298088 chr4 5667561 C T 2.00E-06 Urinary metabolites EVC2 intron 21572414 rs7662476 chr4 5675789 A G 2.17E-06 Socioeconomic Factors EVC2 intron pha003066 rs6446389 chr4 5680311 C T 6.13E-05 Socioeconomic Factors EVC2 intron pha003066 rs4689276 chr4 5682189 C T 3.73E-04 Amyotrophic Lateral Sclerosis EVC2 intron 17362836 rs10937658 chr4 5682811 G A 4.25E-04 Response to cytadine analogues (cytosine arabinoside) EVC2 intron 24483146 rs960055 chr4 5687281 C T 5.58E-05 Body Mass Index EVC2 intron pha003006 rs6855056 chr4 5690283 C T 7.13E-05 Receptive language ability EVC2 intron 24687471 rs11936402 chr4 5696383 T C 5.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EVC2 intron 20877124 rs17746378 chr4 5751826 T A 6.31E-04 Smoking initiation EVC intron 24665060 rs899694 chr4 5753053 C A 5.39E-04 Smoking initiation EVC intron 24665060 rs899691 chr4 5754544 T C 9.69E-06 Multiple complex diseases EVC intron 17554300 rs735172 chr4 5758869 T C 2.00E-06 Prostate cancer (gene x gene interaction) EVC intron 22219177 rs11939527 chr4 5761366 G A 5.86E-05 Serum metabolites EVC intron 19043545 rs11939527 chr4 5761366 G A 9.55E-05 Cognitive decline EVC intron 22054870 rs17690997 chr4 5779317 T G 1.70E-05 Urinary metabolites EVC intron 21572414 rs35926225 chr4 5812152 G A 1.10E-09 HDL cholesterol EVC missense 23063622 rs6813104 chr4 5816938 T C 9.05E-04 Rheumatoid arthritis / / 21452313 rs3821936 chr4 5829257 T C 3.90E-04 Multiple complex diseases CRMP1 intron 17554300 rs6820236 chr4 5831521 A G 2.16E-04 Multiple complex diseases CRMP1 intron 17554300 rs12331 chr4 5838513 C A,G 2.57E-04 Multiple complex diseases CRMP1 cds-synon 17554300 rs7654446 chr4 5838837 G A 4.89E-04 Alcohol dependence CRMP1 intron 21314694 rs16837723 chr4 5841350 A G 3.71E-05 Blood pressure CRMP1 cds-synon 17255346 rs16837723 chr4 5841350 A G 3.05E-05 Intraocular pressure CRMP1 cds-synon 23836780 rs3774885 chr4 5842856 A G 1.00E-06 Urinary metabolites CRMP1 intron 21572414 rs2286282 chr4 5843266 T C 6.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CRMP1 intron 20877124 rs2286282 chr4 5843266 T C 5.82E-04 Response to TNF antagonist treatment CRMP1 intron 21061259 rs2286282 chr4 5843266 T C 4.90E-06 Urinary metabolites CRMP1 intron 21572414 rs2286281 chr4 5843318 G T 9.70E-05 Parkinson's disease (age of onset) CRMP1 intron 19772629 rs11945849 chr4 5850343 A G 1.53E-04 Type 2 diabetes CRMP1 intron 17463246 rs3911870 chr4 5860283 G A 2.10E-05 Urinary metabolites CRMP1 intron 21572414 rs13146086 chr4 5865088 C T 3.42E-05 Cognitive test performance CRMP1 intron 20125193 rs11937144 chr4 5877023 C T 3.67E-04 Alzheimer's disease (late onset) CRMP1 intron 21379329 rs3774895 chr4 5887440 A T 2.00E-05 Anorexia nervosa CRMP1 intron 23568457 rs10937692 chr4 5922917 C T 4.39E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12506399 chr4 5924794 G A 2.45E-05 Cognitive test performance / / 20125193 rs7675169 chr4 5926551 A C 2.21E-05 Cognitive test performance / / 20125193 rs4333127 chr4 5930033 G A 3.00E-06 Blood trace element (Zn levels) / / 23720494 rs16837865 chr4 5939199 T C 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs16837871 chr4 5941112 G A 4.19E-39 Multiple complex diseases / / 17554300 rs7682973 chr4 5945106 A G 8.23E-04 Alcohol dependence / / 24277619 rs733370 chr4 5959135 A G 9.43E-05 Non-alcoholic fatty liver disease histology (other) C4orf50 UTR-3 20708005 rs7434820 chr4 5963465 T C 1.22E-04 Non-small cell lung cancer,hypertriglyceridemia with bexarotene treatment of C4orf50 intron 21737656 rs6446414 chr4 5964345 T C 2.44E-04 Alcohol dependence C4orf50 intron 24277619 rs6839295 chr4 5966801 T C 5.83E-05 Diabetes Mellitus C4orf50 missense pha003059 rs6821688 chr4 5982108 T C 1.00E-05 Coffee consumption C4orf50 intron 21357676 rs16838073 chr4 6004560 G A 1.97E-04 Multiple complex diseases / / 17554300 rs4689318 chr4 6018891 C T 8.41E-04 Multiple complex diseases / / 17554300 rs4355331 chr4 6023254 C G 8.68E-04 Multiple complex diseases / / 17554300 rs11940459 chr4 6025844 G A 9.91E-04 Multiple complex diseases / / 17554300 rs11940459 chr4 6025844 G A 1.76E-04 Smoking cessation / / 18519826 rs16838127 chr4 6056406 T C 1.98E-05 Smoking cessation JAKMIP1 intron 18519826 rs16838127 chr4 6056406 T C 3.27E-04 Smoking cessation JAKMIP1 intron 18519826 rs16838131 chr4 6058497 G A 2.00E-06 Response to angiotensin II receptor blocker therapy JAKMIP1 intron 22566498 rs16838138 chr4 6058701 A G 4.50E-05 Smoking cessation JAKMIP1 intron 18519826 rs17766228 chr4 6065298 T C 8.44E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) JAKMIP1 intron 23648065 rs11943370 chr4 6065975 T C 9.62E-04 Suicide attempts in bipolar disorder JAKMIP1 intron 21423239 rs17766335 chr4 6068267 C T 7.19E-04 Multiple complex diseases JAKMIP1 intron 17554300 rs6446452 chr4 6080817 T C 1.17E-05 Height JAKMIP1 intron pha003010 rs4689334 chr4 6085543 A G 6.77E-04 Type 2 diabetes JAKMIP1 intron 17463246 rs7680061 chr4 6106821 G T 1.90E-05 Urinary metabolites JAKMIP1 intron 21572414 rs11731332 chr4 6113559 C T 2.67E-04 Osteoarthritis JAKMIP1 intron 19508968 rs11930138 chr4 6116456 A G 4.13E-05 Neutrophil count JAKMIP1 intron pha003095 rs6820853 chr4 6120265 A G 8.17E-04 Smoking cessation JAKMIP1 intron 24665060 rs6820853 chr4 6120265 A G 9.06E-05 Waist-Hip Ratio JAKMIP1 intron pha003029 rs4516797 chr4 6135717 G A 1.21E-05 Blood Pressure JAKMIP1 intron pha003050 rs2358576 chr4 6165640 C T 3.09E-04 Multiple complex diseases JAKMIP1 intron 17554300 rs6446469 chr4 6168155 A G 3.60E-05 F-cell distribution JAKMIP1 intron 21326311 rs17773390 chr4 6173521 G A 7.95E-04 Rheumatoid arthritis JAKMIP1 intron 21452313 rs17773514 chr4 6177056 T C 4.87E-04 Rheumatoid arthritis JAKMIP1 intron 21452313 rs17773514 chr4 6177056 T C 6.35E-07 Triglycerides JAKMIP1 intron pha003080 rs17773514 chr4 6177056 T C 9.13E-05 Lipid levels JAKMIP1 intron pha003082 rs7655218 chr4 6181924 A T 4.70E-04 Multiple complex diseases JAKMIP1 intron 17554300 rs10937705 chr4 6183184 T G 4.00E-06 IgG glycosylation JAKMIP1 intron 23382691 rs10937705 chr4 6183184 T G 5.44E-05 Elbow pain JAKMIP1 intron pha003008 rs885420 chr4 6185816 A C 2.43E-04 Rheumatoid arthritis JAKMIP1 intron 21452313 rs1877762 chr4 6191051 C T 3.59E-05 Triglycerides JAKMIP1 intron pha003080 rs11730635 chr4 6198265 C T 9.60E-05 Diabetic retinopathy JAKMIP1 intron 21441570 rs4688973 chr4 6199980 G A 3.69E-05 Insulin-related traits JAKMIP1 intron 19902172 rs10003892 chr4 6206784 G A 3.65E-06 Crohn's disease LOC285484 intron 17804789 rs4274923 chr4 6213622 G A 3.00E-06 Crohn's disease LOC285484 intron 17804789 rs13132796 chr4 6216955 C G 5.83E-06 Crohn's disease LOC285484 intron 17804789 rs4234723 chr4 6219929 A G 4.89E-04 Crohn's disease LOC285484 intron 17804789 rs908016 chr4 6222105 A T 2.81E-06 Crohn's disease LOC285484 intron 17804789 rs4689388 chr4 6270056 G A 1.00E-08 Type 2 diabetes and other traits WFS1 nearGene-5 19734900 rs4689388 chr4 6270056 G A 1.00E-08 Coronary heart disease WFS1 nearGene-5 21347282 rs4689388 chr4 6270056 G A 1.00E-08 Type 2 diabetes WFS1 nearGene-5 21647700 rs4688985 chr4 6285715 A G 0.000000288 Type 2 diabetes WFS1 intron 22325160 rs4689393 chr4 6287241 T C 4.60E-05 Diabetes Mellitus WFS1 intron pha003060 rs4458523 chr4 6289986 T G 0.000001 Fasting blood glucose WFS1 intron 22885922 rs4458523 chr4 6289986 T G 2.00E-15 Type 2 diabetes WFS1 intron 22885922 rs4458523 chr4 6289986 T G 2.00E-09 Type 2 diabetes WFS1 intron 24509480 rs10012946 chr4 6293350 T C 4.11E-05 Obesity (early onset extreme) WFS1 intron 23563609 rs4416547 chr4 6293967 G A 9.60E-11 Type 2 diabetes WFS1 intron 22885922 rs6823148 chr4 6299902 C T 1.49E-09 LDL cholesterol WFS1 intron 23063622 rs6823148 chr4 6299902 C T 3.34E-08 Cholesterol,total WFS1 intron 23063622 rs1801214 chr4 6303022 C A,G,T 3.00E-08 Type 2 diabetes WFS1 missense 20581827 rs1801214 chr4 6303022 C A,G,T 0.0000005 Type 2 diabetes (females) WFS1 missense 22885922 rs1801214 chr4 6303022 C A,G,T 2.90E-12 Type 2 diabetes (males) WFS1 missense 22885922 rs1801214 chr4 6303022 C A,G,T 3.30E-15 Type 2 diabetes WFS1 missense 22885922 rs1801214 chr4 6303022 C A,G,T 3.20E-08 Type 2 diabetes WFS1 missense 23300278 rs1801214 chr4 6303022 C A,G,T 6.96E-04 Type 2 diabetes WFS1 missense 24390345 rs7674423 chr4 6312004 G T 7.01E-04 Lymphocyte counts / / 22286170 rs4689408 chr4 6342213 C T 1.50E-05 Hypertension PPP2R2C intron 22384028 rs7441490 chr4 6345038 G A 9.69E-04 Response to cytadine analogues (cytosine arabinoside) PPP2R2C intron 24483146 rs6856061 chr4 6348191 T C 3.76E-05 Coronary heart disease PPP2R2C intron pha003031 rs11727760 chr4 6352060 A G 9.80E-05 HIV-1 control PPP2R2C intron 20041166 rs6831971 chr4 6367467 T C 7.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) PPP2R2C intron 23648065 rs4272078 chr4 6369384 T C 4.91E-04 Multiple complex diseases PPP2R2C intron 17554300 rs4327561 chr4 6381323 G A 8.43E-05 Basophils PPP2R2C intron pha003087 rs6851340 chr4 6384823 C T 1.80E-05 Hypothyroidism PPP2R2C intron 22493691 rs4689433 chr4 6400507 G T 8.00E-06 Urinary metabolites PPP2R2C intron 21572414 rs5019274 chr4 6400860 T C 1.30E-05 Urinary metabolites PPP2R2C intron 21572414 rs10008136 chr4 6412401 A G 0.000853 Salmonella-induced pyroptosis PPP2R2C intron 22837397 rs16838780 chr4 6417785 T C 0.000199 fMRI brain tests in schizophrenia PPP2R2C intron 22440650 rs13129773 chr4 6465438 G A 7.40E-04 Amyotrophic Lateral Sclerosis PPP2R2C intron 17362836 rs7664714 chr4 6465791 T C 1.40E-05 Fasting plasma glucose PPP2R2C intron 19060907 rs4571410 chr4 6517005 C T 3.09E-05 Glycosylated haemoglobin levels PPP2R2C intron 17255346 rs4565150 chr4 6517066 T C 3.69E-04 Multiple complex diseases PPP2R2C intron 17554300 rs4302525 chr4 6552201 C T 2.64E-04 Alzheimer's disease (late onset) PPP2R2C intron 21379329 rs7654633 chr4 6613605 A G 9.98E-05 Longevity MAN2B2 intron 20304771 rs10937748 chr4 6614168 A G 1.00E-04 Prostate cancer MAN2B2 intron 21743057 rs10049503 chr4 6616948 T C 6.87E-05 Response to hepatitis C treatment MAN2B2 intron 19684573 rs6446516 chr4 6625571 T C 3.08E-05 Coronary restenosis / / 21878436 rs4689495 chr4 6659684 C T 9.86E-04 Iron levels / / pha002876 rs724858 chr4 6671959 T C 5.82E-04 Iron levels / / pha002876 rs28620095 chr4 6675529 A G 3.55E-04 Alcohol dependence / / 20201924 rs4689516 chr4 6687113 G A 1.11E-04 Type 2 diabetes / / 17463246 rs4645287 chr4 6694778 A C 4.07E-04 Parkinson's disease / / 17052657 rs3822262 chr4 6697766 T G 3.00E-06 Obesity-related traits S100P intron 23251661 rs10937751 chr4 6712056 A C 1.42E-04 Iron levels / / pha002876 rs4420983 chr4 6733659 G A 9.25E-04 Aortic root size / / 21223598 rs4689044 chr4 6734367 G A 2.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4626203 chr4 6736064 T C 7.83E-05 Pancreatic cancer / / pha002889 rs7661864 chr4 6736365 G A 5.00E-06 IgG glycosylation / / 23382691 rs10022630 chr4 6868155 T C 0.000709198 Hypertension (early onset hypertension) KIAA0232 intron 22479346 rs11734132 chr4 6891519 G C 1.00E-11 Mean platelet volume / / 22139419 rs11734132 chr4 6891519 G C 6.00E-07 Mean platelet volume / / 24026423 rs4342189 chr4 6908390 A G 4.68E-05 Coronary heart disease / / pha003031 rs4689558 chr4 6920466 G A 7.33E-05 Serum metabolites TBC1D14 intron 19043545 rs6446552 chr4 6924241 G A 5.43E-05 Smoking initiation TBC1D14 intron 24665060 rs9291123 chr4 6937984 C T 5.47E-04 Alzheimer's disease TBC1D14 intron 24755620 rs6838250 chr4 6973184 G C 1.93E-05 Diabetic nephropathy TBC1D14 intron 21150874 rs6838250 chr4 6973184 G C 2.93E-04 Type 2 diabetes TBC1D14 intron 22238593 rs10937777 chr4 7017412 C T 3.29E-04 Response to statin treatment (atorvastatin),change in cholesterol levels TBC1D14 intron 20031582 rs16839553 chr4 7018185 G A 8.00E-06 IgG glycosylation TBC1D14 intron 23382691 rs12648134 chr4 7021107 T C 5.67E-04 Weight loss (gastric bypass surgery) TBC1D14 intron 23643386 rs10937779 chr4 7039326 G A 3.47E-04 Amyotrophic lateral sclerosis (sporadic) LOC100129931 intron 24529757 rs1043704 chr4 7058191 T C 2.68E-04 Type 2 diabetes TADA2B UTR-3 17463246 rs4689584 chr4 7061219 T C 1.00E-04 Volumetric brain MRI / / 17903297 rs3796908 chr4 7061378 G A 5.00E-05 Cognitive test performance / / 20125193 rs907526 chr4 7084835 C T 3.24E-05 Body mass (lean) / / 19268274 rs10027697 chr4 7126063 G A 6.35E-05 Heart Rate / / pha003051 rs10155062 chr4 7133905 G A 8.03E-05 Lipoproteins / / pha003079 rs9994719 chr4 7135167 G C 8.34E-04 Type 2 diabetes / / 17463246 rs10017978 chr4 7135255 C T 4.37E-04 Type 2 diabetes / / 17463246 rs7665697 chr4 7137993 C T 3.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12233740 chr4 7151434 C T 1.12E-04 Hemoglobin concentration / / 20534544 rs10034147 chr4 7158467 G T 4.56E-05 Body Fat Distribution / / pha003017 rs3894944 chr4 7159702 G A 3.00E-06 Coronary artery calcification / / 23870195 rs9991298 chr4 7170562 C T 8.48E-04 Alzheimer's disease / / 24755620 rs9999241 chr4 7174993 A G 1.00E-05 F-cell distribution / / 17767159 rs4689078 chr4 7178278 A G 2.27E-04 Alzheimer's disease / / 24755620 rs4689626 chr4 7190015 T G 5.22E-06 Height / / pha003010 rs4689626 chr4 7190015 T G 9.59E-07 Height / / pha003011 rs4689630 chr4 7195054 G A 0.0000979 fMRI brain tests in schizophrenia SORCS2 intron 22440650 rs3815181 chr4 7204493 T C 1.86E-04 Amyotrophic lateral sclerosis (sporadic) SORCS2 intron 24529757 rs870860 chr4 7210808 C T 9.95E-08 Metabolite levels SORCS2 intron 23281178 rs4234798 chr4 7219933 T G 5.00E-10 Insulin-like growth factors SORCS2 intron 21216879 rs4689651 chr4 7223159 C G 8.88E-04 Type 2 diabetes SORCS2 intron 17463246 rs11931821 chr4 7223367 C G 7.66E-08 Metabolite levels SORCS2 intron 23281178 rs7681336 chr4 7245954 C A 0.0000598 Amyotrophic lateral sclerosis SORCS2 intron 23587638 rs905010 chr4 7253260 C T 9.64E-05 Adipocyte fatty acid-binding protein concentration,in serum SORCS2 intron 21863005 rs904989 chr4 7262170 C T 8.39E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) SORCS2 intron 23648065 rs6814708 chr4 7280324 T C 1.81E-05 Systemic lupus erythematosus and Systemic sclerosis SORCS2 intron 23740937 rs3846421 chr4 7285356 G A 1.20E-04 Alzheimer's disease (late onset) SORCS2 intron 20885792 rs3846421 chr4 7285356 G A 1.20E-04 Alzheimer's disease (late onset) SORCS2 intron 21460841 rs4689682 chr4 7289113 T C 2.50E-05 Urinary metabolites SORCS2 intron 21572414 rs3846429 chr4 7307727 T G 3.75E-05 Intracerebral hemorrhage SORCS2 intron 24656865 rs34168071 chr4 7308268 G A 3.79E-05 Intracerebral hemorrhage SORCS2 intron 24656865 rs4689694 chr4 7309659 G A 3.78E-05 Intracerebral hemorrhage SORCS2 intron 24656865 rs11942816 chr4 7312145 T C 3.74E-04 HIV-1 viral setpoint SORCS2 intron 17641165 rs3892041 chr4 7314962 A C 4.94E-04 HIV-1 viral setpoint SORCS2 intron 17641165 rs6832897 chr4 7318308 T C 3.24E-04 HIV-1 viral setpoint SORCS2 intron 17641165 rs4689705 chr4 7325002 T C 3.82E-05 Brain structure SORCS2 intron 22504417 rs4689705 chr4 7325002 T C 2.87E-05 Coronary heart disease SORCS2 intron pha003031 rs4689707 chr4 7326199 C T 1.00E-04 Cognitive impairment induced by topiramate SORCS2 intron 22091778 rs4689707 chr4 7326199 C T 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SORCS2 intron 22628534 rs3936616 chr4 7334424 G A 4.31E-04 Multiple complex diseases SORCS2 intron 17554300 rs4689710 chr4 7334778 A G 7.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SORCS2 intron 20877124 rs17813558 chr4 7342311 G T 2.00E-04 Cognitive impairment induced by topiramate SORCS2 intron 22091778 rs11724125 chr4 7348593 C T 7.52E-05 Height SORCS2 intron pha003011 rs11734491 chr4 7350677 G A 9.11E-05 Height SORCS2 intron pha003011 rs4689719 chr4 7390415 T C 4.25E-05 Waist Circumference SORCS2 intron pha003023 rs4689721 chr4 7390448 C T 5.50E-05 Waist Circumference SORCS2 intron pha003023 rs6446597 chr4 7414226 A G 5.18E-04 Type 2 diabetes SORCS2 intron 22158537 rs4689116 chr4 7418773 G A 2.74E-04 Smoking quantity SORCS2 intron 24665060 rs7682286 chr4 7420575 A G 5.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SORCS2 intron 20877124 rs7683216 chr4 7422613 C T 1.54E-04 Obesity (extreme) SORCS2 intron 21935397 rs7671061 chr4 7423034 T G 5.85E-05 Height SORCS2 intron pha003011 rs7694661 chr4 7423751 C A 3.00E-06 Obesity-related traits SORCS2 intron 23251661 rs7694661 chr4 7423751 C A 9.00E-06 Obesity-related traits SORCS2 intron 23251661 rs11733360 chr4 7427831 T C 5.30E-06 Urinary metabolites SORCS2 intron 21572414 rs6850206 chr4 7435721 C T 0.00054 Prostate cancer PSAPL1 missense 23555315 rs11548325 chr4 7436486 C A 0.00072 Prostate cancer PSAPL1 missense 23555315 rs7660079 chr4 7438352 C T 8.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SORCS2 intron 20877124 rs4234808 chr4 7442086 G A 2.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SORCS2 intron 20877124 rs17816553 chr4 7464995 G T 3.80E-05 Type 2 diabetes SORCS2 intron 17463246 rs4411993 chr4 7466466 T C 5.00E-04 Bipolar disorder SORCS2 intron 17486107 rs4689126 chr4 7467316 T C 9.25E-04 Type 2 diabetes SORCS2 intron 17463246 rs7683874 chr4 7475424 G A 6.00E-04 Bipolar disorder SORCS2 intron 17486107 rs10937823 chr4 7480422 C T 1.40E-05 Bipolar disorder SORCS2 intron 17486107 rs10937823 chr4 7480422 C T 1.80E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer SORCS2 intron 21483023 rs13139074 chr4 7482051 C G 1.00E-05 Urinary metabolites SORCS2 intron 21572414 rs16840373 chr4 7482622 T C 2.10E-05 Urinary metabolites SORCS2 intron 21572414 rs17828052 chr4 7485775 C T 8.60E-16 Progranulin levels SORCS2 intron 21087763 rs17828052 chr4 7485775 C T 8.60E-16 Myocardial infarction SORCS2 intron 21211798 rs10937830 chr4 7495975 C T 3.54E-04 Multiple complex diseases SORCS2 intron 17554300 rs10000185 chr4 7509758 C T 5.77E-04 Alzheimer's disease SORCS2 intron 17998437 rs4487342 chr4 7517179 A G 3.55E-05 Eosinophil counts SORCS2 intron pha003088 rs13114336 chr4 7519318 G C 8.79E-04 Suicide attempts in bipolar disorder SORCS2 intron 21423239 rs4639075 chr4 7519789 A G 4.80E-04 Suicide attempts in bipolar disorder SORCS2 intron 21423239 rs10002854 chr4 7521146 C T 1.54E-04 Suicide attempts in bipolar disorder SORCS2 intron 21423239 rs13134855 chr4 7521640 G A 9.62E-04 Suicide attempts in bipolar disorder SORCS2 intron 21423239 rs7669478 chr4 7530451 T C 8.18E-05 Insulin-related traits SORCS2 intron pha003063 rs11931489 chr4 7531319 G A 5.27E-05 Crohn's disease SORCS2 intron 18587394 rs7694823 chr4 7533041 A C 0.0000742 Salmonella-induced pyroptosis SORCS2 intron 22837397 rs6812745 chr4 7534603 A G 5.59E-04 Longevity SORCS2 intron 22279548 rs10470723 chr4 7546373 C T 5.41E-05 Bipolar disorder and schizophrenia SORCS2 intron 20889312 rs9291135 chr4 7579715 T G 7.67E-04 Insulin resistance SORCS2 intron 21901158 rs4689786 chr4 7584560 T C 0.0000317 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity SORCS2 intron 22945461 rs10012347 chr4 7584767 T C 0.00008 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity SORCS2 intron 22945461 rs4689788 chr4 7587424 C G 1.29E-04 Aortic root size SORCS2 intron 21223598 rs4689789 chr4 7588936 T C 0.0000815 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity SORCS2 intron 22945461 rs11943985 chr4 7589509 T C 5.50E-04 Insulin resistance SORCS2 intron 21901158 rs4594727 chr4 7592068 T G 7.93E-05 Vaspin levels SORCS2 intron 22907691 rs4594727 chr4 7592068 T G 0.0000793 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks SORCS2 intron 22907730 rs4594727 chr4 7592068 T G 0.0001292 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit SORCS2 intron 22907730 rs757240 chr4 7607757 A G 5.33E-05 Vaspin levels SORCS2 intron 22907691 rs757240 chr4 7607757 A G 0.0000533 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks SORCS2 intron 22907730 rs16840617 chr4 7610540 A G 4.05E-05 Vaspin levels SORCS2 intron 22907691 rs16840617 chr4 7610540 A G 0.0000405 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks SORCS2 intron 22907730 rs16840635 chr4 7611923 C A 5.72E-04 Aortic root size SORCS2 intron 21223598 rs13145735 chr4 7619653 A G 4.21E-05 HIV-1 viral setpoint SORCS2 intron 21490045 rs6838261 chr4 7625412 T C 6.64E-04 Type 2 diabetes SORCS2 intron 17463246 rs6838261 chr4 7625412 T C 3.07E-05 HIV-1 viral setpoint SORCS2 intron 21490045 rs4689148 chr4 7637297 C T 5.00E-05 HIV-1 control SORCS2 intron 20041166 rs2158276 chr4 7639906 A C 7.15E-05 HIV-1 viral setpoint SORCS2 intron 17641165 rs11932646 chr4 7646256 A C 6.46E-04 Amyotrophic Lateral Sclerosis SORCS2 intron 17827064 rs2285789 chr4 7655855 C T 8.75E-05 IgE levels SORCS2 intron 17255346 rs7664871 chr4 7679806 G A 8.25E-04 Body mass index SORCS2 intron 21701565 rs7664871 chr4 7679806 G A 9.13E-05 Body mass index SORCS2 intron 21701565 rs11729581 chr4 7680536 T G 1.84E-06 Serum metabolites SORCS2 intron 19043545 rs10013239 chr4 7680962 A C 3.99E-05 Body mass index SORCS2 intron 21701565 rs10013239 chr4 7680962 A C 5.60E-04 Body mass index SORCS2 intron 21701565 rs7697323 chr4 7683417 G A 4.43E-04 Multiple complex diseases SORCS2 intron 17554300 rs929264 chr4 7691193 G C 1.56E-04 Multiple complex diseases SORCS2 intron 17554300 rs2359630 chr4 7704795 C T 0.0000156 HDL cholesterol particle diameter SORCS2 intron 23263444 rs2253959 chr4 7704818 G T 0.0000103 HDL cholesterol particle diameter SORCS2 intron 23263444 rs2097769 chr4 7722458 G A 9.80E-04 Type 2 diabetes SORCS2 intron 17463246 rs2097769 chr4 7722458 G A 6.80E-05 Personality dimensions SORCS2 intron 18957941 rs2285777 chr4 7726847 A G 5.44E-05 Self-reported allergy SORCS2 intron 23817569 rs2285773 chr4 7735513 C T 3.50E-06 Urinary metabolites SORCS2 intron 21572414 rs886374 chr4 7738369 T C 2.40E-06 Type 2 diabetes SORCS2 intron 17463248 rs16840961 chr4 7740470 A C 2.30E-05 Urinary metabolites SORCS2 intron 21572414 rs2285766 chr4 7762848 G A 1.15E-04 Type 2 diabetes AFAP1 UTR-3 17463246 rs10516187 chr4 7778524 G T 6.00E-04 Chronic fatigue syndrome AFAP1 intron 21912186 rs16841187 chr4 7779105 T G 6.38E-04 Type 2 diabetes AFAP1 intron 17463246 rs11941290 chr4 7792375 C G 3.58E-05 Mammographic density AFAP1 intron 22532574 rs7376483 chr4 7804265 C T 3.21E-04 Insulin resistance AFAP1 intron 21901158 rs1106248 chr4 7807834 T C 8.39E-05 Personality dimensions AFAP1 intron 18957941 rs1106248 chr4 7807834 T C 7.67E-05 Leukocyte Counts AFAP1 intron pha003091 rs4689868 chr4 7809042 A C 7.19E-05 Cognitive impairment induced by topiramate AFAP1 intron 22091778 rs6446628 chr4 7831935 A C 4.49E-06 Leukocyte Counts AFAP1 intron pha003091 rs7682202 chr4 7832100 A T 1.07E-04 Mammographic density AFAP1 intron 22532574 rs4383619 chr4 7863508 T C 1.30E-05 Intraocular pressure AFAP1 intron 24002674 rs6829680 chr4 7912333 G A 2.30E-05 Urinary metabolites AFAP1 intron 21572414 rs6838291 chr4 7917806 C T 1.00E-05 Intraocular pressure AFAP1 intron 24002674 rs9991239 chr4 7929041 G A 2.34E-05 Monocyte chemoattractant protein-1 AFAP1 intron pha003071 rs11930623 chr4 7931682 A C 1.30E-05 Intraocular pressure AFAP1 intron 24002674 rs6447872 chr4 7943106 G A 8.38E-05 Cognitive performance / / 19734545 rs10008860 chr4 7969594 G A 1.27E-05 Coronary heart disease ABLIM2 intron pha003030 rs16841542 chr4 8002391 T G 5.19E-05 Prostate cancer ABLIM2 intron pha002877 rs4696666 chr4 8019447 G A 9.56E-04 Myopia (pathological) ABLIM2 intron 21095009 rs17795172 chr4 8028937 G A 4.89E-05 Lung function (forced expiratory volume in 1 second) ABLIM2 intron 24023788 rs1574131 chr4 8041800 T C 8.90E-04 Multiple complex diseases ABLIM2 intron 17554300 rs7690495 chr4 8046762 G A 1.00E-05 Urinary metabolites ABLIM2 intron 21572414 rs13137881 chr4 8049576 G A 1.50E-05 Urinary metabolites ABLIM2 intron 21572414 rs4696758 chr4 8106249 G A 6.00E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ABLIM2 intron 20031582 rs11733210 chr4 8112851 G C 7.91E-04 Suicide attempts in bipolar disorder ABLIM2 intron 21423239 rs10001300 chr4 8122628 C T 4.75E-04 Suicide attempts in bipolar disorder ABLIM2 intron 21423239 rs10001300 chr4 8122628 C T 8.60E-04 Response to taxane treatment (placlitaxel) ABLIM2 intron 23006423 rs16841848 chr4 8142672 C T 1.40E-06 Urinary metabolites ABLIM2 intron 21572414 rs4696769 chr4 8148159 A G 9.86E-04 Suicide attempts in bipolar disorder ABLIM2 intron 21423239 rs13132877 chr4 8163560 T G 7.93E-05 Basophils / / pha003087 rs1281110 chr4 8187442 G T 2.44E-04 Multiple complex diseases / / 17554300 rs1281132 chr4 8209383 A G 1.30E-05 Urinary metabolites SH3TC1 intron 21572414 rs1281134 chr4 8210051 A G 3.81E-04 Multiple complex diseases SH3TC1 intron 17554300 rs1712316 chr4 8211624 C T 5.40E-06 Urinary metabolites SH3TC1 intron 21572414 rs1298145 chr4 8220400 A G 0.0001 Migraine SH3TC1 intron 22678113 rs3796758 chr4 8228434 A G 2.22E-04 Lymphocyte counts SH3TC1 intron 22286170 rs3756193 chr4 8233341 T C 3.51E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SH3TC1 intron 20877124 rs10938702 chr4 8260812 C G 3.18E-04 Acute lung injury / / 22295056 rs9985550 chr4 8289807 A G 4.11E-05 Serum metabolites HTRA3 intron 19043545 rs4263384 chr4 8289904 A C 3.84E-05 Serum metabolites HTRA3 intron 19043545 rs4235261 chr4 8314620 C T 2.71E-04 Fibrinogen / / 17255346 rs13114241 chr4 8327530 C A 0.000124482 Hypertension (early onset hypertension) / / 22479346 rs1720018 chr4 8327543 C T 9.97E-04 Multiple complex diseases / / 17554300 rs6825003 chr4 8335658 T C 7.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs6858268 chr4 8335737 C T 7.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs1678317 chr4 8336118 A G 5.46E-04 Multiple complex diseases / / 17554300 rs2046028 chr4 8336225 C T 0.000349556 Hypertension (early onset hypertension) / / 22479346 rs2046028 chr4 8336225 C T 3.67E-05 ldl cholesterol / / pha003076 rs2619302 chr4 8337797 G A 3.21E-04 Multiple complex diseases / / 17554300 rs1678305 chr4 8349738 C T 3.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs747584 chr4 8373602 T G 2.90E-05 Urinary metabolites ACOX3 intron 21572414 rs3756187 chr4 8378332 G C 3.24E-04 Birth weight ACOX3 intron 17255346 rs6853292 chr4 8393401 C A 1.40E-05 Urinary metabolites ACOX3 intron 21572414 rs6810854 chr4 8397686 A G 3.03E-04 Smoking quantity ACOX3 intron 24665060 rs11938364 chr4 8400959 A G 5.03E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ACOX3 intron 20031582 rs6845969 chr4 8402465 T A 1.90E-05 Urinary metabolites ACOX3 intron 21572414 rs2631766 chr4 8418779 G C 2.10E-05 Urinary metabolites ACOX3 intron 21572414 rs2631765 chr4 8418997 G C 1.50E-05 Urinary metabolites ACOX3 intron 21572414 rs2140336 chr4 8424831 G A 2.70E-06 Urinary metabolites ACOX3 intron 21572414 rs1949733 chr4 8503359 A G 2.60E-04 Multiple complex diseases / / 17554300 rs1949733 chr4 8503359 A G 8.00E-07 Response to antineoplastic agents / / 21659360 rs6850810 chr4 8534283 A G 3.59E-04 Type 2 diabetes / / 17463246 rs3115401 chr4 8538007 C T 5.52E-04 Type 2 diabetes / / 17463246 rs3103091 chr4 8538981 C T 6.00E-04 Type 2 diabetes / / 17463246 rs10805209 chr4 8549845 C T 2.12E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs7682211 chr4 8566758 T C 7.98E-05 Blood Pressure / / pha003043 rs6823859 chr4 8573917 C T 1.36E-04 Multiple complex diseases / / 17554300 rs6838103 chr4 8579149 T C 2.30E-04 Type 2 diabetes / / 17463246 rs6838127 chr4 8579193 T C 6.53E-04 Type 2 diabetes / / 17463246 rs2286998 chr4 8580087 C G 5.73E-04 Multiple complex diseases / / 17554300 rs2270270 chr4 8580875 G C 5.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs2270269 chr4 8580952 T C 5.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs4696715 chr4 8611176 A C 5.58E-07 Neuroblastoma CPZ intron pha002895 rs10755199 chr4 8617758 G C 4.47E-04 Multiple complex diseases CPZ intron 17554300 rs12510524 chr4 8643085 C A 7.00E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs4696904 chr4 8674871 G A 3.58E-05 Cognitive impairment induced by topiramate / / 22091778 rs6817108 chr4 8694389 T C 2.40E-05 Esophageal cancer (squamous cell) / / 22960999 rs7682634 chr4 8706264 G T 6.77E-05 Erythrocyte counts / / pha003099 rs10938738 chr4 8708723 A G 2.74E-05 Erythrocyte counts / / pha003099 rs4522850 chr4 8722990 A G 7.49E-05 Erythrocyte counts / / pha003099 rs12509371 chr4 9384846 C G 8.34E-05 Acute lung injury / / 22295056 rs11930416 chr4 9387283 T A 6.43E-04 Acute lung injury / / 22295056 rs4974905 chr4 9405523 G A 8.16E-04 Acute lung injury / / 22295056 rs13114077 chr4 9413105 T C 1.37E-12 Urate levels / / 23263486 rs6811069 chr4 9415008 A T 6.91E-17 Urate levels / / 23263486 rs1949921 chr4 9419322 G A 3.38E-17 Urate levels / / 23263486 rs11722202 chr4 9443894 C T 6.85E-11 Urate levels / / 23263486 rs4246697 chr4 9451923 T C 6.13E-04 Suicide attempts in bipolar disorder DEFB131 intron 21423239 rs4974886 chr4 9503349 T C 1.84E-14 Urate levels / / 23263486 rs12513044 chr4 9506678 A T 6.50E-10 Urate levels / / 20884846 rs12513044 chr4 9506678 A T 2.52E-22 Urate levels / / 23263486 rs11722359 chr4 9508214 A C 5.90E-10 Urate levels / / 20884846 rs11722359 chr4 9508214 A C 1.20E-21 Urate levels / / 23263486 rs2127796 chr4 9510832 C T 4.00E-10 Urate levels / / 20884846 rs11737509 chr4 9511324 G A 1.84E-16 Urate levels / / 23263486 rs6448742 chr4 9542759 C T 2.10E-07 Urate levels / / 20884846 rs6448742 chr4 9542759 C T 2.83E-15 Urate levels / / 23263486 rs12233771 chr4 9552965 T A 1.30E-09 Urate levels / / 20884846 rs12233771 chr4 9552965 T A 1.25E-19 Urate levels / / 23263486 rs13110253 chr4 9558556 G T 3.60E-10 Urate levels / / 20884846 rs10013288 chr4 9559218 T A 2.00E-08 Urate levels / / 20884846 rs10013288 chr4 9559218 T A 5.18E-16 Urate levels / / 23263486 rs2170252 chr4 9560062 A C 2.00E-08 Urate levels / / 20884846 rs2170252 chr4 9560062 A C 4.38E-16 Urate levels / / 23263486 rs13117722 chr4 9561639 T C 2.00E-08 Urate levels / / 20884846 rs13117722 chr4 9561639 T C 2.27E-16 Urate levels / / 23263486 rs2061995 chr4 9561739 C A 4.35E-10 Urate levels / / 23263486 rs13116764 chr4 9561759 A G 1.50E-10 Urate levels / / 20884846 rs13116764 chr4 9561759 A G 5.93E-22 Urate levels / / 23263486 rs13131681 chr4 9563930 A G 1.20E-08 Urate levels / / 20884846 rs13131681 chr4 9563930 A G 3.27E-16 Urate levels / / 23263486 rs6448816 chr4 9564484 T C 8.70E-09 Urate levels / / 20884846 rs6448816 chr4 9564484 T C 9.14E-16 Urate levels / / 23263486 rs12646317 chr4 9565838 A G 1.60E-09 Urate levels / / 20884846 rs12646317 chr4 9565838 A G 2.21E-17 Urate levels / / 23263486 rs11939517 chr4 9567260 C T 6.62E-17 Urate levels / / 23263486 rs4102942 chr4 9568478 C T 1.80E-10 Urate levels / / 20884846 rs4102942 chr4 9568478 C T 7.82E-21 Urate levels / / 23263486 rs1825043 chr4 9573740 G A 4.70E-08 Urate levels / / 20884846 rs1825043 chr4 9573740 G A 6.67E-14 Urate levels / / 23263486 rs7669441 chr4 9576926 G A 7.82E-12 Urate levels / / 23263486 rs9683876 chr4 9584058 G A 3.09E-12 Urate levels / / 23263486 rs13138961 chr4 9585147 G T 7.30E-09 Uric acid levels / / 19503597 rs13138961 chr4 9585147 G T 1.00E-14 Urate levels / / 20884846 rs13138961 chr4 9585147 G T 4.81E-35 Urate levels / / 23263486 rs12512447 chr4 9586313 G A 4.08E-11 Uric acid levels / / 19503597 rs12512447 chr4 9586313 G A 6.60E-17 Urate levels / / 20884846 rs12512447 chr4 9586313 G A 2.32E-43 Urate levels / / 23263486 rs10049659 chr4 9586764 C T 8.28E-12 Urate levels / / 23263486 rs1811570 chr4 9587999 A G 3.30E-08 Urate levels / / 20884846 rs1811570 chr4 9587999 A G 6.94E-14 Urate levels / / 23263486 rs6824806 chr4 9589427 G T 5.30E-08 Urate levels / / 20884846 rs6824806 chr4 9589427 G T 1.86E-14 Urate levels / / 23263486 rs6815602 chr4 9592093 C T 5.90E-16 Urate levels / / 20884846 rs6815602 chr4 9592093 C T 1.11E-31 Urate levels / / 23263486 rs16898588 chr4 9595751 C T 1.00E-08 Urate levels / / 20884846 rs16898588 chr4 9595751 C T 1.51E-23 Urate levels / / 23263486 rs6448858 chr4 9595918 T G 1.30E-07 Urate levels / / 20884846 rs6448858 chr4 9595918 T G 1.40E-13 Urate levels / / 23263486 rs4974823 chr4 9602719 G A 8.80E-10 Urate levels / / 20884846 rs4974823 chr4 9602719 G A 1.06E-18 Urate levels / / 23263486 rs12509677 chr4 9602724 G A 9.10E-09 Urate levels / / 20884846 rs12509677 chr4 9602724 G A 7.39E-24 Urate levels / / 23263486 rs13103207 chr4 9603672 C T 6.28E-09 Uric acid levels / / 19503597 rs13103207 chr4 9603672 C T 1.50E-17 Urate levels / / 20884846 rs13103207 chr4 9603672 C T 2.88E-41 Urate levels / / 23263486 rs2077679 chr4 9608089 G A 4.90E-10 Urate levels / / 20884846 rs2077679 chr4 9608089 G A 1.09E-18 Urate levels / / 23263486 rs4974853 chr4 9609115 G C 4.20E-10 Urate levels / / 20884846 rs4974853 chr4 9609115 G C 1.61E-18 Urate levels / / 23263486 rs7375281 chr4 9609506 C T 4.20E-10 Urate levels / / 20884846 rs7375281 chr4 9609506 C T 1.36E-19 Urate levels / / 23263486 rs11724183 chr4 9609894 A G 3.30E-10 Urate levels / / 20884846 rs11724183 chr4 9609894 A G 9.23E-19 Urate levels / / 23263486 rs4974812 chr4 9614598 A C 3.30E-10 Urate levels / / 20884846 rs4974812 chr4 9614598 A C 5.96E-19 Urate levels / / 23263486 rs11735475 chr4 9614926 G T 3.30E-10 Urate levels / / 20884846 rs11735475 chr4 9614926 G T 2.00E-19 Urate levels / / 23263486 rs6838199 chr4 9621333 G C 5.60E-09 Urate levels / / 20884846 rs6838199 chr4 9621333 G C 1.92E-13 Urate levels / / 23263486 rs6837106 chr4 9626304 T C 3.40E-10 Urate levels / / 20884846 rs6837106 chr4 9626304 T C 2.29E-19 Urate levels / / 23263486 rs10049735 chr4 9626409 T C 8.80E-08 Urate levels / / 20884846 rs10049735 chr4 9626409 T C 1.10E-21 Urate levels / / 23263486 rs10005684 chr4 9626897 T G 2.50E-10 Urate levels / / 20884846 rs10005684 chr4 9626897 T G 2.88E-17 Urate levels / / 23263486 rs9998663 chr4 9627053 C T 2.50E-10 Urate levels / / 20884846 rs9998663 chr4 9627053 C T 3.46E-17 Urate levels / / 23263486 rs13151183 chr4 9627066 G A 1.30E-16 Urate levels / / 20884846 rs13151183 chr4 9627066 G A 1.33E-33 Urate levels / / 23263486 rs13107086 chr4 9628088 G T 1.30E-16 Urate levels / / 20884846 rs13107086 chr4 9628088 G T 1.65E-31 Urate levels / / 23263486 rs10939427 chr4 9628538 G A 2.50E-10 Urate levels / / 20884846 rs10939427 chr4 9628538 G A 7.61E-19 Urate levels / / 23263486 rs7698775 chr4 9629051 T C 3.00E-11 Urate levels / / 20884846 rs7693695 chr4 9629380 A G 1.20E-16 Urate levels / / 20884846 rs7693695 chr4 9629380 A G 1.75E-29 Urate levels / / 23263486 rs11939895 chr4 9630402 T C 2.50E-10 Urate levels / / 20884846 rs11939895 chr4 9630402 T C 2.22E-17 Urate levels / / 23263486 rs9291589 chr4 9633410 C G 2.60E-10 Urate levels / / 20884846 rs9291589 chr4 9633410 C G 5.24E-18 Urate levels / / 23263486 rs6842855 chr4 9633990 T A,C 3.00E-10 Urate levels / / 20884846 rs6842855 chr4 9633990 T A,C 1.35E-18 Urate levels / / 23263486 rs11731624 chr4 9637608 A G 3.10E-10 Urate levels / / 20884846 rs11731624 chr4 9637608 A G 4.31E-16 Urate levels / / 23263486 rs11737243 chr4 9641272 T C 3.10E-10 Urate levels / / 20884846 rs11737243 chr4 9641272 T C 6.64E-19 Urate levels / / 23263486 rs11733687 chr4 9643374 G T 7.40E-14 Urate levels / / 20884846 rs11733687 chr4 9643374 G T 2.02E-23 Urate levels / / 23263486 rs10939436 chr4 9647135 T C 3.60E-10 Urate levels / / 20884846 rs10939436 chr4 9647135 T C 6.38E-19 Urate levels / / 23263486 rs7440232 chr4 9651744 T C 3.50E-10 Urate levels / / 20884846 rs7440232 chr4 9651744 T C 5.38E-19 Urate levels / / 23263486 rs7654169 chr4 9654071 T C 3.80E-10 Urate levels / / 20884846 rs7654169 chr4 9654071 T C 5.27E-19 Urate levels / / 23263486 rs6812811 chr4 9672000 T C 4.40E-10 Urate levels / / 20884846 rs6812811 chr4 9672000 T C 1.31E-17 Urate levels / / 23263486 rs7434744 chr4 9672688 A C 4.40E-10 Urate levels / / 20884846 rs7434744 chr4 9672688 A C 1.10E-16 Urate levels / / 23263486 rs10002984 chr4 9680733 T C 4.80E-10 Urate levels / / 20884846 rs10002984 chr4 9680733 T C 1.58E-17 Urate levels / / 23263486 rs6858093 chr4 9681650 G A 5.00E-08 Urate levels / / 20884846 rs6858093 chr4 9681650 G A 6.04E-17 Urate levels / / 23263486 rs13104360 chr4 9684804 C A 4.50E-10 Urate levels / / 20884846 rs13104360 chr4 9684804 C A 2.41E-17 Urate levels / / 23263486 rs7671092 chr4 9687441 C T 1.40E-08 Urate levels / / 20884846 rs7671092 chr4 9687441 C T 1.79E-15 Urate levels / / 23263486 rs7658414 chr4 9687969 G T 2.20E-07 Urate levels / / 20884846 rs7658414 chr4 9687969 G T 4.12E-10 Urate levels / / 23263486 rs7691759 chr4 9688014 T C 2.20E-07 Urate levels / / 20884846 rs7691759 chr4 9688014 T C 1.14E-10 Urate levels / / 23263486 rs6821253 chr4 9690731 T G 4.75E-09 Uric acid levels / / 19503597 rs6821253 chr4 9690731 T G 1.40E-16 Urate levels / / 20884846 rs6821253 chr4 9690731 T G 6.20E-34 Urate levels / / 23263486 rs10022012 chr4 9693182 A T 2.10E-08 Urate levels / / 20884846 rs10022012 chr4 9693182 A T 7.80E-15 Urate levels / / 23263486 rs7678732 chr4 9693253 T C 9.70E-10 Urate levels / / 20884846 rs7678732 chr4 9693253 T C 1.54E-18 Urate levels / / 23263486 rs12649073 chr4 9694490 A G 1.20E-07 Urate levels / / 20884846 rs12649073 chr4 9694490 A G 1.66E-14 Urate levels / / 23263486 rs13103452 chr4 9694662 T C 4.61E-09 Uric acid levels / / 19503597 rs13103452 chr4 9694662 T C 1.90E-16 Urate levels / / 20884846 rs13103452 chr4 9694662 T C 4.90E-34 Urate levels / / 23263486 rs4554078 chr4 9701544 A G 7.30E-09 Urate levels / / 20884846 rs4554078 chr4 9701544 A G 2.53E-18 Urate levels / / 23263486 rs10805313 chr4 9703061 T C 1.50E-08 Urate levels / / 20884846 rs10805313 chr4 9703061 T C 5.21E-18 Urate levels / / 23263486 rs9685887 chr4 9706342 T G 2.40E-08 Urate levels / / 20884846 rs9685887 chr4 9706342 T G 8.31E-19 Urate levels / / 23263486 rs9291607 chr4 9708798 G C 1.80E-08 Urate levels / / 20884846 rs9291607 chr4 9708798 G C 3.09E-17 Urate levels / / 23263486 rs6858393 chr4 9709577 C T 1.90E-09 Urate levels / / 20884846 rs6858393 chr4 9709577 C T 5.89E-22 Urate levels / / 23263486 rs13136075 chr4 9714968 G A 1.16E-08 Uric acid levels / / 19503597 rs13136075 chr4 9714968 G A 1.90E-15 Urate levels / / 20884846 rs13136075 chr4 9714968 G A 5.12E-33 Urate levels / / 23263486 rs6448974 chr4 9715105 A G 1.10E-08 Urate levels / / 20884846 rs6448974 chr4 9715105 A G 3.12E-16 Urate levels / / 23263486 rs9684176 chr4 9716386 T G 8.28E-09 Uric acid levels / / 19503597 rs9684176 chr4 9716386 T G 2.10E-15 Urate levels / / 20884846 rs9684176 chr4 9716386 T G 4.59E-33 Urate levels / / 23263486 rs12501880 chr4 9717975 C T 8.13E-09 Uric acid levels / / 19503597 rs12501880 chr4 9717975 C T 1.70E-15 Urate levels / / 20884846 rs12501880 chr4 9717975 C T 3.07E-33 Urate levels / / 23263486 rs11730320 chr4 9719901 T C 8.68E-09 Uric acid levels / / 19503597 rs11730320 chr4 9719901 T C 2.00E-16 Urate levels / / 20884846 rs11730320 chr4 9719901 T C 5.07E-31 Urate levels / / 23263486 rs11727674 chr4 9719981 C T 4.80E-08 Urate levels / / 20884846 rs11727674 chr4 9719981 C T 1.80E-17 Urate levels / / 23263486 rs11724606 chr4 9720444 G A 3.90E-11 Urate levels / / 20884846 rs11724606 chr4 9720444 G A 2.70E-06 Urinary metabolites / / 21572414 rs11724606 chr4 9720444 G A 1.19E-31 Urate levels / / 23263486 rs7659176 chr4 9721066 A G 4.50E-09 Urate levels / / 20884846 rs7659176 chr4 9721066 A G 1.65E-18 Urate levels / / 23263486 rs10939472 chr4 9721616 G C 4.90E-09 Urate levels / / 20884846 rs10939472 chr4 9721616 G C 2.49E-18 Urate levels / / 23263486 rs12645989 chr4 9722133 C T 2.55E-19 Urate levels / / 23263486 rs13121465 chr4 9722275 T C,G 4.02E-13 Uric acid levels / / 19503597 rs13121465 chr4 9722275 T C,G 7.60E-17 Urate levels / / 20884846 rs13121465 chr4 9722275 T C,G 4.81E-54 Urate levels / / 23263486 rs13136217 chr4 9722292 G T 5.20E-09 Urate levels / / 20884846 rs13136217 chr4 9722292 G T 1.44E-18 Urate levels / / 23263486 rs13128435 chr4 9723672 A G 4.11E-13 Uric acid levels / / 19503597 rs13128435 chr4 9723672 A G 1.00E-15 Urate levels / / 20884846 rs13128435 chr4 9723672 A G 1.87E-45 Urate levels / / 23263486 rs12647851 chr4 9724519 C T 1.38E-10 Urate levels / / 23263486 rs2037313 chr4 9724711 T C 5.30E-09 Urate levels / / 20884846 rs2037313 chr4 9724711 T C 2.10E-18 Urate levels / / 23263486 rs7685513 chr4 9728599 A G 4.70E-09 Urate levels / / 20884846 rs7685513 chr4 9728599 A G 1.95E-18 Urate levels / / 23263486 rs13127001 chr4 9731215 G A 2.81E-12 Uric acid levels / / 19503597 rs13127001 chr4 9731215 G A 8.30E-16 Urate levels / / 20884846 rs13127001 chr4 9731215 G A 2.45E-48 Urate levels / / 23263486 rs6811848 chr4 9732161 C A 6.70E-09 Urate levels / / 20884846 rs6811848 chr4 9732161 C A 8.97E-17 Urate levels / / 23263486 rs10007469 chr4 9732743 G C,T 1.40E-08 Urate levels / / 20884846 rs7684214 chr4 9734585 T C 6.70E-09 Urate levels / / 20884846 rs7684214 chr4 9734585 T C 2.00E-17 Urate levels / / 23263486 rs12645163 chr4 9735520 A G 1.59E-11 Urate levels / / 23263486 rs7675599 chr4 9736516 G A 6.10E-09 Urate levels / / 20884846 rs7675599 chr4 9736516 G A 3.08E-18 Urate levels / / 23263486 rs7667385 chr4 9736696 T A 4.15E-11 Urate levels / / 23263486 rs6832128 chr4 9738151 T C 4.48E-11 Urate levels / / 23263486 rs6448981 chr4 9740325 G C 2.23E-08 Uric acid levels / / 19503597 rs6448981 chr4 9740325 G C 3.30E-14 Urate levels / / 20884846 rs6448981 chr4 9740325 G C 1.29E-36 Urate levels / / 23263486 rs1818670 chr4 9745390 G C 5.90E-09 Urate levels / / 20884846 rs1818670 chr4 9745390 G C 7.65E-19 Urate levels / / 23263486 rs12508809 chr4 9748034 G A 5.68E-16 Urate levels / / 23263486 rs6834270 chr4 9756710 A G 9.30E-10 Urate levels / / 20884846 rs6834270 chr4 9756710 A G 7.31E-20 Urate levels / / 23263486 rs6834512 chr4 9756836 A C 4.08E-14 Urate levels / / 23263486 rs6834697 chr4 9756914 A G 4.70E-08 Urate levels / / 20884846 rs6834697 chr4 9756914 A G 2.12E-18 Urate levels / / 23263486 rs11727873 chr4 9758469 T C 1.70E-11 Urate levels / / 20884846 rs11727873 chr4 9758469 T C 9.14E-34 Urate levels / / 23263486 rs10011621 chr4 9760239 A C 9.80E-12 Urate levels / / 20884846 rs10011621 chr4 9760239 A C 6.10E-34 Urate levels / / 23263486 rs13140817 chr4 9762975 G A 8.87E-14 Uric acid levels / / 19503597 rs13140817 chr4 9762975 G A 3.40E-15 Urate levels / / 20884846 rs11733815 chr4 9764282 A T 5.30E-08 Urate levels / / 20884846 rs11733815 chr4 9764282 A T 4.43E-19 Urate levels / / 23263486 rs11734974 chr4 9764564 T C 2.30E-07 Urate levels / / 20884846 rs11734974 chr4 9764564 T C 5.76E-15 Urate levels / / 23263486 rs11729600 chr4 9764686 T C 5.30E-08 Urate levels / / 20884846 rs11729600 chr4 9764686 T C 4.05E-18 Urate levels / / 23263486 rs7655090 chr4 9765875 A G 8.37E-09 Uric acid levels / / 19503597 rs7655090 chr4 9765875 A G 3.60E-12 Urate levels / / 20884846 rs7655090 chr4 9765875 A G 2.83E-40 Urate levels / / 23263486 rs11731100 chr4 9767180 A T 1.42E-13 Uric acid levels / / 19503597 rs11731100 chr4 9767180 A T 1.30E-19 Urate levels / / 20884846 rs11731100 chr4 9767180 A T 4.44E-60 Urate levels / / 23263486 rs10939504 chr4 9767370 A G 7.00E-08 Urate levels / / 20884846 rs10939504 chr4 9767370 A G 4.42E-18 Urate levels / / 23263486 rs11732272 chr4 9768258 A G 6.67E-09 Uric acid levels / / 19503597 rs11732272 chr4 9768258 A G 6.30E-15 Urate levels / / 20884846 rs11732272 chr4 9768258 A G 5.76E-43 Urate levels / / 23263486 rs10939507 chr4 9768823 T C 1.46E-08 Uric acid levels / / 19503597 rs10939507 chr4 9768823 T C 7.90E-08 Urate levels / / 20884846 rs10939507 chr4 9768823 T C 5.93E-18 Urate levels / / 23263486 rs10939514 chr4 9773196 C T 7.60E-08 Urate levels / / 20884846 rs10939514 chr4 9773196 C T 5.50E-18 Urate levels / / 23263486 rs10939515 chr4 9773296 G A 2.10E-13 Urate levels / / 20884846 rs10939515 chr4 9773296 G A 3.39E-40 Urate levels / / 23263486 rs10033951 chr4 9779580 C T 1.68E-08 Uric acid levels / / 19503597 rs10033951 chr4 9779580 C T 4.00E-12 Urate levels / / 20884846 rs10033951 chr4 9779580 C T 4.86E-40 Urate levels / / 23263486 rs2867383 chr4 9787935 G A 3.04E-08 Uric acid levels / / 19503597 rs2867383 chr4 9787935 G A 3.50E-12 Urate levels / / 20884846 rs2867383 chr4 9787935 G A 4.96E-40 Urate levels / / 23263486 rs1850744 chr4 9790712 T C 1.30E-07 Urate levels / / 20884846 rs1850744 chr4 9790712 T C 4.00E-06 Economic and political preferences / / 22566634 rs1850744 chr4 9790712 T C 2.16E-17 Urate levels / / 23263486 rs7685396 chr4 9794724 C A 8.43E-14 Uric acid levels / / 19503597 rs7685396 chr4 9794724 C A 2.20E-18 Urate levels / / 20884846 rs7685396 chr4 9794724 C A 8.76E-54 Urate levels / / 23263486 rs1850739 chr4 9797343 T C 1.40E-07 Urate levels / / 20884846 rs1850739 chr4 9797343 T C 2.11E-17 Urate levels / / 23263486 rs13106539 chr4 9797703 C T 6.77E-14 Uric acid levels / / 19503597 rs13106539 chr4 9797703 C T 2.60E-19 Urate levels / / 20884846 rs13106539 chr4 9797703 C T 6.10E-60 Urate levels / / 23263486 rs2139240 chr4 9798092 T C 2.50E-09 Urate levels / / 20884846 rs6449000 chr4 9798612 G A 1.50E-07 Urate levels / / 20884846 rs6449000 chr4 9798612 G A 9.80E-17 Urate levels / / 23263486 rs2280207 chr4 9799776 T C 8.33E-14 Uric acid levels / / 19503597 rs2280207 chr4 9799776 T C 2.70E-19 Urate levels / / 20884846 rs2280207 chr4 9799776 T C 7.34E-60 Urate levels / / 23263486 rs2280208 chr4 9800043 A C 1.90E-07 Urate levels / / 20884846 rs2280208 chr4 9800043 A C 2.24E-17 Urate levels / / 23263486 rs938556 chr4 9802366 A T 1.70E-07 Urate levels / / 20884846 rs938556 chr4 9802366 A T 1.09E-16 Urate levels / / 23263486 rs1519097 chr4 9802853 A G 5.98E-09 Uric acid levels / / 19503597 rs1519097 chr4 9802853 A G 9.90E-13 Urate levels / / 20884846 rs1519097 chr4 9802853 A G 1.48E-41 Urate levels / / 23263486 rs1533615 chr4 9804524 T C 1.80E-07 Urate levels / / 20884846 rs1533615 chr4 9804524 T C 7.66E-17 Urate levels / / 23263486 rs1519096 chr4 9805872 T C 4.97E-08 Uric acid levels / / 19503597 rs1519096 chr4 9805872 T C 2.00E-13 Urate levels / / 20884846 rs1519096 chr4 9805872 T C 5.60E-41 Urate levels / / 23263486 rs7664572 chr4 9808709 T C 1.20E-07 Urate levels / / 20884846 rs7664572 chr4 9808709 T C 4.47E-17 Urate levels / / 23263486 rs12500086 chr4 9809859 A G 2.50E-13 Urate levels / / 20884846 rs12500086 chr4 9809859 A G 4.50E-41 Urate levels / / 23263486 rs1519095 chr4 9810931 G C 1.30E-07 Urate levels / / 20884846 rs1519095 chr4 9810931 G C 2.71E-17 Urate levels / / 23263486 rs2280333 chr4 9811133 G A 4.78E-15 Uric acid levels / / 19503597 rs2280333 chr4 9811133 G A 5.00E-20 Urate levels / / 20884846 rs2280333 chr4 9811133 G A 8.88E-62 Urate levels / / 23263486 rs1401438 chr4 9814456 G A 2.69E-08 Uric acid levels / / 19503597 rs1401438 chr4 9814456 G A 4.90E-15 Urate levels / / 20884846 rs1401438 chr4 9814456 G A 2.90E-07 Urinary metabolites / / 21572414 rs1401438 chr4 9814456 G A 2.28E-43 Urate levels / / 23263486 rs13148356 chr4 9817070 G A 4.75E-14 Uric acid levels / / 19503597 rs13148356 chr4 9817070 G A 4.00E-20 Urate levels / / 20884846 rs13148356 chr4 9817070 G A 2.77E-61 Urate levels / / 23263486 rs1519094 chr4 9817286 T C 1.30E-07 Urate levels / / 20884846 rs1519094 chr4 9817286 T C 1.05E-18 Urate levels / / 23263486 rs13141706 chr4 9818345 T C 1.13E-15 Uric acid levels / / 19503597 rs13141706 chr4 9818345 T C 3.40E-21 Urate levels / / 20884846 rs13141706 chr4 9818345 T C 1.31E-61 Urate levels / / 23263486 rs6855095 chr4 9819977 A G 9.85E-16 Uric acid levels / / 19503597 rs6855095 chr4 9819977 A G 5.10E-23 Urate levels / / 20884846 rs6855095 chr4 9819977 A G 1.99E-63 Urate levels / / 23263486 rs1107912 chr4 9820179 A G 4.40E-17 Uric acid levels / / 19503597 rs1107912 chr4 9820179 A G 6.00E-22 Urate levels / / 20884846 rs1107912 chr4 9820179 A G 1.02E-63 Urate levels / / 23263486 rs10020053 chr4 9821648 T C 9.30E-08 Urate levels / / 20884846 rs4697892 chr4 9823837 C A 2.03E-23 Uric acid levels / / 19503597 rs4697892 chr4 9823837 C A 5.10E-28 Urate levels / / 20884846 rs4697892 chr4 9823837 C A 8.08E-82 Urate levels / / 23263486 rs1980220 chr4 9824636 G A 2.71E-25 Uric acid levels / / 19503597 rs1980220 chr4 9824636 G A 2.10E-28 Urate levels / / 20884846 rs1980220 chr4 9824636 G A 1.27E-91 Urate levels / / 23263486 rs4697893 chr4 9826183 T C 1.70E-08 Urate levels / / 20884846 rs4697893 chr4 9826183 T C 3.52E-26 Urate levels / / 23263486 rs6822889 chr4 9826757 C T 2.28E-20 Uric acid levels / / 19503597 rs6822889 chr4 9826757 C T 4.30E-23 Urate levels / / 20884846 rs6822889 chr4 9826757 C T 4.58E-67 Urate levels / / 23263486 rs4621429 chr4 9826870 A G 2.42E-26 Uric acid levels / / 19503597 rs4621429 chr4 9826870 A G 1.80E-28 Urate levels / / 20884846 rs4621429 chr4 9826870 A G 1.80E-92 Urate levels / / 23263486 rs4697895 chr4 9828484 T C 1.59E-26 Uric acid levels SLC2A9 intron 19503597 rs4697895 chr4 9828484 T C 4.10E-28 Urate levels SLC2A9 intron 20884846 rs4697895 chr4 9828484 T C 9.61E-92 Urate levels SLC2A9 intron 23263486 rs1401440 chr4 9832512 C T 2.12E-20 Uric acid levels SLC2A9 intron 19503597 rs1401440 chr4 9832512 C T 4.40E-23 Urate levels SLC2A9 intron 20884846 rs1401440 chr4 9832512 C T 6.32E-67 Urate levels SLC2A9 intron 23263486 rs1464258 chr4 9834107 G T 1.41E-20 Uric acid levels SLC2A9 intron 19503597 rs1464258 chr4 9834107 G T 5.70E-23 Urate levels SLC2A9 intron 20884846 rs1464258 chr4 9834107 G T 2.76E-67 Urate levels SLC2A9 intron 23263486 rs16889260 chr4 9834896 C T 5.54E-27 Uric acid levels SLC2A9 intron 19503597 rs16889260 chr4 9834896 C T 7.30E-32 Urate levels SLC2A9 intron 20884846 rs16889260 chr4 9834896 C T 3.53E-98 Urate levels SLC2A9 intron 23263486 rs16889264 chr4 9834999 T C 3.95E-08 Uric acid levels SLC2A9 intron 19503597 rs16889264 chr4 9834999 T C 1.45E-13 Urate levels SLC2A9 intron 23263486 rs12505312 chr4 9837090 C G 1.25E-26 Uric acid levels SLC2A9 intron 19503597 rs12505312 chr4 9837090 C G 2.10E-28 Urate levels SLC2A9 intron 20884846 rs12505312 chr4 9837090 C G 1.31E-91 Urate levels SLC2A9 intron 23263486 rs10939552 chr4 9838548 C A 1.14E-26 Uric acid levels SLC2A9 intron 19503597 rs10939552 chr4 9838548 C A 2.00E-28 Urate levels SLC2A9 intron 20884846 rs10939552 chr4 9838548 C A 2.04E-91 Urate levels SLC2A9 intron 23263486 rs1914874 chr4 9839490 C A 6.85E-19 Uric acid levels SLC2A9 intron 19503597 rs1914874 chr4 9839490 C A 2.00E-21 Urate levels SLC2A9 intron 20884846 rs1914874 chr4 9839490 C A 2.78E-64 Urate levels SLC2A9 intron 23263486 rs10031303 chr4 9841690 A T 1.37E-20 Uric acid levels SLC2A9 intron 19503597 rs10031303 chr4 9841690 A T 5.60E-23 Urate levels SLC2A9 intron 20884846 rs10031303 chr4 9841690 A T 7.00E-66 Urate levels SLC2A9 intron 23263486 rs950310 chr4 9842850 T A 2.79E-28 Uric acid levels SLC2A9 intron 19503597 rs950310 chr4 9842850 T A 6.50E-32 Urate levels SLC2A9 intron 20884846 rs950310 chr4 9842850 T A 6.28E-98 Urate levels SLC2A9 intron 23263486 rs10939558 chr4 9844162 T C 5.41E-21 Uric acid levels SLC2A9 intron 19503597 rs10939558 chr4 9844162 T C 3.90E-22 Urate levels SLC2A9 intron 20884846 rs10939558 chr4 9844162 T C 9.04E-60 Urate levels SLC2A9 intron 23263486 rs7683831 chr4 9845079 T C 9.35E-19 Uric acid levels SLC2A9 intron 19503597 rs7683831 chr4 9845079 T C 3.60E-20 Urate levels SLC2A9 intron 20884846 rs7683831 chr4 9845079 T C 3.45E-61 Urate levels SLC2A9 intron 23263486 rs13141635 chr4 9845985 T C 1.38E-20 Uric acid levels SLC2A9 intron 19503597 rs13141635 chr4 9845985 T C 1.30E-21 Urate levels SLC2A9 intron 20884846 rs13141635 chr4 9845985 T C 1.71E-63 Urate levels SLC2A9 intron 23263486 rs1976792 chr4 9846309 G A 1.92E-21 Uric acid levels SLC2A9 intron 19503597 rs1976792 chr4 9846309 G A 3.70E-28 Urate levels SLC2A9 intron 20884846 rs1976792 chr4 9846309 G A 1.00E-05 Urinary metabolites SLC2A9 intron 21572414 rs1976792 chr4 9846309 G A 4.21E-82 Urate levels SLC2A9 intron 23263486 rs13119059 chr4 9847860 G C 2.56E-20 Uric acid levels SLC2A9 intron 19503597 rs13119059 chr4 9847860 G C 1.30E-21 Urate levels SLC2A9 intron 20884846 rs13119059 chr4 9847860 G C 2.99E-63 Urate levels SLC2A9 intron 23263486 rs11721988 chr4 9848899 A G 6.51E-28 Uric acid levels SLC2A9 intron 19503597 rs11721988 chr4 9848899 A G 1.10E-28 Urate levels SLC2A9 intron 20884846 rs11721988 chr4 9848899 A G 5.97E-92 Urate levels SLC2A9 intron 23263486 rs2176644 chr4 9849528 C T 5.42E-28 Uric acid levels SLC2A9 intron 19503597 rs2176644 chr4 9849528 C T 1.20E-28 Urate levels SLC2A9 intron 20884846 rs2176644 chr4 9849528 C T 1.71E-91 Urate levels SLC2A9 intron 23263486 rs6812007 chr4 9850220 C A 1.76E-18 Uric acid levels SLC2A9 intron 19503597 rs6812007 chr4 9850220 C A 3.00E-20 Urate levels SLC2A9 intron 20884846 rs6812007 chr4 9850220 C A 4.38E-61 Urate levels SLC2A9 intron 23263486 rs4697898 chr4 9851827 C T 1.12E-10 Uric acid levels SLC2A9 intron 19503597 rs4697898 chr4 9851827 C T 1.80E-07 Urate levels SLC2A9 intron 20884846 rs4697899 chr4 9851875 C A 3.66E-10 Uric acid levels SLC2A9 intron 19503597 rs6831796 chr4 9852898 C G 6.73E-29 Uric acid levels SLC2A9 intron 19503597 rs6831796 chr4 9852898 C G 6.80E-30 Urate levels SLC2A9 intron 20884846 rs6831796 chr4 9852898 C G 7.38E-89 Urate levels SLC2A9 intron 23263486 rs6826806 chr4 9856469 A G 9.21E-27 Uric acid levels SLC2A9 intron 19503597 rs6826806 chr4 9856469 A G 2.60E-27 Urate levels SLC2A9 intron 20884846 rs6826806 chr4 9856469 A G 3.16E-88 Urate levels SLC2A9 intron 23263486 rs4507358 chr4 9857956 G T 9.81E-11 Uric acid levels SLC2A9 intron 19503597 rs4697900 chr4 9859976 A G 4.53E-15 Uric acid levels SLC2A9 intron 19503597 rs4697900 chr4 9859976 A G 1.10E-18 Urate levels SLC2A9 intron 20884846 rs4697900 chr4 9859976 A G 1.86E-44 Urate levels SLC2A9 intron 23263486 rs9684729 chr4 9862036 C T 2.80E-18 Uric acid levels SLC2A9 intron 19503597 rs9684729 chr4 9862036 C T 1.40E-20 Urate levels SLC2A9 intron 20884846 rs9684729 chr4 9862036 C T 4.50E-62 Urate levels SLC2A9 intron 23263486 rs4697903 chr4 9865426 G A 1.90E-26 Uric acid levels SLC2A9 intron 19503597 rs4697903 chr4 9865426 G A 1.60E-27 Urate levels SLC2A9 intron 20884846 rs4697903 chr4 9865426 G A 1.00E-88 Urate levels SLC2A9 intron 23263486 rs2292917 chr4 9867277 C G 3.09E-20 Uric acid levels SLC2A9 intron 19503597 rs2292917 chr4 9867277 C G 7.90E-22 Urate levels SLC2A9 intron 20884846 rs2292917 chr4 9867277 C G 1.98E-63 Urate levels SLC2A9 intron 23263486 rs2139243 chr4 9867502 A G 3.12E-26 Uric acid levels SLC2A9 intron 19503597 rs2139243 chr4 9867502 A G 3.00E-29 Urate levels SLC2A9 intron 20884846 rs2139243 chr4 9867502 A G 2.80E-08 Urate levels SLC2A9 intron 21768215 rs2139243 chr4 9867502 A G 6.27E-90 Urate levels SLC2A9 intron 23263486 rs883041 chr4 9868346 C T 4.31E-26 Uric acid levels SLC2A9 intron 19503597 rs883041 chr4 9868346 C T 1.40E-27 Urate levels SLC2A9 intron 20884846 rs883041 chr4 9868346 C T 2.02E-89 Urate levels SLC2A9 intron 23263486 rs13105954 chr4 9868417 C G 3.17E-20 Uric acid levels SLC2A9 intron 19503597 rs13105954 chr4 9868417 C G 7.10E-22 Urate levels SLC2A9 intron 20884846 rs13105954 chr4 9868417 C G 2.64E-58 Urate levels SLC2A9 intron 23263486 rs939134 chr4 9868593 A T 6.09E-26 Uric acid levels SLC2A9 intron 19503597 rs939134 chr4 9868593 A T 1.40E-27 Urate levels SLC2A9 intron 20884846 rs939134 chr4 9868593 A T 5.98E-90 Urate levels SLC2A9 intron 23263486 rs884573 chr4 9869734 G C 1.67E-18 Uric acid levels SLC2A9 intron 19503597 rs884573 chr4 9869734 G C 1.20E-30 Urate levels SLC2A9 intron 20884846 rs884573 chr4 9869734 G C 2.04E-75 Urate levels SLC2A9 intron 23263486 rs1048252 chr4 9870535 C T 9.02E-15 Uric acid levels SLC2A9 intron 19503597 rs1048252 chr4 9870535 C T 6.20E-25 Urate levels SLC2A9 intron 20884846 rs1048252 chr4 9870535 C T 1.92E-61 Urate levels SLC2A9 intron 23263486 rs1568318 chr4 9871541 T C 2.99E-27 Uric acid levels SLC2A9 intron 19503597 rs1568318 chr4 9871541 T C 1.20E-30 Urate levels SLC2A9 intron 20884846 rs1568318 chr4 9871541 T C 2.00E-96 Urate levels SLC2A9 intron 23263486 rs16889842 chr4 9872013 G A 4.30E-08 Uric acid levels SLC2A9 intron 19503597 rs16889842 chr4 9872013 G A 4.04E-13 Urate levels SLC2A9 intron 23263486 rs2867394 chr4 9872475 G A 3.65E-29 Uric acid levels SLC2A9 intron 19503597 rs2867394 chr4 9872475 G A 1.40E-32 Urate levels SLC2A9 intron 20884846 rs2867394 chr4 9872475 G A 1.27E-99 Urate levels SLC2A9 intron 23263486 rs13148571 chr4 9873855 C A 1.75E-22 Uric acid levels SLC2A9 intron 19503597 rs13148571 chr4 9873855 C A 6.70E-26 Urate levels SLC2A9 intron 20884846 rs13148571 chr4 9873855 C A 6.32E-71 Urate levels SLC2A9 intron 23263486 rs12647883 chr4 9878464 G C 6.90E-13 Urate levels SLC2A9 intron 23263486 rs1519098 chr4 9881158 C A 3.03E-19 Uric acid levels SLC2A9 intron 19503597 rs1519098 chr4 9881158 C A 6.10E-21 Urate levels SLC2A9 intron 20884846 rs1519098 chr4 9881158 C A 3.57E-63 Urate levels SLC2A9 intron 23263486 rs6824636 chr4 9881851 C G 5.52E-26 Uric acid levels SLC2A9 intron 19503597 rs6824636 chr4 9881851 C G 1.70E-26 Urate levels SLC2A9 intron 20884846 rs6824636 chr4 9881851 C G 2.83E-71 Urate levels SLC2A9 intron 23263486 rs6838850 chr4 9884057 C T 5.82E-04 Response to TNF antagonist treatment SLC2A9 intron 21061259 rs6449090 chr4 9884536 T C 4.00E-17 Uric acid levels SLC2A9 intron 19503597 rs6449090 chr4 9884536 T C 3.20E-20 Urate levels SLC2A9 intron 20884846 rs6449090 chr4 9884536 T C 1.11E-60 Urate levels SLC2A9 intron 23263486 rs10939599 chr4 9886860 C A 1.94E-25 Uric acid levels SLC2A9 intron 19503597 rs10939599 chr4 9886860 C A 2.80E-30 Urate levels SLC2A9 intron 20884846 rs10939599 chr4 9886860 C A 1.08E-95 Urate levels SLC2A9 intron 23263486 rs10939600 chr4 9886931 A T 1.95E-17 Uric acid levels SLC2A9 intron 19503597 rs10939600 chr4 9886931 A T 3.20E-20 Urate levels SLC2A9 intron 20884846 rs10939600 chr4 9886931 A T 5.87E-60 Urate levels SLC2A9 intron 23263486 rs9993652 chr4 9888849 G A,C 1.50E-11 Uric acid levels SLC2A9 intron 19503597 rs9993652 chr4 9888849 G A,C 8.20E-15 Urate levels SLC2A9 intron 20884846 rs9993652 chr4 9888849 G A,C 3.87E-54 Urate levels SLC2A9 intron 23263486 rs6818572 chr4 9889448 G A 1.84E-25 Uric acid levels SLC2A9 intron 19503597 rs6818572 chr4 9889448 G A 2.40E-28 Urate levels SLC2A9 intron 20884846 rs6818572 chr4 9889448 G A 1.19E-91 Urate levels SLC2A9 intron 23263486 rs1107710 chr4 9890708 A G 2.71E-27 Uric acid levels SLC2A9 intron 19503597 rs1107710 chr4 9890708 A G 2.70E-30 Urate levels SLC2A9 intron 20884846 rs1107710 chr4 9890708 A G 1.57E-96 Urate levels SLC2A9 intron 23263486 rs938563 chr4 9890998 G C 4.78E-25 Uric acid levels SLC2A9 intron 19503597 rs938563 chr4 9890998 G C 1.80E-28 Urate levels SLC2A9 intron 20884846 rs938563 chr4 9890998 G C 3.44E-93 Urate levels SLC2A9 intron 23263486 rs938562 chr4 9891031 C T 1.39E-27 Uric acid levels SLC2A9 intron 19503597 rs938562 chr4 9891031 C T 2.00E-30 Urate levels SLC2A9 intron 20884846 rs938562 chr4 9891031 C T 6.46E-97 Urate levels SLC2A9 intron 23263486 rs10939602 chr4 9892102 T C 5.28E-17 Uric acid levels SLC2A9 intron 19503597 rs10939602 chr4 9892102 T C 2.30E-20 Urate levels SLC2A9 intron 20884846 rs10939602 chr4 9892102 T C 3.15E-55 Urate levels SLC2A9 intron 23263486 rs4697692 chr4 9893197 C T 2.43E-20 Uric acid levels SLC2A9 intron 19503597 rs4697692 chr4 9893197 C T 4.40E-25 Urate levels SLC2A9 intron 20884846 rs4697692 chr4 9893197 C T 3.53E-82 Urate levels SLC2A9 intron 23263486 rs12644047 chr4 9893403 G A 2.81E-30 Uric acid levels SLC2A9 intron 19503597 rs12644047 chr4 9893403 G A 7.40E-33 Urate levels SLC2A9 intron 20884846 rs12644047 chr4 9893403 G A 2.64E-102 Urate levels SLC2A9 intron 23263486 rs7669444 chr4 9893577 A G 8.72E-17 Uric acid levels SLC2A9 intron 19503597 rs7669444 chr4 9893577 A G 1.90E-20 Urate levels SLC2A9 intron 20884846 rs7669444 chr4 9893577 A G 3.52E-61 Urate levels SLC2A9 intron 23263486 rs4697693 chr4 9895860 A C 1.93E-28 Uric acid levels SLC2A9 intron 19503597 rs4697693 chr4 9895860 A C 3.70E-31 Urate levels SLC2A9 intron 20884846 rs4697693 chr4 9895860 A C 1.14E-92 Urate levels SLC2A9 intron 23263486 rs10939605 chr4 9896293 C A 3.29E-28 Uric acid levels SLC2A9 intron 19503597 rs10939605 chr4 9896293 C A 2.80E-31 Urate levels SLC2A9 intron 20884846 rs10939605 chr4 9896293 C A 2.29E-94 Urate levels SLC2A9 intron 23263486 rs4697694 chr4 9896642 T C 6.51E-28 Uric acid levels SLC2A9 intron 19503597 rs4697694 chr4 9896642 T C 2.40E-31 Urate levels SLC2A9 intron 20884846 rs4697694 chr4 9896642 T C 2.03E-93 Urate levels SLC2A9 intron 23263486 rs6449097 chr4 9896734 T C 2.38E-21 Uric acid levels SLC2A9 intron 19503597 rs6449097 chr4 9896734 T C 1.60E-22 Urate levels SLC2A9 intron 20884846 rs6449097 chr4 9896734 T C 1.06E-69 Urate levels SLC2A9 intron 23263486 rs13115121 chr4 9897342 T G 1.96E-21 Uric acid levels SLC2A9 intron 19503597 rs13115121 chr4 9897342 T G 1.70E-22 Urate levels SLC2A9 intron 20884846 rs13115121 chr4 9897342 T G 1.70E-05 Urinary metabolites SLC2A9 intron 21572414 rs13115121 chr4 9897342 T G 2.85E-69 Urate levels SLC2A9 intron 23263486 rs13129868 chr4 9897372 G A 1.07E-21 Uric acid levels SLC2A9 intron 19503597 rs13129868 chr4 9897372 G A 1.80E-22 Urate levels SLC2A9 intron 20884846 rs13129868 chr4 9897372 G A 1.67E-69 Urate levels SLC2A9 intron 23263486 rs12505366 chr4 9897520 C A 4.85E-13 Urate levels SLC2A9 intron 23263486 rs13122026 chr4 9898207 T C 6.17E-22 Uric acid levels SLC2A9 intron 19503597 rs13122026 chr4 9898207 T C 2.10E-22 Urate levels SLC2A9 intron 20884846 rs13122026 chr4 9898207 T C 1.96E-69 Urate levels SLC2A9 intron 23263486 rs6449100 chr4 9901563 C T 2.30E-20 Uric acid levels SLC2A9 intron 19503597 rs6449100 chr4 9901563 C T 5.10E-21 Urate levels SLC2A9 intron 20884846 rs6449100 chr4 9901563 C T 1.20E-63 Urate levels SLC2A9 intron 23263486 rs4697910 chr4 9901874 G A 2.06E-27 Uric acid levels SLC2A9 intron 19503597 rs4697910 chr4 9901874 G A 2.20E-31 Urate levels SLC2A9 intron 20884846 rs4697910 chr4 9901874 G A 5.95E-94 Urate levels SLC2A9 intron 23263486 rs11732681 chr4 9902876 G A 1.90E-22 Uric acid levels SLC2A9 intron 19503597 rs11732681 chr4 9902876 G A 2.50E-23 Urate levels SLC2A9 intron 20884846 rs11732681 chr4 9902876 G A 2.07E-72 Urate levels SLC2A9 intron 23263486 rs11737685 chr4 9903121 A G 2.68E-27 Uric acid levels SLC2A9 intron 19503597 rs11737685 chr4 9903121 A G 4.60E-29 Urate levels SLC2A9 intron 20884846 rs11737685 chr4 9903121 A G 2.95E-90 Urate levels SLC2A9 intron 23263486 rs6829755 chr4 9903518 G C 3.56E-08 Urate levels SLC2A9 intron 23263486 rs7694136 chr4 9908791 C G 2.51E-22 Uric acid levels SLC2A9 intron 19503597 rs7694136 chr4 9908791 C G 3.80E-22 Urate levels SLC2A9 intron 20884846 rs7694136 chr4 9908791 C G 1.15E-69 Urate levels SLC2A9 intron 23263486 rs2280202 chr4 9909295 T C 1.11E-22 Uric acid levels SLC2A9 intron 19503597 rs2280202 chr4 9909295 T C 3.90E-22 Urate levels SLC2A9 intron 20884846 rs2280202 chr4 9909295 T C 1.62E-64 Urate levels SLC2A9 intron 23263486 rs2280205 chr4 9909923 G A 5.08E-23 Uric acid levels SLC2A9 missense 19503597 rs2280205 chr4 9909923 G A 2.70E-22 Urate levels SLC2A9 missense 20884846 rs2280205 chr4 9909923 G A 1.27E-69 Urate levels SLC2A9 missense 23263486 rs11734893 chr4 9910441 G A 7.45E-23 Uric acid levels SLC2A9 intron 19503597 rs11734893 chr4 9910441 G A 2.60E-22 Urate levels SLC2A9 intron 20884846 rs11734893 chr4 9910441 G A 6.45E-70 Urate levels SLC2A9 intron 23263486 rs13103429 chr4 9910635 C T 9.53E-23 Uric acid levels SLC2A9 intron 19503597 rs13103429 chr4 9910635 C T 2.50E-22 Urate levels SLC2A9 intron 20884846 rs13103429 chr4 9910635 C T 6.40E-70 Urate levels SLC2A9 intron 23263486 rs13108825 chr4 9910663 C G 4.97E-23 Uric acid levels SLC2A9 intron 19503597 rs13108825 chr4 9910663 C G 2.40E-22 Urate levels SLC2A9 intron 20884846 rs13108825 chr4 9910663 C G 3.45E-61 Urate levels SLC2A9 intron 23263486 rs4336225 chr4 9911872 C T 5.83E-04 Insulin resistance SLC2A9 intron 21901158 rs11934363 chr4 9912101 A G 6.03E-09 Esophageal cancer SLC2A9 intron 21642993 rs11722228 chr4 9915741 C T 1.75E-75 Uric acid levels SLC2A9 intron 19503597 rs11722228 chr4 9915741 C T 7.00E-24 Blood cell counts and other traits SLC2A9 intron 20139978 rs11722228 chr4 9915741 C T 7.09E-24 Blood cell counts and other traits SLC2A9 intron 20139978 rs11722228 chr4 9915741 C T 3.70E-90 Urate levels SLC2A9 intron 20884846 rs11722228 chr4 9915741 C T 4.17E-14 Urate levels SLC2A9 intron 21768215 rs11722228 chr4 9915741 C T 3.01E-09 Cardiovascular disease risk factors SLC2A9 intron 21943158 rs11722228 chr4 9915741 C T 3.28E-261 Urate levels SLC2A9 intron 23263486 rs11722228 chr4 9915741 C T 9.00E-31 Serum uric acid levels SLC2A9 intron 24513273 rs4697695 chr4 9915850 A G 5.74E-76 Uric acid levels SLC2A9 intron 19503597 rs4697695 chr4 9915850 A G 4.60E-90 Urate levels SLC2A9 intron 20884846 rs4697695 chr4 9915850 A G 1.99E-15 Urate levels SLC2A9 intron 21768215 rs4697695 chr4 9915850 A G 5.48E-262 Urate levels SLC2A9 intron 23263486 rs7674711 chr4 9916180 T C 3.71E-04 Multiple complex diseases SLC2A9 intron 17554300 rs10516194 chr4 9916209 T C 7.25E-19 Uric acid levels SLC2A9 intron 19503597 rs10516194 chr4 9916209 T C 9.60E-31 Urate levels SLC2A9 intron 20884846 rs10516194 chr4 9916209 T C 1.25E-73 Urate levels SLC2A9 intron 23263486 rs10805346 chr4 9920347 T C 7.89E-131 Uric acid levels SLC2A9 intron 19503597 rs10805346 chr4 9920347 T C 7.20E-167 Urate levels SLC2A9 intron 20884846 rs10805346 chr4 9920347 T C 5.19E-28 Urate levels SLC2A9 intron 21768215 rs10805346 chr4 9920347 T C 4.14E-25 Urate levels SLC2A9 intron 23263486 rs874432 chr4 9920606 T A 7.35E-173 Uric acid levels SLC2A9 intron 19503597 rs874432 chr4 9920606 T A 1.80E-235 Urate levels SLC2A9 intron 20884846 rs874432 chr4 9920606 T A 6.02E-18 Urate levels SLC2A9 intron 21768215 rs874432 chr4 9920606 T A 6.91E-24 Urate levels SLC2A9 intron 23263486 rs6823877 chr4 9921931 T C 7.32E-79 Uric acid levels SLC2A9 intron 19503597 rs6823877 chr4 9921931 T C 9.40E-91 Urate levels SLC2A9 intron 20884846 rs6823877 chr4 9921931 T C 1.69E-221 Urate levels SLC2A9 intron 23263486 rs16890979 chr4 9922167 C T 1.00E-11 Uric acid levels SLC2A9 missense 18759275 rs16890979 chr4 9922167 C T 7.00E-168 Urate levels SLC2A9 missense 18834626 rs16890979 chr4 9922167 C T 3.55E-189 Uric acid levels SLC2A9 missense 19503597 rs16890979 chr4 9922167 C T 3.20E-241 Urate levels SLC2A9 missense 20884846 rs16890979 chr4 9922167 C T 2.53E-18 Urate levels SLC2A9 missense 21768215 rs16890979 chr4 9922167 C T 6.24E-38 Cardiovascular disease risk factors SLC2A9 missense 21943158 rs16890979 chr4 9922167 C T 9.64E-24 Urate levels SLC2A9 missense 23263486 rs938564 chr4 9922573 T G 1.67E-195 Uric acid levels SLC2A9 intron 19503597 rs938564 chr4 9922573 T G 1.70E-238 Urate levels SLC2A9 intron 20884846 rs938564 chr4 9922573 T G 4.51E-24 Urate levels SLC2A9 intron 21768215 rs938564 chr4 9922573 T G 4.56E-25 Urate levels SLC2A9 intron 23263486 rs734553 chr4 9923004 G T 1.00E-192 Uric acid levels SLC2A9 intron 19503597 rs734553 chr4 9923004 G T 1.00E-41 Uric acid levels SLC2A9 intron 19503597 rs734553 chr4 9923004 G T 5.60E-239 Urate levels SLC2A9 intron 20884846 rs734553 chr4 9923004 G T 2.68E-24 Urate levels SLC2A9 intron 21768215 rs734553 chr4 9923004 G T 4.19E-40 Cardiovascular disease risk factors SLC2A9 intron 21943158 rs734553 chr4 9923004 G T 1.00E-80 Urate (in serum),gout SLC2A9 intron 21983786 rs734553 chr4 9923004 G T 2.10E-70 Urate (in serum),gout SLC2A9 intron 21983786 rs734553 chr4 9923004 G T 2.40E-07 Urate (in serum),gout SLC2A9 intron 21983786 rs734553 chr4 9923004 G T 3.40E-04 Urate (in serum),gout SLC2A9 intron 21983786 rs734553 chr4 9923004 G T 5.10E-23 Urate (in serum),gout SLC2A9 intron 21983786 rs734553 chr4 9923004 G T 7.60E-05 Urate (in serum),gout SLC2A9 intron 21983786 rs734553 chr4 9923004 G T 2.78E-24 Urate levels SLC2A9 intron 23263486 rs6832439 chr4 9924319 A G 3.08E-197 Uric acid levels SLC2A9 intron 19503597 rs6832439 chr4 9924319 A G 5.50E-238 Urate levels SLC2A9 intron 20884846 rs6832439 chr4 9924319 A G 6.43E-22 Urate levels SLC2A9 intron 21768215 rs6832439 chr4 9924319 A G 4.15E-25 Urate levels SLC2A9 intron 23263486 rs6832439 chr4 9924319 A G 3.00E-08 Serum uric acid levels SLC2A9 intron 24379826 rs938553 chr4 9925526 C T 3.63E-09 Uric acid levels SLC2A9 intron 19503597 rs938553 chr4 9925526 C T 1.00E-17 Urate levels SLC2A9 intron 20884846 rs938553 chr4 9925526 C T 7.94E-40 Urate levels SLC2A9 intron 23263486 rs938554 chr4 9925692 C G 2.18E-191 Uric acid levels SLC2A9 intron 19503597 rs938554 chr4 9925692 C G 4.30E-238 Urate levels SLC2A9 intron 20884846 rs938554 chr4 9925692 C G 5.04E-19 Urate levels SLC2A9 intron 21768215 rs938554 chr4 9925692 C G 4.19E-25 Urate levels SLC2A9 intron 23263486 rs938554 chr4 9925692 C G 6.00E-93 Blood metabolite levels SLC2A9 intron 24816252 rs938555 chr4 9926051 A G 9.81E-198 Uric acid levels SLC2A9 intron 19503597 rs938555 chr4 9926051 A G 4.30E-238 Urate levels SLC2A9 intron 20884846 rs938555 chr4 9926051 A G 5.50E-19 Urate levels SLC2A9 intron 21768215 rs938555 chr4 9926051 A G 4.25E-25 Urate levels SLC2A9 intron 23263486 rs10939614 chr4 9926613 T C 1.67E-79 Uric acid levels SLC2A9 intron 19503597 rs10939614 chr4 9926613 T C 2.40E-91 Urate levels SLC2A9 intron 20884846 rs10939614 chr4 9926613 T C 6.06E-270 Urate levels SLC2A9 intron 23263486 rs13129697 chr4 9926967 T G 1.00E-09 Biochemical measures SLC2A9 intron 19260141 rs13129697 chr4 9926967 T G 3.84E-193 Uric acid levels SLC2A9 intron 19503597 rs13129697 chr4 9926967 T G 2.00E-242 Urate levels SLC2A9 intron 20884846 rs13129697 chr4 9926967 T G 4.00E-13 Urate levels SLC2A9 intron 20884846 rs13129697 chr4 9926967 T G 3.81E-32 Urate levels SLC2A9 intron 21768215 rs13129697 chr4 9926967 T G 1.04E-37 Cardiovascular disease risk factors SLC2A9 intron 21943158 rs13129697 chr4 9926967 T G 1.20E-22 Urate (in serum),gout SLC2A9 intron 21983786 rs13129697 chr4 9926967 T G 1.30E-69 Urate (in serum),gout SLC2A9 intron 21983786 rs13129697 chr4 9926967 T G 1.60E-79 Urate (in serum),gout SLC2A9 intron 21983786 rs13129697 chr4 9926967 T G 5.10E-06 Urate (in serum),gout SLC2A9 intron 21983786 rs13129697 chr4 9926967 T G 7.50E-04 Urate (in serum),gout SLC2A9 intron 21983786 rs13129697 chr4 9926967 T G 2.00E-19 Uric acid levels SLC2A9 intron 22229870 rs13129697 chr4 9926967 T G 4.23E-22 Urate levels SLC2A9 intron 23263486 rs6838021 chr4 9927620 T C 9.65E-197 Uric acid levels SLC2A9 intron 19503597 rs6838021 chr4 9927620 T C 3.80E-238 Urate levels SLC2A9 intron 20884846 rs6838021 chr4 9927620 T C 1.45E-25 Urate levels SLC2A9 intron 21768215 rs6838021 chr4 9927620 T C 4.16E-25 Urate levels SLC2A9 intron 23263486 rs6838021 chr4 9927620 T C 6.00E-68 Blood metabolite ratios SLC2A9 intron 24816252 rs881971 chr4 9930962 T A,C,G 2.08E-71 Uric acid levels SLC2A9 intron 19503597 rs881971 chr4 9930962 T A,C,G 6.70E-86 Urate levels SLC2A9 intron 20884846 rs881971 chr4 9930962 T A,C,G 6.30E-05 Schizophrenia(age at onset) SLC2A9 intron 21688384 rs881971 chr4 9930962 T A,C,G 1.30E-12 Urate levels SLC2A9 intron 21768215 rs881971 chr4 9930962 T A,C,G 2.62E-257 Urate levels SLC2A9 intron 23263486 rs737267 chr4 9934744 G T 4.00E-04 Serum uric acid levels SLC2A9 intron 17997608 rs737267 chr4 9934744 G T 3.00E-09 Urate levels SLC2A9 intron 18327257 rs737267 chr4 9934744 G T 1.49E-192 Uric acid levels SLC2A9 intron 19503597 rs737267 chr4 9934744 G T 5.20E-14 Urate levels SLC2A9 intron 20884846 rs737267 chr4 9934744 G T 2.05E-24 Urate levels SLC2A9 intron 21768215 rs737267 chr4 9934744 G T 2.41E-40 Cardiovascular disease risk factors SLC2A9 intron 21943158 rs737267 chr4 9934744 G T 8.02E-24 Urate levels SLC2A9 intron 23263486 rs737267 chr4 9934744 G T 1.70E-07 Serum uric acid levels SLC2A9 intron 24379826 rs6855911 chr4 9935910 A G 2.00E-16 Urate levels SLC2A9 intron 17997608 rs6855911 chr4 9935910 A G 2.53E-177 Uric acid levels SLC2A9 intron 19503597 rs6855911 chr4 9935910 A G 3.40E-235 Urate levels SLC2A9 intron 20884846 rs6855911 chr4 9935910 A G 4.40E-24 Urate levels SLC2A9 intron 21768215 rs6855911 chr4 9935910 A G 2.41E-40 Cardiovascular disease risk factors SLC2A9 intron 21943158 rs6855911 chr4 9935910 A G 1.61E-23 Urate levels SLC2A9 intron 23263486 rs7670751 chr4 9938773 A C 2.00E-100 Uric acid levels SLC2A9 intron 19503597 rs7670751 chr4 9938773 A C 7.20E-166 Urate levels SLC2A9 intron 20884846 rs7670751 chr4 9938773 A C 2.11E-24 Urate levels SLC2A9 intron 21768215 rs7670751 chr4 9938773 A C 1.59E-22 Urate levels SLC2A9 intron 23263486 rs4447863 chr4 9938969 T C 3.14E-88 Uric acid levels SLC2A9 intron 19503597 rs4447863 chr4 9938969 T C 5.70E-102 Urate levels SLC2A9 intron 20884846 rs4447863 chr4 9938969 T C 9.25E-18 Urate levels SLC2A9 intron 21768215 rs4447863 chr4 9938969 T C 2.24E-07 Urate levels SLC2A9 intron 23263486 rs4447863 chr4 9938969 T C 1.61E-04 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs4447863 chr4 9938969 T C 2.94E-05 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs938558 chr4 9939205 G A 6.38E-179 Uric acid levels SLC2A9 intron 19503597 rs938558 chr4 9939205 G A 1.20E-241 Urate levels SLC2A9 intron 20884846 rs938558 chr4 9939205 G A 2.78E-30 Urate levels SLC2A9 intron 21768215 rs938558 chr4 9939205 G A 2.91E-22 Urate levels SLC2A9 intron 23263486 rs4511996 chr4 9939818 G A 9.98E-15 Uric acid levels SLC2A9 intron 19503597 rs4511996 chr4 9939818 G A 3.90E-21 Urate levels SLC2A9 intron 20884846 rs4511996 chr4 9939818 G A 5.65E-53 Urate levels SLC2A9 intron 23263486 rs5028843 chr4 9940806 G A 3.71E-196 Uric acid levels SLC2A9 intron 19503597 rs5028843 chr4 9940806 G A 3.40E-236 Urate levels SLC2A9 intron 20884846 rs5028843 chr4 9940806 G A 1.30E-22 Urate levels SLC2A9 intron 21768215 rs5028843 chr4 9940806 G A 3.83E-24 Urate levels SLC2A9 intron 23263486 rs4697913 chr4 9941262 C T 2.17E-187 Uric acid levels SLC2A9 intron 19503597 rs4697913 chr4 9941262 C T 7.60E-236 Urate levels SLC2A9 intron 20884846 rs4697913 chr4 9941262 C T 7.71E-10 Urate levels SLC2A9 intron 21768215 rs4697913 chr4 9941262 C T 3.06E-25 Urate levels SLC2A9 intron 23263486 rs7675964 chr4 9941434 C T 1.43E-181 Uric acid levels SLC2A9 intron 19503597 rs7675964 chr4 9941434 C T 2.10E-242 Urate levels SLC2A9 intron 20884846 rs7675964 chr4 9941434 C T 5.88E-28 Urate levels SLC2A9 intron 21768215 rs7675964 chr4 9941434 C T 1.02E-22 Urate levels SLC2A9 intron 23263486 rs4697698 chr4 9942577 T C 3.83E-09 Serum uric acid levels SLC2A9 intron 17997608 rs4697698 chr4 9942577 T C 1.09E-84 Uric acid levels SLC2A9 intron 19503597 rs4697698 chr4 9942577 T C 3.30E-98 Urate levels SLC2A9 intron 20884846 rs4697698 chr4 9942577 T C 3.56E-05 Schizophrenia(age at onset) SLC2A9 intron 21688384 rs4697698 chr4 9942577 T C 1.95E-17 Urate levels SLC2A9 intron 21768215 rs4697698 chr4 9942577 T C 6.89E-08 Urate levels SLC2A9 intron 23263486 rs7669296 chr4 9942642 G C 9.21E-09 Urate levels SLC2A9 intron 23263486 rs149454410 chr4 9943624 C T 0.00014 Prostate cancer SLC2A9 missense 23555315 rs4292327 chr4 9943700 G A 1.00E-14 Uric acid levels SLC2A9 intron 19503597 rs4292327 chr4 9943700 G A 1.10E-20 Urate levels SLC2A9 intron 20884846 rs4292327 chr4 9943700 G A 5.02E-11 Urate levels SLC2A9 intron 21768215 rs4292327 chr4 9943700 G A 8.13E-55 Urate levels SLC2A9 intron 23263486 rs12498742 chr4 9944052 A G 1.98E-200 Uric acid levels SLC2A9 intron 19503597 rs12498742 chr4 9944052 A G 6.90E-234 Urate levels SLC2A9 intron 20884846 rs12498742 chr4 9944052 A G 1.94E-06 Uric acid levels SLC2A9 intron 21294900 rs12498742 chr4 9944052 A G 8.62E-29 Urate levels SLC2A9 intron 21768215 rs12498742 chr4 9944052 A G 1E-700 Urate levels SLC2A9 intron 23263486 rs6449144 chr4 9944650 T G 1.53E-79 Uric acid levels SLC2A9 intron 19503597 rs6449144 chr4 9944650 T G 5.40E-92 Urate levels SLC2A9 intron 20884846 rs6449144 chr4 9944650 T G 8.08E-271 Urate levels SLC2A9 intron 23263486 rs4235346 chr4 9945296 C T 1.97E-08 Serum uric acid levels SLC2A9 intron 17997608 rs4235346 chr4 9945296 C T 6.36E-79 Uric acid levels SLC2A9 intron 19503597 rs4235346 chr4 9945296 C T 5.70E-98 Urate levels SLC2A9 intron 20884846 rs4235346 chr4 9945296 C T 1.75E-05 Schizophrenia(age at onset) SLC2A9 intron 21688384 rs4235346 chr4 9945296 C T 5.85E-18 Urate levels SLC2A9 intron 21768215 rs4235346 chr4 9945296 C T 6.31E-285 Urate levels SLC2A9 intron 23263486 rs4697700 chr4 9945792 G C 5.52E-15 Serum uric acid levels SLC2A9 intron 17997608 rs4697700 chr4 9945792 G C 2.15E-174 Uric acid levels SLC2A9 intron 19503597 rs4697700 chr4 9945792 G C 4.20E-217 Urate levels SLC2A9 intron 20884846 rs4697700 chr4 9945792 G C 1.06E-15 Urate levels SLC2A9 intron 21768215 rs4697700 chr4 9945792 G C 1.36E-23 Urate levels SLC2A9 intron 23263486 rs4697701 chr4 9946095 G A 1.80E-192 Uric acid levels SLC2A9 intron 19503597 rs4697701 chr4 9946095 G A 9.30E-240 Urate levels SLC2A9 intron 20884846 rs4697701 chr4 9946095 G A 8.17E-23 Urate levels SLC2A9 intron 21768215 rs4697701 chr4 9946095 G A 9.63E-04 Alzheimer's disease SLC2A9 intron 22005930 rs4697701 chr4 9946095 G A 1.49E-24 Urate levels SLC2A9 intron 23263486 rs16891234 chr4 9946163 T C 4.22E-11 Uric acid levels SLC2A9 intron 19503597 rs16891234 chr4 9946163 T C 1.30E-18 Urate levels SLC2A9 intron 20884846 rs16891234 chr4 9946163 T C 4.14E-10 Urate levels SLC2A9 intron 21768215 rs16891234 chr4 9946163 T C 4.07E-42 Urate levels SLC2A9 intron 23263486 rs4475146 chr4 9946656 C A 7.39E-197 Uric acid levels SLC2A9 intron 19503597 rs4475146 chr4 9946656 C A 3.20E-233 Urate levels SLC2A9 intron 20884846 rs4475146 chr4 9946656 C A 1.50E-15 Urate levels SLC2A9 intron 21768215 rs4475146 chr4 9946656 C A 4.00E-26 Gout SLC2A9 intron 23263486 rs2018643 chr4 9947121 T C 1 Drug response to Etoposide SLC2A9 intron 17537913 rs2018643 chr4 9947121 T C 1.69E-72 Uric acid levels SLC2A9 intron 19503597 rs2018643 chr4 9947121 T C 8.40E-82 Urate levels SLC2A9 intron 20884846 rs2018643 chr4 9947121 T C 6.01E-250 Urate levels SLC2A9 intron 23263486 rs1122141 chr4 9947278 T C 3.19E-76 Uric acid levels SLC2A9 intron 19503597 rs1122141 chr4 9947278 T C 1.50E-91 Urate levels SLC2A9 intron 20884846 rs1122141 chr4 9947278 T C 1.28E-13 Urate levels SLC2A9 intron 21768215 rs1122141 chr4 9947278 T C 1.43E-245 Urate levels SLC2A9 intron 23263486 rs4621431 chr4 9947590 G A 1 Drug response to Etoposide SLC2A9 intron 17537913 rs4621431 chr4 9947590 G A 5.26E-72 Uric acid levels SLC2A9 intron 19503597 rs4621431 chr4 9947590 G A 4.90E-82 Urate levels SLC2A9 intron 20884846 rs4621431 chr4 9947590 G A 5.22E-249 Urate levels SLC2A9 intron 23263486 rs4339211 chr4 9947658 C T 1 Drug response to Etoposide SLC2A9 intron 17537913 rs4339211 chr4 9947658 C T 4.62E-66 Uric acid levels SLC2A9 intron 19503597 rs4339211 chr4 9947658 C T 3.70E-82 Urate levels SLC2A9 intron 20884846 rs4339211 chr4 9947658 C T 2.22E-228 Urate levels SLC2A9 intron 23263486 rs7694997 chr4 9947811 A G 3.15E-72 Uric acid levels SLC2A9 intron 19503597 rs7694997 chr4 9947811 A G 2.50E-82 Urate levels SLC2A9 intron 20884846 rs7694997 chr4 9947811 A G 7.91E-250 Urate levels SLC2A9 intron 23263486 rs7686538 chr4 9948077 C T 1 Drug response to Etoposide SLC2A9 intron 17537913 rs7686538 chr4 9948077 C T 3.53E-72 Uric acid levels SLC2A9 intron 19503597 rs7686538 chr4 9948077 C T 2.50E-82 Urate levels SLC2A9 intron 20884846 rs7686538 chr4 9948077 C T 1.40E-228 Urate levels SLC2A9 intron 23263486 rs4580649 chr4 9948461 G A 1 Drug response to Etoposide SLC2A9 intron 17537913 rs4580649 chr4 9948461 G A 3.93E-72 Uric acid levels SLC2A9 intron 19503597 rs4580649 chr4 9948461 G A 2.50E-82 Urate levels SLC2A9 intron 20884846 rs4580649 chr4 9948461 G A 9.24E-250 Urate levels SLC2A9 intron 23263486 rs998676 chr4 9948564 T C 8.30E-85 Uric acid levels SLC2A9 intron 19503597 rs998676 chr4 9948564 T C 4.00E-98 Urate levels SLC2A9 intron 20884846 rs998676 chr4 9948564 T C 3.25E-287 Urate levels SLC2A9 intron 23263486 rs998676 chr4 9948564 T C 1.36E-05 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs998676 chr4 9948564 T C 7.51E-05 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs998675 chr4 9948829 C T 5.13E-09 Serum uric acid levels SLC2A9 intron 17997608 rs998675 chr4 9948829 C T 4.71E-82 Uric acid levels SLC2A9 intron 19503597 rs998675 chr4 9948829 C T 4.00E-98 Urate levels SLC2A9 intron 20884846 rs998675 chr4 9948829 C T 4.92E-14 Urate levels SLC2A9 intron 21768215 rs998675 chr4 9948829 C T 3.26E-288 Urate levels SLC2A9 intron 23263486 rs12498150 chr4 9950537 C T 1 Drug response to Etoposide SLC2A9 intron 17537913 rs12498150 chr4 9950537 C T 7.52E-72 Uric acid levels SLC2A9 intron 19503597 rs12498150 chr4 9950537 C T 2.80E-82 Urate levels SLC2A9 intron 20884846 rs12498150 chr4 9950537 C T 2.78E-250 Urate levels SLC2A9 intron 23263486 rs12498956 chr4 9950705 C A 1 Drug response to Etoposide SLC2A9 intron 17537913 rs12498956 chr4 9950705 C A 2.99E-71 Uric acid levels SLC2A9 intron 19503597 rs12498956 chr4 9950705 C A 2.30E-82 Urate levels SLC2A9 intron 20884846 rs12498956 chr4 9950705 C A 2.10E-250 Urate levels SLC2A9 intron 23263486 rs13328050 chr4 9951120 G T 1 Drug response to Etoposide SLC2A9 intron 17537913 rs13328050 chr4 9951120 G T 6.35E-71 Uric acid levels SLC2A9 intron 19503597 rs13328050 chr4 9951120 G T 2.20E-82 Urate levels SLC2A9 intron 20884846 rs13328050 chr4 9951120 G T 7.19E-05 Schizophrenia(age at onset) SLC2A9 intron 21688384 rs13328050 chr4 9951120 G T 8.01E-251 Urate levels SLC2A9 intron 23263486 rs1079128 chr4 9951221 T C 1 Drug response to Etoposide SLC2A9 intron 17537913 rs1079128 chr4 9951221 T C 8.46E-72 Uric acid levels SLC2A9 intron 19503597 rs1079128 chr4 9951221 T C 2.20E-82 Urate levels SLC2A9 intron 20884846 rs1079128 chr4 9951221 T C 7.10E-09 Urate levels SLC2A9 intron 21768215 rs1079128 chr4 9951221 T C 1.31E-250 Urate levels SLC2A9 intron 23263486 rs9993410 chr4 9951264 C T 1 Drug response to Etoposide SLC2A9 intron 17537913 rs9993410 chr4 9951264 C T 8.44E-72 Uric acid levels SLC2A9 intron 19503597 rs9993410 chr4 9951264 C T 2.30E-82 Urate levels SLC2A9 intron 20884846 rs9993410 chr4 9951264 C T 1.13E-250 Urate levels SLC2A9 intron 23263486 rs11723439 chr4 9951819 C T 1.25E-181 Uric acid levels SLC2A9 intron 19503597 rs11723439 chr4 9951819 C T 4.40E-238 Urate levels SLC2A9 intron 20884846 rs11723439 chr4 9951819 C T 2.27E-09 Urate levels SLC2A9 intron 21768215 rs11723439 chr4 9951819 C T 5.35E-23 Urate levels SLC2A9 intron 23263486 rs4235347 chr4 9951956 C T 6.72E-71 Uric acid levels SLC2A9 intron 19503597 rs4235347 chr4 9951956 C T 2.30E-79 Urate levels SLC2A9 intron 20884846 rs4235347 chr4 9951956 C T 2.58E-242 Urate levels SLC2A9 intron 23263486 rs4697914 chr4 9952266 G A 9.37E-36 Uric acid levels SLC2A9 intron 19503597 rs4697914 chr4 9952266 G A 4.50E-28 Urate levels SLC2A9 intron 20884846 rs4455410 chr4 9953297 T C 1 Drug response to Etoposide SLC2A9 intron 17537913 rs4455410 chr4 9953297 T C 1.23E-07 Serum uric acid levels SLC2A9 intron 17997608 rs4455410 chr4 9953297 T C 1.98E-70 Uric acid levels SLC2A9 intron 19503597 rs4455410 chr4 9953297 T C 1.60E-79 Urate levels SLC2A9 intron 20884846 rs4455410 chr4 9953297 T C 6.19E-05 Schizophrenia(age at onset) SLC2A9 intron 21688384 rs4455410 chr4 9953297 T C 1.11E-241 Urate levels SLC2A9 intron 23263486 rs4560411 chr4 9953361 A G 3.68E-70 Uric acid levels SLC2A9 intron 19503597 rs4560411 chr4 9953361 A G 1.50E-79 Urate levels SLC2A9 intron 20884846 rs4560411 chr4 9953361 A G 8.02E-222 Urate levels SLC2A9 intron 23263486 rs4447861 chr4 9953940 C T 7.24E-59 Uric acid levels SLC2A9 intron 19503597 rs4447861 chr4 9953940 C T 5.50E-70 Urate levels SLC2A9 intron 20884846 rs4447861 chr4 9953940 C T 6.85E-194 Urate levels SLC2A9 intron 23263486 rs4459990 chr4 9954005 T C 3.90E-70 Uric acid levels SLC2A9 intron 19503597 rs4459990 chr4 9954005 T C 9.70E-80 Urate levels SLC2A9 intron 20884846 rs4459990 chr4 9954005 T C 8.81E-222 Urate levels SLC2A9 intron 23263486 rs9994266 chr4 9954450 G A 1 Drug response to Etoposide SLC2A9 intron 17537913 rs9994266 chr4 9954450 G A 2.06E-70 Uric acid levels SLC2A9 intron 19503597 rs9994266 chr4 9954450 G A 9.30E-80 Urate levels SLC2A9 intron 20884846 rs9994266 chr4 9954450 G A 7.60E-242 Urate levels SLC2A9 intron 23263486 rs7376948 chr4 9954708 G A 1 Drug response to Etoposide SLC2A9 intron 17537913 rs7376948 chr4 9954708 G A 8.46E-71 Uric acid levels SLC2A9 intron 19503597 rs7376948 chr4 9954708 G A 9.30E-80 Urate levels SLC2A9 intron 20884846 rs7376948 chr4 9954708 G A 5.43E-242 Urate levels SLC2A9 intron 23263486 rs7375587 chr4 9954758 A T 1.31E-70 Uric acid levels SLC2A9 intron 19503597 rs7375587 chr4 9954758 A T 9.20E-80 Urate levels SLC2A9 intron 20884846 rs7375587 chr4 9954758 A T 6.36E-05 Schizophrenia(age at onset) SLC2A9 intron 21688384 rs7375587 chr4 9954758 A T 6.28E-10 Urate levels SLC2A9 intron 21768215 rs7375587 chr4 9954758 A T 3.07E-242 Urate levels SLC2A9 intron 23263486 rs7378305 chr4 9954893 C T 1 Drug response to Etoposide SLC2A9 intron 17537913 rs7378305 chr4 9954893 C T 8.58E-71 Uric acid levels SLC2A9 intron 19503597 rs7378305 chr4 9954893 C T 6.90E-80 Urate levels SLC2A9 intron 20884846 rs7378305 chr4 9954893 C T 2.14E-242 Urate levels SLC2A9 intron 23263486 rs7375599 chr4 9954918 A G 4.17E-09 Serum uric acid levels SLC2A9 intron 17997608 rs7375599 chr4 9954918 A G 3.94E-83 Uric acid levels SLC2A9 intron 19503597 rs7375599 chr4 9954918 A G 2.30E-98 Urate levels SLC2A9 intron 20884846 rs7375599 chr4 9954918 A G 2.74E-05 Schizophrenia(age at onset) SLC2A9 intron 21688384 rs7375599 chr4 9954918 A G 8.28E-18 Urate levels SLC2A9 intron 21768215 rs7375599 chr4 9954918 A G 7.00E-08 Urate levels SLC2A9 intron 23263486 rs7378340 chr4 9955198 C T 1 Drug response to Etoposide SLC2A9 intron 17537913 rs7378340 chr4 9955198 C T 1.49E-07 Serum uric acid levels SLC2A9 intron 17997608 rs7378340 chr4 9955198 C T 8.35E-70 Uric acid levels SLC2A9 intron 19503597 rs7378340 chr4 9955198 C T 9.00E-80 Urate levels SLC2A9 intron 20884846 rs7378340 chr4 9955198 C T 6.36E-05 Schizophrenia(age at onset) SLC2A9 intron 21688384 rs7378340 chr4 9955198 C T 1.37E-241 Urate levels SLC2A9 intron 23263486 rs4519796 chr4 9955936 A G 1 Drug response to Etoposide SLC2A9 intron 17537913 rs4519796 chr4 9955936 A G 1.35E-70 Uric acid levels SLC2A9 intron 19503597 rs4519796 chr4 9955936 A G 9.30E-80 Urate levels SLC2A9 intron 20884846 rs4519796 chr4 9955936 A G 1.08E-230 Urate levels SLC2A9 intron 23263486 rs4311316 chr4 9955971 C A 1 Drug response to Etoposide SLC2A9 intron 17537913 rs4311316 chr4 9955971 C A 1.42E-07 Serum uric acid levels SLC2A9 intron 17997608 rs4311316 chr4 9955971 C A 5.81E-70 Uric acid levels SLC2A9 intron 19503597 rs4311316 chr4 9955971 C A 9.50E-80 Urate levels SLC2A9 intron 20884846 rs4311316 chr4 9955971 C A 4.89E-05 Schizophrenia(age at onset) SLC2A9 intron 21688384 rs4311316 chr4 9955971 C A 2.91E-241 Urate levels SLC2A9 intron 23263486 rs4481233 chr4 9956079 C T 1.19E-11 Serum uric acid levels SLC2A9 intron 17997608 rs4481233 chr4 9956079 C T 4.79E-186 Uric acid levels SLC2A9 intron 19503597 rs4481233 chr4 9956079 C T 2.30E-230 Urate levels SLC2A9 intron 20884846 rs4481233 chr4 9956079 C T 4.43E-10 Urate levels SLC2A9 intron 21768215 rs4481233 chr4 9956079 C T 6.00E-34 Metabolic traits SLC2A9 intron 21886157 rs4481233 chr4 9956079 C T 2.56E-23 Urate levels SLC2A9 intron 23263486 rs4314284 chr4 9956096 C T 1 Drug response to Etoposide SLC2A9 intron 17537913 rs4314284 chr4 9956096 C T 1.04E-70 Uric acid levels SLC2A9 intron 19503597 rs4314284 chr4 9956096 C T 9.00E-80 Urate levels SLC2A9 intron 20884846 rs4314284 chr4 9956096 C T 6.36E-05 Schizophrenia(age at onset) SLC2A9 intron 21688384 rs4314284 chr4 9956096 C T 4.87E-242 Urate levels SLC2A9 intron 23263486 rs4312757 chr4 9956145 T A 1 Drug response to Etoposide SLC2A9 intron 17537913 rs4312757 chr4 9956145 T A 3.06E-72 Uric acid levels SLC2A9 intron 19503597 rs4312757 chr4 9956145 T A 1.20E-83 Urate levels SLC2A9 intron 20884846 rs4312757 chr4 9956145 T A 1.06E-247 Urate levels SLC2A9 intron 23263486 rs6814664 chr4 9956228 C T 1 Drug response to Etoposide SLC2A9 intron 17537913 rs6814664 chr4 9956228 C T 8.94E-71 Uric acid levels SLC2A9 intron 19503597 rs6814664 chr4 9956228 C T 7.00E-80 Urate levels SLC2A9 intron 20884846 rs6814664 chr4 9956228 C T 3.01E-242 Urate levels SLC2A9 intron 23263486 rs6449155 chr4 9956547 T G 1 Drug response to Etoposide SLC2A9 intron 17537913 rs6449155 chr4 9956547 T G 5.97E-71 Uric acid levels SLC2A9 intron 19503597 rs6449155 chr4 9956547 T G 6.90E-80 Urate levels SLC2A9 intron 20884846 rs6449155 chr4 9956547 T G 3.29E-242 Urate levels SLC2A9 intron 23263486 rs6449156 chr4 9956712 G C 5.33E-76 Uric acid levels SLC2A9 intron 19503597 rs6449156 chr4 9956712 G C 1.30E-82 Urate levels SLC2A9 intron 20884846 rs6449156 chr4 9956712 G C 3.29E-256 Urate levels SLC2A9 intron 23263486 rs17245436 chr4 9958169 A G 4.89E-71 Uric acid levels SLC2A9 intron 19503597 rs17245436 chr4 9958169 A G 7.90E-81 Urate levels SLC2A9 intron 20884846 rs17245436 chr4 9958169 A G 2.09E-243 Urate levels SLC2A9 intron 23263486 rs17185835 chr4 9958180 T G 1 Drug response to Etoposide SLC2A9 intron 17537913 rs17185835 chr4 9958180 T G 4.12E-71 Uric acid levels SLC2A9 intron 19503597 rs17185835 chr4 9958180 T G 9.60E-81 Urate levels SLC2A9 intron 20884846 rs17185835 chr4 9958180 T G 1.37E-243 Urate levels SLC2A9 intron 23263486 rs17185870 chr4 9958214 C A 1 Drug response to Etoposide SLC2A9 intron 17537913 rs17185870 chr4 9958214 C A 5.45E-71 Uric acid levels SLC2A9 intron 19503597 rs17185870 chr4 9958214 C A 2.30E-80 Urate levels SLC2A9 intron 20884846 rs17185870 chr4 9958214 C A 2.25E-243 Urate levels SLC2A9 intron 23263486 rs11724510 chr4 9958583 C T 4.11E-71 Uric acid levels SLC2A9 intron 19503597 rs11724510 chr4 9958583 C T 1.30E-80 Urate levels SLC2A9 intron 20884846 rs11724510 chr4 9958583 C T 8.15E-10 Urate levels SLC2A9 intron 21768215 rs11724510 chr4 9958583 C T 7.40E-244 Urate levels SLC2A9 intron 23263486 rs6815001 chr4 9958662 G C 1 Drug response to Etoposide SLC2A9 intron 17537913 rs6815001 chr4 9958662 G C 4.64E-71 Uric acid levels SLC2A9 intron 19503597 rs6815001 chr4 9958662 G C 1.10E-80 Urate levels SLC2A9 intron 20884846 rs6815001 chr4 9958662 G C 3.73E-223 Urate levels SLC2A9 intron 23263486 rs6849717 chr4 9958719 T C 5.88E-84 Uric acid levels SLC2A9 intron 19503597 rs6849717 chr4 9958719 T C 3.90E-98 Urate levels SLC2A9 intron 20884846 rs6849717 chr4 9958719 T C 1.22E-16 Urate levels SLC2A9 intron 21768215 rs6849717 chr4 9958719 T C 4.28E-08 Urate levels SLC2A9 intron 23263486 rs6849717 chr4 9958719 T C 5.07E-05 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs6849717 chr4 9958719 T C 9.01E-06 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs6849729 chr4 9958732 T C 1 Drug response to Etoposide SLC2A9 intron 17537913 rs6849729 chr4 9958732 T C 4.41E-71 Uric acid levels SLC2A9 intron 19503597 rs6849729 chr4 9958732 T C 6.40E-81 Urate levels SLC2A9 intron 20884846 rs6849729 chr4 9958732 T C 4.58E-244 Urate levels SLC2A9 intron 23263486 rs6843873 chr4 9958788 A C 1 Drug response to Etoposide SLC2A9 intron 17537913 rs6843873 chr4 9958788 A C 4.40E-71 Uric acid levels SLC2A9 intron 19503597 rs6843873 chr4 9958788 A C 6.40E-81 Urate levels SLC2A9 intron 20884846 rs6843873 chr4 9958788 A C 7.99E-244 Urate levels SLC2A9 intron 23263486 rs6850143 chr4 9958924 T C 8.89E-71 Uric acid levels SLC2A9 intron 19503597 rs6850143 chr4 9958924 T C 6.30E-81 Urate levels SLC2A9 intron 20884846 rs6850143 chr4 9958924 T C 2.72E-211 Urate levels SLC2A9 intron 23263486 rs6844316 chr4 9958977 A G 1 Drug response to Etoposide SLC2A9 intron 17537913 rs6844316 chr4 9958977 A G 5.49E-71 Uric acid levels SLC2A9 intron 19503597 rs6844316 chr4 9958977 A G 6.10E-81 Urate levels SLC2A9 intron 20884846 rs6844316 chr4 9958977 A G 2.96E-244 Urate levels SLC2A9 intron 23263486 rs6834893 chr4 9959123 C T 1 Drug response to Etoposide SLC2A9 intron 17537913 rs6834893 chr4 9959123 C T 2.98E-71 Uric acid levels SLC2A9 intron 19503597 rs6834893 chr4 9959123 C T 5.10E-81 Urate levels SLC2A9 intron 20884846 rs6834893 chr4 9959123 C T 8.58E-244 Urate levels SLC2A9 intron 23263486 rs10001964 chr4 9959275 C T 5.07E-61 Uric acid levels SLC2A9 intron 19503597 rs10001964 chr4 9959275 C T 1.30E-74 Urate levels SLC2A9 intron 20884846 rs10001964 chr4 9959275 C T 1.53E-197 Urate levels SLC2A9 intron 23263486 rs4515163 chr4 9959603 C T 1.89E-71 Uric acid levels SLC2A9 intron 19503597 rs4515163 chr4 9959603 C T 4.30E-82 Urate levels SLC2A9 intron 20884846 rs4515163 chr4 9959603 C T 1.05E-244 Urate levels SLC2A9 intron 23263486 rs6449157 chr4 9960442 G A 1 Drug response to Etoposide SLC2A9 intron 17537913 rs6449157 chr4 9960442 G A 2.46E-71 Uric acid levels SLC2A9 intron 19503597 rs6449157 chr4 9960442 G A 1.70E-81 Urate levels SLC2A9 intron 20884846 rs6449157 chr4 9960442 G A 7.95E-10 Urate levels SLC2A9 intron 21768215 rs6449157 chr4 9960442 G A 9.35E-245 Urate levels SLC2A9 intron 23263486 rs6449159 chr4 9960498 G A 1 Drug response to Etoposide SLC2A9 intron 17537913 rs6449159 chr4 9960498 G A 2.46E-71 Uric acid levels SLC2A9 intron 19503597 rs6449159 chr4 9960498 G A 1.40E-81 Urate levels SLC2A9 intron 20884846 rs6449159 chr4 9960498 G A 4.16E-244 Urate levels SLC2A9 intron 23263486 rs7672947 chr4 9961368 G C 1 Drug response to Etoposide SLC2A9 intron 17537913 rs7672947 chr4 9961368 G C 3.18E-71 Uric acid levels SLC2A9 intron 19503597 rs7672947 chr4 9961368 G C 1.70E-81 Urate levels SLC2A9 intron 20884846 rs7672947 chr4 9961368 G C 7.03E-244 Urate levels SLC2A9 intron 23263486 rs17245723 chr4 9962218 A T 8.30E-77 Uric acid levels SLC2A9 intron 19503597 rs17245723 chr4 9962218 A T 2.80E-84 Urate levels SLC2A9 intron 20884846 rs17245723 chr4 9962218 A T 2.57E-258 Urate levels SLC2A9 intron 23263486 rs11942223 chr4 9962765 T C 1.73E-197 Uric acid levels SLC2A9 intron 19503597 rs11942223 chr4 9962765 T C 5.80E-229 Urate levels SLC2A9 intron 20884846 rs11942223 chr4 9962765 T C 3.51E-16 Urate levels SLC2A9 intron 21768215 rs11942223 chr4 9962765 T C 4.31E-25 Urate levels SLC2A9 intron 23263486 rs6823361 chr4 9963127 A G 1 Drug response to Etoposide SLC2A9 intron 17537913 rs6823361 chr4 9963127 A G 2.87E-71 Uric acid levels SLC2A9 intron 19503597 rs6823361 chr4 9963127 A G 3.40E-80 Urate levels SLC2A9 intron 20884846 rs6823361 chr4 9963127 A G 7.84E-10 Urate levels SLC2A9 intron 21768215 rs6823361 chr4 9963127 A G 3.92E-243 Urate levels SLC2A9 intron 23263486 rs6836706 chr4 9964251 T A 1 Drug response to Etoposide SLC2A9 intron 17537913 rs6836706 chr4 9964251 T A 2.83E-71 Uric acid levels SLC2A9 intron 19503597 rs6836706 chr4 9964251 T A 3.30E-80 Urate levels SLC2A9 intron 20884846 rs6836706 chr4 9964251 T A 4.08E-243 Urate levels SLC2A9 intron 23263486 rs6850684 chr4 9964380 G T 1.10E-70 Uric acid levels SLC2A9 intron 19503597 rs6850684 chr4 9964380 G T 3.40E-80 Urate levels SLC2A9 intron 20884846 rs6850684 chr4 9964380 G T 5.04E-243 Urate levels SLC2A9 intron 23263486 rs10018204 chr4 9964570 C T 1 Drug response to Etoposide SLC2A9 intron 17537913 rs10018204 chr4 9964570 C T 3.20E-71 Uric acid levels SLC2A9 intron 19503597 rs10018204 chr4 9964570 C T 3.30E-80 Urate levels SLC2A9 intron 20884846 rs10018204 chr4 9964570 C T 6.37E-243 Urate levels SLC2A9 intron 23263486 rs6839490 chr4 9965000 C G 1 Drug response to Etoposide SLC2A9 intron 17537913 rs6839490 chr4 9965000 C G 6.39E-08 Serum uric acid levels SLC2A9 intron 17997608 rs6839490 chr4 9965000 C G 1.70E-68 Uric acid levels SLC2A9 intron 19503597 rs6839490 chr4 9965000 C G 1.60E-79 Urate levels SLC2A9 intron 20884846 rs6839490 chr4 9965000 C G 4.56E-239 Urate levels SLC2A9 intron 23263486 rs6856127 chr4 9965443 T C 2.78E-71 Uric acid levels SLC2A9 intron 19503597 rs6856127 chr4 9965443 T C 2.70E-80 Urate levels SLC2A9 intron 20884846 rs6856127 chr4 9965443 T C 3.34E-223 Urate levels SLC2A9 intron 23263486 rs6840802 chr4 9965633 C G 4.39E-71 Uric acid levels SLC2A9 intron 19503597 rs6840802 chr4 9965633 C G 1.20E-79 Urate levels SLC2A9 intron 20884846 rs6840802 chr4 9965633 C G 8.55E-05 Schizophrenia(age at onset) SLC2A9 intron 21688384 rs6840802 chr4 9965633 C G 3.61E-241 Urate levels SLC2A9 intron 23263486 rs6449171 chr4 9965998 T C 1 Drug response to Etoposide SLC2A9 intron 17537913 rs6449171 chr4 9965998 T C 3.39E-71 Uric acid levels SLC2A9 intron 19503597 rs6449171 chr4 9965998 T C 1.90E-80 Urate levels SLC2A9 intron 20884846 rs6449171 chr4 9965998 T C 7.49E-05 Schizophrenia(age at onset) SLC2A9 intron 21688384 rs6449171 chr4 9965998 T C 4.05E-244 Urate levels SLC2A9 intron 23263486 rs6449172 chr4 9966036 A T 1 Drug response to Etoposide SLC2A9 intron 17537913 rs6449172 chr4 9966036 A T 1.31E-70 Uric acid levels SLC2A9 intron 19503597 rs6449172 chr4 9966036 A T 1.50E-80 Urate levels SLC2A9 intron 20884846 rs6449172 chr4 9966036 A T 3.84E-243 Urate levels SLC2A9 intron 23263486 rs6449173 chr4 9966105 T G 8.10E-189 Uric acid levels SLC2A9 intron 19503597 rs6449173 chr4 9966105 T G 6.50E-229 Urate levels SLC2A9 intron 20884846 rs6449173 chr4 9966105 T G 7.34E-16 Urate levels SLC2A9 intron 21768215 rs6449173 chr4 9966105 T G 5.38E-25 Urate levels SLC2A9 intron 23263486 rs6847019 chr4 9966249 C T 1.44E-14 Uric acid levels SLC2A9 intron 19503597 rs6847019 chr4 9966249 C T 4.20E-19 Urate levels SLC2A9 intron 20884846 rs6847019 chr4 9966249 C T 3.14E-10 Urate levels SLC2A9 intron 21768215 rs6847019 chr4 9966249 C T 2.62E-53 Urate levels SLC2A9 intron 23263486 rs7442295 chr4 9966380 A G 7.68E-16 Serum uric acid levels SLC2A9 intron 17997608 rs7442295 chr4 9966380 A G 2.00E-15 Urate levels SLC2A9 intron 18179892 rs7442295 chr4 9966380 A G 3.00E-70 Urate levels SLC2A9 intron 18327256 rs7442295 chr4 9966380 A G 5.14E-196 Uric acid levels SLC2A9 intron 19503597 rs7442295 chr4 9966380 A G 9.90E-229 Urate levels SLC2A9 intron 20884846 rs7442295 chr4 9966380 A G 4.01E-16 Urate levels SLC2A9 intron 21768215 rs7442295 chr4 9966380 A G 5.98E-41 Cardiovascular disease risk factors SLC2A9 intron 21943158 rs7442295 chr4 9966380 A G 7.19E-25 Urate levels SLC2A9 intron 23263486 rs6449174 chr4 9966422 C T 1 Drug response to Etoposide SLC2A9 intron 17537913 rs6449174 chr4 9966422 C T 2.35E-70 Uric acid levels SLC2A9 intron 19503597 rs6449174 chr4 9966422 C T 1.10E-80 Urate levels SLC2A9 intron 20884846 rs6449174 chr4 9966422 C T 8.66E-05 Schizophrenia(age at onset) SLC2A9 intron 21688384 rs6449174 chr4 9966422 C T 6.85E-243 Urate levels SLC2A9 intron 23263486 rs9998811 chr4 9966477 G A 1.33E-200 Uric acid levels SLC2A9 intron 19503597 rs9998811 chr4 9966477 G A 7.10E-229 Urate levels SLC2A9 intron 20884846 rs9998811 chr4 9966477 G A 1.01E-13 Urate levels SLC2A9 intron 21768215 rs9998811 chr4 9966477 G A 5.49E-25 Urate levels SLC2A9 intron 23263486 rs7658170 chr4 9966593 T C 1 Drug response to Etoposide SLC2A9 intron 17537913 rs7658170 chr4 9966593 T C 1.20E-07 Serum uric acid levels SLC2A9 intron 17997608 rs7658170 chr4 9966593 T C 9.12E-04 Alzheimer's disease SLC2A9 intron 17998437 rs7658170 chr4 9966593 T C 5.23E-70 Uric acid levels SLC2A9 intron 19503597 rs7658170 chr4 9966593 T C 7.10E-81 Urate levels SLC2A9 intron 20884846 rs7658170 chr4 9966593 T C 6.51E-05 Schizophrenia(age at onset) SLC2A9 intron 21688384 rs7658170 chr4 9966593 T C 2.79E-242 Urate levels SLC2A9 intron 23263486 rs6449175 chr4 9966610 T C 3.27E-15 Uric acid levels SLC2A9 intron 19503597 rs6449175 chr4 9966610 T C 1.60E-19 Urate levels SLC2A9 intron 20884846 rs6449175 chr4 9966610 T C 3.16E-10 Urate levels SLC2A9 intron 21768215 rs6449175 chr4 9966610 T C 2.23E-54 Urate levels SLC2A9 intron 23263486 rs7663097 chr4 9966791 T C 3.52E-76 Uric acid levels SLC2A9 intron 19503597 rs7663097 chr4 9966791 T C 1.80E-91 Urate levels SLC2A9 intron 20884846 rs7663097 chr4 9966791 T C 3.71E-11 Urate levels SLC2A9 intron 21768215 rs7663097 chr4 9966791 T C 1.35E-249 Urate levels SLC2A9 intron 23263486 rs7676733 chr4 9966956 G A 1 Drug response to Etoposide SLC2A9 intron 17537913 rs7676733 chr4 9966956 G A 1.20E-70 Uric acid levels SLC2A9 intron 19503597 rs7676733 chr4 9966956 G A 7.20E-81 Urate levels SLC2A9 intron 20884846 rs7676733 chr4 9966956 G A 2.02E-243 Urate levels SLC2A9 intron 23263486 rs10017674 chr4 9967053 T C 1 Drug response to Etoposide SLC2A9 intron 17537913 rs10017674 chr4 9967053 T C 2.14E-66 Uric acid levels SLC2A9 intron 19503597 rs10017674 chr4 9967053 T C 8.00E-78 Urate levels SLC2A9 intron 20884846 rs10017674 chr4 9967053 T C 3.77E-206 Urate levels SLC2A9 intron 23263486 rs7435196 chr4 9967556 A C 1 Drug response to Etoposide SLC2A9 intron 17537913 rs7435196 chr4 9967556 A C 9.66E-71 Uric acid levels SLC2A9 intron 19503597 rs7435196 chr4 9967556 A C 3.90E-81 Urate levels SLC2A9 intron 20884846 rs7435196 chr4 9967556 A C 6.06E-10 Urate levels SLC2A9 intron 21768215 rs7435196 chr4 9967556 A C 1.07E-243 Urate levels SLC2A9 intron 23263486 rs6449176 chr4 9967843 G A 1 Drug response to Etoposide SLC2A9 intron 17537913 rs6449176 chr4 9967843 G A 1.29E-70 Uric acid levels SLC2A9 intron 19503597 rs6449176 chr4 9967843 G A 4.10E-81 Urate levels SLC2A9 intron 20884846 rs6449176 chr4 9967843 G A 9.35E-244 Urate levels SLC2A9 intron 23263486 rs6449178 chr4 9968684 C T 1 Drug response to Etoposide SLC2A9 intron 17537913 rs6449178 chr4 9968684 C T 9.77E-08 Serum uric acid levels SLC2A9 intron 17997608 rs6449178 chr4 9968684 C T 2.56E-70 Uric acid levels SLC2A9 intron 19503597 rs6449178 chr4 9968684 C T 1.90E-243 Urate levels SLC2A9 intron 23263486 rs6449179 chr4 9969117 G A 1 Drug response to Etoposide SLC2A9 intron 17537913 rs6449179 chr4 9969117 G A 9.88E-71 Uric acid levels SLC2A9 intron 19503597 rs6449179 chr4 9969117 G A 4.50E-81 Urate levels SLC2A9 intron 20884846 rs6449179 chr4 9969117 G A 2.45E-243 Urate levels SLC2A9 intron 23263486 rs7677710 chr4 9969517 T G 1 Drug response to Etoposide SLC2A9 intron 17537913 rs7677710 chr4 9969517 T G 1.11E-70 Uric acid levels SLC2A9 intron 19503597 rs7677710 chr4 9969517 T G 3.40E-81 Urate levels SLC2A9 intron 20884846 rs7677710 chr4 9969517 T G 1.25E-243 Urate levels SLC2A9 intron 23263486 rs7683283 chr4 9969974 T C 1.44E-70 Uric acid levels SLC2A9 intron 19503597 rs7683283 chr4 9969974 T C 3.00E-81 Urate levels SLC2A9 intron 20884846 rs7683283 chr4 9969974 T C 4.40E-243 Urate levels SLC2A9 intron 23263486 rs7376960 chr4 9970570 A G 4.04E-197 Uric acid levels SLC2A9 intron 19503597 rs7376960 chr4 9970570 A G 1.30E-228 Urate levels SLC2A9 intron 20884846 rs7376960 chr4 9970570 A G 1.66E-11 Urate levels SLC2A9 intron 21768215 rs7376960 chr4 9970570 A G 1.28E-24 Urate levels SLC2A9 intron 23263486 rs6449183 chr4 9970691 C A 9.44E-78 Uric acid levels SLC2A9 intron 19503597 rs6449183 chr4 9970691 C A 2.60E-93 Urate levels SLC2A9 intron 20884846 rs6449183 chr4 9970691 C A 1.55E-229 Urate levels SLC2A9 intron 23263486 rs4292328 chr4 9970962 C T 2.54E-84 Uric acid levels SLC2A9 intron 19503597 rs4292328 chr4 9970962 C T 2.10E-100 Urate levels SLC2A9 intron 20884846 rs4292328 chr4 9970962 C T 6.54E-18 Urate levels SLC2A9 intron 21768215 rs4292328 chr4 9970962 C T 6.65E-08 Urate levels SLC2A9 intron 23263486 rs4473653 chr4 9971058 A G 1 Drug response to Etoposide SLC2A9 intron 17537913 rs4473653 chr4 9971058 A G 3.85E-70 Uric acid levels SLC2A9 intron 19503597 rs4473653 chr4 9971058 A G 9.50E-81 Urate levels SLC2A9 intron 20884846 rs4473653 chr4 9971058 A G 3.97E-242 Urate levels SLC2A9 intron 23263486 rs7439210 chr4 9971749 C G 6.73E-187 Uric acid levels SLC2A9 intron 19503597 rs7439210 chr4 9971749 C G 4.40E-217 Urate levels SLC2A9 intron 20884846 rs7439210 chr4 9971749 C G 2.07E-16 Urate levels SLC2A9 intron 21768215 rs7439210 chr4 9971749 C G 9.68E-23 Urate levels SLC2A9 intron 23263486 rs13132625 chr4 9972163 C A 3.10E-11 Urate levels SLC2A9 intron 20884846 rs13132625 chr4 9972163 C A 1.64E-18 Urate levels SLC2A9 intron 23263486 rs13103690 chr4 9972778 T G 3.60E-77 Uric acid levels SLC2A9 intron 19503597 rs13103690 chr4 9972778 T G 3.30E-93 Urate levels SLC2A9 intron 20884846 rs13103690 chr4 9972778 T G 1.52E-16 Urate levels SLC2A9 intron 21768215 rs13103690 chr4 9972778 T G 2.99E-265 Urate levels SLC2A9 intron 23263486 rs13103879 chr4 9972879 T C 1 Drug response to Etoposide SLC2A9 intron 17537913 rs13103879 chr4 9972879 T C 2.60E-77 Uric acid levels SLC2A9 intron 19503597 rs13103879 chr4 9972879 T C 3.60E-93 Urate levels SLC2A9 intron 20884846 rs13103879 chr4 9972879 T C 2.79E-11 Urate levels SLC2A9 intron 21768215 rs13103879 chr4 9972879 T C 8.61E-244 Urate levels SLC2A9 intron 23263486 rs6852441 chr4 9973744 C T 1 Drug response to Etoposide SLC2A9 intron 17537913 rs6852441 chr4 9973744 C T 4.07E-71 Uric acid levels SLC2A9 intron 19503597 rs6852441 chr4 9973744 C T 1.70E-81 Urate levels SLC2A9 intron 20884846 rs6852441 chr4 9973744 C T 1.72E-242 Urate levels SLC2A9 intron 23263486 rs6449201 chr4 9973894 C T 1 Drug response to Etoposide SLC2A9 intron 17537913 rs6449201 chr4 9973894 C T 1.97E-70 Uric acid levels SLC2A9 intron 19503597 rs6449201 chr4 9973894 C T 1.70E-81 Urate levels SLC2A9 intron 20884846 rs6449201 chr4 9973894 C T 1.74E-242 Urate levels SLC2A9 intron 23263486 rs6449202 chr4 9974043 T C 2.82E-70 Uric acid levels SLC2A9 intron 19503597 rs6449202 chr4 9974043 T C 1.70E-81 Urate levels SLC2A9 intron 20884846 rs6449202 chr4 9974043 T C 2.82E-10 Urate levels SLC2A9 intron 21768215 rs6449202 chr4 9974043 T C 2.70E-222 Urate levels SLC2A9 intron 23263486 rs1071988 chr4 9974638 A G 1.31E-185 Uric acid levels SLC2A9 intron 19503597 rs1071988 chr4 9974638 A G 1.30E-217 Urate levels SLC2A9 intron 20884846 rs1071988 chr4 9974638 A G 3.54E-27 Urate levels SLC2A9 intron 21768215 rs1071988 chr4 9974638 A G 1.03E-22 Urate levels SLC2A9 intron 23263486 rs4505821 chr4 9978094 G A 6.99E-15 Uric acid levels SLC2A9 intron 19503597 rs4505821 chr4 9978094 G A 1.80E-20 Urate levels SLC2A9 intron 20884846 rs4505821 chr4 9978094 G A 4.12E-10 Urate levels SLC2A9 intron 21768215 rs4505821 chr4 9978094 G A 7.90E-55 Urate levels SLC2A9 intron 23263486 rs16868246 chr4 9978305 C G 5.83E-186 Uric acid levels SLC2A9 intron 19503597 rs16868246 chr4 9978305 C G 2.60E-217 Urate levels SLC2A9 intron 20884846 rs16868246 chr4 9978305 C G 1.26E-27 Urate levels SLC2A9 intron 21768215 rs16868246 chr4 9978305 C G 1.05E-22 Urate levels SLC2A9 intron 23263486 rs16868246 chr4 9978305 C G 2.00E-14 Blood metabolite levels SLC2A9 intron 24816252 rs13103497 chr4 9979262 A G 1.08E-64 Uric acid levels SLC2A9 intron 19503597 rs13103497 chr4 9979262 A G 5.40E-79 Urate levels SLC2A9 intron 20884846 rs13103497 chr4 9979262 A G 7.12E-213 Urate levels SLC2A9 intron 23263486 rs13144899 chr4 9979302 C T 9.51E-09 Uric acid levels SLC2A9 intron 19503597 rs13144899 chr4 9979302 C T 1.40E-11 Urate levels SLC2A9 intron 20884846 rs13144899 chr4 9979302 C T 5.12E-19 Urate levels SLC2A9 intron 23263486 rs13125476 chr4 9979614 G A 1.40E-11 Urate levels SLC2A9 intron 20884846 rs13125476 chr4 9979614 G A 7.74E-19 Urate levels SLC2A9 intron 23263486 rs11723970 chr4 9980462 T C 1.96E-86 Uric acid levels SLC2A9 intron 19503597 rs11723970 chr4 9980462 T C 4.40E-106 Urate levels SLC2A9 intron 20884846 rs11723970 chr4 9980462 T C 2.42E-18 Urate levels SLC2A9 intron 21768215 rs11723970 chr4 9980462 T C 9.59E-290 Urate levels SLC2A9 intron 23263486 rs11723970 chr4 9980462 T C 4.67E-05 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs11723970 chr4 9980462 T C 8.14E-06 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs11722229 chr4 9980697 C A 1.19E-166 Uric acid levels SLC2A9 intron 19503597 rs11722229 chr4 9980697 C A 7.40E-215 Urate levels SLC2A9 intron 20884846 rs11722229 chr4 9980697 C A 3.41E-27 Urate levels SLC2A9 intron 21768215 rs11722229 chr4 9980697 C A 2.28E-22 Urate levels SLC2A9 intron 23263486 rs882223 chr4 9981625 A C 4.02E-85 Uric acid levels SLC2A9 intron 19503597 rs882223 chr4 9981625 A C 1.90E-99 Urate levels SLC2A9 intron 20884846 rs882223 chr4 9981625 A C 2.10E-18 Urate levels SLC2A9 intron 21768215 rs882223 chr4 9981625 A C 7.02E-09 Urate levels SLC2A9 intron 23263486 rs4364264 chr4 9981683 C T 9.42E-18 Urate levels SLC2A9 intron 23263486 rs13131257 chr4 9981889 T C 2.94E-185 Uric acid levels SLC2A9 intron 19503597 rs13131257 chr4 9981889 T C 5.00E-213 Urate levels SLC2A9 intron 20884846 rs13131257 chr4 9981889 T C 3.25E-27 Urate levels SLC2A9 intron 21768215 rs13131257 chr4 9981889 T C 3.87E-22 Urate levels SLC2A9 intron 23263486 rs13131257 chr4 9981889 T C 8.10E-08 Serum uric acid levels SLC2A9 intron 24379826 rs13145758 chr4 9981997 G A 3.35E-184 Uric acid levels SLC2A9 intron 19503597 rs13145758 chr4 9981997 G A 1.40E-211 Urate levels SLC2A9 intron 20884846 rs13145758 chr4 9981997 G A 4.08E-20 Urate levels SLC2A9 intron 21768215 rs13145758 chr4 9981997 G A 6.48E-22 Urate levels SLC2A9 intron 23263486 rs13125029 chr4 9982029 A G 3.52E-61 Uric acid levels SLC2A9 intron 19503597 rs13125029 chr4 9982029 A G 6.30E-77 Urate levels SLC2A9 intron 20884846 rs13125029 chr4 9982029 A G 2.83E-194 Urate levels SLC2A9 intron 23263486 rs13125209 chr4 9982044 A C 4.70E-155 Uric acid levels SLC2A9 intron 19503597 rs13125209 chr4 9982044 A C 1.30E-199 Urate levels SLC2A9 intron 20884846 rs13125209 chr4 9982044 A C 4.21E-21 Urate levels SLC2A9 intron 23263486 rs13115193 chr4 9982191 C T 9.19E-78 Uric acid levels SLC2A9 intron 19503597 rs13115193 chr4 9982191 C T 8.20E-99 Urate levels SLC2A9 intron 20884846 rs13115193 chr4 9982191 C T 4.22E-16 Urate levels SLC2A9 intron 21768215 rs13115193 chr4 9982191 C T 2.35E-265 Urate levels SLC2A9 intron 23263486 rs13125646 chr4 9982330 A G 5.37E-137 Uric acid levels SLC2A9 cds-synon 19503597 rs13125646 chr4 9982330 A G 1.20E-192 Urate levels SLC2A9 cds-synon 20884846 rs13125646 chr4 9982330 A G 4.42E-19 Urate levels SLC2A9 cds-synon 23263486 rs10003001 chr4 9984475 C T 1.15E-14 Uric acid levels SLC2A9 intron 19503597 rs10003001 chr4 9984475 C T 2.00E-20 Urate levels SLC2A9 intron 20884846 rs10003001 chr4 9984475 C T 7.42E-10 Urate levels SLC2A9 intron 21768215 rs10003001 chr4 9984475 C T 3.98E-55 Urate levels SLC2A9 intron 23263486 rs10033612 chr4 9985006 C T 9.22E-15 Uric acid levels SLC2A9 intron 19503597 rs10033612 chr4 9985006 C T 1.20E-20 Urate levels SLC2A9 intron 20884846 rs10033612 chr4 9985006 C T 4.44E-10 Urate levels SLC2A9 intron 21768215 rs10033612 chr4 9985006 C T 2.96E-55 Urate levels SLC2A9 intron 23263486 rs11723591 chr4 9985398 T A 3.50E-80 Uric acid levels SLC2A9 intron 19503597 rs11723591 chr4 9985398 T A 1.00E-100 Urate levels SLC2A9 intron 20884846 rs11723591 chr4 9985398 T A 5.58E-16 Urate levels SLC2A9 intron 21768215 rs11723591 chr4 9985398 T A 2.59E-265 Urate levels SLC2A9 intron 23263486 rs7660895 chr4 9985445 A G 1.77E-180 Uric acid levels SLC2A9 intron 19503597 rs7660895 chr4 9985445 A G 2.80E-230 Urate levels SLC2A9 intron 20884846 rs7660895 chr4 9985445 A G 5.62E-21 Urate levels SLC2A9 intron 21768215 rs7660895 chr4 9985445 A G 3.39E-23 Urate levels SLC2A9 intron 23263486 rs7680126 chr4 9985596 G A 2.75E-11 Serum uric acid levels SLC2A9 intron 17997608 rs7680126 chr4 9985596 G A 1.07E-186 Uric acid levels SLC2A9 intron 19503597 rs7680126 chr4 9985596 G A 6.70E-225 Urate levels SLC2A9 intron 20884846 rs7680126 chr4 9985596 G A 4.45E-12 Urate levels SLC2A9 intron 21768215 rs7680126 chr4 9985596 G A 3.95E-23 Urate levels SLC2A9 intron 23263486 rs17246501 chr4 9985710 A C 1.54E-08 Serum uric acid levels SLC2A9 intron 17997608 rs17246501 chr4 9985710 A C 3.30E-81 Uric acid levels SLC2A9 intron 19503597 rs17246501 chr4 9985710 A C 7.00E-101 Urate levels SLC2A9 intron 20884846 rs17246501 chr4 9985710 A C 7.75E-05 Schizophrenia(age at onset) SLC2A9 intron 21688384 rs17246501 chr4 9985710 A C 1.15E-14 Urate levels SLC2A9 intron 21768215 rs17246501 chr4 9985710 A C 1.44E-287 Urate levels SLC2A9 intron 23263486 rs9992406 chr4 9986288 C T 6.08E-13 Uric acid levels SLC2A9 intron 19503597 rs9992406 chr4 9986288 C T 1.50E-20 Urate levels SLC2A9 intron 20884846 rs9992406 chr4 9986288 C T 7.73E-55 Urate levels SLC2A9 intron 23263486 rs6849736 chr4 9986783 G A 4.70E-09 Urate levels SLC2A9 intron 20884846 rs6849736 chr4 9986783 G A 1.81E-08 Urate levels SLC2A9 intron 21768215 rs6849736 chr4 9986783 G A 3.12E-17 Urate levels SLC2A9 intron 23263486 rs6836200 chr4 9986915 T C 5.30E-09 Urate levels SLC2A9 intron 20884846 rs6836200 chr4 9986915 T C 1.70E-16 Urate levels SLC2A9 intron 23263486 rs3733590 chr4 9987226 T C 5.30E-09 Urate levels SLC2A9 intron 20884846 rs3733590 chr4 9987226 T C 1.94E-08 Urate levels SLC2A9 intron 21768215 rs3733590 chr4 9987226 T C 5.34E-17 Urate levels SLC2A9 intron 23263486 rs4385059 chr4 9989233 C T 5.75E-182 Uric acid levels SLC2A9 intron 19503597 rs4385059 chr4 9989233 C T 1.60E-228 Urate levels SLC2A9 intron 20884846 rs4385059 chr4 9989233 C T 6.25E-10 Urate levels SLC2A9 intron 21768215 rs4385059 chr4 9989233 C T 2.82E-22 Urate levels SLC2A9 intron 23263486 rs4502681 chr4 9990172 T C 7.20E-13 Urate levels SLC2A9 intron 20884846 rs4502681 chr4 9990172 T C 5.58E-20 Urate levels SLC2A9 intron 23263486 rs17187075 chr4 9990328 G C 9.13E-72 Uric acid levels SLC2A9 intron 19503597 rs17187075 chr4 9990328 G C 2.90E-93 Urate levels SLC2A9 intron 20884846 rs17187075 chr4 9990328 G C 1.10E-10 Urate levels SLC2A9 intron 21768215 rs17187075 chr4 9990328 G C 8.78E-250 Urate levels SLC2A9 intron 23263486 rs17187075 chr4 9990328 G C 1.38E-06 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs17187075 chr4 9990328 G C 8.22E-06 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs10011206 chr4 9991955 C T 7.69E-15 Uric acid levels SLC2A9 intron 19503597 rs10011206 chr4 9991955 C T 2.80E-20 Urate levels SLC2A9 intron 20884846 rs10011206 chr4 9991955 C T 2.82E-55 Urate levels SLC2A9 intron 23263486 rs7678012 chr4 9993772 T C 6.06E-72 Uric acid levels SLC2A9 intron 19503597 rs7678012 chr4 9993772 T C 1.70E-93 Urate levels SLC2A9 intron 20884846 rs7678012 chr4 9993772 T C 3.87E-12 Urate levels SLC2A9 intron 21768215 rs7678012 chr4 9993772 T C 2.40E-250 Urate levels SLC2A9 intron 23263486 rs7663032 chr4 9993838 C T 3.34E-97 Uric acid levels SLC2A9 intron 19503597 rs7663032 chr4 9993838 C T 6.30E-160 Urate levels SLC2A9 intron 20884846 rs7663032 chr4 9993838 C T 1.09E-08 Uric acid levels SLC2A9 intron 21294900 rs7663032 chr4 9993838 C T 1.17E-30 Urate levels SLC2A9 intron 21768215 rs7663032 chr4 9993838 C T 3.78E-04 Alzheimer's disease SLC2A9 intron 22005930 rs7663032 chr4 9993838 C T 9.01E-19 Urate levels SLC2A9 intron 23263486 rs6449213 chr4 9994215 C T 1.29E-13 Serum uric acid levels SLC2A9 intron 17997608 rs6449213 chr4 9994215 C T 4.79E-186 Uric acid levels SLC2A9 intron 19503597 rs6449213 chr4 9994215 C T 3.80E-228 Urate levels SLC2A9 intron 20884846 rs6449213 chr4 9994215 C T 8.38E-07 Uric acid levels SLC2A9 intron 21294900 rs6449213 chr4 9994215 C T 2.84E-14 Urate levels SLC2A9 intron 21768215 rs6449213 chr4 9994215 C T 4.71E-22 Urate levels SLC2A9 intron 23263486 rs6449213 chr4 9994215 C T 2.00E-07 Uric acid levels SLC2A9 intron 23703922 rs6449213 chr4 9994215 C T 3.00E-12 Uric acid levels SLC2A9 intron 23703922 rs6449213 chr4 9994215 C T 5.70E-06 Serum uric acid levels SLC2A9 intron 24379826 rs3775948 chr4 9995182 G C 4.23E-180 Uric acid levels SLC2A9 intron 19503597 rs3775948 chr4 9995182 G C 2.80E-233 Urate levels SLC2A9 intron 20884846 rs3775948 chr4 9995182 G C 1.00E-09 Uric acid levels SLC2A9 intron 21294900 rs3775948 chr4 9995182 G C 1.68E-30 Urate levels SLC2A9 intron 21768215 rs3775948 chr4 9995182 G C 3.42E-04 Alzheimer's disease SLC2A9 intron 22005930 rs3775948 chr4 9995182 G C 2.00E-65 Renal function-related traits (urea) SLC2A9 intron 22797727 rs3775948 chr4 9995182 G C 9.71E-22 Urate levels SLC2A9 intron 23263486 rs12499857 chr4 9995376 G A 1.40E-70 Uric acid levels SLC2A9 intron 19503597 rs12499857 chr4 9995376 G A 1.30E-89 Urate levels SLC2A9 intron 20884846 rs12499857 chr4 9995376 G A 8.15E-16 Urate levels SLC2A9 intron 21768215 rs12499857 chr4 9995376 G A 6.34E-243 Urate levels SLC2A9 intron 23263486 rs12499857 chr4 9995376 G A 1.36E-06 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs12499857 chr4 9995376 G A 8.57E-06 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs3796842 chr4 9995851 A T 4.17E-73 Uric acid levels SLC2A9 intron 19503597 rs3796842 chr4 9995851 A T 1.30E-93 Urate levels SLC2A9 intron 20884846 rs3796842 chr4 9995851 A T 4.91E-12 Urate levels SLC2A9 intron 21768215 rs3796842 chr4 9995851 A T 6.82E-253 Urate levels SLC2A9 intron 23263486 rs9998739 chr4 9996509 G A 9.18E-15 Uric acid levels SLC2A9 intron 19503597 rs9998739 chr4 9996509 G A 3.00E-20 Urate levels SLC2A9 intron 20884846 rs9998739 chr4 9996509 G A 1.60E-55 Urate levels SLC2A9 intron 23263486 rs13111638 chr4 9996890 T C 4.85E-12 Serum uric acid levels SLC2A9 intron 17997608 rs13111638 chr4 9996890 T C 2.86E-168 Uric acid levels SLC2A9 intron 19503597 rs13111638 chr4 9996890 T C 2.80E-232 Urate levels SLC2A9 intron 20884846 rs13111638 chr4 9996890 T C 4.04E-10 Uric acid levels SLC2A9 intron 21294900 rs13111638 chr4 9996890 T C 3.65E-16 Urate levels SLC2A9 intron 21768215 rs13111638 chr4 9996890 T C 5.58E-22 Urate levels SLC2A9 intron 23263486 rs4547795 chr4 9997060 C T 4.78E-14 Uric acid levels SLC2A9 intron 19503597 rs4547795 chr4 9997060 C T 2.00E-20 Urate levels SLC2A9 intron 20884846 rs4547795 chr4 9997060 C T 4.87E-55 Urate levels SLC2A9 intron 23263486 rs4529048 chr4 9997112 C A 7.27E-11 Serum uric acid levels SLC2A9 intron 17997608 rs4529048 chr4 9997112 C A 4.15E-175 Uric acid levels SLC2A9 intron 19503597 rs4529048 chr4 9997112 C A 5.20E-236 Urate levels SLC2A9 intron 20884846 rs4529048 chr4 9997112 C A 3.04E-07 Uric acid levels SLC2A9 intron 21294900 rs4529048 chr4 9997112 C A 1.29E-28 Urate levels SLC2A9 intron 21768215 rs4529048 chr4 9997112 C A 4.13E-04 Alzheimer's disease SLC2A9 intron 22005930 rs4529048 chr4 9997112 C A 1.58E-21 Urate levels SLC2A9 intron 23263486 rs3733588 chr4 9997303 G A 2.97E-11 Serum uric acid levels SLC2A9 intron 17997608 rs3733588 chr4 9997303 G A 9.94E-181 Uric acid levels SLC2A9 intron 19503597 rs3733588 chr4 9997303 G A 6.60E-237 Urate levels SLC2A9 intron 20884846 rs3733588 chr4 9997303 G A 7.16E-07 Uric acid levels SLC2A9 intron 21294900 rs3733588 chr4 9997303 G A 4.22E-29 Urate levels SLC2A9 intron 21768215 rs3733588 chr4 9997303 G A 3.27E-04 Alzheimer's disease SLC2A9 intron 22005930 rs3733588 chr4 9997303 G A 5.71E-22 Urate levels SLC2A9 intron 23263486 rs3733587 chr4 9997434 A G 7.06E-15 Uric acid levels SLC2A9 intron 19503597 rs3733587 chr4 9997434 A G 1.60E-20 Urate levels SLC2A9 intron 20884846 rs3733587 chr4 9997434 A G 8.42E-56 Urate levels SLC2A9 intron 23263486 rs7669607 chr4 9997801 T C 2.87E-14 Serum uric acid levels SLC2A9 intron 17997608 rs7669607 chr4 9997801 T C 3.56E-187 Uric acid levels SLC2A9 intron 19503597 rs7669607 chr4 9997801 T C 1.10E-235 Urate levels SLC2A9 intron 20884846 rs7669607 chr4 9997801 T C 1.79E-06 Uric acid levels SLC2A9 intron 21294900 rs7669607 chr4 9997801 T C 2.79E-18 Urate levels SLC2A9 intron 21768215 rs7669607 chr4 9997801 T C 5.85E-23 Urate levels SLC2A9 intron 23263486 rs16891971 chr4 9998376 C A 2.07E-18 Urate levels SLC2A9 intron 21768215 rs16891971 chr4 9998376 C A 1.48E-15 Urate levels SLC2A9 intron 23263486 rs10939650 chr4 9998440 C T 1.33E-180 Uric acid levels SLC2A9 cds-synon 19503597 rs10939650 chr4 9998440 C T 3.30E-237 Urate levels SLC2A9 cds-synon 20884846 rs10939650 chr4 9998440 C T 3.89E-07 Uric acid levels SLC2A9 cds-synon 21294900 rs10939650 chr4 9998440 C T 1.09E-29 Urate levels SLC2A9 cds-synon 21768215 rs10939650 chr4 9998440 C T 3.58E-04 Alzheimer's disease SLC2A9 cds-synon 22005930 rs10939650 chr4 9998440 C T 1.35E-22 Urate levels SLC2A9 cds-synon 23263486 rs10939650 chr4 9998440 C T 1.22E-05 Cleft palate (environmental tobacco smoke interaction) SLC2A9 cds-synon 24516586 rs10939650 chr4 9998440 C T 3.91E-05 Cleft palate (environmental tobacco smoke interaction) SLC2A9 cds-synon 24516586 rs13113918 chr4 9998493 A G 1.05E-99 Uric acid levels SLC2A9 cds-synon 19503597 rs13113918 chr4 9998493 A G 1.60E-162 Urate levels SLC2A9 cds-synon 20884846 rs13113918 chr4 9998493 A G 8.13E-08 Uric acid levels SLC2A9 cds-synon 21294900 rs13113918 chr4 9998493 A G 1.23E-29 Urate levels SLC2A9 cds-synon 21768215 rs13113918 chr4 9998493 A G 1.42E-19 Urate levels SLC2A9 cds-synon 23263486 rs10008035 chr4 9999335 G T 3.40E-14 Uric acid levels SLC2A9 intron 19503597 rs10008035 chr4 9999335 G T 1.70E-20 Urate levels SLC2A9 intron 20884846 rs10008035 chr4 9999335 G T 5.68E-56 Urate levels SLC2A9 intron 23263486 rs7696536 chr4 10000236 G T 6.53E-15 Uric acid levels SLC2A9 intron 19503597 rs7696536 chr4 10000236 G T 1.70E-20 Urate levels SLC2A9 intron 20884846 rs7696536 chr4 10000236 G T 4.34E-56 Urate levels SLC2A9 intron 23263486 rs1014290 chr4 10001861 G A 2.33E-181 Uric acid levels SLC2A9 intron 19503597 rs1014290 chr4 10001861 G A 8.90E-237 Urate levels SLC2A9 intron 20884846 rs1014290 chr4 10001861 G A 2.41E-06 Uric acid levels SLC2A9 intron 21294900 rs1014290 chr4 10001861 G A 2.57E-25 Urate levels SLC2A9 intron 21768215 rs1014290 chr4 10001861 G A 3.71E-04 Alzheimer's disease SLC2A9 intron 22005930 rs1014290 chr4 10001861 G A 1.08E-22 Urate levels SLC2A9 intron 23263486 rs7696895 chr4 10002425 T C 3.52E-14 Uric acid levels SLC2A9 intron 19503597 rs7696895 chr4 10002425 T C 1.80E-20 Urate levels SLC2A9 intron 20884846 rs7696895 chr4 10002425 T C 1.14E-55 Urate levels SLC2A9 intron 23263486 rs9991278 chr4 10002665 T C 4.89E-182 Uric acid levels SLC2A9 intron 19503597 rs9991278 chr4 10002665 T C 4.90E-236 Urate levels SLC2A9 intron 20884846 rs9991278 chr4 10002665 T C 1.21E-06 Uric acid levels SLC2A9 intron 21294900 rs9991278 chr4 10002665 T C 2.26E-24 Urate levels SLC2A9 intron 21768215 rs9991278 chr4 10002665 T C 3.49E-23 Urate levels SLC2A9 intron 23263486 rs4622999 chr4 10003395 C G 1.03E-72 Uric acid levels SLC2A9 intron 19503597 rs4622999 chr4 10003395 C G 2.50E-94 Urate levels SLC2A9 intron 20884846 rs4622999 chr4 10003395 C G 1.42E-08 Urate levels SLC2A9 intron 21768215 rs4622999 chr4 10003395 C G 1.38E-234 Urate levels SLC2A9 intron 23263486 rs4622999 chr4 10003395 C G 1.28E-06 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs4622999 chr4 10003395 C G 8.08E-06 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs7657096 chr4 10004000 A G 1.60E-09 Urate levels SLC2A9 intron 20884846 rs7657096 chr4 10004000 A G 9.25E-16 Urate levels SLC2A9 intron 23263486 rs7657096 chr4 10004000 A G 2.03E-05 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs7657096 chr4 10004000 A G 7.74E-05 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs17247314 chr4 10004743 C G 1.94E-69 Uric acid levels SLC2A9 intron 19503597 rs17247314 chr4 10004743 C G 9.70E-93 Urate levels SLC2A9 intron 20884846 rs17247314 chr4 10004743 C G 9.09E-05 Schizophrenia(age at onset) SLC2A9 intron 21688384 rs17247314 chr4 10004743 C G 5.34E-14 Urate levels SLC2A9 intron 21768215 rs17247314 chr4 10004743 C G 2.28E-233 Urate levels SLC2A9 intron 23263486 rs10023068 chr4 10004832 A G 1.34E-121 Uric acid levels SLC2A9 intron 19503597 rs10023068 chr4 10004832 A G 8.30E-147 Urate levels SLC2A9 intron 20884846 rs10023068 chr4 10004832 A G 1.13E-21 Urate levels SLC2A9 intron 21768215 rs10023068 chr4 10004832 A G 3.55E-05 Alzheimer's disease SLC2A9 intron 22005930 rs10023068 chr4 10004832 A G 8.81E-16 Urate levels SLC2A9 intron 23263486 rs6853437 chr4 10005435 G A 1.76E-123 Uric acid levels SLC2A9 intron 19503597 rs6853437 chr4 10005435 G A 9.40E-147 Urate levels SLC2A9 intron 20884846 rs6853437 chr4 10005435 G A 2.46E-21 Urate levels SLC2A9 intron 21768215 rs6853437 chr4 10005435 G A 3.42E-05 Alzheimer's disease SLC2A9 intron 22005930 rs6853437 chr4 10005435 G A 4.69E-16 Urate levels SLC2A9 intron 23263486 rs10022499 chr4 10006537 C A 1.08E-121 Uric acid levels SLC2A9 intron 19503597 rs10022499 chr4 10006537 C A 4.70E-147 Urate levels SLC2A9 intron 20884846 rs10022499 chr4 10006537 C A 4.60E-22 Urate levels SLC2A9 intron 21768215 rs10022499 chr4 10006537 C A 3.30E-05 Alzheimer's disease SLC2A9 intron 22005930 rs10022499 chr4 10006537 C A 8.85E-16 Urate levels SLC2A9 intron 23263486 rs10022499 chr4 10006537 C A 1.60E-05 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs10022499 chr4 10006537 C A 5.87E-05 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs10016075 chr4 10006663 G T 2.15E-05 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs10016075 chr4 10006663 G T 8.24E-05 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs9291640 chr4 10007086 C T 1.14E-07 Serum uric acid levels SLC2A9 intron 17997608 rs9291640 chr4 10007086 C T 3.66E-122 Uric acid levels SLC2A9 intron 19503597 rs9291640 chr4 10007086 C T 4.60E-147 Urate levels SLC2A9 intron 20884846 rs9291640 chr4 10007086 C T 5.08E-22 Urate levels SLC2A9 intron 21768215 rs9291640 chr4 10007086 C T 3.98E-05 Alzheimer's disease SLC2A9 intron 22005930 rs9291640 chr4 10007086 C T 9.29E-16 Urate levels SLC2A9 intron 23263486 rs9291642 chr4 10007275 C T 8.33E-08 Serum uric acid levels SLC2A9 intron 17997608 rs9291642 chr4 10007275 C T 1.07E-126 Uric acid levels SLC2A9 intron 19503597 rs9291642 chr4 10007275 C T 1.70E-144 Urate levels SLC2A9 intron 20884846 rs9291642 chr4 10007275 C T 2.04E-14 Urate levels SLC2A9 intron 23263486 rs3796840 chr4 10008121 C T 1.05E-09 Urate levels SLC2A9 intron 21768215 rs4543113 chr4 10008305 G A 6.46E-57 Uric acid levels SLC2A9 intron 19503597 rs4543113 chr4 10008305 G A 3.70E-73 Urate levels SLC2A9 intron 20884846 rs4543113 chr4 10008305 G A 3.73E-202 Urate levels SLC2A9 intron 23263486 rs6845554 chr4 10013173 T G 1.27E-61 Uric acid levels SLC2A9 intron 19503597 rs6845554 chr4 10013173 T G 2.40E-76 Urate levels SLC2A9 intron 20884846 rs6845554 chr4 10013173 T G 2.36E-04 HIV-1 progression to AIDS and death SLC2A9 intron 21811574 rs6845554 chr4 10013173 T G 2.90E-05 HIV-1 progression to AIDS and death SLC2A9 intron 21811574 rs6845554 chr4 10013173 T G 5.96E-217 Urate levels SLC2A9 intron 23263486 rs3756236 chr4 10013463 T A 3.62E-69 Uric acid levels SLC2A9 intron 19503597 rs3756236 chr4 10013463 T A 1.60E-88 Urate levels SLC2A9 intron 20884846 rs3756236 chr4 10013463 T A 9.47E-12 Urate levels SLC2A9 intron 21768215 rs3756236 chr4 10013463 T A 5.46E-243 Urate levels SLC2A9 intron 23263486 rs6827754 chr4 10018153 C A 9.68E-04 Type 2 diabetes SLC2A9 intron 17463246 rs6827754 chr4 10018153 C A 9.58E-63 Uric acid levels SLC2A9 intron 19503597 rs6827754 chr4 10018153 C A 6.80E-76 Urate levels SLC2A9 intron 20884846 rs6827754 chr4 10018153 C A 7.38E-05 Schizophrenia(age at onset) SLC2A9 intron 21688384 rs6827754 chr4 10018153 C A 2.37E-04 HIV-1 progression to AIDS and death SLC2A9 intron 21811574 rs6827754 chr4 10018153 C A 2.97E-05 HIV-1 progression to AIDS and death SLC2A9 intron 21811574 rs6827754 chr4 10018153 C A 3.80E-216 Urate levels SLC2A9 intron 23263486 rs13128385 chr4 10019563 C G 1.24E-13 Urate levels SLC2A9 intron 23263486 rs13133766 chr4 10019732 C T 4.84E-70 Uric acid levels SLC2A9 intron 19503597 rs13133766 chr4 10019732 C T 1.80E-88 Urate levels SLC2A9 intron 20884846 rs13133766 chr4 10019732 C T 1.09E-11 Urate levels SLC2A9 intron 21768215 rs13133766 chr4 10019732 C T 1.50E-242 Urate levels SLC2A9 intron 23263486 rs3775942 chr4 10020307 G A 5.99E-14 Urate levels SLC2A9 intron 21768215 rs3775942 chr4 10020307 G A 8.39E-09 Urate levels SLC2A9 intron 23263486 rs2240720 chr4 10020480 C T 4.37E-70 Uric acid levels SLC2A9 intron 19503597 rs2240720 chr4 10020480 C T 2.60E-88 Urate levels SLC2A9 intron 20884846 rs2240720 chr4 10020480 C T 1.11E-11 Urate levels SLC2A9 intron 21768215 rs2240720 chr4 10020480 C T 1.84E-242 Urate levels SLC2A9 intron 23263486 rs2240721 chr4 10020564 G A 6.35E-65 Uric acid levels SLC2A9 intron 19503597 rs2240721 chr4 10020564 G A 4.10E-88 Urate levels SLC2A9 intron 20884846 rs2240721 chr4 10020564 G A 6.67E-13 Urate levels SLC2A9 intron 21768215 rs2240721 chr4 10020564 G A 2.75E-242 Urate levels SLC2A9 intron 23263486 rs2240723 chr4 10021151 G A 7.70E-14 Urate levels SLC2A9 intron 21768215 rs2240723 chr4 10021151 G A 1.46E-08 Urate levels SLC2A9 intron 23263486 rs2240723 chr4 10021151 G A 3.93E-05 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs2240723 chr4 10021151 G A 8.81E-06 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs2240724 chr4 10021290 G C 3.50E-68 Uric acid levels SLC2A9 intron 19503597 rs2240724 chr4 10021290 G C 1.90E-86 Urate levels SLC2A9 intron 20884846 rs2240724 chr4 10021290 G C 1.35E-11 Urate levels SLC2A9 intron 21768215 rs2240724 chr4 10021290 G C 4.64E-239 Urate levels SLC2A9 intron 23263486 rs13122112 chr4 10021404 G A 7.00E-14 Urate levels SLC2A9 intron 21768215 rs6849273 chr4 10021595 C G,T 7.47E-63 Uric acid levels SLC2A9 intron 19503597 rs6849273 chr4 10021595 C G,T 5.50E-75 Urate levels SLC2A9 intron 20884846 rs6849273 chr4 10021595 C G,T 1.88E-215 Urate levels SLC2A9 intron 23263486 rs13106922 chr4 10021759 A G 1.12E-13 Urate levels SLC2A9 intron 21768215 rs144053854 chr4 10022947 C T 0.00002 Breast cancer(er negative) SLC2A9 missense 23555315 rs12509955 chr4 10024303 T C 6.68E-155 Uric acid levels SLC2A9 intron 19503597 rs12509955 chr4 10024303 T C 1.30E-201 Urate levels SLC2A9 intron 20884846 rs12509955 chr4 10024303 T C 8.21E-18 Urate levels SLC2A9 intron 23263486 rs3775941 chr4 10025093 T A 1.42E-13 Urate levels SLC2A9 intron 21768215 rs3775940 chr4 10025163 T A 7.00E-64 Uric acid levels SLC2A9 intron 19503597 rs3775940 chr4 10025163 T A 2.70E-75 Urate levels SLC2A9 intron 20884846 rs3775940 chr4 10025163 T A 4.94E-05 Schizophrenia(age at onset) SLC2A9 intron 21688384 rs3775940 chr4 10025163 T A 1.25E-215 Urate levels SLC2A9 intron 23263486 rs3775939 chr4 10025296 C G 1.02E-13 Urate levels SLC2A9 intron 21768215 rs3756231 chr4 10025544 A G 2.84E-06 Uric acid levels SLC2A9 intron 21294900 rs3756231 chr4 10025544 A G 4.74E-08 Urate levels SLC2A9 intron 21768215 rs6826764 chr4 10030794 G C 1.26E-110 Uric acid levels SLC2A9 intron 19503597 rs6826764 chr4 10030794 G C 1.10E-137 Urate levels SLC2A9 intron 20884846 rs6826764 chr4 10030794 G C 2.48E-06 Uric acid levels SLC2A9 intron 21294900 rs6826764 chr4 10030794 G C 8.13E-18 Urate levels SLC2A9 intron 21768215 rs6826764 chr4 10030794 G C 1.31E-05 Alzheimer's disease SLC2A9 intron 22005930 rs6826764 chr4 10030794 G C 1.63E-15 Urate levels SLC2A9 intron 23263486 rs6856396 chr4 10031163 A T 5.92E-125 Uric acid levels SLC2A9 intron 19503597 rs6856396 chr4 10031163 A T 5.14E-06 Narcolepsy SLC2A9 intron 20711174 rs6856396 chr4 10031163 A T 7.40E-139 Urate levels SLC2A9 intron 20884846 rs6856396 chr4 10031163 A T 7.47E-06 Uric acid levels SLC2A9 intron 21294900 rs6856396 chr4 10031163 A T 2.62E-13 Urate levels SLC2A9 intron 21768215 rs6856396 chr4 10031163 A T 1.39E-13 Urate levels SLC2A9 intron 23263486 rs12506455 chr4 10031569 T A 6.35E-68 Uric acid levels SLC2A9 intron 19503597 rs12506455 chr4 10031569 T A 1.20E-87 Urate levels SLC2A9 intron 20884846 rs12506455 chr4 10031569 T A 7.73E-12 Urate levels SLC2A9 intron 21768215 rs12506455 chr4 10031569 T A 3.43E-239 Urate levels SLC2A9 intron 23263486 rs10939663 chr4 10032516 T G 1.13E-57 Uric acid levels SLC2A9 intron 19503597 rs10939663 chr4 10032516 T G 7.30E-61 Urate levels SLC2A9 intron 20884846 rs10939663 chr4 10032516 T G 3.08E-191 Urate levels SLC2A9 intron 23263486 rs13135351 chr4 10033525 G A 1.03E-09 Urate levels SLC2A9 intron 21768215 rs12506122 chr4 10033538 C A 2.19E-62 Uric acid levels SLC2A9 intron 19503597 rs12506122 chr4 10033538 C A 2.50E-76 Urate levels SLC2A9 intron 20884846 rs12506122 chr4 10033538 C A 5.82E-214 Urate levels SLC2A9 intron 23263486 rs13146686 chr4 10034933 T C 3.61E-60 Uric acid levels SLC2A9 intron 19503597 rs13146686 chr4 10034933 T C 2.70E-72 Urate levels SLC2A9 intron 20884846 rs13146686 chr4 10034933 T C 4.81E-05 Schizophrenia(age at onset) SLC2A9 intron 21688384 rs13146686 chr4 10034933 T C 5.76E-200 Urate levels SLC2A9 intron 23263486 rs11722930 chr4 10035454 G A 8.38E-68 Uric acid levels SLC2A9 intron 19503597 rs11722930 chr4 10035454 G A 6.40E-88 Urate levels SLC2A9 intron 20884846 rs11722930 chr4 10035454 G A 8.31E-12 Urate levels SLC2A9 intron 21768215 rs11722930 chr4 10035454 G A 5.85E-233 Urate levels SLC2A9 intron 23263486 rs16892419 chr4 10035702 C A 1.16E-09 Urate levels SLC2A9 intron 21768215 rs16892419 chr4 10035702 C A 4.15E-08 Urate levels SLC2A9 intron 23263486 rs16892420 chr4 10035715 G A 1.48E-09 Urate levels SLC2A9 intron 21768215 rs16892420 chr4 10035715 G A 1.88E-08 Urate levels SLC2A9 intron 23263486 rs10006397 chr4 10036140 C A 6.90E-111 Uric acid levels SLC2A9 intron 19503597 rs10006397 chr4 10036140 C A 5.90E-137 Urate levels SLC2A9 intron 20884846 rs10006397 chr4 10036140 C A 8.33E-18 Urate levels SLC2A9 intron 21768215 rs10006397 chr4 10036140 C A 7.13E-06 Alzheimer's disease SLC2A9 intron 22005930 rs10006397 chr4 10036140 C A 1.55E-15 Urate levels SLC2A9 intron 23263486 rs11727199 chr4 10036190 C T 6.18E-68 Uric acid levels SLC2A9 intron 19503597 rs11727199 chr4 10036190 C T 5.70E-88 Urate levels SLC2A9 intron 20884846 rs11727199 chr4 10036190 C T 8.81E-12 Urate levels SLC2A9 intron 21768215 rs11727199 chr4 10036190 C T 1.18E-232 Urate levels SLC2A9 intron 23263486 rs3733585 chr4 10036339 A G 4.98E-68 Uric acid levels SLC2A9 intron 19503597 rs3733585 chr4 10036339 A G 4.90E-88 Urate levels SLC2A9 intron 20884846 rs3733585 chr4 10036339 A G 8.69E-12 Urate levels SLC2A9 intron 21768215 rs3733585 chr4 10036339 A G 1.38E-238 Urate levels SLC2A9 intron 23263486 rs3733585 chr4 10036339 A G 2.00E-06 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs3733585 chr4 10036339 A G 2.26E-07 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs3822250 chr4 10036630 C T 1.52E-09 Urate levels SLC2A9 intron 21768215 rs3822250 chr4 10036630 C T 9.54E-09 Urate levels SLC2A9 intron 23263486 rs11731110 chr4 10037346 T C 4.63E-68 Uric acid levels SLC2A9 intron 19503597 rs11731110 chr4 10037346 T C 6.00E-88 Urate levels SLC2A9 intron 20884846 rs11731110 chr4 10037346 T C 8.66E-12 Urate levels SLC2A9 intron 21768215 rs11731110 chr4 10037346 T C 1.59E-238 Urate levels SLC2A9 intron 23263486 rs12642537 chr4 10037621 G A 1.48E-09 Urate levels SLC2A9 intron 21768215 rs10939665 chr4 10037628 T C 6.86E-68 Uric acid levels SLC2A9 intron 19503597 rs10939665 chr4 10037628 T C 4.50E-88 Urate levels SLC2A9 intron 20884846 rs10939665 chr4 10037628 T C 8.76E-12 Urate levels SLC2A9 intron 21768215 rs10939665 chr4 10037628 T C 6.44E-238 Urate levels SLC2A9 intron 23263486 rs10012779 chr4 10038112 C T 2.97E-24 Uric acid levels SLC2A9 intron 19503597 rs10012779 chr4 10038112 C T 1.20E-42 Urate levels SLC2A9 intron 20884846 rs10012779 chr4 10038112 C T 1.52E-104 Urate levels SLC2A9 intron 23263486 rs13139055 chr4 10038924 G T 1.13E-62 Uric acid levels SLC2A9 intron 19503597 rs13139055 chr4 10038924 G T 1.10E-76 Urate levels SLC2A9 intron 20884846 rs13139055 chr4 10038924 G T 3.31E-212 Urate levels SLC2A9 intron 23263486 rs13115776 chr4 10040189 C G 1.26E-62 Uric acid levels SLC2A9 intron 19503597 rs13115776 chr4 10040189 C G 1.00E-76 Urate levels SLC2A9 intron 20884846 rs13115776 chr4 10040189 C G 2.90E-212 Urate levels SLC2A9 intron 23263486 rs16892474 chr4 10040220 C A 2.06E-09 Urate levels SLC2A9 intron 21768215 rs16892474 chr4 10040220 C A 4.86E-08 Urate levels SLC2A9 intron 23263486 rs16892475 chr4 10040273 A C 7.29E-10 Urate levels SLC2A9 intron 21768215 rs10516196 chr4 10040965 C T 2.51E-09 Urate levels SLC2A9 intron 21768215 rs12508991 chr4 10041104 C T 2.67E-64 Uric acid levels SLC2A9 intron 19503597 rs12508991 chr4 10041104 C T 3.90E-88 Urate levels SLC2A9 intron 20884846 rs12508991 chr4 10041104 C T 1.30E-11 Urate levels SLC2A9 intron 21768215 rs12508991 chr4 10041104 C T 2.07E-222 Urate levels SLC2A9 intron 23263486 rs12508991 chr4 10041104 C T 1.52E-06 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs12508991 chr4 10041104 C T 2.26E-07 Cleft palate (environmental tobacco smoke interaction) SLC2A9 intron 24516586 rs10029311 chr4 10041134 T C 4.29E-23 Uric acid levels SLC2A9 intron 19503597 rs10029311 chr4 10041134 T C 1.60E-42 Urate levels SLC2A9 intron 20884846 rs10029311 chr4 10041134 T C 7.87E-104 Urate levels SLC2A9 intron 23263486 rs16892493 chr4 10041647 C T 2.36E-09 Urate levels SLC2A9 intron 21768215 rs10516197 chr4 10042100 C T 2.35E-09 Urate levels SLC2A9 nearGene-5 21768215 rs7679916 chr4 10042160 C T 1.60E-67 Uric acid levels SLC2A9 nearGene-5 19503597 rs7679916 chr4 10042160 C T 3.40E-88 Urate levels SLC2A9 nearGene-5 20884846 rs7679916 chr4 10042160 C T 1.23E-11 Urate levels SLC2A9 nearGene-5 21768215 rs7679916 chr4 10042160 C T 6.00E-231 Urate levels SLC2A9 nearGene-5 23263486 rs7349721 chr4 10042562 A T 1.87E-110 Uric acid levels SLC2A9 nearGene-5 19503597 rs7349721 chr4 10042562 A T 3.90E-135 Urate levels SLC2A9 nearGene-5 20884846 rs7349721 chr4 10042562 A T 1.23E-06 Uric acid levels SLC2A9 nearGene-5 21294900 rs7349721 chr4 10042562 A T 6.48E-17 Urate levels SLC2A9 nearGene-5 21768215 rs7349721 chr4 10042562 A T 2.60E-15 Urate levels SLC2A9 nearGene-5 23263486 rs13101785 chr4 10042915 T A 1.72E-67 Uric acid levels SLC2A9 nearGene-5 19503597 rs13101785 chr4 10042915 T A 1.20E-87 Urate levels SLC2A9 nearGene-5 20884846 rs13101785 chr4 10042915 T A 1.74E-11 Urate levels SLC2A9 nearGene-5 21768215 rs13101785 chr4 10042915 T A 1.69E-234 Urate levels SLC2A9 nearGene-5 23263486 rs13137343 chr4 10043028 C A 1.47E-67 Uric acid levels SLC2A9 nearGene-5 19503597 rs13137343 chr4 10043028 C A 1.10E-87 Urate levels SLC2A9 nearGene-5 20884846 rs13137343 chr4 10043028 C A 1.77E-11 Urate levels SLC2A9 nearGene-5 21768215 rs13137343 chr4 10043028 C A 6.65E-235 Urate levels SLC2A9 nearGene-5 23263486 rs13110307 chr4 10044364 T C 6.88E-63 Uric acid levels / / 19503597 rs13110307 chr4 10044364 T C 2.40E-76 Urate levels / / 20884846 rs13110307 chr4 10044364 T C 1.41E-211 Urate levels / / 23263486 rs13129453 chr4 10044784 T C 7.81E-63 Uric acid levels / / 19503597 rs13129453 chr4 10044784 T C 2.50E-76 Urate levels / / 20884846 rs13129453 chr4 10044784 T C 9.24E-212 Urate levels / / 23263486 rs4529049 chr4 10045389 C T 6.82E-62 Uric acid levels / / 19503597 rs4529049 chr4 10045389 C T 2.40E-76 Urate levels / / 20884846 rs4529049 chr4 10045389 C T 2.71E-212 Urate levels / / 23263486 rs4637402 chr4 10045430 C T 8.70E-70 Uric acid levels / / 19503597 rs4637402 chr4 10045430 C T 5.80E-71 Urate levels / / 20884846 rs10939669 chr4 10045827 A G 7.44E-68 Uric acid levels / / 19503597 rs10939669 chr4 10045827 A G 6.20E-88 Urate levels / / 20884846 rs10939669 chr4 10045827 A G 1.96E-11 Urate levels / / 21768215 rs10939669 chr4 10045827 A G 1.57E-236 Urate levels / / 23263486 rs4608811 chr4 10049675 A C 8.17E-37 Uric acid levels / / 19503597 rs733175 chr4 10050141 C T 2.53E-111 Uric acid levels / / 19503597 rs733175 chr4 10050141 C T 4.40E-134 Urate levels / / 20884846 rs733175 chr4 10050141 C T 1.80E-06 Uric acid levels / / 21294900 rs733175 chr4 10050141 C T 2.67E-17 Urate levels / / 21768215 rs733175 chr4 10050141 C T 5.00E-06 Alzheimer's disease / / 22005930 rs733175 chr4 10050141 C T 3.86E-15 Urate levels / / 23263486 rs733175 chr4 10050141 C T 1.89E-06 Cleft palate (environmental tobacco smoke interaction) / / 24516586 rs733175 chr4 10050141 C T 6.12E-06 Cleft palate (environmental tobacco smoke interaction) / / 24516586 rs6829727 chr4 10051672 A C 2.86E-19 Uric acid levels / / 19503597 rs6829727 chr4 10051672 A C 4.84E-05 Schizophrenia(age at onset) / / 21688384 rs12499734 chr4 10051761 C T 1.96E-09 Urate levels / / 21768215 rs6821843 chr4 10052528 C A 7.09E-10 Urate levels / / 21768215 rs13120348 chr4 10053155 C G 3.77E-64 Uric acid levels / / 19503597 rs13120348 chr4 10053155 C G 8.10E-76 Urate levels / / 20884846 rs13120348 chr4 10053155 C G 2.85E-05 Schizophrenia(age at onset) / / 21688384 rs13120348 chr4 10053155 C G 4.96E-213 Urate levels / / 23263486 rs10939679 chr4 10055855 T C 1.58E-09 Urate levels / / 21768215 rs10939679 chr4 10055855 T C 7.92E-05 Alzheimer's disease / / 22005930 rs10939681 chr4 10055964 A C 1.14E-09 Urate levels / / 21768215 rs10939681 chr4 10055964 A C 7.81E-05 Alzheimer's disease / / 22005930 rs7683832 chr4 10056082 G A 1.19E-10 Urate levels / / 21768215 rs7683832 chr4 10056082 G A 7.66E-05 Alzheimer's disease / / 22005930 rs7671266 chr4 10056376 T C 1.48E-09 Serum uric acid levels / / 17997608 rs7671266 chr4 10056376 T C 1.04E-04 Alzheimer's disease / / 17998437 rs7671266 chr4 10056376 T C 9.39E-153 Uric acid levels / / 19503597 rs7671266 chr4 10056376 T C 3.00E-193 Urate levels / / 20884846 rs7671266 chr4 10056376 T C 9.00E-71 Cardiovascular disease risk factors / / 21943158 rs7671266 chr4 10056376 T C 4.31E-16 Urate levels / / 23263486 rs10516198 chr4 10059448 T C 1.03E-09 Uric acid levels / / 19503597 rs10516198 chr4 10059448 T C 1.00E-12 Urate levels / / 20884846 rs10516198 chr4 10059448 T C 4.83E-35 Urate levels / / 23263486 rs714873 chr4 10059618 G A 5.40E-80 Uric acid levels / / 19503597 rs714873 chr4 10059618 G A 1.10E-83 Urate levels / / 20884846 rs714873 chr4 10059618 G A 7.28E-18 Urate levels / / 21768215 rs714873 chr4 10059618 G A 3.37E-07 Alzheimer's disease / / 22005930 rs714873 chr4 10059618 G A 1.02E-264 Urate levels / / 23263486 rs6834555 chr4 10062326 G A 3.23E-80 Uric acid levels / / 19503597 rs6834555 chr4 10062326 G A 8.60E-84 Urate levels / / 20884846 rs6834555 chr4 10062326 G A 3.21E-15 Urate levels / / 21768215 rs6834555 chr4 10062326 G A 3.00E-07 Alzheimer's disease / / 22005930 rs6834555 chr4 10062326 G A 1.89E-264 Urate levels / / 23263486 rs6834555 chr4 10062326 G A 2.28E-06 Cleft palate (environmental tobacco smoke interaction) / / 24516586 rs6834555 chr4 10062326 G A 5.61E-06 Cleft palate (environmental tobacco smoke interaction) / / 24516586 rs6820756 chr4 10062849 A G 1.79E-06 Cleft palate (environmental tobacco smoke interaction) / / 24516586 rs6820756 chr4 10062849 A G 4.93E-06 Cleft palate (environmental tobacco smoke interaction) / / 24516586 rs12506004 chr4 10066870 A G 3.67E-44 Uric acid levels / / 19503597 rs12506004 chr4 10066870 A G 8.20E-42 Urate levels / / 20884846 rs12506004 chr4 10066870 A G 7.06E-141 Urate levels / / 23263486 rs16868313 chr4 10068064 C T 3.42E-45 Uric acid levels / / 19503597 rs16868313 chr4 10068064 C T 2.40E-41 Urate levels / / 20884846 rs16868313 chr4 10068064 C T 4.05E-140 Urate levels / / 23263486 rs3775938 chr4 10069531 C G 3.00E-10 Urate levels / / 20884846 rs3775938 chr4 10069531 C G 5.98E-15 Urate levels / / 23263486 rs7667452 chr4 10072912 G T 1.60E-07 Urate levels / / 20884846 rs7667452 chr4 10072912 G T 1.60E-14 Urate levels / / 23263486 rs4320137 chr4 10072969 C T 3.02E-113 Uric acid levels / / 19503597 rs4320137 chr4 10072969 C T 9.20E-131 Urate levels / / 20884846 rs4320137 chr4 10072969 C T 3.02E-113 Uric acid levels / / 21294900 rs4320137 chr4 10072969 C T 4.06E-12 Urate levels / / 21768215 rs4320137 chr4 10072969 C T 3.03E-04 Alzheimer's disease / / 22005930 rs4320137 chr4 10072969 C T 3.28E-14 Urate levels / / 23263486 rs12509082 chr4 10073785 G A 9.37E-05 Alzheimer's disease / / 22005930 rs4461524 chr4 10074170 A T 3.40E-04 Alzheimer's disease / / 17998437 rs4461524 chr4 10074170 A T 2.02E-19 Uric acid levels / / 19503597 rs4461524 chr4 10074170 A T 1.60E-16 Urate levels / / 20884846 rs4461524 chr4 10074170 A T 1.80E-05 Urinary metabolites / / 21572414 rs4461524 chr4 10074170 A T 4.14E-54 Urate levels / / 23263486 rs11731597 chr4 10075485 C T 3.92E-43 Uric acid levels WDR1 nearGene-3 19503597 rs11731597 chr4 10075485 C T 1.90E-40 Urate levels WDR1 nearGene-3 20884846 rs11731597 chr4 10075485 C T 2.72E-29 Urate levels WDR1 nearGene-3 21768215 rs11731597 chr4 10075485 C T 3.03E-137 Urate levels WDR1 nearGene-3 23263486 rs200251830 chr4 10075485 C CAT 3.92E-43 Uric acid levels WDR1 nearGene-3 19503597 rs200251830 chr4 10075485 C CAT 1.90E-40 Urate levels WDR1 nearGene-3 20884846 rs200251830 chr4 10075485 C CAT 2.72E-29 Urate levels WDR1 nearGene-3 21768215 rs200251830 chr4 10075485 C CAT 3.03E-137 Urate levels WDR1 nearGene-3 23263486 rs9926 chr4 10076860 G A 4.94E-26 Uric acid levels WDR1 UTR-3 19503597 rs9926 chr4 10076860 G A 6.80E-25 Urate levels WDR1 UTR-3 20884846 rs9926 chr4 10076860 G A 5.90E-29 Urate levels WDR1 UTR-3 21768215 rs9926 chr4 10076860 G A 1.85E-119 Urate levels WDR1 UTR-3 23263486 rs3775935 chr4 10077638 C A 3.50E-10 Urate levels WDR1 intron 20884846 rs3775935 chr4 10077638 C A 1.65E-15 Urate levels WDR1 intron 23263486 rs2241469 chr4 10080462 A C 3.60E-10 Urate levels WDR1 intron 20884846 rs2241469 chr4 10080462 A C 8.86E-16 Urate levels WDR1 intron 23263486 rs2241469 chr4 10080462 A C 1.97E-05 Cleft palate (environmental tobacco smoke interaction) WDR1 intron 24516586 rs2241469 chr4 10080462 A C 8.73E-05 Cleft palate (environmental tobacco smoke interaction) WDR1 intron 24516586 rs10516200 chr4 10082156 C A 7.36E-42 Uric acid levels WDR1 intron 19503597 rs10516200 chr4 10082156 C A 1.00E-40 Urate levels WDR1 intron 20884846 rs10516200 chr4 10082156 C A 2.80E-29 Urate levels WDR1 intron 21768215 rs10516200 chr4 10082156 C A 5.22E-04 Taste perception WDR1 intron 22132133 rs10516200 chr4 10082156 C A 8.66E-137 Urate levels WDR1 intron 23263486 rs4478188 chr4 10082464 C A 9.45E-04 Alzheimer's disease WDR1 intron 22005930 rs12503195 chr4 10082772 T C 7.36E-04 Taste perception WDR1 intron 22132133 rs3756230 chr4 10083829 C G 9.14E-46 Uric acid levels WDR1 intron 19503597 rs3756230 chr4 10083829 C G 2.40E-39 Urate levels WDR1 intron 20884846 rs3756230 chr4 10083829 C G 7.10E-29 Urate levels WDR1 intron 21768215 rs3756230 chr4 10083829 C G 1.70E-140 Urate levels WDR1 intron 23263486 rs2241470 chr4 10084570 T G 1.36E-20 Uric acid levels WDR1 intron 19503597 rs2241470 chr4 10084570 T G 5.60E-26 Urate levels WDR1 intron 20884846 rs2241470 chr4 10084570 T G 2.46E-29 Urate levels WDR1 intron 21768215 rs2241470 chr4 10084570 T G 4.83E-114 Urate levels WDR1 intron 23263486 rs2241473 chr4 10085949 G A 1.06E-42 Uric acid levels WDR1 intron 19503597 rs2241473 chr4 10085949 G A 8.60E-37 Urate levels WDR1 intron 20884846 rs2241473 chr4 10085949 G A 2.20E-120 Urate levels WDR1 intron 23263486 rs2241475 chr4 10086188 T G 2.10E-10 Uric acid levels WDR1 intron 19503597 rs2241477 chr4 10086670 C T 4.64E-04 Taste perception WDR1 intron 22132133 rs3822249 chr4 10086795 G C 7.09E-04 Taste perception WDR1 intron 22132133 rs3756229 chr4 10087915 G A 6.19E-04 Taste perception WDR1 intron 22132133 rs3756227 chr4 10087995 C A 1.37E-43 Uric acid levels WDR1 intron 19503597 rs3756227 chr4 10087995 C A 9.40E-37 Urate levels WDR1 intron 20884846 rs3756227 chr4 10087995 C A 7.90E-29 Urate levels WDR1 intron 21768215 rs3756227 chr4 10087995 C A 1.28E-128 Urate levels WDR1 intron 23263486 rs2241480 chr4 10089763 C T 3.54E-41 Uric acid levels WDR1 intron 19503597 rs2241480 chr4 10089763 C T 5.80E-40 Urate levels WDR1 intron 20884846 rs2241480 chr4 10089763 C T 2.26E-29 Urate levels WDR1 intron 21768215 rs2241480 chr4 10089763 C T 2.86E-135 Urate levels WDR1 intron 23263486 rs734122 chr4 10089865 G A 1.67E-42 Uric acid levels WDR1 intron 19503597 rs734122 chr4 10089865 G A 2.20E-40 Urate levels WDR1 intron 20884846 rs734122 chr4 10089865 G A 2.78E-29 Urate levels WDR1 intron 21768215 rs734122 chr4 10089865 G A 5.56E-135 Urate levels WDR1 intron 23263486 rs12500653 chr4 10090763 G C 8.26E-04 Taste perception WDR1 intron 22132133 rs3775930 chr4 10091098 A G 6.19E-04 Taste perception WDR1 intron 22132133 rs3796822 chr4 10093651 G C 2.29E-04 Alzheimer's disease WDR1 intron 17998437 rs3796822 chr4 10093651 G C 3.00E-10 Urate levels WDR1 intron 20884846 rs3796822 chr4 10093651 G C 9.64E-15 Urate levels WDR1 intron 23263486 rs3822242 chr4 10094904 T C 5.43E-49 Uric acid levels WDR1 intron 19503597 rs3822242 chr4 10094904 T C 7.50E-61 Urate levels WDR1 intron 20884846 rs3822242 chr4 10094904 T C 7.33E-06 Uric acid levels WDR1 intron 21294900 rs3822242 chr4 10094904 T C 1.85E-169 Urate levels WDR1 intron 23263486 rs3822239 chr4 10095539 T A 3.00E-10 Urate levels WDR1 intron 20884846 rs3822239 chr4 10095539 T A 6.21E-16 Urate levels WDR1 intron 23263486 rs11727087 chr4 10096020 C T 4.91E-53 Uric acid levels WDR1 intron 19503597 rs11727087 chr4 10096020 C T 2.40E-73 Urate levels WDR1 intron 20884846 rs11727087 chr4 10096020 C T 6.69E-05 Schizophrenia(age at onset) WDR1 intron 21688384 rs11727087 chr4 10096020 C T 6.10E-190 Urate levels WDR1 intron 23263486 rs3796818 chr4 10097976 C T 4.91E-46 Uric acid levels WDR1 intron 19503597 rs3796818 chr4 10097976 C T 1.80E-39 Urate levels WDR1 intron 20884846 rs3796818 chr4 10097976 C T 6.37E-29 Urate levels WDR1 intron 21768215 rs3796818 chr4 10097976 C T 3.31E-140 Urate levels WDR1 intron 23263486 rs11726271 chr4 10098192 G A 7.81E-51 Uric acid levels WDR1 intron 19503597 rs11726271 chr4 10098192 G A 1.30E-60 Urate levels WDR1 intron 20884846 rs11726271 chr4 10098192 G A 3.35E-172 Urate levels WDR1 intron 23263486 rs2241482 chr4 10099814 A G 3.59E-05 Alzheimer's disease WDR1 intron 17998437 rs2241482 chr4 10099814 A G 4.70E-10 Urate levels WDR1 intron 20884846 rs2241482 chr4 10099814 A G 2.83E-16 Urate levels WDR1 intron 23263486 rs2241482 chr4 10099814 A G 1.06E-04 Cleft palate (environmental tobacco smoke interaction) WDR1 intron 24516586 rs2241482 chr4 10099814 A G 2.31E-05 Cleft palate (environmental tobacco smoke interaction) WDR1 intron 24516586 rs2241483 chr4 10099831 A G 3.23E-51 Uric acid levels WDR1 intron 19503597 rs2241483 chr4 10099831 A G 1.30E-60 Urate levels WDR1 intron 20884846 rs2241483 chr4 10099831 A G 8.87E-148 Urate levels WDR1 intron 23263486 rs2241486 chr4 10101083 C G 2.51E-42 Uric acid levels WDR1 intron 19503597 rs2241486 chr4 10101083 C G 7.50E-41 Urate levels WDR1 intron 20884846 rs2241486 chr4 10101083 C G 3.00E-29 Urate levels WDR1 intron 21768215 rs2241486 chr4 10101083 C G 1.10E-137 Urate levels WDR1 intron 23263486 rs2241488 chr4 10101131 T C 1.71E-43 Uric acid levels WDR1 intron 19503597 rs2241488 chr4 10101131 T C 1.50E-39 Urate levels WDR1 intron 20884846 rs2241488 chr4 10101131 T C 7.23E-29 Urate levels WDR1 intron 21768215 rs2241488 chr4 10101131 T C 9.14E-129 Urate levels WDR1 intron 23263486 rs6830786 chr4 10101443 C T 1.33E-42 Uric acid levels WDR1 intron 19503597 rs6830786 chr4 10101443 C T 2.20E-42 Urate levels WDR1 intron 20884846 rs6830786 chr4 10101443 C T 2.47E-29 Urate levels WDR1 intron 21768215 rs6830786 chr4 10101443 C T 3.57E-139 Urate levels WDR1 intron 23263486 rs4697917 chr4 10101960 T G 5.30E-10 Urate levels WDR1 intron 20884846 rs4697917 chr4 10101960 T G 3.70E-16 Urate levels WDR1 intron 23263486 rs16868326 chr4 10102593 T A 5.81E-41 Uric acid levels WDR1 intron 19503597 rs16868326 chr4 10102593 T A 5.60E-41 Urate levels WDR1 intron 20884846 rs16868326 chr4 10102593 T A 3.17E-29 Urate levels WDR1 intron 21768215 rs16868326 chr4 10102593 T A 9.56E-137 Urate levels WDR1 intron 23263486 rs12499240 chr4 10103890 T C 5.50E-10 Urate levels WDR1 intron 20884846 rs12499240 chr4 10103890 T C 3.69E-10 Urate levels WDR1 intron 21768215 rs12499240 chr4 10103890 T C 3.41E-15 Urate levels WDR1 intron 23263486 rs717615 chr4 10104670 A G 4.49E-50 Uric acid levels WDR1 intron 19503597 rs717615 chr4 10104670 A G 6.30E-56 Urate levels WDR1 intron 20884846 rs717615 chr4 10104670 A G 5.00E-06 Uric acid levels WDR1 intron 21294900 rs717615 chr4 10104670 A G 4.45E-158 Urate levels WDR1 intron 23263486 rs717615 chr4 10104670 A G 1.67E-05 Cleft palate (environmental tobacco smoke interaction) WDR1 intron 24516586 rs717615 chr4 10104670 A G 2.73E-06 Cleft palate (environmental tobacco smoke interaction) WDR1 intron 24516586 rs717614 chr4 10104788 G C 6.01E-15 Serum uric acid levels WDR1 intron 17997608 rs717614 chr4 10104788 G C 1.10E-44 Uric acid levels WDR1 intron 19503597 rs717614 chr4 10104788 G C 3.20E-70 Urate levels WDR1 intron 20884846 rs717614 chr4 10104788 G C 2.37E-219 Urate levels WDR1 intron 23263486 rs3756223 chr4 10105797 T C 4.05E-29 Uric acid levels WDR1 intron 19503597 rs3756223 chr4 10105797 T C 1.20E-29 Urate levels WDR1 intron 20884846 rs3756223 chr4 10105797 T C 1.81E-77 Urate levels WDR1 intron 23263486 rs12509714 chr4 10107091 C G 2.65E-04 Birth weight WDR1 intron 17255346 rs12509714 chr4 10107091 C G 2.11E-09 Serum uric acid levels WDR1 intron 17997608 rs12509714 chr4 10107091 C G 3.77E-91 Uric acid levels WDR1 intron 19503597 rs12509714 chr4 10107091 C G 1.60E-110 Urate levels WDR1 intron 20884846 rs12509714 chr4 10107091 C G 1.19E-18 Urate levels WDR1 intron 23263486 rs4697922 chr4 10110605 T C 8.80E-10 Urate levels WDR1 intron 20884846 rs4697922 chr4 10110605 T C 4.58E-16 Urate levels WDR1 intron 23263486 rs4697922 chr4 10110605 T C 1.58E-05 Cleft palate (environmental tobacco smoke interaction) WDR1 intron 24516586 rs4697922 chr4 10110605 T C 7.70E-05 Cleft palate (environmental tobacco smoke interaction) WDR1 intron 24516586 rs4459989 chr4 10112602 C T 2.14E-10 Uric acid levels WDR1 intron 19503597 rs4459989 chr4 10112602 C T 1.80E-10 Urate levels WDR1 intron 20884846 rs4459989 chr4 10112602 C T 1.49E-31 Urate levels WDR1 intron 23263486 rs2241468 chr4 10113905 G A 9.89E-43 Uric acid levels WDR1 intron 19503597 rs2241468 chr4 10113905 G A 1.00E-36 Urate levels WDR1 intron 20884846 rs2241468 chr4 10113905 G A 1.38E-28 Urate levels WDR1 intron 21768215 rs2241468 chr4 10113905 G A 1.03E-137 Urate levels WDR1 intron 23263486 rs4604059 chr4 10115065 T C 6.52E-09 Serum uric acid levels WDR1 intron 17997608 rs4604059 chr4 10115065 T C 9.51E-59 Uric acid levels WDR1 intron 19503597 rs4604059 chr4 10115065 T C 4.10E-60 Urate levels WDR1 intron 20884846 rs4604059 chr4 10115065 T C 5.89E-205 Urate levels WDR1 intron 23263486 rs4393994 chr4 10115121 C T 3.30E-10 Urate levels WDR1 intron 20884846 rs4393994 chr4 10115121 C T 2.54E-09 Urate levels WDR1 intron 21768215 rs4393994 chr4 10115121 C T 3.49E-15 Urate levels WDR1 intron 23263486 rs12498927 chr4 10115523 A G 1.61E-10 Serum uric acid levels WDR1 intron 17997608 rs12498927 chr4 10115523 A G 5.24E-61 Uric acid levels WDR1 intron 19503597 rs12498927 chr4 10115523 A G 1.60E-61 Urate levels WDR1 intron 20884846 rs12498927 chr4 10115523 A G 3.64E-214 Urate levels WDR1 intron 23263486 rs10939710 chr4 10116801 T C 1.21E-10 Uric acid levels WDR1 intron 19503597 rs10939710 chr4 10116801 T C 3.10E-12 Urate levels WDR1 intron 20884846 rs10939710 chr4 10116801 T C 5.43E-34 Urate levels WDR1 intron 23263486 rs3822236 chr4 10119961 T G 4.40E-63 Uric acid levels WDR1 nearGene-5 19503597 rs3822236 chr4 10119961 T G 4.50E-81 Urate levels WDR1 nearGene-5 20884846 rs3822236 chr4 10119961 T G 3.70E-09 Urate levels WDR1 nearGene-5 21768215 rs3822236 chr4 10119961 T G 6.53E-231 Urate levels WDR1 nearGene-5 23263486 rs12374320 chr4 10120609 T C 3.14E-08 Uric acid levels / / 19503597 rs12374320 chr4 10120609 T C 5.90E-18 Urate levels / / 20884846 rs12374320 chr4 10120609 T C 3.15E-34 Urate levels / / 23263486 rs4697708 chr4 10121189 T C 1.39E-60 Uric acid levels / / 19503597 rs4697708 chr4 10121189 T C 2.20E-78 Urate levels / / 20884846 rs4697708 chr4 10121189 T C 1.81E-08 Urate levels / / 21768215 rs4697708 chr4 10121189 T C 3.05E-231 Urate levels / / 23263486 rs3756215 chr4 10121260 A G 1.10E-20 Uric acid levels / / 19503597 rs3756215 chr4 10121260 A G 1.70E-17 Urate levels / / 20884846 rs3756215 chr4 10121260 A G 1.63E-28 Urate levels / / 21768215 rs3756215 chr4 10121260 A G 2.88E-102 Urate levels / / 23263486 rs4697710 chr4 10122649 T C 9.93E-61 Uric acid levels / / 19503597 rs4697710 chr4 10122649 T C 2.40E-78 Urate levels / / 20884846 rs4697710 chr4 10122649 T C 2.53E-08 Urate levels / / 21768215 rs4697710 chr4 10122649 T C 2.21E-231 Urate levels / / 23263486 rs6825888 chr4 10122734 T C 5.85E-38 Uric acid levels / / 19503597 rs6825888 chr4 10122734 T C 3.60E-29 Urate levels / / 20884846 rs6825888 chr4 10122734 T C 1.79E-28 Urate levels / / 21768215 rs6825888 chr4 10122734 T C 8.85E-120 Urate levels / / 23263486 rs4235354 chr4 10122942 C A 6.84E-14 Uric acid levels / / 19503597 rs4235354 chr4 10122942 C A 5.80E-08 Urate levels / / 20884846 rs4235354 chr4 10122942 C A 2.79E-25 Urate levels / / 23263486 rs4235355 chr4 10123078 C A 2.61E-60 Uric acid levels / / 19503597 rs4235355 chr4 10123078 C A 2.00E-78 Urate levels / / 20884846 rs4235355 chr4 10123078 C A 2.39E-08 Urate levels / / 21768215 rs4235355 chr4 10123078 C A 3.48E-199 Urate levels / / 23263486 rs4235356 chr4 10123106 G C 7.05E-61 Uric acid levels / / 19503597 rs4235356 chr4 10123106 G C 2.00E-78 Urate levels / / 20884846 rs4235356 chr4 10123106 G C 2.85E-231 Urate levels / / 23263486 rs4311315 chr4 10123191 T C 4.70E-15 Urate levels / / 20884846 rs4311315 chr4 10123191 T C 2.52E-28 Urate levels / / 23263486 rs12506893 chr4 10123665 C T 2.13E-37 Uric acid levels / / 19503597 rs12506893 chr4 10123665 C T 6.80E-29 Urate levels / / 20884846 rs12506893 chr4 10123665 C T 2.19E-28 Urate levels / / 21768215 rs12506893 chr4 10123665 C T 1.69E-119 Urate levels / / 23263486 rs10516201 chr4 10123941 T C 2.75E-37 Uric acid levels / / 19503597 rs10516201 chr4 10123941 T C 7.90E-28 Urate levels / / 20884846 rs10516201 chr4 10123941 T C 2.02E-28 Urate levels / / 21768215 rs10516201 chr4 10123941 T C 2.22E-118 Urate levels / / 23263486 rs4697924 chr4 10124239 T C 4.35E-06 Schizophrenia(age at onset) / / 21688384 rs4697926 chr4 10124567 A C 1.50E-49 Uric acid levels / / 19503597 rs4697926 chr4 10124567 A C 9.20E-63 Urate levels / / 20884846 rs4697926 chr4 10124567 A C 2.06E-05 Schizophrenia(age at onset) / / 21688384 rs4697926 chr4 10124567 A C 1.14E-09 Urate levels / / 21768215 rs4697926 chr4 10124567 A C 1.31E-192 Urate levels / / 23263486 rs4444830 chr4 10124819 T C 2.02E-45 Uric acid levels / / 19503597 rs4444830 chr4 10124819 T C 1.90E-52 Urate levels / / 20884846 rs4444830 chr4 10124819 T C 5.24E-05 Schizophrenia(age at onset) / / 21688384 rs4444830 chr4 10124819 T C 1.19E-154 Urate levels / / 23263486 rs4456954 chr4 10124838 G C 3.72E-30 Uric acid levels / / 19503597 rs4456954 chr4 10124838 G C 1.90E-22 Urate levels / / 20884846 rs4456954 chr4 10124838 G C 2.04E-28 Urate levels / / 21768215 rs4456954 chr4 10124838 G C 3.04E-86 Urate levels / / 23263486 rs715979 chr4 10125242 C G 1.66E-34 Uric acid levels / / 19503597 rs715979 chr4 10125242 C G 1.90E-27 Urate levels / / 20884846 rs715979 chr4 10125242 C G 2.19E-28 Urate levels / / 21768215 rs715979 chr4 10125242 C G 2.58E-114 Urate levels / / 23263486 rs3886038 chr4 10125255 C T 2.68E-37 Uric acid levels / / 19503597 rs3886038 chr4 10125255 C T 3.30E-27 Urate levels / / 20884846 rs3886038 chr4 10125255 C T 1.84E-28 Urate levels / / 21768215 rs3886038 chr4 10125255 C T 2.12E-118 Urate levels / / 23263486 rs7699512 chr4 10125808 C T 5.23E-48 Uric acid levels / / 19503597 rs7699512 chr4 10125808 C T 1.90E-51 Urate levels / / 20884846 rs7699512 chr4 10125808 C T 1.43E-169 Urate levels / / 23263486 rs7699512 chr4 10125808 C T 1.98E-06 Cleft palate (environmental tobacco smoke interaction) / / 24516586 rs7699512 chr4 10125808 C T 9.90E-06 Cleft palate (environmental tobacco smoke interaction) / / 24516586 rs7699671 chr4 10125874 C T 3.38E-53 Uric acid levels / / 19503597 rs7699671 chr4 10125874 C T 9.40E-64 Urate levels / / 20884846 rs7699671 chr4 10125874 C T 2.37E-09 Urate levels / / 21768215 rs7699671 chr4 10125874 C T 3.16E-200 Urate levels / / 23263486 rs11722989 chr4 10126139 A G 1.24E-47 Uric acid levels / / 19503597 rs11722989 chr4 10126139 A G 1.90E-51 Urate levels / / 20884846 rs11722989 chr4 10126139 A G 1.59E-05 Schizophrenia(age at onset) / / 21688384 rs11722989 chr4 10126139 A G 7.09E-168 Urate levels / / 23263486 rs11723016 chr4 10126189 A G 4.68E-45 Uric acid levels / / 19503597 rs11723016 chr4 10126189 A G 2.00E-51 Urate levels / / 20884846 rs11723016 chr4 10126189 A G 1.12E-153 Urate levels / / 23263486 rs6449286 chr4 10126699 T A 6.98E-36 Uric acid levels / / 19503597 rs6449286 chr4 10126699 T A 2.30E-36 Urate levels / / 20884846 rs6449286 chr4 10126699 T A 6.59E-29 Urate levels / / 21768215 rs6449286 chr4 10126699 T A 4.10E-119 Urate levels / / 23263486 rs4619888 chr4 10126978 A C 4.92E-40 Uric acid levels / / 19503597 rs4619888 chr4 10126978 A C 1.90E-31 Urate levels / / 20884846 rs4619888 chr4 10126978 A C 1.98E-28 Urate levels / / 21768215 rs4619888 chr4 10126978 A C 6.89E-126 Urate levels / / 23263486 rs4467562 chr4 10127141 G A 8.84E-39 Uric acid levels / / 19503597 rs4467562 chr4 10127141 G A 2.50E-36 Urate levels / / 20884846 rs4467562 chr4 10127141 G A 7.81E-29 Urate levels / / 21768215 rs4467562 chr4 10127141 G A 1.44E-122 Urate levels / / 23263486 rs10001106 chr4 10127441 T C 1.92E-38 Uric acid levels / / 19503597 rs10001106 chr4 10127441 T C 1.50E-36 Urate levels / / 20884846 rs10001106 chr4 10127441 T C 8.06E-29 Urate levels / / 21768215 rs10001106 chr4 10127441 T C 8.06E-137 Urate levels / / 23263486 rs11722643 chr4 10127484 C T 1.39E-09 Urate levels / / 23263486 rs17250843 chr4 10127978 C G 5.58E-09 Uric acid levels / / 19503597 rs17250843 chr4 10127978 C G 1.50E-09 Urate levels / / 20884846 rs17250843 chr4 10127978 C G 5.19E-24 Urate levels / / 23263486 rs715259 chr4 10128071 G C 1.04E-09 Urate levels / / 23263486 rs715260 chr4 10128146 C G 1.50E-04 Lipid traits / / 17903299 rs715260 chr4 10128146 C G 8.90E-40 Uric acid levels / / 19503597 rs715260 chr4 10128146 C G 2.00E-31 Urate levels / / 20884846 rs715260 chr4 10128146 C G 2.32E-28 Urate levels / / 21768215 rs715260 chr4 10128146 C G 3.23E-127 Urate levels / / 23263486 rs7667775 chr4 10128536 C T 5.68E-38 Uric acid levels / / 19503597 rs7667775 chr4 10128536 C T 1.20E-27 Urate levels / / 20884846 rs7667775 chr4 10128536 C T 3.22E-28 Urate levels / / 21768215 rs7667775 chr4 10128536 C T 4.29E-103 Urate levels / / 23263486 rs10155145 chr4 10128800 C T 5.65E-04 Type 2 diabetes / / 17463246 rs10155145 chr4 10128800 C T 1.84E-10 Urate levels / / 23263486 rs12502342 chr4 10129916 C A 5.22E-10 Urate levels / / 23263486 rs12502368 chr4 10129953 C A 9.02E-10 Urate levels / / 23263486 rs12502556 chr4 10130505 C G 4.87E-45 Uric acid levels / / 19503597 rs12502556 chr4 10130505 C G 2.20E-34 Urate levels / / 20884846 rs12502556 chr4 10130505 C G 2.38E-28 Urate levels / / 21768215 rs12502556 chr4 10130505 C G 3.02E-141 Urate levels / / 23263486 rs10009493 chr4 10132047 C G 5.05E-122 Uric acid levels / / 19503597 rs10009493 chr4 10132047 C G 5.30E-149 Urate levels / / 20884846 rs10009493 chr4 10132047 C G 1.04E-14 Urate levels / / 23263486 rs12501597 chr4 10132137 G T 5.66E-42 Uric acid levels / / 19503597 rs12501597 chr4 10132137 G T 1.70E-30 Urate levels / / 20884846 rs12501597 chr4 10132137 G T 2.98E-28 Urate levels / / 21768215 rs12501597 chr4 10132137 G T 2.23E-127 Urate levels / / 23263486 rs6449289 chr4 10132543 C T 1.81E-45 Uric acid levels / / 19503597 rs6449289 chr4 10132543 C T 5.90E-35 Urate levels / / 20884846 rs6449289 chr4 10132543 C T 7.69E-120 Urate levels / / 23263486 rs881641 chr4 10133747 G A 4.49E-44 Uric acid levels / / 19503597 rs881641 chr4 10133747 G A 8.30E-33 Urate levels / / 20884846 rs881641 chr4 10133747 G A 2.20E-28 Urate levels / / 21768215 rs881641 chr4 10133747 G A 1.90E-136 Urate levels / / 23263486 rs881642 chr4 10133873 C T 1.25E-43 Uric acid levels / / 19503597 rs881642 chr4 10133873 C T 2.40E-30 Urate levels / / 20884846 rs881642 chr4 10133873 C T 3.20E-28 Urate levels / / 21768215 rs881642 chr4 10133873 C T 1.09E-126 Urate levels / / 23263486 rs881643 chr4 10134117 G A 3.68E-43 Uric acid levels / / 19503597 rs881643 chr4 10134117 G A 1.00E-32 Urate levels / / 20884846 rs881643 chr4 10134117 G A 3.06E-28 Urate levels / / 21768215 rs881643 chr4 10134117 G A 7.43E-137 Urate levels / / 23263486 rs17197769 chr4 10134336 C T 5.85E-44 Uric acid levels / / 19503597 rs17197769 chr4 10134336 C T 1.60E-32 Urate levels / / 20884846 rs17197769 chr4 10134336 C T 2.34E-28 Urate levels / / 21768215 rs17197769 chr4 10134336 C T 4.67E-136 Urate levels / / 23263486 rs1109472 chr4 10134448 G C 8.75E-45 Uric acid levels / / 19503597 rs1109472 chr4 10134448 G C 1.70E-32 Urate levels / / 20884846 rs1109472 chr4 10134448 G C 2.24E-28 Urate levels / / 21768215 rs1109472 chr4 10134448 G C 8.49E-136 Urate levels / / 23263486 rs11938608 chr4 10135849 T C 3.03E-44 Uric acid levels / / 19503597 rs11938608 chr4 10135849 T C 4.20E-32 Urate levels / / 20884846 rs11938608 chr4 10135849 T C 3.38E-28 Urate levels / / 21768215 rs11938608 chr4 10135849 T C 5.65E-122 Urate levels / / 23263486 rs4358401 chr4 10136807 T A 1.01E-09 Uric acid levels / / 19503597 rs4358401 chr4 10136807 T A 3.20E-22 Urate levels / / 20884846 rs4358401 chr4 10136807 T A 7.44E-40 Urate levels / / 23263486 rs873984 chr4 10137125 C G 3.97E-12 Uric acid levels / / 19503597 rs873984 chr4 10137125 C G 1.00E-25 Urate levels / / 20884846 rs873984 chr4 10137125 C G 1.26E-44 Urate levels / / 23263486 rs4399989 chr4 10137388 G A 2.73E-10 Uric acid levels / / 19503597 rs4399989 chr4 10137388 G A 3.10E-22 Urate levels / / 20884846 rs4399989 chr4 10137388 G A 1.65E-40 Urate levels / / 23263486 rs4315785 chr4 10137607 A C 2.22E-10 Uric acid levels / / 19503597 rs4315785 chr4 10137607 A C 1.30E-40 Urate levels / / 23263486 rs4235357 chr4 10137756 T C 4.82E-10 Uric acid levels / / 19503597 rs4235357 chr4 10137756 T C 2.60E-22 Urate levels / / 20884846 rs4235357 chr4 10137756 T C 2.59E-40 Urate levels / / 23263486 rs577259500 chr4 10137756 T TCC 4.82E-10 Uric acid levels / / 19503597 rs577259500 chr4 10137756 T TCC 2.60E-22 Urate levels / / 20884846 rs577259500 chr4 10137756 T TCC 2.59E-40 Urate levels / / 23263486 rs12507725 chr4 10137790 T A 1.07E-44 Uric acid levels / / 19503597 rs12507725 chr4 10137790 T A 2.90E-31 Urate levels / / 20884846 rs12507725 chr4 10137790 T A 2.50E-28 Urate levels / / 21768215 rs12507725 chr4 10137790 T A 1.04E-134 Urate levels / / 23263486 rs17198113 chr4 10138470 C T 1.23E-42 Uric acid levels / / 19503597 rs17198113 chr4 10138470 C T 1.20E-28 Urate levels / / 20884846 rs17198113 chr4 10138470 C T 3.07E-28 Urate levels / / 21768215 rs17198113 chr4 10138470 C T 6.15E-124 Urate levels / / 23263486 rs11732828 chr4 10138746 T C 1.46E-10 Uric acid levels / / 19503597 rs11732828 chr4 10138746 T C 6.50E-22 Urate levels / / 20884846 rs11732828 chr4 10138746 T C 2.67E-41 Urate levels / / 23263486 rs10939722 chr4 10139047 G T 1.69E-10 Uric acid levels / / 19503597 rs10939722 chr4 10139047 G T 2.50E-22 Urate levels / / 20884846 rs10939722 chr4 10139047 G T 5.11E-40 Urate levels / / 23263486 rs10939723 chr4 10139105 G T 2.34E-09 Serum uric acid levels / / 17997608 rs10939723 chr4 10139105 G T 1.68E-108 Uric acid levels / / 19503597 rs10939723 chr4 10139105 G T 5.10E-144 Urate levels / / 20884846 rs10939723 chr4 10139105 G T 2.89E-14 Urate levels / / 23263486 rs17198197 chr4 10139157 G A 4.70E-11 Urate levels / / 20884846 rs17198197 chr4 10139157 G A 8.18E-06 Schizophrenia(age at onset) / / 21688384 rs17198197 chr4 10139157 G A 5.21E-24 Urate levels / / 23263486 rs6449300 chr4 10139551 C T 7.16E-45 Uric acid levels / / 19503597 rs6449300 chr4 10139551 C T 5.10E-31 Urate levels / / 20884846 rs6449300 chr4 10139551 C T 2.49E-28 Urate levels / / 21768215 rs6449300 chr4 10139551 C T 5.46E-135 Urate levels / / 23263486 rs6850516 chr4 10139978 G C 2.94E-10 Uric acid levels / / 19503597 rs6850516 chr4 10139978 G C 2.10E-22 Urate levels / / 20884846 rs6850516 chr4 10139978 G C 4.23E-38 Urate levels / / 23263486 rs10025456 chr4 10140259 T C 7.63E-09 Uric acid levels / / 19503597 rs10025456 chr4 10140259 T C 4.80E-16 Urate levels / / 20884846 rs10025456 chr4 10140259 T C 1.32E-29 Urate levels / / 23263486 rs10022911 chr4 10140551 A G 4.71E-113 Uric acid levels / / 19503597 rs10022911 chr4 10140551 A G 2.40E-138 Urate levels / / 20884846 rs10022911 chr4 10140551 A G 1.30E-13 Urate levels / / 23263486 rs10020887 chr4 10140751 C G 2.90E-120 Uric acid levels / / 19503597 rs10020887 chr4 10140751 C G 1.00E-142 Urate levels / / 20884846 rs10020887 chr4 10140751 C G 2.71E-14 Urate levels / / 23263486 rs10012288 chr4 10140953 G A 9.69E-11 Uric acid levels / / 19503597 rs10012288 chr4 10140953 G A 3.40E-22 Urate levels / / 20884846 rs10012288 chr4 10140953 G A 1.57E-41 Urate levels / / 23263486 rs4533775 chr4 10141404 G C 5.20E-11 Urate levels / / 20884846 rs4533775 chr4 10141404 G C 1.59E-24 Urate levels / / 23263486 rs17198547 chr4 10141419 C T 7.29E-10 Serum uric acid levels / / 17997608 rs17198547 chr4 10141419 C T 3.58E-115 Uric acid levels / / 19503597 rs17198547 chr4 10141419 C T 2.10E-142 Urate levels / / 20884846 rs17198547 chr4 10141419 C T 9.04E-14 Urate levels / / 23263486 rs10805356 chr4 10141602 T G 8.73E-11 Uric acid levels / / 19503597 rs10805356 chr4 10141602 T G 2.60E-22 Urate levels / / 20884846 rs10805356 chr4 10141602 T G 1.21E-40 Urate levels / / 23263486 rs4473652 chr4 10141617 G C 2.40E-08 Uric acid levels / / 19503597 rs4473652 chr4 10141617 G C 3.60E-11 Urate levels / / 20884846 rs4473652 chr4 10141617 G C 2.10E-24 Urate levels / / 23263486 rs10028503 chr4 10141927 A G 1.91E-10 Uric acid levels / / 19503597 rs10028503 chr4 10141927 A G 1.90E-22 Urate levels / / 20884846 rs10028503 chr4 10141927 A G 1.13E-40 Urate levels / / 23263486 rs10015494 chr4 10141990 G A 9.60E-11 Uric acid levels / / 19503597 rs10015494 chr4 10141990 G A 1.80E-22 Urate levels / / 20884846 rs10015494 chr4 10141990 G A 8.25E-38 Urate levels / / 23263486 rs10028937 chr4 10142366 A G 5.40E-05 Multiple sclerosis / / 17660530 rs10028937 chr4 10142366 A G 1.99E-10 Uric acid levels / / 19503597 rs10028937 chr4 10142366 A G 1.90E-22 Urate levels / / 20884846 rs10028937 chr4 10142366 A G 8.71E-41 Urate levels / / 23263486 rs10015872 chr4 10142410 G A 6.55E-10 Uric acid levels / / 19503597 rs10015872 chr4 10142410 G A 1.80E-22 Urate levels / / 20884846 rs10015872 chr4 10142410 G A 2.83E-40 Urate levels / / 23263486 rs17251963 chr4 10142561 T C 4.85E-08 Serum uric acid levels / / 17997608 rs17251963 chr4 10142561 T C 4.92E-125 Uric acid levels / / 19503597 rs17251963 chr4 10142561 T C 1.70E-156 Urate levels / / 20884846 rs17251963 chr4 10142561 T C 5.94E-14 Urate levels / / 23263486 rs10031453 chr4 10142659 A G 6.73E-11 Uric acid levels / / 19503597 rs10031453 chr4 10142659 A G 1.90E-22 Urate levels / / 20884846 rs10031453 chr4 10142659 A G 6.94E-38 Urate levels / / 23263486 rs4697713 chr4 10143582 T C 8.97E-10 Uric acid levels / / 19503597 rs4697713 chr4 10143582 T C 2.00E-22 Urate levels / / 20884846 rs4697713 chr4 10143582 T C 6.36E-38 Urate levels / / 23263486 rs4697930 chr4 10143594 C G 3.11E-10 Uric acid levels / / 19503597 rs4697930 chr4 10143594 C G 2.10E-22 Urate levels / / 20884846 rs4697930 chr4 10143594 C G 3.27E-40 Urate levels / / 23263486 rs4697714 chr4 10143786 T A 1.17E-09 Serum uric acid levels / / 17997608 rs4697714 chr4 10143786 T A 1.95E-119 Uric acid levels / / 19503597 rs4697714 chr4 10143786 T A 1.20E-141 Urate levels / / 20884846 rs4697714 chr4 10143786 T A 3.10E-14 Urate levels / / 23263486 rs4292329 chr4 10144459 C G 1.17E-08 Uric acid levels / / 19503597 rs4292329 chr4 10144459 C G 3.90E-11 Urate levels / / 20884846 rs4292329 chr4 10144459 C G 1.28E-05 Schizophrenia(age at onset) / / 21688384 rs4292329 chr4 10144459 C G 3.87E-24 Urate levels / / 23263486 rs4697931 chr4 10145296 C T 1.41E-10 Uric acid levels / / 19503597 rs4697931 chr4 10145296 C T 2.60E-22 Urate levels / / 20884846 rs4697931 chr4 10145296 C T 3.80E-40 Urate levels / / 23263486 rs4574408 chr4 10145568 G A 1.23E-09 Uric acid levels / / 19503597 rs4574408 chr4 10145568 G A 2.00E-22 Urate levels / / 20884846 rs4574408 chr4 10145568 G A 1.63E-37 Urate levels / / 23263486 rs4640669 chr4 10145733 G A 6.43E-08 Serum uric acid levels / / 17997608 rs4640669 chr4 10145733 G A 1.35E-116 Uric acid levels / / 19503597 rs4640669 chr4 10145733 G A 7.20E-141 Urate levels / / 20884846 rs4640669 chr4 10145733 G A 6.16E-13 Urate levels / / 23263486 rs4484300 chr4 10145794 G A 3.08E-10 Uric acid levels / / 19503597 rs4484300 chr4 10145794 G A 8.20E-23 Urate levels / / 20884846 rs4484300 chr4 10145794 G A 1.15E-37 Urate levels / / 23263486 rs4401449 chr4 10145998 C T 9.66E-10 Uric acid levels / / 19503597 rs4401449 chr4 10145998 C T 6.60E-23 Urate levels / / 20884846 rs4401449 chr4 10145998 C T 3.14E-40 Urate levels / / 23263486 rs10939730 chr4 10146049 G C 5.15E-10 Uric acid levels / / 19503597 rs10939730 chr4 10146049 G C 7.10E-23 Urate levels / / 20884846 rs10939730 chr4 10146049 G C 2.85E-37 Urate levels / / 23263486 rs4697933 chr4 10146493 G A 8.92E-116 Uric acid levels / / 19503597 rs4697933 chr4 10146493 G A 3.50E-141 Urate levels / / 20884846 rs4697933 chr4 10146493 G A 3.19E-13 Urate levels / / 23263486 rs4697715 chr4 10146654 A G 4.10E-17 Urate levels / / 20884846 rs4697715 chr4 10146654 A G 2.78E-26 Urate levels / / 23263486 rs6855657 chr4 10148148 T C 2.53E-09 Uric acid levels / / 19503597 rs6855657 chr4 10148148 T C 6.00E-22 Urate levels / / 20884846 rs6855657 chr4 10148148 T C 8.09E-39 Urate levels / / 23263486 rs10939732 chr4 10148390 G A 6.91E-10 Uric acid levels / / 19503597 rs10939732 chr4 10148390 G A 6.90E-22 Urate levels / / 20884846 rs10939732 chr4 10148390 G A 1.99E-36 Urate levels / / 23263486 rs12507586 chr4 10148575 G A 5.29E-45 Uric acid levels / / 19503597 rs12507586 chr4 10148575 G A 2.30E-32 Urate levels / / 20884846 rs12507586 chr4 10148575 G A 3.23E-28 Urate levels / / 21768215 rs12507586 chr4 10148575 G A 1.31E-135 Urate levels / / 23263486 rs4168 chr4 10148609 C A 2.23E-09 Uric acid levels / / 19503597 rs4168 chr4 10148609 C A 9.10E-22 Urate levels / / 20884846 rs4168 chr4 10148609 C A 1.13E-36 Urate levels / / 23263486 rs11735668 chr4 10148655 C G 1.46E-109 Uric acid levels / / 19503597 rs11735668 chr4 10148655 C G 1.90E-134 Urate levels / / 20884846 rs11735668 chr4 10148655 C G 1.39E-12 Urate levels / / 23263486 rs12508413 chr4 10148671 G A 4.71E-45 Uric acid levels / / 19503597 rs12508413 chr4 10148671 G A 1.80E-32 Urate levels / / 20884846 rs12508413 chr4 10148671 G A 3.43E-28 Urate levels / / 21768215 rs12508413 chr4 10148671 G A 1.05E-135 Urate levels / / 23263486 rs6813334 chr4 10148753 T G 4.30E-45 Uric acid levels / / 19503597 rs6813334 chr4 10148753 T G 1.70E-32 Urate levels / / 20884846 rs6813334 chr4 10148753 T G 3.08E-28 Urate levels / / 21768215 rs6813334 chr4 10148753 T G 7.73E-136 Urate levels / / 23263486 rs6813385 chr4 10148828 T C 4.30E-15 Urate levels / / 20884846 rs6813385 chr4 10148828 T C 2.06E-27 Urate levels / / 23263486 rs6846402 chr4 10148881 C T 5.10E-20 Urate levels / / 20884846 rs6846402 chr4 10148881 C T 1.24E-35 Urate levels / / 23263486 rs4697934 chr4 10149064 C T 6.80E-09 Uric acid levels / / 19503597 rs4697934 chr4 10149064 C T 2.60E-21 Urate levels / / 20884846 rs4697934 chr4 10149064 C T 1.32E-38 Urate levels / / 23263486 rs4697936 chr4 10149595 T G 2.33E-23 Uric acid levels / / 19503597 rs4697936 chr4 10149595 T G 1.70E-13 Urate levels / / 20884846 rs4697936 chr4 10149595 T G 1.69E-49 Urate levels / / 23263486 rs4697937 chr4 10149669 T G 6.03E-11 Uric acid levels / / 19503597 rs4697937 chr4 10149669 T G 9.80E-24 Urate levels / / 20884846 rs4697937 chr4 10149669 T G 7.94E-48 Urate levels / / 23263486 rs6826693 chr4 10150739 T C 5.60E-18 Urate levels / / 20884846 rs6826693 chr4 10150739 T C 9.76E-32 Urate levels / / 23263486 rs6840883 chr4 10150864 G A 2.02E-08 Uric acid levels / / 19503597 rs6840883 chr4 10150864 G A 3.80E-18 Urate levels / / 20884846 rs6840883 chr4 10150864 G A 2.81E-36 Urate levels / / 23263486 rs11721682 chr4 10151147 C T 1.07E-116 Uric acid levels / / 19503597 rs11721682 chr4 10151147 C T 3.50E-141 Urate levels / / 20884846 rs11721682 chr4 10151147 C T 5.25E-13 Urate levels / / 23263486 rs6827946 chr4 10151335 T C 6.07E-110 Uric acid levels / / 19503597 rs6827946 chr4 10151335 T C 1.90E-126 Urate levels / / 20884846 rs6827946 chr4 10151335 T C 1.49E-11 Urate levels / / 23263486 rs6827496 chr4 10151656 A G 5.90E-46 Uric acid levels / / 19503597 rs6827496 chr4 10151656 A G 2.00E-33 Urate levels / / 20884846 rs6827496 chr4 10151656 A G 1.97E-28 Urate levels / / 21768215 rs6827496 chr4 10151656 A G 1.89E-139 Urate levels / / 23263486 rs6847379 chr4 10151704 G T 8.25E-09 Uric acid levels / / 19503597 rs6847379 chr4 10151704 G T 3.90E-18 Urate levels / / 20884846 rs6847379 chr4 10151704 G T 8.52E-38 Urate levels / / 23263486 rs4697939 chr4 10152302 G A 2.40E-14 Urate levels / / 20884846 rs4697940 chr4 10152329 G C 1.08E-08 Uric acid levels / / 19503597 rs4697940 chr4 10152329 G C 6.00E-18 Urate levels / / 20884846 rs4697940 chr4 10152329 G C 1.22E-33 Urate levels / / 23263486 rs731069 chr4 10152431 A C 3.15E-08 Uric acid levels / / 19503597 rs731069 chr4 10152431 A C 7.60E-18 Urate levels / / 20884846 rs731069 chr4 10152431 A C 3.03E-34 Urate levels / / 23263486 rs731070 chr4 10152582 C T 3.60E-08 Uric acid levels / / 19503597 rs731070 chr4 10152582 C T 8.00E-18 Urate levels / / 20884846 rs731070 chr4 10152582 C T 9.38E-35 Urate levels / / 23263486 rs747357 chr4 10152878 C G 7.90E-18 Urate levels / / 20884846 rs747357 chr4 10152878 C G 4.81E-26 Urate levels / / 23263486 rs747356 chr4 10153051 G T 1.29E-08 Uric acid levels / / 19503597 rs747356 chr4 10153051 G T 4.50E-18 Urate levels / / 20884846 rs747356 chr4 10153051 G T 3.17E-35 Urate levels / / 23263486 rs737601 chr4 10153233 C T 6.52E-04 Schizophrenia / / 19197363 rs737601 chr4 10153233 C T 2.78E-13 Urate levels / / 23263486 rs6814532 chr4 10154554 G A 1.00E-09 Urate levels / / 23263486 rs11736560 chr4 10154872 C T 1.17E-13 Urate levels / / 23263486 rs6851524 chr4 10155041 C A 4.60E-08 Uric acid levels / / 19503597 rs6851524 chr4 10155041 C A 6.60E-11 Urate levels / / 20884846 rs6851524 chr4 10155041 C A 9.47E-25 Urate levels / / 23263486 rs10939741 chr4 10155346 T C 2.01E-13 Urate levels / / 23263486 rs11932627 chr4 10156177 T G 1.50E-07 Urate levels / / 20884846 rs11932627 chr4 10156177 T G 5.59E-11 Urate levels / / 23263486 rs12513376 chr4 10156222 C T 4.87E-41 Uric acid levels / / 19503597 rs12513376 chr4 10156222 C T 1.10E-30 Urate levels / / 20884846 rs12513376 chr4 10156222 C T 2.36E-12 Urate levels / / 21768215 rs12513376 chr4 10156222 C T 1.12E-116 Urate levels / / 23263486 rs11929718 chr4 10156321 C A 1.45E-47 Uric acid levels / / 19503597 rs11929718 chr4 10156321 C A 5.10E-37 Urate levels / / 20884846 rs11929718 chr4 10156321 C A 4.86E-138 Urate levels / / 23263486 rs12498256 chr4 10156544 C T 7.00E-12 Urate levels / / 23263486 rs6834055 chr4 10158511 A T 2.59E-97 Uric acid levels / / 19503597 rs6834055 chr4 10158511 A T 8.60E-124 Urate levels / / 20884846 rs6834055 chr4 10158511 A T 1.72E-12 Urate levels / / 23263486 rs2241464 chr4 10158961 G A 6.30E-11 Uric acid levels / / 19503597 rs2241464 chr4 10158961 G A 3.70E-17 Urate levels / / 20884846 rs2241464 chr4 10158961 G A 2.31E-37 Urate levels / / 23263486 rs2241465 chr4 10159020 C T 6.27E-51 Uric acid levels / / 19503597 rs2241465 chr4 10159020 C T 3.70E-38 Urate levels / / 20884846 rs2241465 chr4 10159020 C T 2.97E-151 Urate levels / / 23263486 rs4697941 chr4 10160862 C A 2.40E-48 Uric acid levels / / 19503597 rs4697941 chr4 10160862 C A 5.30E-34 Urate levels / / 20884846 rs4697941 chr4 10160862 C A 3.48E-135 Urate levels / / 23263486 rs17450260 chr4 10163789 A T 1.71E-46 Uric acid levels / / 19503597 rs17450260 chr4 10163789 A T 1.10E-32 Urate levels / / 20884846 rs17450260 chr4 10163789 A T 4.45E-126 Urate levels / / 23263486 rs6816215 chr4 10164027 C T 2.32E-19 Uric acid levels / / 19503597 rs6816215 chr4 10164027 C T 3.80E-19 Urate levels / / 20884846 rs6816215 chr4 10164027 C T 1.70E-05 Urinary metabolites / / 21572414 rs6816215 chr4 10164027 C T 1.14E-69 Urate levels / / 23263486 rs17450372 chr4 10164344 T C 1.96E-46 Uric acid levels / / 19503597 rs17450372 chr4 10164344 T C 1.10E-32 Urate levels / / 20884846 rs17450372 chr4 10164344 T C 1.01E-124 Urate levels / / 23263486 rs1009144 chr4 10164931 G T 3.62E-46 Uric acid levels / / 19503597 rs1009144 chr4 10164931 G T 1.00E-34 Urate levels / / 20884846 rs1009144 chr4 10164931 G T 1.20E-132 Urate levels / / 23263486 rs17450434 chr4 10164961 C T 2.40E-45 Uric acid levels / / 19503597 rs17450434 chr4 10164961 C T 9.70E-35 Urate levels / / 20884846 rs17450434 chr4 10164961 C T 1.16E-132 Urate levels / / 23263486 rs16894270 chr4 10165779 G T 1.77E-15 Uric acid levels / / 19503597 rs16894270 chr4 10165779 G T 5.20E-13 Urate levels / / 20884846 rs16894270 chr4 10165779 G T 7.37E-04 Prostate cancer mortality / / 20978177 rs16894270 chr4 10165779 G T 6.30E-49 Urate levels / / 23263486 rs11729371 chr4 10165957 T A 2.02E-45 Uric acid levels / / 19503597 rs11729371 chr4 10165957 T A 1.10E-62 Urate levels / / 20884846 rs11729371 chr4 10165957 T A 3.12E-166 Urate levels / / 23263486 rs11724641 chr4 10166994 G A 1.66E-42 Uric acid levels / / 19503597 rs11724641 chr4 10166994 G A 7.40E-32 Urate levels / / 20884846 rs11724641 chr4 10166994 G A 9.12E-123 Urate levels / / 23263486 rs7659717 chr4 10167217 T C 4.29E-48 Uric acid levels / / 19503597 rs7659717 chr4 10167217 T C 1.50E-37 Urate levels / / 20884846 rs7659717 chr4 10167217 T C 2.04E-139 Urate levels / / 23263486 rs17385112 chr4 10167532 T G 6.16E-71 Uric acid levels / / 19503597 rs17385112 chr4 10167532 T G 8.10E-74 Urate levels / / 20884846 rs17385112 chr4 10167532 T G 1.87E-220 Urate levels / / 23263486 rs17385294 chr4 10168447 G A 1.19E-46 Uric acid levels / / 19503597 rs17385294 chr4 10168447 G A 1.80E-35 Urate levels / / 20884846 rs17385294 chr4 10168447 G A 1.36E-132 Urate levels / / 23263486 rs1001216 chr4 10168849 A G 6.70E-71 Uric acid levels / / 19503597 rs1001216 chr4 10168849 A G 1.10E-73 Urate levels / / 20884846 rs1001216 chr4 10168849 A G 1.93E-219 Urate levels / / 23263486 rs1001217 chr4 10168999 C G 5.44E-11 Uric acid levels / / 19503597 rs1001217 chr4 10168999 C G 1.30E-07 Urate levels / / 20884846 rs1001217 chr4 10168999 C G 1.13E-24 Urate levels / / 23263486 rs11734209 chr4 10170371 T A 1.55E-09 Uric acid levels / / 19503597 rs11734209 chr4 10170371 T A 2.40E-15 Urate levels / / 20884846 rs11734209 chr4 10170371 T A 5.66E-36 Urate levels / / 23263486 rs874079 chr4 10171105 C T 1.49E-10 Uric acid levels / / 19503597 rs874079 chr4 10171105 C T 1.84E-19 Urate levels / / 23263486 rs7686718 chr4 10171487 T C 4.83E-14 Urate levels / / 23263486 rs4697948 chr4 10171567 C G 4.87E-11 Uric acid levels / / 19503597 rs4697948 chr4 10171567 C G 6.60E-08 Urate levels / / 20884846 rs4697948 chr4 10171567 C G 3.34E-25 Urate levels / / 23263486 rs2080076 chr4 10171945 C A 3.05E-11 Uric acid levels / / 19503597 rs2080076 chr4 10171945 C A 9.02E-20 Urate levels / / 23263486 rs2098234 chr4 10172113 G C 6.65E-11 Uric acid levels / / 19503597 rs2098234 chr4 10172113 G C 2.41E-17 Urate levels / / 23263486 rs6835689 chr4 10172479 C T 4.22E-11 Uric acid levels / / 19503597 rs6835689 chr4 10172479 C T 1.20E-07 Urate levels / / 20884846 rs6835689 chr4 10172479 C T 2.93E-25 Urate levels / / 23263486 rs10034405 chr4 10173696 A G 1.45E-19 Uric acid levels / / 19503597 rs10034405 chr4 10173696 A G 9.10E-19 Urate levels / / 20884846 rs4697718 chr4 10174139 T C 1.60E-22 Uric acid levels / / 19503597 rs4697718 chr4 10174139 T C 5.10E-16 Urate levels / / 20884846 rs4697719 chr4 10174158 G A 9.98E-24 Uric acid levels / / 19503597 rs4697719 chr4 10174158 G A 3.50E-16 Urate levels / / 20884846 rs4697721 chr4 10174217 G C 4.07E-49 Uric acid levels / / 19503597 rs4697721 chr4 10174217 G C 3.00E-37 Urate levels / / 20884846 rs4697721 chr4 10174217 G C 2.62E-141 Urate levels / / 23263486 rs4697954 chr4 10174529 A G 4.69E-23 Uric acid levels / / 19503597 rs4697954 chr4 10174529 A G 6.00E-16 Urate levels / / 20884846 rs10017447 chr4 10175536 C A 3.48E-23 Uric acid levels / / 19503597 rs10017447 chr4 10175536 C A 8.30E-14 Urate levels / / 20884846 rs10024152 chr4 10175689 A T 1.37E-23 Uric acid levels / / 19503597 rs10024152 chr4 10175689 A T 3.60E-16 Urate levels / / 20884846 rs2903827 chr4 10175872 C G 4.06E-132 Uric acid levels / / 19503597 rs2903827 chr4 10175872 C G 1.90E-153 Urate levels / / 20884846 rs2903827 chr4 10175872 C G 2.13E-14 Urate levels / / 23263486 rs2868414 chr4 10177120 G C 4.66E-48 Uric acid levels / / 19503597 rs2868414 chr4 10177120 G C 1.60E-36 Urate levels / / 20884846 rs2868414 chr4 10177120 G C 9.61E-139 Urate levels / / 23263486 rs17385872 chr4 10178168 C A 8.47E-47 Uric acid levels / / 19503597 rs17385872 chr4 10178168 C A 3.30E-41 Urate levels / / 20884846 rs17385872 chr4 10178168 C A 5.90E-149 Urate levels / / 23263486 rs16894579 chr4 10178217 C T 1.60E-47 Uric acid levels / / 19503597 rs16894579 chr4 10178217 C T 1.30E-36 Urate levels / / 20884846 rs16894579 chr4 10178217 C T 2.12E-139 Urate levels / / 23263486 rs10033955 chr4 10178556 T A 2.80E-47 Uric acid levels / / 19503597 rs10033955 chr4 10178556 T A 1.40E-36 Urate levels / / 20884846 rs10033955 chr4 10178556 T A 1.67E-127 Urate levels / / 23263486 rs11737347 chr4 10178922 A T 1.55E-47 Uric acid levels / / 19503597 rs11737347 chr4 10178922 A T 1.30E-36 Urate levels / / 20884846 rs11737347 chr4 10178922 A T 2.05E-138 Urate levels / / 23263486 rs7657551 chr4 10179309 T C 1.70E-47 Uric acid levels / / 19503597 rs7657551 chr4 10179309 T C 9.80E-37 Urate levels / / 20884846 rs7657551 chr4 10179309 T C 1.13E-138 Urate levels / / 23263486 rs6449342 chr4 10179769 A G 2.59E-47 Uric acid levels / / 19503597 rs6449342 chr4 10179769 A G 8.30E-37 Urate levels / / 20884846 rs6449342 chr4 10179769 A G 7.89E-139 Urate levels / / 23263486 rs4273473 chr4 10180622 T C 1.91E-47 Uric acid levels / / 19503597 rs4273473 chr4 10180622 T C 6.60E-37 Urate levels / / 20884846 rs4273473 chr4 10180622 T C 2.58E-139 Urate levels / / 23263486 rs11724112 chr4 10180643 T C 8.49E-80 Uric acid levels / / 19503597 rs11724112 chr4 10180643 T C 9.50E-78 Urate levels / / 20884846 rs11724112 chr4 10180643 T C 2.58E-263 Urate levels / / 23263486 rs199984580 chr4 10180643 TG T 8.49E-80 Uric acid levels / / 19503597 rs199984580 chr4 10180643 TG T 9.50E-78 Urate levels / / 20884846 rs199984580 chr4 10180643 TG T 2.58E-263 Urate levels / / 23263486 rs576402731 chr4 10180643 TG T 8.49E-80 Uric acid levels / / 19503597 rs576402731 chr4 10180643 TG T 9.50E-78 Urate levels / / 20884846 rs576402731 chr4 10180643 TG T 2.58E-263 Urate levels / / 23263486 rs6811287 chr4 10180823 C T 1.90E-80 Uric acid levels / / 19503597 rs6811287 chr4 10180823 C T 1.90E-77 Urate levels / / 20884846 rs6811287 chr4 10180823 C T 6.13E-263 Urate levels / / 23263486 rs723663 chr4 10181374 A G 5.76E-48 Uric acid levels / / 19503597 rs723663 chr4 10181374 A G 7.20E-37 Urate levels / / 20884846 rs723663 chr4 10181374 A G 7.42E-139 Urate levels / / 23263486 rs12500891 chr4 10181387 T A 6.99E-46 Uric acid levels / / 19503597 rs12500891 chr4 10181387 T A 2.00E-39 Urate levels / / 20884846 rs12500891 chr4 10181387 T A 3.70E-141 Urate levels / / 23263486 rs4697956 chr4 10181672 C T 1.49E-47 Uric acid levels / / 19503597 rs4697956 chr4 10181672 C T 9.70E-37 Urate levels / / 20884846 rs4697956 chr4 10181672 C T 1.62E-138 Urate levels / / 23263486 rs4697957 chr4 10182254 A G 9.83E-136 Uric acid levels / / 19503597 rs4697957 chr4 10182254 A G 8.70E-156 Urate levels / / 20884846 rs4697957 chr4 10182254 A G 6.10E-15 Urate levels / / 23263486 rs4697958 chr4 10182556 T C 4.95E-47 Uric acid levels / / 19503597 rs4697958 chr4 10182556 T C 1.10E-36 Urate levels / / 20884846 rs4697958 chr4 10182556 T C 1.28E-138 Urate levels / / 23263486 rs887735 chr4 10182845 T C 8.17E-48 Uric acid levels / / 19503597 rs887735 chr4 10182845 T C 2.00E-42 Urate levels / / 20884846 rs887735 chr4 10182845 T C 1.42E-147 Urate levels / / 23263486 rs887733 chr4 10183108 T C 1.74E-45 Uric acid levels / / 19503597 rs887733 chr4 10183108 T C 3.50E-46 Urate levels / / 20884846 rs887733 chr4 10183108 T C 4.08E-142 Urate levels / / 23263486 rs887732 chr4 10183117 G C 1.96E-136 Uric acid levels / / 19503597 rs887732 chr4 10183117 G C 9.00E-156 Urate levels / / 20884846 rs887732 chr4 10183117 G C 6.27E-15 Urate levels / / 23263486 rs887731 chr4 10183186 A C 1.89E-47 Uric acid levels / / 19503597 rs887731 chr4 10183186 A C 1.40E-36 Urate levels / / 20884846 rs887731 chr4 10183186 A C 1.49E-138 Urate levels / / 23263486 rs887729 chr4 10183611 C G 2.73E-45 Uric acid levels / / 19503597 rs887729 chr4 10183611 C G 3.10E-39 Urate levels / / 20884846 rs887729 chr4 10183611 C G 3.07E-141 Urate levels / / 23263486 rs887728 chr4 10183798 A G 1.85E-47 Uric acid levels / / 19503597 rs887728 chr4 10183798 A G 1.90E-36 Urate levels / / 20884846 rs887728 chr4 10183798 A G 1.18E-138 Urate levels / / 23263486 rs887727 chr4 10183819 G A 3.62E-47 Uric acid levels / / 19503597 rs887727 chr4 10183819 G A 3.70E-37 Urate levels / / 20884846 rs887727 chr4 10183819 G A 1.77E-143 Urate levels / / 23263486 rs887725 chr4 10183895 C T 6.50E-15 Urate levels / / 20884846 rs887725 chr4 10183895 C T 1.96E-22 Urate levels / / 23263486 rs11722345 chr4 10186799 C A 4.04E-47 Uric acid levels / / 19503597 rs11722345 chr4 10186799 C A 7.00E-36 Urate levels / / 20884846 rs11722345 chr4 10186799 C A 3.68E-138 Urate levels / / 23263486 rs4697960 chr4 10187263 G C 5.88E-46 Uric acid levels / / 19503597 rs4697960 chr4 10187263 G C 1.00E-36 Urate levels / / 20884846 rs4697960 chr4 10187263 G C 2.97E-143 Urate levels / / 23263486 rs4697727 chr4 10187922 T C 7.22E-47 Uric acid levels / / 19503597 rs4697727 chr4 10187922 T C 3.10E-36 Urate levels / / 20884846 rs4697727 chr4 10187922 T C 1.13E-139 Urate levels / / 23263486 rs956312 chr4 10188326 G A 7.97E-09 Serum uric acid levels / / 17997608 rs956312 chr4 10188326 G A 1.25E-48 Uric acid levels / / 19503597 rs956312 chr4 10188326 G A 2.10E-35 Urate levels / / 20884846 rs956312 chr4 10188326 G A 1.19E-139 Urate levels / / 23263486 rs956311 chr4 10188381 C A 1.72E-09 Serum uric acid levels / / 17997608 rs956311 chr4 10188381 C A 1.22E-48 Uric acid levels / / 19503597 rs956311 chr4 10188381 C A 9.50E-36 Urate levels / / 20884846 rs956311 chr4 10188381 C A 8.65E-139 Urate levels / / 23263486 rs11721530 chr4 10189162 G A 4.54E-46 Uric acid levels / / 19503597 rs11721530 chr4 10189162 G A 7.50E-36 Urate levels / / 20884846 rs11721530 chr4 10189162 G A 7.06E-138 Urate levels / / 23263486 rs4697964 chr4 10189812 A G 6.65E-47 Uric acid levels / / 19503597 rs4697964 chr4 10189812 A G 7.20E-36 Urate levels / / 20884846 rs4697964 chr4 10189812 A G 3.41E-138 Urate levels / / 23263486 rs4697965 chr4 10190058 A G 1.07E-46 Uric acid levels / / 19503597 rs4697965 chr4 10190058 A G 7.10E-36 Urate levels / / 20884846 rs4697965 chr4 10190058 A G 1.37E-138 Urate levels / / 23263486 rs4697966 chr4 10190074 G A 5.31E-46 Uric acid levels / / 19503597 rs4697966 chr4 10190074 G A 6.30E-36 Urate levels / / 20884846 rs4697966 chr4 10190074 G A 9.34E-139 Urate levels / / 23263486 rs2215691 chr4 10192108 C T 2.51E-45 Uric acid levels / / 19503597 rs2215691 chr4 10192108 C T 2.00E-36 Urate levels / / 20884846 rs2215691 chr4 10192108 C T 4.31E-137 Urate levels / / 23263486 rs10489080 chr4 10193427 C G 6.56E-45 Uric acid levels / / 19503597 rs10489080 chr4 10193427 C G 2.70E-39 Urate levels / / 20884846 rs10489080 chr4 10193427 C G 3.57E-139 Urate levels / / 23263486 rs2159864 chr4 10193604 A G 1.23E-43 Uric acid levels / / 19503597 rs2159864 chr4 10193604 A G 1.90E-36 Urate levels / / 20884846 rs2159864 chr4 10193604 A G 1.36E-133 Urate levels / / 23263486 rs6826383 chr4 10194504 A G 2.37E-45 Uric acid levels / / 19503597 rs6826383 chr4 10194504 A G 2.10E-36 Urate levels / / 20884846 rs6826383 chr4 10194504 A G 3.39E-137 Urate levels / / 23263486 rs4697728 chr4 10196638 T C 3.60E-46 Uric acid levels / / 19503597 rs4697728 chr4 10196638 T C 7.20E-37 Urate levels / / 20884846 rs4697728 chr4 10196638 T C 1.27E-133 Urate levels / / 23263486 rs917825 chr4 10196761 A T 1.73E-45 Uric acid levels / / 19503597 rs917825 chr4 10196761 A T 6.90E-37 Urate levels / / 20884846 rs917825 chr4 10196761 A T 5.68E-133 Urate levels / / 23263486 rs1860903 chr4 10196853 G A 5.24E-46 Uric acid levels / / 19503597 rs1860903 chr4 10196853 G A 6.70E-40 Urate levels / / 20884846 rs1860903 chr4 10196853 G A 5.92E-141 Urate levels / / 23263486 rs929575 chr4 10196886 C G 4.46E-134 Uric acid levels / / 19503597 rs929575 chr4 10196886 C G 4.30E-157 Urate levels / / 20884846 rs929575 chr4 10196886 C G 3.70E-15 Urate levels / / 23263486 rs917823 chr4 10197225 C T 5.88E-46 Uric acid levels / / 19503597 rs917823 chr4 10197225 C T 5.40E-37 Urate levels / / 20884846 rs917823 chr4 10197225 C T 2.16E-125 Urate levels / / 23263486 rs4697968 chr4 10198628 C T 1.38E-23 Uric acid levels / / 19503597 rs4697968 chr4 10198628 C T 1.50E-15 Urate levels / / 20884846 rs4697969 chr4 10198981 G C 1.18E-23 Uric acid levels / / 19503597 rs4697969 chr4 10198981 G C 1.50E-15 Urate levels / / 20884846 rs2080075 chr4 10199448 T C 1.16E-45 Uric acid levels / / 19503597 rs2080075 chr4 10199448 T C 7.40E-37 Urate levels / / 20884846 rs2080075 chr4 10199448 T C 6.97E-120 Urate levels / / 23263486 rs4697729 chr4 10200401 G T 1.04E-45 Uric acid levels / / 19503597 rs4697729 chr4 10200401 G T 7.90E-37 Urate levels / / 20884846 rs4697729 chr4 10200401 G T 2.09E-120 Urate levels / / 23263486 rs4697730 chr4 10200496 T C 3.58E-45 Uric acid levels / / 19503597 rs4697730 chr4 10200496 T C 8.30E-37 Urate levels / / 20884846 rs4697730 chr4 10200496 T C 4.06E-121 Urate levels / / 23263486 rs4697971 chr4 10200860 T A 1.88E-45 Uric acid levels / / 19503597 rs4697971 chr4 10200860 T A 8.30E-37 Urate levels / / 20884846 rs4697971 chr4 10200860 T A 4.35E-118 Urate levels / / 23263486 rs4697732 chr4 10201873 G T 9.35E-46 Uric acid levels / / 19503597 rs4697732 chr4 10201873 G T 8.40E-37 Urate levels / / 20884846 rs4697732 chr4 10201873 G T 8.15E-121 Urate levels / / 23263486 rs2868416 chr4 10202574 C T 1.47E-45 Uric acid levels / / 19503597 rs2868416 chr4 10202574 C T 8.10E-37 Urate levels / / 20884846 rs2868416 chr4 10202574 C T 1.61E-122 Urate levels / / 23263486 rs10489079 chr4 10203963 G C 1.24E-45 Uric acid levels / / 19503597 rs10489079 chr4 10203963 G C 9.80E-40 Urate levels / / 20884846 rs10489079 chr4 10203963 G C 1.79E-135 Urate levels / / 23263486 rs6858209 chr4 10204157 A G 1.48E-45 Uric acid levels / / 19503597 rs6858209 chr4 10204157 A G 7.80E-37 Urate levels / / 20884846 rs6858209 chr4 10204157 A G 3.48E-127 Urate levels / / 23263486 rs9283699 chr4 10204189 C T 1.50E-45 Uric acid levels / / 19503597 rs9283699 chr4 10204189 C T 7.70E-37 Urate levels / / 20884846 rs9283699 chr4 10204189 C T 1.50E-127 Urate levels / / 23263486 rs10030776 chr4 10204475 C G 4.02E-45 Uric acid levels / / 19503597 rs10030776 chr4 10204475 C G 1.30E-36 Urate levels / / 20884846 rs10030776 chr4 10204475 C G 2.47E-127 Urate levels / / 23263486 rs10030782 chr4 10204496 C T 2.12E-45 Uric acid levels / / 19503597 rs10030782 chr4 10204496 C T 1.40E-36 Urate levels / / 20884846 rs10030782 chr4 10204496 C T 3.92E-128 Urate levels / / 23263486 rs9990501 chr4 10204593 A G 2.10E-45 Uric acid levels / / 19503597 rs9990501 chr4 10204593 A G 1.60E-36 Urate levels / / 20884846 rs9990501 chr4 10204593 A G 1.36E-128 Urate levels / / 23263486 rs10939766 chr4 10204970 A G 1.01E-46 Uric acid levels / / 19503597 rs10939766 chr4 10204970 A G 1.60E-36 Urate levels / / 20884846 rs10939766 chr4 10204970 A G 1.07E-130 Urate levels / / 23263486 rs16894893 chr4 10205595 A T 1.33E-09 Uric acid levels / / 19503597 rs16894893 chr4 10205595 A T 1.10E-17 Urate levels / / 20884846 rs16894893 chr4 10205595 A T 6.01E-37 Urate levels / / 23263486 rs231 chr4 10205848 C G 1.04E-45 Uric acid levels / / 19503597 rs231 chr4 10205848 C G 1.10E-36 Urate levels / / 20884846 rs231 chr4 10205848 C G 1.83E-132 Urate levels / / 23263486 rs17455117 chr4 10206204 G C 2.98E-29 Uric acid levels / / 19503597 rs17455117 chr4 10206204 G C 6.30E-24 Urate levels / / 20884846 rs17455117 chr4 10206204 G C 1.16E-84 Urate levels / / 23263486 rs6449355 chr4 10206731 T C 4.29E-46 Uric acid levels / / 19503597 rs6449355 chr4 10206731 T C 1.40E-36 Urate levels / / 20884846 rs6449355 chr4 10206731 T C 1.33E-134 Urate levels / / 23263486 rs17389602 chr4 10206926 T A 3.90E-135 Uric acid levels / / 19503597 rs17389602 chr4 10206926 T A 3.10E-155 Urate levels / / 20884846 rs17389602 chr4 10206926 T A 1.95E-15 Urate levels / / 23263486 rs6812780 chr4 10208725 T G 4.28E-45 Uric acid levels / / 19503597 rs6812780 chr4 10208725 T G 1.40E-36 Urate levels / / 20884846 rs6812780 chr4 10208725 T G 1.57E-134 Urate levels / / 23263486 rs6826450 chr4 10208778 G A 8.74E-46 Uric acid levels / / 19503597 rs6826450 chr4 10208778 G A 1.80E-36 Urate levels / / 20884846 rs6826450 chr4 10208778 G A 1.34E-134 Urate levels / / 23263486 rs6845818 chr4 10208794 C T 1.04E-09 Uric acid levels / / 19503597 rs6845818 chr4 10208794 C T 1.20E-17 Urate levels / / 20884846 rs6845818 chr4 10208794 C T 8.62E-39 Urate levels / / 23263486 rs6855489 chr4 10208888 A G 1.31E-46 Uric acid levels / / 19503597 rs6855489 chr4 10208888 A G 2.20E-36 Urate levels / / 20884846 rs6855489 chr4 10208888 A G 2.38E-135 Urate levels / / 23263486 rs11947517 chr4 10209251 A G 8.89E-46 Uric acid levels / / 19503597 rs11947517 chr4 10209251 A G 6.60E-38 Urate levels / / 20884846 rs11947517 chr4 10209251 A G 3.89E-144 Urate levels / / 23263486 rs201759493 chr4 10209251 AGG A 8.89E-46 Uric acid levels / / 19503597 rs201759493 chr4 10209251 AGG A 6.60E-38 Urate levels / / 20884846 rs201759493 chr4 10209251 AGG A 3.89E-144 Urate levels / / 23263486 rs386671621 chr4 10209251 AGGTAGTTAT ATATATA 8.89E-46 Uric acid levels / / 19503597 rs386671621 chr4 10209251 AGGTAGTTAT ATATATA 6.60E-38 Urate levels / / 20884846 rs386671621 chr4 10209251 AGGTAGTTAT ATATATA 3.89E-144 Urate levels / / 23263486 rs4697977 chr4 10210653 C T 1.10E-45 Uric acid levels / / 19503597 rs4697977 chr4 10210653 C T 1.90E-36 Urate levels / / 20884846 rs4697977 chr4 10210653 C T 9.30E-131 Urate levels / / 23263486 rs2080072 chr4 10235622 G C 4.72E-79 Uric acid levels / / 19503597 rs2080072 chr4 10235622 G C 2.30E-80 Urate levels / / 20884846 rs2080072 chr4 10235622 G C 7.01E-262 Urate levels / / 23263486 rs11734783 chr4 10240663 T C 7.40E-110 Uric acid levels / / 19503597 rs11734783 chr4 10240663 T C 5.00E-147 Urate levels / / 20884846 rs11734783 chr4 10240663 T C 2.22E-16 Urate levels / / 23263486 rs917821 chr4 10241132 C A 2.22E-13 Urate levels / / 23263486 rs11727366 chr4 10244841 G A 2.27E-47 Uric acid levels / / 19503597 rs11727366 chr4 10244841 G A 8.70E-40 Urate levels / / 20884846 rs11727366 chr4 10244841 G A 3.87E-148 Urate levels / / 23263486 rs10023177 chr4 10244955 T A 2.18E-48 Uric acid levels / / 19503597 rs10023177 chr4 10244955 T A 9.40E-40 Urate levels / / 20884846 rs10023177 chr4 10244955 T A 1.90E-05 Urinary metabolites / / 21572414 rs10023177 chr4 10244955 T A 4.45E-148 Urate levels / / 23263486 rs1978274 chr4 10245087 T G 6.18E-137 Uric acid levels / / 19503597 rs1978274 chr4 10245087 T G 4.10E-154 Urate levels / / 20884846 rs1978274 chr4 10245087 T G 1.46E-15 Urate levels / / 23263486 rs7675945 chr4 10245340 T C 1.55E-47 Uric acid levels / / 19503597 rs7675945 chr4 10245340 T C 1.00E-39 Urate levels / / 20884846 rs7675945 chr4 10245340 T C 1.37E-147 Urate levels / / 23263486 rs6853056 chr4 10245898 G A 9.22E-49 Uric acid levels / / 19503597 rs6853056 chr4 10245898 G A 7.10E-40 Urate levels / / 20884846 rs6853056 chr4 10245898 G A 9.02E-151 Urate levels / / 23263486 rs10010656 chr4 10246327 G C 3.46E-46 Uric acid levels / / 19503597 rs10010656 chr4 10246327 G C 1.10E-39 Urate levels / / 20884846 rs10010656 chr4 10246327 G C 9.50E-148 Urate levels / / 23263486 rs11732042 chr4 10246448 C A,G,T 1.86E-09 Uric acid levels / / 19503597 rs11732042 chr4 10246448 C A,G,T 5.60E-13 Urate levels / / 20884846 rs11732042 chr4 10246448 C A,G,T 4.62E-30 Urate levels / / 23263486 rs4697983 chr4 10247248 A G 1.61E-19 Uric acid levels / / 19503597 rs4697983 chr4 10247248 A G 2.00E-29 Urate levels / / 20884846 rs4697983 chr4 10247248 A G 1.17E-67 Urate levels / / 23263486 rs10939801 chr4 10247512 G C 1.71E-43 Uric acid levels / / 19503597 rs10939801 chr4 10247512 G C 1.90E-35 Urate levels / / 20884846 rs10939801 chr4 10247512 G C 2.74E-135 Urate levels / / 23263486 rs11730940 chr4 10247893 G A 2.98E-43 Uric acid levels / / 19503597 rs11730940 chr4 10247893 G A 2.00E-35 Urate levels / / 20884846 rs11730940 chr4 10247893 G A 6.14E-134 Urate levels / / 23263486 rs10025702 chr4 10248174 C G 1.16E-46 Uric acid levels / / 19503597 rs10025702 chr4 10248174 C G 1.70E-39 Urate levels / / 20884846 rs10025702 chr4 10248174 C G 1.89E-143 Urate levels / / 23263486 rs2024282 chr4 10249688 A G 1.12E-22 Uric acid levels / / 19503597 rs2024282 chr4 10249688 A G 1.10E-22 Urate levels / / 20884846 rs2024282 chr4 10249688 A G 3.31E-113 Urate levels / / 23263486 rs2024281 chr4 10249751 G A 8.84E-44 Uric acid levels / / 19503597 rs2024281 chr4 10249751 G A 1.90E-35 Urate levels / / 20884846 rs2024281 chr4 10249751 G A 2.14E-134 Urate levels / / 23263486 rs6449395 chr4 10249877 G T 2.42E-09 Urate levels / / 23263486 rs7661555 chr4 10250026 T C 3.30E-45 Uric acid levels / / 19503597 rs7661555 chr4 10250026 T C 2.50E-37 Urate levels / / 20884846 rs7661555 chr4 10250026 T C 6.91E-137 Urate levels / / 23263486 rs17392044 chr4 10250340 C G 2.43E-85 Uric acid levels / / 19503597 rs17392044 chr4 10250340 C G 5.30E-82 Urate levels / / 20884846 rs17392044 chr4 10250340 C G 4.26E-258 Urate levels / / 23263486 rs1017124 chr4 10250399 T C 6.98E-49 Uric acid levels / / 19503597 rs1017124 chr4 10250399 T C 1.70E-38 Urate levels / / 20884846 rs1017124 chr4 10250399 T C 3.58E-150 Urate levels / / 23263486 rs12509424 chr4 10250503 G A 6.89E-45 Uric acid levels / / 19503597 rs12509424 chr4 10250503 G A 1.50E-36 Urate levels / / 20884846 rs12509424 chr4 10250503 G A 6.60E-136 Urate levels / / 23263486 rs1860896 chr4 10250777 T C 3.45E-46 Uric acid levels / / 19503597 rs1860896 chr4 10250777 T C 3.50E-35 Urate levels / / 20884846 rs1860896 chr4 10250777 T C 6.60E-127 Urate levels / / 23263486 rs16895216 chr4 10250983 C A 1.70E-11 Urate levels / / 20884846 rs16895216 chr4 10250983 C A 5.28E-21 Urate levels / / 23263486 rs11735543 chr4 10251652 G T 1.68E-124 Uric acid levels / / 19503597 rs11735543 chr4 10251652 G T 7.40E-142 Urate levels / / 20884846 rs11735543 chr4 10251652 G T 1.06E-14 Urate levels / / 23263486 rs10029208 chr4 10252005 G T 3.72E-49 Uric acid levels / / 19503597 rs10029208 chr4 10252005 G T 2.00E-38 Urate levels / / 20884846 rs10029208 chr4 10252005 G T 1.21E-150 Urate levels / / 23263486 rs6838644 chr4 10252871 T C 6.28E-44 Uric acid levels / / 19503597 rs6838644 chr4 10252871 T C 2.10E-36 Urate levels / / 20884846 rs6838644 chr4 10252871 T C 8.98E-125 Urate levels / / 23263486 rs4522862 chr4 10253015 C G,T 3.86E-49 Uric acid levels / / 19503597 rs4522862 chr4 10253015 C G,T 2.30E-38 Urate levels / / 20884846 rs4522862 chr4 10253015 C G,T 8.78E-151 Urate levels / / 23263486 rs4406017 chr4 10253169 G C 1.92E-09 Urate levels / / 23263486 rs4697984 chr4 10254550 A C 5.17E-49 Uric acid levels / / 19503597 rs4697984 chr4 10254550 A C 2.30E-38 Urate levels / / 20884846 rs4697984 chr4 10254550 A C 1.24E-150 Urate levels / / 23263486 rs12513165 chr4 10256577 C T 2.83E-45 Uric acid levels / / 19503597 rs12513165 chr4 10256577 C T 2.10E-36 Urate levels / / 20884846 rs12513165 chr4 10256577 C T 5.27E-137 Urate levels / / 23263486 rs2192101 chr4 10258057 C G 3.58E-49 Uric acid levels / / 19503597 rs2192101 chr4 10258057 C G 2.80E-38 Urate levels / / 20884846 rs2192101 chr4 10258057 C G 2.50E-150 Urate levels / / 23263486 rs2192100 chr4 10258373 T C 3.19E-09 Urate levels / / 23263486 rs4697986 chr4 10258968 G A 4.12E-44 Uric acid levels / / 19503597 rs4697986 chr4 10258968 G A 8.90E-34 Urate levels / / 20884846 rs4697986 chr4 10258968 G A 1.81E-138 Urate levels / / 23263486 rs4697736 chr4 10259834 G C 7.30E-10 Urate levels / / 23263486 rs17406107 chr4 10263380 T G 6.32E-137 Uric acid levels / / 19503597 rs17406107 chr4 10263380 T G 8.70E-150 Urate levels / / 20884846 rs17406107 chr4 10263380 T G 2.40E-15 Urate levels / / 23263486 rs4697995 chr4 10264276 A C 1.17E-08 Urate levels / / 23263486 rs929577 chr4 10264888 G A 4.06E-45 Uric acid levels / / 19503597 rs929577 chr4 10264888 G A 4.60E-36 Urate levels / / 20884846 rs929577 chr4 10264888 G A 3.32E-138 Urate levels / / 23263486 rs759031 chr4 10265433 T C 3.16E-50 Uric acid levels / / 19503597 rs759031 chr4 10265433 T C 3.00E-37 Urate levels / / 20884846 rs759031 chr4 10265433 T C 1.96E-136 Urate levels / / 23263486 rs17472370 chr4 10270131 C A 2.05E-22 Uric acid levels / / 19503597 rs17472370 chr4 10270131 C A 8.70E-30 Urate levels / / 20884846 rs17472370 chr4 10270131 C A 6.52E-67 Urate levels / / 23263486 rs10489076 chr4 10270848 T C 8.49E-14 Uric acid levels / / 19503597 rs10489076 chr4 10270848 T C 2.00E-16 Urate levels / / 20884846 rs10489076 chr4 10270848 T C 6.41E-42 Urate levels / / 23263486 rs13134726 chr4 10271119 T C 1.50E-08 Urate levels / / 23263486 rs12505222 chr4 10271136 G T 2.15E-13 Uric acid levels / / 19503597 rs12505222 chr4 10271136 G T 2.10E-16 Urate levels / / 20884846 rs12505222 chr4 10271136 G T 6.32E-05 Schizophrenia(age at onset) / / 21688384 rs12505222 chr4 10271136 G T 1.64E-41 Urate levels / / 23263486 rs7676442 chr4 10272591 C T 5.83E-14 Uric acid levels / / 19503597 rs7676442 chr4 10272591 C T 2.90E-17 Urate levels / / 20884846 rs7676442 chr4 10272591 C T 8.88E-46 Urate levels / / 23263486 rs10489074 chr4 10272605 C A 2.70E-14 Urate levels / / 20884846 rs10489074 chr4 10272605 C A 1.02E-35 Urate levels / / 23263486 rs10489073 chr4 10272788 G A 1.58E-12 Uric acid levels / / 19503597 rs10489073 chr4 10272788 G A 2.00E-19 Urate levels / / 20884846 rs10489073 chr4 10272788 G A 4.21E-05 Schizophrenia(age at onset) / / 21688384 rs10489073 chr4 10272788 G A 8.36E-41 Urate levels / / 23263486 rs17407324 chr4 10273043 C A 5.93E-12 Uric acid levels / / 19503597 rs17407324 chr4 10273043 C A 1.70E-19 Urate levels / / 20884846 rs17407324 chr4 10273043 C A 8.88E-05 Schizophrenia(age at onset) / / 21688384 rs17407324 chr4 10273043 C A 1.27E-40 Urate levels / / 23263486 rs10489072 chr4 10273244 T C 8.32E-14 Uric acid levels / / 19503597 rs10489072 chr4 10273244 T C 1.40E-18 Urate levels / / 20884846 rs10489072 chr4 10273244 T C 3.79E-44 Urate levels / / 23263486 rs10489072 chr4 10273244 T C 4.08E-04 Cleft palate (environmental tobacco smoke interaction) / / 24516586 rs10489072 chr4 10273244 T C 7.81E-05 Cleft palate (environmental tobacco smoke interaction) / / 24516586 rs10939814 chr4 10273329 T C 6.44E-14 Uric acid levels / / 19503597 rs10939814 chr4 10273329 T C 1.00E-18 Urate levels / / 20884846 rs10939814 chr4 10273329 T C 9.58E-45 Urate levels / / 23263486 rs10489071 chr4 10273549 G A 9.75E-14 Uric acid levels / / 19503597 rs10489071 chr4 10273549 G A 1.50E-17 Urate levels / / 20884846 rs10489071 chr4 10273549 G A 2.52E-05 Schizophrenia(age at onset) / / 21688384 rs10489071 chr4 10273549 G A 1.83E-42 Urate levels / / 23263486 rs2192095 chr4 10274173 T C 4.82E-14 Uric acid levels / / 19503597 rs2192095 chr4 10274173 T C 4.20E-18 Urate levels / / 20884846 rs2192095 chr4 10274173 T C 1.49E-44 Urate levels / / 23263486 rs4697998 chr4 10274626 G T 1.44E-13 Uric acid levels / / 19503597 rs4697998 chr4 10274626 G T 4.40E-17 Urate levels / / 20884846 rs4697998 chr4 10274626 G T 6.28E-05 Schizophrenia(age at onset) / / 21688384 rs4697998 chr4 10274626 G T 5.53E-41 Urate levels / / 23263486 rs4697999 chr4 10274934 G C 1.54E-11 Uric acid levels / / 19503597 rs4697999 chr4 10274934 G C 1.40E-15 Urate levels / / 20884846 rs4697999 chr4 10274934 G C 7.77E-06 Schizophrenia(age at onset) / / 21688384 rs4697999 chr4 10274934 G C 3.01E-38 Urate levels / / 23263486 rs17407555 chr4 10274994 A G 1.65E-10 Uric acid levels / / 19503597 rs17407555 chr4 10274994 A G 4.70E-17 Urate levels / / 20884846 rs17407555 chr4 10274994 A G 4.56E-06 Schizophrenia(age at onset) / / 21688384 rs17407555 chr4 10274994 A G 3.78E-36 Urate levels / / 23263486 rs1860911 chr4 10275057 C T 3.07E-39 Uric acid levels / / 19503597 rs1860911 chr4 10275057 C T 7.50E-40 Urate levels / / 20884846 rs1860911 chr4 10275057 C T 4.10E-136 Urate levels / / 23263486 rs1860910 chr4 10275470 T G 3.90E-39 Uric acid levels / / 19503597 rs1860910 chr4 10275470 T G 1.20E-39 Urate levels / / 20884846 rs1860910 chr4 10275470 T G 3.25E-136 Urate levels / / 23263486 rs10805364 chr4 10275518 A G 2.09E-134 Uric acid levels / / 19503597 rs10805364 chr4 10275518 A G 1.40E-148 Urate levels / / 20884846 rs10805364 chr4 10275518 A G 4.23E-17 Urate levels / / 23263486 rs10805364 chr4 10275518 A G 8.96E-05 Blood Pressure / / pha003040 rs6823180 chr4 10275831 C T 7.13E-12 Uric acid levels / / 19503597 rs6823180 chr4 10275831 C T 1.20E-14 Urate levels / / 20884846 rs6823180 chr4 10275831 C T 2.36E-36 Urate levels / / 23263486 rs6833142 chr4 10275982 A G 9.25E-12 Uric acid levels / / 19503597 rs6833142 chr4 10275982 A G 1.70E-14 Urate levels / / 20884846 rs6833142 chr4 10275982 A G 6.61E-06 Schizophrenia(age at onset) / / 21688384 rs6833142 chr4 10275982 A G 1.36E-35 Urate levels / / 23263486 rs6833142 chr4 10275982 A G 4.65E-04 Cleft palate (environmental tobacco smoke interaction) / / 24516586 rs6833142 chr4 10275982 A G 8.98E-05 Cleft palate (environmental tobacco smoke interaction) / / 24516586 rs10489070 chr4 10276352 C G 4.32E-09 Serum uric acid levels / / 17997608 rs10489070 chr4 10276352 C G 1.14E-131 Uric acid levels / / 19503597 rs10489070 chr4 10276352 C G 9.00E-149 Urate levels / / 20884846 rs10489070 chr4 10276352 C G 6.49E-18 Urate levels / / 23263486 rs12510549 chr4 10276467 T C 3.07E-08 Serum uric acid levels / / 17997608 rs12510549 chr4 10276467 T C 2.56E-136 Uric acid levels / / 19503597 rs12510549 chr4 10276467 T C 1.10E-148 Urate levels / / 20884846 rs12510549 chr4 10276467 T C 4.70E-18 Urate levels / / 23263486 rs4698000 chr4 10277467 T C 1.16E-12 Uric acid levels / / 19503597 rs4698000 chr4 10277467 T C 6.60E-16 Urate levels / / 20884846 rs4698000 chr4 10277467 T C 4.04E-05 Schizophrenia(age at onset) / / 21688384 rs4698000 chr4 10277467 T C 5.81E-38 Urate levels / / 23263486 rs6836916 chr4 10277792 C G 7.54E-11 Uric acid levels / / 19503597 rs6836916 chr4 10277792 C G 6.30E-16 Urate levels / / 20884846 rs6836916 chr4 10277792 C G 3.40E-38 Urate levels / / 23263486 rs11736814 chr4 10277869 T C 5.01E-12 Urate levels / / 23263486 rs16895836 chr4 10278349 C T 1.18E-14 Uric acid levels / / 19503597 rs16895836 chr4 10278349 C T 1.50E-17 Urate levels / / 20884846 rs16895836 chr4 10278349 C T 4.51E-40 Urate levels / / 23263486 rs7435841 chr4 10278552 G A 3.66E-11 Uric acid levels / / 19503597 rs7435841 chr4 10278552 G A 5.60E-16 Urate levels / / 20884846 rs7435841 chr4 10278552 G A 8.91E-05 Schizophrenia(age at onset) / / 21688384 rs7435841 chr4 10278552 G A 4.51E-38 Urate levels / / 23263486 rs10489069 chr4 10278668 G C 1.77E-44 Uric acid levels / / 19503597 rs10489069 chr4 10278668 G C 9.80E-35 Urate levels / / 20884846 rs10489069 chr4 10278668 G C 1.46E-135 Urate levels / / 23263486 rs16895848 chr4 10278829 T A 1.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs16895848 chr4 10278829 T A 6.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs10032742 chr4 10278893 A G 3.44E-11 Uric acid levels / / 19503597 rs10032742 chr4 10278893 A G 7.30E-16 Urate levels / / 20884846 rs10032742 chr4 10278893 A G 1.51E-37 Urate levels / / 23263486 rs4698001 chr4 10279413 A T 7.18E-13 Uric acid levels / / 19503597 rs4698001 chr4 10279413 A T 7.50E-16 Urate levels / / 20884846 rs4698001 chr4 10279413 A T 1.98E-39 Urate levels / / 23263486 rs1860909 chr4 10279557 C T 5.16E-09 Urate levels / / 23263486 rs17474174 chr4 10281411 T C 5.03E-43 Uric acid levels / / 19503597 rs17474174 chr4 10281411 T C 2.60E-36 Urate levels / / 20884846 rs17474174 chr4 10281411 T C 3.34E-138 Urate levels / / 23263486 rs16895934 chr4 10283053 T G 1.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs16895934 chr4 10283053 T G 5.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs2159868 chr4 10283560 G C 5.56E-10 Urate levels / / 23263486 rs4698005 chr4 10283627 C T 7.21E-10 Urate levels / / 23263486 rs4697740 chr4 10284565 C T 4.90E-09 Urate levels / / 23263486 rs16895984 chr4 10284727 C T 5.21E-88 Uric acid levels / / 19503597 rs16895984 chr4 10284727 C T 5.30E-106 Urate levels / / 20884846 rs16895984 chr4 10284727 C T 1.17E-287 Urate levels / / 23263486 rs4698009 chr4 10284993 T C 5.37E-08 Serum uric acid levels / / 17997608 rs4698009 chr4 10284993 T C 1.13E-127 Uric acid levels / / 19503597 rs4698009 chr4 10284993 T C 1.80E-145 Urate levels / / 20884846 rs4698009 chr4 10284993 T C 8.61E-16 Urate levels / / 23263486 rs4698013 chr4 10285381 T C 3.43E-04 Multiple complex diseases / / 17554300 rs4698014 chr4 10286301 C T 2.97E-131 Uric acid levels / / 19503597 rs4698014 chr4 10286301 C T 3.50E-146 Urate levels / / 20884846 rs4698014 chr4 10286301 C T 1.04E-15 Urate levels / / 23263486 rs4698014 chr4 10286301 C T 8.00E-13 Uric acid levels / / 23703922 rs17409460 chr4 10286427 G C 2.71E-44 Uric acid levels / / 19503597 rs17409460 chr4 10286427 G C 1.90E-36 Urate levels / / 20884846 rs17409460 chr4 10286427 G C 6.25E-138 Urate levels / / 23263486 rs7685241 chr4 10286665 G A 1.20E-47 Uric acid levels / / 19503597 rs7685241 chr4 10286665 G A 1.30E-36 Urate levels / / 20884846 rs7685241 chr4 10286665 G A 5.12E-133 Urate levels / / 23263486 rs12640013 chr4 10286687 C T 9.55E-09 Urate levels / / 23263486 rs10939818 chr4 10286962 G T 2.11E-48 Uric acid levels / / 19503597 rs10939818 chr4 10286962 G T 1.20E-36 Urate levels / / 20884846 rs10939818 chr4 10286962 G T 5.20E-146 Urate levels / / 23263486 rs17475334 chr4 10287170 A G 4.35E-44 Uric acid levels / / 19503597 rs17475334 chr4 10287170 A G 1.70E-36 Urate levels / / 20884846 rs17475334 chr4 10287170 A G 7.16E-138 Urate levels / / 23263486 rs11932349 chr4 10287251 A G 4.71E-48 Uric acid levels / / 19503597 rs11932349 chr4 10287251 A G 1.20E-36 Urate levels / / 20884846 rs11932349 chr4 10287251 A G 6.83E-146 Urate levels / / 23263486 rs10489068 chr4 10287268 A G 1.89E-45 Uric acid levels / / 19503597 rs10489068 chr4 10287268 A G 1.20E-33 Urate levels / / 20884846 rs10489068 chr4 10287268 A G 7.38E-136 Urate levels / / 23263486 rs17475461 chr4 10287677 T C 4.97E-09 Uric acid levels / / 19503597 rs17475461 chr4 10287677 T C 2.60E-15 Urate levels / / 20884846 rs17475461 chr4 10287677 T C 3.89E-30 Urate levels / / 23263486 rs11937220 chr4 10289874 T C 1.62E-47 Uric acid levels / / 19503597 rs11937220 chr4 10289874 T C 2.20E-36 Urate levels / / 20884846 rs11937220 chr4 10289874 T C 1.01E-145 Urate levels / / 23263486 rs7692559 chr4 10290726 A G 2.21E-08 Uric acid levels / / 19503597 rs7692559 chr4 10290726 A G 7.00E-19 Urate levels / / 20884846 rs7692559 chr4 10290726 A G 3.03E-30 Urate levels / / 23263486 rs6449438 chr4 10291063 C T 7.65E-09 Uric acid levels / / 19503597 rs6449438 chr4 10291063 C T 6.50E-19 Urate levels / / 20884846 rs6449438 chr4 10291063 C T 2.92E-31 Urate levels / / 23263486 rs2024280 chr4 10291813 T C 1.01E-128 Uric acid levels / / 19503597 rs2024280 chr4 10291813 T C 2.70E-152 Urate levels / / 20884846 rs2024280 chr4 10291813 T C 1.56E-17 Urate levels / / 23263486 rs2192094 chr4 10291968 T C 7.85E-45 Uric acid levels / / 19503597 rs2192094 chr4 10291968 T C 2.40E-36 Urate levels / / 20884846 rs2192094 chr4 10291968 T C 1.92E-138 Urate levels / / 23263486 rs11730631 chr4 10292968 A G 7.90E-34 Uric acid levels / / 19503597 rs11731652 chr4 10292984 T C 4.46E-121 Uric acid levels / / 19503597 rs11731652 chr4 10292984 T C 3.50E-149 Urate levels / / 20884846 rs11731652 chr4 10292984 T C 7.16E-17 Urate levels / / 23263486 rs917827 chr4 10295500 T C 1.99E-44 Uric acid levels / / 19503597 rs917827 chr4 10295500 T C 3.60E-33 Urate levels / / 20884846 rs917827 chr4 10295500 T C 7.54E-132 Urate levels / / 23263486 rs11728055 chr4 10296298 A C 2.21E-39 Uric acid levels / / 19503597 rs11728055 chr4 10296298 A C 4.40E-60 Urate levels / / 20884846 rs11728055 chr4 10296298 A C 3.52E-168 Urate levels / / 23263486 rs1860907 chr4 10296699 T C 1.40E-45 Uric acid levels / / 19503597 rs1860907 chr4 10296699 T C 2.60E-33 Urate levels / / 20884846 rs1860907 chr4 10296699 T C 7.25E-134 Urate levels / / 23263486 rs17410735 chr4 10297447 T C 7.35E-46 Uric acid levels / / 19503597 rs17410735 chr4 10297447 T C 5.10E-36 Urate levels / / 20884846 rs17410735 chr4 10297447 T C 8.67E-138 Urate levels / / 23263486 rs4697744 chr4 10298147 A G 1.59E-43 Uric acid levels / / 19503597 rs4697744 chr4 10298147 A G 6.10E-34 Urate levels / / 20884846 rs4697744 chr4 10298147 A G 2.75E-134 Urate levels / / 23263486 rs11732729 chr4 10300316 A G 1.60E-08 Uric acid levels / / 19503597 rs11732729 chr4 10300316 A G 2.30E-13 Urate levels / / 20884846 rs11732729 chr4 10300316 A G 5.93E-24 Urate levels / / 23263486 rs2080077 chr4 10300382 A G 3.10E-49 Uric acid levels / / 19503597 rs2080077 chr4 10300382 A G 3.40E-37 Urate levels / / 20884846 rs2080077 chr4 10300382 A G 9.39E-147 Urate levels / / 23263486 rs2098236 chr4 10300472 G C 2.47E-49 Uric acid levels / / 19503597 rs2098236 chr4 10300472 G C 3.20E-37 Urate levels / / 20884846 rs2098236 chr4 10300472 G C 1.28E-146 Urate levels / / 23263486 rs6834574 chr4 10300814 A G 9.87E-46 Uric acid levels / / 19503597 rs6834574 chr4 10300814 A G 2.20E-36 Urate levels / / 20884846 rs6834574 chr4 10300814 A G 8.22E-138 Urate levels / / 23263486 rs10939829 chr4 10300819 G T 9.70E-39 Uric acid levels / / 19503597 rs10939829 chr4 10300819 G T 2.40E-29 Urate levels / / 20884846 rs10939829 chr4 10300819 G T 4.49E-109 Urate levels / / 23263486 rs7683755 chr4 10301757 A G 8.49E-46 Uric acid levels / / 19503597 rs7683755 chr4 10301757 A G 2.20E-36 Urate levels / / 20884846 rs7683755 chr4 10301757 A G 1.45E-137 Urate levels / / 23263486 rs2868937 chr4 10303081 C T 2.58E-131 Uric acid levels / / 19503597 rs2868937 chr4 10303081 C T 4.60E-151 Urate levels / / 20884846 rs2868937 chr4 10303081 C T 1.50E-15 Urate levels / / 23263486 rs4698023 chr4 10304726 A G 9.30E-133 Uric acid levels / / 19503597 rs4698023 chr4 10304726 A G 4.80E-151 Urate levels / / 20884846 rs4698023 chr4 10304726 A G 1.55E-15 Urate levels / / 23263486 rs4698025 chr4 10305157 A G 2.99E-46 Uric acid levels / / 19503597 rs4698025 chr4 10305157 A G 5.00E-36 Urate levels / / 20884846 rs4698025 chr4 10305157 A G 4.68E-141 Urate levels / / 23263486 rs7689060 chr4 10305463 G C 8.03E-10 Serum uric acid levels / / 17997608 rs7689060 chr4 10305463 G C 1.31E-121 Uric acid levels / / 19503597 rs7689060 chr4 10305463 G C 4.00E-145 Urate levels / / 20884846 rs7689060 chr4 10305463 G C 4.12E-14 Urate levels / / 23263486 rs1468692 chr4 10305775 T G 2.46E-08 Uric acid levels / / 19503597 rs1468692 chr4 10305775 T G 3.70E-18 Urate levels / / 20884846 rs1468692 chr4 10305775 T G 6.03E-29 Urate levels / / 23263486 rs991458 chr4 10308756 C T 6.35E-09 Urate levels / / 23263486 rs9991653 chr4 10310495 A G 3.05E-08 Uric acid levels / / 19503597 rs9991653 chr4 10310495 A G 1.90E-19 Urate levels / / 20884846 rs9991653 chr4 10310495 A G 1.10E-35 Urate levels / / 23263486 rs7436833 chr4 10311074 T C 7.92E-10 Uric acid levels / / 19503597 rs7436833 chr4 10311074 T C 7.90E-15 Urate levels / / 20884846 rs7436833 chr4 10311074 T C 2.46E-32 Urate levels / / 23263486 rs6449449 chr4 10311707 C T 2.83E-41 Uric acid levels / / 19503597 rs6449449 chr4 10311707 C T 1.30E-32 Urate levels / / 20884846 rs6449449 chr4 10311707 C T 2.70E-05 Urinary metabolites / / 21572414 rs6449449 chr4 10311707 C T 1.16E-131 Urate levels / / 23263486 rs6449450 chr4 10311887 A G 3.29E-09 Urate levels / / 23263486 rs12511337 chr4 10311972 G A 3.90E-126 Uric acid levels / / 19503597 rs12511337 chr4 10311972 G A 2.00E-151 Urate levels / / 20884846 rs12511337 chr4 10311972 G A 7.08E-16 Urate levels / / 23263486 rs6449451 chr4 10312073 G C 2.40E-41 Uric acid levels / / 19503597 rs6449451 chr4 10312073 G C 3.20E-32 Urate levels / / 20884846 rs6449451 chr4 10312073 G C 2.70E-05 Urinary metabolites / / 21572414 rs6449451 chr4 10312073 G C 2.93E-131 Urate levels / / 23263486 rs6449452 chr4 10312112 T C 2.58E-41 Uric acid levels / / 19503597 rs6449452 chr4 10312112 T C 3.30E-32 Urate levels / / 20884846 rs6449452 chr4 10312112 T C 9.44E-121 Urate levels / / 23263486 rs4698028 chr4 10312216 A G 2.87E-41 Uric acid levels / / 19503597 rs4698028 chr4 10312216 A G 3.30E-32 Urate levels / / 20884846 rs4698028 chr4 10312216 A G 2.70E-05 Urinary metabolites / / 21572414 rs4698028 chr4 10312216 A G 6.01E-131 Urate levels / / 23263486 rs4698029 chr4 10312798 C G 2.00E-124 Uric acid levels / / 19503597 rs4698029 chr4 10312798 C G 5.70E-151 Urate levels / / 20884846 rs4698029 chr4 10312798 C G 8.73E-16 Urate levels / / 23263486 rs2192093 chr4 10313106 C T 2.17E-09 Uric acid levels / / 19503597 rs2192093 chr4 10313106 C T 1.50E-20 Urate levels / / 20884846 rs2192093 chr4 10313106 C T 2.68E-32 Urate levels / / 23263486 rs6810699 chr4 10314025 G A 6.75E-42 Uric acid levels / / 19503597 rs6810699 chr4 10314025 G A 2.50E-32 Urate levels / / 20884846 rs6810699 chr4 10314025 G A 2.70E-05 Urinary metabolites / / 21572414 rs6810699 chr4 10314025 G A 2.62E-131 Urate levels / / 23263486 rs727995 chr4 10314177 T G 2.21E-09 Uric acid levels / / 19503597 rs727995 chr4 10314177 T G 1.50E-20 Urate levels / / 20884846 rs727995 chr4 10314177 T G 1.93E-31 Urate levels / / 23263486 rs727996 chr4 10314188 G T 2.75E-12 Urate levels / / 23263486 rs714436 chr4 10314667 A C 3.81E-128 Uric acid levels / / 19503597 rs714436 chr4 10314667 A C 1.10E-154 Urate levels / / 20884846 rs714436 chr4 10314667 A C 2.84E-16 Urate levels / / 23263486 rs2868939 chr4 10314921 G A 1.58E-09 Uric acid levels / / 19503597 rs2868939 chr4 10314921 G A 2.10E-14 Urate levels / / 20884846 rs2868939 chr4 10314921 G A 3.78E-25 Urate levels / / 23263486 rs17477561 chr4 10315096 T C 1.02E-43 Uric acid levels / / 19503597 rs17477561 chr4 10315096 T C 8.80E-34 Urate levels / / 20884846 rs17477561 chr4 10315096 T C 8.68E-129 Urate levels / / 23263486 rs4698031 chr4 10315921 A G 4.74E-133 Uric acid levels / / 19503597 rs4698031 chr4 10315921 A G 1.60E-157 Urate levels / / 20884846 rs4698031 chr4 10315921 A G 9.37E-17 Urate levels / / 23263486 rs6449453 chr4 10316834 T A 3.01E-43 Uric acid levels / / 19503597 rs6449453 chr4 10316834 T A 4.40E-34 Urate levels / / 20884846 rs6449453 chr4 10316834 T A 3.15E-130 Urate levels / / 23263486 rs17418478 chr4 10316851 G A 2.82E-114 Uric acid levels / / 19503597 rs17418478 chr4 10316851 G A 1.80E-142 Urate levels / / 20884846 rs17418478 chr4 10316851 G A 4.27E-16 Urate levels / / 23263486 rs7666514 chr4 10316879 A C 5.31E-40 Uric acid levels / / 19503597 rs7666514 chr4 10316879 A C 2.60E-32 Urate levels / / 20884846 rs7666514 chr4 10316879 A C 1.66E-119 Urate levels / / 23263486 rs17418533 chr4 10316941 T C 1.52E-133 Uric acid levels / / 19503597 rs17418533 chr4 10316941 T C 1.40E-157 Urate levels / / 20884846 rs17418533 chr4 10316941 T C 9.16E-17 Urate levels / / 23263486 rs6449454 chr4 10317381 C A 9.25E-46 Uric acid levels / / 19503597 rs6449454 chr4 10317381 C A 7.60E-37 Urate levels / / 20884846 rs6449454 chr4 10317381 C A 2.36E-126 Urate levels / / 23263486 rs11722185 chr4 10317482 C G 4.74E-133 Uric acid levels / / 19503597 rs11722185 chr4 10317482 C G 1.20E-157 Urate levels / / 20884846 rs11722185 chr4 10317482 C G 8.97E-17 Urate levels / / 23263486 rs1860905 chr4 10318836 G C 7.86E-46 Uric acid levels / / 19503597 rs1860905 chr4 10318836 G C 4.60E-38 Urate levels / / 20884846 rs1860905 chr4 10318836 G C 5.03E-142 Urate levels / / 23263486 rs11737588 chr4 10319007 G A 1.52E-10 Uric acid levels / / 19503597 rs11737588 chr4 10319007 G A 1.50E-07 Urate levels / / 20884846 rs11737588 chr4 10319007 G A 2.10E-31 Urate levels / / 23263486 rs4698033 chr4 10319571 G T 1.18E-45 Uric acid levels / / 19503597 rs4698033 chr4 10319571 G T 3.80E-38 Urate levels / / 20884846 rs4698033 chr4 10319571 G T 4.81E-142 Urate levels / / 23263486 rs4697748 chr4 10319699 T C 5.46E-46 Uric acid levels / / 19503597 rs4697748 chr4 10319699 T C 2.70E-38 Urate levels / / 20884846 rs4697748 chr4 10319699 T C 2.84E-142 Urate levels / / 23263486 rs12506560 chr4 10322032 T C 1.77E-10 Urate levels / / 23263486 rs12506625 chr4 10322185 T G 2.38E-10 Urate levels / / 23263486 rs993173 chr4 10323935 T C 3.51E-49 Uric acid levels / / 19503597 rs993173 chr4 10323935 T C 7.10E-51 Urate levels / / 20884846 rs993173 chr4 10323935 T C 1.34E-165 Urate levels / / 23263486 rs9291683 chr4 10324160 G A 2.00E-06 Bone mineral density / / 17903296 rs9291683 chr4 10324160 G A 5.50E-38 Uric acid levels / / 19503597 rs9291683 chr4 10324160 G A 3.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9291683 chr4 10324160 G A 3.90E-42 Urate levels / / 20884846 rs9291683 chr4 10324160 G A 2.47E-05 Schizophrenia(age at onset) / / 21688384 rs9291683 chr4 10324160 G A 2.64E-08 Cardiovascular disease risk factors / / 21943158 rs9291683 chr4 10324160 G A 5.65E-134 Urate levels / / 23263486 rs9291683 chr4 10324160 G A 5.81E-05 Amyotrophic lateral sclerosis / / 23624525 rs17478453 chr4 10324312 G T 4.07E-45 Uric acid levels / / 19503597 rs17478453 chr4 10324312 G T 1.20E-36 Urate levels / / 20884846 rs17478453 chr4 10324312 G T 1.86E-135 Urate levels / / 23263486 rs993172 chr4 10324361 A C 1.20E-48 Uric acid levels / / 19503597 rs993172 chr4 10324361 A C 1.30E-50 Urate levels / / 20884846 rs993172 chr4 10324361 A C 1.52E-163 Urate levels / / 23263486 rs1558489 chr4 10325489 T A 3.97E-44 Uric acid levels / / 19503597 rs1558489 chr4 10325489 T A 9.30E-47 Urate levels / / 20884846 rs1558489 chr4 10325489 T A 4.75E-141 Urate levels / / 23263486 rs1558488 chr4 10327414 A G 7.04E-14 Uric acid levels / / 19503597 rs1558488 chr4 10327414 A G 1.70E-17 Urate levels / / 20884846 rs1558488 chr4 10327414 A G 1.25E-38 Urate levels / / 23263486 rs4698036 chr4 10331294 T G 2.85E-134 Uric acid levels / / 19503597 rs4698036 chr4 10331294 T G 1.40E-157 Urate levels / / 20884846 rs4698036 chr4 10331294 T G 3.81E-11 Urate levels / / 21768215 rs4698036 chr4 10331294 T G 2.00E-52 Cardiovascular disease risk factors / / 21943158 rs4698036 chr4 10331294 T G 5.56E-18 Urate levels / / 23263486 rs4698036 chr4 10331294 T G 6.70E-05 Glucose levels / / pha003057 rs11729318 chr4 10336919 G C 6.20E-136 Uric acid levels / / 19503597 rs11729318 chr4 10336919 G C 4.90E-160 Urate levels / / 20884846 rs11729318 chr4 10336919 G C 1.39E-17 Urate levels / / 23263486 rs17419612 chr4 10337263 T G 2.20E-41 Uric acid levels / / 19503597 rs17419612 chr4 10337263 T G 8.90E-34 Urate levels / / 20884846 rs17419612 chr4 10337263 T G 1.43E-124 Urate levels / / 23263486 rs1964268 chr4 10337921 T A 4.67E-47 Uric acid levels / / 19503597 rs1964268 chr4 10337921 T A 3.00E-38 Urate levels / / 20884846 rs1964268 chr4 10337921 T A 1.21E-142 Urate levels / / 23263486 rs13142790 chr4 10339040 A G 3.05E-41 Uric acid levels / / 19503597 rs13142790 chr4 10339040 A G 2.00E-33 Urate levels / / 20884846 rs13142790 chr4 10339040 A G 2.19E-124 Urate levels / / 23263486 rs759024 chr4 10339095 G A 4.88E-48 Uric acid levels / / 19503597 rs759024 chr4 10339095 G A 7.00E-38 Urate levels / / 20884846 rs759024 chr4 10339095 G A 4.59E-145 Urate levels / / 23263486 rs759022 chr4 10339426 A G 4.49E-11 Urate levels / / 23263486 rs10489067 chr4 10340486 T C 7.41E-11 Urate levels / / 23263486 rs2007103 chr4 10341255 A G 2.25E-48 Uric acid levels / / 19503597 rs2007103 chr4 10341255 A G 1.00E-38 Urate levels / / 20884846 rs2007103 chr4 10341255 A G 1.04E-145 Urate levels / / 23263486 rs4306950 chr4 10341419 T G 9.19E-50 Uric acid levels / / 19503597 rs4306950 chr4 10341419 T G 5.50E-39 Urate levels / / 20884846 rs4306950 chr4 10341419 T G 2.54E-147 Urate levels / / 23263486 rs10938761 chr4 10342723 C T 5.21E-11 Urate levels / / 23263486 rs984723 chr4 10344624 T C 6.11E-47 Uric acid levels / / 19503597 rs984723 chr4 10344624 T C 9.90E-39 Urate levels / / 20884846 rs984723 chr4 10344624 T C 2.66E-141 Urate levels / / 23263486 rs2052165 chr4 10345172 C T 1.29E-08 Uric acid levels / / 19503597 rs2052165 chr4 10345172 C T 4.40E-15 Urate levels / / 20884846 rs2052165 chr4 10345172 C T 7.27E-31 Urate levels / / 23263486 rs1035052 chr4 10345339 A G 7.94E-12 Urate levels / / 23263486 rs17420080 chr4 10345548 C T 4.83E-128 Uric acid levels / / 19503597 rs17420080 chr4 10345548 C T 5.90E-147 Urate levels / / 20884846 rs17420080 chr4 10345548 C T 5.10E-16 Urate levels / / 23263486 rs17420080 chr4 10345548 C T 4.99E-06 Blood Pressure / / pha003040 rs13109847 chr4 10346245 T C 2.16E-44 Uric acid levels / / 19503597 rs13109847 chr4 10346245 T C 1.70E-35 Urate levels / / 20884846 rs13109847 chr4 10346245 T C 7.52E-134 Urate levels / / 23263486 rs17479487 chr4 10346550 A G 1.49E-41 Uric acid levels / / 19503597 rs17479487 chr4 10346550 A G 1.60E-32 Urate levels / / 20884846 rs17479487 chr4 10346550 A G 2.42E-127 Urate levels / / 23263486 rs2192084 chr4 10347051 T G 4.29E-48 Uric acid levels / / 19503597 rs2192084 chr4 10347051 T G 7.60E-40 Urate levels / / 20884846 rs2192084 chr4 10347051 T G 1.73E-135 Urate levels / / 23263486 rs16897170 chr4 10347414 C T 8.21E-11 Urate levels / / 23263486 rs2192083 chr4 10347764 T C 1.70E-10 Urate levels / / 23263486 rs6849037 chr4 10348431 G T 9.58E-50 Uric acid levels / / 19503597 rs6849037 chr4 10348431 G T 3.60E-40 Urate levels / / 20884846 rs6849037 chr4 10348431 G T 3.89E-150 Urate levels / / 23263486 rs4698037 chr4 10348895 A G 2.07E-50 Uric acid levels / / 19503597 rs4698037 chr4 10348895 A G 7.50E-40 Urate levels / / 20884846 rs4698037 chr4 10348895 A G 3.11E-151 Urate levels / / 23263486 rs17420450 chr4 10350765 T C 2.69E-29 Uric acid levels / / 19503597 rs17420450 chr4 10350765 T C 2.00E-24 Urate levels / / 20884846 rs17420450 chr4 10350765 T C 1.09E-86 Urate levels / / 23263486 rs13145430 chr4 10350948 T C 2.53E-36 Uric acid levels / / 19503597 rs13145430 chr4 10350948 T C 1.40E-35 Urate levels / / 20884846 rs13145430 chr4 10350948 T C 6.76E-117 Urate levels / / 23263486 rs17420513 chr4 10350975 G A 1.44E-45 Uric acid levels / / 19503597 rs17420513 chr4 10350975 G A 2.20E-36 Urate levels / / 20884846 rs17420513 chr4 10350975 G A 2.23E-137 Urate levels / / 23263486 rs17420562 chr4 10351595 C A 8.85E-45 Uric acid levels / / 19503597 rs17420562 chr4 10351595 C A 1.30E-35 Urate levels / / 20884846 rs17420562 chr4 10351595 C A 2.28E-135 Urate levels / / 23263486 rs4697750 chr4 10351706 A G 3.66E-49 Uric acid levels / / 19503597 rs4697750 chr4 10351706 A G 1.00E-38 Urate levels / / 20884846 rs4697750 chr4 10351706 A G 2.12E-149 Urate levels / / 23263486 rs6853659 chr4 10351970 A C 3.74E-44 Uric acid levels / / 19503597 rs6853659 chr4 10351970 A C 2.40E-37 Urate levels / / 20884846 rs6853659 chr4 10351970 A C 2.57E-138 Urate levels / / 23263486 rs4697751 chr4 10352506 A G 5.20E-47 Uric acid levels / / 19503597 rs4697751 chr4 10352506 A G 4.60E-36 Urate levels / / 20884846 rs4697751 chr4 10352506 A G 4.05E-141 Urate levels / / 23263486 rs4698040 chr4 10352550 C T 6.71E-133 Uric acid levels / / 19503597 rs4698040 chr4 10352550 C T 2.50E-158 Urate levels / / 20884846 rs4698040 chr4 10352550 C T 3.28E-18 Urate levels / / 23263486 rs4697752 chr4 10353381 T C 2.62E-49 Uric acid levels / / 19503597 rs4697752 chr4 10353381 T C 8.70E-39 Urate levels / / 20884846 rs4697752 chr4 10353381 T C 5.51E-150 Urate levels / / 23263486 rs2098235 chr4 10354069 A C 2.26E-11 Urate levels / / 23263486 rs10938768 chr4 10354341 C T 2.34E-49 Uric acid levels / / 19503597 rs10938768 chr4 10354341 C T 1.10E-38 Urate levels / / 20884846 rs10938768 chr4 10354341 C T 1.36E-138 Urate levels / / 23263486 rs6838846 chr4 10355529 A G 2.21E-37 Uric acid levels / / 19503597 rs6838846 chr4 10355529 A G 1.30E-29 Urate levels / / 20884846 rs6838846 chr4 10355529 A G 3.97E-102 Urate levels / / 23263486 rs11931317 chr4 10356348 G A 1.01E-47 Uric acid levels / / 19503597 rs11931317 chr4 10356348 G A 1.30E-38 Urate levels / / 20884846 rs11931317 chr4 10356348 G A 3.72E-150 Urate levels / / 23263486 rs1860904 chr4 10357448 A G 1.35E-10 Uric acid levels / / 19503597 rs7680825 chr4 10358790 G C 2.53E-49 Uric acid levels / / 19503597 rs7680825 chr4 10358790 G C 1.40E-38 Urate levels / / 20884846 rs7680825 chr4 10358790 G C 5.10E-150 Urate levels / / 23263486 rs7681212 chr4 10358964 G C 2.35E-109 Uric acid levels / / 19503597 rs7681212 chr4 10358964 G C 1.70E-126 Urate levels / / 20884846 rs7681212 chr4 10358964 G C 1.33E-14 Urate levels / / 23263486 rs13114042 chr4 10359104 T A 6.58E-10 Urate levels / / 23263486 rs7661209 chr4 10359607 A G 4.84E-50 Uric acid levels / / 19503597 rs7661209 chr4 10359607 A G 1.50E-38 Urate levels / / 20884846 rs7661209 chr4 10359607 A G 1.29E-125 Urate levels / / 23263486 rs11727261 chr4 10363482 A G 8.33E-10 Urate levels / / 23263486 rs4235361 chr4 10365093 A G 8.38E-10 Urate levels / / 23263486 rs4697753 chr4 10366453 T A 3.03E-21 Uric acid levels / / 19503597 rs4697753 chr4 10366453 T A 1.00E-29 Urate levels / / 20884846 rs4697753 chr4 10366453 T A 5.50E-70 Urate levels / / 23263486 rs4698041 chr4 10368235 A G 2.88E-49 Uric acid levels / / 19503597 rs4698041 chr4 10368235 A G 1.80E-38 Urate levels / / 20884846 rs4698041 chr4 10368235 A G 5.21E-150 Urate levels / / 23263486 rs9291406 chr4 10369564 C G 6.34E-10 Urate levels / / 23263486 rs13122923 chr4 10369776 C T 1.30E-09 Urate levels / / 23263486 rs6857135 chr4 10370585 A C 2.83E-49 Uric acid levels / / 19503597 rs6857135 chr4 10370585 A C 1.00E-38 Urate levels / / 20884846 rs6857135 chr4 10370585 A C 9.93E-151 Urate levels / / 23263486 rs6813712 chr4 10370663 A G 2.62E-49 Uric acid levels / / 19503597 rs6813712 chr4 10370663 A G 1.20E-38 Urate levels / / 20884846 rs6813712 chr4 10370663 A G 1.05E-150 Urate levels / / 23263486 rs6813919 chr4 10370791 A C 1.24E-09 Urate levels / / 23263486 rs6849583 chr4 10372790 G A 3.51E-49 Uric acid levels / / 19503597 rs6849583 chr4 10372790 G A 1.30E-38 Urate levels / / 20884846 rs6849583 chr4 10372790 G A 1.06E-150 Urate levels / / 23263486 rs13125564 chr4 10372914 T C 1.50E-09 Urate levels / / 23263486 rs6851536 chr4 10372966 C T 2.97E-49 Uric acid levels / / 19503597 rs6851536 chr4 10372966 C T 1.60E-38 Urate levels / / 20884846 rs6851536 chr4 10372966 C T 8.72E-151 Urate levels / / 23263486 rs11943393 chr4 10374005 A G 3.36E-49 Uric acid levels / / 19503597 rs11943393 chr4 10374005 A G 1.50E-38 Urate levels / / 20884846 rs11943393 chr4 10374005 A G 2.08E-150 Urate levels / / 23263486 rs10938772 chr4 10375328 A G 2.77E-114 Uric acid levels / / 19503597 rs10938772 chr4 10375328 A G 6.00E-127 Urate levels / / 20884846 rs10938772 chr4 10375328 A G 5.98E-15 Urate levels / / 23263486 rs11732092 chr4 10377405 T G 6.78E-04 Taste perception / / 22132133 rs4698043 chr4 10378602 G T 4.04E-49 Uric acid levels / / 19503597 rs4698043 chr4 10378602 G T 1.50E-38 Urate levels / / 20884846 rs4698043 chr4 10378602 G T 2.07E-151 Urate levels / / 23263486 rs7677806 chr4 10383005 C T 2.00E-48 Uric acid levels / / 19503597 rs7677806 chr4 10383005 C T 3.20E-38 Urate levels / / 20884846 rs7677806 chr4 10383005 C T 1.37E-150 Urate levels / / 23263486 rs4302456 chr4 10386674 T C 3.73E-44 Uric acid levels / / 19503597 rs4302456 chr4 10386674 T C 1.10E-37 Urate levels / / 20884846 rs4302456 chr4 10386674 T C 1.92E-137 Urate levels / / 23263486 rs4302457 chr4 10386973 T C 2.26E-44 Uric acid levels / / 19503597 rs4302457 chr4 10386973 T C 7.40E-38 Urate levels / / 20884846 rs4302457 chr4 10386973 T C 6.32E-137 Urate levels / / 23263486 rs9990427 chr4 10388313 A G 2.26E-09 Urate levels / / 23263486 rs371398607 chr4 10388610 AT A 1.41E-08 Uric acid levels / / 19503597 rs371398607 chr4 10388610 AT A 6.30E-04 Taste perception / / 22132133 rs371398607 chr4 10388610 AT A 1.25E-26 Urate levels / / 23263486 rs9990701 chr4 10388610 A G 1.41E-08 Uric acid levels / / 19503597 rs9990701 chr4 10388610 A G 6.30E-04 Taste perception / / 22132133 rs9990701 chr4 10388610 A G 1.25E-26 Urate levels / / 23263486 rs11724536 chr4 10390289 T C 1.47E-09 Urate levels / / 23263486 rs4607209 chr4 10400156 G A 4.76E-20 Urate levels / / 23263486 rs10017305 chr4 10401223 T C 4.54E-104 Uric acid levels / / 19503597 rs10017305 chr4 10401223 T C 2.60E-117 Urate levels / / 20884846 rs10017305 chr4 10401223 T C 3.12E-14 Urate levels / / 23263486 rs11943276 chr4 10403545 T C 1.11E-27 Uric acid levels / / 19503597 rs7654258 chr4 10404512 C T 3.29E-09 Uric acid levels / / 19503597 rs7654258 chr4 10404512 C T 1.09E-19 Urate levels / / 23263486 rs7677318 chr4 10406291 G A 1.88E-09 Urate levels / / 23263486 rs4463062 chr4 10406994 T A 1.31E-40 Uric acid levels / / 19503597 rs4463062 chr4 10406994 T A 1.10E-33 Urate levels / / 20884846 rs4463062 chr4 10406994 T A 2.29E-135 Urate levels / / 23263486 rs6819959 chr4 10407534 A G 2.44E-08 Uric acid levels / / 19503597 rs6819959 chr4 10407534 A G 1.10E-20 Urate levels / / 20884846 rs6819959 chr4 10407534 A G 2.61E-34 Urate levels / / 23263486 rs4643800 chr4 10407572 G T 2.30E-78 Uric acid levels / / 19503597 rs4643800 chr4 10407572 G T 5.40E-95 Urate levels / / 20884846 rs4643800 chr4 10407572 G T 5.93E-278 Urate levels / / 23263486 rs11728025 chr4 10408221 C G 7.49E-70 Uric acid levels / / 19503597 rs11728025 chr4 10408221 C G 2.00E-86 Urate levels / / 20884846 rs11728025 chr4 10408221 C G 4.11E-04 Alzheimer's disease (late onset) / / 21379329 rs11728025 chr4 10408221 C G 1.57E-247 Urate levels / / 23263486 rs7697246 chr4 10408757 C T 1.64E-41 Uric acid levels / / 19503597 rs7697246 chr4 10408757 C T 3.10E-33 Urate levels / / 20884846 rs7697246 chr4 10408757 C T 2.79E-131 Urate levels / / 23263486 rs4698049 chr4 10409770 C G 1.34E-41 Uric acid levels / / 19503597 rs4698049 chr4 10409770 C G 3.20E-33 Urate levels / / 20884846 rs4698049 chr4 10409770 C G 2.69E-131 Urate levels / / 23263486 rs7656072 chr4 10409841 G A 4.10E-18 Urate levels / / 20884846 rs7656072 chr4 10409841 G A 9.26E-31 Urate levels / / 23263486 rs4698050 chr4 10410748 C T 1.50E-09 Serum uric acid levels / / 17997608 rs4698050 chr4 10410748 C T 1.90E-95 Uric acid levels / / 19503597 rs4698050 chr4 10410748 C T 4.90E-112 Urate levels / / 20884846 rs4698050 chr4 10410748 C T 1.81E-13 Urate levels / / 23263486 rs11721485 chr4 10412554 T C 4.10E-10 Urate levels / / 23263486 rs4610325 chr4 10413168 T C 6.08E-41 Uric acid levels / / 19503597 rs4610325 chr4 10413168 T C 1.30E-33 Urate levels / / 20884846 rs4610325 chr4 10413168 T C 5.54E-131 Urate levels / / 23263486 rs7661365 chr4 10413908 A G 5.70E-09 Urate levels / / 23263486 rs11736389 chr4 10416360 T C 7.96E-98 Uric acid levels / / 19503597 rs11736389 chr4 10416360 T C 1.00E-113 Urate levels / / 20884846 rs11736389 chr4 10416360 T C 9.53E-14 Urate levels / / 23263486 rs13125855 chr4 10418078 C G 3.08E-17 Uric acid levels / / 19503597 rs13125855 chr4 10418078 C G 4.10E-20 Urate levels / / 20884846 rs13125855 chr4 10418078 C G 6.86E-57 Urate levels / / 23263486 rs6858510 chr4 10432508 G A 1.34E-08 Uric acid levels / / 19503597 rs6858510 chr4 10432508 G A 2.88E-16 Urate levels / / 23263486 rs7691990 chr4 10434459 A G 1.18E-15 Uric acid levels / / 19503597 rs7691990 chr4 10434459 A G 1.90E-14 Urate levels / / 20884846 rs7691990 chr4 10434459 A G 1.46E-43 Urate levels / / 23263486 rs10003864 chr4 10437391 T C 1.40E-08 Uric acid levels / / 19503597 rs10003864 chr4 10437391 T C 1.20E-07 Urate levels / / 20884846 rs10003864 chr4 10437391 T C 7.08E-27 Urate levels / / 23263486 rs4422413 chr4 10443384 T G 1.38E-11 Uric acid levels ZNF518B UTR-3 19503597 rs4422413 chr4 10443384 T G 8.00E-10 Urate levels ZNF518B UTR-3 20884846 rs4422413 chr4 10443384 T G 6.76E-36 Urate levels ZNF518B UTR-3 23263486 rs10938799 chr4 10443425 G A 2.49E-18 Uric acid levels ZNF518B UTR-3 19503597 rs10938799 chr4 10443425 G A 1.60E-19 Urate levels ZNF518B UTR-3 20884846 rs10938799 chr4 10443425 G A 1.97E-54 Urate levels ZNF518B UTR-3 23263486 rs3217 chr4 10444650 C T 1.13E-11 Uric acid levels ZNF518B UTR-3 19503597 rs3217 chr4 10444650 C T 7.80E-10 Urate levels ZNF518B UTR-3 20884846 rs3217 chr4 10444650 C T 4.20E-36 Urate levels ZNF518B UTR-3 23263486 rs10016022 chr4 10446906 A G 6.06E-15 Uric acid levels ZNF518B cds-synon 19503597 rs10016022 chr4 10446906 A G 1.60E-14 Urate levels ZNF518B cds-synon 20884846 rs10016022 chr4 10446906 A G 2.97E-43 Urate levels ZNF518B cds-synon 23263486 rs10016702 chr4 10447640 A G 2.60E-07 Urate levels ZNF518B missense 20884846 rs10016702 chr4 10447640 A G 1.38E-12 Urate levels ZNF518B missense 23263486 rs7674156 chr4 10452763 G C 2.37E-11 Uric acid levels ZNF518B intron 19503597 rs7674156 chr4 10452763 G C 8.10E-10 Urate levels ZNF518B intron 20884846 rs7674156 chr4 10452763 G C 3.29E-35 Urate levels ZNF518B intron 23263486 rs12019277 chr4 10454994 C A 2.55E-11 Uric acid levels ZNF518B intron 19503597 rs12019277 chr4 10454994 C A 8.10E-10 Urate levels ZNF518B intron 20884846 rs12019277 chr4 10454994 C A 2.91E-35 Urate levels ZNF518B intron 23263486 rs9996284 chr4 10469446 C G 1.30E-11 Uric acid levels / / 19503597 rs9996284 chr4 10469446 C G 2.50E-10 Urate levels / / 20884846 rs9996284 chr4 10469446 C G 3.80E-35 Urate levels / / 23263486 rs10029818 chr4 10472670 G C 7.96E-12 Uric acid levels / / 19503597 rs10029818 chr4 10472670 G C 8.10E-10 Urate levels / / 20884846 rs10029818 chr4 10472670 G C 3.23E-36 Urate levels / / 23263486 rs11732503 chr4 10482614 C G 2.79E-16 Uric acid levels / / 19503597 rs11732503 chr4 10482614 C G 1.70E-19 Urate levels / / 20884846 rs11732503 chr4 10482614 C G 2.52E-51 Urate levels / / 23263486 rs11737650 chr4 10485014 G A 2.31E-15 Uric acid levels / / 19503597 rs11737650 chr4 10485014 G A 9.70E-15 Urate levels / / 20884846 rs11737650 chr4 10485014 G A 2.83E-44 Urate levels / / 23263486 rs11733306 chr4 10488402 C T 1.48E-15 Uric acid levels / / 19503597 rs11733306 chr4 10488402 C T 2.40E-14 Urate levels / / 20884846 rs11733306 chr4 10488402 C T 2.98E-44 Urate levels / / 23263486 rs11737601 chr4 10488568 A G 9.61E-21 Uric acid levels / / 19503597 rs11737601 chr4 10488568 A G 1.20E-18 Urate levels / / 20884846 rs11737601 chr4 10488568 A G 1.45E-60 Urate levels / / 23263486 rs4541501 chr4 10488621 T C 2.13E-13 Uric acid levels / / 19503597 rs4541501 chr4 10488621 T C 1.40E-13 Urate levels / / 20884846 rs4541501 chr4 10488621 T C 4.45E-42 Urate levels / / 23263486 rs13111270 chr4 10489007 T A 8.56E-13 Uric acid levels / / 19503597 rs13111270 chr4 10489007 T A 6.30E-09 Urate levels / / 20884846 rs13111270 chr4 10489007 T A 2.50E-36 Urate levels / / 23263486 rs13130674 chr4 10489600 G A 5.56E-15 Uric acid levels / / 19503597 rs13130674 chr4 10489600 G A 1.20E-13 Urate levels / / 20884846 rs13130674 chr4 10489600 G A 4.55E-44 Urate levels / / 23263486 rs10488945 chr4 10490278 T G 3.69E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs7692088 chr4 10491040 G C 1.76E-20 Uric acid levels / / 19503597 rs7692088 chr4 10491040 G C 8.80E-13 Urate levels / / 20884846 rs7692088 chr4 10491040 G C 1.70E-48 Urate levels / / 23263486 rs9291420 chr4 10492887 C G 3.39E-06 Personality dimensions CLNK intron 18957941 rs9291420 chr4 10492887 C G 3.40E-06 Personality dimensions CLNK intron 21173776 rs9790491 chr4 10493115 A G 1.78E-15 Uric acid levels CLNK intron 19503597 rs9790491 chr4 10493115 A G 8.90E-14 Urate levels CLNK intron 20884846 rs9790491 chr4 10493115 A G 1.33E-44 Urate levels CLNK intron 23263486 rs17467252 chr4 10493614 G T 2.04E-05 Personality dimensions CLNK intron 18957941 rs13115661 chr4 10493961 C T 3.30E-11 Urate levels CLNK intron 20884846 rs13115661 chr4 10493961 C T 1.13E-25 Urate levels CLNK intron 23263486 rs3749558 chr4 10494003 C T 1.05E-15 Uric acid levels CLNK intron 19503597 rs3749558 chr4 10494003 C T 9.10E-14 Urate levels CLNK intron 20884846 rs3749558 chr4 10494003 C T 2.83E-44 Urate levels CLNK intron 23263486 rs7667644 chr4 10495072 T C 9.81E-16 Uric acid levels CLNK intron 19503597 rs7667644 chr4 10495072 T C 8.90E-14 Urate levels CLNK intron 20884846 rs7667644 chr4 10495072 T C 1.56E-44 Urate levels CLNK intron 23263486 rs16869060 chr4 10495790 C G 1.97E-15 Uric acid levels CLNK intron 19503597 rs16869060 chr4 10495790 C G 1.40E-16 Urate levels CLNK intron 20884846 rs16869060 chr4 10495790 C G 2.05E-50 Urate levels CLNK intron 23263486 rs13142053 chr4 10496241 G C 2.30E-13 Uric acid levels CLNK intron 19503597 rs13142053 chr4 10496241 G C 2.00E-11 Urate levels CLNK intron 20884846 rs13142053 chr4 10496241 G C 5.50E-34 Urate levels CLNK intron 23263486 rs10033825 chr4 10496792 C T 9.02E-13 Uric acid levels CLNK intron 19503597 rs10033825 chr4 10496792 C T 1.40E-08 Urate levels CLNK intron 20884846 rs10033825 chr4 10496792 C T 1.63E-35 Urate levels CLNK intron 23263486 rs7698826 chr4 10497423 C A 7.41E-21 Uric acid levels CLNK intron 19503597 rs7698826 chr4 10497423 C A 3.10E-12 Urate levels CLNK intron 20884846 rs7698826 chr4 10497423 C A 1.36E-46 Urate levels CLNK intron 23263486 rs6819820 chr4 10498830 G A 2.40E-09 Uric acid levels CLNK intron 19503597 rs6819820 chr4 10498830 G A 1.54E-23 Urate levels CLNK intron 23263486 rs12504795 chr4 10499344 T C 9.92E-20 Uric acid levels CLNK intron 19503597 rs12504795 chr4 10499344 T C 6.60E-17 Urate levels CLNK intron 20884846 rs12504795 chr4 10499344 T C 6.38E-57 Urate levels CLNK intron 23263486 rs17467273 chr4 10500431 T C 6.72E-13 Uric acid levels CLNK intron 19503597 rs17467273 chr4 10500431 T C 1.90E-08 Urate levels CLNK intron 20884846 rs17467273 chr4 10500431 T C 3.28E-35 Urate levels CLNK intron 23263486 rs13109939 chr4 10501625 T C 4.97E-15 Uric acid levels CLNK intron 19503597 rs13109939 chr4 10501625 T C 6.80E-14 Urate levels CLNK intron 20884846 rs13109939 chr4 10501625 T C 4.95E-45 Urate levels CLNK intron 23263486 rs5000857 chr4 10502334 A G 3.05E-05 Personality dimensions CLNK intron 18957941 rs10488946 chr4 10502650 T C 6.90E-14 Urate levels CLNK intron 23263486 rs6833095 chr4 10506599 G A 5.31E-04 Type 2 diabetes CLNK intron 17463246 rs6833095 chr4 10506599 G A 2.03E-08 Uric acid levels CLNK intron 19503597 rs6833095 chr4 10506599 G A 4.00E-09 Urate levels CLNK intron 20884846 rs6833095 chr4 10506599 G A 8.04E-35 Urate levels CLNK intron 23263486 rs11734599 chr4 10507490 G C 3.42E-15 Uric acid levels CLNK intron 19503597 rs11734599 chr4 10507490 G C 3.20E-14 Urate levels CLNK intron 20884846 rs11734599 chr4 10507490 G C 2.11E-45 Urate levels CLNK intron 23263486 rs887112 chr4 10507984 C T 2.50E-08 Urate levels CLNK intron 20884846 rs887112 chr4 10507984 C T 4.57E-14 Urate levels CLNK intron 23263486 rs13141385 chr4 10508404 C A 4.86E-13 Uric acid levels CLNK intron 19503597 rs13141385 chr4 10508404 C A 2.10E-07 Urate levels CLNK intron 20884846 rs13141385 chr4 10508404 C A 1.60E-35 Urate levels CLNK intron 23263486 rs2868941 chr4 10509699 T C 1.32E-19 Uric acid levels CLNK intron 19503597 rs2868941 chr4 10509699 T C 2.50E-17 Urate levels CLNK intron 20884846 rs2868941 chr4 10509699 T C 3.19E-58 Urate levels CLNK intron 23263486 rs11929850 chr4 10510050 G C 2.90E-08 Urate levels CLNK intron 20884846 rs11929850 chr4 10510050 G C 2.75E-14 Urate levels CLNK intron 23263486 rs13108998 chr4 10510869 G T 2.36E-12 Uric acid levels CLNK intron 19503597 rs13108998 chr4 10510869 G T 4.20E-08 Urate levels CLNK intron 20884846 rs13108998 chr4 10510869 G T 9.03E-32 Urate levels CLNK intron 23263486 rs13109005 chr4 10510881 G T 4.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CLNK intron 20877124 rs13109005 chr4 10510881 G T 3.84E-19 Urate levels CLNK intron 23263486 rs1004327 chr4 10511483 C T 4.47E-13 Uric acid levels CLNK intron 19503597 rs1004327 chr4 10511483 C T 2.90E-14 Urate levels CLNK intron 20884846 rs1004327 chr4 10511483 C T 6.88E-42 Urate levels CLNK intron 23263486 rs12508358 chr4 10512238 C T 1.28E-12 Uric acid levels CLNK intron 19503597 rs12508358 chr4 10512238 C T 1.10E-14 Urate levels CLNK intron 20884846 rs12508358 chr4 10512238 C T 2.74E-42 Urate levels CLNK intron 23263486 rs13125670 chr4 10513072 C T 6.82E-22 Uric acid levels CLNK intron 19503597 rs13125670 chr4 10513072 C T 2.30E-16 Urate levels CLNK intron 20884846 rs13125670 chr4 10513072 C T 5.47E-56 Urate levels CLNK intron 23263486 rs12499142 chr4 10514238 A T 3.96E-14 Uric acid levels CLNK intron 19503597 rs12499142 chr4 10514238 A T 3.50E-13 Urate levels CLNK intron 20884846 rs12499142 chr4 10514238 A T 2.59E-37 Urate levels CLNK intron 23263486 rs2868942 chr4 10514568 C T 1.94E-12 Uric acid levels CLNK intron 19503597 rs2868942 chr4 10514568 C T 8.70E-15 Urate levels CLNK intron 20884846 rs2868942 chr4 10514568 C T 1.92E-41 Urate levels CLNK intron 23263486 rs16869379 chr4 10514681 C T 3.13E-16 Uric acid levels CLNK intron 19503597 rs16869379 chr4 10514681 C T 6.60E-17 Urate levels CLNK intron 20884846 rs16869379 chr4 10514681 C T 1.61E-51 Urate levels CLNK intron 23263486 rs10034180 chr4 10518525 A G 5.80E-16 Uric acid levels CLNK intron 19503597 rs10034180 chr4 10518525 A G 1.10E-10 Urate levels CLNK intron 20884846 rs10034180 chr4 10518525 A G 2.15E-33 Urate levels CLNK intron 23263486 rs16869430 chr4 10519426 C T 2.69E-24 Uric acid levels CLNK intron 19503597 rs16869430 chr4 10519426 C T 1.10E-15 Urate levels CLNK intron 20884846 rs16869430 chr4 10519426 C T 6.36E-55 Urate levels CLNK intron 23263486 rs2041215 chr4 10519982 G T 3.17E-16 Uric acid levels CLNK intron 19503597 rs2041215 chr4 10519982 G T 1.00E-10 Urate levels CLNK intron 20884846 rs2041215 chr4 10519982 G T 3.20E-34 Urate levels CLNK intron 23263486 rs7665423 chr4 10520600 A T 1.39E-12 Urate levels CLNK intron 23263486 rs13125086 chr4 10520693 T C 1.40E-11 Urate levels CLNK intron 20884846 rs13125086 chr4 10520693 T C 8.07E-24 Urate levels CLNK intron 23263486 rs16869474 chr4 10520972 G C 7.31E-24 Uric acid levels CLNK intron 19503597 rs16869474 chr4 10520972 G C 1.10E-15 Urate levels CLNK intron 20884846 rs16869474 chr4 10520972 G C 3.77E-55 Urate levels CLNK intron 23263486 rs2012249 chr4 10521158 C T 4.35E-10 Uric acid levels CLNK intron 19503597 rs2012249 chr4 10521158 C T 1.70E-07 Urate levels CLNK intron 20884846 rs2012249 chr4 10521158 C T 2.03E-27 Urate levels CLNK intron 23263486 rs2012237 chr4 10521221 G T 1.56E-12 Urate levels CLNK intron 23263486 rs10001632 chr4 10521871 A C 5.58E-18 Urate levels CLNK intron 23263486 rs2041216 chr4 10523090 C T 1.30E-16 Uric acid levels CLNK intron 19503597 rs2041216 chr4 10523090 C T 2.20E-10 Urate levels CLNK intron 20884846 rs2041216 chr4 10523090 C T 2.29E-34 Urate levels CLNK intron 23263486 rs997219 chr4 10524671 G A 1.96E-14 Uric acid levels CLNK intron 19503597 rs997219 chr4 10524671 G A 4.40E-10 Urate levels CLNK intron 20884846 rs997219 chr4 10524671 G A 4.02E-34 Urate levels CLNK intron 23263486 rs2108878 chr4 10527342 C T 2.78E-24 Uric acid levels CLNK intron 19503597 rs2108878 chr4 10527342 C T 3.60E-20 Urate levels CLNK intron 20884846 rs2108878 chr4 10527342 C T 5.49E-67 Urate levels CLNK intron 23263486 rs189581402 chr4 10527472 T C 0.0000044 Breast cancer(er negative) CLNK missense 23555315 rs12641877 chr4 10528226 G A 5.26E-24 Uric acid levels CLNK intron 19503597 rs12641877 chr4 10528226 G A 7.60E-20 Urate levels CLNK intron 20884846 rs12641877 chr4 10528226 G A 1.59E-66 Urate levels CLNK intron 23263486 rs2286463 chr4 10532258 A G 5.18E-17 Uric acid levels CLNK intron 19503597 rs2286463 chr4 10532258 A G 3.40E-15 Urate levels CLNK intron 20884846 rs2286463 chr4 10532258 A G 3.04E-47 Urate levels CLNK intron 23263486 rs2286465 chr4 10532634 G A 9.34E-19 Uric acid levels CLNK intron 19503597 rs2286465 chr4 10532634 G A 8.40E-17 Urate levels CLNK intron 20884846 rs2286465 chr4 10532634 G A 3.65E-56 Urate levels CLNK intron 23263486 rs10030521 chr4 10536417 C G 3.06E-08 Uric acid levels CLNK intron 19503597 rs10030521 chr4 10536417 C G 1.70E-17 Urate levels CLNK intron 23263486 rs10488948 chr4 10536544 A G 2.72E-14 Uric acid levels CLNK intron 19503597 rs10488948 chr4 10536544 A G 3.50E-12 Urate levels CLNK intron 20884846 rs10488948 chr4 10536544 A G 8.02E-41 Urate levels CLNK intron 23263486 rs2108879 chr4 10538144 A G 3.70E-16 Urate levels CLNK intron 23263486 rs7688620 chr4 10543318 G C 9.96E-18 Urate levels CLNK intron 23263486 rs6856070 chr4 10545768 A G 2.07E-17 Urate levels CLNK intron 23263486 rs11939512 chr4 10546359 T C 1.17E-17 Urate levels CLNK intron 23263486 rs2159245 chr4 10550193 G A 2.93E-04 Response to taxane treatment (placlitaxel) CLNK intron 23006423 rs10938845 chr4 10551500 C T 1.76E-11 Uric acid levels CLNK intron 19503597 rs10938845 chr4 10551500 C T 6.20E-25 Urate levels CLNK intron 23263486 rs1974584 chr4 10557861 C T 1.70E-10 Uric acid levels CLNK intron 19503597 rs1974584 chr4 10557861 C T 2.60E-22 Urate levels CLNK intron 23263486 rs1558201 chr4 10557918 G C 1.11E-11 Uric acid levels CLNK intron 19503597 rs1558201 chr4 10557918 G C 8.09E-26 Urate levels CLNK intron 23263486 rs4698068 chr4 10558992 A G 3.36E-09 Urate levels CLNK intron 23263486 rs4698069 chr4 10559041 A G 3.85E-14 Urate levels CLNK intron 23263486 rs9994202 chr4 10559396 T G 3.09E-13 Urate levels CLNK intron 23263486 rs12643937 chr4 10577980 C T 3.95E-11 Urate levels CLNK intron 23263486 rs12640119 chr4 10586384 G T 1.11E-10 Urate levels CLNK intron 23263486 rs9684265 chr4 10589661 G A 4.46E-07 Personality dimensions CLNK intron 22628180 rs10488949 chr4 10591448 G T 8.29E-11 Urate levels CLNK intron 23263486 rs2531178 chr4 10601134 A G 4.31E-08 Uric acid levels CLNK intron 19503597 rs2531178 chr4 10601134 A G 2.72E-16 Urate levels CLNK intron 23263486 rs2531185 chr4 10605821 C T 2.26E-09 Urate levels CLNK intron 23263486 rs12504618 chr4 10637221 G A 3.60E-05 Response to statin therapy CLNK intron 20339536 rs13139179 chr4 10643340 C G 3.80E-05 Response to statin therapy CLNK intron 20339536 rs6836007 chr4 10647584 G A 4.50E-05 Response to statin therapy CLNK intron 20339536 rs6836007 chr4 10647584 G A 5.00E-10 Urate levels CLNK intron 23263486 rs4593124 chr4 10648278 A C 5.97E-11 Urate levels CLNK intron 23263486 rs12650571 chr4 10649456 G A 3.90E-05 Response to statin therapy CLNK intron 20339536 rs12650571 chr4 10649456 G A 5.19E-10 Urate levels CLNK intron 23263486 rs7696539 chr4 10649778 G A 4.30E-05 Response to statin therapy CLNK intron 20339536 rs7696539 chr4 10649778 G A 4.79E-10 Urate levels CLNK intron 23263486 rs10516207 chr4 10650693 C T 4.07E-09 Urate levels CLNK intron 23263486 rs13107947 chr4 10651617 C T 2.10E-12 Urate levels CLNK intron 23263486 rs13139842 chr4 10651701 A G 6.81E-12 Urate levels CLNK intron 23263486 rs6821965 chr4 10651981 C T 4.63E-04 Acute lung injury CLNK intron 22295056 rs6822578 chr4 10652262 C G 7.90E-05 Response to statin therapy CLNK intron 20339536 rs6822578 chr4 10652262 C G 2.55E-11 Urate levels CLNK intron 23263486 rs4449408 chr4 10652413 C T 7.80E-05 Response to statin therapy CLNK intron 20339536 rs4449408 chr4 10652413 C T 7.15E-12 Urate levels CLNK intron 23263486 rs35699234 chr4 10654346 T C 8.60E-06 Urinary metabolites CLNK intron 21572414 rs4697768 chr4 10654997 G A 4.19E-04 Acute lung injury CLNK intron 22295056 rs12233843 chr4 10655218 A G 9.60E-04 Parkinson's disease CLNK intron 17052657 rs12233843 chr4 10655218 A G 1.12E-10 Urate levels CLNK intron 23263486 rs10938919 chr4 10655503 G A 6.92E-13 Urate levels CLNK intron 23263486 rs9683460 chr4 10656446 G T 8.40E-05 Response to statin therapy CLNK intron 20339536 rs9683460 chr4 10656446 G T 6.78E-11 Urate levels CLNK intron 23263486 rs6825032 chr4 10661605 A G 3.26E-04 Acute lung injury CLNK intron 22295056 rs10516208 chr4 10661734 A G 3.18E-04 Parkinson's disease CLNK intron 17052657 rs4235336 chr4 10663850 C T 2.61E-04 Parkinson's disease CLNK intron 17052657 rs6814902 chr4 10664869 A C 7.85E-04 Acute lung injury CLNK intron 22295056 rs4302458 chr4 10665758 A G 7.44E-04 Acute lung injury CLNK intron 22295056 rs12502030 chr4 10667476 T C 7.99E-04 Acute lung injury CLNK intron 22295056 rs4697772 chr4 10668182 T C 9.21E-04 Acute lung injury CLNK intron 22295056 rs4323097 chr4 10668791 A G 9.44E-04 Acute lung injury CLNK intron 22295056 rs11933682 chr4 10670911 C G 2.00E-05 Urinary metabolites CLNK intron 21572414 rs6830367 chr4 10671323 G C 2.35E-11 Urate levels CLNK intron 23263486 rs13145414 chr4 10688084 A C 1.13E-04 Type 2 diabetes / / 17463246 rs6827843 chr4 10688637 C A 1.30E-04 Type 2 diabetes / / 17463246 rs4501215 chr4 10689344 A G 1.00E-04 Type 2 diabetes / / 17463246 rs6819946 chr4 10702156 T C 7.33E-04 Multiple complex diseases / / 17554300 rs4274833 chr4 10711631 T C 5.17E-04 Acute lung injury / / 22295056 rs9291444 chr4 10713674 C T 2.43E-04 Multiple complex diseases / / 17554300 rs9291444 chr4 10713674 C T 5.70E-05 Serum metabolites / / 19043545 rs13137278 chr4 10723874 A G 2.48E-04 Multiple complex diseases / / 17554300 rs13137278 chr4 10723874 A G 8.40E-05 Serum metabolites / / 19043545 rs11940117 chr4 10726707 C T 4.81E-06 Vitiligo / / 22561518 rs16872571 chr4 10726853 C T 2.00E-08 Vitiligo / / 22561518 rs16872571 chr4 10726853 C T 2.00E-10 Myopia (pathological) / / 23049088 rs13142500 chr4 10727357 T C 2.00E-06 Rheumatoid arthritis / / 24390342 rs13142500 chr4 10727357 T C 2.80E-04 Rheumatoid arthritis / / 24390342 rs13142500 chr4 10727357 T C 3.00E-09 Rheumatoid arthritis / / 24390342 rs1872090 chr4 10834255 C T 9.71E-05 Blood pressure / / 17255346 rs7673890 chr4 10847303 G A 9.37E-04 Response to alcohol consumption (flushing response) / / 24277619 rs9991940 chr4 10856714 G A 2.28E-04 Blood pressure / / 17255346 rs9991940 chr4 10856714 G A 1.80E-05 Urinary metabolites / / 21572414 rs2869749 chr4 10857992 A G 8.43E-04 Response to alcohol consumption (flushing response) / / 24277619 rs10516213 chr4 10871655 A C 1.10E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13107834 chr4 10874933 G A 1.00E-05 Response to alcohol consumption (flushing response) / / 24277619 rs1483656 chr4 10876658 T C 1.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1483660 chr4 10883658 T C 1.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs2012542 chr4 10900102 C T 4.13E-04 Type 2 diabetes / / 17463246 rs10011464 chr4 10906367 T G 1.40E-05 Urinary metabolites / / 21572414 rs6850904 chr4 10906615 A C 9.40E-04 Type 2 diabetes / / 17463246 rs10028469 chr4 10909225 G T 6.59E-04 Multiple complex diseases / / 17554300 rs1384837 chr4 10910291 G T 9.80E-06 Urinary metabolites / / 21572414 rs4561926 chr4 10910901 A G 8.76E-04 Type 2 diabetes / / 17463246 rs17280896 chr4 10931721 A G 3.96E-04 Multiple complex diseases / / 17554300 rs10009111 chr4 10971423 A G 1.94E-06 Hypertension / / 21082022 rs10011697 chr4 10971832 A G 2.16E-06 Hypertension / / 21082022 rs10516217 chr4 10973261 G A 7.95E-04 Multiple complex diseases / / 17554300 rs10516217 chr4 10973261 G A 3.78E-05 Hypertension / / 21082022 rs3864182 chr4 10979635 A T 6.11E-04 Multiple complex diseases / / 17554300 rs10805258 chr4 10990869 A G 3.07E-05 Hirschsprung's disease / / 19196962 rs6448453 chr4 11026028 A G 4.10E-04 Multiple complex diseases / / 17554300 rs1876266 chr4 11037414 G C 6.57E-04 Multiple complex diseases / / 17554300 rs10015233 chr4 11040406 G C 6.27E-04 Multiple complex diseases / / 17554300 rs10013525 chr4 11057063 C A 1.85E-04 Multiple complex diseases / / 17554300 rs7698375 chr4 11060009 A G 6.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs1567107 chr4 11060541 G A 7.97E-04 Smoking initiation / / 24665060 rs56181784 chr4 11074106 G C 0.0003568 Sarcoidosis / / 22952805 rs10516219 chr4 11080161 G T 0.0001804 Sarcoidosis / / 22952805 rs4697843 chr4 11095758 G A 0.000063 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 / / 21873659 rs6815883 chr4 11100152 C T 3.81E-04 Multiple complex diseases / / 17554300 rs16878079 chr4 11100735 A G 2.99E-04 Alzheimer's disease (late onset) / / 21379329 rs16878083 chr4 11100788 A G 6.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11934416 chr4 11108426 C T 4.37E-04 Multiple complex diseases / / 17554300 rs9291494 chr4 11117827 G A 1.76E-04 Multiple complex diseases / / 17554300 rs1506796 chr4 11119049 G A 3.64E-04 Multiple complex diseases / / 17554300 rs4697674 chr4 11133145 A G 6.85E-05 Alcohol and nictotine co-dependence / / 20158304 rs11724374 chr4 11159968 G A 6.96E-05 Major depressive disorder / / 22472876 rs4697854 chr4 11163372 T A 4.87E-05 Bipolar disorder,schizoaffective / / 19567891 rs4697856 chr4 11191502 A G 9.70E-06 Urinary metabolites / / 21572414 rs11737293 chr4 11220563 A G 1.40E-05 Urinary metabolites / / 21572414 rs12511580 chr4 11229468 A G 5.10E-04 Allergic sensitization / / 23817571 rs4697861 chr4 11268830 G C 0.000659 Asthma / / 22502797 rs6823827 chr4 11292836 A G 6.03E-04 Multiple complex diseases / / 17554300 rs13104553 chr4 11295820 T C 1.45E-05 Hypertension (early onset hypertension) / / 22479346 rs4697869 chr4 11303176 A G 7.20E-04 Major depressive disorder / / 21042317 rs17383790 chr4 11320411 T C 2.58E-05 Alcohol and nictotine co-dependence / / 20158304 rs1997255 chr4 11333310 T C 1.90E-05 Urinary metabolites / / 21572414 rs1997255 chr4 11333310 T C 3.62E-05 Insulin resistance / / 21901158 rs10488972 chr4 11342170 T C 5.30E-04 Parkinson's disease / / 17052657 rs917684 chr4 11352031 A G 2.80E-04 Myasthenia gravis / / 23055271 rs725432 chr4 11380054 A G 1.50E-05 Urinary metabolites / / 21572414 rs10488975 chr4 11394354 A G 0.000686993 Hypertension (early onset hypertension) / / 22479346 rs722212 chr4 11395075 C T 9.29E-05 Hypertension (essential hypertension) / / 22184326 rs1047389 chr4 11401087 A G 7.81E-05 Hypertension (essential hypertension) HS3ST1 cds-synon 22184326 rs224463 chr4 11414037 G A 2.00E-04 Cognitive impairment induced by topiramate HS3ST1 intron 22091778 rs10939298 chr4 11426034 A C 9.40E-06 Urinary metabolites HS3ST1 intron 21572414 rs2240901 chr4 11432698 A G 4.17E-04 Multiple complex diseases / / 17554300 rs22021 chr4 11445486 G A 7.15E-04 Body mass index / / 21701565 rs425002 chr4 11445589 A C 9.11E-05 Multiple complex diseases / / 17554300 rs387835 chr4 11446281 G C,T 7.80E-04 Multiple complex diseases / / 17554300 rs11735035 chr4 11446969 A G 5.18E-04 Multiple complex diseases / / 17554300 rs16881955 chr4 11449210 T C 3.65E-04 Multiple complex diseases / / 17554300 rs11939554 chr4 11459557 G C 4.57E-04 Smoking cessation / / 24665060 rs224477 chr4 11465213 C A 6.28E-04 Multiple complex diseases / / 17554300 rs10004232 chr4 11498145 C T 9.29E-04 Type 2 diabetes / / 17463246 rs1390096 chr4 11503604 G A 2.23E-05 Intelligence / / 21826061 rs1390096 chr4 11503604 G A 3.00E-06 Nonalcoholic fatty liver disease / / 22719876 rs6830264 chr4 11503686 G C 7.99E-04 Multiple complex diseases / / 17554300 rs1874238 chr4 11503860 C A 8.93E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11733548 chr4 11504517 C G 3.85E-04 Smoking initiation / / 24665060 rs13152063 chr4 11506612 G A 9.96E-04 Type 2 diabetes / / 17463246 rs6848315 chr4 11517436 G A 1.64E-05 Serum metabolites / / 19043545 rs12647573 chr4 11531314 G A 2.58E-04 Parkinson's disease / / 17052657 rs13132542 chr4 11533423 G T 9.19E-05 Aging (time to event) / / 21782286 rs12507728 chr4 11533696 A G 1.14E-05 Abdominal aortic aneurysm / / 24046328 rs10155331 chr4 11538001 T C 3.24E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs956469 chr4 11546275 G T 7.85E-05 Cytomegalovirus antibody response / / 21993531 rs11945500 chr4 11547255 T C 7.82E-05 Cytomegalovirus antibody response / / 21993531 rs756418 chr4 11547967 C A 1.84E-06 Bilirubin levels,in serum / / 19389676 rs756418 chr4 11547967 C A 2.56E-04 Scoliosis / / 21216876 rs17491941 chr4 11570985 A G 6.97E-04 Acute lung injury / / 22295056 rs10011689 chr4 11575847 C T 3.57E-04 Alzheimer's disease / / 24755620 rs4834959 chr4 11589030 A G 1.51E-04 Acute lung injury / / 22295056 rs3886917 chr4 11621242 C T 6.93E-04 Longevity / / 22279548 rs6448799 chr4 11630049 T C 7.00E-08 Alzheimer's disease (late onset) / / 24162737 rs7671189 chr4 11674661 T C 3.00E-06 Obesity-related traits / / 23251661 rs16885963 chr4 11700942 A T 6.14E-04 Multiple complex diseases / / 17554300 rs3912887 chr4 11734841 C A 2.65E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11722485 chr4 11748470 G A 2.67E-06 Lipid traits / / 21777205 rs2866056 chr4 11749120 C G 4.28E-06 Lipid traits / / 21777205 rs1388867 chr4 11754426 T C 4.29E-04 Alzheimer's disease (late onset) / / 21379329 rs1388872 chr4 11755043 G A 4.44E-04 Alzheimer's disease (late onset) / / 21379329 rs1388872 chr4 11755043 G A 9.73E-05 Body Mass Index / / pha003020 rs2201186 chr4 11758071 G A 2.83E-04 Longevity / / 22279548 rs2201186 chr4 11758071 G A 9.56E-05 Body Mass Index / / pha003020 rs16886111 chr4 11761011 A G 5.53E-05 Multiple complex diseases / / 17554300 rs1492501 chr4 11764495 A G 9.29E-04 Alzheimer's disease / / 24755620 rs10049894 chr4 11767121 T C 4.01E-04 Myopia (pathological) / / 21095009 rs10049894 chr4 11767121 T C 8.04E-05 Hypertension / / pha003042 rs4552479 chr4 11770896 C T 6.00E-07 Schizophrenia / / 21926974 rs1387470 chr4 11841213 G T 9.34E-05 Cognitive test performance / / 20125193 rs4834876 chr4 11859477 C T 8.81E-05 Cognitive test performance / / 20125193 rs11934095 chr4 11884262 A G 7.57E-04 Smoking cessation / / 24665060 rs7667529 chr4 11904360 C T 5.27E-04 Acute lung injury / / 22295056 rs6824704 chr4 11905240 T A 4.96E-04 Acute lung injury / / 22295056 rs7663728 chr4 11909188 G A 5.17E-04 Acute lung injury / / 22295056 rs7694219 chr4 11909252 T C 5.33E-04 Acute lung injury / / 22295056 rs7670781 chr4 11909661 C A 6.09E-04 Acute lung injury / / 22295056 rs7696439 chr4 11977149 C T 1.90E-04 Rheumatoid arthritis / / 21452313 rs16886509 chr4 11983193 G A 4.92E-04 Rheumatoid arthritis / / 21452313 rs16886509 chr4 11983193 G A 0.0000772 Tuberculosis with late age of onset / / 22551897 rs4351037 chr4 11986162 G A 6.58E-04 Rheumatoid arthritis / / 21452313 rs11946608 chr4 11988877 C T 5.66E-04 Rheumatoid arthritis / / 21452313 rs1530340 chr4 12012509 C T 1.10E-05 Urinary metabolites / / 21572414 rs7660418 chr4 12021139 C T 4.16E-04 Myocardial Infarction / / pha002873 rs9998636 chr4 12025870 G C 3.27E-04 Depression (quantitative trait) / / 20800221 rs16886626 chr4 12079343 A G 3.84E-04 Multiple complex diseases / / 17554300 rs1479273 chr4 12083991 C T 8.01E-04 Type 2 diabetes / / 17463246 rs6831954 chr4 12098949 G T 4.59E-09 Metabolite levels / / 23281178 rs6810659 chr4 12099307 A C 4.59E-09 Metabolite levels / / 23281178 rs1479278 chr4 12099503 A C 3.00E-05 Asperger disorder / / 21182207 rs1031097 chr4 12099850 T C 2.00E-05 Asperger disorder / / 21182207 rs17330070 chr4 12102452 C T 4.59E-09 Metabolite levels / / 23281178 rs4834882 chr4 12108239 T C 2.04E-04 Major depressive disorder / / 22472876 rs187075894 chr4 12111549 T C 8.00E-07 Metabolite levels (MHPG) / / 23319000 rs6856121 chr4 12119860 C G 9.58E-04 Multiple complex diseases / / 17554300 rs6856121 chr4 12119860 C G 1.15E-04 Major depressive disorder / / 22472876 rs1479255 chr4 12124104 T C 1.30E-04 Major depressive disorder / / 22472876 rs7662249 chr4 12125014 G A 1.52E-04 Major depressive disorder / / 22472876 rs1382751 chr4 12138827 C T 4.66E-05 Major depressive disorder / / 22472876 rs1382752 chr4 12143367 G A 7.53E-08 Metabolite levels / / 23281178 rs17265093 chr4 12144279 A G 7.00E-05 Asperger disorder / / 21182207 rs17265093 chr4 12144279 A G 4.59E-09 Metabolite levels / / 23281178 rs17330984 chr4 12144630 C T 7.53E-08 Metabolite levels / / 23281178 rs17331012 chr4 12144655 G A 1.00E-04 Asperger disorder / / 21182207 rs1904330 chr4 12145509 A T 4.59E-09 Metabolite levels / / 23281178 rs7670873 chr4 12171491 T C 2.87E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs11730805 chr4 12174662 T G 7.00E-05 Asperger disorder / / 21182207 rs1961642 chr4 12178690 G C 1.00E-04 Aortic root size / / 21223598 rs2127270 chr4 12182361 T G 3.40E-04 Response to antidepressants / / 19736353 rs1479253 chr4 12247072 A G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1454877 chr4 12355207 T C 6.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10516249 chr4 12375057 T C 5.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10516250 chr4 12375084 C T 6.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9283696 chr4 12375400 C T 6.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1454875 chr4 12379318 T G 3.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7678128 chr4 12403596 T C 8.21E-04 Alzheimer's disease / / 17998437 rs6448889 chr4 12420960 G A 3.78E-04 Multiple complex diseases / / 17554300 rs11727304 chr4 12480889 A G 1.05E-05 Platelet counts / / 21507922 rs7665957 chr4 12498887 C T 5.00E-07 Obesity-related traits / / 23251661 rs62295889 chr4 12500221 T C 6.00E-06 Obesity-related traits / / 23251661 rs16887066 chr4 12520602 A G 7.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12511228 chr4 12538050 T C 3.04E-06 Left ventricular hypertrophy / / pha003052 rs6448925 chr4 12554693 G A 1.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11935262 chr4 12554711 T G 5.31E-06 Obesity-related traits / / 23251661 rs10002492 chr4 12579846 A G 8.00E-06 IgG glycosylation / / 23382691 rs6857588 chr4 12585408 G A 4.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12508370 chr4 12605378 C G,T 6.92E-04 Type 2 diabetes / / 17463246 rs2222309 chr4 12691840 T C 5.30E-04 Breast cancer / / 21060860 rs7666205 chr4 12696000 A G 5.42E-04 Multiple complex diseases / / 17554300 rs1520296 chr4 12697432 T C 7.90E-06 Urinary metabolites / / 21572414 rs17365573 chr4 12702609 G T 1.10E-05 Urinary metabolites / / 21572414 rs1474192 chr4 12702857 A G 2.70E-05 Urinary metabolites / / 21572414 rs1983381 chr4 12713526 A T 1.60E-05 Urinary metabolites / / 21572414 rs16887512 chr4 12734271 C T 1.17E-05 Word reading / / 23738518 rs7692270 chr4 12744304 G T 1.42E-05 Word reading / / 23738518 rs7674264 chr4 12749305 T A 1.56E-05 Word reading / / 23738518 rs7675044 chr4 12749922 A G 1.56E-05 Word reading / / 23738518 rs7692324 chr4 12757442 T G 2.39E-05 Word reading / / 23738518 rs11945798 chr4 12769232 T C 5.00E-06 Word reading / / 23738518 rs16887552 chr4 12773994 A C 5.00E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs16887552 chr4 12773994 A C 8.00E-06 Response to mTOR inhibitor (everolimus) / / 24009623 rs4834896 chr4 12793761 T A 1.69E-04 Coronary heart disease / / 21606135 rs807423 chr4 12802055 C T 5.29E-06 Insulin-related traits / / 19902172 rs807423 chr4 12802055 C T 1.84E-04 Coronary heart disease / / 21606135 rs807424 chr4 12802374 T C 2.22E-04 Coronary heart disease / / 21606135 rs7662165 chr4 12811827 G A 2.12E-05 Insulin-related traits / / 19902172 rs11730580 chr4 12863804 C T 4.94E-05 Serum albumin level / / pha003084 rs9291601 chr4 12876257 A G 6.29E-05 Insulin-related traits / / 19902172 rs223928 chr4 12900235 T A 5.78E-04 Multiple complex diseases / / 17554300 rs223929 chr4 12901753 A C 9.58E-05 Cognitive impairment induced by topiramate / / 22091778 rs759439 chr4 12949656 G A 2.40E-05 Serum metabolites / / 19043545 rs763318 chr4 12963574 G A 6.88E-06 Serum metabolites / / 19043545 rs223981 chr4 12964340 C G 8.01E-05 Serum metabolites / / 19043545 rs115432166 chr4 12970339 A G 2.69E-05 Epilepsy (remission after treatment) / / 23962720 rs13117100 chr4 12971147 G A 8.93E-05 Epilepsy (remission after treatment) / / 23962720 rs4834909 chr4 13005363 T G 7.30E-05 Femoral neck bone geometry / / 22087292 rs2056117 chr4 13010092 C T 3.79E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs7679886 chr4 13026562 T C 4.00E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4834860 chr4 13030876 A G 9.68E-04 Parkinson's disease / / 17052657 rs7677099 chr4 13068647 A G 8.30E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs13136347 chr4 13079264 C T 6.50E-04 Type 2 diabetes / / 17463246 rs11737025 chr4 13085843 C T 8.90E-04 Type 2 diabetes / / 17463246 rs1976491 chr4 13087804 C G 3.96E-04 Type 2 diabetes / / 17463246 rs6856970 chr4 13089281 T C 4.70E-04 Type 2 diabetes / / 17463246 rs16902 chr4 13095942 A G 5.04E-04 Depression (quantitative trait) / / 20800221 rs555931 chr4 13096420 T A 1.55E-04 Depression (quantitative trait) / / 20800221 rs559930 chr4 13096599 T C 1.61E-04 Depression (quantitative trait) / / 20800221 rs479731 chr4 13097600 T C 1.62E-04 Depression (quantitative trait) / / 20800221 rs481820 chr4 13097877 C T 4.36E-04 Depression (quantitative trait) / / 20800221 rs503461 chr4 13098110 C T 4.55E-04 Depression (quantitative trait) / / 20800221 rs504503 chr4 13098267 T C 4.60E-04 Depression (quantitative trait) / / 20800221 rs512244 chr4 13098882 C T 4.61E-04 Depression (quantitative trait) / / 20800221 rs536973 chr4 13099268 A T 4.60E-04 Depression (quantitative trait) / / 20800221 rs542309 chr4 13099816 A G 6.14E-04 Premature ovarian failure / / 19508998 rs543108 chr4 13099886 G A 4.16E-04 Depression (quantitative trait) / / 20800221 rs495276 chr4 13100779 T C 4.57E-04 Depression (quantitative trait) / / 20800221 rs13122273 chr4 13102351 G T 9.00E-07 Inflammatory biomarkers / / 22228203 rs11723376 chr4 13113491 C T 8.21E-04 Depression (quantitative trait) / / 20800221 rs491376 chr4 13116762 G C 2.00E-06 Response to antidepressant treatment / / 22041458 rs573332 chr4 13122535 C T 3.50E-04 Multiple complex diseases / / 17554300 rs573332 chr4 13122535 C T 1.00E-06 Response to antidepressant treatment / / 22041458 rs6836652 chr4 13130999 G A 8.34E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs490325 chr4 13147622 A G 8.73E-05 Tunica Media / / pha003037 rs503506 chr4 13149122 G A 1.57E-05 Alcohol consumption / / 23953852 rs6838271 chr4 13221390 C T 3.29E-05 Heart Rate / / pha003054 rs6843953 chr4 13221747 C T 6.94E-05 Heart Rate / / pha003054 rs733048 chr4 13242797 G A 1.00E-06 Periodontal disease-related phenotypes / / 24347629 rs733048 chr4 13242797 G A 4.00E-06 Periodontal disease-related phenotypes / / 24347629 rs734998 chr4 13252632 C A 5.81E-05 Odorant perception / / 23910658 rs2867467 chr4 13325741 G C 1.84E-04 Obesity (extreme) / / 21935397 rs6842438 chr4 13328373 T C 1.84E-04 Obesity (extreme) / / 21935397 rs10019897 chr4 13330095 C T 2.03E-04 Multiple complex diseases / / 17554300 rs10019897 chr4 13330095 C T 1.77E-04 Obesity (extreme) / / 21935397 rs9996364 chr4 13333413 A G 1.75E-04 Obesity (extreme) / / 21935397 rs11946968 chr4 13334394 C T 1.75E-04 Obesity (extreme) / / 21935397 rs11945340 chr4 13338465 C T 1.74E-04 Obesity (extreme) / / 21935397 rs6839621 chr4 13340249 T C 1.73E-04 Obesity (extreme) / / 21935397 rs6837169 chr4 13344390 C G,T 1.72E-04 Obesity (extreme) / / 21935397 rs11930614 chr4 13346602 C T 1.67E-04 Obesity (extreme) / / 21935397 rs10021881 chr4 13350973 T C 1.67E-04 Obesity (extreme) / / 21935397 rs16888596 chr4 13356393 G A 1.65E-04 Obesity (extreme) / / 21935397 rs11732938 chr4 13357274 A G 1.64E-04 Obesity (extreme) / / 21935397 rs10016671 chr4 13359047 C T 1.63E-04 Obesity (extreme) / / 21935397 rs11947529 chr4 13360622 T A 1.63E-04 Obesity (extreme) / / 21935397 rs12331157 chr4 13363958 A G 1.64E-04 Obesity (extreme) / / 21935397 rs12332023 chr4 13363974 C T 1.64E-04 Obesity (extreme) / / 21935397 rs7673680 chr4 13366481 C T 1.64E-04 Obesity (extreme) / / 21935397 rs10031623 chr4 13369324 C T 1.65E-04 Obesity (extreme) / / 21935397 rs10003958 chr4 13370308 T C 1.65E-04 Obesity (extreme) RAB28 intron 21935397 rs9999851 chr4 13373583 C T 1.66E-04 Obesity (extreme) RAB28 intron 21935397 rs10488957 chr4 13374230 T C 5.69E-04 Multiple complex diseases RAB28 intron 17554300 rs9291610 chr4 13374462 G A 1.65E-04 Obesity (extreme) RAB28 intron 21935397 rs2109590 chr4 13377286 T C 7.55E-04 Smoking initiation RAB28 intron 24665060 rs13435249 chr4 13379449 T C 1.68E-04 Obesity (extreme) RAB28 intron 21935397 rs9993832 chr4 13389590 G T 1.71E-04 Obesity (extreme) RAB28 intron 21935397 rs10022847 chr4 13391088 C A 1.73E-04 Obesity (extreme) RAB28 intron 21935397 rs10001262 chr4 13393883 T C 1.81E-04 Obesity (extreme) RAB28 intron 21935397 rs9998914 chr4 13393897 A T 1.81E-04 Obesity (extreme) RAB28 intron 21935397 rs9999092 chr4 13394042 A G 1.82E-04 Obesity (extreme) RAB28 intron 21935397 rs6820841 chr4 13394792 G A 1.85E-04 Obesity (extreme) RAB28 intron 21935397 rs16888633 chr4 13395424 C T 1.85E-04 Obesity (extreme) RAB28 intron 21935397 rs9998670 chr4 13395897 G A 1.86E-04 Obesity (extreme) RAB28 intron 21935397 rs11943295 chr4 13403855 G A 7.63E-04 Multiple complex diseases RAB28 intron 17554300 rs11943295 chr4 13403855 G A 1.97E-04 Obesity (extreme) RAB28 intron 21935397 rs11943330 chr4 13403998 G A 1.98E-04 Obesity (extreme) RAB28 intron 21935397 rs7677336 chr4 13404130 G T 2.01E-04 Obesity (extreme) RAB28 intron 21935397 rs7673732 chr4 13404717 A C 2.61E-04 Obesity (extreme) RAB28 intron 21935397 rs11737264 chr4 13440031 C G 2.69E-04 Obesity (extreme) RAB28 intron 21935397 rs11737360 chr4 13440271 C T 2.69E-04 Obesity (extreme) RAB28 intron 21935397 rs16888654 chr4 13449532 A C 2.71E-04 Obesity (extreme) RAB28 intron 21935397 rs16888661 chr4 13452022 C A 2.73E-04 Obesity (extreme) RAB28 intron 21935397 rs13145438 chr4 13452265 G A 8.44E-05 Receptive language ability RAB28 intron 24687471 rs11933841 chr4 13463991 T C 2.86E-04 Obesity (extreme) RAB28 intron 21935397 rs11947665 chr4 13465710 T A 2.88E-04 Obesity (extreme) RAB28 intron 21935397 rs2075050 chr4 13526386 G A 1.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10034452 chr4 13530824 T G 2.18E-04 Obesity (extreme) LOC285547 intron 21935397 rs12506352 chr4 13580532 A G 2.03E-04 Suicide attempts in bipolar disorder BOD1L intron 21423239 rs1491265 chr4 13682414 C T 8.78E-04 Multiple complex diseases / / 17554300 rs1873519 chr4 13708154 A T 3.22E-05 Intracerebral hemorrhage / / 24656865 rs13147974 chr4 13713346 G C 6.60E-04 Suicide attempts in bipolar disorder / / 21041247 rs2867535 chr4 13714273 A G 7.06E-06 Intracerebral hemorrhage / / 24656865 rs10939500 chr4 13715121 C A 3.91E-04 Alcohol dependence / / 21314694 rs10489085 chr4 13717262 G A 1.37E-05 Intracerebral hemorrhage / / 24656865 rs13120921 chr4 13717471 T C 4.70E-04 Suicide attempts in bipolar disorder / / 21041247 rs10084768 chr4 13719489 G A 2.18E-04 Longevity / / 22279548 rs55669100 chr4 13723103 A G 1.65E-05 Intracerebral hemorrhage / / 24656865 rs55740084 chr4 13723227 G T 1.62E-05 Intracerebral hemorrhage / / 24656865 rs7687430 chr4 13723887 C T 7.34E-06 Intracerebral hemorrhage / / 24656865 rs1558595 chr4 13727637 C A 1.33E-05 Intracerebral hemorrhage / / 24656865 rs12504648 chr4 13728186 C T 1.44E-05 Intracerebral hemorrhage / / 24656865 rs16889082 chr4 13728706 A T 3.14E-06 Intracerebral hemorrhage / / 24656865 rs16889086 chr4 13728777 T C 4.31E-05 Cognitive performance / / 19734545 rs4698441 chr4 13729419 C T 1.84E-05 Intracerebral hemorrhage / / 24656865 rs16889096 chr4 13730002 C G 9.55E-06 Intracerebral hemorrhage / / 24656865 rs1157386 chr4 13730821 C T 1.31E-05 Intracerebral hemorrhage / / 24656865 rs6823414 chr4 13731092 C T 2.83E-06 Intracerebral hemorrhage / / 24656865 rs16889099 chr4 13732086 T C 1.85E-04 Attention deficit hyperactivity disorder / / pha002875 rs56282218 chr4 13732225 G C 2.98E-06 Intracerebral hemorrhage / / 24656865 rs9994682 chr4 13733371 T C 8.38E-05 Stroke / / pha002886 rs767111 chr4 13733778 A G 2.10E-06 Intracerebral hemorrhage / / 24656865 rs10939503 chr4 13733950 A G 1.24E-05 Intracerebral hemorrhage / / 24656865 rs12641662 chr4 13734458 T C 1.70E-05 Intracerebral hemorrhage / / 24656865 rs4698460 chr4 13749408 T A,C,G 7.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs2270279 chr4 13755011 T G 8.13E-05 Attention deficit hyperactivity disorder / / pha002875 rs1491250 chr4 13780176 T C 2.42E-05 Cognitive impairment induced by topiramate / / 22091778 rs10489087 chr4 13794416 G A 5.00E-06 Hemostatic factors and hematological phenotypes / / 17903294 rs7684636 chr4 13807335 T C 1.72E-05 Blood Pressure / / pha003043 rs10489088 chr4 13808360 A G 2.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10939516 chr4 13815155 A G 5.11E-04 Alcohol dependence / / 20201924 rs4395500 chr4 13824647 C T 1.73E-05 Parkinson's disease / / 21738487 rs1861135 chr4 13861249 G A 1.68E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs7690022 chr4 13872720 T C 6.32E-05 Insulin Resistance / / pha003062 rs7690022 chr4 13872720 T C 3.75E-05 Insulin-related traits / / pha003063 rs1397622 chr4 13883153 A G 4.47E-04 Alzheimer's disease / / 22005930 rs807764 chr4 13883763 G A 6.00E-04 Alzheimer's disease / / 22005930 rs1511042 chr4 13885123 A G 3.69E-04 Alzheimer's disease / / 22005930 rs16889388 chr4 13893168 C T 5.48E-05 Attention deficit hyperactivity disorder / / 23728934 rs1606083 chr4 13897193 A G 5.10E-05 Depression (quantitative trait) / / 20800221 rs807773 chr4 13899000 T A 7.32E-28 Narcolepsy / / 19629137 rs807773 chr4 13899000 T A 3.86E-04 Depression (quantitative trait) / / 20800221 rs10222723 chr4 13904464 C T 1.64E-04 Alzheimer's disease / / 22005930 rs7669174 chr4 13905166 T C 1.47E-04 Alzheimer's disease / / 22005930 rs10805321 chr4 13914373 C A 9.00E-06 Response to antipsychotic therapy (extrapyramidal side effects) / / 21990027 rs7676721 chr4 13916351 G T 6.76E-05 Schizophrenia / / 19197363 rs7676721 chr4 13916351 G T 6.50E-05 Lung function (forced vital capacity) / / pha003104 rs16889439 chr4 13918428 T G 2.44E-04 Alzheimer's disease / / 22005930 rs505703 chr4 13920982 C T 4.18E-05 Schizophrenia / / 19197363 rs10516269 chr4 13937260 T G 7.25E-05 Schizophrenia / / 19197363 rs2120555 chr4 13953713 A G 1.25E-05 Type 2 diabetes / / 17463246 rs556799 chr4 13957583 T A 9.24E-04 Type 2 diabetes / / 17463246 rs7665661 chr4 13997289 G T 7.83E-04 Type 2 diabetes / / 17463246 rs16889552 chr4 14002655 G T 6.18E-04 Type 2 diabetes / / 17463246 rs3843422 chr4 14010614 C T 5.22E-05 Type 2 diabetes / / 17463246 rs480574 chr4 14029531 G A 2.12E-05 Type 2 diabetes / / 17463246 rs519262 chr4 14038489 G A 6.30E-05 Response to statin therapy / / 20339536 rs17340963 chr4 14044696 T C 6.50E-05 Response to statin therapy / / 20339536 rs3843425 chr4 14049906 T A 6.20E-05 Response to statin therapy / / 20339536 rs4101199 chr4 14050732 T C 5.10E-05 Response to statin therapy / / 20339536 rs4698240 chr4 14053263 G T 4.50E-05 Response to statin therapy / / 20339536 rs2867613 chr4 14053357 C G 4.80E-05 Response to statin therapy / / 20339536 rs2120556 chr4 14053566 T G 5.80E-05 Response to statin therapy / / 20339536 rs1036978 chr4 14053922 A G 5.80E-05 Response to statin therapy / / 20339536 rs7441763 chr4 14054746 T C 5.80E-05 Response to statin therapy / / 20339536 rs7673009 chr4 14055736 C A 5.70E-05 Response to statin therapy / / 20339536 rs3857160 chr4 14057063 T C 5.90E-05 Response to statin therapy / / 20339536 rs9790654 chr4 14058224 A G 6.00E-05 Response to statin therapy / / 20339536 rs4273465 chr4 14060100 C A 6.00E-05 Response to statin therapy / / 20339536 rs7682816 chr4 14060248 T C 5.90E-05 Response to statin therapy / / 20339536 rs7659248 chr4 14060703 C A 5.80E-05 Response to statin therapy / / 20339536 rs10029878 chr4 14061268 T C 5.90E-05 Response to statin therapy / / 20339536 rs4698241 chr4 14063649 T C 6.10E-05 Response to statin therapy / / 20339536 rs10516271 chr4 14063844 A G 1.00E-04 Prostate cancer / / 21743057 rs11734304 chr4 14064393 C A 7.90E-05 Response to statin therapy / / 20339536 rs11943313 chr4 14083766 T C 3.20E-05 Response to statin therapy / / 20339536 rs3846375 chr4 14092129 G A 2.50E-05 Response to statin therapy / / 20339536 rs3846377 chr4 14092921 C A 2.01E-04 Multiple complex diseases / / 17554300 rs17342538 chr4 14093776 A G 2.80E-05 Response to statin therapy / / 20339536 rs7695592 chr4 14098403 A G 2.20E-05 Response to statin therapy / / 20339536 rs4608810 chr4 14099183 G A 0.00000358 Sasang constitution (Taeum) / / 22394158 rs12641400 chr4 14100831 A G 1.40E-05 Response to statin therapy / / 20339536 rs12644869 chr4 14113767 C G 3.10E-05 Response to statin therapy / / 20339536 rs6827737 chr4 14119200 A G 2.20E-05 Response to statin therapy LOC152742 intron 20339536 rs7697376 chr4 14130521 G C 9.47E-04 Suicide attempts in bipolar disorder LOC152742 intron 21423239 rs16889726 chr4 14132361 C T 9.56E-04 Suicide attempts in bipolar disorder LOC152742 intron 21423239 rs10516274 chr4 14132572 A G 5.71E-04 Multiple complex diseases LOC152742 intron 17554300 rs7654692 chr4 14133803 A G 7.87E-04 Suicide attempts in bipolar disorder LOC152742 intron 21423239 rs3893808 chr4 14139678 A G 7.74E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines LOC152742 intron 21844884 rs6844339 chr4 14144208 A G 6.00E-06 Obesity-related traits / / 23251661 rs17346188 chr4 14162102 C T 4.20E-05 Alzheimer's disease / / 17998437 rs3111810 chr4 14171487 T C 3.19E-07 Schizophrenia / / 22037552 rs3111816 chr4 14179198 A G 3.04E-05 Depression (quantitative trait) / / 23290196 rs1426134 chr4 14179729 C G 3.78E-05 Depression (quantitative trait) / / 23290196 rs3096573 chr4 14208007 C A 1.00E-04 Prostate cancer / / 21743057 rs17348460 chr4 14221252 C A 2.86E-04 Multiple complex diseases / / 17554300 rs3111828 chr4 14222240 T G 2.20E-05 Coronary heart disease / / pha003031 rs16889909 chr4 14242857 A G 2.54E-08 Narcolepsy / / 19629137 rs11929730 chr4 14243288 C G 7.09E-04 Multiple complex diseases / / 17554300 rs3096579 chr4 14267496 C T 2.34E-05 Cognitive impairment induced by topiramate / / 22091778 rs3111813 chr4 14275327 A C 2.66E-04 Taste perception / / 22132133 rs3111813 chr4 14275327 A C 1.31E-04 Smoking initiation / / 24665060 rs1991268 chr4 14277183 T C 1.04E-04 Taste perception / / 22132133 rs1991268 chr4 14277183 T C 1.93E-04 Smoking initiation / / 24665060 rs10939538 chr4 14286253 T C 1.58E-04 Smoking initiation / / 24665060 rs10488976 chr4 14312437 C T 8.53E-05 Heart Rate / / pha003053 rs6816401 chr4 14362571 C T 1.68E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10488980 chr4 14388846 A G 7.14E-06 Blood Pressure / / pha003049 rs1013284 chr4 14389355 A G 4.93E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs887563 chr4 14394902 C T 6.73E-05 Cardiovascular disease / / pha003065 rs735855 chr4 14395318 A T 4.52E-05 Serum metabolites / / 19043545 rs2010594 chr4 14395985 A G 5.18E-04 Multiple complex diseases / / 17554300 rs218769 chr4 14428542 T G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1501173 chr4 14438302 T C 5.98E-04 Multiple complex diseases / / 17554300 rs218783 chr4 14444138 C T 6.66E-05 Body Composition / / pha003012 rs218783 chr4 14444138 C T 8.49E-05 Body Mass Index / / pha003021 rs17549604 chr4 14447695 C G 2.56E-04 Multiple complex diseases / / 17554300 rs2867711 chr4 14448285 T C 2.86E-04 Multiple complex diseases / / 17554300 rs13126715 chr4 14449216 A C 2.46E-04 Multiple complex diseases / / 17554300 rs11730677 chr4 14450587 C T 9.09E-05 HDL cholesterol / / pha003074 rs6449036 chr4 14451268 C T 7.24E-05 Body Composition / / pha003012 rs6449036 chr4 14451268 C T 7.27E-05 Body Mass Index / / pha003021 rs218787 chr4 14451896 T C 2.53E-04 Multiple complex diseases / / 17554300 rs218798 chr4 14456691 G C 1.01E-04 Multiple complex diseases / / 17554300 rs7678868 chr4 14497307 A G 5.16E-05 Body Composition / / pha003012 rs7678868 chr4 14497307 A G 9.09E-05 Body Mass Index / / pha003021 rs1501177 chr4 14552293 A G 7.54E-05 Personality dimensions / / 18957941 rs12639674 chr4 14562019 C T 5.18E-05 Cognitive impairment induced by topiramate / / 22091778 rs4473649 chr4 14610388 C T 5.34E-05 Cognitive impairment induced by topiramate / / 22091778 rs7668324 chr4 14612064 G A 1.29E-04 Multiple complex diseases / / 17554300 rs956518 chr4 14660437 G A 0.000057 Pancreatic cancer and survival / / 22665904 rs16890931 chr4 14675684 A G 2.37E-05 Serum metabolites / / 19043545 rs16890931 chr4 14675684 A G 6.96E-05 Cognitive test performance / / 20125193 rs4327484 chr4 14700515 C T 0.000153136 Hypertension (early onset hypertension) / / 22479346 rs6832038 chr4 14700869 G T 0.000878357 Hypertension (early onset hypertension) / / 22479346 rs6827975 chr4 14728183 C A 3.36E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs12503865 chr4 14734639 A C 3.19E-04 Multiple complex diseases / / 17554300 rs6835379 chr4 14807194 G A 7.04E-05 Hearing function / / 17255346 rs4443273 chr4 14808684 C T 5.94E-05 Hearing function / / 17255346 rs7692506 chr4 14817096 T C 1.70E-04 Hearing function / / 17255346 rs4367167 chr4 14825726 C G 2.70E-04 Hearing function / / 17255346 rs10939594 chr4 14837288 C A 1.40E-04 Primary sclerosing cholangitis / / 19944697 rs10755214 chr4 14837311 G T 1.40E-04 Primary sclerosing cholangitis / / 19944697 rs12503362 chr4 14843006 C T 3.80E-04 Primary sclerosing cholangitis / / 19944697 rs1389999 chr4 14858341 C T 1.57E-05 Multiple complex diseases / / 17554300 rs9994946 chr4 14882553 G C 5.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs10034460 chr4 14883047 T A 2.60E-05 White matter hyperintensity burden / / 21681796 rs6815830 chr4 14906935 T C 3.90E-05 White matter hyperintensity burden / / 21681796 rs7680772 chr4 14911059 A G 1.46E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6856837 chr4 14926135 G C 6.09E-04 Multiple complex diseases LOC441009 intron 17554300 rs6848655 chr4 14928149 A G 1.21E-04 Hearing function LOC441009 intron 17255346 rs11947254 chr4 14928904 A G 1.47E-04 Hearing function LOC441009 intron 17255346 rs12512985 chr4 14929576 A G 1.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC441009 intron 20877124 rs12641663 chr4 14931459 T C 6.65E-04 Type 2 diabetes LOC441009 intron 17463246 rs10005929 chr4 14931639 G T 1.91E-04 Hearing function LOC441009 intron 17255346 rs11722368 chr4 14934107 C T 5.42E-04 Type 2 diabetes LOC441009 intron 17463246 rs10007527 chr4 14936966 G T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC441009 intron 22628534 rs2132084 chr4 14940055 T A 8.85E-04 Suicide attempts in bipolar disorder LOC441009 intron 21423239 rs2132082 chr4 14955398 T C 2.10E-05 Calcium levels LOC441009 intron pha003085 rs6449093 chr4 14962496 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC441009 intron 22628534 rs1494950 chr4 14967169 A G 9.00E-06 Political ideology LOC441009 intron 24569950 rs4698307 chr4 14978435 G A 4.80E-05 Hypothyroidism LOC441009 intron 22493691 rs2604573 chr4 15038411 T C 5.12E-04 Suicide attempts in bipolar disorder CPEB2 intron 21423239 rs2702578 chr4 15057284 T G 1.60E-04 Suicide attempts in bipolar disorder CPEB2 intron 21423239 rs2702572 chr4 15063545 C T 8.38E-05 Psoriasis CPEB2 intron 20953190 rs12646901 chr4 15102929 T C 1.06E-04 HIV-1 viral setpoint / / 21490045 rs1378343 chr4 15112646 T G 2.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs1378343 chr4 15112646 T G 7.77E-04 Alzheimer's disease / / 24755620 rs9998316 chr4 15113642 G C 9.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs4698316 chr4 15123155 C G 2.10E-05 Urinary metabolites / / 21572414 rs13125054 chr4 15130607 G C 0.0000626 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13125054 chr4 15130607 G C 6.26E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2702525 chr4 15136380 G A 4.85E-05 Lung adenocarcinoma / / 19836008 rs17452586 chr4 15143489 C T 0.000692 Salmonella-induced pyroptosis / / 22837397 rs2604562 chr4 15145180 A C 8.76E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2604560 chr4 15149657 C G 2.40E-05 Urinary metabolites / / 21572414 rs1378339 chr4 15167516 A G 4.20E-04 Fibrinogen / / 17255346 rs10021046 chr4 15184903 T C 5.90E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs732556 chr4 15187699 A G 1.77E-05 Post-operative nausea and vomiting / / 21694509 rs10805344 chr4 15193122 T C 8.69E-05 Cognitive test performance / / 20125193 rs10008462 chr4 15197936 G A 5.78E-04 Multiple complex diseases / / 17554300 rs1869696 chr4 15210204 C A 6.40E-05 Coronary heart disease / / pha003035 rs11733875 chr4 15227300 A G 4.60E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10027043 chr4 15257488 T C 8.71E-05 Blood Pressure / / pha003044 rs10025322 chr4 15260984 C T 2.78E-04 Multiple complex diseases / / 17554300 rs16891662 chr4 15298663 A G 4.57E-06 White blood cell count / / 21738479 rs4453928 chr4 15301196 G A 2.29E-06 White blood cell count / / 21738479 rs13127337 chr4 15303053 C T 3.55E-06 White blood cell count / / 21738479 rs12696946 chr4 15304158 T A 3.55E-06 White blood cell count / / 21738479 rs16891737 chr4 15335626 A G 5.70E-04 Multiple complex diseases / / 17554300 rs114133078 chr4 15354385 T C 2.00E-07 PR interval in Tripanosoma cruzi seropositivity C1QTNF7 intron 24324551 rs4575989 chr4 15392559 T C 6.92E-04 Smoking initiation C1QTNF7 intron 24665060 rs16891867 chr4 15397364 A G 3.00E-09 Conduct disorder (symptom count) C1QTNF7 intron 20585324 rs16891867 chr4 15397364 A G 4.00E-06 Conduct disorder (symptom count) C1QTNF7 intron 20585324 rs1861046 chr4 15397906 G A 6.00E-08 Conduct disorder (symptom count) C1QTNF7 intron 20585324 rs13138481 chr4 15423018 G C 5.59E-04 Type 2 diabetes C1QTNF7 intron 17463246 rs17384915 chr4 15424176 A G 2.66E-04 Response to cytadine analogues (cytosine arabinoside) C1QTNF7 intron 24483146 rs2192356 chr4 15424591 A G 7.96E-04 Smoking quantity C1QTNF7 intron 24665060 rs16891938 chr4 15427684 C T 9.21E-04 Multiple complex diseases C1QTNF7 intron 17554300 rs17385047 chr4 15433195 T C 2.40E-04 Response to cytadine analogues (cytosine arabinoside) C1QTNF7 intron 24483146 rs17469572 chr4 15433978 C T 6.77E-04 Response to cytadine analogues (cytosine arabinoside) C1QTNF7 intron 24483146 rs2215809 chr4 15440633 A C 4.72E-04 Type 2 diabetes C1QTNF7 intron 17463246 rs17469634 chr4 15441980 A G 7.30E-04 Response to cytadine analogues (cytosine arabinoside) C1QTNF7 intron 24483146 rs13108125 chr4 15443685 T G 4.56E-04 Smoking quantity C1QTNF7 intron 24665060 rs2314590 chr4 15445533 C T 6.77E-04 Response to cytadine analogues (cytosine arabinoside) C1QTNF7 UTR-3 24483146 rs12642505 chr4 15456644 T C 9.63E-04 Type 2 diabetes / / 17463246 rs16891995 chr4 15458657 G A 2.36E-05 Multiple complex diseases / / 17554300 rs11728800 chr4 15474996 C T 8.33E-05 Response to cytadine analogues (cytosine arabinoside) CC2D2A intron 24483146 rs1861050 chr4 15482360 C T 8.00E-06 Conduct disorder (symptom count) CC2D2A STOP-GAIN 20585324 rs6810461 chr4 15482809 G A 3.36E-04 Coronary Artery Disease CC2D2A intron 17634449 rs3087622 chr4 15483288 T C 2.66E-05 Response to cytadine analogues (cytosine arabinoside) CC2D2A UTR-3 24483146 rs2160043 chr4 15499251 T C 4.65E-04 Amyotrophic Lateral Sclerosis CC2D2A intron 17362836 rs2160043 chr4 15499251 T C 2.62E-04 Nonalcoholic fatty liver disease CC2D2A intron 21423719 rs1058412 chr4 15513147 C T 3.85E-04 Amyotrophic Lateral Sclerosis CC2D2A intron 17362836 rs1058412 chr4 15513147 C T 3.16E-04 Response to cytadine analogues (cytosine arabinoside) CC2D2A intron 24483146 rs7675761 chr4 15527808 A G 2.87E-04 Response to cytadine analogues (cytosine arabinoside) CC2D2A intron 24483146 rs4698395 chr4 15530124 C A 6.93E-04 Amyotrophic Lateral Sclerosis CC2D2A intron 17362836 rs4698395 chr4 15530124 C A 2.87E-04 Response to cytadine analogues (cytosine arabinoside) CC2D2A intron 24483146 rs10755215 chr4 15533037 C T 5.10E-04 Amyotrophic Lateral Sclerosis CC2D2A intron 17362836 rs7687556 chr4 15535095 A G 3.39E-04 Alzheimer's disease CC2D2A intron 22005930 rs2007633 chr4 15540286 A T 3.66E-04 Alzheimer's disease CC2D2A intron 22005930 rs9918079 chr4 15545410 G A 6.00E-06 Obesity-related traits CC2D2A intron 23251661 rs7690497 chr4 15577414 T C 1.93E-04 Multiple complex diseases CC2D2A intron 17554300 rs10008376 chr4 15623955 C T 8.14E-05 Multiple complex diseases FBXL5 intron 17554300 rs7438356 chr4 15624770 C T 2.22E-04 Multiple complex diseases FBXL5 intron 17554300 rs4235380 chr4 15689928 G A 8.75E-04 Parkinson's disease FAM200B missense 21248740 rs6449161 chr4 15692954 T C 1.99E-04 Multiple complex diseases / / 17554300 rs4583752 chr4 15699005 A G 6.67E-04 Parkinson's disease / / 21248740 rs3213710 chr4 15717321 G A 3.81E-08 Parkinson's disease BST1 intron 22438815 rs11931532 chr4 15725766 T C 1.03E-09 Parkinson's disease BST1 intron 22438815 rs12502586 chr4 15726564 G A 4.05E-04 Parkinson's disease BST1 intron 21248740 rs12645693 chr4 15729534 G A 3.14E-09 Parkinson's disease BST1 intron 22438815 rs12646331 chr4 15729783 G T 9.41E-04 Multiple complex diseases BST1 intron 17554300 rs9790670 chr4 15731374 G C 4.81E-06 Glycemic traits (pregnancy) BST1 intron 23903356 rs16892283 chr4 15731534 A G 2.48E-06 Glycemic traits (pregnancy) BST1 intron 23903356 rs16892287 chr4 15732193 C T 4.82E-06 Glycemic traits (pregnancy) BST1 intron 23903356 rs16892289 chr4 15732303 G C 7.07E-07 Glycemic traits (pregnancy) BST1 intron 23903356 rs4321629 chr4 15732380 C T 5.00E-06 Glycemic traits (pregnancy) BST1 intron 23903356 rs10516290 chr4 15732456 T C 4.12E-06 Glycemic traits (pregnancy) BST1 intron 23903356 rs10516291 chr4 15732791 C T 4.75E-06 Glycemic traits (pregnancy) BST1 intron 23903356 rs16898413 chr4 15732830 T C 4.81E-06 Glycemic traits (pregnancy) BST1 intron 23903356 rs4435745 chr4 15733159 A G 4.75E-06 Glycemic traits (pregnancy) BST1 intron 23903356 rs11724635 chr4 15737101 C A 1.00E-16 Parkinson's disease / / 21292315 rs11724635 chr4 15737101 C A 5.96E-11 Parkinson's disease / / 22438815 rs11724635 chr4 15737101 C A 1.85E-08 Parkinson's disease / / 22451204 rs4698412 chr4 15737348 G A 2.00E-06 Parkinson's disease / / 21084426 rs4698412 chr4 15737348 G A 2.41E-05 Parkinson's disease / / 21738487 rs4698412 chr4 15737348 G A 5.66E-15 Parkinson's disease / / 22438815 rs4698412 chr4 15737348 G A 3.00E-07 Parkinson's disease / / 22451204 rs4698413 chr4 15737882 C T 3.00E-05 Coffee consumption / / 21357676 rs4538475 chr4 15737937 A G 3.00E-09 Parkinson's disease / / 19915576 rs4538475 chr4 15737937 A G 3.94E-09 Prion diseases / / 22210626 rs4538475 chr4 15737937 A G 9.53E-10 Parkinson's disease / / 22438815 rs12646913 chr4 15739276 A G 7.17E-06 Parkinson's disease / / 22438815 rs10516292 chr4 15749703 C T 0.00000147 Child behavior checklist/1.5-5 pervasive developmental problems / / 23049896 rs3796878 chr4 15785659 C T 8.03E-06 Lipid levels CD38 intron 19016617 rs6449191 chr4 15800268 G A 9.18E-04 Type 2 diabetes CD38 intron 17463246 rs3796867 chr4 15818548 G A 7.02E-05 Stroke (pediatric) CD38 intron 22990015 rs3796866 chr4 15835365 T C 1.00E-04 Prostate cancer CD38 intron 21743057 rs2286553 chr4 15835983 C T 1.00E-04 Prostate cancer CD38 intron 21743057 rs2286552 chr4 15836072 T C 1.00E-04 Prostate cancer CD38 intron 21743057 rs16892438 chr4 15836135 G A 1.00E-04 Prostate cancer CD38 intron 21743057 rs16892441 chr4 15836237 G A 1.00E-04 Prostate cancer CD38 intron 21743057 rs11574928 chr4 15840781 G A 1.00E-04 Prostate cancer CD38 intron 21743057 rs16892453 chr4 15849375 T C 1.00E-04 Prostate cancer CD38 intron 21743057 rs1004124 chr4 15849588 C G 1.00E-04 Prostate cancer CD38 intron 21743057 rs10516294 chr4 15856654 T C 1.38E-04 Lymphocyte counts / / 22286170 rs13136270 chr4 15856799 C T 2.40E-05 Urinary metabolites / / 21572414 rs2532083 chr4 15881412 C T 4.81E-05 Triglycerides / / pha003081 rs2191003 chr4 15895791 A G 1.23E-05 Multiple complex diseases / / 17554300 rs727488 chr4 15896341 C T 1.71E-04 Celiac disease / / 23936387 rs2907370 chr4 15916072 A G 5.61E-04 Type 2 diabetes / / 17463246 rs16892579 chr4 15917022 C T 9.60E-06 Urinary metabolites / / 21572414 rs16892645 chr4 15938392 C T 9.27E-04 Depression (quantitative trait) FGFBP1 intron 20800221 rs2245928 chr4 15939193 G A 2.30E-05 Orofacial clefts FGFBP1 intron 19270707 rs2531174 chr4 15940205 G A 2.30E-05 Orofacial clefts FGFBP1 intron 19270707 rs10939642 chr4 15943140 G A 7.70E-05 Cognitive performance / / 19734545 rs2286461 chr4 15963673 G A 9.69E-04 Response to cytadine analogues (cytosine arabinoside) FGFBP2 intron 24483146 rs4698433 chr4 15964863 G T 6.00E-06 QT interval / / 23534349 rs11944619 chr4 15978245 A G 1.73E-04 Age-related macular degeneration PROM1 intron 22125219 rs10428324 chr4 15983317 T C 8.30E-05 HIV-1 control PROM1 intron 20041166 rs7692432 chr4 15983335 C T 8.86E-05 Prion diseases PROM1 intron 22210626 rs3796856 chr4 15984033 A G 2.00E-05 HIV-1 control PROM1 intron 20041166 rs2302169 chr4 15985542 T C 0.000495 Salmonella-induced pyroptosis PROM1 intron 22837397 rs17387100 chr4 15995125 A G 9.53E-06 Major depression (suicidal thoughts and behavior) PROM1 intron 21750702 rs17387100 chr4 15995125 A G 8.00E-07 Suicide attempts in depression or bipolar disorder PROM1 intron 24964207 rs6449211 chr4 15998470 C T 2.12E-04 Multiple complex diseases PROM1 intron 17554300 rs17478107 chr4 16002288 T C 9.00E-06 Self-rated health PROM1 intron 20707712 rs2531154 chr4 16018324 C T 9.00E-07 Dental caries PROM1 intron 23064961 rs2286455 chr4 16020162 C T 5.87E-04 Insulin resistance PROM1 cds-synon 21901158 rs1517598 chr4 16020664 T C 4.45E-04 Longevity PROM1 intron 22279548 rs2677780 chr4 16022540 G A 2.00E-06 Smooth-surface caries PROM1 intron 23470693 rs1517600 chr4 16026481 A G 7.41E-04 Smoking initiation PROM1 intron 24665060 rs16892888 chr4 16053179 C A,T 2.57E-04 Multiple complex diseases PROM1 intron 17554300 rs1554243 chr4 16063055 A G 1.72E-05 Blood Pressure PROM1 intron pha003039 rs7699781 chr4 16065350 C A 1.82E-05 Blood Pressure PROM1 intron pha003039 rs16892920 chr4 16068748 C T 9.00E-05 Multiple complex diseases PROM1 intron 17554300 rs2176445 chr4 16079670 T G 6.02E-04 Aortic root size PROM1 intron 21223598 rs2313731 chr4 16079735 C T 6.38E-04 Myopia (pathological) PROM1 intron 21095009 rs1040206 chr4 16104538 T G 1.60E-05 Major depressive disorder / / 21621269 rs1554246 chr4 16107389 C T 3.70E-05 Serum metabolites / / 19043545 rs13130975 chr4 16107916 A T 2.70E-06 Urinary metabolites / / 21572414 rs1712493 chr4 16113889 C T 2.34E-04 Height / / 17255346 rs317887 chr4 16123232 G A 6.05E-04 Depression (quantitative trait) / / 20800221 rs317894 chr4 16132175 A G 4.08E-05 Body Fat Distribution / / pha003017 rs16893119 chr4 16161137 A G 1.20E-06 Urinary metabolites / / 21572414 rs6821914 chr4 16161675 C T 6.04E-04 Multiple complex diseases / / 17554300 rs2271749 chr4 16167954 C T 3.00E-06 Smoking initiation TAPT1 intron 24665060 rs16893158 chr4 16183109 G A 1.20E-05 Urinary metabolites TAPT1 intron 21572414 rs6835844 chr4 16331467 A C 6.50E-04 Insulin resistance / / 21901158 rs4698483 chr4 16410981 T C 2.35E-04 Multiple complex diseases / / 17554300 rs17420654 chr4 16414810 C T 4.74E-04 Type 2 diabetes / / 17463246 rs17420654 chr4 16414810 C T 4.83E-04 Alzheimer's disease / / 22005930 rs6449247 chr4 16418214 T A 4.50E-04 Cognition,early reading ability / / 17684495 rs4698148 chr4 16443928 C T 8.45E-05 Waist Circumference / / pha003023 rs4698149 chr4 16447313 G A 7.19E-05 Kawasaki disease / / 22081228 rs955943 chr4 16514408 C T 5.00E-06 Rhegmatogenous retinal detachment LDB2 intron 23585552 rs11732672 chr4 16524379 C T 7.67E-04 Suicide attempts in bipolar disorder LDB2 intron 21423239 rs4698491 chr4 16526736 A G 3.71E-05 Serum metabolites LDB2 intron 19043545 rs16893604 chr4 16535471 T C 3.33E-04 Type 2 diabetes LDB2 intron 17463246 rs13134676 chr4 16554347 G C 8.50E-07 Urinary metabolites LDB2 intron 21572414 rs4072813 chr4 16585917 A C 2.38E-06 Blood Pressure LDB2 intron pha003043 rs7669580 chr4 16587201 C T 3.06E-06 Blood Pressure LDB2 intron pha003043 rs10939676 chr4 16610699 A C 9.06E-04 Coronary Artery Disease LDB2 intron 17634449 rs4698501 chr4 16641790 A T 3.20E-05 Sarcoidosis LDB2 intron 19165924 rs3763969 chr4 16648246 C T 0.000449 Salmonella-induced pyroptosis LDB2 intron 22837397 rs13110156 chr4 16656578 C G 5.08E-04 Type 2 diabetes LDB2 intron 17463246 rs6449262 chr4 16668043 G A 8.06E-04 Myocardial Infarction LDB2 intron pha002873 rs16893733 chr4 16671794 T C 8.29E-04 Multiple complex diseases LDB2 intron 17554300 rs17492017 chr4 16677019 G A 9.44E-04 Suicide attempts in bipolar disorder LDB2 intron 21423239 rs17492017 chr4 16677019 G A 9.88E-05 Body Composition LDB2 intron pha003012 rs17492017 chr4 16677019 G A 7.93E-06 Body Mass Index LDB2 intron pha003021 rs6837229 chr4 16679965 A T 9.55E-04 Multiple complex diseases LDB2 intron 17554300 rs7692454 chr4 16681543 T C 9.83E-05 Body Mass Index LDB2 intron pha003021 rs283029 chr4 16698184 A C 6.58E-05 Body Composition LDB2 intron pha003012 rs283029 chr4 16698184 A C 9.70E-06 Body Mass Index LDB2 intron pha003021 rs1399364 chr4 16724354 C T 7.44E-04 Multiple complex diseases LDB2 intron 17554300 rs1995614 chr4 16724803 C G 7.87E-04 Insulin resistance LDB2 intron 21901158 rs16893890 chr4 16726650 G A 8.20E-04 Myocardial Infarction LDB2 intron pha002883 rs16893898 chr4 16733397 C T 3.14E-04 Insulin resistance LDB2 intron 21901158 rs283025 chr4 16736755 C T 7.93E-05 Body Mass Index LDB2 intron pha003021 rs883086 chr4 16744084 T G 5.34E-04 Multiple complex diseases LDB2 intron 17554300 rs883086 chr4 16744084 T G 1.34E-05 Amyotrophic lateral sclerosis (sporadic) LDB2 intron 24529757 rs157613 chr4 16778287 C T 4.13E-117 Multiple complex diseases LDB2 intron 17554300 rs16894028 chr4 16806252 A G 3.26E-04 Multiple complex diseases LDB2 intron 17554300 rs207709 chr4 16834490 A G 6.00E-05 Prostate cancer LDB2 intron 21743057 rs12503223 chr4 16842716 G A 5.26E-07 Lung adenocarcinoma LDB2 intron 19836008 rs1483009 chr4 16892585 C A 3.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LDB2 intron 20877124 rs1483009 chr4 16892585 C A 5.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LDB2 intron 20877124 rs1483012 chr4 16893893 G A 7.00E-06 QT interval LDB2 intron 23534349 rs7690911 chr4 16899946 A G 9.91E-04 Stroke LDB2 intron pha002886 rs992704 chr4 16906388 G A 7.45E-04 Multiple complex diseases / / 17554300 rs992704 chr4 16906388 G A 3.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs6819013 chr4 16908004 A G 6.00E-06 QT interval / / 23534349 rs13129387 chr4 16915245 T C 1.14E-04 Multiple complex diseases / / 17554300 rs13129387 chr4 16915245 T C 9.04E-05 Bone mineral density / / 19181680 rs16894201 chr4 16940391 G T 0.000000145 CD8+ T cell IFN-gamma response to smallpox vaccine / / 22661280 rs6449272 chr4 16974018 C T 9.94E-04 Coronary heart disease / / 21971053 rs11724970 chr4 17041687 G T 2.15E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2314655 chr4 17046272 C G 4.54E-04 Multiple complex diseases / / 17554300 rs9291652 chr4 17048274 T C 6.23E-04 Multiple complex diseases / / 17554300 rs16894264 chr4 17054934 C G 7.80E-06 Urinary metabolites / / 21572414 rs828154 chr4 17062952 G A 2.72E-04 Longevity / / 22279548 rs1533361 chr4 17073543 A C 5.72E-05 Multiple complex diseases / / 17554300 rs4698167 chr4 17082907 C T 0.000409 fMRI brain tests in schizophrenia / / 22440650 rs2056393 chr4 17106331 C T 5.35E-05 Serum metabolites / / 19043545 rs957085 chr4 17107631 G A 4.76E-05 Serum metabolites / / 19043545 rs955609 chr4 17107945 T A 5.77E-05 Serum metabolites / / 19043545 rs675931 chr4 17123778 G A 4.94E-05 Serum metabolites / / 19043545 rs9291654 chr4 17126696 C T 7.40E-06 Urinary metabolites / / 21572414 rs17829676 chr4 17134058 A G 6.64E-04 Coronary heart disease / / 21606135 rs4698169 chr4 17135343 C T 2.00E-06 Temperament (bipolar disorder) / / 22365631 rs643700 chr4 17138174 G A 2.13E-05 Prion diseases / / 22210626 rs6852278 chr4 17138490 G T 9.96E-04 Type 2 diabetes / / 17463246 rs647300 chr4 17138982 T C 7.10E-05 Temperament (bipolar disorder) / / 22365631 rs543525 chr4 17143562 T C 3.79E-04 Type 2 diabetes / / 17463246 rs543525 chr4 17143562 T C 9.16E-05 Serum metabolites / / 19043545 rs584334 chr4 17145114 C G 2.60E-05 Temperament (bipolar disorder) / / 22365631 rs523160 chr4 17153078 T C 4.70E-05 Temperament (bipolar disorder) / / 22365631 rs579010 chr4 17154568 C T 2.10E-05 Temperament (bipolar disorder) / / 22365631 rs532082 chr4 17156876 T G 1.30E-05 Temperament (bipolar disorder) / / 22365631 rs656010 chr4 17158427 A G 1.76E-04 Prion diseases / / 22210626 rs667886 chr4 17158770 A G 7.30E-05 Temperament (bipolar disorder) / / 22365631 rs599753 chr4 17173839 T G 1.36E-04 Prion diseases / / 22210626 rs574427 chr4 17187440 G A 5.90E-05 Cognitive test performance / / 20125193 rs6449278 chr4 17194641 G A 2.05E-05 Cognitive test performance / / 20125193 rs662470 chr4 17195097 C T 1.26E-04 Prion diseases / / 22210626 rs17771233 chr4 17208600 G A 3.75E-04 Coronary heart disease / / 21606135 rs76489600 chr4 17244396 C A 7.76E-04 Breast cancer / / 24143190 rs13136753 chr4 17244840 T G 4.27E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs613801 chr4 17257605 G A 8.94E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12498656 chr4 17273603 A C 8.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10027876 chr4 17273978 C G 1.31E-04 Aortic root size / / 21223598 rs12507444 chr4 17276324 C T 9.20E-05 Personality dimensions / / 18957941 rs11725538 chr4 17303230 G A 2.40E-05 Urinary metabolites / / 21572414 rs730308 chr4 17321714 A G 9.86E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs16894847 chr4 17322823 C T 7.40E-06 Urinary metabolites / / 21572414 rs6823069 chr4 17331894 T G 6.50E-06 Urinary metabolites / / 21572414 rs4698574 chr4 17335530 C T 6.80E-06 Urinary metabolites / / 21572414 rs12649443 chr4 17352825 A G 8.85E-04 Type 2 diabetes / / 17463246 rs2314958 chr4 17361909 A G 4.29E-04 Type 2 diabetes / / 17463246 rs921371 chr4 17372761 T C 3.89E-04 Type 2 diabetes / / 17463246 rs2031007 chr4 17386550 A G 9.49E-04 Obesity (extreme) / / 21935397 rs6821103 chr4 17389207 C T 9.27E-04 Obesity (extreme) / / 21935397 rs28375363 chr4 17402262 C G 6.58E-04 Smoking initiation / / 24665060 rs10012313 chr4 17405513 G A 5.30E-04 Smoking initiation / / 24665060 rs2167234 chr4 17410664 T A 6.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2518590 chr4 17435090 A T 7.59E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1852749 chr4 17447699 T A 9.84E-05 Multiple complex diseases / / 17554300 rs2518651 chr4 17449549 A G 1.35E-04 Multiple complex diseases / / 17554300 rs2697702 chr4 17460651 A G 1.87E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1450669 chr4 17469442 C T 8.87E-04 Type 2 diabetes / / 17463246 rs4698599 chr4 17478268 G A 5.38E-04 Alzheimer's disease / / 24755620 rs3796809 chr4 17503839 G A 4.35E-04 Schizophrenia QDPR intron 20832056 rs2597783 chr4 17516691 T C 0.00000899 Nonsyndromic striae distensae (stretch marks) CLRN2 nearGene-5 23633020 rs7661303 chr4 17518920 C T 1.19E-13 Lymphocyte counts CLRN2 intron 22286170 rs2247952 chr4 17520776 G A 0.0000329 Nonsyndromic striae distensae (stretch marks) CLRN2 intron 23633020 rs2597786 chr4 17522948 C T 0.0000307 Nonsyndromic striae distensae (stretch marks) CLRN2 intron 23633020 rs2518601 chr4 17530218 A C 0.000019 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2535229 chr4 17531762 G C 0.00000914 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9994673 chr4 17547230 C T 4.38E-04 Alzheimer's disease / / 17998437 rs12648232 chr4 17612537 A G 9.52E-04 Multiple complex diseases / / 17554300 rs2302392 chr4 17660051 G A 7.57E-04 Multiple complex diseases FAM184B cds-synon 17554300 rs2315556 chr4 17670861 T C 3.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM184B intron 20877124 rs1558379 chr4 17672884 T C 3.22E-04 Multiple complex diseases FAM184B intron 17554300 rs2058337 chr4 17678649 G A 4.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM184B intron 20877124 rs1008375 chr4 17682834 T C 9.00E-06 Parasitemia in Tripanosoma cruzi seropositivity FAM184B intron 24324551 rs7678436 chr4 17797966 G A 8.00E-15 Height / / 20189936 rs2074974 chr4 17812615 A C 3.60E-09 Height NCAPG UTR-5 21998595 rs16895802 chr4 17815889 C G 1.58E-05 Height NCAPG intron 22021425 rs2302212 chr4 17818885 T C 4.88E-04 Acute lung injury NCAPG cds-synon 22295056 rs2302211 chr4 17819135 T A 4.80E-05 Height NCAPG intron 21998595 rs2286538 chr4 17826860 C G 1.60E-05 Height NCAPG intron 21998595 rs16895878 chr4 17847281 A C 3.90E-05 Height LCORL UTR-3 21998595 rs16895895 chr4 17854768 T C 5.90E-05 Height LCORL intron 21998595 rs6844379 chr4 17856801 C T 7.00E-13 Height LCORL intron 21998595 rs16895927 chr4 17875230 T C 3.03E-04 Height LCORL intron 17255346 rs979532 chr4 17901679 C T 6.76E-06 Height LCORL intron 22021425 rs925098 chr4 17919811 G A 2.30E-15 Height LCORL intron 21998595 rs925098 chr4 17919811 G A 3.00E-14 Height LCORL intron 22021425 rs7663818 chr4 17936443 C T 2.20E-10 Height LCORL intron 21998595 rs7692995 chr4 17936634 T C 4.00E-09 Height LCORL intron 21998595 rs2707450 chr4 17942560 C T 1.20E-10 Height LCORL intron 21998595 rs16896068 chr4 17944840 G A 2.00E-13 Height LCORL intron 18391952 rs2724475 chr4 17946432 T C 2.00E-09 Height LCORL intron 20881960 rs1506613 chr4 17948939 T C 7.24E-04 Acute lung injury LCORL intron 22295056 rs6845078 chr4 17952208 C A,T 3.00E-22 Height LCORL intron 23563607 rs2251890 chr4 17966548 T C 7.24E-04 Acute lung injury LCORL intron 22295056 rs6853216 chr4 17970655 C T 1.50E-08 Height LCORL intron 21998595 rs2320299 chr4 17972372 G A 3.30E-11 Height LCORL intron 21998595 rs2320299 chr4 17972372 G A 2.54E-06 Height LCORL intron 22021425 rs2724473 chr4 17977352 T C 7.37E-04 Acute lung injury LCORL intron 22295056 rs16896210 chr4 17992332 A G 1.60E-09 Height LCORL intron 21998595 rs724577 chr4 17993410 A C 1.00E-15 Height LCORL intron 21998595 rs724577 chr4 17993410 A C 5.00E-11 Birth weight LCORL intron 23202124 rs16896236 chr4 18003812 T C 5.70E-06 Height LCORL intron 21998595 rs2724469 chr4 18004090 T C 7.74E-04 Acute lung injury LCORL intron 22295056 rs961014 chr4 18010384 A G 7.74E-04 Acute lung injury LCORL intron 22295056 rs16896261 chr4 18011202 A G 3.30E-10 Height LCORL intron 21998595 rs6830062 chr4 18017730 T C 1.00E-10 Height LCORL intron 18391951 rs6830062 chr4 18017730 T C 5.00E-09 Height LCORL intron 19343178 rs6830062 chr4 18017730 T C 8.00E-06 Height LCORL intron 20397748 rs6830062 chr4 18017730 T C 1.40E-06 Height LCORL intron 21998595 rs1380294 chr4 18024121 C T 4.60E-09 Height LCORL nearGene-5 21998595 rs2011603 chr4 18025484 G A 5.20E-05 Height / / 19396169 rs2011603 chr4 18025484 G A 6.51E-09 Height / / 22021425 rs6449353 chr4 18033488 T C 7.00E-46 Height / / 20881960 rs12499167 chr4 18064236 A G 9.17E-04 Type 2 diabetes / / 17463246 rs10016578 chr4 18066346 C T 6.67E-04 Type 2 diabetes / / 17463246 rs1563749 chr4 18072500 C T 7.70E-05 Alcoholism (heaviness of drinking) / / 21529783 rs1563749 chr4 18072500 C T 4.95E-05 Orofacial clefts / / 22419666 rs9291662 chr4 18079517 G A 1.00E-04 Alcoholism (heaviness of drinking) / / 21529783 rs9291662 chr4 18079517 G A 6.09E-05 Orofacial clefts / / 22419666 rs7700098 chr4 18102216 C T 0.00002 Salmonella-induced pyroptosis / / 22837397 rs7675644 chr4 18116587 G T 0.000018 Salmonella-induced pyroptosis / / 22837397 rs11942407 chr4 18118576 T G 0.000025 Salmonella-induced pyroptosis / / 22837397 rs1503874 chr4 18128641 G A 1.90E-04 Non-substance related behavioral disinhibition / / 23942779 rs1503874 chr4 18128641 G A 4.00E-06 Illicit drug use / / 23942779 rs7684006 chr4 18140181 G A 0.000012 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10223013 chr4 18140770 C T 0.0000724 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2320289 chr4 18162104 A C 4.52E-04 Type 2 diabetes / / 17463246 rs2320289 chr4 18162104 A C 3.91E-04 Multiple complex diseases / / 17554300 rs2320289 chr4 18162104 A C 4.90E-05 Alcoholism (heaviness of drinking) / / 21529783 rs7673064 chr4 18163381 G A 6.01E-04 Type 2 diabetes / / 17463246 rs56410336 chr4 18166100 T C 0.00000293 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1818172 chr4 18168746 C T 0.00000154 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs56194159 chr4 18169653 G A 0.00000308 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1503886 chr4 18169922 T G 0.00000232 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1503885 chr4 18179853 A C 0.00000413 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62411652 chr4 18192221 A G 0.0000133 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11732945 chr4 18192683 C T 0.0000655 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10939774 chr4 18192901 C G 0.0000666 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6449362 chr4 18194063 C A 0.0000699 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17523800 chr4 18194174 T C 0.0000427 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1553460 chr4 18195861 T A 1.08E-57 Multiple complex diseases / / 17554300 rs1553461 chr4 18196147 T C 8.01E-04 Aortic root size / / 21223598 rs1503881 chr4 18202629 A G 9.26E-04 Type 2 diabetes / / 17463246 rs1503882 chr4 18202684 T C 9.71E-04 Type 2 diabetes / / 17463246 rs2320566 chr4 18232460 T C 9.24E-04 Type 2 diabetes / / 17463246 rs6811915 chr4 18243314 G T 3.01E-04 Type 2 diabetes / / 17463246 rs1503890 chr4 18248942 C T 3.79E-04 Type 2 diabetes / / 17463246 rs2192521 chr4 18264644 G A 2.58E-04 Heart Failure / / pha002885 rs6826519 chr4 18289322 A G 1.22E-04 Type 2 diabetes / / 17463246 rs13147572 chr4 18293144 A G 3.39E-05 Tunica Media / / pha003037 rs6829260 chr4 18293439 C G 4.77E-28 Narcolepsy / / 19629137 rs13122350 chr4 18311265 G A 4.94E-04 Type 2 diabetes / / 17463246 rs4140904 chr4 18315992 A G 1.23E-04 Multiple complex diseases / / 17554300 rs4140904 chr4 18315992 A G 1.40E-07 Colorectal cancer / / 20610541 rs741207 chr4 18321092 C T 8.25E-04 Multiple complex diseases / / 17554300 rs6853846 chr4 18408169 G A 7.29E-04 Response to TNF antagonist treatment / / 21061259 rs6853846 chr4 18408169 G A 6.88E-04 Alzheimer's disease / / 24755620 rs10516322 chr4 18423567 C G 8.88E-04 Type 2 diabetes / / 17846124 rs2320730 chr4 18572026 G A 6.74E-04 Response to TNF antagonist treatment / / 21061259 rs13140305 chr4 18590062 G A 2.50E-05 Urinary metabolites / / 21572414 rs4698703 chr4 18630107 C T 2.50E-05 Urinary metabolites / / 21572414 rs1874288 chr4 18640524 A G 3.76E-05 Birth weight / / 17255346 rs10516326 chr4 18641320 A G 2.80E-05 Urinary metabolites / / 21572414 rs17483809 chr4 18643860 G C 1.72E-05 Multiple complex diseases / / 17554300 rs4235399 chr4 18665579 T C 1.35E-04 Multiple complex diseases / / 17554300 rs11729009 chr4 18670328 A G 9.38E-05 Multiple complex diseases / / 17554300 rs4446300 chr4 18691224 T C 3.24E-04 Alzheimer's disease (late onset) / / 21379329 rs4446300 chr4 18691224 T C 5.15E-05 Post-operative nausea and vomiting / / 21694509 rs4147046 chr4 18700782 C T 2.33E-04 Blood pressure / / 21909110 rs1878644 chr4 18722405 A G 4.94E-05 HDL cholesterol / / pha003075 rs1400930 chr4 18752956 C T 6.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs1002439 chr4 18753305 C T 6.58E-04 Acute lung injury / / 22295056 rs1464189 chr4 18756789 G A 2.15E-04 Acute lung injury / / 22295056 rs6811417 chr4 18787826 T C 3.99E-04 Type 2 diabetes / / 17463246 rs4147045 chr4 18795330 T C 1.00E-06 Colorectal cancer (diet interaction) / / 24743840 rs1356469 chr4 18812368 G A 1.30E-05 Urinary metabolites / / 21572414 rs1356468 chr4 18812552 G T 4.19E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs16897644 chr4 18837642 A G 8.80E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs16897706 chr4 18851850 A G 1.22E-04 Aortic root size / / 21223598 rs6856020 chr4 18862247 C T 1.47E-05 Major depressive disorder / / 21621269 rs10516331 chr4 18863708 G T 8.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6845621 chr4 18866169 G A 2.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) / / 24025145 rs12648927 chr4 18877161 G C 3.70E-04 Aortic root size / / 21223598 rs6449435 chr4 18908518 C T 7.88E-05 Major depressive disorder / / 21621269 rs2123315 chr4 18966569 T C 4.30E-04 Neuroticism / / 17667963 rs17534953 chr4 18971291 C T 1.20E-05 Urinary metabolites / / 21572414 rs10001989 chr4 19035608 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7696128 chr4 19088386 T G 5.02E-06 Ankle-brachial index / / 22199011 rs207307 chr4 19091363 T G 1.18E-04 Self-reported allergy / / 23817569 rs207305 chr4 19092157 C T 1.14E-04 Self-reported allergy / / 23817569 rs207304 chr4 19092933 G C 7.58E-05 Self-reported allergy / / 23817569 rs112199 chr4 19094359 C T 1.12E-04 Self-reported allergy / / 23817569 rs207301 chr4 19095959 G A 1.48E-04 Self-reported allergy / / 23817569 rs11931729 chr4 19100129 C A 2.97E-05 Serum metabolites / / 19043545 rs6827524 chr4 19100871 C T 3.82E-05 Serum metabolites / / 19043545 rs3911265 chr4 19101805 T C 4.48E-05 Serum metabolites / / 19043545 rs9684799 chr4 19110954 C T 5.40E-05 Multiple sclerosis / / 17660530 rs17495401 chr4 19120064 A G 8.64E-05 Serum metabolites / / 19043545 rs4434249 chr4 19126909 A T 3.37E-05 Serum metabolites / / 19043545 rs1478052 chr4 19174460 T C 5.43E-05 Serum metabolites / / 19043545 rs12054497 chr4 19176299 C A 6.25E-05 Serum metabolites / / 19043545 rs17497475 chr4 19242239 C A 4.75E-05 Serum metabolites / / 19043545 rs312353 chr4 19262251 C T 4.13E-05 Serum metabolites / / 19043545 rs312351 chr4 19262843 C T 7.67E-05 Serum metabolites / / 19043545 rs312335 chr4 19302890 T A 7.10E-04 Multiple complex diseases / / 17554300 rs1490867 chr4 19325097 G A 4.79E-04 Type 2 diabetes / / 17463246 rs1532169 chr4 19349720 T A 9.85E-04 Type 2 diabetes / / 17463246 rs35881948 chr4 19381178 A G 8.98E-04 Type 2 diabetes / / 17463246 rs1552660 chr4 19381302 C A 6.24E-04 Coronary heart disease / / 21971053 rs2874685 chr4 19382446 C A 9.30E-04 Multiple complex diseases / / 17554300 rs968264 chr4 19395137 C T 3.41E-04 Type 2 diabetes / / 17463246 rs11734810 chr4 19581835 A G 4.03E-04 Multiple complex diseases / / 17554300 rs4441751 chr4 19582635 C T 4.42E-04 Multiple complex diseases / / 17554300 rs17568214 chr4 19598551 T C 5.70E-05 Parkinson's disease (age of onset) / / 19772629 rs17509863 chr4 19638730 A G,T 1.80E-05 Parkinson's disease (age of onset) / / 19772629 rs16868684 chr4 19674900 T A 1.59E-04 Multiple complex diseases / / 17554300 rs11936151 chr4 19783152 C T 5.43E-04 Stroke / / pha002887 rs4128311 chr4 19788263 T A 5.76E-04 Multiple complex diseases / / 17554300 rs13145150 chr4 19798055 T C 3.06E-04 Multiple complex diseases / / 17554300 rs6833091 chr4 19834012 G T 2.95E-04 Multiple complex diseases / / 17554300 rs4582148 chr4 19863785 G A 6.68E-04 Type 2 diabetes / / 17463246 rs10516339 chr4 19873071 A G 9.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs13125896 chr4 19975070 A G 5.76E-04 Multiple complex diseases / / 17554300 rs4626202 chr4 19983104 T C 1.65E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs4575988 chr4 19984926 T C 3.05E-04 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs4575988 chr4 19984926 T C 3.90E-04 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs2629722 chr4 19992481 C A 6.19E-04 Multiple complex diseases / / 17554300 rs2629718 chr4 20002817 A T 2.72E-04 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs1872469 chr4 20050184 C A 4.07E-04 Smoking cessation / / 24665060 rs28461290 chr4 20069071 T C 6.30E-04 Type 2 diabetes / / 17463246 rs1485572 chr4 20069271 T A 7.82E-04 Multiple complex diseases / / 17554300 rs1485572 chr4 20069271 T A 3.60E-05 Gallstones / / 17632509 rs10938787 chr4 20088468 A G 1.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10938787 chr4 20088468 A G 6.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12512602 chr4 20160977 A G 3.40E-04 Psoriasis / / 20953189 rs11727186 chr4 20164834 C T 6.83E-05 Cognitive test performance / / 20125193 rs685064 chr4 20206215 T C 2.01E-06 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs500869 chr4 20267343 G A 2.10E-06 Urinary metabolites SLIT2 intron 21572414 rs715213 chr4 20267915 C T 9.70E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) SLIT2 intron 24192120 rs17609702 chr4 20425588 A G 9.71E-04 Type 2 diabetes SLIT2 intron 17463246 rs6849536 chr4 20440476 T C 2.63E-05 Brain lesion load SLIT2 intron 19010793 rs666088 chr4 20495135 C T 5.00E-06 Echocardiographic traits SLIT2 intron 17903301 rs522501 chr4 20497277 G A 1.56E-05 Triglycerides SLIT2 intron 19074352 rs522501 chr4 20497277 G A 1.56E-05 Polyunsaturated fatty acid levels,in plasma SLIT2 intron 19148276 rs490478 chr4 20498484 A G 9.59E-05 HDL cholesterol SLIT2 intron pha003074 rs6810790 chr4 20515670 G A 8.17E-05 Response to acetaminophen (hepatotoxicity) SLIT2 intron 21177773 rs6447967 chr4 20516341 T C 4.63E-04 Type 2 diabetes SLIT2 intron 17463246 rs16869706 chr4 20524715 A G 7.04E-04 Type 2 diabetes SLIT2 intron 17463246 rs7690660 chr4 20527864 T G 7.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLIT2 intron 20877124 rs2168801 chr4 20530981 G A 8.32E-05 Cognitive test performance SLIT2 intron 20125193 rs2168801 chr4 20530981 G A 5.38E-04 Suicide attempts in bipolar disorder SLIT2 intron 21423239 rs2322557 chr4 20533014 G A 3.55E-05 Cognitive test performance SLIT2 intron 20125193 rs573118 chr4 20534686 G A 4.29E-04 Common variable immunodeficiency SLIT2 intron 21497890 rs573118 chr4 20534686 G A 1.81E-04 Stroke SLIT2 intron pha002886 rs520535 chr4 20535876 T C 3.20E-05 HDL cholesterol SLIT2 intron pha003074 rs16869739 chr4 20543709 A G 4.27E-05 Cognitive test performance SLIT2 intron 20125193 rs7690492 chr4 20544184 C T 3.28E-05 Body mass (lean) SLIT2 cds-synon 19268274 rs16869751 chr4 20544756 A C 9.90E-06 Urinary metabolites SLIT2 intron 21572414 rs16869756 chr4 20553357 C T 6.05E-04 Multiple complex diseases SLIT2 intron 17554300 rs644607 chr4 20571336 T C 3.00E-04 Cognitive impairment induced by topiramate SLIT2 intron 22091778 rs2168802 chr4 20585883 C T 0.0000387 Follicular lymphoma SLIT2 intron 23025665 rs17543924 chr4 20612039 T C 9.79E-05 Cytomegalovirus antibody response SLIT2 intron 21993531 rs1350400 chr4 20613630 T C 0.0000581 Follicular lymphoma SLIT2 intron 23025665 rs17544103 chr4 20619890 C T 8.67E-05 Cytomegalovirus antibody response SLIT2 intron 21993531 rs1379659 chr4 20620683 G A 1.00E-07 Echocardiographic traits / / 17903301 rs10024417 chr4 20660406 C T 6.21E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10024417 chr4 20660406 C T 8.11E-05 Alzheimer's disease / / 24755620 rs13139200 chr4 20666840 C G 5.69E-04 Type 2 diabetes / / 17463246 rs10755201 chr4 20674761 T C 4.47E-05 Cognitive test performance / / 20125193 rs10516359 chr4 20675834 G A 6.70E-04 Alzheimer's disease / / 24755620 rs11727810 chr4 20675848 T C 2.29E-04 Alzheimer's disease / / 24755620 rs28414076 chr4 20676535 A G 2.15E-04 Alzheimer's disease / / 24755620 rs16869851 chr4 20690057 A C 5.17E-05 Schizophrenia / / 19571809 rs16869851 chr4 20690057 A C 5.14E-05 Bipolar disorder and schizophrenia / / 20889312 rs10032537 chr4 20698104 C T 5.12E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10032537 chr4 20698104 C T 6.59E-04 Alzheimer's disease / / 24755620 rs9291412 chr4 20727464 A G 8.10E-04 Type 2 diabetes and 6 quantitative traits PACRGL intron 17848626 rs9291412 chr4 20727464 A G 9.31E-04 Alzheimer's disease PACRGL intron 24755620 rs16869915 chr4 20730780 A C 3.04E-04 Response to taxane treatment (placlitaxel) KCNIP4 UTR-3 23006423 rs16869915 chr4 20730780 A C 7.40E-04 Alzheimer's disease KCNIP4 UTR-3 24755620 rs4697177 chr4 20760089 T G 6.80E-04 stroke (ischemic) KCNIP4 intron 17434096 rs17623902 chr4 20760683 A G 3.91E-04 Type 2 diabetes KCNIP4 intron 17463246 rs17623902 chr4 20760683 A G 3.84E-05 Serum metabolites KCNIP4 intron 19043545 rs16869949 chr4 20770444 C A 4.19E-04 Type 2 diabetes KCNIP4 intron 17463246 rs16870017 chr4 20807977 C T 2.15E-04 Blood pressure KCNIP4 intron 17255346 rs10013103 chr4 20827366 C A 6.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNIP4 intron 20877124 rs9762164 chr4 20831578 C T 3.57E-04 Alzheimer's disease KCNIP4 intron 24755620 rs17555380 chr4 20832402 T C 6.71E-04 Alzheimer's disease KCNIP4 intron 24755620 rs6447984 chr4 20833134 A G 3.45E-04 Alzheimer's disease KCNIP4 intron 24755620 rs4988679 chr4 20834054 A G 3.57E-04 Alzheimer's disease KCNIP4 intron 24755620 rs902665 chr4 20834721 T C 6.74E-05 Triglycerides KCNIP4 intron pha003080 rs2130920 chr4 20836911 T C 4.73E-05 Alzheimer's disease KCNIP4 intron 24755620 rs10938807 chr4 20840094 T C 2.07E-05 Alzheimer's disease KCNIP4 intron 24755620 rs7682014 chr4 20848925 G A 1.07E-05 Alzheimer's disease KCNIP4 intron 24755620 rs41424045 chr4 20851086 G C 3.12E-05 Multiple complex diseases KCNIP4 intron 17554300 rs2011511 chr4 20870791 G T 8.85E-04 Multiple complex diseases KCNIP4 intron 17554300 rs1388321 chr4 20880744 G A 0.0001 Personality test (tpqNS) in attention deficit-hyperactivity disorder (ADHD) KCNIP4 intron 22981920 rs1388321 chr4 20880744 G A 0.0001 Personality test (tpqRD) in attention deficit-hyperactivity disorder (ADHD) KCNIP4 intron 22981920 rs10516367 chr4 20882971 C A 5.80E-06 Lung cancer KCNIP4 intron 18385738 rs6850182 chr4 20883714 T C 9.86E-04 Multiple complex diseases KCNIP4 intron 17554300 rs17557419 chr4 20883760 C G 1.17E-04 Multiple complex diseases KCNIP4 intron 17554300 rs17557461 chr4 20883905 A G 3.94E-05 Multiple complex diseases KCNIP4 intron 17554300 rs10516368 chr4 20885254 A C 7.99E-04 Type 2 diabetes KCNIP4 intron 17463246 rs13143295 chr4 20898635 C T 4.76E-04 Type 2 diabetes KCNIP4 intron 22158537 rs1491359 chr4 20900977 T C 8.07E-04 Type 2 diabetes KCNIP4 intron 22158537 rs6828208 chr4 20923374 T C 1.70E-05 Urinary metabolites KCNIP4 intron 21572414 rs12650791 chr4 20923393 G A 0.00005686 Sarcoidosis KCNIP4 intron 22952805 rs16870186 chr4 20928231 G C 3.84E-04 Smoking cessation KCNIP4 intron 24665060 rs6841111 chr4 20928497 T C 3.98E-04 Type 2 diabetes KCNIP4 intron 22158537 rs76415597 chr4 20934482 A T 0.00001456 Sarcoidosis KCNIP4 intron 22952805 rs12650955 chr4 20935403 T A 0.000009956 Sarcoidosis KCNIP4 intron 22952805 rs12650301 chr4 20938389 C G 0.000008252 Sarcoidosis KCNIP4 intron 22952805 rs75046792 chr4 20939282 G T 0.00003602 Sarcoidosis KCNIP4 intron 22952805 rs16870225 chr4 20939335 C T 0.000007495 Sarcoidosis KCNIP4 intron 22952805 rs75496382 chr4 20941629 C T 0.00002355 Sarcoidosis KCNIP4 intron 22952805 rs79558178 chr4 20943053 A G 0.000009561 Sarcoidosis KCNIP4 intron 22952805 rs12645600 chr4 20945085 A C 4.54E-04 Smoking cessation KCNIP4 intron 24665060 rs6836818 chr4 20945579 T C 4.54E-04 Smoking cessation KCNIP4 intron 24665060 rs10516373 chr4 20945654 C G 0.00004837 Sarcoidosis KCNIP4 intron 22952805 rs1434955 chr4 20946178 T A 4.54E-04 Smoking cessation KCNIP4 intron 24665060 rs7660907 chr4 20946261 G A 0.00001294 Sarcoidosis KCNIP4 intron 22952805 rs1434954 chr4 20946907 A C 4.54E-04 Smoking cessation KCNIP4 intron 24665060 rs12642219 chr4 20948335 C T 0.00004761 Sarcoidosis KCNIP4 intron 22952805 rs77691447 chr4 20948658 C A 0.00005011 Sarcoidosis KCNIP4 intron 22952805 rs4697201 chr4 20949191 T A 6.73E-04 Type 2 diabetes KCNIP4 intron 22158537 rs4395501 chr4 20950879 T C 6.58E-05 Serum metabolites KCNIP4 intron 19043545 rs6448004 chr4 20954962 G C 6.03E-05 Serum metabolites KCNIP4 intron 19043545 rs10155343 chr4 20959288 C A 4.52E-04 Lung function (forced expiratory volume in 1 second) KCNIP4 intron 24023788 rs971472 chr4 20977648 C T 4.15E-05 Post-operative nausea and vomiting KCNIP4 intron 21694509 rs116693757 chr4 21002801 A G 0.0000983 Nonsyndromic striae distensae (stretch marks) KCNIP4 intron 23633020 rs10938827 chr4 21041975 C T 2.48E-04 Multiple complex diseases KCNIP4 intron 17554300 rs11939115 chr4 21118054 C T 4.84E-04 Multiple complex diseases KCNIP4 intron 17554300 rs11932046 chr4 21122916 T C 7.64E-04 Multiple complex diseases KCNIP4 intron 17554300 rs4697205 chr4 21124529 C T 8.56E-05 Blood Pressure KCNIP4 intron pha003040 rs10033895 chr4 21140095 C T 3.28E-04 Multiple complex diseases KCNIP4 intron 17554300 rs876477 chr4 21156928 C T 2.69E-05 Attention deficit hyperactivity disorder KCNIP4 intron 18980221 rs876477 chr4 21156928 C T 5.40E-06 Attention deficit hyperactivity disorder KCNIP4 intron pha002875 rs6821250 chr4 21172184 A G 9.21E-04 Type 2 diabetes KCNIP4 intron 17463246 rs6821318 chr4 21195017 C T 1.70E-05 Urinary metabolites KCNIP4 intron 21572414 rs6448032 chr4 21196477 A G 5.49E-04 Stroke KCNIP4 intron pha002887 rs17448782 chr4 21198115 C A 5.31E-04 Insulin resistance KCNIP4 intron 21901158 rs6448033 chr4 21200024 G A 2.39E-04 Stroke KCNIP4 intron pha002887 rs1023721 chr4 21206490 T A 1.00E-06 IgG glycosylation KCNIP4 intron 23382691 rs1364837 chr4 21213392 A T 1.30E-05 Urinary metabolites KCNIP4 intron 21572414 rs16870621 chr4 21244892 A T 4.72E-04 Multiple complex diseases KCNIP4 intron 17554300 rs1967398 chr4 21254536 A G 6.05E-06 Body mass index KCNIP4 intron 21701565 rs12642021 chr4 21261591 A G 7.10E-05 Cognitive function KCNIP4 intron 24684796 rs6839994 chr4 21267872 G A 4.77E-06 Body mass index KCNIP4 intron 21701565 rs6839994 chr4 21267872 G A 6.24E-04 Body mass index KCNIP4 intron 21701565 rs6839686 chr4 21268011 A G 2.41E-05 Body mass index KCNIP4 intron 21701565 rs11936275 chr4 21272276 T G 3.06E-04 Body mass index KCNIP4 intron 21701565 rs11936275 chr4 21272276 T G 4.73E-06 Body mass index KCNIP4 intron 21701565 rs11936275 chr4 21272276 T G 5.78E-04 Body mass index KCNIP4 intron 21701565 rs1485512 chr4 21298124 G C 5.60E-05 Coffee consumption KCNIP4 intron 21357676 rs11727207 chr4 21333904 C T 7.34E-05 Pulmonary function KCNIP4 intron 20010835 rs16870831 chr4 21334285 A G 4.59E-05 Pulmonary function KCNIP4 intron 20010835 rs17520919 chr4 21348980 T C 1.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNIP4 intron 20877124 rs13110425 chr4 21351505 T C 4.59E-05 Sudden cardiac arrest KCNIP4 intron 21658281 rs2132274 chr4 21388664 G C 8.91E-04 Multiple complex diseases KCNIP4 intron 17554300 rs10026043 chr4 21407094 T C 2.28E-04 Aortic root size KCNIP4 intron 21223598 rs1495505 chr4 21417980 C T 2.20E-05 Urinary metabolites KCNIP4 intron 21572414 rs10022292 chr4 21425389 C G 2.20E-06 Urinary metabolites KCNIP4 intron 21572414 rs6844284 chr4 21427382 C A 2.20E-06 Urinary metabolites KCNIP4 intron 21572414 rs1020836 chr4 21429378 G A 1.10E-05 Urinary metabolites KCNIP4 intron 21572414 rs11942476 chr4 21455257 C G 1.71E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs11942476 chr4 21455257 C G 6.00E-06 IgG glycosylation KCNIP4 intron 23382691 rs34836460 chr4 21455604 A T 1.61E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs13128830 chr4 21455808 C T 1.17E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs13129400 chr4 21455861 G C 1.69E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs13127669 chr4 21468512 C A 2.00E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs1460488 chr4 21470377 T C 2.53E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs1460489 chr4 21470452 T A 2.82E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs1460490 chr4 21470582 T C 2.88E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs6855589 chr4 21471568 C T 3.24E-04 Type 2 diabetes KCNIP4 intron 17463246 rs13149579 chr4 21471611 C T 2.85E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs17523841 chr4 21472214 G A 2.83E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs13104819 chr4 21472458 A T 2.83E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs17523876 chr4 21475202 T C 2.85E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs3132 chr4 21475723 A G 2.84E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs1495503 chr4 21475807 C A 2.85E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs1495502 chr4 21475856 C T 2.84E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs1495501 chr4 21476040 C A 2.85E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs9685466 chr4 21476699 T C 2.89E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs358592 chr4 21476990 C T 3.00E-06 Suicidal ideation KCNIP4 intron 20877300 rs17464578 chr4 21477273 G A 3.83E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs10516389 chr4 21477402 C T 3.82E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs10516388 chr4 21477592 G T 3.78E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs13108860 chr4 21477696 G T 3.83E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs13135994 chr4 21477716 T C 3.81E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs13136002 chr4 21477726 T C 3.78E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs13136234 chr4 21477826 T A 3.83E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs13109655 chr4 21478188 C T 3.79E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs13137136 chr4 21478213 T A 3.82E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs13109855 chr4 21478268 C A 3.93E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs17464752 chr4 21478417 G A 3.80E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs17464793 chr4 21478658 C T 3.82E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs17464828 chr4 21479027 A C 6.54E-04 Alzheimer's disease KCNIP4 intron 17998437 rs17464828 chr4 21479027 A C 2.61E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs10516386 chr4 21479467 A G 4.53E-04 Alzheimer's disease KCNIP4 intron 17998437 rs10516386 chr4 21479467 A G 2.99E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs13144924 chr4 21479560 T C 3.63E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs10516385 chr4 21479617 T A 1.82E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs2874930 chr4 21479935 C T 2.98E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs17465022 chr4 21480289 C T 3.01E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs17524637 chr4 21481368 A T 3.01E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs17524672 chr4 21481439 C A 3.00E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs17524686 chr4 21481480 A C 2.98E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs17524714 chr4 21482029 C A 3.01E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs17524784 chr4 21482175 A G 3.01E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs13145622 chr4 21482938 G C 2.97E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs7441592 chr4 21483177 G A 2.98E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs13129942 chr4 21484495 T A,C 2.35E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs13121386 chr4 21484887 C T 3.07E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs17524952 chr4 21486091 G C 2.99E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs17525063 chr4 21486293 A G 3.02E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs17465591 chr4 21486854 T A 3.08E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs13143135 chr4 21487690 G T 2.95E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs1565947 chr4 21490361 A G 2.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNIP4 intron 20877124 rs6830109 chr4 21492445 G T 2.62E-05 Lipid levels KCNIP4 intron pha003082 rs17466300 chr4 21494981 C T 4.89E-04 Tourette syndrome KCNIP4 intron 22889924 rs17466300 chr4 21494981 C T 2.18E-05 Lipid levels KCNIP4 intron pha003082 rs358558 chr4 21506851 C A 2.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNIP4 intron 20877124 rs358557 chr4 21506939 T A 9.52E-04 Multiple complex diseases KCNIP4 intron 17554300 rs11737456 chr4 21509796 T A 6.38E-04 Multiple complex diseases KCNIP4 intron 17554300 rs11737456 chr4 21509796 T A 3.40E-07 Urinary metabolites KCNIP4 intron 21572414 rs16871289 chr4 21511383 C T 9.00E-06 Obesity-related traits KCNIP4 intron 23251661 rs2279673 chr4 21519577 C A 4.28E-04 Amyotrophic Lateral Sclerosis KCNIP4 intron 17362836 rs16871317 chr4 21526090 T C 7.48E-04 Multiple complex diseases KCNIP4 intron 17554300 rs1812151 chr4 21551721 T C 5.04E-04 Alzheimer's disease KCNIP4 intron 17998437 rs13119355 chr4 21562013 G A 4.52E-04 Lung function (forced expiratory volume in 1 second) KCNIP4 intron 24023788 rs1604805 chr4 21571087 T C 9.00E-06 Obesity-related traits KCNIP4 intron 23251661 rs429783 chr4 21572568 C A 2.95E-04 Coronary heart disease KCNIP4 intron 21606135 rs1966048 chr4 21575623 G A 9.83E-05 Blood Pressure KCNIP4 intron pha003043 rs41500944 chr4 21583944 T C 6.13E-04 Type 2 diabetes KCNIP4 intron 17463246 rs358830 chr4 21588298 C T 3.78E-05 Information processing speed KCNIP4 intron 21130836 rs1394139 chr4 21607058 C T 5.04E-05 Elbow pain KCNIP4 intron pha003008 rs3913663 chr4 21607597 G T 5.90E-05 Elbow pain KCNIP4 intron pha003008 rs4106119 chr4 21607927 A G 9.84E-04 Alzheimer's disease KCNIP4 intron 17998437 rs6824942 chr4 21618170 T C 2.02E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21041247 rs6848248 chr4 21618181 G A 2.03E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21041247 rs13117892 chr4 21618453 T A 2.04E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21041247 rs10000010 chr4 21618674 T C 2.04E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21041247 rs7671181 chr4 21671519 T C 9.80E-06 Urinary metabolites KCNIP4 intron 21572414 rs1459282 chr4 21707600 A G 7.49E-04 Type 2 diabetes KCNIP4 intron 17463246 rs7375384 chr4 21726677 T C 4.68E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs1827591 chr4 21732186 C T 1.65E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs7697475 chr4 21735319 A G 9.71E-05 Left ventricular hypertrophy KCNIP4 intron pha003052 rs16871838 chr4 21754194 A G 1.36E-04 Insulin resistance KCNIP4 intron 21901158 rs1349383 chr4 21762664 T A 8.95E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21423239 rs1868744 chr4 21781997 A C 9.89E-05 Left ventricular hypertrophy KCNIP4 intron pha003052 rs34833395 chr4 21802323 A G 2.59E-04 Type 2 diabetes KCNIP4 intron 17463246 rs12503736 chr4 21813409 A G 2.66E-04 Type 2 diabetes KCNIP4 intron 17463246 rs9996615 chr4 21813631 T C 4.22E-04 Multiple complex diseases KCNIP4 intron 17554300 rs1398832 chr4 21847547 C T 5.58E-04 Multiple complex diseases KCNIP4 intron 17554300 rs966045 chr4 21848082 C T 1.28E-04 Type 2 diabetes KCNIP4 intron 17463246 rs2063658 chr4 21868758 A T 3.27E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21041247 rs2063657 chr4 21868960 A G 5.57E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21041247 rs2063656 chr4 21869057 C A 5.54E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21041247 rs12512316 chr4 21871674 A G 6.36E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21041247 rs12504827 chr4 21871986 G A 7.11E-04 Suicide attempts in bipolar disorder KCNIP4 intron 21041247 rs17570050 chr4 21888672 T C 0.0006465 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KCNIP4 intron 23233654 rs17570050 chr4 21888672 T C 6.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) KCNIP4 intron 23233662 rs4443267 chr4 21894796 G C 0.000831 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KCNIP4 intron 23233654 rs4443267 chr4 21894796 G C 8.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) KCNIP4 intron 23233662 rs13143995 chr4 21906916 G T 4.47E-04 Smoking cessation KCNIP4 intron 24665060 rs10018691 chr4 21910150 C T 0.0005226 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KCNIP4 intron 23233654 rs10018691 chr4 21910150 C T 5.23E-04 Methotrexate clearance (acute lymphoblastic leukemia) KCNIP4 intron 23233662 rs2874977 chr4 21911866 G T 7.84E-05 Self-reported allergy KCNIP4 intron 23817569 rs9995524 chr4 21913523 T G 2.72E-05 Self-reported allergy KCNIP4 intron 23817569 rs6821401 chr4 21915588 A G 8.33E-04 Type 2 diabetes KCNIP4 intron 17463246 rs6821401 chr4 21915588 A G 3.99E-05 Self-reported allergy KCNIP4 intron 23817569 rs1398838 chr4 21916709 C A,T 3.70E-05 Self-reported allergy KCNIP4 intron 23817569 rs11944614 chr4 21918070 C G 3.19E-05 Self-reported allergy KCNIP4 intron 23817569 rs10516404 chr4 21918146 C T 3.77E-05 Self-reported allergy KCNIP4 intron 23817569 rs7356396 chr4 21918540 C G 3.32E-05 Self-reported allergy KCNIP4 intron 23817569 rs9997450 chr4 21919234 T G 3.33E-05 Self-reported allergy KCNIP4 intron 23817569 rs727633 chr4 21920543 C T 3.53E-05 Self-reported allergy KCNIP4 intron 23817569 rs12646862 chr4 21922119 A C 3.34E-05 Self-reported allergy KCNIP4 intron 23817569 rs10938868 chr4 21923596 A G 3.60E-05 Self-reported allergy KCNIP4 intron 23817569 rs10938869 chr4 21923741 G T 3.60E-05 Self-reported allergy KCNIP4 intron 23817569 rs12507277 chr4 21925257 G A 3.45E-05 Self-reported allergy KCNIP4 intron 23817569 rs10026649 chr4 21928331 C T 6.03E-05 Self-reported allergy KCNIP4 intron 23817569 rs10029403 chr4 21929040 C G 6.67E-05 Self-reported allergy KCNIP4 intron 23817569 rs13102882 chr4 21931211 C T 6.25E-05 Self-reported allergy KCNIP4 intron 23817569 rs13109656 chr4 21931730 G T 6.25E-05 Self-reported allergy KCNIP4 intron 23817569 rs10017055 chr4 21932451 A G 6.63E-05 Self-reported allergy KCNIP4 intron 23817569 rs6831938 chr4 21933996 C T 1.20E-05 Urinary metabolites KCNIP4 intron 21572414 rs13126050 chr4 21934535 G C 5.36E-05 Self-reported allergy KCNIP4 intron 23817569 rs6847752 chr4 21953680 G A 7.17E-05 Bipolar disorder / / 18317468 rs11723575 chr4 21959082 T C 2.14E-05 Serum metabolites / / 19043545 rs9291431 chr4 21965464 C T 8.18E-04 Tourette syndrome / / 22889924 rs2007203 chr4 21973067 C G 7.70E-04 Multiple complex diseases / / 17554300 rs9291432 chr4 21980503 T C 8.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs16872202 chr4 21985996 A G 4.29E-04 Taste perception / / 22132133 rs16872229 chr4 22009677 C T 4.62E-04 Multiple complex diseases / / 17554300 rs16872248 chr4 22021500 C T 6.00E-06 Obesity-related traits / / 23251661 rs17526294 chr4 22061205 G A 1.40E-05 Urinary metabolites / / 21572414 rs7656406 chr4 22073768 C A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6448119 chr4 22091384 C T 7.00E-06 Rheumatoid arthritis / / 21156761 rs13149470 chr4 22094237 T G 3.79E-04 Smoking cessation / / 24665060 rs2323312 chr4 22096199 C T 6.03E-04 Smoking cessation / / 24665060 rs7676498 chr4 22099755 C T 5.88E-04 Smoking cessation / / 24665060 rs10034224 chr4 22120917 C A 0.0002506 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10034224 chr4 22120917 C A 2.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9992275 chr4 22132031 G C 1.05E-04 Attention deficit hyperactivity disorder / / pha002875 rs6828674 chr4 22134361 G T 7.28E-04 Alzheimer's disease / / 22005930 rs7694976 chr4 22135645 G A 7.62E-04 Alzheimer's disease / / 22005930 rs13149022 chr4 22136614 G A 1.73E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7655220 chr4 22137033 A G 5.45E-04 Alzheimer's disease / / 22005930 rs7655595 chr4 22137194 A G 5.43E-04 Alzheimer's disease / / 22005930 rs11722767 chr4 22137682 G C 5.60E-04 Alzheimer's disease / / 22005930 rs6833271 chr4 22140467 A C 1.85E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2875003 chr4 22140636 C T 5.88E-04 Alzheimer's disease / / 22005930 rs4444822 chr4 22141348 G T 5.98E-04 Alzheimer's disease / / 22005930 rs2323260 chr4 22141543 T A 6.33E-04 Alzheimer's disease / / 22005930 rs7666315 chr4 22141923 T G 6.37E-04 Alzheimer's disease / / 22005930 rs2323262 chr4 22144436 G A 4.31E-05 Attention deficit hyperactivity disorder / / pha002875 rs7690130 chr4 22156619 T C 6.54E-04 Alzheimer's disease / / 22005930 rs11942303 chr4 22157620 C T 5.99E-04 Alzheimer's disease / / 22005930 rs11929923 chr4 22157672 T C 6.65E-04 Alzheimer's disease / / 22005930 rs10033940 chr4 22161298 G T 5.50E-04 Alzheimer's disease / / 22005930 rs11732349 chr4 22163642 A C 5.77E-04 Alzheimer's disease / / 22005930 rs9291436 chr4 22165174 T C 1.50E-05 Urinary metabolites / / 21572414 rs2875012 chr4 22194154 G A 2.81E-04 Hearing function / / 17255346 rs16872470 chr4 22203162 A G 1.34E-04 Multiple complex diseases / / 17554300 rs10022457 chr4 22205496 A G 6.33E-05 Cognitive test performance / / 20125193 rs6448134 chr4 22205963 G A 6.08E-04 Multiple complex diseases / / 17554300 rs12374330 chr4 22214964 C T 6.69E-04 Alzheimer's disease / / 22005930 rs3817031 chr4 22331361 T C 1.59E-04 Multiple complex diseases LOC100505912 intron 17554300 rs9002 chr4 22390167 C T 0.00012 Prostate cancer (non-advanced prostate cancer) GPR125 missense 23555315 rs1846731 chr4 22397135 T C 1.50E-05 Urinary metabolites GPR125 intron 21572414 rs11938967 chr4 22438307 C A 5.83E-04 Aortic root size GPR125 intron 21223598 rs16872682 chr4 22462619 G C 5.13E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines GPR125 intron 21844884 rs16872686 chr4 22462730 C T 8.47E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines GPR125 intron 21844884 rs1841823 chr4 22493757 T C 6.92E-05 Diabetes Mellitus GPR125 intron pha003060 rs2086010 chr4 22521890 A G 4.08E-06 Type 2 diabetes / / 17463246 rs7687254 chr4 22524253 T C 1.37E-04 Multiple complex diseases / / 17554300 rs13143909 chr4 22537258 A G 3.34E-05 Cognitive performance / / 19734545 rs10026861 chr4 22538841 T C 5.69E-05 Bipolar disorder / / 17486107 rs10026861 chr4 22538841 T C 1.74E-05 Cognitive performance / / 19734545 rs2045812 chr4 22543894 A G 3.37E-05 Cognitive performance / / 19734545 rs1841829 chr4 22546306 T C 1.90E-05 Cognitive performance / / 19734545 rs7680019 chr4 22556585 T C 5.30E-04 Type 2 diabetes / / 17463246 rs7694947 chr4 22576409 T C 2.42E-05 Cognitive performance / / 19734545 rs7694947 chr4 22576409 T C 2.48E-04 Attention deficit hyperactivity disorder / / 22012869 rs13102727 chr4 22577444 T C 3.46E-04 Type 2 diabetes / / 17463246 rs10938913 chr4 22584439 G A 3.04E-04 Type 2 diabetes / / 17463246 rs17601963 chr4 22586532 T G 2.61E-04 Type 2 diabetes / / 17463246 rs16872963 chr4 22692864 G A 5.74E-04 Multiple complex diseases / / 17554300 rs16873004 chr4 22705374 C G 5.82E-04 Multiple complex diseases GBA3 intron 17554300 rs16873006 chr4 22705994 C T 4.40E-04 Multiple complex diseases GBA3 intron 17554300 rs16873011 chr4 22706514 G C 5.77E-04 Multiple complex diseases GBA3 intron 17554300 rs16873068 chr4 22715030 C T 7.00E-05 Prostate cancer GBA3 intron 21743057 rs2013715 chr4 22718654 C T 7.00E-05 Prostate cancer GBA3 intron 21743057 rs3912484 chr4 22759689 T C 7.54E-04 Myopia (pathological) GBA3 intron 21095009 rs3099557 chr4 22824021 G A 2.00E-39 Blood metabolite levels / / 24816252 rs439863 chr4 22832682 A G 5.91E-04 Alcohol dependence / / 20201924 rs358222 chr4 22849545 T C 8.26E-05 Serum metabolites / / 19043545 rs16873221 chr4 22940211 C T 7.70E-05 Lung adenocarcinoma / / 22797724 rs2271006 chr4 22946924 A G 3.74E-05 Personality dimensions / / 18957941 rs9998680 chr4 22995433 C T 1.55E-04 Multiple complex diseases / / 17554300 rs7664442 chr4 23018704 A G 3.25E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs10470806 chr4 23054405 T G 7.45E-04 Smoking initiation / / 24665060 rs7665871 chr4 23076898 G A 8.40E-05 IgE levels / / 17255346 rs6825402 chr4 23095293 C T 7.48E-04 Multiple complex diseases / / 17554300 rs7673742 chr4 23166641 A G 3.25E-05 Serum metabolites / / 19043545 rs7697052 chr4 23205306 A G 1.64E-06 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs115036347 chr4 23249435 T C 2.89E-04 Acne (severe) / / 24927181 rs6821286 chr4 23265128 G A 1.14E-04 Self-reported allergy / / 23817569 rs12507569 chr4 23265535 A G 9.51E-05 Self-reported allergy / / 23817569 rs16873399 chr4 23265876 G C 8.43E-05 Self-reported allergy / / 23817569 rs12504948 chr4 23266101 T G 8.77E-05 Self-reported allergy / / 23817569 rs10938932 chr4 23266728 C T 6.17E-05 Meningococcal disease / / 20694013 rs10938932 chr4 23266728 C T 8.79E-05 Self-reported allergy / / 23817569 rs10517007 chr4 23267024 T C 8.58E-05 Self-reported allergy / / 23817569 rs16873417 chr4 23267131 C T 7.54E-05 Self-reported allergy / / 23817569 rs10517008 chr4 23272197 G C 6.49E-04 Coronary heart disease / / 21606135 rs10020612 chr4 23272760 G T 3.01E-05 Self-reported allergy / / 23817569 rs6811042 chr4 23273892 T C 1.43E-05 Self-reported allergy / / 23817569 rs6835555 chr4 23274625 G A 3.98E-05 Meningococcal disease / / 20694013 rs6835555 chr4 23274625 G A 1.40E-05 Self-reported allergy / / 23817569 rs16873439 chr4 23275166 G C 6.88E-04 Multiple complex diseases / / 17554300 rs12504520 chr4 23287240 A G 4.43E-05 Self-reported allergy / / 23817569 rs12503311 chr4 23293043 C T 4.20E-05 Self-reported allergy / / 23817569 rs16873468 chr4 23294877 C G 2.05E-05 Self-reported allergy / / 23817569 rs4516701 chr4 23295433 G C 1.82E-05 Self-reported allergy / / 23817569 rs9291446 chr4 23295936 C T 2.01E-05 Self-reported allergy / / 23817569 rs10433830 chr4 23296024 T C 1.56E-05 Self-reported allergy / / 23817569 rs10938939 chr4 23296159 C T 1.52E-05 Self-reported allergy / / 23817569 rs4550909 chr4 23298217 G A 3.56E-05 Self-reported allergy / / 23817569 rs4697384 chr4 23301374 C G 2.60E-05 Self-reported allergy / / 23817569 rs4697384 chr4 23301374 C G 3.40E-04 Smoking initiation / / 24665060 rs12507222 chr4 23307526 G T 2.89E-05 Self-reported allergy / / 23817569 rs12507992 chr4 23307693 C T 2.75E-05 Self-reported allergy / / 23817569 rs12502492 chr4 23309835 A C 5.00E-05 Meningococcal disease / / 20694013 rs12502492 chr4 23309835 A C 1.31E-05 Self-reported allergy / / 23817569 rs10433831 chr4 23315245 G A 2.37E-05 Self-reported allergy / / 23817569 rs10938941 chr4 23316067 A T 2.18E-05 Self-reported allergy / / 23817569 rs1121446 chr4 23318307 G A 1.78E-05 Self-reported allergy / / 23817569 rs9993310 chr4 23319480 C T 1.36E-05 Self-reported allergy / / 23817569 rs16873495 chr4 23320940 A C 1.90E-05 Self-reported allergy / / 23817569 rs16873495 chr4 23320940 A C 5.25E-04 Smoking initiation / / 24665060 rs4697386 chr4 23321206 A G 1.56E-05 Self-reported allergy / / 23817569 rs4697387 chr4 23326313 G T 3.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs1912031 chr4 23329039 A G 6.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs2968711 chr4 23349321 G A 1.24E-04 Coronary heart disease / / 21606135 rs2940774 chr4 23349343 C T 4.26E-05 Coronary heart disease / / 21606135 rs7666498 chr4 23356724 T C 2.73E-04 Coronary heart disease / / 21606135 rs1467030 chr4 23363589 T C 1.40E-04 Coronary heart disease / / 21606135 rs1509241 chr4 23364493 T C 7.89E-04 Coronary heart disease / / 21606135 rs7672988 chr4 23366777 C A 2.54E-05 Coronary heart disease / / 21606135 rs215475 chr4 23388399 A G 3.51E-04 Coronary heart disease / / 21606135 rs215411 chr4 23423603 T A 3.98E-04 Type 2 diabetes / / 17463246 rs215411 chr4 23423603 T A 7.39E-04 Multiple complex diseases / / 17554300 rs1605813 chr4 23430768 A G 8.17E-04 Coronary heart disease / / 21606135 rs177357 chr4 23444445 T C 3.07E-05 Coronary heart disease / / 21606135 rs123495 chr4 23445179 T C 1.09E-05 Coronary heart disease / / 21606135 rs123494 chr4 23445212 G C 2.66E-05 Coronary heart disease / / 21606135 rs215437 chr4 23446906 C G 3.92E-05 Coronary heart disease / / 21606135 rs723394 chr4 23473748 G A 9.36E-05 Orofacial clefts / / 22419666 rs723393 chr4 23473797 G A 3.00E-05 HIV-1 control / / 20041166 rs723393 chr4 23473797 G A 7.57E-05 Orofacial clefts / / 22419666 rs6829223 chr4 23474539 G A 3.00E-05 HIV-1 control / / 20041166 rs6829223 chr4 23474539 G A 9.52E-05 Orofacial clefts / / 22419666 rs740834 chr4 23483330 T C 4.82E-05 Meningococcal disease / / 20694013 rs216108 chr4 23503444 G T 6.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs216113 chr4 23520530 C T 6.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1511445 chr4 23541933 A G 6.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10009448 chr4 23575883 A G 7.26E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1397829 chr4 23587996 A G 1.65E-08 Adiponectin levels / / 20887962 rs1511453 chr4 23588462 G A 5.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1912759 chr4 23593005 G A 2.88E-04 Multiple complex diseases / / 17554300 rs1397828 chr4 23596719 G T 4.53E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs9291451 chr4 23608994 A G,T 4.59E-04 Type 2 diabetes / / 17846124 rs9291451 chr4 23608994 A G,T 9.52E-05 Cognitive impairment induced by topiramate / / 22091778 rs13112409 chr4 23611658 T C 6.93E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs13121107 chr4 23615048 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs13121520 chr4 23622531 G A 5.78E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs16873946 chr4 23630049 A G 0.00000444 Cytarabine sensitivity / / 23538338 rs13118539 chr4 23631863 G A 6.06E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs16873952 chr4 23632143 G A 2.60E-06 Alopecia areata / / 22027810 rs306063 chr4 23649426 G A 5.11E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs3112978 chr4 23657602 C T 4.75E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs306054 chr4 23663453 T G 3.62E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs306050 chr4 23669223 C A 4.47E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs306051 chr4 23673529 A G 4.46E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1948355 chr4 23697758 G A 5.07E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs6830932 chr4 23697950 G C 5.09E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs2035826 chr4 23698717 G A 1.60E-05 Urinary metabolites / / 21572414 rs1491377 chr4 23702558 A G 1.82E-04 Nicotine dependence / / 17158188 rs1038821 chr4 23703647 T G 1.76E-05 Biliary atresia / / 20460270 rs10938957 chr4 23709615 T C 7.06E-05 Biliary atresia / / 20460270 rs7677217 chr4 23716639 G A 2.57E-05 Biliary atresia / / 20460270 rs13138252 chr4 23757800 G A 4.00E-05 Lupus / / 17911428 rs11734001 chr4 23760199 T C 7.42E-05 Heart Rate / / pha003054 rs3774921 chr4 23810647 C T 7.59E-05 Response to taxane treatment (placlitaxel) PPARGC1A intron 23006423 rs4697045 chr4 23812757 G A 8.59E-05 Response to taxane treatment (placlitaxel) PPARGC1A intron 23006423 rs2970848 chr4 23817027 A G 5.96E-05 Longevity PPARGC1A intron 20304771 rs2970848 chr4 23817027 A G 6.84E-05 Aging (time to event) PPARGC1A intron 21782286 rs1472095 chr4 23818077 C T 0.00023 Endometrial cancer PPARGC1A intron 22426144 rs2932971 chr4 23818884 C T 4.40E-04 Lipoprotein A [Lp(a)] levels in plasma PPARGC1A intron 21592478 rs2932976 chr4 23822328 G A 1.90E-04 Lipoprotein A [Lp(a)] levels in plasma PPARGC1A intron 21592478 rs2970855 chr4 23827245 A T 4.43E-08 Metabolite levels PPARGC1A intron 23281178 rs4619879 chr4 23834876 C A 7.59E-08 Metabolite levels PPARGC1A intron 23281178 rs4697046 chr4 23836400 C T 2.48E-08 Metabolite levels PPARGC1A intron 23281178 rs6448226 chr4 23836653 G A 8.37E-08 Metabolite levels PPARGC1A intron 23281178 rs12374310 chr4 23854149 G C 0.00028 Coronary artery calcification PPARGC1A intron 23727086 rs3796407 chr4 23884711 G A 4.20E-04 Anxiety spectrum disorders PPARGC1A intron 21871609 rs12500214 chr4 23885568 G A 3.00E-06 Glaucoma (primary open-angle) PPARGC1A intron 22605921 rs2970878 chr4 23887256 T C 1.34E-04 Multiple complex diseases PPARGC1A intron 17554300 rs4568225 chr4 23898430 C T 5.80E-07 Amyotrophic Lateral Sclerosis / / 17362836 rs2970860 chr4 23901275 G A 0.000884 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2970860 chr4 23901275 G A 8.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17576576 chr4 23907727 A G 0.0005869 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17576576 chr4 23907727 A G 5.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17576640 chr4 23908555 T C 0.000564 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17576640 chr4 23908555 T C 5.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13108219 chr4 23908890 C A 1.35E-04 Multiple complex diseases / / 17554300 rs733111 chr4 23931779 T A 7.27E-04 Acute lung injury / / 22295056 rs10017711 chr4 23955370 A G 3.51E-04 Acute lung injury / / 22295056 rs10020457 chr4 23962961 G A 6.12E-04 Alzheimer's disease / / 17998437 rs10938974 chr4 23966093 A T 3.17E-04 Acute lung injury / / 22295056 rs11729880 chr4 23981706 T G 7.82E-04 Multiple complex diseases / / 17554300 rs13119672 chr4 23984463 T C 2.45E-06 Multiple complex diseases / / 17554300 rs13119672 chr4 23984463 T C 6.92E-05 Glaucoma (primary open-angle) / / 22605921 rs16874486 chr4 23991100 T C 5.60E-04 Smoking cessation / / 24665060 rs597082 chr4 23996637 T C 3.85E-04 Gallstones / / 17632509 rs12504758 chr4 24002450 A G 2.14E-04 Acute lung injury / / 22295056 rs6858449 chr4 24002981 C A 3.24E-04 Acute lung injury / / 22295056 rs16874564 chr4 24009437 C T 6.33E-04 Rheumatoid arthritis / / 21452313 rs7672552 chr4 24011608 C T 7.34E-04 Coronary Artery Disease / / 17634449 rs7672552 chr4 24011608 C T 3.47E-04 Stroke / / pha002887 rs2286788 chr4 24012339 T C 2.19E-04 Acute lung injury / / 22295056 rs6448238 chr4 24015168 A T 9.62E-04 Coronary Artery Disease / / 17634449 rs6819019 chr4 24021782 G A 1.14E-05 Blood Pressure / / pha002898 rs13143473 chr4 24025688 T C 9.56E-04 Rheumatoid arthritis / / 21452313 rs618283 chr4 24035754 C T 2.46E-04 Smoking cessation / / 24665060 rs646314 chr4 24043324 T C 1.20E-04 Smoking cessation / / 24665060 rs683518 chr4 24044941 T C 4.26E-05 Heart Rate / / pha003053 rs640050 chr4 24047686 A G 1.34E-04 Acute lung injury / / 22295056 rs625365 chr4 24048711 T C 1.28E-05 Heart Rate / / pha003053 rs625365 chr4 24048711 T C 1.24E-05 Platelet counts / / pha003100 rs651046 chr4 24055061 A G 3.82E-04 Coronary Artery Disease / / 17634449 rs614457 chr4 24055425 T G 3.45E-05 Monocyte counts / / pha003089 rs590183 chr4 24057266 C T 8.60E-06 Subclinical atherosclerosis / / 17903303 rs6832344 chr4 24057536 A G 1.00E-05 Subclinical atherosclerosis / / 17903303 rs2324152 chr4 24058013 G T 5.87E-05 Coronary Artery Disease / / 17634449 rs647381 chr4 24060605 A G 4.10E-04 Alcohol dependence / / 20201924 rs6824969 chr4 24063297 G T 6.56E-05 Heart Rate / / pha003053 rs16874921 chr4 24066983 G C 3.11E-04 Coronary Artery Disease / / 17634449 rs16874921 chr4 24066983 G C 9.80E-08 Metabolite levels / / 23281178 rs7679405 chr4 24100617 C T 2.04E-08 Metabolite levels / / 23281178 rs17188642 chr4 24105609 C T 1.96E-05 Coronary Artery Disease / / 17634449 rs17188642 chr4 24105609 C T 1.50E-05 Cognitive function / / 24684796 rs12510671 chr4 24106257 C G 3.53E-04 Coronary Artery Disease / / 17634449 rs12650199 chr4 24114047 A G 4.00E-04 Coronary Artery Disease / / 17634449 rs12650199 chr4 24114047 A G 2.93E-08 Metabolite levels / / 23281178 rs10489098 chr4 24125887 T C 4.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12644722 chr4 24130517 C T 2.04E-04 Multiple complex diseases / / 17554300 rs1639376 chr4 24142331 A G 6.00E-05 Multiple complex diseases / / 17554300 rs1705089 chr4 24142612 G A 8.86E-05 Lipoproteins / / pha003079 rs1624041 chr4 24144642 C T 7.76E-05 Lipoproteins / / pha003079 rs1267008 chr4 24145764 G A 8.66E-05 Lipoproteins / / pha003079 rs1267018 chr4 24149767 A C 4.46E-05 Lipoproteins / / pha003079 rs16875258 chr4 24185518 T C 3.47E-05 Type 2 diabetes / / 17463246 rs1397491 chr4 24199678 T C 4.62E-04 Coronary Artery Disease / / 17634449 rs1995917 chr4 24207765 G A 5.16E-05 Lung cancer / / 18978787 rs4697051 chr4 24215638 G A 2.30E-05 Urinary metabolites / / 21572414 rs16875349 chr4 24215917 T C 9.53E-05 Major depressive disorder / / 21621269 rs4697442 chr4 24224119 G A 3.86E-04 Insulin resistance / / 21901158 rs10938982 chr4 24232087 G A 1.53E-05 Major depressive disorder / / 21621269 rs17641468 chr4 24234074 C T 9.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs4697053 chr4 24239257 T C 8.17E-05 Intelligence / / 21826061 rs1355344 chr4 24240884 G C 5.07E-05 Bipolar disorder / / 19488044 rs17580740 chr4 24242353 T C 2.93E-04 Multiple complex diseases / / 17554300 rs6448254 chr4 24255842 G A 3.70E-04 Multiple complex diseases / / 17554300 rs7688742 chr4 24256292 T C 8.95E-05 Information processing speed / / 21130836 rs1473595 chr4 24261249 C T 1.31E-04 Multiple complex diseases / / 17554300 rs938067 chr4 24261509 T C 8.18E-04 Multiple complex diseases / / 17554300 rs938068 chr4 24261567 G A 8.66E-05 Multiple complex diseases / / 17554300 rs17648008 chr4 24261991 T A 1.81E-04 Multiple complex diseases / / 17554300 rs17581643 chr4 24262089 C T 5.28E-04 Multiple complex diseases / / 17554300 rs6852227 chr4 24263853 T C 4.05E-04 Heart Failure / / pha002884 rs17648420 chr4 24267149 T C 6.88E-04 Alzheimer's disease / / 24755620 rs4697055 chr4 24267336 A G 7.32E-04 Myocardial Infarction / / pha002873 rs10517043 chr4 24268623 G A 4.17E-04 Multiple complex diseases / / 17554300 rs1511358 chr4 24268934 T C 8.09E-05 Multiple complex diseases / / 17554300 rs4697447 chr4 24275114 T C 8.55E-04 Taste perception / / 22132133 rs1510787 chr4 24286919 A G 3.36E-05 Vascular dementia / / 22116812 rs9685879 chr4 24324261 T C 7.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1011218 chr4 24352011 C A 1.82E-05 Cognitive impairment induced by topiramate / / 22091778 rs535026867 chr4 24352011 C CT 1.82E-05 Cognitive impairment induced by topiramate / / 22091778 rs17650401 chr4 24375833 C T 2.00E-06 Molar-incisor hypomineralization / / 23918034 rs4697059 chr4 24392837 A C 8.29E-04 Parkinson's disease / / 16252231 rs4588440 chr4 24410662 G A 7.62E-04 Alzheimer's disease / / 22005930 rs7681091 chr4 24413850 G A 6.68E-04 Alzheimer's disease / / 22005930 rs7680809 chr4 24413937 C A 6.16E-04 Alzheimer's disease / / 22005930 rs744790 chr4 24416173 C T 4.82E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6823107 chr4 24444785 C T 3.62E-05 Chronic obstructive pulmonary disease / / 19300482 rs13105131 chr4 24455662 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10026526 chr4 24455932 T C 8.84E-05 Sudden cardiac arrest / / 21658281 rs11737023 chr4 24467089 G A 2.67E-04 Alzheimer's disease (late onset) / / 21379329 rs3857107 chr4 24477340 G A 5.00E-05 Lung cancer LOC729175 intron 18978790 rs17592631 chr4 24486378 C T 2.27E-04 Type 2 diabetes / / 17463246 rs7698250 chr4 24515631 C T 2.00E-10 Pulmonary emphysema / / 24383474 rs7670492 chr4 24552966 A C 5.81E-04 Multiple complex diseases DHX15 intron 17554300 rs13111756 chr4 24557437 G A 5.93E-04 Multiple complex diseases DHX15 intron 17554300 rs6841898 chr4 24578097 C T 3.00E-26 Myopia (pathological) DHX15 cds-synon 23049088 rs10939004 chr4 24652142 C T 0.000813 fMRI brain tests in schizophrenia / / 22440650 rs12507254 chr4 24673420 T G 6.00E-04 Heart Failure / / pha002884 rs11935819 chr4 24694435 T C 7.64E-05 Bipolar disorder and schizophrenia / / 20889312 rs4697472 chr4 24698303 G C 2.04E-05 Bipolar disorder and schizophrenia / / 20889312 rs2875373 chr4 24700151 A T 7.05E-05 Bipolar disorder and schizophrenia / / 20889312 rs12500507 chr4 24705742 G A 1.74E-05 Bipolar disorder and schizophrenia / / 20889312 rs6812181 chr4 24711351 A T 8.44E-05 Bipolar disorder and schizophrenia / / 20889312 rs12500612 chr4 24740958 G T 7.00E-06 Major depressive disorder / / 23377640 rs17621680 chr4 24749535 A G 9.51E-06 Stroke (ischemic) / / 21957438 rs6851578 chr4 24750063 C T 4.84E-06 Stroke (ischemic) / / 21957438 rs10021418 chr4 24750082 T C 4.84E-06 Stroke (ischemic) / / 21957438 rs12505599 chr4 24750934 C T 4.91E-06 Stroke (ischemic) / / 21957438 rs60978593 chr4 24753718 C G 4.83E-06 Stroke (ischemic) / / 21957438 rs7684977 chr4 24761191 G A 8.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs78792420 chr4 24778280 T G 2.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs13138705 chr4 24779506 C T 7.38E-04 HIV-1 viral setpoint / / 17641165 rs1405689 chr4 24784568 C T 2.25E-04 HIV-1 viral setpoint / / 17641165 rs800437 chr4 24790163 A G 3.31E-23 Narcolepsy / / 19629137 rs10026758 chr4 24803564 A G 9.77E-04 Type 2 diabetes / / 17463246 rs10489030 chr4 24844836 A G 5.00E-04 Pulmonary function CCDC149 intron 17903307 rs800464 chr4 24856909 A G 4.94E-04 Response to cytadine analogues (cytosine arabinoside) CCDC149 intron 24483146 rs800478 chr4 24860527 C A 3.05E-04 Response to cytadine analogues (cytosine arabinoside) CCDC149 intron 24483146 rs800377 chr4 24870879 C T 4.72E-05 Response to cytadine analogues (cytosine arabinoside) CCDC149 intron 24483146 rs800379 chr4 24871204 T C 2.99E-05 Response to cytadine analogues (cytosine arabinoside) CCDC149 intron 24483146 rs10004346 chr4 24939997 T C 5.83E-05 Blood Pressure CCDC149 intron pha003050 rs13112159 chr4 24946538 A G 2.00E-05 Urinary metabolites CCDC149 intron 21572414 rs2123743 chr4 24950026 C T 3.05E-05 Blood Pressure CCDC149 intron pha003050 rs7659312 chr4 24961565 T C 4.38E-05 Serum metabolites CCDC149 intron 19043545 rs4235324 chr4 24988013 C T 2.68E-04 Body mass index / / 23669352 rs7689760 chr4 25001439 T C 7.99E-05 Multiple complex diseases LGI2 UTR-3 17554300 rs7689760 chr4 25001439 T C 2.76E-04 Alzheimer's disease LGI2 UTR-3 17998437 rs6827675 chr4 25001842 C G 1.07E-05 Multiple complex diseases LGI2 UTR-3 17554300 rs3796786 chr4 25004757 G T 2.34E-04 Type 2 diabetes LGI2 UTR-3 17463246 rs2232028 chr4 25005193 G A 4.47E-04 Multiple complex diseases LGI2 cds-synon 17554300 rs4235326 chr4 25009491 T C 4.55E-05 Triglycerides LGI2 intron pha003080 rs2024341 chr4 25021906 G A 4.62E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LGI2 intron 20877124 rs2024341 chr4 25021906 G A 1.35E-05 Coronary heart disease LGI2 intron pha003055 rs9998234 chr4 25033280 T C 7.20E-06 Urinary metabolites / / 21572414 rs13124493 chr4 25048536 A G 3.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13116533 chr4 25068062 T C 4.08E-04 Multiple complex diseases / / 17554300 rs13116533 chr4 25068062 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10007566 chr4 25068164 A T 3.39E-06 Response to metformin / / 21186350 rs16876742 chr4 25070475 T C 3.86E-04 Multiple complex diseases / / 17554300 rs4697093 chr4 25115346 C T 1.45E-04 Multiple complex diseases / / 17554300 rs4697549 chr4 25115598 G C 6.34E-04 Multiple complex diseases / / 17554300 rs13106651 chr4 25183445 A G 3.83E-04 Alcohol dependence LOC285540 intron 21314694 rs10006028 chr4 25197686 A G 6.13E-05 Multiple complex diseases LOC285540 intron 17554300 rs1909475 chr4 25200584 T C 1.35E-04 Alcohol dependence / / 21314694 rs7654358 chr4 25227917 G A 5.80E-06 Urinary metabolites / / 21572414 rs4370127 chr4 25282410 C T 6.07E-04 Type 2 diabetes / / 17463246 rs7671799 chr4 25295889 G A,T 9.95E-04 Coronary heart disease / / 21971053 rs6826966 chr4 25308343 C T 1.26E-04 Sudden cardiac arrest / / 21658281 rs1533132 chr4 25312357 A G 2.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs316783 chr4 25342463 A C 2.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZCCHC4 intron 20877124 rs316783 chr4 25342463 A C 3.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZCCHC4 intron 20877124 rs13149511 chr4 25358109 G A 9.05E-04 Multiple complex diseases ZCCHC4 intron 17554300 rs7675034 chr4 25367018 G A 1.55E-04 Multiple complex diseases ZCCHC4 intron 17554300 rs7675034 chr4 25367018 G A 1.20E-04 Intelligence (childhood) ZCCHC4 intron 23358156 rs7684466 chr4 25386468 C T 1.55E-04 Multiple complex diseases A/PC4 intron 17554300 rs10027814 chr4 25386559 G A 1.48E-04 Multiple complex diseases A/PC4 intron 17554300 rs13434763 chr4 25388590 T C 9.38E-04 Multiple complex diseases A/PC4 intron 17554300 rs10032586 chr4 25400468 A G 1.47E-06 Non-obstructive azoospermia A/PC4 intron 22541561 rs16877106 chr4 25403266 C T 1.00E-06 Weight A/PC4 intron 20966902 rs2012286 chr4 25407661 A G 4.40E-04 Multiple complex diseases A/PC4 intron 17554300 rs2012277 chr4 25407804 T C 2.30E-04 Multiple complex diseases A/PC4 intron 17554300 rs3816587 chr4 25417244 C T 9.00E-06 Rheumatoid arthritis A/PC4 intron 17554300 rs10517073 chr4 25417371 G A 1.01E-04 Multiple complex diseases A/PC4 intron 17554300 rs2175905 chr4 25440205 G C 1.41E-04 Multiple complex diseases / / 17554300 rs2875417 chr4 25476612 G A 1.30E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2875417 chr4 25476612 G A 3.34E-05 Lung function (forced vital capacity) / / 24023788 rs2875417 chr4 25476612 G A 7.58E-05 Leukocyte Counts / / pha003091 rs719210 chr4 25482916 T C 3.88E-04 Lung function (forced vital capacity) / / 24023788 rs989263 chr4 25502383 C T 3.57E-05 Post-operative nausea and vomiting / / 21694509 rs6854268 chr4 25505735 A C 4.24E-05 Type 2 diabetes / / 17463246 rs16877207 chr4 25507858 C A 8.46E-04 Multiple complex diseases / / 17554300 rs4626186 chr4 25524087 A G 2.25E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6448367 chr4 25531234 A G 1.34E-04 Lung function (forced vital capacity) / / 24023788 rs6448367 chr4 25531234 A G 2.88E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6448367 chr4 25531234 A G 8.17E-05 Leukocyte Counts / / pha003091 rs10018150 chr4 25536386 A G 1.62E-04 Lung function (forced vital capacity) / / 24023788 rs10018150 chr4 25536386 A G 2.32E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10018150 chr4 25536386 A G 5.00E-05 Leukocyte Counts / / pha003091 rs1980239 chr4 25562241 C T 9.00E-05 Waist Circumference / / pha003023 rs1980239 chr4 25562241 C T 4.82E-05 Waist-Hip Ratio / / pha003029 rs13112011 chr4 25573119 A C 0.0000049 Transmission distortion / / 22377632 rs16877294 chr4 25590852 G A 8.80E-06 Urinary metabolites / / 21572414 rs6448381 chr4 25591895 T C 7.31E-04 Body mass index / / 21701565 rs11732914 chr4 25614935 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12501856 chr4 25659608 T C 4.00E-04 Response to taxane treatment (placlitaxel) SLC34A2 intron 23006423 rs12505556 chr4 25676982 C A 2.10E-05 Urinary metabolites SLC34A2 intron 21572414 rs16877439 chr4 25705821 C T 6.59E-04 Multiple complex diseases / / 17554300 rs7654794 chr4 25729838 C T 7.81E-04 Multiple complex diseases / / 17554300 rs4328902 chr4 25739169 T C 6.10E-06 Asthma (bronchodilator response) / / 22792082 rs11736599 chr4 25755041 T C 1.70E-07 Urinary metabolites SEL1L3 intron 21572414 rs4697616 chr4 25767183 G A 1.44E-05 Post-operative nausea and vomiting SEL1L3 intron 21694509 rs6819016 chr4 25775034 T C 1.61E-04 Attention deficit hyperactivity disorder SEL1L3 intron pha002875 rs4697619 chr4 25780891 A G 3.48E-04 Multiple complex diseases SEL1L3 intron 17554300 rs16877567 chr4 25802489 A G 4.93E-04 Multiple complex diseases SEL1L3 intron 17554300 rs959903 chr4 25810096 G A 7.00E-06 Non-alcoholic fatty liver disease histology (other) SEL1L3 intron 20708005 rs2168521 chr4 25840789 A G 4.59E-05 Cognitive impairment induced by topiramate SEL1L3 intron 22091778 rs139899954 chr4 25849141 C A 0.00000116 Ratio of free to total prostate-specific antigen SEL1L3 missense 23555315 rs6853938 chr4 25854462 A G 0.0005217 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SEL1L3 intron 23233654 rs6853938 chr4 25854462 A G 5.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) SEL1L3 intron 23233662 rs7666901 chr4 25855179 A G 0.0004782 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SEL1L3 intron 23233654 rs6842695 chr4 25861359 T C 0.0004385 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SEL1L3 intron 23233654 rs6842695 chr4 25861359 T C 4.39E-04 Methotrexate clearance (acute lymphoblastic leukemia) SEL1L3 intron 23233662 rs13140429 chr4 25867118 T C 7.62E-04 Type 2 diabetes / / 17463246 rs1545606 chr4 25875261 G A 3.35E-05 Progressive supranuclear palsy / / 21685912 rs936233 chr4 25940811 C T 2.06E-04 Insulin resistance / / 21901158 rs7654585 chr4 25942751 A G 2.00E-07 Obesity-related traits / / 23251661 rs936235 chr4 25970163 T C 7.65E-05 Waist Circumference / / pha003023 rs7377519 chr4 25974048 T C 4.98E-05 Waist Circumference / / pha003023 rs16877848 chr4 25975111 C T 2.34E-05 Interstitial lung disease / / 23583980 rs4234990 chr4 25988674 T C 9.70E-05 Response to statin therapy / / 20339536 rs13134778 chr4 26017953 C T 7.51E-04 Multiple complex diseases / / 17554300 rs4269167 chr4 26025756 T C 5.10E-05 Alcohol dependence / / 24277619 rs9884830 chr4 26027797 C T 9.41E-04 Multiple complex diseases / / 17554300 rs12502605 chr4 26031528 T C 2.57E-06 Waist-hip ratio / / 20935629 rs13126784 chr4 26057402 G A 2.11E-04 Rheumatoid arthritis / / 21452313 rs10019888 chr4 26062990 A G 5.00E-08 HDL cholesterol / / 24097068 rs4692059 chr4 26072751 T C 7.79E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2048507 chr4 26079164 T C 1.34E-04 Common variable immunodeficiency / / 21497890 rs10517086 chr4 26085511 G A 5.00E-10 Type 1 diabetes / / 19430480 rs10517086 chr4 26085511 G A 4.60E-10 Multiple sclerosis / / 22190364 rs17630466 chr4 26086569 A G 5.67E-13 Rheumatoid arthritis / / 23143596 rs932036 chr4 26090862 A T 2.00E-10 Rheumatoid arthritis / / 23143596 rs932036 chr4 26090862 A T 3.55E-10 Rheumatoid arthritis (CCP positive) / / 23143596 rs12506688 chr4 26104113 C T 3.73E-10 Rheumatoid arthritis / / 23143596 rs12506688 chr4 26104113 C T 6.00E-13 Rheumatoid arthritis (CCP positive) / / 23143596 rs874040 chr4 26108197 G C 1.00E-16 Rheumatoid arthritis / / 20453842 rs874040 chr4 26108197 G C 1.00E-16 Celiac disease and Rheumatoid arthritis / / 21383967 rs874040 chr4 26108197 G C 1.00E-16 Multiple sclerosis / / 22190364 rs874040 chr4 26108197 G C 3.30E-07 Rheumatoid arthritis / / 22446963 rs874040 chr4 26108197 G C 4.00E-07 Rheumatoid arthritis / / 24449572 rs10006886 chr4 26118901 A G 7.59E-04 Multiple complex diseases / / 17554300 rs11933540 chr4 26120001 T C 1.76E-04 Type 1 diabetes / / 21980299 rs11933540 chr4 26120001 T C 1.00E-16 Rheumatoid arthritis / / 24390342 rs11933540 chr4 26120001 T C 8.80E-17 Rheumatoid arthritis / / 24390342 rs4692386 chr4 26132361 T C 2.31E-05 Multiple complex diseases / / 17554300 rs907499 chr4 26137019 C T 4.00E-06 Obesity-related traits / / 23251661 rs16878154 chr4 26172899 G A 1.16E-04 Smoking quantity / / 24665060 rs6824647 chr4 26177372 T C 4.35E-04 Smoking quantity / / 24665060 rs4525961 chr4 26187028 G A 6.02E-04 Multiple complex diseases / / 17554300 rs4552442 chr4 26205938 T C 1.40E-06 Urinary metabolites / / 21572414 rs2871198 chr4 26292555 C T 2.91E-05 Waist-Hip Ratio / / pha003029 rs10008046 chr4 26319850 A G 8.76E-05 Acute lymphoblastic leukemia (childhood) RBPJ nearGene-5 22076464 rs11722744 chr4 26363640 A C 8.04E-05 Serum metabolites RBPJ intron 19043545 rs16878337 chr4 26439308 T C 1.76E-04 Multiple complex diseases / / 17554300 rs4586917 chr4 26441499 C T 2.77E-05 Schizophrenia / / 19571811 rs2046784 chr4 26503983 G A 2.50E-05 Malaria / / 19465909 rs2130250 chr4 26504157 G T 3.80E-05 Malaria / / 19465909 rs1565302 chr4 26540784 A G 5.32E-04 Multiple complex diseases / / 17554300 rs4572866 chr4 26795603 T C 5.80E-05 Periodontitis (Chronic) / / 25008200 rs7692829 chr4 26822377 G A 1.89E-04 Attention deficit hyperactivity disorder / / 22420046 rs4519791 chr4 26883764 C T 3.03E-04 Hearing function STIM2 intron 17255346 rs12505133 chr4 26883909 T C 3.78E-05 Neuroblastoma STIM2 intron pha002895 rs7672936 chr4 26884408 C T 1.61E-04 Hearing function STIM2 intron 17255346 rs11737218 chr4 26885773 G T 2.90E-05 Urinary metabolites STIM2 intron 21572414 rs4129747 chr4 26892856 G A 5.99E-04 Multiple complex diseases STIM2 intron 17554300 rs12644073 chr4 26897058 C T 6.70E-06 Urinary metabolites STIM2 intron 21572414 rs10029307 chr4 26904213 G A 2.27E-06 Phospholipid levels (plasma) STIM2 intron 21829377 rs11727649 chr4 26914837 A G 1.88E-05 Neuroblastoma STIM2 intron pha002895 rs11730235 chr4 26924444 G T 8.60E-07 Phospholipid levels (plasma) STIM2 intron 21829377 rs12644232 chr4 26932453 G A 2.24E-04 Hearing function STIM2 intron 17255346 rs6844153 chr4 26944314 C T 6.00E-07 Phospholipid levels (plasma) STIM2 intron 21829377 rs7658174 chr4 26945149 G A 1.05E-04 Hearing function STIM2 intron 17255346 rs6448488 chr4 26950987 C T 2.43E-06 Phospholipid levels (plasma) STIM2 intron 21829377 rs3792685 chr4 26959207 T C 2.57E-06 Phospholipid levels (plasma) STIM2 intron 21829377 rs887794 chr4 26964350 A G 5.75E-04 Multiple complex diseases STIM2 intron 17554300 rs6822297 chr4 27000995 A G 8.00E-06 Obesity-related traits STIM2 intron 23251661 rs12642922 chr4 27027618 T C 8.40E-05 Bone mineral density (spine) / / 19079262 rs7680613 chr4 27045316 T C 4.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12649969 chr4 27046322 T A 3.85E-06 Phospholipid levels (plasma) / / 21829377 rs7654400 chr4 27048542 T A 4.09E-06 Phospholipid levels (plasma) / / 21829377 rs2075094 chr4 27097190 G T 5.08E-05 Hirschsprung's disease / / 19196962 rs6835095 chr4 27103530 C T 3.94E-04 Type 2 diabetes / / 17463246 rs7685249 chr4 27125382 C T 4.65E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs16878892 chr4 27143366 C A 8.37E-05 Waist Circumference / / pha003023 rs7673636 chr4 27178169 G A 7.79E-05 Waist Circumference / / pha003023 rs4692174 chr4 27186432 C T 2.34E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs13149020 chr4 27194071 C A 8.00E-06 QT interval / / 23166209 rs16878969 chr4 27194543 C T 8.66E-06 QT interval / / 23166209 rs4692178 chr4 27203763 A G 8.31E-04 Multiple complex diseases / / 17554300 rs1488270 chr4 27216054 C G 2.90E-05 Urinary metabolites / / 21572414 rs16879065 chr4 27257005 C T 5.60E-06 Urinary metabolites / / 21572414 rs1488297 chr4 27259634 A G 6.52E-04 Insulin resistance / / 21901158 rs1488299 chr4 27261443 T C 8.48E-05 Tourette syndrome / / 22889924 rs732896 chr4 27290273 T C 7.23E-04 Type 2 diabetes / / 17463246 rs6821695 chr4 27298305 T C 5.23E-04 Epilepsy / / 22116939 rs13115333 chr4 27323221 T G 1.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs759097 chr4 27337756 C T 2.20E-05 Coronary heart disease / / pha003056 rs759100 chr4 27338849 C T 2.54E-04 Multiple complex diseases / / 17554300 rs4692196 chr4 27339904 C T 3.59E-05 Coronary heart disease / / pha003056 rs13108948 chr4 27354279 C T 2.78E-04 Height / / 17255346 rs6448513 chr4 27361507 T G 2.89E-04 Smoking initiation / / 24665060 rs11945485 chr4 27365127 T A 1.76E-04 Height / / 17255346 rs10012661 chr4 27373821 T C 5.17E-04 Taste perception / / 22132133 rs16879235 chr4 27387573 G C 7.11E-04 Insulin resistance / / 21901158 rs11943532 chr4 27391945 G C 9.90E-04 Insulin resistance / / 21901158 rs10489016 chr4 27394986 C G 4.71E-04 Insulin resistance / / 21901158 rs1910137 chr4 27411060 A G 4.04E-05 Pulmonary function / / 17903307 rs210760 chr4 27412242 G A 6.78E-05 Height / / pha003010 rs7690192 chr4 27427056 G A 2.31E-04 IgE levels / / 17255346 rs210774 chr4 27428596 A C 3.04E-04 Coronary Artery Disease / / 17634449 rs210781 chr4 27450201 A C 4.84E-04 Coronary Artery Disease / / 17634449 rs1502251 chr4 27525947 T G 6.10E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs16879459 chr4 27528524 A G 6.60E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1993402 chr4 27530694 A C 7.00E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs10939164 chr4 27533346 T G 7.23E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs16879493 chr4 27576781 A C 2.41E-04 Multiple complex diseases / / 17554300 rs1375775 chr4 27597367 C T 1.36E-04 Multiple complex diseases / / 17554300 rs1375775 chr4 27597367 C T 2.33E-06 Serum metabolites / / 19043545 rs7658517 chr4 27602249 C T 3.05E-05 Serum metabolites / / 19043545 rs1574847 chr4 27611759 C G 8.63E-04 Multiple complex diseases / / 17554300 rs1574847 chr4 27611759 C G 2.58E-05 Serum metabolites / / 19043545 rs10013576 chr4 27619553 G T 3.04E-05 Tunica Media / / pha003034 rs1503472 chr4 27646805 T G 5.54E-04 Parkinson's disease / / 17052657 rs297305 chr4 27715979 C T 4.11E-04 Type 2 diabetes / / 17463246 rs297305 chr4 27715979 C T 2.02E-05 Cognitive performance / / 19734545 rs4692256 chr4 27744718 C T 1.00E-06 Brain imaging / / 20100581 rs17669368 chr4 27757473 T C 8.60E-06 Urinary metabolites / / 21572414 rs1875718 chr4 27799478 A T 4.81E-05 Personality dimensions / / 22628180 rs992289 chr4 27800433 T C 4.81E-05 Personality dimensions / / 22628180 rs17608484 chr4 27801717 G A 4.77E-05 Personality dimensions / / 22628180 rs9995889 chr4 27808889 G A 3.49E-05 Personality dimensions / / 22628180 rs6857239 chr4 27814525 C G 4.30E-05 Personality dimensions / / 22628180 rs1905564 chr4 27828999 C A 6.61E-06 Longevity,exceptional / / 20595579 rs7656782 chr4 27878240 A C 5.70E-06 Glucose levels / / pha003058 rs995703 chr4 27894017 G A 4.30E-05 Schizophrenia / / 19571808 rs1026947 chr4 27912160 G A 5.17E-04 Type 2 diabetes / / 17846124 rs2192542 chr4 27948005 G A 1.70E-05 Relative hand skill in reading disability / / 24068947 rs11934750 chr4 27964405 A T 1.00E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs9884781 chr4 27989923 T A 9.80E-06 Mathematical ability / / 24801482 rs7668921 chr4 28038387 C T 3.22E-04 Alzheimer's disease / / 17998437 rs6824412 chr4 28097896 C T 9.87E-04 Type 2 diabetes / / 17463246 rs6824459 chr4 28098026 A C 2.30E-05 Urinary metabolites / / 21572414 rs10007143 chr4 28101628 A T 3.31E-04 Type 2 diabetes / / 17463246 rs2309710 chr4 28103210 C A 4.54E-04 Type 2 diabetes / / 17463246 rs1609116 chr4 28122494 G T 1.10E-04 Type 2 diabetes / / 17463246 rs6448565 chr4 28171678 C G 2.76E-04 Type 2 diabetes / / 17463246 rs7689940 chr4 28176713 G A 7.13E-04 Type 2 diabetes / / 17463246 rs4692290 chr4 28182874 A G 1.98E-04 Coronary heart disease / / 21606135 rs2036182 chr4 28261127 A C 2.61E-05 Sarcoidosis / / 19165924 rs2036181 chr4 28261161 G A 9.22E-04 Multiple complex diseases / / 17554300 rs924237 chr4 28261658 G A 9.50E-04 Multiple complex diseases / / 17554300 rs1553076 chr4 28280508 T A 2.21E-04 Multiple complex diseases / / 17554300 rs73113868 chr4 28288197 G C 6.89E-14 Metabolite levels / / 22286219 rs1603637 chr4 28295658 A G 6.70E-04 Smoking initiation / / 24665060 rs11737313 chr4 28296275 A G 9.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs4257642 chr4 28305626 T C 6.98E-04 Multiple complex diseases / / 17554300 rs4267724 chr4 28315343 G T 6.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs13116091 chr4 28316513 G C 6.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs10025742 chr4 28324928 T C 2.79E-05 Osteosarcoma / / 23727862 rs11722487 chr4 28328940 T C 7.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs12507595 chr4 28342172 T C 7.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs17682996 chr4 28343234 A G 6.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs1874693 chr4 28343903 C T 4.13E-05 Sarcoidosis / / 19165924 rs2036184 chr4 28345775 T C 5.16E-05 Serum metabolites / / 19043545 rs2036184 chr4 28345775 T C 6.47E-05 Sarcoidosis / / 19165924 rs11735854 chr4 28351016 T C 2.10E-04 Multiple complex diseases / / 17554300 rs11735854 chr4 28351016 T C 1.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs10517141 chr4 28352417 C T 1.42E-04 Sarcoidosis / / 19165924 rs13111729 chr4 28356523 A G 9.95E-05 Suicide attempts in bipolar disorder / / 21423239 rs13139194 chr4 28359687 A C 1.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs12512541 chr4 28360964 C A 1.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs12498566 chr4 28362546 C G 1.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs13114507 chr4 28365419 T A 1.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs13145217 chr4 28366169 A G 1.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs557840 chr4 28371985 C T 5.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs664330 chr4 28378795 C A 1.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs1397439 chr4 28380212 T C 1.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs1995910 chr4 28385835 G A 1.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs1024120 chr4 28400119 C T 3.92E-05 Multiple complex diseases / / 17554300 rs986866 chr4 28400914 T C 5.44E-05 Multiple complex diseases / / 17554300 rs1510699 chr4 28401030 G A 5.91E-04 Multiple complex diseases / / 17554300 rs11935060 chr4 28401533 G A 2.56E-04 Multiple complex diseases / / 17554300 rs2309787 chr4 28407135 T G 4.48E-04 Multiple complex diseases / / 17554300 rs10000497 chr4 28417836 A G 5.90E-06 Multiple complex diseases / / 17554300 rs1961016 chr4 28425846 A G 5.25E-04 Multiple complex diseases / / 17554300 rs2250259 chr4 28433243 A G 3.37E-04 Multiple complex diseases / / 17554300 rs292069 chr4 28454606 C T 1.04E-04 Multiple complex diseases / / 17554300 rs292071 chr4 28456089 T C 2.84E-05 Multiple complex diseases / / 17554300 rs292084 chr4 28489008 T C 7.52E-05 Multiple complex diseases / / 17554300 rs16880706 chr4 28489837 T C 0.000000354 CD8+ T cell IFN-gamma response to smallpox vaccine / / 22661280 rs292062 chr4 28499782 A G 9.88E-05 Multiple complex diseases / / 17554300 rs6448587 chr4 28561990 A C 0.000274518 Hypertension (early onset hypertension) / / 22479346 rs1877710 chr4 28572787 A G 1.60E-04 Multiple complex diseases / / 17554300 rs17644064 chr4 28608116 G A 1.76E-05 Cognitive test performance / / 20125193 rs9996729 chr4 28660856 T C 6.80E-05 Substance dependence / / 21818250 rs9999712 chr4 28676594 G A 4.69E-04 Schizophrenia / / 19197363 rs7663065 chr4 28687406 A G 5.43E-05 Pulmonary function in asthmatics / / 23541324 rs2309883 chr4 28732481 C T 3.90E-05 Bone mineral density (BMD),in women / / 20164292 rs12505106 chr4 28810361 C A 7.99E-05 Fibrinogen / / pha003068 rs6844183 chr4 28821006 A G 9.03E-06 Stroke (ischemic) / / 21957438 rs12503203 chr4 28824300 T A 9.33E-06 Stroke (ischemic) / / 21957438 rs4479690 chr4 28827874 T C 5.02E-06 Stroke (ischemic) / / 21957438 rs4461513 chr4 28856499 A C 4.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs9992199 chr4 28860599 T A 7.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs11736200 chr4 28861789 C T 4.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs10008384 chr4 28861911 A G 5.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs7698028 chr4 28863159 A G 4.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs7682215 chr4 28863746 T C 4.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs7439579 chr4 28864153 T C 4.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs3924142 chr4 28864709 C T 4.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs1402499 chr4 28928041 C T 7.30E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1915501 chr4 28936363 A G 1.10E-04 Longevity and age-related phenotypes / / 17903295 rs868938 chr4 28937580 C T 2.99E-04 Alzheimer's disease / / 22005930 rs6448611 chr4 28947110 C G 6.86E-04 Alzheimer's disease / / 17998437 rs1521123 chr4 28948730 A G 7.44E-04 Alzheimer's disease / / 22005930 rs17705257 chr4 28955155 C T 6.43E-04 Rheumatoid arthritis / / 21452313 rs7674882 chr4 28956150 T C 8.35E-04 Rheumatoid arthritis / / 21452313 rs6815902 chr4 28975242 C T 7.41E-05 Rheumatoid arthritis / / 21452313 rs7664803 chr4 28983128 A G 3.24E-04 Rheumatoid arthritis / / 21452313 rs6448625 chr4 29068726 G C 3.20E-06 Urinary metabolites / / 21572414 rs5021773 chr4 29102022 A G 1.80E-06 Urinary metabolites / / 21572414 rs10014019 chr4 29112064 C T 1.60E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12498151 chr4 29124082 G A 1.80E-05 Urinary metabolites / / 21572414 rs10002658 chr4 29124634 T A 2.40E-05 Urinary metabolites / / 21572414 rs10017663 chr4 29124936 T A 2.00E-05 Urinary metabolites / / 21572414 rs10939243 chr4 29125649 G A 1.40E-05 Urinary metabolites / / 21572414 rs12639959 chr4 29139929 G A 1.40E-05 Urinary metabolites / / 21572414 rs1507446 chr4 29156036 A G 5.24E-05 Body Mass Index / / pha003015 rs9997197 chr4 29167992 T C 4.74E-05 HDL cholesterol / / pha003074 rs1507441 chr4 29179713 A G 2.18E-05 HDL cholesterol / / pha003074 rs2019100 chr4 29224491 C T 6.90E-06 Urinary metabolites / / 21572414 rs17656514 chr4 29225668 A G 7.40E-06 Urinary metabolites / / 21572414 rs12646874 chr4 29228847 C T 7.57E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1436073 chr4 29240047 T C 5.30E-06 Urinary metabolites / / 21572414 rs6824303 chr4 29241920 C T 7.26E-04 Multiple complex diseases / / 17554300 rs12510390 chr4 29274568 A G 8.71E-05 Body Mass Index / / pha003015 rs7696776 chr4 29294481 C A 9.47E-04 Multiple complex diseases / / 17554300 rs1369801 chr4 29296845 C T 1.20E-04 Parkinson's disease / / 17052657 rs1436066 chr4 29303808 A C 2.75E-04 Parkinson's disease / / 17052657 rs10517157 chr4 29304758 C T 9.24E-05 Multiple complex diseases / / 17554300 rs1821687 chr4 29309079 C T 8.49E-05 Post-operative nausea and vomiting / / 21694509 rs1369793 chr4 29310803 A G 8.08E-04 Parkinson's disease / / 17052657 rs987157 chr4 29317543 G A 5.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs7695655 chr4 29331793 T C 9.25E-04 Multiple complex diseases / / 17554300 rs7677962 chr4 29332786 G A 6.22E-04 Multiple complex diseases / / 17554300 rs1436058 chr4 29339512 T C 8.65E-04 Bipolar disorder,schizoaffective / / 19567891 rs1898170 chr4 29351338 T A 6.03E-04 Bipolar disorder,schizoaffective / / 19567891 rs965253 chr4 29441493 C A 6.00E-04 Multiple complex diseases / / 17554300 rs41364047 chr4 29456632 G A 2.15E-04 Multiple complex diseases / / 17554300 rs1510791 chr4 29472661 T C 1.90E-05 Urinary metabolites / / 21572414 rs6836397 chr4 29481312 G T 7.50E-06 Urinary metabolites / / 21572414 rs10517165 chr4 29492473 G C 2.10E-05 Urinary metabolites / / 21572414 rs16881881 chr4 29505471 C T 1.20E-05 Urinary metabolites / / 21572414 rs10517168 chr4 29508477 C A 3.50E-06 Urinary metabolites / / 21572414 rs9994852 chr4 29521390 C T 1.80E-05 Urinary metabolites / / 21572414 rs1441689 chr4 29546298 A G 2.10E-05 Urinary metabolites / / 21572414 rs1441688 chr4 29546657 A C 5.97E-05 HDL cholesterol / / pha003074 rs1348188 chr4 29574931 T C 4.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs10517170 chr4 29580814 T G 4.70E-04 Multiple complex diseases / / 17554300 rs9992654 chr4 29586882 T C 8.16E-04 Multiple complex diseases / / 17554300 rs1441670 chr4 29590146 A G 4.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs7688959 chr4 29605776 C T 8.00E-04 Multiple complex diseases / / 17554300 rs10002254 chr4 29626865 A G 5.05E-04 Alzheimer's disease / / 17998437 rs6448666 chr4 29697040 A G 2.26E-04 Type 2 diabetes / / 17463246 rs12641755 chr4 29726094 A G 2.98E-04 Type 2 diabetes / / 17463246 rs10010407 chr4 29763473 T C 7.02E-05 Tardive dyskinesia / / 20939080 rs12645431 chr4 29768874 T C 2.00E-04 Information processing speed / / 21130836 rs11728264 chr4 29777582 C T 9.37E-06 Tardive dyskinesia / / 20939080 rs2047870 chr4 29777723 T C 2.03E-05 Body Mass Index / / pha003019 rs2047870 chr4 29777723 T C 5.46E-05 Body Mass Index / / pha003022 rs2047870 chr4 29777723 T C 1.34E-05 Weight / / pha003026 rs76355427 chr4 29791660 C A 0.00003037 Sarcoidosis / / 22952805 rs11722527 chr4 29804231 A G 8.62E-04 Type 2 diabetes / / 17463246 rs150748260 chr4 29823307 T G 0.00001702 Sarcoidosis / / 22952805 rs74436930 chr4 29826262 T C 0.00001721 Sarcoidosis / / 22952805 rs7442317 chr4 29903052 G A 4.00E-06 Attention deficit hyperactivity disorder motor coordination / / 21473668 rs12499826 chr4 30063389 C T 8.26E-06 Obesity-related traits / / 23251661 rs6818288 chr4 30068213 A C 6.00E-06 Obesity-related traits / / 23251661 rs11930738 chr4 30167980 C T 1.83E-04 Multiple complex diseases / / 17554300 rs7691359 chr4 30169493 T G 2.56E-05 Schizophrenia / / 19571811 rs7667202 chr4 30224009 A G 9.70E-06 Urinary metabolites / / 21572414 rs114341512 chr4 30235586 C T 0.00003011 Sarcoidosis / / 22952805 rs16883115 chr4 30235716 G A 0.00009118 Sarcoidosis / / 22952805 rs79821018 chr4 30236428 T C 0.00003011 Sarcoidosis / / 22952805 rs140402966 chr4 30242550 G T 0.00005269 Sarcoidosis / / 22952805 rs74856875 chr4 30246328 A G 0.00009092 Sarcoidosis / / 22952805 rs60418814 chr4 30246701 G C 0.00009181 Sarcoidosis / / 22952805 rs73809669 chr4 30261750 G A 0.0000727 Sarcoidosis / / 22952805 rs12646352 chr4 30263272 A T 7.50E-06 Urinary metabolites / / 21572414 rs16883166 chr4 30265834 T C 0.00007647 Sarcoidosis / / 22952805 rs16883243 chr4 30290391 C A 9.17E-04 Stroke / / pha002886 rs16883273 chr4 30310687 G A 1.66E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs1435785 chr4 30323321 G A 2.53E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs12510958 chr4 30348364 C T 9.49E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6849592 chr4 30349081 G A 1.47E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs7686347 chr4 30365749 C T 2.62E-04 Acute lung injury / / 22295056 rs7660316 chr4 30369336 A C 2.62E-04 Acute lung injury / / 22295056 rs7698788 chr4 30371605 T C 3.10E-04 Acute lung injury / / 22295056 rs12640977 chr4 30382013 G A 9.94E-04 Acute lung injury / / 22295056 rs2060515 chr4 30385756 C A 5.37E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16883507 chr4 30432141 C A,G,T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11939492 chr4 30435505 T C 3.75E-05 Serum metabolites / / 19043545 rs4260494 chr4 30435544 C G 5.10E-05 Serum metabolites / / 19043545 rs10008824 chr4 30437073 G A 1.45E-04 Acute lung injury / / 22295056 rs9995114 chr4 30443522 T G 1.45E-04 Acute lung injury / / 22295056 rs16867935 chr4 30444046 A G 1.45E-04 Acute lung injury / / 22295056 rs966770 chr4 30451158 T C 7.75E-04 Acute lung injury / / 22295056 rs17763208 chr4 30455150 A G 5.64E-04 Type 2 diabetes / / 17463246 rs1896180 chr4 30467623 C T 4.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs6856768 chr4 30468166 G A 1.60E-05 Urinary metabolites / / 21572414 rs6856768 chr4 30468166 G A 5.00E-06 Alzheimer's disease / / 22832961 rs7659123 chr4 30469494 G T 4.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs2175560 chr4 30473086 C A 4.73E-06 Alzheimer's disease / / 22832961 rs1980054 chr4 30473099 A C 4.94E-06 Alzheimer's disease / / 22832961 rs16867949 chr4 30479662 G C 5.97E-06 Alzheimer's disease / / 22832961 rs4082841 chr4 30484028 T C 6.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs1121412 chr4 30508014 T C 3.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs1818442 chr4 30533811 T G 8.39E-04 Multiple complex diseases / / 17554300 rs1818442 chr4 30533811 T G 3.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs11727470 chr4 30544014 A G 9.68E-06 Alcohol dependence / / 20202923 rs7684435 chr4 30560838 G C 6.23E-04 Type 2 diabetes / / 17463246 rs16883786 chr4 30574574 A G 8.20E-05 Body mass index / / 24827717 rs1906109 chr4 30599062 C T 7.77E-04 Multiple complex diseases / / 17554300 rs16883875 chr4 30623248 A G 8.22E-04 Acute lung injury / / 22295056 rs10939309 chr4 30629103 G C 9.03E-04 Acute lung injury / / 22295056 rs10939310 chr4 30629161 A G 8.97E-04 Acute lung injury / / 22295056 rs767478 chr4 30630382 G A 9.28E-06 Multiple complex diseases / / 17554300 rs767478 chr4 30630382 G A 3.80E-04 Longevity / / 22279548 rs4608753 chr4 30641336 T C 5.80E-04 Body mass index / / 23669352 rs13137924 chr4 30643978 C T 9.56E-04 Multiple complex diseases / / 17554300 rs6448715 chr4 30646834 G C 5.61E-08 Multiple sclerosis / / 17660530 rs13133246 chr4 30651890 T C 5.30E-04 Body mass index / / 23669352 rs6817896 chr4 30670274 G C 7.56E-04 Coronary Artery Disease / / 17634449 rs1486774 chr4 30678394 C T 7.11E-04 Coronary Artery Disease / / 17634449 rs721760 chr4 30678767 A G 3.36E-04 Coronary Artery Disease / / 17634449 rs1486770 chr4 30681665 G C 6.31E-04 Coronary Artery Disease / / 17634449 rs6827656 chr4 30683930 A G 6.48E-04 Coronary Artery Disease / / 17634449 rs7667490 chr4 30701480 A C 3.87E-04 Coronary Artery Disease / / 17634449 rs10461085 chr4 30717744 G A 2.04E-05 Personality dimensions / / 18957941 rs9291547 chr4 30749654 A G 4.58E-04 Coronary heart disease PCDH7 intron 21971053 rs10517215 chr4 30774083 C A 2.45E-05 Lung cancer PCDH7 intron 19414679 rs10517215 chr4 30774083 C A 1.88E-05 Esophageal cancer (squamous cell) PCDH7 intron 22960999 rs1374653 chr4 30789609 G A 6.71E-05 Lung cancer PCDH7 intron 19414679 rs4619848 chr4 30827805 C T 1.89E-04 Schizophrenia PCDH7 intron 21747397 rs4619848 chr4 30827805 C T 0.0000425 Coronary artery calcification PCDH7 intron 23394302 rs1447372 chr4 30834962 T C 1.05E-05 Multiple sclerosis PCDH7 intron 17660530 rs111567587 chr4 30840803 C A 4.68E-05 Intracerebral hemorrhage PCDH7 intron 24656865 rs4422383 chr4 30872098 A C 4.11E-05 Bone mineral density PCDH7 intron 19181680 rs4359861 chr4 30905729 T G 1.94E-05 Multiple complex diseases PCDH7 intron 17554300 rs11735048 chr4 30922078 A C 1.72E-05 Bone mineral density PCDH7 intron 19181680 rs4692493 chr4 30949606 A T 6.39E-05 Serum metabolites PCDH7 intron 19043545 rs4490422 chr4 30954027 A G 3.66E-05 Serum metabolites PCDH7 intron 19043545 rs7659873 chr4 30970763 A G 8.92E-05 Serum metabolites PCDH7 intron 19043545 rs10027212 chr4 30976208 T G 5.70E-04 Myopia (pathological) PCDH7 intron 21095009 rs10805302 chr4 30985128 A G 2.46E-04 Multiple complex diseases PCDH7 intron 17554300 rs10003973 chr4 31032608 C T 6.29E-04 Myopia (pathological) PCDH7 intron 21095009 rs7678773 chr4 31044237 C T 2.70E-06 Orofacial clefts PCDH7 intron 19270707 rs7678773 chr4 31044237 C T 6.19E-05 Orofacial clefts PCDH7 intron 20023658 rs7678773 chr4 31044237 C T 4.34E-05 Waist Circumference PCDH7 intron pha003025 rs7678773 chr4 31044237 C T 9.58E-05 Waist-Hip Ratio PCDH7 intron pha003028 rs4615136 chr4 31055027 A G 5.22E-06 Orofacial clefts PCDH7 intron 19270707 rs4615136 chr4 31055027 A G 4.33E-05 Waist Circumference PCDH7 intron pha003025 rs4615136 chr4 31055027 A G 9.50E-05 Waist-Hip Ratio PCDH7 intron pha003028 rs4352437 chr4 31066670 C T 7.86E-05 Orofacial clefts PCDH7 intron 19270707 rs4352437 chr4 31066670 C T 2.41E-05 Waist Circumference PCDH7 intron pha003025 rs115278829 chr4 31093239 A G 2.21E-06 Intracerebral hemorrhage PCDH7 intron 24656865 rs11933239 chr4 31095861 C T 2.33E-06 Intracerebral hemorrhage PCDH7 intron 24656865 rs16884410 chr4 31142938 C T 0.0000407 Panic disorder PCDH7 intron 23149450 rs16884410 chr4 31142938 C T 4.07E-05 Serum tamsulosin hydrochloride concentration PCDH7 intron 23151678 rs11567 chr4 31148287 C T 0.00004 Panic disorder PCDH7 UTR-3 23149450 rs11567 chr4 31148287 C T 4.00E-05 Serum tamsulosin hydrochloride concentration PCDH7 UTR-3 23151678 rs10517224 chr4 31154607 T C 0.0000433 Panic disorder / / 23149450 rs10517224 chr4 31154607 T C 4.33E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs10517221 chr4 31156148 T C 0.0000447 Panic disorder / / 23149450 rs10517221 chr4 31156148 T C 4.47E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs74879986 chr4 31156178 G A 6.00E-06 Bulimia nervosa / / 23568457 rs1353854 chr4 31158565 T A,C,G 0.0000485 Panic disorder / / 23149450 rs1353854 chr4 31158565 T A,C,G 4.85E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs16884487 chr4 31158655 G A,C 0.0000275 Panic disorder / / 23149450 rs16884487 chr4 31158655 G A,C 2.75E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs9997440 chr4 31208611 A T 2.07E-04 Multiple complex diseases / / 17554300 rs9997440 chr4 31208611 A T 3.83E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs11937481 chr4 31211978 A G 2.86E-05 Blood Pressure / / pha003044 rs1499466 chr4 31217251 C T 4.02E-04 Alzheimer's disease (late onset) / / 21379329 rs7662351 chr4 31222833 T C 7.45E-05 Blood Pressure / / pha003044 rs12651354 chr4 31228310 G A 8.99E-04 HIV-1 viral setpoint / / 17641165 rs4303942 chr4 31319406 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10517227 chr4 31335371 T C 9.37E-05 Leukocyte Counts / / pha003091 rs1426991 chr4 31350033 T C 4.06E-04 Alzheimer's disease (late onset) / / 21379329 rs4692508 chr4 31354090 A C 6.36E-06 Asthma (childhood onset) / / 23829686 rs2081665 chr4 31360789 C T 6.27E-05 Prion diseases / / 22210626 rs10017667 chr4 31365792 C A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6854032 chr4 31367210 T C 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs16884949 chr4 31368134 G A 8.60E-06 Urinary metabolites / / 21572414 rs10000543 chr4 31370788 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12331939 chr4 31374771 G A 1.46E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6448771 chr4 31397618 G A 5.00E-09 Lipid traits / / 22028671 rs169654 chr4 31416268 C T 5.33E-04 Type 2 diabetes / / 17463246 rs412253 chr4 31442750 T A 6.55E-05 Cardiovascular disease / / 17903304 rs746977 chr4 31476327 G A 3.47E-05 Multiple complex diseases / / 17554300 rs1379125 chr4 31549171 T C 7.44E-04 Multiple complex diseases / / 17554300 rs1456759 chr4 31549421 C T 3.73E-04 Multiple complex diseases / / 17554300 rs2061256 chr4 31589870 A G 7.93E-04 Intracranial aneurysm / / 20613766 rs7663471 chr4 31649489 G A 7.78E-04 Coronary Artery Disease / / 17634449 rs11944702 chr4 31660739 T C 4.52E-04 Alcohol dependence / / 24277619 rs980038 chr4 31669915 T G 8.77E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10489008 chr4 31718284 A C 4.30E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs2110503 chr4 31720459 C A 3.53E-05 Body Mass Index / / pha003009 rs11730273 chr4 31760859 G T 6.88E-06 Meningococcal disease / / 20694013 rs10489006 chr4 31768718 T A 3.60E-05 Longevity and age-related phenotypes / / 17903295 rs10016814 chr4 31774053 A G 3.73E-05 HIV-1 viral setpoint / / 21490045 rs887918 chr4 31779135 A G 5.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs887918 chr4 31779135 A G 8.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10029539 chr4 31791952 T C 3.10E-04 Alcohol dependence / / 20201924 rs6811255 chr4 31793650 G T 4.60E-04 Alcohol dependence / / 20201924 rs1523142 chr4 31861263 C T 1.36E-05 Bipolar disorder / / 19259986 rs1523145 chr4 31863889 T C 8.40E-04 Alcohol dependence / / 20201924 rs10009732 chr4 31866101 A C 4.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs17799612 chr4 31937464 G A 2.55E-04 Stroke / / pha002887 rs4446365 chr4 31944649 C T 7.03E-04 Stroke / / pha002887 rs7683244 chr4 31966758 G T 3.45E-04 Alcohol dependence / / 20201924 rs6554006 chr4 32125658 G A 7.60E-05 Celiac disease / / 17558408 rs6554007 chr4 32125671 T G 2.70E-05 Celiac disease / / 17558408 rs4536982 chr4 32140046 G A 3.30E-05 Celiac disease / / 17558408 rs17365051 chr4 32201287 C A,G,T 2.83E-04 Coronary heart disease / / 21606135 rs17299248 chr4 32201406 A G 5.42E-04 Coronary heart disease / / 21606135 rs17080916 chr4 32201563 T C 7.81E-04 Multiple complex diseases / / 17554300 rs6827459 chr4 32207990 G C 1.58E-04 Smoking initiation / / 24665060 rs7673436 chr4 32219149 G T 3.86E-04 Coronary heart disease / / 21606135 rs902658 chr4 32221085 C T 5.95E-04 Coronary heart disease / / 21606135 rs902660 chr4 32221194 A C 7.51E-04 Coronary heart disease / / 21606135 rs2404759 chr4 32221272 C A 6.91E-04 Coronary heart disease / / 21606135 rs874498 chr4 32222002 C T 6.31E-04 Coronary heart disease / / 21606135 rs2130904 chr4 32231031 A G 6.41E-04 Common variable immunodeficiency / / 21497890 rs766436 chr4 32259822 T C 3.62E-05 Diabetes Mellitus / / pha003060 rs12647982 chr4 32318264 C T 9.41E-05 Waist-Hip Ratio / / pha003013 rs12647982 chr4 32318264 C T 4.35E-05 Waist-Hip Ratio / / pha003028 rs9991360 chr4 32331208 T C 6.94E-04 Multiple complex diseases / / 17554300 rs10517249 chr4 32374088 T C 7.33E-05 Cleft lip / / 20436469 rs10049853 chr4 32408020 A C 5.75E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10027083 chr4 32408425 G A 5.69E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9685804 chr4 32434561 G A 5.85E-04 Alzheimer's disease / / 17998437 rs4862926 chr4 32436226 A T 6.06E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11133215 chr4 32437731 A C 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4862932 chr4 32477273 T C 7.40E-05 Alcoholism (heaviness of drinking) / / 21529783 rs4862932 chr4 32477273 T C 1.72E-05 Coronary heart disease / / pha003031 rs17081601 chr4 32586697 A T 4.45E-05 Sudden cardiac arrest / / 21658281 rs11940562 chr4 32592949 C T 1.16E-04 Celiac disease / / 23936387 rs1596722 chr4 32606917 G C 3.10E-06 Urinary metabolites / / 21572414 rs1348664 chr4 32609134 C A 3.04E-05 Post-operative nausea and vomiting / / 21694509 rs7672344 chr4 32623093 A C 6.68E-05 Bipolar disorder / / 20451256 rs6554043 chr4 32714930 G A 8.74E-04 Alzheimer's disease / / 22005930 rs6843282 chr4 32789919 C G 6.62E-04 Multiple complex diseases / / 17554300 rs7663866 chr4 32801473 G A 5.08E-04 Multiple complex diseases / / 17554300 rs7659833 chr4 32879077 A G 8.69E-04 Type 2 diabetes / / 17463246 rs6531531 chr4 32896641 G A 2.63E-16 Multiple complex diseases / / 17554300 rs9784514 chr4 32910385 G A 2.44E-05 Height / / 22021425 rs10033556 chr4 32962030 G A 7.46E-05 Cognitive decline / / 23732972 rs1448284 chr4 33079655 A G 1.32E-06 Temporal lobe volumes / / 20197096 rs10517258 chr4 33152142 T C 1.12E-04 Multiple complex diseases / / 17554300 rs6846113 chr4 33194457 G A 1.43E-05 Common variable immunodeficiency / / 21497890 rs6839692 chr4 33201032 G A 9.34E-06 Alzheimer's disease (age of onset) / / 22005931 rs1373053 chr4 33203015 C T 8.37E-06 Alzheimer's disease (age of onset) / / 22005931 rs10517270 chr4 33203140 G A 4.00E-06 Alzheimer's disease (age of onset) / / 22005931 rs10517272 chr4 33203273 G T 6.21E-06 Alzheimer's disease (age of onset) / / 22005931 rs10517273 chr4 33203342 C T 1.87E-05 Alzheimer's disease (age of onset) / / 22005931 rs16988710 chr4 33203813 G A 1.89E-05 Alzheimer's disease (age of onset) / / 22005931 rs1550634 chr4 33204413 A T 1.88E-05 Alzheimer's disease (age of onset) / / 22005931 rs983298 chr4 33204733 C A 1.94E-05 Alzheimer's disease (age of onset) / / 22005931 rs7680581 chr4 33206192 G A 1.96E-05 Alzheimer's disease (age of onset) / / 22005931 rs7657642 chr4 33206499 C T 1.95E-05 Alzheimer's disease (age of onset) / / 22005931 rs7672887 chr4 33206597 T G 2.11E-05 Alzheimer's disease (age of onset) / / 22005931 rs6830412 chr4 33207405 A G 2.20E-05 Alzheimer's disease (age of onset) / / 22005931 rs6850641 chr4 33207605 G A 2.23E-05 Alzheimer's disease (age of onset) / / 22005931 rs6837482 chr4 33207931 T C 2.35E-04 Multiple complex diseases / / 17554300 rs6837482 chr4 33207931 T C 2.32E-05 Alzheimer's disease (age of onset) / / 22005931 rs16988715 chr4 33208792 C G 2.32E-05 Alzheimer's disease (age of onset) / / 22005931 rs16988717 chr4 33209890 C A 2.37E-05 Alzheimer's disease (age of onset) / / 22005931 rs10028228 chr4 33212652 C T 4.55E-04 Multiple complex diseases / / 17554300 rs10028228 chr4 33212652 C T 2.46E-05 Alzheimer's disease (age of onset) / / 22005931 rs2879039 chr4 33214008 A G 2.73E-05 Alzheimer's disease (age of onset) / / 22005931 rs7658640 chr4 33217330 T A 2.98E-05 Alzheimer's disease (age of onset) / / 22005931 rs16988727 chr4 33217373 T C 3.12E-05 Alzheimer's disease (age of onset) / / 22005931 rs7663398 chr4 33217425 T C 4.61E-05 Alzheimer's disease (age of onset) / / 22005931 rs7663590 chr4 33217494 T C 5.83E-05 Alzheimer's disease (age of onset) / / 22005931 rs7695326 chr4 33217636 C A 6.01E-05 Alzheimer's disease (age of onset) / / 22005931 rs16988734 chr4 33218543 T C 5.55E-05 Alzheimer's disease (age of onset) / / 22005931 rs6841378 chr4 33220693 T G 5.66E-05 Alzheimer's disease (age of onset) / / 22005931 rs2687426 chr4 33225938 C T 0.0000593 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2687425 chr4 33226935 G A 0.0000599 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2586004 chr4 33229277 C T 0.0000499 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2687468 chr4 33229896 T G 0.0000528 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2687469 chr4 33229912 C A 0.0000538 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2586005 chr4 33229984 G A 0.0000625 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2586007 chr4 33232593 G A 0.0000694 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs748907 chr4 33234235 C T 0.000083 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2586009 chr4 33235506 C T 0.0000868 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2687381 chr4 33283761 T C 5.83E-05 Aging (time to event) / / 21782286 rs1443207 chr4 33305495 A G 6.44E-05 Hemoglobin / / pha003096 rs2687410 chr4 33308646 A G 3.98E-04 Acute lung injury / / 22295056 rs2099909 chr4 33317374 A G 2.32E-04 Multiple complex diseases / / 17554300 rs2083785 chr4 33334177 C T 1.47E-04 Multiple complex diseases / / 17554300 rs2585966 chr4 33345798 T C 8.31E-04 Type 2 diabetes / / 17463246 rs12504362 chr4 33349395 A C 1.20E-04 Multiple complex diseases / / 17554300 rs6846367 chr4 33349863 G A 3.55E-04 Multiple complex diseases / / 17554300 rs11722181 chr4 33354946 A C 9.53E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs10001282 chr4 33359261 C G,T 9.24E-04 Multiple complex diseases / / 17554300 rs114366490 chr4 33361664 T G 0.0000556 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs141426898 chr4 33372751 G A 0.0000406 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6827883 chr4 33444407 C T 2.26E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs6827883 chr4 33444407 C T 8.13E-06 Diabetes Mellitus / / pha003059 rs16988983 chr4 33483450 G A 9.12E-04 Type 2 diabetes / / 17463246 rs7665332 chr4 33487061 G A 3.09E-04 Type 2 diabetes / / 17463246 rs7693044 chr4 33487232 A T 7.48E-04 Type 2 diabetes / / 17463246 rs10517285 chr4 33574086 C G 8.68E-04 Type 2 diabetes / / 17463246 rs139210071 chr4 33624609 T C 0.0000926 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10517287 chr4 33624702 G T 2.00E-07 Response to antidepressant treatment / / 22041458 rs73821401 chr4 33634163 A G 0.0000913 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs16989064 chr4 33639398 T C 2.70E-04 Multiple complex diseases / / 17554300 rs719776 chr4 33686660 G C 5.02E-04 Multiple complex diseases / / 17554300 rs7661047 chr4 33689708 A G 9.22E-05 Cytomegalovirus antibody response / / 21993531 rs7680059 chr4 33689724 G A 8.99E-05 Cytomegalovirus antibody response / / 21993531 rs10026556 chr4 33691930 G A 8.88E-05 Cytomegalovirus antibody response / / 21993531 rs1902083 chr4 33695359 G T 8.87E-05 Cytomegalovirus antibody response / / 21993531 rs1378039 chr4 33698200 G A 8.87E-05 Cytomegalovirus antibody response / / 21993531 rs6847997 chr4 33700983 C A 5.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6847997 chr4 33700983 C A 8.86E-05 Cytomegalovirus antibody response / / 21993531 rs2166111 chr4 33703680 T A 8.67E-05 Cytomegalovirus antibody response / / 21993531 rs10021740 chr4 33709675 G A 8.57E-05 Cytomegalovirus antibody response / / 21993531 rs10034901 chr4 33709759 A T 8.50E-05 Cytomegalovirus antibody response / / 21993531 rs10030710 chr4 33709926 C A 8.43E-05 Cytomegalovirus antibody response / / 21993531 rs10025016 chr4 33710817 G T 8.38E-05 Cytomegalovirus antibody response / / 21993531 rs9993419 chr4 33710829 A T 8.35E-05 Cytomegalovirus antibody response / / 21993531 rs11945628 chr4 33714566 C T 8.27E-05 Cytomegalovirus antibody response / / 21993531 rs9995797 chr4 33716311 T A 8.23E-05 Cytomegalovirus antibody response / / 21993531 rs1444377 chr4 33717820 T C 8.18E-05 Cytomegalovirus antibody response / / 21993531 rs16989190 chr4 33718892 G C 8.13E-05 Cytomegalovirus antibody response / / 21993531 rs13139622 chr4 33722764 G C 8.09E-05 Cytomegalovirus antibody response / / 21993531 rs12642628 chr4 33724262 A T 8.04E-05 Cytomegalovirus antibody response / / 21993531 rs2120677 chr4 33725405 C T 7.98E-05 Cytomegalovirus antibody response / / 21993531 rs2166108 chr4 33725631 A G 7.67E-05 Cytomegalovirus antibody response / / 21993531 rs7665615 chr4 33725713 A G 7.61E-05 Cytomegalovirus antibody response / / 21993531 rs6844110 chr4 33729231 A G 9.36E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs6844110 chr4 33729231 A G 7.47E-05 Cytomegalovirus antibody response / / 21993531 rs7691996 chr4 33729776 A G 9.01E-04 Multiple complex diseases / / 17554300 rs7691996 chr4 33729776 A G 7.43E-05 Cytomegalovirus antibody response / / 21993531 rs7664751 chr4 33729933 G A 7.36E-04 Multiple complex diseases / / 17554300 rs7664751 chr4 33729933 G A 7.29E-05 Cytomegalovirus antibody response / / 21993531 rs1813425 chr4 33734008 G T 7.15E-05 Cytomegalovirus antibody response / / 21993531 rs7681658 chr4 33739488 T G 7.12E-05 Cytomegalovirus antibody response / / 21993531 rs4395486 chr4 33740853 C G 7.03E-05 Cytomegalovirus antibody response / / 21993531 rs10011550 chr4 33742001 G A 6.86E-05 Cytomegalovirus antibody response / / 21993531 rs10050065 chr4 33742165 C T 6.78E-05 Cytomegalovirus antibody response / / 21993531 rs13111438 chr4 33745441 T C 6.75E-05 Cytomegalovirus antibody response / / 21993531 rs6858079 chr4 33745577 G C 6.73E-05 Cytomegalovirus antibody response / / 21993531 rs2166110 chr4 33745907 G A 6.70E-05 Cytomegalovirus antibody response / / 21993531 rs13113238 chr4 33746160 T C 7.57E-05 Cytomegalovirus antibody response / / 21993531 rs7694226 chr4 33747192 T C 6.60E-05 Cytomegalovirus antibody response / / 21993531 rs7693464 chr4 33747408 A G 3.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7693464 chr4 33747408 A G 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs7684329 chr4 33747424 C T 3.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7684329 chr4 33747424 C T 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs1373494 chr4 33748526 A C 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs2338361 chr4 33750171 T G 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs7672940 chr4 33752090 G A 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs7691242 chr4 33752150 C T 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs7659816 chr4 33752170 T A 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs7691401 chr4 33752222 C G 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs1822683 chr4 33752968 C T 3.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1822683 chr4 33752968 C T 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs16989207 chr4 33753406 A G 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs1348541 chr4 33753547 A G 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs7676477 chr4 33756525 C T 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs9306981 chr4 33762750 C T 6.31E-05 Cytomegalovirus antibody response / / 21993531 rs1373493 chr4 33766164 C T 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs12643668 chr4 33766824 C G 9.83E-04 Multiple complex diseases / / 17554300 rs12643668 chr4 33766824 C G 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs12645598 chr4 33766955 T C 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs12648131 chr4 33769628 T C 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs6816408 chr4 33771909 C T 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs3863828 chr4 33774322 G A 3.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3863828 chr4 33774322 G A 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs10517294 chr4 33780462 T C 6.59E-05 Cytomegalovirus antibody response / / 21993531 rs10024206 chr4 33782293 A T 2.43E-05 Cytomegalovirus antibody response / / 21993531 rs16989244 chr4 33784564 G A 2.58E-05 Cytomegalovirus antibody response / / 21993531 rs1822681 chr4 33790246 G A 6.96E-05 Cytomegalovirus antibody response / / 21993531 rs6832462 chr4 33799202 C T 6.96E-05 Cytomegalovirus antibody response / / 21993531 rs10022215 chr4 33800585 A C 6.95E-05 Cytomegalovirus antibody response / / 21993531 rs6825189 chr4 33801719 A C 6.95E-05 Cytomegalovirus antibody response / / 21993531 rs10015299 chr4 33803938 A G 6.95E-05 Cytomegalovirus antibody response / / 21993531 rs12645118 chr4 33804015 C T 6.95E-05 Cytomegalovirus antibody response / / 21993531 rs10024171 chr4 33806368 A T 6.96E-05 Cytomegalovirus antibody response / / 21993531 rs13104973 chr4 33810391 A C 6.96E-05 Cytomegalovirus antibody response / / 21993531 rs10010838 chr4 33812235 G A 6.96E-05 Cytomegalovirus antibody response / / 21993531 rs6835901 chr4 33814838 T C 6.96E-05 Cytomegalovirus antibody response / / 21993531 rs7689523 chr4 33821740 T C 6.95E-05 Cytomegalovirus antibody response / / 21993531 rs1838405 chr4 33825143 C T 5.58E-04 Multiple complex diseases / / 17554300 rs1838405 chr4 33825143 C T 6.91E-05 Cytomegalovirus antibody response / / 21993531 rs13143780 chr4 33825499 T G 6.91E-05 Cytomegalovirus antibody response / / 21993531 rs13112261 chr4 33833593 T A 2.62E-05 Cytomegalovirus antibody response / / 21993531 rs2166109 chr4 33840198 A G 6.91E-05 Cytomegalovirus antibody response / / 21993531 rs16995877 chr4 33840835 G A 5.97E-07 Myopia (pathological) / / 21640322 rs13102670 chr4 33850102 G A 6.91E-05 Cytomegalovirus antibody response / / 21993531 rs10010176 chr4 33863879 C T 6.91E-05 Cytomegalovirus antibody response / / 21993531 rs6531286 chr4 33873585 G A 6.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6531286 chr4 33873585 G A 6.90E-05 Cytomegalovirus antibody response / / 21993531 rs6531287 chr4 33879862 G A,C 6.75E-05 Cytomegalovirus antibody response / / 21993531 rs10008587 chr4 33883366 T C 6.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10008587 chr4 33883366 T C 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs725472 chr4 33893997 A T 6.28E-05 Cytomegalovirus antibody response / / 21993531 rs16989258 chr4 33898051 A C,G,T 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs10031964 chr4 33901442 T G 6.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10031964 chr4 33901442 T G 6.55E-05 Cytomegalovirus antibody response / / 21993531 rs13120249 chr4 33910151 G A 2.50E-05 Cytomegalovirus antibody response / / 21993531 rs4144789 chr4 33912277 G A 6.58E-05 Cytomegalovirus antibody response / / 21993531 rs12640723 chr4 33913556 C A 6.58E-05 Cytomegalovirus antibody response / / 21993531 rs10517297 chr4 33914068 C A 3.42E-06 Multiple complex diseases / / 17554300 rs10517297 chr4 33914068 C A 6.60E-05 Cytomegalovirus antibody response / / 21993531 rs10517297 chr4 33914068 C A 3.96E-04 Smoking initiation / / 24665060 rs10517298 chr4 33914418 T G 2.38E-04 Multiple complex diseases / / 17554300 rs10517298 chr4 33914418 T G 6.63E-05 Cytomegalovirus antibody response / / 21993531 rs13133479 chr4 33916706 C G 6.69E-05 Cytomegalovirus antibody response / / 21993531 rs13134840 chr4 33925448 A G 6.78E-05 Cytomegalovirus antibody response / / 21993531 rs13121333 chr4 33927521 G A 6.81E-05 Cytomegalovirus antibody response / / 21993531 rs13152635 chr4 33932477 T C 6.83E-05 Cytomegalovirus antibody response / / 21993531 rs7664105 chr4 33935750 G A 6.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7664105 chr4 33935750 G A 7.55E-05 Cytomegalovirus antibody response / / 21993531 rs12642034 chr4 33940192 C A 6.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12642034 chr4 33940192 C A 7.55E-05 Cytomegalovirus antibody response / / 21993531 rs1446287 chr4 33941745 C T 7.53E-05 Cytomegalovirus antibody response / / 21993531 rs16988170 chr4 33946397 A C 6.63E-05 Cytomegalovirus antibody response / / 21993531 rs2028868 chr4 33948401 C T 6.58E-05 Cytomegalovirus antibody response / / 21993531 rs13142173 chr4 33953964 T C 9.29E-04 Multiple complex diseases / / 17554300 rs13142173 chr4 33953964 T C 6.57E-05 Cytomegalovirus antibody response / / 21993531 rs7690693 chr4 33957800 T C 6.56E-05 Cytomegalovirus antibody response / / 21993531 rs16989273 chr4 33963573 G A 6.55E-05 Cytomegalovirus antibody response / / 21993531 rs16989273 chr4 33963573 G A 7.00E-04 Smoking initiation / / 24665060 rs9306906 chr4 33966367 C T 6.53E-05 Cytomegalovirus antibody response / / 21993531 rs6821209 chr4 33967230 A T 6.50E-05 Cytomegalovirus antibody response / / 21993531 rs16989276 chr4 33967586 C A 6.42E-05 Cytomegalovirus antibody response / / 21993531 rs6531288 chr4 33971884 A C 6.41E-05 Cytomegalovirus antibody response / / 21993531 rs6814473 chr4 33974999 C T 6.39E-05 Cytomegalovirus antibody response / / 21993531 rs13103520 chr4 33977475 C G 7.75E-05 Cytomegalovirus antibody response / / 21993531 rs13137908 chr4 33978585 A G 6.30E-05 Cytomegalovirus antibody response / / 21993531 rs10019147 chr4 33984958 G A 4.84E-05 Cytomegalovirus antibody response / / 21993531 rs13113519 chr4 33987737 A G 4.83E-05 Cytomegalovirus antibody response / / 21993531 rs10002222 chr4 33991474 C T 4.82E-05 Cytomegalovirus antibody response / / 21993531 rs13130481 chr4 33992280 C T 4.81E-05 Cytomegalovirus antibody response / / 21993531 rs10517299 chr4 34005385 C T 4.77E-05 Cytomegalovirus antibody response / / 21993531 rs12645236 chr4 34015067 T C 8.96E-05 Cytomegalovirus antibody response / / 21993531 rs6840811 chr4 34022667 A G 8.95E-05 Cytomegalovirus antibody response / / 21993531 rs12644671 chr4 34024077 C G 4.76E-05 Cytomegalovirus antibody response / / 21993531 rs13150590 chr4 34024705 C T 4.76E-05 Cytomegalovirus antibody response / / 21993531 rs12647107 chr4 34026799 C A 4.76E-05 Cytomegalovirus antibody response / / 21993531 rs16989299 chr4 34028348 C T 4.76E-05 Cytomegalovirus antibody response / / 21993531 rs7676416 chr4 34028814 A G 4.76E-05 Cytomegalovirus antibody response / / 21993531 rs6821548 chr4 34030381 C T 4.76E-05 Cytomegalovirus antibody response / / 21993531 rs1446284 chr4 34035307 A G 4.76E-05 Cytomegalovirus antibody response / / 21993531 rs13112123 chr4 34039192 C T 4.76E-05 Cytomegalovirus antibody response / / 21993531 rs7441223 chr4 34041962 A G 4.76E-05 Cytomegalovirus antibody response / / 21993531 rs13106616 chr4 34043420 G A 4.89E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs13106616 chr4 34043420 G A 4.76E-05 Cytomegalovirus antibody response / / 21993531 rs6856433 chr4 34069259 C T 7.14E-04 Smoking initiation / / 24665060 rs6823176 chr4 34126938 T C 4.16E-04 Smoking initiation / / 24665060 rs10031339 chr4 34319621 G A 1.30E-05 Urinary metabolites / / 21572414 rs10517302 chr4 34336070 C G 1.90E-05 Urinary metabolites / / 21572414 rs6531305 chr4 34341090 A T 1.90E-05 Urinary metabolites / / 21572414 rs7690302 chr4 34341495 T G 1.90E-05 Urinary metabolites / / 21572414 rs13113901 chr4 34341669 A G 1.90E-05 Urinary metabolites / / 21572414 rs7681085 chr4 34344526 C T 2.80E-05 Urinary metabolites / / 21572414 rs7663859 chr4 34344694 T C 2.90E-05 Urinary metabolites / / 21572414 rs12511585 chr4 34377242 C G 0.000035 Mean arterial pressure / / 22510845 rs1946341 chr4 34380803 A G 0.000005 Mean arterial pressure / / 22510845 rs41362647 chr4 34381394 C T 0.000041 Mean arterial pressure / / 22510845 rs34244676 chr4 34382796 T A 0.000027 Mean arterial pressure / / 22510845 rs28637473 chr4 34404023 G A 0.000028 Mean arterial pressure / / 22510845 rs10019658 chr4 34424948 A G 8.59E-07 Glaucoma (primary open-angle) / / 22605921 rs7689329 chr4 34461823 C T 0.000016 Mean arterial pressure / / 22510845 rs998460 chr4 34462558 C T 0.000035 Mean arterial pressure / / 22510845 rs10517312 chr4 34462800 A G 0.000011 Mean arterial pressure / / 22510845 rs1480990 chr4 34561689 C T 9.04E-05 Atopy / / 21625490 rs1480990 chr4 34561689 C T 9.87E-06 Glycemic traits (pregnancy) / / 23903356 rs16989994 chr4 34573079 G A 4.56E-05 Non-word repetition / / 23738518 rs16990009 chr4 34575785 G T 9.52E-06 Glycemic traits (pregnancy) / / 23903356 rs7654593 chr4 34602382 A G 7.46E-04 Multiple complex diseases / / 17554300 rs7656779 chr4 34606977 G A 7.13E-04 Multiple complex diseases / / 17554300 rs28580126 chr4 34616744 A G 4.91E-04 Multiple complex diseases / / 17554300 rs11934463 chr4 34630907 G C 3.21E-05 Non-word repetition / / 23738518 rs7690587 chr4 34635314 G A 3.21E-05 Non-word repetition / / 23738518 rs1599109 chr4 34642659 G A 1.97E-04 Cholesterol / / 17255346 rs1599110 chr4 34642826 C T 2.70E-04 Cholesterol / / 17255346 rs977323 chr4 34673762 G A 9.28E-06 Multiple complex diseases / / 17554300 rs7667760 chr4 34731789 G A 1.65E-04 Attention deficit hyperactivity disorder / / 22420046 rs10517329 chr4 34755753 C T 5.59E-04 Type 2 diabetes / / 17846124 rs1706226 chr4 34841364 C T 5.98E-04 Multiple complex diseases / / 17554300 rs1706226 chr4 34841364 C T 1.10E-05 Urinary metabolites / / 21572414 rs16990420 chr4 34855432 T C 7.35E-05 Platelet counts / / pha003100 rs7687780 chr4 34857773 C A 1.40E-05 Urinary metabolites / / 21572414 rs7683823 chr4 34862471 G A 4.65E-05 Potassium levels / / pha003086 rs10021358 chr4 34863594 C T 4.65E-05 Potassium levels / / pha003086 rs16990444 chr4 34865798 T A 6.70E-06 Urinary metabolites / / 21572414 rs17390445 chr4 34893855 A G 1.00E-07 Response to antipsychotic treatment / / 19721433 rs9998396 chr4 34900365 C T 9.17E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10517336 chr4 34920784 C T 7.25E-05 Lipoproteins / / pha003079 rs1317830 chr4 34925064 A G 3.00E-06 Body mass index (non-asthmatics) / / 23517042 rs1317830 chr4 34925064 A G 5.03E-05 Lipoproteins / / pha003079 rs1317830 chr4 34925064 A G 5.24E-06 Platelet counts / / pha003100 rs11735190 chr4 34943702 G A 1.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11735190 chr4 34943702 G A 8.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4639092 chr4 34976643 T C 3.63E-04 Multiple complex diseases / / 17554300 rs981708 chr4 34996371 C T 3.84E-04 Multiple complex diseases / / 17554300 rs11096754 chr4 34998064 G A 5.97E-05 Lipoproteins / / pha003079 rs16990692 chr4 35045666 A G 7.63E-04 Multiple complex diseases / / 17554300 rs2054129 chr4 35047017 T C 2.26E-05 Colorectal cancer / / 21242260 rs968774 chr4 35047750 G A 8.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs968773 chr4 35047815 C A 8.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs4519816 chr4 35054077 A G 5.80E-04 Multiple complex diseases / / 17554300 rs12504677 chr4 35081710 A G 8.65E-06 Stroke (ischemic) / / 21957438 rs148746864 chr4 35081710 A ATGCCTGCAGCAGAAGCCGG 8.65E-06 Stroke (ischemic) / / 21957438 rs71196002 chr4 35081710 A ATGCCTGCAGCAGAAGCCGG 8.65E-06 Stroke (ischemic) / / 21957438 rs11943039 chr4 35119704 C T 2.04E-04 Alzheimer's disease (late onset) / / 21379329 rs6816663 chr4 35235185 T G 7.14E-05 Taste perception / / 22132133 rs7686175 chr4 35248847 G A 1.01E-05 Elbow pain / / pha003008 rs4615191 chr4 35252743 A G 6.96E-04 Smoking initiation / / 24665060 rs12647577 chr4 35255006 T G 1.50E-05 Urinary metabolites / / 21572414 rs11934682 chr4 35268816 T C 5.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11096770 chr4 35283461 C T 7.79E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6837097 chr4 35295899 T C 2.60E-05 Urinary metabolites / / 21572414 rs1530242 chr4 35334473 T C 1.50E-05 Urinary metabolites / / 21572414 rs1583891 chr4 35343876 A C,G,T 6.26E-04 Multiple complex diseases / / 17554300 rs13112950 chr4 35349248 G C 3.40E-06 Urinary metabolites / / 21572414 rs6531356 chr4 35354596 A G 7.62E-04 Multiple complex diseases / / 17554300 rs6814618 chr4 35354993 C T 4.59E-04 Multiple complex diseases / / 17554300 rs6531358 chr4 35356329 C T 5.88E-05 Cognitive impairment induced by topiramate / / 22091778 rs437943 chr4 35372098 T C 4.00E-06 Response to TNF antagonist treatment / / 18615156 rs317071 chr4 35376715 A C,G,T 2.93E-05 Multiple complex diseases / / 17554300 rs317071 chr4 35376715 A C,G,T 4.30E-06 Urinary metabolites / / 21572414 rs1533317 chr4 35410631 T C 2.00E-06 QT interval / / 20031603 rs317026 chr4 35413747 T C 1.78E-04 Nicotine dependence / / 17158188 rs317025 chr4 35415742 C T 1.50E-04 Multiple complex diseases / / 17554300 rs317031 chr4 35423116 C G 3.02E-04 Nicotine dependence / / 17158188 rs317028 chr4 35425383 C T 2.24E-04 Nicotine dependence / / 17158188 rs317047 chr4 35434710 A G 2.76E-04 Nicotine dependence / / 17158188 rs317047 chr4 35434710 A G 2.44E-04 Multiple complex diseases / / 17554300 rs317045 chr4 35435741 G A 4.84E-04 Nicotine dependence / / 17158188 rs960740 chr4 35459174 T A 2.39E-04 Nicotine dependence / / 17158188 rs1113371 chr4 35462039 A C 4.51E-04 Nicotine dependence / / 17158188 rs6827035 chr4 35475099 G C 2.88E-04 Nicotine dependence / / 17158188 rs907978 chr4 35488909 A G 6.35E-04 Nicotine dependence / / 17158188 rs4613591 chr4 35513350 A C 2.33E-04 Nicotine dependence / / 17158188 rs7659440 chr4 35515410 G T 2.29E-04 Nicotine dependence / / 17158188 rs6531365 chr4 35515481 A C 3.43E-04 Nicotine dependence / / 17158188 rs6531366 chr4 35515514 A C 3.78E-04 Nicotine dependence / / 17158188 rs6531367 chr4 35515627 A G 2.76E-04 Nicotine dependence / / 17158188 rs4566673 chr4 35516795 A C 3.72E-04 Nicotine dependence / / 17158188 rs2375489 chr4 35517156 T C 2.87E-04 Nicotine dependence / / 17158188 rs6814075 chr4 35517877 T C 1.26E-04 Nicotine dependence / / 17158188 rs7664882 chr4 35519356 T A 2.73E-04 Nicotine dependence / / 17158188 rs5002776 chr4 35520477 A T 2.60E-04 Nicotine dependence / / 17158188 rs5002773 chr4 35520550 C G 2.57E-04 Nicotine dependence / / 17158188 rs11721878 chr4 35521021 T C 4.00E-04 Multiple complex diseases / / 17554300 rs4859305 chr4 35522037 T C 2.15E-04 Nicotine dependence / / 17158188 rs4859306 chr4 35522197 A G 2.31E-04 Nicotine dependence / / 17158188 rs4859365 chr4 35522532 G A 7.72E-05 Nicotine dependence / / 17158188 rs4498148 chr4 35523921 C T 2.06E-04 Nicotine dependence / / 17158188 rs4349619 chr4 35524083 T A 3.06E-04 Nicotine dependence / / 17158188 rs4301139 chr4 35524518 T G 4.92E-04 Nicotine dependence / / 17158188 rs6531380 chr4 35530651 C T 1.80E-04 Nicotine dependence / / 17158188 rs10517352 chr4 35554589 T G 1.55E-04 Nicotine dependence / / 17158188 rs11942729 chr4 35556366 T C 1.92E-04 Nicotine dependence / / 17158188 rs6836555 chr4 35558480 C T 1.49E-04 Nicotine dependence / / 17158188 rs1425465 chr4 35559640 A G 1.91E-04 Nicotine dependence / / 17158188 rs11096778 chr4 35568910 T C 5.32E-04 Nicotine dependence / / 17158188 rs73805982 chr4 35595838 T C 8.33E-11 Metabolite levels / / 22286219 rs13145490 chr4 35653192 T A,C,G 0.00061 Prostate cancer / / 23555315 rs12640371 chr4 35668267 A C 1.34E-04 Multiple complex diseases / / 17554300 rs7684638 chr4 35720243 C T 2.88E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1822675 chr4 35731099 A G 7.25E-04 Tourette syndrome / / 22889924 rs11942349 chr4 35731666 C A,T 3.60E-04 Multiple complex diseases / / 17554300 rs17493139 chr4 35731819 A G 0.00006 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1444376 chr4 35823842 C T 9.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7667688 chr4 35863451 G A 5.04E-05 Serum metabolites / / 19043545 rs1655058 chr4 35911736 T C 8.91E-04 Type 2 diabetes / / 17463246 rs1655058 chr4 35911736 T C 2.60E-05 Urinary metabolites / / 21572414 rs1368621 chr4 35929368 C T 2.87E-05 Cognitive test performance / / 20125193 rs1714081 chr4 35938175 C T 4.33E-04 Nicotine dependence / / 17158188 rs6834483 chr4 35983111 C T 3.00E-06 Obesity-related traits / / 23251661 rs6834483 chr4 35983111 C T 6.00E-06 Obesity-related traits / / 23251661 rs6834483 chr4 35983111 C T 6.00E-07 Obesity-related traits / / 23251661 rs6839195 chr4 36020436 C T 7.67E-05 Blood Pressure / / pha003039 rs872322 chr4 36021619 G A 1.40E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs872322 chr4 36021619 G A 2.12E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs872321 chr4 36021678 T C 0.0007767 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs872321 chr4 36021678 T C 7.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1567482 chr4 36026747 T C 6.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs1510657 chr4 36029105 A T 5.50E-04 Alzheimer's disease / / 17998437 rs2175323 chr4 36057116 A G 8.93E-04 Type 2 diabetes / / 17463246 rs11940540 chr4 36066470 G C 9.58E-06 Asthma (childhood onset) / / 23829686 rs17493657 chr4 36076892 T C 3.44E-05 Tuberculosis ARAP2 intron 24057671 rs12651329 chr4 36079594 T C 5.00E-07 Amyotrophic lateral sclerosis (age of onset) ARAP2 intron 22959728 rs6812542 chr4 36089558 T C 1.49E-04 Schizophrenia ARAP2 intron 19197363 rs1011288 chr4 36113030 T C 7.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARAP2 intron 20877124 rs6531411 chr4 36128477 C G 5.04E-04 Type 2 diabetes ARAP2 intron 17463246 rs998293 chr4 36142858 A T 0.0003361 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ARAP2 intron 23233654 rs998293 chr4 36142858 A T 3.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) ARAP2 intron 23233662 rs4569781 chr4 36142906 G A 0.0003374 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ARAP2 intron 23233654 rs4569781 chr4 36142906 G A 3.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) ARAP2 intron 23233662 rs4833124 chr4 36146382 T C 0.0003362 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ARAP2 intron 23233654 rs4833124 chr4 36146382 T C 3.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) ARAP2 intron 23233662 rs13119848 chr4 36155875 G T 3.07E-04 Alzheimer's disease ARAP2 intron 17998437 rs16992033 chr4 36284941 T C 6.92E-04 Amyotrophic lateral sclerosis (sporadic) DTHD1 intron 24529757 rs12507599 chr4 36310049 C T 0.000028 Stroke DTHD1 missense 23422753 rs10003169 chr4 36317551 G A 8.00E-07 Urinary metabolites DTHD1 intron 21572414 rs6833944 chr4 36321676 T A 1.20E-06 Urinary metabolites DTHD1 intron 21572414 rs6855771 chr4 36325303 T C 3.90E-06 Urinary metabolites DTHD1 intron 21572414 rs10517373 chr4 36330773 G A 6.10E-04 Suicide attempts in bipolar disorder DTHD1 intron 21423239 rs11945613 chr4 36342073 G A 2.51E-05 Glycosylated haemoglobin levels DTHD1 intron 17255346 rs11945613 chr4 36342073 G A 5.79E-05 Bipolar disorder,affective DTHD1 intron 20528957 rs16992132 chr4 36350334 G A 8.38E-05 Bipolar disorder,affective / / 20528957 rs4359926 chr4 36361927 A T 1.97E-04 Glycosylated haemoglobin levels / / 17255346 rs4359926 chr4 36361927 A T 6.84E-05 Bipolar disorder,affective / / 20528957 rs7672587 chr4 36373741 T C 1.39E-04 Glycosylated haemoglobin levels / / 17255346 rs7672587 chr4 36373741 T C 2.34E-04 Bipolar disorder,affective / / 20528957 rs10050338 chr4 36479116 G A 4.46E-05 Bipolar disorder,affective / / 20528957 rs6829274 chr4 36490815 C T 3.91E-05 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs16992389 chr4 36536225 G A 9.50E-04 Alzheimer's disease / / 17998437 rs11933944 chr4 36587942 G T 3.69E-09 Adiponectin levels / / 20887962 rs11737439 chr4 36616598 T C 6.40E-05 Elbow pain / / pha003008 rs11737439 chr4 36616598 T C 9.45E-05 Height / / pha003010 rs7685223 chr4 36661859 G A 3.39E-04 Cocaine dependence / / 23958962 rs2889304 chr4 36681523 G C 3.00E-04 Alzheimer's disease / / 17998437 rs1370463 chr4 36711621 T G 4.45E-04 Hemoglobin concentration / / 20534544 rs1838566 chr4 36728529 G T 4.42E-05 Alzheimer's disease / / 17998437 rs6845962 chr4 36789707 T C 9.00E-06 Urinary metabolites / / 21572414 rs1026530 chr4 36812433 A G 8.37E-04 Multiple complex diseases / / 17554300 rs1159440 chr4 36867809 A G 8.90E-04 Multiple complex diseases / / 17554300 rs1459680 chr4 36869719 T C 2.82E-04 Taste perception / / 22132133 rs7662574 chr4 36901406 G T 7.31E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1530431 chr4 36917587 A C 6.42E-04 Alzheimer's disease / / 17998437 rs16995767 chr4 36924561 T A,C 3.14E-05 Reading and spelling / / 23738518 rs2889347 chr4 36936789 T C 3.50E-04 Alzheimer's disease / / 17998437 rs1373471 chr4 36969057 T C 5.36E-05 Type 2 diabetes / / 17463246 rs1373471 chr4 36969057 T C 1.18E-05 Alzheimer's disease / / 17998437 rs959213 chr4 36969951 C G 8.04E-04 Alzheimer's disease / / 17998437 rs6419096 chr4 36980807 T C 3.32E-05 Sudden cardiac arrest / / 21658281 rs4240236 chr4 36982241 G A 8.66E-04 Type 2 diabetes / / 17463246 rs9306942 chr4 36983307 A C 3.65E-04 Hemoglobin concentration / / 20534544 rs6827264 chr4 36988313 T C 4.23E-08 Electroencephalogram traits,in brain / / 20421487 rs11096854 chr4 36990132 T G 4.95E-04 Alzheimer's disease / / 17998437 rs1562094 chr4 36995063 T C 1.24E-04 Alzheimer's disease / / 17998437 rs6819520 chr4 37001762 C T 7.47E-05 Alzheimer's disease / / 17998437 rs11727558 chr4 37002025 C T 4.07E-04 Alzheimer's disease / / 17998437 rs7697261 chr4 37002365 T C 9.52E-05 Alzheimer's disease / / 17998437 rs1010009 chr4 37011297 G T 4.57E-04 Alzheimer's disease / / 17998437 rs2296040 chr4 37021693 A C 1.91E-04 Alzheimer's disease / / 17998437 rs1885879 chr4 37029967 A C 4.17E-04 Alzheimer's disease / / 17998437 rs6840860 chr4 37030041 G T 8.83E-04 Alzheimer's disease / / 17998437 rs1885880 chr4 37034278 C A 2.44E-04 Alzheimer's disease / / 17998437 rs6815622 chr4 37034404 A G 8.35E-04 Alzheimer's disease / / 17998437 rs6822547 chr4 37044986 G T 7.21E-05 Coronary heart disease / / pha003056 rs7439590 chr4 37061318 A G 5.30E-04 Multiple complex diseases / / 17554300 rs4832859 chr4 37062345 A G 2.30E-05 Urinary metabolites / / 21572414 rs6822269 chr4 37062852 T A 6.59E-04 Type 2 diabetes / / 17463246 rs13117816 chr4 37064331 G T 7.00E-06 Multiple sclerosis (brain glutamate levels) / / 20802204 rs1005833 chr4 37073999 C T 1.60E-05 Urinary metabolites / / 21572414 rs17237245 chr4 37075984 A C 3.92E-04 Multiple complex diseases / / 17554300 rs10484210 chr4 37075996 A G 7.54E-04 Multiple complex diseases / / 17554300 rs10484210 chr4 37075996 A G 6.23E-05 Substance dependence / / 21818250 rs10484210 chr4 37075996 A G 1.00E-05 Alcohol consumption / / 23953852 rs10517387 chr4 37076682 G A 1.30E-06 Urinary metabolites / / 21572414 rs17289974 chr4 37080756 T C 5.22E-04 Multiple complex diseases / / 17554300 rs9985748 chr4 37084709 G A 6.16E-05 Alcohol consumption / / 23953852 rs17492624 chr4 37088863 T C 9.60E-07 Urinary metabolites / / 21572414 rs4289452 chr4 37091905 T G 5.47E-05 Tunica Media / / pha003038 rs919103 chr4 37094678 T C 2.90E-04 Multiple complex diseases / / 17554300 rs1365342 chr4 37099533 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1426418 chr4 37100443 C G 3.02E-04 Multiple complex diseases / / 17554300 rs2376241 chr4 37163951 T G 1.92E-04 Lung function (forced vital capacity) / / 24023788 rs16993272 chr4 37165604 A G 4.40E-07 Urinary metabolites / / 21572414 rs10517386 chr4 37166730 G A 7.80E-07 Urinary metabolites / / 21572414 rs1426409 chr4 37173944 G A 4.95E-04 Multiple complex diseases / / 17554300 rs1426409 chr4 37173944 G A 0.00000314 Preeclampsia / / 22748001 rs1613447 chr4 37196241 T A 7.14E-05 Serum metabolites / / 19043545 rs10517384 chr4 37213122 G A 4.94E-04 Multiple complex diseases / / 17554300 rs78606083 chr4 37215824 C T 0.00002319 Sarcoidosis / / 22952805 rs958927 chr4 37248437 T C 1.06E-04 Multiple complex diseases KIAA1239 intron 17554300 rs17492813 chr4 37253667 C T 1.90E-05 Urinary metabolites KIAA1239 intron 21572414 rs1618748 chr4 37254584 A G 6.73E-05 Personality dimensions KIAA1239 intron 23903073 rs10015594 chr4 37258086 G A 2.11E-04 Fibrinogen KIAA1239 intron 17255346 rs1614860 chr4 37273895 A G 9.24E-05 Blood Pressure KIAA1239 intron pha003040 rs1656235 chr4 37293830 C A 8.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KIAA1239 intron 20877124 rs1776534 chr4 37311614 C T 6.99E-04 Multiple complex diseases KIAA1239 intron 17554300 rs4337743 chr4 37322825 G A 5.80E-04 Pulmonary function KIAA1239 intron 20010834 rs17575890 chr4 37329512 T C 0.000022 Amyotrophic lateral sclerosis KIAA1239 intron 23587638 rs17575890 chr4 37329512 T C 0.0000273 Amyotrophic lateral sclerosis KIAA1239 intron 23587638 rs12649785 chr4 37335699 A C 3.04E-05 Job-related exhaustion KIAA1239 intron 23620144 rs12505080 chr4 37349340 T C 8.10E-06 Breast cancer KIAA1239 intron 17529973 rs12505080 chr4 37349340 T C 7.99E-06 Breast cancer KIAA1239 intron pha002853 rs1002363 chr4 37357559 A G 6.98E-05 Glaucoma (primary open-angle) KIAA1239 intron 22605921 rs10517410 chr4 37369204 A G 7.05E-04 Multiple complex diseases KIAA1239 intron 17554300 rs16993503 chr4 37384644 G T 2.73E-04 Amyotrophic lateral sclerosis (sporadic) KIAA1239 intron 24529757 rs1351304 chr4 37385794 C G,T 4.60E-05 Serum metabolites KIAA1239 intron 19043545 rs41468145 chr4 37387519 G C 5.09E-04 Multiple complex diseases KIAA1239 intron 17554300 rs17421729 chr4 37395148 A G 1.94E-04 Multiple complex diseases KIAA1239 intron 17554300 rs10517422 chr4 37405256 C T 8.47E-04 Multiple complex diseases KIAA1239 intron 17554300 rs1382979 chr4 37480687 T G 9.76E-04 Myopia (pathological) C4orf19 intron 21095009 rs6830100 chr4 37530090 G A 1.86E-04 Breast cancer C4orf19 intron pha002853 rs7687449 chr4 37532743 T C 8.50E-04 Depression (quantitative trait) C4orf19 intron 20800221 rs7683012 chr4 37533016 A G 7.96E-04 Multiple complex diseases C4orf19 intron 17554300 rs9306949 chr4 37537257 A G 1.57E-04 Insulin resistance C4orf19 intron 21901158 rs7659133 chr4 37551947 A G 9.82E-04 Insulin resistance C4orf19 intron 21901158 rs11737127 chr4 37552674 T C 9.84E-05 Alzheimer's disease C4orf19 intron 17998437 rs7655445 chr4 37555201 C T 4.67E-04 Amyotrophic Lateral Sclerosis C4orf19 intron 17827064 rs2380763 chr4 37577791 G A 5.03E-05 Parent of origin effect on language impairment (child trend) C4orf19 intron 24571439 rs705099 chr4 37594946 G A 2.86E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) C4orf19 UTR-3 24023788 rs2973278 chr4 37600835 C T 0.0000364 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes RELL1 intron 22628534 rs2973278 chr4 37600835 C T 6.40E-05 Self-reported allergy RELL1 intron 23817569 rs16993717 chr4 37617389 A G 1.91E-04 IgE levels RELL1 intron 17255346 rs16993717 chr4 37617389 A G 6.60E-05 Cognitive performance RELL1 intron 19734545 rs4832928 chr4 37645389 C T 2.00E-06 IgG glycosylation RELL1 intron 23382691 rs13144232 chr4 37647234 G A 6.00E-07 IgG glycosylation RELL1 intron 23382691 rs2292298 chr4 37651155 A G 4.00E-06 IgG glycosylation RELL1 intron 23382691 rs9790339 chr4 37651814 G A 1.32E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) RELL1 intron 24023788 rs7658779 chr4 37656326 G A 8.41E-05 Serum metabolites RELL1 intron 19043545 rs6531560 chr4 37660615 G A 2.22E-04 IgE levels RELL1 intron 17255346 rs13122883 chr4 37702059 G T 4.34E-04 Obesity (extreme) / / 21935397 rs4832734 chr4 37702998 C T 0.00000189 Lumbar spine bone mineral density / / 22692763 rs4832734 chr4 37702998 C T 0.00000199 Lumbar spine bone mineral density (males) / / 22692763 rs7689182 chr4 37716715 A T 8.41E-05 Epilepsy (remission after treatment) / / 23962720 rs12505604 chr4 37720580 T C 1.05E-05 Adverse response to lamotrigine and phenytoin / / 22379998 rs12505604 chr4 37720580 T C 5.60E-05 Epilepsy (remission after treatment) / / 23962720 rs12505935 chr4 37723990 G A 2.64E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7676073 chr4 37724172 G C 3.35E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17605893 chr4 37735232 G A 2.75E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17495870 chr4 37737524 G C 6.13E-27 Narcolepsy / / 19629137 rs2020347 chr4 37746427 C T 3.45E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs17424192 chr4 37762140 T C 7.37E-04 Type 2 diabetes / / 17463246 rs4240241 chr4 37766932 G A 8.83E-04 Multiple complex diseases / / 17554300 rs4240241 chr4 37766932 G A 3.60E-05 Bone mineral density (BMD),in women / / 20164292 rs919005 chr4 37769527 G A 1.80E-05 Urinary metabolites / / 21572414 rs41457545 chr4 37779321 T C 8.03E-04 Alzheimer's disease / / 24755620 rs41352046 chr4 37779600 A G 8.29E-04 Alzheimer's disease / / 24755620 rs870953 chr4 37786987 G A 8.05E-04 Acute lung injury / / 22295056 rs7692977 chr4 37787117 T C 7.68E-04 Acute lung injury / / 22295056 rs890167 chr4 37787332 A G 7.41E-04 Acute lung injury / / 22295056 rs890166 chr4 37787386 T A 7.33E-04 Acute lung injury / / 22295056 rs890165 chr4 37787464 G A 7.33E-04 Acute lung injury / / 22295056 rs1834342 chr4 37789855 G T 8.37E-04 Acute lung injury / / 22295056 rs955868 chr4 37790259 G A 8.15E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs1425323 chr4 37799933 C T 8.63E-05 Multiple complex diseases / / 17554300 rs11096905 chr4 37800240 C T 2.49E-04 Type 2 diabetes / / 17463246 rs4832737 chr4 37812202 G A 5.03E-05 Type 2 diabetes / / 17463246 rs1030349 chr4 37827799 T G 3.89E-04 Schizophrenia / / 19197363 rs2714555 chr4 37837819 G A 6.85E-04 Smoking initiation PGM2 intron 24665060 rs2608307 chr4 37838237 C T 4.42E-04 Schizophrenia PGM2 intron 19197363 rs2714560 chr4 37843161 G A 6.46E-04 Smoking initiation PGM2 intron 24665060 rs2303409 chr4 37846939 A C 4.23E-06 Asthma (childhood onset) PGM2 intron 23829686 rs2290741 chr4 37849004 C T 1.51E-04 Multiple complex diseases PGM2 intron 17554300 rs28571127 chr4 37870300 G A 1.10E-05 Urinary metabolites / / 21572414 rs3893296 chr4 37900371 A C 1.66E-05 IgE levels TBC1D1 intron 22075330 rs3893297 chr4 37900382 G A 1.66E-05 IgE levels TBC1D1 intron 22075330 rs17578878 chr4 37900725 C T 9.87E-07 Osteoarthritis TBC1D1 intron 22763110 rs3860062 chr4 37900779 T C 3.92E-05 IgE levels TBC1D1 intron 22075330 rs10010366 chr4 37900822 G A 4.16E-05 IgE levels TBC1D1 intron 22075330 rs2995919 chr4 37906032 C T 9.08E-04 Type 2 diabetes TBC1D1 intron 17463246 rs16994065 chr4 37909658 A G 2.47E-05 Schizophrenia(age at onset) TBC1D1 intron 21688384 rs2925948 chr4 37909841 G A 3.30E-04 Atrial fibrillation TBC1D1 intron 21846873 rs16994074 chr4 37925978 T C 5.41E-05 Cocaine dependence TBC1D1 intron 23958962 rs10010758 chr4 37938518 T C 4.00E-06 Periodontal microbiota TBC1D1 intron 22699663 rs10517456 chr4 37954732 G A 9.00E-04 Pulmonary function TBC1D1 intron 23932459 rs10517459 chr4 37959926 A G 6.81E-05 Type 2 diabetes and other traits TBC1D1 intron 19734900 rs10517459 chr4 37959926 A G 3.77E-04 Stroke TBC1D1 intron pha002887 rs10517460 chr4 37967083 A C 1.30E-04 Crohn's disease TBC1D1 intron 17684544 rs10517461 chr4 37967177 G C 2.90E-05 Obesity-related traits TBC1D1 intron 17903300 rs1984960 chr4 37968024 A G 3.00E-04 Pulmonary function TBC1D1 intron 23932459 rs7672883 chr4 38006686 C A 4.35E-04 Multiple complex diseases TBC1D1 intron 17554300 rs4144799 chr4 38006966 T A,G 4.78E-04 Multiple complex diseases TBC1D1 intron 17554300 rs4144802 chr4 38007331 T C 3.87E-04 Multiple complex diseases TBC1D1 intron 17554300 rs16994140 chr4 38011565 C T 2.63E-05 Soluble levels of adhesion molecules TBC1D1 intron pha003072 rs16994148 chr4 38016822 T G 1.60E-05 Urinary metabolites TBC1D1 intron 21572414 rs933821 chr4 38026389 G A 9.89E-04 Multiple complex diseases TBC1D1 intron 17554300 rs6845120 chr4 38047545 A G 3.50E-06 Bone mineral density TBC1D1 intron 21927923 rs4832748 chr4 38056045 A G 1.82E-04 Multiple complex diseases TBC1D1 intron 17554300 rs17425670 chr4 38058764 A G 6.70E-05 Bone mineral density TBC1D1 intron 21927923 rs12642052 chr4 38075539 T C 1.00E-04 Cognitive impairment induced by topiramate TBC1D1 intron 22091778 rs933818 chr4 38079294 T C 1.28E-04 Multiple complex diseases TBC1D1 intron 17554300 rs2303422 chr4 38091800 A G 1.23E-04 Multiple complex diseases TBC1D1 intron 17554300 rs6857857 chr4 38128849 C T 0.000000163 Triglycerides TBC1D1 intron 23063622 rs12504099 chr4 38130564 G A 1.50E-05 Parkinson's disease (age of onset) TBC1D1 intron 19772629 rs6854169 chr4 38133667 G A 3.06E-04 Multiple complex diseases TBC1D1 intron 17554300 rs6854169 chr4 38133667 G A 0.00000111 HDL cholesterol TBC1D1 intron 23063622 rs6854169 chr4 38133667 G A 1.38E-18 Triglycerides TBC1D1 intron 23063622 rs10021783 chr4 38145373 G A 4.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6852542 chr4 38146096 G T 3.00E-11 Gout / / pha001406 rs115426111 chr4 38161064 T A 1.00E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs115426111 chr4 38161064 T A 7.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs2380964 chr4 38175276 A G 2.83E-04 Esophageal adenocarcinoma / / 24121790 rs11724778 chr4 38177320 A G 9.60E-04 Type 2 diabetes / / 17463246 rs11932593 chr4 38179990 C T 6.40E-05 Response to statin therapy / / 20339536 rs11937284 chr4 38180005 A G 6.80E-05 Response to statin therapy / / 20339536 rs693978 chr4 38180161 G A 8.20E-05 Response to statin therapy / / 20339536 rs659814 chr4 38180269 C T 8.20E-05 Response to statin therapy / / 20339536 rs663677 chr4 38182674 A G 6.80E-04 Insulin resistance / / 21901158 rs11737462 chr4 38190035 G A 3.06E-05 Lung adenocarcinoma / / 19836008 rs11725633 chr4 38191964 C T 5.59E-04 Parkinson's disease / / 17052657 rs11725633 chr4 38191964 C T 5.57E-05 Male-pattern baldness / / 18849994 rs932010 chr4 38194391 C G 5.59E-04 Parkinson's disease / / 17052657 rs2380962 chr4 38197189 T G 4.85E-04 Smoking initiation / / 24665060 rs17608192 chr4 38231257 T C 1.43E-04 Multiple complex diseases / / 17554300 rs12648494 chr4 38234014 C G 8.76E-04 Multiple complex diseases / / 17554300 rs4833022 chr4 38251292 A C 9.37E-05 Hepatocellular carcinoma / / 22807686 rs907314 chr4 38254453 T C 7.20E-05 Hepatocellular carcinoma / / 22807686 rs16994362 chr4 38259451 T G 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs13119207 chr4 38285407 C A,G,T 4.50E-05 Cognitive function / / 24684796 rs10517472 chr4 38287333 C T 9.61E-04 Type 2 diabetes / / 17463246 rs12645972 chr4 38290546 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12645972 chr4 38290546 C T 5.93E-06 Cognitive impairment induced by topiramate / / 22091778 rs2175447 chr4 38294297 T A 9.67E-04 Multiple complex diseases / / 17554300 rs12649007 chr4 38295917 A T 9.24E-05 Cognitive impairment induced by topiramate / / 22091778 rs6847801 chr4 38298269 C T 0.000000972 Nicotine dependence (smoking) / / 23643383 rs76273539 chr4 38322491 G T 8.35E-04 Crohn's disease / / 23266558 rs4453942 chr4 38324906 A C 4.68E-04 Crohn's disease / / 23266558 rs1906295 chr4 38325003 G A 4.81E-04 Crohn's disease / / 23266558 rs6856616 chr4 38325036 T C 3.57E-04 Crohn's disease / / 23266558 rs6856616 chr4 38325036 T C 4.00E-14 Crohn's disease / / 23850713 rs1906296 chr4 38325062 G A 6.52E-04 Crohn's disease / / 23266558 rs1906297 chr4 38325105 T C 5.80E-04 Crohn's disease / / 23266558 rs6822641 chr4 38327654 A G 5.85E-04 Crohn's disease / / 23266558 rs6829875 chr4 38328777 A G 5.94E-04 Crohn's disease / / 23266558 rs73243350 chr4 38330016 G A 1.15E-05 Crohn's disease / / 23266558 rs73243351 chr4 38335067 G A 1.51E-06 Crohn's disease / / 23266558 rs1487630 chr4 38335823 C T 1.00E-11 Crohn's disease / / 23266558 rs75918970 chr4 38337114 C T 1.84E-05 Crohn's disease / / 23266558 rs73243354 chr4 38345898 A C 1.16E-06 Crohn's disease / / 23266558 rs55843528 chr4 38361416 G A 1.72E-05 Crohn's disease / / 23266558 rs6846728 chr4 38363406 T G 1.51E-05 Crohn's disease / / 23266558 rs62294142 chr4 38364637 G A 3.19E-05 Crohn's disease / / 23266558 rs55818238 chr4 38367910 T C 1.12E-04 Crohn's disease / / 23266558 rs73243363 chr4 38369359 C T 2.14E-04 Crohn's disease / / 23266558 rs1386622 chr4 38372055 T G 3.11E-04 Multiple complex diseases / / 17554300 rs2046643 chr4 38372849 A G 5.31E-05 Weight / / pha003026 rs17581082 chr4 38378603 A G 1.81E-04 Multiple complex diseases / / 17554300 rs12330996 chr4 38379303 C T 1.88E-04 Crohn's disease / / 23266558 rs17581460 chr4 38456404 T C 8.36E-05 Orofacial clefts / / 22419666 rs1004064 chr4 38458620 G A 8.50E-05 Alcoholism (heaviness of drinking) / / 21529783 rs4615179 chr4 38465471 C T 8.00E-06 Obesity-related traits / / 23251661 rs4832774 chr4 38474393 T A 6.20E-04 Multiple complex diseases / / 17554300 rs4832776 chr4 38477280 G C 4.22E-04 Multiple complex diseases / / 17554300 rs4073968 chr4 38491835 C T 1.24E-05 Longevity / / 22279548 rs2637736 chr4 38521490 G A 5.20E-04 Myocardial infarction / / 21107343 rs2637729 chr4 38523522 G A 6.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17615522 chr4 38527901 A C 5.65E-05 HDL cholesterol / / pha003074 rs11942117 chr4 38529130 C T 8.29E-05 Partial epilepsies / / 20522523 rs923665 chr4 38537708 T C 3.74E-05 Partial epilepsies / / 20522523 rs2703888 chr4 38570506 T C 7.60E-05 Intracranial aneurysm / / 20613766 rs6813345 chr4 38581523 G C 6.10E-05 Pericardial fat / / 22589742 rs6531644 chr4 38584276 G A 0.000526 Salmonella-induced pyroptosis / / 22837397 rs922334 chr4 38616758 G A 9.87E-04 Multiple complex diseases FLJ13197 intron 17554300 rs17615966 chr4 38622611 G C 4.11E-11 Multiple complex diseases FLJ13197 intron 17554300 rs337628 chr4 38635144 A T 5.70E-04 Multiple complex diseases FLJ13197 intron 17554300 rs9522 chr4 38666972 C T 2.96E-05 Amyotrophic lateral sclerosis (sporadic) KLF3 intron 24529757 rs5029114 chr4 38703005 A G 9.73E-04 Lymphocyte counts KLF3 UTR-3 22286170 rs17582575 chr4 38703734 C A 2.67E-04 Type 2 diabetes / / 17463246 rs11728133 chr4 38710398 T C 1.10E-08 Helicobacter pylori serologic status / / 23652523 rs13132956 chr4 38711684 C T 8.93E-09 Pam3CSK4-induced interleukin-6 (IL-6) / / 23151486 rs13132956 chr4 38711684 C T 2.69E-09 Helicobacter pylori serologic status / / 23652523 rs6838905 chr4 38712286 A G 6.46E-05 Pancreatic cancer / / pha002874 rs6838905 chr4 38712286 A G 7.66E-05 Pancreatic cancer / / pha002889 rs1005938 chr4 38724249 A G 2.69E-11 Helicobacter pylori serologic status / / 23652523 rs7660102 chr4 38724573 C A 3.81E-11 Pam3CSK4-induced interleukin-6 (IL-6) / / 23151486 rs7660102 chr4 38724573 C A 8.07E-11 Helicobacter pylori serologic status / / 23652523 rs13135770 chr4 38724593 G A 9.58E-11 Helicobacter pylori serologic status / / 23652523 rs12510962 chr4 38724886 G A 1.00E-10 Helicobacter pylori serologic status / / 23652523 rs13137984 chr4 38724945 C A 6.98E-09 Helicobacter pylori serologic status / / 23652523 rs13137984 chr4 38724945 C A 7.00E-09 Helicobacter pylori serologic status / / 23652523 rs13137984 chr4 38724945 C A 8.02E-05 Self-reported allergy / / 23817569 rs4832786 chr4 38726766 C G 3.93E-09 Helicobacter pylori serologic status / / 23652523 rs4832786 chr4 38726766 C G 1.20E-04 Self-reported allergy / / 23817569 rs7658334 chr4 38728076 A G 2.70E-09 Helicobacter pylori serologic status / / 23652523 rs7658334 chr4 38728076 A G 1.00E-04 Self-reported allergy / / 23817569 rs7663292 chr4 38728104 T C 2.88E-09 Helicobacter pylori serologic status / / 23652523 rs7663292 chr4 38728104 T C 8.54E-05 Self-reported allergy / / 23817569 rs10026553 chr4 38732962 A G 8.19E-12 Helicobacter pylori serologic status / / 23652523 rs10026553 chr4 38732962 A G 3.16E-05 Self-reported allergy / / 23817569 rs2890620 chr4 38736550 T C 2.70E-13 Pam3CSK4-induced interleukin-6 (IL-6) / / 23151486 rs2890620 chr4 38736550 T C 4.65E-11 Helicobacter pylori serologic status / / 23652523 rs2890620 chr4 38736550 T C 1.58E-06 Self-reported allergy / / 23817569 rs6531659 chr4 38744030 A G 2.97E-04 Self-reported allergy / / 23817569 rs4072590 chr4 38744489 A T 5.12E-11 Helicobacter pylori serologic status / / 23652523 rs4072590 chr4 38744489 A T 5.49E-07 Self-reported allergy / / 23817569 rs10008032 chr4 38745482 T C 3.58E-06 Obesity (early onset extreme) / / 18159244 rs10008032 chr4 38745482 T C 1.47E-05 Self-reported allergy / / 23817569 rs9761637 chr4 38750185 A G 5.46E-12 Helicobacter pylori serologic status / / 23652523 rs9761637 chr4 38750185 A G 6.38E-07 Self-reported allergy / / 23817569 rs4540058 chr4 38751694 G A 1.35E-11 Helicobacter pylori serologic status / / 23652523 rs4540058 chr4 38751694 G A 9.01E-08 Self-reported allergy / / 23817569 rs6824105 chr4 38754189 G A 1.45E-12 Pam3CSK4-induced interleukin-6 (IL-6) / / 23151486 rs6824105 chr4 38754189 G A 4.92E-06 Self-reported allergy / / 23817569 rs6841698 chr4 38761714 G A 8.74E-08 Self-reported allergy / / 23817569 rs10024216 chr4 38764112 G A 5.67E-05 Amyotrophic lateral sclerosis / / 19193627 rs10024216 chr4 38764112 G A 7.25E-15 Pam3CSK4-induced interleukin-6 (IL-6) / / 23151486 rs10024216 chr4 38764112 G A 4.01E-08 Helicobacter pylori serologic status / / 23652523 rs10024216 chr4 38764112 G A 1.10E-08 Self-reported allergy / / 23817569 rs10008492 chr4 38765720 C T 7.10E-05 Endometriosis / / 21151130 rs10008492 chr4 38765720 C T 1.51E-17 Pam3CSK4-induced interleukin-6 (IL-6) / / 23151486 rs10008492 chr4 38765720 C T 2.06E-08 Helicobacter pylori serologic status / / 23652523 rs10008492 chr4 38765720 C T 1.19E-13 Self-reported allergy / / 23817569 rs10470854 chr4 38768533 A G 8.89E-10 Self-reported allergy / / 23817569 rs4331786 chr4 38769408 C T 1.60E-05 Amyotrophic lateral sclerosis / / 19193627 rs4331786 chr4 38769408 C T 1.72E-16 Pam3CSK4-induced interleukin-6 (IL-6) / / 23151486 rs4331786 chr4 38769408 C T 9.24E-10 Self-reported allergy / / 23817569 rs4331786 chr4 38769408 C T 9.13E-05 Blood Pressure / / pha003050 rs4513579 chr4 38773816 T C 2.54E-13 Self-reported allergy / / 23817569 rs11466661 chr4 38774482 G T 5.36E-16 Pam3CSK4-induced interleukin-6 (IL-6) TLR10 UTR-3 23151486 rs9715841 chr4 38774503 T C 1.61E-24 Pam3CSK4-induced interleukin-6 (IL-6) TLR10 UTR-3 23151486 rs10776482 chr4 38774785 A G 1.61E-24 Pam3CSK4-induced interleukin-6 (IL-6) TLR10 cds-synon 23151486 rs10776482 chr4 38774785 A G 1.57E-10 Helicobacter pylori serologic status TLR10 cds-synon 23652523 rs10776482 chr4 38774785 A G 1.12E-15 Self-reported allergy TLR10 cds-synon 23817569 rs4129009 chr4 38774889 T A,C,G 5.04E-25 Pam3CSK4-induced interleukin-6 (IL-6) TLR10 missense 23151486 rs4129009 chr4 38774889 T A,C,G 3.17E-12 Helicobacter pylori serologic status TLR10 missense 23652523 rs4129009 chr4 38774889 T A,C,G 1.33E-16 Self-reported allergy TLR10 missense 23817569 rs10776483 chr4 38775040 A G 1.61E-24 Pam3CSK4-induced interleukin-6 (IL-6) TLR10 cds-synon 23151486 rs10776483 chr4 38775040 A G 1.46E-10 Helicobacter pylori serologic status TLR10 cds-synon 23652523 rs10776483 chr4 38775040 A G 8.48E-16 Self-reported allergy TLR10 cds-synon 23817569 rs11466657 chr4 38775794 A G 2.66E-05 Self-reported allergy TLR10 missense 23817569 rs11096955 chr4 38776107 T G 5.36E-16 Pam3CSK4-induced interleukin-6 (IL-6) TLR10 missense 23151486 rs11096955 chr4 38776107 T G 6.51E-10 Self-reported allergy TLR10 missense 23817569 rs11466654 chr4 38776129 T C 1.56E-16 Cholesterol,total TLR10 cds-synon 23063622 rs11466654 chr4 38776129 T C 3.81E-56 Triglycerides TLR10 cds-synon 23063622 rs11466654 chr4 38776129 T C 4.90E-09 LDL cholesterol TLR10 cds-synon 23063622 rs11096956 chr4 38776180 C A 5.57E-25 Pam3CSK4-induced interleukin-6 (IL-6) TLR10 cds-synon 23151486 rs11096956 chr4 38776180 C A 1.56E-10 Helicobacter pylori serologic status TLR10 cds-synon 23652523 rs11096956 chr4 38776180 C A 1.05E-15 Self-reported allergy TLR10 cds-synon 23817569 rs11096957 chr4 38776491 T G 2.64E-05 Amyotrophic lateral sclerosis TLR10 missense 19193627 rs11096957 chr4 38776491 T G 9.10E-04 Endometriosis TLR10 missense 23104006 rs11096957 chr4 38776491 T G 1.85E-16 Pam3CSK4-induced interleukin-6 (IL-6) TLR10 missense 23151486 rs11096957 chr4 38776491 T G 5.46E-10 Self-reported allergy TLR10 missense 23817569 rs4274855 chr4 38777471 C T 5.04E-25 Pam3CSK4-induced interleukin-6 (IL-6) TLR10 UTR-5 23151486 rs4274855 chr4 38777471 C T 3.05E-12 Helicobacter pylori serologic status TLR10 UTR-5 23652523 rs4274855 chr4 38777471 C T 1.60E-16 Self-reported allergy TLR10 UTR-5 23817569 rs11466645 chr4 38778203 A T 3.05E-12 Helicobacter pylori serologic status TLR10 intron 23652523 rs11466645 chr4 38778203 A T 2.14E-16 Self-reported allergy TLR10 intron 23817569 rs11466640 chr4 38778903 G A 1.85E-25 Pam3CSK4-induced interleukin-6 (IL-6) TLR10 intron 23151486 rs11466640 chr4 38778903 G A 2.54E-12 Helicobacter pylori serologic status TLR10 intron 23652523 rs11466640 chr4 38778903 G A 2.24E-16 Self-reported allergy TLR10 intron 23817569 rs7694115 chr4 38779094 A G 1.33E-10 Self-reported allergy TLR10 intron 23817569 rs11466617 chr4 38780471 T C 3.05E-12 Helicobacter pylori serologic status TLR10 intron 23652523 rs11466617 chr4 38780471 T C 1.19E-16 Self-reported allergy TLR10 intron 23817569 rs7653908 chr4 38782221 G C 3.60E-15 Helicobacter pylori serologic status TLR10 intron 23652523 rs7653908 chr4 38782221 G C 3.57E-17 Self-reported allergy TLR10 intron 23817569 rs7658893 chr4 38782420 G A 9.86E-14 Helicobacter pylori serologic status TLR10 intron 23652523 rs7658893 chr4 38782420 G A 1.53E-16 Self-reported allergy TLR10 intron 23817569 rs11725309 chr4 38783848 T C 2.35E-13 Helicobacter pylori serologic status TLR10 intron 23652523 rs11725309 chr4 38783848 T C 1.18E-18 Self-reported allergy TLR10 intron 23817569 rs10034903 chr4 38784678 C G 7.03E-16 Self-reported allergy / / 23817569 rs10004195 chr4 38784724 T A 1.00E-18 Helicobacter pylori serologic status / / 23652523 rs10004195 chr4 38784724 T A 7.39E-16 Self-reported allergy / / 23817569 rs113143765 chr4 38784724 T TA 1.00E-18 Helicobacter pylori serologic status / / 23652523 rs113143765 chr4 38784724 T TA 7.39E-16 Self-reported allergy / / 23817569 rs12233670 chr4 38787216 C T 3.76E-04 Multiple complex diseases / / 17554300 rs12233670 chr4 38787216 C T 6.80E-06 Coronary Artery Disease / / 17634449 rs12233670 chr4 38787216 C T 2.93E-05 Lymphocyte counts / / 22286170 rs12233670 chr4 38787216 C T 2.89E-18 Helicobacter pylori serologic status / / 23652523 rs12233670 chr4 38787216 C T 1.25E-19 Self-reported allergy / / 23817569 rs6834581 chr4 38788234 T C 8.18E-06 Alcohol consumption / / 23743675 rs4833093 chr4 38789740 G T 1.38E-05 Alcohol consumption / / 23743675 rs6531663 chr4 38792340 T C 1.38E-05 Alcohol consumption / / 23743675 rs4543123 chr4 38792524 A G 1.84E-05 Amyotrophic lateral sclerosis / / 19193627 rs4543123 chr4 38792524 A G 2.01E-05 Paget's disease / / 20436471 rs4543123 chr4 38792524 A G 1.35E-27 Pam3CSK4-induced interleukin-6 (IL-6) / / 23151486 rs4543123 chr4 38792524 A G 1.75E-18 Helicobacter pylori serologic status / / 23652523 rs4543123 chr4 38792524 A G 9.00E-06 Alcohol consumption / / 23743675 rs4543123 chr4 38792524 A G 4.23E-19 Self-reported allergy / / 23817569 rs4624663 chr4 38797876 T C 5.87E-06 Panic disorder TLR1 UTR-3 19165232 rs5743618 chr4 38798648 C A 7.10E-24 Pam3CSK4-induced interleukin-6 (IL-6) TLR1 missense 23151486 rs5743616 chr4 38798776 C T 6.81E-14 HDL cholesterol TLR1 cds-synon 23063622 rs4833095 chr4 38799710 T C 8.59E-05 Amyotrophic lateral sclerosis TLR1 missense 19193627 rs4833095 chr4 38799710 T C 1.80E-05 Paget's disease TLR1 missense 20436471 rs4833095 chr4 38799710 T C 4.29E-26 Pam3CSK4-induced interleukin-6 (IL-6) TLR1 missense 23151486 rs4833095 chr4 38799710 T C 1.43E-18 Helicobacter pylori serologic status TLR1 missense 23652523 rs4833095 chr4 38799710 T C 5.55E-06 Alcohol consumption TLR1 missense 23743675 rs4833095 chr4 38799710 T C 1.20E-20 Self-reported allergy TLR1 missense 23817569 rs4833095 chr4 38799710 T C 5.00E-12 Asthma and hay fever TLR1 missense 24388013 rs5743604 chr4 38801285 A G 2.22E-18 Helicobacter pylori serologic status TLR1 intron 23652523 rs5743604 chr4 38801285 A G 4.09E-06 Alcohol consumption TLR1 intron 23743675 rs5743604 chr4 38801285 A G 1.70E-19 Self-reported allergy TLR1 intron 23817569 rs5743596 chr4 38802528 G A 2.43E-11 Helicobacter pylori serologic status TLR1 UTR-5 23652523 rs5743596 chr4 38802528 G A 4.55E-16 Self-reported allergy TLR1 UTR-5 23817569 rs5743595 chr4 38802644 A G 7.69E-13 Helicobacter pylori serologic status TLR1 intron 23652523 rs5743595 chr4 38802644 A G 4.99E-19 Self-reported allergy TLR1 intron 23817569 rs5743594 chr4 38802751 G A 3.91E-05 Height TLR1 intron pha003011 rs5743592 chr4 38803063 A G 1.59E-13 Helicobacter pylori serologic status TLR1 intron 23652523 rs5743592 chr4 38803063 A G 3.31E-19 Self-reported allergy TLR1 intron 23817569 rs5743571 chr4 38805489 C T 6.07E-13 Helicobacter pylori serologic status TLR1 intron 23652523 rs5743571 chr4 38805489 C T 2.45E-19 Self-reported allergy TLR1 intron 23817569 rs5743566 chr4 38805942 G C 9.71E-25 Pam3CSK4-induced interleukin-6 (IL-6) TLR1 UTR-5 23151486 rs5743565 chr4 38805983 T C 9.71E-25 Pam3CSK4-induced interleukin-6 (IL-6) TLR1 UTR-5 23151486 rs5743565 chr4 38805983 T C 5.51E-13 Helicobacter pylori serologic status TLR1 UTR-5 23652523 rs5743565 chr4 38805983 T C 2.48E-19 Self-reported allergy TLR1 UTR-5 23817569 rs5743563 chr4 38806019 A G 3.66E-25 Pam3CSK4-induced interleukin-6 (IL-6) TLR1 intron 23151486 rs5743563 chr4 38806019 A G 5.13E-13 Helicobacter pylori serologic status TLR1 intron 23652523 rs5743563 chr4 38806019 A G 2.49E-19 Self-reported allergy TLR1 intron 23817569 rs5743562 chr4 38806096 T C 7.27E-12 Helicobacter pylori serologic status TLR1 intron 23652523 rs5743562 chr4 38806096 T C 3.75E-19 Self-reported allergy TLR1 intron 23817569 rs5743557 chr4 38806827 G A 4.30E-13 Helicobacter pylori serologic status TLR1 nearGene-5 23652523 rs5743557 chr4 38806827 G A 1.98E-19 Self-reported allergy TLR1 nearGene-5 23817569 rs11722813 chr4 38810769 C T 1.44E-08 Helicobacter pylori serologic status / / 23652523 rs2101521 chr4 38811551 G A 1.08E-15 Helicobacter pylori serologic status / / 23652523 rs2101521 chr4 38811551 G A 5.00E-21 Self-reported allergy / / 23817569 rs17616434 chr4 38812876 T C 6.51E-18 Helicobacter pylori serologic status / / 23652523 rs17616434 chr4 38812876 T C 6.71E-06 Alcohol consumption / / 23743675 rs17616434 chr4 38812876 T C 2.89E-20 Self-reported allergy / / 23817569 rs17616434 chr4 38812876 T C 5.00E-11 Allergic sensitization / / 23817571 rs4833103 chr4 38815502 A C 5.87E-11 Pam3CSK4-induced interleukin-6 (IL-6) / / 23151486 rs4833103 chr4 38815502 A C 1.09E-10 Helicobacter pylori serologic status / / 23652523 rs4833103 chr4 38815502 A C 1.35E-12 Self-reported allergy / / 23817569 rs6815814 chr4 38816338 A C 6.95E-18 Helicobacter pylori serologic status / / 23652523 rs6815814 chr4 38816338 A C 3.67E-18 Self-reported allergy / / 23817569 rs7696175 chr4 38820986 T C 1.00E-05 Breast cancer / / 17529973 rs7696175 chr4 38820986 T C 1.51E-12 Multiple complex diseases / / 17554300 rs7696175 chr4 38820986 T C 8.79E-08 Self-reported allergy / / 23817569 rs7696175 chr4 38820986 T C 1.41E-05 Breast cancer / / pha002853 rs5743818 chr4 38829163 A C 1.28E-09 Pam3CSK4-induced interleukin-6 (IL-6) TLR6 cds-synon 23151486 rs5743810 chr4 38830350 A G 6.76E-09 Self-reported allergy TLR6 missense 23817569 rs1039559 chr4 38831596 G A 2.57E-08 Self-reported allergy TLR6 intron 23817569 rs5743794 chr4 38832727 C T 4.54E-04 Suicide attempts in bipolar disorder TLR6 intron 21423239 rs5743794 chr4 38832727 C T 3.63E-12 Helicobacter pylori serologic status TLR6 intron 23652523 rs5743794 chr4 38832727 C T 3.16E-16 Self-reported allergy TLR6 intron 23817569 rs5743788 chr4 38833207 C G 1.40E-07 Self-reported allergy TLR6 intron 23817569 rs6833914 chr4 38840162 C T 9.74E-09 Pam3CSK4-induced interleukin-6 (IL-6) TLR6 intron 23151486 rs7665774 chr4 38843749 G C 4.20E-08 Self-reported allergy TLR6 intron 23817569 rs7673348 chr4 38845198 G A 6.49E-13 Helicobacter pylori serologic status TLR6 intron 23652523 rs7673348 chr4 38845198 G A 8.77E-18 Self-reported allergy TLR6 intron 23817569 rs7687447 chr4 38846979 C G 5.08E-13 Helicobacter pylori serologic status TLR6 intron 23652523 rs7687447 chr4 38846979 C G 1.33E-17 Self-reported allergy TLR6 intron 23817569 rs6531672 chr4 38847011 T C 3.24E-08 Self-reported allergy TLR6 intron 23817569 rs6531673 chr4 38847917 T C 2.94E-07 Self-reported allergy TLR6 intron 23817569 rs7681628 chr4 38856384 G A 3.48E-07 Self-reported allergy TLR6 intron 23817569 rs17429245 chr4 38858760 T C 2.01E-09 Pam3CSK4-induced interleukin-6 (IL-6) TLR6 nearGene-5 23151486 rs2174284 chr4 38859339 C T 9.44E-12 Helicobacter pylori serologic status TLR6 nearGene-5 23652523 rs2174284 chr4 38859339 C T 9.27E-17 Self-reported allergy TLR6 nearGene-5 23817569 rs3860069 chr4 38862121 A C 1.02E-12 Helicobacter pylori serologic status / / 23652523 rs3860069 chr4 38862121 A C 3.45E-17 Self-reported allergy / / 23817569 rs17582830 chr4 38867427 A G 3.37E-11 Helicobacter pylori serologic status / / 23652523 rs17582830 chr4 38867427 A G 3.62E-16 Self-reported allergy / / 23817569 rs6824001 chr4 38872213 C T 2.53E-09 Pam3CSK4-induced interleukin-6 (IL-6) FAM114A1 intron 23151486 rs2130296 chr4 38874802 A G 5.10E-05 Multiple complex diseases FAM114A1 intron 17554300 rs721653 chr4 38878194 T C 5.56E-07 Self-reported allergy FAM114A1 intron 23817569 rs11555334 chr4 38880046 T C 9.74E-10 Pam3CSK4-induced interleukin-6 (IL-6) FAM114A1 missense 23151486 rs902136 chr4 38880313 C A 1.80E-06 Self-reported allergy FAM114A1 intron 23817569 rs11943027 chr4 38881888 G C 3.63E-08 Self-reported allergy FAM114A1 intron 23817569 rs17582893 chr4 38886420 G A 9.81E-04 Suicide attempts in bipolar disorder FAM114A1 intron 21423239 rs17582893 chr4 38886420 G A 5.01E-11 Helicobacter pylori serologic status FAM114A1 intron 23652523 rs17582893 chr4 38886420 G A 4.61E-16 Self-reported allergy FAM114A1 intron 23817569 rs2381345 chr4 38887351 C T 1.83E-06 Self-reported allergy FAM114A1 intron 23817569 rs1873195 chr4 38891173 C T 3.46E-19 Pam3CSK4-induced interleukin-6 (IL-6) FAM114A1 intron 23151486 rs1873195 chr4 38891173 C T 2.35E-11 Helicobacter pylori serologic status FAM114A1 intron 23652523 rs1873195 chr4 38891173 C T 2.92E-16 Self-reported allergy FAM114A1 intron 23817569 rs17582921 chr4 38892649 T C 2.39E-11 Helicobacter pylori serologic status FAM114A1 intron 23652523 rs17582921 chr4 38892649 T C 3.81E-16 Self-reported allergy FAM114A1 intron 23817569 rs6851685 chr4 38893843 G T 3.80E-15 Helicobacter pylori serologic status FAM114A1 intron 23652523 rs6851685 chr4 38893843 G T 1.68E-15 Self-reported allergy FAM114A1 intron 23817569 rs6851685 chr4 38893843 G T 5.06E-04 Smoking initiation FAM114A1 intron 24665060 rs6835514 chr4 38894380 A G 1.62E-04 Multiple complex diseases FAM114A1 intron 17554300 rs6835514 chr4 38894380 A G 1.93E-05 Coronary Artery Disease FAM114A1 intron 17634449 rs6835514 chr4 38894380 A G 1.08E-15 Helicobacter pylori serologic status FAM114A1 intron 23652523 rs6835514 chr4 38894380 A G 5.03E-16 Self-reported allergy FAM114A1 intron 23817569 rs1604834 chr4 38897254 G A 3.00E-04 Multiple complex diseases FAM114A1 intron 17554300 rs1604834 chr4 38897254 G A 4.41E-07 Self-reported allergy FAM114A1 intron 23817569 rs974734 chr4 38898469 G C 4.61E-07 Self-reported allergy FAM114A1 intron 23817569 rs7688418 chr4 38900057 C G 1.91E-06 Self-reported allergy FAM114A1 intron 23817569 rs7665932 chr4 38900133 A C 1.91E-06 Self-reported allergy FAM114A1 intron 23817569 rs6531677 chr4 38900397 A G 7.70E-08 Self-reported allergy FAM114A1 intron 23817569 rs12642243 chr4 38901529 T A 6.37E-07 Self-reported allergy FAM114A1 intron 23817569 rs12641669 chr4 38901769 A C 6.38E-07 Self-reported allergy FAM114A1 intron 23817569 rs1115259 chr4 38902133 C T 5.64E-07 Self-reported allergy FAM114A1 intron 23817569 rs6824769 chr4 38904581 T C 4.54E-04 Multiple complex diseases FAM114A1 intron 17554300 rs6824769 chr4 38904581 T C 5.22E-07 Self-reported allergy FAM114A1 intron 23817569 rs551301661 chr4 38905194 A ATT 5.88E-07 Self-reported allergy FAM114A1 intron 23817569 rs7664107 chr4 38905194 A T 5.88E-07 Self-reported allergy FAM114A1 intron 23817569 rs4832790 chr4 38908038 G A 1.10E-04 Self-reported allergy FAM114A1 intron 23817569 rs17583068 chr4 38908616 G C 7.58E-06 Self-reported allergy FAM114A1 intron 23817569 rs10030125 chr4 38908643 G A 5.06E-06 Self-reported allergy FAM114A1 intron 23817569 rs10026487 chr4 38910730 A G 5.04E-06 Self-reported allergy FAM114A1 intron 23817569 rs2054933 chr4 38910791 C T 3.20E-04 Multiple complex diseases FAM114A1 intron 17554300 rs2054933 chr4 38910791 C T 4.16E-06 Self-reported allergy FAM114A1 intron 23817569 rs16994919 chr4 38911205 A G 1.57E-04 Self-reported allergy FAM114A1 intron 23817569 rs16994921 chr4 38911315 A G 1.31E-04 Self-reported allergy FAM114A1 intron 23817569 rs11730661 chr4 38912484 A G 5.91E-04 Body mass index FAM114A1 intron 21701565 rs7655305 chr4 38912621 G A 2.31E-06 Self-reported allergy FAM114A1 intron 23817569 rs7657170 chr4 38912816 C T 1.83E-06 Self-reported allergy FAM114A1 intron 23817569 rs7681314 chr4 38912884 A C 2.64E-06 Self-reported allergy FAM114A1 intron 23817569 rs7681513 chr4 38912998 A G 2.69E-06 Self-reported allergy FAM114A1 intron 23817569 rs7662500 chr4 38913951 G C 2.26E-06 Self-reported allergy FAM114A1 intron 23817569 rs4240248 chr4 38916914 T G 4.78E-05 Self-reported allergy FAM114A1 intron 23817569 rs11736617 chr4 38917830 A G 4.38E-04 Self-reported allergy FAM114A1 intron 23817569 rs17616765 chr4 38922358 T C 4.16E-04 Self-reported allergy FAM114A1 intron 23817569 rs9999294 chr4 38927230 A G 1.60E-04 Major depressive disorder FAM114A1 intron 21042317 rs2306923 chr4 38930893 G A 0.00061 Breast cancer FAM114A1 missense 23555315 rs7666822 chr4 38932165 C A 8.83E-04 Response to taxane treatment (placlitaxel) FAM114A1 intron 23006423 rs4832792 chr4 38933690 A C 1.05E-08 Pam3CSK4-induced interleukin-6 (IL-6) FAM114A1 intron 23151486 rs17429619 chr4 38933859 G A 4.62E-04 Response to taxane treatment (placlitaxel) FAM114A1 missense 23006423 rs2011590 chr4 38944101 C T 5.02E-04 Type 2 diabetes FAM114A1 intron 17463246 rs13809 chr4 38947014 G A 9.04E-05 Socioeconomic Factors FAM114A1 UTR-3 pha003067 rs6810871 chr4 38959495 C A 3.09E-04 Parkinson's disease / / 17052657 rs6810871 chr4 38959495 C A 3.47E-04 Alzheimer's disease (late onset) / / 21379329 rs6816863 chr4 38960802 G A 7.65E-80 Multiple complex diseases / / 17554300 rs1473578 chr4 38968008 A G 4.58E-04 Self-reported allergy / / 23817569 rs4974983 chr4 38971057 A G 3.62E-04 Suicide attempts in bipolar disorder TMEM156 intron 21423239 rs4974983 chr4 38971057 A G 2.41E-05 Alcohol consumption TMEM156 intron 23953852 rs3821987 chr4 38990784 A G 8.48E-04 Multiple complex diseases TMEM156 intron 17554300 rs2288633 chr4 39030440 A G 7.74E-05 Bipolar disorder TMEM156 intron 20451256 rs2254212 chr4 39031842 C T 6.62E-14 Lymphocyte counts TMEM156 intron 22286170 rs2711943 chr4 39062436 T C 4.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KLHL5 intron 20877124 rs891434 chr4 39070630 T C 4.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KLHL5 intron 20877124 rs2566134 chr4 39074295 A G 4.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KLHL5 intron 20877124 rs1036044 chr4 39084992 A C 1.48E-05 Blood Pressure KLHL5 intron pha003043 rs35141484 chr4 39088341 A C 3.00E-07 Asthma (childhood onset) KLHL5 cds-synon 23829686 rs2711997 chr4 39102010 C T 9.51E-04 Multiple complex diseases KLHL5 intron 17554300 rs7675782 chr4 39121668 G A 3.31E-06 Uric acid levels KLHL5 intron 21294900 rs1061377 chr4 39124750 C A 3.06E-06 Uric acid levels KLHL5 UTR-3 21294900 rs2566163 chr4 39129965 A G 8.35E-05 Blood Pressure / / pha003043 rs6845612 chr4 39135601 C T 2.47E-06 Multiple complex diseases / / 17554300 rs2712001 chr4 39147049 T C 9.20E-04 White matter integrity / / 22425255 rs2566168 chr4 39151673 G A 6.28E-04 Multiple complex diseases / / 17554300 rs2566168 chr4 39151673 G A 7.43E-06 Cognitive function / / 24684796 rs2711990 chr4 39151736 T G 2.00E-05 Cognitive function / / 24684796 rs2711935 chr4 39162457 T C 1.00E-05 Cognitive function / / 24684796 rs4974986 chr4 39166928 T C 6.74E-06 Cognitive function / / 24684796 rs9998591 chr4 39242111 C A 8.65E-05 Blood Pressure WDR19 intron pha003043 rs6835064 chr4 39265966 A T 2.64E-06 Cognitive function WDR19 intron 24684796 rs16988409 chr4 39269350 C T 1.34E-06 Cognitive function WDR19 intron 24684796 rs3733280 chr4 39271541 A G 4.91E-06 Cognitive function WDR19 intron 24684796 rs11096990 chr4 39286949 C T 6.00E-07 Cognitive function WDR19 intron 24684796 rs1564710 chr4 39292798 G T 2.96E-04 Smoking initiation RFC1 intron 24665060 rs9993224 chr4 39300198 C T 3.21E-04 Smoking initiation RFC1 intron 24665060 rs11096991 chr4 39320631 T C 1.50E-06 Height RFC1 intron 21194676 rs11096991 chr4 39320631 T C 5.50E-04 Height RFC1 intron 21194676 rs11096991 chr4 39320631 T C 8.40E-04 Height RFC1 intron 21194676 rs10033019 chr4 39391940 G A 7.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13140731 chr4 39428176 G C 4.33E-04 Aortic root size KLB intron 21223598 rs1458254 chr4 39446807 C T 6.40E-05 Cognitive test performance KLB intron 20125193 rs1458254 chr4 39446807 C T 1.09E-06 Lymphocyte counts KLB intron 22286170 rs4975017 chr4 39450229 C A 8.62E-04 White matter integrity KLB missense 22425255 rs2687971 chr4 39452944 G C 8.75E-04 Type 2 diabetes KLB UTR-3 17463246 rs2687972 chr4 39453668 G A 8.75E-04 Type 2 diabetes / / 17463246 rs10517522 chr4 39453790 A G 8.62E-04 White matter integrity / / 22425255 rs2608829 chr4 39453898 A G 8.75E-04 Type 2 diabetes / / 17463246 rs13143990 chr4 39458591 T C 6.42E-05 Cognitive test performance RPL9 intron 20125193 rs2608830 chr4 39459154 G A 1.29E-06 Electroencephalogram traits,in brain RPL9 intron 20421487 rs16995293 chr4 39462899 A G 6.42E-05 Cognitive test performance LIAS intron 20125193 rs2125314 chr4 39472842 T A 7.69E-04 Type 2 diabetes LIAS intron 17463246 rs2259073 chr4 39475074 A C 4.55E-07 Electroencephalogram traits,in brain LIAS intron 20421487 rs6531719 chr4 39487301 A G 3.93E-05 HIV-1 viral setpoint / / 22174851 rs13111541 chr4 39488473 C T 3.94E-04 Taste perception / / 22132133 rs2687964 chr4 39496272 G T 4.54E-06 Electroencephalogram traits,in brain / / 20421487 rs7667766 chr4 39504305 C A 7.04E-08 Electroencephalogram traits,in brain UGDH intron 20421487 rs2381387 chr4 39531928 G A 1.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7692279 chr4 39545451 T C 5.44E-05 Lymphocyte counts / / 22286170 rs2608822 chr4 39548482 C T 2.00E-04 Information processing speed / / 21130836 rs11941588 chr4 39655457 T C 7.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6531736 chr4 39686517 G A 6.51E-04 Type 2 diabetes / / 17463246 rs7657284 chr4 39688694 A C 6.51E-04 Type 2 diabetes / / 17463246 rs9683743 chr4 39703194 T G 5.70E-05 Pericardial fat UBE2K intron 22589742 rs652162 chr4 39704197 G A 6.62E-04 Multiple complex diseases UBE2K intron 17554300 rs4974948 chr4 39752636 G T 5.90E-05 Pericardial fat UBE2K intron 22589742 rs7687557 chr4 39769260 A C 6.90E-05 Pericardial fat UBE2K intron 22589742 rs4263408 chr4 39785276 T C 8.10E-05 Pericardial fat / / 22589742 rs4263408 chr4 39785276 T C 7.00E-06 Plasma amyloid beta peptide concentrations (ABx-40) / / 24535457 rs6814315 chr4 39793385 T G 7.10E-05 Pericardial fat / / 22589742 rs403611 chr4 39812247 C T 8.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4974949 chr4 39814064 A G 8.45E-05 Bone mineral density / / 19181680 rs7657667 chr4 39836933 A G 4.38E-04 Stroke PDS5A intron pha002887 rs50296 chr4 39837128 C T 7.69E-05 Rheumatoid arthritis PDS5A intron 19503088 rs461304 chr4 39844093 G T 8.34E-07 Rheumatoid arthritis PDS5A intron 19503088 rs2101122 chr4 39858520 C T 4.20E-07 Rheumatoid arthritis PDS5A intron 19503088 rs922749 chr4 39894988 C T 6.47E-06 Rheumatoid arthritis PDS5A intron 19503088 rs7654036 chr4 39900719 T C 4.41E-06 Rheumatoid arthritis PDS5A intron 19503088 rs9996801 chr4 39908500 G A 4.55E-04 Lung function (forced vital capacity) PDS5A intron 24023788 rs9996801 chr4 39908500 G A 5.21E-05 Lung function (forced expiratory volume in 1 second) PDS5A intron 24023788 rs2732072 chr4 39984938 C A 6.60E-05 Personality dimensions / / 18957941 rs2732072 chr4 39984938 C A 6.09E-06 Rheumatoid arthritis / / 19503088 rs7677857 chr4 39989369 C T 3.73E-04 Premature ovarian failure / / 19508998 rs7677857 chr4 39989369 C T 5.67E-06 Cognitive impairment induced by topiramate / / 22091778 rs7674515 chr4 40064563 C T 3.22E-05 Triglycerides N4BP2 intron 19074352 rs7674515 chr4 40064563 C T 3.22E-05 Polyunsaturated fatty acid levels,in plasma N4BP2 intron 19148276 rs7674515 chr4 40064563 C T 1.92E-05 Basophils N4BP2 intron pha003087 rs17439873 chr4 40071926 T C 3.44E-04 Multiple complex diseases N4BP2 intron 17554300 rs1706023 chr4 40074742 G A 8.77E-04 Rheumatoid arthritis N4BP2 intron 21452313 rs17619330 chr4 40120420 C T 2.79E-08 Lymphocyte counts N4BP2 intron 22286170 rs794001 chr4 40121562 G A 2.84E-04 Type 2 diabetes N4BP2 missense 17463246 rs794009 chr4 40139719 T G 2.10E-04 Amyotrophic lateral sclerosis (sporadic) N4BP2 intron 24529757 rs794008 chr4 40140338 C T 3.83E-04 Type 2 diabetes N4BP2 intron 17463246 rs7656730 chr4 40159617 T C 0.00000104 Platelet thrombus as measured by PFA-100ColA closure time upon shear stress N4BP2 UTR-3 22550155 rs9993439 chr4 40160534 C T 2.29E-04 Rheumatoid arthritis / / 21452313 rs1397933 chr4 40187537 T G 6.65E-04 Type 2 diabetes / / 17463246 rs1397933 chr4 40187537 T G 5.44E-05 Sudden cardiac arrest / / 21658281 rs4974970 chr4 40188494 A G 6.53E-04 Type 2 diabetes / / 17463246 rs12501987 chr4 40189325 T C 9.49E-04 Type 2 diabetes / / 17463246 rs1320213 chr4 40193538 C T 5.89E-06 IgE levels / / 17255346 rs11722379 chr4 40261293 C T 4.10E-05 Response to statin therapy / / 20339536 rs12643250 chr4 40262582 G A 1.90E-05 Response to statin therapy / / 20339536 rs11097019 chr4 40266986 A C 3.50E-05 Response to statin therapy / / 20339536 rs9683756 chr4 40279534 G A 5.18E-05 Asthma / / pha003127 rs10213384 chr4 40292196 C T 1.73E-04 Multiple complex diseases / / 17554300 rs10213384 chr4 40292196 C T 1.60E-05 Urinary metabolites / / 21572414 rs11932152 chr4 40293158 T C 1.60E-05 Urinary metabolites / / 21572414 rs10018657 chr4 40301971 T C 3.29E-04 Alzheimer's disease / / 17998437 rs6832151 chr4 40303633 G T 6.11E-05 Systemic sclerosis / / 21750679 rs6832151 chr4 40303633 G T 1.00E-13 Graves' disease / / 21841780 rs6832151 chr4 40303633 G T 1.85E-04 IgA nephropathy / / 22197929 rs11735437 chr4 40318344 A G 7.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs6840316 chr4 40326877 G T 5.49E-04 Parkinson's disease / / 17052657 rs13138234 chr4 40332715 T C 9.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs10805117 chr4 40332838 T A 9.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs4264869 chr4 40355126 C T 6.50E-05 Schizophrenia CHR/9 intron 19571808 rs10938433 chr4 40357326 C T 1.80E-05 Urinary metabolites / / 21572414 rs10021851 chr4 40368848 G A 2.88E-05 Leukocyte Counts / / pha003091 rs1492505 chr4 40373150 T C 1.75E-04 Aortic root size / / 21223598 rs4447895 chr4 40397253 C A 5.83E-05 Bipolar disorder / / 21771265 rs203273 chr4 40418670 C T 0.000007054 Sarcoidosis / / 22952805 rs278940 chr4 40420752 A G 0.00001013 Sarcoidosis / / 22952805 rs278938 chr4 40421327 G A 0.0002675 Sarcoidosis / / 22952805 rs2008438 chr4 40424602 G T 0.00002224 Sarcoidosis / / 22952805 rs278982 chr4 40426677 G A 0.000006113 Sarcoidosis RBM47 UTR-3 22952805 rs4861137 chr4 40442916 T C 1.28E-04 HIV-1 viral setpoint RBM47 intron 21490045 rs10018317 chr4 40447356 G A 4.38E-05 Waist Circumference RBM47 intron pha003023 rs2046987 chr4 40451314 T C 5.24E-04 Multiple complex diseases RBM47 intron 17554300 rs2046987 chr4 40451314 T C 6.53E-05 Insulin resistance RBM47 intron 21901158 rs3105209 chr4 40473784 A G 1.40E-06 Urinary metabolites RBM47 intron 21572414 rs278962 chr4 40475295 T C 7.57E-04 Intracranial aneurysm RBM47 intron 20613766 rs9991419 chr4 40483196 T C 4.73E-04 Obesity (extreme) RBM47 intron 21935397 rs1847118 chr4 40491003 C T 5.13E-06 Coronary heart disease RBM47 intron pha003031 rs10517543 chr4 40491187 G A 5.20E-05 Blood Phenotypes RBM47 intron 17903294 rs2008613 chr4 40495043 G C 2.13E-04 Multiple complex diseases RBM47 intron 17554300 rs17587144 chr4 40503270 G A 6.65E-05 Substance dependence RBM47 intron 21818250 rs6835176 chr4 40504552 C T 9.60E-04 Type 2 diabetes RBM47 intron 21874001 rs278953 chr4 40508004 C A 1.39E-04 Response to taxane treatment (placlitaxel) RBM47 intron 23006423 rs7658681 chr4 40529071 T C 3.63E-04 Multiple complex diseases RBM47 intron 17554300 rs4632692 chr4 40535566 A G 1.79E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) RBM47 intron 24023788 rs4632692 chr4 40535566 A G 3.44E-05 Magnesium levels RBM47 intron pha003092 rs2170438 chr4 40588641 G A 6.97E-04 Multiple complex diseases RBM47 intron 17554300 rs6857625 chr4 40613138 C T 1.09E-05 Diabetes Mellitus RBM47 intron pha003060 rs7682489 chr4 40613961 G A 9.34E-04 Multiple complex diseases RBM47 intron 17554300 rs7659100 chr4 40614065 C A 3.65E-04 Multiple complex diseases RBM47 intron 17554300 rs7664412 chr4 40631309 A G 9.48E-04 Multiple complex diseases RBM47 intron 17554300 rs6830900 chr4 40708301 A G 4.60E-05 Information processing speed / / 21130836 rs2341571 chr4 40710831 A G 4.60E-05 Information processing speed / / 21130836 rs2341571 chr4 40710831 A G 4.41E-05 Brain structure / / 22504417 rs17513709 chr4 40802119 T G 5.32E-04 Suicide attempts in bipolar disorder NSUN7 intron 21041247 rs17441923 chr4 40803370 T C 5.26E-04 Suicide attempts in bipolar disorder NSUN7 intron 21041247 rs882733 chr4 40810978 G A 3.98E-04 Suicide attempts in bipolar disorder NSUN7 UTR-3 21041247 rs116478358 chr4 40828219 T A 2.08E-05 Cocaine dependence APBB2 intron 23958962 rs765850 chr4 40842367 T C 2.60E-04 Longevity APBB2 intron 22279548 rs12504297 chr4 40867839 C T 8.94E-04 Amyotrophic Lateral Sclerosis APBB2 intron 17362836 rs4861330 chr4 40913247 T C 8.08E-04 Aortic root size APBB2 intron 21223598 rs4466078 chr4 40973527 T A 8.00E-06 Dental caries APBB2 intron 23259602 rs12511584 chr4 40977934 T C 5.90E-05 White matter hyperintensity burden APBB2 intron 21681796 rs6829200 chr4 40980047 T C 9.10E-05 White matter hyperintensity burden APBB2 intron 21681796 rs13143389 chr4 40986016 C T 7.60E-05 White matter hyperintensity burden APBB2 intron 21681796 rs6856268 chr4 40986829 C T 5.50E-05 White matter hyperintensity burden APBB2 intron 21681796 rs2048175 chr4 40987622 C T 5.00E-05 White matter hyperintensity burden APBB2 intron 21681796 rs10938478 chr4 40989048 T C 5.00E-05 White matter hyperintensity burden APBB2 intron 21681796 rs4861076 chr4 40989418 T C 4.90E-05 White matter hyperintensity burden APBB2 intron 21681796 rs4861352 chr4 40995879 C T 4.90E-05 White matter hyperintensity burden APBB2 intron 21681796 rs6832976 chr4 41003571 T C 3.08E-05 Aging (time to event) APBB2 intron 21782286 rs12500263 chr4 41004365 C T 8.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) APBB2 intron 20877124 rs4861357 chr4 41009452 T C 5.70E-05 White matter hyperintensity burden APBB2 intron 21681796 rs4861358 chr4 41015899 C T 9.37E-05 Tunica Media APBB2 missense pha003038 rs114070671 chr4 41056716 A G 1.00E-07 Opioid sensitivity APBB2 intron 24143882 rs115368721 chr4 41056839 G A 1.92E-08 Opioid sensitivity APBB2 intron 24143882 rs13129535 chr4 41074389 G A 4.55E-04 Smoking initiation APBB2 intron 24665060 rs1508067 chr4 41078183 A C 1.14E-04 Parkinson's disease APBB2 intron 17052657 rs10516997 chr4 41082483 G C 2.00E-04 Asthma (childhood onset) APBB2 intron 21359210 rs10516997 chr4 41082483 G C 7.84E-05 Blood pressure (response to calcium channel blocker) APBB2 intron 24192120 rs10049948 chr4 41175926 C T 3.48E-04 Hearing function APBB2 intron 17255346 rs12331383 chr4 41176071 G A 5.62E-05 Major depressive disorder (broad) APBB2 intron 20038947 rs7659645 chr4 41181161 C T 5.45E-05 Major depressive disorder (broad) APBB2 intron 20038947 rs2342429 chr4 41191998 T C 5.26E-04 Acute lung injury APBB2 intron 22295056 rs16852900 chr4 41192923 C T 5.26E-04 Acute lung injury APBB2 intron 22295056 rs11932112 chr4 41193113 A C 3.87E-05 Major depressive disorder (broad) APBB2 intron 20038947 rs6841052 chr4 41197127 C T 6.74E-05 Hearing function APBB2 intron 17255346 rs6856881 chr4 41197202 T C 2.80E-04 Hearing function APBB2 intron 17255346 rs7678120 chr4 41202583 G A 8.92E-05 Hearing function APBB2 intron 17255346 rs7683746 chr4 41203125 G A 8.82E-05 Hearing function APBB2 intron 17255346 rs7655737 chr4 41203215 C T 8.82E-05 Hearing function APBB2 intron 17255346 rs7671003 chr4 41203317 T C 8.82E-05 Hearing function APBB2 intron 17255346 rs17660753 chr4 41204005 C G 7.13E-05 Lymphocyte counts APBB2 intron 22286170 rs6835127 chr4 41204395 T C 2.50E-04 Myopia (pathological) APBB2 intron 21095009 rs6835127 chr4 41204395 T C 8.10E-06 Urinary metabolites APBB2 intron 21572414 rs7691440 chr4 41204664 G A 8.80E-06 Urinary metabolites APBB2 intron 21572414 rs16852911 chr4 41205654 A T 1.00E-05 Urinary metabolites APBB2 intron 21572414 rs10517001 chr4 41210665 A G 1.40E-04 Volumetric brain MRI APBB2 intron 17903297 rs11722918 chr4 41234424 C T 4.90E-05 Brain lesion load / / 19010793 rs7693827 chr4 41254862 T C 2.46E-04 Cocaine dependence / / 23958962 rs4861386 chr4 41254954 A C 1.61E-04 Cocaine dependence / / 23958962 rs4861386 chr4 41254954 A C 9.34E-04 Cocaine dependence / / 23958962 rs17528160 chr4 41265921 A G 2.10E-04 Type 2 diabetes UCHL1 intron 17463246 rs3775256 chr4 41266295 C T 3.76E-05 Intelligence UCHL1 intron 21826061 rs4861387 chr4 41268465 G A 1.59E-04 Type 2 diabetes UCHL1 intron 17463246 rs4861096 chr4 41284711 T C 9.00E-06 Cognitive performance / / 19734545 rs4861096 chr4 41284711 T C 1.17E-05 Intelligence / / 21826061 rs17443835 chr4 41285294 T A 1.60E-05 Urinary metabolites / / 21572414 rs6820914 chr4 41297647 G A 1.25E-04 Smoking quantity / / 24665060 rs1453048 chr4 41307008 C T 7.25E-04 Alcohol dependence / / 21314694 rs2010717 chr4 41309822 T C 3.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs1453047 chr4 41310168 T G 3.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs1453046 chr4 41310525 G C 9.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs1119590 chr4 41314220 C T 7.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs6827489 chr4 41315660 G A 5.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs11735648 chr4 41319962 A C 1.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs11723771 chr4 41320231 G T 1.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs11736581 chr4 41320335 A C 2.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs11736653 chr4 41320547 A G 1.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs11736685 chr4 41320635 A G 5.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs877668 chr4 41320781 A G 1.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs877669 chr4 41320919 G A 1.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs1377346 chr4 41322018 T C 1.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs1377345 chr4 41322070 G A 8.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs6838610 chr4 41322398 G A 5.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs6447048 chr4 41322704 C G 8.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs6447050 chr4 41322889 C A 2.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs17444017 chr4 41323426 A G 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs7672783 chr4 41324224 A G 9.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs1840101 chr4 41326784 G T 1.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs7692556 chr4 41327242 A G 1.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs7692580 chr4 41327286 A G 2.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs1982445 chr4 41331817 T G 2.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs6830887 chr4 41333461 C T 1.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs1823788 chr4 41336979 T C 5.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs9637557 chr4 41340526 C T 2.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs9637555 chr4 41340710 T C 2.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs6830701 chr4 41341244 T C 2.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs7697529 chr4 41342296 C T 2.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs6447057 chr4 41343706 C T 3.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs11721762 chr4 41346915 A T 2.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs1377347 chr4 41372602 T G 2.77E-04 Schizophrenia LIMCH1 intron 19197363 rs1869286 chr4 41373402 G A 1.00E-04 Information processing speed LIMCH1 intron 21130836 rs1869286 chr4 41373402 G A 6.27E-06 Cholesterol LIMCH1 intron pha003073 rs1869286 chr4 41373402 G A 6.72E-05 ldl cholesterol LIMCH1 intron pha003076 rs1869286 chr4 41373402 G A 4.33E-06 Cholesterol LIMCH1 intron pha003078 rs1901747 chr4 41376347 C T 8.38E-05 Cholesterol LIMCH1 intron pha003078 rs12643401 chr4 41410387 C T 1.08E-05 Scoliosis LIMCH1 intron 21216876 rs7675059 chr4 41430052 A G 2.75E-04 Scoliosis LIMCH1 intron 21216876 rs7675059 chr4 41430052 A G 3.70E-04 White matter integrity LIMCH1 intron 22425255 rs6447070 chr4 41433991 A G 4.79E-04 White matter integrity LIMCH1 intron 22425255 rs13124842 chr4 41446758 G A 2.75E-04 White matter integrity LIMCH1 intron 22425255 rs4560447 chr4 41447510 G T 1.45E-05 HIV-1 viral setpoint LIMCH1 intron 22174851 rs4861116 chr4 41484189 A G 9.66E-04 Multiple complex diseases LIMCH1 intron 17554300 rs7696430 chr4 41490455 G A 1.23E-04 Glycosylated haemoglobin levels LIMCH1 intron 17255346 rs12696762 chr4 41522232 T C 8.31E-05 Bipolar disorder LIMCH1 intron 19488044 rs6447084 chr4 41531404 C T 1.99E-04 Rheumatoid arthritis LIMCH1 intron 21452313 rs6815819 chr4 41534784 T G 2.28E-04 Rheumatoid arthritis LIMCH1 intron 21452313 rs6447088 chr4 41541119 T C 1.29E-04 Rheumatoid arthritis LIMCH1 intron 21452313 rs4306988 chr4 41607350 C T 2.80E-05 Urinary metabolites LIMCH1 intron 21572414 rs11942246 chr4 41607680 A G 8.16E-05 Orofacial clefts LIMCH1 intron 20023658 rs1105886 chr4 41611575 A G 7.84E-05 Orofacial clefts LIMCH1 intron 20023658 rs1105886 chr4 41611575 A G 4.53E-05 Orofacial clefts LIMCH1 intron 22863734 rs7662775 chr4 41620951 G A 5.15E-04 Multiple complex diseases LIMCH1 intron 17554300 rs4345220 chr4 41639516 A G 2.00E-06 Migraine with aura LIMCH1 intron 23793025 rs7695473 chr4 41655266 C T 5.26E-04 Acute lung injury LIMCH1 intron 22295056 rs16853451 chr4 41680356 T A 5.00E-04 Multiple complex diseases LIMCH1 intron 17554300 rs3765034 chr4 41686809 T C 7.00E-05 Prostate cancer LIMCH1 intron 21743057 rs1061562 chr4 41700361 A G 9.00E-05 Prostate cancer LIMCH1 UTR-3 21743057 rs6857635 chr4 41709538 T C 3.00E-05 Personality dimensions / / 22628180 rs6817913 chr4 41711689 A G 7.60E-06 Urinary metabolites / / 21572414 rs11728925 chr4 41713665 C A 2.37E-08 Meningococcal disease / / 20694013 rs10014254 chr4 41714518 C T 0.000000042 Amygdala reactivity / / 22856363 rs11722038 chr4 41723157 A G 0.000000402 Amygdala reactivity / / 22856363 rs17529323 chr4 41733493 A C 6.07E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17529323 chr4 41733493 A C 4.07E-07 Amygdala reactivity / / 22856363 rs17444879 chr4 41734629 C T 3.30E-07 Urinary metabolites / / 21572414 rs11731281 chr4 41736897 A C 2.46E-04 Lung function (forced vital capacity) / / 24023788 rs16853571 chr4 41753130 A C 2.40E-07 Crohn's disease / / 17435756 rs9283670 chr4 41758803 T C 0.000141 Colorectal cancer (females) / / 22532847 rs7664468 chr4 41812109 A G 2.99E-04 Alzheimer's disease (late onset) / / 21379329 rs7664468 chr4 41812109 A G 4.00E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1106390 chr4 41879969 A T 5.60E-04 Obesity (extreme) / / 21935397 rs4861148 chr4 41882601 T C 4.94E-04 Obesity (extreme) / / 21935397 rs9993759 chr4 41883483 T C 4.36E-04 Obesity (extreme) / / 21935397 rs7675823 chr4 41898908 C G 9.13E-04 Obesity (extreme) / / 21935397 rs16853762 chr4 41926368 G C 8.52E-05 Schizophrenia / / 19571811 rs13122139 chr4 41931781 A G 2.41E-04 Obesity (extreme) / / 21935397 rs17445354 chr4 41964337 A G 7.89E-04 Obesity (extreme) / / 21935397 rs2660343 chr4 41977766 G A 8.89E-04 Obesity (extreme) / / 21935397 rs2660342 chr4 41977804 A G 3.14E-04 Longevity / / 22279548 rs34936554 chr4 42031922 G T 2.50E-05 Cognitive test performance SLC30A9 intron 20125193 rs7692259 chr4 42110454 A C 3.23E-04 Smoking cessation / / 24665060 rs16853969 chr4 42112012 C T 6.31E-04 Smoking cessation / / 24665060 rs17445998 chr4 42112536 C T 1.39E-04 Smoking cessation / / 24665060 rs17446061 chr4 42115810 C T 8.00E-05 Smoking cessation BEND4 UTR-3 24665060 rs16854020 chr4 42117559 G A 6.88E-04 Smoking cessation BEND4 UTR-3 24665060 rs6447132 chr4 42134066 C T 5.59E-05 Serum metabolites BEND4 intron 19043545 rs7664565 chr4 42135019 C T 8.90E-05 Serum metabolites BEND4 intron 19043545 rs10010272 chr4 42165988 A G 8.07E-04 Multiple complex diseases / / 17554300 rs10025984 chr4 42208010 G A 2.70E-06 Urinary metabolites / / 21572414 rs9999533 chr4 42211367 C T 2.60E-06 Urinary metabolites / / 21572414 rs11722892 chr4 42222459 G A 2.90E-05 Information processing speed / / 21130836 rs1565110 chr4 42225194 G A 6.08E-05 Glycosylated haemoglobin levels / / 17255346 rs1565110 chr4 42225194 G A 5.33E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs6829929 chr4 42226548 T C 8.17E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs13117610 chr4 42226924 A G 8.69E-05 Glycosylated haemoglobin levels / / 17255346 rs17530621 chr4 42227497 T G 9.96E-05 Glycosylated haemoglobin levels / / 17255346 rs4861175 chr4 42237898 G A 6.05E-04 Type 2 diabetes / / 17463246 rs4861175 chr4 42237898 G A 2.60E-04 Airway hyperresponsiveness / / 23984888 rs989313 chr4 42243086 C A 5.54E-05 Socioeconomic Factors / / pha003066 rs9291212 chr4 42249776 A G 2.40E-05 Urinary metabolites / / 21572414 rs1023993 chr4 42336312 A C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6447159 chr4 42389740 C A 9.80E-05 Type 2 diabetes / / 17463246 rs7676862 chr4 42397387 C T 1.07E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6815292 chr4 42410264 G A 7.90E-05 Type 2 diabetes / / 17463248 rs7665824 chr4 42411553 G T 7.80E-05 Type 2 diabetes ATP8A1 UTR-3 17463248 rs12639920 chr4 42412687 T G 4.90E-05 Alzheimer's disease (late onset) ATP8A1 UTR-3 20885792 rs12639920 chr4 42412687 T G 4.90E-05 Alzheimer's disease (late onset) ATP8A1 UTR-3 21460841 rs11726581 chr4 42417007 T C 7.70E-05 Type 2 diabetes ATP8A1 intron 17463248 rs11722556 chr4 42417900 C T 7.50E-05 Type 2 diabetes ATP8A1 intron 17463248 rs17630357 chr4 42425114 A T 8.20E-05 Type 2 diabetes ATP8A1 intron 17463248 rs4317238 chr4 42426177 A G 8.10E-05 Type 2 diabetes ATP8A1 intron 17463248 rs16854359 chr4 42428172 G C 5.70E-05 Type 2 diabetes ATP8A1 intron 17463248 rs9994372 chr4 42428210 C T 2.50E-05 Type 2 diabetes ATP8A1 intron 17463248 rs10034439 chr4 42446162 C T 3.10E-05 Type 2 diabetes ATP8A1 intron 17463248 rs10517025 chr4 42453253 C T 2.00E-07 Immune reponse to smallpox (secreted IFN-alpha) ATP8A1 intron 22610502 rs13139219 chr4 42453303 A C 7.80E-05 Type 2 diabetes ATP8A1 intron 17463248 rs10517028 chr4 42473630 A G 3.59E-05 Height ATP8A1 intron 22021425 rs202095934 chr4 42478626 AT A 7.00E-05 Type 2 diabetes ATP8A1 intron 17463248 rs6812080 chr4 42478626 A G 7.00E-05 Type 2 diabetes ATP8A1 intron 17463248 rs13116032 chr4 42479590 T G 7.00E-05 Type 2 diabetes ATP8A1 intron 17463248 rs17531757 chr4 42483659 G A 3.00E-04 Multiple complex diseases ATP8A1 intron 17554300 rs12510610 chr4 42504705 T A 9.81E-04 Type 2 diabetes ATP8A1 intron 17463246 rs10034610 chr4 42504827 G T 6.49E-04 Myocardial Infarction ATP8A1 intron pha002883 rs10517039 chr4 42513936 C A 1.00E-08 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) ATP8A1 intron 17982456 rs3749530 chr4 42593240 A C 7.30E-08 Corneal structure ATP8A1 intron 22003120 rs6812482 chr4 42597824 T G 8.09E-04 Common variable immunodeficiency ATP8A1 intron 21497890 rs7681922 chr4 42605407 A G 9.34E-05 Corneal structure ATP8A1 intron 22003120 rs7654745 chr4 42622970 C T 7.20E-05 Parkinson's disease (age of onset) ATP8A1 intron 19772629 rs898500 chr4 42639186 A G 9.30E-05 Parkinson's disease (age of onset) ATP8A1 intron 19772629 rs2575568 chr4 42660891 A C 9.39E-05 Diabetes Mellitus / / pha003060 rs12501388 chr4 42673312 G A 7.08E-05 Longevity / / 20304771 rs12499249 chr4 42675033 A T 7.13E-05 Longevity / / 20304771 rs17593986 chr4 42686530 G A 4.54E-05 Longevity / / 20304771 rs2612525 chr4 42723076 C T 4.31E-04 Type 2 diabetes / / 17463246 rs2575533 chr4 42737579 G T 3.60E-05 Personality dimensions / / 18957941 rs2575534 chr4 42737828 G A 6.40E-05 Personality dimensions / / 18957941 rs2612510 chr4 42737865 A G 7.80E-05 Personality dimensions / / 18957941 rs2612516 chr4 42740664 G C 5.00E-05 Personality dimensions / / 18957941 rs4279252 chr4 42742250 T C 2.53E-05 Longevity / / 20304771 rs10517048 chr4 42748264 T C 5.60E-05 Personality dimensions / / 18957941 rs10517050 chr4 42748945 C A 7.50E-05 Personality dimensions / / 18957941 rs10213558 chr4 42751258 C T 6.80E-05 Personality dimensions / / 18957941 rs9291223 chr4 42751332 A C 8.10E-05 Personality dimensions / / 18957941 rs6831756 chr4 42751825 T C 7.00E-05 Personality dimensions / / 18957941 rs10000801 chr4 42752421 A T 4.30E-05 Personality dimensions / / 18957941 rs2345904 chr4 42753188 A G 6.80E-05 Personality dimensions / / 18957941 rs2575543 chr4 42776797 A G 6.60E-05 Personality dimensions / / 18957941 rs10938217 chr4 42777142 T G 5.26E-05 Obesity (extreme) / / 21935397 rs10938218 chr4 42779212 C T 5.41E-05 Obesity (extreme) / / 21935397 rs12642750 chr4 42786601 C T 5.47E-05 Obesity (extreme) / / 21935397 rs2575555 chr4 42787157 A T 1.06E-04 Obesity (extreme) / / 21935397 rs12331684 chr4 42790130 G A 9.04E-05 Obesity (extreme) / / 21935397 rs6856377 chr4 42790514 T C 8.90E-05 Obesity (extreme) / / 21935397 rs12506552 chr4 42791826 T C 8.80E-05 Obesity (extreme) / / 21935397 rs12640374 chr4 42796110 G T 8.76E-05 Obesity (extreme) / / 21935397 rs12650389 chr4 42796127 T C 8.67E-05 Obesity (extreme) / / 21935397 rs12640399 chr4 42796163 G C 9.39E-05 Obesity (extreme) / / 21935397 rs12640422 chr4 42796235 G A 8.66E-05 Obesity (extreme) / / 21935397 rs12640425 chr4 42796283 G C 8.65E-05 Obesity (extreme) / / 21935397 rs2575513 chr4 42796294 T C 1.23E-04 Obesity (extreme) / / 21935397 rs12650499 chr4 42796508 T A 8.65E-05 Obesity (extreme) / / 21935397 rs12650501 chr4 42796521 T C 8.65E-05 Obesity (extreme) / / 21935397 rs17637428 chr4 42797090 T C 8.64E-05 Obesity (extreme) / / 21935397 rs7697036 chr4 42797274 T C 6.10E-04 Obesity (extreme) / / 21935397 rs2598306 chr4 42799590 G A 4.56E-04 Myopia (pathological) / / 21095009 rs2598306 chr4 42799590 G A 1.24E-04 Obesity (extreme) / / 21935397 rs2575515 chr4 42800456 T G 1.24E-04 Obesity (extreme) / / 21935397 rs1901224 chr4 42802009 T G 1.23E-04 Obesity (extreme) / / 21935397 rs12505784 chr4 42805601 C T 5.54E-05 Obesity (extreme) / / 21935397 rs12644472 chr4 42809090 C T 8.62E-05 Obesity (extreme) / / 21935397 rs6831242 chr4 42809268 T C 8.62E-05 Obesity (extreme) / / 21935397 rs17637488 chr4 42810120 A G 7.91E-05 Obesity (extreme) / / 21935397 rs1562838 chr4 42813722 A G 4.46E-05 Obesity (extreme) / / 21935397 rs1562839 chr4 42813800 A G 4.43E-05 Obesity (extreme) / / 21935397 rs1450913 chr4 42813890 G A 7.81E-04 Multiple complex diseases / / 17554300 rs1450913 chr4 42813890 G A 2.50E-04 Obesity (extreme) / / 21935397 rs4861224 chr4 42815289 T A 4.55E-05 Obesity (extreme) / / 21935397 rs12642002 chr4 42821495 T G 2.16E-05 Obesity (extreme) / / 21935397 rs13101582 chr4 42823179 G A 2.19E-05 Obesity (extreme) / / 21935397 rs10470752 chr4 42825862 G A 5.01E-04 Coronary heart disease / / 21971053 rs10470752 chr4 42825862 G A 1.36E-05 Height / / pha003011 rs1562840 chr4 42838348 T C 3.80E-05 Myasthenia gravis / / 23055271 rs6447192 chr4 42845169 T C 7.44E-04 Substance dependence / / 21818250 rs13142169 chr4 42854052 T G 3.33E-04 Multiple complex diseases / / 17554300 rs10938223 chr4 42854950 A G 3.05E-04 Multiple complex diseases / / 17554300 rs2044844 chr4 42856639 C A 7.94E-06 Erythrocyte counts / / pha003101 rs10004231 chr4 42857573 C T 1.40E-04 Multiple complex diseases / / 17554300 rs13108577 chr4 42857828 A C 3.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs9985652 chr4 42858453 A G 4.11E-06 Erythrocyte counts / / pha003101 rs6850606 chr4 42864696 G A 3.10E-06 Myasthenia gravis / / 23055271 rs10012449 chr4 42865108 C A 5.70E-05 Myasthenia gravis / / 23055271 rs41493449 chr4 42895715 A G 3.42E-04 Multiple complex diseases GRXCR1 intron 17554300 rs10517055 chr4 42902734 A G 1.80E-06 Breast cancer GRXCR1 intron 22452962 rs1450906 chr4 42906100 A G 5.15E-05 Multiple complex diseases GRXCR1 intron 17554300 rs6830507 chr4 42919640 G A 0.000263372 Hypertension (early onset hypertension) GRXCR1 intron 22479346 rs7439983 chr4 42924853 A G 8.06E-04 Suicide attempts in bipolar disorder GRXCR1 intron 21423239 rs4861238 chr4 42948976 G T 8.62E-05 Angioedema in response to angiotensin-converting enzyme inhibitor GRXCR1 intron 23838604 rs994705 chr4 42963537 T G 9.86E-05 Post-operative nausea and vomiting GRXCR1 intron 21694509 rs2217915 chr4 43011209 A G 1.18E-05 Hemoglobin GRXCR1 intron pha003098 rs2217915 chr4 43011209 A G 2.74E-06 Erythrocyte counts GRXCR1 intron pha003099 rs9997524 chr4 43052186 A C 7.00E-06 Obesity-related traits / / 23251661 rs920152 chr4 43068604 T C 6.34E-06 Hemoglobin / / pha003098 rs920152 chr4 43068604 T C 6.70E-06 Erythrocyte counts / / pha003099 rs7678001 chr4 43088165 T A,G 5.67E-06 Hemoglobin / / pha003098 rs7678001 chr4 43088165 T A,G 4.53E-06 Erythrocyte counts / / pha003099 rs12505258 chr4 43199190 G A 6.89E-04 Aortic root size / / 21223598 rs10938258 chr4 43206669 C T 5.24E-04 Aortic root size / / 21223598 rs6846200 chr4 43207754 T G 1.60E-04 Type 2 diabetes / / 17463246 rs6846200 chr4 43207754 T G 2.09E-04 Multiple complex diseases / / 17554300 rs4277811 chr4 43208770 T C 4.10E-04 Type 2 diabetes / / 17463246 rs4309873 chr4 43210488 G A 3.34E-04 Type 2 diabetes / / 17463246 rs4481267 chr4 43219538 T C 2.07E-05 Multiple complex diseases / / 17554300 rs11728426 chr4 43261324 T C 2.60E-06 Urinary metabolites / / 21572414 rs1442858 chr4 43274263 G A 2.70E-05 Urinary metabolites / / 21572414 rs1442859 chr4 43274485 C T 1.70E-05 Urinary metabolites / / 21572414 rs6851736 chr4 43283272 C T 2.41E-09 Multiple complex diseases / / 17554300 rs2006970 chr4 43320507 C A 9.00E-06 Metabolite levels (5-HIAA/ MHPG Ratio) / / 23319000 rs1398200 chr4 43350370 C A 4.16E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1606284 chr4 43478594 A C 7.70E-04 Multiple complex diseases / / 17554300 rs1606284 chr4 43478594 A C 6.98E-04 Myocardial Infarction / / pha002873 rs13130255 chr4 43537600 T G 3.00E-06 Anticoagulant levels / / 22216198 rs13130255 chr4 43537600 T G 5.05E-04 Heart Failure / / pha002885 rs11939659 chr4 43561857 C T 7.64E-04 Myocardial Infarction / / pha002873 rs5014637 chr4 43567623 C A 9.53E-04 Myocardial Infarction / / pha002873 rs6447290 chr4 43643675 A G 9.61E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1594924 chr4 43663177 G A 6.08E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1962872 chr4 43664997 G A 5.14E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs41407448 chr4 43679078 A G 7.72E-05 Multiple complex diseases / / 17554300 rs1713517 chr4 43689885 G T 4.46E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7659996 chr4 43702376 C T 5.36E-04 Myocardial Infarction / / pha002873 rs1369173 chr4 43729510 T A 8.23E-04 Multiple complex diseases / / 17554300 rs1713526 chr4 43792529 T A 9.50E-05 Parkinson's disease (age of onset) / / 19772629 rs10019693 chr4 43900995 A G 8.64E-06 Hearing function / / 17255346 rs12644632 chr4 43913465 G A 3.39E-04 Alzheimer's disease / / 24755620 rs1870645 chr4 43944901 T C 8.25E-04 Type 2 diabetes / / 17463246 rs9291240 chr4 43945196 A G 4.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7693710 chr4 44091711 C T 2.66E-05 Blood Pressure / / pha003045 rs7693710 chr4 44091711 C T 4.72E-05 Blood Pressure / / pha003047 rs7686284 chr4 44155914 G A 8.20E-09 Brain size / / 22156575 rs17641380 chr4 44161789 T C 1.80E-08 Brain size / / 22156575 rs1027201 chr4 44167271 C T 8.20E-09 Brain size / / 22156575 rs4695701 chr4 44187682 T C 2.00E-05 Brain size KCTD8 intron 22156575 rs716890 chr4 44190394 T G 5.40E-09 Brain size KCTD8 intron 22156575 rs6811002 chr4 44196006 T C 9.30E-09 Brain size KCTD8 intron 22156575 rs17641529 chr4 44212165 A G 9.00E-06 Response to amphetamines KCTD8 intron 22952603 rs7699496 chr4 44236408 A G 1.28E-04 Amyotrophic Lateral Sclerosis KCTD8 intron 17362836 rs10007704 chr4 44276751 T C 1.20E-05 Brain size KCTD8 intron 22156575 rs7682929 chr4 44297909 C A 2.10E-08 Brain size KCTD8 intron 22156575 rs7665717 chr4 44298911 G A,T 6.40E-04 Acute lung injury KCTD8 intron 22295056 rs1490450 chr4 44328130 C T 7.03E-05 Multiple complex diseases KCTD8 intron 17554300 rs17599605 chr4 44334829 C T 7.37E-04 Amyotrophic Lateral Sclerosis KCTD8 intron 17362836 rs17599605 chr4 44334829 C T 4.70E-07 Brain size KCTD8 intron 22156575 rs7689563 chr4 44344941 G A 1.10E-08 Brain size KCTD8 intron 22156575 rs6447330 chr4 44358412 A G 3.90E-08 Brain size KCTD8 intron 22156575 rs4407541 chr4 44381959 G T 4.00E-04 Type 2 diabetes KCTD8 intron 23937595 rs4695718 chr4 44412937 C T 2.00E-04 Type 2 diabetes KCTD8 intron 23937595 rs17461197 chr4 44428788 G A 1.82E-04 Lung function (forced vital capacity) KCTD8 intron 24023788 rs1439381 chr4 44486350 C A 3.55E-05 Waist-Hip Ratio / / pha003013 rs1439381 chr4 44486350 C A 2.29E-05 Waist-Hip Ratio / / pha003028 rs752238 chr4 44489849 G T 2.50E-04 Smoking behavior / / 20418888 rs1347901 chr4 44518235 T C 1.80E-05 Waist-Hip Ratio / / pha003013 rs1347901 chr4 44518235 T C 1.10E-05 Waist-Hip Ratio / / pha003028 rs7684647 chr4 44549846 C T 6.63E-05 Cognitive impairment induced by topiramate / / 22091778 rs12504525 chr4 44575744 C T 6.46E-04 Type 2 diabetes / / 17463246 rs1371237 chr4 44580312 A G 3.62E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1371240 chr4 44623698 G C 1.30E-05 Urinary metabolites / / 21572414 rs17600797 chr4 44626806 C A 1.23E-08 Lymphocyte counts YIPF7 intron 22286170 rs4694776 chr4 44633416 G A 4.74E-05 Response to citalopram treatment YIPF7 intron 19846067 rs17601544 chr4 44843173 A T 8.29E-05 Cytomegalovirus antibody response / / 21993531 rs4145971 chr4 44843214 G T 1.09E-05 Post-operative nausea and vomiting / / 21694509 rs10517121 chr4 44871784 A G 2.61E-04 Vaspin levels / / 22907691 rs10517121 chr4 44871784 A G 0.0002606 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs7670227 chr4 44904253 A C 2.40E-05 Urinary metabolites / / 21572414 rs10001109 chr4 44904653 T C 5.23E-04 Coronary heart disease / / 21606135 rs1390913 chr4 44921565 G A 7.21E-06 Response to lithium treatment in bipolar disorder / / 21961650 rs1845949 chr4 44926420 T A 6.80E-07 Urinary metabolites / / 21572414 rs1497000 chr4 44926711 T G 9.30E-06 Urinary metabolites / / 21572414 rs1390911 chr4 44932251 T C 5.18E-04 Type 2 diabetes / / 17463246 rs7657226 chr4 44932464 A G 1.10E-06 Urinary metabolites / / 21572414 rs10032741 chr4 44960444 T A 4.92E-26 Narcolepsy / / 19629137 rs1948587 chr4 44968603 A C 1.30E-05 Urinary metabolites / / 21572414 rs12645733 chr4 44983208 C T 7.89E-04 Smoking cessation / / 24665060 rs6823641 chr4 44997960 C T 2.80E-05 Urinary metabolites / / 21572414 rs4599451 chr4 45020169 A G 8.39E-05 Height / / pha003011 rs4456994 chr4 45033142 G C 7.55E-05 Multiple complex diseases / / 17554300 rs4305551 chr4 45035197 A G 4.37E-04 Type 2 diabetes / / 17463246 rs4305551 chr4 45035197 A G 9.72E-04 Multiple complex diseases / / 17554300 rs13144044 chr4 45082236 C G 2.16E-05 Obesity (extreme) / / 21935397 rs12503507 chr4 45096723 T C 2.20E-05 Urinary metabolites / / 21572414 rs959904 chr4 45102629 C T 7.75E-04 Obesity (extreme) / / 21935397 rs12643683 chr4 45106693 T A 2.10E-05 Urinary metabolites / / 21572414 rs17655141 chr4 45119572 A G 0.0000437 Coronary artery disease / / 23202125 rs9999372 chr4 45119892 C T 8.91E-06 White blood cell count / / 21738479 rs12504429 chr4 45123011 C T 6.21E-04 Multiple complex diseases / / 17554300 rs12504429 chr4 45123011 C T 5.54E-04 Obesity (extreme) / / 21935397 rs1913018 chr4 45125328 A G 5.55E-04 Obesity (extreme) / / 21935397 rs12650122 chr4 45125503 A G 5.56E-04 Obesity (extreme) / / 21935397 rs10021963 chr4 45128176 A G 2.73E-05 Serum metabolites / / 19043545 rs1512312 chr4 45130474 A G 5.56E-04 Obesity (extreme) / / 21935397 rs12512251 chr4 45131561 A G 5.56E-04 Obesity (extreme) / / 21935397 rs6845132 chr4 45139673 C T 7.56E-04 Multiple complex diseases / / 17554300 rs6845132 chr4 45139673 C T 5.54E-04 Obesity (extreme) / / 21935397 rs1849338 chr4 45142805 A G 1.46E-05 Obesity (extreme) / / 21935397 rs7654230 chr4 45157013 T C 4.86E-04 Obesity (extreme) / / 21935397 rs13130484 chr4 45175691 C T 1.87E-05 Obesity (extreme) / / 21935397 rs13130484 chr4 45175691 C T 1.30E-07 Obesity / / 22484627 rs13130484 chr4 45175691 C T 3.00E-18 Obesity / / 23563607 rs13130484 chr4 45175691 C T 4.00E-28 Obesity / / 23563607 rs13130484 chr4 45175691 C T 6.00E-09 Body mass index / / 23669352 rs16858082 chr4 45175804 T C 4.00E-09 Body mass index / / 24861553 rs12641981 chr4 45179883 C T 1.80E-05 Urinary metabolites / / 21572414 rs12641981 chr4 45179883 C T 2.06E-05 Obesity (extreme) / / 21935397 rs10938397 chr4 45182527 A G 3.00E-16 Body mass index / / 19079261 rs10938397 chr4 45182527 A G 3.40E-16 Smoking behavior / / 20418888 rs10938397 chr4 45182527 A G 4.00E-31 Body mass index / / 20935630 rs10938397 chr4 45182527 A G 8.70E-08 Menarche (age at onset) / / 21102462 rs10938397 chr4 45182527 A G 2.16E-05 Obesity (extreme) / / 21935397 rs10938397 chr4 45182527 A G 9.69E-08 Body mass index / / 22344219 rs10938397 chr4 45182527 A G 3.78E-31 Body mass index / / 23001569 rs10938397 chr4 45182527 A G 2.00E-13 Body mass index / / 23563607 rs10938397 chr4 45182527 A G 3.00E-34 Obesity / / 23563607 rs348495 chr4 45184442 G A 2.00E-10 Body mass index / / 23583978 rs13104545 chr4 45184907 G A 2.81E-04 Obesity (extreme) / / 21935397 rs348509 chr4 45192567 A G 2.40E-05 Urinary metabolites / / 21572414 rs16858292 chr4 45259896 T A 4.97E-04 Multiple complex diseases / / 17554300 rs41333852 chr4 45266500 C T 6.15E-04 Multiple complex diseases / / 17554300 rs6843723 chr4 45310246 G A 9.59E-05 Erythrocyte counts / / pha003099 rs4492036 chr4 45362127 A G 3.46E-05 Height / / 17255346 rs10517133 chr4 45364914 G C 5.00E-06 Adiponectin levels / / 21700879 rs16858465 chr4 45386432 A G 7.89E-05 Multiple complex diseases / / 17554300 rs13114580 chr4 45386990 C T 3.73E-04 Height / / 17255346 rs13114580 chr4 45386990 C T 2.83E-04 Multiple complex diseases / / 17554300 rs4321672 chr4 45391489 T G 3.73E-04 Height / / 17255346 rs4321672 chr4 45391489 T G 4.94E-04 Multiple complex diseases / / 17554300 rs4434289 chr4 45413907 T C 3.73E-04 Height / / 17255346 rs4434289 chr4 45413907 T C 3.72E-04 Multiple complex diseases / / 17554300 rs12512184 chr4 45449634 T G 8.00E-06 Urinary metabolites / / 21572414 rs9993518 chr4 45452366 A C 3.03E-04 Height / / 17255346 rs10012868 chr4 45497448 C T 8.79E-05 Multiple complex diseases / / 17554300 rs699555 chr4 45555426 C T 5.48E-04 Multiple complex diseases / / 17554300 rs840194 chr4 45557780 T G 6.06E-05 Multiple complex diseases / / 17554300 rs4610376 chr4 45658574 C G 1.60E-05 Urinary metabolites / / 21572414 rs1563477 chr4 45661237 G T 1.60E-05 Urinary metabolites / / 21572414 rs4694812 chr4 45661514 A T 1.60E-05 Urinary metabolites / / 21572414 rs2168540 chr4 45664676 A T 2.30E-05 Urinary metabolites / / 21572414 rs10034106 chr4 45676675 A T 1.70E-05 Urinary metabolites / / 21572414 rs6447467 chr4 45682108 G A 1.60E-05 Urinary metabolites / / 21572414 rs7676905 chr4 45682248 G A 8.20E-06 Urinary metabolites / / 21572414 rs12640483 chr4 45702046 C T 1.10E-05 Urinary metabolites / / 21572414 rs1456506 chr4 45717804 T A 6.40E-06 Urinary metabolites / / 21572414 rs1456508 chr4 45720024 C T 1.11E-05 Cognitive test performance / / 20125193 rs7677748 chr4 45730735 T C 9.20E-06 Urinary metabolites / / 21572414 rs7694105 chr4 45730852 G A 2.50E-06 Urinary metabolites / / 21572414 rs9985676 chr4 45756683 A C 5.20E-06 Urinary metabolites / / 21572414 rs9291276 chr4 45757007 C T 3.70E-06 Urinary metabolites / / 21572414 rs1492840 chr4 45767005 A G 9.98E-12 Blood pressure / / 21909110 rs1002055 chr4 45847131 G T 2.40E-05 Reading and spelling / / 23738518 rs11721867 chr4 45858464 A G 1.28E-05 HIV-1 viral setpoint / / 22174851 rs7674482 chr4 45867461 T C 5.00E-06 HIV-1 viral setpoint / / 22174851 rs9291277 chr4 45892423 G A,C,T 4.96E-04 Smoking cessation / / 24665060 rs7666693 chr4 45939268 G A 9.27E-04 Multiple complex diseases / / 17554300 rs7661204 chr4 46033250 C T 5.27E-04 Tourette syndrome / / 22889924 rs7683876 chr4 46042083 G A 8.19E-04 Tourette syndrome GABRG1 UTR-3 22889924 rs16859041 chr4 46046789 T C 1.29E-05 Bipolar disorder (mania) GABRG1 intron 23326512 rs1497571 chr4 46059250 C T 8.10E-04 Tourette syndrome GABRG1 intron 22889924 rs1353642 chr4 46095731 G A 6.59E-05 Type 2 diabetes GABRG1 intron 23937595 rs16859059 chr4 46096135 G C 4.57E-04 Multiple complex diseases GABRG1 intron 17554300 rs16859082 chr4 46103511 T C 9.76E-04 Multiple complex diseases GABRG1 intron 17554300 rs9654078 chr4 46113481 G T 1.34E-05 Bipolar disorder (mania) GABRG1 intron 23326512 rs12511372 chr4 46116432 A G 6.32E-04 Cognitive impairment induced by topiramate GABRG1 intron 22091778 rs904154 chr4 46126371 A C 3.25E-05 Bipolar disorder (mania) / / 23326512 rs34946656 chr4 46129682 G A 1.29E-05 Bipolar disorder (mania) / / 23326512 rs11939005 chr4 46141498 A G 1.29E-05 Bipolar disorder (mania) / / 23326512 rs11936504 chr4 46163485 T A 1.88E-05 Bipolar disorder (mania) / / 23326512 rs11930818 chr4 46163570 C T 2.67E-05 Bipolar disorder (mania) / / 23326512 rs11936542 chr4 46163594 T C 2.62E-05 Bipolar disorder (mania) / / 23326512 rs504696 chr4 46229571 G A 5.47E-04 Alzheimer's disease / / 17998437 rs561779 chr4 46238778 A G 5.63E-04 Alzheimer's disease / / 17998437 rs517350 chr4 46244124 C T 5.24E-04 Alzheimer's disease / / 17998437 rs543809 chr4 46274590 G A 5.31E-04 Alzheimer's disease GABRA2 intron 17998437 rs279856 chr4 46317923 C A 4.00E-04 Type 2 diabetes GABRA2 intron 23937595 rs4695152 chr4 46381657 C G 6.03E-04 Alzheimer's disease (late onset) GABRA2 intron 21460841 rs4695152 chr4 46381657 C G 1.80E-05 Urinary metabolites GABRA2 intron 21572414 rs6847731 chr4 46402152 G A 1.92E-04 Blood pressure / / 17255346 rs6847731 chr4 46402152 G A 6.70E-06 Urinary metabolites / / 21572414 rs4501195 chr4 46589847 G A 6.57E-05 Coronary heart disease / / pha003033 rs10938449 chr4 46625274 G A 4.61E-05 Coronary heart disease / / pha003033 rs9291289 chr4 46685463 A G 2.26E-05 Coronary heart disease / / pha003033 rs6853207 chr4 46721833 C T 5.76E-05 stroke (ischemic) / / 17434096 rs10005129 chr4 46747094 T C 8.32E-04 Type 2 diabetes COX7B2 intron 17463246 rs11945399 chr4 46750333 C T 2.12E-05 Word reading COX7B2 intron 23738518 rs10001459 chr4 46751541 T C 4.00E-06 Parkinson's disease (interaction with coffee consumption) COX7B2 intron 21876681 rs6831990 chr4 46773505 G A 7.42E-04 Type 2 diabetes COX7B2 intron 17463246 rs7438079 chr4 46773598 G C 8.49E-04 Type 2 diabetes COX7B2 intron 17463246 rs13119057 chr4 46807501 C T 1.17E-04 Attention deficit hyperactivity disorder COX7B2 intron 22012869 rs11726563 chr4 46823634 A C 8.00E-06 Migraine - clinic-based COX7B2 intron 23793025 rs10028342 chr4 46880909 C T 5.30E-04 Multiple complex diseases COX7B2 intron 17554300 rs7679715 chr4 46888116 A G 8.01E-04 Myopia (pathological) COX7B2 intron 21095009 rs7679715 chr4 46888116 A G 1.83E-05 Type 2 diabetes COX7B2 intron 23937595 rs10938462 chr4 46890143 C T 7.24E-04 Multiple complex diseases COX7B2 intron 17554300 rs10517169 chr4 46893766 C T 8.69E-04 Multiple complex diseases COX7B2 intron 17554300 rs10050095 chr4 46894198 A T 7.71E-04 Multiple complex diseases COX7B2 intron 17554300 rs16859614 chr4 46894527 C T 6.86E-05 Alcohol consumption COX7B2 intron 23953852 rs6818817 chr4 46896902 G C 7.60E-04 Multiple complex diseases COX7B2 intron 17554300 rs17641065 chr4 46897939 A T 6.59E-04 Multiple complex diseases COX7B2 intron 17554300 rs7683552 chr4 46898265 T C 5.82E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) COX7B2 intron 23648065 rs17598809 chr4 46898391 C T 8.34E-04 Multiple complex diseases COX7B2 intron 17554300 rs13110516 chr4 46907018 C T 5.81E-04 Multiple complex diseases COX7B2 intron 17554300 rs13114476 chr4 46907149 G A 7.67E-04 Multiple complex diseases COX7B2 intron 17554300 rs17641171 chr4 46911209 C T 5.55E-04 Multiple complex diseases COX7B2 UTR-5 17554300 rs1028005 chr4 46941018 A G 8.56E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) GABRA4 intron 23648065 rs10018276 chr4 46942166 C T 5.41E-04 Multiple complex diseases GABRA4 intron 17554300 rs1160092 chr4 46949662 G A 9.61E-04 Multiple complex diseases GABRA4 intron 17554300 rs1512130 chr4 46952471 A G 1.11E-04 Multiple complex diseases GABRA4 intron 17554300 rs1512130 chr4 46952471 A G 9.50E-06 Dietary macronutrient intake GABRA4 intron 23372041 rs9995416 chr4 46954968 C T 9.95E-04 Multiple complex diseases GABRA4 intron 17554300 rs1512132 chr4 46958693 T C 7.30E-04 Multiple complex diseases GABRA4 intron 17554300 rs2221855 chr4 46961617 T G 2.90E-04 Insulin resistance GABRA4 intron 21901158 rs2055942 chr4 46968050 T C 2.16E-04 Multiple complex diseases GABRA4 intron 17554300 rs2055942 chr4 46968050 T C 1.00E-06 Type 2 diabetes GABRA4 intron 23937595 rs7694035 chr4 46985750 A C 7.00E-04 Atrial fibrillation GABRA4 intron 21846873 rs13139021 chr4 47006399 T C 6.10E-04 Iron levels / / pha002876 rs3934674 chr4 47013138 A G 9.32E-04 Multiple complex diseases / / 17554300 rs3934674 chr4 47013138 A G 1.26E-05 Bipolar disorder,schizoaffective / / 19567891 rs6814188 chr4 47019621 T A,C 6.40E-04 Parkinson's disease / / 17052657 rs4368579 chr4 47021228 C G 2.75E-05 Bipolar disorder,schizoaffective / / 19567891 rs10015366 chr4 47057759 A G 4.01E-04 Multiple complex diseases GABRB1 intron 17554300 rs10015366 chr4 47057759 A G 4.21E-04 Schizophrenia GABRB1 intron 19197363 rs4279178 chr4 47068580 G A 2.49E-06 Bipolar disorder,schizoaffective GABRB1 intron 19567891 rs6447530 chr4 47073414 A C 1.90E-05 Bipolar disorder,schizoaffective GABRB1 intron 19567891 rs6447530 chr4 47073414 A C 3.72E-04 Suicide attempts in bipolar disorder GABRB1 intron 21423239 rs4694834 chr4 47079408 A G 3.37E-04 Suicide attempts in bipolar disorder GABRB1 intron 21423239 rs4613538 chr4 47083720 T C 1.96E-04 Suicide attempts in bipolar disorder GABRB1 intron 21423239 rs10003525 chr4 47088349 T C 4.76E-04 Suicide attempts in bipolar disorder GABRB1 intron 21423239 rs4396968 chr4 47089184 T C 3.20E-04 Suicide attempts in bipolar disorder GABRB1 intron 21423239 rs11936304 chr4 47089298 T A 6.96E-04 Suicide attempts in bipolar disorder GABRB1 intron 21423239 rs142800244 chr4 47089298 T TA 6.96E-04 Suicide attempts in bipolar disorder GABRB1 intron 21423239 rs1866990 chr4 47101223 G A 2.68E-05 IgE levels in asthmatics GABRB1 intron 23967269 rs971354 chr4 47103115 G A 2.10E-05 Urinary metabolites GABRB1 intron 21572414 rs6447534 chr4 47137881 A G 1.18E-04 Multiple complex diseases GABRB1 intron 17554300 rs6447534 chr4 47137881 A G 2.47E-05 Bipolar disorder,schizoaffective GABRB1 intron 19567891 rs3906823 chr4 47142218 C T 3.66E-05 Dengue shock syndrome GABRB1 intron 22001756 rs1442101 chr4 47143957 A G 1.87E-04 Multiple complex diseases GABRB1 intron 17554300 rs1442101 chr4 47143957 A G 1.54E-05 Bipolar disorder,schizoaffective GABRB1 intron 19567891 rs7680321 chr4 47145107 C T 6.23E-05 Multiple complex diseases GABRB1 intron 17554300 rs7680321 chr4 47145107 C T 7.28E-06 Bipolar disorder,schizoaffective GABRB1 intron 19567891 rs1442099 chr4 47146099 G A 1.98E-04 Multiple complex diseases GABRB1 intron 17554300 rs1442097 chr4 47150997 T C 1.10E-06 Urinary metabolites GABRB1 intron 21572414 rs11728647 chr4 47186217 A G 9.80E-06 Urinary metabolites GABRB1 intron 21572414 rs1023775 chr4 47195708 A G 2.10E-05 Urinary metabolites GABRB1 intron 21572414 rs10004181 chr4 47203863 C T 9.45E-05 Body Mass Index GABRB1 intron pha003019 rs1372497 chr4 47222338 T C 0.000458155 Hypertension (early onset hypertension) GABRB1 intron 22479346 rs10016894 chr4 47225341 G A 0.000458155 Hypertension (early onset hypertension) GABRB1 intron 22479346 rs7672100 chr4 47265590 A G 6.28E-05 Waist Circumference GABRB1 intron pha003025 rs4426746 chr4 47275670 A G 6.42E-05 Hypertension (early onset hypertension) GABRB1 intron 22479346 rs17653240 chr4 47277298 T C 2.95E-05 Tuberculosis GABRB1 intron 24057671 rs4586906 chr4 47278303 G T 1.00E-04 Information processing speed GABRB1 intron 21130836 rs4586906 chr4 47278303 G T 8.55E-05 Hypertension (early onset hypertension) GABRB1 intron 22479346 rs2078610 chr4 47289054 G T 2.80E-04 Multiple complex diseases GABRB1 intron 17554300 rs4396966 chr4 47291135 T C 5.55E-05 Creatinine levels GABRB1 intron pha003069 rs9996854 chr4 47340895 A G 3.18E-04 Scoliosis GABRB1 intron 21216876 rs11733050 chr4 47375312 G A 1.32E-04 Type 2 diabetes GABRB1 intron 17463246 rs4502656 chr4 47390465 G T 6.33E-04 Suicide attempts in bipolar disorder GABRB1 intron 21423239 rs4502656 chr4 47390465 G T 7.89E-04 Acute lung injury GABRB1 intron 22295056 rs7439087 chr4 47397000 T C 4.46E-05 Vitiligo GABRB1 intron 19890347 rs6289 chr4 47408709 A G 5.00E-06 Obesity-related traits GABRB1 cds-synon 23251661 rs10155173 chr4 47421651 C A 8.48E-05 Response to mTOR inhibitor (everolimus) GABRB1 intron 24009623 rs41311286 chr4 47427873 C G 0.00077 Prostate cancer GABRB1 missense 23555315 rs13102764 chr4 47430927 G A 4.59E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs4356892 chr4 47463845 A G 9.82E-04 Type 2 diabetes COMMD8 intron 17463246 rs13139804 chr4 47544481 A G 0.000499 Schizophrenia ATP10D intron 22440650 rs3924900 chr4 47549705 A G 1.02E-05 Rheumatoid arthritis ATP10D intron 17804836 rs13106975 chr4 47551863 T G 2.00E-19 Sphingolipid levels ATP10D intron 22359512 rs7686393 chr4 47558154 C T 3.34E-04 Multiple complex diseases ATP10D intron 17554300 rs4298115 chr4 47560386 C T 5.98E-09 Sphingolipid levels ATP10D intron 19798445 rs10938494 chr4 47563448 G A 8.00E-19 Sphingolipid levels ATP10D intron 19798445 rs2351791 chr4 47582387 A C 4.64E-18 Sphingolipid levels ATP10D intron 19798445 rs1058793 chr4 47584046 G A 3.43E-05 Coronary heart disease ATP10D missense pha003031 rs17462424 chr4 47598298 T C 1.81E-09 Sphingolipid levels CORIN intron 19798445 rs17462424 chr4 47598298 T C 1.99E-04 Lung function (forced expiratory volume in 1 second) CORIN intron 24023788 rs13150235 chr4 47600312 C T 3.31E-04 Multiple complex diseases CORIN intron 17554300 rs16860432 chr4 47600915 G C 4.19E-08 HDL cholesterol CORIN intron 23063622 rs12650894 chr4 47602599 T G 6.46E-05 Coronary heart disease CORIN intron pha003031 rs6832495 chr4 47609664 G A 2.02E-11 Sphingolipid levels CORIN intron 19798445 rs4694863 chr4 47635586 A C 4.47E-09 Sphingolipid levels CORIN intron 19798445 rs4131134 chr4 47654509 T C 3.70E-04 Type 2 diabetes and 6 quantitative traits CORIN intron 17848626 rs2351784 chr4 47669435 T C 7.72E-10 Sphingolipid levels CORIN intron 19798445 rs4695266 chr4 47672280 T A,C 2.24E-09 Triglycerides CORIN intron 23063622 rs4695266 chr4 47672280 T A,C 2.53E-21 HDL cholesterol CORIN intron 23063622 rs4695267 chr4 47672301 C T 2.39E-12 Sphingolipid levels CORIN intron 19798445 rs16860535 chr4 47675690 G A 0.000000156 HDL cholesterol CORIN intron 23063622 rs13111339 chr4 47682714 T C 1.93E-04 Multiple complex diseases CORIN intron 17554300 rs13137804 chr4 47683456 C A 1.38E-04 Multiple complex diseases CORIN intron 17554300 rs4441728 chr4 47688813 C T 2.02E-04 Multiple complex diseases CORIN intron 17554300 rs6447580 chr4 47691710 A G 1.01E-04 QT interval CORIN intron 22726844 rs2001935 chr4 47708329 T C 6.66E-04 White matter integrity CORIN intron 22425255 rs4473628 chr4 47752554 A G 4.16E-04 Multiple complex diseases CORIN intron 17554300 rs12508460 chr4 47816387 G T 1.79E-04 Prion diseases CORIN intron 22210626 rs1062858 chr4 47843628 T C 0.000021 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity / / 22945461 rs4694872 chr4 47881866 C A 9.43E-05 Erythrocyte counts NFXL1 intron pha003099 rs4695303 chr4 47898234 G T 9.43E-05 Erythrocyte counts NFXL1 intron pha003099 rs4695314 chr4 47932661 G A 3.56E-07 Asthma (childhood onset) / / 23829686 rs9995122 chr4 47945891 C T 0.0000251 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity CNGA1 intron 22945461 rs6832503 chr4 48028442 G A 7.39E-05 Serum metabolites NIPAL1 intron 19043545 rs10938519 chr4 48038584 G A 1.93E-04 Tourette syndrome NIPAL1 UTR-3 22889924 rs7679010 chr4 48083885 C T 6.54E-04 Multiple complex diseases TXK intron 17554300 rs16860968 chr4 48120871 G A 8.88E-05 HIV-1 viral setpoint TXK intron 22174851 rs16861029 chr4 48138374 C T 7.22E-04 Multiple complex diseases TEC UTR-3 17554300 rs2071027 chr4 48139752 T C 6.33E-04 Multiple complex diseases TEC intron 17554300 rs6844543 chr4 48145121 T C 8.82E-05 Multiple complex diseases TEC intron 17554300 rs17574399 chr4 48151356 A T 2.10E-05 Urinary metabolites TEC intron 21572414 rs2456928 chr4 48156135 C T 1.60E-05 Urinary metabolites TEC intron 21572414 rs12502528 chr4 48159351 C T 1.13E-04 Multiple complex diseases TEC intron 17554300 rs11730441 chr4 48168428 C T 1.48E-04 Multiple complex diseases TEC intron 17554300 rs4695340 chr4 48173947 G A 6.83E-04 Multiple complex diseases TEC intron 17554300 rs4695344 chr4 48174251 T G 4.22E-05 Multiple complex diseases TEC intron 17554300 rs11945978 chr4 48178814 C T 2.19E-05 Multiple complex diseases TEC intron 17554300 rs1961975 chr4 48179440 A T 5.41E-05 Multiple complex diseases TEC intron 17554300 rs17471142 chr4 48195725 G A 0.000788 Salmonella-induced pyroptosis TEC intron 22837397 rs11725773 chr4 48196335 G A 9.95E-04 Multiple complex diseases TEC intron 17554300 rs4695357 chr4 48199195 A C 0.000286 Height (Pygmy height) TEC intron 22570615 rs2664035 chr4 48220839 G A 1.00E-07 Rheumatoid arthritis TEC intron 24390342 rs2664035 chr4 48220839 G A 3.00E-08 Rheumatoid arthritis TEC intron 24390342 rs4694890 chr4 48226267 A C 7.09E-04 Response to TNF antagonist treatment TEC intron 21061259 rs6837335 chr4 48363983 A G 2.00E-08 Crohn's disease SLAIN2 intron 23128233 rs11725992 chr4 48387851 T C 7.01E-06 Osteoarthritis SLAIN2 intron 22763110 rs6447636 chr4 48459365 T C 5.67E-05 Rheumatoid arthritis / / 17804836 rs6838613 chr4 48476539 A G 3.30E-05 Rheumatoid arthritis / / 17804836 rs1565217 chr4 48479718 T C 2.20E-04 Cognitive decline / / 23732972 rs13114836 chr4 48495577 C G 4.83E-05 Cognitive decline ZAR1 intron 23732972 rs13114836 chr4 48495577 C G 6.91E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) ZAR1 intron 24236485 rs6447641 chr4 48509050 T C 5.88E-04 Premature ovarian failure FRYL intron 19508998 rs4695391 chr4 48582909 G A 9.44E-04 Type 2 diabetes FRYL cds-synon 17463246 rs776598 chr4 48599280 T C 2.67E-05 Odorant perception FRYL intron 23910658 rs6843340 chr4 48619937 C T 9.00E-04 Breast cancer FRYL intron 17529967 rs796555 chr4 48636595 C T 7.83E-04 Type 2 diabetes FRYL intron 17463246 rs776581 chr4 48657569 T C 9.33E-05 Multiple complex diseases FRYL intron 17554300 rs2354314 chr4 48721327 T C 7.81E-05 Longevity FRYL intron 21612516 rs17576077 chr4 48758991 C T 2.24E-04 Lymphocyte counts FRYL intron 22286170 rs6447662 chr4 48782647 C A 9.51E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17656727 chr4 48856133 A G 3.65E-04 Multiple complex diseases OCIAD1 intron 17554300 rs2605262 chr4 48952209 A G 2.00E-05 Cognitive test performance / / 20125193 rs2605267 chr4 48960863 G A 8.94E-05 Cognitive test performance / / 20125193 rs2572363 chr4 48972651 C A 8.49E-05 Cognitive test performance / / 20125193 rs2605232 chr4 49054680 T G 6.50E-06 Urinary metabolites CWH43 intron 21572414 rs11725957 chr4 49062892 G A 8.00E-06 Response to hepatitis C treatment CWH43 intron 22095909 rs2768948 chr4 49063479 C G 2.50E-06 Urinary metabolites CWH43 intron 21572414 rs372864928 chr4 49657363 T TG 7.25E-05 Serum metabolites / / 19043545 rs4290873 chr4 49657363 T G 7.25E-05 Serum metabolites / / 19043545 rs1996617 chr4 52798624 T C 8.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs6829655 chr4 52810307 T C 8.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs4610360 chr4 52816623 T C 0.0000273 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9714449 chr4 52816718 A G 0.0000272 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35931428 chr4 52816968 G A 0.0000272 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7676869 chr4 52821319 G T 8.30E-05 Serum metabolites / / 19043545 rs11735705 chr4 52830444 T G 8.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs1519588 chr4 52860156 C T 4.82E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) LRRC66 UTR-3 23648065 rs7695726 chr4 52867437 A C 8.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) LRRC66 intron 23648065 rs4864836 chr4 52868518 G A 4.93E-05 Serum metabolites LRRC66 intron 19043545 rs2319750 chr4 52870957 C T 7.54E-04 Suicide attempts in bipolar disorder LRRC66 intron 21041247 rs4610396 chr4 52871894 G T 8.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) LRRC66 intron 23648065 rs225160 chr4 52884239 G A 8.61E-05 Serum metabolites LRRC66 intron 19043545 rs170424 chr4 52888026 A C 8.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) SGCB UTR-3 23648065 rs225165 chr4 52889602 T A 9.73E-06 Serum metabolites SGCB UTR-3 19043545 rs225165 chr4 52889602 T A 1.60E-05 Urinary metabolites SGCB UTR-3 21572414 rs2219576 chr4 52912589 A T 5.07E-05 Serum metabolites / / 19043545 rs2219576 chr4 52912589 A T 2.30E-05 Urinary metabolites / / 21572414 rs999634 chr4 52927113 C A 2.00E-05 Urinary metabolites SPATA18 intron 21572414 rs12500231 chr4 52935445 A T 2.60E-05 Urinary metabolites SPATA18 intron 21572414 rs2253189 chr4 52936585 A C 3.06E-04 Obesity (extreme) SPATA18 intron 21935397 rs2680907 chr4 52936924 T A 4.52E-04 Obesity (extreme) SPATA18 intron 21935397 rs3860707 chr4 52938243 T C 5.25E-04 Obesity (extreme) SPATA18 missense 21935397 rs11727580 chr4 52948118 G A 3.99E-04 Obesity (extreme) SPATA18 intron 21935397 rs7696028 chr4 52950660 A C 3.98E-04 Obesity (extreme) SPATA18 intron 21935397 rs10866420 chr4 52957015 G A 3.97E-04 Obesity (extreme) SPATA18 intron 21935397 rs3214049 chr4 52960908 T A 3.93E-04 Obesity (extreme) SPATA18 intron 21935397 rs6817395 chr4 52966973 G A 3.38E-04 Obesity (extreme) / / 21935397 rs11722603 chr4 52969732 A G 8.81E-04 Obesity (extreme) / / 21935397 rs17084746 chr4 52971803 G C 1.80E-05 Anger / / 24489884 rs4146562 chr4 52972019 T C 2.71E-04 Obesity (extreme) / / 21935397 rs7682221 chr4 52972275 C T 2.65E-04 Obesity (extreme) / / 21935397 rs11133357 chr4 52983386 G A 1.88E-04 Obesity (extreme) / / 21935397 rs4359971 chr4 52994195 T C 7.48E-04 Obesity (extreme) / / 21935397 rs7699031 chr4 52995402 G C 7.68E-04 Obesity (extreme) / / 21935397 rs13128128 chr4 53000155 A C 9.51E-04 Obesity (extreme) / / 21935397 rs1460556 chr4 53001305 T A 9.53E-04 Obesity (extreme) / / 21935397 rs7699248 chr4 53069038 A T 9.71E-04 Obesity (extreme) / / 21935397 rs1482117 chr4 53111802 A G 3.76E-04 Multiple complex diseases / / 17554300 rs10030634 chr4 53126698 T A 0.0000583 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10030634 chr4 53126698 T A 5.83E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17612700 chr4 53127951 G A 0.0000586 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17612700 chr4 53127951 G A 5.86E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1905086 chr4 53129252 G A 0.0000591 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1905086 chr4 53129252 G A 5.91E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs995240 chr4 53130140 C A 0.0000656 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs995240 chr4 53130140 C A 6.56E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs995239 chr4 53130243 A C 0.0000583 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs995239 chr4 53130243 A C 5.83E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs970047 chr4 53131785 A G 0.0000582 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs970047 chr4 53131785 A G 5.82E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs970046 chr4 53131981 T G 0.0000581 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs970046 chr4 53131981 T G 5.81E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs729474 chr4 53133213 C G 0.0000567 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs729474 chr4 53133213 C G 5.67E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs985955 chr4 53133260 C G 0.0000404 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs985955 chr4 53133260 C G 4.04E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17086692 chr4 53134293 G T 0.0000609 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17086692 chr4 53134293 G T 6.09E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17086709 chr4 53136304 C T 0.0000661 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17086709 chr4 53136304 C T 6.61E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10000816 chr4 53136700 T A 0.000124 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10000816 chr4 53136700 T A 1.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10000901 chr4 53136776 T G 0.0000634 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10000901 chr4 53136776 T G 6.34E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs721330 chr4 53154399 C G 0.0000781 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs721330 chr4 53154399 C G 7.81E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4590104 chr4 53154570 C T 0.0000792 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4590104 chr4 53154570 C T 7.92E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17674991 chr4 53156787 C T 0.0000828 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17674991 chr4 53156787 C T 8.28E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10028408 chr4 53171156 T C 0.0001261 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10028408 chr4 53171156 T C 1.26E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17675093 chr4 53179320 C T 0.0001383 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17675093 chr4 53179320 C T 1.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17612939 chr4 53181358 A G 0.0001444 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17612939 chr4 53181358 A G 1.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10029039 chr4 53201986 T C 0.0001861 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10029039 chr4 53201986 T C 1.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13152808 chr4 53203778 T C 0.0001912 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13152808 chr4 53203778 T C 1.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2088889 chr4 53208616 C T 0.0003301 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2088889 chr4 53208616 C T 3.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10017790 chr4 53217422 T C 0.0002418 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10017790 chr4 53217422 T C 2.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs959214 chr4 53233385 G A 8.96E-04 Multiple complex diseases / / 17554300 rs959214 chr4 53233385 G A 0.0004351 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs959214 chr4 53233385 G A 4.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10866445 chr4 53238340 A G 0.0004248 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10866445 chr4 53238340 A G 4.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1903222 chr4 53259081 G A,C 0.0003574 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1903222 chr4 53259081 G A,C 3.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12716054 chr4 53263250 T C 9.66E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs931734 chr4 53296310 G A 9.13E-04 Multiple complex diseases / / 17554300 rs6554516 chr4 53298518 C T 4.48E-04 Schizophrenia / / 19197363 rs6835775 chr4 53305892 G A 4.78E-04 Multiple complex diseases / / 17554300 rs9995769 chr4 53361459 G A 9.01E-04 Multiple complex diseases / / 17554300 rs346923 chr4 53412129 G A 2.00E-06 Biochemical measures / / 19260141 rs346913 chr4 53420920 T C 6.26E-04 Acute lung injury / / 22295056 rs346915 chr4 53425041 T C 8.66E-04 Acute lung injury / / 22295056 rs10029656 chr4 53437722 G C 6.96E-04 Acute lung injury / / 22295056 rs6857807 chr4 53442055 C T 6.96E-04 Acute lung injury / / 22295056 rs17051563 chr4 53443941 C A 6.92E-04 Acute lung injury / / 22295056 rs10517262 chr4 53445076 C G 7.56E-04 Acute lung injury / / 22295056 rs6815408 chr4 53450945 G C 6.48E-04 Acute lung injury / / 22295056 rs17051576 chr4 53453179 A G 5.22E-04 Acute lung injury / / 22295056 rs17051578 chr4 53453449 T C 6.48E-04 Acute lung injury / / 22295056 rs13435337 chr4 53453997 T G 8.68E-04 Acute lung injury / / 22295056 rs13434881 chr4 53454248 G T 8.68E-04 Acute lung injury / / 22295056 rs6828126 chr4 53454588 T G 9.57E-04 Acute lung injury / / 22295056 rs7677999 chr4 53456375 A C 7.93E-04 Acute lung injury / / 22295056 rs7668895 chr4 53456416 C A 7.93E-04 Acute lung injury / / 22295056 rs2270827 chr4 53457420 T C 7.93E-04 Acute lung injury USP46 UTR-3 22295056 rs3733506 chr4 53459620 G A 7.93E-04 Acute lung injury USP46 UTR-3 22295056 rs10034164 chr4 53459731 A G 7.33E-04 Acute lung injury USP46 UTR-3 22295056 rs1053437 chr4 53461980 A T 1.33E-04 Multiple complex diseases USP46 UTR-3 17554300 rs7675404 chr4 53463164 G C 7.33E-04 Acute lung injury USP46 UTR-3 22295056 rs17051586 chr4 53463566 C T 7.33E-04 Acute lung injury USP46 UTR-3 22295056 rs6832794 chr4 53465280 T C 6.11E-04 Acute lung injury USP46 intron 22295056 rs7687075 chr4 53469343 C T 6.11E-04 Acute lung injury USP46 intron 22295056 rs7693087 chr4 53471153 G A 6.52E-04 Acute lung injury USP46 intron 22295056 rs7680727 chr4 53472171 A G 5.55E-04 Acute lung injury USP46 intron 22295056 rs7671541 chr4 53479414 C G 9.43E-04 Acute lung injury USP46 intron 22295056 rs7662693 chr4 53483243 C G 6.52E-04 Acute lung injury USP46 intron 22295056 rs6554557 chr4 53487541 T G 6.52E-04 Acute lung injury USP46 intron 22295056 rs10517263 chr4 53498669 G C 5.60E-04 Acute lung injury USP46 intron 22295056 rs17051640 chr4 53501531 A T 6.67E-04 Acute lung injury USP46 intron 22295056 rs10034052 chr4 53506457 C T 6.71E-04 Acute lung injury USP46 intron 22295056 rs4865395 chr4 53508927 G T 6.71E-04 Acute lung injury USP46 intron 22295056 rs7691678 chr4 53513769 G A 5.77E-04 Acute lung injury USP46 intron 22295056 rs10014556 chr4 53523725 A G 6.69E-04 Acute lung injury USP46 intron 22295056 rs11939490 chr4 53523832 A G 5.40E-04 Acute lung injury USP46 intron 22295056 rs12331910 chr4 53532167 T C 6.51E-04 Acute lung injury / / 22295056 rs7699089 chr4 53537033 C T 6.51E-04 Acute lung injury / / 22295056 rs11946547 chr4 53538715 G A 5.40E-04 Acute lung injury / / 22295056 rs12513298 chr4 53539692 G T 6.51E-04 Acute lung injury / / 22295056 rs746687 chr4 53543414 G A 6.51E-04 Acute lung injury / / 22295056 rs12505070 chr4 53548650 C A 1.42E-04 Acute lung injury / / 22295056 rs10517266 chr4 53549643 T C 1.44E-04 Acute lung injury / / 22295056 rs12500617 chr4 53552627 G A 1.39E-04 Acute lung injury / / 22295056 rs10471215 chr4 53555892 A G 1.36E-04 Acute lung injury / / 22295056 rs7674000 chr4 53557678 C A 1.39E-04 Acute lung injury / / 22295056 rs7694076 chr4 53569317 A T 1.65E-04 Acute lung injury / / 22295056 rs2411261 chr4 53572198 C G 1.72E-04 Acute lung injury / / 22295056 rs10028122 chr4 53578009 G A 1.69E-04 Acute lung injury / / 22295056 rs7699030 chr4 53594766 C G 9.98E-04 Acute lung injury / / 22295056 rs4286600 chr4 53595688 C G 9.98E-04 Acute lung injury / / 22295056 rs6836873 chr4 53598975 C T 9.98E-04 Acute lung injury / / 22295056 rs6817996 chr4 53599068 G A 8.63E-04 Acute lung injury / / 22295056 rs10009096 chr4 53623737 C T 8.29E-04 Acute lung injury / / 22295056 rs7697631 chr4 53624119 C T 8.02E-04 Acute lung injury / / 22295056 rs2411266 chr4 53624357 T A 8.00E-04 Acute lung injury / / 22295056 rs7660838 chr4 53624388 A G 9.74E-04 Acute lung injury / / 22295056 rs6838531 chr4 53627606 A C 1.04E-04 Acute lung injury / / 22295056 rs6839900 chr4 53675334 T C 3.33E-04 Alzheimer's disease LOC152578 intron 17998437 rs6840325 chr4 53675549 T C 2.45E-04 Alzheimer's disease LOC152578 intron 17998437 rs17698672 chr4 53711634 C T 9.90E-06 Urinary metabolites / / 21572414 rs17698672 chr4 53711634 C T 3.29E-06 Lipid traits / / 21777205 rs2898681 chr4 53757000 G A 2.00E-06 optic disc size (cup) SCFD2 intron 20395239 rs4864692 chr4 53758005 T C 3.71E-04 Depression (quantitative trait) SCFD2 intron 20800221 rs301126 chr4 53795651 T C 8.46E-05 Waist-Hip Ratio SCFD2 intron pha003013 rs301126 chr4 53795651 T C 5.55E-05 Waist-Hip Ratio SCFD2 intron pha003028 rs90020 chr4 53806311 G A 7.97E-04 Multiple complex diseases SCFD2 intron 17554300 rs2242310 chr4 53824071 C T 4.34E-05 Body Mass Index SCFD2 intron pha003007 rs2242310 chr4 53824071 C T 1.78E-05 Body Mass Index SCFD2 intron pha003015 rs301088 chr4 53830757 C A 0.000201107 Hypertension (early onset hypertension) SCFD2 intron 22479346 rs301088 chr4 53830757 C A 7.50E-06 Body Mass Index SCFD2 intron pha003007 rs301088 chr4 53830757 C A 8.94E-06 Body Mass Index SCFD2 intron pha003015 rs2101201 chr4 53842714 C T 4.94E-05 Body Mass Index SCFD2 intron pha003007 rs2101201 chr4 53842714 C T 3.30E-05 Body Mass Index SCFD2 intron pha003015 rs1351709 chr4 53846114 A G 7.88E-04 Multiple complex diseases SCFD2 intron 17554300 rs13120717 chr4 53846584 T C 0.000626 Salmonella-induced pyroptosis SCFD2 intron 22837397 rs11133239 chr4 53848506 T C 4.96E-05 Alzheimer's disease (late onset) SCFD2 intron 21460841 rs4530694 chr4 53854666 T G 0.000118563 Hypertension (early onset hypertension) SCFD2 intron 22479346 rs55800656 chr4 53859826 A G 1.54E-05 Body Mass Index SCFD2 intron pha003007 rs55800656 chr4 53859826 A G 2.87E-05 Body Mass Index SCFD2 intron pha003015 rs55800656 chr4 53859826 A G 9.29E-06 Body Fat Distribution SCFD2 intron pha003016 rs55800656 chr4 53859826 A G 2.39E-05 Body Fat Distribution SCFD2 intron pha003017 rs55800656 chr4 53859826 A G 4.20E-06 Body Fat Distribution SCFD2 intron pha003018 rs55800656 chr4 53859826 A G 2.47E-05 Weight SCFD2 intron pha003027 rs11929934 chr4 53867132 A G 9.42E-05 Body Fat Distribution SCFD2 intron pha003017 rs4380575 chr4 53947224 G A 4.53E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SCFD2 intron 24023788 rs9991167 chr4 53957698 A G 2.11E-04 Lung function (forced vital capacity) SCFD2 intron 24023788 rs9991167 chr4 53957698 A G 2.15E-04 Lung function (forced expiratory volume in 1 second) SCFD2 intron 24023788 rs13118742 chr4 53987813 A G 5.00E-06 Urinary metabolites SCFD2 intron 21572414 rs10517279 chr4 53990594 T C 1.70E-05 Urinary metabolites SCFD2 intron 21572414 rs1481822 chr4 54153814 A G 4.62E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SCFD2 intron 21844884 rs17654608 chr4 54183732 C T 5.66E-05 Serum metabolites SCFD2 intron 19043545 rs11725172 chr4 54203701 G T 2.83E-05 Serum metabolites SCFD2 intron 19043545 rs6554093 chr4 54212389 G C 5.36E-05 Serum metabolites SCFD2 intron 19043545 rs6821328 chr4 54217499 A G 1.70E-04 Lipid traits SCFD2 intron 17903299 rs10014172 chr4 54251718 A G 2.11E-04 Multiple complex diseases FIP1L1 intron 17554300 rs10025091 chr4 54264543 T C 7.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FIP1L1 intron 20877124 rs2090117 chr4 54300591 A C 9.23E-05 Serum metabolites FIP1L1 intron 19043545 rs11725230 chr4 54312072 T C 5.52E-05 Potassium levels FIP1L1 intron pha003086 rs17326196 chr4 54314418 T C 8.40E-05 Response to alcohol consumption (flushing response) FIP1L1 intron 24277619 rs17082837 chr4 54327526 T A 7.74E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines LNX1 intron 21844884 rs2412488 chr4 54330867 A G 9.00E-07 DNA methylation (variation) LNX1 intron 23725790 rs2412488 chr4 54330867 A G 2.37E-05 Potassium levels LNX1 intron pha003086 rs6835629 chr4 54346483 C T 7.17E-04 White matter integrity LNX1 intron 22425255 rs17082893 chr4 54353275 G A 6.82E-05 Serum metabolites LNX1 intron 19043545 rs4864767 chr4 54367136 G A 1.60E-05 Potassium levels LNX1 intron pha003086 rs17082951 chr4 54393115 A G 3.15E-05 Body Fat Distribution LNX1 intron pha003016 rs17082951 chr4 54393115 A G 4.07E-05 Body Fat Distribution LNX1 intron pha003017 rs17082951 chr4 54393115 A G 1.92E-05 Body Fat Distribution LNX1 intron pha003018 rs17082957 chr4 54396012 A T 4.56E-04 Insulin resistance LNX1 intron 21901158 rs1435218 chr4 54401899 C T 8.60E-05 Oral cancers (chewing tobacco related) LNX1 intron 22503698 rs4864466 chr4 54403976 G A 9.71E-04 Multiple complex diseases LNX1 intron 17554300 rs11934631 chr4 54405097 G A 1.59E-04 Multiple complex diseases LNX1 intron 17554300 rs17660061 chr4 54410671 T C 7.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LNX1 intron 20877124 rs11936494 chr4 54411330 G C 7.44E-04 Multiple complex diseases LNX1 intron 17554300 rs6820391 chr4 54414696 C A 2.20E-05 Urinary metabolites LNX1 intron 21572414 rs17083184 chr4 54465188 C T 0.000305 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17083184 chr4 54465188 C T 3.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4864809 chr4 54511913 G A 1.13E-05 Triglycerides / / 19074352 rs4864809 chr4 54511913 G A 1.13E-05 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs2668549 chr4 54514353 T A 9.99E-04 Multiple complex diseases / / 17554300 rs2590810 chr4 54548326 C T 6.36E-04 Multiple complex diseases / / 17554300 rs1871029 chr4 54564016 A G 0.000086 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1871029 chr4 54564016 A G 8.60E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17083326 chr4 54569479 C G 1.25E-04 Aortic root size / / 21223598 rs2668537 chr4 54569983 A G 9.86E-04 Depression (quantitative trait) / / 20800221 rs2616390 chr4 54571229 T C 3.38E-04 Depression (quantitative trait) / / 20800221 rs2668539 chr4 54572883 A G 7.79E-04 Depression (quantitative trait) / / 20800221 rs2668540 chr4 54574146 C A 3.96E-04 Depression (quantitative trait) / / 20800221 rs2590786 chr4 54574365 G A 4.77E-04 Depression (quantitative trait) / / 20800221 rs1871028 chr4 54576884 C A 4.70E-04 Depression (quantitative trait) / / 20800221 rs2616398 chr4 54581890 A G 4.56E-04 Depression (quantitative trait) / / 20800221 rs1993838 chr4 54582974 C T 4.54E-04 Depression (quantitative trait) / / 20800221 rs10014722 chr4 54588017 A T 9.54E-04 Type 2 diabetes / / 17463246 rs17083381 chr4 54600122 T C 2.24E-04 Multiple complex diseases / / 17554300 rs17083383 chr4 54600623 G A 4.49E-04 Multiple complex diseases / / 17554300 rs2590767 chr4 54618574 C T 1.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4457010 chr4 54631772 C T 1.37E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6827952 chr4 54637201 A C 2.03E-05 Bipolar disorder / / 22925353 rs2412493 chr4 54638699 A G 1.14E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4495107 chr4 54639835 C G 1.55E-05 Bipolar disorder / / 22925353 rs11728028 chr4 54665421 G A 6.54E-05 Multiple complex diseases / / 17554300 rs6554129 chr4 54669140 A C 2.93E-04 Type 2 diabetes / / 17463246 rs7660140 chr4 54681759 A C 2.92E-05 Multiple complex diseases / / 17554300 rs1014932 chr4 54714753 T C 2.20E-04 Type 2 diabetes / / 17463246 rs6824846 chr4 54717010 G T 9.22E-05 Multiple complex diseases / / 17554300 rs1391759 chr4 54734338 C A,G 1.78E-05 Diabetic nephropathy / / pha002852 rs1391759 chr4 54734338 C A,G 6.11E-05 Diabetic nephropathy / / pha002864 rs1391758 chr4 54734511 T C 1.84E-05 Diabetic nephropathy / / pha002852 rs1391758 chr4 54734511 T C 6.29E-05 Diabetic nephropathy / / pha002864 rs1158846 chr4 54737034 T A 2.91E-05 Type 2 diabetes / / 17463246 rs1498822 chr4 54741286 T C 3.12E-04 Smoking initiation / / 24665060 rs965126 chr4 54741949 G T 2.18E-04 Smoking initiation / / 24665060 rs4394058 chr4 54742413 T C 2.24E-04 Smoking initiation / / 24665060 rs13139909 chr4 54742555 C T 5.68E-04 Type 2 diabetes / / 17463246 rs2102010 chr4 54743246 A G 1.09E-05 Alcohol and nictotine co-dependence / / 20158304 rs2102010 chr4 54743246 A G 4.36E-05 Smoking initiation / / 24665060 rs7659192 chr4 54750921 G A 2.60E-04 Smoking initiation / / 24665060 rs10866415 chr4 54775225 C A 5.95E-05 Body mass (lean) / / 19268274 rs17083701 chr4 54794246 A G 9.09E-05 Cholesterol / / pha003073 rs871606 chr4 54799245 T C 1.00E-08 Blood pressure / / 21909110 rs1996755 chr4 54811258 G A 9.28E-05 Multiple complex diseases / / 17554300 rs6819526 chr4 54821350 G T 4.53E-05 Multiple complex diseases / / 17554300 rs10006658 chr4 54828240 A G 9.00E-05 Multiple complex diseases / / 17554300 rs6828100 chr4 54847381 G A 5.98E-05 Osteoarthritis (knee and hip) / / 21177295 rs6834659 chr4 54866124 T C 5.27E-05 Serum metabolites / / 19043545 rs7659366 chr4 54933243 C T 6.75E-05 Serum metabolites / / 19043545 rs2412522 chr4 54938543 A G 7.00E-08 Blood Phenotypes / / 17903294 rs2412522 chr4 54938543 A G 8.03E-05 Serum metabolites / / 19043545 rs6857264 chr4 54953324 A C 2.41E-05 Serum metabolites / / 19043545 rs13116880 chr4 54960005 G A,C,T 2.50E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs11133304 chr4 54970684 C T 6.69E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs12500475 chr4 54971211 A G 2.64E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs7654979 chr4 54976335 A C 4.78E-04 Type 2 diabetes / / 17463246 rs7654979 chr4 54976335 A C 1.72E-05 Serum metabolites / / 19043545 rs1017280 chr4 55011123 C T 1.24E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1364989 chr4 55011769 T C 5.00E-07 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs12507253 chr4 55016819 C T 1.63E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs6821576 chr4 55042601 T C 8.65E-05 Serum metabolites / / 19043545 rs10027676 chr4 55045716 T C 3.91E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs7659596 chr4 55049751 A G 8.65E-05 Serum metabolites / / 19043545 rs7676985 chr4 55064573 G A 9.70E-12 Corneal curvature / / 23401653 rs1559715 chr4 55073673 G A 5.04E-08 Metabolite levels / / 23281178 rs7682912 chr4 55085620 T C,G 3.53E-13 Corneal curvature / / 23401653 rs17084051 chr4 55087581 C A 2.00E-06 Corneal astigmatism / / 22144915 rs17084051 chr4 55087581 C A 5.00E-14 Corneal curvature / / 23401653 rs2114039 chr4 55092626 T C 1.00E-09 Corneal curvature / / 21665993 rs2114039 chr4 55092626 T C 1.48E-11 Corneal curvature / / 23401653 rs1800813 chr4 55094467 G A 8.00E-09 Corneal curvature PDGFRA nearGene-5 24963161 rs7677751 chr4 55124460 C T 8.00E-09 Corneal astigmatism PDGFRA intron 22144915 rs7677751 chr4 55124460 C T 4.22E-10 Corneal curvature PDGFRA intron 23401653 rs2307049 chr4 55130154 G A 3.14E-10 Corneal curvature PDGFRA intron 23401653 rs2307049 chr4 55130154 G A 4.95E-05 Coronary heart disease PDGFRA intron pha003031 rs7660560 chr4 55134394 G A 2.75E-10 Corneal curvature PDGFRA intron 23401653 rs7660560 chr4 55134394 G A 7.36E-05 Coronary heart disease PDGFRA intron pha003031 rs7656613 chr4 55141843 T C 9.66E-05 Coronary heart disease PDGFRA intron pha003031 rs4864878 chr4 55173715 C T 6.20E-06 Urinary metabolites / / 21572414 rs11726309 chr4 55195743 G A 8.60E-06 Urinary metabolites / / 21572414 rs11729535 chr4 55198205 G A 3.49E-05 Schizophrenia / / 19571809 rs1444043 chr4 55233465 C T 1.53E-04 Amyotrophic lateral sclerosis / / 20801718 rs17690232 chr4 55234825 C G 4.00E-07 Height / / 18193045 rs9312648 chr4 55241581 C T 6.00E-06 Response to amphetamines / / 22952603 rs2412565 chr4 55242372 T G 5.46E-13 Red blood cell traits / / 23222517 rs2166021 chr4 55242960 G T 6.67E-13 Red blood cell traits / / 23222517 rs7697680 chr4 55245541 C T 5.41E-04 Multiple complex diseases / / 17554300 rs7697680 chr4 55245541 C T 2.07E-13 Red blood cell traits / / 23222517 rs11938369 chr4 55245638 C T 6.42E-07 Red blood cell traits / / 23222517 rs4572929 chr4 55245741 A G 6.92E-08 Red blood cell traits / / 23222517 rs11947319 chr4 55245833 G C 7.31E-07 Red blood cell traits / / 23222517 rs1492770 chr4 55245957 T G 1.26E-07 Red blood cell traits / / 23222517 rs6812505 chr4 55246283 G C 1.09E-08 Red blood cell traits / / 23222517 rs10866417 chr4 55248603 T C 8.67E-04 Multiple complex diseases / / 17554300 rs17084241 chr4 55251279 G A 7.75E-07 Red blood cell traits / / 23222517 rs17691182 chr4 55251828 T C 6.99E-05 Schizophrenia / / 24253340 rs1562059 chr4 55253342 A G 5.22E-07 Red blood cell traits / / 23222517 rs11939940 chr4 55259160 G A 1.16E-07 Red blood cell traits / / 23222517 rs1156182 chr4 55259607 C G 2.31E-24 Multiple complex diseases / / 17554300 rs17691473 chr4 55260527 C A 5.16E-04 Multiple complex diseases / / 17554300 rs17691473 chr4 55260527 C A 1.75E-07 Red blood cell traits / / 23222517 rs6824272 chr4 55271372 T C 1.19E-07 Red blood cell traits / / 23222517 rs17084297 chr4 55271596 G C 7.09E-07 Red blood cell traits / / 23222517 rs7686042 chr4 55271890 C T 7.04E-08 Red blood cell traits / / 23222517 rs1553663 chr4 55280100 T C 2.81E-08 Red blood cell traits / / 23222517 rs2120498 chr4 55282289 C T 4.94E-08 Red blood cell traits / / 23222517 rs17084315 chr4 55286840 T A 2.92E-08 Red blood cell traits / / 23222517 rs9918031 chr4 55289471 C T 3.32E-07 Red blood cell traits / / 23222517 rs1553660 chr4 55291724 G T 4.13E-07 Red blood cell traits / / 23222517 rs12651112 chr4 55293294 T A 1.04E-07 Red blood cell traits / / 23222517 rs17749105 chr4 55294492 G A 7.44E-07 Red blood cell traits / / 23222517 rs10517334 chr4 55301708 T C 5.67E-10 Red blood cell traits / / 23222517 rs1507968 chr4 55309493 G C 5.40E-04 Type 2 diabetes / / 17463246 rs1507968 chr4 55309493 G C 1.58E-07 Red blood cell traits / / 23222517 rs17749587 chr4 55312293 G A 1.96E-07 Red blood cell traits / / 23222517 rs17084357 chr4 55314446 A G 5.19E-07 Red blood cell traits / / 23222517 rs17084361 chr4 55315510 A C 4.70E-07 Red blood cell traits / / 23222517 rs11946549 chr4 55318710 A G 3.81E-07 Red blood cell traits / / 23222517 rs13151623 chr4 55321627 G T 1.41E-09 Red blood cell traits / / 23222517 rs17084392 chr4 55340582 T C 4.60E-07 Red blood cell traits / / 23222517 rs11133330 chr4 55343263 G T 8.95E-07 Red blood cell traits / / 23222517 rs17750221 chr4 55345487 G A,C 5.24E-07 Red blood cell traits / / 23222517 rs17750246 chr4 55345973 C A 7.00E-10 Red blood cell traits / / 23222517 rs12646639 chr4 55347148 C T 1.56E-09 Red blood cell traits / / 23222517 rs2412586 chr4 55347852 A T 8.90E-04 Multiple complex diseases / / 17554300 rs2412586 chr4 55347852 A T 3.58E-09 Red blood cell traits / / 23222517 rs2412587 chr4 55347866 C G 3.77E-10 Red blood cell traits / / 23222517 rs2412588 chr4 55348026 A C 4.68E-07 Red blood cell traits / / 23222517 rs11736561 chr4 55348687 A G 1.02E-09 Red blood cell traits / / 23222517 rs12513339 chr4 55349890 A T 1.46E-08 Red blood cell traits / / 23222517 rs7691935 chr4 55350319 G T 1.62E-08 Red blood cell traits / / 23222517 rs12504666 chr4 55350468 C T 5.17E-10 Red blood cell traits / / 23222517 rs12509670 chr4 55351107 T C 5.42E-08 Red blood cell traits / / 23222517 rs7667235 chr4 55353631 C T 4.85E-10 Red blood cell traits / / 23222517 rs1507955 chr4 55354275 G A 1.32E-07 Red blood cell traits / / 23222517 rs7655524 chr4 55354337 T A 5.00E-04 Multiple complex diseases / / 17554300 rs7655524 chr4 55354337 T A 1.18E-10 Red blood cell traits / / 23222517 rs11723914 chr4 55356187 T C 9.70E-07 Red blood cell traits / / 23222517 rs1507953 chr4 55357329 G A 1.83E-11 Red blood cell traits / / 23222517 rs2135970 chr4 55357869 T A 5.10E-06 Coronary spasm / / 18075462 rs7676607 chr4 55357990 T C 4.73E-09 Red blood cell traits / / 23222517 rs13151127 chr4 55358779 G A 1.92E-07 Red blood cell traits / / 23222517 rs13134908 chr4 55359608 A G 3.44E-08 Red blood cell traits / / 23222517 rs17084406 chr4 55362184 A G 1.49E-08 Red blood cell traits / / 23222517 rs1507971 chr4 55364078 C A 3.23E-08 Red blood cell traits / / 23222517 rs13126475 chr4 55365158 G A 3.20E-11 Red blood cell traits / / 23222517 rs6840845 chr4 55366235 G A 3.24E-11 Red blood cell traits / / 23222517 rs995716 chr4 55366631 G C 8.97E-09 Red blood cell traits / / 23222517 rs6838519 chr4 55368702 T C 9.29E-04 Type 2 diabetes / / 17463246 rs13151013 chr4 55368782 C A 3.46E-07 Red blood cell traits / / 23222517 rs1396069 chr4 55369478 C A 8.05E-11 Red blood cell traits / / 23222517 rs6554191 chr4 55374968 C A 8.22E-10 Red blood cell traits / / 23222517 rs4864901 chr4 55379750 T C 8.34E-07 Red blood cell traits / / 23222517 rs4864902 chr4 55379802 A C 7.18E-05 Serum metabolites / / 19043545 rs4864902 chr4 55379802 A C 5.03E-07 Red blood cell traits / / 23222517 rs6814139 chr4 55383120 A T 2.91E-07 Red blood cell traits / / 23222517 rs12501199 chr4 55389723 G A 9.02E-07 Red blood cell traits / / 23222517 rs170117 chr4 55390380 C T 4.99E-09 Red blood cell traits / / 23222517 rs4864904 chr4 55392250 C G 8.90E-07 Urinary metabolites / / 21572414 rs218237 chr4 55394172 C T 5.84E-09 Other erythrocyte phenotypes / / 19862010 rs218237 chr4 55394172 C T 1.92E-17 Blood cell counts and other traits / / 20139978 rs218237 chr4 55394172 C T 2.19E-29 Blood cell counts and other traits / / 20139978 rs218237 chr4 55394172 C T 2.80E-25 Blood cell counts and other traits / / 20139978 rs218237 chr4 55394172 C T 3.00E-25 Blood cell counts and other traits / / 20139978 rs218237 chr4 55394172 C T 0.00000001 Red blood cell count / / 22560525 rs218237 chr4 55394172 C T 3.00E-11 Mean corpuscular hemoglobin / / 22560525 rs218237 chr4 55394172 C T 3.00E-12 Mean corpuscular volume / / 22560525 rs218237 chr4 55394172 C T 1.22E-09 Red blood cell traits / / 23222517 rs218238 chr4 55395024 A T 9.19E-09 Other erythrocyte phenotypes / / 19862010 rs218238 chr4 55395024 A T 3.00E-39 Red blood cell traits / / 23222517 rs218239 chr4 55395102 T A 8.56E-09 Other erythrocyte phenotypes / / 19862010 rs218239 chr4 55395102 T A 1.41E-09 Red blood cell traits / / 23222517 rs218256 chr4 55402409 C G 7.42E-09 Other erythrocyte phenotypes / / 19862010 rs218256 chr4 55402409 C G 2.45E-11 Red blood cell traits / / 23222517 rs10434439 chr4 55402621 G A 2.82E-07 Red blood cell traits / / 23222517 rs218259 chr4 55405948 A G 2.03E-08 Other erythrocyte phenotypes / / 19862010 rs218259 chr4 55405948 A G 8.47E-09 Red blood cell traits / / 23222517 rs172629 chr4 55407762 C G 1.00E-15 Mean corpuscular volume / / 19862010 rs172629 chr4 55407762 C G 1.00E-27 Blood cell counts and other traits / / 20139978 rs172629 chr4 55407762 C G 1.16E-27 Blood cell counts and other traits / / 20139978 rs172629 chr4 55407762 C G 9.64E-10 Red blood cell traits / / 23222517 rs218262 chr4 55407905 C A 1.67E-09 Other erythrocyte phenotypes / / 19862010 rs218262 chr4 55407905 C A 1.82E-08 Red blood cell traits / / 23222517 rs218264 chr4 55408875 A T 8.94E-09 Other erythrocyte phenotypes / / 19862010 rs218264 chr4 55408875 A T 1.82E-10 Red blood cell traits / / 23222517 rs218265 chr4 55408999 T C 9.39E-15 Red blood cell traits / / 23222517 rs218267 chr4 55409815 C T 7.25E-07 Red blood cell traits / / 23222517 rs218268 chr4 55411087 A G 2.73E-08 Red blood cell traits / / 23222517 rs218269 chr4 55411139 T C 2.15E-07 Red blood cell traits / / 23222517 rs218270 chr4 55411564 C T 1.28E-08 Red blood cell traits / / 23222517 rs218271 chr4 55411591 C G 1.66E-08 Red blood cell traits / / 23222517 rs218282 chr4 55424655 A G 8.97E-07 Red blood cell traits / / 23222517 rs13135067 chr4 55426911 G A 9.39E-09 Red blood cell traits / / 23222517 rs2703487 chr4 55434828 C T 2.66E-04 Multiple complex diseases / / 17554300 rs2703487 chr4 55434828 C T 6.40E-04 Alzheimer's disease / / 17998437 rs17826780 chr4 55455944 C T 4.31E-04 Epilepsy / / 22116939 rs2537879 chr4 55472695 A G 5.38E-04 Multiple complex diseases / / 17554300 rs2537879 chr4 55472695 A G 8.29E-04 Alzheimer's disease / / 17998437 rs2703480 chr4 55475409 T G 3.84E-04 Multiple complex diseases / / 17554300 rs2537881 chr4 55477576 G C 9.29E-04 Multiple complex diseases / / 17554300 rs17827152 chr4 55478686 G A 5.20E-06 Hypothyroidism / / 21981779 rs2537859 chr4 55482818 C T 4.00E-06 Bipolar disorder / / 19416921 rs2703457 chr4 55484356 T C 1.85E-05 Hemoglobin concentration / / 20534544 rs17084534 chr4 55490810 C T 1.04E-04 Glaucoma (primary open-angle) / / 22605921 rs17084542 chr4 55494179 G A 6.63E-05 Glaucoma (primary open-angle) / / 22605921 rs13106834 chr4 55501728 A G 4.82E-04 Coronary heart disease / / 21606135 rs11133338 chr4 55513275 T C 9.60E-06 Urinary metabolites / / 21572414 rs13147869 chr4 55519748 A G 2.20E-05 Urinary metabolites / / 21572414 rs2855775 chr4 55552600 G C 2.66E-04 Multiple complex diseases KIT intron 17554300 rs11735550 chr4 55588719 A C 5.94E-04 Smoking cessation KIT intron 24665060 rs17084794 chr4 55620032 C A 1.40E-04 Alcohol dependence / / 21314694 rs3109915 chr4 55639547 A G 6.85E-05 Post-operative nausea and vomiting / / 21694509 rs11732323 chr4 55643116 G A 5.78E-05 Breast cancer / / pha002853 rs11723705 chr4 55751071 T C 3.63E-05 Male fertility / / 22633400 rs6825459 chr4 55751945 A G 3.63E-05 Male fertility / / 22633400 rs6826975 chr4 55768206 T C 4.99E-04 Multiple complex diseases / / 17554300 rs1497482 chr4 55797131 G A 0.0000609 Follicular lymphoma / / 23025665 rs6554217 chr4 55831233 T C 1.10E-05 Weight loss (gastric bypass surgery) / / 23643386 rs4262039 chr4 55876463 G A 4.40E-05 Cognitive impairment induced by topiramate / / 22091778 rs4864948 chr4 55879599 A G 5.13E-06 ldl cholesterol / / pha003077 rs7441352 chr4 55913934 A G 5.78E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs6825958 chr4 55929176 A G 1.10E-04 Multiple complex diseases / / 17554300 rs4241991 chr4 55931246 G A 4.60E-06 Endometriosis / / 23104006 rs10008360 chr4 55952406 G A 7.49E-05 Bipolar disorder,affective KDR intron 20528957 rs17085262 chr4 55959141 C T 3.80E-04 Coronary heart disease KDR intron 21966275 rs17710298 chr4 55966617 C T 2.66E-04 Suicide attempts in bipolar disorder KDR intron 21041247 rs2305949 chr4 55980456 C T 3.46E-05 Alcohol dependence KDR intron 21703634 rs7666097 chr4 55991138 T C 0.000000044 LDL cholesterol KDR intron 23063622 rs7666097 chr4 55991138 T C 3.26E-09 HDL cholesterol KDR intron 23063622 rs7666097 chr4 55991138 T C 4.53E-12 Cholesterol,total KDR intron 23063622 rs10014689 chr4 56082270 C T 7.11E-04 Multiple complex diseases / / 17554300 rs10003420 chr4 56089259 A C 1.90E-07 Multiple complex diseases / / 17554300 rs11133375 chr4 56225353 G A 2.99E-05 Lung adenocarcinoma SRD5A3 intron 19836008 rs11133375 chr4 56225353 G A 6.00E-05 Prostate cancer SRD5A3 intron 21743057 rs7663650 chr4 56231119 C T 9.00E-05 Prostate cancer SRD5A3 intron 21743057 rs2048564 chr4 56274132 G A 1.00E-04 Prostate cancer TMEM165 intron 21743057 rs11945371 chr4 56275230 G T 1.00E-04 Prostate cancer TMEM165 intron 21743057 rs504836 chr4 56285305 C T 6.58E-05 stroke (ischemic) TMEM165 intron 17434096 rs471546 chr4 56286613 A T 6.84E-04 Sleep latency TMEM165 intron 23728906 rs473005 chr4 56288125 A C 2.38E-05 Personality dimensions TMEM165 intron 18957941 rs534654 chr4 56290220 A G 6.58E-05 stroke (ischemic) TMEM165 intron 17434096 rs6832769 chr4 56298194 G A 2.00E-06 Personality dimensions / / 18957941 rs6832769 chr4 56298194 G A 8.70E-06 Personality dimensions / / 21173776 rs1522106 chr4 56307214 C A 3.41E-05 Personality dimensions CLOCK intron 18957941 rs17777927 chr4 56312633 C G 1.91E-05 Pulmonary function CLOCK intron 20010835 rs6824955 chr4 56317136 T G 1.94E-05 Personality dimensions CLOCK intron 18957941 rs4864996 chr4 56319088 A C 1.00E-04 Prostate cancer CLOCK intron 21743057 rs2412648 chr4 56321067 T G 1.00E-04 Prostate cancer CLOCK intron 21743057 rs17085769 chr4 56324794 T C 0.000000414 Triglycerides CLOCK intron 23063622 rs4580704 chr4 56326707 G C 1.63E-05 Personality dimensions CLOCK intron 18957941 rs6843722 chr4 56331332 A C 1.00E-04 Prostate cancer CLOCK intron 21743057 rs9312661 chr4 56342326 G A 4.71E-04 Multiple complex diseases CLOCK intron 17554300 rs11133388 chr4 56344033 G C 7.93E-04 Multiple complex diseases CLOCK intron 17554300 rs13122619 chr4 56345506 C G 4.57E-04 Multiple complex diseases CLOCK intron 17554300 rs9997288 chr4 56347227 T C 1.58E-05 Personality dimensions CLOCK intron 18957941 rs11133389 chr4 56352885 C T 1.00E-04 Prostate cancer CLOCK intron 21743057 rs4864542 chr4 56354087 C G 8.04E-04 Multiple complex diseases CLOCK intron 17554300 rs1522114 chr4 56356062 A G 4.84E-04 Multiple complex diseases CLOCK intron 17554300 rs4864543 chr4 56356395 C T 1.00E-04 Prostate cancer CLOCK intron 21743057 rs17085837 chr4 56359756 G C 3.00E-10 HDL cholesterol CLOCK intron 23063622 rs3805154 chr4 56363927 C T 9.12E-06 Personality dimensions CLOCK intron 18957941 rs13124436 chr4 56368671 G A 1.00E-04 Prostate cancer CLOCK intron 21743057 rs2272073 chr4 56376344 C T 1.00E-04 Prostate cancer CLOCK intron 21743057 rs12649507 chr4 56380484 G A 6.29E-04 Multiple complex diseases CLOCK intron 17554300 rs12649507 chr4 56380484 G A 1.00E-04 Prostate cancer CLOCK intron 21743057 rs9312662 chr4 56386371 T C 1.52E-05 Personality dimensions CLOCK intron 18957941 rs13132420 chr4 56392813 G A 1.00E-04 Prostate cancer CLOCK intron 21743057 rs13140173 chr4 56393331 C T 1.00E-04 Prostate cancer CLOCK intron 21743057 rs2035691 chr4 56395953 C T 1.00E-04 Prostate cancer CLOCK intron 21743057 rs6812042 chr4 56396079 G T 1.68E-05 Personality dimensions CLOCK intron 18957941 rs13113518 chr4 56399648 T C 5.47E-04 Multiple complex diseases CLOCK intron 17554300 rs11726609 chr4 56400869 T A 1.07E-05 Personality dimensions CLOCK intron 18957941 rs4865007 chr4 56403717 C T 7.67E-04 Multiple complex diseases CLOCK intron 17554300 rs4864546 chr4 56404127 G A 2.60E-05 Height CLOCK intron 21194676 rs4864546 chr4 56404127 G A 6.40E-08 Height CLOCK intron 21194676 rs7660980 chr4 56409115 C A 6.89E-04 Multiple complex diseases CLOCK intron 17554300 rs7691799 chr4 56411741 C A 6.61E-04 Multiple complex diseases CLOCK intron 17554300 rs4864548 chr4 56413803 G A 7.19E-04 Multiple complex diseases / / 17554300 rs11133399 chr4 56413831 A G 1.24E-05 Personality dimensions / / 18957941 rs4865010 chr4 56414962 A C 1.65E-05 Personality dimensions / / 18957941 rs11943206 chr4 56437010 T C 5.78E-04 Multiple complex diseases PDCL2 intron 17554300 rs6829182 chr4 56454156 A G 1.60E-05 Personality dimensions PDCL2 intron 18957941 rs13434995 chr4 56467214 A G 5.71E-04 Multiple complex diseases NMU intron 17554300 rs13434995 chr4 56467214 A G 9.00E-06 Adiponectin levels NMU intron 22479202 rs3805383 chr4 56475338 G A 2.35E-05 Pulmonary function in asthmatics NMU cds-synon 23541324 rs17725163 chr4 56475447 T C 9.05E-04 Multiple complex diseases NMU intron 17554300 rs10026315 chr4 56478362 A C 6.71E-04 Multiple complex diseases NMU intron 17554300 rs9999653 chr4 56498249 C T 4.24E-04 Amyotrophic lateral sclerosis (sporadic) NMU intron 24529757 rs10002268 chr4 56519892 T C 2.05E-12 Esophageal cancer / / 21642993 rs9997327 chr4 56545905 G A 6.49E-05 Orofacial clefts / / 19270707 rs12646404 chr4 56584144 C T 2.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4241997 chr4 56588964 G A 7.90E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12507786 chr4 56591013 C T 7.90E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4333263 chr4 56596987 T C 1.12E-04 Attention deficit hyperactivity disorder / / pha002875 rs13120644 chr4 56598502 C G 6.72E-05 Attention deficit hyperactivity disorder / / pha002875 rs3923477 chr4 56599963 C T 7.69E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10517360 chr4 56635884 A G 4.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs753129 chr4 56668431 A G 3.00E-07 Alzheimer's disease / / 22005930 rs7699077 chr4 56671520 C T 1.30E-06 Alzheimer's disease / / 22005930 rs7664728 chr4 56673659 G A 5.98E-04 Alzheimer's disease / / 22005930 rs12498964 chr4 56680240 T C 5.60E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7679852 chr4 56683846 T C 1.07E-05 Odorant perception / / 23910658 rs1447050 chr4 56702995 A G 6.61E-05 Pulmonary function LOC644145 intron 19300500 rs35312459 chr4 56721403 G A 4.67E-06 Liver disease in chronic hepatitis B virus infection EXOC1 intron 24065354 rs3213948 chr4 56734701 C T 5.76E-04 Type 2 diabetes EXOC1 intron 17463246 rs13117307 chr4 56751740 C T 3.00E-10 Cervical cancer EXOC1 intron 23817570 rs2290015 chr4 56758993 A G 4.83E-04 Response to cytidine analogues (gemcitabine) EXOC1 intron 24483146 rs1447045 chr4 56761548 A G 1.41E-06 Cervical cancer EXOC1 intron 23817570 rs11938985 chr4 56779258 G A 9.32E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4865047 chr4 56821806 C T 4.60E-05 Diabetic retinopathy CEP135 intron 21441570 rs4864566 chr4 56829954 T C 6.40E-05 Diabetic retinopathy CEP135 intron 21441570 rs2593087 chr4 56835309 T C 6.04E-04 Amyotrophic lateral sclerosis (sporadic) CEP135 intron 24529757 rs9312669 chr4 56853209 A G 7.70E-05 Diabetic retinopathy CEP135 intron 21441570 rs13138432 chr4 56868342 A G 5.20E-05 Diabetic retinopathy CEP135 intron 21441570 rs6856844 chr4 56869217 T C 5.30E-05 Diabetic retinopathy CEP135 intron 21441570 rs2702340 chr4 56908194 G A 4.56E-05 Bipolar disorder / / 21771265 rs4864568 chr4 56957941 A G 6.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs6849646 chr4 56958365 T C 3.12E-06 Left ventricular mass / / 21212386 rs13121935 chr4 56966559 A G 8.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs17799799 chr4 56968671 T G 7.79E-05 Suicide attempts in bipolar disorder / / 21423239 rs4865052 chr4 56969595 T C 1.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs4865053 chr4 56972069 G C 1.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs976639 chr4 56979924 G A 2.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs976640 chr4 56980231 G A 2.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs4864570 chr4 56984772 G T 3.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs17086308 chr4 56985359 A G 3.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs11728328 chr4 56986929 T C 8.61E-04 Taste perception / / 22132133 rs17086320 chr4 56988744 C T 1.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs13109565 chr4 56991225 C T 4.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs998064 chr4 56997350 A G 8.00E-05 Prostate cancer / / 21743057 rs13143526 chr4 57008387 C T 5.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs6837469 chr4 57014876 T C 1.36E-05 Serum metabolites / / 19043545 rs6818728 chr4 57028934 C T 8.65E-04 Aortic root size / / 21223598 rs6817969 chr4 57070311 A G 5.04E-04 Insulin resistance KIAA1211 intron 21901158 rs10017845 chr4 57074551 C T 9.10E-06 Urinary metabolites KIAA1211 intron 21572414 rs6554336 chr4 57076935 T A 4.65E-04 Multiple complex diseases KIAA1211 intron 17554300 rs13127195 chr4 57084329 T C 5.72E-05 Erythrocyte counts KIAA1211 intron pha003099 rs10007515 chr4 57091842 T C 3.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KIAA1211 intron 20877124 rs4865070 chr4 57093826 G A 0.0004809 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KIAA1211 intron 23233654 rs4865070 chr4 57093826 G A 4.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIAA1211 intron 23233662 rs7698073 chr4 57097742 G A 1.44E-04 Taste perception KIAA1211 intron 22132133 rs13149904 chr4 57102779 C T 0.0005692 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KIAA1211 intron 23233654 rs13149904 chr4 57102779 C T 5.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIAA1211 intron 23233662 rs4865080 chr4 57118730 C G 2.42E-16 Multiple complex diseases KIAA1211 intron 17554300 rs629242 chr4 57143037 C T 7.25E-07 Prostate cancer KIAA1211 intron 18073375 rs629242 chr4 57143037 C T 1.08E-05 Prostate cancer KIAA1211 intron pha002878 rs11133434 chr4 57149026 C T 9.90E-04 Type 2 diabetes KIAA1211 intron 17463246 rs533178 chr4 57149650 G A 9.94E-04 Type 2 diabetes KIAA1211 intron 17463246 rs490591 chr4 57154790 C T 6.49E-05 Body Mass Index KIAA1211 intron pha003009 rs490591 chr4 57154790 C T 7.72E-05 Height KIAA1211 intron pha003011 rs11736632 chr4 57172335 G A 4.59E-05 Multiple sclerosis KIAA1211 intron 19525953 rs1401908 chr4 57285163 C T 3.54E-06 Post-operative nausea and vomiting PPAT intron 21694509 rs1520026 chr4 57300557 C T 5.21E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) PPAT intron 23648065 rs1356787 chr4 57305202 T C 4.26E-04 Schizophrenia(treatment response to risperidone) PAICS intron 19850283 rs7693436 chr4 57327613 G A 9.93E-06 Monocyte counts / / pha003089 rs12505749 chr4 57334112 C G 5.00E-06 Airflow obstruction SRP72 intron 22837378 rs17086853 chr4 57352319 A G 9.49E-04 Coronary heart disease SRP72 intron 21606135 rs4391105 chr4 57387706 G A 4.32E-04 Response to cytidine analogues (gemcitabine) ARL9 intron 24483146 rs7670824 chr4 57457918 A G 3.65E-05 Coronary heart disease THEGL intron pha003035 rs7672789 chr4 57482846 G A 8.56E-05 Lymphocyte counts / / 22286170 rs10004349 chr4 57492998 A G 7.43E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6836932 chr4 57528443 T C 9.10E-04 Multiple complex diseases HOPX intron 17554300 rs4865140 chr4 57537199 A C,G 9.67E-05 Non-alcoholic fatty liver disease histology (other) HOPX intron 20708005 rs12642085 chr4 57549528 C T 8.38E-05 HDL cholesterol / / pha003075 rs6821445 chr4 57576203 G C 7.36E-04 Multiple complex diseases / / 17554300 rs7663813 chr4 57611830 G A 1.45E-05 Hypertension (early onset hypertension) / / 22479346 rs1479890 chr4 57614205 G A 2.78E-05 Relative hand skill / / 24068947 rs2008139 chr4 57652380 G A 2.46E-08 Creatinine levels / / pha003069 rs1708768 chr4 57690713 G A 7.80E-04 Coronary Artery Disease / / 17634449 rs7684253 chr4 57727311 C T 3.52E-04 Age-related macular degeneration / / 21909106 rs9637715 chr4 57731538 C T 5.27E-04 Age-related macular degeneration / / 21909106 rs12650282 chr4 57733604 C T 4.89E-04 Age-related macular degeneration / / 21909106 rs13101682 chr4 57735358 G A 5.11E-04 Age-related macular degeneration / / 21909106 rs4560473 chr4 57741415 T C 2.63E-04 White matter integrity / / 22425255 rs4865158 chr4 57743742 G T 7.83E-04 Multiple complex diseases / / 17554300 rs4339274 chr4 57747634 C T 2.41E-04 Type 2 diabetes / / 17463246 rs4339274 chr4 57747634 C T 1.37E-04 Multiple complex diseases / / 17554300 rs4865165 chr4 57765546 T C 7.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs9998008 chr4 57766052 G A,C,T 7.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs3806746 chr4 57773330 C T 5.70E-05 Age-related macular degeneration REST nearGene-5 21909106 rs1713985 chr4 57786450 G T 2.00E-08 Age-related macular degeneration REST intron 21909106 rs17087265 chr4 57788233 C T 3.49E-04 Age-related macular degeneration REST intron 21909106 rs6847086 chr4 57791864 G A 1.31E-04 Suicide attempts in bipolar disorder REST intron 21423239 rs6847086 chr4 57791864 G A 5.49E-04 Age-related macular degeneration REST intron 21909106 rs1105434 chr4 57793751 G A 4.58E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) REST intron 17982456 rs3796529 chr4 57797414 C T 4.20E-08 Height REST missense 21194676 rs3796529 chr4 57797414 C T 5.70E-08 Height REST missense 21194676 rs3796529 chr4 57797414 C T 1.60E-05 Coronary heart disease REST missense 21966275 rs13108570 chr4 57807083 G C 2.99E-05 Age-related macular degeneration / / 21909106 rs708547 chr4 57821309 T C 9.00E-07 Bleomycin sensitivity / / 21106707 rs7697176 chr4 57823048 C T 5.67E-05 Age-related macular degeneration / / 21909106 rs17081935 chr4 57823476 C T 4.00E-11 Height / / 20881960 rs781668 chr4 57825140 T C 3.86E-04 Multiple complex diseases / / 17554300 rs781668 chr4 57825140 T C 1.18E-04 Schizophrenia / / 21674006 rs10020462 chr4 57825593 C T 2.53E-04 Age-related macular degeneration / / 21909106 rs17087335 chr4 57838583 G T 0.0000101 Coronary artery disease NOA1 intron 23202125 rs1107674 chr4 57838690 T G 1.87E-05 Multiple complex diseases NOA1 intron 17554300 rs1713997 chr4 57843863 G C 7.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs2276897 chr4 57845217 G T 3.66E-04 Age-related macular degeneration POLR2B intron 21909106 rs1625691 chr4 57845740 T C 9.43E-05 Non-alcoholic fatty liver disease histology (other) POLR2B intron 20708005 rs1625691 chr4 57845740 T C 8.55E-04 Suicide attempts in bipolar disorder POLR2B intron 21423239 rs1718886 chr4 57849251 C T 8.24E-05 Multiple complex diseases POLR2B intron 17554300 rs3733309 chr4 57857188 A G 2.11E-04 Multiple complex diseases POLR2B intron 17554300 rs3821994 chr4 57865667 G A 3.80E-04 Age-related macular degeneration POLR2B intron 21909106 rs9918067 chr4 57870544 A G 1.41E-04 Age-related macular degeneration POLR2B intron 21909106 rs1718837 chr4 57871203 T C 2.60E-04 Age-related macular degeneration POLR2B intron 21909106 rs1718878 chr4 57876955 G A 3.80E-04 Age-related macular degeneration POLR2B cds-synon 21909106 rs10023088 chr4 57884435 G A 4.92E-05 Multiple complex diseases POLR2B intron 17554300 rs10023088 chr4 57884435 G A 2.70E-05 Urinary metabolites POLR2B intron 21572414 rs10023088 chr4 57884435 G A 1.06E-04 Age-related macular degeneration POLR2B intron 21909106 rs1403233 chr4 57885053 T C 6.12E-05 Multiple complex diseases POLR2B intron 17554300 rs1056364 chr4 57889677 C T 1.01E-04 Age-related macular degeneration / / 21909106 rs3796532 chr4 57890776 C T 2.36E-04 Age-related macular degeneration POLR2B intron 21909106 rs6843644 chr4 57891239 G A 2.88E-04 Age-related macular degeneration POLR2B intron 21909106 rs12650737 chr4 57892475 G T 6.23E-05 Age-related macular degeneration POLR2B intron 21909106 rs12621 chr4 57897570 G T 2.84E-04 Age-related macular degeneration IGFBP7 intron 21909106 rs1277308 chr4 57897864 C T 3.74E-04 Age-related macular degeneration IGFBP7 intron 21909106 rs11573126 chr4 57899065 C G 2.57E-04 Age-related macular degeneration IGFBP7 intron 21909106 rs11573125 chr4 57899097 C T 2.71E-04 Age-related macular degeneration IGFBP7 intron 21909106 rs2271808 chr4 57899602 C T 7.05E-06 Multiple complex diseases IGFBP7 intron 17554300 rs1277311 chr4 57902761 C T 9.04E-07 Intelligence IGFBP7 intron 21826061 rs41495551 chr4 57903093 A G 6.21E-04 Multiple complex diseases IGFBP7 intron 17554300 rs6841086 chr4 57903268 G A 1.03E-04 Multiple complex diseases IGFBP7 intron 17554300 rs876858 chr4 57914919 C G 6.60E-05 Age-related macular degeneration IGFBP7 intron 21909106 rs881382 chr4 57917346 G T 4.55E-05 Age-related macular degeneration IGFBP7 intron 21909106 rs2412775 chr4 57920189 C T 4.15E-04 Sudden cardiac arrest IGFBP7 intron 21658281 rs1277293 chr4 57931341 G A 6.04E-05 Coronary heart disease IGFBP7 intron pha003032 rs10516162 chr4 57936920 C T 9.90E-04 Bipolar disorder IGFBP7 intron 19259986 rs17087487 chr4 57936947 G A 8.71E-04 Multiple complex diseases IGFBP7 intron 17554300 rs10049992 chr4 57939863 T G 8.00E-06 IgG glycosylation IGFBP7 intron 23382691 rs11934877 chr4 57941026 T C 0.00022 Bisphosphonate-induced osteonecrosis of the jaw IGFBP7 intron 22267851 rs6828580 chr4 57987433 A G 9.17E-04 Multiple complex diseases LOC255130 intron 17554300 rs4377648 chr4 58024744 C T 6.82E-04 Multiple complex diseases LOC255130 intron 17554300 rs10033422 chr4 58027081 A G 3.28E-04 Multiple complex diseases LOC255130 intron 17554300 rs4315858 chr4 58027570 G A 9.50E-05 Multiple complex diseases LOC255130 intron 17554300 rs7696751 chr4 58035857 C G 5.29E-06 Retinopathy in non-diabetics LOC255130 intron 23393555 rs10488927 chr4 58058785 G T 1.30E-05 Urinary metabolites LOC255130 intron 21572414 rs10488927 chr4 58058785 G T 8.62E-07 Retinopathy in non-diabetics LOC255130 intron 23393555 rs17087660 chr4 58068060 G C 4.98E-05 Multiple complex diseases LOC255130 intron 17554300 rs2079916 chr4 58072932 G A 6.68E-04 Taste perception / / 22132133 rs6850123 chr4 58080251 C T 0.0000749 post-traumatic stress disorder / / 22869035 rs6850123 chr4 58080251 C T 7.49E-05 Schizophrenia / / 22883433 rs17425871 chr4 58081173 T G 8.09E-04 Alzheimer's disease / / 17998437 rs1860623 chr4 58081590 A G 0.000086 post-traumatic stress disorder / / 22869035 rs1860623 chr4 58081590 A G 8.60E-05 Schizophrenia / / 22883433 rs4865199 chr4 58082554 C T 9.07E-05 Heart Rate / / pha003053 rs1860621 chr4 58087036 C T 4.68E-04 Alzheimer's disease (late onset) / / 21379329 rs1981687 chr4 58104571 T C 2.80E-05 Urinary metabolites / / 21572414 rs13147707 chr4 58108131 T C 2.82E-06 Intracerebral hemorrhage / / 24656865 rs13147707 chr4 58108131 T C 4.59E-06 Intracerebral hemorrhage / / 24656865 rs13118373 chr4 58110121 A G 1.46E-04 Multiple complex diseases / / 17554300 rs13118373 chr4 58110121 A G 2.98E-04 Smoking quantity / / 24665060 rs11731338 chr4 58116921 A G 6.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10018606 chr4 58138412 G A 1.89E-05 Lung function (forced vital capacity) / / 24023788 rs2215480 chr4 58139397 T C 9.71E-04 Multiple complex diseases / / 17554300 rs1158740 chr4 58139917 G A 4.01E-04 Multiple complex diseases / / 17554300 rs1158740 chr4 58139917 G A 8.10E-06 Urinary metabolites / / 21572414 rs1476844 chr4 58139970 T C 3.62E-06 Multiple complex diseases / / 17554300 rs2191574 chr4 58141367 C T 1.75E-04 Lung function (forced vital capacity) / / 24023788 rs11947043 chr4 58153851 G A 7.92E-04 Multiple complex diseases / / 17554300 rs1917330 chr4 58186260 G A 1.10E-05 Brain structure / / 22504417 rs2535510 chr4 58192240 T C 5.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs10488920 chr4 58192851 G A 8.86E-05 Schizophrenia(age at onset) / / 21688384 rs2535508 chr4 58192937 G A 3.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs1917332 chr4 58193592 T C 4.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs2535504 chr4 58195131 G C 3.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs2535503 chr4 58195196 C T 1.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs2535503 chr4 58195196 C T 0.000701 Salmonella-induced pyroptosis / / 22837397 rs2535502 chr4 58195220 C T 1.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs1357781 chr4 58199142 C T 0.000785 Salmonella-induced pyroptosis / / 22837397 rs1404372 chr4 58203605 C A,G,T 1.52E-05 Orofacial clefts / / 19270707 rs2691390 chr4 58210814 C T 6.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10488919 chr4 58210922 G A 7.26E-04 Multiple complex diseases / / 17554300 rs2535556 chr4 58211868 A G 6.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9312686 chr4 58290890 T C 6.98E-05 Elbow pain / / pha003008 rs2582942 chr4 58312740 G T 8.28E-04 Multiple complex diseases / / 17554300 rs11725660 chr4 58328884 G T 5.68E-05 Blood Pressure / / pha003039 rs1441064 chr4 58356843 A G 3.37E-05 Blood Pressure / / pha003039 rs11944179 chr4 58374377 C T 3.00E-05 Blood Pressure / / pha003039 rs7697011 chr4 58477126 G A 1.65E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10517398 chr4 58497329 A G 4.90E-04 Type 2 diabetes / / 17463246 rs10517399 chr4 58497462 A G 6.61E-04 Multiple complex diseases / / 17554300 rs2042617 chr4 58498461 G C 7.18E-04 Multiple complex diseases / / 17554300 rs11133515 chr4 58531386 A C 5.89E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs510563 chr4 58589489 A C 2.27E-04 Multiple complex diseases / / 17554300 rs2042616 chr4 58596660 T G 8.59E-04 Type 2 diabetes / / 17463246 rs1509537 chr4 58639261 A C 4.44E-04 Multiple complex diseases / / 17554300 rs6844881 chr4 58697912 A T 4.41E-04 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs1904778 chr4 58702467 A G 2.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs983355 chr4 58703510 A G 1.22E-06 Cholesterol / / 17255346 rs13149584 chr4 58721138 T C 2.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs17088838 chr4 58738371 T C 7.16E-04 Type 2 diabetes / / 17463246 rs3913924 chr4 58860052 C A 6.38E-04 Multiple complex diseases / / 17554300 rs2412862 chr4 58860918 A C 7.85E-04 Obesity (extreme) / / 21935397 rs2054261 chr4 58868714 A C 7.04E-04 Obesity (extreme) / / 21935397 rs17290134 chr4 58906629 A G 8.54E-04 Obesity (extreme) / / 21935397 rs166583 chr4 58933336 A G 9.80E-05 Major depressive disorder / / 19107115 rs1507569 chr4 58950602 A G 5.63E-04 Type 2 diabetes / / 17463246 rs2660950 chr4 58956886 T C 3.63E-04 Type 2 diabetes / / 17463246 rs1531305 chr4 58960261 G A 4.60E-04 Multiple complex diseases / / 17554300 rs2610166 chr4 58961150 G A 5.67E-04 Type 2 diabetes / / 17463246 rs6839025 chr4 58964422 G A 9.15E-05 Asthma / / pha003127 rs1459487 chr4 58970286 T C 5.62E-04 Type 2 diabetes / / 17463246 rs6554509 chr4 58970405 A G 3.13E-09 Breast cancer / / 20852631 rs17827094 chr4 58974787 A T 5.88E-04 Type 2 diabetes / / 17463246 rs17827100 chr4 58974871 A G 5.59E-04 Type 2 diabetes / / 17463246 rs995080 chr4 58976281 C T 5.59E-04 Type 2 diabetes / / 17463246 rs1824388 chr4 58983189 T C 4.52E-05 Response to citalopram treatment / / 19846067 rs1471233 chr4 58984308 T C 6.72E-04 Type 2 diabetes / / 17463246 rs1471233 chr4 58984308 T C 2.38E-06 Cardiovascular disease / / 18179892 rs17218077 chr4 58992998 G A 1.50E-05 Urinary metabolites / / 21572414 rs4864645 chr4 58994906 A C 9.41E-05 Asthma / / pha003127 rs10517437 chr4 59008412 G A 4.00E-06 Cognitive performance / / 20125193 rs7654525 chr4 59024033 A G 4.03E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs892307 chr4 59031089 T C 3.12E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs1433412 chr4 59035395 G A 2.22E-06 Suicidal ideation / / 20877300 rs1368607 chr4 59040235 G A 1.76E-06 Suicidal ideation / / 20877300 rs2060321 chr4 59074656 G A 4.62E-05 Asthma / / pha003127 rs2570073 chr4 59087431 A C 4.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs2570071 chr4 59089430 G T 7.62E-05 Suicide attempts in bipolar disorder / / 21041247 rs4353961 chr4 59094592 G A 6.72E-05 Asthma / / pha003127 rs2570089 chr4 59099611 C T 8.00E-05 Suicide attempts in bipolar disorder / / 21041247 rs41444744 chr4 59101076 C T 1.65E-04 Multiple complex diseases / / 17554300 rs2553316 chr4 59107838 G C 1.37E-04 Suicide attempts in bipolar disorder / / 21041247 rs12511928 chr4 59109055 G A 5.27E-05 Asthma / / pha003127 rs11133552 chr4 59123298 G A 8.52E-05 Suicide attempts in bipolar disorder / / 21041247 rs2412885 chr4 59127142 C T 8.62E-05 Suicide attempts in bipolar disorder / / 21041247 rs2244536 chr4 59129952 C A 8.69E-05 Suicide attempts in bipolar disorder / / 21041247 rs13105776 chr4 59133280 C T 1.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs1368608 chr4 59134123 A G 8.79E-05 Suicide attempts in bipolar disorder / / 21041247 rs2553297 chr4 59139089 C T 9.04E-05 Suicide attempts in bipolar disorder / / 21041247 rs17089214 chr4 59154046 T C 3.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs17603347 chr4 59155409 C T 2.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs17237651 chr4 59156514 A G 5.27E-05 Asthma / / pha003127 rs17237658 chr4 59156538 T C 9.06E-04 Type 2 diabetes / / 17463246 rs7690084 chr4 59166227 G A 2.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs13148519 chr4 59167150 G A 2.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs2412887 chr4 59168109 A G 2.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs2140072 chr4 59168763 A G 2.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs11933359 chr4 59171399 T C 2.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs11945898 chr4 59171496 C T 2.71E-04 Suicide attempts in bipolar disorder / / 21041247 rs1402960 chr4 59177178 G A 3.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs9312697 chr4 59183934 A G 7.35E-04 Suicide attempts in bipolar disorder / / 21041247 rs11133555 chr4 59185798 A G 7.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs1522096 chr4 59187811 G A 7.81E-04 Suicide attempts in bipolar disorder / / 21041247 rs7435172 chr4 59191423 C T 7.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs11735710 chr4 59208672 G A 7.06E-04 Suicide attempts in bipolar disorder / / 21041247 rs11727794 chr4 59209089 C A 7.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs17218140 chr4 59209586 G C,T 6.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs13146937 chr4 59209796 G A 7.84E-05 Pulmonary function / / 20010835 rs12647365 chr4 59210869 G A 6.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs12641535 chr4 59210984 C T 6.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs12648067 chr4 59211129 G A 6.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs12648092 chr4 59211220 G A 6.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs2090900 chr4 59211580 C A 6.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs2090901 chr4 59211625 C T 6.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs11133558 chr4 59213287 A G 6.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs10517438 chr4 59213426 A T 5.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs4865328 chr4 59213741 C T 5.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs17218161 chr4 59213845 T C 2.00E-08 Asthma (childhood onset) / / 23829686 rs12511263 chr4 59214105 G A 5.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs11133559 chr4 59214602 C A 5.75E-04 Suicide attempts in bipolar disorder / / 21041247 rs10866458 chr4 59246175 G A 3.62E-04 Response to TNF antagonist treatment / / 21061259 rs1869463 chr4 59305132 A G 9.00E-06 Corneal curvature / / 22969067 rs2007685 chr4 59309284 T C 8.86E-06 Corneal curvature / / 22969067 rs2037458 chr4 59321537 A G 2.02E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12508002 chr4 59363118 C T 2.57E-04 Obesity (extreme) / / 21935397 rs10517441 chr4 59419273 C T 1.02E-04 Myocardial Infarction / / pha002883 rs10517442 chr4 59432230 T C 9.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs282718 chr4 59433764 G A 8.24E-06 Malignant mesothelioma / / 23827383 rs1377717 chr4 59439743 A G 9.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs4286599 chr4 59449633 T C 9.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs282705 chr4 59502687 C T 9.00E-06 Type 2 diabetes / / 17293876 rs282705 chr4 59502687 C T 9.00E-06 Type 2 diabetes / / 19184112 rs282708 chr4 59503726 A G 8.00E-06 Acute lymphoblastic leukemia (childhood) / / 22076464 rs2166999 chr4 59552875 G A 2.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2899130 chr4 59557817 G A 9.43E-05 Response to hepatitis C treatment / / 19684573 rs2899130 chr4 59557817 G A 2.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2899130 chr4 59557817 G A 1.77E-05 Common variable immunodeficiency / / 21497890 rs1472926 chr4 59582759 A G 8.91E-04 HIV-1 viral setpoint / / 17641165 rs13134853 chr4 59596759 C T 6.62E-04 Obesity (extreme) / / 21935397 rs12503260 chr4 59599416 T G 6.62E-04 Obesity (extreme) / / 21935397 rs6843830 chr4 59629835 T G 7.65E-05 Personality dimensions / / 18957941 rs1597268 chr4 59663396 T C 9.18E-05 Personality dimensions / / 18957941 rs10517449 chr4 59667025 T C 1.82E-04 Glaucoma (primary open-angle) / / 22419738 rs6850205 chr4 59674052 C T 4.44E-04 Multiple complex diseases / / 17554300 rs6853837 chr4 59674165 G A 3.57E-04 Multiple complex diseases / / 17554300 rs1584444 chr4 59695246 G A 2.39E-04 Multiple complex diseases / / 17554300 rs7685041 chr4 59720431 G A 6.00E-04 Alcohol dependence / / 20201924 rs17238008 chr4 59729160 T C 9.81E-05 Hypertension / / pha003042 rs28570064 chr4 59734211 A G 7.20E-04 Alcohol dependence / / 20201924 rs4074334 chr4 59805404 G T 7.60E-04 Alcohol dependence / / 20201924 rs9685766 chr4 59813594 C T 2.40E-05 Post-operative nausea and vomiting / / 21694509 rs7667163 chr4 59817797 T C 4.65E-05 Psoriasis / / 20953190 rs7438744 chr4 59825257 A T 4.90E-04 Multiple complex diseases / / 17554300 rs11931812 chr4 59844473 T C 1.80E-04 Asperger disorder / / 21182207 rs7685069 chr4 59882734 C T 3.64E-04 Multiple complex diseases / / 17554300 rs10035063 chr4 59920335 T G 4.83E-04 Multiple complex diseases / / 17554300 rs10028900 chr4 59923634 G T 3.24E-04 Multiple complex diseases / / 17554300 rs9993022 chr4 59923687 C T 1.55E-04 Multiple complex diseases / / 17554300 rs10002600 chr4 59923864 T A 5.67E-04 Multiple complex diseases / / 17554300 rs4510528 chr4 59951933 C T 4.16E-04 Multiple complex diseases / / 17554300 rs9312080 chr4 60062685 G T 5.63E-05 Pulmonary function / / 17903307 rs2009488 chr4 60067129 C G 3.43E-05 Pulmonary function / / 17903307 rs905367 chr4 60067597 G A 2.95E-05 Pulmonary function / / 17903307 rs1393593 chr4 60078923 A T 5.44E-05 Pulmonary function / / 17903307 rs7657311 chr4 60100314 T C 9.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs7671267 chr4 60103284 A G 9.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs7440788 chr4 60155189 C T 2.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs41460845 chr4 60207902 A G 1.10E-05 Multiple complex diseases / / 17554300 rs10049656 chr4 60225960 C T 3.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs1983239 chr4 60249365 G A 4.33E-05 Blood Pressure / / pha003040 rs7681982 chr4 60257454 T C 1.08E-05 Leukocyte Counts / / pha003091 rs1511404 chr4 60283466 A C 1.18E-05 Leukocyte Counts / / pha003091 rs2048462 chr4 60306500 T C 8.08E-04 Heart Failure / / pha002885 rs2048462 chr4 60306500 T C 9.57E-06 Leukocyte Counts / / pha003091 rs6826593 chr4 60314905 T C 1.26E-05 Leukocyte Counts / / pha003091 rs12331299 chr4 60361958 A G 2.60E-05 Urinary metabolites / / 21572414 rs17238254 chr4 60373313 C G 5.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs7692468 chr4 60387255 G A 1.20E-05 Urinary metabolites / / 21572414 rs17089687 chr4 60403334 C T 2.20E-05 Urinary metabolites / / 21572414 rs1486307 chr4 60440722 G A 5.00E-06 Prostate cancer (early onset) / / 24740154 rs17290779 chr4 60442490 T C 9.82E-05 Leukocyte Counts / / pha003091 rs6842739 chr4 60489510 A G 7.19E-06 Osteoarthritis / / 22763110 rs17089754 chr4 60560479 G T 7.21E-04 Multiple complex diseases / / 17554300 rs17089772 chr4 60579003 G C 5.23E-05 Multiple complex diseases / / 17554300 rs17089784 chr4 60615586 G A 8.43E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17089786 chr4 60616622 T C 8.43E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17089787 chr4 60617541 T C 8.43E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9312186 chr4 60674843 C T 1.51E-04 Myocardial Infarction / / pha002873 rs10517480 chr4 60748829 A T 2.00E-07 Metabolite levels / / 19043545 rs11944118 chr4 60752123 C T 8.23E-07 Serum metabolites / / 19043545 rs2125939 chr4 60808849 G A 5.67E-05 Multiple complex diseases / / 17554300 rs349215 chr4 60843933 A G 1.33E-05 Information processing speed / / 21130836 rs17089910 chr4 60849576 A G 1.70E-04 Multiple complex diseases / / 17554300 rs17291023 chr4 60866816 T G 8.26E-05 Cognitive impairment induced by topiramate / / 22091778 rs12499385 chr4 60869291 T A 1.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs9312046 chr4 60873467 C G 4.85E-04 Fibrinogen / / 17255346 rs2880475 chr4 60874182 A G 1.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs12504530 chr4 60959404 C T 8.79E-06 Left ventricular mass / / 21212386 rs17291120 chr4 60965262 G A 8.10E-05 Personality dimensions / / 18957941 rs2044018 chr4 61010420 T C 6.90E-04 Multiple complex diseases / / 17554300 rs6551522 chr4 61022407 C T 6.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs6845525 chr4 61028533 T C 7.13E-04 Multiple complex diseases / / 17554300 rs17291217 chr4 61044372 A T 1.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs1372202 chr4 61047629 G A 1.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs6817774 chr4 61055763 T C 3.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs2119556 chr4 61056394 T C 1.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs2119557 chr4 61056680 C T 1.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs10001264 chr4 61056770 C A 1.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs6834812 chr4 61061173 C A 5.79E-05 Pulmonary function / / 20010835 rs10517493 chr4 61061578 A T 9.73E-05 Pulmonary function / / 20010835 rs6829548 chr4 61062857 T C 2.67E-05 Suicide attempts in bipolar disorder / / 21423239 rs12501685 chr4 61064280 G A 7.96E-05 Suicide attempts in bipolar disorder / / 21423239 rs2333895 chr4 61143085 A G 3.76E-05 Glucose levels / / pha002899 rs10517502 chr4 61154338 T C 9.73E-05 Glucose levels / / pha002899 rs717253 chr4 61163846 T C 5.14E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6827408 chr4 61177831 C T 9.28E-05 Glucose levels / / pha002899 rs7673099 chr4 61187284 A C 9.58E-05 Glucose levels / / pha002899 rs10517498 chr4 61210768 C T 5.09E-04 Premature ovarian failure / / 19508998 rs4860053 chr4 61225009 G A 5.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6833291 chr4 61226507 C T 3.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6815467 chr4 61226648 T C 5.81E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10017324 chr4 61228799 A C 2.82E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1463351 chr4 61233219 C T 3.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4860340 chr4 61247315 C T 7.61E-04 Response to alcohol consumption (flushing response) / / 24277619 rs6815127 chr4 61286729 T A 1.22E-04 Acute lung injury / / 22295056 rs1511104 chr4 61287186 T C 1.22E-04 Acute lung injury / / 22295056 rs1455724 chr4 61313431 G A 8.97E-05 Acute lung injury / / 22295056 rs1455725 chr4 61313675 G A 2.90E-04 Acute lung injury / / 22295056 rs1455726 chr4 61313828 C T 2.90E-04 Acute lung injury / / 22295056 rs925395 chr4 61317176 A G 3.23E-04 Acute lung injury / / 22295056 rs12650670 chr4 61317819 C G 6.61E-04 Acute lung injury / / 22295056 rs976629 chr4 61318014 G T 1.01E-04 Acute lung injury / / 22295056 rs1553863 chr4 61319052 T C 2.84E-04 Acute lung injury / / 22295056 rs1511118 chr4 61319275 T A 2.84E-04 Acute lung injury / / 22295056 rs1511119 chr4 61319465 A G 1.00E-04 Acute lung injury / / 22295056 rs6814822 chr4 61354000 G A 9.81E-04 White matter integrity / / 22425255 rs1588514 chr4 61371578 A C 2.07E-05 Birth weight / / 17255346 rs1511133 chr4 61398938 T C 2.56E-04 Coronary Artery Disease / / 17634449 rs1511133 chr4 61398938 T C 7.63E-05 Personality dimensions / / 18957941 rs6551568 chr4 61399091 C G 2.02E-04 Coronary Artery Disease / / 17634449 rs11732112 chr4 61403969 C T 3.59E-04 Obesity (extreme) / / 21935397 rs17090126 chr4 61405199 G A 2.53E-04 Multiple complex diseases / / 17554300 rs17219457 chr4 61412584 C A 1.56E-04 Multiple complex diseases / / 17554300 rs17090172 chr4 61412808 T C 4.89E-04 Multiple complex diseases / / 17554300 rs1439316 chr4 61415481 C T 2.06E-04 Multiple complex diseases / / 17554300 rs1439316 chr4 61415481 C T 0.000155824 Hypertension (early onset hypertension) / / 22479346 rs6855004 chr4 61423294 G A 6.56E-04 Coronary heart disease / / 21971053 rs17090188 chr4 61427729 T G 6.58E-04 Type 2 diabetes / / 17463246 rs1866497 chr4 61428584 A C 6.36E-04 Type 2 diabetes / / 17463246 rs1561478 chr4 61488486 T C 1.60E-04 Blood Phenotypes / / 17903294 rs17090225 chr4 61511249 T G 4.79E-04 Multiple complex diseases / / 17554300 rs11734262 chr4 61523996 G A 9.13E-05 Coronary heart disease / / 21971053 rs1439317 chr4 61528903 T C 7.19E-05 Coronary heart disease / / 21971053 rs10517515 chr4 61538011 T A 2.44E-04 Type 2 diabetes / / 17463246 rs12650513 chr4 61560936 G A 1.42E-04 Type 2 diabetes / / 17463246 rs4496609 chr4 61641564 A G 1.22E-05 Parkinson's disease / / 21812969 rs10031773 chr4 61649211 C T 1.70E-04 Insulin resistance / / 21901158 rs4272045 chr4 61663916 A G 5.79E-04 Coronary heart disease / / 21971053 rs4272045 chr4 61663916 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17090278 chr4 61679934 T A 7.24E-04 Alzheimer's disease / / 17998437 rs17090286 chr4 61695978 A C 8.55E-04 Alzheimer's disease / / 17998437 rs10017506 chr4 61704706 C G 6.87E-04 Multiple complex diseases / / 17554300 rs17291739 chr4 61709761 T G 3.11E-04 Alzheimer's disease / / 17998437 rs61359316 chr4 61711076 G A 0.00005061 Sarcoidosis / / 22952805 rs12500477 chr4 61712791 T C 0.00008319 Sarcoidosis / / 22952805 rs4478216 chr4 61718150 C A 0.00009386 Sarcoidosis / / 22952805 rs62313267 chr4 61724685 G A 0.00009878 Sarcoidosis / / 22952805 rs1455286 chr4 61753646 C T 7.61E-04 Type 2 diabetes / / 17463246 rs10016361 chr4 61754897 A C 0.00007907 Sarcoidosis / / 22952805 rs1947475 chr4 61757891 T C 0.00009895 Sarcoidosis / / 22952805 rs1471016 chr4 61761945 A G 1.31E-04 Multiple complex diseases / / 17554300 rs1471017 chr4 61762105 G C 7.50E-04 Type 2 diabetes / / 17463246 rs10022351 chr4 61788908 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs3113484 chr4 61813163 T A 8.74E-04 Multiple complex diseases / / 17554300 rs7699903 chr4 61855451 G A 3.85E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7660536 chr4 61907209 G A 4.51E-04 Coronary heart disease / / 21971053 rs4599440 chr4 61966273 T C 2.00E-06 Biochemical measures / / 19260141 rs10517525 chr4 61981727 G A 1.99E-04 Schizophrenia / / 21674006 rs10517524 chr4 61982096 A G 8.22E-05 Schizophrenia / / 21674006 rs930668 chr4 62004333 A G 9.97E-06 Chronic Hepatitis C infection / / 21725309 rs17219704 chr4 62052456 G A 8.47E-04 Multiple complex diseases / / 17554300 rs6841219 chr4 62061051 T C 1.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2122280 chr4 62063012 T G 1.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2342456 chr4 62124053 C A 3.80E-05 Pericardial fat / / 22589742 rs2880363 chr4 62167906 A G 4.29E-04 Schizophrenia / / 19197363 rs13150558 chr4 62187646 G A 5.46E-04 Myocardial Infarction / / pha002873 rs1456863 chr4 62213988 A G 9.48E-04 Myocardial Infarction / / pha002873 rs4860411 chr4 62229733 G A 4.22E-05 Smoking initiation / / 24665060 rs1456860 chr4 62239946 T G 4.78E-05 Smoking initiation / / 24665060 rs6858223 chr4 62240526 A G 1.39E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs11131325 chr4 62240747 T C 3.66E-05 Smoking initiation / / 24665060 rs10866117 chr4 62242432 G A 6.36E-05 Smoking initiation / / 24665060 rs17219773 chr4 62244228 G T 4.56E-06 Asthma / / 20698975 rs6824906 chr4 62290252 A G 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1456873 chr4 62302163 G A 3.10E-05 Obesity-related traits / / 17903300 rs335336 chr4 62333348 A G 1.42E-05 Smoking behavior / / 19188921 rs10029192 chr4 62380911 G A 5.71E-04 Stroke LPHN3 intron pha002887 rs17090501 chr4 62396048 C A 9.09E-05 Multiple complex diseases LPHN3 intron 17554300 rs17226207 chr4 62399244 C A 2.00E-04 Cognitive impairment induced by topiramate LPHN3 intron 22091778 rs1565901 chr4 62407327 C T 5.00E-05 Partial epilepsies LPHN3 intron 20522523 rs2132074 chr4 62416499 G A 1.28E-05 Partial epilepsies LPHN3 intron 20522523 rs10011995 chr4 62418658 T C 3.69E-04 Type 2 diabetes LPHN3 intron 17463246 rs7693763 chr4 62419004 G A 4.32E-04 Type 2 diabetes LPHN3 intron 17463246 rs11131329 chr4 62431199 G A 0.000706 Salmonella-induced pyroptosis LPHN3 intron 22837397 rs6856328 chr4 62437318 C G 8.00E-07 Response to antipsychotic treatment in schizophrenia (working memory) LPHN3 intron 21107309 rs6841033 chr4 62442507 G A 1.83E-05 Cognitive impairment induced by topiramate LPHN3 intron 22091778 rs10018746 chr4 62445246 T C 4.49E-06 Partial epilepsies LPHN3 intron 20522523 rs2172802 chr4 62453209 A G 3.00E-06 Partial epilepsies LPHN3 intron 20522523 rs9996810 chr4 62468670 T C 1.78E-04 Amyotrophic lateral sclerosis (sporadic) LPHN3 intron 24529757 rs1948616 chr4 62487688 C T 8.62E-05 Partial epilepsies LPHN3 intron 20522523 rs6551640 chr4 62518821 T A 9.59E-06 Alcohol and nictotine co-dependence LPHN3 intron 20158304 rs4860425 chr4 62542957 C A 4.43E-04 Diabetic retinopathy LPHN3 intron 20871662 rs6848408 chr4 62585789 G A 1.35E-04 Suicide attempts in bipolar disorder LPHN3 intron 21423239 rs2345049 chr4 62637158 G A 8.64E-06 Intelligence LPHN3 intron 21826061 rs2345047 chr4 62638468 A G 6.49E-05 Intelligence LPHN3 intron 21826061 rs12509742 chr4 62645032 G A 3.93E-05 Intelligence LPHN3 intron 21826061 rs2345043 chr4 62647908 C T 4.85E-05 Intelligence LPHN3 intron 21826061 rs7667861 chr4 62648534 T G 1.44E-05 Suicide attempts in bipolar disorder LPHN3 intron 21423239 rs11725404 chr4 62649923 C T 2.75E-05 Suicide attempts in bipolar disorder LPHN3 intron 21423239 rs6815347 chr4 62651583 C A 2.92E-05 Suicide attempts in bipolar disorder LPHN3 intron 21423239 rs7694929 chr4 62669915 T C 9.54E-04 Suicide attempts in bipolar disorder LPHN3 intron 21423239 rs7662566 chr4 62672376 T C 1.27E-04 Suicide attempts in bipolar disorder LPHN3 intron 21423239 rs7671478 chr4 62674724 A G 2.48E-04 Suicide attempts in bipolar disorder LPHN3 intron 21423239 rs7683391 chr4 62676117 A G 1.87E-04 Suicide attempts in bipolar disorder LPHN3 intron 21423239 rs7690254 chr4 62678785 C T 7.01E-04 Suicide attempts in bipolar disorder LPHN3 intron 21423239 rs7697485 chr4 62680220 C T 7.92E-04 Suicide attempts in bipolar disorder LPHN3 intron 21423239 rs6840216 chr4 62681720 A T 9.39E-04 Suicide attempts in bipolar disorder LPHN3 intron 21423239 rs11724057 chr4 62686490 G A 6.71E-04 Suicide attempts in bipolar disorder LPHN3 intron 21423239 rs11724143 chr4 62686705 G A 7.93E-04 Suicide attempts in bipolar disorder LPHN3 intron 21423239 rs6551657 chr4 62692132 T G 1.99E-04 Suicide attempts in bipolar disorder LPHN3 intron 21423239 rs6842293 chr4 62693425 T C 9.87E-04 Suicide attempts in bipolar disorder LPHN3 intron 21423239 rs6845019 chr4 62701222 C T 6.21E-04 Multiple complex diseases LPHN3 intron 17554300 rs9683662 chr4 62748384 C T 2.76E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LPHN3 intron 24023788 rs6858066 chr4 62754320 A G 6.30E-04 Smoking initiation LPHN3 intron 24665060 rs12648453 chr4 62788111 T C 4.87E-05 Blood Pressure LPHN3 intron pha003044 rs10517549 chr4 62789268 G T 1.11E-05 Bilirubin levels,in serum LPHN3 intron 19389676 rs2122646 chr4 62796294 A G 5.54E-05 Bilirubin levels,in serum LPHN3 intron 19389676 rs995447 chr4 62818468 T C 1.41E-04 Alzheimer's disease (late onset) LPHN3 intron 21379329 rs995447 chr4 62818468 T C 8.80E-07 Cystic fibrosis-related diabetes LPHN3 intron 23670970 rs989295 chr4 62821189 A T 8.63E-04 Alzheimer's disease LPHN3 intron 24755620 rs1397545 chr4 62835102 G A 5.83E-05 Bilirubin levels,in serum LPHN3 intron 19389676 rs10030755 chr4 62844408 A C 5.75E-04 Type 2 diabetes LPHN3 intron 17463246 rs10030755 chr4 62844408 A C 7.24E-04 Bipolar disorder,schizoaffective LPHN3 intron 19567891 rs9995919 chr4 62874191 G T 7.82E-04 Type 2 diabetes LPHN3 intron 17463246 rs997407 chr4 62878316 A T 8.28E-04 Type 2 diabetes LPHN3 intron 17463246 rs10017806 chr4 62878870 C G 5.70E-04 Multiple complex diseases LPHN3 intron 17554300 rs10032372 chr4 62944634 T G 1.95E-04 Smoking initiation LOC100652734 intron 24665060 rs10014304 chr4 63000920 G A 7.31E-05 Post-operative nausea and vomiting LOC100652734 intron 21694509 rs9995712 chr4 63062142 C G 4.63E-04 Smoking initiation / / 24665060 rs1563797 chr4 63116209 C T 5.13E-05 Bipolar disorder / / 21771265 rs7671984 chr4 63243647 G C 5.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11131367 chr4 63250043 C T 6.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs778959 chr4 63255019 C A 7.94E-05 Brain lesion load / / 19010793 rs778959 chr4 63255019 C A 3.87E-04 Smoking initiation / / 24665060 rs10517820 chr4 63280732 A G 8.80E-05 Ankylosing spondylitis / / 20062062 rs6819266 chr4 63342270 G C 8.00E-06 Age-related macular degeneration / / 23326517 rs17082777 chr4 63361327 G A 2.20E-05 Urinary metabolites / / 21572414 rs13126803 chr4 63378266 T G 1.20E-04 stroke (ischemic) / / 17434096 rs6817682 chr4 63391971 T C 8.67E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs969607 chr4 63403138 G A 7.72E-04 Tourette syndrome / / 22889924 rs7699771 chr4 63407474 A C 7.50E-04 Tourette syndrome / / 22889924 rs2168267 chr4 63407579 C T 5.48E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs1551457 chr4 63409756 A G 8.51E-04 Tourette syndrome / / 22889924 rs10517829 chr4 63410009 T G 4.44E-05 Calcium levels / / pha003085 rs7697561 chr4 63413405 T G 6.84E-04 Tourette syndrome / / 22889924 rs11944965 chr4 63424089 C T 2.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs6551714 chr4 63558975 G A 1.48E-04 Glycosylated haemoglobin levels / / 17255346 rs11131405 chr4 63659478 C T 7.37E-04 Alzheimer's disease / / 17998437 rs11131406 chr4 63659659 C T 4.97E-04 Alzheimer's disease / / 17998437 rs12641913 chr4 63694936 C T 9.70E-04 Heart Failure / / pha002885 rs2660598 chr4 63842062 G A 2.31E-04 Alcohol dependence / / 24277619 rs10517836 chr4 63858885 G A 9.60E-05 Iron levels / / 21208937 rs4568267 chr4 63882860 G T 1.58E-04 Alzheimer's disease (late onset) / / 21379329 rs145379083 chr4 63893278 G A 3.00E-06 Bulimia nervosa / / 23568457 rs2346649 chr4 63901724 G A 6.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9312103 chr4 63902089 T C 4.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2346595 chr4 63933658 G A 4.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17669484 chr4 64010031 T G 5.48E-04 Coronary Artery Disease / / 17634449 rs1462605 chr4 64154567 G A 8.50E-04 Multiple complex diseases / / 17554300 rs1462601 chr4 64158622 G A 1.63E-08 Narcolepsy / / 19629137 rs1350958 chr4 64188609 A C 7.17E-04 Acute lung injury / / 22295056 rs10021746 chr4 64190359 G T 8.88E-04 Acute lung injury / / 22295056 rs12510627 chr4 64214506 C T 7.28E-04 Acute lung injury / / 22295056 rs17083650 chr4 64215766 C T 9.93E-06 Obesity-related traits / / 23251661 rs517795 chr4 64227402 A T 9.11E-05 Multiple complex diseases / / 17554300 rs10009946 chr4 64229294 T C 8.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13105340 chr4 64295154 C T 8.32E-04 Multiple complex diseases / / 17554300 rs2347408 chr4 64305860 T A 2.40E-06 Urinary metabolites / / 21572414 rs17679738 chr4 64318770 A T 2.00E-06 Urinary metabolites / / 21572414 rs972651 chr4 64329169 C A 5.49E-05 Coronary heart disease / / pha003035 rs2090189 chr4 64337600 C T 7.97E-05 Neutrophil count / / pha003095 rs13118127 chr4 64390049 C A 2.15E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1456822 chr4 64462524 C G 1.60E-05 Urinary metabolites / / 21572414 rs1947549 chr4 64481847 A G 1.57E-04 Arthritis (juvenile idiopathic) / / 22354554 rs7692181 chr4 64500994 C T 7.63E-05 Nicotine smoking / / 19268276 rs2347824 chr4 64663792 G A 1.32E-05 Height / / pha003010 rs2347824 chr4 64663792 G A 9.20E-06 Height / / pha003011 rs2347824 chr4 64663792 G A 4.32E-05 Weight / / pha003027 rs1344164 chr4 64699179 T C 4.75E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4560443 chr4 64716361 C T 9.58E-06 Height / / pha003010 rs4560443 chr4 64716361 C T 8.53E-06 Height / / pha003011 rs4560443 chr4 64716361 C T 7.17E-05 Weight / / pha003027 rs17688509 chr4 64732043 A G 8.70E-06 Height / / pha003010 rs17688509 chr4 64732043 A G 1.45E-05 Height / / pha003011 rs17688509 chr4 64732043 A G 6.32E-05 Body Fat Distribution / / pha003017 rs17688509 chr4 64732043 A G 8.55E-05 Body Fat Distribution / / pha003018 rs17688509 chr4 64732043 A G 5.75E-05 Weight / / pha003026 rs17688509 chr4 64732043 A G 4.96E-05 Weight / / pha003027 rs1316996 chr4 64747737 G A 9.78E-05 Height / / pha003010 rs1449187 chr4 64933680 C A 4.90E-05 Height / / pha003010 rs1449187 chr4 64933680 C A 6.05E-05 Height / / pha003011 rs10028878 chr4 64934748 C A 4.90E-05 Height / / pha003010 rs10028878 chr4 64934748 C A 6.05E-05 Height / / pha003011 rs1402142 chr4 64970948 C A 8.00E-05 Endometriosis / / 21151130 rs9996291 chr4 64974240 C G 2.08E-04 Smoking initiation / / 24665060 rs1879323 chr4 64990744 G T 4.32E-04 Stroke / / pha002886 rs1464336 chr4 64996680 T A 5.30E-06 Multiple complex diseases / / 17554300 rs4860568 chr4 65008382 G A 2.03E-12 Gender / / 22362730 rs146534688 chr4 65021016 G GTA,GTACACACA 7.53E-12 Metabolite levels / / 22286219 rs72633879 chr4 65021016 G A 7.53E-12 Metabolite levels / / 22286219 rs1483716 chr4 65097893 C T 6.70E-04 Heart Failure / / pha002885 rs12508439 chr4 65108608 C T 3.92E-04 Alzheimer's disease / / 17998437 rs6816298 chr4 65144051 A G 6.97E-05 Kawasaki disease / / 22446961 rs9999095 chr4 65147708 A T 1.00E-06 Parkinson's disease (interaction with coffee consumption) TECRL intron 21876681 rs1384857 chr4 65155879 T C 1.60E-05 Post-operative nausea and vomiting TECRL intron 21694509 rs10517884 chr4 65158091 A G 4.52E-05 Post-operative nausea and vomiting TECRL intron 21694509 rs7656244 chr4 65170415 C A 3.00E-07 Kawasaki disease TECRL intron 22446961 rs1965938 chr4 65180230 T C 5.76E-05 Kawasaki disease TECRL intron 22446961 rs1483293 chr4 65235696 A G 1.48E-04 Nonalcoholic fatty liver disease TECRL intron 21423719 rs4860601 chr4 65272890 G C 4.35E-05 Schizophrenia TECRL intron 20185149 rs6836944 chr4 65273840 C T 3.00E-06 Axial length TECRL intron 24144296 rs1384720 chr4 65275649 C A 1.80E-04 Atrial fibrillation / / 21846873 rs6828446 chr4 65304222 A G 2.36E-04 Multiple complex diseases / / 17554300 rs2086735 chr4 65324353 A C 3.57E-05 Post-operative nausea and vomiting / / 21694509 rs2714934 chr4 65333802 C T 8.41E-04 Type 2 diabetes / / 17463246 rs9312130 chr4 65347726 G A 8.38E-04 Type 2 diabetes / / 17463246 rs2348741 chr4 65352665 T C 9.71E-04 Type 2 diabetes / / 17463246 rs17084975 chr4 65362334 T G 1.56E-04 Type 2 diabetes / / 17463246 rs1425392 chr4 65392212 T C 7.00E-06 Post-traumatic stress disorder (asjusted for relatedness) / / 23726511 rs11735072 chr4 65392633 A C 3.33E-04 Schizophrenia / / 19197363 rs4282220 chr4 65395458 C T 2.90E-04 Type 2 diabetes / / 17463246 rs4434285 chr4 65411094 T A 4.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs7696109 chr4 65434916 G A 5.66E-04 Type 2 diabetes / / 17463246 rs7696109 chr4 65434916 G A 7.67E-04 Multiple complex diseases / / 17554300 rs1425381 chr4 65435505 T A 4.38E-04 Type 2 diabetes / / 17463246 rs1425377 chr4 65436643 A G 5.61E-04 Type 2 diabetes / / 17463246 rs6816036 chr4 65444808 A G 2.18E-04 Multiple complex diseases / / 17554300 rs10008727 chr4 65451712 A G 1.21E-04 Type 2 diabetes / / 17463246 rs10023799 chr4 65458162 G A 7.38E-05 Type 2 diabetes / / 17463246 rs41523544 chr4 65474399 G C 7.20E-05 Type 2 diabetes / / 17463246 rs11723142 chr4 65511843 A G 3.60E-06 Thyroid function / / 20826269 rs200694364 chr4 65511843 A ATG 3.60E-06 Thyroid function / / 20826269 rs11731709 chr4 65654988 A G 3.30E-04 Substance dependence / / 21818250 rs10005234 chr4 65680034 T A 3.82E-06 Asthma (childhood onset) / / 23829686 rs986971 chr4 65716998 G A 1.32E-05 Cholesterol / / pha003083 rs34801717 chr4 65719671 G C 6.09E-04 Multiple complex diseases / / 17554300 rs17085449 chr4 65736609 G A 5.18E-04 Multiple complex diseases / / 17554300 rs17085470 chr4 65744393 A T 1.24E-04 Multiple complex diseases / / 17554300 rs17739717 chr4 65894569 G A 2.38E-05 Multiple complex diseases / / 17554300 rs1440931 chr4 65902264 C A 3.01E-04 Type 2 diabetes / / 17463246 rs1440931 chr4 65902264 C A 8.90E-05 Cognitive function / / 24684796 rs1440929 chr4 65902357 T C 2.81E-04 Type 2 diabetes / / 17463246 rs28370945 chr4 65911098 A T 4.31E-04 Type 2 diabetes / / 17463246 rs441785 chr4 66018891 G T 2.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1551125 chr4 66143112 T G 4.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12501311 chr4 66160175 G A 2.93E-04 Insulin resistance / / 21901158 rs13150204 chr4 66169272 G A 4.20E-05 Insulin resistance / / 21901158 rs3749526 chr4 66185198 T A 3.56E-04 Alzheimer's disease / / 17998437 rs4860650 chr4 66187627 G A 6.69E-04 Smoking cessation EPHA5 UTR-3 24665060 rs7349683 chr4 66197804 C T 1.44E-09 Paclitaxel-induced neuropathy EPHA5 cds-synon 23776197 rs17086144 chr4 66242049 T A 1.80E-05 Intelligence (childhood) EPHA5 intron 23358156 rs745237 chr4 66263011 T A 9.90E-05 Alzheimer's disease EPHA5 intron 22832961 rs17086181 chr4 66267300 C T 5.56E-04 Multiple complex diseases EPHA5 intron 17554300 rs12509018 chr4 66278087 G A 9.79E-04 Multiple complex diseases EPHA5 intron 17554300 rs4371663 chr4 66290312 T C 8.99E-04 Type 2 diabetes EPHA5 intron 17463246 rs10006892 chr4 66308481 G A 2.40E-05 Urinary metabolites EPHA5 intron 21572414 rs4337775 chr4 66359577 A G 9.67E-05 Non-alcoholic fatty liver disease histology (other) EPHA5 intron 20708005 rs6815080 chr4 66362487 C T 9.60E-05 Non-alcoholic fatty liver disease histology (other) EPHA5 intron 20708005 rs6815080 chr4 66362487 C T 1.60E-04 Arthritis (juvenile idiopathic) EPHA5 intron 22354554 rs4365778 chr4 66364587 T C 6.95E-04 Multiple complex diseases EPHA5 intron 17554300 rs4860679 chr4 66401110 C T 2.04E-04 Type 2 diabetes EPHA5 intron 17463246 rs12644315 chr4 66420825 C G 1.08E-04 Type 2 diabetes EPHA5 intron 17463246 rs13127631 chr4 66443874 G T 5.81E-05 Scoliosis EPHA5 intron 21216876 rs6855605 chr4 66456092 C A 9.50E-06 HIV-1 viral setpoint EPHA5 intron 22174851 rs4404602 chr4 66470813 T C 1.00E-06 HIV-1 viral setpoint EPHA5 intron 22174851 rs7697951 chr4 66487141 T C 3.22E-05 Post-operative nausea and vomiting EPHA5 intron 21694509 rs4422467 chr4 66494645 A G 7.32E-05 HIV-1 viral setpoint EPHA5 intron 22174851 rs7659227 chr4 66496170 A G 8.89E-07 Asthma EPHA5 intron 21804549 rs11735820 chr4 66499016 T G 2.27E-07 Asthma EPHA5 intron 21804549 rs4438803 chr4 66507443 T G 9.74E-05 Serum metabolites EPHA5 intron 19043545 rs4611973 chr4 66516396 A G 3.94E-05 HIV-1 viral setpoint EPHA5 intron 22174851 rs4441811 chr4 66521489 C T 3.02E-05 HIV-1 viral setpoint EPHA5 intron 22174851 rs13102535 chr4 66567198 A T 6.94E-04 Coronary Artery Disease / / 17634449 rs4629506 chr4 66583906 T C 4.28E-05 Alcohol and nictotine co-dependence / / 20158304 rs4629506 chr4 66583906 T C 2.24E-05 Coronary heart disease / / pha003035 rs12501488 chr4 66586701 G A 2.80E-05 Cognitive test performance / / 20125193 rs4373205 chr4 66628728 T C 5.60E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs28584438 chr4 66651391 A G 5.70E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs4146479 chr4 66664021 G A 9.15E-05 Multiple complex diseases / / 17554300 rs2350045 chr4 66678437 C A 8.81E-04 Multiple complex diseases / / 17554300 rs13119904 chr4 66682320 A G 7.59E-05 Psoriasis / / 20953190 rs10517943 chr4 66710236 G A 4.21E-04 Multiple complex diseases / / 17554300 rs4146477 chr4 66716433 A T 3.64E-04 Multiple complex diseases / / 17554300 rs2350070 chr4 66716472 G A 5.90E-04 Multiple complex diseases / / 17554300 rs4146476 chr4 66716573 A C 3.39E-04 Multiple complex diseases / / 17554300 rs4434311 chr4 66719318 A G 3.07E-04 Multiple complex diseases / / 17554300 rs6855944 chr4 66719731 C G 3.13E-04 Multiple complex diseases / / 17554300 rs2882385 chr4 66732426 C A 6.70E-05 White matter hyperintensity burden / / 21681796 rs13136864 chr4 66745866 C T 8.25E-04 Multiple complex diseases / / 17554300 rs13136864 chr4 66745866 C T 3.40E-05 White matter hyperintensity burden / / 21681796 rs7683949 chr4 66746021 A C 5.62E-04 Multiple complex diseases / / 17554300 rs7683949 chr4 66746021 A C 3.40E-05 White matter hyperintensity burden / / 21681796 rs6551966 chr4 66750302 C G 3.40E-05 White matter hyperintensity burden / / 21681796 rs6551968 chr4 66750577 G A 6.60E-05 White matter hyperintensity burden / / 21681796 rs7697829 chr4 66750641 G T 2.80E-05 White matter hyperintensity burden / / 21681796 rs12054623 chr4 66752253 G C 7.50E-05 White matter hyperintensity burden / / 21681796 rs6551971 chr4 66754341 A C 4.50E-05 White matter hyperintensity burden / / 21681796 rs11731436 chr4 66755260 C G 3.30E-06 White matter hyperintensity burden / / 21681796 rs13120542 chr4 66756347 C T 7.10E-05 White matter hyperintensity burden / / 21681796 rs13120978 chr4 66756582 C T 6.80E-05 White matter hyperintensity burden / / 21681796 rs1433636 chr4 66757241 T A 6.60E-05 White matter hyperintensity burden / / 21681796 rs1433635 chr4 66757277 C T 6.33E-04 Multiple complex diseases / / 17554300 rs1433635 chr4 66757277 C T 2.90E-05 White matter hyperintensity burden / / 21681796 rs1433634 chr4 66757466 G A 6.51E-04 Multiple complex diseases / / 17554300 rs1433634 chr4 66757466 G A 2.80E-05 White matter hyperintensity burden / / 21681796 rs7669544 chr4 66758121 C G 7.03E-04 Multiple complex diseases / / 17554300 rs7669544 chr4 66758121 C G 2.80E-05 White matter hyperintensity burden / / 21681796 rs7669869 chr4 66758266 C T 2.20E-05 White matter hyperintensity burden / / 21681796 rs11733158 chr4 66758556 A C 8.87E-04 Multiple complex diseases / / 17554300 rs11733158 chr4 66758556 A C 2.90E-05 White matter hyperintensity burden / / 21681796 rs11730974 chr4 66759870 C T 5.03E-04 Multiple complex diseases / / 17554300 rs6816565 chr4 66769502 G C 7.40E-05 White matter hyperintensity burden / / 21681796 rs1368709 chr4 66771112 C G 2.80E-05 White matter hyperintensity burden / / 21681796 rs1433641 chr4 66773038 C T 7.26E-04 Multiple complex diseases / / 17554300 rs1433641 chr4 66773038 C T 3.10E-05 White matter hyperintensity burden / / 21681796 rs1433639 chr4 66773633 C T 8.50E-05 White matter hyperintensity burden / / 21681796 rs4463116 chr4 66774210 C T 9.00E-05 White matter hyperintensity burden / / 21681796 rs7660970 chr4 66777240 T G 0.0000621 Tuberculosis with late age of onset / / 22551897 rs7679437 chr4 66777683 C T 4.63E-04 Alzheimer's disease (late onset) / / 21379329 rs7679437 chr4 66777683 C T 1.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6817536 chr4 66784345 T C 6.39E-05 Alzheimer's disease (late onset) / / 21379329 rs6817536 chr4 66784345 T C 4.30E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17086628 chr4 66791167 A G 8.60E-04 Multiple complex diseases / / 17554300 rs10028068 chr4 66797122 C G 7.80E-05 White matter hyperintensity burden / / 21681796 rs4558912 chr4 66839259 G A 9.75E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11724351 chr4 66891923 C A 7.45E-04 Alzheimer's disease / / 22005930 rs11724351 chr4 66891923 C A 0.0008671 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11724351 chr4 66891923 C A 8.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13102215 chr4 66899906 G A 9.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13149202 chr4 66984331 G A 6.28E-04 Alzheimer's disease / / 22005930 rs13109777 chr4 66987643 A G 4.85E-05 Fibrinogen / / pha003068 rs2611074 chr4 66994621 C T 2.77E-05 Monocyte chemoattractant protein-1 / / pha003071 rs2588740 chr4 67000449 A G 2.61E-05 Monocyte chemoattractant protein-1 / / pha003071 rs2588742 chr4 67000713 C T 8.27E-04 Alzheimer's disease / / 17998437 rs2614870 chr4 67003241 C T 6.24E-04 Alzheimer's disease / / 17998437 rs980449 chr4 67004839 G A 6.49E-04 Alzheimer's disease / / 17998437 rs2350719 chr4 67029494 C A 2.43E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2588666 chr4 67036815 T C 8.59E-05 Weight / / pha003027 rs400524 chr4 67118667 A G 5.24E-04 Stroke / / pha002886 rs450788 chr4 67124222 T C 7.39E-05 HIV-1 viral setpoint / / 22174851 rs434623 chr4 67126645 G A 1.79E-04 Gallbladder cancer / / 22318345 rs434623 chr4 67126645 G A 7.45E-04 Stroke / / pha002886 rs111707099 chr4 67137776 C A 1.67E-11 Metabolite levels / / 22286219 rs13107026 chr4 67139034 T A 9.28E-04 Alzheimer's disease / / 22005930 rs17086964 chr4 67139219 A C 9.80E-04 Alzheimer's disease / / 22005930 rs1397755 chr4 67140834 G A 9.40E-04 Alzheimer's disease / / 22005930 rs1397755 chr4 67140834 G A 4.18E-04 Gallbladder cancer / / 22318345 rs1397753 chr4 67141015 G C 9.40E-04 Alzheimer's disease / / 22005930 rs17082198 chr4 67141454 A G 9.44E-04 Alzheimer's disease / / 22005930 rs17082199 chr4 67141606 G A 9.46E-04 Alzheimer's disease / / 22005930 rs977773 chr4 67141789 G A 9.98E-04 Alzheimer's disease / / 22005930 rs7437072 chr4 67142262 G T 9.53E-04 Alzheimer's disease / / 22005930 rs12645235 chr4 67160054 G A 4.59E-04 Gallbladder cancer / / 22318345 rs13151560 chr4 67160442 C T 9.84E-04 Alzheimer's disease / / 22005930 rs12642661 chr4 67169493 C T 4.45E-04 Gallbladder cancer / / 22318345 rs1511280 chr4 67175819 C G 9.45E-04 Alzheimer's disease / / 22005930 rs6833057 chr4 67178553 C G 9.33E-04 Alzheimer's disease / / 22005930 rs17086994 chr4 67183912 G A 5.60E-04 Alzheimer's disease / / 22005930 rs6820508 chr4 67186241 T C 7.12E-04 Alzheimer's disease / / 22005930 rs6820508 chr4 67186241 T C 4.14E-04 Gallbladder cancer / / 22318345 rs17087006 chr4 67188285 G T 9.64E-04 Alzheimer's disease / / 22005930 rs17087008 chr4 67188696 G A 4.04E-04 Gallbladder cancer / / 22318345 rs12331987 chr4 67188980 C T 6.43E-04 Alzheimer's disease / / 22005930 rs12642012 chr4 67228874 T C 9.08E-04 Gallbladder cancer / / 22318345 rs2009314 chr4 67300802 A G 2.03E-04 IgE levels / / 17255346 rs2009314 chr4 67300802 A G 5.00E-06 Obesity-related traits / / 23251661 rs1949200 chr4 67301042 A T 3.90E-04 Multiple complex diseases / / 17554300 rs1949200 chr4 67301042 A T 9.00E-06 Sleep quality / / 23728906 rs9647493 chr4 67315873 G C 2.98E-04 Multiple complex diseases / / 17554300 rs1512949 chr4 67317062 C T 2.36E-04 Multiple complex diseases / / 17554300 rs971712 chr4 67349863 G A 4.84E-05 Platelet counts / / pha003100 rs17730929 chr4 67357454 A C 3.00E-06 Colorectal cancer / / 23300701 rs11131640 chr4 67363220 T C 6.01E-05 Multiple complex diseases / / 17554300 rs1510740 chr4 67401602 A G 9.40E-05 Cognitive impairment induced by topiramate / / 22091778 rs1510743 chr4 67436220 T C 2.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17087338 chr4 67451328 T G 9.44E-04 Multiple complex diseases / / 17554300 rs4032303 chr4 67463707 C T 4.22E-05 HDL cholesterol / / pha003075 rs1510746 chr4 67469201 G C 6.26E-04 Multiple complex diseases / / 17554300 rs4860765 chr4 67471664 C T 2.70E-06 Urinary metabolites / / 21572414 rs10517988 chr4 67502084 C T 4.62E-04 Bipolar disorder / / 19259986 rs11947910 chr4 67607309 C T 4.51E-04 Multiple complex diseases / / 17554300 rs1584568 chr4 67610038 T G 8.01E-04 Multiple complex diseases / / 17554300 rs4860223 chr4 67614569 T C 1.11E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7662337 chr4 67615172 T C 2.16E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10452261 chr4 67616512 C T 4.51E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10452262 chr4 67616894 C G 5.51E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6552030 chr4 67618573 G A 3.92E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2197965 chr4 67620503 A C 4.22E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9996690 chr4 67624510 T C 1.90E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17791332 chr4 67628916 A T 7.31E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10866174 chr4 67632934 G A 3.89E-04 White matter integrity / / 22425255 rs6816793 chr4 67642191 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6552035 chr4 67643879 G T 0.0000853 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs11131652 chr4 67645785 A G 6.66E-04 Multiple complex diseases / / 17554300 rs1450036 chr4 67657239 C T 8.56E-05 Type 2 diabetes / / 17463246 rs1450036 chr4 67657239 C T 9.26E-05 Serum metabolites / / 19043545 rs7667353 chr4 67657560 A C 1.98E-04 Type 2 diabetes / / 17463246 rs1155865 chr4 67733857 G A 2.00E-06 Cognitive test performance / / 17903297 rs7659876 chr4 67754775 G C 2.07E-04 Multiple complex diseases / / 17554300 rs11131659 chr4 67762845 T C 1.27E-04 Multiple complex diseases / / 17554300 rs1495114 chr4 67780535 G A 5.48E-04 Multiple complex diseases / / 17554300 rs10428499 chr4 67804989 A T 8.36E-04 Type 2 diabetes / / 17463246 rs2164300 chr4 67813017 C T 2.70E-05 Urinary metabolites / / 21572414 rs6552052 chr4 67846491 A G 1.24E-04 Type 2 diabetes / / 17463246 rs17746199 chr4 67879573 C T 2.97E-04 Multiple complex diseases / / 17554300 rs1988507 chr4 67880838 C T 4.43E-06 Glycemic traits (pregnancy) / / 23903356 rs1435426 chr4 67889431 C T 9.40E-06 Glycemic traits (pregnancy) / / 23903356 rs7682598 chr4 68000888 A G 8.23E-04 Heart Failure / / pha002885 rs10518020 chr4 68007388 G A 7.58E-04 HIV-1 viral setpoint / / 17641165 rs10518025 chr4 68064440 T C 4.00E-06 Multiple sclerosis (severity) / / 19010793 rs7699230 chr4 68078033 G A 2.14E-04 Multiple complex diseases / / 17554300 rs4280783 chr4 68089365 C T 1.00E-04 Schizophrenia / / 19197363 rs4639131 chr4 68095870 T C 8.18E-04 Schizophrenia / / 19197363 rs10518027 chr4 68109829 G A 9.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1440561 chr4 68181030 C A 7.22E-04 Multiple complex diseases / / 17554300 rs1371863 chr4 68192816 G A 5.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs2165328 chr4 68195138 A T 7.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs746876 chr4 68198590 C T 6.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs1440564 chr4 68200441 C A 8.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs356310 chr4 68222094 C T 0.000886467 Hypertension (early onset hypertension) / / 22479346 rs10518036 chr4 68222294 A G 6.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10008670 chr4 68237962 C T 6.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6419917 chr4 68241545 T A 1.34E-05 Relative hand skill / / 24068947 rs7669658 chr4 68250856 C T 2.48E-04 Heart Failure / / pha002884 rs6552093 chr4 68285222 A C 2.34E-04 Parkinson's disease / / 17052657 rs7672620 chr4 68296891 C T 5.37E-04 Type 2 diabetes / / 17463246 rs7696553 chr4 68296976 A C 6.91E-04 Type 2 diabetes / / 17463246 rs7678921 chr4 68297763 C T 4.38E-04 Type 2 diabetes / / 17463246 rs6810410 chr4 68309566 T C 3.57E-04 Alcohol dependence / / 20201924 rs7681618 chr4 68314440 A G 1.95E-05 Parkinson's disease / / 17052657 rs7681618 chr4 68314440 A G 2.77E-04 Alcohol dependence / / 20201924 rs11946612 chr4 68335971 T C 1.80E-05 Parkinson's disease / / 17052657 rs11946612 chr4 68335971 T C 7.07E-04 Alcohol dependence / / 20201924 rs9312181 chr4 68336579 A T 1.46E-05 Parkinson's disease / / 17052657 rs1874633 chr4 68337435 A G 3.03E-04 Alcohol dependence / / 20201924 rs1497430 chr4 68357814 A G 1.80E-05 Parkinson's disease CENPC1 intron 17052657 rs768244 chr4 68361240 C T 7.40E-39 Narcolepsy CENPC1 intron 19629137 rs190255 chr4 68376708 T C 1.57E-05 Parkinson's disease CENPC1 intron 17052657 rs355464 chr4 68379124 T C 1.70E-05 Parkinson's disease CENPC1 intron 17052657 rs11250 chr4 68380215 G A 6.78E-05 Parkinson's disease CENPC1 missense 17052657 rs355461 chr4 68380724 C A 1.60E-05 Parkinson's disease CENPC1 intron 17052657 rs17625154 chr4 68384274 T C 7.61E-05 Cholesterol CENPC1 intron pha003073 rs17625154 chr4 68384274 T C 2.90E-05 Cholesterol CENPC1 intron pha003078 rs13104130 chr4 68385372 T C 6.44E-05 Cholesterol CENPC1 intron pha003073 rs13104130 chr4 68385372 T C 2.39E-05 Cholesterol CENPC1 intron pha003078 rs355506 chr4 68386082 T C 1.60E-05 Parkinson's disease CENPC1 intron 17052657 rs355499 chr4 68389841 C T 9.24E-05 Relative hand skill CENPC1 intron 24068947 rs355477 chr4 68396525 G C 1.50E-05 Parkinson's disease CENPC1 intron 17052657 rs2646269 chr4 68403760 T G 2.79E-04 Multiple complex diseases CENPC1 intron 17554300 rs13135430 chr4 68410613 T A,C,G 8.90E-05 Parkinson's disease CENPC1 intron 17052657 rs957582 chr4 68412148 A C 5.66E-04 Parkinson's disease / / 17052657 rs7660528 chr4 68415379 G A 9.67E-06 Relative hand skill / / 24068947 rs7700004 chr4 68419485 C T 9.64E-06 Relative hand skill / / 24068947 rs7672027 chr4 68422438 G A 9.70E-06 Relative hand skill / / 24068947 rs10013617 chr4 68425824 A G 1.20E-05 Relative hand skill STAP1 intron 24068947 rs2046599 chr4 68430123 C T 1.67E-05 Relative hand skill STAP1 intron 24068947 rs6826751 chr4 68433855 C T 2.00E-06 Parkinson's disease STAP1 intron 17052657 rs1487383 chr4 68437251 C T 3.27E-05 Parkinson's disease STAP1 intron 17052657 rs11731488 chr4 68437853 A G 6.71E-04 Obesity (extreme) STAP1 intron 21935397 rs17088473 chr4 68443308 T G 7.38E-04 Amyotrophic Lateral Sclerosis STAP1 intron 17362836 rs17088473 chr4 68443308 T G 0.000349971 Hypertension (early onset hypertension) STAP1 intron 22479346 rs3775866 chr4 68444180 G A 7.80E-06 Parkinson's disease STAP1 intron 17052657 rs3775866 chr4 68444180 G A 0.000306704 Hypertension (early onset hypertension) STAP1 intron 22479346 rs11725922 chr4 68444192 G A 5.94E-04 Obesity (extreme) STAP1 intron 21935397 rs17631747 chr4 68446312 C T 5.88E-04 Obesity (extreme) STAP1 intron 21935397 rs3775870 chr4 68446421 T C 2.50E-05 Urinary metabolites STAP1 intron 21572414 rs11556615 chr4 68447040 C T 5.81E-04 Obesity (extreme) STAP1 missense 21935397 rs2242330 chr4 68447249 A G 2.00E-06 Parkinson's disease STAP1 intron 17052657 rs931360 chr4 68452873 G C 5.65E-04 Obesity (extreme) STAP1 intron 21935397 rs354872 chr4 68515155 T C 5.27E-05 stroke (ischemic) UBA6 intron 17434096 rs13151552 chr4 68531603 A C 4.81E-05 Smoking cessation UBA6 intron 18519826 rs13151552 chr4 68531603 A C 3.63E-05 Tuberculosis UBA6 intron 24057671 rs10010188 chr4 68534392 C T 4.92E-06 Lymphocyte counts UBA6 missense 22286170 rs2170872 chr4 68536966 C T 1.20E-05 Blood Pressure UBA6 intron pha003043 rs2170872 chr4 68536966 C T 7.84E-06 Lung function (forced expiratory volume in 1 second) UBA6 intron pha003102 rs2262366 chr4 68571065 A G 2.19E-06 Lung function (forced expiratory volume in 1 second) LOC550112 intron pha003102 rs2262366 chr4 68571065 A G 7.28E-05 Lung function (forced vital capacity) LOC550112 intron pha003104 rs7671397 chr4 68590823 A T 8.67E-05 Smoking cessation / / 18519826 rs1843593 chr4 68598998 T C 5.30E-05 Pulmonary function in asthmatics / / 23541324 rs17635850 chr4 68605369 A G 9.57E-04 Type 2 diabetes GNRHR UTR-3 17463246 rs3796720 chr4 68614947 G A 8.09E-06 Lung function (forced expiratory volume in 1 second) GNRHR intron pha003102 rs972072 chr4 68617365 T G 2.25E-05 Blood Pressure GNRHR intron pha003043 rs2627249 chr4 68647356 A G 8.19E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs2099778 chr4 68675624 G C 0.0003303 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2099778 chr4 68675624 G C 3.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2083531 chr4 68675665 A G 0.000331 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2083531 chr4 68675665 A G 3.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6552120 chr4 68678613 G C 0.0003323 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6552120 chr4 68678613 G C 3.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10428421 chr4 68683898 G T 0.000628 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10428421 chr4 68683898 G T 6.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6820455 chr4 68684113 T C 0.0006299 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6820455 chr4 68684113 T C 6.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6552123 chr4 68686507 A G 0.0006285 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6552123 chr4 68686507 A G 6.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10780054 chr4 68686957 G C 0.0006645 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMPRSS11D UTR-3 23233654 rs10780054 chr4 68686957 G C 6.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMPRSS11D UTR-3 23233662 rs10518044 chr4 68688452 C T 0.0006174 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMPRSS11D intron 23233654 rs10518044 chr4 68688452 C T 6.17E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMPRSS11D intron 23233662 rs1972895 chr4 68689874 G T 0.0006167 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMPRSS11D intron 23233654 rs1972895 chr4 68689874 G T 6.17E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMPRSS11D intron 23233662 rs1371930 chr4 68690418 C T 0.0006176 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMPRSS11D intron 23233654 rs1371930 chr4 68690418 C T 6.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMPRSS11D intron 23233662 rs12646905 chr4 68693630 A G 0.0006116 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMPRSS11D intron 23233654 rs12646905 chr4 68693630 A G 6.12E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMPRSS11D intron 23233662 rs1994336 chr4 68694002 G A 0.0006124 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMPRSS11D intron 23233654 rs1994336 chr4 68694002 G A 6.12E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMPRSS11D intron 23233662 rs2874031 chr4 68694228 G C 0.0005986 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMPRSS11D intron 23233654 rs2874031 chr4 68694228 G C 5.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMPRSS11D intron 23233662 rs7654002 chr4 68694773 T G 0.0006133 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMPRSS11D intron 23233654 rs7654002 chr4 68694773 T G 6.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMPRSS11D intron 23233662 rs2165362 chr4 68732186 C T 3.85E-04 Multiple complex diseases TMPRSS11D intron 17554300 rs17578509 chr4 68795815 A G 6.26E-04 Multiple complex diseases TMPRSS11A intron 17554300 rs6552131 chr4 68811165 C G 3.80E-04 Type 2 diabetes TMPRSS11A intron 17463246 rs6829501 chr4 68811476 C T 5.14E-04 Type 2 diabetes TMPRSS11A intron 17463246 rs11947613 chr4 68829223 G A 5.00E-04 Smoking initiation TMPRSS11A UTR-5 24665060 rs7692218 chr4 69129457 A G 1.03E-05 Intracerebral hemorrhage / / 24656865 rs7692218 chr4 69129457 A G 1.71E-05 Intracerebral hemorrhage / / 24656865 rs77820753 chr4 69134905 G A 1.16E-05 Intracerebral hemorrhage / / 24656865 rs77820753 chr4 69134905 G A 1.85E-05 Intracerebral hemorrhage / / 24656865 rs7660618 chr4 69135223 C T 1.16E-05 Intracerebral hemorrhage / / 24656865 rs7660618 chr4 69135223 C T 1.86E-05 Intracerebral hemorrhage / / 24656865 rs7661368 chr4 69135567 C G 1.24E-05 Intracerebral hemorrhage / / 24656865 rs7661368 chr4 69135567 C G 2.13E-05 Intracerebral hemorrhage / / 24656865 rs7665069 chr4 69135773 G A 1.14E-05 Intracerebral hemorrhage / / 24656865 rs7665069 chr4 69135773 G A 1.87E-05 Intracerebral hemorrhage / / 24656865 rs10008755 chr4 69136133 G A 1.90E-05 Intracerebral hemorrhage / / 24656865 rs10008755 chr4 69136133 G A 3.97E-05 Intracerebral hemorrhage / / 24656865 rs10008769 chr4 69136174 G A 1.01E-05 Intracerebral hemorrhage / / 24656865 rs10008769 chr4 69136174 G A 1.84E-05 Intracerebral hemorrhage / / 24656865 rs10009194 chr4 69136630 G C 1.05E-05 Intracerebral hemorrhage / / 24656865 rs10009194 chr4 69136630 G C 1.86E-05 Intracerebral hemorrhage / / 24656865 rs10032194 chr4 69136631 C T 1.05E-05 Intracerebral hemorrhage / / 24656865 rs10032194 chr4 69136631 C T 1.86E-05 Intracerebral hemorrhage / / 24656865 rs28812606 chr4 69136747 G A 1.02E-05 Intracerebral hemorrhage / / 24656865 rs28812606 chr4 69136747 G A 1.87E-05 Intracerebral hemorrhage / / 24656865 rs77738469 chr4 69136926 A G 1.10E-05 Intracerebral hemorrhage / / 24656865 rs77738469 chr4 69136926 A G 1.90E-05 Intracerebral hemorrhage / / 24656865 rs28451838 chr4 69137007 T A 1.02E-05 Intracerebral hemorrhage / / 24656865 rs28451838 chr4 69137007 T A 1.88E-05 Intracerebral hemorrhage / / 24656865 rs28412553 chr4 69137137 C A 1.02E-05 Intracerebral hemorrhage / / 24656865 rs28412553 chr4 69137137 C A 1.89E-05 Intracerebral hemorrhage / / 24656865 rs72856446 chr4 69137905 A G 1.03E-05 Intracerebral hemorrhage / / 24656865 rs72856446 chr4 69137905 A G 1.91E-05 Intracerebral hemorrhage / / 24656865 rs7674768 chr4 69138292 T C 3.90E-04 Multiple complex diseases / / 17554300 rs7674768 chr4 69138292 T C 1.05E-05 Intracerebral hemorrhage / / 24656865 rs7674768 chr4 69138292 T C 1.94E-05 Intracerebral hemorrhage / / 24656865 rs7691074 chr4 69138386 G A 2.98E-05 Intracerebral hemorrhage / / 24656865 rs7691074 chr4 69138386 G A 9.85E-06 Intracerebral hemorrhage / / 24656865 rs939207 chr4 69167671 C T 3.00E-06 Obesity-related traits / / 23251661 rs115347518 chr4 69175447 C T 1.26E-05 Intracerebral hemorrhage / / 24656865 rs115347518 chr4 69175447 C T 3.06E-05 Intracerebral hemorrhage / / 24656865 rs10033058 chr4 69177408 C G 2.91E-04 Blood pressure YTHDC1 UTR-3 17255346 rs10033058 chr4 69177408 C G 0.00000238 Behcet's disease YTHDC1 UTR-3 23041938 rs2293595 chr4 69178920 T C 2.94E-04 Blood pressure YTHDC1 UTR-3 17255346 rs2293595 chr4 69178920 T C 0.00000461 Behcet's disease YTHDC1 UTR-3 23041938 rs115207011 chr4 69180171 C T 1.26E-05 Intracerebral hemorrhage YTHDC1 intron 24656865 rs115207011 chr4 69180171 C T 3.07E-05 Intracerebral hemorrhage YTHDC1 intron 24656865 rs115736932 chr4 69183696 T C 1.78E-05 Intracerebral hemorrhage YTHDC1 intron 24656865 rs115736932 chr4 69183696 T C 2.82E-05 Intracerebral hemorrhage YTHDC1 intron 24656865 rs17089267 chr4 69183791 A G 0.00000332 Behcet's disease YTHDC1 intron 23041938 rs116267995 chr4 69189307 C T 1.26E-05 Intracerebral hemorrhage YTHDC1 intron 24656865 rs116267995 chr4 69189307 C T 3.07E-05 Intracerebral hemorrhage YTHDC1 intron 24656865 rs116478185 chr4 69193120 A G 1.26E-05 Intracerebral hemorrhage YTHDC1 intron 24656865 rs116478185 chr4 69193120 A G 3.06E-05 Intracerebral hemorrhage YTHDC1 intron 24656865 rs115252578 chr4 69196477 T C 1.26E-05 Intracerebral hemorrhage YTHDC1 intron 24656865 rs115252578 chr4 69196477 T C 3.07E-05 Intracerebral hemorrhage YTHDC1 intron 24656865 rs115459611 chr4 69197019 T G 1.26E-05 Intracerebral hemorrhage YTHDC1 intron 24656865 rs115459611 chr4 69197019 T G 3.07E-05 Intracerebral hemorrhage YTHDC1 intron 24656865 rs116786722 chr4 69197381 T A 1.26E-05 Intracerebral hemorrhage YTHDC1 intron 24656865 rs116786722 chr4 69197381 T A 3.06E-05 Intracerebral hemorrhage YTHDC1 intron 24656865 rs115010520 chr4 69199195 T C 1.38E-05 Intracerebral hemorrhage YTHDC1 intron 24656865 rs115010520 chr4 69199195 T C 4.34E-05 Intracerebral hemorrhage YTHDC1 intron 24656865 rs115902257 chr4 69201180 A G 1.38E-05 Intracerebral hemorrhage YTHDC1 intron 24656865 rs115902257 chr4 69201180 A G 4.34E-05 Intracerebral hemorrhage YTHDC1 intron 24656865 rs114232966 chr4 69214382 T A 1.34E-05 Intracerebral hemorrhage YTHDC1 intron 24656865 rs17592868 chr4 69214926 T C 1.39E-05 Pulmonary function in asthmatics YTHDC1 intron 23541324 rs1902023 chr4 69536084 A C 1 Drug response to Oxazepam UGT2B15 missense 15044558 rs1902023 chr4 69536084 A C 1 Drug response to Lorazepam UGT2B15 missense 15961980 rs1902023 chr4 69536084 A C 1 Drug response to Oxazepam UGT2B15 missense 19916996 rs293428 chr4 69591782 A G 3.00E-08 Sex hormone-binding globulin levels / / 22829776 rs293428 chr4 69591782 A G 6.00E-06 Sex hormone-binding globulin levels / / 22829776 rs1828703 chr4 69626198 A G 7.86E-04 Myopia (pathological) / / 21095009 rs1513553 chr4 69629461 C T 4.44E-06 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs983346 chr4 69632325 G A 6.54E-04 Multiple complex diseases / / 17554300 rs11726899 chr4 69646009 T C 6.40E-05 Myasthenia gravis / / 23055271 rs17602249 chr4 69650860 T G 1.35E-06 Serum metabolites / / 19043545 rs1513559 chr4 69655555 A G 7.35E-04 Multiple complex diseases / / 17554300 rs10023464 chr4 69659738 C T 4.52E-04 Multiple complex diseases / / 17554300 rs294755 chr4 69665970 G A 9.08E-04 Multiple complex diseases / / 17554300 rs7657958 chr4 69682795 G A 1 Drug response to Nicotine UGT2B10 intron 17909004 rs7657958 chr4 69682795 G A 1 Drug response to Nicotine UGT2B10 intron 18300939 rs835316 chr4 69685853 G A 7.08E-04 Multiple complex diseases UGT2B10 intron 17554300 rs1458234 chr4 69713250 G A 1.56E-04 Multiple complex diseases / / 17554300 rs7665996 chr4 69731469 G C 2.62E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2085571 chr4 69758726 T C 1.27E-04 Multiple complex diseases / / 17554300 rs7658577 chr4 69766993 T C 4.58E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1984569 chr4 69768966 A G 1.28E-04 Multiple complex diseases / / 17554300 rs17147016 chr4 69795226 T A 1.31E-07 Red blood cell traits UGT2A3 UTR-3 23222517 rs3749514 chr4 69795359 A G 5.13E-05 Brain derived neurotrophic factor levels,in serum UGT2A3 UTR-3 22047184 rs2331563 chr4 69813152 C A 7.59E-04 Coronary heart disease UGT2A3 intron 21971053 rs2168842 chr4 69817817 G C 8.15E-07 Red blood cell traits UGT2A3 nearGene-5 23222517 rs7679122 chr4 69820283 C A 8.69E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs11249517 chr4 69824923 G A 8.24E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs2199040 chr4 69825314 C T 8.79E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs17147042 chr4 69828352 G A,C 7.53E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs372606092 chr4 69828352 G GC 7.53E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs2331564 chr4 69830054 C G 6.99E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs3966085 chr4 69830542 G A 7.59E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1598903 chr4 69832315 A G 7.67E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs3886643 chr4 69832836 T C 3.53E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs3886642 chr4 69833007 C T 1.52E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1458230 chr4 69833909 A T 2.46E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs10000481 chr4 69837173 C G 9.40E-04 Multiple complex diseases / / 17554300 rs7695476 chr4 69837898 T C 2.82E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1458229 chr4 69839734 A G 2.37E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1841039 chr4 69847013 C T 2.20E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs10447083 chr4 69852666 C T 8.73E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4590113 chr4 69853849 G A 9.49E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4467643 chr4 69853973 G T 8.97E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1841055 chr4 69859025 A C 2.07E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs1841055 chr4 69859025 A C 9.06E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4419538 chr4 69863439 G A 6.49E-04 Multiple complex diseases / / 17554300 rs1841051 chr4 69866445 G T 8.93E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs17146872 chr4 69878038 G A 7.33E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4604120 chr4 69883217 T A 7.78E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4235106 chr4 69887437 G A 7.10E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7441736 chr4 69891169 C T 3.34E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4235108 chr4 69893854 G A 3.36E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4305590 chr4 69894731 A C 4.31E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4305590 chr4 69894731 A C 4.82E-07 Red blood cell traits / / 23222517 rs4326076 chr4 69897813 A G 1.46E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6827511 chr4 69899513 T C 3.44E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs13147648 chr4 69901663 T C 3.47E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4353969 chr4 69902422 A G 3.48E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs13102620 chr4 69903001 A T 3.48E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4495114 chr4 69903744 T C 3.48E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4299665 chr4 69903924 A G 3.48E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4235111 chr4 69905257 G A 3.48E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs13140844 chr4 69908707 A T 3.44E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs13140844 chr4 69908707 A T 9.44E-07 Red blood cell traits / / 23222517 rs4518318 chr4 69911197 C T 8.95E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7438808 chr4 69916384 G T 5.91E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4377650 chr4 69917073 C T 8.69E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4583828 chr4 69922387 C T 9.82E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs3922514 chr4 69926623 C T 6.44E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7662632 chr4 69927974 T C 4.55E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6820734 chr4 69928642 T C 2.12E-05 Prion diseases / / 22210626 rs4400060 chr4 69936933 T C 4.49E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4400061 chr4 69936999 T C 4.48E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4446390 chr4 69937046 G A 4.48E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs12648830 chr4 69941154 C A 2.81E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs12648830 chr4 69941154 C A 2.35E-05 Esophageal cancer (squamous cell) / / 22960999 rs7677996 chr4 69941191 C T 5.37E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4694610 chr4 69944942 C G 2.91E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7657426 chr4 69945009 C T 2.59E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4587017 chr4 69947398 T G 2.31E-05 Prion diseases / / 22210626 rs6600876 chr4 69956930 T G 2.31E-05 Prion diseases / / 22210626 rs7662029 chr4 69961912 A G 2.31E-05 Prion diseases / / 22210626 rs7668282 chr4 69962114 T C 6.98E-05 HIV-1 control / / 20041166 rs7439366 chr4 69964338 T C 1 Drug response to Codeine UGT2B7 missense 18719619 rs12506962 chr4 69966024 G A 2.31E-05 Prion diseases UGT2B7 intron 22210626 rs7375178 chr4 69969679 C A 3.63E-05 Prion diseases UGT2B7 intron 22210626 rs12513195 chr4 69972086 T G 2.31E-05 Prion diseases UGT2B7 intron 22210626 rs4356975 chr4 69972463 C T 2.00E-07 Obesity-related traits UGT2B7 intron 23251661 rs4274916 chr4 69988378 C T 1.62E-05 Prion diseases / / 22210626 rs12645107 chr4 69988999 G A 5.98E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs17147266 chr4 70259544 A G,T 6.50E-06 Narcolepsy / / 20711174 rs1389930 chr4 70347172 C A,T 8.33E-05 Relative hand skill UGT2B4 intron 24068947 rs1826690 chr4 70352266 A G 1.90E-05 Major depressive disorder UGT2B4 intron 21042317 rs2642872 chr4 70367212 G T 2.03E-05 Multiple complex diseases / / 17554300 rs1594588 chr4 70368400 C T 7.42E-04 Multiple complex diseases / / 17554300 rs2009889 chr4 70381764 T C 5.97E-05 Multiple complex diseases / / 17554300 rs13139521 chr4 70393780 C T 1.90E-05 Urinary metabolites / / 21572414 rs4631116 chr4 70398937 T C 3.66E-05 Multiple complex diseases / / 17554300 rs11736579 chr4 70401931 T A 2.70E-05 Urinary metabolites / / 21572414 rs17672601 chr4 70407499 A C 4.06E-05 Multiple complex diseases / / 17554300 rs6823947 chr4 70411395 A T 2.50E-05 Urinary metabolites / / 21572414 rs12502677 chr4 70438197 A C 8.28E-04 HIV-1 viral setpoint / / 17641165 rs17616887 chr4 70438536 T A 7.63E-05 Multiple complex diseases / / 17554300 rs17147418 chr4 70438570 G A 1.01E-04 Multiple complex diseases / / 17554300 rs17147420 chr4 70438602 A G 6.54E-05 Multiple complex diseases / / 17554300 rs6819633 chr4 70439205 G T 6.52E-05 Multiple complex diseases / / 17554300 rs6846492 chr4 70439382 A G 1.28E-04 Multiple complex diseases / / 17554300 rs6820622 chr4 70439686 G T 6.05E-05 Multiple complex diseases / / 17554300 rs6832167 chr4 70474310 G A 1.32E-05 Major depressive disorder UGT2A1 intron 19107115 rs7655867 chr4 70478183 C T 5.88E-05 Multiple complex diseases UGT2A1 intron 17554300 rs11249452 chr4 70488360 C A 9.02E-04 Type 2 diabetes UGT2A1 intron 17463246 rs7692074 chr4 70502386 T G 2.90E-05 Urinary metabolites UGT2A1 intron 21572414 rs28404221 chr4 70505162 G A 0.000052 Breast cancer UGT2A1 missense 23555315 rs10518065 chr4 70520597 A G 2.51E-05 Intelligence / / 21826061 rs1347047 chr4 70521755 T C 8.44E-04 Type 2 diabetes / / 17463246 rs13144303 chr4 70547253 G T 8.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1587765 chr4 70567104 A G 6.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2331759 chr4 70579214 C T 4.00E-05 Serum metabolites / / 19043545 rs3775781 chr4 70595637 C T 4.97E-04 Myocardial Infarction SULT1B1 intron pha002883 rs17147623 chr4 70630643 T A 4.78E-04 Multiple complex diseases / / 17554300 rs9992466 chr4 70648977 C T 0.0007565 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9992466 chr4 70648977 C T 7.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10021393 chr4 70659045 T C 9.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10017788 chr4 70663551 T G 0.0007955 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10017788 chr4 70663551 T G 7.96E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1813685 chr4 70667744 C T 9.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17147712 chr4 70668568 T C 1.99E-05 Multiple complex diseases / / 17554300 rs6831079 chr4 70669168 C T 8.28E-04 Insulin resistance / / 21901158 rs7698707 chr4 70669724 A G 9.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13145571 chr4 70695169 C T 0.000872 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13145571 chr4 70695169 C T 8.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12499679 chr4 70702911 G A 0.000758 Salmonella-induced pyroptosis / / 22837397 rs13102618 chr4 70704877 A G 9.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2331821 chr4 70708461 C T 0.000842 Salmonella-induced pyroptosis SULT1E1 intron 22837397 rs4149535 chr4 70714171 T G 4.77E-05 Intelligence SULT1E1 intron 21826061 rs4149533 chr4 70718036 T C 9.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) SULT1E1 intron 23233662 rs10019305 chr4 70719533 A G 2.14E-04 Type 2 diabetes SULT1E1 intron 17463246 rs10019305 chr4 70719533 A G 9.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) SULT1E1 intron 23233662 rs3822172 chr4 70723840 C T 8.11E-04 Parkinson's disease SULT1E1 intron 17052657 rs3775770 chr4 70724270 C T 9.83E-04 Methotrexate clearance (acute lymphoblastic leukemia) SULT1E1 intron 23233662 rs4149527 chr4 70724996 G T 9.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) SULT1E1 intron 23233662 rs3775768 chr4 70725112 C T 9.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) SULT1E1 intron 23233662 rs3862053 chr4 70752174 T C 7.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17147830 chr4 70759142 T C 6.29E-05 Cholesterol / / pha003073 rs17147830 chr4 70759142 T C 9.62E-05 ldl cholesterol / / pha003076 rs10518069 chr4 70768646 T G 7.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs6829803 chr4 70777544 T C 8.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs17147844 chr4 70778543 C T 5.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs4694257 chr4 70789170 T C 2.32E-05 Cognitive test performance / / 20125193 rs2291531 chr4 70803765 A G 1.66E-04 Insulin resistance CSN1S1 intron 21901158 rs10031238 chr4 70833357 T G 8.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs923679 chr4 70833687 T G 1.91E-05 Cognitive test performance / / 20125193 rs9994584 chr4 70833723 G T 7.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs10031845 chr4 70834238 A C 7.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs17146480 chr4 70834740 A G 5.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs12648752 chr4 70841254 T C 8.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs2046911 chr4 70848044 C T 5.54E-05 Cognitive test performance / / 20125193 rs10518068 chr4 70857471 G A 3.65E-05 Cognitive test performance / / 20125193 rs776822 chr4 70861285 C T 8.02E-04 Coronary Artery Disease / / 17634449 rs776824 chr4 70861974 A G 4.62E-06 Cognitive test performance STATH intron 20125193 rs6845010 chr4 70907119 C A 9.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs2331856 chr4 70910928 A G 6.31E-04 Stroke (pediatric) / / 22990015 rs17644018 chr4 70932305 T C 1.00E-05 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs2063818 chr4 70935067 G A 4.06E-05 Rheumatoid arthritis CSN1S2AP intron 17804836 rs1709267 chr4 70973527 C T 1.53E-05 Cognitive performance / / 19734545 rs6855744 chr4 70979385 G A 5.24E-05 Chronic Hepatitis C infection / / 21725309 rs1709257 chr4 70983006 A C 4.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs2272040 chr4 71007047 A G 0.0000505 Gains in maximal O2 uptake response CSN1S2BP intron 21183627 rs2272040 chr4 71007047 A G 2.90E-04 Myasthenia gravis CSN1S2BP intron 23055271 rs3775758 chr4 71008910 C T 1.80E-04 Multiple complex diseases / / 17554300 rs3775759 chr4 71008940 C T 7.68E-05 Multiple complex diseases CSN1S2BP intron 17554300 rs17148265 chr4 71021940 T C 1.47E-05 Antineutrophil cytoplasmic antibody-associated vasculitis C4orf40 intron 22808956 rs17148325 chr4 71050180 C T 8.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs17652789 chr4 71051031 C T 0.0000782 Asthma / / 22502797 rs1514401 chr4 71051407 T A 0.000439 Asthma / / 22502797 rs869894 chr4 71052152 A C 9.04E-04 Coronary heart disease / / 21606135 rs869894 chr4 71052152 A C 3.42E-05 Blood Pressure / / pha003044 rs6839328 chr4 71052339 C T 0.0000683 Asthma / / 22502797 rs926004 chr4 71053262 T C 5.67E-06 Multiple complex diseases / / 17554300 rs17148328 chr4 71054211 T C 2.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs17148328 chr4 71054211 T C 1.38E-04 Alzheimer's disease / / 22005930 rs17148330 chr4 71058996 G A 2.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs17148330 chr4 71058996 G A 1.37E-04 Alzheimer's disease / / 22005930 rs2306445 chr4 71063964 G A 2.00E-04 Suicide attempts in bipolar disorder ODAM intron 21041247 rs2306445 chr4 71063964 G A 1.36E-04 Alzheimer's disease ODAM intron 22005930 rs4694273 chr4 71067317 C A 3.86E-05 Blood Pressure ODAM intron pha003044 rs17148361 chr4 71079762 C T 1.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs17148361 chr4 71079762 C T 1.24E-04 Alzheimer's disease / / 22005930 rs1842483 chr4 71083209 A G 0.000446 Asthma / / 22502797 rs10518072 chr4 71090658 T C 1.40E-04 Lipid traits / / 17903299 rs1514405 chr4 71097921 A G 9.62E-04 Insulin resistance FDCSP intron 21901158 rs1825033 chr4 71102000 G A 2.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs1825033 chr4 71102000 G A 1.46E-04 Alzheimer's disease / / 22005930 rs1817460 chr4 71102251 T A 2.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs1817460 chr4 71102251 T A 1.48E-04 Alzheimer's disease / / 22005930 rs1480758 chr4 71103643 G A 4.49E-04 Multiple complex diseases / / 17554300 rs1480758 chr4 71103643 G A 5.70E-05 Height / / pha003010 rs777794 chr4 71104217 A G 1.79E-04 Psoriasis / / 20953187 rs4460073 chr4 71107703 T C 8.01E-05 Suicide attempts in bipolar disorder / / 21041247 rs4460073 chr4 71107703 T C 6.44E-05 Alzheimer's disease / / 22005930 rs777799 chr4 71108903 G A 2.01E-04 Psoriasis CSN3 intron 20953187 rs1849717 chr4 71111521 C T 3.18E-04 Suicide attempts in bipolar disorder CSN3 intron 21041247 rs1849717 chr4 71111521 C T 1.42E-04 Alzheimer's disease CSN3 intron 22005930 rs17520678 chr4 71112283 A C 3.09E-04 Suicide attempts in bipolar disorder CSN3 intron 21041247 rs17520678 chr4 71112283 A C 1.31E-04 Alzheimer's disease CSN3 intron 22005930 rs3775747 chr4 71112943 T C 2.25E-04 Suicide attempts in bipolar disorder CSN3 intron 21041247 rs3775747 chr4 71112943 T C 2.83E-04 Alzheimer's disease CSN3 intron 22005930 rs3775745 chr4 71113074 T G 7.77E-04 Type 2 diabetes CSN3 intron 17846124 rs10518071 chr4 71113633 T C 5.16E-04 Suicide attempts in bipolar disorder CSN3 intron 21041247 rs10518071 chr4 71113633 T C 2.58E-04 Alzheimer's disease CSN3 intron 22005930 rs3775739 chr4 71115060 G A 5.18E-04 Suicide attempts in bipolar disorder CSN3 missense 21041247 rs3775739 chr4 71115060 G A 2.66E-04 Alzheimer's disease CSN3 missense 22005930 rs6811318 chr4 71115376 C T 5.17E-04 Suicide attempts in bipolar disorder CSN3 intron 21041247 rs6811318 chr4 71115376 C T 1.06E-04 Alzheimer's disease CSN3 intron 22005930 rs6811366 chr4 71115443 C T 5.19E-04 Suicide attempts in bipolar disorder CSN3 intron 21041247 rs6811366 chr4 71115443 C T 1.06E-04 Alzheimer's disease CSN3 intron 22005930 rs4694279 chr4 71130671 C T 4.73E-05 Blood Pressure / / pha003044 rs17148495 chr4 71137523 T C 2.71E-04 Hearing function / / 17255346 rs729314 chr4 71165706 C A 3.35E-04 Alcohol dependence / / 20201924 rs17148547 chr4 71167863 A G 4.73E-04 Type 2 diabetes / / 17463246 rs7687274 chr4 71171366 G A 8.12E-04 Multiple complex diseases / / 17554300 rs11947897 chr4 71185721 C A 4.20E-04 Alcohol dependence / / 20201924 rs717360 chr4 71190301 C T 7.94E-05 Alcohol dependence / / 19581569 rs1871710 chr4 71190415 T C 1.00E-04 Myocardial Infarction / / pha002883 rs1351419 chr4 71201388 C T 1.00E-04 Myocardial Infarction CABS1 missense pha002883 rs2291182 chr4 71201648 T G 2.87E-04 Hearing function CABS1 missense 17255346 rs1825032 chr4 71206818 C T 3.85E-04 Coronary heart disease / / 21606135 rs11249495 chr4 71216824 G T 1.52E-06 Cholesterol / / pha003073 rs11249495 chr4 71216824 G T 2.10E-06 Cholesterol / / pha003078 rs3775735 chr4 71229051 G T 4.66E-05 Cholesterol SMR3A intron pha003073 rs6600814 chr4 71235301 G T 5.82E-05 Serum metabolites / / 19043545 rs1817459 chr4 71237277 T C 2.79E-04 Type 2 diabetes / / 17463246 rs11249497 chr4 71237421 C T 6.87E-04 Coronary Artery Disease / / 17634449 rs114576575 chr4 71258171 C A 4.72E-05 Intracerebral hemorrhage / / 24656865 rs17146505 chr4 71291478 T C 1.12E-04 Coronary heart disease / / 21606135 rs962922 chr4 71309233 T C 2.49E-06 Height MUC7 intron pha003010 rs962922 chr4 71309233 T C 5.62E-05 Height MUC7 intron pha003011 rs2172006 chr4 71311646 C A 4.05E-04 Response to cytidine analogues (gemcitabine) MUC7 intron 24483146 rs1580578 chr4 71318810 A G 3.05E-04 Response to cytidine analogues (gemcitabine) MUC7 intron 24483146 rs4694065 chr4 71321473 G A 3.05E-04 Response to cytidine analogues (gemcitabine) MUC7 intron 24483146 rs2029495 chr4 71324066 A G 2.80E-04 Response to cytidine analogues (gemcitabine) MUC7 intron 24483146 rs1109501 chr4 71329490 G A 5.00E-06 Alcoholism (heaviness of drinking) MUC7 intron 21529783 rs2332064 chr4 71330231 C T 9.45E-04 Response to cytidine analogues (gemcitabine) MUC7 intron 24483146 rs7662264 chr4 71337776 T C 4.80E-04 Response to cytidine analogues (gemcitabine) MUC7 UTR-5 24483146 rs6600832 chr4 71353508 C T 3.60E-05 Alcoholism (heaviness of drinking) / / 21529783 rs2609426 chr4 71506120 A G 2.89E-05 Prostate cancer mortality E/M intron 20978177 rs12640848 chr4 71506412 A G 2.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) E/M intron 20877124 rs16845288 chr4 71514505 C T 8.36E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13146209 chr4 71520178 C T 5.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6813178 chr4 71575239 G A 6.90E-04 Iris characteristics RUFY3 intron 21835309 rs6813178 chr4 71575239 G A 0.000818016 Hypertension (early onset hypertension) RUFY3 intron 22479346 rs6834150 chr4 71582963 T C 2.89E-04 Parkinson's disease RUFY3 intron 16252231 rs7678779 chr4 71583087 C A 1.40E-04 Iris characteristics RUFY3 intron 21835309 rs6828698 chr4 71585370 A G 7.15E-05 Multiple complex diseases RUFY3 intron 17554300 rs7686646 chr4 71591894 C T 8.38E-05 Parkinson's disease RUFY3 intron 16252231 rs6815629 chr4 71605391 A G 8.43E-05 Parkinson's disease RUFY3 intron 16252231 rs16845408 chr4 71607152 G A 2.86E-04 Parkinson's disease RUFY3 intron 16252231 rs1020929 chr4 71695541 G C 4.30E-04 Iris characteristics GRSF1 intron 21835309 rs6446909 chr4 71724706 A G 6.78E-05 Prion diseases / / 22210626 rs6850072 chr4 71725868 G A 7.26E-05 Prion diseases / / 22210626 rs2362332 chr4 71728208 A G 1.35E-04 Multiple complex diseases / / 17554300 rs12649012 chr4 71748245 G A 6.49E-05 Prion diseases / / 22210626 rs3775289 chr4 71862674 T C 1 Drug response to Gemcitabine DCK intron 15224082 rs1803484 chr4 71896343 A G 1 Drug response to Gemcitabine DCK UTR-3 15224082 rs1385984 chr4 72013675 C T 2.95E-04 Alzheimer's disease (late onset) / / 21379329 rs6845432 chr4 72016176 A C 3.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs17689531 chr4 72022775 T C 7.86E-04 Alcohol dependence / / 21314694 rs16845938 chr4 72026536 A C 4.25E-06 QT interval / / 23166209 rs7685921 chr4 72028545 A G 9.00E-07 Fractional exhaled nitric oxide (childhood) / / 24315451 rs7685921 chr4 72028545 A G 9.00E-07 Fractional exhaled nitric oxide (childhood) / / 24315451 rs873955 chr4 72032329 A G 4.86E-06 QT interval / / 23166209 rs7672316 chr4 72032945 T C 3.61E-06 QT interval / / 23166209 rs1817143 chr4 72059495 C A 3.58E-06 QT interval SLC4A4 intron 23166209 rs4694092 chr4 72060219 G A 4.84E-06 QT interval SLC4A4 intron 23166209 rs16845974 chr4 72062014 G A 4.04E-06 QT interval SLC4A4 intron 23166209 rs2198341 chr4 72063044 G A 4.73E-06 QT interval SLC4A4 intron 23166209 rs2198341 chr4 72063044 G A 7.24E-04 Alcohol dependence SLC4A4 intron 24277619 rs12505704 chr4 72067196 C T 4.38E-06 QT interval SLC4A4 intron 23166209 rs2579309 chr4 72077830 G A 2.50E-05 Schizophrenia SLC4A4 intron 21791550 rs2579309 chr4 72077830 G A 0.000025 Psychosis SLC4A4 intron 23164818 rs7689609 chr4 72083374 C T 8.69E-06 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs4521314 chr4 72084653 C A 4.19E-06 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs7655668 chr4 72092376 C G 4.17E-06 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs12506660 chr4 72108593 C T 5.84E-06 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs12506660 chr4 72108593 C T 3.73E-04 Intracranial aneurysm SLC4A4 intron 22286173 rs3907208 chr4 72109664 A T 5.75E-06 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs2045012 chr4 72113452 G T 5.42E-06 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs9790757 chr4 72115097 T C 5.02E-06 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs1563045 chr4 72115668 T C 8.13E-06 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs1319630 chr4 72116128 C T 8.14E-06 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs2060903 chr4 72117691 G A 9.41E-06 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs10470737 chr4 72118545 G A 1.03E-05 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs10938138 chr4 72120609 G C 9.33E-06 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs4694387 chr4 72120854 C A 9.57E-06 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs4694388 chr4 72121163 A G 9.76E-06 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs12650549 chr4 72121456 G T 9.84E-06 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs2602072 chr4 72122033 T G 2.13E-05 Multiple complex diseases SLC4A4 intron 17554300 rs2016353 chr4 72122825 G A 1.06E-05 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs2363717 chr4 72124116 T G 1.07E-05 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs2579331 chr4 72126442 A G 2.37E-05 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs2579330 chr4 72126889 C T 1.00E-06 QT interval SLC4A4 intron 23166209 rs1840086 chr4 72135358 A G 2.38E-04 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs2602098 chr4 72135455 T G 8.80E-07 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs7436806 chr4 72135728 G A 2.32E-04 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs1377287 chr4 72136575 A G 2.99E-04 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs1377287 chr4 72136575 A G 4.87E-06 Major depression (suicidal thoughts and behavior) SLC4A4 intron 21750702 rs1542306 chr4 72139160 G C 7.49E-04 Type 2 diabetes SLC4A4 intron 17463246 rs980363 chr4 72139257 A G 2.86E-05 Suicide attempts in bipolar disorder SLC4A4 intron 21041247 rs1156585 chr4 72150808 G A 3.90E-05 Multiple complex diseases SLC4A4 intron 17554300 rs16846228 chr4 72155667 T C 6.55E-04 Multiple complex diseases SLC4A4 intron 17554300 rs980519 chr4 72180823 G A 3.75E-04 Multiple complex diseases SLC4A4 intron 17554300 rs2579352 chr4 72184362 T C 8.26E-04 Multiple complex diseases SLC4A4 intron 17554300 rs148635969 chr4 72316967 G A 8.00E-06 Age-related nuclear cataracts SLC4A4 missense 24951543 rs7656234 chr4 72356146 C T 7.01E-04 Longevity SLC4A4 intron 22279548 rs1530976 chr4 72393391 G C 2.68E-07 Asthma (childhood onset) SLC4A4 intron 23829686 rs1453450 chr4 72399713 A C 0.000373496 Hypertension (early onset hypertension) SLC4A4 intron 22479346 rs7693843 chr4 72405132 T G 0.000359494 Hypertension (early onset hypertension) SLC4A4 intron 22479346 rs7680649 chr4 72410348 T G 0.000408907 Hypertension (early onset hypertension) SLC4A4 intron 22479346 rs12504851 chr4 72410884 G A 7.94E-06 Serum metabolites SLC4A4 intron 19043545 rs3775161 chr4 72412516 G A 0.000408907 Hypertension (early onset hypertension) SLC4A4 intron 22479346 rs1377528 chr4 72425266 G T 7.46E-05 Graves' disease SLC4A4 intron 21841780 rs1453458 chr4 72425863 C T 4.18E-05 Graves' disease / / 21841780 rs1563091 chr4 72428081 T C 3.66E-05 Graves' disease SLC4A4 intron 21841780 rs4694402 chr4 72444076 G A 8.56E-05 Type 2 diabetes / / 17463246 rs1597977 chr4 72453601 T C 2.02E-04 Type 2 diabetes / / 17463246 rs10212827 chr4 72481753 T C 7.35E-05 Heart Rate / / pha003053 rs11722389 chr4 72512211 C T 3.94E-05 Heart Rate / / pha003053 rs1405376 chr4 72515164 C A 7.59E-05 Type 2 diabetes / / 17463246 rs2219070 chr4 72515260 T C 1.18E-04 Type 2 diabetes / / 17463246 rs2219070 chr4 72515260 T C 7.40E-05 Heart Rate / / pha003053 rs7697837 chr4 72524197 T C 1.24E-04 Type 2 diabetes / / 17463246 rs7697837 chr4 72524197 T C 3.25E-05 Heart Rate / / pha003053 rs10937979 chr4 72525480 C T 1.08E-04 Type 2 diabetes / / 17463246 rs4694421 chr4 72545947 T G 5.80E-05 Heart Rate / / pha003053 rs423817 chr4 72561180 G T 9.00E-04 Pulmonary function / / 17903307 rs396047 chr4 72572134 A G 4.79E-04 Type 2 diabetes / / 17463246 rs395371 chr4 72572374 A G 5.23E-04 Type 2 diabetes / / 17463246 rs1526692 chr4 72578724 A G 1.62E-05 Type 2 diabetes / / 17463246 rs1491716 chr4 72595063 G A 1.15E-05 Cognitive impairment induced by topiramate / / 22091778 rs1491711 chr4 72602252 C G 9.47E-04 Type 2 diabetes / / 17463246 rs222054 chr4 72604299 C G 1.00E-06 Non-alcoholic fatty liver disease histology (other) / / 23213074 rs17383291 chr4 72605410 T G 8.50E-07 Brachial circumference / / 22479309 rs705117 chr4 72608115 C T 5.00E-91 Serum vitamin D-binding protein levels GC intron 24740207 rs2282679 chr4 72608383 T G 2.00E-49 Vitamin D levels GC intron 20418485 rs2282679 chr4 72608383 T G 2.00E-109 Vitamin D insufficiency GC intron 20541252 rs2282679 chr4 72608383 T G 2.00E-14 Vitamin D levels GC intron 22673963 rs2298850 chr4 72614267 G C 7.31E-04 Type 2 diabetes GC intron 17463246 rs7041 chr4 72618334 A C 1.00E-246 Serum vitamin D-binding protein levels GC missense 24740207 rs10488854 chr4 72624135 C T 1.46E-06 Lipid levels GC intron 19913121 rs1491719 chr4 72624501 T C 1.10E-05 Urinary metabolites GC intron 21572414 rs11737702 chr4 72689926 G A 9.13E-05 Erythrocyte counts / / pha003090 rs1851024 chr4 72707821 G A 1.00E-14 Metabolite levels (atherosclerosis) / / 22916037 rs7694206 chr4 72731691 T G 9.55E-04 Type 2 diabetes / / 17463246 rs10518097 chr4 72764066 G T 4.75E-04 Multiple complex diseases / / 17554300 rs1474198 chr4 72769012 T C 5.68E-05 Type 2 diabetes and other traits / / 19734900 rs12504562 chr4 72784005 T C 7.87E-04 Multiple complex diseases / / 17554300 rs7668997 chr4 72792132 G T 1.35E-04 Taste perception / / 22132133 rs950110 chr4 72835532 C T 1.00E-05 Prostate cancer / / 21743057 rs1520503 chr4 72835953 A G 1.00E-05 Prostate cancer / / 21743057 rs7666924 chr4 72852357 T C 5.59E-04 Bipolar disorder,schizoaffective / / 19567891 rs11936367 chr4 72884978 A G 6.85E-04 Bipolar disorder,schizoaffective / / 19567891 rs6848138 chr4 72894411 T C 5.86E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs9917990 chr4 72897415 A C 6.12E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs9994192 chr4 72915983 A G 5.23E-04 Type 2 diabetes NPFFR2 intron 17463246 rs9884478 chr4 72934632 C T 1.31E-34 Multiple complex diseases NPFFR2 UTR-5 17554300 rs4543076 chr4 72978658 A G 8.22E-34 Narcolepsy NPFFR2 intron 19629137 rs6816714 chr4 72991368 C G 9.30E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers NPFFR2 intron 21775533 rs10034862 chr4 72993872 C A 8.77E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers NPFFR2 intron 21775533 rs4367144 chr4 73023727 T G 9.48E-05 Taste perception / / 22132133 rs1513895 chr4 73061027 C T 7.69E-04 Multiple complex diseases / / 17554300 rs6829041 chr4 73064330 T G 2.97E-04 Multiple complex diseases / / 17554300 rs10518101 chr4 73104866 C T 3.73E-04 Multiple complex diseases / / 17554300 rs16847697 chr4 73106712 G A 8.75E-04 Multiple complex diseases / / 17554300 rs4694477 chr4 73141022 A G 3.97E-04 Rheumatoid arthritis / / 21452313 rs2365697 chr4 73150789 C T 1.31E-04 Multiple complex diseases ADAMTS3 intron 17554300 rs16847814 chr4 73165274 T G 9.11E-05 Multiple complex diseases ADAMTS3 intron 17554300 rs12504695 chr4 73200125 C T 1.80E-05 Urinary metabolites ADAMTS3 intron 21572414 rs1369093 chr4 73245191 T C 2.40E-05 Cognitive test performance ADAMTS3 intron 20125193 rs10938017 chr4 73246388 T A 2.70E-05 Urinary metabolites ADAMTS3 intron 21572414 rs13112404 chr4 73273605 C T 4.33E-04 Multiple complex diseases ADAMTS3 intron 17554300 rs1481668 chr4 73296364 G T 4.55E-04 Multiple complex diseases ADAMTS3 intron 17554300 rs7657394 chr4 73307597 C T 5.74E-04 Multiple complex diseases ADAMTS3 intron 17554300 rs115136538 chr4 73322565 T C 5.00E-18 Lipid metabolism phenotypes ADAMTS3 intron 22286219 rs7654020 chr4 73327031 T C 4.41E-04 Multiple complex diseases ADAMTS3 intron 17554300 rs1383931 chr4 73334331 T C 1.81E-04 Multiple complex diseases ADAMTS3 intron 17554300 rs788919 chr4 73353894 T C 6.25E-05 Cognitive test performance ADAMTS3 intron 20125193 rs810929 chr4 73379371 T A 1.80E-04 Coronary Artery Disease ADAMTS3 intron 17634449 rs4694123 chr4 73387788 T C 3.02E-05 Cognitive test performance ADAMTS3 intron 20125193 rs16848079 chr4 73412023 C T 1.30E-11 Metabolite levels ADAMTS3 intron 22286219 rs788911 chr4 73413223 G T 3.14E-05 Cognitive test performance ADAMTS3 intron 20125193 rs1383934 chr4 73417524 G A 2.00E-06 Dental caries ADAMTS3 intron 23259602 rs1383934 chr4 73417524 G A 3.00E-07 Dental caries ADAMTS3 intron 23259602 rs9654065 chr4 73497029 C A 8.87E-04 Multiple complex diseases / / 17554300 rs7697556 chr4 73515313 T C 2.00E-14 Height / / 20881960 rs12644269 chr4 73518909 C T 9.16E-04 Multiple complex diseases / / 17554300 rs4694508 chr4 73530159 C T 5.90E-05 Serum metabolites / / 19043545 rs4694513 chr4 73566970 G A 9.58E-04 Coronary heart disease / / 21971053 rs12507628 chr4 73645351 G A 3.00E-09 Metabolite levels (atherosclerosis) / / 22916037 rs1381252 chr4 73673070 A C 0.000103 Height (Pygmy height) / / 22570615 rs1842553 chr4 73674204 A G 0.000103 Height (Pygmy height) / / 22570615 rs7677865 chr4 73762643 T C 5.15E-04 Smoking cessation / / 24665060 rs1346132 chr4 73770690 T G 7.67E-04 Multiple complex diseases / / 17554300 rs6816344 chr4 73783404 A T 1.00E-06 Dialysis-related mortality / / 21546767 rs1582754 chr4 73789266 A C 8.20E-05 Multiple complex diseases / / 17554300 rs13129272 chr4 73853413 G T 1.44E-05 Basophils / / pha003087 rs13137265 chr4 73854746 G A 1.21E-04 Alzheimer's disease (late onset) / / 21379329 rs1460989 chr4 73859163 C T 7.90E-05 Type 2 diabetes / / 23209189 rs10518112 chr4 73863809 C G 5.31E-04 Substance dependence / / 21818250 rs16849146 chr4 73903676 T C 4.30E-05 Monocyte counts / / pha003089 rs4694155 chr4 73931526 T G 5.26E-04 Alcohol dependence COX18 intron 20201924 rs2306058 chr4 73942678 C T 4.19E-05 Oral cancers (chewing tobacco related) ANKRD17 cds-synon 22503698 rs6818964 chr4 73970464 C T 7.00E-07 Smooth-surface caries ANKRD17 intron 24556642 rs6821554 chr4 74192808 A G 4.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs6446920 chr4 74193463 C T 3.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs6446921 chr4 74193520 A G 5.31E-04 Type 2 diabetes / / 17463246 rs6446921 chr4 74193520 A G 3.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs6446921 chr4 74193520 A G 5.40E-06 Urinary metabolites / / 21572414 rs4694161 chr4 74194326 A G 3.37E-04 Type 2 diabetes / / 17463246 rs4694161 chr4 74194326 A G 3.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs6446922 chr4 74196613 G A 3.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs4274815 chr4 74199445 A T 3.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs4408930 chr4 74200869 G A 3.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs4336191 chr4 74201008 T C 3.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs4345145 chr4 74201640 C T 2.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs4694164 chr4 74218542 C T 2.57E-05 C-Reactive Protein / / pha003070 rs6844516 chr4 74234196 A T 2.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs13125875 chr4 74236264 C T 2.57E-05 C-Reactive Protein / / pha003070 rs7675336 chr4 74236628 G A 2.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs16849293 chr4 74241949 A G 2.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs3775486 chr4 74275515 C A 7.18E-05 C-Reactive Protein ALB intron pha003070 rs16849331 chr4 74277908 G T 3.37E-04 Type 2 diabetes ALB intron 17463246 rs16849331 chr4 74277908 G T 2.02E-04 Suicide attempts in bipolar disorder ALB intron 21041247 rs16849372 chr4 74295791 T A 3.37E-04 Type 2 diabetes / / 17463246 rs16849372 chr4 74295791 T A 2.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs4403016 chr4 74298215 A G 2.45E-08 Tumor biomarkers / / 23300138 rs6850155 chr4 74299453 T G 2.48E-08 Tumor biomarkers / / 23300138 rs13138734 chr4 74299599 A G 2.37E-08 Tumor biomarkers / / 23300138 rs4018 chr4 74301313 C T 2.41E-08 Tumor biomarkers AFP nearGene-5 23300138 rs4024 chr4 74301384 G A 2.52E-08 Tumor biomarkers AFP nearGene-5 23300138 rs3796676 chr4 74302215 T A 2.55E-08 Tumor biomarkers AFP intron 23300138 rs16849384 chr4 74302870 T C 2.39E-08 Tumor biomarkers AFP intron 23300138 rs2070849 chr4 74304378 G A 2.60E-08 Tumor biomarkers AFP intron 23300138 rs2298839 chr4 74310844 A G 2.32E-08 Tumor biomarkers AFP intron 23300138 rs7660680 chr4 74311433 C G 2.24E-08 Tumor biomarkers AFP intron 23300138 rs10031441 chr4 74314649 C T 1.10E-08 Tumor biomarkers AFP intron 23300138 rs737241 chr4 74316729 G A 1.19E-08 Tumor biomarkers AFP intron 23300138 rs12506899 chr4 74319283 T G 3.00E-18 Tumor biomarkers AFP intron 23300138 rs10020432 chr4 74321600 A G 1.13E-08 Tumor biomarkers AFP nearGene-3 23300138 rs1894292 chr4 74349158 G A 5.00E-13 Prostate cancer AFM intron 23535732 rs4311283 chr4 74366415 C T 1.11E-04 Suicide attempts in bipolar disorder AFM intron 21041247 rs4694168 chr4 74372754 T C 4.54E-05 Calcium levels / / pha003085 rs1358592 chr4 74373849 A G 7.37E-04 Parkinson's disease / / 17052657 rs12507775 chr4 74451073 A G 0.000284897 Hypertension (early onset hypertension) RASSF6 missense 22479346 rs17192483 chr4 74460827 G T 2.11E-05 Calcium levels RASSF6 intron pha003085 rs4694626 chr4 74494008 C T 2.62E-04 Parkinson's disease / / 17052657 rs10019994 chr4 74544404 T C 6.04E-04 Multiple complex diseases / / 17554300 rs1358594 chr4 74555477 G T 3.00E-04 HIV(mother-to-child transmission) / / 20487506 rs1358594 chr4 74555477 G T 5.90E-05 Calcium levels / / pha003085 rs4694636 chr4 74598809 G T 7.70E-06 Stroke (ischemic) / / 22384361 rs11730667 chr4 74600211 G A 2.60E-06 Stroke (ischemic) / / 22384361 rs2227543 chr4 74607910 C T 8.83E-04 Suicide attempts in bipolar disorder IL8 intron 21423239 rs2227544 chr4 74608623 G A 2.28E-19 Cholesterol,total IL8 UTR-3 23063622 rs2886920 chr4 74626945 C T 2.52E-05 Alcohol dependence / / 21314694 rs17809003 chr4 74647641 A T 4.25E-04 Multiple complex diseases / / 17554300 rs3117597 chr4 74729616 T C 7.59E-06 White blood cell count / / 21738479 rs2886927 chr4 74730231 T A 3.80E-06 Urinary metabolites / / 21572414 rs2367291 chr4 74730380 A C 5.80E-06 Urinary metabolites / / 21572414 rs2367291 chr4 74730380 A C 6.76E-06 White blood cell count / / 21738479 rs3117598 chr4 74731278 G T 3.80E-06 Urinary metabolites / / 21572414 rs3111694 chr4 74731359 G A 3.50E-06 Urinary metabolites / / 21572414 rs1429638 chr4 74737930 C A 3.59E-04 Response to alcohol consumption (flushing response) / / 24277619 rs353030 chr4 74776404 T C 9.14E-05 Multiple complex diseases / / 17554300 rs4694655 chr4 74806082 C T 4.21E-04 Smoking initiation / / 24665060 rs4694656 chr4 74811199 G A 5.98E-04 Heart Failure / / pha002885 rs11574452 chr4 74846661 C A 2.01E-12 Metabolite levels PF4 UTR-3 22286219 rs2472649 chr4 74857708 A G 3.00E-08 Inflammatory bowel disease / / 23128233 rs16850360 chr4 74872445 A G 3.78E-12 Metabolite levels / / 22286219 rs16850360 chr4 74872445 A G 3.00E-10 Metabolite levels (atherosclerosis) / / 22916037 rs7684973 chr4 74936978 A G 3.63E-06 White blood cell count / / 21738479 rs4694182 chr4 74939575 A C 1.55E-06 White blood cell count / / 21738479 rs13124617 chr4 74947348 A G 3.89E-08 White blood cell count / / 21738479 rs546829 chr4 74956372 A T 3.00E-07 White blood cell types / / 21738478 rs9131 chr4 74963049 C T 1.58E-08 White blood cell count CXCL2 UTR-3 21738479 rs3806792 chr4 74965274 T C 3.55E-08 White blood cell count / / 21738479 rs7667376 chr4 74967890 C T 3.80E-08 White blood cell count / / 21738479 rs1371798 chr4 74976781 C T 5.13E-07 White blood cell count / / 21738479 rs1371799 chr4 74977837 T C 2.00E-17 White blood cell count / / 21738479 rs1866755 chr4 74978340 C T 5.25E-08 White blood cell count / / 21738479 rs537061 chr4 75039459 A G 1.37E-05 Smoking initiation MTHFD2L intron 24665060 rs510884 chr4 75055992 T C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes MTHFD2L intron 22628534 rs505019 chr4 75067799 C T 1.66E-04 Multiple complex diseases MTHFD2L intron 17554300 rs734222 chr4 75072915 C T 6.17E-04 Smoking initiation MTHFD2L intron 24665060 rs16850864 chr4 75160824 C T 7.00E-09 Immune reponse to smallpox (secreted IL-1beta) MTHFD2L intron 22610502 rs16850885 chr4 75170140 G A 7.00E-09 Immune reponse to smallpox (secreted IL-1beta) / / 22610502 rs7690538 chr4 75202049 T C 6.20E-05 Temperament (bipolar disorder) / / 22365631 rs1812149 chr4 75212818 C T 6.30E-05 Temperament (bipolar disorder) / / 22365631 rs6846401 chr4 75213167 A G 6.90E-05 Temperament (bipolar disorder) / / 22365631 rs12646889 chr4 75213276 G A 6.20E-05 Temperament (bipolar disorder) / / 22365631 rs12641042 chr4 75213338 C A 6.10E-05 Temperament (bipolar disorder) / / 22365631 rs16851013 chr4 75216238 G A 1.20E-05 Temperament (bipolar disorder) / / 22365631 rs16851014 chr4 75216365 G A 7.89E-05 Obsessive-compulsive disorder / / 24821223 rs16851014 chr4 75216365 G A 7.89E-05 Obsessive-compulsive disorder / / 24821223 rs2168889 chr4 75223711 A G 6.00E-14 Metabolite levels (atherosclerosis) / / 22916037 rs1350666 chr4 75224590 T C 8.00E-06 Attention deficit hyperactivity disorder / / 18821565 rs6836436 chr4 75230930 T G 7.71E-04 Response to taxane treatment (placlitaxel) EREG UTR-5 23006423 rs1017734 chr4 75253120 A C 3.66E-04 Multiple complex diseases EREG UTR-3 17554300 rs6818671 chr4 75255151 C T 9.66E-04 Multiple complex diseases / / 17554300 rs10002688 chr4 75261407 A G 8.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs6819636 chr4 75262870 C T 8.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs9992496 chr4 75263673 A G 8.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs4315746 chr4 75263925 T C 8.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs11727089 chr4 75264863 G A 9.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs718607 chr4 75276524 A G 9.86E-05 Cognitive impairment induced by topiramate / / 22091778 rs1494878 chr4 75282847 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11725706 chr4 75328108 G A 1.61E-04 Multiple complex diseases / / 17554300 rs11725706 chr4 75328108 G A 4.42E-05 Type 1 diabetes / / 18978792 rs11723281 chr4 75329646 A G 8.98E-04 Acute lung injury / / 22295056 rs1389964 chr4 75331054 G A 2.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs1494887 chr4 75333439 C T 2.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs1611884 chr4 75333502 C A 2.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs1691280 chr4 75333819 G A 1.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs1246415 chr4 75336464 C T 3.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs3913031 chr4 75336785 A G 2.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs2125399 chr4 75345885 T C 5.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs1902997 chr4 75348128 A G 4.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs1246397 chr4 75351812 T C 6.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs1494893 chr4 75356565 C T 4.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs1246404 chr4 75365081 T A 5.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs1246403 chr4 75366958 G C 5.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs1797581 chr4 75367956 A G 5.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs6447000 chr4 75377358 T C 5.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs3104128 chr4 75379906 A G 0.0000757 Tuberculosis with late age of onset / / 22551897 rs6447003 chr4 75386914 G C 9.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs1994941 chr4 75400315 T C 0.0000783 Tuberculosis with late age of onset / / 22551897 rs6826055 chr4 75400523 A C 9.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs4694693 chr4 75404507 T C 9.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs4694196 chr4 75404702 C T 9.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs4694197 chr4 75405009 A C 7.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs6447006 chr4 75409327 G A 6.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs7696397 chr4 75421788 C T 9.19E-04 HIV-1 viral setpoint / / 17641165 rs62314947 chr4 75502487 T C 5.00E-08 Breast size / / 22747683 rs9306999 chr4 75516173 C T 7.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs11097821 chr4 75534357 C A 1.92E-05 AIDS / / 19754311 rs12647729 chr4 75537771 A G 9.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs6834996 chr4 75539075 T C 7.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs12642133 chr4 75543289 G A 1.91E-05 AIDS / / 19754311 rs13124944 chr4 75547845 C A 3.34E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs4568308 chr4 75595458 A G 0.00000673 Negative affect (anxiety related behavioral questionnaire) in children / / 23565138 rs16999882 chr4 75738734 A C 8.18E-05 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs6854845 chr4 75746665 G T 1.34E-04 Celiac disease / / 23936387 rs16996713 chr4 75770911 G T 2.37E-04 Coronary heart disease / / 21606135 rs1580043 chr4 75773387 A C 3.40E-04 Coronary heart disease / / 21606135 rs16999951 chr4 75783914 G A 0.000006 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) / / 23080225 rs16999967 chr4 75797003 A C 8.35E-04 Coronary heart disease / / 21606135 rs10518131 chr4 75799592 C T 5.00E-04 Coronary heart disease / / 21606135 rs17248248 chr4 75812047 G A 3.77E-04 Coronary heart disease / / 21606135 rs7660335 chr4 75815881 C G 3.77E-04 Coronary heart disease / / 21606135 rs7668508 chr4 75819940 G C 2.99E-04 Coronary heart disease / / 21606135 rs6533486 chr4 75859572 C T 2.99E-04 Coronary heart disease PARM1 intron 21606135 rs17248887 chr4 75861967 G A 7.20E-04 Coronary heart disease PARM1 intron 21606135 rs11944489 chr4 75980925 T C 2.75E-05 Serum metabolites / / 19043545 rs17000197 chr4 75996853 T C 9.81E-04 Type 2 diabetes / / 17463246 rs6534447 chr4 76005892 G T 2.94E-08 Metabolite levels / / 23281178 rs17000212 chr4 76006821 A G 2.94E-08 Metabolite levels / / 23281178 rs17199632 chr4 76028873 C T 2.94E-08 Metabolite levels / / 23281178 rs17199779 chr4 76030857 C A 2.94E-08 Metabolite levels / / 23281178 rs1426063 chr4 76030921 A G 8.00E-06 QT interval / / 23166209 rs17000249 chr4 76031157 T C 9.78E-04 Multiple complex diseases / / 17554300 rs17000260 chr4 76033786 A C 2.94E-08 Metabolite levels / / 23281178 rs17000261 chr4 76033976 T A 2.94E-08 Metabolite levels / / 23281178 rs17000262 chr4 76034046 C T 2.94E-08 Metabolite levels / / 23281178 rs17000264 chr4 76034172 A G 2.94E-08 Metabolite levels / / 23281178 rs17266308 chr4 76062905 C T 2.94E-08 Metabolite levels / / 23281178 rs6534803 chr4 76064609 A G 6.66E-04 Multiple complex diseases / / 17554300 rs7699626 chr4 76075268 T G 1.36E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6534849 chr4 76075792 T C 7.20E-05 Response to statin therapy / / 20339536 rs1391010 chr4 76081553 C T 1.12E-04 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs1391010 chr4 76081553 C T 8.48E-04 Barrett's esophagus / / 24121790 rs11940311 chr4 76102398 T C 2.32E-04 Osteoarthritis / / 19508968 rs1845983 chr4 76134763 G A 4.20E-04 Crohn's disease / / 17684544 rs7681167 chr4 76161222 A G 2.70E-04 Crohn's disease / / 17684544 rs7681167 chr4 76161222 A G 2.49E-04 Barrett's esophagus / / 24121790 rs6848890 chr4 76163816 C T 3.31E-05 Barrett's esophagus / / 24121790 rs6848890 chr4 76163816 C T 3.71E-05 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs7691721 chr4 76164287 C T 7.08E-05 Osteoarthritis / / 19508968 rs7691721 chr4 76164287 C T 4.33E-04 Barrett's esophagus / / 24121790 rs1497205 chr4 76169067 C T 1.28E-05 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs1497205 chr4 76169067 C T 2.86E-05 Barrett's esophagus / / 24121790 rs10021538 chr4 76180442 A G 3.49E-04 Barrett's esophagus / / 24121790 rs2867289 chr4 76184807 G A 8.96E-05 Multiple complex diseases / / 17554300 rs12502693 chr4 76193404 T C 1.56E-05 Esophageal cancer (squamous cell) / / 22960999 rs7696346 chr4 76194403 C T 1.57E-05 F-cell distribution / / 21326311 rs10518138 chr4 76206696 C G 5.20E-04 Bipolar disorder / / 19259986 rs10518137 chr4 76209646 A G 5.62E-04 Bipolar disorder / / 19259986 rs9993892 chr4 76231406 A G 3.88E-05 Odorant perception / / 23910658 rs4859957 chr4 76249812 C T 8.25E-04 HIV-1 viral setpoint / / 17641165 rs2203431 chr4 76261855 C A,G,T 6.32E-07 Multiple myeloma / / 22120009 rs976368 chr4 76292406 G A 3.63E-04 Fibrinogen / / 17255346 rs11729770 chr4 76323125 G A 8.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs7683530 chr4 76323522 G A 5.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs6834051 chr4 76324403 T C 9.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs11735209 chr4 76332869 G T 7.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs2903698 chr4 76332975 A G 6.00E-06 Prion diseases / / 22210626 rs10033255 chr4 76339852 G A 1.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs10033354 chr4 76339969 G A 5.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs11727923 chr4 76342004 A C 8.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs17278543 chr4 76358370 T C 9.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs11731477 chr4 76359426 G A 5.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs11727082 chr4 76377980 C T 7.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs6851699 chr4 76395005 C A 6.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs1841932 chr4 76404759 C A 2.76E-09 Lymphocyte counts RCHY1 UTR-3 22286170 rs13137105 chr4 76416387 A G 9.00E-07 Response to tocilizumab in rheumatoid arthritis RCHY1 intron 22491018 rs9998529 chr4 76475750 C A 7.57E-04 Heart Failure / / pha002885 rs17000647 chr4 76481730 C A 5.00E-06 Parkinson's disease (motor and cognition) C4orf26 intron 22658654 rs6851864 chr4 76493256 T C 3.75E-04 Alzheimer's disease (late onset) / / 21379329 rs1464071 chr4 76550861 T C 8.60E-04 Iris characteristics CDKL2 intron 21835309 rs17000733 chr4 76580894 G A 9.06E-04 Multiple complex diseases G3BP2 intron 17554300 rs6838240 chr4 76643452 T C 5.45E-05 Prion diseases / / 22210626 rs16996019 chr4 76644744 A T 9.41E-04 Multiple complex diseases / / 17554300 rs10028884 chr4 76684108 A G 3.70E-04 Iris characteristics USO1 intron 21835309 rs324735 chr4 76705014 A T 7.60E-05 Longevity and age-related phenotypes USO1 intron 17903295 rs324735 chr4 76705014 A T 9.98E-05 Cardiovascular disease USO1 intron 17903304 rs324702 chr4 76737790 C G 3.30E-05 Longevity and age-related phenotypes / / 17903295 rs6531960 chr4 76768762 A G 5.88E-06 Left ventricular mass / / 21212386 rs17001163 chr4 76812031 T C 1.09E-04 Depression (quantitative trait) PPEF2 intron 20800221 rs13116688 chr4 76812673 C G 5.34E-04 Depression (quantitative trait) PPEF2 intron 20800221 rs10007472 chr4 76817221 T C 1.04E-04 Depression (quantitative trait) PPEF2 intron 20800221 rs13147538 chr4 76818367 A G 2.01E-04 Depression (quantitative trait) PPEF2 intron 20800221 rs1847731 chr4 76819485 T C 9.06E-05 Depression (quantitative trait) PPEF2 intron 20800221 rs17001210 chr4 76837098 C T 8.28E-05 Multiple complex diseases /AA intron 17554300 rs10518142 chr4 76842874 G T 0.00000889 Aging /AA intron 22445811 rs4859571 chr4 76857309 C T 0.0000156 Aging /AA missense 22445811 rs3796483 chr4 76872684 A G 3.40E-04 Alzheimer's disease SDAD1 intron 17998437 rs1857821 chr4 76881979 A G 0.00000512 Aging SDAD1 intron 22445811 rs2271528 chr4 76888836 G A 5.50E-04 Multiple complex diseases SDAD1 intron 17554300 rs2271528 chr4 76888836 G A 0.0000102 Aging SDAD1 intron 22445811 rs2273 chr4 76889388 C T 1.00E-06 Longevity SDAD1 intron 20834067 rs6849878 chr4 76913973 G A 1.36E-04 Alzheimer's disease / / 17998437 rs2276886 chr4 76928428 C T 1.50E-05 Electrocardiographic traits and heart rate variability CXCL9 intron 17903306 rs12504339 chr4 76947304 T C 3.40E-05 Cognitive impairment induced by topiramate ART3 intron 22091778 rs12504339 chr4 76947304 T C 1.36E-05 Serum albumin level ART3 intron pha003084 rs4129780 chr4 76959624 T G 2.13E-04 Lymphocyte counts ART3 intron 22286170 rs13111494 chr4 76985488 T C 0.0000128 Aging ART3 intron 22445811 rs13141895 chr4 77077885 T C 5.06E-04 Multiple complex diseases / / 17554300 rs7664889 chr4 77087704 G T 9.94E-04 Alzheimer's disease SCARB2 intron 24755620 rs2869851 chr4 77094831 T G 2.94E-05 Parkinson's disease SCARB2 intron 21738487 rs11946079 chr4 77105700 T G 2.16E-05 Parkinson's disease SCARB2 intron 21738487 rs999361 chr4 77117574 A C 7.78E-05 Parkinson's disease SCARB2 intron 21738487 rs17001626 chr4 77119942 T C 4.13E-06 Type 2 diabetes SCARB2 intron 17463246 rs6532244 chr4 77125878 C A 2.09E-04 Breast cancer SCARB2 intron pha002853 rs894251 chr4 77129840 G A 8.30E-04 Obesity (extreme) SCARB2 intron 21935397 rs1441904 chr4 77151880 A G 3.20E-06 Parkinson's disease FAM47E intron 21738487 rs11097297 chr4 77154865 C T 0.000660051 Hypertension (early onset hypertension) FAM47E intron 22479346 rs7666265 chr4 77176281 G A 7.49E-07 Parkinson's disease FAM47E intron 21738487 rs7655536 chr4 77176768 T C 3.04E-07 Parkinson's disease FAM47E intron 21738487 rs6851219 chr4 77179830 C T 4.69E-05 Parkinson's disease FAM47E intron 19915575 rs11097313 chr4 77185293 G A 3.68E-04 Lung function (forced expiratory volume in 1 second) FAM47E intron 17255346 rs11097313 chr4 77185293 G A 8.18E-06 Parkinson's disease FAM47E intron 21738487 rs3733250 chr4 77192868 G A 7.85E-06 Parkinson's disease FAM47E missense 21738487 rs1441910 chr4 77193449 T C 1.45E-05 Parkinson's disease FAM47E intron 21738487 rs6532316 chr4 77198756 A G 2.56E-04 Sudden cardiac arrest FAM47E intron 21658281 rs6812193 chr4 77198986 C T 4.00E-07 Parkinson's disease FAM47E intron 19915575 rs6812193 chr4 77198986 C T 8.00E-10 Parkinson's disease FAM47E intron 21738487 rs6812193 chr4 77198986 C T 2.52E-06 Parkinson's disease FAM47E intron 22451204 rs964051 chr4 77199414 C A 4.72E-04 Lung function (forced expiratory volume in 1 second) FAM47E intron 17255346 rs964051 chr4 77199414 C A 4.24E-06 Parkinson's disease FAM47E intron 21738487 rs1542096 chr4 77204500 C T 8.52E-05 Parkinson's disease FAM47E intron 21738487 rs6852266 chr4 77215852 T C 7.75E-04 Multiple complex diseases FAM47E-STBD1 intron 17554300 rs10019831 chr4 77222933 A C 0.0000109 Fasting blood glucose FAM47E-STBD1 intron 22885924 rs4241592 chr4 77278411 T C 9.45E-04 Aortic root size CCDC158 intron 21223598 rs11097338 chr4 77289952 A G 9.03E-06 Parkinson's disease CCDC158 intron 21738487 rs10022284 chr4 77333030 C T 1.77E-05 Parkinson's disease / / 21738487 rs10006043 chr4 77357747 C T 7.16E-04 Amyotrophic Lateral Sclerosis SHROOM3 intron 17362836 rs9992101 chr4 77360431 G A 6.00E-09 Creatinine levels SHROOM3 intron 20383145 rs7677847 chr4 77364126 A G 1.10E-05 Urinary metabolites SHROOM3 intron 21572414 rs4859673 chr4 77364799 A G 2.10E-06 Urinary metabolites SHROOM3 intron 21572414 rs60529470 chr4 77365883 G A 0.0008198 Sarcoidosis SHROOM3 intron 22952805 rs55940751 chr4 77365891 C T 0.0007535 Sarcoidosis SHROOM3 intron 22952805 rs17253722 chr4 77367287 G A 0.0005227 Sarcoidosis SHROOM3 intron 22952805 rs1398016 chr4 77367688 G A 4.49E-04 Coronary Artery Disease SHROOM3 intron 17634449 rs1398016 chr4 77367688 G A 0.0007408 Sarcoidosis SHROOM3 intron 22952805 rs12640246 chr4 77368470 T C 8.30E-06 Urinary metabolites SHROOM3 intron 21572414 rs17319721 chr4 77368847 G A 1.00E-12 Renal function and chronic kidney disease SHROOM3 intron 19430482 rs17319721 chr4 77368847 G A 1.00E-19 Chronic kidney disease SHROOM3 intron 20383146 rs17319721 chr4 77368847 G A 1.53E-21 Chronic kidney disease SHROOM3 intron 22479191 rs17319721 chr4 77368847 G A 1.00E-08 Glomerular filtration rate SHROOM3 intron 23535967 rs17319721 chr4 77368847 G A 1.10E-05 Glomerular filtration rate SHROOM3 intron 23535967 rs17319721 chr4 77368847 G A 1.30E-09 Glomerular filtration rate SHROOM3 intron 23535967 rs17319721 chr4 77368847 G A 1.50E-06 Glomerular filtration rate SHROOM3 intron 23535967 rs17319721 chr4 77368847 G A 1.50E-08 Glomerular filtration rate SHROOM3 intron 23535967 rs17319721 chr4 77368847 G A 1.80E-05 Glomerular filtration rate SHROOM3 intron 23535967 rs17319721 chr4 77368847 G A 2.40E-07 Glomerular filtration rate SHROOM3 intron 23535967 rs17319721 chr4 77368847 G A 5.20E-06 Glomerular filtration rate SHROOM3 intron 23535967 rs17319721 chr4 77368847 G A 8.60E-10 Glomerular filtration rate SHROOM3 intron 23535967 rs17319721 chr4 77368847 G A 9.20E-10 Glomerular filtration rate SHROOM3 intron 23535967 rs17319721 chr4 77368847 G A 9.80E-09 Glomerular filtration rate SHROOM3 intron 23535967 rs10032549 chr4 77398015 A G 1.00E-08 Glomerular filtration rate SHROOM3 intron 23535967 rs4859682 chr4 77410318 C A 2.00E-09 Glomerular filtration rate SHROOM3 intron 23535967 rs13146355 chr4 77412140 G A 6.00E-13 magnesium levels SHROOM3 intron 20700443 rs13146355 chr4 77412140 G A 7.00E-11 Renal function-related traits (eGRFcrea) SHROOM3 intron 22797727 rs13146355 chr4 77412140 G A 9.00E-12 Renal function-related traits (sCR) SHROOM3 intron 22797727 rs13106227 chr4 77418681 G A 4.00E-06 Eosinophilic esophagitis (pediatric) SHROOM3 intron 20208534 rs1986734 chr4 77420784 C T 1.00E-06 Eosinophilic esophagitis (pediatric) SHROOM3 intron 20208534 rs7666000 chr4 77424006 G A 2.71E-04 Coronary heart disease SHROOM3 intron 21606135 rs7696372 chr4 77424167 T C 3.43E-04 Coronary heart disease SHROOM3 intron 21606135 rs6532433 chr4 77424258 T C 3.69E-04 Coronary heart disease SHROOM3 intron 21606135 rs4859688 chr4 77439979 C T 1.82E-04 Body mass index SHROOM3 intron 21701565 rs9996493 chr4 77441014 A G 5.70E-05 Nonalcoholic fatty liver disease SHROOM3 intron 21423719 rs6817593 chr4 77461011 T C 8.27E-04 Obesity (extreme) SHROOM3 intron 21935397 rs17002074 chr4 77464016 A G 3.56E-05 Coronary heart disease SHROOM3 intron pha003031 rs17002080 chr4 77464524 A G 9.72E-04 Obesity (extreme) SHROOM3 intron 21935397 rs6532475 chr4 77473829 G A 8.06E-04 Obesity (extreme) SHROOM3 intron 21935397 rs11942966 chr4 77490144 A C 2.38E-04 Insulin resistance SHROOM3 intron 21901158 rs11942966 chr4 77490144 A C 3.87E-05 IgE levels SHROOM3 intron 22075330 rs12509930 chr4 77495571 A G 8.30E-06 Personality dimensions SHROOM3 intron 21173776 rs12513013 chr4 77498236 T C 9.70E-06 Personality dimensions SHROOM3 intron 21173776 rs4859453 chr4 77515370 G A 7.14E-04 Alzheimer's disease SHROOM3 intron 24755620 rs11723275 chr4 77528821 A C 5.30E-05 Depression (quantitative trait) SHROOM3 intron 20800221 rs12640320 chr4 77531337 C A 4.69E-05 Cleft lip SHROOM3 intron 20436469 rs3733247 chr4 77536598 G A 7.21E-04 Depression (quantitative trait) SHROOM3 intron 20800221 rs4859697 chr4 77538555 C A 2.06E-05 Depression (quantitative trait) SHROOM3 intron 20800221 rs11734813 chr4 77540746 G A 2.04E-05 Response to mTOR inhibitor (everolimus) SHROOM3 intron 24009623 rs7669852 chr4 77542398 G A 5.41E-04 Depression (quantitative trait) SHROOM3 intron 20800221 rs4330370 chr4 77545018 G T 2.55E-05 Depression (quantitative trait) SHROOM3 intron 20800221 rs6838801 chr4 77549559 G T 9.28E-04 Depression (quantitative trait) SHROOM3 intron 20800221 rs7695340 chr4 77551310 C T 2.68E-05 Depression (quantitative trait) SHROOM3 intron 20800221 rs4582178 chr4 77552782 A G 9.58E-04 Depression (quantitative trait) SHROOM3 intron 20800221 rs6818060 chr4 77553691 G A 9.66E-04 Depression (quantitative trait) SHROOM3 intron 20800221 rs17322488 chr4 77560635 G A 1.65E-04 Depression (quantitative trait) SHROOM3 intron 20800221 rs17322529 chr4 77560811 A G 1.42E-04 Depression (quantitative trait) SHROOM3 intron 20800221 rs7680223 chr4 77582838 A C 2.17E-04 Depression (quantitative trait) SHROOM3 intron 20800221 rs11723588 chr4 77586259 G T 9.82E-06 Personality dimensions SHROOM3 intron 22628180 rs13113020 chr4 77588821 A C 7.80E-06 Personality dimensions SHROOM3 intron 22628180 rs13134149 chr4 77591448 A G 2.11E-04 Depression (quantitative trait) SHROOM3 intron 20800221 rs7695034 chr4 77595358 A T 3.38E-04 Depression (quantitative trait) SHROOM3 intron 20800221 rs4475167 chr4 77610963 G C 6.03E-04 Depression (quantitative trait) SHROOM3 intron 20800221 rs4124581 chr4 77616748 G A 3.12E-04 Depression (quantitative trait) SHROOM3 intron 20800221 rs344117 chr4 77619296 T C 7.91E-04 Amyotrophic Lateral Sclerosis SHROOM3 intron 17362836 rs344117 chr4 77619296 T C 2.69E-04 Depression (quantitative trait) SHROOM3 intron 20800221 rs13121538 chr4 77626887 C T 2.03E-04 Amyotrophic Lateral Sclerosis SHROOM3 intron 17362836 rs12640170 chr4 77631887 C T 2.81E-04 Amyotrophic Lateral Sclerosis SHROOM3 intron 17362836 rs344135 chr4 77652219 T C 1.64E-04 Amyotrophic Lateral Sclerosis SHROOM3 intron 17362836 rs3821978 chr4 77675200 C T 1.62E-04 Amyotrophic Lateral Sclerosis SHROOM3 intron 17362836 rs3733242 chr4 77675505 C T 6.80E-06 Amyotrophic Lateral Sclerosis SHROOM3 missense 17362836 rs3733242 chr4 77675505 C T 2.20E-05 Amyotrophic lateral sclerosis (sporadic) SHROOM3 missense 19740415 rs344126 chr4 77678728 G A 4.48E-04 Depression (quantitative trait) SHROOM3 intron 20800221 rs17002201 chr4 77681958 C T 2.21E-05 Progressive supranuclear palsy SHROOM3 intron 21685912 rs13113476 chr4 77684099 A G 2.62E-04 Amyotrophic Lateral Sclerosis SHROOM3 intron 17362836 rs6826310 chr4 77686695 A G 1.31E-04 Amyotrophic Lateral Sclerosis SHROOM3 intron 17362836 rs17002208 chr4 77707376 T C 4.73E-04 Insulin resistance / / 21901158 rs344107 chr4 77719812 C T 3.16E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6853653 chr4 77725242 T C 7.88E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2865147 chr4 77735709 C T 5.20E-05 Response to statin therapy / / 20339536 rs12645488 chr4 77736601 G A 5.00E-05 Response to statin therapy / / 20339536 rs6821337 chr4 77738163 T C 5.90E-05 Response to statin therapy / / 20339536 rs11938295 chr4 77739602 A G 8.20E-04 White matter integrity / / 22425255 rs7677682 chr4 77740367 A G 4.90E-05 Response to statin therapy / / 20339536 rs17002240 chr4 77742277 G A 4.90E-05 Response to statin therapy / / 20339536 rs11097539 chr4 77754140 A G 3.99E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10518159 chr4 77763998 C T 1.10E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10518159 chr4 77763998 C T 9.32E-04 Epilepsy / / 22116939 rs10518159 chr4 77763998 C T 2.23E-05 IgA nephropathy / / 22197929 rs1994854 chr4 77767645 C T 9.40E-05 Longevity and age-related phenotypes / / 17903295 rs1994854 chr4 77767645 C T 2.10E-04 Lung adenocarcinoma / / 21242121 rs17002253 chr4 77771345 T C 7.00E-06 Adverse response to lamotrigine and phenytoin / / 22379998 rs17002253 chr4 77771345 T C 9.34E-05 Orofacial clefts / / 22419666 rs6829573 chr4 77773610 G A 5.12E-05 Hearing function / / 17255346 rs2703130 chr4 77817874 G T 0.000042 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SOWAHB missense 22628534 rs2703126 chr4 77819842 T C 0.00003 Nicotine dependence (smoking) / / 22377092 rs904050 chr4 77826089 T G 0.0000247 Nicotine dependence (smoking) / / 22377092 rs11722689 chr4 77863211 C T 0.00001 Composite episodic memory score / / 22865056 rs2645668 chr4 77889994 T C 7.25E-08 CD8+ T cell IFN-gamma response to smallpox vaccine SEPT11 intron 22661280 rs6836567 chr4 77916705 A C 3.93E-04 Schizophrenia SEPT11 intron 18282107 rs4859731 chr4 77943171 T C 1.33E-09 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SEPT11 intron 20877124 rs17002331 chr4 77946817 C T 7.15E-04 Type 2 diabetes SEPT11 intron 17463246 rs6824360 chr4 77949096 G A 4.01E-04 Smoking quantity SEPT11 intron 24665060 rs17002342 chr4 77955205 T A 9.00E-06 Waist-to-hip circumference ratio (interaction) SEPT11 intron 23192594 rs4241602 chr4 77987351 A G 6.90E-04 Suicide attempts in bipolar disorder CCNI intron 21423239 rs4252773 chr4 77995945 C T 1.21E-04 Smoking quantity CCNI intron 24665060 rs6817626 chr4 78005837 G T 4.58E-05 Smoking quantity / / 24665060 rs13133761 chr4 78054449 G T 0.000115 Salmonella-induced pyroptosis / / 22837397 rs7659891 chr4 78063308 A G 9.14E-04 Type 2 diabetes / / 17463246 rs80050370 chr4 78064728 T C 0.00001212 Sarcoidosis / / 22952805 rs4150060 chr4 78080963 C T 0.00001318 Sarcoidosis CCNG2 intron 22952805 rs4150092 chr4 78086900 T C 0.00001408 Sarcoidosis CCNG2 intron 22952805 rs4150099 chr4 78088106 G T 0.000002808 Sarcoidosis CCNG2 UTR-3 22952805 rs6823048 chr4 78103744 G A 0.00008838 Sarcoidosis / / 22952805 rs11937061 chr4 78136933 G T 2.00E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs41375744 chr4 78169507 G A 6.99E-04 Multiple complex diseases / / 17554300 rs736600 chr4 78181403 T C 3.89E-05 Blood Pressure / / pha003044 rs1862359 chr4 78182037 G T 3.51E-05 Bipolar disorder,schizoaffective / / 19567891 rs10518169 chr4 78186392 A G 3.04E-05 Bipolar disorder,schizoaffective / / 19567891 rs2059102 chr4 78186989 T A 5.22E-05 Bipolar disorder,schizoaffective / / 19567891 rs2059103 chr4 78187007 G A 4.61E-05 Bipolar disorder,schizoaffective / / 19567891 rs2059104 chr4 78188859 C G 5.25E-05 Bipolar disorder,schizoaffective / / 19567891 rs2059105 chr4 78188874 G C 4.73E-05 Bipolar disorder,schizoaffective / / 19567891 rs2059106 chr4 78189012 G C 5.52E-05 Bipolar disorder,schizoaffective / / 19567891 rs2042229 chr4 78191324 T G 6.28E-05 Bipolar disorder,schizoaffective / / 19567891 rs17395298 chr4 78192172 G A 7.29E-05 Bipolar disorder,schizoaffective / / 19567891 rs10491463 chr4 78192318 T C 1.49E-05 Meningococcal disease / / 20694013 rs2194126 chr4 78192948 A C 5.22E-05 Bipolar disorder,schizoaffective / / 19567891 rs10518170 chr4 78193913 A G 1.12E-04 Epilepsy / / 22116939 rs4475169 chr4 78193995 C T 8.81E-05 Bipolar disorder,schizoaffective / / 19567891 rs4484325 chr4 78195865 G T 9.64E-05 Bipolar disorder,schizoaffective / / 19567891 rs4241616 chr4 78196785 C G 5.43E-05 Bipolar disorder,schizoaffective / / 19567891 rs1988614 chr4 78209129 A G 7.97E-05 Bipolar disorder,schizoaffective / / 19567891 rs10017165 chr4 78209902 G A 6.06E-05 Bipolar disorder,schizoaffective / / 19567891 rs10010146 chr4 78210975 A G 5.83E-05 Bipolar disorder,schizoaffective / / 19567891 rs9307260 chr4 78211121 A G 5.94E-05 Bipolar disorder,schizoaffective / / 19567891 rs4608831 chr4 78211347 T C 7.40E-05 Bipolar disorder,schizoaffective / / 19567891 rs2866045 chr4 78211504 T A 5.41E-05 Bipolar disorder,schizoaffective / / 19567891 rs4859481 chr4 78211666 A C 4.75E-05 Bipolar disorder,schizoaffective / / 19567891 rs888982 chr4 78214065 A G 5.83E-05 Bipolar disorder,schizoaffective / / 19567891 rs10012774 chr4 78226107 C T 4.63E-05 Bipolar disorder,schizoaffective / / 19567891 rs10034292 chr4 78226266 G A 1.05E-04 Bipolar disorder,schizoaffective / / 19567891 rs9991953 chr4 78226351 G A 5.60E-05 Bipolar disorder,schizoaffective / / 19567891 rs17397057 chr4 78228237 A C 6.15E-05 Bipolar disorder,schizoaffective / / 19567891 rs4859783 chr4 78232961 C A 2.99E-05 Bipolar disorder,schizoaffective / / 19567891 rs4859787 chr4 78233346 C G 3.71E-05 Bipolar disorder,schizoaffective / / 19567891 rs960507 chr4 78233856 A G 2.37E-05 Bipolar disorder,schizoaffective / / 19567891 rs17397262 chr4 78234279 G T 2.19E-05 Bipolar disorder,schizoaffective / / 19567891 rs4859790 chr4 78234762 T C 2.89E-05 Bipolar disorder,schizoaffective / / 19567891 rs2042231 chr4 78236618 A T 5.22E-05 Bipolar disorder,schizoaffective / / 19567891 rs2042233 chr4 78236821 C A 2.88E-05 Bipolar disorder,schizoaffective / / 19567891 rs4859487 chr4 78237955 G A 3.93E-04 Myopia (pathological) / / 21095009 rs4859488 chr4 78237977 G A 2.94E-05 Bipolar disorder,schizoaffective / / 19567891 rs752062 chr4 78240303 A G 3.10E-05 Bipolar disorder,schizoaffective / / 19567891 rs2194117 chr4 78250120 C T 5.74E-05 Bipolar disorder,schizoaffective / / 19567891 rs2194118 chr4 78250159 C T 3.74E-05 Bipolar disorder,schizoaffective / / 19567891 rs35735379 chr4 78250159 C CG 3.74E-05 Bipolar disorder,schizoaffective / / 19567891 rs71214348 chr4 78250159 C CG 3.74E-05 Bipolar disorder,schizoaffective / / 19567891 rs4859809 chr4 78250653 C T 2.05E-05 Bipolar disorder,schizoaffective / / 19567891 rs12645407 chr4 78255427 C G 2.20E-05 Bipolar disorder,schizoaffective / / 19567891 rs17002568 chr4 78269396 T C 1.89E-04 Multiple complex diseases / / 17554300 rs17002568 chr4 78269396 T C 8.31E-05 Triglycerides / / pha003081 rs6849731 chr4 78273333 T C 4.51E-05 Triglycerides / / pha003081 rs1559121 chr4 78276420 G T 6.05E-05 Triglycerides / / pha003081 rs10034168 chr4 78280329 G T 6.42E-05 Triglycerides / / pha003081 rs9307270 chr4 78306419 A G 1.51E-04 Lung cancer / / 19414679 rs7682075 chr4 78327333 G A 9.17E-05 Celiac disease / / 23936387 rs17002672 chr4 78333798 C T 9.60E-05 Triglycerides / / pha003081 rs7677281 chr4 78341660 T C 5.54E-06 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7677281 chr4 78341660 T C 6.00E-06 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7690148 chr4 78366365 T G 3.58E-05 Multiple complex diseases / / 17554300 rs17002686 chr4 78367793 C T 6.64E-04 Multiple complex diseases / / 17554300 rs17414505 chr4 78418785 A G 3.94E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10518177 chr4 78420568 C T 8.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs6826277 chr4 78420654 G T 2.52E-06 Carotenoid and tocopherol levels / / 19185284 rs10518176 chr4 78480180 C A 1.00E-05 Multiple complex diseases CXCL13 intron 17554300 rs171388 chr4 78521525 C T 3.44E-05 Lung cancer CXCL13 intron 18978787 rs2270857 chr4 78527309 G C 1.37E-04 Type 2 diabetes CXCL13 intron 17463246 rs958617 chr4 78605369 A G 3.00E-07 Tuberculosis / / 24057671 rs1909938 chr4 78612162 G C 9.00E-06 Iron levels / / 21208937 rs17448536 chr4 78632991 G C 6.20E-04 Type 2 diabetes / / 17463246 rs2102116 chr4 78672168 C T 1.09E-04 Alcohol consumption CNOT6L intron 23743675 rs9307306 chr4 78697786 T C 3.80E-05 Body mass index CNOT6L intron 20818722 rs6828302 chr4 78740132 G C 1.02E-04 Alcohol consumption CNOT6L intron 23743675 rs17002816 chr4 78748751 C T 2.57E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs1996740 chr4 78748977 A G 4.53E-04 Type 2 diabetes / / 17463246 rs1996740 chr4 78748977 A G 1.70E-06 Urinary metabolites / / 21572414 rs2866688 chr4 78749042 G A 9.99E-05 Alcohol consumption / / 23743675 rs9996218 chr4 78750500 A G 9.87E-05 Alcohol consumption / / 23743675 rs17002824 chr4 78759026 G C 1.05E-04 Alcohol consumption / / 23743675 rs11939576 chr4 78761998 A G 6.99E-05 Alcohol consumption / / 23743675 rs7698627 chr4 78774181 C T 5.40E-04 Type 2 diabetes / / 17463246 rs7698627 chr4 78774181 C T 7.51E-04 Multiple complex diseases / / 17554300 rs6854895 chr4 78851940 T G 5.64E-05 Type 2 diabetes MRPL1 intron 17463246 rs6533344 chr4 78852682 C T 1.61E-04 Type 2 diabetes MRPL1 intron 17463246 rs6533344 chr4 78852682 C T 6.75E-04 Multiple complex diseases MRPL1 intron 17554300 rs4577601 chr4 78858515 A G 1.53E-04 Type 2 diabetes MRPL1 intron 17463246 rs4577601 chr4 78858515 A G 9.13E-04 Multiple complex diseases MRPL1 intron 17554300 rs1021826 chr4 78917350 G A 2.11E-04 Type 2 diabetes / / 17463246 rs1021826 chr4 78917350 G A 2.76E-04 Multiple complex diseases / / 17554300 rs4859894 chr4 78918906 C T 2.13E-04 Multiple complex diseases / / 17554300 rs4859902 chr4 78943483 G A 9.74E-06 Central corneal thickness / / 20719862 rs10002506 chr4 78944944 G A 9.80E-06 Central corneal thickness / / 20719862 rs1546318 chr4 78949372 G T 1.38E-05 Cognitive impairment induced by topiramate / / 22091778 rs1393644 chr4 78956707 C A 2.76E-05 Cognitive impairment induced by topiramate / / 22091778 rs12645713 chr4 78958674 G A 7.39E-04 Alzheimer's disease / / 22005930 rs17002887 chr4 78962008 T C 2.30E-26 Narcolepsy / / 19629137 rs1502878 chr4 78962047 G T 7.21E-04 Alzheimer's disease / / 22005930 rs11098030 chr4 78962154 T C 6.96E-04 Alzheimer's disease / / 22005930 rs7663408 chr4 78964075 C A 5.98E-04 Alzheimer's disease / / 22005930 rs1875649 chr4 78967046 T C 7.37E-04 Alzheimer's disease / / 22005930 rs7699042 chr4 78967598 G C 7.58E-04 Alzheimer's disease / / 22005930 rs1502877 chr4 78968798 G T 8.86E-04 Alzheimer's disease / / 22005930 rs7656678 chr4 78970864 T C 2.80E-04 Scoliosis / / 21216876 rs7677984 chr4 78974867 A C 7.12E-06 Body Mass Index / / pha003007 rs7677984 chr4 78974867 A C 6.16E-05 Body Mass Index / / pha003014 rs7677984 chr4 78974867 A C 1.81E-05 Body Fat Distribution / / pha003016 rs7677984 chr4 78974867 A C 5.45E-05 Body Fat Distribution / / pha003017 rs7677984 chr4 78974867 A C 3.27E-05 Body Fat Distribution / / pha003018 rs7677984 chr4 78974867 A C 9.18E-05 Body Mass Index / / pha003019 rs7677984 chr4 78974867 A C 3.25E-06 Waist Circumference / / pha003025 rs7677984 chr4 78974867 A C 4.08E-05 Weight / / pha003027 rs7677984 chr4 78974867 A C 3.95E-07 Hypertension / / pha003041 rs1910301 chr4 78975137 A G 5.76E-05 Multiple complex diseases / / 17554300 rs1502885 chr4 78986514 A T 6.34E-05 Aortic root size FRAS1 intron 21223598 rs873455 chr4 78989939 G A 1.86E-05 Aortic root size FRAS1 intron 21223598 rs873454 chr4 78990229 C A 1.10E-04 Aortic root size FRAS1 intron 21223598 rs6843142 chr4 79002597 G A 8.37E-04 Myopia (pathological) FRAS1 intron 21095009 rs13106755 chr4 79019831 T C 7.54E-05 Serum metabolites FRAS1 intron 19043545 rs17002949 chr4 79050852 G A 2.68E-04 Multiple complex diseases FRAS1 intron 17554300 rs17002961 chr4 79060115 G A 8.48E-04 Multiple complex diseases FRAS1 intron 17554300 rs17002988 chr4 79079757 C T 6.00E-06 Uric acid levels FRAS1 intron 23703922 rs17003021 chr4 79098129 T G 8.25E-05 HIV-1 control FRAS1 intron 20041166 rs7689878 chr4 79106472 C G 7.37E-04 Multiple complex diseases FRAS1 intron 17554300 rs9993864 chr4 79112544 G A 7.54E-05 Multiple complex diseases FRAS1 intron 17554300 rs17003069 chr4 79157696 G T 3.85E-05 Multiple complex diseases FRAS1 intron 17554300 rs6833721 chr4 79162934 A G 2.10E-05 Urinary metabolites FRAS1 intron 21572414 rs6533565 chr4 79184338 T G 0.0000424 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity FRAS1 intron 22945461 rs6533573 chr4 79199503 A T 6.00E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) FRAS1 intron 22566498 rs10008653 chr4 79215430 C T 4.00E-06 Parkinson's disease (interaction with coffee consumption) FRAS1 intron 21876681 rs41537644 chr4 79229435 C G 1.31E-04 Type 2 diabetes FRAS1 intron 17463246 rs168283 chr4 79234317 G A 2.21E-05 Lung function (forced vital capacity) FRAS1 intron pha003104 rs11724700 chr4 79245028 G A 4.50E-05 Response to lithium treatment in bipolar disorder FRAS1 intron 19448189 rs13103319 chr4 79250710 A T 1.16E-06 Hair morphology FRAS1 intron 19896111 rs454598 chr4 79261745 C A,G,T 3.20E-06 Hair morphology FRAS1 intron 19896111 rs366463 chr4 79262696 G A 9.99E-05 Cognitive test performance FRAS1 intron 20125193 rs2008485 chr4 79276588 A G 3.14E-06 Hair morphology FRAS1 intron 19896111 rs17003153 chr4 79277748 T A,G 5.89E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs447200 chr4 79280088 T C 7.47E-08 Hair morphology FRAS1 intron 19896111 rs393285 chr4 79280192 G T 3.38E-06 Hair morphology FRAS1 intron 19896111 rs1268789 chr4 79280693 T C 7.00E-08 Hair morphology FRAS1 intron 19896111 rs431907 chr4 79281028 G A 7.40E-08 Hair morphology FRAS1 intron 19896111 rs375726 chr4 79281750 T C 7.38E-08 Hair morphology FRAS1 intron 19896111 rs120233 chr4 79282348 A G 7.62E-08 Hair morphology FRAS1 intron 19896111 rs22078 chr4 79282532 G C 7.86E-08 Hair morphology FRAS1 intron 19896111 rs1385131 chr4 79282759 G A 8.12E-08 Hair morphology FRAS1 intron 19896111 rs529184 chr4 79283403 T C 8.39E-08 Hair morphology FRAS1 intron 19896111 rs345546 chr4 79283595 A G 8.45E-08 Hair morphology FRAS1 intron 19896111 rs345545 chr4 79283643 G T 8.23E-08 Hair morphology FRAS1 intron 19896111 rs345544 chr4 79283711 A T 8.28E-08 Hair morphology FRAS1 intron 19896111 rs2100484 chr4 79284276 C T 9.42E-06 Hair morphology FRAS1 intron 19896111 rs6833805 chr4 79284428 G T 9.43E-06 Hair morphology FRAS1 intron 19896111 rs17003161 chr4 79285399 A G 7.03E-04 Multiple complex diseases FRAS1 intron 17554300 rs17003161 chr4 79285399 A G 7.52E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs6837091 chr4 79285958 T C 7.61E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs6832281 chr4 79286167 A G 7.56E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs12643932 chr4 79287374 G A 7.51E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs12641891 chr4 79287396 T C 7.55E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs12641245 chr4 79287553 A T 6.59E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs12641246 chr4 79287560 A C 6.01E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs11098154 chr4 79287577 C A 7.63E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs11936477 chr4 79287890 G A 7.73E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs345542 chr4 79288238 C A 4.22E-06 Hair morphology FRAS1 intron 19896111 rs4859926 chr4 79288246 C A 7.28E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs11934555 chr4 79288694 T C 7.49E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs11934756 chr4 79289155 T C 7.44E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs1563259 chr4 79290689 A G 7.60E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs11098159 chr4 79291413 A T 7.23E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs11098161 chr4 79291668 A G 7.15E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs17003167 chr4 79292398 T C 5.66E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs6817887 chr4 79294528 G C 1.22E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs7687731 chr4 79295156 A G 2.55E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs6821458 chr4 79296444 A G 3.80E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs10033307 chr4 79304226 T G 9.08E-06 Hair morphology FRAS1 intron 19896111 rs12511790 chr4 79314264 A T 8.89E-05 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs12643648 chr4 79324480 T C,G 2.23E-05 Major depressive disorder FRAS1 intron 20516156 rs2054722 chr4 79350115 C T 9.44E-06 Hair morphology FRAS1 intron 19896111 rs2035511 chr4 79352460 A G 9.09E-06 Hair morphology FRAS1 intron 19896111 rs1484331 chr4 79355189 A G 4.37E-06 Hair morphology FRAS1 intron 19896111 rs6816851 chr4 79357782 G A 4.88E-06 Hair morphology FRAS1 intron 19896111 rs2903470 chr4 79359009 C G 4.91E-06 Hair morphology FRAS1 intron 19896111 rs7699000 chr4 79363536 G C 5.10E-06 Hair morphology FRAS1 intron 19896111 rs2867068 chr4 79365522 A G 5.16E-06 Hair morphology FRAS1 intron 19896111 rs2867070 chr4 79368674 G T 5.17E-06 Hair morphology FRAS1 intron 19896111 rs11730871 chr4 79368816 T C 5.14E-06 Hair morphology FRAS1 intron 19896111 rs4975067 chr4 79369767 C A 5.15E-06 Hair morphology FRAS1 intron 19896111 rs959539 chr4 79372693 T G 5.17E-06 Hair morphology FRAS1 intron 19896111 rs10026662 chr4 79372856 A C 5.19E-06 Hair morphology FRAS1 intron 19896111 rs753752 chr4 79372930 C T 5.10E-06 Hair morphology FRAS1 cds-synon 19896111 rs2645143 chr4 79375037 G A 4.66E-06 Hair morphology FRAS1 intron 19896111 rs2645144 chr4 79375372 A G 4.46E-06 Hair morphology FRAS1 intron 19896111 rs2645145 chr4 79375400 A G 4.38E-06 Hair morphology FRAS1 intron 19896111 rs1496584 chr4 79375590 G A 4.24E-06 Hair morphology FRAS1 intron 19896111 rs2627650 chr4 79376907 T C 4.08E-06 Hair morphology FRAS1 intron 19896111 rs1496583 chr4 79376996 T C 3.98E-06 Hair morphology FRAS1 intron 19896111 rs1496582 chr4 79377184 C T 3.88E-06 Hair morphology FRAS1 intron 19896111 rs1496581 chr4 79377191 A C 3.81E-06 Hair morphology FRAS1 intron 19896111 rs2627656 chr4 79377889 T C 3.70E-06 Hair morphology FRAS1 intron 19896111 rs12649822 chr4 79378360 A G 7.95E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs2645149 chr4 79378538 A G 3.52E-06 Hair morphology FRAS1 intron 19896111 rs2627654 chr4 79378809 G A 3.44E-06 Hair morphology FRAS1 intron 19896111 rs1484342 chr4 79379425 C T 3.51E-06 Hair morphology FRAS1 intron 19896111 rs2627651 chr4 79382893 G A 3.56E-06 Hair morphology FRAS1 intron 19896111 rs2627653 chr4 79386276 A G 4.14E-06 Hair morphology FRAS1 intron 19896111 rs1027444 chr4 79393874 A G 3.13E-06 Hair morphology FRAS1 intron 19896111 rs949507 chr4 79394086 G A 3.17E-06 Hair morphology FRAS1 intron 19896111 rs17409828 chr4 79402688 G A 7.07E-04 Suicide attempts in bipolar disorder FRAS1 intron 21423239 rs7674053 chr4 79417863 G A 4.37E-06 Hair morphology FRAS1 intron 19896111 rs3749482 chr4 79465559 G A 2.76E-04 Amyotrophic lateral sclerosis (sporadic) FRAS1 nearGene-3 24529757 rs10028001 chr4 79502972 T A 1.20E-05 Rheumatoid arthritis ANXA3 intron 24390342 rs10028001 chr4 79502972 T A 3.40E-04 Rheumatoid arthritis ANXA3 intron 24390342 rs7679218 chr4 79506864 G T 5.00E-06 Amyotrophic lateral sclerosis (sporadic) ANXA3 intron 24529757 rs2867461 chr4 79513215 A G 1.00E-12 Rheumatoid arthritis ANXA3 intron 22446963 rs11733269 chr4 79527009 G A 5.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ANXA3 intron 20877124 rs7661370 chr4 79528957 G T 3.56E-04 Multiple complex diseases ANXA3 intron 17554300 rs41440045 chr4 79540050 G A 7.18E-27 Narcolepsy / / 19629137 rs10007186 chr4 79589045 C T 1.00E-09 Non-albumin protein levels LOC100505702 intron 22558069 rs41441244 chr4 79676810 T C 6.84E-14 Multiple complex diseases / / 17554300 rs7688534 chr4 79753495 T C 8.00E-06 Urinary metabolites BMP2K intron 21572414 rs13150370 chr4 79887043 T C 3.05E-05 Asthma / / 22561531 rs10030550 chr4 79895323 G A 2.31E-04 Osteoarthritis LOC100505875 intron 19508968 rs1545806 chr4 79914339 A G 7.25E-07 Height LOC100505875 intron 22021425 rs1545805 chr4 79914407 A G 2.48E-05 Height LOC100505875 intron 22021425 rs10518211 chr4 79937065 C T 8.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100505875 intron 20877124 rs899900 chr4 79939533 G C 6.66E-07 Height LOC100505875 intron 22021425 rs2086429 chr4 79942524 C G 2.94E-05 Height LOC100505875 intron 22021425 rs6828210 chr4 79943623 C T 2.75E-05 Height LOC100505875 intron 22021425 rs4975155 chr4 79945418 A G 4.02E-08 Multiple complex diseases LOC100505875 intron 17554300 rs1466475 chr4 79956703 A G 4.05E-04 Type 2 diabetes LOC100505875 intron 17463246 rs1455311 chr4 79964587 A G 1.30E-32 Pancreatic cancer LOC100505875 intron 21849791 rs1455311 chr4 79964587 A G 7.65E-12 Pelvic organ prolapse LOC100505875 intron 22105264 rs1455310 chr4 79965691 G A 2.97E-04 Type 2 diabetes LOC100505875 intron 17463246 rs41431044 chr4 79966335 T A 5.69E-04 Multiple complex diseases LOC100505875 intron 17554300 rs2622351 chr4 79981840 C T 4.18E-05 Height LOC100505875 intron 22021425 rs1584984 chr4 80060207 G A 7.85E-04 Obesity (extreme) LOC100505875 intron 21935397 rs11733517 chr4 80062229 A G 7.79E-04 Obesity (extreme) LOC100505875 intron 21935397 rs1037589 chr4 80067067 G T 7.76E-04 Obesity (extreme) LOC100505875 intron 21935397 rs4975160 chr4 80071626 T C 7.69E-04 Obesity (extreme) LOC100505875 intron 21935397 rs10518214 chr4 80085942 C T 6.01E-04 Obesity (extreme) LOC100505875 intron 21935397 rs9790513 chr4 80086448 A C 3.92E-04 Obesity (extreme) LOC100505875 intron 21935397 rs9790513 chr4 80086448 A C 2.90E-04 Coronary heart disease LOC100505875 intron 21966275 rs1455308 chr4 80091507 C T 1.30E-05 Personality dimensions LOC100505875 intron 22628180 rs11729140 chr4 80092116 C T 1.29E-05 Personality dimensions LOC100505875 intron 22628180 rs7662055 chr4 80093828 A C 1.30E-05 Personality dimensions LOC100505875 intron 22628180 rs4975161 chr4 80098425 C T 1.30E-05 Personality dimensions LOC100505875 intron 22628180 rs7356447 chr4 80100104 G A 1.39E-05 Personality dimensions LOC100505875 intron 22628180 rs2010696 chr4 80108859 C G 9.28E-04 Obesity (extreme) LOC100505875 intron 21935397 rs7676343 chr4 80126234 G A 1.44E-04 Multiple complex diseases LOC100505875 intron 17554300 rs4975166 chr4 80127066 C T 3.16E-04 Multiple complex diseases LOC100505875 intron 17554300 rs6534293 chr4 80202960 A G 2.30E-05 Urinary metabolites LOC100505875 intron 21572414 rs17494639 chr4 80218062 T C 1.24E-04 Alzheimer's disease LOC100505875 intron 24755620 rs2903619 chr4 80281513 C A 5.50E-04 Type 2 diabetes / / 23209189 rs11733010 chr4 80283393 G A 2.70E-04 Type 2 diabetes / / 23209189 rs9992718 chr4 80311834 T C 2.10E-04 Type 2 diabetes / / 23209189 rs11930550 chr4 80317724 A T 8.39E-04 Multiple complex diseases / / 17554300 rs10049840 chr4 80332039 C A 2.80E-04 Osteoarthritis / / 19508968 rs9993773 chr4 80434604 G A 2.00E-04 Cognitive impairment induced by topiramate LOC100506035 intron 22091778 rs12502383 chr4 80435307 C T 4.89E-04 Prostate cancer mortality LOC100506035 intron 20978177 rs2165387 chr4 80491820 T C 1.96E-04 Alcohol dependence LOC100506035 intron 20201924 rs9307551 chr4 80530671 A C 1.00E-08 Refractive error / / 23396134 rs13120966 chr4 80544474 T C 9.28E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1371990 chr4 80545715 C T 2.85E-04 Multiple complex diseases / / 17554300 rs10518224 chr4 80564508 G A 7.00E-06 Quantitative traits / / 19197348 rs11933401 chr4 80567753 T C 1.10E-06 Urinary metabolites / / 21572414 rs10518221 chr4 80570500 T C 3.00E-07 Urinary metabolites / / 21572414 rs4470656 chr4 80576083 A G 5.10E-04 Type 2 diabetes / / 17463246 rs13123790 chr4 80598796 A G 0.000107659 Hypertension (early onset hypertension) / / 22479346 rs13123790 chr4 80598796 A G 3.04E-05 Body Mass Index / / pha003007 rs13123790 chr4 80598796 A G 8.20E-05 Body Mass Index / / pha003015 rs13123790 chr4 80598796 A G 5.88E-05 Weight / / pha003027 rs4504285 chr4 80604343 C T 7.16E-05 Hypertension (early onset hypertension) / / 22479346 rs4504285 chr4 80604343 C T 3.04E-05 Body Mass Index / / pha003007 rs4504285 chr4 80604343 C T 8.20E-05 Body Mass Index / / pha003015 rs4504285 chr4 80604343 C T 5.88E-05 Weight / / pha003027 rs6842379 chr4 80606743 T C 2.62E-05 Body Mass Index / / pha003007 rs6842379 chr4 80606743 T C 8.54E-05 Weight / / pha003026 rs6842379 chr4 80606743 T C 3.15E-06 Weight / / pha003027 rs4308382 chr4 80615151 G A 3.21E-05 Body Mass Index / / pha003006 rs4308382 chr4 80615151 G A 1.27E-06 Body Mass Index / / pha003007 rs4308382 chr4 80615151 G A 3.44E-05 Body Mass Index / / pha003009 rs4308382 chr4 80615151 G A 9.52E-07 Waist Circumference / / pha003024 rs4308382 chr4 80615151 G A 4.73E-05 Waist Circumference / / pha003025 rs4308382 chr4 80615151 G A 2.01E-06 Weight / / pha003026 rs4308382 chr4 80615151 G A 5.59E-07 Weight / / pha003027 rs7690868 chr4 80651081 A G 4.00E-05 Body Mass Index / / pha003006 rs7690868 chr4 80651081 A G 1.80E-06 Body Mass Index / / pha003007 rs7690868 chr4 80651081 A G 3.32E-05 Body Mass Index / / pha003009 rs7690868 chr4 80651081 A G 9.60E-07 Waist Circumference / / pha003024 rs7690868 chr4 80651081 A G 5.27E-05 Waist Circumference / / pha003025 rs7690868 chr4 80651081 A G 2.54E-06 Weight / / pha003026 rs7690868 chr4 80651081 A G 7.60E-07 Weight / / pha003027 rs7657079 chr4 80652842 A G 4.68E-06 Body Mass Index / / pha003007 rs7657079 chr4 80652842 A G 6.00E-05 Body Mass Index / / pha003009 rs7657079 chr4 80652842 A G 9.71E-05 Body Fat Distribution / / pha003018 rs7657079 chr4 80652842 A G 2.60E-05 Waist Circumference / / pha003025 rs7657079 chr4 80652842 A G 3.68E-05 Weight / / pha003026 rs7657079 chr4 80652842 A G 2.47E-07 Weight / / pha003027 rs3935850 chr4 80663590 G A 8.09E-05 Bipolar disorder / / 22925353 rs6810531 chr4 80664563 A G 4.64E-04 Coronary Artery Disease / / 17634449 rs6832698 chr4 80664649 G A 1.37E-06 Coronary Artery Disease / / 17634449 rs13129268 chr4 80669947 A G 4.10E-06 Body Mass Index / / pha003007 rs13129268 chr4 80669947 A G 7.28E-05 Body Fat Distribution / / pha003018 rs13129268 chr4 80669947 A G 1.33E-05 Waist Circumference / / pha003025 rs13129268 chr4 80669947 A G 7.96E-05 Weight / / pha003026 rs13129268 chr4 80669947 A G 1.43E-07 Weight / / pha003027 rs13134009 chr4 80675751 A C 3.03E-06 Body Mass Index / / pha003007 rs13134009 chr4 80675751 A C 7.13E-05 Body Fat Distribution / / pha003016 rs13134009 chr4 80675751 A C 7.14E-05 Body Fat Distribution / / pha003017 rs13134009 chr4 80675751 A C 4.06E-05 Body Fat Distribution / / pha003018 rs13134009 chr4 80675751 A C 1.11E-05 Waist Circumference / / pha003025 rs13134009 chr4 80675751 A C 9.10E-05 Weight / / pha003026 rs13134009 chr4 80675751 A C 1.43E-07 Weight / / pha003027 rs17004232 chr4 80678253 G T 4.62E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11730157 chr4 80679143 A C 1.43E-05 Body Mass Index / / pha003007 rs11730157 chr4 80679143 A C 2.61E-05 Waist Circumference / / pha003025 rs11730157 chr4 80679143 A C 5.31E-07 Weight / / pha003027 rs7665764 chr4 80681293 G A 2.74E-06 Body Mass Index / / pha003007 rs7665764 chr4 80681293 G A 9.29E-05 Body Fat Distribution / / pha003018 rs7665764 chr4 80681293 G A 9.54E-05 Waist Circumference / / pha003024 rs7665764 chr4 80681293 G A 3.88E-06 Waist Circumference / / pha003025 rs7665764 chr4 80681293 G A 3.50E-05 Weight / / pha003026 rs7665764 chr4 80681293 G A 4.15E-08 Weight / / pha003027 rs4285108 chr4 80688257 C T 9.73E-06 Type 2 diabetes / / 17463246 rs6534560 chr4 80688396 A G 2.76E-06 Body Mass Index / / pha003007 rs6534560 chr4 80688396 A G 9.91E-05 Body Fat Distribution / / pha003017 rs6534560 chr4 80688396 A G 6.77E-05 Body Fat Distribution / / pha003018 rs6534560 chr4 80688396 A G 9.15E-05 Waist Circumference / / pha003024 rs6534560 chr4 80688396 A G 2.74E-06 Waist Circumference / / pha003025 rs6534560 chr4 80688396 A G 3.91E-05 Weight / / pha003026 rs6534560 chr4 80688396 A G 4.06E-08 Weight / / pha003027 rs7673654 chr4 80696259 A G 1.51E-06 Body Mass Index / / pha003007 rs7673654 chr4 80696259 A G 8.24E-05 Body Fat Distribution / / pha003016 rs7673654 chr4 80696259 A G 8.29E-05 Body Fat Distribution / / pha003017 rs7673654 chr4 80696259 A G 5.40E-05 Body Fat Distribution / / pha003018 rs7673654 chr4 80696259 A G 6.41E-05 Waist Circumference / / pha003024 rs7673654 chr4 80696259 A G 1.13E-06 Waist Circumference / / pha003025 rs7673654 chr4 80696259 A G 3.10E-05 Weight / / pha003026 rs7673654 chr4 80696259 A G 1.62E-08 Weight / / pha003027 rs17004362 chr4 80706062 C T 6.43E-04 Multiple complex diseases / / 17554300 rs11931463 chr4 80731390 T A 9.08E-04 Type 2 diabetes / / 17463246 rs11943513 chr4 80743976 G A 9.46E-05 Weight / / pha003027 rs10031299 chr4 80753792 T C 6.69E-04 Alcohol dependence GDEP intron 20201924 rs7680943 chr4 80758914 G A 3.39E-04 Myocardial Infarction GDEP intron pha002883 rs10014970 chr4 80770939 G A 7.55E-06 Body Mass Index GDEP intron pha003007 rs10014970 chr4 80770939 G A 9.16E-05 Body Fat Distribution GDEP intron pha003018 rs10014970 chr4 80770939 G A 1.03E-05 Waist Circumference GDEP intron pha003025 rs10014970 chr4 80770939 G A 1.36E-06 Weight GDEP intron pha003027 rs6857026 chr4 80773461 C T 1.10E-04 Bone mineral density (BMD),in women GDEP intron 20164292 rs4271959 chr4 80778464 A G 4.20E-05 Body Mass Index GDEP intron pha003007 rs4271959 chr4 80778464 A G 4.20E-05 Weight GDEP intron pha003027 rs10011562 chr4 80799867 G A 8.27E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs11931136 chr4 80807604 A G 3.94E-04 Multiple complex diseases / / 17554300 rs6847975 chr4 80812960 G A 5.40E-06 Body Mass Index / / pha003007 rs6847975 chr4 80812960 G A 1.27E-05 Waist Circumference / / pha003024 rs6847975 chr4 80812960 G A 1.34E-05 Weight / / pha003026 rs6847975 chr4 80812960 G A 7.12E-07 Weight / / pha003027 rs13107909 chr4 80816350 G A 8.39E-04 Alzheimer's disease / / 17998437 rs10008294 chr4 80816695 T C 9.93E-04 Multiple complex diseases / / 17554300 rs11939401 chr4 80818417 T C 0.000000097 Myopia (Age of onset) / / 23468642 rs7690697 chr4 80836126 G C 1.87E-04 Arthritis (juvenile idiopathic) ANTXR2 intron 22354554 rs4234847 chr4 80850758 A C 2.40E-05 Arthritis (juvenile idiopathic) ANTXR2 intron 22354554 rs4234848 chr4 80850805 G A 9.91E-05 Serum metabolites ANTXR2 intron 19043545 rs4234848 chr4 80850805 G A 2.77E-23 Narcolepsy ANTXR2 intron 19629137 rs11098948 chr4 80856622 G C 1.70E-05 Urinary metabolites ANTXR2 intron 21572414 rs12508279 chr4 80886020 T A 1.20E-05 Urinary metabolites ANTXR2 intron 21572414 rs4389526 chr4 80946475 T A 9.00E-08 Ankylosing spondylitis ANTXR2 intron 21743469 rs4640621 chr4 80946541 A C 8.13E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ANTXR2 intron 20031582 rs4333130 chr4 80949829 C T 6.21E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ANTXR2 intron 20031582 rs4333130 chr4 80949829 C T 9.00E-08 Ankylosing spondylitis ANTXR2 intron 20062062 rs2867702 chr4 81060836 A G 8.23E-04 Bipolar disorder / / 19259986 rs12513014 chr4 81061422 A G 0.0000138 Alcohol dependence / / 23089632 rs13129263 chr4 81068101 G A 9.21E-06 Substance dependence phenotypes / / 24832863 rs2867695 chr4 81073220 C T 9.03E-04 Rheumatoid arthritis / / 21452313 rs13102102 chr4 81073672 T C 0.0000111 Alcohol dependence / / 23089632 rs13102102 chr4 81073672 T C 0.0000137 Alcohol dependence / / 23089632 rs11934233 chr4 81079445 C T 1.50E-05 Urinary metabolites / / 21572414 rs13138779 chr4 81087073 G A 0.00000975 Alcohol dependence / / 23089632 rs13138779 chr4 81087073 G A 0.000769 Alcohol dependence / / 23089632 rs13138779 chr4 81087073 G A 7.99E-06 Substance dependence phenotypes / / 24832863 rs1458031 chr4 81153922 T C 4.15E-04 Heart Failure / / pha002885 rs7682543 chr4 81154975 C T 5.47E-04 Type 2 diabetes / / 17463246 rs13149993 chr4 81158545 G A 7.23E-04 Type 2 diabetes / / 17463246 rs13149993 chr4 81158545 G A 2.55E-11 Blood pressure / / 21909110 rs13149993 chr4 81158545 G A 2.39E-04 Blood pressure / / 24001895 rs1458038 chr4 81164723 C T 3.00E-14 Blood pressure / / 21909110 rs1458038 chr4 81164723 C T 2.00E-23 Systolic blood pressure / / 21909115 rs1458038 chr4 81164723 C T 9.00E-25 Diastolic blood pressure / / 21909115 rs11099098 chr4 81169912 G T 7.00E-07 Urate levels / / 23263486 rs11099098 chr4 81169912 G T 2.00E-11 Blood pressure / / 24954895 rs11099098 chr4 81169912 G T 9.00E-08 Blood pressure / / 24954895 rs16998073 chr4 81184341 A T 1.00E-21 Diastolic blood pressure / / 19430483 rs16998073 chr4 81184341 A T 1.00E-21 Coronary heart disease / / 21347282 rs16998073 chr4 81184341 A T 1.00E-21 Blood pressure / / 21378095 rs16998073 chr4 81184341 A T 3.10E-05 Blood pressure / / 21572416 rs16998073 chr4 81184341 A T 4.53E-13 Blood pressure / / 21909110 rs17004857 chr4 81185974 G A 7.58E-04 Prostate cancer mortality FGF5 nearGene-5 20978177 rs112475347 chr4 81188221 G T 0.000024 Breast cancer FGF5 missense 23555315 rs17004865 chr4 81198248 A T 3.83E-04 Multiple complex diseases FGF5 intron 17554300 rs7683390 chr4 81202382 C T 2.90E-05 Urinary metabolites FGF5 intron 21572414 rs2867734 chr4 81228936 C T 9.10E-05 Information processing speed / / 21130836 rs2867709 chr4 81250441 C A 9.10E-05 Alcoholism (heaviness of drinking) / / 21529783 rs6534884 chr4 81288696 C T 4.16E-05 Bipolar disorder,affective C4orf22 intron 20528957 rs17004924 chr4 81445307 G A 7.36E-06 Obesity-related traits C4orf22 intron 23251661 rs1843563 chr4 81454827 G A 9.53E-06 Odorant perception C4orf22 intron 23910658 rs11935979 chr4 81472341 T A 6.75E-04 Multiple complex diseases C4orf22 intron 17554300 rs1486020 chr4 81504292 G A 3.89E-05 Multiple complex diseases C4orf22 cds-synon 17554300 rs1385890 chr4 81535393 G A 4.00E-06 Obesity-related traits C4orf22 intron 23251661 rs10025495 chr4 81540089 G A 4.70E-06 Urinary metabolites C4orf22 intron 21572414 rs4693532 chr4 81549972 G A 7.75E-06 Lipoproteins C4orf22 intron pha003079 rs13136169 chr4 81552878 C T 5.98E-06 Obesity-related traits C4orf22 intron 23251661 rs756237 chr4 81581498 G A 1.00E-04 Prostate cancer C4orf22 intron 21743057 rs10516646 chr4 81605788 G A 1.00E-04 Prostate cancer C4orf22 intron 21743057 rs7662939 chr4 81631326 T C 8.79E-05 Multiple complex diseases C4orf22 intron 17554300 rs17539130 chr4 81677206 A G 9.58E-05 Bipolar disorder C4orf22 intron 17486107 rs2867785 chr4 81712449 C T 2.60E-05 Urinary metabolites C4orf22 intron 21572414 rs13112477 chr4 81775935 T C 5.84E-04 Multiple complex diseases C4orf22 intron 17554300 rs7673771 chr4 81819074 C T 6.61E-04 Type 2 diabetes C4orf22 intron 17463246 rs17005004 chr4 81842668 A G 7.00E-05 Socioeconomic Factors C4orf22 intron pha003066 rs17005010 chr4 81871730 A C 7.38E-04 Multiple complex diseases C4orf22 intron 17554300 rs17005013 chr4 81874643 T A 4.89E-06 Multiple complex diseases C4orf22 intron 17554300 rs1012617 chr4 81877939 T C 3.23E-05 Socioeconomic Factors C4orf22 intron pha003066 rs11946008 chr4 81925707 T A 1.38E-05 Cognitive decline / / 23732972 rs1960445 chr4 81930814 C T 1.00E-06 Refractive error / / 23396134 rs2868128 chr4 81943068 C T 2.97E-04 Cognitive decline / / 23732972 rs17005023 chr4 81945159 T A 8.58E-04 Multiple complex diseases / / 17554300 rs17005024 chr4 81945383 A G 1.29E-05 Cognitive decline / / 23732972 rs5022942 chr4 81959966 A G 1.40E-10 Myopia (Age of onset) BMP3 intron 23468642 rs1495634 chr4 81963418 T C 1.90E-05 Urinary metabolites BMP3 intron 21572414 rs10516736 chr4 81968487 T C 5.10E-05 Electrocardiographic traits and heart rate variability BMP3 intron 17903306 rs13141362 chr4 81968914 A G 9.50E-06 Urinary metabolites BMP3 intron 21572414 rs17005034 chr4 81969769 C T 4.30E-07 Urinary metabolites BMP3 intron 21572414 rs9307778 chr4 81971241 A G 4.93E-04 Multiple complex diseases BMP3 intron 17554300 rs7659948 chr4 81979993 T C 6.99E-04 Aortic root size / / 21223598 rs7659948 chr4 81979993 T C 2.00E-05 Urinary metabolites / / 21572414 rs7659948 chr4 81979993 T C 9.70E-04 Insulin resistance / / 21901158 rs2685471 chr4 81981592 A G 7.87E-05 Serum metabolites / / 19043545 rs2643921 chr4 81986784 G A 8.68E-04 Multiple complex diseases / / 17554300 rs2685468 chr4 81989503 G C 8.52E-04 Multiple complex diseases / / 17554300 rs3796804 chr4 82009707 G T 9.00E-06 HIV-1 susceptibility / / 22174851 rs980720 chr4 82053063 C T 1.25E-05 Type 2 diabetes PRKG2 intron 17846126 rs3733550 chr4 82073295 C T 3.52E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs6828114 chr4 82081988 T C 3.49E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs11722020 chr4 82083217 T C 3.47E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs751296 chr4 82086345 G A 7.81E-05 Potassium levels PRKG2 intron pha003086 rs1517547 chr4 82093190 C T 3.31E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs1546651 chr4 82094045 C T 3.31E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs1546651 chr4 82094045 C T 6.03E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs1972127 chr4 82094069 G A 3.31E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs1972127 chr4 82094069 G A 7.98E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs11933194 chr4 82094546 C T 3.32E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs3943629 chr4 82095000 A T 3.33E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs3943629 chr4 82095000 A T 8.11E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs1545287 chr4 82095146 G A 3.43E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs10516650 chr4 82096820 C A 3.66E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs10516651 chr4 82097451 C T 3.84E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs10003341 chr4 82097777 A C 4.30E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs10005912 chr4 82097836 T G 4.55E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs11099460 chr4 82100660 C A 5.29E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs3733552 chr4 82114303 C G 2.83E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs3733552 chr4 82114303 C G 5.42E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs4149 chr4 82118352 C T 3.15E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs4149 chr4 82118352 C T 6.82E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs7656323 chr4 82120029 T C 7.32E-05 Potassium levels PRKG2 intron pha003086 rs984924 chr4 82120912 A G 6.64E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs984924 chr4 82120912 A G 7.47E-04 Suicide attempts in bipolar disorder PRKG2 intron 21041247 rs41332544 chr4 82124334 A G 7.34E-04 Multiple complex diseases PRKG2 intron 17554300 rs989445 chr4 82133264 C A 3.88E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs710839 chr4 82134787 T C 8.80E-08 Height / / 21998595 rs1662853 chr4 82144926 C G 1.00E-07 Pubertal anthropometrics / / 23449627 rs710841 chr4 82149831 C T 2.00E-06 Height / / 18391951 rs710841 chr4 82149831 C T 2.00E-08 Height / / 19343178 rs710841 chr4 82149831 C T 4.30E-08 Height / / 21998595 rs788867 chr4 82150006 T G 9.00E-28 Height / / 20881960 rs1662840 chr4 82156409 C T 7.30E-09 Height / / 21998595 rs994014 chr4 82165790 T C 6.12E-05 Height / / 17255346 rs994014 chr4 82165790 T C 8.00E-10 Height / / 21998595 rs1115919 chr4 82173397 C T 1.22E-04 Height / / 17255346 rs1115919 chr4 82173397 C T 3.92E-05 Height / / 22021425 rs1443536 chr4 82174165 A G 2.30E-05 Height / / 22021425 rs1961460 chr4 82174498 G A 1.72E-05 Height / / 17255346 rs1878528 chr4 82184234 A G 4.00E-18 Height / / 23563607 rs1901568 chr4 82187030 T C 2.82E-05 Height / / 17255346 rs10488936 chr4 82212170 A C 4.92E-05 Height / / 17255346 rs2011962 chr4 82220324 A C 1.04E-04 Height / / 17255346 rs17499299 chr4 82222389 C T 2.07E-04 Height / / 17255346 rs2034632 chr4 82225114 C T 1.33E-04 Height / / 17255346 rs2034629 chr4 82226349 A G 4.43E-05 Height / / 17255346 rs17427571 chr4 82254908 A G 7.90E-06 Height / / 17255346 rs11731567 chr4 82270069 G A 3.36E-04 Height / / 17255346 rs11725731 chr4 82271434 C T 2.41E-04 Height / / 17255346 rs2109662 chr4 82272565 G A 1.65E-04 Height / / 17255346 rs7696324 chr4 82276881 G A 1.51E-05 Height / / 17255346 rs1473160 chr4 82279399 G A 2.77E-05 Height / / 17255346 rs11725587 chr4 82292376 A G 3.36E-04 Height / / 17255346 rs17427971 chr4 82304359 A G 3.30E-04 Height / / 17255346 rs17500100 chr4 82324437 A G 1.06E-05 Height / / 22021425 rs10488929 chr4 82332475 C T 2.06E-17 Varicose Veins / / pha001414 rs11542053 chr4 82347658 C A 3.29E-06 Lipid traits / / 21777205 rs755527 chr4 82368236 T C 2.03E-05 Intracerebral hemorrhage RASGEF1B intron 24656865 rs1077802 chr4 82369160 C T 2.73E-05 Intracerebral hemorrhage RASGEF1B intron 24656865 rs1077803 chr4 82369205 T A 2.73E-05 Intracerebral hemorrhage RASGEF1B intron 24656865 rs28409763 chr4 82369494 G T 2.67E-05 Intracerebral hemorrhage RASGEF1B intron 24656865 rs1562138 chr4 82372610 T C 1.17E-05 Intracerebral hemorrhage RASGEF1B intron 24656865 rs9307783 chr4 82374847 A G 2.54E-05 Intracerebral hemorrhage RASGEF1B intron 24656865 rs17558056 chr4 82375936 T C 3.29E-06 Lipid traits RASGEF1B intron 21777205 rs2120817 chr4 82376938 C A 1.85E-05 Intracerebral hemorrhage RASGEF1B intron 24656865 rs748436 chr4 82381627 C T 7.22E-06 Intracerebral hemorrhage RASGEF1B intron 24656865 rs6535252 chr4 82390465 A T 4.89E-04 Multiple complex diseases RASGEF1B intron 17554300 rs6840449 chr4 82427419 G A 1.98E-05 Cognitive test performance / / 20125193 rs882043 chr4 82430252 C A 3.58E-05 Cognitive test performance / / 20125193 rs4437240 chr4 82432069 C A,G,T 8.14E-04 Alcohol dependence / / 21314694 rs17005153 chr4 82432524 A G 2.51E-04 Celiac disease / / 23936387 rs13144325 chr4 82434740 T C 4.98E-05 Cognitive test performance / / 20125193 rs13144325 chr4 82434740 T C 2.76E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1822818 chr4 82462597 T C 6.00E-06 Major depressive disorder / / 23377640 rs10016319 chr4 82500097 G A 7.34E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs10776517 chr4 82552200 T C 2.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs4574400 chr4 82608844 T A 6.88E-04 Multiple complex diseases / / 17554300 rs6535272 chr4 82609850 G C 7.67E-04 Multiple complex diseases / / 17554300 rs6817583 chr4 82610728 A T 9.61E-04 Multiple complex diseases / / 17554300 rs6535273 chr4 82616045 T C 2.80E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs13116901 chr4 82624148 C T 7.10E-05 Insulin-related traits / / pha003063 rs10020406 chr4 82629383 G A 7.05E-05 Insulin Resistance / / pha003062 rs10020406 chr4 82629383 G A 1.68E-05 Insulin-related traits / / pha003063 rs4279197 chr4 82643924 G C 9.60E-04 Parkinson's disease / / 17052657 rs669908 chr4 82727097 G A 5.52E-04 Multiple complex diseases / / 17554300 rs669481 chr4 82727177 T C 9.27E-04 Multiple complex diseases / / 17554300 rs555028 chr4 82727198 C T 9.62E-04 Multiple complex diseases / / 17554300 rs653923 chr4 82728376 T G 8.28E-04 Multiple complex diseases / / 17554300 rs6535280 chr4 82738099 A G 8.76E-04 Coronary heart disease / / 21971053 rs10516664 chr4 82739324 T C 6.75E-04 Coronary heart disease / / 21971053 rs590971 chr4 82745501 T C 4.95E-04 Multiple complex diseases / / 17554300 rs506322 chr4 82748458 C T 8.10E-04 Multiple complex diseases / / 17554300 rs604488 chr4 82751372 A C 8.67E-04 Multiple complex diseases / / 17554300 rs570360 chr4 82760169 A G 2.65E-06 Odorant perception / / 23910658 rs1993798 chr4 82762741 A G 1.82E-04 Coronary Artery Disease / / 17634449 rs6535281 chr4 82763010 C T 1.61E-04 Coronary Artery Disease / / 17634449 rs6535281 chr4 82763010 C T 6.78E-05 Bipolar disorder and schizophrenia / / 20889312 rs1824657 chr4 82783136 C T 2.18E-05 Bipolar disorder and schizophrenia / / 20889312 rs7663795 chr4 82812093 A G 6.02E-04 Coronary Artery Disease / / 17634449 rs4693009 chr4 82812532 C G 9.34E-04 Coronary Artery Disease / / 17634449 rs11722328 chr4 82818968 T A 7.60E-05 Coronary Artery Disease / / 17634449 rs10024084 chr4 82819140 C T 8.68E-05 Coronary Artery Disease / / 17634449 rs2199487 chr4 82820008 A G 3.61E-04 Coronary Artery Disease / / 17634449 rs11099506 chr4 82827598 A C 5.83E-05 Coronary Artery Disease / / 17634449 rs1020909 chr4 82830274 G A 4.15E-05 Coronary Artery Disease / / 17634449 rs10516668 chr4 82843970 G A 3.65E-04 Type 2 diabetes / / 17463246 rs6827298 chr4 82865928 A T 3.70E-04 Multiple complex diseases / / 17554300 rs320751 chr4 82872289 G A 4.28E-05 Coronary Artery Disease / / 17634449 rs1381795 chr4 82892052 A G 3.30E-06 Type 2 diabetes / / 17463246 rs1381795 chr4 82892052 A G 6.28E-05 Post-operative nausea and vomiting / / 21694509 rs400801 chr4 82893548 A G 2.41E-06 Coronary Artery Disease / / 17634449 rs423461 chr4 82893845 C T 1.97E-06 Coronary Artery Disease / / 17634449 rs10034564 chr4 82902304 T A 1.63E-04 Arthritis (juvenile idiopathic) / / 22354554 rs1036945 chr4 82906362 C T 9.22E-05 Coronary Artery Disease / / 17634449 rs4411986 chr4 82919801 A G 2.61E-04 Type 2 diabetes / / 17463246 rs10004744 chr4 82925416 G A 3.71E-04 Type 2 diabetes / / 17463246 rs6815297 chr4 82925989 G A 4.05E-04 Type 2 diabetes / / 17463246 rs6535291 chr4 82926694 G A 2.29E-04 Type 2 diabetes / / 17463246 rs1443764 chr4 82927188 A C 2.29E-04 Type 2 diabetes / / 17463246 rs4693414 chr4 82933477 G C 5.05E-06 Type 2 diabetes / / 17463246 rs7695454 chr4 82936650 G C 3.89E-04 Type 2 diabetes / / 17463246 rs7695454 chr4 82936650 G C 5.42E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9996185 chr4 82947537 G C 9.65E-06 Coronary Artery Disease / / 17634449 rs17005319 chr4 82954563 T C 4.28E-05 Multiple complex diseases / / 17554300 rs1003176 chr4 82956997 G A 5.34E-05 Multiple complex diseases / / 17554300 rs1562030 chr4 82962095 G A 3.30E-05 Diabetic retinopathy / / 21441570 rs1443777 chr4 82963186 C T 3.30E-05 Diabetic retinopathy / / 21441570 rs1899694 chr4 82968364 T C 5.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4693418 chr4 82981181 T C 6.78E-04 Type 2 diabetes / / 17463246 rs17005351 chr4 82981713 T C 9.60E-05 Diabetic retinopathy / / 21441570 rs1443781 chr4 82982670 T A 9.30E-05 Diabetic retinopathy / / 21441570 rs6846172 chr4 82985138 C T 9.20E-05 Diabetic retinopathy / / 21441570 rs1027273 chr4 82985699 T A 9.20E-05 Diabetic retinopathy / / 21441570 rs17005374 chr4 82986224 G C 9.20E-05 Diabetic retinopathy / / 21441570 rs9996085 chr4 82990008 C T 8.80E-05 Diabetic retinopathy / / 21441570 rs10010220 chr4 82990379 A G 8.90E-05 Diabetic retinopathy / / 21441570 rs17005381 chr4 82991177 A G 6.78E-04 Type 2 diabetes / / 17463246 rs6852265 chr4 82993613 T G 9.20E-05 Diabetic retinopathy / / 21441570 rs10516671 chr4 82994010 T C 9.20E-05 Diabetic retinopathy / / 21441570 rs1470337 chr4 82994314 A G 8.90E-05 Diabetic retinopathy / / 21441570 rs7671713 chr4 82994642 C T 9.00E-05 Diabetic retinopathy / / 21441570 rs12510329 chr4 82995274 T G 8.14E-04 Smoking initiation / / 24665060 rs13119377 chr4 83003206 C T 1.41E-04 Coronary Artery Disease / / 17634449 rs2035912 chr4 83007475 C T 3.79E-05 Longevity / / 20304771 rs2035912 chr4 83007475 C T 2.20E-05 Diabetic retinopathy / / 21441570 rs11736136 chr4 83018274 A G 6.40E-06 Diabetic retinopathy / / 21441570 rs6535306 chr4 83024429 T C 5.84E-04 Tourette syndrome / / 22889924 rs2011786 chr4 83028150 G A 5.98E-04 Tourette syndrome / / 22889924 rs4550918 chr4 83054449 G T 7.34E-05 Relative hand skill in reading disability / / 24068947 rs7680149 chr4 83062441 A T 5.08E-04 Type 2 diabetes / / 17463246 rs6825436 chr4 83085123 T C 9.61E-06 Relative hand skill in reading disability / / 24068947 rs2101680 chr4 83096524 C T 6.68E-05 Lung adenocarcinoma / / 19836008 rs7660665 chr4 83164184 G A 8.36E-04 Rheumatoid arthritis / / 21452313 rs6815242 chr4 83189631 A G 5.67E-04 Insulin resistance / / 21901158 rs6839784 chr4 83247933 C T 5.04E-06 Height / / 22021425 rs10516672 chr4 83264760 T A 9.27E-05 Type 2 diabetes / / 17463246 rs3762885 chr4 83305278 G T 4.53E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs17005633 chr4 83321808 C T 6.26E-05 Type 2 diabetes and other traits / / 19734900 rs17005669 chr4 83374848 T A 2.24E-04 Type 2 diabetes ENOPH1 intron 17463246 rs1980187 chr4 83378872 G T 3.47E-04 Type 2 diabetes ENOPH1 intron 17463246 rs873931 chr4 83421896 T C 9.38E-05 Cognitive test performance TMEM150C intron 20125193 rs7658637 chr4 83499313 C T 6.00E-07 Cognitive performance / / 20125193 rs11099542 chr4 83513790 T C 0.00073691 Hypertension (early onset hypertension) / / 22479346 rs6837562 chr4 83556408 T C 2.80E-04 Alzheimer's disease (late onset) SCD5 intron 21379329 rs6813901 chr4 83565150 G A 3.11E-04 Alzheimer's disease (late onset) SCD5 intron 21379329 rs17005974 chr4 83569061 T C 3.81E-04 Multiple complex diseases SCD5 intron 17554300 rs1317366 chr4 83569708 G A 4.23E-05 Multiple complex diseases SCD5 intron 17554300 rs7679857 chr4 83569737 A T 9.99E-04 Multiple complex diseases SCD5 intron 17554300 rs17005996 chr4 83570300 T C 5.72E-04 Multiple complex diseases SCD5 intron 17554300 rs7661056 chr4 83570779 G A 4.61E-05 Myocardial Infarction SCD5 intron pha002883 rs7684732 chr4 83575832 A C 6.76E-04 Multiple complex diseases SCD5 intron 17554300 rs17006038 chr4 83575907 C G 7.90E-04 Multiple complex diseases SCD5 intron 17554300 rs4693046 chr4 83576378 T C 1.39E-39 Metabolite levels SCD5 intron 22286219 rs6822801 chr4 83576829 G A 2.15E-04 Alzheimer's disease (late onset) SCD5 intron 21379329 rs10030631 chr4 83596745 T C 5.90E-05 Major depressive disorder SCD5 intron 21042317 rs17353688 chr4 83613357 C T 7.07E-04 Suicide attempts in bipolar disorder SCD5 intron 21423239 rs13106297 chr4 83613632 G C 7.62E-04 Smoking initiation SCD5 intron 24665060 rs17006135 chr4 83616978 T C 6.98E-04 Myocardial Infarction SCD5 intron pha002883 rs12500169 chr4 83644726 C G 6.98E-04 Alcohol dependence SCD5 intron 21314694 rs17006173 chr4 83647622 G A 7.51E-05 Tuberculosis SCD5 intron 24057671 rs1880716 chr4 83647739 A G 7.77E-06 Left ventricular mass SCD5 intron 21212386 rs951500 chr4 83659028 T C 3.65E-06 Phospholipid levels (plasma) SCD5 intron 21829377 rs11732247 chr4 83680552 G A 1.35E-05 Cardiovascular disease SCD5 intron pha003065 rs13120210 chr4 83688665 T C 6.74E-04 Multiple complex diseases SCD5 intron 17554300 rs4256218 chr4 83690679 T C 3.84E-04 Multiple complex diseases SCD5 intron 17554300 rs1980360 chr4 83694283 G A 1.22E-04 HIV-1 viral setpoint SCD5 intron 17641165 rs11722062 chr4 83696412 G A 2.60E-04 Multiple complex diseases SCD5 intron 17554300 rs11099549 chr4 83697854 C T 5.22E-04 Multiple complex diseases SCD5 intron 17554300 rs3897960 chr4 83701791 T A 4.96E-04 Multiple complex diseases SCD5 intron 17554300 rs1967623 chr4 83715793 C T 2.80E-05 Urinary metabolites SCD5 intron 21572414 rs10516679 chr4 83722608 G A 9.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10516679 chr4 83722608 G A 7.00E-04 Kidney function and endocine traits / / 17903292 rs4314275 chr4 83760957 G A 7.30E-08 Lymphocyte counts SEC31A intron 22286170 rs10516682 chr4 83893751 A G 6.40E-04 Type 2 diabetes and 6 quantitative traits LIN54 intron 17848626 rs7679711 chr4 84053233 T C 5.08E-04 Type 2 diabetes / / 17463246 rs12640334 chr4 84070303 T C 8.84E-05 Orofacial clefts / / 22419666 rs4693573 chr4 84099324 C T 8.39E-04 Type 2 diabetes / / 17463246 rs2868760 chr4 84100592 C A 8.67E-05 Cognitive impairment induced by topiramate / / 22091778 rs2868760 chr4 84100592 C A 2.96E-04 Heart Failure / / pha002884 rs12508182 chr4 84130153 T C 6.21E-04 Acute lymphoblastic leukemia (childhood) / / 22076464 rs6841907 chr4 84146996 T C 2.55E-05 Bipolar disorder / / 19488044 rs17352615 chr4 84151064 C T 2.25E-04 Multiple complex diseases / / 17554300 rs6840620 chr4 84153610 T C 7.70E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4590012 chr4 84161522 C T 7.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10029426 chr4 84172399 C A 1.40E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6535450 chr4 84179480 G A 1.88E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4693596 chr4 84189869 C T 1 Drug response to Statins COQ2 intron 17376224 rs11099590 chr4 84224498 T G 1.37E-04 Progressive supranuclear palsy HPSE intron 21685912 rs150258114 chr4 84227441 C T 0.000023 Breast cancer (ER positive) HPSE missense 23555315 rs11099592 chr4 84230619 T C 9.44E-06 Post-operative nausea and vomiting HPSE missense 21694509 rs6535458 chr4 84233449 T C 9.06E-06 Post-operative nausea and vomiting HPSE intron 21694509 rs7670729 chr4 84246090 A G 3.45E-04 Response to statin treatment (atorvastatin),change in cholesterol levels HPSE intron 20031582 rs4320128 chr4 84287807 A G 9.78E-05 Left ventricular hypertrophy / / pha003052 rs12650866 chr4 84295261 A C 2.93E-04 Body mass index / / 17255346 rs4365717 chr4 84351284 C T 4.99E-04 Multiple complex diseases HELQ intron 17554300 rs6817280 chr4 84361071 G A 7.07E-04 Multiple complex diseases HELQ missense 17554300 rs4693625 chr4 84366367 G A 7.05E-04 Parkinson's disease HELQ intron 17052657 rs4693089 chr4 84373622 A G 2.00E-19 Menopause (age at onset) HELQ intron 22267201 rs6821899 chr4 84374229 G A 7.02E-05 Multiple complex diseases HELQ intron 17554300 rs1494961 chr4 84374480 C T 8.37E-04 Type 2 diabetes HELQ missense 17463246 rs1494961 chr4 84374480 C T 6.00E-05 Lung cancer HELQ missense 18978790 rs1494961 chr4 84374480 C T 6.25E-04 Premature ovarian failure HELQ missense 19508998 rs1494961 chr4 84374480 C T 1.00E-08 Upper aerodigestive tract cancers HELQ missense 21437268 rs10516687 chr4 84376443 T C 6.44E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers HELQ intron 21775533 rs3182340 chr4 84377203 C T 1.56E-05 Personality dimensions MRPS18C UTR-5 18957941 rs3182340 chr4 84377203 C T 1.60E-05 Personality dimensions MRPS18C UTR-5 21173776 rs11930653 chr4 84426584 C T 6.04E-04 Type 2 diabetes / / 17463246 rs1980271 chr4 84439820 G A 1.97E-04 Type 2 diabetes / / 17463246 rs572400 chr4 84450747 G A 0.00000981 Stroke / / 23422753 rs17355209 chr4 84453308 C A 9.91E-06 Post-operative nausea and vomiting / / 21694509 rs17355209 chr4 84453308 C A 7.10E-05 Lung function (forced vital capacity) / / 24023788 rs6535481 chr4 84455601 G A 7.13E-04 Premature ovarian failure / / 19508998 rs17355265 chr4 84461507 C T 8.40E-05 Personality dimensions AGPAT9 intron 18957941 rs10516690 chr4 84465613 C T 3.70E-04 Breast cancer and prostate cancer AGPAT9 intron 17903305 rs10516690 chr4 84465613 C T 1.20E-05 Personality dimensions AGPAT9 intron 18957941 rs10032581 chr4 84467747 G A 1.50E-05 Personality dimensions AGPAT9 intron 18957941 rs781430 chr4 84539360 G A 4.24E-05 Panic disorder / / 19165232 rs1458642 chr4 84562362 T G 4.61E-05 Cortisol secretion,in saliva / / 21316860 rs10026591 chr4 84578707 G A 0.000542 Asthma / / 22502797 rs41512947 chr4 84586376 C T 9.50E-04 Multiple complex diseases / / 17554300 rs11099613 chr4 84589904 T C 5.91E-04 Alzheimer's disease / / 17998437 rs11099613 chr4 84589904 T C 9.91E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17356080 chr4 84591041 G A 9.91E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12643503 chr4 84593841 T C 9.91E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17007149 chr4 84598254 A G 9.24E-04 HIV-1 viral setpoint / / 17641165 rs6823695 chr4 84605155 C G 9.62E-04 Multiple complex diseases / / 17554300 rs1458649 chr4 84658591 T C 3.27E-04 Multiple complex diseases / / 17554300 rs6815226 chr4 84691811 G A 1.00E-04 Prostate cancer / / 21743057 rs7679666 chr4 84706464 A G 1.00E-04 Prostate cancer / / 21743057 rs1116649 chr4 84720914 A G 3.74E-05 Hearing function / / 17255346 rs4693646 chr4 84721814 A G 9.00E-06 Obesity-related traits / / 23251661 rs977594 chr4 84731960 G A 2.87E-05 Hearing function / / 17255346 rs12054512 chr4 84733572 A G 2.26E-04 Hearing function / / 17255346 rs10018145 chr4 84750283 A G 3.32E-04 Multiple complex diseases / / 17554300 rs10003040 chr4 84779091 C T 5.01E-04 Hemoglobin concentration / / 20534544 rs1505792 chr4 84784665 T C 7.15E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10021381 chr4 84790267 C T 4.57E-04 Hemoglobin concentration / / 20534544 rs10027658 chr4 84792278 C T 5.42E-06 Height / / 22021425 rs1154956 chr4 84795993 G A 3.01E-04 Tourette syndrome / / 22889924 rs9332469 chr4 84838068 T C 6.72E-04 Multiple complex diseases / / 17554300 rs17007739 chr4 84841250 T G 4.77E-07 Autism / / 22843504 rs4693661 chr4 84857956 G A 3.12E-04 Body mass index / / 21701565 rs4693661 chr4 84857956 G A 3.36E-04 Body mass index / / 21701565 rs3913795 chr4 84902522 C T 0.0000678 Panic disorder / / 23149450 rs3913795 chr4 84902522 C T 6.78E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs9999681 chr4 84902964 C T 4.93E-05 Triglycerides / / pha002904 rs1921886 chr4 84950278 A C 1.35E-05 Odorant perception / / 23910658 rs1921877 chr4 84962653 T C 7.40E-04 Multiple complex diseases / / 17554300 rs1921889 chr4 85089301 G A 6.66E-04 Multiple complex diseases / / 17554300 rs17008234 chr4 85090876 A G 9.68E-05 Multiple complex diseases / / 17554300 rs1532358 chr4 85159891 G A 3.18E-05 Coronary heart disease / / pha003031 rs1532357 chr4 85160070 T C 2.62E-05 Coronary heart disease / / pha003031 rs17008878 chr4 85165195 G A 4.29E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs348701 chr4 85165381 G A 2.21E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs17008416 chr4 85174676 G A 6.80E-07 Brain derived neurotrophic factor levels,in serum / / 22047184 rs17008418 chr4 85174971 G C 6.97E-07 Brain derived neurotrophic factor levels,in serum / / 22047184 rs13131541 chr4 85176082 T C 9.95E-07 Brain derived neurotrophic factor levels,in serum / / 22047184 rs13107419 chr4 85179393 T C 9.45E-07 Brain derived neurotrophic factor levels,in serum / / 22047184 rs13108923 chr4 85180049 T C 9.43E-07 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1495142 chr4 85180857 G A 9.41E-07 Brain derived neurotrophic factor levels,in serum / / 22047184 rs13124982 chr4 85182881 A T 1.27E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1596144 chr4 85184515 G A 1.28E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1390086 chr4 85188394 T C 1.29E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1495140 chr4 85189712 G A 1.47E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1495138 chr4 85190648 C G 1.48E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs13131476 chr4 85192989 G A 1.55E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs17008469 chr4 85195715 G A 1.55E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1992467 chr4 85197642 G A 1.92E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs2165618 chr4 85198099 A C 1.91E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs13122718 chr4 85203880 C T 2.24E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6858150 chr4 85204621 C T 6.91E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1495151 chr4 85205214 G A 9.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs13141237 chr4 85206085 A G 2.23E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs17008523 chr4 85214642 G T 1.72E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1472292 chr4 85229612 A G 5.39E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7678707 chr4 85233038 A T 2.55E-04 Multiple complex diseases / / 17554300 rs7694261 chr4 85239755 T G 2.99E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7654197 chr4 85240664 T C 8.95E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7660492 chr4 85241536 T C 9.16E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7673792 chr4 85243537 T C 9.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs7673792 chr4 85243537 T C 3.70E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6535533 chr4 85244005 A G 9.63E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6832343 chr4 85244426 A G 3.84E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs17008585 chr4 85248800 T C 3.54E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs17008592 chr4 85249352 A T 3.57E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1390088 chr4 85249487 C A 4.34E-05 Multiple sclerosis / / 17660530 rs17008601 chr4 85249751 C T 3.57E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1822222 chr4 85261370 T C 3.95E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6857631 chr4 85262808 G A 9.64E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs11945202 chr4 85263676 C T 9.35E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6841642 chr4 85265750 G A 9.74E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1899391 chr4 85268820 C T 9.35E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1899392 chr4 85268860 G A 9.68E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs17008637 chr4 85271434 G T 9.33E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs2868879 chr4 85273102 C G 2.10E-04 Multiple sclerosis / / 17660530 rs6817184 chr4 85277790 A G 5.78E-04 Schizophrenia / / 19197363 rs6857050 chr4 85289117 A G 1.30E-04 Myocardial Infarction / / pha002883 rs1442173 chr4 85294388 C T 8.95E-04 Schizophrenia / / 19197363 rs402672 chr4 85301481 T G 5.50E-04 Alzheimer's disease / / 24755620 rs385194 chr4 85309078 A G 1.71E-05 Tunica Media / / pha003036 rs7663470 chr4 85339890 C T 2.96E-04 Alzheimer's disease / / 24755620 rs962305 chr4 85357398 G A 4.40E-04 Insulin resistance / / 21901158 rs1444975 chr4 85363428 G A 7.37E-04 Alzheimer's disease / / 24755620 rs752402 chr4 85368880 G A 3.31E-04 Alzheimer's disease / / 24755620 rs1444957 chr4 85377040 C T 3.40E-04 Alzheimer's disease / / 24755620 rs1017559 chr4 85379704 T G 7.07E-04 Alzheimer's disease / / 24755620 rs17009038 chr4 85430800 G A 7.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6812841 chr4 85447672 A G 7.70E-06 Suicidal ideation / / 20877300 rs6535539 chr4 85458301 C G 2.10E-05 Urinary metabolites / / 21572414 rs6535540 chr4 85458579 T C 2.10E-05 Urinary metabolites / / 21572414 rs17009114 chr4 85468070 C T 2.10E-05 Urinary metabolites / / 21572414 rs1373668 chr4 85468682 A G 2.10E-05 Urinary metabolites / / 21572414 rs1373666 chr4 85468897 C T 2.10E-05 Urinary metabolites / / 21572414 rs6535543 chr4 85479865 C T 2.10E-05 Urinary metabolites / / 21572414 rs6826780 chr4 85479990 A G 2.00E-05 Urinary metabolites / / 21572414 rs17009158 chr4 85480494 G T 2.10E-05 Urinary metabolites / / 21572414 rs13134659 chr4 85482049 G C 1.40E-05 Urinary metabolites / / 21572414 rs10776519 chr4 85491267 A G 5.59E-04 Type 2 diabetes / / 22158537 rs2120091 chr4 85537825 C G 4.51E-04 Bipolar disorder CDS1 intron 19259986 rs6829806 chr4 85558840 A C 8.10E-05 Blood Pressure and Arterial Stiffness CDS1 intron 17903302 rs13108722 chr4 85634488 T C 3.59E-04 Alzheimer's disease (late onset) WDFY3 intron 21379329 rs2015631 chr4 85637635 T C 2.40E-05 Duodenal ulcer WDFY3 intron 22387998 rs10516726 chr4 85640424 T C 8.24E-04 Type 2 diabetes WDFY3 intron 17463246 rs6825852 chr4 85662060 T C 3.28E-04 Alzheimer's disease (late onset) WDFY3 intron 21379329 rs894533 chr4 85664294 C T 3.12E-05 Duodenal ulcer WDFY3 intron 22387998 rs12511112 chr4 85676099 C T 6.24E-04 Type 2 diabetes WDFY3 intron 17463246 rs6821491 chr4 85713972 T C 8.41E-04 Multiple complex diseases WDFY3 intron 17554300 rs1484662 chr4 85734049 G A 3.12E-05 Duodenal ulcer WDFY3 intron 22387998 rs1872321 chr4 85770794 C T 6.19E-27 Multiple complex diseases WDFY3 intron 17554300 rs11726635 chr4 85782946 G A 2.05E-04 Amyotrophic Lateral Sclerosis WDFY3 intron 17362836 rs11726635 chr4 85782946 G A 3.12E-05 Duodenal ulcer WDFY3 intron 22387998 rs10516733 chr4 85844157 G A 3.07E-05 Duodenal ulcer WDFY3 intron 22387998 rs12510410 chr4 85866802 T C 4.94E-04 Type 2 diabetes WDFY3 intron 17463246 rs6847811 chr4 85867313 C G 4.60E-04 Type 2 diabetes WDFY3 intron 17463246 rs6820517 chr4 85870625 C T 4.50E-04 Alzheimer's disease (late onset) WDFY3 intron 21379329 rs7699226 chr4 85877561 T C 4.88E-04 Type 2 diabetes WDFY3 intron 17463246 rs4590017 chr4 85898741 G A 8.28E-05 Major depressive disorder WDFY3-AS2 intron 19107115 rs4590017 chr4 85898741 G A 3.92E-04 Alzheimer's disease (late onset) WDFY3-AS2 intron 21379329 rs4533765 chr4 85915570 C T 3.45E-05 Major depressive disorder WDFY3-AS2 intron 19107115 rs6531783 chr4 85932343 C T 4.41E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs4461518 chr4 86036146 A G 9.55E-04 Type 2 diabetes / / 17463246 rs6820757 chr4 86044561 T C 7.55E-04 Smoking initiation / / 24665060 rs4280720 chr4 86088554 A G 6.69E-04 Schizophrenia / / 19197363 rs12507778 chr4 86098946 C A 6.04E-04 Schizophrenia / / 19197363 rs6854963 chr4 86102478 T C 8.73E-04 Type 2 diabetes / / 17463246 rs7691216 chr4 86129616 T G 7.00E-06 IgG glycosylation / / 23382691 rs6818991 chr4 86153942 A G 1.55E-04 Schizophrenia / / 19197363 rs2869282 chr4 86157765 A G 4.95E-04 Schizophrenia / / 19197363 rs4639062 chr4 86166611 C T 5.29E-04 Smoking initiation / / 24665060 rs6825968 chr4 86177991 A G 4.18E-04 Gallstones / / 17632509 rs1563060 chr4 86191312 G A 3.90E-04 Smoking initiation / / 24665060 rs7699990 chr4 86222796 C T 9.40E-05 Parkinson's disease (familial) / / 18985386 rs585787 chr4 86257453 T C 4.09E-04 Smoking initiation / / 24665060 rs7660532 chr4 86277013 A C 2.70E-04 Smoking initiation / / 24665060 rs3100249 chr4 86291465 C T 5.31E-04 Multiple complex diseases / / 17554300 rs1349721 chr4 86336779 T G 3.34E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs2629703 chr4 86345287 A G 9.00E-05 White matter hyperintensity burden / / 21681796 rs340199 chr4 86350683 A C 3.52E-05 Interstitial lung disease / / 23583980 rs1481775 chr4 86358621 T G 3.74E-04 Insulin resistance / / 21901158 rs2869358 chr4 86381780 G A 3.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2869358 chr4 86381780 G A 5.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2869358 chr4 86381780 G A 3.35E-05 Interstitial lung disease / / 23583980 rs10015995 chr4 86426882 A G 2.52E-05 Non-small cell lung cancer ARHGAP24 intron 21866343 rs1481779 chr4 86437055 G A 0.00000178 Stroke ARHGAP24 intron 23422753 rs4693701 chr4 86437529 A G 4.04E-04 Schizophrenia ARHGAP24 intron 20832056 rs1994074 chr4 86463558 T C 6.15E-04 Alcohol dependence ARHGAP24 intron 21314694 rs9307004 chr4 86480286 T C 2.27E-19 Varicose Veins ARHGAP24 intron pha001412 rs7698203 chr4 86604729 T G 1.73E-04 Vaspin levels ARHGAP24 intron 22907691 rs7698203 chr4 86604729 T G 0.0001728 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks ARHGAP24 intron 22907730 rs6849659 chr4 86610456 A G 3.48E-04 Alzheimer's disease (late onset) ARHGAP24 intron 21379329 rs900204 chr4 86622266 G A 9.27E-04 Myopia (pathological) ARHGAP24 intron 21095009 rs7692808 chr4 86641149 A G 6.00E-20 PR interval ARHGAP24 intron 20062060 rs7658797 chr4 86642714 C A 1.42E-14 PR segment ARHGAP24 intron 24850809 rs41477846 chr4 86644130 A G 5.69E-04 Multiple complex diseases ARHGAP24 intron 17554300 rs7660702 chr4 86651464 T C 3.00E-17 Electrocardiographic traits ARHGAP24 intron 20062063 rs7660702 chr4 86651464 T C 1.14E-14 PR segment ARHGAP24 intron 24850809 rs1482091 chr4 86653361 G A 2.05E-04 Myopia (pathological) ARHGAP24 intron 21095009 rs1482091 chr4 86653361 G A 3.30E-05 Parkinson's disease (motor and cognition) ARHGAP24 intron 22658654 rs343849 chr4 86663055 A T 1.17E-14 PR segment ARHGAP24 intron 24850809 rs2601855 chr4 86664940 A T 1.57E-14 PR segment ARHGAP24 intron 24850809 rs2601857 chr4 86665099 A T 3.26E-05 Coronary Artery Disease ARHGAP24 intron 17634449 rs7682971 chr4 86665296 T C 3.82E-05 Parkinson's disease (motor and cognition) ARHGAP24 intron 22658654 rs13106553 chr4 86669762 G A 4.01E-05 Myopia (pathological) ARHGAP24 intron 21095009 rs12507272 chr4 86673888 T C 2.31E-05 Myopia (pathological) ARHGAP24 intron 21095009 rs12507272 chr4 86673888 T C 1.02E-10 PR segment ARHGAP24 intron 24850809 rs13137008 chr4 86674199 G T 1.00E-14 PR segment ARHGAP24 intron 24850809 rs13112493 chr4 86676079 G A 2.23E-04 Myopia (pathological) ARHGAP24 intron 21095009 rs13111293 chr4 86682968 C T 2.55E-14 PR segment ARHGAP24 intron 24850809 rs13111662 chr4 86683121 C T 2.29E-14 PR segment ARHGAP24 intron 24850809 rs11732231 chr4 86683560 G C 3.00E-09 PR interval ARHGAP24 intron 23139255 rs2869382 chr4 86685274 T C 4.98E-04 Multiple complex diseases ARHGAP24 intron 17554300 rs7674888 chr4 86685746 G A 3.41E-08 PR segment ARHGAP24 intron 24850809 rs1966862 chr4 86688061 A G 9.30E-04 Myopia (pathological) ARHGAP24 intron 21095009 rs12054628 chr4 86688769 T A 3.12E-08 PR segment ARHGAP24 intron 24850809 rs6831420 chr4 86692665 G A 3.51E-08 PR segment ARHGAP24 intron 24850809 rs17395020 chr4 86702112 A T 2.66E-08 PR segment ARHGAP24 intron 24850809 rs17399123 chr4 86702170 C T 3.23E-08 PR segment ARHGAP24 intron 24850809 rs10516756 chr4 86703976 T C 3.50E-05 Cortisol secretion,in saliva ARHGAP24 intron 21316860 rs10516757 chr4 86704797 A G 8.47E-06 Obesity-related traits ARHGAP24 intron 23251661 rs17010925 chr4 86713124 T G 7.23E-05 Alzheimer's disease (late onset) ARHGAP24 intron 21379329 rs958800 chr4 86714299 C T 2.00E-06 Atrial fibrillation ARHGAP24 intron 19597491 rs7687906 chr4 86715312 G T 5.00E-06 Obesity-related traits ARHGAP24 intron 23251661 rs7699404 chr4 86720838 T C 9.58E-05 Stroke (ischemic) ARHGAP24 intron 22941190 rs11097076 chr4 86750313 T C 7.76E-04 Multiple complex diseases ARHGAP24 intron 17554300 rs345366 chr4 86754473 C T 4.99E-04 Multiple complex diseases ARHGAP24 intron 17554300 rs345360 chr4 86778943 C T 4.04E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ARHGAP24 intron 24023788 rs345353 chr4 86784168 G T 2.35E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ARHGAP24 intron 24023788 rs1510580 chr4 86817105 T C 7.50E-05 Pericardial fat ARHGAP24 intron 22589742 rs6840989 chr4 86818384 T C 4.47E-04 Response to taxane treatment (placlitaxel) ARHGAP24 intron 23006423 rs1016510 chr4 86819377 C A 7.50E-05 Pericardial fat ARHGAP24 intron 22589742 rs7666429 chr4 86819715 G A 7.00E-05 Pericardial fat ARHGAP24 intron 22589742 rs6851522 chr4 86824223 C A 7.90E-05 Pericardial fat ARHGAP24 intron 22589742 rs1510582 chr4 86824522 T C 8.50E-05 Pericardial fat ARHGAP24 intron 22589742 rs346521 chr4 86847640 A G 1.00E-04 Cognitive impairment induced by topiramate ARHGAP24 intron 22091778 rs346495 chr4 86869876 G A 6.31E-05 Follicle stimulating hormone ARHGAP24 intron 24049095 rs2164537 chr4 86927197 G A 7.27E-05 Schizophrenia / / 20185149 rs17011297 chr4 86933060 G T 6.78E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2575675 chr4 86935890 T C 2.28E-04 Response to cytidine analogues (gemcitabine) MAPK10 nearGene-3 24483146 rs7699978 chr4 86936056 C A 8.66E-04 Response to cytidine analogues (gemcitabine) MAPK10 nearGene-3 24483146 rs6810413 chr4 86966103 G A 1.47E-04 Major depressive disorder MAPK10 intron 22472876 rs10028075 chr4 86967830 C T 8.96E-06 Bipolar disorder MAPK10 intron 21926972 rs10028075 chr4 86967830 C T 2.05E-04 Major depressive disorder MAPK10 intron 22472876 rs3775180 chr4 86979147 A C 1.64E-11 Multiple complex diseases MAPK10 intron 17554300 rs3775182 chr4 86979583 G T 3.00E-06 Response to cytidine analogues (gemcitabine) MAPK10 intron 24483146 rs3775187 chr4 86983232 T C 1.71E-04 Major depressive disorder MAPK10 intron 22472876 rs1469869 chr4 86990027 C A,G,T 1.67E-04 Major depressive disorder MAPK10 intron 22472876 rs13112959 chr4 86998264 T G 1.97E-04 Major depressive disorder MAPK10 intron 22472876 rs9995879 chr4 87001823 C T 2.16E-04 Major depressive disorder MAPK10 intron 22472876 rs4482754 chr4 87011304 G A 1.34E-04 Major depressive disorder MAPK10 intron 22472876 rs12502934 chr4 87014806 C G 2.70E-05 Urinary metabolites MAPK10 intron 21572414 rs12502934 chr4 87014806 C G 1.91E-04 Major depressive disorder MAPK10 intron 22472876 rs9884770 chr4 87019238 A G 2.14E-04 Major depressive disorder MAPK10 intron 22472876 rs12644947 chr4 87021938 G A 5.04E-05 Major depressive disorder MAPK10 intron 22472876 rs12640395 chr4 87023394 A G 0.00072509 Hypertension (early onset hypertension) MAPK10 intron 22479346 rs12640395 chr4 87023394 A G 0.0000655 Asthma MAPK10 intron 22694930 rs11943376 chr4 87027819 T C 0.000072 Asthma MAPK10 intron 22694930 rs6822478 chr4 87076360 T C 5.51E-05 Cognitive impairment induced by topiramate MAPK10 intron 22091778 rs6822478 chr4 87076360 T C 9.68E-05 Asthma MAPK10 intron pha003127 rs1460762 chr4 87097973 G A 1.07E-04 Acne (severe) MAPK10 intron 24927181 rs7668374 chr4 87108510 C T 6.30E-04 Multiple complex diseases MAPK10 intron 17554300 rs7668374 chr4 87108510 C T 6.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAPK10 intron 20877124 rs10029339 chr4 87138765 G A 6.57E-04 Multiple complex diseases MAPK10 intron 17554300 rs6827698 chr4 87147504 T A 9.23E-04 Multiple complex diseases MAPK10 intron 17554300 rs1460759 chr4 87165758 G A 3.98E-04 Alzheimer's disease (late onset) MAPK10 intron 21379329 rs17011645 chr4 87185848 A G 4.59E-04 Alzheimer's disease (late onset) MAPK10 intron 21379329 rs6855169 chr4 87190830 A G 1.90E-05 Coffee consumption MAPK10 intron 21357676 rs1460751 chr4 87219895 A G 1.18E-04 Schizophrenia(treatment response to risperidone) MAPK10 intron 19850283 rs1031737 chr4 87228942 A G 5.10E-04 Type 2 diabetes and 6 quantitative traits MAPK10 intron 17848626 rs7655217 chr4 87231768 C A 3.60E-04 Type 2 diabetes and 6 quantitative traits MAPK10 intron 17848626 rs11726269 chr4 87232984 A G 2.00E-06 Peripheral artery disease MAPK10 intron 25009551 rs7677400 chr4 87252797 C T 2.09E-05 Hypertension MAPK10 intron 19609347 rs2904096 chr4 87304127 A G 2.59E-05 Cognitive impairment induced by topiramate MAPK10 intron 22091778 rs17011893 chr4 87350105 T C 1.82E-04 Multiple complex diseases MAPK10 intron 17554300 rs4488910 chr4 87362834 T C 1.24E-09 Brain activation patterns in response to human facial expressions-for the negative faces task MAPK10 intron 22828495 rs4488910 chr4 87362834 T C 1.24E-09 Airflow obstruction MAPK10 intron 22837378 rs4488910 chr4 87362834 T C 8.68E-05 Interstitial lung disease MAPK10 intron 23583980 rs2869441 chr4 87413424 A G 5.26E-04 Type 2 diabetes / / 17463246 rs4478147 chr4 87473776 G A 4.00E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs4478147 chr4 87473776 G A 2.00E-06 Migraine - clinic-based / / 23793025 rs3775239 chr4 87631353 T C 7.03E-04 Smoking cessation PTPN13 intron 24665060 rs10516780 chr4 87637561 A G 2.31E-05 Tunica Media PTPN13 intron pha003034 rs61757790 chr4 87653856 G C,T 0.00027 Breast cancer (ER positive) PTPN13 missense 23555315 rs10024860 chr4 87656992 G A 1.53E-05 Tunica Media PTPN13 intron pha003034 rs969734 chr4 87665384 T C 2.50E-04 Smoking cessation PTPN13 intron 24665060 rs12499575 chr4 87666595 G A 2.21E-05 Tunica Media PTPN13 intron pha003034 rs2054593 chr4 87673221 C T 6.13E-04 Smoking cessation PTPN13 intron 24665060 rs1035191 chr4 87677257 T G 2.94E-04 Smoking cessation PTPN13 intron 24665060 rs1420624 chr4 87679642 A C 8.09E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer PTPN13 intron 21483023 rs181519890 chr4 87683715 T C 6.00E-06 Serum dimethylarginine levels (symmetric) PTPN13 intron 24159190 rs10033029 chr4 87685796 T G 1.32E-05 Tunica Media PTPN13 missense pha003034 rs2230600 chr4 87690998 A G 8.20E-04 Primary sclerosing cholangitis PTPN13 missense 19944697 rs2230600 chr4 87690998 A G 4.28E-04 Smoking cessation PTPN13 missense 24665060 rs10516783 chr4 87710252 C T 1.67E-05 Tunica Media PTPN13 intron pha003034 rs10009789 chr4 87711806 C A 1.67E-05 Tunica Media PTPN13 intron pha003034 rs11930396 chr4 87731238 G A 5.46E-04 Smoking cessation PTPN13 intron 24665060 rs2287147 chr4 87732483 C T 7.00E-05 Smoking cessation PTPN13 intron 24665060 rs10000226 chr4 87738967 C T 1.15E-05 Tunica Media / / pha003034 rs10050311 chr4 87754419 C T 8.00E-06 Insulin-related traits SLC10A6 intron 22791750 rs10020861 chr4 87777245 T C 6.55E-04 Insulin resistance / / 21901158 rs1010902 chr4 87819155 C T 3.31E-07 Red blood cell traits / / 23222517 rs1010903 chr4 87819193 C T 5.98E-07 Red blood cell traits / / 23222517 rs12641570 chr4 87820574 A G 6.00E-04 Coronary heart disease / / 21971053 rs4235082 chr4 87821920 C T 0.00077 Endometrial cancer / / 22426144 rs3113494 chr4 87832601 G A 9.00E-07 Amyotrophic lateral sclerosis / / 22470424 rs1992876 chr4 87873164 A G 7.96E-04 Response to cytidine analogues (gemcitabine) AFF1 intron 24483146 rs17012200 chr4 87884646 G C 7.70E-07 Red blood cell traits AFF1 intron 23222517 rs10015639 chr4 87891565 A G 8.44E-07 Red blood cell traits AFF1 intron 23222517 rs17752307 chr4 87899285 T G 1.86E-07 Red blood cell traits AFF1 intron 23222517 rs7665282 chr4 87900850 C T 1.94E-07 Red blood cell traits AFF1 intron 23222517 rs17012234 chr4 87911691 G T 2.73E-07 Red blood cell traits AFF1 intron 23222517 rs7682652 chr4 87913444 C T 2.94E-07 Red blood cell traits AFF1 intron 23222517 rs10032244 chr4 87917931 A G 8.45E-04 Alzheimer's disease AFF1 intron 17998437 rs10032244 chr4 87917931 A G 2.99E-07 Red blood cell traits AFF1 intron 23222517 rs340639 chr4 87924979 T C 0.00021 Prostate cancer AFF1 intron 23555315 rs340637 chr4 87929192 C T 6.64E-07 Red blood cell traits AFF1 intron 23222517 rs340635 chr4 87931404 A G 2.00E-07 Alzheimer's disease (cognitive decline) AFF1 intron 23535033 rs340650 chr4 87938685 C G 3.76E-07 Red blood cell traits AFF1 intron 23222517 rs340643 chr4 87947158 A G 7.66E-04 Alzheimer's disease AFF1 intron 17998437 rs17701999 chr4 87955544 C T 7.59E-08 Red blood cell traits AFF1 intron 23222517 rs340630 chr4 87958395 G A 8.00E-09 Systemic lupus erythematosus AFF1 intron 22291604 rs767315 chr4 87960435 C T 7.23E-08 Red blood cell traits AFF1 intron 23222517 rs10516788 chr4 87960857 A G 5.68E-07 Red blood cell traits AFF1 intron 23222517 rs6839933 chr4 87964363 T G 3.61E-04 Alzheimer's disease AFF1 intron 17998437 rs6854749 chr4 87968798 A T 7.46E-08 Red blood cell traits AFF1 intron 23222517 rs6840258 chr4 87973668 C T 6.48E-08 Red blood cell traits AFF1 intron 23222517 rs17012334 chr4 87980748 G A 1.47E-07 Red blood cell traits AFF1 intron 23222517 rs384059 chr4 87982790 G A 0.000257 Common carotid artery thickness (average of near and far wall measures) AFF1 intron 23487405 rs384059 chr4 87982790 G A 0.000429 Internal carotid artery thickness (average of near and far walls) AFF1 intron 23487405 rs7660883 chr4 87982876 C G 3.56E-08 Red blood cell traits AFF1 intron 23222517 rs17012341 chr4 87983116 T A 1.41E-04 Coronary heart disease AFF1 intron 21606135 rs13120301 chr4 87986395 C T 7.10E-08 Red blood cell traits AFF1 intron 23222517 rs236681 chr4 87988508 T G 4.79E-08 Red blood cell traits AFF1 intron 23222517 rs2280954 chr4 87988862 A G 4.88E-08 Red blood cell traits AFF1 intron 23222517 rs3775226 chr4 87989465 G A 8.23E-07 Red blood cell traits AFF1 intron 23222517 rs11097127 chr4 87990334 G T 4.15E-08 Red blood cell traits AFF1 intron 23222517 rs3736668 chr4 87992210 T C 4.04E-07 Red blood cell traits AFF1 intron 23222517 rs3736669 chr4 87992753 G A 4.27E-08 Red blood cell traits AFF1 intron 23222517 rs236995 chr4 88000423 C G 9.65E-08 Red blood cell traits AFF1 intron 23222517 rs236996 chr4 88005203 G A 2.30E-05 Lipid levels AFF1 intron 18193043 rs236996 chr4 88005203 G A 6.16E-10 Triglycerides AFF1 intron 23063622 rs236996 chr4 88005203 G A 1.46E-08 Red blood cell traits AFF1 intron 23222517 rs4693156 chr4 88007227 T C 1.22E-07 Red blood cell traits AFF1 intron 23222517 rs13143182 chr4 88008401 T A 9.52E-04 Type 2 diabetes AFF1 intron 17463246 rs236984 chr4 88008614 G A 1.74E-07 Red blood cell traits AFF1 intron 23222517 rs236985 chr4 88008782 G A 1.69E-07 Red blood cell traits AFF1 intron 23222517 rs236675 chr4 88010601 T C 0.000199 Internal carotid artery thickness (average of near and far walls) AFF1 intron 23487405 rs2045592 chr4 88014346 C G 3.68E-08 Red blood cell traits AFF1 intron 23222517 rs3775220 chr4 88014753 A G 4.46E-08 Red blood cell traits AFF1 intron 23222517 rs236990 chr4 88015386 A G 4.68E-04 Coronary heart disease AFF1 intron 21606135 rs236992 chr4 88016739 A G 1.42E-07 Red blood cell traits AFF1 intron 23222517 rs236993 chr4 88016874 G T 2.41E-07 Red blood cell traits AFF1 intron 23222517 rs342452 chr4 88018408 A G 2.51E-07 Red blood cell traits AFF1 intron 23222517 rs3775214 chr4 88023299 A G 2.30E-06 Lipid levels AFF1 intron 18193043 rs3775214 chr4 88023299 A G 2.47E-09 Triglycerides AFF1 intron 23063622 rs3775214 chr4 88023299 A G 7.26E-07 Red blood cell traits AFF1 intron 23222517 rs342457 chr4 88023916 C T 0.000139 Internal carotid artery thickness (average of near and far walls) AFF1 intron 23487405 rs3755985 chr4 88024738 A G 1.99E-07 Red blood cell traits AFF1 intron 23222517 rs442177 chr4 88030261 G T 9.00E-12 Triglycerides AFF1 intron 20686565 rs442177 chr4 88030261 G T 3.00E-10 Triglycerides AFF1 intron 20864672 rs442177 chr4 88030261 G T 2.28E-07 Red blood cell traits AFF1 intron 23222517 rs442177 chr4 88030261 G T 1.00E-18 Triglycerides AFF1 intron 24097068 rs447990 chr4 88033352 T G 0.00013 Internal carotid artery thickness (average of near and far walls) AFF1 intron 23487405 rs342438 chr4 88040406 A G 5.98E-07 Red blood cell traits AFF1 intron 23222517 rs342437 chr4 88040909 A G 1.91E-07 Red blood cell traits AFF1 intron 23222517 rs19026 chr4 88041256 C T 0.000327 Internal carotid artery thickness (average of near and far walls) AFF1 intron 23487405 rs1037814 chr4 88049850 T C 4.20E-08 Red blood cell traits AFF1 intron 23222517 rs342469 chr4 88050554 G A 2.85E-07 Red blood cell traits AFF1 intron 23222517 rs342467 chr4 88052219 T C 2.72E-07 Red blood cell traits AFF1 intron 23222517 rs342466 chr4 88053085 C T 2.15E-07 Red blood cell traits AFF1 intron 23222517 rs342462 chr4 88057481 G A 0.000317 Internal carotid artery thickness (average of near and far walls) AFF1 UTR-3 23487405 rs342461 chr4 88058472 A G 0.000727 Internal carotid artery thickness (average of near and far walls) AFF1 UTR-3 23487405 rs342459 chr4 88059415 G A 0.000377 Internal carotid artery thickness (average of near and far walls) AFF1 UTR-3 23487405 rs342458 chr4 88060025 C A 0.000487 Internal carotid artery thickness (average of near and far walls) AFF1 UTR-3 23487405 rs10023050 chr4 88064431 A G 1.25E-07 Red blood cell traits / / 23222517 rs10023056 chr4 88064466 A G 7.19E-07 Red blood cell traits / / 23222517 rs115694618 chr4 88076129 A G 4.00E-06 Bulimia nervosa / / 23568457 rs17012552 chr4 88126218 C T 1.21E-04 Coronary heart disease KLHL8 intron 21606135 rs4583723 chr4 88161312 A T 3.29E-07 Red blood cell traits / / 23222517 rs7688657 chr4 88163094 G C 6.01E-07 Red blood cell traits / / 23222517 rs7694379 chr4 88186509 G A 9.00E-09 Platelet counts / / 22139419 rs6531968 chr4 88199484 T G 9.83E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6834314 chr4 88213808 A G 3.00E-09 Liver enzyme levels (alanine transaminase) / / 22001757 rs7691791 chr4 88286409 C T 6.32E-05 Cervical cancer HSD17B11 intron 24700089 rs6827817 chr4 88330987 A G 1.98E-04 Alzheimer's disease / / 22005930 rs4129319 chr4 88395385 C T 4.70E-05 Obesity-related traits SPARCL1 intron 17903300 rs4610302 chr4 88400110 A G 4.00E-06 Esophageal adenocarcinoma SPARCL1 intron 24121790 rs3763392 chr4 88415884 C A 4.70E-07 Urinary metabolites SPARCL1 intron 21572414 rs3763392 chr4 88415884 C A 2.40E-05 Response to Vitamin E supplementation SPARCL1 intron 22437554 rs10025744 chr4 88459299 G A 4.30E-05 Personality dimensions / / 18957941 rs2615486 chr4 88522928 C A 9.73E-04 Type 2 diabetes / / 17463246 rs201110163 chr4 88534411 G A 0.0000093 Breast cancer (ER positive) DSPP missense 23555315 rs201110163 chr4 88534411 G A 0.000054 Breast cancer DSPP missense 23555315 rs936736 chr4 88546861 C T 1.71E-04 Multiple complex diseases / / 17554300 rs1381632 chr4 88568984 T A 1.80E-05 Subclinical atherosclerosis / / 17903303 rs10019009 chr4 88583135 A T 4.01E-04 Lung function (forced expiratory volume in 1 second) DMP1 missense 17255346 rs2627690 chr4 88653616 A G 2.30E-05 Bone mineral density (BMD),in women / / 20164292 rs2627677 chr4 88668581 C G 5.92E-04 Aortic root size / / 21223598 rs2627713 chr4 88687755 G T 6.13E-04 Alzheimer's disease / / 22005930 rs4693869 chr4 88689765 A G 5.74E-04 Alzheimer's disease / / 22005930 rs3113402 chr4 88696359 T G 7.22E-05 Alzheimer's disease / / 22005930 rs12650760 chr4 88705132 C T 2.90E-04 Height / / 17255346 rs2616268 chr4 88707131 G C 3.50E-04 Alzheimer's disease / / 22005930 rs2126650 chr4 88710587 C T 7.70E-05 Bone mineral density (BMD),in women / / 20164292 rs13137552 chr4 88715324 T C 5.65E-06 Kawasaki disease / / 21221998 rs1054627 chr4 88732692 G A 4.60E-05 Bone mineral density (spine) IBSP missense 19079262 rs1054627 chr4 88732692 G A 8.00E-07 Bone mineral density IBSP missense 21533022 rs7698623 chr4 88755828 T C 3.00E-07 Cardiovascular disease risk factors MEPE intron 21779381 rs4466013 chr4 88760413 A G 2.10E-09 Urate levels MEPE intron 20884846 rs4466013 chr4 88760413 A G 1.60E-16 Urate levels MEPE intron 23263486 rs13130999 chr4 88761259 A G 7.18E-04 Suicide attempts in bipolar disorder MEPE intron 21423239 rs12646209 chr4 88770005 G C 2.49E-05 Glycosylated haemoglobin levels / / 17255346 rs1477603 chr4 88770998 C T 6.49E-04 Multiple complex diseases / / 17554300 rs1477603 chr4 88770998 C T 3.33E-05 Serum metabolites / / 19043545 rs7683315 chr4 88773095 T A 2.30E-08 Bone mineral density (spine) / / 19801982 rs6532022 chr4 88773734 G T 2.00E-08 Bone mineral density (spine) / / 19801982 rs6532023 chr4 88773849 T G 2.00E-08 Bone mineral density (spine) / / 19801982 rs6532023 chr4 88773849 T G 1.00E-27 Bone mineral density / / 22504420 rs6532023 chr4 88773849 T G 2.97E-04 Bone mineral density / / 24249740 rs6532023 chr4 88773849 T G 1.09E-04 Bone mineral density (paediatric,lower limb) / / 24945404 rs6532023 chr4 88773849 T G 2.25E-04 Bone mineral density (paediatric,skull) / / 24945404 rs6532023 chr4 88773849 T G 2.66E-06 Bone mineral density (paediatric,total body less head) / / 24945404 rs6532023 chr4 88773849 T G 3.00E-06 Bone mineral density (paediatric,total body less head) / / 24945404 rs1471399 chr4 88774073 A G 1.80E-08 Bone mineral density (spine) / / 19801982 rs1471403 chr4 88775243 T C 2.00E-08 Bone mineral density (spine) / / 19801982 rs1471403 chr4 88775243 T C 8.00E-07 Bone mineral density (hip) / / 19801982 rs6854498 chr4 88776760 G A 2.10E-09 Urate levels / / 20884846 rs6854498 chr4 88776760 G A 1.11E-16 Urate levels / / 23263486 rs6854361 chr4 88776864 C A 2.10E-09 Urate levels / / 20884846 rs6854361 chr4 88776864 C A 5.56E-17 Urate levels / / 23263486 rs62316457 chr4 88779799 T C 0.0000525 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1463095 chr4 88792621 G A 4.35E-04 Multiple complex diseases / / 17554300 rs17013421 chr4 88793888 A G 7.45E-05 Glycosylated haemoglobin levels / / 17255346 rs1463104 chr4 88799710 T C 2.00E-09 Bone mineral density / / 24249740 rs1463104 chr4 88799710 T C 7.08E-07 Bone mineral density / / 24249740 rs11724215 chr4 88801631 A G 1.30E-05 Anger / / 24489884 rs1381964 chr4 88803363 C T 9.43E-06 HIV-1 viral setpoint / / 22174851 rs12644436 chr4 88805208 A G 6.00E-06 HIV-1 viral setpoint / / 22174851 rs10004908 chr4 88807246 G A 1.44E-04 Glycosylated haemoglobin levels / / 17255346 rs10004908 chr4 88807246 G A 3.67E-10 Brain activation patterns in response to human facial expressions-for the negative faces task / / 22828495 rs10004908 chr4 88807246 G A 3.67E-10 Airflow obstruction / / 22837378 rs2169612 chr4 88817414 G C 4.84E-10 Urate levels / / 23263486 rs12651696 chr4 88821873 G A 2.49E-09 Urate levels / / 23263486 rs17013544 chr4 88823643 C A 1.15E-10 Urate levels / / 23263486 rs17013545 chr4 88826327 G A 3.73E-09 Urate levels / / 23263486 rs716202 chr4 88836002 C T 1.13E-08 Urate levels / / 23263486 rs17842205 chr4 88849552 C A 1.10E-17 Urate levels / / 20884846 rs17842205 chr4 88849552 C A 1.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs17842205 chr4 88849552 C A 1.45E-30 Urate levels / / 23263486 rs10516796 chr4 88856733 C T 2.35E-08 Urate levels / / 23263486 rs4693920 chr4 88864775 T C 3.40E-19 Urate levels / / 20884846 rs4693920 chr4 88864775 T C 6.69E-31 Urate levels / / 23263486 rs2728123 chr4 88870795 T C 3.42E-08 Uric acid levels / / 19503597 rs2728123 chr4 88870795 T C 3.50E-18 Urate levels / / 20884846 rs2728123 chr4 88870795 T C 1.17E-31 Urate levels / / 23263486 rs17013584 chr4 88872963 G A 1.30E-18 Urate levels / / 20884846 rs17013584 chr4 88872963 G A 2.54E-11 Urate levels / / 21768215 rs17013584 chr4 88872963 G A 8.00E-30 Urate levels / / 23263486 rs2728119 chr4 88877531 G A 4.60E-24 Urate levels / / 20884846 rs2728119 chr4 88877531 G A 3.98E-08 Urate levels / / 21768215 rs2728119 chr4 88877531 G A 2.29E-40 Urate levels / / 23263486 rs4490426 chr4 88880522 C A 9.10E-13 Urate levels / / 20884846 rs4490426 chr4 88880522 C A 9.01E-15 Urate levels / / 23263486 rs10516798 chr4 88883537 T C 1.20E-12 Urate levels / / 20884846 rs10516798 chr4 88883537 T C 1.64E-14 Urate levels / / 23263486 rs11730059 chr4 88887327 A G 5.21E-10 Uric acid levels / / 19503597 rs11730059 chr4 88887327 A G 7.40E-27 Urate levels / / 20884846 rs11730059 chr4 88887327 A G 2.91E-09 Urate levels / / 21768215 rs11730059 chr4 88887327 A G 1.00E-46 Urate levels / / 23263486 rs4693923 chr4 88888113 A G 2.20E-08 Urate levels / / 20884846 rs12641001 chr4 88888940 C T 2.40E-12 Urate levels / / 20884846 rs12641001 chr4 88888940 C T 8.14E-14 Urate levels / / 23263486 rs10516800 chr4 88891590 G C 7.97E-05 Serum metabolites / / 19043545 rs10516800 chr4 88891590 G C 2.10E-12 Urate levels / / 20884846 rs10516800 chr4 88891590 G C 1.19E-13 Urate levels / / 23263486 rs6813526 chr4 88894235 T C 3.90E-13 Urate levels / / 20884846 rs6813526 chr4 88894235 T C 2.99E-15 Urate levels / / 23263486 rs2853749 chr4 88897814 C T 2.00E-13 Urate levels SPP1 intron 20884846 rs2853749 chr4 88897814 C T 1.21E-15 Urate levels SPP1 intron 23263486 rs10012150 chr4 88905795 T C 1.92E-04 Coronary heart disease / / 21606135 rs7655182 chr4 88905903 G A 2.23E-04 Alcohol dependence / / 21314694 rs547424992 chr4 88906458 TACTATTTAACA T 4.10E-10 Urate levels / / 20884846 rs547424992 chr4 88906458 TACTATTTAACA T 1.76E-12 Urate levels / / 23263486 rs7685225 chr4 88906458 T C 4.10E-10 Urate levels / / 20884846 rs7685225 chr4 88906458 T C 1.76E-12 Urate levels / / 23263486 rs6818927 chr4 88907257 C T 4.30E-10 Urate levels / / 20884846 rs6818927 chr4 88907257 C T 7.90E-13 Urate levels / / 23263486 rs4128340 chr4 88908136 C A 4.10E-10 Urate levels / / 20884846 rs4128340 chr4 88908136 C A 5.29E-13 Urate levels / / 23263486 rs6532041 chr4 88909033 T A 2.30E-10 Urate levels / / 20884846 rs6532041 chr4 88909033 T A 4.66E-12 Urate levels / / 23263486 rs6832511 chr4 88909088 G A 3.80E-10 Urate levels / / 20884846 rs6832511 chr4 88909088 G A 3.92E-13 Urate levels / / 23263486 rs6838095 chr4 88909436 G A 4.40E-10 Urate levels / / 20884846 rs6838095 chr4 88909436 G A 4.40E-13 Urate levels / / 23263486 rs12509864 chr4 88909766 T C 3.90E-10 Urate levels / / 20884846 rs12509864 chr4 88909766 T C 5.44E-11 Urate levels / / 23263486 rs11938988 chr4 88910113 G C 7.10E-10 Urate levels / / 20884846 rs11938988 chr4 88910113 G C 2.01E-13 Urate levels / / 23263486 rs2725236 chr4 88919106 G A 5.00E-06 Caffeine consumption / / 21490707 rs2728116 chr4 88931050 C A 1.70E-10 Urate levels PKD2 intron 21768215 rs2728116 chr4 88931050 C A 4.67E-08 Urate levels PKD2 intron 23263486 rs2725234 chr4 88932272 C T 1.46E-09 Uric acid levels PKD2 intron 19503597 rs2725234 chr4 88932272 C T 3.50E-30 Urate levels PKD2 intron 20884846 rs2725234 chr4 88932272 C T 2.25E-09 Urate levels PKD2 intron 21768215 rs2725234 chr4 88932272 C T 2.21E-43 Urate levels PKD2 intron 23263486 rs12503776 chr4 88932464 C T 4.40E-09 Urate levels PKD2 intron 20884846 rs12503776 chr4 88932464 C T 1.92E-10 Urate levels PKD2 intron 23263486 rs2728113 chr4 88939736 A G 5.27E-10 Uric acid levels PKD2 intron 19503597 rs2728113 chr4 88939736 A G 2.80E-30 Urate levels PKD2 intron 20884846 rs2728113 chr4 88939736 A G 2.10E-09 Urate levels PKD2 intron 21768215 rs2728113 chr4 88939736 A G 1.12E-53 Urate levels PKD2 intron 23263486 rs2725227 chr4 88944511 C T 2.70E-07 Urate levels PKD2 intron 20884846 rs2725227 chr4 88944511 C T 3.02E-12 Urate levels PKD2 intron 21768215 rs2725227 chr4 88944511 C T 7.45E-12 Urate levels PKD2 intron 23263486 rs2467052 chr4 88949175 G T 6.70E-11 Urate levels PKD2 intron 21768215 rs2467052 chr4 88949175 G T 2.27E-11 Urate levels PKD2 intron 23263486 rs13149278 chr4 88951390 G A 1.20E-09 Urate levels PKD2 intron 20884846 rs13149278 chr4 88951390 G A 5.76E-11 Urate levels PKD2 intron 23263486 rs2725225 chr4 88952076 T C 2.20E-07 Urate levels PKD2 intron 20884846 rs2725225 chr4 88952076 T C 2.61E-12 Urate levels PKD2 intron 21768215 rs2725225 chr4 88952076 T C 1.01E-11 Urate levels PKD2 intron 23263486 rs2728110 chr4 88952883 A G 2.40E-07 Urate levels PKD2 intron 20884846 rs2728110 chr4 88952883 A G 2.38E-12 Urate levels PKD2 intron 21768215 rs2728110 chr4 88952883 A G 5.53E-12 Urate levels PKD2 intron 23263486 rs17786456 chr4 88957562 T C 4.80E-09 Urate levels PKD2 intron 20884846 rs17786456 chr4 88957562 T C 9.57E-10 Urate levels PKD2 intron 23263486 rs2728109 chr4 88957723 C A 5.41E-11 Uric acid levels PKD2 intron 19503597 rs2728109 chr4 88957723 C A 5.20E-33 Urate levels PKD2 intron 20884846 rs2728109 chr4 88957723 C A 1.86E-09 Urate levels PKD2 intron 21768215 rs2728109 chr4 88957723 C A 4.83E-60 Urate levels PKD2 intron 23263486 rs2725220 chr4 88959922 G C 4.00E-30 Renal function-related traits (urea) PKD2 intron 22797727 rs7696304 chr4 88959998 A G 1.86E-07 Urate levels PKD2 intron 21768215 rs7696304 chr4 88959998 A G 6.13E-09 Urate levels PKD2 intron 23263486 rs2725217 chr4 88960258 A T 6.63E-11 Uric acid levels PKD2 intron 19503597 rs2725217 chr4 88960258 A T 2.30E-33 Urate levels PKD2 intron 20884846 rs2725217 chr4 88960258 A T 1.56E-61 Urate levels PKD2 intron 23263486 rs2725215 chr4 88961571 C T 2.01E-13 Uric acid levels PKD2 intron 19503597 rs2725215 chr4 88961571 C T 1.70E-35 Urate levels PKD2 intron 20884846 rs2725215 chr4 88961571 C T 2.90E-09 Urate levels PKD2 intron 21768215 rs2725215 chr4 88961571 C T 9.91E-66 Urate levels PKD2 intron 23263486 rs2725212 chr4 88968713 A G 6.59E-11 Uric acid levels PKD2 intron 19503597 rs2725212 chr4 88968713 A G 4.60E-27 Urate levels PKD2 intron 20884846 rs2725212 chr4 88968713 A G 3.45E-53 Urate levels PKD2 intron 23263486 rs2725211 chr4 88970375 C T 6.96E-13 Uric acid levels PKD2 intron 19503597 rs2725211 chr4 88970375 C T 5.30E-32 Urate levels PKD2 intron 20884846 rs2725211 chr4 88970375 C T 2.95E-09 Urate levels PKD2 intron 21768215 rs2725211 chr4 88970375 C T 1.16E-58 Urate levels PKD2 intron 23263486 rs2728106 chr4 88972051 G A 7.15E-11 Uric acid levels PKD2 intron 19503597 rs2728106 chr4 88972051 G A 8.10E-27 Urate levels PKD2 intron 20884846 rs2728106 chr4 88972051 G A 1.24E-08 Urate levels PKD2 intron 21768215 rs2728106 chr4 88972051 G A 7.11E-51 Urate levels PKD2 intron 23263486 rs2728104 chr4 88973006 T C 2.73E-12 Uric acid levels PKD2 intron 19503597 rs2728104 chr4 88973006 T C 1.20E-32 Urate levels PKD2 intron 20884846 rs2728104 chr4 88973006 T C 3.01E-09 Urate levels PKD2 intron 21768215 rs2728104 chr4 88973006 T C 9.01E-57 Urate levels PKD2 intron 23263486 rs2725210 chr4 88973427 A G 2.64E-10 Uric acid levels PKD2 intron 19503597 rs2725210 chr4 88973427 A G 1.30E-26 Urate levels PKD2 intron 20884846 rs2725210 chr4 88973427 A G 1.33E-08 Urate levels PKD2 intron 21768215 rs2725210 chr4 88973427 A G 2.34E-47 Urate levels PKD2 intron 23263486 rs2728099 chr4 88975738 T C 1.18E-11 Uric acid levels PKD2 intron 19503597 rs2728099 chr4 88975738 T C 2.40E-34 Urate levels PKD2 intron 20884846 rs2728099 chr4 88975738 T C 3.68E-09 Urate levels PKD2 intron 21768215 rs2728099 chr4 88975738 T C 3.83E-59 Urate levels PKD2 intron 23263486 rs2725207 chr4 88979529 C A 3.40E-08 Uric acid levels PKD2 intron 19503597 rs2725207 chr4 88979529 C A 8.90E-27 Urate levels PKD2 intron 20884846 rs2725207 chr4 88979529 C A 1.30E-08 Urate levels PKD2 intron 21768215 rs2725207 chr4 88979529 C A 1.67E-47 Urate levels PKD2 intron 23263486 rs2728133 chr4 88981690 T C 4.79E-08 Uric acid levels PKD2 intron 19503597 rs2728133 chr4 88981690 T C 6.50E-27 Urate levels PKD2 intron 20884846 rs2728133 chr4 88981690 T C 1.30E-08 Urate levels PKD2 intron 21768215 rs2728133 chr4 88981690 T C 3.10E-46 Urate levels PKD2 intron 23263486 rs2728132 chr4 88982461 A C 2.44E-08 Uric acid levels PKD2 intron 19503597 rs2728132 chr4 88982461 A C 5.90E-27 Urate levels PKD2 intron 20884846 rs2728132 chr4 88982461 A C 1.36E-08 Urate levels PKD2 intron 21768215 rs2728132 chr4 88982461 A C 1.33E-46 Urate levels PKD2 intron 23263486 rs2725205 chr4 88985711 G A 4.24E-08 Uric acid levels PKD2 intron 19503597 rs2725205 chr4 88985711 G A 5.70E-27 Urate levels PKD2 intron 20884846 rs2725205 chr4 88985711 G A 1.38E-08 Urate levels PKD2 intron 21768215 rs2725205 chr4 88985711 G A 4.85E-46 Urate levels PKD2 intron 23263486 rs11938025 chr4 88987276 A T 5.30E-08 Urate levels PKD2 intron 20884846 rs11938025 chr4 88987276 A T 1.93E-06 Urate levels PKD2 intron 21768215 rs11938025 chr4 88987276 A T 7.74E-10 Urate levels PKD2 intron 23263486 rs4336187 chr4 88987916 A G 4.50E-08 Uric acid levels PKD2 intron 19503597 rs4336187 chr4 88987916 A G 7.50E-27 Urate levels PKD2 intron 20884846 rs4336187 chr4 88987916 A G 1.41E-08 Urate levels PKD2 intron 21768215 rs4336187 chr4 88987916 A G 1.44E-46 Urate levels PKD2 intron 23263486 rs2725203 chr4 88995795 T C 1.90E-26 Urate levels PKD2 intron 20884846 rs2725203 chr4 88995795 T C 1.47E-08 Urate levels PKD2 intron 21768215 rs2725203 chr4 88995795 T C 8.23E-47 Urate levels PKD2 intron 23263486 rs2728121 chr4 88997102 C T 2.38E-10 Uric acid levels PKD2 UTR-3 19503597 rs2728121 chr4 88997102 C T 8.60E-34 Urate levels PKD2 UTR-3 20884846 rs2728121 chr4 88997102 C T 3.38E-09 Urate levels PKD2 UTR-3 21768215 rs2728121 chr4 88997102 C T 6.95E-44 Urate levels PKD2 UTR-3 23263486 rs10965 chr4 88998083 G A 4.20E-08 Urate levels PKD2 UTR-3 20884846 rs10965 chr4 88998083 G A 1.62E-06 Urate levels PKD2 UTR-3 21768215 rs10965 chr4 88998083 G A 1.54E-09 Urate levels PKD2 UTR-3 23263486 rs2728126 chr4 88999222 T A 4.75E-11 Uric acid levels PKD2 nearGene-3 19503597 rs2728126 chr4 88999222 T A 4.60E-39 Urate levels PKD2 nearGene-3 20884846 rs2728126 chr4 88999222 T A 8.26E-09 Urate levels PKD2 nearGene-3 21768215 rs2728126 chr4 88999222 T A 3.46E-49 Urate levels PKD2 nearGene-3 23263486 rs2725201 chr4 88999306 T G 7.19E-04 Response to cytidine analogues (gemcitabine) PKD2 nearGene-3 24483146 rs2728125 chr4 89001893 A G 9.06E-13 Uric acid levels / / 19503597 rs2728125 chr4 89001893 A G 2.10E-41 Urate levels / / 20884846 rs2728125 chr4 89001893 A G 9.17E-09 Urate levels / / 21768215 rs2728125 chr4 89001893 A G 1.35E-57 Urate levels / / 23263486 rs2231164 chr4 89015857 C T 4.10E-36 Urate levels ABCG2 intron 20884846 rs2231164 chr4 89015857 C T 1.04E-06 Urate levels ABCG2 intron 21768215 rs2231164 chr4 89015857 C T 4.77E-54 Urate levels ABCG2 intron 23263486 rs2231156 chr4 89020427 C A 6.69E-16 Uric acid levels ABCG2 intron 19503597 rs2231156 chr4 89020427 C A 4.10E-45 Urate levels ABCG2 intron 20884846 rs2231156 chr4 89020427 C A 7.33E-61 Urate levels ABCG2 intron 23263486 rs4148157 chr4 89020934 G A 1.51E-16 Uric acid levels ABCG2 intron 19503597 rs4148157 chr4 89020934 G A 2.90E-45 Urate levels ABCG2 intron 20884846 rs4148157 chr4 89020934 G A 1.60E-08 Urate levels ABCG2 intron 21768215 rs4148157 chr4 89020934 G A 7.57E-62 Urate levels ABCG2 intron 23263486 rs4693924 chr4 89023224 G A 1.77E-16 Uric acid levels ABCG2 intron 19503597 rs4693924 chr4 89023224 G A 4.20E-45 Urate levels ABCG2 intron 20884846 rs4693924 chr4 89023224 G A 8.51E-63 Urate levels ABCG2 intron 23263486 rs2231148 chr4 89028478 T A 2.10E-09 Urate levels ABCG2 intron 20884846 rs2231148 chr4 89028478 T A 2.27E-12 Urate levels ABCG2 intron 23263486 rs2054576 chr4 89028775 A G 2.91E-16 Uric acid levels ABCG2 intron 19503597 rs2054576 chr4 89028775 A G 2.80E-46 Urate levels ABCG2 intron 20884846 rs2054576 chr4 89028775 A G 1.46E-08 Urate levels ABCG2 intron 21768215 rs2054576 chr4 89028775 A G 3.75E-64 Urate levels ABCG2 intron 23263486 rs12505410 chr4 89030841 T G 2.08E-09 Uric acid levels ABCG2 intron 19503597 rs12505410 chr4 89030841 T G 4.60E-16 Urate levels ABCG2 intron 20884846 rs12505410 chr4 89030841 T G 1.90E-05 Urinary metabolites ABCG2 intron 21572414 rs12505410 chr4 89030841 T G 4.60E-11 Urate levels ABCG2 intron 21768215 rs12505410 chr4 89030841 T G 3.21E-29 Urate levels ABCG2 intron 23263486 rs2622621 chr4 89030920 C G 1.14E-11 Uric acid levels ABCG2 intron 19503597 rs2622621 chr4 89030920 C G 1.60E-27 Urate levels ABCG2 intron 20884846 rs2622621 chr4 89030920 C G 1.32E-18 Urate levels ABCG2 intron 21768215 rs2622621 chr4 89030920 C G 7.41E-55 Urate levels ABCG2 intron 23263486 rs13120400 chr4 89033527 T C 1 Drug response to Methotrexate ABCG2 intron 18256692 rs13120400 chr4 89033527 T C 2.40E-18 Urate levels ABCG2 intron 20884846 rs13120400 chr4 89033527 T C 3.25E-10 Urate levels ABCG2 intron 21768215 rs13120400 chr4 89033527 T C 3.19E-33 Urate levels ABCG2 intron 23263486 rs2725261 chr4 89036353 C T 1.20E-09 Urate (in serum),gout ABCG2 intron 21983786 rs1481012 chr4 89039082 A G 2.55E-24 Uric acid levels ABCG2 intron 19503597 rs1481012 chr4 89039082 A G 8.10E-74 Urate levels ABCG2 intron 20884846 rs1481012 chr4 89039082 A G 1.80E-10 Urate levels ABCG2 intron 21768215 rs1481012 chr4 89039082 A G 5.30E-12 Urate (in serum),gout ABCG2 intron 21983786 rs1481012 chr4 89039082 A G 2.00E-15 Response to statin therapy (LDL-C) ABCG2 intron 22331829 rs1481012 chr4 89039082 A G 2.00E-32 Gout ABCG2 intron 23263486 rs45499402 chr4 89043634 G C 2.90E-12 Urate (in serum),gout ABCG2 intron 21983786 rs75544042 chr4 89045331 A G 3.00E-12 Urate (in serum),gout ABCG2 intron 21983786 rs74904971 chr4 89050026 C A 2.80E-12 Urate (in serum),gout ABCG2 intron 21983786 rs2231142 chr4 89052323 G T 1 Drug response to Diflomotecan ABCG2 missense 15229462 rs2231142 chr4 89052323 G T 1 Drug response to Rosuvastatin ABCG2 missense 16784736 rs2231142 chr4 89052323 G T 1 Drug response to Gefitinib ABCG2 missense 17148776 rs2231142 chr4 89052323 G T 1 Drug response to Lamivudine ABCG2 missense 17509035 rs2231142 chr4 89052323 G T 3.00E-60 Urate levels ABCG2 missense 18834626 rs2231142 chr4 89052323 G T 1 Drug response to Imatinib ABCG2 missense 18981009 rs2231142 chr4 89052323 G T 1 Drug response to Rosuvastatin ABCG2 missense 19474787 rs2231142 chr4 89052323 G T 1.00E-10 Uric acid levels ABCG2 missense 19503597 rs2231142 chr4 89052323 G T 2.00E-18 Uric acid levels ABCG2 missense 19503597 rs2231142 chr4 89052323 G T 1.62E-13 Blood cell counts and other traits ABCG2 missense 20139978 rs2231142 chr4 89052323 G T 2.50E-75 Urate levels ABCG2 missense 20884846 rs2231142 chr4 89052323 G T 3.13E-10 Urate levels ABCG2 missense 21768215 rs2231142 chr4 89052323 G T 1.70E-10 Urate (in serum),gout ABCG2 missense 21983786 rs2231142 chr4 89052323 G T 2.30E-20 Urate (in serum),gout ABCG2 missense 21983786 rs2231142 chr4 89052323 G T 2.80E-12 Urate (in serum),gout ABCG2 missense 21983786 rs2231142 chr4 89052323 G T 4.10E-09 Urate (in serum),gout ABCG2 missense 21983786 rs2231142 chr4 89052323 G T 6.50E-15 Urate (in serum),gout ABCG2 missense 21983786 rs2231142 chr4 89052323 G T 5.00E-06 Uric acid levels ABCG2 missense 22229870 rs2231142 chr4 89052323 G T 1.00E-134 Urate levels ABCG2 missense 23263486 rs2231142 chr4 89052323 G T 3.00E-42 Serum uric acid levels ABCG2 missense 24513273 rs72552713 chr4 89052957 G A 1 Drug response to Lamivudine ABCG2 STOP-GAIN 17509035 rs4148155 chr4 89054667 A G 1.50E-25 Uric acid levels ABCG2 intron 19503597 rs4148155 chr4 89054667 A G 1.00E-13 Blood cell counts and other traits ABCG2 intron 20139978 rs4148155 chr4 89054667 A G 1.14E-13 Blood cell counts and other traits ABCG2 intron 20139978 rs4148155 chr4 89054667 A G 2.10E-75 Urate levels ABCG2 intron 20884846 rs4148155 chr4 89054667 A G 2.73E-10 Urate levels ABCG2 intron 21768215 rs4148155 chr4 89054667 A G 2.80E-12 Urate (in serum),gout ABCG2 intron 21983786 rs4148155 chr4 89054667 A G 8.60E-116 Urate levels ABCG2 intron 23263486 rs17731538 chr4 89055379 G A 1 Drug response to Methotrexate ABCG2 intron 18256692 rs4148152 chr4 89060909 T C 3.00E-18 Serum uric acid levels ABCG2 intron 24513273 rs2231137 chr4 89061114 C T 1 Drug response to Lamivudine ABCG2 missense 17509035 rs13137622 chr4 89062513 G T 2.20E-18 Urate levels ABCG2 intron 20884846 rs13137622 chr4 89062513 G T 8.49E-27 Urate levels ABCG2 intron 23263486 rs2622620 chr4 89063851 C A 2.30E-08 Urate (in serum),gout ABCG2 intron 21983786 rs3114018 chr4 89064581 A C 2.93E-12 Uric acid levels ABCG2 intron 19503597 rs3114018 chr4 89064581 A C 3.30E-21 Urate levels ABCG2 intron 20884846 rs3114018 chr4 89064581 A C 7.28E-14 Urate levels ABCG2 intron 21768215 rs3114018 chr4 89064581 A C 7.00E-08 Dental caries ABCG2 intron 23064961 rs3114018 chr4 89064581 A C 3.38E-52 Urate levels ABCG2 intron 23263486 rs3114018 chr4 89064581 A C 4.00E-20 Serum uric acid levels ABCG2 intron 24513273 rs3109823 chr4 89064602 C T 6.40E-15 Urate levels ABCG2 intron 20884846 rs3109823 chr4 89064602 C T 2.16E-09 Urate levels ABCG2 intron 21768215 rs3109823 chr4 89064602 C T 1.94E-28 Urate levels ABCG2 intron 23263486 rs2622627 chr4 89065353 C A 1.90E-09 Urate (in serum),gout ABCG2 intron 21983786 rs2725249 chr4 89065868 A C 2.00E-09 Urate (in serum),gout ABCG2 intron 21983786 rs6857600 chr4 89066075 C T 8.83E-12 Urate levels ABCG2 intron 23263486 rs2622626 chr4 89066715 C A 2.80E-13 Uric acid levels ABCG2 intron 19503597 rs2622626 chr4 89066715 C A 7.50E-21 Urate levels ABCG2 intron 20884846 rs2622626 chr4 89066715 C A 1.03E-15 Urate levels ABCG2 intron 21768215 rs2622626 chr4 89066715 C A 1.60E-09 Urate (in serum),gout ABCG2 intron 21983786 rs2622626 chr4 89066715 C A 7.71E-54 Urate levels ABCG2 intron 23263486 rs6532049 chr4 89067526 C T 8.40E-11 Urate levels ABCG2 intron 23263486 rs2725248 chr4 89068007 C A 4.60E-08 Urate (in serum),gout ABCG2 intron 21983786 rs2725247 chr4 89068257 G A 4.50E-10 Urate (in serum),gout ABCG2 intron 21983786 rs17731799 chr4 89068455 G T 2.05E-12 Uric acid levels ABCG2 intron 19503597 rs17731799 chr4 89068455 G T 1.30E-26 Urate levels ABCG2 intron 20884846 rs17731799 chr4 89068455 G T 2.14E-16 Urate levels ABCG2 intron 21768215 rs17731799 chr4 89068455 G T 2.80E-10 Urate (in serum),gout ABCG2 intron 21983786 rs17731799 chr4 89068455 G T 9.05E-62 Urate levels ABCG2 intron 23263486 rs2725246 chr4 89068498 G A 4.70E-10 Urate (in serum),gout ABCG2 intron 21983786 rs2622625 chr4 89068737 T C 2.70E-08 Urate (in serum),gout ABCG2 intron 21983786 rs2725245 chr4 89068738 G A 4.70E-10 Urate (in serum),gout ABCG2 intron 21983786 rs2725244 chr4 89068761 T C 1.80E-09 Urate (in serum),gout ABCG2 intron 21983786 rs2622624 chr4 89069406 T C 2.21E-12 Uric acid levels ABCG2 intron 19503597 rs2622624 chr4 89069406 T C 1.10E-26 Urate levels ABCG2 intron 20884846 rs2622624 chr4 89069406 T C 2.20E-16 Urate levels ABCG2 intron 21768215 rs2622624 chr4 89069406 T C 4.70E-10 Urate (in serum),gout ABCG2 intron 21983786 rs2622624 chr4 89069406 T C 7.78E-62 Urate levels ABCG2 intron 23263486 rs2725242 chr4 89069527 T A 1.90E-09 Urate (in serum),gout ABCG2 intron 21983786 rs13109944 chr4 89074405 T C 4.00E-09 Urate (in serum),gout ABCG2 intron 21983786 rs28856119 chr4 89074603 A G 7.10E-10 Urate (in serum),gout ABCG2 intron 21983786 rs34633905 chr4 89074771 C G 7.10E-10 Urate (in serum),gout ABCG2 intron 21983786 rs2725239 chr4 89075623 C A 1.20E-09 Urate (in serum),gout ABCG2 intron 21983786 rs2622603 chr4 89077481 C G 1.30E-09 Urate (in serum),gout ABCG2 intron 21983786 rs2622604 chr4 89078924 T C 7.90E-14 Urate levels ABCG2 intron 20884846 rs2622604 chr4 89078924 T C 8.59E-10 Urate levels ABCG2 intron 21768215 rs2622604 chr4 89078924 T C 6.05E-30 Urate levels ABCG2 intron 23263486 rs2622605 chr4 89079386 T A,C,G 2.75E-12 Uric acid levels ABCG2 intron 19503597 rs2622605 chr4 89079386 T A,C,G 1.50E-28 Urate levels ABCG2 intron 20884846 rs2622605 chr4 89079386 T A,C,G 3.72E-18 Urate levels ABCG2 intron 21768215 rs2622605 chr4 89079386 T A,C,G 1.10E-09 Urate (in serum),gout ABCG2 intron 21983786 rs2622605 chr4 89079386 T A,C,G 3.92E-64 Urate levels ABCG2 intron 23263486 rs3114020 chr4 89083666 T C 4.08E-13 Uric acid levels ABCG2 intron 19503597 rs3114020 chr4 89083666 T C 2.40E-28 Urate levels ABCG2 intron 20884846 rs3114020 chr4 89083666 T C 4.03E-18 Urate levels ABCG2 intron 21768215 rs3114020 chr4 89083666 T C 1.30E-09 Urate (in serum),gout ABCG2 intron 21983786 rs3114020 chr4 89083666 T C 2.58E-66 Urate levels ABCG2 intron 23263486 rs2725226 chr4 89085331 G A 7.50E-10 Urate (in serum),gout ABCG2 intron 21983786 rs2622608 chr4 89086744 A T 2.70E-10 Urate levels ABCG2 intron 20884846 rs2622608 chr4 89086744 A T 7.60E-10 Urate (in serum),gout ABCG2 intron 21983786 rs2622609 chr4 89088475 A C 6.90E-10 Urate (in serum),gout ABCG2 intron 21983786 rs10011796 chr4 89090877 T C 5.06E-10 Uric acid levels ABCG2 intron 19503597 rs10011796 chr4 89090877 T C 5.10E-20 Urate levels ABCG2 intron 20884846 rs10011796 chr4 89090877 T C 1.18E-08 Urate levels ABCG2 intron 21768215 rs10011796 chr4 89090877 T C 2.43E-51 Urate levels ABCG2 intron 23263486 rs10009618 chr4 89094008 C T 7.86E-10 Uric acid levels ABCG2 intron 19503597 rs10009618 chr4 89094008 C T 7.60E-20 Urate levels ABCG2 intron 20884846 rs10009618 chr4 89094008 C T 1.24E-08 Urate levels ABCG2 intron 21768215 rs10009618 chr4 89094008 C T 1.99E-51 Urate levels ABCG2 intron 23263486 rs2622629 chr4 89094064 T C 2.19E-15 Urate levels ABCG2 intron 23263486 rs1481014 chr4 89097151 C A,G,T 4.62E-08 Urate levels ABCG2 intron 23263486 rs1481017 chr4 89097477 C T 4.16E-09 Uric acid levels ABCG2 intron 19503597 rs1481017 chr4 89097477 C T 6.10E-20 Urate levels ABCG2 intron 20884846 rs1481017 chr4 89097477 C T 1.25E-08 Urate levels ABCG2 intron 21768215 rs1481017 chr4 89097477 C T 6.41E-51 Urate levels ABCG2 intron 23263486 rs11724427 chr4 89103172 A C,G,T 1.40E-09 Urate levels ABCG2 intron 20884846 rs11724427 chr4 89103172 A C,G,T 8.89E-24 Urate levels ABCG2 intron 23263486 rs6821227 chr4 89104688 C T 1.40E-09 Urate levels ABCG2 intron 20884846 rs6821227 chr4 89104688 C T 3.86E-19 Urate levels ABCG2 intron 23263486 rs6821239 chr4 89104751 A G 1.20E-09 Urate levels ABCG2 intron 20884846 rs6821239 chr4 89104751 A G 1.96E-17 Urate levels ABCG2 intron 23263486 rs9784454 chr4 89107490 C T 5.90E-09 Urate levels ABCG2 intron 20884846 rs9784454 chr4 89107490 C T 4.42E-16 Urate levels ABCG2 intron 23263486 rs6532053 chr4 89109259 A G 5.40E-09 Urate levels ABCG2 intron 20884846 rs6532053 chr4 89109259 A G 1.26E-20 Urate levels ABCG2 intron 23263486 rs2127863 chr4 89111468 T C 7.20E-09 Urate levels ABCG2 intron 20884846 rs2127863 chr4 89111468 T C 3.38E-19 Urate levels ABCG2 intron 23263486 rs4560364 chr4 89116178 A G 5.70E-09 Urate levels ABCG2 intron 20884846 rs4560364 chr4 89116178 A G 6.95E-21 Urate levels ABCG2 intron 23263486 rs13108900 chr4 89116702 C G 4.40E-09 Urate levels ABCG2 intron 20884846 rs13108900 chr4 89116702 C G 9.95E-21 Urate levels ABCG2 intron 23263486 rs10856870 chr4 89119659 T C 3.00E-16 Urate levels ABCG2 intron 23263486 rs4693930 chr4 89122833 G A 4.94E-22 Urate levels ABCG2 intron 23263486 rs10023457 chr4 89134704 T A 3.06E-19 Urate levels ABCG2 intron 23263486 rs6819328 chr4 89137318 C T 9.65E-16 Urate levels ABCG2 intron 23263486 rs2869736 chr4 89138377 G T 1.72E-11 Urate levels ABCG2 intron 23263486 rs4693935 chr4 89139275 A G 1.90E-08 Urate levels ABCG2 intron 20884846 rs4693935 chr4 89139275 A G 1.08E-15 Urate levels ABCG2 intron 23263486 rs2904185 chr4 89139832 C T 3.91E-15 Urate levels ABCG2 intron 23263486 rs4491984 chr4 89140356 C T 3.96E-18 Urate levels ABCG2 intron 23263486 rs1904903 chr4 89145274 T A 2.86E-20 Urate levels ABCG2 intron 23263486 rs2046132 chr4 89149026 G C 7.20E-05 Multiple complex diseases ABCG2 intron 17554300 rs7655059 chr4 89149144 C G 1.18E-05 Multiple complex diseases ABCG2 intron 17554300 rs9307048 chr4 89149570 C T 5.00E-10 Urate levels ABCG2 intron 20884846 rs9307048 chr4 89149570 C T 5.64E-19 Urate levels ABCG2 intron 23263486 rs10032109 chr4 89152063 C T 1.04E-14 Urate levels ABCG2 missense 23263486 rs4693941 chr4 89156899 A T 1.01E-19 Urate levels / / 23263486 rs1114568 chr4 89159819 G A 3.09E-14 Urate levels / / 23263486 rs13120254 chr4 89160561 C A 5.10E-09 Urate levels / / 20884846 rs13120254 chr4 89160561 C A 4.54E-21 Urate levels / / 23263486 rs13120819 chr4 89160677 G A 5.28E-20 Urate levels / / 23263486 rs6532058 chr4 89161902 C T 1.51E-08 Urate levels / / 23263486 rs997630 chr4 89163853 A G 1.31E-18 Urate levels / / 23263486 rs6532059 chr4 89163923 C T 2.00E-06 Longevity,exceptional / / 20595579 rs4693942 chr4 89165192 C G 3.90E-19 Urate levels / / 23263486 rs6532061 chr4 89165613 C T 8.14E-17 Urate levels / / 23263486 rs17013965 chr4 89170730 G A 3.43E-11 Urate levels / / 23263486 rs11729997 chr4 89171059 C A 5.04E-13 Urate levels / / 23263486 rs6853928 chr4 89172568 C T 8.31E-14 Urate levels / / 23263486 rs11733577 chr4 89174193 C T 2.91E-04 Multiple complex diseases / / 17554300 rs17789027 chr4 89181841 A G 1.50E-13 Metabolite levels PPM1K UTR-3 22286219 rs7658173 chr4 89182518 T C 3.54E-05 Hypertension (essential hypertension) PPM1K UTR-3 22184326 rs7658173 chr4 89182518 T C 1.19E-13 Metabolite levels PPM1K UTR-3 22286219 rs4693209 chr4 89187068 G C 1.82E-13 Metabolite levels PPM1K intron 22286219 rs6843634 chr4 89188993 G A 1.67E-13 Metabolite levels PPM1K intron 22286219 rs6821589 chr4 89192792 A G 5.32E-12 Metabolite levels PPM1K intron 22286219 rs17789147 chr4 89193640 C G 5.31E-12 Metabolite levels PPM1K intron 22286219 rs13125860 chr4 89194928 T A 8.41E-12 Metabolite levels PPM1K intron 22286219 rs34752329 chr4 89195540 G A 5.51E-12 Metabolite levels PPM1K intron 22286219 rs7656367 chr4 89196821 A G 3.04E-13 Metabolite levels PPM1K intron 22286219 rs6819344 chr4 89197519 C A 5.50E-12 Metabolite levels PPM1K intron 22286219 rs7661312 chr4 89201007 T G 2.17E-13 Metabolite levels PPM1K intron 22286219 rs2869926 chr4 89201376 C T 5.71E-12 Metabolite levels PPM1K intron 22286219 rs881561 chr4 89203042 G A 1.06E-11 Metabolite levels PPM1K intron 22286219 rs893971 chr4 89203670 A G 7.00E-06 Conduct disorder (interaction) PPM1K intron 18846501 rs893971 chr4 89203670 A G 6.81E-12 Metabolite levels PPM1K intron 22286219 rs17732955 chr4 89204093 C T 6.05E-05 Serum metabolites PPM1K intron 19043545 rs17732955 chr4 89204093 C T 5.38E-11 Metabolite levels PPM1K intron 22286219 rs9637599 chr4 89206230 A C 1.80E-13 Metabolite levels / / 22286219 rs4423843 chr4 89206756 A G 6.32E-12 Metabolite levels / / 22286219 rs4693210 chr4 89208565 A G 2.04E-13 Metabolite levels / / 22286219 rs958325 chr4 89209681 C T 9.78E-13 Metabolite levels / / 22286219 rs13128713 chr4 89210605 T C 1.20E-11 Metabolite levels / / 22286219 rs6845249 chr4 89211522 C T 1.14E-11 Metabolite levels / / 22286219 rs34813495 chr4 89213077 A G 1.47E-11 Metabolite levels / / 22286219 rs7655241 chr4 89214071 G A 1.16E-10 Metabolite levels / / 22286219 rs28406500 chr4 89215816 G C 2.19E-11 Metabolite levels / / 22286219 rs10024717 chr4 89219645 G A 2.06E-05 Amyotrophic lateral sclerosis / / 18987618 rs10024717 chr4 89219645 G A 5.82E-11 Metabolite levels / / 22286219 rs4693946 chr4 89219705 T C 3.35E-04 Type 2 diabetes / / 17463246 rs4693946 chr4 89219705 T C 1.99E-09 Urate levels / / 23263486 rs9995093 chr4 89220944 T A 7.00E-06 Bipolar disorder / / 22925353 rs7678928 chr4 89222827 C T 2.83E-15 Metabolite levels / / 22286219 rs13151250 chr4 89223058 G A 2.70E-11 Metabolite levels / / 22286219 rs28375859 chr4 89224185 G A 2.43E-11 Metabolite levels / / 22286219 rs11931633 chr4 89224337 C A,T 1.44E-11 Metabolite levels / / 22286219 rs9995984 chr4 89225088 C G 3.56E-14 Metabolite levels / / 22286219 rs10018448 chr4 89225171 A G 3.15E-16 Metabolite levels / / 22286219 rs1440581 chr4 89226422 T C 2.00E-16 Metabolite levels / / 22286219 rs1440581 chr4 89226422 T C 1.00E-10 Metabolite levels (atherosclerosis) / / 22916037 rs1440581 chr4 89226422 T C 3.74E-06 Odorant perception / / 23910658 rs1440581 chr4 89226422 T C 1.00E-16 Blood metabolite levels / / 24816252 rs1440581 chr4 89226422 T C 1.00E-19 Blood metabolite levels / / 24816252 rs1440581 chr4 89226422 T C 3.00E-12 Blood metabolite levels / / 24816252 rs1440580 chr4 89226747 T A 2.06E-14 Metabolite levels / / 22286219 rs17013995 chr4 89227094 A G 3.35E-04 Type 2 diabetes / / 17463246 rs17013995 chr4 89227094 A G 1.47E-09 Urate levels / / 23263486 rs17789621 chr4 89227121 C T 7.70E-12 Metabolite levels / / 22286219 rs7676986 chr4 89227673 G C 3.35E-04 Type 2 diabetes / / 17463246 rs7676986 chr4 89227673 G C 1.56E-09 Urate levels / / 23263486 rs7677533 chr4 89227918 G A 7.01E-12 Metabolite levels / / 22286219 rs7660693 chr4 89228383 T C 1.32E-14 Metabolite levels / / 22286219 rs6841731 chr4 89228928 G A 2.65E-14 Metabolite levels / / 22286219 rs1899132 chr4 89229337 G A 1.99E-16 Metabolite levels / / 22286219 rs28789746 chr4 89230502 T C 1.53E-11 Metabolite levels / / 22286219 rs9998450 chr4 89231125 G C 7.45E-12 Metabolite levels / / 22286219 rs4693947 chr4 89231404 A G 5.49E-14 Metabolite levels / / 22286219 rs28884607 chr4 89231823 G A 7.99E-12 Metabolite levels / / 22286219 rs6532063 chr4 89231955 T C 4.30E-12 Metabolite levels / / 22286219 rs1595911 chr4 89232425 C A 3.20E-12 Metabolite levels / / 22286219 rs1595910 chr4 89232572 C T 6.88E-12 Metabolite levels / / 22286219 rs1808860 chr4 89234709 T C 3.97E-13 Metabolite levels / / 22286219 rs1808859 chr4 89234812 T C 3.43E-13 Metabolite levels / / 22286219 rs28504259 chr4 89235870 C G 1.37E-11 Metabolite levels / / 22286219 rs1545207 chr4 89239492 G A 3.75E-08 Urate levels / / 23263486 rs10022462 chr4 89243818 C T 5.00E-11 Blood metabolite levels / / 24816252 rs17014018 chr4 89248035 G A 2.30E-08 Urate levels / / 20884846 rs17014018 chr4 89248035 G A 9.69E-14 Urate levels / / 23263486 rs4693211 chr4 89249061 T C 8.30E-08 Urate levels / / 20884846 rs4693211 chr4 89249061 T C 1.67E-13 Urate levels / / 23263486 rs4693950 chr4 89249444 C G 3.74E-08 Urate levels / / 23263486 rs12512051 chr4 89252068 C T 1.50E-07 Urate levels / / 20884846 rs12512051 chr4 89252068 C T 2.13E-12 Urate levels / / 23263486 rs9968289 chr4 89281660 T C 4.13E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4693212 chr4 89283496 C T 1.72E-04 Stroke / / pha002887 rs4693957 chr4 89287096 G A 6.65E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4693957 chr4 89287096 G A 8.13E-04 Rheumatoid arthritis / / 21452313 rs12651141 chr4 89287709 G A 4.31E-04 Schizophrenia / / 19197363 rs7677237 chr4 89306659 T C 2.00E-04 Job-related exhaustion HERC6 missense 23620144 rs17790893 chr4 89316509 A G 8.17E-05 Gallbladder cancer HERC6 intron 22318345 rs17014118 chr4 89319296 T C 1.70E-05 Personality dimensions HERC6 missense 18957941 rs41323045 chr4 89348204 G A 4.49E-04 Multiple complex diseases HERC6 intron 17554300 rs41323045 chr4 89348204 G A 7.10E-06 Urinary metabolites HERC6 intron 21572414 rs10516808 chr4 89383662 G A 8.78E-04 Bipolar disorder HERC5 intron 19259986 rs10516809 chr4 89421086 A G 9.00E-06 Pulmonary function decline HERC5 cds-synon 22424883 rs2717533 chr4 89441779 A G 4.23E-04 Lung function (forced vital capacity) / / 24023788 rs4693959 chr4 89445906 G T 1.57E-04 Celiac disease / / 23936387 rs11735201 chr4 89456677 G C 2.03E-04 Multiple complex diseases / / 17554300 rs10516812 chr4 89478101 C T 7.20E-05 Alcoholism (heaviness of drinking) / / 21529783 rs3910143 chr4 89486180 G A 2.53E-05 Acute lung injury / / 22295056 rs3846285 chr4 89491750 T C 2.49E-04 Acute lung injury / / 22295056 rs6532071 chr4 89492542 T C 2.56E-04 Acute lung injury / / 22295056 rs41421447 chr4 89500186 T G 3.48E-04 Multiple complex diseases / / 17554300 rs11732343 chr4 89503891 G A 4.49E-04 Acute lung injury / / 22295056 rs3796660 chr4 89522621 G T 4.49E-04 Acute lung injury HERC3 intron 22295056 rs3822084 chr4 89522699 G T 4.49E-04 Acute lung injury HERC3 intron 22295056 rs17014254 chr4 89526143 T C 2.37E-04 Acute lung injury HERC3 intron 22295056 rs3775418 chr4 89526864 A T 4.49E-04 Acute lung injury HERC3 intron 22295056 rs10034402 chr4 89532647 T C 3.79E-04 Acute lung injury HERC3 intron 22295056 rs10516813 chr4 89534100 T G 4.30E-04 Acute lung injury HERC3 intron 22295056 rs9307051 chr4 89534933 G C 4.30E-04 Acute lung injury HERC3 intron 22295056 rs17014279 chr4 89535270 G A 4.36E-04 Acute lung injury HERC3 intron 22295056 rs2972025 chr4 89538424 G T 4.17E-04 Acute lung injury HERC3 intron 22295056 rs17014304 chr4 89539949 T C 4.33E-04 Acute lung injury HERC3 intron 22295056 rs2930806 chr4 89553158 A T 2.58E-04 Acute lung injury HERC3 intron 22295056 rs2282593 chr4 89576581 C T 3.34E-04 Schizophrenia HERC3 intron 19197363 rs17014344 chr4 89578420 A G 6.91E-04 Acute lung injury HERC3 intron 22295056 rs17014374 chr4 89585781 T C 7.91E-04 Acute lung injury HERC3 intron 22295056 rs10516815 chr4 89587325 G A 8.06E-04 Acute lung injury HERC3 intron 22295056 rs10516816 chr4 89587377 A T 8.06E-04 Acute lung injury HERC3 intron 22295056 rs17014385 chr4 89587411 G A 8.06E-04 Acute lung injury HERC3 intron 22295056 rs2860259 chr4 89587834 T C 9.48E-04 Acute lung injury HERC3 intron 22295056 rs10516817 chr4 89588067 G A 2.69E-04 Schizophrenia HERC3 intron 19197363 rs17014393 chr4 89589690 C A 9.53E-04 Acute lung injury HERC3 intron 22295056 rs17014397 chr4 89590128 G A 9.51E-04 Acute lung injury HERC3 intron 22295056 rs2924354 chr4 89590831 T G 9.44E-04 Acute lung injury HERC3 intron 22295056 rs10516818 chr4 89592188 A G 9.18E-04 Acute lung injury HERC3 intron 22295056 rs17014415 chr4 89592280 T C 9.06E-04 Acute lung injury HERC3 intron 22295056 rs10516821 chr4 89727979 T C 1.27E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FAM13A intron 24023788 rs7691186 chr4 89731909 A G 7.43E-04 Multiple complex diseases FAM13A intron 17554300 rs3775378 chr4 89740078 C T 8.48E-04 Type 2 diabetes FAM13A intron 17463246 rs3822072 chr4 89741269 G A 0.000000018 Body mass index FAM13A intron 22885924 rs3822072 chr4 89741269 G A 0.000000018 Fasting insulin-related traits FAM13A intron 22885924 rs3822072 chr4 89741269 G A 4.00E-12 HDL cholesterol FAM13A intron 24097068 rs3775373 chr4 89743821 G T 1.40E-05 Urinary metabolites FAM13A intron 21572414 rs10021465 chr4 89750361 A G 9.28E-08 Pulmonary function FAM13A intron 20010835 rs11097200 chr4 89761563 T C 5.71E-05 Calcium levels FAM13A intron pha003085 rs11735482 chr4 89776246 C T 8.51E-05 Bone mineral density FAM13A intron 19181680 rs6830970 chr4 89777081 A G 1.92E-08 Pulmonary function FAM13A intron 20010835 rs6830970 chr4 89777081 A G 6.66E-05 Interstitial lung disease FAM13A intron 23583980 rs2085600 chr4 89779909 G A 5.31E-05 Waist-Hip Ratio FAM13A intron pha003029 rs922026 chr4 89789067 A T 1.81E-05 Pulmonary function FAM13A intron 20010835 rs1979290 chr4 89789478 G T 2.05E-05 Pulmonary function FAM13A intron 20010835 rs17815912 chr4 89791075 A G 1.91E-05 Pulmonary function FAM13A intron 20010835 rs2869964 chr4 89791654 G T 3.55E-05 Pulmonary function FAM13A intron 20010835 rs1379932 chr4 89800892 C T 8.54E-04 Multiple complex diseases FAM13A intron 17554300 rs1379932 chr4 89800892 C T 9.08E-05 Pulmonary function FAM13A intron 20010835 rs4693974 chr4 89810395 A G 6.12E-06 Pulmonary function FAM13A intron 20010835 rs2609255 chr4 89811195 G T 5.65E-05 Pulmonary function FAM13A intron 20010835 rs2609255 chr4 89811195 G T 2.00E-11 Interstitial lung disease FAM13A intron 23583980 rs2609255 chr4 89811195 G T 5.27E-06 Interstitial lung disease FAM13A intron 23583980 rs2609255 chr4 89811195 G T 2.08E-04 Iron levels FAM13A intron pha002876 rs2609255 chr4 89811195 G T 5.16E-05 Waist Circumference FAM13A intron pha003023 rs1458551 chr4 89812242 T C 5.59E-05 Pulmonary function FAM13A intron 20010835 rs2704581 chr4 89815404 A G 2.39E-05 Pulmonary function FAM13A intron 20010835 rs2464528 chr4 89817664 C A 4.94E-05 Pulmonary function FAM13A intron 20010835 rs2609265 chr4 89826966 T C 4.75E-05 Pulmonary function FAM13A intron 20010835 rs2609264 chr4 89828080 C T 4.72E-05 Pulmonary function FAM13A intron 20010835 rs2446300 chr4 89831727 T G 3.97E-05 Pulmonary function FAM13A intron 20010835 rs10019681 chr4 89832532 C T 3.73E-05 Interstitial lung disease FAM13A intron 23583980 rs2609262 chr4 89835438 A G 3.33E-05 Pulmonary function FAM13A intron 20010835 rs2609261 chr4 89835485 A G 3.45E-05 Pulmonary function FAM13A intron 20010835 rs2609260 chr4 89836819 C T 9.77E-05 Pulmonary function FAM13A intron 20010835 rs2609259 chr4 89837808 A C 3.19E-05 Pulmonary function FAM13A intron 20010835 rs2609258 chr4 89839594 C T 3.17E-05 Pulmonary function FAM13A intron 20010835 rs1458562 chr4 89853598 C T 2.32E-06 Pulmonary function FAM13A intron 20010835 rs4693978 chr4 89854167 A C 3.80E-06 Pulmonary function FAM13A intron 20010835 rs10008568 chr4 89854192 G A 3.69E-06 Pulmonary function FAM13A intron 20010835 rs2609280 chr4 89854961 A G 3.30E-05 Pulmonary function FAM13A intron 20010835 rs13149750 chr4 89854994 G A 3.69E-06 Pulmonary function FAM13A intron 20010835 rs2609279 chr4 89855495 T C 2.67E-05 Pulmonary function FAM13A intron 20010835 rs1903009 chr4 89856277 C T 5.56E-04 Amyotrophic Lateral Sclerosis FAM13A intron 17362836 rs2446309 chr4 89857152 A G 2.01E-04 Amyotrophic Lateral Sclerosis FAM13A intron 17362836 rs987314 chr4 89862169 G A 4.77E-05 Bipolar disorder FAM13A intron 17486107 rs4416442 chr4 89866713 T C 1.00E-14 Chronic obstructive pulmonary disease (moderate to severe) FAM13A intron 24621683 rs4416442 chr4 89866713 T C 9.00E-15 Chronic obstructive pulmonary disease (severe) FAM13A intron 24621683 rs2869966 chr4 89869078 C T 1.63E-08 Pulmonary function FAM13A intron 20010835 rs2869966 chr4 89869078 C T 2.11E-08 Interstitial lung disease FAM13A intron 23583980 rs2869967 chr4 89869332 T C 1.00E-07 Pulmonary function FAM13A intron 20010835 rs2869967 chr4 89869332 T C 1.80E-07 Chronic obstructive pulmonary disease FAM13A intron 20173748 rs2869967 chr4 89869332 T C 1.41E-06 chronic obstructive pulmonary disease FAM13A intron 21921092 rs2869967 chr4 89869332 T C 2.20E-05 Lung adenocarcinoma FAM13A intron 22797724 rs2869967 chr4 89869332 T C 5.00E-11 Pulmonary function (interaction) FAM13A intron 23284291 rs2869967 chr4 89869332 T C 2.57E-08 Interstitial lung disease FAM13A intron 23583980 rs2869967 chr4 89869332 T C 7.54E-06 Interstitial lung disease FAM13A intron 23583980 rs2045517 chr4 89870964 C T 1.58E-08 Pulmonary function FAM13A intron 20010835 rs2045517 chr4 89870964 C T 2.33E-08 Interstitial lung disease FAM13A intron 23583980 rs1964516 chr4 89875909 C T 2.00E-09 Chronic obstructive pulmonary disease FAM13A intron 22080838 rs7671167 chr4 89883979 C T 6.30E-07 Pulmonary function FAM13A intron 20010835 rs7671167 chr4 89883979 C T 1.00E-11 Chronic obstructive pulmonary disease FAM13A intron 20173748 rs7671167 chr4 89883979 C T 8.22E-08 chronic obstructive pulmonary disease FAM13A intron 21921092 rs7671167 chr4 89883979 C T 4.17E-09 Interstitial lung disease FAM13A intron 23583980 rs7671167 chr4 89883979 C T 7.59E-07 Interstitial lung disease FAM13A intron 23583980 rs2013701 chr4 89885086 G T 6.52E-07 Pulmonary function FAM13A intron 20010835 rs2904259 chr4 89885714 T C 6.84E-07 Pulmonary function FAM13A intron 20010835 rs2904259 chr4 89885714 T C 4.57E-09 Interstitial lung disease FAM13A intron 23583980 rs1903003 chr4 89886297 C T 1.18E-05 Pulmonary function FAM13A intron 20010835 rs1903003 chr4 89886297 C T 7.74E-08 Chronic obstructive pulmonary disease FAM13A intron 20173748 rs1903003 chr4 89886297 C T 6.87E-08 chronic obstructive pulmonary disease FAM13A intron 21921092 rs1903003 chr4 89886297 C T 9.80E-07 Lung adenocarcinoma FAM13A intron 22797724 rs1903003 chr4 89886297 C T 2.11E-08 Interstitial lung disease FAM13A intron 23583980 rs1921679 chr4 89890784 T C 8.49E-05 Interstitial lung disease FAM13A intron 23583980 rs6838424 chr4 89896036 G A 4.80E-06 Lung adenocarcinoma FAM13A intron 22797724 rs16996143 chr4 89897359 A G 4.72E-05 Interstitial lung disease FAM13A intron 23583980 rs11737182 chr4 89898476 T C 5.42E-05 Interstitial lung disease FAM13A intron 23583980 rs10007590 chr4 89917135 A G 4.20E-06 Coronary heart disease FAM13A intron pha003033 rs2869971 chr4 89920691 G A 6.60E-04 Type 2 diabetes and 6 quantitative traits FAM13A intron 17848626 rs6852288 chr4 89925810 C G 4.65E-06 Pulmonary function FAM13A intron 20010835 rs6852928 chr4 89926193 C T 4.86E-06 Pulmonary function FAM13A intron 20010835 rs10015415 chr4 89928203 T C 4.94E-06 Pulmonary function FAM13A intron 20010835 rs6849143 chr4 89928489 T C 5.36E-06 Pulmonary function FAM13A intron 20010835 rs6849143 chr4 89928489 T C 2.93E-05 Interstitial lung disease FAM13A intron 23583980 rs1795739 chr4 89930313 A G 4.80E-06 Pulmonary function FAM13A intron 20010835 rs1398942 chr4 89930392 G A 1.90E-05 Urinary metabolites FAM13A intron 21572414 rs12505696 chr4 89931070 C T 5.35E-06 Interstitial lung disease FAM13A intron 23583980 rs6826407 chr4 89975033 T C 2.30E-05 Urinary metabolites FAM13A intron 21572414 rs1795731 chr4 89976882 T C 4.98E-05 Response to mTOR inhibitor (rapamycin) FAM13A intron 24009623 rs11097211 chr4 89978456 A G 2.30E-05 Urinary metabolites / / 21572414 rs16996151 chr4 89978800 C A 6.00E-06 Response to antipsychotic therapy (extrapyramidal side effects) / / 19875103 rs2670625 chr4 89978867 T C 1.83E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs6835031 chr4 89995425 G A 7.02E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs874147 chr4 89998258 C A 1.30E-05 Urinary metabolites / / 21572414 rs756175 chr4 89999041 A G 6.04E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs7691983 chr4 90025980 A G 1.20E-05 Urinary metabolites / / 21572414 rs17821540 chr4 90049495 C T 5.32E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6828137 chr4 90059434 G T 8.20E-04 Asperger disorder / / 21182207 rs6828137 chr4 90059434 G T 4.19E-05 Interstitial lung disease / / 23583980 rs7690336 chr4 90062409 A G 5.59E-05 Pulmonary function / / 20010835 rs12498498 chr4 90065194 T A 6.03E-05 Pulmonary function / / 20010835 rs756345 chr4 90073214 G A 1.58E-05 Pulmonary function / / 20010835 rs756345 chr4 90073214 G A 7.00E-04 Asperger disorder / / 21182207 rs756345 chr4 90073214 G A 5.73E-05 Interstitial lung disease / / 23583980 rs7684332 chr4 90075384 T C 5.90E-05 Pulmonary function / / 20010835 rs7672894 chr4 90077431 A T 5.84E-05 Pulmonary function / / 20010835 rs636446 chr4 90100155 C T 6.13E-05 Monocyte chemoattractant protein-1 / / pha003071 rs9990512 chr4 90107063 A C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs13353765 chr4 90116432 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17015160 chr4 90116978 T C 1.06E-04 Multiple complex diseases / / 17554300 rs679672 chr4 90126331 A G 1.70E-05 Coronary heart disease / / pha003031 rs557239 chr4 90132664 C T 4.03E-04 Type 2 diabetes / / 17463246 rs538005 chr4 90135739 C T 5.45E-05 Major depressive disorder (broad) / / 20038947 rs12647246 chr4 90138510 C T 8.78E-05 Suicide attempts in bipolar disorder / / 21423239 rs12650544 chr4 90138761 T C 7.06E-05 Suicide attempts in bipolar disorder / / 21423239 rs9307064 chr4 90146649 G A 2.20E-04 Breast cancer and prostate cancer / / 17903305 rs6847228 chr4 90155694 C T 4.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs1431555 chr4 90155732 T C 4.47E-05 Major depressive disorder (broad) / / 20038947 rs12500719 chr4 90157051 G A 4.44E-05 Major depressive disorder (broad) / / 20038947 rs17015231 chr4 90158274 A G 4.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs13110739 chr4 90162842 G A 1.99E-05 Type 2 diabetes / / 17463246 rs6532144 chr4 90164136 T C 4.65E-05 Major depressive disorder (broad) / / 20038947 rs7653897 chr4 90169925 A G 4.99E-05 Major depressive disorder (broad) GPRIN3 missense 20038947 rs4270553 chr4 90172722 A T 7.80E-05 Major depressive disorder (broad) GPRIN3 intron 20038947 rs13126986 chr4 90173451 T C 7.35E-05 Major depressive disorder (broad) GPRIN3 intron 20038947 rs13106955 chr4 90174346 G C 7.52E-05 Major depressive disorder (broad) GPRIN3 intron 20038947 rs17825868 chr4 90174968 T C 7.47E-05 Major depressive disorder (broad) GPRIN3 intron 20038947 rs1125861 chr4 90175113 A G 7.95E-05 Major depressive disorder (broad) GPRIN3 intron 20038947 rs13142984 chr4 90178067 C G 5.84E-05 Major depressive disorder (broad) GPRIN3 intron 20038947 rs13118995 chr4 90178131 T C 7.78E-05 Major depressive disorder (broad) GPRIN3 intron 20038947 rs13149373 chr4 90178671 C T 8.28E-05 Major depressive disorder (broad) GPRIN3 intron 20038947 rs6532149 chr4 90180437 A C 8.49E-05 Major depressive disorder (broad) GPRIN3 intron 20038947 rs7690986 chr4 90180489 G A 8.91E-05 Major depressive disorder (broad) GPRIN3 intron 20038947 rs6532150 chr4 90186759 G A 5.13E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) GPRIN3 intron 24236485 rs4399946 chr4 90194997 C T 8.20E-05 Lung function (forced expiratory volume in 1 second) GPRIN3 intron pha003103 rs1431559 chr4 90235488 G A 9.76E-04 Obesity (extreme) / / 21935397 rs13104039 chr4 90241029 T G 1.18E-04 Coronary heart disease / / 21971053 rs7664724 chr4 90241483 G A 6.74E-04 Obesity (extreme) / / 21935397 rs4106153 chr4 90244476 C A 7.17E-04 Obesity (extreme) / / 21935397 rs4106153 chr4 90244476 C A 9.28E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4106153 chr4 90244476 C A 9.18E-05 Parkinson's disease / / pha002865 rs10002808 chr4 90258402 G C 8.74E-04 Obesity (extreme) / / 21935397 rs1504489 chr4 90258588 T G 8.42E-05 Parkinson's disease / / pha002865 rs12650758 chr4 90309312 T C 9.89E-04 Type 2 diabetes / / 17463246 rs17777845 chr4 90343298 G A 5.81E-04 Type 2 diabetes / / 17463246 rs772492 chr4 90372566 T C 6.30E-05 Bone mineral density (BMD),in women / / 20164292 rs772492 chr4 90372566 T C 5.24E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17015692 chr4 90424103 C T 2.63E-05 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia / / 24039173 rs17175345 chr4 90428534 A T 5.28E-04 Multiple complex diseases / / 17554300 rs17176423 chr4 90460797 C A 7.50E-05 Iron levels / / 21208937 rs1552972 chr4 90473540 A G 0.0000731 Breast cancer early age of onset / / 18463975 rs1552974 chr4 90473728 C T 9.20E-05 Alzheimer's disease / / 22832961 rs12500582 chr4 90478608 T C 2.50E-05 Urinary metabolites / / 21572414 rs4414921 chr4 90500833 C T 3.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2220909 chr4 90505902 C T 1.86E-04 Type 2 diabetes / / 17463246 rs10516839 chr4 90508340 T G 6.05E-08 Parkinson's disease / / 21738487 rs1473533 chr4 90516679 G A 1.15E-05 Personality dimensions / / 22628180 rs1473533 chr4 90516679 G A 3.84E-04 Myocardial Infarction / / pha002883 rs1473532 chr4 90516766 T A 1.15E-05 Personality dimensions / / 22628180 rs17015895 chr4 90527778 T C 1.35E-05 Personality dimensions / / 22628180 rs17015896 chr4 90529920 C G 1.35E-05 Personality dimensions / / 22628180 rs17015906 chr4 90541469 T C 1.48E-05 Personality dimensions / / 22628180 rs17015911 chr4 90541803 A C 1.49E-05 Personality dimensions / / 22628180 rs17015916 chr4 90544349 T G 1.58E-05 Personality dimensions / / 22628180 rs1430961 chr4 90552920 A G 5.92E-06 Parkinson's disease / / 19915575 rs1430961 chr4 90552920 A G 5.24E-05 Parkinson's disease / / 21738487 rs1430961 chr4 90552920 A G 9.54E-05 Attention deficit hyperactivity disorder / / 22012869 rs17793404 chr4 90558634 G A 8.69E-04 Type 2 diabetes / / 17463246 rs11932021 chr4 90565218 C T 6.43E-05 Parkinson's disease / / 21738487 rs12644119 chr4 90603419 C A 6.12E-08 Parkinson's disease / / 19915575 rs12644119 chr4 90603419 C A 5.74E-07 Parkinson's disease / / 22438815 rs12644119 chr4 90603419 C A 2.15E-05 Parkinson's disease / / pha002868 rs356229 chr4 90606597 C T 2.28E-09 Parkinson's disease / / 19915575 rs356229 chr4 90606597 C T 3.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs356229 chr4 90606597 C T 4.84E-13 Parkinson's disease / / 21738487 rs356229 chr4 90606597 C T 5.56E-12 Parkinson's disease / / 22438815 rs356229 chr4 90606597 C T 5.48E-05 Parkinson's disease / / pha002865 rs356180 chr4 90628127 A G 6.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs356180 chr4 90628127 A G 7.65E-07 Parkinson's disease / / 21738487 rs356174 chr4 90630901 G T 3.79E-08 Parkinson's disease / / 21738487 rs356169 chr4 90632768 G T 1.49E-08 Parkinson's disease / / 21738487 rs356169 chr4 90632768 G T 2.05E-04 Parkinson's disease / / 22438815 rs2572323 chr4 90634552 A G 3.99E-10 Parkinson's disease / / 21738487 rs181489 chr4 90635020 T C 4.28E-10 Parkinson's disease / / 21738487 rs181489 chr4 90635020 T C 6.59E-09 Parkinson's disease / / 22438815 rs356219 chr4 90637601 G A 2.00E-47 Parkinson's disease / / 21292315 rs356219 chr4 90637601 G A 7.91E-21 Parkinson's disease / / 21738487 rs356219 chr4 90637601 G A 6.00E-65 Parkinson's disease / / 22438815 rs356219 chr4 90637601 G A 7.90E-06 Parkinson's disease / / 22451204 rs356219 chr4 90637601 G A 1.00E-10 Parkinson's disease / / 24511991 rs356219 chr4 90637601 G A 3.00E-05 Parkinson's disease / / 24511991 rs356219 chr4 90637601 G A 4.00E-09 Parkinson's disease / / 24511991 rs11931074 chr4 90639515 G T 1.62E-14 Parkinson's disease / / 19915575 rs11931074 chr4 90639515 G T 7.00E-17 Parkinson's disease / / 19915576 rs11931074 chr4 90639515 G T 4.34E-04 Parkinson's disease / / 21248740 rs11931074 chr4 90639515 G T 2.06E-11 Parkinson's disease / / 21738487 rs11931074 chr4 90639515 G T 2.52E-47 Parkinson's disease / / 22438815 rs11931074 chr4 90639515 G T 4.78E-08 Parkinson's disease / / pha002868 rs356220 chr4 90641340 T C 3.00E-11 Parkinson's disease / / 20711177 rs356220 chr4 90641340 T C 9.00E-16 Parkinson's disease / / 21044948 rs356220 chr4 90641340 T C 3.00E-08 Parkinson's disease / / 21084426 rs356220 chr4 90641340 T C 2.00E-19 Parkinson's disease / / 21738487 rs356220 chr4 90641340 T C 1.11E-33 Parkinson's disease / / 22438815 rs356220 chr4 90641340 T C 8.00E-35 Parkinson's disease / / 22451204 rs356220 chr4 90641340 T C 1.00E-09 Parkinson's disease / / 24511991 rs356220 chr4 90641340 T C 1.00E-09 Parkinson's disease / / 24511991 rs356220 chr4 90641340 T C 2.00E-05 Parkinson's disease / / 24511991 rs356220 chr4 90641340 T C 2.00E-05 Parkinson's disease / / 24511991 rs356220 chr4 90641340 T C 3.00E-11 Parkinson's disease / / 24511991 rs356220 chr4 90641340 T C 3.00E-11 Parkinson's disease / / 24511991 rs356220 chr4 90641340 T C 5.63E-05 Parkinson's disease / / 24842889 rs356220 chr4 90641340 T C 6.99E-08 Parkinson's disease / / pha002868 rs356221 chr4 90642464 A T 4.55E-20 Parkinson's disease / / 21738487 rs356221 chr4 90642464 A T 9.56E-12 Parkinson's disease / / 22438815 rs168552 chr4 90643144 C T 1.73E-08 Parkinson's disease / / 21738487 rs168552 chr4 90643144 C T 1.38E-05 Parkinson's disease / / 22438815 rs3857053 chr4 90645674 C T 5.15E-11 Parkinson's disease SNCA UTR-3 21738487 rs356165 chr4 90646886 G A 2.62E-19 Parkinson's disease SNCA UTR-3 21738487 rs356165 chr4 90646886 G A 6.98E-11 Parkinson's disease SNCA UTR-3 22438815 rs7684318 chr4 90655003 T C 2.55E-09 Parkinson's disease SNCA intron 21738487 rs7684318 chr4 90655003 T C 4.96E-05 Parkinson's disease SNCA intron 22438815 rs3775423 chr4 90657491 C T 6.23E-11 Parkinson's disease SNCA intron 21738487 rs356204 chr4 90663542 T C 1.38E-08 Parkinson's disease SNCA intron 22438815 rs3822086 chr4 90664794 C T 5.18E-11 Parkinson's disease SNCA intron 21738487 rs3822086 chr4 90664794 C T 4.04E-07 Parkinson's disease SNCA intron 22438815 rs3775424 chr4 90665256 C T 1.33E-05 Parkinson's disease SNCA intron 21738487 rs356203 chr4 90666041 C T 2.06E-19 Parkinson's disease SNCA intron 21738487 rs356203 chr4 90666041 C T 2.07E-07 Parkinson's disease SNCA intron 22438815 rs356200 chr4 90668614 T C 2.25E-19 Parkinson's disease SNCA intron 21738487 rs356168 chr4 90674431 G A 4.60E-08 Parkinson's disease SNCA intron 20711177 rs356168 chr4 90674431 G A 2.32E-19 Parkinson's disease SNCA intron 21738487 rs356168 chr4 90674431 G A 9.14E-06 Parkinson's disease SNCA intron 22438815 rs3857059 chr4 90675238 A G 3.74E-15 Parkinson's disease SNCA intron 19915575 rs3857059 chr4 90675238 A G 3.97E-04 Parkinson's disease SNCA intron 21248740 rs3857059 chr4 90675238 A G 4.12E-11 Parkinson's disease SNCA intron 21738487 rs3857059 chr4 90675238 A G 2.86E-32 Parkinson's disease SNCA intron 22438815 rs3857059 chr4 90675238 A G 3.60E-08 Parkinson's disease SNCA intron pha002868 rs2736990 chr4 90678541 G A 2.00E-16 Parkinson's disease SNCA intron 19915575 rs2736990 chr4 90678541 G A 7.00E-08 Parkinson's disease SNCA intron 20070850 rs2736990 chr4 90678541 G A 5.00E-08 Parkinson's disease SNCA intron 20711177 rs2736990 chr4 90678541 G A 8.26E-06 Parkinson's disease SNCA intron 21248740 rs2736990 chr4 90678541 G A 6.11E-19 Parkinson's disease SNCA intron 21738487 rs2736990 chr4 90678541 G A 2.24E-16 Prion diseases SNCA intron 22210626 rs2736990 chr4 90678541 G A 1.77E-34 Parkinson's disease SNCA intron 22438815 rs2736990 chr4 90678541 G A 1.00E-06 Parkinson's disease SNCA intron 24511991 rs2736990 chr4 90678541 G A 5.00E-05 Parkinson's disease SNCA intron 24511991 rs2736990 chr4 90678541 G A 5.00E-08 Parkinson's disease SNCA intron 24511991 rs2736990 chr4 90678541 G A 5.69E-09 Parkinson's disease SNCA intron pha002868 rs2572324 chr4 90678798 G A 1.05E-04 Parkinson's disease SNCA intron 22438815 rs356199 chr4 90682327 G A 1.34E-06 Parkinson's disease SNCA intron 21738487 rs356198 chr4 90682504 C T 1.00E-04 Parkinson's disease SNCA intron 24511991 rs356198 chr4 90682504 C T 3.00E-04 Parkinson's disease SNCA intron 24511991 rs10516845 chr4 90684278 A G 1.16E-09 Parkinson's disease SNCA intron 21738487 rs3796661 chr4 90687507 C T 2.60E-04 Volumetric brain MRI SNCA intron 17903297 rs3796661 chr4 90687507 C T 2.43E-05 Parkinson's disease SNCA intron 21738487 rs3796661 chr4 90687507 C T 5.51E-12 Parkinson's disease SNCA intron 22438815 rs356192 chr4 90687927 G A 1.00E-04 Prostate cancer SNCA intron 21743057 rs356191 chr4 90688120 G A 1.25E-06 Parkinson's disease SNCA intron 21738487 rs356189 chr4 90691132 T C 1.00E-04 Prostate cancer SNCA intron 21743057 rs356188 chr4 90691537 T C 4.60E-04 Parkinson's disease SNCA intron 21248740 rs356188 chr4 90691537 T C 2.13E-06 Parkinson's disease SNCA intron 21738487 rs356188 chr4 90691537 T C 9.03E-11 Parkinson's disease SNCA intron 22438815 rs356188 chr4 90691537 T C 8.41E-05 Parkinson's disease SNCA intron pha002865 rs356187 chr4 90692468 T C 6.60E-04 Multiple complex diseases SNCA intron 17554300 rs356187 chr4 90692468 T C 2.16E-06 Parkinson's disease SNCA intron 21738487 rs356164 chr4 90693476 C G 4.92E-06 Parkinson's disease SNCA intron 22438815 rs356163 chr4 90696827 A C 2.08E-06 Parkinson's disease SNCA intron 21738487 rs356163 chr4 90696827 A C 1.00E-04 Prostate cancer SNCA intron 21743057 rs356186 chr4 90705364 A G 6.42E-06 Parkinson's disease SNCA intron 21738487 rs356186 chr4 90705364 A G 1.41E-06 Parkinson's disease SNCA intron 22438815 rs2737033 chr4 90707947 T C 3.69E-06 Parkinson's disease SNCA intron 21738487 rs3775439 chr4 90709741 G A 2.99E-08 Parkinson's disease SNCA intron 19915575 rs3775439 chr4 90709741 G A 2.90E-05 Urinary metabolites SNCA intron 21572414 rs3775439 chr4 90709741 G A 7.66E-09 Parkinson's disease SNCA intron 21738487 rs3775439 chr4 90709741 G A 1.11E-09 Parkinson's disease SNCA intron 22438815 rs3775439 chr4 90709741 G A 4.43E-06 Parkinson's disease SNCA intron pha002868 rs2737029 chr4 90711770 T C 2.80E-16 Parkinson's disease SNCA intron 21738487 rs2737029 chr4 90711770 T C 2.78E-15 Parkinson's disease SNCA intron 22438815 rs12502363 chr4 90713064 G A 5.47E-05 Parkinson's disease SNCA intron 21738487 rs3775442 chr4 90715231 C T 3.96E-04 Multiple complex diseases SNCA intron 17554300 rs3775442 chr4 90715231 C T 1.34E-06 Parkinson's disease SNCA intron 22438815 rs2583958 chr4 90720365 T C 1.00E-04 Prostate cancer SNCA intron 21743057 rs2737024 chr4 90721560 A G 1.00E-04 Prostate cancer SNCA intron 21743057 rs2583959 chr4 90721637 C G 1.00E-04 Prostate cancer SNCA intron 21743057 rs2619373 chr4 90722433 G A 1.00E-04 Prostate cancer SNCA intron 21743057 rs2197120 chr4 90729602 A G 5.45E-07 Parkinson's disease SNCA intron 21738487 rs2197120 chr4 90729602 A G 1.26E-07 Parkinson's disease SNCA intron 22438815 rs1866995 chr4 90731709 A G 1.06E-05 Parkinson's disease SNCA intron 21738487 rs894278 chr4 90734535 T G 9.01E-09 Parkinson's disease SNCA intron 19915575 rs894278 chr4 90734535 T G 5.09E-04 Parkinson's disease SNCA intron 21248740 rs894278 chr4 90734535 T G 4.24E-08 Parkinson's disease SNCA intron 21738487 rs894278 chr4 90734535 T G 8.49E-12 Parkinson's disease SNCA intron 22438815 rs894278 chr4 90734535 T G 2.64E-05 Parkinson's disease SNCA intron pha002868 rs2298728 chr4 90742815 G A 1.49E-07 Parkinson's disease SNCA intron 21738487 rs2583978 chr4 90750326 A C 8.23E-04 Parkinson's disease SNCA intron 21248740 rs2583978 chr4 90750326 A C 2.39E-06 Parkinson's disease SNCA intron 21738487 rs2583981 chr4 90752582 A T 3.72E-05 Parkinson's disease SNCA intron 21738487 rs2737000 chr4 90754022 C A 9.21E-04 Multiple complex diseases SNCA intron 17554300 rs2028535 chr4 90756421 G C 5.81E-04 Alzheimer's disease SNCA intron 17998437 rs1372519 chr4 90757309 A G 6.31E-08 Parkinson's disease SNCA intron 21738487 rs1372520 chr4 90757505 T C 5.10E-08 Parkinson's disease SNCA intron 21738487 rs2245801 chr4 90757840 T C 2.18E-06 Parkinson's disease SNCA intron 21738487 rs2619363 chr4 90759047 G T 5.41E-05 Parkinson's disease SNCA intron 21738487 rs2619364 chr4 90759887 A G 5.43E-06 Parkinson's disease LOC644248 intron 22438815 rs2583988 chr4 90760828 C T 9.52E-07 Parkinson's disease LOC644248 intron 22438815 rs2870028 chr4 90765213 C T 3.20E-04 Volumetric brain MRI / / 17903297 rs7678651 chr4 90768371 C A 1.30E-04 Volumetric brain MRI / / 17903297 rs10516848 chr4 90775212 A G 1.60E-04 Volumetric brain MRI / / 17903297 rs2583961 chr4 90779758 A G 1.97E-05 Parkinson's disease / / 21738487 rs2737026 chr4 90779823 A G 2.17E-05 Parkinson's disease / / 21738487 rs2737026 chr4 90779823 A G 7.70E-05 Parkinson's disease / / 22438815 rs6532194 chr4 90780902 C T 9.69E-05 Alcohol dependence / / 21703634 rs6532194 chr4 90780902 C T 5.00E-11 Parkinson's disease / / 22438815 rs2736994 chr4 90784528 A G 2.56E-05 Parkinson's disease / / 21738487 rs11727074 chr4 90795281 T C 2.97E-04 Body mass index / / 17255346 rs17016316 chr4 90797235 A G 5.86E-04 Nicotine dependence / / 17158188 rs6532197 chr4 90797301 A G 1.09E-04 Body mass index / / 17255346 rs6532197 chr4 90797301 A G 1.00E-07 Parkinson's disease / / 19915575 rs6532197 chr4 90797301 A G 6.13E-05 Parkinson's disease / / 21738487 rs6532197 chr4 90797301 A G 3.10E-08 Parkinson's disease / / 22438815 rs1442138 chr4 90816294 A G 1.91E-04 Body mass index MMRN1 missense 17255346 rs1442138 chr4 90816294 A G 3.57E-04 Iron levels MMRN1 missense pha002876 rs3775465 chr4 90827466 A C 1.06E-05 Personality dimensions MMRN1 intron 22628180 rs10433955 chr4 90830783 A G 1.10E-05 Personality dimensions MMRN1 intron 22628180 rs7666981 chr4 90832044 C G 9.45E-06 Personality dimensions MMRN1 intron 22628180 rs3775467 chr4 90832608 C A 1.20E-05 Personality dimensions MMRN1 intron 22628180 rs10516850 chr4 90837127 A G 1.85E-05 Personality dimensions MMRN1 intron 22628180 rs3775473 chr4 90837641 G T 1.95E-05 Personality dimensions MMRN1 intron 22628180 rs10516851 chr4 90837944 C T 1.99E-05 Personality dimensions MMRN1 intron 22628180 rs12644375 chr4 90837980 A G 2.00E-05 Personality dimensions MMRN1 intron 22628180 rs3775477 chr4 90839022 T C 2.13E-05 Personality dimensions MMRN1 intron 22628180 rs12641781 chr4 90841787 G A 2.18E-05 Personality dimensions MMRN1 intron 22628180 rs3775478 chr4 90842840 A G 1.05E-07 Parkinson's disease MMRN1 intron 22438815 rs3775478 chr4 90842840 A G 2.34E-05 Personality dimensions MMRN1 intron 22628180 rs3775478 chr4 90842840 A G 6.07E-05 Parkinson's disease MMRN1 intron pha002865 rs146236543 chr4 90856383 G A 0.00054 Prostate cancer MMRN1 missense 23555315 rs12233759 chr4 90880403 G A 8.31E-05 Orofacial clefts / / 22419666 rs12233759 chr4 90880403 G A 8.45E-05 Breast cancer / / pha002853 rs722936 chr4 90971800 C A 4.25E-05 Serum albumin level / / pha003084 rs2120372 chr4 90983723 A G 4.62E-06 F-cell distribution / / 21326311 rs10516862 chr4 90997171 G T 2.38E-06 Bilirubin levels,in serum / / 19389676 rs6824746 chr4 91029192 T C 3.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6837278 chr4 91069888 A G 4.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM190A intron 20877124 rs17205242 chr4 91070674 A G 7.30E-05 Triglycerides FAM190A intron pha003081 rs17205242 chr4 91070674 A G 3.63E-05 Lipid levels FAM190A intron pha003082 rs1835524 chr4 91080308 T C 4.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM190A intron 20877124 rs1835523 chr4 91080598 A G 4.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM190A intron 20877124 rs2726 chr4 91102650 A G 4.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM190A intron 20877124 rs10516865 chr4 91105301 C A 4.27E-06 Acute lung injury FAM190A intron 22295056 rs17016697 chr4 91165346 A G 2.87E-04 Smoking quantity FAM190A intron 24665060 rs6832140 chr4 91172438 T C 9.42E-05 Parkinson's disease FAM190A intron 21248740 rs1350855 chr4 91194806 G A 1.30E-06 Parkinson's disease FAM190A intron 20711177 rs10015182 chr4 91253355 C T 1.75E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) FAM190A intron 23648065 rs1903579 chr4 91253956 G C 9.69E-04 Multiple complex diseases FAM190A intron 17554300 rs7663699 chr4 91262477 C G 7.77E-04 Multiple complex diseases FAM190A intron 17554300 rs12639691 chr4 91270504 C G 6.70E-04 Multiple complex diseases FAM190A intron 17554300 rs6851151 chr4 91298562 T C 9.26E-04 Suicide attempts in bipolar disorder FAM190A intron 21423239 rs2169398 chr4 91307525 A G 8.28E-05 HDL particle features FAM190A intron pha002900 rs187200046 chr4 91401611 C T 2.00E-06 Metabolite levels (HVA) FAM190A intron 23319000 rs187200046 chr4 91401611 C T 4.00E-06 Metabolite levels (HVA-5-HIAA Factor score) FAM190A intron 23319000 rs2036153 chr4 91460581 A C 3.10E-05 Bilirubin levels,in serum FAM190A intron 19389676 rs7694205 chr4 91461106 C G 2.62E-05 Intracerebral hemorrhage FAM190A intron 24656865 rs6820128 chr4 91481086 G A 1.13E-12 Gender FAM190A intron 22362730 rs7697633 chr4 91496746 A T 9.31E-05 Schizophrenia FAM190A intron pha002859 rs1510795 chr4 91501614 A G 2.95E-05 Hypertension FAM190A intron 22384028 rs17017217 chr4 91504762 C T 6.71E-04 Smoking quantity FAM190A intron 24665060 rs28645201 chr4 91528927 A G 1.22E-09 Beta globulins (%) FAM190A intron 23696881 rs17017280 chr4 91534943 A G 8.99E-05 Multiple complex diseases FAM190A intron 17554300 rs12505502 chr4 91568023 T G 5.62E-05 Attention deficit hyperactivity disorder FAM190A intron 18980221 rs13113267 chr4 91606389 A G 4.37E-04 Alzheimer's disease FAM190A intron 24755620 rs6848750 chr4 91618836 G C 2.05E-05 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia FAM190A intron 24039173 rs13134142 chr4 91642911 T G 3.67E-05 Alcohol dependence FAM190A intron 19581569 rs1399419 chr4 91664577 G A 3.43E-04 HIV-1 viral setpoint FAM190A intron 17641165 rs17244283 chr4 91672350 A G 2.30E-05 Urinary metabolites FAM190A intron 21572414 rs2123959 chr4 91720598 G A 1.99E-05 Schizophrenia FAM190A intron 19571809 rs7698270 chr4 91732329 G A 1.87E-04 Schizophrenia(treatment response to risperidone) FAM190A intron 19850283 rs17017652 chr4 91737500 C A 1.07E-07 Non-albumin protein levels FAM190A intron 22558069 rs17188252 chr4 91746584 G A 3.05E-05 Height FAM190A intron 22021425 rs6843345 chr4 91760762 C T 0.0000187 VLDL cholesterol particle diameter FAM190A intron 23263444 rs34846042 chr4 91763006 C T 4.65E-05 Intracerebral hemorrhage FAM190A intron 24656865 rs17248550 chr4 91766611 G A 0.0000285 Coronary artery calcification FAM190A intron 23394302 rs7662582 chr4 91769382 C A 0.000047 Coronary artery calcification FAM190A intron 23394302 rs13104288 chr4 91794069 T A 3.66E-05 Intracerebral hemorrhage FAM190A intron 24656865 rs35878191 chr4 91802628 T C 1.43E-05 Intracerebral hemorrhage FAM190A intron 24656865 rs34375703 chr4 91822395 G A 1.43E-05 Intracerebral hemorrhage FAM190A intron 24656865 rs1037910 chr4 91825652 G A 2.31E-05 Body Fat Distribution FAM190A intron pha003016 rs1037910 chr4 91825652 G A 1.39E-05 Body Fat Distribution FAM190A intron pha003017 rs1037910 chr4 91825652 G A 5.90E-05 Body Fat Distribution FAM190A intron pha003018 rs6824383 chr4 91840449 C T 5.38E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines FAM190A intron 21844884 rs1454333 chr4 91843130 G A 7.80E-04 Suicidal ideation FAM190A intron 22030708 rs13135875 chr4 91852795 A T 1.45E-05 Serum metabolites FAM190A intron 19043545 rs1454334 chr4 91876491 C T 4.60E-04 Alzheimer's disease FAM190A intron 22005930 rs1381297 chr4 91903868 G A 7.82E-04 Coronary Artery Disease FAM190A intron 17634449 rs10516882 chr4 91908576 C A 4.33E-05 Cardiovascular disease FAM190A intron 17903304 rs17017905 chr4 91911659 T C 1.00E-04 Cognitive impairment induced by topiramate FAM190A intron 22091778 rs2035116 chr4 91917416 A G 2.59E-04 Lung function (forced expiratory volume in 1 second) FAM190A intron 24023788 rs13148851 chr4 91917763 C A 9.96E-06 Cognitive impairment induced by topiramate FAM190A intron 22091778 rs7680898 chr4 91927272 T C 1.00E-04 Cognitive impairment induced by topiramate FAM190A intron 22091778 rs41338244 chr4 91937972 A G 1.30E-04 Type 2 diabetes FAM190A intron 17463246 rs35955130 chr4 91946453 C T 7.66E-06 Height FAM190A intron 22021425 rs12640033 chr4 91949192 A G 4.35E-05 Height FAM190A intron 22021425 rs1461598 chr4 91950488 C G 3.43E-06 Height FAM190A intron 22021425 rs71597222 chr4 91957156 T C 2.54E-05 Intracerebral hemorrhage FAM190A intron 24656865 rs6532271 chr4 92003897 C T 3.00E-06 Response to amphetamines FAM190A intron 22952603 rs11936946 chr4 92012047 C T 7.23E-05 Smoking initiation FAM190A intron 24665060 rs3944131 chr4 92028969 C T 5.00E-04 Amyotrophic lateral sclerosis FAM190A intron 17671248 rs34386665 chr4 92030178 C T 5.91E-06 Intracerebral hemorrhage FAM190A intron 24656865 rs35946853 chr4 92030223 C T 5.91E-06 Intracerebral hemorrhage FAM190A intron 24656865 rs6848271 chr4 92037585 C G 5.20E-06 Urinary metabolites FAM190A intron 21572414 rs17183429 chr4 92037951 G A 9.54E-04 Multiple complex diseases FAM190A intron 17554300 rs2107008 chr4 92056788 T C 8.60E-06 Urinary metabolites FAM190A intron 21572414 rs13104402 chr4 92066776 C T 8.30E-07 Urinary metabolites FAM190A intron 21572414 rs7699169 chr4 92093824 G A 1.20E-06 Urinary metabolites FAM190A intron 21572414 rs7699169 chr4 92093824 G A 5.70E-04 Smoking initiation FAM190A intron 24665060 rs10856882 chr4 92108454 T C 1.20E-06 Urinary metabolites FAM190A intron 21572414 rs9999729 chr4 92240031 C G 1.13E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs9999885 chr4 92240080 G A 1.13E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs7653977 chr4 92240278 A T 1.13E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs7683541 chr4 92240317 T C 3.27E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs7683541 chr4 92240317 T C 6.53E-05 Information processing speed FAM190A intron 21130836 rs7659326 chr4 92240679 A T 8.29E-05 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs6532289 chr4 92240802 C T 1.13E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs6816636 chr4 92240892 C A 8.27E-05 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs6532290 chr4 92240925 T G 3.45E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs6816883 chr4 92241071 A G 3.33E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs1528581 chr4 92242099 T C 1.41E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs1919227 chr4 92243568 T G 1.16E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs6532291 chr4 92243630 G A 1.38E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs6532292 chr4 92243680 T C 1.17E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs6532293 chr4 92244029 G A 1.18E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs955500 chr4 92245446 C T 3.35E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs3762827 chr4 92246344 G A 1.68E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs1528578 chr4 92247173 G C 1.70E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs6532296 chr4 92249995 G A 4.94E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs6532299 chr4 92251839 C T 4.98E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs6833290 chr4 92252092 T C 1.88E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs1406316 chr4 92253926 C T 1.88E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs1528564 chr4 92258471 C T 3.14E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs1534556 chr4 92259485 G A 1.31E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs4593093 chr4 92261676 G T 4.86E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs1881454 chr4 92265620 G C 4.88E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs2870313 chr4 92267559 G A 9.92E-04 Myopia (pathological) FAM190A intron 21095009 rs6841781 chr4 92270710 T C 4.93E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs6841781 chr4 92270710 T C 9.35E-05 Information processing speed FAM190A intron 21130836 rs6532301 chr4 92271993 A G 2.87E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs12507382 chr4 92280933 C T 8.25E-05 Blood Pressure FAM190A intron pha003039 rs4128705 chr4 92283771 T G 6.00E-06 Amyotrophic lateral sclerosis (sporadic) FAM190A intron 24529757 rs4128705 chr4 92283771 T G 6.48E-05 Blood Pressure FAM190A intron pha003039 rs1919225 chr4 92286605 A G 1.60E-04 Type 2 diabetes and 6 quantitative traits FAM190A intron 17848626 rs7654013 chr4 92291237 T G 5.41E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs1358554 chr4 92293482 C T 3.56E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs7672780 chr4 92295468 G A 3.58E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs1554850 chr4 92296559 C A 5.53E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs2178221 chr4 92302266 C T 3.50E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs6837355 chr4 92304224 A G 3.48E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs6844256 chr4 92305124 C G 3.47E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs7668527 chr4 92308384 T A 3.32E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs1528579 chr4 92309228 A T 4.96E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs10856885 chr4 92309543 C T 5.19E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs6820807 chr4 92311625 A T 5.30E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs2904382 chr4 92320024 G A 4.42E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs12648320 chr4 92322333 C A 5.08E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs4301075 chr4 92330203 A T 7.17E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs7672281 chr4 92330355 A C 7.03E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs2091765 chr4 92338803 A G 6.75E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs6845679 chr4 92350342 C T 4.48E-06 Personality dimensions FAM190A intron 22628180 rs2204873 chr4 92367596 T C 1.90E-05 Urinary metabolites FAM190A intron 21572414 rs6842809 chr4 92368285 A G 8.53E-04 Multiple complex diseases FAM190A intron 17554300 rs1922233 chr4 92368346 G A 2.00E-05 Urinary metabolites FAM190A intron 21572414 rs1922232 chr4 92368394 T C 6.74E-04 Multiple complex diseases FAM190A intron 17554300 rs1922230 chr4 92373327 C T 3.96E-05 Personality dimensions FAM190A intron 22628180 rs12649871 chr4 92381080 T C 1.90E-05 Urinary metabolites FAM190A intron 21572414 rs13123986 chr4 92382683 C G 3.32E-05 Personality dimensions FAM190A intron 22628180 rs2141848 chr4 92395356 A C 2.64E-06 Personality dimensions FAM190A intron 22628180 rs7675549 chr4 92399814 T A 4.30E-05 Personality dimensions FAM190A intron 22628180 rs7675583 chr4 92399884 T C 2.79E-06 Personality dimensions FAM190A intron 22628180 rs10007512 chr4 92406115 A T 4.25E-06 Personality dimensions FAM190A intron 22628180 rs13103495 chr4 92408133 A C 2.15E-04 Type 2 diabetes FAM190A intron 17463246 rs13103495 chr4 92408133 A C 5.60E-05 Hematology traits FAM190A intron 23303382 rs11933531 chr4 92415529 G A 3.00E-08 DNA methylation (variation) FAM190A intron 23725790 rs6849851 chr4 92426818 G A 4.12E-04 Suicide attempts in bipolar disorder FAM190A intron 21041247 rs1922224 chr4 92436457 G A 9.07E-04 Multiple complex diseases FAM190A intron 17554300 rs17018584 chr4 92451003 A G 2.45E-11 Multiple complex diseases FAM190A intron 17554300 rs17283537 chr4 92454931 G A 0.0002935 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FAM190A intron 23233654 rs17283537 chr4 92454931 G A 2.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) FAM190A intron 23233662 rs17218334 chr4 92481361 C T 0.0006471 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FAM190A intron 23233654 rs17218334 chr4 92481361 C T 6.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) FAM190A intron 23233662 rs7693738 chr4 92482074 G A 6.21E-04 Type 2 diabetes FAM190A intron 17463246 rs7693738 chr4 92482074 G A 2.40E-04 Multiple complex diseases FAM190A intron 17554300 rs6532321 chr4 92494466 T C 4.58E-04 Multiple complex diseases FAM190A intron 17554300 rs9991015 chr4 92520419 C A 2.47E-05 Height FAM190A UTR-3 pha003011 rs2176312 chr4 92529604 C A 1.99E-04 Multiple complex diseases / / 17554300 rs7687544 chr4 92564090 C T 7.83E-04 Stroke / / pha002886 rs11946091 chr4 92566775 A G 1.82E-04 Multiple complex diseases / / 17554300 rs11941818 chr4 92566887 T A 2.34E-04 Multiple complex diseases / / 17554300 rs6532335 chr4 92575501 A G 2.52E-04 Multiple complex diseases / / 17554300 rs17018661 chr4 92606016 A T 8.56E-04 Multiple complex diseases / / 17554300 rs6532345 chr4 92651110 G A 6.54E-06 ldl cholesterol / / pha003076 rs4290865 chr4 92664701 A C 2.16E-05 Malignant pleural mesothelioma / / 23626673 rs12499250 chr4 92682184 C G 8.87E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10000942 chr4 92702008 A G 3.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs1485991 chr4 92734290 C T 3.42E-05 Major depressive disorder / / 22472876 rs17018779 chr4 92734718 T C 3.28E-05 Major depressive disorder / / 22472876 rs321717 chr4 92855968 T C 1.21E-06 Sickle cell anemia (severity) / / 20029952 rs6821333 chr4 92906931 G C 5.12E-04 Type 2 diabetes / / 17463246 rs6853847 chr4 92917215 A C 2.00E-06 IgG glycosylation / / 23382691 rs6853847 chr4 92917215 A C 5.00E-06 IgG glycosylation / / 23382691 rs1602069 chr4 92972513 G T 3.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7669167 chr4 92974532 C G 1.81E-04 Aortic root size / / 21223598 rs10516905 chr4 93152870 A G 6.19E-11 Gout / / pha001406 rs13122471 chr4 93318804 G A 8.91E-05 Creatinine levels GRID2 intron pha003069 rs7666831 chr4 93321027 C T 8.00E-06 Obesity-related traits GRID2 intron 23251661 rs4133324 chr4 93322977 T C 8.67E-04 Heart Failure GRID2 intron pha002884 rs13140156 chr4 93451321 A G 2.50E-04 Hearing function GRID2 intron 17255346 rs13140156 chr4 93451321 A G 8.69E-06 Job-related exhaustion GRID2 intron 23620144 rs4471526 chr4 93460499 G A 4.24E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs7667109 chr4 93463316 A G 3.81E-05 Attention deficit hyperactivity disorder GRID2 intron 22420046 rs11097340 chr4 93465297 C T 2.03E-04 Type 2 diabetes GRID2 intron 17463246 rs17019538 chr4 93467552 A C 3.41E-05 Attention deficit hyperactivity disorder GRID2 intron 22420046 rs17319672 chr4 93467802 C T 8.72E-06 Substance dependence GRID2 intron 21818250 rs17019545 chr4 93468433 T G 3.64E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs6815704 chr4 93474566 G A 2.09E-05 Attention deficit hyperactivity disorder GRID2 intron 22420046 rs1376117 chr4 93476398 C T 2.44E-04 Type 2 diabetes GRID2 intron 17463246 rs7663643 chr4 93480717 C T 7.68E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs7689379 chr4 93481256 T G 5.27E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs921354 chr4 93484718 T A 5.19E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs11727401 chr4 93487149 A T 3.32E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs6532376 chr4 93487336 G A 3.74E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs6532377 chr4 93487465 C A 5.00E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs7682842 chr4 93489287 G A 5.98E-04 Substance dependence GRID2 intron 21818250 rs7695324 chr4 93490985 G A 4.61E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs12501529 chr4 93492008 C T 4.52E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs7699810 chr4 93496946 G C 6.12E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs6816638 chr4 93498051 C A 7.69E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs11935893 chr4 93498569 G T 4.29E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs16996340 chr4 93499118 A G 6.33E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs6829672 chr4 93499842 A C 4.15E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs6830091 chr4 93499992 C T 4.01E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs17019608 chr4 93500669 C A 3.95E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs17320444 chr4 93500721 C A 6.28E-04 Multiple complex diseases GRID2 intron 17554300 rs11733785 chr4 93501255 T C 5.75E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs11730247 chr4 93501374 C A 2.83E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs11730343 chr4 93501415 G A 5.58E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs7686627 chr4 93502067 G T 4.09E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs7686323 chr4 93502127 A G 3.56E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs6851143 chr4 93503156 C A 3.51E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs9685970 chr4 93504230 T C 4.11E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs17019639 chr4 93505257 C T 4.89E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs10856895 chr4 93506449 T C 6.87E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs12500504 chr4 93506614 A G 1.92E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs13101814 chr4 93508181 T C 5.20E-06 Urinary metabolites GRID2 intron 21572414 rs13101814 chr4 93508181 T C 6.08E-05 Relative hand skill in reading disability GRID2 intron 24068947 rs10516910 chr4 93508342 A G 2.86E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs17019672 chr4 93508367 T A 2.31E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs7663835 chr4 93509159 G A 2.66E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs11934085 chr4 93515166 C T 6.73E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs7687076 chr4 93524996 A G 7.47E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs12643761 chr4 93527235 G A 7.71E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs7670984 chr4 93527446 C A 7.35E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs7672511 chr4 93528040 G A 1.83E-04 Multiple complex diseases GRID2 intron 17554300 rs7672511 chr4 93528040 G A 5.34E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs17019701 chr4 93528443 T C 7.52E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs7683918 chr4 93529370 C A 7.52E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs7692067 chr4 93531273 A G 7.58E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs7675247 chr4 93531361 T C 5.69E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs11734482 chr4 93538394 G A 7.59E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs7668740 chr4 93539532 C T 7.76E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs201034095 chr4 93539640 T TTC 9.75E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs201034095 chr4 93539640 T TTC 7.32E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs7693534 chr4 93539640 T C 9.75E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs7693534 chr4 93539640 T C 7.32E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs12645042 chr4 93541190 A G 7.71E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs11724402 chr4 93545728 T A,G 8.06E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs6532378 chr4 93557939 G A 9.88E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs6532378 chr4 93557939 G A 4.58E-05 Age-related macular degeneration GRID2 intron 21197116 rs12641482 chr4 93564740 T C 9.83E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs11734654 chr4 93569160 C A 5.83E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs1479325 chr4 93578229 G T 9.83E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs12648061 chr4 93579550 A G 5.07E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs10012693 chr4 93584189 C G 9.79E-05 Major depressive disorder (broad) GRID2 intron 20038947 rs12649323 chr4 93589814 T C 4.37E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs12643408 chr4 93593564 A G 3.56E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs12640641 chr4 93593987 T C 3.57E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs6847540 chr4 93596167 A G 3.46E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs6824925 chr4 93596207 T C 3.58E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs6847922 chr4 93596264 C G 3.64E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs6853303 chr4 93596300 G A 5.29E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs12647704 chr4 93597279 C A 4.33E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs1434786 chr4 93640457 G A 4.12E-04 Suicide attempts in bipolar disorder GRID2 intron 21423239 rs10516912 chr4 93646501 G T 6.27E-05 Relative hand skill in reading disability GRID2 intron 24068947 rs6532381 chr4 93653338 T C 4.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRID2 intron 20877124 rs6819856 chr4 93686895 G T 2.00E-05 Pericardial fat GRID2 intron 22589742 rs2168489 chr4 93847904 G A 7.33E-05 Body Mass Index GRID2 intron pha003009 rs17262792 chr4 93918873 T C 3.98E-07 Breast cancer GRID2 intron 20852631 rs13126969 chr4 93987251 G A 6.39E-05 Body Mass Index GRID2 intron pha003009 rs7686545 chr4 94003724 A G 9.66E-04 Response to taxane treatment (placlitaxel) GRID2 intron 23006423 rs11097358 chr4 94064059 G A 9.13E-04 Response to taxane treatment (placlitaxel) GRID2 intron 23006423 rs7661752 chr4 94088158 G A,C 4.95E-05 Prostate cancer GRID2 intron 18264096 rs995906 chr4 94092083 T C 7.37E-05 HIV-1 viral setpoint GRID2 intron 17641165 rs9307122 chr4 94132138 C A 8.78E-04 Amyotrophic Lateral Sclerosis GRID2 intron 17827064 rs3796675 chr4 94146093 A G 4.09E-05 Coronary restenosis GRID2 intron 21878436 rs1503222 chr4 94150099 A G 3.63E-05 Post-operative nausea and vomiting GRID2 intron 21694509 rs11933263 chr4 94156853 C T 1.00E-04 Information processing speed GRID2 intron 21130836 rs1368730 chr4 94236828 C T 9.95E-05 Serum albumin level GRID2 intron pha003084 rs1433666 chr4 94252360 G A 1.00E-04 HIV(mother-to-child transmission) GRID2 intron 20487506 rs10029233 chr4 94263233 T A 1.19E-04 Multiple complex diseases GRID2 intron 17554300 rs10019885 chr4 94263411 C T 3.77E-05 Multiple complex diseases GRID2 intron 17554300 rs10022753 chr4 94358023 A G 2.42E-04 Multiple complex diseases GRID2 intron 17554300 rs9997032 chr4 94386763 G A 3.82E-04 Multiple complex diseases GRID2 intron 17554300 rs9997032 chr4 94386763 G A 3.46E-05 Aging (time to event) GRID2 intron 21782286 rs28624162 chr4 94393810 T G 2.31E-04 Multiple complex diseases GRID2 intron 17554300 rs9307127 chr4 94434770 C G 1.07E-04 Multiple complex diseases GRID2 intron 17554300 rs4286488 chr4 94440026 G A 1.05E-04 Cholesterol GRID2 intron 17255346 rs1369465 chr4 94452948 C T 9.49E-05 Intelligence GRID2 intron 21826061 rs11942069 chr4 94494455 G A 6.79E-04 Smoking initiation GRID2 intron 24665060 rs7676349 chr4 94496499 C T 8.05E-04 Alzheimer's disease GRID2 intron 17998437 rs17276536 chr4 94498409 G A 1.30E-07 Urinary metabolites GRID2 intron 21572414 rs10516926 chr4 94537154 G A 6.18E-04 Acute lung injury GRID2 intron 22295056 rs6816016 chr4 94541559 C T 3.64E-04 Multiple complex diseases GRID2 intron 17554300 rs41525649 chr4 94549401 G A 3.59E-04 Coronary Artery Disease GRID2 intron 17634449 rs1435480 chr4 94550477 C T 1.41E-04 Smoking cessation GRID2 intron 18519826 rs1435481 chr4 94550726 C G 4.50E-04 Coronary Artery Disease GRID2 intron 17634449 rs11932367 chr4 94557555 A G 2.99E-04 Type 2 diabetes GRID2 intron 17463246 rs11932367 chr4 94557555 A G 1.46E-04 Smoking cessation GRID2 intron 18519826 rs6848888 chr4 94572864 T C 1.63E-05 Partial epilepsies GRID2 intron 20522523 rs11097383 chr4 94583840 T C 0.0000597 Otitis media (children 3 years old or younger) GRID2 intron 23133572 rs10516940 chr4 94594199 C T 5.34E-04 Premature ovarian failure GRID2 intron 19508998 rs11945046 chr4 94595550 G A 2.64E-05 HIV-1 viral setpoint GRID2 intron 22174851 rs11946557 chr4 94597101 G A 2.64E-05 HIV-1 viral setpoint GRID2 intron 22174851 rs17021005 chr4 94614339 A C 8.85E-05 Multiple complex diseases GRID2 intron 17554300 rs17021014 chr4 94616966 A G 3.00E-05 Multiple complex diseases GRID2 intron 17554300 rs17021017 chr4 94616989 T C 6.10E-05 Multiple complex diseases GRID2 intron 17554300 rs1371357 chr4 94623649 T C 6.30E-04 Response to taxane treatment (placlitaxel) GRID2 intron 23006423 rs17021035 chr4 94624357 T G 3.24E-04 Multiple complex diseases GRID2 intron 17554300 rs10050093 chr4 94723779 C T 3.12E-04 Multiple complex diseases / / 17554300 rs10033683 chr4 94725853 A G 5.14E-04 Alzheimer's disease / / 17998437 rs11731687 chr4 94745528 A G 0.000516747 Hypertension (early onset hypertension) / / 22479346 rs7699958 chr4 94753879 G T 6.24E-05 Asthma / / 23181788 rs4485792 chr4 94761237 C T 8.20E-06 Urinary metabolites / / 21572414 rs7693338 chr4 94766621 T C 5.19E-04 Acute lung injury / / 22295056 rs4568209 chr4 94775266 T G 7.62E-04 Acute lung injury / / 22295056 rs2578151 chr4 94838593 C T 3.34E-04 Colorectal cancer / / 23266556 rs13152714 chr4 94839209 A C 1.76E-06 Colorectal cancer / / 23266556 rs1898640 chr4 94839349 T G 1.81E-06 Colorectal cancer / / 23266556 rs1898639 chr4 94839419 A G 9.25E-04 Multiple complex diseases / / 17554300 rs1898639 chr4 94839419 A G 1.89E-06 Colorectal cancer / / 23266556 rs1898638 chr4 94839483 C T 1.41E-06 Colorectal cancer / / 23266556 rs2618735 chr4 94840017 T C 4.69E-04 Multiple complex diseases / / 17554300 rs2618735 chr4 94840017 T C 1.23E-05 Bipolar disorder and schizophrenia / / 20889312 rs2618735 chr4 94840017 T C 1.26E-06 Colorectal cancer / / 23266556 rs1370814 chr4 94841598 G A 5.49E-05 Colorectal cancer / / 23266556 rs2618740 chr4 94842269 G T 1.78E-06 Colorectal cancer / / 23266556 rs13129177 chr4 94842318 G C 1.56E-06 Colorectal cancer / / 23266556 rs2618741 chr4 94842437 T C 5.44E-05 Colorectal cancer / / 23266556 rs13105254 chr4 94842776 T C 9.24E-04 Multiple complex diseases / / 17554300 rs13105254 chr4 94842776 T C 1.61E-06 Colorectal cancer / / 23266556 rs2618743 chr4 94845993 T C 8.41E-06 Colorectal cancer / / 23266556 rs2578147 chr4 94847004 G C 1.39E-05 Colorectal cancer / / 23266556 rs1595502 chr4 94854453 C T 1.57E-06 Colorectal cancer / / 23266556 rs1837210 chr4 94858253 A G 1.13E-06 Colorectal cancer / / 23266556 rs1583661 chr4 94862267 C A 9.22E-07 Colorectal cancer / / 23266556 rs2578137 chr4 94862679 G C 9.85E-06 Colorectal cancer / / 23266556 rs13147118 chr4 94862876 G C 1.02E-06 Colorectal cancer / / 23266556 rs10002699 chr4 94863753 T A 1.03E-06 Colorectal cancer / / 23266556 rs1438376 chr4 94865048 T A 1.08E-06 Colorectal cancer / / 23266556 rs7667693 chr4 94865274 T C 9.80E-07 Colorectal cancer / / 23266556 rs1438374 chr4 94866291 C T 1.32E-06 Colorectal cancer / / 23266556 rs10006063 chr4 94866804 A G 1.14E-06 Colorectal cancer / / 23266556 rs2578133 chr4 94868191 T A 2.99E-04 Multiple complex diseases / / 17554300 rs2578133 chr4 94868191 T A 7.69E-05 Colorectal cancer / / 23266556 rs2618760 chr4 94868241 C T 7.63E-05 Colorectal cancer / / 23266556 rs2618761 chr4 94868270 G T 7.65E-05 Colorectal cancer / / 23266556 rs1579659 chr4 94869985 G C 1.15E-06 Colorectal cancer / / 23266556 rs13121186 chr4 94871350 C T 1.17E-06 Colorectal cancer / / 23266556 rs2618768 chr4 94875013 G A 4.58E-04 Multiple complex diseases / / 17554300 rs2618768 chr4 94875013 G A 9.02E-05 Colorectal cancer / / 23266556 rs2033781 chr4 94877850 A C 2.70E-05 Colorectal cancer / / 23266556 rs1370812 chr4 94881967 T C 9.17E-06 Colorectal cancer / / 23266556 rs10017390 chr4 94882341 G A 1.24E-04 Colorectal cancer / / 23266556 rs13113109 chr4 94883286 A G 9.99E-05 Colorectal cancer / / 23266556 rs13130787 chr4 94887031 T C 3.00E-07 Colorectal cancer / / 23266556 rs17365288 chr4 94904738 A G 1.92E-04 Multiple complex diseases / / 17554300 rs17365288 chr4 94904738 A G 1.08E-04 Colorectal cancer / / 23266556 rs17365288 chr4 94904738 A G 5.55E-05 Lipoproteins / / pha003079 rs5021131 chr4 94913451 G C 8.60E-05 Colorectal cancer / / 23266556 rs280113 chr4 94919000 A G 6.35E-05 Lipoproteins / / pha003079 rs11945480 chr4 94919390 A G 9.07E-05 Colorectal cancer / / 23266556 rs1438381 chr4 94920245 C T 2.67E-04 Colorectal cancer / / 23266556 rs1438380 chr4 94928590 C T 2.90E-05 Urinary metabolites / / 21572414 rs11934535 chr4 94936015 A G 8.95E-04 Colorectal cancer / / 23266556 rs10030952 chr4 94938117 C T 3.28E-04 Colorectal cancer / / 23266556 rs1595511 chr4 94938945 A G 3.89E-05 Colorectal cancer / / 23266556 rs1370821 chr4 94943383 C T 3.72E-05 Colorectal cancer / / 23266556 rs13145086 chr4 94954026 T A,G 7.78E-05 Colorectal cancer / / 23266556 rs13145086 chr4 94954026 T A,G 7.98E-05 Lipoproteins / / pha003079 rs280063 chr4 94955042 T A 0.000096 Dyslexia / / 23190410 rs280063 chr4 94955042 T A 8.09E-05 Colorectal cancer / / 23266556 rs280060 chr4 94958025 C A 6.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs280058 chr4 94961303 T C 2.27E-04 Colorectal cancer / / 23266556 rs280054 chr4 94964722 A G 2.22E-04 Colorectal cancer / / 23266556 rs280117 chr4 94970758 T C 2.99E-04 Colorectal cancer / / 23266556 rs10016961 chr4 94973976 T C 2.21E-04 Colorectal cancer / / 23266556 rs280115 chr4 94973985 A G 2.56E-04 Colorectal cancer / / 23266556 rs280084 chr4 94980768 C T 5.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs280078 chr4 94983101 T C 2.86E-04 Colorectal cancer / / 23266556 rs280076 chr4 94984775 T C 2.95E-04 Colorectal cancer / / 23266556 rs9884263 chr4 95041380 G A 1.47E-05 Waist-Hip Ratio / / pha003029 rs17021364 chr4 95047893 T C 9.55E-05 Schizophrenia / / 19571809 rs17021364 chr4 95047893 T C 8.17E-06 Bipolar disorder and schizophrenia / / 20889312 rs10011158 chr4 95056300 C T 8.31E-04 Type 2 diabetes / / 17463246 rs9992640 chr4 95058293 A G 8.80E-04 Alcohol dependence / / 20201924 rs6834248 chr4 95090278 T C 7.93E-04 Type 2 diabetes / / 17463246 rs12505596 chr4 95109600 A G 4.59E-04 Multiple complex diseases / / 17554300 rs17374902 chr4 95128677 T C 1.31E-04 Type 2 diabetes SMARCAD1 nearGene-5 17463246 rs11097407 chr4 95146135 G C 4.00E-06 Bipolar disorder and schizophrenia SMARCAD1 intron 20889312 rs11097407 chr4 95146135 G C 2.46E-05 Schizophrenia SMARCAD1 intron pha002857 rs2664871 chr4 95146281 C T 2.06E-05 Bipolar disorder and schizophrenia SMARCAD1 intron 20889312 rs2664871 chr4 95146281 C T 2.59E-05 Schizophrenia SMARCAD1 intron pha002857 rs2632401 chr4 95147055 C G 1.02E-05 Bipolar disorder and schizophrenia SMARCAD1 intron 20889312 rs2632401 chr4 95147055 C G 1.74E-05 Schizophrenia SMARCAD1 intron pha002857 rs17303283 chr4 95152413 T C 5.16E-06 Waist-Hip Ratio SMARCAD1 intron pha003029 rs3106136 chr4 95153349 T C 7.00E-06 Capecitabine sensitivity SMARCAD1 intron 22864933 rs2087170 chr4 95162960 T G 3.03E-05 Bipolar disorder and schizophrenia SMARCAD1 intron 20889312 rs2087170 chr4 95162960 T G 3.46E-05 Schizophrenia SMARCAD1 intron pha002857 rs10516948 chr4 95168607 C A 1.75E-04 Type 2 diabetes SMARCAD1 intron 17463246 rs10032125 chr4 95169266 C T 1.23E-04 Type 2 diabetes SMARCAD1 intron 17463246 rs12646184 chr4 95183216 C T 1.19E-05 Bipolar disorder and schizophrenia SMARCAD1 intron 20889312 rs12646184 chr4 95183216 C T 1.96E-05 Schizophrenia SMARCAD1 intron pha002857 rs6532476 chr4 95192461 C A 7.19E-05 ldl cholesterol SMARCAD1 intron pha003077 rs17021463 chr4 95224812 T G 9.48E-05 Systemic sclerosis HPGDS intron 21750679 rs17021463 chr4 95224812 T G 1.00E-08 Testicular germ cell tumor HPGDS intron 23666239 rs17021463 chr4 95224812 T G 6.05E-05 ldl cholesterol HPGDS intron pha003077 rs11941250 chr4 95229463 G A 3.43E-09 HDL cholesterol HPGDS intron 23063622 rs10030713 chr4 95238536 G C 7.52E-05 Bipolar disorder and schizophrenia HPGDS intron 20889312 rs10084984 chr4 95254575 T C 1.46E-04 Type 2 diabetes HPGDS intron 17463246 rs2059606 chr4 95255278 G A 7.16E-05 Bipolar disorder and schizophrenia HPGDS intron 20889312 rs2059606 chr4 95255278 G A 5.15E-05 Schizophrenia HPGDS intron pha002857 rs11938688 chr4 95257607 C G 9.39E-10 HDL cholesterol HPGDS intron 23063622 rs724260 chr4 95260685 A G 6.85E-04 Suicide attempts in bipolar disorder HPGDS intron 21041247 rs11727030 chr4 95262665 A G 6.85E-04 Suicide attempts in bipolar disorder HPGDS intron 21041247 rs11727030 chr4 95262665 A G 0.00021 Coronary artery calcification HPGDS intron 23727086 rs7438414 chr4 95265822 T C 6.84E-04 Suicide attempts in bipolar disorder HPGDS nearGene-5 21041247 rs1991316 chr4 95268272 G T 6.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs2865353 chr4 95270878 T C 6.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs4282187 chr4 95273145 T C 6.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs6840479 chr4 95275842 A G 7.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs6532481 chr4 95277311 T G 4.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs6532482 chr4 95277414 A G 4.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs10020236 chr4 95277993 A G 5.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs9997915 chr4 95278027 C T 4.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs1593554 chr4 95278501 C T 4.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs6839224 chr4 95279214 T G 4.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs7696494 chr4 95285174 G A 7.38E-05 Socioeconomic Factors / / pha003067 rs7694491 chr4 95290250 C T 8.46E-05 Cleft lip / / 20436469 rs10516949 chr4 95330180 C A 8.79E-04 Multiple complex diseases / / 17554300 rs2510802 chr4 95410168 A G 0.000004 Salmonella-induced pyroptosis PDLIM5 intron 22837397 rs17379209 chr4 95411302 G A 6.48E-04 Type 2 diabetes PDLIM5 intron 17463246 rs2639793 chr4 95414563 A G 7.55E-04 Type 2 diabetes PDLIM5 intron 17463246 rs2433317 chr4 95428800 A G 0.000008 Salmonella-induced pyroptosis PDLIM5 intron 22837397 rs2510795 chr4 95430064 T C 0.00000325 Salmonella-induced pyroptosis PDLIM5 intron 22837397 rs2433325 chr4 95441592 C T 0.000013 Salmonella-induced pyroptosis PDLIM5 intron 22837397 rs2510785 chr4 95444407 G T 0.000393 Salmonella-induced pyroptosis PDLIM5 intron 22837397 rs766520 chr4 95445791 G A 4.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDLIM5 intron 20877124 rs2452579 chr4 95467531 T G 1.72E-04 Amyotrophic Lateral Sclerosis PDLIM5 intron 17362836 rs1493112 chr4 95472630 C T 6.20E-04 Type 2 diabetes and 6 quantitative traits PDLIM5 intron 17848626 rs2452601 chr4 95497654 G A 6.32E-04 Multiple complex diseases PDLIM5 intron 17554300 rs12500426 chr4 95514609 A C 1.00E-11 Prostate cancer PDLIM5 intron 19767753 rs12500426 chr4 95514609 A C 1.00E-11 Nasopharyngeal carcinoma PDLIM5 intron 20512145 rs11731783 chr4 95519515 G A 2.57E-05 Multiple complex diseases PDLIM5 intron 17554300 rs11724023 chr4 95558854 T C 3.68E-04 Substance dependence PDLIM5 intron 21818250 rs17021918 chr4 95562877 C T 9.90E-04 Multiple complex diseases PDLIM5 intron 17554300 rs17021918 chr4 95562877 C T 3.81E-05 Serum metabolites PDLIM5 intron 19043545 rs17021918 chr4 95562877 C T 4.00E-15 Prostate cancer PDLIM5 intron 19767753 rs17021918 chr4 95562877 C T 4.00E-15 Nasopharyngeal carcinoma PDLIM5 intron 20512145 rs17021918 chr4 95562877 C T 9.28E-05 Vaspin levels PDLIM5 intron 22907691 rs17021918 chr4 95562877 C T 0.0000928 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit PDLIM5 intron 22907730 rs7689746 chr4 95574123 G A 3.50E-06 Dietary macronutrient intake PDLIM5 intron 23372041 rs2280002 chr4 95575323 G A 4.50E-04 Type 2 diabetes and 6 quantitative traits PDLIM5 intron 17848626 rs11097432 chr4 95579705 T C 1.00E-04 Cognitive impairment induced by topiramate PDLIM5 intron 22091778 rs12500116 chr4 95579739 A T 9.73E-04 Multiple complex diseases PDLIM5 intron 17554300 rs12500116 chr4 95579739 A T 8.53E-05 Serum metabolites PDLIM5 intron 19043545 rs6532496 chr4 95580404 C T 0.00004 Aging PDLIM5 intron 22445811 rs1056772 chr4 95585225 A G 8.85E-05 Cognitive impairment induced by topiramate PDLIM5 UTR-3 22091778 rs3762876 chr4 95589477 A G 5.08E-05 Vaspin levels / / 22907691 rs3762876 chr4 95589477 A G 0.0000508 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs998071 chr4 95591976 C G 2.53E-04 Multiple complex diseases / / 17554300 rs998071 chr4 95591976 C G 4.56E-05 Serum metabolites / / 19043545 rs1472961 chr4 95592144 A G 7.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1472962 chr4 95592377 G A 5.55E-04 Multiple complex diseases / / 17554300 rs1472962 chr4 95592377 G A 3.10E-05 Volumetric brain MRI / / 17903297 rs13133845 chr4 95594616 A G 6.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6532503 chr4 95608023 G T 2.71E-05 Major depressive disorder / / 22472876 rs6532503 chr4 95608023 G T 4.74E-04 Response to alcohol consumption (flushing response) / / 24277619 rs17339671 chr4 95613175 A G 1.14E-06 Estradiol plasma levels (breast cancer) / / 23518928 rs17022027 chr4 95614278 C T 9.00E-06 Visceral fat / / 22589738 rs4699587 chr4 95615769 A G 5.00E-07 Estradiol plasma levels (breast cancer) / / 23518928 rs6843164 chr4 95618987 C T 3.72E-04 Hemoglobin concentration / / 20534544 rs7699444 chr4 95638491 A G 9.45E-06 QT interval / / 23166209 rs10027628 chr4 95643957 T C 6.00E-06 QT interval / / 23166209 rs2036755 chr4 95647493 G A 9.38E-04 Alzheimer's disease / / 22005930 rs370352625 chr4 95678443 GGTT G 1.04E-04 Alzheimer's disease LOC100507012 intron 22005930 rs4348103 chr4 95678443 G T 1.04E-04 Alzheimer's disease LOC100507012 intron 22005930 rs4699361 chr4 95680865 G T 5.92E-05 Alzheimer's disease BMPR1B intron 22005930 rs10049681 chr4 95684380 T C 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes BMPR1B intron 22628534 rs7694987 chr4 95692477 G A 6.90E-05 Pericardial fat BMPR1B intron 22589742 rs17022139 chr4 95694316 C T 0.0008613 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BMPR1B intron 23233654 rs17022139 chr4 95694316 C T 8.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) BMPR1B intron 23233662 rs6819188 chr4 95694977 C T 2.04E-04 Lung function (forced expiratory volume in 1 second) BMPR1B intron 24023788 rs12501965 chr4 95706285 T C 4.79E-04 Type 2 diabetes BMPR1B intron 17463246 rs12501965 chr4 95706285 T C 5.20E-04 Diabetic nephropathy BMPR1B intron 20347642 rs925283 chr4 95706337 T C 4.06E-04 Lung function (forced expiratory volume in 1 second) BMPR1B intron 24023788 rs4552469 chr4 95708539 C T 1.65E-04 Lung function (forced expiratory volume in 1 second) BMPR1B intron 24023788 rs4552469 chr4 95708539 C T 2.49E-04 Lung function (forced vital capacity) BMPR1B intron 24023788 rs4599420 chr4 95708561 A G 1.64E-04 Lung function (forced expiratory volume in 1 second) BMPR1B intron 24023788 rs4599420 chr4 95708561 A G 2.38E-04 Lung function (forced vital capacity) BMPR1B intron 24023788 rs11935769 chr4 95731794 T C 9.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) BMPR1B intron 23233662 rs7692640 chr4 95738226 C A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes BMPR1B intron 22628534 rs12503136 chr4 95740776 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes BMPR1B intron 22628534 rs4077885 chr4 95740838 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes BMPR1B intron 22628534 rs6831418 chr4 95750839 T C 1.50E-04 Breast cancer BMPR1B intron pha002853 rs2522528 chr4 95755138 C T 2.00E-04 Cognitive impairment induced by topiramate BMPR1B intron 22091778 rs17428564 chr4 95755436 T C 1.40E-05 Type 2 diabetes BMPR1B intron 17463246 rs4538488 chr4 95775322 G T 1.39E-04 Breast cancer BMPR1B intron pha002853 rs4254781 chr4 95775606 T C 1.91E-04 Breast cancer BMPR1B intron pha002853 rs11932515 chr4 95780702 A G 0.0002492 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BMPR1B intron 23233654 rs11932515 chr4 95780702 A G 2.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) BMPR1B intron 23233662 rs11932610 chr4 95780901 A G 0.0002473 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BMPR1B intron 23233654 rs11932610 chr4 95780901 A G 2.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) BMPR1B intron 23233662 rs17022361 chr4 95781122 C G 0.000247 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BMPR1B intron 23233654 rs17022361 chr4 95781122 C G 2.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) BMPR1B intron 23233662 rs11941775 chr4 95781155 C G 0.000247 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BMPR1B intron 23233654 rs11941775 chr4 95781155 C G 2.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) BMPR1B intron 23233662 rs2865408 chr4 95800500 T A 0.000529 Salmonella-induced pyroptosis BMPR1B intron 22837397 rs2865408 chr4 95800500 T A 0.0003089 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BMPR1B intron 23233654 rs2865408 chr4 95800500 T A 3.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) BMPR1B intron 23233662 rs17022438 chr4 95802144 A C 6.49E-04 Type 2 diabetes BMPR1B intron 17463246 rs17022438 chr4 95802144 A C 0.0003365 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BMPR1B intron 23233654 rs17022438 chr4 95802144 A C 3.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) BMPR1B intron 23233662 rs17022440 chr4 95802576 C T 0.0003535 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BMPR1B intron 23233654 rs17022440 chr4 95802576 C T 3.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) BMPR1B intron 23233662 rs17022443 chr4 95803045 G A 0.0003724 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BMPR1B intron 23233654 rs17022443 chr4 95803045 G A 3.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) BMPR1B intron 23233662 rs17022496 chr4 95821051 T C 2.00E-14 Multiple complex diseases BMPR1B intron 17554300 rs1859156 chr4 95834034 G T 2.00E-06 Attention deficit hyperactivity disorder BMPR1B intron 20732626 rs3775018 chr4 95843866 C T 9.14E-05 Cervical cancer BMPR1B intron 24700089 rs10021303 chr4 95856681 G A 7.00E-06 Hypertension BMPR1B intron 22384028 rs7657460 chr4 95857301 A G 3.01E-05 Response to taxane treatment (placlitaxel) BMPR1B intron 23006423 rs1373651 chr4 95868525 G A 5.35E-05 Cognitive impairment induced by topiramate BMPR1B intron 22091778 rs1373651 chr4 95868525 G A 2.46E-04 Celiac disease BMPR1B intron 23936387 rs1444928 chr4 95876278 T C 1.00E-04 Cognitive impairment induced by topiramate BMPR1B intron 22091778 rs1373649 chr4 95892711 G A 1.94E-04 Celiac disease BMPR1B intron 23936387 rs1444922 chr4 95912221 A G 9.00E-05 Prostate cancer BMPR1B intron 21743057 rs1545328 chr4 95912925 G T 3.00E-05 Prostate cancer BMPR1B intron 21743057 rs1444920 chr4 95925994 A G 1.65E-04 Smoking cessation BMPR1B intron 24665060 rs17345417 chr4 95948486 A G 5.80E-04 Smoking initiation BMPR1B intron 24665060 rs17022885 chr4 95948640 C T 1.32E-04 Smoking initiation BMPR1B intron 24665060 rs1158793 chr4 96004341 A G 0.00055 Salmonella-induced pyroptosis BMPR1B intron 22837397 rs6532530 chr4 96007434 G A 0.000514 Salmonella-induced pyroptosis BMPR1B intron 22837397 rs6816834 chr4 96011233 G A 0.000287 Salmonella-induced pyroptosis BMPR1B intron 22837397 rs1434548 chr4 96025150 G C 9.33E-05 Smoking cessation BMPR1B intron 24665060 rs3796443 chr4 96061509 G A 3.09E-05 Serum metabolites BMPR1B intron 19043545 rs1970801 chr4 96070525 G T 4.37E-04 Smoking cessation BMPR1B intron 24665060 rs11097457 chr4 96076813 A G 1.97E-04 Breast cancer BMPR1B UTR-3 pha002853 rs10155222 chr4 96085186 A T 1.94E-05 Serum metabolites UNC5C UTR-3 19043545 rs10155123 chr4 96085224 T C 3.41E-05 Serum metabolites UNC5C UTR-3 19043545 rs11097458 chr4 96099367 C T 1.10E-05 Serum metabolites UNC5C intron 19043545 rs3775045 chr4 96126884 T C 1.11E-05 Diabetic nephropathy UNC5C intron 21150874 rs3775045 chr4 96126884 T C 1.15E-05 Type 2 diabetes UNC5C intron 22238593 rs3775043 chr4 96128679 T G 1.89E-05 Diabetic nephropathy UNC5C intron 21150874 rs3775043 chr4 96128679 T G 6.82E-05 Type 2 diabetes UNC5C intron 22238593 rs2621452 chr4 96131798 A G 3.30E-06 Urinary metabolites UNC5C intron 21572414 rs12643654 chr4 96159817 A G 5.00E-07 P-tau181p levels UNC5C intron 20932310 rs11730446 chr4 96163244 A G 8.25E-05 Diabetic nephropathy UNC5C intron 21150874 rs11730446 chr4 96163244 A G 6.23E-04 Type 2 diabetes UNC5C intron 22238593 rs7439701 chr4 96167915 G C 9.15E-04 Alzheimer's disease UNC5C intron 22005930 rs3775003 chr4 96171211 T C 2.20E-04 Schizophrenia(treatment response to risperidone) UNC5C intron 19850283 rs3775002 chr4 96171283 T C 6.70E-05 Type 2 diabetes UNC5C intron 22238593 rs17352477 chr4 96180560 T C 1.36E-04 Alzheimer's disease UNC5C intron 22005930 rs4349608 chr4 96204307 T C 2.47E-04 Multiple complex diseases UNC5C intron 17554300 rs17433092 chr4 96226609 C T 7.50E-05 Celiac disease UNC5C intron 23936387 rs41523747 chr4 96233836 G A 5.82E-04 Multiple complex diseases UNC5C intron 17554300 rs2170780 chr4 96244241 G A 1.07E-04 Smoking initiation UNC5C intron 24665060 rs2626053 chr4 96255088 G A 6.54E-07 Osteoarthritis UNC5C intron 22763110 rs6848909 chr4 96281320 C G 1.20E-05 Urinary metabolites UNC5C intron 21572414 rs17023624 chr4 96285730 C T 8.40E-06 Urinary metabolites UNC5C intron 21572414 rs17023644 chr4 96292628 C G 1.80E-05 Urinary metabolites UNC5C intron 21572414 rs6822806 chr4 96298942 T C 1.90E-05 Urinary metabolites UNC5C intron 21572414 rs10222858 chr4 96300827 T C 3.68E-05 Lymphocyte counts UNC5C intron pha003094 rs10222858 chr4 96300827 T C 5.37E-05 Neutrophil count UNC5C intron pha003095 rs7655075 chr4 96301124 G A 4.17E-05 Mammographic density UNC5C intron 22532574 rs12507717 chr4 96303285 T C 9.64E-05 Mammographic density UNC5C intron 22532574 rs17437679 chr4 96305584 C A 2.67E-04 Rheumatoid arthritis UNC5C intron 21452313 rs1384862 chr4 96309211 A G 6.42E-05 Mammographic density UNC5C intron 22532574 rs10516969 chr4 96310163 G A 8.03E-04 Parkinson's disease UNC5C intron 17052657 rs10516969 chr4 96310163 G A 1.23E-05 Iron status biomarkers UNC5C intron 19084217 rs10516970 chr4 96310236 C T 8.03E-04 Parkinson's disease UNC5C intron 17052657 rs10516970 chr4 96310236 C T 1.68E-05 Iron status biomarkers UNC5C intron 19084217 rs10516970 chr4 96310236 C T 2.41E-05 Type 2 diabetes UNC5C intron 20818381 rs10440376 chr4 96311257 A G 3.83E-05 Lymphocyte counts UNC5C intron pha003094 rs10440376 chr4 96311257 A G 3.05E-05 Neutrophil count UNC5C intron pha003095 rs10856913 chr4 96314801 T C 3.42E-05 Self-reported allergy UNC5C intron 23817569 rs10012134 chr4 96314856 G A 3.24E-05 Self-reported allergy UNC5C intron 23817569 rs9307159 chr4 96341886 C T 2.00E-04 Cognitive impairment induced by topiramate UNC5C intron 22091778 rs1026926 chr4 96356534 A G 5.00E-04 Acute lymphoblastic leukemia (childhood) UNC5C intron 20189245 rs17023881 chr4 96362183 C T 9.98E-06 Alopecia areata UNC5C intron 22027810 rs9307160 chr4 96367954 T C 5.90E-04 Type 2 diabetes and 6 quantitative traits UNC5C intron 17848626 rs7684538 chr4 96368305 A T 5.00E-05 Type 2 diabetes and 6 quantitative traits UNC5C intron 17848626 rs4103380 chr4 96370605 G C 3.06E-04 Multiple complex diseases UNC5C intron 17554300 rs265046 chr4 96373850 G A 5.66E-04 Myopia (pathological) UNC5C intron 21095009 rs265045 chr4 96374076 T G 7.66E-04 Myopia (pathological) UNC5C intron 21095009 rs13119662 chr4 96374272 T C 7.36E-05 Insulin Resistance UNC5C intron pha003062 rs3843446 chr4 96380273 A G 3.32E-04 Myocardial Infarction UNC5C intron pha002883 rs265030 chr4 96385457 G T 2.50E-05 Urinary metabolites UNC5C intron 21572414 rs4505826 chr4 96406950 A G 8.76E-04 Schizophrenia UNC5C intron 19197363 rs7698621 chr4 96428565 C G 3.80E-04 Multiple complex diseases UNC5C intron 17554300 rs1905850 chr4 96434992 T C 8.18E-06 Type 2 diabetes UNC5C intron 21573907 rs17024125 chr4 96447504 A C,G,T 1.82E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) UNC5C intron 24192120 rs10032931 chr4 96458433 T C 4.00E-06 Optic nerve measurement (cup-to-disc ratio) UNC5C intron 20395239 rs970689 chr4 96460537 A G 3.40E-04 Coronary Artery Disease UNC5C intron 17634449 rs7686209 chr4 96464197 A G 3.68E-06 Rheumatoid arthritis UNC5C intron 19503088 rs11097470 chr4 96467503 C T 5.00E-06 Obesity-related traits UNC5C intron 23251661 rs6818365 chr4 96485224 A G 1.22E-04 Type 2 diabetes / / 17463246 rs4699434 chr4 96506611 G T 1.96E-04 Coronary heart disease / / 21971053 rs1485611 chr4 96516310 T C 1.04E-04 Height / / 17255346 rs12641406 chr4 96528326 G C 3.60E-04 Height / / 17255346 rs6814460 chr4 96538637 T G 3.38E-04 Height / / 17255346 rs1369985 chr4 96545816 C T 2.14E-05 Serum metabolites / / 19043545 rs12644144 chr4 96562035 G A 3.40E-06 Urinary metabolites / / 21572414 rs12506817 chr4 96564338 C T 1.40E-06 Urinary metabolites / / 21572414 rs12510917 chr4 96564442 T C 7.80E-06 Urinary metabolites / / 21572414 rs6833840 chr4 96580490 A C 5.71E-05 Cognitive impairment induced by topiramate / / 22091778 rs10007047 chr4 96591924 G A 5.10E-06 Urinary metabolites / / 21572414 rs10015906 chr4 96594339 C A 1.40E-05 Urinary metabolites / / 21572414 rs7691945 chr4 96597277 T G 5.00E-05 Bilirubin levels / / 19414484 rs7696585 chr4 96597325 T C 5.00E-05 Bilirubin levels / / 19414484 rs1436578 chr4 96597922 T G 5.00E-05 Bilirubin levels / / 19414484 rs1369995 chr4 96598079 A G 5.00E-05 Bilirubin levels / / 19414484 rs1946737 chr4 96598628 A T 4.90E-05 Bilirubin levels / / 19414484 rs1369994 chr4 96599084 A G 4.10E-05 Bilirubin levels / / 19414484 rs1369993 chr4 96599114 T C 4.90E-05 Bilirubin levels / / 19414484 rs1369992 chr4 96599153 T G 4.90E-05 Bilirubin levels / / 19414484 rs1369991 chr4 96599216 C T 4.90E-05 Bilirubin levels / / 19414484 rs10433974 chr4 96599499 T G 4.90E-05 Bilirubin levels / / 19414484 rs1369988 chr4 96599777 C A 4.90E-05 Bilirubin levels / / 19414484 rs7698297 chr4 96601458 A C 4.80E-05 Bilirubin levels / / 19414484 rs7698666 chr4 96601571 C T 4.80E-05 Bilirubin levels / / 19414484 rs1118570 chr4 96602391 C T 4.80E-05 Bilirubin levels / / 19414484 rs1595202 chr4 96602854 C T 4.80E-05 Bilirubin levels / / 19414484 rs6822198 chr4 96603321 G A 4.80E-05 Bilirubin levels / / 19414484 rs9762308 chr4 96603396 C T 4.80E-05 Bilirubin levels / / 19414484 rs9762310 chr4 96603431 C T 4.80E-05 Bilirubin levels / / 19414484 rs13142665 chr4 96604479 C T 4.80E-05 Bilirubin levels / / 19414484 rs12500730 chr4 96604762 T G 4.80E-05 Bilirubin levels / / 19414484 rs1369987 chr4 96605119 T C 4.80E-05 Bilirubin levels / / 19414484 rs1898250 chr4 96605499 T C 4.80E-05 Bilirubin levels / / 19414484 rs1436573 chr4 96607365 C T 4.80E-05 Bilirubin levels / / 19414484 rs11097478 chr4 96608524 C T 4.80E-05 Bilirubin levels / / 19414484 rs4699446 chr4 96609790 C G 4.80E-05 Bilirubin levels / / 19414484 rs13112339 chr4 96610670 C T 4.80E-05 Bilirubin levels / / 19414484 rs13112562 chr4 96610719 C A 4.70E-05 Bilirubin levels / / 19414484 rs4699274 chr4 96614039 C T 4.50E-05 Bilirubin levels / / 19414484 rs4699449 chr4 96614235 C T 4.50E-05 Bilirubin levels / / 19414484 rs1370004 chr4 96628653 T C 8.81E-05 Serum metabolites / / 19043545 rs1370004 chr4 96628653 T C 1.40E-05 Urinary metabolites / / 21572414 rs6817087 chr4 96630951 C A 7.52E-04 Smoking initiation / / 24665060 rs17470048 chr4 96646841 T C 7.54E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13121624 chr4 96659547 C A 2.20E-06 Urinary metabolites / / 21572414 rs4463073 chr4 96724483 A G 5.14E-04 Type 2 diabetes / / 17463246 rs12510298 chr4 96736478 A G 4.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2054159 chr4 96783302 T C 2.10E-05 Urinary metabolites / / 21572414 rs4699473 chr4 96795786 T C 8.78E-08 Metabolite levels / / 23281178 rs7656696 chr4 96796173 G A 7.30E-08 Metabolite levels / / 23281178 rs1836897 chr4 96796542 G C 6.12E-08 Metabolite levels / / 23281178 rs17024928 chr4 96877723 G T 4.40E-06 Urinary metabolites / / 21572414 rs1598571 chr4 96888681 A G 2.20E-05 Urinary metabolites / / 21572414 rs1378876 chr4 96895350 C T 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7662545 chr4 96919556 G A,C,T 8.02E-05 Attention deficit hyperactivity disorder / / 23728934 rs6532592 chr4 96919816 C T 8.88E-05 Attention deficit hyperactivity disorder / / 23728934 rs1514974 chr4 96923483 A G 2.33E-04 Coronary heart disease / / 21971053 rs17490687 chr4 96926695 C T 9.64E-05 Platelet counts / / pha003100 rs1514972 chr4 96930518 C T 6.43E-05 Attention deficit hyperactivity disorder / / 23728934 rs1514977 chr4 96965646 A G 7.77E-05 Attention deficit hyperactivity disorder / / 23728934 rs10015131 chr4 96971133 G A 5.95E-05 Attention deficit hyperactivity disorder / / 23728934 rs1877918 chr4 96971642 C T 4.89E-05 Attention deficit hyperactivity disorder / / 23728934 rs7674977 chr4 96972374 T C 2.05E-05 Attention deficit hyperactivity disorder / / 23728934 rs1452578 chr4 97035378 A G 4.99E-05 Cognitive test performance / / 20125193 rs6848939 chr4 97059594 C A 6.70E-05 Platelet counts / / pha003100 rs7671563 chr4 97086618 G A 2.03E-05 Cognitive test performance / / 20125193 rs17025268 chr4 97175974 A G 1.84E-07 Multiple complex diseases / / 17554300 rs6831068 chr4 97218418 T C 1.60E-05 Urinary metabolites / / 21572414 rs4146411 chr4 97266060 G A 6.55E-05 stroke (ischemic) / / 17434096 rs1922860 chr4 97697189 A T 9.76E-04 Self-reported allergy / / 23817569 rs2204919 chr4 97723779 T C 7.80E-05 Schizophrenia / / pha002859 rs7683885 chr4 97739513 T C 6.11E-04 Self-reported allergy / / 23817569 rs1922858 chr4 97756259 G C 8.29E-04 Self-reported allergy / / 23817569 rs1922859 chr4 97757127 C T 8.71E-05 stroke (ischemic) / / 17434096 rs17025930 chr4 97759914 T C 1.20E-05 Urinary metabolites / / 21572414 rs17025944 chr4 97766960 T C 2.90E-05 Urinary metabolites / / 21572414 rs4446314 chr4 97769620 T G 8.97E-04 Schizophrenia / / 19197363 rs17025983 chr4 97798669 G A 1.73E-04 Multiple complex diseases / / 17554300 rs10212877 chr4 97802800 T C 1.37E-04 Multiple complex diseases / / 17554300 rs6850883 chr4 97805136 A C 2.19E-04 Multiple complex diseases / / 17554300 rs17026010 chr4 97807070 A G 2.00E-04 Multiple complex diseases / / 17554300 rs10015295 chr4 97807290 G C 3.00E-04 Multiple complex diseases / / 17554300 rs17026019 chr4 97807779 A G 1.16E-04 Multiple complex diseases / / 17554300 rs532321016 chr4 97808839 ACT A 2.75E-04 Multiple complex diseases / / 17554300 rs9998494 chr4 97808839 A C 2.75E-04 Multiple complex diseases / / 17554300 rs10021072 chr4 97808942 C G 2.23E-04 Multiple complex diseases / / 17554300 rs7694207 chr4 97880409 C T 4.00E-06 Response to mTOR inhibitor (everolimus) / / 24009623 rs7694207 chr4 97880409 C T 4.73E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs6830552 chr4 97890041 C T 3.60E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs7685670 chr4 97891494 G A 1.00E-05 Urinary metabolites / / 21572414 rs6835198 chr4 97902998 G A 4.55E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs6834049 chr4 97906295 A G 3.60E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs2525795 chr4 97908904 A C 9.86E-04 Obesity (extreme) / / 21935397 rs7673377 chr4 97917772 A C 3.44E-04 Alzheimer's disease / / 22005930 rs13121156 chr4 97918159 T C 6.89E-04 Alzheimer's disease / / 22005930 rs17246599 chr4 97921253 T C 7.31E-04 Alzheimer's disease / / 22005930 rs2158384 chr4 97921707 A C 6.93E-04 Alzheimer's disease / / 22005930 rs10006108 chr4 97924013 C T 7.80E-04 Body mass index / / 21701565 rs10006108 chr4 97924013 C T 7.25E-04 Alzheimer's disease / / 22005930 rs1013968 chr4 97924403 G A 9.03E-04 Alzheimer's disease / / 22005930 rs7697251 chr4 97926538 C A 9.95E-04 Alzheimer's disease / / 22005930 rs981544 chr4 97931374 C A 4.73E-04 Alzheimer's disease / / 22005930 rs17247004 chr4 97934806 A G 9.02E-04 Alzheimer's disease / / 22005930 rs4141303 chr4 97935617 G A 9.31E-04 Alzheimer's disease / / 22005930 rs6840385 chr4 97936878 G T 8.33E-04 Alzheimer's disease / / 22005930 rs6840021 chr4 97936898 A C 4.44E-04 Alzheimer's disease / / 22005930 rs2214554 chr4 97939225 T A 4.70E-04 Alzheimer's disease / / 22005930 rs2214555 chr4 97939227 A G 7.25E-04 Alzheimer's disease / / 22005930 rs17247425 chr4 97943833 A C 6.59E-04 Alzheimer's disease / / 22005930 rs2189574 chr4 97943856 G A 7.99E-04 Alzheimer's disease / / 22005930 rs2189575 chr4 97943954 G T 6.29E-04 Alzheimer's disease / / 22005930 rs17187902 chr4 97945440 T A 6.95E-04 Alzheimer's disease / / 22005930 rs7679559 chr4 97978546 G A 1.59E-04 Multiple complex diseases / / 17554300 rs10452174 chr4 98151987 T G 1.05E-04 Multiple complex diseases / / 17554300 rs11945291 chr4 98184296 A G 2.39E-04 Multiple complex diseases / / 17554300 rs13119820 chr4 98227375 G T 1.22E-04 Iron levels / / pha002876 rs1462778 chr4 98237090 T C 3.10E-05 Cognitive function / / 24684796 rs12512414 chr4 98266404 A G 5.98E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1462767 chr4 98270800 T C 1.20E-04 Iron levels / / pha002876 rs16996544 chr4 98275053 G A 9.05E-05 Type 2 diabetes / / 17463246 rs11097560 chr4 98286926 G A 3.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7682461 chr4 98297699 G T 5.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs986825 chr4 98307928 A G 5.50E-05 Parkinson's disease (age of onset) / / 19772629 rs1567287 chr4 98509130 C T 8.35E-04 Obesity (extreme) C4orf37 intron 21935397 rs1508466 chr4 98512059 A G 8.26E-04 Obesity (extreme) C4orf37 intron 21935397 rs12649979 chr4 98513928 A G 8.13E-04 Obesity (extreme) C4orf37 intron 21935397 rs13149481 chr4 98520332 A G 8.09E-04 Obesity (extreme) C4orf37 intron 21935397 rs1355044 chr4 98527486 C A 8.07E-04 Obesity (extreme) C4orf37 intron 21935397 rs2865799 chr4 98531675 G C 8.07E-04 Obesity (extreme) C4orf37 intron 21935397 rs4568246 chr4 98540843 C T 8.06E-04 Obesity (extreme) C4orf37 intron 21935397 rs1605637 chr4 98543212 A T 8.06E-04 Obesity (extreme) C4orf37 intron 21935397 rs2136081 chr4 98547227 C T 8.06E-04 Obesity (extreme) C4orf37 intron 21935397 rs4153 chr4 98548220 T C 8.06E-04 Obesity (extreme) C4orf37 intron 21935397 rs1508475 chr4 98549362 G A 9.75E-04 Obesity (extreme) C4orf37 intron 21935397 rs1947516 chr4 98652600 T C 2.83E-06 Systemic lupus erythematosus and Systemic sclerosis C4orf37 intron 23740937 rs1084783 chr4 98887552 T C 1.11E-04 Multiple complex diseases C4orf37 intron 17554300 rs12233741 chr4 98950296 C T 6.00E-04 Iris characteristics C4orf37 intron 21835309 rs7677523 chr4 98965696 T C 0.00000951 Preeclampsia C4orf37 intron 22432041 rs969049 chr4 98988857 C T 1.40E-04 Blood Pressure and Arterial Stiffness C4orf37 intron 17903302 rs2865951 chr4 99040191 G A 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) C4orf37 intron 17982456 rs549467 chr4 99172232 G T 4.81E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2034677 chr4 99187874 A G 4.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RAP1GDS1 intron 20877124 rs17561798 chr4 99235941 A G 3.80E-04 Tourette syndrome RAP1GDS1 intron 22889924 rs10516428 chr4 99237439 T G 1.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RAP1GDS1 intron 20877124 rs3775539 chr4 99304600 A G 5.78E-04 Multiple complex diseases RAP1GDS1 intron 17554300 rs10516430 chr4 99337881 C T 7.20E-04 Lipid traits RAP1GDS1 intron 17903299 rs10516430 chr4 99337881 C T 6.00E-06 Biochemical measures RAP1GDS1 intron 19260141 rs10516430 chr4 99337881 C T 7.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RAP1GDS1 intron 20877124 rs9884594 chr4 99359318 G A 2.28E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RAP1GDS1 intron 20877124 rs4303985 chr4 99399748 G T 1.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TSPAN5 intron 20877124 rs10009693 chr4 99423280 C T 9.72E-04 Myopia (pathological) TSPAN5 intron 21095009 rs10516433 chr4 99443526 C T 7.70E-05 Lipid traits TSPAN5 intron 17903299 rs6853079 chr4 99443611 A T 1.30E-04 Lipid traits TSPAN5 intron 17903299 rs10516434 chr4 99445315 C T 8.60E-05 Lipid traits TSPAN5 intron 17903299 rs2037832 chr4 99459528 C T 9.50E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) TSPAN5 intron 23648065 rs111988552 chr4 99478314 A T 4.50E-07 Response to tocilizumab in rheumatoid arthritis TSPAN5 intron 22491018 rs17801290 chr4 99485507 T C 4.05E-05 Neutrophil count TSPAN5 intron pha003095 rs2866016 chr4 99504235 G A 1.00E-05 Type 2 diabetes TSPAN5 intron 17293876 rs2866016 chr4 99504235 G A 1.00E-05 Type 2 diabetes TSPAN5 intron 19184112 rs10489125 chr4 99507836 C T 2.60E-05 Urinary metabolites TSPAN5 intron 21572414 rs10489126 chr4 99556496 T C 6.95E-04 Coronary heart disease TSPAN5 intron 21971053 rs883509 chr4 99563676 A G 5.98E-04 Coronary heart disease TSPAN5 intron 21971053 rs41374948 chr4 99688628 G A 9.83E-05 Multiple complex diseases / / 17554300 rs10010115 chr4 99698254 T C 9.98E-05 Calcium levels / / pha003085 rs17028081 chr4 99701724 G A 9.98E-05 Calcium levels / / pha003085 rs11939328 chr4 99703236 G A 5.09E-05 Coronary Artery Disease / / 17634449 rs28463044 chr4 99723760 T C 5.00E-05 Intracerebral hemorrhage / / 24656865 rs11097638 chr4 99781443 T G 1.80E-05 Urinary metabolites / / 21572414 rs9332467 chr4 99795324 G A 5.90E-06 Urinary metabolites / / 21572414 rs7665193 chr4 99796587 T C 7.90E-05 Multiple complex diseases / / 17554300 rs7665590 chr4 99796784 T C 1.00E-07 Primary biliary cirrhosis / / 23000144 rs11727086 chr4 99828368 A G 1.50E-05 Urinary metabolites EIF4E intron 21572414 rs17511498 chr4 99855241 A G 1.50E-05 Urinary metabolites / / 21572414 rs12644580 chr4 99862994 T C 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs7688221 chr4 99875857 T G 2.40E-05 Urinary metabolites / / 21572414 rs1230194 chr4 99896306 A G 6.66E-05 Erythrocyte counts / / pha003090 rs2123782 chr4 99926965 T C 8.30E-04 Schizophrenia METAP1 intron 19197363 rs11097642 chr4 99929768 T C 2.94E-04 Alzheimer's disease METAP1 intron 22005930 rs1230186 chr4 99963407 G T 6.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) METAP1 intron 20877124 rs17216446 chr4 99976646 G T 1.10E-05 Urinary metabolites METAP1 intron 21572414 rs1238741 chr4 99983312 T C 6.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) METAP1 UTR-3 20877124 rs1230155 chr4 99989259 G A 6.11E-04 Longevity / / 22279548 rs7662987 chr4 99991642 T C 9.00E-06 Smoking initiation / / 24665060 rs1803037 chr4 99993151 C T 3.58E-04 Smoking initiation ADH5 UTR-3 24665060 rs7683802 chr4 99995138 T G 3.61E-05 Smoking initiation ADH5 intron 24665060 rs13125919 chr4 99999848 C T 4.18E-04 Smoking initiation ADH5 intron 24665060 rs13132688 chr4 100011171 G A 9.00E-06 Obesity-related traits LOC100507053 intron 23251661 rs2602836 chr4 100014805 A G 5.00E-08 HDL cholesterol LOC100507053 intron 24097068 rs2851255 chr4 100042103 C G 1.50E-05 Urinary metabolites LOC100507053 intron 21572414 rs2851253 chr4 100043505 T G 1.60E-05 Urinary metabolites LOC100507053 intron 21572414 rs1042365 chr4 100045500 T G 6.20E-06 Urinary metabolites ADH4 UTR-3 21572414 rs2851248 chr4 100045974 T C 1.20E-05 Urinary metabolites ADH4 intron 21572414 rs2851247 chr4 100046091 G C 3.80E-06 Urinary metabolites ADH4 intron 21572414 rs2851246 chr4 100046104 T C 1.60E-05 Urinary metabolites ADH4 intron 21572414 rs2602896 chr4 100046207 A G 9.80E-06 Urinary metabolites ADH4 intron 21572414 rs34936974 chr4 100052384 G A 2.00E-06 Urinary metabolites ADH4 intron 21572414 rs3805322 chr4 100056998 A G 2.13E-05 Hemoglobin concentration ADH4 intron 20534544 rs3805322 chr4 100056998 A G 4.50E-14 Esophageal cancer (squamous cell) ADH4 intron 20833657 rs3805322 chr4 100056998 A G 6.00E-07 Esophageal cancer (alcohol interaction) ADH4 intron 22960999 rs17218560 chr4 100060794 A G 7.80E-06 Urinary metabolites ADH4 intron 21572414 rs13110176 chr4 100062430 A G 5.00E-06 Urinary metabolites ADH4 intron 21572414 rs4148884 chr4 100066287 C T 3.27E-05 Erythrocyte counts LOC100507053 intron pha003090 rs17028615 chr4 100071924 A G 2.00E-15 Metabolite levels LOC100507053 intron 24625756 rs1893883 chr4 100124716 C G 1.23E-05 Esophageal cancer (squamous cell) ADH6 UTR-3 22960999 rs6820368 chr4 100137494 T C 6.00E-06 QRS duration ADH6 intron 23534349 rs2201728 chr4 100163873 G A 5.00E-06 Cardiac Troponin-T levels LOC100507053 intron 23247143 rs1229977 chr4 100202414 T C 3.22E-06 Esophageal cancer (squamous cell) ADH1A intron 22960999 rs3805324 chr4 100204574 G A 0.00000102 Triglycerides ADH1A intron 23063622 rs1042026 chr4 100228466 T C 1.80E-16 Esophageal cancer (squamous cell) ADH1B UTR-3 20833657 rs1042026 chr4 100228466 T C 3.00E-07 Esophageal cancer (alcohol interaction) ADH1B UTR-3 22960999 rs17033 chr4 100228945 T C 2.80E-07 Esophageal cancer (squamous cell) ADH1B UTR-3 22960999 rs1229984 chr4 100239319 T C 8.00E-24 Esophageal cancer ADH1B missense 19698717 rs1229984 chr4 100239319 T C 8.00E-24 Nasopharyngeal carcinoma ADH1B missense 20512145 rs1229984 chr4 100239319 T C 4.40E-40 Esophageal cancer (squamous cell) ADH1B missense 20833657 rs1229984 chr4 100239319 T C 3.60E-04 Drinking behavior ADH1B missense 21372407 rs1229984 chr4 100239319 T C 1.00E-20 Upper aerodigestive tract cancers ADH1B missense 21437268 rs1229984 chr4 100239319 T C 3.00E-21 Alcohol dependence ADH1B missense 23456092 rs1229984 chr4 100239319 T C 2.00E-08 Alcohol consumption ADH1B missense 23743675 rs1159918 chr4 100243009 A C 4.92E-04 Response to cytidine analogues (gemcitabine) ADH1B nearGene-5 24483146 rs6810842 chr4 100243445 T G 5.96E-04 Response to cytidine analogues (gemcitabine) ADH1B nearGene-5 24483146 rs1693439 chr4 100245489 A G 9.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs1789891 chr4 100250419 C A 3.00E-06 Conduct disorder (interaction) / / 18846501 rs1789891 chr4 100250419 C A 1.00E-08 Alcohol dependence / / 22004471 rs2298753 chr4 100257907 T C 8.11E-04 Alcohol dependence ADH1C UTR-3 21314694 rs1614972 chr4 100258155 C T 1.34E-06 Esophageal cancer (squamous cell) ADH1C intron 22960999 rs698 chr4 100260789 T C 0.0000189 Triglycerides ADH1C missense 23063622 rs1789903 chr4 100262041 C G 3.35E-06 Esophageal cancer (squamous cell) ADH1C intron 22960999 rs4147542 chr4 100268553 T C 0.0000179 Triglycerides ADH1C intron 23063622 rs11936869 chr4 100273173 C G 0.00000979 Triglycerides ADH1C intron 23063622 rs1789924 chr4 100274286 C T 3.00E-07 Upper aerodigestive tract cancers ADH1C nearGene-5 21437268 rs56279505 chr4 100295240 T A 8.00E-07 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs2584457 chr4 100304166 T A 1.60E-05 Urinary metabolites / / 21572414 rs1372679 chr4 100304530 C T 0.000164 Transmission distortion / / 22377632 rs2654841 chr4 100304921 C T 2.08E-05 Hypertension / / 19609347 rs73832804 chr4 100307430 A G 3.78E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs73832805 chr4 100309165 G A 3.82E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1442493 chr4 100321365 G A,C,T 9.60E-04 Multiple complex diseases / / 17554300 rs1442493 chr4 100321365 G A,C,T 7.64E-05 Hypertension / / 19609347 rs991316 chr4 100322445 T C 5.00E-06 Hypertension / / 19609347 rs991316 chr4 100322445 T C 5.00E-06 Coronary heart disease / / 21347282 rs17028973 chr4 100322786 T C 4.61E-07 Esophageal cancer (squamous cell) / / 22960999 rs1442490 chr4 100326403 G A 1.24E-04 Hemoglobin concentration / / 20534544 rs994772 chr4 100327664 C T 3.20E-04 Hemoglobin concentration / / 20534544 rs994771 chr4 100327803 G A 2.68E-05 Hemoglobin concentration / / 20534544 rs1442488 chr4 100328482 A G 8.54E-04 Type 2 diabetes / / 17463246 rs284793 chr4 100330294 G A 9.70E-07 Amyotrophic Lateral Sclerosis / / 17362836 rs284793 chr4 100330294 G A 4.43E-05 Hemoglobin concentration / / 20534544 rs729147 chr4 100333267 G A 2.22E-04 Type 2 diabetes / / 17463246 rs284784 chr4 100335874 C A 5.12E-04 Amyotrophic Lateral Sclerosis ADH7 intron 17362836 rs284784 chr4 100335874 C A 1.09E-04 Hemoglobin concentration ADH7 intron 20534544 rs971074 chr4 100341861 C T 1.97E-04 Nonalcoholic fatty liver disease ADH7 cds-synon 21423719 rs971074 chr4 100341861 C T 9.00E-17 Upper aerodigestive tract cancers ADH7 cds-synon 21437268 rs10032685 chr4 100391317 C T 3.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs148915469 chr4 100395414 A C 8.00E-06 Eating disorders / / 23568457 rs17029087 chr4 100443800 G A 1.30E-05 Urinary metabolites C4orf17 missense 21572414 rs13126513 chr4 100444684 T C 8.00E-06 Metabolite levels (MHPG) C4orf17 intron 23319000 rs4699753 chr4 100446479 C T 3.90E-05 Alzheimer's disease (late onset) C4orf17 intron 21379329 rs867380 chr4 100451517 C T 1.72E-04 Type 2 diabetes C4orf17 intron 17463246 rs10031512 chr4 100457841 T C 4.10E-04 Type 2 diabetes C4orf17 intron 17463246 rs7693979 chr4 100464565 A T 5.84E-04 Type 2 diabetes / / 17463246 rs10009198 chr4 100465028 T A 4.10E-04 Type 2 diabetes / / 17463246 rs6532820 chr4 100467622 C T 4.10E-04 Type 2 diabetes / / 17463246 rs11935423 chr4 100477462 C T 9.57E-05 Type 2 diabetes RG9MTD2 intron 17463246 rs17029173 chr4 100509321 T G 7.65E-06 Celiac disease MTTP intron 23936387 rs1032355 chr4 100539896 T C 5.00E-06 Celiac disease MTTP intron 23936387 rs958868 chr4 100553223 C T 5.50E-04 Coronary heart disease / / 21971053 rs13103880 chr4 100563391 C T 8.98E-04 Coronary heart disease LOC285556 intron 21971053 rs17029269 chr4 100575398 C T 4.40E-04 Fibrinogen LOC285556 cds-synon 17255346 rs13114983 chr4 100575483 G T 4.53E-04 Fibrinogen LOC285556 missense 17255346 rs7677213 chr4 100585373 C T 1.31E-04 Height / / 17255346 rs1027223 chr4 100613859 A G 6.16E-05 Coronary heart disease / / 21971053 rs10516451 chr4 100626549 A G 0.00000608 Stroke / / 23422753 rs13150420 chr4 100651270 A G 3.40E-04 Premature ovarian failure / / 19508998 rs13150420 chr4 100651270 A G 4.21E-04 Alzheimer's disease (late onset) / / 21379329 rs1582793 chr4 100654259 C T 3.74E-04 Coronary heart disease / / 21971053 rs1582793 chr4 100654259 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2866168 chr4 100657673 A G 8.14E-04 Premature ovarian failure / / 19508998 rs13108714 chr4 100661092 T C 5.31E-04 Fibrinogen / / 17255346 rs7666347 chr4 100666364 C T 2.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7666347 chr4 100666364 C T 3.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1426731 chr4 100667705 T C 9.76E-04 Multiple complex diseases / / 17554300 rs11735070 chr4 100713765 G C 1.00E-06 Response to antipsychotic treatment / / 20195266 rs2282588 chr4 100738397 T A 9.19E-04 Suicide attempts in bipolar disorder DAPP1 intron 21423239 rs1863608 chr4 100740434 C T 9.68E-04 Suicide attempts in bipolar disorder DAPP1 intron 21423239 rs4699764 chr4 100740709 A C 8.85E-04 Suicide attempts in bipolar disorder DAPP1 intron 21423239 rs6814895 chr4 100742608 G A 9.16E-04 Suicide attempts in bipolar disorder DAPP1 intron 21423239 rs17029528 chr4 100746076 A G 4.97E-04 Multiple complex diseases DAPP1 intron 17554300 rs4463077 chr4 100751899 A G 1.19E-04 Multiple complex diseases DAPP1 intron 17554300 rs17539393 chr4 100757301 C T 1.18E-05 Menarche (age at onset) DAPP1 intron 19282985 rs17611664 chr4 100758557 G A 2.54E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) DAPP1 intron 24023788 rs4699767 chr4 100772603 T C 7.36E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) DAPP1 intron 24023788 rs3737484 chr4 100784980 C T 7.31E-04 Response to taxane treatment (placlitaxel) DAPP1 cds-synon 23006423 rs191421902 chr4 100789312 G A 0.0004 Breast cancer DAPP1 cds-synon 23555315 rs6532834 chr4 100790328 G A 8.62E-04 Response to taxane treatment (placlitaxel) DAPP1 UTR-3 23006423 rs6829912 chr4 100792483 C T 9.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17029662 chr4 100847105 G A 4.72E-04 Response to taxane treatment (placlitaxel) D/JB14 intron 23006423 rs17029719 chr4 100938090 A G 3.39E-05 Multiple complex diseases / / 17554300 rs17620559 chr4 101082527 C T 5.15E-04 Multiple complex diseases / / 17554300 rs17620626 chr4 101086037 G A 1.35E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2866197 chr4 101106316 T C 2.52E-06 Amyotrophic lateral sclerosis / / 20801717 rs2866197 chr4 101106316 T C 0.00000574 Amyotrophic lateral sclerosis / / 23587638 rs2866197 chr4 101106316 T C 0.0000107 Amyotrophic lateral sclerosis / / 23587638 rs11734827 chr4 101108008 A C 0.0000158 Amyotrophic lateral sclerosis DDIT4L UTR-3 23587638 rs11734827 chr4 101108008 A C 0.0000232 Amyotrophic lateral sclerosis DDIT4L UTR-3 23587638 rs12506292 chr4 101132253 T C 6.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12506292 chr4 101132253 T C 4.43E-04 Alzheimer's disease (late onset) / / 21379329 rs4450933 chr4 101135166 G A 1.10E-05 Urinary metabolites / / 21572414 rs11097701 chr4 101135989 G A 1.60E-05 Urinary metabolites / / 21572414 rs10012792 chr4 101145359 G A 1.70E-05 Urinary metabolites / / 21572414 rs4399998 chr4 101145615 C T 1.70E-05 Urinary metabolites / / 21572414 rs4443296 chr4 101145881 G A 2.00E-05 Urinary metabolites / / 21572414 rs4574420 chr4 101163334 C A 1.50E-05 Urinary metabolites / / 21572414 rs4413414 chr4 101163457 T C 1.10E-05 Urinary metabolites / / 21572414 rs4318660 chr4 101166657 C T 1.10E-05 Urinary metabolites / / 21572414 rs13353574 chr4 101172344 A T 7.40E-06 Urinary metabolites / / 21572414 rs11944421 chr4 101205068 C T 5.76E-04 Multiple complex diseases / / 17554300 rs4235450 chr4 101210715 C T 4.30E-04 Myasthenia gravis / / 23055271 rs11097709 chr4 101251778 C T 5.17E-04 HIV-1 viral setpoint / / 17641165 rs4478196 chr4 101262840 A G 7.32E-04 HIV-1 viral setpoint / / 17641165 rs12651056 chr4 101264735 A G 9.79E-04 Multiple complex diseases / / 17554300 rs13130455 chr4 101274858 A C 5.46E-04 HIV-1 viral setpoint / / 17641165 rs4516726 chr4 101279241 G A 6.91E-04 HIV-1 viral setpoint / / 17641165 rs4699794 chr4 101280196 T C 8.94E-04 HIV-1 viral setpoint / / 17641165 rs11936536 chr4 101293603 C T 9.80E-04 Multiple complex diseases / / 17554300 rs2903213 chr4 101297021 T C 5.78E-04 Bipolar disorder / / 19259986 rs1982086 chr4 101306586 T C 8.79E-04 Schizophrenia / / 19197363 rs13122464 chr4 101306906 G A 4.58E-04 Schizophrenia / / 19197363 rs10516462 chr4 101307674 A G 8.42E-04 Schizophrenia / / 19197363 rs2116992 chr4 101320412 T C 6.03E-04 HIV-1 viral setpoint EMCN intron 17641165 rs1347197 chr4 101341678 C A 9.09E-04 Multiple complex diseases EMCN intron 17554300 rs242596 chr4 101383092 C T 4.52E-04 HIV-1 viral setpoint EMCN intron 17641165 rs357655 chr4 101385409 C A 7.56E-04 HIV-1 viral setpoint EMCN intron 17641165 rs13128919 chr4 101463049 A T 1.70E-05 Urinary metabolites / / 21572414 rs1392874 chr4 101466820 C A 1.90E-06 Urinary metabolites / / 21572414 rs10019286 chr4 101469544 T C 7.49E-05 Body Mass Index / / pha003019 rs2013390 chr4 101479155 C T 2.80E-05 Height / / pha003011 rs7667609 chr4 101481541 G A 4.96E-04 Alzheimer's disease / / 22005930 rs2567397 chr4 101490650 G T 2.52E-05 Serum metabolites / / 19043545 rs1392880 chr4 101495842 C G 1.35E-05 Serum metabolites / / 19043545 rs7664292 chr4 101499249 C T 2.03E-05 Serum metabolites / / 19043545 rs1501098 chr4 101505097 G C 2.58E-05 Serum metabolites / / 19043545 rs1501099 chr4 101505130 A G 2.71E-05 Serum metabolites / / 19043545 rs1501100 chr4 101505266 A G 3.41E-05 Serum metabolites / / 19043545 rs2651558 chr4 101505448 A G 2.26E-04 Aortic root size / / 21223598 rs13148793 chr4 101507299 T C 4.51E-05 Height / / pha003011 rs6831462 chr4 101511084 G A 5.76E-04 Alzheimer's disease / / 22005930 rs17030327 chr4 101512875 A G 3.64E-04 Alzheimer's disease / / 17998437 rs2866217 chr4 101523312 A G 5.37E-05 Height / / pha003011 rs4635820 chr4 101555045 G C 1.91E-04 Aortic root size / / 21223598 rs9759759 chr4 101573688 C A 8.87E-05 Insulin-related traits / / pha003063 rs906600 chr4 101596523 A C 8.28E-05 Insulin-related traits / / pha003063 rs13113346 chr4 101614037 G A 8.63E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7654751 chr4 101680533 C T 6.69E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7697678 chr4 101698032 A G 5.16E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2089540 chr4 101699382 G A 7.00E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2866240 chr4 101700041 T A 2.12E-04 Gallstones / / 17632509 rs2903222 chr4 101768637 G A 9.49E-04 Multiple complex diseases / / 17554300 rs13107740 chr4 101806532 C G 5.00E-06 Response to angiotensin II receptor blocker therapy / / 22566498 rs7665292 chr4 101813966 T C 2.22E-04 Multiple complex diseases / / 17554300 rs13435486 chr4 101833618 G A 5.64E-04 Multiple complex diseases / / 17554300 rs13121097 chr4 101851136 G A 4.62E-04 Multiple complex diseases / / 17554300 rs13148044 chr4 101851184 T C 4.38E-04 Multiple complex diseases / / 17554300 rs12647454 chr4 101862458 C T 3.93E-04 Multiple complex diseases / / 17554300 rs6532916 chr4 101870351 C G 2.94E-04 Multiple complex diseases / / 17554300 rs13136799 chr4 101870464 G A 2.38E-04 Multiple complex diseases / / 17554300 rs10027689 chr4 101875918 G A 5.25E-04 Multiple complex diseases / / 17554300 rs12649554 chr4 101896676 T C 2.32E-05 Serum metabolites / / 19043545 rs12649554 chr4 101896676 T C 4.80E-07 Hepatitis B / / 21750111 rs72927357 chr4 101901410 A C 9.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs2850611 chr4 101904205 C T 6.80E-04 Asperger disorder / / 21182207 rs2851048 chr4 101924060 C T 5.05E-04 Multiple complex diseases / / 17554300 rs1405687 chr4 101931826 G A 5.00E-08 Response to antipsychotic treatment / / 20195266 rs10025768 chr4 101965295 G A 1.03E-04 Celiac disease PPP3CA intron 23936387 rs2851062 chr4 101968611 A G 7.09E-05 Cognitive test performance PPP3CA intron 20125193 rs17030730 chr4 101983369 A G 2.72E-04 Type 2 diabetes PPP3CA intron 17463246 rs10022217 chr4 101986972 A T 5.32E-06 Acne (severe teenage) PPP3CA intron 24114350 rs3804357 chr4 102002123 C A 1.12E-05 Sensory disturbances after bilateral sagittal split ramus osteotomy PPP3CA intron 23834954 rs2732512 chr4 102033997 T C 6.31E-04 Rheumatoid arthritis (ACPA-negative) PPP3CA intron 24532677 rs2659546 chr4 102037719 C T 4.00E-06 Corneal structure PPP3CA intron 21979947 rs1506801 chr4 102043610 C T 2.83E-04 Lung function (forced vital capacity) PPP3CA intron 24023788 rs17030795 chr4 102048076 A G 6.00E-06 Anorexia nervosa PPP3CA intron 24514567 rs2732518 chr4 102061730 T C 2.73E-06 Multiple complex diseases PPP3CA intron 17554300 rs1880943 chr4 102081357 C T 6.50E-05 Multiple sclerosis PPP3CA intron 17660530 rs2695217 chr4 102082033 A G 8.28E-05 Multiple sclerosis PPP3CA intron 17660530 rs17030887 chr4 102098066 T C 3.23E-04 Amyotrophic lateral sclerosis (sporadic) PPP3CA intron 24529757 rs3804375 chr4 102136173 G A 3.97E-05 Panic disorder PPP3CA intron 19165232 rs2119601 chr4 102173886 C T 4.34E-04 Multiple complex diseases PPP3CA intron 17554300 rs2850341 chr4 102191502 C G 3.96E-04 Multiple complex diseases PPP3CA intron 17554300 rs2850356 chr4 102211922 G A 5.39E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PPP3CA intron 20031582 rs6846071 chr4 102402215 T G 1.00E-11 C-reactive protein and white blood cell count / / 22788528 rs11727778 chr4 102422222 T C 1.61E-06 Carotenoid and tocopherol levels / / 19185284 rs890448 chr4 102432702 C T 8.00E-06 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs890448 chr4 102432702 C T 9.28E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs2903269 chr4 102450302 C T 8.73E-08 Carotenoid and tocopherol levels / / 19185284 rs13129752 chr4 102471437 C T 2.50E-05 Urinary metabolites / / 21572414 rs4698964 chr4 102484590 T A 2.70E-05 Urinary metabolites / / 21572414 rs11725488 chr4 102541941 G T 2.54E-04 Alzheimer's disease (late onset) / / 21379329 rs11729520 chr4 102547238 T C 7.28E-06 Carotenoid and tocopherol levels / / 19185284 rs17031508 chr4 102560290 A C 8.00E-08 Blood pressure / / 22763476 rs2866624 chr4 102565132 G A 5.18E-06 Carotenoid and tocopherol levels / / 19185284 rs2866627 chr4 102569368 C T 3.64E-04 Alzheimer's disease (late onset) / / 21379329 rs7676236 chr4 102574367 G A 1.94E-04 Cholesterol / / 17255346 rs6532954 chr4 102588509 T C 6.35E-04 Prostate cancer mortality / / 20978177 rs7700191 chr4 102589283 G A 4.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs2866422 chr4 102603328 C A 5.73E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17251102 chr4 102608288 A G 1.69E-04 Multiple complex diseases / / 17554300 rs4487344 chr4 102611136 G A 1.23E-05 Hypertension / / 21082022 rs13124455 chr4 102611656 G A 3.47E-06 Hypertension / / 21082022 rs7669524 chr4 102614169 G A 3.15E-06 Hypertension / / 21082022 rs10030362 chr4 102622843 T C 3.13E-04 Multiple complex diseases / / 17554300 rs13149930 chr4 102624280 T C 1.60E-04 Alzheimer's disease (late onset) / / 21379329 rs768290 chr4 102635952 A G 6.58E-06 Hypertension / / 21082022 rs12505043 chr4 102655362 C T 2.04E-04 Hypertension / / 21082022 rs12505043 chr4 102655362 C T 4.73E-04 Alzheimer's disease (late onset) / / 21379329 rs4640677 chr4 102658075 G A 6.62E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs4327488 chr4 102659213 C T 3.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12648641 chr4 102659750 C A 9.89E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs871061 chr4 102679337 A C 2.52E-05 Schizophrenia / / 19571811 rs4632664 chr4 102692665 G A 6.28E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs4482766 chr4 102692822 C T 2.52E-05 Hypertension / / 21082022 rs7695738 chr4 102701232 G A 3.65E-04 Alzheimer's disease (late onset) / / 21379329 rs7695738 chr4 102701232 G A 9.05E-04 Alzheimer's disease / / 24755620 rs7695470 chr4 102701262 C T 2.82E-05 AIDS progression / / 19115949 rs7700116 chr4 102701345 C T 1.56E-04 Alzheimer's disease (late onset) / / 21379329 rs4522865 chr4 102715888 G A 5.00E-06 Systemic lupus erythematosus BANK1 intron 23273568 rs13117264 chr4 102719650 T G 1.62E-04 Multiple complex diseases BANK1 intron 17554300 rs10446706 chr4 102721732 G A 3.92E-04 Multiple complex diseases BANK1 intron 17554300 rs4699261 chr4 102725474 G A 5.27E-04 Multiple complex diseases BANK1 intron 17554300 rs4698969 chr4 102725955 C T 5.51E-04 Multiple complex diseases BANK1 intron 17554300 rs6833249 chr4 102726073 A G 1.02E-05 Menarche (age at onset) BANK1 intron 19282985 rs6833249 chr4 102726073 A G 1.20E-05 Urinary metabolites BANK1 intron 21572414 rs4276281 chr4 102746780 C A 1.10E-04 Systemic lupus erythematosus BANK1 intron 23273568 rs11938136 chr4 102750726 G A 1.90E-04 Multiple complex diseases BANK1 intron 17554300 rs17266594 chr4 102750922 T C 4.74E-11 Systemic lupus erythematosus BANK1 intron 18204447 rs10516487 chr4 102751076 G A 9.42E-04 Amyotrophic Lateral Sclerosis BANK1 missense 17362836 rs10516487 chr4 102751076 G A 8.43E-04 Multiple complex diseases BANK1 missense 17554300 rs10516487 chr4 102751076 G A 4.00E-10 Systemic lupus erythematosus BANK1 missense 18204447 rs10516487 chr4 102751076 G A 3.70E-10 Multiple sclerosis BANK1 missense 22190364 rs10516487 chr4 102751076 G A 1.20E-04 Systemic lupus erythematosus BANK1 missense 23273568 rs10516486 chr4 102751276 C T 1.60E-04 Systemic lupus erythematosus BANK1 cds-synon 23273568 rs13129744 chr4 102756731 T C 3.20E-04 Systemic lupus erythematosus BANK1 intron 23273568 rs17031708 chr4 102764358 T C 1.91E-04 Prion diseases BANK1 intron 22210626 rs11940934 chr4 102770557 A G 5.30E-06 Urinary metabolites BANK1 intron 21572414 rs4698971 chr4 102772861 G C 1.40E-05 Urinary metabolites BANK1 intron 21572414 rs12331846 chr4 102790613 G A 2.99E-04 Alzheimer's disease BANK1 intron 22005930 rs7662572 chr4 102791185 G A 1.70E-05 Urinary metabolites BANK1 intron 21572414 rs10516483 chr4 102791905 C G 5.62E-04 Systemic lupus erythematosus BANK1 intron 18204447 rs2216546 chr4 102793500 G T 2.14E-05 Systemic lupus erythematosus and Systemic sclerosis BANK1 intron 23740937 rs11734196 chr4 102796072 G C 3.04E-04 Alzheimer's disease BANK1 intron 22005930 rs13103438 chr4 102805940 T C 1.90E-05 Urinary metabolites BANK1 intron 21572414 rs4345184 chr4 102807050 C T 1.20E-05 Urinary metabolites BANK1 intron 21572414 rs10212684 chr4 102822507 A G 2.14E-04 Alzheimer's disease BANK1 intron 22005930 rs7694392 chr4 102823426 C T 5.56E-05 Parkinson's disease BANK1 intron 16252231 rs4295265 chr4 102835645 C T 9.32E-04 Suicide attempts in bipolar disorder BANK1 intron 21423239 rs4295265 chr4 102835645 C T 2.90E-05 Schizophrenia BANK1 intron 21926974 rs6812874 chr4 102839008 T G 5.82E-04 Alzheimer's disease BANK1 intron 22005930 rs3733197 chr4 102839287 G A 4.67E-05 Systemic lupus erythematosus BANK1 missense 18204447 rs3733197 chr4 102839287 G A 7.94E-04 Suicide attempts in bipolar disorder BANK1 missense 21423239 rs2631255 chr4 102849920 G A 5.54E-04 Parkinson's disease BANK1 intron 16252231 rs2631251 chr4 102864610 A G 6.89E-04 Alzheimer's disease BANK1 intron 22005930 rs13126505 chr4 102865304 G A 2.00E-12 Crohn's disease BANK1 intron 23128233 rs1386175 chr4 102937994 C T 6.17E-04 Response to cytadine analogues (cytosine arabinoside) BANK1 intron 24483146 rs2631267 chr4 102948472 A G 2.10E-05 Hemoglobin BANK1 intron pha003098 rs2631267 chr4 102948472 A G 1.75E-05 Erythrocyte counts BANK1 intron pha003099 rs1872701 chr4 102953681 T G 5.45E-05 Smoking initiation BANK1 intron 24665060 rs2510445 chr4 102967631 A C 1.28E-04 Smoking initiation BANK1 intron 24665060 rs2658535 chr4 102971016 G A 9.01E-04 Coronary heart disease BANK1 intron 21606135 rs17031982 chr4 102979378 C A 3.88E-04 Smoking initiation BANK1 intron 24665060 rs1395306 chr4 102985850 C T 7.38E-04 Coronary heart disease BANK1 intron 21606135 rs1395306 chr4 102985850 C T 1.14E-04 Smoking initiation BANK1 intron 24665060 rs11729100 chr4 102987238 C A 2.51E-04 Multiple complex diseases BANK1 intron 17554300 rs4698987 chr4 102988188 C A 9.65E-05 Smoking initiation BANK1 intron 24665060 rs2129292 chr4 102991139 C G 8.30E-04 Coronary heart disease BANK1 intron 21606135 rs2129292 chr4 102991139 C G 8.01E-05 Smoking initiation BANK1 intron 24665060 rs7675363 chr4 102998867 C T 2.15E-04 Coronary heart disease / / 21606135 rs7675363 chr4 102998867 C T 1.28E-04 Smoking initiation / / 24665060 rs238486 chr4 103020804 T C 1.64E-04 Smoking initiation / / 24665060 rs238487 chr4 103021348 T C 5.29E-05 Smoking initiation / / 24665060 rs173218 chr4 103023049 T C 6.24E-05 Prostate cancer / / 22923026 rs238491 chr4 103024435 T C 4.01E-04 Smoking initiation / / 24665060 rs238476 chr4 103044377 T C 6.77E-04 Prostate cancer mortality / / 20978177 rs1506504 chr4 103047763 C T 8.50E-04 Coronary heart disease / / 21606135 rs1506504 chr4 103047763 C T 7.82E-05 Smoking initiation / / 24665060 rs11937896 chr4 103047980 T C 5.66E-04 Multiple complex diseases / / 17554300 rs2658533 chr4 103048019 T G 8.66E-04 Prostate cancer mortality / / 20978177 rs236754 chr4 103052816 G A 9.27E-05 Smoking initiation / / 24665060 rs236762 chr4 103059680 C A 6.64E-04 Prostate cancer mortality / / 20978177 rs236768 chr4 103075983 G A 4.05E-04 Prostate cancer mortality / / 20978177 rs236781 chr4 103084574 G A 2.84E-04 Prostate cancer mortality / / 20978177 rs189328 chr4 103085133 A G 2.88E-04 Prostate cancer mortality / / 20978177 rs17032126 chr4 103088491 A G 6.48E-06 Hemoglobin / / pha003098 rs17032126 chr4 103088491 A G 2.44E-05 Erythrocyte counts / / pha003099 rs2213028 chr4 103106996 G A 5.54E-04 Parkinson's disease / / 17052657 rs7667281 chr4 103133044 C T 8.62E-05 Personality dimensions / / 18957941 rs151408 chr4 103144711 C T 7.00E-06 Personality dimensions / / 21173776 rs463661 chr4 103151556 T C 7.40E-06 Personality dimensions / / 21173776 rs464969 chr4 103151760 A G 6.32E-04 Multiple complex diseases / / 17554300 rs458318 chr4 103152288 T A 6.00E-06 Personality dimensions / / 21173776 rs458318 chr4 103152288 T A 2.93E-31 Lymphocyte counts / / 22286170 rs464114 chr4 103152517 A C 6.00E-06 Personality dimensions / / 21173776 rs460670 chr4 103154004 T G 5.70E-06 Personality dimensions / / 21173776 rs460610 chr4 103154130 T C 3.70E-04 Type 2 diabetes / / 17846125 rs367659 chr4 103154391 T C 6.30E-06 Personality dimensions / / 21173776 rs151372 chr4 103174196 C T 6.10E-06 Personality dimensions SLC39A8 UTR-3 21173776 rs151369 chr4 103176770 T C 7.50E-06 Personality dimensions SLC39A8 intron 21173776 rs151368 chr4 103181113 A T 6.50E-06 Personality dimensions SLC39A8 intron 21173776 rs6832846 chr4 103181749 G A 6.50E-06 Personality dimensions SLC39A8 intron 21173776 rs9331 chr4 103183218 G A 7.30E-06 Personality dimensions SLC39A8 UTR-3 21173776 rs17032363 chr4 103183423 C T 1.21E-05 Reading and spelling SLC39A8 UTR-3 23738518 rs9705 chr4 103183531 T C 7.10E-06 Personality dimensions SLC39A8 UTR-3 21173776 rs151393 chr4 103184089 A G 7.00E-06 Personality dimensions SLC39A8 UTR-3 21173776 rs151394 chr4 103184652 G C 9.47E-04 Multiple complex diseases SLC39A8 intron 17554300 rs170870 chr4 103186482 T A 6.40E-06 Personality dimensions SLC39A8 intron 21173776 rs151395 chr4 103186708 T C 6.20E-06 Personality dimensions SLC39A8 intron 21173776 rs151396 chr4 103186782 G A 5.80E-06 Personality dimensions SLC39A8 intron 21173776 rs151397 chr4 103186797 G T 5.20E-06 Personality dimensions SLC39A8 intron 21173776 rs151398 chr4 103187076 C G 5.60E-06 Personality dimensions SLC39A8 intron 21173776 rs151399 chr4 103187562 C T 5.20E-06 Personality dimensions SLC39A8 intron 21173776 rs13107325 chr4 103188709 C T 7.00E-11 HDL cholesterol SLC39A8 missense 20686565 rs13107325 chr4 103188709 C T 2.00E-13 Body mass index SLC39A8 missense 20935630 rs13107325 chr4 103188709 C T 1.00E-10 Blood pressure SLC39A8 missense 21909110 rs13107325 chr4 103188709 C T 2.00E-17 Diastolic blood pressure SLC39A8 missense 21909115 rs13107325 chr4 103188709 C T 3.00E-14 Systolic blood pressure SLC39A8 missense 21909115 rs13107325 chr4 103188709 C T 5.00E-07 Hypertension SLC39A8 missense 21909115 rs13107325 chr4 103188709 C T 1.50E-13 Body mass index SLC39A8 missense 23001569 rs13107325 chr4 103188709 C T 0.000026 Nonsyndromic striae distensae (stretch marks) SLC39A8 missense 23633020 rs13107325 chr4 103188709 C T 1.00E-15 HDL cholesterol SLC39A8 missense 24097068 rs13107325 chr4 103188709 C T 1.09E-05 Staphylococcus aureus infection SLC39A8 missense 24847357 rs151402 chr4 103190486 G A 2.90E-06 Personality dimensions SLC39A8 intron 21173776 rs151403 chr4 103191447 A G 4.40E-06 Personality dimensions SLC39A8 intron 21173776 rs13135092 chr4 103198082 A G 0.0000431 Nonsyndromic striae distensae (stretch marks) SLC39A8 intron 23633020 rs10014145 chr4 103200577 A G 1.52E-05 Coronary heart disease SLC39A8 intron pha003031 rs233826 chr4 103203228 T C 2.70E-06 Personality dimensions SLC39A8 intron 21173776 rs233818 chr4 103204734 T C 8.36E-07 Bilirubin levels,in serum SLC39A8 intron 19389676 rs233814 chr4 103208703 T C 9.30E-06 Personality dimensions SLC39A8 intron 21173776 rs6829701 chr4 103227073 G A 1.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC39A8 intron 20877124 rs922361 chr4 103270070 A C 4.04E-04 Multiple complex diseases / / 17554300 rs1471393 chr4 103347309 C T 1.90E-04 Height / / 17255346 rs6533014 chr4 103349740 A G 7.00E-06 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs2045797 chr4 103353074 G C 1.10E-05 Anger / / 24489884 rs6533015 chr4 103355533 C G 9.60E-06 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs4699029 chr4 103360161 C T 7.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13115343 chr4 103365532 G T 4.95E-05 Odorant perception / / 23910658 rs1313925 chr4 103377576 T C 7.48E-04 Type 2 diabetes / / 17463246 rs1313925 chr4 103377576 T C 7.93E-05 Major depressive disorder / / 19107115 rs1314336 chr4 103378866 C T 7.27E-05 Multiple complex diseases / / 17554300 rs17008528 chr4 103383107 G A 0.0000162 Antisocial behavior / / 23077488 rs230489 chr4 103388441 T C 3.83E-05 Alzheimer's disease (late onset) / / 21379329 rs4647972 chr4 103430534 C T 7.40E-04 Coronary heart disease NFKB1 intron 21966275 rs3774937 chr4 103434253 T C 6.16E-05 Weight NFKB1 intron pha003027 rs230530 chr4 103453980 A G 0.0000846 Primary biliary cirrhosis NFKB1 intron 22936693 rs4647992 chr4 103455347 C T 6.08E-04 Longevity NFKB1 intron 22279548 rs230529 chr4 103457418 T C 2.00E-07 Schizophrenia (treatment refractory) NFKB1 intron 22479419 rs230528 chr4 103457585 G T 5.25E-06 Height NFKB1 intron pha003010 rs230528 chr4 103457585 G T 9.19E-05 Height NFKB1 intron pha003011 rs230526 chr4 103458825 A G 5.25E-06 Height NFKB1 intron pha003010 rs230526 chr4 103458825 A G 9.19E-05 Height NFKB1 intron pha003011 rs4648006 chr4 103461559 C T 1.06E-05 Chronic kidney disease NFKB1 intron 21931561 rs4648011 chr4 103475444 G T 5.80E-05 Weight NFKB1 intron pha003027 rs4648024 chr4 103497567 C T 2.29E-04 Smoking initiation NFKB1 intron 24665060 rs4699030 chr4 103503824 G C 1.75E-06 Schizophrenia (treatment refractory) NFKB1 intron 22479419 rs3774959 chr4 103511114 G A 4.00E-12 Ulcerative colitis NFKB1 intron 23128233 rs10489114 chr4 103511388 T C 4.39E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) NFKB1 intron 24023788 rs4648086 chr4 103522150 G A 0.000000574 HDL cholesterol NFKB1 missense 23063622 rs230547 chr4 103536261 C T 1.09E-04 Smoking initiation NFKB1 intron 24665060 rs7677509 chr4 103550006 T C 1.75E-13 Primary biliary cirrhosis / / 22961000 rs7699231 chr4 103550075 A G 1.75E-13 Primary biliary cirrhosis / / 22961000 rs7699678 chr4 103550096 G A 1.75E-13 Primary biliary cirrhosis / / 22961000 rs11724614 chr4 103550248 A G 1.75E-13 Primary biliary cirrhosis / / 22961000 rs7664828 chr4 103551376 C T 1.64E-13 Primary biliary cirrhosis / / 22961000 rs7665090 chr4 103551603 A G 4.00E-12 Primary biliary cirrhosis / / 21399635 rs7665090 chr4 103551603 A G 0.0001 Primary biliary cirrhosis / / 22936693 rs7665090 chr4 103551603 A G 0.00021 Primary biliary cirrhosis (anti-mitochondrial antibody positive) / / 22936693 rs7665090 chr4 103551603 A G 8.48E-14 Primary biliary cirrhosis / / 22961000 rs7690123 chr4 103551759 T C 1.64E-13 Primary biliary cirrhosis / / 22961000 rs7665659 chr4 103551818 C T 1.64E-13 Primary biliary cirrhosis / / 22961000 rs7665854 chr4 103551909 C A 1.64E-13 Primary biliary cirrhosis / / 22961000 rs7690700 chr4 103552068 T C 1.64E-13 Primary biliary cirrhosis / / 22961000 rs13112557 chr4 103552253 T C 1.64E-13 Primary biliary cirrhosis MANBA nearGene-3 22961000 rs12644381 chr4 103552430 A G 1.64E-13 Primary biliary cirrhosis MANBA nearGene-3 22961000 rs1054037 chr4 103552709 C T 4.91E-07 Primary biliary cirrhosis MANBA UTR-3 21399635 rs1054037 chr4 103552709 C T 1.64E-13 Primary biliary cirrhosis MANBA UTR-3 22961000 rs4013 chr4 103552813 C T 1.85E-13 Primary biliary cirrhosis MANBA UTR-3 22961000 rs4019 chr4 103552830 G A 1.86E-13 Primary biliary cirrhosis MANBA UTR-3 22961000 rs3194585 chr4 103553090 A G 2.56E-13 Primary biliary cirrhosis MANBA UTR-3 22961000 rs735403 chr4 103553543 C T 2.58E-13 Primary biliary cirrhosis MANBA intron 22961000 rs735404 chr4 103553665 G A 1.81E-13 Primary biliary cirrhosis MANBA intron 22961000 rs735405 chr4 103553916 A C 2.58E-13 Primary biliary cirrhosis MANBA intron 22961000 rs1077358 chr4 103553926 C T 2.58E-13 Primary biliary cirrhosis MANBA intron 22961000 rs2866406 chr4 103554019 G A 2.73E-13 Primary biliary cirrhosis MANBA intron 22961000 rs2866407 chr4 103554108 C G 2.44E-13 Primary biliary cirrhosis MANBA intron 22961000 rs2866408 chr4 103554113 T A 2.44E-13 Primary biliary cirrhosis MANBA intron 22961000 rs2866409 chr4 103554261 T G 3.60E-13 Primary biliary cirrhosis MANBA intron 22961000 rs2866412 chr4 103554350 T A 3.36E-13 Primary biliary cirrhosis MANBA intron 22961000 rs12498722 chr4 103554522 C T 3.71E-13 Primary biliary cirrhosis MANBA intron 22961000 rs5026476 chr4 103554910 A C 3.78E-13 Primary biliary cirrhosis MANBA intron 22961000 rs13106304 chr4 103554975 A G 2.61E-13 Primary biliary cirrhosis MANBA intron 22961000 rs13106325 chr4 103554992 A G 2.61E-13 Primary biliary cirrhosis MANBA intron 22961000 rs6821119 chr4 103555233 T C 4.00E-13 Primary biliary cirrhosis MANBA intron 22961000 rs6844332 chr4 103555252 G A 4.00E-13 Primary biliary cirrhosis MANBA intron 22961000 rs6812747 chr4 103555417 A C 4.00E-13 Primary biliary cirrhosis MANBA intron 22961000 rs6813322 chr4 103555619 C G 3.79E-13 Primary biliary cirrhosis MANBA intron 22961000 rs6839064 chr4 103555676 T C 3.12E-13 Primary biliary cirrhosis MANBA intron 22961000 rs2272695 chr4 103555803 G C 3.79E-13 Primary biliary cirrhosis MANBA intron 22961000 rs2272696 chr4 103555821 G A 3.79E-13 Primary biliary cirrhosis MANBA intron 22961000 rs2866413 chr4 103557077 G A 5.40E-07 Primary biliary cirrhosis MANBA missense 21399635 rs2866413 chr4 103557077 G A 8.48E-14 Primary biliary cirrhosis MANBA missense 22961000 rs228614 chr4 103578637 G A 1.00E-07 Multiple sclerosis MANBA intron 21833088 rs228614 chr4 103578637 G A 6.40E-05 Diabetes Mellitus MANBA intron pha003060 rs228615 chr4 103579460 A C,T 5.19E-10 Primary biliary cirrhosis MANBA intron 22961000 rs228616 chr4 103579691 G A 2.38E-10 Primary biliary cirrhosis MANBA intron 22961000 rs228617 chr4 103580788 T C 6.44E-05 Diabetes Mellitus MANBA intron pha003060 rs223508 chr4 103632963 C T 2.24E-05 Lymphocyte counts MANBA intron 22286170 rs223502 chr4 103640758 T C 1.36E-04 Lung function (forced expiratory volume in 1 second) MANBA intron 24023788 rs223502 chr4 103640758 T C 3.06E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) MANBA intron 24023788 rs223498 chr4 103651962 A C 2.06E-05 Diabetes Mellitus MANBA intron pha003060 rs223490 chr4 103679117 G T 2.12E-04 Suicide attempts in bipolar disorder MANBA intron 21423239 rs223489 chr4 103680984 A G 6.94E-04 Suicide attempts in bipolar disorder MANBA intron 21423239 rs223486 chr4 103684953 C G 4.57E-04 Multiple complex diseases / / 17554300 rs223482 chr4 103687208 A G 4.47E-06 Diabetes Mellitus / / pha003060 rs223471 chr4 103698786 G C 3.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs223467 chr4 103700878 C T 2.83E-04 Multiple complex diseases / / 17554300 rs223454 chr4 103710930 G A 1.01E-04 Multiple complex diseases / / 17554300 rs223452 chr4 103711434 C T 1.78E-04 Multiple complex diseases / / 17554300 rs150895 chr4 103712589 G A 9.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs150895 chr4 103712589 G A 1.60E-05 Diabetes Mellitus / / pha003060 rs223448 chr4 103713346 A G 9.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs223447 chr4 103713359 C T 8.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs223447 chr4 103713359 C T 3.01E-05 Diabetes Mellitus / / pha003060 rs223446 chr4 103714182 T G 8.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs223445 chr4 103714494 T G 8.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs223441 chr4 103715385 C T 9.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs223438 chr4 103719741 C T 1.60E-04 Multiple complex diseases UBE2D3 intron 17554300 rs223438 chr4 103719741 C T 7.53E-04 Suicide attempts in bipolar disorder UBE2D3 intron 21423239 rs3774987 chr4 103720866 G C 7.83E-04 Suicide attempts in bipolar disorder UBE2D3 intron 21423239 rs65671 chr4 103722238 G A 7.87E-04 Suicide attempts in bipolar disorder UBE2D3 intron 21423239 rs223425 chr4 103723993 T C 7.83E-04 Suicide attempts in bipolar disorder UBE2D3 intron 21423239 rs223420 chr4 103728010 C A 7.94E-04 Suicide attempts in bipolar disorder UBE2D3 intron 21423239 rs223420 chr4 103728010 C A 3.27E-05 Diabetes Mellitus UBE2D3 intron pha003060 rs223419 chr4 103729743 T A 8.92E-04 Suicide attempts in bipolar disorder UBE2D3 intron 21423239 rs223418 chr4 103730493 T G 8.83E-04 Suicide attempts in bipolar disorder UBE2D3 intron 21423239 rs223413 chr4 103732866 C T 3.93E-04 Multiple complex diseases UBE2D3 intron 17554300 rs223413 chr4 103732866 C T 7.03E-04 Suicide attempts in bipolar disorder UBE2D3 intron 21423239 rs223413 chr4 103732866 C T 1.00E-04 Lymphocyte counts UBE2D3 intron 22286170 rs223412 chr4 103733600 T C 9.44E-04 Suicide attempts in bipolar disorder UBE2D3 intron 21423239 rs223410 chr4 103734725 T C 9.28E-04 Suicide attempts in bipolar disorder UBE2D3 intron 21423239 rs223401 chr4 103738972 T C 5.86E-04 Suicide attempts in bipolar disorder UBE2D3 intron 21423239 rs223401 chr4 103738972 T C 4.00E-04 Gamma gluatamyl transferase levels (interaction with age) UBE2D3 intron 22010049 rs223397 chr4 103742651 T C 1.98E-04 Multiple complex diseases UBE2D3 intron 17554300 rs223374 chr4 103758301 T C 6.82E-04 Suicide attempts in bipolar disorder UBE2D3 intron 21423239 rs223363 chr4 103767339 T G 1.13E-04 Multiple complex diseases UBE2D3 intron 17554300 rs223361 chr4 103769304 T C 6.01E-04 Suicide attempts in bipolar disorder UBE2D3 intron 21423239 rs223339 chr4 103785857 T C 9.87E-04 Suicide attempts in bipolar disorder UBE2D3 intron 21423239 rs223334 chr4 103788211 A G 2.81E-04 Multiple complex diseases UBE2D3 intron 17554300 rs223334 chr4 103788211 A G 9.77E-04 Suicide attempts in bipolar disorder UBE2D3 intron 21423239 rs223331 chr4 103793565 T A,C 5.03E-04 Suicide attempts in bipolar disorder CISD2 intron 21423239 rs223330 chr4 103793659 T C 9.56E-04 Suicide attempts in bipolar disorder CISD2 intron 21423239 rs223326 chr4 103794927 T A 9.08E-04 Suicide attempts in bipolar disorder CISD2 intron 21423239 rs223320 chr4 103802165 A T 1.00E-06 Serum dimethylarginine levels (asymmetric) CISD2 intron 24159190 rs576190969 chr4 103802165 A AT 1.00E-06 Serum dimethylarginine levels (asymmetric) CISD2 intron 24159190 rs223318 chr4 103802579 A G 8.53E-04 Suicide attempts in bipolar disorder CISD2 intron 21423239 rs223317 chr4 103802824 T C 5.80E-04 Suicide attempts in bipolar disorder CISD2 intron 21423239 rs223315 chr4 103805443 T C 8.38E-04 Suicide attempts in bipolar disorder CISD2 intron 21423239 rs223313 chr4 103807720 T C 9.67E-04 Suicide attempts in bipolar disorder SLC9B1 intron 21423239 rs223313 chr4 103807720 T C 4.60E-05 Diabetes Mellitus SLC9B1 intron pha003060 rs3974604 chr4 103849758 T C 4.65E-04 Multiple complex diseases SLC9B1 intron 17554300 rs5028609 chr4 103880451 T C 9.53E-04 Suicide attempts in bipolar disorder SLC9B1 intron 21423239 rs2866416 chr4 103880711 G C 7.45E-04 Suicide attempts in bipolar disorder SLC9B1 intron 21423239 rs7663876 chr4 103887331 G A 9.92E-04 Suicide attempts in bipolar disorder SLC9B1 intron 21423239 rs11097796 chr4 103923558 C T 9.70E-04 Suicide attempts in bipolar disorder SLC9B1 intron 21423239 rs4699048 chr4 103926727 A G 8.38E-04 Suicide attempts in bipolar disorder SLC9B1 intron 21423239 rs10006474 chr4 103928047 A G 1.55E-04 Multiple complex diseases SLC9B1 intron 17554300 rs10006474 chr4 103928047 A G 9.18E-04 Suicide attempts in bipolar disorder SLC9B1 intron 21423239 rs4698874 chr4 103930511 T C 6.82E-05 Diabetes Mellitus SLC9B1 intron pha003060 rs724447 chr4 103931306 T C 3.84E-04 Multiple complex diseases SLC9B1 intron 17554300 rs6843738 chr4 103936001 G A 9.82E-04 Suicide attempts in bipolar disorder SLC9B1 intron 21423239 rs7665026 chr4 103936648 T C 8.94E-04 Suicide attempts in bipolar disorder SLC9B1 intron 21423239 rs7676765 chr4 103937933 T C 2.42E-04 Multiple complex diseases SLC9B1 intron 17554300 rs7698608 chr4 103937974 C A 4.60E-04 Type 2 diabetes SLC9B1 intron 17463249 rs7698608 chr4 103937974 C A 3.29E-04 Multiple complex diseases SLC9B1 intron 17554300 rs6816370 chr4 103939433 C T 8.59E-04 Suicide attempts in bipolar disorder SLC9B1 intron 21423239 rs7660298 chr4 103960768 T C 9.47E-04 Suicide attempts in bipolar disorder SLC9B2 intron 21423239 rs1481279 chr4 103977938 T A 1.09E-05 Multiple complex diseases SLC9B2 intron 17554300 rs7691873 chr4 103987899 T C 6.76E-04 Suicide attempts in bipolar disorder SLC9B2 intron 21423239 rs7674212 chr4 103988899 G T 5.12E-04 Suicide attempts in bipolar disorder SLC9B2 intron 21423239 rs7674212 chr4 103988899 G T 1.70E-07 Type 2 diabetes SLC9B2 intron 21647700 rs17215694 chr4 104018033 C T 9.49E-04 Multiple complex diseases BDH2 intron 17554300 rs2069274 chr4 104020781 C G 4.42E-04 Multiple complex diseases BDH2 intron 17554300 rs2720460 chr4 104054686 A G 8.72E-04 Multiple complex diseases CENPE intron 17554300 rs2720460 chr4 104054686 A G 2.00E-10 Testicular germ cell tumor CENPE intron 23666240 rs17033461 chr4 104103811 A G 4.93E-04 Multiple complex diseases CENPE intron 17554300 rs6850461 chr4 104120041 C T 7.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs6533056 chr4 104120997 T C 7.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs6854709 chr4 104129786 T C 7.72E-04 Multiple complex diseases / / 17554300 rs6854709 chr4 104129786 T C 9.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs6533058 chr4 104130986 A C 4.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs6533059 chr4 104133376 T G 3.59E-05 Suicide attempts in bipolar disorder / / 21423239 rs4699052 chr4 104137790 C T 2.00E-07 Testicular germ cell tumor / / 19483681 rs4699052 chr4 104137790 C T 2.00E-07 Nasopharyngeal carcinoma / / 20512145 rs4699052 chr4 104137790 C T 1.52E-05 Suicide attempts in bipolar disorder / / 21423239 rs7661702 chr4 104140129 G C 1.27E-05 Suicide attempts in bipolar disorder / / 21423239 rs1580278 chr4 104140848 C A 3.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs6816055 chr4 104143160 T C 1.28E-05 Suicide attempts in bipolar disorder / / 21423239 rs11733615 chr4 104157164 C T 2.68E-05 Suicide attempts in bipolar disorder / / 21423239 rs6533066 chr4 104163607 C G 3.49E-05 Suicide attempts in bipolar disorder / / 21423239 rs2866634 chr4 104164302 G A 1.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs1870888 chr4 104169326 G C 1.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs6824281 chr4 104170892 C A 5.19E-04 Multiple complex diseases / / 17554300 rs6824281 chr4 104170892 C A 3.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs4699057 chr4 104171123 G A 4.96E-04 Multiple complex diseases / / 17554300 rs4699057 chr4 104171123 G A 3.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs4699058 chr4 104171321 T A 4.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs6856593 chr4 104177699 T C 3.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs11943325 chr4 104178393 T C 5.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs17033498 chr4 104179961 C G 5.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs4698890 chr4 104181878 T C 5.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs4352478 chr4 104212131 T A 4.48E-05 Menarche (age at onset) / / 21102462 rs6533078 chr4 104212156 C T 2.65E-05 Menarche (age at onset) / / 21102462 rs6533078 chr4 104212156 C T 9.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs7672802 chr4 104212233 A T 2.68E-05 Menarche (age at onset) / / 21102462 rs7672802 chr4 104212233 A T 9.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs7679365 chr4 104212980 G C 2.69E-05 Menarche (age at onset) / / 21102462 rs7679365 chr4 104212980 G C 9.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs2866642 chr4 104213866 T G 1.95E-05 Menarche (age at onset) / / 21102462 rs2866642 chr4 104213866 T G 9.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs10516502 chr4 104214616 A G 2.38E-05 Menarche (age at onset) / / 21102462 rs10516502 chr4 104214616 A G 8.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs11097804 chr4 104215137 A T 2.62E-05 Menarche (age at onset) / / 21102462 rs11097804 chr4 104215137 A T 9.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs4456958 chr4 104215332 A G 2.62E-05 Menarche (age at onset) / / 21102462 rs4456958 chr4 104215332 A G 9.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs6820979 chr4 104216086 C T 2.65E-05 Menarche (age at onset) / / 21102462 rs6822379 chr4 104216658 G T 3.91E-06 Menarche (age at onset) / / 21102462 rs6822379 chr4 104216658 G T 7.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs6819022 chr4 104219209 T C 1.87E-05 Menarche (age at onset) / / 21102462 rs6533079 chr4 104220394 A C 1.92E-05 Menarche (age at onset) / / 21102462 rs4699066 chr4 104222582 G T 1.77E-05 Menarche (age at onset) / / 21102462 rs1022348 chr4 104223071 A G 1.02E-05 Menarche (age at onset) / / 21102462 rs2866646 chr4 104223778 C T 1.21E-05 Menarche (age at onset) / / 21102462 rs6838853 chr4 104231098 A G 1.56E-05 Menarche (age at onset) / / 21102462 rs17219677 chr4 104235380 C T 1.41E-05 Menarche (age at onset) / / 21102462 rs17219677 chr4 104235380 C T 1.15E-05 Telomere length / / 21573004 rs12502466 chr4 104240778 G A 1.09E-05 Menarche (age at onset) / / 21102462 rs6822395 chr4 104240987 A G 1.11E-05 Menarche (age at onset) / / 21102462 rs6855777 chr4 104242364 T C 9.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs6844296 chr4 104244578 A G 1.85E-05 Menarche (age at onset) / / 21102462 rs1400363 chr4 104250722 A C 5.70E-05 Telomere length / / 21573004 rs7662107 chr4 104258396 C T 3.38E-07 Menarche (age at onset) / / 21102462 rs7662107 chr4 104258396 C T 2.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs7662107 chr4 104258396 C T 2.38E-05 Telomere length / / 21573004 rs17286262 chr4 104275452 C T 4.61E-06 Menarche (age at onset) / / 21102462 rs6848028 chr4 104279946 G C 4.97E-06 Menarche (age at onset) / / 21102462 rs7675703 chr4 104290492 G A 7.28E-06 Menarche (age at onset) / / 21102462 rs4699069 chr4 104291221 A G 7.42E-06 Menarche (age at onset) / / 21102462 rs10005997 chr4 104301711 C G 9.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs2203640 chr4 104313826 T C 1.27E-06 Menarche (age at onset) / / 21102462 rs2203640 chr4 104313826 T C 6.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs4698894 chr4 104321101 A G 1.24E-05 Menarche (age at onset) / / 21102462 rs1512275 chr4 104321904 C T 1.31E-05 Menarche (age at onset) / / 21102462 rs1849312 chr4 104331359 G A 1.34E-05 Menarche (age at onset) / / 21102462 rs17220904 chr4 104367078 A G 2.51E-05 Menarche (age at onset) / / 21102462 rs17033646 chr4 104368124 C T 2.21E-05 Menarche (age at onset) / / 21102462 rs17033646 chr4 104368124 C T 1.07E-06 Telomere length / / 21573004 rs17221044 chr4 104372029 C T 7.87E-05 Menarche (age at onset) / / 21102462 rs10026360 chr4 104374596 T C 1.54E-04 Menarche (age at onset) / / 21102462 rs1858404 chr4 104391911 G A 9.92E-04 Stroke / / pha002886 rs515160 chr4 104397940 C T 5.89E-05 Bipolar disorder / / 18317468 rs7694802 chr4 104402247 T C 9.21E-06 Inflammation / / pha002897 rs9999400 chr4 104414888 C G 3.50E-06 Urinary metabolites / / 21572414 rs402681 chr4 104414948 T C 4.70E-05 Inflammation / / pha002897 rs340468 chr4 104418239 G T 8.95E-05 Inflammation / / pha002897 rs340457 chr4 104435456 G T 2.08E-04 Multiple complex diseases / / 17554300 rs454937 chr4 104452847 A T 4.90E-04 Multiple complex diseases / / 17554300 rs379873 chr4 104457146 C T 2.26E-04 Multiple complex diseases / / 17554300 rs437124 chr4 104467041 T C 1.89E-04 Multiple complex diseases / / 17554300 rs10002719 chr4 104467267 T C 2.44E-04 Multiple complex diseases / / 17554300 rs10002719 chr4 104467267 T C 8.80E-04 Type 2 diabetes / / 22238593 rs2757685 chr4 104467808 G A 2.88E-04 Multiple complex diseases / / 17554300 rs445716 chr4 104471710 C T 3.29E-04 Multiple complex diseases / / 17554300 rs367877 chr4 104472403 A G 3.50E-04 Multiple complex diseases / / 17554300 rs370831 chr4 104485003 T C 3.54E-04 Multiple complex diseases / / 17554300 rs6533094 chr4 104490813 C T 6.74E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2757673 chr4 104496050 A G 1.30E-04 Multiple complex diseases / / 17554300 rs7687830 chr4 104498061 A T 9.69E-05 Multiple complex diseases / / 17554300 rs3900348 chr4 104509167 T C 5.29E-04 Multiple complex diseases / / 17554300 rs4580655 chr4 104529274 G A 2.82E-04 Multiple complex diseases TACR3 intron 17554300 rs4580655 chr4 104529274 G A 1.00E-04 Asthma (childhood onset) TACR3 intron 21359210 rs7665881 chr4 104542865 A G 2.12E-05 Menarche (age at onset) TACR3 intron 21102462 rs17033903 chr4 104543602 T C 4.46E-05 Menarche (age at onset) TACR3 intron 21102462 rs17303520 chr4 104543891 A C 1.66E-05 Menarche (age at onset) TACR3 intron 21102462 rs3796976 chr4 104544598 C A 4.59E-05 Menarche (age at onset) TACR3 intron 21102462 rs17033914 chr4 104544682 C T 1.16E-04 Multiple complex diseases TACR3 intron 17554300 rs3796974 chr4 104545224 T C 1.73E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) TACR3 intron 23648065 rs12641703 chr4 104552687 G A 3.02E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) TACR3 intron 23648065 rs2086646 chr4 104585957 C T 6.08E-06 Menarche (age at onset) TACR3 intron 21102462 rs1351623 chr4 104587977 C T 1.16E-07 Menarche (age at onset) TACR3 intron 21102462 rs17248388 chr4 104601452 G A 1.14E-06 Menarche (age at onset) TACR3 intron 21102462 rs10019555 chr4 104615281 G A 4.29E-07 Menarche (age at onset) TACR3 intron 21102462 rs6831087 chr4 104619090 C A 3.13E-07 Menarche (age at onset) TACR3 intron 21102462 rs10007754 chr4 104627442 T G 1.93E-07 Menarche (age at onset) TACR3 intron 21102462 rs3733632 chr4 104640935 A G 2.17E-07 Menarche (age at onset) TACR3 UTR-5 21102462 rs3733631 chr4 104641103 G C 2.45E-07 Menarche (age at onset) TACR3 nearGene-5 21102462 rs3775971 chr4 104641920 T C 2.34E-07 Menarche (age at onset) TACR3 nearGene-5 21102462 rs17034020 chr4 104650673 G A 9.69E-07 Menarche (age at onset) / / 21102462 rs1482582 chr4 104651553 A C 2.27E-07 Menarche (age at onset) / / 21102462 rs17249126 chr4 104653263 C T 1.80E-06 Menarche (age at onset) / / 21102462 rs17034041 chr4 104654914 G A 2.59E-04 Multiple complex diseases / / 17554300 rs17249293 chr4 104656784 G A 9.76E-07 Menarche (age at onset) / / 21102462 rs233992 chr4 104657070 T G 5.49E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17196104 chr4 104657246 G T 1.04E-06 Menarche (age at onset) / / 21102462 rs17249363 chr4 104657689 A G 9.59E-07 Menarche (age at onset) / / 21102462 rs17196160 chr4 104657842 T C 9.71E-07 Menarche (age at onset) / / 21102462 rs17196218 chr4 104658371 T C 1.15E-06 Menarche (age at onset) / / 21102462 rs17034046 chr4 104659604 C T 3.24E-07 Menarche (age at onset) / / 21102462 rs7665931 chr4 104660682 C T 7.19E-07 Menarche (age at onset) / / 21102462 rs17196407 chr4 104663521 C T 7.20E-07 Menarche (age at onset) / / 21102462 rs233991 chr4 104665738 C A 5.40E-05 Crohn's disease / / 20570966 rs233990 chr4 104667276 C T 8.88E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs999803 chr4 104695920 G A 5.22E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7656744 chr4 104701818 A C 7.76E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17034106 chr4 104744735 C T 3.50E-04 Multiple complex diseases / / 17554300 rs34450402 chr4 104762857 C T 3.40E-04 Type 2 diabetes / / 17463246 rs11937825 chr4 104792271 C T 6.08E-04 Multiple complex diseases / / 17554300 rs11937871 chr4 104792456 C T 2.72E-09 Non-obstructive azoospermia / / 22197933 rs7658976 chr4 104902475 G T 7.06E-04 Insulin resistance / / 21901158 rs2866673 chr4 104903879 A G 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4566656 chr4 104905009 T A 2.36E-05 Multiple complex diseases / / 17554300 rs12648473 chr4 104941917 C T 1.90E-05 Urinary metabolites / / 21572414 rs4605656 chr4 104944698 G A 9.90E-06 Urinary metabolites / / 21572414 rs12645446 chr4 104963745 C T 7.50E-06 Urinary metabolites / / 21572414 rs2134026 chr4 104972057 C T 9.49E-05 Bone mineral density / / 19181680 rs13133212 chr4 104973196 G C 8.19E-06 Brachial circumference / / 22479309 rs17034285 chr4 104974939 A C,G,T 4.91E-04 Multiple complex diseases / / 17554300 rs950882 chr4 104978031 T C 5.95E-05 Bone mineral density / / 19181680 rs12650956 chr4 104980830 C T 1.60E-05 Urinary metabolites / / 21572414 rs17306296 chr4 104989618 C T 1.20E-05 Urinary metabolites / / 21572414 rs9307290 chr4 105029491 C G 2.10E-05 Urinary metabolites / / 21572414 rs1354090 chr4 105037729 A T 1.67E-22 Narcolepsy / / 19629137 rs1354090 chr4 105037729 A T 2.90E-05 Urinary metabolites / / 21572414 rs1160293 chr4 105038044 G A 9.15E-05 Magnesium levels / / pha003092 rs13108980 chr4 105061306 T C 7.44E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1919117 chr4 105217098 A G 1.25E-05 Magnesium levels / / pha003092 rs7657799 chr4 105375423 T G 6.51E-06 Alopecia areata / / 22027810 rs10516510 chr4 105437362 G A 1.96E-06 Coronary heart disease / / pha003030 rs10516510 chr4 105437362 G A 5.82E-05 Coronary heart disease / / pha003031 rs972583 chr4 105442302 T C 2.47E-06 Coronary heart disease / / pha003030 rs972583 chr4 105442302 T C 6.69E-05 Coronary heart disease / / pha003031 rs17034592 chr4 105454960 T C 2.91E-06 Coronary heart disease / / pha003030 rs17034592 chr4 105454960 T C 1.96E-05 Coronary heart disease / / pha003031 rs2905639 chr4 105490642 C T 1.74E-04 Multiple complex diseases / / 17554300 rs2905642 chr4 105493491 T C 1.54E-04 Multiple complex diseases / / 17554300 rs2023838 chr4 105493636 G A 2.39E-04 Multiple complex diseases / / 17554300 rs2905643 chr4 105494074 G A 1.61E-04 Multiple complex diseases / / 17554300 rs2905649 chr4 105502099 A G 1.57E-04 Multiple complex diseases / / 17554300 rs657510 chr4 105510157 G T 2.96E-04 Height / / 17255346 rs488076 chr4 105515423 C A 2.25E-05 Multiple complex diseases / / 17554300 rs11097867 chr4 105556862 A G 8.97E-04 Insulin resistance / / 21901158 rs624909 chr4 105566441 G T 2.55E-04 Celiac disease / / 23936387 rs61336839 chr4 105590296 A G 0.00003092 Sarcoidosis / / 22952805 rs62331308 chr4 105596229 T G 0.00002139 Sarcoidosis / / 22952805 rs58937981 chr4 105597402 A G 0.00001922 Sarcoidosis / / 22952805 rs11723435 chr4 105600699 T C 0.00001828 Sarcoidosis / / 22952805 rs17034814 chr4 105601915 G A 0.00001751 Sarcoidosis / / 22952805 rs4699137 chr4 105605264 G A 0.000171 Salmonella-induced pyroptosis / / 22837397 rs4699137 chr4 105605264 G A 0.00001271 Sarcoidosis / / 22952805 rs2068250 chr4 105607827 T G 0.00001007 Sarcoidosis / / 22952805 rs189752236 chr4 105609388 T C 0.00005132 Sarcoidosis / / 22952805 rs1012601 chr4 105616848 G C 0.000014 Sarcoidosis / / 22952805 rs2522463 chr4 105622748 G A 0.00001277 Sarcoidosis / / 22952805 rs2522492 chr4 105629203 A C 0.00002536 Sarcoidosis / / 22952805 rs2651334 chr4 105629417 C T 0.000007637 Sarcoidosis / / 22952805 rs2651333 chr4 105629678 T G 0.000007533 Sarcoidosis / / 22952805 rs12505754 chr4 105630142 G A 0.000009615 Sarcoidosis / / 22952805 rs1011962 chr4 105634488 T C 0.000235 Salmonella-induced pyroptosis / / 22837397 rs1011962 chr4 105634488 T C 0.00001245 Sarcoidosis / / 22952805 rs1548486 chr4 105635412 T C 0.00001267 Sarcoidosis / / 22952805 rs2651330 chr4 105635729 G A 0.00001225 Sarcoidosis / / 22952805 rs2522493 chr4 105637993 T C 0.000008221 Sarcoidosis / / 22952805 rs2651329 chr4 105638242 G A 0.0000086 Sarcoidosis / / 22952805 rs2158190 chr4 105638348 T C 0.000008865 Sarcoidosis / / 22952805 rs2651328 chr4 105639761 G C 0.000006727 Sarcoidosis / / 22952805 rs2158192 chr4 105639814 G A 0.000007023 Sarcoidosis / / 22952805 rs2107006 chr4 105642085 A G 0.000226 Salmonella-induced pyroptosis / / 22837397 rs2107006 chr4 105642085 A G 0.000008817 Sarcoidosis / / 22952805 rs2651349 chr4 105655616 G A 0.00041 Salmonella-induced pyroptosis / / 22837397 rs2651349 chr4 105655616 G A 0.0000103 Sarcoidosis / / 22952805 rs2522504 chr4 105655892 T C 0.0000103 Sarcoidosis / / 22952805 rs2522505 chr4 105656262 C T 0.000474 Salmonella-induced pyroptosis / / 22837397 rs2522505 chr4 105656262 C T 0.0000103 Sarcoidosis / / 22952805 rs2522506 chr4 105657028 G A 0.000383 Salmonella-induced pyroptosis / / 22837397 rs2522506 chr4 105657028 G A 0.00003287 Sarcoidosis / / 22952805 rs2651340 chr4 105680212 C T 0.000467 Salmonella-induced pyroptosis / / 22837397 rs2651350 chr4 105686932 T C 0.00006889 Sarcoidosis / / 22952805 rs2725758 chr4 105707209 G A 2.82E-05 Cognitive impairment induced by topiramate / / 22091778 rs2522474 chr4 105745818 G A 2.22E-04 Multiple complex diseases / / 17554300 rs2725771 chr4 105758739 G T 1.05E-04 Multiple complex diseases / / 17554300 rs2725770 chr4 105759425 A T 1.85E-04 Multiple complex diseases / / 17554300 rs10005603 chr4 105844273 T G 7.00E-06 Tuberculosis / / 20694014 rs1490587 chr4 105890224 G C 4.91E-04 Multiple complex diseases / / 17554300 rs17035170 chr4 105892565 G A 7.86E-04 Multiple complex diseases / / 17554300 rs9997118 chr4 105898577 A G 5.29E-05 Odorant perception / / 23910658 rs17035193 chr4 105908782 G A 4.62E-05 Femoral neck bone geometry / / 22087292 rs12500787 chr4 105921314 G T 3.28E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs17035227 chr4 105984033 G A 2.88E-04 Type 2 diabetes / / 17463246 rs195148 chr4 105988057 T C 2.84E-04 Premature ovarian failure / / 19508998 rs10008015 chr4 106005247 C T 1.99E-04 Vaspin levels / / 22907691 rs10008015 chr4 106005247 C T 0.0001989 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs10008015 chr4 106005247 C T 0.0000389 Otitis media (children 3 years old or younger) / / 23133572 rs2301718 chr4 106009763 G A 4.78E-05 Cervical cancer / / 24700089 rs1859161 chr4 106042692 C T 0.000019 Otitis media (children 3 years old or younger) / / 23133572 rs1859161 chr4 106042692 C T 2.10E-05 Lipid levels / / pha003082 rs1541374 chr4 106048360 T A,G 6.00E-07 Pulmonary function / / 21946350 rs7679673 chr4 106061534 C A 3.00E-14 Prostate cancer / / 19767753 rs7679673 chr4 106061534 C A 3.00E-14 Nasopharyngeal carcinoma / / 20512145 rs974801 chr4 106071064 A G 3.27E-11 Fasting insulin-related traits TET2 intron 22885924 rs2866774 chr4 106076726 T A 3.09E-04 Multiple complex diseases TET2 intron 17554300 rs9884482 chr4 106081636 T C 1.40E-11 Fasting insulin-related traits TET2 intron 22885924 rs9790517 chr4 106084778 C T 4.00E-08 Breast cancer TET2 intron 23535729 rs10010325 chr4 106106353 C A 5.03E-05 Crohn's disease TET2 intron 18587394 rs10010325 chr4 106106353 C A 4.00E-11 Height TET2 intron 20881960 rs6855629 chr4 106134316 G A 2.00E-08 Height TET2 intron 23563607 rs4698934 chr4 106139387 T C 8.00E-07 Melanoma TET2 intron 24980573 rs17035354 chr4 106140318 T C 5.20E-05 Multiple complex diseases TET2 intron 17554300 rs6839705 chr4 106144735 A C 5.99E-04 Type 2 diabetes TET2 intron 17463246 rs2647243 chr4 106196092 C T 8.99E-04 Type 2 diabetes TET2 intron 17463246 rs6823995 chr4 106263681 T C 7.44E-05 Melanoma / / 21926416 rs2647264 chr4 106268594 A G 8.67E-06 Parkinson's disease (motor and cognition) / / 22658654 rs2647264 chr4 106268594 A G 9.00E-06 Immune response to anthrax vaccine / / 22658931 rs17035512 chr4 106290060 C G 4.51E-05 Melanoma / / 21926416 rs2726526 chr4 106292121 G C 7.80E-04 Type 2 diabetes and 6 quantitative traits PPA2 intron 17848626 rs2713831 chr4 106294522 T G 6.60E-05 Schizophrenia PPA2 intron 19571808 rs2636697 chr4 106297513 G A 4.00E-07 Response to antipsychotic treatment PPA2 intron 23241943 rs2636726 chr4 106309224 G A 8.44E-06 Osteoarthritis PPA2 intron 22763110 rs2713832 chr4 106310723 C G 9.99E-04 Aortic root size PPA2 intron 21223598 rs17035553 chr4 106321423 C T 3.21E-05 Melanoma PPA2 intron 21926416 rs6811159 chr4 106323058 A G 6.97E-05 Melanoma PPA2 intron 21926416 rs2726516 chr4 106346206 A C 1.14E-04 Multiple complex diseases PPA2 intron 17554300 rs2636739 chr4 106352105 G A 1.56E-04 Multiple complex diseases PPA2 intron 17554300 rs17035581 chr4 106354696 T A 6.20E-05 Response to mTOR inhibitor (rapamycin) PPA2 intron 24009623 rs17035584 chr4 106354786 G A 7.54E-05 Melanoma PPA2 intron 21926416 rs3898404 chr4 106356395 T C 5.10E-05 Melanoma PPA2 intron 21926416 rs2029513 chr4 106382268 T C 1.30E-05 Urinary metabolites PPA2 intron 21572414 rs2298733 chr4 106390734 A C 3.53E-05 Major depressive disorder PPA2 intron 19107115 rs12499086 chr4 106451311 G A 2.00E-06 Economic and political preferences (time) / / 22566634 rs7669317 chr4 106457330 T C 8.00E-08 Response to antipsychotic therapy (extrapyramidal side effects) / / 19875103 rs11730243 chr4 106463713 C T 2.00E-06 Economic and political preferences (time) / / 22566634 rs17617811 chr4 106467767 C T 4.27E-05 Body Fat Distribution / / pha003017 rs17617811 chr4 106467767 C T 1.68E-05 Body Fat Distribution / / pha003018 rs12505821 chr4 106467902 G C 3.22E-05 Alzheimer's disease (age of onset) / / 22005931 rs3756258 chr4 106472259 C T 4.94E-05 Alzheimer's disease (age of onset) / / 22005931 rs3796915 chr4 106474576 A C 1.00E-04 Cognitive impairment induced by topiramate ARHGEF38 intron 22091778 rs17035775 chr4 106479192 C T 2.27E-05 Alzheimer's disease (age of onset) ARHGEF38 intron 22005931 rs11725523 chr4 106517866 G A 6.36E-09 Pulmonary function ARHGEF38 intron 20010835 rs17035917 chr4 106520742 C T 6.71E-09 Pulmonary function ARHGEF38 intron 20010835 rs1374531 chr4 106523932 C A 6.89E-09 Pulmonary function ARHGEF38 intron 20010835 rs4324546 chr4 106526987 A G 5.01E-04 Type 2 diabetes ARHGEF38 intron 17846124 rs4326019 chr4 106527381 A G 4.99E-05 Hypertension ARHGEF38 intron pha003042 rs11735213 chr4 106527508 T G 4.36E-09 Pulmonary function ARHGEF38 intron 20010835 rs17035960 chr4 106531846 C T 3.87E-09 Pulmonary function ARHGEF38 intron 20010835 rs921113 chr4 106534157 C A 8.05E-05 Hypertension ARHGEF38 intron pha003042 rs2305212 chr4 106534691 A G 3.54E-05 Hypertension ARHGEF38 intron pha003042 rs10516521 chr4 106553247 A G 3.62E-06 Hypertension ARHGEF38 intron pha003042 rs10033909 chr4 106559350 T C 4.70E-04 Multiple complex diseases ARHGEF38 intron 17554300 rs1447096 chr4 106559378 G T 9.00E-06 Hypertension ARHGEF38 intron pha003042 rs372438081 chr4 106559378 G GT 9.00E-06 Hypertension ARHGEF38 intron pha003042 rs17036052 chr4 106563379 C T 6.07E-10 Pulmonary function ARHGEF38 intron 20010835 rs1447098 chr4 106563600 A G 6.29E-06 Hypertension ARHGEF38 intron pha003042 rs1374534 chr4 106572456 C T 3.47E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ARHGEF38 intron 24023788 rs17036076 chr4 106575269 A G 7.43E-09 Pulmonary function ARHGEF38 cds-synon 20010835 rs1982346 chr4 106578754 A G 1.00E-07 Lung function (forced expiratory volume in 1 second) ARHGEF38 intron 24023788 rs1982346 chr4 106578754 A G 1.27E-05 Lung function (forced expiratory volume in 1 second) ARHGEF38 intron 24023788 rs17036090 chr4 106593574 T C 1.37E-08 Pulmonary function ARHGEF38 intron 20010835 rs11728044 chr4 106604786 G C 2.75E-09 Pulmonary function INTS12 intron 20010835 rs11726569 chr4 106606608 A G 2.70E-09 Pulmonary function INTS12 intron 20010835 rs12374256 chr4 106617361 G A 2.80E-09 Pulmonary function INTS12 intron 20010835 rs11727189 chr4 106619140 G T 5.00E-17 Pulmonary function INTS12 intron 20010835 rs10516523 chr4 106625263 G T 2.22E-05 Multiple complex diseases INTS12 intron 17554300 rs17262764 chr4 106629009 G A 1.64E-05 Hypertension INTS12 intron pha003042 rs11727735 chr4 106631870 A G 4.27E-09 Pulmonary function GSTCD intron 20010835 rs17036139 chr4 106632657 G A 3.51E-09 Pulmonary function GSTCD intron 20010835 rs17036142 chr4 106634736 T C 3.52E-09 Pulmonary function GSTCD intron 20010835 rs11724839 chr4 106638256 T G 3.52E-09 Pulmonary function GSTCD intron 20010835 rs13148869 chr4 106662946 C T 1.41E-04 Multiple complex diseases GSTCD intron 17554300 rs17036156 chr4 106663234 C T 3.34E-09 Pulmonary function GSTCD intron 20010835 rs11934139 chr4 106663541 T C 2.26E-04 Multiple complex diseases GSTCD intron 17554300 rs10516525 chr4 106668025 T C 2.91E-09 Pulmonary function GSTCD intron 20010835 rs11727348 chr4 106679848 G A 2.91E-09 Pulmonary function GSTCD intron 20010835 rs2866781 chr4 106681251 T C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes GSTCD intron 22628534 rs10516526 chr4 106688904 A G 2.00E-23 Pulmonary function GSTCD intron 20010834 rs10516526 chr4 106688904 A G 3.65E-09 Pulmonary function GSTCD intron 20010835 rs11735851 chr4 106697254 G A 2.64E-09 Pulmonary function GSTCD intron 20010835 rs11732298 chr4 106701679 A T 2.52E-09 Pulmonary function GSTCD intron 20010835 rs11733287 chr4 106705339 G A 2.27E-09 Pulmonary function GSTCD intron 20010835 rs11733225 chr4 106705363 C G 2.23E-09 Pulmonary function GSTCD intron 20010835 rs11736859 chr4 106708785 C T 2.07E-09 Pulmonary function GSTCD intron 20010835 rs17036225 chr4 106710092 A G 2.02E-09 Pulmonary function GSTCD intron 20010835 rs17036230 chr4 106715148 T A 1.97E-09 Pulmonary function GSTCD intron 20010835 rs11727745 chr4 106716527 T G 1.87E-09 Pulmonary function GSTCD intron 20010835 rs2544424 chr4 106718316 G T 1.98E-04 Multiple complex diseases GSTCD intron 17554300 rs2553468 chr4 106722298 C A 1.27E-05 Hypertension GSTCD intron pha003042 rs11097901 chr4 106729933 C T 1.52E-09 Pulmonary function GSTCD intron 20010835 rs2553463 chr4 106730663 G A 3.83E-06 Hypertension GSTCD intron pha003042 rs10516527 chr4 106734346 A G 1.89E-09 Pulmonary function GSTCD intron 20010835 rs2553458 chr4 106737796 G A 2.11E-05 Hypertension GSTCD intron pha003042 rs10516528 chr4 106739593 G T 1.89E-09 Pulmonary function GSTCD intron 20010835 rs11731417 chr4 106746012 A G 2.07E-09 Pulmonary function GSTCD intron 20010835 rs11723225 chr4 106746065 C T 2.10E-09 Pulmonary function GSTCD intron 20010835 rs2216515 chr4 106750214 C T 4.98E-07 Hypertension GSTCD intron pha003042 rs2553456 chr4 106751028 T C 5.46E-07 Hypertension GSTCD intron pha003042 rs11732650 chr4 106754231 G C 1.78E-09 Pulmonary function GSTCD intron 20010835 rs11728716 chr4 106755996 G A 1.80E-09 Pulmonary function GSTCD intron 20010835 rs7676975 chr4 106763811 A T 1.81E-09 Pulmonary function GSTCD intron 20010835 rs11733223 chr4 106765525 C A 1.86E-09 Pulmonary function GSTCD intron 20010835 rs10050333 chr4 106765813 T A 1.94E-09 Pulmonary function GSTCD intron 20010835 rs10050159 chr4 106765915 G A 1.91E-09 Pulmonary function GSTCD intron 20010835 rs11722225 chr4 106766430 T C 1.85E-09 Pulmonary function GSTCD intron 20010835 rs11726124 chr4 106766496 A G 1.82E-09 Pulmonary function GSTCD intron 20010835 rs7660534 chr4 106796047 G C 6.70E-10 Pulmonary function / / 20010835 rs17036341 chr4 106796829 C G 6.29E-10 Pulmonary function / / 20010835 rs10516529 chr4 106799316 T G 8.88E-04 Type 2 diabetes / / 17463246 rs10516529 chr4 106799316 T G 6.64E-10 Pulmonary function / / 20010835 rs2544398 chr4 106799485 C T 8.24E-04 Multiple complex diseases / / 17554300 rs11730660 chr4 106800379 A C 6.68E-10 Pulmonary function / / 20010835 rs17331332 chr4 106808107 G A 4.00E-10 Pulmonary function / / 20010835 rs17331332 chr4 106808107 G A 1.00E-16 Pulmonary function (interaction) / / 23284291 rs11933466 chr4 106812732 G A 2.29E-05 Hypertension / / pha003042 rs4264830 chr4 106870948 C G 2.40E-05 Urinary metabolites NPNT intron 21572414 rs4698952 chr4 106912921 A G 1.48E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs4611932 chr4 106938490 G A 2.07E-05 Blood Pressure / / pha003044 rs6533237 chr4 106954292 T C 8.72E-05 Alzheimer's disease / / 22832961 rs17036511 chr4 106957520 T C 7.41E-05 Heart Rate / / pha003053 rs11097912 chr4 107000462 C T 6.00E-06 Airflow obstruction TBCK intron 22837378 rs3018062 chr4 107287644 C T 7.02E-04 Coronary Artery Disease LOC100507096 intron 17634449 rs2949619 chr4 107302260 G A 5.29E-05 Serum metabolites / / 19043545 rs2949632 chr4 107305565 G A 6.50E-06 Malaria / / 19465909 rs3018076 chr4 107307023 C T 4.36E-05 Serum metabolites / / 19043545 rs3018080 chr4 107309313 G C 3.48E-05 Serum metabolites / / 19043545 rs2949641 chr4 107310444 A G 1.30E-05 Malaria / / 19465909 rs3133176 chr4 107312102 C T 3.12E-05 Serum metabolites / / 19043545 rs1522219 chr4 107429502 A C 4.09E-04 Iron levels / / pha002876 rs2903418 chr4 107434719 G T 6.18E-04 Iron levels / / pha002876 rs17357756 chr4 107455176 A C 2.08E-05 Panic disorder / / 19165232 rs10034263 chr4 107501341 G A 8.69E-04 Obesity (extreme) / / 21935397 rs17036834 chr4 107523900 C T 2.85E-05 Blood Pressure / / pha002903 rs17293880 chr4 107554458 C A 7.14E-05 Longevity / / 20304771 rs17036903 chr4 107580112 C T 4.47E-04 Obesity (extreme) / / 21935397 rs4956263 chr4 107591650 T G 5.35E-06 Parkinson's disease / / 17052657 rs17036934 chr4 107622327 A G 6.10E-05 Multiple complex diseases / / 17554300 rs964263 chr4 107653508 G C 3.60E-06 Urinary metabolites / / 21572414 rs1838249 chr4 107665767 A G 2.70E-06 Urinary metabolites / / 21572414 rs1364805 chr4 107673848 T G 3.94E-05 Cognitive performance / / 19734545 rs1364805 chr4 107673848 T G 1.20E-05 Urinary metabolites / / 21572414 rs1584067 chr4 107676927 A G 3.40E-06 Urinary metabolites / / 21572414 rs3111708 chr4 107737498 T C 2.80E-05 Urinary metabolites / / 21572414 rs12510474 chr4 107745306 A G 5.28E-05 Blood Pressure / / pha003044 rs10001899 chr4 107760275 T C 3.40E-06 Urinary metabolites / / 21572414 rs11943338 chr4 107769255 A G 4.30E-04 Autoimmune hepatitis type-1 / / 24768677 rs12186280 chr4 107827275 G A 7.78E-05 Psoriasis / / 20953190 rs427983 chr4 107828001 T C 3.30E-04 Myasthenia gravis / / 23055271 rs450533 chr4 107830261 T C 1.60E-05 Hypothyroidism / / 22493691 rs17037083 chr4 107841904 G A 2.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs10488898 chr4 107843493 G A 3.99E-04 Suicide attempts in bipolar disorder DKK2 UTR-3 21423239 rs419558 chr4 107844092 C T 8.40E-05 Hypothyroidism DKK2 UTR-3 22493691 rs17509643 chr4 107844298 G C 3.50E-04 Multiple complex diseases DKK2 UTR-3 17554300 rs10488899 chr4 107864811 T G 5.79E-04 Type 2 diabetes DKK2 intron 17463246 rs3851421 chr4 107868983 C T 9.68E-04 Suicide attempts in bipolar disorder DKK2 intron 21423239 rs17431749 chr4 107888737 C T 6.66E-04 Suicide attempts in bipolar disorder DKK2 intron 21423239 rs435887 chr4 108020599 G A 5.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs435887 chr4 108020599 G A 8.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs373586 chr4 108040129 A G 2.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6533280 chr4 108043696 C A 5.12E-04 Taste perception / / 22132133 rs7694364 chr4 108084614 T C 6.69E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs17037473 chr4 108094650 G A 5.33E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs17037483 chr4 108099721 A C 5.33E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs12511906 chr4 108105844 G A 0.00000195 Major depressive disorder / / 23149448 rs17037492 chr4 108109252 G C 4.85E-04 Multiple complex diseases / / 17554300 rs10516541 chr4 108115222 G A 4.00E-06 Mean forced vital capacity from 2 exams / / 17903307 rs11941336 chr4 108121140 G T 1.16E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4956081 chr4 108164882 T G 6.52E-05 Sudden cardiac arrest / / 21658281 rs11732697 chr4 108187241 G A 6.62E-07 Telomere length / / 24478790 rs41511050 chr4 108188671 G A 4.99E-04 Multiple complex diseases / / 17554300 rs7680468 chr4 108304199 G T 5.00E-08 Telomere length / / 24478790 rs203217 chr4 108320885 A G 9.70E-04 White matter integrity / / 22425255 rs203219 chr4 108323762 C T 4.97E-04 Lung function (forced vital capacity) / / 24023788 rs2903433 chr4 108371561 C G 9.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs11733491 chr4 108374237 T C 6.24E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs10023658 chr4 108383641 C A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2189194 chr4 108388432 A G 3.66E-07 Telomere length / / 24478790 rs12498793 chr4 108398187 C T 0.00000549 Cytarabine sensitivity / / 23538338 rs4956103 chr4 108400046 G C 0.00000291 Cytarabine sensitivity / / 23538338 rs17037826 chr4 108449838 A C 4.92E-04 Alcohol dependence / / 20201924 rs1913586 chr4 108455221 T C 5.43E-04 Alcohol dependence / / 21314694 rs4956020 chr4 108572151 C T 8.40E-05 Height PAPSS1 intron 21998595 rs3805343 chr4 108584371 C T 4.19E-04 Statin-induced myopathy PAPSS1 intron 21826682 rs4956119 chr4 108593090 T C 4.60E-04 Height PAPSS1 intron 21998595 rs727137 chr4 108599546 C T 6.99E-04 Type 2 diabetes PAPSS1 intron 17463246 rs2522422 chr4 108611941 A G 2.35E-06 Coronary heart disease PAPSS1 intron pha003055 rs2522422 chr4 108611941 A G 2.06E-06 Coronary heart disease PAPSS1 intron pha003056 rs2522425 chr4 108618232 T C 2.35E-06 Coronary heart disease PAPSS1 intron pha003055 rs2522425 chr4 108618232 T C 1.51E-06 Coronary heart disease PAPSS1 intron pha003056 rs4956130 chr4 108622993 A C 8.95E-04 Stroke PAPSS1 intron pha002886 rs973126 chr4 108641300 T C 3.29E-05 Coronary heart disease PAPSS1 cds-synon pha003055 rs973126 chr4 108641300 T C 1.80E-05 Coronary heart disease PAPSS1 cds-synon pha003056 rs16780 chr4 108642953 G A 6.48E-04 Parkinson's disease / / 17052657 rs16780 chr4 108642953 G A 9.35E-05 Coronary heart disease / / pha003031 rs16780 chr4 108642953 G A 5.17E-05 Coronary heart disease / / pha003055 rs16780 chr4 108642953 G A 3.02E-05 Coronary heart disease / / pha003056 rs2522447 chr4 108664579 T G 8.62E-05 Coronary heart disease / / pha003056 rs11732603 chr4 108671723 C T 2.49E-04 Tourette syndrome / / 22889924 rs7665836 chr4 108731771 G A 7.21E-05 Coronary heart disease / / pha003056 rs13144835 chr4 108829343 T C 6.55E-05 Cholesterol SGMS2 intron pha003078 rs17038228 chr4 108837629 A G 8.36E-05 Cholesterol / / pha003078 rs7340800 chr4 108849394 A C 8.87E-05 Cholesterol / / pha003073 rs7340800 chr4 108849394 A C 3.51E-05 Cholesterol / / pha003078 rs1493131 chr4 108860906 G A 7.00E-05 Type 2 diabetes and 6 quantitative traits CYP2U1 intron 17848626 rs1493131 chr4 108860906 G A 1.68E-05 Cholesterol CYP2U1 intron pha003073 rs1493131 chr4 108860906 G A 1.33E-05 Cholesterol CYP2U1 intron pha003078 rs1493122 chr4 108864651 T C 3.36E-05 Cholesterol CYP2U1 intron pha003073 rs1493122 chr4 108864651 T C 2.62E-05 Cholesterol CYP2U1 intron pha003078 rs17038289 chr4 108912239 A G 0.00000001 Brain microstructure and intellectual performance HADH intron 22723713 rs3796988 chr4 108930049 C G 9.33E-04 Type 2 diabetes HADH intron 17463246 rs4956145 chr4 108931039 T C 4.11E-05 Alcohol and nictotine co-dependence / / 20158304 rs76476980 chr4 108948869 G A,T 0.000095 Breast cancer HADH missense 23555315 rs6851442 chr4 108959282 A G 3.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1380770 chr4 109012353 T C 2.94E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) LEF1 intron 24023788 rs898518 chr4 109016824 C A 0.0000254 Primary sclerosing cholangitis LEF1 intron 23603763 rs898518 chr4 109016824 C A 4.00E-10 Chronic lymphocytic leukemia LEF1 intron 23770605 rs2003869 chr4 109026414 A G 8.45E-08 Chronic lymphocytic leukemia LEF1 intron 23770605 rs10022956 chr4 109033979 T C 1.65E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LEF1 intron 20877124 rs10022956 chr4 109033979 T C 4.35E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LEF1 intron 20877124 rs956237 chr4 109046960 G A 2.00E-06 Systemic lupus erythematosus LEF1 intron 22291604 rs9997081 chr4 109126553 T A 7.46E-06 Brachial circumference / / 22479309 rs11097974 chr4 109163035 C T 9.59E-06 Waist Circumference / / pha003023 rs1393824 chr4 109171067 C A 1.23E-05 Waist Circumference / / pha003023 rs931771 chr4 109172913 C T 5.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs3913354 chr4 109180443 A T 7.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs11725852 chr4 109196994 C T 6.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs13144621 chr4 109217929 T C 1.00E-06 Airflow obstruction / / 22837378 rs7683465 chr4 109223537 G A 7.01E-04 Cognition,early reading ability / / 17684495 rs852269 chr4 109236454 C T 6.94E-05 Erythrocyte counts / / pha003099 rs17038921 chr4 109284961 T C 2.22E-04 Smoking initiation / / 24665060 rs17038960 chr4 109295912 G A 9.95E-05 Schizophrenia / / 19571809 rs17038960 chr4 109295912 G A 3.00E-05 Schizophrenia / / pha002859 rs188721 chr4 109296917 T C 5.55E-05 Eosinophil counts / / pha003088 rs737605 chr4 109298935 G A 7.42E-04 Type 2 diabetes / / 17463246 rs13132148 chr4 109301049 T C 1.40E-05 Urinary metabolites / / 21572414 rs10489028 chr4 109315791 C T 8.70E-05 Information processing speed / / 21130836 rs41406246 chr4 109339576 C T 5.45E-05 Bone mineral density / / 19874204 rs6811130 chr4 109340406 T C 1.59E-04 Alzheimer's disease / / 24755620 rs17039028 chr4 109346722 A G 4.84E-04 Taste perception / / 22132133 rs1377066 chr4 109371094 C T 6.96E-04 Alzheimer's disease / / 24755620 rs7654972 chr4 109407499 C T 6.00E-06 Urinary metabolites / / 21572414 rs1562973 chr4 109408138 C A 2.70E-05 Urinary metabolites / / 21572414 rs6838036 chr4 109411079 C A 1.62E-05 Celiac disease / / 23936387 rs4266352 chr4 109466347 A G 1.20E-04 Breast cancer and prostate cancer LOC285456 intron 17903305 rs11734670 chr4 109486382 C T 4.98E-04 Hemoglobin concentration LOC285456 intron 20534544 rs7676871 chr4 109488632 C T 1.05E-04 Amyotrophic lateral sclerosis (sporadic) LOC285456 intron 24529757 rs3796938 chr4 109511234 T C 2.15E-04 Hemoglobin concentration LOC285456 intron 20534544 rs10856993 chr4 109511500 T C 6.40E-04 Type 2 diabetes LOC285456 intron 17463246 rs3796934 chr4 109541661 T G 4.98E-04 Hemoglobin concentration / / 20534544 rs6533371 chr4 109547017 C T 3.26E-04 Hemoglobin concentration RPL34 intron 20534544 rs11097999 chr4 109552881 G A 4.98E-04 Hemoglobin concentration / / 20534544 rs2880787 chr4 109553331 A G 3.20E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs570434103 chr4 109553331 ACT A 3.20E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2851387 chr4 109565604 G A 9.13E-04 Alzheimer's disease / / 24755620 rs2575649 chr4 109567253 G T 8.90E-04 Alzheimer's disease / / 24755620 rs12643059 chr4 109581094 C G 8.68E-04 Alzheimer's disease OSTC intron 24755620 rs1369962 chr4 109583785 A G 8.47E-04 Alzheimer's disease OSTC intron 24755620 rs2851365 chr4 109596447 G A 7.85E-04 Alzheimer's disease / / 24755620 rs2851362 chr4 109599091 G T 7.32E-04 Alzheimer's disease / / 24755620 rs2851361 chr4 109599306 A C 7.32E-04 Alzheimer's disease / / 24755620 rs2575642 chr4 109605648 T C 8.23E-04 Alzheimer's disease / / 24755620 rs2851349 chr4 109627657 G A 7.01E-04 Alzheimer's disease / / 24755620 rs10029851 chr4 109628025 A C 1.00E-07 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17586539 chr4 109651603 G A 3.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs1377210 chr4 109674116 A G 0.0000411 Transmission distortion AGXT2L1 missense 22377632 rs7687209 chr4 109693926 T C 7.50E-06 Urinary metabolites / / 21572414 rs7654111 chr4 109708777 A G 2.50E-06 Urinary metabolites / / 21572414 rs17528213 chr4 109713981 A G 1.20E-05 Urinary metabolites / / 21572414 rs7692671 chr4 109714155 G A 1.40E-05 Urinary metabolites / / 21572414 rs17039326 chr4 109714172 C T 2.10E-05 Urinary metabolites / / 21572414 rs9996286 chr4 109714529 C T 2.10E-05 Urinary metabolites / / 21572414 rs4956211 chr4 109723126 G A 6.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4956211 chr4 109723126 G A 1.00E-06 Systemic lupus erythematosus / / 21408207 rs4956063 chr4 109759469 C T 2.56E-04 Smoking initiation COL25A1 intron 24665060 rs4956215 chr4 109759534 C T 7.68E-05 Smoking initiation COL25A1 intron 24665060 rs2198329 chr4 109774351 A G 6.35E-04 Multiple complex diseases COL25A1 intron 17554300 rs1377208 chr4 109777933 G T 9.44E-06 Post-operative nausea and vomiting COL25A1 intron 21694509 rs17596971 chr4 109848103 A G 1.01E-05 Odorant perception COL25A1 intron 23910658 rs17039583 chr4 109880730 A G 1.56E-06 Schizophrenia(age at onset) COL25A1 intron 21688384 rs9307326 chr4 109882400 G A 5.49E-06 Schizophrenia(age at onset) COL25A1 intron 21688384 rs9307326 chr4 109882400 G A 7.76E-04 Oral cancers (chewing tobacco related) COL25A1 intron 22503698 rs2194861 chr4 109889251 A G 8.15E-04 Oral cancers (chewing tobacco related) COL25A1 intron 22503698 rs1405154 chr4 109901424 G A 7.49E-05 Schizophrenia(age at onset) COL25A1 intron 21688384 rs1405161 chr4 109932007 C T 1.80E-05 Urinary metabolites COL25A1 intron 21572414 rs1724469 chr4 109932970 T G 1.80E-05 Urinary metabolites COL25A1 intron 21572414 rs2081466 chr4 109938078 T C 3.56E-04 Multiple complex diseases COL25A1 intron 17554300 rs3096507 chr4 109947181 C G 9.54E-05 Serum metabolites COL25A1 intron 19043545 rs3096507 chr4 109947181 C G 2.30E-05 Urinary metabolites COL25A1 intron 21572414 rs10012573 chr4 109948586 A C 6.00E-06 White matter hyperintensity burden COL25A1 intron 21681796 rs1648045 chr4 109948640 A G 1.60E-05 Urinary metabolites COL25A1 intron 21572414 rs794143 chr4 109953214 A G 2.00E-04 Response to interferon beta in multiple sclerosis COL25A1 intron 18195134 rs1863291 chr4 109971378 T C 3.60E-04 Taste perception COL25A1 intron 22132133 rs1991219 chr4 110000675 G T 6.25E-05 Cognitive performance COL25A1 intron 19734545 rs3108958 chr4 110007661 C T 2.70E-05 Urinary metabolites COL25A1 intron 21572414 rs4267808 chr4 110008292 A C 2.70E-05 Urinary metabolites COL25A1 intron 21572414 rs11736110 chr4 110017182 C T 9.54E-05 Left ventricular hypertrophy COL25A1 intron pha003052 rs17039816 chr4 110019454 C A 2.40E-05 Urinary metabolites COL25A1 intron 21572414 rs7696620 chr4 110026849 C G 2.20E-05 Urinary metabolites COL25A1 intron 21572414 rs3113719 chr4 110030731 G A 7.80E-06 Urinary metabolites COL25A1 intron 21572414 rs3113720 chr4 110030786 T C 7.80E-06 Urinary metabolites COL25A1 intron 21572414 rs11946219 chr4 110047740 G A 7.19E-04 Multiple complex diseases COL25A1 intron 17554300 rs2189702 chr4 110085820 G C 1.23E-04 Response to taxane treatment (placlitaxel) COL25A1 intron 23006423 rs2526434 chr4 110097567 T G 2.67E-04 Response to taxane treatment (placlitaxel) COL25A1 intron 23006423 rs2526456 chr4 110101176 C T 7.68E-04 Type 2 diabetes COL25A1 intron 17463246 rs2704102 chr4 110103485 C T 6.43E-04 Type 2 diabetes COL25A1 intron 17463246 rs2345417 chr4 110135175 T C 2.38E-04 Response to taxane treatment (placlitaxel) COL25A1 intron 23006423 rs17304953 chr4 110155038 A G 1.29E-04 Response to taxane treatment (placlitaxel) COL25A1 intron 23006423 rs115921721 chr4 110175673 A G 7.48E-04 Crohn's disease COL25A1 intron 23266558 rs6857726 chr4 110194284 C A 9.73E-04 Alcohol dependence COL25A1 intron 21314694 rs1297940 chr4 110198260 T C 9.40E-06 Urinary metabolites COL25A1 intron 21572414 rs2214375 chr4 110209365 C A 6.45E-05 Blood Pressure COL25A1 intron pha003044 rs4464631 chr4 110222845 T C 3.35E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines COL25A1 intron 21844884 rs11098033 chr4 110324528 T C 2.53E-04 Age-related macular degeneration / / 22125219 rs12650654 chr4 110335870 A G 2.18E-04 Age-related macular degeneration / / 22125219 rs12650654 chr4 110335870 A G 0.0000055 LDL cholesterol particle diameter / / 23263444 rs189098852 chr4 110384078 A C 0.000034 Breast cancer(er negative) SEC24B missense 23555315 rs10516557 chr4 110395406 G A 2.00E-08 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) SEC24B intron 17982456 rs12640500 chr4 110509186 G T 3.07E-04 Alcohol dependence CCDC109B intron 21314694 rs197231 chr4 110514947 A T 5.62E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) CCDC109B intron 17982456 rs9993676 chr4 110530197 T C 9.13E-04 Alzheimer's disease CCDC109B intron 17998437 rs1476545 chr4 110531799 T A 3.53E-04 Alzheimer's disease CCDC109B intron 17998437 rs6533444 chr4 110561106 A G 7.12E-05 Elbow pain CCDC109B intron pha003008 rs9996730 chr4 110570095 G T 8.82E-05 Alcohol and nictotine co-dependence CCDC109B intron 20158304 rs6834701 chr4 110576488 T C 1.51E-05 Alzheimer's disease CCDC109B intron 17998437 rs7699969 chr4 110576823 G A 1.99E-04 Fasting insulin (interaction) CCDC109B intron 24204828 rs7699969 chr4 110576823 G A 2.28E-04 Homeostasis model assessment of insulin resistance (interaction) CCDC109B intron 24204828 rs10488886 chr4 110584696 A G 3.65E-04 Multiple complex diseases CCDC109B intron 17554300 rs4698775 chr4 110590479 G T 7.00E-11 Age-related macular degeneration CCDC109B intron 23455636 rs4698776 chr4 110590821 G A 4.16E-05 Alzheimer's disease CCDC109B intron 17998437 rs3181191 chr4 110612537 G A 2.13E-05 Alzheimer's disease CASP6 intron 17998437 rs3181191 chr4 110612537 G A 5.89E-05 Psoriasis CASP6 intron 18364390 rs3181191 chr4 110612537 G A 4.31E-05 Elbow pain CASP6 intron pha003008 rs3181191 chr4 110612537 G A 5.06E-05 Height CASP6 intron pha003010 rs1800627 chr4 110613658 A G 7.74E-04 Myopia (pathological) CASP6 intron 21095009 rs1541373 chr4 110628894 C T 1.16E-04 Alzheimer's disease / / 17998437 rs2285714 chr4 110638810 C T 3.00E-07 Age-related macular degeneration PLA2G12A cds-synon 20385819 rs2285714 chr4 110638810 C T 7.85E-08 Age-related macular degeneration PLA2G12A cds-synon pha002869 rs2285714 chr4 110638810 C T 3.58E-07 Age-related macular degeneration PLA2G12A cds-synon pha002890 rs7439493 chr4 110656730 G A 1.26E-06 Age-related macular degeneration / / pha002869 rs7439493 chr4 110656730 G A 1.59E-06 Age-related macular degeneration / / pha002890 rs10033900 chr4 110659067 T C 9.00E-09 Age-related macular degeneration / / 20385826 rs10033900 chr4 110659067 T C 4.00E-10 Age-related macular degeneration / / 21665990 rs10033900 chr4 110659067 T C 4.00E-06 Age-related macular degeneration (GA) / / 22705344 rs10033900 chr4 110659067 T C 6.00E-09 Age-related macular degeneration (CNV) / / 22705344 rs10033900 chr4 110659067 T C 6.35E-07 Age-related macular degeneration / / pha002869 rs10033900 chr4 110659067 T C 6.70E-07 Age-related macular degeneration / / pha002890 rs3822272 chr4 110683550 C T 8.40E-05 HIV-1 viral setpoint CFI intron 17641165 rs11929767 chr4 110693535 G A 9.98E-04 Type 2 diabetes CFI intron 17463246 rs4698788 chr4 110719534 T C 2.90E-04 Type 2 diabetes CFI intron 17463246 rs4698790 chr4 110727560 T G 5.00E-06 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs4698790 chr4 110727560 T G 9.00E-06 Fasting insulin (interaction) / / 24204828 rs6847149 chr4 110800097 A G 3.00E-06 Exercise treadmill test traits / / 17903301 rs17316633 chr4 110825634 G A 9.00E-06 Hair morphology / / 19896111 rs2237041 chr4 110839954 C T 5.67E-04 Alzheimer's disease EGF intron 17998437 rs3822288 chr4 110854544 C T 4.84E-04 Alzheimer's disease EGF intron 17998437 rs10029654 chr4 110861927 G A 9.83E-04 Alzheimer's disease EGF intron 17998437 rs7668520 chr4 110867350 G T 6.42E-04 Alzheimer's disease EGF intron 17998437 rs10488881 chr4 110877416 A T 3.83E-04 Alzheimer's disease EGF intron 17998437 rs9992755 chr4 110882590 A G 3.92E-04 Alzheimer's disease EGF intron 17998437 rs7670908 chr4 110892625 G A 4.49E-05 Height EGF intron 22021425 rs17041111 chr4 110893992 A G 1.18E-04 Progressive supranuclear palsy EGF intron 21685912 rs2237048 chr4 110894402 C G 5.69E-05 Multiple complex diseases EGF intron 17554300 rs11568993 chr4 110897315 C T 9.57E-05 Cardiovascular disease EGF cds-synon pha003064 rs11568995 chr4 110897585 G A 1.00E-06 IgG glycosylation EGF intron 23382691 rs11568995 chr4 110897585 G A 4.00E-07 IgG glycosylation EGF intron 23382691 rs11568995 chr4 110897585 G A 5.00E-06 IgG glycosylation EGF intron 23382691 rs6825106 chr4 110904502 G A 5.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EGF intron 20877124 rs971695 chr4 110927928 G A 9.25E-04 Menopause (age at onset) EGF intron 22267201 rs4698804 chr4 110940045 T C 0.000098 Breast cancer / / 23555315 rs17041245 chr4 110945256 C T 8.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6845765 chr4 110958164 C T 2.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6845765 chr4 110958164 C T 3.66E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10012953 chr4 110964362 A G 3.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10012953 chr4 110964362 A G 3.00E-06 Obesity-related traits / / 23251661 rs12108641 chr4 110968599 G T 6.32E-06 Glycemic traits (pregnancy) / / 23903356 rs7682855 chr4 110982146 A G 7.45E-04 Response to cytadine analogues (cytosine arabinoside) ELOVL6 intron 24483146 rs10452184 chr4 110988948 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) ELOVL6 intron 20708005 rs6858695 chr4 110995818 C T 7.21E-04 Type 2 diabetes ELOVL6 intron 17463246 rs11943595 chr4 111006785 G A 9.00E-05 Prostate cancer ELOVL6 intron 21743057 rs10011926 chr4 111026927 C T 8.00E-06 Attention deficit hyperactivity disorder ELOVL6 intron 20732626 rs6533491 chr4 111030787 T C 4.40E-04 Iris characteristics ELOVL6 intron 21835309 rs1315962 chr4 111033550 T C 8.47E-04 Type 2 diabetes ELOVL6 intron 17463246 rs6533492 chr4 111044245 C T 9.47E-05 Non-alcoholic fatty liver disease histology (other) ELOVL6 intron 20708005 rs6533492 chr4 111044245 C T 1.93E-04 Response to cholinesterase inhibitors in Alzheimer's disease ELOVL6 intron 23374588 rs1979469 chr4 111060898 A G 9.60E-05 Schizophrenia ELOVL6 intron 19571809 rs4146697 chr4 111078453 C T 7.90E-06 Urinary metabolites ELOVL6 intron 21572414 rs41320946 chr4 111080240 T C 1.60E-05 Urinary metabolites ELOVL6 intron 21572414 rs13145689 chr4 111109020 A G 2.09E-05 Rheumatoid arthritis ELOVL6 intron 17804836 rs13145689 chr4 111109020 A G 2.40E-05 Urinary metabolites ELOVL6 intron 21572414 rs5022521 chr4 111128587 C T 4.10E-05 Type 2 diabetes / / 17463248 rs17041459 chr4 111136362 T C 8.02E-05 Multiple complex diseases / / 17554300 rs7672908 chr4 111151349 C T 4.55E-04 Alzheimer's disease / / 24755620 rs12512353 chr4 111159920 T A 1.80E-07 Health and aging,CVD and cancer age of onset / / 22174011 rs10516561 chr4 111191861 T G 3.34E-04 Myocardial Infarction / / pha002873 rs244044 chr4 111227309 A C 7.92E-04 Multiple complex diseases / / 17554300 rs13148252 chr4 111227816 G A 4.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs13148252 chr4 111227816 G A 6.00E-06 IgG glycosylation / / 23382691 rs244004 chr4 111262702 C T 4.45E-04 Type 2 diabetes / / 17463246 rs1487258 chr4 111264846 C T 8.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs243996 chr4 111265078 G C 4.89E-04 Type 2 diabetes / / 17463246 rs6812536 chr4 111275436 T C 3.02E-04 Body mass index / / 21701565 rs418757 chr4 111275597 C T 7.60E-04 Multiple complex diseases / / 17554300 rs418757 chr4 111275597 C T 2.40E-04 Coronary heart disease / / 21971053 rs1487257 chr4 111277054 C G 5.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs472305 chr4 111278757 A C 1.26E-04 Coronary heart disease / / 21971053 rs472305 chr4 111278757 A C 2.54E-05 Cognitive impairment induced by topiramate / / 22091778 rs41368645 chr4 111289024 A G 9.40E-05 Postoperative ventricular dysfunction / / 21980348 rs12513172 chr4 111300510 C T 9.71E-05 Postoperative ventricular dysfunction / / 21980348 rs12513172 chr4 111300510 C T 9.19E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2348205 chr4 111313570 A G 5.41E-04 Multiple complex diseases / / 17554300 rs2348205 chr4 111313570 A G 1.55E-04 Coronary heart disease / / 21971053 rs2348205 chr4 111313570 A G 8.84E-05 Cognitive impairment induced by topiramate / / 22091778 rs1487263 chr4 111316132 A G 6.01E-04 Multiple complex diseases / / 17554300 rs10017096 chr4 111324679 G A 2.90E-05 Urinary metabolites / / 21572414 rs2087160 chr4 111334730 G T 7.00E-13 Metabolic traits / / 21886157 rs6825911 chr4 111381638 C T 7.00E-08 Blood pressure / / 21572416 rs6825911 chr4 111381638 C T 9.00E-09 Blood pressure / / 21572416 rs1879053 chr4 111396948 T C 3.00E-04 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs2348427 chr4 111414399 T C 9.80E-04 Suicidal ideation ENPEP intron 22030708 rs16997154 chr4 111419197 G A 5.80E-06 Bladder cancer ENPEP intron 19648920 rs11731078 chr4 111426341 T C 4.61E-05 Serum albumin level ENPEP intron pha003084 rs639194 chr4 111450323 C T 8.13E-05 Serum albumin level ENPEP intron pha003084 rs478454 chr4 111463277 T C 9.67E-05 Non-alcoholic fatty liver disease histology (other) ENPEP intron 20708005 rs17041884 chr4 111463627 C T 7.09E-05 Cholesterol ENPEP intron pha003078 rs9997349 chr4 111473366 G A 5.22E-04 Smoking cessation ENPEP intron 24665060 rs3796879 chr4 111476701 C T 1.39E-04 Multiple complex diseases ENPEP intron 17554300 rs1042279 chr4 111483133 C A 6.68E-04 Multiple complex diseases ENPEP UTR-3 17554300 rs1562640 chr4 111492369 A G 3.70E-05 Cognitive function / / 24684796 rs6533526 chr4 111538827 G A 8.23E-04 Multiple complex diseases PITX2 UTR-3 17554300 rs994978 chr4 111552398 T C 1.20E-05 Atrial fibrillation PITX2 intron 21846873 rs7667461 chr4 111622134 G A 1.10E-06 Urinary metabolites / / 21572414 rs16997168 chr4 111629039 C T 4.70E-05 Atrial fibrillation/atrial flutter / / 17603472 rs16997168 chr4 111629039 C T 1.30E-07 Atrial fibrillation / / 19597491 rs16997168 chr4 111629039 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs998101 chr4 111630615 C T 9.30E-07 Urinary metabolites / / 21572414 rs2723316 chr4 111634287 T C 1.90E-05 Atrial fibrillation/atrial flutter / / 17603472 rs2723316 chr4 111634287 T C 5.90E-08 Atrial fibrillation / / 19597491 rs1448817 chr4 111641053 A G 4.20E-11 Atrial fibrillation/atrial flutter / / 17603472 rs1448817 chr4 111641053 A G 1.60E-10 Atrial fibrillation / / 19597491 rs2634073 chr4 111665783 T C 2.40E-14 Atrial fibrillation/atrial flutter / / 17603472 rs2634073 chr4 111665783 T C 1.40E-14 Atrial fibrillation / / 19597491 rs12646447 chr4 111699326 T C 3.00E-08 Stroke (ischemic) / / 24262325 rs6817105 chr4 111705768 T C 2.00E-74 Atrial fibrillation / / 22544366 rs17042171 chr4 111708287 C A 4.00E-63 Atrial fibrillation / / 19597492 rs2200733 chr4 111710169 C T 3.00E-41 Atrial fibrillation/atrial flutter / / 17603472 rs2200733 chr4 111710169 C T 2.00E-10 Stroke (ischemic) / / 18991354 rs2200733 chr4 111710169 C T 1.00E-14 Atrial fibrillation / / 19597491 rs2200733 chr4 111710169 C T 2.50E-16 Atrial fibrillation / / 21846873 rs2200733 chr4 111710169 C T 1.70E-08 Stroke / / 22306652 rs4611994 chr4 111711041 T C 2.60E-16 Atrial fibrillation / / 21846873 rs1906599 chr4 111712686 T C 7.94E-11 Stroke / / 22306652 rs2220427 chr4 111714889 C T 5.60E-16 Atrial fibrillation/atrial flutter / / 17603472 rs2220427 chr4 111714889 C T 1.40E-14 Atrial fibrillation / / 19597491 rs6843082 chr4 111718067 G A 3.00E-28 Atrial fibrillation / / 20173747 rs6843082 chr4 111718067 G A 2.00E-07 Stroke (ischemic) / / 23041239 rs6843082 chr4 111718067 G A 3.00E-16 Stroke (ischemic) / / 23041239 rs10033464 chr4 111720761 T G 7.00E-11 Atrial fibrillation/atrial flutter / / 17603472 rs10033464 chr4 111720761 T G 5.70E-04 Myocardial Infarction / / pha002873 rs13141190 chr4 111728614 A G 2.00E-10 Atrial fibrillation/atrial flutter / / 17603472 rs13141190 chr4 111728614 A G 2.30E-14 Atrial fibrillation / / 19597491 rs3853444 chr4 111734136 T C 5.00E-06 Coronary heart disease / / 24778558 rs17042224 chr4 111738905 T G 8.84E-04 Multiple complex diseases / / 17554300 rs4576077 chr4 111740457 T C 8.64E-04 Parkinson's disease / / 17052657 rs3853445 chr4 111761487 T C 9.71E-05 Myopia (pathological) / / 21095009 rs4033102 chr4 111784205 G A 7.69E-04 Multiple complex diseases / / 17554300 rs6843250 chr4 111799417 T G 2.25E-05 Creatinine levels / / pha003069 rs7679158 chr4 111812327 G A 4.68E-05 Cognitive impairment induced by topiramate / / 22091778 rs7435672 chr4 111834562 G A 2.20E-05 Urinary metabolites / / 21572414 rs374582 chr4 111849422 G A 1.54E-04 Alzheimer's disease (late onset) / / 21379329 rs17042596 chr4 111903066 A G 0.0000013 Mean arterial pressure / / 22510845 rs7439813 chr4 111913732 G T 3.27E-05 Multiple complex diseases / / 17554300 rs13107191 chr4 111931680 C T 2.30E-05 Urinary metabolites / / 21572414 rs159480 chr4 111947434 T C 6.50E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs9307361 chr4 111949443 A G 4.52E-04 Type 2 diabetes / / 17463246 rs159476 chr4 111952390 T C 8.50E-04 Tourette syndrome / / 22889924 rs1386389 chr4 111953270 A C 5.05E-04 Myocardial Infarction / / pha002883 rs190042 chr4 111986946 C T 8.85E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9784466 chr4 111992160 T C 8.35E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs439192 chr4 112024192 T G 2.60E-05 Urinary metabolites / / 21572414 rs4487431 chr4 112075173 C T 1.40E-06 Urinary metabolites / / 21572414 rs6814577 chr4 112115625 A G 7.80E-06 Urinary metabolites / / 21572414 rs1487052 chr4 112120740 C T 2.90E-06 Urinary metabolites / / 21572414 rs2129498 chr4 112129653 G A 5.80E-06 Urinary metabolites / / 21572414 rs1490901 chr4 112157798 G A 9.34E-05 Alcohol consumption / / pha001397 rs10857014 chr4 112196340 G T 1.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17576345 chr4 112201846 C T 9.66E-05 Major depressive disorder (broad) / / 20038947 rs2349539 chr4 112203767 T A 5.54E-04 Aortic root size / / 21223598 rs4833619 chr4 112217944 T C 4.40E-04 Intelligence (childhood) / / 23358156 rs11098119 chr4 112246563 A G 1.87E-04 Attention deficit hyperactivity disorder / / 22420046 rs17043147 chr4 112287199 C T 2.33E-04 Aortic root size / / 21223598 rs1503659 chr4 112297415 T C 1.24E-04 IgE levels / / 17255346 rs2654735 chr4 112398613 T G 9.03E-05 Parkinson's disease / / pha002865 rs924758 chr4 112419559 C T 9.35E-04 Type 2 diabetes / / 17463246 rs10027375 chr4 112424765 C T 4.47E-05 Creatinine levels / / pha003069 rs10002279 chr4 112432021 T G 5.81E-05 Creatinine levels / / pha003069 rs1806506 chr4 112467251 A G 3.67E-05 Parkinson's disease / / pha002865 rs11729080 chr4 112503872 G A 3.27E-05 Parkinson's disease / / pha002865 rs6830890 chr4 112519126 G A 0.000000798 Lumbar spine bone mineral density / / 22692763 rs6830890 chr4 112519126 G A 0.00000564 Lumbar spine bone mineral density (males) / / 22692763 rs2597893 chr4 112522203 C G 9.81E-04 Type 2 diabetes / / 17463246 rs983966 chr4 112557798 G A 5.34E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs17043540 chr4 112558571 G C 7.96E-04 Multiple complex diseases / / 17554300 rs10029853 chr4 112566774 A G 8.38E-04 Multiple complex diseases / / 17554300 rs2597892 chr4 112568354 G T 2.70E-05 Urinary metabolites / / 21572414 rs17043575 chr4 112569676 C T 5.33E-04 Multiple complex diseases / / 17554300 rs10004873 chr4 112581256 T C 1.25E-04 Type 2 diabetes / / 17463246 rs10004873 chr4 112581256 T C 5.75E-04 Multiple complex diseases / / 17554300 rs1450781 chr4 112588951 T C 1.93E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs2613726 chr4 112597321 A G 2.20E-05 Urinary metabolites / / 21572414 rs2597881 chr4 112597579 T C 1.40E-05 Urinary metabolites / / 21572414 rs10034228 chr4 112611750 T C 8.00E-13 Myopia (pathological) / / 21505071 rs326897 chr4 112669723 A T 2.20E-05 Urinary metabolites / / 21572414 rs7672663 chr4 112674004 C T 8.29E-04 Multiple complex diseases / / 17554300 rs1585471 chr4 112702635 A G 2.00E-06 Myopia (pathological) / / 21505071 rs326880 chr4 112729781 A G 3.34E-04 Lung function (forced vital capacity) / / 24023788 rs17044137 chr4 112795297 T A 4.10E-05 Type 2 diabetes / / 17463246 rs6819454 chr4 112835909 G A 5.69E-04 Type 2 diabetes / / 17463246 rs227897 chr4 112842885 T A 3.58E-05 Serum metabolites / / 19043545 rs17527538 chr4 112851332 C T 5.69E-04 Type 2 diabetes / / 17463246 rs17443132 chr4 112856855 A C 6.87E-04 Type 2 diabetes / / 17463246 rs17589290 chr4 112923237 C G 6.00E-06 Coronary heart disease / / 21347282 rs10488956 chr4 112929419 C T 4.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs12500823 chr4 112929836 G A 8.51E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1521477 chr4 113050302 A C 8.30E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs9995910 chr4 113055291 T C 4.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs4833392 chr4 113058401 A C 3.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs1436136 chr4 113063526 A G 8.30E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1025609 chr4 113069030 C G 4.75E-04 Suicide attempts in bipolar disorder C4orf32 intron 21423239 rs2117917 chr4 113071518 T C 4.69E-04 Suicide attempts in bipolar disorder C4orf32 intron 21423239 rs2164446 chr4 113071834 T A 8.89E-04 Suicide attempts in bipolar disorder C4orf32 intron 21423239 rs4834241 chr4 113120268 T C 5.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs9307379 chr4 113150288 G C 7.45E-04 Alcohol dependence / / 21314694 rs4833401 chr4 113194164 G A 7.54E-04 Lymphocyte counts / / 22286170 rs17627598 chr4 113211494 A C 9.22E-04 Multiple complex diseases / / 17554300 rs11098149 chr4 113221614 A G 6.58E-06 Alopecia areata ALPK1 intron 22027810 rs6810537 chr4 113243265 C T 3.16E-04 Alzheimer's disease (late onset) ALPK1 intron 21379329 rs1544383 chr4 113244470 T C 2.90E-04 Alzheimer's disease (late onset) ALPK1 intron 21379329 rs11098152 chr4 113269731 A G 4.11E-05 Myopia (pathological) ALPK1 intron 23049088 rs1859142 chr4 113290398 T A 1.84E-04 Multiple complex diseases ALPK1 intron 17554300 rs7673053 chr4 113302869 T G 0.000005 Major depressive disorder ALPK1 intron 22915352 rs11728213 chr4 113309647 G A 2.80E-05 Urinary metabolites ALPK1 intron 21572414 rs965013 chr4 113310981 A C 6.41E-04 Type 2 diabetes ALPK1 intron 17463246 rs9307381 chr4 113311353 A G 7.91E-04 Bipolar disorder ALPK1 intron 19259986 rs4833407 chr4 113311790 C A 1.00E-06 Obesity ALPK1 intron 22484627 rs6838440 chr4 113328078 C T 3.00E-06 Epirubicin-induced leukopenia ALPK1 intron 21799462 rs6812485 chr4 113331790 G T 1.40E-04 Birth weight ALPK1 intron 17255346 rs6829461 chr4 113339161 G T 0.0000061 Chronic kidney disease ALPK1 intron 23539754 rs2074388 chr4 113352397 G A 3.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ALPK1 missense 20877124 rs35519493 chr4 113352745 G A 0.00023 Breast cancer ALPK1 missense 23555315 rs2074379 chr4 113352899 G A 3.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ALPK1 missense 20877124 rs231245 chr4 113358759 G A 2.41E-04 Coronary Artery Disease ALPK1 intron 17634449 rs879069 chr4 113379718 C T 7.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7699752 chr4 113415402 T C 7.55E-05 Aging (time to event) / / 21782286 rs6831071 chr4 113452037 C G 7.57E-04 Obesity (extreme) / / 21935397 rs11098163 chr4 113457518 A G 7.85E-04 Obesity (extreme) / / 21935397 rs2306775 chr4 113460927 C A 7.20E-04 Obesity (extreme) C4orf21 intron 21935397 rs1486865 chr4 113465651 A G 6.18E-04 Alcohol dependence C4orf21 intron 20201924 rs12054589 chr4 113465971 A G 8.69E-04 Obesity (extreme) C4orf21 intron 21935397 rs4833414 chr4 113469913 T C 5.62E-04 Alcohol dependence C4orf21 intron 20201924 rs9991830 chr4 113485372 T C 8.70E-04 Alcohol dependence C4orf21 intron 20201924 rs2029211 chr4 113488134 T C 8.70E-04 Alcohol dependence C4orf21 intron 20201924 rs1486863 chr4 113491026 T C 3.81E-04 Obesity (extreme) C4orf21 intron 21935397 rs12503100 chr4 113492978 G T 3.77E-04 Obesity (extreme) C4orf21 intron 21935397 rs10031880 chr4 113510585 G C 3.74E-04 Obesity (extreme) C4orf21 intron 21935397 rs4834293 chr4 113528624 T C 5.35E-05 Suicide attempts in bipolar disorder C4orf21 intron 21423239 rs9307383 chr4 113529834 C T 6.68E-04 Alcohol dependence C4orf21 intron 20201924 rs9993534 chr4 113533796 T C 4.04E-04 Obesity (extreme) C4orf21 intron 21935397 rs2087111 chr4 113536080 A G 8.36E-04 Alcohol dependence C4orf21 intron 20201924 rs4833415 chr4 113536746 A G 3.82E-05 Suicide attempts in bipolar disorder C4orf21 intron 21423239 rs6834538 chr4 113544152 T C 5.00E-06 Free thyroxine concentration C4orf21 intron 24722205 rs13146963 chr4 113558602 A G 4.48E-04 Alcohol dependence LARP7 intron 20201924 rs35865138 chr4 113574409 G A 2.76E-05 Smoking initiation LARP7 intron 24665060 rs6533631 chr4 113578266 G A 6.06E-04 Obesity (extreme) LARP7 intron 21935397 rs1129065 chr4 113578609 C T 5.25E-04 Obesity (extreme) LARP7 UTR-3 21935397 rs6810996 chr4 113584941 A G 3.01E-04 Obesity (extreme) / / 21935397 rs4834296 chr4 113594628 A G 6.52E-05 ldl cholesterol / / pha003076 rs6533635 chr4 113612872 G A 8.21E-05 ldl cholesterol / / pha003076 rs2352050 chr4 113653917 A G 5.45E-05 Lung function (forced vital capacity) / / pha003104 rs17044896 chr4 113664304 G A 5.84E-04 Multiple complex diseases / / 17554300 rs12511494 chr4 113770535 C A 7.43E-05 Lung function (forced vital capacity) ANK2 intron pha003104 rs552009381 chr4 113770535 CTT C 7.43E-05 Lung function (forced vital capacity) ANK2 intron pha003104 rs1448221 chr4 113779891 G T 3.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ANK2 intron 20877124 rs12513140 chr4 113817807 G A 6.71E-04 Smoking cessation ANK2 intron 24665060 rs12500579 chr4 113855477 C G 5.00E-13 Fractional exhaled nitric oxide (childhood) ANK2 intron 24315451 rs12500579 chr4 113855477 C G 8.00E-08 Fractional exhaled nitric oxide (childhood) ANK2 intron 24315451 rs6819908 chr4 113887737 C G 4.42E-05 Parkinson's disease (motor and cognition) ANK2 intron 22658654 rs2174559 chr4 113896299 G A 9.41E-04 Heart Failure ANK2 intron pha002884 rs2174558 chr4 113927365 C T 4.63E-04 Type 2 diabetes ANK2 intron 17463246 rs17618813 chr4 113934034 C T 2.43E-05 Cognitive test performance ANK2 intron 20125193 rs17618813 chr4 113934034 C T 0.0000416 Aging ANK2 intron 22445811 rs10014072 chr4 113948790 A G 1.00E-06 Blood trace element (Cu levels) ANK2 intron 23720494 rs1395114 chr4 113953581 C T 1.80E-04 Type 2 diabetes and 6 quantitative traits ANK2 intron 17848626 rs12504906 chr4 113954301 G T 3.22E-04 Birth weight ANK2 intron 17255346 rs313939 chr4 113966380 T C 9.67E-05 Non-alcoholic fatty liver disease histology (other) ANK2 intron 20708005 rs582050 chr4 113989326 T C 1.49E-05 Bipolar disorder and schizophrenia ANK2 intron 20889312 rs4834311 chr4 113990943 A G 1.30E-05 Urinary metabolites ANK2 intron 21572414 rs7694725 chr4 114000956 T C 2.00E-06 Prostate cancer (gene x gene interaction) ANK2 intron 22219177 rs17045555 chr4 114014365 A G 8.57E-04 Response to taxane treatment (placlitaxel) ANK2 intron 23006423 rs313949 chr4 114021093 C A 4.86E-05 Cognitive test performance ANK2 intron 20125193 rs313950 chr4 114021169 G A 2.20E-07 Urinary metabolites ANK2 intron 21572414 rs2101318 chr4 114021870 C T 8.80E-06 Urinary metabolites ANK2 intron 21572414 rs7660069 chr4 114022002 G T 6.90E-06 Urinary metabolites ANK2 intron 21572414 rs12647986 chr4 114024585 T G 6.59E-04 Rheumatoid arthritis ANK2 intron 21452313 rs7673051 chr4 114029848 G T 7.46E-06 Post-operative nausea and vomiting ANK2 intron 21694509 rs2352185 chr4 114031764 G T 3.31E-05 Type 2 diabetes ANK2 intron 17463246 rs17626532 chr4 114043116 C T 8.40E-06 Urinary metabolites ANK2 intron 21572414 rs17626532 chr4 114043116 C T 9.78E-04 Alzheimer's disease ANK2 intron 24755620 rs17676256 chr4 114061536 G A 5.03E-05 Multiple complex diseases ANK2 intron 17554300 rs17676256 chr4 114061536 G A 7.14E-05 Alzheimer's disease (late onset) ANK2 intron 21379329 rs10021192 chr4 114063451 G A 2.05E-04 Type 2 diabetes ANK2 intron 17463246 rs10021192 chr4 114063451 G A 7.19E-05 Serum metabolites ANK2 intron 19043545 rs13126963 chr4 114063995 G C 1.80E-05 Serum metabolites ANK2 intron 19043545 rs10516593 chr4 114078812 A C 3.55E-05 Paget's disease ANK2 intron 20436471 rs10516593 chr4 114078812 A C 8.83E-05 Hypertension (essential hypertension) ANK2 intron 22184326 rs407709 chr4 114085448 A T 1.60E-05 Urinary metabolites ANK2 intron 21572414 rs407709 chr4 114085448 A T 3.94E-05 Creutzfeldt-Jakob disease (variant) ANK2 intron 22137330 rs7697503 chr4 114086121 C T 9.17E-04 Type 2 diabetes ANK2 intron 20818381 rs399754 chr4 114092317 G A 1.00E-05 Urinary metabolites ANK2 intron 21572414 rs41434448 chr4 114092833 C G 5.95E-05 Multiple complex diseases ANK2 intron 17554300 rs7667099 chr4 114111016 G A 2.44E-06 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines ANK2 intron 21483694 rs967099 chr4 114118650 A G 4.19E-05 Gaucher disease severity ANK2 intron 22388998 rs10019154 chr4 114129195 T A 1.58E-04 Multiple complex diseases ANK2 intron 17554300 rs17445375 chr4 114139043 A T 2.60E-05 Urinary metabolites ANK2 intron 21572414 rs362492 chr4 114139428 T C 9.03E-04 Type 2 diabetes ANK2 intron 17463246 rs17445459 chr4 114142878 A G 4.77E-04 Multiple complex diseases ANK2 intron 17554300 rs3025748 chr4 114144661 A G 3.13E-04 Type 2 diabetes ANK2 intron 17463246 rs10516594 chr4 114237567 A G 8.56E-04 Multiple complex diseases ANK2 intron 17554300 rs10516594 chr4 114237567 A G 1.88E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ANK2 intron 20877124 rs7684392 chr4 114244155 C T 4.25E-04 Type 2 diabetes ANK2 intron 17463246 rs11940206 chr4 114249897 A G 3.15E-04 Alzheimer's disease (late onset) ANK2 intron 21379329 rs17045935 chr4 114254569 T C 3.16E-04 Hearing function ANK2 intron 17255346 rs17045935 chr4 114254569 T C 1.03E-04 Multiple complex diseases ANK2 intron 17554300 rs10015062 chr4 114332302 G A 4.69E-04 Smoking quantity / / 24665060 rs13129686 chr4 114353149 A G 2.33E-04 Multiple complex diseases / / 17554300 rs7667286 chr4 114354242 G A 7.89E-04 Multiple complex diseases / / 17554300 rs9307390 chr4 114356163 G A 1.57E-04 Multiple complex diseases / / 17554300 rs940635 chr4 114359700 G C 1.36E-06 Multiple complex diseases / / 17554300 rs940634 chr4 114359899 C T 9.56E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1880529 chr4 114379379 C T 4.00E-06 White matter integrity (interaction) CAMK2D intron 23218918 rs916873 chr4 114392257 G A 1.79E-06 Multiple complex diseases CAMK2D intron 17554300 rs17629820 chr4 114393844 T C 2.52E-04 Glycosylated haemoglobin levels CAMK2D intron 17255346 rs4834340 chr4 114400669 G A 1.56E-04 Multiple complex diseases CAMK2D intron 17554300 rs2158197 chr4 114416621 G T 5.46E-05 Serum metabolites CAMK2D intron 19043545 rs17446453 chr4 114421712 C T 6.25E-04 Multiple complex diseases CAMK2D intron 17554300 rs17446453 chr4 114421712 C T 6.63E-05 Serum metabolites CAMK2D intron 19043545 rs10488891 chr4 114425474 T C 1.67E-05 Glycosylated haemoglobin levels CAMK2D intron 17255346 rs4834347 chr4 114425934 C A 8.85E-04 Multiple complex diseases CAMK2D intron 17554300 rs4834347 chr4 114425934 C A 9.89E-04 Suicide attempts in bipolar disorder CAMK2D intron 21423239 rs11098193 chr4 114429407 C T 5.57E-04 Multiple complex diseases CAMK2D cds-synon 17554300 rs11098193 chr4 114429407 C T 7.81E-05 Serum metabolites CAMK2D cds-synon 19043545 rs17046126 chr4 114432073 C T 2.55E-04 Multiple complex diseases CAMK2D intron 17554300 rs17046126 chr4 114432073 C T 2.79E-05 Serum metabolites CAMK2D intron 19043545 rs6842409 chr4 114440920 T C 2.61E-05 Multiple complex diseases CAMK2D intron 17554300 rs4240286 chr4 114452724 T C 6.67E-04 Multiple complex diseases CAMK2D intron 17554300 rs4240286 chr4 114452724 T C 1.99E-05 Serum metabolites CAMK2D intron 19043545 rs17592426 chr4 114472019 A G 1.38E-04 Glycosylated haemoglobin levels CAMK2D intron 17255346 rs2285704 chr4 114472984 T C 3.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAMK2D intron 20877124 rs13144613 chr4 114496125 C G 6.16E-04 Multiple complex diseases CAMK2D intron 17554300 rs6855671 chr4 114502911 T C 5.37E-05 Glycosylated haemoglobin levels CAMK2D intron 17255346 rs7665102 chr4 114505498 G A 8.23E-05 Statin-induced myopathy CAMK2D intron 21826682 rs17531701 chr4 114512137 C T 8.79E-05 Prion diseases CAMK2D intron 22210626 rs6857556 chr4 114528019 G A 8.24E-04 Suicide attempts in bipolar disorder CAMK2D intron 21041247 rs12500935 chr4 114540781 G A 1.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAMK2D intron 20877124 rs12500935 chr4 114540781 G A 4.10E-06 Osteoarthritis CAMK2D intron 22763110 rs6533710 chr4 114589266 A G 6.20E-04 Alcohol dependence CAMK2D intron 20201924 rs10461194 chr4 114621548 A G 7.00E-04 Alzheimer's disease CAMK2D intron 17998437 rs9993234 chr4 114635433 T C 9.28E-05 Information processing speed CAMK2D intron 21130836 rs1859229 chr4 114661681 T G 1.00E-04 Information processing speed CAMK2D intron 21130836 rs10488961 chr4 114665832 C T 0.000641229 Hypertension (early onset hypertension) CAMK2D intron 22479346 rs10488961 chr4 114665832 C T 4.88E-05 Body Mass Index CAMK2D intron pha003020 rs10488963 chr4 114666848 G C 4.65E-04 Schizophrenia CAMK2D intron 21674006 rs17593593 chr4 114673734 T C 3.33E-05 Information processing speed CAMK2D intron 21130836 rs6858698 chr4 114683844 G C 3.00E-09 Chronic lymphocytic leukemia / / 24292274 rs1557815 chr4 114696373 G A 6.85E-05 Bone mineral density / / 19181680 rs10461151 chr4 114703773 A G 1.58E-04 Vaspin levels / / 22907691 rs10461151 chr4 114703773 A G 0.0001578 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs7684832 chr4 114751650 G A 9.73E-05 Height / / pha003011 rs7676164 chr4 114755524 G A 9.76E-05 Elbow pain / / pha003008 rs4834359 chr4 114762343 A G 4.97E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6834503 chr4 114771175 T C 1.42E-04 Sudden cardiac arrest / / 21658281 rs6833434 chr4 114785784 C T 1.40E-04 Stroke / / pha002886 rs7441541 chr4 114788069 A G 1.77E-05 Elbow pain / / pha003008 rs10008543 chr4 114804068 G A 3.24E-04 Stroke / / pha002886 rs9994002 chr4 114805925 T C 8.64E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4466108 chr4 114839270 T C 7.98E-05 Stroke ARSJ intron pha002886 rs11729299 chr4 114856175 C T 2.40E-08 Health and aging,CVD and cancer age of onset ARSJ intron 22174011 rs11729299 chr4 114856175 C T 8.60E-07 Health and aging,CVD and cancer age of onset ARSJ intron 22174011 rs17677317 chr4 114856317 A G 1.89E-04 Type 2 diabetes ARSJ intron 17463246 rs4460079 chr4 114861300 C T 1.89E-04 Blood pressure measurement (high sodium and potassium intervention) ARSJ intron 24165912 rs4460079 chr4 114861300 C T 2.00E-07 Blood pressure measurement (high sodium and potassium intervention) ARSJ intron 24165912 rs4460079 chr4 114861300 C T 3.00E-06 Blood pressure measurement (high sodium and potassium intervention) ARSJ intron 24165912 rs7658266 chr4 114863706 T C 1.43E-05 Blood pressure measurement (high sodium and potassium intervention) ARSJ intron 24165912 rs7658266 chr4 114863706 T C 1.83E-05 Blood pressure measurement (high sodium intervention) ARSJ intron 24165912 rs7658266 chr4 114863706 T C 3.00E-07 Blood pressure measurement (high sodium intervention) ARSJ intron 24165912 rs7658266 chr4 114863706 T C 3.91E-07 Blood pressure measurement (high sodium and potassium intervention) ARSJ intron 24165912 rs7658266 chr4 114863706 T C 9.27E-04 Blood pressure measurement (high sodium and potassium intervention) ARSJ intron 24165912 rs12108332 chr4 114869624 T C 7.33E-04 Smoking cessation ARSJ intron 24665060 rs17484427 chr4 114869867 C G 4.90E-06 Urinary metabolites ARSJ intron 21572414 rs17677515 chr4 114876981 C A 2.70E-05 Urinary metabolites ARSJ intron 21572414 rs10012206 chr4 114877120 T C 1.84E-04 Alcohol dependence ARSJ intron 21314694 rs2374219 chr4 114885155 T C 1.30E-05 Urinary metabolites ARSJ intron 21572414 rs17677558 chr4 114893337 C A 9.04E-05 Cognitive test performance ARSJ intron 20125193 rs17677630 chr4 114905001 T G 3.22E-05 Cognitive test performance / / 20125193 rs882308 chr4 114946868 G A 8.40E-05 Height / / pha003010 rs882308 chr4 114946868 G A 8.90E-05 Height / / pha003011 rs7685641 chr4 114951988 C A 7.39E-04 Multiple complex diseases / / 17554300 rs4376209 chr4 114961812 A G 9.29E-05 Height / / pha003011 rs17046841 chr4 115046915 G A 2.29E-04 Multiple complex diseases / / 17554300 rs6854583 chr4 115053885 A C 0.0000646 alzheimer's disease (late onset) / / 22785395 rs4834390 chr4 115081354 C T 6.50E-04 Type 2 diabetes / / 17463246 rs17582094 chr4 115082623 G A 7.44E-04 Smoking cessation / / 24665060 rs3924717 chr4 115241544 G A 1.12E-04 Multiple complex diseases / / 17554300 rs11098234 chr4 115243741 G T 1.18E-04 Multiple complex diseases / / 17554300 rs7440091 chr4 115243896 T C 1.64E-04 Multiple complex diseases / / 17554300 rs10516601 chr4 115255278 G A 7.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12650585 chr4 115256817 A G 4.88E-04 Type 2 diabetes / / 17463246 rs12650585 chr4 115256817 A G 4.13E-04 Multiple complex diseases / / 17554300 rs11946964 chr4 115269275 G A 5.79E-04 Multiple complex diseases / / 17554300 rs4521415 chr4 115287484 T C 5.70E-05 Cognitive function / / 24684796 rs4989308 chr4 115289204 A G 2.58E-05 Blood Pressure / / pha003046 rs11935578 chr4 115316768 T G 3.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs13122887 chr4 115403684 C G 1.70E-04 Type 2 diabetes / / 17463246 rs6813229 chr4 115503877 A C 4.49E-04 Parkinson's disease / / 17052657 rs4834427 chr4 115600000 A G 8.64E-04 Alzheimer's disease / / 17998437 rs4834432 chr4 115620199 G C 4.44E-04 Alzheimer's disease / / 17998437 rs7438824 chr4 115629983 A G 4.53E-04 Type 2 diabetes / / 17463246 rs78557978 chr4 115638601 G C 4.09E-08 HDL cholesterol / / 24886709 rs12108602 chr4 115640569 A G 1.50E-07 Alcohol consumption / / 23953852 rs4833467 chr4 115667187 A G 3.49E-05 Body Mass Index / / pha002896 rs7690104 chr4 115673959 G A 5.49E-04 Alzheimer's disease / / 17998437 rs4356926 chr4 115697774 T C 3.59E-04 Taste perception / / 22132133 rs4574434 chr4 115739428 C T 9.48E-05 Bipolar disorder / / 22925353 rs4512014 chr4 115740908 T G 3.98E-04 Multiple complex diseases / / 17554300 rs12648047 chr4 115751064 C T 5.10E-05 Taste perception NDST4 intron 22132133 rs7666328 chr4 115783305 C T 5.97E-05 Glycosylated haemoglobin levels NDST4 intron 17255346 rs7673947 chr4 115805292 A G 4.00E-05 Iris characteristics NDST4 intron 21835309 rs17047475 chr4 115825004 A C 5.61E-04 Type 2 diabetes NDST4 intron 17463246 rs17486477 chr4 115844385 A G 2.69E-04 Lung function (forced vital capacity) NDST4 intron 24023788 rs2620424 chr4 115889765 G A 3.64E-04 Alzheimer's disease NDST4 intron 17998437 rs6820993 chr4 115897055 T G 8.29E-04 Type 2 diabetes NDST4 intron 17463246 rs1552025 chr4 115955380 G A 2.50E-05 Urinary metabolites NDST4 intron 21572414 rs13150562 chr4 115957593 T C 7.00E-06 Alcohol dependence NDST4 intron 19581569 rs505277 chr4 116028808 T C 4.35E-07 Reading disability and language impairment NDST4 intron 24024963 rs476739 chr4 116029548 A G 4.41E-07 Reading disability and language impairment NDST4 intron 24024963 rs482700 chr4 116067490 G A 1.40E-07 Reading disability and language impairment / / 24024963 rs1940309 chr4 116086961 T C 4.14E-07 Reading disability and language impairment / / 24024963 rs7695228 chr4 116090067 T G 2.94E-07 Reading disability and language impairment / / 24024963 rs6419195 chr4 116091961 C T 3.20E-06 Urinary metabolites / / 21572414 rs2000601 chr4 116099266 T G 1.80E-04 Sudden cardiac arrest LOC441035 intron 21658281 rs867035 chr4 116161974 C T 5.45E-07 Reading disability and language impairment / / 24024963 rs867035 chr4 116161974 C T 2.70E-04 Heart Failure / / pha002885 rs867036 chr4 116162129 C T 5.31E-07 Reading disability and language impairment / / 24024963 rs2048163 chr4 116164027 C T 2.58E-04 Heart Failure / / pha002885 rs1507939 chr4 116165372 C T 0.000291 Salmonella-induced pyroptosis / / 22837397 rs2135966 chr4 116172333 G T 4.59E-05 Heart Failure / / pha002885 rs7694946 chr4 116194139 C T 2.89E-05 Sudden cardiac arrest / / 21658281 rs7694946 chr4 116194139 C T 8.95E-06 Reading disability and language impairment / / 24024963 rs13144478 chr4 116196306 A T 6.00E-18 Resistin levels / / 22843503 rs13123243 chr4 116200743 A T 7.39E-05 Suicide attempts in bipolar disorder / / 21041247 rs6813599 chr4 116207294 T A 7.62E-05 Suicide attempts in bipolar disorder / / 21041247 rs2135965 chr4 116209467 G A 4.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs4464590 chr4 116216151 C T 9.16E-05 Suicide attempts in bipolar disorder / / 21041247 rs6853566 chr4 116218720 T C 5.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs10434023 chr4 116222017 C T 5.20E-04 Suicide attempts in bipolar disorder / / 21041247 rs1396064 chr4 116222801 G T 1.53E-04 Suicide attempts in bipolar disorder / / 21041247 rs10516611 chr4 116223870 T C 4.75E-06 Bilirubin levels,in serum / / 19389676 rs6533848 chr4 116228827 T G 1.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs7698264 chr4 116231191 T C 1.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs6533850 chr4 116234914 T A 1.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs1979975 chr4 116235952 G A 1.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs11098294 chr4 116236202 G C 1.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs17686110 chr4 116237539 A C 4.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs6851203 chr4 116239774 G A 1.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs10516610 chr4 116241218 T C 8.88E-05 Suicide attempts in bipolar disorder / / 21041247 rs6533852 chr4 116242246 T G 8.88E-05 Suicide attempts in bipolar disorder / / 21041247 rs1507942 chr4 116242598 A T 5.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs11727958 chr4 116243567 C T 1.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs1948983 chr4 116244797 G C 8.88E-05 Suicide attempts in bipolar disorder / / 21041247 rs4349617 chr4 116246368 T C 8.88E-05 Suicide attempts in bipolar disorder / / 21041247 rs4519812 chr4 116246663 G A 8.88E-05 Suicide attempts in bipolar disorder / / 21041247 rs7676815 chr4 116249589 C T 8.89E-05 Suicide attempts in bipolar disorder / / 21041247 rs7655124 chr4 116252911 C T 4.57E-04 Suicide attempts in bipolar disorder / / 21041247 rs6533855 chr4 116254112 A G 8.89E-05 Suicide attempts in bipolar disorder / / 21041247 rs13101335 chr4 116255344 G T 6.89E-05 Glycosylated haemoglobin levels / / 17255346 rs13101335 chr4 116255344 G T 8.89E-05 Suicide attempts in bipolar disorder / / 21041247 rs12650886 chr4 116261830 C T 5.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs7439118 chr4 116262453 C T 8.89E-05 Suicide attempts in bipolar disorder / / 21041247 rs13152496 chr4 116262602 A G 4.40E-06 Urinary metabolites / / 21572414 rs4834466 chr4 116263585 C G 8.89E-05 Suicide attempts in bipolar disorder / / 21041247 rs6821637 chr4 116264893 G T 8.91E-05 Suicide attempts in bipolar disorder / / 21041247 rs6828907 chr4 116266165 G C 4.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs6829587 chr4 116266582 C T 8.98E-05 Suicide attempts in bipolar disorder / / 21041247 rs12503088 chr4 116272201 G C 8.88E-05 Suicide attempts in bipolar disorder / / 21041247 rs6533856 chr4 116275707 G T 7.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs12651062 chr4 116279442 A G 4.20E-04 Suicide attempts in bipolar disorder / / 21041247 rs7437909 chr4 116282431 T C 3.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs10000358 chr4 116283010 A G 3.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs10023314 chr4 116283519 C T 5.56E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7685112 chr4 116289290 T C 3.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs7436414 chr4 116295493 G A 3.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs7663921 chr4 116298833 T C 3.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs4834470 chr4 116303849 C T 3.70E-04 Suicide attempts in bipolar disorder / / 21041247 rs7434366 chr4 116316350 A T 9.89E-05 Suicide attempts in bipolar disorder / / 21041247 rs6533870 chr4 116317919 A G 3.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs7687193 chr4 116320991 G A 3.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs12233647 chr4 116321359 A G 3.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs11933617 chr4 116323414 A G 3.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs11947264 chr4 116328636 T C 3.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs6814621 chr4 116328959 C A 3.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs4833478 chr4 116329740 A G 3.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs6836582 chr4 116332722 A G 3.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs7440324 chr4 116334990 T A 3.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs6847969 chr4 116339319 G A 3.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs6847471 chr4 116339355 A G 3.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs6854632 chr4 116340193 G A 3.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs6533889 chr4 116372779 T G 3.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs9997610 chr4 116391247 T A,G 1.12E-05 Brain structure / / 22504417 rs4597904 chr4 116457302 G A 6.90E-05 Personality dimensions / / 18957941 rs4129240 chr4 116505311 A G 7.77E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs4129240 chr4 116505311 A G 1.95E-05 Bilirubin levels,in serum / / 19389676 rs4590119 chr4 116507286 T C 0.0001 Migraine / / 22678113 rs12646836 chr4 116509945 G A 7.08E-06 Left ventricular mass / / 21212386 rs1545763 chr4 116530435 A G 6.26E-05 Glycosylated haemoglobin levels / / 17255346 rs1545763 chr4 116530435 A G 6.43E-04 Smoking quantity / / 24665060 rs10031115 chr4 116532413 A G 9.83E-04 Acute lung injury / / 22295056 rs6829682 chr4 116555138 C T 7.96E-05 Cytomegalovirus antibody response / / 21993531 rs41478747 chr4 116600649 A G 1.15E-04 Multiple complex diseases / / 17554300 rs10005313 chr4 116807543 G A 4.03E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10005313 chr4 116807543 G A 5.22E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7656260 chr4 116809546 T G 5.87E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7688382 chr4 116814100 T C 9.35E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6533942 chr4 116817963 A G 6.03E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6533942 chr4 116817963 A G 9.38E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6812672 chr4 116818662 A G 3.87E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6812672 chr4 116818662 A G 8.07E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9995393 chr4 116825225 T C 4.16E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9995393 chr4 116825225 T C 5.64E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7686539 chr4 116828127 G A 1.15E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7686539 chr4 116828127 G A 3.94E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1430936 chr4 116835648 G A 4.66E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1012863 chr4 116838151 G T 5.70E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7668874 chr4 116841324 T C 3.00E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7668874 chr4 116841324 T C 5.89E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11098326 chr4 116844501 G T 1.92E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11098326 chr4 116844501 G T 8.90E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6817737 chr4 116845661 T C 1.91E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6817737 chr4 116845661 T C 6.78E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6846333 chr4 116846148 C G 2.17E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6846333 chr4 116846148 C G 6.90E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10020267 chr4 116847777 C T 1.37E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10020267 chr4 116847777 C T 6.14E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10020294 chr4 116847858 C T 3.18E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10020294 chr4 116847858 C T 8.34E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1963399 chr4 116849282 T G 2.72E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1963399 chr4 116849282 T G 4.31E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9993212 chr4 116849436 T C 1.64E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9993212 chr4 116849436 T C 1.79E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2099222 chr4 116871502 T C 2.78E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17586843 chr4 116924184 T C 2.00E-06 Age-related macular degeneration / / 23326517 rs7676999 chr4 116934079 C T 1.00E-06 Age-related macular degeneration / / 23326517 rs17625325 chr4 116982102 C T 1.09E-04 Type 2 diabetes / / 17463246 rs814398 chr4 116999470 T A 9.46E-04 Type 2 diabetes / / 17463246 rs814397 chr4 116999572 T C 7.97E-04 Type 2 diabetes / / 17463246 rs814376 chr4 117032530 A G 2.70E-05 Urinary metabolites / / 21572414 rs2135579 chr4 117072013 G A 1.60E-06 Age-related macular degeneration / / 20861866 rs4834522 chr4 117187653 A G 1.88E-04 Sudden cardiac arrest / / 21658281 rs17688098 chr4 117227434 G A 1.63E-05 Sudden cardiac arrest / / 21658281 rs2389202 chr4 117254289 A T 4.00E-07 Sudden cardiac arrest / / 21658281 rs7685403 chr4 117259739 C T 8.60E-05 Sudden cardiac arrest / / 21658281 rs1489014 chr4 117272457 T C 3.47E-05 Sudden cardiac arrest / / 21658281 rs114918764 chr4 117370706 C T 3.65E-07 Prostate cancer / / 24185611 rs12503979 chr4 117445432 G A 2.41E-04 Alzheimer's disease / / 17998437 rs1425624 chr4 117451455 T C 4.07E-04 Alzheimer's disease / / 17998437 rs13124273 chr4 117568631 C T 3.96E-04 Lung function (forced vital capacity) / / 24023788 rs4591681 chr4 117572303 G A 0.000311 Salmonella-induced pyroptosis / / 22837397 rs13106251 chr4 117613353 A G 3.98E-05 Smoking cessation / / 24665060 rs4274920 chr4 117624139 C T 4.49E-04 Multiple complex diseases / / 17554300 rs4077693 chr4 117624880 T A 8.66E-05 Multiple complex diseases / / 17554300 rs13107698 chr4 117636735 C T 2.18E-04 Smoking cessation / / 24665060 rs17048757 chr4 117639394 T C 1.01E-04 Multiple complex diseases / / 17554300 rs12505044 chr4 117684349 G T 1.70E-05 Urinary metabolites / / 21572414 rs10024666 chr4 117690322 T C 6.25E-04 Type 2 diabetes / / 17463246 rs17633000 chr4 117707366 G A 2.70E-05 Urinary metabolites / / 21572414 rs12649281 chr4 117715353 G T 1.60E-06 Urinary metabolites / / 21572414 rs13114307 chr4 117716133 T G 2.10E-05 Urinary metabolites / / 21572414 rs4834587 chr4 117733077 G A 1.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1392764 chr4 117761449 G A 2.90E-05 Endometriosis / / 21151130 rs9997107 chr4 117771423 T C 3.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9684450 chr4 117785317 T G 2.96E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs2389339 chr4 117849449 G T 2.00E-06 IgG glycosylation / / 23382691 rs2389339 chr4 117849449 G T 3.00E-06 IgG glycosylation / / 23382691 rs17048904 chr4 117862520 C A 3.85E-04 Multiple complex diseases / / 17554300 rs11941869 chr4 117863273 G A 8.78E-04 Taste perception / / 22132133 rs5004750 chr4 117868648 C T 6.35E-04 Smoking cessation / / 24665060 rs717903 chr4 117868799 T C 4.71E-04 Taste perception / / 22132133 rs1440306 chr4 117875261 T G 1.00E-06 Bronchopulmonary dysplasia / / 23897914 rs1440306 chr4 117875261 T G 1.30E-06 Bronchopulmonary dysplasia / / 23897914 rs17048977 chr4 117951048 A G 4.62E-04 Alzheimer's disease / / 17998437 rs4834604 chr4 117976033 T C 7.57E-06 Alzheimer's disease / / 17998437 rs9918053 chr4 117992102 T C 9.15E-04 Multiple complex diseases / / 17554300 rs298944 chr4 118000844 A G 7.08E-04 Smoking cessation / / 24665060 rs1370734 chr4 118021130 C T 2.39E-04 Smoking cessation / / 24665060 rs2196712 chr4 118072289 G A 1.11E-04 Osteoarthritis (knee and hip) / / 21177295 rs2196712 chr4 118072289 G A 8.54E-05 Osteoarthritis (knee and hip) / / 21177295 rs2196712 chr4 118072289 G A 2.24E-06 Prostate cancer / / pha002877 rs2196712 chr4 118072289 G A 2.59E-05 Prostate cancer / / pha002878 rs10516635 chr4 118079907 G A 8.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs12644587 chr4 118081229 T C 4.80E-07 Post-operative nausea and vomiting / / 21694509 rs10433903 chr4 118093137 T C 3.00E-06 Obesity (extreme) / / 19553259 rs11098380 chr4 118093624 T C 2.16E-05 Prostate cancer / / pha002878 rs12644393 chr4 118190581 G A 4.36E-05 Prostate cancer / / pha002877 rs11930731 chr4 118208216 A G 0.000835292 Hypertension (early onset hypertension) / / 22479346 rs10033190 chr4 118215853 T C 1.00E-04 Information processing speed / / 21130836 rs9998109 chr4 118244984 A G 5.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4074599 chr4 118246863 G A 1.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6821599 chr4 118254869 A C 5.89E-04 Type 2 diabetes / / 17463246 rs6821599 chr4 118254869 A C 1.72E-04 Multiple complex diseases / / 17554300 rs17861803 chr4 118289409 C T 3.50E-05 Coffee consumption / / 21357676 rs17861811 chr4 118293651 C G 3.00E-06 Urinary metabolites / / 21572414 rs4318720 chr4 118332255 G A 8.00E-07 QT interval / / 20031603 rs12647933 chr4 118361707 T C 1.40E-05 Urinary metabolites / / 21572414 rs7679074 chr4 118384890 C T 5.40E-06 Urinary metabolites / / 21572414 rs4645284 chr4 118394656 C T 6.40E-06 Urinary metabolites / / 21572414 rs9999424 chr4 118416030 A G 1.00E-04 Prostate cancer / / 21743057 rs4304037 chr4 118417057 T G 7.30E-07 Urinary metabolites / / 21572414 rs7666064 chr4 118417970 A T 1.00E-04 Prostate cancer / / 21743057 rs4834618 chr4 118418659 A G 3.10E-07 Urinary metabolites / / 21572414 rs7679549 chr4 118420131 A G 4.10E-06 Urinary metabolites / / 21572414 rs2969625 chr4 118431407 A G 5.70E-06 Urinary metabolites / / 21572414 rs2635369 chr4 118431945 C T 7.70E-06 Urinary metabolites / / 21572414 rs2635190 chr4 118433639 C T 8.29E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs1489545 chr4 118435015 A G 6.10E-06 Urinary metabolites / / 21572414 rs2635240 chr4 118449352 C G 3.50E-06 Urinary metabolites / / 21572414 rs17866976 chr4 118449874 G A 8.00E-05 Prostate cancer / / 21743057 rs1948245 chr4 118454987 T C 2.50E-05 Urinary metabolites / / 21572414 rs1948246 chr4 118456117 A C,G 1.10E-05 Urinary metabolites / / 21572414 rs998817 chr4 118469570 G T 1.00E-05 Urinary metabolites / / 21572414 rs17865054 chr4 118469677 C T 8.00E-05 Prostate cancer / / 21743057 rs10003442 chr4 118472222 A G 8.00E-05 Prostate cancer / / 21743057 rs11562916 chr4 118475602 G A 8.00E-05 Prostate cancer / / 21743057 rs11562934 chr4 118483198 C A 4.46E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11562866 chr4 118492252 C T 4.46E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11732304 chr4 118500850 G A 8.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13129382 chr4 118505637 C T 2.88E-05 Hodgkin's lymphoma / / 24149102 rs13135130 chr4 118513265 A G 9.13E-05 Hepatocellular carcinoma / / 22807686 rs2130238 chr4 118516983 T C 9.95E-05 Schizophrenia / / 24253340 rs2635205 chr4 118560655 A G 1.98E-05 Psoriasis / / 20953190 rs17867526 chr4 118570180 G A 1.94E-05 Podoconiosis / / 22455414 rs17863889 chr4 118571489 T G 2.20E-05 Urinary metabolites / / 21572414 rs7665129 chr4 118594451 T C 3.92E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7677505 chr4 118608729 C T 1.65E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1380376 chr4 118636270 A G 8.04E-05 Pancreatic cancer / / pha002889 rs1459544 chr4 118638573 T G 9.24E-05 Pancreatic cancer / / pha002889 rs10009424 chr4 118641047 T G 3.17E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11098403 chr4 118646907 A G 3.00E-08 Schizophrenia / / 24253340 rs11098403 chr4 118646907 A G 6.55E-09 Schizophrenia / / 24253340 rs11562926 chr4 118650042 T C 1.95E-08 Schizophrenia / / 24253340 rs4422476 chr4 118651823 T C 8.00E-06 Neutrophil count / / 21507922 rs1870481 chr4 118663020 C T 1.23E-07 Colorectal cancer / / 24978480 rs1870482 chr4 118663111 G T 4.86E-05 Body Composition / / pha003012 rs7678262 chr4 118663416 A G 6.41E-08 Schizophrenia / / 24253340 rs9307440 chr4 118664503 G A 8.68E-08 Schizophrenia / / 24253340 rs936437 chr4 118666423 G A 1.02E-05 Multiple complex diseases / / 17554300 rs11945758 chr4 118667234 G T 8.44E-08 Schizophrenia / / 24253340 rs11562835 chr4 118667520 G A 9.58E-05 Bipolar disorder and schizophrenia / / 20889312 rs6838128 chr4 118681261 G A 4.17E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1350618 chr4 118689954 G A 6.40E-08 Schizophrenia / / 24253340 rs1023890 chr4 118701446 G A 5.61E-08 Colorectal cancer / / 24978480 rs4585377 chr4 118705004 T C 7.85E-08 Schizophrenia / / 24253340 rs2169059 chr4 118707190 C A 2.04E-07 Colorectal cancer / / 24978480 rs2125709 chr4 118707424 G A 1.28E-07 Schizophrenia / / 24253340 rs4377657 chr4 118722033 C T 4.32E-08 Schizophrenia / / 24253340 rs4377657 chr4 118722033 C T 2.35E-05 Body Composition / / pha003012 rs4377657 chr4 118722033 C T 9.14E-05 Body Mass Index / / pha003021 rs994619 chr4 118731430 C T 8.06E-08 Schizophrenia / / 24253340 rs6819399 chr4 118736834 G T 1.84E-07 Schizophrenia / / 24253340 rs6852960 chr4 118741585 C T 9.45E-08 Schizophrenia / / 24253340 rs1459528 chr4 118750348 T C 4.57E-07 Colorectal cancer / / 24978480 rs4429786 chr4 118752073 T C 1.35E-07 Schizophrenia / / 24253340 rs4597906 chr4 118758795 C T 9.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs4597906 chr4 118758795 C T 5.62E-07 Schizophrenia / / 24253340 rs3987 chr4 118759055 A G 4.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs3987 chr4 118759055 A G 4.02E-08 Colorectal cancer / / 24978480 rs10031919 chr4 118759228 T C 4.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs7676593 chr4 118763497 C T 4.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs4580717 chr4 118766190 T C 6.73E-05 Bipolar disorder and schizophrenia / / 20889312 rs10006167 chr4 118767115 A G 9.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs12640486 chr4 118770660 C T 9.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs12640486 chr4 118770660 C T 2.14E-05 Body Composition / / pha003012 rs10018600 chr4 118776858 A T 8.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs4580714 chr4 118777687 G A 1.31E-06 Schizophrenia / / 24253340 rs4580714 chr4 118777687 G A 2.05E-05 Body Composition / / pha003012 rs4580714 chr4 118777687 G A 9.71E-05 Body Mass Index / / pha003021 rs12503813 chr4 118784946 C T 5.82E-06 Schizophrenia / / 24253340 rs7675389 chr4 118789858 T C 5.92E-06 Schizophrenia / / 24253340 rs4131119 chr4 118802784 G A 4.71E-07 Schizophrenia / / 24253340 rs6534063 chr4 118803489 A G 3.60E-07 Schizophrenia / / 24253340 rs936891 chr4 118863268 A G 8.49E-04 Multiple complex diseases / / 17554300 rs10034085 chr4 118869326 G T 1.04E-04 Atopy / / 21625490 rs10024875 chr4 118887526 T C 8.83E-05 Serum metabolites / / 19043545 rs11098416 chr4 118891359 G A 8.00E-04 Multiple complex diseases / / 17554300 rs11098416 chr4 118891359 G A 2.60E-04 B cell non-Hodgkin lymphoma / / 23749188 rs10021128 chr4 118990143 C G 2.00E-05 Age-related macular degeneration NDST3 intron 20861866 rs2389527 chr4 119022299 C T 5.18E-04 Multiple complex diseases NDST3 intron 17554300 rs6851494 chr4 119054788 G C 4.97E-04 Alzheimer's disease NDST3 intron 17998437 rs6851494 chr4 119054788 G C 5.31E-04 Alzheimer's disease NDST3 intron 22005930 rs2140475 chr4 119121473 T C 4.29E-04 Alzheimer's disease NDST3 intron 22005930 rs2892799 chr4 119124720 T C 4.26E-04 Alzheimer's disease NDST3 intron 22005930 rs17049695 chr4 119160676 C T 9.75E-30 Narcolepsy NDST3 intron 19629137 rs11722450 chr4 119308603 T C 9.74E-05 Stroke / / pha002887 rs6836144 chr4 119376022 A C 5.36E-25 Gender / / 22362730 rs17642621 chr4 119408351 G A 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs17642621 chr4 119408351 G A 4.36E-04 Alcohol dependence / / 24277619 rs4833582 chr4 119422113 C T 3.94E-06 Brachial circumference / / 22479309 rs6823449 chr4 119499721 A G 9.02E-05 Serum metabolites / / 19043545 rs6823449 chr4 119499721 A G 2.50E-05 Urinary metabolites / / 21572414 rs7656990 chr4 119508720 C T 2.60E-05 Urinary metabolites / / 21572414 rs10022024 chr4 119511022 T G 2.60E-05 Urinary metabolites / / 21572414 rs7692721 chr4 119613917 C G 1.56E-04 Type 2 diabetes METTL14 intron 17463246 rs7692721 chr4 119613917 C G 4.93E-05 Serum metabolites METTL14 intron 19043545 rs2029399 chr4 119630327 C T 8.45E-05 Serum metabolites METTL14 intron 19043545 rs6818055 chr4 119639701 C T 2.50E-04 Type 2 diabetes / / 17463246 rs298988 chr4 119648399 A G 7.80E-05 Blood Pressure and Arterial Stiffness SEC24D intron 17903302 rs6857285 chr4 119650630 G C 8.62E-04 Type 2 diabetes SEC24D intron 17463246 rs6857285 chr4 119650630 G C 9.50E-05 Serum metabolites SEC24D intron 19043545 rs2046779 chr4 119653822 G C 3.92E-04 Type 2 diabetes SEC24D intron 17463246 rs2046779 chr4 119653822 G C 3.17E-05 Serum metabolites SEC24D intron 19043545 rs6847706 chr4 119661552 G C 9.29E-04 Type 2 diabetes SEC24D intron 17463246 rs13114964 chr4 119667184 A G 6.29E-04 Alzheimer's disease SEC24D intron 22005930 rs4572856 chr4 119676138 G A 9.26E-05 Multiple complex diseases SEC24D intron 17554300 rs12505513 chr4 119695102 A G 5.40E-04 Alzheimer's disease SEC24D intron 22005930 rs13120798 chr4 119708441 A T 5.85E-04 Alzheimer's disease SEC24D intron 22005930 rs11098450 chr4 119714711 A G 5.29E-04 Alzheimer's disease SEC24D intron 22005930 rs7670182 chr4 119716338 G A 3.17E-05 Serum metabolites SEC24D intron 19043545 rs10518324 chr4 119717713 T C 4.73E-04 Alzheimer's disease SEC24D intron 22005930 rs10518323 chr4 119718085 G A,C,T 4.77E-04 Alzheimer's disease SEC24D intron 22005930 rs10518322 chr4 119718479 T G 5.04E-04 Alzheimer's disease SEC24D intron 22005930 rs17258830 chr4 119725543 A T 3.83E-05 Multiple complex diseases SEC24D intron 17554300 rs2303512 chr4 119726733 T G 2.36E-04 Alzheimer's disease SEC24D intron 22005930 rs2303513 chr4 119726949 G A 2.71E-04 Alzheimer's disease SEC24D intron 22005930 rs4833592 chr4 119731348 G T 9.59E-04 Alzheimer's disease SEC24D intron 22005930 rs4834706 chr4 119733366 T C 8.20E-05 Magnesium levels SEC24D intron pha003092 rs2389688 chr4 119736796 A C 7.71E-05 Serum metabolites SEC24D cds-synon 19043545 rs2389688 chr4 119736796 A C 2.50E-05 Urinary metabolites SEC24D cds-synon 21572414 rs4833593 chr4 119759568 A G 7.15E-04 Alzheimer's disease / / 22005930 rs10857061 chr4 119781338 C T 2.19E-06 Smoking cessation / / 18519826 rs4834710 chr4 119791446 C G 9.82E-04 Alzheimer's disease / / 22005930 rs4834711 chr4 119793776 C T 4.91E-04 Alzheimer's disease / / 22005930 rs6534110 chr4 119800081 T C 6.22E-05 Major depressive disorder / / 21621269 rs11722846 chr4 119806938 G A 4.15E-04 Type 2 diabetes / / 17463246 rs13117019 chr4 119811735 T C 1.49E-04 Smoking cessation SYNPO2 intron 18519826 rs10518319 chr4 119812197 T C 2.88E-05 Smoking cessation SYNPO2 intron 18519826 rs10518319 chr4 119812197 T C 3.55E-08 Smoking cessation SYNPO2 intron 18519826 rs1472066 chr4 119863476 A G 8.00E-06 IgE levels in asthmatics SYNPO2 intron 23967269 rs4834729 chr4 119865067 C T 4.36E-04 Alcohol dependence SYNPO2 intron 21314694 rs4261974 chr4 119870169 A C 0.0000797 Transmission distortion SYNPO2 intron 22377632 rs1038770 chr4 119874487 G A 8.66E-06 IgE levels in asthmatics SYNPO2 intron 23967269 rs12508843 chr4 119877794 T G 1.10E-05 IgE levels in asthmatics SYNPO2 intron 23967269 rs10518316 chr4 119883564 A G 2.10E-05 Weight loss (gastric bypass surgery) SYNPO2 intron 23643386 rs7698598 chr4 119951647 A G 2.00E-06 Amyotrophic lateral sclerosis (sporadic) SYNPO2 missense 24529757 rs2279506 chr4 119954710 A G 9.28E-05 Information processing speed SYNPO2 UTR-3 21130836 rs3733513 chr4 119955632 A G 5.16E-04 Coronary heart disease SYNPO2 UTR-3 21971053 rs752097 chr4 119956089 G A 5.90E-04 Suicide attempts in bipolar disorder SYNPO2 UTR-3 21423239 rs1870423 chr4 119960818 C T 6.39E-04 Suicide attempts in bipolar disorder SYNPO2 intron 21423239 rs13137064 chr4 119971043 C T 9.79E-04 Multiple complex diseases SYNPO2 intron 17554300 rs11098478 chr4 120005101 T C 2.70E-05 Urinary metabolites / / 21572414 rs11736059 chr4 120017786 A G 1.00E-05 Urinary metabolites / / 21572414 rs6534127 chr4 120047837 A G 7.37E-05 Serum metabolites / / 19043545 rs1459062 chr4 120049658 G A 8.65E-04 Type 2 diabetes / / 17463246 rs1459060 chr4 120049798 A C 7.83E-04 Type 2 diabetes / / 17463246 rs1459060 chr4 120049798 A C 6.27E-05 Serum metabolites / / 19043545 rs6829055 chr4 120072275 G C 6.43E-04 Multiple complex diseases MYOZ2 intron 17554300 rs7669431 chr4 120077220 A G 8.87E-04 Multiple complex diseases MYOZ2 intron 17554300 rs9996382 chr4 120151012 A G 1.81E-04 Type 2 diabetes USP53 intron 17463246 rs10031033 chr4 120151452 T C 2.85E-04 Type 2 diabetes USP53 intron 17463246 rs11944880 chr4 120159334 C T 5.41E-04 Multiple complex diseases USP53 intron 17554300 rs7356185 chr4 120167111 T C 0.000141 Coronary artery disease USP53 intron 23202125 rs11098499 chr4 120187611 C T 9.00E-06 Corneal astigmatism USP53 intron 23322567 rs3749591 chr4 120214030 T G 9.85E-04 Glycosylated haemoglobin levels USP53 missense 17255346 rs17050351 chr4 120233152 C G 4.73E-168 Multiple complex diseases / / 17554300 rs17050312 chr4 120235686 C T 7.94E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1546505 chr4 120241224 A G 8.00E-05 Diabetic nephropathy FABP2 intron pha002866 rs10213554 chr4 120260785 G A 1.16E-04 Diabetic nephropathy / / pha002866 rs4309825 chr4 120314881 A G 8.00E-05 Diabetic nephropathy / / pha002866 rs11098514 chr4 120317374 T C 9.10E-05 Diabetic nephropathy / / pha002866 rs11098524 chr4 120390032 A G 7.70E-05 Diabetic nephropathy LOC645513 intron pha002866 rs9993199 chr4 120392873 G A 9.80E-05 Diabetic nephropathy LOC645513 intron pha002866 rs2389803 chr4 120393511 G A 1.12E-04 Diabetic nephropathy LOC645513 intron pha002866 rs1480931 chr4 120395809 C A 1.11E-04 Diabetic nephropathy LOC645513 intron pha002866 rs10518329 chr4 120401835 A G 1.12E-04 Diabetic nephropathy LOC645513 intron pha002866 rs10006706 chr4 120409152 T C 6.60E-05 Diabetic nephropathy LOC645513 intron pha002866 rs6849561 chr4 120409694 G C 7.90E-05 Diabetic nephropathy LOC645513 intron pha002866 rs12508504 chr4 120410607 A C 9.80E-05 Diabetic nephropathy LOC645513 intron pha002866 rs12510138 chr4 120423935 G C 7.60E-05 Diabetic nephropathy PDE5A intron pha002866 rs4834779 chr4 120425246 G A 2.17E-04 HIV-1 viral setpoint PDE5A intron 17641165 rs7692994 chr4 120427489 C A 9.68E-04 Obesity (extreme) PDE5A intron 21935397 rs1383532 chr4 120434404 T A 6.00E-05 Diabetic nephropathy PDE5A intron pha002866 rs6534139 chr4 120449456 G A 4.40E-05 Diabetic nephropathy PDE5A intron pha002866 rs6835635 chr4 120458867 T C 3.70E-05 Diabetic nephropathy PDE5A intron pha002866 rs13128602 chr4 120459366 A G 3.70E-05 Diabetic nephropathy PDE5A intron pha002866 rs1552095 chr4 120460306 T C 3.70E-05 Diabetic nephropathy PDE5A intron pha002866 rs1010740 chr4 120463409 T C 3.70E-05 Diabetic nephropathy PDE5A intron pha002866 rs3736115 chr4 120488703 G A 2.10E-05 Diabetic nephropathy PDE5A intron pha002866 rs17050695 chr4 120489527 G T 5.00E-05 Diabetic nephropathy PDE5A intron pha002866 rs2389866 chr4 120515263 C T 2.12E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses PDE5A intron 17903301 rs28681016 chr4 120529930 A G 4.97E-04 Multiple complex diseases PDE5A intron 17554300 rs2389882 chr4 120566733 A C 7.43E-04 Obesity (extreme) / / 21935397 rs2389883 chr4 120567635 C T 4.69E-04 Multiple complex diseases / / 17554300 rs2389886 chr4 120570422 G A 7.21E-04 Obesity (extreme) / / 21935397 rs2389887 chr4 120570644 T C 7.19E-04 Obesity (extreme) / / 21935397 rs10022185 chr4 120571765 C G 7.16E-04 Obesity (extreme) / / 21935397 rs7664440 chr4 120578540 A G 6.33E-04 Obesity (extreme) / / 21935397 rs12642411 chr4 120580525 T C 6.49E-04 Obesity (extreme) / / 21935397 rs17051356 chr4 120585308 C T 6.11E-04 Obesity (extreme) / / 21935397 rs4833624 chr4 120585497 C T 0.000519492 Hypertension (early onset hypertension) / / 22479346 rs4833624 chr4 120585497 C T 5.12E-05 Personality dimensions / / 23903073 rs12512646 chr4 120585733 G A 0.000519492 Hypertension (early onset hypertension) / / 22479346 rs17051362 chr4 120587896 T G 7.14E-05 Panic disorder / / 19165232 rs1986695 chr4 120589750 A C 1.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2389894 chr4 120598068 A G 3.23E-05 Cognitive impairment induced by topiramate / / 22091778 rs2389894 chr4 120598068 A G 3.66E-05 Cognitive impairment induced by topiramate / / 22091778 rs2389894 chr4 120598068 A G 4.22E-06 Cognitive impairment induced by topiramate / / 22091778 rs2253534 chr4 120605031 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2253534 chr4 120605031 A G 1.60E-05 Cognitive impairment induced by topiramate / / 22091778 rs2253534 chr4 120605031 A G 4.68E-05 Cognitive impairment induced by topiramate / / 22091778 rs2715023 chr4 120609868 G A 2.75E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2583612 chr4 120612718 C T 7.00E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12510467 chr4 120618359 G A 3.40E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4094 chr4 120619421 T G 3.16E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12502919 chr4 120635917 C T 3.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2714982 chr4 120665038 T G 3.55E-06 Cognitive impairment induced by topiramate / / 22091778 rs2389957 chr4 120695322 T C 5.00E-04 Chronic fatigue syndrome / / 21912186 rs10030662 chr4 120716184 T C 4.34E-04 Multiple complex diseases / / 17554300 rs13114426 chr4 120723085 C T 1.95E-04 Longevity (90 years and older) / / 24688116 rs17363983 chr4 120756608 T G 2.56E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs7690791 chr4 120758258 A G 6.37E-04 Alzheimer's disease / / 24755620 rs6856110 chr4 120759381 C G 2.37E-04 Alzheimer's disease / / 24755620 rs7688177 chr4 120760872 T C 2.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs11941391 chr4 120770947 C A 9.88E-04 Type 2 diabetes / / 17463246 rs1124166 chr4 120773133 T C 7.56E-04 Type 2 diabetes / / 17463246 rs17006982 chr4 120788956 G A 5.86E-04 Alzheimer's disease / / 24755620 rs6857703 chr4 120811883 C T 9.62E-04 Multiple complex diseases / / 17554300 rs9790431 chr4 120825963 T C 8.18E-05 Blood pressure / / 17255346 rs12508689 chr4 120847421 G A 4.40E-06 Blood pressure / / 17255346 rs41390552 chr4 120892803 A C 3.44E-04 Type 2 diabetes / / 17463246 rs41390552 chr4 120892803 A C 2.20E-06 Urinary metabolites / / 21572414 rs1967118 chr4 120946900 C T 1.80E-05 Urinary metabolites / / 21572414 rs1420614 chr4 120947398 G A 2.40E-05 Urinary metabolites / / 21572414 rs6812603 chr4 120948353 C T 3.09E-04 Type 2 diabetes / / 17463246 rs10006038 chr4 120953245 T C 5.00E-06 Asthma / / 21790008 rs1845344 chr4 120962385 G T 5.78E-04 Parkinson's disease / / 17052657 rs1845344 chr4 120962385 G T 7.00E-06 F-cell distribution / / 21326311 rs1845344 chr4 120962385 G T 7.79E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs13126255 chr4 120972981 A T 1.58E-04 Type 2 diabetes / / 17463246 rs13126255 chr4 120972981 A T 2.95E-05 Personality dimensions / / 18957941 rs2908989 chr4 120983259 T C 4.13E-04 Type 2 diabetes MAD2L1 intron 17463246 rs13121806 chr4 120990081 C T 8.56E-04 Type 2 diabetes / / 17463246 rs1493682 chr4 121041286 T G 6.00E-06 HIV-1 viral setpoint / / 22174851 rs4568220 chr4 121055452 T G 3.16E-04 Type 2 diabetes / / 17463246 rs9684604 chr4 121164119 G A 8.80E-06 Urinary metabolites / / 21572414 rs17012481 chr4 121185834 C T 1.34E-04 Multiple complex diseases / / 17554300 rs17394655 chr4 121272795 G C 2.90E-05 Urinary metabolites / / 21572414 rs4834842 chr4 121277392 T C 2.60E-05 Urinary metabolites / / 21572414 rs7683090 chr4 121283480 G A 5.73E-05 Intelligence / / 21826061 rs1448065 chr4 121323123 A G 2.24E-06 Body Mass Index / / pha003022 rs1405240 chr4 121342283 C T 2.34E-06 Body Mass Index / / pha003022 rs705112 chr4 121387642 T C 9.33E-05 Orofacial clefts / / 22419666 rs705114 chr4 121447894 A T 4.34E-04 Multiple complex diseases / / 17554300 rs4833167 chr4 121470002 G T 2.94E-04 Kawasaki disease / / 21326860 rs4833652 chr4 121474572 A G 3.41E-05 Nicotine smoking / / 19268276 rs4395533 chr4 121481950 G A 2.08E-05 F-cell distribution / / 21326311 rs10017284 chr4 121513215 A G 6.00E-06 F-cell distribution / / 21326311 rs11098579 chr4 121538689 A G 5.96E-04 Alzheimer's disease / / 22005930 rs17342461 chr4 121540763 T C 3.62E-04 Alzheimer's disease / / 22005930 rs11736846 chr4 121546342 G A 0.0000667 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13108928 chr4 121548174 A C 0.0000955 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35659163 chr4 121549998 G T 0.000091 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35947901 chr4 121550118 T C 0.0000906 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34128197 chr4 121550203 C T 0.0000945 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13124518 chr4 121550607 A T 0.0000896 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10518368 chr4 121550743 T C 0.0000895 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs67116157 chr4 121551068 A T 0.0000636 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs68063544 chr4 121551073 G C 0.0000631 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11734508 chr4 121551806 A C 0.0000668 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11727139 chr4 121551965 C G 0.0000865 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11732667 chr4 121552890 T C 0.0000856 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11732762 chr4 121553173 T C 0.0000843 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1948540 chr4 121553893 C T 0.0000814 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13121457 chr4 121555267 A C 0.0000784 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13149724 chr4 121555612 T C 0.0000779 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13104063 chr4 121556052 T G 0.0000752 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13128429 chr4 121556053 A G 0.000075 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2047298 chr4 121557637 C T 0.0000742 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs67545956 chr4 121558739 T C 0.0000749 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34091035 chr4 121559816 T C 0.0000748 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1390555 chr4 121560161 C T 0.0000607 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17402740 chr4 121560410 T C 0.000072 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17343362 chr4 121560535 G A 0.0000744 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13113003 chr4 121560941 A G 0.0000716 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs36007284 chr4 121561233 G A 0.0000685 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35683155 chr4 121561663 C T 0.0000681 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13114914 chr4 121561707 C A 0.000052 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13115111 chr4 121561783 C G 0.0000596 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13120782 chr4 121561934 G T 0.0000672 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13148103 chr4 121562114 T C 0.0000665 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13148327 chr4 121562217 T C 0.0000643 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1874441 chr4 121562809 A G 0.0000642 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11733018 chr4 121562821 G A 0.0000623 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1874440 chr4 121562991 C A 0.0000617 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11721967 chr4 121563701 T C 0.0000678 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs66610611 chr4 121563766 A C 0.0000592 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35097976 chr4 121563788 A T 0.0000587 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35880936 chr4 121563858 C A 0.000055 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34376177 chr4 121564276 T C 0.0000661 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs56193841 chr4 121564324 T C 0.0000658 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4543139 chr4 121566607 G T 0.0000483 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4543140 chr4 121566680 G A 0.0000681 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs148026762 chr4 121567373 C T 0.0000619 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34980755 chr4 121569962 C T 0.0000333 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35013646 chr4 121570533 C A 0.0000442 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs66538908 chr4 121570597 G A 0.000041 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17343622 chr4 121570810 C T 0.0000311 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10518370 chr4 121570981 T G 0.0000295 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11737109 chr4 121571144 G A 0.0000462 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11724927 chr4 121571185 T C 0.0000306 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11724930 chr4 121571201 T C 0.0000306 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11737151 chr4 121571446 C T 0.0000304 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13148917 chr4 121571622 C A 0.0000236 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13149281 chr4 121571649 G T 0.0000236 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34883201 chr4 121571725 T C 0.0000423 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13149334 chr4 121571796 C T 0.0000739 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs36148945 chr4 121571891 A G 0.0000322 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34537067 chr4 121571923 T C 0.0000349 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35130646 chr4 121573668 A T 0.0000408 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10518371 chr4 121573754 T C 0.0000375 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10518372 chr4 121573903 A G 0.0000311 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35514445 chr4 121573947 T C 0.0000317 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35883135 chr4 121574101 G T 0.000032 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs72674400 chr4 121574206 C T 0.0000519 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs72674402 chr4 121574207 A G 0.000052 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11732446 chr4 121574765 A T 0.0000361 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10518374 chr4 121574801 C T 0.0000362 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1496261 chr4 121575182 A G 0.0000469 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs67379024 chr4 121575850 C T 0.0000467 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17051185 chr4 121576280 C G 0.0000468 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs67799603 chr4 121576490 T C 0.0000417 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1908698 chr4 121576621 C T 0.000047 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1908697 chr4 121576654 A G 0.0000472 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1908696 chr4 121576765 T C 0.0000412 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35691521 chr4 121577105 C T 0.0000371 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34885860 chr4 121577696 C T 0.0000383 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34981703 chr4 121577699 T C 0.0000525 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35142371 chr4 121577829 C T 0.0000402 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34441682 chr4 121577893 T C 0.0000373 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13108644 chr4 121577949 G A 0.0000376 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13109673 chr4 121578557 C T 0.0000345 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13137585 chr4 121578759 T C 0.0000371 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34954787 chr4 121579243 A T 0.0000372 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11728109 chr4 121579273 T G 0.0000369 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35771660 chr4 121579447 C G 0.0000372 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35513623 chr4 121579530 C T 0.0000368 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34827843 chr4 121579776 C T 0.0000367 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4473670 chr4 121580142 C T 0.0000366 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4555666 chr4 121580445 G A 0.0000365 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs72676317 chr4 121580483 C G 0.0000365 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs67410634 chr4 121580855 A G 0.000036 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35247805 chr4 121580957 T C 0.0000361 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs67177335 chr4 121581169 T C 0.0000474 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs67521998 chr4 121581788 C A 0.0000362 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17403789 chr4 121583271 T C 0.000044 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17403845 chr4 121583471 G A 0.0000457 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35626362 chr4 121583673 C T 0.0000464 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34354392 chr4 121583805 G T 0.0000467 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34026717 chr4 121583839 T A 0.000048 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11733879 chr4 121584146 T C 0.0000496 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11729628 chr4 121584282 G T 0.0000496 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35045796 chr4 121584578 G A,T 0.0000547 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs67061841 chr4 121584631 T G 0.000059 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs67464100 chr4 121584770 T G 0.0000568 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs67781895 chr4 121584846 G A 0.0000598 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs67870439 chr4 121584970 G A 0.0000602 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17403950 chr4 121585479 G A 0.0000656 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17403971 chr4 121585510 A G 0.0000531 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12642805 chr4 121585939 G A 0.0000688 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17344584 chr4 121586344 T C 0.0000987 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17051206 chr4 121586756 C G 8.12E-04 Obesity (extreme) / / 21935397 rs1390559 chr4 121610489 A G 7.85E-04 Obesity (extreme) / / 21935397 rs13147093 chr4 121611505 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1948542 chr4 121623873 T C 9.22E-04 Multiple complex diseases PRDM5 intron 17554300 rs4833668 chr4 121625843 A G 1.06E-04 Suicide attempts in bipolar disorder PRDM5 intron 21423239 rs17345994 chr4 121627842 C T 1.13E-04 Suicide attempts in bipolar disorder PRDM5 intron 21423239 rs11721741 chr4 121629986 A G 2.30E-04 Suicide attempts in bipolar disorder PRDM5 intron 21423239 rs11730092 chr4 121630332 C T 2.74E-04 Suicide attempts in bipolar disorder PRDM5 intron 21423239 rs11721869 chr4 121630369 A G 3.19E-04 Suicide attempts in bipolar disorder PRDM5 intron 21423239 rs1397775 chr4 121633766 T C 4.30E-04 Suicide attempts in bipolar disorder PRDM5 intron 21423239 rs11732068 chr4 121637306 C T 3.19E-04 Suicide attempts in bipolar disorder PRDM5 intron 21423239 rs11732180 chr4 121637647 C T 2.17E-04 Suicide attempts in bipolar disorder PRDM5 intron 21423239 rs6838858 chr4 121642180 C T 1.42E-05 Menarche (age at onset) PRDM5 intron 19282985 rs843577 chr4 121645546 A G 6.44E-04 Multiple complex diseases PRDM5 intron 17554300 rs6813562 chr4 121684267 T C 9.27E-04 Amyotrophic lateral sclerosis (sporadic) PRDM5 intron 24529757 rs907297 chr4 121697884 C T 8.88E-05 Serum metabolites PRDM5 intron 19043545 rs11736662 chr4 121711828 G A 8.21E-04 Multiple complex diseases PRDM5 intron 17554300 rs2597540 chr4 121746232 T C 4.10E-05 Breast cancer PRDM5 intron 22452962 rs3115310 chr4 121774515 T C 1.50E-06 Urinary metabolites PRDM5 intron 21572414 rs180730 chr4 121801790 G A 5.00E-06 Fasting plasma glucose PRDM5 intron 17903298 rs180730 chr4 121801790 G A 6.00E-06 Fasting plasma glucose PRDM5 intron 17903298 rs17051280 chr4 121839142 C T 7.99E-04 Multiple complex diseases PRDM5 intron 17554300 rs1450459 chr4 121846467 A G 3.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10018902 chr4 121862501 G A 1.00E-06 Obesity-related traits / / 23251661 rs6855125 chr4 121889053 T C 6.54E-06 Obesity-related traits / / 23251661 rs12650193 chr4 121900882 C T 9.95E-04 Type 2 diabetes / / 17463246 rs12650193 chr4 121900882 C T 2.82E-04 Multiple complex diseases / / 17554300 rs2167205 chr4 121913912 T C 4.41E-04 Alzheimer's disease / / 22005930 rs2136949 chr4 121963231 C T 3.30E-04 Height NDNF intron 17255346 rs2136947 chr4 121988791 T C 4.18E-04 Multiple complex diseases NDNF intron 17554300 rs2136948 chr4 121995698 G A 7.64E-04 Multiple complex diseases / / 17554300 rs6846553 chr4 122053223 T C 2.43E-04 Taste perception TNIP3 UTR-3 22132133 rs6852366 chr4 122068605 G C 7.43E-04 Multiple complex diseases TNIP3 intron 17554300 rs13129450 chr4 122091233 T G 1.80E-04 HDL particle features TNIP3 intron 21283740 rs17051310 chr4 122106293 G A 2.00E-06 Breast cancer TNIP3 intron 23468962 rs921551 chr4 122110975 T C 2.00E-06 Breast cancer TNIP3 intron 23468962 rs17435444 chr4 122121494 A G 3.00E-07 Breast cancer TNIP3 intron 23468962 rs2278865 chr4 122151897 T C 3.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10012108 chr4 122161053 C T 0.000137 Salmonella-induced pyroptosis / / 22837397 rs12650479 chr4 122163552 T C 3.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13139732 chr4 122184667 C T 6.35E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1452493 chr4 122188858 G T 3.49E-04 Multiple complex diseases / / 17554300 rs1986022 chr4 122197904 C T 2.70E-05 Urinary metabolites / / 21572414 rs2390136 chr4 122238188 A G 1.20E-05 Urinary metabolites / / 21572414 rs12639850 chr4 122244597 G A 1.50E-05 Urinary metabolites / / 21572414 rs41375944 chr4 122258710 G T 3.61E-04 Type 2 diabetes QRFPR intron 17463246 rs4833714 chr4 122259038 T C 5.70E-04 Multiple complex diseases QRFPR intron 17554300 rs2276957 chr4 122261475 T C 4.85E-06 Hearing function QRFPR intron 21493956 rs12499677 chr4 122263138 A G 5.05E-06 Hearing function QRFPR intron 21493956 rs10857080 chr4 122264145 G A 5.09E-06 Hearing function QRFPR intron 21493956 rs17371707 chr4 122264739 G A 9.16E-04 Multiple complex diseases QRFPR intron 17554300 rs17371804 chr4 122265472 C T 9.42E-04 Multiple complex diseases QRFPR intron 17554300 rs13110738 chr4 122268413 G A 7.18E-04 Multiple complex diseases QRFPR intron 17554300 rs13144655 chr4 122269360 T C 6.57E-06 Hearing function QRFPR intron 21493956 rs4240259 chr4 122270493 C T 6.97E-04 Type 2 diabetes QRFPR intron 17463246 rs4240259 chr4 122270493 C T 7.89E-06 Hearing function QRFPR intron 21493956 rs13132035 chr4 122271282 A G 5.22E-04 Type 2 diabetes QRFPR intron 17463246 rs4833207 chr4 122271615 G A 1.52E-04 Multiple complex diseases QRFPR intron 17554300 rs6842600 chr4 122292481 G A 7.96E-05 Lipoprotein A [Lp(a)] levels in plasma QRFPR intron 21592478 rs523815 chr4 122300295 G A 5.20E-04 Alcohol dependence QRFPR intron 20201924 rs7679475 chr4 122314040 A G 8.35E-05 Information processing speed / / 21130836 rs1513695 chr4 122314785 A C 7.41E-05 Information processing speed / / 21130836 rs11932698 chr4 122387663 C T 3.85E-05 Type 2 diabetes and other traits / / 19734900 rs7679849 chr4 122397006 G A 3.12E-05 Type 2 diabetes and other traits / / 19734900 rs7671488 chr4 122399338 T C 2.56E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6534277 chr4 122400763 A G 3.48E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6534277 chr4 122400763 A G 4.58E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4833728 chr4 122406507 C T 6.64E-05 Tunica Media / / pha003037 rs10015843 chr4 122426180 A G 3.39E-04 Age-related macular degeneration / / 22125219 rs7660181 chr4 122429144 C T 7.39E-08 Metabolite levels / / 23281178 rs4833735 chr4 122429320 G A 9.24E-05 Coronary heart disease / / pha003030 rs4833736 chr4 122429378 G A 7.39E-08 Metabolite levels / / 23281178 rs7673847 chr4 122445005 T C 0.0000621 post-traumatic stress disorder / / 22869035 rs7673847 chr4 122445005 T C 6.21E-05 Schizophrenia / / 22883433 rs200748952 chr4 122446695 G T 0.0000966 post-traumatic stress disorder / / 22869035 rs35950299 chr4 122446695 G GT 0.0000966 post-traumatic stress disorder / / 22869035 rs397878254 chr4 122446695 G GT 0.0000966 post-traumatic stress disorder / / 22869035 rs12501209 chr4 122448971 T C 2.10E-05 Response to alcohol consumption (flushing response) / / 24277619 rs3923154 chr4 122459619 C T 1.03E-04 Acute lung injury / / 22295056 rs4460013 chr4 122462118 T A 5.46E-04 Acute lung injury / / 22295056 rs958518 chr4 122476726 T C 2.20E-05 Urinary metabolites / / 21572414 rs6832522 chr4 122479102 A C 2.70E-05 Urinary metabolites / / 21572414 rs1480280 chr4 122505308 G A 1.62E-04 Smoking initiation / / 24665060 rs4833753 chr4 122550874 G A 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs725882 chr4 122568322 A G 3.31E-04 Multiple complex diseases / / 17554300 rs725882 chr4 122568322 A G 1.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6534306 chr4 122569781 G A 2.68E-04 Multiple complex diseases / / 17554300 rs17051381 chr4 122569978 A G 1.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11723566 chr4 122570040 C A 5.80E-05 Intelligence (childhood) / / 23358156 rs2054539 chr4 122570707 G A 1.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10003585 chr4 122572851 C T 9.51E-05 Multiple complex diseases / / 17554300 rs10003585 chr4 122572851 C T 4.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2892948 chr4 122585137 A G 4.78E-04 Multiple complex diseases / / 17554300 rs3756281 chr4 122599249 G A 2.00E-04 Acute lymphoblastic leukemia (childhood) ANXA5 intron 20189245 rs11098637 chr4 122600471 G T 2.00E-04 Acute lymphoblastic leukemia (childhood) ANXA5 intron 20189245 rs1480287 chr4 122601781 C T 2.72E-04 Amyotrophic Lateral Sclerosis ANXA5 intron 17362836 rs6842386 chr4 122605522 T C 1.42E-04 Multiple complex diseases ANXA5 intron 17554300 rs55645543 chr4 122607178 T C 5.00E-07 Chronic obstructive pulmonary disease ANXA5 intron 21685187 rs13151539 chr4 122608681 A G 3.00E-04 Acute lymphoblastic leukemia (childhood) ANXA5 intron 20189245 rs6857766 chr4 122611285 G A 4.82E-04 Amyotrophic Lateral Sclerosis ANXA5 intron 17362836 rs6830321 chr4 122614755 C T 7.00E-05 Tunica Media ANXA5 intron pha003038 rs2306416 chr4 122617688 T C 4.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ANXA5 intron 20877124 rs7676539 chr4 122619946 G A 2.00E-04 Acute lymphoblastic leukemia (childhood) ANXA5 nearGene-5 20189245 rs2127644 chr4 122620150 A T 3.88E-04 Multiple complex diseases / / 17554300 rs1552069 chr4 122625935 T A 1.59E-04 Type 2 diabetes / / 17846124 rs17051396 chr4 122653098 G A 9.60E-04 Response to alcohol consumption (flushing response) / / 24277619 rs2390228 chr4 122662254 G A 4.10E-04 Obesity (extreme) / / 21935397 rs6815973 chr4 122663430 T A 1.61E-05 Multiple complex diseases / / 17554300 rs6815973 chr4 122663430 T A 7.50E-04 Depression (quantitative trait) / / 20800221 rs4283687 chr4 122663460 A G 6.26E-09 Red blood cell traits / / 23222517 rs28532673 chr4 122664323 G A 2.35E-05 Multiple complex diseases / / 17554300 rs7659604 chr4 122665514 C T 9.00E-06 Type 2 diabetes / / 17554300 rs7659604 chr4 122665514 C T 3.20E-07 Height / / 21194676 rs7659604 chr4 122665514 C T 5.60E-07 Height / / 21194676 rs7659604 chr4 122665514 C T 9.00E-06 Coronary heart disease / / 21347282 rs7659604 chr4 122665514 C T 9.00E-06 Type 2 diabetes / / 21647700 rs7659943 chr4 122665560 G A 2.01E-05 Multiple complex diseases / / 17554300 rs4833769 chr4 122672970 G T 1.15E-04 Multiple complex diseases / / 17554300 rs6822155 chr4 122673274 C A 5.16E-07 Red blood cell traits / / 23222517 rs4240264 chr4 122683818 A G 1.20E-04 Multiple complex diseases TMEM155 intron 17554300 rs4075065 chr4 122683906 T C 8.33E-05 Multiple complex diseases TMEM155 UTR-5 17554300 rs9993206 chr4 122686957 A G 1.72E-04 Multiple complex diseases / / 17554300 rs6534323 chr4 122695888 G A 3.47E-04 Depression (quantitative trait) / / 20800221 rs6534324 chr4 122697883 A G 8.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10007956 chr4 122700669 T A 8.58E-04 Multiple complex diseases / / 17554300 rs4833774 chr4 122706003 A G 8.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6819870 chr4 122713059 C A 3.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3811742 chr4 122722693 C G 7.64E-08 Red blood cell traits EXOSC9 intron 23222517 rs10023020 chr4 122724604 G A 2.47E-08 Red blood cell traits EXOSC9 intron 23222517 rs9998785 chr4 122728965 A T 4.06E-08 Red blood cell traits EXOSC9 intron 23222517 rs1803183 chr4 122735142 A G 5.85E-04 Response to taxane treatment (placlitaxel) EXOSC9 missense 23006423 rs3217772 chr4 122739183 C G 4.11E-07 Red blood cell traits CC/2 intron 23222517 rs3217753 chr4 122746325 A G 7.30E-05 Response to lithium treatment in bipolar disorder BBS7 UTR-3 19448189 rs3762840 chr4 122746596 A T 3.30E-07 Red blood cell traits BBS7 UTR-3 23222517 rs1048433 chr4 122748996 A C 1.23E-07 Red blood cell traits BBS7 UTR-3 23222517 rs13145213 chr4 122750079 C T 8.66E-08 Red blood cell traits BBS7 intron 23222517 rs13152701 chr4 122751061 G A 8.98E-10 Red blood cell traits BBS7 intron 23222517 rs13119055 chr4 122755162 T C 4.62E-08 Red blood cell traits BBS7 intron 23222517 rs17005256 chr4 122755245 A G 1.24E-07 Red blood cell traits BBS7 intron 23222517 rs12510839 chr4 122760968 G A 3.39E-08 Red blood cell traits BBS7 intron 23222517 rs10084948 chr4 122765649 C T 8.46E-08 Red blood cell traits BBS7 intron 23222517 rs9995319 chr4 122770677 G C 5.27E-07 Red blood cell traits BBS7 intron 23222517 rs11726196 chr4 122806228 A C 3.58E-04 Blood pressure TRPC3 intron 17255346 rs11726196 chr4 122806228 A C 9.86E-05 Pulmonary function TRPC3 intron 20010835 rs4833778 chr4 122837623 G A 9.80E-06 Urinary metabolites TRPC3 intron 21572414 rs950574 chr4 122864241 G A 8.68E-05 Cognitive test performance TRPC3 intron 20125193 rs1880863 chr4 122881942 A G 4.50E-05 Intelligence (childhood) / / 23358156 rs10032994 chr4 122893191 G A 5.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs10032994 chr4 122893191 G A 1.04E-06 Stroke (ischemic) / / 21957438 rs1358229 chr4 122896734 C T 0.0002532 Hypertension (early onset hypertension) / / 22479346 rs6838639 chr4 122899165 G A 9.38E-04 Alcohol dependence / / 21314694 rs7672750 chr4 122908126 C T 2.14E-04 Alzheimer's disease / / 22005930 rs1465040 chr4 122928256 T C 1.27E-06 Opioid sensitivity / / 23183491 rs1465041 chr4 122928286 T C 7.92E-05 Type 1 diabetes / / 18978792 rs1465041 chr4 122928286 T C 5.87E-04 Alzheimer's disease / / 22005930 rs17005387 chr4 122937198 G A 0.000026 Primary sclerosing cholangitis / / 22521342 rs1965582 chr4 122947939 G A 6.42E-05 Cognitive test performance / / 20125193 rs12649045 chr4 122957607 T C 7.57E-05 HDL cholesterol / / pha003075 rs1405485 chr4 122969254 C T 2.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs10516614 chr4 122973693 T C 3.06E-05 Rheumatoid arthritis / / 17804836 rs10516614 chr4 122973693 T C 5.03E-06 Rheumatoid arthritis / / 19503088 rs10516616 chr4 122974644 A G 5.19E-06 Rheumatoid arthritis / / 19503088 rs1997179 chr4 122984633 T C 4.01E-09 Celiac disease / / 24999842 rs17518038 chr4 122993500 A G 1.40E-04 Self-reported allergy / / 23817569 rs10021288 chr4 123005534 G A 7.39E-05 Self-reported allergy / / 23817569 rs4279237 chr4 123009174 A G 4.97E-05 Paget's disease / / 20436471 rs4279237 chr4 123009174 A G 1.58E-04 Self-reported allergy / / 23817569 rs13132933 chr4 123010587 T C 1.02E-09 Celiac disease / / 24999842 rs11936230 chr4 123016755 T C 0.000019 Primary sclerosing cholangitis / / 22521342 rs10015924 chr4 123019620 T C 1.95E-06 Multiple complex diseases / / 17554300 rs10015924 chr4 123019620 T C 2.31E-05 Multiple sclerosis / / 17660530 rs6534338 chr4 123026869 T C 3.80E-06 Self-reported allergy / / 23817569 rs6534340 chr4 123037548 A C 4.90E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs62323881 chr4 123038295 C A 8.60E-05 Celiac disease / / 22057235 rs62323881 chr4 123038295 C A 0.000086 Celiac disease / / 23143596 rs78560100 chr4 123041471 G C 0.00058 Rheumatoid arthritis / / 23143596 rs13132245 chr4 123049592 A G 0.00000012 Primary sclerosing cholangitis / / 22521342 rs1526923 chr4 123050770 A G 8.58E-04 Self-reported allergy / / 23817569 rs6835946 chr4 123069839 G A 3.69E-04 Self-reported allergy / / 23817569 rs11938795 chr4 123073009 T C 1.70E-04 Celiac disease / / 17558408 rs11938795 chr4 123073009 T C 9.56E-07 Celiac disease / / 24999842 rs4374642 chr4 123101111 T C 2.18E-08 Celiac disease and Rheumatoid arthritis KIAA1109 intron 21383967 rs13151961 chr4 123115502 A G 1.30E-12 Celiac disease KIAA1109 intron 17558408 rs13151961 chr4 123115502 A G 2.00E-27 Celiac disease KIAA1109 intron 20190752 rs13151961 chr4 123115502 A G 2.00E-27 Asthma KIAA1109 intron 21150878 rs13151961 chr4 123115502 A G 2.18E-27 Celiac disease and Rheumatoid arthritis KIAA1109 intron 21383967 rs13151961 chr4 123115502 A G 2.18E-27 Multiple sclerosis KIAA1109 intron 22190364 rs13151961 chr4 123115502 A G 3.00E-11 Celiac disease KIAA1109 intron 24999842 rs7671357 chr4 123126450 C A 4.12E-06 Self-reported allergy KIAA1109 intron 23817569 rs4505848 chr4 123132492 A G 5.00E-13 Type 1 diabetes KIAA1109 intron 19430480 rs4505848 chr4 123132492 A G 5.00E-13 Asthma KIAA1109 intron 21907864 rs4505848 chr4 123132492 A G 4.30E-06 Self-reported allergy KIAA1109 intron 23817569 rs7676847 chr4 123134170 A G 2.92E-04 Self-reported allergy KIAA1109 intron 23817569 rs7658836 chr4 123145751 T A 3.31E-04 Self-reported allergy KIAA1109 cds-synon 23817569 rs7664452 chr4 123146225 T G 3.41E-06 Self-reported allergy KIAA1109 intron 23817569 rs7657746 chr4 123161619 A G 3.00E-13 Inflammatory bowel disease KIAA1109 intron 23128233 rs6822038 chr4 123162842 G A 1.60E-04 Self-reported allergy KIAA1109 intron 23817569 rs4288027 chr4 123183205 A C 1.92E-08 Celiac disease and Rheumatoid arthritis KIAA1109 intron 21383967 rs6827756 chr4 123184411 T C 2.47E-06 Type 1 diabetes KIAA1109 intron 21980299 rs13147049 chr4 123193870 A G 1.63E-06 Self-reported allergy KIAA1109 intron 23817569 rs6534347 chr4 123198435 A G 2.00E-06 Type 1 diabetes KIAA1109 intron 17554300 rs6534347 chr4 123198435 A G 3.55E-05 Self-reported allergy KIAA1109 intron 23817569 rs13119723 chr4 123218313 A G 4.80E-11 Celiac disease KIAA1109 intron 17558408 rs13119723 chr4 123218313 A G 7.00E-07 Rheumatoid arthritis KIAA1109 intron 20453842 rs13119723 chr4 123218313 A G 2.18E-13 Celiac disease and Rheumatoid arthritis KIAA1109 intron 21383967 rs13119723 chr4 123218313 A G 0.000000099 Primary sclerosing cholangitis KIAA1109 intron 22521342 rs11734090 chr4 123228113 T C 2.30E-04 Celiac disease KIAA1109 intron 17558408 rs11734090 chr4 123228113 T C 6.16E-07 Celiac disease KIAA1109 intron 24999842 rs7688384 chr4 123229132 C T 4.32E-05 Self-reported allergy KIAA1109 cds-synon 23817569 rs7693745 chr4 123235583 A G 8.32E-08 Self-reported allergy KIAA1109 intron 23817569 rs4833821 chr4 123238669 T C 2.72E-04 Self-reported allergy KIAA1109 intron 23817569 rs6851362 chr4 123263446 T C 2.01E-07 Celiac disease KIAA1109 intron 24999842 rs7699742 chr4 123264485 T C 2.25E-06 Self-reported allergy KIAA1109 intron 23817569 rs11722421 chr4 123271668 G C 2.52E-06 Self-reported allergy KIAA1109 intron 23817569 rs1127348 chr4 123280860 T C 9.61E-07 Self-reported allergy KIAA1109 cds-synon 23817569 rs7678445 chr4 123282772 G T 9.33E-09 Celiac disease and Rheumatoid arthritis KIAA1109 intron 21383967 rs6814233 chr4 123314132 G T 5.86E-04 Self-reported allergy ADAD1 intron 23817569 rs4145717 chr4 123316076 G T 2.58E-06 Self-reported allergy ADAD1 intron 23817569 rs17388568 chr4 123329362 G A 3.00E-06 Type 1 diabetes ADAD1 intron 17554300 rs17388568 chr4 123329362 G A 9.00E-07 Ulcerative colitis ADAD1 intron 21297633 rs17388568 chr4 123329362 G A 6.00E-06 Type 1 diabetes autoantibodies ADAD1 intron 21829393 rs17388568 chr4 123329362 G A 1.87E-08 Multiple sclerosis ADAD1 intron 22190364 rs17388568 chr4 123329362 G A 1.39E-04 Arthritis (juvenile idiopathic) ADAD1 intron 22354554 rs17388568 chr4 123329362 G A 4.00E-08 Self-reported allergy ADAD1 intron 23817569 rs12499753 chr4 123333177 T C 6.78E-05 Arthritis (juvenile idiopathic) ADAD1 intron 22354554 rs12499753 chr4 123333177 T C 2.12E-06 Self-reported allergy ADAD1 intron 23817569 rs2086346 chr4 123333671 A G 1.39E-04 Multiple complex diseases ADAD1 intron 17554300 rs2086346 chr4 123333671 A G 3.98E-04 Self-reported allergy ADAD1 intron 23817569 rs1904522 chr4 123336918 G A 1.65E-06 Self-reported allergy ADAD1 intron 23817569 rs7684187 chr4 123341159 G A 5.60E-04 Celiac disease ADAD1 intron 17558408 rs17005728 chr4 123344695 A G 1.06E-04 Multiple complex diseases ADAD1 intron 17554300 rs17005728 chr4 123344695 A G 3.71E-04 Self-reported allergy ADAD1 intron 23817569 rs716501 chr4 123351925 G A 2.59E-06 Self-reported allergy / / 23817569 rs17454584 chr4 123353432 A G 1.45E-07 Self-reported allergy / / 23817569 rs17454584 chr4 123353432 A G 6.00E-10 Allergic sensitization / / 23817571 rs4833826 chr4 123353917 A G 3.52E-04 Self-reported allergy / / 23817569 rs3136534 chr4 123369776 T G 0.0000902 HDL cholesterol / / 23063622 rs3136534 chr4 123369776 T G 2.51E-06 Self-reported allergy / / 23817569 rs1479923 chr4 123370387 G A 1.12E-04 Multiple complex diseases / / 17554300 rs1479923 chr4 123370387 G A 2.77E-04 Self-reported allergy / / 23817569 rs2069772 chr4 123373133 T C 1.00E-06 IgE grass sensitization IL2 intron 22036096 rs2069772 chr4 123373133 T C 4.84E-08 Self-reported allergy IL2 intron 23817569 rs2069762 chr4 123377980 A C 5.00E-07 Type 1 diabetes autoantibodies IL2 nearGene-5 21829393 rs2069762 chr4 123377980 A C 2.33E-04 Self-reported allergy IL2 nearGene-5 23817569 rs4833248 chr4 123380405 G A 2.00E-04 Self-reported allergy / / 23817569 rs1479924 chr4 123387600 G A 0.000332 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis / / 23603761 rs1479924 chr4 123387600 G A 2.17E-09 Oligoarticular juvenile idiopathic arthritis / / 23603761 rs1479924 chr4 123387600 G A 6.24E-11 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs11724582 chr4 123391464 A G 1.73E-04 Arthritis (juvenile idiopathic) / / 22354554 rs17005786 chr4 123392271 C T 2.03E-04 Self-reported allergy / / 23817569 rs6848139 chr4 123395041 A C 4.02E-08 Celiac disease and Rheumatoid arthritis / / 21383967 rs7690352 chr4 123395076 A G 7.50E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs7690352 chr4 123395076 A G 2.40E-04 Self-reported allergy / / 23817569 rs11098659 chr4 123396028 T C 9.78E-05 Arthritis (juvenile idiopathic) / / 22354554 rs11098659 chr4 123396028 T C 2.32E-06 Self-reported allergy / / 23817569 rs45475795 chr4 123399491 A G 3.50E-06 Rheumatoid arthritis / / 24390342 rs45475795 chr4 123399491 A G 4.00E-06 Rheumatoid arthritis / / 24390342 rs7673567 chr4 123405984 T C 1.11E-04 Multiple complex diseases / / 17554300 rs4833829 chr4 123422341 G A 3.41E-04 Self-reported allergy / / 23817569 rs11725823 chr4 123425785 G C 1.44E-06 Self-reported allergy / / 23817569 rs6818415 chr4 123438014 A G 1.61E-04 Self-reported allergy / / 23817569 rs9790783 chr4 123439059 G A 1.70E-04 Self-reported allergy / / 23817569 rs4833832 chr4 123456627 G A 1.52E-04 Self-reported allergy / / 23817569 rs4833835 chr4 123470986 G T 8.80E-05 Self-reported allergy / / 23817569 rs6837165 chr4 123476243 A G 8.58E-05 Self-reported allergy / / 23817569 rs6852535 chr4 123478716 G A 1.00E-07 Progressive supranuclear palsy / / 21685912 rs6852535 chr4 123478716 G A 8.08E-05 Self-reported allergy / / 23817569 rs7670532 chr4 123487134 A G 8.52E-05 Self-reported allergy / / 23817569 rs17389644 chr4 123497697 G A 2.80E-07 Self-reported allergy / / 23817569 rs17005850 chr4 123497833 A G 3.36E-05 Multiple complex diseases / / 17554300 rs17005850 chr4 123497833 A G 9.00E-05 Self-reported allergy / / 23817569 rs13140464 chr4 123499745 G T 8.87E-13 Primary sclerosing cholangitis / / 23603763 rs4833836 chr4 123500669 T C 5.31E-05 Multiple complex diseases / / 17554300 rs4833836 chr4 123500669 T C 9.53E-05 Self-reported allergy / / 23817569 rs7681161 chr4 123501086 A G 1.01E-04 Self-reported allergy / / 23817569 rs12504008 chr4 123506351 T C 7.15E-04 Self-reported allergy / / 23817569 rs11098666 chr4 123507914 A G 1.90E-06 Self-reported allergy / / 23817569 rs12642902 chr4 123508501 G A 3.30E-05 Celiac disease / / 17558408 rs6822844 chr4 123509421 G T 1.00E-14 Celiac disease / / 17558408 rs6822844 chr4 123509421 G T 3.00E-13 Celiac disease / / 18311140 rs6822844 chr4 123509421 G T 1.64E-10 Celiac disease and Rheumatoid arthritis / / 21383967 rs6822844 chr4 123509421 G T 1.64E-10 Multiple sclerosis / / 22190364 rs6822844 chr4 123509421 G T 8.30E-04 Rheumatoid arthritis / / 22446963 rs6822844 chr4 123509421 G T 4.32E-09 Rheumatoid arthritis / / 23143596 rs6848834 chr4 123509713 T G 2.22E-06 Self-reported allergy / / 23817569 rs6829845 chr4 123510766 A G 9.40E-06 Urinary metabolites / / 21572414 rs6829845 chr4 123510766 A G 2.37E-05 Arthritis (juvenile idiopathic) / / 22354554 rs6829845 chr4 123510766 A G 2.25E-06 Self-reported allergy / / 23817569 rs6814458 chr4 123520842 G A 3.73E-06 Self-reported allergy / / 23817569 rs1398554 chr4 123522569 G A 2.96E-06 Self-reported allergy / / 23817569 rs7676741 chr4 123523441 G A 2.46E-06 Self-reported allergy / / 23817569 rs7682241 chr4 123523875 G T 4.00E-08 Alopecia areata / / 20596022 rs7682481 chr4 123524026 G C 1.87E-04 Multiple complex diseases / / 17554300 rs7682481 chr4 123524026 G C 3.10E-04 Rheumatoid arthritis / / 24782177 rs1512971 chr4 123525335 C T 1.31E-04 Multiple complex diseases / / 17554300 rs9992580 chr4 123526195 T G 4.10E-06 Self-reported allergy / / 23817569 rs925549 chr4 123530993 C T 4.80E-06 Urinary metabolites / / 21572414 rs925549 chr4 123530993 C T 1.37E-04 Arthritis (juvenile idiopathic) / / 22354554 rs925549 chr4 123530993 C T 4.88E-06 Self-reported allergy / / 23817569 rs2221903 chr4 123538912 C T 4.89E-06 Self-reported allergy IL21 intron 23817569 rs1398553 chr4 123548068 A G 3.15E-06 Self-reported allergy / / 23817569 rs13132308 chr4 123551114 A G 1.90E-38 Celiac disease / / 22057235 rs13132308 chr4 123551114 A G 1.90E-38 Celiac disease / / 23143596 rs2893008 chr4 123552814 A G 6.91E-07 Celiac disease and Rheumatoid arthritis / / 21383967 rs6840978 chr4 123554707 C T 2.34E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6840978 chr4 123554707 C T 1.10E-10 Celiac disease / / 17558408 rs6840978 chr4 123554707 C T 5.07E-13 Celiac disease and Rheumatoid arthritis / / 21383967 rs6840978 chr4 123554707 C T 1.60E-05 Urinary metabolites / / 21572414 rs6840978 chr4 123554707 C T 7.92E-10 Celiac disease / / 24999842 rs1913190 chr4 123554829 A G 8.39E-04 Self-reported allergy / / 23817569 rs17005953 chr4 123556241 C T 4.90E-04 Type 2 diabetes / / 17463246 rs1533236 chr4 123564458 T C 5.10E-05 Cognitive impairment induced by topiramate / / 22091778 rs17006012 chr4 123585547 G C 2.09E-07 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs7664318 chr4 123599124 A G 4.11E-06 Alopecia areata / / 22027810 rs309388 chr4 123610112 T C 4.18E-08 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs13138426 chr4 123652580 C T 2.60E-04 Endometrial cancer CETN4P intron 24096698 rs13138426 chr4 123652580 C T 3.39E-04 Endometrial cancer CETN4P intron 24096698 rs309364 chr4 123658859 G A 8.34E-04 Lymphocyte counts BBS12 intron 22286170 rs13135778 chr4 123664446 G A 1.23E-04 Endometrial cancer BBS12 missense 24096698 rs13135778 chr4 123664446 G A 1.54E-04 Endometrial cancer BBS12 missense 24096698 rs309383 chr4 123669698 G A 4.86E-04 Multiple complex diseases / / 17554300 rs9307510 chr4 123692663 A G 6.61E-05 Multiple complex diseases / / 17554300 rs17006134 chr4 123699121 G A 4.50E-05 Multiple complex diseases / / 17554300 rs7678389 chr4 123724256 C T 8.97E-04 Multiple complex diseases / / 17554300 rs308447 chr4 123738546 C T 4.00E-04 Endometrial cancer / / 24096698 rs308447 chr4 123738546 C T 5.74E-04 Endometrial cancer / / 24096698 rs201495619 chr4 123743827 A G 1.50E-12 Metabolite levels / / 22286219 rs308443 chr4 123775767 G A 3.56E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) FGF2 intron 24023788 rs17006219 chr4 123782196 C T 5.82E-04 Multiple complex diseases FGF2 intron 17554300 rs308381 chr4 123783105 G A 9.76E-05 Body mass index FGF2 intron 23669352 rs308388 chr4 123787079 G A 3.12E-05 Acne (severe) FGF2 intron 24927181 rs7694627 chr4 123788495 T C 5.48E-05 Acne (severe) FGF2 intron 24927181 rs12509014 chr4 123825919 C T 6.61E-04 Aortic root size NUDT6 intron 21223598 rs11733450 chr4 123826834 G T 6.53E-05 Aortic root size NUDT6 intron 21223598 rs17006333 chr4 123851151 A C 1.09E-08 Multiple complex diseases SPATA5 intron 17554300 rs11098682 chr4 123868279 G T 2.40E-06 Urinary metabolites SPATA5 intron 21572414 rs9685166 chr4 123880089 C T 7.60E-07 Urinary metabolites SPATA5 intron 21572414 rs1458756 chr4 123884646 A G 3.05E-06 Stroke (ischemic) SPATA5 intron 22941190 rs7686314 chr4 123887632 T C 2.50E-05 Urinary metabolites SPATA5 intron 21572414 rs4833851 chr4 123897088 T A 2.70E-05 Urinary metabolites SPATA5 intron 21572414 rs11098683 chr4 123901212 A G 2.50E-05 Urinary metabolites SPATA5 intron 21572414 rs11098683 chr4 123901212 A G 6.90E-04 Smoking cessation SPATA5 intron 24665060 rs4833260 chr4 123912790 T C 2.50E-05 Urinary metabolites SPATA5 intron 21572414 rs6816823 chr4 123927754 C T 7.10E-07 Urinary metabolites SPATA5 intron 21572414 rs4833261 chr4 123930517 G A 8.22E-04 Smoking cessation SPATA5 intron 24665060 rs9762613 chr4 123953953 C T 5.92E-04 Smoking cessation SPATA5 intron 24665060 rs13135008 chr4 123957928 A T 9.50E-07 Urinary metabolites SPATA5 intron 21572414 rs977670 chr4 123958551 G A 6.78E-04 Smoking cessation SPATA5 intron 24665060 rs6823893 chr4 123983207 A T 7.20E-04 Smoking cessation SPATA5 intron 24665060 rs12650569 chr4 123989201 G A 6.78E-04 Smoking cessation SPATA5 intron 24665060 rs6534384 chr4 123996079 C T 6.64E-04 Smoking cessation SPATA5 intron 24665060 rs9999118 chr4 124051467 A G 8.00E-08 Irritable bowel syndrome SPATA5 intron 24797007 rs1025286 chr4 124081430 G T 1.75E-04 Major depressive disorder SPATA5 intron 22472876 rs304650 chr4 124083918 C T 2.64E-05 Alopecia areata SPATA5 intron 22027810 rs991183 chr4 124173635 G A 3.33E-05 Acne (severe) SPATA5 intron 24927181 rs7670452 chr4 124184613 C T 6.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPATA5 intron 20877124 rs7663357 chr4 124271321 A G 5.78E-04 Aortic root size / / 21223598 rs12512633 chr4 124286915 T A 5.20E-04 Pulmonary function / / 23932459 rs159864 chr4 124297087 C A 3.16E-04 Multiple complex diseases / / 17554300 rs159864 chr4 124297087 C A 9.85E-05 Sudden cardiac arrest / / 21658281 rs10518414 chr4 124305809 A G 6.13E-05 Multiple complex diseases / / 17554300 rs407317 chr4 124333710 G A 8.55E-04 Multiple complex diseases / / 17554300 rs10001582 chr4 124358570 A C 4.91E-05 Male-pattern baldness / / 18849994 rs17807333 chr4 124387459 G A 2.27E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10029753 chr4 124389966 G A 4.70E-04 Multiple complex diseases / / 17554300 rs4076851 chr4 124477700 G A 1.04E-04 Alcohol dependence / / 20201924 rs6813400 chr4 124483312 A C 1.43E-04 Alcohol dependence / / 20201924 rs4833930 chr4 124496348 T C 8.02E-04 Body mass index / / 21701565 rs752501 chr4 124528377 G A 3.62E-04 Response to alcohol consumption (flushing response) / / 24277619 rs2553377 chr4 124533487 C A 4.66E-04 Longevity / / 22279548 rs2162093 chr4 124548625 C T 8.04E-04 Multiple complex diseases / / 17554300 rs4833285 chr4 124565490 A T 9.39E-04 Multiple complex diseases / / 17554300 rs1425419 chr4 124565964 C T 2.31E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2553355 chr4 124590869 G A 2.17E-04 Birth weight LOC285419 intron 17255346 rs2589839 chr4 124592136 T C 3.35E-04 Alcohol dependence LOC285419 intron 20201924 rs890180 chr4 124621650 T C 4.17E-04 Parkinson's disease LOC285419 intron 17052657 rs17007240 chr4 124659199 T C 5.76E-06 Serum metabolites LOC285419 intron 19043545 rs17007245 chr4 124661571 G A 8.32E-04 Insulin resistance LOC285419 intron 21901158 rs3113384 chr4 124698977 A G 3.95E-07 Statin-induced myopathy LOC285419 intron 21826682 rs10518306 chr4 124736205 C T 7.69E-05 Vaspin levels LOC285419 intron 22907691 rs17007484 chr4 124762079 A C 1.01E-06 Left ventricular mass LOC285419 intron 21212386 rs1433211 chr4 124763465 A G 8.08E-05 Cognitive performance LOC285419 intron 19734545 rs3097903 chr4 124766331 A G 2.67E-04 Alzheimer's disease LOC285419 intron 17998437 rs3113392 chr4 124775472 C T 1.49E-05 Cognitive performance LOC285419 intron 19734545 rs3097940 chr4 124784773 C T 1.13E-08 Leprosy LOC285419 intron 22019778 rs1469720 chr4 124808047 G A 5.25E-05 Cognitive performance LOC285419 intron 19734545 rs999189 chr4 124822986 C G 2.74E-04 Insulin resistance LOC285419 intron 21901158 rs6838706 chr4 124851510 G A 4.97E-04 Insulin resistance / / 21901158 rs4422426 chr4 124892331 G A 4.57E-04 Coronary Artery Disease / / 17634449 rs1519239 chr4 124919498 T A 1.73E-04 Multiple complex diseases / / 17554300 rs11098725 chr4 124919843 C T 1.41E-04 Insulin resistance / / 21901158 rs13145600 chr4 124938502 C G 6.75E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs12647636 chr4 125017034 C T 9.77E-04 Multiple complex diseases / / 17554300 rs10029877 chr4 125020390 C T 7.89E-04 Smoking cessation / / 24665060 rs4392519 chr4 125030525 A T 9.11E-05 Multiple complex diseases / / 17554300 rs13152069 chr4 125034218 C T 5.91E-05 Blood Pressure / / pha003039 rs11737074 chr4 125081373 G A 1.55E-04 Parkinson's disease / / 16252231 rs10021517 chr4 125095613 A G 9.33E-05 Orofacial clefts / / 22419666 rs6834028 chr4 125109084 G A 5.19E-06 Orofacial clefts / / 22419666 rs960925 chr4 125120257 A G 4.77E-06 Orofacial clefts / / 22419666 rs11937163 chr4 125133465 G A 4.01E-05 Cognitive test performance / / 20125193 rs1123772 chr4 125157264 C T 6.18E-05 Orofacial clefts / / 22419666 rs10518427 chr4 125225084 C T 6.25E-05 Insulin-related traits / / pha003063 rs2125000 chr4 125265313 C T 3.00E-06 Major depressive disorder / / 23377640 rs1159819 chr4 125298963 G A 9.20E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs17008117 chr4 125320611 C T 9.20E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs1353004 chr4 125359687 T C 8.65E-04 Heart Failure / / pha002885 rs10005560 chr4 125368381 C G 3.29E-04 Alzheimer's disease / / 24755620 rs11936470 chr4 125380922 A G 6.00E-04 Alzheimer's disease / / 24755620 rs962939 chr4 125404239 T C 3.59E-04 Alzheimer's disease / / 24755620 rs6534441 chr4 125415534 C T 7.00E-06 Major depressive disorder / / 23377640 rs6534441 chr4 125415534 C T 2.07E-04 Alzheimer's disease / / 24755620 rs17768496 chr4 125419243 T C 6.21E-05 Alzheimer's disease / / 24755620 rs1492754 chr4 125421169 A C 4.84E-04 Multiple complex diseases / / 17554300 rs1492753 chr4 125421325 G A 7.07E-04 Multiple complex diseases / / 17554300 rs7675285 chr4 125422463 G A 6.56E-05 Alzheimer's disease / / 24755620 rs6534444 chr4 125425867 C T 2.96E-04 Alzheimer's disease / / 17998437 rs6534444 chr4 125425867 C T 7.94E-05 Alzheimer's disease / / 24755620 rs312504 chr4 125438407 A T 5.54E-05 Alzheimer's disease / / 24755620 rs312489 chr4 125446214 C T 9.60E-06 Alzheimer's disease / / 24755620 rs312495 chr4 125449253 T C 7.60E-05 Chronic obstructive pulmonary disease / / 19300482 rs312495 chr4 125449253 T C 7.60E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10029005 chr4 125451364 G A 5.30E-05 Cognitive test performance / / 20125193 rs10029005 chr4 125451364 G A 4.89E-04 Alzheimer's disease (late onset) / / 21379329 rs1509525 chr4 125455457 G A 5.71E-06 Alzheimer's disease / / 21627779 rs11946186 chr4 125457073 C T 5.71E-06 Alzheimer's disease / / 21627779 rs7692257 chr4 125460344 C T 5.71E-06 Alzheimer's disease / / 21627779 rs7698125 chr4 125461014 C A 5.71E-06 Alzheimer's disease / / 21627779 rs975107 chr4 125462793 T C 2.28E-04 Vaspin levels / / 22907691 rs975107 chr4 125462793 T C 0.0002277 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs6821572 chr4 125463025 A G 5.71E-06 Alzheimer's disease / / 21627779 rs6821572 chr4 125463025 A G 2.34E-05 Alzheimer's disease / / 24755620 rs7666278 chr4 125463533 G A 5.71E-06 Alzheimer's disease / / 21627779 rs7666278 chr4 125463533 G A 2.19E-05 Alzheimer's disease / / 24755620 rs6828748 chr4 125464140 C T 4.18E-04 Alzheimer's disease / / 17998437 rs6828748 chr4 125464140 C T 3.97E-04 Alzheimer's disease (late onset) / / 21379329 rs6828748 chr4 125464140 C T 5.79E-06 Alzheimer's disease / / 21627779 rs1567396 chr4 125465163 G A 2.44E-04 Alzheimer's disease (late onset) / / 21379329 rs1567396 chr4 125465163 G A 4.15E-06 Alzheimer's disease / / 21627779 rs7674724 chr4 125466142 T C 5.79E-06 Alzheimer's disease / / 21627779 rs7674724 chr4 125466142 T C 1.59E-05 Alzheimer's disease / / 24755620 rs4597845 chr4 125469037 T A 5.79E-06 Alzheimer's disease / / 21627779 rs6534446 chr4 125470187 T C 5.79E-06 Alzheimer's disease / / 21627779 rs4833304 chr4 125488843 T G 9.29E-04 Multiple complex diseases / / 17554300 rs1498024 chr4 125555024 A G 7.90E-06 Type 2 diabetes / / 17846124 rs1498024 chr4 125555024 A G 1.70E-05 Type 2 diabetes / / 21647700 rs145437766 chr4 125593261 T C 0.00012 Prostate cancer (advanced) ANKRD50 missense 23555315 rs10518442 chr4 125594268 C A 3.22E-05 Type 2 diabetes ANKRD50 intron 17846124 rs10518442 chr4 125594268 C A 3.20E-05 Type 2 diabetes ANKRD50 intron 21647700 rs11098769 chr4 125649024 T C 7.33E-05 Cognitive impairment induced by topiramate / / 22091778 rs6841569 chr4 125666719 C T 3.98E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11722501 chr4 125670337 T C 3.30E-04 Blood pressure / / 17255346 rs2036203 chr4 125675055 G A 1.44E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs313997 chr4 125682930 G T 3.78E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2658593 chr4 125693776 T C 1.17E-04 Blood pressure / / 17255346 rs2174623 chr4 125705944 G C 6.11E-06 Schizophrenia / / 21674006 rs10518451 chr4 125707440 G A 2.08E-04 Schizophrenia / / 21674006 rs993704 chr4 125712060 G A 0.000023 Primary sclerosing cholangitis / / 22521342 rs10857102 chr4 125717983 G A 0.000032 Primary sclerosing cholangitis / / 22521342 rs11931944 chr4 125720431 G A 7.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs963916 chr4 125727324 A G 9.62E-05 Schizophrenia / / 21674006 rs10518443 chr4 125728477 G A 6.65E-05 Schizophrenia / / 21674006 rs1395330 chr4 125767985 A G 4.04E-04 Myopia (pathological) / / 21095009 rs1395327 chr4 125804337 T C 1.99E-04 Schizophrenia / / 21674006 rs1395325 chr4 125804523 A G 7.50E-05 Schizophrenia / / 21674006 rs9993168 chr4 125807868 A G 1.84E-04 Multiple complex diseases / / 17554300 rs1601120 chr4 125846118 G T 8.80E-04 HIV-1 viral setpoint / / 17641165 rs2173324 chr4 125864789 G T 6.08E-06 Personality dimensions / / 23658558 rs11098783 chr4 125879056 T C 3.56E-05 Post-operative nausea and vomiting / / 21694509 rs17008965 chr4 125912942 A G 8.21E-04 Multiple complex diseases / / 17554300 rs12498985 chr4 125925433 C T 7.30E-05 Pericardial fat / / 22589742 rs12512668 chr4 125964327 T G 4.30E-05 Pericardial fat / / 22589742 rs12499252 chr4 125971288 T C 3.00E-05 Pericardial fat / / 22589742 rs2647130 chr4 125973337 C T 1.80E-05 Bilirubin levels / / 19414484 rs1391397 chr4 125973565 C T 1.40E-05 Bilirubin levels / / 19414484 rs2710818 chr4 125974818 C T 6.30E-06 Serum metabolites / / 19043545 rs2710818 chr4 125974818 C T 9.80E-06 Bilirubin levels / / 19414484 rs1986655 chr4 125993502 A G 2.00E-06 Bilirubin levels / / 19414484 rs2390779 chr4 125995900 A G 2.90E-06 Bilirubin levels / / 19414484 rs17009138 chr4 125996786 T C 4.55E-04 Myopia (pathological) / / 21095009 rs2390798 chr4 126007196 G A 1.64E-04 Alcohol dependence / / 20201924 rs2390771 chr4 126013202 G A 7.04E-04 White matter integrity / / 22425255 rs13102452 chr4 126028567 T C 2.47E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7675988 chr4 126036776 C T 4.01E-05 Caffeine consumption / / 21490707 rs7675988 chr4 126036776 C T 8.57E-05 Blood Pressure / / pha003050 rs6826117 chr4 126056711 T C 4.15E-05 Blood Pressure / / pha003050 rs11098794 chr4 126079097 A C 4.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13145439 chr4 126103475 C T 1.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2390774 chr4 126105391 T C 9.78E-06 Stroke (ischemic) / / 21957438 rs77237251 chr4 126105423 G C 9.71E-06 Stroke (ischemic) / / 21957438 rs10015153 chr4 126108001 C T 3.11E-06 Stroke (ischemic) / / 21957438 rs74446632 chr4 126115911 C T 8.57E-06 Stroke (ischemic) / / 21957438 rs75132432 chr4 126116796 G A 8.74E-06 Stroke (ischemic) / / 21957438 rs17009284 chr4 126120454 C T 6.74E-06 Stroke (ischemic) / / 21957438 rs17009293 chr4 126120908 C T 6.68E-06 Stroke (ischemic) / / 21957438 rs17009295 chr4 126120973 T C 6.66E-06 Stroke (ischemic) / / 21957438 rs75411930 chr4 126121029 T C 5.73E-06 Stroke (ischemic) / / 21957438 rs77848747 chr4 126121347 C T 6.35E-06 Stroke (ischemic) / / 21957438 rs79880362 chr4 126123188 C T 6.16E-06 Stroke (ischemic) / / 21957438 rs77111565 chr4 126123223 A T 6.14E-06 Stroke (ischemic) / / 21957438 rs76347205 chr4 126124653 T C 6.18E-06 Stroke (ischemic) / / 21957438 rs74528143 chr4 126124687 T C 6.18E-06 Stroke (ischemic) / / 21957438 rs77794498 chr4 126124816 G A 6.19E-06 Stroke (ischemic) / / 21957438 rs78584562 chr4 126125193 C T 6.19E-06 Stroke (ischemic) / / 21957438 rs113925077 chr4 126125280 T C 6.19E-06 Stroke (ischemic) / / 21957438 rs113317289 chr4 126125447 C A,T 6.19E-06 Stroke (ischemic) / / 21957438 rs111724418 chr4 126125656 C T 6.19E-06 Stroke (ischemic) / / 21957438 rs80174004 chr4 126125674 T G 6.21E-06 Stroke (ischemic) / / 21957438 rs79089592 chr4 126125703 G T 6.22E-06 Stroke (ischemic) / / 21957438 rs80304652 chr4 126126029 G T 6.22E-06 Stroke (ischemic) / / 21957438 rs79297447 chr4 126126033 T C 6.18E-06 Stroke (ischemic) / / 21957438 rs111871934 chr4 126126050 G T 6.19E-06 Stroke (ischemic) / / 21957438 rs12499358 chr4 126126219 G A 5.08E-05 Basophils / / pha003087 rs181908164 chr4 126126443 C G 6.19E-06 Stroke (ischemic) / / 21957438 rs369671596 chr4 126126454 AAAAAC A 6.20E-06 Stroke (ischemic) / / 21957438 rs74619085 chr4 126126454 A C 6.20E-06 Stroke (ischemic) / / 21957438 rs112971835 chr4 126127051 C T 6.15E-06 Stroke (ischemic) / / 21957438 rs77483077 chr4 126128221 T C 6.12E-06 Stroke (ischemic) / / 21957438 rs79935447 chr4 126128258 C T 6.13E-06 Stroke (ischemic) / / 21957438 rs111868999 chr4 126128557 C T 6.10E-06 Stroke (ischemic) / / 21957438 rs116714449 chr4 126128567 T C 6.10E-06 Stroke (ischemic) / / 21957438 rs76938166 chr4 126129312 A G 6.07E-06 Stroke (ischemic) / / 21957438 rs76916795 chr4 126129362 T C 6.05E-06 Stroke (ischemic) / / 21957438 rs80286028 chr4 126129496 G A 6.05E-06 Stroke (ischemic) / / 21957438 rs74686632 chr4 126129527 T G 6.04E-06 Stroke (ischemic) / / 21957438 rs75378844 chr4 126130124 C G 6.03E-06 Stroke (ischemic) / / 21957438 rs76662258 chr4 126130191 G T 6.03E-06 Stroke (ischemic) / / 21957438 rs78444453 chr4 126130263 C T 6.00E-06 Stroke (ischemic) / / 21957438 rs75997408 chr4 126132763 C T 5.99E-06 Stroke (ischemic) / / 21957438 rs79350978 chr4 126133816 C T 5.99E-06 Stroke (ischemic) / / 21957438 rs74621709 chr4 126134008 C T 5.98E-06 Stroke (ischemic) / / 21957438 rs77791386 chr4 126134308 T C 5.98E-06 Stroke (ischemic) / / 21957438 rs75721283 chr4 126134671 A G 5.96E-06 Stroke (ischemic) / / 21957438 rs79274102 chr4 126137769 A C 5.87E-06 Stroke (ischemic) / / 21957438 rs4358417 chr4 126139305 G A 2.10E-05 Urinary metabolites / / 21572414 rs2390804 chr4 126157482 C T 8.06E-05 Femoral neck bone geometry / / 22087292 rs12648772 chr4 126197858 T C 3.54E-05 Multiple complex diseases / / 17554300 rs17793852 chr4 126198003 T C 6.80E-04 Multiple complex diseases / / 17554300 rs2710551 chr4 126198444 C A 4.75E-04 Multiple complex diseases / / 17554300 rs2663257 chr4 126253153 G T 3.49E-05 Serum metabolites FAT4 intron 19043545 rs7676058 chr4 126270773 T G 1.16E-04 Bipolar disorder FAT4 intron 18317468 rs2710548 chr4 126273530 C T 0.0000279 Aging FAT4 intron 22445811 rs2710560 chr4 126280006 T C 1.21E-04 Lung function (forced expiratory volume in 1 second) FAT4 intron 17255346 rs1396685 chr4 126282761 C A 3.02E-04 Lung function (forced expiratory volume in 1 second) FAT4 intron 17255346 rs9307561 chr4 126286314 T C 1.00E-04 Breast cancer and prostate cancer FAT4 intron 17903305 rs1395241 chr4 126359456 A G 8.00E-06 Bipolar disorder and major depressive disorder (combined) FAT4 intron 20351715 rs111423173 chr4 126373018 C T 0.00038 Breast cancer FAT4 missense 23555315 rs150894545 chr4 126373835 C T 0.00027 Breast cancer (ER positive) FAT4 cds-synon 23555315 rs10021774 chr4 126376172 G C 9.41E-13 Multiple complex diseases FAT4 intron 17554300 rs4834045 chr4 126376478 G C 7.01E-04 Type 2 diabetes FAT4 intron 17463246 rs17009761 chr4 126397321 C T 7.17E-05 Lung function (forced expiratory volume in 1 second) FAT4 intron 17255346 rs6824160 chr4 126402890 G A 9.82E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines FAT4 cds-synon 21844884 rs7686537 chr4 126409317 C T 6.51E-05 Lung function (forced expiratory volume in 1 second) FAT4 intron 17255346 rs7672692 chr4 126414188 C G 7.88E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs12639834 chr4 126426695 C T 6.00E-06 Cognitive performance / / 19734545 rs1567050 chr4 126429271 C T 8.04E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs13114827 chr4 126431339 T A 1.49E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs950063 chr4 126431919 C T 9.00E-06 Smoking behavior / / 19247474 rs950063 chr4 126431919 C T 2.70E-05 Cognitive performance / / 19734545 rs17009964 chr4 126459974 G A 2.26E-05 Bipolar disorder / / 18317468 rs1429901 chr4 126500482 A G 3.02E-04 Type 2 diabetes / / 20818381 rs6534494 chr4 126504601 C T 2.39E-04 Scoliosis / / 21216876 rs6534494 chr4 126504601 C T 8.42E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1864363 chr4 126524825 C A 8.87E-04 Premature ovarian failure / / 19508998 rs6844035 chr4 126603140 T C 1.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7686488 chr4 126645826 G A 1.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12500998 chr4 126742617 C T 2.40E-05 Urinary metabolites / / 21572414 rs1911014 chr4 126774098 G A 3.00E-04 Alzheimer's disease (late onset) / / 21460841 rs2102317 chr4 126783724 A C 8.91E-04 Iron levels / / pha002876 rs2102317 chr4 126783724 A C 5.12E-05 Blood Pressure / / pha003046 rs10031803 chr4 126786482 A C 7.97E-04 Iron levels / / pha002876 rs10031803 chr4 126786482 A C 4.14E-05 Blood Pressure / / pha003046 rs17010396 chr4 126807329 A C 9.69E-06 Obesity-related traits / / 23251661 rs955806 chr4 126810426 A G 7.49E-04 Iron levels / / pha002876 rs955806 chr4 126810426 A G 3.39E-05 Blood Pressure / / pha003046 rs1506169 chr4 126812573 A G 2.66E-04 Iron levels / / pha002876 rs9307579 chr4 126813075 C A 4.64E-05 Blood Pressure / / pha003046 rs1506141 chr4 126824560 C T 7.32E-05 Multiple complex diseases / / 17554300 rs906094 chr4 126890003 T C 7.60E-06 Urinary metabolites / / 21572414 rs9998586 chr4 126890326 A G 7.24E-06 Glycosylated haemoglobin levels / / 17255346 rs11098847 chr4 126896243 T C 1.36E-06 Glycosylated haemoglobin levels / / 17255346 rs10518480 chr4 126898260 A G 2.40E-06 Urinary metabolites / / 21572414 rs17823750 chr4 126910385 G T 4.10E-06 Urinary metabolites / / 21572414 rs12642816 chr4 126919403 C T 0.000832897 Hypertension (early onset hypertension) / / 22479346 rs13135523 chr4 126920257 C T 7.00E-05 Lipoproteins / / pha003079 rs17010566 chr4 126924448 C T 7.41E-04 Multiple complex diseases / / 17554300 rs1320267 chr4 126933292 G C 7.00E-06 Subclinical atherosclerosis / / 17903303 rs6534526 chr4 126937174 G T 1.65E-04 Type 2 diabetes / / 22158537 rs4495049 chr4 126939153 A C 9.43E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs6534528 chr4 126967979 A G 3.90E-05 Asthma (bronchodilator response) / / 22792082 rs1320269 chr4 126973044 T G 2.60E-05 Asthma (bronchodilator response) / / 22792082 rs12509991 chr4 126996870 C T 9.70E-06 Asthma (bronchodilator response) / / 22792082 rs10518485 chr4 126996974 C T 1.40E-05 Asthma (bronchodilator response) / / 22792082 rs10518484 chr4 126997244 C T 9.52E-04 Type 2 diabetes / / 17846124 rs4382051 chr4 127001808 A G 8.00E-06 Asthma (bronchodilator response) / / 22792082 rs11726082 chr4 127004744 C T 8.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs11731526 chr4 127005100 C G 8.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs17010666 chr4 127006583 A C 4.20E-05 Asthma (bronchodilator response) / / 22792082 rs4530647 chr4 127018677 T C 5.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs6820042 chr4 127020140 G A 5.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs17010686 chr4 127023558 A G 5.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs17010704 chr4 127029063 T A 5.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs17010709 chr4 127029170 A C 1.55E-15 Multiple complex diseases / / 17554300 rs7667104 chr4 127033186 A G 5.80E-05 Asthma (bronchodilator response) / / 22792082 rs7677190 chr4 127036380 T G 6.60E-05 Asthma (bronchodilator response) / / 22792082 rs7685518 chr4 127041554 A G 4.90E-05 Asthma (bronchodilator response) / / 22792082 rs11725588 chr4 127044073 G A 2.08E-05 Aging (time to event) / / 21782286 rs565659 chr4 127065892 A C 8.10E-05 Asthma (bronchodilator response) / / 22792082 rs565659 chr4 127065892 A C 8.49E-05 Coronary heart disease / / pha003031 rs1586150 chr4 127074758 C T 9.10E-05 Asthma (bronchodilator response) / / 22792082 rs2390992 chr4 127105360 T C 5.26E-04 Multiple complex diseases / / 17554300 rs7696522 chr4 127113427 C T 6.31E-05 Heart Rate / / pha003053 rs4144814 chr4 127123816 T C 3.06E-04 Type 2 diabetes / / 17463246 rs1483414 chr4 127124897 A C 5.16E-04 Hemoglobin concentration / / 20534544 rs4834101 chr4 127159751 C T 4.49E-04 Hemoglobin concentration / / 20534544 rs1351730 chr4 127178868 G A 6.97E-04 Multiple complex diseases / / 17554300 rs10518490 chr4 127186143 T C 2.37E-04 Multiple complex diseases / / 17554300 rs2128782 chr4 127208717 A G 8.60E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2128782 chr4 127208717 A G 1.83E-04 Iron levels / / pha002876 rs10011584 chr4 127213903 T G 3.00E-05 Multiple complex diseases / / 17554300 rs10011584 chr4 127213903 T G 7.03E-05 Epilepsy / / 22116939 rs17010902 chr4 127215318 A G 8.02E-04 Response to diuretic therapy in hypertension / / 23753411 rs6826123 chr4 127234103 A G 9.47E-04 Multiple complex diseases / / 17554300 rs6534543 chr4 127245675 G T 7.77E-04 Multiple complex diseases / / 17554300 rs6534543 chr4 127245675 G T 1.30E-05 Triglycerides / / 19074352 rs2391031 chr4 127251381 G A 6.99E-06 Varicose Veins / / pha001413 rs9307585 chr4 127259494 A G 8.01E-04 Multiple complex diseases / / 17554300 rs7699436 chr4 127303936 C T 1.90E-05 Urinary metabolites / / 21572414 rs1605759 chr4 127345932 G A 6.92E-05 Smoking quantity / / 24665060 rs9994438 chr4 127378061 C T 3.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs937924 chr4 127410421 T A 3.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs979438 chr4 127443630 A G 5.64E-05 Hypertension / / 19609347 rs992182 chr4 127468159 G C 2.26E-04 Multiple complex diseases / / 17554300 rs885600 chr4 127493571 C A 1.90E-05 Urinary metabolites / / 21572414 rs192856 chr4 127500145 T C 1.10E-12 Mean platelet volume / / 22423221 rs403001 chr4 127504819 A G 1.32E-05 Erythrocyte counts / / pha003090 rs313104 chr4 127510328 G A 8.35E-04 Multiple complex diseases / / 17554300 rs17258452 chr4 127525092 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10025722 chr4 127534011 A G 9.79E-05 Serum metabolites / / 19043545 rs17258848 chr4 127536521 T C 7.67E-05 HIV-1 viral setpoint / / 22174851 rs1511140 chr4 127548421 A C 1.00E-05 Urinary metabolites / / 21572414 rs432446 chr4 127548672 A T 5.19E-06 Bone mass and geometry / / 17903296 rs4833351 chr4 127550385 T C 7.00E-06 Urinary metabolites / / 21572414 rs12509148 chr4 127563253 A T 6.82E-04 Depression (quantitative trait) / / 20800221 rs10005429 chr4 127569959 C T 5.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs313121 chr4 127577302 G A 1.00E-04 Prostate cancer / / 21743057 rs372903 chr4 127580129 C T 2.20E-04 Depression (quantitative trait) / / 20800221 rs313076 chr4 127588709 T A 5.18E-05 Depression (quantitative trait) / / 20800221 rs313071 chr4 127610903 T C 4.40E-06 Urinary metabolites / / 21572414 rs313069 chr4 127611336 T C 6.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs313063 chr4 127620851 G T 9.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs313048 chr4 127624935 T C 9.37E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs313047 chr4 127626494 T C 1.90E-05 Urinary metabolites / / 21572414 rs313047 chr4 127626494 T C 1.00E-04 Prostate cancer / / 21743057 rs313047 chr4 127626494 T C 6.12E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs313111 chr4 127632219 C T 7.00E-05 Prostate cancer / / 21743057 rs313112 chr4 127633098 G A 7.00E-05 Prostate cancer / / 21743057 rs16997921 chr4 127645746 C T 7.15E-05 Stroke / / pha002887 rs1167190 chr4 127656069 A G 1.69E-04 Vaspin levels / / 22907691 rs1167190 chr4 127656069 A G 0.0001688 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs1167190 chr4 127656069 A G 8.81E-05 Blood Pressure / / pha003039 rs1167190 chr4 127656069 A G 1.26E-05 Blood Pressure / / pha003046 rs1167190 chr4 127656069 A G 3.25E-05 Blood Pressure / / pha003048 rs1388240 chr4 127657442 C A 2.48E-04 Stroke / / pha002887 rs13148138 chr4 127677801 G A 1.65E-05 Prion diseases / / 22210626 rs1604724 chr4 127710342 G A 7.51E-05 Blood Pressure / / pha003048 rs17011614 chr4 127713504 C T 4.87E-04 Type 2 diabetes / / 17463246 rs1503603 chr4 127724530 A G 5.57E-04 Type 2 diabetes / / 17463246 rs1393991 chr4 127727051 G A 9.50E-05 Response to statin therapy / / 20339536 rs12502973 chr4 127728097 A T 7.81E-04 Type 2 diabetes / / 17463246 rs6848985 chr4 127732142 G A 9.49E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11098896 chr4 127738558 C T 9.20E-05 Response to statin therapy / / 20339536 rs1393993 chr4 127738766 G C 9.00E-05 Response to statin therapy / / 20339536 rs986907 chr4 127746978 T A 7.60E-05 Response to statin therapy / / 20339536 rs6856064 chr4 127747142 T C 7.70E-05 Response to statin therapy / / 20339536 rs7681140 chr4 127748857 C T 6.60E-05 Response to statin therapy / / 20339536 rs7686181 chr4 127749023 C A 7.80E-05 Response to statin therapy / / 20339536 rs7672155 chr4 127753884 A C 7.50E-05 Response to statin therapy / / 20339536 rs7696767 chr4 127753915 T C 7.50E-05 Response to statin therapy / / 20339536 rs6829454 chr4 127754030 A G 8.30E-05 Response to statin therapy / / 20339536 rs1976483 chr4 127760872 A G 9.10E-05 Response to statin therapy / / 20339536 rs1503606 chr4 127763039 T A 8.60E-05 Response to statin therapy / / 20339536 rs2089061 chr4 127764432 G C 8.30E-05 Response to statin therapy / / 20339536 rs1503608 chr4 127765300 G A 6.50E-05 Response to statin therapy / / 20339536 rs1503611 chr4 127769550 A G 6.10E-05 Response to statin therapy / / 20339536 rs1503612 chr4 127769788 T C 6.00E-05 Response to statin therapy / / 20339536 rs11935382 chr4 127770795 C T 4.80E-05 Response to statin therapy / / 20339536 rs10461207 chr4 127771422 A C 6.80E-05 Response to statin therapy / / 20339536 rs1948827 chr4 127773003 A G 8.40E-05 Response to statin therapy / / 20339536 rs993364 chr4 127793077 A C 6.50E-05 Response to statin therapy / / 20339536 rs1503630 chr4 127800678 G A 6.50E-05 Response to statin therapy / / 20339536 rs12499264 chr4 127804216 A C 6.40E-05 Response to statin therapy / / 20339536 rs17011820 chr4 127810037 C G 4.41E-04 Multiple complex diseases / / 17554300 rs10018143 chr4 127811468 T C 4.50E-05 Response to statin therapy / / 20339536 rs12331011 chr4 127814391 A T 4.50E-05 Response to statin therapy / / 20339536 rs1510666 chr4 127815859 G A 7.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7662706 chr4 127819249 T C 6.20E-05 Response to statin therapy / / 20339536 rs17274049 chr4 127821259 T C 8.50E-05 Response to statin therapy / / 20339536 rs17208298 chr4 127822862 A G 8.60E-05 Response to statin therapy / / 20339536 rs1510674 chr4 127824801 A T 8.30E-05 Response to statin therapy / / 20339536 rs7667215 chr4 127825097 T G 8.20E-05 Response to statin therapy / / 20339536 rs11731081 chr4 127825338 C T 8.20E-05 Response to statin therapy / / 20339536 rs13435810 chr4 127826214 T C 8.90E-05 Response to statin therapy / / 20339536 rs13435387 chr4 127826279 C G 7.70E-05 Response to statin therapy / / 20339536 rs17274383 chr4 127828375 G A 7.70E-05 Response to statin therapy / / 20339536 rs17208690 chr4 127830887 T C 7.20E-05 Response to statin therapy / / 20339536 rs6845533 chr4 127837597 C A 6.00E-05 Response to statin therapy / / 20339536 rs7676052 chr4 127860332 G C 6.00E-05 Response to statin therapy / / 20339536 rs12647371 chr4 127926299 G A 5.70E-05 Response to statin therapy / / 20339536 rs1510683 chr4 127926974 T C 5.80E-05 Response to statin therapy / / 20339536 rs2391122 chr4 127929118 G C 5.50E-05 Response to statin therapy / / 20339536 rs7681543 chr4 127948885 A G 8.30E-05 Response to statin therapy / / 20339536 rs6825686 chr4 127954089 G A 9.70E-05 Response to statin therapy / / 20339536 rs17012036 chr4 127970055 A G 8.45E-05 adolescent idiopathic scoliosis / / 24023777 rs12642242 chr4 128015304 G A 9.98E-04 Multiple complex diseases / / 17554300 rs17012138 chr4 128060750 A C 1.28E-04 Type 2 diabetes / / 17463246 rs10033566 chr4 128061071 G A 5.67E-04 Multiple complex diseases / / 17554300 rs17012147 chr4 128066388 C T 5.82E-05 Type 2 diabetes / / 17463246 rs17012149 chr4 128066785 G A 5.81E-05 Type 2 diabetes / / 17463246 rs12503951 chr4 128072643 G A 2.90E-05 Lung adenocarcinoma / / 22797724 rs2127818 chr4 128099002 C A 4.61E-05 Multiple complex diseases / / 17554300 rs10518514 chr4 128099085 A G 1.33E-04 Type 2 diabetes / / 17463246 rs4560424 chr4 128139132 C G 9.94E-05 Serum metabolites / / 19043545 rs960588 chr4 128169494 A G 7.68E-04 Type 2 diabetes / / 17463246 rs2197201 chr4 128214127 C A 6.07E-05 Type 2 diabetes / / 17463246 rs17012324 chr4 128243401 T C 1.55E-04 Type 2 diabetes / / 17463246 rs1822359 chr4 128259888 C T 7.97E-05 Type 2 diabetes / / 17463246 rs1822359 chr4 128259888 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs13134996 chr4 128293180 T G 1.28E-04 Type 2 diabetes / / 17463246 rs9995457 chr4 128299301 C T 3.59E-05 Type 2 diabetes / / 17463246 rs1443170 chr4 128320908 T C 9.00E-06 Obesity-related traits / / 23251661 rs4374636 chr4 128321832 T C 1.28E-04 Type 2 diabetes / / 17463246 rs10518527 chr4 128336520 A G 1.05E-05 Body Mass Index / / pha003009 rs10518527 chr4 128336520 A G 3.95E-05 Waist Circumference / / pha003025 rs10518527 chr4 128336520 A G 1.40E-05 Weight / / pha003027 rs724950 chr4 128342120 T C 8.00E-06 Obesity-related traits / / 23251661 rs724950 chr4 128342120 T C 1.35E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4833376 chr4 128343762 G A 5.66E-04 Response to alcohol consumption (flushing response) / / 24277619 rs2203374 chr4 128434334 G C 5.71E-05 Major depressive disorder (broad) / / 20038947 rs17012484 chr4 128441567 A C 3.66E-04 Nicotine dependence / / 17158188 rs2090104 chr4 128466700 A G 5.00E-06 IgG glycosylation / / 23382691 rs1514310 chr4 128519236 A G 9.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs10434049 chr4 128528617 G A 2.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs1033175 chr4 128532930 A G 1.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs6847056 chr4 128543742 T C 3.30E-05 Coffee consumption / / 21357676 rs6534637 chr4 128649890 A C 1.06E-06 Testicular cancer / / 19483682 rs6534637 chr4 128649890 A C 1.15E-07 Testicular cancer / / 21551455 rs13147065 chr4 128668806 A G 2.00E-04 Cognitive impairment induced by topiramate SLC25A31 intron 22091778 rs13147065 chr4 128668806 A G 4.58E-04 Response to taxane treatment (placlitaxel) SLC25A31 intron 23006423 rs3214038 chr4 128688444 C T 6.39E-04 Multiple complex diseases SLC25A31 intron 17554300 rs13122568 chr4 128735475 A G 7.36E-04 Response to taxane treatment (placlitaxel) HSPA4L intron 23006423 rs10493147 chr4 128737499 T C 2.10E-05 Kidney function and endocine traits HSPA4L intron 17903292 rs10493147 chr4 128737499 T C 0.00003371 Sarcoidosis HSPA4L intron 22952805 rs2306054 chr4 129012181 G A 9.12E-05 Parkinson's disease LARP1B cds-synon 21738487 rs1064205 chr4 129012638 A G 1.74E-04 Parkinson's disease LARP1B cds-synon 17052657 rs12509092 chr4 129043809 G A 9.44E-05 Parkinson's disease LARP1B intron 21738487 rs11727049 chr4 129068179 G T 3.66E-05 Parkinson's disease LARP1B intron 21738487 rs10000748 chr4 129082491 T C 7.07E-05 Type 2 diabetes LARP1B intron 17463246 rs10000748 chr4 129082491 T C 2.40E-05 Urinary metabolites LARP1B intron 21572414 rs12645577 chr4 129100643 G A 9.61E-05 Parkinson's disease LARP1B missense 21738487 rs4975300 chr4 129160316 T C 4.48E-04 Glaucoma (primary open-angle) / / 22419738 rs10002814 chr4 129162533 C T 8.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4975220 chr4 129195334 C T 6.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PGRMC2 intron 20877124 rs12505763 chr4 129216662 C G 0.0000782 Salmonella-induced pyroptosis / / 22837397 rs9790593 chr4 129216805 G A 0.000159 Salmonella-induced pyroptosis / / 22837397 rs1391980 chr4 129218126 C T 9.53E-04 Type 2 diabetes / / 17463246 rs1391980 chr4 129218126 C T 0.000116 Salmonella-induced pyroptosis / / 22837397 rs17013164 chr4 129281866 G A 1.52E-04 Multiple complex diseases / / 17554300 rs17338075 chr4 129284689 G A 8.33E-04 Multiple complex diseases / / 17554300 rs17013169 chr4 129288791 C T 1.31E-04 Multiple complex diseases / / 17554300 rs7655151 chr4 129296922 G A 1.46E-04 Multiple complex diseases / / 17554300 rs291079 chr4 129303760 C T 3.93E-04 Depression (quantitative trait) / / 20800221 rs7654743 chr4 129307717 A G 8.94E-04 Depression (quantitative trait) / / 20800221 rs7674959 chr4 129310867 C G 6.95E-04 Depression (quantitative trait) / / 20800221 rs3870129 chr4 129311823 T C 4.31E-04 Depression (quantitative trait) / / 20800221 rs3870129 chr4 129311823 T C 9.30E-06 Urinary metabolites / / 21572414 rs10012506 chr4 129332083 T C 2.30E-05 Urinary metabolites / / 21572414 rs1106860 chr4 129347785 T A 2.60E-05 Urinary metabolites / / 21572414 rs10021346 chr4 129349449 G A 1.10E-05 Urinary metabolites / / 21572414 rs12501269 chr4 129367178 G A 2.00E-05 Urinary metabolites / / 21572414 rs4549394 chr4 129431298 C T 3.98E-05 Attention deficit hyperactivity disorder / / 22012869 rs1032673 chr4 129465489 A C 6.54E-04 Multiple complex diseases / / 17554300 rs1216373 chr4 129497164 C T 1.20E-05 Urinary metabolites / / 21572414 rs1216387 chr4 129507333 T G 7.00E-06 Urinary metabolites / / 21572414 rs1216413 chr4 129530116 G A 8.55E-04 Coronary heart disease / / 21606135 rs17401445 chr4 129532437 T C 1.86E-04 Coronary heart disease / / 21606135 rs4975242 chr4 129533368 T A 8.57E-04 Coronary heart disease / / 21606135 rs1216363 chr4 129570447 A G 4.14E-06 Rheumatoid arthritis / / 21452313 rs1216363 chr4 129570447 A G 2.70E-05 Kawasaki disease / / 22446962 rs1553142 chr4 129587449 A G 5.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1364968 chr4 129654127 C T 8.27E-04 Multiple complex diseases / / 17554300 rs11723731 chr4 129685158 G A 9.68E-04 Alzheimer's disease / / 17998437 rs6824067 chr4 129688047 C T 3.47E-05 Hypertension / / pha003042 rs1974942 chr4 129696221 A G 4.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs9991981 chr4 129713511 G A 2.46E-04 Scoliosis / / 21216876 rs1031691 chr4 129721687 T C 1.64E-04 Scoliosis / / 21216876 rs6813405 chr4 129790187 T C 2.61E-04 Multiple complex diseases PHF17 intron 17554300 rs318544 chr4 129836458 T C 4.01E-05 Serum metabolites SCLT1 intron 19043545 rs318546 chr4 129837161 G A 3.22E-05 Serum metabolites SCLT1 intron 19043545 rs17013959 chr4 129865834 A G 9.52E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SCLT1 intron 21844884 rs12500341 chr4 129868282 A C 5.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SCLT1 intron 20877124 rs12500341 chr4 129868282 A C 3.23E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SCLT1 intron 24023788 rs10857134 chr4 129873433 A G 3.09E-05 Serum metabolites SCLT1 intron 19043545 rs6814109 chr4 129887584 A G 4.34E-05 Serum metabolites SCLT1 intron 19043545 rs7655841 chr4 129890790 T C 7.00E-07 Chronic obstructive pulmonary disease (moderate to severe) SCLT1 intron 24621683 rs2044523 chr4 129927804 C T 4.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SCLT1 intron 20877124 rs1450727 chr4 129965026 T C 3.29E-05 Serum metabolites SCLT1 intron 19043545 rs2068135 chr4 130016221 A G 3.77E-04 Multiple complex diseases C4orf33 intron 17554300 rs1757925 chr4 130020791 T C 9.10E-07 Lymphocyte counts C4orf33 intron 22286170 rs1030830 chr4 130025117 C T 5.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C4orf33 intron 20877124 rs2271570 chr4 130030644 C T 8.45E-04 Birth weight C4orf33 missense 17255346 rs2271570 chr4 130030644 C T 3.29E-05 Coronary heart disease C4orf33 missense pha003031 rs17014259 chr4 130060041 A C 6.82E-04 Alzheimer's disease / / 17998437 rs11946237 chr4 130060230 A G 6.79E-04 White matter integrity / / 22425255 rs4616770 chr4 130072652 C T 6.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6857681 chr4 130087132 G T 1.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11725918 chr4 130088657 C T 4.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11725918 chr4 130088657 C T 6.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11734122 chr4 130088740 A C 4.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11734122 chr4 130088740 A C 6.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11735242 chr4 130089540 A G 3.94E-04 White matter integrity / / 22425255 rs10494317 chr4 130094338 T C 7.39E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10494317 chr4 130094338 T C 1.38E-05 Inflammation / / pha002897 rs17790511 chr4 130096106 T C 2.29E-04 White matter integrity / / 22425255 rs1588808 chr4 130099986 A C 1.93E-04 Multiple complex diseases / / 17554300 rs4975196 chr4 130101685 G A 3.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11732261 chr4 130109749 C G 1.74E-04 Multiple complex diseases / / 17554300 rs17790747 chr4 130112972 C A 2.63E-04 Multiple complex diseases / / 17554300 rs12513373 chr4 130113913 C T 1.82E-04 White matter integrity / / 22425255 rs11721729 chr4 130114838 G A 1.51E-04 White matter integrity / / 22425255 rs10518545 chr4 130114848 A G 8.63E-04 White matter integrity / / 22425255 rs11099003 chr4 130115445 G A 8.63E-04 White matter integrity / / 22425255 rs12650648 chr4 130117960 G A 2.68E-04 Multiple complex diseases / / 17554300 rs17014446 chr4 130128403 C T 7.00E-05 Endometriosis / / 21151130 rs6854308 chr4 130139735 C T 7.50E-04 Depression (quantitative trait) / / 20800221 rs533159 chr4 130141449 A T 5.52E-05 Personality dimensions / / 18957941 rs1757939 chr4 130146176 T C 2.90E-05 Cocaine dependence / / 23958962 rs971446 chr4 130155315 T C 9.30E-05 Parkinson's disease (familial) / / 18985386 rs1355962 chr4 130160851 C T 2.40E-05 Urinary metabolites / / 21572414 rs17432813 chr4 130163823 T G 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10084901 chr4 130183094 T A 2.10E-05 Urinary metabolites / / 21572414 rs9994767 chr4 130185974 C T 4.62E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs13119203 chr4 130194362 G A 3.11E-05 Major depressive disorder (broad) / / 20038947 rs4604070 chr4 130196647 G A 1.72E-04 Lung function (forced vital capacity) / / 24023788 rs11735407 chr4 130233602 T G 8.96E-04 Depression (quantitative trait) / / 20800221 rs6534723 chr4 130244708 A T 7.05E-04 Alzheimer's disease / / 17998437 rs4351033 chr4 130248604 G A 9.30E-04 Alzheimer's disease / / 17998437 rs7656960 chr4 130253095 C T 7.10E-04 Alzheimer's disease / / 17998437 rs11939768 chr4 130259010 T C 6.91E-04 Alzheimer's disease / / 17998437 rs11099007 chr4 130260879 A G 7.90E-05 Response to statin therapy / / 20339536 rs11942914 chr4 130288620 A G 7.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11942914 chr4 130288620 A G 9.84E-04 Stroke / / pha002887 rs13135051 chr4 130298557 T C 7.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10014575 chr4 130308015 G T 6.92E-06 Hypertension / / pha003042 rs13151998 chr4 130332421 G A 2.50E-06 Urinary metabolites / / 21572414 rs6837783 chr4 130332644 A G 1.90E-06 Urinary metabolites / / 21572414 rs6837783 chr4 130332644 A G 7.57E-06 Nasopharyngeal carcinoma / / 23209447 rs1836066 chr4 130333906 T A 5.60E-06 Urinary metabolites / / 21572414 rs1433375 chr4 130338059 T C 7.47E-04 Myopia (pathological) / / 21095009 rs17014760 chr4 130340880 G A 9.79E-04 Myopia (pathological) / / 21095009 rs6534730 chr4 130347411 C T 8.60E-07 Urinary metabolites / / 21572414 rs2391428 chr4 130354547 G T 7.40E-07 Urinary metabolites / / 21572414 rs1368585 chr4 130361135 T C 9.70E-04 Myopia (pathological) / / 21095009 rs1368585 chr4 130361135 T C 8.20E-07 Urinary metabolites / / 21572414 rs995638 chr4 130364131 G A 2.00E-06 Urinary metabolites / / 21572414 rs995637 chr4 130364383 A G 9.81E-04 Myopia (pathological) / / 21095009 rs995637 chr4 130364383 A G 8.40E-07 Urinary metabolites / / 21572414 rs1433384 chr4 130375150 T C 1.33E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs619819 chr4 130375945 G C 1.96E-06 Obesity (early onset extreme) / / 18159244 rs17050476 chr4 130412071 G A 7.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17050480 chr4 130412286 C T 6.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs631495 chr4 130459773 C A 1.18E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs655969 chr4 130459828 G A 4.20E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs630599 chr4 130466572 A G 1.48E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs613359 chr4 130469020 C T 1.48E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11935537 chr4 130490140 C G 1.50E-06 Chronic kidney disease / / 22479191 rs644318 chr4 130497597 T C 9.51E-04 Multiple complex diseases / / 17554300 rs628527 chr4 130523279 A G 1.10E-04 IgE levels in asthmatics (D.f. specific) / / 23967269 rs2391477 chr4 130581028 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs16998022 chr4 130595224 C G 5.10E-06 Urinary metabolites / / 21572414 rs7664190 chr4 130603085 C T 1.60E-05 Urinary metabolites / / 21572414 rs2728763 chr4 130615402 C T 4.19E-04 Multiple complex diseases / / 17554300 rs2054983 chr4 130677788 C A 8.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs1352760 chr4 130677996 G A 8.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs6534743 chr4 130714768 G A 4.73E-04 Body mass index / / 23669352 rs2391504 chr4 130731072 A G 5.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs4864201 chr4 130731284 T C 2.00E-07 Obesity / / 22484627 rs10028795 chr4 130767230 G A 6.09E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs17050689 chr4 130767899 T C 6.09E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs2969004 chr4 130781670 C A 1.19E-05 Acne (severe) / / 24927181 rs2969001 chr4 130782792 C G 6.05E-04 Type 2 diabetes / / 17463246 rs2969001 chr4 130782792 C G 1.60E-06 Obesity (early onset extreme) / / 18159244 rs2968983 chr4 130806761 A G 5.13E-04 Type 2 diabetes / / 17463246 rs2391518 chr4 130817060 T C 4.92E-04 Type 2 diabetes / / 17463246 rs2391517 chr4 130817236 G A 3.46E-04 Type 2 diabetes / / 17463246 rs10518558 chr4 130839650 G T 6.97E-04 Aortic root size / / 21223598 rs3109193 chr4 130840209 G A 4.79E-04 Type 2 diabetes / / 17463246 rs2952876 chr4 130841993 G A 7.78E-04 Type 2 diabetes / / 17463246 rs17050754 chr4 130853337 C T 2.11E-04 Multiple complex diseases / / 17554300 rs9992154 chr4 130866843 T C 1.83E-04 Multiple complex diseases / / 17554300 rs9991621 chr4 130875440 C A 8.00E-07 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs17050780 chr4 130907707 G A 1.67E-05 Multiple complex diseases / / 17554300 rs11946653 chr4 130951432 A G 5.73E-06 C-reactive protein / / 22492993 rs6534760 chr4 130961465 A T 9.87E-05 Cholesterol / / 17255346 rs1567193 chr4 130962263 T C 8.86E-05 Cholesterol / / 17255346 rs1567193 chr4 130962263 T C 8.08E-06 Alcohol dependence / / 24277619 rs9307620 chr4 130963247 G A 8.35E-05 Cholesterol / / 17255346 rs1395975 chr4 130965456 G A 6.05E-05 Cholesterol / / 17255346 rs1395975 chr4 130965456 G A 9.79E-06 Body Mass Index / / pha003007 rs1395975 chr4 130965456 G A 2.50E-05 Weight / / pha003027 rs6534761 chr4 130965930 A G 2.02E-04 Cholesterol / / 17255346 rs6534761 chr4 130965930 A G 2.19E-05 Body Mass Index / / pha003007 rs1022006 chr4 130966620 T C 1.09E-05 Blood pressure / / 17255346 rs1022005 chr4 130966863 A C 1.83E-04 Cholesterol / / 17255346 rs1022005 chr4 130966863 A C 2.58E-05 Body Mass Index / / pha003007 rs6534762 chr4 130978989 A G 2.90E-05 Alcohol dependence / / 24277619 rs12499245 chr4 130983605 A G 1.92E-04 Cholesterol / / 17255346 rs12499245 chr4 130983605 A G 2.31E-05 Body Mass Index / / pha003007 rs12499245 chr4 130983605 A G 5.59E-05 Weight / / pha003027 rs1395974 chr4 130993548 T A 1.59E-04 Cholesterol / / 17255346 rs10026751 chr4 130997323 C T 3.05E-04 Cholesterol / / 17255346 rs13134698 chr4 130997758 G T 4.27E-05 Cholesterol / / 17255346 rs1588147 chr4 130998219 T C 4.32E-05 Cholesterol / / 17255346 rs2221618 chr4 130998472 T C 1.78E-05 Cholesterol / / 17255346 rs2221618 chr4 130998472 T C 1.36E-05 Body Mass Index / / pha003007 rs2221618 chr4 130998472 T C 8.34E-05 Weight / / pha003027 rs11933622 chr4 131013066 C T 2.75E-04 Cholesterol / / 17255346 rs11933661 chr4 131013140 C T 4.00E-06 Alcohol dependence / / 24277619 rs1507787 chr4 131016112 C T 8.04E-05 Cholesterol / / 17255346 rs114646238 chr4 131026488 T C 9.00E-06 Metabolite levels (HVA/MHPG ratio) / / 23319000 rs17050842 chr4 131034819 T G 1.01E-05 Cognitive impairment induced by topiramate / / 22091778 rs10518563 chr4 131046911 G A 2.37E-05 Body Mass Index / / pha003007 rs2172478 chr4 131061953 T C 2.33E-06 Obesity (early onset extreme) / / 18159244 rs7656732 chr4 131091376 C T 8.46E-05 Vaspin levels / / 22907691 rs7656732 chr4 131091376 C T 0.0000846 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs13106127 chr4 131104359 T C 8.63E-05 Serum albumin level / / pha003084 rs13141189 chr4 131121392 A G 2.40E-04 Sudden cardiac arrest / / 21658281 rs1908039 chr4 131127633 T C 9.00E-08 Intelligence / / 22449649 rs1024020 chr4 131137761 T C 4.00E-07 RR interval (heart rate) / / 20031603 rs10028531 chr4 131162995 C T 1.30E-04 Vaspin levels / / 22907691 rs10028531 chr4 131162995 C T 0.0001301 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs7437554 chr4 131169265 A G 1.08E-04 Vaspin levels / / 22907691 rs7437554 chr4 131169265 A G 0.000108 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs12506063 chr4 131174088 T C 2.12E-04 Vaspin levels / / 22907691 rs12506063 chr4 131174088 T C 0.0001154 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs12506063 chr4 131174088 T C 0.0002121 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs11099042 chr4 131174498 G A 1.30E-04 Vaspin levels / / 22907691 rs11099042 chr4 131174498 G A 0.0001301 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs6833836 chr4 131175071 A G 1.30E-04 Vaspin levels / / 22907691 rs6833836 chr4 131175071 A G 0.0001301 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs10016932 chr4 131176907 A G 0.00015 Coronary artery calcification / / 23727086 rs10518570 chr4 131200309 G T 2.36E-05 Cognitive impairment induced by topiramate / / 22091778 rs17050940 chr4 131206901 T C 7.35E-04 Smoking initiation / / 24665060 rs1022079 chr4 131238094 C A 6.10E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs7680226 chr4 131249636 T G 1.90E-05 Urinary metabolites / / 21572414 rs1509445 chr4 131282974 G A 9.35E-04 Myopia (pathological) / / 21095009 rs967076 chr4 131293662 T C 8.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10023794 chr4 131297430 C G 8.80E-06 Urinary metabolites / / 21572414 rs2310956 chr4 131307585 G A 5.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9917861 chr4 131312071 C T 2.80E-06 Urinary metabolites / / 21572414 rs1355187 chr4 131342779 A G 2.20E-05 Waist circumference / / 23966867 rs12500688 chr4 131391376 A G 8.58E-04 Body mass index / / 21701565 rs1459302 chr4 131396692 A G 8.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4370149 chr4 131401711 A G 2.40E-05 Urinary metabolites / / 21572414 rs6845004 chr4 131412758 C T 2.50E-05 Urinary metabolites / / 21572414 rs2926412 chr4 131438987 C T 8.49E-04 Schizophrenia / / 19197363 rs4241945 chr4 131452555 C T 6.84E-04 Type 2 diabetes / / 17463246 rs1350594 chr4 131460017 A C 4.09E-04 Type 2 diabetes / / 17463246 rs2085679 chr4 131495706 A G 4.74E-05 Cortisol secretion,in saliva / / 21316860 rs1968821 chr4 131499397 A G 1.83E-05 Cortisol secretion,in saliva / / 21316860 rs1968821 chr4 131499397 A G 9.31E-05 Cortisol secretion,in saliva / / 21316860 rs2311375 chr4 131502194 G A 6.51E-05 Cortisol secretion,in saliva / / 21316860 rs10857146 chr4 131517059 C T 5.91E-04 Multiple complex diseases / / 17554300 rs7664241 chr4 131526935 C T 8.18E-04 Multiple complex diseases / / 17554300 rs2125639 chr4 131532350 A G 3.68E-04 Common variable immunodeficiency / / 21497890 rs1304183 chr4 131569148 A G 0.000534151 Hypertension (early onset hypertension) / / 22479346 rs931418 chr4 131634859 T C 8.76E-04 Acute lung injury / / 22295056 rs17051077 chr4 131651034 A G 1.31E-04 Acute lung injury / / 22295056 rs17051078 chr4 131652629 T C 0.0001 Migraine / / 22678113 rs306353 chr4 131662183 G A 8.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17051084 chr4 131671137 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs17051084 chr4 131671137 T C 4.27E-04 Tourette syndrome / / 22889924 rs12643993 chr4 131688005 A G 1.74E-04 Smoking cessation / / 24665060 rs3113500 chr4 131695431 A G 9.63E-04 Rheumatoid arthritis / / 21452313 rs572322 chr4 131696068 A G 9.33E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11933051 chr4 131707971 C T 4.55E-04 Smoking cessation / / 24665060 rs2312337 chr4 131727377 A C 4.67E-04 Multiple complex diseases / / 17554300 rs2312337 chr4 131727377 A C 5.61E-05 Asthma / / pha003128 rs1478075 chr4 131727847 A G 4.81E-05 Waist-Hip Ratio / / pha003013 rs1478079 chr4 131731916 C T 0.0006818 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1478079 chr4 131731916 C T 6.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs996299 chr4 131733521 A G 3.94E-05 Waist-Hip Ratio / / pha003013 rs6817488 chr4 131734353 G A 0.0008343 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6817488 chr4 131734353 G A 8.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7690766 chr4 131774208 A G 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7690766 chr4 131774208 A G 0.00000335 Migraine / / 22678113 rs7690766 chr4 131774208 A G 3.35E-06 Migraine / / 22683712 rs7694259 chr4 131776437 T A 1.10E-05 Urinary metabolites / / 21572414 rs931047 chr4 131786996 A T 8.93E-04 Multiple complex diseases / / 17554300 rs11930554 chr4 131787382 T C 0.00000284 Migraine / / 22678113 rs11930554 chr4 131787382 T C 2.84E-06 Migraine / / 22683712 rs11936003 chr4 131788092 A G 0.00000284 Migraine / / 22678113 rs11936003 chr4 131788092 A G 2.84E-06 Migraine / / 22683712 rs1478091 chr4 131790501 C T 2.00E-06 Multiple sclerosis (severity) / / 19010793 rs1382177 chr4 131824376 G A 1.10E-05 Urinary metabolites / / 21572414 rs12498616 chr4 131866685 G A 0.000051 Migraine / / 22678113 rs12498616 chr4 131866685 G A 5.10E-05 Migraine / / 22683712 rs2055392 chr4 131868112 C A 5.67E-04 Multiple complex diseases / / 17554300 rs6830509 chr4 131884313 A C 5.31E-05 Waist Circumference / / pha003025 rs12647096 chr4 131920334 G T 4.30E-04 Multiple complex diseases / / 17554300 rs17051141 chr4 131962618 A T 2.72E-05 Multiple complex diseases / / 17554300 rs11939435 chr4 131999915 T G 2.75E-05 Multiple complex diseases / / 17554300 rs6534830 chr4 132031233 T G 2.98E-04 Multiple complex diseases / / 17554300 rs477395 chr4 132116621 C A 8.05E-04 Multiple complex diseases / / 17554300 rs6855567 chr4 132169789 C T 1.40E-05 Urinary metabolites / / 21572414 rs9992638 chr4 132185472 A T 1.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs12641606 chr4 132190225 T C 1.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs11947432 chr4 132191080 G A 1.70E-04 Suicide attempts in bipolar disorder / / 21041247 rs10518587 chr4 132191260 T G 1.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs17051170 chr4 132193301 C A 1.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs17051172 chr4 132193442 T A,C 1.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs10006868 chr4 132201928 C G 1.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs11941498 chr4 132202819 T C 1.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs17051173 chr4 132204983 T C 1.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs2861393 chr4 132206947 G A 1.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs2861394 chr4 132210094 G A 1.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs2861394 chr4 132210094 G A 2.01E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2861394 chr4 132210094 G A 4.94E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4624669 chr4 132215015 A G 6.80E-05 Suicide attempts in bipolar disorder / / 21041247 rs10008591 chr4 132218117 C T 6.77E-05 Suicide attempts in bipolar disorder / / 21041247 rs10018289 chr4 132221147 G A 6.69E-05 Suicide attempts in bipolar disorder / / 21041247 rs12641562 chr4 132226965 A C 8.97E-05 Suicide attempts in bipolar disorder / / 21041247 rs12650292 chr4 132230173 G A 9.05E-05 Suicide attempts in bipolar disorder / / 21041247 rs12641430 chr4 132230540 T C 1.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs11946051 chr4 132230855 G T 1.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs12647579 chr4 132234027 A T 1.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs12641624 chr4 132234337 C T 1.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs9995748 chr4 132234938 T C 1.13E-04 Suicide attempts in bipolar disorder / / 21041247 rs10005249 chr4 132237873 T C 7.19E-04 Multiple complex diseases / / 17554300 rs11940669 chr4 132256594 C T 3.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs1911882 chr4 132262723 T C 3.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs17051177 chr4 132267237 G A 3.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs17051178 chr4 132267442 T G 3.60E-04 Suicide attempts in bipolar disorder / / 21041247 rs11931096 chr4 132268629 C T 3.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs1316758 chr4 132272766 T C 3.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs4585325 chr4 132282009 C T 3.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs1343670 chr4 132284073 T C 4.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs8180150 chr4 132288902 C A 4.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs4146422 chr4 132289020 C T 4.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs8180189 chr4 132289937 C T 4.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs17051181 chr4 132289984 T C 4.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs11099102 chr4 132317324 T C 6.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs11936773 chr4 132318109 G T 6.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs17051188 chr4 132328692 T C 6.14E-04 Body mass index / / 21701565 rs17051188 chr4 132328692 T C 6.45E-04 Body mass index / / 21701565 rs11945624 chr4 132330747 G A 6.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs12648650 chr4 132346486 A C 5.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs7683723 chr4 132350324 G A 8.63E-04 Multiple complex diseases / / 17554300 rs7690600 chr4 132351655 C T 5.52E-04 Multiple complex diseases / / 17554300 rs12649130 chr4 132359258 C G 5.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs10518597 chr4 132382377 C A 1.44E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs995401 chr4 132385208 G A 5.83E-04 Type 2 diabetes / / 17463246 rs351093 chr4 132414142 G A 1.79E-04 Type 2 diabetes / / 17463246 rs351091 chr4 132424371 C A 1.82E-04 Type 2 diabetes / / 17463246 rs2036891 chr4 132455666 A C 1.49E-05 Glucose levels / / pha003058 rs2036891 chr4 132455666 A C 6.58E-05 Cholesterol / / pha003073 rs2036891 chr4 132455666 A C 3.68E-05 ldl cholesterol / / pha003076 rs7692647 chr4 132464732 A G 6.73E-06 Brain structure / / 22504417 rs2062586 chr4 132474137 T C 1.18E-05 Glucose levels / / pha003058 rs2062586 chr4 132474137 T C 7.26E-05 ldl cholesterol / / pha003076 rs979640 chr4 132525794 A G 3.68E-04 Alzheimer's disease / / 17998437 rs350966 chr4 132545944 A C 6.07E-04 Alzheimer's disease / / 17998437 rs11725988 chr4 132718462 A G 6.00E-04 Dietary macronutrient intake / / 23636237 rs6534866 chr4 132826786 C A 1.52E-04 Multiple complex diseases / / 17554300 rs10518602 chr4 132942937 T C 2.58E-04 Type 2 diabetes / / 17846124 rs2163542 chr4 132957347 T A 9.51E-05 Schizophrenia / / 19571809 rs10015186 chr4 132970713 G A 4.35E-05 Schizophrenia / / 19571809 rs1991700 chr4 132972290 T C 9.51E-05 Schizophrenia / / 19571809 rs1431686 chr4 132980813 C T 5.34E-05 Schizophrenia / / 19571809 rs13115673 chr4 132989468 G T 8.83E-05 Schizophrenia / / 19571809 rs116985522 chr4 133068157 A C,G 1.48E-05 Intracerebral hemorrhage / / 24656865 rs11944012 chr4 133079569 G A 7.97E-04 Type 2 diabetes / / 17463246 rs12642306 chr4 133106648 C T 6.35E-06 Serum metabolites / / 19043545 rs10518609 chr4 133252054 G T 1.82E-05 Glucose levels / / pha003058 rs7690467 chr4 133326395 T C 7.00E-06 Eating disorders / / 22911880 rs17494286 chr4 133357204 A C 6.91E-05 Glucose levels / / pha003058 rs13129622 chr4 133400938 T G 1.28E-05 Glucose levels / / pha003058 rs13129622 chr4 133400938 T G 9.49E-05 Glucose levels / / pha003061 rs689569 chr4 133479358 C T 9.68E-04 Insulin resistance / / 21901158 rs1991976 chr4 133486856 G T 2.74E-05 Schizophrenia / / 19571811 rs11732021 chr4 133519291 A G 7.15E-04 Schizophrenia / / 19197363 rs725307 chr4 133562454 A G 3.20E-05 Kidney function and endocine traits / / 17903292 rs725304 chr4 133562918 C T 2.50E-05 Kidney function and endocine traits / / 17903292 rs983784 chr4 133581072 G A 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs723464 chr4 133582591 A G 1.00E-05 Kidney function and endocine traits / / 17903292 rs2419793 chr4 133632428 A G 6.20E-05 Serum albumin level / / pha003084 rs11721419 chr4 133635139 A T 3.00E-06 Urinary metabolites / / 21572414 rs13117639 chr4 133637568 C T 3.33E-05 Serum albumin level / / pha003084 rs11946243 chr4 133653343 A T 3.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs4407519 chr4 133686433 C T 7.33E-05 Serum metabolites / / 19043545 rs2053779 chr4 133718290 G T 5.68E-04 Multiple complex diseases / / 17554300 rs10518627 chr4 133814532 T C 9.84E-05 Tunica Media / / pha003036 rs12510100 chr4 133827600 A G 3.89E-05 Aging (time to event) / / 21782286 rs11099230 chr4 133858930 A G 2.05E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs12641896 chr4 133862954 A G 3.23E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs6854421 chr4 134026309 G A 1.82E-04 Insulin resistance / / 21901158 rs11936591 chr4 134154732 C T 9.95E-05 Alcohol consumption / / 23953852 rs1493499 chr4 134340488 A G 1.40E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs11099240 chr4 134357855 G T 6.50E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs3922637 chr4 134379070 C T 7.25E-04 Multiple complex diseases / / 17554300 rs17024794 chr4 134384791 T C 9.21E-04 Tourette syndrome / / 22889924 rs10518639 chr4 134386173 C T 7.32E-04 Tourette syndrome / / 22889924 rs4864200 chr4 134467929 T G 2.70E-05 Urinary metabolites / / 21572414 rs1493517 chr4 134471862 C T 5.40E-04 Crohn's disease / / 17684544 rs1493517 chr4 134471862 C T 3.46E-05 Lactate dehydrogenase levels / / 20981236 rs1389338 chr4 134471941 G C 6.19E-05 Lactate dehydrogenase levels / / 20981236 rs9307696 chr4 134487011 G C 5.70E-04 Crohn's disease / / 17684544 rs9307696 chr4 134487011 G C 4.88E-05 Lactate dehydrogenase levels / / 20981236 rs1826546 chr4 134491906 T G 2.90E-05 Urinary metabolites / / 21572414 rs1845303 chr4 134492165 C G 1.80E-05 Urinary metabolites / / 21572414 rs925084 chr4 134530386 T G 1.60E-04 Crohn's disease / / 17684544 rs7674505 chr4 134536988 G A 2.63E-05 Crohn's disease / / 17684544 rs2660727 chr4 134554855 G A 3.95E-05 Crohn's disease / / 17684544 rs7700170 chr4 134600991 G A 2.10E-04 Crohn's disease / / 17684544 rs2660693 chr4 134619611 C G 2.20E-04 Crohn's disease / / 17684544 rs950828 chr4 134653452 T A 3.95E-04 Type 2 diabetes / / 17846124 rs950828 chr4 134653452 T A 2.90E-04 Lipid traits / / 17903299 rs7668810 chr4 134710417 T C 5.80E-04 Prostate cancer mortality / / 20978177 rs4613620 chr4 134714897 T C 4.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4415013 chr4 134815036 A G 8.99E-05 HIV-1 viral setpoint / / 22174851 rs12512762 chr4 134824310 T C 9.37E-05 Cognitive impairment induced by topiramate / / 22091778 rs17540695 chr4 134847697 G A 7.59E-05 Cognitive impairment induced by topiramate / / 22091778 rs4305574 chr4 134855440 T C 8.01E-05 Cognitive impairment induced by topiramate / / 22091778 rs11731211 chr4 134888075 G A 8.77E-05 Cognitive impairment induced by topiramate / / 22091778 rs12651137 chr4 134893186 G A 9.77E-05 Coronary heart disease / / pha003031 rs6848935 chr4 134946533 A G 8.99E-04 Multiple complex diseases / / 17554300 rs6848935 chr4 134946533 A G 8.55E-04 Coronary Artery Disease / / 17634449 rs1494978 chr4 134947801 G A 6.00E-06 Lung function (forced expiratory volume in 1 second) / / 24023788 rs17542016 chr4 134952210 A G 3.42E-04 Coronary Artery Disease / / 17634449 rs11940537 chr4 134953040 G A 4.40E-06 Urinary metabolites / / 21572414 rs17614300 chr4 134966413 A G 9.37E-04 Multiple complex diseases / / 17554300 rs17614300 chr4 134966413 A G 5.39E-05 Coronary Artery Disease / / 17634449 rs12642075 chr4 134972554 G A 8.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs1390026 chr4 134973967 T G 8.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs1565912 chr4 134975009 G A 8.20E-04 Suicide attempts in bipolar disorder / / 21041247 rs1565911 chr4 134975053 G T 8.13E-04 Suicide attempts in bipolar disorder / / 21041247 rs1565910 chr4 134975099 A G 7.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs2421069 chr4 134975713 C T 7.69E-04 Suicide attempts in bipolar disorder / / 21041247 rs2421069 chr4 134975713 C T 1.04E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1580700 chr4 134986079 T C 1.54E-04 Taste perception / / 22132133 rs6534995 chr4 134996697 C T 1.50E-05 Urinary metabolites / / 21572414 rs10024145 chr4 135006267 G A 1.50E-05 Urinary metabolites / / 21572414 rs1353309 chr4 135012093 T C 2.20E-05 Urinary metabolites / / 21572414 rs1390022 chr4 135019322 T C 8.67E-04 Taste perception / / 22132133 rs17543450 chr4 135026238 A G 1.28E-04 Taste perception / / 22132133 rs1390020 chr4 135029774 C G 3.51E-05 Bipolar disorder / / 18317468 rs7657583 chr4 135057254 T C 5.33E-05 Bipolar disorder / / 18317468 rs10023277 chr4 135106332 G T 5.34E-05 Bipolar disorder / / 18317468 rs7681133 chr4 135115837 C T 5.16E-05 Bipolar disorder / / 18317468 rs2044116 chr4 135121368 G T 4.91E-05 Bipolar disorder PABPC4L cds-synon 18317468 rs10009368 chr4 135121601 C T 3.48E-05 Bipolar disorder PABPC4L missense 18317468 rs17034860 chr4 135177934 C T 2.37E-05 Multiple complex diseases / / 17554300 rs7675604 chr4 135264608 C T 0.000481 Salmonella-induced pyroptosis / / 22837397 rs1386364 chr4 135288617 T C 0.00043 Salmonella-induced pyroptosis / / 22837397 rs1601648 chr4 135294098 C T 0.000417 Salmonella-induced pyroptosis / / 22837397 rs2421334 chr4 135317096 T C 0.000202 Salmonella-induced pyroptosis / / 22837397 rs11938538 chr4 135318923 T C 0.000138 Salmonella-induced pyroptosis / / 22837397 rs1486973 chr4 135329427 C T 9.71E-05 Hematocrit / / pha003097 rs4388143 chr4 135428455 A C 0.0000911 Tuberculosis with early age of onset / / 22551897 rs11099284 chr4 135438724 T C 0.0000476 Tuberculosis with early age of onset / / 22551897 rs4241952 chr4 135439906 G T 0.0000476 Tuberculosis with early age of onset / / 22551897 rs4543185 chr4 135440831 A G 0.0000476 Tuberculosis with early age of onset / / 22551897 rs10026364 chr4 135522740 C T 4.00E-06 Coronary heart disease / / 21347282 rs13435210 chr4 135594747 T C 6.00E-04 Aortic root size / / 21223598 rs16998184 chr4 135622676 G A 4.87E-04 Multiple complex diseases / / 17554300 rs17040659 chr4 135632543 C T 9.42E-06 Multiple complex diseases / / 17554300 rs17572055 chr4 135657508 G C 2.00E-05 Urinary metabolites / / 21572414 rs475010 chr4 135658683 T C 2.28E-05 Esophageal cancer (squamous cell) / / 22960999 rs664766 chr4 135658741 C T 5.25E-04 Type 2 diabetes / / 17463246 rs548172 chr4 135686477 T C 9.43E-04 Alcohol dependence / / 24277619 rs13144694 chr4 135735591 A G 3.09E-04 Alcohol dependence / / 24277619 rs200733877 chr4 135735591 AT A 3.09E-04 Alcohol dependence / / 24277619 rs12504498 chr4 135742498 C T 1.10E-05 Urinary metabolites / / 21572414 rs2055671 chr4 135766067 C A 5.97E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2055670 chr4 135766089 T G 7.53E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4311359 chr4 135769014 A G 2.31E-06 Multiple complex diseases / / 17554300 rs13151035 chr4 135773459 C T 6.68E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4554132 chr4 135809615 T A 7.42E-04 Multiple complex diseases / / 17554300 rs11930940 chr4 135832737 G A 7.78E-05 Erythrocyte counts / / pha003099 rs10434068 chr4 135840331 A G 4.50E-05 Immunoglobulin A / / 20694011 rs7693757 chr4 135856609 C T 8.83E-04 Multiple complex diseases / / 17554300 rs11099302 chr4 135880751 G T 2.83E-05 Hemoglobin / / pha003098 rs11099302 chr4 135880751 G T 2.39E-05 Erythrocyte counts / / pha003099 rs7687641 chr4 135885739 G A 5.73E-04 Multiple complex diseases / / 17554300 rs7687463 chr4 135885773 C A 4.78E-04 Multiple complex diseases / / 17554300 rs13137075 chr4 135889366 G A 3.81E-05 Erythrocyte counts / / pha003099 rs4569802 chr4 135905371 A C 5.23E-05 Hemoglobin / / pha003098 rs4569802 chr4 135905371 A C 3.21E-05 Erythrocyte counts / / pha003099 rs4496634 chr4 135944011 G A 5.31E-04 Multiple complex diseases / / 17554300 rs4342240 chr4 135948455 C T 4.33E-04 Multiple complex diseases / / 17554300 rs4129152 chr4 136013237 C T 9.89E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4330400 chr4 136037410 A G 0.0000073 Chronic obstructive pulmonary disease (moderate to severe) / / 22986903 rs2404646 chr4 136086281 C G 6.48E-06 Nicotine smoking / / 19268276 rs5006661 chr4 136142498 C T 5.52E-04 Fibrinogen / / 17255346 rs17047592 chr4 136165982 A T 4.65E-04 Type 2 diabetes / / 17463246 rs4356958 chr4 136176700 C T 6.82E-05 Waist-Hip Ratio / / pha003013 rs17639207 chr4 136193340 T C 8.00E-06 Sexual dimorphism in anthropometric traits / / 23754948 rs10461223 chr4 136200409 C A 1.10E-05 Psoriasis / / 20953189 rs7340819 chr4 136261165 A G 9.98E-05 Waist Circumference / / pha003025 rs1380899 chr4 136263687 C T 9.53E-05 Body Mass Index / / pha003007 rs1380899 chr4 136263687 C T 3.05E-05 Waist-Hip Ratio / / pha003013 rs1380899 chr4 136263687 C T 6.53E-05 Body Mass Index / / pha003015 rs1380899 chr4 136263687 C T 1.27E-05 Waist Circumference / / pha003025 rs1380899 chr4 136263687 C T 5.01E-05 Waist-Hip Ratio / / pha003028 rs1380899 chr4 136263687 C T 2.09E-05 Waist-Hip Ratio / / pha003029 rs6535093 chr4 136279446 T C 9.18E-05 Waist Circumference / / pha003025 rs12510384 chr4 136302474 A G 6.21E-05 Height / / pha003010 rs12500596 chr4 136467279 T A 1.24E-04 Multiple complex diseases / / 17554300 rs1479792 chr4 136478228 A G 3.82E-04 Body mass index / / 21701565 rs17047941 chr4 136490198 T G 2.80E-05 Urinary metabolites / / 21572414 rs931121 chr4 136491544 G A 1.34E-04 Body mass index / / 21701565 rs11946618 chr4 136492590 G C 7.95E-04 Suicide attempts in bipolar disorder / / 21041247 rs11935796 chr4 136496620 A G 7.48E-04 Suicide attempts in bipolar disorder / / 21041247 rs11935719 chr4 136503387 G A 7.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs11935664 chr4 136503406 C T 7.35E-04 Suicide attempts in bipolar disorder / / 21041247 rs11940405 chr4 136503429 T G 7.35E-04 Suicide attempts in bipolar disorder / / 21041247 rs2054505 chr4 136503921 C T 7.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs2054506 chr4 136503973 C G 7.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs1842259 chr4 136504466 A G 8.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs2127459 chr4 136504501 G T 7.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs1479787 chr4 136504705 C T 7.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs1479788 chr4 136504738 A T 7.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs6828914 chr4 136504827 A G 3.46E-04 Type 2 diabetes / / 17463246 rs6828914 chr4 136504827 A G 4.72E-04 Body mass index / / 21701565 rs1479789 chr4 136504950 G A 7.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs12643192 chr4 136506407 C G 7.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs13131704 chr4 136506422 A T 7.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs7662409 chr4 136506676 C A,G 7.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs7667350 chr4 136506869 A G 7.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs13145036 chr4 136507979 A G 7.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs13122550 chr4 136508585 T C 7.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs13146643 chr4 136508704 A G 7.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs13122996 chr4 136508797 T A 8.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs13129036 chr4 136509206 T C 8.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs13101421 chr4 136509253 C T 8.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs2086327 chr4 136510557 A C 9.93E-05 Suicide attempts in bipolar disorder / / 21041247 rs2086327 chr4 136510557 A C 9.70E-05 Cognitive impairment induced by topiramate / / 22091778 rs2035291 chr4 136510920 G C 8.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs2035292 chr4 136511122 G A 8.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs2035293 chr4 136511136 A G 9.61E-05 Suicide attempts in bipolar disorder / / 21041247 rs7694930 chr4 136511596 A C 8.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs7654065 chr4 136512022 C A 8.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs7654065 chr4 136512022 C A 5.45E-04 Smoking initiation / / 24665060 rs1038151 chr4 136512755 T G 9.34E-05 Suicide attempts in bipolar disorder / / 21041247 rs1038152 chr4 136512923 A T 8.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs2016168 chr4 136513130 T C 8.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs11935087 chr4 136513592 A G 8.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs11723306 chr4 136514150 T C 8.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs11099350 chr4 136514771 G A 8.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs11944567 chr4 136515143 T C 8.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs7692855 chr4 136516456 C A,T 8.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs13142176 chr4 136516623 T C 8.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs13142176 chr4 136516623 T C 7.96E-04 Smoking initiation / / 24665060 rs11947127 chr4 136516997 T G 2.39E-04 Type 2 diabetes / / 17463246 rs6816076 chr4 136518454 A G 8.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs2174394 chr4 136518701 G A,C,T 7.21E-04 Suicide attempts in bipolar disorder / / 21041247 rs2102279 chr4 136519572 T C 7.21E-04 Suicide attempts in bipolar disorder / / 21041247 rs2089184 chr4 136519783 C G 8.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs11737477 chr4 136521069 G T 8.69E-04 Suicide attempts in bipolar disorder / / 21041247 rs11737486 chr4 136521106 G A 5.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs13112384 chr4 136528471 G C 6.20E-04 Smoking initiation / / 24665060 rs6845272 chr4 136539895 G T 7.97E-05 Waist-Hip Ratio / / pha003029 rs17048042 chr4 136586796 G A 6.03E-04 Alzheimer's disease / / 17998437 rs963645 chr4 136649383 C A 3.49E-05 Blood pressure / / 24001895 rs2018601 chr4 136694463 T C 2.36E-05 Behcet's disease / / 23291587 rs1504858 chr4 136705950 A C 3.90E-04 Breast cancer and prostate cancer / / 17903305 rs6822222 chr4 136761993 G T 7.82E-04 Coronary heart disease / / 21606135 rs12646936 chr4 136762639 T G 2.19E-07 Coronary heart disease / / 21606135 rs7679231 chr4 136882276 G T 5.42E-05 Cognitive test performance / / 20125193 rs35272245 chr4 136932365 A G 0.00087 Salmonella-induced pyroptosis / / 22837397 rs7672273 chr4 136968913 G A 0.0007723 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7672273 chr4 136968913 G A 7.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10519373 chr4 136980201 C T 0.0007517 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10519373 chr4 136980201 C T 7.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13134493 chr4 136980581 C T 0.0007468 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13134493 chr4 136980581 C T 7.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17048466 chr4 137016357 G A 0.0006819 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17048466 chr4 137016357 G A 6.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12511521 chr4 137021516 G A 2.17E-04 Major depressive disorder / / 22472876 rs13140190 chr4 137035493 T C 0.0007007 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13140190 chr4 137035493 T C 7.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4864316 chr4 137059814 A T 0.0007485 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4864316 chr4 137059814 A T 7.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1451125 chr4 137092390 T A 9.50E-05 Breast cancer and prostate cancer / / 17903305 rs2693428 chr4 137115636 T C 5.20E-04 Smoking initiation / / 24665060 rs2034535 chr4 137116996 C T 2.30E-05 Urinary metabolites / / 21572414 rs2034531 chr4 137144610 C T 3.00E-04 Type 2 diabetes / / 17846126 rs2053896 chr4 137154796 G A 0.0000662 Gains in maximal O2 uptake response / / 21183627 rs1115338 chr4 137183507 A C 1.02E-04 Coronary heart disease / / 21606135 rs12649267 chr4 137256253 C T 7.11E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17048615 chr4 137268429 G C 4.38E-04 Multiple complex diseases / / 17554300 rs10004561 chr4 137305676 T C 2.07E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2192204 chr4 137312423 T G 1.29E-05 Response to citalopram treatment / / 19846067 rs11732083 chr4 137349221 C A 4.67E-04 Sarcoidosis / / 19165924 rs7674671 chr4 137382964 G A 7.55E-05 Multiple complex diseases / / 17554300 rs1860966 chr4 137402211 C T 5.95E-05 Waist Circumference / / pha003023 rs1860966 chr4 137402211 C T 9.96E-05 Coronary heart disease / / pha003032 rs6535158 chr4 137445988 T C 5.90E-04 Parkinson's disease / / 17052657 rs10031240 chr4 137476159 A G 7.57E-04 Parkinson's disease / / 17052657 rs10012307 chr4 137526584 T C 2.00E-08 DNA methylation (parent-of-origin) / / 23725790 rs11099401 chr4 137533307 C T 9.24E-04 Myopia (pathological) / / 21095009 rs7685386 chr4 137573579 C T 1.48E-04 IgE levels / / 17255346 rs2406037 chr4 137591468 T C 3.47E-05 IgE levels / / 17255346 rs10519394 chr4 137604609 C A 1.10E-05 Subclinical atherosclerosis / / 17903303 rs17672295 chr4 137612016 G A 8.51E-04 Multiple complex diseases / / 17554300 rs13152384 chr4 137618071 C A 1.47E-05 IgE levels / / 17255346 rs2612180 chr4 137631697 T A 3.52E-04 Multiple complex diseases / / 17554300 rs2612180 chr4 137631697 T A 7.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs2612181 chr4 137632211 T C 9.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs2676110 chr4 137632673 G A 8.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs7658630 chr4 137634247 G A 8.10E-05 Iron levels / / 21208937 rs1460160 chr4 137634874 G A 5.92E-05 Celiac disease / / 23936387 rs6832309 chr4 137638537 T G 2.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs1460133 chr4 137642348 T C 4.43E-08 Multiple complex diseases / / 17554300 rs1460133 chr4 137642348 T C 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs6813479 chr4 137660383 T A 1.00E-06 Longevity / / 20834067 rs7692053 chr4 137662604 A G 1.06E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7692053 chr4 137662604 A G 2.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7692053 chr4 137662604 A G 2.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1460138 chr4 137676856 C A 1.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1460138 chr4 137676856 C A 5.58E-04 Response to alcohol consumption (flushing response) / / 24277619 rs17680173 chr4 137693116 C T 2.70E-04 Type 2 diabetes / / 17463246 rs2612153 chr4 137707089 G T 7.08E-04 Heart Failure / / pha002885 rs2634909 chr4 137730961 A G 6.00E-06 Urinary metabolites / / 21572414 rs17049044 chr4 137739311 C T 1.60E-04 Multiple complex diseases / / 17554300 rs2590762 chr4 137804904 T C 8.87E-06 Monocyte chemoattractant protein-1 / / pha003071 rs13134167 chr4 137814471 T C 2.80E-05 Urinary metabolites / / 21572414 rs10007934 chr4 137824601 G A 2.08E-05 Alcohol consumption / / 23953852 rs994912 chr4 137834967 G T 2.33E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7684426 chr4 137840719 T G 3.63E-04 Rheumatoid arthritis / / 21452313 rs1445522 chr4 137845771 A G 8.12E-04 Rheumatoid arthritis / / 21452313 rs12500811 chr4 137851689 G A 1.29E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1373895 chr4 137851858 C T 6.76E-04 Coronary Artery Disease / / 17634449 rs1589127 chr4 137885582 T C 8.61E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7695609 chr4 137886834 G A 6.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17049202 chr4 137899609 C T 8.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2197468 chr4 137914126 G A 6.61E-04 Type 2 diabetes / / 17463246 rs6841127 chr4 137937334 A G 2.95E-05 Multiple complex diseases / / 17554300 rs1517944 chr4 137937395 C T 1.15E-04 Multiple complex diseases / / 17554300 rs515800 chr4 137953807 T C 7.32E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs7699094 chr4 137964502 G A 4.23E-06 White blood cell count / / 21738479 rs13434771 chr4 137970653 A G 1.00E-05 Urinary metabolites / / 21572414 rs17049311 chr4 137985807 C T 5.08E-04 Alzheimer's disease / / 17998437 rs720733 chr4 137997347 T C 8.50E-04 Suicidal ideation / / 22030708 rs28429570 chr4 138010397 A G 5.31E-08 Narcolepsy / / 19629137 rs28429570 chr4 138010397 A G 1.70E-05 Urinary metabolites / / 21572414 rs10155413 chr4 138037282 T C 1.20E-08 Schizophrenia / / 21926974 rs4864388 chr4 138068118 G T 7.63E-05 Orofacial clefts / / 22419666 rs75900745 chr4 138091012 A G 2.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2406485 chr4 138112990 T C 5.21E-05 Alcohol consumption / / 23743675 rs13148112 chr4 138118905 G A 1.05E-05 Alcohol consumption / / 23743675 rs11937897 chr4 138118960 A G 1.15E-05 Alcohol consumption / / 23743675 rs6833974 chr4 138119083 A G 1.48E-05 Alcohol consumption / / 23743675 rs1554075 chr4 138119507 T C 4.76E-05 Alcohol consumption / / 23743675 rs11099428 chr4 138122354 C T 1.47E-05 Alcohol consumption / / 23743675 rs17644158 chr4 138127845 T G 2.44E-04 Coronary heart disease / / 21606135 rs10001004 chr4 138128799 G A 6.88E-06 Retinopathy in non-diabetics / / 23393555 rs7692267 chr4 138130022 T G 7.33E-06 Retinopathy in non-diabetics / / 23393555 rs992701 chr4 138133137 A G 5.43E-05 Serum metabolites / / 19043545 rs10519410 chr4 138134581 A G 1.00E-06 Adverse response to radiation therapy / / 23719583 rs7666605 chr4 138135531 A G 7.39E-06 Retinopathy in non-diabetics / / 23393555 rs2138071 chr4 138153728 G A 2.50E-04 Coronary heart disease / / 21606135 rs10004839 chr4 138154812 C T 5.00E-06 Retinopathy in non-diabetics / / 23393555 rs1425976 chr4 138158813 C G 5.43E-05 Serum metabolites / / 19043545 rs4561979 chr4 138161364 T C 5.08E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs6535205 chr4 138174833 T G 0.000156 Salmonella-induced pyroptosis / / 22837397 rs1425990 chr4 138180226 A G 0.0000452 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17646082 chr4 138182589 G C 0.0000438 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs72716187 chr4 138189536 A G 0.0000353 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10012193 chr4 138197514 C A,T 0.000513 Salmonella-induced pyroptosis / / 22837397 rs72718009 chr4 138209334 T C 0.000048 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10022270 chr4 138222871 A C 1.94E-04 Hearing function / / 17255346 rs1559781 chr4 138225217 C T 4.40E-04 Crohn's disease / / 17684544 rs987360 chr4 138227609 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs987360 chr4 138227609 C T 2.00E-06 Temperament / / 22832960 rs6535212 chr4 138235156 G T 5.04E-05 Serum metabolites / / 19043545 rs17049524 chr4 138260855 T C 2.55E-04 Insulin resistance / / 21901158 rs17333289 chr4 138260954 G A 4.93E-04 Multiple complex diseases / / 17554300 rs10519423 chr4 138279845 A G 9.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs6811274 chr4 138283405 C T 6.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1425968 chr4 138288819 C T 9.55E-04 Multiple complex diseases / / 17554300 rs1425967 chr4 138288890 A G 1.30E-05 Alzheimer's disease (late onset) / / 21460841 rs17049537 chr4 138294300 A C 1.52E-04 Insulin resistance / / 21901158 rs11099441 chr4 138297591 C T 8.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs766081 chr4 138309262 A G 5.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10519420 chr4 138313173 T C 9.27E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4416533 chr4 138326872 G A 1.10E-05 Alzheimer's disease (late onset) / / 21460841 rs1320342 chr4 138337749 T C 3.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7699794 chr4 138346339 G A 4.37E-05 Alzheimer's disease (late onset) / / 20885792 rs2406739 chr4 138353959 A G 5.94E-04 Parkinson's disease / / 17052657 rs2406739 chr4 138353959 A G 6.00E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2406739 chr4 138353959 A G 9.95E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7698992 chr4 138367052 T C 3.39E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs10519425 chr4 138369786 G A 3.39E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs10000182 chr4 138371307 A G 3.85E-04 Coronary Artery Disease / / 17634449 rs4864420 chr4 138374116 T G 3.04E-05 Elbow pain / / pha003008 rs4864420 chr4 138374116 T G 6.90E-06 Sodium levels / / pha003093 rs7679076 chr4 138380321 A C 3.50E-06 Urinary metabolites / / 21572414 rs2406756 chr4 138390066 G A 3.86E-05 Waist Circumference / / pha003025 rs13112145 chr4 138413244 T C 7.21E-04 Multiple complex diseases / / 17554300 rs13112145 chr4 138413244 T C 4.55E-04 Stroke / / 22306652 rs9761827 chr4 138416511 G A 1.87E-05 Stroke / / 22306652 rs9761827 chr4 138416511 G A 2.27E-05 Vaspin levels / / 22907691 rs9761827 chr4 138416511 G A 0.0000227 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs9761827 chr4 138416511 G A 1.10E-05 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) / / 24325915 rs7439567 chr4 138464842 C T 1.30E-04 Vaspin levels / / 22907691 rs7439567 chr4 138464842 C T 0.00000311 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs7439567 chr4 138464842 C T 0.0001303 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs7439567 chr4 138464842 C T 0.0001303 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at minimum 6 weeks / / 22907730 rs6824771 chr4 138477450 C T 4.34E-04 Multiple complex diseases / / 17554300 rs10021969 chr4 138535434 T G 3.90E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs4487406 chr4 138565294 A G 6.06E-06 Intelligence / / 21826061 rs7666878 chr4 138571663 A C 5.55E-04 Smoking initiation / / 24665060 rs17049735 chr4 138576003 C T 1.23E-06 Obesity-related traits / / 23251661 rs1976929 chr4 138577151 A G 5.32E-04 Smoking initiation / / 24665060 rs6839772 chr4 138578594 G A 7.22E-04 Smoking initiation / / 24665060 rs17275256 chr4 138580743 C T 3.85E-04 Smoking initiation / / 24665060 rs17049741 chr4 138582711 G A 8.00E-07 Obesity-related traits / / 23251661 rs1526248 chr4 138591243 G A 6.14E-04 Smoking initiation / / 24665060 rs2434137 chr4 138593451 T C 2.32E-05 Colorectal cancer / / 19723657 rs6535895 chr4 138635709 C T 2.50E-05 Urinary metabolites / / 21572414 rs1112918 chr4 138672285 G A 2.70E-05 Urinary metabolites / / 21572414 rs7675384 chr4 138691161 G T 2.23E-05 Aortic root size / / 21223598 rs2313132 chr4 138692250 G A 8.00E-06 Systemic lupus erythematosus / / 19165918 rs1509269 chr4 138753724 T C 9.21E-05 Parkinson's disease / / 16252231 rs6823023 chr4 138764286 T C 5.47E-04 Schizophrenia / / 19197363 rs2313982 chr4 138788060 A G 1.79E-05 Parkinson's disease / / 16252231 rs6817569 chr4 138805363 C T 5.89E-05 Cytomegalovirus antibody response / / 21993531 rs6817585 chr4 138805376 C T 5.90E-05 Cytomegalovirus antibody response / / 21993531 rs6812121 chr4 138809340 T C 5.91E-05 Cytomegalovirus antibody response / / 21993531 rs1965443 chr4 138831219 G C 5.60E-05 Cytomegalovirus antibody response / / 21993531 rs13128867 chr4 138840995 T C 2.23E-05 Kawasaki disease / / 21326860 rs7698174 chr4 138857345 A G 5.66E-06 Left ventricular mass / / 21212386 rs4133157 chr4 138874636 C A 8.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs7685800 chr4 138874841 C T 3.54E-04 Multiple complex diseases / / 17554300 rs17050054 chr4 138881713 G A 1.12E-04 Multiple complex diseases / / 17554300 rs938025 chr4 138898310 G A 1.38E-04 Multiple complex diseases / / 17554300 rs8180308 chr4 138902242 A C 3.06E-04 Multiple complex diseases / / 17554300 rs1401589 chr4 138920824 G T 2.22E-04 Alzheimer's disease (late onset) / / 21379329 rs4863751 chr4 138928942 A C 4.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs1519337 chr4 138933074 G A 3.54E-05 Neuroblastoma / / pha002895 rs6838819 chr4 138934982 G A 1.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs1866527 chr4 138936280 G C 6.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs2056275 chr4 138939662 C T 6.22E-05 Suicide attempts in bipolar disorder / / 21423239 rs4863754 chr4 138943249 T C 8.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs1519332 chr4 138947838 T A 2.65E-04 Multiple complex diseases / / 17554300 rs6851967 chr4 138994404 G T 2.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC641365 intron 20877124 rs6841624 chr4 139002645 C T 5.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC641365 intron 20877124 rs11734678 chr4 139005538 T G 2.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC641365 intron 20877124 rs1982203 chr4 139019356 C T 1.80E-05 Urinary metabolites LOC641364 intron 21572414 rs17300453 chr4 139027434 A G 1.20E-05 Urinary metabolites LOC641364 intron 21572414 rs6817559 chr4 139058773 T A 1.70E-05 Urinary metabolites LOC641364 intron 21572414 rs1344976 chr4 139064115 A G 4.87E-04 Alzheimer's disease (late onset) LOC641364 intron 21379329 rs6537156 chr4 139067202 T C 1.70E-05 Urinary metabolites LOC641364 intron 21572414 rs6839130 chr4 139074848 C T 2.80E-05 Urinary metabolites LOC641364 intron 21572414 rs7688870 chr4 139084657 A C 2.70E-05 Urinary metabolites LOC641364 intron 21572414 rs7674870 chr4 139089463 A G 6.52E-04 Parkinson's disease SLC7A11 UTR-3 17052657 rs7674870 chr4 139089463 A G 1.90E-06 Urinary metabolites SLC7A11 UTR-3 21572414 rs11728401 chr4 139097340 C T 1.40E-05 Urinary metabolites SLC7A11 intron 21572414 rs6537201 chr4 139110577 A G 2.39E-05 Cognitive decline SLC7A11 intron 22054870 rs11100834 chr4 139114529 T C 1.03E-06 Multiple complex diseases SLC7A11 intron 17554300 rs17050206 chr4 139152618 G C 3.95E-05 HIV-1 progression SLC7A11 intron 20064070 rs11723658 chr4 139157996 C A 4.01E-04 Alcohol dependence SLC7A11 intron 20201924 rs7657480 chr4 139192424 A G 8.71E-04 Schizophrenia / / 19197363 rs6537323 chr4 139223367 C T 1.45E-04 Blood pressure / / 17255346 rs17050280 chr4 139232229 G A 2.22E-04 Alzheimer's disease / / 24755620 rs17050281 chr4 139232271 G A 2.01E-04 Alzheimer's disease / / 24755620 rs7670671 chr4 139243656 C T 6.45E-04 Response to alcohol consumption (flushing response) / / 24277619 rs756165 chr4 139246504 A C 5.33E-06 Coronary heart disease / / pha003031 rs7669522 chr4 139253392 T C 1.76E-06 Coronary heart disease / / pha003031 rs7669668 chr4 139253454 T C 1.00E-06 Coronary heart disease / / pha003031 rs9994306 chr4 139256527 A G 8.58E-05 Lung adenocarcinoma / / 19836008 rs890447 chr4 139260985 G A 3.09E-80 Multiple complex diseases / / 17554300 rs298466 chr4 139262188 C T 6.40E-05 Coronary heart disease / / pha003031 rs1513774 chr4 139266517 A G 9.70E-07 Urinary metabolites / / 21572414 rs1398927 chr4 139268058 G A 9.62E-04 Obesity (extreme) / / 21935397 rs1398925 chr4 139300684 C T 8.76E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs930013 chr4 139325270 A G 4.89E-04 Type 2 diabetes / / 17463246 rs7693577 chr4 139330181 C T 9.06E-05 Fibrinogen / / pha003068 rs2976499 chr4 139336708 C T 8.38E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs11732157 chr4 139336851 C T 8.88E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs2976481 chr4 139339576 C T 3.81E-05 Fibrinogen / / pha003068 rs890444 chr4 139365038 G A 2.03E-04 Type 2 diabetes / / 17463246 rs11736129 chr4 139385626 C G 6.93E-05 Depression (quantitative trait) / / 20800221 rs2114359 chr4 139437272 T C 3.08E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2114360 chr4 139437395 C A 3.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs299133 chr4 139441717 G A 9.12E-04 Acute lung injury / / 22295056 rs299133 chr4 139441717 G A 6.06E-04 Tourette syndrome / / 22889924 rs299137 chr4 139444081 T C 1.40E-04 Multiple complex diseases / / 17554300 rs2314742 chr4 139454037 C T 3.73E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6853222 chr4 139476568 A C 0.0000681 Salmonella-induced pyroptosis / / 22837397 rs13110116 chr4 139482335 C T 6.47E-05 Waist-Hip Ratio / / pha003029 rs1376082 chr4 139485229 G A 8.06E-05 Waist-Hip Ratio / / pha003029 rs1530798 chr4 139486064 T C 3.10E-06 Urinary metabolites / / 21572414 rs1349345 chr4 139490191 C G 1.39E-05 Lung Function (Forced Expiratory Volume in 1 second) / / 25044411 rs1450439 chr4 139493398 A G 4.00E-06 Lung Function (Forced Expiratory Volume in 1 second) / / 25044411 rs1376086 chr4 139494811 A G 7.91E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs9685123 chr4 139513580 G A 6.09E-04 Parkinson's disease / / 17052657 rs10032519 chr4 139525415 T C 8.83E-05 Serum metabolites / / 19043545 rs7680585 chr4 139530310 C A 1.25E-05 Cognitive test performance / / 20125193 rs10857235 chr4 139567110 C T 0.000403591 Hypertension (early onset hypertension) / / 22479346 rs12506116 chr4 139584960 A G 6.96E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7692637 chr4 139590199 G T 4.65E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10033127 chr4 139600081 C T 8.15E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17050585 chr4 139609452 C T 3.87E-04 Multiple complex diseases / / 17554300 rs7690656 chr4 139609545 T G 9.84E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1505863 chr4 139611302 C T 0.00001 Asthma / / 18401594 rs4863587 chr4 139611745 G T 2.53E-04 Body mass index / / 21701565 rs4863589 chr4 139620025 G T 8.05E-04 Multiple complex diseases / / 17554300 rs7667792 chr4 139624155 T C 8.36E-04 Multiple complex diseases / / 17554300 rs13127451 chr4 139723260 T C 4.69E-04 Smoking cessation / / 24665060 rs7679654 chr4 139773556 T A 8.31E-04 Multiple complex diseases / / 17554300 rs11728621 chr4 139779568 A G 5.47E-05 Lipid levels / / pha003082 rs77803164 chr4 139809181 G A 4.00E-06 Cognitive decline (age-related) / / 24468470 rs13110551 chr4 139820718 C T 8.84E-04 Multiple complex diseases / / 17554300 rs4863602 chr4 139822384 C A 6.17E-04 Multiple complex diseases / / 17554300 rs4639023 chr4 139826720 A G 3.73E-04 Multiple complex diseases / / 17554300 rs11937204 chr4 139830882 G A 7.29E-05 Multiple complex diseases / / 17554300 rs4546191 chr4 139847208 G A 3.35E-05 Psoriasis / / 20953190 rs13101244 chr4 139907427 G T 4.80E-05 Memory performance / / 22105620 rs13116075 chr4 139930032 A G 4.91E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs6824182 chr4 139930982 A C 2.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs6810819 chr4 139936325 A C 5.15E-08 HDL cholesterol / / 23063622 rs7675990 chr4 140081406 C T 1.35E-05 Cognitive impairment induced by topiramate / / 22091778 rs10033117 chr4 140082553 C A 2.40E-05 Type 2 diabetes / / 17460697 rs1487723 chr4 140095627 G A 4.74E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs2029288 chr4 140170092 C A 9.26E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs17278611 chr4 140238360 G A 5.90E-06 Urinary metabolites /A15 intron 21572414 rs17346134 chr4 140422878 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17050782 chr4 140423134 A G 8.00E-06 Smoking behavior / / 19247474 rs17050793 chr4 140443647 T C 4.30E-06 Urinary metabolites SETD7 intron 21572414 rs17346734 chr4 140447084 A G 1.61E-04 Multiple complex diseases SETD7 intron 17554300 rs1037149 chr4 140457430 G T 9.25E-04 Response to taxane treatment (placlitaxel) SETD7 intron 23006423 rs706310 chr4 140481510 A G 8.55E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11726931 chr4 140497312 T C 9.06E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs706334 chr4 140517908 A C 9.20E-05 Height / / pha003011 rs883933 chr4 140560439 C T 6.49E-04 Body mass index / / 21701565 rs795602 chr4 140581932 G A 2.11E-05 Longevity / / 21612516 rs8192013 chr4 140588391 T C 4.55E-05 Pancreatic cancer MGST2 intron pha002889 rs706349 chr4 140600307 C T 5.31E-04 White matter integrity MGST2 intron 22425255 rs8192100 chr4 140616983 A C 7.72E-04 Alzheimer's disease MGST2 intron 17998437 rs17050873 chr4 140631137 C T 6.21E-05 Vascular dementia MGST2 intron 22116812 rs4863509 chr4 140684166 C T 4.29E-10 Multiple complex diseases MAML3 intron 17554300 rs4863689 chr4 140719642 G A 1.00E-04 Cognitive impairment induced by topiramate MAML3 intron 22091778 rs11100314 chr4 140783603 A G 2.06E-04 Schizophrenia MAML3 intron 20832056 rs6825389 chr4 140785463 T C 1.50E-04 Schizophrenia MAML3 intron 20832056 rs795982 chr4 140786845 A C 1.02E-04 Schizophrenia MAML3 intron 19197363 rs4863698 chr4 140793731 G C 9.21E-05 Schizophrenia MAML3 intron 20832056 rs1531070 chr4 140795327 G A 5.00E-12 Congenital heart malformation MAML3 intron 23708190 rs1473056 chr4 140805403 G C 1.22E-04 Response to cytidine analogues (gemcitabine) MAML3 intron 24483146 rs11733737 chr4 140824542 C T 2.01E-04 Celiac disease MAML3 intron 23936387 rs17051003 chr4 140829147 G A 8.44E-06 Carotenoid and tocopherol levels MAML3 intron 19185284 rs1350036 chr4 140831781 C T 3.49E-05 Dietary macronutrient intake MAML3 intron 23636237 rs1350036 chr4 140831781 C T 1.66E-04 Celiac disease MAML3 intron 23936387 rs17005223 chr4 140834736 G A 1.21E-05 Serum metabolites MAML3 intron 19043545 rs4863708 chr4 140873893 C A 4.67E-04 Suicide attempts in bipolar disorder MAML3 intron 21423239 rs966408 chr4 140877608 C A 4.37E-04 Suicide attempts in bipolar disorder MAML3 intron 21423239 rs769673 chr4 140882750 G A 2.14E-05 Multiple sclerosis MAML3 intron 20598377 rs6855142 chr4 140888040 G A 2.45E-04 Suicide attempts in bipolar disorder MAML3 intron 21423239 rs13119079 chr4 140888081 C T 2.03E-04 Suicide attempts in bipolar disorder MAML3 intron 21423239 rs952669 chr4 140888278 T C 8.15E-04 Suicide attempts in bipolar disorder MAML3 intron 21423239 rs952668 chr4 140888449 T C 2.98E-04 Suicide attempts in bipolar disorder MAML3 intron 21423239 rs12711353 chr4 140889736 C G 3.23E-04 Suicide attempts in bipolar disorder MAML3 intron 21423239 rs6838773 chr4 140890766 G T 3.14E-04 Suicide attempts in bipolar disorder MAML3 intron 21423239 rs6822524 chr4 140891061 T C 3.22E-04 Suicide attempts in bipolar disorder MAML3 intron 21423239 rs17372835 chr4 140892101 C T 3.36E-04 Suicide attempts in bipolar disorder MAML3 intron 21423239 rs17313646 chr4 140892233 T G 3.22E-04 Suicide attempts in bipolar disorder MAML3 intron 21423239 rs1877077 chr4 140894372 G A 9.54E-04 Suicide attempts in bipolar disorder MAML3 intron 21423239 rs1877076 chr4 140894612 G A 3.40E-04 Suicide attempts in bipolar disorder MAML3 intron 21423239 rs17373010 chr4 140900049 G A 3.29E-04 Suicide attempts in bipolar disorder MAML3 intron 21423239 rs17313967 chr4 140906641 G A 4.52E-04 Suicide attempts in bipolar disorder MAML3 intron 21423239 rs2048386 chr4 140930353 T C 8.78E-04 Type 2 diabetes MAML3 intron 17463246 rs1402671 chr4 140944844 A C,G 3.51E-05 Serum metabolites MAML3 intron 19043545 rs10440457 chr4 140983576 T C 7.86E-04 Suicide attempts in bipolar disorder MAML3 intron 21423239 rs1402669 chr4 140985905 C T 5.46E-04 Suicide attempts in bipolar disorder MAML3 intron 21423239 rs1877078 chr4 140986357 G T 5.04E-04 Suicide attempts in bipolar disorder MAML3 intron 21423239 rs12646446 chr4 141007734 T C 2.84E-04 Suicide attempts in bipolar disorder MAML3 intron 21423239 rs7691693 chr4 141012918 T C 2.60E-04 Suicide attempts in bipolar disorder MAML3 intron 21423239 rs1402673 chr4 141022942 A G 4.20E-05 Celiac disease MAML3 intron 23936387 rs17323440 chr4 141033891 G A 2.30E-05 Urinary metabolites MAML3 intron 21572414 rs2139926 chr4 141035921 G A 4.23E-04 Alzheimer's disease (late onset) MAML3 intron 21379329 rs12505243 chr4 141142535 A G 6.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs13125710 chr4 141152945 G A 5.72E-04 Longevity / / 22279548 rs11733305 chr4 141155942 T G 3.37E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6831057 chr4 141166281 A G 8.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs7692308 chr4 141180957 C T 2.58E-04 Suicide attempts in bipolar disorder SCOC intron 21423239 rs7675351 chr4 141218757 A C 6.50E-05 Birth weight SCOC intron 17255346 rs6840033 chr4 141228861 C T 7.10E-21 Multiple complex diseases SCOC intron 17554300 rs10519535 chr4 141249662 C T 3.54E-04 Response to taxane treatment (placlitaxel) SCOC intron 23006423 rs4956342 chr4 141254086 A G 6.63E-04 Prostate cancer mortality SCOC intron 20978177 rs6837799 chr4 141351711 C T 3.00E-05 Psoriasis / / 19169255 rs6536958 chr4 141357957 G A 6.90E-05 Psoriasis / / 19169255 rs1594468 chr4 141387438 C T 1.00E-06 Select biomarker traits LOC152586 intron 17903293 rs1594468 chr4 141387438 C T 1.00E-06 Select biomarker traits LOC152586 intron 17903293 rs1431336 chr4 141402192 A T 8.50E-05 Personality dimensions LOC152586 intron 18957941 rs10519561 chr4 141409692 C A 7.20E-05 Personality dimensions LOC152586 intron 18957941 rs2036020 chr4 141451033 G A 4.06E-04 Iron levels ELMOD2 intron pha002876 rs6822807 chr4 141487748 T C 2.30E-04 Coronary heart disease UCP1 intron 21966275 rs1430579 chr4 141492685 G C 0.000091 Prostate cancer / / 22532847 rs4956324 chr4 141533137 C T 2.70E-04 Multiple complex diseases / / 17554300 rs1560440 chr4 141543997 G A 4.00E-04 Myocardial Infarction TBC1D9 cds-synon pha002883 rs7698088 chr4 141551608 A G 8.80E-05 Adverse response to radiation therapy TBC1D9 intron 23719583 rs6823068 chr4 141570319 C T 7.84E-05 Body mass index TBC1D9 intron 17255346 rs4956472 chr4 141579374 G A 2.60E-05 Urinary metabolites TBC1D9 intron 21572414 rs10519539 chr4 141598561 A G 1.70E-06 Urinary metabolites TBC1D9 intron 21572414 rs6537004 chr4 141612308 A G 2.10E-06 Urinary metabolites TBC1D9 intron 21572414 rs923307 chr4 141629176 A G 2.37E-04 Multiple complex diseases TBC1D9 intron 17554300 rs923307 chr4 141629176 A G 1.40E-05 Urinary metabolites TBC1D9 intron 21572414 rs6853171 chr4 141642919 C T 1.93E-08 Metabolite levels TBC1D9 intron 23281178 rs7659321 chr4 141644529 G A 7.74E-09 Metabolite levels TBC1D9 intron 23281178 rs6835008 chr4 141650245 T C 7.74E-09 Metabolite levels TBC1D9 intron 23281178 rs6853487 chr4 141650276 C T 7.74E-09 Metabolite levels TBC1D9 intron 23281178 rs17006401 chr4 141652922 A G 7.74E-09 Metabolite levels TBC1D9 intron 23281178 rs12500421 chr4 141656345 T C 9.37E-09 Metabolite levels TBC1D9 intron 23281178 rs12386428 chr4 141658275 G A 9.37E-09 Metabolite levels TBC1D9 intron 23281178 rs12386422 chr4 141660327 T C 9.37E-09 Metabolite levels TBC1D9 intron 23281178 rs6844563 chr4 141662163 T C 9.37E-09 Metabolite levels TBC1D9 intron 23281178 rs2129646 chr4 141668671 A G 2.08E-04 Multiple complex diseases TBC1D9 intron 17554300 rs12503919 chr4 141692632 G A 1.40E-08 Metabolite levels / / 23281178 rs998013 chr4 141786545 C T 1.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10034843 chr4 141815089 A C 6.80E-04 Response to taxane treatment (placlitaxel) RNF150 intron 23006423 rs767761 chr4 141816657 C A 2.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RNF150 intron 20877124 rs1364886 chr4 141825374 C T 1.04E-05 Odorant perception RNF150 intron 23910658 rs1030356 chr4 141826780 G A 3.61E-05 Lung function (forced expiratory volume in 1 second) RNF150 intron 17255346 rs1030356 chr4 141826780 G A 5.77E-05 ldl cholesterol RNF150 intron pha003076 rs961402 chr4 141830252 A C 1.01E-04 Parkinson's disease RNF150 intron 17052657 rs1834382 chr4 141833535 C T 3.11E-06 Cholesterol RNF150 intron pha003073 rs1834382 chr4 141833535 C T 4.91E-07 ldl cholesterol RNF150 intron pha003076 rs1834382 chr4 141833535 C T 1.48E-05 Cholesterol RNF150 intron pha003078 rs1425442 chr4 141833760 G C 2.51E-05 Multiple complex diseases RNF150 intron 17554300 rs17338560 chr4 141834589 C T 3.84E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) RNF150 intron 24023788 rs6537018 chr4 141836576 G A 2.09E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) RNF150 intron 24023788 rs11930778 chr4 141845689 T C 4.15E-04 Obesity (extreme) RNF150 intron 21935397 rs17339131 chr4 141848200 T C 4.03E-04 Obesity (extreme) RNF150 intron 21935397 rs12642167 chr4 141848258 A G 1.73E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) RNF150 intron 24023788 rs13118519 chr4 141851355 C T 8.21E-04 Acne (severe) RNF150 intron 24399259 rs17423804 chr4 141851779 C T 4.96E-04 Obesity (extreme) RNF150 intron 21935397 rs6537022 chr4 141852682 G A 5.21E-05 Obesity (extreme) RNF150 intron 21935397 rs7658326 chr4 141853440 A G 1.80E-05 Obesity (extreme) RNF150 intron 21935397 rs17006670 chr4 141854382 T C 5.13E-05 Obesity (extreme) RNF150 intron 21935397 rs1001487 chr4 141868515 T C 1.06E-04 Height RNF150 intron 17255346 rs2321689 chr4 141875683 C T 1.51E-04 Blood pressure RNF150 intron 17255346 rs1425443 chr4 141881246 C T 6.12E-05 C-Reactive Protein RNF150 intron pha003070 rs1425431 chr4 141891566 T C 2.00E-04 Cognitive impairment induced by topiramate RNF150 intron 22091778 rs1425431 chr4 141891566 T C 2.00E-04 Cognitive impairment induced by topiramate RNF150 intron 22091778 rs1425431 chr4 141891566 T C 8.05E-05 Cognitive impairment induced by topiramate RNF150 intron 22091778 rs10519574 chr4 141891993 C A 2.00E-04 Cognitive impairment induced by topiramate RNF150 intron 22091778 rs10519574 chr4 141891993 C A 2.00E-04 Cognitive impairment induced by topiramate RNF150 intron 22091778 rs10519574 chr4 141891993 C A 2.00E-04 Cognitive impairment induced by topiramate RNF150 intron 22091778 rs10519574 chr4 141891993 C A 7.65E-05 Cognitive impairment induced by topiramate RNF150 intron 22091778 rs17343501 chr4 141895912 C A 5.02E-04 Gallstones RNF150 intron 17632509 rs1364881 chr4 141896970 C T 1.40E-05 Urinary metabolites RNF150 intron 21572414 rs11726692 chr4 141920037 A G 1.10E-05 Urinary metabolites RNF150 intron 21572414 rs13132043 chr4 141931721 T C 1.00E-04 Cognitive impairment induced by topiramate RNF150 intron 22091778 rs13132043 chr4 141931721 T C 1.00E-04 Cognitive impairment induced by topiramate RNF150 intron 22091778 rs13132043 chr4 141931721 T C 2.26E-05 Cognitive impairment induced by topiramate RNF150 intron 22091778 rs7687054 chr4 141933097 T C 4.42E-04 Multiple complex diseases RNF150 intron 17554300 rs11100699 chr4 141957064 A C 7.77E-04 Alzheimer's disease RNF150 intron 17998437 rs9991795 chr4 141965158 C T 2.67E-04 Multiple complex diseases RNF150 intron 17554300 rs4482847 chr4 141993345 A C 3.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RNF150 intron 20877124 rs3851432 chr4 141996416 C T 2.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RNF150 intron 20877124 rs10007052 chr4 142005573 C A 1.00E-07 Chronic obstructive pulmonary disease-related biomarkers RNF150 intron 23144326 rs17006859 chr4 142009987 A G 3.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RNF150 intron 20877124 rs10454797 chr4 142016173 G A 6.05E-04 Type 2 diabetes RNF150 intron 17463246 rs1027816 chr4 142046828 T C 1.80E-05 Urinary metabolites RNF150 intron 21572414 rs241867 chr4 142068023 T C 5.04E-06 Intracerebral hemorrhage / / 24656865 rs354936 chr4 142070069 C T 9.41E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6856385 chr4 142074933 G A 9.41E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7666238 chr4 142095763 A G 9.00E-04 Neuroticism / / 17667963 rs1550057 chr4 142117424 A G 4.00E-06 Conduct disorder (symptom count) / / 20585324 rs6850055 chr4 142122167 T G 2.75E-04 Hearing function / / 17255346 rs17007017 chr4 142142729 A G 7.00E-06 Conduct disorder (symptom count) ZNF330 intron 20585324 rs1435127 chr4 142159511 C T 1.27E-05 Lymphocyte counts / / 22286170 rs6855721 chr4 142160000 T G 3.55E-04 Insulin resistance / / 21901158 rs2572229 chr4 142206279 G A 2.95E-05 Blood Pressure / / pha003040 rs6857575 chr4 142218748 A G 3.15E-04 Myopia (pathological) / / 21095009 rs6825793 chr4 142235493 G A 5.93E-04 Multiple complex diseases / / 17554300 rs1347599 chr4 142238736 C G 4.87E-04 Multiple complex diseases / / 17554300 rs17456275 chr4 142273090 C A 6.05E-04 Multiple complex diseases / / 17554300 rs746484 chr4 142275621 C T 6.98E-05 Age-related macular degeneration / / pha000002 rs9308140 chr4 142280205 A G 5.26E-05 Age-related macular degeneration / / pha000002 rs1836895 chr4 142363256 A T 4.54E-05 Serum metabolites / / 19043545 rs12505771 chr4 142366446 G A 1.71E-04 Type 2 diabetes / / 17463246 rs12505771 chr4 142366446 G A 9.53E-06 Smoking behavior / / 19188921 rs6838494 chr4 142367404 C A 2.58E-04 Type 2 diabetes / / 17463246 rs6838494 chr4 142367404 C A 9.53E-06 Smoking behavior / / 19188921 rs4956381 chr4 142390713 A G 4.14E-04 Coronary heart disease / / 21971053 rs17354547 chr4 142390869 A C 3.20E-04 Type 2 diabetes / / 17463246 rs17354547 chr4 142390869 A C 5.61E-06 Smoking behavior / / 19188921 rs17354568 chr4 142391371 G T 1.81E-04 Type 2 diabetes / / 17463246 rs17354568 chr4 142391371 G T 1.72E-05 Smoking behavior / / 19188921 rs17007301 chr4 142409979 G A 2.34E-04 Type 2 diabetes / / 17463246 rs17007301 chr4 142409979 G A 1.39E-05 Smoking behavior / / 19188921 rs10519602 chr4 142413650 C T 3.32E-05 Potassium levels / / pha003086 rs17007336 chr4 142423548 C T 6.55E-04 Acute lung injury / / 22295056 rs7693458 chr4 142423973 A C 6.55E-04 Acute lung injury / / 22295056 rs1402812 chr4 142441666 G C 2.12E-04 Type 2 diabetes / / 17463246 rs1402812 chr4 142441666 G C 6.67E-06 Smoking behavior / / 19188921 rs4956396 chr4 142442790 C T 2.14E-04 Type 2 diabetes / / 17463246 rs4956396 chr4 142442790 C T 1.06E-05 Smoking behavior / / 19188921 rs4956397 chr4 142443887 G T 3.32E-05 Potassium levels / / pha003086 rs4956301 chr4 142460479 A G 9.62E-05 Potassium levels / / pha003086 rs1879684 chr4 142462518 G T 2.75E-05 Potassium levels / / pha003086 rs13133830 chr4 142464118 G A 1.22E-05 Smoking behavior / / 19188921 rs4956302 chr4 142464722 A G 2.55E-04 Type 2 diabetes / / 17463246 rs4956302 chr4 142464722 A G 1.19E-06 Smoking behavior / / 19188921 rs1519548 chr4 142530609 C T 2.88E-04 Alcohol dependence / / 20201924 rs12508866 chr4 142565693 T C 8.82E-04 Type 2 diabetes IL15 intron 17463246 rs1519551 chr4 142570472 G A 2.10E-05 Urinary metabolites IL15 intron 21572414 rs17364630 chr4 142602349 C G 8.96E-05 Type 2 diabetes IL15 intron 17463246 rs12498901 chr4 142603130 G C 7.83E-05 Type 2 diabetes IL15 intron 17463246 rs17007565 chr4 142634711 A G 2.92E-10 HDL cholesterol IL15 intron 23063622 rs10519610 chr4 142637101 T C 2.25E-04 Type 2 diabetes IL15 intron 17463246 rs10519613 chr4 142654084 C A 1.13E-04 Type 2 diabetes IL15 UTR-3 17463246 rs1602777 chr4 142661969 G C 1.09E-04 Arthritis (juvenile idiopathic) / / 22354554 rs2322305 chr4 142664259 T G 7.13E-05 Arthritis (juvenile idiopathic) / / 22354554 rs970509 chr4 142677821 G A 7.24E-05 Arthritis (juvenile idiopathic) / / 22354554 rs35964658 chr4 142679588 A G 4.01E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs10519629 chr4 142682770 T C 1.45E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1493015 chr4 142691963 T C 7.75E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs1389099 chr4 142692241 T A 7.75E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs17007695 chr4 142709723 T C 9.00E-07 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs17701271 chr4 142711243 C A 3.00E-04 Asthma (bronchodilator response) / / 23508266 rs7691866 chr4 142728396 G A 4.27E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1493018 chr4 142730076 G A 9.82E-04 Multiple complex diseases / / 17554300 rs2099884 chr4 142763570 G A 8.44E-04 Multiple complex diseases / / 17554300 rs2099884 chr4 142763570 G A 1.27E-05 Body mass index / / 24348519 rs4956418 chr4 142766496 G T 7.22E-04 Multiple complex diseases / / 17554300 rs1372884 chr4 142768316 G A 6.21E-04 Multiple complex diseases / / 17554300 rs12512440 chr4 142772104 G A 1.74E-05 Height / / 22021425 rs16998515 chr4 142776032 A T 7.09E-04 Multiple complex diseases / / 17554300 rs17015108 chr4 142777555 G C 6.14E-04 Multiple complex diseases / / 17554300 rs17015119 chr4 142792211 G A 8.53E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs1500842 chr4 142811893 C T 0.0006546 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1500842 chr4 142811893 C T 6.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1500841 chr4 142811946 C A 0.0006554 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1500841 chr4 142811946 C A 6.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1500840 chr4 142812073 C T 0.0006578 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1500840 chr4 142812073 C T 6.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1500837 chr4 142814856 A G 0.000663 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1500837 chr4 142814856 A G 6.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6844013 chr4 142815639 G A 0.0007181 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6844013 chr4 142815639 G A 7.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1002650 chr4 142831383 T C 0.0002566 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1002650 chr4 142831383 T C 2.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1500847 chr4 142833334 C T 0.0001868 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1500847 chr4 142833334 C T 1.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2133926 chr4 142836161 A G 0.0004148 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2133926 chr4 142836161 A G 4.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13107149 chr4 142836961 A G 0.0002132 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13107149 chr4 142836961 A G 2.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs967004 chr4 142844924 G A 1.77E-09 Non-obstructive azoospermia / / 22197933 rs2667095 chr4 142966229 T A 6.33E-04 Suicide attempts in bipolar disorder INPP4B intron 21423239 rs2667100 chr4 142976073 A G 9.00E-07 Amyotrophic lateral sclerosis (sporadic) INPP4B intron 24529757 rs336408 chr4 143055538 T C 8.35E-08 Metabolite levels INPP4B intron 23281178 rs3775662 chr4 143071515 C T 5.37E-05 Multiple complex diseases INPP4B intron 17554300 rs17015612 chr4 143081958 C T 1.29E-04 Multiple complex diseases INPP4B intron 17554300 rs9308148 chr4 143098939 A G 7.79E-05 Alcohol dependence INPP4B intron 21314694 rs2055212 chr4 143105706 T C 9.67E-05 Non-alcoholic fatty liver disease histology (other) INPP4B intron 20708005 rs17654944 chr4 143173023 C T 6.70E-04 Multiple complex diseases INPP4B intron 17554300 rs1907109 chr4 143184655 A C 0.00000333 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) INPP4B intron 22984439 rs1907109 chr4 143184655 A C 0.00029 Age-related cataract and Alzheimer's disease (cortical cataract) INPP4B intron 22984439 rs2636638 chr4 143230028 G A 1.30E-05 Urinary metabolites INPP4B intron 21572414 rs6844681 chr4 143247240 C A 9.20E-04 Response to taxane treatment (placlitaxel) INPP4B intron 23006423 rs17016123 chr4 143355338 T C 2.80E-05 Height INPP4B intron 19396169 rs1906874 chr4 143370378 G A 4.97E-04 Multiple complex diseases INPP4B intron 17554300 rs13107432 chr4 143444744 A G 9.19E-06 Alzheimer's disease INPP4B intron 24755620 rs6835296 chr4 143455287 A C 9.76E-04 Alzheimer's disease INPP4B intron 24755620 rs2217016 chr4 143464619 G A 6.80E-05 Diabetic retinopathy INPP4B intron 21441570 rs13102150 chr4 143470133 C A 9.03E-05 Alzheimer's disease INPP4B intron 24755620 rs6848419 chr4 143473648 T G 5.47E-04 Insulin resistance INPP4B intron 21901158 rs1425520 chr4 143474601 T C 0.00026154 Hypertension (early onset hypertension) INPP4B intron 22479346 rs1019643 chr4 143503071 A G 9.20E-06 Urinary metabolites INPP4B intron 21572414 rs7688435 chr4 143508339 T C 4.80E-06 Urinary metabolites INPP4B intron 21572414 rs7682731 chr4 143513969 A G 1.20E-05 Urinary metabolites INPP4B intron 21572414 rs1364925 chr4 143516374 G C 3.85E-04 Type 2 diabetes INPP4B intron 17463246 rs1443190 chr4 143553033 A G 1.20E-05 Urinary metabolites INPP4B intron 21572414 rs745719 chr4 143569058 G A 1.20E-05 Urinary metabolites INPP4B intron 21572414 rs7437824 chr4 143579013 T C 6.20E-06 Urinary metabolites INPP4B intron 21572414 rs1017527 chr4 143582924 T C 1.20E-05 Urinary metabolites INPP4B intron 21572414 rs13149611 chr4 143605318 C A 6.10E-06 Urinary metabolites INPP4B intron 21572414 rs10000770 chr4 143614262 C T 4.81E-04 Common variable immunodeficiency INPP4B intron 21497890 rs4690699 chr4 143639498 C T 8.10E-04 Suicide attempts in bipolar disorder INPP4B intron 21423239 rs12507570 chr4 143695542 C G 4.32E-04 Suicide attempts in bipolar disorder INPP4B intron 21423239 rs6831728 chr4 143708256 A G 4.19E-04 Suicide attempts in bipolar disorder INPP4B intron 21423239 rs12504681 chr4 143708921 A G 7.59E-04 Suicide attempts in bipolar disorder INPP4B intron 21423239 rs17016776 chr4 143714120 T C 7.04E-04 Suicide attempts in bipolar disorder INPP4B intron 21423239 rs6831927 chr4 143717164 C T 7.28E-04 Suicide attempts in bipolar disorder INPP4B intron 21423239 rs6819498 chr4 143717643 T C 7.29E-04 Suicide attempts in bipolar disorder INPP4B intron 21423239 rs6845583 chr4 143719082 C T 7.30E-04 Suicide attempts in bipolar disorder INPP4B intron 21423239 rs6844306 chr4 143719195 G C 7.86E-04 Suicide attempts in bipolar disorder INPP4B intron 21423239 rs13435565 chr4 143722951 T C 8.01E-04 Suicide attempts in bipolar disorder INPP4B intron 21423239 rs11100760 chr4 143732619 T G 1.12E-04 Suicide attempts in bipolar disorder INPP4B intron 21423239 rs11100760 chr4 143732619 T G 5.60E-06 Urinary metabolites INPP4B intron 21572414 rs1992418 chr4 143737159 G A 6.65E-04 Smoking cessation INPP4B intron 24665060 rs7661683 chr4 143753450 A G 6.50E-05 Amyotrophic lateral sclerosis (sporadic) INPP4B intron 24529757 rs6537129 chr4 143779613 G A 5.56E-04 Multiple complex diseases / / 17554300 rs6537129 chr4 143779613 G A 6.45E-05 Gallstones / / 17632509 rs11724679 chr4 143800361 A G 3.03E-04 Insulin resistance / / 21901158 rs13148238 chr4 143848478 G A 3.03E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17017012 chr4 143867361 T C 1.93E-05 Serum metabolites / / 19043545 rs10519676 chr4 143899999 T G 8.71E-08 Pure-tone audiometry / / pha001964 rs1588408 chr4 143907480 G A 7.76E-04 Asthma / / 21804548 rs1510140 chr4 143911483 C T 7.76E-04 Asthma / / 21804548 rs1104696 chr4 143936903 A G 4.21E-04 Asthma / / 21804548 rs1588411 chr4 143946132 T C 4.21E-04 Asthma / / 21804548 rs4690752 chr4 143947047 A G 4.21E-04 Asthma / / 21804548 rs1113094 chr4 143959584 G A 4.50E-04 Asthma / / 21804548 rs4690760 chr4 143972745 C T 1.34E-04 Asthma / / 21804548 rs7693348 chr4 143983846 G A 2.80E-05 Urinary metabolites / / 21572414 rs7686660 chr4 144003159 T G 2.00E-12 Asthma / / 21804548 rs7696032 chr4 144030000 A G 5.38E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4410482 chr4 144037651 T A 5.01E-05 Serum metabolites / / 19043545 rs4333135 chr4 144039589 T G 5.49E-05 Serum metabolites / / 19043545 rs12640330 chr4 144043024 C T 0.000496204 Hypertension (early onset hypertension) / / 22479346 rs4270544 chr4 144044338 T C 6.94E-05 Serum metabolites / / 19043545 rs4270544 chr4 144044338 T C 0.000583766 Hypertension (early onset hypertension) / / 22479346 rs4270544 chr4 144044338 T C 5.80E-04 Iron levels / / pha002876 rs7684481 chr4 144054405 C G 9.41E-04 Multiple complex diseases / / 17554300 rs7666785 chr4 144060464 A G 2.74E-04 Asthma / / 21804548 rs7666785 chr4 144060464 A G 0.000620662 Hypertension (early onset hypertension) / / 22479346 rs4337690 chr4 144069561 G T 3.03E-04 Asthma / / 21804548 rs4337690 chr4 144069561 G T 0.000620662 Hypertension (early onset hypertension) / / 22479346 rs11100775 chr4 144073912 A G 5.82E-04 Asthma / / 21804548 rs11100775 chr4 144073912 A G 0.000639792 Hypertension (early onset hypertension) / / 22479346 rs11100775 chr4 144073912 A G 6.20E-04 Iron levels / / pha002876 rs4132266 chr4 144086245 G A 2.74E-04 Asthma / / 21804548 rs4132266 chr4 144086245 G A 0.000465986 Hypertension (early onset hypertension) / / 22479346 rs11100780 chr4 144104906 G A 2.40E-04 Asthma / / 21804548 rs11100780 chr4 144104906 G A 0.000620662 Hypertension (early onset hypertension) / / 22479346 rs11724872 chr4 144140665 C T 8.41E-04 Multiple complex diseases USP38 intron 17554300 rs11940580 chr4 144161525 C G 8.41E-04 Multiple complex diseases / / 17554300 rs17017425 chr4 144165951 C T 2.89E-05 Asthma / / 21804548 rs300934 chr4 144171748 T G 4.55E-04 Asthma / / 21804548 rs10033104 chr4 144173483 A G 6.60E-05 Serum metabolites / / 19043545 rs12501994 chr4 144180955 C G 3.09E-04 Multiple complex diseases / / 17554300 rs6833582 chr4 144181992 G C 4.21E-04 Multiple complex diseases / / 17554300 rs10519678 chr4 144182073 C T 3.95E-04 Multiple complex diseases / / 17554300 rs10519678 chr4 144182073 C T 2.76E-04 Asthma / / 21804548 rs300925 chr4 144184193 C T 3.80E-04 Multiple complex diseases / / 17554300 rs9308169 chr4 144184743 G A 3.25E-04 Multiple complex diseases / / 17554300 rs9308169 chr4 144184743 G A 7.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs542555 chr4 144185956 T C 4.21E-04 Multiple complex diseases / / 17554300 rs542555 chr4 144185956 T C 3.41E-05 Serum metabolites / / 19043545 rs893929 chr4 144187380 G A 2.33E-04 Asthma / / 21804548 rs763918 chr4 144193117 T G 6.58E-04 Asthma / / 21804548 rs300951 chr4 144201383 T C 0.00035844 Hypertension (early onset hypertension) / / 22479346 rs300943 chr4 144206153 T C 3.91E-04 Multiple complex diseases / / 17554300 rs12643013 chr4 144206948 T C 0.000514759 Hypertension (early onset hypertension) / / 22479346 rs12643013 chr4 144206948 T C 5.77E-04 Iron levels / / pha002876 rs17686361 chr4 144207686 G A 5.52E-04 Asthma / / 21804548 rs17686361 chr4 144207686 G A 0.000766473 Hypertension (early onset hypertension) / / 22479346 rs592349 chr4 144220383 C T 4.08E-04 Multiple complex diseases / / 17554300 rs6537153 chr4 144230902 A C 0.000164604 Hypertension (early onset hypertension) / / 22479346 rs300904 chr4 144239825 A G 1.08E-04 Multiple complex diseases / / 17554300 rs300905 chr4 144240473 A G 1.09E-04 Multiple complex diseases / / 17554300 rs300905 chr4 144240473 A G 2.71E-04 Asthma / / 21804548 rs300905 chr4 144240473 A G 3.15E-04 Iron levels / / pha002876 rs300895 chr4 144255838 T C 1.77E-04 Multiple complex diseases / / 17554300 rs300917 chr4 144269849 C G 9.29E-05 Multiple complex diseases GAB1 intron 17554300 rs300916 chr4 144273884 G T 9.98E-06 Multiple complex diseases GAB1 intron 17554300 rs300916 chr4 144273884 G T 5.15E-04 Asthma GAB1 intron 21804548 rs300915 chr4 144274156 A G 7.76E-05 Multiple complex diseases GAB1 intron 17554300 rs300915 chr4 144274156 A G 1.26E-05 Urate levels GAB1 intron 23263486 rs300913 chr4 144276643 C T 8.34E-05 Multiple complex diseases GAB1 intron 17554300 rs300912 chr4 144276717 G A 5.46E-05 Multiple complex diseases GAB1 intron 17554300 rs13107986 chr4 144284526 G A 4.50E-05 Response to statin therapy GAB1 intron 20339536 rs3805254 chr4 144285683 A G 9.55E-05 Asthma GAB1 intron 21804548 rs1510880 chr4 144290998 T A 7.85E-04 Multiple complex diseases GAB1 intron 17554300 rs12649592 chr4 144293524 G A 5.30E-05 Asthma GAB1 intron 21804548 rs3805251 chr4 144295952 C T 8.24E-05 Asthma GAB1 intron 21804548 rs1397528 chr4 144319745 G A 1.42E-04 Asthma GAB1 intron 21804548 rs10519691 chr4 144325021 A C 1.81E-04 Asthma GAB1 intron 21804548 rs1397527 chr4 144326385 G T 2.37E-05 Asthma GAB1 intron 21804548 rs4690785 chr4 144340098 T C 4.67E-04 Asthma GAB1 intron 21804548 rs7691050 chr4 144347239 T C 8.66E-04 Multiple complex diseases GAB1 intron 17554300 rs3805236 chr4 144357737 A G 7.00E-08 Asthma GAB1 intron 21804548 rs3805236 chr4 144357737 A G 2.04E-05 Potassium levels GAB1 intron pha003086 rs11730153 chr4 144426798 C T 1.42E-05 Myopia (pathological) / / 21095009 rs11100790 chr4 144442611 T C 5.19E-05 Lymphocyte counts SMARCA5 STOP-GAIN 22286170 rs7698480 chr4 144453500 T C 8.27E-04 Myopia (pathological) SMARCA5 intron 21095009 rs924233 chr4 144480013 G A 7.11E-04 Myopia (pathological) / / 21095009 rs2323187 chr4 144493185 C A 7.88E-04 Myopia (pathological) / / 21095009 rs1553067 chr4 144555318 A G 9.70E-04 Acute lung injury FREM3 intron 22295056 rs41355648 chr4 144558013 A G 5.34E-04 Type 2 diabetes FREM3 intron 17463246 rs7676614 chr4 144616366 A G 4.37E-04 Amyotrophic Lateral Sclerosis FREM3 intron 17362836 rs7681914 chr4 144629991 A G 8.16E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17694529 chr4 144682805 G C 2.46E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6858195 chr4 144689597 T C 3.10E-04 Pulmonary function / / 23932459 rs1450235 chr4 144704080 C T 4.90E-04 Lymphocyte counts / / 22286170 rs10010757 chr4 144734753 T C 2.91E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs13105102 chr4 144740199 G A 3.70E-24 MNS system S antigen / / 22611595 rs1822841 chr4 144842638 T G 2.77E-04 Coronary heart disease / / 21606135 rs7686794 chr4 144849073 A G 2.75E-04 Coronary heart disease / / 21606135 rs7657795 chr4 145009802 A C 5.70E-04 Coronary Artery Disease / / 17634449 rs13103731 chr4 145056487 C T 1.08E-04 Coronary heart disease GYPA intron 21971053 rs13103731 chr4 145056487 C T 2.50E-20 MNS system N antigen GYPA intron 22611595 rs6812128 chr4 145102264 T G 2.83E-05 Diabetes Mellitus / / pha003060 rs3923603 chr4 145111329 C T 6.00E-05 Asperger disorder / / 21182207 rs3923603 chr4 145111329 C T 4.71E-06 Personality dimensions / / 23658558 rs4599356 chr4 145123453 A G 5.00E-05 Asperger disorder / / 21182207 rs6537267 chr4 145166118 T C 2.53E-04 Multiple complex diseases / / 17554300 rs13123791 chr4 145180928 A G 7.65E-06 Multiple complex diseases / / 17554300 rs4511953 chr4 145193675 G T 1.04E-04 Multiple complex diseases / / 17554300 rs7690204 chr4 145196206 A T 3.18E-06 Bipolar disorder / / 19488044 rs7690204 chr4 145196206 A T 2.21E-05 Bipolar disorder and schizophrenia / / 20889312 rs7690204 chr4 145196206 A T 5.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs7690204 chr4 145196206 A T 5.83E-06 Bipolar Disorder / / pha002858 rs13118083 chr4 145227600 A G 1.10E-05 Pulmonary function / / 20010835 rs2202507 chr4 145257681 T G 3.53E-06 Pulmonary function / / 20010835 rs2202507 chr4 145257681 T G 1.50E-05 Cognitive impairment induced by topiramate / / 22091778 rs2202507 chr4 145257681 T G 6.06E-05 Cognitive impairment induced by topiramate / / 22091778 rs6858668 chr4 145262821 A G 6.81E-04 Insulin resistance / / 21901158 rs13105210 chr4 145262927 C T 3.45E-05 Pulmonary function / / 19300500 rs13105210 chr4 145262927 C T 1.80E-05 Pulmonary function / / 20010835 rs17709487 chr4 145270064 G T 9.65E-05 Multiple complex diseases / / 17554300 rs17709487 chr4 145270064 G T 4.59E-05 Serum metabolites / / 19043545 rs17709487 chr4 145270064 G T 3.02E-05 Pulmonary function / / 19300500 rs17709487 chr4 145270064 G T 5.89E-06 Pulmonary function / / 20010835 rs6834183 chr4 145270955 T C 3.01E-05 Pulmonary function / / 19300500 rs6834183 chr4 145270955 T C 5.93E-06 Pulmonary function / / 20010835 rs7699261 chr4 145271890 G A 5.87E-04 Multiple complex diseases / / 17554300 rs17766168 chr4 145272692 G A 3.01E-05 Pulmonary function / / 19300500 rs17766168 chr4 145272692 G A 5.98E-06 Pulmonary function / / 20010835 rs6849200 chr4 145273780 A C 4.42E-04 Tourette syndrome / / 22889924 rs4835177 chr4 145273928 A G 5.64E-05 Multiple complex diseases / / 17554300 rs4835177 chr4 145273928 A G 7.91E-05 Serum metabolites / / 19043545 rs4835177 chr4 145273928 A G 2.18E-05 Pulmonary function / / 19300500 rs4835177 chr4 145273928 A G 4.48E-05 Pulmonary function / / 20010835 rs17766287 chr4 145278837 T C 2.75E-05 Pulmonary function / / 19300500 rs17766287 chr4 145278837 T C 4.37E-06 Pulmonary function / / 20010835 rs2657799 chr4 145282779 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2657799 chr4 145282779 C T 0.000268787 Hypertension (early onset hypertension) / / 22479346 rs4240362 chr4 145286363 G C 2.78E-05 Pulmonary function / / 19300500 rs4240362 chr4 145286363 G C 4.34E-06 Pulmonary function / / 20010835 rs4469023 chr4 145300434 A C 3.48E-05 Cardiovascular disease / / pha003065 rs1394998 chr4 145302155 C T 2.70E-05 Pulmonary function / / 19300500 rs1394998 chr4 145302155 C T 6.72E-06 Pulmonary function / / 20010835 rs1505766 chr4 145308299 C T 2.48E-05 Pulmonary function / / 19300500 rs1505766 chr4 145308299 C T 6.48E-06 Pulmonary function / / 20010835 rs7654571 chr4 145321006 A G 2.98E-05 Pulmonary function / / 19300500 rs12500355 chr4 145321822 T C 2.79E-05 Pulmonary function / / 19300500 rs12500355 chr4 145321822 T C 6.95E-06 Pulmonary function / / 20010835 rs17019340 chr4 145333783 C A 6.34E-04 Multiple complex diseases / / 17554300 rs17019340 chr4 145333783 C A 8.26E-05 Serum metabolites / / 19043545 rs17019340 chr4 145333783 C A 2.83E-05 Pulmonary function / / 19300500 rs17019340 chr4 145333783 C A 7.80E-06 Pulmonary function / / 20010835 rs4290852 chr4 145336472 C T 2.77E-05 Pulmonary function / / 19300500 rs4290852 chr4 145336472 C T 7.58E-06 Pulmonary function / / 20010835 rs12499537 chr4 145348098 G T 2.63E-05 Pulmonary function / / 19300500 rs12499537 chr4 145348098 G T 1.31E-05 Pulmonary function / / 20010835 rs12499685 chr4 145366500 T C 1.67E-05 Pulmonary function / / 19300500 rs12499685 chr4 145366500 T C 4.47E-06 Pulmonary function / / 20010835 rs17019354 chr4 145366977 G T 1.67E-05 Pulmonary function / / 19300500 rs17019354 chr4 145366977 G T 4.45E-06 Pulmonary function / / 20010835 rs13142439 chr4 145371436 A G 2.67E-05 Pulmonary function / / 19300500 rs13142439 chr4 145371436 A G 1.64E-06 Pulmonary function / / 20010835 rs12510916 chr4 145372248 C T 2.67E-05 Pulmonary function / / 19300500 rs12510916 chr4 145372248 C T 1.63E-06 Pulmonary function / / 20010835 rs6828795 chr4 145374760 C T 2.64E-05 Pulmonary function / / 19300500 rs6828795 chr4 145374760 C T 1.41E-06 Pulmonary function / / 20010835 rs1505770 chr4 145380802 T C 2.63E-06 Pulmonary function / / 19300500 rs1505770 chr4 145380802 T C 1.07E-07 Pulmonary function / / 20010835 rs2130499 chr4 145388834 G T 2.53E-06 Pulmonary function / / 19300500 rs2130499 chr4 145388834 G T 9.10E-08 Pulmonary function / / 20010835 rs13142879 chr4 145410477 C T 2.53E-06 Pulmonary function / / 19300500 rs13142879 chr4 145410477 C T 7.11E-08 Pulmonary function / / 20010835 rs973796 chr4 145423968 A C 5.56E-06 Pulmonary function / / 19300500 rs973796 chr4 145423968 A C 7.54E-08 Pulmonary function / / 20010835 rs1512282 chr4 145431497 A G 5.53E-06 Pulmonary function / / 19300500 rs1512282 chr4 145431497 A G 8.18E-08 Pulmonary function / / 20010835 rs7678427 chr4 145433575 C A 5.46E-06 Pulmonary function / / 19300500 rs7678427 chr4 145433575 C A 7.12E-08 Pulmonary function / / 20010835 rs1032295 chr4 145434584 T G 6.28E-09 Pulmonary function / / 20010835 rs1032296 chr4 145434688 T C 2.87E-06 Pulmonary function / / 19300500 rs1032296 chr4 145434688 T C 6.28E-06 Pulmonary function / / 20010835 rs1032297 chr4 145434744 A G 3.11E-08 Pulmonary function / / 19300500 rs1032297 chr4 145434744 A G 2.01E-10 Pulmonary function / / 20010835 rs1512281 chr4 145434901 A G 1.67E-08 Pulmonary function / / 19300500 rs1512281 chr4 145434901 A G 9.06E-10 Pulmonary function / / 20010835 rs12504628 chr4 145436324 T C 2.11E-08 Pulmonary function / / 19300500 rs12504628 chr4 145436324 T C 6.00E-13 Pulmonary function / / 20010834 rs12504628 chr4 145436324 T C 1.36E-10 Pulmonary function / / 20010835 rs7697189 chr4 145436894 G C 2.09E-08 Pulmonary function / / 19300500 rs7697189 chr4 145436894 G C 1.60E-10 Pulmonary function / / 20010835 rs7681384 chr4 145437014 T C 4.43E-06 Pulmonary function / / 19300500 rs7681384 chr4 145437014 T C 6.03E-05 Pulmonary function / / 20010835 rs4835637 chr4 145439027 A G 2.20E-06 Pulmonary function / / 19300500 rs4835637 chr4 145439027 A G 4.70E-05 Pulmonary function / / 20010835 rs6829956 chr4 145440288 C T 4.39E-06 Pulmonary function / / 19300500 rs6829956 chr4 145440288 C T 6.34E-05 Pulmonary function / / 20010835 rs1512285 chr4 145450959 A G 4.34E-06 Pulmonary function / / 19300500 rs1512285 chr4 145450959 A G 5.97E-05 Pulmonary function / / 20010835 rs6821114 chr4 145452389 A G 1.93E-05 Pulmonary function / / 19300500 rs6845536 chr4 145452783 C T 2.47E-05 Pulmonary function / / 19300500 rs6845536 chr4 145452783 C T 9.56E-05 Socioeconomic Factors / / pha003066 rs1489762 chr4 145454964 T C 2.30E-08 Pulmonary function / / 19300500 rs1489762 chr4 145454964 T C 1.85E-10 Pulmonary function / / 20010835 rs1489761 chr4 145455491 G A 2.37E-05 Pulmonary function / / 19300500 rs1489761 chr4 145455491 G A 9.71E-05 Pulmonary function / / 20010835 rs7692102 chr4 145457141 A G 2.68E-05 Pulmonary function / / 19300500 rs7692102 chr4 145457141 A G 8.03E-05 Pulmonary function / / 20010835 rs13147758 chr4 145460230 A G 8.00E-11 Pulmonary function / / 19300500 rs13147758 chr4 145460230 A G 7.30E-11 Pulmonary function / / 20010835 rs13148031 chr4 145460338 A G 1.97E-08 Pulmonary function / / 19300500 rs13148031 chr4 145460338 A G 7.24E-11 Pulmonary function / / 20010835 rs720484 chr4 145462364 G A 1.99E-08 Pulmonary function / / 19300500 rs720484 chr4 145462364 G A 7.31E-11 Pulmonary function / / 20010835 rs720485 chr4 145462588 A C 2.01E-08 Pulmonary function / / 19300500 rs720485 chr4 145462588 A C 7.80E-11 Pulmonary function / / 20010835 rs6828540 chr4 145463231 G A 2.03E-08 Pulmonary function / / 19300500 rs6828540 chr4 145463231 G A 7.43E-11 Pulmonary function / / 20010835 rs2130339 chr4 145464885 A G 2.06E-08 Pulmonary function / / 19300500 rs2130339 chr4 145464885 A G 7.54E-11 Pulmonary function / / 20010835 rs6830832 chr4 145465491 T G 2.07E-08 Pulmonary function / / 19300500 rs6830832 chr4 145465491 T G 7.60E-11 Pulmonary function / / 20010835 rs11938745 chr4 145465768 T C 2.09E-08 Pulmonary function / / 19300500 rs11938745 chr4 145465768 T C 7.69E-11 Pulmonary function / / 20010835 rs6537292 chr4 145469968 G T 2.04E-08 Pulmonary function / / 19300500 rs6537292 chr4 145469968 G T 6.39E-11 Pulmonary function / / 20010835 rs12511230 chr4 145471245 A T 2.08E-08 Pulmonary function / / 19300500 rs12511230 chr4 145471245 A T 6.50E-11 Pulmonary function / / 20010835 rs1489759 chr4 145474473 A G 2.17E-08 Pulmonary function / / 19300500 rs1489759 chr4 145474473 A G 6.77E-11 Pulmonary function / / 20010835 rs995758 chr4 145478201 C T 2.23E-08 Pulmonary function / / 19300500 rs995758 chr4 145478201 C T 6.89E-11 Pulmonary function / / 20010835 rs12509311 chr4 145478662 C T 1.73E-08 Pulmonary function / / 19300500 rs12509311 chr4 145478662 C T 7.71E-11 Pulmonary function / / 20010835 rs11100860 chr4 145479139 A G 2.39E-08 Pulmonary function / / 19300500 rs11100860 chr4 145479139 A G 7.27E-11 Pulmonary function / / 20010835 rs6842889 chr4 145479880 T C 2.38E-08 Pulmonary function / / 19300500 rs6842889 chr4 145479880 T C 7.19E-11 Pulmonary function / / 20010835 rs10519717 chr4 145480340 T C 4.22E-05 Pulmonary function / / 20010835 rs10519717 chr4 145480340 T C 1.10E-05 Urinary metabolites / / 21572414 rs1828591 chr4 145480780 A G 1.00E-07 Chronic obstructive pulmonary disease / / 19300482 rs1828591 chr4 145480780 A G 2.35E-08 Pulmonary function / / 19300500 rs1828591 chr4 145480780 A G 5.81E-11 Pulmonary function / / 20010835 rs1828591 chr4 145480780 A G 1.18E-07 Chronic obstructive pulmonary disease / / 20173748 rs1980057 chr4 145485738 C T 2.33E-08 Pulmonary function / / 19300500 rs1980057 chr4 145485738 C T 3.00E-20 Pulmonary function / / 20010835 rs1980057 chr4 145485738 C T 5.00E-18 Pulmonary function (interaction) / / 23284291 rs7655625 chr4 145485915 T C 2.38E-08 Pulmonary function / / 19300500 rs7655625 chr4 145485915 T C 4.96E-11 Pulmonary function / / 20010835 rs13118928 chr4 145486389 A G 2.39E-08 Pulmonary function / / 19300500 rs13118928 chr4 145486389 A G 5.00E-07 Chronic obstructive pulmonary disease / / 20173748 rs6537296 chr4 145487934 A G 2.40E-08 Pulmonary function / / 19300500 rs6537296 chr4 145487934 A G 5.78E-11 Pulmonary function / / 20010835 rs6828255 chr4 145489265 A C 6.15E-04 Tourette syndrome / / 22889924 rs1512288 chr4 145491281 G A 2.43E-08 Pulmonary function / / 19300500 rs1512288 chr4 145491281 G A 6.38E-11 Pulmonary function / / 20010835 rs6817273 chr4 145492003 T C 2.44E-08 Pulmonary function / / 19300500 rs6817273 chr4 145492003 T C 7.89E-10 Pulmonary function / / 20010835 rs13141641 chr4 145506456 T C 8.40E-08 Pulmonary function / / 19300500 rs13141641 chr4 145506456 T C 2.97E-10 Pulmonary function / / 20010835 rs13141641 chr4 145506456 T C 3.00E-07 Chronic obstructive pulmonary disease / / 22080838 rs13141641 chr4 145506456 T C 2.00E-12 Chronic obstructive pulmonary disease (moderate to severe) / / 24621683 rs13141641 chr4 145506456 T C 4.00E-15 Chronic obstructive pulmonary disease (severe) / / 24621683 rs6852830 chr4 145506558 C A 6.66E-05 Chronic obstructive pulmonary disease / / 19300482 rs6852830 chr4 145506558 C A 4.93E-05 Pulmonary function / / 20010835 rs1996020 chr4 145511194 A C 4.86E-05 Chronic obstructive pulmonary disease / / 19300482 rs1996020 chr4 145511194 A C 4.86E-05 Pulmonary function / / 20010835 rs7670758 chr4 145511875 A G 9.50E-05 Pulmonary function in asthmatics / / 23541324 rs2353397 chr4 145517578 C T 5.15E-05 Major depressive disorder / / 21621269 rs2353397 chr4 145517578 C T 7.05E-05 Major depressive disorder / / pha002850 rs2353398 chr4 145522758 T A 2.00E-09 Height / / 20881960 rs1398244 chr4 145562457 C T 0.00010438 Primary sclerosing cholangitis / / 23603763 rs7689420 chr4 145568352 T C 6.00E-51 Height HHIP intron 20881960 rs7689420 chr4 145568352 T C 4.00E-21 Height HHIP intron 23563607 rs1812175 chr4 145574844 A G 1.20E-04 Type 2 diabetes and 6 quantitative traits HHIP intron 17848626 rs1812175 chr4 145574844 A G 1.00E-11 Height HHIP intron 18391951 rs1812175 chr4 145574844 A G 4.00E-06 Height HHIP intron 19343178 rs1812175 chr4 145574844 A G 1.00E-09 Height HHIP intron 20397748 rs17721701 chr4 145618719 T C 3.21E-05 Body Mass Index HHIP intron pha003019 rs6854783 chr4 145643079 G A 2.00E-09 Height HHIP intron 18391952 rs1492820 chr4 145650021 G A 1.00E-11 Height HHIP intron 18391950 rs2353930 chr4 145679766 G A 0.000043 Mean arterial pressure / / 22510845 rs17019984 chr4 146191187 A G 4.89E-04 Multiple complex diseases / / 17554300 rs17019992 chr4 146197201 A G 5.27E-05 Heart Failure / / pha002885 rs10006257 chr4 146205494 C T 0.0005427 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10006257 chr4 146205494 C T 5.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13111336 chr4 146214431 G A 1.67E-06 Hemoglobin / / pha003098 rs13111336 chr4 146214431 G A 2.54E-06 Erythrocyte counts / / pha003099 rs2355240 chr4 146215149 C G 0.0005524 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2355240 chr4 146215149 C G 5.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6827799 chr4 146247602 C T 5.15E-05 Acute lung injury / / 22295056 rs4835221 chr4 146248122 C T 1.02E-04 Acute lung injury / / 22295056 rs6537340 chr4 146249655 G A 9.40E-05 Acute lung injury / / 22295056 rs2883622 chr4 146251133 G A 6.01E-04 Acute lung injury / / 22295056 rs2255831 chr4 146256708 C T 1.65E-04 Acute lung injury / / 22295056 rs7668650 chr4 146260382 T C 2.60E-06 Urinary metabolites / / 21572414 rs7663154 chr4 146276932 G A 9.44E-04 Type 2 diabetes / / 17463246 rs1992598 chr4 146334754 C T 8.13E-05 Cognitive performance / / 19734545 rs525600 chr4 146358425 G A 2.03E-04 Alzheimer's disease / / 17998437 rs13109195 chr4 146369756 T C 1.80E-04 Alcohol dependence / / 20201924 rs13109195 chr4 146369756 T C 2.20E-04 Alcohol dependence / / 20201924 rs1866179 chr4 146384775 G T 2.57E-05 Inflammation / / pha002897 rs7694604 chr4 146430293 T G 2.29E-06 Hemoglobin concentration SMAD1 intron 20534544 rs7662541 chr4 146434680 C T 2.82E-06 Hemoglobin concentration SMAD1 intron 20534544 rs7662541 chr4 146434680 C T 3.79E-05 Duodenal ulcer SMAD1 intron 22387998 rs7698944 chr4 146436351 A G 1.40E-06 Hemoglobin concentration SMAD1 intron 20534544 rs2043779 chr4 146447789 T C 1.11E-05 Hemoglobin concentration SMAD1 intron 20534544 rs7670486 chr4 146453921 G A 2.82E-06 Hemoglobin concentration SMAD1 intron 20534544 rs7670486 chr4 146453921 G A 3.92E-05 Duodenal ulcer SMAD1 intron 22387998 rs6848760 chr4 146484997 C A 7.92E-06 Hemoglobin concentration / / 20534544 rs17020467 chr4 146559160 G A 6.96E-04 Smoking cessation MMAA intron 24665060 rs2132778 chr4 146614073 C T 9.77E-04 Stroke C4orf51 intron pha002887 rs7690184 chr4 146662794 C A 3.71E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs9994644 chr4 146668820 G A,C 9.00E-07 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs9998097 chr4 146722324 C T 1.87E-06 Glaucoma (primary open-angle) ZNF827 intron 22605921 rs17020601 chr4 146732548 T C 9.10E-04 Multiple complex diseases ZNF827 intron 17554300 rs11731491 chr4 146746904 G A 4.80E-04 Alzheimer's disease ZNF827 intron 24755620 rs13149290 chr4 146750966 C T 2.56E-05 Prostate cancer ZNF827 intron 18073375 rs17020662 chr4 146751207 A G 5.08E-04 Multiple complex diseases ZNF827 intron 17554300 rs988163 chr4 146764883 C T 4.63E-04 Multiple complex diseases ZNF827 intron 17554300 rs1027841 chr4 146769074 G A 2.00E-06 Behavioural disinhibition (generation interaction) ZNF827 intron 23942779 rs1507928 chr4 146788035 T C 2.94E-05 Serum metabolites ZNF827 intron 19043545 rs4547811 chr4 146794621 T C 3.00E-27 Liver enzyme levels (gamma-glutamyl transferase) ZNF827 intron 22001757 rs1979974 chr4 146800815 A G 4.55E-05 Cognitive performance ZNF827 intron 19734545 rs7679068 chr4 146808682 C T 4.09E-05 Cognitive performance ZNF827 intron 19734545 rs4835265 chr4 146821410 C A 1.00E-14 Gamma glutamyl transpeptidase ZNF827 intron 21909109 rs12331851 chr4 146849295 G A 6.08E-07 Autism ZNF827 intron 22843504 rs2048161 chr4 146853165 A G 2.43E-04 Type 2 diabetes ZNF827 intron 17463246 rs2048161 chr4 146853165 A G 6.00E-12 Immune reponse to smallpox (secreted IFN-alpha) ZNF827 intron 22610502 rs6537382 chr4 146867376 C A 2.37E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs723794 chr4 146875551 G T 6.00E-07 Smooth-surface caries / / 23470693 rs11100904 chr4 146904304 C T 2.00E-06 Dental caries / / 23064961 rs4376168 chr4 146964088 G T 8.89E-04 Multiple complex diseases / / 17554300 rs35153177 chr4 146984683 C G 2.70E-05 Parkinson's disease (motor and cognition) / / 22658654 rs1035803 chr4 146997376 C T 1.65E-04 Birth weight / / 17255346 rs4309852 chr4 147004088 A G 1.36E-04 Birth weight / / 17255346 rs11100914 chr4 147012038 T C 2.60E-05 Urinary metabolites / / 21572414 rs4835286 chr4 147047072 A C 1.50E-04 Endometriosis / / 21151130 rs2007366 chr4 147054644 T G 1.50E-04 Endometriosis / / 21151130 rs2007366 chr4 147054644 T G 4.28E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7695415 chr4 147056235 A T 4.28E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9997120 chr4 147093089 C T 2.66E-06 Alopecia areata / / 22027810 rs7662843 chr4 147112709 G A 4.90E-04 Multiple complex diseases / / 17554300 rs891382 chr4 147152340 G A 2.56E-04 Diabetic nephropathy / / 21150874 rs891382 chr4 147152340 G A 3.19E-04 Type 2 diabetes / / 22238593 rs891383 chr4 147162483 A G 1.79E-05 Post-operative nausea and vomiting / / 21694509 rs1036016 chr4 147176603 C T 3.29E-05 Post-operative nausea and vomiting SLC10A7 UTR-3 21694509 rs1036016 chr4 147176603 C T 6.78E-05 Cognitive impairment induced by topiramate SLC10A7 UTR-3 22091778 rs4516736 chr4 147213912 T C 3.72E-06 Post-operative nausea and vomiting SLC10A7 intron 21694509 rs189095643 chr4 147214188 T C 8.26E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SLC10A7 intron 24159190 rs4835298 chr4 147262634 A G 6.34E-04 Multiple complex diseases SLC10A7 intron 17554300 rs6537417 chr4 147290158 G A 8.41E-04 Multiple complex diseases SLC10A7 intron 17554300 rs1385847 chr4 147299995 C G 5.77E-04 Type 2 diabetes SLC10A7 intron 17463246 rs1385847 chr4 147299995 C G 9.74E-04 Multiple complex diseases SLC10A7 intron 17554300 rs17021447 chr4 147317302 T C 2.86E-04 Multiple complex diseases SLC10A7 intron 17554300 rs17021447 chr4 147317302 T C 0.0000388 Breast cancer early age of onset SLC10A7 intron 18463975 rs17021500 chr4 147350149 C T 2.08E-04 Multiple complex diseases SLC10A7 intron 17554300 rs182218370 chr4 147354666 A G 2.71E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SLC10A7 intron 24159190 rs191493117 chr4 147360131 C T 3.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SLC10A7 intron 24159190 rs11737630 chr4 147411428 C T 8.95E-05 Intelligence SLC10A7 intron 21826061 rs9996620 chr4 147473314 A G 7.59E-05 Multiple complex diseases / / 17554300 rs10032147 chr4 147481344 G T 5.15E-05 Multiple complex diseases / / 17554300 rs10213084 chr4 147499338 G T 4.00E-06 Heart rate / / 23583979 rs17832354 chr4 147499642 G A 5.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2174304 chr4 147507463 G A 1.99E-05 Multiple complex diseases / / 17554300 rs7680105 chr4 147507651 A G 1.73E-04 Multiple complex diseases / / 17554300 rs10010958 chr4 147511918 C T 4.77E-05 Multiple complex diseases / / 17554300 rs1104532 chr4 147519769 C T 5.90E-04 Multiple complex diseases / / 17554300 rs6835151 chr4 147529209 G A 7.33E-04 Multiple complex diseases / / 17554300 rs1394279 chr4 147538833 G C 4.74E-04 Multiple complex diseases / / 17554300 rs17021676 chr4 147548771 A G 3.80E-04 Multiple complex diseases / / 17554300 rs1979904 chr4 147549043 C T 6.29E-04 Multiple complex diseases / / 17554300 rs1979903 chr4 147549303 T G 2.40E-05 Multiple complex diseases / / 17554300 rs970674 chr4 147551074 G A 7.70E-04 Alcohol dependence / / 20201924 rs10011145 chr4 147553803 A C,G,T 4.40E-04 Multiple complex diseases / / 17554300 rs2047894 chr4 147595984 T C 4.36E-04 Type 2 diabetes / / 17463246 rs2047894 chr4 147595984 T C 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2713878 chr4 147641087 T C 6.93E-04 Type 2 diabetes TTC29 intron 17463246 rs6857014 chr4 147642803 C T 7.79E-04 Type 2 diabetes TTC29 intron 17463246 rs4484319 chr4 147651538 T C 3.00E-04 Acute lymphoblastic leukemia (childhood) TTC29 intron 20189245 rs6851396 chr4 147657687 A C 6.00E-04 Acute lymphoblastic leukemia (childhood) TTC29 intron 20189245 rs1509339 chr4 147757175 T C 2.35E-04 Amyotrophic Lateral Sclerosis TTC29 intron 17827064 rs10013280 chr4 147788709 C T 5.75E-04 Response to taxane treatment (placlitaxel) TTC29 missense 23006423 rs12512265 chr4 147795001 T A 5.65E-04 Bipolar disorder,schizoaffective TTC29 intron 19567891 rs1995809 chr4 147844424 A G 2.00E-06 Plasma amyloid beta peptide concentrations (ABx-40) TTC29 intron 24535457 rs7678787 chr4 147888331 G A 1.63E-25 Narcolepsy / / 19629137 rs1370301 chr4 147947622 T G 4.87E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs920208 chr4 147971076 G A 5.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6537450 chr4 147986291 A G 5.34E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs6537450 chr4 147986291 A G 8.81E-04 Myopia (pathological) / / 21095009 rs4835373 chr4 147992074 A C 3.83E-05 Intracerebral hemorrhage / / 24656865 rs4835373 chr4 147992074 A C 4.47E-05 Intracerebral hemorrhage / / 24656865 rs9884610 chr4 147994958 C T 3.23E-05 Intracerebral hemorrhage / / 24656865 rs9884610 chr4 147994958 C T 4.44E-05 Intracerebral hemorrhage / / 24656865 rs1876422 chr4 147997109 C G 3.63E-05 Intracerebral hemorrhage / / 24656865 rs1876422 chr4 147997109 C G 4.64E-05 Intracerebral hemorrhage / / 24656865 rs4356896 chr4 147999338 A G 4.39E-05 Intracerebral hemorrhage / / 24656865 rs3897923 chr4 148005706 C T 4.51E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs1911588 chr4 148021144 T C 7.42E-05 Hypertension (essential hypertension) / / 22184326 rs1395821 chr4 148047550 C T 7.00E-07 Coronary heart disease / / 21378988 rs4485803 chr4 148051452 A G 3.73E-05 Cognitive test performance / / 20125193 rs16998717 chr4 148059086 A G 4.80E-04 Multiple complex diseases / / 17554300 rs1354884 chr4 148075340 G A 1.51E-04 Multiple complex diseases / / 17554300 rs1354884 chr4 148075340 G A 3.83E-05 Cognitive test performance / / 20125193 rs2357604 chr4 148077418 T C 4.25E-05 Cognitive test performance / / 20125193 rs952688 chr4 148081634 C T 9.71E-05 Cognitive test performance / / 20125193 rs4399964 chr4 148084305 A G 3.73E-04 Parkinson's disease / / 17052657 rs1828034 chr4 148090486 A G 3.73E-04 Parkinson's disease / / 17052657 rs2221601 chr4 148159793 G C 4.71E-04 Multiple complex diseases / / 17554300 rs934145 chr4 148208628 A T 6.95E-04 Type 2 diabetes / / 17846124 rs1429138 chr4 148282342 T C 2.00E-07 Dental caries / / 23064961 rs1429139 chr4 148284104 T A 2.54E-06 Esophageal cancer (squamous cell) / / 22960999 rs1429141 chr4 148288067 T C 4.13E-08 Coronary artery disease / / 23202125 rs1429107 chr4 148322387 A G 8.00E-06 Obesity-related traits / / 23251661 rs17023187 chr4 148322929 T C 2.53E-05 Major depression (suicidal thoughts and behavior) / / 21750702 rs1429120 chr4 148345747 C A 6.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs6849837 chr4 148352246 T G 7.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs9993943 chr4 148354114 C A 9.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs4469055 chr4 148385721 C G 0.000136 Coronary artery disease / / 23202125 rs1878406 chr4 148393664 C G,T 7.00E-07 Carotid intima media thickness / / 21909108 rs1878406 chr4 148393664 C G,T 7.00E-12 Carotid intima media thickness / / 21909108 rs1878406 chr4 148393664 C G,T 0.00000532 Coronary artery disease (CAD) age >50 / / 23202125 rs1878406 chr4 148393664 C G,T 0.000143 Coronary artery disease (CAD) age <=50 / / 23202125 rs1878406 chr4 148393664 C G,T 1.32E-13 Coronary artery disease / / 23202125 rs1878406 chr4 148393664 C G,T 6.23E-08 Coronary artery disease (CAD) (males) / / 23202125 rs1878406 chr4 148393664 C G,T 1.00E-06 Coronary artery disease / / 24262325 rs6842241 chr4 148400819 C A 1.00E-08 Intracranial aneurysm EDNRA nearGene-5 22286173 rs6841581 chr4 148401190 G A 9.02E-04 Multiple complex diseases EDNRA nearGene-5 17554300 rs6841581 chr4 148401190 G A 0.000000349 Coronary artery disease EDNRA nearGene-5 23202125 rs6841581 chr4 148401190 G A 2.00E-08 Coronary artery disease or large artery stroke EDNRA nearGene-5 24262325 rs6841473 chr4 148407652 C T 1.50E-04 Coronary heart disease EDNRA intron 21966275 rs6822565 chr4 148437512 T C 5.63E-13 Narcolepsy EDNRA intron 19629137 rs6822565 chr4 148437512 T C 7.00E-04 Blood pressure EDNRA intron 21060006 rs6822565 chr4 148437512 T C 0.0009 Coronary arterial lesions in patients with Kawasaki disease EDNRA intron 23454411 rs11939191 chr4 148438715 G A 7.31E-04 Multiple complex diseases EDNRA intron 17554300 rs10305923 chr4 148460774 T C 9.11E-08 Triglycerides EDNRA intron 23063622 rs6841799 chr4 148460790 C G 0.000635 Salmonella-induced pyroptosis EDNRA intron 22837397 rs7675774 chr4 148503298 A G 3.50E-05 Serum metabolites / / 19043545 rs10519911 chr4 148550590 T C 4.02E-04 Schizophrenia TMEM184C intron 21674006 rs11731298 chr4 148612488 C T 9.00E-06 Obesity-related traits / / 23251661 rs13124167 chr4 148675193 T C 2.28E-07 Breast cancer (survival) ARHGAP10 intron 20332263 rs9332471 chr4 148694170 C T 7.06E-04 Alzheimer's disease ARHGAP10 intron 17998437 rs964170 chr4 148695956 G T 1.49E-06 Alcohol and nictotine co-dependence ARHGAP10 intron 20158304 rs964170 chr4 148695956 G T 4.43E-08 Alcohol and nictotine co-dependence ARHGAP10 intron 20158304 rs11729081 chr4 148696917 T C 3.98E-04 Alzheimer's disease ARHGAP10 intron 17998437 rs4835456 chr4 148730641 A T 3.66E-04 Alzheimer's disease ARHGAP10 intron 17998437 rs7683103 chr4 148734627 A G 7.16E-04 Obesity (extreme) ARHGAP10 intron 21935397 rs10519917 chr4 148735644 C T 1.43E-04 Prostate cancer mortality ARHGAP10 intron 20978177 rs12650219 chr4 148741158 G A 8.25E-05 Calcium intake levels and metabolic syndrome ARHGAP10 intron 22170361 rs10023057 chr4 148779548 G C 5.70E-04 Aortic root size ARHGAP10 intron 21223598 rs1469865 chr4 148781196 G A 8.18E-04 Aortic root size ARHGAP10 intron 21223598 rs4491995 chr4 148824460 T C 2.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARHGAP10 intron 20877124 rs11099672 chr4 148827973 A G 1.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARHGAP10 intron 20877124 rs11099672 chr4 148827973 A G 6.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARHGAP10 intron 20877124 rs4835469 chr4 148832250 C T 5.84E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARHGAP10 intron 20877124 rs4835469 chr4 148832250 C T 6.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARHGAP10 intron 20877124 rs4835469 chr4 148832250 C T 5.24E-05 Cognitive impairment induced by topiramate ARHGAP10 intron 22091778 rs2635268 chr4 148861837 A G 7.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARHGAP10 intron 20877124 rs7658486 chr4 148884189 C T 1.00E-08 Immune reponse to smallpox (secreted IL-12p40) ARHGAP10 intron 22610502 rs10003349 chr4 148928213 G A 1.69E-04 Parkinson's disease ARHGAP10 intron 17052657 rs17676286 chr4 148928719 G A 1.75E-04 Multiple complex diseases ARHGAP10 intron 17554300 rs6845865 chr4 148974602 T C 7.00E-07 QT interval ARHGAP10 intron 20031603 rs3733421 chr4 149002841 T C 4.85E-05 Chronic Hepatitis C infection NR3C2 intron 21725309 rs2063009 chr4 149017126 G A 0.00017 Coronary artery calcification NR3C2 intron 23727086 rs111780107 chr4 149063161 G A 1.03E-05 Intracerebral hemorrhage NR3C2 intron 24656865 rs3931397 chr4 149079497 G T 4.00E-08 Corneal structure NR3C2 intron 23291589 rs6816503 chr4 149084447 G T 4.40E-07 Fasting glucose-related traits NR3C2 intron 20152958 rs6535584 chr4 149090088 T C 4.44E-04 Suicide attempts in bipolar disorder NR3C2 intron 21041247 rs4835490 chr4 149090326 G A 4.95E-05 Vaspin levels NR3C2 intron 22907691 rs4835490 chr4 149090326 G A 0.0000495 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit NR3C2 intron 22907730 rs4835490 chr4 149090326 G A 0.0001452 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit NR3C2 intron 22907730 rs17620330 chr4 149097709 T C 2.60E-05 Urinary metabolites NR3C2 intron 21572414 rs12641471 chr4 149139764 A C 2.23E-04 Aortic root size NR3C2 intron 21223598 rs2356374 chr4 149148298 A G 0.000000119 LDL cholesterol NR3C2 intron 23063622 rs10519948 chr4 149152029 C G 6.95E-17 Triglycerides NR3C2 intron 23063622 rs11724292 chr4 149155370 A C 9.36E-04 Response to cytadine analogues (cytosine arabinoside) NR3C2 intron 24483146 rs3887856 chr4 149170058 C T 2.98E-05 Post-operative nausea and vomiting NR3C2 intron 21694509 rs17024518 chr4 149186930 T C 0.000000194 LDL cholesterol NR3C2 intron 23063622 rs10519952 chr4 149201414 A G 8.70E-06 Urinary metabolites NR3C2 intron 21572414 rs10011595 chr4 149203505 T C 0.00000118 Cholesterol,total NR3C2 intron 23063622 rs10021848 chr4 149210464 C G 7.58E-04 Multiple complex diseases NR3C2 intron 17554300 rs11936376 chr4 149223283 A T 4.53E-05 Recombination rate NR3C2 intron 21698098 rs7688209 chr4 149254670 A T 7.30E-04 Smoking initiation NR3C2 intron 24665060 rs17024633 chr4 149265104 C T 7.61E-05 Bipolar disorder and schizophrenia NR3C2 intron 20889312 rs17484671 chr4 149268136 G T 5.25E-08 Multiple complex diseases NR3C2 intron 17554300 rs2137338 chr4 149292464 A T 3.70E-04 Response to cytadine analogues (cytosine arabinoside) NR3C2 intron 24483146 rs17581884 chr4 149299071 A G 3.92E-04 Coronary Artery Disease NR3C2 intron 17634449 rs11725509 chr4 149311728 A C 1.00E-06 Subcutaneous adipose tissue NR3C2 intron 22589738 rs1490453 chr4 149321346 G A 3.00E-06 Biochemical measures NR3C2 intron 19260141 rs16998733 chr4 149337408 T C 2.00E-05 Breast cancer NR3C2 intron 17529967 rs5525 chr4 149356516 A G 3.78E-05 Nicotine dependence NR3C2 cds-synon 18227835 rs5522 chr4 149357475 C T 1.52E-05 Nicotine dependence NR3C2 missense 18227835 rs6535611 chr4 149379537 A G 9.59E-05 Meningococcal disease / / 20694013 rs13142486 chr4 149385402 T C 2.80E-05 Urinary metabolites / / 21572414 rs1490463 chr4 149386704 C T 4.65E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6535616 chr4 149404430 G C 2.08E-04 Autism spectrum disorders (language delay) / / 21519539 rs145588141 chr4 149421962 C G 9.52E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs191927298 chr4 149479002 T A 9.74E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs17582787 chr4 149562638 G A 1.95E-04 Insulin resistance / / 21901158 rs2358462 chr4 149570680 T C 4.00E-06 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7437928 chr4 149574788 T C 5.60E-05 Hypothyroidism / / 22493691 rs2358469 chr4 149590581 G A 4.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs2358469 chr4 149590581 G A 4.54E-05 Orofacial clefts / / 22419666 rs4435727 chr4 149598985 G C 7.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs17024901 chr4 149600181 A C 1.21E-04 Multiple complex diseases / / 17554300 rs10008892 chr4 149625757 C A 9.60E-05 Hypothyroidism / / 22493691 rs6535627 chr4 149633713 T G 2.00E-05 Hypothyroidism / / 22493691 rs10519980 chr4 149635025 C T 7.00E-06 Hypothyroidism / / 22493691 rs17583283 chr4 149648035 G A 1.01E-06 Kawasaki disease / / 21221998 rs17025017 chr4 149650033 G A 2.70E-05 Hypothyroidism / / 22493691 rs17025017 chr4 149650033 G A 3.39E-08 Thyroid function / / 22494929 rs6535633 chr4 149651602 G A 7.71E-08 Thyroid function / / 22494929 rs11935941 chr4 149652478 A C 7.00E-05 Hypothyroidism / / 22493691 rs11935941 chr4 149652478 A C 7.56E-08 Thyroid function / / 22494929 rs11945082 chr4 149652582 C T 7.54E-08 Thyroid function / / 22494929 rs10028213 chr4 149652610 C G 3.00E-10 Thyroid function / / 22494929 rs10008491 chr4 149653109 A G 7.45E-08 Thyroid function / / 22494929 rs10009291 chr4 149653879 A G 7.33E-08 Thyroid function / / 22494929 rs7677940 chr4 149654577 A G 6.64E-05 Pulmonary function / / 20010835 rs2358648 chr4 149655781 C A 7.04E-08 Thyroid function / / 22494929 rs10021637 chr4 149657642 A G,T 6.78E-08 Thyroid function / / 22494929 rs10002630 chr4 149658675 G C 6.79E-08 Thyroid function / / 22494929 rs11728154 chr4 149660723 G A 2.49E-08 Thyroid function / / 22494929 rs11942028 chr4 149660911 T C 4.00E-05 Hypothyroidism / / 22493691 rs11942028 chr4 149660911 T C 8.36E-08 Thyroid function / / 22494929 rs10857236 chr4 149661024 A T 8.45E-08 Thyroid function / / 22494929 rs17025085 chr4 149662204 T G 9.60E-08 Thyroid function / / 22494929 rs7695440 chr4 149662335 C T 9.74E-08 Thyroid function / / 22494929 rs10004961 chr4 149664898 C T 4.35E-08 Thyroid function / / 22494929 rs11732089 chr4 149665602 T C 7.66E-08 Thyroid function / / 22494929 rs17486337 chr4 149665666 C G 4.95E-06 Kawasaki disease / / 21221998 rs10032216 chr4 149669506 T C 8.24E-08 Thyroid function / / 22494929 rs10032216 chr4 149669506 T C 2.00E-13 Thyroid hormone levels / / 23408906 rs10032216 chr4 149669506 T C 9.00E-16 Thyroid hormone levels / / 23408906 rs6535635 chr4 149673615 G A 4.95E-06 Kawasaki disease / / 21221998 rs6535636 chr4 149673625 A T 5.06E-06 Kawasaki disease / / 21221998 rs6848368 chr4 149697086 A C 3.20E-05 Hypothyroidism / / 22493691 rs10519990 chr4 149712041 A C 3.20E-05 Hypothyroidism / / 22493691 rs9968300 chr4 149722925 C A 1.77E-05 Thyroid stimulating hormone / / 24852370 rs485244 chr4 149733669 G A 2.80E-05 Urinary metabolites / / 21572414 rs471967 chr4 149744518 C T 5.93E-04 Stroke / / pha002887 rs4240350 chr4 149749646 G A 6.64E-04 Coronary heart disease / / 21971053 rs1634070 chr4 149775941 C T 9.00E-04 Coronary heart disease / / 21971053 rs1634079 chr4 149787704 A G 7.69E-04 Coronary heart disease / / 21971053 rs11736001 chr4 149813345 G T 7.89E-05 Serum metabolites / / 19043545 rs2520496 chr4 149817052 G A 6.84E-04 Type 2 diabetes / / 17463246 rs2520496 chr4 149817052 G A 7.37E-04 Coronary heart disease / / 21971053 rs853698 chr4 149824834 G T 1.45E-04 Multiple complex diseases / / 17554300 rs853727 chr4 149835012 C T 2.40E-04 Crohn's disease / / 17684544 rs4835147 chr4 149839912 C A 8.26E-05 Post-operative nausea and vomiting / / 21694509 rs4835147 chr4 149839912 C A 5.70E-04 Coronary heart disease / / 21971053 rs6535643 chr4 149844895 A G 1.90E-04 Multiple complex diseases / / 17554300 rs4407483 chr4 149856841 T C 2.50E-04 Coronary heart disease / / 21606135 rs6535646 chr4 149871390 C A 2.98E-05 Height / / pha003011 rs6535647 chr4 149871703 C T 4.28E-05 Intracerebral hemorrhage / / 24656865 rs6535647 chr4 149871703 C T 4.76E-05 Intracerebral hemorrhage / / 24656865 rs13133607 chr4 149877309 C T 4.22E-05 Intracerebral hemorrhage / / 24656865 rs7655685 chr4 149887051 G A 4.00E-05 Intracerebral hemorrhage / / 24656865 rs2732253 chr4 149893863 C T 4.61E-05 Heart Rate / / pha003051 rs724043 chr4 149901085 G T 3.18E-06 Heart Rate / / pha003051 rs724043 chr4 149901085 G T 1.73E-05 Heart Rate / / pha003054 rs2188536 chr4 149902193 A G 4.41E-05 Heart Rate / / pha003051 rs10489054 chr4 149925300 T C 2.59E-04 Multiple complex diseases / / 17554300 rs2520494 chr4 149929686 C T 0.000432076 Hypertension (early onset hypertension) / / 22479346 rs4586907 chr4 149941383 A G 5.68E-06 Lipid traits / / 21777205 rs6839286 chr4 149943840 G A 9.00E-05 Multiple complex diseases / / 17554300 rs9993561 chr4 149946347 C T 1.05E-04 Multiple complex diseases / / 17554300 rs6824983 chr4 149948850 G T 0.000432076 Hypertension (early onset hypertension) / / 22479346 rs6824983 chr4 149948850 G T 5.30E-05 Height / / pha003010 rs6824983 chr4 149948850 G T 1.16E-05 Height / / pha003011 rs6851434 chr4 149949326 T A 8.71E-04 Coronary Artery Disease / / 17634449 rs11727085 chr4 149949967 G A 3.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4455396 chr4 149952676 A C 1.41E-05 Height / / pha003010 rs4455396 chr4 149952676 A C 1.60E-05 Height / / pha003011 rs17487246 chr4 149970086 G A 6.18E-05 Pulmonary function / / 20010835 rs965921 chr4 150057249 A G 9.35E-05 Post-operative nausea and vomiting / / 21694509 rs7679928 chr4 150068414 A G 2.20E-07 Post-operative nausea and vomiting / / 21694509 rs4522846 chr4 150070596 C T 3.44E-08 Post-operative nausea and vomiting / / 21694509 rs1438764 chr4 150123775 C T 2.70E-06 Post-operative nausea and vomiting / / 21694509 rs10520010 chr4 150125382 C T 6.40E-05 Sleep and circadian phenotypes / / 17903308 rs17487852 chr4 150128848 A G 4.00E-06 Alcohol dependence / / 21956439 rs562329 chr4 150129324 T C 2.29E-07 Post-operative nausea and vomiting / / 21694509 rs10002921 chr4 150250143 C T 0.000511258 Hypertension (early onset hypertension) / / 22479346 rs4835580 chr4 150347573 C T 3.29E-09 Narcolepsy / / 19629137 rs4510455 chr4 150351067 G A 4.13E-04 Multiple complex diseases / / 17554300 rs1394028 chr4 150457508 C T 5.46E-04 Epilepsy LOC285423 intron 22116939 rs11724130 chr4 150477841 C T 1.06E-04 Arthritis (juvenile idiopathic) LOC285423 intron 22354554 rs2654798 chr4 150483241 A G 5.20E-04 Epilepsy LOC285423 intron 22116939 rs10003632 chr4 150484908 G T 0.00000057 Mean arterial pressure LOC285423 missense 22510845 rs2654831 chr4 150520884 T G 3.93E-04 Epilepsy LOC285423 intron 22116939 rs2654831 chr4 150520884 T G 4.74E-04 Smoking quantity LOC285423 intron 24665060 rs1503744 chr4 150547693 T C 2.21E-05 Bilirubin levels,in serum LOC285423 intron 19389676 rs1125051 chr4 150557751 G C 9.96E-05 Arthritis (juvenile idiopathic) LOC285423 intron 22354554 rs958349 chr4 150569388 T C 5.81E-05 Bilirubin levels,in serum LOC285423 intron 19389676 rs6535695 chr4 150617889 C G 9.44E-05 Arthritis (juvenile idiopathic) LOC285423 intron 22354554 rs1503751 chr4 150648816 T C 2.10E-06 Parkinson's disease (familial) LOC285423 intron 18985386 rs2055638 chr4 150674206 A T 1.57E-05 Post-operative nausea and vomiting LOC285423 intron 21694509 rs10030601 chr4 150725212 T C 1.00E-06 Epilepsy (generalized) LOC285423 intron 22949513 rs2884771 chr4 150745265 A T 8.68E-04 Multiple complex diseases / / 17554300 rs7678122 chr4 150791450 A T 7.34E-04 Insulin resistance / / 21901158 rs905900 chr4 150852782 G A 7.61E-04 Type 2 diabetes / / 17463246 rs12646793 chr4 150886317 T C 4.74E-05 Cognitive impairment induced by topiramate / / 22091778 rs12646793 chr4 150886317 T C 6.62E-05 Cognitive impairment induced by topiramate / / 22091778 rs11930273 chr4 150901757 G A 1.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs6823080 chr4 150915157 C A 7.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs12510080 chr4 150940502 A T 5.65E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs6826455 chr4 150941462 T C 5.65E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs10857243 chr4 151063849 T G 8.13E-04 Smoking initiation DCLK2 intron 24665060 rs4513544 chr4 151071601 T C 1.66E-04 Smoking initiation DCLK2 intron 24665060 rs11947645 chr4 151101672 G A 1.00E-06 Social autistic-like traits DCLK2 intron 24133439 rs10520059 chr4 151103731 C T 7.93E-04 Heart Failure DCLK2 intron pha002884 rs1124359 chr4 151119353 G A 9.13E-04 Coronary heart disease DCLK2 intron 21606135 rs9307870 chr4 151130051 G T 3.98E-04 Response to taxane treatment (placlitaxel) DCLK2 intron 23006423 rs7679888 chr4 151144170 T G 8.01E-04 Response to taxane treatment (placlitaxel) DCLK2 intron 23006423 rs12513356 chr4 151152940 G C 9.42E-04 Insulin resistance DCLK2 intron 21901158 rs1459746 chr4 151157772 C T 4.12E-04 Smoking initiation DCLK2 intron 24665060 rs1813134 chr4 151231371 T C 5.69E-06 Parkinson's disease LRBA intron 24842889 rs6535731 chr4 151267543 A G 2.50E-05 Urinary metabolites LRBA intron 21572414 rs17504359 chr4 151307121 C G 9.77E-04 Coronary heart disease LRBA intron 21606135 rs12499470 chr4 151321241 A C 7.96E-04 Coronary heart disease LRBA intron 21606135 rs11936646 chr4 151348200 G A 6.83E-04 Multiple complex diseases LRBA intron 17554300 rs2036552 chr4 151397759 A G 4.80E-04 Coronary heart disease LRBA intron 21606135 rs11932482 chr4 151445791 C T 8.10E-04 Multiple complex diseases LRBA intron 17554300 rs10012087 chr4 151474920 T C 3.49E-04 Type 2 diabetes LRBA intron 17463246 rs7657997 chr4 151515966 A C 2.38E-04 Response to taxane treatment (placlitaxel) LRBA intron 23006423 rs4435730 chr4 151519232 T C 5.97E-04 Response to taxane treatment (placlitaxel) LRBA intron 23006423 rs6825990 chr4 151530148 A G 7.55E-05 Femoral neck bone geometry LRBA intron 22087292 rs13104720 chr4 151579280 C T 2.73E-04 Lung function (forced expiratory volume in 1 second) LRBA intron 24023788 rs13104720 chr4 151579280 C T 5.14E-05 Body Mass Index LRBA intron pha003009 rs13104720 chr4 151579280 C T 4.72E-06 Weight LRBA intron pha003027 rs4318628 chr4 151602118 G A 7.35E-04 Response to taxane treatment (placlitaxel) LRBA intron 23006423 rs10000193 chr4 151617093 A G 2.49E-04 Response to taxane treatment (placlitaxel) LRBA intron 23006423 rs4235251 chr4 151619029 C T 4.10E-04 Response to taxane treatment (placlitaxel) LRBA intron 23006423 rs4455394 chr4 151625361 G A 2.12E-04 Response to taxane treatment (placlitaxel) LRBA intron 23006423 rs10520078 chr4 151641186 A G 9.73E-05 Response to taxane treatment (placlitaxel) LRBA intron 23006423 rs1993109 chr4 151656589 C T 1.52E-04 Response to taxane treatment (placlitaxel) LRBA intron 23006423 rs10028040 chr4 151664792 G T 9.55E-04 Response to taxane treatment (placlitaxel) LRBA intron 23006423 rs1451635 chr4 151668526 A G 3.76E-04 Response to taxane treatment (placlitaxel) LRBA intron 23006423 rs7665654 chr4 151693149 A G 2.24E-04 Response to taxane treatment (placlitaxel) LRBA intron 23006423 rs1129998 chr4 151719263 A G 2.95E-04 Multiple complex diseases LRBA cds-synon 17554300 rs6836854 chr4 151742349 C T 2.17E-05 Word reading LRBA intron 23738518 rs4696636 chr4 151767922 T C 2.54E-05 Reading and spelling LRBA intron 23738518 rs11099777 chr4 151775259 G A 5.12E-04 Alcohol dependence LRBA intron 21314694 rs2407549 chr4 151790540 C A 9.34E-04 Response to taxane treatment (placlitaxel) LRBA intron 23006423 rs1148652 chr4 151801938 T C 7.95E-04 Response to taxane treatment (placlitaxel) LRBA intron 23006423 rs7693278 chr4 151809625 G A 6.38E-04 Response to taxane treatment (placlitaxel) LRBA intron 23006423 rs1201214 chr4 151815783 T C 5.60E-04 Response to taxane treatment (placlitaxel) LRBA intron 23006423 rs13117608 chr4 151822085 G A 3.82E-05 Body Mass Index LRBA intron pha003007 rs13117608 chr4 151822085 G A 4.55E-06 Body Mass Index LRBA intron pha003009 rs13117608 chr4 151822085 G A 8.80E-05 Waist Circumference LRBA intron pha003025 rs13117608 chr4 151822085 G A 1.40E-05 Weight LRBA intron pha003026 rs13117608 chr4 151822085 G A 2.22E-07 Weight LRBA intron pha003027 rs1148645 chr4 151824966 T G 7.53E-04 Response to taxane treatment (placlitaxel) LRBA intron 23006423 rs1201201 chr4 151840850 C T 7.31E-04 Multiple complex diseases LRBA intron 17554300 rs2407548 chr4 151850524 T G 8.59E-04 Response to taxane treatment (placlitaxel) LRBA intron 23006423 rs1201198 chr4 151859674 T C 2.51E-04 Response to taxane treatment (placlitaxel) LRBA intron 23006423 rs9992474 chr4 151880765 A G 9.69E-04 Response to taxane treatment (placlitaxel) LRBA intron 23006423 rs11099780 chr4 151888609 A G 8.03E-04 Response to taxane treatment (placlitaxel) LRBA intron 23006423 rs35198214 chr4 152187377 G A 3.90E-04 Coronary heart disease / / 21606135 rs2407220 chr4 152193825 C T 9.27E-05 Formal thought disorder in schizophrenia / / 22648509 rs6850311 chr4 152203897 C T 8.52E-05 Formal thought disorder in schizophrenia PRSS48 intron 22648509 rs11099804 chr4 152266086 C T 5.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4479686 chr4 152399324 C T 2.58E-04 Antisocial behavior FAM160A1 intron 20345837 rs17690873 chr4 152418466 G A 1.17E-04 Cognitive decline FAM160A1 intron 23732972 rs4696099 chr4 152501951 G C 2.90E-05 Personality dimensions FAM160A1 intron 18957941 rs718801 chr4 152549247 G A 7.70E-05 Personality dimensions FAM160A1 intron 18957941 rs718800 chr4 152549307 A T 7.70E-05 Personality dimensions FAM160A1 intron 18957941 rs1366910 chr4 152588541 T C 7.86E-05 Cognitive test performance / / 20125193 rs2278304 chr4 152593409 T C 4.00E-04 Lymphocyte counts PET112 intron 22286170 rs11732441 chr4 152625446 A G 7.09E-05 Cognitive test performance PET112 intron 20125193 rs11556167 chr4 152682046 G T 2.89E-05 Cognitive test performance PET112 missense 20125193 rs11099827 chr4 152714658 T C 2.72E-05 Cognitive test performance / / 20125193 rs361166 chr4 152792791 G A 8.52E-06 Triglycerides / / pha003080 rs17028049 chr4 152809738 G A 2.71E-28 Narcolepsy / / 19629137 rs561025 chr4 152825303 C A 9.10E-04 Type 2 diabetes / / 17463246 rs361147 chr4 152890563 G T 3.13E-13 Breast cancer(er negative) / / 21062454 rs360929 chr4 152907700 G A 9.00E-06 Volumetric brain MRI / / 17903297 rs360932 chr4 152908169 G A 8.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs6852759 chr4 152912247 C A 6.17E-04 Tourette syndrome / / 22889924 rs750090 chr4 152931436 T C 9.15E-05 Calcium levels / / pha003085 rs12332066 chr4 152939280 T C 5.03E-04 Multiple complex diseases / / 17554300 rs17028407 chr4 152944433 C A 9.59E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs12505581 chr4 152948812 A G 1.80E-05 Urinary metabolites / / 21572414 rs17028429 chr4 152949565 T C 2.50E-05 Urinary metabolites / / 21572414 rs7434739 chr4 152960983 G A 3.54E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs4696313 chr4 152989476 G C 4.13E-04 Multiple complex diseases / / 17554300 rs6535836 chr4 153022292 G A 9.02E-05 Hypertension / / pha003042 rs6535838 chr4 153023402 C A 8.32E-05 Serum metabolites / / 19043545 rs6823091 chr4 153069783 C A 2.70E-05 Type 2 diabetes / / 17293876 rs6823091 chr4 153069783 C A 2.70E-05 Type 2 diabetes / / 19184112 rs6823091 chr4 153069783 C A 9.77E-05 Hypertension / / pha003042 rs6827083 chr4 153075491 A G 1.02E-04 Bipolar disorder / / 17486107 rs6849420 chr4 153090442 T C 9.54E-05 Hypertension / / pha003042 rs6838430 chr4 153211026 A G 7.50E-05 Memory performance / / 22105620 rs10033601 chr4 153252061 A G 1.84E-04 Type 2 diabetes FBXW7 intron 22158537 rs2676330 chr4 153265507 T C 6.87E-04 Suicide attempts in bipolar disorder FBXW7 intron 21423239 rs2676329 chr4 153275395 C T 9.61E-04 Suicide attempts in bipolar disorder FBXW7 intron 21423239 rs2203644 chr4 153275701 T C 8.81E-04 Suicide attempts in bipolar disorder FBXW7 intron 21423239 rs11931711 chr4 153291513 C T 6.21E-04 Suicide attempts in bipolar disorder FBXW7 intron 21423239 rs11931711 chr4 153291513 C T 3.23E-04 Type 2 diabetes FBXW7 intron 22158537 rs7673175 chr4 153301216 T C 7.11E-04 Suicide attempts in bipolar disorder FBXW7 intron 21423239 rs7673175 chr4 153301216 T C 6.12E-04 Type 2 diabetes FBXW7 intron 22158537 rs1516822 chr4 153330301 T C 9.17E-04 Type 2 diabetes FBXW7 intron 22158537 rs4696321 chr4 153342645 T C 8.84E-04 Suicide attempts in bipolar disorder FBXW7 intron 21423239 rs4696321 chr4 153342645 T C 6.71E-04 Type 2 diabetes FBXW7 intron 22158537 rs2406375 chr4 153367257 T C 9.62E-04 Type 2 diabetes FBXW7 intron 22158537 rs10031972 chr4 153371764 A G 2.60E-04 Type 2 diabetes FBXW7 intron 22158537 rs2628570 chr4 153373680 G T 2.83E-04 Type 2 diabetes FBXW7 intron 22158537 rs1516820 chr4 153380801 T C 2.25E-04 Type 2 diabetes FBXW7 intron 22158537 rs7660590 chr4 153397823 C T 9.65E-04 Type 2 diabetes FBXW7 intron 22158537 rs10021011 chr4 153410390 C A 6.74E-05 Type 2 diabetes FBXW7 intron 22158537 rs9991574 chr4 153411843 T C 7.02E-04 Type 2 diabetes FBXW7 intron 22158537 rs718089 chr4 153412394 A G 2.84E-04 Type 2 diabetes FBXW7 intron 22158537 rs17028932 chr4 153415654 T C 3.16E-04 Type 2 diabetes FBXW7 intron 22158537 rs6535851 chr4 153425449 C T 7.96E-04 Suicide attempts in bipolar disorder FBXW7 intron 21423239 rs6535851 chr4 153425449 C T 2.45E-04 Type 2 diabetes FBXW7 intron 22158537 rs1516819 chr4 153433451 A C 5.24E-05 Type 2 diabetes FBXW7 intron 22158537 rs17028954 chr4 153438333 C G 7.27E-04 Type 2 diabetes FBXW7 intron 22158537 rs6816962 chr4 153450360 G T 9.54E-05 Type 2 diabetes FBXW7 intron 22158537 rs1023962 chr4 153451356 T G 1.40E-04 Type 2 diabetes FBXW7 intron 22158537 rs1484879 chr4 153455628 A G 1.64E-04 Type 2 diabetes FBXW7 intron 22158537 rs6832998 chr4 153470666 A T 3.50E-04 Type 2 diabetes / / 22158537 rs4696135 chr4 153510588 T C 7.66E-04 Type 2 diabetes / / 22158537 rs7686797 chr4 153513300 A G 1.78E-04 Type 2 diabetes / / 22158537 rs7669833 chr4 153513369 T A 7.28E-05 Type 2 diabetes / / 22158537 rs4696327 chr4 153515580 A G 2.52E-04 Type 2 diabetes / / 22158537 rs10020796 chr4 153519781 T C 2.12E-04 Type 2 diabetes / / 22158537 rs6813195 chr4 153520475 C T 2.67E-04 Type 2 diabetes / / 22158537 rs6813195 chr4 153520475 C T 4.00E-14 Type 2 diabetes / / 24509480 rs6851065 chr4 153534975 T C 6.30E-06 Cardiovascular disease / / pha003065 rs6851065 chr4 153534975 T C 5.78E-05 Lipid levels / / pha003082 rs6831842 chr4 153535671 G T 2.73E-05 Body Mass Index / / pha003015 rs6831842 chr4 153535671 G T 9.34E-05 Insulin-related traits / / pha003063 rs6831842 chr4 153535671 G T 6.15E-05 Cardiovascular disease / / pha003065 rs6831842 chr4 153535671 G T 1.58E-05 Lipid levels / / pha003082 rs13142121 chr4 153539977 T C 7.33E-04 Acute lung injury / / 22295056 rs13142822 chr4 153540318 T C 2.37E-04 Acute lung injury / / 22295056 rs13116511 chr4 153540807 A T 1.39E-04 Acute lung injury / / 22295056 rs13126552 chr4 153587445 C T 1.08E-06 Body Mass Index TMEM154 intron pha003014 rs6839665 chr4 153625027 G A 2.23E-25 Narcolepsy / / 19629137 rs13124365 chr4 153629791 C T 3.78E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12503416 chr4 153631060 A G 7.96E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10009955 chr4 153660407 C A 0.0000686 Schizophrenia / / 22440650 rs4254753 chr4 153800029 T G 2.68E-04 Response to taxane treatment (placlitaxel) ARFIP1 intron 23006423 rs867322 chr4 153878480 A G 4.69E-05 Brain structure FHDC1 intron 22504417 rs11737767 chr4 153879878 C T 3.33E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) FHDC1 intron 23648065 rs1018316 chr4 153888640 C T 5.62E-04 Suicide attempts in bipolar disorder FHDC1 intron 21423239 rs10020165 chr4 153892856 A G 7.62E-04 Alzheimer's disease FHDC1 intron 17998437 rs11099864 chr4 153893354 G A 9.00E-06 Amyotrophic lateral sclerosis FHDC1 intron 17362836 rs77708442 chr4 153896160 C T 8.00E-06 Obesity-related traits FHDC1 missense 23251661 rs7661720 chr4 153922793 A G 4.82E-05 Alzheimer's disease / / 17998437 rs11726200 chr4 153924163 G A 7.97E-04 Multiple complex diseases / / 17554300 rs11726200 chr4 153924163 G A 6.93E-04 Alzheimer's disease / / 17998437 rs6818398 chr4 153943571 T C 3.44E-04 Tourette syndrome / / 22889924 rs6847599 chr4 153944378 C T 1.60E-05 Urinary metabolites / / 21572414 rs4696381 chr4 153944810 T C 1.60E-05 Urinary metabolites / / 21572414 rs6814889 chr4 153947145 G A 1.10E-05 Urinary metabolites / / 21572414 rs1111986 chr4 153949047 G A 8.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs17029520 chr4 153958198 C T 5.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs10012544 chr4 153958457 T A 5.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs4583737 chr4 153961784 C A 2.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs1516692 chr4 153963155 C A 1.82E-04 Alzheimer's disease / / 17998437 rs2406144 chr4 153965619 T C 2.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs908535 chr4 153968142 A G 2.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs17029545 chr4 153971905 T C 2.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs2056168 chr4 153977593 A G 7.07E-05 Cognitive test performance / / 20125193 rs6832907 chr4 153982885 A G 9.61E-04 Alcohol dependence / / 21314694 rs2090380 chr4 153986325 G A 2.20E-05 Multiple complex diseases / / 17554300 rs10021182 chr4 153996743 T A 2.51E-04 Multiple complex diseases / / 17554300 rs981419 chr4 153997516 G A 5.97E-06 Rheumatoid arthritis / / 19503088 rs6841059 chr4 153999411 T C 2.63E-04 Multiple complex diseases / / 17554300 rs4696397 chr4 154001191 T C 6.46E-06 Smoking cessation / / 18519826 rs12651275 chr4 154009667 C T 1.14E-06 Coronary heart disease / / 22319020 rs17029639 chr4 154011288 G A 3.21E-05 Smoking cessation / / 18519826 rs13111607 chr4 154011438 C T 5.04E-04 Multiple complex diseases / / 17554300 rs13112096 chr4 154011656 A G 5.83E-04 Alzheimer's disease / / 24755620 rs4696168 chr4 154014076 G A 7.62E-05 Smoking cessation / / 18519826 rs17029689 chr4 154017103 T C 1.99E-04 Multiple complex diseases / / 17554300 rs7662116 chr4 154017964 C A 1.90E-05 Longevity and age-related phenotypes / / 17903295 rs6817112 chr4 154080813 C T 5.50E-05 Longevity,exceptional TRIM2 intron 20595579 rs4543093 chr4 154104459 A G 9.31E-05 Major depressive disorder (broad) TRIM2 intron 20038947 rs12511084 chr4 154113457 C A 9.50E-05 Major depressive disorder (broad) TRIM2 intron 20038947 rs6817587 chr4 154118168 G A 4.84E-04 Amyotrophic lateral sclerosis TRIM2 intron 23624525 rs12644284 chr4 154154000 A G 4.00E-06 Multiple sclerosis TRIM2 intron 21654844 rs10021898 chr4 154206361 C T 4.24E-05 Cognitive impairment induced by topiramate TRIM2 intron 22091778 rs893805 chr4 154216710 G A 4.13E-05 Parkinson's disease (motor and cognition) TRIM2 cds-synon 22658654 rs6535914 chr4 154262551 T C 1.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs6821156 chr4 154271902 A T 9.20E-05 Suicide attempts in bipolar disorder MND1 intron 21041247 rs6841435 chr4 154274664 C T 1.17E-04 Suicide attempts in bipolar disorder MND1 intron 21041247 rs7340984 chr4 154277181 C G 1.27E-04 Suicide attempts in bipolar disorder MND1 intron 21041247 rs17029907 chr4 154288126 G A 4.41E-05 Height MND1 intron 22021425 rs10517571 chr4 154314931 C A 4.46E-04 Suicide attempts in bipolar disorder MND1 intron 21041247 rs3852108 chr4 154340519 A C 4.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs13105829 chr4 154369706 C T 3.62E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs13105829 chr4 154369706 C T 8.34E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs11941933 chr4 154371229 C T 3.03E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs11941933 chr4 154371229 C T 6.86E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs11728644 chr4 154373196 G A 2.06E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs11728644 chr4 154373196 G A 2.55E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs6817170 chr4 154374984 T C 9.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs11732163 chr4 154376222 G A 1.35E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs11732163 chr4 154376222 G A 2.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs1560940 chr4 154378572 A G 2.67E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs1836401 chr4 154389653 A G 2.36E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) KIAA0922 intron 23648065 rs1836401 chr4 154389653 A G 3.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) KIAA0922 intron 23648065 rs713247 chr4 154408360 A C 2.12E-04 Response to statin treatment (atorvastatin),change in cholesterol levels KIAA0922 intron 20031582 rs713248 chr4 154408454 A G 1.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) KIAA0922 intron 23648065 rs713248 chr4 154408454 A G 1.92E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) KIAA0922 intron 23648065 rs59530858 chr4 154414675 G A 2.97E-05 Intracerebral hemorrhage KIAA0922 intron 24656865 rs13119846 chr4 154415184 T C 2.02E-05 Pulmonary function in asthmatics KIAA0922 intron 23541324 rs59045097 chr4 154415272 A C 3.47E-05 Intracerebral hemorrhage KIAA0922 intron 24656865 rs6535921 chr4 154450096 T A,C,G 1.90E-05 Psoriasis KIAA0922 intron 18364390 rs6850598 chr4 154452248 G T 4.61E-05 Amyotrophic lateral sclerosis (sporadic) KIAA0922 intron 24529757 rs6850598 chr4 154452248 G T 5.52E-05 Cholesterol KIAA0922 intron pha003073 rs6850598 chr4 154452248 G T 6.06E-05 Cholesterol KIAA0922 intron pha003078 rs6810447 chr4 154461884 T G 7.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KIAA0922 intron 20877124 rs6535924 chr4 154465994 G A 8.36E-05 Cholesterol KIAA0922 intron pha003073 rs7660583 chr4 154471928 G A 6.94E-06 Cholesterol KIAA0922 intron pha003073 rs7660583 chr4 154471928 G A 9.89E-06 Cholesterol KIAA0922 intron pha003078 rs7660583 chr4 154471928 G A 5.62E-05 Cholesterol KIAA0922 intron pha003083 rs10011687 chr4 154474250 A G 8.37E-05 Information processing speed KIAA0922 intron 21130836 rs10011706 chr4 154474340 A C 7.95E-05 Information processing speed KIAA0922 intron 21130836 rs10034657 chr4 154474931 G A 1.88E-05 Cholesterol KIAA0922 intron pha003073 rs10034657 chr4 154474931 G A 1.69E-05 Cholesterol KIAA0922 intron pha003078 rs10034657 chr4 154474931 G A 8.50E-05 Cholesterol KIAA0922 intron pha003083 rs10024442 chr4 154492055 T G 3.07E-27 Narcolepsy KIAA0922 intron 19629137 rs10517575 chr4 154527615 A G 7.87E-04 Myocardial Infarction KIAA0922 intron pha002873 rs13135353 chr4 154532047 G T 1.67E-04 Type 2 diabetes KIAA0922 intron 17463246 rs17370492 chr4 154540530 C T 4.08E-04 Multiple complex diseases KIAA0922 intron 17554300 rs2083290 chr4 154550725 C A 9.27E-05 Bipolar disorder and schizophrenia KIAA0922 intron 20889312 rs2033831 chr4 154559151 A G 8.73E-05 Alcohol dependence / / 21314694 rs2033831 chr4 154559151 A G 3.44E-05 Odorant perception / / 23910658 rs1595627 chr4 154584862 T C 3.23E-04 Alzheimer's disease (late onset) / / 21379329 rs6835636 chr4 154590349 A G 1.87E-04 Alzheimer's disease (late onset) / / 21379329 rs11938228 chr4 154621946 C A 1.30E-05 Electrocardiographic conduction measures TLR2 intron 19389651 rs1869947 chr4 154643503 G A 2.41E-06 Behcet's disease RNF175 intron 23291587 rs2606324 chr4 154652447 A G 7.99E-05 Cognitive impairment induced by topiramate RNF175 intron 22091778 rs2251997 chr4 154654067 C T 7.99E-05 Cognitive impairment induced by topiramate RNF175 intron 22091778 rs2251900 chr4 154654145 C T 7.99E-05 Cognitive impairment induced by topiramate RNF175 intron 22091778 rs4145338 chr4 154654323 T C 7.67E-05 Alcohol dependence RNF175 intron 21314694 rs11099898 chr4 154665021 T C 9.30E-05 Electrocardiographic conduction measures RNF175 intron 19389651 rs12641631 chr4 154665279 A G 2.20E-05 Electrocardiographic conduction measures RNF175 intron 19389651 rs6849882 chr4 154673669 T C 3.20E-05 Cognitive test performance RNF175 intron 20125193 rs6857680 chr4 154678363 A C 5.46E-05 Serum metabolites RNF175 intron 19043545 rs11099905 chr4 154686183 C T 6.00E-05 Electrocardiographic conduction measures / / 19389651 rs17030434 chr4 154703596 T C 5.00E-06 Electrocardiographic conduction measures SFRP2 intron 19389651 rs6853435 chr4 154706016 G A 4.46E-05 Alzheimer's disease SFRP2 intron 21098978 rs35797469 chr4 154706220 C CA 8.60E-06 Electrocardiographic conduction measures SFRP2 intron 19389651 rs6853522 chr4 154706220 C A 8.60E-06 Electrocardiographic conduction measures SFRP2 intron 19389651 rs9799574 chr4 154707933 T C 1.90E-05 Multiple complex diseases SFRP2 intron 17554300 rs3810765 chr4 154709480 G A 4.47E-05 Alzheimer's disease SFRP2 intron 21098978 rs1456389 chr4 154714116 A T 4.50E-05 Alzheimer's disease / / 21098978 rs11732581 chr4 154720238 C T 1.24E-04 Multiple complex diseases / / 17554300 rs1106708 chr4 154726857 C A 3.25E-05 Serum metabolites / / 19043545 rs7667718 chr4 154731642 C T 4.87E-05 Alzheimer's disease / / 21098978 rs10006749 chr4 154731828 T C 4.87E-05 Alzheimer's disease / / 21098978 rs1902467 chr4 154732128 A C 4.88E-05 Alzheimer's disease / / 21098978 rs11723258 chr4 154733070 T C 4.90E-05 Alzheimer's disease / / 21098978 rs7680824 chr4 154733635 C A 3.11E-05 Alzheimer's disease / / 21098978 rs1456401 chr4 154733972 A G 4.90E-05 Alzheimer's disease / / 21098978 rs10031057 chr4 154746806 A G 5.30E-05 Electrocardiographic conduction measures / / 19389651 rs10031057 chr4 154746806 A G 5.21E-05 Alzheimer's disease / / 21098978 rs7682762 chr4 154758602 G A 4.03E-05 Alzheimer's disease / / 21098978 rs7682436 chr4 154758667 A G 5.86E-05 Alzheimer's disease / / 21098978 rs13139425 chr4 154759679 T A 5.92E-05 Alzheimer's disease / / 21098978 rs13119833 chr4 154760896 C T 5.95E-05 Alzheimer's disease / / 21098978 rs13101315 chr4 154761285 T C 6.08E-05 Alzheimer's disease / / 21098978 rs5018782 chr4 154761936 A G 5.96E-05 Alzheimer's disease / / 21098978 rs5018783 chr4 154761977 A G 5.99E-05 Alzheimer's disease / / 21098978 rs5018784 chr4 154761987 G A 6.04E-05 Alzheimer's disease / / 21098978 rs5018785 chr4 154762060 C T 6.51E-05 Alzheimer's disease / / 21098978 rs2405206 chr4 154762808 C G 6.09E-05 Alzheimer's disease / / 21098978 rs1598633 chr4 154762837 C A 6.13E-05 Alzheimer's disease / / 21098978 rs7680792 chr4 154763599 G T 6.14E-05 Alzheimer's disease / / 21098978 rs4401438 chr4 154765194 T G 6.26E-05 Alzheimer's disease / / 21098978 rs4513550 chr4 154765293 T C 6.32E-05 Alzheimer's disease / / 21098978 rs6823476 chr4 154765334 T C 6.33E-05 Alzheimer's disease / / 21098978 rs897612 chr4 154765417 A G 6.37E-05 Alzheimer's disease / / 21098978 rs12509282 chr4 154766634 G A 6.44E-05 Alzheimer's disease / / 21098978 rs17299673 chr4 154797919 C T 2.87E-06 Body mass index / / 19557197 rs1456404 chr4 154805172 T C 1.52E-06 Body mass index / / 19557197 rs11099924 chr4 154850835 A G 3.50E-05 Serum alpha1-antitrypsin levels / / 23990791 rs4411966 chr4 154854591 A G 3.90E-05 Serum alpha1-antitrypsin levels / / 23990791 rs4622983 chr4 154854674 G A 4.71E-05 Serum alpha1-antitrypsin levels / / 23990791 rs13135284 chr4 154864750 T C 5.00E-08 DNA methylation (parent-of-origin) / / 23725790 rs10024897 chr4 154867538 C T 3.29E-05 Body Mass Index / / pha003022 rs2897074 chr4 154937685 G T 9.98E-05 Post-operative nausea and vomiting / / 21694509 rs2404917 chr4 154995223 G A 3.26E-05 Bipolar disorder / / 17486107 rs2404916 chr4 154995463 A G 9.00E-06 Obesity-related traits / / 23251661 rs1316990 chr4 154995958 C T 6.83E-04 Multiple complex diseases / / 17554300 rs2404913 chr4 155001042 C G 4.03E-04 Type 2 diabetes / / 17463246 rs4328897 chr4 155014356 C A 7.25E-04 Type 2 diabetes / / 17463246 rs4328897 chr4 155014356 C A 6.39E-05 Serum metabolites / / 19043545 rs7667046 chr4 155039514 A G 7.17E-05 Gallstones / / 17632509 rs7667046 chr4 155039514 A G 5.43E-05 Serum metabolites / / 19043545 rs6815898 chr4 155043741 C G 9.02E-04 Acute lung injury / / 22295056 rs2014131 chr4 155047531 C T 5.64E-04 Type 2 diabetes / / 17463246 rs2014131 chr4 155047531 C T 6.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs938716 chr4 155049484 C T 9.20E-05 Cognitive test performance / / 20125193 rs4349583 chr4 155071789 A C 3.26E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6823540 chr4 155197891 G T 7.19E-04 Response to cytadine analogues (cytosine arabinoside) DCHS2 intron 24483146 rs6830115 chr4 155251674 G A 7.41E-04 Multiple complex diseases DCHS2 intron 17554300 rs10517592 chr4 155258749 A G 0.0003423 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DCHS2 intron 23233654 rs10517592 chr4 155258749 A G 3.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) DCHS2 intron 23233662 rs13138970 chr4 155275060 G A 7.52E-05 C-Reactive Protein DCHS2 intron pha003070 rs10017772 chr4 155287535 T C 3.91E-04 Alzheimer's disease (late onset) DCHS2 missense 21379329 rs12651106 chr4 155301059 C A 2.00E-12 Fibrinogen DCHS2 intron 21757653 rs12651106 chr4 155301059 C A 6.07E-05 Alzheimer's disease (age of onset) DCHS2 intron 22005931 rs10857274 chr4 155307426 T C 2.83E-05 Lipoproteins DCHS2 intron pha003079 rs17314785 chr4 155315302 G C 8.84E-04 Multiple complex diseases DCHS2 intron 17554300 rs902464 chr4 155316122 T C 3.00E-07 Immune reponse to smallpox (secreted IL-1beta) DCHS2 intron 22610502 rs10857275 chr4 155328698 C T 5.92E-05 Alzheimer's disease (age of onset) DCHS2 intron 22005931 rs990185 chr4 155330882 G C 6.56E-05 Alzheimer's disease (age of onset) DCHS2 intron 22005931 rs12500118 chr4 155344634 C T 5.11E-07 Alzheimer's disease (age of onset) DCHS2 intron 22005931 rs4696564 chr4 155346362 T C 6.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DCHS2 intron 20877124 rs4696564 chr4 155346362 T C 8.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DCHS2 intron 20877124 rs1466662 chr4 155347393 A T 5.00E-07 Alzheimer's disease (age of onset) DCHS2 intron 22005931 rs7677032 chr4 155352444 G A 7.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DCHS2 intron 20877124 rs7677032 chr4 155352444 G A 8.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DCHS2 intron 20877124 rs4696572 chr4 155354916 T C 6.77E-07 Alzheimer's disease (age of onset) DCHS2 intron 22005931 rs1388087 chr4 155357085 G T 4.80E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) DCHS2 intron 24023788 rs1490648 chr4 155357830 G A 6.84E-05 Alzheimer's disease (age of onset) DCHS2 intron 22005931 rs1490649 chr4 155357937 G A 6.08E-05 Alzheimer's disease (age of onset) DCHS2 intron 22005931 rs12504201 chr4 155358687 C A 4.13E-06 Alzheimer's disease (age of onset) DCHS2 intron 22005931 rs11099955 chr4 155360315 A T 9.83E-05 Alzheimer's disease (age of onset) DCHS2 intron 22005931 rs10014536 chr4 155360533 C T 9.42E-05 Alzheimer's disease (age of onset) DCHS2 intron 22005931 rs10014635 chr4 155360593 C A 8.74E-05 Alzheimer's disease (age of onset) DCHS2 intron 22005931 rs1032336 chr4 155360919 C T 8.47E-05 Alzheimer's disease (age of onset) DCHS2 intron 22005931 rs1032335 chr4 155361010 A G 8.20E-05 Alzheimer's disease (age of onset) DCHS2 intron 22005931 rs1907155 chr4 155361244 T G 7.79E-05 Alzheimer's disease (age of onset) DCHS2 intron 22005931 rs1907154 chr4 155361275 G A 6.48E-05 Alzheimer's disease (age of onset) DCHS2 intron 22005931 rs1490685 chr4 155361974 A T 5.09E-05 Alzheimer's disease (age of onset) DCHS2 intron 22005931 rs1490684 chr4 155362154 C A 4.37E-05 Alzheimer's disease (age of onset) DCHS2 intron 22005931 rs12646456 chr4 155362549 T A 3.35E-05 Alzheimer's disease (age of onset) DCHS2 intron 22005931 rs1490683 chr4 155362876 T C 1.03E-06 Alzheimer's disease (age of onset) DCHS2 intron 22005931 rs17031671 chr4 155389247 T C 2.34E-12 Bilirubin levels,in serum DCHS2 intron 20639394 rs6834179 chr4 155440450 A G 6.91E-06 Stroke (ischemic) / / 21957438 rs4482740 chr4 155446305 G A 3.23E-06 Stroke (ischemic) / / 21957438 rs12511469 chr4 155451759 T A 2.00E-36 Fibrinogen / / 21757653 rs7673587 chr4 155480434 C T 1.41E-08 Fibrinogen / / 20978265 rs4508864 chr4 155481289 C T 1.65E-38 Fibrinogen / / 20978265 rs4508864 chr4 155481289 C T 6.00E-06 Chronic obstructive pulmonary disease-related biomarkers / / 23144326 rs1800789 chr4 155482743 G A 2.00E-30 Fibrinogen FGB nearGene-5 20031576 rs1800789 chr4 155482743 G A 2.00E-127 Fibrinogen FGB nearGene-5 23969696 rs1800790 chr4 155483708 G A 6.25E-11 Fibrinogen FGB nearGene-5 20978265 rs1800788 chr4 155483914 C T 1.00E-39 Fibrinogen FGB nearGene-5 21757653 rs1800787 chr4 155484015 C T 1.40E-39 Fibrinogen FGB nearGene-5 20978265 rs6056 chr4 155488821 C T 8.00E-39 Fibrinogen FGB cds-synon 20031577 rs6056 chr4 155488821 C T 9.25E-35 Fibrinogen FGB cds-synon 20978265 rs6054 chr4 155489608 C T 1.20E-17 Fibrinogen FGB missense 20978265 rs6058 chr4 155490344 G T 9.50E-07 Fibrinogen FGB cds-synon 20978265 rs4220 chr4 155491759 G A 1.04E-34 Fibrinogen FGB missense 20978265 rs2227421 chr4 155492224 A C 3.04E-08 Fibrinogen FGB UTR-3 20978265 rs1044291 chr4 155493352 C T 3.19E-04 Multiple complex diseases FGB UTR-3 17554300 rs2059503 chr4 155493419 A T 6.93E-35 Fibrinogen FGB UTR-3 20978265 rs4463047 chr4 155495533 T C 7.30E-07 Fibrinogen / / 20978265 rs4463047 chr4 155495533 T C 3.05E-05 Post-operative nausea and vomiting / / 21694509 rs370396210 chr4 155501188 T TAC 4.32E-12 Venous thromboembolism / / 21980494 rs370396210 chr4 155501188 T TAC 2.15E-05 Fibrinogen / / pha003068 rs6825454 chr4 155501188 T C 4.32E-12 Venous thromboembolism / / 21980494 rs6825454 chr4 155501188 T C 2.15E-05 Fibrinogen / / pha003068 rs56010410 chr4 155502869 T C 1.65E-12 Venous thrombosis / / 22675575 rs11099961 chr4 155503212 C T 2.32E-12 Venous thrombosis / / 22675575 rs6050 chr4 155507590 T C 9.00E-90 Fibrinogen FGA missense 21757653 rs6050 chr4 155507590 T C 1.41E-12 Venous thromboembolism FGA missense 21980494 rs6050 chr4 155507590 T C 2.32E-12 Venous thrombosis FGA missense 22675575 rs2070016 chr4 155510314 A G 2.69E-27 Fibrinogen FGA intron 20978265 rs13109457 chr4 155514879 G A 3.00E-18 D-dimer levels / / 21502573 rs13109457 chr4 155514879 G A 1.30E-12 Venous thromboembolism / / 21980494 rs13109457 chr4 155514879 G A 8.68E-13 Venous thrombosis / / 22675575 rs35147053 chr4 155517842 A G 1.26E-12 Venous thrombosis / / 22675575 rs10034922 chr4 155520628 G A 3.90E-07 Fibrinogen / / 20978265 rs7659024 chr4 155520930 G A 2.00E-13 Venous thromboembolism / / 21980494 rs7659024 chr4 155520930 G A 1.93E-13 Venous thrombosis / / 22675575 rs7659024 chr4 155520930 G A 2.99E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7659024 chr4 155520930 G A 8.06E-07 Fibrinogen / / pha003068 rs2066865 chr4 155525276 G A 7.00E-05 Endometriosis FGG nearGene-3 21151130 rs2066865 chr4 155525276 G A 2.29E-13 Venous thromboembolism FGG nearGene-3 21980494 rs2066865 chr4 155525276 G A 1.93E-13 Venous thrombosis FGG nearGene-3 22675575 rs2066865 chr4 155525276 G A 3.49E-04 Response to cytadine analogues (cytosine arabinoside) FGG nearGene-3 24483146 rs2066865 chr4 155525276 G A 9.10E-07 Fibrinogen FGG nearGene-3 pha003068 rs2066880 chr4 155525545 A T 0.00000111 LDL cholesterol FGG intron 23063622 rs2066864 chr4 155525695 G A 2.29E-13 Venous thromboembolism FGG intron 21980494 rs2066864 chr4 155525695 G A 2.27E-13 Venous thrombosis FGG intron 22675575 rs2066861 chr4 155527436 C T 8.00E-12 Fibrinogen FGG intron 20978265 rs2066861 chr4 155527436 C T 3.01E-13 Venous thromboembolism FGG intron 21980494 rs2066861 chr4 155527436 C T 2.04E-13 Venous thrombosis FGG intron 22675575 rs2066861 chr4 155527436 C T 3.40E-04 Response to cytadine analogues (cytosine arabinoside) FGG intron 24483146 rs2066867 chr4 155532639 A G 2.20E-04 Atrial fibrillation FGG intron 21846873 rs2066854 chr4 155535181 T A 1.65E-13 Venous thrombosis FGG nearGene-5 22675575 rs12644950 chr4 155537321 G A 2.77E-13 Venous thromboembolism / / 21980494 rs12644950 chr4 155537321 G A 9.20E-14 Venous thrombosis / / 22675575 rs13130318 chr4 155538470 T G 4.52E-12 Venous thromboembolism / / 21980494 rs13130318 chr4 155538470 T G 2.80E-13 Venous thrombosis / / 22675575 rs7681423 chr4 155542248 C T 1.00E-109 Fibrinogen / / 21757653 rs7681423 chr4 155542248 C T 4.05E-13 Venous thromboembolism / / 21980494 rs7681423 chr4 155542248 C T 1.32E-13 Venous thrombosis / / 22675575 rs6536024 chr4 155543369 T C 2.00E-13 Venous thromboembolism / / 23650146 rs7654093 chr4 155545072 A T 3.67E-13 Venous thromboembolism / / 21980494 rs7654093 chr4 155545072 A T 2.02E-13 Venous thrombosis / / 22675575 rs10050268 chr4 155549354 C T 4.37E-05 Blood Pressure / / pha003043 rs6828439 chr4 155580418 C T 9.90E-05 Blood Pressure / / pha003044 rs17031902 chr4 155609285 C A 9.00E-06 Urinary metabolites / / 21572414 rs17031911 chr4 155619582 G A 4.22E-08 Multiple complex diseases / / 17554300 rs10517601 chr4 155633844 A G 3.98E-05 Blood Pressure / / pha003044 rs7672174 chr4 155640777 G A 1.20E-05 Waist circumference / / 23966867 rs11939475 chr4 155644119 G A 3.58E-04 Multiple complex diseases / / 17554300 rs10517602 chr4 155653240 A T 9.36E-04 Multiple complex diseases / / 17554300 rs727153 chr4 155654421 T C 3.00E-06 Alzheimer's disease / / 18823527 rs727153 chr4 155654421 T C 3.40E-06 Alzheimer's disease (late onset) / / 21460841 rs201825 chr4 155666935 T G 6.10E-07 Alzheimer's disease (late onset) LRAT intron 21460841 rs201824 chr4 155668710 G A 6.60E-04 Alzheimer's disease (late onset) LRAT intron 21460841 rs201823 chr4 155668885 T C 4.00E-04 Alzheimer's disease (late onset) LRAT intron 21460841 rs41510546 chr4 155699661 C T 4.38E-04 Multiple complex diseases / / 17554300 rs6832964 chr4 155771631 C T 9.89E-05 AIDS progression / / 19115949 rs3925665 chr4 155776405 C A 4.00E-05 Prostate cancer / / 21743057 rs6536033 chr4 155777902 C G 4.00E-05 Prostate cancer / / 21743057 rs6536034 chr4 155777927 A G 4.00E-05 Prostate cancer / / 21743057 rs6826923 chr4 155778084 G A 4.00E-05 Prostate cancer / / 21743057 rs6832295 chr4 155778598 A G 4.00E-05 Prostate cancer / / 21743057 rs6832974 chr4 155778672 G A 4.00E-05 Prostate cancer / / 21743057 rs1559690 chr4 155778784 G A 4.00E-05 Prostate cancer / / 21743057 rs1559689 chr4 155778844 C T 4.00E-05 Prostate cancer / / 21743057 rs1559688 chr4 155778978 A C 4.00E-05 Prostate cancer / / 21743057 rs1566470 chr4 155779283 A G 4.00E-05 Prostate cancer / / 21743057 rs1566471 chr4 155779367 G A 4.00E-05 Prostate cancer / / 21743057 rs1566472 chr4 155779475 T C 4.00E-05 Prostate cancer / / 21743057 rs17032131 chr4 155779863 G A 4.00E-05 Prostate cancer / / 21743057 rs17032135 chr4 155781759 T C 4.00E-05 Prostate cancer / / 21743057 rs11936192 chr4 155782044 G A 4.00E-05 Prostate cancer / / 21743057 rs10517604 chr4 155785658 C T 4.00E-05 Prostate cancer / / 21743057 rs10033629 chr4 155826061 G A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs924482 chr4 155834792 G A 0.0000922 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1002098 chr4 155848688 C A 9.97E-04 Longevity / / 22279548 rs2124656 chr4 155867729 A G 0.0000476 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs16998933 chr4 155890462 A G 6.39E-04 Alzheimer's disease / / 17998437 rs4691555 chr4 155891502 T C 0.00000322 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7668612 chr4 155906246 C T 2.92E-04 Multiple complex diseases / / 17554300 rs1902498 chr4 155916575 C T 3.32E-04 Iron levels / / pha002876 rs7684755 chr4 155934407 T G 5.20E-05 Diabetic nephropathy / / pha002866 rs7436102 chr4 155947430 A G 2.08E-05 Schizophrenia / / 24253340 rs17032390 chr4 155969710 T C 4.75E-05 Schizophrenia / / 24253340 rs7669967 chr4 156049070 A G 2.10E-05 Diabetic retinopathy / / 21441570 rs1902491 chr4 156055333 C A 5.20E-05 Diabetic retinopathy / / 21441570 rs4318601 chr4 156056310 C T 1.78E-04 Aortic root size / / 21223598 rs17032517 chr4 156061965 T C 9.36E-05 Insulin resistance / / 21901158 rs17032524 chr4 156062435 C T 5.84E-04 Multiple complex diseases / / 17554300 rs13114936 chr4 156062755 A G 3.12E-04 Insulin resistance / / 21901158 rs4444779 chr4 156063012 G T 5.20E-05 Diabetic retinopathy / / 21441570 rs13122070 chr4 156063727 A C 2.90E-05 Diabetic retinopathy / / 21441570 rs4463024 chr4 156064766 T C 1.92E-04 Fibrinogen / / 17255346 rs11735124 chr4 156065084 G A 5.60E-05 Diabetic retinopathy / / 21441570 rs13138293 chr4 156074074 T G 5.47E-05 Systemic sclerosis / / 21750679 rs2880417 chr4 156080728 A G 9.57E-05 Systemic sclerosis / / 21750679 rs1317400 chr4 156091935 C T 7.81E-04 Response to TNF antagonist treatment / / 21061259 rs10212938 chr4 156128332 T C 1.29E-08 HDL cholesterol / / 23063622 rs17304901 chr4 156138372 G A 3.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs9990860 chr4 156140065 A G 1.49E-06 Elbow pain / / pha003008 rs9990860 chr4 156140065 A G 5.46E-05 Height / / pha003010 rs9990860 chr4 156140065 A G 1.95E-05 Height / / pha003011 rs17032704 chr4 156169943 C A 2.95E-04 Type 2 diabetes / / 17463246 rs9998104 chr4 156170359 G A 1.62E-06 Elbow pain / / pha003008 rs9998104 chr4 156170359 G A 5.08E-05 Height / / pha003010 rs9998104 chr4 156170359 G A 2.86E-05 Height / / pha003011 rs983146 chr4 156213709 A C 7.97E-05 Elbow pain / / pha003008 rs750068 chr4 156245641 G A 7.38E-05 Elbow pain / / pha003008 rs13141128 chr4 156284169 G T 3.25E-04 Suicide attempts in bipolar disorder MAP9 intron 21423239 rs985468 chr4 156293458 T C 4.77E-05 Elbow pain MAP9 intron pha003008 rs1037028 chr4 156296821 T C 3.31E-04 Suicide attempts in bipolar disorder MAP9 intron 21423239 rs3775255 chr4 156300040 C T 9.86E-05 Elbow pain / / pha003008 rs7663620 chr4 156311510 G A 7.77E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs17032954 chr4 156319821 A G 7.26E-04 Multiple complex diseases / / 17554300 rs11100000 chr4 156322989 C T 4.59E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs962491 chr4 156359672 A G 9.68E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4691643 chr4 156378568 C T 7.67E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs11100001 chr4 156379973 G T 5.94E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4690974 chr4 156393641 T C 0.0000249 Coronary artery disease / / 23202125 rs952130 chr4 156470828 C A 4.83E-04 Multiple complex diseases / / 17554300 rs6850722 chr4 156472766 T C 2.84E-05 Serum metabolites / / 19043545 rs6847588 chr4 156482874 T A 1.10E-05 Blood pressure / / 24001895 rs1976041 chr4 156486040 A G 4.89E-05 Serum metabolites / / 19043545 rs2625274 chr4 156488140 A T 8.34E-06 Serum metabolites / / 19043545 rs716428 chr4 156506869 T C 5.30E-05 Serum metabolites / / 19043545 rs1842896 chr4 156511459 G T 1.00E-11 Coronary heart disease / / 22751097 rs6835414 chr4 156514942 A T 6.21E-05 Serum metabolites / / 19043545 rs12650590 chr4 156540021 G T 7.55E-05 Esophageal cancer (squamous cell) / / 22960999 rs10012315 chr4 156562059 A G 1.67E-04 Multiple complex diseases / / 17554300 rs2705462 chr4 156569802 G T 8.30E-04 Tourette syndrome / / 22889924 rs3806782 chr4 156587887 T C 9.48E-04 Response to taxane treatment (placlitaxel) GUCY1A3 UTR-5 23006423 rs4691047 chr4 156598008 C T 3.79E-05 Post-operative nausea and vomiting GUCY1A3 intron 21694509 rs4691048 chr4 156598020 C T 8.04E-05 Post-operative nausea and vomiting GUCY1A3 intron 21694509 rs4691842 chr4 156598081 A G 4.85E-07 Post-operative nausea and vomiting GUCY1A3 intron 21694509 rs3796590 chr4 156631491 G A 8.86E-04 Multiple complex diseases GUCY1A3 intron 17554300 rs7692387 chr4 156635309 G A 0.00000112 Coronary artery disease (CAD) (males) GUCY1A3 intron 23202125 rs7692387 chr4 156635309 G A 0.00000406 Coronary artery disease (CAD) age >50 GUCY1A3 intron 23202125 rs7692387 chr4 156635309 G A 0.0000335 Diastolic blood pressure GUCY1A3 intron 23202125 rs7692387 chr4 156635309 G A 0.0000887 Coronary artery disease with myocardial infarction GUCY1A3 intron 23202125 rs7692387 chr4 156635309 G A 2.65E-11 Coronary artery disease GUCY1A3 intron 23202125 rs7692387 chr4 156635309 G A 1.07E-05 Coronary artery disease GUCY1A3 intron 24262325 rs9993460 chr4 156644655 T C 7.75E-04 Multiple complex diseases GUCY1A3 intron 17554300 rs13139571 chr4 156645513 C A 3.00E-07 Blood pressure GUCY1A3 intron 21909110 rs13139571 chr4 156645513 C A 1.00E-06 Systolic blood pressure GUCY1A3 intron 21909115 rs13139571 chr4 156645513 C A 2.00E-10 Diastolic blood pressure GUCY1A3 intron 21909115 rs3796570 chr4 156699636 C A 5.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GUCY1B3 intron 20877124 rs17033513 chr4 156705026 C T 4.26E-05 Bipolar disorder GUCY1B3 intron 22925353 rs17033585 chr4 156735439 G A 2.52E-04 Eating disorders / / 23568457 rs12507760 chr4 156742265 C T 3.71E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6817090 chr4 156780170 C T 4.71E-04 Rheumatoid arthritis ASIC5 intron 21452313 rs13122250 chr4 156808288 C T 9.00E-12 Blood metabolite levels / / 24816252 rs3775085 chr4 156823379 A C 0.000155623 Hypertension (early onset hypertension) TDO2 nearGene-5 22479346 rs2271538 chr4 156829068 A G 1.56E-04 Glycosylated haemoglobin levels TDO2 intron 17255346 rs2878125 chr4 156834361 A G 7.63E-04 Multiple complex diseases TDO2 intron 17554300 rs6536124 chr4 156871702 T A 4.81E-04 Smoking initiation CTSO intron 24665060 rs4691182 chr4 156886528 G A 4.77E-04 Smoking initiation / / 24665060 rs11723896 chr4 156890261 C G 5.84E-04 Smoking initiation / / 24665060 rs6852748 chr4 156893892 G A 2.10E-05 Speech perception in dyslexia / / 19786962 rs4234893 chr4 156911991 T C 6.62E-04 Smoking initiation / / 24665060 rs4605601 chr4 156986004 G A 3.42E-04 Schizophrenia / / 19197363 rs4501171 chr4 156996991 A T 4.83E-05 Intracerebral hemorrhage / / 24656865 rs4234898 chr4 156998541 T C 5.00E-08 Speech perception in dyslexia / / 19786962 rs4626150 chr4 157053619 A C 1.70E-04 Multiple complex diseases / / 17554300 rs6536146 chr4 157060456 A T 2.77E-04 Multiple complex diseases / / 17554300 rs11734500 chr4 157068139 A C 4.00E-04 Polycystic ovary syndrome / / 22178785 rs5027023 chr4 157089605 C A 8.18E-04 Alcohol dependence / / 24277619 rs17380820 chr4 157100613 A G 3.80E-05 Iron levels / / 21208937 rs12508572 chr4 157104958 T C 9.79E-05 Leukocyte Counts / / pha003091 rs7677311 chr4 157113047 T C 8.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs4691309 chr4 157121214 G A 2.57E-06 Phospholipid levels (plasma) / / 21829377 rs2340252 chr4 157129218 G T 3.17E-04 Parkinson's disease / / 17052657 rs13102097 chr4 157131028 G A 1.58E-04 Intracranial aneurysm / / 20613766 rs4600965 chr4 157144661 G A 2.72E-04 Parkinson's disease / / 17052657 rs10517634 chr4 157145352 C T 5.50E-04 Crohn's disease / / 17684544 rs11100052 chr4 157151035 C T 5.03E-04 Parkinson's disease / / 17052657 rs6844119 chr4 157162251 T G 5.40E-04 Parkinson's disease / / 17052657 rs17034293 chr4 157174686 G T 3.86E-04 Multiple complex diseases / / 17554300 rs17034315 chr4 157185914 T G 3.00E-05 Major depressive disorder (broad) / / 20038947 rs17034346 chr4 157212247 C G 3.14E-04 Multiple complex diseases / / 17554300 rs17034361 chr4 157222741 C G 1.34E-04 Multiple complex diseases / / 17554300 rs10030326 chr4 157235050 A G 2.43E-04 Multiple complex diseases / / 17554300 rs9968522 chr4 157247537 C A 3.27E-04 Multiple complex diseases / / 17554300 rs11100056 chr4 157248148 T C 2.90E-04 Multiple complex diseases / / 17554300 rs1532154 chr4 157279663 T C 2.22E-05 Obsessive-compulsive disorder / / 24821223 rs1907101 chr4 157325388 T C 4.78E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs13141142 chr4 157354250 T C 1.09E-05 Multiple complex diseases / / 17554300 rs9784536 chr4 157367389 A G 5.14E-04 Multiple complex diseases / / 17554300 rs1586690 chr4 157383920 G A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1490568 chr4 157402522 T C 1.00E-05 Rheumatoid arthritis / / 17804836 rs1490568 chr4 157402522 T C 6.93E-07 Rheumatoid arthritis / / 19503088 rs1490568 chr4 157402522 T C 1.06E-04 Coronary heart disease / / 21971053 rs2090870 chr4 157480074 C T 3.54E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17034961 chr4 157531230 A C 1.40E-05 Urinary metabolites / / 21572414 rs8180255 chr4 157548520 G A 2.32E-04 Coronary heart disease / / 21971053 rs12498803 chr4 157560957 A C 9.25E-04 Obesity (extreme) / / 21935397 rs10000121 chr4 157574035 A G 5.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11100075 chr4 157578308 G A 6.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2139980 chr4 157617198 G A 3.80E-04 Type 2 diabetes / / 17463246 rs2139980 chr4 157617198 G A 3.10E-04 Type 2 diabetes / / 17463249 rs2139980 chr4 157617198 G A 1.15E-04 Multiple complex diseases / / 17554300 rs10023994 chr4 157629701 C A 2.75E-04 Multiple complex diseases / / 17554300 rs17811827 chr4 157634867 C T 8.88E-04 Multiple complex diseases / / 17554300 rs17811863 chr4 157635043 G A 8.90E-04 Multiple complex diseases / / 17554300 rs1469244 chr4 157641990 T G 3.33E-04 Multiple complex diseases / / 17554300 rs6827631 chr4 157643582 T C 3.13E-04 Multiple complex diseases / / 17554300 rs1364907 chr4 157650304 T C 7.15E-04 Multiple complex diseases / / 17554300 rs10017970 chr4 157655677 A G 7.63E-04 Multiple complex diseases / / 17554300 rs1425486 chr4 157683685 C T 7.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) PDGFC UTR-3 23648065 rs7682653 chr4 157694858 G A 0.000276 Type 2 diabetes PDGFC intron 22325160 rs17035231 chr4 157700394 A G 8.30E-06 Urinary metabolites PDGFC intron 21572414 rs7672622 chr4 157705551 A G 2.00E-05 Urinary metabolites PDGFC intron 21572414 rs12651147 chr4 157712959 C T 9.39E-04 Alcohol dependence PDGFC intron 21314694 rs4691380 chr4 157720124 C T 4.83E-04 Multiple complex diseases PDGFC intron 17554300 rs4691380 chr4 157720124 C T 5.00E-09 Fasting insulin-related traits (interaction with BMI) PDGFC intron 22581228 rs4691381 chr4 157730274 T C 1.10E-05 Urinary metabolites PDGFC intron 21572414 rs6822892 chr4 157734675 A C,G,T 0.0000903 Type 2 diabetes PDGFC intron 22325160 rs6822892 chr4 157734675 A C,G,T 2.58E-10 Fasting insulin-related traits PDGFC intron 22885924 rs17035315 chr4 157772224 T C 1.00E-04 Information processing speed PDGFC intron 21130836 rs6811964 chr4 157785454 G A 1.30E-05 Blood Phenotypes PDGFC intron 17903294 rs17230544 chr4 157786734 C G 3.83E-04 Type 2 diabetes PDGFC intron 17463246 rs7676376 chr4 157842159 C T 1.72E-04 Cardiovascular disease PDGFC intron 17903304 rs7676376 chr4 157842159 C T 6.08E-04 Coronary heart disease PDGFC intron 21606135 rs2083789 chr4 157845436 T C 9.43E-05 Non-alcoholic fatty liver disease histology (other) PDGFC intron 20708005 rs6845322 chr4 157884105 A G 6.61E-04 Suicide attempts in bipolar disorder PDGFC intron 21423239 rs17035469 chr4 157887044 C T 7.22E-04 Suicide attempts in bipolar disorder PDGFC intron 21423239 rs6822796 chr4 157887357 C T 7.66E-04 Suicide attempts in bipolar disorder PDGFC intron 21423239 rs4691389 chr4 157959931 A G 6.95E-05 Cognitive impairment induced by topiramate / / 22091778 rs4234905 chr4 157962081 T C 2.92E-04 Multiple complex diseases / / 17554300 rs6853797 chr4 157962713 G A 3.88E-04 Multiple complex diseases / / 17554300 rs17035797 chr4 158072438 A G 6.71E-14 Multiple complex diseases GLRB intron 17554300 rs17035840 chr4 158102854 A G 4.80E-04 Smoking initiation / / 24665060 rs4392549 chr4 158263582 A G 8.58E-05 Cognitive impairment induced by topiramate GRIA2 intron 22091778 rs4591653 chr4 158323929 C T 6.20E-04 Parkinson's disease / / 17052657 rs6823909 chr4 158327705 T C 7.48E-05 Cleft lip / / 20436469 rs6823909 chr4 158327705 T C 4.28E-06 Myopia (pathological) / / 21640322 rs10517668 chr4 158357403 T C 5.94E-04 Multiple complex diseases / / 17554300 rs1529802 chr4 158451965 G A 5.23E-04 Smoking cessation / / 24665060 rs1025554 chr4 158455363 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17036354 chr4 158477973 T A 8.35E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1036342 chr4 158492974 A G 6.64E-05 Sudden cardiac arrest / / 21658281 rs6830776 chr4 158502750 C T 9.68E-04 Celiac disease / / 23936387 rs10857301 chr4 158503661 T C 0.0004275 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10857301 chr4 158503661 T C 4.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2344819 chr4 158533054 C T 9.87E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10517671 chr4 158536160 T A 0.0003696 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10517671 chr4 158536160 T A 3.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7697239 chr4 158541687 A G 8.97E-05 Cognitive test performance / / 20125193 rs1352695 chr4 158562269 C T 5.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4691425 chr4 158564280 A G 5.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1352693 chr4 158591563 T C 5.15E-05 Sudden cardiac arrest / / 21658281 rs9307971 chr4 158593406 A G 8.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs727755 chr4 158724848 C T 9.57E-05 Pulmonary function in asthmatics / / 23541324 rs10517675 chr4 158728552 G C 9.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7434819 chr4 158731019 G A 7.34E-05 Pulmonary function in asthmatics / / 23541324 rs2345278 chr4 158753747 C T 9.94E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs9991982 chr4 158782030 C T 3.80E-05 Asthma / / 23181788 rs6836401 chr4 158786983 G A 5.77E-05 Cognitive performance / / 19734545 rs13119669 chr4 158804986 T C 7.74E-05 Personality dimensions / / 18957941 rs10008901 chr4 158805030 A G 2.49E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs13104818 chr4 158810144 T G 7.22E-04 Type 2 diabetes / / 17463246 rs2053816 chr4 158817047 T C 6.42E-04 Type 2 diabetes / / 17463246 rs17209584 chr4 158817102 G T 1.36E-04 Smoking initiation / / 24665060 rs1020453 chr4 158825008 T C 4.21E-04 Multiple complex diseases / / 17554300 rs10212653 chr4 158898321 T C 2.47E-06 Suicide attempts in bipolar disorder / / 21423239 rs4072169 chr4 158901664 G A 1.61E-06 Suicide attempts in bipolar disorder / / 21423239 rs7664129 chr4 158969682 C A 1.97E-04 Colorectal cancer / / 24978480 rs11100146 chr4 158971526 T C 2.23E-06 Suicide attempts in bipolar disorder / / 21423239 rs2881374 chr4 159039106 C A 8.36E-04 Insulin resistance / / 21901158 rs2881373 chr4 159092633 A G 6.86E-06 Colorectal cancer FAM198B UTR-5 24978480 rs11728753 chr4 159182407 A C 8.58E-04 Type 2 diabetes / / 17463246 rs1328925 chr4 159190290 C T 4.22E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs72701704 chr4 159195032 T C 1.89E-05 Acne (severe teenage) LOC646890 intron 24114350 rs4292373 chr4 159260054 A C 3.04E-04 Multiple complex diseases / / 17554300 rs6536309 chr4 159314091 A G 5.40E-05 Body mass index / / 20818722 rs11931209 chr4 159332036 A T 2.00E-04 Response to antidepressant treatment (citalopram) / / 23726668 rs7672102 chr4 159352869 A G 8.71E-04 Type 2 diabetes / / 17463246 rs2346793 chr4 159365684 G T 2.00E-04 Response to antidepressant treatment (citalopram) / / 23726668 rs10032252 chr4 159377474 G A 3.00E-04 Response to antidepressant treatment (citalopram) / / 23726668 rs10517691 chr4 159399146 A G 4.30E-05 LDL lipoproteins / / pha002902 rs7437278 chr4 159399963 G C 4.49E-04 Type 2 diabetes / / 17463246 rs7377670 chr4 159429037 T C 4.12E-04 Type 2 diabetes / / 17463246 rs7436353 chr4 159430469 T G 3.58E-04 Type 2 diabetes / / 17463246 rs7377646 chr4 159430701 G A 7.17E-04 Type 2 diabetes / / 17463246 rs7436941 chr4 159435073 G A 6.91E-04 Smoking initiation / / 24665060 rs1455453 chr4 159440665 C T 7.12E-04 Type 2 diabetes / / 17463246 rs936094 chr4 159444314 T C 4.74E-04 Acute lymphoblastic leukemia (childhood) RXFP1 intron 22076464 rs4234922 chr4 159562129 T C 1.90E-05 Urinary metabolites RXFP1 intron 21572414 rs4690909 chr4 159629151 G C 2.00E-57 Blood metabolite ratios ETFDH intron 24816252 rs8396 chr4 159630817 T C 4.00E-24 Metabolite levels PPID UTR-3 20037589 rs8396 chr4 159630817 T C 6.00E-15 Metabolic traits PPID UTR-3 21886157 rs8396 chr4 159630817 T C 1.00E-31 Blood metabolite levels PPID UTR-3 24816252 rs8396 chr4 159630817 T C 9.00E-13 Blood metabolite levels PPID UTR-3 24816252 rs8396 chr4 159630817 T C 9.00E-38 Blood metabolite levels PPID UTR-3 24816252 rs3922426 chr4 159658190 A G 4.70E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs4331733 chr4 159698086 A G 9.57E-04 Multiple complex diseases FNIP2 intron 17554300 rs9998057 chr4 159835140 C A 9.99E-04 Multiple complex diseases C4orf45 intron 17554300 rs9998057 chr4 159835140 C A 2.80E-05 Urinary metabolites C4orf45 intron 21572414 rs11100203 chr4 159857539 A G 2.32E-04 Alzheimer's disease (late onset) C4orf45 intron 21379329 rs2114489 chr4 159867342 C T 5.76E-04 Alzheimer's disease C4orf45 intron 24755620 rs10003821 chr4 159877388 C T 7.14E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) C4orf45 intron 22566498 rs474719 chr4 159888162 C T 4.20E-05 Femoral neck bone geometry C4orf45 intron 22087292 rs10517694 chr4 159888178 C G 9.53E-05 Femoral neck bone geometry C4orf45 intron 22087292 rs6857434 chr4 159892122 G A 2.47E-05 Femoral neck bone geometry C4orf45 intron 22087292 rs17037864 chr4 159894391 G A 3.93E-06 Femoral neck bone geometry C4orf45 missense 22087292 rs7692170 chr4 159912037 T G 2.21E-05 Femoral neck bone geometry C4orf45 intron 22087292 rs17223094 chr4 159914232 A G 7.85E-05 Serum metabolites C4orf45 intron 19043545 rs588122 chr4 159916043 A G 2.09E-05 Femoral neck bone geometry C4orf45 intron 22087292 rs12512814 chr4 159927284 G A 9.70E-04 Type 2 diabetes C4orf45 intron 17463246 rs12512814 chr4 159927284 G A 8.89E-05 Serum metabolites C4orf45 intron 19043545 rs12498847 chr4 159928907 G A 1.61E-05 Femoral neck bone geometry C4orf45 intron 22087292 rs17223410 chr4 159929359 C G 1.65E-05 Femoral neck bone geometry C4orf45 intron 22087292 rs11931163 chr4 159934179 G A,C,T 6.00E-05 Prostate cancer C4orf45 intron 21743057 rs10016573 chr4 159934356 A G 6.00E-05 Prostate cancer C4orf45 intron 21743057 rs7660477 chr4 159948180 C T 7.37E-04 Type 2 diabetes C4orf45 intron 17463246 rs7681750 chr4 160084403 A G 5.55E-04 Prostate cancer mortality / / 20978177 rs12502799 chr4 160143615 G T 5.68E-04 Alzheimer's disease / / 24755620 rs34947842 chr4 160143615 GT G 5.68E-04 Alzheimer's disease / / 24755620 rs11730876 chr4 160147159 C T 5.68E-04 Alzheimer's disease / / 24755620 rs7668932 chr4 160149875 C T 2.38E-04 Hemoglobin concentration / / 20534544 rs7668932 chr4 160149875 C T 7.52E-04 Endometrial cancer / / 24096698 rs11931932 chr4 160161916 T C 3.64E-04 Alzheimer's disease / / 24755620 rs4691549 chr4 160173911 T C 3.84E-04 Alzheimer's disease / / 24755620 rs13119443 chr4 160176918 G A 3.45E-04 Alzheimer's disease / / 24755620 rs4396948 chr4 160208630 G A 7.93E-04 Amyotrophic Lateral Sclerosis RAPGEF2 intron 17827064 rs11723634 chr4 160267334 T C 1.50E-05 Urinary metabolites RAPGEF2 intron 21572414 rs11723634 chr4 160267334 T C 1.70E-05 Asthma RAPGEF2 intron 23181788 rs11727094 chr4 160270232 T C 1.50E-05 Urinary metabolites RAPGEF2 intron 21572414 rs6536413 chr4 160282718 C A 6.00E-06 Intelligence (childhood) / / 23358156 rs10517702 chr4 160288440 T C 7.85E-05 Lactate dehydrogenase levels / / 20981236 rs11732785 chr4 160312930 A G 3.00E-07 Urinary metabolites / / 21572414 rs11732754 chr4 160319789 G A 2.40E-05 Urinary metabolites / / 21572414 rs1852870 chr4 160319812 C A 3.90E-07 Urinary metabolites / / 21572414 rs1881755 chr4 160326708 C T 1.10E-06 Urinary metabolites / / 21572414 rs4690942 chr4 160355746 G A 1.60E-05 Urinary metabolites / / 21572414 rs13147261 chr4 160356254 A G 9.57E-04 Acute lung injury / / 22295056 rs2699006 chr4 160381253 G T 2.70E-05 Urinary metabolites / / 21572414 rs2851806 chr4 160381942 G T 2.20E-05 Urinary metabolites / / 21572414 rs2707697 chr4 160382115 G A 2.10E-05 Urinary metabolites / / 21572414 rs10517697 chr4 160383267 T C 9.30E-06 Urinary metabolites / / 21572414 rs7689344 chr4 160386481 G T 9.40E-06 Urinary metabolites / / 21572414 rs17038268 chr4 160388488 C A 1.10E-05 Urinary metabolites / / 21572414 rs13125107 chr4 160390380 A T 1.30E-05 Urinary metabolites / / 21572414 rs4260489 chr4 160390691 T C 1.30E-05 Urinary metabolites / / 21572414 rs2851781 chr4 160396943 A G 1.30E-05 Urinary metabolites / / 21572414 rs1922642 chr4 160423997 G A 1.90E-05 Urinary metabolites / / 21572414 rs7659664 chr4 160424386 A G 1.51E-04 Multiple complex diseases / / 17554300 rs11724165 chr4 160442645 G A 5.00E-06 Urinary metabolites / / 21572414 rs12645160 chr4 160469420 G A 3.03E-04 Alzheimer's disease (late onset) / / 20885792 rs1893953 chr4 160474408 G T 3.08E-04 Alzheimer's disease (late onset) / / 20885792 rs1393576 chr4 160488212 A G 9.20E-04 Alzheimer's disease (late onset) / / 20885792 rs998885 chr4 160493274 G T 7.94E-04 Multiple complex diseases / / 17554300 rs1354252 chr4 160498966 G T 5.75E-06 Malignant pleural mesothelioma / / 23626673 rs1119663 chr4 160602776 C T 5.19E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4358345 chr4 160606236 C A 4.50E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4358346 chr4 160606255 C T 4.46E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs17038655 chr4 160608143 C T 2.65E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6536455 chr4 160626250 G A 1.90E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6536464 chr4 160641060 C A 2.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs17038749 chr4 160666896 G A 0.00004545 Sarcoidosis / / 22952805 rs62338532 chr4 160669904 A G 0.00002962 Sarcoidosis / / 22952805 rs62338533 chr4 160669930 C G 0.00002026 Sarcoidosis / / 22952805 rs62338534 chr4 160669983 A G 0.00002026 Sarcoidosis / / 22952805 rs192372936 chr4 160670346 C T 0.00002026 Sarcoidosis / / 22952805 rs75106831 chr4 160672257 T C 0.00002335 Sarcoidosis / / 22952805 rs4690956 chr4 160684694 A G 3.80E-05 Malaria / / 19465909 rs1457805 chr4 160749263 C A 7.15E-04 Alcohol dependence / / 20201924 rs13150069 chr4 160751151 T G 4.64E-04 Smoking cessation / / 24665060 rs6830252 chr4 160806780 T C 4.89E-04 Aortic root size / / 21223598 rs4690963 chr4 160817334 A G 4.42E-05 Attention deficit hyperactivity disorder / / 22420046 rs2348997 chr4 160821991 A G 3.81E-05 Attention deficit hyperactivity disorder / / 22420046 rs4119125 chr4 160822830 G A 2.70E-05 Urinary metabolites / / 21572414 rs2348996 chr4 160825866 G A 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4414908 chr4 160828885 T C 8.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs13142965 chr4 160904953 C T 5.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs7665221 chr4 160906146 T C 6.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs2882060 chr4 160906981 T C 7.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs10033594 chr4 160909718 T C 6.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs13118592 chr4 160914080 A C 3.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs12499733 chr4 160920501 G A 6.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs11100271 chr4 160929800 T C 6.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs1035895 chr4 160930806 T G 4.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs10011091 chr4 160932189 T C 8.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs13112886 chr4 160934687 T G 3.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs6844344 chr4 160936071 A C 4.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs6844763 chr4 160936214 C T 5.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs6821733 chr4 160939378 A G 2.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs17258576 chr4 160941928 T C 3.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs12501418 chr4 160954990 A C 3.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs6832509 chr4 160959050 C T 2.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs10006351 chr4 160960782 T A 2.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs17039206 chr4 161028125 C A 6.19E-04 Coronary Artery Disease / / 17634449 rs17261688 chr4 161028817 A G 3.00E-06 DNA methylation (variation) / / 23725790 rs1950167 chr4 161109431 T C 8.60E-05 Serum albumin level / / pha003084 rs13138661 chr4 161135028 G A 1.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs7665838 chr4 161136360 T C 1.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs7680522 chr4 161139200 T G 2.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs17264548 chr4 161151579 T C 1.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs6836934 chr4 161205623 A G 4.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs13145112 chr4 161206712 G A 5.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs13145112 chr4 161206712 G A 9.65E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13144965 chr4 161206814 C T 4.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs1495602 chr4 161208233 G A 4.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs6858454 chr4 161208754 G A 7.73E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs13127222 chr4 161216281 G A 3.38E-05 Suicide attempts in bipolar disorder / / 21423239 rs4490418 chr4 161218094 G A 3.23E-05 Suicide attempts in bipolar disorder / / 21423239 rs12374311 chr4 161224554 A G 4.86E-07 Schizophrenia / / 21926974 rs12374311 chr4 161224554 A G 6.55E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs13136900 chr4 161235359 C T 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs13137161 chr4 161235528 C G 2.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs6846953 chr4 161255092 A G 5.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs6847137 chr4 161255167 A C 5.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs6818044 chr4 161257623 A G 1.45E-04 Myopia (pathological) / / 21095009 rs13142418 chr4 161267440 T C 4.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs13115184 chr4 161267468 A G 1.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs2350009 chr4 161267968 G A 5.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs6536515 chr4 161305612 C T 5.11E-04 Multiple complex diseases / / 17554300 rs13112097 chr4 161332169 C G 4.47E-04 Obesity (extreme) / / 21935397 rs7377326 chr4 161336514 C A 1.46E-04 Multiple complex diseases / / 17554300 rs13124867 chr4 161337411 T C 3.79E-04 Smoking quantity / / 24665060 rs6536520 chr4 161343981 C T 1.06E-05 Multiple complex diseases / / 17554300 rs4691661 chr4 161348302 T C 1.67E-04 Type 2 diabetes / / 17463246 rs4691664 chr4 161348621 G T 3.16E-05 Type 2 diabetes / / 17463246 rs12640159 chr4 161366623 G A 3.16E-05 Tuberculosis / / 24057671 rs1371251 chr4 161381482 A G 7.59E-05 Multiple complex diseases / / 17554300 rs10517718 chr4 161394871 A G 4.43E-05 Varicose Veins / / pha001411 rs1595665 chr4 161410867 T C 8.86E-04 Type 2 diabetes / / 23300278 rs1595665 chr4 161410867 T C 1.69E-05 Tuberculosis / / 24057671 rs1439414 chr4 161417526 T G 7.33E-04 Multiple complex diseases / / 17554300 rs2882364 chr4 161422765 C T 6.52E-04 Multiple complex diseases / / 17554300 rs4690983 chr4 161429238 C T 7.03E-04 Smoking initiation / / 24665060 rs10019936 chr4 161431498 T C 4.10E-06 Soluble leptin receptor levels / / 20167575 rs10517719 chr4 161441065 T G 1.90E-06 HIV-1 control / / 20041166 rs4591549 chr4 161473570 T C 1.57E-04 Smoking initiation / / 24665060 rs17039750 chr4 161477815 T G 7.00E-05 HIV-1 control / / 20041166 rs17291045 chr4 161506897 C T 5.00E-08 HIV-1 control / / 20041166 rs981516 chr4 161565370 A C,G,T 2.27E-05 Asthma / / 22561531 rs981516 chr4 161565370 A C,G,T 0.000622 Salmonella-induced pyroptosis / / 22837397 rs9308012 chr4 161623467 T G 5.50E-05 Endometriosis / / 21151130 rs17040055 chr4 161629457 G A 1.41E-04 Multiple complex diseases / / 17554300 rs11100310 chr4 161678539 C T 1.96E-04 Multiple complex diseases / / 17554300 rs10517724 chr4 161685456 C T 3.80E-05 HIV-1 control / / 20041166 rs6835611 chr4 161689479 C T 1.20E-04 Multiple complex diseases / / 17554300 rs6836037 chr4 161689684 C T 1.20E-04 Multiple complex diseases / / 17554300 rs6848547 chr4 161740871 T G 3.77E-04 Multiple complex diseases / / 17554300 rs17040246 chr4 161761676 T G 2.60E-06 Brain size / / 22156575 rs1549008 chr4 161773099 T C 2.56E-04 Multiple complex diseases / / 17554300 rs6854952 chr4 161785781 A G 4.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9308019 chr4 161873925 A G 7.28E-04 Multiple complex diseases / / 17554300 rs4382003 chr4 161893186 A C 5.53E-04 Parkinson's disease / / 17052657 rs12508741 chr4 161921412 T C 9.59E-04 Multiple complex diseases / / 17554300 rs2068177 chr4 161932459 C A 6.33E-04 Multiple complex diseases / / 17554300 rs12499276 chr4 161937422 T C 3.13E-04 Multiple complex diseases / / 17554300 rs4690999 chr4 161953423 T C 6.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1439263 chr4 161955450 C T 5.48E-04 Multiple complex diseases / / 17554300 rs4295215 chr4 161955829 G A 6.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1523553 chr4 161987905 C T 1.81E-04 Parkinson's disease / / 21248740 rs4591550 chr4 162003624 C T 8.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1255832 chr4 162097832 A T 4.32E-05 Statin-induced myopathy / / 21826682 rs17040750 chr4 162110975 T C 4.93E-04 Blood pressure (response to calcium channel blocker) / / 24192120 rs13106265 chr4 162111190 G A 9.98E-04 Type 2 diabetes / / 17463246 rs6844056 chr4 162132728 G A 5.85E-04 Type 2 diabetes / / 17463246 rs6844056 chr4 162132728 G A 6.80E-06 Urinary metabolites / / 21572414 rs7683367 chr4 162135488 T C 1.47E-04 Blood pressure (response to calcium channel blocker) / / 24192120 rs6536583 chr4 162145663 T C 6.15E-04 Type 2 diabetes / / 17463246 rs6536583 chr4 162145663 T C 1.60E-05 Urinary metabolites / / 21572414 rs6536584 chr4 162145781 A G 6.31E-04 Type 2 diabetes / / 17463246 rs6536584 chr4 162145781 A G 7.50E-06 Urinary metabolites / / 21572414 rs719880 chr4 162147112 G A 6.70E-06 Urinary metabolites / / 21572414 rs7676384 chr4 162173480 C T 8.00E-06 Response to amphetamines / / 22952603 rs7658820 chr4 162223481 A G 2.85E-04 White matter integrity / / 22425255 rs5010471 chr4 162235875 A T 1.58E-04 Multiple complex diseases / / 17554300 rs2218426 chr4 162246075 A G 9.82E-06 Periodontitis (DPAL) / / 24024966 rs17335892 chr4 162246176 C T 9.82E-06 Periodontitis (DPAL) / / 24024966 rs4470583 chr4 162250932 A G 4.00E-07 Diabetic retinopathy / / 21310492 rs12512282 chr4 162255770 C T 9.66E-05 Cognitive impairment induced by topiramate / / 22091778 rs4691007 chr4 162257301 T G 2.09E-04 Glycosylated haemoglobin levels / / 17255346 rs2314138 chr4 162266319 T C 9.26E-04 Multiple complex diseases / / 17554300 rs10007083 chr4 162272259 G A 8.24E-04 Coronary Artery Disease / / 17634449 rs10007083 chr4 162272259 G A 5.30E-06 Urinary metabolites / / 21572414 rs17395886 chr4 162279385 C A 2.18E-05 Bipolar disorder / / 21926972 rs12643813 chr4 162284626 A G 5.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17040974 chr4 162301366 C T 9.89E-05 Glycosylated haemoglobin levels / / 17255346 rs17040984 chr4 162307060 G T 8.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FSTL5 cds-synon 20877124 rs17040984 chr4 162307060 G T 2.89E-04 Alzheimer's disease (late onset) FSTL5 cds-synon 21379329 rs10213523 chr4 162309814 C T 3.29E-04 Parkinson's disease FSTL5 intron 16252231 rs12374210 chr4 162311913 G T 6.21E-04 Blood pressure FSTL5 intron 24001895 rs2314133 chr4 162312156 G A 1.09E-05 Major depressive disorder FSTL5 intron 22472876 rs6849141 chr4 162312771 T C 3.08E-04 Alzheimer's disease (late onset) FSTL5 intron 21379329 rs9998941 chr4 162324862 G A 6.00E-07 Ankle-brachial index FSTL5 intron 22199011 rs12639796 chr4 162328955 A G 2.81E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FSTL5 intron 24023788 rs4691761 chr4 162362473 T G 1.82E-04 Hemoglobin concentration FSTL5 intron 20534544 rs4691761 chr4 162362473 T G 7.47E-04 Coronary heart disease FSTL5 intron 21971053 rs16999322 chr4 162379746 A G 1.47E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FSTL5 intron 24023788 rs4358350 chr4 162384818 G A 3.02E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FSTL5 intron 24023788 rs41433445 chr4 162389274 A T 8.89E-27 Narcolepsy FSTL5 intron 19629137 rs17399121 chr4 162422036 A G 8.57E-05 Type 2 diabetes FSTL5 intron 17463246 rs17340154 chr4 162428196 C T 2.88E-04 Height FSTL5 intron 17255346 rs17340154 chr4 162428196 C T 4.62E-04 Type 2 diabetes FSTL5 intron 17463246 rs4691773 chr4 162507230 G T 1.92E-04 Multiple complex diseases FSTL5 intron 17554300 rs4602454 chr4 162550871 A G 5.81E-04 HIV-1 viral setpoint FSTL5 intron 17641165 rs17638464 chr4 162602209 G A 2.00E-06 Height FSTL5 intron 20966902 rs10857341 chr4 162611902 T C 1.31E-05 Age-related macular degeneration FSTL5 intron 23577725 rs12644286 chr4 162642780 T C 4.20E-04 Smoking initiation FSTL5 intron 24665060 rs1440588 chr4 162764014 A G 4.80E-04 Alcohol dependence FSTL5 intron 20201924 rs17458343 chr4 162779626 G A 2.98E-04 Type 2 diabetes FSTL5 intron 17463246 rs17536600 chr4 162793885 A G 4.36E-04 Type 2 diabetes FSTL5 intron 17463246 rs2033404 chr4 162822306 T G 5.18E-05 Prostate cancer FSTL5 intron pha002878 rs1440606 chr4 162826777 T C 5.27E-05 Prostate cancer FSTL5 intron pha002878 rs11730709 chr4 162842540 A G 1.52E-04 Alzheimer's disease FSTL5 intron 17998437 rs4586881 chr4 162843802 T C 3.55E-04 Schizophrenia(treatment response to risperidone) FSTL5 intron 19850283 rs7674142 chr4 162845712 G A 1.60E-04 Alzheimer's disease FSTL5 intron 17998437 rs41461449 chr4 162858888 G T 1.97E-04 Type 2 diabetes FSTL5 intron 17463246 rs359515 chr4 162879495 G A 7.18E-04 Aortic root size FSTL5 intron 21223598 rs7674343 chr4 162903715 C A 7.81E-04 Type 2 diabetes FSTL5 intron 17463246 rs359486 chr4 162907833 T C 6.11E-05 Asthma FSTL5 intron 20159242 rs10022486 chr4 162923324 T G 9.74E-04 Suicide attempts in bipolar disorder FSTL5 intron 21423239 rs1483550 chr4 162925724 C A 9.20E-04 Alzheimer's disease FSTL5 intron 17998437 rs7658962 chr4 162934834 T G 2.42E-04 Type 2 diabetes FSTL5 intron 17463246 rs6811170 chr4 162938109 C T 3.00E-04 Type 2 diabetes FSTL5 intron 17463246 rs6824038 chr4 162939782 C T 3.85E-04 Type 2 diabetes FSTL5 intron 17463246 rs6821913 chr4 162944705 C A 2.37E-04 Type 2 diabetes FSTL5 intron 17463246 rs17459609 chr4 162945053 C G 2.67E-04 Type 2 diabetes FSTL5 intron 17463246 rs17459630 chr4 162949827 C T 2.37E-04 Type 2 diabetes FSTL5 intron 17463246 rs17459658 chr4 162951956 T C 2.37E-04 Type 2 diabetes FSTL5 intron 17463246 rs1564713 chr4 162952487 C T 2.58E-04 Type 2 diabetes FSTL5 intron 17463246 rs1023957 chr4 162953152 C G 4.32E-04 Type 2 diabetes FSTL5 intron 17463246 rs1471693 chr4 162953565 G A 3.64E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) FSTL5 intron 23648065 rs12508126 chr4 162957578 T C 5.07E-04 Suicide attempts in bipolar disorder FSTL5 intron 21423239 rs10517758 chr4 162967929 T G 2.05E-04 Type 2 diabetes FSTL5 intron 17463246 rs1492457 chr4 162985367 G A 3.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) FSTL5 intron 23648065 rs17459954 chr4 162985402 C T 2.09E-04 Type 2 diabetes FSTL5 intron 17463246 rs2086754 chr4 162992246 A C 5.58E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) FSTL5 intron 23648065 rs1492465 chr4 163028973 C A 9.95E-04 Obesity (extreme) FSTL5 intron 21935397 rs1994771 chr4 163034145 T C 9.25E-04 Obesity (extreme) FSTL5 intron 21935397 rs12512615 chr4 163048597 A G 3.51E-04 Sudden cardiac arrest FSTL5 intron 21658281 rs13117227 chr4 163054728 A T 4.34E-04 Glycemic traits (pregnancy) FSTL5 intron 23903356 rs13117227 chr4 163054728 A T 4.73E-04 Glycemic traits (pregnancy) FSTL5 intron 23903356 rs17042027 chr4 163056767 G C 6.84E-04 Type 2 diabetes FSTL5 intron 17463246 rs17042027 chr4 163056767 G C 9.25E-04 Alzheimer's disease FSTL5 intron 17998437 rs17042030 chr4 163057016 G A 1.15E-05 Anorexia nervosa FSTL5 intron 21079607 rs17042031 chr4 163057153 T C 7.41E-04 Alzheimer's disease FSTL5 intron 17998437 rs12513313 chr4 163059187 A G 7.34E-04 Type 2 diabetes FSTL5 intron 17463246 rs12513313 chr4 163059187 A G 5.31E-04 Alzheimer's disease FSTL5 intron 17998437 rs12505723 chr4 163059330 C T 4.54E-04 Type 2 diabetes FSTL5 intron 17463246 rs12505723 chr4 163059330 C T 9.13E-04 Alzheimer's disease FSTL5 intron 17998437 rs4691817 chr4 163080189 T C 6.96E-05 Coronary heart disease FSTL5 intron pha003033 rs1546093 chr4 163084036 A G 6.96E-05 Coronary heart disease FSTL5 intron pha003033 rs4691041 chr4 163211495 G A 7.16E-05 Panic disorder / / 19165232 rs4440177 chr4 163243053 G A 4.16E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs4440177 chr4 163243053 G A 4.10E-04 Nicotine use / / 23942779 rs4440177 chr4 163243053 G A 5.30E-05 Illicit drug use / / 23942779 rs4440177 chr4 163243053 G A 6.00E-06 Alcohol dependence / / 23942779 rs4440177 chr4 163243053 G A 6.60E-04 Alcohol consumption / / 23942779 rs7684439 chr4 163245174 T C 1.83E-05 Waist-Hip Ratio / / pha003029 rs4691830 chr4 163247886 G A 4.38E-05 Waist Circumference / / pha003023 rs1993028 chr4 163260848 G A 5.76E-05 Waist Circumference / / pha003023 rs10517763 chr4 163263758 C T 1.78E-04 Multiple complex diseases / / 17554300 rs11933008 chr4 163285615 G A 3.06E-05 Cognitive test performance / / 20125193 rs12645916 chr4 163290333 C T 3.02E-04 Multiple complex diseases / / 17554300 rs1011376 chr4 163300195 C A 4.05E-05 Cognitive test performance / / 20125193 rs2597498 chr4 163335540 T G 7.03E-04 Bipolar disorder,schizoaffective / / 19567891 rs2044796 chr4 163385985 C T 5.13E-04 HIV-1 viral setpoint / / 17641165 rs2100763 chr4 163461192 T C 4.69E-04 Psoriasis / / 20953187 rs1870594 chr4 163464386 A T 1.30E-05 Urinary metabolites / / 21572414 rs10428343 chr4 163475257 G T 2.06E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7662432 chr4 163482554 T G 4.40E-06 Urinary metabolites / / 21572414 rs6856230 chr4 163484868 A G 1.26E-04 Alzheimer's disease (late onset) / / 21379329 rs10776536 chr4 163485223 C T 9.04E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10776536 chr4 163485223 C T 2.00E-05 Urinary metabolites / / 21572414 rs10776536 chr4 163485223 C T 1.00E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1471263 chr4 163488168 C A 8.09E-05 Alzheimer's disease (late onset) / / 21379329 rs7694400 chr4 163493092 T C 6.38E-32 Narcolepsy / / 19629137 rs10025660 chr4 163499998 A G 8.83E-05 Alzheimer's disease (late onset) / / 21379329 rs7670731 chr4 163510465 A G 9.44E-04 Alzheimer's disease / / 24755620 rs6855411 chr4 163514607 A G 5.20E-06 Urinary metabolites / / 21572414 rs6855760 chr4 163514693 C G 5.00E-06 Urinary metabolites / / 21572414 rs6856902 chr4 163515298 A G 1.26E-05 Longevity,exceptional / / 20595579 rs6856902 chr4 163515298 A G 1.50E-04 Alzheimer's disease (late onset) / / 21379329 rs7688628 chr4 163525786 A G 5.25E-05 Alzheimer's disease (late onset) / / 21379329 rs17042707 chr4 163540897 T C 4.65E-04 Multiple complex diseases / / 17554300 rs6849368 chr4 163543945 C A 4.06E-04 Alzheimer's disease (late onset) / / 21379329 rs17042725 chr4 163558705 A G 4.53E-04 Multiple complex diseases / / 17554300 rs195913 chr4 163573991 T C 6.17E-04 Multiple complex diseases / / 17554300 rs195937 chr4 163580271 T C 8.95E-05 Alzheimer's disease (late onset) / / 21379329 rs17042773 chr4 163596716 C T 4.46E-04 Multiple complex diseases / / 17554300 rs17042793 chr4 163609960 T C 4.89E-04 Multiple complex diseases / / 17554300 rs17042793 chr4 163609960 T C 5.90E-05 Cognitive function / / 24684796 rs195542 chr4 163627640 G T 1.57E-04 Alzheimer's disease (late onset) / / 21379329 rs1003527 chr4 163654881 G A 1.10E-04 Alzheimer's disease (late onset) / / 21379329 rs10517771 chr4 163686772 G A 1.45E-04 Alzheimer's disease (late onset) / / 21379329 rs11728682 chr4 163708676 C T 1.76E-04 Multiple complex diseases / / 17554300 rs10517772 chr4 163712570 A G 8.01E-05 Multiple complex diseases / / 17554300 rs17573261 chr4 163714149 A G 7.01E-05 Multiple complex diseases / / 17554300 rs13130233 chr4 163718686 A G 3.29E-05 Multiple complex diseases / / 17554300 rs10027421 chr4 163731790 A T 3.78E-06 Hair morphology / / 19896111 rs6840361 chr4 163738121 C G 4.00E-06 Hair morphology / / 19896111 rs1458142 chr4 163754207 A G 7.00E-06 Urinary metabolites / / 21572414 rs10033012 chr4 163766726 C T 4.59E-05 Blood Pressure / / pha003049 rs17470149 chr4 163770664 T C 4.80E-04 Aortic root size / / 21223598 rs1551592 chr4 163774044 T C 1.20E-06 Urinary metabolites / / 21572414 rs4691873 chr4 163779723 A G 1.30E-06 Urinary metabolites / / 21572414 rs2012358 chr4 163795102 T C 5.43E-04 Smoking cessation / / 24665060 rs6842513 chr4 163843642 G A 3.48E-04 Multiple complex diseases / / 17554300 rs4317161 chr4 163845381 G A 1.11E-04 Bladder cancer / / 19648920 rs11725452 chr4 163936185 C G 7.65E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4130504 chr4 163955092 A G 7.70E-04 Endometrial cancer / / 24096698 rs6850650 chr4 163957430 C T 1.90E-05 Bipolar disorder and schizophrenia / / 20889312 rs1123884 chr4 163984315 C T 1.18E-04 Multiple complex diseases / / 17554300 rs6847195 chr4 164002552 C T 4.79E-05 Erythrocyte counts / / pha003099 rs13132042 chr4 164003858 T C 3.72E-05 Erythrocyte counts / / pha003099 rs7675998 chr4 164007820 A G 4.35E-16 Telomere length / / 23535734 rs936564 chr4 164019763 A G 7.37E-06 Telomere length / / 23001564 rs10019236 chr4 164038624 T C 2.63E-05 Coronary Artery Disease / / 17634449 rs2320615 chr4 164069949 A G 3.30E-04 Telomere length /F1 intron 23900074 rs1351222 chr4 164076558 G A 4.52E-04 Telomere length /F1 intron 23900074 rs2086242 chr4 164112130 A G 7.19E-05 Telomere length / / 23900074 rs12644622 chr4 164114844 C T 8.10E-05 Telomere length / / 23900074 rs3967768 chr4 164189863 G A 6.25E-04 Nicotine dependence / / 17158188 rs6811330 chr4 164230038 G T 4.61E-05 Serum metabolites / / 19043545 rs6828820 chr4 164230540 C T 3.86E-05 Serum metabolites / / 19043545 rs4146926 chr4 164230788 C G 2.11E-05 Serum metabolites / / 19043545 rs9764 chr4 164245405 T C 1.98E-06 Serum metabolites NPY1R UTR-3 19043545 rs10033119 chr4 164245854 A G 7.14E-05 Telomere length NPY1R UTR-3 23900074 rs11100494 chr4 164270253 C A 1.00E-04 Cognitive impairment induced by topiramate NPY5R intron 22091778 rs11100494 chr4 164270253 C A 1.00E-04 Cognitive impairment induced by topiramate NPY5R intron 22091778 rs11100494 chr4 164270253 C A 1.54E-05 Cognitive impairment induced by topiramate NPY5R intron 22091778 rs11100494 chr4 164270253 C A 6.77E-05 Cognitive impairment induced by topiramate NPY5R intron 22091778 rs4691911 chr4 164274849 T A 2.50E-04 Parkinson's disease / / 16252231 rs6851444 chr4 164283085 T C 8.07E-04 Multiple complex diseases / / 17554300 rs13128283 chr4 164295403 A G 8.23E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4437207 chr4 164301975 T C 6.85E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1441716 chr4 164325064 C T 8.46E-05 Type 2 diabetes / / 17846125 rs13130937 chr4 164343495 C T 3.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs6816145 chr4 164418994 G A 7.71E-04 Response to taxane treatment (placlitaxel) TMA16 intron 23006423 rs17576350 chr4 164446514 G A 4.09E-04 Response to taxane treatment (placlitaxel) MARCH1 UTR-3 23006423 rs1992441 chr4 164451948 C T 2.51E-04 Myocardial Infarction MARCH1 intron pha002883 rs3797023 chr4 164459307 T C 1.25E-04 Response to taxane treatment (placlitaxel) MARCH1 intron 23006423 rs17473108 chr4 164463778 A G 9.49E-04 Response to taxane treatment (placlitaxel) MARCH1 intron 23006423 rs13130399 chr4 164466824 C T 4.26E-04 Glaucoma (primary open-angle) MARCH1 cds-synon 22605921 rs9631750 chr4 164474770 T C 7.89E-06 Left ventricular hypertrophy MARCH1 intron pha003052 rs1355504 chr4 164522410 C G 2.20E-05 Urinary metabolites MARCH1 intron 21572414 rs1912822 chr4 164524609 C T 1.44E-05 Follicular lymphoma MARCH1 intron 21533074 rs3792615 chr4 164532801 T C 9.00E-06 Type 2 diabetes MARCH1 intron 21490949 rs13123027 chr4 164560851 C T 1.69E-04 Glaucoma (primary open-angle) MARCH1 intron 22605921 rs17473710 chr4 164571285 G A 2.71E-04 Suicide attempts in bipolar disorder MARCH1 intron 21423239 rs1533151 chr4 164575991 A C 1.51E-04 Smoking initiation MARCH1 intron 24665060 rs1511776 chr4 164582457 G A 3.02E-04 Body mass index MARCH1 intron 21701565 rs13114557 chr4 164589328 G C 4.67E-04 Smoking initiation MARCH1 intron 24665060 rs1039959 chr4 164617856 G C 2.94E-04 Suicide,with and without major depression MARCH1 intron 22059935 rs1170300 chr4 164623358 G C 2.67E-04 Acute lung injury MARCH1 intron 22295056 rs1565840 chr4 164634372 C A 9.18E-04 Response to taxane treatment (placlitaxel) MARCH1 intron 23006423 rs6818812 chr4 164637972 C T 7.49E-05 Monocyte counts MARCH1 intron pha003089 rs6536751 chr4 164646996 C T 6.00E-04 Suicide attempts in bipolar disorder MARCH1 intron 21423239 rs17577474 chr4 164666859 G A 3.52E-04 Type 2 diabetes MARCH1 intron 17463246 rs12504820 chr4 164669428 C T 2.15E-05 Monocyte counts MARCH1 intron pha003089 rs1038975 chr4 164701659 G A 6.90E-05 Monocyte counts MARCH1 intron pha003089 rs2131862 chr4 164748523 G A 1.42E-05 Monocyte counts MARCH1 intron pha003089 rs1874094 chr4 164753387 C T 9.25E-05 Response to mTOR inhibitor (everolimus) MARCH1 intron 24009623 rs11939053 chr4 164758471 A C 8.91E-04 Alzheimer's disease MARCH1 intron 22005930 rs11939053 chr4 164758471 A C 3.14E-05 Monocyte counts MARCH1 intron pha003089 rs7680927 chr4 164758578 A G 5.18E-04 Alzheimer's disease MARCH1 intron 22005930 rs7681115 chr4 164758636 A G 5.96E-04 Alzheimer's disease MARCH1 intron 22005930 rs978402 chr4 164780120 T C 4.10E-04 Type 2 diabetes and 6 quantitative traits MARCH1 intron 17848626 rs7655259 chr4 164782515 C A 4.41E-05 Amyotrophic lateral sclerosis (sporadic) MARCH1 intron 24529757 rs12645283 chr4 164796501 T C 9.27E-05 Cytomegalovirus antibody response MARCH1 intron 21993531 rs4554022 chr4 164798037 G T 8.35E-05 Cytomegalovirus antibody response MARCH1 intron 21993531 rs10023694 chr4 164809025 G T 6.06E-04 Response to taxane treatment (placlitaxel) MARCH1 intron 23006423 rs3890761 chr4 164829751 T C 6.12E-04 Response to taxane treatment (placlitaxel) MARCH1 intron 23006423 rs12510039 chr4 164915259 G A 9.63E-05 Multiple complex diseases MARCH1 intron 17554300 rs4453901 chr4 164916190 A C 8.04E-04 Multiple complex diseases MARCH1 intron 17554300 rs11736201 chr4 164922631 C T 7.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MARCH1 intron 20877124 rs11736266 chr4 164922836 C T 8.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MARCH1 intron 20877124 rs10007601 chr4 164934874 G A 1.60E-04 Body mass index MARCH1 intron 21701565 rs17044409 chr4 164941538 A G 1.52E-04 Multiple complex diseases MARCH1 intron 17554300 rs10001082 chr4 164958626 T C 3.00E-06 Parkinson's disease (interaction with coffee consumption) MARCH1 intron 21876681 rs4533720 chr4 164959804 A G 4.00E-07 Urinary uromodulin levels MARCH1 intron 24578125 rs6536779 chr4 164972162 T C 7.21E-05 Tunica Media MARCH1 intron pha003036 rs13130053 chr4 164980534 C T 1.90E-05 Urinary metabolites MARCH1 intron 21572414 rs17613361 chr4 164981604 A G 2.41E-04 Height MARCH1 intron 17255346 rs41513048 chr4 165007900 G A 2.35E-04 Multiple complex diseases MARCH1 intron 17554300 rs919574 chr4 165013565 G A 2.64E-05 Telomere length MARCH1 intron 23001564 rs7659197 chr4 165014174 G T 5.14E-04 Multiple complex diseases MARCH1 intron 17554300 rs17044483 chr4 165029168 A T 2.30E-05 Urinary metabolites MARCH1 intron 21572414 rs2952334 chr4 165043263 A G 1.30E-05 Urinary metabolites MARCH1 intron 21572414 rs919572 chr4 165054490 A T 3.58E-04 Multiple complex diseases MARCH1 intron 17554300 rs982257 chr4 165060898 T C 1.31E-04 Body mass index MARCH1 intron 17255346 rs6840738 chr4 165077427 A C 3.38E-04 Multiple complex diseases MARCH1 intron 17554300 rs1431001 chr4 165085789 A T 2.39E-04 Glycosylated haemoglobin levels MARCH1 intron 17255346 rs1430999 chr4 165085902 G A 3.13E-05 Glucose levels MARCH1 intron pha003061 rs17044711 chr4 165093156 C T 1.73E-05 Glucose levels MARCH1 intron pha003061 rs1160724 chr4 165095228 C T 2.40E-04 Body mass index MARCH1 intron 17255346 rs1430979 chr4 165099463 T A,G 2.04E-04 Body mass index MARCH1 intron 17255346 rs1549807 chr4 165106489 G A 2.24E-04 Body mass index MARCH1 intron 17255346 rs1430977 chr4 165108780 G A 2.07E-05 Glucose levels MARCH1 intron pha003061 rs2288676 chr4 165118253 T C 9.53E-05 Glycosylated haemoglobin levels ANP32C missense 17255346 rs10001526 chr4 165132967 G T 1.20E-05 Urinary metabolites MARCH1 intron 21572414 rs17614208 chr4 165147509 G A 7.98E-06 Height MARCH1 intron 17255346 rs3890821 chr4 165160898 A C 1.66E-05 Glycosylated haemoglobin levels MARCH1 intron 17255346 rs17044858 chr4 165201409 G A 1.76E-08 Adiponectin levels MARCH1 intron 20887962 rs2321376 chr4 165202782 G A 1.75E-04 Coronary Artery Disease MARCH1 intron 17634449 rs4611881 chr4 165216639 G C 7.85E-04 Coronary Artery Disease MARCH1 intron 17634449 rs6829588 chr4 165221971 G T 8.31E-04 Obesity (extreme) MARCH1 intron 21935397 rs13125269 chr4 165268349 A G 3.23E-04 Multiple complex diseases MARCH1 intron 17554300 rs12506846 chr4 165278592 C T 6.02E-04 Multiple complex diseases MARCH1 intron 17554300 rs4431170 chr4 165284574 A G 0.00000728 Bisphosphonate-induced osteonecrosis of the jaw MARCH1 intron 22267851 rs7658861 chr4 165305889 T C 5.02E-05 Serum albumin level / / pha003084 rs11732658 chr4 165336497 T C 7.86E-04 Multiple complex diseases / / 17554300 rs989731 chr4 165360517 C A,T 2.50E-05 Urinary metabolites / / 21572414 rs1505387 chr4 165363909 A C 6.00E-05 Coronary heart disease / / 21606135 rs2874568 chr4 165364934 C T 1.59E-05 Colorectal cancer / / 21242260 rs325597 chr4 165383521 T C 1.11E-04 Coronary heart disease / / 21606135 rs1587920 chr4 165388886 A G 9.59E-05 Coronary heart disease / / 21606135 rs1960980 chr4 165395936 T C 2.69E-04 Multiple complex diseases / / 17554300 rs1394807 chr4 165400016 T G 1.30E-05 Urinary metabolites / / 21572414 rs4691122 chr4 165404456 T G 4.58E-04 Epilepsy / / 22116939 rs1463926 chr4 165409446 C A 6.96E-05 Coronary heart disease / / 21606135 rs13126860 chr4 165411056 C G 3.29E-04 Type 2 diabetes / / 17463246 rs13126860 chr4 165411056 C G 2.00E-04 Multiple complex diseases / / 17554300 rs325586 chr4 165423835 T C 9.74E-05 Schizophrenia / / 19571809 rs12508710 chr4 165456150 A G 5.90E-04 HIV-1 viral setpoint / / 17641165 rs17621228 chr4 165493107 T C 5.06E-04 Multiple complex diseases / / 17554300 rs35732053 chr4 165579600 C T 6.26E-04 Multiple complex diseases / / 17554300 rs1406365 chr4 165579891 G A 2.65E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1110049 chr4 165606432 G A 6.62E-05 Smoking initiation / / 24665060 rs7693015 chr4 165608965 G C 6.27E-04 Smoking initiation / / 24665060 rs6536844 chr4 165613831 G A 1.78E-04 Smoking initiation / / 24665060 rs6536845 chr4 165614039 G T 1.27E-04 Smoking initiation / / 24665060 rs6814429 chr4 165615963 G A 4.49E-05 Smoking initiation / / 24665060 rs10010369 chr4 165616794 T C 7.09E-04 Smoking initiation / / 24665060 rs13133773 chr4 165618481 C T 4.06E-04 Smoking initiation / / 24665060 rs17678704 chr4 165643475 C G 6.20E-06 Urinary metabolites / / 21572414 rs17622224 chr4 165644643 T C 6.20E-06 Urinary metabolites / / 21572414 rs12650938 chr4 165683201 G A 3.09E-05 Colorectal cancer LOC100505989 intron 24448986 rs10002510 chr4 165684300 T C 1.35E-05 Smoking initiation LOC100505989 intron 24665060 rs10003667 chr4 165688462 G T 4.50E-05 Biliary atresia LOC100505989 intron 20460270 rs4234977 chr4 165689057 T C 4.50E-05 Biliary atresia LOC100505989 intron 20460270 rs12331505 chr4 165691327 C T 9.57E-04 Multiple complex diseases LOC100505989 intron 17554300 rs4539996 chr4 165707728 A C 4.75E-04 Body mass index LOC100505989 intron 21701565 rs9991207 chr4 165709039 C T 2.16E-04 Body mass index LOC100505989 intron 21701565 rs9991207 chr4 165709039 C T 3.86E-04 Body mass index LOC100505989 intron 21701565 rs4572830 chr4 165726891 C T 1.11E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4572830 chr4 165726891 C T 5.33E-05 Osteoarthritis (knee and hip) / / 21177295 rs4572830 chr4 165726891 C T 7.24E-05 Osteoarthritis (knee and hip) / / 21177295 rs4280691 chr4 165727071 C G 1.31E-04 Multiple complex diseases / / 17554300 rs7683083 chr4 165737589 C A 5.14E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11723570 chr4 165742801 T C 5.15E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17583808 chr4 165743174 C T 4.33E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12500207 chr4 165746041 C T 3.51E-05 Body Fat Distribution / / pha003017 rs13144179 chr4 165811733 T C 2.32E-04 Type 2 diabetes LOC100506013 intron 17463246 rs10517818 chr4 165817608 T C 3.11E-04 Type 2 diabetes / / 17463246 rs13127852 chr4 165823898 C G 0.000019 HDL cholesterol particle diameter / / 23263444 rs4429695 chr4 165836060 G A 0.00000226 HDL cholesterol particle diameter / / 23263444 rs17487218 chr4 165837436 T C 2.08E-04 Endometrial cancer / / 24096698 rs17487218 chr4 165837436 T C 9.65E-04 Endometrial cancer / / 24096698 rs4690796 chr4 165872825 T G 5.50E-06 Urinary metabolites / / 21572414 rs3733418 chr4 165878335 A G 9.00E-06 Obesity-related traits FAM218A missense 23251661 rs17623445 chr4 165894658 G A 5.40E-05 Triglycerides TRIM61 intron 19074352 rs7680569 chr4 165899225 T G 2.44E-05 Coronary heart disease / / pha003032 rs4691139 chr4 165908721 A G 3.00E-08 Ovarian cancer in BRCA1 mutation carriers / / 23544013 rs4691139 chr4 165908721 A G 3.45E-08 Ovarian cancer in BRCA1 mutation carriers / / 23544013 rs4690798 chr4 165926586 C T 7.56E-04 Type 2 diabetes / / 17463246 rs4691142 chr4 165926786 G A 7.47E-04 Type 2 diabetes / / 17463246 rs7684974 chr4 165944299 C A 9.41E-04 Endometrial cancer / / 24096698 rs6837162 chr4 165986546 T C 4.24E-04 Type 2 diabetes / / 17463246 rs17623941 chr4 166051266 G A 2.56E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17585041 chr4 166052580 C T 1.80E-05 Urinary metabolites / / 21572414 rs4691170 chr4 166074611 G A 1.60E-05 Urinary metabolites / / 21572414 rs41530947 chr4 166076044 C T 1.60E-05 Urinary metabolites / / 21572414 rs9968334 chr4 166095555 C G 1.11E-05 Multiple complex diseases / / 17554300 rs9968334 chr4 166095555 C G 5.10E-05 Cognitive function / / 24684796 rs6834975 chr4 166095828 A G 6.41E-06 Multiple complex diseases / / 17554300 rs6834975 chr4 166095828 A G 3.40E-05 Cognitive function / / 24684796 rs4132377 chr4 166098718 C G 6.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs4690807 chr4 166101341 C A 3.90E-05 Multiple complex diseases / / 17554300 rs17585306 chr4 166112868 G A 2.67E-05 Multiple complex diseases / / 17554300 rs17585333 chr4 166114231 A G 4.66E-05 Multiple complex diseases / / 17554300 rs9993501 chr4 166116807 G A 1.10E-05 Multiple complex diseases / / 17554300 rs12513327 chr4 166145820 G A 1.65E-05 Alcohol and nictotine co-dependence KLHL2 intron 20158304 rs12500138 chr4 166147712 C T 7.26E-05 Multiple complex diseases KLHL2 intron 17554300 rs12500138 chr4 166147712 C T 6.00E-06 Cognitive function KLHL2 intron 24684796 rs17009130 chr4 166166636 A G 8.28E-04 Acute lung injury KLHL2 intron 22295056 rs1550271 chr4 166254953 A C 1.32E-06 Insulin-related traits MSMO1 intron 22791750 rs2118496 chr4 166254973 A G 3.51E-07 Insulin-related traits MSMO1 intron 22791750 rs17046216 chr4 166255704 T A 2.00E-08 Insulin-related traits MSMO1 intron 22791750 rs17046216 chr4 166255704 T A 3.00E-08 Insulin-related traits MSMO1 intron 22791750 rs17488534 chr4 166255940 G A 6.68E-07 Insulin-related traits MSMO1 intron 22791750 rs1866218 chr4 166256812 G C 7.24E-05 Longevity MSMO1 intron 20304771 rs2322292 chr4 166258433 T C 7.13E-05 Longevity MSMO1 intron 20304771 rs17046259 chr4 166259719 T G 1.02E-13 Multiple complex diseases MSMO1 intron 17554300 rs1059209 chr4 166263213 A G 3.76E-05 Multiple complex diseases MSMO1 UTR-3 17554300 rs4691183 chr4 166266727 C T 7.13E-05 Longevity / / 20304771 rs7667236 chr4 166267119 G A 7.05E-05 Longevity / / 20304771 rs7655392 chr4 166280502 A C 3.52E-05 Longevity / / 20304771 rs4690810 chr4 166280680 T C 1.86E-05 Longevity / / 20304771 rs934814 chr4 166286326 C A,G 5.48E-04 Multiple complex diseases / / 17554300 rs7664542 chr4 166290407 T C 3.37E-14 Multiple complex diseases / / 17554300 rs9631752 chr4 166311686 A T 1.43E-05 Cocaine dependence CPE intron 23958962 rs9631752 chr4 166311686 A T 7.12E-05 Cocaine dependence CPE intron 23958962 rs4691188 chr4 166312500 C T 2.94E-06 Cocaine dependence CPE intron 23958962 rs4691188 chr4 166312500 C T 3.49E-05 Cocaine dependence CPE intron 23958962 rs4691188 chr4 166312500 C T 4.64E-04 Cocaine dependence CPE intron 23958962 rs35355030 chr4 166315500 T C 6.60E-05 Cocaine dependence CPE intron 23958962 rs35355030 chr4 166315500 T C 7.18E-04 Cocaine dependence CPE intron 23958962 rs35355030 chr4 166315500 T C 7.56E-06 Cocaine dependence CPE intron 23958962 rs17686882 chr4 166322398 G A 2.31E-04 Cocaine dependence CPE intron 23958962 rs17686882 chr4 166322398 G A 2.89E-04 Cocaine dependence CPE intron 23958962 rs10517844 chr4 166334391 T C 8.08E-05 Blood Pressure CPE intron pha003050 rs729699 chr4 166335181 C A,T 6.39E-05 Alcohol dependence CPE intron 21703634 rs729699 chr4 166335181 C A,T 8.97E-05 Blood Pressure CPE intron pha003050 rs1946816 chr4 166340959 A C 1.85E-04 Smoking cessation CPE intron 24665060 rs11728337 chr4 166348916 T G 4.29E-04 Smoking cessation CPE intron 24665060 rs11724900 chr4 166348993 G A 6.03E-04 Smoking cessation CPE intron 24665060 rs10517849 chr4 166358532 A G 2.76E-04 Smoking cessation CPE intron 24665060 rs11727980 chr4 166358552 T C 1.83E-04 Smoking cessation CPE intron 24665060 rs4481204 chr4 166359421 T C 8.40E-04 Parkinson's disease CPE intron 17052657 rs4481204 chr4 166359421 T C 2.29E-04 Smoking cessation CPE intron 24665060 rs10517850 chr4 166360236 A G 2.63E-04 Smoking cessation CPE intron 24665060 rs1898593 chr4 166362750 G T 3.89E-05 Multiple sclerosis (age of onset) CPE intron 19010793 rs6536915 chr4 166384367 C T 4.60E-04 Alcohol dependence CPE intron 20201924 rs1583646 chr4 166396222 C T 3.51E-05 Serum metabolites CPE intron 19043545 rs11737095 chr4 166403897 A G 0.000208 Salmonella-induced pyroptosis CPE intron 22837397 rs1530044 chr4 166427411 T A 4.40E-06 Urinary metabolites / / 21572414 rs2280322 chr4 166428294 A C 3.68E-04 Alzheimer's disease (late onset) / / 21379329 rs7679286 chr4 166474584 A G 6.33E-04 Premature ovarian failure / / 19508998 rs10155080 chr4 166475580 G T 8.50E-05 Lipid levels / / 18193043 rs17046758 chr4 166497386 A T 8.79E-05 Type 2 diabetes / / 17463246 rs6536921 chr4 166501396 G A 3.07E-04 Type 2 diabetes / / 17463246 rs17046894 chr4 166545642 T C 5.23E-04 Type 2 diabetes / / 17463246 rs17503811 chr4 166550442 T G 5.83E-04 Type 2 diabetes / / 17463246 rs2611219 chr4 166570869 T C 2.94E-04 Type 2 diabetes / / 17463246 rs17503957 chr4 166573929 A T 5.90E-05 Type 2 diabetes / / 17463246 rs764240 chr4 166575899 G A 1.49E-04 Major depressive disorder / / 22472876 rs2611209 chr4 166578236 G T 2.91E-04 Major depressive disorder / / 22472876 rs2714807 chr4 166591321 T C 1.38E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs17504069 chr4 166592849 C T 6.14E-04 Multiple complex diseases / / 17554300 rs2611249 chr4 166606298 T C 3.19E-04 Multiple complex diseases / / 17554300 rs2714842 chr4 166616746 A C 5.04E-05 Kawasaki disease / / 22446961 rs2611259 chr4 166619952 A G 2.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2611258 chr4 166621498 G A 6.04E-05 Kawasaki disease / / 22446961 rs17632423 chr4 166632989 G A 1.01E-05 Kawasaki disease / / 22446961 rs17632440 chr4 166641918 G T 1.30E-05 Kawasaki disease / / 22446961 rs2611228 chr4 166655729 A C 9.55E-04 Multiple complex diseases / / 17554300 rs1903176 chr4 166664102 T A 9.87E-04 Multiple complex diseases / / 17554300 rs881821 chr4 166666480 T C 4.40E-05 Coffee consumption / / 21357676 rs881821 chr4 166666480 T C 9.49E-05 Heart Rate / / pha003053 rs355186 chr4 166678799 C T 2.57E-04 Multiple complex diseases / / 17554300 rs355183 chr4 166681765 A G 2.80E-04 Multiple complex diseases / / 17554300 rs355168 chr4 166691492 T C 9.01E-04 Multiple complex diseases / / 17554300 rs17632649 chr4 166709866 T C 7.10E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4613526 chr4 166711689 G C 5.41E-04 Multiple complex diseases / / 17554300 rs7687480 chr4 166734530 G A 9.49E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1460060 chr4 166815429 A C 6.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TLL1 intron 20877124 rs12513380 chr4 166830364 G A 3.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TLL1 intron 20877124 rs12513380 chr4 166830364 G A 5.00E-06 Multiple sclerosis TLL1 intron 23412934 rs10517872 chr4 166849974 G A 1.40E-10 Gout TLL1 intron pha001406 rs7654070 chr4 166854660 A G 4.35E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TLL1 intron 24023788 rs873242 chr4 166865109 G A 0.000000051 Mean arterial pressure TLL1 intron 22510845 rs7691872 chr4 166865585 G T 1.22E-07 Post-traumatic stress disorder TLL1 intron 23726511 rs6812849 chr4 166872536 C A 1.00E-06 Post-traumatic stress disorder TLL1 intron 23726511 rs6812849 chr4 166872536 C A 1.00E-07 Post-traumatic stress disorder (asjusted for relatedness) TLL1 intron 23726511 rs6812849 chr4 166872536 C A 3.00E-09 Post-traumatic stress disorder TLL1 intron 23726511 rs6812849 chr4 166872536 C A 5.00E-07 Post-traumatic stress disorder (asjusted for relatedness) TLL1 intron 23726511 rs7696087 chr4 166882179 G A 4.85E-04 Hemoglobin concentration TLL1 intron 20534544 rs4485771 chr4 166893533 A G 8.34E-05 Post-operative nausea and vomiting TLL1 intron 21694509 rs4485771 chr4 166893533 A G 1.06E-05 HIV-1 progression to AIDS and death TLL1 intron 21811574 rs4485771 chr4 166893533 A G 1.99E-04 HIV-1 progression to AIDS and death TLL1 intron 21811574 rs17689952 chr4 166939154 A G 1.81E-05 Attention deficit hyperactivity disorder TLL1 intron pha002875 rs954709 chr4 166959819 G T 4.20E-04 Breast cancer and prostate cancer TLL1 intron 17903305 rs9991292 chr4 166971075 C T 2.74E-04 Multiple complex diseases TLL1 intron 17554300 rs6536942 chr4 166986194 G A 4.23E-06 Follicular lymphoma TLL1 intron 21533074 rs2292083 chr4 166996414 G A 1.96E-04 Glycosylated haemoglobin levels TLL1 intron 17255346 rs2292083 chr4 166996414 G A 0.000679 Salmonella-induced pyroptosis TLL1 intron 22837397 rs7664119 chr4 166996799 G A 0.000701 Salmonella-induced pyroptosis TLL1 intron 22837397 rs1826956 chr4 167019072 T C 6.40E-06 Kawasaki disease TLL1 intron 22446962 rs2279723 chr4 167022359 C A 2.09E-04 Alzheimer's disease (late onset) TLL1 UTR-3 21379329 rs993926 chr4 167042848 G A 2.40E-05 Urinary metabolites / / 21572414 rs1391332 chr4 167049629 T C 6.40E-06 Urinary metabolites / / 21572414 rs2874823 chr4 167074691 C A 2.00E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6838888 chr4 167099571 G A 4.77E-05 Pulmonary function / / 19300500 rs4691248 chr4 167099950 C G 4.76E-05 Pulmonary function / / 19300500 rs949794 chr4 167107023 T C 4.55E-05 Pulmonary function / / 19300500 rs1497956 chr4 167109588 G A 4.34E-05 Pulmonary function / / 19300500 rs1497957 chr4 167110433 C T 8.20E-05 Blood Pressure / / pha002898 rs1459835 chr4 167174293 C T 5.96E-04 Heart Failure / / pha002884 rs396402 chr4 167208043 C T 4.60E-05 Multiple complex diseases / / 17554300 rs422779 chr4 167220658 A T 7.35E-04 Multiple complex diseases / / 17554300 rs420844 chr4 167223366 G A,T 4.76E-04 Multiple complex diseases / / 17554300 rs10517897 chr4 167284784 G T 5.34E-04 Diabetic retinopathy / / 20871662 rs2199226 chr4 167296709 G A 2.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17635075 chr4 167343939 A G 8.00E-06 Obesity-related traits / / 23251661 rs2131247 chr4 167347496 C T 5.76E-04 Coronary Artery Disease / / 17634449 rs1492523 chr4 167352346 C T 7.88E-04 Type 2 diabetes / / 17463246 rs1492523 chr4 167352346 C T 4.49E-04 Smoking cessation / / 24665060 rs4691276 chr4 167359900 C T 2.58E-04 Type 2 diabetes / / 17463246 rs17518771 chr4 167380513 G C 4.27E-04 Type 2 diabetes / / 17463246 rs10857379 chr4 167400016 A G 3.31E-04 Smoking cessation / / 24665060 rs1388886 chr4 167412572 C T 4.89E-05 Blood Pressure / / pha003040 rs1388886 chr4 167412572 C T 2.90E-06 Blood Pressure / / pha003050 rs11100654 chr4 167413008 T C 2.05E-05 Blood Pressure / / pha003040 rs11100654 chr4 167413008 T C 5.30E-05 Blood Pressure / / pha003048 rs11100654 chr4 167413008 T C 2.90E-06 Blood Pressure / / pha003050 rs978230 chr4 167422116 C T 8.78E-04 Alcohol dependence / / 24277619 rs1388884 chr4 167433177 G A 6.20E-04 Heart Failure / / pha002884 rs1388884 chr4 167433177 G A 1.69E-05 Blood Pressure / / pha003040 rs1388884 chr4 167433177 G A 4.57E-06 Blood Pressure / / pha003050 rs875439 chr4 167448512 A G 2.35E-04 Multiple complex diseases / / 17554300 rs875440 chr4 167448957 C G 2.65E-04 Multiple complex diseases / / 17554300 rs12506794 chr4 167454287 C T 7.64E-04 Alcohol dependence / / 24277619 rs11941399 chr4 167455493 G A 1.00E-06 Capecitabine sensitivity / / 22864933 rs6845804 chr4 167490086 G C 3.98E-04 Type 2 diabetes / / 17463246 rs4691296 chr4 167500615 C A 1.66E-05 Blood Pressure / / pha003050 rs6536987 chr4 167528623 A G 1.25E-04 Alcohol dependence / / 24277619 rs10007526 chr4 167606779 T C 2.00E-05 Urinary metabolites / / 21572414 rs9990895 chr4 167633858 C T 1.90E-05 Urinary metabolites / / 21572414 rs954217 chr4 167634639 A T 1.90E-05 Urinary metabolites / / 21572414 rs2318484 chr4 167662287 C A 2.40E-05 Urinary metabolites SPOCK3 intron 21572414 rs6811155 chr4 167689983 T C 5.39E-04 Suicide attempts in bipolar disorder SPOCK3 intron 21423239 rs17052602 chr4 167714310 A G 6.18E-04 Smoking cessation SPOCK3 intron 24665060 rs41369447 chr4 167725156 A G 3.62E-05 Odorant perception SPOCK3 intron 23910658 rs17519960 chr4 167727185 G C 2.74E-04 Type 2 diabetes SPOCK3 intron 17463246 rs10034594 chr4 167730577 C A 2.16E-04 Smoking cessation SPOCK3 intron 24665060 rs7660401 chr4 167780915 T C 1.52E-04 Birth weight SPOCK3 intron 17255346 rs9996973 chr4 167801275 T C 4.20E-04 Type 2 diabetes SPOCK3 intron 17463246 rs9997140 chr4 167801478 T C 4.20E-04 Type 2 diabetes SPOCK3 intron 17463246 rs17520371 chr4 167801983 C G 4.14E-04 Type 2 diabetes SPOCK3 intron 17463246 rs10517907 chr4 167814606 C T 2.00E-04 Birth weight SPOCK3 intron 17255346 rs10014713 chr4 167816995 G C 4.49E-04 Type 2 diabetes SPOCK3 intron 17463246 rs12646167 chr4 167817347 G A 3.54E-04 Multiple complex diseases SPOCK3 intron 17554300 rs2010146 chr4 167917926 T C 2.15E-05 Multiple complex diseases SPOCK3 intron 17554300 rs2010146 chr4 167917926 T C 4.30E-05 Endometriosis SPOCK3 intron 21151130 rs10517919 chr4 167962448 G A 4.63E-04 Type 2 diabetes SPOCK3 intron 17463246 rs12505847 chr4 168013069 A C 2.20E-05 Iron levels SPOCK3 intron 21208937 rs815212 chr4 168036224 C T 3.66E-05 Height SPOCK3 intron pha003010 rs815217 chr4 168039440 G A 7.33E-05 Height SPOCK3 intron pha003010 rs1079310 chr4 168076695 G A 3.79E-05 Height SPOCK3 intron pha003010 rs10213065 chr4 168118840 C A 7.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPOCK3 intron 20877124 rs7683098 chr4 168137979 T C 1.10E-05 Urinary metabolites SPOCK3 intron 21572414 rs9312517 chr4 168139380 A G 3.00E-06 Obesity-related traits SPOCK3 intron 23251661 rs9312517 chr4 168139380 A G 8.00E-07 Obesity-related traits SPOCK3 intron 23251661 rs7657608 chr4 168154181 C T 2.96E-05 Attention deficit hyperactivity disorder SPOCK3 intron 18980221 rs7657608 chr4 168154181 C T 2.65E-05 Attention deficit hyperactivity disorder SPOCK3 intron pha002875 rs11933479 chr4 168167952 G T 2.90E-05 Urinary metabolites / / 21572414 rs13134784 chr4 168169633 T G 2.30E-05 Urinary metabolites / / 21572414 rs17522315 chr4 168190916 C T 1.97E-05 Personality dimensions / / 22628180 rs11132983 chr4 168256989 C A 1.48E-05 Schizophrenia / / 24253340 rs13111850 chr4 168264249 C T 3.00E-11 Immune reponse to smallpox (secreted IL-10) / / 22610502 rs17053218 chr4 168294976 A G 8.49E-05 Schizophrenia / / 24253340 rs6854438 chr4 168375863 T G 3.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12646941 chr4 168390248 T C 8.96E-04 Type 2 diabetes / / 17463246 rs9790358 chr4 168406872 G A 8.40E-06 Urinary metabolites / / 21572414 rs1160487 chr4 168430822 T A 2.10E-05 Urinary metabolites / / 21572414 rs10517942 chr4 168431604 T C 1.80E-05 Urinary metabolites / / 21572414 rs17053323 chr4 168433754 A G 9.30E-04 Multiple complex diseases / / 17554300 rs17053323 chr4 168433754 A G 5.37E-05 IgE levels in asthmatics / / 23967269 rs1120854 chr4 168455953 C T 1.00E-05 Urinary metabolites / / 21572414 rs7668194 chr4 168472046 T G 4.50E-06 Urinary metabolites / / 21572414 rs872946 chr4 168520792 A G 7.68E-04 Type 2 diabetes / / 17463246 rs7657818 chr4 168523786 A G 4.85E-05 Type 2 diabetes / / 17463246 rs1518179 chr4 168534035 G T 7.86E-04 Multiple complex diseases / / 17554300 rs1304665 chr4 168539066 T C 7.89E-04 Multiple complex diseases / / 17554300 rs1518182 chr4 168544111 T C 5.16E-04 Multiple complex diseases / / 17554300 rs10866384 chr4 168565471 T C 3.08E-04 Type 2 diabetes / / 17463246 rs6850404 chr4 168576599 A C 6.03E-04 Multiple complex diseases / / 17554300 rs11936099 chr4 168579301 C T 1.79E-04 Multiple complex diseases / / 17554300 rs13129385 chr4 168585227 C T 3.50E-04 Type 2 diabetes / / 17463246 rs7677398 chr4 168586326 T C 3.00E-04 Type 2 diabetes / / 17463246 rs13130886 chr4 168588255 G T 6.60E-04 Multiple complex diseases / / 17554300 rs7674967 chr4 168591546 A G 4.18E-04 Type 2 diabetes / / 17463246 rs11131749 chr4 168592133 G A 1.18E-04 Type 2 diabetes / / 17463246 rs11131750 chr4 168592174 C T 5.63E-04 Type 2 diabetes / / 17463246 rs12642843 chr4 168592289 C T 5.78E-05 Tunica Media / / pha003034 rs6552196 chr4 168602424 A G 0.000739 Salmonella-induced pyroptosis / / 22837397 rs7683366 chr4 168610160 T C 0.0000928 Salmonella-induced pyroptosis / / 22837397 rs10014562 chr4 168619280 G A 4.49E-04 Type 2 diabetes / / 17463246 rs1518176 chr4 168635030 G A 9.27E-04 Multiple complex diseases / / 17554300 rs7656265 chr4 168635180 C T 7.48E-06 Retinopathy in non-diabetics / / 23393555 rs41508747 chr4 168636549 C T 8.38E-04 Multiple complex diseases / / 17554300 rs1850579 chr4 168643806 G A 6.39E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12511498 chr4 168653597 G C 2.08E-04 Coronary heart disease / / 21606135 rs4331802 chr4 168656374 T G 1.18E-05 Coronary heart disease / / 21606135 rs7686609 chr4 168658931 A G 8.17E-05 Coronary heart disease / / 21606135 rs11131794 chr4 168660101 A G 5.37E-04 Multiple complex diseases / / 17554300 rs11131794 chr4 168660101 A G 3.43E-06 Coronary heart disease / / 21606135 rs12511577 chr4 168666375 C T 2.04E-04 Multiple complex diseases / / 17554300 rs6552243 chr4 168679351 G A 9.29E-05 Multiple complex diseases / / 17554300 rs4560441 chr4 168709618 C T 9.32E-04 Multiple complex diseases / / 17554300 rs1838509 chr4 168743638 T C 1.43E-05 Gaucher disease severity / / 22388998 rs1444943 chr4 168786912 G A 3.71E-05 Parkinson's disease / / 21248740 rs304347 chr4 168820221 C T 2.72E-05 Parkinson's disease / / 21248740 rs10014961 chr4 168823272 A G 4.28E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs10014961 chr4 168823272 A G 3.11E-05 Parkinson's disease / / 21248740 rs440380 chr4 168823765 A G 9.76E-05 Parkinson's disease / / 21248740 rs7685473 chr4 168888096 G A 4.00E-06 Prostate cancer / / 21743057 rs11944588 chr4 169032483 A G 8.33E-05 Orofacial clefts ANXA10 intron 22419666 rs9991416 chr4 169041179 A G 1.60E-05 Response to lithium treatment in bipolar disorder ANXA10 intron 19448189 rs2292734 chr4 169085593 C T 5.62E-04 Cognition,early reading ability ANXA10 intron 17684495 rs610495 chr4 169096954 G A 3.83E-04 Tourette syndrome ANXA10 intron 22889924 rs477897 chr4 169098914 A G 3.10E-04 Tourette syndrome ANXA10 cds-synon 22889924 rs9685866 chr4 169134128 T C 3.56E-04 Aortic root size / / 21223598 rs1378223 chr4 169168329 A G 3.96E-05 Schizophrenia DDX60 intron 24253340 rs522085 chr4 169244726 G A 8.20E-05 Serum metabolites / / 19043545 rs13118834 chr4 169282854 G C 4.90E-05 Response to lithium treatment in bipolar disorder DDX60L intron 19448189 rs13110927 chr4 169299528 T C 3.00E-05 Breast cancer DDX60L missense 17529967 rs61740720 chr4 169300938 C T 0.00016 Breast cancer DDX60L missense 23555315 rs9631781 chr4 169323445 G A 9.42E-05 Cognitive impairment induced by topiramate DDX60L intron 22091778 rs9284933 chr4 169323978 G A 5.52E-05 Cognitive impairment induced by topiramate DDX60L intron 22091778 rs17649898 chr4 169325886 C T 1.23E-05 Body mass index DDX60L intron 21701565 rs17649898 chr4 169325886 C T 3.17E-06 Body mass index DDX60L intron 21701565 rs17649898 chr4 169325886 C T 9.38E-06 Kawasaki disease DDX60L intron 22446961 rs17612303 chr4 169330221 T G 2.96E-06 Body mass index DDX60L intron 21701565 rs17612303 chr4 169330221 T G 7.99E-06 Body mass index DDX60L intron 21701565 rs17054112 chr4 169330306 T C 5.00E-06 Urinary metabolites DDX60L intron 21572414 rs17612333 chr4 169330384 C A 1.98E-06 Body mass index DDX60L intron 21701565 rs17612333 chr4 169330384 C A 7.64E-06 Body mass index DDX60L intron 21701565 rs11938927 chr4 169333245 C G 1.15E-05 Body mass index DDX60L intron 21701565 rs11938927 chr4 169333245 C G 4.75E-05 Body mass index DDX60L intron 21701565 rs6820060 chr4 169333837 T G 3.04E-06 Body mass index DDX60L intron 21701565 rs6820060 chr4 169333837 T G 8.99E-06 Body mass index DDX60L intron 21701565 rs6820060 chr4 169333837 T G 9.26E-05 Kawasaki disease DDX60L intron 22446961 rs1963569 chr4 169338520 A C 8.00E-06 Obesity-related traits DDX60L intron 23251661 rs61740705 chr4 169343044 A G 0.00023 Breast cancer DDX60L missense 23555315 rs2634971 chr4 169350278 C T 8.52E-05 Blood Pressure DDX60L intron pha003043 rs2451039 chr4 169360558 A G 4.27E-04 Response to taxane treatment (placlitaxel) DDX60L intron 23006423 rs2710833 chr4 169409958 T C 6.00E-07 Non-alcoholic fatty liver disease histology (AST) / / 20708005 rs2710833 chr4 169409958 T C 2.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11939452 chr4 169439280 C T 3.09E-04 Alzheimer's disease PALLD intron 24755620 rs7661751 chr4 169440368 A G 2.62E-04 Alzheimer's disease PALLD intron 24755620 rs6552873 chr4 169441779 C T 2.83E-04 Alzheimer's disease PALLD intron 24755620 rs6552874 chr4 169441797 A T 2.83E-04 Alzheimer's disease PALLD intron 24755620 rs6848015 chr4 169448109 C G 5.17E-05 Bipolar disorder PALLD intron 18317468 rs9312333 chr4 169448628 C T 2.02E-04 Alzheimer's disease PALLD intron 24755620 rs17054309 chr4 169454317 C A 1.10E-05 Urinary metabolites PALLD intron 21572414 rs10031058 chr4 169456787 G A 3.54E-04 Alzheimer's disease PALLD intron 24755620 rs17541301 chr4 169475517 G A 2.40E-05 Urinary metabolites PALLD intron 21572414 rs11132322 chr4 169476590 C T 4.09E-05 Bipolar disorder PALLD intron 21771265 rs17613517 chr4 169486507 G A 2.60E-05 Urinary metabolites PALLD intron 21572414 rs17650886 chr4 169500402 G A 3.99E-04 Prostate cancer mortality PALLD intron 20978177 rs11935367 chr4 169508428 G A 9.50E-04 Alzheimer's disease PALLD intron 24755620 rs17054375 chr4 169514438 G A 3.50E-04 Multiple complex diseases PALLD intron 17554300 rs4435706 chr4 169515675 G C 3.02E-04 Hearing function PALLD intron 17255346 rs4144994 chr4 169517130 A G 8.07E-04 Insulin resistance PALLD intron 21901158 rs4518206 chr4 169526020 G C 7.44E-04 Alzheimer's disease PALLD intron 24755620 rs17054392 chr4 169530258 T C 3.00E-06 Response to iloperidone treatment (QT prolongation) PALLD intron 18521091 rs2723696 chr4 169551542 A G 4.52E-04 Response to cytadine analogues (cytosine arabinoside) PALLD intron 24483146 rs2723696 chr4 169551542 A G 3.80E-04 Smoking initiation PALLD intron 24665060 rs12643131 chr4 169567817 G A 4.74E-04 Type 2 diabetes PALLD intron 17463246 rs6846708 chr4 169586731 A G 1.50E-05 Paclitaxel-induced neuropathy PALLD intron 23776197 rs17054463 chr4 169603230 G A 5.63E-04 Type 2 diabetes PALLD intron 17463246 rs10013443 chr4 169606920 T C 4.37E-27 Narcolepsy PALLD intron 19629137 rs6824965 chr4 169621191 G A 9.67E-05 Non-alcoholic fatty liver disease histology (other) PALLD intron 20708005 rs7680228 chr4 169626430 A C 9.47E-05 Non-alcoholic fatty liver disease histology (other) PALLD intron 20708005 rs9312352 chr4 169627964 A G 1.26E-04 Type 2 diabetes PALLD intron 17846125 rs9884230 chr4 169641425 C T 5.26E-04 Endometrial cancer PALLD intron 24096698 rs11935476 chr4 169643668 C T 2.79E-04 Obesity (extreme) PALLD intron 21935397 rs2062591 chr4 169655480 G A,C 2.32E-04 Obesity (extreme) PALLD intron 21935397 rs13122019 chr4 169658315 A G 1.97E-04 Obesity (extreme) PALLD intron 21935397 rs2320079 chr4 169663130 T C 1.96E-04 Obesity (extreme) PALLD intron 21935397 rs2320080 chr4 169663164 T G 5.54E-05 Obesity (extreme) PALLD intron 21935397 rs6811238 chr4 169663615 T G 1.96E-04 Obesity (extreme) PALLD intron 21935397 rs7657509 chr4 169665244 A C 1.96E-04 Obesity (extreme) PALLD intron 21935397 rs955911 chr4 169667179 T G 1.96E-04 Obesity (extreme) PALLD intron 21935397 rs6857155 chr4 169667766 C T 1.96E-04 Obesity (extreme) PALLD intron 21935397 rs1392756 chr4 169668821 A G 1.89E-04 Obesity (extreme) PALLD intron 21935397 rs11132458 chr4 169669361 C A 1.84E-04 Obesity (extreme) PALLD intron 21935397 rs9654305 chr4 169669891 C T 1.77E-04 Obesity (extreme) PALLD intron 21935397 rs6854697 chr4 169672489 C A 1.79E-04 Obesity (extreme) PALLD intron 21935397 rs6831359 chr4 169672630 A G 8.25E-04 Alcohol dependence PALLD intron 21314694 rs1039385 chr4 169673677 G A 1.87E-04 Obesity (extreme) PALLD intron 21935397 rs2247733 chr4 169694079 T C 4.27E-04 Stroke PALLD intron pha002887 rs999958 chr4 169698873 C A 5.47E-05 Blood pressure PALLD intron 21909110 rs17614715 chr4 169701578 T A 2.88E-04 Multiple complex diseases PALLD intron 17554300 rs13110398 chr4 169702232 A G 4.28E-04 Multiple complex diseases PALLD intron 17554300 rs13134292 chr4 169702367 G A 8.26E-04 Multiple complex diseases PALLD intron 17554300 rs13116423 chr4 169702402 T C 2.73E-04 Multiple complex diseases PALLD intron 17554300 rs924511 chr4 169702964 A G 2.92E-04 Multiple complex diseases PALLD intron 17554300 rs924511 chr4 169702964 A G 3.25E-05 Cognitive impairment induced by topiramate PALLD intron 22091778 rs12331592 chr4 169708457 T C 4.47E-05 Cognitive impairment induced by topiramate PALLD intron 22091778 rs10005789 chr4 169740931 A G 3.52E-05 Hemoglobin PALLD intron pha003096 rs10005789 chr4 169740931 A G 9.80E-05 Hematocrit PALLD intron pha003097 rs1392750 chr4 169745078 C T 2.44E-05 Hemoglobin PALLD intron pha003096 rs1392750 chr4 169745078 C T 4.64E-05 Hematocrit PALLD intron pha003097 rs12641626 chr4 169760004 G A 2.50E-05 Urinary metabolites PALLD intron 21572414 rs973990 chr4 169763252 C T 4.89E-04 Lung function (forced expiratory volume in 1 second) PALLD intron 24023788 rs7688533 chr4 169766595 G A 1.00E-04 Cognitive impairment induced by topiramate PALLD intron 22091778 rs4692553 chr4 169769793 T C 6.17E-05 Insulin-related traits PALLD intron 19902172 rs13114906 chr4 169771612 G A 4.47E-05 Height PALLD intron pha003010 rs13114906 chr4 169771612 G A 3.51E-06 Height PALLD intron pha003011 rs2062588 chr4 169772342 T C 6.60E-05 Height PALLD intron pha003011 rs6852229 chr4 169773066 G A 3.70E-06 Urinary metabolites PALLD intron 21572414 rs7685014 chr4 169774552 A G 1.60E-05 Urinary metabolites PALLD intron 21572414 rs7682227 chr4 169778942 T A 2.88E-05 Multiple complex diseases PALLD intron 17554300 rs4441723 chr4 169785081 C T 9.30E-06 Urinary metabolites PALLD intron 21572414 rs7690353 chr4 169788148 A G 3.38E-05 Height PALLD intron pha003010 rs1500802 chr4 169789254 G C 1.00E-05 Urinary metabolites PALLD intron 21572414 rs12643097 chr4 169801952 G A 2.67E-05 Cleft lip PALLD intron 20436469 rs12643097 chr4 169801952 G A 3.77E-05 Height PALLD intron pha003010 rs2047633 chr4 169815472 T G 5.61E-05 Bipolar disorder PALLD intron 17486107 rs6819031 chr4 169827618 G A 5.75E-04 Iron levels PALLD intron pha002876 rs1500795 chr4 169828862 T C 8.56E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PALLD intron 20031582 rs1500795 chr4 169828862 T C 8.86E-05 Height PALLD intron pha003010 rs6817551 chr4 169829345 A G 1.20E-05 Urinary metabolites PALLD intron 21572414 rs6817551 chr4 169829345 A G 7.95E-05 Height PALLD intron pha003010 rs3733656 chr4 169846255 T C 7.89E-04 Type 2 diabetes PALLD intron 17463246 rs3733656 chr4 169846255 T C 4.10E-06 Urinary metabolites PALLD intron 21572414 rs13116548 chr4 169874620 T G 8.30E-06 Urinary metabolites / / 21572414 rs17543378 chr4 169874986 A C 3.57E-05 Height / / pha003011 rs10023864 chr4 169877173 A G 2.20E-05 Urinary metabolites / / 21572414 rs1531254 chr4 169881245 T C 1.40E-05 Urinary metabolites / / 21572414 rs11733251 chr4 169881917 A C,T 4.39E-04 Type 2 diabetes / / 17463246 rs6831613 chr4 169892793 G C 5.80E-06 Urinary metabolites / / 21572414 rs10518037 chr4 169899023 T C 9.28E-04 Type 2 diabetes / / 17463246 rs6843588 chr4 169899960 G A 1.11E-07 Biliary atresia / / 20460270 rs11732949 chr4 169900720 C T 4.80E-04 Type 2 diabetes / / 17463246 rs11732949 chr4 169900720 C T 4.70E-06 Urinary metabolites / / 21572414 rs2331450 chr4 169901225 A G 1.80E-05 Urinary metabolites / / 21572414 rs898002 chr4 169917245 T C 5.25E-05 Height CBR4 intron pha003010 rs1870306 chr4 169923672 T G 4.90E-04 Type 2 diabetes CBR4 intron 17463246 rs2877380 chr4 169928842 G T 1.60E-05 Height CBR4 missense pha003010 rs2877380 chr4 169928842 G T 3.90E-05 Height CBR4 missense pha003011 rs4692684 chr4 169934205 C G 7.10E-06 Urinary metabolites / / 21572414 rs1458292 chr4 169935881 G A 1.70E-05 Urinary metabolites / / 21572414 rs6826001 chr4 169946694 G T 3.60E-04 Myocardial Infarction / / pha002883 rs11132793 chr4 169948000 C T 6.18E-04 Multiple complex diseases / / 17554300 rs10518033 chr4 169948058 C G 6.73E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10014681 chr4 169948140 C T 1.77E-05 Multiple complex diseases / / 17554300 rs10014681 chr4 169948140 C T 3.57E-05 Odorant perception / / 23910658 rs752625 chr4 169971917 G A 4.06E-04 Type 2 diabetes / / 17463246 rs10009678 chr4 169972311 T C 0.0000309 Panic disorder / / 23149450 rs10009678 chr4 169972311 T C 3.09E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs4692694 chr4 169991158 A G 1.47E-04 HIV-1 viral setpoint / / 17641165 rs13139803 chr4 170015977 C T 8.74E-04 Alzheimer's disease SH3RF1 UTR-3 24755620 rs17544108 chr4 170036090 T C 4.70E-04 Alzheimer's disease SH3RF1 intron 24755620 rs10017472 chr4 170037323 G A 9.66E-05 Parkinson's disease SH3RF1 intron 17052657 rs17544115 chr4 170039555 C G 3.18E-04 Type 2 diabetes SH3RF1 intron 17463246 rs17709556 chr4 170040583 A C 4.17E-04 Alzheimer's disease SH3RF1 intron 24755620 rs10023601 chr4 170052555 A T 9.66E-05 Parkinson's disease SH3RF1 intron 17052657 rs7660681 chr4 170072418 A G 2.47E-04 Parkinson's disease SH3RF1 intron 17052657 rs2660432 chr4 170075171 T C 2.24E-04 Parkinson's disease SH3RF1 intron 17052657 rs10024401 chr4 170077540 A G 6.18E-05 Parkinson's disease SH3RF1 intron 17052657 rs10518039 chr4 170077789 A G 1.42E-04 Parkinson's disease SH3RF1 cds-synon 17052657 rs17544477 chr4 170101700 G A 3.97E-05 HDL cholesterol SH3RF1 intron pha003075 rs2706740 chr4 170115171 G A 7.24E-05 HDL cholesterol SH3RF1 intron pha003075 rs6847734 chr4 170138985 T C 0.0000674 Tuberculosis with early age of onset SH3RF1 intron 22551897 rs1876398 chr4 170146632 G A 2.57E-04 Epilepsy SH3RF1 intron 22116939 rs2706727 chr4 170147015 C T 5.83E-05 HDL cholesterol SH3RF1 intron pha003075 rs2660404 chr4 170149701 A C 5.83E-05 HDL cholesterol SH3RF1 intron pha003075 rs10518041 chr4 170165979 T C 6.68E-06 HDL cholesterol SH3RF1 intron pha003075 rs1876396 chr4 170166749 C T 1.99E-04 Epilepsy SH3RF1 intron 22116939 rs12650909 chr4 170192890 G A 8.68E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs13112591 chr4 170203848 A C 1.33E-04 Epilepsy / / 22116939 rs992939 chr4 170208954 A G 4.33E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4295223 chr4 170230174 A G 2.31E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs13128807 chr4 170232880 G A 1.41E-05 HDL cholesterol / / pha003075 rs13128807 chr4 170232880 G A 7.30E-05 Leukocyte Counts / / pha003091 rs10017932 chr4 170237660 G A 6.69E-06 Schizophrenia / / 19571811 rs6849776 chr4 170292992 A G 7.08E-04 Stroke / / pha002887 rs10866338 chr4 170302498 C T 2.57E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4334719 chr4 170362151 T C 1.70E-05 Urinary metabolites NEK1 intron 21572414 rs11931954 chr4 170464440 T C 8.21E-04 Response to taxane treatment (placlitaxel) NEK1 intron 23006423 rs13435226 chr4 170550825 T C 2.95E-04 Smoking initiation CLCN3 intron 24665060 rs17659581 chr4 170559440 T C 2.58E-04 Response to taxane treatment (placlitaxel) CLCN3 intron 23006423 rs13120831 chr4 170562598 G A 2.82E-05 HDL cholesterol CLCN3 intron pha003075 rs6857404 chr4 170569172 C T 9.59E-06 Coronary arterial lesions in patients with Kawasaki disease CLCN3 intron 23677057 rs4692741 chr4 170651797 A T 7.20E-05 Type 2 diabetes C4orf27 intron 17463246 rs10021555 chr4 170665961 T C 1.00E-04 Lymphocyte counts C4orf27 intron 22286170 rs1500929 chr4 170731116 C T 6.48E-04 Multiple complex diseases / / 17554300 rs11132822 chr4 170754012 A G 1.10E-11 Multiple complex diseases / / 17554300 rs4634183 chr4 170834427 G A 2.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs11723530 chr4 170880883 G A 4.00E-06 Myopia (pathological) LOC100506085 intron 23049088 rs12650424 chr4 170975204 T C 2.35E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs2466990 chr4 170993771 A G 4.94E-05 Alcohol withdrawal symptoms AADAT intron 22072270 rs963660 chr4 170995066 C T 1.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) AADAT intron 20877124 rs2622069 chr4 171001659 C G 3.47E-06 Multiple complex diseases AADAT intron 17554300 rs11726248 chr4 171053519 G A 4.00E-07 Thyroid hormone levels / / 23408906 rs11726248 chr4 171053519 G A 5.00E-09 Thyroid hormone levels / / 23408906 rs519847 chr4 171055490 A G 3.42E-04 Smoking initiation / / 24665060 rs17629339 chr4 171109394 T C 9.83E-04 Type 2 diabetes / / 17463246 rs10009954 chr4 171109611 A T 5.62E-04 Smoking initiation / / 24665060 rs1718802 chr4 171121333 A T 1.21E-04 Smoking initiation / / 24665060 rs2687227 chr4 171180425 T A 6.68E-05 Bipolar disorder / / 18317468 rs2140146 chr4 171183290 G A 6.07E-05 Bipolar disorder / / 18317468 rs2030549 chr4 171191191 A T 2.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs7654083 chr4 171194143 C A 6.24E-05 Bipolar disorder / / 18317468 rs7698213 chr4 171197420 A G 5.53E-05 Bipolar disorder / / 18317468 rs17055545 chr4 171203364 T G 4.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs13109743 chr4 171311501 T A 6.62E-05 Sarcoidosis / / 19165924 rs13109743 chr4 171311501 T A 1.15E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2141474 chr4 171312585 C G 7.48E-04 Multiple complex diseases / / 17554300 rs7674021 chr4 171315144 C T 4.64E-04 Multiple complex diseases / / 17554300 rs2612407 chr4 171336251 A C 8.30E-06 Urinary metabolites / / 21572414 rs12504091 chr4 171339819 A G 3.91E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1609380 chr4 171340897 C T 8.82E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2135900 chr4 171388510 A G 8.33E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2202722 chr4 171391594 T C 8.33E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1581676 chr4 171402225 A G 2.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2612420 chr4 171403782 A G 4.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1507680 chr4 171409039 C T 9.34E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2135899 chr4 171413205 T C 1.37E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1022004 chr4 171413827 C T 1.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13120637 chr4 171418232 C A 8.08E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2020059 chr4 171418411 A C 3.19E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2661079 chr4 171423826 G T 1.80E-05 Monocyte chemoattractant protein-1 / / pha003071 rs1507699 chr4 171442296 T A 1.10E-05 Iron status biomarkers / / 19084217 rs1507696 chr4 171448234 T C 9.29E-04 Coronary heart disease / / 21606135 rs2612412 chr4 171459354 A G 4.03E-04 Coronary heart disease / / 21606135 rs413812 chr4 171509449 T C 7.91E-09 Esophageal cancer HSP90AA6P intron 21642993 rs368771 chr4 171513737 C A 5.07E-04 Coronary heart disease HSP90AA6P intron 21606135 rs368771 chr4 171513737 C A 1.46E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines HSP90AA6P intron 21844884 rs4692845 chr4 171535281 G A 5.15E-04 Coronary heart disease / / 21606135 rs1348330 chr4 171552857 T C 2.79E-04 Coronary heart disease / / 21606135 rs10030592 chr4 171590438 C T 2.14E-04 Multiple complex diseases / / 17554300 rs10030592 chr4 171590438 C T 4.95E-05 Taste perception / / 22132133 rs7669074 chr4 171590908 G T 7.15E-04 Multiple complex diseases / / 17554300 rs4591556 chr4 171594387 T G 4.40E-04 Taste perception / / 22132133 rs7663379 chr4 171634933 T C 5.47E-05 Epilepsy / / 22116939 rs1403211 chr4 171640683 C T 8.23E-06 Rheumatoid arthritis / / 19503088 rs1533835 chr4 171645207 G T 3.61E-04 Coronary heart disease / / 21606135 rs9312490 chr4 171651895 A G 1.88E-05 Cognitive impairment induced by topiramate / / 22091778 rs17730495 chr4 171659813 G A 9.97E-04 Multiple complex diseases / / 17554300 rs2332027 chr4 171672038 G A 8.84E-05 Waist-Hip Ratio / / pha003013 rs10084822 chr4 171680223 T G 2.65E-05 Cognitive impairment induced by topiramate / / 22091778 rs10084822 chr4 171680223 T G 6.79E-05 Cognitive impairment induced by topiramate / / 22091778 rs17056206 chr4 171733181 T C 5.65E-05 Multiple complex diseases / / 17554300 rs34572584 chr4 171790532 G T 2.15E-07 Body mass index / / 19584900 rs34572584 chr4 171790532 G T 2.52E-06 Body mass index / / 19584900 rs7673440 chr4 171807535 A C 2.09E-04 Age-related macular degeneration / / 22125219 rs7673440 chr4 171807535 A C 3.66E-04 Smoking initiation / / 24665060 rs17056316 chr4 171813485 A G 5.00E-09 Hepatitis B / / 24162738 rs2332074 chr4 171821267 C T 4.92E-04 Smoking initiation / / 24665060 rs1368005 chr4 171865495 G T 4.10E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs6831331 chr4 171869645 C T 3.52E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs6856523 chr4 171869735 A C 3.52E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs13121066 chr4 171872498 G A 2.67E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs13122956 chr4 171872654 C T 3.50E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs13128132 chr4 171879302 G A 1.73E-04 Birth weight / / 17255346 rs13128132 chr4 171879302 G A 2.67E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1223314 chr4 171880122 A G 3.47E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1560560 chr4 171880580 A C,G,T 2.67E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs970432 chr4 171881521 C A 3.42E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs970431 chr4 171881792 C T 3.40E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs970430 chr4 171881872 C A 3.42E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1236448 chr4 171882080 C T 8.14E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2567965 chr4 171883321 T C 3.42E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs17245674 chr4 171884710 G A 8.14E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2567960 chr4 171885533 T C 8.16E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2567959 chr4 171886287 A G 3.40E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs967616 chr4 171888222 G A 2.00E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs17186473 chr4 171889465 C T 3.60E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2567957 chr4 171889623 G A 1.94E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2567956 chr4 171889742 C T 8.14E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs17186543 chr4 171890171 C T 8.16E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2661923 chr4 171890667 C A 8.13E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs13139444 chr4 171890676 G A 7.89E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2567952 chr4 171893150 C T 8.06E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2661917 chr4 171893393 C T 8.06E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs12331863 chr4 171897197 G A 8.33E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1396323 chr4 171905607 G A 1.10E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs7681844 chr4 171906096 C A 1.11E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs13148831 chr4 171909506 G T 1.13E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2332086 chr4 171911181 G A 1.13E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs7682721 chr4 171914470 T G 1.14E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs13126363 chr4 171919389 G A 2.24E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1546445 chr4 171921530 A G 3.74E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1605651 chr4 171926337 A G 1.28E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs13115632 chr4 171927813 A G 1.28E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs11132865 chr4 171928371 C A 1.28E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs4692627 chr4 171929062 T C 1.28E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1396325 chr4 171931201 G A 1.28E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs6858075 chr4 171935468 A G 1.28E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1508507 chr4 171936205 A G 1.28E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1508508 chr4 171936344 C T 4.18E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9968437 chr4 171936831 C T 1.27E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs25512 chr4 171938957 G T 1.28E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs25511 chr4 171938984 T C 1.27E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs25510 chr4 171939004 A G 1.28E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs12648447 chr4 171939094 T C 1.27E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs6849128 chr4 171939426 A G 1.28E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs6811103 chr4 171939600 T C 1.17E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs6811337 chr4 171939724 T C 8.91E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs6553556 chr4 171939951 A G 1.21E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs7673070 chr4 171940057 C T 1.21E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs13151801 chr4 171940284 C T 1.21E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs10012648 chr4 171940465 C A 1.21E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs6812562 chr4 171940486 A G 1.21E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs6817733 chr4 171940502 T C 6.75E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs13138342 chr4 171940605 T C 1.21E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs11735676 chr4 171941088 T C 1.21E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs7340816 chr4 171943010 A C 1.51E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs6827582 chr4 171943217 A G 1.17E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs17246620 chr4 171963260 A G 9.50E-06 Lupus nephritis in systemic lupus erythematosus LOC100506122 intron 24925725 rs17187123 chr4 171969779 G A 1.36E-05 Lupus nephritis in systemic lupus erythematosus LOC100506122 intron 24925725 rs17246878 chr4 171972225 C T 1.39E-05 Lupus nephritis in systemic lupus erythematosus LOC100506122 intron 24925725 rs1508296 chr4 171972374 T C 1.49E-05 Lupus nephritis in systemic lupus erythematosus LOC100506122 intron 24925725 rs13110268 chr4 171974687 A G 1.50E-05 Lupus nephritis in systemic lupus erythematosus LOC100506122 intron 24925725 rs13110811 chr4 171983768 C T 4.35E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs7671063 chr4 172034857 G A 1.60E-05 Urinary metabolites / / 21572414 rs11725022 chr4 172056196 C A 5.80E-06 Urinary metabolites / / 21572414 rs10520201 chr4 172104856 G A 4.35E-04 Diabetic retinopathy / / 20871662 rs9991990 chr4 172144100 T A 8.83E-04 Type 2 diabetes / / 17463246 rs9991990 chr4 172144100 T A 1.41E-04 Multiple complex diseases / / 17554300 rs6830239 chr4 172147796 G A 1.32E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs17249941 chr4 172177809 G A 6.58E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs13435593 chr4 172287657 G A 7.43E-04 Type 2 diabetes / / 17463246 rs17199134 chr4 172325253 A G 8.05E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6832175 chr4 172331641 T C 2.82E-04 Alzheimer's disease (late onset) / / 21379329 rs7694458 chr4 172350228 G A 4.05E-04 Alzheimer's disease (late onset) / / 21379329 rs4692884 chr4 172367775 A G 1.57E-04 Alzheimer's disease (late onset) / / 21379329 rs17056925 chr4 172368442 T G 4.06E-04 Smoking initiation / / 24665060 rs4692885 chr4 172373388 C T 1.59E-04 Alzheimer's disease (late onset) / / 21379329 rs2178299 chr4 172383439 C T 4.73E-04 Alzheimer's disease (late onset) / / 21379329 rs7664076 chr4 172388728 A G 1.62E-04 Birth weight / / 17255346 rs7665693 chr4 172393057 G T 1.11E-04 Smoking initiation / / 24665060 rs4144862 chr4 172405095 T G 2.96E-04 Iron levels / / pha002876 rs1391207 chr4 172413977 A G 3.80E-04 Iron levels / / pha002876 rs6553576 chr4 172486332 A G 8.81E-05 Myocardial Infarction / / pha002883 rs7654240 chr4 172509162 C T 9.92E-05 Birth weight / / 17255346 rs7683440 chr4 172516685 A G 9.20E-05 Triglycerides / / pha002904 rs836028 chr4 172661677 G T 9.51E-04 Multiple complex diseases / / 17554300 rs11722206 chr4 172686095 G T 7.19E-04 Obesity (extreme) / / 21935397 rs580091 chr4 172750974 A G 4.08E-05 Parent of origin effect on language impairment (maternal) GALNTL6 intron 24571439 rs1994306 chr4 172761218 A G 3.56E-04 Birth weight GALNTL6 intron 17255346 rs11132917 chr4 172764187 T G 3.13E-04 Birth weight GALNTL6 intron 17255346 rs11132917 chr4 172764187 T G 5.94E-05 HIV-1 viral setpoint GALNTL6 intron 22174851 rs7691431 chr4 172772005 A G 5.71E-04 Amyotrophic Lateral Sclerosis GALNTL6 intron 17362836 rs7691431 chr4 172772005 A G 2.36E-05 Body Fat Distribution GALNTL6 intron pha003016 rs7691431 chr4 172772005 A G 1.02E-05 Body Fat Distribution GALNTL6 intron pha003017 rs7691431 chr4 172772005 A G 2.61E-05 Body Fat Distribution GALNTL6 intron pha003018 rs332983 chr4 172857022 T C 4.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNTL6 intron 20877124 rs332983 chr4 172857022 T C 5.37E-06 Post-operative nausea and vomiting GALNTL6 intron 21694509 rs7690646 chr4 172868945 G A 9.73E-07 Post-operative nausea and vomiting GALNTL6 intron 21694509 rs184564 chr4 172902011 G A 4.17E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) GALNTL6 intron 24023788 rs13122067 chr4 172904310 C T 2.81E-04 Celiac disease GALNTL6 intron 23936387 rs956998 chr4 172914208 A G 9.35E-05 Major depressive disorder GALNTL6 intron 21621269 rs2135196 chr4 172920376 C T 5.48E-05 Lung function (forced vital capacity) GALNTL6 intron pha003104 rs12645492 chr4 172948884 G A 4.17E-04 Smoking cessation GALNTL6 intron 24665060 rs17057954 chr4 172955489 G A 5.62E-04 Multiple complex diseases GALNTL6 intron 17554300 rs1505483 chr4 172966378 G C 1.00E-04 Prostate cancer GALNTL6 intron 21743057 rs7654286 chr4 172968055 T C 9.32E-05 Body Mass Index GALNTL6 intron pha003022 rs6851464 chr4 172981543 C T 1.44E-05 Blood Pressure GALNTL6 intron pha002903 rs2877689 chr4 172999916 G A 5.97E-04 Smoking cessation GALNTL6 intron 24665060 rs2067512 chr4 173026078 T C 4.51E-05 Coronary Artery Disease GALNTL6 intron 17634449 rs17058064 chr4 173028600 T C 4.01E-05 Coronary Artery Disease GALNTL6 intron 17634449 rs10016776 chr4 173047549 T C 1.20E-04 Alzheimer's disease (late onset) GALNTL6 intron 21379329 rs6553608 chr4 173052098 A C 1.28E-04 Alzheimer's disease (late onset) GALNTL6 intron 21379329 rs3886930 chr4 173083454 T C 1.06E-04 Alzheimer's disease (late onset) GALNTL6 intron 21379329 rs6825169 chr4 173125742 G A 8.33E-05 Body Fat Distribution GALNTL6 intron pha003016 rs41516045 chr4 173129747 G A 9.57E-04 Type 2 diabetes GALNTL6 intron 17463246 rs836326 chr4 173151257 T C 8.75E-05 Type 2 diabetes and other traits GALNTL6 intron 19734900 rs10012505 chr4 173152405 T C 9.34E-04 Multiple complex diseases GALNTL6 intron 17554300 rs2626612 chr4 173214721 T C 3.16E-06 Uric acid levels GALNTL6 intron 21294900 rs2626613 chr4 173214779 A G 3.16E-06 Uric acid levels GALNTL6 intron 21294900 rs111363536 chr4 173215791 A AC 2.81E-06 Uric acid levels GALNTL6 intron 21294900 rs1484022 chr4 173215791 A C 2.81E-06 Uric acid levels GALNTL6 intron 21294900 rs567997701 chr4 173215791 A AC 2.81E-06 Uric acid levels GALNTL6 intron 21294900 rs9997921 chr4 173216873 C T 3.16E-06 Uric acid levels GALNTL6 intron 21294900 rs6553622 chr4 173217227 C T 3.90E-06 Uric acid levels GALNTL6 intron 21294900 rs2626622 chr4 173223883 T G 2.81E-06 Uric acid levels GALNTL6 intron 21294900 rs2054684 chr4 173238445 G A 0.0000324 Amyotrophic lateral sclerosis GALNTL6 intron 23587638 rs333381 chr4 173250321 C G 4.38E-06 Multiple complex diseases GALNTL6 intron 17554300 rs336006 chr4 173360945 G T 9.46E-05 Smoking cessation GALNTL6 intron 18519826 rs10004745 chr4 173394997 C T 1.95E-04 Smoking cessation GALNTL6 intron 18519826 rs10019934 chr4 173405278 C T 9.41E-04 Amyotrophic Lateral Sclerosis GALNTL6 intron 17362836 rs10019934 chr4 173405278 C T 9.55E-05 Alzheimer's disease (late onset) GALNTL6 intron 21379329 rs1995068 chr4 173409387 T C 9.95E-04 Amyotrophic Lateral Sclerosis GALNTL6 intron 17362836 rs1995068 chr4 173409387 T C 6.72E-05 Non-alcoholic fatty liver disease histology (other) GALNTL6 intron 20708005 rs1995068 chr4 173409387 T C 1.90E-04 Alzheimer's disease (late onset) GALNTL6 intron 21379329 rs6553634 chr4 173418304 A G 3.30E-04 Celiac disease GALNTL6 intron 23936387 rs17305821 chr4 173439265 T C 2.29E-04 Alzheimer's disease (late onset) GALNTL6 intron 21379329 rs1455126 chr4 173467522 C G 1.01E-04 Smoking cessation GALNTL6 intron 18519826 rs17307651 chr4 173541485 C T 9.00E-04 Acute lymphoblastic leukemia (childhood) GALNTL6 intron 20189245 rs17307783 chr4 173545377 A G 9.46E-04 Type 2 diabetes GALNTL6 intron 17463246 rs17058705 chr4 173571676 A G 5.00E-04 Acute lymphoblastic leukemia (childhood) GALNTL6 intron 20189245 rs1158684 chr4 173584086 G A 5.00E-04 Acute lymphoblastic leukemia (childhood) GALNTL6 intron 20189245 rs837196 chr4 173586429 T C 2.00E-04 Acute lymphoblastic leukemia (childhood) GALNTL6 intron 20189245 rs1437844 chr4 173596754 T G 7.66E-04 Multiple complex diseases GALNTL6 intron 17554300 rs1437843 chr4 173596949 A C 6.70E-04 Multiple complex diseases GALNTL6 intron 17554300 rs10520242 chr4 173598033 C T 2.00E-04 Acute lymphoblastic leukemia (childhood) GALNTL6 intron 20189245 rs7659511 chr4 173614205 G A 5.00E-04 Acute lymphoblastic leukemia (childhood) GALNTL6 intron 20189245 rs1540470 chr4 173614590 C G 5.00E-04 Acute lymphoblastic leukemia (childhood) GALNTL6 intron 20189245 rs12649426 chr4 173618831 G A 7.00E-04 Acute lymphoblastic leukemia (childhood) GALNTL6 intron 20189245 rs12647340 chr4 173618934 T A 5.00E-04 Acute lymphoblastic leukemia (childhood) GALNTL6 intron 20189245 rs1347700 chr4 173620934 C A 5.00E-04 Acute lymphoblastic leukemia (childhood) GALNTL6 intron 20189245 rs10031202 chr4 173628589 A G 4.06E-04 Multiple complex diseases GALNTL6 intron 17554300 rs1540466 chr4 173635963 T C 4.00E-04 Acute lymphoblastic leukemia (childhood) GALNTL6 intron 20189245 rs17058802 chr4 173643640 A C 4.00E-04 Acute lymphoblastic leukemia (childhood) GALNTL6 intron 20189245 rs4696031 chr4 173750107 C T 4.80E-05 Parkinson's disease (age of onset) GALNTL6 intron 19772629 rs6810619 chr4 173803914 T C 2.99E-04 Rheumatoid arthritis GALNTL6 intron 21452313 rs17059038 chr4 173867325 A G 7.22E-04 Multiple complex diseases GALNTL6 intron 17554300 rs3966014 chr4 174057435 T C 0.000012 VLDL cholesterol particle diameter / / 23263444 rs7669267 chr4 174081834 C T 1.89E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2332655 chr4 174093002 G A 2.46E-04 Type 2 diabetes GALNT7 intron 17463246 rs2332655 chr4 174093002 G A 0.0000134 VLDL cholesterol particle diameter GALNT7 intron 23263444 rs4535319 chr4 174127031 G A 0.00000882 VLDL cholesterol particle diameter GALNT7 intron 23263444 rs10213525 chr4 174129740 A G 0.00000884 VLDL cholesterol particle diameter GALNT7 intron 23263444 rs10001613 chr4 174132146 G A 0.00000969 VLDL cholesterol particle diameter GALNT7 intron 23263444 rs17059215 chr4 174135795 A G 8.30E-04 Multiple complex diseases GALNT7 intron 17554300 rs12503914 chr4 174146026 C T 8.86E-07 Coronary heart disease GALNT7 intron 22319020 rs17059221 chr4 174147508 C T 0.0000101 VLDL cholesterol particle diameter GALNT7 intron 23263444 rs9683937 chr4 174155654 G T 0.0000102 VLDL cholesterol particle diameter GALNT7 intron 23263444 rs9685946 chr4 174155666 A C 0.0000103 VLDL cholesterol particle diameter GALNT7 intron 23263444 rs13112928 chr4 174158132 A G 0.00000541 VLDL cholesterol particle diameter GALNT7 intron 23263444 rs12640749 chr4 174267226 C T 2.40E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1561792 chr4 174369908 C T 5.19E-05 ldl cholesterol / / pha003076 rs7655560 chr4 174438897 G A 3.27E-05 Paclitaxel-induced neuropathy / / 23776197 rs17059546 chr4 174453062 T C 1.19E-04 Coronary heart disease NBLA00301 intron 21606135 rs2332691 chr4 174455297 C T 3.27E-05 Gaucher disease severity NBLA00301 intron 22388998 rs12646107 chr4 174515682 A C 4.00E-06 Response to amphetamines / / 22952603 rs10025532 chr4 174516367 G A 3.71E-04 Suicide attempts in bipolar disorder / / 21041247 rs11132998 chr4 174516590 C T 3.97E-06 Response to amphetamines / / 22952603 rs4639045 chr4 174521315 T C 3.24E-05 Cocaine dependence / / 23958962 rs4639045 chr4 174521315 T C 8.13E-06 Cocaine dependence / / 23958962 rs4129566 chr4 174547157 T C 3.00E-06 Cocaine dependence / / 23958962 rs11944332 chr4 174554832 A G 2.00E-06 Cocaine dependence / / 23958962 rs7675142 chr4 174559691 G A 1.12E-06 Multiple complex diseases / / 17554300 rs4282145 chr4 174565021 T G 5.32E-05 Longevity / / 21612516 rs11723864 chr4 174574406 C G 7.00E-07 Type 1 diabetes nephropathy / / 23028342 rs17059668 chr4 174584663 C G 1.36E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs17059677 chr4 174595925 A G 6.27E-04 Multiple complex diseases / / 17554300 rs10018807 chr4 174596609 G A 1.21E-04 Heart Failure / / pha002884 rs4501198 chr4 174599358 A G 4.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs11727767 chr4 174602048 A G 7.00E-06 Obesity-related traits / / 23251661 rs17059740 chr4 174627835 C T 2.60E-05 Urinary metabolites / / 21572414 rs6830684 chr4 174628454 A G 3.29E-04 Multiple complex diseases / / 17554300 rs4521323 chr4 174655914 A C 9.00E-06 Multiple myeloma (IgH translocation) / / 23502783 rs7657203 chr4 174660965 A G 0.0001 Migraine / / 22678113 rs7657203 chr4 174660965 A G 5.11E-04 Stroke / / pha002887 rs6830691 chr4 174667332 C T 3.51E-09 Non-obstructive azoospermia / / 22197933 rs4645198 chr4 174673416 T C 5.23E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4645198 chr4 174673416 T C 4.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13108803 chr4 174679198 G A 4.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11929802 chr4 174684932 C T 3.50E-05 Iron levels / / 21208937 rs4695885 chr4 174686346 G A 5.36E-04 Smoking initiation / / 24665060 rs6833126 chr4 174751009 T C 9.06E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs6820522 chr4 174758521 C A 3.50E-05 Major depressive disorder / / 21042317 rs11133017 chr4 174761895 G A 3.30E-05 Major depressive disorder / / 21042317 rs12505092 chr4 174766775 C G 2.40E-05 Major depressive disorder / / 21042317 rs6813541 chr4 174772568 T G 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs13138013 chr4 174777578 C T 2.60E-05 Major depressive disorder / / 21042317 rs13107098 chr4 174786039 C T 4.60E-05 Major depressive disorder / / 21042317 rs4600896 chr4 174802918 A G 1.28E-04 Multiple sclerosis / / 17660530 rs3889926 chr4 174859997 T C 1.90E-05 Lung adenocarcinoma / / 22797724 rs4488918 chr4 174860815 A T 3.08E-04 Type 2 diabetes / / 17463246 rs4388064 chr4 174863156 T G 4.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7657182 chr4 174873969 A G 8.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13119610 chr4 174908521 C T 8.40E-05 Lung adenocarcinoma / / 22797724 rs4495020 chr4 174920657 G A 2.20E-05 Lung adenocarcinoma / / 22797724 rs7674902 chr4 174939417 T C 1.75E-04 Multiple complex diseases / / 17554300 rs13144752 chr4 174945087 T C 6.00E-05 Lung adenocarcinoma / / 22797724 rs1992014 chr4 174947952 C T 6.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17060160 chr4 175002343 A G 8.33E-05 Formal thought disorder in schizophrenia / / 22648509 rs4695907 chr4 175008790 G A 8.16E-05 Formal thought disorder in schizophrenia / / 22648509 rs4695908 chr4 175008954 A T 8.89E-05 Formal thought disorder in schizophrenia / / 22648509 rs5009513 chr4 175027192 C A 7.90E-05 Personality dimensions / / 18957941 rs12507634 chr4 175071602 A G 4.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs2164380 chr4 175089750 A G 2.86E-04 White matter integrity / / 22425255 rs7661496 chr4 175097637 A G 2.93E-04 Celiac disease / / 23936387 rs7670919 chr4 175109603 A G 9.65E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs4235204 chr4 175125617 C T 9.96E-05 Cognitive test performance / / 20125193 rs12651414 chr4 175126378 C A 2.02E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10520274 chr4 175130244 G C 1.20E-05 Urinary metabolites / / 21572414 rs17060389 chr4 175134040 T C 3.32E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs970096 chr4 175135624 A G 2.39E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7681841 chr4 175162649 C T 7.80E-06 Urinary metabolites FBXO8 intron 21572414 rs6824643 chr4 175168083 G A 7.57E-05 Amyotrophic Lateral Sclerosis FBXO8 intron 18057069 rs6851312 chr4 175168153 A G 7.34E-05 Amyotrophic Lateral Sclerosis FBXO8 intron 18057069 rs6851312 chr4 175168153 A G 1.87E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) FBXO8 intron 24023788 rs10520276 chr4 175183493 T C 2.72E-04 Amyotrophic Lateral Sclerosis FBXO8 intron 17362836 rs11933187 chr4 175209932 C T 1.10E-05 Amyotrophic Lateral Sclerosis CEP44 intron 17362836 rs11933187 chr4 175209932 C T 1.46E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CEP44 intron 24023788 rs4695918 chr4 175225452 G A 1.04E-04 Amyotrophic Lateral Sclerosis CEP44 missense 17362836 rs17060465 chr4 175242433 C T 9.63E-04 Response to cytadine analogues (cytosine arabinoside) CEP44 intron 24483146 rs6553786 chr4 175300604 C T 3.58E-04 Multiple complex diseases / / 17554300 rs6553786 chr4 175300604 C T 8.16E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs6852435 chr4 175300779 T C 6.00E-06 Response to acetaminophen (hepatotoxicity) / / 21177773 rs7665426 chr4 175325686 G T 2.17E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs7664475 chr4 175351787 A G 6.17E-05 Insulin-related traits / / pha003063 rs2251316 chr4 175458289 C A 6.98E-04 Alzheimer's disease / / 17998437 rs2251316 chr4 175458289 C A 1.02E-04 Amyotrophic Lateral Sclerosis / / 18057069 rs2251316 chr4 175458289 C A 6.73E-04 Premature ovarian failure / / 19508998 rs2251316 chr4 175458289 C A 2.00E-06 Urinary metabolites / / 21572414 rs2257187 chr4 175458881 A T 8.60E-06 Urinary metabolites / / 21572414 rs17295603 chr4 175461517 G A 6.35E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2555639 chr4 175461530 T C 1.32E-04 Celiac disease / / 23936387 rs9990951 chr4 175462630 C A 1.96E-04 Celiac disease / / 23936387 rs6811079 chr4 175466963 G A 1.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs6837393 chr4 175476462 G A 7.73E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2612655 chr4 175493589 T C 1.93E-04 Parkinson's disease / / 21248740 rs2612683 chr4 175496276 G C 5.31E-04 Multiple complex diseases / / 17554300 rs2250175 chr4 175503012 G A 6.50E-05 Parkinson's disease / / 21248740 rs3113891 chr4 175509973 T C 4.21E-05 Serum metabolites / / 19043545 rs2555675 chr4 175523040 A G 6.32E-05 Serum metabolites / / 19043545 rs17297591 chr4 175524462 A G 2.84E-04 Multiple complex diseases / / 17554300 rs2332838 chr4 175526690 C T 9.21E-06 Personality dimensions / / 23658558 rs4695937 chr4 175552622 T C 8.42E-05 Body Fat Distribution / / pha003016 rs4695937 chr4 175552622 T C 8.69E-05 Body Fat Distribution / / pha003018 rs4695937 chr4 175552622 T C 6.18E-05 Blood Pressure / / pha003043 rs4695938 chr4 175567639 T A 3.36E-04 Multiple complex diseases GLRA3 intron 17554300 rs4622971 chr4 175569169 G A 3.89E-04 Multiple complex diseases GLRA3 intron 17554300 rs12511536 chr4 175579442 G A 9.77E-05 Magnesium levels GLRA3 intron pha003092 rs4425356 chr4 175582984 A G 9.63E-05 Hypertension (essential hypertension) GLRA3 intron 22184326 rs4425356 chr4 175582984 A G 9.77E-05 Magnesium levels GLRA3 intron pha003092 rs6847235 chr4 175598873 G A 3.18E-06 Cognitive impairment induced by topiramate GLRA3 intron 22091778 rs1485945 chr4 175632405 G A 2.64E-04 Multiple complex diseases GLRA3 intron 17554300 rs17298140 chr4 175632988 A G 1.50E-05 Urinary metabolites GLRA3 intron 21572414 rs11725853 chr4 175642699 G A,C 8.00E-07 Urinary albumin excretion rate in type 1 diabetes GLRA3 intron 24595857 rs13113891 chr4 175674144 A G 9.39E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) GLRA3 intron 23648065 rs11727514 chr4 175682850 A G 9.91E-04 Endometrial cancer GLRA3 intron 24096698 rs4695963 chr4 175713278 A G 4.67E-04 Response to TNF antagonist treatment GLRA3 intron 21061259 rs1994313 chr4 175716626 G A 1.18E-05 Type 2 diabetes and other traits GLRA3 intron 19734900 rs6851555 chr4 175729707 G C 7.12E-06 Multiple complex diseases GLRA3 intron 17554300 rs6851555 chr4 175729707 G C 1.70E-05 Urinary metabolites GLRA3 intron 21572414 rs17365870 chr4 175733865 T G 2.40E-05 Urinary metabolites GLRA3 intron 21572414 rs1352062 chr4 175734620 A G 2.10E-05 Urinary metabolites GLRA3 intron 21572414 rs6824735 chr4 175740569 T C 3.90E-05 Alcoholism GLRA3 intron pha002893 rs4695970 chr4 175777247 T C 7.08E-04 Insulin resistance / / 21901158 rs1491411 chr4 175777871 T C 2.87E-05 Body Fat Distribution / / pha003016 rs1491411 chr4 175777871 T C 7.67E-05 Body Fat Distribution / / pha003017 rs1491411 chr4 175777871 T C 4.52E-05 Body Fat Distribution / / pha003018 rs1491411 chr4 175777871 T C 4.20E-05 Weight / / pha003026 rs923677 chr4 175781686 T C 6.93E-05 Body Mass Index / / pha003015 rs923677 chr4 175781686 T C 1.61E-05 Body Fat Distribution / / pha003016 rs923677 chr4 175781686 T C 1.46E-05 Waist Circumference / / pha003024 rs923677 chr4 175781686 T C 8.58E-05 Waist Circumference / / pha003025 rs923677 chr4 175781686 T C 1.25E-05 Weight / / pha003026 rs2130938 chr4 175786729 C T 2.75E-05 Body Fat Distribution / / pha003016 rs2130938 chr4 175786729 C T 7.95E-05 Body Fat Distribution / / pha003017 rs2130938 chr4 175786729 C T 4.78E-05 Body Fat Distribution / / pha003018 rs2130938 chr4 175786729 C T 3.03E-05 Weight / / pha003026 rs1121336 chr4 175796630 T C 5.76E-05 Asthma / / 23181788 rs6858430 chr4 175816129 T C 1.00E-08 Venous thromboembolism (gene x gene interaction) / / 23509962 rs6858430 chr4 175816129 T C 3.24E-05 Body Fat Distribution / / pha003016 rs6858430 chr4 175816129 T C 2.31E-05 Weight / / pha003026 rs6826366 chr4 175846110 G A 4.70E-04 Multiple complex diseases ADAM29 intron 17554300 rs6828523 chr4 175846426 C A 5.99E-04 Multiple complex diseases ADAM29 intron 17554300 rs6828523 chr4 175846426 C A 4.00E-16 Breast cancer ADAM29 intron 23535729 rs9998487 chr4 175849984 T A 5.36E-04 Multiple complex diseases ADAM29 intron 17554300 rs6553850 chr4 175855572 T C 9.21E-05 Cholesterol ADAM29 intron 17255346 rs4273448 chr4 175856460 G T 8.17E-05 Cholesterol ADAM29 intron 17255346 rs4550895 chr4 175887462 G C 9.64E-04 Type 2 diabetes ADAM29 intron 17463246 rs4128923 chr4 175889975 A G 3.84E-04 Suicide attempts in bipolar disorder ADAM29 intron 21423239 rs4695994 chr4 175905542 T C 8.27E-04 Type 2 diabetes / / 17463246 rs10013344 chr4 175909711 C T 3.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs10026079 chr4 175913798 C T 3.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs10005382 chr4 175919987 G C 4.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs1119254 chr4 175924733 C T 2.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs12640583 chr4 175935746 G T 7.34E-04 Depression (quantitative trait) / / 20800221 rs13111482 chr4 175936475 G A 7.21E-04 Depression (quantitative trait) / / 20800221 rs6553853 chr4 175936490 C A 7.16E-04 Depression (quantitative trait) / / 20800221 rs6824013 chr4 175936529 A G 6.24E-04 Depression (quantitative trait) / / 20800221 rs12513233 chr4 175939626 G A 7.21E-04 Depression (quantitative trait) / / 20800221 rs13129897 chr4 175940265 A G 6.24E-04 Depression (quantitative trait) / / 20800221 rs13141617 chr4 175940831 T G 7.17E-04 Depression (quantitative trait) / / 20800221 rs12509972 chr4 175948807 C A 7.29E-04 Depression (quantitative trait) / / 20800221 rs1479385 chr4 175950930 C A 9.63E-04 Depression (quantitative trait) / / 20800221 rs12640173 chr4 175952615 C T 5.99E-04 Depression (quantitative trait) / / 20800221 rs13106889 chr4 175960753 T A 9.83E-04 Depression (quantitative trait) / / 20800221 rs1904344 chr4 175962993 G C 5.02E-06 Glycemic traits (pregnancy) / / 23903356 rs56387698 chr4 175973436 T C 4.76E-05 Epilepsy (remission after treatment) / / 23962720 rs55970345 chr4 175976788 G A 4.65E-05 Epilepsy (remission after treatment) / / 23962720 rs72712137 chr4 175977899 C T 4.46E-05 Epilepsy (remission after treatment) / / 23962720 rs113540526 chr4 175980285 G A 4.27E-05 Epilepsy (remission after treatment) / / 23962720 rs111480711 chr4 175980510 G A 4.25E-05 Epilepsy (remission after treatment) / / 23962720 rs115615130 chr4 175980818 T A 4.24E-05 Epilepsy (remission after treatment) / / 23962720 rs72712145 chr4 175982048 C A 3.55E-05 Epilepsy (remission after treatment) / / 23962720 rs17061121 chr4 175982253 G A 4.10E-05 Epilepsy (remission after treatment) / / 23962720 rs72712146 chr4 175982607 T C 4.06E-05 Epilepsy (remission after treatment) / / 23962720 rs72712147 chr4 175983415 G A 5.73E-06 Epilepsy (remission after treatment) / / 23962720 rs72712149 chr4 175983980 G C 3.96E-05 Epilepsy (remission after treatment) / / 23962720 rs72712151 chr4 175984893 G A 3.91E-05 Epilepsy (remission after treatment) / / 23962720 rs72712153 chr4 175986019 A G 3.81E-05 Epilepsy (remission after treatment) / / 23962720 rs72712155 chr4 175986274 T C 3.80E-05 Epilepsy (remission after treatment) / / 23962720 rs72712157 chr4 175986289 T A 3.80E-05 Epilepsy (remission after treatment) / / 23962720 rs72698604 chr4 175988942 G A 3.65E-05 Epilepsy (remission after treatment) / / 23962720 rs72698605 chr4 175989789 T C 3.58E-05 Epilepsy (remission after treatment) / / 23962720 rs72698607 chr4 175991335 C G 3.52E-05 Epilepsy (remission after treatment) / / 23962720 rs72698608 chr4 175993070 T C 3.45E-05 Epilepsy (remission after treatment) / / 23962720 rs72698609 chr4 175993988 T G 3.36E-05 Epilepsy (remission after treatment) / / 23962720 rs56276124 chr4 175994332 A G 2.88E-05 Epilepsy (remission after treatment) / / 23962720 rs72698611 chr4 175995478 A G 1.62E-05 Epilepsy (remission after treatment) / / 23962720 rs72698613 chr4 176008218 G A 4.00E-06 Epilepsy (remission after treatment) / / 23962720 rs55952332 chr4 176008859 C T 1.39E-05 Epilepsy (remission after treatment) / / 23962720 rs72698614 chr4 176009604 T G 1.38E-05 Epilepsy (remission after treatment) / / 23962720 rs112368511 chr4 176014360 A C 1.36E-05 Epilepsy (remission after treatment) / / 23962720 rs72698621 chr4 176022414 A T 1.58E-05 Epilepsy (remission after treatment) / / 23962720 rs72698623 chr4 176025153 T A 2.63E-05 Epilepsy (remission after treatment) / / 23962720 rs75343663 chr4 176025879 A G 3.72E-05 Epilepsy (remission after treatment) / / 23962720 rs72698627 chr4 176028884 G A 4.88E-05 Epilepsy (remission after treatment) / / 23962720 rs7673181 chr4 176030994 A T 1.59E-05 Epilepsy (remission after treatment) / / 23962720 rs72698629 chr4 176033128 G A 5.80E-05 Epilepsy (remission after treatment) / / 23962720 rs72698630 chr4 176033249 A C 5.85E-05 Epilepsy (remission after treatment) / / 23962720 rs72698632 chr4 176036352 T C 7.70E-05 Epilepsy (remission after treatment) / / 23962720 rs72698633 chr4 176036370 A G 7.72E-05 Epilepsy (remission after treatment) / / 23962720 rs72698638 chr4 176038276 C T 7.85E-05 Epilepsy (remission after treatment) / / 23962720 rs72698643 chr4 176042497 C T 8.04E-05 Epilepsy (remission after treatment) / / 23962720 rs75768954 chr4 176046604 A T 8.29E-05 Epilepsy (remission after treatment) / / 23962720 rs72698653 chr4 176048024 C T 8.44E-05 Epilepsy (remission after treatment) / / 23962720 rs115671005 chr4 176049254 T G 8.45E-05 Epilepsy (remission after treatment) / / 23962720 rs72698655 chr4 176050664 A G 8.46E-05 Epilepsy (remission after treatment) / / 23962720 rs72698656 chr4 176050876 T A 8.49E-05 Epilepsy (remission after treatment) / / 23962720 rs72698660 chr4 176052202 A G 8.50E-05 Epilepsy (remission after treatment) / / 23962720 rs330483 chr4 176052494 T C 1.05E-04 Multiple complex diseases / / 17554300 rs72698665 chr4 176056866 C T 8.84E-05 Epilepsy (remission after treatment) / / 23962720 rs330523 chr4 176063333 A G 9.03E-05 Epilepsy (remission after treatment) / / 23962720 rs13131873 chr4 176120312 G A 5.10E-05 Epilepsy (remission after treatment) / / 23962720 rs1609792 chr4 176125782 A G 2.68E-05 Epilepsy (remission after treatment) / / 23962720 rs4146 chr4 176164722 C T 5.80E-06 Personality dimensions / / 21173776 rs4417946 chr4 176227974 A G 7.03E-05 Smoking behavior / / 20418889 rs646077 chr4 176230652 A G 6.69E-05 Smoking behavior / / 20418889 rs13133504 chr4 176252966 T C 5.61E-05 Smoking behavior / / 20418889 rs13129016 chr4 176257036 G A 9.84E-05 Smoking behavior / / 20418889 rs13135411 chr4 176257561 G A 6.31E-05 Smoking behavior / / 20418889 rs13353684 chr4 176258130 G A 8.45E-05 Smoking behavior / / 20418889 rs13353541 chr4 176258518 C T 7.71E-05 Smoking behavior / / 20418889 rs6553864 chr4 176260059 A C 7.91E-05 Smoking behavior / / 20418889 rs7673648 chr4 176260543 T C 8.44E-05 Smoking behavior / / 20418889 rs6820003 chr4 176268902 C T 9.28E-05 Smoking behavior / / 20418889 rs2333163 chr4 176270885 T C 5.00E-06 Obesity-related traits / / 23251661 rs6851885 chr4 176273451 G A 5.39E-05 Hemoglobin concentration / / 20534544 rs2333166 chr4 176285962 T C 6.37E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs7658467 chr4 176298445 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6553872 chr4 176325771 C T 5.47E-05 Hypertension / / 19609347 rs6842506 chr4 176332540 T G 4.83E-05 Hypertension / / 19609347 rs6842506 chr4 176332540 T G 1.32E-04 Hemoglobin concentration / / 20534544 rs10866376 chr4 176334902 T C 6.35E-05 Hypertension / / 19609347 rs6814305 chr4 176350260 C T 5.53E-04 Aortic root size / / 21223598 rs12715964 chr4 176364478 A G 7.78E-04 Aortic root size / / 21223598 rs6829020 chr4 176410587 C A 9.25E-04 White matter integrity / / 22425255 rs12646092 chr4 176499957 G C 7.29E-04 Multiple complex diseases / / 17554300 rs4318597 chr4 176517651 A G 5.44E-04 Type 2 diabetes / / 17463246 rs2333242 chr4 176548762 G C 1.90E-05 Immunoglobulin A / / 20694011 rs11732917 chr4 176570788 A G 1.30E-04 Multiple complex diseases GPM6A intron 17554300 rs4429679 chr4 176571011 C A 3.15E-05 Glucose levels GPM6A intron pha003057 rs2333255 chr4 176582766 C A 0.000028 Uterine leiomyomata GPM6A intron 23040493 rs17061806 chr4 176617540 T C 1.18E-04 Gallstones GPM6A intron 17632509 rs12640626 chr4 176626272 G A 7.00E-06 Educational attainment GPM6A intron 23722424 rs9284954 chr4 176648332 C A 5.00E-06 IgG glycosylation GPM6A intron 23382691 rs12507816 chr4 176652698 A G 4.96E-05 Cognitive impairment induced by topiramate GPM6A intron 22091778 rs17061928 chr4 176655160 C T 1.76E-05 Cognitive impairment induced by topiramate GPM6A intron 22091778 rs13152426 chr4 176660420 G A 5.11E-05 Dengue shock syndrome GPM6A intron 22001756 rs17599018 chr4 176662087 T C 2.00E-06 Temperament (bipolar disorder) GPM6A intron 22365631 rs13144140 chr4 176666186 G A 4.78E-05 Dengue shock syndrome GPM6A intron 22001756 rs13144140 chr4 176666186 G A 3.00E-05 Temperament (bipolar disorder) GPM6A intron 22365631 rs11939763 chr4 176668028 G A 4.40E-05 Temperament (bipolar disorder) GPM6A intron 22365631 rs2047246 chr4 176673554 C T 1.35E-04 Alzheimer's disease (late onset) GPM6A intron 21379329 rs722825 chr4 176677770 C T 5.26E-04 Response to taxane treatment (placlitaxel) GPM6A intron 23006423 rs17658458 chr4 176680675 C A 4.04E-04 Response to taxane treatment (placlitaxel) GPM6A intron 23006423 rs1390343 chr4 176706135 T C 3.04E-04 Myopia (pathological) GPM6A intron 21095009 rs1390343 chr4 176706135 T C 8.70E-05 Lipoproteins GPM6A intron pha003079 rs17062019 chr4 176707862 C T 9.43E-05 Non-alcoholic fatty liver disease histology (other) GPM6A intron 20708005 rs13140287 chr4 176711191 G A 9.53E-04 Myopia (pathological) GPM6A intron 21095009 rs1495716 chr4 176728576 T C 5.84E-06 Brain structure GPM6A intron 22504417 rs2132339 chr4 176745747 G A 5.82E-05 Parent of origin effect on language impairment (paternal) GPM6A intron 24571439 rs6838421 chr4 176747173 A G 5.54E-05 Parent of origin effect on language impairment (paternal) GPM6A intron 24571439 rs4306906 chr4 176795898 G A 5.98E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GPM6A intron 20877124 rs11133119 chr4 176820049 C T 1.91E-04 Suicide attempts in bipolar disorder GPM6A intron 21423239 rs1495712 chr4 176820265 C T 7.27E-05 Suicide attempts in bipolar disorder GPM6A intron 21423239 rs7436322 chr4 176823651 C T 2.98E-04 Suicide attempts in bipolar disorder GPM6A intron 21423239 rs10012096 chr4 176825040 C T 2.60E-04 Suicide attempts in bipolar disorder GPM6A intron 21423239 rs10520315 chr4 176832197 T A 5.84E-04 Multiple complex diseases GPM6A intron 17554300 rs1495714 chr4 176837789 C A 1.78E-05 Behcet's disease GPM6A intron 23291587 rs1495714 chr4 176837789 C A 1.93E-05 Behcet's disease GPM6A intron pha002888 rs9683504 chr4 176839524 A G 1.49E-04 Multiple complex diseases GPM6A intron 17554300 rs9685517 chr4 176839744 C A 1.27E-05 Multiple complex diseases GPM6A intron 17554300 rs200410843 chr4 176859026 A AT 4.00E-06 Heart failure GPM6A intron 20400778 rs7687921 chr4 176859026 A T 4.00E-06 Heart failure GPM6A intron 20400778 rs4690647 chr4 176872920 G A 1.10E-05 Behcet's disease GPM6A intron 23291587 rs4690647 chr4 176872920 G A 1.13E-05 Behcet's disease GPM6A intron pha002888 rs7659781 chr4 176949041 T C 1.30E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6553905 chr4 176973932 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1385614 chr4 176993039 T C 4.60E-05 Parent of origin effect on language impairment (paternal) WDR17 intron 24571439 rs7698815 chr4 177025984 A G 3.22E-04 Birth weight WDR17 intron 17255346 rs10004325 chr4 177106289 G C 1.95E-05 Telomere length SPATA4 intron 24795349 rs12502935 chr4 177113779 T C 8.16E-04 Body mass index SPATA4 cds-synon 21701565 rs2291244 chr4 177113956 A G 2.57E-04 Body mass index SPATA4 cds-synon 21701565 rs11731185 chr4 177123850 A C 4.09E-06 Attention deficit hyperactivity disorder / / 20732627 rs2333406 chr4 177126245 G A 2.76E-05 Erythrocyte counts / / pha003101 rs7676562 chr4 177210373 T G 1.60E-06 Urinary metabolites / / 21572414 rs4077385 chr4 177228514 A T 1.80E-05 Urinary metabolites / / 21572414 rs6844359 chr4 177230172 A G 1.86E-04 Type 2 diabetes / / 17463246 rs7693236 chr4 177231251 A G 1.32E-04 Type 2 diabetes / / 17463246 rs7693236 chr4 177231251 A G 9.52E-05 Serum metabolites / / 19043545 rs9992247 chr4 177235286 T C 2.49E-04 Type 2 diabetes / / 17463246 rs9992247 chr4 177235286 T C 6.40E-05 Serum metabolites / / 19043545 rs6811405 chr4 177235800 C T 3.11E-04 Type 2 diabetes / / 17463246 rs13127237 chr4 177283245 C T 8.16E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1454158 chr4 177290945 G A 6.90E-05 Tooth agenesis (mandibular third molar) / / 24172245 rs9968491 chr4 177296833 A T 5.83E-04 Multiple complex diseases / / 17554300 rs6553951 chr4 177308667 A G 6.13E-05 Type 2 diabetes / / 17463246 rs6553952 chr4 177308851 T C 6.76E-05 Type 2 diabetes / / 17463246 rs9312601 chr4 177367042 T A 7.03E-04 Bone mass and geometry / / 17903296 rs2167096 chr4 177372753 G A 7.58E-04 Taste perception / / 22132133 rs12642356 chr4 177383080 C T 9.78E-04 Type 2 diabetes / / 17463246 rs365051 chr4 177391167 T C 9.60E-05 Coronary heart disease / / pha003031 rs553346 chr4 177394162 C T 2.87E-04 Heart Failure / / pha002884 rs553346 chr4 177394162 C T 9.83E-05 Coronary heart disease / / pha003031 rs4690445 chr4 177406393 G T 9.79E-05 Taste perception / / 22132133 rs369560 chr4 177422715 T C 2.80E-05 Coronary heart disease / / pha003031 rs309703 chr4 177429154 A G 7.41E-05 Cognitive performance / / 19734545 rs448261 chr4 177438117 G A 4.64E-05 Schizophrenia / / 19571809 rs374816 chr4 177438265 T G 5.00E-05 Schizophrenia / / 19571809 rs410203 chr4 177438636 C T 7.13E-05 Schizophrenia / / 19571809 rs395003 chr4 177439074 A G 3.70E-04 Alzheimer's disease / / 17998437 rs395003 chr4 177439074 A G 6.58E-05 Schizophrenia / / 19571809 rs443233 chr4 177439156 T C 3.74E-05 Schizophrenia / / 19571809 rs4690448 chr4 177439477 G T 2.40E-05 Urinary metabolites / / 21572414 rs425571 chr4 177444335 A G 1.20E-05 Schizophrenia / / 19571809 rs13137758 chr4 177469451 A G 7.23E-05 Schizophrenia / / 19571809 rs13148526 chr4 177469582 T C 3.19E-05 Schizophrenia / / 19571809 rs6848215 chr4 177486073 A T 8.16E-05 Parkinson's disease / / 23793441 rs13141633 chr4 177489261 G A 9.20E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6810584 chr4 177497213 T G 9.18E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10025889 chr4 177500004 G T 8.52E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13139256 chr4 177530733 C A 7.21E-04 Multiple complex diseases / / 17554300 rs6824464 chr4 177531891 G A 6.71E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13111989 chr4 177542973 A G 2.00E-07 HIV-1 viral setpoint / / 22174851 rs7690549 chr4 177553409 G A 7.64E-04 Multiple complex diseases / / 17554300 rs17063436 chr4 177555700 G A 3.30E-05 Personality dimensions / / 18957941 rs4690458 chr4 177556755 A C 1.91E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4690458 chr4 177556755 A C 1.44E-05 HIV-1 viral setpoint / / 22174851 rs2333491 chr4 177558864 G A 9.87E-05 Longevity / / 20304771 rs1872500 chr4 177559121 A G 9.95E-05 Longevity / / 20304771 rs4527434 chr4 177579211 T C 6.35E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9654285 chr4 177611557 A T 6.96E-04 Multiple complex diseases VEGFC intron 17554300 rs3775196 chr4 177620950 A G 8.63E-04 Multiple complex diseases VEGFC intron 17554300 rs3775195 chr4 177621110 T A,G 0.000085 Coronary artery calcification VEGFC intron 23727086 rs41501449 chr4 177787607 T C 2.70E-05 Anger / / 24489884 rs13104005 chr4 177895429 C T 2.83E-05 Depression (quantitative trait) / / 20800221 rs1595154 chr4 177897312 A G 9.00E-25 Multiple complex diseases / / 17554300 rs1865744 chr4 177901883 C A 9.62E-04 Depression (quantitative trait) / / 20800221 rs13143572 chr4 177905575 A C 2.13E-04 Depression (quantitative trait) / / 20800221 rs13110230 chr4 177916874 T G 1.36E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs1125172 chr4 177925312 C A 3.79E-04 Depression (quantitative trait) / / 20800221 rs17720291 chr4 177966548 C T 6.98E-04 Multiple complex diseases / / 17554300 rs17720291 chr4 177966548 C T 7.10E-05 Prostate cancer mortality / / 20978177 rs12512817 chr4 177971842 C A 3.58E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs6817291 chr4 177985087 T C 5.36E-04 Multiple complex diseases / / 17554300 rs62329179 chr4 178018857 G A 1.64E-05 Intracerebral hemorrhage / / 24656865 rs6846031 chr4 178019148 G T 5.64E-05 Multiple complex diseases / / 17554300 rs17721806 chr4 178022268 T C 1.43E-05 Intracerebral hemorrhage / / 24656865 rs57486023 chr4 178025392 G A 4.75E-06 Intracerebral hemorrhage / / 24656865 rs17721897 chr4 178028260 A G 1.79E-05 Intracerebral hemorrhage / / 24656865 rs17665526 chr4 178031539 G A 3.86E-06 Intracerebral hemorrhage / / 24656865 rs61277341 chr4 178036752 T C 7.68E-06 Intracerebral hemorrhage / / 24656865 rs1898856 chr4 178045296 T C 4.55E-06 Intracerebral hemorrhage / / 24656865 rs62329185 chr4 178046479 A G 1.96E-05 Intracerebral hemorrhage / / 24656865 rs17722524 chr4 178047394 G C 5.41E-06 Intracerebral hemorrhage / / 24656865 rs72700535 chr4 178051270 C T 1.16E-05 Intracerebral hemorrhage / / 24656865 rs6811719 chr4 178051454 G A 1.57E-05 Intracerebral hemorrhage / / 24656865 rs72700536 chr4 178052721 G A 1.40E-05 Intracerebral hemorrhage / / 24656865 rs2580073 chr4 178064683 T C 3.59E-04 Multiple complex diseases / / 17554300 rs62329208 chr4 178071440 C T 4.58E-05 Intracerebral hemorrhage / / 24656865 rs28711479 chr4 178075396 C T 1.42E-05 Intracerebral hemorrhage / / 24656865 rs28821242 chr4 178077865 G A 1.29E-05 Intracerebral hemorrhage / / 24656865 rs4299533 chr4 178084093 C T 1.88E-05 Intracerebral hemorrhage / / 24656865 rs62329213 chr4 178084994 C T 1.91E-05 Intracerebral hemorrhage / / 24656865 rs58865616 chr4 178085158 T C 1.88E-05 Intracerebral hemorrhage / / 24656865 rs61069662 chr4 178085223 G A 1.63E-05 Intracerebral hemorrhage / / 24656865 rs10013076 chr4 178085467 G A 1.47E-05 Intracerebral hemorrhage / / 24656865 rs62345686 chr4 178087578 C T 7.32E-06 Intracerebral hemorrhage / / 24656865 rs28599599 chr4 178090740 T C 2.28E-05 Intracerebral hemorrhage / / 24656865 rs62345687 chr4 178092434 G C 6.49E-06 Intracerebral hemorrhage / / 24656865 rs10005430 chr4 178092923 G A 1.09E-05 Intracerebral hemorrhage / / 24656865 rs62342386 chr4 178093529 G T 8.11E-06 Intracerebral hemorrhage / / 24656865 rs58534500 chr4 178093573 G T 9.00E-06 Intracerebral hemorrhage / / 24656865 rs28587349 chr4 178096526 T C 1.15E-05 Intracerebral hemorrhage / / 24656865 rs966023 chr4 178106459 T C 4.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs3913977 chr4 178116714 A T 5.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs1009523 chr4 178151435 C T 6.08E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1347894 chr4 178167282 G A 2.27E-04 Multiple complex diseases / / 17554300 rs11131790 chr4 178193637 G A 5.11E-04 Type 2 diabetes / / 17463246 rs1567111 chr4 178197237 C T 9.31E-06 Triglycerides / / pha003081 rs1567111 chr4 178197237 C T 4.61E-06 Lipid levels / / pha003082 rs6856498 chr4 178199486 T G 1.49E-04 Progressive supranuclear palsy / / 21685912 rs4690504 chr4 178201257 C T 5.07E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs1844483 chr4 178209089 T C 3.56E-05 HDL cholesterol / / pha003075 rs1844483 chr4 178209089 T C 3.79E-05 Lipid levels / / pha003082 rs17064552 chr4 178210084 C A 7.00E-05 Glycosylated haemoglobin levels / / 17255346 rs6850861 chr4 178236402 T C 5.42E-04 Type 2 diabetes NEIL3 intron 17463246 rs12501016 chr4 178269253 A G 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes NEIL3 intron 22628534 rs2048074 chr4 178274565 A G 9.20E-04 Amyotrophic Lateral Sclerosis NEIL3 frameshift 17362836 rs10007075 chr4 178274694 T G 9.64E-05 Bipolar disorder NEIL3 cds-synon 22925353 rs13112358 chr4 178274750 C T 9.20E-04 Amyotrophic Lateral Sclerosis NEIL3 missense 17362836 rs13112390 chr4 178274835 A C 4.42E-04 Height NEIL3 missense 17255346 rs13112390 chr4 178274835 A C 5.24E-04 Amyotrophic Lateral Sclerosis NEIL3 missense 17362836 rs17739461 chr4 178296647 C T 1.76E-04 Multiple complex diseases / / 17554300 rs10866213 chr4 178298825 T G 6.68E-04 Multiple complex diseases / / 17554300 rs1506807 chr4 178317692 A G 3.00E-07 Serum selenium levels / / 23698163 rs1506807 chr4 178317692 A G 4.43E-07 Substance dependence phenotypes / / 24832863 rs1506807 chr4 178317692 A G 9.12E-04 Substance dependence phenotypes / / 24832863 rs1395477 chr4 178317952 C T 7.06E-04 Myopia (pathological) / / 21095009 rs1395479 chr4 178318191 C A 7.00E-06 Heart rate variability traits / / 17903306 rs1395479 chr4 178318191 C A 3.00E-07 Serum selenium levels / / 23698163 rs7681546 chr4 178319270 A G 9.15E-04 Multiple complex diseases / / 17554300 rs1395483 chr4 178321418 T C 4.83E-04 Multiple complex diseases / / 17554300 rs7691205 chr4 178332637 C A 4.76E-04 Parkinson's disease / / 17052657 rs2135616 chr4 178336670 C G 2.80E-06 Urinary metabolites / / 21572414 rs3749480 chr4 178351803 A G 2.20E-05 Urinary metabolites AGA nearGene-3 21572414 rs3805167 chr4 178353046 G C 1.90E-05 Urinary metabolites AGA intron 21572414 rs2271101 chr4 178359719 A G 1.43E-05 Lymphocyte counts AGA intron 22286170 rs12504521 chr4 178384657 G A 0.000163 Height (Pygmy height) / / 22570615 rs12513098 chr4 178389044 C G,T 2.42E-04 Multiple complex diseases / / 17554300 rs6819153 chr4 178405595 A T 8.02E-05 Bipolar disorder / / 22925353 rs11936727 chr4 178429837 G A 1.29E-04 Response to TNF antagonist treatment / / 21061259 rs6827612 chr4 178460162 G A 2.65E-04 Multiple complex diseases / / 17554300 rs4690536 chr4 178491443 A G 3.25E-04 Smoking initiation / / 24665060 rs1920972 chr4 178495591 A G 4.44E-04 Smoking initiation / / 24665060 rs1920968 chr4 178501293 T C 2.41E-04 Multiple complex diseases / / 17554300 rs13116233 chr4 178503993 A C 8.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs17065006 chr4 178506363 T G 6.29E-04 Smoking initiation / / 24665060 rs10520381 chr4 178532041 G A 1.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4234868 chr4 178532762 G A 4.44E-05 Waist-Hip Ratio / / pha003013 rs4234868 chr4 178532762 G A 9.74E-05 Waist-Hip Ratio / / pha003028 rs13102468 chr4 178556723 A C 0.000869 Height (Pygmy height) / / 22570615 rs13147867 chr4 178579037 A G 2.16E-04 Lung function (forced vital capacity) / / 24023788 rs7697897 chr4 178679198 T G 3.52E-05 Monocyte chemoattractant protein-1 LOC285501 intron pha003071 rs12508768 chr4 178682906 C T 4.98E-04 Multiple complex diseases LOC285501 intron 17554300 rs2085067 chr4 178689242 C T 0.000572 Height (Pygmy height) LOC285501 intron 22570615 rs10520385 chr4 178694450 G A 1.50E-04 Type 2 diabetes LOC285501 intron 17846125 rs12506671 chr4 178709040 A G 4.97E-05 Monocyte chemoattractant protein-1 LOC285501 intron pha003071 rs4305466 chr4 178735786 G A 8.57E-04 Type 2 diabetes LOC285501 intron 17463246 rs10015378 chr4 178736851 T C 8.57E-04 Type 2 diabetes LOC285501 intron 17463246 rs4997952 chr4 178740532 A T 8.57E-04 Type 2 diabetes LOC285501 intron 17463246 rs17065243 chr4 178744050 G T 2.86E-04 Type 2 diabetes LOC285501 intron 17463246 rs6827227 chr4 178755843 C T 2.86E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LOC285501 intron 24023788 rs11131831 chr4 178773349 A G 3.69E-04 Taste perception LOC285501 intron 22132133 rs6849372 chr4 178776502 A G 7.39E-04 Taste perception LOC285501 intron 22132133 rs6824106 chr4 178801018 G A 9.27E-05 Sudden cardiac arrest LOC285501 intron 21658281 rs12645056 chr4 178841353 T G 3.90E-04 Intelligence (childhood) LOC285501 intron 23358156 rs4690589 chr4 178908200 A G 0.000627953 Hypertension (early onset hypertension) LOC285501 intron 22479346 rs4690591 chr4 178917059 T C 0.000747883 Hypertension (early onset hypertension) / / 22479346 rs1585576 chr4 178926024 T C 4.96E-04 Stroke / / pha002887 rs2054380 chr4 178943989 G A 8.66E-04 Multiple complex diseases / / 17554300 rs10520400 chr4 178966254 C T 0.000670688 Hypertension (early onset hypertension) / / 22479346 rs966108 chr4 178969993 G A 0.000178 Height (Pygmy height) / / 22570615 rs35684555 chr4 178977698 G T 8.04E-04 Smoking quantity / / 24665060 rs601315 chr4 179019246 A G 5.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs13117571 chr4 179019696 T C 7.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs484851 chr4 179021015 C T 8.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs533025 chr4 179023206 A G 6.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs521470 chr4 179024958 T G 6.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs574042 chr4 179026694 T C 7.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs672041 chr4 179032994 G A 7.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs898088 chr4 179033236 C A 5.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs6830186 chr4 179035772 T A 6.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs4690604 chr4 179035790 C A 6.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs685292 chr4 179040275 T A 3.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs13122905 chr4 179042054 G A 7.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs553372 chr4 179046619 G A 6.23E-04 Alcohol dependence / / 20201924 rs553372 chr4 179046619 G A 5.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs605996 chr4 179048351 T C 5.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs12510690 chr4 179048839 A G 5.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs482208 chr4 179060626 C T 1.02E-04 Type 2 diabetes / / 17463246 rs13145748 chr4 179103301 G A 3.84E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2219449 chr4 179104097 A G 4.30E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs716948 chr4 179106142 C T 6.73E-04 Type 2 diabetes / / 17463246 rs1841096 chr4 179118018 G T 9.64E-05 Serum metabolites / / 19043545 rs4690620 chr4 179198970 G T 0.0000754 Height (Pygmy height) / / 22570615 rs2705962 chr4 179279965 A G 7.76E-04 Alcohol dependence / / 20201924 rs2705988 chr4 179290393 G A 7.01E-04 Alcohol dependence / / 20201924 rs1567479 chr4 179307893 G A 6.33E-04 Alcohol dependence / / 20201924 rs2705972 chr4 179327856 G A 7.47E-04 Multiple complex diseases / / 17554300 rs2666055 chr4 179344420 G A 0.000029 Alcohol craving with or without dependence / / 22481050 rs2705990 chr4 179346811 C T 0.000212 Height (Pygmy height) / / 22570615 rs2085913 chr4 179375575 C T 6.01E-04 Smoking initiation / / 24665060 rs1903524 chr4 179380467 A G 4.47E-05 Multiple sclerosis (age of onset) / / 19010793 rs1903524 chr4 179380467 A G 1.04E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2702385 chr4 179383805 G A 8.27E-04 Smoking initiation / / 24665060 rs7658429 chr4 179386405 A G 7.42E-04 Smoking initiation / / 24665060 rs2614609 chr4 179388852 T C 8.60E-06 Urinary metabolites / / 21572414 rs2702413 chr4 179399253 A T 4.89E-04 Smoking initiation / / 24665060 rs2702414 chr4 179399523 G A 8.63E-06 Intracerebral hemorrhage / / 24656865 rs2702449 chr4 179401433 G A 7.00E-06 Response to mTOR inhibitor (everolimus) / / 24009623 rs2702449 chr4 179401433 G A 9.34E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs1903532 chr4 179407255 A C 0.000198 Ovarian cancer / / 22794196 rs17066280 chr4 179452941 G T 0.000584 Height (Pygmy height) / / 22570615 rs2702403 chr4 179461752 G A 5.16E-05 Cognitive impairment induced by topiramate / / 22091778 rs2702403 chr4 179461752 G A 5.56E-05 Triglycerides / / pha003080 rs1903568 chr4 179470439 A G 3.42E-05 Triglycerides / / pha003080 rs17066329 chr4 179471262 C T 0.000154 Transmission distortion / / 22377632 rs4470674 chr4 179489581 T A 9.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs880240 chr4 179492948 G T 8.11E-05 Waist-Hip Ratio / / pha003013 rs880240 chr4 179492948 G T 1.66E-05 Waist-Hip Ratio / / pha003028 rs2378913 chr4 179513299 C G 9.45E-04 Type 2 diabetes / / 17463246 rs2715515 chr4 179513612 T C 9.45E-04 Type 2 diabetes / / 17463246 rs2614583 chr4 179513656 C T 7.43E-04 Type 2 diabetes / / 17463246 rs2715521 chr4 179514892 G A 7.81E-04 Type 2 diabetes / / 17463246 rs9999864 chr4 179518618 G A 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs17066498 chr4 179537855 T G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17066514 chr4 179539412 G C 0.000484 Height (Pygmy height) / / 22570615 rs10434287 chr4 179549653 G A 7.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs720093 chr4 179550874 T C 4.30E-04 Acute lung injury / / 22295056 rs1434039 chr4 179589796 A C 7.97E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs346101 chr4 179604212 G A 6.69E-05 Major depressive disorder (broad) / / 20038947 rs12506809 chr4 179606545 G A 7.84E-05 Major depressive disorder (broad) / / 20038947 rs406797 chr4 179607090 T C 6.71E-05 Major depressive disorder (broad) / / 20038947 rs13136757 chr4 179608992 C T 9.54E-05 Major depressive disorder (broad) / / 20038947 rs6827191 chr4 179612707 T G 9.43E-05 Major depressive disorder (broad) / / 20038947 rs4862035 chr4 179614998 A G 3.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10520412 chr4 179627762 A C 6.67E-05 Multiple complex diseases / / 17554300 rs17732173 chr4 179646969 G A 8.28E-04 Type 2 diabetes / / 17463246 rs13149322 chr4 179647630 A G 2.00E-05 Urinary metabolites / / 21572414 rs436324 chr4 179651447 C A 1.11E-04 Heart Failure / / pha002885 rs2082603 chr4 179675395 C T 3.43E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs346119 chr4 179683403 T C 4.83E-04 Longevity / / 22279548 rs17066770 chr4 179697552 C T 4.79E-04 Multiple complex diseases / / 17554300 rs17066772 chr4 179699624 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2044699 chr4 179708382 C G 4.02E-04 Multiple complex diseases / / 17554300 rs1448952 chr4 179713813 A G 8.76E-05 Multiple complex diseases / / 17554300 rs972940 chr4 179715588 C T 6.43E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11933373 chr4 179762028 G A 1.45E-04 Multiple complex diseases / / 17554300 rs1376544 chr4 179918551 C T 9.20E-06 Biomarkers / / 17903293 rs2167371 chr4 179921683 G A 2.59E-04 Stroke / / pha002886 rs13118957 chr4 179927002 A G 9.67E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13151036 chr4 179932861 T C 4.26E-05 Blood Pressure / / pha003046 rs1839764 chr4 179947944 A C,T 4.36E-05 Hemoglobin / / pha003098 rs1839764 chr4 179947944 A C,T 8.15E-05 Erythrocyte counts / / pha003099 rs9312239 chr4 179962359 T G 2.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9312239 chr4 179962359 T G 8.14E-05 Hemoglobin / / pha003098 rs4862564 chr4 179966005 G A 2.84E-05 Hemoglobin / / pha003098 rs4862564 chr4 179966005 G A 7.80E-05 Erythrocyte counts / / pha003099 rs1993095 chr4 180000268 G A 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6552333 chr4 180009586 A G 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs716846 chr4 180015892 A G 9.86E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7699104 chr4 180032926 A C 7.86E-05 Alzheimer's disease (late onset) / / 21379329 rs9994287 chr4 180047302 T G 2.42E-06 Alzheimer's disease (late onset) / / 21379329 rs17067123 chr4 180048362 C T 8.00E-06 Response to hepatitis C treatment / / 19684573 rs6850226 chr4 180052577 T G 7.10E-05 Response to hepatitis C treatment / / 19684573 rs1036767 chr4 180068417 G A 8.35E-05 Response to hepatitis C treatment / / 19684573 rs17067173 chr4 180085873 A C 6.84E-04 Acute lung injury / / 22295056 rs1379410 chr4 180131863 A G 5.95E-05 Triglycerides / / pha003080 rs6848106 chr4 180193431 T G 8.77E-04 Multiple complex diseases / / 17554300 rs6828433 chr4 180193914 G A 2.11E-04 Tourette syndrome / / 22889924 rs6812195 chr4 180203808 G A 3.45E-04 Tourette syndrome / / 22889924 rs17067333 chr4 180207433 T C 4.04E-04 Tourette syndrome / / 22889924 rs2100515 chr4 180251679 G C 8.88E-06 Alzheimer's disease / / 17998437 rs41498145 chr4 180257426 G C 2.66E-04 Multiple complex diseases / / 17554300 rs41479945 chr4 180257697 C A 3.01E-04 Multiple complex diseases / / 17554300 rs10520423 chr4 180261198 G A 3.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7657084 chr4 180281632 G A 3.08E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6811556 chr4 180284814 T C 9.00E-06 Ulcerative colitis / / 20848476 rs10520425 chr4 180285435 C G 5.50E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4861770 chr4 180292661 G A 4.76E-04 Alzheimer's disease (late onset) / / 21379329 rs4861770 chr4 180292661 G A 4.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4861771 chr4 180292791 A T 4.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4861773 chr4 180293616 G A 6.88E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs12505720 chr4 180301379 A C 4.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1378554 chr4 180302451 C T 2.55E-04 Alzheimer's disease (late onset) / / 21379329 rs2061147 chr4 180307360 C A 3.80E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7688643 chr4 180319752 C T 3.78E-05 Coronary restenosis / / 21878436 rs6837023 chr4 180330521 G A 5.90E-06 Urinary metabolites / / 21572414 rs7670329 chr4 180341676 A G 5.08E-04 Coronary heart disease / / 21971053 rs1455661 chr4 180344099 T C 5.90E-04 Coronary heart disease / / 21971053 rs2716816 chr4 180383312 C T 7.00E-06 Breast size / / 22747683 rs2681344 chr4 180392442 G C 5.39E-04 Acute lung injury / / 22295056 rs2605070 chr4 180420134 T G 9.90E-04 Acute lung injury / / 22295056 rs2681359 chr4 180425739 G A 8.98E-04 Acute lung injury / / 22295056 rs4861784 chr4 180446118 T C 8.41E-05 Erythrocyte counts / / pha003101 rs17067775 chr4 180464674 A G 5.03E-04 Acute lung injury / / 22295056 rs10017041 chr4 180466309 T C 2.70E-04 Alcohol dependence / / 20201924 rs3911604 chr4 180467437 G A 8.53E-04 Acute lung injury / / 22295056 rs2611010 chr4 180494660 T G 9.42E-04 Acute lung injury / / 22295056 rs2333689 chr4 180499234 T G 3.51E-04 Coronary heart disease / / 21971053 rs3902658 chr4 180514510 C T 3.90E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs3849594 chr4 180530417 T A 1.60E-05 Urinary metabolites / / 21572414 rs3849596 chr4 180530545 A T 3.80E-06 Urinary metabolites / / 21572414 rs17067866 chr4 180537212 T C 1.16E-04 Acute lung injury / / 22295056 rs17067866 chr4 180537212 T C 6.23E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs10022153 chr4 180540018 A T 1.32E-05 Acute lung injury / / 22295056 rs10033362 chr4 180578801 A C 2.34E-04 Multiple complex diseases / / 17554300 rs6836146 chr4 180579444 A C 6.30E-05 Body mass index / / 20818722 rs6840953 chr4 180586598 C T 3.70E-04 Smoking initiation / / 24665060 rs17067921 chr4 180611295 G A 2.32E-04 Acute lung injury / / 22295056 rs17067948 chr4 180614451 G C 6.09E-04 Acute lung injury / / 22295056 rs10084816 chr4 180638233 T C 4.51E-05 Femoral neck bone geometry / / 22087292 rs17746001 chr4 180655625 C T 3.00E-07 Bipolar disorder and schizophrenia / / 22688191 rs2383393 chr4 180664653 A G 2.00E-06 Body mass index / / 19851299 rs17090640 chr4 180667647 G A 3.00E-06 Multiple sclerosis / / 23412934 rs10520433 chr4 180669418 T C 1.21E-05 Anxiety and major depressive disorder / / 24047446 rs13125519 chr4 180678226 A C 9.36E-04 Alzheimer's disease / / 17998437 rs17068150 chr4 180685225 G T 1.59E-04 Sudden cardiac arrest / / 21658281 rs17068153 chr4 180686209 A T 6.97E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6844851 chr4 180688000 C T 5.43E-06 Multiple complex diseases / / 17554300 rs6844851 chr4 180688000 C T 9.00E-07 Bipolar disorder / / 21254220 rs11495908 chr4 180704918 A G 2.00E-06 Obesity-related traits / / 23251661 rs11495908 chr4 180704918 A G 4.00E-06 Obesity-related traits / / 23251661 rs1903027 chr4 180715010 T C 3.03E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs17068194 chr4 180715058 G A 2.75E-04 Multiple complex diseases / / 17554300 rs10520437 chr4 180763969 A G 7.72E-05 Bone mass and geometry / / 17903296 rs6832008 chr4 180774423 A G 1.35E-04 Bipolar disorder,schizoaffective / / 19567891 rs2383360 chr4 180776662 C T 1.65E-04 Bipolar disorder,schizoaffective / / 19567891 rs1458692 chr4 180787571 A T 1.22E-04 Bipolar disorder,schizoaffective / / 19567891 rs922028 chr4 180787754 A G 1.53E-05 Bone mass and geometry / / 17903296 rs1458696 chr4 180797158 A G 9.60E-04 Alzheimer's disease / / 17998437 rs1458696 chr4 180797158 A G 8.55E-05 Bipolar disorder,schizoaffective / / 19567891 rs4298171 chr4 180797274 G A 4.91E-04 Alzheimer's disease / / 17998437 rs4298171 chr4 180797274 G A 7.44E-05 Bipolar disorder,schizoaffective / / 19567891 rs202204052 chr4 180798886 A AC 2.78E-05 Eosinophil counts / / pha003088 rs7654672 chr4 180798886 A C 2.78E-05 Eosinophil counts / / pha003088 rs6826314 chr4 180801466 G A 5.78E-04 Smoking initiation / / 24665060 rs7659679 chr4 180842442 A G 5.37E-05 Cytomegalovirus antibody response / / 21993531 rs10033823 chr4 180844859 C T 7.17E-04 Type 2 diabetes / / 17463246 rs12512992 chr4 180844991 C T 4.80E-07 Urinary metabolites / / 21572414 rs13112173 chr4 180846512 A G 9.74E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4861426 chr4 180863539 T C 1.11E-04 Cognitive function / / 24684796 rs17768926 chr4 180869437 T C 7.31E-05 Cytomegalovirus antibody response / / 21993531 rs6848283 chr4 180873138 T G 6.96E-05 Cytomegalovirus antibody response / / 21993531 rs17769849 chr4 180899465 C T 5.40E-04 Alcohol dependence / / 20201924 rs17068502 chr4 180901257 A G 2.40E-05 Urinary metabolites / / 21572414 rs6836201 chr4 180902757 C T 7.41E-05 Monocyte chemoattractant protein-1 / / pha003071 rs6836406 chr4 180902914 A G 7.20E-04 Alcohol dependence / / 20201924 rs6836406 chr4 180902914 A G 6.78E-05 Monocyte chemoattractant protein-1 / / pha003071 rs17068518 chr4 180903415 T C 9.96E-05 Cytomegalovirus antibody response / / 21993531 rs4861824 chr4 180903852 A G 4.86E-04 Alzheimer's disease (late onset) / / 21379329 rs4861824 chr4 180903852 A G 7.66E-04 Heart Failure / / pha002885 rs17068523 chr4 180903980 C T 9.97E-05 Cytomegalovirus antibody response / / 21993531 rs6851375 chr4 180905257 G T 1.80E-04 Alzheimer's disease (late onset) / / 21379329 rs10011033 chr4 180915243 A G 8.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs2871089 chr4 180916384 C T 1.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs6835516 chr4 180929339 T C 8.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs6858229 chr4 180929378 A G 1.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs7684057 chr4 180930013 T C 1.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs9683583 chr4 180951694 G A 8.91E-04 Type 1 diabetes nephropathy / / 23028342 rs2309127 chr4 180955027 C G 1.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs1112857 chr4 180959787 T C 1.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs1994816 chr4 180968431 G A 5.00E-07 Multiple myeloma (IgH translocation) / / 23502783 rs1447338 chr4 181043395 G A 3.10E-05 Age-related macular degeneration / / 20861866 rs1447338 chr4 181043395 G A 5.02E-06 Age-related macular degeneration / / 21197116 rs1447338 chr4 181043395 G A 2.10E-07 Age-related macular degeneration / / pha000001 rs1447338 chr4 181043395 G A 3.10E-05 Age-related macular degeneration / / pha002856 rs9990459 chr4 181046018 C T 1.70E-05 Urinary metabolites / / 21572414 rs1689021 chr4 181056626 C A 7.10E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1689021 chr4 181056626 C A 7.84E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17068752 chr4 181076107 C T 8.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs13129209 chr4 181076187 T C 5.94E-05 Age-related macular degeneration / / 21197116 rs13129209 chr4 181076187 T C 3.93E-06 Age-related macular degeneration / / pha000001 rs11938994 chr4 181095054 T C 7.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs17068809 chr4 181096645 G A 2.00E-04 Information processing speed / / 21130836 rs7660942 chr4 181100582 A G 8.35E-05 Cognitive test performance / / 20125193 rs1868056 chr4 181124250 C A 1.18E-04 Stroke / / pha002887 rs7655191 chr4 181137134 G A 2.14E-04 Age-related macular degeneration / / 22125219 rs1447324 chr4 181150585 C T 7.50E-06 Urinary metabolites / / 21572414 rs1447323 chr4 181152554 A G 3.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17069038 chr4 181169328 A C 9.53E-04 Type 2 diabetes / / 17463246 rs17069038 chr4 181169328 A C 5.23E-06 Heart Rate / / pha003051 rs17069038 chr4 181169328 A C 6.35E-05 Heart Rate / / pha003054 rs1542204 chr4 181179545 G A 3.43E-06 Heart Rate / / pha003051 rs1542204 chr4 181179545 G A 1.65E-05 Heart Rate / / pha003054 rs17069063 chr4 181209986 T C 7.63E-06 Metabolite levels (MHPG) / / 23319000 rs17069141 chr4 181222689 T G 2.06E-04 Multiple complex diseases / / 17554300 rs17834570 chr4 181225219 A C 7.17E-06 Basophils / / pha003087 rs17834666 chr4 181229200 G A 1.00E-06 Metabolite levels (HVA/MHPG ratio) / / 23319000 rs17834666 chr4 181229200 G A 8.00E-06 Metabolite levels (HVA) / / 23319000 rs73869758 chr4 181234993 C T 3.93E-06 Metabolite levels (MHPG) / / 23319000 rs12512821 chr4 181237230 T C 8.22E-06 Acne (severe teenage) / / 24114350 rs17778403 chr4 181237984 G T 8.25E-06 Acne (severe teenage) / / 24114350 rs4290930 chr4 181239651 G A 6.24E-05 Serum metabolites / / 19043545 rs17835436 chr4 181243766 T C 6.40E-06 Basophils / / pha003087 rs7678371 chr4 181260410 T C 2.90E-05 Urinary metabolites / / 21572414 rs2309336 chr4 181261323 C T 7.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6830593 chr4 181263217 G A 1.99E-04 Parkinson's disease / / 17052657 rs11934830 chr4 181289100 A C 2.20E-05 Urinary metabolites / / 21572414 rs9995051 chr4 181298739 C T 1.38E-05 Heart Failure / / pha002885 rs10520447 chr4 181300520 G A 2.28E-05 Personality dimensions / / 22628180 rs10780063 chr4 181310204 A G 1.19E-04 Body mass index / / 21701565 rs10780063 chr4 181310204 A G 1.73E-04 Body mass index / / 21701565 rs10780063 chr4 181310204 A G 3.46E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs6824472 chr4 181314643 A G 1.27E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs4473690 chr4 181315369 T G 5.00E-04 Type 2 diabetes / / 17463246 rs4484340 chr4 181315495 G C 8.93E-04 Type 2 diabetes / / 17463246 rs4484340 chr4 181315495 G C 2.33E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs4604091 chr4 181338155 G T 1.80E-05 Urinary metabolites / / 21572414 rs17793705 chr4 181347530 G A 8.86E-05 Body mass (lean) / / 19268274 rs1320083 chr4 181350614 T C 7.40E-05 Immunoglobulin A / / 20694011 rs13127074 chr4 181361180 A G 7.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4552520 chr4 181366289 T C 4.16E-04 Body mass index / / 21701565 rs17069668 chr4 181465287 G A 9.24E-04 Obesity (extreme) / / 21935397 rs7656346 chr4 181489069 G A 2.37E-05 Information processing speed / / 21130836 rs3113749 chr4 181492677 G T 1.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3113749 chr4 181492677 G T 5.73E-05 HIV-1 viral setpoint / / 22174851 rs7669125 chr4 181498188 C T 1.93E-09 Metabolite levels / / 23281178 rs6851295 chr4 181499830 C G 1.74E-09 Metabolite levels / / 23281178 rs1422505 chr4 181504039 T C 5.56E-10 Metabolite levels / / 23281178 rs11132005 chr4 181506435 T A 2.45E-09 Metabolite levels / / 23281178 rs1559101 chr4 181526927 A G 7.24E-05 Asthma / / pha003127 rs2613097 chr4 181639323 T G 3.17E-04 Lung function (forced vital capacity) / / 24023788 rs2545305 chr4 181719685 G A 1.40E-05 Urinary metabolites / / 21572414 rs2250756 chr4 181720516 A G 3.30E-06 Urinary metabolites / / 21572414 rs6831911 chr4 181749157 T C 9.01E-05 Multiple complex diseases / / 17554300 rs7657018 chr4 181757422 G A,C,T 8.70E-06 Urinary metabolites / / 21572414 rs4241727 chr4 181764559 C T 0.0000027 Mean arterial pressure / / 22510845 rs11737773 chr4 181766112 C T 1.10E-05 Urinary metabolites / / 21572414 rs11726362 chr4 181771857 T A 1.80E-05 Urinary metabolites / / 21572414 rs17810271 chr4 181772318 G A 1.80E-05 Urinary metabolites / / 21572414 rs7692001 chr4 181801052 A G 2.93E-05 Personality dimensions / / 22628180 rs6845611 chr4 181825020 G A 3.84E-05 Stroke / / pha002887 rs17070289 chr4 181825319 T G 1.41E-04 Breast cancer / / 21060860 rs6821660 chr4 181863910 C A 1.46E-04 Breast cancer / / 21060860 rs1969401 chr4 181886803 C T 7.78E-04 Depression (quantitative trait) / / 20800221 rs10018261 chr4 181888903 A G 3.79E-04 Stroke / / pha002887 rs6850916 chr4 181896388 C T 7.69E-05 Longevity / / 20304771 rs10016729 chr4 181907769 A G 1.40E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs144528140 chr4 181908501 T C 2.24E-05 Acne (severe) / / 24927181 rs1916109 chr4 181910926 A C 4.74E-04 Type 2 diabetes / / 17463246 rs1916109 chr4 181910926 A C 3.65E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2222427 chr4 181912396 T C 8.44E-04 Type 2 diabetes / / 17463246 rs6843038 chr4 181925065 C T 6.18E-04 Alzheimer's disease / / 17998437 rs6843038 chr4 181925065 C T 4.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17813262 chr4 181928612 C T 8.17E-05 Multiple complex diseases / / 17554300 rs71619046 chr4 181929214 T C 0.0000621 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7659915 chr4 181945777 A G 1.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10520463 chr4 181972841 G A 1.15E-06 Central corneal thickness / / 20719862 rs35938219 chr4 181978025 C T 0.0000834 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13120104 chr4 181979722 C T 9.30E-06 Central corneal thickness / / 20719862 rs11734667 chr4 181985175 T C 0.0000343 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11132043 chr4 181990780 A G 1.30E-06 Central corneal thickness LINC00290 intron 20719862 rs7664603 chr4 181992356 G T 2.52E-04 Obesity (extreme) LINC00290 intron 21935397 rs10213366 chr4 181997755 C T 5.39E-04 Type 2 diabetes LINC00290 intron 17463246 rs10213366 chr4 181997755 C T 2.53E-04 Obesity (extreme) LINC00290 intron 21935397 rs7440625 chr4 182048692 A G,T 3.25E-04 Obesity (extreme) LINC00290 intron 21935397 rs12651346 chr4 182062778 T C 2.30E-04 Obesity (extreme) LINC00290 intron 21935397 rs12649204 chr4 182064241 G T 2.27E-04 Obesity (extreme) LINC00290 intron 21935397 rs17070655 chr4 182068819 G A 8.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00290 intron 20877124 rs10520465 chr4 182068883 A G 5.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00290 intron 20877124 rs10520467 chr4 182072142 A G 8.60E-04 Type 2 diabetes and 6 quantitative traits LINC00290 intron 17848626 rs1454709 chr4 182108103 T A 4.72E-04 Type 2 diabetes / / 17463246 rs10003686 chr4 182122202 G A 3.28E-05 Type 2 diabetes / / 17463246 rs4861470 chr4 182123833 A T 2.90E-04 Body mass index / / 21701565 rs5019445 chr4 182126122 A G 7.58E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs5019445 chr4 182126122 A G 3.62E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11730886 chr4 182126183 G A 6.06E-04 Type 2 diabetes / / 17463246 rs17070761 chr4 182126334 C G 1.63E-04 Body mass index / / 21701565 rs1378119 chr4 182127477 C T 0.0004967 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1378119 chr4 182127477 C T 4.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9995325 chr4 182131530 A G 2.03E-05 Type 2 diabetes / / 17463246 rs11725133 chr4 182138518 A G 0.0004865 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11725133 chr4 182138518 A G 4.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9994253 chr4 182140400 T C 3.28E-05 Type 2 diabetes / / 17463246 rs11935203 chr4 182143403 T C 0.0003347 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11935203 chr4 182143403 T C 3.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17070807 chr4 182145664 G A 0.0003347 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17070807 chr4 182145664 G A 3.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17090652 chr4 182145869 T C 0.000321 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17090652 chr4 182145869 T C 3.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17829410 chr4 182145994 T C 3.02E-05 Type 2 diabetes / / 17463246 rs11726323 chr4 182146539 G T 0.0003179 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11726323 chr4 182146539 G T 3.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17070813 chr4 182146681 A G 3.76E-04 Body mass index / / 21701565 rs10012888 chr4 182155026 C T 8.34E-04 Tourette syndrome / / 22889924 rs10024557 chr4 182163907 G A 7.99E-04 Multiple complex diseases / / 17554300 rs4861929 chr4 182164515 C T 2.60E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7669856 chr4 182178058 G A 6.42E-05 Body Mass Index / / pha003009 rs7669856 chr4 182178058 G A 3.22E-05 Weight / / pha003027 rs17090656 chr4 182183963 A G 3.32E-05 Multiple complex diseases / / 17554300 rs9999587 chr4 182191327 C T 8.92E-04 Multiple complex diseases / / 17554300 rs17070928 chr4 182195136 T C 2.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1454694 chr4 182197947 T C 9.00E-08 Non-small cell lung cancer (recurrence rate) / / 24737549 rs10019279 chr4 182198479 T C 7.96E-07 Non-small cell lung cancer (recurrence rate) / / 24737549 rs1563213 chr4 182199391 G A 2.46E-05 Cognitive test performance / / 20125193 rs5012808 chr4 182203251 C A 2.67E-06 Non-small cell lung cancer (recurrence rate) / / 24737549 rs17241910 chr4 182207818 G A 1.32E-06 Non-small cell lung cancer (recurrence rate) / / 24737549 rs4861938 chr4 182210944 A C 3.25E-05 Personality dimensions / / 22628180 rs4861939 chr4 182210989 C T 3.31E-05 Personality dimensions / / 22628180 rs17070987 chr4 182211105 G A 3.32E-05 Personality dimensions / / 22628180 rs7681232 chr4 182213030 A G 3.77E-05 Personality dimensions / / 22628180 rs28431436 chr4 182217227 A G 4.59E-05 Non-small cell lung cancer (recurrence rate) / / 24737549 rs2309470 chr4 182222033 T C 3.31E-05 Cognitive test performance / / 20125193 rs17183114 chr4 182222727 G T 8.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs6842553 chr4 182255873 A T 8.10E-04 Multiple complex diseases / / 17554300 rs7674604 chr4 182271880 G A 7.70E-08 Metabolite levels / / 23281178 rs17244695 chr4 182272486 G A 3.17E-05 Aging (time to event) / / 21782286 rs17071193 chr4 182284295 G A 5.82E-04 Multiple complex diseases / / 17554300 rs7692027 chr4 182287004 G A 7.79E-04 Type 2 diabetes / / 17463246 rs17246459 chr4 182291443 A G 6.64E-04 Alzheimer's disease / / 22005930 rs13102450 chr4 182292161 T C 5.03E-04 Alzheimer's disease / / 22005930 rs10520479 chr4 182292713 T C 4.88E-04 Alzheimer's disease / / 22005930 rs10520479 chr4 182292713 T C 1.16E-05 Blood Pressure / / pha003046 rs13145131 chr4 182297666 T C 3.94E-05 Blood Pressure / / pha003046 rs4522908 chr4 182304873 G T 6.40E-04 Smoking cessation / / 24665060 rs2309474 chr4 182309105 G A 3.49E-04 Smoking cessation / / 24665060 rs4861952 chr4 182321030 T C 3.50E-05 Blood Phenotypes / / 17903294 rs6857599 chr4 182329856 T G 5.40E-08 Metabolite levels / / 23281178 rs4549432 chr4 182350657 T C 4.33E-04 Multiple complex diseases / / 17554300 rs12507878 chr4 182362541 G A 3.48E-04 Multiple complex diseases / / 17554300 rs10520494 chr4 182372186 G A 2.56E-04 Multiple complex diseases / / 17554300 rs10027214 chr4 182377628 A C 5.33E-04 Rheumatoid arthritis / / 21452313 rs41336947 chr4 182383893 A G 1.04E-04 Multiple complex diseases / / 17554300 rs7687690 chr4 182396586 G T 2.85E-04 Smoking cessation / / 24665060 rs17198232 chr4 182397985 C G 1.90E-05 Urinary metabolites / / 21572414 rs7672826 chr4 182399695 G A 9.82E-04 Multiple complex diseases / / 17554300 rs7672826 chr4 182399695 G A 8.00E-06 Multiple sclerosis / / 19010793 rs4861969 chr4 182407633 T C 6.51E-04 Smoking cessation / / 24665060 rs4861478 chr4 182411624 T C 4.60E-04 Smoking cessation / / 24665060 rs920083 chr4 182431113 A G 1.40E-05 Tunica Media / / pha003034 rs10520484 chr4 182433814 C A 4.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1439278 chr4 182450209 T C 5.61E-05 Post-operative nausea and vomiting / / 21694509 rs7676402 chr4 182463644 T A 9.35E-05 Bipolar disorder / / 19488044 rs11132079 chr4 182470191 T C 8.81E-04 Glaucoma (primary open-angle) / / 22419738 rs4362864 chr4 182472791 T C 9.45E-05 Glucose levels / / pha003058 rs2043893 chr4 182477386 G A 2.87E-06 Obesity-related traits / / 23251661 rs10049737 chr4 182482567 G A 5.80E-07 Multiple complex diseases / / 17554300 rs1439283 chr4 182484769 C T 2.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1439283 chr4 182484769 C T 1.00E-06 Obesity-related traits / / 23251661 rs10000299 chr4 182507884 T G 3.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs17071906 chr4 182537084 A C 3.34E-04 Acute lung injury / / 22295056 rs10019370 chr4 182538514 G A 3.24E-04 Multiple complex diseases / / 17554300 rs17071911 chr4 182538969 C T 2.94E-04 Acute lung injury / / 22295056 rs17071912 chr4 182539137 T C 1.54E-04 Multiple complex diseases / / 17554300 rs1545184 chr4 182542610 T C 3.65E-04 Acute lung injury / / 22295056 rs745705 chr4 182544594 A G 3.01E-04 Acute lung injury / / 22295056 rs11725036 chr4 182547331 C T 5.03E-04 Multiple complex diseases / / 17554300 rs6815916 chr4 182553043 A G 7.00E-10 Venous thromboembolism (gene x gene interaction) / / 23509962 rs17212276 chr4 182571325 T G 2.28E-04 Multiple complex diseases / / 17554300 rs11727308 chr4 182572180 A G 4.51E-04 Multiple complex diseases / / 17554300 rs17212405 chr4 182573669 T C 3.04E-04 Multiple complex diseases / / 17554300 rs17278459 chr4 182576403 A G 6.71E-04 Multiple complex diseases / / 17554300 rs6552517 chr4 182576586 C T 3.00E-04 Alcohol dependence / / 20201924 rs10520504 chr4 182602106 A T 4.30E-06 Urinary metabolites / / 21572414 rs12641856 chr4 182609865 G A 2.00E-06 Preeclampsia / / 23551011 rs2309573 chr4 182614559 T G 0.0000308 Panic disorder / / 23149450 rs2309573 chr4 182614559 T G 3.08E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs2010595 chr4 182615103 G T 7.28E-05 Coronary heart disease / / 21606135 rs715654 chr4 182615493 A G 1.09E-04 Gallstones / / 17632509 rs715654 chr4 182615493 A G 2.42E-05 Coronary heart disease / / 21606135 rs7696504 chr4 182616495 C G 4.71E-05 Coronary heart disease / / 21606135 rs7697691 chr4 182616957 G A 6.88E-05 Coronary heart disease / / 21606135 rs4861491 chr4 182627579 A G 3.41E-04 Alzheimer's disease / / 22005930 rs6848193 chr4 182638513 A G 7.40E-05 Schizophrenia / / 19571808 rs6848193 chr4 182638513 A G 1.50E-05 Intraocular pressure / / 24002674 rs12502114 chr4 182641214 G A 3.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs7660940 chr4 182659258 G A 3.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs7685364 chr4 182659274 T A 5.63E-04 Multiple complex diseases / / 17554300 rs10520510 chr4 182686437 C T 8.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs7659598 chr4 182699379 G A 3.65E-05 Parkinson's disease / / 21812969 rs12504073 chr4 182700658 A C 4.63E-04 Suicide attempts in bipolar disorder / / 21041247 rs6855088 chr4 182704551 A G 9.00E-07 Obesity-related traits / / 23251661 rs6552523 chr4 182720291 C T 1.90E-06 Obesity-related traits / / 23251661 rs12505472 chr4 182749585 C T 2.73E-05 Body Mass Index / / pha003014 rs17072378 chr4 182753524 T C 4.52E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2048917 chr4 182757120 C T 6.69E-04 Type 2 diabetes / / 17463246 rs11931121 chr4 182775986 A G 1.10E-05 Urinary metabolites / / 21572414 rs7655087 chr4 182777782 G T 1.20E-05 Urinary metabolites / / 21572414 rs10520514 chr4 182782545 T A 5.00E-06 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs9312281 chr4 182783183 A G 1.10E-06 Urinary metabolites / / 21572414 rs2063955 chr4 182786746 A G 5.92E-05 Creatinine levels / / pha003069 rs6841841 chr4 182790626 A G 5.51E-04 Response to TNF antagonist treatment / / 21061259 rs11724059 chr4 182805092 G A 3.51E-04 Response to TNF antagonist treatment / / 21061259 rs1028166 chr4 182813298 G A 6.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1878468 chr4 182822332 G A 5.15E-04 Response to TNF antagonist treatment / / 21061259 rs2048914 chr4 182825247 A G 5.02E-04 Response to TNF antagonist treatment / / 21061259 rs10027694 chr4 182825370 C T 2.67E-05 Telomere length / / 23900074 rs17286513 chr4 182830928 C T 4.37E-04 Response to TNF antagonist treatment / / 21061259 rs6813301 chr4 182859352 C A 9.67E-04 Type 2 diabetes / / 17463246 rs17072596 chr4 182872449 C T 3.15E-07 Alzheimer's disease / / 17998437 rs17072597 chr4 182872485 C T 1.66E-06 Alzheimer's disease / / 17998437 rs17072597 chr4 182872485 C T 4.62E-04 Bipolar disorder,schizoaffective / / 19567891 rs7671217 chr4 182878750 G A 2.31E-06 Alzheimer's disease / / 17998437 rs7671217 chr4 182878750 G A 7.74E-04 Bipolar disorder,schizoaffective / / 19567891 rs7671091 chr4 182889455 G A 3.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12163894 chr4 182895904 C G 9.26E-04 Blood pressure / / 24001895 rs11132102 chr4 182918025 G C 6.27E-04 Alzheimer's disease / / 22005930 rs12503812 chr4 182918564 G A 2.19E-05 Triglycerides / / 19074352 rs12503812 chr4 182918564 G A 2.19E-05 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs10520516 chr4 182944981 A G 4.29E-04 Aortic root size / / 21223598 rs7693462 chr4 182965163 A G 9.26E-04 Type 2 diabetes / / 17463246 rs17072682 chr4 182965593 G A,C 5.92E-05 Type 2 diabetes / / 17463246 rs17072702 chr4 182976765 T C 6.34E-05 Lung adenocarcinoma / / 19836008 rs1458898 chr4 182992054 A G 1.10E-05 Urinary metabolites / / 21572414 rs10520520 chr4 183024077 C T 9.42E-04 Myocardial Infarction / / pha002883 rs2597131 chr4 183027158 G A 9.22E-04 Insulin resistance / / 21901158 rs6815885 chr4 183030136 G A 3.99E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1458893 chr4 183033029 C T 3.56E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs335069 chr4 183047776 G A 2.72E-04 Myocardial Infarction / / pha002873 rs335067 chr4 183048696 T C 2.66E-04 Multiple complex diseases / / 17554300 rs335090 chr4 183055232 T C 9.96E-04 Multiple complex diseases / / 17554300 rs9312290 chr4 183067139 A G 8.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9312290 chr4 183067139 A G 9.43E-05 Height / / pha003011 rs35306465 chr4 183069703 G C 5.48E-04 Coronary heart disease / / 21606135 rs13126808 chr4 183091203 T C 8.15E-05 Serum metabolites / / 19043545 rs2060645 chr4 183107423 T C 0.000527 5-fluorouracil induced nausea/vomiting in response to colorectal cancer treatment / / 22310351 rs6815953 chr4 183109012 T G 4.75E-05 Telomere length / / 21573004 rs17307191 chr4 183114014 A G 7.69E-04 Alzheimer's disease / / 24755620 rs13115107 chr4 183117920 A G 5.00E-04 Alzheimer's disease (late onset) / / 21460841 rs17307378 chr4 183121623 A G 1.85E-04 Bipolar disorder / / 18317468 rs17235597 chr4 183131995 A G 2.18E-06 Creatinine levels / / pha003069 rs1031313 chr4 183132303 C T 9.77E-05 Multiple sclerosis (age of onset) / / 19010793 rs1031313 chr4 183132303 C T 1.56E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2726806 chr4 183132796 G A 4.18E-05 Creatinine levels / / pha003069 rs17235716 chr4 183134367 A G 1.48E-06 Creatinine levels / / pha003069 rs17072860 chr4 183136858 A G 8.09E-04 Endometrial cancer / / 24096698 rs2726807 chr4 183137398 T C 6.00E-06 Schizophrenia / / 22885689 rs2726814 chr4 183141104 T G 2.30E-04 Smoking behavior / / 20418888 rs2726816 chr4 183143952 G A 1.66E-04 Insulin resistance / / 21901158 rs2726817 chr4 183146482 G A 1.83E-04 Multiple complex diseases / / 17554300 rs6840036 chr4 183163929 C T 6.21E-04 Suicide attempts in bipolar disorder / / 21041247 rs7696796 chr4 183166469 G A 8.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs7696796 chr4 183166469 G A 7.37E-05 Creatinine levels / / pha003069 rs13124389 chr4 183166539 G A 2.70E-05 Urinary metabolites / / 21572414 rs7656126 chr4 183166980 G T 5.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs6552548 chr4 183167536 A C 3.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs7687160 chr4 183170004 A G 2.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12648007 chr4 183184352 G T 9.57E-04 Alzheimer's disease / / 24755620 rs11935520 chr4 183196403 A C 9.87E-06 Smoking initiation / / 24665060 rs2063905 chr4 183198752 T G 3.63E-05 Smoking initiation / / 24665060 rs17072951 chr4 183199772 C T 1.10E-04 Smoking initiation / / 24665060 rs11724903 chr4 183200145 A G 3.00E-07 Smoking initiation / / 24665060 rs17072957 chr4 183201342 C T 1.71E-05 Smoking initiation / / 24665060 rs11732877 chr4 183206596 A G 3.11E-04 Smoking initiation / / 24665060 rs938526 chr4 183213736 T C 5.17E-04 Smoking initiation / / 24665060 rs4862036 chr4 183215747 G A 2.41E-05 Smoking initiation / / 24665060 rs17073007 chr4 183216767 G A 2.23E-04 Smoking initiation / / 24665060 rs4862037 chr4 183218840 C G 1.76E-04 Smoking initiation / / 24665060 rs17073019 chr4 183219189 T C 8.19E-04 Smoking initiation / / 24665060 rs2871298 chr4 183221491 A G 5.80E-04 Smoking initiation / / 24665060 rs1113762 chr4 183221707 C T 9.32E-04 Alzheimer's disease / / 17998437 rs6820425 chr4 183226376 C A 6.19E-06 Smoking initiation / / 24665060 rs6552549 chr4 183229221 A C 6.62E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17073039 chr4 183233693 T C 7.47E-04 Multiple complex diseases / / 17554300 rs1516537 chr4 183255434 G A 8.88E-05 Partial epilepsies ODZ3 intron 20522523 rs10520528 chr4 183260601 T G 2.00E-06 Systolic blood pressure in sickle cell anemia ODZ3 intron 24058526 rs4861505 chr4 183271349 G T 6.37E-05 Eosinophil counts ODZ3 intron pha003088 rs2168682 chr4 183271631 T C 6.47E-04 Myopia (pathological) ODZ3 intron 21095009 rs13148469 chr4 183272312 T C 7.64E-04 Myopia (pathological) ODZ3 intron 21095009 rs10021816 chr4 183300126 G A 9.92E-06 Personality dimensions ODZ3 intron 22628180 rs4862046 chr4 183300614 A G 6.00E-07 IgG glycosylation ODZ3 intron 23382691 rs4862046 chr4 183300614 A G 9.00E-06 IgG glycosylation ODZ3 intron 23382691 rs2045405 chr4 183313353 C T 4.14E-04 Multiple complex diseases ODZ3 intron 17554300 rs17073259 chr4 183330801 T C 2.62E-04 Multiple complex diseases ODZ3 intron 17554300 rs10027571 chr4 183361936 C T 1.60E-06 Retinopathy in non-diabetics ODZ3 intron 23393555 rs961532 chr4 183404294 G A 2.40E-04 Response to taxane treatment (placlitaxel) ODZ3 intron 23006423 rs961533 chr4 183404353 C T 1.91E-04 Response to taxane treatment (placlitaxel) ODZ3 intron 23006423 rs961534 chr4 183404568 T A 2.92E-04 Response to taxane treatment (placlitaxel) ODZ3 intron 23006423 rs10013166 chr4 183477329 G A 2.00E-06 Preschool internalizing problems ODZ3 intron 24839885 rs13145682 chr4 183504017 C T 9.46E-05 Attention deficit hyperactivity disorder ODZ3 intron 22420046 rs17324527 chr4 183538955 T A 1.42E-04 Alzheimer's disease ODZ3 intron 24755620 rs17258738 chr4 183539691 T C 1.60E-04 Alzheimer's disease ODZ3 intron 24755620 rs11132138 chr4 183543770 C T 3.15E-04 Type 2 diabetes ODZ3 intron 17463246 rs10520539 chr4 183556999 C T 3.96E-04 Multiple complex diseases ODZ3 intron 17554300 rs6552587 chr4 183567188 T G 6.63E-05 Cognitive impairment induced by topiramate ODZ3 intron 22091778 rs6850978 chr4 183572390 C T 1.64E-04 Multiple complex diseases ODZ3 intron 17554300 rs11937177 chr4 183576221 G A 4.23E-04 Multiple complex diseases ODZ3 intron 17554300 rs17073719 chr4 183576908 T C 4.09E-04 Multiple complex diseases ODZ3 intron 17554300 rs12498348 chr4 183582696 A G 8.79E-04 Body mass index ODZ3 intron 21701565 rs11132143 chr4 183584690 A G 3.90E-05 Cognitive function ODZ3 intron 24684796 rs2309759 chr4 183593318 A G 8.73E-05 Myocardial Infarction ODZ3 intron pha002883 rs4861517 chr4 183602252 G A 6.10E-04 Iron levels ODZ3 intron pha002876 rs6845497 chr4 183611553 A G 6.91E-04 Type 2 diabetes ODZ3 intron 17463246 rs7670260 chr4 183663971 A G 4.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ODZ3 intron 20877124 rs10520541 chr4 183680605 C G 3.95E-04 Type 2 diabetes ODZ3 intron 17463246 rs10520541 chr4 183680605 C G 7.00E-05 Subclinical atherosclerosis ODZ3 intron 17903303 rs9312304 chr4 183680868 G A 8.88E-04 Multiple complex diseases ODZ3 intron 17554300 rs10028158 chr4 183680961 G A 5.03E-04 Multiple complex diseases ODZ3 intron 17554300 rs4862087 chr4 183681048 C G 3.37E-04 Type 2 diabetes ODZ3 intron 17463246 rs17329750 chr4 183681864 T C 3.91E-04 Type 2 diabetes ODZ3 intron 17463246 rs10017238 chr4 183687789 T C 7.00E-06 Response to amphetamines ODZ3 intron 22952603 rs4862110 chr4 183751029 T C 1.70E-05 Myasthenia gravis / / 23055271 rs4862110 chr4 183751029 T C 2.00E-06 Wegener's granulomatosis / / 23740775 rs4861532 chr4 183791275 A G 1.07E-04 Multiple complex diseases / / 17554300 rs17074159 chr4 183792885 T C 7.64E-05 Bipolar disorder and schizophrenia / / 20889312 rs7698606 chr4 183805438 T C 2.00E-05 Urinary metabolites / / 21572414 rs2515683 chr4 183813147 T C 1.80E-05 Urinary metabolites DCTD intron 21572414 rs12507552 chr4 183813425 C T 5.92E-04 Multiple complex diseases DCTD intron 17554300 rs4742 chr4 183815688 A C,G,T 1 Drug response to Gemcitabine DCTD cds-synon 15224082 rs3886768 chr4 183817324 G A 1.30E-05 Urinary metabolites DCTD intron 21572414 rs13148414 chr4 183817674 G C 2.60E-05 Urinary metabolites DCTD intron 21572414 rs13114435 chr4 183821662 T C 2.00E-06 Obesity-related traits DCTD intron 23251661 rs13101260 chr4 183823597 A G 9.52E-04 Response to alcohol consumption (flushing response) DCTD intron 24277619 rs13116494 chr4 183825702 C A 2.40E-06 Adiposity DCTD intron 19557161 rs11730323 chr4 183836490 C T 2.20E-05 Urinary metabolites DCTD intron 21572414 rs5016499 chr4 183840898 G T 3.10E-04 Stroke / / pha002886 rs11736864 chr4 183853143 C A 2.30E-06 Urinary metabolites / / 21572414 rs17074296 chr4 183854483 C G 6.60E-06 Urinary metabolites / / 21572414 rs13120036 chr4 183874157 G A 1.90E-06 Urinary metabolites / / 21572414 rs4862135 chr4 183904055 A G 9.12E-04 Depression (quantitative trait) / / 20800221 rs1377943 chr4 183929581 C T 9.62E-04 Alcohol dependence / / 21314694 rs2714545 chr4 183935289 C T 4.48E-04 Type 2 diabetes / / 17463246 rs17074380 chr4 183944794 T C 6.98E-04 Type 2 diabetes / / 17463246 rs2085102 chr4 183991637 C T 3.86E-04 Smoking cessation / / 24665060 rs17354774 chr4 183996424 G T 9.59E-04 Type 2 diabetes / / 17463246 rs11132168 chr4 184053187 C T 2.90E-05 Major depressive disorder WWC2 intron 19065144 rs11132168 chr4 184053187 C T 6.29E-05 Major depressive disorder WWC2 intron pha002850 rs17074536 chr4 184180384 C T 8.22E-05 HIV-1 viral setpoint WWC2 intron 22174851 rs17291527 chr4 184183623 G C 7.00E-04 Type 2 diabetes WWC2 intron 17463246 rs1473070 chr4 184192037 C T 2.24E-05 Blood Pressure WWC2 intron pha003049 rs1473070 chr4 184192037 C T 7.34E-05 Blood Pressure WWC2 intron pha003050 rs955748 chr4 184215675 A G 4.00E-08 Height WWC2 intron 20881960 rs955748 chr4 184215675 A G 1.23E-05 Blood Pressure WWC2 intron pha003049 rs2063492 chr4 184231465 C A 9.55E-05 Blood Pressure WWC2 intron pha003049 rs907360 chr4 184234587 T C 3.67E-05 Blood Pressure WWC2 intron pha003049 rs7688467 chr4 184243528 G A 9.55E-05 Blood Pressure CLDN24 missense pha003049 rs907365 chr4 184252789 T G 4.63E-05 Blood Pressure / / pha003049 rs7669080 chr4 184271019 A G 6.88E-04 Parkinson's disease / / 17052657 rs13122009 chr4 184271627 T C 7.34E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10010816 chr4 184272307 G A 7.34E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17074631 chr4 184277307 A G 4.00E-05 Major depressive disorder / / 19065144 rs17074631 chr4 184277307 A G 4.09E-05 Major depressive disorder / / 21621269 rs17074636 chr4 184278131 T G 7.00E-07 Gout / / 23263486 rs907363 chr4 184278705 G C 2.07E-04 Smoking initiation / / 24665060 rs907364 chr4 184278868 G T 9.60E-04 Parkinson's disease / / 17052657 rs7687627 chr4 184279303 C A 8.45E-05 Coronary Artery Disease / / 17634449 rs17074703 chr4 184300125 C T 6.43E-04 Multiple complex diseases / / 17554300 rs17359646 chr4 184304331 T C 1.41E-04 Multiple complex diseases / / 17554300 rs1588571 chr4 184305340 T C 0.000000492 Secreted IFN-gamma response to smallpox vaccine / / 22661280 rs4862188 chr4 184355370 C T 2.07E-16 Coronary Artery Disease / / 17634449 rs4862188 chr4 184355370 C T 7.78E-20 Gender / / 22362730 rs6844630 chr4 184373811 G A 1.12E-05 Pulmonary function / / 20010835 rs6844862 chr4 184373945 G C 1.12E-05 Pulmonary function / / 20010835 rs4395546 chr4 184451627 T C 5.11E-04 Multiple complex diseases / / 17554300 rs4550975 chr4 184462577 T C 5.78E-05 Heart Rate / / pha003053 rs10050045 chr4 184463473 A C 8.14E-04 Multiple complex diseases / / 17554300 rs7699347 chr4 184463695 A G 3.10E-06 Urinary metabolites / / 21572414 rs7699682 chr4 184463799 C T 3.20E-06 Urinary metabolites / / 21572414 rs4862221 chr4 184473301 A C 1.10E-06 Urinary metabolites / / 21572414 rs6841248 chr4 184479445 C A 3.18E-04 Multiple complex diseases / / 17554300 rs6841248 chr4 184479445 C A 6.94E-04 Coronary Artery Disease / / 17634449 rs11735611 chr4 184494224 G T 7.00E-06 Urinary metabolites / / 21572414 rs13118994 chr4 184530109 T C 4.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs6552695 chr4 184571085 A G 6.23E-05 Rheumatoid arthritis RWDD4 intron 17804836 rs13130564 chr4 184583230 A G 1.45E-05 Orofacial clefts TRAPPC11 intron 22419666 rs7684339 chr4 184590150 C T 7.24E-04 Insulin resistance TRAPPC11 intron 21901158 rs4422454 chr4 184590750 T C 3.39E-04 Lung function (forced expiratory volume in 1 second) TRAPPC11 intron 17255346 rs7680950 chr4 184592515 T G 2.09E-04 Lung function (forced expiratory volume in 1 second) TRAPPC11 intron 17255346 rs4241779 chr4 184600601 A G 4.21E-04 Lung function (forced expiratory volume in 1 second) TRAPPC11 cds-synon 17255346 rs9312316 chr4 184607970 T C 2.43E-04 Lung function (forced expiratory volume in 1 second) TRAPPC11 intron 17255346 rs67383011 chr4 184612553 G C 3.00E-06 Stroke (ischemic) TRAPPC11 missense 22384361 rs9312318 chr4 184629794 G A 6.20E-04 Heart Failure TRAPPC11 intron pha002885 rs11132209 chr4 184651302 G A 5.20E-06 Urinary metabolites / / 21572414 rs28689940 chr4 184682940 C G 0.0000399 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4862250 chr4 184686219 C A 0.0000428 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4862251 chr4 184687644 T C 2.10E-05 Reading and spelling / / 23738518 rs4538533 chr4 184689409 G A 0.00001594 Sarcoidosis / / 22952805 rs4568278 chr4 184689417 G A 0.00001454 Sarcoidosis / / 22952805 rs13117971 chr4 184692389 C T 2.06E-05 Diabetes Mellitus / / pha003060 rs62342214 chr4 184693218 C T 0.000004029 Sarcoidosis / / 22952805 rs4129955 chr4 184694074 C T 6.69E-05 Cognitive decline / / 22054870 rs6845392 chr4 184697574 G T 2.76E-05 Body Composition / / pha003012 rs6845392 chr4 184697574 G T 5.62E-05 Body Mass Index / / pha003021 rs13142457 chr4 184704385 T C 6.47E-05 Hepatocellular carcinoma / / 22807686 rs7684311 chr4 184715142 G C 2.20E-06 Urinary metabolites / / 21572414 rs930306 chr4 184725906 C T 3.86E-05 Glucose levels / / pha003058 rs930306 chr4 184725906 C T 6.43E-06 Glucose levels / / pha003061 rs17294478 chr4 184727418 C T 3.16E-05 Glucose levels / / pha003061 rs7690848 chr4 184739143 C T 5.76E-04 Multiple complex diseases / / 17554300 rs6824804 chr4 184784920 G A 1.80E-06 Urinary metabolites / / 21572414 rs11946426 chr4 184789019 C T 5.60E-06 Urinary metabolites / / 21572414 rs12644463 chr4 184792373 T C 3.30E-06 Urinary metabolites / / 21572414 rs2164303 chr4 184794696 T C 7.00E-06 Urinary metabolites / / 21572414 rs7688995 chr4 184799985 T C 9.38E-04 Multiple complex diseases / / 17554300 rs7688995 chr4 184799985 T C 1.30E-05 Urinary metabolites / / 21572414 rs1469809 chr4 184808546 A G 2.47E-04 Multiple complex diseases / / 17554300 rs1369445 chr4 184813876 A G 4.55E-05 Serum metabolites / / 19043545 rs7675746 chr4 184814324 C T 6.63E-05 Serum metabolites / / 19043545 rs6552716 chr4 184823946 A T 2.90E-05 Pericardial fat / / 22589742 rs13136254 chr4 184824884 C T 2.60E-05 Pericardial fat / / 22589742 rs4862266 chr4 184831454 C T 2.71E-04 Myocardial Infarction STOX2 intron pha002873 rs12502711 chr4 184866656 A G 2.28E-05 Acute lung injury STOX2 intron 22295056 rs12498735 chr4 184921299 C T 8.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients STOX2 intron 23400010 rs61730738 chr4 184930646 G A 0.00056 Prostate cancer STOX2 missense 23555315 rs3749531 chr4 184943274 T C,G 7.91E-05 Bipolar disorder and schizophrenia / / 20889312 rs6552737 chr4 184955461 T A 7.60E-06 Urinary metabolites / / 21572414 rs11724849 chr4 184965956 A T 2.60E-05 Urinary metabolites / / 21572414 rs6846007 chr4 184991604 C T 5.72E-04 Smoking initiation / / 24665060 rs112172480 chr4 185005680 A G 6.44E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs4862307 chr4 185007393 A T 6.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs10024098 chr4 185012101 C A 6.26E-04 Alzheimer's disease ENPP6 UTR-3 17998437 rs17075294 chr4 185012209 C T 8.56E-04 Alzheimer's disease ENPP6 UTR-3 17998437 rs4241784 chr4 185032985 T G 8.16E-05 Information processing speed ENPP6 intron 21130836 rs4241784 chr4 185032985 T G 7.81E-05 Intelligence ENPP6 intron 21826061 rs13103966 chr4 185038691 A G 7.03E-04 Type 2 diabetes ENPP6 intron 17463246 rs6815145 chr4 185063454 T A 8.96E-04 Body mass index ENPP6 intron 21701565 rs11132226 chr4 185065295 G A 1.16E-05 Alcohol and nictotine co-dependence ENPP6 intron 20158304 rs11132226 chr4 185065295 G A 3.08E-06 Alcohol and nictotine co-dependence ENPP6 intron 20158304 rs13147555 chr4 185074686 A C 7.97E-05 Intelligence ENPP6 intron 21826061 rs1921564 chr4 185078076 A G 7.15E-05 Intelligence ENPP6 intron 21826061 rs1921561 chr4 185088648 T C 2.30E-05 Urinary metabolites ENPP6 intron 21572414 rs2178570 chr4 185096468 A G 9.88E-04 Alzheimer's disease ENPP6 intron 22005930 rs6842767 chr4 185104471 A G 7.34E-04 Alzheimer's disease ENPP6 intron 22005930 rs1921569 chr4 185107045 A C 9.41E-04 Alzheimer's disease ENPP6 intron 22005930 rs6552767 chr4 185109994 G A 9.52E-04 Alcohol dependence ENPP6 intron 21314694 rs1882331 chr4 185123766 T C 1.40E-05 Alcoholism (heaviness of drinking) ENPP6 intron 21529783 rs2310001 chr4 185127217 T C 4.43E-05 Cortisol secretion,in saliva ENPP6 intron 21316860 rs10034135 chr4 185127879 A T 4.91E-05 Odorant perception ENPP6 intron 23910658 rs1882328 chr4 185137253 T C 7.86E-04 Rheumatoid arthritis ENPP6 intron 21452313 rs1317078 chr4 185143375 C T 4.76E-05 Blood Pressure / / pha003048 rs17584650 chr4 185160596 G A 2.40E-05 IgE levels / / 17255346 rs1217955 chr4 185166663 C G 5.12E-08 Metabolite levels / / 23281178 rs1217948 chr4 185170357 T C 3.03E-08 Metabolite levels / / 23281178 rs2136757 chr4 185175493 A G 3.26E-04 Smoking initiation / / 24665060 rs13143328 chr4 185177783 T C 2.75E-04 Parkinson's disease / / 16252231 rs953359 chr4 185191512 G A 8.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs812666 chr4 185197061 G A 2.91E-04 Smoking initiation / / 24665060 rs17487801 chr4 185203124 G A 2.98E-04 Age-related macular degeneration / / 22125219 rs3796692 chr4 185205210 C T 9.67E-05 Cytomegalovirus antibody response / / 21993531 rs1217974 chr4 185211829 A G 5.26E-04 Smoking initiation / / 24665060 rs12650550 chr4 185241316 T C 2.88E-04 IgE levels / / 17255346 rs12650550 chr4 185241316 T C 4.54E-04 Multiple complex diseases / / 17554300 rs12650550 chr4 185241316 T C 3.13E-04 Sudden cardiac arrest / / 21658281 rs793892 chr4 185249147 C T 7.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs793894 chr4 185250369 A G 9.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs793915 chr4 185276203 T C 6.04E-05 Suicide attempts in bipolar disorder / / 21423239 rs4326049 chr4 185278885 A G 6.33E-05 Suicide attempts in bipolar disorder / / 21423239 rs4590089 chr4 185279284 T C 1.11E-04 Multiple complex diseases / / 17554300 rs4590089 chr4 185279284 T C 6.30E-05 Suicide attempts in bipolar disorder / / 21423239 rs1105207 chr4 185304463 T C 4.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1131553 chr4 185310218 C T 4.00E-05 HIV-1 viral setpoint IRF2 cds-synon 22174851 rs3775545 chr4 185310997 T C 6.37E-05 Smoking initiation IRF2 intron 24665060 rs3756089 chr4 185315792 C T 8.79E-05 Pulmonary function in asthmatics IRF2 intron 23541324 rs724528 chr4 185323726 G A 7.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IRF2 intron 20877124 rs724528 chr4 185323726 G A 8.75E-04 Substance dependence IRF2 intron 21818250 rs17624154 chr4 185330669 T C 6.60E-04 Suicide attempts in bipolar disorder IRF2 intron 21423239 rs796988 chr4 185333092 A G 2.79E-05 Bipolar disorder IRF2 intron 19488044 rs796988 chr4 185333092 A G 2.64E-05 Bipolar Disorder IRF2 intron pha002863 rs3756091 chr4 185335866 A G 1.93E-04 Multiple complex diseases IRF2 intron 17554300 rs3756091 chr4 185335866 A G 1.74E-04 Gallstones IRF2 intron 17632509 rs17488206 chr4 185338506 A T 2.46E-04 Multiple complex diseases IRF2 intron 17554300 rs2288246 chr4 185339517 C A,G,T 8.28E-05 Erythrocyte counts IRF2 intron pha003099 rs793798 chr4 185382061 C T 1.45E-05 Pulmonary function IRF2 intron 20010835 rs2310047 chr4 185384470 G C 4.84E-04 Response to cytadine analogues (cytosine arabinoside) IRF2 intron 24483146 rs1863316 chr4 185390455 T A 7.46E-05 Pulmonary function IRF2 intron 20010835 rs13146124 chr4 185391408 G A 5.60E-05 Pulmonary function IRF2 intron 20010835 rs17585837 chr4 185425574 C T 2.99E-04 Alzheimer's disease / / 17998437 rs10520563 chr4 185491838 A G 6.18E-05 Information processing speed / / 21130836 rs1976955 chr4 185514341 T C 6.32E-04 Myocardial Infarction / / pha002873 rs4862396 chr4 185543672 T C 4.40E-05 Hemoglobin / / pha003096 rs4647693 chr4 185550764 T C 5.85E-05 Hemoglobin CASP3 intron pha003096 rs4647693 chr4 185550764 T C 3.95E-05 Hematocrit CASP3 intron pha003097 rs4647667 chr4 185555625 G A 0.000000161 Triglycerides CASP3 intron 23063622 rs4647665 chr4 185555866 A G 3.80E-10 Triglycerides CASP3 intron 23063622 rs4647641 chr4 185561390 T G 6.87E-11 LDL cholesterol CASP3 intron 23063622 rs4647614 chr4 185567503 T C 6.56E-09 Triglycerides CASP3 intron 23063622 rs4647608 chr4 185568237 C T 0.000000915 Triglycerides CASP3 intron 23063622 rs4647600 chr4 185570899 T C 2.65E-09 LDL cholesterol CCDC111 UTR-5 23063622 rs12108497 chr4 185571557 C T 4.72E-04 Menopause (age at onset) CCDC111 intron 22267201 rs28463742 chr4 185611005 G A 0.00006461 Sarcoidosis CCDC111 intron 22952805 rs10015956 chr4 185614705 T C 0.00008562 Sarcoidosis CCDC111 intron 22952805 rs6825561 chr4 185615532 A T 0.00009752 Sarcoidosis MLF1IP UTR-3 22952805 rs13478 chr4 185616438 C T 3.80E-06 Kawasaki disease MLF1IP UTR-3 22446962 rs10000507 chr4 185619281 C T 0.00006249 Sarcoidosis MLF1IP intron 22952805 rs10022818 chr4 185619282 A G 0.00008929 Sarcoidosis MLF1IP intron 22952805 rs7683799 chr4 185632164 T C 0.00008933 Sarcoidosis MLF1IP intron 22952805 rs28608669 chr4 185632890 T C 0.00008933 Sarcoidosis MLF1IP intron 22952805 rs7656993 chr4 185635159 T C 0.00007333 Sarcoidosis MLF1IP intron 22952805 rs35533356 chr4 185639134 A G 0.00007681 Sarcoidosis MLF1IP intron 22952805 rs2130392 chr4 185639169 G A 3.00E-08 Kawasaki disease MLF1IP intron 22446962 rs4416519 chr4 185639502 T C 0.00009214 Sarcoidosis MLF1IP intron 22952805 rs57086463 chr4 185639525 G A 0.00009214 Sarcoidosis MLF1IP intron 22952805 rs1401359 chr4 185640216 T C 0.00006876 Sarcoidosis MLF1IP intron 22952805 rs6552807 chr4 185640531 A G 0.00008039 Sarcoidosis MLF1IP intron 22952805 rs7667449 chr4 185641711 T C 0.00008039 Sarcoidosis MLF1IP intron 22952805 rs2130393 chr4 185642335 T C 0.00008039 Sarcoidosis MLF1IP intron 22952805 rs7668789 chr4 185642381 T C 4.61E-04 Suicide attempts in bipolar disorder MLF1IP intron 21423239 rs4623060 chr4 185642943 A G 0.00008039 Sarcoidosis MLF1IP intron 22952805 rs59307711 chr4 185645272 C T 0.00007273 Sarcoidosis MLF1IP intron 22952805 rs902176 chr4 185654320 C T 2.00E-06 Kawasaki disease MLF1IP intron 22446962 rs7671400 chr4 185654651 T C 4.56E-04 Multiple complex diseases MLF1IP intron 17554300 rs6851816 chr4 185654837 C T 2.90E-05 Kawasaki disease MLF1IP intron 22446962 rs12374289 chr4 185687687 A C 5.89E-04 Multiple complex diseases ACSL1 intron 17554300 rs4862417 chr4 185690601 A G 3.76E-05 Attention deficit hyperactivity disorder ACSL1 intron 22420046 rs3792311 chr4 185695324 G A 6.96E-04 White matter integrity ACSL1 intron 22425255 rs6552828 chr4 185725416 A G 0.00000131 Gains in maximal O2 uptake response ACSL1 intron 21183627 rs902177 chr4 185728839 T C 6.10E-05 Major depressive disorder ACSL1 intron 21042317 rs13126272 chr4 185731940 G T 1.82E-46 Multiple complex diseases ACSL1 intron 17554300 rs2280297 chr4 185736113 G C 6.42E-04 Body mass index ACSL1 intron 21701565 rs9997745 chr4 185737843 G A 8.54E-04 Stroke ACSL1 intron pha002887 rs10027540 chr4 185750840 A G 2.54E-05 Hypertension / / 19609347 rs10018054 chr4 185754915 C T 4.96E-04 Multiple complex diseases / / 17554300 rs4862426 chr4 185766634 T C 9.88E-04 Type 2 diabetes / / 17463246 rs2046813 chr4 185769159 C T 3.60E-18 Serum metabolites / / 20037589 rs9996462 chr4 185807582 C T 1.51E-04 Insulin resistance / / 21901158 rs4862453 chr4 185807764 T A 1.85E-04 Insulin resistance / / 21901158 rs6828765 chr4 185809489 C G 1.67E-04 Insulin resistance / / 21901158 rs7672676 chr4 185809788 G A 4.93E-05 Insulin resistance / / 21901158 rs6552838 chr4 185810136 C T 2.65E-04 Insulin resistance / / 21901158 rs6835984 chr4 185810760 A G 5.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4862455 chr4 185821036 G A 2.36E-05 Cognitive performance / / 19734545 rs10032937 chr4 185822934 A T 7.60E-04 Multiple complex diseases / / 17554300 rs6818135 chr4 185823888 T C 3.83E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4476645 chr4 185835222 T G 7.50E-04 Multiple complex diseases / / 17554300 rs9992707 chr4 185841910 G A 4.99E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6419946 chr4 185882454 T G 2.70E-05 Urinary metabolites / / 21572414 rs4355430 chr4 185885897 C T 7.69E-05 Lymphocyte counts / / pha003094 rs10009538 chr4 185892515 C T 8.52E-05 Alcohol dependence / / 21314694 rs11934369 chr4 185906368 T C 4.39E-04 Multiple complex diseases / / 17554300 rs12640177 chr4 185906873 G A 3.50E-04 Multiple complex diseases / / 17554300 rs35677723 chr4 185906873 G GA 3.50E-04 Multiple complex diseases / / 17554300 rs1078461 chr4 185940952 C G 5.50E-04 Suicide attempts in bipolar disorder HELT missense 21423239 rs6851788 chr4 185946538 T C 7.39E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs10023344 chr4 185999348 T C 1.63E-05 HIV-1 viral setpoint / / 22174851 rs4861656 chr4 186008402 C T 7.51E-04 Alzheimer's disease / / 17998437 rs4861657 chr4 186008444 C G 7.86E-04 Alzheimer's disease / / 17998437 rs7682828 chr4 186012464 G T 2.59E-04 Alzheimer's disease / / 17998437 rs1545950 chr4 186012559 C G 6.43E-04 Alzheimer's disease / / 17998437 rs1545951 chr4 186012601 C T 2.78E-04 Alzheimer's disease / / 17998437 rs1545952 chr4 186012666 T C 6.66E-04 Alzheimer's disease / / 17998437 rs11943238 chr4 186032936 G T 2.04E-04 Alzheimer's disease / / 24755620 rs10026207 chr4 186039201 C A 9.23E-05 Type 2 diabetes / / 17463246 rs6818704 chr4 186046473 A G 4.66E-05 Alcohol dependence / / 20201924 rs6818704 chr4 186046473 A G 4.66E-05 Alcoholism / / pha002891 rs2046535 chr4 186070432 T C 3.22E-04 Type 2 diabetes SLC25A4 UTR-3 17463246 rs2046535 chr4 186070432 T C 9.51E-04 Multiple complex diseases SLC25A4 UTR-3 17554300 rs1534143 chr4 186139971 C A 7.50E-04 Type 2 diabetes SNX25 intron 17463246 rs7675903 chr4 186159445 C A 8.44E-05 Waist Circumference SNX25 intron pha003023 rs3112861 chr4 186186389 G A 4.94E-04 Multiple complex diseases SNX25 intron 17554300 rs2587163 chr4 186220035 G C 3.74E-04 Multiple complex diseases SNX25 intron 17554300 rs753359 chr4 186227532 T G 3.10E-04 Multiple complex diseases SNX25 intron 17554300 rs1288567 chr4 186229268 G A 3.96E-04 Multiple complex diseases SNX25 intron 17554300 rs3756275 chr4 186267751 A G 8.67E-04 Amyotrophic lateral sclerosis (sporadic) SNX25 missense 24529757 rs1048329 chr4 186299758 G A 3.10E-06 Asthma LRP2BP UTR-5 20698975 rs1288548 chr4 186299985 G A 8.70E-07 Asthma LRP2BP UTR-5 20698975 rs10018215 chr4 186302406 G T 9.78E-06 Obesity-related traits / / 23251661 rs6818425 chr4 186309757 C T 3.21E-05 Alzheimer's disease (late onset) / / 21379329 rs3733646 chr4 186321447 C G 5.40E-06 Lymphocyte counts UFSP2 UTR-3 22286170 rs10032989 chr4 186336583 G A 8.22E-05 Alzheimer's disease (late onset) UFSP2 intron 21379329 rs2028701 chr4 186346239 C A 1.76E-04 Alzheimer's disease (late onset) UFSP2 intron 21379329 rs7672394 chr4 186353670 G T 1.99E-04 Alzheimer's disease (late onset) C4orf47 intron 21379329 rs2120414 chr4 186366315 T C 1.99E-04 Alzheimer's disease (late onset) C4orf47 intron 21379329 rs6849514 chr4 186386587 C T 4.53E-04 Type 2 diabetes CCDC110 intron 17463246 rs4862538 chr4 186413797 G A 8.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs3805379 chr4 186455966 C G 2.68E-04 Suicide attempts in bipolar disorder PDLIM3 intron 21423239 rs6854675 chr4 186457759 C T 1.63E-06 Suicide attempts in bipolar disorder PDLIM3 nearGene-5 21423239 rs10866277 chr4 186466968 G A 2.76E-04 Body mass index / / 21701565 rs10866277 chr4 186466968 G A 8.92E-05 Body mass index / / 21701565 rs2310322 chr4 186467147 A G 7.34E-05 Suicide attempts in bipolar disorder / / 21423239 rs2310322 chr4 186467147 A G 5.25E-05 Waist Circumference / / pha003024 rs2310322 chr4 186467147 A G 4.28E-05 Waist Circumference / / pha003025 rs12645545 chr4 186467489 A G 2.61E-04 Body mass index / / 21701565 rs12645545 chr4 186467489 A G 6.26E-05 Body mass index / / 21701565 rs7698802 chr4 186468723 A G 1.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs12649063 chr4 186470421 C T 1.46E-04 Body mass index / / 21701565 rs12649063 chr4 186470421 C T 4.39E-04 Body mass index / / 21701565 rs7437897 chr4 186472399 G A 7.55E-04 Body mass index / / 21701565 rs7442285 chr4 186472467 T G 8.65E-04 Body mass index / / 21701565 rs11132327 chr4 186485243 C T 2.64E-05 Multiple complex diseases / / 17554300 rs10866278 chr4 186499546 C T 8.26E-04 Multiple complex diseases / / 17554300 rs2310320 chr4 186501965 T C 3.40E-05 Response to antidepressants / / 19736353 rs6818789 chr4 186522953 C T 6.91E-04 Alzheimer's disease SORBS2 intron 17998437 rs2101307 chr4 186526185 T C 1.00E-04 Information processing speed SORBS2 intron 21130836 rs12503636 chr4 186529468 G A 1.07E-05 Cognitive test performance SORBS2 intron 20125193 rs12503636 chr4 186529468 G A 2.75E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SORBS2 intron 24023788 rs12502295 chr4 186535247 A G 6.59E-06 Coronary heart disease SORBS2 intron pha003031 rs13144235 chr4 186537232 C T 2.42E-06 Coronary heart disease SORBS2 intron pha003031 rs1471794 chr4 186551624 T G 8.36E-04 Alzheimer's disease SORBS2 intron 24755620 rs2306707 chr4 186559109 T C 9.78E-04 Multiple complex diseases SORBS2 intron 17554300 rs3749579 chr4 186562877 G A 9.63E-04 Alzheimer's disease SORBS2 intron 24755620 rs7663827 chr4 186570855 C A 4.03E-05 Odorant perception SORBS2 intron 23910658 rs6821894 chr4 186571441 C T 9.20E-05 Multiple sclerosis SORBS2 intron 21833088 rs4241809 chr4 186581859 C T 1.10E-06 Digit length ratio SORBS2 intron 20303062 rs13150700 chr4 186610123 T C 0.000277 Schizophrenia SORBS2 intron 23637625 rs4376189 chr4 186612675 G A 2.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio SORBS2 intron 22589738 rs6825669 chr4 186636805 C T 5.60E-06 Urinary metabolites SORBS2 intron 21572414 rs6826210 chr4 186636931 G A 9.30E-06 Urinary metabolites SORBS2 intron 21572414 rs10014995 chr4 186650131 C A 1.31E-04 Telomere length SORBS2 intron 21573004 rs2276911 chr4 186658094 C T 3.22E-04 Amyotrophic Lateral Sclerosis SORBS2 intron 17827064 rs2173479 chr4 186671479 T C 2.63E-04 IgE levels SORBS2 intron 17255346 rs11132344 chr4 186672603 A T 8.58E-04 Multiple complex diseases SORBS2 intron 17554300 rs11132344 chr4 186672603 A T 1.20E-05 Urinary metabolites SORBS2 intron 21572414 rs7655720 chr4 186692629 C T 7.49E-04 Myocardial Infarction SORBS2 intron pha002873 rs4487396 chr4 186695208 C T 2.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) SORBS2 intron 23648065 rs10021308 chr4 186716984 G A 1 Drug response to Etoposide SORBS2 intron 17537913 rs11132350 chr4 186725449 G T 3.09E-05 Diabetes Mellitus SORBS2 intron pha003059 rs1566347 chr4 186732566 T C 9.15E-07 Osteoarthritis SORBS2 intron 22763110 rs12504307 chr4 186743257 C G 4.35E-05 Coronary heart disease SORBS2 intron 21606135 rs1499012 chr4 186759155 G A 9.12E-04 Coronary heart disease SORBS2 intron 21606135 rs1027524 chr4 186776769 A C 9.32E-04 Multiple complex diseases SORBS2 intron 17554300 rs11940126 chr4 186790909 G A 0.000057 Otitis media (children 3 years old or younger) SORBS2 intron 23133572 rs13110782 chr4 186808581 G A 8.48E-04 Suicide attempts in bipolar disorder SORBS2 intron 21041247 rs4862585 chr4 186809714 C T 5.90E-05 Asthma SORBS2 intron 23181788 rs200740524 chr4 186838212 C CT 4.12E-05 Bladder cancer SORBS2 intron 19648920 rs7672034 chr4 186838212 C T 4.12E-05 Bladder cancer SORBS2 intron 19648920 rs4862600 chr4 186853014 C T 1.00E-05 Urinary metabolites SORBS2 intron 21572414 rs830838 chr4 186913109 C T 0.0000326 Panic disorder / / 23149450 rs830838 chr4 186913109 C T 3.26E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs11132376 chr4 186928529 C T 5.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs2603732 chr4 186934287 C T 4.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs11721827 chr4 186991137 A C 2.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TLR3 intron 20877124 rs5743316 chr4 187003691 A T 0.00000164 HDL cholesterol TLR3 missense 23063622 rs5743316 chr4 187003691 A T 1.19E-14 Triglycerides TLR3 missense 23063622 rs5743316 chr4 187003691 A T 8.77E-15 LDL cholesterol TLR3 missense 23063622 rs10025405 chr4 187006806 A G 4.29E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4608848 chr4 187010104 C T 7.88E-06 Intelligence / / 21826061 rs4608848 chr4 187010104 C T 3.83E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs4862644 chr4 187057812 C T 5.43E-05 Type 2 diabetes / / 17463246 rs7660462 chr4 187059719 C T 2.88E-04 Stroke / / pha002887 rs2276915 chr4 187072891 G C 1.48E-04 Body mass index FAM149A intron 21701565 rs2276915 chr4 187072891 G C 3.35E-04 Body mass index FAM149A intron 21701565 rs2276922 chr4 187078866 C T 9.14E-05 Eosinophil counts FAM149A missense pha003088 rs2276920 chr4 187078938 G A 7.00E-06 Amyotrophic Lateral Sclerosis FAM149A intron 17362836 rs2276919 chr4 187079047 A G 4.19E-05 Pancreatic cancer FAM149A intron pha002889 rs2292426 chr4 187120753 A G 7.37E-09 Venous thrombosis CYP4V2 intron 22675575 rs7687961 chr4 187122009 C A 9.91E-08 Metabolite levels CYP4V2 intron 23281178 rs3736455 chr4 187122319 T G 9.19E-09 Venous thromboembolism CYP4V2 cds-synon 21980494 rs1877320 chr4 187131279 G A 1.02E-06 Venous thromboembolism CYP4V2 intron 22672568 rs9995366 chr4 187131384 T C 1.12E-06 Venous thromboembolism CYP4V2 intron 22672568 rs2102575 chr4 187131504 G A 3.32E-07 Venous thromboembolism CYP4V2 intron 22672568 rs6842047 chr4 187133576 A C 1.16E-06 Venous thromboembolism CYP4V2 UTR-3 22672568 rs13136536 chr4 187138463 C G 1.24E-11 Metabolite levels / / 22286219 rs35328399 chr4 187138463 C CTTG 1.24E-11 Metabolite levels / / 22286219 rs11132382 chr4 187143802 T G 1.08E-12 Metabolite levels / / 22286219 rs4862669 chr4 187145222 G C 5.30E-13 Metabolite levels / / 22286219 rs4253236 chr4 187148071 T C 6.77E-12 Metabolite levels KLKB1 nearGene-5 22286219 rs2048 chr4 187148133 G T 8.11E-13 Metabolite levels KLKB1 nearGene-5 22286219 rs4253238 chr4 187148387 C T 3.90E-13 Metabolite levels KLKB1 nearGene-5 22286219 rs4253238 chr4 187148387 C T 1.29E-07 Obesity-related traits KLKB1 nearGene-5 23251661 rs4253238 chr4 187148387 C T 1.00E-122 Circulating vasoactive peptide levels KLKB1 nearGene-5 23381795 rs4253238 chr4 187148387 C T 4.00E-52 Circulating vasoactive peptide levels KLKB1 nearGene-5 23381795 rs1912826 chr4 187149540 G A 7.98E-13 Metabolite levels KLKB1 intron 22286219 rs1912826 chr4 187149540 G A 4.00E-12 Metabolite levels (atherosclerosis) KLKB1 intron 22916037 rs1912826 chr4 187149540 G A 4.47E-07 Obesity-related traits KLKB1 intron 23251661 rs1912826 chr4 187149540 G A 2.07E-51 Circulating vasoactive peptide levels KLKB1 intron 23381795 rs3775298 chr4 187150478 A G 5.67E-13 Metabolite levels KLKB1 intron 22286219 rs1511801 chr4 187150710 A T 8.50E-13 Metabolite levels KLKB1 intron 22286219 rs4241815 chr4 187152142 C T 6.07E-13 Metabolite levels KLKB1 intron 22286219 rs4241816 chr4 187152327 A T 6.00E-13 Metabolite levels KLKB1 intron 22286219 rs4241817 chr4 187152658 T C 1.98E-12 Metabolite levels KLKB1 intron 22286219 rs4253244 chr4 187153775 C A 8.61E-12 Metabolite levels KLKB1 intron 22286219 rs4241818 chr4 187153786 T C 6.28E-13 Metabolite levels KLKB1 intron 22286219 rs4253248 chr4 187155488 G A 7.15E-13 Metabolite levels KLKB1 intron 22286219 rs4253252 chr4 187157458 T G 7.00E-18 Metabolic traits KLKB1 intron 21886157 rs4253252 chr4 187157458 T G 1.49E-12 Metabolite levels KLKB1 intron 22286219 rs4253252 chr4 187157458 T G 3.00E-22 Blood metabolite levels KLKB1 intron 24816252 rs3733402 chr4 187158034 G A,C,T 1.23E-12 Metabolite levels KLKB1 missense 22286219 rs3733402 chr4 187158034 G A,C,T 9.00E-08 Obesity-related traits KLKB1 missense 23251661 rs3733402 chr4 187158034 G A,C,T 2.71E-36 Circulating vasoactive peptide levels KLKB1 missense 23381795 rs3733402 chr4 187158034 G A,C,T 7.00E-25 Metabolite levels KLKB1 missense 24625756 rs3733402 chr4 187158034 G A,C,T 9.00E-27 Metabolite levels KLKB1 missense 24625756 rs4253255 chr4 187158922 G C 8.64E-13 Metabolite levels KLKB1 intron 22286219 rs4253256 chr4 187159282 G C 8.57E-12 Metabolite levels KLKB1 intron 22286219 rs35984397 chr4 187161501 G A 1.17E-11 Metabolite levels KLKB1 intron 22286219 rs4253356 chr4 187161922 G T 3.82E-04 Multiple complex diseases KLKB1 intron 17554300 rs4253281 chr4 187164349 G A 2.07E-12 Metabolite levels KLKB1 intron 22286219 rs4253282 chr4 187164399 C T 1.64E-12 Metabolite levels KLKB1 intron 22286219 rs34899763 chr4 187165433 T A 5.44E-06 Obesity-related traits KLKB1 intron 23251661 rs4253292 chr4 187168866 A G 1.00E-04 Cognitive impairment induced by topiramate KLKB1 intron 22091778 rs4253294 chr4 187169650 A G 6.88E-11 Metabolite levels KLKB1 intron 22286219 rs4253296 chr4 187170545 T C 9.10E-05 Personality dimensions KLKB1 intron 18957941 rs2304595 chr4 187172280 G A 0.00000036 Activated partial thromboplastin time KLKB1 intron 23188048 rs4253301 chr4 187173012 T G 5.32E-05 Cognitive test performance KLKB1 missense 20125193 rs4253304 chr4 187173571 G C 6.15E-08 Activated partial thromboplastin time KLKB1 intron 23188048 rs4253311 chr4 187174683 A G 7.49E-12 Metabolite levels KLKB1 intron 22286219 rs4253311 chr4 187174683 A G 4.00E-48 Blood metabolite levels KLKB1 intron 24816252 rs4861709 chr4 187178186 C T 9.92E-11 Metabolite levels KLKB1 intron 22286219 rs28671360 chr4 187178788 A G 3.82E-11 Metabolite levels KLKB1 intron 22286219 rs33930717 chr4 187178788 A ATTG,ATTT 3.82E-11 Metabolite levels KLKB1 intron 22286219 rs925453 chr4 187179210 T C 5.90E-05 Personality dimensions KLKB1 cds-synon 18957941 rs925453 chr4 187179210 T C 8.57E-11 Metabolite levels KLKB1 cds-synon 22286219 rs925453 chr4 187179210 T C 4.35E-06 Obesity-related traits KLKB1 cds-synon 23251661 rs3087505 chr4 187179486 A G 4.22E-07 Venous thromboembolism KLKB1 UTR-3 22672568 rs4253332 chr4 187179803 T C 8.26E-11 Metabolite levels KLKB1 nearGene-3 22286219 rs11132383 chr4 187182660 T C 9.94E-04 Aortic root size / / 21223598 rs3756008 chr4 187185385 A T 6.00E-11 Venous thromboembolism F11 nearGene-5 21980494 rs3756008 chr4 187185385 A T 2.16E-07 Venous thromboembolism F11 nearGene-5 22672568 rs3756008 chr4 187185385 A T 1.98E-10 Venous thrombosis F11 nearGene-5 22675575 rs3756009 chr4 187186111 A G 4.93E-10 Venous thromboembolism F11 nearGene-5 21980494 rs3756009 chr4 187186111 A G 8.78E-07 Venous thromboembolism F11 nearGene-5 22672568 rs3756009 chr4 187186111 A G 1.06E-10 Venous thrombosis F11 nearGene-5 22675575 rs925451 chr4 187187569 G A 5.38E-10 Venous thromboembolism F11 intron 21980494 rs925451 chr4 187187569 G A 8.65E-07 Venous thromboembolism F11 intron 22672568 rs925451 chr4 187187569 G A 1.26E-10 Venous thrombosis F11 intron 22675575 rs4253399 chr4 187188094 T G 2.04E-10 Venous thromboembolism F11 intron 21980494 rs4253399 chr4 187188094 T G 1.69E-06 Venous thromboembolism F11 intron 22672568 rs4253399 chr4 187188094 T G 2.63E-10 Venous thrombosis F11 intron 22675575 rs4253399 chr4 187188094 T G 6.22E-08 Plasma factor XI level and activated partial thromboplastin time F11 intron 22701019 rs4253399 chr4 187188094 T G 3.00E-14 Venous thromboembolism F11 intron 23650146 rs4241824 chr4 187191787 G A 1.40E-09 Venous thromboembolism F11 intron 21980494 rs4241824 chr4 187191787 G A 2.92E-10 Venous thrombosis F11 intron 22675575 rs4241824 chr4 187191787 G A 1.16E-08 Plasma factor XI level and activated partial thromboplastin time F11 intron 22701019 rs4253832 chr4 187192284 T G 0.000000262 Cholesterol,total F11 intron 23063622 rs2036914 chr4 187192481 T C 1.04E-09 Venous thromboembolism F11 intron 21980494 rs2036914 chr4 187192481 T C 1.66E-10 Venous thrombosis F11 intron 22675575 rs4253407 chr4 187193308 A T 1.68E-10 Venous thrombosis F11 intron 22675575 rs1593 chr4 187195551 T A 1.01E-10 Venous thromboembolism F11 intron 21980494 rs1593 chr4 187195551 T A 7.87E-12 Venous thrombosis F11 intron 22675575 rs1593 chr4 187195551 T A 2.00E-18 Activated partial thromboplastin time F11 intron 22703881 rs2055916 chr4 187196510 G A 8.37E-11 Venous thrombosis F11 intron 22675575 rs4253416 chr4 187197994 C T 4.08E-09 Venous thrombosis F11 intron 22675575 rs4253417 chr4 187199005 T C 6.97E-10 Venous thromboembolism F11 intron 21980494 rs4253417 chr4 187199005 T C 4.88E-06 Venous thromboembolism F11 intron 22672568 rs4253417 chr4 187199005 T C 2.06E-10 Venous thrombosis F11 intron 22675575 rs5974 chr4 187201211 A G 5.48E-04 Multiple complex diseases F11 cds-synon 17554300 rs5974 chr4 187201211 A G 7.81E-06 Crohn's disease F11 cds-synon 18587394 rs4253425 chr4 187205929 T C 1.89E-12 Venous thrombosis F11 intron 22675575 rs3756011 chr4 187206249 C A 4.41E-10 Venous thrombosis F11 intron 22675575 rs2289252 chr4 187207381 C T 2.89E-06 Venous thromboembolism F11 intron 22672568 rs2289252 chr4 187207381 C T 3.70E-10 Venous thrombosis F11 intron 22675575 rs2289252 chr4 187207381 C T 6.00E-43 Activated partial thromboplastin time F11 intron 22703881 rs4253431 chr4 187210620 G A 4.20E-04 Multiple complex diseases F11 UTR-3 17554300 rs4253431 chr4 187210620 G A 1.33E-05 Crohn's disease F11 UTR-3 18587394 rs6843711 chr4 187212953 T C 3.69E-12 Venous thrombosis LOC285441 intron 22675575 rs4444878 chr4 187213883 C A 6.46E-10 Venous thrombosis LOC285441 intron 22675575 rs6824705 chr4 187213889 C T 6.01E-09 Venous thrombosis LOC285441 intron 22675575 rs11132387 chr4 187218723 G A 9.19E-09 Venous thromboembolism LOC285441 intron 21980494 rs11132388 chr4 187219418 T C,G 2.91E-10 Venous thrombosis LOC285441 intron 22675575 rs907439 chr4 187220747 C T 1.95E-09 Venous thromboembolism LOC285441 intron 21980494 rs907439 chr4 187220747 C T 2.24E-10 Venous thrombosis LOC285441 intron 22675575 rs4613610 chr4 187222271 A G 4.23E-09 Venous thrombosis LOC285441 intron 22675575 rs10029715 chr4 187222600 T C 1.56E-09 Venous thromboembolism LOC285441 intron 21980494 rs10029715 chr4 187222600 T C 2.16E-10 Venous thrombosis LOC285441 intron 22675575 rs4572916 chr4 187223583 A C 1.52E-09 Venous thromboembolism LOC285441 intron 21980494 rs4572916 chr4 187223583 A C 4.23E-10 Venous thrombosis LOC285441 intron 22675575 rs28864974 chr4 187224394 A G 2.60E-10 Venous thrombosis LOC285441 intron 22675575 rs6815076 chr4 187224558 G C 2.68E-10 Venous thrombosis LOC285441 intron 22675575 rs28690003 chr4 187224562 G A 2.62E-10 Venous thrombosis LOC285441 intron 22675575 rs10025152 chr4 187225304 G A 1.32E-09 Venous thromboembolism LOC285441 intron 21980494 rs10025152 chr4 187225304 G A 2.10E-10 Venous thrombosis LOC285441 intron 22675575 rs1008728 chr4 187226673 C T 1.27E-09 Venous thromboembolism LOC285441 intron 21980494 rs1008728 chr4 187226673 C T 1.35E-09 Venous thrombosis LOC285441 intron 22675575 rs12500826 chr4 187227451 T C 1.39E-09 Venous thromboembolism LOC285441 intron 21980494 rs12500826 chr4 187227451 T C 1.57E-09 Venous thrombosis LOC285441 intron 22675575 rs13133050 chr4 187230737 A C 9.30E-04 Myopia (pathological) LOC285441 intron 21095009 rs112477227 chr4 187232050 C A 3.61E-10 Venous thrombosis LOC285441 intron 22675575 rs10020303 chr4 187235998 A G 7.63E-05 Body mass index LOC285441 intron 17255346 rs6839415 chr4 187237305 T C 1.18E-04 Sudden cardiac arrest LOC285441 intron 21658281 rs7687352 chr4 187239747 A G 5.85E-04 Myopia (pathological) LOC285441 intron 21095009 rs7349633 chr4 187247089 T G 3.80E-06 Response to statin therapy LOC285441 intron 20339536 rs11132389 chr4 187251860 A G 2.04E-04 Blood pressure (response to angiotensin II receptor blocker) LOC285441 intron 24192120 rs11132389 chr4 187251860 A G 3.41E-05 Blood pressure (response to angiotensin II receptor blocker) LOC285441 intron 24192120 rs11132389 chr4 187251860 A G 3.34E-04 Iron levels LOC285441 intron pha002876 rs7689330 chr4 187255631 T A 3.70E-06 Response to statin therapy LOC285441 intron 20339536 rs6552974 chr4 187257078 T C 3.40E-06 Response to statin therapy LOC285441 intron 20339536 rs13143852 chr4 187257332 G A 3.30E-06 Response to statin therapy LOC285441 intron 20339536 rs13148903 chr4 187257576 A G 3.00E-06 Response to statin therapy LOC285441 intron 20339536 rs13150040 chr4 187257780 G T 2.90E-06 Response to statin therapy LOC285441 intron 20339536 rs13149934 chr4 187257955 C T 3.00E-06 Response to statin therapy LOC285441 intron 20339536 rs13150348 chr4 187258118 C T 2.90E-06 Response to statin therapy LOC285441 intron 20339536 rs746643 chr4 187268199 C T 3.12E-04 Lymphocyte counts LOC285441 intron 22286170 rs1901314 chr4 187286307 C T 1.88E-04 Response to cytidine analogues (gemcitabine) LOC285441 intron 24483146 rs4861712 chr4 187299349 C T 4.63E-04 Multiple complex diseases LOC285441 intron 17554300 rs11935103 chr4 187338335 C T 1.00E-06 Response to citalopram treatment LOC285441 intron 22760553 rs11935103 chr4 187338335 C T 2.00E-06 Response to citalopram treatment LOC285441 intron 22760553 rs11931790 chr4 187340688 C T 7.14E-04 Amyotrophic Lateral Sclerosis LOC285441 intron 17362836 rs2084729 chr4 187365864 C T 4.81E-05 Height LOC285441 intron pha003010 rs2100281 chr4 187380057 T C 4.91E-04 Response to taxane treatment (placlitaxel) LOC285441 intron 23006423 rs12506228 chr4 187382294 C A 2.67E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) LOC285441 intron 23648065 rs6846710 chr4 187382542 A G 3.31E-04 Response to taxane treatment (placlitaxel) LOC285441 intron 23006423 rs6832915 chr4 187391215 C A 2.78E-04 Multiple complex diseases LOC285441 intron 17554300 rs12498245 chr4 187392009 A T 6.13E-04 Response to TNF antagonist treatment LOC285441 intron 21061259 rs6854525 chr4 187411620 A G 3.57E-04 Major depressive disorder LOC285441 intron 22472876 rs4861722 chr4 187489383 G A 8.01E-05 Body mass (lean) / / 19268274 rs1280102 chr4 187505765 C T 3.59E-05 HIV-1 viral setpoint / / 17641165 rs1973352 chr4 187511861 G A 5.76E-04 HIV-1 viral setpoint FAT1 intron 17641165 rs2637777 chr4 187525020 A C 6.62E-04 HIV-1 viral setpoint FAT1 missense 17641165 rs2584345 chr4 187527818 T C 3.02E-11 Non-obstructive azoospermia FAT1 intron 22197933 rs11941966 chr4 187529904 G A 1.19E-04 HIV-1 viral setpoint FAT1 intron 17641165 rs328438 chr4 187548829 A G 4.87E-05 Blood Pressure FAT1 intron pha003043 rs7663350 chr4 187561798 C T 8.17E-05 Cleft lip FAT1 intron 20436469 rs6553017 chr4 187581476 G T 5.50E-06 Alcohol and nictotine co-dependence FAT1 intron 22488850 rs2130910 chr4 187586210 C T 9.30E-05 Interstitial lung disease FAT1 intron 23583980 rs10155467 chr4 187587980 C T 3.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAT1 intron 20877124 rs327070 chr4 187624194 G T 5.32E-04 Multiple complex diseases FAT1 intron 17554300 rs3733413 chr4 187629538 C T 3.20E-04 Scoliosis FAT1 missense 21216876 rs7698262 chr4 187661911 C T 1.94E-04 Prion diseases / / 22210626 rs925642 chr4 187678866 C T 7.00E-06 Obesity / / 21552555 rs6847347 chr4 187707798 C T 7.89E-05 HDL cholesterol / / pha003074 rs766685 chr4 187712375 G A 7.50E-05 Myopia (pathological) / / 21095009 rs4862733 chr4 187714369 T C 5.96E-04 Body mass index / / 21701565 rs4862733 chr4 187714369 T C 7.34E-04 Body mass index / / 21701565 rs1431935 chr4 187717917 C A 3.74E-05 HDL cholesterol / / pha003074 rs1431935 chr4 187717917 C A 3.37E-05 HDL cholesterol / / pha003075 rs7698529 chr4 187719659 G A 0.0000795 post-traumatic stress disorder / / 22869035 rs7698529 chr4 187719659 G A 7.95E-05 Schizophrenia / / 22883433 rs11132409 chr4 187722479 C T 0.0000989 post-traumatic stress disorder / / 22869035 rs11132409 chr4 187722479 C T 9.89E-05 Schizophrenia / / 22883433 rs12512853 chr4 187753636 C T 3.15E-04 Birth weight / / 17255346 rs322442 chr4 187788311 A G 2.40E-05 Urinary metabolites / / 21572414 rs403263 chr4 187812637 A G 7.67E-05 Multiple complex diseases / / 17554300 rs433477 chr4 187814866 G C 7.26E-04 Type 2 diabetes / / 17463246 rs433477 chr4 187814866 G C 5.29E-04 Multiple complex diseases / / 17554300 rs397321 chr4 187815647 A G 2.09E-04 Sudden cardiac arrest / / 21658281 rs4862742 chr4 187817303 A G 5.34E-04 Multiple complex diseases / / 17554300 rs10033110 chr4 187845057 T C 0.000677 Salmonella-induced pyroptosis / / 22837397 rs7657521 chr4 187851352 C T 1.49E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs7660345 chr4 187921499 A T 3.00E-06 Acne (severe) / / 24399259 rs6814129 chr4 187969329 A G 2.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4476657 chr4 187978589 A G 3.48E-05 Erythrocyte counts / / pha003090 rs13129961 chr4 188022194 G A 9.66E-05 Tuberculosis / / 22306650 rs1487590 chr4 188030901 G A 4.79E-05 Creutzfeldt-Jakob disease (variant) / / 22137330 rs13145604 chr4 188071834 G T 4.53E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11730573 chr4 188079254 G A 9.27E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs1565105 chr4 188100086 G A 2.00E-04 Information processing speed / / 21130836 rs3860698 chr4 188100664 A G 1.00E-04 Information processing speed / / 21130836 rs2046632 chr4 188101826 G A 6.31E-05 Post-operative nausea and vomiting / / 21694509 rs901689 chr4 188113028 T C 0.000351 Salmonella-induced pyroptosis / / 22837397 rs13106946 chr4 188114025 C T 1.50E-05 Urinary metabolites / / 21572414 rs7692743 chr4 188114879 G A 2.95E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs1021287 chr4 188116718 A G 9.80E-06 Urinary metabolites / / 21572414 rs7660073 chr4 188117453 C T 2.20E-05 Urinary metabolites / / 21572414 rs1565106 chr4 188136307 G A 2.87E-05 HIV-1 viral setpoint / / 22174851 rs7699015 chr4 188138856 C T 4.18E-04 Type 2 diabetes / / 17463246 rs11724244 chr4 188158462 C A 7.90E-06 Urinary metabolites / / 21572414 rs1532021 chr4 188159641 C T 1.85E-05 Coronary heart disease / / pha003030 rs7681831 chr4 188161271 A G 1.40E-05 Urinary metabolites / / 21572414 rs11726022 chr4 188170467 G A 1.80E-05 Urinary metabolites / / 21572414 rs6553048 chr4 188171689 G A 2.17E-05 Bipolar disorder and schizophrenia / / 20889312 rs6553050 chr4 188185489 T C 1.06E-06 Triglycerides / / 19074352 rs6553050 chr4 188185489 T C 1.06E-06 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs6553050 chr4 188185489 T C 1.02E-05 Coronary heart disease / / pha003030 rs6553051 chr4 188190117 C T 2.60E-04 Major depressive disorder / / 21042317 rs6553051 chr4 188190117 C T 2.06E-05 Major depressive disorder / / 22472876 rs6553052 chr4 188190219 G T 3.50E-04 Major depressive disorder / / 21042317 rs6553052 chr4 188190219 G T 1.75E-05 Major depressive disorder / / 22472876 rs4478239 chr4 188191306 C A 2.70E-04 Major depressive disorder / / 21042317 rs4478239 chr4 188191306 C A 5.00E-06 Major depressive disorder / / 22472876 rs4478240 chr4 188191516 C T 1.50E-04 Major depressive disorder / / 21042317 rs4478240 chr4 188191516 C T 2.01E-05 Major depressive disorder / / 22472876 rs7694910 chr4 188198154 A G 1.80E-05 Urinary metabolites / / 21572414 rs4862792 chr4 188201350 T G 6.80E-06 Parkinson's disease / / 17052657 rs4862792 chr4 188201350 T G 2.09E-05 Major depressive disorder / / 22472876 rs10005568 chr4 188205839 C T 2.20E-05 Urinary metabolites / / 21572414 rs1564041 chr4 188215556 T C 3.20E-05 HIV-1 control / / 20041166 rs6553055 chr4 188219193 C A 3.20E-05 HIV-1 control / / 20041166 rs6832990 chr4 188225183 G A 6.85E-05 Major depressive disorder / / 22472876 rs1870852 chr4 188280616 C T 1.82E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines LOC339975 intron 21844884 rs7676864 chr4 188321485 T C 2.43E-05 Basophils LOC339975 intron pha003087 rs11736831 chr4 188343185 A G 0.000184841 Hypertension (early onset hypertension) LOC339975 intron 22479346 rs1431005 chr4 188345368 G A 2.00E-07 Response to statin therapy LOC339975 intron 20339536 rs978629 chr4 188347395 A G 9.15E-05 Hypertension (early onset hypertension) LOC339975 intron 22479346 rs6553067 chr4 188363123 G A 0.000388137 Hypertension (early onset hypertension) LOC339975 intron 22479346 rs11132451 chr4 188364027 T C 0.000145934 Hypertension (early onset hypertension) LOC339975 intron 22479346 rs12641785 chr4 188364088 G A 0.000145934 Hypertension (early onset hypertension) LOC339975 intron 22479346 rs4862806 chr4 188395719 T C 7.47E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LOC339975 intron 20031582 rs1367555 chr4 188420909 A G 2.30E-05 Urinary metabolites LOC339975 intron 21572414 rs2036590 chr4 188455415 C T 1.38E-05 Serum metabolites LOC100506272 intron 19043545 rs7668312 chr4 188457879 T G 5.61E-05 Multiple complex diseases LOC100506272 intron 17554300 rs6857356 chr4 188469538 G A 1.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100506272 intron 20877124 rs12651293 chr4 188477282 T C 6.99E-04 Response to taxane treatment (placlitaxel) LOC100506272 intron 23006423 rs4862815 chr4 188479049 T G 3.68E-04 Amyotrophic Lateral Sclerosis LOC100506272 intron 17827064 rs1553566 chr4 188480913 T C 1.60E-05 Elbow pain LOC100506272 intron pha003008 rs11132469 chr4 188504166 A T 6.15E-04 Alzheimer's disease LOC100506272 intron 22005930 rs4307013 chr4 188517589 G A 4.43E-04 Type 2 diabetes LOC100506272 intron 17463246 rs1505502 chr4 188517935 G A 3.02E-04 Type 2 diabetes LOC100506272 intron 17463246 rs10213208 chr4 188520784 G A 9.56E-04 Type 2 diabetes LOC100506272 intron 17463246 rs952178 chr4 188525897 T C 3.66E-04 Type 2 diabetes LOC100506272 intron 17463246 rs952178 chr4 188525897 T C 5.52E-10 Biliary atresia LOC100506272 intron 20460270 rs1605099 chr4 188549237 T C 4.12E-04 Alzheimer's disease LOC100506272 intron 22005930 rs1857809 chr4 188562501 A G 3.73E-04 Alzheimer's disease LOC100506272 intron 22005930 rs2292161 chr4 188581325 G A 1.78E-04 Alzheimer's disease (late onset) LOC100506272 intron 21379329 rs6826655 chr4 188608053 G T 4.53E-04 Alzheimer's disease / / 22005930 rs7687115 chr4 188608857 A G 4.71E-04 Alzheimer's disease / / 22005930 rs11132476 chr4 188620769 T C 3.41E-04 Multiple complex diseases / / 17554300 rs12509746 chr4 188623989 A G 4.06E-04 Alzheimer's disease / / 22005930 rs6822091 chr4 188625261 A G 4.12E-04 Alzheimer's disease / / 22005930 rs12648438 chr4 188628654 A C 7.98E-04 Alzheimer's disease / / 22005930 rs4274906 chr4 188634395 T G 6.11E-04 Alzheimer's disease / / 22005930 rs7668935 chr4 188637746 G A 2.56E-04 Alzheimer's disease / / 22005930 rs4530690 chr4 188639218 G C 1.76E-04 Alzheimer's disease / / 22005930 rs4558913 chr4 188639406 A G 1.79E-04 Alzheimer's disease / / 22005930 rs7665752 chr4 188646362 T G 1.11E-04 Alzheimer's disease / / 22005930 rs6810480 chr4 188648305 A G 1.22E-04 Alzheimer's disease / / 22005930 rs6828769 chr4 188648976 C T 1.61E-04 Alzheimer's disease / / 22005930 rs7438821 chr4 188650233 G T 2.64E-04 Alzheimer's disease / / 22005930 rs7683009 chr4 188698095 C T 5.35E-04 Multiple complex diseases / / 17554300 rs7683009 chr4 188698095 C T 3.29E-06 Osteoarthritis (knee and hip) / / 21177295 rs7683009 chr4 188698095 C T 3.62E-05 Osteoarthritis (knee and hip) / / 21177295 rs7683009 chr4 188698095 C T 4.20E-05 Alcohol dependence / / 22096494 rs6820806 chr4 188725383 G T 0.000015 LDL cholesterol particle diameter / / 23263444 rs7686928 chr4 188733829 C T 1.80E-05 Urinary metabolites / / 21572414 rs6829286 chr4 188735086 T C 1.80E-05 Urinary metabolites / / 21572414 rs4632716 chr4 188805939 G C 7.62E-05 Schizophrenia / / 19571809 rs4632716 chr4 188805939 G C 7.25E-05 Schizophrenia / / pha002859 rs11132490 chr4 188834175 A C 8.65E-04 White matter integrity / / 22425255 rs4861762 chr4 188892958 T G 7.69E-04 Body mass index / / 21701565 rs6815391 chr4 188924979 C T 0.000709 5-fluorouracil induced nausea/vomiting in response to colorectal cancer treatment ZFP42 UTR-3 22310351 rs1388935 chr4 188927822 C T 6.59E-05 Orofacial clefts / / 22419666 rs952727 chr4 188935105 C T 0.0008424 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs952727 chr4 188935105 C T 8.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs952726 chr4 188935183 C T 0.0007639 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs952726 chr4 188935183 C T 7.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6553131 chr4 188935730 A G 0.0007111 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6553131 chr4 188935730 A G 7.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6813061 chr4 188936949 G A 0.0007281 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6813061 chr4 188936949 G A 7.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6838857 chr4 188937186 T C 0.0007758 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6838857 chr4 188937186 T C 7.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10026182 chr4 188937625 C G 0.0007803 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10026182 chr4 188937625 C G 7.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6839055 chr4 188939077 G A 0.0007889 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6839055 chr4 188939077 G A 7.89E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6553133 chr4 188939914 T A 0.0007946 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6553133 chr4 188939914 T A 7.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11736230 chr4 188940718 T C 9.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7672735 chr4 188941176 T A 0.0007092 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7672735 chr4 188941176 T A 7.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2172339 chr4 188944051 C T 1.90E-05 Urinary metabolites / / 21572414 rs2889360 chr4 188957800 T G 1.77E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs13435183 chr4 188963946 C T 7.73E-06 Triglycerides / / 19074352 rs13435183 chr4 188963946 C T 7.73E-06 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs4241849 chr4 188964613 G A 9.00E-04 Multiple complex diseases / / 17554300 rs1492632 chr4 188969751 A C 2.80E-05 Urinary metabolites / / 21572414 rs1540663 chr4 188981386 A G 1.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4862857 chr4 189017058 A G 0.00000624 Coronary artery calcification TRIML2 intron 23394302 rs902910 chr4 189020348 G A 5.45E-05 Parkinson's disease TRIML2 intron 21738487 rs13116982 chr4 189036322 G A 3.13E-05 Major depressive disorder / / 20516156 rs6419960 chr4 189055298 G A 4.90E-05 Diabetic retinopathy / / 21441570 rs7376345 chr4 189057120 G A 4.90E-05 Diabetic retinopathy / / 21441570 rs57365206 chr4 189059078 C CTTTT 1.86E-04 Taste perception / / 22132133 rs7441586 chr4 189059078 C T 1.86E-04 Taste perception / / 22132133 rs6857559 chr4 189120911 T C 3.00E-21 Myopia (pathological) / / 23049088 rs7376568 chr4 189133207 G T 3.78E-05 Cognitive impairment induced by topiramate / / 22091778 rs11734807 chr4 189144306 C G 1.04E-05 Multiple sclerosis / / 17660530 rs3924963 chr4 189144799 C T 1.90E-05 Left ventricular hypertrophy / / pha003052 rs7686911 chr4 189182563 G C 4.90E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs111874200 chr4 189188713 G A 3.56E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs10024857 chr4 189188765 G A,T 3.92E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs11725970 chr4 189189463 A G 4.94E-08 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs71607999 chr4 189191111 G A 7.00E-09 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs11736476 chr4 189191166 G A 3.28E-08 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs13115076 chr4 189194478 C T 2.22E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs13121835 chr4 189195068 G A 6.02E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs13129087 chr4 189196141 C T 2.81E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs9790703 chr4 189203711 T C 8.90E-08 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs4538553 chr4 189216291 T A 3.44E-04 Type 2 diabetes / / 17463246 rs4618385 chr4 189216438 G T 6.20E-04 Multiple complex diseases / / 17554300 rs6828177 chr4 189233294 G A 9.82E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11930915 chr4 189247773 G A 2.51E-05 Alcohol and nictotine co-dependence / / 20158304 rs7375343 chr4 189260808 A G 6.10E-06 Urinary metabolites / / 21572414 rs7694772 chr4 189263081 T A 1.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs7376789 chr4 189263717 G C 3.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs7376783 chr4 189263803 C G 2.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs1606234 chr4 189296032 G A 2.69E-05 Rheumatoid arthritis / / 19503088 rs1606234 chr4 189296032 G A 1.78E-05 Common variable immunodeficiency / / 21497890 rs115975951 chr4 189299683 T G 0.00009953 Sarcoidosis / / 22952805 rs12504780 chr4 189334197 C T 7.43E-04 Suicide attempts in bipolar disorder / / 21041247 rs12504808 chr4 189334307 C T 7.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs178329 chr4 189336147 A G 7.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs2292433 chr4 189338469 C T 8.68E-04 Alzheimer's disease / / 17998437 rs713507 chr4 189342369 G A 6.19E-05 Neutrophil count / / pha003095 rs11132551 chr4 189343008 T C 0.000519344 Hypertension (early onset hypertension) / / 22479346 rs2292434 chr4 189371244 A G 7.20E-04 Tourette syndrome / / 22889924 rs6553202 chr4 189449669 G A 8.10E-06 Gamma gluatamyl transferase levels (interaction with age) LOC401164 intron 22010049 rs7679676 chr4 189456233 T G 1.44E-06 Neuroblastoma LOC401164 intron pha002895 rs6838418 chr4 189473758 T C 8.75E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines LOC401164 intron 21844884 rs1600203 chr4 189488734 T C 9.20E-05 Celiac disease LOC401164 intron 17558408 rs7666129 chr4 189498064 C T 0.0000754 Polycystic ovary syndrome LOC401164 intron 22951595 rs7666129 chr4 189498064 C T 7.54E-05 Intracranial aneurysm LOC401164 intron 22961961 rs4241895 chr4 189528831 C T 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs4241895 chr4 189528831 C T 9.01E-04 Coronary heart disease / / 21606135 rs464466 chr4 189543953 G A 6.76E-04 Type 2 diabetes / / 17463246 rs464466 chr4 189543953 G A 6.40E-06 Urinary metabolites / / 21572414 rs6834498 chr4 189565170 C T 5.00E-06 Anger / / 24489884 rs7686384 chr4 189584353 C T 6.00E-06 Obesity-related traits / / 23251661 rs7691644 chr4 189584733 C T 1.48E-05 Cognitive test performance / / 20125193 rs7659062 chr4 189587079 C T 8.00E-06 Cognitive performance / / 20125193 rs7659062 chr4 189587079 C T 9.00E-06 Cognitive performance / / 20125193 rs7662358 chr4 189590859 C A 8.00E-06 Cognitive performance / / 20125193 rs7662358 chr4 189590859 C A 9.00E-06 Cognitive performance / / 20125193 rs1851566 chr4 189645569 A G 4.74E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11935605 chr4 189645845 G A 2.00E-05 Urinary metabolites / / 21572414 rs10033120 chr4 189647819 A G 1.20E-05 Urinary metabolites / / 21572414 rs7681177 chr4 189653624 A G 7.22E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7681177 chr4 189653624 A G 7.95E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs930995 chr4 189654390 T C 5.32E-04 Tourette syndrome / / 22889924 rs6849122 chr4 189673094 C T 2.61E-05 Potassium levels / / pha003086 rs2377334 chr4 189673284 A G 6.25E-04 Tourette syndrome / / 22889924 rs4254824 chr4 189680142 A G 4.10E-04 Tourette syndrome / / 22889924 rs4863387 chr4 189687397 C T 2.34E-05 Blood Pressure / / pha003043 rs12649676 chr4 189704189 G C 5.19E-04 Body mass index / / 21701565 rs12649676 chr4 189704189 G C 5.79E-04 Body mass index / / 21701565 rs2377467 chr4 189730989 T G 4.10E-05 Schizophrenia / / 20185149 rs3911069 chr4 189737788 C A 2.19E-05 Coronary heart disease / / pha003055 rs7684990 chr4 189760251 A G 8.09E-04 Multiple complex diseases / / 17554300 rs1947184 chr4 189769090 C T 3.38E-04 Multiple complex diseases / / 17554300 rs6828833 chr4 189792991 C T 9.31E-04 Major depressive disorder / / 22472876 rs1375272 chr4 189797261 A C 2.48E-04 Body mass index / / 21701565 rs1375272 chr4 189797261 A C 2.86E-04 Body mass index / / 21701565 rs2376963 chr4 189805763 T A 1.21E-04 Body mass index / / 21701565 rs2376963 chr4 189805763 T A 1.61E-04 Body mass index / / 21701565 rs2376962 chr4 189805789 A G 3.94E-04 Body mass index / / 21701565 rs2376962 chr4 189805789 A G 4.83E-04 Body mass index / / 21701565 rs11737653 chr4 189832650 T C 2.40E-04 Smoking cessation / / 24665060 rs7349617 chr4 189836953 T C 1.81E-04 Smoking cessation / / 24665060 rs1448745 chr4 189846631 G A 1.16E-04 Smoking cessation / / 24665060 rs3860664 chr4 189851017 G A 1.87E-04 Smoking cessation / / 24665060 rs3913154 chr4 189852468 A G 3.10E-06 Urinary metabolites / / 21572414 rs13120060 chr4 189857087 C T 1.71E-04 Smoking cessation / / 24665060 rs11731175 chr4 189861251 G T 5.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs7696076 chr4 189862346 A G 5.69E-04 Smoking cessation / / 24665060 rs12501939 chr4 189880877 C T 2.80E-05 Urinary metabolites / / 21572414 rs7658965 chr4 189881357 G A 3.91E-04 Taste perception / / 22132133 rs6835613 chr4 189884242 C T 1.40E-05 Urinary metabolites / / 21572414 rs1532439 chr4 189970929 G A 5.80E-07 Urinary metabolites / / 21572414 rs1353581 chr4 189989989 G A 2.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4285137 chr4 190050735 A G 3.02E-04 Alzheimer's disease / / 17998437 rs11729064 chr4 190050820 T C 5.56E-04 Alzheimer's disease / / 17998437 rs6822346 chr4 190065197 G A 7.00E-04 Coronary Artery Disease / / 17634449 rs4302526 chr4 190069486 G A 0.000772 Salmonella-induced pyroptosis / / 22837397 rs7699928 chr4 190088167 C T 3.20E-04 Type 2 diabetes / / 17463246 rs4241857 chr4 190098562 C T 7.48E-04 Multiple complex diseases / / 17554300 rs4241858 chr4 190098770 T A 5.93E-04 Multiple complex diseases / / 17554300 rs4422479 chr4 190098802 A G 3.64E-04 Multiple complex diseases / / 17554300 rs4273546 chr4 190100496 A C 4.83E-04 Type 2 diabetes / / 17463246 rs4241860 chr4 190102390 A G 6.45E-04 Multiple complex diseases / / 17554300 rs6855006 chr4 190103064 G A 3.20E-04 Multiple complex diseases / / 17554300 rs7676106 chr4 190106915 C T 6.00E-05 Suicidal ideation / / 22030708 rs7665939 chr4 190123318 C T 9.00E-06 Amyotrophic lateral sclerosis / / 22959728 rs7685314 chr4 190126254 A G 3.00E-04 Suicidal ideation / / 22030708 rs11932479 chr4 190132623 A G 5.44E-05 Cognitive test performance / / 20125193 rs6833202 chr4 190137076 A C 6.25E-04 Multiple complex diseases / / 17554300 rs12640997 chr4 190245038 C T 8.57E-04 Multiple complex diseases / / 17554300 rs1563455 chr4 190293157 T G 9.98E-06 Venous thromboembolism / / 22672568 rs4863145 chr4 190296345 T G 6.90E-04 Smoking cessation / / 24665060 rs11132643 chr4 190298622 C A 2.70E-05 Urinary metabolites / / 21572414 rs1456348 chr4 190319160 C G 2.93E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6553315 chr4 190328590 T C 1.60E-04 Premature ovarian failure / / 19508998 rs2085363 chr4 190333556 A C 3.25E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1456354 chr4 190357461 A G 0.0004 Salmonella-induced pyroptosis / / 22837397 rs10023451 chr4 190369851 G A 3.29E-04 Alzheimer's disease / / 17998437 rs9997163 chr4 190375485 C A 3.02E-05 Alzheimer's disease (late onset) / / 21460841 rs13107731 chr4 190390399 C T 3.36E-05 Alzheimer's disease (late onset) / / 21460841 rs10030180 chr4 190398267 T C 6.18E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4862968 chr4 190407970 G T 8.79E-05 Orofacial clefts / / 22419666 rs9312400 chr4 190413642 C T 4.69E-05 Alzheimer's disease (late onset) / / 21460841 rs9884117 chr4 190413958 G A 3.36E-05 Alzheimer's disease (late onset) / / 21460841 rs11132664 chr4 190414910 T C 7.74E-04 Multiple complex diseases / / 17554300 rs11722601 chr4 190415265 C T 1.90E-05 Urinary metabolites / / 21572414 rs6553321 chr4 190423873 G T 3.77E-04 Multiple complex diseases / / 17554300 rs7686524 chr4 190427447 G A,C 4.11E-04 Multiple complex diseases / / 17554300 rs1451213 chr4 190442028 A G 5.84E-05 Parkinson's disease / / 16252231 rs1597620 chr4 190450305 G A 3.68E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3885379 chr4 190477915 C T 2.56E-04 Schizophrenia / / 21674006 rs1971199 chr4 190495017 A G 9.28E-04 Type 2 diabetes / / 17463246 rs2763774 chr4 190514569 T A 4.28E-04 Response to TNF antagonist treatment / / 21061259 rs3911167 chr4 190523941 C G 7.19E-04 Response to TNF antagonist treatment / / 21061259 rs13145041 chr4 190538063 A C,G 7.00E-07 Periodontitis (CDC/AAP) / / 24024966 rs34600205 chr4 190538063 A AG 7.00E-07 Periodontitis (CDC/AAP) / / 24024966 rs11724073 chr4 190551954 C T 6.27E-06 Periodontitis (CDC/AAP) / / 24024966 rs9990436 chr4 190562142 A C 7.64E-06 Periodontitis (CDC/AAP) / / 24024966 rs6849237 chr4 190604047 G A 3.68E-04 Multiple complex diseases / / 17554300 rs4043279 chr4 190633273 T C 4.30E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs11132733 chr4 190641170 T C 3.00E-06 Testosterone levels / / 22675492 rs2739532 chr4 190707430 C G 1.14E-05 Longevity / / 20304771 rs1996801 chr4 190710253 T C 6.42E-04 Parkinson's disease / / 17052657 rs3813280 chr4 190724416 A G 5.86E-09 Biliary atresia / / 20460270 rs2739556 chr4 190737737 G C 3.47E-04 Aortic root size / / 21223598 rs2293134 chr4 190742793 G A 2.80E-06 Urinary metabolites / / 21572414 rs6844114 chr4 190745892 G A 5.24E-04 Multiple complex diseases / / 17554300 rs341260 chr5 90199 T C 2.31E-04 Vaspin levels / / 22907691 rs341260 chr5 90199 T C 0.0002312 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs341267 chr5 118406 C T 2.89E-04 Obesity (extreme) / / 21935397 rs6889904 chr5 177264 A C,G,T 1.00E-04 Cognitive impairment induced by topiramate PLEKHG4B intron 22091778 rs7717734 chr5 181463 T C 2.76E-04 Lymphocyte counts PLEKHG4B intron 22286170 rs4956991 chr5 183516 A G 4.88E-05 Lung adenocarcinoma PLEKHG4B UTR-3 19836008 rs4956993 chr5 184702 A G 2.68E-05 Lung adenocarcinoma PLEKHG4B UTR-3 19836008 rs3810865 chr5 189799 T C 2.86E-05 Lung adenocarcinoma PLEKHG4B UTR-3 19836008 rs9312960 chr5 204082 C A 0.000191 Oxaliplatin induced neuropathy in response to colorectal cancer treatment / / 22310351 rs2162869 chr5 251792 A G 1.48E-04 Heart rate SDHA intron 23583979 rs3756712 chr5 309096 A C 3.50E-06 Lung adenocarcinoma PDCD6 intron 19836008 rs4957018 chr5 314011 G A 6.93E-06 Lung adenocarcinoma PDCD6 intron 19836008 rs4957020 chr5 314346 C T 0.000191 Oxaliplatin induced neuropathy in response to colorectal cancer treatment PDCD6 intron 22310351 rs2672737 chr5 356381 C T 0.000305389 Hypertension (early onset hypertension) AHRR intron 22479346 rs4956935 chr5 403118 A C 7.40E-06 Urinary metabolites AHRR intron 21572414 rs11743226 chr5 404713 C T 7.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) AHRR intron 20877124 rs17562461 chr5 411361 G A 1.04E-05 Lymphocyte counts AHRR intron 22286170 rs201183475 chr5 428070 C T 0.00025 Breast cancer AHRR missense 23555315 rs12188164 chr5 428236 C A 4.00E-06 Cystic fibrosis severity AHRR intron 21602797 rs957792 chr5 429989 G A 3.65E-04 Amyotrophic lateral sclerosis (sporadic) AHRR intron 24529757 rs10078 chr5 438102 G T 7.40E-06 Subcutaneous adipose tissue volume in HIV-infected men AHRR UTR-3 21897333 rs4541696 chr5 581053 A G 6.10E-06 Adiposity / / 19461586 rs4957048 chr5 583442 G A 1.00E-09 Ulcerative colitis / / 20228799 rs4957048 chr5 583442 G A 1.20E-09 Multiple sclerosis / / 22190364 rs4957048 chr5 583442 G A 3.42E-06 Osteoarthritis / / 22763110 rs11739663 chr5 594083 T C 3.00E-08 Ulcerative colitis / / 21297633 rs11739663 chr5 594083 T C 2.00E-08 Ulcerative colitis / / 23128233 rs11739663 chr5 594083 T C 3.25E-06 Obesity-related traits / / 23251661 rs4956954 chr5 607388 G A 7.90E-06 Obesity-related traits / / 23251661 rs1697952 chr5 614963 G A 8.57E-05 Psoriasis CEP72 intron 20953190 rs1697952 chr5 614963 G A 7.95E-06 Obesity-related traits CEP72 intron 23251661 rs7726839 chr5 618586 A G 1.00E-06 Obesity-related traits CEP72 intron 23251661 rs1697991 chr5 622399 A G 4.62E-06 Lymphocyte counts CEP72 intron 22286170 rs1697985 chr5 635709 C T 2.80E-04 Type 2 diabetes CEP72 intron 17463246 rs1697976 chr5 647816 T A 4.25E-04 Type 2 diabetes CEP72 intron 17463246 rs1689671 chr5 659605 G A 2.55E-04 Type 2 diabetes / / 17463246 rs386057 chr5 685748 G A 6.94E-05 Otitis media (chronic/recurrent) TPPP intron 23974705 rs41447549 chr5 718097 A T 2.79E-06 Multiple complex diseases / / 17554300 rs1804865 chr5 895053 G T 3.20E-09 Health and aging,CVD and cancer age of onset TRIP13 missense 22174011 rs1804865 chr5 895053 G T 8.00E-21 Health and aging,CVD and cancer age of onset TRIP13 missense 22174011 rs1804865 chr5 895053 G T 8.00E-32 Health and aging,CVD and cancer age of onset TRIP13 missense 22174011 rs16868701 chr5 964250 G A 8.48E-04 Alcohol dependence / / 21314694 rs2289827 chr5 979148 C T 6.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4975533 chr5 988510 C T 5.78E-04 Type 2 diabetes LOC100506688 UTR-3 17463246 rs326047 chr5 995270 G T 1.00E-04 Cognitive impairment induced by topiramate LOC100506688 intron 22091778 rs4975569 chr5 1054831 T C 2.20E-04 Multiple complex diseases SLC12A7 intron 17554300 rs143024441 chr5 1085534 C A 0.00015 Breast cancer SLC12A7 missense 23555315 rs4580814 chr5 1113244 G T 5.00E-10 Blood cell counts and other traits / / 20139978 rs4580814 chr5 1113244 G T 2.42E-05 Platelet counts / / pha003100 rs7379059 chr5 1143298 C T 6.63E-05 Multiple complex diseases / / 17554300 rs7702150 chr5 1169112 A G 4.50E-08 Urinary metabolites / / 21572414 rs6554634 chr5 1186121 G A 3.95E-05 Pulmonary function / / 20010835 rs4640842 chr5 1187074 G A 3.98E-05 Pulmonary function / / 20010835 rs4072529 chr5 1187281 T A 3.95E-05 Pulmonary function / / 20010835 rs4975596 chr5 1189347 C T 1.20E-05 Urinary metabolites / / 21572414 rs7719875 chr5 1190088 A G 2.10E-05 Urinary metabolites / / 21572414 rs13159461 chr5 1203437 G A 3.89E-05 Asthma SLC6A19 intron 20159242 rs6554660 chr5 1207527 G A 3.67E-04 Heart Failure SLC6A19 intron pha002884 rs4975542 chr5 1222480 C T 3.84E-04 Acute lung injury SLC6A19 UTR-3 22295056 rs7728667 chr5 1225626 T A 0.00025 Prostate cancer SLC6A18 missense 23555315 rs7445640 chr5 1236212 T G 2.73E-04 Alzheimer's disease SLC6A18 intron 17998437 rs6554677 chr5 1236291 G A 7.63E-05 Acute lung injury SLC6A18 intron 22295056 rs4075202 chr5 1243475 C A 6.47E-05 Acute lung injury SLC6A18 intron 22295056 rs10069690 chr5 1279790 C T 3.71E-08 Testicular germ cell cancer TERT intron 20543847 rs10069690 chr5 1279790 C T 1.00E-10 Breast cancer TERT intron 22037553 rs10069690 chr5 1279790 C T 3.56E-06 Telomere length TERT intron 23001564 rs10069690 chr5 1279790 C T 7.00E-09 Breast cancer TERT intron 23535729 rs10069690 chr5 1279790 C T 5.00E-12 Breast cancer TERT intron 23535733 rs10069690 chr5 1279790 C T 3.31E-11 Interstitial lung disease TERT intron 23583980 rs10069690 chr5 1279790 C T 1.92E-07 Chronic lymphocytic leukemia TERT intron 23770605 rs10069690 chr5 1279790 C T 1.00E-07 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) TERT intron 24325915 rs2242652 chr5 1280028 G A 3.00E-24 Prostate cancer TERT intron 21743467 rs13167280 chr5 1280477 G A 4.66E-04 Telomere length TERT intron 23900074 rs7726159 chr5 1282319 C A 4.67E-17 Telomere length TERT intron 23900074 rs7725218 chr5 1282414 G A 8.26E-15 Telomere length TERT intron 23900074 rs2736100 chr5 1286516 C A 3.00E-08 Idiopathic pulmonary fibrosis TERT intron 18835860 rs2736100 chr5 1286516 C A 4.00E-06 Lung cancer TERT intron 18978790 rs2736100 chr5 1286516 C A 2.00E-17 Glioma TERT intron 19578367 rs2736100 chr5 1286516 C A 2.00E-10 Lung adenocarcinoma TERT intron 19836008 rs2736100 chr5 1286516 C A 3.00E-08 Blood cell counts and other traits TERT intron 20139978 rs2736100 chr5 1286516 C A 3.01E-08 Blood cell counts and other traits TERT intron 20139978 rs2736100 chr5 1286516 C A 2.00E-17 Nasopharyngeal carcinoma TERT intron 20512145 rs2736100 chr5 1286516 C A 8.00E-15 Testicular germ cell cancer TERT intron 20543847 rs2736100 chr5 1286516 C A 2.00E-22 Lung adenocarcinoma TERT intron 20700438 rs2736100 chr5 1286516 C A 3.00E-11 Lung adenocarcinoma TERT intron 20871597 rs2736100 chr5 1286516 C A 1.00E-14 Glioma TERT intron 21531791 rs2736100 chr5 1286516 C A 1.00E-27 Lung cancer TERT intron 21725308 rs2736100 chr5 1286516 C A 7.00E-09 Glioma TERT intron 21827660 rs2736100 chr5 1286516 C A 7.30E-12 Lung adenocarcinoma TERT intron 22797724 rs2736100 chr5 1286516 C A 4.00E-09 Glioma TERT intron 22886559 rs2736100 chr5 1286516 C A 5.00E-08 Lung cancer TERT intron 22899653 rs2736100 chr5 1286516 C A 4.00E-27 Lung cancer TERT intron 23143601 rs2736100 chr5 1286516 C A 4.38E-19 Telomere length TERT intron 23535734 rs2736100 chr5 1286516 C A 2.00E-19 Interstitial lung disease TERT intron 23583980 rs2736100 chr5 1286516 C A 2.20E-14 Interstitial lung disease TERT intron 23583980 rs2736100 chr5 1286516 C A 7.60E-14 Interstitial lung disease TERT intron 23583980 rs2736100 chr5 1286516 C A 4.82E-05 Testicular germ cell tumor TERT intron 23666239 rs2736100 chr5 1286516 C A 6.12E-18 Testicular germ cell tumor TERT intron 23666240 rs2736100 chr5 1286516 C A 1.58E-15 Telomere length TERT intron 23900074 rs2736100 chr5 1286516 C A 2.00E-05 Telomere length TERT intron 24465473 rs2736100 chr5 1286516 C A 1.00E-15 Glioma (high-grade) TERT intron 24908248 rs2853677 chr5 1287194 G A 3.00E-40 Lung adenocarcinoma TERT intron 22797724 rs2853677 chr5 1287194 G A 5.56E-09 Telomere length TERT intron 23900074 rs2736099 chr5 1287340 A G 1.44E-07 Telomere length TERT intron 23900074 rs2853676 chr5 1288547 T C 4.00E-14 Glioma TERT intron 19578367 rs2853676 chr5 1288547 T C 4.00E-14 Nasopharyngeal carcinoma TERT intron 20512145 rs2853676 chr5 1288547 T C 6.18E-07 Testicular germ cell cancer TERT intron 20543847 rs2853676 chr5 1288547 T C 1.39E-14 Glioma TERT intron 21531791 rs2853676 chr5 1288547 T C 3.06E-08 Interstitial lung disease TERT intron 23583980 rs2853676 chr5 1288547 T C 8.93E-07 Interstitial lung disease TERT intron 23583980 rs2853672 chr5 1292983 C A 4.16E-09 Interstitial lung disease TERT intron 23583980 rs2853672 chr5 1292983 C A 1.74E-08 Telomere length TERT intron 23900074 rs2736098 chr5 1294086 C T 2.21E-06 Testicular germ cell cancer TERT cds-synon 20543847 rs2736098 chr5 1294086 C T 8.80E-07 Prostate-specific antigen levels TERT cds-synon 21160077 rs2735940 chr5 1296486 A G 3.59E-08 Telomere length TERT nearGene-5 23900074 rs2736108 chr5 1297488 C T 1.41E-08 Telomere length / / 23900074 rs2736108 chr5 1297488 C T 8.33E-06 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) / / 24325915 rs2853668 chr5 1300025 G T 3.32E-05 Type 2 diabetes / / 17463246 rs2853668 chr5 1300025 G T 2.20E-05 Malaria / / 19465909 rs2735845 chr5 1300584 C G 3.40E-05 Telomere length / / 23900074 rs4635969 chr5 1308552 G A 2.17E-07 Lung cancer / / 19654303 rs4635969 chr5 1308552 G A 2.15E-08 Lung adenocarcinoma / / 19836008 rs4635969 chr5 1308552 G A 1.00E-23 Testicular germ cell cancer / / 20543847 rs4635969 chr5 1308552 G A 4.90E-07 Lung cancer / / 22899653 rs4635969 chr5 1308552 G A 2.22E-04 Testicular germ cell tumor / / 23666239 rs4635969 chr5 1308552 G A 5.00E-24 Testicular germ cell tumor / / 23666240 rs4635969 chr5 1308552 G A 1.05E-06 Pancreatic cancer / / pha002889 rs4975615 chr5 1315343 G A 2.50E-08 Testicular germ cell cancer / / 20543847 rs4975615 chr5 1315343 G A 1.50E-05 Lung cancer / / 21725308 rs4975616 chr5 1315660 G A 8.90E-06 Lung cancer / / 18978787 rs4975616 chr5 1315660 G A 2.00E-05 Lung cancer / / 18978790 rs4975616 chr5 1315660 G A 3.00E-09 Lung cancer / / 19654303 rs4975616 chr5 1315660 G A 2.03E-09 Lung adenocarcinoma / / 19836008 rs4975616 chr5 1315660 G A 3.00E-09 Nasopharyngeal carcinoma / / 20512145 rs4975616 chr5 1315660 G A 5.91E-07 Testicular germ cell cancer / / 20543847 rs4975616 chr5 1315660 G A 1.30E-05 Lung cancer / / 21725308 rs4975616 chr5 1315660 G A 3.20E-05 Lung cancer / / 22899653 rs4975616 chr5 1315660 G A 8.29E-06 Pancreatic cancer / / pha002889 rs451360 chr5 1319680 C A 1.16E-15 Testicular germ cell cancer CLPTM1L intron 20543847 rs451360 chr5 1319680 C A 6.60E-05 Lung cancer CLPTM1L intron 21725308 rs451360 chr5 1319680 C A 2.68E-04 Lung cancer CLPTM1L intron 23143601 rs421629 chr5 1320136 G A 7.44E-07 Testicular germ cell cancer CLPTM1L intron 20543847 rs380286 chr5 1320247 G A 7.44E-07 Testicular germ cell cancer CLPTM1L intron 20543847 rs402710 chr5 1320722 C T 4.00E-06 Lung cancer CLPTM1L intron 18978790 rs402710 chr5 1320722 C T 4.00E-06 Nasopharyngeal carcinoma CLPTM1L intron 20512145 rs10073340 chr5 1321873 C T 1.20E-05 Urinary metabolites CLPTM1L intron 21572414 rs10073340 chr5 1321873 C T 4.51E-06 Diabetes Mellitus CLPTM1L intron pha003059 rs401681 chr5 1322087 C T 8.00E-09 Lung cancer CLPTM1L intron 18978787 rs401681 chr5 1322087 C T 2.00E-06 Lung cancer CLPTM1L intron 18978790 rs401681 chr5 1322087 C T 4.00E-12 Basal cell carcinoma CLPTM1L intron 19151717 rs401681 chr5 1322087 C T 6.65E-11 Lung adenocarcinoma CLPTM1L intron 19836008 rs401681 chr5 1322087 C T 7.00E-07 Pancreatic cancer CLPTM1L intron 20101243 rs401681 chr5 1322087 C T 8.00E-09 Nasopharyngeal carcinoma CLPTM1L intron 20512145 rs401681 chr5 1322087 C T 4.24E-22 Testicular germ cell cancer CLPTM1L intron 20543847 rs401681 chr5 1322087 C T 5.00E-07 Bladder cancer CLPTM1L intron 20972438 rs401681 chr5 1322087 C T 1.00E-10 Prostate-specific antigen levels CLPTM1L intron 21160077 rs401681 chr5 1322087 C T 3.00E-08 Melanoma CLPTM1L intron 21983787 rs401681 chr5 1322087 C T 1.70E-07 Lung cancer CLPTM1L intron 22899653 rs401681 chr5 1322087 C T 7.24E-04 Lung cancer CLPTM1L intron 23143601 rs401681 chr5 1322087 C T 4.00E-11 Bladder cancer CLPTM1L intron 24163127 rs401681 chr5 1322087 C T 2.00E-12 Basal cell carcinoma CLPTM1L intron 24403052 rs401681 chr5 1322087 C T 3.66E-07 Pancreatic cancer CLPTM1L intron pha002889 rs428499 chr5 1322663 T C 7.32E-05 Telomere length CLPTM1L intron 23900074 rs466502 chr5 1325767 A G 3.08E-07 Testicular germ cell cancer CLPTM1L intron 20543847 rs466502 chr5 1325767 A G 2.50E-06 Lung cancer CLPTM1L intron 21725308 rs465498 chr5 1325803 A G 7.48E-07 Testicular germ cell cancer CLPTM1L intron 20543847 rs465498 chr5 1325803 A G 3.20E-06 Lung cancer CLPTM1L intron 21725308 rs452932 chr5 1330253 T C 7.44E-07 Testicular germ cell cancer CLPTM1L intron 20543847 rs452932 chr5 1330253 T C 2.20E-06 Lung cancer CLPTM1L intron 21725308 rs452384 chr5 1330840 T C 7.48E-07 Testicular germ cell cancer CLPTM1L intron 20543847 rs452384 chr5 1330840 T C 5.70E-06 Lung cancer CLPTM1L intron 21725308 rs467095 chr5 1336221 T C 7.49E-07 Testicular germ cell cancer CLPTM1L intron 20543847 rs467095 chr5 1336221 T C 6.30E-06 Lung cancer CLPTM1L intron 21725308 rs31484 chr5 1337906 A T 7.48E-07 Testicular germ cell cancer CLPTM1L intron 20543847 rs31484 chr5 1337906 A T 3.80E-05 Lung cancer CLPTM1L intron 21725308 rs31489 chr5 1342714 C A 2.48E-05 Lung cancer CLPTM1L intron 18978787 rs31489 chr5 1342714 C A 8.00E-07 Lung cancer CLPTM1L intron 18978790 rs31489 chr5 1342714 C A 5.62E-08 Lung cancer CLPTM1L intron 19654303 rs31489 chr5 1342714 C A 2.00E-10 Lung adenocarcinoma CLPTM1L intron 19836008 rs31489 chr5 1342714 C A 2.00E-10 Nasopharyngeal carcinoma CLPTM1L intron 20512145 rs31489 chr5 1342714 C A 3.27E-08 Testicular germ cell cancer CLPTM1L intron 20543847 rs31489 chr5 1342714 C A 5.30E-05 Lung cancer CLPTM1L intron 21725308 rs31489 chr5 1342714 C A 1.10E-06 Lung cancer CLPTM1L intron 22899653 rs31489 chr5 1342714 C A 1.64E-06 Pancreatic cancer CLPTM1L intron pha002889 rs31490 chr5 1344458 G A 3.05E-07 Testicular germ cell cancer CLPTM1L intron 20543847 rs31490 chr5 1344458 G A 2.00E-07 Chronic lymphocytic leukemia CLPTM1L intron 24292274 rs27070 chr5 1346303 G C 8.03E-09 Testicular germ cell cancer / / 20543847 rs27070 chr5 1346303 G C 6.00E-05 Lung cancer / / 21725308 rs27061 chr5 1362793 T C 5.35E-04 Insulin resistance / / 21901158 rs246995 chr5 1374712 G A 2.59E-04 Multiple complex diseases LOC100506791 intron 17554300 rs6869645 chr5 1404548 C T 2.40E-05 Urinary metabolites SLC6A3 intron 21572414 rs6869645 chr5 1404548 C T 4.96E-05 Orofacial clefts SLC6A3 intron 22419666 rs115254960 chr5 1409938 G A 0.000000163 Prostate-specific antigen SLC6A3 cds-synon 23555315 rs10053602 chr5 1428135 T C 7.53E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SLC6A3 intron 21844884 rs2963242 chr5 1437726 C T 6.83E-04 Multiple complex diseases SLC6A3 intron 17554300 rs403636 chr5 1438354 A C 7.46E-04 Acute lung injury SLC6A3 intron 22295056 rs2617605 chr5 1442521 T C 3.32E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SLC6A3 intron 21844884 rs2617605 chr5 1442521 T C 5.28E-06 Blood Pressure SLC6A3 intron pha003039 rs4975648 chr5 1468287 C A 9.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) LPCAT1 intron 23648065 rs27053 chr5 1470578 G A 6.04E-04 Lymphocyte counts LPCAT1 intron 22286170 rs27059 chr5 1479678 G C 4.25E-04 IgE levels LPCAT1 intron 17255346 rs36991 chr5 1496622 C T 8.63E-05 Major depressive disorder LPCAT1 intron 22472876 rs36987 chr5 1499175 C T 4.83E-04 Myocardial Infarction LPCAT1 intron pha002873 rs36982 chr5 1503205 C T 2.67E-04 Myocardial Infarction LPCAT1 intron pha002873 rs36967 chr5 1507508 G C 8.58E-04 Type 2 diabetes LPCAT1 intron 17463246 rs2963282 chr5 1512208 G A 2.20E-04 Alcohol dependence LPCAT1 intron 20201924 rs13167887 chr5 1514462 A G 9.36E-05 Lung function (forced expiratory volume in 1 second) LPCAT1 intron pha003102 rs4608970 chr5 1519197 T C 2.30E-05 Alcohol dependence LPCAT1 intron 20201924 rs4608970 chr5 1519197 T C 8.50E-05 Alcohol dependence LPCAT1 intron 20201924 rs4608970 chr5 1519197 T C 8.48E-05 Alcoholism LPCAT1 intron pha002892 rs4608970 chr5 1519197 T C 2.35E-05 Alcoholism LPCAT1 intron pha002893 rs7700579 chr5 1525880 C T 2.46E-04 Type 2 diabetes / / 17463246 rs4551123 chr5 1536257 A G 4.30E-05 Alcohol dependence / / 20201924 rs4551123 chr5 1536257 A G 6.90E-04 Alcohol dependence / / 20201924 rs4551123 chr5 1536257 A G 4.31E-05 Alcoholism / / pha002893 rs10079102 chr5 1550942 T C 9.06E-05 Orofacial clefts / / 22419666 rs2963271 chr5 1553239 C T 3.43E-04 Age-related macular degeneration / / 22125219 rs4975556 chr5 1565371 C T 5.94E-04 Parkinson's disease / / 17052657 rs4975556 chr5 1565371 C T 4.77E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs13188792 chr5 1568463 T C 8.61E-08 Metabolite levels / / 23281178 rs7734561 chr5 1594096 A G 1.85E-05 Erythrocyte counts SDHAP3 intron pha003090 rs7734561 chr5 1594096 A G 9.16E-06 Hemoglobin SDHAP3 intron pha003096 rs7734561 chr5 1594096 A G 4.63E-05 Hemoglobin SDHAP3 intron pha003098 rs41408448 chr5 1642155 G A 2.83E-04 Coronary Artery Disease / / 17634449 rs4551124 chr5 1645242 C T 1.29E-05 Blood Pressure / / pha003039 rs1392400 chr5 1674938 C T 1.70E-05 Serum metabolites / / 19043545 rs6897438 chr5 1676963 A G 3.39E-06 Serum metabolites / / 19043545 rs16883212 chr5 1689029 A C 0.00077 Asthma / / 22502797 rs1875196 chr5 1691202 C G 4.71E-05 Major depressive disorder / / 22472876 rs12519991 chr5 1699151 G A 2.20E-05 Urinary metabolites / / 21572414 rs16883787 chr5 1720602 A G 8.58E-04 Multiple complex diseases / / 17554300 rs6554987 chr5 1739266 T C 9.70E-06 Urinary metabolites / / 21572414 rs1392466 chr5 1744484 G A 5.50E-04 Alcohol dependence / / 24277619 rs2353591 chr5 1764750 G A 6.70E-04 Type 2 diabetes / / 23209189 rs904756 chr5 1765278 A G 7.83E-04 Multiple complex diseases / / 17554300 rs6555008 chr5 1769749 C T 7.18E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4975845 chr5 1794148 T C 3.71E-04 Multiple complex diseases / / 17554300 rs4588629 chr5 1798138 G A 1.42E-04 Lymphocyte counts MRPL36 nearGene-3 22286170 rs17536666 chr5 1844315 T C 9.66E-04 Nicotine dependence / / 17158188 rs4975744 chr5 1860049 A G 2.50E-05 Urinary metabolites / / 21572414 rs931508 chr5 1861224 G C 2.10E-05 Urinary metabolites / / 21572414 rs4975709 chr5 1877280 A C 8.00E-07 Cardiovascular disease risk factors / / 21779381 rs12653946 chr5 1895829 C T 4.00E-18 Prostate cancer / / 20676098 rs12653946 chr5 1895829 C T 3.00E-07 Prostate cancer / / 22923026 rs12653946 chr5 1895829 C T 0.00000041 Prostate cancer / / 23555315 rs12653946 chr5 1895829 C T 0.0000009 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs2129470 chr5 1936443 C A 4.56E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs17538179 chr5 1945495 T C 1.28E-04 Obesity (extreme) / / 21935397 rs13183501 chr5 1948303 C T 1.98E-05 Blood Pressure / / pha003039 rs16902181 chr5 1966852 C T 9.76E-05 stroke (ischemic) / / 17434096 rs1123391 chr5 1976478 T C 5.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10038119 chr5 1992286 A G 2.97E-04 Schizophrenia / / 20832056 rs13153232 chr5 1992423 G A 1.79E-04 Schizophrenia / / 20832056 rs17611544 chr5 1993900 G A 7.60E-04 Type 2 diabetes / / 23209189 rs2101404 chr5 1996039 C T 4.32E-04 Schizophrenia / / 20832056 rs2101404 chr5 1996039 C T 2.20E-05 Urinary metabolites / / 21572414 rs4975807 chr5 2032660 T C 1.06E-04 Hemoglobin concentration / / 20534544 rs4975838 chr5 2050483 T C 8.70E-04 Type 2 diabetes / / 17463246 rs6555046 chr5 2056586 A G 1.62E-04 Hemoglobin concentration / / 20534544 rs4975727 chr5 2058143 A G 4.42E-04 Hemoglobin concentration / / 20534544 rs4320305 chr5 2075233 G A 0.0007702 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4320305 chr5 2075233 G A 7.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10066597 chr5 2089968 A C 0.0006123 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10066597 chr5 2089968 A C 6.12E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10076573 chr5 2094148 T C 0.000296 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10076573 chr5 2094148 T C 2.96E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4568402 chr5 2097011 G A 0.000065 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4568402 chr5 2097011 G A 6.50E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4299769 chr5 2097562 G A 0.0005619 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4299769 chr5 2097562 G A 5.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6879627 chr5 2109901 T C 8.00E-06 Pancreatic cancer / / 20686608 rs6879627 chr5 2109901 T C 3.99E-07 Autism / / 22843504 rs11950809 chr5 2113672 C A 5.84E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10068854 chr5 2134888 C T 4.82E-04 Multiple complex diseases / / 17554300 rs7379705 chr5 2141556 C T 3.46E-04 Multiple complex diseases / / 17554300 rs4866625 chr5 2171041 C G 7.10E-05 Cervical cancer / / 24700089 rs6555067 chr5 2173056 T C 8.15E-04 Alzheimer's disease / / 24755620 rs6878643 chr5 2174313 T C 6.35E-04 Alzheimer's disease / / 24755620 rs4866652 chr5 2186956 A G 8.19E-04 Schizophrenia / / 19197363 rs6555071 chr5 2190280 A T 8.76E-04 Type 2 diabetes / / 17463246 rs4866654 chr5 2194596 G A 2.14E-04 Parkinson's disease / / 17052657 rs1542429 chr5 2216680 A G 4.17E-04 Acute lung injury / / 22295056 rs10073263 chr5 2217896 C T 7.94E-04 Acute lung injury / / 22295056 rs11741203 chr5 2218025 G A 7.57E-04 Obesity (extreme) / / 21935397 rs17646078 chr5 2218094 T A 6.64E-04 Acute lung injury / / 22295056 rs7717939 chr5 2224557 G C 6.91E-05 Lipid traits / / 22028671 rs1458521 chr5 2229014 T C 9.90E-06 Urinary metabolites / / 21572414 rs1379917 chr5 2231570 T C 7.34E-04 Obesity (extreme) / / 21935397 rs10475138 chr5 2239725 T C 7.42E-04 Obesity (extreme) / / 21935397 rs11739676 chr5 2241153 G C 4.95E-05 Acute lung injury / / 22295056 rs6882404 chr5 2251313 A G 8.70E-06 Urinary metabolites / / 21572414 rs2020430 chr5 2251386 A G 1.02E-05 Coronary Artery Disease / / 17634449 rs13165559 chr5 2253823 G C 9.75E-04 Acute lung injury / / 22295056 rs2004010 chr5 2259217 C T 5.66E-04 Alzheimer's disease / / 17998437 rs6875273 chr5 2272248 G A 2.12E-05 Response to hepatitis C treatment / / 19684573 rs923048 chr5 2279866 G A 3.94E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs547706 chr5 2280105 G A 2.02E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs17586674 chr5 2335581 A G 5.00E-06 Cognitive performance / / 20125193 rs17586674 chr5 2335581 A G 2.64E-04 Alzheimer's disease (late onset) / / 21379329 rs13182644 chr5 2337339 C T 1.27E-05 Cognitive test performance / / 20125193 rs13182644 chr5 2337339 C T 8.07E-05 Alzheimer's disease (late onset) / / 21379329 rs92833 chr5 2338908 C T 5.80E-06 Orofacial clefts / / 22419666 rs462894 chr5 2341949 G T 1.83E-05 Alzheimer's disease / / 17998437 rs468976 chr5 2346621 A G 8.04E-05 Orofacial clefts / / 22419666 rs10036054 chr5 2352730 C T 3.05E-05 Cognitive test performance / / 20125193 rs10036054 chr5 2352730 C T 3.92E-05 Alzheimer's disease (late onset) / / 21379329 rs10069375 chr5 2356789 A C,G 3.64E-05 Multiple complex diseases / / 17554300 rs10056812 chr5 2360093 C T 9.96E-04 Multiple complex diseases / / 17554300 rs16868434 chr5 2360168 A T 9.89E-04 Multiple complex diseases / / 17554300 rs10071449 chr5 2367274 T C 9.57E-04 Multiple complex diseases / / 17554300 rs465850 chr5 2378836 T C 5.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs458479 chr5 2382979 G A 0.00000891 Tuberculosis with early age of onset / / 22551897 rs624376 chr5 2400149 T C 0.0000168 Tuberculosis with early age of onset / / 22551897 rs10052956 chr5 2404085 A G 5.82E-04 Iron levels / / pha002876 rs11952610 chr5 2409851 G A 8.53E-04 Type 2 diabetes / / 17463246 rs4866482 chr5 2409988 T C 4.04E-04 Iron levels / / pha002876 rs4866643 chr5 2410248 G A 9.19E-04 Type 2 diabetes / / 17463246 rs4866483 chr5 2410332 G A 8.11E-04 Type 2 diabetes / / 17463246 rs17648791 chr5 2417417 G A 7.18E-04 Type 2 diabetes / / 17463246 rs4866484 chr5 2418025 A G 5.64E-04 Type 2 diabetes / / 17463246 rs4866484 chr5 2418025 A G 3.96E-04 Lung function (forced vital capacity) / / 24023788 rs4866484 chr5 2418025 A G 3.42E-04 Iron levels / / pha002876 rs1039096 chr5 2433691 G A 1.01E-04 Iron levels / / pha002876 rs370672 chr5 2448146 G A 5.07E-06 Alzheimer's disease / / 17998437 rs370672 chr5 2448146 G A 6.66E-05 Alzheimer's disease / / pha002879 rs1908159 chr5 2453377 A G 3.43E-04 Suicide attempts in bipolar disorder / / 21041247 rs1908159 chr5 2453377 A G 8.81E-04 Suicide attempts in bipolar disorder / / 21041247 rs315892 chr5 2458057 T C 1.19E-04 Suicide attempts in bipolar disorder / / 21041247 rs315892 chr5 2458057 T C 7.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs11133949 chr5 2462225 A G 2.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs11133949 chr5 2462225 A G 7.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs6877519 chr5 2463858 A G 3.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs6877519 chr5 2463858 A G 7.24E-05 Suicide attempts in bipolar disorder / / 21041247 rs13175490 chr5 2464882 A G 1.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs13175490 chr5 2464882 A G 4.85E-05 Suicide attempts in bipolar disorder / / 21041247 rs13156277 chr5 2464988 C T 1.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs13156277 chr5 2464988 C T 5.86E-05 Suicide attempts in bipolar disorder / / 21041247 rs924134 chr5 2468375 C A 4.79E-05 Suicide attempts in bipolar disorder / / 21041247 rs924134 chr5 2468375 C A 6.12E-06 Suicide attempts in bipolar disorder / / 21041247 rs6880842 chr5 2469415 A G 3.20E-05 Suicide attempts in bipolar disorder / / 21041247 rs6880842 chr5 2469415 A G 7.36E-06 Suicide attempts in bipolar disorder / / 21041247 rs1496447 chr5 2471705 A G 0.0003871 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1496447 chr5 2471705 A G 3.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6555113 chr5 2472928 A T 4.29E-05 Suicide attempts in bipolar disorder / / 21041247 rs6555113 chr5 2472928 A T 6.32E-06 Suicide attempts in bipolar disorder / / 21041247 rs3104229 chr5 2473843 C G,T 2.96E-05 Suicide attempts in bipolar disorder / / 21041247 rs3104229 chr5 2473843 C G,T 7.23E-06 Suicide attempts in bipolar disorder / / 21041247 rs9312996 chr5 2474518 C G 2.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs9312996 chr5 2474518 C G 4.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs10055939 chr5 2477430 G T 2.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs10055939 chr5 2477430 G T 3.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs10058639 chr5 2479184 G A 2.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs10058639 chr5 2479184 G A 7.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs10075636 chr5 2479446 C T 2.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs10075636 chr5 2479446 C T 4.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs16869822 chr5 2479515 A G 2.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs16869822 chr5 2479515 A G 6.63E-04 Suicide attempts in bipolar disorder / / 21041247 rs10475154 chr5 2479789 T G 1.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs10475154 chr5 2479789 T G 4.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs3112426 chr5 2481088 A C 7.26E-05 Suicide attempts in bipolar disorder / / 21041247 rs3112426 chr5 2481088 A C 8.03E-06 Suicide attempts in bipolar disorder / / 21041247 rs3112424 chr5 2482544 T C 1.70E-05 Cognitive impairment induced by topiramate / / 22091778 rs1992827 chr5 2488341 T C 1.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs1992827 chr5 2488341 T C 8.70E-06 Suicide attempts in bipolar disorder / / 21041247 rs462437 chr5 2491585 A C,G,T 3.43E-06 Alcohol and nictotine co-dependence / / 20158304 rs2453814 chr5 2493280 A C 2.88E-04 Multiple complex diseases / / 17554300 rs2453814 chr5 2493280 A C 1.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs2453814 chr5 2493280 A C 4.92E-05 Suicide attempts in bipolar disorder / / 21041247 rs895658 chr5 2494273 C T 6.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs895658 chr5 2494273 C T 7.52E-05 Suicide attempts in bipolar disorder / / 21041247 rs1562414 chr5 2497120 G A 7.82E-04 Suicide attempts in bipolar disorder / / 21041247 rs1562414 chr5 2497120 G A 9.32E-05 Suicide attempts in bipolar disorder / / 21041247 rs6896543 chr5 2507645 A T 0.000527 Asthma / / 22502797 rs3112414 chr5 2508221 C G 1.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs3099592 chr5 2510027 A G 2.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs378257 chr5 2518738 C T 2.40E-06 Urinary metabolites / / 21572414 rs6875477 chr5 2533617 A G 1.20E-04 IgE levels in asthmatics / / 23967269 rs12517190 chr5 2538080 C T 4.35E-06 Monocyte counts / / pha003089 rs13436812 chr5 2544880 C A 2.17E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7702425 chr5 2549211 A G 8.36E-04 Alcohol dependence / / 20201924 rs6888228 chr5 2553159 T C 2.34E-04 Alcohol dependence / / 20201924 rs407360 chr5 2608294 C T 3.95E-05 Monocyte chemoattractant protein-1 / / pha003071 rs2897047 chr5 2640123 A G 0.00000406 Cytarabine sensitivity / / 23538338 rs17660394 chr5 2643974 T G 8.86E-05 Receptive language ability / / 24687471 rs950864 chr5 2667858 G T 7.23E-05 Post-operative nausea and vomiting / / 21694509 rs7704762 chr5 2679511 A G 1.02E-04 Multiple complex diseases / / 17554300 rs2935620 chr5 2685567 G A 1.61E-04 Multiple complex diseases / / 17554300 rs2935621 chr5 2685812 C T 8.30E-05 Multiple complex diseases / / 17554300 rs2935624 chr5 2688597 A G 3.88E-04 Multiple complex diseases / / 17554300 rs16870285 chr5 2688941 G A 5.95E-05 Birth weight / / 17255346 rs2962615 chr5 2689899 C A 9.14E-04 Multiple complex diseases / / 17554300 rs2962615 chr5 2689899 C A 8.70E-07 Urinary metabolites / / 21572414 rs2962612 chr5 2691343 A T 1.90E-05 Urinary metabolites / / 21572414 rs78383867 chr5 2697371 G A 1.04E-04 Acne (severe) / / 24927181 rs875221 chr5 2699110 C G 1.97E-04 Multiple complex diseases / / 17554300 rs1106115 chr5 2700155 A G 5.60E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs78804414 chr5 2707454 C T 1.50E-05 Acne (severe) / / 24927181 rs2173226 chr5 2724362 T C 8.00E-06 Obesity-related traits / / 23251661 rs12189449 chr5 2735161 G A 3.20E-04 Aortic root size / / 21223598 rs11432 chr5 2747127 A G 8.63E-04 Myopia (pathological) IRX2 UTR-3 21095009 rs7729458 chr5 2799100 C A 8.94E-05 Body Mass Index / / pha003021 rs11738198 chr5 2808621 T A 7.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs16870505 chr5 2813509 G T 2.87E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1122217 chr5 2815488 A G 4.26E-04 Coronary Artery Disease / / 17634449 rs12655083 chr5 2852127 G A 1.40E-05 Urinary metabolites / / 21572414 rs2934543 chr5 2856417 C T 9.23E-05 Left ventricular hypertrophy / / pha003052 rs963872 chr5 2857542 G A 5.07E-05 Psoriasis / / 20953190 rs16870583 chr5 2861216 T C 5.06E-05 Left ventricular hypertrophy / / pha003052 rs16870615 chr5 2876127 C T 5.24E-04 Schizophrenia / / 19197363 rs2934550 chr5 2878637 G A 2.12E-05 Orofacial clefts / / 22419666 rs2974656 chr5 2901360 C A 3.71E-04 Multiple complex diseases / / 17554300 rs1565808 chr5 2908616 G A 2.38E-04 Multiple complex diseases / / 17554300 rs2974688 chr5 2915423 A T 9.56E-04 Multiple complex diseases / / 17554300 rs7727227 chr5 2917651 A G 0.000522 Height (Pygmy height) / / 22570615 rs1304798 chr5 2937136 C A,G,T 1.10E-06 Urinary metabolites / / 21572414 rs4270702 chr5 2941405 T A 9.79E-08 Multiple complex diseases / / 17554300 rs7737453 chr5 2949174 T C 3.30E-06 Urinary metabolites / / 21572414 rs12152896 chr5 2949226 G A 1.20E-06 Urinary metabolites / / 21572414 rs16870692 chr5 2949898 G A 9.67E-04 Multiple complex diseases / / 17554300 rs11133966 chr5 2950010 G A 2.60E-06 Urinary metabolites / / 21572414 rs1494066 chr5 2970320 A G 3.27E-06 Stroke / / pha002886 rs2961793 chr5 3010613 C T 1.96E-05 Telomere length / / 23001564 rs7702868 chr5 3024410 G C 3.90E-07 Urinary metabolites / / 21572414 rs160885 chr5 3063903 T G 7.06E-04 Type 2 diabetes / / 17463246 rs461017 chr5 3073624 A G 9.86E-05 Cytomegalovirus antibody response / / 21993531 rs466896 chr5 3073671 A G 9.85E-05 Cytomegalovirus antibody response / / 21993531 rs465025 chr5 3078063 A G 0.000471156 Hypertension (early onset hypertension) / / 22479346 rs464918 chr5 3079057 C T 0.000471156 Hypertension (early onset hypertension) / / 22479346 rs2442698 chr5 3089029 C A 6.80E-06 Urinary metabolites / / 21572414 rs6873793 chr5 3092192 C T 1.00E-06 QT interval / / 23166209 rs17620715 chr5 3095783 G C 8.55E-04 Multiple complex diseases / / 17554300 rs314002 chr5 3106162 G T 3.73E-05 Colorectal cancer / / 24448986 rs160758 chr5 3117180 A G 4.63E-04 Type 2 diabetes / / 17463246 rs465705 chr5 3126445 A G 9.97E-04 Type 2 diabetes / / 17463246 rs469508 chr5 3132559 C T 4.22E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs597099 chr5 3139158 C T 9.50E-05 Alcohol dependence / / 24277619 rs181860 chr5 3146907 C T 5.60E-05 Diabetic retinopathy / / 21441570 rs3110972 chr5 3152227 A T 5.84E-04 Multiple complex diseases / / 17554300 rs160559 chr5 3154650 T A 5.62E-04 Multiple complex diseases / / 17554300 rs6861522 chr5 3154670 C T 4.95E-04 Multiple complex diseases / / 17554300 rs461401 chr5 3156508 C T 6.97E-05 Receptive language ability / / 24687471 rs468700 chr5 3157181 T A 6.32E-05 Receptive language ability / / 24687471 rs467651 chr5 3157365 A G 5.85E-05 Receptive language ability / / 24687471 rs665795 chr5 3158987 A G 6.70E-05 Lipid levels / / 18193043 rs467873 chr5 3159357 A C 8.06E-05 Receptive language ability / / 24687471 rs467974 chr5 3160194 C G 8.06E-05 Receptive language ability / / 24687471 rs666410 chr5 3160404 A G 7.17E-05 Receptive language ability / / 24687471 rs1661110 chr5 3161133 C T 5.60E-05 Receptive language ability / / 24687471 rs1691132 chr5 3161324 A G 8.10E-05 Receptive language ability / / 24687471 rs1691133 chr5 3161367 T G 8.06E-05 Receptive language ability / / 24687471 rs11740370 chr5 3165158 T G 6.51E-04 Type 2 diabetes / / 17463246 rs13171158 chr5 3171701 A G 2.15E-05 Major depressive disorder (broad) / / 20038947 rs12657403 chr5 3174785 G A 9.91E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs446095 chr5 3180897 C A 3.74E-06 Cholesterol / / 17255346 rs421093 chr5 3211391 T C 5.27E-05 Major depressive disorder / / 21621269 rs6894463 chr5 3213546 G A 4.81E-05 Neuroticism / / 23229837 rs1661074 chr5 3216271 C T 2.58E-04 Multiple complex diseases / / 17554300 rs2099821 chr5 3223744 G A 1.33E-04 Coronary heart disease / / 21606135 rs12658153 chr5 3224850 A G 9.45E-05 Coronary heart disease / / 21606135 rs4866533 chr5 3225839 C G 2.80E-05 Serum metabolites / / 19043545 rs1027362 chr5 3232868 C T 4.65E-05 Intracerebral hemorrhage / / 24656865 rs6892726 chr5 3235797 C T 4.20E-05 Coronary heart disease / / 21606135 rs427867 chr5 3245702 A G 8.58E-05 Dengue shock syndrome / / 22001756 rs1691017 chr5 3246853 A G 9.95E-05 Epilepsy (remission after treatment) / / 23962720 rs1691016 chr5 3246919 G T 1.78E-08 Narcolepsy / / 19629137 rs13165026 chr5 3249967 C T 5.33E-06 Coronary heart disease / / 21606135 rs6893167 chr5 3258871 C A 4.82E-04 Heart Failure / / pha002884 rs35418482 chr5 3270745 G A 2.92E-06 Epilepsy (remission after treatment) / / 23962720 rs13188161 chr5 3271873 C A 3.65E-06 Epilepsy (remission after treatment) / / 23962720 rs10063962 chr5 3271982 G T 2.08E-06 Epilepsy (remission after treatment) / / 23962720 rs61670327 chr5 3276696 G A 7.00E-07 Epilepsy (remission after treatment) / / 23962720 rs34432833 chr5 3282691 G A 1.02E-05 Epilepsy (remission after treatment) / / 23962720 rs4509027 chr5 3285633 A G 1.50E-05 Urinary metabolites / / 21572414 rs6894263 chr5 3297751 A G 5.74E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6896919 chr5 3317260 T C 8.28E-05 Hemoglobin / / pha003098 rs7711130 chr5 3335397 A G 7.57E-04 Type 2 diabetes / / 17463246 rs7723053 chr5 3347725 T C 5.21E-05 Aortic root size / / 21223598 rs4866555 chr5 3348418 G A 3.49E-05 Aortic root size / / 21223598 rs6864026 chr5 3348613 C T 5.45E-05 Aortic root size / / 21223598 rs7723199 chr5 3361181 A G 2.20E-05 Urinary metabolites / / 21572414 rs200956115 chr5 3362103 A AATT 9.92E-04 Multiple complex diseases / / 17554300 rs4376274 chr5 3362103 A T 9.92E-04 Multiple complex diseases / / 17554300 rs251433 chr5 3380046 G A 4.35E-05 Blood Pressure / / pha003050 rs32689 chr5 3384836 C T 9.20E-05 Waist-Hip Ratio / / pha003028 rs17683231 chr5 3416372 T A 3.90E-04 Multiple complex diseases / / 17554300 rs11742901 chr5 3429107 C T 5.20E-06 Urinary metabolites LOC285577 intron 21572414 rs415467 chr5 3449329 T C 7.47E-04 Response to cytadine analogues (cytosine arabinoside) LOC285577 intron 24483146 rs32723 chr5 3451906 T G 6.19E-05 Systemic sclerosis LOC285577 intron 21750679 rs32725 chr5 3452314 A C 4.95E-04 Multiple complex diseases LOC285577 intron 17554300 rs17686287 chr5 3507990 G A 2.30E-06 Coronary Artery Disease LOC285577 intron 17634449 rs710989 chr5 3523131 C T 1.20E-07 Urinary metabolites LOC285577 intron 21572414 rs710987 chr5 3525440 A G 3.80E-07 Urinary metabolites LOC285577 intron 21572414 rs710986 chr5 3529660 T C 2.90E-07 Urinary metabolites LOC285577 intron 21572414 rs710984 chr5 3530294 A G 5.50E-06 Urinary metabolites LOC285577 intron 21572414 rs9313052 chr5 3538762 G C 3.70E-09 Urinary metabolites / / 21572414 rs13155882 chr5 3543787 C G,T 9.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs13189312 chr5 3545313 T C 6.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs10070669 chr5 3546200 G A 5.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs828323 chr5 3546657 G C 1.30E-05 Urinary metabolites / / 21572414 rs1651468 chr5 3552145 C A 8.80E-06 Urinary metabolites / / 21572414 rs1428741 chr5 3552597 C A 1.70E-05 Urinary metabolites / / 21572414 rs1664740 chr5 3555933 C T 7.40E-06 Urinary metabolites / / 21572414 rs10512697 chr5 3558538 T C 6.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs10512697 chr5 3558538 T C 9.00E-07 Immune response to smallpox vaccine (IL-6) / / 22542470 rs10512697 chr5 3558538 T C 6.86E-05 Calcium levels / / pha003085 rs1428739 chr5 3559973 C T 3.17E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2591649 chr5 3562484 T C 1.96E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2591649 chr5 3562484 T C 6.00E-06 Urinary metabolites / / 21572414 rs828308 chr5 3566830 C G 3.87E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2197506 chr5 3567686 T G 2.92E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs865468 chr5 3568178 C G 2.98E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs17637167 chr5 3570088 G A 1.80E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1867710 chr5 3576229 G A 6.50E-05 Cognitive function / / 24684796 rs10042985 chr5 3581760 G A 1.23E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs860439 chr5 3584368 C A 1.28E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs860439 chr5 3584368 C A 1.07E-04 Lung function (forced vital capacity) / / 24023788 rs16872167 chr5 3614425 C G 1.00E-05 Urinary metabolites / / 21572414 rs7729527 chr5 3616637 T C 6.12E-04 Alcohol dependence / / 21314694 rs1445864 chr5 3621731 A T 4.35E-05 Serum metabolites / / 19043545 rs4866587 chr5 3624590 T C 3.00E-06 Urinary metabolites / / 21572414 rs6878244 chr5 3657491 G A 5.06E-05 Serum metabolites / / 19043545 rs10065876 chr5 3657787 A G 2.70E-06 Urinary metabolites / / 21572414 rs1502643 chr5 3671136 T C 3.54E-04 Multiple complex diseases / / 17554300 rs4866599 chr5 3674775 C G 5.01E-04 Obesity (extreme) / / 21935397 rs871879 chr5 3677182 G A 2.14E-04 Alcohol dependence / / 21314694 rs13359418 chr5 3688426 T C 9.17E-05 Neuroblastoma / / pha002895 rs16872251 chr5 3688588 G A 9.48E-05 Neuroblastoma / / pha002895 rs17696019 chr5 3696174 G A 5.06E-04 Aortic root size / / 21223598 rs13186537 chr5 3702896 C A 0.00013 Cognitive impairment (no dementia) / / 23042215 rs7714769 chr5 3711914 G A 4.73E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2398624 chr5 3714522 C A 7.95E-04 Depression (quantitative trait) / / 20800221 rs2398624 chr5 3714522 C A 8.30E-05 Tooth agenesis (third molar) / / 24172245 rs2398625 chr5 3741566 C T 6.33E-04 Multiple complex diseases / / 17554300 rs4866470 chr5 3742035 C T 7.94E-04 Multiple complex diseases / / 17554300 rs13436004 chr5 3765311 T C 7.62E-04 Depression (quantitative trait) / / 20800221 rs10462777 chr5 3794274 C T 4.19E-04 Coronary heart disease / / 21606135 rs17652726 chr5 3798490 T G 4.46E-06 White blood cell count / / 21738479 rs12659399 chr5 3802888 C T 5.66E-05 Cognitive performance / / 19734545 rs17698545 chr5 3815995 T C 8.79E-04 Alzheimer's disease / / 17998437 rs2963791 chr5 3844541 C A 7.87E-04 Multiple complex diseases / / 17554300 rs2963790 chr5 3848856 T C 3.61E-05 Cortisol secretion,in saliva / / 21316860 rs2963789 chr5 3850165 G A 4.22E-04 Fibrinogen / / 17255346 rs2963788 chr5 3850437 G A 3.50E-04 Fibrinogen / / 17255346 rs2932318 chr5 3872717 T C 7.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs594459 chr5 3890330 G T 4.70E-04 Myocardial Infarction / / pha002873 rs492478 chr5 3939476 G A 4.00E-06 Cognitive performance / / 20125193 rs749905 chr5 4001782 A G 7.29E-04 Type 2 diabetes / / 17463246 rs10052418 chr5 4002117 A G 1.70E-05 Urinary metabolites / / 21572414 rs4449537 chr5 4002250 A C 9.26E-04 Type 2 diabetes / / 17463246 rs2398652 chr5 4002448 C A,T 7.46E-04 Type 2 diabetes / / 17463246 rs10069532 chr5 4006452 G A 2.10E-05 Urinary metabolites / / 21572414 rs540937 chr5 4014659 G A 4.36E-04 Myocardial Infarction / / pha002883 rs11748327 chr5 4029789 C T 5.00E-13 Myocardial infarction / / 21107343 rs10041378 chr5 4094165 G T 1.70E-05 Urinary metabolites / / 21572414 rs2136175 chr5 4114818 G A 9.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs2174981 chr5 4115116 G A 9.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs11134032 chr5 4117568 T C 1.25E-06 Esophageal cancer (squamous cell) / / 20729853 rs17664513 chr5 4121368 G A 9.10E-05 Schizophrenia / / 19571809 rs16872841 chr5 4121455 A G 2.26E-04 Multiple complex diseases / / 17554300 rs6860112 chr5 4136154 T C 1.03E-06 Esophageal cancer (squamous cell) / / 20729853 rs7729688 chr5 4143900 C T 3.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs7734161 chr5 4144326 C A 3.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs10073612 chr5 4145133 T C 5.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs10075187 chr5 4145329 T G 7.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs2136180 chr5 4145367 C G 8.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs2136181 chr5 4145392 T C 9.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs11953297 chr5 4186632 G A 6.18E-06 Cholesterol / / 17255346 rs10051866 chr5 4193777 C T 2.70E-05 Urinary metabolites / / 21572414 rs4702522 chr5 4194199 A G 7.70E-06 Urinary metabolites / / 21572414 rs4702522 chr5 4194199 A G 6.00E-06 Political ideology / / 24569950 rs10043296 chr5 4196495 G C 5.00E-06 Political ideology / / 24569950 rs6555254 chr5 4197672 A G 5.00E-06 Political ideology / / 24569950 rs10079205 chr5 4197974 C G 5.00E-06 Political ideology / / 24569950 rs6555259 chr5 4198117 A G 3.35E-05 Schizophrenia / / 24253340 rs6555259 chr5 4198117 A G 5.00E-06 Political ideology / / 24569950 rs6555260 chr5 4198374 G C 4.00E-06 Political ideology / / 24569950 rs6555261 chr5 4198436 T C 3.54E-05 Schizophrenia / / 24253340 rs6555261 chr5 4198436 T C 4.00E-06 Political ideology / / 24569950 rs6555262 chr5 4198545 T C 3.26E-04 Multiple complex diseases / / 17554300 rs6555262 chr5 4198545 T C 5.00E-06 Political ideology / / 24569950 rs6882308 chr5 4198822 A G 4.00E-06 Political ideology / / 24569950 rs10036180 chr5 4199756 C T 4.00E-06 Political ideology / / 24569950 rs10036225 chr5 4199933 C G 4.00E-06 Political ideology / / 24569950 rs7712941 chr5 4200604 C T 4.00E-06 Political ideology / / 24569950 rs6894281 chr5 4201144 A G 6.14E-04 Multiple complex diseases / / 17554300 rs6894281 chr5 4201144 A G 4.00E-06 Political ideology / / 24569950 rs6555263 chr5 4201731 G T 4.00E-06 Political ideology / / 24569950 rs6555264 chr5 4201764 G C 4.00E-06 Political ideology / / 24569950 rs6555265 chr5 4219375 C G,T 6.70E-05 Multiple complex diseases / / 17554300 rs153991 chr5 4256252 C A 5.65E-04 Spine bone size / / 23207799 rs11739066 chr5 4257463 G T 4.62E-05 Prion diseases / / 22210626 rs11739066 chr5 4257463 G T 8.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs458537 chr5 4266325 G A 9.37E-05 Multiple complex diseases / / 17554300 rs463803 chr5 4267126 G C 5.31E-05 Lactate dehydrogenase levels / / 20981236 rs462922 chr5 4277958 T C 2.08E-04 Multiple complex diseases / / 17554300 rs11134041 chr5 4281425 A G 1.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs255675 chr5 4281719 T C 2.54E-04 Multiple complex diseases / / 17554300 rs16873166 chr5 4282049 C A 1.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs12659526 chr5 4282851 T C 1.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs12659095 chr5 4282875 A G 5.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs11134043 chr5 4285241 A G 1.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs11739091 chr5 4285444 A C 9.83E-05 Suicide attempts in bipolar disorder / / 21423239 rs12653070 chr5 4286646 A G 1.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs12654993 chr5 4286657 G A 6.01E-05 Suicide attempts in bipolar disorder / / 21423239 rs12659292 chr5 4286880 C T 4.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs11738790 chr5 4290132 T C 5.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs7722419 chr5 4290527 G A 6.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs6888652 chr5 4291656 G A 8.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs6890880 chr5 4292211 C T 8.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs1039603 chr5 4292616 T C 5.00E-06 Asthma / / 20698975 rs11742174 chr5 4293345 T G 8.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs11742174 chr5 4293345 T G 3.46E-04 Body mass index / / 21701565 rs11742174 chr5 4293345 T G 3.70E-04 Body mass index / / 21701565 rs11742174 chr5 4293345 T G 7.27E-04 Body mass index / / 21701565 rs7700616 chr5 4293378 G A,T 7.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs7700616 chr5 4293378 G A,T 2.72E-04 Body mass index / / 21701565 rs7700616 chr5 4293378 G A,T 4.95E-04 Body mass index / / 21701565 rs7702429 chr5 4293859 C T 7.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs11134045 chr5 4305172 G A 7.12E-04 Body mass index / / 21701565 rs11134045 chr5 4305172 G A 8.26E-04 Body mass index / / 21701565 rs261159 chr5 4343987 C T 3.40E-06 Asthma / / 20698975 rs11745620 chr5 4358037 C T 1.92E-04 Body mass index / / 21701565 rs11745620 chr5 4358037 C T 2.03E-04 Body mass index / / 21701565 rs11745620 chr5 4358037 C T 3.18E-04 Body mass index / / 21701565 rs11745620 chr5 4358037 C T 0.000351 Salmonella-induced pyroptosis / / 22837397 rs261137 chr5 4361120 C T 1.20E-06 Asthma / / 20698975 rs261119 chr5 4365468 G A 4.20E-06 Asthma / / 20698975 rs1909986 chr5 4369247 A G 1.62E-04 Body mass index / / 21701565 rs1909986 chr5 4369247 A G 2.09E-04 Body mass index / / 21701565 rs1909986 chr5 4369247 A G 3.01E-04 Body mass index / / 21701565 rs17727542 chr5 4369807 A C 7.96E-05 Glycemic traits (pregnancy) / / 23903356 rs261125 chr5 4369887 G T 6.60E-06 Asthma / / 20698975 rs6881405 chr5 4445976 T C 2.29E-06 Multiple complex diseases / / 17554300 rs10077386 chr5 4453627 A T 2.35E-05 Multiple complex diseases / / 17554300 rs10512730 chr5 4469773 G A 2.99E-06 Height / / pha003010 rs10512730 chr5 4469773 G A 5.70E-08 Height / / pha003011 rs10462794 chr5 4488245 C T 5.00E-06 DNA methylation (variation) / / 23725790 rs6879721 chr5 4511165 T C 8.16E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs293064 chr5 4586832 T C 2.51E-05 F-cell distribution / / 21326311 rs1469468 chr5 4589761 G A 3.47E-04 Multiple complex diseases / / 17554300 rs293105 chr5 4633275 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs293105 chr5 4633275 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10512743 chr5 4633984 G A 1.56E-04 Glycosylated haemoglobin levels / / 17255346 rs10512743 chr5 4633984 G A 8.20E-05 Celiac disease / / 23936387 rs7713961 chr5 4638885 A G 2.89E-04 Alzheimer's disease (late onset) / / 21379329 rs7713961 chr5 4638885 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7713961 chr5 4638885 A G 3.69E-05 Cognitive impairment induced by topiramate / / 22091778 rs7713961 chr5 4638885 A G 5.58E-06 Cognitive impairment induced by topiramate / / 22091778 rs418752 chr5 4648002 A G 1.40E-05 Urinary metabolites / / 21572414 rs16873802 chr5 4664457 T C 6.04E-06 Cognitive impairment induced by topiramate / / 22091778 rs2895497 chr5 4665724 T C 4.87E-05 Intelligence / / 21826061 rs4407602 chr5 4668289 G A 2.23E-04 Coronary heart disease / / 21606135 rs6555306 chr5 4671383 T C 5.66E-05 Cognitive test performance / / 20125193 rs10067738 chr5 4703625 T C 2.13E-05 Bipolar disorder and schizophrenia / / 20889312 rs78697546 chr5 4719730 C G 0.0000812 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7727102 chr5 4720585 G C 1.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs1501761 chr5 4758455 C T 7.74E-05 Parkinson's disease (motor and cognition) / / 22658654 rs1501761 chr5 4758455 C T 7.74E-05 Immune response to anthrax vaccine / / 22658931 rs1173196 chr5 4816811 G A 1.70E-05 Urinary metabolites / / 21572414 rs1173198 chr5 4818616 T C 2.00E-06 Urinary metabolites / / 21572414 rs1173201 chr5 4819918 C T 2.50E-05 Urinary metabolites / / 21572414 rs816475 chr5 4831601 T C 3.00E-06 Heart rate / / 23534349 rs816478 chr5 4833867 T C 5.40E-06 Urinary metabolites / / 21572414 rs860987 chr5 4853391 A G 5.10E-06 Urinary metabolites / / 21572414 rs540736 chr5 4880927 G A 8.85E-04 Multiple complex diseases / / 17554300 rs10051514 chr5 4887171 A G 2.92E-05 Cognitive impairment induced by topiramate / / 22091778 rs26878 chr5 4903383 C T 4.68E-05 QT interval / / 16648850 rs7714932 chr5 4909055 G A 1.29E-04 Tuberculosis / / 22306650 rs654685 chr5 4936235 G A 5.23E-04 Premature ovarian failure / / 19508998 rs6868240 chr5 4938915 A C 2.42E-04 Bipolar disorder / / 18317468 rs466277 chr5 4948859 G A 0.000264 Salmonella-induced pyroptosis / / 22837397 rs2561729 chr5 4960761 A G 9.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs2561728 chr5 4961929 A C 9.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs1593961 chr5 4962316 G A 9.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs1597762 chr5 4962498 C T 8.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs2600619 chr5 4965581 A G 6.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs2561724 chr5 4966732 T C 9.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs2115289 chr5 4966895 A G 1.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs1947339 chr5 4967017 C A 1.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs1376855 chr5 4967646 C T 6.45E-05 Suicide attempts in bipolar disorder / / 21423239 rs1452027 chr5 4968029 C T 9.58E-05 Suicide attempts in bipolar disorder / / 21423239 rs1452026 chr5 4968498 G A 1.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs2561723 chr5 4968573 C T 1.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs1452024 chr5 4968706 A G 1.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs2561722 chr5 4969207 C G 1.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs1901498 chr5 4969240 A G 1.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs1035914 chr5 4969905 G A 9.89E-05 Suicide attempts in bipolar disorder / / 21423239 rs935857 chr5 4970912 T C 9.87E-05 Suicide attempts in bipolar disorder / / 21423239 rs2561721 chr5 4971790 C T 8.36E-05 Suicide attempts in bipolar disorder / / 21423239 rs9313095 chr5 4971881 T C 7.01E-05 Suicide attempts in bipolar disorder / / 21423239 rs2561720 chr5 4972764 G T 6.86E-05 Suicide attempts in bipolar disorder / / 21423239 rs374207 chr5 4975491 T C 1.41E-05 Suicide attempts in bipolar disorder / / 21423239 rs42546 chr5 4977036 C T 5.68E-05 Suicide attempts in bipolar disorder / / 21423239 rs42545 chr5 4977266 A G 6.22E-05 Suicide attempts in bipolar disorder / / 21423239 rs39853 chr5 4977533 G A 9.24E-05 Suicide attempts in bipolar disorder / / 21423239 rs42401 chr5 4978270 T G 5.54E-05 Suicide attempts in bipolar disorder / / 21423239 rs39586 chr5 4978290 A G 6.55E-05 Suicide attempts in bipolar disorder / / 21423239 rs30474 chr5 4978678 A G 6.59E-05 Suicide attempts in bipolar disorder / / 21423239 rs42400 chr5 4978695 C G 6.60E-05 Suicide attempts in bipolar disorder / / 21423239 rs30473 chr5 4982575 C T 1.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs30472 chr5 4982643 G A 8.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs30472 chr5 4982643 G A 7.54E-05 Receptive language ability / / 24687471 rs40468 chr5 4982814 A G 1.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs719183 chr5 4985134 G A 1.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs30468 chr5 4986077 C T 8.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs30467 chr5 4986095 T G 1.32E-04 Multiple complex diseases / / 17554300 rs30466 chr5 4986174 T A 8.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs30465 chr5 4986334 A C 8.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs30464 chr5 4986450 A G 8.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs190355 chr5 4987075 A T 7.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs61475604 chr5 4987075 A AT 7.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs30463 chr5 4987376 T C 9.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs39850 chr5 4988081 G A 8.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs39849 chr5 4988097 T C 7.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs181822 chr5 4990412 G T 8.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs168733 chr5 4991172 A G 8.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs30451 chr5 4992163 C T 8.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs30450 chr5 4992441 C T 6.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs30449 chr5 4992930 T C 7.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs249459 chr5 4994609 G A 6.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs249458 chr5 4995298 C A 6.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs10058490 chr5 4995900 A T 6.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs249462 chr5 4996414 T A 3.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs173624 chr5 4996740 T A 5.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs249461 chr5 4997085 A G 7.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs16874580 chr5 5021796 G C 2.85E-04 Aortic root size / / 21223598 rs16874607 chr5 5035740 T C 1.74E-04 Multiple complex diseases LOC340094 intron 17554300 rs446464 chr5 5038540 T G 1.80E-05 Kawasaki disease LOC340094 intron 22081228 rs2652067 chr5 5038650 G A 2.82E-05 Kawasaki disease LOC340094 intron 22081228 rs9313097 chr5 5060591 C A 8.30E-05 HIV-1 control LOC340094 intron 20041166 rs3733787 chr5 5078313 C T 6.66E-04 Multiple complex diseases / / 17554300 rs16874709 chr5 5106180 T G 6.34E-04 Coronary Artery Disease / / 17634449 rs7720792 chr5 5110972 G C 1.59E-04 Multiple complex diseases / / 17554300 rs1092985 chr5 5115509 C T 1.07E-04 Alcohol consumption / / 23743675 rs814786 chr5 5119641 C T 1.05E-04 Alcohol consumption / / 23743675 rs814782 chr5 5120802 A G 1.07E-04 Alcohol consumption / / 23743675 rs270188 chr5 5124149 G A 5.96E-05 Alcohol consumption / / 23743675 rs270184 chr5 5124579 C T 1.08E-04 Alcohol consumption / / 23743675 rs860085 chr5 5125333 A C 1.03E-04 Alcohol consumption / / 23743675 rs814778 chr5 5125672 A G 1.13E-04 Alcohol consumption / / 23743675 rs11748898 chr5 5137060 T C 8.62E-04 Response to TNF antagonist treatment / / 21061259 rs2560413 chr5 5149769 T A 3.71E-04 Multiple complex diseases ADAMTS16 intron 17554300 rs992542 chr5 5162228 C T 8.98E-05 Cognitive impairment induced by topiramate ADAMTS16 intron 22091778 rs1079295 chr5 5165952 T C 6.57E-05 Cognitive impairment induced by topiramate ADAMTS16 intron 22091778 rs997428 chr5 5167648 T C 1.18E-05 Blood pressure ADAMTS16 intron 17255346 rs10038199 chr5 5183642 T G 7.33E-05 Lipoprotein-associated phospholipase A2 activity and mass ADAMTS16 intron 20442857 rs1808529 chr5 5183700 A G 9.52E-04 Alzheimer's disease ADAMTS16 intron 17998437 rs1808529 chr5 5183700 A G 9.39E-05 Lipoprotein-associated phospholipase A2 activity and mass ADAMTS16 intron 20442857 rs4702245 chr5 5212079 G A 9.56E-04 Type 2 diabetes ADAMTS16 intron 17463246 rs1366163 chr5 5217994 T G 8.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADAMTS16 intron 20877124 rs1366163 chr5 5217994 T G 1.95E-05 Cardiovascular disease ADAMTS16 intron pha003065 rs4702248 chr5 5222336 A G 2.00E-05 Brain lesion load ADAMTS16 intron 19010793 rs4702249 chr5 5223923 T C 1.82E-05 Brain lesion load ADAMTS16 intron 19010793 rs16875084 chr5 5224299 G A 1.21E-05 Cardiovascular disease ADAMTS16 intron pha003065 rs2913634 chr5 5238434 C T 3.40E-05 Multiple complex diseases ADAMTS16 intron 17554300 rs16875119 chr5 5239081 T G 9.67E-04 Suicide attempts in bipolar disorder ADAMTS16 intron 21423239 rs16875141 chr5 5248501 C A 6.75E-05 Parent of origin effect on language impairment (paternal) ADAMTS16 intron 24571439 rs2913645 chr5 5251790 G T 0.0000127 HDL cholesterol particle diameter ADAMTS16 intron 23263444 rs4323203 chr5 5260903 G T 1.63E-04 Attention deficit hyperactivity disorder ADAMTS16 intron pha002875 rs2913657 chr5 5263152 T C 6.22E-04 Smoking initiation ADAMTS16 intron 24665060 rs9313108 chr5 5270394 T C 9.16E-05 Type 2 diabetes ADAMTS16 intron 17463246 rs10044817 chr5 5273945 A G 0.0000113 HDL cholesterol particle diameter ADAMTS16 intron 23263444 rs11738891 chr5 5281887 A T 6.91E-04 Multiple complex diseases ADAMTS16 intron 17554300 rs11745231 chr5 5290942 G A 3.71E-05 Femoral neck bone geometry ADAMTS16 intron 22087292 rs16875288 chr5 5297200 A T 6.00E-08 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia ADAMTS16 intron 24039173 rs41524744 chr5 5307913 T C 4.70E-08 Glaucoma (primary open-angle) ADAMTS16 intron 22428042 rs7721079 chr5 5314703 A C 8.10E-05 Femoral neck bone geometry ADAMTS16 intron 22087292 rs7721079 chr5 5314703 A C 7.79E-04 Response to cytidine analogues (gemcitabine) ADAMTS16 intron 24483146 rs4128586 chr5 5316866 C T 1.40E-04 White matter integrity ADAMTS16 intron 22425255 rs3806872 chr5 5320256 C A 3.00E-06 Breast cancer ADAMTS16 UTR-3 23468962 rs7736623 chr5 5336887 C T 1.11E-04 Type 2 diabetes / / 17463246 rs16875358 chr5 5337933 C T 3.25E-05 Type 2 diabetes / / 17463246 rs7723605 chr5 5354615 T C 3.30E-05 Parkinson's disease / / 16252231 rs13181461 chr5 5355521 T A 3.44E-04 Multiple complex diseases / / 17554300 rs2964456 chr5 5372288 G A 5.22E-04 Multiple complex diseases / / 17554300 rs16875511 chr5 5385388 T C 1.85E-05 Brain structure / / 22504417 rs2964139 chr5 5390365 A G 2.87E-04 Multiple complex diseases / / 17554300 rs2964133 chr5 5399379 A G 6.30E-06 Urinary metabolites / / 21572414 rs2964385 chr5 5404366 T C 9.86E-04 Type 2 diabetes / / 17463246 rs2964475 chr5 5407814 T G 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs2964448 chr5 5414835 C T 6.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2913356 chr5 5415012 T C 4.94E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs2913368 chr5 5418022 C T 5.89E-04 Coronary Artery Disease / / 17634449 rs2913372 chr5 5418404 A G 9.84E-04 Coronary Artery Disease / / 17634449 rs3806873 chr5 5462607 A G 0.000000932 Amyotrophic lateral sclerosis KIAA0947 missense 23587638 rs3806874 chr5 5462620 G A 0.0000012 Amyotrophic lateral sclerosis KIAA0947 missense 23587638 rs16875617 chr5 5483722 C G 8.10E-04 Multiple complex diseases KIAA0947 intron 17554300 rs16875619 chr5 5487311 T C 6.98E-04 Multiple complex diseases KIAA0947 intron 17554300 rs4702271 chr5 5491290 T C 1.60E-04 Iris characteristics / / 21835309 rs1871473 chr5 5546157 T G 4.75E-04 Multiple complex diseases / / 17554300 rs2928234 chr5 5547221 G A 8.50E-06 Urinary metabolites / / 21572414 rs13174920 chr5 5557682 C T 7.41E-05 Waist-Hip Ratio / / pha003029 rs16875765 chr5 5575229 A G 7.70E-05 Major depressive disorder / / 21042317 rs2438483 chr5 5596140 G A 4.84E-04 Alzheimer's disease / / 24755620 rs2913314 chr5 5597448 T G 7.59E-04 Alzheimer's disease / / 24755620 rs252601 chr5 5607865 T G 2.20E-05 Urinary metabolites / / 21572414 rs13185585 chr5 5614515 G T 2.39E-04 Alzheimer's disease (late onset) / / 21379329 rs7726107 chr5 5616314 A G 2.39E-04 Alzheimer's disease (late onset) / / 21379329 rs11950687 chr5 5689346 T G 1.81E-05 Alcohol consumption / / 23953852 rs11134123 chr5 5701291 G C 4.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs11134123 chr5 5701291 G C 8.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs11948250 chr5 5704234 G A 5.39E-06 Alcohol consumption / / 23953852 rs256481 chr5 5722063 C T 2.58E-06 Cognitive impairment induced by topiramate / / 22091778 rs34950 chr5 5768140 G A 2.20E-06 Urinary metabolites / / 21572414 rs2561845 chr5 5772601 A G 4.48E-04 Smoking quantity / / 24665060 rs2560463 chr5 5783653 A G 9.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs26803 chr5 5787298 C G 1.80E-04 Smoking quantity / / 24665060 rs3891830 chr5 5788380 G A 0.0000542 Panic disorder / / 23149450 rs3891830 chr5 5788380 G A 5.42E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs32566 chr5 5792507 C T 2.00E-09 Morbidity-free survival / / 17903295 rs39964 chr5 5796906 G A 1.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1864117 chr5 5818164 G A 1.70E-04 Iron levels / / pha002876 rs3852160 chr5 5822647 C T 2.00E-06 Mean arterial pressure (alcohol consumption interaction) / / 24376456 rs10058530 chr5 5840726 C T 7.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs1698011 chr5 5841108 A G 1.91E-04 Smoking cessation / / 24665060 rs7715747 chr5 5855016 T C 4.77E-05 Coronary heart disease / / pha003056 rs2561858 chr5 5859422 A C 4.08E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs950651 chr5 5876623 T C 1.39E-04 Schizophrenia / / 21674006 rs10512840 chr5 5878031 T A 5.14E-04 Smoking cessation / / 24665060 rs1913763 chr5 5881234 G A 9.11E-04 Type 2 diabetes / / 17463246 rs2256415 chr5 5894870 A G 7.72E-04 Parkinson's disease / / 17052657 rs2256415 chr5 5894870 A G 2.92E-05 Coronary heart disease / / pha003056 rs7728043 chr5 5897694 T C 1.00E-06 QT interval / / 20031603 rs1492276 chr5 5903697 T C 4.70E-05 Coronary heart disease / / pha003056 rs1150461 chr5 5911381 A G 4.84E-05 Multiple complex diseases / / 17554300 rs1150462 chr5 5911422 G A 8.32E-05 Multiple complex diseases / / 17554300 rs16876639 chr5 5949236 A G 1.48E-05 Aging (time to event) / / 21782286 rs308216 chr5 5962426 A T 6.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs11134134 chr5 5974390 C T 4.10E-06 Primary sclerosing cholangitis / / 19944697 rs306254 chr5 5981228 A G 4.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs306254 chr5 5981228 A G 5.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs306256 chr5 5984746 T C 1.58E-04 Multiple complex diseases / / 17554300 rs17818147 chr5 5998938 G T 2.29E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs17767636 chr5 6009018 G A 1.86E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs466721 chr5 6014413 G A 5.30E-04 Primary sclerosing cholangitis / / 19944697 rs7735511 chr5 6050134 G A 2.43E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs12187733 chr5 6058009 A G 2.21E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs160061 chr5 6116659 A G 7.61E-04 Multiple complex diseases / / 17554300 rs6863223 chr5 6160214 A G 8.88E-04 Multiple complex diseases / / 17554300 rs10059895 chr5 6172968 G A 3.67E-05 Hypertension / / pha003042 rs17771831 chr5 6179627 G A 8.20E-05 Serum metabolites / / 19043545 rs2937796 chr5 6183827 C T 5.05E-05 Hypertension / / pha003042 rs17771960 chr5 6188186 A T 7.16E-05 Serum metabolites / / 19043545 rs2937785 chr5 6197044 T C 8.98E-06 Hypertension / / pha003042 rs7727548 chr5 6216046 G T 7.19E-05 Serum metabolites / / 19043545 rs2964748 chr5 6227738 C T 6.01E-19 Multiple complex diseases / / 17554300 rs4702326 chr5 6262981 C A 7.50E-05 Information processing speed / / 21130836 rs4702326 chr5 6262981 C A 6.06E-05 Cognitive impairment induced by topiramate / / 22091778 rs11134152 chr5 6272266 T C 5.60E-05 Amyotrophic lateral sclerosis / / 19193627 rs2925702 chr5 6286955 C T 4.10E-06 Urinary metabolites / / 21572414 rs2914746 chr5 6296991 G A 5.32E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2914746 chr5 6296991 G A 9.91E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12716179 chr5 6317306 T C 3.60E-04 Alcohol dependence FLJ33360 intron 20201924 rs12716179 chr5 6317306 T C 5.90E-04 Alcohol dependence FLJ33360 intron 20201924 rs17825723 chr5 6320673 A G 2.92E-07 Socioeconomic Factors FLJ33360 intron pha003067 rs12518614 chr5 6324293 A G 2.00E-09 End-stage coagulation FLJ33360 intron 23381943 rs4345283 chr5 6325850 A C 8.22E-04 Alcohol dependence FLJ33360 intron 20201924 rs17831594 chr5 6345055 G A 4.18E-04 HIV-1 viral setpoint / / 17641165 rs10040610 chr5 6353815 T C 1.54E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs7711308 chr5 6358449 G A 9.02E-04 HIV-1 viral setpoint / / 17641165 rs271399 chr5 6368521 G A 8.38E-04 Multiple complex diseases / / 17554300 rs930105 chr5 6369804 C T 9.06E-05 Triglycerides / / pha003080 rs4701726 chr5 6384283 T G 7.05E-05 Schizophrenia / / 20185149 rs16877262 chr5 6400181 T C 1.72E-04 Type 2 diabetes / / 17463246 rs1393067 chr5 6402598 C T 5.74E-04 Iron levels / / pha002876 rs16877286 chr5 6418689 T C 4.31E-05 Personality dimensions / / 22628180 rs4702348 chr5 6420219 T C 7.17E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs272474 chr5 6462338 A G 3.78E-08 Asthma UBE2QL1 intron 23181788 rs6555395 chr5 6466583 C T 3.59E-04 Suicide attempts in bipolar disorder UBE2QL1 intron 21423239 rs487740 chr5 6518618 C T 1.80E-05 Urinary metabolites / / 21572414 rs931062 chr5 6520684 T C 2.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs4702359 chr5 6521202 A G 1.13E-04 Suicide attempts in bipolar disorder / / 21041247 rs11742039 chr5 6521824 T G 2.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs563624 chr5 6521837 A C 6.12E-05 Behcet's disease / / pha002888 rs11134164 chr5 6522043 A G 2.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs992285 chr5 6539117 C T 1.50E-05 Urinary metabolites / / 21572414 rs12189073 chr5 6540593 A G 7.77E-04 Type 2 diabetes / / 17463246 rs12189073 chr5 6540593 A G 9.90E-06 Urinary metabolites / / 21572414 rs12189254 chr5 6540747 T C 1.30E-05 Urinary metabolites / / 21572414 rs577060 chr5 6545276 T C 9.85E-05 Pulmonary function / / 20010835 rs16877522 chr5 6546244 C A 8.90E-06 Urinary metabolites / / 21572414 rs2617534 chr5 6548889 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10058390 chr5 6576320 A G 1.91E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3776453 chr5 6588367 G A 1.84E-06 Response to amphetamines / / 22952603 rs7720545 chr5 6591094 C T 1.56E-06 Response to amphetamines / / 22952603 rs11960378 chr5 6593741 G A 1.97E-06 Response to amphetamines / / 22952603 rs11960407 chr5 6593822 G A 8.73E-07 Response to amphetamines / / 22952603 rs11738379 chr5 6594911 G C 1.59E-06 Response to amphetamines / / 22952603 rs545493 chr5 6597622 C T 4.89E-05 Insulin Resistance / / pha003062 rs13163940 chr5 6598107 A T 6.55E-06 Response to amphetamines / / 22952603 rs6876835 chr5 6599222 A G 3.00E-06 Visceral fat NSUN2 nearGene-3 22589738 rs6876835 chr5 6599222 A G 4.51E-05 Body Fat Distribution NSUN2 nearGene-3 pha003016 rs6555404 chr5 6606445 G A 9.98E-06 Response to amphetamines NSUN2 intron 22952603 rs6884320 chr5 6612027 T C 4.52E-06 Response to amphetamines NSUN2 intron 22952603 rs4701742 chr5 6613827 T C 6.04E-04 Insulin resistance NSUN2 intron 21901158 rs3776431 chr5 6618756 T C 3.52E-06 Response to amphetamines NSUN2 intron 22952603 rs2288445 chr5 6620092 C T 1.10E-06 Response to amphetamines NSUN2 intron 22952603 rs2303705 chr5 6622017 T G 2.80E-06 Response to amphetamines NSUN2 intron 22952603 rs11744948 chr5 6622790 G A 2.70E-06 Response to amphetamines NSUN2 intron 22952603 rs12691276 chr5 6623085 T C 7.00E-07 Urinary metabolites NSUN2 intron 21572414 rs10037161 chr5 6624294 C A 2.56E-06 Response to amphetamines NSUN2 intron 22952603 rs6874005 chr5 6624371 C T 2.84E-06 Response to amphetamines NSUN2 intron 22952603 rs2288447 chr5 6626091 G A 9.03E-06 Response to amphetamines NSUN2 intron 22952603 rs10076470 chr5 6632875 G A 1.14E-06 Response to amphetamines NSUN2 intron 22952603 rs571550 chr5 6632909 G A 7.26E-06 Response to amphetamines NSUN2 intron 22952603 rs193743 chr5 6632942 G T 7.53E-06 Response to amphetamines NSUN2 intron 22952603 rs4702373 chr5 6633222 C T 1.32E-06 Response to amphetamines NSUN2 UTR-5 22952603 rs531290 chr5 6634688 C G 5.64E-07 Response to amphetamines SRD5A1 intron 22952603 rs472402 chr5 6635591 G C 3.00E-07 Response to amphetamines SRD5A1 intron 22952603 rs501999 chr5 6635601 T C 2.86E-07 Response to amphetamines SRD5A1 intron 22952603 rs7707559 chr5 6635740 C A 2.39E-06 Response to amphetamines SRD5A1 intron 22952603 rs477930 chr5 6635882 G T 5.64E-07 Response to amphetamines SRD5A1 intron 22952603 rs7706809 chr5 6635971 G T 1.65E-06 Response to amphetamines SRD5A1 intron 22952603 rs8192130 chr5 6636450 G A 1.15E-06 Response to amphetamines SRD5A1 intron 22952603 rs8192131 chr5 6636465 C T 2.25E-06 Response to amphetamines SRD5A1 intron 22952603 rs8192133 chr5 6636645 A G 2.00E-06 Response to amphetamines SRD5A1 intron 22952603 rs7720479 chr5 6640049 A G 4.60E-06 Response to amphetamines SRD5A1 intron 22952603 rs10050691 chr5 6647937 T A 4.70E-06 Response to amphetamines SRD5A1 intron 22952603 rs3822430 chr5 6651970 A G 3.58E-06 Response to amphetamines SRD5A1 cds-synon 22952603 rs8192186 chr5 6652009 G A 2.44E-06 Response to amphetamines SRD5A1 cds-synon 22952603 rs3733773 chr5 6652252 G A 3.04E-06 Response to amphetamines SRD5A1 intron 22952603 rs10055803 chr5 6654416 C T 2.54E-06 Response to amphetamines SRD5A1 intron 22952603 rs10065299 chr5 6654489 T C 2.42E-06 Response to amphetamines SRD5A1 intron 22952603 rs8192207 chr5 6656161 C T 9.16E-04 Type 2 diabetes SRD5A1 intron 17463246 rs11738248 chr5 6657494 C T 1.81E-06 Response to amphetamines SRD5A1 intron 22952603 rs10060745 chr5 6658003 T C 1.43E-06 Response to amphetamines SRD5A1 intron 22952603 rs248801 chr5 6659517 T C 1.75E-06 Response to amphetamines SRD5A1 intron 22952603 rs11134173 chr5 6659696 C A 3.62E-06 Response to amphetamines SRD5A1 intron 22952603 rs248797 chr5 6661323 G A 6.22E-07 Response to amphetamines SRD5A1 intron 22952603 rs6883294 chr5 6661926 G A 3.23E-06 Response to amphetamines SRD5A1 intron 22952603 rs6884552 chr5 6661966 C T 4.58E-06 Response to amphetamines SRD5A1 intron 22952603 rs4702382 chr5 6665681 T G 5.28E-06 Response to amphetamines SRD5A1 intron 22952603 rs10512874 chr5 6683000 A G 2.53E-05 Cognitive test performance / / 20125193 rs100841 chr5 6705857 G A 2.46E-04 Schizophrenia / / 19197363 rs274724 chr5 6717558 G A 5.64E-04 Fibrinogen PAPD7 intron 17255346 rs274718 chr5 6720988 C A 4.28E-04 Suicide attempts in bipolar disorder PAPD7 intron 21423239 rs274692 chr5 6734625 C T 8.35E-04 Suicide attempts in bipolar disorder PAPD7 intron 21423239 rs28363340 chr5 6735844 A G 5.43E-04 Smoking initiation PAPD7 intron 24665060 rs274689 chr5 6736215 G C 9.26E-04 Suicide attempts in bipolar disorder PAPD7 intron 21423239 rs200841 chr5 6737134 T C 5.18E-04 Suicide attempts in bipolar disorder PAPD7 intron 21423239 rs274682 chr5 6748518 A G 4.78E-04 Multiple complex diseases PAPD7 intron 17554300 rs274678 chr5 6752385 G A 9.58E-04 Suicide attempts in bipolar disorder PAPD7 intron 21423239 rs274674 chr5 6755460 C T 3.16E-04 Suicide attempts in bipolar disorder PAPD7 UTR-3 21423239 rs13163920 chr5 6759714 C T 6.89E-04 Insulin resistance / / 21901158 rs13163920 chr5 6759714 C T 2.23E-05 Paclitaxel-induced neuropathy / / 23776197 rs12520016 chr5 6767312 T G 9.00E-07 Eye color / / 23548203 rs274658 chr5 6768200 A T 6.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs1552914 chr5 6769016 T C 8.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs274646 chr5 6788282 A G 1.14E-05 Sickle cell anemia (severity) / / 20029952 rs106415 chr5 6792839 T C 1.26E-04 Parkinson's disease / / 17052657 rs106415 chr5 6792839 T C 8.62E-05 Hypertension / / 21082022 rs13177725 chr5 6795764 A G 1.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs275456 chr5 6813937 G T 3.00E-06 Paclitaxel-induced neuropathy / / 23776197 rs275454 chr5 6816013 G A 2.12E-04 Parkinson's disease / / 17052657 rs12109729 chr5 6817709 C T 3.40E-04 Type 2 diabetes / / 17463246 rs1566039 chr5 6821914 G A 1.00E-08 Sphingolipid levels / / 22359512 rs11134178 chr5 6834167 T C 3.00E-06 Attention deficit hyperactivity disorder / / 18821564 rs924127 chr5 6834441 A C 8.68E-05 Schizophrenia / / 19571811 rs10512889 chr5 6868922 C T 4.17E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs275437 chr5 6879978 T C 3.00E-06 Obesity-related traits / / 23251661 rs41387251 chr5 6880169 A C 8.21E-04 Multiple complex diseases / / 17554300 rs7723194 chr5 6895734 A G 9.10E-06 Urinary metabolites / / 21572414 rs1353502 chr5 6902045 T G 9.10E-06 Urinary metabolites / / 21572414 rs1353502 chr5 6902045 T G 5.89E-05 Glucose levels / / pha003058 rs1353502 chr5 6902045 T G 9.79E-05 Glucose levels / / pha003061 rs17804457 chr5 6907502 C A 1.30E-05 Urinary metabolites / / 21572414 rs17191542 chr5 6915880 C A 2.56E-04 Multiple complex diseases / / 17554300 rs6860567 chr5 6926519 A G 2.90E-05 Urinary metabolites / / 21572414 rs6862164 chr5 6944267 A G 1.38E-04 Multiple complex diseases / / 17554300 rs6888607 chr5 6983968 T C 4.41E-04 Multiple complex diseases / / 17554300 rs6873965 chr5 6985430 C T 4.77E-05 Multiple complex diseases / / 17554300 rs4702413 chr5 6987629 T C 2.40E-05 Urinary metabolites / / 21572414 rs6555421 chr5 6990363 T C 3.90E-05 HIV-1 control / / 20041166 rs4235565 chr5 7001842 G A 1.60E-05 Serum metabolites / / 19043545 rs10056446 chr5 7003920 G A 6.50E-06 Serum metabolites / / 19043545 rs4446428 chr5 7005949 A G 5.20E-05 Height / / pha003010 rs6555423 chr5 7017756 C T 2.40E-06 Urinary metabolites / / 21572414 rs12658529 chr5 7023296 T C 7.48E-05 Type 2 diabetes / / 17463246 rs6859571 chr5 7053506 C T 8.66E-04 Schizophrenia / / 19197363 rs13190346 chr5 7083694 G A 6.86E-05 Weight / / pha003026 rs1390626 chr5 7099381 G T 7.97E-04 Schizophrenia / / 19197363 rs16878364 chr5 7113974 G A 1.52E-04 Multiple complex diseases / / 17554300 rs2132538 chr5 7116396 C T 3.45E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs13161773 chr5 7118462 G A 4.71E-04 Smoking initiation / / 24665060 rs1496361 chr5 7136893 G T 8.51E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs4702429 chr5 7137379 G A 5.37E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs4702435 chr5 7155612 C T 5.00E-06 Obesity-related traits / / 23251661 rs12659620 chr5 7155958 T C 5.56E-05 Pulmonary function in asthmatics / / 23541324 rs17202561 chr5 7165264 G T 6.16E-04 Iron levels / / pha002876 rs10051593 chr5 7184639 G T 4.52E-04 Smoking initiation / / 24665060 rs13155334 chr5 7189524 C A 5.33E-04 Iron levels / / pha002876 rs4702440 chr5 7191074 C T 8.94E-05 Lung adenocarcinoma / / 19836008 rs7701629 chr5 7193206 A G 2.06E-05 Cognitive performance / / 19734545 rs11740932 chr5 7204935 C T 4.36E-06 Cognitive performance / / 19734545 rs13155746 chr5 7218137 G A 4.22E-04 Iron levels / / pha002876 rs7729273 chr5 7228047 C T 1.00E-06 Cognitive performance / / 19734545 rs4537030 chr5 7243981 T G 7.00E-07 Mean arterial pressure (alcohol consumption interaction) / / 24376456 rs4702457 chr5 7324451 A C 1.39E-05 Cognitive test performance / / 20125193 rs3763057 chr5 7345815 C T 0.0003375 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs3763057 chr5 7345815 C T 3.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1505080 chr5 7345847 A G 9.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1505080 chr5 7345847 A G 0.0000183 LDL cholesterol particle diameter / / 23263444 rs1505081 chr5 7345929 C T 9.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1505081 chr5 7345929 C T 0.0000169 LDL cholesterol particle diameter / / 23263444 rs3812025 chr5 7347593 A C 0.0000168 LDL cholesterol particle diameter / / 23263444 rs1505089 chr5 7351342 T G 0.00000798 LDL cholesterol particle diameter / / 23263444 rs1505089 chr5 7351342 T G 0.0000192 HDL cholesterol particle diameter / / 23263444 rs6891243 chr5 7361980 A T 3.94E-05 Bipolar disorder / / 19488044 rs6891243 chr5 7361980 A T 3.42E-05 Bipolar disorder and schizophrenia / / 20889312 rs6891243 chr5 7361980 A T 2.10E-05 Bipolar Disorder / / pha002858 rs13172324 chr5 7368845 C G,T 3.00E-10 Myopia (pathological) / / 23049088 rs13153439 chr5 7398546 A C 4.09E-04 Alzheimer's disease ADCY2 intron 22005930 rs11741244 chr5 7405952 C T 6.12E-04 White matter integrity ADCY2 intron 22425255 rs17813652 chr5 7425788 C T 2.14E-04 Alzheimer's disease ADCY2 intron 17998437 rs17227580 chr5 7425981 A T 7.33E-04 Alzheimer's disease ADCY2 intron 17998437 rs7730403 chr5 7429254 G A 8.14E-04 Alzheimer's disease ADCY2 intron 17998437 rs11742602 chr5 7440607 G T 4.09E-04 Alzheimer's disease ADCY2 intron 17998437 rs7733194 chr5 7441829 G A 2.07E-05 Age-related macular degeneration ADCY2 intron 22125219 rs34843 chr5 7460236 T G 1.64E-04 Tourette syndrome ADCY2 intron 22889924 rs252546 chr5 7478914 G A 2.15E-05 Cognitive test performance ADCY2 intron 20125193 rs11948030 chr5 7493177 T C 2.08E-07 Bipolar disorder ADCY2 intron 24618891 rs17826395 chr5 7503056 A C 1.96E-07 Bipolar disorder ADCY2 intron 24618891 rs17826588 chr5 7516555 C T 7.63E-04 Amyotrophic Lateral Sclerosis ADCY2 intron 17362836 rs17826588 chr5 7516555 C T 8.78E-06 Bipolar disorder ADCY2 intron 24618891 rs10038196 chr5 7517418 T G 1 Drug response to Etoposide ADCY2 intron 17537913 rs9313193 chr5 7518186 A G 9.85E-04 Multiple complex diseases ADCY2 intron 17554300 rs17826816 chr5 7519298 A G 1.00E-08 Bipolar disorder ADCY2 intron 24618891 rs6867567 chr5 7519762 G A 3.59E-04 Acute lung injury ADCY2 intron 22295056 rs13166360 chr5 7520881 G T 1.81E-08 Bipolar disorder ADCY2 missense 24618891 rs34043481 chr5 7520929 G A 8.60E-09 LDL cholesterol ADCY2 missense 23063622 rs7721273 chr5 7524548 T C 6.31E-05 Fibrinogen ADCY2 intron 17255346 rs4702473 chr5 7528558 T C 1 Drug response to Etoposide ADCY2 intron 17537913 rs6555474 chr5 7529813 G A 1.00E-06 Fasting plasma glucose ADCY2 intron 19060907 rs6880956 chr5 7530324 A G 1 Drug response to Etoposide ADCY2 intron 17537913 rs1846681 chr5 7530741 A G 1 Drug response to Etoposide ADCY2 intron 17537913 rs13174252 chr5 7530931 A G 1 Drug response to Etoposide ADCY2 intron 17537913 rs10061240 chr5 7535800 G A 4.37E-05 Bipolar disorder ADCY2 intron 24618891 rs13180878 chr5 7536194 G C 4.04E-05 Bipolar disorder ADCY2 intron 24618891 rs17231202 chr5 7546287 A G 9.09E-08 Bipolar disorder ADCY2 intron 24618891 rs10512928 chr5 7546411 C T 7.32E-05 Asthma ADCY2 intron 11022011 rs10512928 chr5 7546411 C T 4.14E-04 Multiple complex diseases ADCY2 intron 17554300 rs10512928 chr5 7546411 C T 2.92E-07 Bipolar disorder ADCY2 intron 24618891 rs884964 chr5 7548854 T C 3.68E-07 Bipolar disorder ADCY2 intron 24618891 rs12522444 chr5 7553501 G A 7.06E-07 Bipolar disorder ADCY2 intron 24618891 rs4451024 chr5 7563335 G C 4.99E-04 Multiple complex diseases ADCY2 intron 17554300 rs4530734 chr5 7565152 G T 4.23E-07 Bipolar disorder ADCY2 intron 24618891 rs12519539 chr5 7583156 A G 5.54E-07 Bipolar disorder ADCY2 intron 24618891 rs13166852 chr5 7595762 T C 2.07E-05 Bipolar disorder ADCY2 intron 24618891 rs1946468 chr5 7617232 A G 1 Drug response to Etoposide ADCY2 intron 17537913 rs1428530 chr5 7625795 T C 5.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADCY2 intron 20877124 rs4702484 chr5 7649860 C T 5.00E-08 Capecitabine sensitivity ADCY2 intron 22864933 rs4702484 chr5 7649860 C T 6.00E-07 Capecitabine sensitivity ADCY2 intron 22864933 rs2973322 chr5 7652518 G A 7.13E-04 Bipolar disorder,schizoaffective ADCY2 intron 19567891 rs2914295 chr5 7652834 C T 1 Drug response to Etoposide ADCY2 intron 17537913 rs12189243 chr5 7737474 T C 3.46E-05 Stroke ADCY2 intron pha002887 rs6870738 chr5 7805774 G A 1.57E-06 Phospholipid levels (plasma) ADCY2 intron 21829377 rs326155 chr5 7816645 A G 4.00E-06 Visceral fat ADCY2 intron 22589738 rs10059539 chr5 7828404 C T 1.11E-04 Response to cytidine analogues (gemcitabine) ADCY2 UTR-3 24483146 rs17243407 chr5 7858121 G A 1.28E-04 Fibrinogen LOC100288963 intron 17255346 rs16879258 chr5 7865891 C A 9.51E-05 Longevity FASTKD3 intron 20304771 rs17184211 chr5 7866106 A T 6.86E-05 Fibrinogen FASTKD3 intron 17255346 rs17184211 chr5 7866106 A T 1.89E-04 Type 2 diabetes FASTKD3 intron 17463246 rs16879334 chr5 7891506 C G 0.000064 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 MTRR missense 21873659 rs16879418 chr5 7914632 C T 3.10E-04 Asperger disorder / / 21182207 rs16879418 chr5 7914632 C T 9.90E-05 Lymphocyte counts / / 22286170 rs13173919 chr5 7919212 T C 3.61E-04 Fibrinogen / / 17255346 rs179171 chr5 7924914 T C 2.89E-04 Type 2 diabetes / / 17463246 rs10440693 chr5 7930866 G A 1.45E-04 Fibrinogen / / 17255346 rs10462849 chr5 7934219 C T 3.87E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17246850 chr5 7943354 C A 2.12E-04 Multiple complex diseases / / 17554300 rs17187270 chr5 7943942 A G 1.85E-04 Multiple complex diseases / / 17554300 rs1471620 chr5 7946127 G A 2.09E-04 Multiple complex diseases / / 17554300 rs1471621 chr5 7946262 G A 1.99E-04 Multiple complex diseases / / 17554300 rs1564592 chr5 7950600 A G 3.89E-04 Multiple complex diseases / / 17554300 rs331413 chr5 7958031 G A 9.06E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1482277 chr5 7984232 C T 5.14E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10041150 chr5 7988772 A C 4.45E-04 Multiple complex diseases / / 17554300 rs1503317 chr5 7992135 C T 5.23E-04 Coronary Artery Disease / / 17634449 rs2968311 chr5 8010610 A T 9.43E-04 Coronary Artery Disease / / 17634449 rs17195685 chr5 8015032 G A 5.77E-04 Acute lung injury / / 22295056 rs7719537 chr5 8023674 G A 4.48E-04 Acute lung injury / / 22295056 rs1453358 chr5 8024562 T A,G 6.27E-04 Acute lung injury / / 22295056 rs6871063 chr5 8047445 T C 8.93E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1565198 chr5 8155254 A C 4.14E-05 Blood Pressure / / pha002903 rs336174 chr5 8177920 A G 9.07E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1506123 chr5 8180669 T G 6.26E-05 Body Mass Index / / pha003007 rs16880024 chr5 8186128 G A 2.25E-04 Multiple complex diseases / / 17554300 rs7702422 chr5 8188395 T C 3.93E-05 Suicidal ideation / / 20877300 rs11134291 chr5 8204135 T A 3.53E-04 Type 2 diabetes / / 17463246 rs16880072 chr5 8211969 C T 4.12E-04 Type 2 diabetes / / 17463246 rs16880088 chr5 8213532 C T 4.71E-04 Type 2 diabetes / / 17463246 rs13170406 chr5 8213918 G C 8.11E-04 Depression (quantitative trait) / / 20800221 rs10037687 chr5 8214073 G A 8.08E-04 Depression (quantitative trait) / / 20800221 rs10035204 chr5 8214218 A G 8.10E-04 Depression (quantitative trait) / / 20800221 rs10038291 chr5 8214296 G A 8.13E-04 Depression (quantitative trait) / / 20800221 rs10038296 chr5 8214344 G A 8.17E-04 Depression (quantitative trait) / / 20800221 rs11134297 chr5 8214841 A G 8.20E-04 Depression (quantitative trait) / / 20800221 rs11134298 chr5 8214996 C A 8.22E-04 Depression (quantitative trait) / / 20800221 rs12521845 chr5 8215104 C T 8.28E-04 Depression (quantitative trait) / / 20800221 rs4702534 chr5 8215439 C A 8.28E-04 Depression (quantitative trait) / / 20800221 rs4701804 chr5 8218692 T C 7.59E-04 Depression (quantitative trait) / / 20800221 rs4701805 chr5 8218718 C T 7.63E-04 Depression (quantitative trait) / / 20800221 rs4702536 chr5 8219678 G A 9.38E-04 Depression (quantitative trait) / / 20800221 rs6892570 chr5 8226339 G T 7.61E-04 Depression (quantitative trait) / / 20800221 rs6874030 chr5 8228502 G A 7.70E-04 Depression (quantitative trait) / / 20800221 rs6555529 chr5 8232117 T G 8.08E-04 Depression (quantitative trait) / / 20800221 rs2087291 chr5 8233974 A T 9.29E-04 Depression (quantitative trait) / / 20800221 rs7721147 chr5 8254598 G T 4.68E-04 Insulin resistance / / 21901158 rs1189843 chr5 8319632 G A 2.74E-04 Longevity / / 22279548 rs925203 chr5 8328783 G T 1.46E-04 adolescent idiopathic scoliosis / / 24023777 rs13361808 chr5 8410155 G A 2.28E-04 Response to taxane treatment (placlitaxel) LOC729506 intron 23006423 rs16880521 chr5 8411410 G C 2.27E-04 Response to taxane treatment (placlitaxel) LOC729506 intron 23006423 rs10512959 chr5 8438022 T C 4.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) LOC729506 intron 17982456 rs340669 chr5 8438531 C T 1 Drug response to Etoposide LOC729506 intron 17537913 rs12187557 chr5 8439670 T C 1 Drug response to Etoposide LOC729506 intron 17537913 rs6555545 chr5 8440728 G A 1 Drug response to Etoposide LOC729506 intron 17537913 rs6555546 chr5 8440904 C A 1 Drug response to Etoposide LOC729506 intron 17537913 rs2388449 chr5 8444205 A G 1 Drug response to Etoposide LOC729506 intron 17537913 rs16880661 chr5 8465020 C T 9.90E-06 Urinary metabolites / / 21572414 rs13170576 chr5 8467174 C T 2.36E-04 HIV-1 viral setpoint / / 17641165 rs13170576 chr5 8467174 C T 1.20E-05 Information processing speed / / 21130836 rs11745490 chr5 8502544 T A 2.75E-06 Serum metabolites / / 19043545 rs1505005 chr5 8506298 C T 2.16E-05 Serum metabolites / / 19043545 rs6870322 chr5 8516509 A G 7.65E-04 White matter integrity / / 22425255 rs1002548 chr5 8523982 A G 9.65E-04 Type 2 diabetes / / 17463246 rs13189206 chr5 8524441 A T 4.87E-05 Serum metabolites / / 19043545 rs1700569 chr5 8538868 A G 1.42E-04 Age-related macular degeneration / / 22125219 rs1666795 chr5 8539813 C T 1.60E-04 Age-related macular degeneration / / 22125219 rs402825 chr5 8543658 A G 3.40E-06 Urinary metabolites / / 21572414 rs11743542 chr5 8580301 C T 2.03E-04 HIV-1 viral setpoint / / 17641165 rs11741773 chr5 8593659 T C 1.00E-05 Memory performance / / 22105620 rs1501342 chr5 8602353 G A 2.20E-05 Memory performance / / 22105620 rs6886296 chr5 8606556 T C 4.15E-04 Acute lung injury / / 22295056 rs4702563 chr5 8617680 C T 1.40E-05 Memory performance / / 22105620 rs1501347 chr5 8628753 A G 2.80E-05 Urinary metabolites / / 21572414 rs4702564 chr5 8633805 C T 2.30E-05 Urinary metabolites / / 21572414 rs200113 chr5 8652870 T C 7.00E-08 Uric acid levels / / 22229870 rs200094 chr5 8661907 C T 3.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs200091 chr5 8662504 T A 5.65E-04 Multiple complex diseases / / 17554300 rs1080423 chr5 8674114 G A 8.55E-04 HIV-1 viral setpoint / / 17641165 rs1080423 chr5 8674114 G A 8.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs199187 chr5 8676369 A G 9.67E-04 HIV-1 viral setpoint / / 17641165 rs199187 chr5 8676369 A G 8.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs199187 chr5 8676369 A G 9.08E-04 Heart Failure / / pha002884 rs200044 chr5 8688962 G T 3.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs200034 chr5 8690829 G A 3.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11134323 chr5 8691906 A G 0.0008 Salmonella-induced pyroptosis / / 22837397 rs200012 chr5 8695751 A G 3.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs200008 chr5 8697444 T C 3.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs199999 chr5 8700487 G A 3.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs199998 chr5 8701366 T C 3.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs199997 chr5 8701920 T C 5.70E-04 Smoking quantity / / 24665060 rs16881265 chr5 8743744 T G 2.20E-05 Urinary metabolites / / 21572414 rs13356951 chr5 8766155 A G 3.58E-05 Multiple complex diseases / / 17554300 rs16881298 chr5 8766520 T G 2.70E-05 Urinary metabolites / / 21572414 rs999426 chr5 8770185 T C 8.24E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1505028 chr5 8777256 G A 0.00076115 Hypertension (early onset hypertension) / / 22479346 rs2938822 chr5 8782277 A G 0.000625557 Hypertension (early onset hypertension) / / 22479346 rs4701822 chr5 8808777 G A 4.95E-05 Cholesterol / / pha003083 rs10491222 chr5 8817497 G A 3.66E-05 Cholesterol / / pha003083 rs995554 chr5 8828344 G A 5.52E-05 Cholesterol / / pha003083 rs13182390 chr5 8829311 A C 2.52E-04 Blood pressure / / 17255346 rs13182390 chr5 8829311 A C 1.85E-05 Serum metabolites / / 19043545 rs2388344 chr5 8833852 T C 3.74E-05 Brain structure / / 22504417 rs1394650 chr5 8837390 A G 8.96E-05 Cholesterol / / pha003083 rs2904938 chr5 8842947 A C 5.60E-05 Alzheimer's disease / / 17998437 rs16881529 chr5 8869756 T C 3.54E-04 Coronary Artery Disease / / 17634449 rs2962694 chr5 8889910 T A 1.46E-06 Multiple sclerosis / / 17660530 rs2963341 chr5 8908533 G C 4.84E-05 Multiple sclerosis / / 17660530 rs10077656 chr5 8951952 G C 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs13359910 chr5 8960917 C T 5.52E-04 Multiple complex diseases / / 17554300 rs13359910 chr5 8960917 C T 2.41E-04 Multiple sclerosis / / 17660530 rs9313264 chr5 8961561 C T 1.19E-04 Multiple sclerosis / / 17660530 rs6555588 chr5 8977866 A G 1.01E-04 Multiple sclerosis / / 17660530 rs11134338 chr5 8983721 G A 8.00E-06 Obesity-related traits / / 23251661 rs2388004 chr5 8996618 T C 6.00E-04 Myocardial Infarction / / pha002873 rs2962655 chr5 9012855 T C 2.33E-04 Coronary Artery Disease / / 17634449 rs2100642 chr5 9014917 C T 0.000886465 Hypertension (early onset hypertension) / / 22479346 rs2962699 chr5 9018565 T A 3.66E-04 Coronary Artery Disease / / 17634449 rs1598826 chr5 9021310 T C 0.000886465 Hypertension (early onset hypertension) / / 22479346 rs11134347 chr5 9029842 T C 0.000717397 Hypertension (early onset hypertension) / / 22479346 rs16881875 chr5 9038043 G A 3.79E-04 Multiple complex diseases SEMA5A UTR-3 17554300 rs187688 chr5 9046526 T C 1.56E-04 Coronary Artery Disease SEMA5A intron 17634449 rs16881898 chr5 9058104 A G 4.49E-04 Multiple complex diseases SEMA5A intron 17554300 rs707635 chr5 9061130 G A 1.30E-04 Coronary Artery Disease SEMA5A intron 17634449 rs786849 chr5 9064425 G A 2.71E-04 Coronary Artery Disease SEMA5A intron 17634449 rs786848 chr5 9065425 C T 9.69E-04 Multiple complex diseases SEMA5A intron 17554300 rs16881912 chr5 9071551 C G 3.01E-04 Multiple complex diseases SEMA5A intron 17554300 rs2388001 chr5 9077099 A G 4.64E-04 Multiple complex diseases SEMA5A intron 17554300 rs1013720 chr5 9087921 T C 4.64E-04 Myocardial Infarction SEMA5A intron pha002873 rs1505065 chr5 9094746 C T 1.60E-05 Urinary metabolites SEMA5A intron 21572414 rs190423 chr5 9121472 T C 7.50E-05 Parkinson's disease (familial) SEMA5A intron 18985386 rs984425 chr5 9153379 T C 7.84E-05 HIV-1 viral setpoint SEMA5A intron 22174851 rs886509 chr5 9156012 T C 1.00E-05 F-cell distribution SEMA5A intron 17767159 rs2619915 chr5 9161347 G A 4.92E-04 Smoking initiation SEMA5A intron 24665060 rs3777281 chr5 9177932 T C 1.65E-04 Gallstones SEMA5A intron 17632509 rs1806119 chr5 9194990 A G 5.85E-08 Metabolite levels SEMA5A intron 23281178 rs1805971 chr5 9204142 C T 1.60E-04 Celiac disease SEMA5A intron 23936387 rs1806067 chr5 9205587 T C 5.55E-05 Cholesterol SEMA5A intron 17255346 rs1806066 chr5 9205700 A G 8.43E-05 Cholesterol SEMA5A intron 17255346 rs877191 chr5 9214028 A G 5.76E-04 Smoking initiation SEMA5A intron 24665060 rs1805962 chr5 9215068 G A 2.95E-04 Smoking initiation SEMA5A intron 24665060 rs16882243 chr5 9226440 C G 9.49E-07 Asthma (childhood onset) SEMA5A intron 23829686 rs1805959 chr5 9234090 A G 1.13E-04 Type 2 diabetes SEMA5A intron 17463246 rs1805939 chr5 9266755 A G 9.26E-04 Response to alcohol consumption (flushing response) SEMA5A intron 24277619 rs3026313 chr5 9266755 A AA,AG 9.26E-04 Response to alcohol consumption (flushing response) SEMA5A intron 24277619 rs4702617 chr5 9267171 A G 7.98E-04 Rheumatoid arthritis SEMA5A intron 21452313 rs1805918 chr5 9268737 C T 4.11E-04 Rheumatoid arthritis SEMA5A intron 21452313 rs3777303 chr5 9280338 A G 7.23E-04 Rheumatoid arthritis SEMA5A intron 21452313 rs3822787 chr5 9293213 G A 3.10E-05 Tunica Media SEMA5A intron pha003036 rs3797980 chr5 9328316 G A 2.65E-05 Elbow pain SEMA5A intron pha003008 rs7702187 chr5 9332281 T A 8.00E-06 Parkinson's disease SEMA5A intron 16252231 rs1205731 chr5 9335344 G A 4.77E-05 stroke (ischemic) SEMA5A intron 17434096 rs1205731 chr5 9335344 G A 9.43E-05 Non-alcoholic fatty liver disease histology (other) SEMA5A intron 20708005 rs1205725 chr5 9343913 T C 9.67E-05 Non-alcoholic fatty liver disease histology (other) SEMA5A intron 20708005 rs1024487 chr5 9357007 C T 4.79E-05 Smoking cessation SEMA5A intron 18519826 rs1205718 chr5 9357103 T C 2.01E-04 Smoking cessation SEMA5A intron 18519826 rs3798004 chr5 9370945 C T 3.48E-05 Response to hepatitis C treatment SEMA5A intron 19684573 rs1805243 chr5 9380110 T C 4.60E-04 Alcohol dependence SEMA5A UTR-5 20201924 rs1805243 chr5 9380110 T C 6.10E-04 Alcohol dependence SEMA5A UTR-5 20201924 rs16882600 chr5 9386310 C T 4.28E-04 HIV-1 viral setpoint SEMA5A intron 17641165 rs380206 chr5 9390722 T C 1.75E-04 Acute lymphoblastic leukemia (childhood) SEMA5A intron 22076464 rs16882610 chr5 9391637 C A 6.42E-04 Smoking cessation SEMA5A intron 24665060 rs415024 chr5 9392358 A C 1.15E-04 Multiple complex diseases SEMA5A intron 17554300 rs415024 chr5 9392358 A C 5.11E-04 Suicide attempts in bipolar disorder SEMA5A intron 21423239 rs10513007 chr5 9395453 T C 5.23E-04 HIV-1 viral setpoint SEMA5A intron 17641165 rs16882648 chr5 9401401 T A 4.15E-04 Multiple complex diseases SEMA5A intron 17554300 rs17323208 chr5 9403456 T C 9.90E-05 Blood Pressure SEMA5A intron pha003046 rs268487 chr5 9403974 A G 8.50E-04 Alcohol dependence SEMA5A intron 20201924 rs425620 chr5 9413362 G A 1.54E-04 Blood pressure SEMA5A intron 17255346 rs448038 chr5 9413495 A C 2.15E-04 Blood pressure SEMA5A intron 17255346 rs448038 chr5 9413495 A C 5.51E-05 Response to antidepressant treatment (citalopram) SEMA5A intron 23726668 rs666617 chr5 9420374 T C 9.23E-04 Suicide attempts in bipolar disorder SEMA5A intron 21423239 rs414293 chr5 9420832 G A 1.54E-04 Suicide attempts in bipolar disorder SEMA5A intron 21423239 rs17258120 chr5 9423834 G T 1.66E-05 Alzheimer's disease (late onset) SEMA5A intron 21379329 rs268486 chr5 9426734 C T 3.75E-04 Suicide attempts in bipolar disorder SEMA5A intron 21423239 rs11951666 chr5 9429290 T G 5.49E-04 Suicide attempts in bipolar disorder SEMA5A intron 21423239 rs268479 chr5 9430216 G C 4.27E-04 Suicide attempts in bipolar disorder SEMA5A intron 21423239 rs268480 chr5 9430337 G A 4.22E-04 Suicide attempts in bipolar disorder SEMA5A intron 21423239 rs16882748 chr5 9432725 G A 3.90E-04 Suicide attempts in bipolar disorder SEMA5A intron 21423239 rs268481 chr5 9434606 G C 5.56E-04 Suicide attempts in bipolar disorder SEMA5A intron 21423239 rs10068683 chr5 9435158 A T 4.39E-04 Suicide attempts in bipolar disorder SEMA5A intron 21423239 rs13174956 chr5 9436697 T C 1.80E-05 Smoking cessation SEMA5A intron 18519826 rs17324408 chr5 9436878 C T 1.77E-04 Multiple complex diseases SEMA5A intron 17554300 rs1858428 chr5 9438538 A G 6.89E-04 Alzheimer's disease SEMA5A intron 22005930 rs1512509 chr5 9440094 T C 7.96E-04 Smoking quantity SEMA5A intron 24665060 rs3822796 chr5 9442029 C T 1.46E-04 Smoking quantity SEMA5A intron 24665060 rs440396 chr5 9450621 C T 1.57E-05 Glucose levels SEMA5A intron pha003061 rs11134359 chr5 9467579 A G 7.58E-04 Multiple complex diseases SEMA5A intron 17554300 rs12657858 chr5 9468865 G A 4.99E-05 Blood Pressure SEMA5A intron pha003043 rs198686 chr5 9473658 A T 9.17E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SEMA5A intron 21844884 rs433755 chr5 9474946 A C 5.00E-07 Obesity-related traits SEMA5A intron 23251661 rs411172 chr5 9483744 A G 2.63E-04 Multiple complex diseases SEMA5A intron 17554300 rs169163 chr5 9484935 A G 7.86E-05 Alzheimer's disease SEMA5A intron 17998437 rs7735345 chr5 9517081 T G 2.60E-05 Urinary metabolites SEMA5A intron 21572414 rs462057 chr5 9528021 C G 7.92E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SEMA5A intron 20031582 rs268551 chr5 9534206 G T 8.95E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SEMA5A intron 20031582 rs930076 chr5 9550642 T C 1.67E-05 Alcohol dependence / / 21703634 rs930076 chr5 9550642 T C 3.54E-06 Hodgkin's lymphoma / / 24149102 rs1508798 chr5 9556694 T C 2.20E-05 Personality dimensions / / 18957941 rs6866978 chr5 9561397 C A 4.06E-04 Tourette syndrome / / 22889924 rs11951988 chr5 9564496 C G 7.80E-06 Urinary metabolites / / 21572414 rs3846591 chr5 9606166 C T 7.47E-05 Cholesterol / / pha003073 rs3846591 chr5 9606166 C T 9.91E-05 Cholesterol / / pha003078 rs395 chr5 9617945 C T 1.60E-05 Urinary metabolites / / 21572414 rs77202753 chr5 9619864 C T 8.00E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs10513025 chr5 9623622 T C 3.00E-07 Autism / / 19812673 rs10513027 chr5 9624355 C G 4.24E-04 Type 2 diabetes / / 17846125 rs3213627 chr5 9641628 G A 4.05E-04 Amyotrophic Lateral Sclerosis LOC285692 intron 17362836 rs3213627 chr5 9641628 G A 3.35E-04 Multiple complex diseases LOC285692 intron 17554300 rs2285622 chr5 9652429 G A 8.16E-04 Multiple complex diseases LOC285692 intron 17554300 rs1393232 chr5 9661352 A G 7.73E-04 Multiple complex diseases LOC285692 intron 17554300 rs28800 chr5 9666545 A G 6.34E-05 Alzheimer's disease (late onset) LOC285692 intron 21460841 rs12109904 chr5 9681798 C T 1.75E-04 Alzheimer's disease (late onset) LOC285692 intron 21460841 rs194070 chr5 9684672 C T 1.64E-06 Cognitive impairment induced by topiramate LOC285692 intron 22091778 rs10039101 chr5 9689026 G T 5.63E-05 Alzheimer's disease (late onset) LOC285692 intron 21460841 rs41491 chr5 9695667 T C 5.14E-05 Lung adenocarcinoma LOC285692 intron 19836008 rs41491 chr5 9695667 T C 8.60E-06 Urinary metabolites LOC285692 intron 21572414 rs168788 chr5 9708576 T C 6.82E-05 Cognitive test performance LOC285692 intron 20125193 rs16883448 chr5 9723470 G A 0.0000033 Asthma (exacerbation) LOC285692 intron 23706709 rs2214018 chr5 9748135 C T 0.000424707 Hypertension (early onset hypertension) LOC285692 intron 22479346 rs3094355 chr5 9749900 C T 6.44E-04 Type 2 diabetes LOC285692 intron 17463246 rs7725217 chr5 9756329 A C 1.00E-06 Hypersomnia (HLA-DQB1*06:02 negative) LOC285692 intron 23646285 rs3110986 chr5 9758916 C T 6.49E-04 Type 2 diabetes LOC285692 intron 17463246 rs1016898 chr5 9779910 C T 0.000226229 Hypertension (early onset hypertension) LOC285692 intron 22479346 rs11134371 chr5 9792158 G A 5.63E-05 Serum metabolites LOC285692 intron 19043545 rs17788846 chr5 9794554 G A 9.63E-06 Kawasaki disease LOC285692 intron 21221998 rs17788857 chr5 9811931 C T 5.75E-04 Type 2 diabetes LOC285692 intron 17463246 rs2027996 chr5 9816942 T C 2.07E-05 Hypertension (early onset hypertension) LOC285692 intron 22479346 rs17196719 chr5 9828770 T C 7.80E-04 Multiple complex diseases LOC285692 intron 17554300 rs1015587 chr5 9832022 G A 4.30E-05 White matter hyperintensity burden LOC285692 intron 21681796 rs16883650 chr5 9837650 A G 8.34E-04 Insulin resistance LOC285692 intron 21901158 rs2905209 chr5 9886038 T C 2.27E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LOC285692 intron 24023788 rs17275422 chr5 9894959 T C 4.18E-04 Response to alcohol consumption (flushing response) LOC285692 intron 24277619 rs10513034 chr5 9896556 C T 5.65E-04 Suicide attempts in bipolar disorder LOC285692 intron 21423239 rs10513039 chr5 9921028 G A 6.09E-05 Height / / pha003010 rs10036550 chr5 9923477 T C 7.13E-05 Orofacial clefts / / 20023658 rs1035961 chr5 9928862 A C 1.80E-06 Alcohol and nictotine co-dependence / / 20158304 rs13179743 chr5 9933220 A G 5.09E-04 Rheumatoid arthritis / / 21452313 rs1366625 chr5 9948723 G A 1.60E-05 Lung cancer / / 18385738 rs7708238 chr5 9951112 G A 1.85E-04 Birth weight / / 17255346 rs16883905 chr5 9956338 C T 7.17E-06 Dengue shock syndrome / / 22001756 rs6860874 chr5 9962103 C T 0.0007494 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6860874 chr5 9962103 C T 7.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs553169 chr5 9979084 T C 9.00E-06 Age-related macular degeneration (smoking status interaction) / / 23577725 rs38070 chr5 9982040 C T 9.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs1896785 chr5 9987734 A G 3.40E-04 Alcohol dependence / / 20201924 rs1896785 chr5 9987734 A G 5.40E-04 Alcohol dependence / / 20201924 rs1395093 chr5 10018290 G A 2.11E-04 Taste perception / / 22132133 rs6554565 chr5 10021677 T C 4.69E-04 Taste perception / / 22132133 rs7734914 chr5 10032335 A G 4.81E-05 Acute lymphoblastic leukemia (childhood) / / 22076464 rs718401 chr5 10037446 A G 4.80E-04 Multiple complex diseases / / 17554300 rs16884026 chr5 10041935 G A 1.48E-04 Multiple complex diseases / / 17554300 rs7729241 chr5 10044149 G A 4.42E-04 Type 2 diabetes / / 22158537 rs16884057 chr5 10059605 T C 2.06E-04 Multiple complex diseases / / 17554300 rs16884060 chr5 10060297 C A 1.00E-05 Urinary metabolites / / 21572414 rs7736555 chr5 10063198 G A 5.41E-04 Multiple complex diseases / / 17554300 rs868927 chr5 10085210 G A 2.30E-05 Multiple complex diseases / / 17554300 rs906069 chr5 10109105 G A 3.23E-05 Alzheimer's disease (late onset) / / 21379329 rs906071 chr5 10109385 T C 9.38E-05 Nicotine smoking / / 19268276 rs884355 chr5 10109791 C A 1.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11744434 chr5 10111180 A G 3.64E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10052112 chr5 10111690 C T 6.78E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1876152 chr5 10113778 G A 3.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10060513 chr5 10115416 G T 1.39E-04 Alzheimer's disease (late onset) / / 21379329 rs10060606 chr5 10115751 C T 3.81E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4438847 chr5 10116217 G T 2.58E-04 Alzheimer's disease (late onset) / / 21379329 rs4484395 chr5 10116479 A G 7.96E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10073259 chr5 10117760 G T 1.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2662415 chr5 10125556 T C 1.62E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2658109 chr5 10127437 A G 5.36E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1395095 chr5 10132963 T G 3.40E-04 Alzheimer's disease (late onset) / / 21379329 rs2662411 chr5 10133704 G A 6.36E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs3111083 chr5 10141550 G A 5.61E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7705202 chr5 10146995 A G 5.24E-05 Body mass (lean) / / 19268274 rs7443032 chr5 10148156 T G 5.88E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6884905 chr5 10148421 C T 9.18E-05 Asthma / / 11022011 rs6884905 chr5 10148421 C T 3.64E-05 Alzheimer's disease / / 24755620 rs10513044 chr5 10149225 A G 1.21E-06 Alzheimer's disease (late onset) / / 21379329 rs6868282 chr5 10152686 G A 4.17E-04 Alzheimer's disease / / 24755620 rs3111085 chr5 10154907 G A 4.93E-04 Multiple complex diseases / / 17554300 rs112890441 chr5 10158297 T TC 5.52E-04 Aortic root size / / 21223598 rs1911942 chr5 10158297 T C 5.52E-04 Aortic root size / / 21223598 rs2202815 chr5 10159036 C T 2.04E-06 Alzheimer's disease (late onset) / / 21379329 rs2009501 chr5 10159541 T C 2.00E-06 Metabolite levels (HVA/MHPG ratio) / / 23319000 rs1033008 chr5 10159589 G A 2.43E-06 Metabolite levels (MHPG) / / 23319000 rs6895377 chr5 10162790 G A 6.70E-07 Urinary metabolites / / 21572414 rs13361160 chr5 10169823 T C 5.00E-07 Pain / / 22956598 rs2892069 chr5 10198605 T G 1.53E-05 Multiple complex diseases / / 17554300 rs17294086 chr5 10217604 T C 2.82E-04 Taste perception / / 22132133 rs10866471 chr5 10219168 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6889488 chr5 10219547 G A 7.06E-04 Stroke / / pha002886 rs4701865 chr5 10221905 C T 4.00E-05 Cognitive impairment induced by topiramate / / 22091778 rs6871733 chr5 10223386 G A 7.28E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2136197 chr5 10227548 C A 7.25E-04 Smoking cessation FAM173B UTR-3 24665060 rs2445871 chr5 10239993 A G 2.86E-06 Cognitive impairment induced by topiramate FAM173B intron 22091778 rs2445871 chr5 10239993 A G 3.20E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FAM173B intron 24023788 rs369534000 chr5 10239993 ATATCT A 2.86E-06 Cognitive impairment induced by topiramate FAM173B intron 22091778 rs369534000 chr5 10239993 ATATCT A 3.20E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FAM173B intron 24023788 rs370829738 chr5 10239993 ATATCT A 2.86E-06 Cognitive impairment induced by topiramate FAM173B intron 22091778 rs370829738 chr5 10239993 ATATCT A 3.20E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FAM173B intron 24023788 rs2578629 chr5 10241409 C T 3.48E-04 Multiple complex diseases FAM173B intron 17554300 rs2607329 chr5 10241674 G C 3.12E-04 Multiple complex diseases FAM173B intron 17554300 rs2578624 chr5 10245114 C T 7.71E-05 Cognitive impairment induced by topiramate FAM173B intron 22091778 rs2578624 chr5 10245114 C T 9.92E-05 Cognitive impairment induced by topiramate FAM173B intron 22091778 rs12516390 chr5 10261065 C T 6.30E-05 Response to statin therapy CCT5 intron 20339536 rs2292267 chr5 10263582 G A 1.44E-04 Multiple complex diseases CCT5 intron 17554300 rs2292267 chr5 10263582 G A 3.04E-05 Lymphocyte counts CCT5 intron 22286170 rs3843011 chr5 10275870 G C 5.56E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10067744 chr5 10282396 A G 1.36E-04 Lymphocyte counts CMBL cds-synon 22286170 rs6892818 chr5 10283490 T C 7.71E-04 Response to taxane treatment (placlitaxel) CMBL intron 23006423 rs6876709 chr5 10284270 C G 1.28E-04 Response to taxane treatment (placlitaxel) CMBL intron 23006423 rs13168213 chr5 10289503 C T 4.10E-05 Coronary heart disease CMBL intron pha003032 rs555521 chr5 10318976 G A 2.33E-04 Bipolar disorder / / 18317468 rs7720490 chr5 10352123 T G 5.94E-06 Body mass index / / 22446040 rs2607292 chr5 10372618 T C 4.00E-06 Body mass index MARCH6 intron 22446040 rs6554581 chr5 10377813 C T 8.52E-04 Multiple complex diseases MARCH6 intron 17554300 rs2567564 chr5 10394583 A G 1.76E-05 Body mass index MARCH6 intron 22446040 rs2640707 chr5 10400113 T C 4.93E-06 Body mass index MARCH6 intron 22446040 rs16884665 chr5 10412682 A G 1.98E-08 Multiple complex diseases MARCH6 intron 17554300 rs2589668 chr5 10434643 A G 4.43E-06 Body mass index MARCH6 UTR-3 22446040 rs16884726 chr5 10455225 G C 5.82E-04 Multiple complex diseases ROPN1L intron 17554300 rs2967951 chr5 10464107 C T 1.00E-06 Body mass index ROPN1L intron 22446040 rs1092913 chr5 10467702 G A 2.00E-06 Breast cancer / / 21424380 rs814597 chr5 10468929 C T 1.69E-06 Body mass index / / 22446040 rs2936582 chr5 10476759 G T 1.56E-05 Body mass index / / 22446040 rs2936581 chr5 10476857 A G 1.13E-04 Multiple complex diseases / / 17554300 rs2919756 chr5 10503977 A G 9.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs78721097 chr5 10511726 G A 8.67E-06 Metabolite levels (MHPG) / / 23319000 rs6883094 chr5 10512454 T G 8.67E-06 Metabolite levels (MHPG) / / 23319000 rs111426949 chr5 10512697 C T 6.00E-06 Metabolite levels (HVA/MHPG ratio) / / 23319000 rs2962333 chr5 10531757 T C 1.68E-04 Multiple complex diseases / / 17554300 rs2936590 chr5 10547018 T C 3.80E-06 Urinary metabolites / / 21572414 rs2454606 chr5 10550973 A G 0.0008141 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2454606 chr5 10550973 A G 8.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1399830 chr5 10552667 C T 0.0008085 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1399830 chr5 10552667 C T 8.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2673886 chr5 10555321 C G 0.0008261 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2673886 chr5 10555321 C G 8.26E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2673887 chr5 10555362 G A 0.0008549 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2673887 chr5 10555362 G A 8.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2648802 chr5 10569829 C T 6.75E-04 Multiple complex diseases ANKRD33B intron 17554300 rs6864906 chr5 10579714 T C 5.05E-04 White matter integrity ANKRD33B intron 22425255 rs12657745 chr5 10585399 A G,T 5.72E-04 Type 2 diabetes ANKRD33B intron 17463246 rs12657745 chr5 10585399 A G,T 9.69E-04 Multiple complex diseases ANKRD33B intron 17554300 rs2128760 chr5 10597986 G A 6.07E-04 Multiple complex diseases ANKRD33B intron 17554300 rs17761026 chr5 10607762 C T 3.80E-04 Multiple complex diseases ANKRD33B intron 17554300 rs10474877 chr5 10611579 T C 9.65E-05 Heart Rate ANKRD33B intron pha003053 rs4701875 chr5 10617984 G A 2.89E-05 Heart Rate ANKRD33B intron pha003053 rs4702718 chr5 10671040 A G 3.00E-06 Obesity-related traits / / 23251661 rs4702719 chr5 10671703 G T 3.59E-04 Smoking initiation / / 24665060 rs1531842 chr5 10675766 G T 8.31E-04 Schizophrenia / / 19197363 rs5745308 chr5 10678281 C T 3.12E-04 Smoking initiation / / 24665060 rs7973 chr5 10679746 T C 2.97E-04 Smoking initiation DAP UTR-3 24665060 rs10271 chr5 10680749 G A 2.93E-04 Smoking initiation DAP UTR-3 24665060 rs5745296 chr5 10681110 A G 8.06E-05 Smoking initiation DAP UTR-3 24665060 rs2930047 chr5 10695526 T C 4.60E-06 Urinary metabolites DAP intron 21572414 rs2930047 chr5 10695526 T C 1.00E-08 Inflammatory bowel disease DAP intron 23128233 rs5745254 chr5 10697388 G A 5.21E-04 Smoking initiation DAP intron 24665060 rs5745250 chr5 10697576 T C 2.27E-04 Smoking initiation DAP intron 24665060 rs3756407 chr5 10701514 A G 5.00E-06 Metabolite levels (Pyroglutamine) DAP intron 23934736 rs2930052 chr5 10707026 G A 2.82E-04 Multiple complex diseases DAP intron 17554300 rs267988 chr5 10710716 A G 7.15E-04 Response to cytidine analogues (gemcitabine) DAP intron 24483146 rs5745219 chr5 10724104 G C 3.91E-04 Smoking initiation DAP intron 24665060 rs5745212 chr5 10725661 G A 3.79E-04 Smoking initiation DAP intron 24665060 rs413846 chr5 10732289 T C 5.07E-05 Multiple complex diseases DAP intron 17554300 rs16885262 chr5 10734193 C T 2.50E-04 Smoking initiation DAP intron 24665060 rs267950 chr5 10743433 C T 5.07E-05 Multiple complex diseases DAP intron 17554300 rs267950 chr5 10743433 C T 8.84E-04 White matter integrity DAP intron 22425255 rs267943 chr5 10748462 C T 2.29E-04 Multiple complex diseases DAP intron 17554300 rs267939 chr5 10752315 C T 6.00E-12 Ulcerative colitis DAP intron 21297633 rs410608 chr5 10768935 G A 2.30E-05 Urinary metabolites / / 21572414 rs2918405 chr5 10776404 C T 2.90E-05 Urinary metabolites / / 21572414 rs6882716 chr5 10797886 G A 2.00E-06 Alcohol consumption (maxi-drinks) / / 24277619 rs1470023 chr5 10800150 T C 8.13E-05 Multiple complex diseases / / 17554300 rs10043680 chr5 10804522 C T 5.09E-05 Multiple complex diseases / / 17554300 rs7725091 chr5 10810604 C T 8.90E-05 Alcohol consumption (maxi-drinks) / / 24277619 rs17176973 chr5 10811474 C G 2.16E-06 Schizophrenia / / 19571809 rs17176973 chr5 10811474 C G 5.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs17176973 chr5 10811474 C G 2.27E-05 Schizophrenia / / pha002857 rs6554603 chr5 10819285 T C 3.20E-06 Alcohol consumption (maxi-drinks) / / 24277619 rs9312745 chr5 10827690 A G 3.42E-06 Alcohol consumption (maxi-drinks) / / 24277619 rs2918406 chr5 10829619 A C 3.42E-06 Alcohol consumption (maxi-drinks) / / 24277619 rs12716076 chr5 10838090 A G 1.36E-04 Type 2 diabetes / / 17463246 rs4398608 chr5 10847970 G T 1.25E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs11743009 chr5 10852242 A G 7.45E-05 Diabetes Mellitus / / pha003059 rs6860099 chr5 10883440 A G 8.45E-05 Telomere length / / 21573004 rs1995364 chr5 10903781 A G 8.79E-07 Alcohol dependence / / 23089632 rs13357458 chr5 10935007 C T 4.88E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12188188 chr5 10968872 T G 4.12E-05 Smoking initiation / / 24665060 rs16901185 chr5 10970593 C A 1.31E-04 Smoking initiation / / 24665060 rs10052295 chr5 10977322 A G 1.62E-04 Opioid sensitivity CTNND2 intron 23183491 rs706306 chr5 10998665 T C 3.23E-05 Multiple sclerosis CTNND2 intron 17660530 rs6871769 chr5 11009237 G C 6.88E-04 Multiple complex diseases CTNND2 intron 17554300 rs17180143 chr5 11038986 T C 9.27E-04 Type 2 diabetes CTNND2 intron 17463246 rs17180143 chr5 11038986 T C 0.00000544 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs13189742 chr5 11041787 A C 0.00000596 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs2973488 chr5 11043917 A T 1.81E-07 Cognitive decline CTNND2 intron 22054870 rs1860242 chr5 11069269 A G 1.08E-04 Longevity CTNND2 intron 22279548 rs16901233 chr5 11073282 T C 7.39E-33 Narcolepsy CTNND2 intron 19629137 rs10513066 chr5 11076061 T C 7.40E-05 Lupus nephritis in systemic lupus erythematosus CTNND2 intron 24925725 rs10513069 chr5 11079274 G A 0.00000363 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs10513069 chr5 11079274 G A 0.000473 Age-related cataract and Alzheimer's disease (cortical cataract) CTNND2 intron 22984439 rs11749459 chr5 11082612 A G 0.00000362 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs11749459 chr5 11082612 A G 0.000454 Age-related cataract and Alzheimer's disease (cortical cataract) CTNND2 intron 22984439 rs11744876 chr5 11084712 G A 0.00000359 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs11744876 chr5 11084712 G A 0.000339 Age-related cataract and Alzheimer's disease (cortical cataract) CTNND2 intron 22984439 rs11744876 chr5 11084712 G A 3.00E-08 Amyotrophic lateral sclerosis (sporadic) CTNND2 intron 24529757 rs11133637 chr5 11087563 G A 2.52E-04 Insulin resistance CTNND2 intron 21901158 rs2973515 chr5 11089542 A G 0.00000361 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs2973515 chr5 11089542 A G 0.000287 Age-related cataract and Alzheimer's disease (cortical cataract) CTNND2 intron 22984439 rs16901246 chr5 11089822 G T 3.93E-04 Type 2 diabetes CTNND2 intron 17463246 rs16901246 chr5 11089822 G T 0.0000035 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs16901246 chr5 11089822 G T 0.000288 Age-related cataract and Alzheimer's disease (cortical cataract) CTNND2 intron 22984439 rs2973514 chr5 11090210 A G 0.00000344 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs2973514 chr5 11090210 A G 0.000289 Age-related cataract and Alzheimer's disease (cortical cataract) CTNND2 intron 22984439 rs2907108 chr5 11090229 G A 0.00000339 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs2907108 chr5 11090229 G A 0.000289 Age-related cataract and Alzheimer's disease (cortical cataract) CTNND2 intron 22984439 rs2973513 chr5 11091008 A G 0.0000031 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs2973513 chr5 11091008 A G 0.000293 Age-related cataract and Alzheimer's disease (cortical cataract) CTNND2 intron 22984439 rs1024622 chr5 11092620 G A 0.00000283 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs1024622 chr5 11092620 G A 0.000303 Age-related cataract and Alzheimer's disease (cortical cataract) CTNND2 intron 22984439 rs1024623 chr5 11092757 G C 0.0000028 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs1024623 chr5 11092757 G C 0.000304 Age-related cataract and Alzheimer's disease (cortical cataract) CTNND2 intron 22984439 rs10513071 chr5 11096727 A T 0.00000276 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs10513071 chr5 11096727 A T 0.000307 Age-related cataract and Alzheimer's disease (cortical cataract) CTNND2 intron 22984439 rs13184045 chr5 11100669 C T 2.10E-04 Type 2 diabetes CTNND2 intron 17463246 rs13184045 chr5 11100669 C T 0.00000221 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs13184045 chr5 11100669 C T 0.00053 Age-related cataract and Alzheimer's disease (cortical cataract) CTNND2 intron 22984439 rs10513072 chr5 11101508 T C 0.00000169 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs10513072 chr5 11101508 T C 0.000447 Age-related cataract and Alzheimer's disease (cortical cataract) CTNND2 intron 22984439 rs2973505 chr5 11104289 T A 0.000000414 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs2973505 chr5 11104289 T A 0.00021 Age-related cataract and Alzheimer's disease (cortical cataract) CTNND2 intron 22984439 rs739955 chr5 11104670 G T 0.000000354 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs739955 chr5 11104670 G T 0.000193 Age-related cataract and Alzheimer's disease (cortical cataract) CTNND2 intron 22984439 rs17787646 chr5 11105908 A G 2.20E-04 Type 2 diabetes CTNND2 intron 17463246 rs17787646 chr5 11105908 A G 0.0000012 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs1018967 chr5 11106572 G A 7.91E-05 Lupus nephritis in systemic lupus erythematosus CTNND2 intron 24925725 rs13155993 chr5 11108155 C T 0.000000203 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs13155993 chr5 11108155 C T 0.0000687 Age-related cataract and Alzheimer's disease (cortical cataract) CTNND2 intron 22984439 rs13170756 chr5 11110349 C A 0.000000151 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs13170756 chr5 11110349 C A 0.000116 Age-related cataract and Alzheimer's disease (cortical cataract) CTNND2 intron 22984439 rs17183619 chr5 11111253 T G 1.20E-05 Urinary metabolites CTNND2 intron 21572414 rs17183619 chr5 11111253 T G 0.000000129 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) CTNND2 intron 22984439 rs17183619 chr5 11111253 T G 0.00000013 Age-related cataract and Alzheimer's disease CTNND2 intron 22984439 rs17183619 chr5 11111253 T G 0.00004 Age-related cataract and Alzheimer's disease (cortical cataract) CTNND2 intron 22984439 rs6884431 chr5 11111771 A G 6.00E-06 Pulmonary function decline CTNND2 intron 22424883 rs6554619 chr5 11118144 C A 8.51E-05 Lipoprotein-associated phospholipase A2 activity and mass CTNND2 intron 20442857 rs17184251 chr5 11119119 C T 7.44E-05 Serum metabolites CTNND2 intron 19043545 rs11133647 chr5 11119490 C T 7.28E-05 Cognitive test performance CTNND2 intron 20125193 rs1547940 chr5 11127359 T C 6.02E-04 Type 2 diabetes CTNND2 intron 17463246 rs1547940 chr5 11127359 T C 4.80E-05 Cognitive function CTNND2 intron 24684796 rs7732720 chr5 11136164 G A 4.79E-04 Myopia (pathological) CTNND2 intron 21095009 rs10059890 chr5 11146698 C T 2.47E-04 Glycosylated haemoglobin levels CTNND2 intron 17255346 rs6885587 chr5 11147114 G C 2.50E-05 Urinary metabolites CTNND2 intron 21572414 rs12516262 chr5 11147575 T G 7.03E-06 Glycosylated haemoglobin levels CTNND2 intron 17255346 rs13358276 chr5 11154447 C T 4.52E-05 Odorant perception CTNND2 intron 23910658 rs6892303 chr5 11158453 C A 2.23E-05 Lupus nephritis in systemic lupus erythematosus CTNND2 intron 24925725 rs2277054 chr5 11160043 A G 3.26E-05 Blood Pressure CTNND2 intron pha003048 rs7704256 chr5 11160431 C G 2.60E-06 Urinary metabolites CTNND2 intron 21572414 rs2023916 chr5 11161237 C T 2.24E-05 Lupus nephritis in systemic lupus erythematosus CTNND2 intron 24925725 rs1978156 chr5 11161625 T C 2.33E-05 Lupus nephritis in systemic lupus erythematosus CTNND2 intron 24925725 rs12716080 chr5 11166948 G T 7.06E-05 Myopia (pathological) CTNND2 intron 21095009 rs7713461 chr5 11167277 G A 5.20E-06 Urinary metabolites CTNND2 intron 21572414 rs6885224 chr5 11169945 C T 8.00E-06 Myopia (pathological) CTNND2 intron 21095009 rs6885224 chr5 11169945 C T 2.60E-06 Urinary metabolites CTNND2 intron 21572414 rs6885224 chr5 11169945 C T 3.03E-05 Blood Pressure CTNND2 intron pha003046 rs6885224 chr5 11169945 C T 3.80E-05 Blood Pressure CTNND2 intron pha003048 rs1018964 chr5 11175919 G T 8.30E-07 Urinary metabolites CTNND2 intron 21572414 rs32275 chr5 11190339 T C 3.26E-05 Leukocyte Counts CTNND2 intron pha003091 rs116210778 chr5 11197142 G A 3.22E-13 Metabolite levels CTNND2 intron 22286219 rs27520 chr5 11218488 C T 8.08E-05 Bipolar disorder and schizophrenia CTNND2 intron 20889312 rs245137 chr5 11229114 C T 4.85E-04 Myocardial Infarction CTNND2 intron pha002873 rs2188857 chr5 11252872 C T 5.61E-04 Myocardial Infarction CTNND2 intron pha002873 rs194188 chr5 11294265 C T 6.23E-04 Type 2 diabetes CTNND2 intron 17463246 rs2530215 chr5 11298223 T C 7.00E-06 Bipolar disorder and schizophrenia CTNND2 intron 20889312 rs6869903 chr5 11300854 T C 3.47E-04 Alcohol dependence CTNND2 intron 20201924 rs26001 chr5 11303908 C T 8.16E-04 Amyotrophic Lateral Sclerosis CTNND2 intron 17362836 rs2012187 chr5 11322037 A G 3.60E-04 Obesity-related traits CTNND2 intron 17903300 rs28812 chr5 11322276 T C 2.06E-04 Gallstones CTNND2 intron 17632509 rs32136 chr5 11336674 T C 2.65E-04 Lung function (forced expiratory volume in 1 second) CTNND2 intron 17255346 rs32136 chr5 11336674 T C 1.22E-05 Cognitive impairment induced by topiramate CTNND2 intron 22091778 rs42687 chr5 11342293 G A 6.80E-05 Cognitive impairment induced by topiramate CTNND2 intron 22091778 rs32128 chr5 11343384 T C 7.65E-04 Endometrial cancer CTNND2 intron 24096698 rs6881516 chr5 11347020 A G 4.60E-05 Psoriasis CTNND2 intron 19169255 rs10513097 chr5 11353101 A G 4.40E-05 Obesity-related traits CTNND2 intron 17903300 rs10513097 chr5 11353101 A G 5.48E-06 Cognitive impairment induced by topiramate CTNND2 intron 22091778 rs4702802 chr5 11360893 C T 1.33E-04 Lung function (forced expiratory volume in 1 second) CTNND2 intron 17255346 rs20476 chr5 11366157 C T 4.00E-06 PR interval in Tripanosoma cruzi seropositivity CTNND2 intron 24324551 rs11750088 chr5 11366401 C T 7.07E-05 Blood Pressure CTNND2 intron pha003045 rs6875838 chr5 11368864 A C 5.62E-04 Smoking initiation CTNND2 intron 24665060 rs6891903 chr5 11371305 A G 7.80E-07 Autism CTNND2 intron 22843504 rs7702488 chr5 11378282 C T 2.00E-04 Cognitive impairment induced by topiramate CTNND2 intron 22091778 rs31837 chr5 11397573 C A 2.55E-05 Orofacial clefts CTNND2 intron 20023658 rs31837 chr5 11397573 C A 4.88E-04 Lung function (forced expiratory volume in 1 second) CTNND2 intron 24023788 rs10044218 chr5 11413046 A G 2.34E-04 Nicotine smoking CTNND2 intron 19268276 rs31887 chr5 11423592 T C 5.06E-04 Multiple complex diseases CTNND2 intron 17554300 rs9312776 chr5 11515720 C T 7.76E-04 Myocardial Infarction CTNND2 intron pha002883 rs4702810 chr5 11518226 C T 2.12E-05 Asthma CTNND2 intron 23181788 rs17218749 chr5 11519547 T G 9.15E-05 Cytomegalovirus antibody response CTNND2 intron 21993531 rs28016 chr5 11522397 A G 2.33E-04 Birth weight CTNND2 intron 17255346 rs32434 chr5 11523516 G A 2.29E-04 Birth weight CTNND2 intron 17255346 rs6893111 chr5 11538379 T G 5.62E-04 Myopia (pathological) CTNND2 intron 21095009 rs2727602 chr5 11539622 A G 6.26E-06 Common variable immunodeficiency CTNND2 intron 21497890 rs2727602 chr5 11539622 A G 3.00E-04 Cognitive impairment induced by topiramate CTNND2 intron 22091778 rs12659996 chr5 11548374 G C 1.77E-05 Glycosylated haemoglobin levels CTNND2 intron 17255346 rs2429307 chr5 11585335 G C 4.00E-06 Urinary metabolites CTNND2 intron 21572414 rs2251418 chr5 11589030 C T 2.75E-04 Osteoarthritis (knee and hip) CTNND2 intron 21177295 rs2251418 chr5 11589030 C T 3.26E-04 Osteoarthritis (knee and hip) CTNND2 intron 21177295 rs2251418 chr5 11589030 C T 7.63E-06 Osteoarthritis (knee and hip) CTNND2 intron 21177295 rs11745876 chr5 11592576 G A 4.04E-05 Lipoproteins CTNND2 intron pha003079 rs2561624 chr5 11595494 T C 7.38E-05 Lipoproteins CTNND2 intron pha003079 rs17221495 chr5 11597332 C A 6.75E-05 Lipoproteins CTNND2 intron pha003079 rs11738796 chr5 11609642 G A 3.70E-05 Lipoproteins CTNND2 intron pha003079 rs16901801 chr5 11618018 C A 6.60E-04 Smoking initiation CTNND2 intron 24665060 rs2727585 chr5 11624869 C T 9.53E-05 Lipoproteins CTNND2 intron pha003079 rs2434668 chr5 11626069 C T 3.52E-04 Smoking initiation CTNND2 intron 24665060 rs2727603 chr5 11663510 C T 8.20E-07 Red blood cell traits CTNND2 intron 23222517 rs10067236 chr5 11674686 A G 4.60E-04 Taste perception CTNND2 intron 22132133 rs6861373 chr5 11720017 C T 3.00E-04 Response to taxane treatment (placlitaxel) CTNND2 intron 23006423 rs13166019 chr5 11722011 G A 8.80E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CTNND2 intron 20031582 rs7716895 chr5 11735134 G T 1.45E-04 Response to taxane treatment (placlitaxel) CTNND2 intron 23006423 rs4702830 chr5 11795809 G A 5.14E-04 Multiple complex diseases CTNND2 intron 17554300 rs4466166 chr5 11811571 T C 3.90E-05 Schizophrenia CTNND2 intron 21791550 rs4466166 chr5 11811571 T C 0.000039 Psychosis CTNND2 intron 23164818 rs1458475 chr5 11839171 T C 2.03E-04 Multiple complex diseases CTNND2 intron 17554300 rs7733427 chr5 11843303 A G 1.00E-04 Cognitive impairment induced by topiramate CTNND2 intron 22091778 rs4533886 chr5 11850759 C T 2.61E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) CTNND2 intron 24192120 rs6887632 chr5 11854879 C T 2.61E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) CTNND2 intron 24192120 rs1870329 chr5 11874565 A G 2.50E-05 Urinary metabolites CTNND2 intron 21572414 rs12523341 chr5 11891727 A C 2.60E-05 Urinary metabolites CTNND2 intron 21572414 rs1458471 chr5 11898482 T G 1.70E-05 Urinary metabolites CTNND2 intron 21572414 rs17223875 chr5 11900775 A G 2.00E-05 Urinary metabolites CTNND2 intron 21572414 rs4702840 chr5 11902453 G A 2.00E-05 Urinary metabolites CTNND2 intron 21572414 rs13173187 chr5 11913471 A G 4.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs730925 chr5 11977349 A T 5.79E-04 Multiple complex diseases / / 17554300 rs10065698 chr5 12080963 C A 2.39E-04 Multiple complex diseases / / 17554300 rs10054180 chr5 12095032 G A 1.26E-04 Multiple complex diseases / / 17554300 rs4602627 chr5 12102650 T A 1.52E-04 Multiple complex diseases / / 17554300 rs13162305 chr5 12122698 A T 3.57E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs173671 chr5 12164918 C G 1.11E-04 Multiple complex diseases / / 17554300 rs43154 chr5 12170883 A G 3.60E-05 Multiple complex diseases / / 17554300 rs2968097 chr5 12198381 T C 0.000163 Salmonella-induced pyroptosis / / 22837397 rs10075629 chr5 12216062 G A 2.00E-05 Urinary metabolites / / 21572414 rs2215201 chr5 12392539 T C 6.53E-04 Multiple complex diseases / / 17554300 rs1024614 chr5 12403285 A G 4.28E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4568365 chr5 12412666 A C 3.90E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4702885 chr5 12616305 T C 8.15E-05 Psoriasis TAG intron 18364390 rs7721328 chr5 12652832 T C 5.99E-05 Asthma TAG intron 23181788 rs4558991 chr5 12699253 C G 4.49E-05 Asthma TAG intron 23181788 rs4295393 chr5 12710129 A G 1.20E-05 Urinary metabolites TAG intron 21572414 rs12657966 chr5 12731349 G A 1.20E-05 Urinary metabolites TAG intron 21572414 rs6862501 chr5 12749695 T C 3.40E-06 Urinary metabolites TAG intron 21572414 rs4327597 chr5 12756012 A G 8.80E-07 Urinary metabolites TAG intron 21572414 rs7720744 chr5 12756504 G C 8.90E-07 Urinary metabolites TAG intron 21572414 rs6861390 chr5 12765292 G A 4.50E-06 Urinary metabolites TAG intron 21572414 rs13166311 chr5 12781480 T C 3.64E-05 Insulin resistance TAG intron 21901158 rs10073652 chr5 12786980 C T 1.60E-05 HIV-1 control TAG intron 20041166 rs1017454 chr5 12975322 G A 2.80E-04 Alcohol dependence / / 20201924 rs1017454 chr5 12975322 G A 9.00E-04 Alcohol dependence / / 20201924 rs17237639 chr5 12975934 A G 3.10E-04 Alcohol dependence / / 20201924 rs17164233 chr5 12997810 T C 4.99E-07 Multiple complex diseases / / 17554300 rs10491239 chr5 13173664 T C 8.90E-05 Type 2 diabetes / / 17463246 rs13360518 chr5 13205665 C G 2.35E-04 Type 2 diabetes / / 17463246 rs16902421 chr5 13209817 C T 2.41E-04 Type 2 diabetes / / 17463246 rs16898876 chr5 13210200 T C 4.69E-05 Tuberculosis / / 24057671 rs32518 chr5 13213930 G A 7.03E-04 Acute lung injury / / 22295056 rs28207 chr5 13214852 C T 1.90E-05 Subclinical atherosclerosis / / 17903303 rs28207 chr5 13214852 C T 6.20E-04 Acute lung injury / / 22295056 rs1373950 chr5 13221613 A G 4.74E-04 Schizophrenia / / 19197363 rs11744248 chr5 13237036 C T 5.54E-04 Acute lung injury / / 22295056 rs6879350 chr5 13239055 C T 6.07E-04 Acute lung injury / / 22295056 rs10066447 chr5 13242974 C T 7.00E-06 Visceral fat / / 22589738 rs7703890 chr5 13260439 G T 8.88E-04 Type 2 diabetes / / 17463246 rs1374089 chr5 13312470 C A 9.44E-04 Type 2 diabetes / / 17463246 rs11133745 chr5 13339905 A G 7.34E-04 Acute lung injury / / 22295056 rs1037112 chr5 13374095 A G 1.20E-04 Alcohol dependence / / 20201924 rs1037112 chr5 13374095 A G 3.20E-04 Alcohol dependence / / 20201924 rs7703596 chr5 13378325 C T 2.28E-04 Acute lung injury / / 22295056 rs6554786 chr5 13378714 C A 2.06E-04 Acute lung injury / / 22295056 rs882981 chr5 13379003 G A 6.85E-04 Multiple complex diseases / / 17554300 rs1374090 chr5 13391377 T C 3.57E-04 Acute lung injury / / 22295056 rs1867742 chr5 13392571 C T 4.53E-05 Blood Pressure / / pha003048 rs2067586 chr5 13393043 G A 9.14E-04 Multiple complex diseases / / 17554300 rs985765 chr5 13394171 G A 1.00E-04 Alcohol dependence / / 20201924 rs985765 chr5 13394171 G A 2.30E-04 Alcohol dependence / / 20201924 rs985765 chr5 13394171 G A 9.96E-05 Alcoholism / / pha002893 rs11956313 chr5 13395707 T C 8.62E-04 Multiple complex diseases / / 17554300 rs7721512 chr5 13399475 A G 3.54E-04 Acute lung injury / / 22295056 rs7721685 chr5 13399634 A G 1.50E-04 Alcohol dependence / / 20201924 rs7721685 chr5 13399634 A G 6.60E-05 Alcohol dependence / / 20201924 rs7721685 chr5 13399634 A G 6.64E-05 Alcoholism / / pha002893 rs7735905 chr5 13405410 T C 2.57E-04 Acute lung injury / / 22295056 rs17257851 chr5 13407211 T C 2.57E-04 Acute lung injury / / 22295056 rs4702942 chr5 13413515 T C 9.87E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10064110 chr5 13438458 T C 7.55E-04 Multiple complex diseases / / 17554300 rs10068542 chr5 13440568 T C 7.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4702944 chr5 13444967 G T 2.06E-04 Acute lung injury / / 22295056 rs1864097 chr5 13450794 C T 4.20E-04 Alcohol dependence / / 20201924 rs1864097 chr5 13450794 C T 6.40E-05 Alcohol dependence / / 20201924 rs1864097 chr5 13450794 C T 6.42E-05 Alcoholism / / pha002893 rs956195 chr5 13453436 G A 9.99E-04 Acute lung injury / / 22295056 rs1373995 chr5 13455563 G A 7.81E-04 Acute lung injury / / 22295056 rs16902590 chr5 13473523 C T 2.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs6861792 chr5 13478967 A C 5.44E-06 Multiple complex diseases / / 17554300 rs3853114 chr5 13481754 A G 1.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3915771 chr5 13483969 G A 8.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs151152 chr5 13488800 C T 3.17E-05 Suicide attempts in bipolar disorder / / 21041247 rs3853117 chr5 13488819 C T 3.26E-05 Suicide attempts in bipolar disorder / / 21041247 rs11952402 chr5 13491938 T C 3.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs230059 chr5 13495289 C T 5.17E-04 Multiple complex diseases / / 17554300 rs6874889 chr5 13498578 G A 3.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs4463179 chr5 13505432 G A 5.43E-04 Suicide attempts in bipolar disorder / / 21041247 rs4463179 chr5 13505432 G A 2.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs112897 chr5 13505522 G A 6.74E-05 Bipolar disorder and schizophrenia / / 20889312 rs1010527 chr5 13508265 A G 7.12E-04 Type 2 diabetes / / 17463246 rs1992711 chr5 13510918 G A 7.12E-04 Type 2 diabetes / / 17463246 rs233379 chr5 13581311 C A 6.42E-04 Multiple complex diseases / / 17554300 rs233379 chr5 13581311 C A 9.77E-07 Schizophrenia / / 21926974 rs2676246 chr5 13626495 C T 8.03E-05 Multiple complex diseases / / 17554300 rs6871272 chr5 13668821 A G 2.29E-04 Alzheimer's disease (late onset) / / 21379329 rs1445688 chr5 13677225 G A 2.93E-04 Alzheimer's disease (late onset) / / 21379329 rs2034221 chr5 13681326 A G 9.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs986986 chr5 13683016 A G 2.59E-04 Alzheimer's disease (late onset) / / 21379329 rs3734110 chr5 13701536 T C 6.50E-04 Schizophrenia D/H5 missense 19197363 rs3734110 chr5 13701536 T C 4.20E-04 Alzheimer's disease (late onset) D/H5 missense 21379329 rs10513149 chr5 13703843 C T 6.17E-04 Schizophrenia D/H5 intron 19197363 rs10513149 chr5 13703843 C T 2.29E-04 Alzheimer's disease (late onset) D/H5 intron 21379329 rs30168 chr5 13719089 G A,C,T 2.51E-04 Schizophrenia D/H5 missense 19197363 rs39829 chr5 13719997 A C 1.83E-04 Schizophrenia D/H5 intron 19197363 rs10513151 chr5 13728151 T C 3.18E-04 Schizophrenia D/H5 intron 19197363 rs6554809 chr5 13740976 C T 3.00E-06 IgE grass sensitization D/H5 intron 22036096 rs6554809 chr5 13740976 C T 8.91E-04 White matter integrity D/H5 intron 22425255 rs2401809 chr5 13754394 C T 4.39E-04 Multiple complex diseases D/H5 cds-synon 17554300 rs1354187 chr5 13760721 T C 1.47E-04 Birth weight D/H5 intron 17255346 rs2896103 chr5 13764419 G A 5.00E-06 Subclinical atherosclerosis D/H5 intron 17903303 rs2134256 chr5 13768653 C T 8.72E-05 Birth weight D/H5 intron 17255346 rs7715811 chr5 13769974 C T 7.23E-04 Type 2 diabetes D/H5 intron 17463246 rs7715811 chr5 13769974 C T 6.00E-06 Subclinical atherosclerosis D/H5 intron 17903303 rs10039621 chr5 13772457 G A 8.57E-04 Type 2 diabetes D/H5 intron 17463246 rs10039621 chr5 13772457 G A 7.89E-04 Multiple complex diseases D/H5 intron 17554300 rs1502050 chr5 13779743 T C 8.05E-04 Type 2 diabetes D/H5 intron 17463246 rs1502050 chr5 13779743 T C 9.00E-06 Subclinical atherosclerosis D/H5 intron 17903303 rs1910092 chr5 13781480 G A 8.77E-04 Multiple complex diseases D/H5 intron 17554300 rs1910092 chr5 13781480 G A 2.50E-05 Urinary metabolites D/H5 intron 21572414 rs795544 chr5 13798559 A C 1.00E-06 Corneal astigmatism D/H5 intron 23322567 rs17205894 chr5 13801151 T C 6.60E-04 Response to statin treatment (atorvastatin),change in cholesterol levels D/H5 intron 20031582 rs16902777 chr5 13816740 G A 8.38E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) D/H5 intron 23648065 rs16902820 chr5 13834706 T G 9.66E-04 Alcohol dependence D/H5 intron 21314694 rs17208191 chr5 13846802 T G 5.80E-05 Major depressive disorder D/H5 intron 21042317 rs895314 chr5 13847984 G A 1.83E-05 Hypertension (essential hypertension) D/H5 intron 22184326 rs1470461 chr5 13861175 G T 1.51E-04 Lung function (forced vital capacity) D/H5 intron 24023788 rs11958022 chr5 13866054 A C 1.00E-04 Cognitive impairment induced by topiramate D/H5 intron 22091778 rs35090077 chr5 13901641 A C 0.00006 Breast cancer D/H5 missense 23555315 rs35090077 chr5 13901641 A C 0.00013 Breast cancer (ER positive) D/H5 missense 23555315 rs10474696 chr5 13910684 G C 3.44E-04 Birth weight D/H5 intron 17255346 rs10474696 chr5 13910684 G C 8.41E-04 Type 2 diabetes D/H5 intron 17463246 rs4546379 chr5 13910739 G A 1.60E-04 Suicide attempts in bipolar disorder D/H5 intron 21423239 rs3765045 chr5 13911405 G T 8.20E-04 Suicide attempts in bipolar disorder D/H5 intron 21423239 rs17276782 chr5 13911991 T C 1.40E-04 Suicide attempts in bipolar disorder D/H5 intron 21423239 rs35339484 chr5 13926057 C T 3.22E-04 Suicide attempts in bipolar disorder D/H5 intron 21423239 rs1550811 chr5 13933553 T C 5.14E-04 Suicide attempts in bipolar disorder D/H5 intron 21423239 rs17278234 chr5 13937476 T C 8.00E-04 Mathematical ability D/H5 intron 20039944 rs17278234 chr5 13937476 T C 8.00E-04 Mathematical ability D/H5 intron 20039944 rs339447 chr5 13942973 G A 8.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) D/H5 intron 20877124 rs7704220 chr5 13950343 C T 2.18E-04 Blood pressure / / 17255346 rs1866836 chr5 13952047 G A 8.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs339439 chr5 13957216 C T 5.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs10070815 chr5 13957465 G C 8.90E-05 Triglycerides / / 19074352 rs10050676 chr5 13958443 T G 8.70E-04 Multiple complex diseases / / 17554300 rs2017013 chr5 13962264 C T 1.58E-05 Coronary heart disease / / pha003032 rs11133773 chr5 13964588 G A 6.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs750137 chr5 13965451 G C 6.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs11952833 chr5 13972933 G A 8.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs2582685 chr5 13976839 C A 2.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs339431 chr5 13977854 C G 1.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs170952 chr5 13978345 G A 1.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs339429 chr5 13979101 G A 4.63E-05 Potassium levels / / pha003086 rs339425 chr5 13980278 C T 1.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs339424 chr5 13981968 C A,G 5.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs339423 chr5 13981994 T A 9.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs17292523 chr5 13985879 A G 3.23E-04 Nicotine dependence / / 17158188 rs11959989 chr5 13986248 G A 2.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs339416 chr5 13986526 G A 8.20E-07 Fasting plasma glucose / / 19060907 rs1031006 chr5 13987103 A G 4.30E-05 Nicotine dependence / / 17158188 rs1031006 chr5 13987103 A G 7.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs10055489 chr5 13987466 A G 3.82E-04 Nicotine dependence / / 17158188 rs10055489 chr5 13987466 A G 4.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs10042709 chr5 13988069 C T 6.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs11957853 chr5 13989208 C G 4.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs7727798 chr5 13993530 T C 6.20E-04 Alcohol dependence / / 20201924 rs7727798 chr5 13993530 T C 6.49E-05 Cognitive impairment induced by topiramate / / 22091778 rs7702277 chr5 14020756 G T 9.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs7702277 chr5 14020756 G T 2.60E-05 Urinary metabolites / / 21572414 rs12186457 chr5 14036509 T C 1.40E-04 Alzheimer's disease (late onset) / / 21379329 rs339951 chr5 14052451 G A 2.18E-05 Alzheimer's disease (late onset) / / 21379329 rs6554837 chr5 14052748 A G 6.38E-04 Response to TNF antagonist treatment / / 21061259 rs7712871 chr5 14052904 C T 9.46E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs339959 chr5 14058036 A G 1.07E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs339959 chr5 14058036 A G 1.64E-04 Alzheimer's disease (late onset) / / 21379329 rs6898434 chr5 14062414 C T 6.39E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs11955108 chr5 14068995 C T 2.80E-05 Urinary metabolites / / 21572414 rs163818 chr5 14072057 T C 6.00E-07 Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel) / / 24025145 rs17295893 chr5 14072258 G A 5.80E-04 Type 2 diabetes / / 17463246 rs7712859 chr5 14082966 C T 9.15E-04 Type 2 diabetes / / 17463246 rs7712859 chr5 14082966 C T 6.82E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs656208 chr5 14105848 C T 8.39E-05 Alcohol consumption / / 23743675 rs386450 chr5 14106136 A G 5.59E-05 Alcohol consumption / / 23743675 rs446989 chr5 14106171 G A 9.11E-05 Alcohol consumption / / 23743675 rs366563 chr5 14106613 G T 7.45E-05 Alcohol consumption / / 23743675 rs252217 chr5 14118565 G T 3.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs252217 chr5 14118565 G T 8.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs348116 chr5 14120586 C T 5.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs16903207 chr5 14135269 A T 1.76E-05 Height / / 22021425 rs250848 chr5 14157040 G A 7.85E-04 Alzheimer's disease TRIO intron 17998437 rs17298767 chr5 14157376 C T 4.00E-06 Urinary metabolites TRIO intron 21572414 rs7724830 chr5 14160447 C G 3.20E-06 Urinary metabolites TRIO intron 21572414 rs26286 chr5 14166402 T G 5.38E-05 Parkinson's disease TRIO intron 19915575 rs16903250 chr5 14168094 C T 3.87E-04 Multiple complex diseases TRIO intron 17554300 rs32571 chr5 14174106 T C 1.23E-04 Type 2 diabetes TRIO intron 17463246 rs33005 chr5 14206537 G T 4.69E-04 Type 2 diabetes TRIO intron 17463246 rs11747251 chr5 14238242 T A,G 5.00E-05 Parkinson's disease (age of onset) TRIO intron 19772629 rs370265972 chr5 14238242 TC TAT,TTC 5.00E-05 Parkinson's disease (age of onset) TRIO intron 19772629 rs4702023 chr5 14244357 A G 7.16E-04 Multiple complex diseases TRIO intron 17554300 rs16903338 chr5 14253187 A G 1.68E-05 Attention deficit hyperactivity disorder TRIO intron 22420046 rs773765 chr5 14291614 T C 3.21E-07 Elbow pain TRIO intron pha003008 rs42204 chr5 14301803 A G 3.08E-05 Attention deficit hyperactivity disorder TRIO intron 22420046 rs16903375 chr5 14302488 T C 2.53E-06 Elbow pain TRIO intron pha003008 rs42405 chr5 14312410 T C 3.30E-05 Attention deficit hyperactivity disorder TRIO intron 22420046 rs30623 chr5 14332325 T C 7.63E-04 Type 2 diabetes TRIO intron 17463246 rs17304347 chr5 14339527 A T 8.54E-04 Type 2 diabetes TRIO intron 17463246 rs16903421 chr5 14367568 T C 3.51E-04 Coronary Artery Disease TRIO intron 17634449 rs10513174 chr5 14379820 A G 2.39E-04 Type 2 diabetes TRIO intron 17463246 rs30791 chr5 14384453 A C 4.80E-05 Orofacial clefts TRIO intron 22419666 rs42259 chr5 14386655 T C 6.76E-06 Attention deficit hyperactivity disorder TRIO intron 22420046 rs10065203 chr5 14393621 C T 4.00E-06 Paclitaxel-induced neuropathy TRIO intron 23776197 rs30774 chr5 14397238 T C 2.77E-05 Orofacial clefts TRIO cds-synon 22419666 rs28343 chr5 14400123 G A 3.28E-05 Orofacial clefts TRIO intron 22419666 rs42206 chr5 14400955 T C 1.63E-05 Orofacial clefts TRIO intron 22419666 rs6883134 chr5 14415590 A G 4.97E-04 Coronary Artery Disease TRIO intron 17634449 rs6887662 chr5 14419552 A T 1.49E-05 Multiple complex diseases TRIO intron 17554300 rs7706559 chr5 14483164 G A 5.17E-05 Serum metabolites TRIO intron 19043545 rs26098 chr5 14485386 T C 1.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRIO intron 20877124 rs117297784 chr5 14486307 A G 1.13E-07 Coronary heart disease TRIO intron 22751097 rs27480 chr5 14495485 T C 5.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRIO intron 20877124 rs27480 chr5 14495485 T C 8.49E-04 Response to cytidine analogues (gemcitabine) TRIO intron 24483146 rs27479 chr5 14499395 C A 8.17E-04 Response to cytidine analogues (gemcitabine) TRIO intron 24483146 rs26086 chr5 14507905 A G 7.22E-04 Response to cytidine analogues (gemcitabine) TRIO intron 24483146 rs152621 chr5 14583006 G A 8.40E-06 Dietary macronutrient intake FAM105A intron 23372041 rs153822 chr5 14627833 A G 2.92E-04 Multiple complex diseases / / 17554300 rs152749 chr5 14639407 C T 1.45E-04 Multiple complex diseases / / 17554300 rs17363829 chr5 14693398 C T 2.51E-05 Hemoglobin FAM105B UTR-3 pha003096 rs25952 chr5 14695247 A C 1.46E-04 Alzheimer's disease (late onset) FAM105B UTR-3 21379329 rs25952 chr5 14695247 A C 7.24E-04 Alcohol consumption (maxi-drinks) FAM105B UTR-3 24277619 rs27911 chr5 14707378 G A 1.48E-04 Alzheimer's disease (late onset) ANKH UTR-3 21379329 rs25992 chr5 14707600 C A,G,T 7.24E-04 Alcohol consumption (maxi-drinks) ANKH UTR-3 24277619 rs10060885 chr5 14724089 T C 1.49E-05 Response to radiotherapy in cancer (late toxicity) ANKH intron 24785509 rs17250963 chr5 14752850 G A 7.00E-06 Homeostasis model assessment of insulin resistance (interaction) ANKH intron 24204828 rs10475028 chr5 14763229 G A 9.33E-04 Type 2 diabetes ANKH intron 17463246 rs10513185 chr5 14765010 C T 2.53E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ANKH intron 24023788 rs25946 chr5 14787064 A C 2.13E-04 Multiple complex diseases ANKH intron 17554300 rs258229 chr5 14803299 C A 7.50E-05 Multiple complex diseases ANKH intron 17554300 rs258229 chr5 14803299 C A 2.30E-06 Urinary metabolites ANKH intron 21572414 rs31916 chr5 14814883 A G 1.10E-05 Urinary metabolites ANKH intron 21572414 rs26306 chr5 14815699 T G 4.94E-04 Multiple complex diseases ANKH intron 17554300 rs27353 chr5 14816622 T C 7.51E-04 Multiple complex diseases ANKH intron 17554300 rs1620976 chr5 14830512 T C 4.25E-05 Multiple complex diseases ANKH intron 17554300 rs1550826 chr5 14840668 T C 6.91E-05 Multiple complex diseases ANKH intron 17554300 rs1374080 chr5 14852610 T C 1.08E-04 Multiple complex diseases ANKH intron 17554300 rs835154 chr5 14876569 G A 1.00E-10 Blood metabolite levels / / 24816252 rs835153 chr5 14877474 A G 8.08E-04 Type 2 diabetes / / 17463246 rs2592017 chr5 14901900 T C 2.60E-05 Urinary metabolites / / 21572414 rs835129 chr5 14911568 A G 5.57E-04 Coronary heart disease / / 21606135 rs10077552 chr5 14911899 C T 5.15E-04 Coronary heart disease / / 21606135 rs728844 chr5 14927488 C A 3.86E-04 Hearing function / / 17255346 rs728844 chr5 14927488 C A 9.86E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs835102 chr5 14949696 T C 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs835088 chr5 14972441 A G 1.42E-04 Multiple complex diseases / / 17554300 rs835087 chr5 14973023 C T 2.03E-04 Multiple complex diseases / / 17554300 rs835079 chr5 14980517 A C 9.67E-04 Type 2 diabetes / / 17463246 rs835079 chr5 14980517 A C 1.78E-04 Multiple complex diseases / / 17554300 rs12521797 chr5 14980784 C T 3.28E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs835071 chr5 14983623 C T 1.53E-04 Multiple complex diseases / / 17554300 rs835070 chr5 14983743 C A 3.39E-04 Multiple complex diseases / / 17554300 rs835067 chr5 14985797 C T 4.21E-04 Multiple complex diseases / / 17554300 rs1992707 chr5 14986700 T C 8.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs835066 chr5 14986922 T A 3.65E-04 Multiple complex diseases / / 17554300 rs2402022 chr5 14989823 T C 6.36E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs7341022 chr5 15014182 G A 9.97E-08 Chronic obstructive pulmonary disease / / 19300482 rs9686327 chr5 15018537 G A 9.84E-08 Chronic obstructive pulmonary disease / / 19300482 rs6862081 chr5 15020367 T A 6.49E-04 Multiple complex diseases / / 17554300 rs6881461 chr5 15020458 G T 7.10E-04 Multiple complex diseases / / 17554300 rs7727670 chr5 15022112 G T 8.38E-08 Chronic obstructive pulmonary disease / / 19300482 rs735243 chr5 15039327 G A 2.02E-07 Chronic obstructive pulmonary disease / / 19300482 rs30539 chr5 15044842 G A 9.42E-04 Multiple complex diseases / / 17554300 rs30539 chr5 15044842 G A 3.38E-06 Chronic obstructive pulmonary disease / / 19300482 rs30538 chr5 15045871 G A 1.60E-05 Urinary metabolites / / 21572414 rs1080879 chr5 15054802 T C 7.69E-07 Chronic obstructive pulmonary disease / / 19300482 rs2121183 chr5 15082673 G A 1.12E-04 Premature ovarian failure / / 19508998 rs32466 chr5 15087791 C T 8.31E-07 Chronic obstructive pulmonary disease / / 19300482 rs16903825 chr5 15114063 T C 2.35E-05 Chronic obstructive pulmonary disease / / 19300482 rs32447 chr5 15117438 G A 6.46E-05 Chronic obstructive pulmonary disease / / 19300482 rs32446 chr5 15117531 A G 8.72E-05 Multiple complex diseases / / 17554300 rs251547 chr5 15133778 G C 7.78E-04 Bipolar disorder,schizoaffective / / 19567891 rs17646652 chr5 15188264 T C 6.76E-04 Aortic root size / / 21223598 rs745978 chr5 15285414 T C 7.00E-06 Visceral fat / / 22589738 rs1457155 chr5 15322777 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs303354 chr5 15333012 T C 7.82E-04 Alzheimer's disease / / 17998437 rs17600469 chr5 15338073 G T 5.15E-04 Type 2 diabetes / / 17463246 rs1447276 chr5 15364484 G A 2.00E-06 Obesity-related traits / / 23251661 rs303352 chr5 15366156 T C 0.000016 Coronary artery calcification / / 23394302 rs1978633 chr5 15582005 T G 5.00E-06 Economic and political preferences (feminism/equality) FBXL7 intron 22566634 rs7706439 chr5 15586293 G A 6.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FBXL7 intron 20877124 rs7706439 chr5 15586293 G A 7.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FBXL7 intron 20877124 rs4510586 chr5 15604978 C T 3.54E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FBXL7 intron 24023788 rs12659622 chr5 15618181 G A 9.00E-07 Obesity-related traits FBXL7 intron 23251661 rs12652729 chr5 15633019 A G 4.05E-04 Type 2 diabetes FBXL7 intron 17463246 rs6897885 chr5 15651836 T C 5.41E-04 Response to cytadine analogues (cytosine arabinoside) FBXL7 intron 24483146 rs17602097 chr5 15688927 G A 3.75E-04 Type 2 diabetes FBXL7 intron 17463246 rs4701641 chr5 15697062 G A 1.90E-05 Urinary metabolites FBXL7 intron 21572414 rs11748700 chr5 15723346 A G 2.37E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) FBXL7 intron 24236485 rs4289558 chr5 15735014 A G 5.05E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) FBXL7 intron 24236485 rs4146556 chr5 15735956 A G 8.20E-04 Heart Failure FBXL7 intron pha002884 rs2937075 chr5 15747814 A G 7.34E-04 Heart Failure FBXL7 intron pha002884 rs2937076 chr5 15752604 T G 3.21E-04 Heart Failure FBXL7 intron pha002884 rs10044254 chr5 15783596 A G 9.00E-08 Asthma (corticosteroid response) FBXL7 intron 24486069 rs13183703 chr5 15785038 C T 8.57E-05 Height FBXL7 intron pha003010 rs13158449 chr5 15832573 G T 4.22E-05 Diabetes Mellitus FBXL7 intron pha003060 rs6554906 chr5 15937910 T C 1.50E-05 Response to statin therapy FBXL7 UTR-3 20339536 rs3810847 chr5 15938553 A G 2.10E-05 Response to statin therapy FBXL7 UTR-3 20339536 rs6859383 chr5 15956987 C T 8.44E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2599492 chr5 15975021 C G 5.28E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs250490 chr5 15975251 G A 2.34E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs250497 chr5 16000639 A C 2.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs250496 chr5 16000650 G A 2.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs171633 chr5 16002472 A G 7.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs171633 chr5 16002472 A G 6.37E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs32830 chr5 16008251 C T 6.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs250503 chr5 16009984 G A 3.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs168747 chr5 16010717 C A 5.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs2599503 chr5 16012917 C G 3.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs17525772 chr5 16029567 C G 7.03E-08 Metabolite levels / / 23281178 rs4702121 chr5 16031799 T G 5.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6866525 chr5 16034232 C T 8.33E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs32199 chr5 16037234 A G 1.37E-05 Tunica Media / / pha003038 rs1039443 chr5 16038102 T C 8.00E-06 IgG glycosylation / / 23382691 rs13158763 chr5 16093630 G A 4.00E-05 Diabetic nephropathy MARCH11 intron pha002866 rs17526289 chr5 16117706 C T 8.52E-04 Type 2 diabetes MARCH11 intron 17463246 rs3910973 chr5 16149673 C G 8.88E-04 Type 2 diabetes MARCH11 intron 17463246 rs342549 chr5 16178920 G A 4.84E-04 Crohn's disease MARCH11 intron 23266558 rs342559 chr5 16184180 G A 1.07E-04 Vaspin levels / / 22907691 rs342559 chr5 16184180 G A 0.000107 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs6554914 chr5 16236711 C T 7.91E-04 Insulin resistance / / 21901158 rs7730897 chr5 16256380 A G 6.42E-04 Alzheimer's disease / / 24755620 rs2582662 chr5 16272637 G A 2.60E-05 Alcoholism (heaviness of drinking) / / 21529783 rs953206 chr5 16323245 T C 7.25E-05 Information processing speed / / 21130836 rs12656374 chr5 16346572 C T 7.80E-05 Cocaine dependence / / 23958962 rs17649710 chr5 16375098 G T 1.05E-04 Multiple complex diseases / / 17554300 rs6878840 chr5 16377302 C G 8.56E-04 Multiple complex diseases / / 17554300 rs6885471 chr5 16379041 A G 6.69E-06 Serum metabolites / / 19043545 rs831179 chr5 16384646 G A 3.26E-05 Serum metabolites / / 19043545 rs163065 chr5 16434890 G C 1.81E-09 Non-obstructive azoospermia / / 22197933 rs163065 chr5 16434890 G C 1.60E-05 Diabetic nephropathy / / pha002866 rs171817 chr5 16441586 G A 3.60E-05 Diabetic nephropathy / / pha002866 rs154790 chr5 16447904 C T 4.81E-05 Cognitive impairment induced by topiramate / / 22091778 rs154791 chr5 16449037 G A 2.37E-04 Alcohol dependence / / 21314694 rs26017 chr5 16451431 C G 3.60E-05 Diabetic nephropathy / / pha002866 rs26020 chr5 16455266 T C 8.51E-05 Cognitive impairment induced by topiramate ZNF622 intron 22091778 rs32146 chr5 16460462 C T 7.30E-05 Diabetic retinopathy ZNF622 intron 21441570 rs27453 chr5 16464596 A G 9.16E-05 IgE levels ZNF622 intron 22075330 rs16868635 chr5 16467413 A G 8.94E-04 Multiple complex diseases / / 17554300 rs149511 chr5 16469593 T C 5.60E-05 Diabetic retinopathy / / 21441570 rs26015 chr5 16472705 T C 2.50E-05 Diabetic nephropathy FAM134B nearGene-3 pha002866 rs32147 chr5 16474644 T G 6.90E-05 Diabetic retinopathy FAM134B UTR-3 21441570 rs162848 chr5 16478200 G A 6.70E-05 Diabetic retinopathy FAM134B cds-synon 21441570 rs33692 chr5 16479220 A G 6.60E-05 Diabetic retinopathy FAM134B intron 21441570 rs16868670 chr5 16479919 G A 2.80E-05 Diabetic nephropathy FAM134B intron pha002866 rs189142 chr5 16485299 A G 5.40E-05 Diabetic retinopathy FAM134B intron 21441570 rs26379 chr5 16486271 C T 4.90E-05 Diabetic retinopathy FAM134B intron 21441570 rs12187267 chr5 16491052 A G 5.11E-04 Smoking initiation FAM134B intron 24665060 rs163281 chr5 16516778 C A 4.23E-05 HDL particle features FAM134B intron pha002900 rs1240951 chr5 16524541 A G 9.01E-04 Breast cancer FAM134B intron 21060860 rs334493 chr5 16528257 T C 9.80E-06 Brain size FAM134B intron 22156575 rs2115066 chr5 16550476 C A 5.57E-05 Cocaine dependence FAM134B intron 23958962 rs994429 chr5 16552399 T A 6.74E-05 Cocaine dependence FAM134B intron 23958962 rs12521478 chr5 16607196 T C 1.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM134B intron 20877124 rs17541315 chr5 16608454 A G 8.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM134B intron 20877124 rs12516207 chr5 16608493 C T 5.67E-05 Hemoglobin FAM134B intron pha003096 rs35004 chr5 16617903 C A 8.00E-04 Alcohol dependence FAM134B nearGene-5 20201924 rs386845 chr5 16642272 G T 1.50E-06 Urinary metabolites / / 21572414 rs386845 chr5 16642272 G T 7.58E-04 Acute lung injury / / 22295056 rs588367 chr5 16656570 A G 1.30E-05 Colorectal cancer / / 24978480 rs876095 chr5 16656803 A G 3.00E-05 Colorectal cancer / / 24978480 rs428263 chr5 16658495 A G 2.60E-05 Colorectal cancer / / 24978480 rs252446 chr5 16659284 C A 2.51E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs257159 chr5 16660145 T G 1.30E-05 Urinary metabolites / / 21572414 rs7722385 chr5 16661282 C T 1.80E-04 Celiac disease / / 23936387 rs13537 chr5 16662297 G A 9.80E-05 Lymphocyte counts MYO10 UTR-3 pha003094 rs13537 chr5 16662297 G A 7.42E-05 Neutrophil count MYO10 UTR-3 pha003095 rs27431 chr5 16670618 C T 3.23E-04 Alzheimer's disease (late onset) MYO10 intron 21379329 rs27431 chr5 16670618 C T 3.30E-05 Lung function (forced vital capacity) MYO10 intron pha003104 rs4702164 chr5 16672639 T C 2.94E-04 Multiple complex diseases MYO10 intron 17554300 rs61744227 chr5 16676247 G A 0.00078 Prostate cancer MYO10 missense 23555315 rs2303703 chr5 16684109 T C 6.77E-04 Multiple complex diseases MYO10 intron 17554300 rs31313 chr5 16690754 C T 5.70E-04 Type 2 diabetes MYO10 intron 17668382 rs31313 chr5 16690754 C T 3.69E-05 HIV-1 viral setpoint MYO10 intron 22174851 rs25910 chr5 16694309 T C 8.14E-04 Alzheimer's disease MYO10 intron 22005930 rs256930 chr5 16699512 G A,C,T 9.14E-04 Alzheimer's disease MYO10 intron 22005930 rs112696559 chr5 16701796 A C,G,T 0.00042 Prostate cancer MYO10 missense 23555315 rs173738 chr5 16725880 A G 3.70E-04 Type 2 diabetes MYO10 intron 17668382 rs13356962 chr5 16732791 A G 5.13E-04 Suicide attempts in bipolar disorder MYO10 intron 21423239 rs12189316 chr5 16733947 G T 4.37E-04 Suicide attempts in bipolar disorder MYO10 intron 21423239 rs11133857 chr5 16737513 G A 4.20E-04 Suicide attempts in bipolar disorder MYO10 intron 21423239 rs31510 chr5 16762392 G T 0.00047 Salmonella-induced pyroptosis MYO10 intron 22837397 rs39900 chr5 16763908 G A 0.000103 Salmonella-induced pyroptosis MYO10 intron 22837397 rs7705482 chr5 16765821 G A 7.69E-05 Hypertension MYO10 intron pha003042 rs11133860 chr5 16785077 A G 6.77E-05 Serum metabolites MYO10 intron 19043545 rs6877202 chr5 16785622 A T 1.73E-04 Blood pressure MYO10 intron 17255346 rs17541774 chr5 16787384 G A 5.16E-04 Response to taxane treatment (placlitaxel) MYO10 intron 23006423 rs496033 chr5 16795287 T C 7.95E-04 Coronary Artery Disease MYO10 intron 17634449 rs253365 chr5 16797415 C T 4.36E-05 Cognitive test performance MYO10 intron 20125193 rs17651119 chr5 16812638 C T 2.00E-08 Major depressive disorder MYO10 intron 23377640 rs12188582 chr5 16818363 A G 8.33E-04 Alcohol dependence MYO10 intron 20201924 rs10063505 chr5 16822171 C A 8.86E-04 Alcohol dependence MYO10 intron 20201924 rs1366233 chr5 16824389 T C 5.77E-04 Amyotrophic Lateral Sclerosis MYO10 intron 17362836 rs253336 chr5 16840641 A C 6.70E-04 Type 2 diabetes MYO10 intron 17668382 rs10213765 chr5 16848200 C T 1.09E-04 Schizophrenia MYO10 intron 20832056 rs9312938 chr5 16850125 C T 3.51E-04 Alzheimer's disease (late onset) MYO10 intron 21379329 rs253314 chr5 16871264 A C 6.46E-09 Gallstones MYO10 intron 17632509 rs2625210 chr5 16875690 T C 2.39E-04 Iron levels MYO10 intron pha002876 rs16869212 chr5 16882090 G A 1.90E-04 Suicide attempts in bipolar disorder MYO10 intron 21041247 rs2560851 chr5 16887383 C T 3.30E-04 Smoking quantity MYO10 intron 24665060 rs29452 chr5 16910605 C A 6.92E-04 Alcohol dependence MYO10 intron 20201924 rs17614462 chr5 16913855 G A 2.00E-06 Obesity-related traits MYO10 intron 23251661 rs13178744 chr5 16920867 G A 1.80E-05 Urinary metabolites MYO10 intron 21572414 rs12653955 chr5 16949845 C T 8.30E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6870542 chr5 17003017 C T 0.000794 Salmonella-induced pyroptosis / / 22837397 rs6870564 chr5 17003085 A G 4.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs11953330 chr5 17006372 C T 3.68E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs11959796 chr5 17006405 A T 3.68E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs4374758 chr5 17018543 T C 1.63E-04 Celiac disease / / 23936387 rs4374758 chr5 17018543 T C 1.67E-05 Soluble levels of adhesion molecules / / pha003072 rs17542943 chr5 17070705 A G 7.60E-07 Recombination rate / / 21698098 rs682748 chr5 17148911 A G 8.00E-06 Hippocampal atrophy LOC285696 intron 19668339 rs2731796 chr5 17153618 C G 6.25E-04 Type 2 diabetes LOC285696 intron 17463246 rs4602628 chr5 17181964 C T 2.00E-04 Cognitive impairment induced by topiramate LOC285696 intron 22091778 rs638191 chr5 17183851 C A 5.46E-05 Type 2 diabetes LOC285696 intron 17463246 rs2128307 chr5 17191616 G A 3.11E-05 Cognitive impairment induced by topiramate LOC285696 intron 22091778 rs586971 chr5 17193856 T C 4.25E-05 Smoking initiation LOC285696 intron 24665060 rs587887 chr5 17194063 T C 4.70E-07 Urinary metabolites LOC285696 intron 21572414 rs2929711 chr5 17194395 G A 7.86E-05 Smoking initiation LOC285696 intron 24665060 rs2929714 chr5 17196540 T A 1.30E-06 Urinary metabolites LOC285696 intron 21572414 rs2962360 chr5 17200189 C T 4.60E-07 Urinary metabolites LOC285696 intron 21572414 rs2929723 chr5 17200271 C T 4.20E-07 Urinary metabolites LOC285696 intron 21572414 rs2962359 chr5 17200302 A G 5.88E-05 Smoking initiation LOC285696 intron 24665060 rs2929724 chr5 17200427 C G 2.10E-06 Urinary metabolites LOC285696 intron 21572414 rs2962370 chr5 17215444 G C 2.09E-04 Suicide attempts in bipolar disorder LOC285696 intron 21423239 rs2962370 chr5 17215444 G C 5.00E-06 Bipolar disorder (mood-incongruent) LOC285696 intron 23092984 rs2242415 chr5 17225333 A C 5.46E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BASP1 intron 20877124 rs2291236 chr5 17228908 C T 5.64E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BASP1 intron 20877124 rs298525 chr5 17231485 T C 1.44E-04 Response to taxane treatment (placlitaxel) BASP1 intron 23006423 rs10037574 chr5 17232808 C T 9.74E-04 Suicide attempts in bipolar disorder BASP1 intron 21423239 rs12716119 chr5 17234794 G A 9.65E-04 Suicide attempts in bipolar disorder BASP1 intron 21423239 rs953431 chr5 17249420 A G 4.28E-04 Smoking cessation BASP1 intron 24665060 rs11133892 chr5 17255026 A G 3.05E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BASP1 intron 20877124 rs11133896 chr5 17279638 A T 4.51E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs298568 chr5 17293761 A C 2.40E-06 Asthma (bronchodilator response) / / 22792082 rs2652653 chr5 17296431 A G 2.20E-06 Asthma (bronchodilator response) / / 22792082 rs298566 chr5 17298004 C T 2.10E-06 Asthma (bronchodilator response) / / 22792082 rs10475103 chr5 17321707 A G 4.91E-04 Alzheimer's disease (late onset) / / 21379329 rs298547 chr5 17359260 C T 7.17E-04 Multiple complex diseases / / 17554300 rs159606 chr5 17374898 A G 5.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2459811 chr5 17391228 C G 6.61E-04 Multiple complex diseases / / 17554300 rs6555002 chr5 17408036 G A 4.81E-05 Body Composition / / pha003012 rs10071892 chr5 17410452 G C 3.20E-06 Urinary metabolites / / 21572414 rs7738030 chr5 17414624 A G 8.50E-05 Response to statin therapy / / 20339536 rs17658764 chr5 17415197 G A 1.28E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1553847 chr5 17430052 G A 3.13E-06 Coronary heart disease / / pha003031 rs7718456 chr5 17430238 T G 1.04E-35 Metabolite levels / / 22286219 rs871722 chr5 17437494 A G 1.72E-05 Spine bone size / / 23207799 rs6886394 chr5 17671091 T C 3.72E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6450962 chr5 17730304 A G 3.00E-07 Urinary metabolites / / 21572414 rs1915785 chr5 17742344 T A 9.77E-04 Multiple complex diseases / / 17554300 rs11959046 chr5 17761225 G A 0.0000816 post-traumatic stress disorder / / 22869035 rs11959046 chr5 17761225 G A 8.16E-05 Schizophrenia / / 22883433 rs16887626 chr5 17775485 C T 1.00E-04 Prostate cancer / / 21743057 rs10071764 chr5 17811133 C T 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs7341145 chr5 17818316 C T 8.76E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1355701 chr5 17830266 G A 1.51E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs3995724 chr5 17894062 G A 1.36E-05 Lipoproteins / / pha003079 rs3860736 chr5 17896589 C T 8.35E-06 Lipoproteins / / pha003079 rs9292968 chr5 17911394 G A 8.17E-06 Lipoproteins / / pha003079 rs10520853 chr5 17912219 T C 1.26E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1443402 chr5 17922072 C T 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs505682 chr5 18007227 A G 1.07E-05 Anxiety and major depressive disorder / / 24047446 rs7714990 chr5 18051124 T G 8.11E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16887248 chr5 18116967 G A 6.88E-04 Type 2 diabetes / / 17463246 rs2443547 chr5 18173672 C T 3.57E-04 Osteoarthritis / / 19508968 rs442958 chr5 18176583 A G 3.36E-04 Osteoarthritis / / 19508968 rs2923765 chr5 18177252 C T 1.80E-05 Urinary metabolites / / 21572414 rs2923756 chr5 18192581 A G 9.30E-06 Urinary metabolites / / 21572414 rs4866305 chr5 18194227 A G 9.00E-06 Urinary metabolites / / 21572414 rs12514191 chr5 18198169 C G 1.30E-05 Urinary metabolites / / 21572414 rs2386870 chr5 18201001 A T 3.70E-04 Multiple complex diseases / / 17554300 rs12518234 chr5 18202758 A G 1.40E-05 Urinary metabolites / / 21572414 rs4866086 chr5 18213433 G A 1.40E-05 Urinary metabolites / / 21572414 rs2938451 chr5 18236104 A T 1.20E-05 Urinary metabolites / / 21572414 rs2962166 chr5 18258575 T G 8.30E-06 Urinary metabolites / / 21572414 rs2972911 chr5 18258703 A G 7.00E-06 Urinary metabolites / / 21572414 rs314022 chr5 18319588 G C 6.79E-05 Multiple complex diseases / / 17554300 rs314022 chr5 18319588 G C 9.92E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs2962961 chr5 18330545 T A 4.18E-04 Multiple complex diseases / / 17554300 rs41515349 chr5 18334348 G A 3.00E-04 Multiple complex diseases / / 17554300 rs1165576 chr5 18338132 C T 2.07E-04 Multiple complex diseases / / 17554300 rs7720380 chr5 18386675 T C 8.18E-05 Serum metabolites / / 19043545 rs4866100 chr5 18396384 A C 1.19E-04 Age-related macular degeneration / / 22125219 rs2962910 chr5 18414588 G T 3.44E-04 Multiple complex diseases / / 17554300 rs1527386 chr5 18416511 G A 5.16E-04 Multiple complex diseases / / 17554300 rs4866334 chr5 18483651 C T 4.00E-06 IgG glycosylation / / 23382691 rs1527383 chr5 18492554 A G 1.98E-05 Multiple complex diseases / / 17554300 rs1405708 chr5 18495883 G T 3.92E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10942238 chr5 18518569 G T 1.17E-04 Diabetic nephropathy / / pha002866 rs6876174 chr5 18529071 A G 3.43E-05 Cognitive performance / / 19734545 rs12697189 chr5 18568081 T C 4.15E-04 Depression (quantitative trait) / / 20800221 rs12656579 chr5 18570590 G A 4.18E-04 Depression (quantitative trait) / / 20800221 rs12654064 chr5 18578054 C T 9.90E-04 Depression (quantitative trait) / / 20800221 rs12658762 chr5 18579606 G T 9.90E-04 Depression (quantitative trait) / / 20800221 rs12658762 chr5 18579606 G T 7.68E-05 Blood Pressure / / pha002903 rs36058922 chr5 18608409 T A 9.05E-05 Blood Pressure / / pha002903 rs1390566 chr5 18624481 C T 3.52E-04 Alzheimer's disease (late onset) / / 21379329 rs1390566 chr5 18624481 C T 9.56E-06 Leprosy / / pha002872 rs1845830 chr5 18629409 G A 9.81E-06 Leprosy / / pha002872 rs16886725 chr5 18692338 A C 1.45E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10054604 chr5 18692871 A C 2.93E-04 Alzheimer's disease (late onset) / / 21379329 rs10054604 chr5 18692871 A C 9.23E-05 Blood Pressure / / pha003045 rs10054604 chr5 18692871 A C 3.01E-05 Blood Pressure / / pha003047 rs6861651 chr5 18695365 T C 2.93E-04 Alzheimer's disease (late onset) / / 21379329 rs6861651 chr5 18695365 T C 5.32E-05 Blood Pressure / / pha003045 rs6861651 chr5 18695365 T C 1.67E-05 Blood Pressure / / pha003047 rs11959018 chr5 18712359 T A 2.80E-06 Urinary metabolites / / 21572414 rs9292313 chr5 18713832 A T 3.82E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs748418 chr5 18714208 C T 1.28E-05 Blood Pressure / / pha002903 rs2062691 chr5 18725394 C G 4.04E-04 Cocaine dependence / / 23958962 rs16886683 chr5 18733182 T G 7.87E-05 Dental caries / / 21940522 rs16886683 chr5 18733182 T G 9.64E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2962209 chr5 18738896 T C 6.40E-05 Parkinson's disease (age of onset) / / 19772629 rs10040259 chr5 18797589 A G 1.50E-05 Urinary metabolites / / 21572414 rs12518042 chr5 18799045 G T 1.80E-05 Urinary metabolites / / 21572414 rs17730662 chr5 18813396 T G 5.45E-04 Smoking quantity / / 24665060 rs9292382 chr5 18832735 C T 2.49E-06 Multiple complex diseases / / 17554300 rs16886534 chr5 18881107 A G 9.31E-05 Bipolar disorder,affective / / 20528957 rs3935803 chr5 18944261 A G 6.33E-06 Kawasaki disease / / 22081228 rs3935803 chr5 18944261 A G 9.39E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6450841 chr5 18958747 C T 6.60E-04 Multiple complex diseases / / 17554300 rs7447711 chr5 18986102 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10044670 chr5 18998725 C G 4.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs4530759 chr5 18999139 A C 8.87E-04 Multiple complex diseases / / 17554300 rs4866134 chr5 18999510 C T 0.0000199 Circulating PCSK9 levels / / 22460556 rs10040815 chr5 19018089 C G 8.05E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs10040815 chr5 19018089 C G 8.05E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs7732527 chr5 19020191 A G 0.0000114 Circulating PCSK9 levels / / 22460556 rs4327600 chr5 19093749 T C 6.69E-05 Formal thought disorder in schizophrenia / / 22648509 rs10755253 chr5 19093918 T C 8.37E-04 Multiple complex diseases / / 17554300 rs4461634 chr5 19103049 A G 1.11E-04 Longevity / / 22279548 rs6450937 chr5 19115144 T C 1.75E-05 Cognitive impairment induced by topiramate / / 22091778 rs6450937 chr5 19115144 T C 5.21E-06 Cognitive impairment induced by topiramate / / 22091778 rs10805579 chr5 19127527 A G 8.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11740707 chr5 19148952 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11740707 chr5 19148952 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7720434 chr5 19152050 G A 2.04E-05 Cognitive impairment induced by topiramate / / 22091778 rs7720434 chr5 19152050 G A 4.01E-05 Cognitive impairment induced by topiramate / / 22091778 rs7709474 chr5 19155786 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7709474 chr5 19155786 G T 6.92E-05 Cognitive impairment induced by topiramate / / 22091778 rs10941077 chr5 19158050 C T 1.10E-05 Cognitive impairment induced by topiramate / / 22091778 rs10941077 chr5 19158050 C T 2.34E-05 Cognitive impairment induced by topiramate / / 22091778 rs9637779 chr5 19160015 A G 3.28E-05 Partial epilepsies / / 20522523 rs12518778 chr5 19171872 G A 3.45E-05 Cognitive impairment induced by topiramate / / 22091778 rs12518778 chr5 19171872 G A 7.46E-05 Cognitive impairment induced by topiramate / / 22091778 rs4289561 chr5 19173299 A G 2.58E-05 Cognitive impairment induced by topiramate / / 22091778 rs4289561 chr5 19173299 A G 5.79E-05 Cognitive impairment induced by topiramate / / 22091778 rs4505952 chr5 19188359 A G 1.81E-06 Cognitive impairment induced by topiramate / / 22091778 rs4505952 chr5 19188359 A G 3.55E-06 Cognitive impairment induced by topiramate / / 22091778 rs4318784 chr5 19189948 C T 1.88E-05 Cognitive impairment induced by topiramate / / 22091778 rs4318784 chr5 19189948 C T 3.07E-06 Cognitive impairment induced by topiramate / / 22091778 rs10941111 chr5 19193452 A G 0.00000835 HDL cholesterol particle diameter / / 23263444 rs13188021 chr5 19195578 G A 1.45E-05 Cognitive impairment induced by topiramate / / 22091778 rs13188021 chr5 19195578 G A 9.37E-05 Cognitive impairment induced by topiramate / / 22091778 rs10079725 chr5 19195609 C A 4.97E-05 Cognitive impairment induced by topiramate / / 22091778 rs10079725 chr5 19195609 C A 8.22E-05 Cognitive impairment induced by topiramate / / 22091778 rs9687338 chr5 19202067 G A 2.77E-05 Cognitive impairment induced by topiramate / / 22091778 rs9687338 chr5 19202067 G A 9.81E-05 Cognitive impairment induced by topiramate / / 22091778 rs13170316 chr5 19204022 C A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs13170316 chr5 19204022 C A 1.43E-05 Cognitive impairment induced by topiramate / / 22091778 rs4286667 chr5 19233618 C G 3.50E-05 Pericardial fat / / 22589742 rs6868154 chr5 19240987 A G 4.50E-05 Pericardial fat / / 22589742 rs10472930 chr5 19251806 G A,T 5.10E-05 Pericardial fat / / 22589742 rs4490578 chr5 19266101 A G 6.00E-05 Pericardial fat / / 22589742 rs6872790 chr5 19271243 T C 8.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs11957162 chr5 19274600 G A 2.50E-06 Pericardial fat / / 22589742 rs2942321 chr5 19329470 G A 6.30E-04 Type 2 diabetes / / 17463246 rs2942321 chr5 19329470 G A 1.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17211274 chr5 19334470 G C 4.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs17271140 chr5 19343925 G A 8.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs10941253 chr5 19358778 A C 1.60E-05 Urinary metabolites / / 21572414 rs2967004 chr5 19383621 C G 9.78E-04 Type 2 diabetes / / 17463246 rs2967003 chr5 19383697 T C 5.26E-04 Type 2 diabetes / / 17463246 rs2221880 chr5 19384743 G A 3.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2221880 chr5 19384743 G A 3.00E-05 Obesity-related traits / / 17903300 rs2942296 chr5 19385274 A G 2.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2387729 chr5 19385518 A G 8.62E-05 Type 2 diabetes / / 17463246 rs2967001 chr5 19386243 T C 3.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2967001 chr5 19386243 T C 6.00E-05 Obesity-related traits / / 17903300 rs1512550 chr5 19391360 G A 8.71E-05 Type 2 diabetes / / 17463246 rs2942329 chr5 19393903 C T 1.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2942329 chr5 19393903 C T 4.50E-05 Obesity-related traits / / 17903300 rs10055665 chr5 19394955 A T 3.61E-04 Type 2 diabetes / / 17463246 rs4242063 chr5 19415040 T A 2.40E-05 Urinary metabolites / / 21572414 rs17214157 chr5 19415764 A T 3.50E-05 Odorant perception / / 23910658 rs976064 chr5 19416262 C T 6.10E-04 Multiple complex diseases / / 17554300 rs2942304 chr5 19419826 C T 5.45E-04 Type 2 diabetes / / 17463246 rs2967027 chr5 19423257 C T 8.39E-04 Type 2 diabetes / / 17463246 rs10059911 chr5 19426784 T C 4.04E-04 Alzheimer's disease / / 22005930 rs346775 chr5 19433362 C G 2.54E-05 Depression (quantitative trait) / / 20800221 rs349475 chr5 19440168 T C 2.00E-06 Depression (quantitative trait) / / 20800221 rs349475 chr5 19440168 T C 2.40E-06 Depression (quantitative trait) / / 23290196 rs349475 chr5 19440168 T C 0.00043 Breast cancer / / 23555315 rs10520861 chr5 19441735 T C 6.93E-05 Depression (quantitative trait) / / 20800221 rs10520861 chr5 19441735 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs623213 chr5 19446308 C A 5.11E-04 Depression (quantitative trait) / / 20800221 rs621084 chr5 19446761 G A 3.41E-04 Depression (quantitative trait) / / 20800221 rs17280924 chr5 19448847 C T 1.60E-05 Formal thought disorder in schizophrenia / / 22648509 rs1707015 chr5 19448955 T C 2.50E-04 Depression (quantitative trait) / / 20800221 rs17281015 chr5 19450474 A G 3.65E-05 Telomere length / / 20139977 rs12055355 chr5 19454083 G C 1.23E-04 Depression (quantitative trait) / / 20800221 rs349455 chr5 19454190 T C 2.74E-04 Depression (quantitative trait) / / 20800221 rs349455 chr5 19454190 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs168385 chr5 19457588 G C 7.05E-04 Alzheimer's disease / / 22005930 rs349474 chr5 19462474 T C 2.35E-04 Alzheimer's disease / / 22005930 rs16885921 chr5 19487558 A G 8.27E-04 Multiple complex diseases CDH18 intron 17554300 rs1386320 chr5 19502477 C T 4.57E-04 Multiple complex diseases CDH18 intron 17554300 rs347748 chr5 19542375 G A 2.18E-05 Smoking initiation CDH18 intron 24665060 rs1374489 chr5 19623143 C T 1.60E-05 Obesity-related traits CDH18 intron 17903300 rs1158558 chr5 19739333 G T 8.06E-05 Left ventricular hypertrophy CDH18 intron pha003052 rs6878236 chr5 19741507 C T 6.05E-05 Multiple complex diseases CDH18 intron 17554300 rs17221318 chr5 19742587 T C 5.68E-04 Type 2 diabetes CDH18 intron 17463246 rs17839317 chr5 19742733 T C 8.63E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CDH18 intron 24023788 rs12109816 chr5 19751140 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CDH18 intron 22628534 rs1546209 chr5 19785386 T C 4.08E-04 Type 2 diabetes CDH18 intron 17463246 rs6451476 chr5 19827322 T G 0.00000943 Nicotine dependence (smoking) CDH18 intron 23643383 rs4242066 chr5 19840945 C A 0.000000095 Nicotine dependence (smoking) CDH18 intron 23643383 rs1391429 chr5 19848325 A G 0.000000943 Nicotine dependence (smoking) CDH18 intron 23643383 rs4461636 chr5 19885216 T G 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CDH18 intron 22628534 rs4461636 chr5 19885216 T G 0.000000141 Nicotine dependence (smoking) CDH18 intron 23643383 rs4866159 chr5 19892934 T C 0.00000111 Nicotine dependence (smoking) CDH18 intron 23643383 rs1911856 chr5 19919301 T C 8.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDH18 intron 20877124 rs1911856 chr5 19919301 T C 1.04E-05 Systemic sclerosis CDH18 intron 21750679 rs12655266 chr5 19923791 A G 3.08E-05 Systemic sclerosis CDH18 intron 21750679 rs2202798 chr5 19926525 T C 2.60E-05 Systemic sclerosis CDH18 intron 21750679 rs11955587 chr5 20031683 A G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4866044 chr5 20047284 G A,T 9.41E-05 Weight / / pha003027 rs1898162 chr5 20053906 A G 9.94E-05 Weight / / pha003027 rs1435972 chr5 20124530 A G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10066940 chr5 20165589 T C 5.13E-04 Multiple complex diseases / / 17554300 rs2388129 chr5 20166988 C T 0.0001 Migraine / / 22678113 rs9292895 chr5 20174836 G T 8.01E-04 Intracranial aneurysm / / 20613766 rs10941683 chr5 20274641 T G 5.34E-04 Multiple complex diseases / / 17554300 rs10071089 chr5 20325233 G A 2.00E-06 Parkinson's disease (interaction with coffee consumption) LOC100506187 intron 21876681 rs6870586 chr5 20355032 T G 4.12E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7723030 chr5 20392735 T C 9.97E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6451823 chr5 20397544 A C 0.000749 Salmonella-induced pyroptosis / / 22837397 rs10057595 chr5 20401544 C T 1.10E-05 Urinary metabolites / / 21572414 rs12652510 chr5 20485746 A C 0.000527 Salmonella-induced pyroptosis / / 22837397 rs906629 chr5 20507115 C A 4.14E-05 Gaucher disease severity / / 22388998 rs1025307 chr5 20539936 G C 3.78E-05 Bilirubin levels,in serum / / 19389676 rs2388427 chr5 20555487 G A 4.46E-05 Bilirubin levels,in serum / / 19389676 rs2471123 chr5 20562906 G T 2.81E-05 Glucose levels / / pha003058 rs2471123 chr5 20562906 G T 2.59E-05 Glucose levels / / pha003061 rs986251 chr5 20570987 T G 7.91E-05 Type 2 diabetes and other traits / / 19734900 rs986251 chr5 20570987 T G 4.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1030479 chr5 20574412 G A 4.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10063333 chr5 20587263 C T 6.60E-05 Type 2 diabetes and other traits / / 19734900 rs7713439 chr5 20608881 T C 6.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11958512 chr5 20633323 C T 5.14E-05 Orofacial clefts / / 22419666 rs6865528 chr5 20634924 C T 9.46E-04 Multiple complex diseases / / 17554300 rs7734812 chr5 20642907 T G 7.53E-05 Serum metabolites / / 19043545 rs6451870 chr5 20650471 G A 8.34E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs4866207 chr5 20664766 C A 2.25E-04 Multiple complex diseases / / 17554300 rs4866207 chr5 20664766 C A 8.34E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7447602 chr5 20687905 A C 7.17E-04 Smoking quantity / / 24665060 rs7448884 chr5 20736784 T A 7.48E-04 Multiple complex diseases / / 17554300 rs12519026 chr5 20820895 A G 5.12E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4555765 chr5 20856417 G A 1.80E-05 Urinary metabolites / / 21572414 rs9292961 chr5 20940129 G A 5.30E-07 Atopy / / 19961619 rs7707616 chr5 20954185 G A 2.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs17238567 chr5 20964216 G A 4.00E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11958577 chr5 20969933 T C 1.89E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs10037215 chr5 20978240 G A 3.34E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs10045749 chr5 20978294 A G 3.33E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7719042 chr5 21004946 A C 1.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17239680 chr5 21027996 A G 6.40E-04 Depression (quantitative trait) / / 20800221 rs1027544 chr5 21047987 G T 0.00000545 Circulating PCSK9 levels / / 22460556 rs159171 chr5 21186326 T C 1.23E-148 Multiple complex diseases / / 17554300 rs2172239 chr5 21232485 G C 2.79E-05 Panic disorder / / 19165232 rs10063110 chr5 21391540 A G 7.73E-04 Type 2 diabetes / / 17463246 rs9292982 chr5 21504581 A C 8.43E-05 HIV-1 viral setpoint GUSBP1 intron 22174851 rs16888770 chr5 21586180 A G 8.63E-05 Otosclerosis / / 19230858 rs9292991 chr5 21617664 G C 1.80E-05 Schizophrenia / / 19571809 rs9292991 chr5 21617664 G C 2.23E-05 Schizophrenia / / pha002857 rs1452007 chr5 21697425 G T 5.89E-04 Multiple complex diseases / / 17554300 rs11750402 chr5 21698469 A T 6.66E-05 Bipolar disorder / / 22925353 rs16888540 chr5 21727340 T C 5.23E-04 Multiple complex diseases / / 17554300 rs12652874 chr5 21746911 G C 5.51E-05 Type 2 diabetes / / 17463246 rs12109285 chr5 21749348 T C 1.00E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs13164873 chr5 21768286 G A 2.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDH12 intron 20877124 rs4701252 chr5 21779154 T C 2.00E-06 Waist circumference CDH12 intron 19557197 rs4566756 chr5 21795642 T C 2.30E-05 Urinary metabolites CDH12 intron 21572414 rs11955980 chr5 21807274 T A 2.60E-05 Urinary metabolites CDH12 intron 21572414 rs11958844 chr5 21813054 G A 2.20E-05 Urinary metabolites CDH12 intron 21572414 rs6862546 chr5 21826564 C T 2.80E-05 Urinary metabolites CDH12 intron 21572414 rs17839323 chr5 21842436 A G 4.87E-04 Nicotine dependence CDH12 cds-synon 17158188 rs10045440 chr5 21872292 C T 3.65E-04 Lung function (forced expiratory volume in 1 second) CDH12 intron 24023788 rs10045440 chr5 21872292 C T 4.48E-04 Lung function (forced vital capacity) CDH12 intron 24023788 rs7445360 chr5 21904035 C A 2.55E-05 Type 2 diabetes CDH12 intron 17463246 rs7445285 chr5 21904526 G C 1.09E-04 Type 2 diabetes CDH12 intron 17463246 rs6452029 chr5 21907093 C T 1.33E-05 Type 2 diabetes CDH12 intron 17463246 rs16888800 chr5 21909011 G T 5.77E-05 Type 2 diabetes CDH12 intron 17463246 rs10472472 chr5 21915298 T G 4.91E-04 Type 2 diabetes CDH12 intron 17463246 rs7730479 chr5 21919536 C T 4.26E-05 Schizophrenia CDH12 intron 21926974 rs16888715 chr5 21922026 C G 8.72E-05 Type 2 diabetes CDH12 intron 17463246 rs9293012 chr5 22161224 A G 6.34E-05 Orofacial clefts CDH12 intron 22419666 rs7702067 chr5 22175214 T C 9.27E-05 Serum metabolites CDH12 intron 19043545 rs6452065 chr5 22179927 T A 7.49E-05 Serum metabolites CDH12 intron 19043545 rs4555751 chr5 22184722 A G 6.57E-04 Multiple complex diseases CDH12 intron 17554300 rs6865522 chr5 22227895 C T 5.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDH12 intron 20877124 rs7722786 chr5 22296872 T G 8.13E-04 Multiple complex diseases CDH12 intron 17554300 rs2968392 chr5 22323163 G A 7.34E-08 Pure-tone audiometry CDH12 intron pha001968 rs16894341 chr5 22344250 T C 1.27E-04 Nicotine smoking CDH12 intron 19268276 rs1261397 chr5 22397625 G A 3.28E-04 Lung function (forced expiratory volume in 1 second) CDH12 intron 17255346 rs1911963 chr5 22445794 A G 4.38E-04 Type 2 diabetes CDH12 intron 17463246 rs1261255 chr5 22455560 T C 5.89E-05 Serum metabolites CDH12 intron 19043545 rs1948748 chr5 22522625 T C 1.16E-04 Vaspin levels CDH12 intron 22907691 rs1948748 chr5 22522625 T C 0.0001156 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit CDH12 intron 22907730 rs7727953 chr5 22526332 G A 6.90E-04 Multiple complex diseases CDH12 intron 17554300 rs1477441 chr5 22533473 C T 2.17E-04 Vaspin levels CDH12 intron 22907691 rs1477441 chr5 22533473 C T 0.0002167 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit CDH12 intron 22907730 rs10520880 chr5 22598246 G C 8.50E-05 Breast cancer and prostate cancer CDH12 intron 17903305 rs268979 chr5 22646448 A G 6.70E-05 Endometriosis CDH12 intron 21151130 rs268971 chr5 22656141 A C 5.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDH12 intron 20877124 rs268971 chr5 22656141 A C 7.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDH12 intron 20877124 rs10053320 chr5 22657926 G T 9.73E-05 Body Composition CDH12 intron pha003012 rs7727355 chr5 22678952 C T 6.55E-04 Aortic root size CDH12 intron 21223598 rs404639 chr5 22681454 T C 2.23E-04 Aortic root size CDH12 intron 21223598 rs269027 chr5 22710858 T C 6.02E-04 Aortic root size CDH12 intron 21223598 rs4701295 chr5 22716674 G A 4.06E-04 Suicide attempts in bipolar disorder CDH12 intron 21423239 rs378003 chr5 22716848 G C 8.12E-04 Suicide attempts in bipolar disorder CDH12 intron 21423239 rs16898725 chr5 22719871 A G 5.71E-04 Multiple complex diseases CDH12 intron 17554300 rs11740186 chr5 22722716 A C 6.22E-04 Suicide attempts in bipolar disorder CDH12 intron 21423239 rs6882018 chr5 22729193 A T 9.93E-04 Suicide attempts in bipolar disorder CDH12 intron 21423239 rs12188887 chr5 22733519 G A 9.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH12 intron 23233662 rs1487415 chr5 22734966 C T 3.94E-04 Response to cytadine analogues (cytosine arabinoside) CDH12 intron 24483146 rs4701297 chr5 22737399 T C 6.07E-05 Orofacial clefts CDH12 intron 22419666 rs2129612 chr5 22740008 G A 5.28E-05 Orofacial clefts CDH12 intron 22419666 rs7720171 chr5 22741428 A G 7.97E-04 Suicide attempts in bipolar disorder CDH12 intron 21423239 rs6452095 chr5 22741835 A G 3.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDH12 intron 20877124 rs6452095 chr5 22741835 A G 7.50E-04 Suicide attempts in bipolar disorder CDH12 intron 21423239 rs12188447 chr5 22750338 A C 3.61E-04 Multiple complex diseases CDH12 intron 17554300 rs17358685 chr5 22756398 G A 6.47E-05 Major depressive disorder CDH12 intron 21621269 rs17358685 chr5 22756398 G A 0.0007942 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH12 intron 23233654 rs17358685 chr5 22756398 G A 7.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH12 intron 23233662 rs17358685 chr5 22756398 G A 7.51E-05 Major depressive disorder CDH12 intron pha002850 rs958614 chr5 22759508 A C 0.0008927 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH12 intron 23233654 rs958614 chr5 22759508 A C 8.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH12 intron 23233662 rs16899078 chr5 22761272 C T 5.55E-05 Tunica Media CDH12 intron pha003037 rs9885072 chr5 22761809 T G 7.03E-04 Multiple complex diseases CDH12 intron 17554300 rs958625 chr5 22762903 C A 2.17E-04 Multiple complex diseases CDH12 intron 17554300 rs4701304 chr5 22764586 T C 5.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDH12 intron 20877124 rs4701304 chr5 22764586 T C 5.34E-04 Suicide attempts in bipolar disorder CDH12 intron 21423239 rs7704414 chr5 22764980 G T 5.26E-04 Suicide attempts in bipolar disorder CDH12 intron 21423239 rs16899124 chr5 22765967 G A 3.91E-04 Blood pressure (response to angiotensin II receptor blocker) CDH12 intron 24192120 rs10461807 chr5 22767705 G A 7.04E-04 Suicide attempts in bipolar disorder CDH12 intron 21423239 rs1372670 chr5 22768866 C G 7.25E-04 Suicide attempts in bipolar disorder CDH12 intron 21423239 rs11952980 chr5 22770327 T A 8.01E-04 Suicide attempts in bipolar disorder CDH12 intron 21423239 rs11953047 chr5 22770504 T A 9.42E-04 Suicide attempts in bipolar disorder CDH12 intron 21423239 rs11955287 chr5 22770557 G T 8.54E-04 Suicide attempts in bipolar disorder CDH12 intron 21423239 rs780188 chr5 22790036 T G 5.29E-04 Amyotrophic Lateral Sclerosis CDH12 intron 17827064 rs1561836 chr5 22794657 A G 0.0002 Migraine CDH12 intron 22678113 rs780179 chr5 22812264 T C 4.78E-04 Amyotrophic Lateral Sclerosis CDH12 intron 17827064 rs780179 chr5 22812264 T C 9.00E-07 Multiple myeloma (IgH translocation) CDH12 intron 23502783 rs1707069 chr5 22826252 G A 8.98E-04 Multiple complex diseases CDH12 intron 17554300 rs17294204 chr5 22833423 T G 2.34E-04 Multiple complex diseases CDH12 intron 17554300 rs12521133 chr5 22845094 C T 6.70E-06 Urinary metabolites CDH12 intron 21572414 rs4235522 chr5 22866540 T C 2.54E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10462231 chr5 22902746 G A 0.0003622 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10462231 chr5 22902746 G A 3.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10520881 chr5 22911058 G A 2.80E-05 Urinary metabolites / / 21572414 rs12518494 chr5 22938343 A G 8.28E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4701211 chr5 22952742 T C 9.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4701212 chr5 22952760 T C 9.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2059862 chr5 22953311 T C 9.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13157973 chr5 22953668 G A 9.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1850827 chr5 22953854 A T 9.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13189142 chr5 22955512 A G 9.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1975040 chr5 22958675 C T 9.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1975039 chr5 22958955 G A 9.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13176809 chr5 22962088 G C 9.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4701323 chr5 22962596 G T 9.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9293044 chr5 22974392 A G 9.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10434581 chr5 22981126 T G 9.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6866185 chr5 22984279 T C 2.80E-05 Urinary metabolites / / 21572414 rs2203871 chr5 22991806 G T 1.47E-04 Smoking quantity / / 24665060 rs6879343 chr5 23056410 C T 5.80E-05 Body mass (lean) / / 19268274 rs6879343 chr5 23056410 C T 4.00E-04 Asperger disorder / / 21182207 rs12517133 chr5 23068712 G A 3.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs4701341 chr5 23073374 C T 5.65E-05 Bipolar disorder / / 20451256 rs9293054 chr5 23123829 C T 7.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9293054 chr5 23123829 C T 0.0002 Migraine / / 22678113 rs10053648 chr5 23127912 A G 2.84E-04 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs12332357 chr5 23132615 A G 2.84E-04 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs6874684 chr5 23137960 C G 6.22E-04 Aortic root size / / 21223598 rs1995264 chr5 23138951 A G 8.49E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10038745 chr5 23139973 C A,T 5.39E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17301389 chr5 23155859 G A 2.20E-05 Urinary metabolites / / 21572414 rs1435240 chr5 23159406 T A 4.27E-04 Multiple complex diseases / / 17554300 rs10072467 chr5 23216237 C T 2.60E-05 Lung cancer / / 18385738 rs6866502 chr5 23219699 C T 4.53E-04 Sudden cardiac arrest / / 21658281 rs975072 chr5 23239214 A G 3.18E-04 Longevity / / 22279548 rs17376026 chr5 23244025 C T 6.00E-06 Economic and political preferences (immigration/crime) / / 22566634 rs16892299 chr5 23261842 A G 7.72E-05 HIV-1 viral setpoint / / 22174851 rs5009031 chr5 23364376 G C 5.17E-05 Multiple complex diseases / / 17554300 rs5009031 chr5 23364376 G C 1.61E-04 Bipolar disorder,schizoaffective / / 19567891 rs4451017 chr5 23364549 C T 1.13E-04 Multiple complex diseases / / 17554300 rs10043071 chr5 23492226 C A 1.04E-04 Alzheimer's disease (late onset) / / 21379329 rs10075972 chr5 23493956 C T 3.80E-04 Myasthenia gravis / / 23055271 rs10805751 chr5 23495320 G A 5.94E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6889665 chr5 23532643 T C 5.53E-04 Alcohol dependence / / 20201924 rs2914276 chr5 23542711 T C 1.00E-100 Recombination (females) / / 20981099 rs41502455 chr5 23572943 T A 1.30E-08 Recombination rate / / 21698098 rs16892567 chr5 23579740 G A 3.72E-04 Multiple complex diseases / / 17554300 rs16892567 chr5 23579740 G A 5.12E-04 Alcohol dependence / / 21314694 rs10077618 chr5 23604239 A G 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs7705488 chr5 23623207 T C 5.10E-05 Aging (time to event) / / 21782286 rs1402426 chr5 23627668 G T 1.08E-04 Blood pressure / / 17255346 rs1402410 chr5 23635910 C T 2.01E-04 Blood pressure / / 17255346 rs6861791 chr5 23655774 C T 1.52E-04 Blood pressure / / 17255346 rs1910358 chr5 23907573 C T 7.00E-09 Venous thromboembolism (gene x gene interaction) / / 23509962 rs4701241 chr5 23963446 T C 8.85E-07 Height C5orf17 intron pha003011 rs4701242 chr5 23968345 G A 1.04E-05 Height C5orf17 intron pha003011 rs16899418 chr5 24077186 A G 6.03E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs16893121 chr5 24102044 C T 6.03E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs13360743 chr5 24103188 T C 4.21E-04 Multiple complex diseases / / 17554300 rs13362289 chr5 24103502 G A 9.96E-04 Multiple complex diseases / / 17554300 rs7731830 chr5 24155536 C A,G,T 7.04E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs16893187 chr5 24162543 T C 4.31E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6452189 chr5 24163109 C T 5.88E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9637784 chr5 24172252 C A 1.53E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17506115 chr5 24183331 T A 6.90E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs10074062 chr5 24183515 C T 2.25E-04 Multiple complex diseases / / 17554300 rs12654722 chr5 24198232 A C 2.21E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6868533 chr5 24230888 T C 6.82E-06 Lung function (forced expiratory volume in 1 second) / / pha003102 rs6868533 chr5 24230888 T C 6.45E-05 Lung function (forced vital capacity) / / pha003104 rs13178734 chr5 24262450 T C 7.25E-05 stroke (ischemic) / / 17434096 rs7700267 chr5 24269794 G A 5.96E-05 stroke (ischemic) / / 17434096 rs6452197 chr5 24309607 T G 4.96E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs184542 chr5 24348812 A G 1.74E-05 Telomere length / / 23001564 rs972303 chr5 24355555 C T 0.0002483 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs972303 chr5 24355555 C T 2.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4701244 chr5 24357784 C T 0.0002485 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4701244 chr5 24357784 C T 2.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2099068 chr5 24457730 C A 7.30E-06 Urinary metabolites / / 21572414 rs1428365 chr5 24482475 T C 6.64E-04 White matter integrity / / 22425255 rs3797173 chr5 24497247 A C 1.43E-04 Nicotine smoking CDH10 intron 19268276 rs1505874 chr5 24497516 G T 3.31E-05 Height CDH10 intron pha003011 rs4701447 chr5 24528847 T G 9.94E-04 Heart Failure CDH10 intron pha002884 rs4701450 chr5 24577659 C T 4.58E-04 Multiple complex diseases CDH10 intron 17554300 rs7716158 chr5 24585329 A G 1.43E-04 Response to platinum-based chemotherapy in small-cell lung cancer CDH10 intron 20463552 rs7720811 chr5 24602650 G A 8.29E-05 Lung function (forced vital capacity) CDH10 intron pha003104 rs9293140 chr5 24607446 C T 2.10E-05 Volumetric brain MRI CDH10 intron 17903297 rs2217383 chr5 24665518 A G 0.000497 Salmonella-induced pyroptosis / / 22837397 rs16893872 chr5 24730006 C T 1.84E-05 Multiple complex diseases / / 17554300 rs16893874 chr5 24730444 C A 1.87E-05 Multiple complex diseases / / 17554300 rs1820873 chr5 24731391 A G 3.15E-05 Multiple complex diseases / / 17554300 rs16894002 chr5 24817630 A G 1.52E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4421074 chr5 24833154 T C 2.37E-05 Cognitive test performance / / 20125193 rs4421074 chr5 24833154 T C 3.30E-04 Stroke / / pha002886 rs6884872 chr5 24844413 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs962088 chr5 24868417 C A,T 5.49E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs962087 chr5 24868444 T C 5.84E-05 Multiple complex diseases / / 17554300 rs1389221 chr5 24884260 T C 6.30E-05 Alcoholism (heaviness of drinking) / / 21529783 rs1389220 chr5 24884379 G A 6.38E-04 Obesity (extreme) / / 21935397 rs1389219 chr5 24884394 A T 6.39E-04 Obesity (extreme) / / 21935397 rs6452233 chr5 24905718 G A 6.13E-04 Obesity (extreme) / / 21935397 rs6452234 chr5 24922789 G A 5.29E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs6452234 chr5 24922789 G A 1.13E-05 Obsessive-compulsive disorder / / 24821223 rs2055073 chr5 24924797 A G 6.79E-05 Post-operative nausea and vomiting / / 21694509 rs10520903 chr5 24930711 G A 7.74E-04 Type 2 diabetes / / 17463246 rs333531 chr5 24934107 C T 6.18E-04 Type 2 diabetes / / 17463246 rs17343580 chr5 25024992 C T 4.11E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs12332704 chr5 25050772 C T 5.35E-04 Alzheimer's disease / / 22005930 rs10041282 chr5 25053581 G A 9.74E-04 Alzheimer's disease / / 22005930 rs2047267 chr5 25087725 G A 4.00E-06 Uric acid levels / / 21294900 rs6452245 chr5 25088129 G A 3.86E-06 Uric acid levels / / 21294900 rs10059755 chr5 25088841 A G 3.86E-06 Uric acid levels / / 21294900 rs10942087 chr5 25091472 C T 6.33E-05 Depression (quantitative trait) / / 23290196 rs2047268 chr5 25092432 A C 6.36E-05 Depression (quantitative trait) / / 23290196 rs12654558 chr5 25092779 C T 6.45E-05 Depression (quantitative trait) / / 23290196 rs12657561 chr5 25092994 T C 6.55E-05 Depression (quantitative trait) / / 23290196 rs995431 chr5 25093717 T A 7.00E-05 Depression (quantitative trait) / / 23290196 rs12521551 chr5 25095178 A G 7.90E-05 Depression (quantitative trait) / / 23290196 rs12519063 chr5 25095635 C T 8.64E-05 Depression (quantitative trait) / / 23290196 rs11746102 chr5 25097916 A G 9.74E-05 Depression (quantitative trait) / / 23290196 rs7728789 chr5 25097969 C T 9.97E-05 Depression (quantitative trait) / / 23290196 rs13189107 chr5 25108834 A T 1.00E-04 Prostate cancer / / 21743057 rs3913960 chr5 25228227 T C 1.26E-04 Lung function (forced vital capacity) / / 24023788 rs3846547 chr5 25255666 G A 9.23E-05 Coronary heart disease / / pha003031 rs16894266 chr5 25258870 A G 9.03E-04 Nicotine dependence / / 17158188 rs6452254 chr5 25280027 C T 1.11E-05 Lung function (forced vital capacity) / / 24023788 rs6452254 chr5 25280027 C T 4.53E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6875442 chr5 25303740 C A 6.01E-05 Depression (quantitative trait) / / 23290196 rs13163964 chr5 25315404 G A 6.80E-05 Depression (quantitative trait) / / 23290196 rs4627955 chr5 25315980 G A 6.43E-05 Depression (quantitative trait) / / 23290196 rs10520926 chr5 25325937 T A 2.60E-05 Type 2 diabetes / / 17846125 rs13157155 chr5 25326757 G C 6.38E-05 Depression (quantitative trait) / / 23290196 rs2331970 chr5 25387242 T A 8.20E-06 Urinary metabolites / / 21572414 rs7349775 chr5 25390463 C G 7.40E-06 Urinary metabolites / / 21572414 rs16894372 chr5 25411980 T C 3.04E-04 Multiple complex diseases / / 17554300 rs16894373 chr5 25412204 A G 3.30E-06 Urinary metabolites / / 21572414 rs1904173 chr5 25420089 G A 5.50E-06 Urinary metabolites / / 21572414 rs1904173 chr5 25420089 G A 7.00E-06 IgG glycosylation / / 23382691 rs10447154 chr5 25428141 A T 7.25E-04 Multiple complex diseases / / 17554300 rs10942119 chr5 25450175 G T 7.26E-04 Multiple complex diseases / / 17554300 rs17525260 chr5 25468315 C T 2.31E-04 Myopia (pathological) / / 21095009 rs2126967 chr5 25470513 A G 2.79E-04 Myopia (pathological) / / 21095009 rs13164982 chr5 25490994 C T 3.59E-04 Alzheimer's disease / / 24755620 rs11956010 chr5 25493462 T A 7.74E-05 Type 2 diabetes / / 17463246 rs4701486 chr5 25528242 T G 4.83E-05 Response to metformin / / 21186350 rs1428241 chr5 25543266 T C 3.10E-05 Vaspin levels / / 22907691 rs1428241 chr5 25543266 T C 0.000031 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs6876547 chr5 25572301 T G 2.00E-06 Obsessive-compulsive disorder / / 24821223 rs13158186 chr5 25576239 A G 9.43E-04 Alzheimer's disease / / 22005930 rs13183626 chr5 25595178 C T 8.99E-04 Alzheimer's disease / / 22005930 rs6859698 chr5 25598148 A T 9.12E-04 Alzheimer's disease / / 22005930 rs6899062 chr5 25610763 A C 6.99E-04 Parkinson's disease / / 17052657 rs387456 chr5 25679253 G A 9.84E-06 Response to amphetamines / / 22952603 rs193741 chr5 25692973 G A 2.00E-06 beta2-Glycoprotein I (beta2-GPI) plasma levels / / 23279374 rs400196 chr5 25717507 A G 8.00E-04 Alcohol dependence / / 20201924 rs400196 chr5 25717507 A G 1.98E-04 Lung function (forced vital capacity) / / 24023788 rs400196 chr5 25717507 A G 8.36E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1678934 chr5 25752159 A G 3.82E-05 Hippocampal atrophy / / 19668339 rs7727656 chr5 25760679 G T 8.00E-06 Hippocampal atrophy / / 19668339 rs2928266 chr5 25781613 T C 2.80E-04 Crohn's disease / / 17684544 rs12521681 chr5 25782399 G A 9.81E-05 Autism / / 19404256 rs2972314 chr5 25786777 G A 3.83E-04 Type 2 diabetes / / 17463246 rs386093 chr5 25791261 A T 9.28E-04 Type 2 diabetes / / 17463246 rs438142 chr5 25794827 C T 6.47E-05 Orofacial clefts / / 22419666 rs443439 chr5 25797388 G A 7.36E-05 Autism / / 19404256 rs437316 chr5 25797453 G A 7.50E-05 Autism / / 19404256 rs438137 chr5 25798716 C A 9.76E-05 Autism / / 19404256 rs374014 chr5 25799092 A G 6.97E-05 Autism / / 19404256 rs10491401 chr5 25801089 C T 7.14E-05 Autism / / 19404256 rs423116 chr5 25801289 G A 5.30E-05 Autism / / 19404256 rs2619939 chr5 25801590 T C 2.70E-05 Endometriosis / / 21151130 rs2619940 chr5 25801732 T C 7.38E-05 Autism / / 19404256 rs2619941 chr5 25801771 G A 6.75E-05 Autism / / 19404256 rs2619942 chr5 25801818 G A 6.52E-05 Autism / / 19404256 rs367519 chr5 25802828 T C 6.01E-05 Autism / / 19404256 rs11740209 chr5 25840136 C T 1.25E-06 Autism / / 19404256 rs10065041 chr5 25840450 T C 1.01E-06 Autism / / 19404256 rs10065041 chr5 25840450 T C 1.68E-05 Orofacial clefts / / 22419666 rs409649 chr5 25841163 A G 1.80E-07 Autism / / 19404256 rs396045 chr5 25841613 G A 7.00E-06 Obesity-related traits / / 23251661 rs11949113 chr5 25864758 T G 1.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs11949195 chr5 25865196 A T 1.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs922551 chr5 25867540 A G 1.67E-07 Autism / / 19404256 rs12521157 chr5 25869401 C T 1.82E-04 Type 2 diabetes / / 17463246 rs12521157 chr5 25869401 C T 1.25E-07 Autism / / 19404256 rs1366465 chr5 25870090 T C 1.03E-05 Autism / / 19404256 rs1366465 chr5 25870090 T C 1.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs12658597 chr5 25870330 C T 1.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs13164425 chr5 25874921 G A 3.51E-05 Blood Pressure / / pha003046 rs13164425 chr5 25874921 G A 3.35E-05 Blood Pressure / / pha003048 rs6452297 chr5 25878699 T C 1.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs1428660 chr5 25882059 C T 1.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs10058083 chr5 25894398 G A 3.15E-08 Autism / / 19404256 rs4701511 chr5 25896004 C A 1.69E-09 Autism / / 19404256 rs6894102 chr5 25897556 T C 2.87E-08 Autism / / 19404256 rs7704909 chr5 25898921 T C 9.94E-10 Autism / / 19404256 rs1896731 chr5 25899020 T C 4.80E-08 Autism / / 19404256 rs7705715 chr5 25899414 T C 2.04E-09 Autism / / 19404256 rs13176113 chr5 25900440 G A 3.08E-09 Autism / / 19404256 rs4701259 chr5 25901098 A G 2.63E-09 Autism / / 19404256 rs17482975 chr5 25901608 C T 1.90E-09 Autism / / 19404256 rs10038113 chr5 25902342 T C 7.36E-08 Autism / / 19404256 rs10038113 chr5 25902342 T C 3.00E-06 Autism / / 19456320 rs10038113 chr5 25902342 T C 0.000059 Breast cancer / / 23555315 rs13187934 chr5 25902368 C T 2.29E-09 Autism / / 19404256 rs7727848 chr5 25906385 G A 2.44E-05 Multiple complex diseases / / 17554300 rs11739167 chr5 25909764 C T 1.95E-08 Autism / / 19404256 rs10942147 chr5 25910929 G A 1.59E-09 Autism / / 19404256 rs9293194 chr5 25911136 C A 1.21E-08 Autism / / 19404256 rs12521388 chr5 25912113 G A 1.52E-09 Autism / / 19404256 rs7447989 chr5 25915032 A G 1.03E-05 Autism / / 19404256 rs1346536 chr5 25915652 A G 2.42E-08 Autism / / 19404256 rs12697669 chr5 25919023 C A 2.27E-06 Autism / / 19404256 rs12659830 chr5 25920401 G T 1.84E-05 Autism / / 19404256 rs6452304 chr5 25924228 T C 3.28E-09 Autism / / 19404256 rs6452305 chr5 25924622 A C 3.33E-09 Autism / / 19404256 rs7380139 chr5 25926366 A G 2.38E-09 Autism / / 19404256 rs16895144 chr5 25926946 T C 2.61E-04 Alzheimer's disease (late onset) / / 21379329 rs6873221 chr5 25928566 G A 1.05E-08 Autism / / 19404256 rs12697671 chr5 25929832 C A 1.48E-04 Type 2 diabetes / / 17463246 rs10063934 chr5 25932607 G A 1.66E-05 Autism / / 19404256 rs12519594 chr5 25934805 G A 3.01E-09 Autism / / 19404256 rs12187724 chr5 25935070 A C 1.55E-05 Autism / / 19404256 rs10155569 chr5 25944378 C T 3.91E-04 Type 2 diabetes / / 17463246 rs6894838 chr5 25944946 T C 9.06E-07 Autism / / 19404256 rs10214380 chr5 25946935 T C 1.86E-05 Autism / / 19404256 rs11959743 chr5 25947398 A C 4.17E-04 Type 2 diabetes / / 17463246 rs10064843 chr5 25948451 G A 3.17E-04 Type 2 diabetes / / 17463246 rs12518194 chr5 25951561 A G 1.07E-09 Autism / / 19404256 rs4475231 chr5 25955317 C T 1.81E-09 Autism / / 19404256 rs4701260 chr5 25958905 G A 6.79E-06 Autism / / 19404256 rs4701260 chr5 25958905 G A 5.18E-04 Hemoglobin concentration / / 20534544 rs12187661 chr5 25959546 C T 1.59E-05 Autism / / 19404256 rs10472547 chr5 25962208 C T 1.87E-04 Type 2 diabetes / / 17463246 rs4307059 chr5 25967703 T C 2.00E-10 Autism / / 19404256 rs6891206 chr5 25969379 T C 4.09E-08 Autism / / 19404256 rs7732252 chr5 25970666 A G 2.00E-04 Body mass index / / 17255346 rs13166776 chr5 25971356 T C 3.84E-09 Autism / / 19404256 rs4327572 chr5 25972821 C T 2.71E-09 Autism / / 19404256 rs4327572 chr5 25972821 C T 1.82E-09 Narcolepsy / / 19629137 rs7703726 chr5 25984115 C T 1.45E-12 Metabolite levels / / 22286219 rs6880807 chr5 26005243 G T 6.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs4404644 chr5 26028389 T C 2.97E-04 Schizophrenia / / 19197363 rs6898772 chr5 26046052 T C 3.52E-05 Autism / / 19404256 rs12516367 chr5 26048424 T C 3.45E-05 Autism / / 19404256 rs12514304 chr5 26057117 G T 4.14E-05 Autism / / 19404256 rs10072518 chr5 26064803 C T 1.29E-05 Autism / / 19404256 rs7720426 chr5 26065402 G A 1.40E-05 Autism / / 19404256 rs12173236 chr5 26071476 C T 1.37E-05 Autism / / 19404256 rs1330642 chr5 26073238 C T 3.51E-05 Autism / / 19404256 rs11953897 chr5 26138706 G A 4.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs4701523 chr5 26139138 A T 3.00E-06 Visceral fat / / 22589738 rs1541079 chr5 26141651 G A 6.19E-05 Alzheimer's disease (late onset) / / 21379329 rs4701526 chr5 26142872 G C 5.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs10062689 chr5 26181001 A G 3.20E-05 Alzheimer's disease (late onset) / / 21379329 rs6884362 chr5 26193999 G A 1.96E-04 Alzheimer's disease (late onset) / / 21379329 rs10035131 chr5 26229996 A C 1.24E-04 Autism spectrum disorders (language delay) / / 21519539 rs4543230 chr5 26238133 C T 8.66E-05 AIDS progression / / 19115949 rs6452328 chr5 26281948 C T 0.000578 Salmonella-induced pyroptosis / / 22837397 rs4406110 chr5 26292815 C T 0.000626 Salmonella-induced pyroptosis / / 22837397 rs10061965 chr5 26310818 T C 1.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10061965 chr5 26310818 T C 3.99E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10070748 chr5 26315469 A C 8.13E-06 Cocaine dependence / / 23958962 rs2036010 chr5 26321661 C A 3.83E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs6862088 chr5 26322668 G A 0.000549 Salmonella-induced pyroptosis / / 22837397 rs12189045 chr5 26357027 T C 4.38E-05 AIDS progression / / 19115949 rs2319809 chr5 26365593 G A 3.73E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs1565873 chr5 26374931 G A 1.02E-04 Intracranial aneurysm / / 20613766 rs969088 chr5 26389262 G C 2.00E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs969088 chr5 26389262 G C 3.00E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs1428716 chr5 26508802 G T 8.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs6877069 chr5 26509802 A G 5.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs4469170 chr5 26510094 A G 5.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs4469171 chr5 26510335 A C 5.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs10054962 chr5 26512120 C G 6.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs10069706 chr5 26512151 G A 4.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs10059731 chr5 26514835 C G 9.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs1544943 chr5 26516452 T A 3.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs9293239 chr5 26517516 G A 2.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs1030477 chr5 26519364 C T 3.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs10070409 chr5 26520465 T A 8.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs1896746 chr5 26529638 C T 9.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs7716179 chr5 26533173 T C 4.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs13177712 chr5 26540316 T C 8.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs1428723 chr5 26543849 C T 2.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs12109692 chr5 26545249 A G 4.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs6867412 chr5 26555788 A G 5.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs1500193 chr5 26558313 T C 5.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs1353954 chr5 26560653 C T 5.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs6452345 chr5 26568243 T C 3.21E-04 Alzheimer's disease / / 24755620 rs6875141 chr5 26568838 A G 3.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs9293241 chr5 26570421 G A 4.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs1553235 chr5 26574228 T C 5.88E-04 Smoking cessation / / 24665060 rs13157691 chr5 26575966 C T 7.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs17559514 chr5 26577464 G T 2.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs9293242 chr5 26577573 A G 5.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs1604096 chr5 26602860 A G 2.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs10054272 chr5 26607629 G A 3.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs6452348 chr5 26626794 A T 4.77E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17494747 chr5 26671727 T C 4.66E-04 Alzheimer's disease / / 17998437 rs4479806 chr5 26723783 C A 8.00E-06 Anorexia nervosa / / 21079607 rs2135068 chr5 26755905 G A 8.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs966640 chr5 26763749 A G 5.76E-04 White matter integrity / / 22425255 rs12522491 chr5 26788362 A G 9.51E-04 Alzheimer's disease / / 24755620 rs1155345 chr5 26791199 C T 6.34E-04 Alzheimer's disease / / 24755620 rs1154736 chr5 26795776 C T 8.18E-04 Alzheimer's disease / / 24755620 rs1505053 chr5 26805069 A C 8.34E-04 Alzheimer's disease / / 24755620 rs818735 chr5 26833363 T A 5.74E-04 Multiple complex diseases / / 17554300 rs818736 chr5 26833919 A C 5.87E-04 Multiple complex diseases / / 17554300 rs12519694 chr5 26838935 A G 3.52E-04 Smoking cessation / / 24665060 rs12519694 chr5 26838935 A G 1.88E-04 Myocardial Infarction / / pha002883 rs3846559 chr5 26847198 C A 1.90E-05 Urinary metabolites / / 21572414 rs7718817 chr5 26849808 G C 3.31E-04 Alzheimer's disease / / 17998437 rs1479679 chr5 26882085 T C 4.36E-05 Bone mass and geometry CDH9 intron 17903296 rs1479679 chr5 26882085 T C 7.37E-05 Intelligence CDH9 intron 21826061 rs1156358 chr5 26907873 A G 1.10E-06 Sickle cell anemia (severity) CDH9 intron 20029952 rs10057565 chr5 26928066 T C 8.00E-06 Coronary artery calcification CDH9 intron 23870195 rs7725061 chr5 26951682 C T 9.42E-04 Response to taxane treatment (placlitaxel) CDH9 intron 23006423 rs2288467 chr5 26988424 T C 4.69E-04 Amyotrophic lateral sclerosis (sporadic) CDH9 missense 24529757 rs6874394 chr5 26992816 A T 9.87E-04 Response to taxane treatment (placlitaxel) CDH9 intron 23006423 rs10942230 chr5 27005194 T C 9.00E-04 Lipid levels CDH9 intron 18193043 rs10461828 chr5 27022711 C A 3.01E-05 Brain structure CDH9 intron 22504417 rs4355486 chr5 27118856 C T 3.15E-05 Hemoglobin / / pha003098 rs4632762 chr5 27159309 A G 0.000512 Salmonella-induced pyroptosis / / 22837397 rs16896571 chr5 27255768 T A 1.70E-04 Multiple complex diseases / / 17554300 rs1021003 chr5 27262189 A G 5.30E-04 Multiple complex diseases / / 17554300 rs10473829 chr5 27301522 G T 5.96E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1020813 chr5 27304891 A G 9.03E-04 Alzheimer's disease / / 24755620 rs2329426 chr5 27343904 T C 5.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs10058813 chr5 27387385 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7732187 chr5 27424981 T C 5.69E-05 Smoking initiation / / 24665060 rs7710599 chr5 27428073 T C 5.07E-05 Smoking initiation / / 24665060 rs13156155 chr5 27431789 C T 3.39E-04 Smoking initiation / / 24665060 rs13165859 chr5 27433158 C A 5.65E-05 Smoking initiation / / 24665060 rs6888033 chr5 27441315 G A 5.50E-04 Smoking initiation / / 24665060 rs4421076 chr5 27447863 A G 1.58E-04 Smoking initiation / / 24665060 rs10039598 chr5 27448804 A G 1.78E-04 Smoking initiation / / 24665060 rs17584737 chr5 27488028 G A 7.71E-06 Alzheimer's disease LOC643401 intron 21627779 rs10057344 chr5 27504666 C T 6.75E-04 Multiple complex diseases / / 17554300 rs10213971 chr5 27532751 T G 6.24E-06 Alzheimer's disease / / 21627779 rs10213971 chr5 27532751 T G 7.35E-04 Alzheimer's disease / / 24755620 rs6878811 chr5 27535516 T G 3.70E-06 Alzheimer's disease / / 21627779 rs6878811 chr5 27535516 T G 7.35E-04 Alzheimer's disease / / 24755620 rs4701558 chr5 27539782 T G 3.70E-06 Alzheimer's disease / / 21627779 rs4701558 chr5 27539782 T G 7.08E-04 Alzheimer's disease / / 24755620 rs4574515 chr5 27540794 T G 3.41E-06 Alzheimer's disease / / 21627779 rs7735324 chr5 27547882 C A 3.70E-06 Alzheimer's disease / / 21627779 rs2329639 chr5 27551764 A G 3.70E-06 Alzheimer's disease / / 21627779 rs6452395 chr5 27553567 A T 3.70E-06 Alzheimer's disease / / 21627779 rs10940661 chr5 27553585 G T 3.70E-06 Alzheimer's disease / / 21627779 rs10940662 chr5 27553808 T G 3.70E-06 Alzheimer's disease / / 21627779 rs10805520 chr5 27553955 G A 8.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs10805520 chr5 27553955 G A 3.70E-06 Alzheimer's disease / / 21627779 rs10805521 chr5 27554074 A G 9.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs10805521 chr5 27554074 A G 3.70E-06 Alzheimer's disease / / 21627779 rs13182293 chr5 27555275 T A 3.70E-06 Alzheimer's disease / / 21627779 rs7703012 chr5 27556869 T C 3.70E-06 Alzheimer's disease / / 21627779 rs10073761 chr5 27557799 G A 4.65E-06 Alzheimer's disease / / 21627779 rs10073761 chr5 27557799 G A 6.17E-04 Alzheimer's disease / / 24755620 rs13169838 chr5 27558119 T C 5.16E-06 Alzheimer's disease / / 21627779 rs13169838 chr5 27558119 T C 5.37E-04 Alzheimer's disease / / 24755620 rs6870385 chr5 27559659 A C 5.76E-06 Alzheimer's disease / / 21627779 rs6870385 chr5 27559659 A C 4.78E-04 Alzheimer's disease / / 24755620 rs10036200 chr5 27560226 A C 9.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs10036200 chr5 27560226 A C 5.76E-06 Alzheimer's disease / / 21627779 rs10044686 chr5 27560287 T A 9.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs10044686 chr5 27560287 T A 4.75E-06 Alzheimer's disease / / 21627779 rs10036269 chr5 27560541 A G 6.42E-04 Alzheimer's disease / / 24755620 rs6878836 chr5 27565829 A G 9.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs6878836 chr5 27565829 A G 4.75E-06 Alzheimer's disease / / 21627779 rs2329645 chr5 27567936 T G 4.75E-06 Alzheimer's disease / / 21627779 rs2329645 chr5 27567936 T G 7.19E-04 Alzheimer's disease / / 24755620 rs4701271 chr5 27581487 A C 3.49E-06 Alzheimer's disease / / 21627779 rs10051873 chr5 27584310 A G 3.96E-06 Alzheimer's disease / / 21627779 rs10051873 chr5 27584310 A G 5.49E-04 Alzheimer's disease / / 24755620 rs12054895 chr5 27611431 G T 3.00E-08 Major depressive disorder / / 23377640 rs4867154 chr5 27723087 A C 2.86E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs13190613 chr5 27750670 T C 1.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12659895 chr5 27766240 C T 6.40E-04 Pulmonary function / / 23932459 rs4254923 chr5 27773935 A G 9.98E-05 Schizophrenia / / 19571809 rs4516860 chr5 27792192 T C 9.23E-05 Bipolar disorder and schizophrenia / / 20889312 rs6862995 chr5 27824645 A G 1.07E-05 Hemoglobin / / pha003096 rs6862995 chr5 27824645 A G 5.85E-06 Hematocrit / / pha003097 rs10068816 chr5 27861517 C T 6.16E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11960086 chr5 27931123 G A 3.76E-05 Diabetes Mellitus / / pha003060 rs1428596 chr5 27934484 C T 8.09E-05 Diabetes Mellitus / / pha003060 rs1366436 chr5 27935737 C A 5.88E-05 Diabetes Mellitus / / pha003060 rs30810 chr5 27950483 C T 8.95E-05 Celiac disease / / 23936387 rs389719 chr5 27957438 G A 2.01E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs4537065 chr5 27987104 G A 7.12E-04 Schizophrenia / / 19197363 rs4537065 chr5 27987104 G A 6.50E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs2876936 chr5 27992491 C T 6.50E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs4398645 chr5 28006650 T C 6.50E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs1494617 chr5 28017229 T C 6.50E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs1546138 chr5 28017816 C A 3.11E-04 Depression (quantitative trait) / / 20800221 rs903396 chr5 28018647 A G 9.51E-04 Alzheimer's disease / / 17998437 rs7710236 chr5 28025934 C T 2.86E-04 Schizophrenia / / 19197363 rs7726201 chr5 28059042 C T 6.36E-04 Alzheimer's disease / / 17998437 rs17531726 chr5 28086068 T C 4.87E-04 Depression (quantitative trait) / / 20800221 rs4365847 chr5 28133034 C T 7.10E-04 Type 2 diabetes / / 17463246 rs9292242 chr5 28133129 A G 8.85E-04 Multiple complex diseases / / 17554300 rs7729381 chr5 28133764 T C 6.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs10940707 chr5 28177969 A G 8.18E-06 Hypertension / / pha003042 rs10940707 chr5 28177969 A G 2.54E-06 Blood Pressure / / pha003048 rs10070878 chr5 28184320 T C 3.53E-06 Hypertension / / pha003042 rs10070878 chr5 28184320 T C 1.53E-06 Blood Pressure / / pha003048 rs7715438 chr5 28209875 C G 4.60E-06 Urinary metabolites / / 21572414 rs6869148 chr5 28214620 A G 8.10E-06 Urinary metabolites / / 21572414 rs13158220 chr5 28230717 T C 1.10E-05 Urinary metabolites / / 21572414 rs2455187 chr5 28233737 T G 8.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2455206 chr5 28256876 C T 8.88E-04 Type 2 diabetes / / 17463246 rs2455206 chr5 28256876 C T 8.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10520942 chr5 28270559 C A 1.93E-04 Arthritis (juvenile idiopathic) / / 22354554 rs12517235 chr5 28288986 G T 2.70E-05 Urinary metabolites / / 21572414 rs2468449 chr5 28316657 G T 2.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs2468449 chr5 28316657 G T 2.48E-04 Iron levels / / pha002876 rs2434551 chr5 28316806 A G 2.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs17534779 chr5 28327101 T A 8.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs890916 chr5 28328236 T C 3.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs890916 chr5 28328236 T C 2.82E-04 Obesity (extreme) / / 21935397 rs1582922 chr5 28329573 C T 3.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs1582922 chr5 28329573 C T 2.94E-04 Obesity (extreme) / / 21935397 rs1582924 chr5 28329667 A G 7.82E-04 Obesity (extreme) / / 21935397 rs1582924 chr5 28329667 A G 9.29E-04 Iron levels / / pha002876 rs1582925 chr5 28329939 C T 7.79E-04 Obesity (extreme) / / 21935397 rs2434556 chr5 28331059 G A 3.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs2468462 chr5 28332067 C T 3.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs2468463 chr5 28332220 C G 7.75E-04 Obesity (extreme) / / 21935397 rs2434557 chr5 28332415 A G 3.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs1593900 chr5 28332671 A G,T 2.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs1593900 chr5 28332671 A G,T 2.88E-04 Obesity (extreme) / / 21935397 rs1593901 chr5 28332792 T G 3.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs1593901 chr5 28332792 T G 2.85E-04 Obesity (extreme) / / 21935397 rs1593902 chr5 28332835 T C 3.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs1593902 chr5 28332835 T C 2.82E-04 Obesity (extreme) / / 21935397 rs1593903 chr5 28332976 T G 3.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs1593903 chr5 28332976 T G 2.80E-04 Obesity (extreme) / / 21935397 rs1074316 chr5 28333188 C T 7.55E-04 Obesity (extreme) / / 21935397 rs2115179 chr5 28333878 G C 4.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs2115179 chr5 28333878 G C 2.73E-04 Obesity (extreme) / / 21935397 rs2115180 chr5 28333972 A G 3.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs2115180 chr5 28333972 A G 2.71E-04 Obesity (extreme) / / 21935397 rs2329736 chr5 28334784 C T 1.00E-05 Urinary metabolites / / 21572414 rs2329737 chr5 28334818 C T 8.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs7725564 chr5 28335477 A T 3.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs11949289 chr5 28340173 G A 2.00E-07 Response to antidepressant treatment / / 22041458 rs4867532 chr5 28345493 A G 5.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs4867532 chr5 28345493 A G 2.56E-04 Obesity (extreme) / / 21935397 rs6450614 chr5 28345603 C T 5.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs6450614 chr5 28345603 C T 2.58E-04 Obesity (extreme) / / 21935397 rs10472127 chr5 28375022 T A 5.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs10472127 chr5 28375022 T A 9.33E-04 Obesity (extreme) / / 21935397 rs4596393 chr5 28391152 C T 8.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs4266409 chr5 28489325 G A 1.59E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs10076066 chr5 28551094 T C 9.05E-04 Multiple complex diseases / / 17554300 rs10076497 chr5 28581874 T C 6.40E-06 Urinary metabolites / / 21572414 rs10074643 chr5 28584419 C T 1.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs4478333 chr5 28585628 G A 4.09E-04 Epilepsy / / 22116939 rs7727242 chr5 28615775 T C 8.90E-05 Body Mass Index / / pha003006 rs7727242 chr5 28615775 T C 7.51E-05 Waist Circumference / / pha003024 rs7727242 chr5 28615775 T C 9.27E-06 Weight / / pha003026 rs13357735 chr5 28646108 A G 8.64E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs13158740 chr5 28681311 G A 6.08E-04 White matter integrity / / 22425255 rs16897978 chr5 28696504 C A 5.00E-06 Alcohol dependence (age at onset) / / 24962325 rs11747943 chr5 28696590 A G 9.10E-06 Alcohol dependence (age at onset) / / 24962325 rs2433288 chr5 28730106 C G 5.60E-05 Breast cancer / / 21060860 rs2433288 chr5 28730106 C G 7.60E-06 Personality dimensions / / 21173776 rs2548003 chr5 28747323 G C 2.00E-07 Hip geometry / / 17903296 rs1345787 chr5 28754303 C T 1.66E-04 Breast cancer / / 21060860 rs1423298 chr5 28771898 C T 7.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs2548014 chr5 28809054 T C 1.16E-09 Narcolepsy / / 19629137 rs16898178 chr5 28815962 A C 7.81E-04 Suicide attempts in bipolar disorder / / 21041247 rs10520944 chr5 28839100 A C 7.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs17616969 chr5 28860081 A G 7.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs12523276 chr5 28887556 G A 3.45E-04 Multiple complex diseases / / 17554300 rs694336 chr5 28932369 G A 8.36E-05 Multiple complex diseases / / 17554300 rs2173972 chr5 28932390 G C 5.38E-04 Multiple complex diseases / / 17554300 rs182611 chr5 28954448 G C 5.34E-04 Multiple complex diseases / / 17554300 rs10057056 chr5 28954553 A G 1.97E-05 Multiple complex diseases / / 17554300 rs17583873 chr5 28954822 T C 7.75E-04 Suicide attempts in bipolar disorder / / 21041247 rs10520945 chr5 28977502 A T 4.20E-04 Smoking initiation / / 24665060 rs16898339 chr5 28979663 G A 5.36E-04 Multiple complex diseases / / 17554300 rs16898412 chr5 29001077 C T 3.69E-04 Multiple complex diseases / / 17554300 rs923626 chr5 29005455 A C 1.48E-04 Multiple complex diseases / / 17554300 rs16898522 chr5 29017101 G A 1.47E-04 Multiple complex diseases / / 17554300 rs16898551 chr5 29020576 A G 2.94E-12 Multiple complex diseases / / 17554300 rs488884 chr5 29040121 T G 1.00E-06 Migraine without aura / / 23793025 rs488884 chr5 29040121 T G 4.03E-05 Migraine / / 23793025 rs514676 chr5 29042479 G A 6.54E-04 Alzheimer's disease / / 17998437 rs579276 chr5 29047468 G A 5.49E-04 Alzheimer's disease / / 17998437 rs504531 chr5 29077070 G A 8.40E-04 Alzheimer's disease / / 17998437 rs824326 chr5 29077782 G A 9.45E-04 Alzheimer's disease / / 17998437 rs824329 chr5 29078099 A G 6.25E-04 Alzheimer's disease / / 17998437 rs824343 chr5 29157365 C T 8.59E-04 Alzheimer's disease / / 17998437 rs17553624 chr5 29158325 A T 6.48E-04 Type 2 diabetes / / 17463246 rs10520947 chr5 29182198 G T 7.43E-05 Blood Pressure / / pha003039 rs10520947 chr5 29182198 G T 8.23E-05 Blood Pressure / / pha003045 rs4507498 chr5 29195987 G A 2.50E-05 Urinary metabolites / / 21572414 rs10060554 chr5 29204186 G A 1.38E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7726399 chr5 29226086 C A 0.0000248 Panic disorder / / 23149450 rs7726399 chr5 29226086 C A 2.48E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs4331913 chr5 29246809 C T 3.00E-05 Breast cancer / / 17529967 rs7717683 chr5 29249544 A G 1.18E-04 Cognitive decline / / 23732972 rs6450681 chr5 29266323 C T 8.56E-04 Myopia (pathological) / / 21095009 rs3924368 chr5 29268243 T C 5.33E-04 Iron levels / / pha002876 rs75104673 chr5 29283857 T C 1.09E-05 Response to methotrexate in juvenile idiopathic arthritis / / 24709693 rs7712371 chr5 29313442 A G 1.46E-05 Magnesium levels / / pha003092 rs7444137 chr5 29313927 T C 3.52E-04 Cognitive decline / / 23732972 rs4867173 chr5 29336245 C T 4.41E-08 Multiple complex diseases / / 17554300 rs7706299 chr5 29342140 A C 4.03E-04 Myopia (pathological) / / 21095009 rs13184483 chr5 29351213 C T 7.00E-04 Myopia (pathological) / / 21095009 rs2217273 chr5 29416226 A G 6.98E-04 Myopia (pathological) / / 21095009 rs17509178 chr5 29418204 C T 5.47E-04 Myopia (pathological) / / 21095009 rs630887 chr5 29426592 T C 6.98E-04 Myopia (pathological) / / 21095009 rs676568 chr5 29434099 T C 6.33E-05 Body Mass Index / / pha003006 rs1665478 chr5 29463277 T G 7.79E-05 Serum metabolites / / 19043545 rs905860 chr5 29470186 C T 5.80E-05 Response to statin therapy / / 20339536 rs905858 chr5 29470422 G A 1.20E-04 Alzheimer's disease / / 22005930 rs905858 chr5 29470422 G A 5.75E-05 Tunica Media / / pha003036 rs905858 chr5 29470422 G A 6.94E-06 Cardiovascular disease / / pha003064 rs6880256 chr5 29478324 C T 8.68E-04 Alzheimer's disease / / 22005930 rs610436 chr5 29485353 T C 6.97E-05 Alzheimer's disease / / 22005930 rs669916 chr5 29485841 G A 1.31E-04 Alzheimer's disease / / 22005930 rs651843 chr5 29485903 A C 1.31E-04 Alzheimer's disease / / 22005930 rs607077 chr5 29495564 G A 2.07E-04 Alzheimer's disease / / 22005930 rs642717 chr5 29498754 T C 1.14E-04 Alzheimer's disease / / 22005930 rs683004 chr5 29503935 T C 4.72E-05 Alzheimer's disease / / 22005930 rs620508 chr5 29507295 C T 4.51E-05 Alzheimer's disease / / 22005930 rs629225 chr5 29507496 G A 8.88E-04 Alzheimer's disease / / 22005930 rs16899048 chr5 29507658 T G 4.40E-04 Sarcoidosis / / 19165924 rs788579 chr5 29509942 C T 4.05E-04 Smoking initiation / / 24665060 rs329882 chr5 29513178 A G 7.34E-04 Depression (quantitative trait) / / 20800221 rs624343 chr5 29515854 C T 3.22E-04 Depression (quantitative trait) / / 20800221 rs636643 chr5 29518942 G A 4.08E-04 Depression (quantitative trait) / / 20800221 rs788542 chr5 29520477 C G 2.75E-04 Depression (quantitative trait) / / 20800221 rs182778 chr5 29550404 T C 8.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs10073723 chr5 29557328 A C 1.86E-05 Alzheimer's disease / / 17998437 rs6865142 chr5 29583131 G T 9.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs10472704 chr5 29585062 C T 3.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs16899175 chr5 29585422 G A 1.44E-04 Multiple complex diseases / / 17554300 rs4559004 chr5 29585580 G T 3.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs7726881 chr5 29585613 G A 9.74E-04 Alzheimer's disease / / 17998437 rs7726881 chr5 29585613 G A 3.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs4364395 chr5 29587901 A G 2.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs6450694 chr5 29593075 A G 9.37E-05 ldl cholesterol / / pha003076 rs10074734 chr5 29596752 T C 3.60E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4331915 chr5 29604899 A G 4.20E-04 Response to antidepressants / / 19736353 rs4331915 chr5 29604899 A G 2.14E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4331915 chr5 29604899 A G 1.76E-05 Elbow pain / / pha003008 rs4288125 chr5 29606615 G A 7.15E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4397141 chr5 29611889 C T 3.02E-06 Parkinson's disease / / 21738487 rs17573102 chr5 29635164 G A 9.82E-04 Multiple complex diseases / / 17554300 rs2330264 chr5 29649703 G A 1.88E-05 Waist-Hip Ratio / / pha003013 rs2330264 chr5 29649703 G A 4.16E-05 Waist-Hip Ratio / / pha003028 rs3114569 chr5 29670567 T G 9.73E-04 Multiple complex diseases / / 17554300 rs2124721 chr5 29671461 T C 2.26E-05 Waist-Hip Ratio / / pha003013 rs2124721 chr5 29671461 T C 3.88E-05 Waist-Hip Ratio / / pha003028 rs6862977 chr5 29675879 C A 0.000009323 Sarcoidosis / / 22952805 rs10940806 chr5 29676824 A C 0.000009323 Sarcoidosis / / 22952805 rs3100989 chr5 29676860 A T 6.47E-04 Multiple complex diseases / / 17554300 rs11738288 chr5 29680345 T C 0.000008816 Sarcoidosis / / 22952805 rs10940808 chr5 29681472 G A 0.000007991 Sarcoidosis / / 22952805 rs10940810 chr5 29684371 T A 0.00002981 Sarcoidosis / / 22952805 rs7735264 chr5 29687497 A G 0.00001735 Sarcoidosis / / 22952805 rs35331385 chr5 29694347 T A 0.0000257 Sarcoidosis / / 22952805 rs10461870 chr5 29697762 G A 0.00004473 Sarcoidosis / / 22952805 rs11750532 chr5 29703931 T C 0.00002212 Sarcoidosis / / 22952805 rs12187620 chr5 29711970 A G 0.00004156 Sarcoidosis / / 22952805 rs3100963 chr5 29715664 A G 4.25E-04 Obesity (extreme) / / 21935397 rs13153028 chr5 29731636 C T 6.99E-05 ldl cholesterol / / pha003076 rs6876965 chr5 29756538 A G 7.21E-04 Tourette syndrome / / 22889924 rs9292340 chr5 29761861 C T 5.19E-05 Hirschsprung's disease / / 19196962 rs16899370 chr5 29773999 T G 1.73E-05 Hirschsprung's disease / / 19196962 rs4597986 chr5 29794387 A G 2.20E-06 Urinary metabolites / / 21572414 rs4597986 chr5 29794387 A G 4.25E-07 Schizophrenia / / 21926974 rs7709002 chr5 29831967 C T 9.44E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs10940827 chr5 29849609 C T 2.37E-05 Hirschsprung's disease / / 19196962 rs7712093 chr5 29850762 C G 1.70E-05 Urinary metabolites / / 21572414 rs10035947 chr5 29855627 C G 5.11E-04 Type 2 diabetes / / 17463246 rs4867222 chr5 29879015 A G 8.17E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs2288448 chr5 29882284 G A 1.60E-05 Urinary metabolites / / 21572414 rs17579256 chr5 29883007 T G 9.84E-04 Coronary heart disease / / 21606135 rs9292347 chr5 29884436 C T 1.00E-05 Urinary metabolites / / 21572414 rs2972794 chr5 29950471 A G 1.43E-05 Type 2 diabetes / / 17463246 rs2198175 chr5 29955646 G A 1.17E-05 Type 2 diabetes / / 17463246 rs13157231 chr5 29955859 A G 3.01E-04 Insulin resistance / / 21901158 rs17431464 chr5 29955960 A G 3.97E-04 Insulin resistance / / 21901158 rs1868963 chr5 29969866 C A 5.39E-04 Insulin resistance / / 21901158 rs4867023 chr5 29971508 G T 3.15E-04 Insulin resistance / / 21901158 rs7443690 chr5 29994909 G A 6.04E-05 Alzheimer's disease / / 24755620 rs17431811 chr5 30028447 G A 9.82E-04 Type 2 diabetes / / 17463246 rs16899782 chr5 30028462 C G,T 1.30E-05 Multiple complex diseases / / 17554300 rs7711039 chr5 30032816 G A 9.76E-05 Cholesterol / / pha003073 rs7711039 chr5 30032816 G A 4.88E-05 ldl cholesterol / / pha003076 rs7711039 chr5 30032816 G A 6.02E-05 Lipoproteins / / pha003079 rs2218892 chr5 30044759 C T 5.20E-05 Cholesterol / / pha003073 rs2218892 chr5 30044759 C T 4.45E-05 ldl cholesterol / / pha003076 rs2218892 chr5 30044759 C T 6.05E-05 Cholesterol / / pha003078 rs2218892 chr5 30044759 C T 6.52E-05 Lipoproteins / / pha003079 rs10755244 chr5 30070180 C G 5.26E-05 Suicide attempts in bipolar disorder / / 21423239 rs4867249 chr5 30084605 T C 7.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs10063305 chr5 30089279 A G 2.74E-05 Type 2 diabetes / / 17463246 rs10940870 chr5 30093584 T C 9.20E-04 Multiple complex diseases / / 17554300 rs10044555 chr5 30125447 A C 5.32E-05 Cognitive test performance / / 20125193 rs4391181 chr5 30137225 G A 4.21E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4529208 chr5 30145212 T C 2.40E-04 Alzheimer's disease / / 24755620 rs13154270 chr5 30148855 A G 2.14E-04 Alzheimer's disease / / 24755620 rs13178362 chr5 30179013 T C 7.00E-07 Alzheimer's disease / / 24755620 rs11749859 chr5 30180440 T C 7.02E-04 Alzheimer's disease / / 24755620 rs4134393 chr5 30190699 A G 6.08E-04 Alzheimer's disease / / 24755620 rs13177282 chr5 30207798 G A 1.71E-05 Alzheimer's disease / / 24755620 rs17652083 chr5 30218112 A G 1.07E-04 Multiple complex diseases / / 17554300 rs4403185 chr5 30218153 A G 7.00E-04 Alzheimer's disease / / 24755620 rs4446473 chr5 30226419 A G 4.94E-04 Multiple complex diseases / / 17554300 rs4446473 chr5 30226419 A G 3.48E-04 Alzheimer's disease / / 24755620 rs11743010 chr5 30231724 C T 1.15E-04 Multiple complex diseases / / 17554300 rs4295402 chr5 30242594 G A 1.70E-05 Prostate cancer / / pha002878 rs7700615 chr5 30267158 A T 1.96E-04 Multiple complex diseases / / 17554300 rs6862488 chr5 30274160 T C 2.97E-04 Multiple complex diseases / / 17554300 rs10071127 chr5 30302035 T A 6.56E-04 Multiple complex diseases / / 17554300 rs10053256 chr5 30343289 T G 9.11E-04 Multiple complex diseases / / 17554300 rs10805543 chr5 30356073 G A 1.95E-04 Multiple complex diseases / / 17554300 rs12654311 chr5 30395852 G A 5.17E-05 Alzheimer's disease / / 24755620 rs4131884 chr5 30434848 T G 7.36E-05 Cognitive impairment induced by topiramate / / 22091778 rs4131884 chr5 30434848 T G 0.000036 Tuberculosis with late age of onset / / 22551897 rs4867280 chr5 30639282 G A 7.29E-04 Smoking quantity / / 24665060 rs9292394 chr5 30661573 G T 2.00E-06 Emphysema-related traits / / 20709820 rs7736249 chr5 30668491 C T 3.51E-04 Alzheimer's disease / / 24755620 rs10472747 chr5 30671988 T G 3.71E-04 Alzheimer's disease / / 24755620 rs9283723 chr5 30787271 T G 3.27E-04 Bipolar disorder / / 19259986 rs7704589 chr5 30792526 G A 3.76E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1500210 chr5 30793659 A G 3.76E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs11744440 chr5 30810514 A G 5.90E-04 Alzheimer's disease / / 17998437 rs2178491 chr5 30829677 T C 3.16E-04 Alzheimer's disease / / 17998437 rs12652364 chr5 30836079 G A 6.00E-07 Response to methotrexate in juvenile idiopathic arthritis / / 24709693 rs12173144 chr5 30851050 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10520976 chr5 30857762 G C 2.50E-05 Bipolar disorder / / 19259986 rs1921110 chr5 30867556 A T 8.34E-04 Multiple complex diseases / / 17554300 rs7708718 chr5 30880852 A G 1.97E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7708718 chr5 30880852 A G 0.000739 Salmonella-induced pyroptosis / / 22837397 rs1921093 chr5 30884070 T C 8.91E-05 Serum metabolites / / 19043545 rs6870943 chr5 30899448 A T 2.09E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6871087 chr5 30899517 A G 1.00E-06 Response to angiotensin II receptor blocker therapy / / 22566498 rs1276198 chr5 30922027 G A 5.90E-04 Myocardial Infarction / / pha002873 rs1276198 chr5 30922027 G A 5.68E-05 Calcium levels / / pha003085 rs1546251 chr5 30923858 C G 5.03E-05 Serum metabolites / / 19043545 rs12374429 chr5 30936245 G A 2.22E-04 Acute lung injury / / 22295056 rs4867297 chr5 31000116 T C 8.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs980147 chr5 31000743 A G 4.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs1500167 chr5 31001737 C G 5.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs2133753 chr5 31002440 T C 5.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs4394136 chr5 31004966 A G 5.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs6450821 chr5 31012050 A G 5.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs10055379 chr5 31013713 C T 7.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs6450822 chr5 31016217 C G 5.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs6866365 chr5 31016713 G A 5.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs6888304 chr5 31020521 A G 1.00E-09 Liver enzyme levels (gamma-glutamyl transferase) / / 22001757 rs13185432 chr5 31022780 A C 9.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs7706684 chr5 31023727 G A 9.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs41479545 chr5 31052177 T C 7.42E-04 Type 2 diabetes / / 17463246 rs36003087 chr5 31053384 A C 6.65E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13162806 chr5 31058626 G A 4.80E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs6872040 chr5 31075755 A G 3.12E-05 Parkinson's disease (motor and cognition) / / 22658654 rs6881843 chr5 31080763 T G 1.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs6881843 chr5 31080763 T G 6.70E-04 Prostate cancer / / 23023329 rs10065647 chr5 31081857 A T 5.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs9292420 chr5 31084270 G T 4.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs6450826 chr5 31088572 G A 2.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs13355548 chr5 31089349 G A 1.14E-06 Mathematical ability / / 24801482 rs11743965 chr5 31089694 T C 4.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs7724054 chr5 31102469 A G 5.62E-04 Multiple complex diseases / / 17554300 rs16900696 chr5 31113414 C G 7.12E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs6450831 chr5 31121250 G A 9.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs4602638 chr5 31122961 T A 6.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs12697252 chr5 31129429 A G 8.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs13165994 chr5 31131887 C T 5.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs6870556 chr5 31134837 G A 2.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs4266413 chr5 31136051 C T 3.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs7721702 chr5 31136848 G C 3.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs12517009 chr5 31137136 T A 3.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs4867313 chr5 31144641 G A 1.20E-05 Urinary metabolites / / 21572414 rs11749974 chr5 31147634 A T 5.60E-06 Urinary metabolites / / 21572414 rs4516871 chr5 31177628 C T 1.24E-04 Sudden cardiac arrest / / 21658281 rs7716554 chr5 31200936 G A 8.27E-04 Alcohol dependence CDH6 intron 21314694 rs4457092 chr5 31235230 A C 1.55E-05 Parkinson's disease CDH6 intron 21044948 rs4072916 chr5 31237336 G A 6.52E-04 Multiple complex diseases CDH6 intron 17554300 rs4072916 chr5 31237336 G A 5.67E-05 Parkinson's disease CDH6 intron 21044948 rs6884544 chr5 31250588 A G 4.33E-04 Alcohol consumption (maxi-drinks) CDH6 intron 24277619 rs13186740 chr5 31250964 C T 0.000463 Salmonella-induced pyroptosis CDH6 intron 22837397 rs9637776 chr5 31279305 G A 5.40E-05 Pericardial fat CDH6 intron 22589742 rs2287582 chr5 31302288 C T 7.60E-04 Urinary metabolites CDH6 cds-synon 21572414 rs2287581 chr5 31305265 C T 2.32E-05 Creatinine levels CDH6 intron pha003069 rs2962787 chr5 31308581 G A 9.00E-04 Urinary metabolites CDH6 intron 21572414 rs2017469 chr5 31314216 T A 6.80E-04 Urinary metabolites CDH6 intron 21572414 rs2909569 chr5 31315377 C T 6.60E-04 Urinary metabolites CDH6 intron 21572414 rs2962788 chr5 31316876 T G 6.70E-04 Urinary metabolites CDH6 intron 21572414 rs2302904 chr5 31317494 C T 6.70E-04 Urinary metabolites CDH6 cds-synon 21572414 rs2302903 chr5 31317529 A G 7.40E-04 Urinary metabolites CDH6 cds-synon 21572414 rs2229575 chr5 31317952 T C 7.20E-04 Urinary metabolites CDH6 cds-synon 21572414 rs2909570 chr5 31318405 G T 6.70E-04 Urinary metabolites CDH6 intron 21572414 rs2909571 chr5 31318594 C T 6.70E-04 Urinary metabolites CDH6 intron 21572414 rs1566618 chr5 31319072 T C 6.80E-04 Urinary metabolites CDH6 intron 21572414 rs1318821 chr5 31319179 G A 6.70E-04 Urinary metabolites CDH6 intron 21572414 rs2962789 chr5 31320142 T C 7.20E-04 Urinary metabolites CDH6 intron 21572414 rs655619 chr5 31320475 A G 7.40E-04 Urinary metabolites CDH6 intron 21572414 rs639386 chr5 31321812 A G 5.57E-04 Multiple complex diseases CDH6 intron 17554300 rs518451 chr5 31335274 T C 7.42E-05 Creatinine levels / / pha003069 rs2047723 chr5 31342174 A G 6.37E-04 Smoking cessation / / 24665060 rs12188662 chr5 31345259 A G 1.50E-06 Calcium levels / / pha003085 rs7733250 chr5 31352576 A C 2.62E-05 Creatinine levels / / pha003069 rs16901030 chr5 31370518 C A 2.74E-04 Multiple complex diseases / / 17554300 rs12188067 chr5 31370759 G T 6.94E-05 Obesity (extreme) / / 21935397 rs6872363 chr5 31373300 A T 2.73E-05 Obesity (extreme) / / 21935397 rs13175906 chr5 31373920 G A 2.71E-05 Obesity (extreme) / / 21935397 rs10940946 chr5 31374653 T A 2.46E-05 Obesity (extreme) / / 21935397 rs13186629 chr5 31376053 C T 2.21E-05 Obesity (extreme) / / 21935397 rs13186629 chr5 31376053 C T 8.76E-04 Iron levels / / pha002876 rs10940948 chr5 31376487 G T 2.61E-05 Obesity (extreme) / / 21935397 rs7717134 chr5 31377123 C T 5.69E-05 Obesity (extreme) / / 21935397 rs17482570 chr5 31378026 A T 6.03E-05 Obesity (extreme) / / 21935397 rs6883386 chr5 31378528 A G 1.04E-04 Obesity (extreme) / / 21935397 rs5015013 chr5 31378849 A T 4.72E-05 Obesity (extreme) / / 21935397 rs5015009 chr5 31379042 C G 1.19E-04 Obesity (extreme) / / 21935397 rs5015008 chr5 31379058 C A 1.21E-04 Obesity (extreme) / / 21935397 rs12652221 chr5 31379771 T C 6.51E-04 Obesity (extreme) / / 21935397 rs12652698 chr5 31380090 T C 6.79E-04 Obesity (extreme) / / 21935397 rs6876179 chr5 31380674 T C 7.04E-04 Obesity (extreme) / / 21935397 rs6895674 chr5 31380739 G A 7.21E-04 Obesity (extreme) / / 21935397 rs576070 chr5 31385490 G T 2.44E-05 Body Mass Index / / pha003009 rs550517 chr5 31385936 A C 9.56E-04 Obesity (extreme) / / 21935397 rs16901064 chr5 31386997 C A 7.80E-06 White matter hyperintensity burden / / 21681796 rs16901064 chr5 31386997 C A 8.74E-04 Myocardial Infarction / / pha002883 rs16901064 chr5 31386997 C A 3.36E-05 Body Mass Index / / pha003009 rs12189086 chr5 31387598 A C 8.20E-06 White matter hyperintensity burden / / 21681796 rs7714912 chr5 31388980 C T 9.60E-06 White matter hyperintensity burden / / 21681796 rs3805521 chr5 31410306 C T 7.36E-04 Premature ovarian failure DROSHA intron 19508998 rs615344 chr5 31425788 G T 7.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DROSHA intron 20877124 rs17409275 chr5 31514127 C T 1.19E-05 Chronic Hepatitis C infection DROSHA intron 21725309 rs17409275 chr5 31514127 C T 2.16E-05 Lung function (forced vital capacity) DROSHA intron pha003104 rs250834 chr5 31602210 C T 5.42E-04 Intracranial aneurysm / / 20613766 rs185258 chr5 31633251 C T 8.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs183711 chr5 31638475 T G 6.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs805231 chr5 31646857 A G 1.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs805231 chr5 31646857 A G 4.99E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9292436 chr5 31647977 G A 4.78E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs10071670 chr5 31649538 A G 4.81E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs40262 chr5 31664465 A C 1.08E-04 Coronary Artery Disease / / 17634449 rs16901423 chr5 31679344 T C 1.70E-05 Urinary metabolites / / 21572414 rs17413207 chr5 31681041 G A 6.11E-04 Coronary Artery Disease / / 17634449 rs1531618 chr5 31682155 G T 2.80E-04 Parkinson's disease / / 17052657 rs6874845 chr5 31690559 G A 5.60E-08 Urinary metabolites / / 21572414 rs4867370 chr5 31690794 C G 8.10E-08 Urinary metabolites / / 21572414 rs390961 chr5 31713076 T C 7.05E-05 Cognitive decline / / 22054870 rs253922 chr5 31723260 C T 3.03E-04 Nicotine dependence / / 17158188 rs6879013 chr5 31751061 A T 1.07E-04 Body mass index / / 21701565 rs6879013 chr5 31751061 A T 1.28E-04 Body mass index / / 21701565 rs7707027 chr5 31761519 A G 5.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2059865 chr5 31766433 T A 3.00E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs10461903 chr5 31766703 T C 5.99E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs16901541 chr5 31767650 T C 5.91E-04 Aortic root size / / 21223598 rs16901543 chr5 31769180 G A 5.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs16901545 chr5 31770263 G A 4.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs34884728 chr5 31781647 G A 4.33E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs7707966 chr5 31789679 C T 5.10E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs6870534 chr5 31795384 A T 1.75E-05 Serum metabolites / / 19043545 rs17507185 chr5 31802554 G A 5.40E-04 Alzheimer's disease PDZD2 intron 24755620 rs7731219 chr5 31804573 A G 9.88E-04 Alcohol dependence PDZD2 intron 21314694 rs13182171 chr5 31812179 A C 8.02E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) PDZD2 intron 24528284 rs34301697 chr5 31813639 A G 8.42E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) PDZD2 intron 24528284 rs4867084 chr5 31818948 G A 4.00E-05 Asthma (aspirin-intolerant) PDZD2 intron 21072201 rs4867084 chr5 31818948 G A 6.51E-04 Alcohol dependence PDZD2 intron 21314694 rs10042146 chr5 31833816 A G 9.21E-05 Orofacial clefts PDZD2 intron 22419666 rs6874198 chr5 31838491 A G 2.81E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) PDZD2 intron 23648065 rs7710487 chr5 31853188 T G 5.78E-05 Cognitive test performance PDZD2 intron 20125193 rs6882892 chr5 31872998 T G 0.0000945 Panic disorder PDZD2 intron 23149450 rs6882892 chr5 31872998 T G 9.45E-05 Serum tamsulosin hydrochloride concentration PDZD2 intron 23151678 rs12519922 chr5 31891018 G C 7.91E-06 Serum metabolites PDZD2 intron 19043545 rs11957407 chr5 31917242 G A 3.00E-06 Bipolar disorder (body mass index interaction) PDZD2 intron 24322204 rs35888615 chr5 31924212 G A 7.80E-04 Urinary metabolites PDZD2 intron 21572414 rs9292449 chr5 31925190 A C 4.03E-04 Type 2 diabetes PDZD2 intron 17463246 rs6450876 chr5 31925423 A G 5.39E-04 Type 2 diabetes PDZD2 intron 17463246 rs7719829 chr5 31927317 A G 4.00E-06 Obesity-related traits PDZD2 intron 23251661 rs7719829 chr5 31927317 A G 4.62E-04 Lung function (forced expiratory volume in 1 second) PDZD2 intron 24023788 rs4867405 chr5 31944975 G A 2.00E-05 Response to taxane treatment (placlitaxel) PDZD2 intron 23006423 rs7724279 chr5 31957885 A G 3.04E-04 Response to taxane treatment (placlitaxel) PDZD2 intron 23006423 rs7726919 chr5 31967192 T G 9.47E-04 Response to taxane treatment (placlitaxel) PDZD2 intron 23006423 rs12110008 chr5 31969830 C T 3.32E-04 Alzheimer's disease (late onset) PDZD2 intron 21379329 rs12186888 chr5 31974510 C T 9.54E-04 Amyotrophic Lateral Sclerosis PDZD2 intron 17362836 rs12186888 chr5 31974510 C T 8.60E-05 Monocyte counts PDZD2 intron pha003089 rs6450883 chr5 31980113 G T 9.26E-04 Methotrexate clearance (acute lymphoblastic leukemia) PDZD2 intron 23233662 rs6450884 chr5 31980161 C T 9.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) PDZD2 intron 23233662 rs13179903 chr5 31982574 G A 7.20E-04 Urinary metabolites PDZD2 intron 21572414 rs6878827 chr5 31988389 T G 4.89E-06 Type 2 diabetes PDZD2 intron 17463246 rs6861526 chr5 31992572 T C 2.97E-04 Multiple complex diseases PDZD2 intron 17554300 rs6861526 chr5 31992572 T C 1.51E-04 Multiple sclerosis PDZD2 intron 17660530 rs10054504 chr5 32000483 T C 4.00E-06 Urinary metabolites PDZD2 intron 21572414 rs10054504 chr5 32000483 T C 1.11E-04 White matter integrity PDZD2 intron 22425255 rs10054504 chr5 32000483 T C 8.00E-07 Renal cell carcinoma PDZD2 intron 23184150 rs4867100 chr5 32007713 C T 7.00E-06 Urinary metabolites PDZD2 intron 21572414 rs1532269 chr5 32018841 C G 7.11E-04 Response to TNF antagonist treatment PDZD2 intron 21061259 rs10039073 chr5 32042760 G A 5.46E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) PDZD2 intron 24023788 rs323827 chr5 32044573 G A 8.64E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) PDZD2 intron 24023788 rs422224 chr5 32049293 G C 1.39E-04 Multiple complex diseases PDZD2 intron 17554300 rs17433352 chr5 32049787 C T 7.60E-04 Multiple complex diseases PDZD2 intron 17554300 rs328620 chr5 32050651 C G 2.02E-04 Obesity (extreme) PDZD2 intron 21935397 rs161535 chr5 32053321 C T 3.72E-05 Body mass index PDZD2 intron 17255346 rs161533 chr5 32056026 C T 8.33E-05 Body mass index PDZD2 intron 17255346 rs157500 chr5 32060695 C T 3.65E-05 White matter integrity PDZD2 intron 22425255 rs11955676 chr5 32061570 C T 3.60E-05 Information processing speed PDZD2 intron 21130836 rs12110295 chr5 32062984 T G 4.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDZD2 intron 20877124 rs12110295 chr5 32062984 T G 5.42E-05 White matter integrity PDZD2 intron 22425255 rs12054657 chr5 32067373 G A 3.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDZD2 intron 20877124 rs10065850 chr5 32067398 A G 6.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDZD2 intron 20877124 rs283129 chr5 32067671 T C 1.83E-05 Glucose levels PDZD2 intron pha003061 rs6862076 chr5 32069910 T C 4.01E-04 Insulin resistance PDZD2 intron 21901158 rs3797064 chr5 32072213 A C 8.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDZD2 intron 20877124 rs4867417 chr5 32076782 A G 7.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDZD2 intron 20877124 rs4867417 chr5 32076782 A G 8.93E-05 White matter integrity PDZD2 intron 22425255 rs157494 chr5 32087228 C T 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes PDZD2 intron 22628534 rs3101878 chr5 32087326 C A 4.20E-04 Urinary metabolites PDZD2 missense 21572414 rs3135427 chr5 32087430 G A 1.90E-04 Urinary metabolites PDZD2 cds-synon 21572414 rs3101873 chr5 32088500 C T 1.40E-04 Urinary metabolites PDZD2 missense 21572414 rs336517 chr5 32179888 A G 7.00E-04 Body mass index / / 21701565 rs12697267 chr5 32196389 G A 5.12E-04 Multiple complex diseases / / 17554300 rs10063369 chr5 32210617 T G 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs8180531 chr5 32215515 T C 2.89E-04 Alcohol dependence / / 20201924 rs11745268 chr5 32221259 C T 3.17E-05 Coronary heart disease / / pha003055 rs11738821 chr5 32221465 A C,G 3.09E-05 Coronary heart disease / / pha003055 rs1873921 chr5 32229677 G A 1.63E-05 Serum metabolites MTMR12 UTR-3 19043545 rs4078204 chr5 32275467 G A 1.28E-04 Alcohol dependence MTMR12 intron 20201924 rs4867424 chr5 32295574 C T 3.61E-04 Response to statin treatment (atorvastatin),change in cholesterol levels MTMR12 intron 20031582 rs641221 chr5 32439324 A G 7.56E-04 Alcohol dependence ZFR intron 21314694 rs10520999 chr5 32462753 C T 4.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs647684 chr5 32464300 A G 2.90E-05 Urinary metabolites / / 21572414 rs659803 chr5 32471615 T A 1.39E-04 Multiple complex diseases / / 17554300 rs678978 chr5 32512876 G A 5.38E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1008023 chr5 32525644 C A 7.38E-05 Cognitive performance / / 19734545 rs10078887 chr5 32538313 G T 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs10941010 chr5 32561800 C T 3.39E-05 Alcohol consumption / / 23743675 rs7726475 chr5 32575914 G A 1.70E-04 Blood pressure / / 21422096 rs7726475 chr5 32575914 G A 2.17E-07 Blood pressure / / 21422096 rs7726475 chr5 32575914 G A 2.29E-04 Blood pressure / / 21422096 rs7726475 chr5 32575914 G A 6.28E-07 Blood pressure / / 21422096 rs6860505 chr5 32647457 T C 2.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4867116 chr5 32651271 G A 5.45E-04 Bipolar disorder,schizoaffective / / 19567891 rs4102432 chr5 32654035 C G 9.17E-05 Coronary Artery Disease / / 17634449 rs1862523 chr5 32670800 C T 4.61E-05 Cardiovascular disease / / 22029572 rs6450922 chr5 32689718 C G 1.00E-10 Height / / 23563607 rs7729447 chr5 32689773 G A 3.00E-06 Blood pressure / / 24954895 rs1421811 chr5 32714270 C G 1.90E-06 Height NPR3 intron 21194676 rs1421811 chr5 32714270 C G 1.07E-05 Blood pressure NPR3 intron 22100073 rs1421811 chr5 32714270 C G 2.36E-06 Blood pressure NPR3 intron 22100073 rs1421811 chr5 32714270 C G 3.40E-07 Blood pressure NPR3 intron 22100073 rs1421811 chr5 32714270 C G 4.80E-07 Blood pressure NPR3 intron 22100073 rs1421811 chr5 32714270 C G 7.39E-05 Blood pressure NPR3 intron 22100073 rs1421811 chr5 32714270 C G 2.00E-07 Blood pressure NPR3 intron 24954895 rs10062135 chr5 32738539 C T 0.0000785 Menopause (age at onset) NPR3 intron 23424626 rs10061804 chr5 32748637 G A 1.00E-06 Ovarian reserve NPR3 intron 22116950 rs9292467 chr5 32764572 A G 2.15E-05 Multiple complex diseases NPR3 intron 17554300 rs3811966 chr5 32766822 T C 4.38E-04 Suicide,with and without major depression NPR3 intron 22059935 rs3792752 chr5 32768634 A G 7.00E-10 Height NPR3 intron 20881960 rs11740452 chr5 32770750 G A 6.65E-05 Schizophrenia(age at onset) NPR3 intron 21688384 rs1173736 chr5 32771938 A G 1.20E-05 Height NPR3 intron 21194676 rs1173736 chr5 32771938 A G 1.20E-07 Height NPR3 intron 21194676 rs1173736 chr5 32771938 A G 7.30E-12 Height NPR3 intron 21194676 rs3792751 chr5 32773314 C T 9.69E-04 Amyotrophic Lateral Sclerosis NPR3 intron 17827064 rs1173756 chr5 32789852 T C 6.85E-09 Blood pressure NPR3 UTR-3 21909110 rs1173766 chr5 32804528 T C 1.00E-07 Blood pressure / / 21572416 rs1173766 chr5 32804528 T C 2.00E-08 Blood pressure / / 21572416 rs1173771 chr5 32815028 A G 4.00E-09 Blood pressure / / 21909110 rs1173771 chr5 32815028 A G 5.00E-09 Blood pressure / / 21909110 rs1173771 chr5 32815028 A G 2.00E-16 Systolic blood pressure / / 21909115 rs1173771 chr5 32815028 A G 3.00E-10 Hypertension / / 21909115 rs1173771 chr5 32815028 A G 9.00E-12 Diastolic blood pressure / / 21909115 rs1158645 chr5 32817515 A T 2.70E-05 Urinary metabolites / / 21572414 rs9292468 chr5 32819073 T C 2.00E-16 Height / / 23563607 rs7733331 chr5 32828846 T C 3.89E-05 Serum metabolites / / 19043545 rs1173727 chr5 32830521 T C 2.00E-21 Height / / 20881960 rs1183395 chr5 32846818 A C,T 7.50E-04 Type 2 diabetes / / 17463246 rs745798 chr5 32852037 T A,C,G 3.86E-05 Self-reported allergy / / 23817569 rs1472261 chr5 32887610 G A 5.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10472828 chr5 32888818 C T 1.69E-04 Height / / 17255346 rs10472828 chr5 32888818 C T 3.00E-07 Height / / 19343178 rs10472828 chr5 32888818 C T 3.00E-07 Height / / 19570815 rs2331101 chr5 32889284 C T 2.44E-04 Longevity / / 22279548 rs17447868 chr5 32905619 T C 9.88E-04 Stroke / / pha002886 rs6899228 chr5 32909367 G A 1.24E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10079889 chr5 32975490 A G 1.38E-05 Corneal astigmatism / / 23761726 rs4076512 chr5 33023138 T C 1.20E-04 Height / / 21998595 rs10055961 chr5 33071575 G T 3.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs16890712 chr5 33082366 T G 8.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7712171 chr5 33104956 A C 5.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6894272 chr5 33114638 C T 3.83E-08 Multiple complex diseases / / 17554300 rs6894272 chr5 33114638 C T 8.14E-05 Blood Pressure / / pha003050 rs6894272 chr5 33114638 C T 9.94E-05 Creatinine levels / / pha003069 rs10472219 chr5 33139773 T G 7.95E-04 Multiple complex diseases / / 17554300 rs9292482 chr5 33140667 C T 8.31E-04 Multiple complex diseases / / 17554300 rs9292484 chr5 33153247 T A 6.43E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4547940 chr5 33176114 C T 2.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs10041417 chr5 33182745 C T 2.58E-05 Reading disability and language impairment / / 24024963 rs5011173 chr5 33194967 G T 4.82E-04 Parkinson's disease / / 16252231 rs7702091 chr5 33198330 C T 9.48E-05 Kawasaki disease / / 22446961 rs6450967 chr5 33234059 G A 9.36E-04 Parkinson's disease / / 16252231 rs7728935 chr5 33291123 G C 5.80E-05 Personality dimensions / / 18957941 rs16890948 chr5 33299468 T C 1.96E-05 Multiple complex diseases / / 17554300 rs6896697 chr5 33330807 T C 5.16E-05 Personality dimensions / / 18957941 rs268731 chr5 33364684 C T 5.80E-05 Triglycerides / / 19074352 rs268706 chr5 33405597 G A 3.38E-04 Stroke / / pha002887 rs3777074 chr5 33463111 T G 2.27E-04 Blood pressure TARS intron 17255346 rs4867522 chr5 33518227 G A 7.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10941060 chr5 33522078 T C 7.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10941060 chr5 33522078 T C 3.74E-04 Body mass index / / 21701565 rs10941060 chr5 33522078 T C 3.80E-04 Body mass index / / 21701565 rs16891281 chr5 33527307 A G 1.43E-04 Multiple complex diseases ADAMTS12 missense 17554300 rs10521004 chr5 33529263 T C 3.20E-04 Type 2 diabetes and 6 quantitative traits ADAMTS12 intron 17848626 rs256651 chr5 33578470 C T 0.000217489 Hypertension (early onset hypertension) ADAMTS12 intron 22479346 rs6882270 chr5 33590968 C A 5.59E-04 Type 2 diabetes ADAMTS12 intron 17463246 rs10521006 chr5 33602891 G C 1.12E-04 Fibrinogen ADAMTS12 intron 17255346 rs12520271 chr5 33615552 A G 4.29E-04 Fibrinogen ADAMTS12 intron 17255346 rs7703871 chr5 33620887 T C 7.18E-06 Telomere length ADAMTS12 intron 21573004 rs4242077 chr5 33628345 T A 8.67E-04 Parkinson's disease ADAMTS12 intron 17052657 rs4337859 chr5 33631739 C A 6.53E-05 Prion diseases ADAMTS12 intron 22210626 rs6868223 chr5 33636594 G A 6.27E-04 Type 2 diabetes ADAMTS12 intron 17463246 rs6868223 chr5 33636594 G A 2.00E-06 Heart failure ADAMTS12 intron 20400778 rs4263503 chr5 33638872 T A 4.62E-04 Type 2 diabetes ADAMTS12 intron 17463246 rs3935844 chr5 33639682 G A 5.86E-04 Type 2 diabetes ADAMTS12 intron 17463246 rs12188318 chr5 33667602 C T 7.72E-04 Suicide attempts in bipolar disorder ADAMTS12 intron 21423239 rs4866362 chr5 33690120 G A 5.99E-04 Premature ovarian failure ADAMTS12 intron 19508998 rs2877318 chr5 33718160 T G 2.78E-05 Serum metabolites ADAMTS12 intron 19043545 rs7719861 chr5 33784613 A C 2.56E-05 Serum metabolites ADAMTS12 intron 19043545 rs895367 chr5 33816433 T C 2.65E-04 Smoking initiation ADAMTS12 intron 24665060 rs2548032 chr5 33820448 T C 7.05E-05 Serum metabolites ADAMTS12 intron 19043545 rs11749356 chr5 33824254 A G 2.81E-04 Smoking initiation ADAMTS12 intron 24665060 rs977842 chr5 33828203 G A 1.70E-05 Urinary metabolites ADAMTS12 intron 21572414 rs977842 chr5 33828203 G A 4.62E-05 Nephrolithiasis ADAMTS12 intron 22396660 rs1423300 chr5 33832433 G A 6.60E-04 Response to cytidine analogues (gemcitabine) ADAMTS12 intron 24483146 rs2910639 chr5 33856307 A G 1.97E-05 Multiple complex diseases ADAMTS12 intron 17554300 rs1030240 chr5 33871768 T C 2.02E-05 Multiple complex diseases ADAMTS12 intron 17554300 rs1030240 chr5 33871768 T C 4.81E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ADAMTS12 intron 22566498 rs13160471 chr5 33878205 C T 2.66E-04 Type 2 diabetes ADAMTS12 intron 17463246 rs1364044 chr5 33879792 C T 3.00E-06 Stroke (pediatric) ADAMTS12 intron 22990015 rs4866399 chr5 33887419 G A 3.16E-04 Type 2 diabetes ADAMTS12 intron 17463246 rs4866399 chr5 33887419 G A 9.74E-04 Lymphocyte counts ADAMTS12 intron 22286170 rs10521009 chr5 33894764 G A 4.57E-08 Metabolite levels / / 23281178 rs42868 chr5 33936076 C G 6.53E-05 Alzheimer's disease / / 22832961 rs35405 chr5 33945758 C T 7.82E-04 Nicotine smoking SLC45A2 intron 19268276 rs35394 chr5 33948319 T C 1.41E-10 Common traits (Other) SLC45A2 intron 20585627 rs40132 chr5 33950703 A G 1.40E-09 Tanning SLC45A2 intron 19340012 rs40132 chr5 33950703 A G 2.24E-10 Common traits (Other) SLC45A2 intron 20585627 rs35397 chr5 33951116 G T 1.40E-05 Height SLC45A2 intron 21998595 rs16891982 chr5 33951693 C G 3.00E-11 Skin pigmentation / / 17999355 rs16891982 chr5 33951693 C G 1.00E-12 Eye color / / 20585627 rs16891982 chr5 33951693 C G 4.00E-20 Hair color / / 20585627 rs35398 chr5 33951826 G T 1.41E-10 Common traits (Other) SLC45A2 intron 20585627 rs2287949 chr5 33954511 T C 1.40E-04 IgE levels in asthmatics / / 23967269 rs387906317 chr5 33954511 TG T 1.40E-04 IgE levels in asthmatics / / 23967269 rs35389 chr5 33954880 G A 4.74E-04 Multiple complex diseases SLC45A2 intron 17554300 rs35389 chr5 33954880 G A 2.20E-04 Blood pressure SLC45A2 intron 21422096 rs2113097 chr5 33955252 T C 1.40E-04 IgE levels in asthmatics SLC45A2 intron 23967269 rs2113097 chr5 33955252 T C 1.89E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SLC45A2 intron 24023788 rs35390 chr5 33955326 C A 2.00E-07 Melanoma SLC45A2 intron 21983787 rs35391 chr5 33955673 T C 3.00E-10 Tanning SLC45A2 intron 19340012 rs1010872 chr5 33958910 A C 1.50E-04 IgE levels in asthmatics SLC45A2 intron 23967269 rs28777 chr5 33958959 C A 1.00E-17 Black vs. red hair color SLC45A2 intron 18483556 rs28777 chr5 33958959 C A 9.00E-14 Black vs. red hair color SLC45A2 intron 18483556 rs26722 chr5 33963870 C T 1.78E-08 Common traits (Other) SLC45A2 missense 20585627 rs183671 chr5 33964210 T G 2.40E-05 Height SLC45A2 intron 21998595 rs35408 chr5 33964938 C T 2.76E-04 Hemoglobin concentration SLC45A2 intron 20534544 rs10040206 chr5 33992395 T C 2.06E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) AMACR intron 24023788 rs34684 chr5 34005562 A G 1.90E-05 Urinary metabolites AMACR intron 21572414 rs7379110 chr5 34053621 T C 2.80E-05 Schizophrenia C1QTNF3-AMACR intron 19197363 rs299620 chr5 34056020 C A 2.58E-06 Lymphocyte counts C1QTNF3-AMACR intron 22286170 rs35130581 chr5 34176643 C G 6.22E-04 Multiple complex diseases / / 17554300 rs17585602 chr5 34402152 A G 9.77E-05 Cognitive impairment induced by topiramate / / 22091778 rs4571447 chr5 34428293 T C 1.63E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6860110 chr5 34455165 A C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10941189 chr5 34489548 C A 6.80E-06 Fasting plasma glucose / / 19060907 rs10941189 chr5 34489548 C A 9.70E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs10056815 chr5 34493934 C T 7.07E-04 Type 2 diabetes / / 17463246 rs10075914 chr5 34525931 A G 7.33E-05 Asthma / / 11022011 rs4409068 chr5 34539407 A C 3.17E-04 Insulin resistance / / 21901158 rs6451146 chr5 34564023 C T 5.00E-04 Type 2 diabetes / / 17463246 rs6451146 chr5 34564023 C T 4.00E-05 Type 2 diabetes / / 22238593 rs7736168 chr5 34567310 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10035360 chr5 34604636 C T 3.22E-32 Narcolepsy / / 19629137 rs409045 chr5 34628627 C T 8.00E-07 Left ventricular mass / / 19454037 rs11740818 chr5 34700704 A G 9.60E-04 Urinary metabolites RAI14 intron 21572414 rs7709378 chr5 34701005 T C 4.20E-04 Urinary metabolites RAI14 intron 21572414 rs6892244 chr5 34707297 C A 7.00E-04 Urinary metabolites RAI14 intron 21572414 rs10461944 chr5 34710332 G T 5.10E-04 Urinary metabolites RAI14 intron 21572414 rs35468221 chr5 34710915 G A 4.80E-04 Urinary metabolites RAI14 intron 21572414 rs1867714 chr5 34716120 G A 4.10E-04 Urinary metabolites RAI14 intron 21572414 rs1867715 chr5 34716124 A G 4.10E-04 Urinary metabolites RAI14 intron 21572414 rs1867716 chr5 34716270 A C 1.80E-04 Urinary metabolites RAI14 intron 21572414 rs6878294 chr5 34716815 G A 4.10E-04 Urinary metabolites RAI14 intron 21572414 rs34674630 chr5 34717324 G A 4.20E-04 Urinary metabolites RAI14 intron 21572414 rs1545348 chr5 34718343 T G 1.70E-04 Urinary metabolites RAI14 intron 21572414 rs61251364 chr5 34719923 G A 4.30E-04 Urinary metabolites RAI14 intron 21572414 rs13187147 chr5 34721608 A C 2.30E-04 Urinary metabolites RAI14 intron 21572414 rs6880536 chr5 34726063 T G 8.10E-04 Urinary metabolites RAI14 intron 21572414 rs6893661 chr5 34732224 A G 1.00E-04 Cognitive impairment induced by topiramate RAI14 intron 22091778 rs16903850 chr5 34737944 T C 5.40E-05 Parkinson's disease (motor and cognition) RAI14 intron 22658654 rs16903850 chr5 34737944 T C 5.40E-05 Immune response to anthrax vaccine RAI14 intron 22658931 rs56142210 chr5 34743608 C A 8.00E-04 Urinary metabolites RAI14 intron 21572414 rs10472251 chr5 34744311 C T 9.70E-04 Urinary metabolites RAI14 intron 21572414 rs4544805 chr5 34748336 T G 9.40E-05 Urinary metabolites RAI14 intron 21572414 rs4499805 chr5 34749014 C T 3.10E-05 Urinary metabolites RAI14 intron 21572414 rs7702603 chr5 34751669 A G 5.40E-05 Urinary metabolites RAI14 intron 21572414 rs6867213 chr5 34752601 C T 4.50E-05 Urinary metabolites RAI14 intron 21572414 rs334912 chr5 34753340 T C 7.72E-04 Insulin resistance RAI14 intron 21901158 rs334913 chr5 34754305 T G 7.20E-05 Urinary metabolites RAI14 intron 21572414 rs3852181 chr5 34760705 C T 9.88E-05 Femoral neck bone geometry RAI14 intron 22087292 rs164311 chr5 34762166 A G 2.59E-04 Birth weight RAI14 intron 17255346 rs11957242 chr5 34765164 G A 4.30E-05 Urinary metabolites RAI14 intron 21572414 rs3845172 chr5 34769216 A G 1.70E-05 Urinary metabolites RAI14 intron 21572414 rs12658204 chr5 34771848 G A 1.20E-07 Urinary metabolites RAI14 intron 21572414 rs162909 chr5 34772786 A G 2.19E-04 HIV-1 viral setpoint RAI14 intron 17641165 rs13188691 chr5 34774344 A G 1.80E-05 Urinary metabolites RAI14 intron 21572414 rs13155829 chr5 34775046 C T 1.80E-05 Urinary metabolites RAI14 intron 21572414 rs164309 chr5 34775716 C T 2.00E-04 Information processing speed RAI14 intron 21130836 rs11949354 chr5 34775958 G A 1.90E-05 Urinary metabolites RAI14 intron 21572414 rs11959452 chr5 34778357 C G 1.30E-05 Urinary metabolites RAI14 intron 21572414 rs11949850 chr5 34778371 T G 1.40E-05 Urinary metabolites RAI14 intron 21572414 rs13182502 chr5 34778523 G C 1.30E-05 Urinary metabolites RAI14 intron 21572414 rs34691532 chr5 34778920 A G 1.30E-05 Urinary metabolites RAI14 intron 21572414 rs13165695 chr5 34782379 G C 1.30E-05 Urinary metabolites RAI14 intron 21572414 rs11956393 chr5 34785681 T C 1.10E-05 Urinary metabolites RAI14 intron 21572414 rs114990421 chr5 34786231 G A 0.0000745 Sarcoidosis RAI14 intron 22952805 rs34095278 chr5 34786815 C T 1.30E-05 Urinary metabolites RAI14 intron 21572414 rs11954570 chr5 34786929 C T 1.30E-05 Urinary metabolites RAI14 intron 21572414 rs11954106 chr5 34788112 T C 1.40E-05 Urinary metabolites RAI14 intron 21572414 rs10521017 chr5 34789178 G T 1.10E-08 Urinary metabolites RAI14 intron 21572414 rs7737880 chr5 34790966 A T 3.12E-04 Suicide attempts in bipolar disorder RAI14 intron 21423239 rs34477153 chr5 34791383 G A 3.30E-05 Urinary metabolites RAI14 intron 21572414 rs163121 chr5 34794128 G A 3.47E-04 Multiple complex diseases RAI14 intron 17554300 rs10070053 chr5 34794789 G A 2.80E-05 Urinary metabolites RAI14 intron 21572414 rs12186844 chr5 34794805 A C 4.70E-05 Urinary metabolites RAI14 intron 21572414 rs17594094 chr5 34795433 A G 8.20E-08 Urinary metabolites RAI14 intron 21572414 rs338266 chr5 34797531 T C 2.90E-04 Urinary metabolites RAI14 intron 21572414 rs112574551 chr5 34798391 G A 7.69E-06 Serum dimethylarginine levels (symmetric) RAI14 intron 24159190 rs469033 chr5 34799411 G T 3.10E-04 Urinary metabolites RAI14 intron 21572414 rs469033 chr5 34799411 G T 6.85E-06 Serum dimethylarginine levels (symmetric) RAI14 intron 24159190 rs12659689 chr5 34800351 T C 4.60E-04 Weight loss (gastric bypass surgery) RAI14 intron 23643386 rs336465 chr5 34806670 G A 1.70E-04 Urinary metabolites RAI14 intron 21572414 rs336465 chr5 34806670 G A 9.18E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) RAI14 intron 24159190 rs179844 chr5 34806698 G A 2.30E-04 Urinary metabolites RAI14 intron 21572414 rs179844 chr5 34806698 G A 9.46E-06 Serum dimethylarginine levels (symmetric) RAI14 intron 24159190 rs10472940 chr5 34810095 G A 2.02E-04 Birth weight RAI14 intron 17255346 rs10472940 chr5 34810095 G A 7.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RAI14 intron 20877124 rs7705004 chr5 34818558 T C 5.61E-04 Parkinson's disease RAI14 intron 16252231 rs3852183 chr5 34821557 C T 5.20E-04 Urinary metabolites RAI14 intron 21572414 rs10472941 chr5 34823442 G C 1.00E-17 Health and aging,CVD and cancer age of onset RAI14 missense 22174011 rs10472941 chr5 34823442 G C 2.60E-23 Health and aging,CVD and cancer age of onset RAI14 missense 22174011 rs10472941 chr5 34823442 G C 3.20E-08 Health and aging,CVD and cancer age of onset RAI14 missense 22174011 rs57729438 chr5 34833067 T C 3.20E-05 Urinary metabolites / / 21572414 rs67452918 chr5 34833067 T TA 3.20E-05 Urinary metabolites / / 21572414 rs336485 chr5 34839428 G A 7.50E-04 Urinary metabolites TTC23L intron 21572414 rs17523495 chr5 34840488 C T 8.20E-04 Urinary metabolites TTC23L intron 21572414 rs336486 chr5 34845473 C A 5.77E-04 Smoking quantity TTC23L intron 24665060 rs447933 chr5 34853965 T C 2.76E-04 Smoking quantity TTC23L intron 24665060 rs10521019 chr5 34854281 A G 7.50E-04 Urinary metabolites TTC23L intron 21572414 rs368823 chr5 34854491 A G 2.10E-04 Urinary metabolites TTC23L intron 21572414 rs368823 chr5 34854491 A G 4.44E-06 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs16868534 chr5 34857445 A G 3.29E-04 Alzheimer's disease TTC23L intron 17998437 rs16868534 chr5 34857445 A G 5.27E-05 Glucose levels TTC23L intron pha003058 rs16868534 chr5 34857445 A G 2.78E-05 Glucose levels TTC23L intron pha003061 rs16868536 chr5 34857470 C T 3.87E-04 Alzheimer's disease TTC23L intron 17998437 rs56046724 chr5 34861615 C T 7.00E-10 Urinary metabolites TTC23L intron 21572414 rs11744123 chr5 34862125 C T 9.59E-06 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs10941221 chr5 34862360 T A 1.34E-07 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs4703481 chr5 34862541 G A 9.26E-04 Amyotrophic lateral sclerosis (sporadic) TTC23L intron 24529757 rs3846632 chr5 34863220 G T 4.28E-06 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs3846633 chr5 34863933 T C 4.70E-04 Urinary metabolites TTC23L intron 21572414 rs3846633 chr5 34863933 T C 2.62E-08 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs13167483 chr5 34865528 A G 4.31E-06 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs10461949 chr5 34868792 C T 4.82E-07 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs10461949 chr5 34868792 C T 6.11E-04 Smoking initiation TTC23L intron 24665060 rs10941222 chr5 34871397 A G 4.12E-06 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs6877989 chr5 34871932 G A 8.90E-04 Urinary metabolites TTC23L intron 21572414 rs6877989 chr5 34871932 G A 3.22E-08 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs12153054 chr5 34872235 A G 4.30E-05 Urinary metabolites TTC23L intron 21572414 rs12153054 chr5 34872235 A G 6.35E-09 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs10941223 chr5 34872544 T C 4.55E-06 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs7717477 chr5 34875478 A G 3.90E-04 Urinary metabolites TTC23L intron 21572414 rs7717477 chr5 34875478 A G 3.87E-10 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs7717477 chr5 34875478 A G 7.80E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) TTC23L intron 24159190 rs11948433 chr5 34875814 G A 6.58E-06 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs251647 chr5 34884128 T C 7.80E-06 Urinary metabolites TTC23L intron 21572414 rs251647 chr5 34884128 T C 1.24E-11 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs251647 chr5 34884128 T C 6.94E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) TTC23L intron 24159190 rs192237 chr5 34884588 A T 7.50E-05 Urinary metabolites TTC23L intron 21572414 rs192237 chr5 34884588 A T 2.36E-11 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs192237 chr5 34884588 A T 4.21E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) TTC23L intron 24159190 rs153013 chr5 34885215 C T 2.60E-04 Urinary metabolites TTC23L intron 21572414 rs153013 chr5 34885215 C T 2.78E-10 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs153013 chr5 34885215 C T 6.09E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) TTC23L intron 24159190 rs13168113 chr5 34888511 G T 7.77E-07 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs56820085 chr5 34889928 G A 5.04E-08 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs112673672 chr5 34890101 G T 3.64E-06 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs153012 chr5 34890728 G A 4.53E-07 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs153017 chr5 34891108 A G 8.80E-07 Urinary metabolites TTC23L intron 21572414 rs153017 chr5 34891108 A G 2.35E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) TTC23L intron 24159190 rs153017 chr5 34891108 A G 3.54E-13 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs13183939 chr5 34891639 A T 1.08E-07 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs340991 chr5 34892042 G A 8.10E-07 Urinary metabolites TTC23L intron 21572414 rs340991 chr5 34892042 G A 1.10E-14 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs340991 chr5 34892042 G A 5.93E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) TTC23L intron 24159190 rs7707427 chr5 34894630 T C 1.32E-06 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs138425947 chr5 34896132 A G 2.07E-06 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs138425947 chr5 34896132 A G 5.41E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) TTC23L intron 24159190 rs557860 chr5 34896529 C T 3.60E-05 Urinary metabolites TTC23L intron 21572414 rs557860 chr5 34896529 C T 4.72E-13 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs557860 chr5 34896529 C T 7.44E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) TTC23L intron 24159190 rs251638 chr5 34898304 T C 3.40E-05 Urinary metabolites TTC23L intron 21572414 rs251638 chr5 34898304 T C 3.59E-13 Serum dimethylarginine levels (symmetric) TTC23L intron 24159190 rs251638 chr5 34898304 T C 5.78E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) TTC23L intron 24159190 rs35134290 chr5 34904206 G T 4.60E-04 Urinary metabolites / / 21572414 rs35134290 chr5 34904206 G T 3.32E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs2069481 chr5 34908365 G A 1.42E-06 Serum dimethylarginine levels (symmetric) RAD1 UTR-3 24159190 rs2069478 chr5 34909596 C T 1.44E-05 B cell non-Hodgkin lymphoma RAD1 intron 23749188 rs37436 chr5 34912819 C T 2.90E-06 Urinary metabolites RAD1 intron 21572414 rs37436 chr5 34912819 C T 2.52E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) RAD1 intron 24159190 rs37436 chr5 34912819 C T 2.85E-16 Serum dimethylarginine levels (symmetric) RAD1 intron 24159190 rs37434 chr5 34918415 A G 1.10E-05 Urinary metabolites BRIX1 intron 21572414 rs37434 chr5 34918415 A G 1.42E-13 Serum dimethylarginine levels (symmetric) BRIX1 intron 24159190 rs37434 chr5 34918415 A G 2.61E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) BRIX1 intron 24159190 rs37433 chr5 34920257 T C 1.30E-05 Urinary metabolites BRIX1 intron 21572414 rs37433 chr5 34920257 T C 1.30E-13 Serum dimethylarginine levels (symmetric) BRIX1 intron 24159190 rs37433 chr5 34920257 T C 2.35E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) BRIX1 intron 24159190 rs185186 chr5 34920596 G A 1.30E-05 Urinary metabolites BRIX1 intron 21572414 rs185186 chr5 34920596 G A 1.37E-13 Serum dimethylarginine levels (symmetric) BRIX1 intron 24159190 rs185186 chr5 34920596 G A 2.55E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) BRIX1 intron 24159190 rs13188540 chr5 34922011 G A 2.20E-07 Urinary metabolites BRIX1 intron 21572414 rs13188540 chr5 34922011 G A 1.57E-16 Serum dimethylarginine levels (symmetric) BRIX1 intron 24159190 rs13188540 chr5 34922011 G A 5.27E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) BRIX1 intron 24159190 rs37431 chr5 34923435 A C 1.14E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) BRIX1 intron 24159190 rs37431 chr5 34923435 A C 1.36E-17 Serum dimethylarginine levels (symmetric) BRIX1 intron 24159190 rs3776603 chr5 34924502 A G 4.44E-07 Serum dimethylarginine levels (symmetric) BRIX1 intron 24159190 rs27164 chr5 34927511 C T 6.40E-08 Urinary metabolites / / 21572414 rs27164 chr5 34927511 C T 8.32E-18 Serum dimethylarginine levels (symmetric) / / 24159190 rs27164 chr5 34927511 C T 8.61E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs27162 chr5 34928514 A C 1.20E-09 Urinary metabolites / / 21572414 rs27162 chr5 34928514 A C 4.26E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs27162 chr5 34928514 A C 5.08E-21 Serum dimethylarginine levels (symmetric) / / 24159190 rs27161 chr5 34928716 C A 4.70E-12 Urinary metabolites / / 21572414 rs27161 chr5 34928716 C A 2.73E-17 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs27161 chr5 34928716 C A 3.22E-26 Serum dimethylarginine levels (symmetric) / / 24159190 rs27555 chr5 34929368 T G 1.70E-09 Urinary metabolites / / 21572414 rs27555 chr5 34929368 T G 1.75E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs27555 chr5 34929368 T G 6.20E-21 Serum dimethylarginine levels (symmetric) / / 24159190 rs35176895 chr5 34930387 T C 3.80E-07 Urinary metabolites D/JC21 intron 21572414 rs35176895 chr5 34930387 T C 1.01E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) D/JC21 intron 24159190 rs35176895 chr5 34930387 T C 6.67E-15 Serum dimethylarginine levels (symmetric) D/JC21 intron 24159190 rs37429 chr5 34931886 T G 2.10E-09 Urinary metabolites D/JC21 intron 21572414 rs37429 chr5 34931886 T G 2.51E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) D/JC21 intron 24159190 rs37429 chr5 34931886 T G 2.61E-21 Serum dimethylarginine levels (symmetric) D/JC21 intron 24159190 rs37428 chr5 34933504 G A 1.50E-09 Urinary metabolites D/JC21 intron 21572414 rs37428 chr5 34933504 G A 2.12E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) D/JC21 intron 24159190 rs37428 chr5 34933504 G A 2.12E-21 Serum dimethylarginine levels (symmetric) D/JC21 intron 24159190 rs188594614 chr5 34933505 T C 4.20E-07 Serum dimethylarginine levels (symmetric) D/JC21 intron 24159190 rs40202 chr5 34938373 A G 2.90E-09 Urinary metabolites D/JC21 intron 21572414 rs40202 chr5 34938373 A G 1.69E-21 Serum dimethylarginine levels (symmetric) D/JC21 intron 24159190 rs40202 chr5 34938373 A G 1.71E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) D/JC21 intron 24159190 rs6859898 chr5 34939630 A G 1.04E-14 Serum dimethylarginine levels (symmetric) D/JC21 intron 24159190 rs6859898 chr5 34939630 A G 7.13E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) D/JC21 intron 24159190 rs34349127 chr5 34940757 T C 4.90E-11 Urinary metabolites D/JC21 intron 21572414 rs34349127 chr5 34940757 T C 1.55E-10 Serum dimethylarginine levels (symmetric) D/JC21 intron 24159190 rs34349127 chr5 34940757 T C 2.74E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) D/JC21 intron 24159190 rs17244776 chr5 34942466 G A 4.90E-09 Urinary metabolites D/JC21 intron 21572414 rs17244776 chr5 34942466 G A 3.44E-08 Serum dimethylarginine levels (symmetric) D/JC21 intron 24159190 rs17244776 chr5 34942466 G A 5.86E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) D/JC21 intron 24159190 rs251640 chr5 34942537 C T 9.60E-12 Urinary metabolites D/JC21 intron 21572414 rs251640 chr5 34942537 C T 1.01E-26 Serum dimethylarginine levels (symmetric) D/JC21 intron 24159190 rs251640 chr5 34942537 C T 1.12E-17 Serum dimethylarginine levels (asymmetric/symetric ratio) D/JC21 intron 24159190 rs251641 chr5 34943496 C T 2.70E-10 Urinary metabolites D/JC21 intron 21572414 rs251641 chr5 34943496 C T 1.13E-17 Serum dimethylarginine levels (asymmetric/symetric ratio) D/JC21 intron 24159190 rs251641 chr5 34943496 C T 9.81E-27 Serum dimethylarginine levels (symmetric) D/JC21 intron 24159190 rs6864535 chr5 34945653 G A 7.90E-08 Urinary metabolites D/JC21 intron 21572414 rs6864535 chr5 34945653 G A 2.80E-15 Serum dimethylarginine levels (symmetric) D/JC21 intron 24159190 rs6864535 chr5 34945653 G A 6.19E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) D/JC21 intron 24159190 rs6864139 chr5 34945663 A G 7.90E-08 Urinary metabolites D/JC21 intron 21572414 rs6864139 chr5 34945663 A G 2.78E-15 Serum dimethylarginine levels (symmetric) D/JC21 intron 24159190 rs6864139 chr5 34945663 A G 6.13E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) D/JC21 intron 24159190 rs6868348 chr5 34945812 A G 1.20E-08 Urinary metabolites D/JC21 intron 21572414 rs6868348 chr5 34945812 A G 2.78E-15 Serum dimethylarginine levels (symmetric) D/JC21 intron 24159190 rs6868348 chr5 34945812 A G 6.14E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) D/JC21 intron 24159190 rs37442 chr5 34945944 A T 1.20E-13 Urinary metabolites D/JC21 intron 21572414 rs37442 chr5 34945944 A T 1.09E-26 Serum dimethylarginine levels (symmetric) D/JC21 intron 24159190 rs37442 chr5 34945944 A T 1.28E-17 Serum dimethylarginine levels (asymmetric/symetric ratio) D/JC21 intron 24159190 rs11404640 chr5 34947761 G GT 2.70E-07 Urinary metabolites D/JC21 intron 21572414 rs12518581 chr5 34947761 G T 2.70E-07 Urinary metabolites D/JC21 intron 21572414 rs199741397 chr5 34947761 GT G 2.70E-07 Urinary metabolites D/JC21 intron 21572414 rs377415684 chr5 34947761 G GT 2.70E-07 Urinary metabolites D/JC21 intron 21572414 rs37440 chr5 34948532 T C 5.40E-06 Urinary metabolites D/JC21 intron 21572414 rs37440 chr5 34948532 T C 8.07E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) D/JC21 intron 24159190 rs37440 chr5 34948532 T C 9.18E-14 Serum dimethylarginine levels (symmetric) D/JC21 intron 24159190 rs35223036 chr5 34948704 G T 8.30E-08 Urinary metabolites D/JC21 intron 21572414 rs35223036 chr5 34948704 G T 2.23E-07 Serum dimethylarginine levels (symmetric) D/JC21 intron 24159190 rs114678528 chr5 34949192 G A 3.37E-08 Serum dimethylarginine levels (symmetric) D/JC21 intron 24159190 rs114678528 chr5 34949192 G A 5.49E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) D/JC21 intron 24159190 rs37439 chr5 34951150 C A 9.00E-06 Response to angiotensin II receptor blocker therapy D/JC21 intron 22566498 rs251636 chr5 34957444 T C 5.37E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) D/JC21 UTR-3 22566498 rs10755257 chr5 34961196 G A 1.60E-07 Urinary metabolites / / 21572414 rs10755257 chr5 34961196 G A 3.14E-15 Serum dimethylarginine levels (symmetric) / / 24159190 rs10755257 chr5 34961196 G A 5.93E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs153008 chr5 34961357 G C 8.90E-04 Urinary metabolites / / 21572414 rs153008 chr5 34961357 G C 1.55E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs153008 chr5 34961357 G C 8.24E-10 Serum dimethylarginine levels (symmetric) / / 24159190 rs10941225 chr5 34961480 T A 7.50E-10 Urinary metabolites / / 21572414 rs10941225 chr5 34961480 T A 3.34E-15 Serum dimethylarginine levels (symmetric) / / 24159190 rs10941225 chr5 34961480 T A 7.17E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs114021680 chr5 34962703 G A 1.41E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs114021680 chr5 34962703 G A 1.89E-10 Serum dimethylarginine levels (symmetric) / / 24159190 rs11956668 chr5 34965265 G A 3.90E-07 Urinary metabolites / / 21572414 rs11956668 chr5 34965265 G A 3.98E-15 Serum dimethylarginine levels (symmetric) / / 24159190 rs11956668 chr5 34965265 G A 8.09E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs1115964 chr5 34965682 G T 7.20E-09 Urinary metabolites / / 21572414 rs1115964 chr5 34965682 G T 5.56E-10 Serum dimethylarginine levels (symmetric) / / 24159190 rs1115964 chr5 34965682 G T 8.79E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs2397416 chr5 34967114 G A 1.40E-10 Urinary metabolites / / 21572414 rs2397416 chr5 34967114 G A 1.51E-17 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs2397416 chr5 34967114 G A 1.81E-26 Serum dimethylarginine levels (symmetric) / / 24159190 rs35566392 chr5 34967123 C T 1.40E-10 Urinary metabolites / / 21572414 rs35566392 chr5 34967123 C T 1.52E-17 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs35566392 chr5 34967123 C T 1.82E-26 Serum dimethylarginine levels (symmetric) / / 24159190 rs10941226 chr5 34968302 C T 4.39E-15 Serum dimethylarginine levels (symmetric) / / 24159190 rs10941226 chr5 34968302 C T 7.45E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs460053 chr5 34971390 A G 1.20E-09 Urinary metabolites / / 21572414 rs460053 chr5 34971390 A G 1.53E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs460053 chr5 34971390 A G 2.06E-21 Serum dimethylarginine levels (symmetric) / / 24159190 rs34531945 chr5 34973719 T C 1.30E-10 Urinary metabolites / / 21572414 rs7710189 chr5 34973989 G A 4.35E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs7710189 chr5 34973989 G A 6.95E-13 Serum dimethylarginine levels (symmetric) / / 24159190 rs11749934 chr5 34973992 C G 8.38E-21 Serum dimethylarginine levels (symmetric) / / 24159190 rs11749934 chr5 34973992 C G 9.33E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs251642 chr5 34974835 A G 2.70E-08 Urinary metabolites / / 21572414 rs251642 chr5 34974835 A G 1.56E-25 Serum dimethylarginine levels (symmetric) / / 24159190 rs251642 chr5 34974835 A G 1.70E-16 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs171655 chr5 34975095 C G 3.80E-11 Urinary metabolites / / 21572414 rs171655 chr5 34975095 C G 1.50E-25 Serum dimethylarginine levels (symmetric) / / 24159190 rs171655 chr5 34975095 C G 1.65E-16 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs13158182 chr5 34976174 G A 4.10E-04 Urinary metabolites / / 21572414 rs163585 chr5 34977408 C T 4.60E-11 Urinary metabolites / / 21572414 rs163585 chr5 34977408 C T 1.41E-21 Serum dimethylarginine levels (symmetric) / / 24159190 rs163585 chr5 34977408 C T 3.51E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs153009 chr5 34977542 G A 2.30E-11 Urinary metabolites / / 21572414 rs153009 chr5 34977542 G A 1.18E-25 Serum dimethylarginine levels (symmetric) / / 24159190 rs153009 chr5 34977542 G A 1.38E-16 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs58885582 chr5 34978152 A G 4.30E-07 Urinary metabolites / / 21572414 rs58885582 chr5 34978152 A G 2.33E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs58885582 chr5 34978152 A G 7.41E-15 Serum dimethylarginine levels (symmetric) / / 24159190 rs163588 chr5 34978170 G A 1.40E-10 Urinary metabolites / / 21572414 rs163588 chr5 34978170 G A 1.87E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs163588 chr5 34978170 G A 4.96E-16 Serum dimethylarginine levels (symmetric) / / 24159190 rs163590 chr5 34978995 T C 9.50E-06 Urinary metabolites / / 21572414 rs163590 chr5 34978995 T C 3.24E-13 Serum dimethylarginine levels (symmetric) / / 24159190 rs163590 chr5 34978995 T C 4.00E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs163591 chr5 34979803 T G 6.80E-07 Urinary metabolites / / 21572414 rs163591 chr5 34979803 T G 3.25E-13 Serum dimethylarginine levels (symmetric) / / 24159190 rs163591 chr5 34979803 T G 4.08E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs163592 chr5 34980516 G A 7.10E-07 Urinary metabolites / / 21572414 rs163592 chr5 34980516 G A 3.31E-13 Serum dimethylarginine levels (symmetric) / / 24159190 rs163592 chr5 34980516 G A 4.15E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs116116288 chr5 34982167 C T 1.09E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs116116288 chr5 34982167 C T 7.13E-09 Serum dimethylarginine levels (symmetric) / / 24159190 rs163594 chr5 34986704 A C 5.60E-11 Urinary metabolites / / 21572414 rs163594 chr5 34986704 A C 1.52E-25 Serum dimethylarginine levels (symmetric) / / 24159190 rs163594 chr5 34986704 A C 2.41E-16 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs11957653 chr5 34987541 T C 2.80E-13 Urinary metabolites / / 21572414 rs11957653 chr5 34987541 T C 1.56E-17 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs11957653 chr5 34987541 T C 2.46E-22 Serum dimethylarginine levels (symmetric) / / 24159190 rs192235 chr5 34988020 T C 6.50E-12 Urinary metabolites / / 21572414 rs192235 chr5 34988020 T C 1.53E-25 Serum dimethylarginine levels (symmetric) / / 24159190 rs192235 chr5 34988020 T C 2.18E-16 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs149151 chr5 34989000 A G 2.70E-11 Urinary metabolites / / 21572414 rs149151 chr5 34989000 A G 1.49E-25 Serum dimethylarginine levels (symmetric) / / 24159190 rs149151 chr5 34989000 A G 2.32E-16 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs163595 chr5 34990495 A T 1.30E-06 Urinary metabolites / / 21572414 rs163595 chr5 34990495 A T 3.86E-13 Serum dimethylarginine levels (symmetric) / / 24159190 rs163595 chr5 34990495 A T 6.15E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs163596 chr5 34990818 C T 4.42E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs163596 chr5 34990818 C T 4.45E-10 Serum dimethylarginine levels (symmetric) / / 24159190 rs163597 chr5 34991062 A C 2.70E-11 Urinary metabolites / / 21572414 rs163597 chr5 34991062 A C 1.42E-25 Serum dimethylarginine levels (symmetric) / / 24159190 rs163597 chr5 34991062 A C 2.56E-16 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs163598 chr5 34991923 A G 2.80E-11 Urinary metabolites / / 21572414 rs163598 chr5 34991923 A G 2.24E-16 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs163598 chr5 34991923 A G 7.74E-26 Serum dimethylarginine levels (symmetric) / / 24159190 rs163599 chr5 34991946 A G 2.80E-11 Urinary metabolites / / 21572414 rs163599 chr5 34991946 A G 1.46E-25 Serum dimethylarginine levels (symmetric) / / 24159190 rs163599 chr5 34991946 A G 3.00E-16 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs163600 chr5 34992556 G A 4.20E-09 Urinary metabolites / / 21572414 rs163600 chr5 34992556 G A 4.07E-13 Serum dimethylarginine levels (symmetric) / / 24159190 rs163600 chr5 34992556 G A 7.30E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs11744796 chr5 34993215 G A 4.50E-11 Urinary metabolites / / 21572414 rs11744796 chr5 34993215 G A 1.57E-14 Serum dimethylarginine levels (symmetric) / / 24159190 rs11744796 chr5 34993215 G A 7.56E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs606241 chr5 34994143 G A 5.37E-13 Serum dimethylarginine levels (symmetric) / / 24159190 rs606241 chr5 34994143 G A 9.21E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs4518366 chr5 34997389 G A 6.00E-14 Urinary metabolites / / 21572414 rs4518366 chr5 34997389 G A 1.81E-37 Serum dimethylarginine levels (symmetric) / / 24159190 rs4518366 chr5 34997389 G A 8.77E-22 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs4357012 chr5 34997883 T C 1.27E-35 Serum dimethylarginine levels (symmetric) / / 24159190 rs4357012 chr5 34997883 T C 5.98E-16 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs16899972 chr5 34998778 C A 2.50E-10 Urinary metabolites AGXT2 UTR-3 21572414 rs16899972 chr5 34998778 C A 5.74E-18 Serum dimethylarginine levels (symmetric) AGXT2 UTR-3 24159190 rs16899972 chr5 34998778 C A 7.49E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 UTR-3 24159190 rs16899972 chr5 34998778 C A 1.10E-13 Urinary metabolites (H-NMR features) AGXT2 UTR-3 24586186 rs16899974 chr5 34998877 C A 1.00E-17 Urinary metabolites AGXT2 missense 21572414 rs16899974 chr5 34998877 C A 1.53E-38 Serum dimethylarginine levels (symmetric) AGXT2 missense 24159190 rs16899974 chr5 34998877 C A 8.18E-24 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 missense 24159190 rs16899975 chr5 34999057 G C 8.80E-15 Urinary metabolites AGXT2 intron 21572414 rs16899975 chr5 34999057 G C 1.23E-19 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs16899975 chr5 34999057 G C 2.76E-38 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs77117323 chr5 34999145 C T 2.68E-08 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs9292570 chr5 35000312 T C 5.40E-06 Urinary metabolites AGXT2 intron 21572414 rs9292570 chr5 35000312 T C 5.51E-07 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs163838 chr5 35000525 G A 1.12E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs163838 chr5 35000525 G A 2.07E-08 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs7717823 chr5 35000795 C T 3.80E-19 Urinary metabolites AGXT2 intron 21572414 rs7717823 chr5 35000795 C T 1.69E-18 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs7717823 chr5 35000795 C T 2.89E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs7717823 chr5 35000795 C T 1.80E-12 Urinary metabolites (H-NMR features) AGXT2 intron 24586186 rs7717823 chr5 35000795 C T 3.00E-29 Urinary metabolites (H-NMR features) AGXT2 intron 24586186 rs7717823 chr5 35000795 C T 3.40E-29 Urinary metabolites (H-NMR features) AGXT2 intron 24586186 rs163910 chr5 35001208 G A 1.60E-25 Urinary metabolites AGXT2 intron 21572414 rs163910 chr5 35001208 G A 3.22E-18 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs163910 chr5 35001208 G A 5.00E-09 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs163908 chr5 35001317 A T 2.60E-25 Urinary metabolites AGXT2 intron 21572414 rs163908 chr5 35001317 A T 3.17E-18 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs163908 chr5 35001317 A T 4.83E-09 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs13169995 chr5 35001678 G C 2.70E-18 Urinary metabolites AGXT2 intron 21572414 rs13169995 chr5 35001678 G C 3.67E-18 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs13169995 chr5 35001678 G C 4.37E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13170299 chr5 35001859 G A 1.50E-04 Urinary metabolites AGXT2 intron 21572414 rs13170299 chr5 35001859 G A 1.80E-06 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs13173819 chr5 35001963 C T 2.40E-18 Urinary metabolites AGXT2 intron 21572414 rs13173819 chr5 35001963 C T 4.49E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13173819 chr5 35001963 C T 7.56E-18 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs13173943 chr5 35002005 C T 2.40E-18 Urinary metabolites AGXT2 intron 21572414 rs13173943 chr5 35002005 C T 4.49E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13173943 chr5 35002005 C T 7.78E-18 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs13174300 chr5 35002251 C A 2.30E-18 Urinary metabolites AGXT2 intron 21572414 rs13174300 chr5 35002251 C A 4.54E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13174300 chr5 35002251 C A 7.11E-18 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs163837 chr5 35002766 C T 2.30E-34 Urinary metabolites AGXT2 intron 21572414 rs163837 chr5 35002766 C T 2.02E-22 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs163837 chr5 35002766 C T 3.57E-25 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs468327 chr5 35003112 G A 3.00E-44 Urinary metabolites AGXT2 intron 21572414 rs468327 chr5 35003112 G A 3.05E-25 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs468327 chr5 35003112 G A 8.45E-28 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs468327 chr5 35003112 G A 1.10E-33 Urinary metabolites (H-NMR features) AGXT2 intron 24586186 rs468327 chr5 35003112 G A 1.30E-15 Urinary metabolites (H-NMR features) AGXT2 intron 24586186 rs468327 chr5 35003112 G A 1.50E-18 Urinary metabolites (H-NMR features) AGXT2 intron 24586186 rs468327 chr5 35003112 G A 3.40E-19 Urinary metabolites (H-NMR features) AGXT2 intron 24586186 rs468327 chr5 35003112 G A 4.00E-15 Urinary metabolites (H-NMR features) AGXT2 intron 24586186 rs468327 chr5 35003112 G A 4.20E-15 Urinary metabolites (H-NMR features) AGXT2 intron 24586186 rs468327 chr5 35003112 G A 9.40E-15 Urinary metabolites (H-NMR features) AGXT2 intron 24586186 rs1428281 chr5 35006151 C T 3.80E-33 Urinary metabolites AGXT2 intron 21572414 rs1428281 chr5 35006151 C T 1.84E-26 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs1428281 chr5 35006151 C T 5.73E-20 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs2195352 chr5 35006192 G A 2.10E-17 Urinary metabolites AGXT2 intron 21572414 rs2195352 chr5 35006192 G A 4.82E-16 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs2195352 chr5 35006192 G A 7.84E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs163843 chr5 35006569 A C 1.30E-33 Urinary metabolites AGXT2 intron 21572414 rs163843 chr5 35006569 A C 1.24E-26 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs163843 chr5 35006569 A C 4.51E-20 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs163841 chr5 35007085 A G 3.60E-20 Urinary metabolites AGXT2 intron 21572414 rs163841 chr5 35007085 A G 3.86E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs163841 chr5 35007085 A G 5.92E-15 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs13163727 chr5 35007535 C T 3.70E-17 Urinary metabolites AGXT2 intron 21572414 rs13163727 chr5 35007535 C T 5.48E-16 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs13163727 chr5 35007535 C T 8.65E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13178208 chr5 35008262 C T 1.20E-16 Urinary metabolites AGXT2 intron 21572414 rs13178208 chr5 35008262 C T 4.99E-16 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs13178208 chr5 35008262 C T 7.55E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs34623800 chr5 35009593 C T 2.54E-15 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs34623800 chr5 35009593 C T 7.39E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs4991043 chr5 35010456 C T 1.30E-17 Urinary metabolites AGXT2 intron 21572414 rs4991043 chr5 35010456 C T 3.60E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs4991043 chr5 35010456 C T 4.16E-16 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs4703492 chr5 35010657 G C 2.21E-21 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs4703492 chr5 35010657 G C 8.36E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs11960801 chr5 35010872 C T 1.50E-17 Urinary metabolites AGXT2 intron 21572414 rs11960801 chr5 35010872 C T 3.31E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs11960801 chr5 35010872 C T 4.06E-16 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs55895806 chr5 35012118 A G 1.00E-29 Urinary metabolites AGXT2 intron 21572414 rs55895806 chr5 35012118 A G 2.50E-24 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs55895806 chr5 35012118 A G 2.94E-17 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs186937 chr5 35012425 C T 8.00E-20 Urinary metabolites AGXT2 intron 21572414 rs186937 chr5 35012425 C T 2.06E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs186937 chr5 35012425 C T 2.38E-16 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs114286107 chr5 35013058 C T 1.12E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 splice-3 24159190 rs1973391 chr5 35013747 C T 2.75E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs1973391 chr5 35013747 C T 3.54E-16 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs62357055 chr5 35013908 G A 5.60E-04 Urinary metabolites AGXT2 intron 21572414 rs163840 chr5 35014462 A G 3.30E-21 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs163840 chr5 35014462 A G 9.66E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs163904 chr5 35015485 T A 3.10E-25 Urinary metabolites AGXT2 intron 21572414 rs163904 chr5 35015485 T A 1.59E-21 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs163904 chr5 35015485 T A 4.29E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13178458 chr5 35015682 C T 2.84E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13178458 chr5 35015682 C T 3.80E-16 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs184123187 chr5 35019681 T C 2.69E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs184123187 chr5 35019681 T C 9.21E-18 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs140646852 chr5 35020097 C G 1.61E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs140646852 chr5 35020097 C G 2.42E-16 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs13187164 chr5 35022258 G A 3.05E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13187164 chr5 35022258 G A 3.65E-16 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs13155120 chr5 35023520 G A 1.10E-19 Urinary metabolites AGXT2 intron 21572414 rs13155120 chr5 35023520 G A 1.25E-16 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs13155120 chr5 35023520 G A 8.67E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs56144819 chr5 35023622 T G 3.30E-25 Urinary metabolites AGXT2 intron 21572414 rs56144819 chr5 35023622 T G 1.33E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs56144819 chr5 35023622 T G 3.01E-21 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs344517 chr5 35023825 T G 4.60E-26 Urinary metabolites AGXT2 intron 21572414 rs344517 chr5 35023825 T G 2.74E-21 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs344517 chr5 35023825 T G 6.41E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs67542136 chr5 35024288 G A 2.48E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs67542136 chr5 35024288 G A 3.23E-16 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs56362812 chr5 35024753 G A 4.80E-26 Urinary metabolites AGXT2 intron 21572414 rs56362812 chr5 35024753 G A 1.48E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs56362812 chr5 35024753 G A 2.44E-21 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs55990414 chr5 35024791 C T 4.80E-26 Urinary metabolites AGXT2 intron 21572414 rs55990414 chr5 35024791 C T 1.47E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs55990414 chr5 35024791 C T 2.43E-21 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs2642675 chr5 35024836 C G 1.12E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs2642675 chr5 35024836 C G 2.12E-19 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs10070227 chr5 35024934 G A 1.57E-21 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs10070227 chr5 35024934 G A 5.12E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs11956455 chr5 35024967 C T 2.89E-16 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs11956455 chr5 35024967 C T 3.48E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13165070 chr5 35025292 C T 2.68E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13165070 chr5 35025292 C T 7.93E-16 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs1808007 chr5 35025423 G A 1.23E-19 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs1808007 chr5 35025423 G A 2.07E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs344515 chr5 35025770 G A 3.60E-18 Urinary metabolites AGXT2 intron 21572414 rs344515 chr5 35025770 G A 1.80E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs344515 chr5 35025770 G A 2.26E-16 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs344514 chr5 35026237 T C 3.30E-06 Urinary metabolites AGXT2 intron 21572414 rs13170466 chr5 35026239 C T 1.60E-17 Urinary metabolites AGXT2 intron 21572414 rs13170466 chr5 35026239 C T 2.47E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13170466 chr5 35026239 C T 3.33E-16 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs62358266 chr5 35026698 G A 8.40E-05 Urinary metabolites AGXT2 intron 21572414 rs34248297 chr5 35027171 C G 8.56E-07 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs344512 chr5 35027754 A G 1.90E-18 Urinary metabolites AGXT2 intron 21572414 rs13158903 chr5 35027807 T C 3.70E-20 Urinary metabolites AGXT2 intron 21572414 rs13158903 chr5 35027807 T C 8.65E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13158903 chr5 35027807 T C 9.51E-17 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs13172280 chr5 35027911 T C 2.50E-19 Urinary metabolites AGXT2 intron 21572414 rs13172280 chr5 35027911 T C 7.11E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13172280 chr5 35027911 T C 8.39E-17 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs3816929 chr5 35028035 C T 2.50E-19 Urinary metabolites AGXT2 intron 21572414 rs3816929 chr5 35028035 C T 7.15E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs3816929 chr5 35028035 C T 8.47E-17 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs35058264 chr5 35028196 C A 6.29E-07 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs3816930 chr5 35028272 C T 6.90E-20 Urinary metabolites AGXT2 intron 21572414 rs3816930 chr5 35028272 C T 1.15E-16 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs3816930 chr5 35028272 C T 7.79E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs344507 chr5 35029862 G A 1.30E-14 Urinary metabolites AGXT2 intron 21572414 rs344507 chr5 35029862 G A 1.33E-08 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs344507 chr5 35029862 G A 1.69E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs10521021 chr5 35030311 T G 3.00E-16 Urinary metabolites AGXT2 intron 21572414 rs10521021 chr5 35030311 T G 1.50E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs10521021 chr5 35030311 T G 1.87E-17 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs11959896 chr5 35030830 T C 1.90E-11 Urinary metabolites AGXT2 intron 21572414 rs11959896 chr5 35030830 T C 2.92E-15 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs11959896 chr5 35030830 T C 6.85E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs10941228 chr5 35030963 C G 1.60E-11 Urinary metabolites AGXT2 intron 21572414 rs10941228 chr5 35030963 C G 1.08E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs10941228 chr5 35030963 C G 3.99E-15 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs10941229 chr5 35030976 C T 1.90E-11 Urinary metabolites AGXT2 intron 21572414 rs10941229 chr5 35030976 C T 1.15E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs10941229 chr5 35030976 C T 3.84E-15 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs344161 chr5 35031652 A C 8.60E-04 Urinary metabolites AGXT2 intron 21572414 rs13174311 chr5 35032345 C T 9.40E-16 Urinary metabolites AGXT2 intron 21572414 rs13174311 chr5 35032345 C T 1.26E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13174311 chr5 35032345 C T 2.17E-17 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs13174848 chr5 35032542 G A 7.00E-16 Urinary metabolites AGXT2 intron 21572414 rs13174848 chr5 35032542 G A 1.27E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13174848 chr5 35032542 G A 2.17E-17 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs237252 chr5 35032769 G A 7.10E-16 Urinary metabolites AGXT2 intron 21572414 rs237252 chr5 35032769 G A 2.71E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs237252 chr5 35032769 G A 3.99E-17 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs2291698 chr5 35033047 C T 6.90E-16 Urinary metabolites AGXT2 intron 21572414 rs2291698 chr5 35033047 C T 1.24E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs2291698 chr5 35033047 C T 2.14E-17 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs2291699 chr5 35033225 G A 2.70E-11 Urinary metabolites AGXT2 intron 21572414 rs2291699 chr5 35033225 G A 1.52E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs2291699 chr5 35033225 G A 3.22E-15 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs2291701 chr5 35033526 C T 5.50E-15 Urinary metabolites AGXT2 intron 21572414 rs2291701 chr5 35033526 C T 1.28E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs2291701 chr5 35033526 C T 2.22E-17 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs2291702 chr5 35033706 T C 1.80E-11 Urinary metabolites AGXT2 intron 21572414 rs2291702 chr5 35033706 T C 2.69E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs2291702 chr5 35033706 T C 2.93E-15 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs344158 chr5 35034094 C A 3.20E-16 Urinary metabolites AGXT2 intron 21572414 rs344158 chr5 35034094 C A 2.57E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs344158 chr5 35034094 C A 4.94E-17 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs455423 chr5 35034130 C T 1.90E-06 Urinary metabolites AGXT2 intron 21572414 rs13185264 chr5 35034419 C A 4.70E-16 Urinary metabolites AGXT2 intron 21572414 rs13185264 chr5 35034419 C A 1.18E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13185264 chr5 35034419 C A 2.00E-17 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs4703495 chr5 35034473 T C 2.20E-12 Urinary metabolites AGXT2 intron 21572414 rs13185749 chr5 35034704 C T 5.20E-16 Urinary metabolites AGXT2 intron 21572414 rs13185749 chr5 35034704 C T 1.20E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13185749 chr5 35034704 C T 2.06E-17 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs35314502 chr5 35034831 C G 2.60E-16 Urinary metabolites AGXT2 intron 21572414 rs35314502 chr5 35034831 C G 1.19E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs35314502 chr5 35034831 C G 2.06E-17 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs140785363 chr5 35035096 G A 3.35E-06 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs344156 chr5 35035579 A G 6.60E-16 Urinary metabolites AGXT2 intron 21572414 rs344156 chr5 35035579 A G 2.56E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs344156 chr5 35035579 A G 3.78E-17 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs71615838 chr5 35036203 T G 3.25E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs71615838 chr5 35036203 T G 7.08E-08 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs35550809 chr5 35036342 G A 7.90E-13 Urinary metabolites AGXT2 intron 21572414 rs344152 chr5 35036398 G A 2.00E-16 Urinary metabolites AGXT2 intron 21572414 rs344152 chr5 35036398 G A 5.36E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs344152 chr5 35036398 G A 9.39E-17 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs171081 chr5 35037006 T C 2.70E-22 Urinary metabolites AGXT2 intron 21572414 rs171081 chr5 35037006 T C 1.77E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs171081 chr5 35037006 T C 4.97E-13 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs37369 chr5 35037115 C T 2.00E-182 Urinary metabolites AGXT2 missense 21572414 rs37369 chr5 35037115 C T 1.00E-06 Metabolite levels AGXT2 missense 21931564 rs37369 chr5 35037115 C T 4.96E-11 Homoarginine levels AGXT2 missense 24047826 rs37369 chr5 35037115 C T 1.00E-40 Serum dimethylarginine levels (symmetric) AGXT2 missense 24159190 rs37369 chr5 35037115 C T 2.00E-32 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 missense 24159190 rs37369 chr5 35037115 C T 5.57E-07 Serum dimethylarginine levels (asymmetric) AGXT2 missense 24159190 rs37369 chr5 35037115 C T 1.00E-63 Urinary metabolites (H-NMR features) AGXT2 missense 24586186 rs37369 chr5 35037115 C T 2.00E-31 Urinary metabolites (H-NMR features) AGXT2 missense 24586186 rs37369 chr5 35037115 C T 2.40E-31 Urinary metabolites (H-NMR features) AGXT2 missense 24586186 rs37369 chr5 35037115 C T 3.00E-16 Urinary metabolites (H-NMR features) AGXT2 missense 24586186 rs37369 chr5 35037115 C T 3.00E-16 Urinary metabolites (H-NMR features) AGXT2 missense 24586186 rs37369 chr5 35037115 C T 3.00E-23 Urinary metabolites (H-NMR features) AGXT2 missense 24586186 rs37369 chr5 35037115 C T 3.00E-26 Urinary metabolites (H-NMR features) AGXT2 missense 24586186 rs37369 chr5 35037115 C T 3.10E-23 Urinary metabolites (H-NMR features) AGXT2 missense 24586186 rs37369 chr5 35037115 C T 3.40E-26 Urinary metabolites (H-NMR features) AGXT2 missense 24586186 rs37369 chr5 35037115 C T 5.50E-15 Urinary metabolites (H-NMR features) AGXT2 missense 24586186 rs37369 chr5 35037115 C T 6.00E-15 Urinary metabolites (H-NMR features) AGXT2 missense 24586186 rs37369 chr5 35037115 C T 7.90E-15 Urinary metabolites (H-NMR features) AGXT2 missense 24586186 rs37369 chr5 35037115 C T 8.00E-15 Urinary metabolites (H-NMR features) AGXT2 missense 24586186 rs37369 chr5 35037115 C T 9.70E-64 Urinary metabolites (H-NMR features) AGXT2 missense 24586186 rs40199 chr5 35037681 G A 8.90E-77 Urinary metabolites AGXT2 intron 21572414 rs40199 chr5 35037681 G A 1.11E-07 Serum dimethylarginine levels (asymmetric) AGXT2 intron 24159190 rs40199 chr5 35037681 G A 2.76E-35 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs40199 chr5 35037681 G A 4.84E-30 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13177884 chr5 35038178 C T 9.30E-13 Urinary metabolites AGXT2 intron 21572414 rs13177884 chr5 35038178 C T 6.48E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13177884 chr5 35038178 C T 8.56E-07 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs6892674 chr5 35038424 C T 6.00E-19 Urinary metabolites AGXT2 intron 21572414 rs6892674 chr5 35038424 C T 5.16E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs6892674 chr5 35038424 C T 7.20E-14 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs11952305 chr5 35038582 A C 1.10E-12 Urinary metabolites AGXT2 intron 21572414 rs11952305 chr5 35038582 A C 6.35E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs11952305 chr5 35038582 A C 8.98E-07 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs2279651 chr5 35039437 A G 3.80E-17 Urinary metabolites AGXT2 cds-synon 21572414 rs2279651 chr5 35039437 A G 1.35E-13 Serum dimethylarginine levels (symmetric) AGXT2 cds-synon 24159190 rs2279651 chr5 35039437 A G 9.22E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 cds-synon 24159190 rs37370 chr5 35039486 C A,G,T 6.00E-66 Urinary metabolites AGXT2 missense 21572414 rs37370 chr5 35039486 C A,G,T 1.00E-07 Serum dimethylarginine levels (asymmetric) AGXT2 missense 24159190 rs37370 chr5 35039486 C A,G,T 1.88E-35 Serum dimethylarginine levels (symmetric) AGXT2 missense 24159190 rs37370 chr5 35039486 C A,G,T 5.35E-30 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 missense 24159190 rs11950974 chr5 35040113 T C 3.00E-13 Urinary metabolites AGXT2 intron 21572414 rs11950974 chr5 35040113 T C 1.38E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs11950974 chr5 35040113 T C 5.80E-11 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs43160 chr5 35040154 G A 8.30E-64 Urinary metabolites AGXT2 intron 21572414 rs43160 chr5 35040154 G A 1.46E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs43160 chr5 35040154 G A 1.59E-07 Serum dimethylarginine levels (asymmetric) AGXT2 intron 24159190 rs43160 chr5 35040154 G A 4.02E-16 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs37371 chr5 35040230 A G 3.70E-65 Urinary metabolites AGXT2 intron 21572414 rs37371 chr5 35040230 A G 1.05E-07 Serum dimethylarginine levels (asymmetric) AGXT2 intron 24159190 rs37371 chr5 35040230 A G 5.14E-35 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs37371 chr5 35040230 A G 9.66E-27 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs10521022 chr5 35043020 C T 6.10E-13 Urinary metabolites AGXT2 intron 21572414 rs10521022 chr5 35043020 C T 2.67E-06 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs10521022 chr5 35043020 C T 8.66E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13171891 chr5 35044076 C T 4.20E-13 Urinary metabolites AGXT2 intron 21572414 rs13171891 chr5 35044076 C T 8.45E-12 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs13171891 chr5 35044076 C T 9.45E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13172279 chr5 35044165 G T 2.50E-13 Urinary metabolites AGXT2 intron 21572414 rs13172279 chr5 35044165 G T 3.27E-13 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs13172279 chr5 35044165 G T 4.87E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs28305 chr5 35044298 C G 5.30E-60 Urinary metabolites AGXT2 intron 21572414 rs28305 chr5 35044298 C G 2.11E-07 Serum dimethylarginine levels (asymmetric) AGXT2 intron 24159190 rs28305 chr5 35044298 C G 2.38E-29 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs28305 chr5 35044298 C G 5.87E-35 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs6896900 chr5 35044541 C T 4.80E-13 Urinary metabolites AGXT2 intron 21572414 rs6896900 chr5 35044541 C T 3.75E-12 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs6896900 chr5 35044541 C T 8.15E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs37376 chr5 35044716 G C 6.10E-63 Urinary metabolites AGXT2 intron 21572414 rs37376 chr5 35044716 G C 2.46E-35 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs37376 chr5 35044716 G C 6.83E-30 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs37376 chr5 35044716 G C 9.94E-08 Serum dimethylarginine levels (asymmetric) AGXT2 intron 24159190 rs37377 chr5 35045494 G T 1.70E-61 Urinary metabolites AGXT2 intron 21572414 rs37377 chr5 35045494 G T 1.00E-07 Serum dimethylarginine levels (asymmetric) AGXT2 intron 24159190 rs37377 chr5 35045494 G T 2.60E-35 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs37377 chr5 35045494 G T 6.96E-30 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13177986 chr5 35045533 A C 4.00E-12 Urinary metabolites AGXT2 intron 21572414 rs13177986 chr5 35045533 A C 5.58E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs13177986 chr5 35045533 A C 7.31E-07 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs40200 chr5 35045745 A G 3.65E-05 Alcohol and nictotine co-dependence AGXT2 intron 20158304 rs40200 chr5 35045745 A G 1.80E-62 Urinary metabolites AGXT2 intron 21572414 rs40200 chr5 35045745 A G 1.62E-07 Serum dimethylarginine levels (asymmetric) AGXT2 intron 24159190 rs40200 chr5 35045745 A G 3.80E-35 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs40200 chr5 35045745 A G 4.83E-28 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs40200 chr5 35045745 A G 9.00E-37 Urinary metabolites (H-NMR features) AGXT2 intron 24586186 rs40200 chr5 35045745 A G 9.30E-37 Urinary metabolites (H-NMR features) AGXT2 intron 24586186 rs11952373 chr5 35045766 G C 1.00E-11 Urinary metabolites AGXT2 intron 21572414 rs11952373 chr5 35045766 G C 5.36E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs11952373 chr5 35045766 G C 5.46E-07 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs37379 chr5 35045826 A G 1.50E-62 Urinary metabolites AGXT2 intron 21572414 rs37379 chr5 35045826 A G 1.03E-07 Serum dimethylarginine levels (asymmetric) AGXT2 intron 24159190 rs37379 chr5 35045826 A G 2.66E-35 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs37379 chr5 35045826 A G 7.32E-30 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs11959527 chr5 35045895 A C 1.34E-08 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs11959527 chr5 35045895 A C 7.65E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs2003147 chr5 35046130 A C 8.39E-06 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs13184057 chr5 35046744 G T 4.30E-11 Urinary metabolites AGXT2 intron 21572414 rs13184057 chr5 35046744 G T 2.63E-06 Serum dimethylarginine levels (symmetric) AGXT2 intron 24159190 rs13184057 chr5 35046744 G T 3.48E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) AGXT2 intron 24159190 rs249522 chr5 35060319 C T 1.60E-05 Urinary metabolites PRLR UTR-3 21572414 rs146459777 chr5 35065328 C G 0.00032 Breast cancer PRLR missense 23555315 rs16871815 chr5 35096441 C T 5.10E-05 Multiple complex diseases PRLR intron 17554300 rs4703390 chr5 35103897 G A 4.80E-05 Urinary metabolites PRLR intron 21572414 rs4703499 chr5 35104367 C T 4.90E-05 Urinary metabolites PRLR intron 21572414 rs7734558 chr5 35114611 G A 1.56E-05 Glucose levels PRLR intron pha003058 rs7734558 chr5 35114611 G A 9.54E-06 Glucose levels PRLR intron pha003061 rs6880595 chr5 35161332 A G 1.38E-04 Endometrial cancer PRLR intron 24096698 rs6880595 chr5 35161332 A G 2.68E-04 Endometrial cancer PRLR intron 24096698 rs16872491 chr5 35164895 T C 3.96E-05 Tunica Media PRLR intron pha003038 rs1039427 chr5 35165935 C T 1.40E-06 Urinary metabolites PRLR intron 21572414 rs1039427 chr5 35165935 C T 9.65E-04 Iron levels PRLR intron pha002876 rs1039427 chr5 35165935 C T 9.80E-05 Tunica Media PRLR intron pha003038 rs7729932 chr5 35168370 G A 1.30E-06 Urinary metabolites PRLR intron 21572414 rs4703505 chr5 35172021 G A 1.30E-06 Urinary metabolites PRLR intron 21572414 rs4703506 chr5 35172207 T C 2.60E-06 Urinary metabolites PRLR intron 21572414 rs13154347 chr5 35181833 G A 1.10E-06 Urinary metabolites PRLR intron 21572414 rs7713837 chr5 35183976 T C 9.00E-07 Urinary metabolites PRLR intron 21572414 rs6897259 chr5 35188444 T C 1.40E-06 Urinary metabolites PRLR intron 21572414 rs12514742 chr5 35188476 G T 2.63E-04 Endometrial cancer PRLR intron 24096698 rs12514742 chr5 35188476 G T 4.34E-04 Endometrial cancer PRLR intron 24096698 rs12514742 chr5 35188476 G T 5.78E-05 Endometrial cancer PRLR intron 24096698 rs12521272 chr5 35190327 A G 5.50E-05 Endometrial cancer PRLR intron 24096698 rs12521272 chr5 35190327 A G 6.82E-05 Endometrial cancer PRLR intron 24096698 rs12521272 chr5 35190327 A G 7.37E-05 Endometrial cancer PRLR intron 24096698 rs1587607 chr5 35198462 A G 6.40E-06 Urinary metabolites PRLR intron 21572414 rs11955662 chr5 35199919 G C 2.40E-06 Urinary metabolites PRLR intron 21572414 rs7718468 chr5 35201036 A G 8.00E-04 Amyotrophic Lateral Sclerosis PRLR intron 17827064 rs12187337 chr5 35208791 A C 4.50E-04 Urinary metabolites PRLR intron 21572414 rs10038062 chr5 35220519 C T 6.36E-04 Type 2 diabetes PRLR intron 17463246 rs7731153 chr5 35220865 G A 7.64E-04 Type 2 diabetes PRLR intron 17463246 rs1587610 chr5 35224242 T C 2.88E-04 Type 2 diabetes PRLR intron 17463246 rs10036454 chr5 35225617 A G 1.30E-05 Urinary metabolites PRLR intron 21572414 rs7727306 chr5 35237860 C T 7.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs9292582 chr5 35239150 C T 7.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs1587601 chr5 35254610 A G 3.78E-09 Leprosy / / 22019778 rs7701255 chr5 35270560 C T 6.25E-05 Triglycerides / / pha003080 rs1604413 chr5 35286554 A G 4.06E-05 Triglycerides / / pha003080 rs1025324 chr5 35345497 G A 2.70E-05 Triglycerides / / pha003080 rs244776 chr5 35365857 T C 8.81E-04 Multiple complex diseases / / 17554300 rs413206 chr5 35369453 C T 8.86E-04 Schizophrenia / / 19197363 rs32776 chr5 35378034 T C 9.83E-04 Multiple complex diseases / / 17554300 rs32784 chr5 35382353 T C 9.39E-04 Multiple complex diseases / / 17554300 rs421175 chr5 35395998 T C 2.90E-04 Alzheimer's disease (late onset) / / 21379329 rs10491349 chr5 35418784 A G 4.49E-06 Multiple complex diseases / / 17554300 rs32790 chr5 35431096 G A 9.63E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs16902021 chr5 35431463 G C 4.94E-04 Multiple complex diseases / / 17554300 rs6888863 chr5 35435047 T G 5.67E-04 Multiple complex diseases / / 17554300 rs284737 chr5 35461200 T C 8.00E-06 Metabolite levels (HVA/5-HIAA ratio) / / 23319000 rs2136138 chr5 35486420 T C 6.10E-04 Urinary metabolites / / 21572414 rs286405 chr5 35577257 C T 6.70E-07 Type 1 diabetes / / 19875614 rs4703414 chr5 35580601 A G 8.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs10512623 chr5 35585387 C T 8.51E-05 Blood Pressure / / pha003040 rs140014553 chr5 35596037 G A 1.28E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs12657936 chr5 35616027 G A 4.68E-05 Lipid traits / / 24023261 rs16902377 chr5 35652823 G A 7.83E-05 Personality dimensions SPEF2 intron 18957941 rs2172754 chr5 35668036 A G 1.89E-04 Epilepsy SPEF2 intron 22116939 rs6872795 chr5 35677385 A G 1.32E-04 Epilepsy SPEF2 intron 22116939 rs12515119 chr5 35708492 G A 5.22E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs13170082 chr5 35709095 C T 5.36E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 missense 24159190 rs13170390 chr5 35709184 G C 5.39E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 missense 24159190 rs7447772 chr5 35710038 C T 7.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPEF2 intron 20877124 rs7447772 chr5 35710038 C T 5.40E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs7444550 chr5 35710113 T C 5.39E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs13356541 chr5 35710330 G A 5.38E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs11958367 chr5 35710386 A G 4.15E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs7729774 chr5 35710728 C T 4.78E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs6451208 chr5 35711333 A T 3.26E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs13182061 chr5 35711748 G C 3.42E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs10039940 chr5 35712138 C A 3.54E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs10040024 chr5 35712310 G C 3.28E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs12697346 chr5 35712513 C T 4.74E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs12697347 chr5 35712556 C T 4.71E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs12697348 chr5 35712599 A T 4.68E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs10078803 chr5 35712780 A G 4.67E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs10073537 chr5 35713007 T G 4.63E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs13153876 chr5 35713136 G A 4.62E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs13153894 chr5 35713173 G A 4.62E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs13153665 chr5 35713265 A G 8.31E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs13153802 chr5 35713281 C A 8.30E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs13173900 chr5 35713322 T C 8.30E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs13154215 chr5 35713324 G A 8.30E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs13153955 chr5 35713348 C T 5.85E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs66496382 chr5 35713409 G A 5.72E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs10066293 chr5 35713797 G A 5.10E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs7723050 chr5 35714231 G C 3.56E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs7726714 chr5 35714258 C T 3.81E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs7727052 chr5 35714535 C T 3.81E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs7727246 chr5 35714704 A C 3.73E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs6887970 chr5 35714851 A G 8.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPEF2 intron 20877124 rs6887970 chr5 35714851 A G 2.81E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs6869545 chr5 35714981 T C 2.47E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs6869545 chr5 35714981 T C 8.75E-06 Serum dimethylarginine levels (symmetric) SPEF2 intron 24159190 rs6893432 chr5 35715266 G A 2.47E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs6893432 chr5 35715266 G A 8.75E-06 Serum dimethylarginine levels (symmetric) SPEF2 intron 24159190 rs6893470 chr5 35715342 G A 2.47E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs6893470 chr5 35715342 G A 8.75E-06 Serum dimethylarginine levels (symmetric) SPEF2 intron 24159190 rs10070465 chr5 35715699 G C 3.71E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs10072048 chr5 35716042 G C 3.70E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs10072009 chr5 35716099 C T 3.69E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs10941259 chr5 35716368 G C 3.69E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs10037597 chr5 35716420 A G 3.69E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs10043180 chr5 35716506 C T 3.68E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs10043224 chr5 35716534 G A 3.68E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs10037620 chr5 35716568 A T 3.67E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs10057421 chr5 35716878 A G 3.67E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs7725060 chr5 35717308 T G 8.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPEF2 intron 20877124 rs7725060 chr5 35717308 T G 3.31E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs7705347 chr5 35717575 A G 4.99E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs7705633 chr5 35717673 C T 5.08E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs7725807 chr5 35717757 T C 2.54E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs7725807 chr5 35717757 T C 8.99E-06 Serum dimethylarginine levels (symmetric) SPEF2 intron 24159190 rs7705851 chr5 35717924 A C 3.55E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs7706122 chr5 35718013 C T 3.54E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs6451209 chr5 35718189 G C 3.54E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs6451211 chr5 35718262 T G 3.54E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs6870156 chr5 35718606 A G 5.91E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs6870755 chr5 35718889 C T 3.62E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs6871358 chr5 35719090 G A 3.63E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs6875846 chr5 35719353 G T 3.69E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs6897149 chr5 35719435 T C 2.64E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs6897149 chr5 35719435 T C 9.41E-06 Serum dimethylarginine levels (symmetric) SPEF2 intron 24159190 rs11954310 chr5 35725509 A G 4.46E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs34181885 chr5 35726449 T G 5.13E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs6451212 chr5 35729642 A G 4.66E-04 Type 2 diabetes SPEF2 intron 17463246 rs9688012 chr5 35751101 A G 1.50E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs9688012 chr5 35751101 A G 5.01E-06 Serum dimethylarginine levels (symmetric) SPEF2 intron 24159190 rs7736028 chr5 35758733 C T 4.42E-04 Type 2 diabetes SPEF2 intron 17463246 rs57276516 chr5 35762592 G A 2.84E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs6895801 chr5 35763916 A G 4.42E-04 Type 2 diabetes SPEF2 intron 17463246 rs4130605 chr5 35766895 G A 4.40E-04 Type 2 diabetes SPEF2 intron 17463246 rs11749262 chr5 35776239 A G 4.02E-05 Weight SPEF2 intron pha003026 rs3822735 chr5 35799994 A G 2.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) SPEF2 intron 23648065 rs2361394 chr5 35800547 A G 5.08E-04 Multiple complex diseases SPEF2 intron 17554300 rs931555 chr5 35803577 C T 1.87E-05 Multiple sclerosis SPEF2 intron 19525953 rs931555 chr5 35803577 C T 4.00E-07 Multiple sclerosis SPEF2 intron 21244703 rs11742689 chr5 35806148 C T 6.82E-04 Obesity (extreme) SPEF2 intron 21935397 rs142338941 chr5 35810760 T A 5.20E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SPEF2 intron 24159190 rs4869672 chr5 35811282 C T 9.88E-04 Multiple complex diseases SPEF2 intron 17554300 rs7709856 chr5 35819133 A C 1.95E-05 Parkinson's disease (motor and cognition) / / 22658654 rs145860897 chr5 35824942 G A 6.12E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs903389 chr5 35827665 C G 8.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6890853 chr5 35852311 G A 4.00E-08 Primary biliary cirrhosis / / 23000144 rs6890853 chr5 35852311 G A 9.70E-04 Self-reported allergy / / 23817569 rs11567694 chr5 35857704 A G 7.35E-04 Self-reported allergy IL7R intron 23817569 rs10213865 chr5 35857850 A C 7.52E-04 Self-reported allergy IL7R intron 23817569 rs11567697 chr5 35858324 A G 8.96E-04 Obesity (extreme) IL7R intron 21935397 rs11567698 chr5 35858343 T G 8.95E-04 Obesity (extreme) IL7R intron 21935397 rs7717955 chr5 35862841 C T 9.04E-04 Aortic root size IL7R intron 21223598 rs7717955 chr5 35862841 C T 3.23E-10 Primary biliary cirrhosis IL7R intron 21399635 rs11567714 chr5 35862985 C T 8.92E-04 Obesity (extreme) IL7R intron 21935397 rs11567762 chr5 35873201 G A 1.32E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines IL7R intron 21844884 rs11567765 chr5 35874246 C T 1.93E-04 Insulin resistance IL7R intron 21901158 rs6897932 chr5 35874575 C T 8.00E-06 Type 1 diabetes IL7R missense 17554260 rs6897932 chr5 35874575 C T 5.47E-04 Multiple complex diseases IL7R missense 17554300 rs6897932 chr5 35874575 C T 3.00E-07 Multiple sclerosis IL7R missense 17660530 rs6897932 chr5 35874575 C T 2.00E-06 Multiple sclerosis IL7R missense 19525953 rs6897932 chr5 35874575 C T 3.16E-10 Primary biliary cirrhosis IL7R missense 21399635 rs6897932 chr5 35874575 C T 2.00E-08 Multiple sclerosis IL7R missense 21833088 rs6897932 chr5 35874575 C T 7.70E-04 Multiple sclerosis IL7R missense 22190364 rs6897932 chr5 35874575 C T 0.00000508 Primary biliary cirrhosis IL7R missense 22936693 rs6897932 chr5 35874575 C T 4.52E-13 Primary biliary cirrhosis IL7R missense 22961000 rs3194051 chr5 35876274 A G 4.00E-08 Ulcerative colitis IL7R missense 21297633 rs10491434 chr5 35877914 A G 7.36E-04 Multiple complex diseases / / 17554300 rs6881270 chr5 35879095 C T 0.000265 Primary biliary cirrhosis / / 22936693 rs6881706 chr5 35879156 G T 9.62E-04 Multiple complex diseases / / 17554300 rs10214237 chr5 35883734 T C 5.84E-04 Self-reported allergy / / 23817569 rs2194225 chr5 35883804 T C 6.57E-05 Breast cancer / / pha002853 rs10214273 chr5 35883986 T G 6.51E-04 Self-reported allergy / / 23817569 rs6871748 chr5 35885982 T C 2.26E-13 Primary biliary cirrhosis / / 22961000 rs6871748 chr5 35885982 T C 4.17E-04 Self-reported allergy / / 23817569 rs990716 chr5 35899264 T C 8.14E-04 Type 2 diabetes / / 17463246 rs990716 chr5 35899264 T C 3.00E-04 Multiple complex diseases / / 17554300 rs990716 chr5 35899264 T C 8.10E-06 Urinary metabolites / / 21572414 rs1025039 chr5 35901857 G T 1.57E-05 Multiple complex diseases / / 17554300 rs2287900 chr5 35903997 C T 9.12E-04 Type 2 diabetes / / 17463246 rs2287900 chr5 35903997 C T 5.28E-04 Multiple complex diseases / / 17554300 rs2287900 chr5 35903997 C T 6.20E-06 Urinary metabolites / / 21572414 rs1833907 chr5 35904614 G T 3.90E-06 Urinary metabolites CAPSL UTR-3 21572414 rs1345827 chr5 35904889 C A 6.62E-06 Multiple complex diseases CAPSL intron 17554300 rs984164 chr5 35908015 A T 3.27E-06 Multiple complex diseases CAPSL intron 17554300 rs1010599 chr5 35908474 A G 3.37E-06 Multiple complex diseases CAPSL intron 17554300 rs1445898 chr5 35910529 C T 8.00E-06 Type 1 diabetes CAPSL missense 17554260 rs4024109 chr5 35919618 T C 7.04E-06 Multiple complex diseases CAPSL intron 17554300 rs4024110 chr5 35919651 G T 7.77E-04 Type 2 diabetes CAPSL intron 17463246 rs4024110 chr5 35919651 G T 2.17E-04 Multiple complex diseases CAPSL intron 17554300 rs17311549 chr5 35920258 T C 6.85E-04 Multiple complex diseases CAPSL intron 17554300 rs11948151 chr5 35926341 C T 8.66E-05 Basophils CAPSL intron pha003087 rs700175 chr5 35930917 C T 5.39E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CAPSL intron 21844884 rs696733 chr5 35932539 G A 3.75E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CAPSL intron 21844884 rs700172 chr5 35934157 T C 0.000000782 Primary biliary cirrhosis (anti-mitochondrial antibody positive) CAPSL intron 22936693 rs700172 chr5 35934157 T C 0.00000163 Primary biliary cirrhosis CAPSL intron 22936693 rs700172 chr5 35934157 T C 0.0000784 Primary biliary cirrhosis in females CAPSL intron 22936693 rs10941269 chr5 35935110 T A 5.04E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CAPSL intron 21844884 rs10472267 chr5 35940365 A G 8.70E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs860413 chr5 35943042 A C 1.00E-11 Primary biliary cirrhosis / / 21399635 rs852238 chr5 35943952 C T 8.27E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs852236 chr5 35945733 G T 8.32E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10491431 chr5 35968000 C A 2.00E-11 Blood metabolite levels UGT3A1 intron 24816252 rs2447876 chr5 36028200 C T 2.10E-05 Urinary metabolites / / 21572414 rs2441081 chr5 36029709 T C 1.10E-05 Urinary metabolites / / 21572414 rs2453299 chr5 36031870 A G 2.80E-05 Urinary metabolites / / 21572414 rs1287271 chr5 36050048 G A 2.30E-05 Urinary metabolites UGT3A2 intron 21572414 rs2047176 chr5 36056800 C T 1.95E-06 adolescent idiopathic scoliosis UGT3A2 intron 24023777 rs1287262 chr5 36057228 C G 1.50E-04 Statin-induced myopathy UGT3A2 intron 21826682 rs267770 chr5 36064673 A G 0.000404713 Hypertension (early onset hypertension) UGT3A2 intron 22479346 rs2270909 chr5 36109797 T C 2.40E-08 Metabolite levels LMBRD2 intron 23281178 rs267759 chr5 36137620 A G 7.00E-06 Response to treatment for acute lymphoblastic leukemia LMBRD2 intron 19176441 rs267759 chr5 36137620 A G 7.58E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) LMBRD2 intron 24236485 rs267766 chr5 36143392 C T 4.30E-06 adolescent idiopathic scoliosis LMBRD2 cds-synon 24023777 rs12657634 chr5 36147439 G A 2.40E-08 Metabolite levels LMBRD2 intron 23281178 rs10941274 chr5 36147528 T C 2.40E-08 Metabolite levels LMBRD2 intron 23281178 rs12655052 chr5 36149661 T C 2.40E-08 Metabolite levels LMBRD2 intron 23281178 rs13160147 chr5 36191407 C T 5.16E-04 Endometrial cancer / / 24096698 rs7719357 chr5 36192025 G A 8.60E-05 Parkinson's disease (age of onset) / / 19772629 rs7716788 chr5 36196428 G A 9.44E-05 Brain derived neurotrophic factor levels,in serum /DKD1 intron 22047184 rs10941278 chr5 36204074 T G 8.74E-05 Serum metabolites /DKD1 intron 19043545 rs11741164 chr5 36281625 C T 1.73E-04 Multiple complex diseases RANBP3L intron 17554300 rs11741164 chr5 36281625 C T 3.80E-05 Serum metabolites RANBP3L intron 19043545 rs952303 chr5 36299709 T C 3.82E-04 Tuberculosis RANBP3L intron 22239941 rs16902947 chr5 36309097 A G 1.00E-07 Serum tamsulosin hydrochloride concentration / / 23151678 rs4354072 chr5 36367860 C T 1.61E-04 Attention deficit hyperactivity disorder / / pha002875 rs2967072 chr5 36398377 A G 6.74E-05 Caffeine consumption / / 21490707 rs4337871 chr5 36405303 A T 7.18E-06 Glycemic traits (pregnancy) / / 23903356 rs7735940 chr5 36423931 G T 5.00E-13 Hypertension / / 21626137 rs12522034 chr5 36425593 G C 5.00E-13 Hypertension / / 21626137 rs12515142 chr5 36426411 T C 3.91E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4571496 chr5 36430755 A G 7.39E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4602648 chr5 36431978 C T 2.01E-05 Cognitive impairment induced by topiramate / / 22091778 rs10941293 chr5 36435494 C A 5.54E-04 Alzheimer's disease / / 24755620 rs114846327 chr5 36436579 A G 2.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2468502 chr5 36443080 A C 7.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs10061011 chr5 36443160 G A 7.75E-05 Cognitive test performance / / 20125193 rs10061011 chr5 36443160 G A 7.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs10061011 chr5 36443160 G A 3.53E-05 Blood Pressure / / pha003046 rs10061011 chr5 36443160 G A 5.64E-05 Blood Pressure / / pha003048 rs2468503 chr5 36444227 A G 8.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs2468504 chr5 36448895 C T 8.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs10066222 chr5 36452065 T C 9.19E-05 Alzheimer's disease / / 24755620 rs12516155 chr5 36452318 C T 9.14E-05 Alzheimer's disease / / 24755620 rs2455277 chr5 36459584 T C 9.70E-05 Cognitive function / / 24684796 rs2455277 chr5 36459584 T C 9.47E-06 Blood Pressure / / pha003040 rs2455279 chr5 36460209 T G 1.37E-04 Cognitive function / / 24684796 rs2967055 chr5 36472990 G A 8.97E-05 Coronary heart disease / / pha003030 rs2937550 chr5 36473237 C T 8.00E-06 Height / / 21998595 rs2937550 chr5 36473237 C T 9.00E-06 IgG glycosylation / / 23382691 rs4869483 chr5 36520513 A C 3.20E-04 Birth weight / / 17255346 rs2562544 chr5 36524757 T C 1.18E-05 Multiple complex diseases / / 17554300 rs9292633 chr5 36541302 C T 4.13E-05 Birth weight / / 17255346 rs9292633 chr5 36541302 C T 8.34E-04 Iron levels / / pha002876 rs7715271 chr5 36569753 G T 1.52E-04 Iron levels / / pha002876 rs1549688 chr5 36580791 A G 1.40E-05 Urinary metabolites / / 21572414 rs4421130 chr5 36581914 G A 1.90E-05 Urinary metabolites / / 21572414 rs7728680 chr5 36613053 A G 9.85E-05 Waist-Hip Ratio SLC1A3 intron pha003013 rs7728680 chr5 36613053 A G 9.60E-05 Waist-Hip Ratio SLC1A3 intron pha003028 rs1366638 chr5 36616535 A G 4.70E-05 Blood Pressure SLC1A3 intron pha002903 rs3776568 chr5 36632611 G C 9.44E-05 Chronic Hepatitis C infection SLC1A3 intron 21725309 rs1366632 chr5 36635565 G T 2.00E-04 Cognitive impairment induced by topiramate SLC1A3 intron 22091778 rs432268 chr5 36636816 A G 2.70E-05 Chronic Hepatitis C infection SLC1A3 intron 21725309 rs3776578 chr5 36651986 T C 4.14E-04 Fibrinogen SLC1A3 intron 17255346 rs3776579 chr5 36654493 T G 1.91E-04 Fibrinogen SLC1A3 intron 17255346 rs4869685 chr5 36659084 C T 5.20E-05 HIV-1 control SLC1A3 intron 20041166 rs3776587 chr5 36684598 G A 5.33E-07 Height SLC1A3 intron pha003010 rs3776587 chr5 36684598 G A 9.36E-07 Height SLC1A3 intron pha003011 rs918642 chr5 36703653 G A 5.24E-08 Post-operative nausea and vomiting / / 21694509 rs6451305 chr5 36719979 C T 4.80E-04 Multiple complex diseases / / 17554300 rs36652 chr5 36723323 A G 9.51E-05 Multiple complex diseases / / 17554300 rs36651 chr5 36723395 C T 5.58E-05 Multiple complex diseases / / 17554300 rs736917 chr5 36728340 G T 1.71E-05 Post-operative nausea and vomiting / / 21694509 rs12653677 chr5 36730711 C G 5.50E-04 Multiple complex diseases / / 17554300 rs245675 chr5 36730813 C T 1.92E-05 Multiple complex diseases / / 17554300 rs10941315 chr5 36732788 G T 1.71E-04 Obesity (extreme) / / 21935397 rs245677 chr5 36735107 G A 3.18E-05 Body Mass Index / / pha003009 rs36678 chr5 36735871 C T 3.30E-04 Multiple complex diseases / / 17554300 rs6869867 chr5 36739499 G A 1.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6892066 chr5 36749082 G T 8.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13158310 chr5 36789654 T G 6.93E-05 Smoking initiation / / 24665060 rs1466862 chr5 36791812 G A 5.91E-05 Smoking initiation / / 24665060 rs7712559 chr5 36792815 A G 6.72E-04 Multiple complex diseases / / 17554300 rs172384 chr5 36804225 A G 1.51E-04 Hypertension / / 21082022 rs158796 chr5 36878780 A G 3.79E-04 Smoking initiation NIPBL intron 24665060 rs158622 chr5 36887895 T C 3.57E-04 Smoking initiation NIPBL intron 24665060 rs293748 chr5 36900843 G A 7.00E-06 Obesity-related traits NIPBL intron 23251661 rs292196 chr5 36914179 C T 1.01E-04 Hypertension NIPBL intron 21082022 rs2123010 chr5 36921325 T C 2.71E-04 Alzheimer's disease (late onset) NIPBL intron 21379329 rs168662 chr5 36925735 C T 2.40E-04 Smoking initiation NIPBL intron 24665060 rs11743833 chr5 36933947 C T 2.07E-05 Height NIPBL intron pha003010 rs11743833 chr5 36933947 C T 5.64E-05 Height NIPBL intron pha003011 rs292194 chr5 36941767 T C 3.90E-05 Smoking initiation NIPBL intron 24665060 rs292179 chr5 36947613 A G 2.04E-04 Multiple complex diseases NIPBL intron 17554300 rs158791 chr5 36948362 C G 2.51E-04 Smoking initiation NIPBL intron 24665060 rs16903415 chr5 36948466 A G 5.94E-04 Multiple complex diseases NIPBL intron 17554300 rs292182 chr5 36954812 G A 2.40E-04 Smoking initiation NIPBL intron 24665060 rs296962 chr5 36990483 C T 3.35E-04 Smoking initiation NIPBL intron 24665060 rs41364149 chr5 36991133 G A 2.09E-04 Multiple complex diseases NIPBL intron 17554300 rs159751 chr5 36999998 A G 3.35E-04 Smoking initiation NIPBL intron 24665060 rs159753 chr5 37007629 T C 2.21E-04 Smoking initiation NIPBL intron 24665060 rs300060 chr5 37019354 G A 2.88E-04 Smoking initiation NIPBL intron 24665060 rs300064 chr5 37025871 C A 1.90E-04 Statin-induced myopathy NIPBL intron 21826682 rs12187383 chr5 37027258 C A 2.95E-05 Height NIPBL intron pha003010 rs12187383 chr5 37027258 C A 9.41E-05 Height NIPBL intron pha003011 rs16903459 chr5 37031416 A G 4.36E-04 Hypertension NIPBL intron 21082022 rs6861906 chr5 37075936 T C 1.39E-04 Multiple complex diseases / / 17554300 rs6861906 chr5 37075936 T C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2098713 chr5 37144574 C T 3.00E-06 Telomere length C5orf42 intron 24795349 rs10061157 chr5 37161618 A G 1.70E-05 Urinary metabolites C5orf42 intron 21572414 rs10076911 chr5 37173930 A C 5.50E-04 Myopia (pathological) C5orf42 missense 21095009 rs12658479 chr5 37206621 T C 1.91E-04 Hypertension C5orf42 intron 21082022 rs16903599 chr5 37356911 G A 1.66E-06 Multiple complex diseases NUP155 intron 17554300 rs11955258 chr5 37369958 A C 6.90E-05 HIV-1 control NUP155 intron 20041166 rs13178300 chr5 37409579 C T 2.20E-04 Vaspin levels WDR70 intron 22907691 rs13178300 chr5 37409579 C T 0.0002196 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks WDR70 intron 22907730 rs2056871 chr5 37424855 C T 7.00E-06 Urinary metabolites WDR70 intron 21572414 rs7715951 chr5 37492210 T A 8.00E-07 Urinary metabolites WDR70 intron 21572414 rs11957546 chr5 37506332 T C 8.00E-07 Urinary metabolites WDR70 intron 21572414 rs2088077 chr5 37556926 A G 0.000609 Schizophrenia WDR70 intron 22440650 rs665327 chr5 37585849 G A 5.00E-06 Urinary metabolites WDR70 intron 21572414 rs677084 chr5 37586211 G A 5.00E-06 Urinary metabolites WDR70 intron 21572414 rs10941345 chr5 37587570 A C 5.88E-04 Multiple complex diseases WDR70 intron 17554300 rs12656733 chr5 37648563 G T 5.00E-06 Urinary metabolites WDR70 intron 21572414 rs12521063 chr5 37671746 T C 1.00E-04 Cognitive impairment induced by topiramate WDR70 intron 22091778 rs6451339 chr5 37696178 T C 1.30E-06 Urinary metabolites WDR70 intron 21572414 rs6451339 chr5 37696178 T C 1.00E-04 Cognitive impairment induced by topiramate WDR70 intron 22091778 rs4869544 chr5 37700516 C T 4.74E-10 Biliary atresia WDR70 intron 20460270 rs4242252 chr5 37716067 A G 9.55E-05 Weight WDR70 intron pha003027 rs1019505 chr5 37731359 T A 5.00E-06 Urinary metabolites WDR70 intron 21572414 rs6451341 chr5 37743077 G C 4.20E-04 Type 2 diabetes WDR70 intron 17463246 rs2366673 chr5 37753872 C T 6.50E-07 Urinary metabolites / / 21572414 rs10472290 chr5 37772566 G T 1.10E-05 Urinary metabolites / / 21572414 rs7719968 chr5 37775258 T C 1.16E-05 Serum metabolites / / 19043545 rs11745243 chr5 37777974 C T 2.03E-05 Magnesium levels / / pha003092 rs7737481 chr5 37782403 A G 2.06E-06 Blood pressure / / 21422096 rs7737481 chr5 37782403 A G 8.23E-05 Blood pressure / / 21422096 rs2973062 chr5 37788489 C T 7.83E-05 Serum metabolites / / 19043545 rs2973062 chr5 37788489 C T 7.74E-06 Smoking behavior / / 19188921 rs9292673 chr5 37791733 A G 2.20E-07 Urinary metabolites / / 21572414 rs11748343 chr5 37805942 G A 5.11E-05 Height / / pha003011 rs11111 chr5 37814102 T C 8.50E-05 Diabetic retinopathy GDNF UTR-3 21441570 rs3749692 chr5 37814148 A G 3.96E-05 Cognitive performance GDNF UTR-3 19734545 rs2910797 chr5 37820365 C T 8.90E-08 Urinary metabolites GDNF intron 21572414 rs1549250 chr5 37821221 C A 3.15E-05 Coronary heart disease GDNF intron pha003031 rs17386472 chr5 37832798 C T 6.90E-05 Body Mass Index GDNF intron pha003022 rs10941370 chr5 37833419 T C 3.78E-05 Height GDNF intron pha003010 rs10941370 chr5 37833419 T C 6.05E-05 Height GDNF intron pha003011 rs10941370 chr5 37833419 T C 8.75E-05 Coronary heart disease GDNF intron pha003031 rs1862573 chr5 37849688 G A 1.10E-04 Myasthenia gravis / / 23055271 rs2973116 chr5 37854738 G A 7.67E-04 Aortic root size / / 21223598 rs1423449 chr5 37865750 G A 2.66E-04 Alzheimer's disease (late onset) / / 21379329 rs10461985 chr5 37874409 G A 1.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10461985 chr5 37874409 G A 8.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11956009 chr5 37879544 C A 1.40E-04 Alzheimer's disease (late onset) / / 21379329 rs881041 chr5 37882093 A C 3.86E-04 Alzheimer's disease (late onset) / / 21379329 rs889268 chr5 37882172 G A 6.05E-05 Alzheimer's disease (late onset) / / 21379329 rs2910744 chr5 37886625 G A 2.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13187321 chr5 37896640 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2973084 chr5 37901942 G A 3.28E-04 Parkinson's disease / / 17052657 rs11959616 chr5 37912995 G T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10512670 chr5 37913544 A C 1.42E-04 Multiple complex diseases / / 17554300 rs10512670 chr5 37913544 A C 2.41E-05 Crohn's disease / / 18587394 rs10512670 chr5 37913544 A C 0.0000085 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2216712 chr5 37918703 C T 7.90E-06 Alcoholism (heaviness of drinking) / / 21529783 rs35850755 chr5 37927717 G T 6.90E-04 Urinary metabolites / / 21572414 rs1423431 chr5 37929958 T C 2.51E-04 Hemoglobin concentration / / 20534544 rs10067610 chr5 37933612 G A 6.50E-04 Urinary metabolites / / 21572414 rs764569 chr5 37935286 C T 2.60E-04 Urinary metabolites / / 21572414 rs16903808 chr5 37946913 C G 8.52E-04 Obesity (extreme) / / 21935397 rs10941373 chr5 37947990 G A 9.50E-04 Urinary metabolites / / 21572414 rs10043844 chr5 37948142 T G 9.40E-04 Urinary metabolites / / 21572414 rs35795154 chr5 37949542 G T 4.10E-04 Urinary metabolites / / 21572414 rs67887820 chr5 37949542 G GT 4.10E-04 Urinary metabolites / / 21572414 rs10041827 chr5 37949867 C T 3.90E-04 Urinary metabolites / / 21572414 rs9292683 chr5 37950691 T C 8.50E-04 Urinary metabolites / / 21572414 rs13180820 chr5 37952959 A C 6.40E-04 Urinary metabolites / / 21572414 rs7726463 chr5 37955073 T C 8.01E-13 Esophageal cancer / / 21642993 rs72730654 chr5 37955768 T C 7.63E-05 Epilepsy (remission after treatment) / / 23962720 rs6893050 chr5 37956236 T A 2.60E-04 Urinary metabolites / / 21572414 rs6898456 chr5 37957085 T C 4.60E-04 Urinary metabolites / / 21572414 rs10473076 chr5 37958803 A G 6.50E-04 Urinary metabolites / / 21572414 rs13180084 chr5 37965613 C T 2.60E-04 Urinary metabolites / / 21572414 rs13162604 chr5 37965810 T G 7.20E-04 Urinary metabolites / / 21572414 rs2292262 chr5 37966315 C G 6.80E-04 Urinary metabolites / / 21572414 rs4072686 chr5 37967352 A G 6.20E-04 Urinary metabolites / / 21572414 rs4072685 chr5 37967498 G T 6.90E-04 Urinary metabolites / / 21572414 rs13183095 chr5 37970920 G C 7.60E-04 Urinary metabolites / / 21572414 rs2136192 chr5 37972576 G A 6.50E-04 Urinary metabolites / / 21572414 rs6451352 chr5 37972586 C T 6.40E-04 Urinary metabolites / / 21572414 rs7735288 chr5 37975867 A G 7.40E-04 Urinary metabolites / / 21572414 rs1304732 chr5 37986493 C T 9.77E-05 Multiple sclerosis (age of onset) / / 19010793 rs1508833 chr5 38014253 C A 2.63E-05 HIV-1 viral setpoint / / 21490045 rs270568 chr5 38022879 T C 8.46E-04 Type 2 diabetes / / 17846124 rs270562 chr5 38029329 A T 9.73E-04 Type 2 diabetes / / 17846124 rs172012 chr5 38031591 C T 8.59E-04 Type 2 diabetes / / 17846124 rs270552 chr5 38038345 G A 7.38E-05 Orofacial clefts / / 22863734 rs270550 chr5 38040195 T C 6.58E-05 Orofacial clefts / / 22863734 rs7722472 chr5 38046009 C T 4.50E-05 Major depressive disorder (broad) / / 20038947 rs380930 chr5 38046170 T C 8.73E-04 Type 2 diabetes / / 17463246 rs380930 chr5 38046170 T C 2.79E-04 Substance dependence / / 21818250 rs16903843 chr5 38051241 T C 7.05E-05 Major depressive disorder (broad) / / 20038947 rs270545 chr5 38051593 G A 3.39E-06 Major depressive disorder (broad) / / 20038947 rs270545 chr5 38051593 G A 1.00E-06 Major depressive disorder / / 20125088 rs6897687 chr5 38051703 T C 5.08E-05 Major depressive disorder (broad) / / 20038947 rs270543 chr5 38052046 G A 3.41E-06 Major depressive disorder (broad) / / 20038947 rs10073812 chr5 38052113 C T 5.76E-05 Major depressive disorder (broad) / / 20038947 rs270538 chr5 38053333 A G 3.77E-06 Major depressive disorder (broad) / / 20038947 rs270537 chr5 38053488 A G 3.64E-06 Major depressive disorder (broad) / / 20038947 rs6883823 chr5 38054327 T C 5.27E-05 Major depressive disorder (broad) / / 20038947 rs270599 chr5 38055273 C A 4.50E-06 Major depressive disorder (broad) / / 20038947 rs169187 chr5 38056271 A G 4.97E-06 Major depressive disorder (broad) / / 20038947 rs10512674 chr5 38056753 A C 6.74E-05 Major depressive disorder (broad) / / 20038947 rs10512674 chr5 38056753 A C 5.58E-06 Hepatitis C induced liver cirrhosis / / 23321320 rs270596 chr5 38057728 C T 5.32E-06 Major depressive disorder (broad) / / 20038947 rs1729011 chr5 38058518 G A 5.28E-06 Major depressive disorder (broad) / / 20038947 rs1703301 chr5 38058559 C T 5.40E-06 Major depressive disorder (broad) / / 20038947 rs6867522 chr5 38058965 T C 7.11E-05 Major depressive disorder (broad) / / 20038947 rs6891116 chr5 38059375 C A 5.89E-05 Major depressive disorder (broad) / / 20038947 rs6891116 chr5 38059375 C A 9.14E-06 Hepatitis C induced liver cirrhosis / / 23321320 rs270594 chr5 38060688 T C 5.94E-06 Major depressive disorder (broad) / / 20038947 rs368758 chr5 38063061 G A 7.55E-05 Major depressive disorder (broad) / / 20038947 rs425092 chr5 38064945 A G 1.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs270592 chr5 38066586 G A 1.88E-06 Major depressive disorder (broad) / / 20038947 rs270589 chr5 38070112 A C 1.69E-04 Type 2 diabetes / / 17463246 rs270586 chr5 38072705 A G 4.00E-04 Type 2 diabetes / / 17463246 rs270584 chr5 38074854 C A 2.06E-06 Major depressive disorder (broad) / / 20038947 rs270581 chr5 38076563 T A 5.34E-04 Type 2 diabetes / / 17463246 rs270580 chr5 38076684 G A 4.16E-04 Type 2 diabetes / / 17463246 rs270578 chr5 38078180 A G 1.51E-05 Major depressive disorder (broad) / / 20038947 rs1874170 chr5 38085159 T G 8.89E-05 Major depressive disorder (broad) / / 20038947 rs2471046 chr5 38087078 C A 9.10E-05 Major depressive disorder (broad) / / 20038947 rs2453332 chr5 38087361 A G 9.20E-05 Major depressive disorder (broad) / / 20038947 rs2471047 chr5 38087397 T C 9.33E-05 Major depressive disorder (broad) / / 20038947 rs1817900 chr5 38087767 A G 9.36E-05 Major depressive disorder (broad) / / 20038947 rs1817901 chr5 38087810 A G 9.43E-05 Major depressive disorder (broad) / / 20038947 rs2453333 chr5 38088411 T C 9.59E-05 Major depressive disorder (broad) / / 20038947 rs2471049 chr5 38088444 A G 9.72E-05 Major depressive disorder (broad) / / 20038947 rs2471050 chr5 38088520 T C 7.74E-05 Major depressive disorder (broad) / / 20038947 rs12653109 chr5 38089107 T C 9.76E-05 Major depressive disorder (broad) / / 20038947 rs2463769 chr5 38089284 A G 9.55E-05 Major depressive disorder (broad) / / 20038947 rs2453335 chr5 38089427 A T 9.53E-05 Major depressive disorder (broad) / / 20038947 rs2471052 chr5 38090175 T C 9.54E-05 Major depressive disorder (broad) / / 20038947 rs4413560 chr5 38090806 G C 9.71E-05 Major depressive disorder (broad) / / 20038947 rs2471070 chr5 38091354 T C 9.72E-05 Major depressive disorder (broad) / / 20038947 rs2471074 chr5 38091684 C T 9.68E-05 Major depressive disorder (broad) / / 20038947 rs2453337 chr5 38091763 C G 2.97E-04 Type 2 diabetes / / 17463246 rs2463765 chr5 38094717 A G 3.99E-05 Major depressive disorder (broad) / / 20038947 rs2453338 chr5 38094871 A T 1.69E-05 Major depressive disorder (broad) / / 20038947 rs2471065 chr5 38095315 G T 1.93E-05 Major depressive disorder (broad) / / 20038947 rs2013340 chr5 38099612 A G 2.49E-04 Type 2 diabetes / / 17463246 rs2453328 chr5 38120428 A G 1.00E-07 Urinary metabolites / / 21572414 rs2453329 chr5 38123006 A G 1.87E-04 Smoking initiation / / 24665060 rs4269309 chr5 38150689 T A 9.77E-05 Insulin resistance / / 21901158 rs6451374 chr5 38203031 G T 4.22E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs4869576 chr5 38210894 T C 1.52E-06 Schizophrenia / / 22037555 rs6886259 chr5 38234603 C T 9.73E-04 Aortic root size / / 21223598 rs2006889 chr5 38264735 A G 4.78E-05 Prostate cancer EGFLAM intron 22923026 rs2006889 chr5 38264735 A G 0.00011 Prostate cancer EGFLAM intron 23555315 rs10941389 chr5 38278416 T C 8.19E-05 Prostate cancer EGFLAM intron 22923026 rs1428247 chr5 38281744 T C 2.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EGFLAM intron 20877124 rs1428247 chr5 38281744 T C 8.30E-05 Prostate cancer EGFLAM intron 22923026 rs2451018 chr5 38305547 G A 9.88E-05 Serum metabolites EGFLAM intron 19043545 rs9292705 chr5 38346665 G A 4.40E-08 Urinary metabolites EGFLAM intron 21572414 rs10045133 chr5 38351102 T G 4.21E-06 Left ventricular mass EGFLAM intron 21212386 rs2255207 chr5 38362043 T C 5.35E-05 Socioeconomic Factors EGFLAM intron pha003066 rs10214135 chr5 38366662 T C 2.17E-05 Brain structure EGFLAM intron 22504417 rs16903957 chr5 38370256 T C 4.68E-04 Alzheimer's disease EGFLAM intron 24755620 rs6879031 chr5 38371063 A G 4.64E-05 Calcium levels EGFLAM intron pha003085 rs3110232 chr5 38381015 A G 9.56E-06 Sleep quality EGFLAM intron 23728906 rs10512684 chr5 38417839 A G 7.94E-04 Schizophrenia EGFLAM intron 21674006 rs3812046 chr5 38425008 G A 2.52E-05 Lymphocyte counts EGFLAM intron pha003094 rs3812046 chr5 38425008 G A 5.61E-06 Neutrophil count EGFLAM intron pha003095 rs2956597 chr5 38440601 A G 9.25E-06 Heart Failure EGFLAM intron pha002884 rs6875081 chr5 38445553 G A 1.40E-26 Narcolepsy EGFLAM intron 19629137 rs11737983 chr5 38446764 C A 2.06E-04 Heart Failure EGFLAM intron pha002884 rs2561805 chr5 38450430 T C 9.34E-06 Heart Failure EGFLAM intron pha002884 rs7715172 chr5 38452894 C G 3.00E-06 Response to citalopram treatment EGFLAM intron 22760553 rs2731968 chr5 38456766 T C 3.76E-06 Heart Failure EGFLAM intron pha002884 rs1005017 chr5 38481335 C T 3.75E-04 Multiple complex diseases LIFR UTR-3 17554300 rs3729740 chr5 38496637 C T 5.18E-05 Colorectal cancer (drug response in metastatic colorectal cancer) LIFR missense 21239504 rs3729734 chr5 38527308 G A 0.00025 Prostate cancer LIFR missense 23555315 rs17427485 chr5 38569857 A G 4.43E-04 Multiple complex diseases LIFR intron 17554300 rs10512687 chr5 38581262 C T 7.61E-04 Heart Failure LIFR intron pha002884 rs1562134 chr5 38601073 G A 4.52E-04 Smoking initiation LIFR-AS1 intron 24665060 rs1444884 chr5 38615656 A G 1.40E-05 Biliary atresia / / 20460270 rs6893077 chr5 38619513 G T 6.18E-04 Type 2 diabetes / / 17463246 rs7705509 chr5 38622131 A C 2.52E-04 HIV-1 viral setpoint / / 17641165 rs327276 chr5 38633264 C T 3.68E-05 Serum metabolites / / 19043545 rs327263 chr5 38653634 A G 1.73E-05 HIV-1 viral setpoint / / 17641165 rs6451402 chr5 38684635 A G 3.99E-04 HIV-1 viral setpoint / / 17641165 rs1428499 chr5 38694483 G T 5.69E-05 Prostate cancer / / pha002878 rs10070418 chr5 38724924 C G 5.01E-04 Multiple complex diseases / / 17554300 rs10055279 chr5 38725043 A C 6.20E-04 Multiple complex diseases / / 17554300 rs12332238 chr5 38726143 A G 1.10E-05 Urinary metabolites / / 21572414 rs4337869 chr5 38728218 G A 1.80E-05 Urinary metabolites / / 21572414 rs4131821 chr5 38728759 A G 2.30E-05 Urinary metabolites / / 21572414 rs16867681 chr5 38735263 G A 2.90E-06 Urinary metabolites / / 21572414 rs4869598 chr5 38743568 C T 8.91E-05 Brain lesion load / / 19010793 rs7706715 chr5 38792486 C A 4.62E-05 Alcohol consumption / / 23953852 rs4373300 chr5 38798749 G A 4.67E-06 Alcohol consumption / / 23953852 rs11749831 chr5 38804215 C T 7.15E-05 Cognitive impairment induced by topiramate / / 22091778 rs420444 chr5 38857366 T G 8.36E-04 Multiple complex diseases OSMR intron 17554300 rs395157 chr5 38867732 C T 6.94E-05 IgE levels in asthmatics OSMR intron 23967269 rs357273 chr5 38875436 A G 7.66E-04 Multiple complex diseases OSMR intron 17554300 rs357271 chr5 38876573 T C 6.94E-06 Esophageal cancer (squamous cell) OSMR intron 22960999 rs533654 chr5 38877966 G A 6.94E-04 Alzheimer's disease OSMR intron 24755620 rs3792856 chr5 38879218 T C 8.09E-05 Body Mass Index OSMR intron pha003022 rs525735 chr5 38881628 G T 1.86E-05 Bone mineral density OSMR intron 19181680 rs391463 chr5 38887780 C T 6.12E-04 Alzheimer's disease OSMR intron 17998437 rs3792860 chr5 38891897 G A 5.21E-05 Inflammation OSMR intron pha002897 rs10036224 chr5 38900046 A G 3.58E-04 Multiple complex diseases OSMR intron 17554300 rs1239334 chr5 38904363 C T 2.10E-04 Alzheimer's disease OSMR intron 24755620 rs10040172 chr5 38905288 A G 3.55E-04 Tourette syndrome OSMR intron 22889924 rs10941412 chr5 38919158 G A 3.42E-04 Multiple complex diseases OSMR missense 17554300 rs610912 chr5 38919619 A G 8.00E-04 Type 2 diabetes OSMR intron 17463246 rs168568 chr5 38924916 T C 8.68E-04 Alzheimer's disease OSMR intron 17998437 rs1239344 chr5 38933749 C T 1.16E-06 Obesity-related traits OSMR UTR-3 23251661 rs2043112 chr5 38955796 G A 8.00E-07 Obesity-related traits RICTOR missense 23251661 rs13160161 chr5 39058356 G A 2.00E-06 Obesity-related traits RICTOR intron 23251661 rs6869095 chr5 39074696 C T 3.30E-06 Obesity-related traits / / 23251661 rs6895953 chr5 39084471 G A 2.30E-06 Obesity-related traits / / 23251661 rs13165383 chr5 39089342 G A 8.97E-06 Obesity-related traits / / 23251661 rs10045011 chr5 39175369 C T 7.18E-05 Schizophrenia FYB intron 24253340 rs696741 chr5 39206235 G A 1.56E-04 Multiple complex diseases FYB intron 17554300 rs696748 chr5 39213696 A G 1.53E-05 Alcohol and nictotine co-dependence FYB intron 20158304 rs7700754 chr5 39253022 G A 1.89E-05 Alcohol and nictotine co-dependence FYB intron 20158304 rs1362811 chr5 39254765 T C 1.00E-04 Cognitive impairment induced by topiramate FYB intron 22091778 rs1362811 chr5 39254765 T C 4.77E-04 Lymphocyte counts FYB intron 22286170 rs155453 chr5 39259461 T C 7.57E-05 Blood pressure (response to angiotensin II receptor blocker) FYB intron 24192120 rs6879555 chr5 39261513 C T 3.99E-04 Multiple complex diseases FYB intron 17554300 rs12655171 chr5 39263661 C T 2.62E-05 Cognitive impairment induced by topiramate FYB intron 22091778 rs659639 chr5 39264883 A G 8.81E-05 Bone mineral density FYB intron 19181680 rs659639 chr5 39264883 A G 9.58E-05 Magnesium levels FYB intron pha003092 rs3776535 chr5 39309090 G A 1.07E-04 Smoking cessation C9 intron 24665060 rs3776534 chr5 39310183 C G 1.08E-04 Smoking cessation C9 intron 24665060 rs3822462 chr5 39338358 G A 7.70E-04 Iron levels C9 intron pha002876 rs4957473 chr5 39343163 A G 4.24E-06 Parkinson's disease C9 intron pha002868 rs700220 chr5 39356591 G A 3.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C9 intron 20877124 rs10074282 chr5 39392083 A T 1.00E-06 Parkinson's disease (interaction with coffee consumption) DAB2 intron 21876681 rs2255280 chr5 39394989 C A 4.00E-10 Pancreatic cancer DAB2 intron 22158540 rs2686172 chr5 39395533 G T 1.15E-06 Pancreatic cancer DAB2 intron 22158540 rs2855509 chr5 39396944 A G 2.69E-06 Pancreatic cancer DAB2 intron 22158540 rs11959928 chr5 39397132 T A 1.00E-07 Chronic kidney disease DAB2 intron 20383146 rs11959928 chr5 39397132 T A 5.19E-13 Chronic kidney disease DAB2 intron 22479191 rs11959928 chr5 39397132 T A 4.00E-04 Glomerular filtration rate DAB2 intron 23535967 rs11959928 chr5 39397132 T A 4.20E-04 Glomerular filtration rate DAB2 intron 23535967 rs11959928 chr5 39397132 T A 5.80E-04 Glomerular filtration rate DAB2 intron 23535967 rs11959928 chr5 39397132 T A 7.00E-04 Glomerular filtration rate DAB2 intron 23535967 rs2367584 chr5 39412568 G A 3.62E-06 Pancreatic cancer DAB2 intron 22158540 rs6872083 chr5 39418421 A G 5.74E-05 Schizophrenia DAB2 intron 24253340 rs3860796 chr5 39438575 A G 1.30E-05 Urinary metabolites / / 21572414 rs10512706 chr5 39441157 T A 1.00E-04 Response to interferon beta in multiple sclerosis / / 18195134 rs4596408 chr5 39447059 T G 0.0002 Migraine / / 22678113 rs3909475 chr5 39471176 T C 6.51E-05 Serum albumin level / / pha003084 rs2910951 chr5 39525266 C T 3.66E-04 Smoking initiation / / 24665060 rs16869031 chr5 39526068 C T 2.25E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs16869048 chr5 39533992 C T 6.36E-05 Waist-Hip Ratio / / pha003029 rs16869048 chr5 39533992 C T 1.92E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs11951152 chr5 39534183 A G 5.32E-05 Waist-Hip Ratio / / pha003029 rs11951152 chr5 39534183 A G 2.84E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs1501699 chr5 39548143 G T 2.32E-04 Type 2 diabetes / / 17463246 rs1501698 chr5 39548192 G T 5.01E-04 Type 2 diabetes / / 17463246 rs2962483 chr5 39549314 G T 9.97E-04 Type 2 diabetes / / 17463246 rs1501720 chr5 39557684 T C 7.59E-04 Type 2 diabetes / / 17463246 rs1501718 chr5 39561256 A G 8.07E-04 Type 2 diabetes / / 17463246 rs4957483 chr5 39587710 A T 4.92E-04 Type 2 diabetes / / 17463246 rs4957489 chr5 39609436 T G 8.96E-04 Type 2 diabetes / / 17463246 rs7708079 chr5 39648564 C T 3.44E-04 Sudden cardiac arrest / / 21658281 rs4957217 chr5 39676277 T C 5.53E-05 Blood pressure / / 21422096 rs4957217 chr5 39676277 T C 6.61E-04 Blood pressure / / 21422096 rs4957217 chr5 39676277 T C 7.59E-06 Blood pressure / / 21422096 rs10512712 chr5 39692332 C T 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs970692 chr5 39694505 A G 1.97E-04 Aortic root size / / 21223598 rs1499237 chr5 39698129 G T 4.92E-04 Multiple complex diseases / / 17554300 rs7716130 chr5 39703121 C T 9.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs7722702 chr5 39721625 G T 6.72E-04 Hearing function / / 17255346 rs1353835 chr5 39748470 G T 2.55E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs6860457 chr5 39782692 G T 4.66E-05 Telomere length / / 21573004 rs1994882 chr5 39806164 C A 2.14E-07 Platelet aggregation(pre- and post-aspirin) / / 20529293 rs1994882 chr5 39806164 C A 1.56E-06 Parent of origin effect on language impairment (maternal) / / 24571439 rs12658486 chr5 39806217 A G 1.43E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs10075021 chr5 39806878 A G 1.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs7712189 chr5 39807589 C T 2.14E-07 Platelet aggregation(pre- and post-aspirin) / / 20529293 rs6881454 chr5 39814425 G A 3.20E-06 Urinary metabolites / / 21572414 rs980306 chr5 39816835 C T 3.91E-07 Parent of origin effect on language impairment (maternal) / / 24571439 rs10447141 chr5 39817167 C T 1.16E-07 Parent of origin effect on language impairment (maternal) / / 24571439 rs17194068 chr5 39821317 A G 1.04E-06 Parent of origin effect on language impairment (maternal) / / 24571439 rs6895329 chr5 39825740 T C 1.02E-06 Parent of origin effect on language impairment (maternal) / / 24571439 rs1816088 chr5 39861826 T G 1.73E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs1816088 chr5 39861826 T G 4.72E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs618051 chr5 39866913 G T 4.62E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs537289 chr5 39869265 C T 2.05E-04 Type 2 diabetes / / 17463246 rs544283 chr5 39878219 G A 8.73E-04 Aortic root size / / 21223598 rs11954519 chr5 39902365 A T 4.00E-06 Urate levels / / 23263486 rs4464722 chr5 39903405 G A 6.95E-04 Multiple complex diseases / / 17554300 rs538752 chr5 39906115 G C 9.24E-04 Type 2 diabetes / / 17463246 rs16869399 chr5 39906377 A C 6.04E-04 Multiple complex diseases / / 17554300 rs696770 chr5 39918453 G A 4.75E-04 Type 2 diabetes / / 17463246 rs542708 chr5 39932268 T C 8.42E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs482375 chr5 39942619 C T 3.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13168130 chr5 39947569 G A 5.58E-04 Multiple complex diseases / / 17554300 rs13168130 chr5 39947569 G A 1.87E-05 Serum metabolites / / 19043545 rs17804894 chr5 39947777 C T 7.67E-04 Multiple complex diseases / / 17554300 rs17804894 chr5 39947777 C T 3.87E-05 Serum metabolites / / 19043545 rs1354697 chr5 39956456 G A 9.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs10473156 chr5 39960584 C A 1.89E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs10053502 chr5 39979172 C T 1.44E-04 Type 2 diabetes / / 17463246 rs10053502 chr5 39979172 C T 1.00E-16 Myopia (pathological) / / 23049088 rs1506180 chr5 39986432 G T 7.40E-04 Multiple complex diseases / / 17554300 rs1506181 chr5 39988952 G C 9.47E-04 Multiple complex diseases / / 17554300 rs1506181 chr5 39988952 G C 9.89E-06 Serum metabolites / / 19043545 rs17217096 chr5 39989758 T C 2.39E-05 Serum metabolites / / 19043545 rs9292757 chr5 39990417 G A 1.28E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs1024099 chr5 39998845 C A 9.84E-05 Multiple complex diseases / / 17554300 rs1024099 chr5 39998845 C A 6.38E-05 Serum metabolites / / 19043545 rs6893266 chr5 39999656 C G 5.34E-04 Multiple complex diseases / / 17554300 rs1506185 chr5 40014359 T A 1.66E-04 Multiple complex diseases / / 17554300 rs1506185 chr5 40014359 T A 5.69E-06 Serum metabolites / / 19043545 rs6883670 chr5 40015706 C G 5.82E-05 Serum metabolites / / 19043545 rs17218399 chr5 40025962 A G 7.54E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs2967214 chr5 40040457 C T 1.88E-04 Multiple complex diseases / / 17554300 rs2967214 chr5 40040457 C T 1.65E-05 Serum metabolites / / 19043545 rs2939378 chr5 40042245 G A 3.43E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs1567010 chr5 40050301 A G 9.93E-06 Parent of origin effect on language impairment (maternal) / / 24571439 rs10059203 chr5 40052085 C A 4.92E-05 Sudden cardiac arrest / / 21658281 rs1395157 chr5 40055538 C T 6.76E-04 Multiple complex diseases / / 17554300 rs13161247 chr5 40058129 T C 6.46E-04 Parkinson's disease / / 16252231 rs12516769 chr5 40070383 A C 3.14E-04 Parkinson's disease / / 16252231 rs4957239 chr5 40077002 C T 3.92E-04 Parkinson's disease / / 16252231 rs1857869 chr5 40093632 G A 1.08E-05 Triglycerides / / 19074352 rs1857869 chr5 40093632 G A 1.08E-05 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs17819573 chr5 40094936 A C 4.25E-04 Parkinson's disease / / 16252231 rs11748571 chr5 40107282 A T 8.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs2548145 chr5 40134777 G A 2.00E-06 Alcoholism (alcohol use disorder factor score) / / 21529783 rs4957121 chr5 40136619 G A 6.59E-05 Multiple complex diseases / / 17554300 rs4403223 chr5 40138069 C T 4.35E-05 Type 2 diabetes / / 17463246 rs17820911 chr5 40155262 C T 3.30E-04 Parkinson's disease / / 16252231 rs350058 chr5 40211802 G A 1.00E-04 Multiple sclerosis / / 21833088 rs351651 chr5 40227586 G A 7.74E-04 Type 2 diabetes / / 17463246 rs351651 chr5 40227586 G A 1.35E-05 Response to citalopram treatment / / 19846067 rs13353952 chr5 40233464 G A 4.83E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs36019094 chr5 40237374 C A 2.21E-06 Asthma / / 21790008 rs36019094 chr5 40237374 C A 8.19E-26 Gender / / 22362730 rs36019094 chr5 40237374 C A 1.00E-06 Obesity-related traits / / 23251661 rs34868670 chr5 40237843 T C 9.58E-06 Asthma / / 21790008 rs34868670 chr5 40237843 T C 1.53E-30 Gender / / 22362730 rs2279170 chr5 40267930 T C 3.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs11950581 chr5 40269213 A G 6.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs7723858 chr5 40286862 A C 3.50E-05 Hypothyroidism / / 22493691 rs348621 chr5 40286967 T C 2.10E-05 Multiple complex diseases / / 17554300 rs348566 chr5 40307979 A G 5.17E-10 Multiple complex diseases / / 17554300 rs1445002 chr5 40319877 C A 3.94E-05 Crohn's disease / / 17684544 rs348601 chr5 40320006 T C 5.10E-07 Crohn's disease / / 17447842 rs10043093 chr5 40324220 C A 7.59E-06 Suicidal ideation / / 20877300 rs348604 chr5 40331364 G A 8.60E-05 Multiple complex diseases / / 17554300 rs7726744 chr5 40343276 T C 3.93E-09 Multiple complex diseases / / 17554300 rs7725523 chr5 40372223 A G 7.30E-04 Crohn's disease / / 17684544 rs10473185 chr5 40375167 T C 1.22E-04 Multiple complex diseases / / 17554300 rs16869864 chr5 40379689 G A 5.44E-09 Multiple complex diseases / / 17554300 rs1002922 chr5 40386555 T C 1.70E-09 Crohn's disease / / 17447842 rs12658567 chr5 40391932 T G 6.05E-04 Type 2 diabetes / / 22158537 rs2371685 chr5 40392226 A T 1.47E-04 Alzheimer's disease / / 17998437 rs4613763 chr5 40392728 T C 1.21E-04 Crohn's disease / / 17435756 rs4613763 chr5 40392728 T C 1.20E-09 Crohn's disease / / 17447842 rs4613763 chr5 40392728 T C 7.00E-27 Crohn's disease / / 18587394 rs4613763 chr5 40392728 T C 7.00E-27 Asthma / / 21150878 rs4613763 chr5 40392728 T C 3.00E-16 Multiple sclerosis / / 21833088 rs4613763 chr5 40392728 T C 6.82E-27 Multiple sclerosis / / 22190364 rs4613763 chr5 40392728 T C 1.40E-04 Multiple sclerosis / / 24234648 rs10512734 chr5 40393605 A G 9.20E-11 Crohn's disease / / 17447842 rs10512734 chr5 40393605 A G 1.38E-11 Multiple complex diseases / / 17554300 rs1992662 chr5 40393852 A G 1.56E-07 Crohn's disease / / 17684544 rs16869934 chr5 40397352 C T 5.66E-13 Multiple complex diseases / / 17554300 rs9292769 chr5 40397911 C T 1.10E-05 Volumetric brain MRI / / 17903297 rs17234657 chr5 40401509 T G 2.00E-12 Crohn's disease / / 17554300 rs17234657 chr5 40401509 T G 8.87E-05 Alzheimer's disease / / 17998437 rs17234657 chr5 40401509 T G 3.41E-27 Crohn's disease / / 18587394 rs17234657 chr5 40401509 T G 8.82E-05 Neutrophil count / / pha003095 rs11742570 chr5 40410584 T C 7.00E-36 Crohn's disease / / 21102463 rs11742570 chr5 40410584 T C 1.00E-06 Crohn's disease / / 22936669 rs11742570 chr5 40410584 T C 2.00E-82 Inflammatory bowel disease / / 23128233 rs6451493 chr5 40410935 G T 3.00E-09 Ulcerative colitis / / 21297633 rs1992660 chr5 40415067 C T 4.00E-07 Crohn's disease / / 17684544 rs6896969 chr5 40424426 A C 2.00E-07 Multiple sclerosis / / 19525953 rs6896969 chr5 40424426 A C 7.50E-10 Multiple sclerosis / / 21833088 rs1373692 chr5 40431183 A C 5.37E-04 Crohn's disease / / 17435756 rs1373692 chr5 40431183 A C 2.00E-12 Crohn's disease / / 17447842 rs1373692 chr5 40431183 A C 7.34E-05 Platelet counts / / pha003100 rs1445001 chr5 40431664 A G 7.34E-05 Platelet counts / / pha003100 rs6414887 chr5 40435315 T C 4.10E-04 Urinary metabolites / / 21572414 rs9292777 chr5 40437948 C T 3.00E-18 Crohn's disease / / 17554261 rs9292777 chr5 40437948 C T 1.89E-12 Multiple complex diseases / / 17554300 rs9292777 chr5 40437948 C T 2.00E-11 Crohn's disease / / 22412388 rs9292777 chr5 40437948 C T 1.00E-09 Multiple sclerosis / / 22570697 rs10213846 chr5 40442869 G T 3.81E-12 Multiple complex diseases / / 17554300 rs11957215 chr5 40445681 T C 2.51E-12 Multiple complex diseases / / 17554300 rs4957295 chr5 40447997 G A 3.79E-12 Multiple complex diseases / / 17554300 rs4957297 chr5 40455074 G A 5.37E-12 Multiple complex diseases / / 17554300 rs7728925 chr5 40456652 T C 3.98E-05 Self-reported allergy / / 23817569 rs4957300 chr5 40463739 T C 9.59E-12 Multiple complex diseases / / 17554300 rs4957300 chr5 40463739 T C 2.00E-04 Crohn's disease / / 17684544 rs4495224 chr5 40477515 C A 2.20E-07 Crohn's disease / / 17447842 rs6871834 chr5 40480187 G A 8.73E-12 Multiple complex diseases / / 17554300 rs6871834 chr5 40480187 G A 7.95E-06 Self-reported allergy / / 23817569 rs7717304 chr5 40481206 C T 2.96E-05 Self-reported allergy / / 23817569 rs6882351 chr5 40481654 G A 5.92E-07 Multiple complex diseases / / 17554300 rs7720838 chr5 40486896 G T 8.00E-11 Self-reported allergy / / 23817569 rs7725052 chr5 40487270 C T 3.24E-06 Crohn's disease / / 17684544 rs7725052 chr5 40487270 C T 3.43E-10 Self-reported allergy / / 23817569 rs9283753 chr5 40490609 C T 1.39E-10 Self-reported allergy / / 23817569 rs10440635 chr5 40490790 G A 3.00E-07 Ankylosing spondylitis / / 21743469 rs10440635 chr5 40490790 G A 1.01E-10 Self-reported allergy / / 23817569 rs10041894 chr5 40493234 G A 3.90E-08 Self-reported allergy / / 23817569 rs4957310 chr5 40495380 G A,C 9.16E-10 Self-reported allergy / / 23817569 rs9687948 chr5 40496276 G A 5.70E-10 Self-reported allergy / / 23817569 rs9687958 chr5 40496423 G T 5.96E-10 Self-reported allergy / / 23817569 rs10076944 chr5 40496951 G A 5.21E-10 Self-reported allergy / / 23817569 rs4286721 chr5 40497604 G A 0.0000408 Primary sclerosing cholangitis / / 23603763 rs4286721 chr5 40497604 G A 8.39E-10 Self-reported allergy / / 23817569 rs1505992 chr5 40498577 A T 9.38E-10 Multiple complex diseases / / 17554300 rs1505992 chr5 40498577 A T 5.86E-10 Self-reported allergy / / 23817569 rs6889990 chr5 40500667 G A 1.68E-05 Self-reported allergy / / 23817569 rs1553575 chr5 40502932 A G 1.68E-06 Crohn's disease / / 17684544 rs1553575 chr5 40502932 A G 1.77E-09 Self-reported allergy / / 23817569 rs7734013 chr5 40507243 G A 2.82E-09 Self-reported allergy / / 23817569 rs1553576 chr5 40509655 T A 2.53E-08 Multiple complex diseases / / 17554300 rs1553576 chr5 40509655 T A 3.24E-09 Self-reported allergy / / 23817569 rs1553577 chr5 40510007 T C 1.62E-08 Multiple complex diseases / / 17554300 rs1553577 chr5 40510007 T C 3.25E-09 Self-reported allergy / / 23817569 rs7703539 chr5 40513314 C T 3.40E-09 Self-reported allergy / / 23817569 rs6451513 chr5 40514752 G A 3.41E-09 Self-reported allergy / / 23817569 rs4957312 chr5 40515134 T A,C 3.72E-09 Self-reported allergy / / 23817569 rs4957313 chr5 40515522 G A 3.07E-08 Multiple complex diseases / / 17554300 rs4957313 chr5 40515522 G A 3.77E-09 Self-reported allergy / / 23817569 rs6896604 chr5 40516017 T C 2.92E-08 Multiple complex diseases / / 17554300 rs6896604 chr5 40516017 T C 3.46E-09 Self-reported allergy / / 23817569 rs6866402 chr5 40517331 T C 2.85E-08 Multiple complex diseases / / 17554300 rs6866402 chr5 40517331 T C 4.71E-09 Self-reported allergy / / 23817569 rs4957317 chr5 40517725 C T 7.32E-09 Multiple complex diseases / / 17554300 rs4957317 chr5 40517725 C T 6.10E-09 Self-reported allergy / / 23817569 rs10068204 chr5 40519351 T C 6.11E-09 Self-reported allergy / / 23817569 rs1876144 chr5 40521550 G A 7.05E-09 Self-reported allergy / / 23817569 rs1876143 chr5 40521648 A G 8.11E-06 Multiple complex diseases / / 17554300 rs10941516 chr5 40522212 A G 9.87E-07 Multiple complex diseases / / 17554300 rs10941516 chr5 40522212 A G 0.0000611 Panic disorder / / 23149450 rs10941516 chr5 40522212 A G 6.11E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs10941516 chr5 40522212 A G 2.50E-08 Self-reported allergy / / 23817569 rs1876141 chr5 40525735 G A 7.74E-09 Self-reported allergy / / 23817569 rs1505994 chr5 40527024 T C 7.77E-09 Self-reported allergy / / 23817569 rs6873494 chr5 40528126 G A 8.13E-09 Self-reported allergy / / 23817569 rs7718129 chr5 40528679 C G 1.44E-05 Multiple complex diseases / / 17554300 rs7718129 chr5 40528679 C G 6.86E-04 Aortic root size / / 21223598 rs7718309 chr5 40528899 A G 1.76E-05 Multiple complex diseases / / 17554300 rs7718309 chr5 40528899 A G 8.63E-04 Aortic root size / / 21223598 rs954688 chr5 40529798 T A 9.36E-09 Self-reported allergy / / 23817569 rs4512170 chr5 40530534 T A 3.08E-07 Self-reported allergy / / 23817569 rs10043301 chr5 40530886 C T 2.87E-07 Self-reported allergy / / 23817569 rs2202528 chr5 40531620 G C 0.0000392 Panic disorder / / 23149450 rs2202528 chr5 40531620 G C 3.92E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs2202528 chr5 40531620 G C 8.54E-07 Self-reported allergy / / 23817569 rs6451519 chr5 40540869 T C 3.13E-07 Self-reported allergy / / 23817569 rs13160426 chr5 40551478 A G 3.06E-07 Self-reported allergy / / 23817569 rs6451523 chr5 40553935 C T 4.46E-07 Self-reported allergy / / 23817569 rs6451525 chr5 40554269 C T 1.64E-05 Crohn's disease / / 17684544 rs6451525 chr5 40554269 C T 4.46E-07 Self-reported allergy / / 23817569 rs7735058 chr5 40555138 A C 4.46E-07 Self-reported allergy / / 23817569 rs12697413 chr5 40556327 A G 4.63E-07 Self-reported allergy / / 23817569 rs11750156 chr5 40561358 G T 1.09E-08 Multiple complex diseases / / 17554300 rs11750156 chr5 40561358 G T 4.58E-07 Self-reported allergy / / 23817569 rs2135331 chr5 40569087 A T 4.41E-07 Self-reported allergy / / 23817569 rs10055860 chr5 40569953 C T 1.13E-08 Multiple complex diseases / / 17554300 rs10055860 chr5 40569953 C T 4.76E-07 Self-reported allergy / / 23817569 rs10055946 chr5 40570075 C T 1.60E-05 Multiple complex diseases / / 17554300 rs11742349 chr5 40572443 G A 5.24E-07 Self-reported allergy / / 23817569 rs9292780 chr5 40573745 T C 7.42E-05 Neutrophil count / / pha003095 rs6878963 chr5 40574256 G A 3.39E-04 Multiple complex diseases / / 17554300 rs10075020 chr5 40575839 T C 4.69E-07 Self-reported allergy / / 23817569 rs1948901 chr5 40577768 A G 4.91E-07 Self-reported allergy / / 23817569 rs1948902 chr5 40577958 G C 4.74E-07 Self-reported allergy / / 23817569 rs9292781 chr5 40578557 A G 2.73E-07 Self-reported allergy / / 23817569 rs1122433 chr5 40578922 T C 1.17E-08 Multiple complex diseases / / 17554300 rs1122433 chr5 40578922 T C 4.76E-07 Self-reported allergy / / 23817569 rs7708395 chr5 40579871 A G 5.32E-07 Self-reported allergy / / 23817569 rs16900114 chr5 40585638 A G 2.77E-04 Multiple complex diseases / / 17554300 rs16900114 chr5 40585638 A G 4.55E-05 Self-reported allergy / / 23817569 rs9292782 chr5 40594738 A T 6.35E-07 Self-reported allergy / / 23817569 rs16870138 chr5 40596084 G A 6.26E-05 Self-reported allergy / / 23817569 rs6869535 chr5 40597618 G A 7.73E-05 Glioma / / 19578367 rs4434422 chr5 40600917 G A 4.39E-05 Multiple complex diseases / / 17554300 rs906062 chr5 40601157 A G 9.01E-07 Self-reported allergy / / 23817569 rs2135330 chr5 40602209 C T 5.41E-05 Multiple complex diseases / / 17554300 rs6878874 chr5 40602600 T G 9.92E-07 Self-reported allergy / / 23817569 rs10473203 chr5 40606294 A T 3.36E-08 Multiple complex diseases / / 17554300 rs10473203 chr5 40606294 A T 2.27E-06 Self-reported allergy / / 23817569 rs13163402 chr5 40607910 T C 2.43E-06 Self-reported allergy / / 23817569 rs16870170 chr5 40607956 C G 2.26E-05 Multiple complex diseases / / 17554300 rs13181692 chr5 40607998 G A 4.92E-05 Multiple complex diseases / / 17554300 rs1979937 chr5 40617402 A C 3.05E-06 Self-reported allergy / / 23817569 rs10214209 chr5 40618465 C T 3.60E-06 Self-reported allergy / / 23817569 rs4957138 chr5 40622940 G A 7.94E-07 Self-reported allergy / / 23817569 rs4957326 chr5 40622949 C T 3.42E-06 Self-reported allergy / / 23817569 rs11955175 chr5 40626753 T C 6.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs11739531 chr5 40629347 C T 1.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs7716982 chr5 40646560 G T 1.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs7716982 chr5 40646560 G T 8.38E-09 Schizophrenia / / 22037555 rs6882769 chr5 40647763 C T 6.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs6882769 chr5 40647763 C T 1.96E-10 Schizophrenia / / 22037555 rs7730020 chr5 40657952 T C 1.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs7730020 chr5 40657952 T C 8.38E-09 Schizophrenia / / 22037555 rs11954639 chr5 40674979 C T 8.44E-06 Bipolar disorder and schizophrenia / / 20889312 rs28540420 chr5 40687463 C T 0.00033 Coronary artery calcification PTGER4 intron 23727086 rs7730368 chr5 40694966 A C 0.000018 Coronary artery calcification / / 23727086 rs4957343 chr5 40695070 T C 7.80E-04 Type 2 diabetes / / 17463246 rs1345778 chr5 40712797 A C 6.55E-10 Schizophrenia TTC33 UTR-3 22037555 rs2329353 chr5 40748268 G A 2.10E-04 Multiple complex diseases TTC33 intron 17554300 rs2329353 chr5 40748268 G A 1.94E-04 Autism spectrum disorders (language delay) TTC33 intron 21519539 rs2329353 chr5 40748268 G A 7.35E-10 Schizophrenia TTC33 intron 22037555 rs6868517 chr5 40752536 A G 5.35E-10 Schizophrenia TTC33 intron 22037555 rs3792826 chr5 40753877 G A 1.84E-11 Schizophrenia TTC33 intron 22037555 rs1002424 chr5 40767397 A G 5.21E-10 Schizophrenia PRKAA1 intron 22037555 rs3792822 chr5 40775297 C T 9.80E-04 Major depressive disorder PRKAA1 intron 21042317 rs10074991 chr5 40790551 G A 2.54E-04 Multiple complex diseases PRKAA1 intron 17554300 rs10074991 chr5 40790551 G A 7.10E-04 Major depressive disorder PRKAA1 intron 21042317 rs10074991 chr5 40790551 G A 1.94E-04 Autism spectrum disorders (language delay) PRKAA1 intron 21519539 rs10074991 chr5 40790551 G A 5.11E-05 Parkinson's disease PRKAA1 intron 21738487 rs10074991 chr5 40790551 G A 4.21E-10 Schizophrenia PRKAA1 intron 22037555 rs13361707 chr5 40791884 C T 2.25E-04 Multiple complex diseases PRKAA1 intron 17554300 rs13361707 chr5 40791884 C T 6.80E-04 Major depressive disorder PRKAA1 intron 21042317 rs13361707 chr5 40791884 C T 2.30E-05 Urinary metabolites PRKAA1 intron 21572414 rs13361707 chr5 40791884 C T 8.00E-29 Gastric cancer PRKAA1 intron 22037551 rs13361707 chr5 40791884 C T 7.77E-08 Schizophrenia PRKAA1 intron 22037555 rs1001684 chr5 40810426 C A 5.08E-07 Schizophrenia / / 22037555 rs6876367 chr5 40829311 C T 8.82E-07 Schizophrenia / / 22037555 rs2291782 chr5 40831808 G A 0.000366 Breast cancer early age of onset RPL37 UTR-3 18463975 rs10065570 chr5 40835627 C T 6.40E-05 Bipolar disorder and schizophrenia / / 20889312 rs10065570 chr5 40835627 C T 1.90E-05 Urinary metabolites / / 21572414 rs10065570 chr5 40835627 C T 9.80E-07 Schizophrenia / / 22037555 rs173969 chr5 40841956 C T 3.52E-04 Hearing function CARD6 intron 17255346 rs704034 chr5 40842116 A G 2.57E-04 Nicotine dependence CARD6 intron 17158188 rs323565 chr5 40848803 A G 1.95E-04 Parkinson's disease CARD6 intron 21248740 rs323564 chr5 40850343 T C 0.00000407 Inter-adventitial common carotid artery diameter CARD6 intron 23246012 rs7715597 chr5 40872152 C T 2.88E-04 Hearing function / / 17255346 rs404223 chr5 40875879 G T 2.80E-04 Type 2 diabetes / / 17463246 rs11744923 chr5 40881478 G A 2.06E-04 Heart Failure / / pha002885 rs11744119 chr5 40904992 G A 2.86E-04 Heart Failure / / pha002885 rs16870514 chr5 40915165 G A 6.90E-04 Multiple complex diseases C7 intron 17554300 rs324062 chr5 40920533 G T 3.03E-04 Heart Failure C7 intron pha002885 rs1901167 chr5 40961164 A G 6.40E-05 Blood Pressure and Arterial Stiffness C7 intron 17903302 rs2034492 chr5 40974159 A G 8.85E-04 Type 2 diabetes C7 intron 23945395 rs3792648 chr5 40976117 A T 4.32E-05 Type 2 diabetes C7 intron 17463246 rs1078375 chr5 40977760 C T 0.000823308 Hypertension (early onset hypertension) C7 intron 22479346 rs4957361 chr5 40985604 C T 2.50E-05 Urinary metabolites / / 21572414 rs2122564 chr5 40987374 T C 6.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1878291 chr5 40997614 G A 5.64E-04 Depression (quantitative trait) / / 20800221 rs896117 chr5 40999419 G A 4.39E-04 Depression (quantitative trait) HEATR7B2 intron 20800221 rs1001420 chr5 41000343 G A 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes HEATR7B2 cds-synon 22628534 rs2167229 chr5 41001023 G A 8.78E-04 Depression (quantitative trait) HEATR7B2 intron 20800221 rs2305314 chr5 41004807 C T 3.87E-04 Depression (quantitative trait) HEATR7B2 intron 20800221 rs10941529 chr5 41005791 T C 2.91E-04 Depression (quantitative trait) HEATR7B2 intron 20800221 rs13155319 chr5 41006488 G A 2.05E-05 Depression (quantitative trait) HEATR7B2 intron 20800221 rs10805656 chr5 41006951 G A 2.06E-05 Depression (quantitative trait) HEATR7B2 intron 20800221 rs10061334 chr5 41009282 G A 1.98E-05 Depression (quantitative trait) HEATR7B2 intron 20800221 rs1878290 chr5 41009899 A G 2.01E-05 Depression (quantitative trait) HEATR7B2 intron 20800221 rs962274 chr5 41010731 A T 2.04E-05 Depression (quantitative trait) HEATR7B2 intron 20800221 rs1160833 chr5 41011187 T C 2.05E-05 Depression (quantitative trait) HEATR7B2 intron 20800221 rs12054764 chr5 41013467 A T 2.08E-05 Depression (quantitative trait) HEATR7B2 intron 20800221 rs2876851 chr5 41014117 G T 1.60E-04 Depression (quantitative trait) HEATR7B2 intron 20800221 rs10054110 chr5 41018452 A T 2.04E-05 Depression (quantitative trait) HEATR7B2 missense 20800221 rs1820152 chr5 41035222 C T 2.40E-05 Urinary metabolites HEATR7B2 intron 21572414 rs325857 chr5 41044616 G C 3.09E-04 Multiple complex diseases HEATR7B2 intron 17554300 rs325869 chr5 41051782 C T 0.0004131 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) HEATR7B2 intron 23233654 rs325869 chr5 41051782 C T 4.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) HEATR7B2 intron 23233662 rs325870 chr5 41051939 T C 1.71E-04 Multiple complex diseases HEATR7B2 intron 17554300 rs325870 chr5 41051939 T C 1.10E-05 Urinary metabolites HEATR7B2 intron 21572414 rs325874 chr5 41054934 A G 0.0004236 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) HEATR7B2 cds-synon 23233654 rs325874 chr5 41054934 A G 4.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) HEATR7B2 cds-synon 23233662 rs609356 chr5 41056685 C T 0.0003456 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) HEATR7B2 intron 23233654 rs609356 chr5 41056685 C T 3.46E-04 Methotrexate clearance (acute lymphoblastic leukemia) HEATR7B2 intron 23233662 rs387699 chr5 41060011 A T 7.04E-04 Multiple complex diseases HEATR7B2 intron 17554300 rs167815 chr5 41066128 C G 4.72E-05 Multiple complex diseases HEATR7B2 intron 17554300 rs2876852 chr5 41084303 C A 6.95E-04 Bipolar disorder / / 19259986 rs1423405 chr5 41097510 A G 2.70E-04 Multiple complex diseases / / 17554300 rs436607 chr5 41104690 A C 8.30E-04 Multiple complex diseases / / 17554300 rs1423416 chr5 41142632 A G 6.31E-04 Multiple complex diseases C6 UTR-3 17554300 rs7718610 chr5 41148502 A G 9.33E-04 Methotrexate clearance (acute lymphoblastic leukemia) C6 intron 23233662 rs4957374 chr5 41154150 A C 0.0008013 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) C6 intron 23233654 rs4957374 chr5 41154150 A C 8.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) C6 intron 23233662 rs3805715 chr5 41158489 A G 8.73E-04 Multiple complex diseases C6 intron 17554300 rs6865420 chr5 41158572 A C 0.0007776 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) C6 intron 23233654 rs6865420 chr5 41158572 A C 7.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) C6 intron 23233662 rs10075985 chr5 41158671 T C 0.0007715 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) C6 intron 23233654 rs10075985 chr5 41158671 T C 7.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) C6 intron 23233662 rs3805717 chr5 41161521 A C 0.0007588 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) C6 intron 23233654 rs3805717 chr5 41161521 A C 7.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) C6 intron 23233662 rs4245976 chr5 41185361 T C 7.00E-05 Asthma (aspirin-intolerant) C6 intron 21072201 rs4245977 chr5 41195700 C T 8.92E-05 Cognitive test performance C6 intron 20125193 rs10473238 chr5 41196230 C T 6.11E-05 Cognitive test performance C6 intron 20125193 rs7443270 chr5 41234046 C T 5.00E-06 Response to fenofibrate (adiponectin levels) C6 intron 23149075 rs1822824 chr5 41280364 T C 8.24E-04 Multiple complex diseases / / 17554300 rs17263342 chr5 41287911 G A 7.54E-05 Multiple complex diseases / / 17554300 rs320614 chr5 41302815 G A 4.24E-05 Epilepsy / / 22116939 rs6872806 chr5 41336050 G A 7.87E-06 Smoking cessation PLCXD3 intron 18519826 rs7725517 chr5 41356113 C A 6.22E-04 Smoking cessation PLCXD3 intron 18519826 rs7725517 chr5 41356113 C A 8.11E-05 Smoking cessation PLCXD3 intron 18519826 rs319003 chr5 41363888 C T 8.23E-05 Schizophrenia PLCXD3 intron 19197363 rs16871303 chr5 41376639 G C 1.34E-05 Smoking cessation PLCXD3 intron 18519826 rs16871303 chr5 41376639 G C 5.85E-05 Smoking cessation PLCXD3 intron 18519826 rs319005 chr5 41376727 T C 0.0005717 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PLCXD3 intron 23233654 rs319005 chr5 41376727 T C 5.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) PLCXD3 intron 23233662 rs1380998 chr5 41405529 C A 0.0002162 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PLCXD3 intron 23233654 rs1380998 chr5 41405529 C A 2.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) PLCXD3 intron 23233662 rs6451574 chr5 41409846 C A 0.0002226 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PLCXD3 intron 23233654 rs6451574 chr5 41409846 C A 2.23E-04 Methotrexate clearance (acute lymphoblastic leukemia) PLCXD3 intron 23233662 rs1037690 chr5 41413101 G A 0.0001045 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PLCXD3 intron 23233654 rs1037690 chr5 41413101 G A 1.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) PLCXD3 intron 23233662 rs9654393 chr5 41413696 T C 1.99E-04 Smoking cessation PLCXD3 intron 18519826 rs7714031 chr5 41476347 C T 5.95E-05 Prion diseases PLCXD3 intron 22210626 rs662066 chr5 41504813 A G 9.28E-06 Creutzfeldt-Jakob disease (variant) PLCXD3 intron 22137330 rs676328 chr5 41505689 T C 5.73E-07 Creutzfeldt-Jakob disease (variant) PLCXD3 intron 22137330 rs3863150 chr5 41506860 T C 5.73E-07 Creutzfeldt-Jakob disease (variant) PLCXD3 intron 22137330 rs4957397 chr5 41533615 A G 7.40E-05 Height / / 21998595 rs4957398 chr5 41533647 T A 2.20E-05 Height / / 21998595 rs668732 chr5 41574561 C A 4.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3863156 chr5 41584803 C T 8.24E-05 Hematocrit / / pha003097 rs650073 chr5 41587285 G A,T 9.24E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs675785 chr5 41648335 C T 5.10E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs623078 chr5 41666637 A G 5.71E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs316746 chr5 41683141 T G 1.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs685396 chr5 41688787 T C 7.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs600645 chr5 41701237 G T 7.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs588469 chr5 41701618 A G 7.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs316768 chr5 41711886 A G 1.15E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1027348 chr5 41786266 C T 3.15E-04 Response to taxane treatment (placlitaxel) OXCT1 intron 23006423 rs1027348 chr5 41786266 C T 5.63E-04 Response to cytadine analogues (cytosine arabinoside) OXCT1 intron 24483146 rs12186512 chr5 41802771 A G 5.37E-05 Brain lesion load OXCT1 intron 19010793 rs9292826 chr5 41828669 G A 3.15E-04 Response to taxane treatment (placlitaxel) OXCT1 intron 23006423 rs9292826 chr5 41828669 G A 4.29E-04 Response to cytadine analogues (cytosine arabinoside) OXCT1 intron 24483146 rs9292828 chr5 41838232 T C 8.63E-04 Response to taxane treatment (placlitaxel) OXCT1 intron 23006423 rs7723992 chr5 41853514 T G 3.55E-04 Response to taxane treatment (placlitaxel) OXCT1 intron 23006423 rs7723992 chr5 41853514 T G 4.29E-04 Response to cytadine analogues (cytosine arabinoside) OXCT1 intron 24483146 rs10052226 chr5 41955746 G A 2.88E-06 Cognitive test performance / / 20125193 rs10052226 chr5 41955746 G A 9.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10053522 chr5 41961622 C T 9.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs276295 chr5 42045856 C A 4.30E-05 Serum metabolites / / 19043545 rs12332782 chr5 42119990 C T 8.49E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4245983 chr5 42231896 T C 1.76E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11959168 chr5 42243481 G A 1.24E-05 Elbow pain / / pha003008 rs13157622 chr5 42270514 T C 8.82E-05 Hematocrit / / pha003097 rs11748684 chr5 42288593 C T 3.00E-06 Response to taxane treatment (docetaxel) / / 23006423 rs6887313 chr5 42304953 A G 6.58E-06 Response to taxane treatment (placlitaxel) / / 23006423 rs10051562 chr5 42312716 T C 2.09E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10064948 chr5 42315700 A G 8.50E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10472369 chr5 42321011 A G 8.50E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs979233 chr5 42375243 A C 4.00E-06 Systemic lupus erythematosus / / 18204098 rs10755268 chr5 42384347 G T 7.49E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1567374 chr5 42384876 G A 4.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2972394 chr5 42390038 A C 2.02E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1876790 chr5 42422855 C T 5.82E-04 Response to cytadine analogues (cytosine arabinoside) GHR nearGene-5 24483146 rs17574527 chr5 42436043 C G 9.62E-05 Alzheimer's disease GHR intron 17998437 rs1960498 chr5 42450774 T C 2.45E-04 Response to cytadine analogues (cytosine arabinoside) GHR intron 24483146 rs2972407 chr5 42455956 A G 4.96E-04 Response to cytadine analogues (cytosine arabinoside) GHR intron 24483146 rs2972411 chr5 42466116 G T 4.96E-04 Response to cytadine analogues (cytosine arabinoside) GHR intron 24483146 rs2940917 chr5 42467455 G A 5.56E-04 Response to cytadine analogues (cytosine arabinoside) GHR intron 24483146 rs2972412 chr5 42468040 G C 1.85E-04 Response to cytadine analogues (cytosine arabinoside) GHR intron 24483146 rs2940918 chr5 42470585 T G 3.04E-04 Response to cytadine analogues (cytosine arabinoside) GHR intron 24483146 rs2940918 chr5 42470585 T G 9.26E-04 Response to cytidine analogues (gemcitabine) GHR intron 24483146 rs2940919 chr5 42470730 A G 2.85E-04 Response to cytadine analogues (cytosine arabinoside) GHR intron 24483146 rs17575164 chr5 42471017 T C 2.36E-04 Alzheimer's disease GHR intron 17998437 rs13188386 chr5 42473555 G A 8.00E-06 Iron status biomarkers GHR intron 19084217 rs4242116 chr5 42655123 A G 2.00E-04 Information processing speed GHR intron 21130836 rs6180 chr5 42719239 A C 3.10E-12 Height GHR missense 21194676 rs6180 chr5 42719239 A C 3.30E-05 Height GHR missense 21194676 rs6180 chr5 42719239 A C 9.60E-08 Height GHR missense 21194676 rs4866796 chr5 42744895 G A 2.60E-05 Urinary metabolites / / 21572414 rs2972756 chr5 42820125 A G 9.73E-05 Information processing speed / / 21130836 rs10512806 chr5 42838556 G A,C 1.55E-05 Tunica Media / / pha003037 rs10072749 chr5 42883971 A T 4.77E-04 Multiple complex diseases / / 17554300 rs10941594 chr5 42918789 C T 9.61E-05 Type 2 diabetes / / 17463246 rs6451656 chr5 42919685 C T 9.29E-04 Multiple complex diseases / / 17554300 rs2548373 chr5 42928100 A G 0.000127106 Hypertension (early onset hypertension) / / 22479346 rs2247280 chr5 42928720 A G 2.85E-04 Multiple complex diseases / / 17554300 rs309910 chr5 42939436 A G 1.62E-04 Multiple complex diseases / / 17554300 rs188693 chr5 42940230 C T 9.26E-05 Hypertension (early onset hypertension) / / 22479346 rs3893725 chr5 42951941 G A 0.000517159 Hypertension (early onset hypertension) / / 22479346 rs3849698 chr5 42953802 C T 6.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6899257 chr5 42956696 A G 0.000627625 Hypertension (early onset hypertension) / / 22479346 rs6883097 chr5 42961249 G A 0.000386515 Hypertension (early onset hypertension) / / 22479346 rs2924819 chr5 42967215 G T 0.000691789 Hypertension (early onset hypertension) / / 22479346 rs309923 chr5 42969129 T A 8.90E-05 Multiple complex diseases / / 17554300 rs2548345 chr5 42978175 A G 0.000572525 Hypertension (early onset hypertension) / / 22479346 rs309909 chr5 42983823 T G 0.000572525 Hypertension (early onset hypertension) / / 22479346 rs2603656 chr5 42992040 G A 0.000828455 Hypertension (early onset hypertension) / / 22479346 rs316414 chr5 43004280 A G 1.93E-04 Multiple complex diseases / / 17554300 rs316414 chr5 43004280 A G 4.50E-07 Malaria / / 19465909 rs2329995 chr5 43011640 T A 2.05E-04 Multiple complex diseases / / 17554300 rs160709 chr5 43015214 A C 4.00E-04 Multiple complex diseases / / 17554300 rs222060 chr5 43016650 C T 4.89E-04 Multiple complex diseases LOC648987 intron 17554300 rs222060 chr5 43016650 C T 7.40E-05 Malaria LOC648987 intron 19465909 rs9292862 chr5 43028221 G A 6.26E-04 Multiple complex diseases / / 17554300 rs316401 chr5 43053246 T C 0.000301651 Hypertension (early onset hypertension) / / 22479346 rs316404 chr5 43071156 A G 6.83E-04 Type 2 diabetes LOC100506639 intron 17463246 rs178415 chr5 43078218 T G 0.000804035 Hypertension (early onset hypertension) LOC100506639 intron 22479346 rs316413 chr5 43094029 T C 9.29E-04 Type 2 diabetes / / 17463246 rs316413 chr5 43094029 T C 7.90E-05 Malaria / / 19465909 rs10045186 chr5 43150500 C T 7.80E-05 Response to cytadine analogues (cytosine arabinoside) ZNF131 intron 24483146 rs11744749 chr5 43164060 G A 1.33E-04 Type 2 diabetes ZNF131 intron 17463246 rs6862639 chr5 43166254 T C 2.30E-05 Urinary metabolites ZNF131 intron 21572414 rs2444779 chr5 43203125 T C 0.000860049 Hypertension (early onset hypertension) NIM1 intron 22479346 rs6887169 chr5 43208238 A G 2.87E-04 Response to cytadine analogues (cytosine arabinoside) NIM1 intron 24483146 rs10512821 chr5 43212590 C A 4.43E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer NIM1 intron 21483023 rs7701546 chr5 43222326 A G 2.86E-04 Response to cytadine analogues (cytosine arabinoside) NIM1 intron 24483146 rs10056788 chr5 43232637 A G 3.89E-04 Response to cytadine analogues (cytosine arabinoside) NIM1 intron 24483146 rs4866811 chr5 43237188 C T 0.000429009 Hypertension (early onset hypertension) NIM1 intron 22479346 rs6867229 chr5 43237644 T C 7.00E-04 Response to cytadine analogues (cytosine arabinoside) NIM1 intron 24483146 rs10473304 chr5 43243774 G T 2.87E-04 Response to cytadine analogues (cytosine arabinoside) NIM1 intron 24483146 rs367847463 chr5 43243774 G GTTTGC 2.87E-04 Response to cytadine analogues (cytosine arabinoside) NIM1 intron 24483146 rs12523436 chr5 43276469 C T 1.70E-05 Alcohol withdrawal symptoms NIM1 intron 22072270 rs9292872 chr5 43304835 C T 9.87E-05 Multiple complex diseases HMGCS1 intron 17554300 rs11951515 chr5 43382858 T C 4.00E-07 Metabolite levels (X-11787) CCL28 intron 23934736 rs754527 chr5 43402437 T C 5.41E-04 Suicide attempts in bipolar disorder CCL28 intron 21423239 rs16873319 chr5 43418520 A G 2.66E-04 Multiple complex diseases / / 17554300 rs17246391 chr5 43448321 C T 2.81E-04 Alzheimer's disease (late onset) C5orf28 intron 21379329 rs17246391 chr5 43448321 C T 1.54E-05 Lung function (forced expiratory volume in 1 second) C5orf28 intron 24023788 rs17246391 chr5 43448321 C T 3.41E-05 Lung function (forced vital capacity) C5orf28 intron 24023788 rs6451695 chr5 43452252 T C 9.51E-05 Bipolar disorder and schizophrenia C5orf28 intron 20889312 rs6895327 chr5 43497905 G A 6.73E-05 Coronary heart disease C5orf34 intron pha003031 rs2042950 chr5 43584348 T A 6.55E-04 Type 2 diabetes LOC100652772 intron 17463246 rs11949083 chr5 43584889 A G 4.65E-05 Coronary heart disease LOC100652772 intron pha003031 rs6451718 chr5 43588948 G A 2.68E-05 Coronary heart disease LOC100652772 intron pha003031 rs10059993 chr5 43598352 A G 8.44E-05 Lymphocyte counts LOC100652772 intron 22286170 rs10065863 chr5 43604497 T C 1.43E-04 Sarcoidosis NNT intron 19165924 rs12187908 chr5 43609272 T C 5.69E-06 Coronary heart disease NNT UTR-5 pha003031 rs6899051 chr5 43829619 G A 4.79E-04 Multiple complex diseases / / 17554300 rs4866844 chr5 43959373 G A 2.85E-12 Multiple complex diseases / / 17554300 rs4587082 chr5 44012472 C A 4.14E-04 Alcohol dependence / / 20201924 rs7730111 chr5 44132277 T C 5.81E-07 Post-operative nausea and vomiting / / 21694509 rs12518724 chr5 44155102 G A 2.40E-05 Aging (time to event) / / 21782286 rs4296809 chr5 44186668 C A 9.00E-07 Brain structure / / 20171287 rs4866773 chr5 44218513 A C 8.05E-07 Post-operative nausea and vomiting / / 21694509 rs4643965 chr5 44224808 T C 2.84E-05 Post-operative nausea and vomiting / / 21694509 rs10512836 chr5 44228425 T C 7.82E-04 Alzheimer's disease / / 24755620 rs1011814 chr5 44335820 T C 1.24E-05 Post-operative nausea and vomiting FGF10 intron 21694509 rs339502 chr5 44364007 A T 1.66E-09 Narcolepsy FGF10 intron 19629137 rs2121875 chr5 44365545 C A 4.00E-08 Prostate cancer FGF10 intron 21743467 rs11750845 chr5 44373060 C T 3.33E-06 Post-operative nausea and vomiting FGF10 intron 21694509 rs10512849 chr5 44384223 C T 1.40E-04 Breast cancer and prostate cancer FGF10 intron 17903305 rs11949823 chr5 44396679 T A 1.00E-04 Prostate cancer / / 21743057 rs10078685 chr5 44397285 G A 1.00E-04 Prostate cancer / / 21743057 rs9292905 chr5 44402722 T C 1.00E-04 Prostate cancer / / 21743057 rs16901843 chr5 44403117 T C 7.44E-05 Height / / pha003010 rs16901843 chr5 44403117 T C 2.26E-05 Waist Circumference / / pha003023 rs4866898 chr5 44403631 G A 4.49E-05 Height / / pha003010 rs11741260 chr5 44412065 G A 1.00E-04 Information processing speed / / 21130836 rs10039581 chr5 44414594 C T 1.00E-04 Prostate cancer / / 21743057 rs11950089 chr5 44423773 A G 1.00E-04 Prostate cancer / / 21743057 rs10473359 chr5 44425624 C A 1.00E-04 Prostate cancer / / 21743057 rs6865277 chr5 44425702 C T 7.00E-05 Prostate cancer / / 21743057 rs10472395 chr5 44427163 C T 1.00E-04 Prostate cancer / / 21743057 rs9292907 chr5 44428516 A G 8.43E-05 Waist-Hip Ratio / / pha003013 rs9292907 chr5 44428516 A G 7.36E-05 Waist Circumference / / pha003025 rs9292907 chr5 44428516 A G 4.60E-05 Waist-Hip Ratio / / pha003028 rs13361348 chr5 44431402 C A 7.00E-05 Prostate cancer / / 21743057 rs1351637 chr5 44441703 A G 7.36E-05 Waist Circumference / / pha003023 rs8180484 chr5 44471963 A C 2.00E-05 Urinary metabolites / / 21572414 rs12516346 chr5 44488156 C A 2.66E-05 Height / / 22021425 rs2062140 chr5 44496415 G A 6.50E-05 Bone mineral density (BMD),in women / / 20164292 rs2062140 chr5 44496415 G A 2.44E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs16901892 chr5 44513069 T C 9.58E-05 Bone mineral density (BMD),in women / / 20164292 rs10512860 chr5 44539953 C G 3.35E-05 Height / / 22021425 rs13169538 chr5 44570040 G A 7.90E-05 Bone mineral density (BMD),in women / / 20164292 rs13169538 chr5 44570040 G A 2.14E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4415084 chr5 44662515 C T 8.00E-11 Breast cancer / / 21263130 rs10941679 chr5 44706498 A G 2.00E-37 Breast cancer / / 23535729 rs17321708 chr5 44724514 G A,T 1.79E-04 Type 2 diabetes / / 17463246 rs13362132 chr5 44858260 T G 8.90E-04 Multiple complex diseases / / 17554300 rs6451780 chr5 44860457 A G 2.15E-09 Multiple complex diseases / / 17554300 rs7716600 chr5 44875005 A C 7.00E-07 Breast cancer / / 20872241 rs7716600 chr5 44875005 A C 0.000063 Breast cancer / / 23555315 rs7705343 chr5 44879577 G A 9.08E-04 Multiple complex diseases / / 17554300 rs10044321 chr5 44890760 G A 4.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs9790896 chr5 44900091 G A 7.96E-04 Multiple complex diseases / / 17554300 rs7703618 chr5 44914579 G A 5.30E-07 Breast cancer / / 17529974 rs6894974 chr5 45020531 G A 1.21E-04 Multiple complex diseases / / 17554300 rs7731099 chr5 45038026 G A 2.43E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs10805692 chr5 45099458 G A 6.14E-05 Multiple complex diseases / / 17554300 rs10941694 chr5 45197779 G A 9.00E-06 Chronic kidney disease and serum creatinine levels / / 20686651 rs13180087 chr5 45265768 T C 8.49E-04 Tourette syndrome HCN1 intron 22889924 rs4866929 chr5 45266589 A G 9.10E-06 Crohn's disease HCN1 intron 20570966 rs4866929 chr5 45266589 A G 7.17E-05 Breast cancer HCN1 intron pha002853 rs981782 chr5 45285718 A C 9.00E-06 Breast cancer HCN1 intron 17529967 rs981782 chr5 45285718 A C 9.00E-06 Nasopharyngeal carcinoma HCN1 intron 20512145 rs16902088 chr5 45286097 T C 1.78E-05 Pulmonary function HCN1 intron 20010835 rs6451797 chr5 45359026 C T 4.98E-04 Multiple complex diseases HCN1 intron 17554300 rs12517615 chr5 45366788 T C 5.51E-05 Cognitive performance HCN1 intron 19734545 rs6874279 chr5 45393261 G A 5.08E-05 Alcohol dependence HCN1 intron 20201924 rs6874279 chr5 45393261 G A 5.08E-05 Alcoholism HCN1 intron pha002891 rs10043792 chr5 45537620 T C 4.00E-06 Parkinson's disease (interaction with coffee consumption) HCN1 intron 21876681 rs6881805 chr5 45690994 G A 3.03E-04 Multiple complex diseases HCN1 intron 17554300 rs12110137 chr5 45727866 T C 9.00E-05 Prostate cancer / / 21743057 rs7706116 chr5 45742624 G T 9.00E-05 Prostate cancer / / 21743057 rs4455566 chr5 45752862 T C 9.00E-05 Prostate cancer / / 21743057 rs12654213 chr5 45759165 T G 9.00E-05 Prostate cancer / / 21743057 rs9687260 chr5 45759876 A G 9.00E-05 Prostate cancer / / 21743057 rs7725177 chr5 45784939 C T 6.07E-04 Multiple complex diseases / / 17554300 rs4492121 chr5 46099553 A T 4.38E-04 Multiple complex diseases / / 17554300 rs8185226 chr5 46160787 T C 8.11E-04 Alcohol dependence / / 20201924 rs8188245 chr5 46174864 A G 9.38E-05 Serum metabolites / / 19043545 rs7293423 chr5 46192220 G A 3.71E-04 Alcohol dependence / / 20201924 rs11958464 chr5 46211903 C T 3.71E-04 Alcohol dependence / / 20201924 rs7293345 chr5 46332383 C T 6.39E-04 Alcohol dependence / / 20201924 rs10071996 chr5 46399149 A G 1.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs7293378 chr5 49488236 G A 1.64E-04 Alcohol dependence / / 20201924 rs559096 chr5 49522346 C T 9.08E-05 Alcohol dependence / / 20201924 rs559096 chr5 49522346 C T 9.08E-05 Alcoholism / / pha002891 rs1674512 chr5 49564628 G A 9.15E-05 Alcohol dependence / / 20201924 rs1674512 chr5 49564628 G A 9.15E-05 Alcoholism / / pha002891 rs4865676 chr5 49575177 A C 9.06E-05 Alcohol dependence / / 20201924 rs4865676 chr5 49575177 A C 9.06E-05 Alcoholism / / pha002891 rs6891163 chr5 49615106 A T 8.74E-06 Brain structure / / 22504417 rs10064702 chr5 49632762 T G 9.15E-05 Alcohol dependence / / 20201924 rs10064702 chr5 49632762 T G 9.15E-05 Alcoholism / / pha002891 rs7710841 chr5 49645820 C T 9.06E-05 Alcohol dependence / / 20201924 rs7710841 chr5 49645820 C T 9.06E-05 Alcoholism / / pha002891 rs10042504 chr5 49682163 A G 9.15E-05 Alcohol dependence / / 20201924 rs10042504 chr5 49682163 A G 9.15E-05 Alcoholism / / pha002891 rs10512892 chr5 49691275 G T 0.00000711 LDL cholesterol particle diameter / / 23263444 rs2036902 chr5 49696932 A G 9.88E-05 Alcohol dependence EMB intron 20201924 rs2036902 chr5 49696932 A G 9.88E-05 Alcoholism EMB intron pha002891 rs13157992 chr5 49739908 C T 9.03E-05 Alcohol dependence / / 20201924 rs13157992 chr5 49739908 C T 9.03E-05 Alcoholism / / pha002891 rs7720960 chr5 49746323 A G 7.28E-05 Alcohol dependence / / 20201924 rs7720960 chr5 49746323 A G 7.28E-05 Alcoholism / / pha002891 rs7378969 chr5 49767759 T C 6.04E-05 Alcohol dependence / / 20201924 rs7378969 chr5 49767759 T C 6.04E-05 Alcoholism / / pha002891 rs1016620 chr5 49786597 A G 9.80E-05 Alcohol dependence / / 20201924 rs1016620 chr5 49786597 A G 9.80E-05 Alcoholism / / pha002891 rs10940335 chr5 49798429 T C 1.26E-04 Alcohol dependence / / 20201924 rs6892149 chr5 49925547 T C 9.21E-06 Height / / 20400458 rs282544 chr5 50026465 C T 4.00E-06 Myopia (pathological) PARP8 intron 22685421 rs6889539 chr5 50103878 A C 8.47E-04 Aortic root size PARP8 intron 21223598 rs32396 chr5 50106439 G A 4.40E-05 Parkinson's disease (age of onset) PARP8 intron 19772629 rs27964 chr5 50152467 T C 3.51E-07 Schizophrenia / / 22037555 rs11958274 chr5 50165927 A G 1.63E-04 Self-reported allergy / / 23817569 rs26090 chr5 50170071 T C 3.45E-04 Type 2 diabetes / / 17463246 rs3846496 chr5 50175821 C T 3.16E-04 Self-reported allergy / / 23817569 rs11949212 chr5 50177108 C G 2.45E-04 Self-reported allergy / / 23817569 rs10055305 chr5 50177886 C T 2.37E-04 Self-reported allergy / / 23817569 rs27476 chr5 50178160 T A 4.13E-04 Type 2 diabetes / / 17463246 rs6889829 chr5 50181021 C A 1.63E-04 Self-reported allergy / / 23817569 rs7701586 chr5 50182742 C G 4.68E-04 Self-reported allergy / / 23817569 rs27270 chr5 50183712 C T 1.68E-04 Type 2 diabetes / / 17463246 rs1505050 chr5 50186790 C T 1.39E-04 Self-reported allergy / / 23817569 rs1847064 chr5 50190082 A T 1.22E-04 Self-reported allergy / / 23817569 rs6450439 chr5 50203772 A G 1.07E-04 Self-reported allergy / / 23817569 rs6868983 chr5 50205913 A T 2.23E-04 Self-reported allergy / / 23817569 rs16887538 chr5 50215319 A G 2.25E-04 Self-reported allergy / / 23817569 rs889227 chr5 50218340 G A 2.08E-04 Self-reported allergy / / 23817569 rs889218 chr5 50218729 G C 2.06E-04 Self-reported allergy / / 23817569 rs16887696 chr5 50228368 T C 1.70E-04 Self-reported allergy / / 23817569 rs27246 chr5 50229851 G A 5.01E-05 Multiple complex diseases / / 17554300 rs27248 chr5 50232547 G A 4.02E-04 Multiple complex diseases / / 17554300 rs27249 chr5 50232678 G A 6.01E-04 Type 2 diabetes / / 17463246 rs151997 chr5 50233199 T C 7.38E-04 Type 2 diabetes / / 17463246 rs151997 chr5 50233199 T C 5.00E-06 Callous-unemotional behaviour / / 23874384 rs3846498 chr5 50253625 G T 6.64E-04 Type 2 diabetes / / 17463246 rs10472047 chr5 50254866 T G 9.90E-04 Type 2 diabetes / / 17463246 rs1345777 chr5 50263788 C T 1.34E-04 Type 2 diabetes / / 17463246 rs679678 chr5 50279776 A G 3.82E-04 Multiple complex diseases / / 17554300 rs250212 chr5 50292595 A G 5.37E-05 Information processing speed / / 21130836 rs10512927 chr5 50311076 G T 8.50E-04 Volumetric brain MRI / / 17903297 rs11954874 chr5 50326588 G A 7.78E-04 Multiple complex diseases / / 17554300 rs4866023 chr5 50345255 A G 2.03E-05 Attention deficit hyperactivity disorder / / 20732625 rs17820197 chr5 50391229 C T 7.17E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs4141540 chr5 50623533 C T 3.80E-07 Urinary metabolites / / 21572414 rs6449586 chr5 50634878 C T 1.00E-06 Barrett's esophagus / / 24121790 rs6449586 chr5 50634878 C T 3.25E-05 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs6884007 chr5 50640414 C T 3.20E-07 Urinary metabolites / / 21572414 rs7706482 chr5 50641154 A T 6.50E-07 Urinary metabolites / / 21572414 rs12188225 chr5 50668000 G C 2.80E-05 Urinary metabolites / / 21572414 rs6449600 chr5 50675297 C T 1.70E-05 Urinary metabolites LOC642366 intron 21572414 rs6867101 chr5 50697678 C G 1.70E-05 Urinary metabolites / / 21572414 rs1423611 chr5 50771114 G T 4.94E-04 Heart Failure / / pha002884 rs16878913 chr5 50774090 A T 4.00E-04 Spine bone size / / 21947420 rs17824783 chr5 50774235 T A 2.80E-05 Urinary metabolites / / 21572414 rs11746878 chr5 50802257 A C 4.72E-04 Type 2 diabetes / / 17463246 rs10052591 chr5 50812738 T C 0.00011 Breast cancer / / 23555315 rs12189442 chr5 50821162 C T 6.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs6867598 chr5 50842005 A C 9.75E-04 Type 2 diabetes / / 17463246 rs16879019 chr5 50876533 T C 9.99E-07 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs2405421 chr5 50894079 G A 8.69E-04 Type 2 diabetes / / 17463246 rs7719291 chr5 50905979 C G 9.93E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4865673 chr5 50928810 G A 9.00E-06 Dental caries / / 23259602 rs2161539 chr5 51010325 T A 7.02E-05 Bipolar disorder and schizophrenia / / 20889312 rs16879138 chr5 51023152 A G 4.34E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs11740943 chr5 51101048 C T 3.65E-04 Type 2 diabetes / / 17463246 rs4146568 chr5 51123678 C T 6.47E-04 Intracranial aneurysm / / 20613766 rs7713485 chr5 51124949 C T 8.20E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs12186641 chr5 51164115 C T 7.00E-06 Congenital heart disease / / 23708191 rs17835853 chr5 51173324 G A 4.00E-06 IgG glycosylation / / 23382691 rs17835853 chr5 51173324 G A 6.00E-06 IgG glycosylation / / 23382691 rs10036878 chr5 51182660 G A 2.03E-05 Congenital heart disease / / 23708191 rs9291912 chr5 51215874 G A 1.40E-05 Bipolar disorder and schizophrenia / / 20889312 rs10042348 chr5 51217851 C G 5.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs6449937 chr5 51219824 G A 3.69E-05 Bipolar disorder and schizophrenia / / 20889312 rs12690623 chr5 51222041 A G 5.56E-05 Bipolar disorder and schizophrenia / / 20889312 rs4865525 chr5 51234935 C A 3.43E-05 Bipolar disorder and schizophrenia / / 20889312 rs16879308 chr5 51236326 C T 2.00E-06 Migraine without aura / / 23793025 rs4397086 chr5 51243645 T C 6.00E-05 Cognitive impairment induced by topiramate / / 22091778 rs4397086 chr5 51243645 T C 6.34E-04 Myocardial Infarction / / pha002873 rs4342276 chr5 51246728 T C 1.66E-05 Bipolar disorder and schizophrenia / / 20889312 rs4296747 chr5 51257127 T C 5.51E-04 Multiple complex diseases / / 17554300 rs13164338 chr5 51444207 T C 1.28E-05 Bipolar disorder and schizophrenia / / 20889312 rs13165318 chr5 51483914 C T 3.39E-05 Bipolar disorder and schizophrenia / / 20889312 rs10512953 chr5 51502753 C T 2.75E-06 QT interval / / 16648850 rs16879486 chr5 51528556 T C 9.23E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10512950 chr5 51531910 A G 1.37E-04 Parkinson's disease / / 17052657 rs7703314 chr5 51565236 G A 2.61E-04 Parkinson's disease / / 17052657 rs7442675 chr5 51569542 G A 7.96E-04 Parkinson's disease / / 17052657 rs4572960 chr5 51572584 T A,C 1.59E-07 Non-small cell lung cancer,hypertriglyceridemia with bexarotene treatment of / / 21737656 rs4288087 chr5 51583022 A C 8.79E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1424895 chr5 51606511 C T 7.91E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10058324 chr5 51643523 G A 1.59E-05 Non-small cell lung cancer,hypertriglyceridemia with bexarotene treatment of / / 21737656 rs1559578 chr5 51660682 C T 2.95E-06 QT interval / / 16648850 rs1424894 chr5 51690015 A G 5.29E-05 Amyotrophic lateral sclerosis / / 19193627 rs12655897 chr5 51699878 C T 2.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs2911766 chr5 51699948 G A 3.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs10074792 chr5 51700018 T C 1.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs6889746 chr5 51706906 A G 6.00E-06 Presence of antiphospholipid antibodies / / 23509613 rs2216904 chr5 51733481 A G 9.23E-05 Cognitive performance / / 19734545 rs1113266 chr5 51737413 T C 4.80E-04 Myasthenia gravis / / 23055271 rs1364625 chr5 51743012 T C 1.10E-05 Urinary metabolites / / 21572414 rs10045166 chr5 51746682 T C 8.96E-05 Major depressive disorder / / 19107115 rs750544 chr5 51749055 G A 9.07E-04 Multiple complex diseases / / 17554300 rs7703173 chr5 51761230 T A 2.90E-05 Urinary metabolites / / 21572414 rs10044460 chr5 51792982 G T 2.60E-05 Urinary metabolites / / 21572414 rs7702276 chr5 51805742 C T 1.00E-06 Alzheimer's disease biomarkers / / 23419831 rs12514124 chr5 51818671 C T 9.60E-04 Multiple complex diseases / / 17554300 rs4296761 chr5 51819014 G A 9.53E-05 Major depressive disorder / / 19107115 rs7730948 chr5 51841526 T C 8.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs10054300 chr5 51847658 G A 8.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs1585698 chr5 51860911 T G 2.80E-04 Obesity (extreme) / / 21935397 rs10512971 chr5 51861437 A G 3.34E-05 Major depressive disorder / / 20516156 rs10512971 chr5 51861437 A G 2.72E-04 Obesity (extreme) / / 21935397 rs10512971 chr5 51861437 A G 9.29E-05 Major depressive disorder / / 22472876 rs830867 chr5 51916910 G T 1.16E-04 Multiple complex diseases / / 17554300 rs830868 chr5 51917914 G T 1.12E-05 F-cell distribution / / 21326311 rs1450949 chr5 51919136 G A 1.37E-04 Alzheimer's disease / / 24755620 rs636028 chr5 51978302 T C 8.71E-04 Multiple complex diseases / / 17554300 rs623193 chr5 51979514 T C 1.09E-05 Cognitive performance / / 19734545 rs17265753 chr5 51989647 A G 6.10E-04 Type 2 diabetes / / 17463246 rs351929 chr5 52003387 A C 7.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs830884 chr5 52020396 C T 2.00E-06 Response to platinum-based agents / / 22020760 rs12152867 chr5 52025719 C T 8.10E-06 Urinary metabolites / / 21572414 rs13176939 chr5 52031088 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6881021 chr5 52037755 C T 3.77E-04 Multiple complex diseases / / 17554300 rs7713338 chr5 52039850 A C 4.29E-05 Cognitive impairment induced by topiramate / / 22091778 rs2406208 chr5 52056339 C T 9.41E-05 Cognitive impairment induced by topiramate / / 22091778 rs11742611 chr5 52063679 C G 0.0000071 Colorectal cancer vs. adenoma controls / / 22532847 rs11745801 chr5 52069025 A G 9.75E-05 Multiple complex diseases / / 17554300 rs17208683 chr5 52069314 A G 1.41E-04 Multiple complex diseases / / 17554300 rs3762991 chr5 52085403 T C 6.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ITGA1 intron 20877124 rs2432143 chr5 52131315 T C 2.53E-04 Longevity ITGA1 intron 22279548 rs2432144 chr5 52133266 T C 2.27E-04 Smoking cessation ITGA1 intron 24665060 rs1351140 chr5 52175726 T C 6.71E-05 Sodium levels ITGA1 intron pha003093 rs2456223 chr5 52177346 A T 9.00E-04 Type 2 diabetes ITGA1 intron 17463246 rs2456223 chr5 52177346 A T 6.11E-06 Pulmonary function ITGA1 intron 20010835 rs2456223 chr5 52177346 A T 6.54E-04 Alzheimer's disease ITGA1 intron 22005930 rs2447859 chr5 52178056 G A 4.25E-06 Pulmonary function ITGA1 intron 20010835 rs2447859 chr5 52178056 G A 9.51E-04 Alzheimer's disease ITGA1 intron 22005930 rs2447861 chr5 52178339 A G 3.69E-06 Pulmonary function ITGA1 intron 20010835 rs2447861 chr5 52178339 A G 8.26E-04 Alzheimer's disease ITGA1 intron 22005930 rs2456206 chr5 52179119 C T 4.23E-06 Pulmonary function ITGA1 intron 20010835 rs2456206 chr5 52179119 C T 4.51E-04 Alzheimer's disease ITGA1 intron 22005930 rs2447863 chr5 52179151 T A 4.12E-06 Pulmonary function ITGA1 intron 20010835 rs2456205 chr5 52179458 G T 6.95E-06 Pulmonary function ITGA1 intron 20010835 rs2456205 chr5 52179458 G T 5.65E-04 Alzheimer's disease ITGA1 intron 22005930 rs2456204 chr5 52179477 C T 3.97E-06 Pulmonary function ITGA1 intron 20010835 rs2456204 chr5 52179477 C T 6.43E-04 Alzheimer's disease ITGA1 intron 22005930 rs2456203 chr5 52179790 T C 3.54E-06 Pulmonary function ITGA1 intron 20010835 rs2456203 chr5 52179790 T C 6.67E-04 Alzheimer's disease ITGA1 intron 22005930 rs2456203 chr5 52179790 T C 2.00E-07 Pulmonary function (interaction) ITGA1 intron 23284291 rs2456202 chr5 52179825 T A 7.12E-04 Type 2 diabetes ITGA1 intron 17463246 rs2456202 chr5 52179825 T A 3.41E-06 Pulmonary function ITGA1 intron 20010835 rs2456202 chr5 52179825 T A 4.90E-04 Alzheimer's disease ITGA1 intron 22005930 rs2447864 chr5 52179868 C T 3.29E-06 Pulmonary function ITGA1 intron 20010835 rs2447864 chr5 52179868 C T 4.92E-04 Alzheimer's disease ITGA1 intron 22005930 rs2447865 chr5 52180732 C G 4.71E-06 Pulmonary function ITGA1 intron 20010835 rs2447866 chr5 52182593 C G 3.54E-06 Pulmonary function ITGA1 intron 20010835 rs2447866 chr5 52182593 C G 7.54E-04 Alzheimer's disease ITGA1 intron 22005930 rs1110350 chr5 52189049 A G 7.70E-05 Pulmonary function ITGA1 intron 20010835 rs7735139 chr5 52192098 A G 8.98E-05 Pulmonary function ITGA1 intron 20010835 rs7735139 chr5 52192098 A G 2.90E-05 Urinary metabolites ITGA1 intron 21572414 rs4074793 chr5 52193125 A G 3.00E-10 Liver enzyme levels (gamma-glutamyl transferase) ITGA1 intron 22001757 rs870992 chr5 52193237 A G 4.70E-05 Response to hepatitis C treatment ITGA1 intron 19684573 rs870992 chr5 52193237 A G 5.61E-05 Heart rate ITGA1 intron 23583979 rs17829997 chr5 52193518 A C 6.30E-04 Diabetic nephropathy ITGA1 intron 20347642 rs1979398 chr5 52194327 A G 3.77E-05 Attention deficit hyperactivity disorder ITGA1 intron 23728934 rs1551943 chr5 52195033 G A 2.56E-06 Pulmonary function ITGA1 intron 20010835 rs1551943 chr5 52195033 G A 1.40E-05 Urinary metabolites ITGA1 intron 21572414 rs1551943 chr5 52195033 G A 2.00E-06 Pulmonary function ITGA1 intron 21946350 rs1466445 chr5 52195127 T C 1.19E-04 Attention deficit hyperactivity disorder ITGA1 intron 23728934 rs16880453 chr5 52195507 G C 5.98E-05 Attention deficit hyperactivity disorder ITGA1 intron 23728934 rs4145748 chr5 52201722 C T 6.03E-04 HIV-1 viral setpoint ITGA1 missense 17641165 rs7701575 chr5 52201927 G A 2.88E-05 Personality dimensions ITGA1 intron 22628180 rs2279587 chr5 52214581 G A 7.96E-04 HIV-1 viral setpoint ITGA1 missense 17641165 rs2279586 chr5 52214848 C A 7.96E-04 HIV-1 viral setpoint ITGA1 intron 17641165 rs2302960 chr5 52233027 C T 6.05E-04 HIV-1 viral setpoint ITGA1 intron 17641165 rs1871186 chr5 52234615 C T 2.93E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ITGA1 intron 24023788 rs3212383 chr5 52283961 C T 0.0000422 LDL cholesterol ITGA2 nearGene-5 23063622 rs3797499 chr5 52333744 T C 6.17E-04 Alzheimer's disease ITGA2 intron 24755620 rs988557 chr5 52336982 G A 6.42E-04 Alzheimer's disease ITGA2 intron 24755620 rs3212435 chr5 52337326 G T 1.94E-05 Amyotrophic lateral sclerosis (sporadic) ITGA2 intron 24529757 rs1421933 chr5 52344610 A G 1.45E-05 Lymphocyte counts ITGA2 intron 22286170 rs3212512 chr5 52349072 G A 1.20E-12 Triglycerides ITGA2 intron 23063622 rs3212594 chr5 52370944 G A 6.33E-12 Triglycerides ITGA2 cds-synon 23063622 rs3212601 chr5 52373429 T C 1.00E-04 Information processing speed ITGA2 intron 21130836 rs2303122 chr5 52379277 C T 2.00E-04 Information processing speed ITGA2 cds-synon 21130836 rs12521915 chr5 52382218 C G 8.09E-06 Cardiovascular disease ITGA2 intron 18179892 rs7725246 chr5 52390415 A C 1.00E-04 Information processing speed ITGA2 UTR-3 21130836 rs2233213 chr5 52398005 T C 4.59E-04 Height MOCS2 missense 17255346 rs30099 chr5 52418582 G A 1.00E-04 Prostate cancer / / 21743057 rs27420 chr5 52420522 T A 1.00E-04 Prostate cancer / / 21743057 rs30097 chr5 52422063 G A 2.76E-04 Multiple complex diseases / / 17554300 rs9292010 chr5 52443830 A G 4.39E-04 Type 2 diabetes / / 17463246 rs17233845 chr5 52444713 C T 2.48E-04 Type 2 diabetes / / 17463246 rs10059321 chr5 52447354 T C 1.21E-04 Type 2 diabetes / / 17463246 rs30637 chr5 52447552 G A 8.76E-04 Multiple complex diseases / / 17554300 rs117931 chr5 52453866 C A 9.72E-04 Multiple complex diseases / / 17554300 rs254629 chr5 52469294 T A 3.52E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs153682 chr5 52477252 G A 2.40E-05 HIV-1 control / / 20041166 rs254481 chr5 52495682 A G 2.05E-04 Multiple complex diseases / / 17554300 rs251513 chr5 52502644 G A 2.88E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs251516 chr5 52508337 C T 4.07E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs152976 chr5 52526063 G C 5.26E-04 Multiple complex diseases / / 17554300 rs254142 chr5 52548545 T C 1.37E-04 Scoliosis / / 21216876 rs27323 chr5 52552239 G A 9.00E-06 IgG glycosylation / / 23382691 rs38055 chr5 52560644 A G 5.00E-09 Acne (severe) / / 24927181 rs4865763 chr5 52596390 A G 9.99E-04 Multiple complex diseases / / 17554300 rs7737662 chr5 52624189 A G 5.63E-04 Type 2 diabetes / / 17463246 rs1423422 chr5 52631507 A G 6.57E-04 Type 2 diabetes / / 17463246 rs37781 chr5 52637446 T A 6.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs37784 chr5 52640726 C T 8.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs37787 chr5 52642056 A G 4.80E-04 Myasthenia gravis / / 23055271 rs16881355 chr5 52648078 A G 1.16E-04 Multiple complex diseases / / 17554300 rs252046 chr5 52650747 C T 6.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs10471379 chr5 52658588 C G 6.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs4621519 chr5 52674671 G A 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11740573 chr5 52677451 A G 3.89E-04 Tourette syndrome / / 22889924 rs7718197 chr5 52682016 C T 8.52E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs11746701 chr5 52688918 T C 7.81E-05 Type 2 diabetes / / 17463246 rs11746701 chr5 52688918 T C 3.11E-04 Schizophrenia / / 19197363 rs10805450 chr5 52699931 A G 8.75E-04 Schizophrenia / / 19197363 rs11740124 chr5 52710955 C T 1.80E-04 Schizophrenia / / 19197363 rs12653439 chr5 52716489 C T 8.13E-04 Coronary heart disease / / 21971053 rs41433449 chr5 52745884 T C 1.76E-04 Multiple complex diseases / / 17554300 rs3756498 chr5 52778210 G A 5.40E-06 Type 2 diabetes FST intron 23209189 rs1469101 chr5 52783408 T C 3.38E-05 Response to TNF antagonist treatment / / 21061259 rs12520984 chr5 52787358 G C 4.99E-05 Bipolar disorder / / 19488044 rs12521153 chr5 52788201 G A 1.49E-05 Bipolar disorder / / 19488044 rs7703177 chr5 52799456 T C 5.10E-06 Bipolar disorder / / 21738484 rs1363972 chr5 52799618 T C 4.86E-04 Tourette syndrome / / 22889924 rs10065003 chr5 52843945 G C 7.62E-06 Multiple complex diseases / / 17554300 rs10513019 chr5 52944428 T C,G 4.28E-04 Type 2 diabetes NDUFS4 intron 17846124 rs4147743 chr5 52977472 T A 9.99E-10 Brain activation patterns in response to human facial expressions-for the negative faces task NDUFS4 intron 22828495 rs4147743 chr5 52977472 T A 9.99E-10 Airflow obstruction NDUFS4 intron 22837378 rs530216 chr5 53049825 G A 4.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs271221 chr5 53119409 C T 1.38E-05 Age-related macular degeneration / / pha000001 rs1504212 chr5 53119955 C A 6.60E-08 Parkinson's disease / / 17052657 rs37539 chr5 53179771 C T 1.38E-05 Age-related macular degeneration / / pha000001 rs702614 chr5 53184849 A G 1.00E-04 Information processing speed ARL15 intron 21130836 rs271243 chr5 53186783 G T 1.33E-05 Age-related macular degeneration ARL15 intron pha000001 rs702616 chr5 53222030 C G 2.82E-04 Aortic root size ARL15 intron 21223598 rs2035769 chr5 53223720 T C 4.09E-04 Alzheimer's disease (late onset) ARL15 intron 21379329 rs2035769 chr5 53223720 T C 4.19E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ARL15 intron 24023788 rs10075461 chr5 53264073 A T 1.00E-06 Parkinson's disease (interaction with coffee consumption) ARL15 intron 21876681 rs702634 chr5 53271420 G A 7.00E-09 Type 2 diabetes ARL15 intron 24509480 rs4865796 chr5 53272664 G A 2.16E-12 Fasting insulin-related traits ARL15 intron 22885924 rs10059074 chr5 53281025 A G 9.15E-04 Acute lung injury ARL15 intron 22295056 rs6450176 chr5 53298025 G A 5.00E-08 HDL cholesterol ARL15 intron 20686565 rs6450176 chr5 53298025 G A 6.00E-08 Adiponectin levels ARL15 intron 22479202 rs6450176 chr5 53298025 G A 7.00E-10 HDL cholesterol ARL15 intron 24097068 rs4311394 chr5 53300662 A G 3.00E-08 Adiponectin levels ARL15 intron 20011104 rs12654393 chr5 53302620 G T 2.65E-05 Multiple complex diseases ARL15 intron 17554300 rs6886510 chr5 53303127 C T 2.82E-05 Multiple complex diseases ARL15 intron 17554300 rs6876198 chr5 53303595 T C 4.51E-05 Multiple complex diseases ARL15 intron 17554300 rs255758 chr5 53311502 C A 7.00E-06 Rheumatoid arthritis ARL15 intron 23918589 rs255746 chr5 53317990 A T 7.85E-04 Multiple complex diseases ARL15 intron 17554300 rs255761 chr5 53321956 G T 1.63E-04 Multiple complex diseases ARL15 intron 17554300 rs11742692 chr5 53343576 G A 7.63E-04 Multiple complex diseases ARL15 intron 17554300 rs273218 chr5 53380555 T C 2.00E-06 Migraine ARL15 intron 23793025 rs702628 chr5 53396938 C T 7.90E-04 Suicide attempts in bipolar disorder ARL15 intron 21423239 rs1703368 chr5 53399217 A G 8.05E-04 Type 2 diabetes ARL15 intron 17463246 rs279744 chr5 53412620 C A 2.40E-04 Multiple complex diseases ARL15 intron 17554300 rs3797269 chr5 53464403 C T 4.18E-05 Personality dimensions ARL15 intron 23903073 rs17413044 chr5 53476717 C A 6.12E-05 Multiple complex diseases ARL15 intron 17554300 rs3846492 chr5 53484470 G A 8.65E-05 Multiple complex diseases ARL15 intron 17554300 rs11748223 chr5 53496239 C T 1.79E-05 Nonalcoholic fatty liver disease ARL15 intron 21423719 rs3797255 chr5 53499540 A G 6.07E-04 Smoking initiation ARL15 intron 24665060 rs3797246 chr5 53510501 G A 3.03E-04 Hemoglobin concentration ARL15 intron 20534544 rs26770 chr5 53519661 T C 4.21E-04 Smoking initiation ARL15 intron 24665060 rs33282 chr5 53531305 C T 2.09E-06 Alcohol dependence (age at onset) ARL15 intron 24962325 rs3910951 chr5 53535247 C T 4.69E-07 Alcohol dependence (age at onset) ARL15 intron 24962325 rs12233919 chr5 53535544 A G 4.69E-07 Alcohol dependence (age at onset) ARL15 intron 24962325 rs9292042 chr5 53536998 C T 4.69E-07 Alcohol dependence (age at onset) ARL15 intron 24962325 rs10044346 chr5 53537154 C T 8.14E-05 Bipolar disorder and schizophrenia ARL15 intron 20889312 rs10044346 chr5 53537154 C T 4.69E-07 Alcohol dependence (age at onset) ARL15 intron 24962325 rs2407405 chr5 53537546 C T 4.69E-07 Alcohol dependence (age at onset) ARL15 intron 24962325 rs250378 chr5 53537599 G T 9.95E-07 Alcohol dependence (age at onset) ARL15 intron 24962325 rs3797237 chr5 53537742 G A 3.30E-06 Alcohol dependence (age at onset) ARL15 intron 24962325 rs3797236 chr5 53537836 G T 2.80E-05 Urinary metabolites ARL15 intron 21572414 rs166093 chr5 53540925 G A 2.90E-06 Alcohol dependence (age at onset) ARL15 intron 24962325 rs6872062 chr5 53541553 G A 7.83E-07 Alcohol dependence (age at onset) ARL15 intron 24962325 rs6872430 chr5 53541755 G A 7.83E-07 Alcohol dependence (age at onset) ARL15 intron 24962325 rs3857282 chr5 53543905 G C 2.60E-06 Alcohol dependence (age at onset) ARL15 intron 24962325 rs17440928 chr5 53547082 C A 8.40E-04 Suicide attempts in bipolar disorder ARL15 intron 21423239 rs17512701 chr5 53547813 A T 6.69E-04 Suicide attempts in bipolar disorder ARL15 intron 21423239 rs3797235 chr5 53547960 T C 1.06E-04 Myocardial Infarction ARL15 intron pha002873 rs388337 chr5 53557538 C T 5.90E-06 Alcohol dependence (age at onset) ARL15 intron 24962325 rs200457189 chr5 53565054 GAATAA G 5.06E-07 Alcohol dependence (age at onset) ARL15 intron 24962325 rs41151 chr5 53565054 G A,C,T 5.06E-07 Alcohol dependence (age at onset) ARL15 intron 24962325 rs10077344 chr5 53568086 C A 2.54E-05 Bipolar disorder and schizophrenia ARL15 intron 20889312 rs35922 chr5 53568444 C T 2.20E-05 Response to statin therapy ARL15 intron 20339536 rs3776649 chr5 53574945 A T 1.65E-05 Bipolar disorder and schizophrenia ARL15 intron 20889312 rs10940373 chr5 53575691 A G 1.60E-06 Alcohol dependence (age at onset) ARL15 intron 24962325 rs11954928 chr5 53577647 T C 9.97E-04 Suicide attempts in bipolar disorder ARL15 intron 21423239 rs1469096 chr5 53578315 G A 9.73E-04 Suicide attempts in bipolar disorder ARL15 intron 21423239 rs3776642 chr5 53582226 T G 5.52E-07 Alcohol dependence (age at onset) ARL15 intron 24962325 rs3776641 chr5 53582252 C T 9.42E-07 Alcohol dependence (age at onset) ARL15 intron 24962325 rs7725454 chr5 53582400 A T 9.42E-07 Alcohol dependence (age at onset) ARL15 intron 24962325 rs6450184 chr5 53582505 G C 9.42E-07 Alcohol dependence (age at onset) ARL15 intron 24962325 rs250385 chr5 53583083 G C 1.20E-05 Response to statin therapy ARL15 intron 20339536 rs7704911 chr5 53587702 C T 6.83E-05 Bipolar disorder and schizophrenia ARL15 intron 20889312 rs7704911 chr5 53587702 C T 9.88E-06 Alcohol dependence (age at onset) ARL15 intron 24962325 rs35953 chr5 53591785 C G 1.00E-05 Response to statin therapy ARL15 intron 20339536 rs35952 chr5 53592163 C T 2.21E-08 Alcohol dependence (age at onset) ARL15 intron 24962325 rs35951 chr5 53592361 G T 1.00E-08 Alcohol dependence (age at onset) ARL15 intron 24962325 rs11739911 chr5 53597527 A G 4.98E-06 Post-operative nausea and vomiting ARL15 intron 21694509 rs35947 chr5 53600443 G A 2.61E-07 Post-operative nausea and vomiting ARL15 intron 21694509 rs6882064 chr5 53694171 T C 1.71E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7731258 chr5 53711122 G A 5.10E-04 Alcohol dependence / / 20201924 rs17342535 chr5 53744849 T C 2.51E-05 Dengue shock syndrome / / 22001756 rs13184726 chr5 53763375 G A 1.76E-05 Post-operative nausea and vomiting / / 21694509 rs6889172 chr5 53770686 T C 7.28E-04 Smoking initiation / / 24665060 rs6450206 chr5 53775024 G C 5.61E-04 Smoking initiation / / 24665060 rs10066174 chr5 53775596 G A 6.60E-04 Smoking initiation / / 24665060 rs2407721 chr5 53776729 A G 5.06E-04 Smoking initiation / / 24665060 rs6450210 chr5 53779715 A G 9.36E-04 Type 2 diabetes / / 17463246 rs4416562 chr5 53786857 G A 6.97E-04 Smoking initiation / / 24665060 rs10068815 chr5 53805159 A G 3.67E-04 Smoking initiation / / 24665060 rs2548617 chr5 53812952 A G 1.78E-05 Smoking initiation / / 24665060 rs2548616 chr5 53813122 A G 1.25E-05 Smoking initiation / / 24665060 rs2548612 chr5 53815495 A C 3.14E-04 Smoking initiation SNX18 missense 24665060 rs2564990 chr5 53816782 T C 2.72E-04 Smoking initiation SNX18 UTR-3 24665060 rs2565007 chr5 53820267 C A 2.32E-04 Smoking initiation SNX18 intron 24665060 rs1991006 chr5 53820538 G C 1.38E-04 Smoking initiation SNX18 intron 24665060 rs2565004 chr5 53823285 G A 1.38E-04 Smoking initiation SNX18 intron 24665060 rs2565004 chr5 53823285 G A 5.94E-05 Coronary heart disease SNX18 intron pha003032 rs2548649 chr5 53823802 T C 1.52E-05 Smoking initiation SNX18 intron 24665060 rs2161586 chr5 53824661 G T 7.49E-05 Cognitive test performance SNX18 intron 20125193 rs2565002 chr5 53826427 T C 1.37E-04 Smoking initiation SNX18 intron 24665060 rs2565002 chr5 53826427 T C 1.36E-05 Coronary heart disease SNX18 intron pha003032 rs2548644 chr5 53843527 T C 5.65E-05 Smoking initiation / / 24665060 rs875988 chr5 53851203 C T 7.09E-04 Smoking initiation / / 24665060 rs6859999 chr5 53852534 C T 5.56E-04 Smoking initiation / / 24665060 rs11960494 chr5 53854564 T G 8.12E-05 Smoking initiation / / 24665060 rs11957553 chr5 53856755 T A 7.82E-04 Smoking initiation / / 24665060 rs2564996 chr5 53867321 T C 8.88E-04 Type 2 diabetes / / 17463246 rs2548638 chr5 53869576 T G 2.51E-05 Smoking initiation / / 24665060 rs2962549 chr5 53870483 A G 2.84E-05 Body mass (lean) / / 19268274 rs17442098 chr5 53872402 C T 4.27E-05 Sudden cardiac arrest / / 21658281 rs766529 chr5 53873455 G C 2.01E-04 Smoking initiation / / 24665060 rs10067633 chr5 53874176 T C 7.22E-04 Smoking initiation / / 24665060 rs2548631 chr5 53875569 G A 6.19E-05 Body mass (lean) / / 19268274 rs1122401 chr5 53875982 T C 4.00E-06 Smoking initiation / / 24665060 rs1122400 chr5 53876002 T G 8.09E-06 Smoking initiation / / 24665060 rs2548629 chr5 53876988 G T 3.97E-05 Body mass (lean) / / 19268274 rs4865845 chr5 53877934 G A 7.28E-05 Smoking initiation / / 24665060 rs1006885 chr5 53878831 G A 2.20E-04 Smoking initiation / / 24665060 rs2548628 chr5 53881925 G A 7.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs2910810 chr5 53889908 C A 7.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs2564987 chr5 53890238 T C 1.91E-04 Type 2 diabetes / / 17463246 rs2564988 chr5 53900087 C T 5.28E-04 Type 2 diabetes / / 17463246 rs2548621 chr5 53902339 G A 9.00E-07 Immune response to smallpox vaccine (IL-6) / / 22542470 rs2548620 chr5 53902940 A G 4.75E-05 Soluble levels of adhesion molecules / / pha003072 rs7720197 chr5 53949560 G A 1.00E-04 Prostate cancer / / 21743057 rs11749226 chr5 53953264 T C 1.00E-04 Prostate cancer / / 21743057 rs11745165 chr5 53953279 C A 1.00E-04 Prostate cancer / / 21743057 rs6414829 chr5 53968122 T A 5.14E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4865859 chr5 53969773 G A 6.56E-05 Neutrophil count / / pha003095 rs1373990 chr5 53991566 A C 1.81E-04 Multiple complex diseases / / 17554300 rs4865582 chr5 53993648 T C 2.16E-04 Multiple complex diseases / / 17554300 rs4865582 chr5 53993648 T C 4.28E-05 Cognitive test performance / / 20125193 rs6894873 chr5 53994294 G A 7.33E-05 Cognitive test performance / / 20125193 rs6876610 chr5 53994444 A G 1.93E-04 Multiple complex diseases / / 17554300 rs985444 chr5 54004482 T C 7.50E-06 Urinary metabolites / / 21572414 rs4282276 chr5 54011945 A G 1.69E-04 Multiple complex diseases / / 17554300 rs2121132 chr5 54028661 C A 3.34E-04 Multiple complex diseases / / 17554300 rs4353984 chr5 54031511 A C 9.73E-05 Cognitive test performance / / 20125193 rs11741898 chr5 54046722 A G 2.96E-04 Multiple complex diseases / / 17554300 rs10066710 chr5 54047137 G A 9.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs13180747 chr5 54047162 T C 8.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs13180905 chr5 54047476 A G 5.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs1445837 chr5 54048853 T G 8.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs1445838 chr5 54048916 G A 9.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs9292071 chr5 54061132 T C 8.14E-04 Multiple complex diseases / / 17554300 rs10068073 chr5 54074654 T C 7.75E-05 Taste perception / / 22132133 rs10072474 chr5 54083159 A G 2.85E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4472223 chr5 54087671 C T 7.05E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6450249 chr5 54088619 C T 7.05E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6892315 chr5 54090159 T C 1.26E-04 Taste perception / / 22132133 rs10058571 chr5 54104560 C T 4.68E-04 Taste perception / / 22132133 rs10940428 chr5 54104649 C T 4.82E-04 Taste perception / / 22132133 rs10036606 chr5 54120372 G A 1.79E-04 Taste perception / / 22132133 rs4865879 chr5 54160345 C T 6.81E-05 Behcet's disease / / pha002888 rs36000196 chr5 54174285 T C 7.36E-05 Intelligence / / 21826061 rs10940434 chr5 54174906 T C 3.27E-05 Behcet's disease / / pha002888 rs2075401 chr5 54184663 A C 8.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs2407759 chr5 54197973 G A 4.50E-05 Amyotrophic lateral sclerosis / / 20801718 rs4242051 chr5 54198775 T C 7.28E-05 Postoperative ventricular dysfunction / / 21980348 rs9283715 chr5 54223263 G A 7.87E-04 Multiple complex diseases / / 17554300 rs3815916 chr5 54252825 T G 3.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1816086 chr5 54253033 C T 3.47E-04 Multiple complex diseases / / 17554300 rs10491370 chr5 54257812 C A 4.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3756298 chr5 54281715 G A 6.36E-04 Smoking quantity / / 24665060 rs1396499 chr5 54301408 C T 2.85E-04 Rheumatoid arthritis / / 21452313 rs4865908 chr5 54316028 T C 1.77E-04 Rheumatoid arthritis / / 21452313 rs6891823 chr5 54317900 C T 7.48E-05 Major depressive disorder / / 22472876 rs1848502 chr5 54322476 C G 0.0000463 Major depressive disorder GZMK intron 23149448 rs6875661 chr5 54324622 T C 1.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GZMK intron 20877124 rs2112938 chr5 54327955 G T 4.17E-05 Major depressive disorder GZMK intron 21621269 rs9292085 chr5 54370957 T G 9.08E-04 Multiple complex diseases / / 17554300 rs10043664 chr5 54428310 C A 4.59E-05 Major depressive disorder CDC20B intron 20516156 rs12109297 chr5 54488824 G A 3.53E-05 Alcohol and nictotine co-dependence / / 20158304 rs12110186 chr5 54488919 C T 9.64E-04 Lymphocyte counts / / 22286170 rs334889 chr5 54525240 C A 6.81E-04 Type 2 diabetes / / 17463246 rs334890 chr5 54525472 G A 6.27E-04 Type 2 diabetes / / 17463246 rs334890 chr5 54525472 G A 7.60E-04 Multiple complex diseases / / 17554300 rs12523234 chr5 54550699 A G 1.73E-05 Alcohol and nictotine co-dependence / / 20158304 rs897669 chr5 54558972 G A 1.80E-05 Alcohol and nictotine co-dependence DHX29 intron 20158304 rs897669 chr5 54558972 G A 3.06E-05 Hypertension (young onset) DHX29 intron 24892410 rs7730986 chr5 54576263 C T 8.16E-04 White matter integrity DHX29 intron 22425255 rs13154710 chr5 54611733 A G 2.53E-05 Alcohol and nictotine co-dependence SKIV2L2 intron 20158304 rs6450303 chr5 54658658 G A 5.88E-04 Bipolar disorder,schizoaffective SKIV2L2 intron 19567891 rs6886473 chr5 54670639 C T 5.24E-04 Bipolar disorder,schizoaffective SKIV2L2 intron 19567891 rs12518892 chr5 54699883 A G 2.53E-05 Alcohol and nictotine co-dependence SKIV2L2 intron 20158304 rs230769 chr5 54708490 A T 5.68E-04 Bipolar disorder,schizoaffective SKIV2L2 intron 19567891 rs230753 chr5 54718618 G C 5.79E-04 Bipolar disorder,schizoaffective SKIV2L2 intron 19567891 rs230737 chr5 54727661 C T 5.26E-04 Bipolar disorder,schizoaffective PPAP2A intron 19567891 rs11741874 chr5 54737008 A G 0.000126984 Primary sclerosing cholangitis PPAP2A intron 23603763 rs6868292 chr5 54753045 T G 9.97E-04 Multiple complex diseases PPAP2A intron 17554300 rs7701019 chr5 54756374 T C 5.94E-04 Bipolar disorder,schizoaffective PPAP2A intron 19567891 rs6450311 chr5 54763074 T A 4.66E-04 Bipolar disorder,schizoaffective PPAP2A intron 19567891 rs11747553 chr5 54769420 G A 8.11E-07 Schizophrenia PPAP2A intron 21926974 rs6870449 chr5 54771380 A G 2.27E-04 Bipolar disorder,schizoaffective PPAP2A intron 19567891 rs992017 chr5 54777403 T C 4.26E-04 Bipolar disorder,schizoaffective PPAP2A intron 19567891 rs10940474 chr5 54880701 C T 9.87E-05 Serum metabolites / / 19043545 rs10940474 chr5 54880701 C T 3.26E-05 Melanoma / / 21926416 rs7721054 chr5 54890802 T C 0.000762576 Hypertension (early onset hypertension) / / 22479346 rs2897834 chr5 54938579 C A 6.84E-05 Neuroblastoma SLC38A9 intron pha002895 rs16884436 chr5 54980895 T A 3.65E-05 Serum metabolites SLC38A9 intron 19043545 rs6897117 chr5 54986775 T C 9.00E-04 Acute lymphoblastic leukemia (childhood) SLC38A9 intron 20189245 rs3761769 chr5 54994064 C T 4.65E-05 Serum metabolites SLC38A9 intron 19043545 rs11958779 chr5 55001899 G A 2.00E-12 Height SLC38A9 intron 20881960 rs7707639 chr5 55010963 G A 8.99E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7707639 chr5 55010963 G A 5.04E-04 Alcohol dependence / / 20201924 rs3846513 chr5 55028160 T C 0.00000774 Schizophrenia / / 22440650 rs13173625 chr5 55030944 C T 2.73E-05 Bipolar disorder and schizophrenia / / 20889312 rs3761772 chr5 55034088 A G 3.36E-05 Job-related exhaustion DDX4 intron 23620144 rs6863874 chr5 55046489 A G 4.15E-05 Job-related exhaustion DDX4 intron 23620144 rs7730742 chr5 55060656 G A 6.04E-04 Myopia (pathological) DDX4 intron 21095009 rs7730742 chr5 55060656 G A 9.29E-05 Neuroblastoma DDX4 intron pha002895 rs10035707 chr5 55062523 C T 6.04E-04 Myopia (pathological) DDX4 intron 21095009 rs10035707 chr5 55062523 C T 5.09E-05 Neuroblastoma DDX4 intron pha002895 rs4865988 chr5 55071251 G A 8.34E-05 Bipolar disorder and schizophrenia DDX4 intron 20889312 rs957459 chr5 55082474 C T 6.84E-04 Myopia (pathological) DDX4 cds-synon 21095009 rs957459 chr5 55082474 C T 4.21E-05 Neuroblastoma DDX4 cds-synon pha002895 rs17643358 chr5 55086961 A G 2.43E-05 Neuroblastoma (low-risk) DDX4 intron 21436895 rs2619046 chr5 55097534 G A 6.84E-04 Myopia (pathological) DDX4 intron 21095009 rs2619046 chr5 55097534 G A 6.41E-07 Neuroblastoma (low-risk) DDX4 intron 21436895 rs2619046 chr5 55097534 G A 1.76E-05 Neuroblastoma DDX4 intron pha002895 rs6450352 chr5 55108732 A C 4.77E-06 Phospholipid levels (plasma) DDX4 intron 21829377 rs162097 chr5 55115342 G A 6.80E-05 Serum metabolites / / 19043545 rs162089 chr5 55118675 T C 2.70E-05 Height / / 19396169 rs162096 chr5 55129428 A G 7.16E-04 Myopia (pathological) / / 21095009 rs162096 chr5 55129428 A G 3.33E-05 Neuroblastoma / / pha002895 rs6876491 chr5 55145935 C T 3.02E-04 Myopia (pathological) IL31RA nearGene-5 21095009 rs6876491 chr5 55145935 C T 1.94E-04 Neuroblastoma (low-risk) IL31RA nearGene-5 21436895 rs10055201 chr5 55161102 A G 6.95E-04 Myopia (pathological) IL31RA intron 21095009 rs10055201 chr5 55161102 A G 4.80E-06 Neuroblastoma (low-risk) IL31RA intron 21436895 rs10062991 chr5 55169853 A C 2.10E-05 Urinary metabolites IL31RA intron 21572414 rs13357543 chr5 55223929 T C 9.98E-05 Neuroblastoma (low-risk) / / 21436895 rs10940493 chr5 55237911 C G 1.07E-09 HDL cholesterol IL6ST intron 23063622 rs11741953 chr5 55267814 T C 8.49E-04 Amyotrophic lateral sclerosis (sporadic) IL6ST intron 24529757 rs17348299 chr5 55322895 C A 6.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs17348299 chr5 55322895 C A 1.00E-10 IgG glycosylation / / 23382691 rs17348299 chr5 55322895 C A 2.00E-06 IgG glycosylation / / 23382691 rs17348299 chr5 55322895 C A 2.00E-06 IgG glycosylation / / 23382691 rs17348299 chr5 55322895 C A 2.00E-07 IgG glycosylation / / 23382691 rs17348299 chr5 55322895 C A 2.00E-09 IgG glycosylation / / 23382691 rs17348299 chr5 55322895 C A 3.00E-10 IgG glycosylation / / 23382691 rs17348299 chr5 55322895 C A 4.00E-06 IgG glycosylation / / 23382691 rs17348299 chr5 55322895 C A 7.00E-11 IgG glycosylation / / 23382691 rs17348299 chr5 55322895 C A 8.00E-06 IgG glycosylation / / 23382691 rs16884711 chr5 55324802 A C 2.00E-06 IgG glycosylation / / 23382691 rs16884711 chr5 55324802 A C 3.00E-06 IgG glycosylation / / 23382691 rs10042443 chr5 55352770 C T 1.00E-04 Information processing speed / / 21130836 rs10491472 chr5 55366704 A C 2.74E-05 Weight / / pha003027 rs322019 chr5 55384562 G A 4.34E-05 Hypertension / / pha003041 rs9647530 chr5 55384909 C T 5.70E-05 Hypothyroidism / / 22493691 rs689379 chr5 55389477 A G 7.12E-05 Hypertension / / pha003041 rs186451 chr5 55395112 C T 9.58E-05 Hypertension / / pha003041 rs321776 chr5 55407542 C T 6.19E-05 Hypertension ANKRD55 missense pha003041 rs12659696 chr5 55418136 T C 1.09E-05 Psoriasis ANKRD55 intron 20953190 rs321768 chr5 55422681 C T 9.02E-06 Rheumatoid arthritis ANKRD55 intron 19503088 rs318791 chr5 55424472 A G 4.50E-04 Myasthenia gravis ANKRD55 intron 23055271 rs6876431 chr5 55434432 A G 3.91E-05 Intelligence ANKRD55 intron 21826061 rs10040327 chr5 55435220 C A 4.19E-06 Rheumatoid arthritis ANKRD55 intron 19503088 rs6859219 chr5 55438580 C A 2.89E-07 Multiple complex diseases ANKRD55 intron 17554300 rs6859219 chr5 55438580 C A 1.00E-11 Rheumatoid arthritis ANKRD55 intron 20453842 rs6859219 chr5 55438580 C A 9.60E-12 Celiac disease and Rheumatoid arthritis ANKRD55 intron 21383967 rs6859219 chr5 55438580 C A 9.60E-12 Multiple sclerosis ANKRD55 intron 22190364 rs6859219 chr5 55438580 C A 5.10E-09 Rheumatoid arthritis ANKRD55 intron 22446963 rs10065637 chr5 55438851 C T 4.00E-12 Crohn's disease ANKRD55 intron 23128233 rs71624119 chr5 55440730 G A 1.20E-11 Rheumatoid arthritis (CCP positive) ANKRD55 intron 23143596 rs71624119 chr5 55440730 G A 5.18E-12 Rheumatoid arthritis (CCP negative) ANKRD55 intron 23143596 rs71624119 chr5 55440730 G A 5.59E-20 Rheumatoid arthritis ANKRD55 intron 23143596 rs71624119 chr5 55440730 G A 0.0000121 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis ANKRD55 intron 23603761 rs71624119 chr5 55440730 G A 4.40E-11 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) ANKRD55 intron 23603761 rs71624119 chr5 55440730 G A 6.45E-08 Oligoarticular juvenile idiopathic arthritis ANKRD55 intron 23603761 rs10213692 chr5 55442249 T C 2.73E-11 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) ANKRD55 intron 23603761 rs7731626 chr5 55444683 G A 7.30E-24 Rheumatoid arthritis ANKRD55 intron 24390342 rs7731626 chr5 55444683 G A 8.00E-23 Rheumatoid arthritis ANKRD55 intron 24390342 rs16884951 chr5 55460756 G C 4.75E-05 Brain structure ANKRD55 intron 22504417 rs35930212 chr5 55467155 T A 6.07E-04 Type 2 diabetes ANKRD55 intron 17463246 rs6876474 chr5 55471740 C G 4.62E-05 Brain structure ANKRD55 intron 22504417 rs159566 chr5 55509554 G A 2.90E-06 Celiac disease and Rheumatoid arthritis ANKRD55 intron 21383967 rs4700060 chr5 55510656 C T 1.00E-08 Alzheimer's disease (cognitive decline) ANKRD55 intron 23535033 rs12652011 chr5 55511394 C T 5.54E-04 Taste perception ANKRD55 intron 22132133 rs12654754 chr5 55511683 T C 5.54E-04 Taste perception ANKRD55 intron 22132133 rs149489 chr5 55528815 T C 8.45E-04 Obesity (extreme) ANKRD55 intron 21935397 rs152347 chr5 55536488 G A 8.22E-04 Obesity (extreme) / / 21935397 rs36734 chr5 55544924 G A 8.04E-04 Obesity (extreme) / / 21935397 rs32498 chr5 55548797 T C 7.95E-04 Obesity (extreme) / / 21935397 rs152345 chr5 55559697 T C 6.76E-04 Obesity (extreme) / / 21935397 rs152344 chr5 55559884 A G 6.74E-04 Obesity (extreme) / / 21935397 rs1020388 chr5 55560027 T G 3.00E-07 Celiac disease and Rheumatoid arthritis / / 21383967 rs152343 chr5 55560577 T C 6.92E-04 Obesity (extreme) / / 21935397 rs387432 chr5 55565096 C G 2.50E-05 Urinary metabolites / / 21572414 rs27006 chr5 55567581 G A 1.40E-04 Alcohol dependence / / 20201924 rs27573 chr5 55567749 A C 7.71E-06 Coronary heart disease / / 21606135 rs1862524 chr5 55575355 A G 5.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs158592 chr5 55576562 A T 1.30E-05 Urinary metabolites / / 21572414 rs26095 chr5 55587012 G T 1.96E-04 Multiple complex diseases / / 17554300 rs149091 chr5 55605091 G C 2.80E-05 Urinary metabolites / / 21572414 rs16885221 chr5 55610849 C T 2.20E-05 Multiple complex diseases / / 17554300 rs158342 chr5 55625333 T G 2.86E-05 Hematocrit / / pha003097 rs32497 chr5 55641055 C T 1.92E-05 Hematocrit / / pha003097 rs1567341 chr5 55645791 C T 6.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11950693 chr5 55647984 G A 6.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16885269 chr5 55651822 C T 5.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16885269 chr5 55651822 C T 9.70E-05 Calcium levels / / pha003085 rs442647 chr5 55653858 A G 4.48E-04 Multiple complex diseases / / 17554300 rs6892034 chr5 55653889 A G 4.79E-05 Serum metabolites / / 19043545 rs398588 chr5 55654171 G C 6.01E-04 Multiple complex diseases / / 17554300 rs397430 chr5 55654508 G A 8.58E-04 Multiple complex diseases / / 17554300 rs12523475 chr5 55656564 C T 0.0000883 Placental abruption / / 23205182 rs12523475 chr5 55656564 C T 6.08E-05 Body Mass Index / / pha003007 rs1645483 chr5 55656875 T C 5.36E-04 Multiple complex diseases / / 17554300 rs1858085 chr5 55665535 A C,G,T 5.79E-04 Taste perception / / 22132133 rs9292114 chr5 55673940 A G 2.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs285994 chr5 55685356 C G 5.05E-04 Type 2 diabetes / / 17463246 rs286003 chr5 55706122 C G 0.000377 Breast cancer early age of onset / / 18463975 rs286002 chr5 55706469 T C 4.24E-04 Parkinson's disease / / 17052657 rs158214 chr5 55711291 C T 1.20E-05 Urinary metabolites / / 21572414 rs6874301 chr5 55738212 T C 2.76E-07 Central corneal thickness / / 20719862 rs39838 chr5 55742353 C T 8.54E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13355587 chr5 55742395 G A 2.77E-07 Central corneal thickness / / 20719862 rs3844303 chr5 55742710 C A 2.74E-06 Central corneal thickness / / 20719862 rs10056675 chr5 55743019 G A 2.56E-07 Central corneal thickness / / 20719862 rs6890031 chr5 55746585 A G 6.63E-06 Central corneal thickness / / 20719862 rs6450392 chr5 55747268 C T 6.62E-06 Central corneal thickness / / 20719862 rs7707109 chr5 55749106 T A 8.21E-07 Central corneal thickness / / 20719862 rs13356699 chr5 55749615 G A 8.22E-07 Central corneal thickness / / 20719862 rs10471977 chr5 55750383 T C 8.23E-07 Central corneal thickness / / 20719862 rs3852139 chr5 55750914 C T 7.69E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs3852139 chr5 55750914 C T 9.72E-04 Type 2 diabetes / / 17463246 rs7737440 chr5 55752112 C A 8.17E-07 Central corneal thickness / / 20719862 rs10064714 chr5 55752164 G T 8.16E-07 Central corneal thickness / / 20719862 rs12697147 chr5 55758400 A G 7.84E-07 Central corneal thickness / / 20719862 rs16885581 chr5 55796172 A G 5.00E-04 Multiple complex diseases / / 17554300 rs40271 chr5 55796319 C T 3.63E-04 Multiple complex diseases / / 17554300 rs157843 chr5 55799184 C A 3.44E-04 Multiple complex diseases / / 17554300 rs459193 chr5 55806751 A G 0.000000002 Type 2 diabetes / / 22885922 rs459193 chr5 55806751 A G 0.000000066 Fasting insulin-related traits / / 22885922 rs459193 chr5 55806751 A G 0.0000016 Fasting blood glucose / / 22885922 rs459193 chr5 55806751 A G 0.0000034 Type 2 diabetes (males) / / 22885922 rs459193 chr5 55806751 A G 0.000011 Type 2 diabetes (females) / / 22885922 rs459193 chr5 55806751 A G 0.000047 Triglycerides / / 22885922 rs459193 chr5 55806751 A G 0.00038 HDL cholesterol / / 22885922 rs459193 chr5 55806751 A G 0.00000158 Fasting blood glucose / / 22885924 rs459193 chr5 55806751 A G 1.12E-10 Fasting insulin-related traits / / 22885924 rs459193 chr5 55806751 A G 8.90E-04 Type 2 diabetes / / 24509480 rs456867 chr5 55811092 C T 3.00E-06 Urate levels / / 23263486 rs10461608 chr5 55827264 T C 6.73E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs40565 chr5 55828636 C T 9.10E-05 Epilepsy (remission after treatment) / / 23962720 rs30361 chr5 55831895 G A 1.65E-04 Hearing function / / 17255346 rs30360 chr5 55833519 G T 1.00E-06 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs30360 chr5 55833519 G T 9.00E-07 Fasting insulin (interaction) / / 24204828 rs28130 chr5 55834230 G A 3.19E-04 Hearing function / / 17255346 rs28130 chr5 55834230 G A 9.79E-05 Multiple complex diseases / / 17554300 rs16885701 chr5 55836867 T C 2.92E-04 Type 2 diabetes / / 17463246 rs154250 chr5 55837949 C G 1.25E-04 Multiple complex diseases / / 17554300 rs157518 chr5 55838485 A C 1.31E-04 Hearing function / / 17255346 rs157518 chr5 55838485 A C 2.08E-04 Multiple complex diseases / / 17554300 rs464650 chr5 55845382 A G 9.33E-05 Smoking initiation / / 24665060 rs457587 chr5 55845916 A G 8.34E-04 Multiple complex diseases / / 17554300 rs2431116 chr5 55846981 A G 1.05E-04 Hearing function / / 17255346 rs2431116 chr5 55846981 A G 1.44E-04 Multiple complex diseases / / 17554300 rs30353 chr5 55848972 C G 1.15E-04 Hearing function / / 17255346 rs30353 chr5 55848972 C G 3.20E-04 Multiple complex diseases / / 17554300 rs39836 chr5 55849831 A G 1.25E-04 Hearing function / / 17255346 rs462520 chr5 55853878 G A 1.30E-04 Multiple complex diseases / / 17554300 rs6867983 chr5 55854153 C T 3.00E-06 Triglycerides / / 20864672 rs6867983 chr5 55854153 C T 1.00E-07 Waist circumference / / 23966867 rs3843467 chr5 55856375 G T 9.91E-05 Response to metformin / / 21186350 rs4301182 chr5 55857675 A C 1.19E-04 Multiple sclerosis / / 17660530 rs11743303 chr5 55859952 A G 8.00E-07 Sexual dimorphism in anthropometric traits / / 23754948 rs9686661 chr5 55861786 C T 1.00E-10 Triglycerides / / 20686565 rs9686661 chr5 55861786 C T 3.00E-16 Triglycerides / / 24097068 rs4406105 chr5 55874173 C T 7.27E-04 Multiple complex diseases / / 17554300 rs16885750 chr5 55874809 C T 1.30E-05 HIV-1 control / / 20041166 rs6450394 chr5 55875713 T C 8.97E-04 Insulin resistance / / 21901158 rs4129542 chr5 55878680 A C,G,T 8.90E-05 Response to statin therapy / / 20339536 rs12697148 chr5 55878971 G T 8.76E-05 Meningococcal disease / / 20694013 rs12109266 chr5 55888260 T A 7.42E-04 Multiple complex diseases / / 17554300 rs13168904 chr5 55890282 C A 5.90E-05 Alzheimer's disease / / 22005930 rs10471982 chr5 55890709 G A,T 7.27E-05 Alzheimer's disease / / 22005930 rs10471983 chr5 55890753 C G 4.72E-05 Alzheimer's disease / / 22005930 rs16885766 chr5 55892229 T C 4.52E-05 Alzheimer's disease / / 22005930 rs16885767 chr5 55892284 G A 3.66E-05 Alzheimer's disease / / 22005930 rs10471426 chr5 55893167 G C 5.49E-05 Alzheimer's disease / / 22005930 rs12697149 chr5 55894919 C T 5.44E-05 Alzheimer's disease / / 22005930 rs13359799 chr5 55895372 G A 5.44E-05 Alzheimer's disease / / 22005930 rs13436402 chr5 55895762 A T 5.42E-05 Alzheimer's disease / / 22005930 rs13436633 chr5 55895873 G A 8.51E-05 Alzheimer's disease / / 22005930 rs13154282 chr5 55896081 T C 3.75E-05 Alzheimer's disease / / 22005930 rs10037447 chr5 55896239 C A 5.36E-05 Alzheimer's disease / / 22005930 rs10037963 chr5 55896258 C A 5.29E-05 Alzheimer's disease / / 22005930 rs10040839 chr5 55896325 A C 5.24E-05 Alzheimer's disease / / 22005930 rs10040902 chr5 55896630 A C 3.69E-04 Alzheimer's disease / / 22005930 rs16885777 chr5 55896950 A G 3.66E-04 Alzheimer's disease / / 22005930 rs16885784 chr5 55897014 C T 4.26E-05 Alzheimer's disease / / 22005930 rs13178221 chr5 55897451 C T 6.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs16885787 chr5 55897467 T C 3.62E-05 Alzheimer's disease / / 22005930 rs16885789 chr5 55897825 T C 3.60E-05 Alzheimer's disease / / 22005930 rs13160425 chr5 55897856 A G 3.58E-05 Alzheimer's disease / / 22005930 rs13160682 chr5 55897964 A C 3.81E-05 Alzheimer's disease / / 22005930 rs10077190 chr5 55898770 G A 2.13E-04 Alzheimer's disease / / 22005930 rs10513086 chr5 55899127 T A 5.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10513086 chr5 55899127 T A 6.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs13187546 chr5 55899269 G A 5.48E-05 Alzheimer's disease / / 22005930 rs10072528 chr5 55899713 A G 7.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs10074134 chr5 55899739 T C 4.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs10074351 chr5 55900059 T C 8.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs10074351 chr5 55900059 T C 3.70E-04 Alzheimer's disease / / 22005930 rs9292118 chr5 55900196 C T 8.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs7702507 chr5 55900328 G C 7.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs17659562 chr5 55904385 A G 6.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs17716202 chr5 55904898 T C 7.70E-06 Alzheimer's disease / / 22005930 rs17716231 chr5 55904947 C T 3.37E-05 Post-operative nausea and vomiting / / 21694509 rs1574461 chr5 55910697 T C 9.18E-05 Post-operative nausea and vomiting / / 21694509 rs1296958 chr5 55913744 C T 8.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs2448424 chr5 55918201 G A 6.41E-04 Alzheimer's disease / / 22005930 rs7725982 chr5 55935049 C G 1.58E-04 Multiple complex diseases / / 17554300 rs889310 chr5 55965167 C T 1.60E-05 Height / / pha003010 rs889310 chr5 55965167 C T 3.12E-05 Height / / pha003011 rs16886018 chr5 55978051 C A 7.12E-07 Glaucoma (primary open-angle) / / 22605921 rs13362504 chr5 55979129 A C 1.18E-05 Parkinson's disease / / 17052657 rs16886034 chr5 55983856 T A,C,G 2.00E-09 Breast cancer (early onset) / / 24493630 rs6897035 chr5 55994947 G T 7.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16886113 chr5 55995035 T G 1.70E-04 Alcohol dependence / / 20201924 rs16886113 chr5 55995035 T G 3.20E-04 Alcohol dependence / / 20201924 rs16886113 chr5 55995035 T G 4.00E-11 Breast cancer (early onset) / / 24493630 rs7700506 chr5 55996598 A G 8.52E-04 Multiple complex diseases / / 17554300 rs6862199 chr5 56009012 T C 1.43E-08 Breast cancer (early onset) / / 24493630 rs10940511 chr5 56012880 T C 4.85E-09 Breast cancer (early onset) / / 24493630 rs7720499 chr5 56021821 C T 7.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16886165 chr5 56023083 T G 5.00E-07 Breast cancer / / 19330030 rs16886165 chr5 56023083 T G 5.00E-07 Nasopharyngeal carcinoma / / 20512145 rs12656399 chr5 56026843 T C 8.73E-04 Parkinson's disease / / 17052657 rs16886181 chr5 56029243 T C 9.00E-14 Breast cancer (early onset) / / 24493630 rs889312 chr5 56031884 C A 7.00E-20 Breast cancer / / 17529967 rs889312 chr5 56031884 C A 5.00E-09 Breast cancer / / 20453838 rs889312 chr5 56031884 C A 7.00E-20 Nasopharyngeal carcinoma / / 20512145 rs889312 chr5 56031884 C A 3.00E-36 Breast cancer / / 23535729 rs889312 chr5 56031884 C A 1.00E-08 Breast cancer (early onset) / / 24493630 rs4700485 chr5 56034207 A G 2.69E-06 Serum metabolites / / 19043545 rs12658073 chr5 56040364 A G 7.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs961847 chr5 56041064 C T 1.04E-13 Breast cancer (early onset) / / 24493630 rs4700008 chr5 56044186 A G 8.65E-09 Breast cancer (early onset) / / 24493630 rs10077075 chr5 56056724 C T 5.30E-05 White matter hyperintensity burden / / 21681796 rs112497245 chr5 56060954 G A 6.17E-05 Breast cancer / / 24143190 rs1862618 chr5 56096315 G C 3.74E-04 Multiple complex diseases / / 17554300 rs6893754 chr5 56100006 G A 4.35E-05 Endometrial cancer / / 24096698 rs1423621 chr5 56101035 C A 1.50E-06 Type 2 diabetes / / 23209189 rs4146566 chr5 56101894 C A,G 2.70E-05 White matter hyperintensity burden / / 21681796 rs10461617 chr5 56104308 A G 4.00E-06 Type 2 diabetes / / 23209189 rs11960484 chr5 56109154 A G 2.45E-05 Serum metabolites MAP3K1 nearGene-5 19043545 rs11960484 chr5 56109154 A G 1.08E-12 Breast cancer (early onset) MAP3K1 nearGene-5 24493630 rs832552 chr5 56113850 G T 0.000087 Coronary artery calcification MAP3K1 intron 23727086 rs832552 chr5 56113850 G T 1.11E-12 Breast cancer (early onset) MAP3K1 intron 24493630 rs702691 chr5 56114526 T G 8.67E-13 Breast cancer (early onset) MAP3K1 intron 24493630 rs252905 chr5 56118875 G A 1.26E-05 Serum metabolites MAP3K1 intron 19043545 rs252905 chr5 56118875 G A 9.22E-13 Breast cancer (early onset) MAP3K1 intron 24493630 rs252906 chr5 56119190 C A 1.71E-05 Serum metabolites MAP3K1 intron 19043545 rs252906 chr5 56119190 C A 1.07E-12 Breast cancer (early onset) MAP3K1 intron 24493630 rs16886364 chr5 56122344 A G 5.00E-12 Breast cancer (early onset) MAP3K1 intron 24493630 rs252919 chr5 56124111 T C 1.20E-06 Type 2 diabetes MAP3K1 intron 23209189 rs866223 chr5 56125353 A G 0.00018 Coronary artery calcification MAP3K1 intron 23727086 rs832585 chr5 56125904 T C 1.04E-12 Breast cancer (early onset) MAP3K1 intron 24493630 rs16886397 chr5 56134276 A G 4.00E-12 Breast cancer (early onset) MAP3K1 intron 24493630 rs860580 chr5 56149429 T G 4.86E-07 Lymphocyte counts MAP3K1 intron 22286170 rs832566 chr5 56151744 G A 1.80E-05 Serum metabolites MAP3K1 intron 19043545 rs832566 chr5 56151744 G A 1.06E-12 Breast cancer (early onset) MAP3K1 intron 24493630 rs1017226 chr5 56153392 T C 6.00E-11 Breast cancer (early onset) MAP3K1 intron 24493630 rs832575 chr5 56161787 G A 7.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP3K1 cds-synon 20877124 rs832577 chr5 56163787 G A 0.00036 Coronary artery calcification MAP3K1 intron 23727086 rs832577 chr5 56163787 G A 1.82E-12 Breast cancer (early onset) MAP3K1 intron 24493630 rs16886445 chr5 56166028 A G 3.20E-04 Type 2 diabetes MAP3K1 intron 17463246 rs16886445 chr5 56166028 A G 4.70E-05 White matter hyperintensity burden MAP3K1 intron 21681796 rs16886445 chr5 56166028 A G 5.40E-04 Type 2 diabetes MAP3K1 intron 23209189 rs2229882 chr5 56168712 C T 3.80E-04 Alcohol dependence MAP3K1 cds-synon 20201924 rs2229882 chr5 56168712 C T 5.40E-04 Alcohol dependence MAP3K1 cds-synon 20201924 rs2229882 chr5 56168712 C T 1.00E-14 Breast cancer (early onset) MAP3K1 cds-synon 24493630 rs2229882 chr5 56168712 C T 1.02E-14 Breast cancer (early onset) MAP3K1 cds-synon 24493630 rs16886448 chr5 56170813 C G 2.00E-12 Breast cancer (early onset) MAP3K1 intron 24493630 rs832582 chr5 56177743 G A 1.70E-06 Type 2 diabetes MAP3K1 missense 23209189 rs3822625 chr5 56178111 A G 5.00E-12 Breast cancer (early onset) MAP3K1 cds-synon 24493630 rs12655019 chr5 56195790 A G 3.00E-10 Breast cancer (early onset) / / 24493630 rs252913 chr5 56195846 A G 4.66E-13 Breast cancer (early onset) / / 24493630 rs832540 chr5 56199202 G A 8.38E-13 Breast cancer (early onset) / / 24493630 rs252925 chr5 56203773 G A 1.16E-12 Breast cancer (early onset) / / 24493630 rs252890 chr5 56226410 T C 1.81E-10 Breast cancer (early onset) MIER3 intron 24493630 rs832529 chr5 56229288 C T 1.64E-10 Breast cancer (early onset) MIER3 intron 24493630 rs1445996 chr5 56235548 C T 1.60E-10 Breast cancer (early onset) MIER3 intron 24493630 rs331498 chr5 56249842 C G 6.35E-10 Breast cancer (early onset) / / 24493630 rs331497 chr5 56251660 G T 1.23E-09 Breast cancer (early onset) / / 24493630 rs7726354 chr5 56256483 C T 7.00E-11 Breast cancer (early onset) / / 24493630 rs2662024 chr5 56257515 T C 1.65E-09 Breast cancer (early onset) / / 24493630 rs10039338 chr5 56260363 A G 3.96E-08 Breast cancer (early onset) / / 24493630 rs6890270 chr5 56260606 A G 1.47E-12 Breast cancer (early onset) / / 24493630 rs832404 chr5 56267431 C T 6.50E-04 Endometrial cancer / / 24096698 rs10940518 chr5 56270794 C T 3.55E-08 Breast cancer (early onset) / / 24493630 rs17732475 chr5 56301157 C T 7.25E-04 Multiple complex diseases / / 17554300 rs17732475 chr5 56301157 C T 4.49E-04 Aortic root size / / 21223598 rs16886678 chr5 56343247 A G 0.0000055 Asthma (exacerbation) / / 23706709 rs10059300 chr5 56368573 C T 0.000573 Salmonella-induced pyroptosis / / 22837397 rs331038 chr5 56451035 C T 6.04E-26 Narcolepsy / / 19629137 rs7718423 chr5 56481011 C A 2.60E-06 Urinary metabolites GPBP1 intron 21572414 rs13361596 chr5 56540855 C T 3.20E-06 Urinary metabolites GPBP1 intron 21572414 rs3087980 chr5 56541806 G A 1.70E-05 Urinary metabolites GPBP1 intron 21572414 rs10052004 chr5 56666500 G A 4.00E-06 Schizophrenia / / 23212062 rs2408760 chr5 56695644 A G 2.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs10805497 chr5 56727379 A G 9.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs11950872 chr5 56742262 A G 3.96E-05 Blood Pressure / / pha003044 rs10037753 chr5 56742984 A G 4.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs2220846 chr5 56774934 T C 6.69E-05 Alcohol consumption / / pha001399 rs12658182 chr5 56794319 C T 9.92E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16887016 chr5 56797293 T C 4.15E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6892553 chr5 56810138 T C 6.08E-04 Type 2 diabetes / / 17463246 rs6892553 chr5 56810138 T C 2.00E-06 Orthostatic hypotension / / 24124408 rs1820124 chr5 56817523 G A 6.14E-04 Aortic root size / / 21223598 rs7718757 chr5 56930116 C T 5.79E-05 Type 2 diabetes / / 17463246 rs230874 chr5 56933347 G A 6.14E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2109479 chr5 56944239 A G 4.20E-04 Volumetric brain MRI / / 17903297 rs854140 chr5 56949522 T C 4.31E-04 Type 2 diabetes / / 17463246 rs854140 chr5 56949522 T C 3.50E-06 Femoral neck bone geometry / / 22087292 rs13161897 chr5 56950505 C T 2.04E-04 Amyotrophic lateral sclerosis / / 23624525 rs854139 chr5 56950590 C G 2.12E-05 Femoral neck bone geometry / / 22087292 rs10940567 chr5 56951481 C T 4.10E-06 Urinary metabolites / / 21572414 rs2191450 chr5 56951744 C T 1.50E-05 Amyotrophic lateral sclerosis / / 23624525 rs230828 chr5 56954182 G A 2.20E-06 Urinary metabolites / / 21572414 rs230823 chr5 56957896 A T 2.08E-04 Multiple complex diseases / / 17554300 rs230852 chr5 56960742 A G 4.39E-04 Multiple complex diseases / / 17554300 rs10940569 chr5 56978187 C T 1.46E-04 Multiple complex diseases / / 17554300 rs10940570 chr5 56981001 G T 1.01E-04 Multiple complex diseases / / 17554300 rs7714534 chr5 56982227 G T 1.25E-04 Multiple complex diseases / / 17554300 rs6450430 chr5 56982315 C G 7.04E-04 Multiple complex diseases / / 17554300 rs10940571 chr5 57000546 T A 5.46E-04 Type 2 diabetes / / 17463246 rs10940572 chr5 57000717 C T 6.90E-04 Type 2 diabetes / / 17463246 rs2408848 chr5 57019508 A T 9.71E-04 Type 2 diabetes / / 17463246 rs12519287 chr5 57053569 A G 4.20E-04 Insulin resistance / / 21901158 rs11739108 chr5 57055966 C T 3.04E-04 Insulin resistance / / 21901158 rs11739839 chr5 57056263 C A 4.12E-04 Insulin resistance / / 21901158 rs6875712 chr5 57064861 G T 6.75E-04 Multiple complex diseases / / 17554300 rs2539732 chr5 57081450 G T 9.88E-05 Serum metabolites / / 19043545 rs854041 chr5 57094700 G T 2.33E-05 Schizophrenia / / 19571811 rs10940579 chr5 57130818 T A,C 4.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs4460105 chr5 57167434 T C 7.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4432842 chr5 57172078 T C 5.00E-08 Birth weight / / 23202124 rs2898074 chr5 57189995 T C 7.03E-04 Insulin resistance / / 21901158 rs1844438 chr5 57214179 A G 3.71E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs10041935 chr5 57214817 A C 3.00E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1454909 chr5 57252398 C T 4.31E-05 Neuroblastoma / / pha002895 rs4256311 chr5 57299194 A C 5.50E-05 Insulin resistance / / 21901158 rs10472030 chr5 57311558 C T 6.24E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1844437 chr5 57320954 C G 2.00E-06 Hoarding / / 21302353 rs1826106 chr5 57337744 A G 7.20E-04 Cognition,early reading ability / / 17684495 rs1352615 chr5 57343578 A G 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs10461641 chr5 57351813 G C 8.70E-06 Urinary metabolites / / 21572414 rs6859725 chr5 57355531 C T 1.33E-06 Bipolar disorder / / 21771265 rs1387638 chr5 57360670 C T 2.50E-05 Response to statin therapy / / 20339536 rs1472034 chr5 57378468 C T 3.55E-05 Bipolar disorder / / 21771265 rs4543222 chr5 57383115 G A 4.31E-05 Orofacial clefts / / 22419666 rs6894496 chr5 57391846 C T 2.50E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs11958003 chr5 57393130 A G 3.46E-04 Type 2 diabetes / / 17463246 rs11958003 chr5 57393130 A G 8.19E-04 Response to TNF antagonist treatment / / 21061259 rs11958003 chr5 57393130 A G 1.59E-05 Bipolar disorder / / 21771265 rs7701601 chr5 57393238 C T 2.72E-04 Type 2 diabetes / / 17463246 rs7701601 chr5 57393238 C T 8.71E-04 Response to TNF antagonist treatment / / 21061259 rs7729088 chr5 57393417 T C 3.46E-04 Type 2 diabetes / / 17463246 rs7729088 chr5 57393417 T C 7.11E-04 Response to TNF antagonist treatment / / 21061259 rs7725226 chr5 57393463 A G 3.46E-04 Type 2 diabetes / / 17463246 rs7725226 chr5 57393463 A G 8.71E-04 Response to TNF antagonist treatment / / 21061259 rs7729416 chr5 57393650 T G 2.59E-04 Type 2 diabetes / / 17463246 rs7729416 chr5 57393650 T G 8.71E-04 Response to TNF antagonist treatment / / 21061259 rs13159266 chr5 57402038 T C 6.86E-04 Response to TNF antagonist treatment / / 21061259 rs1971058 chr5 57421606 G T 9.86E-08 Bipolar disorder / / 21771265 rs733250 chr5 57431053 T C 1.61E-05 Bipolar disorder / / 21771265 rs17436453 chr5 57438758 C A 9.10E-06 Urinary metabolites / / 21572414 rs6880607 chr5 57460246 C T 1.42E-04 Multiple complex diseases / / 17554300 rs56160829 chr5 57460834 G T 1.29E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs2962010 chr5 57473703 G C 2.12E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs1981838 chr5 57474848 T C 1.42E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2964182 chr5 57476508 G T 2.27E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs2964183 chr5 57477809 G C 1.43E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs2964186 chr5 57480693 C T 8.00E-07 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs2964187 chr5 57481184 C T 8.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs2964189 chr5 57482938 T C 9.56E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs2910597 chr5 57487610 A C 8.62E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs73757719 chr5 57487665 T C 3.07E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs2910596 chr5 57491176 C A 4.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs2910596 chr5 57491176 C A 3.06E-04 Schizophrenia / / 21747397 rs2409014 chr5 57494453 T A 3.29E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs7713811 chr5 57496382 T A,C,G 1.03E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs9292156 chr5 57537229 A G 9.60E-04 Type 2 diabetes / / 17463246 rs9292156 chr5 57537229 A G 1.28E-04 Alzheimer's disease / / 17998437 rs9292156 chr5 57537229 A G 3.50E-04 Response to TNF antagonist treatment / / 21061259 rs2112901 chr5 57553153 T C 1.05E-05 Cognitive test performance / / 20125193 rs245288 chr5 57595644 G A 3.70E-04 Alzheimer's disease / / 17998437 rs245285 chr5 57633367 C T 8.50E-06 Urinary metabolites / / 21572414 rs181745 chr5 57636031 C A 9.40E-06 Urinary metabolites / / 21572414 rs26977 chr5 57658416 T G 8.68E-04 Multiple complex diseases / / 17554300 rs26977 chr5 57658416 T G 2.58E-04 Cognitive decline / / 23732972 rs375523 chr5 57686575 A G 2.58E-04 Cognitive decline / / 23732972 rs17709103 chr5 57691003 C T 3.40E-06 Urinary metabolites / / 21572414 rs11745076 chr5 57694684 G A 3.40E-06 Urinary metabolites / / 21572414 rs11742895 chr5 57697579 G A 3.40E-06 Urinary metabolites / / 21572414 rs905199 chr5 57698294 C T 4.50E-06 Urinary metabolites / / 21572414 rs10513146 chr5 57715512 A G 2.10E-06 Urinary metabolites / / 21572414 rs154475 chr5 57718996 A G 6.43E-04 Multiple complex diseases / / 17554300 rs17241103 chr5 57726979 G A 2.20E-05 Urinary metabolites / / 21572414 rs42739 chr5 57747180 T G 8.09E-04 Type 2 diabetes / / 17463246 rs42739 chr5 57747180 T G 5.34E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs702720 chr5 57757383 T A,C,G 6.21E-04 Smoking initiation / / 24665060 rs6450476 chr5 57771087 A G 1.08E-04 Cognitive decline / / 23732972 rs16888206 chr5 57774538 G A 5.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16888206 chr5 57774538 G A 8.48E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6895889 chr5 57786543 G T 5.97E-04 Alcohol dependence / / 20201924 rs2307117 chr5 57787376 A G 1.33E-04 Smoking quantity GAPT intron 24665060 rs10057028 chr5 57795822 G A 5.21E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs11948189 chr5 57799581 C T 6.82E-04 Smoking quantity / / 24665060 rs4700297 chr5 57822482 A T 5.04E-04 Substance dependence / / 21818250 rs167132 chr5 57905474 G T 8.97E-05 Hypertension (essential hypertension) RAB3C intron 22184326 rs167132 chr5 57905474 G T 9.72E-04 Response to taxane treatment (placlitaxel) RAB3C intron 23006423 rs292969 chr5 57911704 T C 6.92E-04 Aortic root size RAB3C intron 21223598 rs2279980 chr5 57913379 A G 5.97E-05 Multiple complex diseases RAB3C intron 17554300 rs2279980 chr5 57913379 A G 1.12E-04 Amyotrophic lateral sclerosis RAB3C intron 23624525 rs425203 chr5 57917792 G A 7.64E-05 Myopia (pathological) RAB3C intron 21095009 rs425203 chr5 57917792 G A 3.05E-05 Prostate cancer RAB3C intron 22923026 rs17344335 chr5 57917862 G A 4.35E-04 Suicide attempts in bipolar disorder RAB3C intron 21423239 rs292988 chr5 57933998 G A 7.49E-05 Suicide attempts in bipolar disorder RAB3C intron 21423239 rs1022055 chr5 57937240 G C 5.96E-05 Aortic root size RAB3C intron 21223598 rs1022055 chr5 57937240 G C 1.50E-05 Urinary metabolites RAB3C intron 21572414 rs12054892 chr5 57945250 C T 7.32E-04 Multiple complex diseases RAB3C intron 17554300 rs17280356 chr5 57950993 A C 5.23E-05 Aortic root size RAB3C intron 21223598 rs17280356 chr5 57950993 A C 1.20E-05 Urinary metabolites RAB3C intron 21572414 rs17280874 chr5 57962746 A G 1.90E-05 Urinary metabolites RAB3C intron 21572414 rs293031 chr5 57964175 A G 4.63E-05 Myopia (pathological) RAB3C intron 21095009 rs159009 chr5 57967142 A G 3.99E-05 Myopia (pathological) RAB3C intron 21095009 rs158990 chr5 57972853 A G 5.51E-04 Schizophrenia RAB3C intron 19197363 rs158990 chr5 57972853 A G 5.04E-05 Chronic obstructive pulmonary disease RAB3C intron 19300482 rs158990 chr5 57972853 A G 5.04E-05 Response to statin treatment (atorvastatin),change in cholesterol levels RAB3C intron 20031582 rs158986 chr5 57998935 C T 4.28E-04 Multiple complex diseases RAB3C intron 17554300 rs293018 chr5 58005683 T G 6.52E-04 Multiple complex diseases RAB3C intron 17554300 rs293007 chr5 58024896 A G 4.36E-04 Multiple complex diseases RAB3C intron 17554300 rs2545789 chr5 58031619 T C 4.65E-04 Multiple complex diseases RAB3C intron 17554300 rs293002 chr5 58034966 G A 3.77E-04 Multiple complex diseases RAB3C intron 17554300 rs720084 chr5 58039641 A G 5.69E-05 HDL cholesterol RAB3C intron pha003074 rs963443 chr5 58071799 A G 3.30E-04 Dental caries RAB3C intron 21940522 rs10065350 chr5 58082723 C T 9.00E-06 IgG glycosylation RAB3C intron 23382691 rs10461442 chr5 58104566 G A 2.30E-06 Urinary metabolites RAB3C intron 21572414 rs10461652 chr5 58104701 C G 1.30E-06 Urinary metabolites RAB3C intron 21572414 rs7728528 chr5 58106295 T G 1.29E-04 Parkinson's disease RAB3C intron 17052657 rs10472074 chr5 58107093 T C 1.29E-04 Parkinson's disease RAB3C intron 17052657 rs10060763 chr5 58110324 C T 9.67E-04 Alzheimer's disease RAB3C intron 17998437 rs299915 chr5 58123362 T C 2.11E-04 Multiple complex diseases RAB3C intron 17554300 rs2112978 chr5 58125594 T C 8.27E-04 Tourette syndrome RAB3C intron 22889924 rs16888672 chr5 58126581 C A 2.00E-05 Urinary metabolites RAB3C intron 21572414 rs16888700 chr5 58143627 T C 1.10E-05 Urinary metabolites RAB3C intron 21572414 rs295677 chr5 58150803 C T 7.09E-04 Type 2 diabetes / / 17463246 rs159381 chr5 58171932 A G 2.12E-04 Lung function (forced vital capacity) / / 24023788 rs17367618 chr5 58177715 T C 7.70E-06 Urinary metabolites / / 21572414 rs538776 chr5 58183187 T C 7.87E-04 Stroke / / pha002887 rs538776 chr5 58183187 T C 1.20E-05 Cholesterol / / pha003073 rs538776 chr5 58183187 T C 2.76E-05 Cholesterol / / pha003078 rs10472076 chr5 58184061 T C 3.00E-08 Breast cancer / / 23535729 rs299907 chr5 58193121 C A 5.56E-05 Cardiovascular disease / / pha003065 rs17774945 chr5 58202930 C T 5.98E-05 Triglycerides / / pha003080 rs13354132 chr5 58214089 G A 3.49E-04 Multiple complex diseases / / 17554300 rs299900 chr5 58230707 G T 7.94E-04 Multiple complex diseases / / 17554300 rs12657171 chr5 58291208 C T 9.02E-04 Type 2 diabetes PDE4D intron 17463246 rs12657171 chr5 58291208 C T 3.26E-06 Glaucoma (primary open-angle) PDE4D intron 22605921 rs13355401 chr5 58294359 A G 2.46E-04 Hemoglobin concentration PDE4D intron 20534544 rs7714708 chr5 58295014 A G 1.25E-04 Smoking initiation PDE4D intron 24665060 rs1546221 chr5 58302980 G A 3.06E-04 Hemoglobin concentration PDE4D intron 20534544 rs4479801 chr5 58304499 C T 2.75E-04 Hemoglobin concentration PDE4D intron 20534544 rs7735570 chr5 58330269 C T 8.94E-04 Multiple complex diseases PDE4D intron 17554300 rs2279737 chr5 58334645 A G 4.50E-04 Coronary heart disease PDE4D intron 21966275 rs1353747 chr5 58337481 T G 4.50E-04 Myasthenia gravis PDE4D intron 23055271 rs1353747 chr5 58337481 T G 3.00E-08 Breast cancer PDE4D intron 23535729 rs1498608 chr5 58343067 T A 4.00E-04 Bone mineral density PDE4D intron 15752431 rs10043404 chr5 58355458 G A 8.81E-04 Multiple complex diseases PDE4D intron 17554300 rs10066573 chr5 58356126 A T 3.95E-04 Type 2 diabetes PDE4D intron 17463246 rs6450502 chr5 58360478 A T 7.32E-04 Type 2 diabetes PDE4D intron 17463246 rs2910642 chr5 58396111 A G 5.86E-04 Response to taxane treatment (placlitaxel) PDE4D intron 23006423 rs11957770 chr5 58398243 C T 8.24E-04 Multiple complex diseases PDE4D intron 17554300 rs6865647 chr5 58399201 A G 1.49E-07 Chronic kidney disease PDE4D intron 21931561 rs12654485 chr5 58407448 A G 4.66E-04 Sleep duration PDE4D intron 23728906 rs10052657 chr5 58407771 C A 2.00E-19 Esophageal cancer PDE4D intron 21642993 rs33927508 chr5 58423113 A G 2.20E-05 Urinary metabolites PDE4D intron 21572414 rs3901540 chr5 58429733 C T 0.000056 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 PDE4D intron 21873659 rs1961 chr5 58445393 A G 2.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE4D intron 20877124 rs6877743 chr5 58454191 A C 7.46E-04 Type 2 diabetes PDE4D intron 17463246 rs2081106 chr5 58478599 C A 4.91E-06 Femoral neck bone geometry PDE4D intron 22087292 rs9292198 chr5 58503271 G A 9.85E-04 Tourette syndrome PDE4D intron 22889924 rs6450512 chr5 58511501 G A 2.07E-05 Alzheimer's disease PDE4D intron 17998437 rs10064893 chr5 58531754 C A 6.19E-04 Multiple complex diseases PDE4D intron 17554300 rs1838733 chr5 58533392 C T 1.01E-04 Multiple complex diseases PDE4D intron 17554300 rs26704 chr5 58533653 A G 9.38E-07 Esophageal cancer (squamous cell) PDE4D intron 22960999 rs17528285 chr5 58540847 A G 6.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE4D intron 20877124 rs10036406 chr5 58552313 A C 0.000091 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 PDE4D intron 21873659 rs17444059 chr5 58560717 T C 5.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE4D intron 20877124 rs17444059 chr5 58560717 T C 2.00E-08 Immune response to smallpox vaccine (IL-6) PDE4D intron 22610502 rs2112959 chr5 58569284 T C 6.02E-04 Prostate cancer mortality PDE4D intron 20978177 rs10491353 chr5 58575133 G A 4.87E-04 Bipolar disorder PDE4D intron 19259986 rs1374028 chr5 58575831 A G 3.89E-05 Bilirubin levels,in serum PDE4D intron 19389676 rs28044 chr5 58588269 T C 5.18E-04 Response to cytidine analogues (gemcitabine) PDE4D intron 24483146 rs17780175 chr5 58589786 G A 2.65E-04 Nicotine smoking PDE4D intron 19268276 rs27168 chr5 58613132 C T 0.0000813 Paraoxonase activity PDE4D intron 23160181 rs1824159 chr5 58618644 C T 0.00003 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 PDE4D intron 21873659 rs27171 chr5 58618889 A G 3.84E-04 Bipolar disorder PDE4D intron 19259986 rs27171 chr5 58618889 A G 9.43E-05 Non-alcoholic fatty liver disease histology (other) PDE4D intron 20708005 rs35260 chr5 58632547 A G 0.000002 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 PDE4D intron 21873659 rs35259 chr5 58633591 T C 0.0000086 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 PDE4D intron 21873659 rs17782374 chr5 58663831 T C 4.56E-05 Bipolar disorder PDE4D intron 22925353 rs17782374 chr5 58663831 T C 8.60E-04 Sleep latency PDE4D intron 23728906 rs1823068 chr5 58676049 A G 3.00E-08 Sleepiness PDE4D intron 17903308 rs181736 chr5 58677233 G A 1 Drug response to Etoposide PDE4D intron 17537913 rs244593 chr5 58679020 T C 9.59E-05 Body Composition PDE4D intron pha003012 rs2702363 chr5 58679668 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes PDE4D intron 22628534 rs1445918 chr5 58681857 C T 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes PDE4D intron 22628534 rs525099 chr5 58690251 C T 4.22E-04 Multiple complex diseases PDE4D intron 17554300 rs258106 chr5 58697340 T A 8.80E-05 Femoral neck bone geometry PDE4D intron 22087292 rs258110 chr5 58698145 T C 7.10E-05 Femoral neck bone geometry PDE4D intron 22087292 rs2547917 chr5 58713680 G A 3.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) PDE4D intron 23648065 rs2607347 chr5 58721609 T C 1 Drug response to Etoposide PDE4D intron 17537913 rs2607347 chr5 58721609 T C 9.97E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) PDE4D intron 23648065 rs702543 chr5 58842774 C T 2.00E-06 Neuroticism PDE4D intron 17667963 rs295936 chr5 58865857 C T 4.63E-04 Alzheimer's disease PDE4D intron 22005930 rs893190 chr5 58905050 G A 9.69E-04 Alzheimer's disease PDE4D intron 22005930 rs12520633 chr5 58907592 A G 9.79E-04 Alzheimer's disease PDE4D intron 22005930 rs295973 chr5 58910109 T C 5.30E-04 Volumetric brain MRI PDE4D intron 17903297 rs298024 chr5 58941676 C A 8.02E-05 Neuroticism PDE4D intron 23229837 rs298061 chr5 58968501 C T 3.45E-04 Multiple complex diseases PDE4D intron 17554300 rs17382202 chr5 58979946 C T 4.00E-08 Response to antipsychotic treatment PDE4D intron 23241943 rs7701573 chr5 59017895 A G 7.06E-04 Multiple complex diseases PDE4D intron 17554300 rs7701748 chr5 59018033 A G 6.88E-04 Multiple complex diseases PDE4D intron 17554300 rs7701748 chr5 59018033 A G 1.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE4D intron 20877124 rs1992112 chr5 59020054 G A 1.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE4D intron 20877124 rs6897073 chr5 59039723 A C 9.80E-04 Type 2 diabetes PDE4D intron 17846125 rs981230 chr5 59039858 C T 6.41E-04 Response to taxane treatment (placlitaxel) PDE4D intron 23006423 rs4235477 chr5 59061282 A G 3.03E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE4D intron 20877124 rs2963826 chr5 59096923 C T 2.00E-06 Obesity-related traits PDE4D intron 23251661 rs2938784 chr5 59111349 T C 4.05E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE4D intron 20877124 rs905834 chr5 59113301 A G 4.05E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE4D intron 20877124 rs6869459 chr5 59119583 A C 4.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE4D intron 20877124 rs6869459 chr5 59119583 A C 8.33E-04 Alzheimer's disease PDE4D intron 24755620 rs6868846 chr5 59128754 G A 2.10E-04 Suicidal ideation PDE4D intron 22030708 rs10514882 chr5 59134525 A C 6.40E-05 Volumetric brain MRI PDE4D intron 17903297 rs17371592 chr5 59139938 T C 9.74E-04 Depression (quantitative trait) PDE4D intron 20800221 rs9292216 chr5 59152129 A G 2.40E-04 Volumetric brain MRI PDE4D intron 17903297 rs13175506 chr5 59154182 G A 9.72E-04 Depression (quantitative trait) PDE4D intron 20800221 rs16890369 chr5 59230156 T G 1.80E-04 Cholesterol PDE4D intron 17255346 rs10069878 chr5 59232230 T C 0.0000634 Major depressive disorder PDE4D intron 23149448 rs1545070 chr5 59304437 G A 8.66E-04 Suicide attempts in bipolar disorder PDE4D intron 21423239 rs10068304 chr5 59306723 T A 3.10E-06 Urinary metabolites PDE4D intron 21572414 rs2409682 chr5 59309441 T A 5.80E-07 Urinary metabolites PDE4D intron 21572414 rs7732249 chr5 59366269 C T 1.23E-07 Schizophrenia PDE4D intron 21926974 rs1588265 chr5 59369794 A G 3.00E-08 Asthma PDE4D intron 19426955 rs1588265 chr5 59369794 A G 5.11E-07 Asthma PDE4D intron 20698975 rs1588265 chr5 59369794 A G 2.50E-08 Asthma PDE4D intron 21907864 rs2548659 chr5 59383886 A G 1.50E-07 Asthma PDE4D intron 19426955 rs2548659 chr5 59383886 A G 2.07E-07 Asthma PDE4D intron 20698975 rs13354486 chr5 59414136 T A 1.50E-05 Urinary metabolites PDE4D intron 21572414 rs1544791 chr5 59439082 T C 9.70E-07 Asthma PDE4D intron 19426955 rs1544791 chr5 59439082 T C 1.16E-06 Asthma PDE4D intron 20698975 rs983280 chr5 59445137 C T 4.80E-07 Asthma PDE4D intron 19426955 rs983280 chr5 59445137 C T 5.71E-07 Asthma PDE4D intron 20698975 rs2910830 chr5 59467203 G A 7.79E-06 Asthma PDE4D intron 20698975 rs7710822 chr5 59528197 A T 2.76E-04 Type 2 diabetes PDE4D intron 17463246 rs4235479 chr5 59544653 T C 1.15E-04 Type 2 diabetes PDE4D intron 17463246 rs16877816 chr5 59568716 G A 9.57E-05 Insulin resistance PDE4D intron 21901158 rs7714765 chr5 59569008 G A 9.74E-04 Multiple complex diseases PDE4D intron 17554300 rs12515974 chr5 59569523 C T 9.59E-08 Metabolite levels PDE4D intron 23281178 rs12521358 chr5 59578444 T C 1.16E-04 IgE levels PDE4D intron 17255346 rs12521358 chr5 59578444 T C 6.95E-04 Type 2 diabetes PDE4D intron 17463246 rs4700371 chr5 59587720 C T 7.54E-04 Type 2 diabetes PDE4D intron 17463246 rs16877898 chr5 59606247 T C 4.75E-04 Multiple complex diseases PDE4D intron 17554300 rs6897671 chr5 59620281 C T 0.00071 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines PDE4D intron 23204130 rs6862735 chr5 59634176 G A 2.47E-04 Multiple complex diseases PDE4D intron 17554300 rs12522161 chr5 59644785 T C 5.66E-04 Type 2 diabetes PDE4D intron 17463246 rs7737905 chr5 59648716 G T 9.41E-04 Response to taxane treatment (placlitaxel) PDE4D intron 23006423 rs9291689 chr5 59705316 A C 9.77E-04 Response to cytadine analogues (cytosine arabinoside) PDE4D intron 24483146 rs26956 chr5 59790985 C A 9.63E-04 Type 2 diabetes PART1 intron 17463246 rs35387 chr5 59802669 C G 4.26E-04 Type 2 diabetes PART1 intron 17463246 rs35386 chr5 59802783 T C 4.95E-04 Type 2 diabetes PART1 intron 17463246 rs7737629 chr5 59803807 G T 1.12E-04 Multiple complex diseases PART1 intron 17554300 rs613373 chr5 59811432 T C 8.90E-04 Alzheimer's disease PART1 intron 22005930 rs26954 chr5 59814843 A G 1.24E-04 Alzheimer's disease PART1 intron 22005930 rs35384 chr5 59820870 A G 1.51E-04 Alzheimer's disease PART1 intron 22005930 rs35383 chr5 59821233 T C 1.55E-04 Alzheimer's disease PART1 intron 22005930 rs35382 chr5 59821543 A G 1.83E-04 Alzheimer's disease PART1 intron 22005930 rs10065640 chr5 59821598 A G 5.54E-04 Response to taxane treatment (placlitaxel) PART1 intron 23006423 rs26950 chr5 59823118 C T 5.03E-04 Alzheimer's disease PART1 intron 22005930 rs10056275 chr5 59829465 C T 5.59E-04 Response to taxane treatment (placlitaxel) PART1 intron 23006423 rs10939851 chr5 59841361 A G 5.80E-06 Urinary metabolites PART1 intron 21572414 rs10939851 chr5 59841361 A G 3.43E-05 Sudden cardiac arrest PART1 intron 21658281 rs2409791 chr5 59884317 C T 3.83E-04 Type 2 diabetes / / 17463246 rs206789 chr5 59903971 C T 4.91E-04 Type 2 diabetes DEPDC1B intron 17463246 rs7719726 chr5 59949537 T C 2.61E-04 Hemoglobin concentration DEPDC1B intron 20534544 rs7704338 chr5 59986155 C T 4.17E-04 Alzheimer's disease DEPDC1B intron 22005930 rs7719611 chr5 59988547 G A 4.21E-04 Alzheimer's disease DEPDC1B intron 22005930 rs4298206 chr5 60012235 T C 3.45E-04 Hemoglobin concentration / / 20534544 rs4273559 chr5 60066069 C T 9.49E-04 Alzheimer's disease ELOVL7 intron 22005930 rs3857238 chr5 60066325 C G 9.16E-04 Alzheimer's disease ELOVL7 intron 22005930 rs16878412 chr5 60066844 A G 8.02E-04 Alzheimer's disease ELOVL7 intron 22005930 rs2305680 chr5 60067550 C T 4.19E-04 Type 2 diabetes ELOVL7 intron 17463246 rs7726875 chr5 60072779 A G 5.47E-04 Alzheimer's disease ELOVL7 intron 22005930 rs13159372 chr5 60116533 C T 0.000125 Salmonella-induced pyroptosis ELOVL7 intron 22837397 rs6869332 chr5 60129361 A G 5.56E-04 Stroke ELOVL7 intron pha002887 rs6449508 chr5 60167020 A C 0.000101 Salmonella-induced pyroptosis / / 22837397 rs2306350 chr5 60186618 C T 0.0000735 Salmonella-induced pyroptosis ERCC8 intron 22837397 rs2306351 chr5 60186975 C A 0.0000778 Salmonella-induced pyroptosis ERCC8 intron 22837397 rs4647108 chr5 60197715 C T 0.0000909 Salmonella-induced pyroptosis ERCC8 intron 22837397 rs4647078 chr5 60217038 G A 0.0000447 Salmonella-induced pyroptosis ERCC8 intron 22837397 rs158928 chr5 60227923 A G 0.0000671 Salmonella-induced pyroptosis ERCC8 intron 22837397 rs158916 chr5 60245145 A G 0.0000716 Salmonella-induced pyroptosis NDUFAF2 intron 22837397 rs158926 chr5 60251207 G T 0.00007 Salmonella-induced pyroptosis NDUFAF2 intron 22837397 rs1609041 chr5 60261889 C T 0.0000786 Salmonella-induced pyroptosis NDUFAF2 intron 22837397 rs167912 chr5 60284996 G A 0.0000679 Salmonella-induced pyroptosis NDUFAF2 intron 22837397 rs10044183 chr5 60286962 T G 7.00E-07 Parkinson's disease (interaction with coffee consumption) NDUFAF2 intron 21876681 rs290505 chr5 60296556 C T 0.0000843 Salmonella-induced pyroptosis NDUFAF2 intron 22837397 rs290506 chr5 60298360 A G 3.39E-08 Lymphocyte counts NDUFAF2 intron 22286170 rs329614 chr5 60304171 A G 0.0000862 Salmonella-induced pyroptosis NDUFAF2 intron 22837397 rs13179721 chr5 60308836 A G 0.000129 Salmonella-induced pyroptosis NDUFAF2 intron 22837397 rs162235 chr5 60313015 T C 0.0000833 Salmonella-induced pyroptosis NDUFAF2 intron 22837397 rs295557 chr5 60401606 A G 0.0000726 Salmonella-induced pyroptosis NDUFAF2 intron 22837397 rs295573 chr5 60426260 T C 5.76E-04 Multiple complex diseases NDUFAF2 intron 17554300 rs2270822 chr5 60459040 C T 6.98E-05 Parkinson's disease / / 21738487 rs34624 chr5 60459716 G A 8.44E-04 Multiple complex diseases / / 17554300 rs159358 chr5 60469912 T C 8.17E-04 Multiple complex diseases / / 17554300 rs171748 chr5 60499131 A G 4.00E-08 Schizophrenia / / 23974872 rs581318 chr5 60515794 A T 6.88E-04 Type 2 diabetes / / 17463246 rs2055375 chr5 60531220 T G 8.63E-04 Type 2 diabetes / / 17463246 rs4379148 chr5 60555388 C A 3.64E-05 Aortic root size / / 21223598 rs13355792 chr5 60556317 T C 6.51E-05 Aortic root size / / 21223598 rs10939892 chr5 60564322 T C 4.56E-06 Triglycerides / / pha003080 rs13175564 chr5 60564993 T C 4.56E-06 Triglycerides / / pha003080 rs7709645 chr5 60731458 G C 4.00E-08 Schizophrenia ZSWIM6 intron 22688191 rs10514908 chr5 60759524 T C 5.92E-04 Coronary Artery Disease ZSWIM6 intron 17634449 rs10514909 chr5 60759598 C A 6.77E-04 Coronary Artery Disease ZSWIM6 intron 17634449 rs1374043 chr5 60774227 G A 3.71E-04 Multiple complex diseases ZSWIM6 intron 17554300 rs16891983 chr5 60806765 A G 9.90E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) ZSWIM6 intron 24192120 rs13162534 chr5 60819833 A G 1.18E-04 Smoking initiation ZSWIM6 intron 24665060 rs6898746 chr5 60843706 T A 4.88E-04 Multiple complex diseases / / 17554300 rs1550816 chr5 60847019 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs13164150 chr5 60848204 G T 1.72E-05 Tunica Media / / pha003038 rs7714276 chr5 60851776 T C 1.55E-04 Multiple complex diseases / / 17554300 rs17340123 chr5 60854916 C T 8.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17340123 chr5 60854916 C T 1.41E-05 Tunica Media / / pha003038 rs16892457 chr5 60858446 C G 9.35E-04 Alzheimer's disease / / 22005930 rs10053423 chr5 60859416 C T 4.87E-05 Diabetes Mellitus / / pha003060 rs1971513 chr5 60863461 A G 8.64E-05 Cognitive impairment induced by topiramate / / 22091778 rs420518 chr5 60886299 A C 4.05E-04 Alzheimer's disease / / 24755620 rs1472615 chr5 60887302 A G 3.03E-04 Multiple complex diseases / / 17554300 rs26914 chr5 60928771 T C 5.52E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs26914 chr5 60928771 T C 5.63E-04 Acute lung injury / / 22295056 rs26913 chr5 60929982 C T 4.99E-04 Alcohol dependence / / 21314694 rs26913 chr5 60929982 C T 1.17E-04 Acute lung injury / / 22295056 rs36088 chr5 60930305 A G 7.73E-04 Multiple complex diseases / / 17554300 rs36088 chr5 60930305 A G 7.06E-04 Acute lung injury / / 22295056 rs1867732 chr5 60936935 T G 1.60E-05 Urinary metabolites C5orf64 intron 21572414 rs13174785 chr5 60938249 C A 1.31E-04 Taste perception C5orf64 intron 22132133 rs13174785 chr5 60938249 C A 6.34E-05 Alzheimer's disease C5orf64 intron 22832961 rs6880041 chr5 60940776 T A 1.27E-05 Alzheimer's disease C5orf64 intron 22832961 rs7728181 chr5 60947302 T C 1.29E-05 Alzheimer's disease C5orf64 intron 22832961 rs36049054 chr5 60949237 A AT 7.29E-06 Alzheimer's disease C5orf64 intron 22832961 rs7714841 chr5 60949237 A G 7.29E-06 Alzheimer's disease C5orf64 intron 22832961 rs11738335 chr5 60950211 T G 7.12E-04 Taste perception C5orf64 intron 22132133 rs11738335 chr5 60950211 T G 5.00E-06 Alzheimer's disease C5orf64 intron 22832961 rs11750531 chr5 60952547 G C 7.53E-06 Alzheimer's disease C5orf64 intron 22832961 rs16893320 chr5 60953099 G T 1.26E-05 Alzheimer's disease C5orf64 intron 22832961 rs16893322 chr5 60953327 G C 1.12E-05 Alzheimer's disease C5orf64 intron 22832961 rs36033 chr5 60960727 T C 5.07E-05 Cholesterol C5orf64 intron pha003078 rs6883938 chr5 60962986 G T 2.78E-05 Alzheimer's disease C5orf64 intron 22832961 rs414976 chr5 60965517 C A 4.91E-05 Cholesterol C5orf64 intron pha003078 rs7704929 chr5 60971822 A G 8.25E-08 Facial morphology C5orf64 intron 22341974 rs11746049 chr5 60972283 C T 8.43E-08 Facial morphology C5orf64 intron 22341974 rs11747208 chr5 60973577 G C 8.50E-08 Facial morphology C5orf64 intron 22341974 rs11750644 chr5 60974063 T C 8.50E-08 Facial morphology C5orf64 intron 22341974 rs1501845 chr5 60976610 A G 8.51E-08 Facial morphology C5orf64 intron 22341974 rs13175459 chr5 60985699 A G 8.46E-08 Facial morphology C5orf64 intron 22341974 rs11740126 chr5 60990953 G A 9.45E-08 Facial morphology C5orf64 intron 22341974 rs2030888 chr5 60993594 T C 9.12E-05 Blood Pressure C5orf64 intron pha003043 rs11743702 chr5 60994828 G A 1.20E-07 Facial morphology C5orf64 intron 22341974 rs11747263 chr5 60994867 T C 1.19E-07 Facial morphology C5orf64 intron 22341974 rs13186555 chr5 60995037 C T 1.18E-07 Facial morphology C5orf64 intron 22341974 rs6870236 chr5 60995876 C T 1.15E-07 Facial morphology C5orf64 intron 22341974 rs13163936 chr5 60996142 G A 1.14E-07 Facial morphology C5orf64 intron 22341974 rs4700430 chr5 60997309 G A 1.12E-07 Facial morphology C5orf64 intron 22341974 rs11748959 chr5 60998679 A G 1.10E-07 Facial morphology C5orf64 intron 22341974 rs12520360 chr5 60999360 T C 1.08E-07 Facial morphology C5orf64 intron 22341974 rs13156637 chr5 61001389 A G 1.08E-07 Facial morphology C5orf64 UTR-3 22341974 rs13160822 chr5 61007446 G T 4.55E-08 Facial morphology / / 22341974 rs12521924 chr5 61010938 G A 1.77E-08 Facial morphology / / 22341974 rs13159935 chr5 61011112 T C 1.79E-08 Facial morphology / / 22341974 rs12514378 chr5 61011200 T C 1.80E-08 Facial morphology / / 22341974 rs13154578 chr5 61013268 A T 1.77E-08 Facial morphology / / 22341974 rs11738462 chr5 61013776 G A 1.77E-08 Facial morphology / / 22341974 rs4699982 chr5 61025082 A T 9.00E-06 IgG glycosylation / / 23382691 rs6873285 chr5 61029525 T C 9.89E-04 Multiple complex diseases / / 17554300 rs9291736 chr5 61029567 G C 4.47E-04 Multiple complex diseases / / 17554300 rs921038 chr5 61035590 T C 7.52E-04 White matter integrity / / 22425255 rs2030889 chr5 61049167 G A 1.96E-04 Parkinson's disease / / 17052657 rs2077786 chr5 61053123 T C 1.60E-04 Parkinson's disease / / 17052657 rs1374065 chr5 61063602 G C 9.61E-05 Parkinson's disease / / 17052657 rs4133155 chr5 61075772 C T 2.54E-04 Parkinson's disease / / 17052657 rs367717880 chr5 61085552 CAT C 4.38E-05 Parkinson's disease / / 17052657 rs376748198 chr5 61085552 CAT C 4.38E-05 Parkinson's disease / / 17052657 rs6449558 chr5 61085552 C T 4.38E-05 Parkinson's disease / / 17052657 rs6449559 chr5 61107460 G T 6.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2197509 chr5 61140085 T A 2.98E-04 Alzheimer's disease / / 17998437 rs10062532 chr5 61164989 G A 6.20E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs10062532 chr5 61164989 G A 6.20E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs1995274 chr5 61165960 G A 9.81E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1445875 chr5 61172249 G A 3.97E-04 Stroke / / pha002886 rs4461596 chr5 61174237 G A 2.40E-05 Urinary metabolites / / 21572414 rs16897690 chr5 61280740 T C 7.26E-05 Height / / pha003010 rs10514931 chr5 61285098 A T 4.46E-05 Schizophrenia / / 21674006 rs4699997 chr5 61297283 T A 6.73E-04 Multiple complex diseases / / 17554300 rs16898046 chr5 61314761 G C 1.86E-111 Multiple complex diseases / / 17554300 rs4388169 chr5 61359597 A C 4.01E-04 Multiple complex diseases / / 17554300 rs2343697 chr5 61371306 T A 4.89E-04 Multiple complex diseases / / 17554300 rs6859556 chr5 61390145 G T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10939931 chr5 61476901 A G 1.63E-04 Taste perception / / 22132133 rs17366217 chr5 61495113 C T 2.00E-06 Stroke (ischemic) / / 22384361 rs7709787 chr5 61530911 T C 1.62E-04 Multiple complex diseases / / 17554300 rs1995782 chr5 61563586 G A 1.38E-05 Creatinine levels / / pha003069 rs12659814 chr5 61569169 T C 1.02E-05 Creatinine levels / / pha003069 rs4441833 chr5 61604456 T C 7.02E-04 Multiple complex diseases KIF2A intron 17554300 rs7711530 chr5 61606610 T C 3.91E-04 Multiple complex diseases KIF2A intron 17554300 rs7718580 chr5 61611989 A G 0.000561 Salmonella-induced pyroptosis KIF2A intron 22837397 rs3213940 chr5 61642937 T C 0.000191 Salmonella-induced pyroptosis KIF2A intron 22837397 rs784901 chr5 61672733 A G 8.12E-04 Schizophrenia KIF2A intron 21674006 rs152189 chr5 61680448 T C 5.85E-04 Multiple complex diseases KIF2A intron 17554300 rs15807 chr5 61683125 G C 5.90E-04 Multiple complex diseases / / 17554300 rs152186 chr5 61719506 A G 8.93E-05 Creatinine levels IPO11 intron pha003069 rs26642 chr5 61784389 G A 2.43E-04 Type 2 diabetes IPO11 intron 23300278 rs10058598 chr5 61871009 A G 9.49E-05 Creatinine levels IPO11 intron pha003069 rs16890857 chr5 61895124 A G 7.72E-04 Multiple complex diseases IPO11 intron 17554300 rs4700505 chr5 61978989 C T 7.00E-04 Parkinson's disease / / 17052657 rs1423386 chr5 61984853 A G 2.00E-09 Venous thromboembolism (gene x gene interaction) / / 23509962 rs977877 chr5 62004183 A G 7.06E-04 Bipolar disorder,schizoaffective / / 19567891 rs6871803 chr5 62011983 G T 8.00E-06 Uric acid levels / / 21294900 rs6896436 chr5 62026621 G C 1.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs251170 chr5 62027073 C T 1.08E-05 Suicide attempts in bipolar disorder / / 21423239 rs251172 chr5 62029339 G A 8.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs16890992 chr5 62029827 A G 2.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs11745652 chr5 62038924 C T 2.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs16891019 chr5 62039960 A G 3.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs1540533 chr5 62064092 G A 5.26E-04 Type 2 diabetes / / 17463246 rs16891063 chr5 62069757 T C 8.04E-04 Multiple complex diseases / / 17554300 rs16891077 chr5 62074718 G A 1.00E-09 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs16891077 chr5 62074718 G A 9.00E-10 Fasting insulin (interaction) / / 24204828 rs4700512 chr5 62076745 T A 1.61E-09 Fasting insulin (interaction) / / 24204828 rs4700512 chr5 62076745 T A 2.36E-09 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs4700021 chr5 62078302 C T 1.52E-08 Fasting insulin (interaction) / / 24204828 rs4700021 chr5 62078302 C T 2.60E-08 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs10058718 chr5 62084114 C G 1.70E-07 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs10058718 chr5 62084114 C G 9.97E-08 Fasting insulin (interaction) / / 24204828 rs4700517 chr5 62085481 C T 3.49E-07 Fasting insulin (interaction) / / 24204828 rs4700517 chr5 62085481 C T 6.28E-07 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs4700518 chr5 62085508 A C 5.01E-07 Fasting insulin (interaction) / / 24204828 rs4700518 chr5 62085508 A C 8.87E-07 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs16891097 chr5 62091796 G A 0.000017 Mean arterial pressure / / 22510845 rs7708428 chr5 62094034 A G 4.54E-05 Systemic sclerosis / / 21750679 rs7708428 chr5 62094034 A G 5.21E-07 Fasting insulin (interaction) / / 24204828 rs7708428 chr5 62094034 A G 9.17E-07 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs10055171 chr5 62094344 A C 1.01E-07 Fasting insulin (interaction) / / 24204828 rs10055171 chr5 62094344 A C 1.66E-07 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs10078232 chr5 62094462 T C 1.33E-07 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs10078232 chr5 62094462 T C 8.10E-08 Fasting insulin (interaction) / / 24204828 rs7709357 chr5 62108178 T C 1.18E-07 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs7709357 chr5 62108178 T C 7.25E-08 Fasting insulin (interaction) / / 24204828 rs10059856 chr5 62119505 G T 1.43E-07 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs10059856 chr5 62119505 G T 8.15E-08 Fasting insulin (interaction) / / 24204828 rs6869062 chr5 62125289 T G 1.95E-06 Fasting insulin (interaction) / / 24204828 rs6869062 chr5 62125289 T G 3.14E-06 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs4700530 chr5 62127288 C T 2.19E-06 Fasting insulin (interaction) / / 24204828 rs4700530 chr5 62127288 C T 3.55E-06 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs10059071 chr5 62131733 A G 1.95E-06 Fasting insulin (interaction) / / 24204828 rs10059071 chr5 62131733 A G 3.14E-06 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs10058229 chr5 62171303 A C 7.02E-06 Fasting insulin (interaction) / / 24204828 rs3107559 chr5 62173122 A G 4.84E-04 Alzheimer's disease (late onset) / / 21379329 rs1402912 chr5 62175815 A G 1.27E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1402912 chr5 62175815 A G 7.33E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13359556 chr5 62194602 C T 2.59E-04 Multiple complex diseases / / 17554300 rs13359556 chr5 62194602 C T 6.21E-04 HIV-1 viral setpoint / / 17641165 rs112730887 chr5 62240926 T C 5.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs1915847 chr5 62254668 G A 3.52E-04 Alzheimer's disease / / 17998437 rs883031 chr5 62263797 G A 4.03E-04 Type 2 diabetes / / 17463246 rs2049198 chr5 62278020 T G 1.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs11953497 chr5 62313080 T G 7.51E-04 Multiple complex diseases / / 17554300 rs71627250 chr5 62384699 C T 6.00E-06 Bronchopulmonary dysplasia / / 23897914 rs10066628 chr5 62416834 A G 2.00E-04 Smoking cessation / / 24665060 rs1110380 chr5 62419235 C T 8.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs181156 chr5 62473343 G A 5.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs346405 chr5 62513738 A C 6.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs347670 chr5 62526755 T C 6.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs164105 chr5 62528445 G A 6.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs346420 chr5 62529212 T G 6.82E-04 Suicide attempts in bipolar disorder / / 21041247 rs346421 chr5 62529983 G T 6.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs346423 chr5 62532892 A G 7.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs17481124 chr5 62538957 C G 5.44E-04 Depression (quantitative trait) / / 20800221 rs346416 chr5 62541894 C A 5.78E-05 Bipolar disorder / / 17486107 rs346416 chr5 62541894 C A 7.30E-05 Asthma (aspirin-intolerant) / / 21072201 rs10939962 chr5 62549356 T C 8.26E-04 Depression (quantitative trait) / / 20800221 rs349497 chr5 62554047 A C 3.50E-04 Alcohol dependence / / 20201924 rs349493 chr5 62556494 G C 0.0000138 Antisocial behavior / / 23077488 rs349487 chr5 62557765 G T 5.92E-05 Weight loss (gastric bypass surgery) / / 23633212 rs401859 chr5 62558371 A G 0.0000113 Antisocial behavior / / 23077488 rs373666 chr5 62558482 G C 0.0000112 Antisocial behavior / / 23077488 rs462861 chr5 62559094 G T 0.0000101 Antisocial behavior / / 23077488 rs460325 chr5 62559408 A G 0.0000101 Antisocial behavior / / 23077488 rs460949 chr5 62559466 T C 0.00001 Antisocial behavior / / 23077488 rs455575 chr5 62559827 G T 0.0000154 Antisocial behavior / / 23077488 rs458362 chr5 62560532 A G 0.0000097 Antisocial behavior / / 23077488 rs1676146 chr5 62560987 C T 0.00000968 Antisocial behavior / / 23077488 rs434640 chr5 62561826 T A 0.000015 Antisocial behavior / / 23077488 rs443543 chr5 62564660 A T 0.00000961 Antisocial behavior / / 23077488 rs418226 chr5 62566536 T G 0.0000149 Antisocial behavior / / 23077488 rs392246 chr5 62566742 G A 0.0000149 Antisocial behavior / / 23077488 rs387996 chr5 62566931 G A 0.0000149 Antisocial behavior / / 23077488 rs427421 chr5 62567045 C A 0.0000148 Antisocial behavior / / 23077488 rs448936 chr5 62567554 T C 2.04E-05 Weight loss (gastric bypass surgery) / / 23633212 rs444037 chr5 62570415 C A 0.0000123 Antisocial behavior / / 23077488 rs369747 chr5 62570637 G A 0.0000147 Antisocial behavior / / 23077488 rs369747 chr5 62570637 G A 1.59E-05 Weight loss (gastric bypass surgery) / / 23633212 rs424672 chr5 62576964 G A 0.0000144 Antisocial behavior / / 23077488 rs424672 chr5 62576964 G A 2.14E-05 Weight loss (gastric bypass surgery) / / 23633212 rs409363 chr5 62577126 G C 0.0000143 Antisocial behavior / / 23077488 rs386661 chr5 62582833 G C 0.0000169 Antisocial behavior / / 23077488 rs1494579 chr5 62583232 C T 1.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs346431 chr5 62584515 T A 0.0000169 Antisocial behavior / / 23077488 rs7445832 chr5 62586301 T A 2.26E-06 Alcohol dependence / / 20202923 rs7445832 chr5 62586301 T A 3.04E-05 Alcohol dependence / / 21703634 rs7445832 chr5 62586301 T A 4.20E-04 Alcohol dependence / / 21956439 rs7445832 chr5 62586301 T A 7.00E-09 Alcohol and nictotine co-dependence / / 22488850 rs7445832 chr5 62586301 T A 1.00E-09 Alcohol and nictotine co-dependence / / 23216389 rs1494578 chr5 62586429 A G 4.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs9291778 chr5 62586957 C A 9.38E-05 Suicide attempts in bipolar disorder / / 21423239 rs7702856 chr5 62594366 A G 3.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs4700575 chr5 62595976 T G 3.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs4700575 chr5 62595976 T G 2.80E-07 Alcohol and nictotine co-dependence / / 22488850 rs346425 chr5 62596244 T C 2.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs346425 chr5 62596244 T C 0.000000251 Antisocial behavior / / 23077488 rs2169520 chr5 62598453 T C 6.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs2169520 chr5 62598453 T C 3.00E-07 Alcohol and nictotine co-dependence / / 22488850 rs1017776 chr5 62599460 C G 2.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs11950497 chr5 62614342 A G 1.64E-05 Depression (quantitative trait) / / 20800221 rs7714594 chr5 62654682 C A 6.10E-07 Alcohol and nictotine co-dependence / / 22488850 rs4326098 chr5 62658697 T A 5.26E-04 Type 2 diabetes / / 17463246 rs4326098 chr5 62658697 T A 3.68E-04 Multiple complex diseases / / 17554300 rs4455508 chr5 62658782 G A 8.22E-04 Type 2 diabetes / / 17463246 rs4470713 chr5 62658859 A C 3.05E-04 Multiple complex diseases / / 17554300 rs4700577 chr5 62690724 A T 3.42E-04 Type 2 diabetes / / 17463246 rs2886223 chr5 62732342 G A 4.10E-07 Rheumatoid arthritis / / 19503088 rs10053427 chr5 62746638 G C 0.000774 Salmonella-induced pyroptosis / / 22837397 rs4426873 chr5 62747021 G A 0.00077 Salmonella-induced pyroptosis / / 22837397 rs624941 chr5 62752724 G A 0.000774 Salmonella-induced pyroptosis / / 22837397 rs663217 chr5 62760970 C T 0.000689 Salmonella-induced pyroptosis / / 22837397 rs2112508 chr5 62761734 C A 4.14E-06 Rheumatoid arthritis / / 19503088 rs1862276 chr5 62764129 A G 9.58E-04 Type 2 diabetes / / 17463246 rs255414 chr5 62817900 G A 1.00E-06 Body mass index / / 20935630 rs40647 chr5 62825112 C A 1.40E-05 Rheumatoid arthritis / / 19503088 rs10939975 chr5 62839693 A G 5.85E-06 Rheumatoid arthritis / / 19503088 rs11950223 chr5 62903235 C A 6.61E-05 Body Mass Index / / pha003007 rs1566780 chr5 62946149 C A 3.86E-05 Body Mass Index / / pha003006 rs1566780 chr5 62946149 C A 7.07E-05 Body Mass Index / / pha003007 rs4700055 chr5 62954884 G A 3.19E-05 Fibrinogen / / 17255346 rs10044158 chr5 62962713 G A 1.20E-04 Fibrinogen / / 17255346 rs1910421 chr5 62971192 C T 7.77E-05 Blood Pressure / / pha003046 rs1503511 chr5 62990697 C T 6.32E-05 Information processing speed / / 21130836 rs10038179 chr5 63004339 G A 2.39E-04 Heart Failure / / pha002885 rs12515008 chr5 63026219 A G 8.30E-05 Alcohol dependence / / 21703634 rs7721046 chr5 63031191 T C 7.70E-07 Rheumatoid arthritis / / 19503088 rs10042968 chr5 63033718 A G 8.00E-07 Alcohol and nictotine co-dependence / / 23216389 rs4551015 chr5 63036898 G A 1.46E-05 Fibrinogen / / 17255346 rs13173277 chr5 63037537 G A 3.37E-05 Fibrinogen / / 17255346 rs13173277 chr5 63037537 G A 6.26E-04 Tourette syndrome / / 22889924 rs426101 chr5 63069308 G A 1.00E-05 Urinary metabolites / / 21572414 rs7706163 chr5 63080654 T G 2.30E-05 Urinary metabolites / / 21572414 rs10939982 chr5 63093004 G A 5.59E-04 Type 2 diabetes / / 17463246 rs724418 chr5 63113976 C G 6.22E-04 Type 2 diabetes / / 17463246 rs16892342 chr5 63154824 A G 6.44E-05 Multiple complex diseases / / 17554300 rs358528 chr5 63226159 T C 5.53E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17484837 chr5 63226451 G C 9.55E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1364043 chr5 63250851 T G 1 Drug response to Fluvoxamine / / 18484082 rs1364043 chr5 63250851 T G 1 Drug response to Paroxetine / / 18484082 rs6295 chr5 63258565 C G 1 Drug response to Fluvoxamine / / 18484082 rs6295 chr5 63258565 C G 1 Drug response to Paroxetine / / 18484082 rs10042486 chr5 63261329 C T 1 Drug response to Fluvoxamine / / 18484082 rs10042486 chr5 63261329 C T 1 Drug response to Paroxetine / / 18484082 rs1364041 chr5 63288619 T G 1.40E-04 Premature ovarian failure / / 19508998 rs10036420 chr5 63452939 T C 2.99E-04 Hearing function / / 17255346 rs17798594 chr5 63793107 C T 6.03E-05 HIV-1 control / / 20041166 rs7730085 chr5 63877325 A G 9.04E-05 Intelligence RGS7BP intron 21826061 rs10044070 chr5 63888627 G A 4.94E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RGS7BP intron 20877124 rs10044070 chr5 63888627 G A 5.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RGS7BP intron 20877124 rs10044070 chr5 63888627 G A 7.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RGS7BP intron 20877124 rs993706 chr5 63891146 T C 8.30E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RGS7BP intron 20877124 rs993706 chr5 63891146 T C 8.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RGS7BP intron 20877124 rs889248 chr5 63905068 A G 7.64E-05 Schizophrenia RGS7BP missense 20185149 rs918604 chr5 63913687 T C 5.38E-05 Schizophrenia / / 20185149 rs113730713 chr5 63936736 A AG 8.55E-05 Hearing function / / 17255346 rs4700064 chr5 63936736 A G 8.55E-05 Hearing function / / 17255346 rs275829 chr5 63981474 T A 1.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs275829 chr5 63981474 T A 3.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs275828 chr5 63982806 G A 3.20E-04 Suicide attempts in bipolar disorder / / 21041247 rs275828 chr5 63982806 G A 8.40E-05 Suicide attempts in bipolar disorder / / 21041247 rs182149 chr5 63993189 C T 1.23E-04 Suicide attempts in bipolar disorder FAM159B intron 21041247 rs182149 chr5 63993189 C T 3.34E-04 Suicide attempts in bipolar disorder FAM159B intron 21041247 rs275832 chr5 63994186 A G 1.07E-04 Suicide attempts in bipolar disorder FAM159B intron 21041247 rs275832 chr5 63994186 A G 3.43E-04 Suicide attempts in bipolar disorder FAM159B intron 21041247 rs183917 chr5 64012080 T C 1.14E-04 Suicide attempts in bipolar disorder FAM159B intron 21041247 rs183917 chr5 64012080 T C 3.78E-04 Suicide attempts in bipolar disorder FAM159B intron 21041247 rs10075967 chr5 64019841 C T 1.19E-04 Suicide attempts in bipolar disorder SREK1IP1 UTR-3 21041247 rs10075967 chr5 64019841 C T 4.22E-04 Suicide attempts in bipolar disorder SREK1IP1 UTR-3 21041247 rs4700651 chr5 64027592 T A 1.96E-04 Suicide attempts in bipolar disorder SREK1IP1 intron 21041247 rs4700651 chr5 64027592 T A 5.24E-04 Suicide attempts in bipolar disorder SREK1IP1 intron 21041247 rs2610243 chr5 64030352 T G 1.92E-04 Suicide attempts in bipolar disorder SREK1IP1 intron 21041247 rs2610243 chr5 64030352 T G 7.68E-04 Suicide attempts in bipolar disorder SREK1IP1 intron 21041247 rs6449751 chr5 64036541 C G 2.95E-04 Suicide attempts in bipolar disorder SREK1IP1 intron 21041247 rs6449751 chr5 64036541 C G 5.75E-04 Suicide attempts in bipolar disorder SREK1IP1 intron 21041247 rs275820 chr5 64040823 T G 2.06E-04 Suicide attempts in bipolar disorder SREK1IP1 intron 21041247 rs275820 chr5 64040823 T G 6.07E-04 Suicide attempts in bipolar disorder SREK1IP1 intron 21041247 rs188027 chr5 64041741 C T 1.94E-04 Suicide attempts in bipolar disorder SREK1IP1 intron 21041247 rs188027 chr5 64041741 C T 6.27E-04 Suicide attempts in bipolar disorder SREK1IP1 intron 21041247 rs7715910 chr5 64049168 T C 2.93E-04 Suicide attempts in bipolar disorder SREK1IP1 intron 21041247 rs7715910 chr5 64049168 T C 6.13E-04 Suicide attempts in bipolar disorder SREK1IP1 intron 21041247 rs275823 chr5 64052362 C T 1.95E-04 Suicide attempts in bipolar disorder SREK1IP1 intron 21041247 rs275823 chr5 64052362 C T 6.13E-04 Suicide attempts in bipolar disorder SREK1IP1 intron 21041247 rs6868521 chr5 64093781 A G 1.40E-05 Urinary metabolites CWC27 intron 21572414 rs6449760 chr5 64096170 G T 1.40E-05 Urinary metabolites CWC27 intron 21572414 rs10059206 chr5 64106918 G A 3.87E-07 Waist Circumference CWC27 intron pha003023 rs1433612 chr5 64109114 T C 1.20E-05 Urinary metabolites CWC27 intron 21572414 rs1368704 chr5 64115004 T G 1.10E-05 Urinary metabolites CWC27 intron 21572414 rs16893172 chr5 64125381 T C 1.20E-05 Urinary metabolites CWC27 intron 21572414 rs6872595 chr5 64157581 A G 8.40E-06 Urinary metabolites CWC27 intron 21572414 rs7733752 chr5 64166882 G T 3.10E-06 Urinary metabolites CWC27 intron 21572414 rs10050395 chr5 64167550 C T 1.62E-05 Waist Circumference CWC27 intron pha003023 rs10461382 chr5 64182980 C T 2.50E-05 Urinary metabolites CWC27 intron 21572414 rs975081 chr5 64196669 A G 1.50E-05 Urinary metabolites CWC27 intron 21572414 rs975081 chr5 64196669 A G 1.04E-04 Smoking initiation CWC27 intron 24665060 rs2117122 chr5 64198564 C A 1.70E-06 Urinary metabolites CWC27 intron 21572414 rs10059139 chr5 64222962 T C 4.50E-05 Waist Circumference CWC27 intron pha003023 rs1347246 chr5 64239523 C T 8.38E-05 Waist Circumference CWC27 intron pha003023 rs10056155 chr5 64240458 G A 0.0000545 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs6896392 chr5 64240738 T C 0.0000214 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs2196078 chr5 64241800 T G 0.0000483 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs2163955 chr5 64241943 G A 0.0000297 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs13355440 chr5 64246017 C G 0.0000418 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs1433619 chr5 64247280 C A 0.0000427 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs1433618 chr5 64248900 A G 0.0000588 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs16893264 chr5 64249786 T C 0.0000457 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs12656191 chr5 64250923 C T 0.0000829 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs13166212 chr5 64252840 G A 0.0000865 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs28492766 chr5 64253063 G T 0.0000478 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs10050854 chr5 64254232 T C 0.0000394 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs1433607 chr5 64257700 A G 0.0000517 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs6449767 chr5 64258862 G A 0.0000216 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs10073992 chr5 64259577 C T 0.000095 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs1433608 chr5 64259995 T G 4.74E-04 Type 2 diabetes CWC27 intron 17463246 rs1433609 chr5 64260198 A G 0.0000531 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs1433611 chr5 64260661 A G 0.0000955 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs1433611 chr5 64260661 A G 9.88E-05 Coronary heart disease CWC27 intron pha003056 rs1431507 chr5 64262064 C G 0.0000641 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs1431506 chr5 64262740 T A 0.0000595 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs13178969 chr5 64263967 T C 2.31E-04 Suicide attempts in bipolar disorder CWC27 intron 21041247 rs2278353 chr5 64267234 G A 0.0000525 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs2968198 chr5 64268260 T C 0.000051 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs2968200 chr5 64270320 G A 0.0000491 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs2968201 chr5 64270797 C T 0.000049 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs2968202 chr5 64270823 G T 0.0000494 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs1311245 chr5 64272107 G A 0.0000501 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs1309579 chr5 64274571 G A 0.0000509 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs1309578 chr5 64274587 G A 0.0000478 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs1309577 chr5 64275537 T G 0.0000492 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs1309576 chr5 64275893 C T 0.0000983 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs1309575 chr5 64276536 G A 0.0000532 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs1309574 chr5 64276648 C G 0.0000509 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs1309570 chr5 64279481 C T 0.0000603 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs4632749 chr5 64280127 C T 2.07E-05 Waist Circumference CWC27 intron pha003023 rs1309569 chr5 64280231 C T 0.0000612 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs266556 chr5 64280981 T A 0.0000628 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs266558 chr5 64282379 C T 0.0000643 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs266559 chr5 64282492 A G 0.0000663 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs266560 chr5 64283761 G T 0.0000827 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs266561 chr5 64284524 G A 0.0000828 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs266562 chr5 64284810 A G 0.0000861 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs266563 chr5 64285227 C A 0.0000742 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs1309556 chr5 64287460 G A 0.000091 Nonsyndromic striae distensae (stretch marks) CWC27 intron 23633020 rs1309540 chr5 64293570 G A 2.00E-04 Suicide attempts in bipolar disorder CWC27 intron 21041247 rs1309534 chr5 64302584 G A 1.64E-04 Suicide attempts in bipolar disorder CWC27 intron 21041247 rs3797046 chr5 64306538 T G 3.20E-10 Corneal structure CWC27 intron 23291589 rs266581 chr5 64310839 A T 9.14E-05 Suicide attempts in bipolar disorder CWC27 intron 21041247 rs266580 chr5 64311542 A G 5.84E-04 Type 2 diabetes CWC27 intron 17463246 rs2915438 chr5 64312057 T A 1.21E-04 Smoking cessation CWC27 intron 18519826 rs2915441 chr5 64315793 C T 3.82E-06 Smoking cessation / / 18519826 rs1363952 chr5 64317066 C A 8.79E-06 Waist Circumference / / pha003023 rs266590 chr5 64347621 A G 9.00E-06 Obesity-related traits / / 23251661 rs1159105 chr5 64357890 T G 4.24E-10 Corneal structure / / 23291589 rs264737 chr5 64363583 T A 5.90E-05 Intelligence (childhood) / / 23358156 rs264747 chr5 64370818 C G 3.34E-04 Multiple complex diseases / / 17554300 rs16893364 chr5 64372897 A G 7.74E-05 Cognitive test performance / / 20125193 rs10434530 chr5 64376348 T C 8.50E-10 Corneal structure / / 23291589 rs1117707 chr5 64389665 A G 8.40E-11 Corneal structure / / 23291589 rs264776 chr5 64395452 G A 9.01E-04 Insulin resistance / / 21901158 rs10073124 chr5 64410258 T G 1.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs7729539 chr5 64417678 T C 1.00E-06 QT interval / / 23166209 rs17205854 chr5 64422902 C T 0.00000374 Aging / / 22445811 rs17811551 chr5 64427237 A G 0.00000374 Aging / / 22445811 rs17206232 chr5 64433400 C A 1.00E-06 Schizophrenia / / 23212062 rs17206779 chr5 64447777 C T 5.00E-07 Osteosarcoma ADAMTS6 intron 23727862 rs1549249 chr5 64455558 T C 4.23E-05 Psoriasis ADAMTS6 intron 20953190 rs16893468 chr5 64467770 G A 2.98E-05 Brain structure ADAMTS6 intron 22504417 rs1862571 chr5 64484802 A G 6.76E-05 Psoriasis ADAMTS6 intron 20953190 rs10805395 chr5 64485573 G A 1.84E-04 Insulin resistance ADAMTS6 intron 21901158 rs13183791 chr5 64534641 C A 6.00E-06 Bipolar disorder and schizophrenia ADAMTS6 intron 20889312 rs3776042 chr5 64558111 T C 9.34E-04 Myocardial Infarction ADAMTS6 intron pha002883 rs2307121 chr5 64625512 C T 5.48E-05 Parkinson's disease ADAMTS6 intron 21738487 rs2307121 chr5 64625512 C T 6.00E-11 Corneal structure ADAMTS6 intron 23291589 rs1389319 chr5 64626453 T C 5.48E-04 Myocardial Infarction ADAMTS6 intron pha002883 rs7713110 chr5 64631395 C T 2.92E-05 Cardiovascular disease ADAMTS6 intron pha003065 rs6878202 chr5 64643101 A C 3.54E-05 Cardiovascular disease ADAMTS6 intron pha003065 rs10038927 chr5 64649516 A G 4.80E-05 Parkinson's disease ADAMTS6 intron 21738487 rs9291836 chr5 64680267 T C 0.000002 Change in depression severity with Serotonin reuptake inhibitors (SRI) ADAMTS6 intron 23091423 rs7708972 chr5 64688741 G A 0.0000019 Change in depression severity with Serotonin reuptake inhibitors (SRI) ADAMTS6 intron 23091423 rs7708972 chr5 64688741 G A 0.00000249 Change in depression severity with antidepressants (NRI or SRI) ADAMTS6 intron 23091423 rs10042191 chr5 64697866 T C 0.00000103 Change in depression severity with Serotonin reuptake inhibitors (SRI) ADAMTS6 intron 23091423 rs10069691 chr5 64707040 C A 0.00000143 Change in depression severity with Serotonin reuptake inhibitors (SRI) ADAMTS6 intron 23091423 rs9291837 chr5 64708119 G C 0.00000212 Change in depression severity with Serotonin reuptake inhibitors (SRI) ADAMTS6 intron 23091423 rs6886919 chr5 64709775 A C 6.87E-04 Intracranial aneurysm ADAMTS6 intron 20613766 rs10072030 chr5 64725524 A G 0.00000233 Change in depression severity with Serotonin reuptake inhibitors (SRI) ADAMTS6 intron 23091423 rs1493451 chr5 64726440 C T 0.00000235 Change in depression severity with Serotonin reuptake inhibitors (SRI) ADAMTS6 intron 23091423 rs6449784 chr5 64730851 T C 0.00000205 Change in depression severity with Serotonin reuptake inhibitors (SRI) ADAMTS6 intron 23091423 rs2047064 chr5 64733927 A G 0.00000204 Change in depression severity with Serotonin reuptake inhibitors (SRI) ADAMTS6 intron 23091423 rs7728131 chr5 64734702 G A 0.00000216 Change in depression severity with Serotonin reuptake inhibitors (SRI) ADAMTS6 intron 23091423 rs6876189 chr5 64735540 G A 0.0000018 Change in depression severity with Serotonin reuptake inhibitors (SRI) ADAMTS6 intron 23091423 rs7705423 chr5 64740765 C A 0.00000174 Change in depression severity with Serotonin reuptake inhibitors (SRI) ADAMTS6 intron 23091423 rs2131587 chr5 64745925 C T 0.00000153 Change in depression severity with Serotonin reuptake inhibitors (SRI) ADAMTS6 intron 23091423 rs11960235 chr5 64747513 T C 3.06E-08 HDL cholesterol ADAMTS6 intron 23063622 rs7725105 chr5 64749723 C A 0.00000171 Change in depression severity with Serotonin reuptake inhibitors (SRI) ADAMTS6 intron 23091423 rs386188 chr5 64759675 T C 1.20E-10 Corneal structure ADAMTS6 intron 23291589 rs7704471 chr5 64770346 C T 7.83E-04 Multiple complex diseases ADAMTS6 intron 17554300 rs10514987 chr5 64778931 G A 9.85E-04 HIV-1 viral setpoint / / 17641165 rs402552 chr5 64795196 G A 7.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12517057 chr5 64805104 A G 3.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6897886 chr5 64829258 C A 4.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CENPK intron 20877124 rs16894005 chr5 64870687 A C 2.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PPWD1 intron 20877124 rs17829698 chr5 64888529 C A 3.53E-05 Cognitive test performance TRIM23 intron 20125193 rs12517858 chr5 64894150 G A 2.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRIM23 intron 20877124 rs16894099 chr5 64909487 A G 4.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRIM23 intron 20877124 rs16894099 chr5 64909487 A G 4.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRIM23 intron 20877124 rs2161279 chr5 64916006 G A 2.15E-04 Hearing function TRIM23 intron 17255346 rs10074627 chr5 64934262 C A 3.53E-04 Obesity (extreme) C5orf44 intron 21935397 rs17241135 chr5 64949594 G A 9.63E-04 Alcohol dependence C5orf44 intron 21314694 rs2441130 chr5 65087420 T C 1.04E-05 HIV-1 viral setpoint NLN intron 17641165 rs6896574 chr5 65088175 G A 5.95E-04 HIV-1 viral setpoint NLN intron 17641165 rs2591933 chr5 65090545 G A 7.78E-04 HIV-1 viral setpoint NLN intron 17641165 rs16875218 chr5 65092147 T G 7.35E-04 Type 2 diabetes NLN intron 17463246 rs2561193 chr5 65112729 T G 8.61E-04 HIV-1 viral setpoint NLN intron 17641165 rs16894422 chr5 65129485 T C 1.76E-06 Age-related macular degeneration / / 22125219 rs16894435 chr5 65132930 G A 9.53E-05 Age-related macular degeneration / / 22125219 rs6449794 chr5 65139475 T C 8.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6449794 chr5 65139475 T C 9.36E-05 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs10057505 chr5 65149815 A G 2.79E-04 Osteoarthritis / / 19508968 rs10057505 chr5 65149815 A G 2.90E-05 Urinary metabolites / / 21572414 rs12109329 chr5 65157265 A G 5.04E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11948927 chr5 65160065 C A 3.56E-04 Osteoarthritis / / 19508968 rs16894473 chr5 65162023 C T 2.30E-05 Urinary metabolites / / 21572414 rs10071239 chr5 65164991 T A 4.33E-04 Multiple complex diseases / / 17554300 rs173193 chr5 65180258 G A 1.66E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2113030 chr5 65185421 A G 5.75E-04 Type 2 diabetes / / 17463246 rs2561242 chr5 65203041 A C 4.63E-04 Type 2 diabetes / / 17463246 rs2432133 chr5 65203299 C T 9.49E-04 Type 2 diabetes / / 17463246 rs9291849 chr5 65203673 G A 8.46E-04 Type 2 diabetes / / 17463246 rs2561241 chr5 65206565 C T 7.05E-05 Bone mineral density / / 19181680 rs42321 chr5 65220342 G A 1.28E-05 Bone mineral density / / 19181680 rs251614 chr5 65228251 G C 2.86E-04 Schizophrenia ERBB2IP intron 20832056 rs251614 chr5 65228251 G C 5.70E-05 Eating disorders ERBB2IP intron 23568457 rs4019045 chr5 65278508 A AGACTG 2.78E-34 Metabolite levels ERBB2IP intron 22286219 rs78260048 chr5 65278508 A G 2.78E-34 Metabolite levels ERBB2IP intron 22286219 rs417152 chr5 65316205 G A 1.73E-04 Multiple complex diseases ERBB2IP intron 17554300 rs10059665 chr5 65328948 C T 5.29E-05 Multiple complex diseases ERBB2IP intron 17554300 rs201995478 chr5 65350441 A G 0.00017 Breast cancer (ER positive) ERBB2IP missense 23555315 rs201995478 chr5 65350441 A G 0.00058 Breast cancer ERBB2IP missense 23555315 rs3805466 chr5 65350481 C T 1.27E-04 Schizophrenia(treatment response to risperidone) ERBB2IP missense 19850283 rs148508319 chr5 65390287 A G 7.38E-05 Acne (severe) / / 24927181 rs153374 chr5 65424875 G A 7.20E-04 Multiple complex diseases / / 17554300 rs16894942 chr5 65435228 T C 7.45E-04 Multiple complex diseases / / 17554300 rs153396 chr5 65498546 T C 4.21E-05 Bone mineral density FLJ46010 intron 19181680 rs13185121 chr5 65506262 A G 1.50E-05 Urinary metabolites FLJ46010 intron 21572414 rs39565 chr5 65529512 C T 7.98E-05 Smoking cessation FLJ46010 intron 18519826 rs10940057 chr5 65532167 A G 1.78E-04 Alcohol dependence FLJ46010 intron 21314694 rs29456 chr5 65539847 T C 1.23E-07 Autism FLJ46010 intron 22843504 rs12522102 chr5 65583098 A G 8.53E-04 Alcohol dependence FLJ46010 intron 20201924 rs2997131 chr5 65619374 G A 1.54E-05 Smoking cessation FLJ46010 intron 18519826 rs7708487 chr5 65649824 A T 1.69E-04 Smoking cessation FLJ46010 intron 18519826 rs1469419 chr5 65659121 A G 5.47E-06 Triglycerides FLJ46010 intron pha003081 rs1469419 chr5 65659121 A G 1.44E-05 Lipid levels FLJ46010 intron pha003082 rs3121685 chr5 65662133 C T 2.00E-05 Systolic blood pressure FLJ46010 intron 19430483 rs2968194 chr5 65673986 G A 2.30E-05 Urinary metabolites FLJ46010 intron 21572414 rs10053460 chr5 65730663 T G 5.67E-04 Multiple complex diseases FLJ46010 intron 17554300 rs10514995 chr5 65739439 T C 1.00E-06 RR interval (heart rate) FLJ46010 intron 20031603 rs1962397 chr5 65768007 T C 9.46E-04 Type 2 diabetes FLJ46010 intron 22158537 rs4392584 chr5 65826548 C A 1.25E-04 Multiple complex diseases FLJ46010 intron 17554300 rs4583845 chr5 65830624 C T 8.87E-06 Multiple complex diseases FLJ46010 intron 17554300 rs7733618 chr5 65865292 G A 1.87E-04 Multiple complex diseases FLJ46010 intron 17554300 rs12514219 chr5 65874665 C G 6.47E-04 Multiple complex diseases / / 17554300 rs11749989 chr5 65877962 C T 5.19E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4699882 chr5 65908576 C T 7.41E-04 Body mass index MAST4 intron 21701565 rs4613646 chr5 65913392 C T 7.43E-04 Coronary heart disease MAST4 intron 21606135 rs10063997 chr5 65917185 T C 4.50E-05 Orofacial clefts MAST4 intron 19270707 rs10063997 chr5 65917185 T C 6.72E-06 Orofacial clefts MAST4 intron 20023658 rs4256308 chr5 65920308 A T 3.55E-04 Multiple complex diseases MAST4 intron 17554300 rs17210621 chr5 65952489 C T 1.64E-04 Multiple complex diseases MAST4 intron 17554300 rs7706654 chr5 65955258 G A 1.99E-04 Multiple complex diseases MAST4 intron 17554300 rs4499783 chr5 65967123 T C 2.60E-06 Ovarian response to FSH stimulation in IVF MAST4 intron 21316307 rs4374700 chr5 65968868 T C 7.54E-05 Multiple complex diseases MAST4 intron 17554300 rs4700148 chr5 65978497 G A 4.34E-05 Information processing speed MAST4 intron 21130836 rs10057708 chr5 65982329 G A 2.14E-04 Amyotrophic lateral sclerosis (sporadic) MAST4 intron 24529757 rs16895466 chr5 65985859 G C 4.01E-04 Multiple complex diseases MAST4 intron 17554300 rs10940079 chr5 65998262 C T 7.26E-05 Information processing speed MAST4 intron 21130836 rs6892312 chr5 66002616 A G 7.00E-04 Acute lymphoblastic leukemia (childhood) MAST4 intron 20189245 rs4700159 chr5 66002754 G A 7.08E-05 Prostate cancer MAST4 intron 22923026 rs4700160 chr5 66002788 G A 6.00E-04 Acute lymphoblastic leukemia (childhood) MAST4 intron 20189245 rs17278159 chr5 66012846 C T 3.73E-04 Taste perception MAST4 intron 22132133 rs26382 chr5 66124226 G A 7.02E-05 Serum metabolites MAST4 intron 19043545 rs258082 chr5 66130596 A G 1.92E-05 Serum metabolites MAST4 intron 19043545 rs28636 chr5 66149113 C T 1.58E-06 Obesity MAST4 intron 22484627 rs39861 chr5 66152258 A G 3.00E-07 Epilepsy (generalized) MAST4 intron 22949513 rs26923 chr5 66170504 G T 9.74E-04 Type 2 diabetes MAST4 intron 17463246 rs192295 chr5 66178233 G A 9.48E-04 Multiple complex diseases MAST4 intron 17554300 rs10056426 chr5 66203615 T C 4.96E-04 Type 2 diabetes MAST4 intron 17463246 rs16896057 chr5 66251173 T C 4.34E-04 Multiple complex diseases MAST4 intron 17554300 rs1423463 chr5 66256426 G A 4.76E-05 Cognitive impairment induced by topiramate MAST4 intron 22091778 rs16896062 chr5 66260128 A G 8.82E-04 Amyotrophic Lateral Sclerosis MAST4 intron 17362836 rs16896069 chr5 66265041 A G 8.37E-04 Response to taxane treatment (placlitaxel) MAST4 intron 23006423 rs1946260 chr5 66275052 T C 4.76E-05 Cognitive impairment induced by topiramate MAST4 intron 22091778 rs1946260 chr5 66275052 T C 7.80E-04 Response to taxane treatment (placlitaxel) MAST4 intron 23006423 rs16896085 chr5 66275284 T C 1.55E-04 Multiple complex diseases MAST4 intron 17554300 rs2048213 chr5 66276904 G A 0.0000212 Amyotrophic lateral sclerosis MAST4 intron 23587638 rs2048213 chr5 66276904 G A 0.0000443 Amyotrophic lateral sclerosis MAST4 intron 23587638 rs2888109 chr5 66277028 T G 0.00000467 Change in depression severity with Norepinephrine reuptake inhibitors (NRI) MAST4 intron 23091423 rs1083523 chr5 66278913 C T 2.75E-06 Osteoarthritis MAST4 intron 22763110 rs34691 chr5 66287883 A G 5.43E-06 Schizophrenia MAST4 intron 19571811 rs1030231 chr5 66317265 A G 9.30E-05 Type 2 diabetes MAST4 intron 17463248 rs6866391 chr5 66324075 A G 3.79E-04 Alcohol dependence MAST4 intron 20201924 rs40602 chr5 66327007 A G 0.0000126 Menopause (age at onset) MAST4 intron 23424626 rs1697137 chr5 66452175 G A 2.00E-06 Carotid atherosclerosis in HIV infection MAST4 intron 20009918 rs7708143 chr5 66457907 A G 5.54E-04 Tourette syndrome MAST4 intron 22889924 rs10223101 chr5 66501820 C T 1.70E-05 Urinary metabolites / / 21572414 rs13157304 chr5 66512152 G C 1.80E-05 Urinary metabolites / / 21572414 rs16896427 chr5 66520183 A G 1.63E-04 Type 2 diabetes / / 17463246 rs9291879 chr5 66526209 C T 1.07E-05 Blood pressure / / 17255346 rs9291879 chr5 66526209 C T 5.05E-04 Type 2 diabetes / / 17463246 rs16896548 chr5 66579508 C T 1.94E-04 Multiple complex diseases / / 17554300 rs11950678 chr5 66654519 A G 3.20E-05 Lung cancer / / 18385738 rs7725744 chr5 66661694 A G 6.90E-23 Narcolepsy / / 19629137 rs1428608 chr5 66691614 T C 8.23E-04 Type 2 diabetes / / 17463246 rs1428608 chr5 66691614 T C 6.58E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs407455 chr5 66692401 C T 5.74E-04 Type 2 diabetes / / 17463246 rs32035 chr5 66735551 T G 6.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs32035 chr5 66735551 T G 5.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs160845 chr5 66737591 C T 5.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs160845 chr5 66737591 C T 8.66E-05 Alzheimer's disease (age of onset) / / 22005931 rs32030 chr5 66739338 T C 4.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs32030 chr5 66739338 T C 3.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs317998 chr5 66741307 G A 5.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs317997 chr5 66741946 T C 4.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs317996 chr5 66742863 T C 6.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs1489753 chr5 66755843 C T 1.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs6877643 chr5 66756828 T A 1.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs10940109 chr5 66760831 C T 2.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs2782321 chr5 66761346 G T 2.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs13362272 chr5 66763696 G A 7.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10052862 chr5 66770980 C G 1.56E-04 Multiple complex diseases / / 17554300 rs10036774 chr5 66771634 G C 2.36E-04 Multiple complex diseases / / 17554300 rs751768 chr5 66773955 T C 9.72E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4282273 chr5 66789202 C T 7.30E-07 Urinary metabolites / / 21572414 rs1532122 chr5 66797723 G T 9.04E-05 Height / / pha003010 rs4976079 chr5 66807042 C T 1.50E-05 Asthma (bronchodilator response) / / 22792082 rs7715410 chr5 66807910 C A 4.10E-06 Asthma (bronchodilator response) / / 22792082 rs10940113 chr5 66814842 T C 6.10E-06 Asthma (bronchodilator response) / / 22792082 rs6414806 chr5 66820274 C T 8.10E-05 Asthma (bronchodilator response) / / 22792082 rs1472032 chr5 66823711 A G 5.48E-04 Smoking cessation / / 24665060 rs7717572 chr5 66833257 G A 3.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs6449879 chr5 66865019 G A 1.90E-05 Urinary metabolites / / 21572414 rs6862758 chr5 66876159 C T 9.91E-04 Multiple complex diseases / / 17554300 rs4128309 chr5 66910080 C T 7.35E-04 Insulin resistance / / 21901158 rs6889882 chr5 66910637 A G 1.89E-04 Multiple complex diseases / / 17554300 rs4976096 chr5 66912233 C T 3.40E-05 Asthma (bronchodilator response) / / 22792082 rs3934546 chr5 66932238 C G 4.36E-04 Multiple complex diseases / / 17554300 rs4078050 chr5 66936150 G A 4.94E-04 Alcohol dependence / / 24277619 rs4078050 chr5 66936150 G A 8.49E-05 Height / / pha003011 rs10058651 chr5 66992140 A T 9.06E-04 Alzheimer's disease / / 17998437 rs4607305 chr5 67010538 T C 5.00E-04 Alcohol dependence / / 20201924 rs4470720 chr5 67022879 T G 6.32E-04 Multiple complex diseases / / 17554300 rs4597917 chr5 67045034 G C 0.000424 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4597917 chr5 67045034 G C 4.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7711033 chr5 67047907 G A 0.0005923 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7711033 chr5 67047907 G A 5.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7380465 chr5 67098280 G A 1.05E-04 Obesity (extreme) / / 21935397 rs6414812 chr5 67099642 G A 1.78E-04 Body mass index / / 17255346 rs41418845 chr5 67101342 C T 6.62E-04 Multiple complex diseases / / 17554300 rs17317337 chr5 67101866 G A 7.07E-04 Multiple complex diseases / / 17554300 rs7379303 chr5 67102574 G A 3.28E-04 Body mass index / / 17255346 rs7723009 chr5 67105201 C T 7.28E-05 Obesity (extreme) / / 21935397 rs6449925 chr5 67106319 G A 6.23E-05 Body mass index / / 17255346 rs17317826 chr5 67108133 T G 6.00E-05 Asperger disorder / / 21182207 rs1007047 chr5 67110717 C T 2.04E-04 Obesity (extreme) / / 21935397 rs17317938 chr5 67111022 A G 2.03E-04 Obesity (extreme) / / 21935397 rs11744254 chr5 67112632 G C 8.19E-04 Type 2 diabetes / / 17463246 rs11744254 chr5 67112632 G C 2.73E-04 Multiple complex diseases / / 17554300 rs12520934 chr5 67126863 G A 7.81E-07 Age-related macular degeneration / / pha002869 rs12520934 chr5 67126863 G A 1.00E-05 Age-related macular degeneration / / pha002890 rs12520934 chr5 67126863 G A 1.13E-05 HDL cholesterol / / pha003075 rs1490813 chr5 67139113 T C 5.15E-04 Longevity / / 22279548 rs16897098 chr5 67141138 G T 3.58E-05 HDL cholesterol / / pha003075 rs10038754 chr5 67150765 G A 8.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10065943 chr5 67158729 G A 6.48E-05 Schizophrenia / / 24253340 rs1490801 chr5 67166508 A G 7.57E-05 Age-related macular degeneration / / pha002890 rs1490800 chr5 67166547 T C 1.57E-04 Multiple complex diseases / / 17554300 rs10940137 chr5 67166890 A C 3.46E-05 HDL cholesterol / / pha003075 rs1490796 chr5 67167585 G C 1.32E-04 Multiple complex diseases / / 17554300 rs1490795 chr5 67168246 T A 1.68E-04 Multiple complex diseases / / 17554300 rs1490794 chr5 67168343 G A 3.46E-05 HDL cholesterol / / pha003075 rs6859671 chr5 67179407 T C 4.38E-04 Myopia (pathological) / / 21095009 rs16897141 chr5 67184584 C T 5.49E-04 Type 2 diabetes / / 17463246 rs10940138 chr5 67194469 C T 4.00E-07 Menarche (age at onset) / / 23599027 rs963996 chr5 67203828 T G 2.10E-05 Urinary metabolites / / 21572414 rs10515058 chr5 67209875 T A 2.09E-04 Birth weight / / 17255346 rs4976138 chr5 67221332 C G 3.27E-05 Panic disorder / / 19165232 rs12234107 chr5 67221604 T G 9.16E-04 Multiple complex diseases / / 17554300 rs1388125 chr5 67230690 G A 1.80E-05 Urinary metabolites / / 21572414 rs4976139 chr5 67231863 G A 1.69E-05 Suicidal ideation / / 20877300 rs7720751 chr5 67235057 A C 6.73E-05 Amyotrophic lateral sclerosis / / 20801718 rs6872437 chr5 67239886 T C 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs9291908 chr5 67240236 T C 6.20E-05 Response to antidepressants / / 19736353 rs11950162 chr5 67243415 C T 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs6878860 chr5 67244515 A G 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1366315 chr5 67256569 T C 1.80E-04 Asperger disorder / / 21182207 rs999826 chr5 67275356 G A 8.50E-04 Asperger disorder / / 21182207 rs1370232 chr5 67282490 G C 8.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs157411 chr5 67294907 G A 2.67E-04 Myopia (pathological) / / 21095009 rs281448 chr5 67295522 G T 1.52E-04 Multiple complex diseases / / 17554300 rs281448 chr5 67295522 G T 3.76E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs464332 chr5 67299387 C T 4.18E-04 Myopia (pathological) / / 21095009 rs11744801 chr5 67301383 A C 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17235387 chr5 67301753 A G 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1864053 chr5 67302928 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10067755 chr5 67307462 A G 2.00E-06 Waist-to-hip circumference ratio (interaction) / / 23192594 rs4976031 chr5 67329833 T C 2.00E-04 Information processing speed / / 21130836 rs7737981 chr5 67384201 C A 7.19E-04 Acute lung injury / / 22295056 rs17237251 chr5 67412203 T C 4.61E-04 Hemoglobin concentration / / 20534544 rs17309601 chr5 67412429 C A 2.80E-05 Urinary metabolites / / 21572414 rs2888306 chr5 67412484 T C 1.20E-05 Hemoglobin concentration / / 20534544 rs17309796 chr5 67415779 C G 2.10E-05 Urinary metabolites / / 21572414 rs17316202 chr5 67415973 A T 2.80E-05 Urinary metabolites / / 21572414 rs10940152 chr5 67416371 A T 2.00E-05 Urinary metabolites / / 21572414 rs6449947 chr5 67416409 C T 5.76E-05 Hemoglobin concentration / / 20534544 rs13176053 chr5 67423286 A G 1.85E-05 Hemoglobin concentration / / 20534544 rs897316 chr5 67436395 C T 1.35E-05 Hemoglobin concentration / / 20534544 rs6449952 chr5 67452950 T G 1.70E-05 Urinary metabolites / / 21572414 rs10805422 chr5 67463231 G A 9.89E-05 Serum metabolites / / 19043545 rs4277860 chr5 67475952 A G 4.09E-04 Hemoglobin concentration / / 20534544 rs4277860 chr5 67475952 A G 1.00E-06 Urinary metabolites / / 21572414 rs6886884 chr5 67487328 A G 9.50E-04 Alzheimer's disease / / 17998437 rs12188596 chr5 67492833 A G 3.40E-04 Smoking initiation / / 24665060 rs16897464 chr5 67494957 C T 6.45E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs16897466 chr5 67494991 T G 6.99E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7701498 chr5 67514509 G A 5.43E-04 Insulin resistance PIK3R1 intron 21901158 rs921003 chr5 67515894 T C 7.01E-04 Insulin resistance PIK3R1 intron 21901158 rs6449959 chr5 67517563 C T 5.33E-04 Insulin resistance PIK3R1 intron 21901158 rs7709243 chr5 67534039 C T 9.95E-05 Attention deficit hyperactivity disorder PIK3R1 intron 22420046 rs251409 chr5 67573463 C T 0.00019 Coronary artery calcification PIK3R1 intron 23727086 rs3815701 chr5 67575642 A G 6.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIK3R1 intron 20877124 rs695166 chr5 67604628 C G 2.85E-04 Type 2 diabetes / / 17463246 rs453940 chr5 67610482 A C 4.22E-04 Type 2 diabetes / / 17463246 rs34294 chr5 67653782 A C 2.78E-04 Parkinson's disease / / 16252231 rs7719763 chr5 67681425 G A 2.61E-05 Cognitive impairment induced by topiramate / / 22091778 rs16897810 chr5 67711123 A G 1.27E-05 Telomere length / / 23001564 rs6885345 chr5 67712408 G A 3.53E-05 Tunica Media / / pha003036 rs6862818 chr5 67729637 T C 6.53E-04 Smoking initiation / / 24665060 rs853812 chr5 67738430 G A 8.16E-04 Multiple complex diseases / / 17554300 rs256456 chr5 67740062 A G 2.90E-06 Urinary metabolites / / 21572414 rs17322187 chr5 67745048 G A 2.75E-04 Type 2 diabetes / / 17463246 rs42905 chr5 67751221 A C 5.33E-04 Alcohol dependence / / 20201924 rs853803 chr5 67762103 A G 4.99E-05 Blood Pressure / / pha002898 rs853803 chr5 67762103 A G 7.22E-05 Body Mass Index / / pha003015 rs10515085 chr5 67762400 T A 4.58E-04 Type 2 diabetes / / 17463246 rs16897859 chr5 67768278 G T 8.49E-04 Type 2 diabetes / / 17463246 rs853795 chr5 67770083 C T 1.90E-05 Urinary metabolites / / 21572414 rs706724 chr5 67773324 C T 1.13E-05 Body Mass Index / / pha003015 rs1896627 chr5 67778491 G A 7.11E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10515087 chr5 67781764 C T 8.84E-05 Coronary heart disease / / pha003033 rs11738020 chr5 67791030 C T 5.50E-06 Osteoarthritis / / 22566624 rs10043473 chr5 67799515 A G 2.81E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs16897892 chr5 67805131 T C 1.29E-04 Type 2 diabetes / / 17463246 rs6896511 chr5 67808212 A G 1.41E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs6890400 chr5 67892937 T G 8.68E-04 Multiple complex diseases / / 17554300 rs6883966 chr5 67900727 A G 8.63E-04 Multiple complex diseases / / 17554300 rs2547988 chr5 67938108 C T 1.52E-05 Personality dimensions / / 22628180 rs182227 chr5 67938513 G A 1.52E-05 Personality dimensions / / 22628180 rs282424 chr5 67938885 A C 1.52E-05 Personality dimensions / / 22628180 rs282422 chr5 67938981 G A 0.000153 Height (Pygmy height) / / 22570615 rs282422 chr5 67938981 G A 1.48E-05 Personality dimensions / / 22628180 rs33355 chr5 67944870 A G 3.62E-05 Multiple complex diseases / / 17554300 rs33353 chr5 67950831 T C 2.08E-04 Alzheimer's disease / / 24755620 rs7713001 chr5 67963615 C T 9.69E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs12188464 chr5 67963949 A G 9.69E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs13171512 chr5 67965031 C T 7.86E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs2607378 chr5 67979800 T G 7.03E-04 Alzheimer's disease / / 24755620 rs1286371 chr5 67994198 T C 1.16E-05 Body mass index / / 17255346 rs35239 chr5 68029078 A C 4.60E-04 Breast cancer and prostate cancer / / 17903305 rs12516844 chr5 68038077 T G 2.66E-05 Age-related macular degeneration (extreme sampling) / / 23577725 rs12516844 chr5 68038077 T G 3.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs28289 chr5 68060559 G A 2.68E-05 Orofacial clefts / / 22419666 rs1366108 chr5 68114936 A G 4.50E-06 C-reactive protein / / 22492993 rs2913278 chr5 68115600 T G 5.95E-06 C-reactive protein / / 22492993 rs1427905 chr5 68118222 G A 5.95E-06 C-reactive protein / / 22492993 rs7718291 chr5 68200642 A G 5.27E-04 Common variable immunodeficiency / / 21497890 rs11747940 chr5 68209404 T C 6.84E-04 HIV-1 viral setpoint / / 17641165 rs4505911 chr5 68241637 G A 0.000751 Height (Pygmy height) / / 22570615 rs6414814 chr5 68263602 C T 6.95E-04 Multiple complex diseases / / 17554300 rs1982773 chr5 68336136 A G 6.98E-04 Myopia (pathological) / / 21095009 rs2434343 chr5 68364871 T G 4.50E-04 Blood pressure / / 17255346 rs10037187 chr5 68366875 T C 4.43E-04 Multiple complex diseases / / 17554300 rs164396 chr5 68407716 C T 0.000361 Height (Pygmy height) SLC30A5 intron 22570615 rs164393 chr5 68409094 A C,G,T 2.20E-06 Urinary metabolites SLC30A5 intron 21572414 rs2617403 chr5 68429040 C A 1.60E-05 Body mass index / / 23669352 rs11951414 chr5 68431872 C T 7.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4976175 chr5 68448694 C T 8.77E-04 White matter integrity / / 22425255 rs389686 chr5 68455166 C T 7.51E-04 Depression (quantitative trait) / / 20800221 rs1976101 chr5 68496452 T G 8.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CENPH intron 20877124 rs2972390 chr5 68529783 A G 0.000675 Height (Pygmy height) CDK7 nearGene-5 22570615 rs12656423 chr5 68569259 G A 7.18E-04 Alzheimer's disease CDK7 intron 22005930 rs12656449 chr5 68569487 G A 7.18E-04 Alzheimer's disease CDK7 intron 22005930 rs12656918 chr5 68576014 C G 7.18E-04 Alzheimer's disease / / 22005930 rs12651858 chr5 68577467 T C 3.00E-04 Alzheimer's disease CCDC125 UTR-3 22005930 rs12651858 chr5 68577467 T C 3.72E-04 White matter integrity CCDC125 UTR-3 22425255 rs12187268 chr5 68625786 T C 8.85E-05 Blood Pressure / / pha003040 rs2083643 chr5 68628929 C T 0.000801 Height (Pygmy height) / / 22570615 rs9291949 chr5 68648770 G A 4.91E-05 Lung adenocarcinoma TAF9 intron 19836008 rs2561159 chr5 68725130 T C 0.000667 Height (Pygmy height) MARVELD2 intron 22570615 rs299075 chr5 68728544 G A 7.38E-05 Blood Pressure MARVELD2 intron pha003040 rs6453529 chr5 70704077 G A 1.50E-05 Urinary metabolites / / 21572414 rs7443752 chr5 70716555 A G 1.10E-06 Urinary metabolites / / 21572414 rs35131626 chr5 70834892 C A 9.00E-06 Obesity-related traits BDP1 cds-synon 23251661 rs277990 chr5 70918903 A C,G,T 3.03E-05 Recombination rate MCCC2 intron 21698098 rs277979 chr5 70927686 C A,G,T 4.90E-14 Progranulin levels MCCC2 intron 21087763 rs277979 chr5 70927686 C A,G,T 4.90E-14 Myocardial infarction MCCC2 intron 21211798 rs277921 chr5 70965063 C T 0.00078614 Hypertension (early onset hypertension) / / 22479346 rs281128 chr5 70974576 G A,C,T 0.0000623 Panic disorder / / 23149450 rs281128 chr5 70974576 G A,C,T 6.23E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs1028161 chr5 70992769 A G 9.21E-04 Type 2 diabetes / / 17463246 rs11575893 chr5 71015451 C T 7.29E-05 Suicide attempts in bipolar disorder CARTPT intron 21423239 rs16871468 chr5 71017951 T G 8.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs17358300 chr5 71018057 T C 4.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs16871471 chr5 71018557 A T 9.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs13158073 chr5 71076878 A G 2.18E-04 HIV-1 viral setpoint / / 17641165 rs6862707 chr5 71081151 T A,C,G 1.26E-04 HIV-1 viral setpoint / / 17641165 rs2251262 chr5 71112707 G C 8.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs2721775 chr5 71132351 T C 1.64E-04 Hearing function / / 17255346 rs7710638 chr5 71138813 G A 9.43E-06 Lipid traits / / 21777205 rs1911937 chr5 71140304 G A 3.25E-06 Lipid traits / / 21777205 rs7446139 chr5 71155701 A T 7.87E-04 Parkinson's disease / / 16252231 rs7446139 chr5 71155701 A T 4.79E-06 Lipid traits / / 21777205 rs7709495 chr5 71168204 G A 2.20E-06 Lipid traits / / 21777205 rs7736888 chr5 71188232 C A 3.02E-04 Smoking initiation / / 24665060 rs4602602 chr5 71200670 G A 1.80E-05 Hemoglobin / / pha003096 rs4602602 chr5 71200670 G A 1.32E-05 Hematocrit / / pha003097 rs2879027 chr5 71204261 T G 8.26E-04 Rheumatoid arthritis / / 21452313 rs4337837 chr5 71215271 G A 8.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs12188232 chr5 71217113 T C 8.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs1631857 chr5 71236045 C T 8.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs1629473 chr5 71236411 A G 8.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs1629473 chr5 71236411 A G 8.83E-05 Hematocrit / / pha003097 rs2610429 chr5 71239238 C A 8.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs2457125 chr5 71239658 C G 7.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs745780 chr5 71239665 G C 7.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs2644977 chr5 71239861 T C 8.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs1217744 chr5 71245810 T C 4.87E-05 Aortic root size / / 21223598 rs1217744 chr5 71245810 T C 1.60E-05 Urinary metabolites / / 21572414 rs2610424 chr5 71256659 T C 6.62E-06 Osteoarthritis / / 22763110 rs2662341 chr5 71265263 T C 8.32E-04 Multiple complex diseases / / 17554300 rs2662321 chr5 71267378 T A 9.21E-04 Multiple complex diseases / / 17554300 rs7719321 chr5 71273460 A T 9.94E-04 Multiple complex diseases / / 17554300 rs7703322 chr5 71293879 T C 9.81E-04 Multiple complex diseases / / 17554300 rs1010376 chr5 71303308 G A 6.67E-04 Multiple complex diseases / / 17554300 rs1217770 chr5 71307380 A G 4.44E-05 Parkinson's disease / / 21248740 rs1235703 chr5 71326427 C T 3.29E-04 Type 2 diabetes / / 17463246 rs1217766 chr5 71333899 T A 9.95E-04 Type 2 diabetes / / 17463246 rs7704902 chr5 71350666 G A 9.21E-04 Type 2 diabetes / / 17463246 rs1692403 chr5 71358495 G A 9.05E-04 Alzheimer's disease / / 22005930 rs1692404 chr5 71359777 T C 5.11E-04 Alzheimer's disease / / 22005930 rs6894569 chr5 71368999 A G 2.86E-06 Multiple complex diseases / / 17554300 rs1217793 chr5 71372881 G A 3.18E-04 Heart Failure / / pha002884 rs1217817 chr5 71389751 G A 1.85E-07 Lymphocyte counts / / 22286170 rs2199161 chr5 71410356 G C 2.00E-06 Attention deficit hyperactivity disorder MAP1B intron 18839057 rs2337692 chr5 71455618 A G 6.56E-05 Blood Pressure MAP1B intron pha003046 rs17301591 chr5 71462065 C T 7.77E-04 Alzheimer's disease MAP1B intron 17998437 rs11951269 chr5 71475851 C A 4.37E-05 Aortic root size MAP1B intron 21223598 rs16876762 chr5 71541942 T G 5.40E-04 Multiple complex diseases MRPS27 intron 17554300 rs10454918 chr5 71543014 A G 5.05E-04 Self-reported allergy MRPS27 intron 23817569 rs4703855 chr5 71693899 C T 5.90E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7445013 chr5 71697977 A G 5.30E-06 Homocysteine levels,in plasma / / 19525478 rs3891932 chr5 71698104 G A 4.40E-04 Type 2 diabetes / / 17463246 rs3891932 chr5 71698104 G A 2.06E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10462377 chr5 71699064 C A 2.82E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2338216 chr5 71701814 C T 3.30E-06 Homocysteine levels,in plasma / / 19525478 rs2338216 chr5 71701814 C T 2.06E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs16878312 chr5 71705384 C A 1.87E-04 Schizophrenia / / 19197363 rs10942294 chr5 71711269 G T 3.72E-04 Type 2 diabetes / / 17463246 rs10942294 chr5 71711269 G T 5.10E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10515148 chr5 71716928 C G 6.00E-07 Hip geometry / / 17903296 rs7723734 chr5 71717605 A C 3.38E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4703536 chr5 71718848 C G 2.06E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4703872 chr5 71723644 C T 8.70E-04 Type 2 diabetes / / 17463246 rs4703872 chr5 71723644 C T 5.30E-06 Homocysteine levels,in plasma / / 19525478 rs4703872 chr5 71723644 C T 4.14E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12054750 chr5 71729221 G A 2.16E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7710292 chr5 71741790 C T 1.34E-04 Taste perception ZNF366 intron 22132133 rs10043368 chr5 71743322 G A 2.63E-04 Taste perception ZNF366 intron 22132133 rs10060299 chr5 71744242 C T 6.27E-04 Multiple complex diseases ZNF366 intron 17554300 rs6862221 chr5 71754962 T C 8.24E-06 Post-operative nausea and vomiting ZNF366 intron 21694509 rs2278600 chr5 71756670 C T 6.05E-05 Cognitive test performance / / 20125193 rs4703902 chr5 71757953 A G 4.80E-05 Schizophrenia(age at onset) ZNF366 intron 21688384 rs6874676 chr5 71763715 A G 1.90E-05 Urinary metabolites ZNF366 intron 21572414 rs2112298 chr5 71765539 G A 9.91E-06 Stroke (ischemic) ZNF366 intron 21957438 rs10079381 chr5 71768906 C G 9.04E-06 Stroke (ischemic) ZNF366 intron 21957438 rs10061668 chr5 71771346 A G 8.78E-06 Stroke (ischemic) ZNF366 intron 21957438 rs246565 chr5 71809247 G T 2.93E-05 Schizophrenia / / 19197363 rs246562 chr5 71810246 G A 1.70E-05 Urinary metabolites / / 21572414 rs417769 chr5 71811478 T A 3.04E-05 Multiple complex diseases / / 17554300 rs246580 chr5 71815614 G A 2.93E-05 Schizophrenia / / 19197363 rs246580 chr5 71815614 G A 8.07E-06 Post-operative nausea and vomiting / / 21694509 rs453701 chr5 71834039 T C 1.40E-05 Urinary metabolites / / 21572414 rs397868 chr5 71836996 C T 7.62E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs381642 chr5 71837509 C T 3.37E-04 Type 2 diabetes / / 17463246 rs406813 chr5 71837606 G A 7.39E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs381734 chr5 71843755 G A 7.62E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs420024 chr5 71844918 A C 7.98E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs417407 chr5 71845000 T C 2.48E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs417407 chr5 71845000 T C 4.60E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs16899738 chr5 71863286 G C 6.47E-04 Multiple complex diseases / / 17554300 rs17590803 chr5 71901874 T A 1.05E-05 Type 2 diabetes LOC389300 intron 17463246 rs17590866 chr5 71908620 C A 5.02E-06 Type 2 diabetes / / 17463246 rs17164415 chr5 71916402 T G 8.58E-06 Type 2 diabetes / / 17463246 rs980229 chr5 71929274 A G 8.43E-06 Type 2 diabetes / / 17463246 rs17164429 chr5 71930092 C A 4.08E-06 Type 2 diabetes / / 17463246 rs17164443 chr5 71940298 A G 1.64E-05 Type 2 diabetes / / 17463246 rs16900380 chr5 71942261 A G 3.05E-05 Type 2 diabetes / / 17463246 rs2925678 chr5 71955093 C G 1.62E-05 Type 2 diabetes / / 17463246 rs3010251 chr5 71985379 C T 2.72E-05 Type 2 diabetes / / 17463246 rs10515153 chr5 71989150 T C 3.50E-15 Alcohol consumption / / pha001398 rs2943791 chr5 71994464 A T 1.95E-04 Type 2 diabetes / / 17463246 rs3010239 chr5 72010301 G A 3.63E-05 Type 2 diabetes / / 17463246 rs3010276 chr5 72014569 G A 1.57E-05 Type 2 diabetes / / 17463246 rs9654412 chr5 72040659 A G 5.26E-04 Multiple complex diseases / / 17554300 rs13174766 chr5 72057135 G A 7.57E-04 Multiple complex diseases / / 17554300 rs13170247 chr5 72069684 T C 8.00E-04 Multiple complex diseases / / 17554300 rs10077575 chr5 72084557 T G 4.54E-04 Multiple complex diseases / / 17554300 rs153320 chr5 72138452 A G 3.83E-04 Multiple complex diseases TNPO1 intron 17554300 rs34653 chr5 72146480 A G 3.35E-04 Multiple complex diseases TNPO1 intron 17554300 rs266444 chr5 72181404 G A 3.00E-04 Multiple complex diseases TNPO1 intron 17554300 rs478575 chr5 72339109 T C 2.59E-04 Type 2 diabetes FCHO2 intron 17463246 rs478575 chr5 72339109 T C 2.00E-05 Urinary metabolites FCHO2 intron 21572414 rs185435 chr5 72348272 A G 5.29E-04 Multiple complex diseases FCHO2 missense 17554300 rs1156398 chr5 72362150 A G 9.12E-04 Multiple complex diseases FCHO2 intron 17554300 rs1200485 chr5 72385058 A G 2.00E-05 Urinary metabolites FCHO2 UTR-3 21572414 rs683633 chr5 72400190 T C 1.71E-05 Prostate cancer / / pha002878 rs608104 chr5 72407538 C T 8.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs692811 chr5 72409094 G A,C,T 8.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs636607 chr5 72409334 A C 7.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs602307 chr5 72412780 T A 1.50E-05 Urinary metabolites / / 21572414 rs149174030 chr5 72419402 G A,C 0.00083 Breast cancer TMEM171 missense 23555315 rs17632159 chr5 72431482 G C 4.00E-11 Urate levels / / 23263486 rs17663555 chr5 72432036 C G 2.00E-06 Renal function-related traits (BUN) / / 22797727 rs13160226 chr5 72434224 A G 8.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs575416 chr5 72437534 A G 3.63E-09 Urate levels / / 23263486 rs13353984 chr5 72438805 A G 8.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs622704 chr5 72439029 A G 9.15E-09 Urate levels / / 23263486 rs636266 chr5 72439774 G A 6.88E-09 Urate levels / / 23263486 rs484573 chr5 72441107 C A 9.80E-09 Urate levels / / 23263486 rs587189 chr5 72441476 G A 9.03E-09 Urate levels / / 23263486 rs527511 chr5 72446334 C T 5.55E-09 Urate levels / / 23263486 rs6881806 chr5 72451309 G A 6.30E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs522152 chr5 72452355 C T 9.63E-09 Urate levels / / 23263486 rs1916642 chr5 72452547 C T 2.28E-05 Response to hepatitis C treatment / / 19684573 rs1916642 chr5 72452547 C T 3.41E-06 Parkinson's disease / / 21812969 rs17731153 chr5 72456421 C T 1.52E-05 Orofacial clefts / / 22419666 rs6879012 chr5 72462881 G A 2.50E-05 Response to hepatitis C treatment / / 19684573 rs6879012 chr5 72462881 G A 7.78E-06 Parkinson's disease / / 21812969 rs12651896 chr5 72502029 C T 9.10E-05 Suicide attempts in bipolar disorder / / 21423239 rs7702331 chr5 72551134 A G 6.00E-12 Crohn's disease / / 21102463 rs7702331 chr5 72551134 A G 6.00E-10 Crohn's disease / / 23128233 rs4704066 chr5 72565488 G T 2.96E-04 Multiple complex diseases / / 17554300 rs10037479 chr5 72574933 C A,G,T 3.61E-05 Multiple complex diseases / / 17554300 rs4582253 chr5 72580411 T C 5.20E-04 Schizophrenia / / 20832056 rs7706114 chr5 72679453 G A 7.46E-04 Type 2 diabetes / / 17463246 rs7706114 chr5 72679453 G A 4.49E-04 Multiple complex diseases / / 17554300 rs4403158 chr5 72689228 A G 5.28E-04 Multiple complex diseases / / 17554300 rs6863278 chr5 72691388 G A 0.0000061 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4292434 chr5 72703541 C T 2.75E-05 Multiple complex diseases / / 17554300 rs7707634 chr5 72714553 C T 2.28E-04 Multiple complex diseases / / 17554300 rs1449272 chr5 72750163 T C 4.17E-04 Type 2 diabetes / / 17463246 rs7731261 chr5 72774789 T C 5.21E-05 Personality dimensions / / 18957941 rs819561 chr5 72819206 G A 5.47E-05 Multiple complex diseases / / 17554300 rs819552 chr5 72824400 G A 1.35E-04 Multiple complex diseases / / 17554300 rs819550 chr5 72824956 T C 2.88E-04 Alzheimer's disease (late onset) / / 21379329 rs819549 chr5 72825229 A G 2.72E-04 Multiple complex diseases / / 17554300 rs6867430 chr5 72827496 G C 9.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs347236 chr5 72862289 G A 4.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) UTP15 intron 20877124 rs1220627 chr5 72871063 A G 6.24E-04 Multiple complex diseases UTP15 intron 17554300 rs343122 chr5 72874907 A C 9.02E-04 Multiple complex diseases UTP15 cds-synon 17554300 rs13170849 chr5 72882128 G A 8.47E-05 Height / / pha003011 rs343110 chr5 72884115 C T 4.09E-04 Multiple complex diseases / / 17554300 rs6453015 chr5 72904983 C T 9.96E-04 Multiple complex diseases / / 17554300 rs17552357 chr5 72995398 C T 9.89E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) RGNEF intron 23648065 rs10515160 chr5 72996117 C A 4.95E-04 Multiple complex diseases RGNEF intron 17554300 rs16870743 chr5 73016810 A G 1.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) RGNEF intron 23648065 rs17664701 chr5 73034123 A T 1.21E-04 Alzheimer's disease RGNEF intron 24755620 rs952995 chr5 73041784 A G 9.97E-04 Heart Failure RGNEF intron pha002885 rs11749197 chr5 73042232 G A 3.38E-04 Alzheimer's disease RGNEF intron 24755620 rs7710068 chr5 73071952 A G 9.60E-05 Insulin resistance RGNEF intron 21901158 rs7714670 chr5 73072354 T C 2.00E-09 Venous thromboembolism (gene x gene interaction) RGNEF missense 23509962 rs716707 chr5 73097869 C T 9.11E-04 Multiple complex diseases RGNEF intron 17554300 rs4703613 chr5 73108573 G A 8.83E-04 Suicide attempts in bipolar disorder RGNEF intron 21423239 rs16870904 chr5 73113650 T C 8.19E-04 Multiple complex diseases RGNEF intron 17554300 rs2931440 chr5 73146222 T G 9.44E-04 Multiple complex diseases RGNEF intron 17554300 rs6869486 chr5 73159601 T C 4.61E-06 Leprosy RGNEF intron pha002872 rs3749642 chr5 73196640 C T 2.05E-05 Cognitive test performance RGNEF intron 20125193 rs283622 chr5 73198364 G A 3.09E-05 Cognitive test performance RGNEF intron 20125193 rs283624 chr5 73198901 G T 8.26E-05 Cognitive test performance RGNEF intron 20125193 rs17634878 chr5 73206993 A G 1.89E-04 Type 2 diabetes RGNEF intron 17463246 rs16871023 chr5 73215237 G A 1.00E-06 D-dimer levels RGNEF intron 21502573 rs423333 chr5 73218954 C T 8.16E-04 Response to cytadine analogues (cytosine arabinoside) RGNEF missense 24483146 rs423333 chr5 73218954 C T 7.75E-04 Myocardial Infarction RGNEF missense pha002873 rs2927703 chr5 73232536 G C 8.90E-06 Urinary metabolites RGNEF intron 21572414 rs283595 chr5 73242130 C T 1.23E-04 Arthritis (juvenile idiopathic) / / 22354554 rs283610 chr5 73248512 A G 7.00E-06 Obesity-related traits / / 23251661 rs283612 chr5 73250492 T C 3.43E-04 Suicide attempts in bipolar disorder / / 21041247 rs283615 chr5 73251124 T A 3.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs283616 chr5 73251321 G C 3.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs283618 chr5 73251516 T A 3.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs1684851 chr5 73257386 A C 6.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs416286 chr5 73262113 A G 6.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs416286 chr5 73262113 A G 8.22E-04 Insulin resistance / / 21901158 rs416286 chr5 73262113 A G 3.95E-04 Smoking initiation / / 24665060 rs282401 chr5 73263353 C A 8.12E-04 Alzheimer's disease / / 22005930 rs436777 chr5 73264580 A G 6.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs384834 chr5 73273696 C A 2.30E-05 Urinary metabolites / / 21572414 rs6894385 chr5 73276903 A C 1.00E-06 QT interval / / 23534349 rs255601 chr5 73277573 G A 2.40E-05 Urinary metabolites / / 21572414 rs17666317 chr5 73280705 C T 7.80E-06 Urinary metabolites / / 21572414 rs2973538 chr5 73281714 C T 1.50E-05 Urinary metabolites / / 21572414 rs12514102 chr5 73284411 A G 5.80E-06 Urinary metabolites / / 21572414 rs194274 chr5 73308343 C T 5.25E-05 Smoking initiation / / 24665060 rs11952583 chr5 73309105 A C 5.00E-06 Smoking initiation / / 24665060 rs285599 chr5 73339114 C T 1.21E-04 Smoking initiation / / 24665060 rs285598 chr5 73339605 C T 1.17E-04 Smoking initiation / / 24665060 rs386083 chr5 73341245 T C 2.40E-04 Smoking initiation / / 24665060 rs924624 chr5 73382351 A G 1.17E-04 Blood pressure (response to calcium channel blocker) / / 24192120 rs4568344 chr5 73386320 G A 6.84E-04 Multiple complex diseases / / 17554300 rs10045219 chr5 73391725 C T 5.70E-05 Cognitive decline / / 23732972 rs725144 chr5 73397114 G A 3.19E-04 Cognitive decline / / 23732972 rs288855 chr5 73403215 C T 7.73E-04 Bipolar disorder / / 19259986 rs10064733 chr5 73420066 C T 7.56E-04 Alzheimer's disease / / 24755620 rs10072489 chr5 73420143 A G 7.99E-04 Alzheimer's disease / / 24755620 rs17555780 chr5 73423525 A G 1.27E-05 Cognitive decline / / 23732972 rs288864 chr5 73428043 A G 6.80E-04 Alcohol dependence / / 20201924 rs4703622 chr5 73430161 A G 2.42E-04 Cognitive decline / / 23732972 rs12517914 chr5 73432001 G A 2.04E-04 Cognitive decline / / 23732972 rs10058853 chr5 73433080 A T 2.51E-04 Cognitive decline / / 23732972 rs4704110 chr5 73437503 T C 7.13E-05 Cognitive decline / / 23732972 rs4704110 chr5 73437503 T C 4.27E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs392079 chr5 73441848 G C 1.26E-04 Cognitive decline / / 23732972 rs2120729 chr5 73442438 G A 9.82E-05 Cognitive decline / / 23732972 rs2926721 chr5 73450088 G A 1.12E-04 Cognitive decline / / 23732972 rs2926720 chr5 73450695 G A 1.92E-04 Cognitive decline / / 23732972 rs290725 chr5 73461072 T C 2.88E-05 Cognitive decline / / 23732972 rs158807 chr5 73474602 T G 8.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs158807 chr5 73474602 T G 2.56E-04 Longevity / / 22279548 rs7725214 chr5 73485801 G C 4.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs158813 chr5 73491141 T C 6.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs158814 chr5 73492598 A T 7.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs4703624 chr5 73494599 A G 4.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs158819 chr5 73499180 G A 9.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs158810 chr5 73506111 T C 3.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs158811 chr5 73506563 T C 3.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs292203 chr5 73506784 C T 6.20E-04 Alcohol dependence / / 20201924 rs627834 chr5 73539736 A G 3.30E-04 Alzheimer's disease (late onset) / / 21379329 rs292210 chr5 73556664 G A 1.10E-05 Urinary metabolites / / 21572414 rs11738478 chr5 73559582 T C 5.28E-05 Celiac disease / / 23936387 rs630979 chr5 73579075 G C 8.03E-04 Multiple complex diseases / / 17554300 rs10515167 chr5 73580484 A G 9.36E-04 Diabetic retinopathy / / 20871662 rs292201 chr5 73591094 A C 2.72E-05 Sudden cardiac arrest / / 21658281 rs533886 chr5 73618792 A C 1.10E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4704134 chr5 73633836 T C 1.97E-05 Socioeconomic Factors / / pha003066 rs294982 chr5 73661110 G C 4.69E-05 Schizophrenia / / 19571809 rs188404 chr5 73676439 G A 1.70E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1687349 chr5 73677709 C T 6.46E-06 stroke (ischemic) / / 17434096 rs1687349 chr5 73677709 C T 1.80E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs294986 chr5 73683039 A G 1.29E-05 Sudden cardiac arrest / / 21658281 rs294986 chr5 73683039 A G 1.20E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10065639 chr5 73690349 A G 4.54E-06 Blood Pressure / / pha003048 rs10474415 chr5 73694418 A C 7.97E-04 Type 2 diabetes / / 17463246 rs10474415 chr5 73694418 A C 7.93E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs295691 chr5 73702310 A G 6.60E-04 Myopia (pathological) / / 21095009 rs295692 chr5 73704926 G A 6.22E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs413430 chr5 73710424 A G 4.14E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs16871811 chr5 73710784 C T 2.13E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs467147 chr5 73711546 C T 7.68E-05 Sudden cardiac arrest / / 21658281 rs467147 chr5 73711546 C T 4.14E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs454012 chr5 73712747 A G 1.08E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs435958 chr5 73713209 C T 1.81E-05 Triglycerides / / 19074352 rs435958 chr5 73713209 C T 1.81E-05 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs10515181 chr5 73715484 G A 5.84E-04 Multiple complex diseases / / 17554300 rs460738 chr5 73719660 T C 1.34E-04 Myopia (pathological) / / 21095009 rs2115281 chr5 73784037 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2115281 chr5 73784037 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10805888 chr5 73785547 A G 8.52E-07 Lymphocyte counts / / 22286170 rs6874566 chr5 73786880 T C 8.74E-04 Alcohol dependence / / 24277619 rs1544939 chr5 73787278 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs298380 chr5 73794009 A G 7.01E-04 Coronary Artery Disease / / 17634449 rs1001114 chr5 73802976 A G 8.08E-04 Depression (quantitative trait) / / 20800221 rs737541 chr5 73803417 A G 5.06E-04 Depression (quantitative trait) / / 20800221 rs1651352 chr5 73807043 A G 4.27E-04 Depression (quantitative trait) / / 20800221 rs298366 chr5 73810372 C G 4.56E-04 Depression (quantitative trait) / / 20800221 rs212925 chr5 73810478 T C 1.68E-04 Multiple complex diseases / / 17554300 rs212925 chr5 73810478 T C 4.58E-04 Depression (quantitative trait) / / 20800221 rs11745925 chr5 73811250 C T 4.19E-04 Coronary Artery Disease / / 17634449 rs186139 chr5 73816110 T C 4.63E-04 Depression (quantitative trait) / / 20800221 rs186140 chr5 73817655 T C 3.48E-04 Depression (quantitative trait) / / 20800221 rs298393 chr5 73821242 C T 3.82E-04 Depression (quantitative trait) / / 20800221 rs298403 chr5 73828332 C T 4.09E-04 Depression (quantitative trait) / / 20800221 rs298407 chr5 73829775 C T 4.37E-04 Depression (quantitative trait) / / 20800221 rs298410 chr5 73831661 A G 4.84E-04 Depression (quantitative trait) / / 20800221 rs167232 chr5 73831867 C A 3.30E-04 Depression (quantitative trait) / / 20800221 rs1651350 chr5 73833731 G C 4.64E-04 Depression (quantitative trait) / / 20800221 rs1510935 chr5 73834286 A G 2.32E-04 Coronary Artery Disease / / 17634449 rs1651348 chr5 73835470 G T 3.36E-04 Depression (quantitative trait) / / 20800221 rs11747100 chr5 73968934 A C,G 3.49E-04 Body mass index / / 21701565 rs11747100 chr5 73968934 A C,G 4.43E-04 Body mass index / / 21701565 rs11747317 chr5 73969653 A G 1.33E-04 Multiple complex diseases / / 17554300 rs11747317 chr5 73969653 A G 6.23E-04 Body mass index / / 21701565 rs10942717 chr5 73974275 A G 7.35E-04 Alzheimer's disease / / 17998437 rs4460123 chr5 73977524 G A 8.59E-04 Alzheimer's disease / / 17998437 rs4460123 chr5 73977524 G A 4.87E-04 Body mass index / / 21701565 rs4460123 chr5 73977524 G A 4.95E-04 Body mass index / / 21701565 rs820889 chr5 73985534 T C 2.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HEXB intron 20877124 rs820889 chr5 73985534 T C 1.28E-04 Amyotrophic lateral sclerosis (sporadic) HEXB intron 24529757 rs1048167 chr5 74017499 C T 4.53E-04 Lymphocyte counts GFM2 missense 22286170 rs10044287 chr5 74095542 T C 9.04E-04 Myopia (pathological) FAM169A intron 21095009 rs10515199 chr5 74099634 C T 3.80E-05 Electrocardiographic traits and heart rate variability FAM169A intron 17903306 rs11739301 chr5 74172468 G A 2.07E-04 Cholesterol / / 17255346 rs11746561 chr5 74212928 C T 2.24E-05 Cholesterol / / 17255346 rs3934476 chr5 74242852 A G 2.23E-05 Post-operative nausea and vomiting / / 21694509 rs3934476 chr5 74242852 A G 8.08E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7706365 chr5 74263040 A G 4.62E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6870053 chr5 74276566 A C 6.03E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7707671 chr5 74287742 T C 6.15E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6860492 chr5 74292483 A C 7.91E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10067703 chr5 74292694 T G 6.62E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4334860 chr5 74299317 C T 8.60E-06 Urinary metabolites / / 21572414 rs4555772 chr5 74302658 A G 4.00E-06 Stearic acid (18:0) plasma levels / / 23362303 rs7714420 chr5 74340327 A C,T 3.10E-08 Triglycerides / / 19060911 rs10040209 chr5 74353535 G A 1.50E-04 White blood cell types / / 21738478 rs7700965 chr5 74356857 T C 1.66E-09 Triglycerides / / 19060911 rs4626318 chr5 74365757 A C 1.82E-06 Cocaine dependence ANKRD31 intron 23958962 rs3923323 chr5 74372141 T C 4.13E-04 Alzheimer's disease ANKRD31 intron 17998437 rs3923323 chr5 74372141 T C 3.88E-12 Triglycerides ANKRD31 intron 19060911 rs4345300 chr5 74376571 C T 1.64E-09 Triglycerides ANKRD31 intron 19060911 rs4632781 chr5 74376658 G C 2.62E-04 Weight loss (gastric bypass surgery) ANKRD31 intron 23643386 rs961098 chr5 74400386 G C 2.35E-05 Cocaine dependence ANKRD31 missense 23958962 rs2035191 chr5 74413713 T C 3.42E-12 Triglycerides ANKRD31 intron 19060911 rs1422698 chr5 74443132 C T 3.46E-11 Triglycerides ANKRD31 missense 19060911 rs10054860 chr5 74446804 T G 2.53E-06 Cocaine dependence ANKRD31 intron 23958962 rs4704187 chr5 74480288 T C 6.00E-06 Response to amphetamines ANKRD31 intron 22952603 rs6866661 chr5 74534372 A G 1.92E-09 Triglycerides / / 19060911 rs10062361 chr5 74565153 C T 4.95E-06 LDL lipoproteins / / pha002902 rs4704200 chr5 74569856 G T 6.66E-05 LDL lipoproteins / / pha002902 rs1551894 chr5 74570531 G A 1.05E-14 Triglycerides / / 19060911 rs1551894 chr5 74570531 G A 6.59E-06 LDL lipoproteins / / pha002902 rs2126736 chr5 74574984 A G 6.90E-05 LDL lipoproteins / / pha002902 rs7731875 chr5 74588854 C T 2.51E-04 Type 2 diabetes / / 17463246 rs918623 chr5 74596682 T G 9.86E-04 Type 2 diabetes / / 17463246 rs1423527 chr5 74602699 C A 8.60E-05 Response to statin therapy / / 20339536 rs2335418 chr5 74603479 G A 1.51E-08 Triglycerides / / 19060911 rs6871667 chr5 74604742 G A 7.10E-05 Response to statin therapy / / 20339536 rs10056811 chr5 74605220 G A 2.57E-05 LDL lipoproteins / / pha002902 rs17671591 chr5 74615021 C T 7.05E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10474433 chr5 74616843 T C 3.25E-08 Triglycerides / / 19060911 rs10474433 chr5 74616843 T C 5.23E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10474433 chr5 74616843 T C 0.000031 LDL cholesterol / / 23100282 rs2878417 chr5 74617262 G A 9.50E-05 Response to statin therapy / / 20339536 rs13354746 chr5 74619132 C T 0.00086 LDL cholesterol / / 23100282 rs6878576 chr5 74620912 C T 1.17E-05 Breast cancer / / 21060860 rs7703051 chr5 74625487 C A 1.43E-04 Type 2 diabetes / / 17463246 rs7703051 chr5 74625487 C A 1.00E-08 LDL cholesterol / / 18802019 rs7703051 chr5 74625487 C A 1.00E-08 Coronary heart disease / / 21347282 rs3761739 chr5 74631501 C T 3.79E-08 Cholesterol,total HMGCR nearGene-5 23063622 rs3761739 chr5 74631501 C T 5.83E-08 LDL cholesterol HMGCR nearGene-5 23063622 rs3761740 chr5 74632133 C A 3.22E-09 Triglycerides HMGCR nearGene-5 19060911 rs3761740 chr5 74632133 C A 1.44E-05 LDL lipoproteins HMGCR nearGene-5 pha002902 rs10045497 chr5 74636484 C A 1.00E-12 Lipid traits HMGCR intron 24386095 rs10045497 chr5 74636484 C A 2.00E-08 Lipid traits HMGCR intron 24386095 rs10038095 chr5 74637711 A T 4.29E-08 Lipid levels HMGCR intron 19913121 rs10038095 chr5 74637711 A T 8.05E-06 Lipid levels HMGCR intron 19913121 rs10038095 chr5 74637711 A T 1.35E-31 Cholesterol,total HMGCR intron 23063622 rs10038095 chr5 74637711 A T 6.84E-29 LDL cholesterol HMGCR intron 23063622 rs10474434 chr5 74644681 G T 2.05E-06 Lipid levels HMGCR intron 19913121 rs10474434 chr5 74644681 G T 6.59E-04 Lipid levels HMGCR intron 19913121 rs10474434 chr5 74644681 G T 1.84E-17 LDL cholesterol HMGCR intron 23063622 rs10474434 chr5 74644681 G T 3.52E-20 Cholesterol,total HMGCR intron 23063622 rs6453131 chr5 74644706 T G 4.59E-08 Lipid levels HMGCR intron 19913121 rs6453131 chr5 74644706 T G 6.34E-06 Lipid levels HMGCR intron 19913121 rs6453131 chr5 74644706 T G 2.91E-34 Cholesterol,total HMGCR intron 23063622 rs6453131 chr5 74644706 T G 6.12E-30 LDL cholesterol HMGCR intron 23063622 rs17238484 chr5 74648496 G T 1.79E-06 Lipid levels HMGCR intron 19913121 rs17238484 chr5 74648496 G T 8.08E-04 Lipid levels HMGCR intron 19913121 rs17238484 chr5 74648496 G T 3.14E-17 LDL cholesterol HMGCR intron 23063622 rs17238484 chr5 74648496 G T 5.59E-20 Cholesterol,total HMGCR intron 23063622 rs12654264 chr5 74648603 A T 1.82E-04 Type 2 diabetes HMGCR intron 17463246 rs12654264 chr5 74648603 A T 1.00E-20 LDL cholesterol HMGCR intron 18193044 rs12654264 chr5 74648603 A T 5.76E-08 Lipid levels HMGCR intron 19913121 rs12654264 chr5 74648603 A T 9.25E-06 Lipid levels HMGCR intron 19913121 rs12654264 chr5 74648603 A T 1.00E-20 Coronary heart disease HMGCR intron 21347282 rs12654264 chr5 74648603 A T 1.00E-20 Metabolite levels HMGCR intron 21909109 rs12654264 chr5 74648603 A T 3.11E-30 LDL cholesterol HMGCR intron 23063622 rs12654264 chr5 74648603 A T 4.33E-34 Cholesterol,total HMGCR intron 23063622 rs3846662 chr5 74651084 A G 1 Drug response to Simvastatin HMGCR intron 18559695 rs3846662 chr5 74651084 A G 2.00E-11 LDL cholesterol HMGCR intron 19060911 rs3846662 chr5 74651084 A G 3.00E-19 Cholesterol,total HMGCR intron 19060911 rs3846662 chr5 74651084 A G 2.20E-05 Lipid levels HMGCR intron 19802338 rs3846662 chr5 74651084 A G 5.17E-08 Lipid levels HMGCR intron 19913121 rs3846662 chr5 74651084 A G 8.57E-06 Lipid levels HMGCR intron 19913121 rs3846662 chr5 74651084 A G 1.60E-12 Lipid levels HMGCR intron 19936222 rs3846662 chr5 74651084 A G 3.57E-10 Lipid levels HMGCR intron 19936222 rs3846662 chr5 74651084 A G 8.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HMGCR intron 20877124 rs3846662 chr5 74651084 A G 2.00E-11 Coronary heart disease HMGCR intron 21347282 rs3846662 chr5 74651084 A G 7.09E-33 Cholesterol,total HMGCR intron 23063622 rs3846662 chr5 74651084 A G 9.97E-33 LDL cholesterol HMGCR intron 23063622 rs3846662 chr5 74651084 A G 1.50E-09 LDL cholesterol HMGCR intron 23100282 rs3846662 chr5 74651084 A G 6.50E-09 Apolipoprotein B levels HMGCR intron 23100282 rs3846662 chr5 74651084 A G 1.50E-09 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) HMGCR intron 23103227 rs3846662 chr5 74651084 A G 1.47E-05 Lipid traits HMGCR intron 24386095 rs3846663 chr5 74655726 C T 1.89E-04 Type 2 diabetes HMGCR intron 17463246 rs3846663 chr5 74655726 C T 8.00E-12 LDL cholesterol HMGCR intron 19060906 rs3846663 chr5 74655726 C T 1.00E-06 Quantitative traits HMGCR intron 19197348 rs3846663 chr5 74655726 C T 6.00E-06 Quantitative traits HMGCR intron 19197348 rs3846663 chr5 74655726 C T 8.00E-12 Coronary heart disease HMGCR intron 21347282 rs3846663 chr5 74655726 C T 3.82E-06 Lipid traits HMGCR intron 24386095 rs12916 chr5 74656539 T C 2.42E-06 Lipid levels HMGCR UTR-3 19913121 rs12916 chr5 74656539 T C 6.66E-09 Lipid levels HMGCR UTR-3 19913121 rs12916 chr5 74656539 T C 5.00E-45 LDL cholesterol HMGCR UTR-3 20686565 rs12916 chr5 74656539 T C 9.00E-47 Cholesterol,total HMGCR UTR-3 20686565 rs12916 chr5 74656539 T C 1.00E-11 LDL cholesterol HMGCR UTR-3 20864672 rs12916 chr5 74656539 T C 0.000000134 LDL cholesterol (male) HMGCR UTR-3 22629316 rs12916 chr5 74656539 T C 0.000000223 LDL cholesterol (female) HMGCR UTR-3 22629316 rs12916 chr5 74656539 T C 5.50E-13 LDL cholesterol HMGCR UTR-3 22629316 rs12916 chr5 74656539 T C 2.90E-39 Cholesterol,total HMGCR UTR-3 23063622 rs12916 chr5 74656539 T C 9.51E-37 LDL cholesterol HMGCR UTR-3 23063622 rs12916 chr5 74656539 T C 5.00E-74 Cholesterol,total HMGCR UTR-3 24097068 rs12916 chr5 74656539 T C 8.00E-78 LDL cholesterol HMGCR UTR-3 24097068 rs7700468 chr5 74675076 T C 1.52E-04 Weight loss (gastric bypass surgery) COL4A3BP intron 23643386 rs6453133 chr5 74692776 A G 2.06E-14 LDL cholesterol COL4A3BP intron 23063622 rs6453133 chr5 74692776 A G 5.60E-17 Cholesterol,total COL4A3BP intron 23063622 rs3804231 chr5 74696779 G A 3.90E-04 Lipid levels COL4A3BP intron 19913121 rs3804231 chr5 74696779 G A 5.15E-06 Lipid levels COL4A3BP intron 19913121 rs3804231 chr5 74696779 G A 1.56E-12 LDL cholesterol COL4A3BP intron 23063622 rs3804231 chr5 74696779 G A 1.89E-13 Cholesterol,total COL4A3BP intron 23063622 rs6453134 chr5 74717767 G A 1.27E-04 Weight loss (gastric bypass surgery) COL4A3BP intron 23643386 rs181686584 chr5 74725808 C T 0.000000285 Menopause (age at onset) COL4A3BP intron 23424626 rs4385188 chr5 74734362 A G 4.30E-08 Triglycerides COL4A3BP intron 19060911 rs4385188 chr5 74734362 A G 1.44E-13 Cholesterol,total COL4A3BP intron 23063622 rs4385188 chr5 74734362 A G 2.28E-11 LDL cholesterol COL4A3BP intron 23063622 rs6872314 chr5 74736065 A C 4.48E-08 Triglycerides COL4A3BP intron 19060911 rs4704220 chr5 74757556 G A 8.05E-06 Lipid levels COL4A3BP intron 19913121 rs4704220 chr5 74757556 G A 8.17E-05 Lipid levels COL4A3BP intron 19913121 rs4704220 chr5 74757556 G A 0.000000104 Body mass index COL4A3BP intron 23001569 rs4704220 chr5 74757556 G A 2.04E-22 LDL cholesterol COL4A3BP intron 23063622 rs4704220 chr5 74757556 G A 4.49E-27 Cholesterol,total COL4A3BP intron 23063622 rs10061689 chr5 74771387 G A 3.40E-04 Type 2 diabetes COL4A3BP intron 17463246 rs10942739 chr5 74786083 G A 1.57E-04 Weight loss (gastric bypass surgery) COL4A3BP intron 23643386 rs6896136 chr5 74787310 T C 7.87E-17 Triglycerides COL4A3BP intron 19060911 rs6896136 chr5 74787310 T C 7.69E-05 LDL lipoproteins COL4A3BP intron pha002902 rs6891560 chr5 74796757 G A 2.97E-04 Type 2 diabetes COL4A3BP intron 17463246 rs10055011 chr5 74798156 G A 3.56E-09 Triglycerides COL4A3BP intron 19060911 rs1988728 chr5 74868562 C T 5.58E-04 Smoking initiation POLK intron 24665060 rs5744680 chr5 74879890 G A 3.68E-09 Lipid levels POLK intron 19936222 rs5744680 chr5 74879890 G A 8.76E-09 Lipid levels POLK intron 19936222 rs5744712 chr5 74892002 T C 1.84E-04 Type 2 diabetes POLK intron 17463246 rs1051795 chr5 74896798 G A 9.99E-09 Triglycerides / / 19060911 rs1051795 chr5 74896798 G A 3.99E-04 Smoking initiation / / 24665060 rs4045166 chr5 74909446 C G 8.31E-06 Body mass index / / 19557197 rs904743 chr5 74917862 A G 9.25E-11 Triglycerides ANKDD1B intron 19060911 rs9293656 chr5 74925162 C T 5.78E-04 Smoking initiation ANKDD1B intron 24665060 rs34341 chr5 74934009 A T 3.82E-06 Body mass index ANKDD1B intron 19557197 rs253411 chr5 74954633 A T 1.33E-05 Brain derived neurotrophic factor levels,in serum ANKDD1B intron 22047184 rs253412 chr5 74955841 G A 1.06E-05 Brain derived neurotrophic factor levels,in serum ANKDD1B intron 22047184 rs253414 chr5 74956517 C T 5.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ANKDD1B intron 20877124 rs253414 chr5 74956517 C T 1.02E-05 Brain derived neurotrophic factor levels,in serum ANKDD1B intron 22047184 rs11750595 chr5 74963600 T C 1.07E-05 Cognitive test performance ANKDD1B intron 20125193 rs34358 chr5 74965122 G A 2.23E-08 Triglycerides ANKDD1B STOP-GAIN 19060911 rs34358 chr5 74965122 G A 2.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ANKDD1B STOP-GAIN 20877124 rs34358 chr5 74965122 G A 3.62E-05 Brain derived neurotrophic factor levels,in serum ANKDD1B STOP-GAIN 22047184 rs42302 chr5 74965554 A G 2.03E-05 Brain derived neurotrophic factor levels,in serum ANKDD1B intron 22047184 rs40060 chr5 74967386 C T 1.98E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs34359 chr5 74967693 G C 1.97E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs34360 chr5 74967708 C A 1.97E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs17648910 chr5 74970556 T G 6.71E-06 Cognitive test performance POC5 intron 20125193 rs888786 chr5 74970850 G A 5.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) POC5 intron 20877124 rs16872768 chr5 74982207 T C 1.50E-05 Brain derived neurotrophic factor levels,in serum POC5 intron 22047184 rs888789 chr5 74988369 A G 4.00E-06 Body mass index POC5 intron 24861553 rs10057967 chr5 74997756 T C 1.30E-05 Brain derived neurotrophic factor levels,in serum POC5 intron 22047184 rs6874626 chr5 74999576 G A 1.32E-05 Brain derived neurotrophic factor levels,in serum POC5 intron 22047184 rs3797580 chr5 75003056 A G 1.16E-05 Brain derived neurotrophic factor levels,in serum POC5 intron 22047184 rs2307111 chr5 75003678 T C 3.00E-12 Obesity POC5 missense 23563607 rs2112347 chr5 75015242 T G 2.00E-13 Body mass index / / 20935630 rs2112347 chr5 75015242 T G 1.53E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs2112347 chr5 75015242 T G 2.17E-13 Body mass index / / 23001569 rs2112347 chr5 75015242 T G 1.00E-08 Obesity / / 23563607 rs2112347 chr5 75015242 T G 4.00E-09 Obesity / / 23563607 rs6453143 chr5 75023210 G C 3.00E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7730516 chr5 75030034 G A 3.63E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7715806 chr5 75034387 C T 7.90E-06 Body mass index / / 19557197 rs7715806 chr5 75034387 C T 5.75E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs258494 chr5 75038718 C G 1.30E-09 LDL cholesterol / / 21977987 rs258494 chr5 75038718 C G 1.80E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs11960372 chr5 75226481 G A 2.25E-04 Multiple complex diseases / / 17554300 rs4425488 chr5 75294346 T C 4.28E-04 Alzheimer's disease (late onset) / / 21379329 rs11750465 chr5 75300224 A G 3.40E-04 Alzheimer's disease (late onset) / / 21379329 rs4074651 chr5 75304492 G A 5.28E-05 Serum metabolites / / 19043545 rs1393204 chr5 75336411 G A 8.16E-04 Multiple complex diseases / / 17554300 rs6896716 chr5 75374223 C T 7.64E-05 Multiple complex diseases / / 17554300 rs1021782 chr5 75423550 G A 3.07E-04 Body mass index SV2C intron 17255346 rs10070440 chr5 75427935 G A 9.03E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12522597 chr5 75431699 G A 6.60E-05 Personality dimensions SV2C intron 18957941 rs17746851 chr5 75433601 C T 9.67E-05 Type 2 diabetes SV2C intron 17463246 rs13170945 chr5 75441524 C G 9.52E-04 Suicide attempts in bipolar disorder SV2C intron 21423239 rs13179555 chr5 75448194 C A 6.97E-04 Suicide attempts in bipolar disorder SV2C intron 21423239 rs13184915 chr5 75456411 C T 6.28E-04 Suicide attempts in bipolar disorder SV2C intron 21423239 rs13167138 chr5 75458297 C T 6.77E-04 Suicide attempts in bipolar disorder SV2C intron 21423239 rs10072459 chr5 75462736 A G 5.73E-04 Age-related macular degeneration SV2C intron 22125219 rs12653182 chr5 75465507 G C 8.27E-04 Suicide attempts in bipolar disorder SV2C intron 21423239 rs2055439 chr5 75475258 T C 6.53E-04 Suicide attempts in bipolar disorder SV2C intron 21423239 rs10514062 chr5 75478216 T A 2.44E-04 Self-employment SV2C intron 23593239 rs2358531 chr5 75479786 G A 1.42E-04 Self-employment SV2C intron 23593239 rs17651269 chr5 75483144 C G 8.14E-04 Suicide attempts in bipolar disorder SV2C intron 21423239 rs12153396 chr5 75485855 A G 8.08E-04 Suicide attempts in bipolar disorder SV2C intron 21423239 rs7703461 chr5 75493412 C T 7.60E-05 Multiple complex diseases SV2C intron 17554300 rs4704296 chr5 75502410 G C 6.00E-06 Migraine - clinic-based SV2C intron 23793025 rs4703699 chr5 75505950 G A 3.10E-04 Diabetic nephropathy SV2C intron 20347642 rs4703699 chr5 75505950 G A 8.66E-04 Suicide attempts in bipolar disorder SV2C intron 21423239 rs6870971 chr5 75518429 T C 9.84E-06 Waist circumference SV2C intron 19557197 rs6870971 chr5 75518429 T C 2.30E-05 Urinary metabolites SV2C intron 21572414 rs981113 chr5 75520928 T G 9.82E-07 Waist circumference SV2C intron 19557197 rs10059683 chr5 75521600 A G 2.19E-06 Waist circumference SV2C intron 19557197 rs10066756 chr5 75521810 G C 2.04E-06 Waist circumference SV2C intron 19557197 rs10068332 chr5 75521980 G A 2.04E-06 Waist circumference SV2C intron 19557197 rs11952928 chr5 75531403 C T 1.93E-04 Smoking initiation SV2C intron 24665060 rs6879020 chr5 75545035 A G 9.20E-05 Triglycerides SV2C intron pha003081 rs6862529 chr5 75551209 C T 4.75E-05 Triglycerides SV2C intron pha003081 rs10064140 chr5 75562798 C T 4.39E-05 Triglycerides SV2C intron pha003081 rs2937715 chr5 75568053 A G 5.70E-06 Urinary metabolites SV2C intron 21572414 rs2972843 chr5 75602391 C A 6.08E-04 Type 2 diabetes SV2C intron 17463246 rs1971744 chr5 75611597 C T 5.53E-04 Type 2 diabetes SV2C intron 17463246 rs2972850 chr5 75612005 C T 3.38E-04 Type 2 diabetes SV2C intron 17463246 rs3733860 chr5 75622814 C A 8.00E-06 Venous thromboembolism / / 23650146 rs2913251 chr5 75623689 A G 5.19E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs10805900 chr5 75626370 G A 6.55E-05 Potassium levels / / pha003086 rs2913248 chr5 75632745 G A 2.61E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs73117804 chr5 75649280 C T 9.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs9293683 chr5 75700310 C T 1.40E-04 Type 2 diabetes IQGAP2 intron 17463246 rs3886043 chr5 75704085 G A 8.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IQGAP2 intron 20877124 rs4296785 chr5 75710783 C T 0.0003 Coronary artery calcification IQGAP2 intron 23727086 rs6865628 chr5 75718214 T A 5.95E-04 Multiple complex diseases IQGAP2 intron 17554300 rs6453220 chr5 75718828 C T 3.23E-04 Multiple complex diseases IQGAP2 intron 17554300 rs10044370 chr5 75719788 G A 8.03E-04 Multiple complex diseases IQGAP2 intron 17554300 rs10072221 chr5 75720544 T C 5.39E-04 Multiple complex diseases IQGAP2 intron 17554300 rs10077372 chr5 75720649 G A 9.14E-04 Multiple complex diseases IQGAP2 intron 17554300 rs10038589 chr5 75769258 T C 5.60E-04 Multiple complex diseases IQGAP2 intron 17554300 rs10038589 chr5 75769258 T C 9.66E-04 Response to taxane treatment (placlitaxel) IQGAP2 intron 23006423 rs6859984 chr5 75769568 C T 4.89E-04 Response to taxane treatment (placlitaxel) IQGAP2 intron 23006423 rs5009957 chr5 75770419 G A 1.60E-05 Urinary metabolites IQGAP2 intron 21572414 rs10942782 chr5 75781290 T C 2.82E-04 Alcohol dependence IQGAP2 intron 20201924 rs13154264 chr5 75785264 A G 1.35E-04 Response to taxane treatment (placlitaxel) IQGAP2 intron 23006423 rs7710225 chr5 75801337 G A 7.52E-04 Alzheimer's disease IQGAP2 intron 24755620 rs10035948 chr5 75828859 G C 0.000067 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) IQGAP2 intron 23233654 rs10035948 chr5 75828859 G C 4.06E-04 Methotrexate clearance (acute lymphoblastic leukemia) IQGAP2 intron 23233662 rs16873461 chr5 75834448 T C 8.38E-05 Response to cytadine analogues (cytosine arabinoside) IQGAP2 intron 24483146 rs4704327 chr5 75836032 A G 1.18E-04 Response to cytadine analogues (cytosine arabinoside) IQGAP2 intron 24483146 rs2202113 chr5 75837297 T A 0.0003082 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) IQGAP2 intron 23233654 rs2202113 chr5 75837297 T A 3.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) IQGAP2 intron 23233662 rs9293688 chr5 75839165 C T 0.0002501 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) IQGAP2 intron 23233654 rs9293688 chr5 75839165 C T 2.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) IQGAP2 intron 23233662 rs10064543 chr5 75839369 G A 0.0002489 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) IQGAP2 intron 23233654 rs10064543 chr5 75839369 G A 2.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) IQGAP2 intron 23233662 rs16873476 chr5 75840039 T C 1.91E-04 Response to cytadine analogues (cytosine arabinoside) IQGAP2 intron 24483146 rs12513951 chr5 75840225 C T 0.0001934 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) IQGAP2 intron 23233654 rs12513951 chr5 75840225 C T 1.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) IQGAP2 intron 23233662 rs3885957 chr5 75848393 T C 0.0002117 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) IQGAP2 intron 23233654 rs3885957 chr5 75848393 T C 2.12E-04 Methotrexate clearance (acute lymphoblastic leukemia) IQGAP2 intron 23233662 rs10044688 chr5 75850020 G A 4.34E-04 Type 2 diabetes IQGAP2 intron 17463246 rs10942784 chr5 75854050 C A 4.80E-05 Amyotrophic lateral sclerosis IQGAP2 intron 17671248 rs10072548 chr5 75855218 C T 0.000025 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) IQGAP2 intron 23233654 rs10072548 chr5 75855218 C T 2.50E-05 Methotrexate clearance (acute lymphoblastic leukemia) IQGAP2 intron 23233662 rs7710523 chr5 75856773 T A 0.0000369 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) IQGAP2 intron 23233654 rs7710523 chr5 75856773 T A 3.69E-05 Methotrexate clearance (acute lymphoblastic leukemia) IQGAP2 intron 23233662 rs4704336 chr5 75863619 A G 4.00E-04 Amyotrophic lateral sclerosis IQGAP2 intron 17671248 rs7735089 chr5 75868904 G C 0.0000384 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) IQGAP2 intron 23233654 rs7735089 chr5 75868904 G C 3.84E-05 Methotrexate clearance (acute lymphoblastic leukemia) IQGAP2 intron 23233662 rs3756514 chr5 75871279 G T 3.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) IQGAP2 intron 23648065 rs3797373 chr5 75872448 T C 0.0003268 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) IQGAP2 intron 23233654 rs3797373 chr5 75872448 T C 3.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) IQGAP2 intron 23233662 rs3797376 chr5 75873569 A G 0.0000302 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) IQGAP2 intron 23233654 rs3797376 chr5 75873569 A G 3.02E-05 Methotrexate clearance (acute lymphoblastic leukemia) IQGAP2 intron 23233662 rs17680811 chr5 75874655 T C 4.56E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) IQGAP2 intron 23648065 rs12109754 chr5 75875379 A G 0.0000312 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) IQGAP2 intron 23233654 rs12109754 chr5 75875379 A G 3.12E-05 Methotrexate clearance (acute lymphoblastic leukemia) IQGAP2 intron 23233662 rs17748322 chr5 75875629 T C 8.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) IQGAP2 intron 23648065 rs1501788 chr5 75890020 C T 5.78E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) IQGAP2 intron 23648065 rs6888854 chr5 75892749 C T 2.76E-04 Type 2 diabetes IQGAP2 intron 17463246 rs3797385 chr5 75899214 A T 3.24E-05 Type 2 diabetes IQGAP2 intron 17463246 rs2069698 chr5 75916887 C T 2.96E-04 Response to platinum-based chemotherapy in small-cell lung cancer F2RL2 intron 20463552 rs2069656 chr5 75917633 A G 8.04E-05 Smoking initiation F2RL2 intron 24665060 rs2069655 chr5 75917720 G A 5.74E-04 Taste perception F2RL2 intron 22132133 rs457717 chr5 75920972 A G 4.00E-07 Hearing impairment IQGAP2 intron 20068591 rs17567779 chr5 75925916 G A 7.94E-05 Attention deficit hyperactivity disorder IQGAP2 intron 22420046 rs3797418 chr5 75935414 G T 3.93E-04 Response to cytadine analogues (cytosine arabinoside) IQGAP2 intron 24483146 rs2059221 chr5 75941762 A G 9.23E-04 Lymphocyte counts IQGAP2 intron 22286170 rs460562 chr5 75942990 G T 9.63E-04 Response to cytadine analogues (cytosine arabinoside) IQGAP2 intron 24483146 rs456801 chr5 75943257 T C 3.75E-04 Response to cytadine analogues (cytosine arabinoside) IQGAP2 intron 24483146 rs457745 chr5 75949805 T A 6.94E-05 Response to cytadine analogues (cytosine arabinoside) IQGAP2 intron 24483146 rs462307 chr5 75950193 A G 7.44E-05 Response to cytadine analogues (cytosine arabinoside) IQGAP2 intron 24483146 rs465731 chr5 75950707 G A 4.65E-04 Response to cytadine analogues (cytosine arabinoside) IQGAP2 intron 24483146 rs3797446 chr5 75959063 G A 4.68E-04 Alzheimer's disease IQGAP2 intron 24755620 rs6869755 chr5 75959469 C T 3.36E-04 Suicide attempts in bipolar disorder IQGAP2 intron 21423239 rs6890835 chr5 75959705 A G 6.51E-04 Suicide attempts in bipolar disorder IQGAP2 intron 21423239 rs6873558 chr5 75960097 G A 5.58E-04 Suicide attempts in bipolar disorder IQGAP2 intron 21423239 rs4704350 chr5 75962386 G A 1.22E-04 Suicide attempts in bipolar disorder IQGAP2 intron 21423239 rs7734335 chr5 75967232 A G 0.000084 Migraine IQGAP2 intron 22678113 rs7734335 chr5 75967232 A G 8.40E-05 Migraine IQGAP2 intron 22683712 rs17652917 chr5 75968099 C T 5.84E-05 Blood Pressure IQGAP2 intron pha003047 rs2287933 chr5 75970219 A C 1.50E-04 Suicide attempts in bipolar disorder IQGAP2 intron 21423239 rs10805907 chr5 75982670 T C 2.98E-05 Body Mass Index IQGAP2 intron pha003020 rs468648 chr5 75996865 A G 2.83E-05 Brain structure IQGAP2 intron 22504417 rs2227777 chr5 76020200 A G 7.54E-14 LDL cholesterol F2R intron 23063622 rs2227831 chr5 76023494 A G 1.00E-15 Mean platelet volume F2R intron 22139419 rs2227831 chr5 76023494 A G 9.00E-04 Mean platelet volume F2R intron 24026423 rs2227811 chr5 76033266 T C 5.16E-05 Multiple complex diseases / / 17554300 rs17568628 chr5 76046939 T C 1.00E-09 Platelet counts / / 22139419 rs2054192 chr5 76048623 A G 9.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs615986 chr5 76093207 C T 2.17E-05 Common variable immunodeficiency / / 21497890 rs2243060 chr5 76128367 G A 7.70E-04 Coronary heart disease F2RL1 intron 21966275 rs2243083 chr5 76129303 A G 0.000000189 Triglycerides F2RL1 missense 23063622 rs2243083 chr5 76129303 A G 8.39E-10 HDL cholesterol F2RL1 missense 23063622 rs2460498 chr5 76141779 A G 7.87E-05 Hypertension / / 21082022 rs2460508 chr5 76156381 T C 1.10E-05 Schizophrenia S100Z intron 21791550 rs2460508 chr5 76156381 T C 0.0000024 Psychosis S100Z intron 23164818 rs7722773 chr5 76187308 G A 7.13E-05 Cognitive performance S100Z intron 19734545 rs17749734 chr5 76187777 G A 6.06E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) S100Z intron 20877124 rs2460504 chr5 76224171 G C 5.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1700687 chr5 76233004 C T 3.90E-04 Asthma / / 20698975 rs2055627 chr5 76234644 G A 4.02E-04 Amyotrophic lateral sclerosis / / 23624525 rs3792738 chr5 76247784 C A 2.19E-05 Parkinson's disease / / pha002868 rs32897 chr5 76250972 T C 1.88E-05 Amyotrophic lateral sclerosis CRHBP intron 23624525 rs1875999 chr5 76264982 T C 8.80E-04 Asthma CRHBP UTR-3 20698975 rs1053989 chr5 76265035 C A 7.17E-05 Parent of origin effect on language impairment (paternal) CRHBP UTR-3 24571439 rs1035887 chr5 76303699 C T 1.05E-04 Telomere length / / 21573004 rs13178527 chr5 76311858 T C 6.08E-05 Major depressive disorder (broad) / / 20038947 rs13178527 chr5 76311858 T C 8.55E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11743718 chr5 76317553 C T 9.99E-05 Acute lung injury / / 22295056 rs247754 chr5 76319217 A G 8.89E-05 Acute lung injury / / 22295056 rs382543 chr5 76323206 C T 3.37E-04 Acute lung injury / / 22295056 rs3762982 chr5 76323488 T C 1.22E-04 Acute lung injury / / 22295056 rs17682661 chr5 76324766 T C 1.36E-04 Acute lung injury AGGF1 nearGene-5 22295056 rs17682661 chr5 76324766 T C 6.69E-05 Asthma AGGF1 nearGene-5 23181788 rs2278241 chr5 76326885 G A 4.04E-04 Acute lung injury AGGF1 intron 22295056 rs3934500 chr5 76393896 C T 4.03E-04 Multiple complex diseases LOC728723 intron 17554300 rs3934500 chr5 76393896 C T 5.44E-06 Bipolar disorder,schizoaffective LOC728723 intron 19567891 rs13170206 chr5 76395815 A C 9.60E-06 Bipolar disorder,schizoaffective LOC728723 intron 19567891 rs13154602 chr5 76395917 C A 5.53E-04 Multiple complex diseases LOC728723 intron 17554300 rs13154602 chr5 76395917 C A 2.99E-06 Bipolar disorder,schizoaffective LOC728723 intron 19567891 rs6453278 chr5 76417042 G A,T 6.28E-04 Bipolar disorder,schizoaffective LOC728723 intron 19567891 rs4128573 chr5 76423217 A C 9.66E-17 Varicose Veins LOC728723 intron pha001414 rs4457053 chr5 76424949 G A 3.00E-12 Type 2 diabetes LOC728723 intron 20581827 rs4457053 chr5 76424949 G A 3.00E-12 Type 2 diabetes LOC728723 intron 21647700 rs4457053 chr5 76424949 G A 1.80E-10 Type 2 diabetes LOC728723 intron 22885922 rs4457053 chr5 76424949 G A 4.20E-08 Type 2 diabetes LOC728723 intron 23300278 rs7708285 chr5 76425867 G A 1.50E-10 Type 2 diabetes LOC728723 intron 22885922 rs7708285 chr5 76425867 G A 0.000000012 Fasting blood glucose LOC728723 intron 22885924 rs12521058 chr5 76426987 C A 1.99E-04 Hemoglobin concentration LOC728723 intron 20534544 rs6878122 chr5 76427311 G A 0.0000033 Fasting blood glucose LOC728723 intron 22885922 rs6878122 chr5 76427311 G A 0.00023 Type 2 diabetes (females) LOC728723 intron 22885922 rs6878122 chr5 76427311 G A 2.60E-10 Type 2 diabetes (males) LOC728723 intron 22885922 rs6878122 chr5 76427311 G A 5.00E-11 Type 2 diabetes LOC728723 intron 22885922 rs6878122 chr5 76427311 G A 0.00000334 Fasting blood glucose LOC728723 intron 22885924 rs6878122 chr5 76427311 G A 6.30E-05 Type 2 diabetes LOC728723 intron 24509480 rs10052560 chr5 76430302 G A 1.99E-04 Hemoglobin concentration LOC728723 intron 20534544 rs7707527 chr5 76430636 C G 7.59E-05 IgE levels LOC728723 intron 22075330 rs4426900 chr5 76460800 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs16874057 chr5 76469106 G A 3.48E-04 Gallstones / / 17632509 rs6453292 chr5 76480761 G A 8.10E-05 Bipolar disorder / / 17486107 rs1382880 chr5 76504243 C G 4.44E-04 Multiple complex diseases / / 17554300 rs9687206 chr5 76515824 A G 8.21E-11 Thyroid function PDE8B intron 22494929 rs4704397 chr5 76518442 G A 2.00E-20 Thyroid stimulating hormone PDE8B intron 18514160 rs4704397 chr5 76518442 G A 2.00E-06 Hypothyroidism PDE8B intron 22493691 rs4704397 chr5 76518442 G A 3.82E-10 Thyroid function PDE8B intron 22494929 rs1382879 chr5 76521868 T C 4.40E-06 Hypothyroidism PDE8B intron 22493691 rs1382879 chr5 76521868 T C 7.79E-13 Thyroid function PDE8B intron 22494929 rs1479567 chr5 76528022 G A 7.65E-13 Thyroid function PDE8B intron 22494929 rs6885099 chr5 76530349 A G 3.10E-06 Hypothyroidism PDE8B intron 22493691 rs6885099 chr5 76530349 A G 6.92E-13 Thyroid function PDE8B intron 22494929 rs6885099 chr5 76530349 A G 2.00E-26 Thyroid hormone levels PDE8B intron 23408906 rs6885099 chr5 76530349 A G 3.00E-38 Thyroid hormone levels PDE8B intron 23408906 rs6885099 chr5 76530349 A G 6.00E-24 Thyroid hormone levels PDE8B intron 23408906 rs2061909 chr5 76531648 C A 7.60E-13 Thyroid function PDE8B intron 22494929 rs70988661 chr5 76531648 C CA 7.60E-13 Thyroid function PDE8B intron 22494929 rs2046045 chr5 76535811 T G 4.70E-06 Hypothyroidism PDE8B intron 22493691 rs2046045 chr5 76535811 T G 3.00E-27 Thyroid function PDE8B intron 22494929 rs10056404 chr5 76539997 T C 2.79E-11 Thyroid function PDE8B intron 22494929 rs11950697 chr5 76540496 T A 4.00E-11 Thyroid function PDE8B intron 22494929 rs10037599 chr5 76541325 A C 1.10E-05 Hypothyroidism PDE8B intron 22493691 rs10037599 chr5 76541325 A C 5.79E-13 Thyroid function PDE8B intron 22494929 rs10036386 chr5 76543603 C T 1.25E-09 Thyroid function PDE8B intron 22494929 rs6867654 chr5 76543768 G A 1.35E-09 Thyroid function PDE8B intron 22494929 rs1351284 chr5 76544051 A C 1.52E-09 Thyroid function PDE8B intron 22494929 rs1479565 chr5 76544157 G A 1.59E-09 Thyroid function PDE8B intron 22494929 rs1479564 chr5 76544412 A G 1.78E-09 Thyroid function PDE8B intron 22494929 rs1351283 chr5 76544942 A G 4.89E-08 Thyroid function PDE8B intron 22494929 rs989758 chr5 76544960 G A 1.90E-05 Hypothyroidism PDE8B intron 22493691 rs989758 chr5 76544960 G A 7.84E-08 Thyroid function PDE8B intron 22494929 rs7729842 chr5 76547212 C T 5.77E-08 Thyroid function PDE8B intron 22494929 rs1096752 chr5 76549558 T C 5.08E-05 Orofacial clefts PDE8B intron 22419666 rs4704400 chr5 76551010 T C 4.30E-05 Type 2 diabetes PDE8B intron 17460697 rs832790 chr5 76568292 C A 3.90E-05 Hypothyroidism PDE8B intron 22493691 rs832790 chr5 76568292 C A 8.89E-08 Thyroid function PDE8B intron 22494929 rs1479597 chr5 76594514 A G 4.81E-04 Multiple complex diseases PDE8B intron 17554300 rs10074631 chr5 76618380 A C 1.00E-06 Parkinson's disease (interaction with coffee consumption) PDE8B intron 21876681 rs10474500 chr5 76620002 G A 5.95E-05 Serum metabolites PDE8B intron 19043545 rs7717216 chr5 76623931 A G 4.95E-04 Multiple complex diseases PDE8B intron 17554300 rs10514096 chr5 76665184 G A 1.10E-04 Blood Pressure and Arterial Stiffness PDE8B intron 17903302 rs4704417 chr5 76695327 T G 9.50E-04 Multiple complex diseases PDE8B intron 17554300 rs6874493 chr5 76701739 A G 2.24E-04 Type 2 diabetes PDE8B intron 22238593 rs9293713 chr5 76705255 G A 5.77E-04 Multiple complex diseases PDE8B intron 17554300 rs890717 chr5 76712575 T C 9.13E-04 Suicide attempts in bipolar disorder PDE8B intron 21423239 rs335643 chr5 76718070 T G 4.69E-04 Parkinson's disease PDE8B intron 17052657 rs6860843 chr5 76718697 G C 9.36E-05 Obesity (extreme) PDE8B intron 21935397 rs2114950 chr5 76726202 A G 3.38E-04 Glaucoma (primary open-angle) / / 22922875 rs335628 chr5 76729538 C G 3.21E-06 Lymphocyte counts WDR41 intron 22286170 rs2169140 chr5 76778108 C T 2.35E-05 Multiple complex diseases WDR41 intron 17554300 rs2169139 chr5 76778146 C T 1.67E-05 Multiple complex diseases WDR41 intron 17554300 rs163030 chr5 76781471 A C 2.00E-07 Caudate nucleus volume WDR41 intron 21502949 rs2359879 chr5 76805269 C A 2.12E-05 Major depressive disorder / / 20516156 rs6453313 chr5 76807505 A C 4.70E-04 Multiple complex diseases / / 17554300 rs4432863 chr5 76826794 C G 1.31E-04 Multiple complex diseases / / 17554300 rs17603636 chr5 76835647 T G 7.24E-04 Multiple complex diseases / / 17554300 rs12655063 chr5 76865969 C A 1.10E-04 Hemoglobin concentration / / 20534544 rs10474519 chr5 76893947 C T 5.45E-05 Type 2 diabetes and other traits / / 19734900 rs10474519 chr5 76893947 C T 3.45E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12019306 chr5 76895830 C T 9.61E-04 Type 2 diabetes / / 17463246 rs3933483 chr5 76903692 T C 1.53E-05 Creatinine levels / / pha003069 rs1422406 chr5 76945406 A C 9.72E-04 Multiple complex diseases / / 17554300 rs385375 chr5 76973108 A G 3.26E-04 Response to alcohol consumption (flushing response) / / 24277619 rs351871 chr5 76976039 A G 3.82E-07 Autism / / 22843504 rs13156814 chr5 76979394 C A 2.07E-05 Glycosylated haemoglobin levels / / 17255346 rs16874482 chr5 76981809 G T 6.61E-06 Glycosylated haemoglobin levels / / 17255346 rs2652212 chr5 77017623 A T 1.38E-05 Lymphocyte counts TBCA intron 22286170 rs11954532 chr5 77026166 G A 9.77E-05 Glycosylated haemoglobin levels TBCA intron 17255346 rs458403 chr5 77052232 G A 9.37E-04 Type 2 diabetes TBCA intron 17463246 rs7719017 chr5 77052630 C T 7.03E-05 Glycosylated haemoglobin levels TBCA intron 17255346 rs254411 chr5 77079857 C T 6.27E-05 Serum metabolites / / 19043545 rs16874658 chr5 77080632 C T 7.46E-04 Multiple complex diseases / / 17554300 rs423449 chr5 77100977 T G 2.95E-05 Body mass index / / 24827717 rs353958 chr5 77113617 G A 5.22E-04 Aortic root size / / 21223598 rs353967 chr5 77120058 C T 3.75E-04 Response to alcohol consumption (flushing response) / / 24277619 rs10514122 chr5 77128654 C T 6.70E-05 Smoking initiation / / 24665060 rs6881736 chr5 77144066 A G 3.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6881736 chr5 77144066 A G 5.22E-04 Smoking quantity / / 24665060 rs6877994 chr5 77146981 C G 4.50E-04 Smoking quantity / / 24665060 rs10514124 chr5 77159396 G A 5.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2289599 chr5 77208149 A G 1.20E-05 Amyotrophic Lateral Sclerosis / / 17362836 rs5014235 chr5 77209661 T C 9.00E-06 Amyotrophic Lateral Sclerosis / / 17362836 rs4704458 chr5 77210168 G A 2.56E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4704458 chr5 77210168 G A 4.47E-04 Type 2 diabetes / / 17463246 rs7712357 chr5 77224666 T C 5.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7712357 chr5 77224666 T C 5.64E-05 Prostate cancer / / pha002878 rs355447 chr5 77228136 G T 9.63E-06 Kawasaki disease / / 21221998 rs10044946 chr5 77247878 G T 1.14E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10044946 chr5 77247878 G T 1.72E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6864833 chr5 77266289 A G 2.17E-05 Coronary heart disease / / pha003056 rs6884769 chr5 77274512 T C 2.47E-05 Hearing function / / 17255346 rs16874965 chr5 77283893 G C 1.76E-06 Multiple complex diseases / / 17554300 rs12655917 chr5 77291940 G A 3.94E-04 Body mass index / / 21701565 rs12655917 chr5 77291940 G A 6.00E-07 Insulin resistance / / 21901158 rs252761 chr5 77380723 G T 6.13E-04 Parkinson's disease AP3B1 intron 21044948 rs425102 chr5 77396400 T G 9.78E-04 Multiple complex diseases AP3B1 intron 17554300 rs12656439 chr5 77501715 T C 6.85E-04 Smoking cessation AP3B1 intron 24665060 rs10039931 chr5 77514173 C A 5.24E-04 Parkinson's disease AP3B1 intron 21044948 rs6881634 chr5 77630854 G A 2.00E-06 Hippocampal atrophy / / 19668339 rs4235708 chr5 77677603 G C 1.40E-04 Lymphocyte counts SCAMP1 intron 22286170 rs1159929 chr5 77768820 G A 7.63E-04 Type 2 diabetes SCAMP1 intron 17463246 rs10065805 chr5 77769002 C G 1.10E-04 Response to antidepressants SCAMP1 intron 19736353 rs6874309 chr5 77774498 T A 7.57E-04 Type 2 diabetes SCAMP1 UTR-3 17463246 rs1050674 chr5 77783089 G C 2.00E-04 Response to antidepressants LHFPL2 UTR-3 19736353 rs10044028 chr5 77794750 A G 4.94E-04 Type 2 diabetes LHFPL2 intron 17463246 rs11738126 chr5 77797646 A C 1.30E-05 Urinary metabolites LHFPL2 intron 21572414 rs9293752 chr5 77798432 C T 3.28E-04 Type 2 diabetes LHFPL2 intron 17463246 rs10474554 chr5 77799158 C T 5.20E-04 Type 2 diabetes LHFPL2 intron 17463246 rs10474555 chr5 77799193 C T 4.59E-04 Type 2 diabetes LHFPL2 intron 17463246 rs16875564 chr5 77809331 G C 9.50E-06 Urinary metabolites LHFPL2 intron 21572414 rs1346565 chr5 77816976 C G 1.80E-05 Urinary metabolites LHFPL2 intron 21572414 rs344652 chr5 77848586 T C 9.20E-05 Personality dimensions LHFPL2 intron 18957941 rs344651 chr5 77852998 T C 9.34E-05 Bipolar disorder LHFPL2 intron 17486107 rs9293756 chr5 77918136 A C 1.00E-04 Cognitive impairment induced by topiramate LHFPL2 intron 22091778 rs341930 chr5 77937453 T C 4.93E-04 Myocardial Infarction LHFPL2 intron pha002883 rs784420 chr5 77987524 A G 8.00E-06 Economic and political preferences / / 22566634 rs569523 chr5 78024366 T C 4.08E-04 HIV-1 viral setpoint / / 17641165 rs2029905 chr5 78062410 A G 6.76E-05 Blood Pressure / / pha003048 rs7732938 chr5 78072760 A G 9.19E-05 Blood Pressure ARSB nearGene-3 pha003046 rs7704939 chr5 78074198 A C 8.00E-05 Suicidal ideation ARSB UTR-3 22030708 rs7727110 chr5 78095390 T C 7.22E-04 Myopia (pathological) ARSB intron 21095009 rs16875947 chr5 78100800 A T 0.00000098 Change in depression severity with Norepinephrine reuptake inhibitors (NRI) ARSB intron 23091423 rs7711802 chr5 78102483 G A 8.49E-04 Multiple complex diseases ARSB intron 17554300 rs7711802 chr5 78102483 G A 0.00000105 Change in depression severity with Norepinephrine reuptake inhibitors (NRI) ARSB intron 23091423 rs16876279 chr5 78103605 C T 0.00000098 Change in depression severity with Norepinephrine reuptake inhibitors (NRI) ARSB intron 23091423 rs6453417 chr5 78110532 C T 5.00E-06 Attention deficit hyperactivity disorder ARSB intron 23728934 rs337835 chr5 78180482 C T 9.13E-04 Suicide attempts in bipolar disorder ARSB intron 21423239 rs10039384 chr5 78181174 G A 6.18E-04 Suicide attempts in bipolar disorder ARSB intron 21423239 rs180049 chr5 78181850 T C 5.58E-04 Parkinson's disease ARSB intron 17052657 rs337875 chr5 78194997 C T 1.59E-05 Coronary heart disease ARSB intron pha003030 rs337875 chr5 78194997 C T 5.02E-05 Coronary heart disease ARSB intron pha003031 rs234688 chr5 78199454 C A 1.24E-05 Coronary heart disease ARSB intron pha003030 rs234688 chr5 78199454 C A 8.83E-05 Coronary heart disease ARSB intron pha003031 rs10052939 chr5 78204065 T C 2.50E-05 Urinary metabolites ARSB intron 21572414 rs337888 chr5 78228199 A G 8.37E-05 Lymphocyte counts ARSB intron pha003094 rs337887 chr5 78229036 C T 8.37E-05 Lymphocyte counts ARSB intron pha003094 rs12658000 chr5 78234830 T G 7.80E-06 Urinary metabolites ARSB intron 21572414 rs337865 chr5 78245106 A G 3.47E-04 Multiple complex diseases ARSB intron 17554300 rs234687 chr5 78253122 A G 9.31E-05 Lymphocyte counts ARSB intron pha003094 rs337847 chr5 78259888 G A 7.00E-06 Hippocampal atrophy ARSB intron 19668339 rs921945 chr5 78261957 A G 8.72E-05 Neutrophil count ARSB intron pha003095 rs13178105 chr5 78268128 C T 8.17E-05 Hemoglobin ARSB intron pha003098 rs2052550 chr5 78272942 T C 8.00E-06 Iron status biomarkers ARSB intron 19084217 rs1841991 chr5 78276148 T C 6.39E-04 Multiple complex diseases ARSB intron 17554300 rs1717570 chr5 78276474 A G 9.65E-04 Multiple complex diseases ARSB intron 17554300 rs163125 chr5 78282670 G A 3.83E-05 Lymphocyte counts ARSB nearGene-5 pha003094 rs163125 chr5 78282670 G A 9.24E-05 Neutrophil count ARSB nearGene-5 pha003095 rs28326 chr5 78295854 T G 7.17E-04 White matter integrity DMGDH intron 22425255 rs479405 chr5 78302859 C A 4.06E-05 Coronary heart disease DMGDH intron pha003031 rs653275 chr5 78308731 A G 5.90E-07 Urinary metabolites DMGDH intron 21572414 rs2034900 chr5 78315964 G A 3.62E-04 Response to alcohol consumption (flushing response) DMGDH intron 24277619 rs10514153 chr5 78316430 C T 9.20E-04 Type 2 diabetes DMGDH intron 17846124 rs921943 chr5 78316476 C T 9.00E-28 Blood trace element (Se levels) DMGDH intron 23720494 rs16876318 chr5 78318710 C T 4.17E-05 Multiple complex diseases DMGDH intron 17554300 rs10514154 chr5 78323434 A G 3.62E-04 Response to alcohol consumption (flushing response) DMGDH intron 24277619 rs248386 chr5 78330227 C A 1.10E-07 Urinary metabolites DMGDH intron 21572414 rs248383 chr5 78339755 C T 1.58E-04 Myopia (pathological) DMGDH intron 21095009 rs248383 chr5 78339755 C T 1.01E-04 Response to alcohol consumption (flushing response) DMGDH intron 24277619 rs532964 chr5 78340286 A G 1.60E-04 Myopia (pathological) DMGDH missense 21095009 rs17823642 chr5 78341297 C T 2.00E-09 Metabolite levels (Glycine metabolism) DMGDH intron 23378610 rs16876394 chr5 78346769 T C 1.00E-19 Blood metabolite levels DMGDH intron 24816252 rs673752 chr5 78367092 T C 4.00E-07 Urinary metabolites BHMT2 intron 21572414 rs486580 chr5 78367424 T C 1.10E-06 Urinary metabolites BHMT2 intron 21572414 rs626105 chr5 78369901 A G 1.20E-04 Atopy BHMT2 intron 21625490 rs575425 chr5 78389912 A G 2.49E-05 Coronary heart disease / / pha003031 rs631305 chr5 78403378 T C 7.35E-04 Multiple complex diseases / / 17554300 rs631305 chr5 78403378 T C 9.70E-07 Urinary metabolites / / 21572414 rs631305 chr5 78403378 T C 3.36E-04 White matter integrity / / 22425255 rs16876503 chr5 78404401 A G 2.60E-04 Alzheimer's disease / / 17998437 rs492842 chr5 78409987 C T 5.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BHMT intron 20877124 rs492842 chr5 78409987 C T 6.31E-06 Coronary heart disease BHMT intron pha003031 rs7700970 chr5 78411324 C T 1.72E-18 Blood trace element (Se levels) BHMT intron 23720494 rs506500 chr5 78414337 T C 1.60E-06 Urinary metabolites BHMT intron 21572414 rs506500 chr5 78414337 T C 8.00E-12 Blood trace element (Se levels) BHMT intron 23720494 rs6860725 chr5 78419809 T C 2.00E-07 Urinary metabolites BHMT intron 21572414 rs949645 chr5 78442522 T A 6.38E-04 Type 2 diabetes / / 22158537 rs1291041 chr5 78443735 G T 9.81E-04 Type 2 diabetes / / 22158537 rs10079160 chr5 78479709 A C 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs13354432 chr5 78521044 A G 2.25E-04 Insulin resistance / / 21901158 rs9885487 chr5 78639376 C T 9.83E-04 Multiple complex diseases / / 17554300 rs9885487 chr5 78639376 C T 0.000023 Salmonella-induced pyroptosis / / 22837397 rs9885025 chr5 78639435 A G 0.000018 Salmonella-induced pyroptosis / / 22837397 rs9293775 chr5 78641253 C A 0.000689 Salmonella-induced pyroptosis / / 22837397 rs10474583 chr5 78662084 A G 2.69E-04 Multiple complex diseases / / 17554300 rs6879014 chr5 78663158 C T 6.19E-05 Coronary heart disease / / pha003035 rs11743792 chr5 78666513 G A 3.74E-04 Multiple complex diseases / / 17554300 rs12187625 chr5 78673236 T C 2.25E-04 Parkinson's disease HOMER1 intron 16252231 rs12187625 chr5 78673236 T C 2.88E-05 Coronary heart disease HOMER1 intron pha003035 rs7719054 chr5 78728923 T C 2.90E-05 Response to antidepressants HOMER1 intron 19736353 rs10078095 chr5 78756778 T C 3.00E-06 Height HOMER1 intron 18193045 rs11948804 chr5 78803778 C T 3.74E-04 Coronary heart disease HOMER1 intron 21971053 rs7713917 chr5 78829249 A G 1.00E-06 Major depressive disorder / / 20673876 rs7704425 chr5 78831504 G A 2.80E-05 Urinary metabolites / / 21572414 rs10942894 chr5 78831995 G A 1.40E-05 Urinary metabolites / / 21572414 rs41527045 chr5 78832082 G A 2.60E-05 Urinary metabolites / / 21572414 rs13358260 chr5 78845711 T C 5.00E-06 Adiponectin levels / / 21700879 rs6894248 chr5 78853921 C T 3.70E-06 Urinary metabolites / / 21572414 rs7704901 chr5 78876335 T C 3.70E-05 Intelligence / / 21826061 rs6859704 chr5 78943648 G A,C 8.00E-06 IgG glycosylation PAPD4 intron 23382691 rs9784710 chr5 78994362 C T 3.98E-05 HDL particle features CMYA5 intron pha002900 rs16877062 chr5 78998903 C T 5.72E-04 Type 2 diabetes CMYA5 intron 17463246 rs10942901 chr5 79025157 A G 1.78E-05 Heart rate CMYA5 frameshift 23583979 rs6453484 chr5 79081713 A G 4.04E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CMYA5 intron 20031582 rs1129770 chr5 79086883 G A 9.67E-05 Heart Rate CMYA5 missense pha003053 rs2287673 chr5 79088995 A G 3.31E-05 Major depressive disorder CMYA5 intron 21621269 rs7343 chr5 79095721 G A 8.29E-05 Multiple complex diseases CMYA5 UTR-3 17554300 rs746486 chr5 79098186 G A 3.35E-04 Alcohol dependence / / 21314694 rs259067 chr5 79098998 C T 1.00E-06 Obesity / / 23818313 rs7735699 chr5 79099464 A C 6.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs7735699 chr5 79099464 A C 1.78E-05 Schizophrenia / / pha002857 rs259065 chr5 79100717 A G 9.40E-05 Malaria / / 19465909 rs4704591 chr5 79103471 G C 7.73E-04 Multiple complex diseases / / 17554300 rs4704591 chr5 79103471 G C 9.29E-05 Bipolar disorder and schizophrenia / / 20889312 rs393062 chr5 79105154 G A 8.70E-06 Urinary metabolites / / 21572414 rs17471700 chr5 79106163 A C 2.65E-04 Multiple complex diseases / / 17554300 rs17471700 chr5 79106163 A C 7.11E-05 Major depressive disorder (broad) / / 20038947 rs17471700 chr5 79106163 A C 1.73E-05 Major depressive disorder / / 21621269 rs265010 chr5 79137177 G A 2.67E-04 Alzheimer's disease / / pha002879 rs9790975 chr5 79137792 G T 8.54E-06 Serum metabolites / / 19043545 rs10491456 chr5 79152076 G A 4.92E-04 Type 2 diabetes / / 17463246 rs10491456 chr5 79152076 G A 5.30E-05 Serum metabolites / / 19043545 rs7727189 chr5 79154114 G C 4.87E-04 Type 2 diabetes / / 17463246 rs7727189 chr5 79154114 G C 7.17E-05 Serum metabolites / / 19043545 rs264985 chr5 79170601 C T 7.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6888630 chr5 79175246 A G 1.09E-04 Multiple complex diseases / / 17554300 rs16877319 chr5 79190176 T C 5.04E-05 Hepatocellular carcinoma / / 22807686 rs1032342 chr5 79251343 C A 9.68E-05 Blood Pressure / / pha003043 rs6453494 chr5 79260219 C T 9.22E-05 Blood Pressure / / pha003043 rs1017998 chr5 79263211 A G 8.37E-05 Blood Pressure / / pha003043 rs10064975 chr5 79277215 A G 9.93E-07 Lymphocyte counts MTX3 UTR-3 22286170 rs10064975 chr5 79277215 A G 1.16E-04 Amyotrophic lateral sclerosis (sporadic) MTX3 UTR-3 24529757 rs1438739 chr5 79288995 A G 7.45E-05 Blood Pressure / / pha003043 rs6878264 chr5 79307752 C T 7.80E-05 Response to statin therapy / / 20339536 rs385771 chr5 79320677 T C 1.80E-05 Urinary metabolites / / 21572414 rs366471 chr5 79320878 A G 1.80E-05 Urinary metabolites / / 21572414 rs256447 chr5 79339951 T C 1.00E-05 Urinary metabolites THBS4 intron 21572414 rs256444 chr5 79341162 A C 1.30E-05 Urinary metabolites THBS4 intron 21572414 rs12332694 chr5 79341989 C A 2.71E-05 HIV-1 progression THBS4 intron 20064070 rs16877442 chr5 79344618 T C 4.68E-05 Elbow pain THBS4 intron pha003008 rs404375 chr5 79348759 G A 8.00E-05 Asperger disorder THBS4 intron 21182207 rs10474606 chr5 79352986 G A 4.70E-04 Diabetic nephropathy THBS4 intron 20347642 rs401302 chr5 79355471 C T 7.08E-05 Asthma THBS4 intron pha003127 rs443095 chr5 79362550 G A 5.00E-05 Blood pressure THBS4 intron 21060006 rs443095 chr5 79362550 G A 6.80E-04 Blood pressure THBS4 intron 21060006 rs12110039 chr5 79368392 A G 6.20E-05 Tooth agenesis (maxillary third molar) THBS4 intron 24172245 rs2288395 chr5 79375724 G C 5.37E-04 Type 2 diabetes THBS4 intron 17463246 rs10514175 chr5 79376231 G A 6.30E-05 Blood Pressure THBS4 intron pha003043 rs2438632 chr5 79392193 G T 4.03E-04 Acute lung injury / / 22295056 rs6865426 chr5 79398709 C T 9.04E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2099651 chr5 79398911 G A 6.89E-04 Stroke / / pha002886 rs421837 chr5 79401417 T C 2.28E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs4703798 chr5 79412328 T C 7.50E-06 Serum alpha1-antitrypsin levels SERINC5 intron 23990791 rs2289290 chr5 79422105 G A 1.07E-04 Multiple complex diseases SERINC5 intron 17554300 rs10053887 chr5 79437621 A C 7.90E-05 Bipolar disorder SERINC5 UTR-3 19488044 rs6882423 chr5 79444409 T G 9.36E-07 Borderline personality disorder features SERINC5 intron 23979607 rs6866910 chr5 79446102 G A 5.03E-07 Borderline personality disorder features SERINC5 intron 23979607 rs73772260 chr5 79446904 G A 3.61E-07 Borderline personality disorder features SERINC5 intron 23979607 rs73772260 chr5 79446904 G A 4.00E-07 Borderline personality disorder features SERINC5 intron 23979607 rs6888413 chr5 79448082 G T 4.10E-07 Borderline personality disorder features SERINC5 intron 23979607 rs6894288 chr5 79449099 G T 7.41E-07 Borderline personality disorder features SERINC5 intron 23979607 rs73125991 chr5 79457403 T A 1.27E-06 Borderline personality disorder features SERINC5 intron 23979607 rs11951568 chr5 79459101 C T 2.85E-06 Borderline personality disorder features SERINC5 intron 23979607 rs74582458 chr5 79489573 C T 0.0000589 Nonsyndromic striae distensae (stretch marks) SERINC5 intron 23633020 rs6876176 chr5 79495456 C T 7.77E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SERINC5 intron 20031582 rs4704633 chr5 79496939 C A 4.08E-04 White matter integrity SERINC5 intron 22425255 rs12519047 chr5 79498180 C A 4.78E-04 White matter integrity SERINC5 intron 22425255 rs6860041 chr5 79501150 A T 9.46E-04 Acute lung injury SERINC5 intron 22295056 rs10058567 chr5 79503869 T C 9.46E-04 Acute lung injury SERINC5 intron 22295056 rs13188069 chr5 79504689 G A 2.62E-04 Fibrinogen SERINC5 intron 17255346 rs17259420 chr5 79506057 G A 9.06E-05 Prostate cancer SERINC5 intron 22923026 rs6872447 chr5 79507194 G A 6.33E-05 Coronary heart disease SERINC5 intron pha003033 rs6872447 chr5 79507194 G A 5.75E-05 Serum albumin level SERINC5 intron pha003084 rs16877607 chr5 79512268 A C 9.32E-04 Acute lung injury SERINC5 intron 22295056 rs13157900 chr5 79654971 A C 3.50E-20 Health and aging,CVD and cancer age of onset / / 22174011 rs13157900 chr5 79654971 A C 4.20E-13 Health and aging,CVD and cancer age of onset / / 22174011 rs13157900 chr5 79654971 A C 7.10E-20 Health and aging,CVD and cancer age of onset / / 22174011 rs16877757 chr5 79683363 G A 6.61E-04 Type 2 diabetes / / 17463246 rs16877757 chr5 79683363 G A 6.18E-05 Bipolar disorder,affective / / 20528957 rs1423113 chr5 79694829 C A 2.81E-04 Type 2 diabetes / / 17463246 rs1423113 chr5 79694829 C A 7.74E-06 Bipolar disorder,affective / / 20528957 rs171821 chr5 79697210 T C 1.12E-05 Bipolar disorder,affective / / 20528957 rs259043 chr5 79697808 G T 9.13E-06 Bipolar disorder,affective / / 20528957 rs259025 chr5 79720762 G C 2.11E-06 Bipolar disorder,affective ZFYVE16 intron 20528957 rs259024 chr5 79720786 C T 3.67E-04 Type 2 diabetes ZFYVE16 intron 17463246 rs259024 chr5 79720786 C T 7.74E-06 Bipolar disorder,affective ZFYVE16 intron 20528957 rs259023 chr5 79721557 G T 2.76E-04 Type 2 diabetes ZFYVE16 intron 17463246 rs259023 chr5 79721557 G T 7.74E-06 Bipolar disorder,affective ZFYVE16 intron 20528957 rs259033 chr5 79739685 G A 1.75E-05 Bipolar disorder,affective ZFYVE16 intron 20528957 rs248995 chr5 79800322 C T 1.63E-06 Bipolar disorder,affective FAM151B intron 20528957 rs148781457 chr5 79809558 G T 0.00028 Breast cancer FAM151B missense 23555315 rs9687094 chr5 79841683 T C 7.27E-05 Multiple complex diseases / / 17554300 rs2405867 chr5 79888450 G A 2.22E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs2405867 chr5 79888450 G A 7.67E-05 Heart Rate / / pha003051 rs70991108 chr5 79950163 C CTGGCGCGTCCCGCCCAGGT 1 Drug response to Folic Acid DHFR intron 18247058 rs70991108 chr5 79950163 C CTGGCGCGTCCCGCCCAGGT 1 Drug response to Methotrexate DHFR intron 19648163 rs380691 chr5 79952034 A G 8.10E-07 Lymphocyte counts MSH3 intron 22286170 rs380691 chr5 79952034 A G 5.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) MSH3 intron 23648065 rs380691 chr5 79952034 A G 0.00034 Coronary artery calcification MSH3 intron 23727086 rs6151627 chr5 79965536 A G 8.00E-04 Atrial fibrillation MSH3 intron 21846873 rs1805355 chr5 79966029 G A 3.04E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) MSH3 cds-synon 23648065 rs6151640 chr5 79967129 C G 2.09E-04 Multiple complex diseases MSH3 intron 17554300 rs2195291 chr5 79975483 T G 7.21E-08 Metabolite levels MSH3 intron 23281178 rs836817 chr5 79992418 A C 1.40E-05 Urinary metabolites MSH3 intron 21572414 rs865644 chr5 80000152 A G 5.50E-06 Urinary metabolites MSH3 intron 21572414 rs1428030 chr5 80008704 T C 4.94E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) MSH3 intron 23648065 rs33013 chr5 80060016 G A 6.00E-04 Chronic fatigue syndrome MSH3 intron 21912186 rs245403 chr5 80069930 A G 4.97E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) MSH3 intron 24023788 rs245408 chr5 80072451 G A 3.55E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) MSH3 intron 24023788 rs6151826 chr5 80080681 A G 2.47E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) MSH3 intron 23648065 rs3797896 chr5 80093800 C G 4.02E-06 Multiple complex diseases MSH3 intron 17554300 rs2306371 chr5 80109258 T C 1.20E-04 Alcohol dependence MSH3 intron 20201924 rs2306371 chr5 80109258 T C 5.90E-04 Alcohol dependence MSH3 intron 20201924 rs6151896 chr5 80121646 G T 1.90E-04 Alcohol dependence MSH3 intron 20201924 rs6151896 chr5 80121646 G T 6.70E-04 Alcohol dependence MSH3 intron 20201924 rs3797898 chr5 80123311 C T 1.80E-04 Alcohol dependence MSH3 intron 20201924 rs3797898 chr5 80123311 C T 6.60E-04 Alcohol dependence MSH3 intron 20201924 rs249633 chr5 80126153 A G 3.19E-04 Mammographic density MSH3 intron 22532574 rs6874652 chr5 80130712 C T 1.80E-04 Alcohol dependence MSH3 intron 20201924 rs6874652 chr5 80130712 C T 6.30E-04 Alcohol dependence MSH3 intron 20201924 rs16878204 chr5 80168005 T C 2.57E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) MSH3 intron 23648065 rs27385 chr5 80169672 C T 5.50E-05 Mammographic density MSH3 intron 22532574 rs12522063 chr5 80187929 T G 4.22E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs16878216 chr5 80188765 C G 6.04E-04 Multiple complex diseases / / 17554300 rs6864713 chr5 80201284 G A 7.11E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs372735391 chr5 80203678 A AAGGAATGAAGAAAAAAAGGAGAAAC 5.99E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7737445 chr5 80203678 A C 5.99E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12513906 chr5 80231585 T G 3.38E-05 Suicidal ideation / / 20877300 rs3991138 chr5 80241653 T G 5.77E-06 Central corneal thickness / / 20719862 rs2161221 chr5 80241899 T C 5.40E-06 Central corneal thickness / / 20719862 rs960990 chr5 80244913 C T 4.55E-06 Central corneal thickness / / 20719862 rs888821 chr5 80256909 T C 5.91E-06 Central corneal thickness RASGRF2 intron 20719862 rs517880 chr5 80262170 T C 4.37E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) RASGRF2 intron 24023788 rs7717830 chr5 80278998 G T 2.87E-05 Vascular dementia RASGRF2 intron 22116812 rs11741039 chr5 80286370 G A 8.85E-04 Insulin resistance RASGRF2 intron 21901158 rs701394 chr5 80296487 A G 9.70E-06 Urinary metabolites RASGRF2 intron 21572414 rs528441 chr5 80299561 C A 1.70E-05 Urinary metabolites RASGRF2 intron 21572414 rs6879497 chr5 80300524 A G 5.18E-04 Type 2 diabetes RASGRF2 intron 17463246 rs547899 chr5 80301228 G A 8.30E-06 Urinary metabolites RASGRF2 intron 21572414 rs539983 chr5 80311519 G A 5.50E-06 Urinary metabolites RASGRF2 intron 21572414 rs506598 chr5 80315670 G A 4.29E-04 Nicotine dependence RASGRF2 intron 17158188 rs473139 chr5 80317020 A G 1.80E-06 Urinary metabolites RASGRF2 intron 21572414 rs10491487 chr5 80323368 T G 3.65E-08 Vascular dementia RASGRF2 intron 22116812 rs34973 chr5 80343441 A G 7.89E-05 Personality dimensions RASGRF2 intron 18957941 rs2592093 chr5 80344844 T C 6.00E-05 Magnesium levels RASGRF2 intron pha003092 rs26906 chr5 80364887 T C 4.01E-07 Vascular dementia RASGRF2 intron 22116812 rs17211233 chr5 80368763 T C 1.48E-04 Urinary albumin excretion rate in type 1 diabetes RASGRF2 intron 24595857 rs11741062 chr5 80370772 A C 4.75E-04 Lung function (forced expiratory volume in 1 second) RASGRF2 intron 17255346 rs7733625 chr5 80382806 G T 4.22E-05 Alcohol dependence RASGRF2 intron 19581569 rs540564 chr5 80403392 G A 9.76E-05 Orofacial clefts RASGRF2 intron 22419666 rs540564 chr5 80403392 G A 8.00E-04 Response to alcohol consumption (flushing response) RASGRF2 intron 24277619 rs138206701 chr5 80406566 A G 1.00E-07 Eating disorders (purging via substances) RASGRF2 intron 23568457 rs138206701 chr5 80406566 A G 4.00E-06 Eating disorders RASGRF2 intron 23568457 rs4704699 chr5 80410276 C T 6.65E-05 Orofacial clefts RASGRF2 intron 22419666 rs4703822 chr5 80411221 G A 4.00E-06 Orofacial clefts RASGRF2 intron 22419666 rs153239 chr5 80425860 G A 3.90E-05 HIV-1 control RASGRF2 intron 20041166 rs153236 chr5 80427640 C T 6.65E-05 HIV-1 control RASGRF2 intron 20041166 rs42430 chr5 80442724 G T 3.52E-05 Postoperative ventricular dysfunction RASGRF2 intron 21980348 rs369844 chr5 80447626 A G 2.01E-04 Alzheimer's disease RASGRF2 intron 17998437 rs13353953 chr5 80462407 A G 8.32E-06 Malignant mesothelioma RASGRF2 intron 23827383 rs12697916 chr5 80462439 G A 8.05E-06 Malignant mesothelioma RASGRF2 intron 23827383 rs10942943 chr5 80462935 G T 7.89E-06 Malignant mesothelioma RASGRF2 intron 23827383 rs1379270 chr5 80468463 C T 1.38E-06 Malignant mesothelioma RASGRF2 intron 23827383 rs11952133 chr5 80471121 T G 2.97E-06 Malignant mesothelioma RASGRF2 intron 23827383 rs10514211 chr5 80482514 A G 5.00E-04 Chronic fatigue syndrome RASGRF2 intron 21912186 rs17227696 chr5 80488122 G A 6.56E-04 Response to taxane treatment (placlitaxel) RASGRF2 intron 23006423 rs17228156 chr5 80502903 T C 8.00E-06 Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure) RASGRF2 intron 21130132 rs17228156 chr5 80502903 T C 0.0000661 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RASGRF2 intron 23233654 rs17228156 chr5 80502903 T C 6.61E-05 Methotrexate clearance (acute lymphoblastic leukemia) RASGRF2 intron 23233662 rs750728 chr5 80529756 C T 4.43E-04 Multiple complex diseases CKMT2 intron 17554300 rs2897390 chr5 80530817 C T 3.43E-05 Multiple complex diseases CKMT2 intron 17554300 rs16876403 chr5 80535750 C T 0.0000743 Panic disorder CKMT2 intron 23149450 rs16876403 chr5 80535750 C T 7.43E-05 Serum tamsulosin hydrochloride concentration CKMT2 intron 23151678 rs2277037 chr5 80538143 G A 0.0000997 Panic disorder CKMT2 intron 23149450 rs2277037 chr5 80538143 G A 9.97E-05 Serum tamsulosin hydrochloride concentration CKMT2 intron 23151678 rs10041063 chr5 80545341 A G 3.79E-04 Multiple complex diseases CKMT2 intron 17554300 rs4704717 chr5 80551423 A G 2.00E-04 Cognitive impairment induced by topiramate CKMT2 intron 22091778 rs12514420 chr5 80612629 T C 0.0000242 Panic disorder / / 23149450 rs12514420 chr5 80612629 T C 2.42E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs6868743 chr5 80616472 G T 0.000051 Panic disorder / / 23149450 rs6868743 chr5 80616472 G T 5.10E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs4502795 chr5 80619534 T A 0.0000604 Panic disorder / / 23149450 rs4502795 chr5 80619534 T A 6.04E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs7729671 chr5 80648695 G A 3.00E-06 Smoking initiation ACOT12 intron 24665060 rs7706593 chr5 80650890 G T 9.39E-04 Multiple complex diseases ACOT12 intron 17554300 rs4703516 chr5 80654966 T G 3.38E-04 HIV-1 viral setpoint ACOT12 intron 17641165 rs4703516 chr5 80654966 T G 1.87E-05 Orofacial clefts ACOT12 intron 20023658 rs4703516 chr5 80654966 T G 3.00E-06 Orofacial clefts ACOT12 intron 22863734 rs10942262 chr5 80675496 G A 4.50E-04 Coronary heart disease ACOT12 intron 21966275 rs7732320 chr5 80719125 C T 1.00E-06 Glioblastoma SSBP2 intron 22472174 rs445410 chr5 81068474 G A 5.76E-04 Smoking initiation / / 24665060 rs457008 chr5 81074655 C T 7.50E-05 Birth weight / / 17255346 rs457008 chr5 81074655 C T 6.96E-06 Anorexia nervosa / / 21079607 rs457008 chr5 81074655 C T 3.37E-06 Osteoarthritis / / 22763110 rs457008 chr5 81074655 C T 4.27E-04 Smoking initiation / / 24665060 rs410644 chr5 81087534 G T 1.61E-04 Birth weight / / 17255346 rs410644 chr5 81087534 G T 7.00E-06 Anorexia nervosa / / 21079607 rs10514222 chr5 81131428 A G 7.42E-04 Smoking initiation / / 24665060 rs17241969 chr5 81146156 T C 7.67E-04 Smoking initiation / / 24665060 rs2047733 chr5 81199750 C T 3.24E-04 Height / / 17255346 rs6452435 chr5 81202981 G A 8.31E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1001797 chr5 81203903 T C 8.31E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs687543 chr5 81220187 C T 4.63E-06 Vascular dementia / / 22116812 rs589080 chr5 81226548 A C 3.37E-06 Vascular dementia / / 22116812 rs589080 chr5 81226548 A C 4.40E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4410626 chr5 81232844 T C 1.75E-04 Multiple complex diseases / / 17554300 rs4410626 chr5 81232844 T C 2.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4703857 chr5 81234145 G A 4.91E-04 Alzheimer's disease (late onset) / / 21379329 rs4703858 chr5 81234197 A G 4.76E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4703859 chr5 81234311 T C 4.91E-04 Alzheimer's disease (late onset) / / 21379329 rs12153769 chr5 81246140 C T 4.28E-04 Alzheimer's disease (late onset) / / 21379329 rs1542596 chr5 81247381 G A 4.53E-05 Height / / 17255346 rs2101146 chr5 81253212 A C 1.66E-04 Alzheimer's disease (late onset) / / 21379329 rs10036653 chr5 81266382 A T 6.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs12108833 chr5 81371755 A G 1.49E-04 Lymphocyte counts ATG10 intron 22286170 rs4703871 chr5 81515446 T C 1.58E-04 Multiple complex diseases ATG10 intron 17554300 rs6888977 chr5 81533735 C T 3.17E-04 Gallstones ATG10 intron 17632509 rs2195448 chr5 81541238 C T 3.16E-04 Alzheimer's disease (late onset) ATG10 intron 21379329 rs12523353 chr5 81546918 C A 1.88E-10 Lymphocyte counts ATG10 intron 22286170 rs2215128 chr5 81595084 T C 8.44E-05 Height / / pha003011 rs658912 chr5 81612479 G A 6.07E-06 Personality dimensions ATP6AP1L intron 23658558 rs224833 chr5 81670407 T G 2.49E-05 Bipolar disorder / / 22925353 rs224833 chr5 81670407 T G 3.53E-04 Smoking quantity / / 24665060 rs224963 chr5 81693894 C T 5.15E-04 Multiple complex diseases / / 17554300 rs224962 chr5 81694346 A G 8.05E-04 Multiple complex diseases / / 17554300 rs13180039 chr5 81697020 T C 8.60E-06 Urinary metabolites / / 21572414 rs13158292 chr5 81702047 A G 8.69E-05 Cognitive test performance / / 20125193 rs13158292 chr5 81702047 A G 7.37E-04 White matter integrity / / 22425255 rs224952 chr5 81706460 T C 8.50E-04 Multiple complex diseases / / 17554300 rs224945 chr5 81714463 C T 5.97E-05 Bipolar disorder / / 22925353 rs224938 chr5 81717176 C T 9.60E-07 Opioid sensitivity / / 23183491 rs1476742 chr5 81720590 G A 8.69E-04 Diabetic retinopathy / / 20871662 rs2429239 chr5 81736795 A C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2429239 chr5 81736795 A C 4.90E-07 Opioid sensitivity / / 23183491 rs6452462 chr5 81809458 G A 0.00000884 HDL cholesterol particle diameter / / 23263444 rs1002042 chr5 81820460 T C 2.20E-05 Urinary metabolites / / 21572414 rs9293305 chr5 81849746 C T 0.00000465 HDL cholesterol particle diameter / / 23263444 rs6452464 chr5 81855821 T C 1.90E-05 Urinary metabolites / / 21572414 rs4703896 chr5 81856222 C T 2.20E-05 Urinary metabolites / / 21572414 rs4703897 chr5 81857276 G C 1.60E-05 Urinary metabolites / / 21572414 rs10062090 chr5 81870165 A G 2.85E-05 Aging (time to event) / / 21782286 rs4147321 chr5 81882571 C G 7.73E-08 Metabolite levels / / 23281178 rs1847052 chr5 81883470 T C 8.60E-05 Creatinine levels / / pha003069 rs16899741 chr5 81895731 A C 5.37E-04 Multiple complex diseases / / 17554300 rs10072866 chr5 81898168 C A 8.93E-04 Multiple complex diseases / / 17554300 rs6877560 chr5 81915301 A G 1.18E-04 Opioid sensitivity / / 23183491 rs4703905 chr5 81938017 G T 4.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1032757 chr5 81939318 G A 2.00E-06 Eosinophilic esophagitis (pediatric) / / 20208534 rs10514242 chr5 81958326 A G 2.69E-05 Serum metabolites / / 19043545 rs2055438 chr5 81962788 C T 7.44E-05 Scoliosis / / 21216876 rs2385957 chr5 81976414 G A 3.19E-04 Multiple complex diseases / / 17554300 rs1972039 chr5 81984337 A G 5.69E-04 Multiple complex diseases / / 17554300 rs1827389 chr5 81996724 C A,G,T 3.10E-04 Multiple complex diseases / / 17554300 rs7722067 chr5 81996913 T C 5.47E-05 Multiple complex diseases / / 17554300 rs168534 chr5 82004716 C T 2.73E-04 Multiple complex diseases / / 17554300 rs355285 chr5 82008501 G C 2.47E-04 Multiple complex diseases / / 17554300 rs6863156 chr5 82018271 G T 3.63E-04 Tourette syndrome / / 22889924 rs13176318 chr5 82034686 C T 6.99E-04 Coronary Artery Disease / / 17634449 rs1423515 chr5 82062544 G A 6.99E-05 Amyotrophic lateral sclerosis / / 20801717 rs1423515 chr5 82062544 G A 0.0000257 Amyotrophic lateral sclerosis / / 23587638 rs10514244 chr5 82070143 A C 6.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11954026 chr5 82084509 C T 5.95E-05 Bipolar Disorder / / pha002863 rs1862598 chr5 82094671 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11952923 chr5 82123527 C G 3.22E-06 Glaucoma (primary open-angle) / / 22605921 rs9293317 chr5 82157158 T C 3.25E-04 Multiple complex diseases / / 17554300 rs12517180 chr5 82158572 G T 9.13E-05 Multiple complex diseases / / 17554300 rs6880701 chr5 82169620 G A 8.82E-04 Taste perception / / 22132133 rs4383715 chr5 82177857 G A 6.98E-04 Taste perception / / 22132133 rs2656984 chr5 82189112 T C 5.30E-04 Myopia (pathological) / / 21095009 rs1875980 chr5 82190592 C A 8.20E-06 Urinary metabolites / / 21572414 rs2731841 chr5 82192191 A G 2.30E-05 Urinary metabolites / / 21572414 rs2731842 chr5 82192972 T C 5.84E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs37551 chr5 82220268 C T 6.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs37543 chr5 82237287 T A,C,G 2.21E-04 Type 2 diabetes / / 17463246 rs32880 chr5 82264985 G A 3.14E-04 Multiple complex diseases / / 17554300 rs10035349 chr5 82273379 G A 0.0000298 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4703941 chr5 82280498 T C 0.0000429 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1366566 chr5 82281043 A G 0.0000421 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6863505 chr5 82282675 T C 0.0000779 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6882635 chr5 82282683 G C 0.0000846 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4320239 chr5 82286335 A G 0.0000497 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2042976 chr5 82286965 C T 0.0000433 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2042975 chr5 82287036 C T 0.0000517 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11959656 chr5 82287304 T C 0.0000553 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6891678 chr5 82289348 G A 0.0000354 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6873419 chr5 82292889 G T 0.000062 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7736398 chr5 82309128 T C 2.92E-04 Cognitive decline / / 23732972 rs440499 chr5 82311564 C T 9.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9293327 chr5 82338006 T C 2.49E-20 Varicose Veins / / pha001412 rs255561 chr5 82350810 C A 3.90E-04 Breast cancer and prostate cancer TMEM167A UTR-3 17903305 rs255561 chr5 82350810 C A 9.42E-04 Bipolar disorder TMEM167A UTR-3 19259986 rs10474079 chr5 82373917 G A 1.12E-04 Response to cytadine analogues (cytosine arabinoside) XRCC4 intron 24483146 rs16900160 chr5 82396839 G A 3.71E-04 Suicide attempts in bipolar disorder XRCC4 intron 21423239 rs4703944 chr5 82401850 G A 3.65E-04 Suicide attempts in bipolar disorder XRCC4 intron 21423239 rs6452524 chr5 82433781 G A 2.00E-07 Hypertension XRCC4 intron 21626137 rs6887846 chr5 82436361 G A 2.00E-07 Hypertension XRCC4 intron 21626137 rs16900189 chr5 82438979 A C 3.67E-04 Suicide attempts in bipolar disorder XRCC4 intron 21423239 rs6866839 chr5 82441229 T G 8.04E-04 Suicide attempts in bipolar disorder XRCC4 intron 21423239 rs2126987 chr5 82451069 G A 7.44E-04 Suicide attempts in bipolar disorder XRCC4 intron 21423239 rs1382367 chr5 82451212 G A 8.10E-05 Lipid levels XRCC4 intron pha003082 rs10076056 chr5 82457521 T C 9.78E-04 Suicide attempts in bipolar disorder XRCC4 intron 21423239 rs13180316 chr5 82459453 G A 3.40E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) XRCC4 intron 24023788 rs13180316 chr5 82459453 G A 6.63E-04 Smoking cessation XRCC4 intron 24665060 rs925199 chr5 82495074 G C 7.14E-04 Suicide attempts in bipolar disorder XRCC4 intron 21423239 rs2089566 chr5 82502023 A G 5.80E-04 Suicide attempts in bipolar disorder XRCC4 intron 21423239 rs6891117 chr5 82529944 A G 5.35E-04 Suicide attempts in bipolar disorder XRCC4 intron 21423239 rs1193693 chr5 82537319 G A 8.26E-05 Suicide attempts in bipolar disorder XRCC4 intron 21423239 rs12515149 chr5 82537382 T G 4.43E-04 Suicide attempts in bipolar disorder XRCC4 intron 21423239 rs16900261 chr5 82543063 C T 5.43E-04 Suicide attempts in bipolar disorder XRCC4 intron 21423239 rs35256 chr5 82547602 A G 7.63E-04 Suicide attempts in bipolar disorder XRCC4 intron 21423239 rs10514252 chr5 82558592 C G 4.68E-04 Suicide attempts in bipolar disorder XRCC4 intron 21423239 rs1562227 chr5 82575673 A T 4.25E-04 Suicide attempts in bipolar disorder XRCC4 intron 21423239 rs6892929 chr5 82673682 C A 8.38E-04 Multiple complex diseases / / 17554300 rs1445780 chr5 82709977 T C 3.70E-06 Urinary metabolites / / 21572414 rs17284420 chr5 82713020 G C 1.00E-04 Nicotine smoking / / 19268276 rs924584 chr5 82744472 T C 2.33E-04 Longevity / / 22279548 rs28899 chr5 82763083 A G 2.99E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs1393084 chr5 82792520 T A 4.67E-05 Hypertension VCAN intron 19609347 rs2292013 chr5 82792625 A C 7.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VCAN intron 20877124 rs310511 chr5 82826722 T G 7.67E-04 Multiple complex diseases VCAN intron 17554300 rs529998 chr5 82841764 T C 1.09E-05 Menopause (age at onset) VCAN intron 19448619 rs529998 chr5 82841764 T C 0.000712542 Hypertension (early onset hypertension) VCAN intron 22479346 rs309586 chr5 82858047 T C 1.57E-04 Multiple complex diseases VCAN intron 17554300 rs12653308 chr5 82858828 A G 4.62E-04 Amyotrophic Lateral Sclerosis VCAN intron 17362836 rs13164785 chr5 82861400 T G 1.31E-04 Amyotrophic Lateral Sclerosis VCAN intron 17362836 rs160280 chr5 82862919 G A 8.41E-05 Multiple complex diseases VCAN intron 17554300 rs309585 chr5 82868173 G A 9.20E-04 Obesity (extreme) VCAN intron 21935397 rs309583 chr5 82870085 G C 9.22E-04 Obesity (extreme) VCAN intron 21935397 rs10514258 chr5 82871757 A G 8.33E-07 Polycystic ovary syndrome VCAN intron 21151128 rs310501 chr5 82889910 G A 7.00E-06 Major depressive disorder / / 20516156 rs6865544 chr5 82897384 T C 1.01E-07 Multiple complex diseases / / 17554300 rs309568 chr5 82897718 C T 7.49E-05 Type 2 diabetes and other traits / / 19734900 rs12697730 chr5 82908474 A G 6.76E-05 Type 2 diabetes and other traits / / 19734900 rs6864342 chr5 82937538 T C 6.27E-06 Multiple complex diseases HAPLN1 missense 17554300 rs3846635 chr5 82960734 A G 2.00E-06 Visceral fat HAPLN1 intron 22589738 rs336963 chr5 82969704 G A 2.60E-05 Longevity and age-related phenotypes HAPLN1 intron 17903295 rs6886442 chr5 82973210 C A 3.05E-05 Type 2 diabetes HAPLN1 intron 17463246 rs336958 chr5 82973396 T C 8.04E-04 Type 2 diabetes HAPLN1 intron 17463246 rs7735782 chr5 82980449 G A 3.87E-04 Myocardial Infarction HAPLN1 intron pha002883 rs4466137 chr5 82985739 T G 3.00E-06 Prostate cancer HAPLN1 intron 17903305 rs4466137 chr5 82985739 T G 8.14E-04 Alzheimer's disease HAPLN1 intron 17998437 rs4466137 chr5 82985739 T G 2.00E-04 Response to interferon beta in multiple sclerosis HAPLN1 intron 18195134 rs4466137 chr5 82985739 T G 3.00E-06 Nasopharyngeal carcinoma HAPLN1 intron 20512145 rs4466137 chr5 82985739 T G 0.00059 Prostate cancer HAPLN1 intron 23555315 rs4703961 chr5 82996199 C T 6.37E-04 Type 2 diabetes HAPLN1 intron 17463246 rs6869296 chr5 83007333 G C 3.17E-05 Type 2 diabetes HAPLN1 intron 17463246 rs1563551 chr5 83021826 A G 4.97E-04 Alcohol dependence / / 20201924 rs6882023 chr5 83139409 T G 7.92E-05 Orofacial clefts / / 19270707 rs10044480 chr5 83156500 C T 7.48E-04 Multiple complex diseases / / 17554300 rs6885336 chr5 83161278 G A 6.96E-04 Alcohol dependence / / 21314694 rs7726603 chr5 83170227 T C 6.69E-04 Type 2 diabetes / / 17463246 rs4552569 chr5 83173593 C T 9.00E-10 Ankylosing spondylitis / / 22138694 rs4368707 chr5 83232813 C A 4.50E-05 Left ventricular hypertrophy / / pha003052 rs4703977 chr5 83243314 G A 9.76E-05 Lung function (forced expiratory volume in 1 second) EDIL3 intron pha003103 rs4304064 chr5 83278874 T G 2.70E-06 Urinary metabolites EDIL3 intron 21572414 rs4703978 chr5 83326597 A T 3.22E-05 Schizophrenia EDIL3 intron pha002857 rs2301085 chr5 83341806 G A 2.20E-05 Urinary metabolites EDIL3 intron 21572414 rs4590163 chr5 83368290 G A 6.66E-05 Glucose levels EDIL3 intron pha003058 rs6859618 chr5 83381999 C T 0.000571 Salmonella-induced pyroptosis EDIL3 intron 22837397 rs1445744 chr5 83457674 A G 1.22E-04 Serum selenium levels EDIL3 intron 23698163 rs153253 chr5 83464348 C T 2.80E-05 Urinary metabolites EDIL3 intron 21572414 rs153248 chr5 83469915 T C 6.20E-04 Alcohol dependence EDIL3 intron 20201924 rs342405 chr5 83477654 G T 9.67E-05 Waist Circumference EDIL3 intron pha003024 rs342406 chr5 83482308 G A 3.30E-05 Personality dimensions EDIL3 intron 18957941 rs342406 chr5 83482308 G A 2.60E-06 Urinary metabolites EDIL3 intron 21572414 rs347344 chr5 83499643 T C 1.00E-06 Chemerin levels EDIL3 intron 20237162 rs347345 chr5 83500730 C T 9.96E-04 Multiple complex diseases EDIL3 intron 17554300 rs342418 chr5 83511806 C T 8.32E-04 Coronary heart disease EDIL3 intron 21971053 rs2121105 chr5 83523495 T C 4.97E-04 Fibrinogen EDIL3 intron 17255346 rs1159734 chr5 83529363 T C 0.0000103 HDL cholesterol particle diameter EDIL3 intron 23263444 rs3797655 chr5 83530071 C T 7.31E-04 Acute lung injury EDIL3 intron 22295056 rs3776886 chr5 83534642 A G 6.26E-04 Acute lung injury EDIL3 intron 22295056 rs16901000 chr5 83534911 T A 6.26E-04 Acute lung injury EDIL3 intron 22295056 rs3797652 chr5 83539860 G A 6.26E-04 Acute lung injury EDIL3 intron 22295056 rs1531259 chr5 83541281 A T 8.78E-04 Acute lung injury EDIL3 intron 22295056 rs1445754 chr5 83575631 T A 4.38E-04 Diabetic retinopathy EDIL3 intron 20871662 rs16901052 chr5 83616535 A T 4.77E-04 Multiple complex diseases EDIL3 intron 17554300 rs16901053 chr5 83616815 T C 8.12E-04 Myopia (pathological) EDIL3 intron 21095009 rs305661 chr5 83681037 C T 2.75E-04 Myopia (pathological) / / 21095009 rs974660 chr5 83702304 A G 2.86E-05 Blood Pressure / / pha003045 rs974660 chr5 83702304 A G 2.33E-05 Blood Pressure / / pha003047 rs10462410 chr5 83890606 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs72766477 chr5 83907229 G A 5.00E-07 Asthma and hay fever / / 24388013 rs10514267 chr5 83963326 T C 7.68E-04 Coronary heart disease / / 21971053 rs7713225 chr5 83974401 A C 8.45E-04 Type 2 diabetes / / 17463246 rs7710912 chr5 83978954 A G 1.49E-04 Type 2 diabetes / / 17463246 rs7727817 chr5 83982461 C A 1.61E-04 Type 2 diabetes / / 17463246 rs2386467 chr5 83991292 A G 1.56E-04 Type 2 diabetes / / 17463246 rs4533888 chr5 84010328 A T 8.80E-05 Personality dimensions / / 18957941 rs4293919 chr5 84023574 A G 0.0000663 Tuberculosis with early age of onset / / 22551897 rs4458567 chr5 84027805 A G 0.0000602 Tuberculosis with early age of onset / / 22551897 rs10462316 chr5 84030377 A C 0.0000706 Tuberculosis with early age of onset / / 22551897 rs7734550 chr5 84036064 C G 9.30E-05 Personality dimensions / / 18957941 rs6888165 chr5 84061023 T C 5.37E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6871305 chr5 84065374 T C 5.99E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6871305 chr5 84065374 T C 9.95E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7735534 chr5 84066833 A G 1.11E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs113524839 chr5 84084776 C T 8.00E-07 Alzheimer's disease biomarkers / / 23419831 rs7707956 chr5 84091283 C T 1.76E-04 Type 2 diabetes / / 17463246 rs4345320 chr5 84099716 C A 9.63E-05 Bipolar disorder / / 22925353 rs959670 chr5 84099828 C T 7.82E-04 Rheumatoid arthritis / / 21452313 rs4418103 chr5 84099867 A C 1.89E-14 Metabolite levels / / 22286219 rs4418103 chr5 84099867 A C 0.0000215 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4418103 chr5 84099867 A C 2.15E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4235661 chr5 84111924 A G 8.56E-04 Rheumatoid arthritis / / 21452313 rs4432885 chr5 84120872 T C 5.73E-04 Type 2 diabetes / / 17463246 rs4432885 chr5 84120872 T C 5.07E-05 Prostate cancer mortality / / 20978177 rs10063582 chr5 84166462 G A 3.09E-04 Type 2 diabetes / / 17463246 rs4235662 chr5 84167824 T C 1.05E-05 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs1605987 chr5 84216014 T C 5.43E-04 Alzheimer's disease / / 17998437 rs4331899 chr5 84231159 A G 6.21E-06 Type 2 diabetes / / 17463246 rs4331899 chr5 84231159 A G 6.84E-04 Multiple complex diseases / / 17554300 rs3913424 chr5 84234232 G A 4.47E-04 Alzheimer's disease / / 17998437 rs10085144 chr5 84240377 A G 0.000675425 Hypertension (early onset hypertension) / / 22479346 rs1858246 chr5 84251124 C T 2.39E-04 Alzheimer's disease / / 17998437 rs10070960 chr5 84266766 T C 3.70E-04 Body mass index / / 17255346 rs4704022 chr5 84270117 T C 5.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4704022 chr5 84270117 T C 4.49E-06 Post-operative nausea and vomiting / / 21694509 rs6872764 chr5 84305316 A C 7.41E-04 Type 2 diabetes / / 17463246 rs7444607 chr5 84335924 T A 3.27E-04 Type 2 diabetes / / 17463246 rs4920689 chr5 84409005 G C 2.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs7727192 chr5 84411618 C T 3.86E-04 Alzheimer's disease / / 22005930 rs4920821 chr5 84438604 G A 9.66E-05 Age-related macular degeneration / / pha002890 rs10056414 chr5 84439020 G A 6.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs10064396 chr5 84439094 T C 4.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs10058925 chr5 84440501 G C 9.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs10058933 chr5 84440531 G T 9.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs10040483 chr5 84443364 C T 9.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs9293425 chr5 84473732 T C 5.47E-05 Suicide attempts in bipolar disorder / / 21423239 rs13360020 chr5 84476243 G A 6.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs10068805 chr5 84480308 G A 2.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs6884538 chr5 84482974 G A 7.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6884538 chr5 84482974 G A 8.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12108773 chr5 84488565 T A 2.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs7733623 chr5 84490162 G A 3.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs10054183 chr5 84498196 C T 6.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs4608955 chr5 84503499 G A 4.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs4920737 chr5 84512521 A G 2.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs4920745 chr5 84516908 G A 3.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs4492144 chr5 84518245 T C 2.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs5007858 chr5 84519570 T C 6.57E-04 Alzheimer's disease / / 17998437 rs5007858 chr5 84519570 T C 3.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs4920749 chr5 84520002 G A 3.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs4920772 chr5 84558410 A T 5.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs4920781 chr5 84571181 A C 5.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs16901653 chr5 84583688 C T 2.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs12153606 chr5 84583769 G T 2.00E-06 Blood trace element (Cu levels) / / 23720494 rs17285111 chr5 84590616 A G 5.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs1486283 chr5 84596557 C T 7.08E-04 Multiple complex diseases / / 17554300 rs4920799 chr5 84606528 T C 7.00E-06 Echocardiographic traits / / 17903301 rs305742 chr5 84637517 G A 7.01E-04 Alzheimer's disease / / 17998437 rs177710 chr5 84701663 C T 7.12E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs247660 chr5 84758140 A C 7.30E-09 Crohn's disease / / 18587394 rs1604390 chr5 84763461 C T 7.24E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs507798 chr5 84811200 C G 4.80E-07 Facial morphology / / 22341974 rs612777 chr5 84811723 G A 4.80E-07 Facial morphology / / 22341974 rs413927 chr5 84813168 C T 4.80E-07 Facial morphology / / 22341974 rs488160 chr5 84814220 A G 4.80E-07 Facial morphology / / 22341974 rs800837 chr5 84817409 G A 1.52E-05 Alzheimer's disease / / 17998437 rs800837 chr5 84817409 G A 4.80E-07 Facial morphology / / 22341974 rs1697833 chr5 84818190 T G 4.90E-07 Facial morphology / / 22341974 rs405852 chr5 84818315 T C 4.90E-07 Facial morphology / / 22341974 rs373272 chr5 84818656 A G 4.90E-07 Facial morphology / / 22341974 rs395495 chr5 84820993 C T 4.90E-07 Facial morphology / / 22341974 rs576581 chr5 84822345 G A 4.90E-07 Facial morphology / / 22341974 rs596598 chr5 84822397 G C 4.90E-07 Facial morphology / / 22341974 rs425542 chr5 84822780 A T 2.64E-05 Alzheimer's disease / / 17998437 rs425542 chr5 84822780 A T 5.00E-07 Facial morphology / / 22341974 rs414692 chr5 84822809 T C 5.00E-07 Facial morphology / / 22341974 rs375536 chr5 84823277 C T 2.16E-05 Alzheimer's disease / / 17998437 rs479076 chr5 84826893 G A 2.11E-05 Alzheimer's disease / / 17998437 rs214296 chr5 84828913 A G 5.64E-04 Alzheimer's disease / / 17998437 rs467359 chr5 84833754 T G 4.11E-04 Alzheimer's disease / / 17998437 rs7726205 chr5 84860681 C T 9.60E-04 Multiple complex diseases / / 17554300 rs1428898 chr5 84865749 T C 8.91E-04 Multiple complex diseases / / 17554300 rs1428893 chr5 84869273 C G 1.99E-04 Body mass index / / 21701565 rs414536 chr5 84899446 A G 3.77E-06 Cognitive decline / / 23207651 rs413964 chr5 84925569 A C 9.16E-06 Cognitive decline / / 23207651 rs7718784 chr5 84966584 G A 5.98E-04 Body mass index / / 21701565 rs4920832 chr5 85043444 G A 5.78E-04 Stroke / / pha002887 rs17206761 chr5 85044268 T A 8.71E-04 Body mass index / / 21701565 rs17285314 chr5 85048330 T C 3.27E-04 Multiple complex diseases / / 17554300 rs1500148 chr5 85084936 C T 2.35E-05 Age-related macular degeneration / / pha002856 rs12520429 chr5 85132635 T C 8.33E-05 C-Reactive Protein / / pha003070 rs12523369 chr5 85132877 A G 8.56E-05 C-Reactive Protein / / pha003070 rs11949617 chr5 85158651 C A 4.56E-06 Cognitive decline / / 23207651 rs577680200 chr5 85158651 CATT C 4.56E-06 Cognitive decline / / 23207651 rs6877270 chr5 85168399 T G 7.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7700443 chr5 85172112 T G 7.53E-07 Cognitive decline / / 23207651 rs2974085 chr5 85197109 T C 9.71E-06 Response to amphetamines / / 22952603 rs1595564 chr5 85208760 T C 1.90E-05 Urinary metabolites / / 21572414 rs1583686 chr5 85217869 T C 1.00E-06 Obesity-related traits / / 23251661 rs73146464 chr5 85218186 G A 8.96E-06 Response to amphetamines / / 22952603 rs10043696 chr5 85218360 G A 2.40E-05 Urinary metabolites / / 21572414 rs113830031 chr5 85221835 G T 4.67E-06 Response to amphetamines / / 22952603 rs2898534 chr5 85231414 G A 3.60E-06 Urinary metabolites / / 21572414 rs2410709 chr5 85231473 A C 4.20E-06 Urinary metabolites / / 21572414 rs2898535 chr5 85231636 A G 4.20E-06 Urinary metabolites / / 21572414 rs893554 chr5 85232203 G A 2.50E-05 Urinary metabolites / / 21572414 rs7721932 chr5 85233991 T A 4.20E-06 Urinary metabolites / / 21572414 rs13186353 chr5 85266730 T G 4.60E-06 Urinary metabolites / / 21572414 rs11747694 chr5 85267123 G A 6.30E-06 Urinary metabolites / / 21572414 rs7718298 chr5 85267381 A C 1.40E-06 Post-operative nausea and vomiting / / 21694509 rs4920706 chr5 85270782 A G 1.37E-06 Post-operative nausea and vomiting / / 21694509 rs2974097 chr5 85333953 T A 1.30E-05 Mathematical ability / / 24801482 rs10942426 chr5 85370847 A C 1.60E-06 Urinary metabolites / / 21572414 rs11750318 chr5 85412640 T G 1.12E-06 Serum metabolites / / 19043545 rs16902074 chr5 85439065 T C 5.24E-04 Multiple complex diseases / / 17554300 rs17285531 chr5 85440517 G T 8.47E-04 Multiple complex diseases / / 17554300 rs987280 chr5 85448604 A G 7.97E-04 Multiple complex diseases / / 17554300 rs13181836 chr5 85467970 A G 1.50E-04 Type 2 diabetes / / 17463246 rs1363269 chr5 85475137 A G 6.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs34441754 chr5 85506147 C T 1.22E-04 Type 2 diabetes / / 17463246 rs13182191 chr5 85508862 G C 1.21E-04 Type 2 diabetes / / 17463246 rs2909866 chr5 85512273 T C 2.28E-04 Smoking initiation / / 24665060 rs2909866 chr5 85512273 T C 5.83E-05 Height / / pha003010 rs2909866 chr5 85512273 T C 3.45E-05 Height / / pha003011 rs11959230 chr5 85515333 C T 6.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs11748175 chr5 85519655 C T 1.33E-04 Type 2 diabetes / / 17463246 rs10069795 chr5 85541926 C T 8.00E-06 Stroke (ischemic) / / 22384361 rs10070239 chr5 85602617 G T 4.20E-06 Obesity,menopause / / 21424828 rs16902182 chr5 85611991 T C 2.53E-05 Left ventricular hypertrophy / / pha003052 rs7700699 chr5 85619565 T A 2.90E-06 Stroke (ischemic) / / 22384361 rs10514277 chr5 85631025 C A 3.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10514277 chr5 85631025 C A 4.25E-05 Left ventricular hypertrophy / / pha003052 rs16902198 chr5 85632931 A G 5.55E-04 Type 2 diabetes / / 17463246 rs7700535 chr5 85635829 C G 8.24E-04 Major depressive disorder / / 22472876 rs16902206 chr5 85642232 C T 7.07E-04 Type 2 diabetes / / 17463246 rs12657213 chr5 85655306 G A 8.07E-04 Smoking quantity / / 24665060 rs6888744 chr5 85681088 C T 1.58E-04 Smoking initiation / / 24665060 rs10059045 chr5 85687037 A C 7.35E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs33957059 chr5 85702852 T C 6.49E-04 Multiple complex diseases / / 17554300 rs114765196 chr5 85720729 G C 0.00006107 Sarcoidosis / / 22952805 rs1500258 chr5 85746871 A G 2.85E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs116662164 chr5 85757340 G A 0.00005875 Sarcoidosis / / 22952805 rs1553241 chr5 85764555 A C 5.35E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs2962878 chr5 85765522 T G 5.60E-05 Immunoglobulin A / / 20694011 rs17476297 chr5 85910124 A G 5.53E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs2195349 chr5 85942744 T C 8.86E-04 Type 2 diabetes / / 17463246 rs7733888 chr5 85943936 T C 2.50E-04 Alcohol dependence / / 20201924 rs9293471 chr5 85960197 G A 4.47E-04 Alzheimer's disease / / 17998437 rs10491416 chr5 85986822 C T 1.27E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16902356 chr5 86011404 C G 7.92E-04 Type 2 diabetes / / 17463246 rs16902363 chr5 86016527 T C 4.22E-04 Body mass index / / 21701565 rs7731832 chr5 86019612 T C 9.06E-04 Multiple complex diseases / / 17554300 rs9293478 chr5 86094715 C T 1.42E-05 Colorectal cancer / / 19723657 rs7726138 chr5 86122767 A G 5.44E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs11749320 chr5 86125940 T C 5.42E-04 Myocardial Infarction / / pha002873 rs10055138 chr5 86132101 A C 3.37E-04 Heart Failure / / pha002884 rs16902429 chr5 86151620 T G 3.10E-04 Multiple complex diseases / / 17554300 rs4133446 chr5 86155113 T C 7.15E-05 Neutrophil count / / pha003095 rs16902440 chr5 86158455 A G 2.34E-04 Multiple complex diseases / / 17554300 rs10040791 chr5 86167205 A C 2.39E-04 Multiple complex diseases / / 17554300 rs1493354 chr5 86174147 A G 2.38E-04 Alzheimer's disease (late onset) / / 21379329 rs1493354 chr5 86174147 A G 9.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule) / / 24025145 rs2452753 chr5 86175928 G C 9.96E-04 Multiple complex diseases / / 17554300 rs12516449 chr5 86176744 G A 5.70E-04 Multiple complex diseases / / 17554300 rs7727185 chr5 86177591 A G 1.40E-05 Alcoholism (heaviness of drinking) / / 21529783 rs2471042 chr5 86177773 A G 8.33E-05 Alzheimer's disease (late onset) / / 21379329 rs2471042 chr5 86177773 A G 5.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule) / / 24025145 rs13161175 chr5 86179008 A C 8.53E-06 Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule) / / 24025145 rs2452759 chr5 86186490 A G 9.26E-06 Personality dimensions / / 21173776 rs2452759 chr5 86186490 A G 2.50E-05 Alzheimer's disease (late onset) / / 21379329 rs7714020 chr5 86186986 G A 7.44E-06 Personality dimensions / / 21173776 rs7714020 chr5 86186986 G A 2.79E-04 Alzheimer's disease (late onset) / / 21379329 rs2452761 chr5 86187316 T C 8.41E-06 Personality dimensions / / 21173776 rs4920774 chr5 86194028 A G 1.88E-04 Multiple complex diseases / / 17554300 rs983809 chr5 86204395 G A 3.02E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10052248 chr5 86243827 G A 9.20E-06 Alzheimer's disease (late onset) / / 21379329 rs4244387 chr5 86250613 C T 1.07E-04 Multiple complex diseases / / 17554300 rs4478354 chr5 86251571 G A 2.85E-05 Alzheimer's disease (late onset) / / 21379329 rs4478354 chr5 86251571 G A 5.60E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1073933 chr5 86271618 T C 1.99E-04 Celiac disease / / 23936387 rs1602843 chr5 86288586 G T 1.11E-04 Multiple complex diseases / / 17554300 rs7717290 chr5 86293796 G A 9.96E-05 Stroke (ischemic) / / 22941190 rs7722135 chr5 86294669 C T 1.70E-05 Multiple complex diseases / / 17554300 rs7722135 chr5 86294669 C T 4.59E-05 Type 1 diabetes / / 18978792 rs13182221 chr5 86311455 A G 5.71E-04 Multiple complex diseases / / 17554300 rs10942487 chr5 86319195 T C 1.30E-05 Stroke (ischemic) / / 22941190 rs2640457 chr5 86319936 C T 3.49E-05 Multiple complex diseases / / 17554300 rs2640457 chr5 86319936 C T 4.30E-05 Type 1 diabetes / / 18978792 rs4283829 chr5 86331748 C T 3.74E-06 Stroke (ischemic) / / 22941190 rs2410729 chr5 86339887 G A 4.70E-05 Alcoholism (heaviness of drinking) / / 21529783 rs2410729 chr5 86339887 G A 1.94E-04 Heart Failure / / pha002884 rs7715840 chr5 86350878 A C 8.14E-05 Multiple complex diseases / / 17554300 rs7715840 chr5 86350878 A C 4.30E-05 Alcoholism (heaviness of drinking) / / 21529783 rs7715840 chr5 86350878 A C 3.61E-06 Stroke (ischemic) / / 22941190 rs6885404 chr5 86357920 A G 8.16E-04 Heart Failure / / pha002884 rs2898547 chr5 86367865 C T 1.66E-04 Multiple complex diseases / / 17554300 rs2544689 chr5 86374758 C T 6.30E-05 Alcoholism (heaviness of drinking) / / 21529783 rs2544688 chr5 86378336 A G 3.57E-06 Stroke (ischemic) / / 22941190 rs2624189 chr5 86386565 G A 9.38E-06 Stroke (ischemic) / / 22941190 rs2544677 chr5 86399262 G A,C 8.23E-06 Multiple complex diseases / / 17554300 rs2544677 chr5 86399262 G A,C 1.80E-05 Type 1 diabetes / / 18978792 rs2624195 chr5 86399654 G T 4.35E-04 Multiple complex diseases / / 17554300 rs2112168 chr5 86404890 C T 3.07E-05 Multiple complex diseases / / 17554300 rs2112168 chr5 86404890 C T 7.55E-05 Type 1 diabetes / / 18978792 rs2112166 chr5 86409436 A G 7.71E-06 Stroke (ischemic) / / 22941190 rs1004988 chr5 86410998 T G 3.60E-05 Alcoholism (heaviness of drinking) / / 21529783 rs1004988 chr5 86410998 T G 5.95E-05 Stroke (ischemic) / / 22941190 rs1004988 chr5 86410998 T G 3.10E-04 Heart Failure / / pha002884 rs16902538 chr5 86417013 C T 1.76E-07 Personality dimensions / / 21173776 rs2624171 chr5 86418751 A G 2.31E-05 Body Fat Distribution / / pha003016 rs2624171 chr5 86418751 A G 8.65E-05 Body Fat Distribution / / pha003017 rs2624171 chr5 86418751 A G 4.04E-05 Body Fat Distribution / / pha003018 rs17591778 chr5 86420392 G A 8.73E-08 Personality dimensions / / 21173776 rs17629700 chr5 86420508 C T 1.73E-07 Personality dimensions / / 21173776 rs17629760 chr5 86424059 G A 1.50E-07 Personality dimensions / / 21173776 rs4141503 chr5 86424676 C T 1.20E-07 Personality dimensions / / 21173776 rs1477268 chr5 86427866 T C 2.04E-05 Personality dimensions / / 18957941 rs1477268 chr5 86427866 T C 2.79E-08 Personality dimensions / / 21173776 rs1477268 chr5 86427866 T C 4.59E-05 Bipolar disorder / / 21771265 rs2032794 chr5 86432617 T C 2.00E-06 Personality dimensions / / 21173776 rs2032794 chr5 86432617 T C 6.38E-05 Bipolar disorder / / 21771265 rs16902548 chr5 86433719 G T 3.34E-06 Personality dimensions / / 21173776 rs2032793 chr5 86450305 G A 7.90E-05 Alcoholism (heaviness of drinking) / / 21529783 rs2544698 chr5 86454831 C G 9.72E-07 Personality dimensions / / 21173776 rs30421 chr5 86460539 G A 4.09E-06 Personality dimensions / / 21173776 rs2637074 chr5 86461699 C A 1.17E-06 Personality dimensions / / 21173776 rs254653 chr5 86468214 G A 2.16E-04 Multiple complex diseases / / 17554300 rs17446600 chr5 86487388 G T 8.95E-05 Suicide attempts in bipolar disorder / / 21423239 rs6890495 chr5 86524315 G A 1.39E-10 CD8+ T cell IFN-gamma response to smallpox vaccine / / 22661280 rs16902608 chr5 86571293 A G 2.52E-10 LDL cholesterol RASA1 intron 23063622 rs35148638 chr5 86610989 A C 5.00E-05 HIV-1 control RASA1 intron 20041166 rs3752862 chr5 86633973 G A 8.51E-04 Alcohol dependence RASA1 intron 21314694 rs3093816 chr5 86697387 A G 2.50E-05 Response to lithium treatment in bipolar disorder CCNH intron 19448189 rs1158076 chr5 86712641 G C 4.33E-05 Serum metabolites / / 19043545 rs7702514 chr5 86727027 C T 2.16E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs13177543 chr5 86842168 G A 5.16E-05 Insulin Resistance / / pha003062 rs13177543 chr5 86842168 G A 8.58E-05 Hemoglobin / / pha003096 rs16902684 chr5 86868586 G A 3.30E-06 Left ventricular mass / / 21212386 rs984026 chr5 86893820 A G 1.02E-04 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs4976236 chr5 86905677 T G 1.34E-06 Left ventricular hypertrophy / / pha003052 rs11749237 chr5 86913066 A G 9.34E-05 Left ventricular hypertrophy / / pha003052 rs840814 chr5 86972448 G A 1.12E-06 Left ventricular hypertrophy / / pha003052 rs866821 chr5 87000310 C T 6.54E-05 Left ventricular hypertrophy / / pha003052 rs840831 chr5 87001557 G A 1.12E-06 Left ventricular hypertrophy / / pha003052 rs710391 chr5 87027398 T C 3.80E-08 Metabolite levels / / 23281178 rs1673101 chr5 87034352 G A 4.00E-06 Major depressive disorder / / 23377640 rs16902803 chr5 87078367 C T 1.46E-04 Alzheimer's disease / / 17998437 rs16902806 chr5 87081822 G A 5.31E-04 Depression (quantitative trait) / / 20800221 rs710375 chr5 87082276 C T 4.97E-04 Depression (quantitative trait) / / 20800221 rs710374 chr5 87082947 T C 6.74E-04 Depression (quantitative trait) / / 20800221 rs710373 chr5 87083187 C T 5.03E-04 Depression (quantitative trait) / / 20800221 rs11740855 chr5 87086974 T C 5.73E-04 Depression (quantitative trait) / / 20800221 rs16902816 chr5 87087913 G A 5.63E-05 Major depressive disorder / / 21621269 rs16902819 chr5 87089786 G A 4.81E-04 Depression (quantitative trait) / / 20800221 rs16902822 chr5 87090932 T G 2.48E-04 Alzheimer's disease / / 17998437 rs16902824 chr5 87095826 A G 3.84E-04 Alzheimer's disease / / 17998437 rs6885160 chr5 87099119 T C 1.09E-05 Fibrinogen / / pha003068 rs12520006 chr5 87100609 A G 5.70E-06 Urinary metabolites / / 21572414 rs1345818 chr5 87138466 C T 5.19E-05 Major depressive disorder / / 21621269 rs1350439 chr5 87191781 T C 2.91E-05 Insulin Resistance / / pha003062 rs1350439 chr5 87191781 T C 4.08E-05 Insulin-related traits / / pha003063 rs881601 chr5 87313537 G A 2.59E-04 Multiple complex diseases / / 17554300 rs6877822 chr5 87397560 A G 6.61E-05 Major depressive disorder / / 21621269 rs7716850 chr5 87430517 C T 6.11E-06 Asthma (childhood onset) / / 23829686 rs7730772 chr5 87445193 G A 9.96E-04 Type 2 diabetes / / 17463246 rs4916890 chr5 87450438 T C 1.45E-05 Left ventricular hypertrophy / / pha003052 rs4916890 chr5 87450438 T C 8.50E-07 Insulin Resistance / / pha003062 rs4916890 chr5 87450438 T C 1.07E-06 Insulin-related traits / / pha003063 rs7716599 chr5 87525513 A G 8.01E-05 Asthma TMEM161B intron pha003128 rs33704 chr5 87561765 T C 9.89E-04 Alzheimer's disease TMEM161B intron 24755620 rs33703 chr5 87566731 C T 9.95E-04 Alzheimer's disease LOC100505894 intron 24755620 rs2115885 chr5 87598818 G A 7.94E-04 Alzheimer's disease LOC100505894 intron 24755620 rs2410763 chr5 87666641 G T 9.35E-04 Multiple complex diseases LOC100505894 intron 17554300 rs2410763 chr5 87666641 G T 7.21E-04 Alzheimer's disease LOC100505894 intron 24755620 rs2898557 chr5 87683806 T G 7.92E-04 Type 2 diabetes LOC100505894 intron 17463246 rs4562904 chr5 87686639 A C 4.14E-04 Taste perception LOC100505894 intron 22132133 rs7728883 chr5 87751752 G A 7.86E-04 Urinary albumin excretion rate in type 1 diabetes / / 24595857 rs16903184 chr5 87787332 T C 6.53E-04 Type 2 diabetes / / 17463246 rs7737179 chr5 87795525 G A 5.53E-04 Alzheimer's disease / / 24755620 rs2194025 chr5 87798236 G C 2.00E-12 Retinal arteriolar caliber / / 23776548 rs6860708 chr5 87800881 C T 2.48E-04 Myopia (pathological) / / 21095009 rs2194026 chr5 87801273 G T 1.94E-04 Myopia (pathological) / / 21095009 rs2194026 chr5 87801273 G T 3.43E-12 Retinal arteriolar caliber / / 23776548 rs16903232 chr5 87831734 C T 7.50E-05 Myopia (pathological) / / 21095009 rs10474278 chr5 87841490 A G 8.03E-04 Suicide attempts in bipolar disorder LINC00461 intron 21423239 rs17421627 chr5 87847586 T G 7.00E-16 Retinal vascular caliber LINC00461 intron 21060863 rs16903241 chr5 87850522 G C 2.91E-05 Multiple complex diseases LINC00461 intron 17554300 rs13179395 chr5 87851669 A G 1.95E-04 Suicide attempts in bipolar disorder LINC00461 intron 21423239 rs933647 chr5 87889197 G A 3.19E-04 Fibrinogen LINC00461 intron 17255346 rs7721099 chr5 87936379 T C 3.24E-04 Multiple complex diseases LINC00461 intron 17554300 rs7703782 chr5 87938557 T A 1.01E-04 Multiple complex diseases LINC00461 intron 17554300 rs16903275 chr5 87950543 C A 9.72E-04 Type 2 diabetes LINC00461 intron 17463246 rs16903275 chr5 87950543 C A 6.87E-04 Multiple complex diseases LINC00461 intron 17554300 rs1501672 chr5 87963761 A G 2.02E-04 Multiple complex diseases LINC00461 intron 17554300 rs6893807 chr5 87965021 A G 8.53E-04 Type 2 diabetes LINC00461 intron 17463246 rs6893807 chr5 87965021 A G 9.84E-04 Multiple complex diseases LINC00461 intron 17554300 rs6893807 chr5 87965021 A G 1.00E-06 Body mass index LINC00461 intron 24861553 rs254778 chr5 88009593 G A 8.33E-04 Alcohol dependence / / 21314694 rs10514302 chr5 88027217 T C 5.32E-04 Tourette syndrome MEF2C intron 22889924 rs652660 chr5 88041932 C G 0.0002 Coronary artery calcification MEF2C intron 23727086 rs674747 chr5 88079010 G T 0.000488 Salmonella-induced pyroptosis MEF2C intron 22837397 rs12521662 chr5 88081496 G A 1.88E-04 Coronary heart disease MEF2C intron 21606135 rs17558256 chr5 88083453 T C 3.15E-08 Bone mineral density MEF2C intron 23572186 rs770189 chr5 88088439 G C 3.00E-06 Tonometry MEF2C intron 17903302 rs4521516 chr5 88099951 G C 2.00E-09 Mean platelet volume MEF2C intron 22139419 rs4521516 chr5 88099951 G C 5.00E-04 Mean platelet volume MEF2C intron 24026423 rs11956763 chr5 88104422 C T 2.14E-04 Lung function (forced vital capacity) MEF2C intron 24023788 rs11958689 chr5 88106853 C G 3.35E-07 Bone mineral density MEF2C intron 23572186 rs11958689 chr5 88106853 C G 4.16E-08 Bone mineral density MEF2C intron 23572186 rs244760 chr5 88111209 C G 4.34E-06 Thiazide-induced adverse metabolic effects in hypertensive patients MEF2C intron 23400010 rs12521522 chr5 88112761 T A 3.15E-08 Bone mineral density MEF2C intron 23572186 rs11955542 chr5 88113228 C T 3.15E-08 Bone mineral density MEF2C intron 23572186 rs770525 chr5 88123550 T A 0.000666 Salmonella-induced pyroptosis MEF2C intron 22837397 rs11951031 chr5 88138731 C T 4.16E-08 Bone mineral density MEF2C intron 23572186 rs11951031 chr5 88138731 C T 9.00E-09 Bone mineral density MEF2C intron 23572186 rs302483 chr5 88144091 T C 0.00031 Coronary artery calcification MEF2C intron 23727086 rs302482 chr5 88144234 G A 0.00024 Coronary artery calcification MEF2C intron 23727086 rs700585 chr5 88152117 C T 1.00E-09 Platelet counts MEF2C intron 22139419 rs12515983 chr5 88154075 T A 6.12E-08 Bone mineral density MEF2C intron 23572186 rs304162 chr5 88156970 C T 7.12E-05 Body Mass Index MEF2C intron pha003006 rs304162 chr5 88156970 C T 7.61E-05 Body Mass Index MEF2C intron pha003014 rs17560407 chr5 88183651 A G 5.00E-07 Thiazide-induced adverse metabolic effects in hypertensive patients MEF2C intron 23400010 rs17560451 chr5 88184003 T C 5.81E-07 Thiazide-induced adverse metabolic effects in hypertensive patients MEF2C intron 23400010 rs3850653 chr5 88186954 A G 8.76E-07 Thiazide-induced adverse metabolic effects in hypertensive patients MEF2C intron 23400010 rs12522630 chr5 88188367 G A 3.35E-07 Bone mineral density MEF2C intron 23572186 rs12522630 chr5 88188367 G A 5.19E-08 Bone mineral density MEF2C intron 23572186 rs17494872 chr5 88193159 G A 4.55E-07 Bone mineral density MEF2C intron 23572186 rs17494872 chr5 88193159 G A 6.82E-08 Bone mineral density MEF2C intron 23572186 rs190982 chr5 88223420 G A 3.00E-08 Alzheimer's disease (late onset) / / 24162737 rs7700950 chr5 88236942 G T 9.65E-04 HIV-1 viral setpoint / / 17641165 rs16876775 chr5 88258855 T C 5.71E-04 Smoking initiation / / 24665060 rs6894139 chr5 88327782 T G 7.00E-18 Bone mineral density / / 24249740 rs10037512 chr5 88354675 T C 2.00E-18 Height / / 20881960 rs3861964 chr5 88371651 T C 1.26E-09 Bone mineral density / / 24249740 rs1366594 chr5 88376061 A C 1.00E-13 Bone mineral density (hip) / / 19801982 rs1366594 chr5 88376061 A C 1.00E-07 Bone mineral density / / 21533022 rs1366594 chr5 88376061 A C 8.00E-10 Bone mineral density / / 21533022 rs1366594 chr5 88376061 A C 4.00E-61 Bone mineral density / / 22504420 rs1366594 chr5 88376061 A C 1.41E-09 Bone mineral density / / 24249740 rs1366594 chr5 88376061 A C 1.54E-04 Bone mineral density / / 24249740 rs1864180 chr5 88421363 A G 4.11E-04 Multiple complex diseases / / 17554300 rs1366596 chr5 88474003 C T 1.01E-04 Bipolar disorder / / 18317468 rs4916749 chr5 88588302 T C 1.19E-04 Bipolar disorder / / 18317468 rs13170203 chr5 88613641 T C 7.67E-13 Metabolite levels / / 22286219 rs9293514 chr5 88736275 T C 9.42E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1528589 chr5 88748768 C T 5.06E-04 Bipolar disorder / / 19259986 rs10070532 chr5 88764215 G A 5.65E-05 Coronary heart disease / / 21606135 rs10070532 chr5 88764215 G A 8.50E-05 Memory performance / / 22105620 rs12658195 chr5 88871745 C T 3.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7733743 chr5 88956857 A T 5.60E-06 Urinary metabolites / / 21572414 rs6414953 chr5 88964150 A G 7.60E-06 Triglycerides / / 19074352 rs10214238 chr5 88971208 G A 1.99E-04 Multiple complex diseases / / 17554300 rs10069451 chr5 88994840 C A 2.53E-05 Hemoglobin / / pha003098 rs6452846 chr5 89005227 G A 2.69E-04 Sudden cardiac arrest / / 21658281 rs17512705 chr5 89011412 T A 6.69E-06 Cognitive function / / 24684796 rs10514310 chr5 89021578 A G 7.00E-06 Obesity-related traits / / 23251661 rs6864869 chr5 89051857 G C 3.00E-06 Cognitive function / / 24684796 rs10474306 chr5 89069875 A G 7.21E-06 Cognitive function / / 24684796 rs10514317 chr5 89109750 C T 7.00E-07 Sex hormone-binding globulin levels / / 22675492 rs1363179 chr5 89111529 T G 8.05E-05 Depression (quantitative trait) / / 23290196 rs10514316 chr5 89112538 A G 3.99E-04 Multiple complex diseases / / 17554300 rs1421908 chr5 89113060 C T 8.25E-05 Depression (quantitative trait) / / 23290196 rs10474308 chr5 89139924 C T 1.81E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs6889835 chr5 89148875 A T 2.61E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs6873061 chr5 89153327 A G 1.75E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs6873061 chr5 89153327 A G 7.81E-04 Smoking initiation / / 24665060 rs10052296 chr5 89206800 G A 9.73E-06 Response to cytidine analogues (gemcitabine) / / 24483146 rs13362216 chr5 89265958 T C 8.95E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs256515 chr5 89375165 G T 6.75E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs157566 chr5 89378726 C T 3.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs157563 chr5 89382503 A G 8.45E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs176107 chr5 89392662 A G 6.71E-04 Schizophrenia / / 19197363 rs256514 chr5 89410113 C T 6.95E-05 Aortic root size / / 21223598 rs2973361 chr5 89418018 A T 3.92E-04 Aortic root size / / 21223598 rs9293535 chr5 89442298 C T 0.00034627 Hypertension (early onset hypertension) / / 22479346 rs1133384 chr5 89456355 T G 0.000493309 Hypertension (early onset hypertension) / / 22479346 rs2973403 chr5 89460396 C T 9.04E-05 Bipolar disorder / / 22925353 rs1443888 chr5 89468151 G A 8.22E-05 Bipolar disorder / / 22925353 rs6899159 chr5 89469753 A G 0.00034627 Hypertension (early onset hypertension) / / 22479346 rs2935504 chr5 89540468 C T 6.10E-06 Multiple complex diseases / / 17554300 rs12518099 chr5 89546109 A G 7.00E-07 Type 2 diabetes and other traits / / 19734900 rs12518099 chr5 89546109 A G 7.00E-07 Coronary heart disease / / 21347282 rs12518099 chr5 89546109 A G 7.00E-07 Type 2 diabetes / / 21647700 rs2916612 chr5 89578774 C T 9.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2972956 chr5 89620100 A G 6.07E-06 Systemic lupus erythematosus / / pha002867 rs1897833 chr5 89649118 G T 0.0000015 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) / / 23080225 rs2366614 chr5 89654177 A G 1.74E-04 Osteoarthritis (knee and hip) / / 21177295 rs2366614 chr5 89654177 A G 3.29E-06 Osteoarthritis (knee and hip) / / 21177295 rs2366614 chr5 89654177 A G 3.96E-04 Osteoarthritis (knee and hip) / / 21177295 rs2366614 chr5 89654177 A G 7.41E-04 Osteoarthritis (knee and hip) / / 21177295 rs2935515 chr5 89668829 A G 5.28E-04 Type 2 diabetes / / 17463246 rs2162987 chr5 89743881 C T 3.56E-06 Lipid traits / / 21777205 rs2562519 chr5 89780971 C T 5.00E-06 Nevirapine-induced rash POLR3G intron 21810746 rs27657 chr5 89847869 G A 1.83E-04 Multiple complex diseases / / 17554300 rs40205 chr5 89857574 A G 1.74E-04 Multiple complex diseases GPR98 intron 17554300 rs9293546 chr5 89906540 G A 9.10E-05 Type 2 diabetes GPR98 intron 17463246 rs9293546 chr5 89906540 G A 1.12E-04 Multiple complex diseases GPR98 intron 17554300 rs490812 chr5 89907016 A C 7.79E-04 Smoking quantity GPR98 intron 24665060 rs16868876 chr5 89929350 A G 3.64E-04 Multiple complex diseases GPR98 intron 17554300 rs11952742 chr5 89937694 T C 7.93E-05 Type 2 diabetes GPR98 intron 17463246 rs16868901 chr5 89940489 C G 6.57E-05 Type 2 diabetes GPR98 intron 17463246 rs950692 chr5 89943433 A G 6.72E-06 Type 2 diabetes GPR98 cds-synon 17463246 rs11748911 chr5 89951585 A C 1.76E-04 Arthritis (juvenile idiopathic) GPR98 intron 22354554 rs4916809 chr5 89956765 G A 8.39E-06 Type 2 diabetes GPR98 intron 17463246 rs4916681 chr5 89957017 C T 8.86E-04 Multiple complex diseases GPR98 intron 17554300 rs35791889 chr5 89979485 C G,T 4.00E-04 Atrial fibrillation GPR98 missense 21846873 rs16868972 chr5 89979750 G T 6.25E-05 Coronary heart disease GPR98 missense pha003031 rs10942606 chr5 89999968 A G 0.00029 Coronary artery calcification GPR98 intron 23727086 rs1996551 chr5 90002596 T C 5.38E-06 Type 2 diabetes GPR98 intron 17463246 rs4916687 chr5 90022712 A G 3.36E-05 Telomere length GPR98 intron 23900074 rs12658994 chr5 90064784 G A 5.03E-05 Schizophrenia (cytomegalovirus infection interaction) GPR98 intron 23358160 rs2460175 chr5 90082396 T C 4.87E-05 Recombination rate GPR98 intron 21698098 rs2438361 chr5 90090437 G A 2.00E-04 Multiple complex diseases GPR98 intron 17554300 rs2438362 chr5 90090791 A G 3.32E-04 Type 2 diabetes GPR98 intron 17463246 rs2443074 chr5 90099333 T G 2.00E-11 Triglycerides GPR98 intron 23063622 rs7729495 chr5 90103487 T C 5.00E-12 Health and aging,CVD and cancer age of onset GPR98 missense 22174011 rs7729495 chr5 90103487 T C 5.70E-15 Health and aging,CVD and cancer age of onset GPR98 missense 22174011 rs7729495 chr5 90103487 T C 8.10E-19 Health and aging,CVD and cancer age of onset GPR98 missense 22174011 rs7729495 chr5 90103487 T C 8.40E-10 Health and aging,CVD and cancer age of onset GPR98 missense 22174011 rs2443068 chr5 90182824 A G 1.10E-07 Urinary metabolites GPR98 intron 21572414 rs4244205 chr5 90188886 A G 4.57E-04 Alzheimer's disease (late onset) GPR98 intron 21379329 rs4916827 chr5 90189111 C G 3.80E-08 Urinary metabolites GPR98 intron 21572414 rs4916827 chr5 90189111 C G 1.73E-04 Response to cytadine analogues (cytosine arabinoside) GPR98 intron 24483146 rs4496735 chr5 90190417 C G 2.90E-06 Urinary metabolites GPR98 intron 21572414 rs4916829 chr5 90195447 T G 5.05E-05 Response to cytadine analogues (cytosine arabinoside) GPR98 intron 24483146 rs10052015 chr5 90209063 T C 2.73E-05 Response to cytadine analogues (cytosine arabinoside) GPR98 intron 24483146 rs10052015 chr5 90209063 T C 9.96E-05 Response to cytidine analogues (gemcitabine) GPR98 intron 24483146 rs10074525 chr5 90209824 C T 9.00E-06 Obesity-related traits GPR98 intron 23251661 rs12522395 chr5 90210518 G C 1.60E-06 Urinary metabolites GPR98 intron 21572414 rs12522395 chr5 90210518 G C 1.97E-05 Response to cytadine analogues (cytosine arabinoside) GPR98 intron 24483146 rs12522395 chr5 90210518 G C 6.58E-05 Response to cytidine analogues (gemcitabine) GPR98 intron 24483146 rs10060641 chr5 90213250 T C 1.90E-05 Response to cytadine analogues (cytosine arabinoside) GPR98 intron 24483146 rs10060641 chr5 90213250 T C 6.79E-05 Response to cytidine analogues (gemcitabine) GPR98 intron 24483146 rs7724016 chr5 90217889 T C 2.80E-06 Urinary metabolites GPR98 intron 21572414 rs12054681 chr5 90217927 C A 2.09E-05 Response to cytadine analogues (cytosine arabinoside) GPR98 intron 24483146 rs12054681 chr5 90217927 C A 7.89E-05 Response to cytidine analogues (gemcitabine) GPR98 intron 24483146 rs3105793 chr5 90226061 G A 9.90E-06 Urinary metabolites GPR98 intron 21572414 rs4916698 chr5 90239135 A G 4.49E-04 Response to cytadine analogues (cytosine arabinoside) GPR98 intron 24483146 rs2063245 chr5 90239911 A G 1.70E-05 Urinary metabolites GPR98 intron 21572414 rs6452916 chr5 90252232 C A 7.09E-05 Myopia (pathological) GPR98 intron 23049088 rs1967256 chr5 90299223 G C 9.42E-04 Multiple complex diseases GPR98 intron 17554300 rs1967256 chr5 90299223 G C 3.00E-08 Response to antipsychotic treatment GPR98 intron 20195266 rs16869330 chr5 90301599 A G 5.79E-04 Response to alcohol consumption (flushing response) GPR98 intron 24277619 rs11954387 chr5 90302117 A G 4.35E-04 Multiple complex diseases GPR98 intron 17554300 rs4244206 chr5 90389450 A C 7.57E-04 Type 2 diabetes GPR98 intron 17463246 rs1852731 chr5 90392621 A G 6.39E-05 Multiple complex diseases GPR98 intron 17554300 rs2367281 chr5 90403175 C T 7.82E-14 Triglycerides GPR98 intron 23063622 rs10514345 chr5 90424279 C T 2.00E-07 Hip geometry GPR98 intron 17903296 rs6873773 chr5 90438473 C T 6.12E-04 Obesity (extreme) GPR98 intron 21935397 rs10059760 chr5 90440102 A T 9.63E-04 Obesity (extreme) GPR98 intron 21935397 rs13158963 chr5 90449154 G A 5.04E-04 Obesity (extreme) GPR98 cds-synon 21935397 rs13158963 chr5 90449154 G A 9.00E-04 Coronary heart disease GPR98 cds-synon 21966275 rs13160072 chr5 90449807 G A 5.04E-04 Obesity (extreme) GPR98 intron 21935397 rs13184171 chr5 90450113 T C 5.03E-04 Obesity (extreme) GPR98 intron 21935397 rs2048454 chr5 90523669 T C 4.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4916858 chr5 90601290 C T 8.51E-04 Type 2 diabetes / / 17463246 rs1363837 chr5 90695282 T G 4.85E-04 Response to cytidine analogues (gemcitabine) LOC100129716 intron 24483146 rs4432929 chr5 90725887 C T 1.30E-04 Malaria / / 19465909 rs2059208 chr5 90732065 T A 2.70E-05 Urinary metabolites / / 21572414 rs6867091 chr5 90734333 C G 4.40E-05 Parkinson's disease (familial) / / 18985386 rs6867091 chr5 90734333 C G 2.40E-05 Urinary metabolites / / 21572414 rs12655973 chr5 90736537 T C 7.70E-05 Parkinson's disease (familial) / / 18985386 rs933688 chr5 90762748 G A 6.00E-06 Smoking behavior / / 19247474 rs332545 chr5 90779286 C A 9.00E-04 Type 2 diabetes / / 17463246 rs52308 chr5 90782147 T C 2.76E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10038508 chr5 90797244 G A 3.71E-05 Brain structure / / 22504417 rs16869805 chr5 90817701 C T 9.77E-06 Brain structure / / 22504417 rs231383 chr5 90830204 C G 1.93E-05 Brain structure / / 22504417 rs1661037 chr5 90838345 A G 2.81E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1661037 chr5 90838345 A G 4.97E-05 Lung function (forced vital capacity) / / 24023788 rs10043890 chr5 90867639 A T 4.19E-05 Brain structure / / 22504417 rs6452960 chr5 90881388 A G 1.12E-04 Lung function (forced vital capacity) / / 24023788 rs6452960 chr5 90881388 A G 9.36E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1505851 chr5 90893954 T C 5.26E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1505851 chr5 90893954 T C 5.42E-05 Lung function (forced vital capacity) / / 24023788 rs1566996 chr5 90945677 C G 9.06E-04 Alzheimer's disease / / 24755620 rs13153333 chr5 90981387 A G 8.00E-06 Subcutaneous adipose tissue / / 22589738 rs11956241 chr5 91003944 T G 4.24E-08 Multiple complex diseases / / 17554300 rs12516181 chr5 91039040 T C 1.00E-04 Alcohol dependence / / 20201924 rs12516181 chr5 91039040 T C 1.50E-04 Alcohol dependence / / 20201924 rs6881283 chr5 91055657 C T 1.10E-04 Alcohol dependence / / 20201924 rs6881283 chr5 91055657 C T 5.60E-05 Alcohol dependence / / 20201924 rs6881283 chr5 91055657 C T 5.58E-05 Alcoholism / / pha002892 rs7716005 chr5 91075841 T C 7.12E-04 Tourette syndrome / / 22889924 rs4244209 chr5 91083687 G A 0.000513 Salmonella-induced pyroptosis / / 22837397 rs4916875 chr5 91088078 A G 0.000254 Salmonella-induced pyroptosis / / 22837397 rs4509055 chr5 91090469 G A 0.000693 Salmonella-induced pyroptosis / / 22837397 rs10057238 chr5 91130565 A G 3.00E-04 Alcohol dependence / / 20201924 rs16870132 chr5 91144564 T C 7.40E-04 Alcohol dependence / / 20201924 rs7722750 chr5 91161330 G T 5.00E-04 Alcohol dependence / / 20201924 rs10063941 chr5 91221647 G T 6.00E-04 Adiposity / / 19461586 rs16870279 chr5 91247371 A G 1.11E-04 Multiple complex diseases / / 17554300 rs1862555 chr5 91257927 T C 8.11E-04 Type 2 diabetes / / 17463246 rs421379 chr5 91275313 T C 1.00E-06 Breast cancer (prognosis) / / 23319801 rs421379 chr5 91275313 T C 4.05E-04 Myocardial Infarction / / pha002873 rs10474381 chr5 91285173 T G 3.86E-04 Smoking cessation / / 24665060 rs7356540 chr5 91303719 T C 3.40E-04 Osteoarthritis / / 19508968 rs2112945 chr5 91322882 A G 1.94E-04 Osteoarthritis / / 19508968 rs9293596 chr5 91324764 T C 6.52E-04 Depression (quantitative trait) / / 20800221 rs11959544 chr5 91354136 T A 5.80E-05 Multiple complex diseases / / 17554300 rs13173857 chr5 91379509 C A 1.21E-04 Type 2 diabetes / / 17463246 rs4538643 chr5 91425371 T C 7.03E-05 Body Mass Index / / pha003007 rs4481377 chr5 91456133 T C 4.16E-04 Alzheimer's disease / / 17998437 rs10040401 chr5 91477046 G A 8.16E-05 Body Mass Index / / pha003006 rs10040401 chr5 91477046 G A 3.06E-05 Body Mass Index / / pha003007 rs4640831 chr5 91499442 A C,T 7.69E-05 Body Mass Index / / pha003007 rs4585491 chr5 91502103 G A 8.23E-04 White matter integrity / / 22425255 rs10055544 chr5 91518721 G A 1.00E-07 Immune reponse to smallpox (secreted IL-10) / / 22610502 rs10066413 chr5 91541023 A G 4.10E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4448024 chr5 91567488 T C 4.89E-04 White matter integrity / / 22425255 rs7703201 chr5 91601492 A G 5.63E-04 White matter integrity / / 22425255 rs12517182 chr5 91730563 G A 6.92E-04 Alzheimer's disease / / 17998437 rs10036476 chr5 91733517 C T 3.49E-04 White matter integrity / / 22425255 rs12516076 chr5 91738363 T C 9.17E-04 Alzheimer's disease / / 17998437 rs4398622 chr5 91744895 G T 3.62E-04 White matter integrity / / 22425255 rs10036746 chr5 91754932 A G 9.86E-06 Osteoarthritis / / 22763110 rs62366689 chr5 91768593 A T 0.00002411 Sarcoidosis / / 22952805 rs13168674 chr5 91791151 T C 6.27E-04 White matter integrity / / 22425255 rs11135398 chr5 91840153 G A 1.07E-04 Type 2 diabetes / / 17463246 rs6887553 chr5 91845809 A G 5.35E-10 Wilms tumor / / 22544364 rs10060683 chr5 91859029 T C 2.41E-10 Wilms tumor / / 22544364 rs6861029 chr5 91893095 T C 7.37E-04 Multiple complex diseases / / 17554300 rs1027643 chr5 91893792 C T 5.00E-10 Wilms tumor / / 22544364 rs61344503 chr5 91904447 G T 2.40E-10 Wilms tumor / / 22544364 rs10514354 chr5 91906602 A G 3.34E-05 Varicose Veins / / pha001411 rs2221269 chr5 91907006 A G 1.45E-10 Wilms tumor / / 22544364 rs2221271 chr5 91938390 A G 5.40E-05 Major depressive disorder / / 21042317 rs1393221 chr5 91938705 T C 4.80E-05 Major depressive disorder / / 21042317 rs7709237 chr5 91942698 A G 3.17E-04 Multiple sclerosis / / 17660530 rs1532694 chr5 91982004 T C 9.82E-05 Body mass (lean) / / 19268274 rs10068351 chr5 91988332 G C 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs7710144 chr5 91990116 C T 9.16E-06 Blood Pressure / / pha002903 rs7720378 chr5 92022022 C A 9.46E-04 Alzheimer's disease / / 22005930 rs258954 chr5 92065595 A C 3.45E-04 Smoking initiation / / 24665060 rs166085 chr5 92067325 G A 5.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs166085 chr5 92067325 G A 9.30E-05 Volumetric brain MRI / / 17903297 rs166085 chr5 92067325 G A 3.32E-04 Smoking initiation / / 24665060 rs258959 chr5 92110386 C T 9.17E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs27540 chr5 92134273 G A 3.18E-06 Obesity-related traits / / 23251661 rs1429056 chr5 92149000 T C 9.20E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs10463170 chr5 92150839 C T 0.0002088 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10463170 chr5 92150839 C T 2.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17668565 chr5 92154579 T C 2.00E-06 Obesity-related traits / / 23251661 rs17668565 chr5 92154579 T C 5.00E-07 Obesity-related traits / / 23251661 rs17668565 chr5 92154579 T C 7.00E-06 Obesity-related traits / / 23251661 rs17668565 chr5 92154579 T C 9.00E-06 Obesity-related traits / / 23251661 rs732478 chr5 92226359 G C 5.82E-05 Personality dimensions / / 18957941 rs1988145 chr5 92232724 A C 3.73E-04 Schizophrenia / / 19197363 rs10057574 chr5 92233582 G A 3.56E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9687590 chr5 92234728 T G 6.66E-05 Personality dimensions / / 18957941 rs7724557 chr5 92236275 G A 5.22E-05 Platelet counts / / pha003100 rs2578495 chr5 92242635 A C 1.90E-05 Urinary metabolites / / 21572414 rs11953766 chr5 92267794 A G 2.70E-05 Urinary metabolites / / 21572414 rs7734991 chr5 92333217 G A 5.80E-05 Prion diseases / / 22210626 rs147721431 chr5 92343195 C T 1.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs1496341 chr5 92387956 T G 3.11E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs2017806 chr5 92403727 C T 4.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17082905 chr5 92418690 T C 2.10E-05 Urinary metabolites / / 21572414 rs1353492 chr5 92446044 G A 6.80E-05 Myopia (pathological) / / 21640322 rs12519773 chr5 92464416 T C 2.00E-06 Migraine / / 23793025 rs13173682 chr5 92487543 T C 6.00E-06 Obesity-related traits / / 23251661 rs13173682 chr5 92487543 T C 9.00E-06 Obesity-related traits / / 23251661 rs4869419 chr5 92567539 A G 4.00E-06 Natriuretic peptide levels / / 21273288 rs4632782 chr5 92588151 G T 7.90E-04 Depression (quantitative trait) / / 20800221 rs7701128 chr5 92595749 A C 7.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4256329 chr5 92595939 C T 3.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7443698 chr5 92649716 A G 2.09E-04 Alzheimer's disease (late onset) / / 21379329 rs7443364 chr5 92655132 T C 9.26E-06 Serum metabolites / / 19043545 rs7443364 chr5 92655132 T C 3.39E-04 Alzheimer's disease (late onset) / / 21379329 rs6557078 chr5 92665043 C A 9.02E-06 Serum metabolites / / 19043545 rs719492 chr5 92665721 C T 4.20E-04 Alzheimer's disease (late onset) / / 21379329 rs1460744 chr5 92667984 G A 4.62E-06 Serum metabolites / / 19043545 rs9314084 chr5 92691746 A G 2.22E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13360184 chr5 92693167 T C 2.22E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs269700 chr5 92714691 T G 6.74E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6870082 chr5 92717119 G A 4.97E-04 Multiple complex diseases / / 17554300 rs6891846 chr5 92720473 G T 8.10E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs318108 chr5 92933747 T C 7.15E-04 Body mass index / / 21701565 rs318108 chr5 92933747 T C 8.17E-04 Body mass index / / 21701565 rs12186878 chr5 92980916 C A 6.10E-04 Parkinson's disease FAM172A intron 17052657 rs12186878 chr5 92980916 C A 2.07E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) FAM172A intron 23648065 rs17083335 chr5 93114005 A C 0.000835 Salmonella-induced pyroptosis FAM172A intron 22837397 rs10066088 chr5 93119374 G T 6.28E-04 Multiple complex diseases FAM172A intron 17554300 rs2924377 chr5 93157266 T A 8.74E-04 Multiple complex diseases FAM172A intron 17554300 rs4380636 chr5 93178103 A G 9.66E-04 Multiple complex diseases FAM172A intron 17554300 rs11135394 chr5 93187135 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FAM172A intron 22628534 rs11135394 chr5 93187135 C T 9.46E-06 Osteoarthritis FAM172A intron 22763110 rs12188163 chr5 93250608 G A 7.19E-04 Multiple complex diseases FAM172A intron 17554300 rs7701447 chr5 93389907 T C 0.000458 Salmonella-induced pyroptosis FAM172A intron 22837397 rs7378943 chr5 93548292 G T 8.56E-05 Type 2 diabetes KIAA0825 intron 17463246 rs17376456 chr5 93557702 A G 3.00E-15 Diabetic retinopathy KIAA0825 intron 21310492 rs2881301 chr5 93590268 G T 9.40E-06 Personality dimensions KIAA0825 intron 21173776 rs6859083 chr5 93624507 C T 7.99E-06 Response to inhaled corticosteroid treatment in asthma (percentage change of FEV1) KIAA0825 intron 24792382 rs6884527 chr5 93624644 T C 0.00041 Salmonella-induced pyroptosis KIAA0825 intron 22837397 rs10491400 chr5 93643170 T G 7.80E-06 Response to inhaled corticosteroid treatment in asthma (percentage change of FEV1) KIAA0825 intron 24792382 rs17083580 chr5 93648131 G C 2.52E-06 Asthma (childhood onset) KIAA0825 intron 23829686 rs7715295 chr5 93670789 T C 0.000463 Salmonella-induced pyroptosis KIAA0825 intron 22837397 rs2926571 chr5 93673162 G A 3.15E-04 Response to statin treatment (atorvastatin),change in cholesterol levels KIAA0825 intron 20031582 rs29959 chr5 93693070 A G 1.00E-04 Cognitive impairment induced by topiramate KIAA0825 intron 22091778 rs2434364 chr5 93697852 C T 6.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KIAA0825 intron 20877124 rs2434364 chr5 93697852 C T 2.95E-05 Cognitive impairment induced by topiramate KIAA0825 intron 22091778 rs2434364 chr5 93697852 C T 7.00E-06 Response to inhaled corticosteroid treatment in asthma (percentage change of FEV1) KIAA0825 intron 24792382 rs29922 chr5 93730184 G A 0.0002546 Sarcoidosis KIAA0825 intron 22952805 rs29923 chr5 93730204 G A 0.0002123 Sarcoidosis KIAA0825 intron 22952805 rs308206 chr5 93732334 C T 6.98E-05 Lung function (forced expiratory volume in 1 second) KIAA0825 intron pha003102 rs731809 chr5 93750111 C T 4.01E-04 Alzheimer's disease KIAA0825 intron 24755620 rs2042003 chr5 93767365 T G 6.80E-04 Prostate cancer mortality KIAA0825 intron 20978177 rs2042003 chr5 93767365 T G 4.50E-05 Recombination rate KIAA0825 intron 21698098 rs2042003 chr5 93767365 T G 5.86E-05 Coronary heart disease KIAA0825 intron pha003032 rs13183621 chr5 93774617 C A 8.08E-05 Monocyte counts KIAA0825 intron pha003089 rs2160758 chr5 93780422 C T 4.10E-05 Coronary heart disease KIAA0825 intron pha003031 rs9314112 chr5 93795658 A G 6.20E-04 Suicide attempts in bipolar disorder KIAA0825 intron 21041247 rs952663 chr5 93798670 A G 3.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KIAA0825 intron 20877124 rs952663 chr5 93798670 A G 6.18E-04 Suicide attempts in bipolar disorder KIAA0825 intron 21041247 rs7728878 chr5 93801801 T C 7.42E-04 Suicide attempts in bipolar disorder KIAA0825 intron 21041247 rs10514384 chr5 93803817 T C 1.00E-04 Body mass index KIAA0825 intron 24827717 rs6869388 chr5 93810208 T C 7.00E-06 Gallbladder cancer KIAA0825 intron 22318345 rs9314117 chr5 93891091 T C 8.39E-04 Acute lung injury KIAA0825 intron 22295056 rs6898585 chr5 93896128 T C 4.27E-04 Type 2 diabetes KIAA0825 intron 17463246 rs7707464 chr5 93915009 C A 4.12E-04 Acute lung injury KIAA0825 intron 22295056 rs10052066 chr5 93966749 A T 2.62E-04 Multiple complex diseases ANKRD32 intron 17554300 rs10070258 chr5 93980014 T G 9.78E-04 Acute lung injury ANKRD32 intron 22295056 rs12659597 chr5 93991319 G A 6.64E-04 Multiple complex diseases ANKRD32 intron 17554300 rs845725 chr5 94040908 G C 2.25E-04 Acute lung injury / / 22295056 rs10076188 chr5 94062539 C T 7.09E-08 Lymphocyte counts MCTP1 intron 22286170 rs7700629 chr5 94067063 C T 1.59E-04 Acute lung injury MCTP1 intron 22295056 rs17083994 chr5 94082049 C T 9.07E-05 Acute lung injury MCTP1 intron 22295056 rs4869219 chr5 94083115 G A 4.78E-05 Acute lung injury MCTP1 intron 22295056 rs6556852 chr5 94083237 C T 6.86E-04 Response to statin treatment (atorvastatin),change in cholesterol levels MCTP1 intron 20031582 rs4869220 chr5 94083321 A G 4.63E-05 Acute lung injury MCTP1 intron 22295056 rs166241 chr5 94096010 A G 1.38E-04 Acute lung injury MCTP1 intron 22295056 rs255375 chr5 94111315 T G 9.42E-07 Multiple complex diseases MCTP1 intron 17554300 rs255375 chr5 94111315 T G 9.72E-04 Acute lung injury MCTP1 intron 22295056 rs255371 chr5 94118098 C G 7.67E-04 Acute lung injury MCTP1 intron 22295056 rs185310 chr5 94118789 G A 2.83E-04 Acute lung injury MCTP1 intron 22295056 rs255339 chr5 94136815 C T 1.00E-04 Acute lung injury MCTP1 intron 22295056 rs469339 chr5 94148538 G A 3.00E-06 Anorexia nervosa MCTP1 intron 23568457 rs17418283 chr5 94154588 T C 1.00E-07 Bipolar disorder MCTP1 intron 19416921 rs17418283 chr5 94154588 T C 5.25E-05 Acute lung injury MCTP1 intron 22295056 rs17335178 chr5 94199328 G C 8.71E-04 Type 2 diabetes MCTP1 intron 22158537 rs27004 chr5 94200774 C G 7.07E-06 Multiple complex diseases MCTP1 intron 17554300 rs159030 chr5 94212620 A C 6.73E-05 Cognitive impairment induced by topiramate MCTP1 intron 22091778 rs27000 chr5 94235345 G C 4.16E-05 Multiple complex diseases MCTP1 intron 17554300 rs26999 chr5 94235506 T C 1.74E-04 Multiple complex diseases MCTP1 intron 17554300 rs26998 chr5 94237398 C T 7.16E-05 Multiple complex diseases MCTP1 intron 17554300 rs17421267 chr5 94257081 C A 3.71E-04 Multiple complex diseases MCTP1 intron 17554300 rs293049 chr5 94258730 C T 6.00E-04 Smoking cessation MCTP1 intron 24665060 rs293051 chr5 94262304 C T 4.90E-04 Acute lung injury MCTP1 intron 22295056 rs293052 chr5 94262642 T G 5.27E-04 Acute lung injury MCTP1 intron 22295056 rs6862634 chr5 94262747 C T 3.53E-04 Multiple complex diseases MCTP1 intron 17554300 rs293053 chr5 94271243 G A 2.64E-04 Acute lung injury MCTP1 intron 22295056 rs293053 chr5 94271243 G A 3.70E-04 Smoking cessation MCTP1 intron 24665060 rs159022 chr5 94277497 A G 4.41E-04 Smoking cessation MCTP1 intron 24665060 rs293035 chr5 94278129 T C 7.62E-05 Acute lung injury MCTP1 cds-synon 22295056 rs293035 chr5 94278129 T C 3.60E-04 Smoking cessation MCTP1 cds-synon 24665060 rs293033 chr5 94281668 G A 5.38E-04 Acute lung injury MCTP1 intron 22295056 rs10476618 chr5 94282515 C T 8.40E-06 Personality dimensions MCTP1 intron 23658558 rs7702101 chr5 94290138 G A 9.28E-04 Multiple complex diseases MCTP1 intron 17554300 rs7703557 chr5 94290337 C T 8.75E-04 Multiple complex diseases MCTP1 intron 17554300 rs10043438 chr5 94297348 T C 6.40E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MCTP1 intron 20877124 rs32922 chr5 94304059 A G 8.58E-04 Myocardial Infarction MCTP1 intron pha002873 rs32921 chr5 94304323 G A 8.70E-06 Urinary metabolites MCTP1 intron 21572414 rs13180001 chr5 94308966 C T 6.76E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MCTP1 intron 20877124 rs13160334 chr5 94317666 G A 5.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MCTP1 intron 20877124 rs295208 chr5 94322109 T C 1.24E-04 Myocardial Infarction MCTP1 intron pha002873 rs977578 chr5 94323708 T G 2.10E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MCTP1 intron 21844884 rs1426100 chr5 94365306 G A 9.41E-05 Menopause (age at onset) MCTP1 intron 19448619 rs890294 chr5 94405027 T C 1.91E-04 Vaspin levels MCTP1 intron 22907691 rs890294 chr5 94405027 T C 0.000191 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks MCTP1 intron 22907730 rs4869233 chr5 94425542 T C 2.28E-05 Response to acetaminophen (hepatotoxicity) MCTP1 intron 21177773 rs11960770 chr5 94428936 G A 1.18E-04 Vaspin levels MCTP1 intron 22907691 rs11960770 chr5 94428936 G A 0.0001179 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks MCTP1 intron 22907730 rs6868622 chr5 94469728 C T 2.47E-05 Body Composition MCTP1 intron pha003012 rs3885090 chr5 94495666 G A 8.00E-08 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) MCTP1 intron 17982456 rs10044143 chr5 94533213 C T 2.56E-04 Response to taxane treatment (placlitaxel) MCTP1 intron 23006423 rs669335 chr5 94610224 C T 9.75E-04 Alzheimer's disease MCTP1 intron 22005930 rs33811 chr5 94621783 C T 1.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs255957 chr5 94640373 G A 8.01E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs255969 chr5 94649904 C T 1.41E-07 Crohn's disease / / 17804789 rs255982 chr5 94653873 G A 1.61E-04 Alzheimer's disease / / 17998437 rs255982 chr5 94653873 G A 8.00E-06 IgG glycosylation / / 23382691 rs17084641 chr5 94739690 C T 2.30E-04 Height FAM81B intron 17255346 rs17084641 chr5 94739690 C T 7.83E-04 Multiple complex diseases FAM81B intron 17554300 rs6860735 chr5 94739778 G A 7.60E-04 Multiple complex diseases FAM81B intron 17554300 rs7714652 chr5 94744241 T A 1.42E-04 Height FAM81B intron 17255346 rs7714652 chr5 94744241 T A 4.04E-04 Multiple complex diseases FAM81B intron 17554300 rs6556865 chr5 94744693 A G 1.47E-04 Height FAM81B intron 17255346 rs6870030 chr5 94746513 G A 1.14E-04 Height FAM81B intron 17255346 rs7726891 chr5 94749723 G A 2.66E-04 Height FAM81B cds-synon 17255346 rs6556866 chr5 94749969 C G 1.48E-04 Height FAM81B intron 17255346 rs10515226 chr5 94764006 A G 8.32E-05 Hypertension FAM81B intron pha003042 rs10035220 chr5 95026005 C T 3.24E-05 Aortic root size / / 21223598 rs4470783 chr5 95026294 C T 5.82E-05 Aortic root size / / 21223598 rs2548131 chr5 95028846 C T 4.71E-04 Aortic root size / / 21223598 rs153916 chr5 95036700 C T 1.86E-04 Aortic root size / / 21223598 rs153916 chr5 95036700 C T 2.00E-08 Pulmonary function / / 21946350 rs153916 chr5 95036700 C T 6.14E-04 Pulmonary function (interaction) / / 23284291 rs11745143 chr5 95089373 C T 7.12E-04 Schizophrenia RHOBTB3 intron 19197363 rs34899 chr5 95091201 A G 3.00E-04 Cognitive impairment induced by topiramate RHOBTB3 missense 22091778 rs3777218 chr5 95112866 T C 3.32E-05 Breast cancer(er negative) RHOBTB3 intron 21062454 rs888808 chr5 95119408 T C 1.94E-05 Longevity RHOBTB3 intron 21612516 rs9314158 chr5 95142318 A G 9.83E-04 Multiple complex diseases / / 17554300 rs7700814 chr5 95148129 T G 3.15E-05 Blood Pressure / / pha003045 rs7700814 chr5 95148129 T G 4.42E-06 Blood Pressure / / pha003047 rs1047420 chr5 95150245 G A 8.00E-04 Acute lymphoblastic leukemia (childhood) GLRX UTR-3 20189245 rs6556883 chr5 95152085 A G 9.16E-04 Type 2 diabetes GLRX intron 17463246 rs3777209 chr5 95153956 T C 2.00E-04 Alzheimer's disease GLRX intron 22005930 rs9314160 chr5 95156457 A G 8.30E-05 Parkinson's disease (familial) GLRX intron 18985386 rs9314160 chr5 95156457 A G 5.00E-04 Acute lymphoblastic leukemia (childhood) GLRX intron 20189245 rs871775 chr5 95158768 G A 2.17E-05 Blood Pressure GLRX nearGene-5 pha003045 rs871775 chr5 95158768 G A 1.85E-05 Blood Pressure GLRX nearGene-5 pha003047 rs17085165 chr5 95169503 T C 9.05E-04 Multiple complex diseases / / 17554300 rs17085170 chr5 95172331 G T 2.17E-05 Multiple complex diseases / / 17554300 rs2546194 chr5 95193312 A G 2.24E-04 Suicide attempts in bipolar disorder C5orf27 intron 21423239 rs154447 chr5 95198252 G A 9.21E-05 Multiple sclerosis / / 17660530 rs1465446 chr5 95202236 A G 2.24E-05 Reading and spelling / / 23738518 rs1004654 chr5 95203134 C A 2.24E-05 Reading and spelling / / 23738518 rs147295 chr5 95219261 T C 1.17E-04 Multiple complex diseases / / 17554300 rs147295 chr5 95219261 T C 3.67E-05 Longevity / / 22279548 rs3777200 chr5 95234791 C T 1.00E-08 Serum total protein level ELL2 intron 23022100 rs10069748 chr5 95241222 T C 5.00E-06 IgG glycosylation ELL2 intron 23382691 rs3777193 chr5 95246760 G A 4.00E-06 IgG glycosylation ELL2 intron 23382691 rs11738945 chr5 95262513 C T 1.00E-06 IgG glycosylation ELL2 intron 23382691 rs7700895 chr5 95273410 T A 1.00E-06 IgG glycosylation ELL2 intron 23382691 rs2161318 chr5 95288576 T C 2.60E-04 Multiple complex diseases ELL2 intron 17554300 rs3777165 chr5 95291425 G A 8.64E-04 Multiple complex diseases ELL2 intron 17554300 rs918629 chr5 95301463 G A 1.00E-06 IgG glycosylation / / 23382691 rs1870270 chr5 95367082 A T 2.50E-05 Urinary metabolites / / 21572414 rs11951463 chr5 95383587 G A 1.40E-05 Urinary metabolites / / 21572414 rs11951463 chr5 95383587 G A 1.59E-06 Glycemic traits (pregnancy) / / 23903356 rs11951463 chr5 95383587 G A 9.76E-06 Glycemic traits (pregnancy) / / 23903356 rs17085428 chr5 95388015 G A 6.01E-07 Glycemic traits (pregnancy) / / 23903356 rs17085428 chr5 95388015 G A 9.30E-07 Glycemic traits (pregnancy) / / 23903356 rs4538631 chr5 95405343 C T 1.13E-06 Glycemic traits (pregnancy) / / 23903356 rs4538631 chr5 95405343 C T 1.90E-06 Glycemic traits (pregnancy) / / 23903356 rs4416625 chr5 95405538 A G 9.60E-06 Urinary metabolites / / 21572414 rs4128178 chr5 95410393 C T 9.60E-06 Urinary metabolites / / 21572414 rs6879847 chr5 95416676 A G 9.60E-06 Urinary metabolites / / 21572414 rs7734985 chr5 95428684 G A 2.00E-06 IgG glycosylation / / 23382691 rs4365863 chr5 95437611 G A 1.32E-06 Glycemic traits (pregnancy) / / 23903356 rs4365863 chr5 95437611 G A 7.97E-07 Glycemic traits (pregnancy) / / 23903356 rs4330486 chr5 95445319 G C 1.15E-06 Glycemic traits (pregnancy) / / 23903356 rs4330486 chr5 95445319 G C 6.90E-07 Glycemic traits (pregnancy) / / 23903356 rs73136503 chr5 95453623 A G 6.07E-05 Acne (severe) / / 24927181 rs13164421 chr5 95464398 G A 5.21E-05 Psoriasis / / 20953187 rs13164421 chr5 95464398 G A 6.24E-04 Tourette syndrome / / 22889924 rs6875999 chr5 95470989 A G 1.37E-06 Glycemic traits (pregnancy) / / 23903356 rs6875999 chr5 95470989 A G 5.28E-07 Glycemic traits (pregnancy) / / 23903356 rs4869264 chr5 95477589 C A 2.10E-05 Urinary metabolites / / 21572414 rs4869266 chr5 95486940 A G 3.00E-06 IgG glycosylation / / 23382691 rs10037565 chr5 95498990 G A 4.51E-05 Multiple complex diseases / / 17554300 rs13358858 chr5 95516072 C T 7.88E-04 Taste perception / / 22132133 rs4869272 chr5 95539448 C T 3.05E-16 Fasting blood glucose / / 22885924 rs4869272 chr5 95539448 C T 2.84E-08 Glycemic traits (pregnancy) / / 23903356 rs4869272 chr5 95539448 C T 8.34E-10 Glycemic traits (pregnancy) / / 23903356 rs4869272 chr5 95539448 C T 4.92E-05 Insulin-related traits / / pha002901 rs4869273 chr5 95539536 C T 1.03E-07 Glycemic traits (pregnancy) / / 23903356 rs4869273 chr5 95539536 C T 4.88E-09 Glycemic traits (pregnancy) / / 23903356 rs13179048 chr5 95542726 C A 2.00E-10 Fasting glucose-related traits (interaction with BMI) / / 22581228 rs13179048 chr5 95542726 C A 2.80E-09 Glycemic traits (pregnancy) / / 23903356 rs13179048 chr5 95542726 C A 4.49E-11 Glycemic traits (pregnancy) / / 23903356 rs4336380 chr5 95614860 C T 7.13E-04 Taste perception / / 22132133 rs6895503 chr5 95616506 C T 5.80E-05 Taste perception / / 22132133 rs12186664 chr5 95630225 A T 1.20E-09 Glycemic traits (pregnancy) / / 23903356 rs12186664 chr5 95630225 A T 4.12E-08 Glycemic traits (pregnancy) / / 23903356 rs17085593 chr5 95630705 C G 2.01E-14 Glycemic traits (pregnancy) / / 23903356 rs17085593 chr5 95630705 C G 3.13E-15 Glycemic traits (pregnancy) / / 23903356 rs10515235 chr5 95659056 G A 8.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10040098 chr5 95674266 C T 2.24E-10 Glycemic traits (pregnancy) / / 23903356 rs10040098 chr5 95674266 C T 5.80E-12 Glycemic traits (pregnancy) / / 23903356 rs35123095 chr5 95674266 C CC,CT 2.24E-10 Glycemic traits (pregnancy) / / 23903356 rs35123095 chr5 95674266 C CC,CT 5.80E-12 Glycemic traits (pregnancy) / / 23903356 rs1995186 chr5 95678301 C T 5.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs6863434 chr5 95695673 C T 2.24E-09 Glycemic traits (pregnancy) / / 23903356 rs6863434 chr5 95695673 C T 3.44E-08 Glycemic traits (pregnancy) / / 23903356 rs10476552 chr5 95709132 T C 4.70E-05 Fasting plasma glucose / / 19060907 rs10476552 chr5 95709132 T C 1.66E-10 Glycemic traits (pregnancy) / / 23903356 rs10476552 chr5 95709132 T C 5.84E-09 Glycemic traits (pregnancy) / / 23903356 rs10476552 chr5 95709132 T C 1.71E-05 Glucose levels / / pha002899 rs10476552 chr5 95709132 T C 8.37E-05 Insulin-related traits / / pha002901 rs7713317 chr5 95716722 A G 0.00028 2-hour glucose tolerance test / / 22885924 rs7713317 chr5 95716722 A G 4.43E-18 Fasting blood glucose / / 22885924 rs7713317 chr5 95716722 A G 1.23E-11 Glycemic traits (pregnancy) / / 23903356 rs7713317 chr5 95716722 A G 3.95E-10 Glycemic traits (pregnancy) / / 23903356 rs7722200 chr5 95717440 T C 3.22E-10 Glycemic traits (pregnancy) / / 23903356 rs7722200 chr5 95717440 T C 9.58E-09 Glycemic traits (pregnancy) / / 23903356 rs10213965 chr5 95719667 G C 2.74E-10 Glycemic traits (pregnancy) / / 23903356 rs10213965 chr5 95719667 G C 8.47E-09 Glycemic traits (pregnancy) / / 23903356 rs17085655 chr5 95719804 A G 2.89E-10 Glycemic traits (pregnancy) / / 23903356 rs17085655 chr5 95719804 A G 8.80E-09 Glycemic traits (pregnancy) / / 23903356 rs17085675 chr5 95727664 A T 1.76E-08 Glycemic traits (pregnancy) PCSK1 UTR-3 23903356 rs17085675 chr5 95727664 A T 3.95E-10 Glycemic traits (pregnancy) PCSK1 UTR-3 23903356 rs6235 chr5 95728898 C G 1.00E-26 Proinsulin levels PCSK1 missense 21873549 rs6235 chr5 95728898 C G 0.000000023 Insulin processing and secretion PCSK1 missense 23263489 rs6235 chr5 95728898 C G 1.29E-13 Glycemic traits (pregnancy) PCSK1 missense 23903356 rs6235 chr5 95728898 C G 5.00E-15 Glycemic traits (pregnancy) PCSK1 missense 23903356 rs6234 chr5 95728974 G C 1.08E-08 Glycemic traits (pregnancy) PCSK1 missense 23903356 rs6234 chr5 95728974 G C 6.37E-07 Glycemic traits (pregnancy) PCSK1 missense 23903356 rs13168460 chr5 95732569 A T 1.23E-07 Glycemic traits (pregnancy) PCSK1 intron 23903356 rs13168460 chr5 95732569 A T 2.08E-09 Glycemic traits (pregnancy) PCSK1 intron 23903356 rs113318 chr5 95741480 A G 2.50E-04 Type 2 diabetes and 6 quantitative traits PCSK1 intron 17848626 rs10515237 chr5 95751549 A G 4.51E-07 Glycemic traits (pregnancy) PCSK1 intron 23903356 rs17386243 chr5 95753680 A C 8.77E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) PCSK1 intron 22566498 rs3811951 chr5 95762477 A G 1.73E-07 Glycemic traits (pregnancy) PCSK1 intron 23903356 rs3811951 chr5 95762477 A G 6.77E-06 Glycemic traits (pregnancy) PCSK1 intron 23903356 rs6556924 chr5 95790308 T C 5.18E-04 Alzheimer's disease / / 24755620 rs10074809 chr5 95818902 C T 2.92E-05 Waist Circumference / / pha003023 rs7737742 chr5 95845247 T C 1.08E-10 Body mass index / / 22344219 rs10077823 chr5 95846330 A G 1.16E-10 Body mass index / / 22344219 rs261964 chr5 95848076 T C 1.16E-10 Body mass index / / 22344219 rs6556926 chr5 95848613 T A 1.18E-10 Body mass index / / 22344219 rs3853212 chr5 95849348 C T 9.77E-11 Body mass index / / 22344219 rs261966 chr5 95849587 T C 1.91E-10 Body mass index / / 22344219 rs261967 chr5 95850250 A C 5.00E-09 Body mass index / / 22344219 rs261967 chr5 95850250 A C 8.00E-13 Body mass index / / 24861553 rs263349 chr5 95851624 T A,G 9.54E-11 Body mass index / / 22344219 rs1026534 chr5 95855091 G C 1.65E-10 Body mass index / / 22344219 rs2611742 chr5 95856501 T C 2.99E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2611742 chr5 95856501 T C 1.22E-10 Body mass index / / 22344219 rs2570467 chr5 95856679 A G 3.23E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2570467 chr5 95856679 A G 1.00E-06 Waist circumference / / 23966867 rs10476682 chr5 95858258 A G 1.74E-10 Body mass index / / 22344219 rs1837269 chr5 95859144 C T 1.04E-10 Body mass index / / 22344219 rs11951673 chr5 95861012 C T 1.54E-10 Body mass index / / 22344219 rs6882366 chr5 95864693 C T 1.22E-10 Body mass index / / 22344219 rs13178437 chr5 95882162 A G 4.18E-04 Insulin resistance / / 21901158 rs10055259 chr5 95883847 C A 9.84E-05 Bipolar disorder and schizophrenia / / 20889312 rs9918149 chr5 95900634 C T 4.77E-05 Bipolar Disorder / / pha002863 rs1459841 chr5 95910465 A G 2.00E-04 Suicidal ideation / / 22030708 rs897746 chr5 95921529 G A 1.03E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs261218 chr5 95930564 T C 8.22E-04 Body mass index / / 21701565 rs261214 chr5 95939825 A G 7.03E-06 Central corneal thickness / / 20719862 rs261212 chr5 95941365 C T 6.39E-06 Central corneal thickness / / 20719862 rs17086379 chr5 95958386 G A 7.20E-06 Bipolar disorder / / 20451256 rs4869304 chr5 95983469 C T 8.31E-04 Parkinson's disease / / 17052657 rs4400148 chr5 95988787 T C 1.80E-04 Multiple complex diseases / / 17554300 rs1421912 chr5 96000795 C A 1.84E-04 Multiple complex diseases CAST intron 17554300 rs1421911 chr5 96000947 A G 2.77E-04 Type 2 diabetes CAST intron 17463246 rs17399347 chr5 96021928 A G 8.72E-04 Type 2 diabetes CAST intron 17463246 rs4434401 chr5 96039025 T C 7.23E-05 Parkinson's disease CAST intron 17052657 rs10053056 chr5 96043420 T C 1.96E-05 Parkinson's disease CAST intron 17052657 rs42442 chr5 96044060 G C 3.62E-04 Multiple complex diseases CAST intron 17554300 rs17086588 chr5 96044914 A G 1.25E-05 Parkinson's disease (motor and cognition) CAST intron 22658654 rs11745122 chr5 96060738 T C 4.62E-06 Parkinson's disease (motor and cognition) CAST intron 22658654 rs13362120 chr5 96071194 T C 4.29E-04 Amyotrophic Lateral Sclerosis CAST intron 17362836 rs13362120 chr5 96071194 T C 9.65E-06 Alcohol dependence CAST intron 19581569 rs26503 chr5 96078309 G A 2.55E-04 Type 2 diabetes CAST intron 17463246 rs26506 chr5 96079402 C T 1.90E-05 Urinary metabolites CAST intron 21572414 rs27851 chr5 96082401 C T 4.92E-05 Blood Pressure CAST intron pha003050 rs27772 chr5 96089976 A G 2.76E-04 Alzheimer's disease (late onset) CAST intron 21379329 rs27037 chr5 96094694 T G 8.20E-11 Ankylosing spondylitis CAST intron 20062062 rs27524 chr5 96101944 A G 3.00E-11 Psoriasis CAST intron 20953190 rs27524 chr5 96101944 A G 7.00E-06 Hodgkin's lymphoma CAST intron 22286212 rs28096 chr5 96109244 G A 3.15E-04 Amyotrophic Lateral Sclerosis CAST UTR-3 17362836 rs13160562 chr5 96111371 G A 7.00E-06 Alcohol dependence ERAP1 UTR-3 19581569 rs13160562 chr5 96111371 G A 7.64E-05 Cognitive test performance ERAP1 UTR-3 20125193 rs149481 chr5 96114346 A C 4.61E-05 Kawasaki disease ERAP1 intron 21326860 rs27042 chr5 96116940 G A 1.53E-04 Kawasaki disease ERAP1 intron 21326860 rs17482078 chr5 96118866 C T 4.00E-08 Behcet's disease ERAP1 missense 23291587 rs17482078 chr5 96118866 C T 5.00E-11 Behcet's disease ERAP1 missense 23291587 rs27432 chr5 96119273 A G 1.90E-20 Psoriasis ERAP1 intron 23143594 rs10050860 chr5 96122210 C T 1.10E-08 Ankylosing spondylitis ERAP1 missense 21743469 rs30187 chr5 96124330 T C 2.00E-27 Ankylosing spondylitis ERAP1 missense 21743469 rs13170045 chr5 96125785 G T 7.70E-10 Ankylosing spondylitis ERAP1 intron 21743469 rs27710 chr5 96126197 A G 5.55E-05 Serum metabolites ERAP1 intron 19043545 rs27710 chr5 96126197 A G 7.60E-10 Ankylosing spondylitis ERAP1 intron 21743469 rs27529 chr5 96126308 A G 4.73E-05 Serum metabolites ERAP1 cds-synon 19043545 rs27434 chr5 96129512 A G 5.00E-12 Ankylosing spondylitis ERAP1 cds-synon 20062062 rs26618 chr5 96130836 T A,C,G 4.83E-04 Atopic dermatitis ERAP1 missense 21666691 rs26654 chr5 96140367 C T 1.20E-19 Leukemia(T-cell recognition in patients) ERAP1 intron 21062987 rs34755 chr5 96151760 G T 4.18E-04 Aortic root size ERAP1 nearGene-5 21223598 rs18036 chr5 96155608 T C 3.01E-04 Atopic dermatitis / / 21666691 rs151823 chr5 96159992 A C 4.41E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs151823 chr5 96159992 A C 1.00E-09 Psoriasis / / 20953187 rs151823 chr5 96159992 A C 9.32E-09 Psoriasis / / 20953187 rs12520537 chr5 96163905 A G 5.66E-05 Cognitive impairment induced by topiramate / / 22091778 rs7708451 chr5 96180913 C T 8.88E-05 Blood Pressure / / pha003050 rs1230358 chr5 96211741 T G 5.08E-04 Multiple complex diseases ERAP2 UTR-5 17554300 rs41506651 chr5 96215680 C T 7.09E-04 Multiple complex diseases ERAP2 cds-synon 17554300 rs4869315 chr5 96229272 G A 7.82E-04 Psoriasis ERAP2 intron 20953187 rs2248374 chr5 96235896 A G 0.00000018 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) ERAP2 intron 23603761 rs2549794 chr5 96244549 C T 6.97E-04 Multiple complex diseases ERAP2 intron 17554300 rs2549794 chr5 96244549 C T 1.00E-10 Crohn's disease ERAP2 intron 21102463 rs17486915 chr5 96244719 T C 2.26E-04 Multiple complex diseases ERAP2 cds-synon 17554300 rs1363907 chr5 96252803 G A 6.00E-13 Inflammatory bowel disease ERAP2 intron 23128233 rs1019503 chr5 96254817 G A 5.10E-09 2-hour glucose tolerance test ERAP2 UTR-3 22885924 rs7705093 chr5 96290647 C T 2.00E-09 Birdshot chorioretinopathy LNPEP intron 24957906 rs3909451 chr5 96295121 G T 9.00E-04 Multiple complex diseases LNPEP intron 17554300 rs3909451 chr5 96295121 G T 1.36E-42 Lymphocyte counts LNPEP intron 22286170 rs27290 chr5 96350088 G A 0.000124 Oligoarticular juvenile idiopathic arthritis LNPEP intron 23603761 rs27290 chr5 96350088 G A 7.50E-09 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) LNPEP intron 23603761 rs27293 chr5 96357178 A G 7.37E-09 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) LNPEP intron 23603761 rs27300 chr5 96363407 C T 9.82E-04 Multiple complex diseases LNPEP intron 17554300 rs17087256 chr5 96375018 A G 3.41E-06 Uric acid levels / / 21294900 rs17087274 chr5 96379169 A G 4.19E-06 Uric acid levels / / 21294900 rs316223 chr5 96413667 T C 5.40E-04 Insulin resistance / / 21901158 rs6884540 chr5 96417188 C T 3.24E-04 Multiple complex diseases / / 17554300 rs6863597 chr5 96483480 T C 1.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs27311 chr5 96505108 A C 8.78E-04 Type 2 diabetes RIOK2 intron 17463246 rs2548417 chr5 96534619 A T 3.39E-05 Serum metabolites / / 19043545 rs10045981 chr5 96546305 G T 6.69E-05 Myopia (severe) / / 23933737 rs17630601 chr5 96546318 G A 9.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7733541 chr5 96658577 A C 4.05E-05 Anxiety in major depressive disorder / / 24047446 rs10476564 chr5 96671793 A G 3.78E-06 Serum metabolites / / 19043545 rs10054076 chr5 96701779 G A 1.66E-05 Gallstones / / 17632509 rs2220200 chr5 96728948 C T 2.11E-05 Serum metabolites / / 19043545 rs13356240 chr5 96771374 T C 5.97E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9314208 chr5 96788162 G A 3.51E-04 Hearing function / / 17255346 rs1385583 chr5 96823754 T C 8.43E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2035550 chr5 96835489 G T 8.40E-05 Pericardial fat / / 22589742 rs6893784 chr5 96845353 G A 8.60E-05 Pericardial fat / / 22589742 rs55988457 chr5 96949073 T C 6.00E-08 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs1560325 chr5 97027698 C A 6.10E-05 Schizophrenia / / 21674006 rs10476724 chr5 97030575 T C 2.60E-05 Bipolar disorder and schizophrenia / / 20889312 rs7709586 chr5 97062961 A G 2.00E-05 Urinary metabolites / / 21572414 rs1429862 chr5 97072819 C T 9.00E-06 Body mass index / / 20818722 rs10515260 chr5 97076548 T C 6.00E-07 Estradiol plasma levels (breast cancer) / / 23518928 rs4585475 chr5 97088566 G A 2.40E-05 Urinary metabolites / / 21572414 rs11742228 chr5 97244970 A T 1.60E-05 Urinary metabolites / / 21572414 rs1363886 chr5 97315918 T C 2.10E-05 Glaucoma (primary open-angle) / / 20835238 rs257226 chr5 97423476 A G 1.75E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs17088027 chr5 97432181 C T 1.89E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1421791 chr5 97436504 T C 2.70E-06 Urinary metabolites / / 21572414 rs1124028 chr5 97447980 C A 6.80E-06 Urinary metabolites / / 21572414 rs10062992 chr5 97478870 G A 5.39E-04 Multiple complex diseases / / 17554300 rs10063003 chr5 97478920 G A 4.88E-04 Multiple complex diseases / / 17554300 rs13359033 chr5 97483290 T G 1.50E-05 Urinary metabolites / / 21572414 rs7708036 chr5 97501044 G A 4.87E-05 Tunica Media / / pha003034 rs7708036 chr5 97501044 G A 9.04E-05 Tunica Media / / pha003036 rs12521722 chr5 97507280 T C 7.65E-05 Tunica Media / / pha003034 rs4131052 chr5 97512104 C T 1.80E-05 Urinary metabolites / / 21572414 rs10070145 chr5 97555396 A G 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs4132141 chr5 97598306 A G 1.32E-05 Insulin-related traits / / pha003063 rs17165849 chr5 97655286 G T 2.00E-05 Asperger disorder / / 21182207 rs17165849 chr5 97655286 G T 2.43E-05 Tunica Media / / pha003036 rs6889185 chr5 97659388 T C 6.62E-04 Multiple complex diseases / / 17554300 rs6596729 chr5 97674522 T C 3.83E-04 HIV-1 viral setpoint / / 17641165 rs725763 chr5 97692587 A C 7.91E-04 Multiple complex diseases / / 17554300 rs1378441 chr5 97744026 C A 2.00E-05 Asperger disorder / / 21182207 rs11241318 chr5 97754900 G T 1.30E-04 Asperger disorder / / 21182207 rs1455420 chr5 97756382 T G 3.00E-05 Asperger disorder / / 21182207 rs1563317 chr5 97768486 A G 1.00E-05 Asperger disorder / / 21182207 rs1037597 chr5 97783046 T C 5.00E-05 Asperger disorder / / 21182207 rs10515272 chr5 97793130 A G 0.000748 Salmonella-induced pyroptosis / / 22837397 rs11954735 chr5 97801476 G A 4.00E-05 Asperger disorder / / 21182207 rs10515276 chr5 97836794 T C 1.13E-05 Magnesium levels / / pha003092 rs4703129 chr5 97888736 C A 1.00E-06 Asperger disorder / / 21182207 rs17166099 chr5 97903140 C T 8.60E-04 Alzheimer's disease / / 17998437 rs27787 chr5 97915918 C T 1.01E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs461409 chr5 97929966 C T 8.86E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs461409 chr5 97929966 C T 4.32E-06 Schizophrenia (treatment refractory) / / 22479419 rs461409 chr5 97929966 C T 3.00E-06 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs7701903 chr5 97940938 G C 3.27E-04 Cognition,early reading ability / / 17684495 rs467650 chr5 97969453 T C 4.20E-06 Smoking behavior / / 20418888 rs467650 chr5 97969453 T C 1.00E-08 Venous thromboembolism (gene x gene interaction) / / 23509962 rs162675 chr5 97991394 G C 7.40E-07 Urinary metabolites / / 21572414 rs316510 chr5 98009178 A T 7.20E-07 Urinary metabolites / / 21572414 rs316508 chr5 98010420 T C 1.50E-07 Urinary metabolites / / 21572414 rs6877710 chr5 98016115 C T 7.99E-04 Smoking cessation / / 24665060 rs160714 chr5 98016834 A G 7.20E-07 Urinary metabolites / / 21572414 rs408005 chr5 98022320 G A 7.00E-07 Urinary metabolites / / 21572414 rs456367 chr5 98035618 A T 1.30E-06 Urinary metabolites / / 21572414 rs2547952 chr5 98051255 T C 1.60E-06 Urinary metabolites / / 21572414 rs1592853 chr5 98051737 G C 6.70E-06 Urinary metabolites / / 21572414 rs977028 chr5 98056508 T C 4.75E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17166337 chr5 98064721 T C 1.55E-04 Multiple complex diseases / / 17554300 rs10900866 chr5 98087319 T C 8.51E-05 Alcohol dependence / / 19581569 rs330419 chr5 98193164 C T 1.10E-05 Urinary metabolites CHD1 intron 21572414 rs325204 chr5 98196883 G C 1.50E-05 Urinary metabolites CHD1 intron 21572414 rs161940 chr5 98237602 G T 1.80E-05 Urinary metabolites CHD1 intron 21572414 rs161749 chr5 98252488 T C 1.70E-05 Urinary metabolites CHD1 intron 21572414 rs161747 chr5 98256137 G T 5.60E-06 Urinary metabolites CHD1 intron 21572414 rs161950 chr5 98260237 G A 4.20E-06 Urinary metabolites CHD1 intron 21572414 rs9327919 chr5 98270725 T C 6.46E-04 Multiple complex diseases / / 17554300 rs161937 chr5 98273862 A G 4.05E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs17166455 chr5 98275939 T C 2.54E-04 Nicotine dependence / / 17158188 rs327807 chr5 98278152 G A 8.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs467728 chr5 98289567 G A 1.33E-04 Attention deficit hyperactivity disorder / / pha002875 rs7707061 chr5 98363240 A C 2.40E-05 Multiple complex diseases / / 17554300 rs4554256 chr5 98392418 A G 4.99E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2121668 chr5 98423044 A G 3.54E-05 Tunica Media / / pha003037 rs7716372 chr5 98428184 A G 7.65E-05 Panic disorder / / 19165232 rs17166666 chr5 98435558 G A 1.51E-05 Vitiligo / / 19890347 rs10900893 chr5 98450813 G A 6.40E-06 Multiple complex diseases / / 17554300 rs1447383 chr5 98456213 A G 4.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs6875635 chr5 98457210 T C 8.12E-06 Multiple complex diseases / / 17554300 rs7708845 chr5 98458109 C T 4.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs6868877 chr5 98469429 A G 2.52E-06 Multiple complex diseases / / 17554300 rs1348926 chr5 98470314 T G 5.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs2121669 chr5 98471061 C T 6.96E-06 Multiple complex diseases / / 17554300 rs17166707 chr5 98472620 G A 3.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs4277937 chr5 98497977 C A 8.21E-05 Schizophrenia / / 24253340 rs2369577 chr5 98509289 G A 1.10E-04 Multiple complex diseases / / 17554300 rs2369629 chr5 98524496 G T 5.10E-05 Multiple complex diseases / / 17554300 rs2887526 chr5 98524812 T C 1.66E-04 Multiple complex diseases / / 17554300 rs1374663 chr5 98524874 G A 8.09E-05 Multiple complex diseases / / 17554300 rs2166724 chr5 98532010 C T 9.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2121665 chr5 98537121 T C 6.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4703054 chr5 98548315 C A 3.33E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1121306 chr5 98552184 G T 3.33E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1574968 chr5 98569709 G A 4.75E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6863194 chr5 98575406 C G 9.88E-06 Periodontitis (Mean PAL) / / 24024966 rs17736767 chr5 98579964 C G 7.00E-06 Renal sinus fat / / 22044751 rs1500251 chr5 98593453 G A 9.00E-06 Periodontitis (Mean PAL) / / 24024966 rs17166824 chr5 98618694 A G 5.90E-05 Cholesterol / / pha003073 rs17166824 chr5 98618694 A G 9.91E-05 ldl cholesterol / / pha003076 rs17166824 chr5 98618694 A G 7.17E-05 Cholesterol / / pha003078 rs4702966 chr5 98644175 C T 5.78E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs4464723 chr5 98653715 C T 1.22E-05 Aortic root size / / 21223598 rs1523358 chr5 98686197 T C 6.18E-04 Aortic root size / / 21223598 rs11745890 chr5 98715768 T C 4.00E-06 IgG glycosylation / / 23382691 rs2511925 chr5 98721872 G A 7.83E-05 Body Mass Index / / pha003015 rs2948756 chr5 98726889 T C 4.84E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2948756 chr5 98726889 T C 1.20E-05 Body Mass Index / / pha003015 rs1879360 chr5 98775330 G A 6.65E-05 Body Mass Index / / pha003015 rs1829883 chr5 98781103 C T 6.00E-06 Hemostatic factors and hematological phenotypes / / 17903294 rs6885370 chr5 98802762 C T 7.86E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs17167021 chr5 98880299 A G 1.00E-07 Large artery stroke / / 24262325 rs17167077 chr5 98919157 T C 8.13E-04 Suicide attempts in bipolar disorder / / 21041247 rs2548098 chr5 98921515 G A 1.10E-05 Body Mass Index / / pha003015 rs2682160 chr5 98921572 G A 9.51E-05 Body Mass Index / / pha003015 rs2682158 chr5 98922899 A G 9.23E-05 Body Mass Index / / pha003015 rs681634 chr5 98931151 C A 6.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10900675 chr5 98941127 A G 4.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3850905 chr5 98951156 G A 3.22E-05 Body Mass Index / / pha003015 rs6892152 chr5 98954234 T C 7.80E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10035117 chr5 98989782 G T 2.79E-05 Body Mass Index / / pha003015 rs3850896 chr5 99001877 T G 2.80E-05 Urinary metabolites / / 21572414 rs1462419 chr5 99052680 G A 4.84E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1462419 chr5 99052680 G A 6.36E-05 Body Mass Index / / pha003015 rs10059664 chr5 99062564 A G 8.50E-05 Response to statin therapy / / 20339536 rs10478109 chr5 99068661 A C 6.91E-04 Multiple complex diseases / / 17554300 rs2118735 chr5 99082357 G A 7.19E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4626370 chr5 99088514 G A 1.27E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs749527 chr5 99124408 C T 2.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1161252 chr5 99127127 T G 1.78E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1161257 chr5 99129327 G A 2.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11950209 chr5 99134657 C T 1.07E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7449116 chr5 99136563 T C 1.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6594760 chr5 99140203 A G 2.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10067053 chr5 99141638 A C 7.45E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2369765 chr5 99143862 T G 2.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1901968 chr5 99145743 C T 4.25E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2123812 chr5 99146521 A G 2.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7705032 chr5 99147433 C G 2.37E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7705200 chr5 99147531 C G 2.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4451090 chr5 99149553 T C 3.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6879586 chr5 99150166 G A 2.21E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11955182 chr5 99150534 C T 2.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1078772 chr5 99151377 A G 2.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6877816 chr5 99152672 T G 1.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6878343 chr5 99153139 A G 2.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2369754 chr5 99156362 C A 4.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2168006 chr5 99159595 T C 9.82E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11740912 chr5 99161947 A C 3.10E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2123808 chr5 99183797 A G 4.09E-05 Coronary heart disease / / pha003056 rs13356795 chr5 99235642 G T 1.16E-04 White matter integrity / / 22425255 rs13356795 chr5 99235642 G T 4.18E-04 Smoking initiation / / 24665060 rs2602989 chr5 99236162 G A 1.49E-13 Multiple complex diseases / / 17554300 rs17167387 chr5 99238090 A G 3.77E-04 Smoking initiation / / 24665060 rs3912083 chr5 99275788 A C 3.57E-05 Intracerebral hemorrhage / / 24656865 rs10071953 chr5 99286674 G A 3.54E-05 Intracerebral hemorrhage / / 24656865 rs10038494 chr5 99287783 C G 3.30E-05 Intracerebral hemorrhage / / 24656865 rs10515289 chr5 99287946 T C 2.21E-05 Pulmonary function / / 17903307 rs73775963 chr5 99289169 C A 3.00E-05 Intracerebral hemorrhage / / 24656865 rs9326957 chr5 99290038 A G 2.76E-05 Intracerebral hemorrhage / / 24656865 rs9326958 chr5 99290311 A G 3.25E-05 Intracerebral hemorrhage / / 24656865 rs13359551 chr5 99292103 C G 2.32E-05 Intracerebral hemorrhage / / 24656865 rs10079213 chr5 99292308 T G 1.07E-04 Amyotrophic lateral sclerosis / / 20801718 rs10079213 chr5 99292308 T G 1.88E-05 Intracerebral hemorrhage / / 24656865 rs17695461 chr5 99325303 A C 1.04E-04 Amyotrophic lateral sclerosis / / 20801718 rs10067427 chr5 99342047 A G 5.00E-06 Non-alcoholic fatty liver disease histology (lobular) / / 20708005 rs59014024 chr5 99405223 C T 9.79E-06 Intracerebral hemorrhage / / 24656865 rs13360055 chr5 99444898 A G 2.96E-05 Intracerebral hemorrhage / / 24656865 rs10038187 chr5 99447747 C A 3.16E-05 Intracerebral hemorrhage / / 24656865 rs1504529 chr5 99536420 C G 2.43E-04 Multiple complex diseases / / 17554300 rs17131902 chr5 99538338 T C 1.94E-05 Multiple complex diseases / / 17554300 rs1824777 chr5 99614601 G T 1.88E-04 Multiple complex diseases / / 17554300 rs1824777 chr5 99614601 G T 2.16E-27 Narcolepsy / / 19629137 rs1824780 chr5 99644079 A C 1.91E-05 Multiple complex diseases / / 17554300 rs463144 chr5 99651049 C T 9.34E-05 Multiple complex diseases / / 17554300 rs468216 chr5 99653975 G C 1.13E-04 Multiple complex diseases / / 17554300 rs797013 chr5 99656064 A G 2.71E-05 Multiple complex diseases / / 17554300 rs161320 chr5 99661931 T C 3.24E-04 Multiple complex diseases / / 17554300 rs898765 chr5 99742364 T C 5.52E-05 Rheumatoid arthritis / / 17804836 rs4703099 chr5 99772825 C G 4.53E-05 Multiple complex diseases / / 17554300 rs1350847 chr5 99793079 G A 1.77E-05 Multiple complex diseases / / 17554300 rs10073692 chr5 99815102 A C 2.38E-05 Multiple complex diseases / / 17554300 rs574689 chr5 99864113 G A 6.97E-05 Multiple complex diseases / / 17554300 rs17447382 chr5 99883371 G A 1.13E-06 Multiple complex diseases FAM174A intron 17554300 rs6874840 chr5 99897866 G A 1.66E-05 Multiple complex diseases FAM174A cds-synon 17554300 rs247938 chr5 99898851 T C 3.35E-05 Body Mass Index FAM174A intron pha003021 rs258540 chr5 99928263 T G 1.90E-05 Urinary metabolites / / 21572414 rs247963 chr5 99931937 T C 2.30E-05 Urinary metabolites / / 21572414 rs247951 chr5 99942803 T C 6.73E-05 Multiple complex diseases / / 17554300 rs383830 chr5 99948982 A T 5.71E-06 Multiple complex diseases / / 17554300 rs383830 chr5 99948982 A T 5.72E-06 Coronary Artery Disease / / 17634449 rs449650 chr5 99949018 T G 6.74E-06 Multiple complex diseases / / 17554300 rs449650 chr5 99949018 T G 6.74E-06 Coronary Artery Disease / / 17634449 rs445632 chr5 99950589 T G 9.81E-05 Body Mass Index / / pha003020 rs445632 chr5 99950589 T G 8.08E-05 Body Mass Index / / pha003021 rs492880 chr5 99952136 G C 1.01E-04 Multiple complex diseases / / 17554300 rs431850 chr5 99952213 C T 1.06E-04 Multiple complex diseases / / 17554300 rs436495 chr5 99952282 A G 5.93E-06 Multiple complex diseases / / 17554300 rs436495 chr5 99952282 A G 7.06E-05 Body Mass Index / / pha003020 rs436495 chr5 99952282 A G 2.35E-05 Body Mass Index / / pha003021 rs388609 chr5 99953303 G C 1.56E-04 Multiple complex diseases / / 17554300 rs371136 chr5 99953557 A T 7.17E-05 Multiple complex diseases / / 17554300 rs565928 chr5 99953690 T C 5.71E-06 Multiple complex diseases / / 17554300 rs565928 chr5 99953690 T C 5.71E-06 Coronary Artery Disease / / 17634449 rs2456175 chr5 99953772 C T 7.29E-05 Multiple complex diseases / / 17554300 rs185066 chr5 99957513 A C 8.39E-05 Multiple complex diseases / / 17554300 rs247932 chr5 99959205 C T 9.67E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs282072 chr5 99978638 A C 2.40E-05 Urinary metabolites / / 21572414 rs282072 chr5 99978638 A C 2.22E-04 Sudden cardiac arrest / / 21658281 rs4702982 chr5 99991648 C T 5.75E-05 Multiple complex diseases / / 17554300 rs4702982 chr5 99991648 C T 6.00E-06 Panic disorder / / 19165232 rs17158313 chr5 99994937 G C 1.42E-04 Multiple complex diseases / / 17554300 rs17158384 chr5 100006438 A G 8.85E-04 Multiple complex diseases / / 17554300 rs2725107 chr5 100031644 G A 9.66E-04 Myopia (pathological) / / 21095009 rs2725122 chr5 100054906 T G 5.70E-04 Multiple complex diseases / / 17554300 rs17158782 chr5 100062683 T C 4.51E-11 HDL cholesterol / / 23063622 rs279109 chr5 100082233 G A 7.27E-04 Coronary Artery Disease / / 17634449 rs279109 chr5 100082233 G A 5.37E-04 Alzheimer's disease / / 17998437 rs13356977 chr5 100083402 T C 1.53E-04 Multiple complex diseases / / 17554300 rs4703116 chr5 100128913 T C 6.00E-04 Alcohol dependence / / 20201924 rs32477 chr5 100132577 C G 1.79E-07 Multiple sclerosis / / 17660530 rs2548278 chr5 100165117 T C 3.04E-04 Myopia (pathological) ST8SIA4 intron 21095009 rs2548276 chr5 100168066 T C 0.0000619 Primary sclerosing cholangitis ST8SIA4 intron 23603763 rs32479 chr5 100172595 A C 9.80E-05 Response to statin therapy ST8SIA4 intron 20339536 rs1423380 chr5 100221189 T C 9.30E-05 Response to statin therapy ST8SIA4 UTR-3 20339536 rs3776176 chr5 100232575 A C 7.90E-05 Response to statin therapy ST8SIA4 intron 20339536 rs1423384 chr5 100234439 C T 8.60E-05 Response to statin therapy ST8SIA4 intron 20339536 rs1428439 chr5 100238801 A G 9.70E-05 Response to statin therapy ST8SIA4 UTR-5 20339536 rs4703131 chr5 100248643 T C 9.00E-05 Response to statin therapy / / 20339536 rs1152127 chr5 100248867 A G 2.82E-04 Multiple complex diseases / / 17554300 rs17782250 chr5 100249342 T A 7.90E-05 Response to statin therapy / / 20339536 rs10214216 chr5 100249728 C T 7.70E-05 Response to statin therapy / / 20339536 rs4702993 chr5 100254164 A G 7.70E-05 Response to statin therapy / / 20339536 rs10059470 chr5 100259241 A T 7.70E-05 Response to statin therapy / / 20339536 rs11742323 chr5 100263707 C T 5.20E-05 Response to statin therapy / / 20339536 rs11742323 chr5 100263707 C T 0.000761 Salmonella-induced pyroptosis / / 22837397 rs11748772 chr5 100263907 G A 9.40E-05 Response to statin therapy / / 20339536 rs10515303 chr5 100275313 C T 7.50E-05 Response to statin therapy / / 20339536 rs17726244 chr5 100277256 C T 2.60E-05 Response to statin therapy / / 20339536 rs13354021 chr5 100279289 T C 9.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17726346 chr5 100280335 A C 8.90E-05 Response to statin therapy / / 20339536 rs4703134 chr5 100284962 C T 3.50E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17161553 chr5 100301806 T C 1.00E-06 IgG glycosylation / / 23382691 rs17161553 chr5 100301806 T C 6.00E-06 IgG glycosylation / / 23382691 rs7711997 chr5 100340406 C T 7.37E-04 Parkinson's disease / / 17052657 rs575018 chr5 100379393 C T 3.52E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs575018 chr5 100379393 C T 7.00E-07 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs505994 chr5 100383763 A C 1.97E-06 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs557953 chr5 100400668 G A 1.71E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs557953 chr5 100400668 G A 3.53E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs1567663 chr5 100478431 G T 6.75E-05 Body Mass Index / / pha003021 rs6595846 chr5 100623751 C A 4.29E-04 Multiple complex diseases / / 17554300 rs1903187 chr5 100630658 A C 4.57E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1459583 chr5 100633738 T C 3.86E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9654535 chr5 100634067 T G 2.60E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17134275 chr5 100634999 G A 4.05E-04 Multiple complex diseases / / 17554300 rs17134277 chr5 100635462 T C 5.45E-04 Multiple complex diseases / / 17554300 rs6882884 chr5 100636842 C T 3.72E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10069443 chr5 100637267 C T 3.86E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7716543 chr5 100665557 C T 4.17E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7448378 chr5 100668241 C G 4.44E-04 Smoking quantity / / 24665060 rs1599132 chr5 100669673 C A 2.27E-04 Smoking quantity / / 24665060 rs6861743 chr5 100675524 G A 9.54E-04 Multiple complex diseases / / 17554300 rs10058511 chr5 100712084 T C 6.74E-06 White blood cell count / / 21738479 rs2172106 chr5 100770172 T C 5.84E-04 Multiple complex diseases / / 17554300 rs6860058 chr5 100775607 G A 1.44E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs6860058 chr5 100775607 G A 1.97E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs350535 chr5 100867055 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs13188771 chr5 100948545 C A 2.00E-06 Conduct disorder (interaction) / / 18846501 rs1479063 chr5 101023689 C T 3.70E-06 Urinary metabolites / / 21572414 rs1382652 chr5 101032308 A G 3.70E-05 Aging (time to event) / / 21782286 rs12521068 chr5 101060923 T C 8.91E-05 Fibrinogen / / pha003068 rs11743671 chr5 101096801 T A 8.00E-06 Urinary metabolites / / 21572414 rs354670 chr5 101110298 C T 7.02E-05 Information processing speed / / 21130836 rs1453109 chr5 101116850 T C 1.30E-05 Urinary metabolites / / 21572414 rs13166990 chr5 101215710 G T 2.97E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs13166990 chr5 101215710 G T 2.99E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1453115 chr5 101261800 G A 2.60E-05 Urinary metabolites / / 21572414 rs1453115 chr5 101261800 G A 7.94E-04 Alzheimer's disease / / 24755620 rs6870397 chr5 101291960 T C 7.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1564154 chr5 101306806 T C 2.19E-04 Multiple complex diseases / / 17554300 rs10039226 chr5 101318530 G C 9.90E-06 Urinary metabolites / / 21572414 rs4272111 chr5 101319870 T C 7.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6877249 chr5 101320175 G A 9.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1011624 chr5 101320305 A G 2.30E-05 Urinary metabolites / / 21572414 rs5020202 chr5 101341123 C A 8.44E-04 Alzheimer's disease / / 24755620 rs4419568 chr5 101344133 G A 4.68E-04 Multiple complex diseases / / 17554300 rs4419568 chr5 101344133 G A 9.63E-06 Alzheimer's disease / / 24755620 rs3846609 chr5 101344804 C T 4.20E-04 Multiple complex diseases / / 17554300 rs3846609 chr5 101344804 C T 9.26E-04 Alzheimer's disease / / 24755620 rs1477612 chr5 101360694 C T 4.19E-04 Multiple complex diseases / / 17554300 rs881236 chr5 101367263 A C 2.34E-04 Multiple complex diseases / / 17554300 rs881236 chr5 101367263 A C 1.24E-05 Alzheimer's disease / / 24755620 rs1381972 chr5 101373586 A T 1.75E-04 Alzheimer's disease / / 24755620 rs12188653 chr5 101383803 G C 0.000143 Oxaliplatin induced neuropathy in response to colorectal cancer treatment / / 22310351 rs6861497 chr5 101403586 A G 5.00E-06 QRS duration / / 23534349 rs17145875 chr5 101404149 T C 3.00E-04 Multiple complex diseases / / 17554300 rs922372 chr5 101413002 G A 1.42E-04 Multiple complex diseases / / 17554300 rs1026664 chr5 101439319 T C 9.35E-04 Multiple complex diseases / / 17554300 rs1827149 chr5 101452776 C T 7.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs382521 chr5 101457609 C A 6.05E-04 Multiple complex diseases / / 17554300 rs12659729 chr5 101475627 T A 7.62E-04 Multiple complex diseases / / 17554300 rs10515322 chr5 101511644 A T 5.40E-04 Breast cancer and prostate cancer / / 17903305 rs3995228 chr5 101513985 C A 8.19E-04 Multiple complex diseases / / 17554300 rs6869113 chr5 101519171 C G 1.50E-05 Urinary metabolites / / 21572414 rs261113 chr5 101553265 G C 2.30E-05 Urinary metabolites / / 21572414 rs379079 chr5 101557971 G C 2.60E-05 Urinary metabolites / / 21572414 rs433400 chr5 101564111 C G 1.90E-05 Urinary metabolites / / 21572414 rs11957520 chr5 101567053 T C 8.30E-06 Urinary metabolites / / 21572414 rs1469104 chr5 101569545 A G 4.78E-04 Parkinson's disease / / 17052657 rs2548724 chr5 101620174 T C 9.78E-04 Multiple complex diseases SLCO4C1 intron 17554300 rs2600825 chr5 101620464 A C 8.29E-04 Multiple complex diseases SLCO4C1 intron 17554300 rs896545 chr5 101633610 G A 9.48E-05 Type 2 diabetes / / 21799836 rs1982418 chr5 101638381 G A 6.94E-05 Leukocyte Counts / / pha003091 rs7734926 chr5 101647925 C T 8.66E-04 Parkinson's disease / / 17052657 rs7734926 chr5 101647925 C T 2.30E-05 Schizophrenia / / 19571808 rs6899078 chr5 101651873 A G 3.24E-06 Hearing function / / 21493956 rs9327836 chr5 101660913 T C 9.85E-04 Parkinson's disease / / 17052657 rs9327836 chr5 101660913 T C 2.20E-05 Schizophrenia / / 19571808 rs12655961 chr5 101669015 G A 9.70E-06 Leukocyte Counts / / pha003091 rs1901513 chr5 101711558 G A 4.02E-06 Hearing function SLCO6A1 intron 21493956 rs10041015 chr5 101712324 T C 6.08E-04 Weight loss (gastric bypass surgery) SLCO6A1 intron 23643386 rs10055840 chr5 101724448 G C 3.88E-06 Hearing function SLCO6A1 missense 21493956 rs10073892 chr5 101726770 T C 7.00E-07 Cognitive decline (age-related) SLCO6A1 intron 24468470 rs1562960 chr5 101729504 C T 1.70E-05 Schizophrenia SLCO6A1 intron 19571808 rs2060833 chr5 101745019 G A 1.60E-05 Schizophrenia SLCO6A1 intron 19571808 rs6878284 chr5 101769726 C T 9.00E-09 Schizophrenia SLCO6A1 intron 23974872 rs2400796 chr5 101775394 C T 9.03E-05 Type 2 diabetes SLCO6A1 intron 21799836 rs11746217 chr5 101795490 A G 1.70E-05 Schizophrenia SLCO6A1 intron 19571808 rs953280 chr5 101843759 T C 3.93E-05 Type 2 diabetes / / 21799836 rs953280 chr5 101843759 T C 3.45E-05 Leukocyte Counts / / pha003091 rs1502844 chr5 101859317 C T 1.00E-06 Schizophrenia / / 19571808 rs1502844 chr5 101859317 C T 1.30E-07 Schizophrenia / / 21791550 rs1502844 chr5 101859317 C T 0.0000038 Psychosis / / 23164818 rs17334370 chr5 101914562 C T 9.67E-05 Suicide attempts in bipolar disorder / / 21423239 rs17152228 chr5 101918893 T C 1.82E-04 Lung function (forced vital capacity) / / 24023788 rs7445614 chr5 101922421 G T 5.14E-05 Suicide attempts in bipolar disorder / / 21423239 rs13188378 chr5 101930688 A G 1.37E-04 Educational attainment / / 23722424 rs2134452 chr5 101940526 A G 8.93E-04 Bipolar disorder / / 19259986 rs7705924 chr5 101946798 A G 2.00E-08 Crohn's disease / / 22412388 rs6596510 chr5 101957366 T C 2.04E-04 Aortic root size / / 21223598 rs6596513 chr5 101972560 T C 4.63E-04 Aortic root size / / 21223598 rs2671569 chr5 102003138 A G 9.95E-05 Leukocyte Counts / / pha003091 rs17355759 chr5 102044030 A G 1.18E-04 Tourette syndrome / / 22889924 rs2545581 chr5 102047150 T C 3.89E-04 Tourette syndrome / / 22889924 rs1833585 chr5 102047758 A G 9.92E-05 Relative hand skill in reading disability / / 24068947 rs6875170 chr5 102052602 G C 9.18E-05 Relative hand skill in reading disability / / 24068947 rs421696 chr5 102075037 T C 6.34E-05 Relative hand skill in reading disability / / 24068947 rs647343 chr5 102076550 A T 5.01E-05 Relative hand skill in reading disability / / 24068947 rs2657459 chr5 102077130 A G 5.07E-05 Relative hand skill in reading disability / / 24068947 rs451819 chr5 102078587 G A 5.05E-05 Relative hand skill in reading disability / / 24068947 rs1645534 chr5 102079057 A G 3.12E-04 Tourette syndrome / / 22889924 rs1645534 chr5 102079057 A G 5.08E-05 Relative hand skill in reading disability / / 24068947 rs382946 chr5 102079138 T C 5.02E-05 Relative hand skill in reading disability / / 24068947 rs370175 chr5 102079162 C T 5.08E-05 Relative hand skill in reading disability / / 24068947 rs370166 chr5 102079177 C A 8.17E-05 Relative hand skill in reading disability / / 24068947 rs425025 chr5 102080890 G A 5.12E-05 Relative hand skill in reading disability / / 24068947 rs369099 chr5 102081276 A G 5.13E-05 Relative hand skill in reading disability / / 24068947 rs369875 chr5 102081520 C G 5.13E-05 Relative hand skill in reading disability / / 24068947 rs442443 chr5 102081834 T A 5.27E-05 Relative hand skill in reading disability / / 24068947 rs379574 chr5 102082368 A G 6.20E-05 Relative hand skill in reading disability / / 24068947 rs444366 chr5 102082776 C T 4.73E-05 Relative hand skill in reading disability / / 24068947 rs694481 chr5 102083354 A C 6.22E-05 Relative hand skill in reading disability / / 24068947 rs439009 chr5 102084824 A C 5.57E-05 Relative hand skill in reading disability / / 24068947 rs441226 chr5 102085919 C G 6.30E-05 Relative hand skill in reading disability / / 24068947 rs451598 chr5 102086345 C T 6.31E-05 Relative hand skill in reading disability / / 24068947 rs450667 chr5 102086434 T C 6.31E-05 Relative hand skill in reading disability / / 24068947 rs438126 chr5 102087272 T A 5.30E-05 Relative hand skill in reading disability / / 24068947 rs585901 chr5 102087732 G A 6.35E-05 Relative hand skill in reading disability / / 24068947 rs401320 chr5 102088078 G T 5.29E-05 Relative hand skill in reading disability / / 24068947 rs419099 chr5 102089442 A G 5.32E-05 Relative hand skill in reading disability / / 24068947 rs382964 chr5 102092070 C T 5.41E-05 Relative hand skill in reading disability / / 24068947 rs401114 chr5 102093145 C T 8.46E-05 Relative hand skill in reading disability / / 24068947 rs694832 chr5 102094000 T C 6.54E-05 Relative hand skill in reading disability / / 24068947 rs2431329 chr5 102094138 G A 6.55E-05 Relative hand skill in reading disability / / 24068947 rs462957 chr5 102096425 C T 8.86E-05 Relative hand skill in reading disability / / 24068947 rs460657 chr5 102096744 A G 8.42E-05 Relative hand skill in reading disability / / 24068947 rs467186 chr5 102096919 A G 4.50E-04 Tourette syndrome / / 22889924 rs467186 chr5 102096919 A G 4.67E-05 Relative hand skill in reading disability / / 24068947 rs466235 chr5 102098582 T C 5.54E-05 Relative hand skill in reading disability / / 24068947 rs187717 chr5 102100525 A G 5.91E-05 Relative hand skill in reading disability / / 24068947 rs258130 chr5 102102540 C G 8.28E-05 Relative hand skill in reading disability / / 24068947 rs258139 chr5 102103608 G T 8.35E-05 Relative hand skill in reading disability / / 24068947 rs258136 chr5 102104051 G A 8.50E-05 Relative hand skill in reading disability / / 24068947 rs459760 chr5 102107262 T C 9.17E-04 Tourette syndrome / / 22889924 rs2431322 chr5 102125747 C G 9.56E-04 Lymphocyte counts / / 22286170 rs28092 chr5 102149795 G A 5.50E-04 Tourette syndrome / / 22889924 rs1423138 chr5 102225847 T C 5.23E-04 Smoking initiation PAM intron 24665060 rs6596529 chr5 102317042 C T 7.89E-04 Schizophrenia PAM intron 19197363 rs11242483 chr5 102323766 C T 5.51E-04 Schizophrenia PAM intron 19197363 rs35658696 chr5 102338811 A G 0.000000019 Insulin processing and secretion PAM missense 23263489 rs3776859 chr5 102352034 A C 6.57E-04 Schizophrenia PAM intron 19197363 rs11948273 chr5 102362929 A T 9.50E-04 Multiple complex diseases PAM intron 17554300 rs26434 chr5 102363402 C T 2.59E-04 Schizophrenia PAM intron 19197363 rs34813 chr5 102433409 G A 4.04E-04 Schizophrenia GIN1 missense 19197363 rs34767 chr5 102489511 T G 2.70E-05 Urinary metabolites PPIP5K2 intron 21572414 rs183752 chr5 102507812 T C 2.85E-04 Schizophrenia PPIP5K2 intron 19197363 rs26821 chr5 102520400 A C 4.79E-04 Schizophrenia / / 19197363 rs36046591 chr5 102537285 A G 0.000000023 Insulin processing and secretion PPIP5K2 missense 23263489 rs17155168 chr5 102566438 G C 7.79E-04 Type 2 diabetes / / 17463246 rs26232 chr5 102596720 C T 4.00E-08 Rheumatoid arthritis C5orf30 intron 20453842 rs26232 chr5 102596720 C T 4.10E-08 Celiac disease and Rheumatoid arthritis C5orf30 intron 21383967 rs26232 chr5 102596720 C T 5.87E-06 Primary biliary cirrhosis C5orf30 intron 21399635 rs26232 chr5 102596720 C T 4.10E-08 Multiple sclerosis C5orf30 intron 22190364 rs26232 chr5 102596720 C T 7.30E-07 Rheumatoid arthritis C5orf30 intron 22446963 rs26232 chr5 102596720 C T 9.64E-05 Rheumatoid arthritis C5orf30 intron 24449572 rs39984 chr5 102597292 G T 0.00000304 Rheumatoid arthritis (CCP positive) C5orf30 intron 23143596 rs39984 chr5 102597292 G T 0.000132 Rheumatoid arthritis (CCP negative) C5orf30 intron 23143596 rs39984 chr5 102597292 G T 9.29E-08 Rheumatoid arthritis C5orf30 intron 23143596 rs411648 chr5 102602902 A T 5.35E-06 Serum metabolites C5orf30 intron 19043545 rs2561477 chr5 102608924 G A 6.52E-10 Rheumatoid arthritis C5orf30 intron 23143596 rs2561477 chr5 102608924 G A 8.56E-08 Rheumatoid arthritis (CCP positive) C5orf30 intron 23143596 rs2561477 chr5 102608924 G A 1.00E-10 Rheumatoid arthritis C5orf30 intron 24390342 rs2561477 chr5 102608924 G A 2.00E-11 Rheumatoid arthritis C5orf30 intron 24390342 rs35797 chr5 102614327 C T 2.08E-04 Multiple complex diseases C5orf30 UTR-3 17554300 rs556560 chr5 102623924 A G 2.44E-04 Multiple complex diseases / / 17554300 rs187580 chr5 102627355 T G 3.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs674726 chr5 102677364 C A 8.15E-06 Primary biliary cirrhosis / / 21399635 rs12654624 chr5 102710525 C T 1.41E-04 Multiple complex diseases / / 17554300 rs9327881 chr5 102725095 G A 5.00E-09 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7734355 chr5 102747930 A G 6.48E-04 Lymphocyte counts / / 22286170 rs17155315 chr5 102759658 G A 7.00E-06 QT interval / / 23166209 rs2099077 chr5 102764048 C A 8.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs10515345 chr5 102786159 A G 5.85E-04 Bipolar disorder / / 19259986 rs294084 chr5 102851624 T C 3.69E-05 Amyotrophic lateral sclerosis / / 23624525 rs12516214 chr5 102852240 G A 6.75E-05 Schizophrenia / / 19571809 rs12516214 chr5 102852240 G A 1.61E-05 Bipolar disorder and schizophrenia / / 20889312 rs12516214 chr5 102852240 G A 1.79E-05 Schizophrenia / / pha002857 rs291838 chr5 102852837 A G 4.36E-05 Amyotrophic lateral sclerosis / / 23624525 rs1345615 chr5 102853825 T C 2.46E-04 Tourette syndrome / / 22889924 rs34224 chr5 102863759 A G 6.62E-04 Multiple complex diseases / / 17554300 rs463102 chr5 102871927 C G 4.54E-04 Multiple complex diseases / / 17554300 rs294041 chr5 102877469 C T 4.86E-04 Multiple complex diseases / / 17554300 rs822422 chr5 102907599 G A 0.000319 Height (Pygmy height) / / 22570615 rs11242497 chr5 102926108 G A 2.70E-05 Information processing speed / / 21130836 rs1422046 chr5 102930270 C T 2.00E-04 Information processing speed / / 21130836 rs11742538 chr5 102931962 T C 1.00E-04 Information processing speed / / 21130836 rs12188475 chr5 102941298 T C 6.34E-04 Multiple complex diseases / / 17554300 rs17155553 chr5 102942201 G T 2.95E-06 Uric acid levels / / 21294900 rs7731680 chr5 102942477 A G 3.61E-06 Uric acid levels / / 21294900 rs6596536 chr5 102942794 G A 3.71E-06 Uric acid levels / / 21294900 rs10075546 chr5 102944712 A G 3.92E-06 Uric acid levels / / 21294900 rs7734977 chr5 102948145 A G 4.48E-06 Uric acid levels / / 21294900 rs7701241 chr5 102948156 T G 4.48E-06 Uric acid levels / / 21294900 rs7704545 chr5 102953237 C T 5.82E-05 Multiple complex diseases / / 17554300 rs10054393 chr5 102958770 T C 4.43E-06 Uric acid levels / / 21294900 rs4122274 chr5 102970690 G A 5.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs11737975 chr5 102992263 A G 1.24E-04 Scoliosis / / 21216876 rs2665182 chr5 102996464 A G 1.81E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs722821 chr5 103008422 C T 9.21E-04 Type 2 diabetes / / 17846125 rs11950651 chr5 103009768 C T 2.09E-05 Staphylococcus aureus infection / / 24847357 rs634234 chr5 103023500 G A 2.90E-05 Urinary metabolites / / 21572414 rs7712812 chr5 103038495 T G 9.60E-06 Parkinson's disease (familial) / / 18985386 rs17155772 chr5 103071415 A G 4.62E-04 Multiple complex diseases / / 17554300 rs6874267 chr5 103073470 G C 7.52E-05 Bipolar disorder and schizophrenia / / 20889312 rs6596546 chr5 103074561 A G 8.41E-05 Bipolar disorder and schizophrenia / / 20889312 rs1820121 chr5 103104452 T C 8.30E-06 Glaucoma (primary open-angle) / / 20835238 rs2545618 chr5 103116239 A G 3.15E-04 Multiple complex diseases / / 17554300 rs635331 chr5 103119105 A T 6.22E-05 Multiple complex diseases / / 17554300 rs1345621 chr5 103129506 A C 4.40E-06 Glaucoma (primary open-angle) / / 20835238 rs10041231 chr5 103170089 T C 2.70E-05 Urinary metabolites / / 21572414 rs4145648 chr5 103176234 T C 9.68E-05 Alcohol consumption / / 23743675 rs7715548 chr5 103182563 A C 6.97E-05 Height / / pha003011 rs2545625 chr5 103199121 G A 2.32E-05 Height / / pha003011 rs6899204 chr5 103211063 G C 8.70E-05 Coffee consumption / / 21357676 rs7702424 chr5 103219668 T C 9.00E-04 Multiple complex diseases / / 17554300 rs62364226 chr5 103223587 A G 0.0000428 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34244 chr5 103231731 T C 5.85E-05 Cytomegalovirus antibody response / / 21993531 rs39653 chr5 103238413 G A 8.60E-04 Alzheimer's disease / / 17998437 rs808041 chr5 103252652 T G 3.09E-05 Height / / pha003010 rs808041 chr5 103252652 T G 3.37E-05 Height / / pha003011 rs7736954 chr5 103253764 G A 9.83E-05 Height / / pha003011 rs718377 chr5 103261943 G A 5.78E-05 Fibrinogen / / pha003068 rs1363258 chr5 103269694 A C 9.20E-06 Biomarkers / / 17903293 rs1363258 chr5 103269694 A C 4.99E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs173486 chr5 103277290 C T 7.81E-05 Coronary heart disease / / pha003033 rs2431337 chr5 103287479 C T 7.81E-05 Coronary heart disease / / pha003033 rs319134 chr5 103322064 G A 5.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs950664 chr5 103353936 C T 1.40E-04 Type 2 diabetes / / 17846126 rs6859143 chr5 103390664 A G 8.54E-04 Parkinson's disease / / 17052657 rs1289192 chr5 103408356 A G 5.91E-05 stroke (ischemic) / / 17434096 rs1362694 chr5 103425608 T C 7.74E-07 Multiple complex diseases / / 17554300 rs1289168 chr5 103443156 T C 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs17156182 chr5 103480433 G A 4.94E-04 Multiple complex diseases / / 17554300 rs11748709 chr5 103480474 T A 3.40E-04 Multiple complex diseases / / 17554300 rs4419569 chr5 103501241 A C 4.37E-05 Pure-tone audiometry / / pha001963 rs6898163 chr5 103529711 C G 3.44E-04 Multiple complex diseases / / 17554300 rs17400865 chr5 103533329 T C 4.14E-04 HIV-1 viral setpoint / / 17641165 rs349586 chr5 103678705 G A 2.58E-04 Multiple complex diseases / / 17554300 rs964040 chr5 103705506 A G 1.75E-04 Multiple complex diseases / / 17554300 rs2963227 chr5 103705870 G A 1.91E-04 Multiple complex diseases / / 17554300 rs1530303 chr5 103723455 C T 8.22E-04 Multiple complex diseases / / 17554300 rs1530303 chr5 103723455 C T 8.68E-05 Depression (quantitative trait) / / 23290196 rs10464004 chr5 103728978 A G 4.15E-04 Alzheimer's disease / / 24755620 rs13162928 chr5 103736802 T C 8.04E-05 Depression (quantitative trait) / / 23290196 rs13181679 chr5 103737890 G A 7.15E-05 Depression (quantitative trait) / / 23290196 rs13177473 chr5 103745044 A G 4.75E-05 Depression (quantitative trait) / / 23290196 rs1583953 chr5 103750804 C T 4.37E-05 Depression (quantitative trait) / / 23290196 rs768792 chr5 103757005 A G 4.45E-05 Depression (quantitative trait) / / 23290196 rs2028526 chr5 103766154 T C 5.31E-05 Depression (quantitative trait) / / 23290196 rs1442111 chr5 103771206 G T 3.26E-05 Depression (quantitative trait) / / 23290196 rs2919955 chr5 103771766 G A 3.12E-05 Depression (quantitative trait) / / 23290196 rs920623 chr5 103771888 G A 3.71E-05 Depression (quantitative trait) / / 23290196 rs41349146 chr5 103774112 C G 9.13E-09 Multiple complex diseases / / 17554300 rs6881764 chr5 103810310 G A 7.48E-05 Depression (quantitative trait) / / 23290196 rs1592757 chr5 103889998 G C 1.05E-05 Depression (quantitative trait) / / 23290196 rs1421669 chr5 103902161 G C 1.47E-05 Depression (quantitative trait) / / 23290196 rs17156700 chr5 103919615 G A 4.70E-05 Waist Circumference / / pha003023 rs2052450 chr5 103925210 C A 7.45E-04 Tourette syndrome / / 22889924 rs2052450 chr5 103925210 C A 8.21E-05 Platelet counts / / pha003100 rs2447838 chr5 103927579 C T 1.63E-05 Depression (quantitative trait) / / 23290196 rs12513556 chr5 103927774 C T 8.03E-05 Waist Circumference / / pha003023 rs2447832 chr5 103933473 C T 2.05E-05 Depression (quantitative trait) / / 23290196 rs181888 chr5 103936246 C G 2.70E-04 Cholesterol / / 17255346 rs254035 chr5 103936343 T A 2.01E-05 Depression (quantitative trait) / / 23290196 rs254025 chr5 103943938 C G 2.87E-05 Depression (quantitative trait) / / 23290196 rs2161097 chr5 103945178 C T 3.43E-05 Depression (quantitative trait) / / 23290196 rs2112163 chr5 103946482 C T 3.62E-05 Depression (quantitative trait) / / 23290196 rs2447828 chr5 103947205 C T 3.51E-05 Depression (quantitative trait) / / 23290196 rs10515354 chr5 103947366 G A 6.40E-04 Tourette syndrome / / 22889924 rs10515354 chr5 103947366 G A 8.82E-05 Platelet counts / / pha003100 rs10515355 chr5 103947537 G T 8.78E-04 Tourette syndrome / / 22889924 rs10515355 chr5 103947537 G T 9.07E-05 Platelet counts / / pha003100 rs254020 chr5 103950251 C T 2.94E-05 Depression (quantitative trait) / / 23290196 rs254023 chr5 103955361 T C 3.11E-05 Depression (quantitative trait) / / 23290196 rs185260 chr5 103965223 A C 2.71E-05 Depression (quantitative trait) / / 23290196 rs326235 chr5 103969462 C T 2.01E-06 Serum metabolites / / 19043545 rs12514247 chr5 103973932 T C 7.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs325487 chr5 103975415 T A 8.19E-04 Type 2 diabetes / / 17463246 rs17156764 chr5 103976814 C A 7.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs33817 chr5 103978326 G A 2.38E-05 Depression (quantitative trait) / / 23290196 rs11242529 chr5 103979572 T C 7.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs40465 chr5 103981726 T G 4.78E-08 Depression (quantitative trait) / / 23290196 rs1120480 chr5 103986282 C T 8.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs12522864 chr5 103987923 A G 8.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs6859797 chr5 103989098 C A 4.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs12189083 chr5 103990057 C T 8.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs12189097 chr5 103990314 C T 8.60E-04 Suicide attempts in bipolar disorder / / 21041247 rs7445539 chr5 103992528 G A 8.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs325485 chr5 103995368 A G 5.42E-05 Depression (quantitative trait) / / 23290196 rs6892501 chr5 104000136 C A 8.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs325481 chr5 104000752 G A 4.27E-05 Depression (quantitative trait) / / 23290196 rs325501 chr5 104007433 G C 4.19E-05 Depression (quantitative trait) / / 23290196 rs17415237 chr5 104009875 C A 8.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs325506 chr5 104012303 C G 6.81E-05 Depression (quantitative trait) / / 23290196 rs542345 chr5 104019292 A G 9.93E-05 Blood Pressure / / pha003039 rs12516369 chr5 104019775 G A 8.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs407240 chr5 104022314 G T 7.49E-06 Serum metabolites / / 19043545 rs502025 chr5 104022597 C T 1.48E-06 Serum metabolites / / 19043545 rs502025 chr5 104022597 C T 5.38E-05 Platelet counts / / pha003100 rs387013 chr5 104023020 A T 1.48E-06 Serum metabolites / / 19043545 rs17350038 chr5 104027483 G C 8.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs576547 chr5 104028909 G A 9.77E-05 Multiple sclerosis (age of onset) / / 19010793 rs17416034 chr5 104036672 C T 6.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs11750377 chr5 104039911 G A 1.85E-04 Parkinson's disease / / 17052657 rs113164363 chr5 104042643 A AC 5.82E-06 Depression (quantitative trait) / / 23290196 rs1976423 chr5 104042643 A C 5.82E-06 Depression (quantitative trait) / / 23290196 rs12514766 chr5 104044900 T A 6.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs325522 chr5 104045307 G C 6.06E-04 Suicide attempts in bipolar disorder / / 21041247 rs325524 chr5 104046021 G C 7.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs325526 chr5 104047089 A G 5.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs325527 chr5 104048555 C T 5.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs325528 chr5 104048590 C G 5.30E-05 Cognitive function / / 24684796 rs106451 chr5 104048870 C A 5.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs325529 chr5 104049229 T C 5.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs325530 chr5 104049450 G T 5.95E-04 Suicide attempts in bipolar disorder / / 21041247 rs325531 chr5 104049712 A G 5.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs325532 chr5 104049851 T C 6.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs325533 chr5 104052605 G A 6.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs325538 chr5 104053647 A G 2.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs325563 chr5 104059042 G A 6.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs325564 chr5 104059678 C G 6.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs325565 chr5 104060025 T G 6.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs325567 chr5 104060591 C T 6.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs325569 chr5 104061474 A T 6.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs325571 chr5 104062106 G A 3.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs12520736 chr5 104063002 T C 6.48E-04 Suicide attempts in bipolar disorder / / 21041247 rs161456 chr5 104063025 C T 6.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs161457 chr5 104063038 T C 6.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs161782 chr5 104063459 G A 6.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs161783 chr5 104063964 C T 6.57E-04 Suicide attempts in bipolar disorder / / 21041247 rs161785 chr5 104064942 A C 6.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs161786 chr5 104065340 T C 6.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs161787 chr5 104065427 C T 6.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs161788 chr5 104067877 T C 6.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs161645 chr5 104069917 A G 8.00E-08 Depression (quantitative trait) / / 23290196 rs161790 chr5 104073099 C T 7.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs161791 chr5 104073260 T G 7.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs6421926 chr5 104075130 T C 9.96E-08 Depression (quantitative trait) / / 23290196 rs60271 chr5 104078233 A C 2.54E-07 Depression (quantitative trait) / / 23290196 rs17351308 chr5 104088019 G A 7.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs325492 chr5 104090636 C T 8.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs161776 chr5 104091478 G C 8.06E-04 Suicide attempts in bipolar disorder / / 21041247 rs161777 chr5 104092037 T C 8.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs12518236 chr5 104092550 G A 6.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs13155692 chr5 104106441 T C 3.18E-05 Depression (quantitative trait) / / 23290196 rs11242536 chr5 104110119 A G 6.91E-05 Prostate cancer / / 18264096 rs7701167 chr5 104152321 T C 2.30E-05 Urinary metabolites / / 21572414 rs1659044 chr5 104168021 T C 2.70E-05 Urinary metabolites / / 21572414 rs322872 chr5 104178282 T C 2.90E-04 Schizophrenia / / 19197363 rs6892243 chr5 104178789 G A 3.24E-07 Blood pressure / / 21996601 rs1632744 chr5 104199060 T C 5.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs10074959 chr5 104208013 G A 1.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs1217461 chr5 104214088 G T 1.72E-04 Schizophrenia / / 19197363 rs60825 chr5 104231294 T C 8.63E-05 Blood Pressure / / pha003047 rs1153989 chr5 104239516 T C 2.10E-05 Urinary metabolites / / 21572414 rs1153986 chr5 104242641 A G 1.90E-06 Urinary metabolites / / 21572414 rs1153986 chr5 104242641 A G 7.52E-04 Tourette syndrome / / 22889924 rs1152318 chr5 104243053 G T 4.30E-07 Urinary metabolites / / 21572414 rs1152319 chr5 104243462 T A 1.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs319899 chr5 104253119 G A 7.61E-04 Type 2 diabetes / / 17463246 rs319899 chr5 104253119 G A 1.18E-04 Multiple complex diseases / / 17554300 rs1438656 chr5 104278663 T C 2.84E-04 Multiple complex diseases / / 17554300 rs6864348 chr5 104294590 A G 9.26E-04 Multiple complex diseases / / 17554300 rs17564984 chr5 104298208 A G 2.30E-06 Urinary metabolites / / 21572414 rs3852178 chr5 104324279 A T 1.60E-06 Urinary metabolites / / 21572414 rs17566231 chr5 104332433 A G 1.40E-05 Urinary metabolites / / 21572414 rs2403256 chr5 104335746 A T 5.00E-05 Malaria / / 19465909 rs13178964 chr5 104347649 A G 5.00E-07 Blood pressure measurement (low sodium intervention) / / 24165912 rs13178964 chr5 104347649 A G 7.20E-04 Blood pressure measurement (low sodium intervention) / / 24165912 rs13157625 chr5 104367623 T C 2.22E-04 Multiple complex diseases / / 17554300 rs12518136 chr5 104370570 C T 2.55E-04 Multiple complex diseases / / 17554300 rs4259147 chr5 104371350 G A 2.12E-04 Multiple complex diseases / / 17554300 rs17157488 chr5 104406509 A G 1.67E-04 Multiple complex diseases / / 17554300 rs10515352 chr5 104409760 A G 6.54E-04 Multiple complex diseases / / 17554300 rs10078418 chr5 104418227 T G 4.65E-04 Multiple complex diseases / / 17554300 rs4389663 chr5 104423684 A T 2.19E-04 Multiple complex diseases / / 17554300 rs4389663 chr5 104423684 A T 8.08E-05 Bipolar disorder / / 19488044 rs6596598 chr5 104424297 T C 1.19E-04 Multiple complex diseases / / 17554300 rs10035820 chr5 104424968 C T 4.93E-04 Multiple complex diseases / / 17554300 rs10043572 chr5 104490887 C T 4.10E-04 Epilepsy / / 22116939 rs291128 chr5 104544085 A T 3.34E-04 Multiple complex diseases / / 17554300 rs2436365 chr5 104582841 C T 3.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17157849 chr5 104639792 T C 1.30E-05 Urinary metabolites / / 21572414 rs7341006 chr5 104709892 G A 3.77E-05 stroke (ischemic) / / 17434096 rs10074087 chr5 104724885 T C 3.41E-06 stroke (ischemic) / / 17434096 rs13168375 chr5 104738026 C T 9.84E-05 Cholesterol / / pha003073 rs4373258 chr5 104745584 A C 2.60E-05 HIV-1 control / / 20041166 rs10073707 chr5 104784402 T C 1.63E-05 stroke (ischemic) / / 17434096 rs10038910 chr5 104788643 T C 3.41E-06 stroke (ischemic) / / 17434096 rs4397103 chr5 104789427 A G 4.99E-06 Cholesterol / / pha003073 rs4397103 chr5 104789427 A G 2.98E-05 ldl cholesterol / / pha003076 rs4397103 chr5 104789427 A G 9.89E-05 Cholesterol / / pha003078 rs4479819 chr5 104794603 G A 8.96E-06 stroke (ischemic) / / 17434096 rs7447447 chr5 104867936 C T 7.00E-06 Caffeine consumption / / 21490707 rs13180609 chr5 104911468 G A 4.26E-05 Caffeine consumption / / 21490707 rs10479334 chr5 104954328 C T 2.00E-09 Personality dimensions / / 21368711 rs2312164 chr5 104993059 G A 8.37E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1480583 chr5 105022790 C T 5.97E-05 Major depressive disorder / / 21621269 rs1480583 chr5 105022790 C T 3.20E-05 Hypothyroidism / / 22493691 rs1904833 chr5 105031008 A G 7.47E-05 Colorectal cancer / / 19723657 rs1383370 chr5 105065177 T A 8.79E-05 Major depressive disorder / / 21621269 rs9327948 chr5 105067703 C T 3.67E-05 Telomere length / / 20139977 rs10060851 chr5 105071875 G A 1.24E-05 Bipolar disorder / / 20451256 rs10072908 chr5 105100737 T C 1.31E-05 Bipolar disorder / / 20451256 rs1482912 chr5 105117603 C T 6.03E-04 Alcohol dependence / / 20201924 rs11744593 chr5 105131707 C T 8.90E-05 Orofacial clefts / / 22419666 rs11744593 chr5 105131707 C T 8.94E-05 Body Mass Index / / pha003022 rs286726 chr5 105137836 G C 3.65E-05 Bipolar disorder / / 20451256 rs1680952 chr5 105167523 T C 3.19E-05 Bipolar disorder / / 20451256 rs9327952 chr5 105209225 A G 8.32E-04 Myocardial Infarction / / pha002873 rs13189969 chr5 105297529 T G 8.00E-06 Obesity-related traits / / 23251661 rs4308456 chr5 105321087 A C,G,T 7.17E-04 Type 2 diabetes / / 17463246 rs13164411 chr5 105377638 T C 4.45E-05 Response to hepatitis C treatment / / 19684573 rs10056331 chr5 105388290 T C 3.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs13162459 chr5 105404097 G A 6.13E-05 Response to hepatitis C treatment / / 19684573 rs12656675 chr5 105405016 A G 1.86E-05 Response to hepatitis C treatment / / 19684573 rs1404170 chr5 105405167 T C 7.92E-05 Alcohol dependence / / 19581569 rs6894797 chr5 105419513 A G 9.00E-06 Obesity-related traits / / 23251661 rs10059955 chr5 105425352 T C 5.70E-04 Schizophrenia / / 19197363 rs1991970 chr5 105430841 C A 1.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs1435194 chr5 105453357 C A 1.92E-05 Schizophrenia / / 19197363 rs9327956 chr5 105460973 T C 1.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs1435195 chr5 105462307 C G 4.35E-05 Suicide attempts in bipolar disorder / / 21041247 rs974073 chr5 105465733 T G 1.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs972529 chr5 105467463 A C 1.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs4527577 chr5 105476589 C T 4.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs12719550 chr5 105479717 A T 1.06E-04 Suicide attempts in bipolar disorder / / 21041247 rs10073985 chr5 105547101 C T 5.50E-05 Suicide attempts in bipolar disorder / / 21041247 rs10040995 chr5 105568551 C T 3.12E-05 Suicide attempts in bipolar disorder / / 21041247 rs7705866 chr5 105568943 T C 3.11E-05 Suicide attempts in bipolar disorder / / 21041247 rs6878200 chr5 105580928 C T 2.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs13154869 chr5 105591452 G T 1.94E-05 Suicide attempts in bipolar disorder / / 21041247 rs11242575 chr5 105599070 A G 5.05E-04 Type 2 diabetes / / 17463246 rs11242575 chr5 105599070 A G 9.49E-04 Multiple complex diseases / / 17554300 rs10479364 chr5 105603953 C T 1.94E-05 Suicide attempts in bipolar disorder / / 21041247 rs6883970 chr5 105604520 C T 1.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs10063657 chr5 105610240 T C 2.96E-05 Suicide attempts in bipolar disorder / / 21041247 rs10068181 chr5 105615021 G A 7.69E-05 Suicide attempts in bipolar disorder / / 21041247 rs6891526 chr5 105616917 G A 1.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs7718256 chr5 105621152 G C 7.17E-04 Type 2 diabetes / / 17463246 rs13361333 chr5 105621527 T C 9.53E-05 Suicide attempts in bipolar disorder / / 21041247 rs13185392 chr5 105622804 T C 7.63E-05 Suicide attempts in bipolar disorder / / 21041247 rs13185419 chr5 105623066 A C 7.68E-05 Suicide attempts in bipolar disorder / / 21041247 rs11741503 chr5 105635825 G A 2.66E-05 Scoliosis / / 21216876 rs6863010 chr5 105663646 T C 8.81E-05 Orofacial clefts / / 22419666 rs13166413 chr5 105790223 A G 2.74E-06 Multiple complex diseases / / 17554300 rs7712742 chr5 105808801 G A 2.44E-04 Multiple complex diseases / / 17554300 rs2135048 chr5 105817579 A G 4.62E-04 Multiple complex diseases / / 17554300 rs12659329 chr5 105820614 G C 1.30E-05 Urinary metabolites / / 21572414 rs11242585 chr5 105832427 C G 5.39E-04 Multiple complex diseases / / 17554300 rs12657564 chr5 105847867 G A 5.19E-04 Multiple complex diseases / / 17554300 rs6891659 chr5 105854131 G A 3.01E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs4280854 chr5 105895302 C T 0.0000385 Aging / / 22445811 rs1437642 chr5 105972148 A C 4.63E-06 Central corneal thickness / / 21098505 rs12517578 chr5 105980831 C G 1.00E-04 Sudden cardiac arrest / / 21738491 rs12517578 chr5 105980831 C G 5.21E-05 C-reactive protein / / 24763700 rs4957664 chr5 105997975 G A 1.60E-05 Urinary metabolites / / 21572414 rs6872983 chr5 105999317 T G 6.10E-06 Urinary metabolites / / 21572414 rs1898510 chr5 106005568 T A 2.10E-05 Urinary metabolites / / 21572414 rs10515365 chr5 106034797 C T 4.35E-04 Type 2 diabetes / / 17463246 rs6596696 chr5 106039980 T A 4.24E-04 Type 2 diabetes / / 17463246 rs430123 chr5 106081733 T C 2.00E-04 Type 2 diabetes / / 17846126 rs1561350 chr5 106089594 A G 1.68E-04 Type 2 diabetes / / 17463246 rs11952719 chr5 106090828 C T 6.02E-08 Schizophrenia / / 22037555 rs7730725 chr5 106091186 A G 1.70E-05 Urinary metabolites / / 21572414 rs7734840 chr5 106091211 T C 8.95E-05 Type 2 diabetes / / 17463246 rs4475247 chr5 106097514 A G 4.69E-04 Type 2 diabetes / / 17463246 rs2410874 chr5 106101078 G C 5.89E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12374447 chr5 106103975 A G 3.50E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs13156926 chr5 106116276 G T 9.58E-06 Nephrolithiasis / / 22396660 rs296206 chr5 106149393 G A 9.25E-04 Rheumatoid arthritis / / 21452313 rs296211 chr5 106155538 A G 6.09E-04 Rheumatoid arthritis / / 21452313 rs17159187 chr5 106190158 C T 1.00E-04 Prostate cancer / / 21743057 rs10491495 chr5 106255758 C T 1.90E-05 Urinary metabolites / / 21572414 rs2463031 chr5 106263197 T G 6.79E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10051122 chr5 106266421 T C 8.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs10079531 chr5 106266514 A T 1.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs13182714 chr5 106272371 A G 3.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs6880898 chr5 106276532 C T 2.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs4382150 chr5 106308008 G A 1.12E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10075477 chr5 106329791 A C 1.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs4464676 chr5 106349850 T C 2.97E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4470754 chr5 106367151 G C 4.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs6596714 chr5 106372054 C T 5.42E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6864971 chr5 106396918 C T 2.23E-05 Non-word repetition / / 23738518 rs4429838 chr5 106403714 A G 2.42E-05 Non-word repetition / / 23738518 rs10078331 chr5 106430672 T C 8.78E-05 Cytomegalovirus antibody response / / 21993531 rs17450801 chr5 106452479 A G 4.28E-04 Myopia (pathological) / / 21095009 rs2410946 chr5 106454395 C T 2.13E-04 Type 2 diabetes / / 17463246 rs2410936 chr5 106473749 A G 8.90E-05 Alzheimer's disease / / 21098978 rs6888172 chr5 106478316 C A 5.35E-04 Type 2 diabetes / / 17463246 rs4957691 chr5 106500969 G A 6.70E-04 Type 2 diabetes / / 17463246 rs6596730 chr5 106557132 A C 9.49E-04 Type 2 diabetes / / 17463246 rs6862168 chr5 106563875 C A 3.55E-05 Premature ovarian failure / / 19508998 rs6862168 chr5 106563875 C A 3.55E-05 Other erythrocyte phenotypes / / 19862010 rs7719658 chr5 106584019 C G 3.13E-04 Birth weight / / 17255346 rs7732995 chr5 106586798 A G 3.03E-04 Multiple complex diseases / / 17554300 rs1645610 chr5 106588171 G A 5.04E-04 Multiple complex diseases / / 17554300 rs2548751 chr5 106593748 A G 4.05E-04 Multiple complex diseases / / 17554300 rs1645618 chr5 106594254 G T 6.64E-04 Multiple complex diseases / / 17554300 rs422261 chr5 106660530 A G 7.80E-05 Temporomandibular joint disorders / / 23746317 rs443277 chr5 106662978 G A 2.90E-05 Temporomandibular joint disorders / / 23746317 rs185211 chr5 106664983 A G 2.00E-05 Temporomandibular joint disorders / / 23746317 rs1423341 chr5 106665710 A G 8.09E-05 Bipolar disorder and schizophrenia / / 20889312 rs17344779 chr5 106675142 G C 9.90E-05 Bipolar disorder and schizophrenia / / 20889312 rs7729948 chr5 106716140 A G 3.50E-04 Multiple complex diseases EF/5 UTR-3 17554300 rs17159868 chr5 106720912 T C 1.38E-04 Multiple complex diseases EF/5 intron 17554300 rs17159868 chr5 106720912 T C 3.47E-04 Gallstones EF/5 intron 17632509 rs252817 chr5 106724588 C T 2.00E-06 Bipolar disorder and schizophrenia EF/5 intron 20889312 rs17159895 chr5 106736571 A G 7.66E-04 Multiple complex diseases EF/5 intron 17554300 rs252801 chr5 106757399 G A 2.09E-05 Bipolar disorder and schizophrenia EF/5 intron 20889312 rs152608 chr5 106771209 C T 4.22E-04 Type 2 diabetes EF/5 intron 17463246 rs152608 chr5 106771209 C T 8.00E-05 Type 2 diabetes and 6 quantitative traits EF/5 intron 17848626 rs152589 chr5 106786281 T C 5.40E-04 Type 2 diabetes and 6 quantitative traits EF/5 intron 17848626 rs537500 chr5 106793591 G A 8.69E-04 Type 2 diabetes EF/5 intron 17463246 rs151957 chr5 106803918 T C 4.63E-05 Serum metabolites EF/5 intron 19043545 rs151957 chr5 106803918 T C 1.55E-04 Alzheimer's disease (late onset) EF/5 intron 21379329 rs25998 chr5 106804832 T C 2.01E-04 Alzheimer's disease EF/5 intron 24755620 rs25999 chr5 106805007 T A 2.56E-04 Alzheimer's disease EF/5 intron 24755620 rs25994 chr5 106811645 T C 9.65E-04 Alzheimer's disease EF/5 intron 24755620 rs27750 chr5 106814090 T C 1.39E-05 Alzheimer's disease EF/5 intron 24755620 rs27681 chr5 106831574 G A 2.66E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) EF/5 intron 17982456 rs28826 chr5 106839365 T C 3.49E-04 Multiple complex diseases EF/5 intron 17554300 rs152562 chr5 106841783 C T 2.32E-04 Parkinson's disease EF/5 intron 16252231 rs152562 chr5 106841783 C T 1.24E-04 Alzheimer's disease EF/5 intron 24755620 rs10491394 chr5 106844951 T C 3.70E-04 Type 2 diabetes and 6 quantitative traits EF/5 intron 17848626 rs152556 chr5 106848995 A T 3.28E-04 Alzheimer's disease EF/5 intron 24755620 rs395561 chr5 106861975 A C 1.69E-05 Multiple sclerosis EF/5 intron 17660530 rs341277 chr5 106869642 T C 8.68E-04 Multiple complex diseases EF/5 intron 17554300 rs609539 chr5 106904997 A G 2.05E-04 Alzheimer's disease EF/5 intron 17998437 rs6881619 chr5 106909060 T C 3.24E-05 Alcohol and nictotine co-dependence EF/5 intron 20158304 rs10043302 chr5 106909498 G C 6.52E-05 Hearing function EF/5 intron 17255346 rs597083 chr5 106913589 G A 8.98E-05 Heart Rate EF/5 intron pha003054 rs641406 chr5 106914027 A G 1.53E-05 Heart Rate EF/5 intron pha003054 rs103840 chr5 106914733 T C 1.03E-05 Heart Rate EF/5 intron pha003054 rs9328010 chr5 106924829 G A 1.44E-05 Heart Rate EF/5 intron pha003054 rs4090594 chr5 106956443 A G 2.67E-05 Hippocampal atrophy EF/5 intron 19668339 rs10074258 chr5 106982560 C T 2.00E-07 Hippocampal atrophy EF/5 intron 19668339 rs1572255 chr5 107014713 A G 1.55E-04 Multiple complex diseases / / 17554300 rs17160356 chr5 107018108 A C 1.78E-06 Multiple complex diseases / / 17554300 rs12654281 chr5 107040442 C T 3.94E-07 Hippocampal atrophy / / 19668339 rs12654281 chr5 107040442 C T 2.30E-05 Urinary metabolites / / 21572414 rs6864800 chr5 107046317 C A 4.71E-05 Hippocampal atrophy / / 19668339 rs6864800 chr5 107046317 C A 7.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12657273 chr5 107046698 T C 9.25E-06 Hippocampal atrophy / / 19668339 rs12657273 chr5 107046698 T C 8.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17160425 chr5 107049874 C T 1.80E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs13358604 chr5 107110446 A G 8.17E-05 Orofacial clefts / / 22419666 rs1422438 chr5 107111176 G T 6.00E-07 Alzheimer's disease biomarkers / / 23419831 rs770182 chr5 107118140 G T 3.65E-06 Alcohol withdrawal symptoms / / 22072270 rs770172 chr5 107121419 A G 6.52E-05 Alcohol withdrawal symptoms / / 22072270 rs10515377 chr5 107129003 T C 9.65E-05 Lipid levels / / pha003082 rs6891749 chr5 107138981 G A 7.14E-04 Alcohol dependence / / 21314694 rs1559096 chr5 107139167 A G 3.49E-05 Lymphocyte counts / / 22286170 rs10464043 chr5 107139503 T C 7.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs3843492 chr5 107140556 G A 9.48E-05 Blood Pressure / / pha002903 rs11745426 chr5 107186734 A G 1.30E-05 Urinary metabolites / / 21572414 rs1865015 chr5 107196976 G A 3.10E-05 Insulin Resistance FBXL17 UTR-3 pha003062 rs11740286 chr5 107199977 T C 2.30E-06 Urinary metabolites FBXL17 intron 21572414 rs6596759 chr5 107202929 C A 3.10E-05 Insulin Resistance FBXL17 intron pha003062 rs7708343 chr5 107205182 G A 9.75E-04 Obesity (extreme) FBXL17 intron 21935397 rs7726739 chr5 107233155 C G 7.30E-07 Urinary metabolites FBXL17 intron 21572414 rs10069340 chr5 107233791 G A 9.76E-04 Alcohol dependence FBXL17 intron 21314694 rs11743737 chr5 107263580 T C 8.77E-05 Coronary heart disease FBXL17 intron 24778558 rs7719403 chr5 107274258 C T 1.32E-04 Smoking cessation FBXL17 intron 24665060 rs10070308 chr5 107281621 C T 4.00E-06 Bipolar disorder (body mass index interaction) FBXL17 intron 24322204 rs72795979 chr5 107282348 T C 3.00E-06 Bipolar disorder (body mass index interaction) FBXL17 intron 24322204 rs72795980 chr5 107282349 C T 2.00E-06 Bipolar disorder (body mass index interaction) FBXL17 intron 24322204 rs885624 chr5 107300655 T C 5.19E-04 Nicotine dependence FBXL17 intron 17158188 rs11744308 chr5 107310203 A T 6.69E-04 Nicotine dependence FBXL17 intron 17158188 rs10793832 chr5 107320230 T C 8.13E-05 Nicotine dependence FBXL17 intron 17158188 rs13157529 chr5 107320882 G T 5.00E-05 Response to lithium treatment in bipolar disorder FBXL17 intron 19448189 rs12514413 chr5 107323866 T C 4.30E-04 Nicotine dependence FBXL17 intron 17158188 rs723397 chr5 107348043 C T 3.00E-04 Type 2 diabetes FBXL17 intron 17846126 rs288144 chr5 107395234 G T 7.79E-04 Type 2 diabetes FBXL17 intron 17463246 rs7728371 chr5 107397314 G T 3.57E-06 Response to amphetamines FBXL17 intron 22952603 rs288139 chr5 107400505 G A 1.00E-06 Eye color FBXL17 intron 23118974 rs11242661 chr5 107401451 C T 1.00E-06 Response to amphetamines FBXL17 intron 22952603 rs10035292 chr5 107402223 C T 4.22E-06 Response to amphetamines FBXL17 intron 22952603 rs286751 chr5 107402938 C T 2.10E-05 Electrocardiographic traits and heart rate variability FBXL17 intron 17903306 rs289227 chr5 107405476 C G 6.71E-04 Type 2 diabetes FBXL17 intron 17463246 rs286794 chr5 107410205 G T 5.80E-06 Response to amphetamines FBXL17 intron 22952603 rs158415 chr5 107412941 C T 9.32E-06 Response to amphetamines FBXL17 intron 22952603 rs11242662 chr5 107417744 T A 1.50E-05 Urinary metabolites FBXL17 intron 21572414 rs40062 chr5 107447121 G A 8.35E-04 Suicide attempts in bipolar disorder FBXL17 intron 21423239 rs286809 chr5 107458637 G A 5.28E-04 Type 2 diabetes FBXL17 intron 17463246 rs12652687 chr5 107459529 T C 7.76E-05 Body Mass Index FBXL17 intron pha003014 rs34430 chr5 107466006 A C 8.43E-04 Suicide attempts in bipolar disorder FBXL17 intron 21423239 rs40072 chr5 107467243 T A 9.49E-04 Suicide attempts in bipolar disorder FBXL17 intron 21423239 rs286797 chr5 107482854 C T 4.70E-04 Statin-induced myopathy FBXL17 intron 21826682 rs12515105 chr5 107485161 C A 5.55E-05 Orofacial clefts FBXL17 intron 22419666 rs34424 chr5 107500144 T C 6.71E-04 Type 2 diabetes FBXL17 intron 17463246 rs10063866 chr5 107504326 T C 5.34E-06 Response to amphetamines FBXL17 intron 22952603 rs6883082 chr5 107511609 T C 4.82E-06 Response to amphetamines FBXL17 intron 22952603 rs6596770 chr5 107512145 C T 4.60E-06 Response to amphetamines FBXL17 intron 22952603 rs6596771 chr5 107512536 G A 4.54E-06 Response to amphetamines FBXL17 intron 22952603 rs10463586 chr5 107513703 T G 3.66E-06 Response to amphetamines FBXL17 intron 22952603 rs7713705 chr5 107514366 G C 5.42E-06 Response to amphetamines FBXL17 intron 22952603 rs286767 chr5 107521134 T C 6.53E-06 Response to amphetamines FBXL17 intron 22952603 rs286763 chr5 107531302 T C 2.68E-06 Statin-induced myopathy FBXL17 intron 21826682 rs2966821 chr5 107534886 A C 2.64E-04 Statin-induced myopathy FBXL17 intron 21826682 rs13187816 chr5 107557861 T C 2.53E-05 HDL cholesterol FBXL17 intron pha003074 rs2122158 chr5 107561614 T C 9.19E-06 Response to amphetamines FBXL17 intron 22952603 rs10045002 chr5 107630494 C A 9.58E-04 Suicide attempts in bipolar disorder FBXL17 intron 21423239 rs2966833 chr5 107671932 G A 8.07E-04 Suicide attempts in bipolar disorder FBXL17 intron 21423239 rs989001 chr5 107676321 G A 5.81E-04 Nicotine dependence FBXL17 intron 17158188 rs1862195 chr5 107684324 C T 1.44E-05 HDL cholesterol FBXL17 intron pha003074 rs1862195 chr5 107684324 C T 8.96E-05 Cholesterol FBXL17 intron pha003083 rs12521975 chr5 107687616 A T 9.07E-04 Lymphocyte counts FBXL17 intron 22286170 rs11240962 chr5 107721366 C A 1.81E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs10035966 chr5 107724017 T G 1.81E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs4634342 chr5 107731684 G T 1.12E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs1001579 chr5 107731958 G A 7.00E-06 IgG glycosylation / / 23382691 rs1122826 chr5 107732317 G A 1.81E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs10455007 chr5 107742569 A C 4.10E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs12187433 chr5 107768782 T C 2.44E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs9326727 chr5 107769631 G A 1.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs2112303 chr5 107770325 A T 1.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs918399 chr5 107781571 C T 4.71E-05 Gallbladder cancer / / 22318345 rs6865111 chr5 107799236 G A 9.85E-05 Suicide attempts in bipolar disorder / / 21423239 rs4571457 chr5 107834247 C T 7.00E-06 Ulcerative colitis / / 20848476 rs10078003 chr5 107861567 G A 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs10447248 chr5 107915736 A G 5.00E-08 Adiponectin levels / / 21700879 rs10477917 chr5 107927705 G A 2.08E-04 Gallstones / / 17632509 rs10077221 chr5 107931452 C T 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs7449365 chr5 107953221 A G 6.80E-05 Serum metabolites / / 19043545 rs6594323 chr5 107954485 T C 7.22E-04 Type 2 diabetes / / 17463246 rs7443963 chr5 107972764 A G 5.02E-05 Serum metabolites / / 19043545 rs12656502 chr5 107981747 G A 3.00E-06 Plasma amyloid beta peptide concentrations (ABx-42) / / 24535457 rs7448313 chr5 107985674 A G 1.97E-05 Serum metabolites / / 19043545 rs13187102 chr5 107995317 C T 5.42E-05 Alzheimer's disease / / 22832961 rs17161438 chr5 108008236 A G 4.77E-05 Alzheimer's disease / / 22832961 rs13153111 chr5 108008438 G A 4.66E-05 Alzheimer's disease / / 22832961 rs2940516 chr5 108008923 T C 0.0003972 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2940516 chr5 108008923 T C 3.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17469069 chr5 108010974 G C 3.88E-05 Alzheimer's disease / / 22832961 rs6873702 chr5 108015658 T A 6.16E-04 Multiple complex diseases / / 17554300 rs10055167 chr5 108028387 A G 0.0003427 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10055167 chr5 108028387 A G 3.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10078314 chr5 108028710 T C 0.0003459 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10078314 chr5 108028710 T C 3.46E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13353876 chr5 108029723 T A 0.0003498 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13353876 chr5 108029723 T A 3.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10050689 chr5 108029900 T C 5.73E-04 Fibrinogen / / 17255346 rs10050689 chr5 108029900 T C 0.0003526 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10050689 chr5 108029900 T C 3.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10044769 chr5 108031376 C T 0.0001815 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10044769 chr5 108031376 C T 1.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10477929 chr5 108032231 A G 1.74E-04 Fibrinogen / / 17255346 rs10477929 chr5 108032231 A G 0.0001847 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10477929 chr5 108032231 A G 1.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs112020835 chr5 108046013 G A 1.00E-04 Telomere length / / 24795349 rs78869517 chr5 108050074 C G 2.78E-05 Telomere length / / 24795349 rs2900035 chr5 108098218 G A 2.66E-05 Monocyte chemoattractant protein-1 FER intron pha003071 rs13177718 chr5 108113344 C T 3.00E-08 Height FER intron 20881960 rs10073668 chr5 108135965 G A 4.27E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) FER intron 24023788 rs17472083 chr5 108192421 G A,C 4.06E-05 Bipolar disorder,affective FER intron 20528957 rs10515396 chr5 108245089 G T 3.67E-04 Coronary Artery Disease FER intron 17634449 rs11955321 chr5 108252231 G A 7.18E-05 Post-operative nausea and vomiting FER intron 21694509 rs3797817 chr5 108284342 A G 0.000000028 Autism FER intron 22935194 rs7734110 chr5 108295521 T A 7.94E-04 Coronary Artery Disease FER intron 17634449 rs10515397 chr5 108346952 T C 1.39E-04 Amyotrophic Lateral Sclerosis FER intron 17827064 rs10043540 chr5 108443526 A G 5.66E-04 Response to TNF antagonist treatment FER intron 21061259 rs4957798 chr5 108444554 C T 1.43E-04 Response to TNF antagonist treatment FER intron 21061259 rs9326761 chr5 108469444 A G 2.68E-05 Interstitial lung disease FER intron 23583980 rs4365877 chr5 108524616 G A 6.85E-04 Alcohol dependence / / 20201924 rs10070978 chr5 108609599 T C 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs868260 chr5 108654729 G A 4.41E-04 Type 2 diabetes / / 17463246 rs868260 chr5 108654729 G A 7.35E-05 Eosinophil counts / / pha003088 rs1862204 chr5 108658898 T G 5.65E-04 Type 2 diabetes / / 17463246 rs784291 chr5 108666767 C T 1.55E-04 Type 2 diabetes / / 17463246 rs784291 chr5 108666767 C T 1.40E-06 Serum uric acid levels / / 17997608 rs413387 chr5 108683248 G C 1.81E-04 Type 2 diabetes PJA2 intron 17463246 rs11738695 chr5 108699161 C A 3.20E-04 Type 2 diabetes PJA2 intron 17463246 rs2963024 chr5 108730773 C T 7.05E-04 Type 2 diabetes PJA2 intron 17463246 rs2963046 chr5 108749075 A G 7.50E-04 Type 2 diabetes / / 17463246 rs2914679 chr5 108788824 G A 3.58E-04 Type 2 diabetes / / 17463246 rs2914719 chr5 108791406 T A 5.32E-04 Type 2 diabetes / / 17463246 rs4365878 chr5 108804104 T C 4.10E-04 Type 2 diabetes / / 17463246 rs10039159 chr5 108805905 T C 5.12E-04 Type 2 diabetes / / 17463246 rs4635977 chr5 108840166 A T 8.73E-04 Multiple complex diseases / / 17554300 rs7448843 chr5 108843934 A C 6.41E-04 Alcohol dependence / / 24277619 rs17161887 chr5 108855035 C T 8.33E-09 Lymphocyte counts / / 22286170 rs17161951 chr5 108930590 C T 1.14E-04 Alcohol dependence / / 24277619 rs367615 chr5 108948937 C T 4.00E-08 Colorectal cancer / / 23300701 rs25915 chr5 108992687 A G 4.17E-06 C-reactive protein / / 22492993 rs25914 chr5 108993021 C T 2.30E-05 C-reactive protein / / 22492993 rs25913 chr5 108993934 T C 1.57E-06 C-reactive protein / / 22492993 rs31614 chr5 108995505 C T 1.90E-05 C-reactive protein / / 22492993 rs31610 chr5 108997418 A T 4.12E-06 C-reactive protein / / 22492993 rs845741 chr5 109001791 A G 1.01E-05 C-reactive protein / / 22492993 rs31600 chr5 109006376 G T 1.73E-04 Hearing function / / 17255346 rs1438663 chr5 109027851 C T 1.40E-05 Glucose levels MAN2A1 intron pha002899 rs2284988 chr5 109041308 G C 1.73E-04 Multiple complex diseases MAN2A1 intron 17554300 rs6877440 chr5 109044067 T C 6.27E-05 Panic disorder MAN2A1 intron 19165232 rs6877440 chr5 109044067 T C 1.90E-04 Aortic root size MAN2A1 intron 21223598 rs6897334 chr5 109044558 C A 2.90E-05 Multiple complex diseases MAN2A1 intron 17554300 rs724784 chr5 109053335 A C 4.36E-04 Multiple complex diseases MAN2A1 intron 17554300 rs13180410 chr5 109085685 G A 5.00E-04 Acute lymphoblastic leukemia (childhood) MAN2A1 intron 20189245 rs2269207 chr5 109122743 G A 5.88E-05 Multiple complex diseases MAN2A1 intron 17554300 rs2301010 chr5 109132461 T C 5.00E-04 Acute lymphoblastic leukemia (childhood) MAN2A1 intron 20189245 rs17162263 chr5 109134832 C T 3.28E-04 Multiple complex diseases MAN2A1 intron 17554300 rs1008661 chr5 109135496 A G 5.65E-05 Multiple complex diseases MAN2A1 intron 17554300 rs10452541 chr5 109139335 T C 2.85E-05 Monocyte chemoattractant protein-1 MAN2A1 intron pha003071 rs2161123 chr5 109141527 T G 5.56E-05 Amyotrophic lateral sclerosis MAN2A1 intron 20801717 rs112884546 chr5 109159494 T A 0.000064 Breast cancer MAN2A1 missense 23555315 rs3797680 chr5 109160251 T G 6.54E-05 Amyotrophic lateral sclerosis MAN2A1 intron 20801717 rs12518635 chr5 109172348 C T 1.52E-04 Multiple complex diseases MAN2A1 intron 17554300 rs3776932 chr5 109185988 T G 1.00E-04 Acute lymphoblastic leukemia (childhood) MAN2A1 intron 20189245 rs112984105 chr5 109190943 C T 0.000064 Breast cancer MAN2A1 missense 23555315 rs12656073 chr5 109200553 A C 9.00E-04 Acute lymphoblastic leukemia (childhood) MAN2A1 intron 20189245 rs3797672 chr5 109201823 C T 9.00E-04 Acute lymphoblastic leukemia (childhood) MAN2A1 intron 20189245 rs1047004 chr5 109202725 A G 1.85E-05 Serum albumin level MAN2A1 UTR-3 pha003084 rs1946607 chr5 109217428 G T 2.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs112724034 chr5 109221026 C T 9.00E-13 Alzheimer's disease (cognitive decline) / / 23535033 rs2163762 chr5 109226017 G C 7.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs6884296 chr5 109230397 G A 7.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs245243 chr5 109230735 G A 2.77E-04 Multiple complex diseases / / 17554300 rs6868508 chr5 109266084 T C 9.82E-04 Parkinson's disease / / 16252231 rs17162540 chr5 109348449 A G 4.72E-05 Asthma / / pha003127 rs2966780 chr5 109354719 T C 1.43E-24 Narcolepsy / / 19629137 rs2925073 chr5 109364250 A G 2.94E-04 Multiple complex diseases / / 17554300 rs4957850 chr5 109369160 G T 6.89E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2966762 chr5 109383219 T C 2.00E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs17162591 chr5 109384306 A G 3.81E-04 Response to TNF antagonist treatment / / 21061259 rs6594417 chr5 109386824 T C 9.75E-04 Coronary heart disease / / 21971053 rs1378506 chr5 109391230 G A 4.50E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs1378506 chr5 109391230 G A 1.40E-04 Breast cancer / / 19330027 rs751146 chr5 109392158 G A 2.08E-05 Alzheimer's disease (late onset) / / 21379329 rs11957089 chr5 109396784 G C 9.40E-06 Urinary metabolites / / 21572414 rs1585047 chr5 109410958 G A 6.81E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10515410 chr5 109411322 A T 6.04E-04 Multiple complex diseases / / 17554300 rs10155650 chr5 109417408 A G 9.16E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4460176 chr5 109496960 T A,G 3.00E-06 Hemostatic factors and hematological phenotypes / / 17903294 rs4448049 chr5 109502957 G A 2.20E-05 Urinary metabolites / / 21572414 rs4957878 chr5 109505808 C T 0.000457085 Hypertension (early onset hypertension) / / 22479346 rs11744416 chr5 109513342 C A 9.91E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11744416 chr5 109513342 C A 4.49E-04 Type 2 diabetes / / 17463246 rs11744416 chr5 109513342 C A 0.000523393 Hypertension (early onset hypertension) / / 22479346 rs10062617 chr5 109517541 C T 1.40E-05 Urinary metabolites / / 21572414 rs4507535 chr5 109517668 C T 2.40E-05 Urinary metabolites / / 21572414 rs6881297 chr5 109518551 G C 4.20E-06 Urinary metabolites / / 21572414 rs6869337 chr5 109544592 T C 1.10E-06 White blood cell count / / 21738479 rs4254949 chr5 109594268 A G 4.59E-04 Type 2 diabetes / / 17463246 rs17131936 chr5 109659356 T C 2.22E-04 Multiple complex diseases / / 17554300 rs17131943 chr5 109661302 T G 4.74E-04 Multiple complex diseases / / 17554300 rs7708924 chr5 109699498 C T 2.27E-04 Multiple complex diseases / / 17554300 rs7711677 chr5 109712221 A G 2.00E-05 Urinary metabolites / / 21572414 rs7714521 chr5 109730678 G A 9.86E-04 Multiple complex diseases / / 17554300 rs7714521 chr5 109730678 G A 1.30E-05 Urinary metabolites / / 21572414 rs720402 chr5 109802199 T C 8.20E-05 Heart Rate TMEM232 intron pha003054 rs313617 chr5 109817549 A G 3.30E-04 Coronary heart disease TMEM232 intron 21966275 rs10067777 chr5 109826296 A G 6.32E-08 Atopic dermatitis TMEM232 intron 21666691 rs10051407 chr5 109850641 C A 7.04E-04 Multiple complex diseases TMEM232 intron 17554300 rs7701890 chr5 109858821 A G 4.33E-08 Atopic dermatitis TMEM232 intron 21666691 rs6875167 chr5 109931110 C T 4.70E-04 Self-reported allergy TMEM232 intron 23817569 rs4277958 chr5 109946411 G A 3.06E-04 Depression (quantitative trait) TMEM232 intron 20800221 rs6886299 chr5 109963106 C T 3.07E-04 Self-reported allergy TMEM232 intron 23817569 rs1363477 chr5 109974582 G T 3.64E-04 Self-reported allergy TMEM232 intron 23817569 rs17132261 chr5 110008214 C T 9.00E-07 Cardiac structure and function TMEM232 intron 19584346 rs244408 chr5 110021869 T C 2.65E-04 Lymphocyte counts TMEM232 intron 22286170 rs244408 chr5 110021869 T C 3.57E-04 Self-reported allergy TMEM232 intron 23817569 rs244410 chr5 110023332 G A,C 3.73E-04 Self-reported allergy TMEM232 intron 23817569 rs409326 chr5 110027005 T G 7.85E-04 Multiple complex diseases TMEM232 intron 17554300 rs13360927 chr5 110035756 A G 2.80E-07 Atopic dermatitis TMEM232 intron 21666691 rs13361382 chr5 110048954 G A 2.09E-07 Atopic dermatitis TMEM232 intron 21666691 rs2443513 chr5 110052499 T G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) TMEM232 intron 17982456 rs27122 chr5 110061137 T C 3.01E-04 Multiple complex diseases TMEM232 intron 17554300 rs10061929 chr5 110061254 C T 2.95E-04 Self-reported allergy TMEM232 intron 23817569 rs10059343 chr5 110065511 C A 4.40E-04 Type 2 diabetes / / 17463246 rs665063 chr5 110075414 C A 4.87E-04 Depression (quantitative trait) SLC25A46 intron 20800221 rs12187004 chr5 110076352 A G 4.82E-04 Depression (quantitative trait) SLC25A46 intron 20800221 rs244923 chr5 110080363 T C 5.28E-04 Depression (quantitative trait) SLC25A46 intron 20800221 rs6892259 chr5 110085742 A C 2.48E-04 Depression (quantitative trait) SLC25A46 intron 20800221 rs3843243 chr5 110088247 T G 6.34E-04 Type 2 diabetes SLC25A46 intron 17463246 rs12522587 chr5 110089350 C A 3.73E-04 Depression (quantitative trait) SLC25A46 intron 20800221 rs4957918 chr5 110093673 C A,G,T 1.69E-04 Depression (quantitative trait) SLC25A46 intron 20800221 rs11548494 chr5 110100318 G A 4.44E-04 Self-reported allergy / / 23817569 rs17447355 chr5 110110254 G C 8.89E-05 Self-reported allergy / / 23817569 rs10060413 chr5 110143168 A G 4.13E-04 Self-reported allergy / / 23817569 rs17513503 chr5 110146446 C G 1.00E-08 IgE grass sensitization / / 22036096 rs17513503 chr5 110146446 C G 7.00E-07 Allergic rhinitis / / 22036096 rs17513503 chr5 110146446 C G 1.37E-05 Self-reported allergy / / 23817569 rs13354207 chr5 110151791 G C,T 1.69E-04 Self-reported allergy / / 23817569 rs7735519 chr5 110153341 C A 2.45E-09 Self-reported allergy / / 23817569 rs7717615 chr5 110153356 T C 6.35E-05 Self-reported allergy / / 23817569 rs3853750 chr5 110154309 T C 3.13E-09 Self-reported allergy / / 23817569 rs3853750 chr5 110154309 T C 2.00E-07 Asthma and hay fever / / 24388013 rs7723767 chr5 110154786 T C 8.57E-05 Self-reported allergy / / 23817569 rs6883714 chr5 110156524 A G 6.67E-05 Self-reported allergy / / 23817569 rs3844182 chr5 110159594 T C 7.15E-05 Self-reported allergy / / 23817569 rs12517265 chr5 110161781 C T 7.33E-05 Self-reported allergy / / 23817569 rs6869477 chr5 110165995 C G 8.28E-08 Self-reported allergy / / 23817569 rs7731580 chr5 110166945 T C 4.89E-04 Self-reported allergy / / 23817569 rs12655815 chr5 110168518 G A 9.07E-05 Self-reported allergy / / 23817569 rs6868547 chr5 110169510 T C 7.70E-05 Self-reported allergy / / 23817569 rs6594475 chr5 110170834 A G 7.15E-05 Self-reported allergy / / 23817569 rs2081082 chr5 110173029 C T 7.20E-05 Self-reported allergy / / 23817569 rs6594479 chr5 110173599 A T 7.94E-05 Self-reported allergy / / 23817569 rs6594480 chr5 110173859 A G 4.00E-09 Self-reported allergy / / 23817569 rs7729730 chr5 110175048 A G 9.94E-08 Self-reported allergy / / 23817569 rs6892351 chr5 110175795 G T 7.64E-05 Self-reported allergy / / 23817569 rs3851453 chr5 110176302 A G 8.06E-05 Self-reported allergy / / 23817569 rs1350294 chr5 110177281 C A 7.46E-05 Self-reported allergy / / 23817569 rs2416246 chr5 110178687 C A 6.75E-05 Self-reported allergy / / 23817569 rs2416247 chr5 110178704 G T 6.75E-05 Self-reported allergy / / 23817569 rs2416248 chr5 110178806 A G 7.95E-05 Self-reported allergy / / 23817569 rs6890286 chr5 110178910 T G 6.83E-08 Self-reported allergy / / 23817569 rs2416249 chr5 110180193 A G 6.49E-05 Self-reported allergy / / 23817569 rs10447257 chr5 110181237 T G 4.63E-08 Self-reported allergy / / 23817569 rs1423155 chr5 110181893 A G 6.09E-05 Self-reported allergy / / 23817569 rs1870072 chr5 110182071 A C 6.88E-08 Self-reported allergy / / 23817569 rs1363800 chr5 110182238 A G 4.96E-05 Self-reported allergy / / 23817569 rs7736241 chr5 110183699 G A 6.46E-08 Self-reported allergy / / 23817569 rs7718121 chr5 110183740 T C 5.71E-08 Self-reported allergy / / 23817569 rs10036968 chr5 110186827 A G 5.05E-05 Self-reported allergy / / 23817569 rs12659961 chr5 110187004 T C 1.88E-09 Self-reported allergy / / 23817569 rs1423158 chr5 110188254 G T 4.41E-05 Self-reported allergy / / 23817569 rs7707733 chr5 110188610 A C 3.87E-05 Self-reported allergy / / 23817569 rs7712464 chr5 110189156 C T 1.13E-05 Self-reported allergy / / 23817569 rs7712806 chr5 110189471 A G 4.70E-08 Self-reported allergy / / 23817569 rs7733093 chr5 110189526 T C 4.40E-05 Self-reported allergy / / 23817569 rs10056340 chr5 110190052 T G 2.41E-09 Self-reported allergy / / 23817569 rs10056340 chr5 110190052 T G 5.00E-14 Allergic sensitization / / 23817571 rs13357752 chr5 110190401 A G 4.76E-05 Self-reported allergy / / 23817569 rs6883435 chr5 110191278 A T 2.41E-05 Self-reported allergy / / 23817569 rs17514103 chr5 110191481 T C 4.46E-08 Self-reported allergy / / 23817569 rs17132442 chr5 110192122 G A 2.59E-09 Self-reported allergy / / 23817569 rs6895490 chr5 110193286 G C 5.11E-05 Self-reported allergy / / 23817569 rs7734638 chr5 110193712 A G 4.76E-05 Self-reported allergy / / 23817569 rs4432941 chr5 110193731 G T 4.76E-05 Self-reported allergy / / 23817569 rs4377748 chr5 110193769 A G 5.46E-05 Self-reported allergy / / 23817569 rs4382205 chr5 110193962 A T 1.92E-04 Self-reported allergy / / 23817569 rs4259213 chr5 110193977 C G 1.92E-04 Self-reported allergy / / 23817569 rs1423156 chr5 110194962 T G 7.21E-05 Self-reported allergy / / 23817569 rs1423157 chr5 110195168 C A 1.31E-04 Self-reported allergy / / 23817569 rs9326810 chr5 110196625 A T 1.52E-04 Self-reported allergy / / 23817569 rs9326811 chr5 110196646 C A 1.52E-04 Self-reported allergy / / 23817569 rs7722517 chr5 110196921 A G 2.10E-05 Self-reported allergy / / 23817569 rs7709594 chr5 110197425 T A 7.67E-05 Self-reported allergy / / 23817569 rs6888588 chr5 110197966 A G 7.64E-05 Self-reported allergy / / 23817569 rs6893213 chr5 110198114 C T 7.08E-06 Self-reported allergy / / 23817569 rs1423153 chr5 110201574 C G 1.09E-04 Self-reported allergy / / 23817569 rs17514409 chr5 110202896 G C 2.49E-07 Self-reported allergy / / 23817569 rs7720905 chr5 110203177 A C 1.66E-07 Self-reported allergy / / 23817569 rs7721895 chr5 110203503 G A 1.03E-04 Self-reported allergy / / 23817569 rs7726932 chr5 110204551 A T 1.12E-04 Self-reported allergy / / 23817569 rs1363797 chr5 110207981 A G 9.46E-05 Self-reported allergy / / 23817569 rs885293 chr5 110208301 A G 1.04E-04 Self-reported allergy / / 23817569 rs10463615 chr5 110224363 C T 7.60E-06 Urinary metabolites / / 21572414 rs17132484 chr5 110237388 G A 7.50E-06 Urinary metabolites / / 21572414 rs10054380 chr5 110258653 C T 2.40E-05 Urinary metabolites / / 21572414 rs13362072 chr5 110280203 G C 5.50E-06 Urinary metabolites / / 21572414 rs13357478 chr5 110290161 A G 8.49E-04 Multiple complex diseases / / 17554300 rs10079816 chr5 110291023 C T 3.70E-04 Multiple complex diseases / / 17554300 rs9326815 chr5 110299845 C A 4.90E-06 Urinary metabolites / / 21572414 rs10070058 chr5 110302047 T A 1.40E-05 Urinary metabolites / / 21572414 rs1366331 chr5 110302270 C A 1.20E-05 Urinary metabolites / / 21572414 rs10035184 chr5 110309111 A G 4.40E-06 Urinary metabolites / / 21572414 rs7723699 chr5 110309325 G A 6.90E-06 Urinary metabolites / / 21572414 rs17132582 chr5 110319359 G A 2.10E-06 Urinary metabolites / / 21572414 rs12109885 chr5 110333886 T C 1.60E-06 Urinary metabolites / / 21572414 rs6861164 chr5 110335525 C G 3.00E-06 Urinary metabolites / / 21572414 rs1837253 chr5 110401872 T C 7.52E-08 Asthma / / 20860503 rs1837253 chr5 110401872 T C 1.00E-16 Asthma / / 21804548 rs1837253 chr5 110401872 T C 1.00E-14 Asthma / / 21804549 rs1837253 chr5 110401872 T C 5.52E-06 Asthma / / 22561531 rs1837253 chr5 110401872 T C 0.00076 Asthma / / 22694930 rs1837253 chr5 110401872 T C 2.30E-10 Self-reported allergy / / 23817569 rs1837253 chr5 110401872 T C 1.00E-09 Asthma and hay fever / / 24388013 rs12654933 chr5 110402755 C A 5.25E-05 Self-reported allergy / / 23817569 rs10061842 chr5 110402855 C A 2.41E-05 Self-reported allergy / / 23817569 rs4304115 chr5 110403346 C G 4.36E-05 Self-reported allergy / / 23817569 rs17551370 chr5 110404185 G A 2.79E-05 Self-reported allergy / / 23817569 rs10455025 chr5 110404999 A C 9.02E-04 Type 2 diabetes / / 17463246 rs10455025 chr5 110404999 A C 4.27E-11 Self-reported allergy / / 23817569 rs3806932 chr5 110405675 A G 3.00E-09 Eosinophilic esophagitis (pediatric) / / 20208534 rs3806932 chr5 110405675 A G 3.00E-09 Asthma / / 21907864 rs3806932 chr5 110405675 A G 1.10E-13 Self-reported allergy / / 23817569 rs3806933 chr5 110406742 C T 5.82E-14 Self-reported allergy / / 23817569 rs2289276 chr5 110407507 C T 1.23E-06 Self-reported allergy TSLP UTR-5 23817569 rs1898671 chr5 110408002 C T 5.00E-06 Allergic rhinitis TSLP intron 22036096 rs1898671 chr5 110408002 C T 2.46E-11 Self-reported allergy TSLP intron 23817569 rs10062929 chr5 110408179 C A 1.78E-05 Self-reported allergy TSLP intron 23817569 rs11466741 chr5 110408705 C T 1.08E-06 Self-reported allergy TSLP intron 23817569 rs2289277 chr5 110409067 C A,G 7.55E-14 Self-reported allergy TSLP UTR-5 23817569 rs2289278 chr5 110409148 C G 9.66E-05 Self-reported allergy TSLP UTR-5 23817569 rs11466749 chr5 110412585 A G 9.25E-04 Type 2 diabetes TSLP UTR-3 17463246 rs11466749 chr5 110412585 A G 1.98E-06 Self-reported allergy TSLP UTR-3 23817569 rs11466750 chr5 110412894 G A 1.72E-05 Self-reported allergy TSLP UTR-3 23817569 rs13156086 chr5 110415469 A C 1.05E-06 Self-reported allergy / / 23817569 rs6594497 chr5 110415868 A T 6.59E-14 Self-reported allergy / / 23817569 rs7713025 chr5 110416223 T C 1.85E-05 Self-reported allergy / / 23817569 rs12110124 chr5 110416590 T C 1.47E-06 Self-reported allergy / / 23817569 rs252706 chr5 110416860 G A 1.81E-04 Self-reported allergy / / 23817569 rs17132762 chr5 110417875 G A 1.74E-04 Self-reported allergy / / 23817569 rs2416259 chr5 110419742 G A 1.52E-04 Self-reported allergy / / 23817569 rs2416258 chr5 110419888 C T 1.59E-04 Self-reported allergy / / 23817569 rs897801 chr5 110420445 C T 9.70E-05 Self-reported allergy / / 23817569 rs7723819 chr5 110427347 G A 2.11E-04 Type 2 diabetes WDR36 nearGene-5 17463246 rs7723819 chr5 110427347 G A 2.28E-15 Self-reported allergy WDR36 nearGene-5 23817569 rs7729832 chr5 110428744 G A 1.42E-05 Self-reported allergy WDR36 intron 23817569 rs1971050 chr5 110429241 C T 1.59E-04 Self-reported allergy WDR36 intron 23817569 rs1370964 chr5 110429955 A G 2.61E-05 Self-reported allergy WDR36 intron 23817569 rs17623144 chr5 110430488 C G 7.97E-04 Type 2 diabetes WDR36 intron 17463246 rs17623144 chr5 110430488 C G 1.10E-11 Self-reported allergy WDR36 intron 23817569 rs13185610 chr5 110433086 A G 1.09E-07 Self-reported allergy WDR36 intron 23817569 rs1993465 chr5 110433098 A G 1.33E-15 Self-reported allergy WDR36 intron 23817569 rs13357747 chr5 110433391 C A 2.44E-05 Self-reported allergy WDR36 intron 23817569 rs7705304 chr5 110434261 T G 3.15E-05 Self-reported allergy WDR36 intron 23817569 rs13153937 chr5 110434307 G A 1.14E-07 Self-reported allergy WDR36 intron 23817569 rs6859041 chr5 110435231 G A 1.42E-15 Self-reported allergy WDR36 intron 23817569 rs2416257 chr5 110435490 C T 1.00E-06 Eosinophil counts WDR36 intron 19198610 rs2416257 chr5 110435490 C T 1.88E-05 Self-reported allergy WDR36 intron 23817569 rs10038177 chr5 110436450 C T 1.64E-15 Self-reported allergy WDR36 intron 23817569 rs6865932 chr5 110436852 G C 1.78E-15 Self-reported allergy WDR36 intron 23817569 rs17132782 chr5 110437494 A G 1.84E-04 Multiple complex diseases WDR36 intron 17554300 rs10045255 chr5 110438357 A G 1.82E-15 Self-reported allergy WDR36 intron 23817569 rs11241095 chr5 110439509 A G 1.47E-07 Self-reported allergy WDR36 missense 23817569 rs1379300 chr5 110441439 T C 7.20E-04 Type 2 diabetes WDR36 intron 17463246 rs1379300 chr5 110441439 T C 1.25E-15 Self-reported allergy WDR36 intron 23817569 rs2034896 chr5 110441533 G A 8.09E-16 Self-reported allergy WDR36 intron 23817569 rs10056179 chr5 110442137 A G 2.78E-05 Self-reported allergy WDR36 intron 23817569 rs10038058 chr5 110443281 A G 1.40E-15 Self-reported allergy WDR36 intron 23817569 rs10039043 chr5 110444909 A G 7.24E-05 Self-reported allergy WDR36 intron 23817569 rs12515367 chr5 110447853 A G 1.53E-07 Self-reported allergy WDR36 intron 23817569 rs12521169 chr5 110448313 G A 1.12E-07 Self-reported allergy WDR36 intron 23817569 rs2112541 chr5 110449346 T C 3.67E-14 Self-reported allergy WDR36 intron 23817569 rs10060003 chr5 110449357 A G 2.00E-14 Self-reported allergy WDR36 intron 23817569 rs10055177 chr5 110450584 T G 2.12E-14 Self-reported allergy WDR36 intron 23817569 rs10051830 chr5 110452845 G A 1.49E-14 Self-reported allergy WDR36 intron 23817569 rs10491424 chr5 110453806 T C 2.36E-10 Self-reported allergy WDR36 intron 23817569 rs10491423 chr5 110453977 C A 1.37E-07 Self-reported allergy WDR36 intron 23817569 rs17553936 chr5 110454681 A C,G,T 1.26E-07 Self-reported allergy WDR36 intron 23817569 rs12522383 chr5 110455266 G A 1.21E-07 Self-reported allergy WDR36 intron 23817569 rs13186912 chr5 110456704 A T 1.20E-07 Self-reported allergy WDR36 cds-synon 23817569 rs4957924 chr5 110457095 C T 1.74E-04 Self-reported allergy WDR36 intron 23817569 rs17624673 chr5 110457158 C T 8.51E-12 Self-reported allergy WDR36 intron 23817569 rs43203 chr5 110457983 G A 9.03E-05 Self-reported allergy WDR36 intron 23817569 rs7722241 chr5 110460747 T A 1.46E-09 Self-reported allergy WDR36 intron 23817569 rs7702774 chr5 110460851 G T 1.13E-14 Self-reported allergy WDR36 intron 23817569 rs4530809 chr5 110462230 A G 2.90E-04 Type 2 diabetes WDR36 intron 17463246 rs4530809 chr5 110462230 A G 1.79E-10 Self-reported allergy WDR36 intron 23817569 rs1043828 chr5 110464008 T C 1.10E-08 Asthma WDR36 UTR-3 21907864 rs1043828 chr5 110464008 T C 5.98E-12 Self-reported allergy WDR36 UTR-3 23817569 rs11948089 chr5 110464393 A T 7.60E-05 Self-reported allergy WDR36 UTR-3 23817569 rs6869774 chr5 110467086 A G 2.89E-05 Self-reported allergy / / 23817569 rs6870356 chr5 110467237 G A 2.04E-05 Self-reported allergy / / 23817569 rs1438673 chr5 110467499 C T 3.20E-06 Asthma / / 21907864 rs1438673 chr5 110467499 C T 2.00E-20 Self-reported allergy / / 23817569 rs1438673 chr5 110467499 C T 3.00E-11 Asthma and hay fever / / 24388013 rs7731821 chr5 110467918 T A 1.34E-05 Self-reported allergy / / 23817569 rs2021813 chr5 110469070 A G 2.69E-04 Self-reported allergy / / 23817569 rs6594499 chr5 110470137 C A 1.80E-05 Asthma / / 23181788 rs6594499 chr5 110470137 C A 4.56E-20 Self-reported allergy / / 23817569 rs7714869 chr5 110471635 T C 8.41E-06 Self-reported allergy / / 23817569 rs464275 chr5 110472967 G C 9.61E-11 Self-reported allergy / / 23817569 rs457087 chr5 110473586 G C 3.63E-04 Self-reported allergy / / 23817569 rs252710 chr5 110479610 G C 8.76E-10 Self-reported allergy / / 23817569 rs252711 chr5 110480574 A G 3.22E-07 Self-reported allergy / / 23817569 rs252712 chr5 110481203 T C 9.75E-07 Self-reported allergy / / 23817569 rs91068 chr5 110485574 T C 6.94E-06 Self-reported allergy / / 23817569 rs32704 chr5 110488845 A G 7.62E-06 Self-reported allergy / / 23817569 rs252869 chr5 110491174 C G 7.45E-06 Self-reported allergy / / 23817569 rs252872 chr5 110491379 G A 4.72E-06 Self-reported allergy / / 23817569 rs183699 chr5 110491712 T C 1.35E-05 Self-reported allergy / / 23817569 rs151800 chr5 110494282 C A 6.86E-08 Self-reported allergy / / 23817569 rs1821908 chr5 110496071 C A 9.71E-04 Iron levels / / pha002876 rs17132862 chr5 110498972 G A 1.82E-06 Periodontitis (PAL4Q3) / / 24024966 rs244513 chr5 110500987 T C 9.22E-08 Self-reported allergy / / 23817569 rs244515 chr5 110501681 A G 1.55E-04 Self-reported allergy / / 23817569 rs10060762 chr5 110502044 G A 8.99E-04 Iron levels / / pha002876 rs17132883 chr5 110502429 C T 2.00E-06 Periodontitis (PAL4Q3) / / 24024966 rs1806352 chr5 110504049 C T 1.18E-04 Self-reported allergy / / 23817569 rs1072056 chr5 110504115 C A 1.06E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs10040556 chr5 110504412 G T 4.56E-05 Self-reported allergy / / 23817569 rs244507 chr5 110508516 A T 1.12E-04 Self-reported allergy / / 23817569 rs244508 chr5 110508660 C T 7.09E-08 Self-reported allergy / / 23817569 rs153281 chr5 110511475 T C 1.08E-04 Self-reported allergy / / 23817569 rs407166 chr5 110519604 A C 4.12E-06 Self-reported allergy / / 23817569 rs10056568 chr5 110521329 T G 1.04E-06 Periodontitis (PAL4Q3) / / 24024966 rs17132909 chr5 110522803 G A 1.21E-06 Periodontitis (PAL4Q3) / / 24024966 rs32702 chr5 110523293 G C 4.87E-11 Self-reported allergy / / 23817569 rs17460372 chr5 110523787 C G 1.33E-04 Self-reported allergy / / 23817569 rs457734 chr5 110527665 C A 3.63E-08 Self-reported allergy / / 23817569 rs466545 chr5 110529043 T G 5.46E-08 Self-reported allergy / / 23817569 rs455997 chr5 110529588 G A 7.35E-08 Self-reported allergy / / 23817569 rs10071052 chr5 110533593 T A 8.60E-07 Periodontitis (PAL4Q3) / / 24024966 rs11953602 chr5 110533968 G C 8.60E-07 Periodontitis (PAL4Q3) / / 24024966 rs10055755 chr5 110535029 G A 8.60E-07 Periodontitis (PAL4Q3) / / 24024966 rs13360546 chr5 110536663 A G 8.68E-07 Periodontitis (PAL4Q3) / / 24024966 rs13358530 chr5 110536795 T C 8.69E-07 Periodontitis (PAL4Q3) / / 24024966 rs9326830 chr5 110537597 G C 8.58E-07 Periodontitis (PAL4Q3) / / 24024966 rs244518 chr5 110538615 G A 5.05E-08 Self-reported allergy / / 23817569 rs1370966 chr5 110539349 G A 8.56E-07 Periodontitis (PAL4Q3) / / 24024966 rs1370967 chr5 110539392 G A 8.00E-07 Periodontitis (PAL4Q3) / / 24024966 rs184941 chr5 110539892 C T 8.06E-05 Self-reported allergy / / 23817569 rs763439 chr5 110540436 C T 9.29E-07 Periodontitis (PAL4Q3) / / 24024966 rs763440 chr5 110540525 C T 8.62E-07 Periodontitis (PAL4Q3) / / 24024966 rs11738066 chr5 110543145 T C 2.70E-04 Self-reported allergy / / 23817569 rs252860 chr5 110544004 T C 7.02E-08 Self-reported allergy / / 23817569 rs1870079 chr5 110546055 A G 1.68E-07 Self-reported allergy / / 23817569 rs957924 chr5 110547418 G A 7.87E-07 Periodontitis (PAL4Q3) / / 24024966 rs1864119 chr5 110549925 C T 7.16E-08 Self-reported allergy / / 23817569 rs2162893 chr5 110558064 A G 6.35E-11 Self-reported allergy / / 23817569 rs1551566 chr5 110561455 C A 3.04E-06 Self-reported allergy CAMK4 intron 23817569 rs1551565 chr5 110561639 A G 3.16E-06 Self-reported allergy CAMK4 intron 23817569 rs727922 chr5 110562500 T C 2.40E-06 Urinary metabolites CAMK4 intron 21572414 rs727922 chr5 110562500 T C 3.80E-06 Self-reported allergy CAMK4 intron 23817569 rs727923 chr5 110562604 A G 3.56E-06 Self-reported allergy CAMK4 intron 23817569 rs1457115 chr5 110567598 C T 8.36E-04 Oral cancers (chewing tobacco related) CAMK4 intron 22503698 rs1457115 chr5 110567598 C T 3.11E-06 Self-reported allergy CAMK4 intron 23817569 rs9285875 chr5 110568458 T C 1.55E-04 Statin-induced myopathy CAMK4 intron 21826682 rs6875225 chr5 110568929 C T 7.16E-05 Self-reported allergy CAMK4 intron 23817569 rs17461314 chr5 110570176 G T 1.00E-07 Urinary metabolites CAMK4 intron 21572414 rs17461314 chr5 110570176 G T 4.64E-05 Self-reported allergy CAMK4 intron 23817569 rs1469442 chr5 110576081 C T 2.15E-04 Self-reported allergy CAMK4 intron 23817569 rs17521129 chr5 110577553 C T 4.85E-05 Self-reported allergy CAMK4 intron 23817569 rs3898862 chr5 110581640 A T 1.07E-04 Self-reported allergy CAMK4 intron 23817569 rs2434723 chr5 110583710 G A 6.65E-05 Self-reported allergy CAMK4 intron 23817569 rs2434722 chr5 110584334 A G 5.56E-05 Self-reported allergy CAMK4 intron 23817569 rs1650794 chr5 110597382 A G 3.08E-05 Self-reported allergy CAMK4 intron 23817569 rs1618689 chr5 110606055 C G 1.30E-07 Urinary metabolites CAMK4 intron 21572414 rs306104 chr5 110631265 T C 8.16E-06 Response to gemcitabine in pancreatic cancer CAMK4 intron 22142827 rs10500205 chr5 110631991 A C 6.60E-23 Varicose Veins CAMK4 intron pha001414 rs4478365 chr5 110645337 A G 4.94E-04 Multiple complex diseases CAMK4 intron 17554300 rs77636885 chr5 110719187 C A 2.00E-06 Alzheimer's disease (cognitive decline) CAMK4 intron 23535033 rs10491334 chr5 110772404 C T 4.00E-06 Blood pressure CAMK4 intron 17903302 rs10491334 chr5 110772404 C T 2.00E-06 Longevity CAMK4 intron 21612516 rs10491334 chr5 110772404 C T 5.56E-06 Body Fat Distribution CAMK4 intron pha003016 rs10491334 chr5 110772404 C T 1.31E-05 Body Fat Distribution CAMK4 intron pha003017 rs759950 chr5 110772720 C T 8.83E-04 Type 2 diabetes CAMK4 intron 17463246 rs759949 chr5 110772929 C G 5.26E-04 Type 2 diabetes CAMK4 intron 17463246 rs759947 chr5 110773100 A G 5.25E-04 Type 2 diabetes CAMK4 intron 17463246 rs11241123 chr5 110773457 A G 9.62E-04 Type 2 diabetes CAMK4 intron 17463246 rs2300782 chr5 110788785 C T 5.74E-05 Diabetic retinopathy CAMK4 intron 20871662 rs6889265 chr5 110794624 G A 2.39E-05 Multiple complex diseases CAMK4 intron 17554300 rs1347112 chr5 110805772 G A 8.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAMK4 intron 20877124 rs31623 chr5 110813041 A T 7.76E-04 Multiple complex diseases CAMK4 intron 17554300 rs3733995 chr5 110818421 C T 2.93E-05 Body Fat Distribution CAMK4 intron pha003016 rs3733995 chr5 110818421 C T 8.60E-05 Body Fat Distribution CAMK4 intron pha003017 rs2059041 chr5 110834179 T C 9.67E-04 Suicide attempts in bipolar disorder STARD4 UTR-3 21423239 rs432983 chr5 110920898 T A 3.27E-04 Multiple complex diseases LOC100505678 intron 17554300 rs10477467 chr5 110921349 A G 1.44E-04 Multiple complex diseases LOC100505678 intron 17554300 rs11748447 chr5 110938816 G A 2.83E-04 Multiple complex diseases LOC100505678 intron 17554300 rs7704547 chr5 110941247 T C 2.34E-04 Multiple complex diseases LOC100505678 intron 17554300 rs10434752 chr5 110941664 G T 3.51E-04 Multiple complex diseases LOC100505678 intron 17554300 rs10041076 chr5 110954027 C T 3.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100505678 intron 20877124 rs10041076 chr5 110954027 C T 7.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100505678 intron 20877124 rs11241130 chr5 110958782 G A 8.00E-06 Obesity-related traits LOC100505678 intron 23251661 rs1438681 chr5 110960712 A G 3.29E-05 Multiple complex diseases LOC100505678 intron 17554300 rs10036739 chr5 110964494 T G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC100505678 intron 22628534 rs1379552 chr5 110979158 T C 4.03E-07 Schizophrenia LOC100505678 intron 19197363 rs10515433 chr5 110983350 A G 3.15E-04 Amyotrophic lateral sclerosis (sporadic) LOC100505678 intron 24529757 rs6885593 chr5 110987667 A C 0.0000228 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC100505678 intron 22628534 rs6594525 chr5 110991602 T C 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC100505678 intron 22628534 rs13182708 chr5 110992525 G A 0.0000777 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC100505678 intron 22628534 rs17133574 chr5 111004758 T C 4.91E-04 Schizophrenia LOC100505678 intron 19197363 rs255892 chr5 111004991 A C 2.10E-05 Urinary metabolites LOC100505678 intron 21572414 rs1145123 chr5 111026598 T C 7.29E-05 Intelligence LOC100505678 intron 21826061 rs1145124 chr5 111027410 C T 6.32E-05 Rheumatoid arthritis LOC100505678 intron 17804836 rs17133649 chr5 111033422 C G 8.04E-04 Response to taxane treatment (placlitaxel) LOC100505678 intron 23006423 rs10515434 chr5 111036745 G A 2.48E-04 Alzheimer's disease (late onset) LOC100505678 intron 21379329 rs17133655 chr5 111036995 G A 2.66E-04 Response to taxane treatment (placlitaxel) LOC100505678 intron 23006423 rs42283 chr5 111040322 G A 5.78E-04 Alcohol dependence LOC100505678 intron 24277619 rs26056 chr5 111041083 A C 7.52E-05 Intelligence LOC100505678 intron 21826061 rs17842609 chr5 111056726 C A 7.89E-05 Alzheimer's disease (late onset) LOC100505678 intron 21379329 rs32262 chr5 111081497 T C 4.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NREP intron 20877124 rs3797730 chr5 111081708 G A 4.67E-05 Response to taxane treatment (placlitaxel) NREP intron 23006423 rs574298668 chr5 111081708 GGTAGA G 4.67E-05 Response to taxane treatment (placlitaxel) NREP intron 23006423 rs3797734 chr5 111083884 T A 2.99E-04 Depression (quantitative trait) NREP intron 20800221 rs17133711 chr5 111084118 A C 8.91E-04 Depression (quantitative trait) NREP intron 20800221 rs17133713 chr5 111084245 T C 3.90E-04 Depression (quantitative trait) NREP intron 20800221 rs17133719 chr5 111089355 A G 8.75E-04 Depression (quantitative trait) NREP intron 20800221 rs872622 chr5 111099156 A C 2.46E-04 Smoking initiation NREP intron 24665060 rs173896 chr5 111107115 T A 7.00E-06 Bipolar disorder and schizophrenia NREP intron 20889312 rs173896 chr5 111107115 T A 5.04E-05 Schizophrenia NREP intron pha002857 rs9326843 chr5 111119554 G A 1.60E-05 Urinary metabolites NREP intron 21572414 rs1948671 chr5 111121409 A G 1.40E-05 Urinary metabolites NREP intron 21572414 rs12655884 chr5 111124268 C A 8.60E-05 Height NREP intron 17255346 rs7722878 chr5 111124678 A G 5.22E-04 Multiple complex diseases NREP intron 17554300 rs7720261 chr5 111141976 G T 5.26E-04 Type 2 diabetes NREP intron 17463246 rs11241138 chr5 111142040 C A 8.03E-04 Type 2 diabetes NREP intron 17463246 rs4296844 chr5 111175320 C T 9.95E-04 Type 2 diabetes NREP intron 17463246 rs11241140 chr5 111190020 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes NREP intron 22628534 rs1466735 chr5 111241954 T C 8.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NREP intron 20877124 rs17133895 chr5 111271496 A G 2.25E-04 Multiple complex diseases NREP intron 17554300 rs4957995 chr5 111300851 G A 1.48E-06 Angioedema in response to angiotensin-converting enzyme inhibitor NREP intron 23838604 rs255927 chr5 111334000 C T 2.97E-04 Multiple complex diseases / / 17554300 rs30431 chr5 111343934 C G 3.50E-04 Multiple complex diseases / / 17554300 rs27515 chr5 111396678 T G 5.13E-04 Coronary heart disease / / 21606135 rs154082 chr5 111401031 A G 7.95E-04 Type 2 diabetes / / 17463246 rs12152753 chr5 111443094 G A 1.73E-04 Blood pressure / / 17255346 rs26566 chr5 111443754 T C 7.81E-05 Chronic obstructive pulmonary disease / / 19300482 rs25796 chr5 111444522 T C 6.43E-05 Chronic obstructive pulmonary disease / / 19300482 rs10515440 chr5 111454288 A G 5.81E-04 Aortic root size / / 21223598 rs17252737 chr5 111458013 C T 9.28E-04 Multiple complex diseases / / 17554300 rs30293 chr5 111462207 G A,C,T 2.38E-04 Multiple complex diseases / / 17554300 rs173584 chr5 111462626 G C 3.12E-04 Multiple complex diseases / / 17554300 rs17134154 chr5 111480534 T C 4.22E-04 Alzheimer's disease (late onset) / / 21379329 rs17134154 chr5 111480534 T C 4.83E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs7711158 chr5 111516285 G A 3.25E-04 Coronary Artery Disease EPB41L4A intron 17634449 rs4958010 chr5 111524095 T C 2.25E-04 Coronary Artery Disease EPB41L4A intron 17634449 rs11739263 chr5 111532234 A G 3.59E-05 Left ventricular hypertrophy EPB41L4A intron pha003052 rs10515441 chr5 111535501 T C 8.82E-04 Multiple complex diseases EPB41L4A intron 17554300 rs10515441 chr5 111535501 T C 2.15E-05 Acute lung injury EPB41L4A intron 22295056 rs12518022 chr5 111535516 G A 2.40E-05 Urinary metabolites EPB41L4A intron 21572414 rs2162733 chr5 111541688 G A 1.83E-06 Serum metabolites EPB41L4A intron 19043545 rs6876893 chr5 111542008 A C 1.06E-04 Coronary Artery Disease EPB41L4A intron 17634449 rs6873051 chr5 111555760 T C 4.68E-04 Smoking initiation EPB41L4A intron 24665060 rs4958023 chr5 111581966 T C 4.65E-05 Smoking initiation EPB41L4A intron 24665060 rs4130532 chr5 111590916 T C 1.64E-06 Waist-Hip Ratio EPB41L4A intron pha003013 rs4130532 chr5 111590916 T C 2.24E-05 Waist-Hip Ratio EPB41L4A intron pha003028 rs3923454 chr5 111599268 T G 1.96E-04 Multiple complex diseases EPB41L4A intron 17554300 rs9326851 chr5 111609210 A G 4.68E-04 Insulin resistance EPB41L4A intron 21901158 rs1464766 chr5 111613342 A G 4.14E-05 Male-pattern baldness EPB41L4A intron 18849994 rs7706772 chr5 111628901 C T 4.93E-05 Formal thought disorder in schizophrenia EPB41L4A intron 22648509 rs821736 chr5 111667502 G A 8.84E-04 Multiple complex diseases EPB41L4A intron 17554300 rs6894036 chr5 111684581 T C 2.53E-05 Odorant perception EPB41L4A intron 23910658 rs379440 chr5 111693371 T C 1.00E-06 vWF and FVIII levels EPB41L4A intron 21810271 rs366180 chr5 111699317 A G 4.20E-05 Soluble levels of adhesion molecules EPB41L4A intron pha003072 rs388383 chr5 111703635 C T 1.37E-04 Orofacial clefts EPB41L4A intron 22863734 rs17345175 chr5 111715590 T G 5.98E-04 Alzheimer's disease EPB41L4A intron 22005930 rs10515444 chr5 111749879 G A 4.80E-06 Age-related macular degeneration EPB41L4A intron pha000001 rs712675 chr5 111753343 G C 7.48E-04 Alzheimer's disease EPB41L4A intron 22005930 rs3985058 chr5 111756424 T G 4.80E-06 Age-related macular degeneration / / pha000001 rs7702830 chr5 111770880 A G 4.05E-04 Alzheimer's disease / / 22005930 rs12189127 chr5 111772360 A T 4.22E-04 Alzheimer's disease / / 22005930 rs12189152 chr5 111772638 A G 4.25E-04 Alzheimer's disease / / 22005930 rs9326854 chr5 111778778 G A 5.93E-04 Alzheimer's disease / / 22005930 rs163622 chr5 111793954 C T 3.77E-04 Coronary heart disease / / 21606135 rs10066268 chr5 111795276 G A 5.26E-04 Alzheimer's disease / / 22005930 rs7725590 chr5 111795910 G T 5.37E-04 Alzheimer's disease / / 22005930 rs17281712 chr5 111804491 T G 5.66E-04 Alzheimer's disease / / 22005930 rs6871304 chr5 111805269 G A 5.84E-04 Alzheimer's disease / / 22005930 rs6871040 chr5 111805307 A G 5.90E-04 Alzheimer's disease / / 22005930 rs17281726 chr5 111806028 T C 2.20E-05 Urinary metabolites / / 21572414 rs17134541 chr5 111806242 A G 5.90E-04 Alzheimer's disease / / 22005930 rs10050440 chr5 111807417 C T 6.00E-04 Alzheimer's disease / / 22005930 rs1345686 chr5 111807579 C T 5.01E-04 Alzheimer's disease / / 22005930 rs1345685 chr5 111807621 G A 5.95E-04 Alzheimer's disease / / 22005930 rs10050630 chr5 111807744 C T 5.93E-04 Alzheimer's disease / / 22005930 rs17354763 chr5 111815048 T C 1.45E-04 Smoking quantity / / 24665060 rs17354833 chr5 111815824 C T 2.00E-05 Urinary metabolites / / 21572414 rs341313 chr5 111830039 C T 3.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs338852 chr5 111865497 A G 6.88E-04 Multiple complex diseases / / 17554300 rs163446 chr5 111873853 G T 2.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13154524 chr5 111890072 G A 2.67E-05 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs13154524 chr5 111890072 G A 3.41E-05 Fasting insulin (interaction) / / 24204828 rs7378714 chr5 111893547 G T 4.64E-05 Vaspin levels / / 22907691 rs7378714 chr5 111893547 G T 0.0000464 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs4958063 chr5 111911276 G A 5.89E-04 Multiple complex diseases / / 17554300 rs4958063 chr5 111911276 G A 1.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4958063 chr5 111911276 G A 4.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13188321 chr5 111914106 C T 1.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6594619 chr5 111915524 C T 6.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6594619 chr5 111915524 C T 8.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7445994 chr5 111919415 C T 7.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10067709 chr5 111933873 A C 8.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10067709 chr5 111933873 A C 8.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6887003 chr5 111938738 C A 4.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12516949 chr5 111942769 G A 3.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12516949 chr5 111942769 G A 4.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7378752 chr5 111946854 G C 3.42E-04 Sarcoidosis / / 19165924 rs6594641 chr5 111953572 A G 7.19E-04 Multiple complex diseases / / 17554300 rs4705616 chr5 111962676 G A 9.19E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12719151 chr5 112026480 T C 2.29E-04 Stroke / / pha002886 rs6594646 chr5 112081924 A G 5.24E-04 Stroke APC intron pha002886 rs2431512 chr5 112118956 C T 6.89E-04 Stroke APC intron pha002886 rs411356 chr5 112172219 G A 3.65E-04 Stroke APC intron pha002886 rs712665 chr5 112227799 A G 4.57E-04 Stroke SRP19 UTR-3 pha002886 rs465454 chr5 112230331 T C 3.73E-05 Serum metabolites REEP5 intron 19043545 rs151977 chr5 112234549 A T 3.13E-05 Serum metabolites REEP5 intron 19043545 rs469727 chr5 112242968 C T 8.00E-06 Attention deficit hyperactivity disorder REEP5 intron 18839057 rs10515450 chr5 112276647 T C 8.81E-05 Multiple complex diseases / / 17554300 rs9885540 chr5 112302521 C T 2.60E-06 Urinary metabolites / / 21572414 rs33557 chr5 112310396 T C 1.47E-04 Premature ovarian failure / / 19508998 rs33551 chr5 112318928 C T 1.29E-04 Premature ovarian failure DCP2 intron 19508998 rs2112454 chr5 112323738 A G 7.08E-05 Premature ovarian failure DCP2 intron 19508998 rs2112454 chr5 112323738 A G 7.08E-05 Other erythrocyte phenotypes DCP2 intron 19862010 rs9784647 chr5 112325869 C T 7.51E-04 Premature ovarian failure DCP2 intron 19508998 rs3733968 chr5 112328267 C T 4.78E-04 Premature ovarian failure DCP2 intron 19508998 rs6892784 chr5 112349297 T C 1.40E-05 Urinary metabolites DCP2 UTR-3 21572414 rs6876686 chr5 112350098 C T 1.60E-05 Urinary metabolites DCP2 UTR-3 21572414 rs7033 chr5 112357922 T C 2.50E-05 Urinary metabolites MCC UTR-3 21572414 rs9122 chr5 112358131 T C 4.50E-05 Premature ovarian failure MCC UTR-3 19508998 rs9122 chr5 112358131 T C 4.50E-05 Other erythrocyte phenotypes MCC UTR-3 19862010 rs17314002 chr5 112365716 A G 1.54E-05 Multiple complex diseases MCC intron 17554300 rs6594658 chr5 112374408 A G 1.35E-30 Narcolepsy MCC intron 19629137 rs9326876 chr5 112428787 C T 5.32E-04 Multiple complex diseases MCC intron 17554300 rs4078252 chr5 112455467 C T 2.00E-07 Response to cytadine analogues (cytosine arabinoside) MCC intron 24483146 rs4078254 chr5 112456067 A C 6.35E-04 Response to cytadine analogues (cytosine arabinoside) MCC intron 24483146 rs4078253 chr5 112456373 G C 2.31E-04 Response to cytadine analogues (cytosine arabinoside) MCC intron 24483146 rs6594683 chr5 112461641 A G 2.34E-04 Response to cytadine analogues (cytosine arabinoside) MCC intron 24483146 rs2416305 chr5 112483604 G A 4.70E-05 Methamphetamine dependence MCC intron 23594818 rs2165929 chr5 112485155 A G 6.99E-05 Response to cytadine analogues (cytosine arabinoside) MCC intron 24483146 rs1443685 chr5 112490223 G A 1.80E-05 Urinary metabolites MCC intron 21572414 rs2120348 chr5 112545898 C G 4.00E-04 Gamma gluatamyl transferase levels (interaction with age) MCC intron 22010049 rs41420244 chr5 112560457 G C 3.58E-04 Multiple complex diseases MCC intron 17554300 rs1997521 chr5 112579419 G A 4.27E-04 Body mass index MCC intron 17255346 rs17323670 chr5 112580290 T C 7.00E-06 Bipolar disorder and schizophrenia MCC intron 20889312 rs17135515 chr5 112598947 T C 4.67E-04 Body mass index MCC intron 17255346 rs1822487 chr5 112604611 G C 4.67E-04 Multiple complex diseases MCC intron 17554300 rs17135526 chr5 112606338 G A 4.44E-04 Body mass index MCC intron 17255346 rs1922679 chr5 112637754 G A 3.10E-04 Response to cytadine analogues (cytosine arabinoside) MCC intron 24483146 rs11739509 chr5 112650751 T C 1.23E-04 Age-related macular degeneration MCC intron 22125219 rs11241200 chr5 112675099 T G 6.32E-04 Coronary Artery Disease MCC intron 17634449 rs11241200 chr5 112675099 T G 3.45E-05 Hirschsprung's disease MCC intron 19196962 rs10067046 chr5 112676024 C G 3.90E-04 Coronary Artery Disease MCC intron 17634449 rs10900684 chr5 112676191 A G 2.42E-05 Hirschsprung's disease MCC intron 19196962 rs13171482 chr5 112701966 G A 0.000000929 Cytarabine sensitivity MCC intron 23538338 rs13189050 chr5 112706511 T C 0.000000411 Cytarabine sensitivity MCC intron 23538338 rs17135586 chr5 112712929 T C 4.02E-04 Multiple complex diseases MCC intron 17554300 rs6594713 chr5 112715374 A C 2.00E-06 Brain cytoarchitecture MCC intron 20308991 rs6594713 chr5 112715374 A C 0.000000606 Cytarabine sensitivity MCC intron 23538338 rs7729269 chr5 112720394 T C 0.000000367 Cytarabine sensitivity MCC intron 23538338 rs17327526 chr5 112720648 C A 7.90E-04 Multiple complex diseases MCC intron 17554300 rs1318772 chr5 112723567 A G 1.00E-06 F-cell distribution MCC intron 21326311 rs13181534 chr5 112724641 T C 0.000000606 Cytarabine sensitivity MCC intron 23538338 rs13181732 chr5 112724778 T C 3.09E-04 Coronary heart disease MCC intron 21606135 rs10061462 chr5 112726205 A T 0.00000167 Cytarabine sensitivity MCC intron 23538338 rs7714760 chr5 112735231 T C 0.00000345 Cytarabine sensitivity MCC intron 23538338 rs6870401 chr5 112738364 C G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) MCC intron 17982456 rs6870401 chr5 112738364 C G 0.000000874 Cytarabine sensitivity MCC intron 23538338 rs6594714 chr5 112738620 C G 0.00000391 Cytarabine sensitivity MCC intron 23538338 rs6887482 chr5 112741433 A C 0.00000102 Cytarabine sensitivity MCC intron 23538338 rs6894687 chr5 112742953 G C 3.90E-06 Urinary metabolites MCC intron 21572414 rs6894687 chr5 112742953 G C 2.07E-07 Esophageal cancer (squamous cell) MCC intron 22960999 rs36613 chr5 112758471 G A 1.69E-04 Age-related macular degeneration MCC intron 22125219 rs10053341 chr5 112784007 G T 0.000000818 Cytarabine sensitivity MCC intron 23538338 rs10043783 chr5 112786116 T A 1.77E-04 Multiple complex diseases MCC intron 17554300 rs26990 chr5 112786843 C T 1.96E-05 stroke (ischemic) MCC intron 17434096 rs7707443 chr5 112790219 C T 7.76E-04 Alzheimer's disease MCC intron 22005930 rs13174075 chr5 112795352 A T 0.00000618 Cytarabine sensitivity MCC intron 23538338 rs6883441 chr5 112798855 G A 8.14E-04 Alzheimer's disease MCC intron 22005930 rs2248930 chr5 112811119 G T 3.81E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) MCC intron 17982456 rs3846722 chr5 112825424 G A 8.99E-04 Alzheimer's disease MCC nearGene-5 22005930 rs2416282 chr5 112848767 C A 6.56E-05 Personality dimensions / / 18957941 rs12523145 chr5 112852568 G A 1.90E-06 Urinary metabolites YTHDC2 intron 21572414 rs9326890 chr5 112859994 C T 9.57E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) YTHDC2 intron 17982456 rs4705826 chr5 112870387 A C 8.46E-04 Alzheimer's disease YTHDC2 intron 22005930 rs4705827 chr5 112870454 T C 6.72E-04 Multiple complex diseases YTHDC2 intron 17554300 rs12519323 chr5 112894805 A G 8.78E-04 Alzheimer's disease YTHDC2 intron 22005930 rs6864369 chr5 112916780 T G 9.00E-04 Alzheimer's disease YTHDC2 intron 22005930 rs6883547 chr5 112916853 G A 0.00000693 Cytarabine sensitivity YTHDC2 intron 23538338 rs11748794 chr5 112917278 T G 9.31E-04 Alzheimer's disease YTHDC2 cds-synon 22005930 rs4705558 chr5 112919585 T G 9.17E-04 Alzheimer's disease YTHDC2 intron 22005930 rs10077431 chr5 112927686 C A 2.40E-05 Urinary metabolites YTHDC2 intron 21572414 rs17333442 chr5 112947050 A C 1.03E-04 Age-related macular degeneration / / 22125219 rs6889348 chr5 112965145 A G 7.27E-05 Panic disorder / / 19165232 rs4705563 chr5 112979539 T C 1.75E-05 Type 2 diabetes and other traits / / 19734900 rs12189067 chr5 112981528 C A 1.13E-05 F-cell distribution / / 21326311 rs17135859 chr5 112996654 T C 8.00E-06 F-cell distribution / / 21326311 rs12515653 chr5 113007302 G T 5.76E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6891711 chr5 113009026 T G 6.44E-04 Multiple complex diseases / / 17554300 rs10519361 chr5 113023069 C T 3.72E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs10519361 chr5 113023069 C T 6.31E-04 Bipolar disorder / / 19259986 rs4621553 chr5 113030164 G A 4.00E-08 Sudden cardiac arrest / / 21658281 rs4568351 chr5 113043687 A G 5.50E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs13188669 chr5 113053462 G T 0.000211 Salmonella-induced pyroptosis / / 22837397 rs1871912 chr5 113054499 T C 4.56E-05 Sudden cardiac arrest / / 21658281 rs10071833 chr5 113132750 A G 2.21E-04 Type 2 diabetes / / 22158537 rs729455 chr5 113133906 A G 6.58E-05 Type 2 diabetes / / 22158537 rs6870057 chr5 113134137 A G 2.75E-04 Type 2 diabetes / / 22158537 rs6871811 chr5 113134918 G A 4.19E-04 Type 2 diabetes / / 22158537 rs10477505 chr5 113137884 A C 4.32E-04 Lung function (forced vital capacity) / / 24023788 rs17337236 chr5 113143478 A G 1.95E-04 Type 2 diabetes / / 22158537 rs6898372 chr5 113144727 G A 3.20E-04 Type 2 diabetes / / 22158537 rs4705475 chr5 113145402 T G 5.51E-04 Type 2 diabetes / / 22158537 rs1482365 chr5 113145628 T C 2.37E-04 Type 2 diabetes / / 22158537 rs10040195 chr5 113146931 C T 1.56E-04 Type 2 diabetes / / 22158537 rs2128317 chr5 113147332 C T 2.19E-04 Type 2 diabetes / / 22158537 rs6594762 chr5 113148267 C T 3.83E-04 Type 2 diabetes / / 22158537 rs1384282 chr5 113149124 C T 8.17E-04 Type 2 diabetes / / 22158537 rs1905138 chr5 113149526 A T 9.77E-04 Multiple complex diseases / / 17554300 rs1116657 chr5 113166137 T C 7.77E-04 Alcohol dependence / / 20201924 rs997933 chr5 113184211 C T 2.20E-05 Urinary metabolites / / 21572414 rs13173395 chr5 113196826 A G 1.10E-06 Urinary metabolites / / 21572414 rs2035413 chr5 113204536 C G 1.30E-05 Urinary metabolites / / 21572414 rs957704 chr5 113210869 C T 6.29E-04 Type 2 diabetes / / 22158537 rs13187257 chr5 113211544 C T 1.30E-05 Urinary metabolites / / 21572414 rs7723550 chr5 113212117 C T 1.30E-05 Urinary metabolites / / 21572414 rs11738369 chr5 113212970 A G 5.85E-04 Type 2 diabetes / / 22158537 rs12522099 chr5 113218875 T C 2.84E-04 Type 2 diabetes / / 22158537 rs12522099 chr5 113218875 T C 2.17E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1482377 chr5 113225701 T C 1.56E-05 Post-operative nausea and vomiting / / 21694509 rs4449520 chr5 113227270 G C 4.90E-05 Malaria / / 19465909 rs991601 chr5 113247386 T C 7.20E-05 Cognitive function / / 24684796 rs12520671 chr5 113250047 C T 8.96E-05 Lipoproteins / / pha003079 rs1905155 chr5 113273198 G T 1.60E-05 Subclinical atherosclerosis / / 17903303 rs10076899 chr5 113298428 G C 4.62E-05 Serum metabolites / / 19043545 rs17136138 chr5 113299037 A C 6.67E-06 Height / / 20400458 rs995360 chr5 113306805 T G 1.31E-05 Hemoglobin / / pha003098 rs995360 chr5 113306805 T G 2.06E-06 Erythrocyte counts / / pha003099 rs2974558 chr5 113327484 C T 9.28E-04 Multiple complex diseases / / 17554300 rs404471 chr5 113328803 A C 4.59E-05 Multiple complex diseases / / 17554300 rs1487228 chr5 113396285 T C 6.92E-05 Rheumatoid arthritis / / 17804836 rs7702107 chr5 113421087 A G 7.89E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1158117 chr5 113429984 A G 7.81E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2632115 chr5 113433793 G A,C,T 6.51E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2974486 chr5 113436889 C T 6.64E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1487222 chr5 113440892 G A 7.30E-06 Schizophrenia / / 21791550 rs1487222 chr5 113440892 G A 0.0000073 Psychosis / / 23164818 rs1487222 chr5 113440892 G A 4.64E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17136296 chr5 113457760 A G 2.69E-32 Multiple complex diseases / / 17554300 rs6876085 chr5 113458989 A G 3.29E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2954369 chr5 113469561 C T 3.57E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4076577 chr5 113488521 T C 6.90E-05 Height / / pha003010 rs11747037 chr5 113503422 A G 0.00062 Erectile dysfunction after radiotherapy for prostate cancer / / 23021708 rs13174507 chr5 113515277 A G 7.58E-04 Tourette syndrome / / 22889924 rs13174507 chr5 113515277 A G 7.50E-05 Height / / pha003010 rs4705634 chr5 113524524 T G 7.22E-05 Height / / pha003010 rs13184901 chr5 113596392 T G 8.73E-05 Height / / pha003010 rs36954 chr5 113670154 A G 1.10E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10519381 chr5 113672242 C T 6.57E-04 Multiple complex diseases / / 17554300 rs10519381 chr5 113672242 C T 4.40E-05 Obesity-related traits / / 17903300 rs36952 chr5 113673427 C T 4.91E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs36951 chr5 113673772 C A 6.04E-04 Multiple complex diseases / / 17554300 rs36951 chr5 113673772 C A 2.00E-05 Urinary metabolites / / 21572414 rs1976311 chr5 113676005 C G 0.0000498 Menopause (age at onset) / / 23424626 rs36936 chr5 113679204 T C 3.36E-05 Attention deficit hyperactivity disorder / / 20732627 rs1457762 chr5 113711389 G T 2.35E-05 Multiple complex diseases KCNN2 intron 17554300 rs13176052 chr5 113723831 G A 2.30E-04 Multiple complex diseases KCNN2 intron 17554300 rs1496389 chr5 113725671 A G 9.67E-04 Multiple complex diseases KCNN2 intron 17554300 rs1496389 chr5 113725671 A G 9.80E-05 Obesity-related traits KCNN2 intron 17903300 rs4705665 chr5 113743653 A G 2.55E-05 Alcohol withdrawal symptoms KCNN2 intron 22072270 rs2416371 chr5 113775870 C T 1.32E-05 Alcohol withdrawal symptoms KCNN2 intron 22072270 rs7710366 chr5 113780187 T G 1.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNN2 intron 20877124 rs7710366 chr5 113780187 T G 3.48E-05 Diabetic nephropathy KCNN2 intron 21150874 rs1841249 chr5 113788151 A G 9.50E-07 Urinary metabolites KCNN2 intron 21572414 rs17136627 chr5 113798986 C T 2.00E-08 Coronary arterial lesions in patients with Kawasaki disease KCNN2 intron 23677057 rs10519387 chr5 113832780 C T 6.13E-04 Bipolar disorder / / 19259986 rs1364937 chr5 113838579 A C 2.32E-04 Parkinson's disease / / 17052657 rs400028 chr5 113849294 C T 5.00E-06 Obesity-related traits / / 23251661 rs17136716 chr5 113849350 G T 2.13E-05 Elbow pain / / pha003008 rs2559995 chr5 113850052 G A 2.43E-05 Bilirubin levels,in serum / / 19389676 rs985525 chr5 113858286 G A 1.82E-05 Bilirubin levels,in serum / / 19389676 rs1427867 chr5 113898201 C T 6.61E-05 Elbow pain / / pha003008 rs3096548 chr5 113910679 G A 6.08E-04 Multiple complex diseases / / 17554300 rs694788 chr5 113926936 T C 3.48E-05 Bilirubin levels,in serum / / 19389676 rs686349 chr5 113957246 C T 4.36E-04 Aortic root size / / 21223598 rs10478173 chr5 113961148 G A 1.92E-05 Elbow pain / / pha003008 rs12521060 chr5 113986879 C A 2.61E-05 Elbow pain / / pha003008 rs285901 chr5 114019748 C T 2.09E-04 Alzheimer's disease / / 22005930 rs10491499 chr5 114023787 A G 9.21E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs285912 chr5 114027841 G C 1.52E-05 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs6594833 chr5 114119208 T C 1.90E-05 Multiple complex diseases / / 17554300 rs10062925 chr5 114119283 A C 1.04E-10 Multiple complex diseases / / 17554300 rs289034 chr5 114122165 T C 9.40E-05 LDL lipoproteins / / pha002902 rs10478183 chr5 114127793 G A 1.45E-05 Elbow pain / / pha003008 rs13182382 chr5 114407661 G A 6.91E-05 Elbow pain / / pha003008 rs9326945 chr5 114425513 T C 6.34E-05 Elbow pain / / pha003008 rs2974508 chr5 114434999 A G 8.47E-05 Elbow pain / / pha003008 rs2034246 chr5 114451587 A C 2.35E-05 Intelligence / / 21826061 rs7737426 chr5 114508588 T A 5.44E-04 Response to taxane treatment (placlitaxel) TRIM36 intron 23006423 rs3805589 chr5 114509072 G C 7.57E-05 Serum metabolites TRIM36 intron 19043545 rs265408 chr5 114520006 G C 2.50E-05 Urinary metabolites / / 21572414 rs265412 chr5 114530113 C G 1.70E-05 Urinary metabolites / / 21572414 rs1422075 chr5 114530301 C G,T 1.60E-05 Urinary metabolites / / 21572414 rs2059061 chr5 114550708 T C 9.07E-04 Obesity (extreme) PGGT1B intron 21935397 rs4705731 chr5 114564400 A G 9.79E-04 Obesity (extreme) PGGT1B intron 21935397 rs169127 chr5 114626755 T C 9.67E-04 Obesity (extreme) CCDC112 intron 21935397 rs2124396 chr5 114650716 A T 1.10E-05 Urinary metabolites / / 21572414 rs269498 chr5 114657243 A G 6.16E-04 Coronary heart disease / / 21606135 rs2121099 chr5 114672368 T C 9.40E-05 Parkinson's disease (age of onset) / / 19772629 rs2963764 chr5 114696135 T C 3.22E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11740600 chr5 114709455 T C 2.75E-04 Coronary Artery Disease / / 17634449 rs1455849 chr5 114718044 T A 2.70E-05 Urinary metabolites / / 21572414 rs2605190 chr5 114733752 G A 3.52E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11950882 chr5 114743708 G C 1.90E-04 Obesity (extreme) / / 21935397 rs790669 chr5 114785465 C T 6.45E-05 Aging (time to event) / / 21782286 rs2546483 chr5 114841286 C T 4.34E-04 Type 2 diabetes / / 17463246 rs256940 chr5 114866191 G A 3.84E-05 Educational attainment FEM1C intron 21694764 rs256957 chr5 114877920 A G 3.30E-05 C-Reactive Protein FEM1C intron pha003070 rs256989 chr5 114911565 T C 4.50E-10 Narcolepsy / / 19629137 rs256994 chr5 114912646 C T 9.76E-05 Serum metabolites / / 19043545 rs256962 chr5 114942711 A G 2.00E-05 Type 2 diabetes TMED7-TICAM2 intron 17903298 rs2052834 chr5 114952645 G A 2.10E-04 Major depressive disorder TMED7 intron 21042317 rs6863960 chr5 114995781 G A 0.000227 Oxaliplatin induced neuropathy in response to colorectal cancer treatment / / 22310351 rs13177645 chr5 115003874 A G 2.10E-05 Melanoma / / 21983785 rs424347 chr5 115007424 C T 8.30E-05 Major depressive disorder / / 21042317 rs365818 chr5 115017389 C T 8.99E-06 Erythrocyte counts / / pha003090 rs249721 chr5 115022257 A G 2.70E-04 Crohn's disease / / 17684544 rs166082 chr5 115030677 A C 8.20E-05 Major depressive disorder / / 21042317 rs403039 chr5 115044230 T C 1.37E-05 Erythrocyte counts / / pha003090 rs251891 chr5 115050362 G T 6.90E-05 Major depressive disorder / / 21042317 rs152415 chr5 115055703 T C 5.67E-04 Multiple complex diseases / / 17554300 rs10071991 chr5 115058148 T C 1.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs249706 chr5 115063678 T A 6.20E-04 Multiple complex diseases / / 17554300 rs10060156 chr5 115091586 C A 8.41E-04 Acute lung injury / / 22295056 rs4921024 chr5 115093244 C T 8.41E-04 Acute lung injury / / 22295056 rs10067851 chr5 115100036 G A 8.52E-04 Acute lung injury / / 22295056 rs7706913 chr5 115103321 C A 8.93E-04 Acute lung injury / / 22295056 rs1472623 chr5 115108261 C T 7.58E-04 Prostate cancer mortality / / 20978177 rs731649 chr5 115113448 C G 6.45E-04 Prostate cancer mortality / / 20978177 rs13174348 chr5 115138748 G A 3.00E-06 IgG glycosylation / / 23382691 rs26531 chr5 115150525 T G 6.59E-05 Major depressive disorder CDO1 intron 22472876 rs11958116 chr5 115254723 T C 3.47E-04 Myopia (pathological) / / 21095009 rs13357651 chr5 115258955 G A 1.58E-04 Coronary heart disease / / 21606135 rs2081861 chr5 115271986 A G 8.09E-04 Multiple complex diseases / / 17554300 rs17480476 chr5 115275361 A G 1.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs7738029 chr5 115276436 T C 8.07E-04 Aortic root size / / 21223598 rs17402213 chr5 115280710 A G 7.75E-05 Suicide attempts in bipolar disorder / / 21423239 rs17480637 chr5 115281872 A C 8.93E-05 Suicide attempts in bipolar disorder / / 21423239 rs6878289 chr5 115283903 A C 3.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs6594911 chr5 115284546 T A 9.78E-04 Multiple complex diseases / / 17554300 rs17138463 chr5 115286059 T A 1.56E-04 Type 2 diabetes / / 17463246 rs7722770 chr5 115287957 C G 8.40E-04 Weight loss (gastric bypass surgery) / / 23643386 rs17138468 chr5 115288424 C G 1.61E-04 Type 2 diabetes / / 17463246 rs17138494 chr5 115296773 G A 7.34E-04 Multiple complex diseases / / 17554300 rs7341066 chr5 115310760 C T 3.58E-05 Erythrocyte counts AQPEP intron pha003090 rs6594925 chr5 115312671 A G 6.37E-05 Monocyte chemoattractant protein-1 AQPEP intron pha003071 rs17138520 chr5 115316588 A G 5.57E-04 Suicide attempts in bipolar disorder AQPEP intron 21423239 rs1366200 chr5 115321819 T G 6.98E-04 Multiple complex diseases AQPEP intron 17554300 rs1366200 chr5 115321819 T G 6.35E-05 ldl cholesterol AQPEP intron pha003077 rs1366200 chr5 115321819 T G 1.28E-05 Cholesterol AQPEP intron pha003083 rs10519435 chr5 115322822 G A 5.38E-05 Serum metabolites AQPEP intron 19043545 rs17138562 chr5 115323234 G A 6.76E-05 Monocyte chemoattractant protein-1 AQPEP intron pha003071 rs10044122 chr5 115330927 T C 1.79E-05 Orofacial clefts AQPEP intron 22419666 rs10078748 chr5 115341611 G T 5.49E-05 IgE levels AQPEP cds-synon 17255346 rs10078748 chr5 115341611 G T 1.59E-04 HIV-1 viral setpoint AQPEP cds-synon 17641165 rs10078759 chr5 115341638 G C 2.83E-04 IgE levels AQPEP missense 17255346 rs17138642 chr5 115342913 T A 9.70E-06 Urinary metabolites AQPEP intron 21572414 rs7729142 chr5 115343719 C T 9.39E-05 Type 2 diabetes AQPEP intron 17463246 rs1593872 chr5 115344224 C A 3.66E-04 Weight loss (gastric bypass surgery) AQPEP intron 23643386 rs17138656 chr5 115348816 G A 7.64E-05 IgE levels AQPEP intron 17255346 rs17138656 chr5 115348816 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes AQPEP intron 22628534 rs1529442 chr5 115349375 C T 9.41E-04 Alcohol dependence AQPEP intron 21314694 rs1428089 chr5 115361188 G A 7.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) AQPEP intron 20877124 rs1508886 chr5 115362148 A G 1.75E-04 Multiple complex diseases AQPEP UTR-3 17554300 rs1508886 chr5 115362148 A G 7.94E-05 Aortic root size AQPEP UTR-3 21223598 rs10060276 chr5 115385416 A G 3.11E-04 Multiple complex diseases / / 17554300 rs12655399 chr5 115399176 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1133186 chr5 115420415 A C 5.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4920906 chr5 115480986 C A 6.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COMMD10 intron 20877124 rs11957382 chr5 115484252 T C 1.96E-04 Schizophrenia COMMD10 intron 19197363 rs1396485 chr5 115512352 G A 7.00E-07 Inflammatory biomarkers COMMD10 intron 22228203 rs11241374 chr5 115519754 T C 6.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COMMD10 intron 20877124 rs10063312 chr5 115520611 T C 6.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COMMD10 intron 20877124 rs7709377 chr5 115540573 A G 4.00E-06 Metabolite levels (X-11787) COMMD10 intron 23934736 rs1382342 chr5 115561128 C A 2.57E-05 Schizophrenia COMMD10 intron 19197363 rs6594958 chr5 115566636 C T 1.99E-05 Height COMMD10 intron pha003010 rs6594958 chr5 115566636 C T 9.02E-05 Height COMMD10 intron pha003011 rs253959 chr5 115568757 T C 8.00E-06 Bipolar disorder and schizophrenia COMMD10 intron 22688191 rs1896684 chr5 115584159 G T 1.33E-05 Height COMMD10 intron pha003010 rs1896684 chr5 115584159 G T 5.66E-05 Height COMMD10 intron pha003011 rs10036292 chr5 115595871 A G 4.99E-06 Asthma or chronic obstructive pulmonary disease COMMD10 intron 24993907 rs10043228 chr5 115597048 C T 4.00E-06 Asthma or chronic obstructive pulmonary disease COMMD10 intron 24993907 rs7706895 chr5 115601629 T C 8.05E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) COMMD10 intron 22566498 rs254149 chr5 115605920 C G 1.20E-05 Asthma or chronic obstructive pulmonary disease COMMD10 intron 24993907 rs17139366 chr5 115616014 G C 9.44E-04 Multiple complex diseases COMMD10 intron 17554300 rs11739446 chr5 115620224 A G 4.99E-06 Hearing function COMMD10 intron 21493956 rs37181 chr5 115630004 T G 2.20E-05 Prostate cancer / / 21743467 rs37181 chr5 115630004 T G 4.18E-05 Cognitive impairment induced by topiramate / / 22091778 rs6897052 chr5 115633855 G A 3.90E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs712572 chr5 115634127 A G 5.66E-05 Cognitive impairment induced by topiramate / / 22091778 rs17139432 chr5 115634203 G A 3.88E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7728830 chr5 115637800 G T 3.87E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs712577 chr5 115649941 G A 6.03E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs712593 chr5 115657397 G T 4.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs712600 chr5 115658895 T C 3.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs166204 chr5 115692083 G A 3.26E-04 Schizophrenia / / 19197363 rs27368 chr5 115693892 G A 2.95E-04 Schizophrenia / / 19197363 rs1363154 chr5 115696048 C T 9.95E-04 Type 2 diabetes / / 17463246 rs1363153 chr5 115696118 A G 9.63E-04 Type 2 diabetes / / 17463246 rs17139559 chr5 115698634 T A 1.03E-04 Type 2 diabetes / / 17463246 rs1421847 chr5 115701098 T C 2.87E-04 Schizophrenia / / 19197363 rs17139611 chr5 115707933 A G 7.69E-05 Height / / pha003010 rs17139611 chr5 115707933 A G 4.37E-05 Height / / pha003011 rs9327000 chr5 115709156 A C 2.65E-04 Schizophrenia / / 19197363 rs9327000 chr5 115709156 A C 5.66E-04 Lymphocyte counts / / 22286170 rs12654903 chr5 115724366 A C 5.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs12654903 chr5 115724366 A C 4.20E-05 Height / / pha003010 rs12654903 chr5 115724366 A C 8.69E-06 Height / / pha003011 rs7702057 chr5 115727838 G T 8.00E-06 Amyotrophic lateral sclerosis / / 19451621 rs1990878 chr5 115729783 G A 2.80E-05 Urinary metabolites / / 21572414 rs1421845 chr5 115729919 G A 2.50E-05 Urinary metabolites / / 21572414 rs1990877 chr5 115731448 T C 8.77E-04 Type 2 diabetes / / 17463246 rs11952185 chr5 115731993 T C 2.10E-05 Urinary metabolites / / 21572414 rs7734156 chr5 115733805 G C 7.00E-06 IgG glycosylation / / 23382691 rs1421844 chr5 115734080 C T 4.08E-04 Iron levels / / pha002876 rs12521753 chr5 115746567 A G 3.61E-04 Iron levels / / pha002876 rs254082 chr5 115751889 T C 7.93E-06 Erythrocyte counts / / pha003101 rs33073 chr5 115756874 A T 1.10E-05 Urinary metabolites / / 21572414 rs26595 chr5 115759490 G A 2.00E-08 Wegener's granulomatosis / / 23740775 rs26602 chr5 115788104 T C 8.50E-05 AIDS SEMA6A intron 19754311 rs26604 chr5 115792368 G A 1.11E-05 Gallstones SEMA6A intron 17632509 rs258019 chr5 115807688 T C 4.46E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SEMA6A intron 20877124 rs423834 chr5 115811220 T C 1.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SEMA6A intron 20877124 rs469035 chr5 115815607 A C 4.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SEMA6A intron 20877124 rs2278264 chr5 115816823 G A 2.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SEMA6A intron 20877124 rs2287685 chr5 115822923 G C 7.71E-04 Insulin resistance SEMA6A intron 21901158 rs32972 chr5 115831092 C T 2.13E-05 Suicide attempts in bipolar disorder SEMA6A intron 21041247 rs32973 chr5 115831305 G A 2.22E-04 Suicide attempts in bipolar disorder SEMA6A intron 21041247 rs2287686 chr5 115831330 A G 4.75E-04 Tourette syndrome SEMA6A intron 22889924 rs4920916 chr5 115847241 A G 8.44E-04 Alzheimer's disease SEMA6A intron 24755620 rs7728185 chr5 115850398 G A 5.03E-04 Smoking initiation SEMA6A intron 24665060 rs154576 chr5 115861632 G A 7.00E-06 Alcohol dependence SEMA6A intron 21956439 rs154576 chr5 115861632 G A 0.000000203 Trichophyton tonsurans susceptibility SEMA6A intron 22704677 rs254234 chr5 115888195 T C 2.30E-05 Urinary metabolites SEMA6A intron 21572414 rs254079 chr5 115891083 A G 2.55E-17 Crohn's disease SEMA6A intron 18587394 rs17140205 chr5 115942140 A G 5.66E-04 Multiple complex diseases / / 17554300 rs607930 chr5 115943194 T C 8.39E-05 Multiple complex diseases / / 17554300 rs632993 chr5 115948109 G A 7.12E-06 Lipoproteins / / pha003079 rs6898653 chr5 115975656 A G 1.00E-06 Allergic rhinitis / / 22036096 rs17140266 chr5 115988580 C T 3.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs1948429 chr5 115994775 C A 4.05E-04 Type 2 diabetes / / 17846124 rs1124239 chr5 116008931 A G 6.44E-04 Type 2 diabetes / / 17846124 rs2909825 chr5 116063353 A G 8.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2909823 chr5 116064934 T C 7.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2068933 chr5 116088853 A G 1.94E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17366227 chr5 116105353 A T 1.35E-04 Multiple complex diseases / / 17554300 rs924454 chr5 116124275 A G 1.77E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2964675 chr5 116126220 A G 1.20E-05 Urinary metabolites / / 21572414 rs6896154 chr5 116161059 T C 1.59E-04 Multiple complex diseases / / 17554300 rs4920937 chr5 116165532 T C 2.18E-04 Multiple complex diseases / / 17554300 rs10051209 chr5 116168372 C T 1.92E-04 Multiple complex diseases / / 17554300 rs6882638 chr5 116180180 C T 3.30E-04 Multiple complex diseases / / 17554300 rs1428006 chr5 116180565 C T 4.02E-05 Multiple complex diseases / / 17554300 rs1428007 chr5 116180873 G A 2.66E-04 Multiple complex diseases / / 17554300 rs153585 chr5 116182353 G T 4.31E-04 Nicotine dependence / / 17158188 rs11956132 chr5 116185389 A G 4.69E-04 Multiple complex diseases / / 17554300 rs6878801 chr5 116207905 C T 6.77E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs6878801 chr5 116207905 C T 8.52E-04 Heart Failure / / pha002885 rs253890 chr5 116218278 C T 8.57E-06 Major depressive disorder / / 20516156 rs253890 chr5 116218278 C T 1.50E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1643886 chr5 116223053 C A 6.30E-06 Urinary metabolites / / 21572414 rs5025004 chr5 116223272 G A 8.30E-06 Urinary metabolites / / 21572414 rs17310469 chr5 116224877 A G 6.32E-04 Bipolar disorder,schizoaffective / / 19567891 rs1643889 chr5 116225123 C T 1.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1643889 chr5 116225123 C T 1.70E-05 Urinary metabolites / / 21572414 rs1631048 chr5 116225310 G A 1.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6594987 chr5 116228312 A C 6.00E-05 Type 2 diabetes / / 17903298 rs6594987 chr5 116228312 A C 6.61E-05 Varicose Veins / / pha001413 rs1643898 chr5 116231506 T C 1.90E-05 Urinary metabolites / / 21572414 rs1073781 chr5 116232352 A G 2.30E-05 Urinary metabolites / / 21572414 rs2605897 chr5 116240273 C A 1.90E-05 Urinary metabolites / / 21572414 rs4920863 chr5 116276974 C T 8.78E-04 Type 2 diabetes / / 17463246 rs1459084 chr5 116403077 C T 8.81E-05 HIV-1 control / / 20041166 rs6885944 chr5 116409672 C G 8.20E-05 White matter hyperintensity burden / / 21681796 rs7706447 chr5 116513164 A C 2.30E-05 Urinary metabolites / / 21572414 rs7706447 chr5 116513164 A C 7.13E-06 Periodontitis (DPAL) / / 24024966 rs12153048 chr5 116513605 C G 2.00E-06 Periodontitis (DPAL) / / 24024966 rs12153048 chr5 116513605 C G 6.00E-06 Periodontitis (DPAL) / / 24024966 rs7718941 chr5 116529909 T C 3.69E-05 Asthma or chronic obstructive pulmonary disease / / 24993907 rs7736676 chr5 116529930 A G 2.01E-04 Cocaine dependence / / 23958962 rs7736676 chr5 116529930 A G 9.83E-04 Cocaine dependence / / 23958962 rs7735145 chr5 116647725 A G 5.07E-05 Insulin-related traits / / pha002901 rs1565891 chr5 116662355 G A 4.03E-04 Multiple complex diseases / / 17554300 rs6880664 chr5 116669707 A C 9.33E-05 Information processing speed / / 21130836 rs2560606 chr5 116723208 C T 5.18E-04 Type 2 diabetes / / 17463246 rs1834933 chr5 116736882 T A 2.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2624448 chr5 116746532 T C 1.75E-04 Multiple complex diseases / / 17554300 rs919251 chr5 116763563 A G 1.30E-04 Type 2 diabetes and 6 quantitative traits LOC728342 intron 17848626 rs2162750 chr5 116766701 G A 8.91E-05 Multiple complex diseases LOC728342 intron 17554300 rs17141793 chr5 116781855 T C 3.00E-04 Body mass index LOC728342 intron 24827717 rs17141844 chr5 116815238 A G 5.00E-05 Triglycerides LOC728342 intron pha003080 rs17343133 chr5 116920849 A T 0.0000999 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs365600 chr5 116930421 A T 3.27E-04 Multiple complex diseases / / 17554300 rs1827704 chr5 116969125 G A 6.81E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs34775988 chr5 116994728 C A 0.000081 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2416472 chr5 117005946 T C 1.28E-22 Multiple complex diseases / / 17554300 rs17412135 chr5 117012266 A G 1.70E-05 Urinary metabolites / / 21572414 rs17142750 chr5 117012539 C T 3.37E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1918159 chr5 117028357 G C 6.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4337885 chr5 117061745 T G 1.10E-05 Urinary metabolites / / 21572414 rs12520471 chr5 117085745 T C 1.50E-04 Blood pressure / / 17255346 rs10074078 chr5 117108490 A G 1.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs6595052 chr5 117112284 G A 8.82E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12110276 chr5 117116443 A C,G,T 5.26E-05 Glaucoma (primary open-angle) / / 22605921 rs11948707 chr5 117147971 A G 7.44E-04 Alzheimer's disease / / 24755620 rs4365869 chr5 117254988 A T 6.83E-05 Major depressive disorder / / 21621269 rs4301259 chr5 117260126 C T 3.09E-04 Schizophrenia / / 19197363 rs17143339 chr5 117282234 G A 0.0000896 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17143401 chr5 117287958 G C 0.000029 Mean arterial pressure / / 22510845 rs6595079 chr5 117315725 C T 6.72E-05 Osteoarthritis (knee and hip) / / 21177295 rs6595079 chr5 117315725 C T 7.15E-05 Osteoarthritis (knee and hip) / / 21177295 rs13156476 chr5 117330216 C T 2.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs12519742 chr5 117331154 A T 5.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs13162213 chr5 117331544 A G 6.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs13166814 chr5 117337753 G A 5.00E-07 Subcutaneous adipose tissue / / 22589738 rs11241444 chr5 117369877 C T 7.06E-05 Pulmonary function / / 20010835 rs10040138 chr5 117371464 G A 5.00E-04 Schizophrenia / / 19197363 rs10071435 chr5 117390364 G A 2.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10074757 chr5 117396992 G C 1.93E-05 Pulmonary function / / 20010835 rs13160770 chr5 117401611 A T 2.65E-05 Pulmonary function / / 20010835 rs12655432 chr5 117402719 T A 2.64E-05 Pulmonary function / / 20010835 rs2416504 chr5 117409092 T C 1.59E-05 Pulmonary function / / 20010835 rs11241446 chr5 117410931 G C 1.59E-05 Pulmonary function / / 20010835 rs2900115 chr5 117414350 G A 2.22E-05 Pulmonary function / / 19300500 rs2900115 chr5 117414350 G A 3.14E-05 Pulmonary function / / 20010835 rs17143538 chr5 117420286 T C 5.81E-04 Smoking quantity / / 24665060 rs10058547 chr5 117421736 A G 2.00E-05 Pulmonary function / / 20010835 rs9327068 chr5 117431695 G T 4.21E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4267900 chr5 117455029 C A 6.87E-04 Nicotine dependence / / 17158188 rs17143755 chr5 117531681 T C 1.28E-04 Type 2 diabetes / / 17463246 rs7448647 chr5 117532148 G A 5.72E-05 Serum metabolites / / 19043545 rs11746578 chr5 117555721 C T 5.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs1479210 chr5 117580961 T C 8.84E-05 Rheumatoid arthritis / / 17804836 rs17143913 chr5 117590540 T C 1.00E-04 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17143914 chr5 117590594 A G 5.21E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11741910 chr5 117595910 T G 9.54E-05 Suicide attempts in bipolar disorder / / 21423239 rs35594225 chr5 117595910 TTGTG T 9.54E-05 Suicide attempts in bipolar disorder / / 21423239 rs374798984 chr5 117595910 TTG T 9.54E-05 Suicide attempts in bipolar disorder / / 21423239 rs71621368 chr5 117595910 TTGTG T 9.54E-05 Suicide attempts in bipolar disorder / / 21423239 rs17143929 chr5 117596135 T C 4.01E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17143931 chr5 117596298 C G 4.01E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10519537 chr5 117596369 C T 4.17E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17143934 chr5 117596411 G A 6.86E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17143937 chr5 117596791 T C 7.32E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11740221 chr5 117597242 G A 7.32E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11740297 chr5 117597551 G T 7.32E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17143961 chr5 117598341 C T 7.32E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2127260 chr5 117609133 C A 7.37E-05 Coronary heart disease / / pha003033 rs5000371 chr5 117612754 T C 8.61E-05 Serum metabolites / / 19043545 rs9327069 chr5 117615167 A G 8.61E-05 Serum metabolites / / 19043545 rs10519541 chr5 117615198 T C 8.14E-05 Serum metabolites / / 19043545 rs41456648 chr5 117617632 A G 1.60E-05 Urinary metabolites / / 21572414 rs11953466 chr5 117643335 A G 0.000511 Salmonella-induced pyroptosis / / 22837397 rs10037911 chr5 117644171 T A 0.000597 Salmonella-induced pyroptosis / / 22837397 rs6880706 chr5 117649475 A G 4.31E-05 Hypertension (essential hypertension) / / 22184326 rs10478387 chr5 117670079 C T 2.11E-04 Alzheimer's disease (late onset) / / 21379329 rs6595113 chr5 117676469 T C 1.37E-04 Alzheimer's disease (late onset) / / 21379329 rs4921019 chr5 117678182 C T 9.08E-05 Serum metabolites / / 19043545 rs6595122 chr5 117716589 A C 9.19E-05 Alzheimer's disease / / 24755620 rs11958566 chr5 117717520 C G 7.39E-05 Alzheimer's disease / / 24755620 rs11951938 chr5 117754341 G A 4.25E-04 Alzheimer's disease / / 24755620 rs6867291 chr5 117768233 T G 7.81E-06 Liver disease in chronic hepatitis B virus infection / / 24065354 rs6867291 chr5 117768233 T G 8.02E-06 Liver disease in chronic hepatitis B virus infection / / 24065354 rs12516655 chr5 117784597 G C 6.29E-04 Multiple complex diseases / / 17554300 rs10046044 chr5 117795654 G A 6.05E-04 Iron levels / / pha002876 rs4073021 chr5 117805637 G A 1.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs4073021 chr5 117805637 G A 4.71E-05 Alzheimer's disease / / 24755620 rs4440398 chr5 117856289 T C 2.82E-04 Multiple complex diseases / / 17554300 rs6595143 chr5 117869174 C T 5.63E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs17435181 chr5 117883257 T C 1.40E-05 Urinary metabolites / / 21572414 rs17144166 chr5 117885003 A G 9.84E-04 Multiple complex diseases / / 17554300 rs7719749 chr5 117902629 G A,C 8.39E-05 Type 2 diabetes / / 17463246 rs10213999 chr5 117907292 C A 4.31E-04 Type 2 diabetes / / 17463246 rs12153575 chr5 117911994 C G 8.76E-04 Type 2 diabetes / / 17463246 rs7726317 chr5 117921244 G A 5.23E-04 Multiple complex diseases / / 17554300 rs995881 chr5 117924208 C G 4.23E-08 Narcolepsy / / 19629137 rs6885758 chr5 117926616 G T 1.80E-04 Type 2 diabetes / / 17463246 rs6885758 chr5 117926616 G T 6.48E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2043052 chr5 117928101 G A 2.40E-05 Urinary metabolites / / 21572414 rs6870913 chr5 117943259 C T 9.20E-05 Meningococcal disease / / 20694013 rs4895235 chr5 117966650 C T 5.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs4895148 chr5 117967296 A C 3.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs4895236 chr5 117967472 C T 4.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs2972219 chr5 117983612 C A 2.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1429711 chr5 118012200 T C 3.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10463702 chr5 118014946 T C 2.00E-04 Information processing speed / / 21130836 rs1864329 chr5 118015605 G T 1.00E-04 Information processing speed / / 21130836 rs10068737 chr5 118036547 T C 8.70E-07 Chronic kidney disease / / 22479191 rs10055210 chr5 118043996 T C 6.09E-04 Iron levels / / pha002876 rs7727675 chr5 118064125 G A 8.60E-05 Myasthenia gravis / / 23055271 rs17144495 chr5 118073087 T G 0.000411 Sarcoidosis / / 22952805 rs873723 chr5 118074236 A G 0.0003945 Sarcoidosis / / 22952805 rs1510973 chr5 118089798 A G 9.05E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17144655 chr5 118132058 C A 3.08E-04 Type 2 diabetes / / 17463246 rs1428638 chr5 118154368 T C 1.63E-04 Arthritis (juvenile idiopathic) / / 22354554 rs17144687 chr5 118159935 A C 9.27E-08 Alcohol consumption / / 23953852 rs6871241 chr5 118179160 G A 8.21E-05 Bone mineral density DTWD2 intron 19181680 rs7722194 chr5 118191798 G A 6.91E-06 Triglycerides DTWD2 intron pha003080 rs4895183 chr5 118216318 C T 2.55E-06 Primary nonsyndromic vesicoureteric reflex DTWD2 intron 19959718 rs17144806 chr5 118240507 A T 5.81E-07 Primary nonsyndromic vesicoureteric reflex DTWD2 intron 19959718 rs6868097 chr5 118245193 T C 2.00E-04 Cognitive impairment induced by topiramate DTWD2 intron 22091778 rs439156 chr5 118322042 G T 1.70E-05 Urinary metabolites DTWD2 intron 21572414 rs201681130 chr5 118324108 C G 0.000011 Breast cancer(er negative) DTWD2 missense 23555315 rs55741500 chr5 118346572 C G,T 6.70E-06 Response to amphetamines / / 22952603 rs112326445 chr5 118347796 G C 4.06E-06 Response to amphetamines / / 22952603 rs11952762 chr5 118355551 A G 3.64E-07 Alzheimer's disease (late onset) / / 21460841 rs111649495 chr5 118356415 C T 2.00E-06 Response to amphetamines / / 22952603 rs4392657 chr5 118358569 T C 6.24E-06 Response to amphetamines / / 22952603 rs17144877 chr5 118359535 C G 7.17E-06 Response to amphetamines / / 22952603 rs113460744 chr5 118360910 G A 6.35E-06 Response to amphetamines / / 22952603 rs55805551 chr5 118363042 T A 6.46E-06 Response to amphetamines / / 22952603 rs17144883 chr5 118368516 G A 6.35E-06 Response to amphetamines / / 22952603 rs77792902 chr5 118368701 A T 6.81E-06 Response to amphetamines / / 22952603 rs11959554 chr5 118371439 T A 4.60E-05 Alzheimer's disease / / 19734903 rs11959554 chr5 118371439 T A 3.30E-06 Alzheimer's disease (late onset) / / 21460841 rs80240034 chr5 118374401 G A 7.11E-06 Response to amphetamines / / 22952603 rs112536816 chr5 118376906 G A 7.36E-06 Response to amphetamines / / 22952603 rs112150350 chr5 118379168 G A,T 7.42E-06 Response to amphetamines / / 22952603 rs74789059 chr5 118379498 T C 7.63E-06 Response to amphetamines / / 22952603 rs116348108 chr5 118435127 A G 9.00E-07 Alzheimer's disease (cognitive decline) DMXL1 intron 23535033 rs4895185 chr5 118474109 A G 1.69E-04 Anorexia nervosa DMXL1 intron 23568457 rs4895361 chr5 118474205 A G 2.26E-05 Brain structure DMXL1 intron 22504417 rs7717384 chr5 118481205 G A 5.68E-04 Alcohol consumption (maxi-drinks) DMXL1 intron 24277619 rs3923326 chr5 118516878 G A 1.70E-05 Urinary metabolites DMXL1 intron 21572414 rs3992620 chr5 118530872 A G 6.10E-04 Type 2 diabetes DMXL1 intron 17463246 rs3992620 chr5 118530872 A G 7.79E-04 Multiple complex diseases DMXL1 intron 17554300 rs2404397 chr5 118594602 G A 9.45E-05 Type 2 diabetes / / 17463246 rs13361153 chr5 118608175 G A 4.08E-04 Suicide attempts in bipolar disorder TNFAIP8 intron 21041247 rs13361153 chr5 118608175 G A 4.98E-05 Height TNFAIP8 intron pha003010 rs4895363 chr5 118617170 T C 2.44E-05 Major depressive disorder TNFAIP8 intron 22472876 rs1394631 chr5 118639270 C T 1.45E-05 Waist-Hip Ratio TNFAIP8 intron pha003029 rs2052473 chr5 118661882 T G 7.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TNFAIP8 intron 20877124 rs7704398 chr5 118667642 C T 5.41E-05 Alcohol and nictotine co-dependence TNFAIP8 intron 20158304 rs17164572 chr5 118673697 C T 5.29E-05 Alcohol and nictotine co-dependence TNFAIP8 intron 20158304 rs3813301 chr5 118675246 A G 5.41E-05 Alcohol and nictotine co-dependence TNFAIP8 intron 20158304 rs250303 chr5 118677093 A G 4.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TNFAIP8 intron 20877124 rs3203922 chr5 118728953 G C 0.0000664 Triglycerides TNFAIP8 cds-synon 23063622 rs1105769 chr5 118731067 A C 1.20E-04 Multiple sclerosis / / 17660530 rs1105770 chr5 118731247 T G 7.24E-05 Multiple sclerosis / / 17660530 rs10478424 chr5 118789020 A T 2.66E-04 Sexual dimorphism in anthropometric traits HSD17B4 intron 23754948 rs32662 chr5 118844486 C T 1.62E-04 Multiple complex diseases HSD17B4 intron 17554300 rs13188833 chr5 118911343 C A 6.50E-06 Urinary metabolites / / 21572414 rs721676 chr5 118947467 T C 1.27E-04 Type 2 diabetes / / 17846125 rs328661 chr5 118951870 C T 0.000021 Breast cancer / / 23555315 rs184497 chr5 118953519 T C 6.86E-05 Alcoholism / / pha002893 rs328699 chr5 118968221 C T 1.30E-06 Urinary metabolites FAM170A intron 21572414 rs328695 chr5 118969452 G A 9.00E-07 Urinary metabolites FAM170A intron 21572414 rs328694 chr5 118969960 C T 0.000093 Breast cancer FAM170A missense 23555315 rs988465 chr5 118970935 A G 5.39E-04 Smoking initiation FAM170A intron 24665060 rs17145587 chr5 118972113 C T 5.34E-05 Multiple complex diseases / / 17554300 rs17145587 chr5 118972113 C T 7.41E-05 Serum metabolites / / 19043545 rs17145587 chr5 118972113 C T 6.39E-04 Smoking initiation / / 24665060 rs17145587 chr5 118972113 C T 9.94E-04 Heart Failure / / pha002884 rs2443744 chr5 118983414 G A 7.50E-04 Multiple complex diseases / / 17554300 rs2443744 chr5 118983414 G A 1.30E-05 Urinary metabolites / / 21572414 rs1346520 chr5 118985988 G A,C 1.70E-05 Menarche (age at onset) / / 19448622 rs1346520 chr5 118985988 G A,C 5.99E-05 Alcohol consumption / / 23953852 rs780428 chr5 118996156 G A 2.27E-04 Multiple complex diseases / / 17554300 rs780428 chr5 118996156 G A 2.20E-05 Urinary metabolites / / 21572414 rs10071133 chr5 119002213 G A 1.00E-05 Urinary metabolites / / 21572414 rs1597713 chr5 119002347 C T 2.98E-05 Multiple complex diseases / / 17554300 rs330205 chr5 119015750 C G 6.37E-04 Multiple complex diseases / / 17554300 rs330205 chr5 119015750 C G 4.13E-04 Alzheimer's disease / / 17998437 rs12153752 chr5 119016981 G A 1.10E-05 Urinary metabolites / / 21572414 rs330201 chr5 119017300 T C 5.92E-04 Multiple complex diseases / / 17554300 rs10519606 chr5 119048816 G T 4.55E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13173473 chr5 119063955 G T 3.08E-05 Coronary heart disease / / pha003032 rs259174 chr5 119093698 G A 6.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs259195 chr5 119100616 T A,C,G 6.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs259195 chr5 119100616 T A,C,G 2.00E-05 Urinary metabolites / / 21572414 rs10793801 chr5 119159236 G A 0.000100031 Hypertension (early onset hypertension) / / 22479346 rs2896894 chr5 119159629 C T 0.000608037 Hypertension (early onset hypertension) / / 22479346 rs10519615 chr5 119161277 G A 2.83E-04 Bipolar disorder / / 19259986 rs4496729 chr5 119290814 G A 1.20E-07 Urinary metabolites / / 21572414 rs10035423 chr5 119306380 A G 5.40E-08 Urinary metabolites / / 21572414 rs931453 chr5 119317631 G A,C,T 8.80E-06 Urinary metabolites / / 21572414 rs17145950 chr5 119328170 G C 1.70E-07 Urinary metabolites / / 21572414 rs17145952 chr5 119328777 A G 3.80E-07 Urinary metabolites / / 21572414 rs6875179 chr5 119329324 A C 1.50E-05 Urinary metabolites / / 21572414 rs2042217 chr5 119333029 G T 9.14E-04 Alzheimer's disease / / 17998437 rs2042217 chr5 119333029 G T 2.10E-07 Urinary metabolites / / 21572414 rs2042218 chr5 119333244 A G 1.80E-07 Urinary metabolites / / 21572414 rs171252 chr5 119351703 T C 4.70E-06 Urinary metabolites / / 21572414 rs7722124 chr5 119369068 T C 8.90E-06 Urinary metabolites / / 21572414 rs7702706 chr5 119369334 C T 8.90E-06 Urinary metabolites / / 21572414 rs4895221 chr5 119377796 A G 1.00E-05 Urinary metabolites / / 21572414 rs1191748 chr5 119411275 G C 1.79E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10039249 chr5 119411891 A G 1.78E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10045387 chr5 119411987 G A 2.94E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1191747 chr5 119412293 G C 1.92E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1191743 chr5 119413303 T C 1.30E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1191741 chr5 119413345 T G 4.84E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2636978 chr5 119413353 G A 1.97E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1907196 chr5 119413874 T A 1.33E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1363456 chr5 119415119 T C 3.55E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs255788 chr5 119417067 G A 1.77E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs255790 chr5 119417494 G T 1.82E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs347559 chr5 119418017 G A 2.32E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs255793 chr5 119420974 A G 3.69E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1443985 chr5 119425507 T C 3.88E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1373324 chr5 119427165 C G 3.94E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6874504 chr5 119429912 C G 4.04E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs994630 chr5 119432137 A G 3.37E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1348478 chr5 119434193 G A 5.11E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2166013 chr5 119435037 G A 9.08E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2166013 chr5 119435037 G A 0.0000411 Transmission distortion / / 22377632 rs6898633 chr5 119442385 T C 4.07E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11951498 chr5 119443847 T C 7.57E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1388109 chr5 119447896 A C 4.06E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1154650 chr5 119448371 A T 4.34E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7732537 chr5 119450945 A G 7.17E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7735332 chr5 119456365 A G 4.30E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9327129 chr5 119457738 C G 5.68E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7707700 chr5 119458013 A T 6.01E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6868780 chr5 119458803 G A 4.06E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6595211 chr5 119475676 G A 4.05E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs982605 chr5 119477137 T A 9.44E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1443969 chr5 119478495 T C 6.06E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10053118 chr5 119495589 G A 7.02E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1373314 chr5 119500641 A G 3.12E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs982476 chr5 119502826 G A 5.80E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10491467 chr5 119586814 A G 6.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7704977 chr5 119653309 A G 7.77E-05 Alzheimer's disease (age of onset) / / 22005931 rs13172992 chr5 119658961 G A 8.81E-05 Alzheimer's disease (age of onset) / / 22005931 rs6867625 chr5 119659058 A G 8.20E-05 Alzheimer's disease (age of onset) / / 22005931 rs4895241 chr5 119659092 T A 1.21E-04 Multiple complex diseases / / 17554300 rs17146446 chr5 119660331 T C 2.56E-05 Alzheimer's disease (age of onset) / / 22005931 rs12523275 chr5 119661107 G A 8.54E-05 Alzheimer's disease (age of onset) / / 22005931 rs7725880 chr5 119662883 C A 1.51E-05 Alzheimer's disease (age of onset) / / 22005931 rs10053881 chr5 119663843 G A 1.58E-05 Alzheimer's disease (age of onset) / / 22005931 rs10051178 chr5 119667832 G T 9.85E-04 Rheumatoid arthritis / / 21452313 rs78979090 chr5 119679448 C G 3.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs11948803 chr5 119680955 A T 3.85E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs77726200 chr5 119684200 T G 4.85E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs919708 chr5 119685152 T C 4.96E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs115909428 chr5 119685854 T C 5.34E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs17146503 chr5 119690431 T C 3.79E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs139749488 chr5 119692855 T C 4.33E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs17422211 chr5 119698012 G A 7.19E-04 Type 2 diabetes / / 17463246 rs10036031 chr5 119703382 C A 4.97E-05 Longevity / / 20304771 rs17146625 chr5 119782997 C A 6.41E-04 Multiple complex diseases / / 17554300 rs13171094 chr5 119783146 A T 1.98E-05 Alcohol consumption / / 23743675 rs10477601 chr5 119783561 G A 6.31E-05 Alcohol consumption / / 23743675 rs17424128 chr5 119789615 C T 8.08E-05 Waist Circumference / / pha003023 rs17146647 chr5 119791039 T G 2.20E-04 Hearing function / / 17255346 rs17146651 chr5 119791278 A G 2.20E-04 Hearing function / / 17255346 rs1823926 chr5 119854721 C A 1.27E-05 Bone mass and geometry PRR16 intron 17903296 rs300974 chr5 119869763 G A 8.00E-04 Alcohol dependence PRR16 intron 21314694 rs6897843 chr5 119870483 G A 1.18E-06 Multiple complex diseases PRR16 intron 17554300 rs300969 chr5 119878926 G A 4.04E-04 Response to cytadine analogues (cytosine arabinoside) PRR16 intron 24483146 rs300969 chr5 119878926 G A 6.24E-04 Response to cytidine analogues (gemcitabine) PRR16 intron 24483146 rs10063554 chr5 119879082 G A 6.45E-05 Orofacial clefts PRR16 intron 22419666 rs10063554 chr5 119879082 G A 5.91E-04 Response to cytadine analogues (cytosine arabinoside) PRR16 intron 24483146 rs10063718 chr5 119879295 G A 7.00E-05 Prostate cancer PRR16 intron 21743057 rs10063718 chr5 119879295 G A 3.18E-04 Response to cytadine analogues (cytosine arabinoside) PRR16 intron 24483146 rs7442772 chr5 119879922 T G 4.33E-04 Response to cytadine analogues (cytosine arabinoside) PRR16 intron 24483146 rs300962 chr5 119881943 G A 5.47E-05 Response to cytadine analogues (cytosine arabinoside) PRR16 intron 24483146 rs1404304 chr5 119882713 G C 7.09E-05 Response to cytadine analogues (cytosine arabinoside) PRR16 intron 24483146 rs10062601 chr5 119885302 T G 3.77E-04 Response to cytadine analogues (cytosine arabinoside) PRR16 intron 24483146 rs12109575 chr5 119887839 T C 5.18E-04 Response to cytadine analogues (cytosine arabinoside) PRR16 intron 24483146 rs10076191 chr5 119888854 A G 3.77E-04 Response to cytadine analogues (cytosine arabinoside) PRR16 intron 24483146 rs10077688 chr5 119892906 T C 3.77E-04 Response to cytadine analogues (cytosine arabinoside) PRR16 intron 24483146 rs10478477 chr5 119901019 A G 5.54E-04 Response to cytadine analogues (cytosine arabinoside) PRR16 intron 24483146 rs10478479 chr5 119902208 T G 5.39E-04 Response to cytadine analogues (cytosine arabinoside) PRR16 intron 24483146 rs10519639 chr5 119905174 G A 2.37E-04 Response to cytadine analogues (cytosine arabinoside) PRR16 intron 24483146 rs10519640 chr5 119905683 C T 1.15E-04 Response to cytadine analogues (cytosine arabinoside) PRR16 intron 24483146 rs1524571 chr5 119906115 G C 5.24E-04 Response to cytadine analogues (cytosine arabinoside) PRR16 intron 24483146 rs2077726 chr5 119908064 T G 4.46E-04 Multiple complex diseases PRR16 intron 17554300 rs1037569 chr5 119926305 T C 2.80E-05 Breast cancer and prostate cancer PRR16 intron 17903305 rs1584468 chr5 119937691 G A,C,T 8.85E-06 Lung adenocarcinoma PRR16 intron 19836008 rs1584468 chr5 119937691 G A,C,T 9.00E-08 Immune reponse to smallpox (secreted IL-12p40) PRR16 intron 22610502 rs1449159 chr5 119950084 C T 4.09E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) PRR16 intron 24023788 rs17428430 chr5 119950138 T A 2.35E-05 Insulin resistance PRR16 intron 21901158 rs7719971 chr5 119962576 A G 2.00E-05 Type 2 diabetes and 6 quantitative traits PRR16 intron 17848626 rs991672 chr5 119974750 G C 3.00E-05 Type 2 diabetes PRR16 intron 17903298 rs9285894 chr5 120049065 A G 1.10E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs10073050 chr5 120084472 G A 3.48E-04 Smoking quantity / / 24665060 rs1080833 chr5 120095803 A G 8.00E-05 Prostate cancer / / 21743057 rs7728842 chr5 120097830 G C 1.00E-04 Prostate cancer / / 21743057 rs7701417 chr5 120099815 A G 1.00E-04 Prostate cancer / / 21743057 rs7701827 chr5 120099875 G A 1.00E-04 Prostate cancer / / 21743057 rs7701686 chr5 120099898 C T 1.00E-04 Prostate cancer / / 21743057 rs7705746 chr5 120100197 A T 1.00E-04 Prostate cancer / / 21743057 rs7705890 chr5 120100225 C A 1.00E-04 Prostate cancer / / 21743057 rs9327166 chr5 120140317 G T 1.10E-04 Multiple complex diseases / / 17554300 rs9327168 chr5 120141352 G A 7.49E-04 Smoking quantity / / 24665060 rs78975256 chr5 120216037 T C 4.00E-06 Bronchopulmonary dysplasia / / 23897914 rs3213800 chr5 120252695 C T 5.20E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1121707 chr5 120293328 C T 7.13E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7730936 chr5 120316026 A G 2.00E-04 Multiple complex diseases / / 17554300 rs2973163 chr5 120331625 A G 1.76E-04 Smoking quantity / / 24665060 rs2973162 chr5 120331891 T C 5.08E-04 Type 2 diabetes / / 17463246 rs1422601 chr5 120334802 T C 2.46E-04 Type 2 diabetes / / 17463246 rs12514616 chr5 120346283 C G 2.50E-04 Type 2 diabetes / / 17463246 rs17147260 chr5 120369453 A C 1.49E-04 Epilepsy / / 22116939 rs17446625 chr5 120374562 A G 7.85E-05 Triglycerides / / pha003080 rs4305661 chr5 120484783 T C 5.22E-05 Sudden cardiac arrest / / 21658281 rs7724812 chr5 120501442 T G 4.59E-05 Blood Pressure / / pha003045 rs2914084 chr5 120515118 T C 7.92E-05 Type 2 diabetes / / 17463246 rs2914083 chr5 120517758 T G 5.90E-06 Urinary metabolites / / 21572414 rs919289 chr5 120565523 C T 3.20E-06 Alzheimer's disease / / 21059989 rs919289 chr5 120565523 C T 4.68E-04 Alzheimer's disease / / 21059989 rs6595288 chr5 120566658 G C 4.86E-05 Odorant perception / / 23910658 rs4895298 chr5 120569108 G A 2.00E-06 Alzheimer's disease / / 21059989 rs4895298 chr5 120569108 G A 4.77E-04 Alzheimer's disease / / 21059989 rs2973413 chr5 120569311 T C 5.35E-06 Alzheimer's disease / / 21059989 rs2973413 chr5 120569311 T C 5.71E-04 Alzheimer's disease / / 21059989 rs2973414 chr5 120569420 C G 5.51E-04 Fibrinogen / / 17255346 rs2973414 chr5 120569420 C G 5.99E-04 Type 2 diabetes / / 17463246 rs609929 chr5 120591425 T C 3.32E-04 Fibrinogen / / 17255346 rs609929 chr5 120591425 T C 5.99E-04 Type 2 diabetes / / 17463246 rs609929 chr5 120591425 T C 7.80E-06 Urinary metabolites / / 21572414 rs4409129 chr5 120626646 C T 6.57E-04 Type 2 diabetes / / 17463246 rs1363396 chr5 120635045 T G 6.70E-05 Body Mass Index / / pha003020 rs4146401 chr5 120638684 C T 0.000691294 Hypertension (early onset hypertension) / / 22479346 rs6861011 chr5 120645496 T C 3.24E-05 Body Mass Index / / pha003020 rs9885119 chr5 120661074 C T 1.70E-05 Glucose levels / / pha003061 rs6865013 chr5 120686298 T C 8.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs160122 chr5 120722413 A C 7.03E-05 Glucose levels / / pha003058 rs33584 chr5 120727051 T C 1.44E-06 Acute lymphoblastic leukemia (B-cell precursor) / / 23996088 rs795181 chr5 120735755 T C 1.25E-04 Insulin resistance / / 21901158 rs1428689 chr5 120741900 T C 5.51E-05 Longevity / / 21612516 rs1025303 chr5 120752065 C G 2.16E-05 Type 2 diabetes / / 17463246 rs6882369 chr5 120758647 G A 2.36E-05 Cognitive test performance / / 20125193 rs10065963 chr5 120776767 C T 5.56E-04 Alcohol dependence / / 20201924 rs10463741 chr5 120779886 A G 8.47E-05 Alcohol dependence / / 20201924 rs10463741 chr5 120779886 A G 8.47E-05 Alcoholism / / pha002891 rs1594002 chr5 120782266 C G 2.68E-05 Schizophrenia / / 19571811 rs1469447 chr5 120790528 C A 8.60E-04 Alcohol dependence / / 20201924 rs10213966 chr5 120797151 A G 7.44E-04 Alcohol dependence / / 20201924 rs7732409 chr5 120818132 G A 7.72E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs13189608 chr5 120883361 G A 7.96E-05 Cognitive test performance / / 20125193 rs13182650 chr5 120885003 C T 3.82E-05 Bipolar disorder / / 17486107 rs11738537 chr5 120887552 A C 6.92E-04 Alzheimer's disease / / 17998437 rs12109307 chr5 120906482 T C 2.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs4559029 chr5 120908778 G A 1.50E-05 Vitamin D concentrations / / 20600896 rs4559029 chr5 120908778 G A 1.50E-05 Vitamin D concentrations / / 20600896 rs4559029 chr5 120908778 G A 3.34E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs76616598 chr5 120911106 T C 2.37E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs13166683 chr5 120919205 G A 9.07E-05 Information processing speed / / 21130836 rs10055397 chr5 120922897 T G 1.00E-04 Information processing speed / / 21130836 rs7734808 chr5 120931849 A G 1.84E-05 Information processing speed / / 21130836 rs1508805 chr5 120970448 A G 1.04E-05 Malignant pleural mesothelioma / / 23626673 rs4612103 chr5 120974416 C T 0.000782 Salmonella-induced pyroptosis / / 22837397 rs13187208 chr5 120986421 G A 4.76E-05 Response to metformin / / 21186350 rs4895332 chr5 120988738 G A 9.95E-06 Cognitive performance / / 19734545 rs17148213 chr5 121044553 A C 7.44E-04 Multiple complex diseases / / 17554300 rs17148275 chr5 121067314 T G 1.20E-05 Urinary metabolites / / 21572414 rs1588260 chr5 121077574 T C 3.43E-06 Blood Pressure and Arterial Stiffness / / 17903302 rs10075540 chr5 121122064 C G 0.000000987 HDL cholesterol particle diameter / / 23263444 rs17148434 chr5 121126392 A G 0.000000963 HDL cholesterol particle diameter / / 23263444 rs13436296 chr5 121131064 T A 0.000000918 HDL cholesterol particle diameter / / 23263444 rs13436690 chr5 121133079 A G 0.000000924 HDL cholesterol particle diameter / / 23263444 rs10055277 chr5 121137683 C T 0.000000924 HDL cholesterol particle diameter / / 23263444 rs7702652 chr5 121138788 A T 0.000000924 HDL cholesterol particle diameter / / 23263444 rs6863862 chr5 121154974 T C 0.000000889 HDL cholesterol particle diameter / / 23263444 rs7736854 chr5 121155521 G T 0.000000866 HDL cholesterol particle diameter / / 23263444 rs1431941 chr5 121156405 C T 0.000000864 HDL cholesterol particle diameter / / 23263444 rs17148541 chr5 121173869 C A 7.38E-04 Multiple complex diseases / / 17554300 rs11959845 chr5 121174252 T C 8.04E-04 Multiple complex diseases / / 17554300 rs10519685 chr5 121175062 T C 8.47E-04 Multiple complex diseases / / 17554300 rs114266291 chr5 121188729 A C 9.56E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs17148568 chr5 121190450 A C 3.74E-04 Alcohol dependence / / 21314694 rs10066691 chr5 121218257 C T 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs4895337 chr5 121240630 A G 6.22E-06 Malignant mesothelioma / / 23827383 rs4243442 chr5 121250054 C A 1.40E-06 Urinary metabolites / / 21572414 rs4345341 chr5 121278751 A T 2.37E-04 Multiple complex diseases / / 17554300 rs9327236 chr5 121279021 A C 2.44E-04 Multiple complex diseases / / 17554300 rs116348029 chr5 121293808 G A 7.59E-11 Metabolite levels / / 22286219 rs2972350 chr5 121297115 T C 9.91E-05 Post-operative nausea and vomiting / / 21694509 rs4496732 chr5 121317920 C T 6.35E-05 Alcohol and nictotine co-dependence SRFBP1 intron 20158304 rs840468 chr5 121351626 A G 8.87E-04 Heart Failure SRFBP1 intron pha002884 rs10519692 chr5 121395749 C T 6.40E-05 Post-operative nausea and vomiting / / 21694509 rs3792801 chr5 121403410 C T 6.17E-04 Multiple complex diseases LOX intron 17554300 rs890750 chr5 121435579 G T 8.10E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs2077638 chr5 121436563 G A 2.19E-05 Type 2 diabetes / / 22158537 rs890749 chr5 121436596 C T 8.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1834915 chr5 121437519 A T 7.93E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs2560322 chr5 121439335 G C 7.97E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs970041 chr5 121439669 A C 8.79E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1427943 chr5 121444031 A T 9.94E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs10900755 chr5 121505407 A G 9.43E-05 White matter integrity LOC100505841 intron 22425255 rs1427936 chr5 121506678 A G 1.50E-04 White matter integrity LOC100505841 intron 22425255 rs17148957 chr5 121523176 T C 2.09E-04 White matter integrity / / 22425255 rs1862175 chr5 121532861 T C 4.90E-04 Primary sclerosing cholangitis / / 19944697 rs13161508 chr5 121550456 A C 8.47E-04 Type 2 diabetes / / 22158537 rs1421877 chr5 121562235 C T 6.36E-04 Type 2 diabetes / / 22158537 rs1421878 chr5 121569525 G A 6.88E-04 Type 2 diabetes / / 22158537 rs1421879 chr5 121569669 G T 6.03E-04 Type 2 diabetes / / 22158537 rs13356385 chr5 121570617 G A 8.85E-05 Alcohol dependence / / 21314694 rs1363163 chr5 121572250 T C 6.52E-04 Type 2 diabetes / / 22158537 rs2407110 chr5 121592698 G A 2.37E-04 Type 2 diabetes / / 22158537 rs2193963 chr5 121596196 A G 5.77E-04 Type 2 diabetes / / 22158537 rs9327244 chr5 121597391 C G 7.99E-04 Type 2 diabetes / / 22158537 rs1363164 chr5 121598606 T A 2.30E-05 Urinary metabolites / / 21572414 rs731312 chr5 121600387 T C 6.94E-04 Type 2 diabetes / / 22158537 rs10052589 chr5 121611142 T G 3.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs1421881 chr5 121636440 C T 6.56E-05 Bipolar disorder / / 17486107 rs6871588 chr5 121695988 T C 2.30E-05 Urinary metabolites SNCAIP intron 21572414 rs6595362 chr5 121699067 T G 7.21E-04 Multiple complex diseases SNCAIP intron 17554300 rs6595362 chr5 121699067 T G 4.90E-06 Urinary metabolites SNCAIP intron 21572414 rs6595363 chr5 121703547 C G 2.30E-05 Urinary metabolites SNCAIP intron 21572414 rs17149115 chr5 121726123 C T 5.11E-04 Multiple complex diseases SNCAIP intron 17554300 rs17149128 chr5 121729917 A G 7.25E-04 Multiple complex diseases SNCAIP intron 17554300 rs12719304 chr5 121734393 G C 7.86E-05 Insulin resistance SNCAIP intron 21901158 rs17149141 chr5 121740909 G A 9.48E-04 Multiple complex diseases SNCAIP intron 17554300 rs304389 chr5 121754725 G A 2.40E-06 Urinary metabolites SNCAIP intron 21572414 rs304382 chr5 121765302 C T 3.30E-06 Urinary metabolites SNCAIP intron 21572414 rs304381 chr5 121768542 G C 1.30E-05 Urinary metabolites SNCAIP intron 21572414 rs10478555 chr5 121781531 C T 1.77E-04 C-reactive protein SNCAIP intron 24763700 rs3811876 chr5 121782511 G T 4.82E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SNCAIP intron 20031582 rs2737089 chr5 121783796 C G 0.00000235 HDL cholesterol particle diameter SNCAIP intron 23263444 rs1841972 chr5 121796138 T G 1.61E-04 C-reactive protein SNCAIP intron 24763700 rs41534644 chr5 121800881 T C 1.30E-04 Coronary Artery Disease / / 17634449 rs1000590 chr5 121826721 G A 6.89E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs2407209 chr5 121826941 G A 6.89E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs4835803 chr5 121852531 C T 1.05E-04 Alcohol consumption / / 23743675 rs4836019 chr5 121853417 A T 1.14E-04 Alcohol consumption / / 23743675 rs10519705 chr5 121856471 G C 7.16E-05 Suicide attempts in bipolar disorder / / 21423239 rs754071 chr5 121862207 C T 6.31E-04 Type 2 diabetes / / 17463246 rs73293604 chr5 121863536 A G 0.00000328 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4835804 chr5 121863682 C T 0.00000777 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17149293 chr5 121864140 G T 1.60E-05 Urinary metabolites / / 21572414 rs12188392 chr5 121864452 C G 0.00000814 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs73293616 chr5 121865442 G T 0.00000801 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs73293622 chr5 121865912 G A 0.00000477 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs77999392 chr5 121869382 G A 0.0000203 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11241649 chr5 121871189 A G 0.00000445 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7703430 chr5 121883624 G T 6.90E-06 Urinary metabolites / / 21572414 rs2407211 chr5 121884439 G A 5.10E-06 Urinary metabolites / / 21572414 rs2407212 chr5 121884501 G A 2.10E-06 Urinary metabolites / / 21572414 rs2045902 chr5 121887289 A G 3.70E-06 Urinary metabolites / / 21572414 rs4836049 chr5 121889627 A G 2.30E-05 Urinary metabolites / / 21572414 rs1382309 chr5 121895056 C T 1.10E-05 Urinary metabolites / / 21572414 rs2407214 chr5 121902428 A G 6.50E-06 Urinary metabolites / / 21572414 rs1871167 chr5 121905003 A T 6.20E-06 Urinary metabolites / / 21572414 rs1478369 chr5 121907730 A C 0.000043 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10477633 chr5 121914334 G A 6.62E-05 Suicide attempts in bipolar disorder / / 21423239 rs4836067 chr5 121927602 A G 2.78E-05 Suicide attempts in bipolar disorder / / 21423239 rs6873059 chr5 121939965 T C 1.90E-05 Tooth agenesis (maxillary third molar) / / 24172245 rs9327261 chr5 121990722 G A 5.40E-05 Tooth agenesis (maxillary third molar) / / 24172245 rs4835860 chr5 122010221 G A 6.53E-04 Myopia (pathological) / / 21095009 rs959300 chr5 122042655 A G 9.98E-08 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs2125856 chr5 122045488 T C 7.05E-05 Alopecia areata / / 22027810 rs2305988 chr5 122131353 A G 6.30E-08 Urinary metabolites SNX2 intron 21572414 rs7718104 chr5 122155359 G C 1.20E-04 Longevity and age-related phenotypes SNX2 intron 17903295 rs27976 chr5 122206460 A G 8.42E-04 Multiple complex diseases SNX24 intron 17554300 rs10066638 chr5 122209192 G A 2.15E-04 Tourette syndrome SNX24 intron 22889924 rs246285 chr5 122244968 C G 5.50E-04 Multiple complex diseases SNX24 intron 17554300 rs246287 chr5 122245426 A T 6.76E-04 Multiple complex diseases SNX24 intron 17554300 rs384483 chr5 122261573 A C 8.81E-04 Multiple complex diseases SNX24 intron 17554300 rs431878 chr5 122261791 T G 8.14E-04 Multiple complex diseases SNX24 intron 17554300 rs2447820 chr5 122264736 G T 4.00E-06 Migraine SNX24 intron 23793025 rs30045 chr5 122271619 C T 7.78E-04 Multiple complex diseases SNX24 intron 17554300 rs3776186 chr5 122273637 C T 3.00E-07 Urinary metabolites SNX24 intron 21572414 rs30039 chr5 122277179 G T 8.56E-04 Multiple complex diseases SNX24 intron 17554300 rs30038 chr5 122277362 T G 3.43E-04 Multiple complex diseases SNX24 intron 17554300 rs30029 chr5 122283170 C A 8.58E-04 Multiple complex diseases SNX24 intron 17554300 rs30028 chr5 122283269 G T 7.66E-04 Multiple complex diseases SNX24 intron 17554300 rs28892 chr5 122283826 G A 9.08E-04 Multiple complex diseases SNX24 intron 17554300 rs246322 chr5 122307269 T C 5.99E-04 Multiple complex diseases SNX24 intron 17554300 rs246317 chr5 122309860 G A 2.20E-04 Multiple complex diseases SNX24 intron 17554300 rs982926 chr5 122354892 G A 3.20E-04 Myasthenia gravis / / 23055271 rs3924912 chr5 122406325 T C 2.00E-05 Prostate cancer / / 21743057 rs929772 chr5 122420169 T C 2.90E-05 Urinary metabolites / / 21572414 rs337128 chr5 122441482 A C,T 2.30E-05 Urinary metabolites PRDM6 intron 21572414 rs335145 chr5 122444585 A G 0.000802589 Hypertension (early onset hypertension) PRDM6 intron 22479346 rs151283 chr5 122446619 C A 0.000804309 Hypertension (early onset hypertension) PRDM6 intron 22479346 rs151283 chr5 122446619 C A 9.75E-04 Glycemic traits (pregnancy) PRDM6 intron 23903356 rs6872465 chr5 122462587 C T 3.42E-05 Multiple complex diseases PRDM6 intron 17554300 rs7705950 chr5 122473962 A G 7.54E-04 Response to taxane treatment (placlitaxel) PRDM6 intron 23006423 rs10044090 chr5 122475727 T C 2.46E-05 Multiple complex diseases PRDM6 intron 17554300 rs10041191 chr5 122475830 C T 1.44E-05 Multiple complex diseases PRDM6 intron 17554300 rs466686 chr5 122476620 G A 4.04E-04 Multiple complex diseases PRDM6 intron 17554300 rs466686 chr5 122476620 G A 4.25E-04 Insulin resistance PRDM6 intron 21901158 rs461097 chr5 122482505 G C 6.53E-04 Insulin resistance PRDM6 intron 21901158 rs6890251 chr5 122486419 C T 2.67E-05 Multiple complex diseases PRDM6 intron 17554300 rs189189 chr5 122492523 G A 3.21E-04 Response to taxane treatment (placlitaxel) PRDM6 intron 23006423 rs459743 chr5 122496931 T C 7.20E-04 Type 2 diabetes and 6 quantitative traits PRDM6 intron 17848626 rs10071061 chr5 122503488 T C 3.02E-04 Multiple complex diseases PRDM6 intron 17554300 rs10071061 chr5 122503488 T C 0.000221 Breast cancer early age of onset PRDM6 intron 18463975 rs10077908 chr5 122503511 A G 3.09E-04 Multiple complex diseases PRDM6 intron 17554300 rs335200 chr5 122510129 G T 5.40E-04 Type 2 diabetes and 6 quantitative traits PRDM6 intron 17848626 rs335200 chr5 122510129 G T 3.85E-04 Response to taxane treatment (placlitaxel) PRDM6 intron 23006423 rs163041 chr5 122512699 C T 3.21E-04 Response to taxane treatment (placlitaxel) PRDM6 intron 23006423 rs179805 chr5 122513814 C T 7.44E-04 Response to taxane treatment (placlitaxel) PRDM6 intron 23006423 rs335194 chr5 122520209 C T 3.21E-04 Response to taxane treatment (placlitaxel) PRDM6 intron 23006423 rs337112 chr5 122528772 G A 2.20E-05 Type 2 diabetes / / 17903298 rs17470137 chr5 122531347 G A 1.00E-11 Aortic root size / / 19584346 rs748312 chr5 122551343 A G 2.70E-05 Urinary metabolites / / 21572414 rs1565059 chr5 122555432 G A 8.30E-06 Urinary metabolites / / 21572414 rs17470838 chr5 122555744 G A 8.30E-06 Urinary metabolites / / 21572414 rs3853113 chr5 122565773 G T 2.40E-05 Urinary metabolites / / 21572414 rs255665 chr5 122570650 C T 2.14E-04 Tourette syndrome / / 22889924 rs17150263 chr5 122572116 T C 5.08E-04 Response to alcohol consumption (flushing response) / / 24277619 rs35824 chr5 122598142 C T 7.21E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs255629 chr5 122606296 C T 3.96E-06 Self-reported allergy / / 23817569 rs17150285 chr5 122608483 A G 3.75E-06 Self-reported allergy / / 23817569 rs41533245 chr5 122609817 T C 4.72E-04 Multiple complex diseases / / 17554300 rs59170767 chr5 122614522 C T 0.0000347 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6881280 chr5 122615524 A G 2.00E-06 Self-reported allergy / / 23817569 rs35833 chr5 122619833 T C 3.61E-05 Self-reported allergy / / 23817569 rs10055144 chr5 122630230 A G 5.32E-04 Smoking quantity / / 24665060 rs2897737 chr5 122632423 G T 7.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs878658 chr5 122640379 A G 6.46E-05 Self-reported allergy / / 23817569 rs1582931 chr5 122657199 G A 2.00E-10 Height / / 20881960 rs4836002 chr5 122676161 G A 9.25E-06 Multiple complex diseases / / 17554300 rs1047440 chr5 122681834 C T 8.40E-04 Smoking behavior CEP120 UTR-3 20418888 rs2115172 chr5 122685128 A G 2.00E-06 Weight CEP120 intron 19079260 rs2115172 chr5 122685128 A G 9.70E-04 Smoking behavior CEP120 intron 20418888 rs10061683 chr5 122696882 G T 1.89E-05 Magnesium levels CEP120 intron pha003092 rs10065634 chr5 122698367 G A 1.89E-05 Magnesium levels CEP120 intron pha003092 rs752200 chr5 122705110 A G 1.88E-05 Magnesium levels CEP120 intron pha003092 rs1428387 chr5 122705244 C T 1.50E-04 Multiple complex diseases CEP120 intron 17554300 rs10519724 chr5 122712563 G A 0.000472869 Hypertension (early onset hypertension) CEP120 intron 22479346 rs7713551 chr5 122721253 G T 0.000472869 Hypertension (early onset hypertension) CEP120 intron 22479346 rs10051787 chr5 122732236 T C 3.05E-05 Magnesium levels CEP120 intron pha003092 rs10900767 chr5 122733703 T C 3.11E-04 Type 2 diabetes CEP120 intron 17463246 rs9327295 chr5 122742602 T G 0.000472869 Hypertension (early onset hypertension) CEP120 intron 22479346 rs6595442 chr5 122743242 C T 2.56E-04 Type 2 diabetes CEP120 intron 17463246 rs6595443 chr5 122743325 A T 2.31E-04 Type 2 diabetes CEP120 intron 17463246 rs7705033 chr5 122774785 G C 2.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs12653807 chr5 122814684 G A 0.000335649 Hypertension (early onset hypertension) / / 22479346 rs4530754 chr5 122855416 G A 2.00E-09 Cholesterol,total CSNK1G3 intron 24097068 rs4530754 chr5 122855416 G A 4.00E-12 LDL cholesterol CSNK1G3 intron 24097068 rs1579036 chr5 122921103 G A 4.88E-05 Alcohol and nictotine co-dependence CSNK1G3 intron 20158304 rs10519731 chr5 122941704 A G 4.21E-04 Response to cytadine analogues (cytosine arabinoside) CSNK1G3 intron 24483146 rs12659062 chr5 122957239 A G 0.000330722 Hypertension (early onset hypertension) / / 22479346 rs11750246 chr5 122970815 G A 2.21E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17476911 chr5 122994649 C T 1.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4569864 chr5 123009413 T C 8.03E-04 Alzheimer's disease / / 22005930 rs12658763 chr5 123009579 C T 0.0000813 Tuberculosis with early age of onset / / 22551897 rs2194046 chr5 123024195 G A 0.0000746 Tuberculosis with early age of onset / / 22551897 rs6889596 chr5 123030802 C T 5.00E-05 Brain structure / / 22504417 rs12515947 chr5 123050342 G A 0.0000764 Tuberculosis with early age of onset / / 22551897 rs171777 chr5 123053647 C T 3.03E-04 Alzheimer's disease / / 22005930 rs10478591 chr5 123058338 C T 0.0000218 Tuberculosis with early age of onset / / 22551897 rs29561 chr5 123088481 T C 6.45E-04 Alzheimer's disease / / 22005930 rs11241713 chr5 123119565 C A 3.00E-06 Amyotrophic lateral sclerosis / / 19451621 rs13174485 chr5 123126976 G A 1.30E-05 Urinary metabolites / / 21572414 rs10043442 chr5 123129656 T G 2.19E-04 Response to alcohol consumption (flushing response) / / 24277619 rs11746266 chr5 123131879 G A 1.93E-04 Vaspin levels / / 22907691 rs11746266 chr5 123131879 G A 0.0001934 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs13163021 chr5 123131940 A G 1.30E-05 Urinary metabolites / / 21572414 rs4835811 chr5 123132945 C T 4.90E-04 Alzheimer's disease (late onset) / / 21379329 rs4835811 chr5 123132945 C T 1.03E-04 Response to alcohol consumption (flushing response) / / 24277619 rs257143 chr5 123136907 G C 3.13E-04 Alzheimer's disease / / 22005930 rs154293 chr5 123139220 A G 6.52E-04 Alzheimer's disease / / 24755620 rs6895877 chr5 123144113 A G 6.70E-04 Alzheimer's disease / / 24755620 rs6595478 chr5 123146444 C G 5.10E-04 Type 2 diabetes / / 17463246 rs6882579 chr5 123147064 A C 4.06E-04 Alzheimer's disease / / 24755620 rs29645 chr5 123148436 A C 3.22E-04 Alzheimer's disease / / 22005930 rs27340 chr5 123151206 G C 2.08E-05 Alzheimer's disease / / 22005930 rs13162753 chr5 123152620 T C 3.53E-04 Alzheimer's disease / / 24755620 rs153884 chr5 123152672 C A 7.46E-06 Alzheimer's disease / / 22005930 rs257016 chr5 123157422 A G 4.00E-06 Alzheimer's disease / / 22005930 rs255240 chr5 123160098 G T 5.01E-04 Alzheimer's disease / / 22005930 rs6595483 chr5 123168895 A G 3.40E-05 Alzheimer's disease / / 22005930 rs153877 chr5 123171873 C T 6.77E-06 Uric acid levels / / 21294900 rs11738363 chr5 123172629 C G 7.70E-04 Alzheimer's disease / / 22005930 rs166238 chr5 123173066 T C 3.38E-06 Uric acid levels / / 21294900 rs166238 chr5 123173066 T C 2.98E-04 Alzheimer's disease / / 24755620 rs11747272 chr5 123179990 A G 9.85E-04 Alzheimer's disease / / 22005930 rs11741651 chr5 123181218 C T 3.37E-05 Alzheimer's disease / / 22005930 rs7717565 chr5 123183833 A C 2.47E-04 Alzheimer's disease / / 22005930 rs1021769 chr5 123192434 T C 7.00E-06 Cognitive decline (age-related) / / 24468470 rs2202111 chr5 123251334 C T 7.71E-04 Alzheimer's disease / / 17998437 rs10063948 chr5 123280043 T C 2.47E-04 Multiple complex diseases / / 17554300 rs330454 chr5 123287402 G A 3.97E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2250107 chr5 123296147 G A 3.01E-06 Leprosy / / pha002872 rs330438 chr5 123313221 C A 2.34E-05 Alcohol consumption / / 23953852 rs330438 chr5 123313221 C A 3.87E-05 Glucose levels / / pha003058 rs17151068 chr5 123337585 G A 7.67E-04 Multiple complex diseases / / 17554300 rs2067077 chr5 123337844 C A 8.70E-04 Multiple complex diseases / / 17554300 rs2067075 chr5 123337931 T A 7.28E-04 Multiple complex diseases / / 17554300 rs7448080 chr5 123398098 T C 2.81E-05 Type 2 diabetes / / 17463246 rs7448080 chr5 123398098 T C 4.00E-06 Alcohol dependence (age at onset) / / 24962325 rs7719325 chr5 123472576 A G 7.60E-04 Suicidal ideation / / 22030708 rs17151283 chr5 123510199 C T 7.38E-05 Vaspin levels / / 22907691 rs7702700 chr5 123534021 C A 5.78E-05 Acute lymphoblastic leukemia (childhood) / / 22076464 rs17501712 chr5 123571160 G T 7.00E-07 Subcutaneous adipose tissue / / 22589738 rs316388 chr5 123572810 A T 4.18E-04 Response to TNF antagonist treatment / / 21061259 rs7705981 chr5 123575610 G A 5.10E-04 Obesity (extreme) / / 21935397 rs17151495 chr5 123589859 C A 0.000384 Salmonella-induced pyroptosis / / 22837397 rs319635 chr5 123617298 T C 4.26E-04 Alzheimer's disease (late onset) / / 21379329 rs2561483 chr5 123637299 C T 1.35E-04 Insulin resistance / / 21901158 rs2545699 chr5 123637411 G A 8.91E-05 Post-operative nausea and vomiting / / 21694509 rs2665904 chr5 123638487 G A 3.81E-04 Insulin resistance / / 21901158 rs2591374 chr5 123647491 A T 1.37E-04 Insulin resistance / / 21901158 rs10035383 chr5 123649793 A T 5.02E-04 Smoking initiation / / 24665060 rs696479 chr5 123672096 T A 7.26E-04 Multiple complex diseases / / 17554300 rs12658088 chr5 123719448 T C 2.47E-05 Post-operative nausea and vomiting / / 21694509 rs988409 chr5 123730483 G A 2.50E-06 Post-operative nausea and vomiting / / 21694509 rs469053 chr5 123735241 G A 8.22E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs257706 chr5 123740639 G A 1.64E-04 Multiple complex diseases / / 17554300 rs201919583 chr5 123740778 G GA 7.14E-04 Multiple complex diseases / / 17554300 rs2076922 chr5 123740778 G A 7.14E-04 Multiple complex diseases / / 17554300 rs467401 chr5 123741828 T C 5.85E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs257731 chr5 123743102 T A 7.43E-04 Multiple complex diseases / / 17554300 rs12518621 chr5 123744036 C A 5.16E-04 Multiple complex diseases / / 17554300 rs154463 chr5 123754638 G T 6.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11241745 chr5 123801827 A C 1.30E-05 Urinary metabolites / / 21572414 rs4293912 chr5 123809401 G A 2.20E-05 Urinary metabolites / / 21572414 rs12513663 chr5 123832652 C T 2.00E-06 Major depressive disorder / / 23377640 rs10046065 chr5 123867087 G T 2.75E-04 Alzheimer's disease / / 24755620 rs1494672 chr5 123873685 T C 2.82E-05 Pancreatic cancer / / pha002889 rs13436452 chr5 123874849 G T 1.10E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1494671 chr5 123880851 A G 4.84E-05 Pancreatic cancer / / pha002889 rs10061885 chr5 123888331 C T 1.80E-04 Alcohol dependence / / 20201924 rs9327332 chr5 123889581 A C 1.40E-04 Alcohol dependence / / 20201924 rs10076166 chr5 123891477 T C 6.53E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6873640 chr5 123909500 T C 4.70E-04 Suicidal ideation / / 22030708 rs1389881 chr5 123918548 A C 1.70E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs10075237 chr5 123935176 C A 8.86E-05 Insulin Resistance / / pha003062 rs13162151 chr5 124004404 G A 3.04E-04 Osteoarthritis ZNF608 intron 19508968 rs6895878 chr5 124006906 T C 9.06E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) ZNF608 intron 23648065 rs6860706 chr5 124023943 G A 1.97E-05 Alzheimer's disease ZNF608 intron 17998437 rs4285214 chr5 124024281 T G 0.00000079 Pancreatic cancer and survival ZNF608 intron 22665904 rs4340915 chr5 124037236 A G 1.65E-04 Type 2 diabetes ZNF608 intron 17463246 rs4340915 chr5 124037236 A G 5.65E-04 Smoking quantity ZNF608 intron 24665060 rs12513661 chr5 124038251 G A 7.21E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) ZNF608 intron 23648065 rs4836112 chr5 124043721 C T 4.05E-04 Smoking quantity ZNF608 intron 24665060 rs12517574 chr5 124045105 T C 1.38E-05 Type 2 diabetes ZNF608 intron 17463246 rs4623140 chr5 124055918 C A 3.24E-04 Smoking quantity ZNF608 intron 24665060 rs4623140 chr5 124055918 C A 6.60E-04 Colorectal cancer ZNF608 intron 24737748 rs4432878 chr5 124056045 G C 9.85E-06 Type 2 diabetes ZNF608 intron 17463246 rs4432878 chr5 124056045 G C 5.10E-04 Smoking quantity ZNF608 intron 24665060 rs4541655 chr5 124056105 A G 1.02E-05 Type 2 diabetes ZNF608 intron 17463246 rs4541655 chr5 124056105 A G 5.64E-04 Smoking quantity ZNF608 intron 24665060 rs7727239 chr5 124056941 G A 1.02E-05 Type 2 diabetes ZNF608 intron 17463246 rs4629598 chr5 124073861 G A 2.30E-05 Orofacial clefts ZNF608 intron 22419666 rs6870431 chr5 124088879 A G 7.30E-04 Heart Failure / / pha002885 rs4435859 chr5 124127720 T C 4.04E-05 Progressive supranuclear palsy / / 21685912 rs6882715 chr5 124129139 T C 1.97E-05 Elbow pain / / pha003008 rs10045691 chr5 124132647 C A 8.91E-05 Intelligence / / 21826061 rs6595551 chr5 124139895 C T 6.00E-06 Type 2 diabetes (young onset) and obesity / / 24465431 rs13168430 chr5 124146728 G A 6.66E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11241771 chr5 124179292 G A 8.30E-04 Rheumatoid arthritis / / 21452313 rs7724246 chr5 124191013 G A 5.39E-04 Type 2 diabetes / / 17463246 rs13166738 chr5 124193973 C T 1.40E-05 Urinary metabolites / / 21572414 rs12654041 chr5 124242910 C G 3.60E-05 Intracerebral hemorrhage / / 24656865 rs11241777 chr5 124250896 A C 3.76E-05 Intracerebral hemorrhage / / 24656865 rs10793807 chr5 124252542 C T 4.86E-05 Intracerebral hemorrhage / / 24656865 rs10041713 chr5 124252550 C T 4.76E-05 Intracerebral hemorrhage / / 24656865 rs6895765 chr5 124253140 C A 4.69E-05 Intracerebral hemorrhage / / 24656865 rs10078386 chr5 124253737 T G 3.74E-05 Intracerebral hemorrhage / / 24656865 rs56110557 chr5 124254061 A C 3.72E-05 Intracerebral hemorrhage / / 24656865 rs6898265 chr5 124255135 T A 4.64E-05 Intracerebral hemorrhage / / 24656865 rs1026010 chr5 124256262 A G 3.82E-05 Intracerebral hemorrhage / / 24656865 rs12652881 chr5 124258221 A G 4.01E-05 Intracerebral hemorrhage / / 24656865 rs12652885 chr5 124258259 A G 4.03E-05 Intracerebral hemorrhage / / 24656865 rs114053807 chr5 124262201 A G 4.41E-05 Intracerebral hemorrhage / / 24656865 rs4240384 chr5 124291402 T C 5.01E-04 Rheumatoid arthritis / / 21452313 rs17152193 chr5 124294448 T C 2.68E-04 Rheumatoid arthritis / / 21452313 rs7701094 chr5 124317011 G C 3.78E-04 Body mass index / / 24861553 rs4132388 chr5 124323247 C A 1.57E-05 Reading and spelling / / 23738518 rs4518389 chr5 124327862 T G 1.41E-05 Reading and spelling / / 23738518 rs10440778 chr5 124329306 A G 3.62E-05 Intelligence / / 21826061 rs6864049 chr5 124330522 A G 4.71E-06 Brain structure / / 22504417 rs4836133 chr5 124332103 C A,G 2.00E-09 Body mass index / / 20935630 rs4836133 chr5 124332103 C A,G 1.97E-09 Body mass index / / 23001569 rs10057590 chr5 124335247 A C 1.91E-06 Brain structure / / 22504417 rs4272129 chr5 124337948 T C 7.23E-04 Multiple complex diseases / / 17554300 rs3936060 chr5 124347088 C G 5.00E-06 Body mass index / / 23669352 rs4286660 chr5 124350288 T C 9.48E-04 HIV-1 viral setpoint / / 17641165 rs6862844 chr5 124365967 A C 3.43E-04 Multiple complex diseases / / 17554300 rs6862844 chr5 124365967 A C 4.00E-06 Erectile dysfunction and prostate cancer treatment / / 20932654 rs10061638 chr5 124367001 A G 1.27E-04 Multiple complex diseases / / 17554300 rs1550357 chr5 124477401 A G 5.99E-05 HIV-1 control / / 20041166 rs11741331 chr5 124488902 C T 8.31E-05 HIV-1 control / / 20041166 rs17152323 chr5 124490153 C T 1.54E-06 Multiple complex diseases / / 17554300 rs1866543 chr5 124490816 G A 7.50E-06 Urinary metabolites / / 21572414 rs1866543 chr5 124490816 G A 2.39E-04 Celiac disease / / 23936387 rs1439592 chr5 124513012 A G 9.11E-05 Erythrocyte counts / / pha003099 rs883044 chr5 124523547 G C 2.70E-05 Urinary metabolites / / 21572414 rs17152386 chr5 124524799 A C 4.95E-04 Multiple complex diseases / / 17554300 rs6895323 chr5 124529455 G C 4.29E-05 Cocaine dependence / / 23958962 rs6895323 chr5 124529455 G C 4.30E-06 Cocaine dependence / / 23958962 rs2119001 chr5 124530606 C T 2.48E-04 Smoking cessation / / 24665060 rs7736638 chr5 124542150 A G 2.65E-04 Multiple complex diseases / / 17554300 rs6595593 chr5 124544330 T C 2.06E-05 Smoking behavior / / 19188921 rs1439568 chr5 124545732 T C 0.00000836 Cognitive impairment (no dementia) / / 23042215 rs13183660 chr5 124559084 T G 4.66E-04 Schizophrenia(age at onset) / / 21688384 rs719829 chr5 124581782 T G 1.30E-04 Lipid traits / / 17903299 rs1347923 chr5 124585390 C A 7.91E-04 Type 2 diabetes / / 17463246 rs13184952 chr5 124612485 T C 2.27E-04 Multiple complex diseases / / 17554300 rs13184952 chr5 124612485 T C 5.89E-05 Coronary Artery Disease / / 17634449 rs6595606 chr5 124616828 A G 4.94E-04 Type 2 diabetes / / 17463246 rs10519810 chr5 124627321 T C 0.000362 Salmonella-induced pyroptosis / / 22837397 rs17521821 chr5 124629015 T C 6.73E-04 Insulin resistance / / 21901158 rs1017470 chr5 124651294 A G 0.000836 Salmonella-induced pyroptosis / / 22837397 rs10519815 chr5 124660883 T C 4.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17463483 chr5 124661788 A G 3.61E-04 Insulin resistance / / 21901158 rs7720003 chr5 124664780 A G 9.97E-04 Multiple complex diseases / / 17554300 rs10039759 chr5 124665384 T A 2.60E-07 Urinary metabolites / / 21572414 rs1822758 chr5 124672949 C T 0.00084 Salmonella-induced pyroptosis / / 22837397 rs1607278 chr5 124674015 T C 8.17E-04 Multiple complex diseases / / 17554300 rs11241803 chr5 124682768 T C 7.57E-04 Rheumatoid arthritis / / 21452313 rs9885024 chr5 124683432 G A 5.78E-04 Rheumatoid arthritis / / 21452313 rs17523724 chr5 124685311 C A 1.57E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17523724 chr5 124685311 C A 4.72E-05 Smoking initiation / / 24665060 rs332042 chr5 124694295 T A 1.90E-04 Type 2 diabetes / / 17463246 rs2589398 chr5 124716158 C A 4.78E-05 Post-operative nausea and vomiting / / 21694509 rs17465113 chr5 124734492 C T 1.02E-05 Brain structure / / 22504417 rs2637496 chr5 124743267 T C 9.00E-06 HIV-1 control / / 20041166 rs9791105 chr5 124744271 G A 9.88E-04 Rheumatoid arthritis / / 21452313 rs1491068 chr5 124746481 A G 7.31E-04 Type 2 diabetes / / 17463246 rs2637502 chr5 124764147 G A 4.00E-05 Bone mineral density (BMD),in women / / 20164292 rs6888542 chr5 124790536 T C 2.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17152833 chr5 124824336 T C 1.80E-05 Multiple complex diseases / / 17554300 rs331755 chr5 124847603 C T 3.29E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17468244 chr5 124848906 A G 8.00E-06 Obesity-related traits / / 23251661 rs17152872 chr5 124852419 G T 4.25E-05 Smoking quantity / / 24665060 rs7712191 chr5 124856792 G T 6.89E-05 Body Mass Index / / pha003007 rs7712191 chr5 124856792 G T 3.46E-05 Body Mass Index / / pha003009 rs4144674 chr5 124858870 T G 4.21E-04 Smoking initiation / / 24665060 rs79515560 chr5 124860357 G A 0.00008565 Sarcoidosis / / 22952805 rs6899200 chr5 124861277 G A 0.00009822 Sarcoidosis / / 22952805 rs61202049 chr5 124862060 G A 0.00008988 Sarcoidosis / / 22952805 rs331742 chr5 124867489 C G 2.94E-04 Self-reported allergy / / 23817569 rs10037999 chr5 124867823 C T 5.16E-05 Body Mass Index / / pha003007 rs331727 chr5 124878619 A G 2.53E-04 Self-reported allergy / / 23817569 rs1490996 chr5 124946532 A G 9.28E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs1602402 chr5 124977016 C T 4.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs10077175 chr5 124992023 G A 8.17E-05 Cognitive impairment induced by topiramate / / 22091778 rs10077175 chr5 124992023 G A 7.17E-04 Smoking initiation / / 24665060 rs10064872 chr5 124993933 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10064872 chr5 124993933 A G 4.00E-04 Smoking initiation / / 24665060 rs1000318 chr5 124996711 G C 6.89E-04 Smoking initiation / / 24665060 rs10519829 chr5 125017426 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2451943 chr5 125075206 C T 4.51E-04 Multiple complex diseases / / 17554300 rs330238 chr5 125082217 A G 6.04E-04 Multiple complex diseases / / 17554300 rs445665 chr5 125099477 C A 1.10E-05 Lipid levels / / pha003082 rs2431596 chr5 125121030 A C 1.88E-05 Lipid levels / / pha003082 rs2431598 chr5 125127876 C T 2.97E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13159131 chr5 125130933 G C 8.26E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs329174 chr5 125132123 A G 2.10E-06 Amyotrophic lateral sclerosis / / 19193627 rs388910 chr5 125137593 C T 8.59E-06 Amyotrophic lateral sclerosis / / 19193627 rs17153375 chr5 125145154 A C 2.65E-05 Telomere length / / 23001564 rs327838 chr5 125159259 G T 3.93E-04 Lung function (forced vital capacity) / / 24023788 rs72792924 chr5 125234972 T A 5.20E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs465384 chr5 125243020 T C 1.00E-06 Select biomarker traits / / 17903293 rs465384 chr5 125243020 T C 1.00E-06 Select biomarker traits / / 17903293 rs451573 chr5 125263605 C T 2.60E-05 Urinary metabolites / / 21572414 rs17564095 chr5 125284737 G A 8.64E-04 Multiple complex diseases / / 17554300 rs76815036 chr5 125301172 C T 3.13E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs17153722 chr5 125301250 C T 3.13E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs11241851 chr5 125301672 A G 3.44E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs11241852 chr5 125301692 G T 2.95E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs11241853 chr5 125301721 A C 2.87E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs12152825 chr5 125301917 G A 2.87E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs59002887 chr5 125302179 A G 2.86E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs59562349 chr5 125302396 C A 2.85E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs17153728 chr5 125303083 A G 2.83E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs72795058 chr5 125303415 G C 2.80E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs72795060 chr5 125303533 A G 2.82E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs55673267 chr5 125303789 T C 2.81E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs2221261 chr5 125304404 A C 2.79E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs1910003 chr5 125304547 G A 2.00E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs59663074 chr5 125305118 A G 2.78E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs58014928 chr5 125305326 G A 2.79E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs2568399 chr5 125305451 T C 2.80E-05 Urinary metabolites / / 21572414 rs72795063 chr5 125305740 T A 2.78E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs72795065 chr5 125306286 T A 2.78E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs72795066 chr5 125306370 A G 2.78E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs72795068 chr5 125306580 G A 2.78E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs11241854 chr5 125308246 A T 2.96E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs12374456 chr5 125308528 C T 2.92E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs12374458 chr5 125308588 G A,C 2.91E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs34705560 chr5 125308703 G A 2.76E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs4082667 chr5 125308712 G C 2.75E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs17165007 chr5 125309543 A G 2.85E-04 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs1073203 chr5 125319456 C G 9.00E-06 Diabetic retinopathy / / 21441570 rs13169113 chr5 125338475 A C 9.00E-06 Cognitive performance / / 20125193 rs13177657 chr5 125352333 A G 1.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17153890 chr5 125378386 G A 2.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs955626 chr5 125385126 C T 6.07E-04 Insulin resistance / / 21901158 rs3909388 chr5 125393586 A T 1.37E-04 Multiple complex diseases / / 17554300 rs17509254 chr5 125398539 G A 3.83E-04 Lung function (forced vital capacity) / / 24023788 rs6595660 chr5 125399541 C G 2.21E-04 Multiple complex diseases / / 17554300 rs17153978 chr5 125410838 A G 5.54E-04 Type 2 diabetes / / 22158537 rs7716003 chr5 125411957 A G 5.63E-04 Type 2 diabetes / / 22158537 rs10064839 chr5 125412411 G A 1.62E-04 Multiple complex diseases / / 17554300 rs3849069 chr5 125417543 G A 5.13E-04 Multiple complex diseases / / 17554300 rs12658896 chr5 125428224 G A 6.03E-04 Multiple complex diseases / / 17554300 rs11241866 chr5 125428734 C T 4.95E-04 Multiple complex diseases / / 17554300 rs3860119 chr5 125428791 A C 2.70E-05 Urinary metabolites / / 21572414 rs10070545 chr5 125441453 T C 3.20E-04 Type 2 diabetes / / 22158537 rs6595669 chr5 125450788 T C 3.16E-04 Type 2 diabetes / / 22158537 rs10067528 chr5 125519180 C T 3.68E-04 Amyotrophic lateral sclerosis / / 23624525 rs17584191 chr5 125533130 C T 1.87E-05 Cardiovascular disease / / 22029572 rs9327396 chr5 125575513 G A 8.19E-05 Sodium levels / / pha003093 rs11241878 chr5 125580205 G A 8.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17154260 chr5 125589461 A G 8.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17154260 chr5 125589461 A G 3.76E-04 Amyotrophic lateral sclerosis / / 23624525 rs11241880 chr5 125592270 C A 6.25E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs964186 chr5 125603626 A G 1.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2408613 chr5 125605106 A G 1.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17154287 chr5 125611476 G A 1.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs989374 chr5 125650234 A G 6.06E-04 Alzheimer's disease / / 17998437 rs11738463 chr5 125679739 C T 2.85E-04 Multiple complex diseases / / 17554300 rs17154471 chr5 125696991 T C 7.33E-04 Multiple complex diseases GRAMD3 intron 17554300 rs1469044 chr5 125722130 C T 9.48E-04 Multiple complex diseases GRAMD3 intron 17554300 rs7732081 chr5 125726117 C T 7.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRAMD3 intron 20877124 rs7732081 chr5 125726117 C T 0.000625 Salmonella-induced pyroptosis GRAMD3 intron 22837397 rs4388209 chr5 125758373 T C 4.70E-04 Alcohol dependence GRAMD3 intron 20201924 rs6897488 chr5 125769679 C T 2.05E-04 Age-related macular degeneration GRAMD3 intron 22125219 rs11744511 chr5 125779180 A C 7.42E-05 AIDS GRAMD3 intron 19754311 rs10075722 chr5 125787282 C T 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRAMD3 intron 21876681 rs6595709 chr5 125795305 A G 3.18E-04 Multiple complex diseases GRAMD3 intron 17554300 rs7734622 chr5 125800401 T C 1.81E-04 Birth weight GRAMD3 intron 17255346 rs7713989 chr5 125860351 A G 7.90E-05 Personality dimensions / / 18957941 rs730870 chr5 125874993 A G 9.06E-05 Cognitive test performance / / 20125193 rs730870 chr5 125874993 A G 8.79E-05 Myopia (pathological) / / 21640322 rs4836272 chr5 125883341 T C 6.72E-05 Cholesterol ALDH7A1 intron pha003073 rs4836272 chr5 125883341 T C 7.40E-05 Cholesterol ALDH7A1 intron pha003078 rs13179664 chr5 125884934 G A 7.20E-04 Multiple complex diseases ALDH7A1 intron 17554300 rs1038378 chr5 125885214 T C 6.69E-05 Lung adenocarcinoma ALDH7A1 intron 19836008 rs2306619 chr5 125887856 A G 5.47E-05 Lung adenocarcinoma ALDH7A1 intron 19836008 rs11742381 chr5 125904994 C G 0.000479 Salmonella-induced pyroptosis ALDH7A1 intron 22837397 rs17154676 chr5 125912120 A G 5.33E-04 Smoking initiation ALDH7A1 intron 24665060 rs7714044 chr5 125918041 C T 2.86E-04 Smoking initiation ALDH7A1 intron 24665060 rs13182402 chr5 125918148 A G 2.00E-09 Osteoporosis ALDH7A1 intron 20072603 rs13182402 chr5 125918148 A G 1.12E-08 Lymphocyte counts ALDH7A1 intron 22286170 rs6861395 chr5 125928737 C T 7.73E-04 Smoking initiation ALDH7A1 intron 24665060 rs10063061 chr5 125943743 A C 6.15E-04 Multiple complex diseases PHAX intron 17554300 rs35726580 chr5 125969749 G A 7.14E-04 Smoking initiation C5orf48 intron 24665060 rs12654569 chr5 125972282 A G 8.55E-04 Multiple complex diseases / / 17554300 rs6892167 chr5 125972830 T C 4.60E-06 Urinary metabolites / / 21572414 rs7701818 chr5 125986096 A G 0.000019 Salmonella-induced pyroptosis / / 22837397 rs1546498 chr5 126032964 C T 2.00E-06 QT interval / / 23166209 rs10478752 chr5 126087378 T C 1.96E-05 Cognitive test performance / / 20125193 rs1533106 chr5 126087712 G T 3.24E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9327420 chr5 126088249 G T 8.56E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6595734 chr5 126089163 G C 1.89E-04 Type 2 diabetes / / 17463246 rs17598783 chr5 126135382 A G 7.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LMNB1 intron 20877124 rs959573 chr5 126181862 T C 5.00E-06 Parkinson's disease (motor and cognition) / / 22658654 rs884241 chr5 126186957 G A 9.04E-05 C-Reactive Protein / / pha003070 rs9637916 chr5 126211262 C T 8.15E-04 Type 2 diabetes MARCH3 intron 17463246 rs3812061 chr5 126213764 G T 6.44E-04 Type 2 diabetes MARCH3 intron 17463246 rs12655258 chr5 126267351 C T 6.00E-04 Type 2 diabetes MARCH3 intron 17463246 rs12652390 chr5 126322102 C T 2.89E-04 Type 2 diabetes MARCH3 intron 17463246 rs3828668 chr5 126365228 C T 8.62E-04 Type 2 diabetes MARCH3 intron 17463246 rs2240800 chr5 126387694 A G 6.10E-04 Type 2 diabetes C5orf63 intron 17463246 rs2240800 chr5 126387694 A G 8.40E-05 Monocyte chemoattractant protein-1 C5orf63 intron pha003071 rs17165249 chr5 126395511 G A 3.08E-04 Type 2 diabetes C5orf63 intron 17463246 rs17165234 chr5 126403635 A G 3.27E-04 Type 2 diabetes C5orf63 intron 17463246 rs12655006 chr5 126407602 G A 6.33E-04 Type 2 diabetes C5orf63 intron 17463246 rs2159424 chr5 126487366 G A 2.52E-06 Asthma (childhood onset) / / 23829686 rs12188873 chr5 126506531 A T 1.70E-05 Urinary metabolites / / 21572414 rs6874893 chr5 126580450 G A 2.02E-04 Type 2 diabetes / / 17463246 rs17673147 chr5 126673342 C A 9.48E-06 Parkinson's disease MEGF10 intron 23793441 rs17165041 chr5 126676554 A G 2.97E-05 Parkinson's disease MEGF10 intron 23793441 rs187514 chr5 126683416 T C 4.79E-04 Lung function (forced vital capacity) MEGF10 intron 24023788 rs17165038 chr5 126692337 A G 3.60E-04 Multiple complex diseases MEGF10 intron 17554300 rs10519937 chr5 126721853 C T 9.00E-06 IgG glycosylation MEGF10 intron 23382691 rs9327438 chr5 126723562 G A 5.00E-05 Type 2 diabetes and 6 quantitative traits MEGF10 intron 17848626 rs143954261 chr5 126729450 G C 8.00E-07 Alzheimer's disease (cognitive decline) MEGF10 intron 23535033 rs984024 chr5 126821947 A G 6.57E-04 Type 2 diabetes / / 17463246 rs7718640 chr5 126822042 C T 7.61E-04 Intracranial aneurysm / / 20613766 rs17211634 chr5 126921427 C T 6.35E-05 Monocyte chemoattractant protein-1 / / pha003071 rs10519947 chr5 126937464 T G 3.91E-04 Bipolar disorder / / 19259986 rs791333 chr5 126938115 A C 4.80E-04 Insulin resistance / / 21901158 rs2408996 chr5 126972005 T C 5.97E-05 Coronary heart disease / / pha003055 rs11241936 chr5 126978108 T C 2.00E-07 Plasma amyloid beta peptide concentrations (ABx-42) / / 24535457 rs11241936 chr5 126978108 T C 3.42E-05 Coronary heart disease / / pha003055 rs791077 chr5 126986357 A G 6.15E-05 Body Mass Index CTXN3 intron pha003022 rs7711139 chr5 126991456 G A 4.85E-04 Suicide attempts in bipolar disorder CTXN3 intron 21423239 rs248707 chr5 126993922 T C 5.00E-06 Parkinson's disease (familial) CTXN3 UTR-3 18985386 rs248707 chr5 126993922 T C 7.81E-04 Suicide attempts in bipolar disorder CTXN3 UTR-3 21423239 rs248707 chr5 126993922 T C 2.20E-05 Urinary metabolites CTXN3 UTR-3 21572414 rs248705 chr5 126994381 A G 5.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs248701 chr5 126995218 T G 9.00E-06 Urinary metabolites / / 21572414 rs248695 chr5 126999493 T G 7.00E-06 Parkinson's disease (familial) / / 18985386 rs248695 chr5 126999493 T G 5.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs248694 chr5 126999937 G A 3.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs248689 chr5 127003890 T C 1.50E-05 Urinary metabolites / / 21572414 rs790837 chr5 127004506 G A 5.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs10519953 chr5 127004689 G A 1.50E-05 Urinary metabolites / / 21572414 rs1816404 chr5 127028099 A G 3.39E-04 Taste perception / / 22132133 rs2673762 chr5 127029700 A T 5.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs10072627 chr5 127032021 G A 4.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs248727 chr5 127037482 T C 1.70E-05 Urinary metabolites / / 21572414 rs248726 chr5 127038132 C T 8.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs248725 chr5 127038316 C T 3.90E-06 Parkinson's disease (familial) / / 18985386 rs248725 chr5 127038316 C T 9.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs248725 chr5 127038316 C T 2.30E-05 Urinary metabolites / / 21572414 rs248724 chr5 127039078 A G 1.50E-05 Urinary metabolites / / 21572414 rs248729 chr5 127051573 T C 3.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs248728 chr5 127051694 A T 3.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs4835929 chr5 127054278 T G 7.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs1228885 chr5 127055616 G A 3.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs790835 chr5 127059558 G C 3.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs12513840 chr5 127059942 A G 7.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs790833 chr5 127060766 A G 4.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs790832 chr5 127061016 C T 3.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs12523164 chr5 127061971 T C 6.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs12515892 chr5 127062190 A G 2.80E-05 Urinary metabolites / / 21572414 rs12515892 chr5 127062190 A G 7.24E-04 Taste perception / / 22132133 rs790830 chr5 127062937 A G 3.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs790830 chr5 127062937 A G 1.80E-05 Urinary metabolites / / 21572414 rs1088164 chr5 127066193 A G 4.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs2673748 chr5 127069127 A G 5.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs10054323 chr5 127078541 G A 6.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs13182486 chr5 127092344 A C 6.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs2569146 chr5 127096801 C A 8.20E-05 White matter hyperintensity burden / / 21681796 rs1515640 chr5 127097363 A G 8.50E-05 White matter hyperintensity burden / / 21681796 rs9327450 chr5 127098999 A C 6.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs4835930 chr5 127101419 T C 5.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs10463832 chr5 127110486 C A 5.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs10463833 chr5 127122312 G A 5.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs7722425 chr5 127125762 T C 5.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs1515641 chr5 127139616 G A 4.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs10051423 chr5 127147382 C T 9.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs10057750 chr5 127150176 G C 6.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs1421746 chr5 127151976 A G 6.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs1421746 chr5 127151976 A G 8.00E-06 Amyotrophic lateral sclerosis (age of onset) / / 22959728 rs245201 chr5 127169212 A G 9.00E-08 Brain imaging in schizophrenia (interaction) / / 19023125 rs151879 chr5 127200523 T C 7.86E-05 Brain imaging in schizophrenia (interaction) / / 19023125 rs245178 chr5 127203192 C T 1.22E-06 Brain imaging in schizophrenia (interaction) / / 19023125 rs1421750 chr5 127212228 C A 2.60E-05 White matter hyperintensity burden / / 21681796 rs2764766 chr5 127213625 C G 2.70E-05 White matter hyperintensity burden / / 21681796 rs2544780 chr5 127214163 T C 2.70E-05 White matter hyperintensity burden / / 21681796 rs122730 chr5 127220271 C T 3.10E-05 White matter hyperintensity burden / / 21681796 rs151855 chr5 127222108 C A 3.20E-05 White matter hyperintensity burden / / 21681796 rs245173 chr5 127224153 C G 3.20E-05 White matter hyperintensity burden / / 21681796 rs122734 chr5 127224322 T C 3.30E-05 White matter hyperintensity burden / / 21681796 rs151853 chr5 127227184 G A 3.40E-05 White matter hyperintensity burden / / 21681796 rs245167 chr5 127229195 T C 3.90E-05 White matter hyperintensity burden / / 21681796 rs2409033 chr5 127234574 T C 4.70E-05 White matter hyperintensity burden / / 21681796 rs193495 chr5 127234944 T C 4.40E-05 White matter hyperintensity burden / / 21681796 rs193495 chr5 127234944 T C 4.45E-04 Tourette syndrome / / 22889924 rs245221 chr5 127239400 A T 4.60E-05 White matter hyperintensity burden / / 21681796 rs245156 chr5 127245143 G A 8.70E-05 White matter hyperintensity burden / / 21681796 rs17164526 chr5 127246723 T A 8.94E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs245158 chr5 127247600 A T 4.70E-05 White matter hyperintensity burden / / 21681796 rs7711172 chr5 127257406 G A 2.31E-04 Multiple complex diseases / / 17554300 rs1520246 chr5 127266725 A G 9.28E-04 Multiple complex diseases / / 17554300 rs4835938 chr5 127377031 C G 7.11E-05 Sudden cardiac arrest FLJ33630 intron 21658281 rs17675435 chr5 127378502 A G 3.53E-06 Schizophrenia FLJ33630 intron 21926974 rs146579248 chr5 127382302 C T 4.00E-07 Alzheimer's disease (cognitive decline) FLJ33630 intron 23535033 rs10067555 chr5 127427533 T C 1.12E-04 Lung function (forced vital capacity) SLC12A2 intron 24023788 rs3805608 chr5 127480998 G A 8.36E-04 Stroke SLC12A2 intron pha002886 rs2568928 chr5 127487603 A G 8.52E-04 Multiple complex diseases SLC12A2 intron 17554300 rs10089 chr5 127522543 C T 2.00E-06 Ileal carcinoids SLC12A2 UTR-3 21139019 rs173700 chr5 127532924 A G 7.11E-04 Myocardial Infarction / / pha002873 rs36701 chr5 127552529 C T 2.80E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2112547 chr5 127566639 T A 6.43E-05 Serum metabolites / / 19043545 rs6595812 chr5 127575603 G A 8.40E-05 Multiple complex diseases / / 17554300 rs17676236 chr5 127589221 G C 3.67E-05 Multiple complex diseases / / 17554300 rs17676242 chr5 127589648 G A 5.76E-04 Type 2 diabetes / / 17463246 rs10070942 chr5 127592521 G A 4.11E-04 Multiple complex diseases / / 17554300 rs2042327 chr5 127622983 C T 9.70E-04 Height FBN2 intron 21998595 rs27855 chr5 127640861 A G 4.00E-06 Height FBN2 intron 21998595 rs10057405 chr5 127653022 A C 9.00E-06 Temperament FBN2 intron 22832960 rs467610 chr5 127667613 C T 1.53E-04 Scoliosis FBN2 intron 21216876 rs28763945 chr5 127681100 C A 8.04E-06 Lipid levels FBN2 missense 19913121 rs32218 chr5 127691233 A G 2.43E-05 Osteoarthritis FBN2 intron 19508968 rs374748 chr5 127699375 G A 4.00E-06 Obesity (extreme) FBN2 intron 19553259 rs17608902 chr5 127716567 C A 1.00E-07 Migraine - clinic-based FBN2 intron 23793025 rs17608902 chr5 127716567 C A 9.00E-06 Migraine with aura FBN2 intron 23793025 rs1396477 chr5 127720268 C T 2.14E-05 Coronary heart disease FBN2 intron pha003031 rs28763952 chr5 127727853 G A 8.04E-06 Lipid levels FBN2 intron 19913121 rs989549 chr5 127740036 G A 6.20E-06 Coronary heart disease FBN2 intron pha003031 rs989548 chr5 127740383 T G 5.68E-06 Coronary heart disease FBN2 intron pha003031 rs3805647 chr5 127741163 A G 1.70E-05 Myocardial Infarction FBN2 intron pha002873 rs10519994 chr5 127772621 C T 6.75E-06 Coronary heart disease FBN2 intron pha003031 rs17164127 chr5 127773702 C T 6.45E-04 Multiple complex diseases FBN2 intron 17554300 rs11241959 chr5 127787964 A G 4.13E-04 Multiple complex diseases FBN2 intron 17554300 rs11949017 chr5 127809413 C T 6.83E-06 Coronary heart disease FBN2 intron pha003031 rs6595828 chr5 127817549 T C 2.54E-04 Multiple complex diseases FBN2 intron 17554300 rs7726680 chr5 127821251 C G 3.76E-04 Multiple complex diseases FBN2 intron 17554300 rs7719223 chr5 127824981 A C 4.95E-04 Multiple complex diseases FBN2 intron 17554300 rs968008 chr5 127825485 C T 4.16E-05 Coronary heart disease FBN2 intron pha003031 rs764368 chr5 127826095 A C 3.53E-04 Multiple complex diseases FBN2 intron 17554300 rs17839642 chr5 127833080 A G 9.59E-04 Tourette syndrome FBN2 intron 22889924 rs6595831 chr5 127835642 G A 7.49E-05 Recombination rate FBN2 intron 21698098 rs9327478 chr5 127850129 G T 5.40E-04 Multiple complex diseases FBN2 intron 17554300 rs6595836 chr5 127860887 C T 5.02E-04 Multiple complex diseases FBN2 intron 17554300 rs13181926 chr5 127861074 C T 6.50E-04 Type 2 diabetes FBN2 intron 17463246 rs6860901 chr5 127871750 C T 0.0000809 Nonsyndromic striae distensae (stretch marks) FBN2 intron 23633020 rs7732639 chr5 127873605 T C 0.0000893 Nonsyndromic striae distensae (stretch marks) FBN2 UTR-5 23633020 rs186263310 chr5 127875736 A G 5.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs6863262 chr5 127887453 C T 5.61E-04 Multiple complex diseases / / 17554300 rs10055140 chr5 127898518 A G 0.0000829 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13167932 chr5 127907915 T C 1.61E-05 Coronary heart disease / / pha003031 rs11954127 chr5 127911777 T C 7.77E-05 Insulin resistance / / 21901158 rs4339399 chr5 127915443 C T 2.88E-04 Insulin resistance / / 21901158 rs11952247 chr5 127918698 C T 3.22E-04 Insulin resistance / / 21901158 rs11952334 chr5 127918878 G A 2.98E-04 Insulin resistance / / 21901158 rs11952334 chr5 127918878 G A 1.92E-05 Coronary heart disease / / pha003031 rs3924301 chr5 127920146 A G 2.01E-04 Insulin resistance / / 21901158 rs11954070 chr5 127920535 G A 2.98E-04 Insulin resistance / / 21901158 rs11956881 chr5 127923763 C T 5.70E-07 Primary tooth development (time to first tooth eruption) / / 23704328 rs6883598 chr5 127926190 A C 2.17E-04 Multiple complex diseases / / 17554300 rs6883598 chr5 127926190 A C 3.66E-04 Prostate cancer mortality / / 20978177 rs4317372 chr5 127926973 T C 2.60E-04 Insulin resistance / / 21901158 rs4318822 chr5 127927192 T C 2.46E-04 Insulin resistance / / 21901158 rs4129959 chr5 127930965 C T 1.92E-05 Coronary heart disease / / pha003031 rs7711017 chr5 127934429 T G 8.75E-04 Multiple complex diseases / / 17554300 rs13173831 chr5 127935382 C G 9.41E-05 Insulin resistance / / 21901158 rs6864907 chr5 127956351 T A 3.70E-04 Insulin resistance / / 21901158 rs9327479 chr5 127962841 G A 1.28E-04 Multiple complex diseases / / 17554300 rs9327479 chr5 127962841 G A 4.42E-04 Prostate cancer mortality / / 20978177 rs6897794 chr5 127983935 C T 2.16E-04 Multiple complex diseases / / 17554300 rs6897794 chr5 127983935 C T 5.57E-04 Prostate cancer mortality / / 20978177 rs10520006 chr5 127999225 A G 1.22E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7715766 chr5 128002118 A G 1.88E-05 Coronary heart disease / / pha003031 rs4355569 chr5 128008356 T C 1.67E-04 Parkinson's disease / / 17052657 rs10053477 chr5 128010071 C T 8.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs4382207 chr5 128010091 G A 8.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs11951994 chr5 128018873 C T 1.34E-05 Bipolar disorder / / 21771265 rs7726945 chr5 128034399 C T 8.64E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs34350121 chr5 128049456 C T 6.37E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1019136 chr5 128063276 A G 5.20E-05 Pericardial fat / / 22589742 rs247168 chr5 128068125 A G 4.40E-05 Pericardial fat / / 22589742 rs247205 chr5 128083481 G A 3.92E-06 Type 2 diabetes / / 22238593 rs247207 chr5 128085442 T C 2.90E-05 Pericardial fat / / 22589742 rs189687 chr5 128092820 A T 9.82E-04 Multiple complex diseases / / 17554300 rs189687 chr5 128092820 A T 5.70E-05 Pericardial fat / / 22589742 rs247096 chr5 128093877 T C 7.14E-06 Diabetic nephropathy / / 21150874 rs247096 chr5 128093877 T C 2.56E-04 Type 2 diabetes / / 22238593 rs1422448 chr5 128103028 A C 7.32E-04 Multiple complex diseases / / 17554300 rs2161305 chr5 128105507 T A 3.86E-06 Diabetic nephropathy / / 21150874 rs2161305 chr5 128105507 T A 2.06E-04 Type 2 diabetes / / 22238593 rs10074635 chr5 128106470 G T 1.99E-04 Diabetic nephropathy / / 21150874 rs10074635 chr5 128106470 G T 7.35E-05 Post-operative nausea and vomiting / / 21694509 rs1422447 chr5 128106790 C T 7.23E-05 Diabetes Mellitus / / pha003059 rs1422447 chr5 128106790 C T 3.30E-05 Diabetes Mellitus / / pha003060 rs11742783 chr5 128114425 C T 7.58E-05 Diabetes Mellitus / / pha003059 rs11742783 chr5 128114425 C T 2.29E-05 Diabetes Mellitus / / pha003060 rs17790915 chr5 128118887 G A 1.81E-05 Post-operative nausea and vomiting / / 21694509 rs2310808 chr5 128142473 C G 4.13E-04 Multiple complex diseases / / 17554300 rs10068756 chr5 128158288 C T 5.07E-04 Type 2 diabetes / / 17463246 rs1496348 chr5 128190750 C A 0.0007 Asthma / / 18401594 rs10050439 chr5 128200502 T C 2.08E-04 Multiple complex diseases / / 17554300 rs6872488 chr5 128202303 C T 1.48E-04 Multiple complex diseases / / 17554300 rs17616306 chr5 128207539 T C 2.43E-04 Multiple complex diseases / / 17554300 rs7712497 chr5 128207868 G A 3.67E-04 Multiple complex diseases / / 17554300 rs6873372 chr5 128232901 C T 6.18E-05 Type 1 diabetes / / 18978792 rs6873372 chr5 128232901 C T 8.33E-05 B cell non-Hodgkin lymphoma / / 23749188 rs6873372 chr5 128232901 C T 5.54E-05 Creatinine levels / / pha003069 rs12523161 chr5 128233529 G A 9.20E-05 Age-related macular degeneration / / pha002890 rs10520013 chr5 128240648 T C 6.64E-04 Type 2 diabetes / / 17463246 rs10520013 chr5 128240648 T C 1.14E-04 Multiple complex diseases / / 17554300 rs3863171 chr5 128241116 T G 5.33E-04 Type 2 diabetes / / 17463246 rs756455 chr5 128261265 C G 8.77E-04 Type 2 diabetes / / 17463246 rs2577497 chr5 128264973 C T 2.93E-04 Type 2 diabetes / / 17463246 rs2526186 chr5 128265120 C G 4.90E-04 Type 2 diabetes / / 17463246 rs2577499 chr5 128265662 A T 4.42E-04 Type 2 diabetes / / 17463246 rs2526195 chr5 128267853 G A 6.84E-04 Type 2 diabetes / / 17463246 rs1898544 chr5 128287228 C T 6.85E-04 Type 2 diabetes / / 17463246 rs6861915 chr5 128288652 C T 4.19E-04 Type 2 diabetes / / 17463246 rs17678653 chr5 128289533 T C 4.99E-04 Type 2 diabetes / / 17463246 rs2577446 chr5 128291964 C T 7.39E-04 Type 2 diabetes / / 17463246 rs2577445 chr5 128292120 C T 5.32E-04 Type 2 diabetes / / 17463246 rs7706059 chr5 128292292 T G 7.27E-04 Type 2 diabetes / / 17463246 rs142676290 chr5 128302185 G A 0.000037 Breast cancer (ER positive) SLC27A6 missense 23555315 rs142676290 chr5 128302185 G A 0.000059 Breast cancer SLC27A6 missense 23555315 rs17616974 chr5 128303336 G A 7.22E-04 Type 2 diabetes SLC27A6 intron 17463246 rs17617241 chr5 128317267 T G 3.02E-04 Type 2 diabetes SLC27A6 intron 17463246 rs1181981 chr5 128330174 G C 5.70E-04 Multiple complex diseases SLC27A6 intron 17554300 rs174006 chr5 128331456 C T 2.13E-06 Cognitive test performance SLC27A6 intron 20125193 rs257926 chr5 128390167 T C 1.32E-05 Post-operative nausea and vomiting / / 21694509 rs42563 chr5 128400356 C T 4.05E-06 Post-operative nausea and vomiting / / 21694509 rs3756747 chr5 128428962 C T 8.22E-05 Post-operative nausea and vomiting / / 21694509 rs13186750 chr5 128548120 T C 6.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs10072264 chr5 128582254 T C 4.64E-04 Myopia (pathological) / / 21095009 rs1978159 chr5 128594907 G A 4.64E-04 Myopia (pathological) / / 21095009 rs7705332 chr5 128595494 A G 9.32E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs252668 chr5 128627794 A C 8.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs252668 chr5 128627794 A C 1.13E-04 Smoking quantity / / 24665060 rs17163509 chr5 128651624 A G 2.00E-04 Myopia (pathological) / / 21095009 rs10079852 chr5 128658431 G T 2.84E-04 Myopia (pathological) / / 21095009 rs6873564 chr5 128718147 T C 8.87E-05 Smoking quantity / / 24665060 rs6893553 chr5 128718653 C T 2.88E-05 Serum albumin level / / pha003084 rs10077875 chr5 128722696 G A 9.00E-06 Obesity-related traits / / 23251661 rs10053585 chr5 128730528 G T 6.88E-04 Depression (quantitative trait) / / 20800221 rs17680257 chr5 128734625 A G 5.20E-04 Alzheimer's disease / / 22005930 rs17618372 chr5 128735170 G A 4.13E-04 Alzheimer's disease / / 22005930 rs12514226 chr5 128735235 G A 1.71E-04 Alzheimer's disease / / 22005930 rs10068116 chr5 128735787 A G 2.77E-04 Alzheimer's disease / / 22005930 rs12517814 chr5 128736840 T A 1.91E-04 Alzheimer's disease / / 22005930 rs12515721 chr5 128737229 G A 5.86E-04 Alzheimer's disease / / 22005930 rs990714 chr5 128737336 T A 5.40E-04 Alzheimer's disease / / 22005930 rs10069235 chr5 128739207 T C 4.49E-04 Alzheimer's disease / / 22005930 rs10061634 chr5 128739908 C T 4.84E-04 Alzheimer's disease / / 22005930 rs10065474 chr5 128741195 C A 4.97E-04 Alzheimer's disease / / 22005930 rs11957867 chr5 128746927 T C 1.41E-05 Body Composition / / pha003012 rs11957867 chr5 128746927 T C 9.45E-05 Body Mass Index / / pha003021 rs17163425 chr5 128747841 T C 1.41E-05 Body Composition / / pha003012 rs17163425 chr5 128747841 T C 9.45E-05 Body Mass Index / / pha003021 rs12656498 chr5 128763144 T C 9.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6886494 chr5 128768047 T C 1.48E-05 Body Composition / / pha003012 rs6886494 chr5 128768047 T C 9.08E-05 Body Mass Index / / pha003021 rs13359525 chr5 128801108 A T 2.90E-05 Urinary metabolites ADAMTS19 intron 21572414 rs1862164 chr5 128813527 C T 8.30E-06 Urinary metabolites ADAMTS19 intron 21572414 rs10058781 chr5 128838809 C T 9.96E-04 Depression (quantitative trait) ADAMTS19 intron 20800221 rs1559060 chr5 128839856 C A 1.40E-05 Urinary metabolites ADAMTS19 intron 21572414 rs1363145 chr5 128846774 A G 9.08E-04 Depression (quantitative trait) ADAMTS19 intron 20800221 rs7705041 chr5 128859368 T A 4.62E-05 Aging (time to event) ADAMTS19 intron 21782286 rs1363148 chr5 128882914 A G 9.35E-04 Bipolar disorder ADAMTS19 intron 19259986 rs7718327 chr5 128883145 A G 3.09E-04 Smoking cessation ADAMTS19 intron 24665060 rs17617039 chr5 128960315 T G 1.91E-04 Multiple complex diseases ADAMTS19 intron 17554300 rs3909548 chr5 128969615 G A 2.76E-04 Multiple complex diseases ADAMTS19 intron 17554300 rs40972 chr5 128987225 C T 0.0000211 Colorectal cancer (males) ADAMTS19 intron 22532847 rs25820 chr5 128991232 C T 1.08E-05 Bipolar disorder and schizophrenia ADAMTS19 intron 20889312 rs25806 chr5 128998935 A C 7.45E-04 Type 2 diabetes ADAMTS19 intron 17463246 rs439604 chr5 128999982 A G 8.37E-04 Type 2 diabetes ADAMTS19 intron 17463246 rs13436218 chr5 129000386 T G 1.00E-06 Sexual dysfunction (SSRI/SNRI-related) ADAMTS19 intron 22445761 rs30665 chr5 129005735 G A 3.85E-05 Bipolar disorder and schizophrenia ADAMTS19 intron 20889312 rs30650 chr5 129013257 C T 8.80E-04 Type 2 diabetes ADAMTS19 intron 17463246 rs39589 chr5 129017603 T C 8.03E-04 Type 2 diabetes ADAMTS19 intron 17463246 rs431265 chr5 129017649 G C 7.15E-04 Type 2 diabetes ADAMTS19 intron 17463246 rs30642 chr5 129018092 T C 8.37E-04 Type 2 diabetes ADAMTS19 intron 17463246 rs26207 chr5 129036096 T G 5.08E-04 Bipolar disorder ADAMTS19 intron 19259986 rs32796 chr5 129036516 C A 1.12E-04 Premature ovarian failure ADAMTS19 intron 19508998 rs7737760 chr5 129050648 A G 1.30E-05 Urinary metabolites ADAMTS19 intron 21572414 rs246246 chr5 129056759 G T 5.98E-07 Premature ovarian failure ADAMTS19 intron 19508998 rs246246 chr5 129056759 G T 5.98E-07 Other erythrocyte phenotypes ADAMTS19 intron 19862010 rs7705150 chr5 129081652 A G 3.38E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11956778 chr5 129090236 C T 4.30E-06 Urinary metabolites / / 21572414 rs13183333 chr5 129093608 G A 5.98E-05 Schizophrenia / / 19571809 rs6866940 chr5 129097638 A G 6.96E-05 Premature ovarian failure / / 19508998 rs6866940 chr5 129097638 A G 6.96E-05 Other erythrocyte phenotypes / / 19862010 rs2080945 chr5 129100424 C T 4.40E-06 Urinary metabolites / / 21572414 rs1025467 chr5 129148790 A G 6.74E-04 Multiple complex diseases / / 17554300 rs10053519 chr5 129149447 A G 4.42E-06 Crohn's disease and psoriasis / / 22482804 rs244455 chr5 129213033 C T 1.60E-05 Coffee consumption / / 21357676 rs13356198 chr5 129257092 A G 0.0000047 Confectionary intake CHSY3 intron 23408455 rs4530793 chr5 129279813 G A 2.74E-04 Iron levels CHSY3 intron pha002876 rs9285916 chr5 129404945 A C,G 2.98E-05 Postoperative ventricular dysfunction CHSY3 intron 21980348 rs10050470 chr5 129436666 G A 5.07E-05 Crohn's disease CHSY3 intron 17804789 rs6858978 chr5 129439574 A G 7.14E-05 Crohn's disease CHSY3 intron 17804789 rs17692371 chr5 129444097 G A 9.81E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CHSY3 intron 24023788 rs4836493 chr5 129471722 G A 1.30E-05 Urinary metabolites CHSY3 intron 21572414 rs4836493 chr5 129471722 G A 6.19E-06 Postoperative ventricular dysfunction CHSY3 intron 21980348 rs173632 chr5 129510197 G A 2.00E-05 Urinary metabolites CHSY3 intron 21572414 rs2015018 chr5 129521126 A G 7.24E-05 stroke (ischemic) CHSY3 missense 17434096 rs10072529 chr5 129545775 A T 7.88E-04 Acute lung injury / / 22295056 rs6861345 chr5 129552816 A G 8.86E-05 stroke (ischemic) / / 17434096 rs10076208 chr5 129554111 C T 7.96E-04 Acute lung injury / / 22295056 rs10075474 chr5 129555759 T C 7.96E-04 Acute lung injury / / 22295056 rs10073914 chr5 129558756 C T 7.96E-04 Acute lung injury / / 22295056 rs1015565 chr5 129604219 G T 2.70E-05 Urinary metabolites / / 21572414 rs10064779 chr5 129619562 A G 5.03E-04 Alzheimer's disease / / 22005930 rs2214640 chr5 129623638 T C 5.71E-04 Alzheimer's disease / / 22005930 rs13179136 chr5 129624919 G A 6.16E-04 Insulin resistance / / 21901158 rs264126 chr5 129638069 C T 6.76E-04 Alzheimer's disease / / 22005930 rs17165505 chr5 129656242 G A 1.80E-05 Urinary metabolites / / 21572414 rs1541441 chr5 129660159 T C 5.14E-04 Multiple complex diseases / / 17554300 rs11242022 chr5 129661649 C T 3.21E-04 Coronary Artery Disease / / 17634449 rs6595948 chr5 129669537 C T 4.93E-05 Crohn's disease / / 17804789 rs6898857 chr5 129673919 T C 1.82E-04 Parkinson's disease / / 17052657 rs6869287 chr5 129684556 G T 8.81E-05 Crohn's disease / / 17804789 rs4835994 chr5 129721857 T C 3.38E-05 Serum alpha1-antitrypsin levels / / 23990791 rs255578 chr5 129737723 C G 7.67E-06 Response to amphetamines / / 22952603 rs12188544 chr5 129740524 C A 4.93E-05 Corneal structure / / 22003120 rs35020650 chr5 129768929 C T 4.63E-06 Response to amphetamines / / 22952603 rs13176262 chr5 129784684 C T 8.70E-06 Response to amphetamines / / 22952603 rs6894216 chr5 129792134 C T 4.00E-06 Response to amphetamines / / 22952603 rs2189381 chr5 129792625 T C 3.33E-04 Multiple complex diseases / / 17554300 rs2189381 chr5 129792625 T C 8.12E-05 Serum metabolites / / 19043545 rs6893779 chr5 129797899 A C 4.63E-05 Serum alpha1-antitrypsin levels / / 23990791 rs11242025 chr5 129817919 G A 8.67E-05 Schizophrenia / / 19571811 rs6893341 chr5 129818555 T C 5.65E-04 Corneal structure / / 22003120 rs2191106 chr5 129825523 C T 4.32E-06 Response to amphetamines / / 22952603 rs9918267 chr5 129831624 A G 4.27E-06 Response to amphetamines / / 22952603 rs10520081 chr5 129834311 T C 3.25E-05 Corneal structure / / 22003120 rs2215257 chr5 129925322 T C 7.77E-05 Glucose levels / / pha002899 rs10520083 chr5 129940006 C G 1.09E-04 Multiple complex diseases / / 17554300 rs7731657 chr5 129943319 T C 7.00E-06 Fasting plasma glucose / / 17903298 rs2419065 chr5 129982203 G T 5.23E-05 Glucose levels / / pha002899 rs4836519 chr5 130017287 T C 4.00E-10 Inflammatory bowel disease / / 23128233 rs10078677 chr5 130055924 C T 1.60E-05 Body mass index (education interaction) / / 24281739 rs12518350 chr5 130096260 A G 6.00E-06 Body mass index (education interaction) / / 24281739 rs12518350 chr5 130096260 A G 2.21E-05 Glucose levels / / pha002899 rs1862647 chr5 130102023 G A 7.15E-05 Glucose levels / / pha002899 rs10051722 chr5 130104076 A C 5.38E-05 Crohn's disease / / 17804789 rs10051722 chr5 130104076 A C 6.82E-05 Glucose levels / / pha002899 rs2024309 chr5 130137814 G A 2.63E-04 Multiple complex diseases / / 17554300 rs12652579 chr5 130140680 A G 3.88E-04 Multiple complex diseases / / 17554300 rs3981405 chr5 130164900 A G 2.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10478953 chr5 130185380 G T 1.16E-04 Multiple complex diseases / / 17554300 rs10477723 chr5 130187390 G A 1.35E-04 Premature ovarian failure / / 19508998 rs10520092 chr5 130202197 A G 1.05E-04 Multiple complex diseases / / 17554300 rs4705917 chr5 130206326 T C 5.19E-04 Multiple complex diseases / / 17554300 rs4705850 chr5 130220358 T C 1.29E-04 Multiple complex diseases / / 17554300 rs4705851 chr5 130220592 C T 2.08E-04 Multiple complex diseases / / 17554300 rs2522031 chr5 130242429 C T 9.28E-05 Multiple complex diseases / / 17554300 rs1074840 chr5 130251717 G A 8.20E-04 Multiple complex diseases / / 17554300 rs6887982 chr5 130275716 G C 6.63E-05 Multiple complex diseases / / 17554300 rs10040560 chr5 130300594 T C 9.23E-05 Multiple complex diseases / / 17554300 rs17839577 chr5 130308754 G T 6.53E-04 Multiple complex diseases / / 17554300 rs2158352 chr5 130309465 G A 6.91E-05 Multiple complex diseases / / 17554300 rs10478956 chr5 130318514 G C 5.30E-05 Multiple complex diseases / / 17554300 rs6595983 chr5 130335755 A G 5.14E-05 Multiple complex diseases / / 17554300 rs6595984 chr5 130335884 T C 9.72E-05 Multiple complex diseases / / 17554300 rs12719432 chr5 130354295 A G 9.60E-05 Multiple complex diseases / / 17554300 rs6859119 chr5 130356643 T G 7.93E-04 Insulin resistance / / 21901158 rs6595989 chr5 130359215 T C 7.02E-05 Multiple complex diseases / / 17554300 rs6595989 chr5 130359215 T C 9.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs973900 chr5 130362467 C A 3.14E-06 Multiple complex diseases / / 17554300 rs3981333 chr5 130375045 A T 4.05E-05 Multiple complex diseases / / 17554300 rs6867265 chr5 130413981 A G 2.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs6867265 chr5 130413981 A G 0.00062 Prostate cancer / / 23555315 rs1549231 chr5 130416902 C T 9.73E-04 Bipolar disorder / / 19259986 rs6870861 chr5 130432955 C G 3.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs1035440 chr5 130446040 C T 7.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs11954454 chr5 130482270 A G 3.88E-04 Lung function (forced vital capacity) / / 24023788 rs9327594 chr5 130486560 G A 3.88E-04 Lung function (forced vital capacity) / / 24023788 rs2551038 chr5 130496139 C G 3.53E-04 Suicide attempts in bipolar disorder HINT1 intron 21423239 rs7735084 chr5 130505701 C T 3.47E-04 Fibrinogen / / 17255346 rs17165949 chr5 130522914 A G 2.26E-04 Lymphocyte counts LYRM7 intron 22286170 rs17165964 chr5 130529122 A G 3.32E-04 Multiple complex diseases LYRM7 intron 17554300 rs6882231 chr5 130543648 T C 8.59E-05 Post-operative nausea and vomiting / / 21694509 rs6596006 chr5 130575413 C T 1.76E-04 Scoliosis / / 21216876 rs6875363 chr5 130581195 C T 5.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6596008 chr5 130603119 A G 3.87E-05 Crohn's disease CDC42SE2 intron 17804789 rs1468328 chr5 130611700 A T 5.56E-05 Crohn's disease CDC42SE2 intron 17804789 rs12513768 chr5 130616792 G A 2.96E-05 Crohn's disease CDC42SE2 intron 17804789 rs11242070 chr5 130626621 A G 2.34E-05 Crohn's disease CDC42SE2 intron 17804789 rs2549011 chr5 130657418 G C 2.31E-05 Crohn's disease CDC42SE2 intron 17804789 rs35707316 chr5 130657418 G GC 2.31E-05 Crohn's disease CDC42SE2 intron 17804789 rs4706020 chr5 130674076 G A 3.61E-06 Crohn's disease CDC42SE2 intron 17804789 rs798407 chr5 130688378 C G 2.85E-05 Crohn's disease CDC42SE2 intron 17804789 rs30735 chr5 130709422 G A 1.94E-05 Crohn's disease CDC42SE2 intron 17804789 rs6897210 chr5 130731038 C T 1.95E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs257391 chr5 130740005 C A 1.15E-05 Crohn's disease / / 17804789 rs10040442 chr5 130753077 C G 5.83E-06 Crohn's disease / / 17804789 rs6596024 chr5 130769785 C A 3.03E-05 Crohn's disease RAPGEF6 intron 17804789 rs6896132 chr5 130773561 G C 1.78E-05 Crohn's disease RAPGEF6 intron 17804789 rs3776027 chr5 130802970 T C 2.89E-05 Crohn's disease RAPGEF6 intron 17804789 rs31241 chr5 130808198 T C 2.10E-05 Crohn's disease RAPGEF6 intron 17804789 rs31240 chr5 130811146 T A 4.25E-05 Crohn's disease RAPGEF6 intron 17804789 rs31239 chr5 130813377 T G 2.09E-05 Crohn's disease RAPGEF6 intron 17804789 rs31258 chr5 130824536 G A 3.70E-05 Crohn's disease RAPGEF6 intron 17804789 rs39600 chr5 130828649 A T 3.70E-05 Crohn's disease RAPGEF6 intron 17804789 rs40400 chr5 130831365 T C 4.25E-05 Crohn's disease RAPGEF6 intron 17804789 rs31252 chr5 130833433 T C 2.19E-05 Crohn's disease RAPGEF6 intron 17804789 rs31251 chr5 130833946 C T 1.01E-04 Multiple complex diseases RAPGEF6 intron 17554300 rs7720194 chr5 130837077 T C 2.37E-05 Crohn's disease RAPGEF6 intron 17804789 rs4705890 chr5 130855000 T C 2.32E-05 Crohn's disease RAPGEF6 intron 17804789 rs3776013 chr5 130867404 C T 2.42E-05 Crohn's disease RAPGEF6 intron 17804789 rs994453 chr5 130872520 T G 2.05E-05 Crohn's disease RAPGEF6 intron 17804789 rs3776006 chr5 130875538 C T 2.10E-05 Crohn's disease RAPGEF6 intron 17804789 rs17671387 chr5 130883996 T A,C,G 0.000052 Asthma RAPGEF6 intron 22694930 rs984616 chr5 130891101 C T 7.10E-06 Crohn's disease RAPGEF6 intron 17804789 rs9327616 chr5 130902196 C T 2.77E-05 Crohn's disease RAPGEF6 intron 17804789 rs8180462 chr5 130907189 T C 2.67E-05 Crohn's disease RAPGEF6 intron 17804789 rs11750704 chr5 130911578 C A 4.25E-05 Crohn's disease RAPGEF6 intron 17804789 rs9687376 chr5 130918037 A C 2.77E-05 Crohn's disease RAPGEF6 intron 17804789 rs2021774 chr5 130920831 G A 5.36E-05 Crohn's disease RAPGEF6 intron 17804789 rs3756291 chr5 130926822 T C 6.15E-06 Crohn's disease RAPGEF6 intron 17804789 rs11242084 chr5 130935777 T C 2.71E-05 Crohn's disease RAPGEF6 intron 17804789 rs1422870 chr5 130942624 G T 1.13E-05 Crohn's disease RAPGEF6 intron 17804789 rs3756290 chr5 130951750 A G 8.13E-06 Crohn's disease RAPGEF6 intron 17804789 rs3776001 chr5 130957992 T A 2.13E-05 Crohn's disease RAPGEF6 intron 17804789 rs6872682 chr5 130966026 T C 3.13E-05 Crohn's disease RAPGEF6 intron 17804789 rs3756289 chr5 130982194 A G 2.64E-05 Crohn's disease FNIP1 intron 17804789 rs26003 chr5 130990384 T C 2.64E-05 Crohn's disease FNIP1 intron 17804789 rs27450 chr5 131006082 A G 2.38E-05 Crohn's disease FNIP1 intron 17804789 rs26010 chr5 131013815 G A 2.73E-05 Crohn's disease FNIP1 intron 17804789 rs32112 chr5 131048122 G A 1.82E-05 Crohn's disease FNIP1 intron 17804789 rs548635 chr5 131055546 T G 2.68E-05 Crohn's disease FNIP1 intron 17804789 rs10051003 chr5 131072410 C T 2.10E-05 Crohn's disease FNIP1 intron 17804789 rs4705893 chr5 131075921 C T 0.0000449 Asthma FNIP1 intron 22694930 rs1019122 chr5 131099227 C T 2.22E-05 Crohn's disease FNIP1 intron 17804789 rs3775992 chr5 131107381 T G 1.92E-05 Crohn's disease FNIP1 intron 17804789 rs10042334 chr5 131114979 A T 2.07E-05 Crohn's disease FNIP1 intron 17804789 rs9327621 chr5 131118943 T C 2.04E-05 Crohn's disease FNIP1 intron 17804789 rs3756287 chr5 131135478 A G 2.37E-05 Crohn's disease / / 17804789 rs4705901 chr5 131146993 T C 8.41E-06 Crohn's disease LOC100505572 intron 17804789 rs11242095 chr5 131152575 T C 2.07E-05 Crohn's disease LOC100505572 intron 17804789 rs2133706 chr5 131165216 T G 2.07E-05 Crohn's disease LOC100505572 intron 17804789 rs10069521 chr5 131174215 A G 1.86E-05 Crohn's disease LOC100505572 intron 17804789 rs1875176 chr5 131202457 G A 2.07E-05 Crohn's disease / / 17804789 rs113905823 chr5 131258378 A AC 8.55E-06 Crohn's disease LOC728637 intron 17804789 rs630044 chr5 131258378 A C 8.55E-06 Crohn's disease LOC728637 intron 17804789 rs578637 chr5 131267609 G A 2.03E-05 Crohn's disease LOC728637 intron 17804789 rs519240 chr5 131269453 G A 2.10E-05 Crohn's disease LOC728637 intron 17804789 rs667437 chr5 131275509 G A 2.07E-05 Crohn's disease LOC728637 intron 17804789 rs648304 chr5 131286708 T C 8.09E-06 Crohn's disease ACSL6 UTR-3 17804789 rs40819 chr5 131305384 G T 1.84E-05 Crohn's disease ACSL6 intron 17804789 rs2240525 chr5 131315884 G A 5.27E-06 Schizophrenia ACSL6 intron 21747397 rs399714 chr5 131318788 C T 2.44E-05 Crohn's disease ACSL6 intron 17804789 rs17132288 chr5 131336105 C T 2.38E-06 Multiple complex diseases ACSL6 intron 17554300 rs440970 chr5 131336287 T G 9.68E-04 Multiple complex diseases ACSL6 intron 17554300 rs7714191 chr5 131341541 G C 7.20E-05 Multiple complex diseases ACSL6 intron 17554300 rs10040809 chr5 131343017 A C 6.41E-06 Crohn's disease ACSL6 intron 17804789 rs246998 chr5 131348878 A G 8.63E-05 Crohn's disease ACSL6 nearGene-5 17804789 rs555662 chr5 131350903 G A 9.64E-05 Crohn's disease / / 17804789 rs3914026 chr5 131353059 G A 1.10E-05 Urinary metabolites / / 21572414 rs17132324 chr5 131363979 A G 2.91E-05 Crohn's disease / / 17804789 rs3916442 chr5 131369168 G A 2.10E-09 Crohn's disease / / 17804789 rs10074987 chr5 131370712 G A 7.00E-05 Malaria / / 19465909 rs1858074 chr5 131371999 A G 8.97E-07 Crohn's disease / / 17804789 rs7728344 chr5 131379656 C T 3.29E-07 Crohn's disease / / 17804789 rs2073506 chr5 131394738 C T 1.22E-05 Bipolar disorder / / 20451256 rs2073506 chr5 131394738 C T 0.000069 Asthma / / 22694930 rs181781 chr5 131395115 G A 8.46E-06 Bipolar disorder / / 20451256 rs31481 chr5 131397202 G A 4.13E-06 Crohn's disease IL3 intron 17804789 rs246844 chr5 131401334 G A 1.41E-06 Crohn's disease / / 17804789 rs246844 chr5 131401334 G A 1.99E-04 Taste perception / / 22132133 rs246841 chr5 131402186 C T 2.26E-05 Bipolar disorder / / 20451256 rs3091338 chr5 131402738 C T 4.00E-08 Crohn's disease / / 22412388 rs31474 chr5 131405027 T C 2.91E-05 Crohn's disease / / 17804789 rs25879 chr5 131407044 A G 0.0000645 Asthma / / 22694930 rs3864277 chr5 131420249 G A 1.17E-06 Crohn's disease / / 17804789 rs657075 chr5 131430118 G A 3.00E-10 Rheumatoid arthritis / / 22446963 rs657075 chr5 131430118 G A 6.00E-06 Rheumatoid arthritis / / 24390342 rs657075 chr5 131430118 G A 8.00E-07 Rheumatoid arthritis / / 24390342 rs39897 chr5 131436896 C T 3.74E-04 Type 2 diabetes / / 17463246 rs27437 chr5 131436961 A G 4.25E-05 Type 2 diabetes / / 17463246 rs27437 chr5 131436961 A G 1.41E-05 Multiple complex diseases / / 17554300 rs247008 chr5 131447104 A G 8.32E-04 Multiple complex diseases / / 17554300 rs246836 chr5 131459972 G A 8.70E-05 Sarcoidosis / / 19165924 rs246835 chr5 131474025 T C 2.97E-04 Bipolar disorder / / 18317468 rs246835 chr5 131474025 T C 1.18E-04 Sarcoidosis / / 19165924 rs115545556 chr5 131479497 C T 5.00E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs715285 chr5 131485383 A G 2.28E-05 Type 2 diabetes / / 17463246 rs715285 chr5 131485383 A G 2.16E-05 Multiple complex diseases / / 17554300 rs156031 chr5 131526190 A G 1.90E-04 Myasthenia gravis / / 23055271 rs2278398 chr5 131530441 A G 3.55E-05 Type 2 diabetes P4HA2 intron 17463246 rs2278398 chr5 131530441 A G 1.83E-05 Multiple complex diseases P4HA2 intron 17554300 rs4361509 chr5 131536753 G A 7.56E-05 Type 2 diabetes P4HA2 intron 17463246 rs4361509 chr5 131536753 G A 1.94E-05 Multiple complex diseases P4HA2 intron 17554300 rs3792894 chr5 131547271 G A 4.12E-05 Type 2 diabetes P4HA2 intron 17463246 rs3792894 chr5 131547271 G A 1.95E-05 Multiple complex diseases P4HA2 intron 17554300 rs2077380 chr5 131568617 T C 1.80E-05 Multiple complex diseases / / 17554300 rs9791170 chr5 131569627 T C 5.10E-07 Hypertension / / 19609347 rs2405271 chr5 131573393 G C 1.43E-05 Multiple complex diseases / / 17554300 rs907368 chr5 131573981 T A 1.27E-05 Multiple complex diseases / / 17554300 rs12521097 chr5 131575338 G A 1.00E-07 Crohn's disease / / 17804789 rs2136187 chr5 131577894 T C 1.88E-05 Crohn's disease / / 17804789 rs4705928 chr5 131578637 C T 7.11E-05 Hypertension / / 19609347 rs10900805 chr5 131580851 G A 3.04E-04 Multiple complex diseases / / 17554300 rs3844312 chr5 131582356 C T 1.10E-07 Crohn's disease / / 17804789 rs3763112 chr5 131586480 A G 1.79E-05 Crohn's disease / / 17804789 rs4594848 chr5 131586598 C A 7.35E-05 Neuroblastoma / / pha002895 rs7727544 chr5 131590534 C T 7.00E-16 Blood metabolite levels / / 24816252 rs162904 chr5 131595784 T C 3.03E-04 Fibrinogen PDLIM4 intron 17255346 rs7737937 chr5 131614981 G A 3.47E-04 Fibrinogen / / 17255346 rs162899 chr5 131615593 A G 1.41E-04 Fibrinogen / / 17255346 rs7721296 chr5 131615966 T C 0.0000761 Asthma / / 22694930 rs162889 chr5 131624386 C T 3.01E-05 ldl cholesterol / / pha003076 rs419291 chr5 131633355 T C 3.00E-18 Blood metabolite levels SLC22A4 intron 24816252 rs3792880 chr5 131644965 G T 4.32E-04 Multiple complex diseases SLC22A4 intron 17554300 rs13179900 chr5 131647590 G A 8.29E-04 Multiple complex diseases SLC22A4 intron 17554300 rs11568510 chr5 131647954 A G 1 Drug response to Betaine SLC22A4 missense 19940846 rs270607 chr5 131649186 A G 2.00E-08 Fibrinogen SLC22A4 intron 20978265 rs2073838 chr5 131649222 G A 0.00000129 Asthma SLC22A4 intron 22694930 rs2073838 chr5 131649222 G A 9.35E-04 Tourette syndrome SLC22A4 intron 22889924 rs11568500 chr5 131649424 G A 1 Drug response to Betaine SLC22A4 missense 19940846 rs3792884 chr5 131651261 A G 8.92E-05 Multiple complex diseases SLC22A4 intron 17554300 rs11950562 chr5 131652529 A C 2.00E-41 Blood metabolite levels SLC22A4 intron 24816252 rs11950562 chr5 131652529 A C 7.00E-11 Blood metabolite levels SLC22A4 intron 24816252 rs11950562 chr5 131652529 A C 3.88E-05 Neuroblastoma SLC22A4 intron pha002895 rs11739484 chr5 131656760 A G 4.70E-04 Alcohol dependence SLC22A4 intron 20201924 rs273914 chr5 131660431 A T 3.00E-11 Blood metabolite levels SLC22A4 intron 24816252 rs273913 chr5 131661156 T C 8.49E-04 Alzheimer's disease SLC22A4 intron 17998437 rs273913 chr5 131661156 T C 1.00E-25 Blood metabolite levels SLC22A4 intron 24816252 rs11568503 chr5 131662989 C T 1 Drug response to Betaine SLC22A4 STOP-GAIN 19940846 rs272893 chr5 131663062 T C 1.93E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SLC22A4 missense 24023788 rs272889 chr5 131665378 A G 4.33E-04 Alzheimer's disease SLC22A4 intron 17998437 rs272889 chr5 131665378 A G 7.90E-15 Serum metabolites SLC22A4 intron 20037589 rs272889 chr5 131665378 A G 7.00E-16 Metabolic traits SLC22A4 intron 21886157 rs272889 chr5 131665378 A G 3.00E-51 Blood metabolite ratios SLC22A4 intron 24816252 rs272888 chr5 131665423 T C 4.79E-07 Crohn's disease SLC22A4 intron 17804789 rs272887 chr5 131665713 A G 5.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC22A4 intron 20877124 rs3792892 chr5 131665877 G A 1.00E-04 Cognitive impairment induced by topiramate SLC22A4 intron 22091778 rs273909 chr5 131667353 A G 0.000000914 Coronary artery disease (CAD) (males) SLC22A4 intron 23202125 rs273909 chr5 131667353 A G 0.0000558 Coronary artery disease (CAD) age >50 SLC22A4 intron 23202125 rs273909 chr5 131667353 A G 0.00036 LDL cholesterol SLC22A4 intron 23202125 rs273909 chr5 131667353 A G 9.62E-10 Coronary artery disease SLC22A4 intron 23202125 rs2304081 chr5 131667548 G A 3.65E-04 Multiple complex diseases SLC22A4 intron 17554300 rs12777 chr5 131671662 C G 1.00E-06 Fibrinogen SLC22A4 cds-synon 20031577 rs12777 chr5 131671662 C G 1.00E-06 Fibrinogen SLC22A4 cds-synon 20031577 rs272873 chr5 131675408 G A 2.00E-04 Cognitive impairment induced by topiramate SLC22A4 intron 22091778 rs2306772 chr5 131675981 C T 0.00000217 Asthma SLC22A4 intron 22694930 rs2306772 chr5 131675981 C T 9.17E-04 Tourette syndrome SLC22A4 intron 22889924 rs1050152 chr5 131676320 C T 2.14E-07 Crohn's disease SLC22A4 missense 17804789 rs1050152 chr5 131676320 C T 1.54E-06 Crohn's disease SLC22A4 missense 18587394 rs1050152 chr5 131676320 C T 1 Drug response to Gabapentin SLC22A4 missense 19940846 rs272869 chr5 131677997 A G 1.00E-11 Blood metabolite levels SLC22A4 intron 24816252 rs10058074 chr5 131686146 G A 4.00E-12 Height LOC553103 intron 23563607 rs4705938 chr5 131694077 T C 2.88E-08 Multiple complex diseases LOC553103 intron 17554300 rs273901 chr5 131694360 G T 5.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC553103 intron 20877124 rs274546 chr5 131699867 A G 7.00E-16 Height LOC553103 intron 20881960 rs2631367 chr5 131705458 C G 1 Drug response to L-Carnitine SLC22A5 UTR-5 19940846 rs11568520 chr5 131705715 C G 1 Drug response to L-Carnitine SLC22A5 missense 19940846 rs10040427 chr5 131714106 C T 1.19E-04 Multiple complex diseases SLC22A5 missense 17554300 rs274567 chr5 131714409 C T 9.67E-04 Alzheimer's disease SLC22A5 intron 17998437 rs274567 chr5 131714409 C T 3.00E-12 Blood metabolite levels SLC22A5 intron 24816252 rs17622208 chr5 131717050 G A 1.30E-07 Height SLC22A5 intron 21194676 rs17622208 chr5 131717050 G A 3.20E-12 Height SLC22A5 intron 21194676 rs274559 chr5 131720070 A G 3.81E-06 Plasma omega-6 polyunsaturated fatty acid levels SLC22A5 intron 24823311 rs274558 chr5 131721174 A G 3.66E-06 Plasma omega-6 polyunsaturated fatty acid levels SLC22A5 cds-synon 24823311 rs274557 chr5 131721204 T C 4.00E-06 Plasma omega-6 polyunsaturated fatty acid levels SLC22A5 intron 24823311 rs7731390 chr5 131721749 C G 2.00E-06 IgG glycosylation SLC22A5 intron 23382691 rs7731390 chr5 131721749 C G 3.00E-06 IgG glycosylation SLC22A5 intron 23382691 rs17689550 chr5 131723065 C T 7.90E-04 Alcohol dependence SLC22A5 intron 20201924 rs2073643 chr5 131723288 T C 2.00E-07 Asthma SLC22A5 intron 20860503 rs2073643 chr5 131723288 T C 9.31E-07 Fibrinogen SLC22A5 intron 20978265 rs2073643 chr5 131723288 T C 2.20E-07 Asthma SLC22A5 intron 21907864 rs2073643 chr5 131723288 T C 2.20E-07 Asthma SLC22A5 intron 22561531 rs2073643 chr5 131723288 T C 1.40E-05 Asthma (childhood,severe) SLC22A5 intron 24241537 rs274554 chr5 131724950 T C 1.35E-07 Multiple complex diseases SLC22A5 intron 17554300 rs274552 chr5 131727346 G C 2.03E-07 Multiple complex diseases SLC22A5 intron 17554300 rs274551 chr5 131727680 T C 5.50E-05 Alcohol and nictotine co-dependence SLC22A5 intron 20158304 rs11568513 chr5 131728298 G A 1 Drug response to L-Carnitine SLC22A5 missense 19940846 rs274547 chr5 131731304 A T 1.20E-07 Multiple complex diseases SLC22A5 UTR-3 17554300 rs2405522 chr5 131741696 A G 4.00E-29 Blood metabolite levels / / 24816252 rs6596075 chr5 131742228 G C 3.00E-06 Crohn's disease / / 17554300 rs1016988 chr5 131744574 T C 1.00E-12 Fibrinogen / / 20031577 rs1016988 chr5 131744574 T C 8.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10071051 chr5 131752620 G A 4.99E-05 Pulmonary function C5orf56 intron 20010835 rs10071051 chr5 131752620 G A 1.94E-05 Eosinophil counts C5orf56 intron pha003088 rs1003533 chr5 131755651 C T 9.55E-09 Longevity,exceptional C5orf56 intron 20595579 rs2285673 chr5 131755969 C T 5.27E-07 Multiple complex diseases C5orf56 intron 17554300 rs2285673 chr5 131755969 C T 2.67E-05 Pulmonary function C5orf56 intron 20010835 rs11242111 chr5 131756058 A G 2.00E-21 Fibrinogen C5orf56 intron 23969696 rs10076733 chr5 131760731 G T 5.33E-05 Pulmonary function C5orf56 intron 20010835 rs2106854 chr5 131769174 C T 2.00E-48 Fibrinogen C5orf56 intron 23969696 rs2158101 chr5 131769273 G A 5.75E-05 Pulmonary function C5orf56 intron 20010835 rs2188962 chr5 131770805 C T 2.00E-18 Crohn's disease C5orf56 intron 18587394 rs2188962 chr5 131770805 C T 1.00E-07 Crohn's disease C5orf56 intron 20570966 rs2188962 chr5 131770805 C T 2.00E-18 Asthma C5orf56 intron 21150878 rs2188962 chr5 131770805 C T 2.32E-18 Multiple sclerosis C5orf56 intron 22190364 rs2188962 chr5 131770805 C T 1.00E-52 Inflammatory bowel disease C5orf56 intron 23128233 rs11741543 chr5 131771315 G T 6.56E-05 Pulmonary function C5orf56 intron 20010835 rs10062371 chr5 131778413 G A 8.29E-05 Pulmonary function C5orf56 intron 20010835 rs6874639 chr5 131778716 A G 4.30E-20 Fibrinogen C5orf56 intron 20978265 rs11744116 chr5 131779760 C T 8.89E-08 Multiple complex diseases C5orf56 intron 17554300 rs11744116 chr5 131779760 C T 9.52E-05 Pulmonary function C5orf56 intron 20010835 rs4540166 chr5 131779857 T C 8.31E-08 Multiple complex diseases C5orf56 intron 17554300 rs4540166 chr5 131779857 T C 9.28E-05 Pulmonary function C5orf56 intron 20010835 rs4371745 chr5 131779955 T C 1.15E-07 Multiple complex diseases C5orf56 intron 17554300 rs4371745 chr5 131779955 T C 9.29E-05 Pulmonary function C5orf56 intron 20010835 rs4235802 chr5 131782837 C A 9.42E-05 Pulmonary function C5orf56 intron 20010835 rs7703152 chr5 131783213 C T 9.17E-05 Pulmonary function C5orf56 intron 20010835 rs12521868 chr5 131784393 G T 1.00E-20 Crohn's disease C5orf56 intron 21102463 rs10036896 chr5 131785178 C T 6.73E-05 Pulmonary function C5orf56 intron 20010835 rs10069798 chr5 131788421 T A 6.00E-05 Pulmonary function C5orf56 intron 20010835 rs2706395 chr5 131796803 A T 0.0000486 Polycystic ovary syndrome C5orf56 UTR-3 22951595 rs2706395 chr5 131796803 A T 4.86E-05 Intracranial aneurysm C5orf56 UTR-3 22961961 rs11745587 chr5 131796922 G A 5.95E-06 IgE levels C5orf56 UTR-3 22075330 rs11745587 chr5 131796922 G A 2.00E-06 Asthma C5orf56 UTR-3 22561531 rs6894249 chr5 131797547 A G 1.43E-05 IgE levels C5orf56 UTR-3 22075330 rs6894249 chr5 131797547 A G 9.73E-10 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) C5orf56 UTR-3 23603761 rs2522051 chr5 131797578 T C 6.90E-04 Type 2 diabetes C5orf56 UTR-3 17463246 rs10077785 chr5 131801158 C T 2.25E-09 Multiple complex diseases C5orf56 intron 17554300 rs10077785 chr5 131801158 C T 5.31E-05 Pulmonary function C5orf56 intron 20010835 rs2522056 chr5 131801726 G A 1.00E-15 Fibrinogen C5orf56 intron 20031576 rs2522057 chr5 131801947 G C 1.62E-11 Multiple complex diseases C5orf56 intron 17554300 rs2522057 chr5 131801947 G C 3.16E-08 Crohn's disease C5orf56 intron 17804789 rs2522057 chr5 131801947 G C 3.94E-04 Lymphocyte counts C5orf56 intron 22286170 rs10067603 chr5 131803868 A G 4.54E-05 Pulmonary function C5orf56 intron 20010835 rs2248116 chr5 131804347 C A 3.16E-08 Crohn's disease C5orf56 intron 17804789 rs10039559 chr5 131804507 T C 4.48E-05 Pulmonary function C5orf56 intron 20010835 rs2706379 chr5 131805735 C T 3.73E-04 Fibrinogen C5orf56 intron 17255346 rs3846729 chr5 131806768 G C 5.90E-05 Pulmonary function C5orf56 intron 20010835 rs3846730 chr5 131806780 C T 5.88E-05 Pulmonary function C5orf56 intron 20010835 rs2057657 chr5 131809316 A G 5.96E-05 Pulmonary function C5orf56 intron 20010835 rs4705862 chr5 131813219 A T 1.02E-08 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) C5orf56 intron 23603761 rs4705862 chr5 131813219 A T 4.46E-10 Oligoarticular juvenile idiopathic arthritis C5orf56 intron 23603761 rs17715481 chr5 131815384 A G 2.17E-05 Sudden cardiac arrest C5orf56 intron 21658281 rs10072700 chr5 131816903 A C 4.58E-04 Multiple complex diseases C5orf56 intron 17554300 rs6873426 chr5 131818631 G T 2.10E-10 Fibrinogen IRF1 UTR-3 20978265 rs2070729 chr5 131819921 C A 1.00E-10 Platelet counts IRF1 intron 22139419 rs2549003 chr5 131829297 G A 9.00E-07 Asthma (sex interaction) / / 24824216 rs2548999 chr5 131831058 G T 3.27E-05 Multiple complex diseases / / 17554300 rs736801 chr5 131833599 C T 1.69E-06 Crohn's disease / / 17804789 rs2548997 chr5 131835395 G A 4.56E-05 Multiple complex diseases / / 17554300 rs2548997 chr5 131835395 G A 1.82E-04 Arthritis (juvenile idiopathic) / / 22354554 rs4705952 chr5 131839618 G A 1.00E-08 C-reactive protein / / 21300955 rs4143832 chr5 131862977 T G 1.00E-10 Eosinophil counts / / 19198610 rs2706399 chr5 131867702 A G 2.18E-06 Fibrinogen / / 20978265 rs2706399 chr5 131867702 A G 2.10E-06 Coronary heart disease / / 21966275 rs2706399 chr5 131867702 A G 6.65E-06 Coronary heart disease / / 21966275 rs17690122 chr5 131867835 A G 1.79E-10 Fibrinogen / / 20978265 rs743562 chr5 131872383 C T 8.05E-09 Fibrinogen / / 20978265 rs2069807 chr5 131880722 G A 0.00000157 Cholesterol,total / / 23063622 rs2244012 chr5 131901225 A G 3.55E-04 Fibrinogen RAD50 intron 17255346 rs2244012 chr5 131901225 A G 3.00E-07 Asthma RAD50 intron 20159242 rs2244012 chr5 131901225 A G 8.94E-04 Osteosarcoma RAD50 intron 23727862 rs2706346 chr5 131904757 G A 6.98E-25 Narcolepsy RAD50 intron 19629137 rs2706347 chr5 131905117 G T 2.12E-05 Serum metabolites RAD50 intron 19043545 rs2897443 chr5 131929594 G T 3.08E-04 Fibrinogen RAD50 intron 17255346 rs2897443 chr5 131929594 G T 2.74E-06 Asthma RAD50 intron 20159242 rs2897443 chr5 131929594 G T 1.47E-06 Asthma RAD50 intron 20860503 rs2897443 chr5 131929594 G T 8.95E-13 Atopic dermatitis RAD50 intron 23886662 rs17166063 chr5 131930026 G C 1.35E-04 Multiple complex diseases RAD50 intron 17554300 rs17622991 chr5 131932753 G A 0.0000107 Asthma RAD50 intron 23666277 rs2522395 chr5 131945913 C G 4.09E-04 Multiple complex diseases RAD50 intron 17554300 rs7709318 chr5 131951235 T C 3.91E-04 Multiple complex diseases RAD50 intron 17554300 rs17772565 chr5 131952405 C T 9.56E-05 Fibrinogen RAD50 intron 17255346 rs17772583 chr5 131953510 A G 2.58E-23 Coronary heart disease RAD50 intron 21966275 rs3798135 chr5 131965109 C T 4.65E-04 Fibrinogen RAD50 intron 17255346 rs3798135 chr5 131965109 C T 9.29E-05 Serum metabolites RAD50 intron 19043545 rs6871536 chr5 131969874 T C 2.58E-04 Fibrinogen RAD50 intron 17255346 rs6871536 chr5 131969874 T C 9.03E-07 Asthma RAD50 intron 20159242 rs6871536 chr5 131969874 T C 1.81E-07 Asthma RAD50 intron 20860503 rs6871536 chr5 131969874 T C 2.40E-09 Asthma RAD50 intron 21907864 rs6871536 chr5 131969874 T C 2.11E-15 Atopic dermatitis RAD50 intron 23886662 rs6871536 chr5 131969874 T C 8.00E-07 Asthma (childhood,severe) RAD50 intron 24241537 rs2040704 chr5 131973177 A G 4.00E-08 IgE levels RAD50 intron 18846228 rs2040704 chr5 131973177 A G 6.61E-05 Serum metabolites RAD50 intron 19043545 rs7737470 chr5 131974063 T A 2.72E-04 Fibrinogen RAD50 intron 17255346 rs7737470 chr5 131974063 T A 9.15E-05 Serum metabolites RAD50 intron 19043545 rs2240032 chr5 131977127 C T 9.74E-05 Fibrinogen RAD50 intron 17255346 rs2240032 chr5 131977127 C T 3.47E-07 Asthma RAD50 intron 20860503 rs2158177 chr5 131984058 A G 9.00E-08 Fibrinogen / / 20978265 rs2158177 chr5 131984058 A G 9.31E-06 IgE levels / / 22075330 rs2158177 chr5 131984058 A G 5.90E-11 Atopic dermatitis / / 23886662 rs3091307 chr5 131989136 A G 1.32E-08 Fibrinogen / / 20978265 rs1295687 chr5 131994462 C G 2.10E-05 Urinary metabolites IL13 intron 21572414 rs1295686 chr5 131995843 T C 1.00E-07 Asthma IL13 intron 20860503 rs1295686 chr5 131995843 T C 1.40E-07 Asthma IL13 intron 21907864 rs1295686 chr5 131995843 T C 3.55E-08 IgE levels IL13 intron 22075330 rs1295686 chr5 131995843 T C 1.40E-07 Asthma IL13 intron 22561531 rs1295686 chr5 131995843 T C 2.00E-06 Atopic dermatitis IL13 intron 23042114 rs1295686 chr5 131995843 T C 1.73E-06 Self-reported allergy IL13 intron 23817569 rs1295686 chr5 131995843 T C 2.00E-17 Atopic dermatitis IL13 intron 23886662 rs1295686 chr5 131995843 T C 2.00E-06 Asthma (childhood,severe) IL13 intron 24241537 rs1295686 chr5 131995843 T C 1.37E-05 Height IL13 intron pha003010 rs1295686 chr5 131995843 T C 1.58E-05 Height IL13 intron pha003011 rs20541 chr5 131995964 A G 5.00E-15 Psoriasis IL13 missense 19169254 rs20541 chr5 131995964 A G 1.24E-06 Asthma IL13 missense 20860503 rs20541 chr5 131995964 A G 5.00E-15 Psoriasis IL13 missense 20953187 rs20541 chr5 131995964 A G 3.00E-18 IgE levels IL13 missense 22075330 rs20541 chr5 131995964 A G 5.00E-15 Multiple sclerosis IL13 missense 22190364 rs20541 chr5 131995964 A G 1.00E-08 Hodgkin's lymphoma IL13 missense 22286212 rs20541 chr5 131995964 A G 0.000417 Asthma IL13 missense 22694930 rs20541 chr5 131995964 A G 1.00E-06 Self-reported allergy IL13 missense 23817569 rs20541 chr5 131995964 A G 1.79E-08 Atopic dermatitis IL13 missense 23886662 rs20541 chr5 131995964 A G 1.93E-14 Atopic dermatitis IL13 missense 23886662 rs20541 chr5 131995964 A G 1.00E-10 Hodgkin's lymphoma IL13 missense 24920014 rs20541 chr5 131995964 A G 9.40E-05 Height IL13 missense pha003010 rs1295685 chr5 131996445 A G 8.93E-08 IgE levels IL13 UTR-3 22075330 rs1295685 chr5 131996445 A G 3.40E-10 Psoriasis IL13 UTR-3 23143594 rs1295685 chr5 131996445 A G 1.53E-06 Self-reported allergy IL13 UTR-3 23817569 rs1295685 chr5 131996445 A G 4.94E-09 Atopic dermatitis IL13 UTR-3 23886662 rs848 chr5 131996500 A C 9.01E-08 IgE levels IL13 UTR-3 22075330 rs848 chr5 131996500 A C 1.67E-06 Self-reported allergy IL13 UTR-3 23817569 rs847 chr5 131996669 T C 7.60E-08 IgE levels IL13 UTR-3 22075330 rs847 chr5 131996669 T C 3.23E-06 Self-reported allergy IL13 UTR-3 23817569 rs2069757 chr5 131998413 G A 8.46E-05 IgE levels / / 22075330 rs2069757 chr5 131998413 G A 2.00E-11 Hodgkin's lymphoma / / 24920014 rs2243297 chr5 131999171 T A 2.50E-04 HDL particle features / / 21283740 rs2243297 chr5 131999171 T A 7.19E-05 IgE levels / / 22075330 rs2243204 chr5 131999494 C T 1.30E-05 Atopic dermatitis / / 23886662 rs2243218 chr5 132002024 G A 1.80E-04 Fibrinogen / / 17255346 rs2227284 chr5 132012725 T G 2.70E-04 Type 2 diabetes IL4 intron 17463246 rs2227282 chr5 132013179 C G 8.70E-04 Type 2 diabetes IL4 intron 17463246 rs2243290 chr5 132018169 C A 3.97E-04 Multiple complex diseases IL4 intron 17554300 rs2023822 chr5 132034346 A G 6.31E-04 Alzheimer's disease KIF3A intron 17998437 rs17691077 chr5 132043351 A C 2.46E-06 Serum albumin level KIF3A intron pha003084 rs2897442 chr5 132049027 C T 4.00E-08 Atopic dermatitis KIF3A intron 22197932 rs2897442 chr5 132049027 C T 1.18E-04 Atopic dermatitis KIF3A intron 23886662 rs30523 chr5 132111043 G A 0.0000152 Uterine leiomyomata SEPT8 intron 23040493 rs803137 chr5 132132647 A G 4.79E-04 Multiple complex diseases / / 17554300 rs10070396 chr5 132454440 C G 7.10E-07 Urinary metabolites / / 21572414 rs6876812 chr5 132456186 C A 8.21E-04 Type 2 diabetes / / 17463246 rs1428150 chr5 132490807 A G 5.12E-04 Lymphocyte counts / / 22286170 rs13178251 chr5 132495185 A G 3.13E-04 Cognitive decline / / 23732972 rs4958165 chr5 132515495 G C 1.30E-05 Urinary metabolites / / 21572414 rs3798104 chr5 132534021 C T 5.30E-06 Urinary metabolites FSTL4 UTR-3 21572414 rs720622 chr5 132536038 A G 8.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FSTL4 intron 20877124 rs2162769 chr5 132540109 T C 6.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FSTL4 intron 20877124 rs2162769 chr5 132540109 T C 6.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FSTL4 intron 20877124 rs2162769 chr5 132540109 T C 8.90E-06 Urinary metabolites FSTL4 intron 21572414 rs2303671 chr5 132559950 T G 4.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FSTL4 intron 20877124 rs1017307 chr5 132578203 G A 5.01E-04 Myocardial Infarction FSTL4 intron pha002873 rs9327649 chr5 132588357 T C 9.93E-05 Schizophrenia FSTL4 intron 19571811 rs6874556 chr5 132591531 G C 5.00E-05 Anger FSTL4 intron 24489884 rs6876130 chr5 132600339 T C 6.83E-06 Coronary arterial lesions in patients with Kawasaki disease FSTL4 intron 23677057 rs6596118 chr5 132626997 T C 6.20E-05 Insulin Resistance FSTL4 intron pha003062 rs17166496 chr5 132628884 G C 5.00E-06 Type 1 diabetes FSTL4 intron 17554300 rs733023 chr5 132655625 A G 2.68E-05 Asthma FSTL4 intron pha003128 rs114491858 chr5 132656091 G A 5.89E-06 Intracerebral hemorrhage FSTL4 intron 24656865 rs114491858 chr5 132656091 G A 7.11E-06 Intracerebral hemorrhage FSTL4 intron 24656865 rs17166584 chr5 132669374 G A 5.20E-05 Prostate cancer mortality FSTL4 intron 20978177 rs10515458 chr5 132669995 C A 1.39E-04 Prostate cancer mortality FSTL4 intron 20978177 rs17166592 chr5 132671786 T C 3.81E-04 Multiple complex diseases FSTL4 intron 17554300 rs13159148 chr5 132680491 T G 9.44E-05 Prostate cancer mortality FSTL4 intron 20978177 rs17166628 chr5 132690232 A G 6.00E-05 Prostate cancer mortality FSTL4 intron 20978177 rs10515460 chr5 132690433 T C 9.44E-05 Prostate cancer mortality FSTL4 intron 20978177 rs250858 chr5 132716935 A C 8.90E-05 Temporomandibular joint disorders FSTL4 intron 23746317 rs250856 chr5 132728928 C T 1.30E-05 Urinary metabolites FSTL4 intron 21572414 rs10060919 chr5 132763717 G C 2.66E-04 Type 2 diabetes FSTL4 intron 17463246 rs11740470 chr5 132766865 G A 7.16E-05 Cognitive impairment induced by topiramate FSTL4 intron 22091778 rs28335 chr5 132790478 T A 8.69E-04 Type 2 diabetes FSTL4 intron 17463246 rs27435 chr5 132791882 C T 8.69E-04 Type 2 diabetes FSTL4 intron 17463246 rs31344 chr5 132807148 G A 6.30E-08 Adiponectin levels FSTL4 intron 20887962 rs823994 chr5 132867270 G C 0.00000776 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment FSTL4 intron 23392654 rs823994 chr5 132867270 G C 7.76E-06 Thiazide-induced adverse metabolic effects in hypertensive patients FSTL4 intron 23400010 rs17166751 chr5 132867437 C T 3.80E-04 Fibrinogen FSTL4 intron 17255346 rs10479044 chr5 132895893 G A 3.49E-05 Hemoglobin FSTL4 intron pha003098 rs10479044 chr5 132895893 G A 1.05E-05 Erythrocyte counts FSTL4 intron pha003099 rs10479044 chr5 132895893 G A 3.19E-05 Erythrocyte counts FSTL4 intron pha003101 rs1552918 chr5 132900729 C T 5.61E-05 Erythrocyte counts FSTL4 intron pha003099 rs10491291 chr5 132916359 C T 4.82E-06 Bipolar disorder FSTL4 intron 21771265 rs256259 chr5 132917106 C T 2.35E-05 Hemoglobin FSTL4 intron pha003098 rs256259 chr5 132917106 C T 4.56E-06 Erythrocyte counts FSTL4 intron pha003099 rs256259 chr5 132917106 C T 9.21E-08 Erythrocyte counts FSTL4 intron pha003101 rs35724862 chr5 132918122 G A 9.61E-04 Type 2 diabetes FSTL4 intron 17463246 rs256263 chr5 132918549 C A 2.87E-05 Hemoglobin FSTL4 intron pha003098 rs256263 chr5 132918549 C A 6.12E-06 Erythrocyte counts FSTL4 intron pha003099 rs256263 chr5 132918549 C A 1.40E-07 Erythrocyte counts FSTL4 intron pha003101 rs369853 chr5 132929310 A G 3.78E-05 Erythrocyte counts FSTL4 intron pha003099 rs11948984 chr5 132930325 C T 5.75E-05 Hemoglobin FSTL4 intron pha003098 rs11948984 chr5 132930325 C T 1.59E-05 Erythrocyte counts FSTL4 intron pha003099 rs11948984 chr5 132930325 C T 2.19E-07 Erythrocyte counts FSTL4 intron pha003101 rs256249 chr5 132936076 T C 1.30E-05 Erythrocyte counts FSTL4 intron pha003099 rs256225 chr5 132974469 G T 8.11E-04 Alzheimer's disease / / 22005930 rs256229 chr5 132975474 G A 6.72E-04 Alzheimer's disease / / 22005930 rs256230 chr5 132975495 C G 7.02E-04 Alzheimer's disease / / 22005930 rs7706203 chr5 132996659 A C 5.22E-04 Acute lung injury / / 22295056 rs4958136 chr5 132998708 A G 6.74E-05 Acute lung injury / / 22295056 rs11242168 chr5 133003135 T C 1.00E-06 Asthma / / 21790008 rs11242168 chr5 133003135 T C 2.00E-06 Asthma / / 21790008 rs6865119 chr5 133003449 G T 1.00E-06 Asthma / / 21790008 rs6865119 chr5 133003449 G T 2.00E-06 Asthma / / 21790008 rs2215189 chr5 133005341 C T 8.80E-05 Parkinson's disease (age of onset) / / 19772629 rs2270088 chr5 133009547 C T 2.76E-04 Acute lung injury / / 22295056 rs758309 chr5 133017882 G A 2.67E-04 Schizophrenia / / 19197363 rs6596140 chr5 133021851 C T 9.00E-08 Hypertension / / 22384028 rs6596142 chr5 133021940 A G 5.95E-06 Hypertension / / 22384028 rs10751462 chr5 133023122 A G 2.90E-07 Urinary metabolites / / 21572414 rs10751462 chr5 133023122 A G 1.43E-04 Epilepsy / / 22116939 rs62373491 chr5 133027267 C T 2.30E-05 Intracerebral hemorrhage / / 24656865 rs12109241 chr5 133027986 A G 1.30E-05 Intracerebral hemorrhage / / 24656865 rs12110187 chr5 133028032 G C 1.30E-05 Intracerebral hemorrhage / / 24656865 rs6876108 chr5 133028324 A G 1.39E-05 Intracerebral hemorrhage / / 24656865 rs6596146 chr5 133028493 A G 1.30E-05 Intracerebral hemorrhage / / 24656865 rs7703486 chr5 133029003 T G 1.16E-05 Intracerebral hemorrhage / / 24656865 rs7721131 chr5 133029010 C A 1.23E-05 Intracerebral hemorrhage / / 24656865 rs10065215 chr5 133029538 A G 1.22E-05 Intracerebral hemorrhage / / 24656865 rs11242172 chr5 133030002 A G 1.21E-05 Intracerebral hemorrhage / / 24656865 rs62373493 chr5 133030698 T C 1.19E-05 Intracerebral hemorrhage / / 24656865 rs62373494 chr5 133030745 T C 1.19E-05 Intracerebral hemorrhage / / 24656865 rs60036598 chr5 133032032 T C 1.30E-05 Intracerebral hemorrhage / / 24656865 rs10515463 chr5 133032214 T C 1.16E-05 Intracerebral hemorrhage / / 24656865 rs4958096 chr5 133034165 T C 1.66E-05 Intracerebral hemorrhage / / 24656865 rs4958097 chr5 133034195 A T 2.13E-05 Intracerebral hemorrhage / / 24656865 rs10039028 chr5 133034752 C G 1.38E-05 Intracerebral hemorrhage / / 24656865 rs10039095 chr5 133034874 G A 1.71E-05 Intracerebral hemorrhage / / 24656865 rs11242174 chr5 133035170 G A 1.70E-05 Intracerebral hemorrhage / / 24656865 rs12186474 chr5 133035344 G A 1.70E-05 Intracerebral hemorrhage / / 24656865 rs12188071 chr5 133035435 A G 1.29E-05 Intracerebral hemorrhage / / 24656865 rs4958146 chr5 133036287 G A 1.69E-05 Intracerebral hemorrhage / / 24656865 rs4958147 chr5 133036637 G A 1.36E-05 Intracerebral hemorrhage / / 24656865 rs720770 chr5 133037459 C T 1.81E-04 Epilepsy / / 22116939 rs10065792 chr5 133038091 T C 1.18E-05 Intracerebral hemorrhage / / 24656865 rs6596147 chr5 133047775 T C 2.97E-05 Epilepsy / / 22116939 rs6870951 chr5 133064960 C T 2.50E-05 Kawasaki disease / / 22446962 rs9327668 chr5 133066805 C T 8.02E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7719165 chr5 133076898 G A 3.39E-04 Prostate cancer mortality / / 20978177 rs721077 chr5 133090197 C T 6.58E-04 Prostate cancer mortality / / 20978177 rs258067 chr5 133101508 C A 9.04E-04 Prostate cancer mortality / / 20978177 rs10061439 chr5 133115939 G A 1.48E-05 Orofacial clefts / / 22419666 rs17167044 chr5 133122844 T C 4.94E-04 Alzheimer's disease / / 22005930 rs3888616 chr5 133128648 A G 7.29E-04 Multiple complex diseases / / 17554300 rs6895072 chr5 133144207 C T 4.51E-04 Coronary heart disease / / 21971053 rs245583 chr5 133156721 A G 1.10E-05 Urinary metabolites / / 21572414 rs6596154 chr5 133160498 T C 9.50E-05 Basophils / / pha003087 rs2457174 chr5 133179080 C T 7.00E-08 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7719102 chr5 133190639 T G 1.89E-04 Prostate cancer mortality / / 20978177 rs4246020 chr5 133191011 C T 1.89E-04 Prostate cancer mortality / / 20978177 rs4958196 chr5 133195480 T C 9.31E-05 Body Mass Index / / pha003007 rs4958196 chr5 133195480 T C 5.99E-05 Weight / / pha003026 rs17518545 chr5 133197481 T G 2.42E-06 Glycemic traits (pregnancy) / / 23903356 rs17518545 chr5 133197481 T G 9.09E-06 Glycemic traits (pregnancy) / / 23903356 rs1644308 chr5 133199549 C T 9.62E-05 Cardiovascular disease / / pha003065 rs12515157 chr5 133202612 G A 8.91E-05 Body Mass Index / / pha003007 rs12515157 chr5 133202612 G A 9.76E-05 Weight / / pha003026 rs1644305 chr5 133203596 G A 8.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs4269328 chr5 133223816 T C 8.76E-04 Multiple complex diseases / / 17554300 rs731590 chr5 133224088 C T 6.99E-04 Prostate cancer mortality / / 20978177 rs731590 chr5 133224088 C T 3.27E-04 Alcohol dependence / / 21314694 rs903077 chr5 133224404 G A 9.36E-04 Prostate cancer mortality / / 20978177 rs1618181 chr5 133240927 A G 4.59E-04 Smoking initiation / / 24665060 rs3936585 chr5 133246615 C T 4.91E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2869178 chr5 133268881 C T 3.89E-05 Duodenal ulcer / / 22387998 rs13169435 chr5 133303819 C T 6.84E-04 Depression (quantitative trait) C5orf15 intron 20800221 rs10068191 chr5 133310248 T C 2.00E-04 Information processing speed VDAC1 intron 21130836 rs10491289 chr5 133328560 A G 9.07E-04 Alzheimer's disease VDAC1 intron 24755620 rs11954900 chr5 133333988 T C 9.61E-04 Alzheimer's disease VDAC1 intron 24755620 rs13357750 chr5 133384491 A G 7.44E-04 Alzheimer's disease / / 24755620 rs244689 chr5 133422816 A G 6.90E-05 Myasthenia gravis / / 23055271 rs244660 chr5 133434914 A G 1.65E-04 Age-related macular degeneration / / 22125219 rs756699 chr5 133446575 C T 6.00E-07 Multiple sclerosis / / 21833088 rs756699 chr5 133446575 C T 2.40E-04 Myasthenia gravis / / 23055271 rs244693 chr5 133455153 A C 1.07E-04 Age-related macular degeneration TCF7 intron 22125219 rs3867426 chr5 133463269 G A 3.05E-04 Aortic root size TCF7 intron 21223598 rs3867426 chr5 133463269 G A 2.34E-04 Response to cytidine analogues (gemcitabine) TCF7 intron 24483146 rs3776841 chr5 133514972 T G 1.42E-04 Age-related macular degeneration / / 22125219 rs10051026 chr5 133531449 C T 7.16E-05 Pulmonary function in asthmatics / / 23541324 rs13187105 chr5 133551445 T G 5.54E-05 Pulmonary function in asthmatics PPP2CA intron 23541324 rs34484624 chr5 133698224 T C 8.90E-05 HIV-1 control CDKL3 intron 20041166 rs4958233 chr5 133725148 T C 7.20E-04 Multiple complex diseases UBE2B intron 17554300 rs4637596 chr5 133730455 G A 3.65E-04 Smoking cessation / / 24665060 rs7701346 chr5 133828356 A G 3.46E-05 Kawasaki disease / / 22081228 rs1476096 chr5 133837021 A C 6.09E-04 Obesity (extreme) / / 21935397 rs1981627 chr5 133838180 A G 8.64E-04 Obesity (extreme) / / 21935397 rs10079478 chr5 133840796 T C 9.11E-04 Alcohol dependence / / 21314694 rs10079478 chr5 133840796 T C 1.01E-05 Odorant perception / / 23910658 rs4997055 chr5 133844545 T C 4.35E-04 Type 2 diabetes / / 17463246 rs6877546 chr5 133845112 T C 4.20E-04 Myasthenia gravis / / 23055271 rs6877546 chr5 133845112 T C 5.68E-05 Waist Circumference / / pha003023 rs1860059 chr5 133847179 C T 1.40E-04 Myasthenia gravis / / 23055271 rs13187289 chr5 133849177 C G 2.00E-10 Menarche (age at onset) / / 21102462 rs329122 chr5 133864599 G A 4.36E-05 Lung adenocarcinoma PHF15 intron 19836008 rs329125 chr5 133871101 C A 1.10E-04 Suicide attempts in bipolar disorder PHF15 intron 21423239 rs329302 chr5 133877677 G A 9.58E-04 Multiple complex diseases PHF15 intron 17554300 rs2569340 chr5 133881485 A G 9.17E-04 Heart Failure PHF15 intron pha002885 rs17167609 chr5 133883906 C A 5.28E-04 Suicide attempts in bipolar disorder PHF15 intron 21423239 rs12163993 chr5 133887780 G A 1.90E-05 Urinary metabolites PHF15 cds-synon 21572414 rs2084007 chr5 133891282 C T 5.43E-04 Suicide attempts in bipolar disorder PHF15 intron 21423239 rs4958190 chr5 133897000 C T 7.71E-04 Suicide attempts in bipolar disorder PHF15 intron 21423239 rs2569343 chr5 133897103 G A 7.56E-04 Suicide attempts in bipolar disorder PHF15 intron 21423239 rs329304 chr5 133897829 C T 7.45E-04 Suicide attempts in bipolar disorder PHF15 intron 21423239 rs329317 chr5 133903814 T C 3.55E-05 Tourette syndrome PHF15 intron 22889924 rs329319 chr5 133906609 A G 5.96E-05 Cognitive test performance PHF15 intron 20125193 rs4377750 chr5 133978909 A G 6.08E-04 Multiple complex diseases / / 17554300 rs29540 chr5 134152001 A C 5.44E-04 Multiple complex diseases DDX46 intron 17554300 rs7717860 chr5 134190225 C A 9.70E-05 Alcoholism (heaviness of drinking) C5orf24 intron 21529783 rs319598 chr5 134240235 T C 2.00E-06 Type 2 diabetes / / 24509480 rs319594 chr5 134250146 C T 6.51E-05 Response to acetaminophen (hepatotoxicity) PCBD2 intron 21177773 rs319590 chr5 134254788 G T 2.76E-05 Response to acetaminophen (hepatotoxicity) PCBD2 intron 21177773 rs10515465 chr5 134267557 G C 4.69E-05 Response to acetaminophen (hepatotoxicity) PCBD2 intron 21177773 rs12515798 chr5 134305197 C T 2.78E-06 Osteoarthritis CATSPER3 intron 22763110 rs299362 chr5 134321546 G A 3.00E-06 Bulimia nervosa CATSPER3 intron 23568457 rs526896 chr5 134356705 T G 2.00E-13 Height / / 20881960 rs526896 chr5 134356705 T G 9.00E-10 Height / / 23563607 rs3805663 chr5 134366200 A G 2.00E-08 Testicular germ cell tumor PITX1 intron 23666240 rs31198 chr5 134372685 T C 8.00E-06 Height / / 18391951 rs39881 chr5 134379311 C A 6.88E-04 Alzheimer's disease / / 24755620 rs2112186 chr5 134392420 G A 2.52E-05 Intelligence / / 21826061 rs1875957 chr5 134395125 A G 3.16E-05 Intelligence / / 21826061 rs13436118 chr5 134405161 G A 5.08E-05 Vascular dementia / / 22116812 rs254560 chr5 134443606 G A 1.00E-09 Ulcerative colitis / / 21297633 rs254560 chr5 134443606 G A 3.00E-09 Ulcerative colitis / / 23128233 rs254560 chr5 134443606 G A 4.96E-05 Anxiety in major depressive disorder / / 24047446 rs477687 chr5 134467700 G A 6.00E-06 AIDS progression / / 21502085 rs596342 chr5 134469185 T C 5.59E-05 Orofacial clefts / / 22419666 rs1559050 chr5 134470030 G A 1.28E-05 Colorectal cancer / / 21242260 rs11745068 chr5 134475494 G T 1.55E-05 Colorectal cancer / / 21242260 rs17716322 chr5 134477118 G C 6.70E-04 Type 2 diabetes / / 17463246 rs12652626 chr5 134483588 C T 6.39E-05 Type 2 diabetes and other traits / / 19734900 rs566750 chr5 134485285 G A 9.47E-06 Colorectal cancer / / 21242260 rs3909811 chr5 134488349 G T 1.59E-05 Colorectal cancer / / 21242260 rs17660170 chr5 134493323 G T 1.40E-05 F-cell distribution / / 21326311 rs647161 chr5 134499092 C A 1.00E-10 Colorectal cancer / / 23263487 rs647161 chr5 134499092 C A 4.00E-10 Colorectal cancer / / 23263487 rs647161 chr5 134499092 C A 2.00E-14 Colorectal cancer / / 24836286 rs1122171 chr5 134509987 C T 2.39E-05 Serum metabolites / / 19043545 rs10076673 chr5 134550729 C G 2.21E-04 Depression (quantitative trait) / / 20800221 rs10061785 chr5 134550790 A C 2.90E-05 Obesity,menopause / / 21424828 rs634308 chr5 134563157 C T 3.51E-06 Parkinson's disease (motor and cognition) / / 22658654 rs634308 chr5 134563157 C T 4.00E-06 Immune response to anthrax vaccine / / 22658931 rs688622 chr5 134564405 G A 4.58E-04 Multiple complex diseases / / 17554300 rs606854 chr5 134572229 A G,T 6.00E-06 Obesity-related traits / / 23251661 rs1346440 chr5 134573007 C T 1.95E-05 Coronary heart disease / / 24778558 rs2019973 chr5 134573992 C T 1.10E-05 Urinary metabolites LOC340073 intron 21572414 rs2019973 chr5 134573992 C T 5.31E-05 Coronary heart disease LOC340073 intron 24778558 rs2114961 chr5 134574232 T G 7.49E-05 Attention deficit hyperactivity disorder LOC340073 intron 22012869 rs890731 chr5 134574406 T G 4.50E-06 Urinary metabolites LOC340073 intron 21572414 rs4976249 chr5 134575869 C A 1.80E-05 Urinary metabolites LOC340073 intron 21572414 rs13175863 chr5 134579640 C T 5.25E-04 Suicide attempts in bipolar disorder LOC340073 intron 21423239 rs1650464 chr5 134583563 T C 6.50E-06 Urinary metabolites LOC340073 intron 21572414 rs11242237 chr5 134590912 C A 1.51E-04 Type 2 diabetes / / 17463246 rs10515470 chr5 134633657 T G 3.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10515470 chr5 134633657 T G 3.81E-04 Suicide,with and without major depression / / 22059935 rs10515470 chr5 134633657 T G 4.62E-04 Suicide,with and without major depression / / 22059935 rs2603014 chr5 134643116 T C 6.95E-05 Bone mineral density / / 19181680 rs2652092 chr5 134652489 A G 6.94E-05 Waist-Hip Ratio / / pha003029 rs7712997 chr5 134663097 G T 7.15E-04 Alcohol dependence / / 20201924 rs13163460 chr5 134665082 G T 2.66E-04 Multiple complex diseases / / 17554300 rs3210047 chr5 134670765 A G 2.10E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) H2AFY cds-synon 24023788 rs703253 chr5 134730520 G A 6.21E-05 Aortic root size H2AFY intron 21223598 rs6893238 chr5 134765762 C T 7.22E-05 Aortic root size / / 21223598 rs6874297 chr5 134765844 T C 2.37E-04 Multiple complex diseases / / 17554300 rs4976297 chr5 134769827 G T 2.67E-04 Age-related macular degeneration / / 22125219 rs11242246 chr5 134773951 C T 6.76E-05 Coronary heart disease / / pha003032 rs740657 chr5 134828617 G T 0.000029 Mean arterial pressure / / 22510845 rs7714565 chr5 134830781 T C 2.66E-05 Prion diseases / / 22210626 rs12374511 chr5 134846824 A C 4.61E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs7728312 chr5 134847527 C T 2.19E-04 Multiple complex diseases / / 17554300 rs10040564 chr5 134853207 C T 4.67E-05 Smoking initiation / / 24665060 rs13356152 chr5 134876123 T C 7.95E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs17168703 chr5 134929690 A G 5.58E-04 Alcohol dependence / / 21314694 rs17168705 chr5 134930005 C A 4.10E-04 Alcohol dependence / / 21314694 rs17168730 chr5 134943444 C T 9.06E-04 Multiple complex diseases / / 17554300 rs17168730 chr5 134943444 C T 7.31E-05 Serum metabolites / / 19043545 rs7715094 chr5 134945082 A G 2.60E-05 Urinary metabolites / / 21572414 rs7735523 chr5 134945199 T C 4.08E-04 Multiple complex diseases / / 17554300 rs17735434 chr5 134967390 C T 1.10E-05 Urinary metabolites / / 21572414 rs11242260 chr5 135021957 T G 9.80E-06 QT interval / / 23166209 rs4976321 chr5 135047254 G A 9.80E-05 Cognitive test performance / / 20125193 rs4976323 chr5 135052055 C T 7.42E-05 Cognitive test performance / / 20125193 rs4386730 chr5 135150207 A G 9.01E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9986164 chr5 135162763 A C 2.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13178541 chr5 135164618 A C 5.00E-06 IgG glycosylation / / 23382691 rs7703565 chr5 135168540 G A 8.01E-04 Acute lung injury / / 22295056 rs2288833 chr5 135170671 G C 7.88E-04 Acute lung injury SLC25A48 intron 22295056 rs2304075 chr5 135178124 T C 6.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC25A48 cds-synon 20877124 rs4976493 chr5 135182123 A G 6.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC25A48 intron 20877124 rs4976493 chr5 135182123 A G 6.66E-05 Parkinson's disease SLC25A48 intron 21812969 rs11744615 chr5 135184805 C T 6.03E-05 Cognitive test performance SLC25A48 intron 20125193 rs4246802 chr5 135199709 A C 7.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC25A48 intron 20877124 rs6872151 chr5 135210557 C T 6.89E-04 Type 2 diabetes SLC25A48 intron 17463246 rs6872507 chr5 135210795 A T 5.82E-04 Type 2 diabetes SLC25A48 intron 17463246 rs7717673 chr5 135211466 C T 6.00E-06 Smoking behavior SLC25A48 intron 20418888 rs7734448 chr5 135214677 G A 3.00E-06 Obesity-related traits SLC25A48 intron 23251661 rs12522916 chr5 135246790 G A 6.66E-05 Orofacial clefts / / 22419666 rs1859428 chr5 135251107 T G 4.67E-04 Myocardial Infarction / / pha002873 rs17701996 chr5 135267337 A G 7.15E-05 Multiple complex diseases FBXL21 intron 17554300 rs6895541 chr5 135267808 A T 7.16E-05 Multiple complex diseases FBXL21 intron 17554300 rs6870177 chr5 135275622 A G 6.94E-05 Magnesium levels FBXL21 intron pha003092 rs977691 chr5 135283222 T A 8.00E-04 Acute lymphoblastic leukemia (childhood) LECT2 intron 20189245 rs2107506 chr5 135300277 C G 6.25E-05 Response to lithium treatment in bipolar disorder / / 21961650 rs2428158 chr5 135313852 C T 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs17169582 chr5 135315168 A G 9.80E-06 Bipolar disorder / / 19416921 rs30737 chr5 135323434 T G 2.23E-05 Gallbladder cancer / / 22318345 rs13356494 chr5 135327555 C G 4.05E-07 Panic disorder / / 19165232 rs30743 chr5 135332571 T C 2.20E-05 Urinary metabolites / / 21572414 rs6882087 chr5 135335579 A G 6.24E-05 Magnesium levels / / pha003092 rs6892697 chr5 135344163 G A 1.00E-04 Information processing speed / / 21130836 rs2106491 chr5 135348376 C T 4.37E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs30756 chr5 135352495 G A 6.90E-06 Multiple complex diseases / / 17554300 rs6894906 chr5 135355038 G A 1.00E-04 Information processing speed / / 21130836 rs6894906 chr5 135355038 G A 6.31E-04 Aortic root size / / 21223598 rs30757 chr5 135355223 C T 8.19E-06 Multiple complex diseases / / 17554300 rs2282790 chr5 135363875 A G 6.14E-05 Response to cytidine analogues (gemcitabine) TGFBI nearGene-5 24483146 rs2237065 chr5 135367220 G A 4.53E-05 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs2237066 chr5 135367603 C T 1.38E-04 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs756462 chr5 135367945 T C 5.93E-05 Iron levels TGFBI intron 19880490 rs756462 chr5 135367945 T C 5.93E-05 Iron levels TGFBI intron pha002876 rs4141306 chr5 135375473 A G 1.27E-05 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs2107331 chr5 135377349 C A 3.24E-04 Alcohol dependence TGFBI intron 20201924 rs2107331 chr5 135377349 C A 6.26E-06 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs7719624 chr5 135377566 C T 4.00E-06 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs2282791 chr5 135377730 T G 2.28E-05 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs1989972 chr5 135377802 A C 3.00E-05 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs3805700 chr5 135378781 A G 7.59E-05 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs1060433 chr5 135385700 T C 1.90E-04 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs2237072 chr5 135386800 C T 1.34E-05 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs6860369 chr5 135391326 A G 3.36E-04 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs2074811 chr5 135391947 T C 4.30E-04 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs4669 chr5 135392426 T C 4.87E-04 Response to cytidine analogues (gemcitabine) TGFBI cds-synon 24483146 rs2072239 chr5 135392507 G A 2.74E-04 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs6871571 chr5 135393197 A G 4.87E-04 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs3792900 chr5 135393754 T C 9.33E-05 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs1990201 chr5 135395203 T C 1.33E-04 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs6894815 chr5 135395864 G C 2.97E-04 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs10042825 chr5 135396084 A T 3.67E-04 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs13168506 chr5 135396452 A G 7.77E-04 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs6880837 chr5 135396669 T C 3.32E-04 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs2302038 chr5 135397018 T C 1.57E-04 Response to cytidine analogues (gemcitabine) TGFBI intron 24483146 rs4572 chr5 135399452 T G 4.31E-04 Response to cytidine analogues (gemcitabine) TGFBI UTR-3 24483146 rs10043360 chr5 135400057 T A 3.62E-05 Bipolar disorder and schizophrenia / / 20889312 rs10045924 chr5 135400096 A G 1.08E-05 Multiple complex diseases / / 17554300 rs17169786 chr5 135401678 A G 4.24E-05 Serum metabolites / / 19043545 rs17169786 chr5 135401678 A G 4.03E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11742191 chr5 135410863 A G 4.34E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs917303 chr5 135418032 G A 2.24E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs917303 chr5 135418032 G A 8.08E-05 Coronary heart disease / / pha003031 rs4976472 chr5 135418717 C G 2.29E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs2215011 chr5 135420135 G A 2.29E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs1558095 chr5 135429640 T C 1.79E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs12654032 chr5 135434609 A G 1.40E-04 Bone mineral density (BMD),in women / / 20164292 rs2346361 chr5 135448505 G T 1.32E-05 Body Composition / / pha003012 rs2346361 chr5 135448505 G T 8.93E-05 Body Mass Index / / pha003021 rs9327743 chr5 135467309 C G 9.58E-05 Bipolar disorder and schizophrenia SMAD5-AS1 intron 20889312 rs3764941 chr5 135469527 T G 2.37E-04 Parkinson's disease SMAD5 intron 17052657 rs10085013 chr5 135470041 T A 1.84E-04 Parkinson's disease SMAD5 intron 17052657 rs6596284 chr5 135470544 T C 1.81E-04 Parkinson's disease SMAD5 intron 17052657 rs7356756 chr5 135471034 T C 2.03E-04 Parkinson's disease SMAD5 intron 17052657 rs6596287 chr5 135479348 A C 1.27E-04 Parkinson's disease SMAD5 intron 17052657 rs6596288 chr5 135484563 A G 6.58E-05 Bipolar disorder and schizophrenia SMAD5 intron 20889312 rs10056474 chr5 135491396 C G 4.94E-05 Bipolar disorder and schizophrenia SMAD5 intron 20889312 rs13179769 chr5 135493860 C A 1.84E-04 Parkinson's disease SMAD5 intron 17052657 rs13166063 chr5 135494074 T C 1.84E-04 Parkinson's disease SMAD5 intron 17052657 rs1109158 chr5 135499211 T A 1.84E-04 Parkinson's disease SMAD5 intron 17052657 rs4585442 chr5 135508381 A G 6.00E-04 Parkinson's disease SMAD5 intron 17052657 rs4146185 chr5 135510033 T A 1.84E-04 Parkinson's disease SMAD5 intron 17052657 rs12719481 chr5 135514055 A G 1.84E-04 Parkinson's disease SMAD5 UTR-3 17052657 rs6865297 chr5 135515708 A G 1.84E-04 Parkinson's disease SMAD5 UTR-3 17052657 rs6886699 chr5 135515738 T C 3.43E-05 Bipolar disorder and schizophrenia SMAD5 UTR-3 20889312 rs3206633 chr5 135516188 T G 2.79E-04 Parkinson's disease SMAD5 UTR-3 17052657 rs3206634 chr5 135516203 T C 2.79E-04 Parkinson's disease SMAD5 UTR-3 17052657 rs3206635 chr5 135516282 G A 1.14E-04 Parkinson's disease SMAD5 UTR-3 17052657 rs6596293 chr5 135516707 A G 1.39E-04 Parkinson's disease SMAD5 UTR-3 17052657 rs6596294 chr5 135516836 T C 1.65E-04 Parkinson's disease SMAD5 UTR-3 17052657 rs1057898 chr5 135517150 T C 1.84E-04 Parkinson's disease SMAD5 UTR-3 17052657 rs11242316 chr5 135519848 C G 4.49E-05 Bipolar disorder and schizophrenia / / 20889312 rs7732110 chr5 135520009 G A 5.19E-05 Bipolar disorder and schizophrenia / / 20889312 rs10041689 chr5 135537777 G A 1.94E-05 Bipolar disorder and schizophrenia LOC100506219 intron 20889312 rs6596299 chr5 135570567 A C 6.63E-05 Body Composition TRPC7 intron pha003012 rs10463951 chr5 135574111 C T 4.51E-05 Body Composition TRPC7 intron pha003012 rs171101 chr5 135618204 G A 8.10E-06 Urinary metabolites TRPC7 intron 21572414 rs7701815 chr5 135622098 C A 2.00E-05 Urinary metabolites TRPC7 intron 21572414 rs1392170 chr5 135631302 A C 6.80E-06 Urinary metabolites TRPC7 intron 21572414 rs10454295 chr5 135643943 C T 3.29E-05 Response to platinum-based chemotherapy in small-cell lung cancer TRPC7 intron 20463552 rs1353885 chr5 135645015 C T 6.17E-04 Response to taxane treatment (placlitaxel) TRPC7 intron 23006423 rs4976485 chr5 135650298 A G 1.63E-04 Nicotine dependence TRPC7 intron 17158188 rs10070699 chr5 135651940 G A 1.62E-04 Nicotine dependence TRPC7 intron 17158188 rs2216640 chr5 135655101 C T 6.46E-04 Nicotine dependence TRPC7 intron 17158188 rs1499764 chr5 135664188 T C 1.75E-04 Nicotine dependence TRPC7 intron 17158188 rs4976489 chr5 135678957 C T 1.09E-04 Nicotine dependence TRPC7 intron 17158188 rs950715 chr5 135680239 A G 6.80E-06 Urinary metabolites TRPC7 intron 21572414 rs2546657 chr5 135683735 T A 4.96E-05 Nicotine dependence TRPC7 intron 17158188 rs12515628 chr5 135685025 G A 3.70E-06 Urinary metabolites TRPC7 intron 21572414 rs2673931 chr5 135689436 C T 3.89E-05 Nicotine dependence TRPC7 intron 17158188 rs2673926 chr5 135697624 G A 8.78E-05 Pulmonary function TRPC7 intron 19300500 rs2673926 chr5 135697624 G A 9.42E-05 Bipolar disorder TRPC7 intron 19488044 rs2673926 chr5 135697624 G A 2.20E-05 Bipolar disorder and schizophrenia TRPC7 intron 20889312 rs2673926 chr5 135697624 G A 8.27E-05 Bipolar Disorder TRPC7 intron pha002858 rs2673925 chr5 135705674 G A 8.36E-05 Bipolar disorder / / 19488044 rs2673925 chr5 135705674 G A 2.66E-05 Bipolar disorder and schizophrenia / / 20889312 rs2673925 chr5 135705674 G A 7.34E-05 Bipolar Disorder / / pha002858 rs2649696 chr5 135706851 T C 6.77E-05 Bipolar disorder and schizophrenia / / 20889312 rs1392174 chr5 135713346 G A 8.09E-05 Multiple complex diseases / / 17554300 rs2524282 chr5 135717640 T G 5.26E-05 Bipolar disorder and schizophrenia / / 20889312 rs2673913 chr5 135721447 C G 9.89E-05 Bipolar disorder / / 19488044 rs2673913 chr5 135721447 C G 3.58E-05 Bipolar disorder and schizophrenia / / 20889312 rs2673913 chr5 135721447 C G 8.51E-05 Bipolar Disorder / / pha002858 rs1499762 chr5 135733441 C A 6.92E-05 Bipolar disorder and schizophrenia / / 20889312 rs4141140 chr5 135952213 C T 4.23E-05 Kawasaki disease / / 22081228 rs1989821 chr5 135966786 G T 4.27E-04 Parkinson's disease / / 16252231 rs7730672 chr5 135969163 A T 3.27E-04 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs10515481 chr5 135980047 T C 6.64E-04 Parkinson's disease / / 16252231 rs10515481 chr5 135980047 T C 2.35E-04 Multiple complex diseases / / 17554300 rs1331980 chr5 135980919 A G 3.90E-05 Kawasaki disease / / 22081228 rs1331984 chr5 135995691 A G 1.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2073970 chr5 136002047 A G 1.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2188464 chr5 136027890 C T 7.34E-04 Multiple complex diseases / / 17554300 rs726846 chr5 136072054 G A 1.10E-05 Longevity and age-related phenotypes / / 17903295 rs2881668 chr5 136136878 C G 2.23E-04 Multiple complex diseases / / 17554300 rs12515398 chr5 136137191 T C 8.56E-04 Multiple complex diseases / / 17554300 rs9285936 chr5 136146502 C T 6.95E-04 Myopia (pathological) / / 21095009 rs17712154 chr5 136156408 A G 4.80E-06 Urinary metabolites / / 21572414 rs12658291 chr5 136172769 A C 1.50E-05 Urinary metabolites / / 21572414 rs17712730 chr5 136189770 G A 8.60E-06 Urinary metabolites / / 21572414 rs17702421 chr5 136221582 A C 7.09E-05 Atopy / / 21625490 rs1125470 chr5 136221940 C A 8.18E-04 Schizophrenia / / 21674006 rs7448833 chr5 136228845 G A 7.65E-05 C-Reactive Protein / / pha003070 rs258563 chr5 136269272 A G 1.86E-05 Lung adenocarcinoma / / 19836008 rs2429088 chr5 136305460 T G 1.20E-05 Urinary metabolites / / 21572414 rs2429085 chr5 136312787 A G 1.80E-05 Urinary metabolites SPOCK1 UTR-3 21572414 rs1051853 chr5 136313801 T G 9.44E-04 Multiple complex diseases SPOCK1 UTR-3 17554300 rs1051853 chr5 136313801 T G 2.53E-04 Non-small cell lung cancer,hypertriglyceridemia with bexarotene treatment of SPOCK1 UTR-3 21737656 rs2190619 chr5 136318739 A G 5.43E-04 Multiple complex diseases SPOCK1 intron 17554300 rs2190619 chr5 136318739 A G 6.74E-05 Alzheimer's disease SPOCK1 intron 17998437 rs6872714 chr5 136319856 G A 8.20E-04 Alzheimer's disease SPOCK1 intron 17998437 rs7722698 chr5 136321413 C G 5.43E-04 Multiple complex diseases SPOCK1 intron 17554300 rs7722698 chr5 136321413 C G 5.38E-04 Alzheimer's disease SPOCK1 intron 17998437 rs17599677 chr5 136350718 C T 1.18E-05 Parkinson's disease (motor and cognition) SPOCK1 intron 22658654 rs6596364 chr5 136370488 A G 1.71E-15 Multiple complex diseases SPOCK1 intron 17554300 rs2189597 chr5 136387259 C G 1.14E-05 Telomere length SPOCK1 intron 23001564 rs2348186 chr5 136423759 T C 4.92E-07 Menarche (age at onset) SPOCK1 intron 19282985 rs4976408 chr5 136431804 G A 0.0002344 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPOCK1 intron 23233654 rs4976408 chr5 136431804 G A 2.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) SPOCK1 intron 23233662 rs7701979 chr5 136435483 G T 8.03E-06 Menarche (age at onset) SPOCK1 intron 19282985 rs13357391 chr5 136441082 T C 5.77E-06 Menarche (age at onset) SPOCK1 intron 19282985 rs1468294 chr5 136442651 C T 9.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) SPOCK1 intron 23233662 rs11741632 chr5 136443115 C T 9.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) SPOCK1 intron 23233662 rs11742757 chr5 136444759 G A 5.88E-04 Smoking initiation SPOCK1 intron 24665060 rs1859345 chr5 136447420 T C 1.58E-05 Menarche (age at onset) SPOCK1 intron 19282985 rs1859346 chr5 136447574 A C 7.10E-04 Crohn's disease SPOCK1 intron 17684544 rs2905968 chr5 136457836 G C 8.12E-04 Alzheimer's disease SPOCK1 intron 17998437 rs11746979 chr5 136459983 G C 6.70E-05 Parkinson's disease (age of onset) SPOCK1 intron 19772629 rs1434665 chr5 136493839 A T 3.21E-05 Menarche (age at onset) SPOCK1 intron 19282985 rs2043478 chr5 136498493 A G 2.06E-04 Lung function (forced vital capacity) SPOCK1 intron 24023788 rs6881218 chr5 136530123 T A 3.73E-05 Multiple complex diseases SPOCK1 intron 17554300 rs17778739 chr5 136551998 C G 7.00E-04 Multiple complex diseases SPOCK1 intron 17554300 rs9327778 chr5 136559250 G A 9.75E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SPOCK1 intron 24023788 rs10054991 chr5 136559812 A G 1.20E-05 Menarche (age at onset) SPOCK1 intron 19282985 rs17171110 chr5 136562671 T C 2.00E-05 Multiple complex diseases SPOCK1 intron 17554300 rs12653349 chr5 136565248 A G 1.61E-05 Menarche (age at onset) SPOCK1 intron 19282985 rs10900848 chr5 136571412 T C 9.17E-04 Alzheimer's disease SPOCK1 intron 17998437 rs17779700 chr5 136572793 A G 9.79E-04 Multiple complex diseases SPOCK1 intron 17554300 rs17779700 chr5 136572793 A G 4.81E-06 Menarche (age at onset) SPOCK1 intron 19282985 rs17779700 chr5 136572793 A G 2.64E-04 Cognitive decline SPOCK1 intron 23732972 rs9327783 chr5 136643868 G A 6.62E-05 Orofacial clefts SPOCK1 intron 22863734 rs10479152 chr5 136668694 A G 2.28E-04 Multiple complex diseases SPOCK1 intron 17554300 rs1229729 chr5 136686608 T C 2.02E-05 Diabetes Mellitus SPOCK1 intron pha003059 rs1229728 chr5 136686834 C T 8.67E-05 Serum metabolites SPOCK1 intron 19043545 rs7737378 chr5 136713000 C T 5.20E-05 Memory performance SPOCK1 intron 22105620 rs1229742 chr5 136715749 A G 1.85E-04 Breast cancer SPOCK1 intron pha002853 rs2005698 chr5 136726751 C A 1.71E-04 Breast cancer SPOCK1 intron pha002853 rs17703757 chr5 136736272 C T 9.85E-05 Bipolar disorder SPOCK1 intron 17486107 rs1229717 chr5 136745093 G C 1.20E-05 Urinary metabolites SPOCK1 intron 21572414 rs6893152 chr5 136765015 C T 2.86E-04 Age-related macular degeneration SPOCK1 intron 22125219 rs2974501 chr5 136772683 C T 2.30E-05 Urinary metabolites SPOCK1 intron 21572414 rs1528964 chr5 136787759 G A 1.77E-06 Multiple complex diseases SPOCK1 intron 17554300 rs4246794 chr5 136846053 C T 5.06E-05 Multiple sclerosis / / 17660530 rs1541364 chr5 136902696 G A 8.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1541364 chr5 136902696 G A 8.50E-06 Bronchopulmonary dysplasia / / 23897914 rs1541364 chr5 136902696 G A 9.00E-06 Bronchopulmonary dysplasia / / 23897914 rs6878439 chr5 136940216 G A 7.36E-04 Multiple complex diseases / / 17554300 rs757157 chr5 136953007 T C 1.30E-04 Iris characteristics KLHL3 nearGene-3 21835309 rs3813318 chr5 136955707 T G 2.00E-04 Cognitive impairment induced by topiramate KLHL3 UTR-3 22091778 rs3777376 chr5 136965249 T C 3.00E-05 Intelligence (childhood) KLHL3 intron 23358156 rs4835709 chr5 136992179 T C 7.26E-05 Multiple complex diseases KLHL3 intron 17554300 rs11242395 chr5 136996852 C T 6.12E-04 Parkinson's disease KLHL3 intron 17052657 rs10037465 chr5 136998182 T C 9.13E-06 Coronary heart disease KLHL3 intron pha003033 rs11242396 chr5 137000965 A G 4.85E-05 Response to tocilizumab in rheumatoid arthritis KLHL3 intron 22491018 rs4371746 chr5 137016586 G A 6.94E-04 Tourette syndrome KLHL3 intron 22889924 rs2905589 chr5 137018387 A G 9.90E-04 Tourette syndrome KLHL3 intron 22889924 rs11949856 chr5 137066853 C T 8.05E-04 Tourette syndrome KLHL3 intron 22889924 rs7722600 chr5 137194762 A G 3.00E-07 Heart rate / / 23583979 rs7703767 chr5 137224007 T A 0.00000285 VLDL cholesterol particle diameter / / 23263444 rs9327807 chr5 137350478 T C 9.07E-05 Amyotrophic lateral sclerosis FAM13B intron 20801717 rs4835757 chr5 137399014 T G 8.41E-04 Parkinson's disease / / 17052657 rs2040862 chr5 137419989 C T 3.00E-07 Atrial fibrillation WNT8A intron 22544366 rs12332207 chr5 137438834 G A 2.44E-04 Multiple complex diseases / / 17554300 rs12516561 chr5 137445000 C T 2.67E-05 Alzheimer's disease (age of onset) / / 22005931 rs12516561 chr5 137445000 C T 0.00017 Endometrial cancer / / 22426144 rs17234961 chr5 137522908 A C 1.59E-04 Amyotrophic lateral sclerosis (sporadic) KIF20A missense 24529757 rs7713177 chr5 137588059 G A 9.48E-05 HIV-1 control / / 20041166 rs11242417 chr5 137599334 T G 6.00E-08 Immune reponse to smallpox (secreted IL-12p40) GFRA3 intron 22610502 rs1052648 chr5 137684732 G A 9.65E-05 Schizophrenia FAM53C UTR-3 19571809 rs10055995 chr5 137698299 C T 1.09E-04 Multiple complex diseases KDM3B intron 17554300 rs757647 chr5 137707315 G A 6.32E-05 Bipolar disorder and schizophrenia KDM3B intron 20889312 rs757647 chr5 137707315 G A 5.00E-08 Menarche (age at onset) KDM3B intron 21102462 rs4835678 chr5 137708434 C T 1.82E-04 Multiple complex diseases KDM3B cds-synon 17554300 rs10073922 chr5 137717213 G A 6.85E-04 Multiple complex diseases KDM3B cds-synon 17554300 rs12517410 chr5 137736611 G T 5.53E-05 Multiple complex diseases KDM3B intron 17554300 rs4835789 chr5 137739040 A T 9.33E-05 Bipolar disorder and schizophrenia KDM3B intron 20889312 rs10040792 chr5 137759010 T C 1.40E-04 Multiple complex diseases KDM3B intron 17554300 rs2240334 chr5 137763615 A C 6.68E-04 Multiple complex diseases KDM3B intron 17554300 rs4835681 chr5 137783690 G C 8.67E-05 Multiple complex diseases / / 17554300 rs13184188 chr5 137789519 G C 6.80E-04 Multiple complex diseases / / 17554300 rs10900855 chr5 137937537 C T 1.84E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10900855 chr5 137937537 C T 2.04E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10900855 chr5 137937537 C T 7.12E-04 Alzheimer's disease / / 24755620 rs11948669 chr5 137964009 A G 5.49E-05 Cognitive impairment induced by topiramate / / 22091778 rs3849047 chr5 137980476 C T 1.26E-04 Obesity (extreme) / / 21935397 rs6596446 chr5 137980855 T C 6.64E-04 Obesity (extreme) / / 21935397 rs882740 chr5 137992709 G A 3.10E-04 Lymphocyte counts / / 22286170 rs3804204 chr5 138151191 G C 0.00000102 HDL cholesterol CTN/1 intron 23063622 rs10515503 chr5 138218178 A G 5.03E-06 Fibrinogen CTN/1 intron 17255346 rs10515503 chr5 138218178 A G 0.00035 Coronary artery calcification CTN/1 intron 23727086 rs17207814 chr5 138288530 G A 4.21E-04 Celiac disease SIL1 intron 23936387 rs11747454 chr5 138318158 G A 5.18E-04 Insulin resistance SIL1 intron 21901158 rs7731574 chr5 138454192 G A 4.29E-05 Smoking cessation SIL1 intron 18519826 rs1549203 chr5 138468344 C T 5.02E-04 Alzheimer's disease SIL1 intron 17998437 rs1560656 chr5 138470789 G A 3.85E-04 Alzheimer's disease SIL1 intron 17998437 rs10900859 chr5 138487483 G A 1.70E-05 Urinary metabolites SIL1 intron 21572414 rs13171855 chr5 138489338 G A 2.60E-05 Urinary metabolites SIL1 intron 21572414 rs11744695 chr5 138498728 A G 1.60E-05 Urinary metabolites SIL1 intron 21572414 rs13160445 chr5 138517235 A G 2.13E-04 Smoking cessation SIL1 intron 18519826 rs13160445 chr5 138517235 A G 1.90E-05 Urinary metabolites SIL1 intron 21572414 rs11745848 chr5 138517485 C T 1.60E-05 Urinary metabolites SIL1 intron 21572414 rs11745848 chr5 138517485 C T 5.62E-05 Bipolar disorder SIL1 intron 21771265 rs869026 chr5 138576800 C A 6.57E-04 Parkinson's disease / / 17052657 rs11747498 chr5 138614277 A G 6.57E-04 Parkinson's disease MATR3 intron 17052657 rs877826 chr5 138618797 T G 8.99E-04 Parkinson's disease MATR3 intron 17052657 rs3805436 chr5 138632030 G T 7.92E-04 Parkinson's disease MATR3 intron 17052657 rs3805436 chr5 138632030 G T 2.61E-04 Taste perception MATR3 intron 22132133 rs3816021 chr5 138657944 C A 5.81E-04 Parkinson's disease MATR3 intron 17052657 rs4835726 chr5 138733811 C T 9.30E-04 Response to taxane treatment (placlitaxel) SPATA24 intron 23006423 rs11242465 chr5 138762305 T G 7.57E-04 Response to taxane treatment (placlitaxel) D/JC18 intron 23006423 rs10900864 chr5 138773090 A G 7.70E-04 Alzheimer's disease D/JC18 cds-synon 24755620 rs13181561 chr5 138850905 G A 3.00E-14 Immune reponse to smallpox (secreted IFN-alpha) / / 22610502 rs13181561 chr5 138850905 G A 6.00E-06 Chronic obstructive pulmonary disease-related biomarkers / / 23144326 rs261532 chr5 138949362 G T 3.00E-07 Immune reponse to smallpox (secreted IFN-alpha) UBE2D2 intron 22610502 rs356453 chr5 139053563 G A 4.18E-05 Lipoproteins CXXC5 intron pha003079 rs682164 chr5 139058589 A G 7.75E-04 Multiple complex diseases CXXC5 intron 17554300 rs2336880 chr5 139063728 G A 2.92E-05 Lipoproteins / / pha003079 rs356433 chr5 139071193 C T 4.81E-06 Multiple complex diseases / / 17554300 rs356486 chr5 139085103 C G 7.53E-05 Multiple complex diseases / / 17554300 rs187804 chr5 139094061 T C 4.85E-04 Multiple complex diseases / / 17554300 rs165196 chr5 139094172 G A 3.77E-04 Multiple complex diseases / / 17554300 rs260735 chr5 139103881 G A 6.27E-04 Multiple complex diseases / / 17554300 rs749125 chr5 139166808 G A 2.14E-05 Triglycerides / / 19074352 rs749125 chr5 139166808 G A 2.14E-05 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs3797904 chr5 139222208 G A 5.50E-04 Aortic root size PSD2 UTR-3 21223598 rs10078529 chr5 139222591 G A 7.40E-04 Aortic root size PSD2 UTR-3 21223598 rs1800954 chr5 139245086 A G 2.76E-05 Waist-Hip Ratio NRG2 intron pha003029 rs6860347 chr5 139262117 A G 8.13E-05 Alzheimer's disease (age of onset) NRG2 intron 22005931 rs1422186 chr5 139276863 G A 2.93E-04 Stroke NRG2 intron pha002887 rs17118532 chr5 139295646 A G 6.31E-04 Multiple complex diseases NRG2 intron 17554300 rs9686629 chr5 139329066 A G 9.13E-05 Body Mass Index NRG2 intron pha003007 rs9686629 chr5 139329066 A G 2.71E-05 Weight NRG2 intron pha003027 rs7736276 chr5 139335948 C T 9.13E-05 Body Mass Index NRG2 intron pha003007 rs7736276 chr5 139335948 C T 2.71E-05 Weight NRG2 intron pha003027 rs10515508 chr5 139375070 T C 1.71E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses NRG2 intron 17903301 rs265157 chr5 139390007 C T 6.41E-04 Multiple complex diseases NRG2 intron 17554300 rs155941 chr5 139433638 G C 9.90E-05 Personality dimensions / / 18957941 rs6889324 chr5 139440463 G A 3.81E-04 Coronary heart disease / / 21971053 rs269761 chr5 139460183 G C 1.60E-05 Urinary metabolites / / 21572414 rs1623177 chr5 139460236 T G 4.92E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs269778 chr5 139471723 C T 4.70E-04 Body mass index / / 21701565 rs10477292 chr5 139475611 G T 3.49E-04 Coronary heart disease / / 21971053 rs269771 chr5 139477504 C G 6.60E-04 Body mass index / / 21701565 rs2013169 chr5 139497605 T A 5.90E-04 Body mass index PURA UTR-3 21701565 rs2429310 chr5 139508705 G A 3.71E-04 Coronary heart disease / / 21971053 rs2429310 chr5 139508705 G A 7.13E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4913069 chr5 139545110 G A 9.52E-05 Attention deficit hyperactivity disorder / / pha002875 rs10079869 chr5 139594149 G C 2.00E-04 Insulin resistance CYSTM1 intron 21901158 rs7268 chr5 139712550 A C 0.000106 Body mass index HBEGF UTR-3 23001569 rs13385 chr5 139712878 G A 6.49E-05 Interstitial lung disease HBEGF UTR-3 23583980 rs4150212 chr5 139721701 C T 7.09E-04 Multiple complex diseases HBEGF intron 17554300 rs6889768 chr5 139929877 T G 3.81E-07 Prostate cancer SRA1 UTR-3 24185611 rs7715021 chr5 139941943 C G 2.09E-06 Prostate cancer APBB3 missense 24185611 rs17119623 chr5 139961837 T C 1.19E-06 Prostate cancer / / 24185611 rs1864255 chr5 139974473 T G 3.91E-05 Blood Pressure / / pha002903 rs2569163 chr5 139975466 A G 3.32E-05 Blood Pressure / / pha002903 rs778584 chr5 140005212 T C 9.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs778584 chr5 140005212 T C 1.06E-05 Lung adenocarcinoma / / 19836008 rs778584 chr5 140005212 T C 5.50E-09 Soluble CD14 / / 23162014 rs7721577 chr5 140005786 T C 1.35E-05 Lung adenocarcinoma / / 19836008 rs2569188 chr5 140008419 G A 1.42E-05 Lung adenocarcinoma / / 19836008 rs5744455 chr5 140013307 G A 3.50E-26 Soluble CD14 CD14 nearGene-5 23162014 rs5744441 chr5 140016847 G A 2.98E-23 Soluble CD14 / / 23162014 rs3822356 chr5 140022436 A G 3.15E-05 Lung adenocarcinoma TMCO6 intron 19836008 rs1583005 chr5 140031537 G A 6.97E-05 Blood Pressure IK intron pha002903 rs115338764 chr5 140041187 G A 1.98E-07 Prostate cancer IK intron 24185611 rs11954514 chr5 140056775 A C 2.30E-05 Urinary metabolites HARS intron 21572414 rs7706544 chr5 140070148 C T 1.94E-07 Prostate cancer HARS intron 24185611 rs12188417 chr5 140098596 T G 5.31E-04 Alzheimer's disease / / 22005930 rs2531349 chr5 140120953 G A 8.31E-05 Lung adenocarcinoma / / 19836008 rs2098058 chr5 140157427 G T 8.44E-04 Alzheimer's disease / / 17998437 rs4451093 chr5 140158542 C T 5.98E-04 Alzheimer's disease / / 17998437 rs34575154 chr5 140166953 A G 3.56E-06 Prostate cancer PCDHA1 missense 24185611 rs3733712 chr5 140167220 A C 7.33E-04 Body mass index PCDHA1 missense 23669352 rs12717860 chr5 140171442 C T 4.82E-04 Alzheimer's disease PCDHA1 intron 17998437 rs116776862 chr5 140177075 G A 6.86E-06 Prostate cancer PCDHA2 intron 24185611 rs113425597 chr5 140187201 G C 6.36E-07 Prostate cancer PCDHA4 cds-synon 24185611 rs4151685 chr5 140213805 A C 3.52E-06 Prostate cancer PCDHA6 intron 24185611 rs6880234 chr5 140215956 C G 7.49E-07 Prostate cancer PCDHA7 missense 24185611 rs140013560 chr5 140230548 C A 0.000069 Prostate cancer (advanced) PCDHA9 missense 23555315 rs251369 chr5 140242479 T A 9.63E-04 Type 2 diabetes PCDHA9 intron 17463246 rs251370 chr5 140246287 C T 8.89E-05 Lung adenocarcinoma PCDHA9 intron 19836008 rs251370 chr5 140246287 C T 2.84E-06 Blood Pressure PCDHA9 intron pha002903 rs251373 chr5 140252615 C T 2.32E-06 Blood Pressure PCDHA9 intron pha002903 rs11741879 chr5 140253787 T C 1.40E-05 Urinary metabolites PCDHA9 intron 21572414 rs246037 chr5 140331846 C T 6.27E-05 Blood Pressure PCDHA9 intron pha002898 rs246037 chr5 140331846 C T 3.14E-06 Blood Pressure PCDHA9 intron pha002903 rs155806 chr5 140349840 A G 9.57E-10 Metabolite levels PCDHA9 intron 23281178 rs13153056 chr5 140366901 G A 2.90E-05 Urinary metabolites PCDHA9 intron 21572414 rs31874 chr5 140369318 C T 7.08E-05 Interstitial lung disease PCDHA9 intron 23583980 rs3822343 chr5 140370339 G A 1.54E-05 Body Mass Index PCDHA9 intron pha003006 rs3822343 chr5 140370339 G A 2.70E-06 Body Mass Index PCDHA9 intron pha003019 rs3822343 chr5 140370339 G A 8.42E-06 Body Mass Index PCDHA9 intron pha003020 rs3822343 chr5 140370339 G A 8.01E-05 Body Mass Index PCDHA9 intron pha003022 rs31872 chr5 140372222 G A 3.00E-06 Visceral adipose tissue adjusted for BMI PCDHA9 intron 22589738 rs13163241 chr5 140373888 C T 2.70E-05 Body Mass Index PCDHA9 intron pha003006 rs13163241 chr5 140373888 C T 4.65E-06 Body Mass Index PCDHA9 intron pha003019 rs13163241 chr5 140373888 C T 1.01E-05 Body Mass Index PCDHA9 intron pha003020 rs246584 chr5 140436063 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs702390 chr5 140442209 G A 2.96E-06 Interstitial lung disease / / 23583980 rs12521934 chr5 140464559 G A 2.78E-04 Type 2 diabetes / / 20818381 rs31853 chr5 140474756 G A 2.24E-05 Body Mass Index PCDHB2 missense pha003019 rs31853 chr5 140474756 G A 1.74E-05 Body Mass Index PCDHB2 missense pha003020 rs3776103 chr5 140476894 A G 3.44E-06 Body Mass Index PCDHB2 UTR-3 pha003019 rs3776103 chr5 140476894 A G 3.38E-07 Body Mass Index PCDHB2 UTR-3 pha003020 rs13178255 chr5 140477932 T G 2.24E-05 Body Mass Index / / pha003019 rs13178255 chr5 140477932 T G 1.74E-05 Body Mass Index / / pha003020 rs31850 chr5 140479622 A G 8.39E-05 Interstitial lung disease / / 23583980 rs31849 chr5 140480355 A G 2.24E-05 Body Mass Index PCDHB3 missense pha003019 rs31849 chr5 140480355 A G 1.74E-05 Body Mass Index PCDHB3 missense pha003020 rs3733697 chr5 140502344 C T 1.61E-04 Type 2 diabetes PCDHB4 missense 20818381 rs246723 chr5 140519166 A G 6.18E-04 Multiple complex diseases / / 17554300 rs246723 chr5 140519166 A G 9.85E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs7730410 chr5 140519271 T C 7.49E-04 Multiple complex diseases / / 17554300 rs246690 chr5 140544992 G A 9.56E-05 Bone mineral density / / 19181680 rs17286891 chr5 140552774 G A 5.74E-04 Coronary Artery Disease PCDHB7 missense 17634449 rs2910330 chr5 140595183 G A,C,T 5.07E-04 Eating disorders PCDHB13 cds-synon 23568457 rs200378467 chr5 140603601 A G 0.000000163 Prostate-specific antigen PCDHB14 missense 23555315 rs61734412 chr5 140604011 A T 0.000049 Prostate cancer (advanced) PCDHB14 missense 23555315 rs2907320 chr5 140606802 C T 2.56E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs2907309 chr5 140614038 G A 2.56E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs2907308 chr5 140614830 G A 2.56E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs2907307 chr5 140615269 A G 2.56E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs2910337 chr5 140631925 T G 2.56E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs10044936 chr5 140653258 C T 1.20E-05 Eating disorders (purging via substances) / / 23568457 rs113951537 chr5 140668925 G T 9.77E-06 Eating disorders (purging via substances) / / 23568457 rs10491308 chr5 140678474 A G 3.66E-04 Multiple complex diseases / / 17554300 rs10491309 chr5 140679023 A G 1.67E-04 Bulimia nervosa / / 23568457 rs3749779 chr5 140682891 A C 7.00E-06 Obesity-related traits SLC25A2 missense 23251661 rs10875595 chr5 140700489 T G 1.00E-06 Pulmonary function decline TAF7 nearGene-5 22424883 rs13359820 chr5 140701730 A G 7.47E-04 Myopia (pathological) TAF7 nearGene-5 21095009 rs17097185 chr5 140711097 C G 2.70E-06 Prostate cancer PCDHGA1 missense 24185611 rs116679801 chr5 140711954 C G 8.49E-06 Prostate cancer PCDHGA1 missense 24185611 rs10491311 chr5 140717739 T C 7.47E-04 Myopia (pathological) PCDHGA1 intron 21095009 rs3822359 chr5 140717962 G A 7.31E-04 Myopia (pathological) PCDHGA1 intron 21095009 rs6878145 chr5 140718552 A G 1.93E-06 Prostate cancer PCDHGA2 missense 24185611 rs6878145 chr5 140718552 A G 4.94E-06 Prostate cancer PCDHGA2 missense 24185611 rs61749035 chr5 140718750 G T 7.50E-07 Prostate cancer PCDHGA2 missense 24185611 rs3806837 chr5 140723174 T C 6.77E-05 Major depressive disorder PCDHGA2 intron 21621269 rs115115119 chr5 140736146 A G 0.000037 Prostate cancer (advanced) PCDHGA4 missense 23555315 rs3749769 chr5 140784427 T C 7.55E-04 Multiple complex diseases PCDHGA9 cds-synon 17554300 rs11167744 chr5 140801104 T C 2.48E-04 Amyotrophic Lateral Sclerosis PCDHGA11 missense 17362836 rs3792898 chr5 140820846 C T 5.23E-04 Amyotrophic Lateral Sclerosis PCDHGB4 intron 17362836 rs1059029 chr5 140822723 A G 9.31E-04 Alzheimer's disease PCDHGB4 intron 22005930 rs7723254 chr5 140823300 C T 2.48E-04 Amyotrophic Lateral Sclerosis PCDHGB4 intron 17362836 rs11167748 chr5 140835866 A G 7.98E-04 Alzheimer's disease PCDHGB4 intron 22005930 rs10058370 chr5 140840220 G A 8.06E-04 Alzheimer's disease PCDHGB4 intron 22005930 rs4151701 chr5 140855329 G A 3.45E-05 Creutzfeldt-Jakob disease (variant) PCDHGB4 intron 22137330 rs1423149 chr5 140867347 C T 7.77E-05 Lymphocyte counts PCDHGC4 cds-synon pha003094 rs2302103 chr5 140955777 C T 5.40E-04 Multiple sclerosis DIAPH1 intron 21833088 rs2052455 chr5 141025581 A G 7.50E-05 HIV-1 control FCHSD1 intron 20041166 rs251177 chr5 141026884 T C 1.88E-04 Prostate cancer FCHSD1 intron 18073375 rs116801073 chr5 141029036 G A 0.000037 Breast cancer(er negative) FCHSD1 missense 23555315 rs6580194 chr5 141034123 T A 1.28E-05 Smoking behavior ARAP3 intron 19188921 rs7704263 chr5 141036676 A G 2.12E-05 Suicide attempts in bipolar disorder ARAP3 intron 21423239 rs6895094 chr5 141037277 T G 4.20E-05 Suicide attempts in bipolar disorder ARAP3 intron 21423239 rs3749759 chr5 141041435 G A 4.36E-04 Alzheimer's disease (late onset) ARAP3 intron 21379329 rs17208495 chr5 141043268 C T 5.55E-04 Suicide attempts in bipolar disorder ARAP3 intron 21423239 rs17097438 chr5 141046936 C T 7.64E-04 Suicide attempts in bipolar disorder ARAP3 intron 21423239 rs6875012 chr5 141075980 G A 0.0006594 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6875012 chr5 141075980 G A 6.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17097481 chr5 141087689 T C 6.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs248626 chr5 141097725 A G 3.06E-06 Hearing function / / 21493956 rs248626 chr5 141097725 A G 4.19E-06 Hearing function / / 21493956 rs1421894 chr5 141098377 C T 3.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs248638 chr5 141103117 T C 8.81E-04 Tourette syndrome / / 22889924 rs7711255 chr5 141113274 A G 3.10E-05 Parkinson's disease (age of onset) / / 19772629 rs887269 chr5 141114617 G A 3.11E-04 Obesity (extreme) / / 21935397 rs7703270 chr5 141115815 C T 1.10E-05 Parkinson's disease (age of onset) / / 19772629 rs17097521 chr5 141118619 G T 5.18E-04 Alzheimer's disease / / 24755620 rs32926 chr5 141119040 T C 7.36E-04 Obesity (extreme) / / 21935397 rs32926 chr5 141119040 T C 3.52E-05 Alzheimer's disease / / 24755620 rs248525 chr5 141128436 C T 1.93E-04 Alzheimer's disease / / 22005930 rs3797057 chr5 141129129 G C 2.08E-04 Obesity (extreme) / / 21935397 rs32943 chr5 141130853 C T 7.44E-04 Multiple complex diseases / / 17554300 rs32935 chr5 141133945 C T 2.58E-04 Alzheimer's disease / / 22005930 rs42757 chr5 141137297 C G 2.71E-04 Obesity (extreme) / / 21935397 rs248528 chr5 141142760 T G 6.30E-05 Parkinson's disease (familial) / / 18985386 rs152270 chr5 141143711 C T 5.40E-05 Parkinson's disease (familial) / / 18985386 rs152274 chr5 141155155 G A 1.30E-04 Sudden cardiac arrest / / 21658281 rs17648613 chr5 141160268 T C 6.47E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs248492 chr5 141165875 A G 3.72E-05 Coronary heart disease / / pha003031 rs248491 chr5 141166695 T C 1.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs152275 chr5 141167481 T C 4.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs466022 chr5 141171326 A G 3.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs457639 chr5 141171742 T C 2.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs457518 chr5 141185061 A G 3.76E-23 Narcolepsy / / 19629137 rs2974707 chr5 141187233 G A 4.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs17097654 chr5 141188315 G T 1.27E-05 Alcohol and nictotine co-dependence / / 20158304 rs248471 chr5 141189168 G A 2.00E-06 Myopia (pathological) / / 23406873 rs248472 chr5 141189541 T C 8.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs116557 chr5 141203359 G T 8.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs166040 chr5 141210753 A G 5.00E-06 Major depressive disorder / / 23377640 rs10491313 chr5 141216310 A G 5.05E-05 C-Reactive Protein / / pha003070 rs7700706 chr5 141294362 A G 5.41E-04 Smoking cessation / / 24665060 rs252139 chr5 141345218 T C 7.04E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs187542 chr5 141354220 G C 4.99E-06 Lymphocyte counts RNF14 intron 22286170 rs252095 chr5 141362162 A G 4.58E-05 Amyotrophic Lateral Sclerosis RNF14 intron 18057069 rs409037 chr5 141374203 C T 4.58E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs6580215 chr5 141395998 T G 1.00E-04 Prostate cancer / / 21743057 rs10078983 chr5 141398031 G A 1.20E-05 Urinary metabolites / / 21572414 rs252200 chr5 141400028 T C 1.60E-06 Urinary metabolites / / 21572414 rs252128 chr5 141406997 T C 3.10E-06 Urinary metabolites / / 21572414 rs6867913 chr5 141445980 G A 4.00E-06 Asthma / / 22561531 rs11167764 chr5 141479065 A C 2.40E-04 Alcohol dependence / / 20201924 rs11167764 chr5 141479065 A C 2.00E-09 Crohn's disease / / 21102463 rs11167764 chr5 141479065 A C 2.00E-09 Asthma / / 21907864 rs11745990 chr5 141482792 G A 6.89E-04 Alzheimer's disease / / 22005930 rs9324865 chr5 141488792 T C 1.15E-04 Alcohol dependence NDFIP1 intron 20201924 rs4912622 chr5 141490587 G A 4.85E-04 Alcohol dependence NDFIP1 intron 20201924 rs4912622 chr5 141490587 G A 6.84E-04 Self-reported allergy NDFIP1 intron 23817569 rs7705042 chr5 141492419 C A 6.86E-04 Self-reported allergy NDFIP1 intron 23817569 rs10875596 chr5 141495715 T C 6.51E-04 Self-reported allergy NDFIP1 intron 23817569 rs9324866 chr5 141497650 A G 6.92E-04 Self-reported allergy NDFIP1 intron 23817569 rs11749731 chr5 141500436 A C 8.04E-04 Alcohol dependence NDFIP1 intron 20201924 rs11749731 chr5 141500436 A C 7.19E-04 Self-reported allergy NDFIP1 intron 23817569 rs1835966 chr5 141501508 C T 7.39E-04 Self-reported allergy NDFIP1 intron 23817569 rs2338822 chr5 141503059 T C 7.20E-04 Self-reported allergy NDFIP1 intron 23817569 rs11739961 chr5 141508488 T G 7.21E-04 Self-reported allergy NDFIP1 intron 23817569 rs6860138 chr5 141509985 G A 7.22E-04 Self-reported allergy NDFIP1 intron 23817569 rs6863411 chr5 141513204 A T 6.27E-04 Alcohol dependence NDFIP1 intron 20201924 rs6863411 chr5 141513204 A T 4.00E-14 Inflammatory bowel disease NDFIP1 intron 23128233 rs6863411 chr5 141513204 A T 7.03E-04 Self-reported allergy NDFIP1 intron 23817569 rs2043280 chr5 141513691 C G 7.04E-04 Self-reported allergy NDFIP1 intron 23817569 rs35521724 chr5 141513691 C CG 7.04E-04 Self-reported allergy NDFIP1 intron 23817569 rs7709361 chr5 141513854 T C 6.08E-04 Alcohol dependence NDFIP1 intron 20201924 rs7709361 chr5 141513854 T C 7.04E-04 Self-reported allergy NDFIP1 intron 23817569 rs7723666 chr5 141513966 C T 6.84E-04 Self-reported allergy NDFIP1 intron 23817569 rs7733850 chr5 141515564 C T 5.37E-04 Alcohol dependence NDFIP1 intron 20201924 rs7733850 chr5 141515564 C T 6.84E-04 Self-reported allergy NDFIP1 intron 23817569 rs3765011 chr5 141517665 G C 6.62E-04 Self-reported allergy NDFIP1 intron 23817569 rs1062158 chr5 141523000 C T 5.37E-04 Alcohol dependence NDFIP1 intron 20201924 rs1062158 chr5 141523000 C T 2.00E-06 Multiple sclerosis NDFIP1 intron 21833088 rs1062158 chr5 141523000 C T 6.79E-04 Self-reported allergy NDFIP1 intron 23817569 rs10068466 chr5 141524612 C T 1.06E-04 Self-reported allergy NDFIP1 intron 23817569 rs249643 chr5 141524746 C G 6.21E-04 Self-reported allergy NDFIP1 intron 23817569 rs249642 chr5 141524980 G C 6.94E-04 Self-reported allergy NDFIP1 intron 23817569 rs249641 chr5 141525305 A G 6.06E-04 Self-reported allergy NDFIP1 intron 23817569 rs13185299 chr5 141525620 A G 1.11E-04 Endometrial cancer NDFIP1 intron 24096698 rs13185299 chr5 141525620 A G 2.05E-04 Endometrial cancer NDFIP1 intron 24096698 rs181826 chr5 141526057 C A 6.76E-04 Self-reported allergy NDFIP1 intron 23817569 rs166079 chr5 141528959 C T 6.58E-04 Self-reported allergy NDFIP1 intron 23817569 rs249638 chr5 141530696 G C 6.23E-04 Self-reported allergy NDFIP1 intron 23817569 rs449454 chr5 141533062 A G 5.88E-04 Self-reported allergy NDFIP1 UTR-3 23817569 rs3850578 chr5 141535572 G A 2.57E-04 Insulin resistance / / 21901158 rs249677 chr5 141539339 C A 8.47E-04 Self-reported allergy LOC100505675 intron 23817569 rs2338819 chr5 141540017 C T 1.08E-04 Self-reported allergy LOC100505675 intron 23817569 rs17705913 chr5 141540911 C T 9.48E-04 Alzheimer's disease LOC100505675 intron 22005930 rs2915866 chr5 141544204 C A 6.97E-04 Self-reported allergy / / 23817569 rs2288820 chr5 141548024 A G 1.60E-04 Smoking cessation / / 24665060 rs17649451 chr5 141549536 C T 5.12E-04 Self-reported allergy / / 23817569 rs3764 chr5 141551128 T C 3.80E-04 Self-reported allergy / / 23817569 rs3899510 chr5 141551453 A G 4.00E-04 Self-reported allergy / / 23817569 rs11742584 chr5 141552310 A G 4.46E-04 Self-reported allergy / / 23817569 rs11745706 chr5 141552745 G T 4.47E-04 Self-reported allergy / / 23817569 rs10491314 chr5 141555464 G A 9.66E-05 Alzheimer's disease / / 22005930 rs2961693 chr5 141564645 A G 6.21E-05 Cognitive test performance / / 20125193 rs2906076 chr5 141571965 T C 4.20E-06 Urinary metabolites / / 21572414 rs249660 chr5 141577451 T C 1.11E-04 Type 2 diabetes / / 17463246 rs2906069 chr5 141579649 A G 1.50E-05 Urinary metabolites / / 21572414 rs4912630 chr5 141582204 A G 6.27E-05 Type 2 diabetes / / 17463246 rs17649631 chr5 141611957 C T 7.10E-06 Scoliosis / / 21216876 rs17706123 chr5 141623022 A G 7.48E-04 Multiple complex diseases / / 17554300 rs4244027 chr5 141642966 C T 3.42E-05 Hearing function / / 17255346 rs11167772 chr5 141656556 T C 1.50E-11 Testicular germ cell cancer / / 20543847 rs4912837 chr5 141660464 C T 6.79E-13 Testicular germ cell cancer / / 20543847 rs12521013 chr5 141663364 A C 1.99E-06 Testicular cancer / / 19483682 rs12521013 chr5 141663364 A C 2.09E-06 Testicular cancer / / 21551455 rs4324715 chr5 141669507 C T 2.72E-06 Testicular cancer / / 19483682 rs4324715 chr5 141669507 C T 1.42E-07 Testicular germ cell tumor / / 23666239 rs4624820 chr5 141681788 G A 3.00E-13 Testicular germ cell tumor / / 19483681 rs4624820 chr5 141681788 G A 3.00E-13 Nasopharyngeal carcinoma / / 20512145 rs4624820 chr5 141681788 G A 1.00E-14 Testicular germ cell cancer / / 20543847 rs4624820 chr5 141681788 G A 8.00E-10 Testicular germ cell tumor / / 23666239 rs4624820 chr5 141681788 G A 3.00E-31 Testicular germ cell tumor / / 23666240 rs6897876 chr5 141687639 T C 1.77E-06 Testicular cancer / / 19483682 rs6897876 chr5 141687639 T C 1.87E-06 Testicular cancer / / 21551455 rs959662 chr5 141707606 A G 4.97E-08 Testicular germ cell cancer / / 20543847 rs930892 chr5 141721245 G T 9.00E-04 Polycystic ovary syndrome / / 22178785 rs450988 chr5 141758788 G A 3.68E-06 Erythrocyte counts / / pha003101 rs253443 chr5 141793905 T A 4.31E-04 Multiple complex diseases / / 17554300 rs153423 chr5 141813945 A G 1.42E-04 Multiple complex diseases / / 17554300 rs9800206 chr5 141825324 C A 5.68E-06 Central corneal thickness / / 21098505 rs9800206 chr5 141825324 C A 1.28E-04 Stroke / / pha002886 rs2560868 chr5 141826254 A G 8.97E-05 Bipolar disorder / / 22925353 rs3861862 chr5 141842692 C G 4.95E-04 Coronary heart disease / / 21606135 rs17098701 chr5 141856709 T C 7.36E-05 Type 2 diabetes and other traits / / 19734900 rs17577085 chr5 141863604 T G 4.00E-06 Coronary heart disease / / 21347282 rs17098760 chr5 141880078 C G 4.05E-27 Narcolepsy / / 19629137 rs249740 chr5 141894261 G A 8.51E-04 Response to alcohol consumption (flushing response) / / 24277619 rs4912864 chr5 141911748 G A 4.35E-05 Serum metabolites / / 19043545 rs4244029 chr5 141912841 C T 8.71E-04 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs152447 chr5 141922621 A T 4.09E-04 Type 2 diabetes / / 17463246 rs152447 chr5 141922621 A T 9.27E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs152438 chr5 141924132 C T 8.74E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs152439 chr5 141924395 T C 4.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs33962 chr5 141929551 T C 7.10E-06 Central corneal thickness / / 20485516 rs3853482 chr5 141931217 A G 6.30E-05 Alzheimer's disease (late onset) / / 21379329 rs33973 chr5 141935793 C T 4.38E-04 Bipolar disorder / / 19259986 rs11750296 chr5 141936472 G A 2.60E-06 Central corneal thickness / / 20485516 rs17706715 chr5 141945931 G A 1.13E-06 Common variable immunodeficiency / / 21497890 rs41123 chr5 141958831 T C 5.75E-04 Bipolar disorder / / 19259986 rs152528 chr5 142017860 C T 8.00E-07 Cardiac hypertrophy FGF1 intron 21348951 rs10070885 chr5 142020380 C T 1.23E-04 Amyotrophic Lateral Sclerosis FGF1 intron 17362836 rs10070885 chr5 142020380 C T 6.34E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) FGF1 intron 23648065 rs2070715 chr5 142024256 T C 5.39E-04 Rheumatoid arthritis FGF1 intron 21452313 rs17099186 chr5 142044010 C T 9.64E-04 Type 2 diabetes FGF1 intron 17463246 rs11742776 chr5 142047191 A G 9.11E-04 Response to taxane treatment (placlitaxel) FGF1 intron 23006423 rs10477189 chr5 142048715 T C 5.24E-04 Response to taxane treatment (placlitaxel) FGF1 intron 23006423 rs7708257 chr5 142055537 T G 5.24E-04 Response to taxane treatment (placlitaxel) FGF1 intron 23006423 rs7722035 chr5 142055973 G C 7.85E-04 Response to taxane treatment (placlitaxel) FGF1 intron 23006423 rs1867663 chr5 142058904 T C 6.87E-04 Response to taxane treatment (placlitaxel) FGF1 intron 23006423 rs9324892 chr5 142059400 T C 2.59E-04 Response to taxane treatment (placlitaxel) FGF1 intron 23006423 rs17208908 chr5 142059978 G A 8.48E-04 Multiple complex diseases FGF1 intron 17554300 rs11167785 chr5 142063729 T C 3.71E-04 Response to taxane treatment (placlitaxel) FGF1 intron 23006423 rs1916998 chr5 142074132 G T 6.01E-04 Nicotine smoking FGF1 intron 19268276 rs2879382 chr5 142079282 G A 7.50E-04 Multiple complex diseases / / 17554300 rs7727333 chr5 142087016 G A 6.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17099396 chr5 142097317 A G 1.08E-05 Heart rate / / 23583979 rs10476844 chr5 142116718 C T 3.50E-05 Type 2 diabetes / / 17463248 rs7732591 chr5 142125177 T C 5.05E-04 Hemoglobin concentration / / 20534544 rs930208 chr5 142131150 G A 5.05E-04 Hemoglobin concentration / / 20534544 rs961730 chr5 142133942 T C 2.40E-05 Type 2 diabetes / / 17463248 rs1347133 chr5 142134106 T C 2.10E-05 Type 2 diabetes / / 17463248 rs968076 chr5 142136307 A G 2.00E-05 Type 2 diabetes / / 17463248 rs7714907 chr5 142145386 A G 1.20E-05 Type 2 diabetes / / 17463248 rs7732207 chr5 142145429 G A 1.20E-05 Type 2 diabetes / / 17463248 rs764387 chr5 142145685 C T 1.20E-05 Type 2 diabetes / / 17463248 rs7737018 chr5 142146099 G C 1.30E-05 Type 2 diabetes / / 17463248 rs6898675 chr5 142151659 C T 1.40E-05 Type 2 diabetes ARHGAP26 intron 17463248 rs6894433 chr5 142153351 T C 1.40E-05 Type 2 diabetes ARHGAP26 intron 17463248 rs415786 chr5 142183997 T A 8.70E-04 Type 2 diabetes ARHGAP26 intron 17463246 rs3733734 chr5 142199167 T C 2.99E-04 Lymphocyte counts ARHGAP26 intron 22286170 rs10044036 chr5 142238119 C T 8.14E-05 AIDS ARHGAP26 intron 19754311 rs3733732 chr5 142246733 C G 5.76E-04 Alzheimer's disease ARHGAP26 intron 22005930 rs707177 chr5 142251892 G A 6.40E-05 Type 2 diabetes ARHGAP26 intron 17463248 rs447923 chr5 142252257 C T 9.20E-05 Type 2 diabetes ARHGAP26 intron 17463248 rs10039856 chr5 142252549 C T 9.57E-05 Body Mass Index ARHGAP26 intron pha003014 rs26707 chr5 142253673 C G 3.00E-05 Type 2 diabetes ARHGAP26 intron 17463248 rs26706 chr5 142256860 G C 3.20E-05 Type 2 diabetes ARHGAP26 intron 17463248 rs10515517 chr5 142256913 G A 2.30E-04 Multiple complex diseases ARHGAP26 intron 17554300 rs27779 chr5 142259083 C A 2.50E-05 Type 2 diabetes ARHGAP26 intron 17463248 rs27546 chr5 142265745 A T 3.50E-05 Type 2 diabetes ARHGAP26 intron 17463248 rs830532 chr5 142289541 C T 3.70E-05 Malarial infection ARHGAP26 intron 20657648 rs3822398 chr5 142387961 C T 1.59E-05 Schizophrenia ARHGAP26 intron 19571811 rs245852 chr5 142394380 A G 6.94E-05 Neuroblastoma ARHGAP26 intron pha002895 rs7723504 chr5 142395016 T C 5.15E-04 Multiple complex diseases ARHGAP26 intron 17554300 rs246664 chr5 142421931 G T 1.50E-05 Urinary metabolites ARHGAP26 intron 21572414 rs3776331 chr5 142441794 T C 9.42E-04 Multiple complex diseases ARHGAP26 intron 17554300 rs3776331 chr5 142441794 T C 8.00E-06 Uric acid levels ARHGAP26 intron 18759275 rs2398613 chr5 142484605 C T 9.77E-04 Type 2 diabetes ARHGAP26 intron 17463246 rs246600 chr5 142516897 C T 7.67E-08 Coronary artery disease ARHGAP26 intron 23202125 rs258799 chr5 142529960 T G 1.90E-04 Epilepsy ARHGAP26 intron 22116939 rs853169 chr5 142538417 G A 1.70E-05 Urinary metabolites ARHGAP26 intron 21572414 rs853165 chr5 142550251 G A 8.20E-04 Acute lung injury ARHGAP26 intron 22295056 rs7720909 chr5 142565658 A G 6.91E-05 Multiple complex diseases ARHGAP26 intron 17554300 rs244468 chr5 142604421 A G 3.10E-04 Suicide attempts in bipolar disorder ARHGAP26 UTR-3 21423239 rs187729 chr5 142605569 C T 4.38E-04 Suicide attempts in bipolar disorder ARHGAP26 UTR-3 21423239 rs154787 chr5 142606301 C A 4.75E-04 Suicide attempts in bipolar disorder ARHGAP26 UTR-3 21423239 rs154786 chr5 142606971 T C 4.16E-04 Suicide attempts in bipolar disorder ARHGAP26 UTR-3 21423239 rs13359372 chr5 142612938 A G 7.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs174047 chr5 142623288 T G 8.31E-05 Cognitive impairment induced by topiramate / / 22091778 rs852977 chr5 142687494 A G 1 Drug response to Escitalopram NR3C1 intron 19365399 rs852977 chr5 142687494 A G 1 Drug response to Nortriptyline NR3C1 intron 19365399 rs17100234 chr5 142714642 C A 0.000000508 HDL cholesterol NR3C1 intron 23063622 rs2918415 chr5 142744963 A C 4.38E-04 Amyotrophic lateral sclerosis (sporadic) NR3C1 intron 24529757 rs10066267 chr5 142746653 A G 2.00E-06 Parkinson's disease (interaction with coffee consumption) NR3C1 intron 21876681 rs10482633 chr5 142750533 T G 1 Drug response to Escitalopram NR3C1 intron 19365399 rs10482633 chr5 142750533 T G 1 Drug response to Nortriptyline NR3C1 intron 19365399 rs13182800 chr5 142801480 G T 0.00000212 Cholesterol,total NR3C1 intron 23063622 rs13182800 chr5 142801480 G T 0.0000571 LDL cholesterol NR3C1 intron 23063622 rs4912911 chr5 142807032 G A 9.74E-05 Height NR3C1 intron pha003010 rs4912918 chr5 142837711 A G 9.39E-05 Suicide attempts in bipolar disorder / / 21423239 rs7701487 chr5 142837798 T A 9.31E-05 Suicide attempts in bipolar disorder / / 21423239 rs4130381 chr5 142838582 A G 9.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs6871464 chr5 142839717 T C 2.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs6887822 chr5 142842276 T C 7.53E-05 Suicide attempts in bipolar disorder / / 21423239 rs11167813 chr5 142849104 T G 5.93E-05 Suicide attempts in bipolar disorder / / 21423239 rs13181162 chr5 142849379 T C 7.71E-05 Suicide attempts in bipolar disorder / / 21423239 rs17100309 chr5 142849609 A G 7.27E-05 Suicide attempts in bipolar disorder / / 21423239 rs1348702 chr5 142850320 C G 6.41E-05 Suicide attempts in bipolar disorder / / 21423239 rs7714402 chr5 142852148 T C 7.84E-04 Multiple complex diseases / / 17554300 rs7728928 chr5 142852275 C T 7.95E-04 Multiple complex diseases / / 17554300 rs2895177 chr5 142854349 T A 1.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs17100323 chr5 142862611 C G 7.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs12187548 chr5 142862747 A C 4.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs12187548 chr5 142862747 A C 4.67E-08 Metabolite levels / / 23281178 rs7721458 chr5 142863240 C A,T 6.00E-05 Blood Pressure / / pha003046 rs7721458 chr5 142863240 C A,T 7.59E-05 Blood Pressure / / pha003048 rs6860760 chr5 142868379 A G 6.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs6860760 chr5 142868379 A G 4.89E-08 Metabolite levels / / 23281178 rs17341585 chr5 142871503 G A 1.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs13158686 chr5 142874217 C A 1.56E-06 Multiple complex diseases / / 17554300 rs4244034 chr5 142885780 T G 9.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs4244034 chr5 142885780 T G 6.36E-08 Metabolite levels / / 23281178 rs10057473 chr5 142887378 G C 5.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs10057473 chr5 142887378 G C 7.82E-08 Metabolite levels / / 23281178 rs4912652 chr5 142888684 C T 4.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs4912652 chr5 142888684 C T 2.83E-08 Metabolite levels / / 23281178 rs17341992 chr5 142893637 T C 6.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs17401501 chr5 142894711 G A 8.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs1946237 chr5 142895450 A T 8.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs2895168 chr5 142895518 A G 8.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs1445873 chr5 142895811 T C 6.24E-04 Multiple complex diseases / / 17554300 rs1445873 chr5 142895811 T C 6.94E-04 Smoking quantity / / 24665060 rs12153243 chr5 142899801 A T 1.75E-04 Migraine - clinic-based / / 23793025 rs12153243 chr5 142899801 A T 3.66E-04 Migraine with aura / / 23793025 rs12153243 chr5 142899801 A T 6.00E-06 Migraine / / 23793025 rs7700977 chr5 142904949 T G 4.75E-05 Waist Circumference / / pha003023 rs6580287 chr5 142905613 G T 2.82E-05 Waist Circumference / / pha003023 rs7732768 chr5 142933619 T C 8.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs6580292 chr5 142942241 C G 8.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs17403174 chr5 142945746 A G 9.59E-05 Parkinson's disease / / 23793441 rs655458 chr5 142954168 T A 6.93E-04 Multiple complex diseases / / 17554300 rs185057 chr5 142962119 G A 2.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs153512 chr5 142969131 T C 4.11E-05 Waist Circumference / / pha003023 rs246539 chr5 142969974 G A 9.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs11167821 chr5 142974644 A G 7.98E-05 Behcet's disease / / pha002888 rs153516 chr5 142979183 G A 2.45E-05 Waist Circumference / / pha003023 rs17100498 chr5 143003605 T C 5.00E-07 Response to antipsychotic treatment / / 20195266 rs17404863 chr5 143003648 T C 1.82E-04 Smoking initiation / / 24665060 rs4912929 chr5 143018221 T C 5.85E-05 Schizophrenia(age at onset) / / 21688384 rs6898504 chr5 143019997 C T 8.17E-05 Schizophrenia(age at onset) / / 21688384 rs1427864 chr5 143036860 A C 6.86E-05 Height / / pha003010 rs1427864 chr5 143036860 A C 1.05E-05 Height / / pha003011 rs10070905 chr5 143039972 G A 4.26E-05 Height / / pha003011 rs9324928 chr5 143096916 G A 8.96E-05 Asthma / / pha003127 rs12656580 chr5 143110247 C G 7.05E-04 Multiple complex diseases / / 17554300 rs188975 chr5 143110997 C T 2.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs188975 chr5 143110997 C T 3.60E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs17414396 chr5 143112659 G A 3.13E-04 Multiple complex diseases / / 17554300 rs167801 chr5 143117818 G A 9.51E-04 Depression (quantitative trait) / / 20800221 rs325247 chr5 143119511 T C 5.95E-05 Relative hand skill in reading disability / / 24068947 rs325239 chr5 143125856 G A 6.47E-04 Depression (quantitative trait) / / 20800221 rs325238 chr5 143126090 C T 6.54E-04 Depression (quantitative trait) / / 20800221 rs325235 chr5 143127750 C T 4.69E-04 Depression (quantitative trait) / / 20800221 rs325232 chr5 143128591 C T 4.67E-04 Depression (quantitative trait) / / 20800221 rs325232 chr5 143128591 C T 3.92E-05 Relative hand skill in reading disability / / 24068947 rs325229 chr5 143130044 G C 2.82E-04 Depression (quantitative trait) / / 20800221 rs6580301 chr5 143130488 G A 2.78E-04 Depression (quantitative trait) / / 20800221 rs6580302 chr5 143130523 G A 2.77E-04 Depression (quantitative trait) / / 20800221 rs2636103 chr5 143131673 C T 3.85E-04 Depression (quantitative trait) / / 20800221 rs12153050 chr5 143141345 C T 1.00E-04 Information processing speed / / 21130836 rs6864427 chr5 143151880 T C 8.77E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2636101 chr5 143158281 A G 3.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7715118 chr5 143168435 C T 1.63E-05 Information processing speed / / 21130836 rs13180909 chr5 143172351 C T 1.86E-05 Information processing speed / / 21130836 rs833748 chr5 143173023 C T 9.41E-04 Depression (quantitative trait) / / 20800221 rs7717084 chr5 143207851 A G 7.65E-04 Multiple complex diseases / / 17554300 rs7721447 chr5 143208050 T G 9.64E-04 Multiple complex diseases / / 17554300 rs323983 chr5 143222470 C T 2.06E-05 Lymphocyte counts / / 22286170 rs323985 chr5 143223005 T C 8.37E-05 Information processing speed / / 21130836 rs10075045 chr5 143254308 C T 1.90E-04 Multiple complex diseases / / 17554300 rs9324934 chr5 143265146 G A 5.50E-04 Multiple complex diseases / / 17554300 rs2112197 chr5 143275201 T C 2.85E-05 Atopy / / 21625490 rs456304 chr5 143298046 A G 1.30E-04 Multiple complex diseases / / 17554300 rs312578 chr5 143342108 T C 9.72E-04 Multiple complex diseases / / 17554300 rs312578 chr5 143342108 T C 8.45E-04 Coronary Artery Disease / / 17634449 rs312575 chr5 143343530 A G 8.97E-04 Multiple complex diseases / / 17554300 rs17101280 chr5 143347763 T C 9.38E-04 Multiple complex diseases / / 17554300 rs17101280 chr5 143347763 T C 2.60E-05 Urinary metabolites / / 21572414 rs312620 chr5 143360478 T A 2.08E-10 Non-obstructive azoospermia / / 22197933 rs391760 chr5 143411346 G T 2.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs17580442 chr5 143416299 T A 9.08E-04 Type 2 diabetes / / 17463246 rs17580874 chr5 143422768 T A 9.08E-04 Type 2 diabetes / / 17463246 rs409220 chr5 143422945 C T 3.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs2398716 chr5 143470345 T C 2.63E-05 Personality dimensions / / 18957941 rs904208 chr5 143470927 C A 1.77E-05 Personality dimensions / / 18957941 rs904208 chr5 143470927 C A 1.80E-05 Personality dimensions / / 21173776 rs754108 chr5 143483165 A G 8.53E-05 Personality dimensions / / 18957941 rs4513726 chr5 143504102 A G 3.91E-04 Coronary Artery Disease / / 17634449 rs4374781 chr5 143506829 G T 5.82E-04 Coronary Artery Disease / / 17634449 rs11167846 chr5 143530915 T C 1.11E-06 Lipoproteins / / pha003079 rs1833501 chr5 143546466 T C 5.47E-04 Parkinson's disease YIPF5 intron 17052657 rs1833501 chr5 143546466 T C 3.92E-05 Lipoproteins YIPF5 intron pha003079 rs1862140 chr5 143549711 A C 5.47E-04 Parkinson's disease YIPF5 intron 17052657 rs1862140 chr5 143549711 A C 3.00E-05 Lipoproteins YIPF5 intron pha003079 rs6887917 chr5 143554780 G A 3.55E-04 Suicide attempts in bipolar disorder KCTD16 intron 21041247 rs6876352 chr5 143557864 C T 8.35E-04 Coronary Artery Disease KCTD16 intron 17634449 rs7727648 chr5 143568266 A G 1.65E-05 Lipoproteins KCTD16 intron pha003079 rs10463368 chr5 143569586 C T 4.50E-06 Urinary metabolites KCTD16 intron 21572414 rs10463368 chr5 143569586 C T 8.61E-05 Post-operative nausea and vomiting KCTD16 intron 21694509 rs10463368 chr5 143569586 C T 7.27E-05 Lipoproteins KCTD16 intron pha003079 rs2398721 chr5 143588414 C T 9.22E-05 Lung function (forced vital capacity) KCTD16 intron 24023788 rs6868068 chr5 143589949 A G 2.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCTD16 intron 20877124 rs2546532 chr5 143595109 A G 5.53E-04 Endometrial cancer KCTD16 intron 24096698 rs7711546 chr5 143669068 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes KCTD16 intron 22628534 rs9324949 chr5 143670079 T A 8.17E-04 Coronary Artery Disease KCTD16 intron 17634449 rs6878187 chr5 143678790 T G 2.82E-04 Response to taxane treatment (placlitaxel) KCTD16 intron 23006423 rs1422715 chr5 143688636 A G 3.26E-04 Response to taxane treatment (placlitaxel) KCTD16 intron 23006423 rs17440108 chr5 143694251 A G 9.50E-04 Suicide attempts in bipolar disorder KCTD16 intron 21423239 rs960963 chr5 143703515 C G 7.22E-04 Coronary Artery Disease KCTD16 intron 17634449 rs960963 chr5 143703515 C G 8.57E-05 Smoking cessation KCTD16 intron 18519826 rs244536 chr5 143715489 T A 8.02E-05 Smoking cessation KCTD16 intron 18519826 rs244525 chr5 143728091 G A 9.22E-04 Coronary Artery Disease KCTD16 intron 17634449 rs244525 chr5 143728091 G A 2.54E-05 Smoking cessation KCTD16 intron 18519826 rs17101811 chr5 143732890 C G 4.00E-04 Multiple complex diseases KCTD16 intron 17554300 rs10040935 chr5 143747325 T G 6.15E-04 Response to taxane treatment (placlitaxel) KCTD16 intron 23006423 rs723223 chr5 143747601 G A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes KCTD16 intron 22628534 rs10515542 chr5 143758377 G A 4.45E-04 Coronary Artery Disease KCTD16 intron 17634449 rs1023679 chr5 143766166 A G 3.82E-04 Coronary Artery Disease KCTD16 intron 17634449 rs1023679 chr5 143766166 A G 9.66E-05 Smoking cessation KCTD16 intron 18519826 rs10055809 chr5 143766246 C T 9.69E-06 Multiple complex diseases KCTD16 intron 17554300 rs10055809 chr5 143766246 C T 7.08E-04 Response to taxane treatment (placlitaxel) KCTD16 intron 23006423 rs6580317 chr5 143772718 C T 4.29E-04 Coronary Artery Disease KCTD16 intron 17634449 rs145716 chr5 143847218 T C 3.07E-05 Coronary Artery Disease KCTD16 intron 17634449 rs145716 chr5 143847218 T C 1.76E-04 Smoking cessation KCTD16 intron 18519826 rs349696 chr5 143857323 C A 5.00E-05 Coronary Artery Disease / / 17634449 rs468579 chr5 143947058 A G 1.98E-05 Cognitive impairment induced by topiramate / / 22091778 rs9324962 chr5 143961456 G T 9.96E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs165444 chr5 143966170 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs171818 chr5 144025843 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs31385 chr5 144028395 C A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17451739 chr5 144030993 C T 9.22E-04 Type 2 diabetes / / 17463246 rs7704625 chr5 144064654 G A 7.60E-05 Height / / 21998595 rs724382 chr5 144065162 A G 1.10E-04 Height / / 21998595 rs10065677 chr5 144070311 C T 7.60E-06 Emphysema-related traits / / 20709820 rs10058739 chr5 144074365 G A 2.06E-06 Glaucoma (primary open-angle) / / 22605921 rs13154970 chr5 144116622 A G 9.60E-05 Cognitive impairment induced by topiramate / / 22091778 rs10053832 chr5 144119992 C T 2.67E-05 Coronary Artery Disease / / 17634449 rs3866869 chr5 144135871 T C 1.61E-04 Coronary Artery Disease / / 17634449 rs3866869 chr5 144135871 T C 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs247567 chr5 144159839 T C 2.01E-04 Multiple complex diseases / / 17554300 rs247567 chr5 144159839 T C 9.70E-04 Obesity (extreme) / / 21935397 rs17102446 chr5 144168008 T C 2.14E-04 Smoking cessation / / 24665060 rs10041348 chr5 144192894 A G 7.42E-05 Coronary Artery Disease / / 17634449 rs248576 chr5 144202677 G A 3.18E-04 Multiple complex diseases / / 17554300 rs950032 chr5 144211951 A G 4.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1545029 chr5 144216017 G T 2.91E-04 Multiple complex diseases / / 17554300 rs7730684 chr5 144230419 T C 3.24E-04 Multiple complex diseases / / 17554300 rs13178033 chr5 144235147 C T 2.36E-04 Multiple complex diseases / / 17554300 rs7730610 chr5 144241355 A G 5.95E-04 Obesity (extreme) / / 21935397 rs13181482 chr5 144242950 A C 5.64E-04 Obesity (extreme) / / 21935397 rs1368338 chr5 144243287 A G 5.94E-04 Obesity (extreme) / / 21935397 rs6887305 chr5 144244112 C T 6.35E-04 Obesity (extreme) / / 21935397 rs6887503 chr5 144244236 C T 6.35E-04 Obesity (extreme) / / 21935397 rs13185780 chr5 144258035 C G 6.32E-04 Obesity (extreme) / / 21935397 rs1549895 chr5 144261986 G A 8.16E-05 Multiple complex diseases / / 17554300 rs1549896 chr5 144262743 G A 2.45E-04 Multiple complex diseases / / 17554300 rs1549896 chr5 144262743 G A 2.38E-04 Hemoglobin concentration / / 20534544 rs7712842 chr5 144267106 T C 5.40E-06 Type 2 diabetes / / 17293876 rs7712842 chr5 144267106 T C 5.40E-06 Type 2 diabetes / / 19184112 rs1368335 chr5 144275245 G T 4.76E-04 Hemoglobin concentration / / 20534544 rs2190810 chr5 144286808 T C 5.01E-05 Serum metabolites / / 19043545 rs6894954 chr5 144314363 A G 5.00E-06 Type 2 diabetes / / 17293876 rs6894954 chr5 144314363 A G 5.00E-06 Type 2 diabetes / / 19184112 rs248012 chr5 144342253 G T 5.38E-04 Type 2 diabetes / / 17463246 rs10059999 chr5 144393385 C T 7.41E-06 Stroke (ischemic) / / 21957438 rs11167889 chr5 144430300 T C 5.94E-04 Smoking quantity / / 24665060 rs6892136 chr5 144441278 T C 3.01E-04 Smoking cessation / / 24665060 rs11167892 chr5 144460435 T C 2.40E-05 Urinary metabolites / / 21572414 rs11167892 chr5 144460435 T C 2.06E-05 Coronary heart disease / / pha003030 rs1422839 chr5 144461281 C G 5.84E-05 Depression (quantitative trait) / / 20800221 rs10875610 chr5 144461473 A G 0.0000635 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10875611 chr5 144461683 G C 0.0000659 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9324976 chr5 144464260 A C 2.30E-05 Urinary metabolites / / 21572414 rs9324976 chr5 144464260 A C 1.53E-05 Coronary heart disease / / pha003030 rs2190793 chr5 144468669 A T 0.0000354 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs3861860 chr5 144475242 A T 0.000048 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2190791 chr5 144478094 C G 0.0000554 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2190790 chr5 144478215 C T 0.0000269 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs28671333 chr5 144478637 A C 0.0000265 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2190788 chr5 144484261 G T 0.0000803 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6866653 chr5 144486353 T C 0.0000128 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13178930 chr5 144490411 A G 0.0000804 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7447393 chr5 144492907 C T 0.0000408 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6863059 chr5 144495467 C G 0.0000344 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6862136 chr5 144495743 G A 0.0000429 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10071014 chr5 144497166 G A 0.0000487 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1860057 chr5 144499834 C A 0.0000511 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13188372 chr5 144501151 G A 0.0000447 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34177852 chr5 144503307 A C 0.0000493 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6875288 chr5 144506078 A G 0.0000824 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10454999 chr5 144510131 A G 0.0000521 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs3995520 chr5 144510516 A T 0.0000536 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs961748 chr5 144511162 T C 0.0000388 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12652320 chr5 144511211 A G 7.72E-05 Depression (quantitative trait) / / 20800221 rs4256374 chr5 144512126 C T 0.0000502 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6884441 chr5 144512659 T C 0.0000545 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7710868 chr5 144514290 C A 0.0000605 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs55700177 chr5 144520311 T C 0.0000325 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2190785 chr5 144521182 C G 0.0000151 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs28580671 chr5 144522988 G A 0.0000167 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs28618243 chr5 144523083 T C 0.00000878 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2058115 chr5 144523415 A G 0.0000181 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7736959 chr5 144524955 C G 0.0000186 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7718515 chr5 144524959 A G 0.000019 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10056402 chr5 144527350 C G 0.0000277 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13168909 chr5 144527685 C T 0.0000155 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7724694 chr5 144527935 C T 0.0000139 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6580342 chr5 144528126 A T 0.0000262 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6580343 chr5 144528420 C T 0.0000293 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1981626 chr5 144528455 T C 8.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1002807 chr5 144528984 C T 0.0000302 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17391588 chr5 144529101 T A 0.0000304 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs271073 chr5 144532957 C T 0.0000298 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs271074 chr5 144532999 G C 0.0000311 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs271075 chr5 144534035 T C 0.0000175 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs271076 chr5 144535481 A C 0.000024 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs271077 chr5 144535710 T C 0.0000178 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs271078 chr5 144536751 G A 0.0000308 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs271079 chr5 144538201 C G 0.0000224 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7715541 chr5 144539801 A T 0.0000289 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs271081 chr5 144540504 T C 0.0000288 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6890604 chr5 144541531 T C 0.0000333 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs271084 chr5 144543375 C A 0.0000173 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs271085 chr5 144543593 A G 0.0000263 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7703576 chr5 144543996 T C 0.000078 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2400170 chr5 144545930 A C 0.0000369 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2110042 chr5 144546544 A C 0.0000347 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7708883 chr5 144547439 G A 0.0000361 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6580344 chr5 144548902 G A 0.0000389 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6580345 chr5 144548934 A G 0.0000765 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11949788 chr5 144549262 G A 7.12E-05 Cognitive test performance / / 20125193 rs2400174 chr5 144573096 G A 5.83E-04 Multiple complex diseases / / 17554300 rs7719533 chr5 144586077 C T 3.55E-04 Schizophrenia / / 21674006 rs2547002 chr5 144605231 C A 6.08E-05 Bipolar disorder and schizophrenia / / 20889312 rs4912691 chr5 144607666 A G 6.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17102958 chr5 144627728 C T 4.71E-04 Sarcoidosis / / 19165924 rs6880903 chr5 144652413 T C 9.63E-06 Obesity-related traits / / 23251661 rs10515549 chr5 144697489 A G 1.25E-04 Attention deficit hyperactivity disorder / / 22012869 rs154495 chr5 144718058 T C 7.00E-05 Response to statin therapy / / 20339536 rs154495 chr5 144718058 T C 7.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs2442760 chr5 144726896 T C 7.50E-05 Response to statin therapy / / 20339536 rs2442760 chr5 144726896 T C 6.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs1450332 chr5 144735126 G A 4.22E-04 Heart Failure / / pha002884 rs26158 chr5 144739514 C T 6.60E-05 Response to statin therapy / / 20339536 rs26158 chr5 144739514 C T 5.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs32197 chr5 144742977 A G 6.60E-05 Response to statin therapy / / 20339536 rs1450326 chr5 144745265 G A 5.00E-05 Response to statin therapy / / 20339536 rs1450326 chr5 144745265 G A 4.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs1597460 chr5 144747242 A G 7.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs2442988 chr5 144747783 C T 5.40E-05 Response to statin therapy / / 20339536 rs2442988 chr5 144747783 C T 7.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs2431748 chr5 144754441 T C 8.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs2839745 chr5 144759960 A C 7.20E-05 Response to statin therapy / / 20339536 rs7444042 chr5 144763704 A T 7.40E-05 Response to statin therapy / / 20339536 rs7444042 chr5 144763704 A T 8.12E-04 Depression (quantitative trait) / / 20800221 rs282462 chr5 144764931 T C 1.98E-04 Lung function (forced vital capacity) / / 24023788 rs282461 chr5 144765247 C G 6.90E-05 Response to statin therapy / / 20339536 rs282461 chr5 144765247 C G 7.90E-04 Depression (quantitative trait) / / 20800221 rs32196 chr5 144766803 A G 8.08E-04 Depression (quantitative trait) / / 20800221 rs32196 chr5 144766803 A G 7.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs32193 chr5 144768423 G A 1.27E-04 Depression (quantitative trait) / / 20800221 rs32192 chr5 144768513 C T 1.27E-04 Depression (quantitative trait) / / 20800221 rs32191 chr5 144768756 C T 1.26E-04 Depression (quantitative trait) / / 20800221 rs32190 chr5 144769376 T C 5.50E-05 Response to statin therapy / / 20339536 rs32190 chr5 144769376 T C 5.41E-04 Depression (quantitative trait) / / 20800221 rs282457 chr5 144773424 T C 8.25E-04 Depression (quantitative trait) / / 20800221 rs282457 chr5 144773424 T C 4.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs282457 chr5 144773424 T C 1.03E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs282457 chr5 144773424 T C 7.93E-05 Lung function (forced vital capacity) / / 24023788 rs282455 chr5 144774188 A C 6.40E-05 Response to statin therapy / / 20339536 rs282455 chr5 144774188 A C 5.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs32200 chr5 144777730 T C 2.98E-04 Depression (quantitative trait) / / 20800221 rs7736243 chr5 144779164 A T 1.04E-04 Depression (quantitative trait) / / 20800221 rs711171 chr5 144782381 C A 1.10E-04 Depression (quantitative trait) / / 20800221 rs813188 chr5 144782407 A C 1.10E-04 Depression (quantitative trait) / / 20800221 rs1086849 chr5 144786806 C G 3.06E-04 Depression (quantitative trait) / / 20800221 rs796940 chr5 144793716 C A 5.18E-04 Depression (quantitative trait) / / 20800221 rs6875732 chr5 144806973 T A 1.09E-04 Depression (quantitative trait) / / 20800221 rs6886139 chr5 144807446 A G 1.09E-04 Depression (quantitative trait) / / 20800221 rs17475118 chr5 144807495 T C 1.62E-04 Depression (quantitative trait) / / 20800221 rs1946246 chr5 144809625 G A 5.47E-04 Depression (quantitative trait) / / 20800221 rs7721549 chr5 144810692 G A 1.18E-04 Depression (quantitative trait) / / 20800221 rs10515550 chr5 144812693 C T 1.20E-04 Depression (quantitative trait) / / 20800221 rs10515550 chr5 144812693 C T 9.93E-06 Osteoarthritis / / 22763110 rs11949093 chr5 144812772 A G 1.17E-04 Depression (quantitative trait) / / 20800221 rs365874 chr5 144813876 C T 5.64E-04 Depression (quantitative trait) / / 20800221 rs7725009 chr5 144813968 T C 6.28E-05 Serum metabolites / / 19043545 rs415600 chr5 144817144 T A 4.41E-04 Depression (quantitative trait) / / 20800221 rs17103175 chr5 144818318 C A 7.46E-06 Serum metabolites / / 19043545 rs17103175 chr5 144818318 C A 6.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs17103176 chr5 144818733 C T 5.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs17103176 chr5 144818733 C T 2.81E-05 Magnesium levels / / pha003092 rs433924 chr5 144819407 C T 3.31E-04 Depression (quantitative trait) / / 20800221 rs10477276 chr5 144821606 G A 4.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs6861903 chr5 144823021 A C 7.46E-06 Serum metabolites / / 19043545 rs6861903 chr5 144823021 A C 4.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs13168832 chr5 144828514 C T 5.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs4913029 chr5 144828854 A G 5.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs4913029 chr5 144828854 A G 2.17E-05 Magnesium levels / / pha003092 rs4913030 chr5 144829287 C T 6.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs10068420 chr5 144829826 T C 6.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs13177728 chr5 144830128 G A 4.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs6860664 chr5 144831823 G A 7.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs10054460 chr5 144841167 A T 7.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs10054534 chr5 144841340 A T 7.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs4530816 chr5 144843077 T C 6.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs2431606 chr5 144843397 A G 3.26E-04 Depression (quantitative trait) / / 20800221 rs2974572 chr5 144845050 G A 3.09E-04 Depression (quantitative trait) / / 20800221 rs13190418 chr5 144846339 A G 7.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs2974571 chr5 144846633 G A 3.08E-04 Depression (quantitative trait) / / 20800221 rs6872426 chr5 144846813 T A 6.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs2910271 chr5 144849242 T G 3.09E-04 Depression (quantitative trait) / / 20800221 rs1422922 chr5 144849881 T G 1.63E-05 Serum metabolites / / 19043545 rs1422922 chr5 144849881 T G 6.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs2910272 chr5 144851525 A G 3.27E-04 Depression (quantitative trait) / / 20800221 rs2910272 chr5 144851525 A G 7.61E-04 Smoking cessation / / 24665060 rs3851494 chr5 144854382 A C 6.00E-06 Serum metabolites / / 19043545 rs450337 chr5 144855154 G A 3.92E-04 Smoking quantity / / 24665060 rs118978 chr5 144855438 C A,G,T 2.90E-04 Depression (quantitative trait) / / 20800221 rs3901056 chr5 144856449 G A 9.02E-06 Serum metabolites / / 19043545 rs3901056 chr5 144856449 G A 8.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs717076 chr5 144861632 G A 6.99E-04 Smoking quantity / / 24665060 rs1363551 chr5 144864560 G A,C 4.56E-05 Serum metabolites / / 19043545 rs7733492 chr5 144865268 C T 9.87E-07 Magnesium levels / / pha003092 rs12657926 chr5 144890837 A G 3.10E-06 Magnesium levels / / pha003092 rs4913034 chr5 144911771 A C 2.18E-06 Magnesium levels / / pha003092 rs7713855 chr5 144924504 T C 3.64E-04 Multiple complex diseases / / 17554300 rs7713855 chr5 144924504 T C 5.52E-04 Coronary heart disease / / 21971053 rs17103543 chr5 145011870 G A 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs10515552 chr5 145038831 T C 4.00E-08 Vitamin B12 levels / / 22367966 rs6883434 chr5 145039897 G A 1.54E-05 Hearing function / / 17255346 rs1025472 chr5 145099204 G A 7.52E-04 Alzheimer's disease / / 24755620 rs1025473 chr5 145099317 A G 8.38E-04 Alzheimer's disease / / 24755620 rs1654242 chr5 145103312 G A 7.02E-04 Alzheimer's disease / / 24755620 rs1654236 chr5 145108829 A G 6.77E-04 Alzheimer's disease / / 24755620 rs1897543 chr5 145116272 C A 7.17E-04 Alzheimer's disease / / 24755620 rs12651915 chr5 145124401 T C 9.35E-04 Alzheimer's disease / / 24755620 rs11740064 chr5 145131972 T C 3.98E-05 Celiac disease / / 23936387 rs338897 chr5 145145568 C G 4.30E-05 Cognitive function PRELID2 intron 24684796 rs587224 chr5 145150886 C T 7.60E-05 Cognitive function PRELID2 intron 24684796 rs13184016 chr5 145160343 C T 5.93E-04 Coronary heart disease PRELID2 intron 21606135 rs421289 chr5 145200074 A G 3.60E-04 Age-related macular degeneration PRELID2 intron 22125219 rs7725012 chr5 145203736 A C 3.74E-06 Multiple complex diseases PRELID2 intron 17554300 rs12655088 chr5 145210955 T G 4.54E-05 Multiple complex diseases PRELID2 intron 17554300 rs455117 chr5 145239004 A G 9.60E-05 Tourette syndrome / / 22889924 rs10037373 chr5 145252574 C T 8.14E-04 Multiple complex diseases / / 17554300 rs1821251 chr5 145270339 A G 8.90E-05 Information processing speed / / 21130836 rs11167915 chr5 145289001 T C 7.11E-05 Attention deficit hyperactivity disorder / / 22420046 rs868777 chr5 145313228 T A 4.50E-05 Personality dimensions / / 18957941 rs868776 chr5 145313273 C T 4.40E-05 Personality dimensions / / 18957941 rs7725688 chr5 145315962 T C 1.65E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17104037 chr5 145316958 T C 3.63E-04 Response to cytidine analogues (gemcitabine) SH3RF2 intron 24483146 rs2400207 chr5 145380097 A G 3.00E-05 Type 2 diabetes SH3RF2 intron 17903298 rs1859894 chr5 145386138 T G 1.50E-05 Urinary metabolites SH3RF2 intron 21572414 rs758038 chr5 145387254 G C 2.80E-05 Urinary metabolites SH3RF2 intron 21572414 rs11743632 chr5 145409070 G A 4.47E-04 Coronary Artery Disease SH3RF2 intron 17634449 rs7706656 chr5 145418274 A G 8.21E-04 Coronary Artery Disease SH3RF2 intron 17634449 rs2962522 chr5 145425583 C T 9.26E-04 Coronary Artery Disease SH3RF2 intron 17634449 rs9325002 chr5 145426248 T C 7.00E-05 Type 2 diabetes SH3RF2 intron 17903298 rs2963921 chr5 145513868 C A 5.67E-05 Bipolar disorder LARS intron 19488044 rs17500483 chr5 145532859 T C 4.81E-04 Response to taxane treatment (placlitaxel) LARS intron 23006423 rs17429180 chr5 145598283 A T 4.31E-04 Lymphocyte counts RBM27 intron 22286170 rs17104331 chr5 145612822 A G 2.94E-04 Response to statin treatment (atorvastatin),change in cholesterol levels RBM27 intron 20031582 rs1368402 chr5 145717285 A C 1.02E-04 Coronary Artery Disease POU4F3 nearGene-5 17634449 rs7718446 chr5 145749535 A G 1.41E-05 Migraine / / 23793025 rs7718446 chr5 145749535 A G 4.00E-06 Migraine without aura / / 23793025 rs1991800 chr5 145753001 G A 4.66E-04 Schizophrenia / / 19197363 rs2304066 chr5 145780692 C T 1.00E-04 Schizophrenia / / 19197363 rs6868716 chr5 145789259 T C 1.00E-04 Schizophrenia / / 19197363 rs6889741 chr5 145820412 C T 4.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17104665 chr5 145842469 A G 4.54E-06 Obesity (extreme) TCERG1 intron 21935397 rs10068201 chr5 145849426 A G 7.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TCERG1 intron 20877124 rs2400219 chr5 145851897 C T 7.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TCERG1 intron 20877124 rs2288811 chr5 145859789 A G 7.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TCERG1 intron 20877124 rs3797299 chr5 145873365 T C 1.36E-26 Narcolepsy TCERG1 intron 19629137 rs998051 chr5 145875259 T G 4.64E-06 Obesity (extreme) TCERG1 intron 21935397 rs2033471 chr5 145877568 C G 4.68E-06 Obesity (extreme) TCERG1 intron 21935397 rs3797302 chr5 145889123 G C 9.00E-04 Chronic fatigue syndrome TCERG1 intron 21912186 rs1802027 chr5 145890228 G A 4.82E-06 Obesity (extreme) TCERG1 UTR-3 21935397 rs17104742 chr5 145895558 G A 5.42E-06 Obesity (extreme) GPR151 missense 21935397 rs4705423 chr5 145915073 G T 7.68E-04 Type 2 diabetes / / 17463246 rs2116784 chr5 145915951 G A 0.00005421 Sarcoidosis / / 22952805 rs17104772 chr5 145919548 G A 3.38E-04 Type 2 diabetes / / 17463246 rs6580429 chr5 145920170 G T 7.30E-05 Cognitive function / / 24684796 rs9325015 chr5 145921229 A T 7.14E-04 Multiple complex diseases / / 17554300 rs9325015 chr5 145921229 A T 6.00E-05 Cognitive function / / 24684796 rs7717186 chr5 145921524 T C 8.90E-05 Cognitive function / / 24684796 rs12658526 chr5 145921933 C G 2.30E-05 Urinary metabolites / / 21572414 rs7709368 chr5 145924935 G T 5.52E-05 Erythrocyte counts / / pha003090 rs7701284 chr5 145928230 G A 1.02E-04 Parkinson's disease / / 17052657 rs13174108 chr5 145952456 A T 9.27E-04 Insulin resistance / / 21901158 rs64827 chr5 145964567 C T 6.41E-04 Insulin resistance / / 21901158 rs322477 chr5 145964897 T G 4.74E-04 Insulin resistance / / 21901158 rs167723 chr5 145972189 T G 1.29E-04 Insulin resistance PPP2R2B intron 21901158 rs322475 chr5 145974943 T A 2.65E-04 Insulin resistance PPP2R2B intron 21901158 rs715891 chr5 145986083 C T 6.86E-06 Multiple complex diseases PPP2R2B intron 17554300 rs1530419 chr5 146028540 A C 1.93E-08 Schizophrenia PPP2R2B intron 22037555 rs1663333 chr5 146032060 A C 6.10E-04 Heart Failure PPP2R2B intron pha002885 rs3096085 chr5 146046418 G A 8.50E-04 Crohn's disease PPP2R2B intron 17684544 rs3910815 chr5 146111707 C T 4.81E-04 Schizophrenia PPP2R2B intron 19197363 rs7715375 chr5 146126245 G A 4.06E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) PPP2R2B intron 23648065 rs249904 chr5 146153055 T C 3.77E-04 Longevity PPP2R2B intron 22279548 rs160974 chr5 146169511 A G 7.06E-04 Response to cytidine analogues (gemcitabine) PPP2R2B intron 24483146 rs9325024 chr5 146205786 A G 1.70E-05 Breast cancer and prostate cancer PPP2R2B intron 17903305 rs319152 chr5 146207456 T C 6.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PPP2R2B intron 20877124 rs609412 chr5 146225244 A G 3.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PPP2R2B intron 20877124 rs609412 chr5 146225244 A G 2.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) PPP2R2B intron 23453885 rs10037107 chr5 146229102 A G 1.70E-04 Alcohol dependence PPP2R2B intron 21314694 rs319175 chr5 146275313 C G 0.000437 Breast cancer early age of onset PPP2R2B intron 18463975 rs563943 chr5 146284693 C T 0.000437 Breast cancer early age of onset PPP2R2B intron 18463975 rs319138 chr5 146307423 G A 0.000287 Breast cancer early age of onset PPP2R2B intron 18463975 rs1864982 chr5 146320823 G T 3.00E-06 Alcohol dependence PPP2R2B intron 19581569 rs7726431 chr5 146337694 G A 1.54E-04 Insulin resistance PPP2R2B intron 21901158 rs13170982 chr5 146337743 G A 2.60E-05 Urinary metabolites PPP2R2B intron 21572414 rs17105791 chr5 146344847 A C 1.00E-04 Information processing speed PPP2R2B intron 21130836 rs9325032 chr5 146415216 C T 3.00E-06 Cognitive test performance PPP2R2B intron 17903297 rs1031915 chr5 146429843 C T 8.51E-04 Type 2 diabetes PPP2R2B intron 17463246 rs11746185 chr5 146436304 A C 6.46E-05 IgE levels PPP2R2B intron 22075330 rs11167957 chr5 146436523 C T 6.42E-05 IgE levels PPP2R2B intron 22075330 rs7724608 chr5 146437636 G A 3.09E-05 IgE levels PPP2R2B intron 22075330 rs1480150 chr5 146454825 C T 6.07E-05 Heart Rate PPP2R2B intron pha003054 rs1480162 chr5 146471808 C T 5.08E-05 Heart Rate / / pha003054 rs1480163 chr5 146496726 T C 2.38E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7349784 chr5 146498458 T G 1.60E-05 Urinary metabolites / / 21572414 rs6898182 chr5 146524256 C A 8.90E-04 Aortic root size / / 21223598 rs10071830 chr5 146527214 C A 1.70E-05 Urinary metabolites / / 21572414 rs7712342 chr5 146528602 A G 6.90E-06 Urinary metabolites / / 21572414 rs39874 chr5 146575625 G A 8.23E-05 Coronary heart disease / / pha003030 rs31031 chr5 146610829 T C 0.0000168 post-traumatic stress disorder / / 22869035 rs31031 chr5 146610829 T C 1.68E-05 Schizophrenia / / 22883433 rs31036 chr5 146615260 C A 9.02E-04 Heart Failure STK32A intron pha002885 rs7716813 chr5 146651673 T C 4.11E-06 Sleep latency STK32A intron 23728906 rs987651 chr5 146652943 A G 4.14E-05 IgE levels in asthmatics (D.p. specific) STK32A intron 23967269 rs1549881 chr5 146658253 A G 7.60E-05 IgE levels in asthmatics (D.p. specific) STK32A intron 23967269 rs13170855 chr5 146675133 C T 8.27E-06 Alcohol and nictotine co-dependence STK32A intron 20158304 rs13170855 chr5 146675133 C T 7.10E-05 IgE levels in asthmatics (D.p. specific) STK32A intron 23967269 rs11956931 chr5 146683300 A T 0.00000879 Antisocial behavior STK32A intron 23077488 rs4705038 chr5 146733598 C A 2.88E-06 Longevity,exceptional STK32A intron 20595579 rs1432838 chr5 146762381 T C 2.25E-04 Multiple complex diseases STK32A intron 17554300 rs2288807 chr5 146775377 G C 2.56E-05 Word reading DPYSL3 intron 23738518 rs3816013 chr5 146781440 A C 9.66E-05 Pure-tone audiometry DPYSL3 intron pha001965 rs17550902 chr5 146789792 T C 9.79E-05 Information processing speed DPYSL3 intron 21130836 rs11167990 chr5 146791756 A G 7.19E-04 Alcohol dependence DPYSL3 intron 21314694 rs10064194 chr5 146810610 A C 2.50E-05 Urinary metabolites DPYSL3 intron 21572414 rs10056132 chr5 146831553 A G 3.00E-06 Parkinson's disease (interaction with coffee consumption) DPYSL3 intron 21876681 rs10056132 chr5 146831553 A G 6.24E-04 Smoking cessation DPYSL3 intron 24665060 rs1368366 chr5 146866283 G A 2.65E-04 Lung function (forced vital capacity) DPYSL3 intron 24023788 rs7706630 chr5 146890363 G A 1.18E-04 Lung function (forced vital capacity) / / 24023788 rs17651412 chr5 146938140 T C 7.59E-04 Obesity (extreme) / / 21935397 rs10041339 chr5 146949107 C G 4.00E-06 Parkinson's disease (interaction with coffee consumption) LOC153469 intron 21876681 rs7706398 chr5 146951712 A G 9.26E-05 Lipoproteins LOC153469 intron pha003079 rs17106906 chr5 146961115 C T 6.95E-05 Aortic root size LOC153469 intron 21223598 rs17107133 chr5 147059015 G A 9.21E-04 Type 2 diabetes JAKMIP2 intron 17463246 rs6580493 chr5 147059645 G A 9.14E-35 Narcolepsy JAKMIP2 intron 19629137 rs17561784 chr5 147059845 C T 6.54E-04 Multiple complex diseases JAKMIP2 intron 17554300 rs17561784 chr5 147059845 C T 6.70E-06 Urinary metabolites JAKMIP2 intron 21572414 rs6895278 chr5 147122020 T C 8.15E-05 stroke (ischemic) JAKMIP2 intron 17434096 rs7716258 chr5 147168492 G C 5.09E-04 Fibrinogen / / 17255346 rs7709589 chr5 147170350 A T 5.09E-04 Fibrinogen / / 17255346 rs4583876 chr5 147180483 G A 4.70E-04 Fibrinogen / / 17255346 rs891992 chr5 147225514 T C 6.00E-06 Obesity-related traits / / 23251661 rs12519829 chr5 147241470 T C 2.15E-05 Height / / 22021425 rs10515595 chr5 147241726 C T 3.10E-04 Alcohol dependence / / 20201924 rs17625543 chr5 147280377 C T 7.81E-05 Obesity (extreme) C5orf46 intron 21935397 rs17703848 chr5 147281029 G A 7.96E-05 Obesity (extreme) C5orf46 intron 21935397 rs1432974 chr5 147286612 T C 4.08E-04 Multiple complex diseases / / 17554300 rs7715716 chr5 147289799 A G 4.97E-04 Obesity (extreme) / / 21935397 rs2400440 chr5 147298497 C T 6.45E-05 Orofacial clefts / / 22419666 rs17107473 chr5 147299503 T A 2.36E-04 Parkinson's disease / / 16252231 rs17774641 chr5 147302365 C A 1.80E-05 Urinary metabolites / / 21572414 rs17717956 chr5 147303741 C T 2.90E-05 Urinary metabolites / / 21572414 rs10515599 chr5 147332977 G C 2.90E-05 Urinary metabolites / / 21572414 rs6580511 chr5 147333945 G A 4.54E-05 Response to methylphenidate treatment / / 21130132 rs6580511 chr5 147333945 G A 2.98E-04 Longevity / / 22279548 rs10515600 chr5 147335875 C A 4.25E-05 Cognitive impairment induced by topiramate / / 22091778 rs17704205 chr5 147337164 G T 6.69E-04 Multiple complex diseases / / 17554300 rs1363530 chr5 147344371 A G 7.52E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1345689 chr5 147345190 C T 7.52E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4421091 chr5 147348988 G A 9.26E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6859940 chr5 147376778 A G 7.80E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10477360 chr5 147404281 G A 5.60E-05 Lung function (forced vital capacity) / / 24023788 rs10463396 chr5 147415342 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10463396 chr5 147415342 A G 7.54E-05 Lung function (forced vital capacity) / / 24023788 rs1422982 chr5 147420024 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1422982 chr5 147420024 A G 5.01E-05 Lung function (forced vital capacity) / / 24023788 rs1422993 chr5 147503820 A C 5.78E-05 Cognitive impairment induced by topiramate SPINK5 intron 22091778 rs201942775 chr5 147505341 G A 0.00000016 Breast cancer(er negative) SPINK5 missense 23555315 rs4705227 chr5 147520415 G A 6.21E-06 Asthma / / 21790008 rs1117507 chr5 147537156 A G 7.20E-04 Alcohol dependence / / 20201924 rs10037701 chr5 147541163 C T 7.15E-04 Alcohol dependence / / 20201924 rs10067334 chr5 147548021 A C 6.82E-04 Type 2 diabetes / / 17463246 rs4499819 chr5 147558546 A G 7.27E-04 Type 2 diabetes / / 17463246 rs11745313 chr5 147572263 A G 2.48E-04 Type 2 diabetes / / 17463246 rs11168039 chr5 147573999 G A 1.77E-04 Type 2 diabetes / / 17463246 rs4705232 chr5 147576457 T C 1.69E-04 Type 2 diabetes / / 17463246 rs4705233 chr5 147576629 A T 2.68E-04 Type 2 diabetes / / 17463246 rs6862717 chr5 147579666 C T 1.32E-06 Sleep duration / / 22105623 rs17096690 chr5 147582317 A G 1.86E-04 Type 2 diabetes / / 17463246 rs1368304 chr5 147603067 A G 9.00E-06 IgG glycosylation / / 23382691 rs6580539 chr5 147609363 G C 3.44E-06 Sleep duration / / 22105623 rs6895242 chr5 147646834 A C 3.50E-06 Sleep duration / / 22105623 rs4513684 chr5 147652085 A C 4.07E-06 Sleep duration SPINK13 intron 22105623 rs1432687 chr5 147653852 G A 4.13E-06 Sleep duration SPINK13 intron 22105623 rs1432691 chr5 147665208 A G 4.13E-06 Sleep duration SPINK13 intron 22105623 rs7707813 chr5 147666044 T C 4.15E-06 Sleep duration / / 22105623 rs7707656 chr5 147666128 A G 4.16E-06 Sleep duration / / 22105623 rs10515606 chr5 147667621 G C 4.16E-06 Sleep duration / / 22105623 rs11953020 chr5 147669411 T G 8.86E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs10515607 chr5 147671253 A G 4.19E-06 Sleep duration / / 22105623 rs10515607 chr5 147671253 A G 3.17E-08 Pure-tone audiometry / / pha001968 rs7724380 chr5 147671850 G A 4.29E-06 Sleep duration / / 22105623 rs1368303 chr5 147672389 A G 4.30E-06 Sleep duration / / 22105623 rs17108131 chr5 147673350 A T 4.30E-06 Sleep duration / / 22105623 rs7701787 chr5 147674270 G A 4.30E-06 Sleep duration / / 22105623 rs7709159 chr5 147675836 C T 4.72E-06 Sleep duration / / 22105623 rs17108149 chr5 147676149 T G 4.71E-06 Sleep duration / / 22105623 rs17108151 chr5 147677460 G C 4.71E-06 Sleep duration / / 22105623 rs17108153 chr5 147677775 A T 4.69E-06 Sleep duration / / 22105623 rs4705247 chr5 147688568 T C 5.26E-05 Multiple complex diseases / / 17554300 rs1422969 chr5 147703416 C T 1.85E-04 Multiple complex diseases / / 17554300 rs2161430 chr5 147703881 G T 1.27E-04 Multiple complex diseases / / 17554300 rs13153619 chr5 147723506 G A,C,T 3.91E-04 Multiple complex diseases / / 17554300 rs6891724 chr5 147733045 C G 2.56E-04 Multiple complex diseases / / 17554300 rs1981826 chr5 147738005 G A 3.59E-04 Multiple complex diseases / / 17554300 rs10477374 chr5 147741803 G C 1.08E-04 Multiple complex diseases / / 17554300 rs12521065 chr5 147754554 C T 3.52E-04 Multiple complex diseases / / 17554300 rs7714735 chr5 147757588 C T 4.18E-05 Pulmonary function / / 20010835 rs10068216 chr5 147773318 A G 1.03E-04 Multiple complex diseases FBXO38 intron 17554300 rs10068216 chr5 147773318 A G 5.91E-04 Bipolar disorder,schizoaffective FBXO38 intron 19567891 rs10041283 chr5 147776798 C G 6.37E-05 Multiple complex diseases FBXO38 intron 17554300 rs10041283 chr5 147776798 C G 4.15E-04 Bipolar disorder,schizoaffective FBXO38 intron 19567891 rs9325095 chr5 147785158 T G 7.88E-05 Multiple complex diseases FBXO38 intron 17554300 rs9325095 chr5 147785158 T G 2.82E-04 Bipolar disorder,schizoaffective FBXO38 intron 19567891 rs9325095 chr5 147785158 T G 2.78E-04 Statin-induced myopathy FBXO38 intron 21826682 rs10477376 chr5 147785214 A G 1.07E-04 Multiple complex diseases FBXO38 intron 17554300 rs10477376 chr5 147785214 A G 4.46E-04 Bipolar disorder,schizoaffective FBXO38 intron 19567891 rs7730971 chr5 147790860 C G 1.72E-06 Pulmonary function FBXO38 intron 20010835 rs10043775 chr5 147805120 T C 2.00E-06 Periodontal microbiota FBXO38 missense 22699663 rs6861078 chr5 147812901 T G 7.34E-04 Type 2 diabetes FBXO38 intron 17463246 rs6861078 chr5 147812901 T G 3.12E-05 Multiple complex diseases FBXO38 intron 17554300 rs6861078 chr5 147812901 T G 4.55E-04 Bipolar disorder,schizoaffective FBXO38 intron 19567891 rs3734120 chr5 147821469 C T 1.77E-04 Multiple complex diseases FBXO38 intron 17554300 rs7721661 chr5 147827921 A G 2.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs13156542 chr5 147836609 C T 1.28E-06 Pulmonary function HTR4 intron 20010835 rs12374521 chr5 147836880 C T 2.70E-07 Pulmonary function HTR4 intron 20010835 rs10463406 chr5 147838844 C T 1.74E-07 Pulmonary function HTR4 intron 20010835 rs11168048 chr5 147842353 T C 1.00E-11 Pulmonary function HTR4 intron 20010835 rs11168048 chr5 147842353 T C 5.00E-17 Pulmonary function (interaction) HTR4 intron 23284291 rs7735184 chr5 147844392 G T 1.74E-07 Pulmonary function HTR4 intron 20010835 rs3995090 chr5 147845815 A C 4.00E-09 Pulmonary function HTR4 intron 20010834 rs6889822 chr5 147846707 A G 6.14E-07 Pulmonary function HTR4 intron 20010834 rs6889822 chr5 147846707 A G 3.20E-07 Pulmonary function HTR4 intron 20010835 rs4597955 chr5 147847273 G A 7.79E-08 Pulmonary function HTR4 intron 20010835 rs1985524 chr5 147847788 G C 6.22E-07 Pulmonary function HTR4 intron 20010835 rs3995091 chr5 147849759 G A 6.36E-07 Pulmonary function HTR4 intron 20010835 rs6887366 chr5 147851270 A T 6.40E-07 Pulmonary function HTR4 intron 20010835 rs10037493 chr5 147854970 C T 1.48E-06 Pulmonary function HTR4 intron 20010835 rs11168049 chr5 147855264 T C 2.80E-07 Pulmonary function HTR4 intron 20010835 rs7733088 chr5 147856333 G A 2.90E-07 Pulmonary function HTR4 intron 20010835 rs7733088 chr5 147856333 G A 4.00E-09 Airflow obstruction HTR4 intron 22837378 rs10061244 chr5 147858148 A G 0.00000703 Fasting blood glucose HTR4 intron 22885924 rs10053530 chr5 147858171 C T 2.40E-05 Urinary metabolites HTR4 intron 21572414 rs7702840 chr5 147865882 T G 1.66E-04 Oral cancers (chewing tobacco related) HTR4 intron 22503698 rs1368387 chr5 147896308 G A 1.84E-08 Delayed encephalopathy in acute carbon monoxide poisoning HTR4 intron 24265751 rs1368387 chr5 147896308 G A 5.33E-07 Delayed encephalopathy in acute carbon monoxide poisoning HTR4 intron 24265751 rs2278392 chr5 147928225 C T 3.50E-04 Multiple complex diseases HTR4 intron 17554300 rs12055273 chr5 147934727 C T 6.84E-04 Multiple complex diseases HTR4 intron 17554300 rs17720733 chr5 147950478 A C 2.59E-04 Multiple complex diseases HTR4 intron 17554300 rs867522 chr5 147966246 C T 5.57E-07 Delayed encephalopathy in acute carbon monoxide poisoning HTR4 intron 24265751 rs867522 chr5 147966246 C T 9.01E-07 Delayed encephalopathy in acute carbon monoxide poisoning HTR4 intron 24265751 rs4280857 chr5 147972619 G A 8.65E-04 Tourette syndrome HTR4 intron 22889924 rs2068190 chr5 148007013 G A 8.80E-06 Urinary metabolites HTR4 intron 21572414 rs10477387 chr5 148013742 G C 3.55E-06 Menarche (age at onset) HTR4 intron 19282985 rs10477387 chr5 148013742 G C 1.50E-05 Urinary metabolites HTR4 intron 21572414 rs1862342 chr5 148030064 C T 4.45E-05 Follicle stimulating hormone HTR4 intron 24049095 rs1862345 chr5 148038305 T C 2.00E-04 Longevity and age-related phenotypes / / 17903295 rs1833714 chr5 148054900 G A 7.77E-04 Type 2 diabetes / / 17846124 rs9325113 chr5 148098003 C T 2.50E-04 Statin-induced myopathy / / 21826682 rs9325113 chr5 148098003 C T 7.00E-06 Hypertension / / 22384028 rs6885118 chr5 148115827 G C 6.99E-06 Kawasaki disease / / 21221998 rs1465405 chr5 148116202 T G 3.16E-06 Kawasaki disease / / 21221998 rs10059336 chr5 148116653 C T 5.32E-06 Kawasaki disease / / 21221998 rs2400644 chr5 148119941 T C 6.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs6885216 chr5 148129249 A G 9.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs7702609 chr5 148131716 T C 9.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs2116719 chr5 148135026 A G 8.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs6882470 chr5 148138102 T C 8.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs6882476 chr5 148138114 T C 7.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs10875640 chr5 148138278 T C 7.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs6883606 chr5 148138790 T C 7.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs11747905 chr5 148139371 T G 7.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs919723 chr5 148140697 T G 7.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs919724 chr5 148140858 A G 7.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs4705265 chr5 148141793 A C 7.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs6865781 chr5 148142638 T C 7.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs2400702 chr5 148144270 A G 7.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs2400704 chr5 148144664 C T 7.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs2163752 chr5 148145138 C T 7.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs12517142 chr5 148145545 G C 5.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs12653443 chr5 148146577 A G 5.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs12189260 chr5 148147997 A G 6.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs2082398 chr5 148148422 T G 3.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs2082397 chr5 148148637 A G 5.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs11168062 chr5 148148803 G A 8.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs6870415 chr5 148149224 A G 6.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs6580580 chr5 148151374 A G 6.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs30306 chr5 148152364 A G 6.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs30308 chr5 148152781 T C 7.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs30309 chr5 148153281 C A 8.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs30310 chr5 148154122 G A 7.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs30311 chr5 148155532 C A 5.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs30312 chr5 148156653 T C 7.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs30313 chr5 148157301 T C 9.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs30314 chr5 148157474 G A 7.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs30315 chr5 148159600 C T 7.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs30318 chr5 148160727 A G 8.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs30323 chr5 148162244 G T 8.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs3097815 chr5 148165952 C G 7.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs30329 chr5 148167834 T C 8.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs246503 chr5 148171714 G A 7.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs246502 chr5 148171951 T A 7.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs6580582 chr5 148173382 T C 6.45E-04 Type 2 diabetes / / 17463246 rs2082395 chr5 148200600 A G 5.51E-05 Alzheimer's disease / / 17998437 rs11168066 chr5 148201255 C A 2.13E-05 Alzheimer's disease / / 17998437 rs2400707 chr5 148205052 A G 2.89E-05 Alzheimer's disease ADRB2 nearGene-5 17998437 rs1042713 chr5 148206440 G A 1 Drug response to Salbutamol / / 15500895 rs1042713 chr5 148206440 G A 1 Drug response to Salmeterol / / 16322642 rs1042713 chr5 148206440 G A 1 Drug response to Budesonide / / 18156033 rs1042713 chr5 148206440 G A 1 Drug response to Fluticasone Propionate / / 18156033 rs1042713 chr5 148206440 G A 1 Drug response to Formoterol / / 18156033 rs1042713 chr5 148206440 G A 1 Drug response to Salmeterol / / 18156033 rs1042713 chr5 148206440 G A 1 Drug response to Atenolol / / 18615004 rs1042713 chr5 148206440 G A 1 Drug response to Verapamil / / 18615004 rs1042714 chr5 148206473 G C 1 Drug response to Carvedilol / / 12835612 rs1042714 chr5 148206473 G C 1 Drug response to Atenolol / / 18615004 rs1042714 chr5 148206473 G C 1 Drug response to Verapamil / / 18615004 rs1042717 chr5 148206646 G A 5.59E-05 Alcohol withdrawal symptoms ADRB2 cds-synon 22072270 rs1042718 chr5 148206917 C A 1 Drug response to Atenolol ADRB2 cds-synon 18615004 rs1042718 chr5 148206917 C A 1 Drug response to Verapamil ADRB2 cds-synon 18615004 rs1042718 chr5 148206917 C A 9.54E-05 Pulmonary function ADRB2 cds-synon 20010835 rs1042718 chr5 148206917 C A 5.71E-05 Alcohol withdrawal symptoms ADRB2 cds-synon 22072270 rs34989676 chr5 148210267 G A 0.000000054 HDL cholesterol / / 23063622 rs34989676 chr5 148210267 G A 0.00000238 Triglycerides / / 23063622 rs11746220 chr5 148293683 A C 3.47E-05 Serum metabolites / / 19043545 rs11746220 chr5 148293683 A C 1.20E-05 Urinary metabolites / / 21572414 rs11740851 chr5 148306141 T G 8.21E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7729953 chr5 148312767 T C 1.37E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs10491337 chr5 148331046 G T 1.03E-05 Birth weight / / 17255346 rs919734 chr5 148349273 G C 1.26E-06 Blood pressure / / 21909110 rs3763022 chr5 148381078 A G 7.66E-04 Tourette syndrome SH3TC2 UTR-3 22889924 rs1036190 chr5 148387612 A G 1.30E-04 Amyotrophic Lateral Sclerosis SH3TC2 intron 17827064 rs1549906 chr5 148393947 A G 6.88E-04 Multiple complex diseases SH3TC2 intron 17554300 rs1432793 chr5 148408101 A G 5.49E-05 Amyotrophic Lateral Sclerosis SH3TC2 cds-synon 17827064 rs36077 chr5 148431964 G A 0.00000493 Polycystic ovary syndrome SH3TC2 intron 22951595 rs36077 chr5 148431964 G A 4.93E-06 Intracranial aneurysm SH3TC2 intron 22961961 rs40525 chr5 148432932 A C 5.89E-05 Serum metabolites SH3TC2 intron 19043545 rs40521 chr5 148439639 A G 7.64E-04 Type 2 diabetes SH3TC2 intron 17463246 rs250671 chr5 148446523 T C 4.84E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7730999 chr5 148468691 G A 2.81E-05 Serum metabolites / / 19043545 rs6862219 chr5 148474041 A G 2.51E-05 Serum metabolites / / 19043545 rs1422586 chr5 148490063 G A 3.16E-04 Smoking initiation / / 24665060 rs11746996 chr5 148499460 T C 4.74E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4705318 chr5 148500629 T C 1.60E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs13153796 chr5 148501158 C T 6.76E-04 Age-related macular degeneration / / 22125219 rs13153796 chr5 148501158 C T 2.08E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10044396 chr5 148501891 T C 9.09E-05 Serum metabolites / / 19043545 rs10044396 chr5 148501891 T C 3.87E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11168091 chr5 148505628 C T 2.86E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10463283 chr5 148508102 A G 3.45E-05 Serum metabolites / / 19043545 rs4291001 chr5 148519187 A G 1.90E-05 Serum metabolites / / 19043545 rs4361503 chr5 148544809 T C 9.62E-05 Socioeconomic Factors ABLIM3 intron pha003067 rs6876815 chr5 148555290 C T 6.88E-05 Serum metabolites ABLIM3 intron 19043545 rs4613692 chr5 148556056 G T 7.42E-05 Serum metabolites ABLIM3 intron 19043545 rs6886262 chr5 148562890 G A 1.65E-05 Serum metabolites ABLIM3 intron 19043545 rs13167773 chr5 148586989 C T 3.87E-06 Osteoarthritis ABLIM3 intron 22763110 rs2918268 chr5 148606756 A G 4.82E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses ABLIM3 intron 17903301 rs998583 chr5 148612619 G T 3.19E-04 Blood pressure (response to angiotensin II receptor blocker) ABLIM3 intron 24192120 rs10079296 chr5 148613189 C T 3.19E-04 Blood pressure (response to angiotensin II receptor blocker) ABLIM3 intron 24192120 rs1438689 chr5 148631433 T C 9.23E-05 Blood pressure (response to angiotensin II receptor blocker) ABLIM3 intron 24192120 rs12659695 chr5 148641093 G A 4.29E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs1617849 chr5 148672177 T C 3.90E-04 Tourette syndrome AFAP1L1 intron 22889924 rs1659091 chr5 148675225 G A 4.93E-04 Tourette syndrome AFAP1L1 intron 22889924 rs7715371 chr5 148678994 G T 5.05E-05 Type 2 diabetes and other traits AFAP1L1 intron 19734900 rs17642472 chr5 148683087 G A 6.76E-05 Type 2 diabetes and other traits AFAP1L1 intron 19734900 rs10058380 chr5 148689959 A G 1.06E-04 Multiple complex diseases AFAP1L1 intron 17554300 rs10044242 chr5 148706299 C G 9.00E-06 Obesity-related traits AFAP1L1 intron 23251661 rs352336 chr5 148708417 A G 8.77E-05 ldl cholesterol AFAP1L1 intron pha003076 rs4705336 chr5 148747902 G C 8.36E-04 Suicide attempts in bipolar disorder PCYOX1L missense 21423239 rs2227447 chr5 148758027 G T 1.35E-04 Suicide attempts in bipolar disorder IL17B intron 21423239 rs168483 chr5 148763645 T C 2.83E-04 Type 2 diabetes / / 17463246 rs353266 chr5 148776470 G T 6.58E-04 Smoking cessation / / 24665060 rs17796636 chr5 148785449 C T 9.25E-05 Alzheimer's disease / / 17998437 rs353286 chr5 148792761 A C 7.25E-05 Triglycerides MIR143HG intron pha003080 rs17796714 chr5 148800089 G A 6.71E-05 Alzheimer's disease MIR143HG intron 17998437 rs17796714 chr5 148800089 G A 1.02E-04 Alzheimer's disease MIR143HG intron pha002879 rs3733845 chr5 148804646 G A 1.90E-05 Urinary metabolites / / 21572414 rs368337 chr5 148815759 T C 8.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs403084 chr5 148819714 T C 1.47E-05 Body Mass Index / / pha003009 rs353249 chr5 148824756 C T 3.86E-04 Type 2 diabetes / / 17463246 rs729319 chr5 148834935 C A 3.36E-05 Chronic obstructive pulmonary disease / / 19300482 rs729319 chr5 148834935 C A 3.36E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs550016 chr5 148845694 G C 7.66E-04 Sleep duration / / 22105623 rs386763 chr5 148846557 A C 4.31E-04 Sleep duration / / 22105623 rs10039868 chr5 148869227 C T 6.58E-04 Sleep duration / / 22105623 rs10058728 chr5 148904092 A T 5.00E-09 Esophageal cancer CSNK1A1 intron 21642993 rs10058728 chr5 148904092 A T 6.28E-04 Smoking initiation CSNK1A1 intron 24665060 rs13184089 chr5 148932568 T C 2.81E-04 Smoking initiation / / 24665060 rs7705454 chr5 148971305 A C,G 5.02E-04 Sleep duration ARHGEF37 intron 22105623 rs2895864 chr5 148971625 C T 2.72E-04 Sleep duration ARHGEF37 intron 22105623 rs2895864 chr5 148971625 C T 6.62E-04 Smoking initiation ARHGEF37 intron 24665060 rs7731610 chr5 148972711 T G 7.88E-04 Sleep duration ARHGEF37 intron 22105623 rs2400889 chr5 148978105 T C 8.10E-04 Amyotrophic Lateral Sclerosis ARHGEF37 intron 17362836 rs6579746 chr5 148986376 C G 7.82E-04 Smoking initiation ARHGEF37 intron 24665060 rs4705075 chr5 148990213 T G 2.51E-05 Smoking initiation ARHGEF37 intron 24665060 rs1379545 chr5 148992604 G A 2.94E-04 Smoking initiation ARHGEF37 intron 24665060 rs9324624 chr5 149006640 C T 5.76E-04 Fibrinogen ARHGEF37 missense 17255346 rs6894391 chr5 149007059 C T 5.33E-04 Smoking initiation ARHGEF37 intron 24665060 rs6874995 chr5 149008751 C G 3.88E-04 Fibrinogen ARHGEF37 intron 17255346 rs1056189 chr5 149014418 A G 8.50E-04 Malarial infection ARHGEF37 UTR-3 20657648 rs10074889 chr5 149031582 T C 8.26E-04 Insulin resistance / / 21901158 rs17710780 chr5 149036976 T C 4.00E-06 Major depressive disorder / / 23377640 rs12153727 chr5 149057371 G A 7.53E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10078478 chr5 149082704 C A 7.14E-06 Cognitive impairment induced by topiramate / / 22091778 rs4705079 chr5 149096383 C T 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer / / 21245432 rs6892794 chr5 149124131 A G 7.77E-05 Acute lung injury PPARGC1B intron 21257790 rs11746929 chr5 149133874 G A 8.35E-06 Brain infarcts,covert MRI-defined PPARGC1B intron 20044523 rs4705088 chr5 149136632 T G 2.01E-04 Alcohol dependence PPARGC1B intron 21314694 rs4705371 chr5 149137624 C A 5.46E-04 Alcohol dependence PPARGC1B intron 20201924 rs9285640 chr5 149142067 G A 3.00E-07 Response to fenofibrate PPARGC1B intron 22890011 rs880770 chr5 149154835 G A 7.39E-04 Alcohol dependence PPARGC1B intron 21314694 rs17110429 chr5 149179894 A C 4.96E-04 Multiple complex diseases PPARGC1B intron 17554300 rs17110429 chr5 149179894 A C 0.000000903 LDL cholesterol PPARGC1B intron 23063622 rs17110447 chr5 149192846 A G 8.55E-04 Multiple complex diseases PPARGC1B intron 17554300 rs32589 chr5 149199889 G A 0.000111 Rate of forced expiratory volume in 1 second (FEV1) decline (young adult women) PPARGC1B intron 23527081 rs32588 chr5 149200043 T C 0.000111 Rate of forced expiratory volume in 1 second (FEV1) decline (young adult women) PPARGC1B cds-synon 23527081 rs17462080 chr5 149200402 A G 2.53E-04 Multiple complex diseases PPARGC1B intron 17554300 rs32586 chr5 149200920 A G 0.000111 Rate of forced expiratory volume in 1 second (FEV1) decline (young adult women) PPARGC1B intron 23527081 rs10491361 chr5 149208768 A G 2.78E-04 Multiple complex diseases PPARGC1B intron 17554300 rs32579 chr5 149210848 C T 4.00E-06 Tanning PPARGC1B intron 19340012 rs32576 chr5 149213456 A G 5.00E-06 Obesity-related traits PPARGC1B intron 23251661 rs138772212 chr5 149219663 G A 0.0000026 Prostate cancer (advanced) PPARGC1B missense 23555315 rs17110644 chr5 149245754 A G 3.48E-04 Type 2 diabetes PDE6A cds-synon 17463246 rs10223111 chr5 149253955 T C 8.11E-04 Multiple complex diseases PDE6A intron 17554300 rs17110665 chr5 149275457 T A 3.25E-04 Major depressive disorder PDE6A intron 22472876 rs152949 chr5 149291008 A G 4.42E-04 Multiple complex diseases PDE6A intron 17554300 rs17725010 chr5 149313344 C T 4.05E-04 Multiple complex diseases PDE6A intron 17554300 rs3776069 chr5 149315287 T C 5.76E-04 Multiple complex diseases PDE6A intron 17554300 rs6579764 chr5 149335379 T G 1.40E-05 Urinary metabolites / / 21572414 rs104893915 chr5 149359991 C T 0.0006 Breast cancer SLC26A2 missense 23555315 rs10038824 chr5 149369776 G A 6.40E-05 HIV-1 control / / 20041166 rs2304069 chr5 149406733 G T 7.00E-06 HIV-1 control HMGXB3 intron 20041166 rs2340462 chr5 149415219 G A 7.40E-06 HIV-1 control HMGXB3 intron 20041166 rs6866616 chr5 149415401 A G 4.82E-06 Lymphocyte counts HMGXB3 intron 22286170 rs216132 chr5 149431259 A G 6.00E-05 HIV-1 control HMGXB3 intron 20041166 rs216140 chr5 149443298 C T 7.00E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) CSF1R intron 23648065 rs216145 chr5 149445595 A G 8.72E-04 Response to TNF antagonist treatment CSF1R intron 21061259 rs216146 chr5 149445921 T C 3.70E-04 Intraocular pressure CSF1R intron 22570627 rs216148 chr5 149446487 G A 5.77E-04 Longevity CSF1R intron 22279548 rs216150 chr5 149447628 A G 3.10E-04 Obesity,menopause CSF1R intron 21424828 rs216150 chr5 149447628 A G 2.70E-06 Intraocular pressure CSF1R intron 22570627 rs10079250 chr5 149450132 T C 0.00000923 HIV-1-specific cross-reactive neutralizing activity CSF1R missense 23372753 rs12651699 chr5 149454918 C T 4.24E-04 Alzheimer's disease (late onset) CSF1R intron 21379329 rs13188584 chr5 149459574 C T 1.78E-04 Atopy CSF1R intron 21625490 rs1465692 chr5 149481535 T C 2.59E-04 Alzheimer's disease (late onset) CSF1R intron 21379329 rs6865659 chr5 149485772 A G 3.86E-04 Alzheimer's disease (late onset) CSF1R intron 21379329 rs1010101 chr5 149489110 C T 2.00E-04 Alzheimer's disease (late onset) CSF1R intron 21379329 rs11740298 chr5 149492455 C T 2.60E-04 Alzheimer's disease (late onset) CSF1R intron 21379329 rs3756309 chr5 149505624 T C 2.80E-05 Urinary metabolites PDGFRB intron 21572414 rs2304058 chr5 149508544 C G 4.78E-05 Odorant perception PDGFRB intron 23910658 rs887343 chr5 149548823 G A 8.69E-04 Response to taxane treatment (placlitaxel) CDX1 intron 23006423 rs887344 chr5 149549022 C T 2.78E-04 Aortic root size CDX1 intron 21223598 rs2237091 chr5 149549797 A G 9.79E-05 Aortic root size CDX1 intron 21223598 rs3776084 chr5 149568093 G A 8.13E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11954180 chr5 149577969 C T 5.54E-04 Alzheimer's disease SLC6A7 intron 17998437 rs11954180 chr5 149577969 C T 5.17E-04 Longevity SLC6A7 intron 22279548 rs731376 chr5 149578999 T A 3.45E-04 Glycemic traits (pregnancy) SLC6A7 intron 23903356 rs2240785 chr5 149581584 T C 2.86E-04 Suicide attempts in bipolar disorder SLC6A7 intron 21041247 rs2240787 chr5 149581795 C T 2.98E-04 Suicide attempts in bipolar disorder SLC6A7 intron 21041247 rs2240791 chr5 149582660 G A 3.06E-04 Suicide attempts in bipolar disorder SLC6A7 intron 21041247 rs2240794 chr5 149583336 T C 1.17E-04 Glycemic traits (pregnancy) SLC6A7 cds-synon 23903356 rs9885318 chr5 149585405 A T 9.83E-04 Alzheimer's disease SLC6A7 intron 24755620 rs3822607 chr5 149611793 G A 7.94E-04 Premature ovarian failure CAMK2A intron 19508998 rs10066581 chr5 149615681 A G 6.10E-06 Urinary metabolites CAMK2A intron 21572414 rs4958456 chr5 149623365 C T 5.00E-07 Obesity-related traits CAMK2A intron 23251661 rs3756578 chr5 149625087 T C 8.78E-04 Premature ovarian failure CAMK2A intron 19508998 rs869191 chr5 149625399 C G 1 Drug response to Etoposide CAMK2A intron 17537913 rs3756577 chr5 149628644 C T 4.69E-04 Smoking quantity CAMK2A intron 24665060 rs10463293 chr5 149636073 T G 2.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAMK2A intron 20877124 rs3776820 chr5 149643395 G T 2.39E-04 Response to cytidine analogues (gemcitabine) CAMK2A intron 24483146 rs874083 chr5 149650925 C T 3.77E-04 Response to cytidine analogues (gemcitabine) CAMK2A intron 24483146 rs11750343 chr5 149707778 A G 9.64E-05 LDL lipoproteins / / pha002902 rs10055648 chr5 149728306 C T 1.30E-05 Urinary metabolites / / 21572414 rs1104959 chr5 149742236 G T 1.80E-04 Weight loss (gastric bypass surgery) TCOF1 intron 23643386 rs75583421 chr5 149755362 G A 0.000076 Breast cancer TCOF1 missense 23555315 rs1864959 chr5 149766790 G A 4.42E-04 Type 2 diabetes TCOF1 intron 17463246 rs2288817 chr5 149787068 A G 1.79E-04 Heart Failure CD74 intron pha002885 rs12520101 chr5 149810923 G A 3.10E-04 Type 2 diabetes / / 17463246 rs2569107 chr5 149821847 C T 1.70E-04 Coronary heart disease / / 21966275 rs13181401 chr5 149822596 T C 3.69E-04 Taste perception / / 22132133 rs3900644 chr5 149822922 T A 3.69E-04 Taste perception / / 22132133 rs2545347 chr5 149823394 G A 1.84E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2070844 chr5 149823785 G A 3.69E-04 Taste perception / / 22132133 rs13177918 chr5 149825870 C T 8.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio RPS14 intron 22589738 rs12109637 chr5 149834718 G T 8.44E-05 Taste perception / / 22132133 rs6893057 chr5 149842164 C A 6.42E-05 Taste perception / / 22132133 rs145198292 chr5 149900889 A G 0.00071 Prostate cancer NDST1 missense 23555315 rs2545342 chr5 149915676 C G 2.50E-08 Progranulin levels NDST1 intron 21087763 rs2545342 chr5 149915676 C G 2.50E-08 Myocardial infarction NDST1 intron 21211798 rs253296 chr5 149952749 G A 7.15E-10 Non-obstructive azoospermia / / 22197933 rs7716420 chr5 149957548 A G 3.96E-05 Autism spectrum disorders (language delay) / / 21519539 rs10071150 chr5 149964314 G A 2.04E-05 Height / / 22021425 rs10068581 chr5 149998757 C A 1.72E-08 Glycosylated haemoglobin levels SYNPO intron 17255346 rs10068581 chr5 149998757 C A 5.65E-04 Multiple complex diseases SYNPO intron 17554300 rs7719412 chr5 150000145 G A 2.65E-08 Glycosylated haemoglobin levels SYNPO intron 17255346 rs7719412 chr5 150000145 G A 4.65E-04 Multiple complex diseases SYNPO intron 17554300 rs9918250 chr5 150001729 G A 5.87E-09 Glycosylated haemoglobin levels SYNPO intron 17255346 rs9918250 chr5 150001729 G A 6.52E-04 Multiple complex diseases SYNPO intron 17554300 rs6887087 chr5 150050982 T C 0.000578 Salmonella-induced pyroptosis MYOZ3 intron 22837397 rs3733925 chr5 150090344 T C 2.78E-04 Type 2 diabetes DCTN4 UTR-3 17463246 rs10056483 chr5 150130084 A G 5.49E-04 Multiple complex diseases DCTN4 intron 17554300 rs10071236 chr5 150140140 G A 8.12E-04 Multiple complex diseases / / 17554300 rs9324654 chr5 150157424 T G 4.63E-04 Type 2 diabetes / / 17463246 rs9324654 chr5 150157424 T G 0.000134 Salmonella-induced pyroptosis / / 22837397 rs9324655 chr5 150157486 G T 0.000151 Salmonella-induced pyroptosis / / 22837397 rs12653541 chr5 150158199 C T 0.0000919 Salmonella-induced pyroptosis C5orf62 UTR-5 22837397 rs12657686 chr5 150158226 A C 0.00024 Salmonella-induced pyroptosis C5orf62 UTR-5 22837397 rs13360680 chr5 150171812 C T 3.08E-04 Type 2 diabetes C5orf62 intron 17463246 rs146226203 chr5 150185826 C G 0.00000003 Vitamin B12 / / 23696881 rs10075411 chr5 150202491 C A 1.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs13361189 chr5 150223387 T C 2.00E-10 Crohn's disease / / 17554261 rs13361189 chr5 150223387 T C 4.38E-08 Multiple complex diseases / / 17554300 rs13361189 chr5 150223387 T C 7.33E-16 Crohn's disease / / 18587394 rs11949556 chr5 150229801 A C 2.27E-06 Multiple complex diseases / / 17554300 rs11957134 chr5 150230950 G A 8.90E-08 Multiple complex diseases / / 17554300 rs6893009 chr5 150233304 C A 9.62E-06 Multiple complex diseases / / 17554300 rs4958847 chr5 150239587 G A 2.41E-06 Multiple complex diseases / / 17554300 rs1000113 chr5 150240076 C T 3.00E-07 Crohn's disease / / 17554300 rs1428555 chr5 150257391 C T 3.29E-07 Multiple complex diseases / / 17554300 rs11747270 chr5 150258867 A G 4.26E-08 Multiple complex diseases / / 17554300 rs11747270 chr5 150258867 A G 3.00E-16 Crohn's disease / / 18587394 rs11747270 chr5 150258867 A G 3.00E-16 Asthma / / 21150878 rs11747270 chr5 150258867 A G 3.40E-16 Multiple sclerosis / / 22190364 rs10041072 chr5 150259642 T C 2.18E-07 Multiple complex diseases / / 17554300 rs3900064 chr5 150264414 C G 2.30E-07 Multiple complex diseases / / 17554300 rs7714584 chr5 150270420 A G 8.00E-19 Crohn's disease / / 21102463 rs11741861 chr5 150277909 A G 3.00E-37 Inflammatory bowel disease ZNF300 intron 23128233 rs2290989 chr5 150282784 T C 8.38E-04 Type 2 diabetes ZNF300 intron 17463246 rs6895705 chr5 150316850 A G 2.75E-04 Multiple complex diseases ZNF300P1 intron 17554300 rs931058 chr5 150333698 A T 9.78E-09 Multiple complex diseases / / 17554300 rs10050426 chr5 150350990 G A 2.75E-05 Multiple complex diseases / / 17554300 rs3886104 chr5 150351529 T C 4.81E-05 Multiple complex diseases / / 17554300 rs4368715 chr5 150351665 C G 9.35E-04 Multiple complex diseases / / 17554300 rs7710643 chr5 150357846 G T 5.07E-06 Multiple complex diseases / / 17554300 rs11950220 chr5 150358459 C A 5.66E-05 Multiple complex diseases / / 17554300 rs11739412 chr5 150365022 A G 1.66E-05 Multiple complex diseases / / 17554300 rs11957416 chr5 150371635 C G 3.84E-05 Height / / 22021425 rs2054440 chr5 150384959 A G 6.09E-06 Rheumatoid arthritis / / 19503088 rs4958872 chr5 150402334 C T 6.67E-05 Serum metabolites GPX3 intron 19043545 rs2277940 chr5 150409477 T C 1.27E-07 Schizophrenia TNIP1 nearGene-3 21926974 rs2233299 chr5 150425467 G A 2.10E-04 Myasthenia gravis TNIP1 cds-synon 23055271 rs888989 chr5 150431030 C T 2.74E-05 Multiple sclerosis TNIP1 intron 20598377 rs2112635 chr5 150432153 C T 0.000425 Asthma TNIP1 intron 22694930 rs17111695 chr5 150432446 T C 6.55E-05 Type 2 diabetes TNIP1 intron 17463246 rs17111695 chr5 150432446 T C 5.70E-05 Methamphetamine dependence TNIP1 intron 23594818 rs6579837 chr5 150434894 G T 0.00000171 Rheumatoid arthritis (CCP positive) TNIP1 intron 23143596 rs6579837 chr5 150434894 G T 0.0000404 Rheumatoid arthritis TNIP1 intron 23143596 rs3805433 chr5 150435480 C G 0.00047 Endometrial cancer TNIP1 intron 22426144 rs1422673 chr5 150438988 C T 0.000000272 Asthma TNIP1 intron 22694930 rs1422673 chr5 150438988 C T 6.20E-09 Myasthenia gravis TNIP1 intron 23055271 rs1422673 chr5 150438988 C T 1.78E-05 Asthma TNIP1 intron pha003127 rs2233287 chr5 150440097 G A 5.00E-09 Systemic sclerosis TNIP1 intron 21750679 rs2233287 chr5 150440097 G A 0.0000865 Asthma TNIP1 intron 22694930 rs2233287 chr5 150440097 G A 4.60E-09 Myasthenia gravis TNIP1 intron 23055271 rs2233287 chr5 150440097 G A 5.83E-05 Asthma TNIP1 intron pha003127 rs147561136 chr5 150441761 T C 0.000069 Prostate cancer (advanced) TNIP1 missense 23555315 rs4562032 chr5 150446316 C A 0.0000044 Mean arterial pressure TNIP1 intron 22510845 rs4958881 chr5 150450236 T C 1.19E-05 Systemic sclerosis TNIP1 intron 21750679 rs4958881 chr5 150450236 T C 0.000158 Asthma TNIP1 intron 22694930 rs4958881 chr5 150450236 T C 3.00E-10 Myasthenia gravis TNIP1 intron 23055271 rs3792785 chr5 150451650 T C 0.0000611 Asthma TNIP1 intron 22694930 rs3792785 chr5 150451650 T C 3.60E-08 Myasthenia gravis TNIP1 intron 23055271 rs3792785 chr5 150451650 T C 6.18E-05 Asthma TNIP1 intron pha003127 rs3792783 chr5 150455732 A G 1.14E-05 Systemic sclerosis TNIP1 intron 21750679 rs3792783 chr5 150455732 A G 0.0000526 Asthma TNIP1 intron 22694930 rs3792783 chr5 150455732 A G 1.70E-08 Myasthenia gravis TNIP1 intron 23055271 rs7708392 chr5 150457485 G C 3.80E-13 Multiple sclerosis TNIP1 intron 22190364 rs10036748 chr5 150458146 C T 2.00E-09 Systemic lupus erythematosus TNIP1 intron 19838193 rs10036748 chr5 150458146 C T 0.00000114 Asthma TNIP1 intron 22694930 rs10036748 chr5 150458146 C T 3.00E-06 Systemic lupus erythematosus TNIP1 intron 23273568 rs10036748 chr5 150458146 C T 3.44E-05 Asthma TNIP1 intron pha003127 rs960709 chr5 150461049 A G 2.00E-08 Systemic lupus erythematosus and Systemic sclerosis TNIP1 intron 23740937 rs13168551 chr5 150462638 T C 0.000551 Asthma TNIP1 intron 22694930 rs13168551 chr5 150462638 T C 6.00E-06 Myasthenia gravis TNIP1 intron 23055271 rs13168551 chr5 150462638 T C 4.00E-06 Systemic lupus erythematosus TNIP1 intron 23273568 rs2233278 chr5 150467189 G C 2.20E-42 Psoriasis TNIP1 UTR-5 23143594 rs3762999 chr5 150469426 C T 1.16E-21 Psoriasis / / 20953187 rs3762999 chr5 150469426 C T 4.60E-19 Psoriasis / / 20953187 rs3762999 chr5 150469426 C T 5.20E-07 Psoriasis / / 20953187 rs999556 chr5 150473674 A G 1.90E-05 Psoriasis / / 20953187 rs999556 chr5 150473674 A G 4.50E-20 Psoriasis / / 20953187 rs999556 chr5 150473674 A G 8.89E-22 Psoriasis / / 20953187 rs999556 chr5 150473674 A G 1.00E-15 Myopia (pathological) / / 23049088 rs17728338 chr5 150478318 G A 1.00E-20 Psoriasis / / 19169254 rs17728338 chr5 150478318 G A 1.00E-20 Psoriasis / / 20953187 rs17728338 chr5 150478318 G A 1.00E-20 Multiple sclerosis / / 22190364 rs868641 chr5 150485241 T C 3.77E-04 Taste perception ANXA6 intron 22132133 rs868641 chr5 150485241 T C 1.20E-05 Systemic lupus erythematosus ANXA6 intron 23273568 rs4958893 chr5 150486991 T C 3.26E-04 Taste perception ANXA6 intron 22132133 rs4958893 chr5 150486991 T C 8.90E-06 Systemic lupus erythematosus ANXA6 intron 23273568 rs4958894 chr5 150487174 T C 4.60E-06 Systemic lupus erythematosus ANXA6 intron 23273568 rs1133202 chr5 150489390 A G 4.21E-05 Taste perception ANXA6 cds-synon 22132133 rs7716383 chr5 150501247 G A 2.56E-04 Lymphocyte counts ANXA6 intron 22286170 rs3792775 chr5 150503337 G A 6.06E-04 Rheumatoid arthritis ANXA6 intron 21452313 rs2303025 chr5 150503675 T C 8.39E-05 Rheumatoid arthritis ANXA6 intron 21452313 rs10045859 chr5 150505177 C T 9.75E-04 Rheumatoid arthritis ANXA6 intron 21452313 rs17728511 chr5 150508459 A G 3.05E-04 Lung function (forced expiratory volume in 1 second) ANXA6 intron 24023788 rs11952969 chr5 150516492 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ANXA6 intron 22628534 rs10039049 chr5 150517899 T C 9.91E-04 Tourette syndrome ANXA6 intron 22889924 rs371586 chr5 150544620 T C 2.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs366307 chr5 150547144 C T 4.90E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs10515645 chr5 150551827 G A 9.97E-04 Tourette syndrome / / 22889924 rs7349812 chr5 150556327 C T 7.56E-04 Tourette syndrome / / 22889924 rs7717323 chr5 150559721 C G 9.47E-04 Alzheimer's disease / / 24755620 rs12518395 chr5 150563302 G T 2.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCDC69 intron 20877124 rs10044052 chr5 150578950 C T 6.98E-05 Multiple complex diseases CCDC69 intron 17554300 rs402770 chr5 150580700 G C 9.18E-05 Epilepsy (remission after treatment) CCDC69 intron 23962720 rs7724774 chr5 150585867 G A 7.00E-06 Bulimia nervosa CCDC69 intron 23568457 rs979455 chr5 150594802 T C 9.00E-06 Obesity-related traits CCDC69 intron 23251661 rs153462 chr5 150605070 A G 1.24E-04 Smoking initiation / / 24665060 rs173567 chr5 150618829 T C 7.64E-04 Smoking initiation / / 24665060 rs168700 chr5 150619002 G A 8.05E-04 Alcohol dependence / / 20201924 rs168700 chr5 150619002 G A 3.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs152266 chr5 150635429 A G 3.00E-04 HIV-1 viral setpoint GM2A intron 17641165 rs16838 chr5 150639162 C G 2.54E-05 Multiple complex diseases GM2A intron 17554300 rs153479 chr5 150639778 G A 1.18E-04 Multiple complex diseases GM2A intron 17554300 rs6579845 chr5 150642265 A G 9.55E-04 Multiple complex diseases GM2A intron 17554300 rs2075783 chr5 150646780 A C 5.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GM2A intron 20877124 rs10061997 chr5 150658987 T C 1 Drug response to Etoposide SLC36A3 intron 17537913 rs3846710 chr5 150698806 T C 2.00E-08 Urinary metabolites SLC36A2 intron 21572414 rs382178 chr5 150699327 C G 2.50E-05 Urinary metabolites SLC36A2 intron 21572414 rs6876572 chr5 150739002 T C 1.60E-05 Asthma / / 22561531 rs10463316 chr5 150746034 A G 2.00E-10 Metabolite levels (Pyroglutamine) / / 23934736 rs10515648 chr5 150751378 G A 6.08E-04 Parkinson's disease / / 17052657 rs10515648 chr5 150751378 G A 8.20E-04 Depression (quantitative trait) / / 20800221 rs13357969 chr5 150751557 A G 9.30E-05 Celiac disease / / 17558408 rs11741064 chr5 150760877 C T 8.92E-04 Depression (quantitative trait) / / 20800221 rs7702931 chr5 150764714 C T 6.03E-04 Depression (quantitative trait) / / 20800221 rs17802576 chr5 150766681 T A 5.66E-04 Depression (quantitative trait) / / 20800221 rs11742559 chr5 150767778 C G 5.65E-04 Depression (quantitative trait) / / 20800221 rs17740447 chr5 150768279 C T 5.59E-04 Depression (quantitative trait) / / 20800221 rs11167544 chr5 150777798 G A 3.87E-04 Depression (quantitative trait) / / 20800221 rs7708940 chr5 150789051 A G 5.40E-05 Celiac disease / / 17558408 rs7713313 chr5 150789173 G A 3.89E-04 Depression (quantitative trait) / / 20800221 rs7713313 chr5 150789173 G A 2.30E-05 Urinary metabolites / / 21572414 rs9918182 chr5 150793379 G A 2.30E-05 Urinary metabolites / / 21572414 rs17740556 chr5 150794323 A G 3.60E-04 Depression (quantitative trait) / / 20800221 rs17740573 chr5 150794720 T G 3.61E-04 Depression (quantitative trait) / / 20800221 rs11167546 chr5 150795336 C A 5.42E-04 Depression (quantitative trait) / / 20800221 rs12658833 chr5 150795813 T C 5.76E-04 Depression (quantitative trait) / / 20800221 rs17740585 chr5 150795975 C G 5.86E-04 Depression (quantitative trait) / / 20800221 rs17740585 chr5 150795975 C G 2.80E-05 Urinary metabolites / / 21572414 rs2161224 chr5 150797895 A G 6.13E-04 Depression (quantitative trait) / / 20800221 rs11747813 chr5 150799295 T C 6.90E-04 Depression (quantitative trait) / / 20800221 rs17802762 chr5 150799529 C T 8.81E-04 Depression (quantitative trait) / / 20800221 rs17740620 chr5 150800243 C T 9.34E-04 Depression (quantitative trait) / / 20800221 rs729057 chr5 150828004 T G 0.000046 Panic disorder SLC36A1 intron 23149450 rs729057 chr5 150828004 T G 4.60E-05 Serum tamsulosin hydrochloride concentration SLC36A1 intron 23151678 rs17740674 chr5 150831352 A G 6.01E-04 Taste perception SLC36A1 intron 22132133 rs4958272 chr5 150831642 G T 7.89E-04 Major depressive disorder SLC36A1 intron 22472876 rs17802828 chr5 150836580 C T 6.10E-04 Type 1 diabetes nephropathy SLC36A1 intron 23028342 rs35060330 chr5 150838085 C T 5.44E-04 Taste perception SLC36A1 intron 22132133 rs35060330 chr5 150838085 C T 3.30E-06 Hematology traits SLC36A1 intron 23303382 rs17112008 chr5 150838118 C A 3.30E-06 Hematology traits SLC36A1 intron 23303382 rs6892322 chr5 150838995 C G 2.75E-05 Multiple complex diseases SLC36A1 intron 17554300 rs17741008 chr5 150896898 C T 2.64E-04 Suicide attempts in bipolar disorder FAT2 intron 21423239 rs1009091 chr5 150906198 A C 6.98E-04 Type 2 diabetes FAT2 intron 17463246 rs3822700 chr5 150907299 A C 2.55E-04 Suicide attempts in bipolar disorder FAT2 intron 21423239 rs6579879 chr5 150921805 G A 4.75E-04 Aortic root size FAT2 intron 21223598 rs998076 chr5 150924769 G A 7.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAT2 cds-synon 20877124 rs3097775 chr5 150933411 A G 6.55E-04 Schizophrenia FAT2 intron 19197363 rs3097776 chr5 150936361 G C 9.63E-05 Aortic root size FAT2 intron 21223598 rs10058833 chr5 150937193 A G 1.64E-04 Amyotrophic lateral sclerosis (sporadic) FAT2 intron 24529757 rs3097779 chr5 150939707 A C 7.47E-04 Aortic root size FAT2 intron 21223598 rs766206 chr5 150967836 C T 4.17E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs7722497 chr5 150997221 A G 5.57E-04 Smoking cessation / / 24665060 rs1529691 chr5 150999990 G A 7.38E-04 Multiple complex diseases / / 17554300 rs6579884 chr5 151036298 A G 3.60E-04 Multiple complex diseases / / 17554300 rs2033467 chr5 151039626 C T 0.000000212 Fetal hemoglobin levels LOC100505813 intron 22936743 rs17718324 chr5 151058179 G A 7.64E-07 Triglycerides SPARC intron 19074352 rs17718324 chr5 151058179 G A 7.64E-07 Polyunsaturated fatty acid levels,in plasma SPARC intron 19148276 rs11745387 chr5 151059231 G A 5.00E-05 Cognitive impairment induced by topiramate SPARC intron 22091778 rs6579888 chr5 151071719 C T 0.0000628 Salmonella-induced pyroptosis / / 22837397 rs6579891 chr5 151074609 T C 2.03E-05 Elbow pain / / pha003008 rs6872241 chr5 151081537 T C 8.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6872241 chr5 151081537 T C 1.25E-05 Elbow pain / / pha003008 rs7719111 chr5 151086492 A T 4.32E-04 Coronary Artery Disease / / 17634449 rs1062177 chr5 151184701 C T 8.00E-06 Preschool internalizing problems G3BP1 UTR-3 24839885 rs1465555 chr5 151289698 T C 9.20E-04 Stroke GLRA1 intron pha002887 rs2059121 chr5 151310198 A G 7.69E-04 Stroke / / pha002887 rs17112398 chr5 151327514 G C 9.89E-04 Type 2 diabetes / / 17463246 rs17112398 chr5 151327514 G C 9.40E-06 Urinary metabolites / / 21572414 rs10067788 chr5 151333011 A C 3.67E-05 Bipolar disorder and schizophrenia / / 20889312 rs10067788 chr5 151333011 A C 8.90E-06 Urinary metabolites / / 21572414 rs7711643 chr5 151333124 C T 1.10E-05 Urinary metabolites / / 21572414 rs170020 chr5 151344558 G A 4.00E-06 Interstitial lung disease / / 21787189 rs707165 chr5 151388677 G C 3.65E-06 Statin-induced myopathy / / 21826682 rs29658 chr5 151410888 A G 5.73E-05 HDL cholesterol / / pha003074 rs159938 chr5 151420240 G A 9.20E-05 HDL cholesterol / / pha003074 rs255481 chr5 151423814 A G 4.14E-06 Statin-induced myopathy / / 21826682 rs564489 chr5 151435875 G A 2.15E-05 Heart Rate / / pha003053 rs17718794 chr5 151435970 G A 4.40E-04 Type 2 diabetes / / 17463246 rs17718794 chr5 151435970 G A 2.87E-04 Multiple complex diseases / / 17554300 rs3864271 chr5 151436643 A G 3.91E-04 Type 2 diabetes / / 17463246 rs3909851 chr5 151443825 C A 5.46E-04 Type 2 diabetes / / 17463246 rs3909854 chr5 151448761 C T 5.96E-04 Type 2 diabetes / / 17463246 rs29854 chr5 151466968 T C 7.07E-04 Nicotine dependence / / 17158188 rs154104 chr5 151481730 A G 3.78E-05 Asthma / / 11022011 rs154101 chr5 151483363 A C 7.59E-04 Nicotine dependence / / 17158188 rs29843 chr5 151502574 T A 3.21E-06 Glycemic traits (pregnancy) / / 23903356 rs29843 chr5 151502574 T A 8.92E-06 Glycemic traits (pregnancy) / / 23903356 rs29842 chr5 151503524 T C 4.71E-06 Glycemic traits (pregnancy) / / 23903356 rs29842 chr5 151503524 T C 9.11E-06 Glycemic traits (pregnancy) / / 23903356 rs10515653 chr5 151508200 C T 5.10E-04 Type 2 diabetes / / 17463246 rs10515653 chr5 151508200 C T 3.49E-04 Multiple complex diseases / / 17554300 rs40266 chr5 151513383 A G 1.56E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs17662766 chr5 151521211 G T 5.04E-04 Type 2 diabetes / / 17463246 rs154690 chr5 151524210 T C 9.40E-05 Bipolar disorder and schizophrenia / / 20889312 rs6874463 chr5 151527585 C T 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17112847 chr5 151546416 G A 8.50E-04 Type 2 diabetes / / 17463246 rs10515652 chr5 151561278 C T 7.07E-04 Diabetic retinopathy / / 20871662 rs294959 chr5 151566100 A G 9.75E-05 Bipolar disorder and schizophrenia / / 20889312 rs211496 chr5 151566652 C T 5.56E-06 Periodontitis (PAL4Q3) / / 24024966 rs294958 chr5 151568099 A G 5.00E-06 Periodontitis (PAL4Q3) / / 24024966 rs294945 chr5 151569417 C A 6.42E-06 Periodontitis (PAL4Q3) / / 24024966 rs2434975 chr5 151572805 T C 5.35E-06 Periodontitis (PAL4Q3) / / 24024966 rs1156008 chr5 151575731 T C 9.19E-06 Periodontitis (PAL4Q3) / / 24024966 rs167169 chr5 151576313 T C 5.36E-06 Periodontitis (PAL4Q3) / / 24024966 rs2434976 chr5 151579579 G A 6.02E-06 Periodontitis (PAL4Q3) / / 24024966 rs169819 chr5 151580934 A T 6.11E-06 Periodontitis (PAL4Q3) / / 24024966 rs10059821 chr5 151617492 C T 7.46E-07 Multiple complex diseases / / 17554300 rs11167574 chr5 151623192 G T 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1922672 chr5 151643474 C G 4.94E-05 Type 2 diabetes / / 17463246 rs11951018 chr5 151651110 C T 3.88E-04 Type 2 diabetes / / 17463246 rs9324721 chr5 151665189 G A 7.58E-04 Type 2 diabetes / / 17463246 rs6876527 chr5 151668260 G A 5.00E-04 Type 2 diabetes / / 17463246 rs4958525 chr5 151669984 G A 8.46E-05 Diabetic nephropathy / / pha002852 rs2161400 chr5 151670129 G C 7.57E-04 Type 2 diabetes / / 17463246 rs11743409 chr5 151671964 A G 7.31E-04 Type 2 diabetes / / 17463246 rs10078065 chr5 151672044 G A 5.00E-04 Type 2 diabetes / / 17463246 rs13155261 chr5 151676560 T A 6.01E-04 Type 2 diabetes / / 17463246 rs1862397 chr5 151676858 T C 6.24E-04 Type 2 diabetes / / 17463246 rs1862396 chr5 151676890 A G 4.92E-04 Type 2 diabetes / / 17463246 rs2216643 chr5 151677550 A C 4.87E-04 Type 2 diabetes / / 17463246 rs17113106 chr5 151712952 A G 2.90E-05 Cognitive function / / 24684796 rs1010254 chr5 151734109 C T 8.00E-06 optic disc size (cup) / / 20395239 rs2161291 chr5 151738612 G A 4.40E-04 Type 2 diabetes / / 17463246 rs3792906 chr5 151773331 T C 2.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NMUR2 intron 20877124 rs3792906 chr5 151773331 T C 6.49E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NMUR2 intron 20877124 rs139903210 chr5 151784533 C A 0.000042 Breast cancer(er negative) NMUR2 missense 23555315 rs10051177 chr5 151803207 G A 4.16E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11959584 chr5 151854302 C T 6.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7717092 chr5 151876462 G A 8.08E-06 Taste perception / / 22132133 rs7717550 chr5 151876757 G A 6.83E-06 Taste perception / / 22132133 rs10515673 chr5 151896509 G A 3.70E-06 Aortic stiffness / / 22068335 rs4569857 chr5 151912745 A G 2.00E-05 Urinary metabolites / / 21572414 rs6877248 chr5 152043215 T C 7.37E-04 Smoking cessation / / 24665060 rs7701379 chr5 152056734 A T 1.60E-04 Smoking cessation / / 24665060 rs17565727 chr5 152081338 G A 9.58E-04 Insulin resistance / / 21901158 rs17565839 chr5 152082740 C T 9.58E-04 Insulin resistance / / 21901158 rs78188806 chr5 152179283 C A 9.23E-05 Acne (severe) / / 24927181 rs11958854 chr5 152206046 T C 7.27E-04 Insulin resistance / / 21901158 rs4262150 chr5 152288453 T G 7.00E-06 Bipolar disorder and schizophrenia / / 22688191 rs6864972 chr5 152347463 T C 2.02E-04 Insulin resistance / / 21901158 rs1371060 chr5 152363117 C T 6.75E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1438937 chr5 152370448 G T 8.10E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs75380573 chr5 152371336 G A 1.37E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs1438938 chr5 152371647 C T 2.27E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs79210417 chr5 152372721 T C 1.37E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs10515679 chr5 152373633 C T 9.28E-05 Potassium levels / / pha003086 rs2118788 chr5 152374021 G C 8.10E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs75703928 chr5 152375466 G A 1.39E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs17113869 chr5 152375478 A G 2.27E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs113013679 chr5 152377099 G A 1.41E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs112895793 chr5 152387311 T C 1.32E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs78040934 chr5 152388885 G A 1.44E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs78988005 chr5 152389640 T C 1.24E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs192943752 chr5 152391935 T C 1.44E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs79872771 chr5 152393076 T A 5.76E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs59900286 chr5 152396186 A G 1.44E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs115143232 chr5 152396588 C T 1.44E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs56994551 chr5 152398137 T A 1.89E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs76768621 chr5 152400186 C A 1.45E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs111911908 chr5 152402054 C T 2.80E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs1595586 chr5 152402347 G A 8.93E-05 Potassium levels / / pha003086 rs181619037 chr5 152405017 G A 1.46E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs112669240 chr5 152406750 T C 2.81E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs9716680 chr5 152406813 C G,T 1.54E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs966088 chr5 152409030 T C 2.27E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs76483517 chr5 152411331 C T 5.18E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs79228075 chr5 152412656 C T 1.47E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs114440438 chr5 152412740 C T 1.47E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs75173757 chr5 152418484 T G 1.49E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs113356988 chr5 152423064 C A 1.51E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs111685453 chr5 152423186 G A 1.51E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs75515828 chr5 152424396 A G 1.51E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs146717151 chr5 152427025 A C 1.52E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs56760618 chr5 152427700 G A 1.52E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs61419327 chr5 152427767 A G 1.52E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs57884840 chr5 152427892 C T 1.52E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs78188846 chr5 152430061 G T 1.53E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs80314334 chr5 152431809 A G 1.54E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs78748990 chr5 152434768 T C 1.91E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs73798901 chr5 152437123 A G 2.60E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs1561417 chr5 152438006 C A 8.54E-05 Mammographic density / / 22532574 rs73798902 chr5 152438925 C T 2.70E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs73802005 chr5 152440009 T C 2.12E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs73802006 chr5 152440597 A T 4.78E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs17576757 chr5 152448472 T C 5.58E-04 Alzheimer's disease / / 22005930 rs2349026 chr5 152460391 A G 6.55E-04 Schizophrenia / / 19197363 rs73802034 chr5 152472939 A G 6.80E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs73802035 chr5 152474843 A G 9.34E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs17578145 chr5 152491465 A G 9.56E-04 Alzheimer's disease / / 22005930 rs61056587 chr5 152496013 G T 9.52E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs73798703 chr5 152499207 T C 9.24E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs57917647 chr5 152503938 C T 2.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs1438949 chr5 152504929 A G 6.00E-06 Response to amphetamines / / 22952603 rs11167612 chr5 152506255 A G 5.88E-06 Response to amphetamines / / 22952603 rs17501123 chr5 152518117 A G 1.73E-04 Insulin resistance / / 21901158 rs2910032 chr5 152540354 C T 4.00E-08 Schizophrenia / / 23974872 rs2910036 chr5 152548160 G C 2.89E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs2080950 chr5 152571970 G A 3.29E-05 Multiple complex diseases / / 17554300 rs296171 chr5 152604066 G A 0.0000837 Sarcoidosis / / 22952805 rs2546333 chr5 152604757 G A 0.00006609 Sarcoidosis / / 22952805 rs1841685 chr5 152605240 G A 0.00006609 Sarcoidosis / / 22952805 rs1363497 chr5 152605682 C T 0.00007528 Sarcoidosis / / 22952805 rs1363498 chr5 152605690 A G 0.00006609 Sarcoidosis / / 22952805 rs72793628 chr5 152605794 G A 0.00003911 Sarcoidosis / / 22952805 rs60970806 chr5 152607414 C A 0.00004453 Sarcoidosis / / 22952805 rs111582573 chr5 152607907 A G 0.00004453 Sarcoidosis / / 22952805 rs727809 chr5 152610222 A C 2.41E-05 Bone mineral density / / 19181680 rs177001 chr5 152610561 A G 9.89E-06 Lipid traits / / 21777205 rs56118692 chr5 152610767 C T 0.00004453 Sarcoidosis / / 22952805 rs72793634 chr5 152611538 C T 0.00008119 Sarcoidosis / / 22952805 rs72793635 chr5 152614164 G A 0.00004109 Sarcoidosis / / 22952805 rs10515687 chr5 152636793 C T 3.01E-04 Wegener's granulomatosis / / 23740775 rs3112530 chr5 152639677 A G 7.00E-06 Aging (time to event) / / 21782286 rs17504622 chr5 152654479 C T 3.00E-09 Schizophrenia / / 23974872 rs160163 chr5 152725255 T C 9.28E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10037511 chr5 152728406 T C 8.98E-04 Tourette syndrome / / 22889924 rs304850 chr5 152754143 C G 3.21E-04 Aortic root size / / 21223598 rs304842 chr5 152783598 T C 8.81E-04 Coronary heart disease / / 21606135 rs12522297 chr5 152797487 G A 7.24E-06 Schizophrenia / / 21926974 rs512938 chr5 152838052 T C 7.46E-05 Type 2 diabetes / / 17463246 rs522610 chr5 152841607 T C 1.95E-04 Type 2 diabetes / / 17463246 rs498660 chr5 152842463 C T 7.73E-05 Type 2 diabetes / / 17463246 rs519968 chr5 152845246 A G 7.73E-05 Type 2 diabetes / / 17463246 rs506622 chr5 152846195 G A 7.48E-05 Type 2 diabetes / / 17463246 rs2162979 chr5 152854349 T C 7.70E-05 HIV-1 control / / 20041166 rs518277 chr5 152856287 A G 1.95E-04 Type 2 diabetes / / 17463246 rs541544 chr5 152858887 G C 7.57E-05 Type 2 diabetes / / 17463246 rs525208 chr5 152865781 T C 1.80E-04 Type 2 diabetes / / 17463246 rs1353086 chr5 152918858 C A 4.32E-04 Alzheimer's disease GRIA1 intron 22005930 rs4958344 chr5 152927244 T C 8.15E-04 Alzheimer's disease GRIA1 intron 22005930 rs1552834 chr5 152928591 G A 8.13E-04 Alzheimer's disease GRIA1 intron 22005930 rs1552833 chr5 152928843 A C 8.14E-04 Alzheimer's disease GRIA1 intron 22005930 rs10065813 chr5 152940405 C T 8.00E-06 Obesity-related traits GRIA1 intron 23251661 rs17114836 chr5 152955821 T C 5.00E-06 Urinary metabolites GRIA1 intron 21572414 rs1973372 chr5 152961624 C T 9.18E-04 Alcohol dependence GRIA1 intron 21314694 rs1973372 chr5 152961624 C T 8.40E-06 Urinary metabolites GRIA1 intron 21572414 rs778816 chr5 152968158 C T 6.98E-04 Coronary Artery Disease GRIA1 intron 17634449 rs12658202 chr5 152979554 C A 9.00E-06 Anthropometric traits GRIA1 intron 19260139 rs812389 chr5 152983125 C T 1.99E-04 Type 2 diabetes GRIA1 intron 17463246 rs2910268 chr5 152993589 G T 3.62E-04 Depression (quantitative trait) GRIA1 intron 20800221 rs1493403 chr5 152998172 C T 6.25E-04 Type 2 diabetes GRIA1 intron 17463246 rs11748478 chr5 153004995 C A 7.27E-04 Stroke GRIA1 intron pha002886 rs1422884 chr5 153009489 T C 7.74E-04 Depression (quantitative trait) GRIA1 intron 20800221 rs7737904 chr5 153012184 C T 2.12E-05 Height GRIA1 intron 22216288 rs1422892 chr5 153017520 A C 8.92E-04 Depression (quantitative trait) GRIA1 intron 20800221 rs11955628 chr5 153022881 T C 5.63E-04 Stroke GRIA1 intron pha002886 rs1363677 chr5 153034687 G A 2.40E-05 Urinary metabolites GRIA1 intron 21572414 rs2963957 chr5 153043060 G C 2.50E-05 Urinary metabolites GRIA1 intron 21572414 rs4385264 chr5 153053735 G A 2.00E-04 Cognitive impairment induced by topiramate GRIA1 intron 22091778 rs4385264 chr5 153053735 G A 6.13E-05 Cognitive impairment induced by topiramate GRIA1 intron 22091778 rs4385264 chr5 153053735 G A 7.42E-04 Cognitive impairment induced by topiramate GRIA1 intron 22091778 rs7714428 chr5 153055075 A C 8.89E-04 Multiple complex diseases GRIA1 intron 17554300 rs12189362 chr5 153057548 C T 3.00E-10 Sudden cardiac arrest GRIA1 intron 21658281 rs9324755 chr5 153064097 T C 7.86E-05 HIV-1 control GRIA1 intron 20041166 rs10035262 chr5 153065746 A G 6.28E-04 Multiple complex diseases GRIA1 intron 17554300 rs10035262 chr5 153065746 A G 7.86E-05 HIV-1 control GRIA1 intron 20041166 rs10073988 chr5 153066015 T C 8.04E-04 Multiple complex diseases GRIA1 intron 17554300 rs10075495 chr5 153066088 T C 8.93E-04 Multiple complex diseases GRIA1 intron 17554300 rs4336409 chr5 153093323 G T 7.94E-04 Multiple complex diseases GRIA1 intron 17554300 rs4273649 chr5 153120048 A G 8.50E-05 Alcoholism (heaviness of drinking) GRIA1 intron 21529783 rs4424038 chr5 153120264 A G 1.50E-06 Urinary metabolites GRIA1 intron 21572414 rs6889909 chr5 153123433 C T 9.18E-05 Cognitive decline GRIA1 intron 22054870 rs6889794 chr5 153123455 A G 5.30E-05 Alcoholism (heaviness of drinking) GRIA1 intron 21529783 rs4128572 chr5 153128715 A G 7.90E-05 Alcoholism (heaviness of drinking) GRIA1 intron 21529783 rs11167640 chr5 153132306 T C 2.20E-06 Urinary metabolites GRIA1 intron 21572414 rs7445323 chr5 153136785 T G 9.80E-05 Alcoholism (heaviness of drinking) GRIA1 intron 21529783 rs17356099 chr5 153143048 T C 9.81E-05 Cognitive decline GRIA1 intron 22054870 rs922235 chr5 153160081 A G 5.68E-05 Cognitive decline GRIA1 intron 22054870 rs1461232 chr5 153162173 C G 6.33E-04 Multiple complex diseases GRIA1 intron 17554300 rs4958351 chr5 153170374 G A,C,T 4.00E-07 Asparaginase hypersensitivity in acute lymphoblastic leukemia GRIA1 intron 20592726 rs2963998 chr5 153177053 C T 7.10E-05 Alcoholism (heaviness of drinking) GRIA1 intron 21529783 rs10070447 chr5 153178814 C T 6.78E-06 Smoking cessation GRIA1 intron 18519826 rs1461225 chr5 153182725 T G 7.03E-04 Cognitive impairment induced by topiramate GRIA1 intron 22091778 rs13354399 chr5 153189431 G A 2.17E-04 Smoking cessation GRIA1 intron 18519826 rs13354399 chr5 153189431 G A 7.33E-04 Smoking cessation GRIA1 intron 18519826 rs2964013 chr5 153197696 T A 2.42E-04 Multiple complex diseases / / 17554300 rs2926862 chr5 153212219 G T 3.59E-05 Cognitive impairment induced by topiramate / / 22091778 rs1461236 chr5 153241171 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2964027 chr5 153241647 C A 2.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1461235 chr5 153241839 G A 2.16E-05 Platelet counts / / pha003100 rs1461229 chr5 153257636 C A 2.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1350804 chr5 153264228 C T 1.70E-04 Multiple complex diseases / / 17554300 rs11743150 chr5 153264577 G C 1.14E-04 Multiple complex diseases / / 17554300 rs6873055 chr5 153273168 G T 8.85E-05 Coronary restenosis / / 21878436 rs6873055 chr5 153273168 G T 7.76E-05 Platelet counts / / pha003100 rs898709 chr5 153286964 A G 2.21E-04 Multiple complex diseases / / 17554300 rs1870738 chr5 153287549 T A 2.90E-04 Multiple complex diseases / / 17554300 rs2614119 chr5 153289425 A G 2.17E-05 Multiple complex diseases / / 17554300 rs2614123 chr5 153300215 C T 3.58E-04 Multiple complex diseases / / 17554300 rs286969 chr5 153321768 A G 2.18E-05 Post-operative nausea and vomiting / / 21694509 rs286969 chr5 153321768 A G 1.61E-04 Alzheimer's disease / / 22005930 rs17115481 chr5 153358226 G A 6.06E-04 Type 2 diabetes / / 17463246 rs286964 chr5 153359476 C T 2.57E-04 HIV-1 viral setpoint / / 17641165 rs2053311 chr5 153368223 G A 3.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs2560039 chr5 153390449 T A 8.52E-04 Multiple complex diseases FAM114A2 intron 17554300 rs2560053 chr5 153413082 T C 2.05E-04 Multiple complex diseases FAM114A2 intron 17554300 rs1370912 chr5 153430783 A G 9.21E-04 Multiple complex diseases MFAP3 intron 17554300 rs816010 chr5 153462708 G A 5.73E-04 Type 2 diabetes / / 17846124 rs984078 chr5 153477465 G A 5.51E-06 Schizophrenia / / 19571811 rs1093167 chr5 153480536 T C 2.31E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs707184 chr5 153485826 T C 4.07E-04 Type 2 diabetes / / 17846124 rs2033195 chr5 153509596 T C 6.00E-06 Basal cell carcinoma / / 21700618 rs2033195 chr5 153509596 T C 6.00E-06 Body mass index / / 21701570 rs7708584 chr5 153543466 A G 5.00E-14 Body mass index / / 23583978 rs7701541 chr5 153554443 G A 7.47E-04 Multiple complex diseases / / 17554300 rs4958705 chr5 153564109 T C 7.87E-04 Multiple complex diseases / / 17554300 rs7719182 chr5 153566379 T C 6.67E-04 Multiple complex diseases / / 17554300 rs890793 chr5 153573938 C T 1.10E-05 Alcohol dependence GALNT10 intron 23089632 rs6580058 chr5 153577919 T C 1.79E-04 Multiple complex diseases GALNT10 intron 17554300 rs10515706 chr5 153578518 C T 1.36E-04 Multiple complex diseases GALNT10 intron 17554300 rs4958362 chr5 153583420 G A 5.95E-05 Multiple complex diseases GALNT10 intron 17554300 rs4958711 chr5 153584363 A G 8.85E-05 Multiple complex diseases GALNT10 intron 17554300 rs4958711 chr5 153584363 A G 5.05E-05 Insulin resistance GALNT10 intron 21901158 rs12654449 chr5 153585114 T A 7.40E-04 Multiple complex diseases GALNT10 intron 17554300 rs12654449 chr5 153585114 T A 9.94E-04 Insulin resistance GALNT10 intron 21901158 rs12652301 chr5 153585868 C T 1.08E-04 Multiple complex diseases GALNT10 intron 17554300 rs12652301 chr5 153585868 C T 5.77E-04 Insulin resistance GALNT10 intron 21901158 rs11744052 chr5 153596545 C T 8.96E-04 Tourette syndrome GALNT10 intron 22889924 rs575740 chr5 153642670 C T 9.45E-04 Coronary Artery Disease GALNT10 intron 17634449 rs7737215 chr5 153645178 T C 7.62E-04 Multiple complex diseases GALNT10 intron 17554300 rs2443526 chr5 153656530 C T 6.10E-06 Urinary metabolites GALNT10 intron 21572414 rs2443527 chr5 153657712 A G 2.55E-04 Multiple complex diseases GALNT10 intron 17554300 rs576374 chr5 153663103 G A 4.67E-05 Multiple complex diseases GALNT10 intron 17554300 rs11954189 chr5 153668639 T C 1.46E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines GALNT10 intron 21844884 rs11954290 chr5 153668948 T C 2.24E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines GALNT10 intron 21844884 rs6890748 chr5 153688100 G A 7.20E-05 Cognitive function GALNT10 intron 24684796 rs6891838 chr5 153688682 G T 9.20E-05 Cognitive function GALNT10 intron 24684796 rs17629792 chr5 153695948 C A 9.53E-04 Multiple complex diseases GALNT10 intron 17554300 rs27152 chr5 153734582 C T 2.05E-04 Smoking initiation GALNT10 intron 24665060 rs27827 chr5 153735045 A C 4.59E-04 Smoking initiation GALNT10 intron 24665060 rs27154 chr5 153741843 A G 8.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GALNT10 intron 20877124 rs2032850 chr5 153756297 C T 2.83E-06 Serum metabolites GALNT10 intron 19043545 rs1422665 chr5 153757052 C T 7.61E-05 Suicide attempts in bipolar disorder GALNT10 intron 21041247 rs7728507 chr5 153758351 C T 7.50E-05 Suicide attempts in bipolar disorder GALNT10 intron 21041247 rs17116042 chr5 153760329 T C 7.24E-05 Suicide attempts in bipolar disorder GALNT10 intron 21041247 rs750063 chr5 153760704 G A 8.88E-04 Alzheimer's disease GALNT10 intron 22005930 rs6870010 chr5 153765431 T C 1.23E-04 Suicide attempts in bipolar disorder GALNT10 intron 21041247 rs13154706 chr5 153769293 T C 2.05E-04 Suicide attempts in bipolar disorder GALNT10 intron 21041247 rs10064618 chr5 153772289 G A 4.44E-04 Asthma GALNT10 intron 21804549 rs17116065 chr5 153774171 G A 8.34E-04 Response to cytadine analogues (cytosine arabinoside) GALNT10 intron 24483146 rs17637385 chr5 153774793 C A 8.52E-05 Body Mass Index GALNT10 intron pha003021 rs4516909 chr5 153777436 A G 2.00E-05 Cognitive test performance GALNT10 intron 20125193 rs4516909 chr5 153777436 A G 9.06E-06 Parent of origin effect on language impairment (maternal) GALNT10 intron 24571439 rs3172941 chr5 153797880 C T 0.000292405 Hypertension (early onset hypertension) GALNT10 UTR-3 22479346 rs3172941 chr5 153797880 C T 8.87E-04 Response to cytadine analogues (cytosine arabinoside) GALNT10 UTR-3 24483146 rs10037670 chr5 153811490 A G 3.50E-04 Behavioural disinhibition (generation interaction) FLJ38109 intron 23942779 rs10037670 chr5 153811490 A G 4.00E-06 Behavioural disinhibition (generation interaction) FLJ38109 intron 23942779 rs10037670 chr5 153811490 A G 5.70E-05 Behavioural disinhibition (generation interaction) FLJ38109 intron 23942779 rs4958739 chr5 153828955 T C 5.92E-06 Diabetes Mellitus SAP30L intron pha003060 rs4958739 chr5 153828955 T C 7.37E-05 Glucose levels SAP30L intron pha003061 rs148763909 chr5 153837106 C T 1.00E-08 Alzheimer's disease (cognitive decline) SAP30L UTR-3 23535033 rs2351482 chr5 153837908 T C 1.55E-05 Diabetes Mellitus SAP30L UTR-3 pha003059 rs2351482 chr5 153837908 T C 5.24E-07 Diabetes Mellitus SAP30L UTR-3 pha003060 rs2351482 chr5 153837908 T C 8.00E-05 Glucose levels SAP30L UTR-3 pha003061 rs880083 chr5 153861047 C T 0.000847251 Hypertension (early onset hypertension) / / 22479346 rs283434 chr5 153868709 A G 1.10E-05 Diabetes Mellitus / / pha003060 rs13165478 chr5 153869040 G A 7.00E-14 Ventricular conduction / / 21076409 rs283438 chr5 153873560 T C 3.82E-06 Diabetes Mellitus / / pha003060 rs12655409 chr5 153960485 G A 8.80E-04 Premature ovarian failure / / 19508998 rs12655409 chr5 153960485 G A 1.20E-05 IgE levels / / 22075330 rs1824936 chr5 153986044 C T 5.30E-06 Urinary metabolites / / 21572414 rs1824935 chr5 153986313 G C 3.20E-06 Urinary metabolites / / 21572414 rs2351755 chr5 153989572 G C 4.60E-06 Urinary metabolites / / 21572414 rs7731137 chr5 154005654 T G 1.73E-05 Behcet's disease / / 23291587 rs7731137 chr5 154005654 T G 9.50E-05 Behcet's disease / / pha002888 rs12513744 chr5 154037358 A G 5.46E-07 Red blood cell traits / / 23222517 rs4958756 chr5 154045825 T C 9.69E-04 Parkinson's disease / / 17052657 rs11167699 chr5 154050914 C T 4.71E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs13154131 chr5 154087054 C T 2.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12055015 chr5 154091904 G A 5.21E-04 Type 2 diabetes / / 17463246 rs13178728 chr5 154119471 C T 5.75E-05 Orofacial clefts LARP1 intron 22419666 rs11167702 chr5 154200263 G A 8.18E-04 Multiple complex diseases C5orf4 intron 17554300 rs7726729 chr5 154307794 G A 5.90E-04 Multiple complex diseases GEMIN5 intron 17554300 rs158134 chr5 154359159 T G 5.60E-06 Urinary metabolites / / 21572414 rs17116670 chr5 154368404 G C 2.41E-04 Smoking cessation / / 24665060 rs6580132 chr5 154423356 G A 3.88E-06 Lipid traits / / 21777205 rs467330 chr5 154441640 A C 2.10E-05 Urinary metabolites / / 21572414 rs10059123 chr5 154442093 A C 9.55E-06 Asthma (childhood onset) / / 23829686 rs286607 chr5 154443069 C A 5.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs351294 chr5 154448739 C T 7.40E-05 Vaspin levels / / 22907691 rs351294 chr5 154448739 C T 0.000074 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs1428675 chr5 154456835 G C 1.74E-05 Serum metabolites / / 19043545 rs2134150 chr5 154464197 T A 1.92E-04 Multiple complex diseases / / 17554300 rs1008795 chr5 154489437 C T 5.20E-04 Depression (quantitative trait) / / 20800221 rs7703759 chr5 154493253 A G 6.73E-04 Depression (quantitative trait) / / 20800221 rs13155597 chr5 154493531 C A 6.80E-04 Depression (quantitative trait) / / 20800221 rs1005789 chr5 154496941 A G 7.79E-04 Depression (quantitative trait) / / 20800221 rs7703459 chr5 154498866 C T 5.43E-04 Depression (quantitative trait) / / 20800221 rs10066223 chr5 154499047 C T 3.59E-05 Body Mass Index / / pha003021 rs7728292 chr5 154499570 T C 4.85E-04 Depression (quantitative trait) / / 20800221 rs6873028 chr5 154500533 A G 4.81E-04 Depression (quantitative trait) / / 20800221 rs1564885 chr5 154505490 C T 6.78E-04 Depression (quantitative trait) / / 20800221 rs7702812 chr5 154505580 G A 5.62E-05 Intracranial aneurysm / / 20613766 rs6882113 chr5 154507095 A G 6.07E-04 Stroke / / pha002887 rs3909899 chr5 154507618 G A 1.34E-04 Type 2 diabetes / / 17463246 rs6866348 chr5 154511881 G A 5.37E-04 Stroke / / pha002887 rs3851502 chr5 154527423 C T 3.72E-04 Multiple complex diseases / / 17554300 rs17117020 chr5 154529922 G A 4.39E-04 Multiple complex diseases / / 17554300 rs6580146 chr5 154532193 G A 4.72E-05 Body Mass Index / / pha003021 rs1864125 chr5 154569150 T C 8.03E-05 Colorectal cancer / / 19723657 rs17117083 chr5 154569688 C T 9.36E-08 Alzheimer's disease / / 17998437 rs17117138 chr5 154614881 G A 2.80E-06 Urinary metabolites / / 21572414 rs4958401 chr5 154648174 T G 9.07E-05 Creatinine levels / / pha003069 rs12657212 chr5 154653619 A C 6.44E-06 Parkinson's disease (motor and cognition) / / 22658654 rs12657212 chr5 154653619 A C 9.84E-04 Telomere length / / 23900074 rs12187859 chr5 154668311 G A 1.93E-05 Hypertension / / pha003041 rs154966 chr5 154699695 G A 5.17E-04 Multiple complex diseases / / 17554300 rs1366584 chr5 154761863 T G 2.22E-04 Type 2 diabetes / / 17463246 rs17656910 chr5 154778790 A C 6.34E-04 Serum selenium levels / / 23698163 rs17598647 chr5 154782082 T G 7.98E-04 Serum selenium levels / / 23698163 rs9324820 chr5 154813400 G A 9.75E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs461355 chr5 154840829 T G 9.82E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6881846 chr5 154843554 A G 4.36E-07 Statin-induced myopathy / / 21826682 rs17660218 chr5 154889410 C A 1.24E-05 Non-word repetition / / 23738518 rs6884002 chr5 154891822 A G 4.82E-05 Blood Pressure / / pha003050 rs17602857 chr5 154907076 A G 2.21E-05 Non-word repetition / / 23738518 rs7704817 chr5 154988107 A C 3.20E-04 Multiple complex diseases / / 17554300 rs6865003 chr5 154988618 C A 2.75E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs13354678 chr5 154992289 T C 2.25E-04 Multiple complex diseases / / 17554300 rs7723600 chr5 155000515 T C 1.73E-04 Multiple complex diseases / / 17554300 rs6891593 chr5 155005574 G A 6.30E-04 Serum selenium levels / / 23698163 rs6580170 chr5 155006426 C T 7.60E-05 Multiple complex diseases / / 17554300 rs6884215 chr5 155009815 C T 6.27E-04 Serum selenium levels / / 23698163 rs2552992 chr5 155010218 G T 3.30E-05 Cognitive function / / 24684796 rs3863202 chr5 155010605 G A 3.70E-05 Multiple complex diseases / / 17554300 rs2194712 chr5 155014044 A G 4.42E-04 Multiple complex diseases / / 17554300 rs2194711 chr5 155014075 A G 4.37E-05 Multiple complex diseases / / 17554300 rs2552979 chr5 155027573 T C 5.60E-05 Cognitive function / / 24684796 rs6898274 chr5 155029966 G A 6.24E-04 Serum selenium levels / / 23698163 rs17118166 chr5 155030089 A G 6.21E-04 Serum selenium levels / / 23698163 rs17118168 chr5 155031830 C T 6.19E-04 Serum selenium levels / / 23698163 rs11951343 chr5 155049324 C T 4.40E-04 Response to antidepressants / / 19736353 rs4585515 chr5 155066776 G A 3.20E-04 Alcohol dependence / / 20201924 rs1363121 chr5 155072951 G T 1.90E-05 Urinary metabolites / / 21572414 rs10045068 chr5 155081309 A G 0.00000672 HIV-1-specific cross-reactive neutralizing activity / / 23372753 rs716651 chr5 155087160 G A 4.22E-04 Smoking initiation / / 24665060 rs991563 chr5 155087347 T A 1.30E-05 Urinary metabolites / / 21572414 rs11954814 chr5 155088339 G T 2.10E-05 Urinary metabolites / / 21572414 rs10077093 chr5 155114977 T C 1.30E-05 Urinary metabolites / / 21572414 rs9324842 chr5 155121837 A G 1.31E-04 Aortic root size / / 21223598 rs10044666 chr5 155128570 G T 2.03E-05 Personality dimensions / / 22628180 rs11134474 chr5 155202528 A G 8.00E-06 Smoking behavior / / 22006218 rs1545773 chr5 155239884 A G 7.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3846688 chr5 155252073 A T 2.45E-05 Personality dimensions / / 22628180 rs6556568 chr5 155252462 T A 2.45E-05 Personality dimensions / / 22628180 rs1432816 chr5 155253747 G A 2.38E-05 Personality dimensions / / 22628180 rs1432723 chr5 155302582 G A 9.00E-06 Obesity-related traits / / 23251661 rs1432721 chr5 155305537 A G 6.59E-04 Type 2 diabetes / / 17463246 rs6860291 chr5 155309249 C G 6.59E-04 Type 2 diabetes / / 17463246 rs2116739 chr5 155311168 C T 6.59E-04 Type 2 diabetes / / 17463246 rs7733552 chr5 155316248 G A 6.59E-04 Type 2 diabetes / / 17463246 rs244975 chr5 155323385 T C 7.31E-04 Acute lung injury / / 22295056 rs244974 chr5 155323533 A G 7.31E-04 Acute lung injury / / 22295056 rs244971 chr5 155326608 G C 7.31E-04 Acute lung injury / / 22295056 rs244969 chr5 155328654 G A 6.08E-04 Acute lung injury / / 22295056 rs244968 chr5 155329416 T C 6.08E-04 Acute lung injury / / 22295056 rs244967 chr5 155330665 G A 6.40E-04 Acute lung injury / / 22295056 rs244955 chr5 155333533 A G 3.97E-04 Acute lung injury / / 22295056 rs11960137 chr5 155338081 C G 9.86E-04 Multiple complex diseases / / 17554300 rs430625 chr5 155342732 G A 2.18E-04 Alzheimer's disease / / 17998437 rs17053032 chr5 155369024 G T 5.95E-05 Monocyte chemoattractant protein-1 / / pha003071 rs17053040 chr5 155370467 C T 7.31E-05 Monocyte chemoattractant protein-1 / / pha003071 rs6894361 chr5 155371739 A G 7.56E-05 Monocyte chemoattractant protein-1 / / pha003071 rs1368329 chr5 155374745 C T 7.22E-04 Multiple complex diseases / / 17554300 rs6556228 chr5 155391933 G A 0.000295 Salmonella-induced pyroptosis / / 22837397 rs17053082 chr5 155394230 C T 4.00E-07 Type 2 diabetes / / 23300278 rs6888324 chr5 155394630 C T 0.000569 Salmonella-induced pyroptosis / / 22837397 rs1432726 chr5 155396210 T G 0.000383 Salmonella-induced pyroptosis / / 22837397 rs7726727 chr5 155409530 G A 0.000173 Salmonella-induced pyroptosis / / 22837397 rs17537018 chr5 155458803 A G 8.15E-04 Obesity (extreme) / / 21935397 rs4601027 chr5 155467437 T C 9.24E-04 Obesity (extreme) / / 21935397 rs17537158 chr5 155468133 T G 9.23E-04 Obesity (extreme) / / 21935397 rs7736045 chr5 155468496 C G 9.29E-04 Obesity (extreme) / / 21935397 rs4704943 chr5 155470446 T C 9.38E-04 Obesity (extreme) / / 21935397 rs6556352 chr5 155471714 C T 5.01E-05 Multiple sclerosis (age of onset) / / 19010793 rs6556352 chr5 155471714 C T 3.32E-05 Epilepsy (remission after treatment) / / 23962720 rs11949606 chr5 155474996 A C 9.22E-05 Epilepsy (remission after treatment) / / 23962720 rs10476272 chr5 155499060 A G 9.22E-05 Epilepsy (remission after treatment) / / 23962720 rs4704970 chr5 155500992 G A 7.00E-06 Multiple sclerosis (age of onset) / / 19010793 rs1368321 chr5 155528034 C T 5.57E-05 Post-operative nausea and vomiting / / 21694509 rs1368321 chr5 155528034 C T 8.55E-05 Lipoproteins / / pha003079 rs3097865 chr5 155528085 T C 4.65E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1368320 chr5 155528225 C T 4.56E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1368319 chr5 155540311 G A 7.01E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1368319 chr5 155540311 G A 9.70E-05 Lipoproteins / / pha003079 rs10866716 chr5 155593908 C T 5.41E-05 Cognitive test performance / / 20125193 rs10866716 chr5 155593908 C T 1.49E-05 Prostate cancer / / pha002878 rs6877647 chr5 155605963 C T 2.15E-04 Multiple complex diseases / / 17554300 rs249881 chr5 155642709 G A 9.55E-05 Prostate cancer / / pha002878 rs249888 chr5 155666794 C T 6.01E-05 Prostate cancer / / pha002878 rs10515734 chr5 155694257 G T 5.67E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs12655476 chr5 155699582 G A 7.29E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs2312061 chr5 155720672 G A 2.36E-05 Alzheimer's disease (late onset) / / 21379329 rs6875001 chr5 155746538 A G 6.76E-05 Brain lesion load / / 19010793 rs10057826 chr5 155752007 T C 9.30E-05 Response to statin therapy SGCD nearGene-5 20339536 rs4705005 chr5 155759270 A G 4.23E-05 Cognitive performance SGCD intron 19734545 rs2135038 chr5 155766979 G A 0.00039 Coronary artery calcification SGCD intron 23727086 rs2055608 chr5 155772896 C T 2.16E-04 Type 2 diabetes SGCD intron 17463246 rs17053465 chr5 155780885 C T 5.19E-04 Type 2 diabetes SGCD intron 17463246 rs12514604 chr5 155781119 A G 3.25E-04 Type 2 diabetes SGCD intron 17463246 rs10043401 chr5 155790030 A C 4.94E-04 Hemoglobin concentration SGCD intron 20534544 rs17053491 chr5 155798966 G A 8.91E-05 Multiple complex diseases SGCD intron 17554300 rs7732608 chr5 155799466 G A 9.11E-04 Stroke SGCD intron pha002887 rs7715464 chr5 155809052 G A 1.04E-06 Paclitaxel sensitivity in NCI60 cancer cell lines SGCD intron 21314952 rs7715464 chr5 155809052 G A 3.87E-06 F-cell distribution SGCD intron 21326311 rs6556570 chr5 155812596 G C 1.00E-04 Prostate cancer SGCD intron 21743057 rs7723660 chr5 155813177 C T 2.72E-06 Alzheimer's disease (late onset) SGCD intron 21379329 rs7708513 chr5 155815634 A T 4.85E-04 Suicide attempts in bipolar disorder SGCD intron 21423239 rs6862189 chr5 155819278 G A 3.23E-05 Alzheimer's disease (late onset) SGCD intron 21379329 rs7731517 chr5 155834919 G T 1.73E-05 Alzheimer's disease (late onset) SGCD intron 21379329 rs17053572 chr5 155894497 A G 5.07E-04 Nicotine smoking SGCD intron 19268276 rs9313941 chr5 155896817 A G 4.40E-04 Type 2 diabetes and 6 quantitative traits SGCD intron 17848626 rs4704804 chr5 155907487 A G 3.06E-04 Multiple complex diseases SGCD intron 17554300 rs256846 chr5 155918768 C T 6.40E-04 Type 2 diabetes and 6 quantitative traits SGCD intron 17848626 rs11960617 chr5 155921043 C T 3.17E-09 HDL cholesterol SGCD intron 23063622 rs11960617 chr5 155921043 C T 3.48E-08 Cholesterol,total SGCD intron 23063622 rs6869314 chr5 155950696 T G 3.50E-09 HDL particle features SGCD intron 21283740 rs6869314 chr5 155950696 T G 5.00E-05 HDL particle features SGCD intron 21283740 rs1368301 chr5 155978502 C A 7.80E-05 Blood Pressure SGCD intron pha003045 rs1368301 chr5 155978502 C A 1.47E-05 Blood Pressure SGCD intron pha003047 rs10071215 chr5 156012193 C T 3.50E-09 HDL particle features SGCD intron 21283740 rs7710178 chr5 156013831 G T 9.08E-05 Blood Pressure SGCD intron pha003045 rs7710178 chr5 156013831 G T 2.78E-05 Blood Pressure SGCD intron pha003047 rs10515739 chr5 156017631 T C 2.65E-10 Alcohol consumption SGCD intron pha001398 rs10515739 chr5 156017631 T C 7.15E-41 Alcohol consumption SGCD intron pha001400 rs10515739 chr5 156017631 T C 1.83E-59 Alcohol consumption SGCD intron pha001402 rs10515737 chr5 156022529 A C 7.27E-11 Alcohol consumption SGCD intron pha001398 rs10515737 chr5 156022529 A C 4.71E-37 Alcohol consumption SGCD intron pha001400 rs10515737 chr5 156022529 A C 7.33E-65 Alcohol consumption SGCD intron pha001402 rs6877118 chr5 156039988 G A 7.20E-09 HDL particle features SGCD intron 21283740 rs6877118 chr5 156039988 G A 8.59E-06 HDL particle features SGCD intron 21283740 rs32063 chr5 156065593 T C 1.44E-07 Schizophrenia SGCD intron 22037555 rs6877490 chr5 156065646 A G 7.28E-07 Schizophrenia SGCD intron 22037555 rs281040 chr5 156080749 A G 4.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) SGCD intron 17982456 rs32076 chr5 156111223 T C 6.74E-07 Selenium resistance in NCI60 cancer cell lines SGCD intron 20830292 rs282472 chr5 156118540 T C 8.07E-04 Heart Failure SGCD intron pha002885 rs157341 chr5 156133899 T C 0.000097 Coronary artery calcification SGCD intron 23727086 rs157346 chr5 156136082 A G 7.93E-05 Hypertension SGCD intron pha003042 rs157350 chr5 156139569 G A 4.00E-06 Anthropometric traits SGCD intron 19260139 rs157350 chr5 156139569 G A 6.00E-06 Anthropometric traits SGCD intron 19260139 rs157350 chr5 156139569 G A 5.34E-05 Hypertension SGCD intron pha003042 rs157672 chr5 156140082 C T 8.17E-11 Alcohol consumption SGCD intron pha001398 rs157672 chr5 156140082 C T 1.22E-36 Alcohol consumption SGCD intron pha001400 rs157672 chr5 156140082 C T 1.94E-64 Alcohol consumption SGCD intron pha001402 rs10515741 chr5 156141714 C T 6.77E-05 Femoral neck bone geometry SGCD intron 22087292 rs456290 chr5 156155155 C T 9.67E-07 Kawasaki disease SGCD intron 21221998 rs456290 chr5 156155155 C T 2.00E-04 Asthma (childhood onset) SGCD intron 21359210 rs11135380 chr5 156182048 G A 8.95E-05 Lung function (forced expiratory volume in 1 second) SGCD intron 24023788 rs11135380 chr5 156182048 G A 9.00E-06 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SGCD intron 24023788 rs1845479 chr5 156191214 T C 1.77E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SGCD UTR-3 24023788 rs11953631 chr5 156192264 C T 1.11E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SGCD UTR-3 24023788 rs17053943 chr5 156250595 T C 1.36E-04 Multiple complex diseases / / 17554300 rs4476703 chr5 156279475 T C 9.42E-06 Triglycerides / / pha002904 rs10060710 chr5 156280556 C A 1.87E-05 Triglycerides / / pha002904 rs17053982 chr5 156288822 G A 7.33E-04 Alcohol dependence / / 21314694 rs6876040 chr5 156291605 T C 1.04E-05 Triglycerides / / pha002904 rs6872306 chr5 156359402 A G 1.41E-05 Cognitive performance TIMD4 intron 19734545 rs1363232 chr5 156383422 A G 2.20E-04 Lipid levels TIMD4 intron 19936222 rs1363232 chr5 156383422 A G 3.30E-06 Lipid levels TIMD4 intron 19936222 rs1363232 chr5 156383422 A G 3.50E-04 Lipid levels TIMD4 intron 19936222 rs1363232 chr5 156383422 A G 4.00E-05 Lipid levels TIMD4 intron 19936222 rs1363232 chr5 156383422 A G 4.60E-07 Lipid levels TIMD4 intron 19936222 rs1363232 chr5 156383422 A G 5.50E-06 Lipid levels TIMD4 intron 19936222 rs1363232 chr5 156383422 A G 5.60E-05 Lipid levels TIMD4 intron 19936222 rs6882076 chr5 156390297 T C 2.00E-22 LDL cholesterol / / 20686565 rs6882076 chr5 156390297 T C 4.00E-12 Triglycerides / / 20686565 rs6882076 chr5 156390297 T C 7.00E-28 Cholesterol,total / / 20686565 rs6882076 chr5 156390297 T C 2.00E-15 Triglycerides / / 24097068 rs6882076 chr5 156390297 T C 3.00E-31 LDL cholesterol / / 24097068 rs6882076 chr5 156390297 T C 5.00E-41 Cholesterol,total / / 24097068 rs62382402 chr5 156391818 C T 1.58E-05 Alcohol consumption / / 23743675 rs10043150 chr5 156396475 C A 1.26E-05 Alcohol consumption / / 23743675 rs1501908 chr5 156398169 G C 1.66E-04 Cholesterol / / 17255346 rs1501908 chr5 156398169 G C 1.00E-11 LDL cholesterol / / 19060906 rs1501908 chr5 156398169 G C 1.00E-11 Coronary heart disease / / 21347282 rs6883317 chr5 156398253 G A 1.19E-05 Alcohol consumption / / 23743675 rs7715848 chr5 156401478 C G 1.36E-05 Alcohol consumption / / 23743675 rs1501910 chr5 156418790 A G 3.55E-04 Multiple complex diseases / / 17554300 rs1354163 chr5 156420703 G A 1.50E-04 Lipid levels / / 19936222 rs1354163 chr5 156420703 G A 3.00E-04 Lipid levels / / 19936222 rs6873137 chr5 156434253 T C 9.01E-05 Parkinson's disease / / 21738487 rs7731951 chr5 156449685 T A 3.46E-05 Multiple complex diseases / / 17554300 rs2277025 chr5 156460095 T C 2.30E-04 Lipid levels HAVCR1 intron 19936222 rs2036402 chr5 156464242 T C 3.00E-06 Hypertriglyceridemia HAVCR1 intron 23505323 rs10038271 chr5 156470401 C T 3.62E-08 Common variable immunodeficiency HAVCR1 intron 21497890 rs7706174 chr5 156475398 T G 6.00E-04 Lipid levels HAVCR1 intron 19936222 rs7706174 chr5 156475398 T G 9.00E-05 Lipid levels HAVCR1 intron 19936222 rs12152865 chr5 156503767 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12152865 chr5 156503767 T C 4.08E-05 Orofacial clefts / / 22419666 rs193098517 chr5 156506652 G A 8.00E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs139597553 chr5 156510499 G C 2.49E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs72805186 chr5 156514189 G A 1.02E-06 Serum dimethylarginine levels (asymmetric) HAVCR2 missense 24159190 rs72805187 chr5 156514396 A G 3.28E-06 Serum dimethylarginine levels (asymmetric) HAVCR2 intron 24159190 rs150794106 chr5 156514798 C A 3.57E-06 Serum dimethylarginine levels (asymmetric) HAVCR2 intron 24159190 rs72805188 chr5 156520957 G A 3.79E-06 Serum dimethylarginine levels (asymmetric) HAVCR2 intron 24159190 rs74657365 chr5 156530846 C A 4.06E-06 Serum dimethylarginine levels (asymmetric) HAVCR2 intron 24159190 rs919747 chr5 156531330 A G 3.80E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) HAVCR2 intron 24023788 rs246879 chr5 156556846 T G 5.74E-04 Iron levels / / pha002876 rs246876 chr5 156564456 C T 2.43E-04 Response to TNF antagonist treatment / / 21061259 rs246864 chr5 156582214 C T 2.20E-05 Urinary metabolites / / 21572414 rs6555873 chr5 156584519 G A 2.19E-05 Cognitive impairment induced by topiramate / / 22091778 rs6555873 chr5 156584519 G A 4.57E-05 Cognitive impairment induced by topiramate / / 22091778 rs17054294 chr5 156585154 A G 3.32E-05 Cognitive impairment induced by topiramate / / 22091778 rs17054294 chr5 156585154 A G 8.21E-05 Cognitive impairment induced by topiramate / / 22091778 rs31208 chr5 156589585 A G 6.50E-04 Iron levels FAM71B missense pha002876 rs411174 chr5 156609000 G A 1.00E-06 Personality dimensions ITK intron 21368711 rs452223 chr5 156611493 T C 5.68E-04 Rheumatoid arthritis ITK intron 21452313 rs2436384 chr5 156620451 C T 7.45E-04 Rheumatoid arthritis ITK intron 21452313 rs30117 chr5 156664978 C T 2.01E-06 Alopecia areata ITK intron 22027810 rs17054397 chr5 156680876 A G 2.74E-05 Cervical cancer ITK UTR-3 24700089 rs2032934 chr5 156697149 T G 7.80E-04 Coronary Artery Disease CYFIP2 intron 17634449 rs4144670 chr5 156697654 A G 1.90E-05 Urinary metabolites CYFIP2 intron 21572414 rs7729111 chr5 156744053 A G 7.86E-05 Heart Rate CYFIP2 intron pha003054 rs13156380 chr5 156772844 C A 6.26E-05 Heart Rate CYFIP2 intron pha003054 rs17598343 chr5 156772886 A G 2.79E-04 Alzheimer's disease (late onset) CYFIP2 intron 21379329 rs10515749 chr5 156805787 G A 1.49E-04 Smoking initiation CYFIP2 intron 24665060 rs11738586 chr5 156807779 C G 6.00E-05 Pulmonary function CYFIP2 intron 20010835 rs3822691 chr5 156809248 C T 4.67E-04 Smoking initiation CYFIP2 intron 24665060 rs10063413 chr5 156811443 G A 1.26E-05 Bipolar disorder and schizophrenia CYFIP2 intron 20889312 rs871012 chr5 156815763 G C 5.00E-06 IgG glycosylation CYFIP2 intron 23382691 rs17599222 chr5 156817266 G T 4.10E-04 Asthma CYFIP2 intron 19910030 rs7724666 chr5 156817376 C T 5.11E-05 Pulmonary function CYFIP2 intron 20010835 rs6862302 chr5 156821313 T C 6.16E-05 Pulmonary function CYFIP2 UTR-3 20010835 rs2161396 chr5 156868224 A C 2.82E-04 Heart Failure / / pha002884 rs4704742 chr5 156891353 T C 6.01E-04 Heart Failure NIPAL4 intron pha002884 rs11745566 chr5 156891953 T C 8.99E-05 Pulmonary function NIPAL4 intron 20010835 rs10076407 chr5 156896154 T C 2.60E-05 Urinary metabolites NIPAL4 intron 21572414 rs6860507 chr5 156898690 A G 6.05E-04 Heart Failure NIPAL4 missense pha002884 rs10476050 chr5 156898874 C A 9.28E-05 Pulmonary function NIPAL4 intron 20010835 rs9313608 chr5 156900047 C T 6.75E-05 Pulmonary function NIPAL4 UTR-3 20010835 rs9313608 chr5 156900047 C T 3.70E-07 Urinary metabolites NIPAL4 UTR-3 21572414 rs10476052 chr5 156900534 C A 6.61E-05 Pulmonary function NIPAL4 UTR-3 20010835 rs11749762 chr5 156901615 T C 6.01E-05 Pulmonary function NIPAL4 UTR-3 20010835 rs11749762 chr5 156901615 T C 3.70E-07 Urinary metabolites NIPAL4 UTR-3 21572414 rs11739062 chr5 156901701 G T 5.88E-05 Pulmonary function NIPAL4 UTR-3 20010835 rs11466816 chr5 156907110 G T 1.62E-05 Pulmonary function ADAM19 UTR-3 20010835 rs11134766 chr5 156908317 C T 8.47E-05 Pulmonary function ADAM19 intron 20010835 rs10052412 chr5 156913453 C T 1.61E-05 Pulmonary function ADAM19 intron 20010835 rs11466807 chr5 156914928 A G 6.53E-05 Pulmonary function ADAM19 intron 20010835 rs11466805 chr5 156915133 G A 1.80E-04 Suicide attempts in bipolar disorder ADAM19 intron 21423239 rs13155908 chr5 156916589 A G 1.53E-05 Pulmonary function ADAM19 intron 20010835 rs10058865 chr5 156916611 C A 1.53E-05 Pulmonary function ADAM19 intron 20010835 rs2287749 chr5 156918850 C T 1.34E-05 Pulmonary function ADAM19 missense 20010835 rs1990950 chr5 156920756 G T 3.99E-07 Pulmonary function ADAM19 intron 20010835 rs1990950 chr5 156920756 G T 4.90E-05 Major depressive disorder ADAM19 intron 21042317 rs1990951 chr5 156920911 C T 5.84E-04 Heart Failure ADAM19 intron pha002884 rs11744671 chr5 156921231 T C 2.02E-05 Pulmonary function ADAM19 intron 20010835 rs11466784 chr5 156921651 G A 4.43E-05 Pulmonary function ADAM19 intron 20010835 rs17054657 chr5 156927875 C T 9.11E-04 Rheumatoid arthritis ADAM19 intron 21452313 rs2863747 chr5 156930784 C G 2.58E-06 Pulmonary function ADAM19 intron 20010835 rs2277027 chr5 156932376 A C 1.00E-10 Pulmonary function ADAM19 intron 20010835 rs2277027 chr5 156932376 A C 2.00E-11 Pulmonary function (interaction) ADAM19 intron 23284291 rs11134775 chr5 156932954 G C 2.65E-06 Pulmonary function ADAM19 intron 20010835 rs10078178 chr5 156932984 A T 8.86E-10 Pulmonary function ADAM19 intron 20010835 rs1422795 chr5 156936364 T C 2.00E-05 Bone mineral density (spine) ADAM19 missense 19079262 rs1422795 chr5 156936364 T C 1.16E-09 Pulmonary function ADAM19 missense 20010835 rs11134779 chr5 156936766 A G 1.01E-09 Pulmonary function ADAM19 intron 20010835 rs10866659 chr5 156937043 A G 1.01E-09 Pulmonary function ADAM19 intron 20010835 rs4579242 chr5 156939498 T G 1.01E-09 Pulmonary function ADAM19 intron 20010835 rs11740562 chr5 156942285 A G 5.70E-05 Bipolar disorder ADAM19 intron 19488044 rs11740562 chr5 156942285 A G 5.90E-05 Pulmonary function ADAM19 intron 20010835 rs11740562 chr5 156942285 A G 1.00E-06 Bipolar disorder and schizophrenia ADAM19 intron 20889312 rs11740562 chr5 156942285 A G 1.61E-05 Bipolar Disorder ADAM19 intron pha002858 rs6899205 chr5 156943285 G A 7.57E-06 Pulmonary function ADAM19 intron 20010835 rs4331881 chr5 156944475 G T 7.72E-07 Pulmonary function ADAM19 intron 20010834 rs4331881 chr5 156944475 G T 1.54E-09 Pulmonary function ADAM19 intron 20010835 rs4368711 chr5 156944671 C T 4.28E-05 Pulmonary function ADAM19 intron 20010835 rs58873874 chr5 156945148 T C 3.00E-06 Bipolar disorder (body mass index interaction) ADAM19 intron 24322204 rs7721142 chr5 156952408 C G 3.24E-06 Pulmonary function ADAM19 intron 20010835 rs11742401 chr5 156953340 C T 3.17E-06 Pulmonary function ADAM19 intron 20010835 rs2902556 chr5 156957416 G A 1.20E-05 Urinary metabolites ADAM19 intron 21572414 rs11465283 chr5 156958127 C T 2.06E-05 Tunica Media ADAM19 intron pha003034 rs11465283 chr5 156958127 C T 8.44E-05 Potassium levels ADAM19 intron pha003086 rs1035434 chr5 156959973 C T 3.01E-06 Pulmonary function ADAM19 intron 20010835 rs13353878 chr5 156960581 G A 8.25E-06 Pulmonary function ADAM19 intron 20010835 rs17054692 chr5 156962401 A G 2.60E-05 Urinary metabolites ADAM19 intron 21572414 rs6872356 chr5 156962658 C T 1.23E-05 Pulmonary function ADAM19 intron 20010835 rs11134803 chr5 156964498 G T 1.74E-05 Pulmonary function ADAM19 intron 20010835 rs559798400 chr5 156964498 GCA G 1.74E-05 Pulmonary function ADAM19 intron 20010835 rs17054697 chr5 156966225 G A 1.86E-05 Pulmonary function ADAM19 intron 20010835 rs6875485 chr5 156966595 A C 1.87E-05 Pulmonary function ADAM19 intron 20010835 rs77372450 chr5 156970144 A C 6.00E-06 Bipolar disorder (body mass index interaction) ADAM19 intron 24322204 rs17054709 chr5 156973288 C T 2.40E-05 Urinary metabolites ADAM19 intron 21572414 rs6896064 chr5 156975016 T G 1.55E-04 Acne (severe) ADAM19 intron 24399259 rs11744800 chr5 156982059 A C 3.13E-04 Coronary Artery Disease ADAM19 intron 17634449 rs7705444 chr5 156988798 T C 4.72E-06 Pulmonary function ADAM19 intron 20010835 rs13356677 chr5 156990173 G A 4.86E-06 Pulmonary function ADAM19 intron 20010835 rs11465270 chr5 156990850 A G 5.09E-06 Pulmonary function ADAM19 intron 20010835 rs11465269 chr5 156990896 G A 5.26E-06 Pulmonary function ADAM19 intron 20010835 rs11134819 chr5 156991508 G A 1.26E-06 Pulmonary function ADAM19 intron 20010835 rs6878446 chr5 156992215 G A 2.84E-05 Bipolar disorder and schizophrenia ADAM19 intron 20889312 rs6876128 chr5 156994437 T C 7.25E-06 Pulmonary function ADAM19 intron 20010835 rs6875939 chr5 156994466 A G 7.36E-06 Pulmonary function ADAM19 intron 20010835 rs6860257 chr5 156995869 G A 6.58E-06 Pulmonary function ADAM19 intron 20010835 rs7707786 chr5 156996758 C G 6.99E-06 Pulmonary function ADAM19 intron 20010835 rs11749965 chr5 156997414 T C 5.28E-05 Bipolar disorder and schizophrenia ADAM19 intron 20889312 rs6556089 chr5 157000854 C G 7.17E-06 Pulmonary function ADAM19 intron 20010835 rs6556090 chr5 157001183 A C 8.34E-06 Pulmonary function ADAM19 intron 20010835 rs6556091 chr5 157001325 A T 6.43E-05 Bipolar disorder and schizophrenia ADAM19 intron 20889312 rs10476093 chr5 157007001 C A 4.85E-05 Cognitive performance / / 19734545 rs10476093 chr5 157007001 C A 8.90E-06 Pulmonary function / / 20010835 rs13356635 chr5 157014121 A T 8.79E-06 Pulmonary function / / 20010835 rs10052322 chr5 157014420 C A 6.28E-06 Pulmonary function / / 20010835 rs6889910 chr5 157014912 A T 8.22E-06 Pulmonary function / / 20010835 rs10063216 chr5 157020610 A G 4.78E-05 Bipolar disorder and schizophrenia / / 20889312 rs6890471 chr5 157024032 C T 8.84E-06 Pulmonary function / / 20010835 rs6877434 chr5 157028947 G T 8.09E-06 Pulmonary function / / 20010835 rs6879084 chr5 157029188 C T 8.41E-06 Pulmonary function / / 20010835 rs11748443 chr5 157029457 C T 9.16E-06 Pulmonary function / / 20010835 rs10035961 chr5 157030395 A C 1.92E-05 Pulmonary function / / 20010835 rs13153959 chr5 157031235 C T 1.47E-05 Pulmonary function / / 20010835 rs13361606 chr5 157031661 T C 1.49E-05 Pulmonary function / / 20010835 rs13358963 chr5 157031881 C T 1.54E-05 Pulmonary function / / 20010835 rs868176 chr5 157040002 T G 6.13E-05 Tunica Media / / pha003038 rs12188530 chr5 157118579 T C 3.56E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7701930 chr5 157143521 C T 1.30E-05 Urinary metabolites / / 21572414 rs6892723 chr5 157167317 C G 5.02E-19 Lymphocyte counts / / 22286170 rs13183577 chr5 157174660 T C 8.53E-04 Myocardial Infarction LSM11 intron pha002883 rs17054866 chr5 157201270 T C 4.56E-04 Multiple complex diseases / / 17554300 rs436964 chr5 157224369 A G 9.16E-06 Left ventricular mass CLINT1 intron 21212386 rs4704753 chr5 157233521 C T 1.40E-04 Response to alcohol consumption (flushing response) CLINT1 intron 24277619 rs10515754 chr5 157233538 T C 5.15E-07 Paclitaxel sensitivity in NCI60 cancer cell lines CLINT1 intron 21314952 rs6556290 chr5 157302089 T C 7.96E-05 Schizophrenia / / 19571811 rs6556290 chr5 157302089 T C 4.67E-05 Smoking initiation / / 24665060 rs1202314 chr5 157306246 C T 4.74E-04 Multiple complex diseases / / 17554300 rs149623824 chr5 157306246 C CAGCACTGTTGG 4.74E-04 Multiple complex diseases / / 17554300 rs1211159 chr5 157341414 C T 6.50E-04 Multiple complex diseases / / 17554300 rs1209063 chr5 157342660 T G 8.26E-04 Multiple complex diseases / / 17554300 rs3095984 chr5 157397360 C T 8.15E-05 Mammographic density / / 22532574 rs3095982 chr5 157406279 T C 5.04E-05 Mammographic density / / 22532574 rs11958404 chr5 157410278 A T 1.00E-06 IgG glycosylation / / 23382691 rs11958404 chr5 157410278 A T 8.00E-06 IgG glycosylation / / 23382691 rs3096019 chr5 157411641 G A 5.49E-05 Mammographic density / / 22532574 rs10041480 chr5 157451420 C T 1.66E-04 Birth weight / / 17255346 rs1957563 chr5 157474590 C T 3.96E-07 Blood pressure / / 21909110 rs2419388 chr5 157489847 G C 7.39E-04 Alzheimer's disease / / 17998437 rs2475777 chr5 157513404 G T 7.25E-04 Multiple complex diseases / / 17554300 rs7732107 chr5 157513737 C A 2.86E-04 Multiple complex diseases / / 17554300 rs1650590 chr5 157514044 C T 2.60E-05 Urinary metabolites / / 21572414 rs13361398 chr5 157521087 T C 3.13E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13361398 chr5 157521087 T C 4.51E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1744343 chr5 157522100 G T 5.69E-04 Age-related macular degeneration / / 22125219 rs17229266 chr5 157528286 T G 5.00E-05 Gallstones / / 17632509 rs1614336 chr5 157551868 C A 4.78E-04 Type 2 diabetes / / 17463246 rs1614336 chr5 157551868 C A 5.80E-05 Amyotrophic lateral sclerosis / / 20801717 rs1614336 chr5 157551868 C A 0.0000625 Amyotrophic lateral sclerosis / / 23587638 rs2913539 chr5 157553413 T G 2.24E-04 Alzheimer's disease / / 17998437 rs1173472 chr5 157555823 C T 1.83E-04 Type 2 diabetes / / 17463246 rs1173472 chr5 157555823 C T 6.19E-05 Amyotrophic lateral sclerosis / / 20801717 rs1173472 chr5 157555823 C T 0.0000576 Amyotrophic lateral sclerosis / / 23587638 rs17683723 chr5 157558404 C T 4.07E-04 Alzheimer's disease / / 17998437 rs10055302 chr5 157565338 C T 4.57E-04 Stroke / / pha002886 rs1173485 chr5 157569829 G A 0.0000318 Amyotrophic lateral sclerosis / / 23587638 rs10515758 chr5 157571219 T C 8.77E-04 Parkinson's disease / / 17052657 rs10515758 chr5 157571219 T C 1.92E-04 Alzheimer's disease / / 17998437 rs10515758 chr5 157571219 T C 9.67E-04 Stroke / / pha002886 rs2984648 chr5 157574133 C T 5.33E-04 Parkinson's disease / / 17052657 rs1173454 chr5 157582088 C T 6.08E-04 Type 2 diabetes / / 17463246 rs2419398 chr5 157588271 T C 3.52E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1027355 chr5 157592608 T C 3.65E-04 Lung function (forced vital capacity) / / 24023788 rs1027355 chr5 157592608 T C 4.59E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1173447 chr5 157600753 C T 2.20E-05 Urinary metabolites / / 21572414 rs202819 chr5 157603863 C A 2.70E-05 Urinary metabolites / / 21572414 rs1874161 chr5 157615710 C A 7.51E-05 Coronary heart disease / / 21606135 rs1874160 chr5 157616148 C T 8.70E-05 Coronary heart disease / / 21606135 rs71591374 chr5 157628846 A T 0.00000174 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs202806 chr5 157630068 C T 2.50E-06 Urinary metabolites / / 21572414 rs35941713 chr5 157630146 C T 0.0000597 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs202804 chr5 157630569 C T 2.50E-06 Urinary metabolites / / 21572414 rs202793 chr5 157637276 C T 2.85E-05 Pancreatic cancer / / pha002874 rs202793 chr5 157637276 C T 7.42E-05 Pancreatic cancer / / pha002889 rs11746023 chr5 157647316 C T 4.47E-04 Coronary heart disease / / 21606135 rs1145625 chr5 157652081 A G 4.44E-05 Pancreatic cancer / / pha002874 rs66562743 chr5 157675068 A G 0.00000554 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs66527147 chr5 157675934 C A 0.00000694 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34344733 chr5 157678716 C A 0.0000139 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11957368 chr5 157683525 C T 4.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) / / 23934736 rs2172745 chr5 157717906 C A 4.65E-05 Pancreatic cancer / / pha002874 rs12173156 chr5 157722057 C T 3.89E-04 Alzheimer's disease (late onset) / / 21379329 rs2988320 chr5 157741761 C A 8.06E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2988320 chr5 157741761 C A 4.85E-05 Erythrocyte counts / / pha003101 rs34507801 chr5 157744297 G A 0.0000656 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34891568 chr5 157752036 A T 0.0000403 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1952659 chr5 157766879 T C 9.21E-04 Tourette syndrome / / 22889924 rs1952658 chr5 157773645 T C 2.85E-04 Multiple complex diseases / / 17554300 rs4415062 chr5 157774008 G A 7.63E-04 Multiple complex diseases / / 17554300 rs4415062 chr5 157774008 G A 8.93E-04 Tourette syndrome / / 22889924 rs13179426 chr5 157798652 T C 0.0000318 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9313772 chr5 157804457 C T 1.00E-11 Blood pressure / / 21909110 rs74717972 chr5 157814926 C T 8.49E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs75248416 chr5 157815979 G C 8.51E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs76457712 chr5 157816148 C T 8.48E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs74544835 chr5 157817379 C A 8.48E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs75897066 chr5 157817553 G A 8.48E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs75184948 chr5 157817775 G A 8.48E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs75999723 chr5 157818302 G T 8.48E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs74918733 chr5 157818491 C T 8.48E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs76180878 chr5 157818655 T C 8.48E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs74620148 chr5 157818740 C A 6.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs78409910 chr5 157818814 G A 8.48E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs76406105 chr5 157820030 T C 8.48E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs77308452 chr5 157820035 G T 8.48E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2149954 chr5 157820602 C T 2.00E-08 Longevity (90 years and older) / / 24688116 rs2149954 chr5 157820602 C T 4.00E-06 Longevity (85 years and older) / / 24688116 rs112125540 chr5 157820682 G A 8.48E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs76404868 chr5 157820923 C T 8.48E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs111874800 chr5 157821658 C T 8.80E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs187361198 chr5 157823584 T A 6.37E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs201124069 chr5 157823584 TTA T 6.37E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs76709770 chr5 157824284 G T 8.52E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs7701003 chr5 157824481 A G 8.48E-04 Coronary Artery Disease / / 17634449 rs11953630 chr5 157845402 C T 7.16E-04 Blood pressure / / 21909110 rs11953630 chr5 157845402 C T 2.00E-07 Hypertension / / 21909115 rs11953630 chr5 157845402 C T 3.00E-11 Systolic blood pressure / / 21909115 rs11953630 chr5 157845402 C T 4.00E-13 Diastolic blood pressure / / 21909115 rs2901006 chr5 157860813 G A 8.04E-04 Multiple complex diseases / / 17554300 rs2964481 chr5 157892530 C T 3.59E-04 Multiple complex diseases / / 17554300 rs2963455 chr5 157924306 C T 3.24E-04 Type 2 diabetes / / 17463246 rs2946176 chr5 157925863 G T 5.34E-04 Type 2 diabetes / / 17463246 rs10515764 chr5 157945180 G A 2.91E-04 Multiple complex diseases / / 17554300 rs2963436 chr5 157953813 C T 2.60E-04 Multiple complex diseases / / 17554300 rs7732691 chr5 157957642 G A 3.77E-05 Post-operative nausea and vomiting / / 21694509 rs2946178 chr5 157958432 C T 2.20E-04 Multiple complex diseases / / 17554300 rs17055847 chr5 157983114 T C 8.03E-06 Eosinophil counts / / pha003088 rs890945 chr5 157992223 T A 4.70E-05 Kidney function and endocine traits / / 17903292 rs890945 chr5 157992223 T A 8.00E-05 Lipid traits / / 17903299 rs1428445 chr5 157995803 G A 1.80E-05 Lipid traits / / 17903299 rs1428445 chr5 157995803 G A 3.94E-04 Diabetic retinopathy / / 20871662 rs1122080 chr5 158015903 G A 2.50E-04 Lipid traits / / 17903299 rs1896695 chr5 158033070 G T 6.37E-04 Multiple complex diseases / / 17554300 rs824871 chr5 158038771 G A 3.84E-04 Type 2 diabetes / / 17463246 rs699082 chr5 158040399 C T 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10042061 chr5 158044539 A G 8.33E-05 Smoking quantity / / 24665060 rs824883 chr5 158045955 C T 6.75E-04 Type 2 diabetes / / 17463246 rs824890 chr5 158052650 G A 1.63E-04 Type 2 diabetes / / 17463246 rs386503 chr5 158059517 T C 6.03E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs33137 chr5 158064276 C T 2.88E-04 Smoking initiation / / 24665060 rs381659 chr5 158066629 G A 5.89E-04 Smoking initiation / / 24665060 rs403334 chr5 158096651 T G 7.13E-04 Alcohol dependence / / 20201924 rs10515769 chr5 158096975 G A 3.01E-04 Smoking initiation / / 24665060 rs2112262 chr5 158101763 A G 5.68E-04 Smoking initiation / / 24665060 rs17056109 chr5 158137439 C T 9.99E-05 Vascular dementia EBF1 intron 22116812 rs6870922 chr5 158141955 C T 7.86E-04 Multiple complex diseases EBF1 intron 17554300 rs7716399 chr5 158150646 T C 2.49E-05 Lactate dehydrogenase levels EBF1 intron 20981236 rs7716399 chr5 158150646 T C 3.03E-04 Stroke EBF1 intron pha002887 rs13170526 chr5 158175669 T G 4.00E-06 Obesity-related traits EBF1 intron 23251661 rs17713494 chr5 158203512 A G 8.59E-04 Type 2 diabetes EBF1 intron 17463246 rs6893851 chr5 158212621 A C 7.88E-04 Type 2 diabetes EBF1 intron 17463246 rs1345610 chr5 158217039 T C 8.74E-04 Type 2 diabetes EBF1 intron 17463246 rs17641627 chr5 158233732 C G 5.85E-04 Type 2 diabetes EBF1 intron 17463246 rs1432679 chr5 158244083 C T 2.00E-14 Breast cancer EBF1 intron 23535729 rs1432679 chr5 158244083 C T 7.00E-06 Breast cancer EBF1 intron 23535733 rs4704967 chr5 158259699 T G 9.94E-04 Coronary heart disease EBF1 intron 21606135 rs891904 chr5 158267473 G A 8.16E-04 Acute lung injury EBF1 intron 22295056 rs6875710 chr5 158268426 C T 7.64E-04 Acute lung injury EBF1 intron 22295056 rs10052777 chr5 158269081 T C 7.64E-04 Acute lung injury EBF1 intron 22295056 rs17715535 chr5 158269734 G A 7.64E-04 Acute lung injury EBF1 intron 22295056 rs7707918 chr5 158270225 A C 7.64E-04 Acute lung injury EBF1 intron 22295056 rs17643057 chr5 158274491 A G 7.95E-04 Acute lung injury EBF1 intron 22295056 rs10515773 chr5 158286847 C T 9.64E-17 Varicose Veins EBF1 intron pha001416 rs2072495 chr5 158296996 C T 7.85E-04 Acute lung injury EBF1 intron 22295056 rs1363619 chr5 158298711 C A 9.95E-04 Type 2 diabetes EBF1 intron 17463246 rs7737500 chr5 158317804 G C 6.60E-04 Acute lung injury EBF1 intron 22295056 rs1422799 chr5 158321121 C G 6.60E-04 Acute lung injury EBF1 intron 22295056 rs17543752 chr5 158332380 T C 6.38E-04 Acute lung injury EBF1 intron 22295056 rs7736883 chr5 158343969 A G 5.46E-04 Acute lung injury EBF1 intron 22295056 rs4130208 chr5 158348912 A C 3.11E-05 Body Fat Distribution EBF1 intron pha003016 rs1081071 chr5 158381663 T C 8.23E-04 Acute lung injury EBF1 intron 22295056 rs6556377 chr5 158393580 C T 6.20E-06 Urinary metabolites EBF1 intron 21572414 rs13180086 chr5 158394342 T C 6.70E-06 Urinary metabolites EBF1 intron 21572414 rs6556379 chr5 158399387 C G 7.88E-04 Multiple complex diseases EBF1 intron 17554300 rs10447210 chr5 158418490 C T 7.75E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) EBF1 intron 23648065 rs10040979 chr5 158424391 G A 5.00E-07 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) EBF1 intron 23648065 rs10066782 chr5 158432118 T C 7.65E-04 Multiple complex diseases EBF1 intron 17554300 rs10515785 chr5 158443352 G T 7.10E-05 Coronary heart disease EBF1 intron pha003031 rs6890049 chr5 158451492 C T 1.90E-05 Urinary metabolites EBF1 intron 21572414 rs6890049 chr5 158451492 C T 4.60E-05 Amyotrophic lateral sclerosis (sporadic) EBF1 intron 24529757 rs7720283 chr5 158459721 T C 4.15E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) EBF1 intron 23648065 rs13174549 chr5 158462476 C T 6.30E-04 Alcohol dependence EBF1 intron 20201924 rs4921252 chr5 158473524 C T 4.05E-05 Heart Rate EBF1 intron pha003053 rs4921121 chr5 158486993 A G 1.60E-05 Urinary metabolites EBF1 intron 21572414 rs6898290 chr5 158513546 T C 4.20E-05 Erythrocyte counts EBF1 intron pha003101 rs7442845 chr5 158518768 G C 7.77E-05 Serum metabolites EBF1 intron 19043545 rs7447732 chr5 158529135 C T 6.69E-05 Glucose levels / / pha003058 rs7447732 chr5 158529135 C T 1.41E-05 Erythrocyte counts / / pha003101 rs6897374 chr5 158541200 C A 3.69E-04 Alcohol dependence / / 24277619 rs270654 chr5 158565109 T C 2.53E-05 Cognitive test performance / / 20125193 rs1473247 chr5 158603571 T C 3.00E-07 Mean platelet volume RNF145 intron 19820697 rs10076782 chr5 158604963 G A 4.00E-08 Mean platelet volume RNF145 intron 22139419 rs10076782 chr5 158604963 G A 2.00E-04 Mean platelet volume RNF145 intron 24026423 rs6884239 chr5 158624569 A G 6.80E-05 Parkinson's disease (age of onset) RNF145 intron 19772629 rs2043268 chr5 158635424 A G 1.60E-05 Parkinson's disease (age of onset) RNF145 intron 19772629 rs7721001 chr5 158650814 C T 6.76E-04 Alcohol dependence / / 24277619 rs10515778 chr5 158658012 A G 8.07E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs17056627 chr5 158659707 G A 2.60E-06 Urinary metabolites / / 21572414 rs254850 chr5 158666731 C T 3.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7719425 chr5 158670938 T C 5.47E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs17664636 chr5 158678059 T C 2.40E-05 Urinary metabolites / / 21572414 rs2569252 chr5 158679641 T C 1.17E-04 Type 2 diabetes / / 17463246 rs4921437 chr5 158690951 T C 1.42E-04 Lung function (forced expiratory volume in 1 second) UBLCP1 intron 24023788 rs10515780 chr5 158691793 C G 7.13E-04 Multiple complex diseases UBLCP1 intron 17554300 rs2420825 chr5 158697131 C T 2.98E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) UBLCP1 intron 24023788 rs2420825 chr5 158697131 C T 3.24E-04 Lung function (forced expiratory volume in 1 second) UBLCP1 intron 24023788 rs13153734 chr5 158706713 C T 8.10E-07 Urinary metabolites UBLCP1 intron 21572414 rs6887080 chr5 158708065 A G 9.41E-04 Type 2 diabetes UBLCP1 intron 17463246 rs10515782 chr5 158709277 C T 5.79E-04 Multiple complex diseases UBLCP1 intron 17554300 rs10515782 chr5 158709277 C T 1.47E-04 Statin-induced myopathy UBLCP1 intron 21826682 rs10042630 chr5 158710768 A T 5.23E-04 Multiple complex diseases UBLCP1 intron 17554300 rs4921209 chr5 158711219 A G 8.30E-04 Type 2 diabetes UBLCP1 intron 17463246 rs2082412 chr5 158717789 G A 2.00E-28 Psoriasis / / 19169254 rs2082412 chr5 158717789 G A 2.00E-28 Multiple sclerosis / / 22190364 rs6874870 chr5 158729521 T C 4.85E-04 Multiple complex diseases / / 17554300 rs2099327 chr5 158730851 G C 8.50E-07 Urinary metabolites / / 21572414 rs3181225 chr5 158740623 G A 1.70E-06 Urinary metabolites / / 21572414 rs2853696 chr5 158744660 T C 1.47E-04 Multiple complex diseases IL12B intron 17554300 rs3213096 chr5 158750329 C T 2.00E-05 Atrial fibrillation IL12B missense 21846873 rs3213094 chr5 158750769 C T 3.00E-26 Psoriasis IL12B intron 19169255 rs3213094 chr5 158750769 C T 5.00E-11 Psoriasis IL12B intron 20953190 rs3212220 chr5 158754195 C A 1.64E-06 Statin-induced myopathy IL12B intron 21826682 rs3213087 chr5 158755088 C T 3.29E-16 LDL cholesterol IL12B intron 23063622 rs2546892 chr5 158755475 G A 7.10E-07 Urinary metabolites IL12B intron 21572414 rs1433048 chr5 158755845 G A 2.41E-05 Alcohol dependence IL12B intron 21703634 rs2546890 chr5 158759900 A G 1.00E-20 Psoriasis / / 20953188 rs2546890 chr5 158759900 A G 1.00E-11 Multiple sclerosis / / 21833088 rs2546890 chr5 158759900 A G 8.00E-08 Multiple sclerosis / / 22190364 rs2546890 chr5 158759900 A G 3.80E-06 Multiple sclerosis / / 24234648 rs7709212 chr5 158764177 T C 7.00E-04 Psoriasis LOC285626 intron 17587057 rs7709212 chr5 158764177 T C 2.00E-06 Psoriasis LOC285626 intron 19169255 rs953861 chr5 158772582 G A 6.21E-18 Psoriasis LOC285626 intron 20953188 rs1363670 chr5 158784111 C G 3.19E-05 Multiple complex diseases LOC285626 intron 17554300 rs6556412 chr5 158787385 G A 5.00E-14 Crohn's disease LOC285626 intron 21102463 rs10045431 chr5 158814533 A C 1.00E-04 Psoriasis / / 17587057 rs10045431 chr5 158814533 A C 4.00E-13 Crohn's disease / / 18587394 rs10045431 chr5 158814533 A C 7.00E-08 Crohn's disease / / 20570966 rs10045431 chr5 158814533 A C 4.00E-13 Asthma / / 21150878 rs10045431 chr5 158814533 A C 1.10E-04 Ankylosing spondylitis / / 21743469 rs10045431 chr5 158814533 A C 3.86E-13 Multiple sclerosis / / 22190364 rs6556416 chr5 158818745 A C 2.00E-08 Ankylosing spondylitis / / 21743469 rs6861600 chr5 158819615 C G 1.17E-04 Multiple complex diseases / / 17554300 rs6861600 chr5 158819615 C G 2.32E-08 Psoriasis risk prediction / / 21214922 rs6887695 chr5 158822645 G C 9.00E-06 Crohn's disease / / 17554261 rs6887695 chr5 158822645 G C 1.36E-04 Multiple complex diseases / / 17554300 rs6887695 chr5 158822645 G C 3.96E-08 Psoriasis risk prediction / / 21214922 rs6887695 chr5 158822645 G C 4.08E-10 Multiple sclerosis / / 22190364 rs17388425 chr5 158824174 C G 4.11E-04 Multiple complex diseases / / 17554300 rs6871626 chr5 158826792 C A 1.00E-21 Ulcerative colitis / / 21297633 rs6871626 chr5 158826792 C A 1.00E-42 Inflammatory bowel disease / / 23128233 rs12188300 chr5 158829527 A T 7.00E-17 Psoriatic arthritis / / 20953186 rs12188300 chr5 158829527 A T 3.20E-53 Psoriasis / / 23143594 rs4921496 chr5 158848071 T C 4.98E-04 White matter integrity / / 22425255 rs1422882 chr5 158865362 G A 8.25E-05 Body mass (lean) / / 19268274 rs4921230 chr5 158880396 C T 5.36E-04 Multiple complex diseases LOC285627 splice-3 17554300 rs4921230 chr5 158880396 C T 5.59E-04 Suicide attempts in bipolar disorder LOC285627 splice-3 21041247 rs6869688 chr5 158883027 A G 7.72E-04 Response to taxane treatment (placlitaxel) LOC285627 intron 23006423 rs6869688 chr5 158883027 A G 7.07E-06 Coronary heart disease LOC285627 intron pha003031 rs12657996 chr5 158904313 G A 9.00E-06 Response to taxane treatment (placlitaxel) / / 23006423 rs7706354 chr5 158904390 T C 5.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs10515794 chr5 158908227 A G 9.04E-04 Parkinson's disease / / 17052657 rs13360243 chr5 158915511 C T 6.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs7721518 chr5 158916574 G A 7.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs11742514 chr5 158917633 G A 6.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs11750157 chr5 158918493 C T 5.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs10866713 chr5 158918894 G A 7.00E-07 Multiple sclerosis / / 22190364 rs11747171 chr5 158935479 T C 5.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs2421050 chr5 158943044 T C 7.27E-05 Glucose levels / / pha003058 rs10045568 chr5 158949047 C T 9.20E-05 Tooth agenesis (third molar) / / 24172245 rs4334868 chr5 158984287 G A 3.70E-04 Type 2 diabetes / / 17463246 rs4334868 chr5 158984287 G A 3.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4334868 chr5 158984287 G A 5.63E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17729321 chr5 158987729 T C 4.17E-05 Alcohol and nictotine co-dependence / / 20158304 rs4315909 chr5 159001299 A G 2.81E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs34618866 chr5 159005439 G A 2.19E-04 Type 2 diabetes / / 17463246 rs34618866 chr5 159005439 G A 9.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10065906 chr5 159007778 C A 2.00E-06 Major depressive disorder / / 23377640 rs10065906 chr5 159007778 C A 5.00E-08 Major depressive disorder / / 23377640 rs11958511 chr5 159013045 T G 1.00E-04 Information processing speed / / 21130836 rs11958511 chr5 159013045 T G 6.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17056819 chr5 159015248 G A 4.24E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6882632 chr5 159017398 C T 3.67E-06 Asthma (childhood onset) / / 23829686 rs2421057 chr5 159025716 G T 2.50E-05 Urinary metabolites / / 21572414 rs11957668 chr5 159029124 G A 1.00E-06 Urinary metabolites / / 21572414 rs4640778 chr5 159031373 G A 2.00E-04 Information processing speed / / 21130836 rs4640778 chr5 159031373 G A 3.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6880554 chr5 159037292 T C 1.30E-06 Urinary metabolites / / 21572414 rs17056837 chr5 159040534 A G 7.06E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs5014831 chr5 159042229 G A 4.83E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs5014833 chr5 159042345 C T 8.22E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11949241 chr5 159056499 C A 7.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1363656 chr5 159068245 C T 7.19E-04 Multiple complex diseases / / 17554300 rs1422844 chr5 159070058 T A 6.33E-04 Alzheimer's disease (late onset) / / 21460841 rs1422844 chr5 159070058 T A 2.00E-05 Urinary metabolites / / 21572414 rs6556439 chr5 159071666 G A 5.37E-04 Alzheimer's disease (late onset) / / 21460841 rs6556439 chr5 159071666 G A 1.70E-05 Urinary metabolites / / 21572414 rs10515793 chr5 159072451 T C 8.39E-04 Multiple complex diseases / / 17554300 rs10428678 chr5 159073178 A C 4.01E-04 Multiple complex diseases / / 17554300 rs11135070 chr5 159076347 G A 6.50E-06 Urinary metabolites / / 21572414 rs12152750 chr5 159076473 A G 4.84E-04 Alzheimer's disease (late onset) / / 21460841 rs7709089 chr5 159078346 A G 7.79E-04 Smoking quantity / / 24665060 rs11949129 chr5 159083348 A G 2.23E-04 Alzheimer's disease (late onset) / / 21460841 rs11949129 chr5 159083348 A G 1.40E-05 Urinary metabolites / / 21572414 rs17056877 chr5 159083692 G A 2.27E-04 Alzheimer's disease (late onset) / / 21460841 rs17056877 chr5 159083692 G A 2.10E-05 Urinary metabolites / / 21572414 rs4921515 chr5 159092417 G A 1.60E-05 Urinary metabolites / / 21572414 rs4921515 chr5 159092417 G A 3.56E-04 White matter integrity / / 22425255 rs1422853 chr5 159103367 C T 9.77E-04 Multiple complex diseases / / 17554300 rs1363659 chr5 159125765 T G 1.30E-05 Urinary metabolites / / 21572414 rs9313818 chr5 159126775 T C 0.00011 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines / / 23204130 rs1422857 chr5 159128719 C T 0.00008 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines / / 23204130 rs6890497 chr5 159141973 G A 6.21E-04 Body mass index / / 21701565 rs41321151 chr5 159155509 C T 1.45E-33 Narcolepsy / / 19629137 rs10035228 chr5 159155592 C T 2.97E-04 Hearing function / / 17255346 rs17057062 chr5 159175966 G A 3.39E-05 Multiple complex diseases / / 17554300 rs2436336 chr5 159197552 T A 0.0000977 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6888211 chr5 159211761 C T 8.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs2116732 chr5 159214513 G A 8.48E-04 Suicide attempts in bipolar disorder / / 21041247 rs11957357 chr5 159231127 A C 6.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs1432711 chr5 159232062 C T 6.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs6884390 chr5 159235997 C T 6.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs6883903 chr5 159236378 G A 6.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs6862385 chr5 159240488 A C 6.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs17057166 chr5 159248014 C T 3.39E-04 Type 2 diabetes / / 17463246 rs17057166 chr5 159248014 C T 7.55E-04 Multiple complex diseases / / 17554300 rs17057166 chr5 159248014 C T 5.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs17057166 chr5 159248014 C T 8.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs6865924 chr5 159270169 G A 0.000522 Salmonella-induced pyroptosis / / 22837397 rs959931 chr5 159270713 C T 3.49E-05 LDL lipoproteins / / pha002902 rs751221 chr5 159275428 G A 8.76E-04 Multiple complex diseases / / 17554300 rs31684 chr5 159282902 C T 2.31E-04 Schizophrenia / / 19197363 rs9313828 chr5 159284727 C T 1.26E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs31694 chr5 159292703 A G 5.29E-05 stroke (ischemic) / / 17434096 rs11954917 chr5 159297173 C T 6.00E-04 Asthma / / 19910028 rs10077860 chr5 159298312 T A 4.10E-05 Asthma / / 19910028 rs10045099 chr5 159303793 A G 9.90E-05 Cholesterol / / pha003073 rs10045099 chr5 159303793 A G 1.45E-05 ldl cholesterol / / pha003076 rs10060486 chr5 159310105 A G 9.95E-05 Alzheimer's disease (late onset) / / 21379329 rs7729960 chr5 159316358 A T 5.78E-04 Multiple complex diseases / / 17554300 rs7734749 chr5 159316987 A G 3.04E-05 Multiple complex diseases / / 17554300 rs6556460 chr5 159317416 C T 8.67E-04 Multiple complex diseases / / 17554300 rs976207 chr5 159321697 C T 1.58E-04 Alzheimer's disease (late onset) / / 21379329 rs12656915 chr5 159323677 T G 5.27E-05 ldl cholesterol / / pha003076 rs4921240 chr5 159327355 G T 2.19E-04 Alzheimer's disease (late onset) / / 21379329 rs1025466 chr5 159333536 T C 8.13E-05 Hemoglobin / / pha003098 rs1025466 chr5 159333536 T C 1.91E-05 Erythrocyte counts / / pha003101 rs10515807 chr5 159364998 G A 3.57E-06 Asthma ADRA1B intron 19910028 rs10515806 chr5 159365289 G A 6.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) ADRA1B intron 17982456 rs11750092 chr5 159367971 C T 7.00E-06 Migraine ADRA1B intron 23793025 rs952037 chr5 159390877 C T 1.42E-05 Bipolar disorder and schizophrenia ADRA1B intron 20889312 rs952037 chr5 159390877 C T 8.24E-05 Bipolar Disorder ADRA1B intron pha002858 rs876528 chr5 159391646 G A 2.24E-17 LDL cholesterol ADRA1B intron 23063622 rs876528 chr5 159391646 G A 9.28E-11 Triglycerides ADRA1B intron 23063622 rs11953285 chr5 159391811 A C 2.84E-04 Celiac disease ADRA1B intron 23936387 rs10515804 chr5 159447213 A G 3.40E-05 Kawasaki disease TTC1 intron 22446962 rs10515804 chr5 159447213 A G 0.0000607 Polycystic ovary syndrome TTC1 intron 22951595 rs10515804 chr5 159447213 A G 6.07E-05 Intracranial aneurysm TTC1 intron 22961961 rs2176830 chr5 159448136 C T 0.000142 Gains in maximal O2 uptake response TTC1 intron 21183627 rs2176830 chr5 159448136 C T 9.21E-06 Schizophrenia TTC1 intron 22037555 rs2271944 chr5 159463556 G C 9.32E-06 Schizophrenia TTC1 intron 22037555 rs11749533 chr5 159473094 C A 7.42E-06 Schizophrenia TTC1 intron 22037555 rs10515803 chr5 159474865 G A 3.68E-05 Telomere length TTC1 intron 23001564 rs3733870 chr5 159478541 G A 1.89E-04 Response to taxane treatment (placlitaxel) TTC1 intron 23006423 rs17057399 chr5 159494552 G A 1.78E-04 Multiple complex diseases / / 17554300 rs2546371 chr5 159592857 C T 8.62E-05 Waist-Hip Ratio / / pha003029 rs4921110 chr5 159608980 C T 8.65E-05 Waist-Hip Ratio / / pha003029 rs918480 chr5 159646094 A G 4.55E-04 Response to TNF antagonist treatment FABP6 intron 21061259 rs6874570 chr5 159677743 C A 4.81E-06 Type 2 diabetes / / 17463246 rs6874570 chr5 159677743 C A 1.50E-04 Multiple complex diseases / / 17554300 rs4921270 chr5 159679636 C T 3.84E-05 Type 2 diabetes CCNJL UTR-3 17463246 rs4921270 chr5 159679636 C T 1.32E-04 Multiple complex diseases CCNJL UTR-3 17554300 rs3749799 chr5 159682777 C T 9.35E-05 Heart Failure CCNJL intron pha002885 rs6875660 chr5 159686256 T C 4.81E-06 Type 2 diabetes CCNJL intron 17463246 rs6875660 chr5 159686256 T C 1.14E-04 Multiple complex diseases CCNJL intron 17554300 rs13362036 chr5 159686503 G A 6.57E-05 Heart Failure CCNJL missense pha002885 rs1549236 chr5 159688546 G A 4.93E-05 Type 2 diabetes CCNJL intron 17463246 rs9313842 chr5 159690031 T C 1.38E-04 Type 2 diabetes CCNJL intron 17463246 rs754111 chr5 159721672 G A 1.52E-05 Socioeconomic Factors CCNJL intron pha003066 rs17057624 chr5 159732687 T A 5.51E-05 Brain derived neurotrophic factor levels,in serum CCNJL intron 22047184 rs13155668 chr5 159733561 G C 7.62E-05 Brain derived neurotrophic factor levels,in serum CCNJL intron 22047184 rs9313845 chr5 159778268 C T 6.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C1QTNF2 intron 20877124 rs2961923 chr5 159794511 G A 4.98E-06 Uric acid levels C1QTNF2 intron 21294900 rs10515808 chr5 159820931 C A 4.00E-07 Weight loss (gastric bypass surgery) C5orf54 missense 23643386 rs1895320 chr5 159849586 A G 0.000732048 Hypertension (early onset hypertension) PTTG1 intron 22479346 rs1895320 chr5 159849586 A G 6.00E-06 Insulin-related traits PTTG1 intron 22791750 rs4921281 chr5 159851054 A C 7.23E-04 Iron levels PTTG1 intron pha002876 rs11747093 chr5 159861510 T C 1.91E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2961911 chr5 159861575 C T 5.44E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4921283 chr5 159870611 G A 0.000343309 Primary sclerosing cholangitis / / 23603763 rs4921283 chr5 159870611 G A 3.73E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs2431697 chr5 159879978 T C 1.00E-10 Systemic lupus erythematosus / / 18204446 rs2431697 chr5 159879978 T C 1.11E-08 Psoriasis / / 20953187 rs2431697 chr5 159879978 T C 1.30E-08 Psoriasis / / 20953187 rs2431697 chr5 159879978 T C 2.00E-06 Systemic lupus erythematosus / / 21408207 rs2431697 chr5 159879978 T C 1.00E-10 Multiple sclerosis / / 22190364 rs2431697 chr5 159879978 T C 1.40E-05 Myasthenia gravis / / 23055271 rs11951834 chr5 159880356 C T 2.35E-05 Platelet counts / / pha003100 rs883517 chr5 159904729 T C 5.94E-05 Alzheimer's disease / / pha002879 rs6556494 chr5 159913228 T C 3.11E-08 LDL cholesterol / / 23063622 rs17057882 chr5 159926960 A G 2.00E-05 Urinary metabolites / / 21572414 rs4921296 chr5 159934161 A G 3.95E-04 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs4921144 chr5 159934877 T C 2.51E-04 Alzheimer's disease / / 17998437 rs1592743 chr5 159942144 T C 8.41E-04 Type 2 diabetes / / 17463246 rs9313850 chr5 159945676 C G 9.20E-04 Alzheimer's disease / / 17998437 rs10052694 chr5 159965401 G A 1.99E-04 Alzheimer's disease / / 17998437 rs1592749 chr5 159972021 T G 1.00E-06 Response to anti-TNF alpha therapy in inflammatory bowel disease / / 20014019 rs12514981 chr5 159973834 T C 9.58E-05 Cognitive performance / / 19734545 rs12514981 chr5 159973834 T C 7.68E-05 Neuroblastoma / / pha002895 rs17057960 chr5 159979317 C T 7.86E-04 Type 2 diabetes / / 17463246 rs10515811 chr5 159980580 C A 4.29E-04 Type 2 diabetes / / 17463246 rs150012142 chr5 160042905 T C 0.0000036 Breast cancer(er negative) ATP10B missense 23555315 rs10476328 chr5 160050162 T G 5.88E-04 Taste perception ATP10B intron 22132133 rs3828608 chr5 160063527 T C 2.18E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ATP10B intron 24023788 rs1549905 chr5 160091381 A G 5.29E-05 Body mass (lean) ATP10B intron 19268274 rs965103 chr5 160096293 C T 9.21E-05 Body mass (lean) ATP10B intron 19268274 rs11135109 chr5 160099440 G T 6.41E-05 Gallbladder cancer ATP10B intron 22318345 rs6862022 chr5 160105344 G A 8.80E-04 Type 2 diabetes and 6 quantitative traits ATP10B intron 17848626 rs17058110 chr5 160106482 C T 2.57E-05 Gallbladder cancer ATP10B intron 22318345 rs1421949 chr5 160111441 T G 5.20E-05 Bone mineral density ATP10B intron 19181680 rs1477280 chr5 160118748 G A 3.31E-04 Alzheimer's disease (late onset) ATP10B intron 21379329 rs17058155 chr5 160129370 T C 9.60E-04 Coronary heart disease ATP10B intron 21971053 rs11135114 chr5 160187121 G A 7.77E-04 Response to taxane treatment (placlitaxel) ATP10B intron 23006423 rs4371793 chr5 160188914 C A 9.69E-04 Response to taxane treatment (placlitaxel) ATP10B intron 23006423 rs12656418 chr5 160190132 C T 3.27E-04 Response to taxane treatment (placlitaxel) ATP10B intron 23006423 rs11958424 chr5 160196659 C A 6.20E-04 Parkinson's disease ATP10B intron 17052657 rs17058247 chr5 160201741 C T 8.74E-04 Response to taxane treatment (placlitaxel) ATP10B intron 23006423 rs4921336 chr5 160208277 A G 9.08E-04 Response to taxane treatment (placlitaxel) ATP10B intron 23006423 rs4569911 chr5 160235125 T C 1.50E-04 HIV-1 viral setpoint ATP10B intron 17641165 rs13180602 chr5 160281038 G A 2.79E-05 Alzheimer's disease / / 17998437 rs12188645 chr5 160296233 C T 4.42E-05 Alcohol and nictotine co-dependence / / 20158304 rs10039306 chr5 160306956 A G,T 7.76E-04 Alzheimer's disease / / 17998437 rs17427187 chr5 160315446 G T 9.48E-05 Male fertility / / 22633400 rs11956144 chr5 160315600 A G 5.96E-05 Male fertility / / 22633400 rs17427250 chr5 160315633 A G 8.30E-05 Male fertility / / 22633400 rs10069908 chr5 160316265 A C 8.00E-05 Prostate cancer / / 21743057 rs4130562 chr5 160316848 C A 9.48E-05 Male fertility / / 22633400 rs12658840 chr5 160318988 A G 5.00E-05 Breast cancer / / 17529967 rs6898138 chr5 160343115 T C 1.47E-04 Fibrinogen / / 17255346 rs6860382 chr5 160347654 C G 9.91E-05 Serum metabolites / / 19043545 rs938541 chr5 160356606 C A 5.99E-04 Parkinson's disease / / 17052657 rs17058486 chr5 160357338 G A 1.60E-05 Urinary metabolites / / 21572414 rs17058486 chr5 160357338 G A 0.000425 Salmonella-induced pyroptosis / / 22837397 rs938544 chr5 160357415 G A 3.63E-04 Coronary Artery Disease / / 17634449 rs11950230 chr5 160367452 C T 1.30E-05 Urinary metabolites / / 21572414 rs17058505 chr5 160379427 T C 6.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs2901562 chr5 160387941 G T 2.79E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs1400334 chr5 160390969 C T 2.79E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs7723902 chr5 160470907 T C 1.27E-04 Multiple complex diseases / / 17554300 rs17058759 chr5 160531764 T C 7.77E-04 Multiple complex diseases / / 17554300 rs1489707 chr5 160537180 A G 4.40E-04 Multiple complex diseases / / 17554300 rs7718721 chr5 160544715 G A 6.43E-04 Alzheimer's disease / / 17998437 rs9313871 chr5 160548063 A G 7.91E-04 Multiple complex diseases / / 17554300 rs1875526 chr5 160556882 G A 4.10E-04 Multiple complex diseases / / 17554300 rs10058183 chr5 160559870 T C 6.22E-04 Multiple complex diseases / / 17554300 rs349753 chr5 160573507 G A 9.26E-04 Alzheimer's disease / / 22005930 rs1686632 chr5 160605866 C T 1.30E-05 Urinary metabolites / / 21572414 rs248361 chr5 160611791 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs469226 chr5 160615998 T C 9.66E-05 Amyotrophic lateral sclerosis / / 19193627 rs10075015 chr5 160684388 T A 9.62E-04 Multiple complex diseases / / 17554300 rs173564 chr5 160689448 T C 5.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs679722 chr5 160701395 C A 2.92E-04 Type 2 diabetes / / 17463246 rs674439 chr5 160701419 C T 3.47E-04 Type 2 diabetes / / 17463246 rs601861 chr5 160704994 T C 4.80E-04 Type 2 diabetes / / 17463246 rs3850733 chr5 160738317 C A 5.39E-04 Heart Failure GABRB2 intron pha002885 rs253002 chr5 160748479 T C 8.85E-04 Cognitive impairment induced by topiramate GABRB2 intron 22091778 rs1677381 chr5 160752997 T C 8.85E-04 Cognitive impairment induced by topiramate GABRB2 intron 22091778 rs10515827 chr5 160754957 C T 3.00E-04 Heroin addiction GABRB2 intron 20520587 rs194072 chr5 160758655 A G 4.44E-04 Cognitive impairment induced by topiramate GABRB2 intron 22091778 rs194072 chr5 160758655 A G 6.91E-04 Cognitive impairment induced by topiramate GABRB2 intron 22091778 rs4566829 chr5 160762673 G T 1.73E-04 Cognitive impairment induced by topiramate GABRB2 intron 22091778 rs2962403 chr5 160770795 C T 9.51E-04 Response to taxane treatment (placlitaxel) GABRB2 intron 23006423 rs4921390 chr5 160802427 T C 1.00E-04 Cognitive impairment induced by topiramate GABRB2 intron 22091778 rs4921390 chr5 160802427 T C 3.02E-04 Taste perception GABRB2 intron 22132133 rs2910291 chr5 160812482 C T 1.93E-04 Taste perception GABRB2 intron 22132133 rs17059403 chr5 160818786 A G 1.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GABRB2 intron 20877124 rs7714930 chr5 160859923 T C 1.90E-05 Urinary metabolites GABRB2 intron 21572414 rs10515829 chr5 160882045 G T 2.80E-04 Type 2 diabetes and 6 quantitative traits GABRB2 intron 17848626 rs10051667 chr5 160898328 T C 2.18E-04 Cognitive impairment induced by topiramate GABRB2 intron 22091778 rs10061302 chr5 160907835 T C 3.44E-04 Cognitive impairment induced by topiramate GABRB2 intron 22091778 rs10061302 chr5 160907835 T C 1.09E-04 Taste perception GABRB2 intron 22132133 rs6881515 chr5 160911968 T C 3.41E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs11135150 chr5 160915001 T C 2.10E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs12153198 chr5 160915124 A G 2.78E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs12153421 chr5 160917585 A G 2.52E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs10069900 chr5 160917953 A G 3.60E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs12153038 chr5 160921475 C T 2.52E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs11748071 chr5 160921545 G A 1.04E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs12189094 chr5 160923428 G C 2.83E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs17462847 chr5 160927699 G A 3.69E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs17462861 chr5 160928221 G A 2.03E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs6880996 chr5 160933922 C A 2.61E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs6882041 chr5 160942400 T C 3.97E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs17463015 chr5 160942683 A G 3.41E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs17522604 chr5 160942725 C T 2.33E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs17463127 chr5 160952502 A T 2.89E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs17522737 chr5 160952734 A G 5.25E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs4921397 chr5 160954490 C A 5.75E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs17522861 chr5 160955349 C T 7.44E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs2066949 chr5 160957960 G A 5.07E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs11741542 chr5 160958985 G T 5.81E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs12187676 chr5 160966394 G C 4.28E-04 Suicide attempts in bipolar disorder GABRB2 intron 21423239 rs3816596 chr5 160975332 C T 8.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs9313891 chr5 161020788 A G 1.37E-04 Multiple complex diseases / / 17554300 rs9313891 chr5 161020788 A G 4.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs6893149 chr5 161103142 A G 2.90E-04 Gallstones / / 17632509 rs10476364 chr5 161184326 G A 1.39E-05 Bipolar disorder / / 21771265 rs11951528 chr5 161217476 G A 1.99E-05 Bipolar disorder / / 21771265 rs4317369 chr5 161228374 A G 3.09E-05 Bipolar disorder / / 21771265 rs7734447 chr5 161292038 A G 1.18E-05 Coronary heart disease GABRA1 intron pha003032 rs11745164 chr5 161400376 T C 5.33E-04 Taste perception / / 22132133 rs7713655 chr5 161447161 G A 3.77E-04 Multiple complex diseases / / 17554300 rs6883423 chr5 161453718 C T 1.62E-04 Alzheimer's disease (late onset) / / 21379329 rs11956128 chr5 161464255 G T 4.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11956128 chr5 161464255 G T 7.77E-05 Height / / pha003010 rs11956128 chr5 161464255 G T 3.67E-05 Height / / pha003011 rs183292 chr5 161472293 C T 4.16E-04 Alzheimer's disease (late onset) / / 21379329 rs2268582 chr5 161515215 C T 0.000674939 Hypertension (early onset hypertension) GABRG2 intron 22479346 rs209353 chr5 161517059 C T 3.55E-05 Gaucher disease severity GABRG2 intron 22388998 rs211015 chr5 161575653 G A 1.38E-04 Multiple complex diseases GABRG2 intron 17554300 rs210993 chr5 161619504 G A 0.0002 Migraine / / 22678113 rs211001 chr5 161646240 G A 8.04E-04 Multiple complex diseases / / 17554300 rs17462769 chr5 161648147 G A 4.23E-04 Esophageal adenocarcinoma / / 24121790 rs4354086 chr5 161668337 G C 1.81E-04 Multiple complex diseases / / 17554300 rs17060196 chr5 161697175 G T 7.12E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2963163 chr5 161702081 C T 5.04E-05 Interstitial lung disease / / 23583980 rs2963162 chr5 161702316 G T 1.54E-05 Chronic obstructive pulmonary disease / / 19300482 rs2963162 chr5 161702316 G T 1.54E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4326180 chr5 161725512 T C 5.87E-04 Obesity (extreme) / / 21935397 rs4560589 chr5 161751583 C T 7.35E-04 Type 2 diabetes / / 17463246 rs4560589 chr5 161751583 C T 3.71E-04 Multiple complex diseases / / 17554300 rs12522255 chr5 161761003 C T 2.30E-05 HIV-1 control / / 20041166 rs4921450 chr5 161764847 T C 4.31E-04 Multiple complex diseases / / 17554300 rs10434673 chr5 161765636 T C 2.70E-04 Type 2 diabetes / / 17463246 rs10434673 chr5 161765636 T C 3.90E-04 Multiple complex diseases / / 17554300 rs13155424 chr5 161766576 A C 2.68E-04 Type 2 diabetes / / 17463246 rs13155424 chr5 161766576 A C 4.20E-04 Multiple complex diseases / / 17554300 rs6871616 chr5 161790414 G A 6.84E-04 Schizophrenia / / 19197363 rs11135206 chr5 161844215 A G 3.21E-04 Multiple complex diseases / / 17554300 rs11135214 chr5 161897136 C T 1.13E-06 Height / / pha003010 rs11135214 chr5 161897136 C T 3.85E-05 Height / / pha003011 rs17560232 chr5 161900842 C T 9.59E-04 Type 2 diabetes / / 17463246 rs1484363 chr5 161925856 A G 5.19E-04 Premature ovarian failure / / 19508998 rs1484363 chr5 161925856 A G 0.000427602 Hypertension (early onset hypertension) / / 22479346 rs2422213 chr5 161936021 G T 0.000732782 Hypertension (early onset hypertension) / / 22479346 rs2170903 chr5 161955116 G T 7.95E-04 Premature ovarian failure / / 19508998 rs17561517 chr5 161970410 T A 9.72E-04 Type 2 diabetes / / 17463246 rs17060479 chr5 161973937 C T 2.51E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2431268 chr5 162023980 G A 3.23E-04 Schizophrenia / / 19197363 rs312312 chr5 162060365 A G 6.80E-04 Alcohol dependence / / 20201924 rs7711337 chr5 162083518 G A 8.00E-07 Autism / / 22843504 rs245610 chr5 162099767 G A 8.90E-04 Pulmonary function / / 23932459 rs245609 chr5 162107672 G A 5.24E-05 Height / / pha003010 rs699107 chr5 162128483 G A 7.47E-04 Multiple complex diseases / / 17554300 rs3914991 chr5 162175154 G A 8.27E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs562293 chr5 162235216 C G,T 8.55E-04 Multiple complex diseases / / 17554300 rs41512445 chr5 162253670 A G 9.50E-06 Obesity-related traits / / 17658951 rs2165576 chr5 162361968 G A 2.02E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10061092 chr5 162363317 C A 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs11746554 chr5 162488010 T C 8.77E-04 Multiple complex diseases / / 17554300 rs11949411 chr5 162524977 C A 2.67E-04 Multiple complex diseases / / 17554300 rs4361535 chr5 162528960 C T 1.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs6876146 chr5 162529098 T C 8.21E-05 Suicide attempts in bipolar disorder / / 21423239 rs6556651 chr5 162529357 G A 9.42E-05 Suicide attempts in bipolar disorder / / 21423239 rs4608939 chr5 162529568 C A 1.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs9313953 chr5 162531495 C T 7.32E-04 Smoking initiation / / 24665060 rs6891361 chr5 162536985 T A 3.40E-05 Suicide attempts in bipolar disorder / / 21423239 rs4605811 chr5 162538159 C A 1.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs4336377 chr5 162550726 G A 3.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs10054530 chr5 162550979 T G 1.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs10515850 chr5 162551332 G A 2.80E-04 Multiple complex diseases / / 17554300 rs10515850 chr5 162551332 G A 2.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs9313955 chr5 162554883 G A 1.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs6872196 chr5 162582264 A T 6.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs4376293 chr5 162589858 T C 2.08E-04 Response to diuretic therapy in hypertension / / 23753411 rs13171969 chr5 162599739 T G 4.42E-04 Type 2 diabetes / / 17463246 rs4323251 chr5 162602605 C T 9.86E-04 Type 2 diabetes / / 17463246 rs13162905 chr5 162608402 G A 8.43E-04 Type 2 diabetes / / 17463246 rs11750487 chr5 162617516 C T 5.44E-04 Type 2 diabetes / / 17463246 rs1366150 chr5 162627644 T C 6.49E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2913568 chr5 162632615 T C 5.12E-04 Multiple complex diseases / / 17554300 rs17061325 chr5 162647465 A G 0.0000988 Follicular lymphoma / / 23025665 rs2964344 chr5 162650793 G A 3.79E-05 Smoking initiation / / 24665060 rs2114997 chr5 162651614 G A 1.48E-04 Smoking initiation / / 24665060 rs2964375 chr5 162655376 C T 6.34E-04 Smoking initiation / / 24665060 rs6893843 chr5 162680419 T C 9.27E-05 Type 2 diabetes / / 17463246 rs6893843 chr5 162680419 T C 9.44E-05 Psoriasis / / 20953190 rs6883415 chr5 162680781 C T 1.28E-04 Type 2 diabetes / / 17463246 rs13180689 chr5 162681559 C T 4.10E-06 Urinary metabolites / / 21572414 rs214115 chr5 162683796 A C 6.95E-04 Type 2 diabetes / / 17463246 rs300194 chr5 162698789 G T 4.38E-04 Type 2 diabetes / / 17463246 rs300196 chr5 162699081 A T 2.80E-05 Serum metabolites / / 19043545 rs1863962 chr5 162710577 G A 4.01E-04 Type 2 diabetes / / 17463246 rs1154758 chr5 162716850 T C 3.34E-06 Serum metabolites / / 19043545 rs11742012 chr5 162754151 T C 5.13E-04 Myopia (pathological) / / 21095009 rs300213 chr5 162759022 A G 7.83E-04 Myopia (pathological) / / 21095009 rs300214 chr5 162759175 C T 5.13E-04 Myopia (pathological) / / 21095009 rs734442 chr5 162769175 A G 1.36E-04 Multiple complex diseases / / 17554300 rs13354373 chr5 162775966 A G 2.10E-05 Urinary metabolites / / 21572414 rs10060800 chr5 162780114 A C 8.66E-04 Multiple complex diseases / / 17554300 rs17061563 chr5 162794447 C T 4.60E-06 Alzheimer's disease / / 17998437 rs999580 chr5 162796228 C T 9.70E-05 Multiple complex diseases / / 17554300 rs10515857 chr5 162809963 G A 3.38E-04 Alzheimer's disease / / 17998437 rs10515857 chr5 162809963 G A 2.78E-05 Varicose Veins / / pha001413 rs13186063 chr5 162826613 A C 2.78E-05 Insulin-related traits / / pha003063 rs2112237 chr5 162830483 C A 7.84E-04 Type 2 diabetes / / 17463246 rs4869081 chr5 162833287 A G 4.67E-04 Smoking cessation / / 24665060 rs13172782 chr5 162836090 T G 6.92E-05 Insulin Resistance / / pha003062 rs13172782 chr5 162836090 T G 1.24E-05 Insulin-related traits / / pha003063 rs427056 chr5 162849759 A C 5.24E-05 Insulin-related traits / / pha003063 rs299284 chr5 162896650 C T 5.29E-05 Smoking cessation HMMR missense 24665060 rs299282 chr5 162899017 A G 1.80E-04 Smoking cessation HMMR intron 24665060 rs11748030 chr5 162916413 C T 8.51E-05 Insulin-related traits HMMR intron pha003063 rs425680 chr5 162936251 T C 8.45E-04 Response to statin treatment (atorvastatin),change in cholesterol levels MAT2B intron 20031582 rs1114752 chr5 162951982 A G 8.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs6897573 chr5 162966722 G A 2.00E-05 Urinary metabolites / / 21572414 rs7712208 chr5 162970656 A T 1.60E-05 Urinary metabolites / / 21572414 rs2017870 chr5 162972426 G C 2.30E-05 Urinary metabolites / / 21572414 rs17061881 chr5 162976478 C T 2.60E-05 Urinary metabolites / / 21572414 rs297968 chr5 162981015 A C 3.01E-05 Cognitive performance / / 19734545 rs1433779 chr5 162995063 G A 8.20E-06 Urinary metabolites / / 21572414 rs294593 chr5 162995755 T C 1.80E-04 Blood Pressure and Arterial Stiffness / / 17903302 rs10037424 chr5 162997610 C T 5.90E-06 Urinary metabolites / / 21572414 rs294588 chr5 162998515 T C 8.00E-04 White matter integrity / / 22425255 rs294588 chr5 162998515 T C 1.00E-06 Aging / / 22773346 rs294582 chr5 163018061 T C 1.76E-04 Tuberculosis / / 22306650 rs6876181 chr5 163021335 G A 5.95E-04 Coronary heart disease / / 21971053 rs292402 chr5 163022788 T G 8.66E-04 Coronary Artery Disease / / 17634449 rs1368287 chr5 163028887 C T 3.02E-04 Coronary Artery Disease / / 17634449 rs292410 chr5 163043385 T C 7.37E-06 Sleep latency / / 23728906 rs545702 chr5 163082713 C G 1.87E-04 Multiple complex diseases / / 17554300 rs545702 chr5 163082713 C G 2.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs158829 chr5 163088969 C T 1.06E-05 Smoking initiation / / 24665060 rs376717 chr5 163097478 G C 9.25E-04 Multiple complex diseases / / 17554300 rs376717 chr5 163097478 G C 4.55E-06 Smoking initiation / / 24665060 rs509502 chr5 163098390 A G 7.48E-05 Cognitive impairment induced by topiramate / / 22091778 rs292404 chr5 163100680 A G 2.00E-06 Smoking initiation / / 24665060 rs3133041 chr5 163103426 A C 7.60E-06 Smoking initiation / / 24665060 rs493108 chr5 163104597 G A 7.24E-05 Multiple complex diseases / / 17554300 rs10057965 chr5 163119808 A C 2.74E-06 Smoking initiation / / 24665060 rs602759 chr5 163129539 A G 7.48E-04 Type 2 diabetes / / 17463246 rs41490845 chr5 163130679 A G 3.99E-04 Multiple complex diseases / / 17554300 rs489816 chr5 163136976 G A 1.50E-04 Type 2 diabetes / / 17463246 rs669427 chr5 163139556 C G 2.69E-05 Type 2 diabetes / / 17463246 rs501869 chr5 163143017 A G 1.20E-05 Type 2 diabetes / / 17463246 rs2635174 chr5 163179965 C A 5.00E-04 Type 2 diabetes / / 17463246 rs2035734 chr5 163184934 G A 6.28E-04 Type 2 diabetes / / 17463246 rs10060854 chr5 163185573 T C 2.48E-04 Type 2 diabetes / / 17463246 rs17539428 chr5 163211005 C T 2.88E-04 Multiple complex diseases / / 17554300 rs1873172 chr5 163262469 T A 8.35E-04 Type 2 diabetes / / 17463246 rs7713437 chr5 163267157 A G 9.68E-05 Depression (quantitative trait) / / 23290196 rs6895949 chr5 163273413 G A 8.50E-05 Depression (quantitative trait) / / 23290196 rs10060591 chr5 163293601 C T 4.26E-04 Coronary heart disease / / 21971053 rs1421860 chr5 163297762 C T 1.44E-04 Multiple complex diseases / / 17554300 rs2546324 chr5 163340237 G A 8.04E-05 Prostate cancer / / 22923026 rs2546316 chr5 163345700 C T 2.58E-05 Postoperative ventricular dysfunction / / 21980348 rs1017213 chr5 163348578 G A 2.65E-05 Postoperative ventricular dysfunction / / 21980348 rs2544995 chr5 163349081 T A 5.10E-05 Age-related macular degeneration / / 20861866 rs2544995 chr5 163349081 T A 4.34E-05 Postoperative ventricular dysfunction / / 21980348 rs1895178 chr5 163351263 G A 9.10E-05 Age-related macular degeneration / / 20861866 rs1895178 chr5 163351263 G A 3.73E-05 Postoperative ventricular dysfunction / / 21980348 rs7720295 chr5 163382675 C T 1.04E-04 Osteoarthritis / / 19508968 rs4269302 chr5 163507966 G T 2.50E-05 Urinary metabolites / / 21572414 rs9313999 chr5 163511991 A G 1.55E-04 Cardiovascular disease / / 17903304 rs10515869 chr5 163512226 G A 4.72E-05 Cardiovascular disease / / 17903304 rs6862056 chr5 163560093 T C 5.36E-05 Schizophrenia / / 19571809 rs7732882 chr5 163586269 G A 3.49E-04 Insulin resistance / / 21901158 rs4321764 chr5 163598608 G A 7.55E-08 Metabolite levels / / 23281178 rs1422767 chr5 163602147 G A 7.99E-08 Metabolite levels / / 23281178 rs1017217 chr5 163603203 G A 7.99E-08 Metabolite levels / / 23281178 rs1023616 chr5 163604611 T C 7.99E-08 Metabolite levels / / 23281178 rs1895304 chr5 163607685 A G 7.99E-08 Metabolite levels / / 23281178 rs1895305 chr5 163608117 C T 7.99E-08 Metabolite levels / / 23281178 rs2161384 chr5 163621832 G A 1.80E-04 Parkinson's disease / / 17052657 rs17284960 chr5 163623502 C T 0.0000075 Femoral neck bone mineral density / / 22692763 rs17284960 chr5 163623502 C T 0.0000169 Femoral neck bone mineral density (males) / / 22692763 rs17284960 chr5 163623502 C T 6.29E-04 Glycemic traits (pregnancy) / / 23903356 rs2964912 chr5 163714075 G A 2.64E-04 Parkinson's disease / / 17052657 rs2964912 chr5 163714075 G A 9.52E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2964911 chr5 163724281 A G 6.57E-05 Nicotine smoking LOC100507193 intron 19268276 rs13179075 chr5 163845736 T C 2.59E-06 Personality dimensions LOC100507193 intron 21173776 rs7718356 chr5 163849108 G T 3.20E-06 Personality dimensions LOC100507193 intron 21173776 rs11135312 chr5 163850395 A G 4.73E-06 Personality dimensions LOC100507193 intron 21173776 rs12513673 chr5 163851303 C T 5.16E-06 Personality dimensions LOC100507193 intron 21173776 rs6556752 chr5 163869843 C T 1.32E-04 Musician's dystonia LOC100507193 intron 24375517 rs6866447 chr5 163873302 A G 6.19E-04 Multiple complex diseases LOC100507193 intron 17554300 rs9314026 chr5 163873906 C A 4.96E-04 Multiple complex diseases LOC100507193 intron 17554300 rs17063360 chr5 163877022 C T 7.94E-04 Multiple complex diseases LOC100507193 intron 17554300 rs6556756 chr5 163889280 G T 5.00E-07 Breast cancer LOC100507193 intron 17903305 rs6556756 chr5 163889280 G T 5.00E-07 Nasopharyngeal carcinoma LOC100507193 intron 20512145 rs9314033 chr5 163890206 A C 1.20E-05 Breast cancer and prostate cancer LOC100507193 intron 17903305 rs17063523 chr5 163906721 C G 8.00E-05 Prostate cancer LOC100507193 intron 21743057 rs10515881 chr5 163908589 C A 8.00E-05 Prostate cancer LOC100507193 intron 21743057 rs17081859 chr5 163912860 G T 8.00E-05 Prostate cancer LOC100507193 intron 21743057 rs17081861 chr5 163912895 C T 8.00E-05 Prostate cancer LOC100507193 intron 21743057 rs17839824 chr5 163920951 A T 8.00E-05 Prostate cancer LOC100507193 intron 21743057 rs17068611 chr5 163928148 C T 8.00E-05 Prostate cancer LOC100507193 intron 21743057 rs17074604 chr5 163932882 A G 1.34E-04 Multiple complex diseases LOC100507193 intron 17554300 rs17311376 chr5 163933160 G A 7.00E-06 Prostate cancer LOC100507193 intron 21743057 rs726336 chr5 163979328 C A 1.10E-05 Longevity and age-related phenotypes LOC100507193 intron 17903295 rs2909775 chr5 164010482 A G 3.96E-05 Multiple complex diseases LOC100507193 intron 17554300 rs17313050 chr5 164011266 G A 1.19E-04 Insulin resistance LOC100507193 intron 21901158 rs2913719 chr5 164015195 T C 1.81E-05 Multiple complex diseases LOC100507193 intron 17554300 rs2964318 chr5 164017907 C T 3.61E-05 Age-related macular degeneration LOC100507193 intron pha000002 rs356016 chr5 164025054 G A 7.40E-04 Heart Failure LOC100507193 intron pha002884 rs17065889 chr5 164056296 G A 2.41E-04 Multiple complex diseases LOC100507193 intron 17554300 rs7708842 chr5 164074140 A T 2.08E-04 Multiple complex diseases LOC100507193 intron 17554300 rs17066358 chr5 164086912 G A 1.03E-10 Multiple complex diseases LOC100507193 intron 17554300 rs10077775 chr5 164103083 G A 2.34E-04 HIV-1 viral setpoint LOC100507193 intron 17641165 rs6868079 chr5 164111192 G A 3.10E-04 Coronary heart disease LOC100507193 intron 21606135 rs1293554 chr5 164148566 G A 2.14E-04 Epilepsy LOC100507193 intron 22116939 rs11739137 chr5 164182884 C G 8.62E-04 Coronary heart disease LOC100507193 intron 21606135 rs17323370 chr5 164236091 A G 9.32E-05 Aging (time to event) LOC100507193 intron 21782286 rs2963136 chr5 164287024 A T 7.63E-05 Kawasaki disease LOC100507193 intron 22446961 rs17377570 chr5 164295560 G A 1.10E-05 Urinary metabolites LOC100507193 intron 21572414 rs7723455 chr5 164296456 C A 6.79E-04 Suicide attempts in bipolar disorder LOC100507193 intron 21041247 rs2962851 chr5 164297814 G A 7.06E-04 Suicide attempts in bipolar disorder LOC100507193 intron 21041247 rs2962852 chr5 164297861 G A 7.10E-04 Suicide attempts in bipolar disorder LOC100507193 intron 21041247 rs4481363 chr5 164474719 C A 4.94E-04 Type 2 diabetes LOC100507193 intron 17463246 rs7714851 chr5 164475774 T C 3.91E-04 Type 2 diabetes LOC100507193 intron 17463246 rs4563645 chr5 164476355 C A 4.90E-04 Smoking initiation LOC100507193 intron 24665060 rs4077278 chr5 164481996 C G 9.04E-04 Type 2 diabetes LOC100507193 intron 17463246 rs4077278 chr5 164481996 C G 8.56E-05 Depression (quantitative trait) LOC100507193 intron 23290196 rs4346787 chr5 164483794 G A 3.71E-04 Type 2 diabetes LOC100507193 intron 17463246 rs4288138 chr5 164484199 G C 8.07E-04 Type 2 diabetes LOC100507193 intron 17463246 rs4543289 chr5 164484948 T G 5.83E-04 Type 2 diabetes LOC100507193 intron 17463246 rs2112172 chr5 164490086 C T 1.00E-07 Platelet aggregation(pre- and post-aspirin) LOC100507193 intron 20529293 rs6879291 chr5 164493042 A G 4.59E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LOC100507193 intron 24023788 rs4499853 chr5 164502750 C T 3.38E-04 Type 2 diabetes LOC100507193 intron 22158537 rs1946191 chr5 164504641 G C 6.74E-04 Type 2 diabetes LOC100507193 intron 22158537 rs4868908 chr5 164506950 C T 6.91E-05 Type 2 diabetes LOC100507193 intron 22158537 rs6896670 chr5 164512911 T C 7.35E-04 Type 2 diabetes LOC100507193 intron 17463246 rs10073086 chr5 164532314 C T 8.96E-04 Obesity (extreme) LOC100507193 intron 21935397 rs1592758 chr5 164539177 T C 8.78E-04 Obesity (extreme) LOC100507193 intron 21935397 rs4577712 chr5 164546211 C T 8.06E-04 Obesity (extreme) LOC100507193 intron 21935397 rs17072825 chr5 164547400 A G 6.49E-04 Type 2 diabetes LOC100507193 intron 22158537 rs766120 chr5 164548126 G A 5.49E-04 Type 2 diabetes LOC100507193 intron 17463246 rs4323250 chr5 164548747 T C 7.55E-04 Obesity (extreme) LOC100507193 intron 21935397 rs1363113 chr5 164550569 A G 7.28E-04 Obesity (extreme) LOC100507193 intron 21935397 rs9784692 chr5 164551209 T G 6.88E-05 Type 2 diabetes LOC100507193 intron 17463246 rs10476496 chr5 164551653 T C 7.10E-04 Obesity (extreme) LOC100507193 intron 21935397 rs2901859 chr5 164553884 A T 8.31E-04 Type 2 diabetes LOC100507193 intron 22158537 rs17072886 chr5 164554767 C T 8.81E-04 Acute lung injury LOC100507193 intron 22295056 rs13162946 chr5 164555279 C G 6.82E-04 Obesity (extreme) LOC100507193 intron 21935397 rs1473186 chr5 164555759 C T 6.02E-04 Type 2 diabetes LOC100507193 intron 17463246 rs12513654 chr5 164556905 A G 6.77E-04 Type 2 diabetes LOC100507193 intron 17463246 rs2861089 chr5 164557954 A T 4.86E-04 Type 2 diabetes LOC100507193 intron 17463246 rs6876275 chr5 164558583 T G 6.50E-04 Obesity (extreme) LOC100507193 intron 21935397 rs10515891 chr5 164562155 T C 6.42E-04 Obesity (extreme) LOC100507193 intron 21935397 rs918373 chr5 164563089 A G 8.30E-04 Acute lung injury LOC100507193 intron 22295056 rs6556809 chr5 164563948 T A 6.12E-04 Obesity (extreme) LOC100507193 intron 21935397 rs1990866 chr5 164564797 C T 8.16E-04 Acute lung injury LOC100507193 intron 22295056 rs7447491 chr5 164566706 A G 5.14E-04 Obesity (extreme) LOC100507193 intron 21935397 rs4397144 chr5 164570320 T C 5.44E-04 Acute lung injury LOC100507193 intron 22295056 rs10035627 chr5 164578495 G A 5.43E-04 Smoking initiation LOC100507193 intron 24665060 rs10475748 chr5 164582120 G A 4.96E-04 Smoking initiation LOC100507193 intron 24665060 rs1421713 chr5 164583556 G A 4.56E-04 Obesity (extreme) LOC100507193 intron 21935397 rs1421713 chr5 164583556 G A 0.0002 Migraine LOC100507193 intron 22678113 rs4400143 chr5 164585515 C T 2.43E-04 Type 2 diabetes LOC100507193 intron 17463246 rs4400143 chr5 164585515 C T 1.75E-04 Multiple complex diseases LOC100507193 intron 17554300 rs4400143 chr5 164585515 C T 1.92E-04 Alzheimer's disease (late onset) LOC100507193 intron 21460841 rs4400143 chr5 164585515 C T 9.30E-05 Cognitive function LOC100507193 intron 24684796 rs6556811 chr5 164585964 C T 4.44E-04 Obesity (extreme) LOC100507193 intron 21935397 rs9314055 chr5 164588083 G T 5.53E-04 Obesity (extreme) LOC100507193 intron 21935397 rs3095954 chr5 164594958 C T 7.49E-05 Smoking initiation LOC100507193 intron 24665060 rs253537 chr5 164600485 A C 8.88E-05 Smoking initiation / / 24665060 rs1363117 chr5 164616397 C T 2.66E-04 Obesity (extreme) / / 21935397 rs13156646 chr5 164619355 G C 2.57E-04 Obesity (extreme) / / 21935397 rs13186159 chr5 164626203 A G 2.19E-04 Obesity (extreme) / / 21935397 rs11135356 chr5 164631618 T C 2.07E-04 Obesity (extreme) / / 21935397 rs11135357 chr5 164631708 A G 2.04E-04 Obesity (extreme) / / 21935397 rs13178865 chr5 164637211 A G 7.31E-04 Smoking initiation / / 24665060 rs7715290 chr5 164638632 G A 4.59E-04 Smoking initiation / / 24665060 rs17332900 chr5 164640086 T G 8.91E-04 Type 2 diabetes / / 17463246 rs6870178 chr5 164643336 C T 5.22E-04 Obesity (extreme) / / 21935397 rs885477 chr5 164645714 A G 2.33E-04 Obesity (extreme) / / 21935397 rs2013312 chr5 164645925 A T 2.34E-04 Obesity (extreme) / / 21935397 rs4868753 chr5 164650294 T C 5.14E-04 Smoking initiation / / 24665060 rs13186057 chr5 164652537 G A 1.78E-04 Smoking initiation / / 24665060 rs13165528 chr5 164655628 C T 2.31E-04 Obesity (extreme) / / 21935397 rs1578900 chr5 164658422 T G 1.91E-04 Smoking initiation / / 24665060 rs4367315 chr5 164660539 T C 9.19E-05 Smoking initiation / / 24665060 rs2043283 chr5 164663832 T G 3.29E-06 Lipid traits / / 21777205 rs7720663 chr5 164666230 A G 2.25E-04 Obesity (extreme) / / 21935397 rs1422680 chr5 164666384 T C 3.11E-04 Smoking initiation / / 24665060 rs10064661 chr5 164668926 A C 1.68E-04 Smoking initiation / / 24665060 rs1433004 chr5 164673402 T G 2.37E-04 Obesity (extreme) / / 21935397 rs1433006 chr5 164678517 C T 7.23E-04 Smoking initiation / / 24665060 rs6556813 chr5 164679036 A G 4.83E-04 Obesity (extreme) / / 21935397 rs1024997 chr5 164680288 C T 8.90E-04 Obesity (extreme) / / 21935397 rs7732563 chr5 164692816 G A 9.57E-04 Multiple complex diseases / / 17554300 rs7732563 chr5 164692816 G A 9.77E-05 Schizophrenia / / 19571809 rs17419172 chr5 164699410 C G 2.72E-04 Type 2 diabetes / / 17463246 rs7719559 chr5 164700216 T C 0.0000345 Tuberculosis with late age of onset / / 22551897 rs17074571 chr5 164701201 A G 0.0000155 Tuberculosis with late age of onset / / 22551897 rs17074826 chr5 164723673 A G 7.54E-04 Insulin resistance / / 21901158 rs17074826 chr5 164723673 A G 0.0000229 Tuberculosis with late age of onset / / 22551897 rs17075255 chr5 164759108 C T 0.0000217 Tuberculosis with late age of onset / / 22551897 rs17075255 chr5 164759108 C T 2.68E-05 HDL particle features / / pha002900 rs10515893 chr5 164759496 G A 0.00000093 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs10515893 chr5 164759496 G A 0.00000137 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs9314061 chr5 164760466 C T 0.0003 Migraine / / 22678113 rs1145652 chr5 164764087 A G 8.00E-08 Phospholipid levels (plasma) / / 21829377 rs17075358 chr5 164764508 G T 1.74E-04 Smoking initiation / / 24665060 rs12515866 chr5 164774447 C T 0.0003 Migraine / / 22678113 rs9790890 chr5 164786295 G A 0.0000184 Tuberculosis with late age of onset / / 22551897 rs10071625 chr5 164857290 C T 7.41E-04 Type 2 diabetes / / 17463246 rs17077103 chr5 164902580 C T 9.66E-05 Cognitive impairment induced by topiramate / / 22091778 rs17052794 chr5 164913511 A C 2.07E-04 Type 2 diabetes / / 17463246 rs17052794 chr5 164913511 A C 7.53E-04 Multiple complex diseases / / 17554300 rs10476512 chr5 164915281 G A 2.00E-05 Urinary metabolites / / 21572414 rs2216637 chr5 164979595 A G 5.76E-04 Obesity (extreme) / / 21935397 rs1421784 chr5 164989544 T C 2.00E-04 Response to interferon beta in multiple sclerosis / / 18195134 rs7710774 chr5 164989568 A G 9.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs7715064 chr5 164989822 T A 9.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs7715320 chr5 164993708 A G 4.54E-04 Alzheimer's disease (late onset) / / 21379329 rs7728593 chr5 165017688 G A 2.59E-04 Height / / 17255346 rs262747 chr5 165046698 G A 9.35E-04 Type 2 diabetes / / 17463246 rs17348303 chr5 165047906 G C 9.20E-04 Multiple complex diseases / / 17554300 rs17065434 chr5 165052540 C T 2.48E-04 Suicide attempts in bipolar disorder / / 21041247 rs958994 chr5 165063884 G A 8.00E-06 Carotid atherosclerosis in HIV infection / / 20009918 rs10041088 chr5 165067818 G A 0.0000636 Nicotine dependence (smoking) / / 22377092 rs262776 chr5 165079673 G A 3.15E-05 Schizophrenia / / 20185149 rs262776 chr5 165079673 G A 5.27E-05 Bipolar disorder / / 20451256 rs3909281 chr5 165096435 T G 1.28E-05 Soluble levels of adhesion molecules / / pha003072 rs262737 chr5 165101938 C A 1.22E-06 Odorant perception / / 23910658 rs12657428 chr5 165148145 T C 5.76E-04 Rheumatoid arthritis (ACPA-negative) / / 24532677 rs3909349 chr5 165155489 T G 3.20E-04 Multiple complex diseases / / 17554300 rs17065819 chr5 165172613 C T 6.87E-04 Multiple complex diseases / / 17554300 rs1363374 chr5 165187776 C T 8.50E-05 White matter hyperintensity burden / / 21681796 rs11959450 chr5 165195559 G A 9.58E-04 HIV-1 viral setpoint / / 17641165 rs754857 chr5 165200614 A C 6.95E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs13185011 chr5 165205415 T C 8.45E-05 Response to hepatitis C treatment / / 19684573 rs13169858 chr5 165206198 A G 9.39E-04 Alzheimer's disease / / 24755620 rs6555665 chr5 165235298 G T 3.74E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1833580 chr5 165244179 G T 2.84E-04 Alzheimer's disease / / 24755620 rs9942373 chr5 165247018 C T 6.91E-04 Coronary heart disease / / 21971053 rs10076290 chr5 165252035 T G 6.90E-05 HIV-1 control / / 20041166 rs10462950 chr5 165264288 C T 3.80E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs248278 chr5 165272417 C T 3.41E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs248279 chr5 165273083 T C 6.16E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs32764 chr5 165278640 A G 6.33E-04 Alzheimer's disease / / 24755620 rs26435 chr5 165308407 A G 8.30E-06 Urinary metabolites / / 21572414 rs26442 chr5 165373210 G C 1.12E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10078950 chr5 165375029 A G 3.04E-05 Multiple complex diseases / / 17554300 rs9313296 chr5 165377699 G C 6.00E-06 Waist circumference / / 20966902 rs9313296 chr5 165377699 G C 7.00E-07 Weight / / 20966902 rs1107154 chr5 165387313 G A 3.10E-04 Intelligence (childhood) / / 23358156 rs9313297 chr5 165405228 A G 2.70E-06 Urinary metabolites / / 21572414 rs2591578 chr5 165407709 C A 2.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3812010 chr5 165429598 T C 3.18E-04 Alzheimer's disease (late onset) / / 21379329 rs73354940 chr5 165440158 C T 2.58E-05 Intracerebral hemorrhage / / 24656865 rs73354945 chr5 165442356 G A 2.13E-05 Intracerebral hemorrhage / / 24656865 rs115715570 chr5 165444892 T C 1.77E-05 Intracerebral hemorrhage / / 24656865 rs17066228 chr5 165454800 G T 9.05E-06 Intracerebral hemorrhage / / 24656865 rs17066233 chr5 165457156 T A 1.19E-05 Intracerebral hemorrhage / / 24656865 rs7717411 chr5 165472108 G T 4.23E-05 Intracerebral hemorrhage / / 24656865 rs10515915 chr5 165472605 G C 3.33E-05 Intracerebral hemorrhage / / 24656865 rs60168053 chr5 165472696 T G 3.65E-05 Intracerebral hemorrhage / / 24656865 rs17066274 chr5 165482802 G A 3.21E-05 Intracerebral hemorrhage / / 24656865 rs31760 chr5 165503482 T C 7.27E-04 Multiple complex diseases / / 17554300 rs2861667 chr5 165511601 C T 4.83E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs13184263 chr5 165514755 G T 7.19E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13184263 chr5 165514755 G T 7.24E-05 Creatinine levels / / pha003069 rs2644732 chr5 165516543 A G 7.60E-05 Coronary heart disease / / pha003032 rs2644732 chr5 165516543 A G 8.18E-05 Creatinine levels / / pha003069 rs2644731 chr5 165518937 A G 8.37E-05 Creatinine levels / / pha003069 rs10053725 chr5 165547449 A T 3.63E-04 Multiple complex diseases / / 17554300 rs6897561 chr5 165575765 A G 1.57E-04 Type 2 diabetes / / 17463246 rs10516010 chr5 165654695 A T 2.51E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs1353920 chr5 165655853 G T 3.06E-07 Schizophrenia / / 21926974 rs17066536 chr5 165673818 A G 3.90E-05 Cognitive test performance / / 20125193 rs9313313 chr5 165674398 G A 3.75E-04 Schizophrenia / / 19197363 rs9313313 chr5 165674398 G A 2.11E-05 Height / / pha003010 rs1392281 chr5 165675616 G A 1.37E-05 Height / / pha003010 rs17066552 chr5 165678126 T C,G 3.50E-04 Type 2 diabetes / / 17463246 rs2173636 chr5 165680534 G A 3.43E-05 Schizophrenia / / 19197363 rs2173636 chr5 165680534 G A 2.36E-05 Height / / pha003010 rs1499995 chr5 165687214 C T 4.86E-04 Schizophrenia / / 19197363 rs17465342 chr5 165687403 C T 2.90E-04 Alzheimer's disease / / 17998437 rs1392279 chr5 165720606 C T 1.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1527822 chr5 165723695 A G 1.16E-04 Schizophrenia / / 19197363 rs6871234 chr5 165741622 G A 4.50E-04 Tourette syndrome / / 22889924 rs17066694 chr5 165761302 A G 3.20E-07 Fasting plasma glucose / / 19060907 rs1799546 chr5 165767227 C T 5.70E-05 Iron levels / / 21208937 rs1799550 chr5 165775731 A G 9.91E-04 Myocardial Infarction / / pha002873 rs17384913 chr5 165828308 A T 1.26E-04 Attention deficit hyperactivity disorder / / pha002875 rs17066876 chr5 165847422 G A 8.75E-04 Parkinson's disease / / 17052657 rs4868768 chr5 165859784 C T 1.20E-04 Multiple complex diseases / / 17554300 rs1450629 chr5 165887675 G A,C,T 4.08E-04 Multiple complex diseases / / 17554300 rs1450629 chr5 165887675 G A,C,T 1.60E-05 Urinary metabolites / / 21572414 rs1527827 chr5 165899741 A C 6.21E-04 Type 2 diabetes / / 17463246 rs6897150 chr5 165900798 T C 3.00E-04 Type 2 diabetes / / 17846126 rs1405909 chr5 165904495 T G 9.86E-05 Serum metabolites / / 19043545 rs9313321 chr5 165920056 T C 1.60E-05 Urinary metabolites / / 21572414 rs17067019 chr5 165922575 G C 7.72E-04 Type 2 diabetes / / 17463246 rs10076410 chr5 165928002 C T 1.60E-05 Urinary metabolites / / 21572414 rs1450631 chr5 165928295 T C 8.17E-04 Type 2 diabetes / / 17463246 rs1450632 chr5 165928322 T G 2.90E-06 Urinary metabolites / / 21572414 rs2964300 chr5 165953269 C G 7.54E-04 Alzheimer's disease / / 17998437 rs2122554 chr5 165957086 T G 3.00E-06 Conduct disorder (symptom count) / / 20585324 rs11134429 chr5 165996853 G A 3.03E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2161413 chr5 166008290 C T 1.10E-05 Urinary metabolites / / 21572414 rs6878847 chr5 166061635 A G 1.50E-04 Glycosylated haemoglobin levels / / 17255346 rs17476801 chr5 166077573 T C 0.0008775 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17476801 chr5 166077573 T C 8.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10462960 chr5 166125560 G T 5.13E-04 Coronary heart disease / / 21606135 rs347433 chr5 166134659 C T 9.87E-05 Schizophrenia / / 19571809 rs347433 chr5 166134659 C T 4.22E-05 Bipolar disorder and schizophrenia / / 20889312 rs13189908 chr5 166148030 A G 1.30E-05 Urinary metabolites / / 21572414 rs12109919 chr5 166157160 G C 1.40E-05 Urinary metabolites / / 21572414 rs10056300 chr5 166173738 C A 9.53E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11743528 chr5 166200153 C T 1.01E-04 Autism spectrum disorders (language delay) / / 21519539 rs1432929 chr5 166233056 T C 3.19E-04 Alzheimer's disease / / 24755620 rs9313348 chr5 166252148 A G 5.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2116798 chr5 166266941 A G 6.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12656909 chr5 166268258 C A 2.73E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs13168449 chr5 166286588 G A 7.12E-04 Multiple complex diseases / / 17554300 rs13168449 chr5 166286588 G A 1.20E-05 Urinary metabolites / / 21572414 rs7708097 chr5 166308101 G C 3.13E-04 Multiple complex diseases / / 17554300 rs4460157 chr5 166308869 C T 8.32E-04 Multiple complex diseases / / 17554300 rs10072565 chr5 166310089 C T 4.34E-04 Multiple complex diseases / / 17554300 rs10072565 chr5 166310089 C T 1.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs3853240 chr5 166318190 A G 1.00E-06 Adverse response to lamotrigine and phenytoin / / 22379998 rs6872687 chr5 166331865 C T 4.47E-05 Personality dimensions / / 18957941 rs4324703 chr5 166341778 T G 7.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs13169373 chr5 166345088 C T 8.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10060669 chr5 166359355 G A 3.77E-04 Height / / 17255346 rs12520749 chr5 166365731 T G 2.65E-04 Height / / 17255346 rs12520749 chr5 166365731 T G 2.74E-05 Coronary heart disease / / pha003031 rs10070710 chr5 166369413 G A 2.32E-04 Height / / 17255346 rs244436 chr5 166373903 G T 4.70E-05 Creatinine levels / / 20222955 rs2910281 chr5 166378281 A G 1.73E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2910281 chr5 166378281 A G 3.47E-04 Lung function (forced vital capacity) / / 24023788 rs3853241 chr5 166379772 C T 6.25E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs17404956 chr5 166389493 A G 1.00E-06 Diabetic retinopathy / / 21441570 rs384227 chr5 166389709 T G 3.47E-04 Tourette syndrome / / 22889924 rs10516030 chr5 166402297 G C 7.00E-06 Diabetic retinopathy / / 21441570 rs402360 chr5 166408664 T C 7.21E-04 Stroke / / pha002886 rs7707688 chr5 166416817 T G 4.91E-04 HIV-1 viral setpoint / / 17641165 rs7707688 chr5 166416817 T G 0.00067 Endometrial cancer / / 22426144 rs6878841 chr5 166428172 C A 1.66E-04 Multiple complex diseases / / 17554300 rs1501797 chr5 166439746 G A 1.96E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1501797 chr5 166439746 G A 1.08E-04 Myopia (pathological) / / 21095009 rs1027635 chr5 166443856 C T 8.70E-06 Urinary metabolites / / 21572414 rs1393150 chr5 166444023 A G 4.40E-06 Urinary metabolites / / 21572414 rs2902101 chr5 166448679 C A 0.000104 Bipolar disorder / / 23637625 rs1432935 chr5 166499878 C T 2.19E-04 Alzheimer's disease (late onset) / / 21379329 rs2915855 chr5 166509116 G A 3.35E-04 Myopia (pathological) / / 21095009 rs3095942 chr5 166514264 A G 3.35E-04 Myopia (pathological) / / 21095009 rs2915858 chr5 166542621 A G 1.15E-04 Myopia (pathological) / / 21095009 rs2915858 chr5 166542621 A G 8.51E-05 Waist-Hip Ratio / / pha003029 rs1432947 chr5 166560502 A G 6.21E-04 Multiple complex diseases / / 17554300 rs17495520 chr5 166639905 C T 3.00E-04 Asthma (bronchodilator response) / / 23508266 rs10063592 chr5 166672257 C T 2.25E-05 Post-operative nausea and vomiting / / 21694509 rs17068248 chr5 166712759 G C 7.80E-11 Multiple complex diseases ODZ2 intron 17554300 rs11134458 chr5 166787908 T C 7.48E-04 Multiple complex diseases ODZ2 intron 17554300 rs4869035 chr5 166807089 C T 2.80E-05 Urinary metabolites ODZ2 intron 21572414 rs6555743 chr5 166823638 A C 2.30E-05 Urinary metabolites ODZ2 intron 21572414 rs6863407 chr5 166831694 C T 3.46E-05 Personality dimensions ODZ2 intron 18957941 rs4317341 chr5 166837231 A G 2.50E-05 Urinary metabolites ODZ2 intron 21572414 rs10043275 chr5 166837602 T G 9.00E-05 Personality dimensions ODZ2 intron 18957941 rs7704674 chr5 166839285 A G 9.15E-04 Heart Failure ODZ2 intron pha002885 rs6887079 chr5 166866436 C T 1.85E-04 Multiple complex diseases ODZ2 intron 17554300 rs6887079 chr5 166866436 C T 3.95E-06 Type 1 diabetes ODZ2 intron 18978792 rs4869044 chr5 166882756 G A 1.15E-04 Coronary Artery Disease ODZ2 intron 17634449 rs1864975 chr5 166887629 T C 3.39E-04 Epilepsy ODZ2 intron 22116939 rs172137 chr5 167031862 G A 5.95E-08 Narcolepsy ODZ2 intron 19629137 rs11134465 chr5 167037934 G A 3.94E-05 Personality dimensions ODZ2 intron 18957941 rs17068860 chr5 167051620 A G 6.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) ODZ2 intron 23648065 rs17068925 chr5 167090534 C T 3.37E-05 Schizophrenia ODZ2 intron 20185149 rs11950863 chr5 167099985 C T 8.21E-05 Schizophrenia ODZ2 intron 20185149 rs4431367 chr5 167100512 G C 1.40E-04 Multiple complex diseases ODZ2 intron 17554300 rs11134467 chr5 167101161 G A 1.78E-04 Multiple complex diseases ODZ2 intron 17554300 rs11134467 chr5 167101161 G A 8.40E-05 Schizophrenia ODZ2 intron 20185149 rs41378648 chr5 167113041 A T 1.32E-06 Multiple complex diseases ODZ2 intron 17554300 rs10516036 chr5 167114591 C T 2.76E-04 Multiple complex diseases ODZ2 intron 17554300 rs10516036 chr5 167114591 C T 1.90E-05 Schizophrenia ODZ2 intron 20185149 rs10057680 chr5 167147874 A G 8.37E-04 Suicide attempts in bipolar disorder ODZ2 intron 21423239 rs10057680 chr5 167147874 A G 7.95E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) ODZ2 intron 23648065 rs2337015 chr5 167150165 T C 9.16E-04 Suicide attempts in bipolar disorder ODZ2 intron 21423239 rs875208 chr5 167150560 G C 1.30E-04 Suicide attempts in bipolar disorder ODZ2 intron 21423239 rs2244456 chr5 167156345 A T 2.91E-04 Suicide attempts in bipolar disorder ODZ2 intron 21423239 rs2337020 chr5 167157931 A G 3.25E-04 Suicide attempts in bipolar disorder ODZ2 intron 21423239 rs4479863 chr5 167174799 T G 4.49E-05 Personality dimensions ODZ2 intron 18957941 rs12187148 chr5 167177556 A G 8.21E-05 Information processing speed ODZ2 intron 21130836 rs10516038 chr5 167189612 T C 3.49E-04 Type 2 diabetes ODZ2 intron 17846125 rs10516038 chr5 167189612 T C 9.33E-04 Bipolar disorder ODZ2 intron 19259986 rs13357822 chr5 167201714 G C 5.41E-05 Alzheimer's disease ODZ2 intron 21098978 rs2973662 chr5 167210472 A G 5.00E-07 Immune response to smallpox vaccine (IL-6) ODZ2 intron 22610502 rs1549309 chr5 167226979 G A 2.00E-06 Dietary macronutrient intake ODZ2 intron 23636237 rs10045595 chr5 167230004 T G 8.06E-10 Narcolepsy ODZ2 intron 19629137 rs7707689 chr5 167234061 G A 1.00E-05 Urinary metabolites ODZ2 intron 21572414 rs1421989 chr5 167258672 C T 1.94E-05 Personality dimensions ODZ2 intron 18957941 rs1421989 chr5 167258672 C T 2.50E-05 Urinary metabolites ODZ2 intron 21572414 rs4869075 chr5 167259210 A G 1.10E-05 Urinary metabolites ODZ2 intron 21572414 rs7725644 chr5 167276307 T G 9.85E-05 Type 2 diabetes ODZ2 intron 17463246 rs17525725 chr5 167293652 A G 4.93E-04 Multiple complex diseases ODZ2 intron 17554300 rs1035373 chr5 167296428 G A 3.50E-05 Taste perception ODZ2 intron 22132133 rs1592800 chr5 167303239 G A 1.30E-05 Urinary metabolites ODZ2 intron 21572414 rs11951480 chr5 167336827 A G 5.42E-04 Multiple complex diseases ODZ2 intron 17554300 rs12109455 chr5 167340025 A C 7.25E-04 Type 2 diabetes ODZ2 intron 17463246 rs7708105 chr5 167343309 T C 2.11E-04 Parkinson's disease ODZ2 intron 17052657 rs32400 chr5 167348060 A G 2.41E-04 Parkinson's disease ODZ2 intron 17052657 rs39950 chr5 167351652 A G 2.01E-04 Lung function (forced expiratory volume in 1 second) ODZ2 intron 17255346 rs9647570 chr5 167370263 T G 6.87E-04 Body mass index ODZ2 intron 21701565 rs1422930 chr5 167397593 C T 5.68E-04 Type 2 diabetes ODZ2 intron 17846126 rs2617958 chr5 167430057 A G 3.20E-04 Type 2 diabetes ODZ2 intron 17846124 rs3909403 chr5 167430886 A G 8.59E-04 Type 2 diabetes ODZ2 intron 17463246 rs3909402 chr5 167431268 C G 8.59E-04 Type 2 diabetes ODZ2 intron 17463246 rs3909402 chr5 167431268 C G 9.74E-05 Cognitive decline ODZ2 intron 22054870 rs17069617 chr5 167444365 A G 7.08E-05 Response to taxane treatment (placlitaxel) ODZ2 intron 23006423 rs10052830 chr5 167446601 C T 4.78E-06 Cognitive decline ODZ2 intron 22054870 rs17069629 chr5 167447748 C T 8.59E-04 Type 2 diabetes ODZ2 intron 17463246 rs17069629 chr5 167447748 C T 7.45E-06 Cognitive decline ODZ2 intron 22054870 rs17069636 chr5 167449057 T A 2.93E-04 Substance dependence ODZ2 intron 21818250 rs1432820 chr5 167470410 G C 8.22E-04 Multiple complex diseases ODZ2 intron 17554300 rs247995 chr5 167477752 G A 7.86E-05 Erythrocyte counts ODZ2 intron pha003101 rs3860783 chr5 167482305 A G 9.74E-05 Heart Failure ODZ2 intron pha002885 rs9313396 chr5 167499832 G T 2.10E-05 Serum metabolites ODZ2 intron 19043545 rs13358864 chr5 167500460 T A 5.00E-06 Uric acid levels ODZ2 intron 22229870 rs7736530 chr5 167520826 G T 6.65E-05 HDL cholesterol ODZ2 intron pha003074 rs6866450 chr5 167534846 A G 9.31E-04 Depression (quantitative trait) ODZ2 intron 20800221 rs6866450 chr5 167534846 A G 3.40E-06 Urinary metabolites ODZ2 intron 21572414 rs6867056 chr5 167535028 G T 9.40E-04 Depression (quantitative trait) ODZ2 intron 20800221 rs12187313 chr5 167543435 A C 2.65E-04 Multiple complex diseases ODZ2 intron 17554300 rs4976576 chr5 167586356 G A 5.29E-04 Tourette syndrome ODZ2 intron 22889924 rs1560651 chr5 167598272 G A 7.20E-04 Amyotrophic Lateral Sclerosis ODZ2 intron 17362836 rs2132545 chr5 167611655 T C 2.80E-05 Urinary metabolites ODZ2 intron 21572414 rs903850 chr5 167620250 G A 4.54E-04 Response to taxane treatment (placlitaxel) ODZ2 intron 23006423 rs2173018 chr5 167624416 A G 4.84E-05 Lung adenocarcinoma ODZ2 intron 19836008 rs4976539 chr5 167637274 A G 1.27E-04 Telomere length ODZ2 intron 21573004 rs17731147 chr5 167637755 T C 2.91E-05 Coronary Artery Disease ODZ2 intron 17634449 rs17070005 chr5 167641067 A G 2.71E-04 Type 2 diabetes ODZ2 intron 17463246 rs6885116 chr5 167643545 A G 1.00E-06 Periodontal microbiota ODZ2 intron 22699663 rs12519946 chr5 167665598 C G 8.38E-05 Serum metabolites ODZ2 intron 19043545 rs6887837 chr5 167669233 C T 1.04E-04 Response to taxane treatment (placlitaxel) ODZ2 intron 23006423 rs17070023 chr5 167674472 G A 6.69E-04 Response to taxane treatment (placlitaxel) ODZ2 cds-synon 23006423 rs6875551 chr5 167721201 T C 3.76E-05 Alzheimer's disease WWC1 intron 17998437 rs6555793 chr5 167725721 T A 6.09E-05 Alzheimer's disease WWC1 intron 17998437 rs17070088 chr5 167761398 T C 8.97E-04 Multiple complex diseases WWC1 intron 17554300 rs17731499 chr5 167764600 A C 6.30E-04 Type 2 diabetes WWC1 intron 17463246 rs12332615 chr5 167767862 C G 1.10E-04 Self-reported allergy WWC1 intron 23817569 rs1035421 chr5 167768114 C T 9.21E-05 Hypertension (essential hypertension) WWC1 intron 22184326 rs6555802 chr5 167773074 A C 1.13E-05 Hypertension (essential hypertension) WWC1 intron 22184326 rs4976593 chr5 167777443 G A 3.75E-06 Hypertension (essential hypertension) WWC1 intron 22184326 rs2059090 chr5 167784624 G A 1.05E-04 Glycosylated haemoglobin levels WWC1 intron 17255346 rs2059090 chr5 167784624 G A 2.30E-05 Major depressive disorder WWC1 intron 19107115 rs998864 chr5 167785204 G T 2.70E-05 Urinary metabolites WWC1 intron 21572414 rs2161299 chr5 167809259 G A 6.25E-04 Smoking initiation WWC1 intron 24665060 rs10051783 chr5 167822652 C T 6.94E-06 Osteoarthritis WWC1 intron 22763110 rs6555807 chr5 167826166 A G 6.40E-06 Urinary metabolites WWC1 intron 21572414 rs6555807 chr5 167826166 A G 1.03E-05 Monocyte chemoattractant protein-1 WWC1 intron pha003071 rs11134510 chr5 167831555 C T 0.0000202 Panic disorder WWC1 intron 23149450 rs11134510 chr5 167831555 C T 2.02E-05 Serum tamsulosin hydrochloride concentration WWC1 intron 23151678 rs4976549 chr5 167831633 G T 0.0000196 Panic disorder WWC1 intron 23149450 rs4976549 chr5 167831633 G T 1.96E-05 Serum tamsulosin hydrochloride concentration WWC1 intron 23151678 rs1004940 chr5 167836641 G T 7.87E-05 Blood Pressure WWC1 intron pha003046 rs1965673 chr5 167838237 C G 0.000000491 Behcet's disease WWC1 intron 23041938 rs1465400 chr5 167838336 G C 0.00000158 Behcet's disease WWC1 intron 23041938 rs17070145 chr5 167845791 C T 4.00E-06 Memory performance WWC1 intron 17053149 rs4976609 chr5 167863844 G A 6.35E-04 Smoking cessation WWC1 intron 24665060 rs3733981 chr5 167868779 A G 1.23E-04 Acute lung injury WWC1 cds-synon 22295056 rs3733980 chr5 167868809 C T 1.59E-04 Acute lung injury WWC1 cds-synon 22295056 rs12514426 chr5 167893708 G A 9.30E-04 Alzheimer's disease (late onset) WWC1 intron 21460841 rs888775 chr5 167893913 T C 1.79E-17 Multiple complex diseases WWC1 intron 17554300 rs6894208 chr5 167903844 C A 8.94E-04 Multiple complex diseases / / 17554300 rs6876713 chr5 167907762 G A 1.56E-04 Myopia (pathological) / / 21095009 rs244899 chr5 167911040 C T 1.49E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs244900 chr5 167912022 G A 7.67E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs244903 chr5 167913510 G A 5.35E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines RARS missense 21844884 rs590784 chr5 167917504 C A 9.71E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines RARS intron 21844884 rs244898 chr5 167918926 T C 1.01E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines RARS intron 21844884 rs2432642 chr5 167921047 C G 4.43E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines RARS intron 21844884 rs2445785 chr5 167924928 C T 4.86E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines RARS intron 21844884 rs244889 chr5 167932109 C A 7.18E-04 Myopia (pathological) RARS intron 21095009 rs2305737 chr5 167946261 C A 1.00E-04 Cognitive impairment induced by topiramate RARS UTR-3 22091778 rs2432646 chr5 167946935 T C 6.36E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs35783321 chr5 167955301 C A 4.64E-04 Multiple complex diseases / / 17554300 rs244895 chr5 167959307 C G 9.63E-05 Multiple complex diseases / / 17554300 rs6555817 chr5 167964735 G A 9.58E-04 Type 2 diabetes / / 17463246 rs6555817 chr5 167964735 G A 4.22E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4976562 chr5 167965753 C T 1.75E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4976562 chr5 167965753 C T 8.95E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2446751 chr5 167972024 A G 3.14E-05 Multiple complex diseases / / 17554300 rs158900 chr5 167991954 A G 6.40E-04 Stroke PANK3 intron pha002887 rs158574 chr5 168025424 T C 2.52E-04 Type 2 diabetes / / 17463246 rs158574 chr5 168025424 T C 1.78E-04 Multiple complex diseases / / 17554300 rs158910 chr5 168033163 T G 3.21E-04 Myocardial Infarction / / pha002883 rs12519740 chr5 168066517 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1120242 chr5 168073355 T G 9.32E-04 Type 2 diabetes / / 17463246 rs4867894 chr5 168080275 G A 4.48E-04 Coronary heart disease / / 21971053 rs744544 chr5 168115732 T C 1.09E-06 Glycosylated haemoglobin levels SLIT3 intron 17255346 rs744544 chr5 168115732 T C 3.65E-05 Cognitive impairment induced by topiramate SLIT3 intron 22091778 rs11750308 chr5 168117393 G A 4.13E-04 Suicide attempts in bipolar disorder SLIT3 intron 21423239 rs11749992 chr5 168146549 C A 9.74E-04 Suicide attempts in bipolar disorder SLIT3 intron 21423239 rs17665285 chr5 168152309 G A 8.76E-04 Suicide attempts in bipolar disorder SLIT3 intron 21423239 rs12518165 chr5 168156158 T C 4.40E-05 Glycosylated haemoglobin levels SLIT3 intron 17255346 rs10462978 chr5 168170445 T C 1.80E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SLIT3 intron 23648065 rs11746188 chr5 168179549 A G 5.29E-04 Body mass index SLIT3 intron 21701565 rs11746188 chr5 168179549 A G 6.81E-04 Body mass index SLIT3 intron 21701565 rs10036727 chr5 168180081 C T 1.16E-04 Myopia (pathological) SLIT3 missense 21095009 rs1549909 chr5 168180670 C T 2.67E-04 Myopia (pathological) SLIT3 intron 21095009 rs6860854 chr5 168194176 C T 6.29E-04 Myopia (pathological) SLIT3 intron 21095009 rs13185422 chr5 168205202 G A 5.46E-04 Multiple complex diseases SLIT3 intron 17554300 rs13185422 chr5 168205202 G A 5.41E-05 Bipolar disorder SLIT3 intron 18317468 rs2163761 chr5 168211254 C T 6.04E-04 Response to taxane treatment (placlitaxel) SLIT3 intron 23006423 rs11134531 chr5 168212168 A G 2.58E-04 Suicide attempts in bipolar disorder SLIT3 intron 21041247 rs7728604 chr5 168220102 T C 2.06E-05 HIV-1 viral setpoint SLIT3 intron 17641165 rs7728604 chr5 168220102 T C 2.80E-05 HIV-1 control SLIT3 intron 20041166 rs4867939 chr5 168223681 T C 2.77E-04 Multiple complex diseases SLIT3 intron 17554300 rs4867939 chr5 168223681 T C 4.27E-04 HIV-1 viral setpoint SLIT3 intron 17641165 rs4867939 chr5 168223681 T C 3.60E-04 Suicide attempts in bipolar disorder SLIT3 intron 21041247 rs867477 chr5 168234991 C A 9.70E-05 Body mass index SLIT3 intron 20818722 rs9885206 chr5 168242544 T C 8.07E-05 Multiple complex diseases SLIT3 intron 17554300 rs905800 chr5 168244805 A C 1.24E-04 Multiple complex diseases SLIT3 intron 17554300 rs7726584 chr5 168254897 T G 1.29E-04 Multiple complex diseases SLIT3 intron 17554300 rs4282339 chr5 168256240 G A 7.00E-16 Height SLIT3 intron 20881960 rs1394618 chr5 168260216 C T 2.25E-04 Amyotrophic Lateral Sclerosis SLIT3 intron 17362836 rs2974428 chr5 168265244 C T 9.93E-04 Amyotrophic Lateral Sclerosis SLIT3 intron 17362836 rs7736650 chr5 168286590 T C 3.21E-04 Fibrinogen SLIT3 intron 17255346 rs2938769 chr5 168292739 C T 2.86E-05 Systemic sclerosis SLIT3 intron 21750679 rs13183458 chr5 168305161 C T 1.40E-04 Alzheimer's disease SLIT3 intron 17998437 rs13188090 chr5 168305571 G A 5.09E-04 Multiple complex diseases SLIT3 intron 17554300 rs6897408 chr5 168306155 C T 8.64E-04 Multiple complex diseases SLIT3 intron 17554300 rs11134544 chr5 168320056 G T 2.45E-04 Alzheimer's disease (late onset) SLIT3 intron 21379329 rs7714853 chr5 168323234 T C 5.25E-05 Cognitive impairment induced by topiramate SLIT3 intron 22091778 rs12658168 chr5 168357720 G A 8.59E-05 Tuberculosis SLIT3 intron 24057671 rs13166368 chr5 168368994 C A 1.43E-05 Magnesium levels SLIT3 intron pha003092 rs10078651 chr5 168378392 A C 3.92E-04 Multiple complex diseases SLIT3 intron 17554300 rs6555838 chr5 168381494 G A 3.41E-05 Body Mass Index SLIT3 intron pha003022 rs1432910 chr5 168391557 T C 3.00E-04 Myasthenia gravis SLIT3 intron 23055271 rs7708885 chr5 168395929 C T 9.82E-05 Schizophrenia SLIT3 intron 19571811 rs11739950 chr5 168414374 G A 6.40E-04 Type 2 diabetes SLIT3 intron 24509480 rs10045549 chr5 168435781 G A 8.79E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SLIT3 intron 20031582 rs17734396 chr5 168442027 G A 9.45E-05 Response to mTOR inhibitor (everolimus) SLIT3 intron 24009623 rs1432906 chr5 168446370 C T 6.83E-05 Body Mass Index SLIT3 intron pha003015 rs1432906 chr5 168446370 C T 5.51E-06 Body Mass Index SLIT3 intron pha003019 rs1432906 chr5 168446370 C T 2.15E-05 Body Mass Index SLIT3 intron pha003020 rs1432906 chr5 168446370 C T 4.06E-05 Body Mass Index SLIT3 intron pha003022 rs17734503 chr5 168466203 A G 4.80E-04 Body mass index SLIT3 intron 18325910 rs7717558 chr5 168469978 G T 8.82E-04 HIV-1 viral setpoint SLIT3 intron 17641165 rs17070766 chr5 168476787 C A 8.28E-04 Multiple complex diseases SLIT3 intron 17554300 rs12654448 chr5 168481771 C T 5.92E-04 Body mass index SLIT3 intron 18325910 rs10516057 chr5 168485970 T C 3.03E-04 Response to cytadine analogues (cytosine arabinoside) SLIT3 intron 24483146 rs10516057 chr5 168485970 T C 8.70E-04 Response to cytidine analogues (gemcitabine) SLIT3 intron 24483146 rs882015 chr5 168486293 G T 2.61E-05 Body Mass Index SLIT3 intron pha003022 rs882015 chr5 168486293 G T 6.99E-05 Cardiovascular disease SLIT3 intron pha003065 rs9284977 chr5 168488958 G A 9.97E-04 Response to cytidine analogues (gemcitabine) SLIT3 intron 24483146 rs9313443 chr5 168489198 A G 9.93E-04 Response to cytidine analogues (gemcitabine) SLIT3 intron 24483146 rs1469683 chr5 168489333 T C 2.65E-05 Body Mass Index SLIT3 intron pha003022 rs1469683 chr5 168489333 T C 6.99E-05 Cardiovascular disease SLIT3 intron pha003065 rs2668040 chr5 168508432 A G 4.90E-05 Cognitive test performance SLIT3 intron 20125193 rs7735612 chr5 168509732 T C 0.000511357 Hypertension (early onset hypertension) SLIT3 intron 22479346 rs296006 chr5 168514867 G A 6.03E-04 Alzheimer's disease SLIT3 intron 24755620 rs167194 chr5 168517022 A C 6.28E-04 Taste perception SLIT3 intron 22132133 rs10067964 chr5 168525690 C T 2.45E-04 Coronary heart disease SLIT3 intron 21606135 rs296001 chr5 168527047 G C 1.60E-05 Bilirubin levels,in serum SLIT3 intron 19389676 rs295994 chr5 168531488 C G 2.34E-04 Type 2 diabetes SLIT3 intron 17463246 rs295994 chr5 168531488 C G 2.41E-04 Multiple complex diseases SLIT3 intron 17554300 rs6863538 chr5 168543245 G A 6.92E-05 Information processing speed SLIT3 intron 21130836 rs188431 chr5 168555866 C A 3.61E-04 Response to cytadine analogues (cytosine arabinoside) SLIT3 intron 24483146 rs13176240 chr5 168582325 C T 6.40E-05 Diabetic retinopathy SLIT3 intron 21441570 rs297812 chr5 168583966 G A 8.16E-05 Cholesterol SLIT3 intron pha003083 rs12515725 chr5 168591300 C G 9.26E-04 Type 2 diabetes SLIT3 intron 17463246 rs7700961 chr5 168595437 C T 1.47E-05 Cholesterol SLIT3 intron pha003083 rs1006329 chr5 168599851 A G 6.94E-04 Myopia (pathological) SLIT3 intron 21095009 rs297884 chr5 168612835 C A 4.03E-05 Cholesterol SLIT3 intron pha003083 rs7733887 chr5 168618855 A G 2.13E-05 Hypertension (essential hypertension) SLIT3 intron 22184326 rs297838 chr5 168621773 G A 7.45E-05 Cleft lip SLIT3 intron 20436469 rs744579 chr5 168626241 T C 5.66E-05 Cleft lip SLIT3 intron 20436469 rs744579 chr5 168626241 T C 3.55E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SLIT3 intron 24023788 rs17735410 chr5 168627798 G A 8.71E-04 Multiple complex diseases SLIT3 intron 17554300 rs1345591 chr5 168630615 C T 1.00E-04 Cognitive impairment induced by topiramate SLIT3 intron 22091778 rs10059292 chr5 168637547 T C 4.06E-05 Cognitive impairment induced by topiramate SLIT3 intron 22091778 rs6859754 chr5 168649662 C T 7.55E-04 Multiple complex diseases SLIT3 intron 17554300 rs17735629 chr5 168653502 T C 5.03E-05 Obsessive-compulsive disorder SLIT3 intron 24821223 rs17735629 chr5 168653502 T C 5.03E-05 Obsessive-compulsive disorder SLIT3 intron 24821223 rs751348 chr5 168710623 C T 6.59E-04 Response to cytadine analogues (cytosine arabinoside) SLIT3 intron 24483146 rs17071071 chr5 168722859 A C 7.38E-04 Suicide attempts in bipolar disorder SLIT3 intron 21423239 rs6864818 chr5 168734867 T C 9.32E-05 Serum metabolites / / 19043545 rs1001869 chr5 168760826 C T 1.57E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs731398 chr5 168840498 T C 5.85E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs13177680 chr5 168847968 A C 7.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs6864076 chr5 168861603 A G 7.10E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6890239 chr5 168875288 T C 2.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs255742 chr5 168889900 C A 2.10E-05 Urinary metabolites / / 21572414 rs10440704 chr5 168893535 A C 2.10E-05 Urinary metabolites / / 21572414 rs7727768 chr5 168894112 C T 2.10E-05 Urinary metabolites / / 21572414 rs13156607 chr5 168899987 T C 5.00E-06 Waist circumference / / 20966902 rs2546700 chr5 168943227 C T 1.29E-04 Alzheimer's disease (late onset) / / 21379329 rs12654922 chr5 168948878 G A 2.54E-04 Alzheimer's disease (late onset) / / 21379329 rs17643975 chr5 168959888 G C 8.24E-04 Alzheimer's disease / / 17998437 rs255827 chr5 168970505 A C 9.54E-04 Type 2 diabetes / / 17846124 rs25748 chr5 169001157 C T 2.16E-04 Alzheimer's disease (late onset) / / 21379329 rs3797713 chr5 169028481 T C 2.66E-04 Alzheimer's disease (late onset) CCDC99 missense 21379329 rs169082 chr5 169074056 C T 1.00E-06 Protein quantitative trait loci DOCK2 intron 18464913 rs36101422 chr5 169080798 T C 1.42E-04 Multiple complex diseases DOCK2 intron 17554300 rs7713640 chr5 169099398 A G 1.57E-04 Multiple complex diseases DOCK2 intron 17554300 rs2112704 chr5 169126552 G A 8.54E-05 IgE levels DOCK2 intron 17255346 rs264843 chr5 169131080 G A 7.49E-04 Multiple complex diseases DOCK2 intron 17554300 rs262865 chr5 169162033 A G 9.79E-04 Multiple complex diseases DOCK2 intron 17554300 rs262851 chr5 169169196 A G 9.59E-04 Multiple complex diseases DOCK2 intron 17554300 rs10053930 chr5 169175917 G A 0.000824577 Hypertension (early onset hypertension) DOCK2 intron 22479346 rs17669636 chr5 169202770 A T 0.0000769 Nonsyndromic striae distensae (stretch marks) DOCK2 intron 23633020 rs966595 chr5 169203598 A G 7.42E-05 Serum metabolites DOCK2 intron 19043545 rs17669654 chr5 169204246 T C 0.000232807 Hypertension (early onset hypertension) DOCK2 intron 22479346 rs6879663 chr5 169206312 A C 9.63E-06 Ejection fraction in Tripanosoma cruzi seropositivity DOCK2 intron 24324551 rs261590 chr5 169226130 A C 3.65E-04 Smoking cessation DOCK2 intron 24665060 rs1114033 chr5 169235078 G A 1.52E-04 Fibrinogen DOCK2 intron 17255346 rs10065492 chr5 169244499 G A 8.56E-05 IgE levels DOCK2 intron 17255346 rs39823 chr5 169255406 C T 1.42E-04 Response to taxane treatment (placlitaxel) DOCK2 intron 23006423 rs168678 chr5 169270812 A G 9.12E-05 Multiple sclerosis (age of onset) DOCK2 intron 19010793 rs30079 chr5 169272610 C T 8.00E-05 Iris characteristics DOCK2 intron 21835309 rs30080 chr5 169273557 G C 4.70E-05 Bulimia nervosa DOCK2 intron 23568457 rs261038 chr5 169283210 G A 4.46E-04 Multiple complex diseases DOCK2 intron 17554300 rs261030 chr5 169290559 G A 2.30E-05 Urinary metabolites DOCK2 intron 21572414 rs261076 chr5 169304372 G A 4.13E-04 Myocardial Infarction DOCK2 intron pha002873 rs12515095 chr5 169305153 G A 6.33E-04 Multiple complex diseases DOCK2 intron 17554300 rs17071870 chr5 169341337 T C 2.23E-04 Suicide attempts in bipolar disorder DOCK2 intron 21423239 rs33373 chr5 169350967 T C 7.94E-06 White blood cell count DOCK2 intron 21738479 rs33374 chr5 169351134 T A 9.12E-06 White blood cell count DOCK2 intron 21738479 rs888712 chr5 169353757 T A 0.00024 Salmonella-induced pyroptosis DOCK2 intron 22837397 rs4867577 chr5 169355553 T C 0.0000981 Salmonella-induced pyroptosis DOCK2 intron 22837397 rs2624252 chr5 169356315 T A 0.000576 Salmonella-induced pyroptosis DOCK2 intron 22837397 rs2546507 chr5 169356831 C A 6.72E-04 Premature ovarian failure DOCK2 intron 19508998 rs2546507 chr5 169356831 C A 9.26E-04 Tourette syndrome DOCK2 intron 22889924 rs6896240 chr5 169356966 A G 0.000486 Salmonella-induced pyroptosis DOCK2 intron 22837397 rs259892 chr5 169357503 T G 1.10E-05 Asthma DOCK2 intron 11022011 rs194787 chr5 169359960 C T 9.20E-06 Response to antidepressants DOCK2 intron 19736353 rs13181166 chr5 169361187 C T 0.000266 Salmonella-induced pyroptosis DOCK2 intron 22837397 rs1363576 chr5 169400124 A G 1.00E-05 Height DOCK2 intron pha003010 rs2042237 chr5 169434978 T C 9.67E-05 Height DOCK2 intron pha003010 rs10065067 chr5 169439954 G A 9.60E-07 Urinary metabolites DOCK2 intron 21572414 rs6884677 chr5 169450011 C G 5.73E-06 Esophageal cancer (squamous cell) DOCK2 intron 22960999 rs6866324 chr5 169450290 T G 6.00E-05 Eosinophil counts DOCK2 intron pha003088 rs3763048 chr5 169461547 C T 9.00E-06 IgG glycosylation DOCK2 cds-synon 23382691 rs1316638 chr5 169477011 T C 2.66E-05 Alcohol dependence DOCK2 intron 21314694 rs1316638 chr5 169477011 T C 2.53E-05 Cognitive impairment induced by topiramate DOCK2 intron 22091778 rs1316638 chr5 169477011 T C 8.99E-05 Cognitive impairment induced by topiramate DOCK2 intron 22091778 rs6860533 chr5 169479360 T C 3.65E-06 Orofacial clefts DOCK2 intron 20023658 rs7700885 chr5 169480559 G A 5.24E-04 Suicide attempts in bipolar disorder DOCK2 intron 21423239 rs13361200 chr5 169481492 T C 2.98E-05 Asthma DOCK2 intron 11022011 rs17738710 chr5 169483512 T G 3.11E-04 Bipolar disorder,schizoaffective DOCK2 intron 19567891 rs10043114 chr5 169484033 C T 9.51E-04 Suicide attempts in bipolar disorder DOCK2 intron 21423239 rs11134604 chr5 169485351 C A 6.68E-04 Suicide attempts in bipolar disorder DOCK2 intron 21423239 rs7727777 chr5 169485851 C T 7.98E-04 Suicide attempts in bipolar disorder DOCK2 intron 21423239 rs7710251 chr5 169485975 T C 5.39E-04 Suicide attempts in bipolar disorder DOCK2 intron 21423239 rs7710410 chr5 169486087 T G 6.19E-04 Suicide attempts in bipolar disorder DOCK2 intron 21423239 rs10475540 chr5 169486419 C T 5.79E-04 Suicide attempts in bipolar disorder DOCK2 intron 21423239 rs10045458 chr5 169486815 G A 6.53E-04 Suicide attempts in bipolar disorder DOCK2 intron 21423239 rs9313490 chr5 169486826 G A 5.84E-04 Suicide attempts in bipolar disorder DOCK2 intron 21423239 rs10045492 chr5 169487107 C G,T 5.83E-04 Suicide attempts in bipolar disorder DOCK2 intron 21423239 rs17072047 chr5 169487658 C A 5.65E-04 Suicide attempts in bipolar disorder DOCK2 intron 21423239 rs12186383 chr5 169488319 C T 7.95E-04 Suicide attempts in bipolar disorder DOCK2 intron 21423239 rs17072052 chr5 169488637 G A 5.80E-04 Suicide attempts in bipolar disorder DOCK2 intron 21423239 rs17072057 chr5 169488822 G A 9.33E-04 Suicide attempts in bipolar disorder DOCK2 intron 21423239 rs10052633 chr5 169488903 C A 5.36E-04 Suicide attempts in bipolar disorder DOCK2 intron 21423239 rs10060672 chr5 169489027 T G 8.26E-04 Suicide attempts in bipolar disorder DOCK2 intron 21423239 rs10052906 chr5 169489145 G T 9.19E-04 Suicide attempts in bipolar disorder DOCK2 intron 21423239 rs7731058 chr5 169489667 T C 6.89E-04 Suicide attempts in bipolar disorder DOCK2 intron 21423239 rs7731587 chr5 169490007 T C 7.89E-04 Suicide attempts in bipolar disorder DOCK2 intron 21423239 rs7731587 chr5 169490007 T C 2.75E-04 Heart Failure DOCK2 intron pha002885 rs10516070 chr5 169512860 A C 5.80E-05 Personality dimensions / / 18957941 rs10516070 chr5 169512860 A C 2.96E-04 Schizophrenia / / 19197363 rs955078 chr5 169516283 A C 5.80E-05 Personality dimensions / / 18957941 rs1553299 chr5 169518034 T A 2.50E-05 Urinary metabolites / / 21572414 rs2879269 chr5 169534533 G A 1.70E-05 Urinary metabolites FOXI1 intron 21572414 rs10063424 chr5 169535522 T C 4.85E-04 Response to taxane treatment (placlitaxel) FOXI1 cds-synon 23006423 rs6555888 chr5 169536150 A G 4.67E-04 Response to taxane treatment (placlitaxel) FOXI1 UTR-3 23006423 rs4867917 chr5 169538188 A G 4.34E-04 Multiple complex diseases / / 17554300 rs4867917 chr5 169538188 A G 8.21E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4867918 chr5 169538372 G A 3.78E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs17647921 chr5 169538436 C T 2.20E-04 Type 2 diabetes / / 17463246 rs17647921 chr5 169538436 C T 2.90E-05 Urinary metabolites / / 21572414 rs1477320 chr5 169540204 A G 3.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12653012 chr5 169540547 G A 4.22E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs1895302 chr5 169542600 C T 7.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs78953487 chr5 169547573 C T 0.0000511 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11134612 chr5 169551236 G A 2.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4867922 chr5 169551625 C T 1.36E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs6861611 chr5 169563583 G A 2.60E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1422752 chr5 169565429 T C 3.08E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs1469066 chr5 169566044 C T 3.60E-04 Allergic sensitization / / 23817571 rs1035424 chr5 169583173 C T 9.00E-05 Blood Pressure / / pha003048 rs12651794 chr5 169594544 T C 8.84E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1363602 chr5 169606878 G A 3.55E-04 Rheumatoid arthritis / / 21452313 rs4077700 chr5 169610074 A G 8.74E-04 Rheumatoid arthritis / / 21452313 rs13153995 chr5 169624772 T C 9.38E-05 Rheumatoid arthritis / / 21452313 rs13153995 chr5 169624772 T C 3.00E-06 Acne (severe) / / 24927181 rs10447195 chr5 169627657 C A 1.80E-05 Urinary metabolites / / 21572414 rs10447197 chr5 169627842 T C 8.60E-06 Urinary metabolites / / 21572414 rs9313494 chr5 169628024 T A 8.90E-06 Urinary metabolites / / 21572414 rs10447198 chr5 169628099 C T 2.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs12189473 chr5 169628404 C A 4.40E-06 Urinary metabolites / / 21572414 rs6883745 chr5 169629171 T G 2.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs12513823 chr5 169629183 C T 2.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs4867946 chr5 169629225 A G 2.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs4867947 chr5 169629403 C A 8.39E-05 Rheumatoid arthritis / / 21452313 rs4867590 chr5 169631546 A C 9.60E-06 Urinary metabolites / / 21572414 rs4867591 chr5 169631604 A T 5.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs6889648 chr5 169632261 A G 1.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs12515639 chr5 169633156 T G 5.05E-05 Suicide attempts in bipolar disorder / / 21423239 rs1025003 chr5 169644845 A G 3.45E-04 Alzheimer's disease (late onset) / / 21379329 rs1025003 chr5 169644845 A G 5.42E-05 Height / / pha003010 rs6879880 chr5 169646064 T C 2.53E-04 Alzheimer's disease (late onset) / / 21379329 rs6879880 chr5 169646064 T C 5.55E-04 Lymphocyte counts / / 22286170 rs10475932 chr5 169647369 A G 1.50E-05 Urinary metabolites / / 21572414 rs957998 chr5 169661994 G A,C 8.30E-04 Multiple complex diseases C5orf58 missense 17554300 rs10068619 chr5 169717739 C T 1.09E-04 Type 2 diabetes LCP2 intron 17463246 rs10050695 chr5 169719672 T C 8.80E-04 Type 2 diabetes LCP2 intron 17463246 rs315782 chr5 169731198 G A 3.36E-05 IgE levels in asthmatics / / 23967269 rs4867956 chr5 169743612 C T 9.54E-05 Asthma / / 20159242 rs315805 chr5 169746734 C T 9.10E-04 Insulin resistance / / 21901158 rs41389446 chr5 169747593 G T 5.39E-09 Multiple complex diseases / / 17554300 rs315808 chr5 169750158 G T 6.26E-04 Insulin resistance / / 21901158 rs13170456 chr5 169755110 C T 3.34E-06 Personality dimensions / / 18957941 rs7725699 chr5 169765425 T C 3.99E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11742042 chr5 169773596 C G 5.72E-05 Bipolar disorder and schizophrenia / / 20889312 rs906361 chr5 169777274 C T 2.76E-05 Bipolar disorder and schizophrenia / / 20889312 rs906359 chr5 169777358 T C 5.23E-05 Bipolar disorder and schizophrenia / / 20889312 rs906358 chr5 169777436 C T 3.90E-05 Bipolar disorder and schizophrenia / / 20889312 rs12657389 chr5 169779216 C T 5.64E-04 Insulin resistance KCNMB1 nearGene-5 21901158 rs17648820 chr5 169782630 C A 9.72E-04 Type 2 diabetes KCNIP1 intron 17463246 rs905784 chr5 169788967 T C 7.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNIP1 intron 20877124 rs314155 chr5 169805123 A G 3.26E-04 Parkinson's disease KCNIP1 intron 17052657 rs827778 chr5 169816565 A G 4.82E-04 Amyotrophic Lateral Sclerosis KCNMB1 UTR-5 17362836 rs3860757 chr5 169822004 G C 8.19E-04 Type 2 diabetes KCNIP1 intron 17463246 rs314123 chr5 169822721 C T 4.98E-04 Multiple complex diseases KCNIP1 intron 17554300 rs10475543 chr5 169830319 A C 7.85E-04 Type 2 diabetes KCNIP1 intron 17463246 rs13175143 chr5 169843630 C T 7.58E-04 Substance dependence KCNIP1 intron 21818250 rs17649320 chr5 169846558 T C 4.97E-04 Alzheimer's disease KCNIP1 intron 24755620 rs115329309 chr5 169851043 C T 2.94E-05 Intracerebral hemorrhage KCNIP1 intron 24656865 rs17672572 chr5 169856439 C T 7.90E-04 Body mass index KCNIP1 intron 21701565 rs6872566 chr5 169872420 A G 8.71E-04 Depression (quantitative trait) KCNIP1 intron 20800221 rs6877607 chr5 169872995 A G 2.53E-04 Alzheimer's disease KCNIP1 intron 24755620 rs10076544 chr5 169910062 A G 8.45E-05 Erythrocyte counts KCNIP1 intron pha003099 rs888934 chr5 169923732 A G 2.11E-05 Colorectal cancer KCNIP1 intron 21242260 rs888934 chr5 169923732 A G 5.53E-05 IgE levels KCNIP1 intron 22075330 rs888936 chr5 169923903 C T 5.60E-05 Alcoholism (heaviness of drinking) KCNIP1 intron 21529783 rs13172157 chr5 169946867 T A 7.10E-05 Personality dimensions KCNIP1 intron 18957941 rs13182384 chr5 169948541 T C 2.82E-04 Age-related macular degeneration KCNIP1 intron 22125219 rs11957313 chr5 169950394 G A 9.00E-06 Normalized brain volume KCNIP1 intron 19010793 rs1862331 chr5 169955453 C T 6.57E-04 Multiple complex diseases KCNIP1 intron 17554300 rs13189171 chr5 169959403 G A 1.97E-04 Type 2 diabetes KCNIP1 intron 17463246 rs4867612 chr5 169994556 C T 6.41E-05 Orofacial clefts KCNIP1 intron 22419666 rs6892193 chr5 170007232 T C 5.09E-04 Multiple complex diseases KCNIP1 intron 17554300 rs11134638 chr5 170007503 A G 4.59E-04 Alcohol dependence KCNIP1 intron 20201924 rs10066905 chr5 170018185 C G 4.90E-04 Alzheimer's disease KCNIP1 intron 24755620 rs17072775 chr5 170037782 G A 2.10E-06 Urinary metabolites KCNIP1 intron 21572414 rs953601 chr5 170064713 C T 2.59E-06 Smoking cessation KCNIP1 intron 18519826 rs883848 chr5 170070942 G T 4.01E-04 Multiple complex diseases KCNIP1 intron 17554300 rs4867625 chr5 170088602 G A 1.22E-04 Smoking cessation KCNIP1 intron 18519826 rs11134643 chr5 170098380 A G 5.27E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines KCNIP1 intron 21844884 rs4868011 chr5 170099077 A C 0.00082 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines KCNIP1 intron 23204130 rs2292147 chr5 170105647 C G 4.35E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines KCNIP1 intron 21844884 rs872436 chr5 170126075 G A 1.20E-04 Smoking cessation KCNIP1 intron 18519826 rs984559 chr5 170138659 G A 6.76E-05 Smoking cessation KCNIP1 intron 18519826 rs329476 chr5 170140188 G A 3.61E-04 Multiple complex diseases KCNIP1 intron 17554300 rs1541665 chr5 170142917 C T 5.60E-05 Attention deficit hyperactivity disorder KCNIP1 intron 18980221 rs2277951 chr5 170149554 T C 4.04E-04 Depression (quantitative trait) KCNIP1 intron 20800221 rs11134647 chr5 170157819 T A 7.42E-04 Depression (quantitative trait) KCNIP1 intron 20800221 rs4867628 chr5 170159072 T C 5.37E-04 Depression (quantitative trait) KCNIP1 intron 20800221 rs1363713 chr5 170163094 G T 6.12E-06 Smoking cessation KCNIP1 UTR-3 18519826 rs1363714 chr5 170163908 A G 7.65E-04 Depression (quantitative trait) KCNIP1 nearGene-3 20800221 rs17673653 chr5 170166594 A T 9.07E-05 Attention deficit hyperactivity disorder / / pha002875 rs4867629 chr5 170167013 C A 3.93E-04 Depression (quantitative trait) / / 20800221 rs1363715 chr5 170167974 G A 7.04E-04 Depression (quantitative trait) / / 20800221 rs1544762 chr5 170171271 T G 2.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs4642385 chr5 170173510 G A 3.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs17673687 chr5 170174699 C A 4.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs17746614 chr5 170174830 G A 4.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs7705420 chr5 170174859 T A 8.60E-05 Suicide attempts in bipolar disorder / / 21423239 rs2042314 chr5 170177580 C T 8.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs7701794 chr5 170178139 C T 7.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs4868023 chr5 170198563 A G 3.64E-04 Gallstones / / 17632509 rs41382746 chr5 170215441 C T 4.11E-04 Coronary Artery Disease GABRP intron 17634449 rs11134654 chr5 170240423 A C 2.00E-07 Smooth-surface caries GABRP UTR-3 23470693 rs3805455 chr5 170240494 T C 7.60E-06 Heart Failure GABRP UTR-3 pha002884 rs1422160 chr5 170243433 A G 1.40E-04 Heart Failure / / pha002884 rs1363281 chr5 170247298 G A 7.88E-05 Heart Failure / / pha002884 rs1808374 chr5 170253981 C T 4.00E-04 Alcohol dependence / / 20201924 rs1808374 chr5 170253981 C T 7.50E-04 Alcohol dependence / / 20201924 rs7737600 chr5 170286530 T C 9.67E-05 Multiple complex diseases / / 17554300 rs2339170 chr5 170313644 A G 2.47E-04 Multiple complex diseases RANBP17 intron 17554300 rs9637852 chr5 170318866 A G 1.27E-04 Multiple complex diseases RANBP17 intron 17554300 rs10044718 chr5 170321959 G C 5.41E-04 Multiple complex diseases RANBP17 intron 17554300 rs1422156 chr5 170334100 T C 1.40E-04 Multiple complex diseases RANBP17 intron 17554300 rs918420 chr5 170335722 C T 1.19E-04 Multiple complex diseases RANBP17 intron 17554300 rs1833597 chr5 170342120 T C 1.75E-04 Multiple complex diseases RANBP17 intron 17554300 rs2339174 chr5 170342632 G A 1.86E-04 Multiple complex diseases RANBP17 intron 17554300 rs10062666 chr5 170364929 C G 1.20E-04 Multiple complex diseases RANBP17 intron 17554300 rs7701805 chr5 170369601 T C 4.95E-06 Alcohol and nictotine co-dependence RANBP17 intron 20158304 rs930890 chr5 170380153 T A 2.42E-04 Multiple complex diseases RANBP17 intron 17554300 rs3860763 chr5 170397896 G A 9.55E-05 Multiple complex diseases RANBP17 intron 17554300 rs3849714 chr5 170398243 A G 1.66E-04 Multiple complex diseases RANBP17 intron 17554300 rs4868053 chr5 170400826 C T 2.07E-04 Multiple complex diseases RANBP17 intron 17554300 rs1457695 chr5 170401291 T A 9.68E-05 Multiple complex diseases RANBP17 intron 17554300 rs10055216 chr5 170408566 A G 2.16E-04 Multiple complex diseases RANBP17 intron 17554300 rs12716267 chr5 170423534 C T 8.94E-05 Multiple complex diseases RANBP17 intron 17554300 rs11134675 chr5 170449872 C G 1.07E-04 Multiple complex diseases RANBP17 intron 17554300 rs4242161 chr5 170458381 T C 1.52E-04 Multiple complex diseases RANBP17 intron 17554300 rs1902791 chr5 170466712 G A 2.19E-04 Multiple complex diseases RANBP17 intron 17554300 rs245749 chr5 170483093 A G 1.08E-04 Multiple complex diseases RANBP17 intron 17554300 rs779663 chr5 170504514 C T 1.70E-04 Multiple complex diseases RANBP17 intron 17554300 rs968039 chr5 170510416 T C 1.50E-04 Multiple complex diseases RANBP17 intron 17554300 rs17073355 chr5 170536837 T G 1.01E-05 Amyotrophic lateral sclerosis (sporadic) RANBP17 intron 24529757 rs29650 chr5 170547130 C T 2.06E-04 Multiple complex diseases RANBP17 intron 17554300 rs1445799 chr5 170600023 T C 4.88E-04 Multiple complex diseases RANBP17 intron 17554300 rs6890394 chr5 170617859 C A 1.17E-04 Multiple complex diseases RANBP17 intron 17554300 rs10074614 chr5 170637472 T C 3.08E-04 Multiple complex diseases RANBP17 intron 17554300 rs957778 chr5 170692954 T C 3.85E-05 Paget's disease RANBP17 intron 20436471 rs2914341 chr5 170703078 A G 4.12E-05 Paget's disease RANBP17 intron 20436471 rs10516081 chr5 170712531 C T 2.15E-05 Paget's disease RANBP17 intron 20436471 rs2964519 chr5 170714609 C A 7.23E-06 Heart Failure RANBP17 intron pha002884 rs2278255 chr5 170720733 C G 5.00E-06 Visceral fat RANBP17 intron 22589738 rs6555942 chr5 170772645 A G 7.13E-04 Multiple complex diseases / / 17554300 rs7707008 chr5 170801952 C T 7.52E-04 Common variable immunodeficiency / / 21497890 rs4302608 chr5 170840504 A G 8.31E-05 Hemoglobin / / pha003096 rs4076077 chr5 170863509 C T 4.68E-04 Multiple complex diseases FGF18 intron 17554300 rs9313548 chr5 170961300 C T 0.00000062 Dyslexia / / 23190410 rs9790986 chr5 170973103 C G 5.32E-04 Depression (quantitative trait) / / 20800221 rs1864993 chr5 170983223 A G 2.58E-05 Height / / pha003011 rs1030676 chr5 170999070 C T 7.82E-05 Height / / pha003011 rs891978 chr5 171009471 C T 9.84E-06 Height / / pha003010 rs891978 chr5 171009471 C T 3.71E-06 Height / / pha003011 rs11134705 chr5 171009918 A G 1.63E-05 Height / / pha003010 rs11134705 chr5 171009918 A G 5.94E-06 Height / / pha003011 rs6892884 chr5 171015623 T C 4.00E-08 Height / / 20881960 rs11950887 chr5 171016954 A G 1.68E-05 Height / / pha003010 rs11950887 chr5 171016954 A G 6.42E-06 Height / / pha003011 rs154367 chr5 171020891 T C 8.19E-06 Height / / pha003010 rs154367 chr5 171020891 T C 3.12E-06 Height / / pha003011 rs1654162 chr5 171048254 T C 2.90E-05 Telomere length / / 23001564 rs254870 chr5 171068259 A G 1.33E-04 Premature ovarian failure / / 19508998 rs254893 chr5 171076227 G A 6.00E-06 Quantitative traits / / 19197348 rs257352 chr5 171081906 C A 7.88E-04 Premature ovarian failure / / 19508998 rs26408 chr5 171093383 C A 3.72E-04 Premature ovarian failure / / 19508998 rs26413 chr5 171098125 C T 9.50E-06 Urinary metabolites / / 21572414 rs26413 chr5 171098125 C T 5.71E-05 Body Composition / / pha003012 rs26413 chr5 171098125 C T 3.67E-05 Body Mass Index / / pha003019 rs26413 chr5 171098125 C T 1.77E-07 Body Mass Index / / pha003020 rs33376 chr5 171101726 G A 3.02E-05 Body Mass Index / / pha003020 rs7729995 chr5 171115557 T G 3.43E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2339325 chr5 171119140 G A 2.42E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10055794 chr5 171121911 A G 0.0000893 5-fluorouracil induced haematologic in response to colorectal cancer treatment / / 22310351 rs6555969 chr5 171128464 T C 1.17E-09 Primary biliary cirrhosis / / 23000144 rs6555969 chr5 171128464 T C 1.17E-09 Facial morphology / / 23028347 rs254907 chr5 171131700 A G 3.18E-04 Multiple complex diseases C5orf50 intron 17554300 rs11747135 chr5 171146441 G A 8.99E-05 Multiple complex diseases C5orf50 intron 17554300 rs33830 chr5 171148170 T A 5.49E-04 Multiple complex diseases C5orf50 intron 17554300 rs10516088 chr5 171150423 C T 5.57E-04 Response to taxane treatment (placlitaxel) C5orf50 intron 23006423 rs10516089 chr5 171151231 T C 4.00E-09 Venous thromboembolism (gene x gene interaction) C5orf50 intron 23509962 rs4868109 chr5 171160537 C A 5.60E-04 Multiple complex diseases C5orf50 intron 17554300 rs4868110 chr5 171164168 A T 6.10E-04 Multiple complex diseases C5orf50 intron 17554300 rs3933807 chr5 171166173 G A 4.04E-05 Smoking initiation C5orf50 intron 24665060 rs33863 chr5 171166685 G A 6.78E-04 Multiple complex diseases C5orf50 intron 17554300 rs12658131 chr5 171168572 T C 5.51E-05 Multiple complex diseases C5orf50 intron 17554300 rs153750 chr5 171181237 T G 3.00E-10 Height C5orf50 intron 23563607 rs33855 chr5 171192037 G A 6.20E-05 Kidney function and endocine traits C5orf50 intron 17903292 rs17653609 chr5 171201195 T C 2.50E-05 Urinary metabolites C5orf50 intron 21572414 rs12153391 chr5 171203438 C A 4.00E-12 Height C5orf50 intron 20881960 rs12153391 chr5 171203438 C A 8.13E-06 Uric acid levels C5orf50 intron 21294900 rs6869153 chr5 171204055 C T 7.44E-04 Myopia (pathological) C5orf50 intron 21095009 rs6874056 chr5 171204415 G A 8.35E-04 Myopia (pathological) C5orf50 intron 21095009 rs6874056 chr5 171204415 G A 1.10E-06 Urinary metabolites C5orf50 intron 21572414 rs7718767 chr5 171218138 G A 1.11E-04 Telomere length C5orf50 intron 21573004 rs181906 chr5 171218516 C A 1.80E-05 Urinary metabolites C5orf50 intron 21572414 rs181906 chr5 171218516 C A 5.74E-05 Smoking initiation C5orf50 intron 24665060 rs838574 chr5 171218901 T A 7.87E-04 Multiple complex diseases C5orf50 intron 17554300 rs6898156 chr5 171262268 C T 2.06E-04 Multiple complex diseases / / 17554300 rs6891834 chr5 171268203 C T 2.39E-05 F-cell distribution / / 21326311 rs1368380 chr5 171285632 C T 4.11E-05 Suicidal ideation / / 20877300 rs10475992 chr5 171335293 C T 3.00E-09 Height FBXW11 intron 23563607 rs839273 chr5 171350313 A G 2.30E-04 Statin-induced myopathy FBXW11 intron 21826682 rs10040841 chr5 171362662 C T 7.17E-04 Response to taxane treatment (placlitaxel) FBXW11 intron 23006423 rs10475994 chr5 171373215 C T 7.17E-04 Response to taxane treatment (placlitaxel) FBXW11 intron 23006423 rs6892217 chr5 171474120 C T 0.0000781 post-traumatic stress disorder STK10 intron 22869035 rs6892217 chr5 171474120 C T 7.81E-05 Schizophrenia STK10 intron 22883433 rs4075705 chr5 171480733 A C 1.60E-05 Urinary metabolites STK10 intron 21572414 rs4073700 chr5 171481296 T C 1.90E-05 Urinary metabolites STK10 intron 21572414 rs4868141 chr5 171523436 G A 2.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) STK10 cds-synon 20877124 rs2279515 chr5 171553833 T C 3.60E-04 Type 2 diabetes STK10 intron 17463246 rs17570583 chr5 171559531 G A 9.00E-06 Migraine - clinic-based STK10 intron 23793025 rs10223190 chr5 171579380 T C 3.91E-04 Response to taxane treatment (placlitaxel) STK10 intron 23006423 rs11134732 chr5 171584982 A T 6.37E-04 Type 2 diabetes STK10 intron 17463246 rs11134732 chr5 171584982 A T 9.94E-05 Multiple complex diseases STK10 intron 17554300 rs6555999 chr5 171586242 A G 6.37E-04 Type 2 diabetes STK10 intron 17463246 rs6555999 chr5 171586242 A G 1.09E-04 Multiple complex diseases STK10 intron 17554300 rs3797327 chr5 171597452 G A 1.69E-05 Cholesterol STK10 intron pha003073 rs3797327 chr5 171597452 G A 2.53E-05 Cholesterol STK10 intron pha003078 rs9313584 chr5 171617824 G T 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17074413 chr5 171626110 T C 3.25E-04 Response to cytadine analogues (cytosine arabinoside) EFCAB9 intron 24483146 rs6890087 chr5 171631769 C T 3.19E-05 Femoral neck bone geometry / / 22087292 rs17701158 chr5 171638165 T C 1.75E-04 Cholesterol UBTD2 UTR-3 17255346 rs17074475 chr5 171649347 T A 7.63E-04 Multiple complex diseases UBTD2 intron 17554300 rs41495146 chr5 171653121 T G 6.37E-04 Multiple complex diseases UBTD2 intron 17554300 rs13165241 chr5 171656546 T C 8.91E-05 Cholesterol UBTD2 intron 17255346 rs12659926 chr5 171658346 A G 9.22E-04 Multiple complex diseases UBTD2 intron 17554300 rs4560562 chr5 171733971 C T 9.73E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2339423 chr5 171753739 C T 7.63E-05 Coronary heart disease / / pha003030 rs4868163 chr5 171772583 G A 1.23E-05 Lung adenocarcinoma SH3PXD2B intron 19836008 rs6556014 chr5 171781974 G T 6.87E-04 Suicide attempts in bipolar disorder SH3PXD2B intron 21423239 rs10053291 chr5 171782884 C G 6.07E-04 Suicide attempts in bipolar disorder SH3PXD2B intron 21423239 rs17703000 chr5 171785702 A G 6.14E-04 Suicide attempts in bipolar disorder SH3PXD2B intron 21423239 rs13182040 chr5 171786861 G T 9.75E-05 Aging (time to event) SH3PXD2B intron 21782286 rs2569208 chr5 171800383 T C 9.04E-05 Longevity SH3PXD2B intron 20304771 rs2247647 chr5 171817044 C T 7.67E-05 Longevity SH3PXD2B intron 20304771 rs2116811 chr5 171820052 C T 5.50E-04 Suicide attempts in bipolar disorder SH3PXD2B intron 21423239 rs13356223 chr5 171821671 T C 5.91E-05 Body mass index SH3PXD2B intron 18325910 rs7713684 chr5 171840079 T C 9.86E-04 Suicide attempts in bipolar disorder SH3PXD2B intron 21423239 rs10077897 chr5 171840387 G A 1.39E-04 Body mass index SH3PXD2B intron 18325910 rs13436547 chr5 171840725 G A 4.27E-04 Body mass index SH3PXD2B intron 18325910 rs2569235 chr5 171897090 C T 4.77E-04 Parkinson's disease / / 17052657 rs11958604 chr5 171909024 C A 5.60E-05 Fibrinogen / / pha003068 rs4868171 chr5 171910504 G A 4.00E-04 Alzheimer's disease / / 22005930 rs4868172 chr5 171915319 C T 4.68E-04 Alzheimer's disease / / 22005930 rs4868175 chr5 171915910 T C 4.62E-04 Alzheimer's disease / / 22005930 rs4868176 chr5 171917008 A G 6.40E-04 Alzheimer's disease / / 22005930 rs6898730 chr5 171922102 C T 4.79E-04 Type 2 diabetes / / 17463246 rs6898730 chr5 171922102 C T 3.78E-04 Smoking initiation / / 24665060 rs11745118 chr5 171922637 A G 2.27E-04 Type 2 diabetes / / 17463246 rs11738223 chr5 171934492 A G 3.49E-04 Type 2 diabetes / / 17463246 rs6865962 chr5 171948268 C T 2.08E-04 Smoking initiation / / 24665060 rs11741273 chr5 171952135 T C 2.08E-04 Lung function (forced vital capacity) / / 24023788 rs1433021 chr5 171960073 C T 2.88E-05 Lung function (forced vital capacity) / / 24023788 rs1433021 chr5 171960073 C T 4.92E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1347155 chr5 171969348 C T 1.98E-07 Statin-induced myopathy / / 21826682 rs1541918 chr5 171971486 C A 1.10E-06 Alcoholism (heaviness of drinking) / / 21529783 rs1433019 chr5 171984913 A C 3.09E-06 Schizophrenia / / 21926974 rs7734791 chr5 171991419 A G 1.50E-05 Urinary metabolites / / 21572414 rs17655343 chr5 171991967 C A 1.50E-05 Urinary metabolites / / 21572414 rs17074917 chr5 171993320 A G 3.60E-04 Multiple complex diseases / / 17554300 rs10476042 chr5 172003564 A G 3.12E-04 Rheumatoid arthritis / / 21452313 rs10063826 chr5 172004039 G A 1.97E-04 Self-reported allergy / / 23817569 rs10043108 chr5 172007756 G A 0.000818 Salmonella-induced pyroptosis / / 22837397 rs874709 chr5 172022097 A C 4.06E-04 Parkinson's disease / / 17052657 rs931802 chr5 172031249 A G 9.63E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs931803 chr5 172031468 A G 3.42E-04 Alzheimer's disease / / 17998437 rs931804 chr5 172034100 T C 3.99E-04 Coronary Artery Disease / / 17634449 rs949845 chr5 172050910 G T 5.78E-05 Caffeine consumption / / 21490707 rs7703578 chr5 172083279 G A 1.60E-05 Urinary metabolites NEURL1B intron 21572414 rs10039225 chr5 172084050 T C 9.26E-04 Type 2 diabetes NEURL1B intron 17463246 rs10065159 chr5 172095867 T C 9.76E-04 Multiple complex diseases NEURL1B intron 17554300 rs10065159 chr5 172095867 T C 6.40E-06 Urinary metabolites NEURL1B intron 21572414 rs6875344 chr5 172098744 T C 1.50E-05 Urinary metabolites NEURL1B intron 21572414 rs12659021 chr5 172128357 A G 6.61E-04 Multiple complex diseases / / 17554300 rs324332 chr5 172130774 C T 2.96E-04 Multiple complex diseases / / 17554300 rs172860 chr5 172138212 A G 2.11E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs172860 chr5 172138212 A G 2.97E-05 Smoking cessation / / 24665060 rs324338 chr5 172139506 T C 1.40E-04 Smoking cessation / / 24665060 rs12657303 chr5 172142551 C A 1.17E-04 Smoking cessation / / 24665060 rs792690 chr5 172143121 A G 4.02E-04 Smoking cessation / / 24665060 rs11739319 chr5 172148934 C T 5.40E-06 Urinary metabolites / / 21572414 rs4867686 chr5 172150990 G A 2.30E-05 Urinary metabolites / / 21572414 rs2618346 chr5 172151081 A C,G,T 1.88E-04 Type 2 diabetes / / 17463246 rs2618345 chr5 172151289 C T 2.05E-04 Type 2 diabetes / / 17463246 rs322359 chr5 172188213 G A 1.00E-04 Information processing speed / / 21130836 rs2431664 chr5 172203911 G A 1.50E-05 Educational attainment / / 21694764 rs2246477 chr5 172208454 A G 7.27E-06 Educational attainment / / 21694764 rs10057387 chr5 172230003 T C 4.49E-05 Educational attainment / / 21694764 rs17075237 chr5 172246071 G A 4.66E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs792978 chr5 172269595 C T 1.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) ERGIC1 intron 23648065 rs792975 chr5 172271007 A G 5.36E-04 Multiple complex diseases ERGIC1 intron 17554300 rs792975 chr5 172271007 A G 8.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) ERGIC1 intron 23648065 rs792969 chr5 172272207 T C 9.94E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) ERGIC1 intron 23648065 rs792968 chr5 172272552 G A 2.44E-04 Multiple complex diseases ERGIC1 intron 17554300 rs710109 chr5 172272571 G A 1.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) ERGIC1 intron 23648065 rs710109 chr5 172272571 G A 6.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ERGIC1 intron 23648065 rs792965 chr5 172275263 G A 5.16E-06 Recombination rate ERGIC1 intron 21698098 rs13155834 chr5 172283930 A G 9.25E-05 Personality dimensions ERGIC1 intron 18957941 rs13155834 chr5 172283930 A G 1.20E-04 Celiac disease ERGIC1 intron 23936387 rs793017 chr5 172286508 G A 5.95E-04 Longevity ERGIC1 intron 22279548 rs13176814 chr5 172291249 A G 6.39E-04 Alcohol dependence ERGIC1 intron 20201924 rs6890783 chr5 172292306 G A 5.00E-06 Periodontitis (CDC/AAP) ERGIC1 intron 24024966 rs6881530 chr5 172309853 A C 3.28E-04 Coronary Artery Disease ERGIC1 intron 17634449 rs564349 chr5 172324978 G A 1.60E-15 Leukemia(T-cell recognition in patients) ERGIC1 intron 21062987 rs485710 chr5 172350638 A G 2.61E-04 Amyotrophic Lateral Sclerosis ERGIC1 intron 17827064 rs2339745 chr5 172360034 G A 7.90E-16 Progranulin levels ERGIC1 intron 21087763 rs2339745 chr5 172360034 G A 7.90E-16 Myocardial infarction ERGIC1 intron 21211798 rs544421 chr5 172376178 A G 4.96E-04 Alzheimer's disease ERGIC1 intron 24755620 rs544421 chr5 172376178 A G 5.62E-05 Blood Pressure ERGIC1 intron pha003040 rs544421 chr5 172376178 A G 9.97E-05 Blood Pressure ERGIC1 intron pha003047 rs2305896 chr5 172382902 G A 6.54E-04 Alzheimer's disease LOC100268168 intron 24755620 rs6865010 chr5 172454998 G T 6.17E-05 Smoking initiation ATP6V0E1 intron 24665060 rs13165855 chr5 172474355 C T 3.80E-10 Infantile hypertrophic pyloric stenosis / / 22306654 rs251253 chr5 172480336 C T 9.00E-13 PR interval / / 20062060 rs251253 chr5 172480336 C T 6.00E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs29778 chr5 172481089 C T 6.01E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs29777 chr5 172481414 G C 2.68E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs29776 chr5 172481818 G C 8.10E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs435216 chr5 172492592 C T 8.95E-11 Infantile hypertrophic pyloric stenosis CREBRF intron 22306654 rs412673 chr5 172494872 G A 1.10E-10 Infantile hypertrophic pyloric stenosis CREBRF intron 22306654 rs171644 chr5 172499339 C T 2.60E-07 Infantile hypertrophic pyloric stenosis CREBRF intron 22306654 rs3095843 chr5 172501829 G A 8.79E-11 Infantile hypertrophic pyloric stenosis CREBRF intron 22306654 rs13153580 chr5 172512089 G A 8.91E-11 Infantile hypertrophic pyloric stenosis CREBRF intron 22306654 rs251230 chr5 172526570 G A 3.32E-09 Infantile hypertrophic pyloric stenosis CREBRF intron 22306654 rs623576 chr5 172527466 C T 9.86E-11 Infantile hypertrophic pyloric stenosis CREBRF intron 22306654 rs400858 chr5 172529008 C T 9.87E-11 Infantile hypertrophic pyloric stenosis CREBRF intron 22306654 rs40264 chr5 172540512 C T 1.18E-12 Infantile hypertrophic pyloric stenosis CREBRF intron 22306654 rs3095847 chr5 172557985 C T 1.04E-10 Infantile hypertrophic pyloric stenosis CREBRF intron 22306654 rs17730451 chr5 172566698 G A 0.0000753 Menopause (age at onset) / / 23424626 rs2544580 chr5 172569015 A T 1.07E-10 Infantile hypertrophic pyloric stenosis / / 22306654 rs255307 chr5 172570405 C T 2.33E-09 Infantile hypertrophic pyloric stenosis / / 22306654 rs255305 chr5 172572600 G A 3.84E-09 Infantile hypertrophic pyloric stenosis BNIP1 intron 22306654 rs29796 chr5 172576236 G A 1.55E-10 Infantile hypertrophic pyloric stenosis BNIP1 intron 22306654 rs29794 chr5 172577769 T A 3.74E-09 Infantile hypertrophic pyloric stenosis BNIP1 intron 22306654 rs255291 chr5 172580291 C T 1.57E-10 Infantile hypertrophic pyloric stenosis BNIP1 intron 22306654 rs255294 chr5 172582720 T C 3.65E-09 Infantile hypertrophic pyloric stenosis BNIP1 intron 22306654 rs255295 chr5 172583068 C T 1.55E-10 Infantile hypertrophic pyloric stenosis BNIP1 intron 22306654 rs255300 chr5 172586338 G A 1.56E-10 Infantile hypertrophic pyloric stenosis BNIP1 intron 22306654 rs255302 chr5 172587274 G T 1.56E-10 Infantile hypertrophic pyloric stenosis BNIP1 intron 22306654 rs28199 chr5 172592132 A G 3.78E-09 Infantile hypertrophic pyloric stenosis / / 22306654 rs29785 chr5 172595203 A G 1.69E-10 Infantile hypertrophic pyloric stenosis / / 22306654 rs29784 chr5 172595308 C T 1.00E-15 Infantile hypertrophic pyloric stenosis / / 22306654 rs29784 chr5 172595308 C T 8.00E-18 Infantile hypertrophic pyloric stenosis / / 23989729 rs39796 chr5 172595861 T C 3.60E-15 Infantile hypertrophic pyloric stenosis / / 22306654 rs34803014 chr5 172599878 A C 6.24E-10 Infantile hypertrophic pyloric stenosis / / 22306654 rs1819985 chr5 172600749 C T 5.98E-10 Infantile hypertrophic pyloric stenosis / / 22306654 rs255312 chr5 172604541 C T 5.70E-10 Infantile hypertrophic pyloric stenosis / / 22306654 rs173877 chr5 172605854 C T 3.99E-10 Infantile hypertrophic pyloric stenosis / / 22306654 rs255309 chr5 172605949 G A 3.73E-10 Infantile hypertrophic pyloric stenosis / / 22306654 rs29783 chr5 172606818 C T 8.94E-09 Infantile hypertrophic pyloric stenosis / / 22306654 rs29782 chr5 172608204 T C 2.76E-10 Infantile hypertrophic pyloric stenosis / / 22306654 rs255308 chr5 172609227 T C 1.10E-10 Infantile hypertrophic pyloric stenosis / / 22306654 rs166240 chr5 172611318 C T 1.62E-10 Infantile hypertrophic pyloric stenosis / / 22306654 rs255313 chr5 172611648 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs255315 chr5 172613028 C T 1.70E-10 Infantile hypertrophic pyloric stenosis / / 22306654 rs255316 chr5 172613415 G A 9.75E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs194255 chr5 172613785 C T 4.47E-09 Infantile hypertrophic pyloric stenosis / / 22306654 rs255322 chr5 172619063 G A 1.18E-10 Infantile hypertrophic pyloric stenosis / / 22306654 rs255323 chr5 172619274 A T 7.80E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs255324 chr5 172619345 G A 1.17E-10 Infantile hypertrophic pyloric stenosis / / 22306654 rs255325 chr5 172619432 C G 7.75E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs2879599 chr5 172620700 T G 7.60E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs10516096 chr5 172621424 C T 5.16E-04 Multiple complex diseases / / 17554300 rs7701353 chr5 172624482 A C 9.72E-09 Infantile hypertrophic pyloric stenosis / / 22306654 rs875235 chr5 172625555 A C 5.94E-10 Infantile hypertrophic pyloric stenosis / / 22306654 rs111320503 chr5 172625966 T C 5.98E-11 Infantile hypertrophic pyloric stenosis / / 22306654 rs13160268 chr5 172626051 C T 1.05E-09 Infantile hypertrophic pyloric stenosis / / 22306654 rs4868241 chr5 172632400 C T 5.98E-11 Infantile hypertrophic pyloric stenosis / / 22306654 rs888690 chr5 172636130 T C 7.16E-11 Infantile hypertrophic pyloric stenosis / / 22306654 rs7733318 chr5 172636398 A G 7.11E-11 Infantile hypertrophic pyloric stenosis / / 22306654 rs6891174 chr5 172640590 A G 7.81E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs9688157 chr5 172640902 G A 5.45E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs55884259 chr5 172642370 G A 4.67E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs4868242 chr5 172642750 A C 4.63E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs9313619 chr5 172644265 C T 1.96E-05 Multiple complex diseases / / 17554300 rs9313619 chr5 172644265 C T 5.20E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs7356620 chr5 172644520 A G 3.70E-09 Infantile hypertrophic pyloric stenosis / / 22306654 rs7356622 chr5 172644619 C T 5.28E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs7356623 chr5 172644630 C T 5.30E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs7356624 chr5 172644654 C G 5.31E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs4995713 chr5 172644886 C G 5.41E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs4410656 chr5 172645095 A G 5.48E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs7448948 chr5 172645164 T C 4.85E-09 Infantile hypertrophic pyloric stenosis / / 22306654 rs6860312 chr5 172645473 T C 5.59E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs6860510 chr5 172645586 T A 5.58E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs6556059 chr5 172645766 T C 7.95E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs6556060 chr5 172645946 T A 1.18E-11 Infantile hypertrophic pyloric stenosis / / 22306654 rs71579714 chr5 172645946 TT TAAA,TTTT 1.18E-11 Infantile hypertrophic pyloric stenosis / / 22306654 rs373799938 chr5 172645947 T TAAA 2.02E-09 Infantile hypertrophic pyloric stenosis / / 22306654 rs6556061 chr5 172645947 T A 2.02E-09 Infantile hypertrophic pyloric stenosis / / 22306654 rs6556062 chr5 172646003 C T 7.89E-12 Infantile hypertrophic pyloric stenosis / / 22306654 rs7712882 chr5 172647851 T G 1.35E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs954637 chr5 172648002 A G 1.06E-11 Infantile hypertrophic pyloric stenosis / / 22306654 rs2216553 chr5 172650524 C T 1.58E-11 Infantile hypertrophic pyloric stenosis / / 22306654 rs13176674 chr5 172651996 G C 1.14E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs1965668 chr5 172653401 G C 1.13E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs10475588 chr5 172654747 T C 3.74E-08 Triglycerides / / 23063622 rs3132138 chr5 172655663 T G 6.03E-09 Infantile hypertrophic pyloric stenosis / / 22306654 rs3132139 chr5 172655733 A G 1.08E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs3095873 chr5 172655963 A C 6.36E-09 Infantile hypertrophic pyloric stenosis / / 22306654 rs3095872 chr5 172656191 T C 1.47E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs3132140 chr5 172656217 A G 1.46E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs3131917 chr5 172657021 T G 1.52E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs3131916 chr5 172657155 A G 1.50E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs2339832 chr5 172658139 C A 1.29E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs6882776 chr5 172664163 G A 1.46E-06 PR duration NKX2-5 nearGene-5 23583979 rs6882776 chr5 172664163 G A 2.00E-12 Heart rate NKX2-5 nearGene-5 23583979 rs6882776 chr5 172664163 G A 2.27E-05 QT duration NKX2-5 nearGene-5 23583979 rs6882776 chr5 172664163 G A 4.41E-08 Atrial fibrillation NKX2-5 nearGene-5 23583979 rs6884881 chr5 172673319 T C 4.28E-08 Infantile hypertrophic pyloric stenosis / / 22306654 rs6874428 chr5 172674877 G C 1.30E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs6884962 chr5 172682382 G A 7.31E-05 HIV(mother-to-child transmission) / / 20487506 rs4868246 chr5 172682953 A G 2.88E-05 Eosinophil counts / / pha003088 rs876579 chr5 172685288 G A 9.82E-05 Eosinophil counts / / pha003088 rs9313625 chr5 172690224 A C 4.20E-06 Phospholipid levels (plasma) / / 21829377 rs1559052 chr5 172692327 T C 6.05E-04 Insulin resistance / / 21901158 rs3132148 chr5 172700938 A G 1.26E-04 Fibrinogen / / 17255346 rs11134782 chr5 172702998 C T 4.69E-04 Multiple complex diseases / / 17554300 rs11134782 chr5 172702998 C T 9.53E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17675810 chr5 172724274 G C 4.70E-04 Type 2 diabetes / / 17463246 rs17675810 chr5 172724274 G C 3.04E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4242166 chr5 172726334 A G 6.62E-04 Smoking initiation / / 24665060 rs17075777 chr5 172732127 G A 7.12E-04 Type 2 diabetes / / 17463246 rs4868257 chr5 172749522 C T 8.48E-05 Attention deficit hyperactivity disorder STC2 intron 22420046 rs895312 chr5 172764398 G T 8.82E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1862428 chr5 172784614 C T 7.20E-05 Parkinson's disease (age of onset) / / 19772629 rs17075826 chr5 172791437 T G 9.83E-05 Personality dimensions / / 18957941 rs6892138 chr5 172793659 G A 1.40E-04 Coronary Artery Disease / / 17634449 rs4868270 chr5 172827954 C A 2.90E-04 Response to alcohol consumption (flushing response) / / 24277619 rs10866664 chr5 172839237 A G 4.86E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1445787 chr5 172852878 T C 7.90E-05 Parkinson's disease (age of onset) / / 19772629 rs13178402 chr5 172860292 A G 3.97E-05 Nonalcoholic fatty liver disease / / 21423719 rs6878606 chr5 172864110 A G 2.87E-04 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs17735046 chr5 172869675 C T 2.40E-06 Urinary metabolites / / 21572414 rs11744776 chr5 172881712 T C 2.60E-06 Urinary metabolites / / 21572414 rs17075979 chr5 172892026 A T 1.30E-05 Urinary metabolites / / 21572414 rs17075980 chr5 172892328 C T 8.40E-05 Body mass index / / 20818722 rs17075980 chr5 172892328 C T 1.60E-05 Urinary metabolites / / 21572414 rs4867713 chr5 172899502 T C 6.60E-06 Urinary metabolites / / 21572414 rs7722022 chr5 172934898 C A 9.00E-06 Adiponectin levels / / 19165155 rs6869841 chr5 172939426 C T 5.00E-08 Prostate cancer / / 23535732 rs4867716 chr5 172965383 G C 2.50E-05 Urinary metabolites / / 21572414 rs17076079 chr5 172966152 T G 5.63E-77 Multiple complex diseases / / 17554300 rs10045354 chr5 172966778 C A,G 2.60E-05 Urinary metabolites / / 21572414 rs11744306 chr5 172967460 A G 2.50E-04 Alzheimer's disease (late onset) / / 21379329 rs12520258 chr5 172980714 A G 2.90E-05 Urinary metabolites / / 21572414 rs6885032 chr5 172983279 G C 1.20E-05 Urinary metabolites / / 21572414 rs9313636 chr5 172983353 C T 1.50E-05 Urinary metabolites / / 21572414 rs9313636 chr5 172983353 C T 9.71E-06 Pancreatic cancer / / 22158540 rs889014 chr5 172984114 C T 9.00E-16 Height / / 20881960 rs889014 chr5 172984114 C T 1.20E-05 Urinary metabolites / / 21572414 rs11747139 chr5 172994744 T C 2.60E-05 Urinary metabolites / / 21572414 rs12520643 chr5 172994912 T A 1.80E-05 Urinary metabolites / / 21572414 rs12517954 chr5 172995003 G A 1.10E-05 Urinary metabolites / / 21572414 rs12517986 chr5 172995160 G A 6.60E-06 Urinary metabolites / / 21572414 rs7704555 chr5 173000002 T C 8.72E-04 Type 2 diabetes / / 17463246 rs7704555 chr5 173000002 T C 5.90E-06 Urinary metabolites / / 21572414 rs2339962 chr5 173003224 G A 1.86E-04 Type 2 diabetes / / 17463246 rs10077254 chr5 173006447 C T 5.58E-04 Alcohol dependence / / 24277619 rs12152984 chr5 173007836 T C 5.63E-04 Type 2 diabetes LOC285593 intron 17463246 rs746214 chr5 173011115 C T 2.38E-04 Birth weight / / 17255346 rs746215 chr5 173011353 T C 9.05E-04 Alcohol dependence / / 24277619 rs1363605 chr5 173017087 C T 6.80E-05 Alcohol dependence / / 21956439 rs384187 chr5 173019003 G C 9.53E-04 Multiple complex diseases / / 17554300 rs13174811 chr5 173030080 C T 1.64E-04 Smoking initiation / / 24665060 rs258873 chr5 173045602 T G 3.90E-05 Creatinine levels / / 20222955 rs258873 chr5 173045602 T G 3.83E-04 Common variable immunodeficiency / / 21497890 rs7738022 chr5 173085912 A G 1.74E-04 Multiple complex diseases / / 17554300 rs791645 chr5 173103337 G T 2.10E-05 Urinary metabolites / / 21572414 rs791643 chr5 173104555 A G 1.30E-05 Urinary metabolites / / 21572414 rs2546725 chr5 173129604 T G 9.20E-04 Alzheimer's disease / / 17998437 rs2561054 chr5 173132198 A G 4.65E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs749408 chr5 173136182 A G 4.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs791628 chr5 173136387 G C 8.11E-04 Multiple complex diseases / / 17554300 rs874445 chr5 173136650 C A,G,T 8.15E-06 Serum metabolites / / 19043545 rs874445 chr5 173136650 C A,G,T 6.03E-05 Bipolar disorder / / 19488044 rs812064 chr5 173138928 G A 1.45E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs812064 chr5 173138928 G A 5.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12651740 chr5 173143912 C T 9.75E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs12651740 chr5 173143912 C T 4.49E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2339989 chr5 173146043 T C 3.62E-04 Taste perception / / 22132133 rs2339990 chr5 173146525 G A 1.58E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs6888150 chr5 173148985 C A 3.00E-04 Rheumatoid arthritis / / 21452313 rs10039804 chr5 173149670 C T 9.83E-04 Type 2 diabetes / / 17463246 rs10039804 chr5 173149670 C T 6.88E-04 Rheumatoid arthritis / / 21452313 rs6869795 chr5 173151171 C T 6.22E-04 Taste perception / / 22132133 rs6860531 chr5 173159426 T C 7.77E-05 Serum metabolites / / 19043545 rs10071956 chr5 173160684 T C 5.92E-05 Diabetes (gestational) / / 22233651 rs4868311 chr5 173165659 T C 5.08E-05 Diabetes (gestational) / / 22233651 rs9313650 chr5 173173816 G A 5.83E-04 Multiple complex diseases / / 17554300 rs17076407 chr5 173180696 G A 5.74E-04 Multiple complex diseases / / 17554300 rs2122003 chr5 173183362 C T 2.21E-05 Major depressive disorder / / 22472876 rs4867728 chr5 173194882 G A 1.08E-04 IgE levels / / 17255346 rs4867728 chr5 173194882 G A 2.00E-05 Urinary metabolites / / 21572414 rs16821 chr5 173207311 A G 7.32E-05 Fibrinogen / / 17255346 rs791365 chr5 173214249 C T 3.44E-04 Fibrinogen / / 17255346 rs3849719 chr5 173248856 T C 0.000308773 Primary sclerosing cholangitis / / 23603763 rs17076598 chr5 173273313 A G 8.54E-05 Serum metabolites / / 19043545 rs359457 chr5 173279842 C T 3.00E-12 Crohn's disease / / 21102463 rs165533 chr5 173292977 C A 6.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs359439 chr5 173297899 T C 4.96E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs359440 chr5 173298462 G T 6.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs359467 chr5 173316729 G A 1.27E-05 Dengue shock syndrome CPEB4 UTR-5 22001756 rs2594867 chr5 173334792 G A 2.13E-05 Dengue shock syndrome CPEB4 intron 22001756 rs17695092 chr5 173337853 T G 5.00E-09 Crohn's disease CPEB4 intron 23128233 rs17695328 chr5 173345409 G T 7.24E-04 Multiple complex diseases CPEB4 intron 17554300 rs359419 chr5 173346651 T C 2.00E-04 Obesity (extreme) CPEB4 intron 21935397 rs1106693 chr5 173352763 G A 2.06E-04 Obesity (extreme) CPEB4 intron 21935397 rs1106693 chr5 173352763 G A 2.00E-06 Obesity-related traits CPEB4 intron 23251661 rs17076706 chr5 173354286 T C 1.80E-05 Urinary metabolites CPEB4 intron 21572414 rs17763373 chr5 173359331 A G 7.00E-06 Prion diseases CPEB4 intron 22210626 rs6556096 chr5 173362457 T C 5.40E-04 Obesity (extreme) CPEB4 intron 21935397 rs6861681 chr5 173362458 G A 2.00E-09 Waist-hip ratio CPEB4 intron 20935629 rs11739436 chr5 173363925 G C 2.45E-04 Obesity (extreme) CPEB4 intron 21935397 rs1564823 chr5 173383194 C A 1.23E-08 Lymphocyte counts CPEB4 UTR-3 22286170 rs2170951 chr5 173389733 A C 2.19E-04 Obesity (extreme) / / 21935397 rs6875935 chr5 173390382 C T 4.11E-06 Dengue shock syndrome / / 22001756 rs7726709 chr5 173412816 A G 8.31E-04 Multiple complex diseases / / 17554300 rs6891369 chr5 173504716 T C 3.02E-04 Smoking initiation HMP19 intron 24665060 rs7715876 chr5 173526714 T A 8.43E-04 Multiple complex diseases HMP19 intron 17554300 rs4355538 chr5 173535087 C T 2.03E-04 Multiple complex diseases / / 17554300 rs10062755 chr5 173538531 C T 6.31E-04 Smoking initiation / / 24665060 rs1368276 chr5 173558600 T C 4.05E-04 Type 2 diabetes / / 17463246 rs11738844 chr5 173563868 G A 3.80E-05 Coffee consumption / / 21357676 rs7726844 chr5 173567955 G C 1.55E-04 Type 2 diabetes / / 17463246 rs7732052 chr5 173569104 A G 3.50E-04 Type 2 diabetes / / 17463246 rs6556114 chr5 173571677 G A 4.51E-04 Type 2 diabetes / / 17463246 rs10516111 chr5 173592360 A G 6.63E-05 Coronary heart disease / / pha003032 rs7730528 chr5 173592587 T C 6.63E-05 Coronary heart disease / / pha003032 rs871503 chr5 173601704 C T 5.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs871503 chr5 173601704 C T 3.50E-04 Amyotrophic lateral sclerosis / / 23624525 rs6556120 chr5 173616699 G A 8.43E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6863418 chr5 173625154 T C 7.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs6897549 chr5 173632898 G C 1.48E-06 Malignant pleural mesothelioma / / 23626673 rs4295404 chr5 173647712 C T 5.99E-06 Information processing speed / / 21130836 rs10475598 chr5 173648438 T C 8.00E-07 Information processing speed / / 21130836 rs17077053 chr5 173667026 G A 7.67E-04 Multiple complex diseases / / 17554300 rs17711587 chr5 173670147 G C 6.00E-04 Alzheimer's disease / / 17998437 rs11952171 chr5 173695778 A G 7.00E-06 Subcutaneous adipose tissue / / 22589738 rs10516115 chr5 173711503 A G 7.00E-06 Primary sclerosing cholangitis / / 19944697 rs10516115 chr5 173711503 A G 4.10E-06 Lipid traits / / 21777205 rs7715861 chr5 173711537 C T 3.32E-10 Multiple complex diseases / / 17554300 rs1909704 chr5 173711892 T C 6.62E-04 Multiple complex diseases / / 17554300 rs11952522 chr5 173713787 C T 0.0000396 Breast cancer early age of onset / / 18463975 rs2964073 chr5 173728091 T C 4.02E-04 Acute lung injury / / 22295056 rs10058766 chr5 173750017 A C 3.29E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2913472 chr5 173753469 C A 2.89E-05 Diabetes (gestational) / / 22233651 rs2913474 chr5 173753932 C A 9.04E-04 Multiple complex diseases / / 17554300 rs2913474 chr5 173753932 C A 4.00E-04 Coronary Artery Disease / / 17634449 rs17077348 chr5 173766430 G A 8.52E-04 Multiple complex diseases / / 17554300 rs12659144 chr5 173777520 T C 3.00E-06 Multiple myeloma (hyperdiploidy) / / 23502783 rs962880 chr5 173791376 T G 1.42E-04 Lung function (forced vital capacity) / / 24023788 rs2964117 chr5 173798385 G A 3.82E-04 Multiple complex diseases / / 17554300 rs2936953 chr5 173806074 T G 2.60E-05 Cortisol secretion,in saliva / / 21316860 rs2964037 chr5 173813348 G A 5.82E-04 Aortic root size / / 21223598 rs1427958 chr5 173819523 T G 6.47E-04 Schizophrenia / / 21674006 rs1427958 chr5 173819523 T G 6.10E-05 Coronary heart disease / / pha003030 rs4868395 chr5 173824597 T C 6.52E-05 Acute lung injury / / 22295056 rs2936940 chr5 173827151 A G 9.69E-05 Insulin-related traits / / pha003063 rs6876769 chr5 173828150 T C 7.48E-05 Acute lung injury / / 22295056 rs1427959 chr5 173828955 C T 7.48E-05 Acute lung injury / / 22295056 rs1421642 chr5 173829195 C T 7.54E-05 Acute lung injury / / 22295056 rs2964049 chr5 173830622 A G 9.47E-04 Acute lung injury / / 22295056 rs2913510 chr5 173832343 G A 9.48E-04 Acute lung injury / / 22295056 rs11134839 chr5 173832889 C T 3.03E-04 Acute lung injury / / 22295056 rs4867763 chr5 173835016 C T 1.84E-05 Insulin-related traits / / pha003063 rs4868397 chr5 173835118 C T 2.22E-04 Multiple complex diseases / / 17554300 rs7721965 chr5 173838067 G T 1.67E-04 Acute lung injury / / 22295056 rs12517028 chr5 173838801 C T 1.69E-04 Acute lung injury / / 22295056 rs718927 chr5 173839160 G A 5.71E-05 Cortisol secretion,in saliva / / 21316860 rs10866675 chr5 173842200 A G 1.34E-04 Acute lung injury / / 22295056 rs17778961 chr5 173846587 G C 2.64E-04 Acute lung injury / / 22295056 rs6556132 chr5 173848018 G A 1.08E-04 Acute lung injury / / 22295056 rs888643 chr5 173853273 T C 1.63E-05 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia / / 24039173 rs2909705 chr5 173854793 A G 8.86E-04 Multiple complex diseases / / 17554300 rs2964057 chr5 173854937 G A 5.59E-04 Hepatocellular carcinoma / / 22807686 rs1007775 chr5 173923890 G A,C,T 5.04E-04 Smoking initiation / / 24665060 rs10045904 chr5 173934069 C T 3.92E-04 Multiple complex diseases / / 17554300 rs1490046 chr5 173956047 G A 2.87E-05 Attention deficit hyperactivity disorder / / 22420046 rs2242419 chr5 173959332 A G 3.38E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11134853 chr5 173970989 T G 6.99E-05 Psoriasis / / 20953190 rs923520 chr5 173975145 T C 5.72E-04 Longevity / / 22279548 rs6556142 chr5 173975601 G A 8.09E-05 Psoriasis / / 20953190 rs13164416 chr5 173978606 C T 2.14E-04 Heart Failure / / pha002885 rs11134855 chr5 173978707 C A 3.97E-05 Psoriasis / / 20953190 rs11134855 chr5 173978707 C A 2.86E-06 Post-operative nausea and vomiting / / 21694509 rs11134856 chr5 173981106 G A 4.05E-04 Multiple complex diseases / / 17554300 rs4868424 chr5 173986118 G A 4.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1844516 chr5 173989235 G C 8.31E-04 Prostate cancer mortality / / 20978177 rs17726502 chr5 173991947 T A 5.69E-04 Type 2 diabetes / / 22158537 rs7718690 chr5 174000936 C A,T 2.74E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10057145 chr5 174013325 C T 7.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs145848414 chr5 174014114 G A 7.00E-08 Alzheimer's disease (late onset) / / 23571587 rs12515393 chr5 174025065 A G 4.78E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4868432 chr5 174032728 C T 9.91E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12186684 chr5 174036190 C T 2.90E-04 Smoking cessation / / 24665060 rs1812351 chr5 174038537 G T 2.08E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7723988 chr5 174069193 G A 8.12E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7710278 chr5 174069458 T G 8.29E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6888000 chr5 174074955 G C 2.90E-05 Urinary metabolites / / 21572414 rs11744357 chr5 174076669 C T 1.50E-05 Urinary metabolites / / 21572414 rs7701069 chr5 174105199 C T 4.00E-05 Bladder cancer / / 19648920 rs17796183 chr5 174120131 C T 6.02E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs17063876 chr5 174136429 A G 3.53E-06 Gallstones / / 17632509 rs4242182 chr5 174156168 T C 4.11E-05 Orofacial clefts MSX2 missense 22863734 rs4242182 chr5 174156168 T C 2.24E-04 Lung function (forced vital capacity) MSX2 missense 24023788 rs7705461 chr5 174186729 T G 7.86E-05 Blood Pressure / / pha003046 rs6895879 chr5 174204603 A G 2.43E-04 Acute lung injury / / 22295056 rs6556160 chr5 174204662 C T 6.33E-04 Acute lung injury / / 22295056 rs6881715 chr5 174210982 T C 7.88E-04 Acute lung injury / / 22295056 rs12660057 chr5 174223234 G A 4.07E-04 Acute lung injury / / 22295056 rs10077488 chr5 174242478 T C 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs4072263 chr5 174247434 G A 8.25E-05 Cognitive impairment induced by topiramate / / 22091778 rs6871270 chr5 174249930 G A 9.49E-04 Acute lung injury / / 22295056 rs7726244 chr5 174250895 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6882780 chr5 174274989 C T 1.60E-07 Urinary metabolites / / 21572414 rs10060014 chr5 174297799 G A 9.17E-05 Acute lung injury / / 22295056 rs376592 chr5 174299696 T A 8.51E-05 Acute lung injury / / 22295056 rs396585 chr5 174302292 G A 9.86E-05 Acute lung injury / / 22295056 rs12520919 chr5 174309210 C T 7.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9313699 chr5 174315293 A G 8.00E-05 Age-related macular degeneration / / 20861866 rs255627 chr5 174330780 T C 9.58E-04 Acute lung injury / / 22295056 rs10044660 chr5 174363946 A G 1.20E-04 Lung function (forced expiratory volume in 1 second) FLJ16171 intron 24023788 rs2042158 chr5 174364087 A G 2.31E-04 Lung function (forced expiratory volume in 1 second) FLJ16171 intron 24023788 rs11956577 chr5 174368402 G A 2.26E-04 Lung function (forced expiratory volume in 1 second) FLJ16171 intron 24023788 rs13189951 chr5 174370845 G A 3.78E-05 Basophils FLJ16171 intron pha003087 rs17064145 chr5 174375709 C A 8.04E-05 Alcohol dependence FLJ16171 intron 21703634 rs4868468 chr5 174379564 G A 4.10E-04 Alcohol dependence FLJ16171 intron 20201924 rs1421780 chr5 174402671 G A 5.00E-05 Suicidal ideation FLJ16171 intron 22030708 rs10516123 chr5 174428848 T C 1.14E-04 IgE levels / / 17255346 rs12522449 chr5 174443233 T C 9.73E-04 Type 2 diabetes / / 17463246 rs12522449 chr5 174443233 T C 2.30E-05 Urinary metabolites / / 21572414 rs12522449 chr5 174443233 T C 7.34E-05 Elbow pain / / pha003008 rs1566890 chr5 174474862 A G 1.51E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10516126 chr5 174481433 A G 9.54E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6894193 chr5 174489788 G T 3.97E-04 HIV-1 viral setpoint / / 17641165 rs6885304 chr5 174503805 G T 4.67E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs949637 chr5 174515327 C T 2.69E-05 Arthritis (juvenile idiopathic) / / 22354554 rs41475055 chr5 174518045 T C 5.04E-05 Multiple complex diseases / / 17554300 rs12519623 chr5 174537664 C T 6.65E-05 Hypertension / / 19609347 rs6556186 chr5 174545693 G A 5.96E-04 Smoking initiation / / 24665060 rs1587859 chr5 174567871 C A 3.56E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6889467 chr5 174577240 G T 4.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4868487 chr5 174586309 G T 5.26E-04 Smoking initiation / / 24665060 rs11134913 chr5 174588311 G A 6.10E-04 Smoking initiation / / 24665060 rs10213884 chr5 174594583 T C 0.000279 Breast cancer early age of onset / / 18463975 rs11956268 chr5 174605024 T C 1.31E-04 Myocardial Infarction / / pha002873 rs4336372 chr5 174611340 T C 1.00E-06 Response to anti-TNF treatment in rheumatoid arthritis / / 23555300 rs4336372 chr5 174611340 T C 2.91E-06 Response to anti-TNF treatment in rheumatoid arthritis / / 23555300 rs4336372 chr5 174611340 T C 3.00E-06 Response to anti-TNF treatment in rheumatoid arthritis / / 23555300 rs4336372 chr5 174611340 T C 8.10E-07 Response to anti-TNF treatment in rheumatoid arthritis / / 23555300 rs2381986 chr5 174615289 G C 3.68E-04 Type 2 diabetes / / 17463246 rs17064682 chr5 174619797 C T 1.87E-04 Cholesterol / / 17255346 rs4868506 chr5 174638216 A G 7.22E-05 Waist Circumference / / pha003023 rs17064692 chr5 174640738 A C 9.40E-05 Parkinson's disease (familial) / / 18985386 rs1345732 chr5 174646985 G A 7.21E-04 Body mass index / / 21701565 rs1345731 chr5 174647080 C G 4.12E-04 Body mass index / / 21701565 rs1345731 chr5 174647080 C G 8.57E-04 Body mass index / / 21701565 rs6556195 chr5 174648663 T C 7.05E-04 Body mass index / / 21701565 rs7703919 chr5 174649467 C T 2.80E-05 Urinary metabolites / / 21572414 rs10516128 chr5 174672156 T C 3.91E-05 Bipolar disorder / / 17486107 rs10516128 chr5 174672156 T C 2.54E-04 Myocardial Infarction / / pha002883 rs12656156 chr5 174684808 A G 6.42E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs11959983 chr5 174706213 A G 3.37E-04 Multiple complex diseases / / 17554300 rs1902602 chr5 174743514 G T 4.80E-04 Parkinson's disease / / 17052657 rs12652255 chr5 174761095 C A 8.00E-06 Treatment response for severe sepsis / / 22310353 rs10069450 chr5 174768846 G A 4.73E-04 Multiple complex diseases / / 17554300 rs17064931 chr5 174774285 A G 6.70E-04 Asperger disorder / / 21182207 rs1379274 chr5 174777584 G A 6.36E-04 Multiple complex diseases / / 17554300 rs1379274 chr5 174777584 G A 2.66E-04 Fasting insulin (interaction) / / 24204828 rs1379274 chr5 174777584 G A 2.99E-04 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs251925 chr5 174782119 T C 5.00E-06 Obesity-related traits / / 23251661 rs703745 chr5 174794364 G A 2.59E-04 Coronary heart disease / / 21606135 rs2431135 chr5 174809308 G T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7445117 chr5 174810090 C T 0.0000169 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7341045 chr5 174831696 A T 7.46E-04 Multiple complex diseases / / 17554300 rs6873756 chr5 174832789 C T 4.44E-04 Depression (quantitative trait) / / 20800221 rs265983 chr5 174835117 A T 2.88E-04 Type 2 diabetes / / 17463246 rs6893554 chr5 174845001 T A 2.60E-05 Urinary metabolites / / 21572414 rs265992 chr5 174846655 C A 1.20E-06 Left ventricular hypertrophy / / 21828061 rs2644640 chr5 174855411 C T 9.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs265973 chr5 174860699 T C 1.96E-04 Premature ovarian failure / / 19508998 rs835540 chr5 174863891 T C 3.46E-04 Alzheimer's disease (late onset) / / 21379329 rs686 chr5 174868700 G A 1.00E-04 Personality dimensions DRD1 UTR-3 23903073 rs5326 chr5 174870196 C T 2.49E-05 Neuroblastoma DRD1 UTR-5 pha002895 rs6882300 chr5 174876427 A T 0.0000663 Type 2 diabetes / / 22325160 rs1039089 chr5 174892501 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1022042 chr5 174896699 G T 2.40E-05 Urinary metabolites / / 21572414 rs2644648 chr5 174898012 T C 6.14E-05 Type 2 diabetes / / 17463246 rs6861032 chr5 174901052 A G 2.29E-05 Asthma / / 20159242 rs12658801 chr5 174910619 A G 2.24E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SFXN1 intron 24023788 rs267377 chr5 174917424 T C 4.91E-04 Multiple complex diseases SFXN1 intron 17554300 rs267382 chr5 174918392 G A 9.73E-06 Schizophrenia SFXN1 intron 24253340 rs925197 chr5 174939214 C T 3.90E-07 Urinary metabolites SFXN1 intron 21572414 rs925197 chr5 174939214 C T 1.07E-04 Progressive supranuclear palsy SFXN1 intron 21685912 rs157474 chr5 174948557 A G 8.73E-04 Prostate cancer mortality SFXN1 intron 20978177 rs157476 chr5 174949873 A G 1.70E-06 Urinary metabolites SFXN1 intron 21572414 rs166641 chr5 174955572 A T 7.42E-04 Multiple complex diseases SFXN1 UTR-3 17554300 rs166641 chr5 174955572 A T 1.10E-06 Urinary metabolites SFXN1 UTR-3 21572414 rs273078 chr5 174955584 C T 1.10E-06 Urinary metabolites SFXN1 UTR-3 21572414 rs267399 chr5 174956467 A G 3.50E-06 Urinary metabolites / / 21572414 rs267398 chr5 174958276 T C 1.60E-06 Urinary metabolites / / 21572414 rs267397 chr5 174958552 T A 1.10E-06 Urinary metabolites / / 21572414 rs2662176 chr5 174965974 G T 6.52E-04 Multiple complex diseases / / 17554300 rs10476160 chr5 174974576 A G 9.00E-09 Venous thromboembolism (gene x gene interaction) / / 23509962 rs2936711 chr5 175007610 G A 9.05E-07 Carotenoid and tocopherol levels / / 19185284 rs882978 chr5 175012009 C G 9.09E-04 Multiple complex diseases / / 17554300 rs867339 chr5 175012488 C A 0.000837161 Hypertension (early onset hypertension) / / 22479346 rs6861000 chr5 175025995 G A 2.04E-06 Rheumatoid arthritis / / 19503088 rs2913217 chr5 175030363 C T 7.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs890707 chr5 175055515 A G 5.71E-05 Heart Rate / / pha003053 rs879185 chr5 175056547 C T 5.26E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs17572757 chr5 175059713 T C 3.09E-05 Cognitive test performance / / 20125193 rs2937445 chr5 175066771 C T 7.44E-05 Information processing speed / / 21130836 rs645574 chr5 175107463 T C 6.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HRH2 intron 20877124 rs678591 chr5 175113038 G T 6.40E-04 Kawasaki disease HRH2 UTR-3 21326860 rs632994 chr5 175120898 A G 0.000702341 Hypertension (early onset hypertension) / / 22479346 rs17601481 chr5 175123151 G A 2.95E-04 Kawasaki disease / / 21326860 rs17065340 chr5 175127280 G A 6.56E-04 Multiple complex diseases / / 17554300 rs718907 chr5 175143632 C A 3.78E-04 Alcohol dependence / / 20201924 rs6893002 chr5 175154654 C T 5.85E-04 Multiple complex diseases / / 17554300 rs10039217 chr5 175178875 A G 3.00E-07 Obesity-related traits / / 23251661 rs2084763 chr5 175206596 G A 0.000456 Salmonella-induced pyroptosis / / 22837397 rs2434237 chr5 175224905 C A 2.50E-17 Progranulin levels CPLX2 intron 21087763 rs2434237 chr5 175224905 C A 2.50E-17 Myocardial infarction CPLX2 intron 21211798 rs11744346 chr5 175240207 A G 0.000326 Salmonella-induced pyroptosis CPLX2 intron 22837397 rs17065522 chr5 175242385 C T 6.82E-05 Post-operative nausea and vomiting CPLX2 intron 21694509 rs7448069 chr5 175244034 C T 1.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) CPLX2 intron 23527680 rs2382123 chr5 175244408 G A 4.73E-04 Type 2 diabetes CPLX2 intron 17463246 rs55914911 chr5 175244437 A G 1.00E-06 Age-related nuclear cataracts CPLX2 intron 24951543 rs17065524 chr5 175245365 A C 5.61E-05 Post-operative nausea and vomiting CPLX2 intron 21694509 rs1863931 chr5 175256526 G A 4.23E-04 Suicide attempts in bipolar disorder CPLX2 intron 21041247 rs10061059 chr5 175261050 G A 3.89E-04 Suicide attempts in bipolar disorder CPLX2 intron 21041247 rs6887241 chr5 175261076 A G 4.23E-04 Type 2 diabetes CPLX2 intron 17463246 rs999065 chr5 175274468 C A 6.77E-04 Type 2 diabetes CPLX2 intron 17463246 rs871853 chr5 175282310 G T 2.40E-04 Type 2 diabetes and 6 quantitative traits CPLX2 intron 17848626 rs871853 chr5 175282310 G T 3.33E-05 Serum metabolites CPLX2 intron 19043545 rs1560033 chr5 175286271 C A 8.79E-05 Triglycerides CPLX2 intron pha003080 rs4867809 chr5 175308022 A G 1.33E-05 Triglycerides CPLX2 UTR-3 pha003080 rs2114968 chr5 175313487 T C 5.86E-06 Triglycerides / / pha003080 rs4868543 chr5 175317351 T C 3.86E-04 Myocardial Infarction / / pha002873 rs4868543 chr5 175317351 T C 6.75E-06 Triglycerides / / pha003080 rs973356 chr5 175438435 C T 1.72E-04 Hearing function / / 17255346 rs7443800 chr5 175559839 G A 3.22E-04 Bulimia nervosa / / 23568457 rs6884080 chr5 175586230 G A 9.89E-04 Multiple complex diseases LOC643201 intron 17554300 rs13169783 chr5 175764368 T C 3.54E-05 Alcohol dependence C5orf25 intron 20201924 rs13169783 chr5 175764368 T C 3.54E-05 Alcoholism C5orf25 intron pha002891 rs4428433 chr5 175765356 C T 2.70E-05 Urinary metabolites C5orf25 intron 21572414 rs3915381 chr5 175765988 A G 2.80E-05 Urinary metabolites C5orf25 intron 21572414 rs13164495 chr5 175766479 G A 6.07E-07 Alzheimer's disease (late onset) C5orf25 intron 21379329 rs11134972 chr5 175770421 G A 1.63E-05 Alcohol dependence C5orf25 intron 20201924 rs11134972 chr5 175770421 G A 1.63E-05 Alcoholism C5orf25 intron pha002891 rs11134973 chr5 175770422 C T 2.29E-05 Alcohol dependence C5orf25 intron 20201924 rs11134973 chr5 175770422 C T 2.29E-05 Alcoholism C5orf25 intron pha002891 rs3749804 chr5 175776155 A G 3.54E-05 Alcohol dependence KIAA1191 intron 20201924 rs3749804 chr5 175776155 A G 3.54E-05 Alcoholism KIAA1191 intron pha002891 rs11134974 chr5 175781959 C T 4.26E-05 Alcohol dependence KIAA1191 intron 20201924 rs11134974 chr5 175781959 C T 4.26E-05 Alcoholism KIAA1191 intron pha002891 rs10063877 chr5 175784920 T C 3.75E-05 Alcohol dependence KIAA1191 intron 20201924 rs10063877 chr5 175784920 T C 3.75E-05 Alcoholism KIAA1191 intron pha002891 rs150819260 chr5 175793395 G A 0.00012 Breast cancer ARL10 missense 23555315 rs13170785 chr5 175795666 G A 5.84E-04 Alcohol dependence ARL10 intron 20201924 rs6882450 chr5 175809210 C T 1.85E-04 Multiple complex diseases / / 17554300 rs1065212 chr5 175811133 T C 3.43E-04 Alzheimer's disease (late onset) NOP16 missense 21379329 rs11956701 chr5 175825311 A G 1.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CLTB intron 20877124 rs11956701 chr5 175825311 A G 9.92E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CLTB intron 20877124 rs7703742 chr5 175831645 T C 1.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CLTB intron 20877124 rs11959740 chr5 175836978 T C 2.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CLTB intron 20877124 rs2913737 chr5 175849989 G A 8.00E-06 Obesity-related traits / / 23251661 rs2913732 chr5 175869357 C T 2.00E-04 Information processing speed / / 21130836 rs2033198 chr5 175893063 G A 9.73E-05 Cognitive test performance FAF2 intron 20125193 rs2033198 chr5 175893063 G A 5.69E-05 Erythrocyte counts FAF2 intron pha003099 rs11134975 chr5 175898997 C A 7.64E-05 Cognitive test performance FAF2 intron 20125193 rs13154670 chr5 175901585 T C 1.26E-04 Alzheimer's disease (late onset) FAF2 intron 21379329 rs2963672 chr5 175935316 T C 8.77E-04 Multiple complex diseases FAF2 UTR-3 17554300 rs9313736 chr5 175948316 G A 1.67E-04 Endometrial cancer / / 24096698 rs9313736 chr5 175948316 G A 3.18E-04 Endometrial cancer / / 24096698 rs890835 chr5 175956271 A C,G,T 6.00E-06 Menopause (age at onset) RNF44 intron 22267201 rs1366240 chr5 175960676 C T 4.27E-05 Odorant perception RNF44 intron 23910658 rs4868648 chr5 175980113 T C 3.62E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) CDHR2 intron 23648065 rs4868651 chr5 175989028 A G 8.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDHR2 intron 20877124 rs752139 chr5 176011264 T C 7.65E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) CDHR2 intron 23648065 rs116138699 chr5 176013823 C T 0.00008 Breast cancer(er negative) CDHR2 missense 23555315 rs10476200 chr5 176092933 T C 6.88E-04 Multiple complex diseases / / 17554300 rs7713194 chr5 176095902 C T 2.50E-05 Urinary metabolites / / 21572414 rs7737146 chr5 176118380 C T 9.83E-04 Multiple complex diseases / / 17554300 rs10079158 chr5 176122948 G A 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs11741729 chr5 176140341 A G 1.01E-05 Relative hand skill / / 24068947 rs4867856 chr5 176144471 T C 5.26E-05 Relative hand skill / / 24068947 rs11134996 chr5 176151747 C T 7.71E-05 Relative hand skill / / 24068947 rs2358716 chr5 176152934 G A 7.82E-05 Relative hand skill / / 24068947 rs7701834 chr5 176153641 C T 3.23E-05 Relative hand skill / / 24068947 rs490332 chr5 176165086 A G 2.80E-04 Response to gemcitabine in pancreatic cancer / / 22142827 rs478253 chr5 176305678 C T 1.01E-09 End-stage coagulation UNC5A intron 23381943 rs2278494 chr5 176313982 C T 8.55E-04 Aortic root size HK3 intron 21223598 rs2278493 chr5 176314434 C T 6.17E-04 Body mass index HK3 intron 21701565 rs6875296 chr5 176314639 G A 3.85E-04 Schizophrenia(treatment response to risperidone) HK3 cds-synon 19850283 rs4976662 chr5 176315299 C T 7.46E-04 Body mass index HK3 intron 21701565 rs2940531 chr5 176333769 A G 1.70E-05 Urinary metabolites UIMC1 intron 21572414 rs365132 chr5 176378574 G T 8.00E-14 Menarche and menopause (age at onset) UIMC1 cds-synon 19448621 rs365132 chr5 176378574 G T 9.00E-32 Menopause (age at onset) UIMC1 cds-synon 22267201 rs3733876 chr5 176382995 G A 6.60E-04 Type 2 diabetes UIMC1 missense 17463248 rs142822891 chr5 176467009 G A 0.0000294 Nonsyndromic striae distensae (stretch marks) ZNF346 intron 23633020 rs1966265 chr5 176516631 G A 2.77E-10 End-stage coagulation FGFR4 missense 23381943 rs1966265 chr5 176516631 G A 3.05E-04 Response to cytidine analogues (gemcitabine) FGFR4 missense 24483146 rs442856 chr5 176517292 A G 2.90E-05 Urinary metabolites FGFR4 intron 21572414 rs422421 chr5 176517326 T C 1.00E-12 Height FGFR4 intron 20881960 rs351855 chr5 176520243 G A 1 Drug response to Cisplatin FGFR4 missense 11830541 rs351855 chr5 176520243 G A 1 Drug response to Cyclophosphamide FGFR4 missense 11830541 rs351855 chr5 176520243 G A 1 Drug response to Fluorouracil FGFR4 missense 11830541 rs351855 chr5 176520243 G A 1 Drug response to Methotrexate FGFR4 missense 11830541 rs351855 chr5 176520243 G A 1 Drug response to Tamoxifen FGFR4 missense 11830541 rs351855 chr5 176520243 G A 1 Drug response to Cisplatin FGFR4 missense 15197773 rs351855 chr5 176520243 G A 1 Drug response to Cyclophosphamide FGFR4 missense 15197773 rs351855 chr5 176520243 G A 1 Drug response to Fluorouracil FGFR4 missense 15197773 rs351855 chr5 176520243 G A 1 Drug response to Methotrexate FGFR4 missense 15197773 rs351855 chr5 176520243 G A 1 Drug response to Tamoxifen FGFR4 missense 15197773 rs351855 chr5 176520243 G A 1 Drug response to Cisplatin FGFR4 missense 16822847 rs351855 chr5 176520243 G A 1 Drug response to Cyclophosphamide FGFR4 missense 16822847 rs351855 chr5 176520243 G A 1 Drug response to Fluorouracil FGFR4 missense 16822847 rs351855 chr5 176520243 G A 1 Drug response to Methotrexate FGFR4 missense 16822847 rs351855 chr5 176520243 G A 1 Drug response to Tamoxifen FGFR4 missense 16822847 rs351855 chr5 176520243 G A 1 Drug response to Cisplatin FGFR4 missense 17084840 rs351855 chr5 176520243 G A 1 Drug response to Cyclophosphamide FGFR4 missense 17084840 rs351855 chr5 176520243 G A 1 Drug response to Fluorouracil FGFR4 missense 17084840 rs351855 chr5 176520243 G A 1 Drug response to Methotrexate FGFR4 missense 17084840 rs351855 chr5 176520243 G A 1 Drug response to Tamoxifen FGFR4 missense 17084840 rs351855 chr5 176520243 G A 1 Drug response to Cisplatin FGFR4 missense 18487077 rs351855 chr5 176520243 G A 0.0002 Prostate cancer FGFR4 missense 23555315 rs628506 chr5 176534423 A C 2.68E-09 End-stage coagulation / / 23381943 rs244731 chr5 176539679 G A 4.82E-05 Telomere length / / 24795349 rs351861 chr5 176541937 C A 6.05E-16 End-stage coagulation / / 23381943 rs17078781 chr5 176544228 G A 1.08E-10 End-stage coagulation / / 23381943 rs4976636 chr5 176545092 A G 6.06E-16 End-stage coagulation / / 23381943 rs7732930 chr5 176548594 C T 8.17E-19 End-stage coagulation / / 23381943 rs4976639 chr5 176550301 C A 9.84E-04 Multiple complex diseases / / 17554300 rs4976639 chr5 176550301 C A 8.18E-19 End-stage coagulation / / 23381943 rs4976640 chr5 176552007 A G 6.09E-16 End-stage coagulation / / 23381943 rs12519145 chr5 176555523 G A 2.60E-12 End-stage coagulation / / 23381943 rs1052432 chr5 176564189 G A 8.29E-19 End-stage coagulation NSD1 intron 23381943 rs9885210 chr5 176569188 T C 6.28E-16 End-stage coagulation NSD1 intron 23381943 rs11955537 chr5 176574088 A G 8.39E-19 End-stage coagulation NSD1 intron 23381943 rs10039241 chr5 176578072 G A 6.17E-19 End-stage coagulation NSD1 intron 23381943 rs244708 chr5 176589585 A G 5.12E-04 Response to cytidine analogues (gemcitabine) NSD1 intron 24483146 rs9313749 chr5 176597694 C A 7.59E-04 Multiple complex diseases NSD1 intron 17554300 rs9313749 chr5 176597694 C A 5.53E-20 End-stage coagulation NSD1 intron 23381943 rs10035180 chr5 176598502 T C 6.98E-04 Multiple complex diseases NSD1 intron 17554300 rs1546363 chr5 176601031 C T 1.05E-15 End-stage coagulation NSD1 intron 23381943 rs1546363 chr5 176601031 C T 3.51E-05 Leukocyte Counts NSD1 intron pha003091 rs12658510 chr5 176605273 G A 1.15E-10 End-stage coagulation NSD1 intron 23381943 rs2431501 chr5 176606052 T A 5.32E-18 End-stage coagulation NSD1 intron 23381943 rs6872021 chr5 176610012 G A 0.000000159 Joint damage severity in rheumatoid arthritis NSD1 intron 23696630 rs7710269 chr5 176614529 G A 6.59E-19 End-stage coagulation NSD1 intron 23381943 rs2878686 chr5 176633749 C T 8.66E-19 End-stage coagulation NSD1 intron 23381943 rs1363405 chr5 176636882 C T 6.43E-16 End-stage coagulation NSD1 cds-synon 23381943 rs3733875 chr5 176637240 G T 8.49E-11 End-stage coagulation NSD1 missense 23381943 rs28932178 chr5 176637576 T C 0.000061 Prostate cancer NSD1 missense 23555315 rs12187932 chr5 176643151 A G 4.20E-04 Response to cytidine analogues (gemcitabine) NSD1 intron 24483146 rs9313751 chr5 176644175 G A 7.01E-19 End-stage coagulation NSD1 intron 23381943 rs6890580 chr5 176653520 G A 6.36E-16 End-stage coagulation NSD1 intron 23381943 rs10072499 chr5 176655237 T G 1.22E-10 End-stage coagulation NSD1 intron 23381943 rs11957608 chr5 176655345 T C 7.00E-19 End-stage coagulation NSD1 intron 23381943 rs7724098 chr5 176659570 G A 5.20E-05 Attention deficit hyperactivity disorder NSD1 intron 22420046 rs7724098 chr5 176659570 G A 0.00000034 Joint damage severity in rheumatoid arthritis NSD1 intron 23696630 rs2336237 chr5 176665879 G A 6.40E-16 End-stage coagulation NSD1 intron 23381943 rs918459 chr5 176669030 A G 5.22E-05 Attention deficit hyperactivity disorder NSD1 intron 22420046 rs10056655 chr5 176676351 T C 1.44E-10 End-stage coagulation NSD1 intron 23381943 rs7719125 chr5 176689166 C A 2.02E-04 Response to cytidine analogues (gemcitabine) NSD1 intron 24483146 rs10037055 chr5 176691279 T G 3.76E-14 End-stage coagulation NSD1 intron 23381943 rs10037055 chr5 176691279 T G 5.00E-06 Migraine without aura NSD1 intron 23793025 rs10077929 chr5 176697844 C T 4.23E-16 End-stage coagulation NSD1 intron 23381943 rs12660023 chr5 176700885 G A 4.17E-16 End-stage coagulation NSD1 intron 23381943 rs6880798 chr5 176704457 G A 1.18E-10 End-stage coagulation NSD1 intron 23381943 rs11949435 chr5 176714932 C G 3.95E-16 End-stage coagulation NSD1 intron 23381943 rs6886255 chr5 176718361 A G 3.66E-14 End-stage coagulation NSD1 intron 23381943 rs6872201 chr5 176720766 A G 3.77E-04 Response to cytidine analogues (gemcitabine) NSD1 intron 24483146 rs4976682 chr5 176726002 T C 2.56E-05 Multiple sclerosis NSD1 UTR-3 19525953 rs4976682 chr5 176726002 T C 1.11E-10 End-stage coagulation NSD1 UTR-3 23381943 rs3088050 chr5 176726635 G A 3.01E-12 End-stage coagulation NSD1 UTR-3 23381943 rs4073745 chr5 176733341 A G 1.34E-05 Urate levels MXD3 UTR-3 23263486 rs72813183 chr5 176734648 G A 2.00E-06 Obesity-related traits MXD3 missense 23251661 rs11949767 chr5 176740244 A G 5.29E-07 Multiple sclerosis / / 17660530 rs11949767 chr5 176740244 A G 3.71E-11 End-stage coagulation / / 23381943 rs6885410 chr5 176740996 C A 5.27E-06 Multiple sclerosis / / 17660530 rs6885410 chr5 176740996 C A 3.74E-13 End-stage coagulation / / 23381943 rs6875461 chr5 176754665 T C 6.64E-09 End-stage coagulation / / 23381943 rs6876677 chr5 176755342 T C 6.65E-09 End-stage coagulation / / 23381943 rs6860069 chr5 176755841 C T 1.80E-12 End-stage coagulation / / 23381943 rs4976643 chr5 176760227 A C 6.70E-09 End-stage coagulation LMAN2 intron 23381943 rs11738681 chr5 176761535 A G 5.24E-09 End-stage coagulation LMAN2 intron 23381943 rs11748912 chr5 176765395 G A 6.75E-09 End-stage coagulation LMAN2 intron 23381943 rs11949401 chr5 176765989 T C 6.00E-09 End-stage coagulation LMAN2 intron 23381943 rs11749830 chr5 176766547 G A 1.82E-12 End-stage coagulation LMAN2 intron 23381943 rs9313758 chr5 176773091 T G 6.16E-09 End-stage coagulation LMAN2 intron 23381943 rs4532376 chr5 176774403 G A 6.17E-09 End-stage coagulation LMAN2 intron 23381943 rs4131289 chr5 176780545 G A 4.63E-09 End-stage coagulation / / 23381943 rs4976688 chr5 176784439 T C 3.45E-05 Nephrolithiasis / / 22396660 rs4976688 chr5 176784439 T C 0.000000275 Joint damage severity in rheumatoid arthritis / / 23696630 rs4075958 chr5 176784512 G A 5.00E-07 Multiple sclerosis / / 21833088 rs4075958 chr5 176784512 G A 3.74E-05 Nephrolithiasis / / 22396660 rs4075958 chr5 176784512 G A 3.10E-11 End-stage coagulation / / 23381943 rs4075958 chr5 176784512 G A 0.00000017 Joint damage severity in rheumatoid arthritis / / 23696630 rs4976646 chr5 176788570 T C 0.00000017 Joint damage severity in rheumatoid arthritis RGS14 intron 23696630 rs6556312 chr5 176789719 G T 2.53E-28 End-stage coagulation RGS14 intron 23381943 rs12654812 chr5 176794191 G A 1.98E-05 Nephrolithiasis RGS14 intron 22396660 rs12654812 chr5 176794191 G A 2.00E-07 Renal function-related traits (eGRFcrea) RGS14 intron 22797727 rs12654812 chr5 176794191 G A 5.00E-07 Renal function-related traits (sCR) RGS14 intron 22797727 rs12654812 chr5 176794191 G A 2.00E-08 Inflammatory bowel disease RGS14 intron 23128233 rs12654812 chr5 176794191 G A 3.00E-08 End-stage coagulation RGS14 intron 23381943 rs4074995 chr5 176797343 G A 6.25E-08 Phosphorus levels RGS14 intron 20558539 rs4074995 chr5 176797343 G A 1.95E-05 Nephrolithiasis RGS14 intron 22396660 rs4074995 chr5 176797343 G A 6.78E-12 End-stage coagulation RGS14 intron 23381943 rs4074995 chr5 176797343 G A 5.00E-06 Calcium levels RGS14 intron 24068962 rs11746443 chr5 176798306 G A 9.00E-12 Nephrolithiasis RGS14 intron 22396660 rs11746443 chr5 176798306 G A 0.00000107 Joint damage severity in rheumatoid arthritis RGS14 intron 23696630 rs10866705 chr5 176801131 C A 7.43E-05 Nephrolithiasis / / 22396660 rs10866705 chr5 176801131 C A 1.03E-11 End-stage coagulation / / 23381943 rs35716097 chr5 176806636 C T 1.98E-05 Nephrolithiasis / / 22396660 rs7708314 chr5 176809618 C T 3.05E-13 End-stage coagulation SLC34A1 nearGene-5 23381943 rs3812036 chr5 176813404 C T 1.48E-05 Nephrolithiasis SLC34A1 intron 22396660 rs3812036 chr5 176813404 C T 5.69E-14 End-stage coagulation SLC34A1 intron 23381943 rs3812035 chr5 176817143 G T 1.33E-21 End-stage coagulation SLC34A1 UTR-3 23381943 rs6420094 chr5 176817636 A G 1.00E-14 Chronic kidney disease SLC34A1 intron 20383146 rs6420094 chr5 176817636 A G 5.75E-14 Chronic kidney disease SLC34A1 intron 22479191 rs6420094 chr5 176817636 A G 1.10E-21 End-stage coagulation SLC34A1 intron 23381943 rs6420094 chr5 176817636 A G 1.30E-05 Glomerular filtration rate SLC34A1 intron 23535967 rs6420094 chr5 176817636 A G 1.80E-07 Glomerular filtration rate SLC34A1 intron 23535967 rs6420094 chr5 176817636 A G 2.40E-07 Glomerular filtration rate SLC34A1 intron 23535967 rs6420094 chr5 176817636 A G 2.50E-07 Glomerular filtration rate SLC34A1 intron 23535967 rs6420094 chr5 176817636 A G 2.80E-07 Glomerular filtration rate SLC34A1 intron 23535967 rs6420094 chr5 176817636 A G 3.50E-07 Glomerular filtration rate SLC34A1 intron 23535967 rs6420094 chr5 176817636 A G 5.00E-04 Glomerular filtration rate SLC34A1 intron 23535967 rs6420094 chr5 176817636 A G 7.60E-04 Glomerular filtration rate SLC34A1 intron 23535967 rs6420094 chr5 176817636 A G 8.80E-07 Glomerular filtration rate SLC34A1 intron 23535967 rs6862195 chr5 176822512 G T 9.41E-05 Nephrolithiasis SLC34A1 intron 22396660 rs6862195 chr5 176822512 G T 2.61E-21 End-stage coagulation SLC34A1 intron 23381943 rs7447593 chr5 176824137 C G,T 1.81E-09 Activated partial thromboplastin time SLC34A1 intron 23188048 rs7447593 chr5 176824137 C G,T 5.41E-21 End-stage coagulation SLC34A1 intron 23381943 rs17876049 chr5 176827753 C G 0.000000242 Triglycerides PFN3 nearGene-5 23063622 rs4976691 chr5 176827815 C G 9.50E-05 Nephrolithiasis PFN3 nearGene-5 22396660 rs4976691 chr5 176827815 C G 1.38E-59 End-stage coagulation PFN3 nearGene-5 23381943 rs17876032 chr5 176830627 G A 1.40E-37 Activated partial thromboplastin time F12 intron 23188048 rs1801020 chr5 176836532 A G 4.95E-11 Metabolite levels F12 UTR-5 22286219 rs1801020 chr5 176836532 A G 1.55E-59 Activated partial thromboplastin time F12 UTR-5 23188048 rs1801020 chr5 176836532 A G 4.81E-88 End-stage coagulation F12 UTR-5 23381943 rs7381103 chr5 176838312 C G 4.35E-09 Activated partial thromboplastin time F12 nearGene-5 23188048 rs2731674 chr5 176839890 T G 6.05E-11 Metabolite levels / / 22286219 rs2731673 chr5 176839898 T C 6.07E-11 Metabolite levels / / 22286219 rs2545801 chr5 176841339 T C 9.00E-11 Metabolite levels / / 22286219 rs2545801 chr5 176841339 T C 6.00E-88 Activated partial thromboplastin time / / 22703881 rs2545801 chr5 176841339 T C 1.39E-59 Activated partial thromboplastin time / / 23188048 rs2545801 chr5 176841339 T C 4.32E-22 Circulating vasoactive peptide levels / / 23381795 rs2545801 chr5 176841339 T C 2.29E-94 End-stage coagulation / / 23381943 rs2731672 chr5 176842474 T C 2.00E-30 Activated partial thromboplastin time / / 20303064 rs2731672 chr5 176842474 T C 1.00E-06 Platelet function and related traits / / 21546496 rs2731672 chr5 176842474 T C 8.71E-11 Metabolite levels / / 22286219 rs2731672 chr5 176842474 T C 3.00E-14 Metabolite levels (atherosclerosis) / / 22916037 rs2731672 chr5 176842474 T C 1.00E-67 Circulating vasoactive peptide levels / / 23381795 rs2731672 chr5 176842474 T C 6.00E-24 Circulating vasoactive peptide levels / / 23381795 rs2731672 chr5 176842474 T C 1.29E-115 End-stage coagulation / / 23381943 rs2731672 chr5 176842474 T C 6.00E-26 Blood metabolite ratios / / 24816252 rs2731670 chr5 176848019 A C 1.03E-08 End-stage coagulation / / 23381943 rs13177732 chr5 176856925 T G 0.000000256 Activated partial thromboplastin time GRK6 intron 23188048 rs2731665 chr5 176857270 T C 2.31E-16 End-stage coagulation GRK6 intron 23381943 rs883576 chr5 176857512 C T 2.31E-16 End-stage coagulation GRK6 intron 23381943 rs867755 chr5 176858049 C T 2.35E-16 End-stage coagulation GRK6 intron 23381943 rs2731664 chr5 176859848 C A,G,T 2.61E-05 Dengue shock syndrome GRK6 intron 22001756 rs2287694 chr5 176860293 T C 0.000000139 Activated partial thromboplastin time GRK6 intron 23188048 rs2287694 chr5 176860293 T C 1.47E-09 End-stage coagulation GRK6 intron 23381943 rs4976694 chr5 176862829 T G 4.35E-05 Alzheimer's disease (age of onset) GRK6 intron 22005931 rs1130857 chr5 176863519 G C 3.04E-08 End-stage coagulation GRK6 cds-synon 23381943 rs335434 chr5 176867276 T C 3.04E-08 End-stage coagulation GRK6 intron 23381943 rs335435 chr5 176867943 A G 3.04E-08 End-stage coagulation GRK6 cds-synon 23381943 rs2731662 chr5 176872494 A G 3.04E-08 End-stage coagulation LOC340037 intron 23381943 rs466256 chr5 176875956 C A 3.04E-08 End-stage coagulation PRR7 intron 23381943 rs2630765 chr5 176876825 T C 2.72E-08 End-stage coagulation PRR7 intron 23381943 rs465670 chr5 176877624 C T 3.04E-08 End-stage coagulation PRR7 intron 23381943 rs2630764 chr5 176880085 C T 3.04E-08 End-stage coagulation PRR7 intron 23381943 rs2544809 chr5 176885499 T C 4.23E-05 Dengue shock syndrome DBN1 missense 22001756 rs2544809 chr5 176885499 T C 4.53E-08 End-stage coagulation DBN1 missense 23381943 rs335466 chr5 176889530 C A 3.04E-08 End-stage coagulation DBN1 intron 23381943 rs337374 chr5 176890416 G A 3.04E-08 End-stage coagulation DBN1 intron 23381943 rs335467 chr5 176890642 A G 3.04E-08 End-stage coagulation DBN1 intron 23381943 rs335468 chr5 176892349 G A 3.04E-08 End-stage coagulation DBN1 intron 23381943 rs2545794 chr5 176894756 C T 1.97E-09 End-stage coagulation DBN1 cds-synon 23381943 rs2029164 chr5 176896412 G A 4.41E-05 Heart Failure DBN1 intron pha002885 rs335420 chr5 176898619 T C 3.04E-08 End-stage coagulation DBN1 intron 23381943 rs57960711 chr5 177019262 C G 8.00E-06 Obesity-related traits TMED9 missense 23251661 rs4958980 chr5 177357964 A G 7.50E-05 Asthma (bronchodilator response) / / 22792082 rs7730346 chr5 177373525 T G 7.00E-05 Asthma (bronchodilator response) / / 22792082 rs11741476 chr5 177380624 T G 1.52E-05 Panic disorder / / 19165232 rs4580789 chr5 177390271 C T 3.79E-04 Lymphocyte counts / / 22286170 rs6874931 chr5 177393155 G A 7.69E-05 Obesity (extreme) / / 21935397 rs11957941 chr5 177400248 C A 5.82E-05 Hypertension / / 19609347 rs4413548 chr5 177413659 C T 4.70E-05 Cognitive function / / 24684796 rs1800197 chr5 177419967 C T 3.18E-06 Brain structure PROP1 missense 22504417 rs1800197 chr5 177419967 C T 0.000828 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PROP1 missense 23233654 rs1800197 chr5 177419967 C T 8.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) PROP1 missense 23233662 rs12517913 chr5 177505795 C T 3.21E-04 Opioid sensitivity / / 23183491 rs4470773 chr5 177507080 C G 9.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4518421 chr5 177507302 C T 9.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4976806 chr5 177507767 T C 0.0005464 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4976806 chr5 177507767 T C 5.46E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6881402 chr5 177518612 A G 2.05E-05 Waist-Hip Ratio / / pha003013 rs6881402 chr5 177518612 A G 4.71E-05 Waist-Hip Ratio / / pha003028 rs6601221 chr5 177574421 C T 1.62E-04 Gallstones RMND5B intron 17632509 rs17080239 chr5 177604268 G A 8.13E-05 Glucose levels / / pha003058 rs17080239 chr5 177604268 G A 5.70E-05 Glucose levels / / pha003061 rs10074810 chr5 177604679 G T 1.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs6897423 chr5 177608195 T C 4.67E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs9329136 chr5 177611648 G A 5.91E-05 Alcohol dependence / / 21703634 rs7380658 chr5 177612034 G T 4.85E-05 Alcohol dependence / / 21703634 rs7719717 chr5 177612293 T G 6.47E-05 Alcohol dependence / / 21703634 rs7715618 chr5 177612634 A C 6.55E-05 Alcohol dependence / / 21703634 rs2961663 chr5 177613544 C T 4.00E-06 Rheumatoid arthritis / / 21156761 rs2961663 chr5 177613544 C T 9.83E-05 Alcohol dependence / / 21703634 rs2961669 chr5 177616669 A G 4.14E-05 Schizophrenia / / 19571809 rs2961674 chr5 177632527 G A 2.00E-05 Hypothyroidism HNRNPAB intron 22493691 rs2913752 chr5 177636571 C T 1.60E-05 Hypothyroidism HNRNPAB intron 22493691 rs3749813 chr5 177649986 G A 1.40E-05 Urinary metabolites AGXT2L2 intron 21572414 rs752283 chr5 177682664 T C 4.18E-04 Alzheimer's disease (late onset) COL23A1 intron 21379329 rs2913848 chr5 177684022 C T 7.70E-04 Alcohol dependence COL23A1 intron 20201924 rs6868187 chr5 177711741 A G 7.65E-04 Suicide attempts in bipolar disorder COL23A1 intron 21423239 rs2913774 chr5 177739628 C T 6.48E-05 Lupus nephritis in systemic lupus erythematosus COL23A1 intron 24925725 rs890813 chr5 177751488 C T 2.64E-05 Coronary heart disease COL23A1 intron pha003032 rs11948332 chr5 177753208 G C 9.61E-05 Major depressive disorder COL23A1 intron 21621269 rs2973808 chr5 177766580 T C 2.30E-05 Urinary metabolites COL23A1 intron 21572414 rs17641413 chr5 177773700 C T 8.80E-06 Urinary metabolites COL23A1 intron 21572414 rs7708757 chr5 177777888 C T 8.80E-06 Urinary metabolites COL23A1 intron 21572414 rs10440797 chr5 177788462 T C 9.75E-05 Alzheimer's disease (age of onset) COL23A1 intron 22005931 rs7445039 chr5 177795627 A G 1.73E-04 Hearing function COL23A1 intron 17255346 rs12519834 chr5 177802373 G A 5.00E-05 Crohn's disease COL23A1 intron 20570966 rs2973725 chr5 177804032 G A 4.85E-04 Lung function (forced expiratory volume in 1 second) COL23A1 intron 24023788 rs2910124 chr5 177808675 C T 6.00E-06 Bulimia nervosa COL23A1 intron 23568457 rs17648049 chr5 177830814 G A 4.63E-04 Multiple complex diseases COL23A1 intron 17554300 rs10070303 chr5 177840382 C T 6.00E-06 Obesity-related traits COL23A1 intron 23251661 rs17081200 chr5 177844658 C T 2.45E-04 Multiple complex diseases COL23A1 intron 17554300 rs4349734 chr5 177845760 C T 6.46E-05 Alzheimer's disease (late onset) COL23A1 intron 21379329 rs11956401 chr5 177848109 G A 2.00E-06 Smoking behavior COL23A1 intron 20418888 rs6601236 chr5 177862845 G A 6.10E-04 Multiple complex diseases COL23A1 intron 17554300 rs2647691 chr5 177886182 T C 8.40E-05 Monocyte chemoattractant protein-1 COL23A1 intron pha003071 rs2672824 chr5 177887732 T C 7.70E-05 Monocyte chemoattractant protein-1 COL23A1 intron pha003071 rs13159176 chr5 177899270 C T 9.71E-05 Body Mass Index COL23A1 intron pha003020 rs17589948 chr5 177904577 A G 3.07E-04 Smoking quantity COL23A1 intron 24665060 rs603852 chr5 177905384 T G 3.10E-04 Smoking quantity COL23A1 intron 24665060 rs539707 chr5 177906494 C T 1.38E-04 Smoking quantity COL23A1 intron 24665060 rs1106072 chr5 177912033 C T 2.98E-05 Smoking quantity COL23A1 intron 24665060 rs1996223 chr5 177916502 A G 4.75E-05 Smoking quantity COL23A1 intron 24665060 rs118078182 chr5 177922198 G A 1.82E-04 Bronchopulmonary dysplasia COL23A1 intron 23897914 rs1709746 chr5 177925725 G T 6.57E-05 Smoking quantity COL23A1 intron 24665060 rs6868242 chr5 177942798 C T 9.63E-05 Smoking quantity COL23A1 intron 24665060 rs2546643 chr5 177964444 G A 5.94E-04 Tourette syndrome COL23A1 intron 22889924 rs596279 chr5 177966921 C T 6.85E-05 Potassium levels COL23A1 intron pha003086 rs4976733 chr5 177968251 C T 1.23E-05 Potassium levels COL23A1 intron pha003086 rs642624 chr5 177969010 T C 9.94E-05 Prion diseases COL23A1 intron 22210626 rs504596 chr5 177974127 G A 3.29E-05 Prion diseases COL23A1 intron 22210626 rs564487 chr5 177977679 G T 5.30E-04 Type 2 diabetes and 6 quantitative traits COL23A1 intron 17848626 rs6600941 chr5 178011820 C T 8.84E-04 Type 2 diabetes COL23A1 intron 17463246 rs628857 chr5 178014668 G C 9.37E-04 Type 2 diabetes COL23A1 intron 17463246 rs628857 chr5 178014668 G C 8.32E-05 Calcium intake levels and metabolic syndrome COL23A1 intron 22170361 rs530542 chr5 178022626 A G 8.10E-04 Type 2 diabetes / / 17463246 rs262023 chr5 178025087 A G 9.24E-05 Sudden cardiac arrest / / 21658281 rs7717346 chr5 178028356 T C 6.47E-15 Gallbladder disease / / pha001404 rs11737903 chr5 178058108 T A 2.50E-04 Type 2 diabetes / / 17463246 rs3925517 chr5 178072334 T C 4.16E-04 Type 2 diabetes / / 17463246 rs4413550 chr5 178072635 T G 6.19E-05 Progressive supranuclear palsy / / 21685912 rs12189095 chr5 178073319 G A 6.09E-04 Type 2 diabetes / / 17463246 rs12523265 chr5 178085216 G A 5.98E-04 Type 2 diabetes / / 17463246 rs10076133 chr5 178103348 G A 3.91E-05 Creatinine levels / / pha003069 rs7735583 chr5 178189651 C G 2.00E-05 Urinary metabolites / / 21572414 rs6600952 chr5 178196412 C T 6.43E-04 Multiple complex diseases AACSP1 intron 17554300 rs9717043 chr5 178203585 G A 5.23E-04 Multiple complex diseases / / 17554300 rs7713731 chr5 178237864 G A 4.53E-04 Coronary heart disease / / 21971053 rs10055695 chr5 178246618 C A 4.57E-04 Coronary heart disease / / 21971053 rs12655480 chr5 178280271 C G 7.81E-04 Multiple complex diseases / / 17554300 rs12658098 chr5 178280334 T A 9.43E-04 Multiple complex diseases / / 17554300 rs11948690 chr5 178293873 C G 4.99E-04 Suicide attempts in bipolar disorder ZNF354B intron 21041247 rs11948175 chr5 178294983 A C 5.04E-04 Suicide attempts in bipolar disorder ZNF354B intron 21041247 rs11949892 chr5 178296523 T C 5.08E-04 Suicide attempts in bipolar disorder ZNF354B intron 21041247 rs11949180 chr5 178296536 A G 5.11E-04 Suicide attempts in bipolar disorder ZNF354B intron 21041247 rs11958887 chr5 178296577 C T 5.14E-04 Suicide attempts in bipolar disorder ZNF354B intron 21041247 rs11958941 chr5 178296776 C T 5.16E-04 Suicide attempts in bipolar disorder ZNF354B intron 21041247 rs11950641 chr5 178296906 T C 7.90E-04 Suicide attempts in bipolar disorder ZNF354B intron 21041247 rs6870926 chr5 178300191 T C 5.32E-04 Suicide attempts in bipolar disorder ZNF354B intron 21041247 rs6862829 chr5 178306588 C T 5.45E-04 Suicide attempts in bipolar disorder ZNF354B intron 21041247 rs6883566 chr5 178306589 A G 5.47E-04 Suicide attempts in bipolar disorder ZNF354B intron 21041247 rs6894878 chr5 178311993 G A 5.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs6865216 chr5 178319537 G A 4.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs11954382 chr5 178320846 C T 5.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs6895371 chr5 178324784 C T 5.97E-04 Suicide attempts in bipolar disorder ZFP2 intron 21041247 rs10060764 chr5 178369673 T C 7.70E-04 Multiple complex diseases ZNF454 intron 17554300 rs903981 chr5 178390237 T G 3.47E-04 Alzheimer's disease (late onset) ZNF454 intron 21379329 rs1826862 chr5 178390407 C T 2.57E-04 Body mass index ZNF454 intron 17255346 rs17078852 chr5 178408544 G C 1.91E-05 Multiple complex diseases GRM6 UTR-3 17554300 rs1475950 chr5 178410538 A C 1.65E-04 Body mass index GRM6 intron 17255346 rs2645339 chr5 178416063 G A 2.72E-04 Nicotine dependence GRM6 cds-synon 18227835 rs1969025 chr5 178425192 G A 9.52E-05 Cognitive performance / / 19734545 rs1969025 chr5 178425192 G A 0.0000201 Panic disorder / / 23149450 rs1969025 chr5 178425192 G A 2.01E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs11249608 chr5 178426319 T C 6.00E-07 Pubertal anthropometrics / / 23449627 rs4105175 chr5 178455747 A G 4.74E-04 Parkinson's disease ZNF879 intron 17052657 rs1049532 chr5 178510048 C T 2.83E-04 Height / / 17255346 rs9687070 chr5 178569149 G A 2.98E-06 Attention deficit hyperactivity disorder (time to onset) ADAMTS2 intron 18937294 rs10039254 chr5 178570914 A G 8.00E-06 Attention deficit hyperactivity disorder (time to onset) ADAMTS2 intron 18937294 rs3776816 chr5 178574868 A G 4.64E-06 Attention deficit hyperactivity disorder (time to onset) ADAMTS2 intron 18937294 rs6862563 chr5 178604465 G A 9.00E-04 Gamma gluatamyl transferase levels (interaction with age) ADAMTS2 intron 22010049 rs10040944 chr5 178610730 G A 3.68E-04 Suicide attempts in bipolar disorder ADAMTS2 intron 21423239 rs11249616 chr5 178617695 G A 9.66E-06 Obesity-related traits ADAMTS2 intron 23251661 rs6895999 chr5 178618707 C A 6.03E-04 Suicide attempts in bipolar disorder ADAMTS2 intron 21423239 rs6894805 chr5 178618727 G A 4.79E-04 Suicide attempts in bipolar disorder ADAMTS2 intron 21423239 rs379589 chr5 178619896 A T 1.45E-04 Suicide attempts in bipolar disorder ADAMTS2 intron 21423239 rs17668593 chr5 178622958 C T 5.30E-05 Suicide attempts in bipolar disorder ADAMTS2 intron 21423239 rs2411812 chr5 178637059 T A 4.89E-04 Suicide attempts in bipolar disorder ADAMTS2 intron 21423239 rs7447544 chr5 178637502 T G 8.16E-04 Suicide attempts in bipolar disorder ADAMTS2 intron 21423239 rs442406 chr5 178640982 C T 7.45E-04 Suicide attempts in bipolar disorder ADAMTS2 intron 21423239 rs459490 chr5 178641578 A G 7.61E-04 Suicide attempts in bipolar disorder ADAMTS2 intron 21423239 rs459668 chr5 178641701 G A 9.53E-04 Suicide attempts in bipolar disorder ADAMTS2 intron 21423239 rs458272 chr5 178642008 A C 8.59E-04 Suicide attempts in bipolar disorder ADAMTS2 intron 21423239 rs17079224 chr5 178651122 A T 2.31E-04 Multiple complex diseases ADAMTS2 intron 17554300 rs7716184 chr5 178652227 G A 0.0008542 Sarcoidosis ADAMTS2 intron 22952805 rs469568 chr5 178663408 A C 8.00E-06 Stroke (pediatric) ADAMTS2 intron 22990015 rs4701085 chr5 178674076 A G 1.75E-04 Malignant pleural mesothelioma ADAMTS2 intron 23626673 rs4701085 chr5 178674076 A G 1.93E-05 Malignant pleural mesothelioma ADAMTS2 intron 23626673 rs901254 chr5 178699311 C T 9.00E-06 Visceral adipose tissue adjusted for BMI ADAMTS2 intron 22589738 rs166031 chr5 178720968 A G 5.44E-04 Alcohol dependence ADAMTS2 intron 24277619 rs340114 chr5 178742625 C G 1.08E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ADAMTS2 intron 20031582 rs163498 chr5 178748987 A G 5.00E-06 Urinary metabolites ADAMTS2 intron 21572414 rs2450191 chr5 178752095 C A 5.84E-05 Body Mass Index ADAMTS2 intron pha003014 rs7734278 chr5 178761358 G A 7.37E-05 Multiple complex diseases ADAMTS2 intron 17554300 rs443725 chr5 178797837 G A 8.50E-05 Personality dimensions / / 18957941 rs7731436 chr5 178826910 T C 3.18E-05 Coronary heart disease / / pha003031 rs4701170 chr5 178897590 G A 7.92E-06 Post-traumatic stress disorder / / 24080187 rs12516534 chr5 178901458 G A 4.10E-06 Urinary metabolites / / 21572414 rs6866664 chr5 178902471 A G 2.20E-05 Urinary metabolites / / 21572414 rs12109210 chr5 178905485 A G 8.90E-05 Hypothyroidism / / 22493691 rs11249632 chr5 178921964 C T 2.79E-05 Schizophrenia / / 24253340 rs6862387 chr5 178947661 A G 4.86E-05 Schizophrenia / / 19571809 rs1344158 chr5 178950761 G A 8.27E-05 Left ventricular hypertrophy / / pha003052 rs6894268 chr5 179032488 A G 3.00E-06 Eating disorders RUFY1 intron 22911880 rs4700811 chr5 179033401 A G 5.64E-04 Insulin resistance RUFY1 intron 21901158 rs12374446 chr5 179131143 T C 2.01E-04 Body mass index CANX intron 21701565 rs12374446 chr5 179131143 T C 2.91E-04 Body mass index CANX intron 21701565 rs7735702 chr5 179132612 T A 2.16E-08 Resting heart rate CANX intron 24680774 rs6893300 chr5 179135815 C A 9.00E-09 Resting heart rate CANX intron 24680774 rs13172523 chr5 179167050 G A 8.35E-04 Type 2 diabetes MAML1 intron 17463246 rs17617068 chr5 179168097 T C 1.00E-08 Resting heart rate MAML1 intron 24680774 rs4700838 chr5 179185121 A G 1.21E-08 Resting heart rate MAML1 intron 24680774 rs4700839 chr5 179186397 C A 2.30E-05 Urinary metabolites MAML1 intron 21572414 rs3797776 chr5 179193598 C T 2.09E-08 Resting heart rate MAML1 cds-synon 24680774 rs3797762 chr5 179202688 A G 0.00034 Coronary artery calcification MAML1 UTR-3 23727086 rs17617710 chr5 179206107 G A 0.00046 Coronary artery calcification / / 23727086 rs1019443 chr5 179207547 G A 5.26E-04 Body mass index / / 21701565 rs1019443 chr5 179207547 G A 8.31E-04 Body mass index / / 21701565 rs11738269 chr5 179209059 C A 1.87E-08 Resting heart rate / / 24680774 rs1469020 chr5 179214024 G A 1.67E-08 Resting heart rate / / 24680774 rs730012 chr5 179220638 A C 1 Drug response to Montelukast LTC4S nearGene-5 16293801 rs730012 chr5 179220638 A C 1 Drug response to Aspirin LTC4S nearGene-5 16433794 rs730012 chr5 179220638 A C 1 Drug response to Aspirin LTC4S nearGene-5 19862937 rs730012 chr5 179220638 A C 1.66E-08 Resting heart rate LTC4S nearGene-5 24680774 rs72807343 chr5 179238261 C T 7.00E-07 Alzheimer's disease (late onset) SQSTM1 intron 24162737 rs7711505 chr5 179250130 C T 1.05E-04 Acute lung injury SQSTM1 intron 22295056 rs3734007 chr5 179252537 A G 2.36E-04 Multiple complex diseases SQSTM1 intron 17554300 rs2450484 chr5 179259842 G C 6.18E-04 Multiple complex diseases SQSTM1 intron 17554300 rs199537217 chr5 179285781 G A 0.0000021 Breast cancer C5orf45 missense 23555315 rs269452 chr5 179290007 A G 8.72E-04 Insulin resistance TBC1D9B UTR-3 21901158 rs248328 chr5 179377085 T C 1.90E-05 Biomarkers / / 17903293 rs6884272 chr5 179395326 C A 7.07E-05 Bronchopulmonary dysplasia RNF130 intron 23897914 rs27011 chr5 179400446 T C 3.59E-04 Multiple complex diseases RNF130 intron 17554300 rs27011 chr5 179400446 T C 6.79E-04 Body mass index RNF130 intron 21701565 rs11750102 chr5 179450851 G A 6.06E-04 Aortic root size RNF130 intron 21223598 rs10036834 chr5 179454428 G A 6.03E-05 HIV-1 viral setpoint RNF130 intron 22174851 rs6862105 chr5 179470642 A G 5.64E-05 HIV-1 viral setpoint RNF130 intron 22174851 rs13161895 chr5 179471201 C T 6.00E-07 Coronary heart disease RNF130 intron 21347282 rs4129403 chr5 179476610 T C 7.27E-04 Body mass index RNF130 intron 21701565 rs11249671 chr5 179557156 C A 4.42E-04 Type 2 diabetes RASGEF1C intron 17463246 rs4700718 chr5 179589868 G A,T 4.65E-04 Taste perception RASGEF1C intron 22132133 rs6896628 chr5 179591023 G A 2.27E-04 Taste perception RASGEF1C intron 22132133 rs13356323 chr5 179594023 T G 1.49E-04 Taste perception RASGEF1C intron 22132133 rs11749727 chr5 179608360 T C 2.74E-04 Obesity (extreme) RASGEF1C intron 21935397 rs11749727 chr5 179608360 T C 2.60E-04 Type 2 diabetes RASGEF1C intron 23209189 rs7380160 chr5 179608656 G A 0.0000479 Tuberculosis with early age of onset RASGEF1C intron 22551897 rs13168609 chr5 179613262 G T 8.42E-04 Obesity (extreme) RASGEF1C intron 21935397 rs1562083 chr5 179625630 G A 8.21E-04 Heart Failure RASGEF1C intron pha002885 rs6601097 chr5 179633767 C A 8.40E-06 Personality dimensions RASGEF1C intron 21173776 rs3111532 chr5 179641662 C T 8.90E-04 Aortic root size / / 21223598 rs6896886 chr5 179648871 G A 1.53E-04 Alzheimer's disease / / 17998437 rs11743623 chr5 179676661 C T 6.23E-05 Coronary Artery Disease MAPK9 intron 17634449 rs13190345 chr5 179676979 C T 5.85E-05 Coronary Artery Disease MAPK9 intron 17634449 rs3812067 chr5 179709154 T C 4.00E-04 Response to cytidine analogues (gemcitabine) MAPK9 intron 24483146 rs6879260 chr5 179731014 T C 2.00E-09 Height GFPT2 intron 20881960 rs2303010 chr5 179752031 C T 9.48E-04 Coronary heart disease GFPT2 intron 21606135 rs6859159 chr5 179761769 C T 6.72E-06 Odorant perception GFPT2 intron 23910658 rs2303011 chr5 179763789 C T 2.71E-04 Smoking quantity GFPT2 intron 24665060 rs10464059 chr5 179794208 G A 3.00E-06 Parkinson's disease / / 20070850 rs6601116 chr5 179805370 T C 8.19E-04 Multiple complex diseases / / 17554300 rs10479469 chr5 179812668 A G 2.40E-06 Subcutaneous adipose tissue volume in HIV-infected men / / 21897333 rs7705745 chr5 179821150 G C 2.00E-04 Bipolar disorder / / 18317468 rs17080306 chr5 179861507 C G 1.11E-04 Arthritis (juvenile idiopathic) / / 22354554 rs4700921 chr5 179861583 T C 9.70E-05 Arthritis (juvenile idiopathic) / / 22354554 rs17629918 chr5 179869595 A G 9.56E-04 Alzheimer's disease / / 17998437 rs17629918 chr5 179869595 A G 1.78E-04 Arthritis (juvenile idiopathic) / / 22354554 rs10078649 chr5 179877533 G A 6.82E-05 Cognitive impairment induced by topiramate / / 22091778 rs13166976 chr5 179898700 G C 8.93E-04 Coronary Artery Disease / / 17634449 rs10479576 chr5 179908092 C A 7.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs2279622 chr5 180028743 C T 1.63E-05 Smoking cessation FLT4 UTR-3 24665060 rs307835 chr5 180033605 T C 0.000349 Salmonella-induced pyroptosis FLT4 intron 22837397 rs307833 chr5 180035504 C T 0.000605 Salmonella-induced pyroptosis FLT4 intron 22837397 rs307805 chr5 180077487 T C 5.76E-05 Cleft lip FLT4 nearGene-5 20436469 rs307805 chr5 180077487 T C 8.94E-04 Stroke (pediatric) FLT4 nearGene-5 22990015 rs10042049 chr5 180109638 T C 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2387207 chr5 180111144 C T 4.50E-05 Alcoholism / / pha002893 rs7731780 chr5 180120192 G T 6.11E-05 C-Reactive Protein / / pha003070 rs7731780 chr5 180120192 G T 2.59E-05 Monocyte chemoattractant protein-1 / / pha003071 rs4700754 chr5 180131124 T G 3.73E-04 Smoking initiation / / 24665060 rs12517906 chr5 180170819 C T 6.00E-06 Body mass index / / 19851299 rs12517906 chr5 180170819 C T 7.00E-08 Weight / / 19851299 rs7702121 chr5 180199253 C A 1.90E-05 Urinary metabolites / / 21572414 rs7702121 chr5 180199253 C A 8.55E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1013443 chr5 180201114 A T 3.30E-08 Smoking behavior / / 22832964 rs1021001 chr5 180204104 G C 8.46E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs6859974 chr5 180205938 C T 8.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs7725365 chr5 180210118 A C 2.10E-05 Urinary metabolites / / 21572414 rs682828 chr5 180214474 C T 7.94E-04 Celiac disease / / 23936387 rs655601 chr5 180226673 A C 5.00E-06 Quantitative traits MGAT1 intron 19197348 rs655601 chr5 180226673 A C 1.47E-06 Monocyte chemoattractant protein-1 MGAT1 intron pha003071 rs17141222 chr5 180282933 T C 1.18E-04 Multiple complex diseases ZFP62 intron 17554300 rs4701007 chr5 180342707 C T 2.39E-05 Smoking quantity BTNL8 intron 24665060 rs2387714 chr5 180361240 C A 5.53E-05 Smoking quantity BTNL8 intron 24665060 rs3733755 chr5 180374484 C A 3.37E-04 Type 2 diabetes BTNL8 intron 17463246 rs7711990 chr5 180374898 A G 8.40E-05 Breast cancer and prostate cancer BTNL8 intron 17903305 rs7721042 chr5 180439488 T C 7.33E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs730545 chr5 180513467 G A 8.05E-05 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs728916 chr5 180548151 C T 1.00E-04 Information processing speed / / 21130836 rs11950731 chr5 180584434 T C 2.80E-04 Type 2 diabetes / / 17463246 rs1279754 chr5 180586413 T G 9.16E-05 Basophils / / pha003087 rs1279750 chr5 180595138 C T 2.00E-06 Platelet counts / / 21507922 rs10066307 chr5 180634426 T C 1.00E-04 Prostate cancer / / 21743057 rs750788 chr5 180638895 G A 6.57E-04 Lymphocyte counts / / 22286170 rs2545098 chr5 180650744 T C 8.71E-04 Suicide attempts in bipolar disorder TRIM41 UTR-5 21423239 rs112739547 chr5 180656749 T C 7.08E-06 Osteoarthritis TRIM41 intron 21871595 rs2770994 chr5 180663700 G A 4.18E-05 Lymphocyte counts GNB2L1 nearGene-3 22286170 rs888708 chr5 180692321 T A 2.72E-05 Breast cancer / / 21060860 rs1418707 chr6 205800 A G 5.84E-05 Self-reported allergy / / 23817569 rs17133789 chr6 209462 T G 2.96E-04 Coronary Artery Disease / / 17634449 rs17133789 chr6 209462 T G 2.13E-04 Atopy / / 21625490 rs6899567 chr6 212595 G A 0.0000376 Alcohol craving with or without dependence / / 22481050 rs6899567 chr6 212595 G A 3.27E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs9501753 chr6 221146 G A 1.00E-08 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) / / 24554482 rs13196509 chr6 242049 T G 7.76E-05 Heart Rate / / pha003053 rs6596860 chr6 247899 A G 4.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6927090 chr6 252145 G T 4.00E-06 Hematology traits / / 23303382 rs12197235 chr6 252772 C T 9.50E-05 Hematology traits / / 23303382 rs11242795 chr6 322256 A G 9.25E-05 Response to statin treatment (atorvastatin),change in cholesterol levels DUSP22 intron 20031582 rs9328127 chr6 329869 G A 8.48E-05 Progressive supranuclear palsy DUSP22 intron 21685912 rs3800250 chr6 334825 C T 4.49E-04 Multiple complex diseases DUSP22 intron 17554300 rs7763092 chr6 349386 T G 2.62E-04 Multiple complex diseases DUSP22 intron 17554300 rs9501958 chr6 378970 G A 1.06E-05 Multiple complex diseases / / 17554300 rs2797296 chr6 379834 C G 3.31E-05 Personality dimensions / / 22628180 rs1033180 chr6 383546 C T 6.00E-08 Celiac disease / / 20190752 rs1033180 chr6 383546 C T 3.89E-07 Common traits (Other) / / 20585627 rs9503555 chr6 389319 T C 0.0000683 Menopause (age at onset) / / 23424626 rs12203592 chr6 396321 C T 7.00E-127 Black vs. red hair color IRF4 intron 18483556 rs12203592 chr6 396321 C T 9.00E-28 Black vs. red hair color IRF4 intron 18483556 rs12203592 chr6 396321 C T 2.00E-15 Eye color IRF4 intron 20585627 rs12203592 chr6 396321 C T 2.00E-28 Hair color IRF4 intron 20585627 rs12203592 chr6 396321 C T 2.00E-91 Freckling IRF4 intron 20585627 rs12203592 chr6 396321 C T 4.00E-07 Hair color IRF4 intron 20585627 rs12203592 chr6 396321 C T 1.90E-10 Nevus count IRF4 intron 20602913 rs12203592 chr6 396321 C T 1.90E-49 Nevus count IRF4 intron 20602913 rs12203592 chr6 396321 C T 2.50E-05 Nevus count IRF4 intron 20602913 rs12203592 chr6 396321 C T 6.00E-15 Progressive supranuclear palsy IRF4 intron 21685912 rs12203592 chr6 396321 C T 2.60E-04 Celiac disease IRF4 intron 22057235 rs12203592 chr6 396321 C T 8.12E-05 Acute lung injury IRF4 intron 22295056 rs12203592 chr6 396321 C T 1.00E-28 Hair color IRF4 intron 23548203 rs12203592 chr6 396321 C T 2.00E-06 Sunburns IRF4 intron 23548203 rs12203592 chr6 396321 C T 3.00E-23 Tanning IRF4 intron 23548203 rs12203592 chr6 396321 C T 7.00E-14 Non-melanoma skin cancer IRF4 intron 23548203 rs12203592 chr6 396321 C T 4.90E-05 Neuroblastoma IRF4 intron pha002895 rs2671422 chr6 398775 G A 2.50E-04 Vaspin levels IRF4 intron 22907691 rs2671422 chr6 398775 G A 0.0002503 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit IRF4 intron 22907730 rs3778607 chr6 403799 A G 2.14E-13 Common traits (Other) IRF4 intron 20585627 rs2001508 chr6 404632 A C 9.42E-04 Type 2 diabetes IRF4 intron 17463246 rs1050975 chr6 408012 G A 8.13E-07 Common traits (Other) IRF4 UTR-3 20585627 rs1050976 chr6 408079 C T 1.80E-09 Celiac disease IRF4 UTR-3 22057235 rs1050976 chr6 408079 C T 5.83E-20 Chronic lymphocytic leukemia IRF4 UTR-3 23770605 rs872071 chr6 411064 A G 2.00E-20 Chronic lymphocytic leukemia IRF4 UTR-3 18758461 rs872071 chr6 411064 A G 2.00E-20 Nasopharyngeal carcinoma IRF4 UTR-3 20512145 rs872071 chr6 411064 A G 4.17E-15 Common traits (Other) IRF4 UTR-3 20585627 rs872071 chr6 411064 A G 8.00E-14 Chronic lymphocytic leukemia IRF4 UTR-3 22700719 rs872071 chr6 411064 A G 7.54E-14 Erectile dysfunction IRF4 UTR-3 22704111 rs872071 chr6 411064 A G 6.00E-20 Chronic lymphocytic leukemia IRF4 UTR-3 23770605 rs872071 chr6 411064 A G 3.00E-16 Chronic lymphocytic leukemia IRF4 UTR-3 24292274 rs7757906 chr6 412741 A G 9.55E-07 Common traits (Other) / / 20585627 rs9503644 chr6 415406 A C,G,T 7.76E-08 Common traits (Other) / / 20585627 rs9378805 chr6 417727 A C 5.39E-13 Multiple complex diseases / / 17554300 rs9378805 chr6 417727 A C 7.70E-10 Skin sensitivity to sun / / 18488028 rs9378805 chr6 417727 A C 1.23E-13 Common traits (Other) / / 20585627 rs9378805 chr6 417727 A C 2.00E-06 Chronic lymphocytic leukemia / / 21131588 rs9378805 chr6 417727 A C 3.22E-11 Chronic lymphocytic leukemia / / 22700719 rs9378805 chr6 417727 A C 3.22E-11 Erectile dysfunction / / 22704111 rs9378805 chr6 417727 A C 0.0000297 Primary sclerosing cholangitis / / 23603763 rs9378815 chr6 426155 G C,T 1.00E-07 Rheumatoid arthritis / / 24390342 rs9378815 chr6 426155 G C,T 2.00E-10 Rheumatoid arthritis / / 24390342 rs9378815 chr6 426155 G C,T 2.30E-04 Rheumatoid arthritis / / 24390342 rs1473602 chr6 428722 A G 8.79E-04 Multiple complex diseases / / 17554300 rs950286 chr6 429457 G A 3.98E-08 Common traits (Other) / / 20585627 rs2048698 chr6 433962 C T 8.14E-04 Multiple complex diseases / / 17554300 rs7454545 chr6 434348 C T 8.94E-04 Multiple complex diseases / / 17554300 rs9328192 chr6 434364 A G 7.50E-10 Skin sensitivity to sun / / 18488028 rs9328192 chr6 434364 A G 4.07E-10 Common traits (Other) / / 20585627 rs9405675 chr6 444600 G A 1.91E-09 Common traits (Other) / / 20585627 rs9405675 chr6 444600 G A 9.60E-06 Rheumatoid arthritis / / 22446963 rs9405681 chr6 449358 T C 5.40E-08 Skin sensitivity to sun / / 18488028 rs9405681 chr6 449358 T C 4.57E-08 Common traits (Other) / / 20585627 rs908026 chr6 455419 T C 7.29E-04 Acute lung injury / / 22295056 rs4959270 chr6 457748 C A 2.20E-08 Hair,eye and skin pigmentation / / 17952075 rs4959270 chr6 457748 C A 1.50E-14 Skin sensitivity to sun / / 18488028 rs4959270 chr6 457748 C A 1.17E-12 Common traits (Other) / / 20585627 rs4959270 chr6 457748 C A 6.14E-07 Bipolar disorder / / 22182935 rs4959270 chr6 457748 C A 8.04E-04 Acute lung injury / / 22295056 rs11242899 chr6 460302 G A 2.93E-04 Acute lung injury / / 22295056 rs12661290 chr6 462341 C T 4.09E-04 Acute lung injury / / 22295056 rs868094 chr6 464426 T C 4.19E-07 Bipolar disorder / / 22182935 rs1540771 chr6 466033 C T 4.00E-18 Freckles / / 17952075 rs1540771 chr6 466033 C T 1.30E-14 Skin sensitivity to sun / / 18488028 rs1540771 chr6 466033 C T 5.75E-14 Common traits (Other) / / 20585627 rs1540771 chr6 466033 C T 4.63E-04 Acute lung injury / / 22295056 rs12202284 chr6 471136 C A 6.30E-07 basal cell carcinoma / / 21700618 rs12202284 chr6 471136 C A 5.00E-08 Non-melanoma skin cancer / / 23548203 rs9503977 chr6 475154 C T 9.65E-05 Prostate cancer / / 22923026 rs12210050 chr6 475489 C T 5.00E-14 Tanning / / 19340012 rs12210050 chr6 475489 C T 1.00E-09 Basal cell carcinoma / / 21700618 rs12210050 chr6 475489 C T 3.00E-06 Schizophrenia / / 22885689 rs12210050 chr6 475489 C T 4.00E-06 Schizophrenia / / 22885689 rs12210050 chr6 475489 C T 0.00000677 Primary sclerosing cholangitis / / 23603763 rs7750350 chr6 477738 C T 7.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs950039 chr6 493976 G A 4.79E-07 Common traits (Other) EXOC2 intron 20585627 rs12206548 chr6 506231 G A 6.38E-05 Height EXOC2 intron pha003011 rs2493013 chr6 516350 A C 2.92E-05 Multiple complex diseases EXOC2 intron 17554300 rs2493013 chr6 516350 A C 6.57E-04 Obesity (extreme) EXOC2 intron 21935397 rs9392056 chr6 518078 G A 9.33E-08 Common traits (Other) EXOC2 intron 20585627 rs6918152 chr6 542159 A G 5.00E-07 Black vs. red hair color EXOC2 intron 18483556 rs6918152 chr6 542159 A G 6.00E-08 Black vs. blond hair color EXOC2 intron 18483556 rs6918152 chr6 542159 A G 8.51E-08 Common traits (Other) EXOC2 intron 20585627 rs2476847 chr6 549390 C T 7.76E-05 Psoriasis EXOC2 intron 20953190 rs2476846 chr6 551352 C T 7.14E-04 Suicide attempts in bipolar disorder EXOC2 intron 21423239 rs2064302 chr6 556106 G A 7.43E-04 Myopia (pathological) EXOC2 intron 21095009 rs3765438 chr6 563210 G A 6.31E-04 Myopia (pathological) EXOC2 intron 21095009 rs2476842 chr6 566741 A G 3.00E-06 Dental caries EXOC2 intron 23064961 rs846167 chr6 570556 C T 2.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EXOC2 intron 20877124 rs846167 chr6 570556 C T 9.75E-04 Myopia (pathological) EXOC2 intron 21095009 rs3799307 chr6 571463 T C 2.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EXOC2 intron 20877124 rs3799307 chr6 571463 T C 9.75E-04 Myopia (pathological) EXOC2 intron 21095009 rs2281252 chr6 572330 A G 4.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EXOC2 intron 20877124 rs2073010 chr6 573088 T C 5.16E-04 Suicide attempts in bipolar disorder EXOC2 intron 21423239 rs9504361 chr6 577820 A G 3.22E-05 Psoriasis EXOC2 intron 20953190 rs9504361 chr6 577820 A G 2.10E-11 Psoriasis EXOC2 intron 23143594 rs9504361 chr6 577820 A G 6.00E-06 Pit-and-Fissure caries EXOC2 intron 23470693 rs4960092 chr6 597871 G A 5.52E-04 Multiple complex diseases EXOC2 intron 17554300 rs3757122 chr6 611030 T C 6.75E-04 Type 2 diabetes EXOC2 intron 17463246 rs2073008 chr6 638345 A T 5.33E-05 Type 2 diabetes EXOC2 intron 17463246 rs1737539 chr6 641162 C A 9.38E-04 Type 2 diabetes EXOC2 intron 17463246 rs1338456 chr6 647616 A G 0.000149 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) EXOC2 intron 23233654 rs1338456 chr6 647616 A G 1.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) EXOC2 intron 23233662 rs17136239 chr6 656343 T C 6.60E-04 Parkinson's disease HUS1B missense 16252231 rs9405909 chr6 679344 C G 8.28E-04 Parkinson's disease EXOC2 intron 16252231 rs4959381 chr6 696058 A G 3.26E-04 Lung function (forced vital capacity) / / 24023788 rs2788212 chr6 698538 G C 4.49E-04 Insulin resistance / / 21901158 rs2804737 chr6 715196 G A 0.000477237 Hypertension (early onset hypertension) / / 22479346 rs2788223 chr6 720465 G A 3.74E-04 Multiple complex diseases / / 17554300 rs2788223 chr6 720465 G A 0.000354338 Hypertension (early onset hypertension) / / 22479346 rs9504898 chr6 724586 C A 5.10E-07 Urinary metabolites / / 21572414 rs2788234 chr6 742311 G A 3.24E-05 Glycosylated haemoglobin levels / / 17255346 rs1538325 chr6 743995 A C 2.60E-05 Urinary metabolites / / 21572414 rs2804756 chr6 753586 T C 2.16E-04 Glycosylated haemoglobin levels / / 17255346 rs1933646 chr6 755033 A T 2.00E-05 Urinary metabolites / / 21572414 rs13219492 chr6 780441 G A 3.19E-04 Alzheimer's disease / / 24755620 rs17239807 chr6 784680 C T 1.90E-04 Alzheimer's disease / / 24755620 rs4960299 chr6 787110 T C 4.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12198560 chr6 787703 T G 5.98E-05 Multiple complex diseases / / 17554300 rs12198560 chr6 787703 T G 8.78E-04 Alzheimer's disease / / 24755620 rs9328417 chr6 788169 T C 8.53E-04 Alzheimer's disease / / 24755620 rs6597267 chr6 795414 G A 3.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2317217 chr6 796484 A C 8.15E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4960355 chr6 830293 A G 8.17E-05 Serum metabolites / / 19043545 rs9405366 chr6 858296 A C 7.81E-04 Multiple complex diseases / / 17554300 rs1572438 chr6 858970 C T 9.00E-06 Aging / / 22773346 rs1572438 chr6 858970 C T 4.00E-05 Left ventricular hypertrophy / / pha003052 rs884126 chr6 870244 A G 2.09E-04 Multiple complex diseases / / 17554300 rs7768444 chr6 880234 C A 5.60E-05 Crohn's disease / / 20570966 rs4532481 chr6 890165 C T 1.41E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4532481 chr6 890165 C T 8.11E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2784968 chr6 903764 A G 2.80E-04 Myopia (pathological) / / 21095009 rs2756313 chr6 904145 T C 1.60E-06 Urinary metabolites / / 21572414 rs9392234 chr6 918550 C T 1.99E-05 Alzheimer's disease (late onset) / / 21460841 rs7752019 chr6 929946 G A 1.10E-05 Urinary metabolites / / 21572414 rs845869 chr6 998062 T C 8.71E-05 Fibrinogen LOC285768 intron pha003068 rs1331485 chr6 1045462 A T 2.92E-04 Multiple complex diseases LOC285768 intron 17554300 rs6925338 chr6 1049017 G A 0.00024 Endometrial cancer LOC285768 intron 22426144 rs9505672 chr6 1057137 C T 4.18E-04 Acute lung injury LOC285768 intron 22295056 rs6931405 chr6 1057956 T G 3.95E-04 Acute lung injury LOC285768 intron 22295056 rs6917581 chr6 1057990 C T 1.01E-04 Sudden cardiac arrest LOC285768 intron 21658281 rs1883628 chr6 1058314 C T 5.86E-05 Neuroblastoma LOC285768 intron pha002895 rs12212095 chr6 1083696 G A 7.74E-05 Lung function (forced expiratory volume in 1 second) LOC285768 intron pha003103 rs6911992 chr6 1092761 T C 4.05E-04 Type 2 diabetes LOC285768 intron 17463246 rs6912722 chr6 1093354 A G 9.11E-05 Orofacial clefts LOC285768 intron 22419666 rs2050158 chr6 1100777 A G 7.91E-05 Bipolar disorder and schizophrenia / / 20889312 rs6596786 chr6 1103242 G A 1.93E-04 Multiple complex diseases / / 17554300 rs6596786 chr6 1103242 G A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs9378277 chr6 1119424 A G 4.20E-04 Alzheimer's disease (late onset) / / 21379329 rs6926322 chr6 1122544 G A 9.13E-04 Multiple complex diseases / / 17554300 rs410173 chr6 1163541 A G 7.77E-05 Cognitive impairment induced by topiramate / / 22091778 rs914413 chr6 1168387 G C 1.55E-04 Multiple complex diseases / / 17554300 rs12525258 chr6 1189622 G A 3.39E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12525258 chr6 1189622 G A 1.30E-05 Urinary metabolites / / 21572414 rs4959523 chr6 1193415 A G 1.08E-11 Non-obstructive azoospermia / / 22197933 rs460780 chr6 1199694 G A 1.30E-05 Urinary metabolites / / 21572414 rs465582 chr6 1214290 A G 8.95E-04 Obesity (extreme) / / 21935397 rs369656 chr6 1214888 C T 5.04E-04 Premature ovarian failure / / 19508998 rs9378283 chr6 1221578 A G 4.03E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12174024 chr6 1254489 G A 2.70E-06 Urinary metabolites / / 21572414 rs2459602 chr6 1264403 G A 5.71E-04 Multiple complex diseases / / 17554300 rs12191625 chr6 1270673 T C 2.70E-05 Urinary metabolites / / 21572414 rs2496296 chr6 1275620 G A 2.60E-05 Urinary metabolites / / 21572414 rs12209110 chr6 1289462 C T 2.87E-04 Multiple complex diseases / / 17554300 rs1025672 chr6 1308143 A T 6.56E-04 Smoking initiation / / 24665060 rs1550199 chr6 1308575 G C 5.04E-04 Multiple complex diseases / / 17554300 rs11242675 chr6 1318878 C T 7.00E-09 Breast cancer / / 23535729 rs6903955 chr6 1331850 C T 2.68E-05 Post-operative nausea and vomiting / / 21694509 rs9502893 chr6 1340189 C T 3.00E-07 Pancreatic cancer / / 20686608 rs1737766 chr6 1361844 T C 7.80E-06 Post-operative nausea and vomiting / / 21694509 rs9405470 chr6 1363890 G C 1.93E-04 Type 2 diabetes / / 17463246 rs12524544 chr6 1366220 T C 8.38E-05 Post-operative nausea and vomiting / / 21694509 rs9328048 chr6 1379871 C T 2.60E-04 Age-related macular degeneration / / 21665990 rs1711973 chr6 1402537 T C 3.00E-06 Bladder cancer (smoking interaction) / / 24662972 rs4959559 chr6 1409798 A G 4.09E-05 Schizophrenia / / 24253340 rs12665337 chr6 1415811 G A 1.48E-05 Femoral neck bone geometry / / 22087292 rs1711961 chr6 1417720 T C 6.10E-04 Response to TNF antagonist treatment / / 21061259 rs1711961 chr6 1417720 T C 1.70E-05 Urinary metabolites / / 21572414 rs17202895 chr6 1443801 T C 5.71E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9501722 chr6 1443898 A G 1.10E-06 Urinary metabolites / / 21572414 rs9328053 chr6 1444295 T C 4.70E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs6937692 chr6 1451455 A G 9.50E-06 Obesity-related traits / / 23251661 rs723138 chr6 1471717 C G 3.40E-05 Personality dimensions / / 18957941 rs17262881 chr6 1480280 A G 1.51E-05 Hypertension / / pha003041 rs9392297 chr6 1495398 C T 3.86E-04 Insulin resistance / / 21901158 rs9405484 chr6 1498457 G T 2.26E-06 Multiple complex diseases / / 17554300 rs12660207 chr6 1500565 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9405488 chr6 1506156 G A 9.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs9405488 chr6 1506156 G A 1.90E-05 Urinary metabolites / / 21572414 rs9328058 chr6 1514799 C T 9.41E-05 Coronary heart disease / / pha003055 rs3935776 chr6 1515374 A C 6.53E-04 Iron levels / / pha002876 rs2569872 chr6 1524570 G C 8.00E-06 Metabolite levels (HVA/MHPG ratio) / / 23319000 rs11242704 chr6 1535998 A G 5.00E-06 Response to hepatitis C treatment / / 22095909 rs13214070 chr6 1573477 G T 7.54E-04 Smoking initiation / / 24665060 rs2338 chr6 1573613 G A 5.00E-06 Response to platinum-based agents / / 22020760 rs4959580 chr6 1584974 T C 8.94E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2569881 chr6 1620037 G A 7.10E-05 Coronary heart disease / / 21966275 rs742556 chr6 1633682 T C 1.00E-04 Information processing speed GMDS intron 21130836 rs2569844 chr6 1649347 G T 4.53E-04 Amyotrophic Lateral Sclerosis GMDS intron 17362836 rs2569879 chr6 1663565 A C 2.42E-04 Amyotrophic Lateral Sclerosis GMDS intron 17362836 rs7759035 chr6 1663631 C A 7.30E-04 Amyotrophic Lateral Sclerosis GMDS intron 17362836 rs9501751 chr6 1666963 G A 5.01E-04 Amyotrophic Lateral Sclerosis GMDS intron 17362836 rs2814820 chr6 1686599 A G 1.01E-04 Amyotrophic Lateral Sclerosis GMDS intron 17362836 rs9405506 chr6 1708871 T A,C,G 1.82E-04 Suicide attempts in bipolar disorder GMDS intron 21041247 rs12197419 chr6 1709037 C T 1.90E-06 Urinary metabolites GMDS intron 21572414 rs12206258 chr6 1709703 T C 6.40E-05 White matter hyperintensity burden GMDS intron 21681796 rs12203614 chr6 1713390 T C 9.60E-05 White matter hyperintensity burden GMDS intron 21681796 rs761147 chr6 1716710 C T 9.80E-07 Urinary metabolites GMDS intron 21572414 rs9405507 chr6 1723854 C T 2.90E-05 Urinary metabolites GMDS intron 21572414 rs7754428 chr6 1725261 T C 2.50E-05 Urinary metabolites GMDS intron 21572414 rs3800030 chr6 1729592 T C 2.20E-04 White matter integrity GMDS intron 22425255 rs3823261 chr6 1730212 T C 4.29E-04 White matter integrity GMDS intron 22425255 rs1013064 chr6 1731692 A G 9.80E-06 Urinary metabolites GMDS intron 21572414 rs6924173 chr6 1732770 A C 0.000288 Salmonella-induced pyroptosis GMDS intron 22837397 rs3800043 chr6 1764324 C T 6.93E-05 Alcohol dependence GMDS intron 21703634 rs3823270 chr6 1781973 A G 6.50E-04 Nicotine smoking GMDS intron 19268276 rs3800065 chr6 1783630 G A 1.05E-04 Depression (quantitative trait) GMDS intron 20800221 rs9391933 chr6 1825339 G A 3.68E-04 Multiple complex diseases GMDS intron 17554300 rs3800083 chr6 1831050 C T 6.21E-05 Waist-Hip Ratio GMDS intron pha003029 rs1028714 chr6 1833041 C G 5.60E-04 Multiple complex diseases GMDS intron 17554300 rs3800091 chr6 1837828 T C 9.43E-05 Serum albumin level GMDS intron pha003084 rs3800100 chr6 1858536 C A,T 8.10E-05 Serum albumin level GMDS intron pha003084 rs3800101 chr6 1859130 G A 0.000729501 Hypertension (early onset hypertension) GMDS intron 22479346 rs7776397 chr6 1867102 C A 8.36E-04 Alzheimer's disease GMDS intron 17998437 rs3800119 chr6 1885972 C T 0.00000928 Autism spectrum disorders GMDS intron 22412387 rs3800119 chr6 1885972 C T 1.04E-05 Serum albumin level GMDS intron pha003084 rs3800122 chr6 1899671 T C 3.18E-06 Serum albumin level GMDS intron pha003084 rs1570534 chr6 1901495 C T 7.44E-04 Spine bone size GMDS intron 23207799 rs3800131 chr6 1918262 A C 9.00E-06 Obesity-related traits GMDS intron 23251661 rs4463305 chr6 1918572 T C 3.19E-04 Alcohol dependence GMDS intron 21314694 rs3800143 chr6 1942538 T C 1.55E-04 Alzheimer's disease (late onset) GMDS intron 21379329 rs3800143 chr6 1942538 T C 0.00000412 Autism spectrum disorders GMDS intron 22412387 rs3800150 chr6 1955764 A G 8.06E-05 Alzheimer's disease (late onset) GMDS intron 21379329 rs6596866 chr6 1995508 G A 6.19E-04 Type 2 diabetes GMDS intron 17463246 rs4959621 chr6 1997212 A G 6.54E-04 Type 2 diabetes GMDS intron 17463246 rs9378672 chr6 2042092 A T 7.60E-05 Temperament (bipolar disorder) GMDS intron 22365631 rs11242735 chr6 2055677 G C 3.00E-05 Temperament (bipolar disorder) GMDS intron 22365631 rs10484947 chr6 2104972 C T 0.0004369 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) GMDS intron 23233654 rs10484947 chr6 2104972 C T 4.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) GMDS intron 23233662 rs10484948 chr6 2108585 A G 0.0004449 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) GMDS intron 23233654 rs10484948 chr6 2108585 A G 4.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) GMDS intron 23233662 rs9503125 chr6 2213255 G A 9.29E-04 Obesity (extreme) GMDS intron 21935397 rs3778566 chr6 2213785 T C 9.29E-04 Obesity (extreme) GMDS intron 21935397 rs9501818 chr6 2214632 G A 9.21E-04 Obesity (extreme) GMDS intron 21935397 rs6903476 chr6 2222462 G A 8.95E-04 Obesity (extreme) GMDS intron 21935397 rs9503127 chr6 2222733 G C 8.99E-04 Obesity (extreme) GMDS intron 21935397 rs3778568 chr6 2225680 C T 6.45E-04 Multiple complex diseases GMDS intron 17554300 rs9378688 chr6 2235633 G A 6.00E-06 Caudate nucleus volume GMDS intron 21502949 rs1196396 chr6 2256627 A G 1.28E-04 Multiple complex diseases LOC100508120 intron 17554300 rs9503146 chr6 2346269 C A 8.94E-04 Obesity (extreme) LOC100508120 intron 21935397 rs2505675 chr6 2355675 C T 9.57E-04 Coronary heart disease LOC100508120 intron 21606135 rs2505675 chr6 2355675 C T 4.00E-06 Tuberculosis LOC100508120 intron 24057671 rs6917662 chr6 2357934 T G 9.69E-04 Obesity (extreme) LOC100508120 intron 21935397 rs9503155 chr6 2369492 G A 4.83E-08 Metabolite levels LOC100508120 intron 23281178 rs11242766 chr6 2405609 G C 3.91E-08 Metabolite levels LOC100508120 intron 23281178 rs4959663 chr6 2412228 C T 8.96E-04 Response to taxane treatment (placlitaxel) LOC100508120 intron 23006423 rs9503185 chr6 2413911 C T 3.96E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9501836 chr6 2414213 C G 7.05E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6911665 chr6 2414740 T C 5.31E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3817904 chr6 2415244 C T 3.55E-05 Height / / pha003011 rs11242770 chr6 2436364 A G 7.03E-08 Metabolite levels / / 23281178 rs12209322 chr6 2437165 A C 7.03E-08 Metabolite levels / / 23281178 rs9328099 chr6 2437545 C T 4.00E-04 Type 2 diabetes / / 17846126 rs12206851 chr6 2441087 A C 5.95E-04 Smoking quantity / / 24665060 rs742487 chr6 2447699 C T 7.21E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9391949 chr6 2452024 A G 6.34E-05 Multiple complex diseases / / 17554300 rs9391949 chr6 2452024 A G 3.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6926842 chr6 2472613 G T 7.13E-04 Multiple complex diseases / / 17554300 rs2325963 chr6 2479402 T C 6.53E-05 Cognitive impairment induced by topiramate / / 22091778 rs6911560 chr6 2485808 A G 4.40E-05 Bipolar disorder / / 19488044 rs6911560 chr6 2485808 A G 1.79E-05 Bipolar Disorder / / pha002863 rs4959677 chr6 2500820 G C 9.00E-06 Orthostatic hypotension / / 24124408 rs7749514 chr6 2524946 C T 7.42E-04 Alcohol dependence / / 21314694 rs4959190 chr6 2561352 A G 1.05E-06 Obesity-related traits / / 23251661 rs12195826 chr6 2565752 A G 4.00E-07 Obesity-related traits / / 23251661 rs9378715 chr6 2573814 A G 8.10E-05 Response to statin therapy / / 20339536 rs1254728 chr6 2583443 T C 7.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs1001729 chr6 2595478 C T 2.26E-05 Body Mass Index / / pha002896 rs4959195 chr6 2596934 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6918808 chr6 2608995 G A 2.90E-05 Urinary metabolites / / 21572414 rs7750686 chr6 2625101 G C 2.30E-05 Urinary metabolites C6orf195 intron 21572414 rs7771891 chr6 2625304 A G 3.13E-05 Coronary heart disease C6orf195 intron pha003031 rs7759042 chr6 2629151 T C 2.21E-05 Coronary heart disease C6orf195 intron pha003031 rs1324495 chr6 2671256 A G 1.05E-04 Schizophrenia MYLK4 intron 21926974 rs2038761 chr6 2680767 C T 2.02E-05 Migraine MYLK4 intron 20802479 rs6939996 chr6 2680805 G A 3.47E-05 Brain lesion load MYLK4 intron 19010793 rs6935206 chr6 2689064 T C 1.50E-05 Urinary metabolites MYLK4 intron 21572414 rs3926503 chr6 2711003 A G 5.60E-06 Urinary metabolites MYLK4 intron 21572414 rs17291546 chr6 2715682 A G 7.65E-06 Aging (time to event) MYLK4 intron 21782286 rs17135660 chr6 2743674 T C 1.53E-04 Multiple complex diseases MYLK4 intron 17554300 rs1466390 chr6 2754794 C A 2.50E-05 Urinary metabolites / / 21572414 rs160699 chr6 2776303 T C 6.86E-05 Fibrinogen WRNIP1 intron pha003068 rs17135709 chr6 2781800 G T 9.01E-04 Type 2 diabetes WRNIP1 intron 17463246 rs4083550 chr6 2783304 A G 1.38E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) WRNIP1 intron 24023788 rs160704 chr6 2784353 C G 9.75E-04 Coronary Artery Disease WRNIP1 intron 17634449 rs460677 chr6 2787925 A G 5.24E-04 Type 2 diabetes / / 17463246 rs460677 chr6 2787925 A G 6.86E-04 Coronary Artery Disease / / 17634449 rs178399 chr6 2791683 G A 4.70E-04 Type 2 diabetes / / 17463246 rs178399 chr6 2791683 G A 3.66E-04 Coronary Artery Disease / / 17634449 rs160690 chr6 2799060 A C 5.98E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1350849 chr6 2807760 G T 5.49E-04 Type 2 diabetes / / 17463246 rs408265 chr6 2842425 T C 4.40E-04 Parkinson's disease / / 17052657 rs11242804 chr6 2845099 T C 1.24E-04 Smoking initiation / / 24665060 rs380821 chr6 2862941 C T 8.96E-04 Parkinson's disease MGC39372 intron 16252231 rs318491 chr6 2898596 A G 6.44E-04 Premature ovarian failure SERPINB9 intron 19508998 rs318497 chr6 2912277 G A 2.86E-04 Premature ovarian failure / / 19508998 rs318497 chr6 2912277 G A 5.00E-09 Venous thromboembolism (gene x gene interaction) / / 23509962 rs17135977 chr6 2913443 A T 7.49E-05 Alzheimer's disease / / 22005930 rs7759176 chr6 2915664 G T 1.73E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7757819 chr6 2918547 A G 4.59E-04 Lymphocyte counts / / 22286170 rs318448 chr6 2931354 C A 9.80E-05 Alzheimer's disease / / 22005930 rs318448 chr6 2931354 C A 1.74E-05 Acne (severe teenage) / / 24114350 rs318449 chr6 2932455 A G 9.47E-04 Alzheimer's disease / / 22005930 rs318449 chr6 2932455 A G 1.75E-05 Acne (severe teenage) / / 24114350 rs318427 chr6 2945331 A G 1.10E-05 Urinary metabolites / / 21572414 rs2295767 chr6 2954557 C T 6.58E-05 Panic disorder SERPINB6 intron 19165232 rs911540 chr6 2958584 C T 6.60E-06 Urinary metabolites SERPINB6 intron 21572414 rs2038562 chr6 3016057 A G 1.08E-04 Lung function (forced expiratory volume in 1 second) NQO2 intron 17255346 rs12214551 chr6 3046749 T C 5.64E-26 Gender / / 22362730 rs2272990 chr6 3077141 T C 5.00E-07 Preschool internalizing problems RIPK1 cds-synon 24839885 rs6907943 chr6 3078266 C A 8.68E-04 Lymphocyte counts RIPK1 intron 22286170 rs7745598 chr6 3099418 A G 0.00047 Coronary artery calcification RIPK1 intron 23727086 rs17548259 chr6 3099884 C T 0.00044 Coronary artery calcification RIPK1 intron 23727086 rs17513478 chr6 3101555 G A 1.41E-15 Cholesterol,total RIPK1 intron 23063622 rs17513478 chr6 3101555 G A 4.37E-08 LDL cholesterol RIPK1 intron 23063622 rs17513478 chr6 3101555 G A 4.47E-10 HDL cholesterol RIPK1 intron 23063622 rs17513222 chr6 3105522 T C 0.00047 Coronary artery calcification RIPK1 intron 23727086 rs17548308 chr6 3112056 C G 1.38E-08 HDL cholesterol RIPK1 intron 23063622 rs9501935 chr6 3174947 C T 1.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4448134 chr6 3189096 G A 7.49E-04 Response to alcohol consumption (flushing response) LOC100507194 intron 24277619 rs11970389 chr6 3250656 C T 9.20E-05 Type 2 diabetes LOC100507294 intron 17463248 rs9503490 chr6 3251749 T C 8.70E-04 Multiple complex diseases LOC100507294 intron 17554300 rs4339509 chr6 3256770 C T 1.19E-04 Multiple complex diseases LOC100507294 intron 17554300 rs13193012 chr6 3264671 T C 4.75E-05 Blood Pressure PSMG4 intron pha003049 rs3813487 chr6 3270064 T C 2.24E-05 Lymphocyte counts SLC22A23 UTR-3 22286170 rs4959796 chr6 3287486 C A 1.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC22A23 intron 20877124 rs9378357 chr6 3294824 G T 1.00E-06 Obesity-related traits SLC22A23 intron 23251661 rs3935358 chr6 3295190 A G 6.83E-06 Obesity-related traits SLC22A23 intron 23251661 rs3935359 chr6 3295251 C A 1.94E-06 Obesity-related traits SLC22A23 intron 23251661 rs9391988 chr6 3307863 G A 2.00E-06 Homeostasis model assessment of insulin resistance (interaction) SLC22A23 intron 24204828 rs4959813 chr6 3320151 T C 1.36E-04 Multiple complex diseases SLC22A23 intron 17554300 rs4546534 chr6 3321204 T C 9.06E-04 Multiple complex diseases SLC22A23 intron 17554300 rs6928108 chr6 3343075 T C 1.75E-04 Height SLC22A23 intron 17255346 rs7766646 chr6 3353709 C T 4.47E-05 Hypertension SLC22A23 intron 19609347 rs4959235 chr6 3359337 T C 2.00E-07 Antipsychotic-induced QTc interval prolongation SLC22A23 intron 20921969 rs13219577 chr6 3368956 G T 6.90E-06 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) SLC22A23 intron 21221126 rs981946 chr6 3371291 G A 2.80E-06 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) SLC22A23 intron 21221126 rs1079284 chr6 3372545 G A 2.90E-06 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) SLC22A23 intron 21221126 rs6911308 chr6 3375697 T G 2.80E-06 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) SLC22A23 intron 21221126 rs913533 chr6 3376492 C T 1.60E-06 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) SLC22A23 intron 21221126 rs4959825 chr6 3412240 T C 1.69E-06 Blood Pressure SLC22A23 intron pha003044 rs4452682 chr6 3415302 G A 3.20E-06 Asthma (bronchodilator response) SLC22A23 intron 22792082 rs4959239 chr6 3418794 C G 0.00008838 Sarcoidosis SLC22A23 intron 22952805 rs9405639 chr6 3419149 T C 5.30E-05 Multiple complex diseases SLC22A23 intron 17554300 rs9405639 chr6 3419149 T C 3.31E-05 Coronary Artery Disease SLC22A23 intron 17634449 rs10498663 chr6 3430439 T C 3.58E-04 Multiple complex diseases SLC22A23 intron 17554300 rs10498663 chr6 3430439 T C 8.60E-05 Response to statin therapy SLC22A23 intron 20339536 rs7774747 chr6 3430996 C T 2.50E-04 Multiple complex diseases SLC22A23 intron 17554300 rs17309827 chr6 3433318 T G 3.12E-05 Multiple complex diseases SLC22A23 intron 17554300 rs17309827 chr6 3433318 T G 3.70E-07 Crohn's disease SLC22A23 intron 18587394 rs17309827 chr6 3433318 T G 7.00E-09 Crohn's disease SLC22A23 intron 21102463 rs4959830 chr6 3434242 G A 3.85E-05 Multiple complex diseases SLC22A23 intron 17554300 rs4959830 chr6 3434242 G A 2.83E-06 Crohn's disease SLC22A23 intron 18587394 rs10900943 chr6 3481313 C T 2.40E-05 Urinary metabolites / / 21572414 rs4959247 chr6 3499963 T C 7.91E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs9392501 chr6 3518466 C T 6.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs34599590 chr6 3522099 C T 0.00008483 Sarcoidosis / / 22952805 rs9503618 chr6 3543701 A G 9.29E-04 Insulin resistance / / 21901158 rs17716079 chr6 3546794 T C 1.00E-04 Prostate cancer / / 21743057 rs7747217 chr6 3576944 A T 3.43E-04 Multiple complex diseases / / 17554300 rs7743238 chr6 3587548 T C 2.00E-05 Prostate cancer / / 21743057 rs9502023 chr6 3594782 G T 1.00E-04 Prostate cancer / / 21743057 rs9502029 chr6 3608887 A G 1.00E-04 Prostate cancer / / 21743057 rs9502033 chr6 3615820 T G 1.00E-04 Prostate cancer / / 21743057 rs9502039 chr6 3665573 C T 8.71E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs9503675 chr6 3671630 G C 7.82E-04 Multiple complex diseases / / 17554300 rs17136887 chr6 3686521 A C 4.45E-05 Multiple complex diseases / / 17554300 rs226930 chr6 3699703 T C 8.03E-05 Alzheimer's disease (late onset) / / 21379329 rs12207353 chr6 3700255 G A 9.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs226929 chr6 3701118 T G 6.60E-06 Urinary metabolites / / 21572414 rs226927 chr6 3701232 A G 5.70E-06 Urinary metabolites / / 21572414 rs226938 chr6 3709845 C T 1.38E-04 Alzheimer's disease (late onset) / / 21379329 rs226966 chr6 3720301 C T 9.11E-04 Multiple complex diseases / / 17554300 rs11242871 chr6 3740307 T C 9.43E-04 Type 2 diabetes PXDC1 intron 17463246 rs6902924 chr6 3781456 A G 9.93E-04 Alzheimer's disease / / 22005930 rs9378384 chr6 3808855 C A 2.62E-04 Longevity / / 22279548 rs9503746 chr6 3816555 T G 1.80E-05 Urinary metabolites / / 21572414 rs12174470 chr6 3833652 C G 3.58E-05 Multiple complex diseases / / 17554300 rs6597005 chr6 3833922 A C 1.81E-05 Multiple complex diseases / / 17554300 rs17318866 chr6 3837198 G A 3.89E-04 Multiple complex diseases / / 17554300 rs17318866 chr6 3837198 G A 1.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs2496388 chr6 3857624 G A 3.46E-04 Myopia (pathological) / / 21095009 rs7761276 chr6 3857887 A G 8.01E-04 Multiple complex diseases / / 17554300 rs2252854 chr6 3859096 T G 9.01E-04 Myopia (pathological) / / 21095009 rs7738894 chr6 3880894 T A 8.88E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9328204 chr6 3887765 A G 4.43E-05 Cognitive impairment induced by topiramate / / 22091778 rs4959896 chr6 3919714 C T 1.75E-05 Aging (time to event) / / 21782286 rs9503817 chr6 3920619 C T 5.64E-04 Smoking quantity / / 24665060 rs4631335 chr6 3943739 T G 0.0000821 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs4959901 chr6 3944424 C T 2.36E-04 Dental caries / / 21940522 rs9405676 chr6 3947984 G A 9.86E-05 Glucose levels / / pha003057 rs9405684 chr6 3960888 T C 6.10E-05 Taste perception / / 22132133 rs7743464 chr6 3961288 C T 8.91E-05 Type 2 diabetes / / 23300278 rs9503867 chr6 3982525 T C 5.66E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs9378836 chr6 3989106 T C 2.76E-05 Multiple complex diseases / / 17554300 rs9328211 chr6 3989654 A G 1.90E-05 Serum metabolites / / 19043545 rs10458166 chr6 4012929 T C 7.70E-05 Memory performance / / 22105620 rs10458166 chr6 4012929 T C 2.37E-05 Creatinine levels / / pha003069 rs9503893 chr6 4031998 A G 4.01E-05 Cognitive test performance PRPF4B missense 20125193 rs707980 chr6 4043847 A C 7.97E-05 Cognitive test performance PRPF4B intron 20125193 rs853406 chr6 4057160 T G 2.20E-05 Subclinical atherosclerosis PRPF4B intron 17903303 rs853407 chr6 4057233 C T 2.20E-05 Subclinical atherosclerosis PRPF4B intron 17903303 rs853407 chr6 4057233 C T 5.90E-05 Cognitive test performance PRPF4B intron 20125193 rs9503907 chr6 4057542 T G 6.10E-04 Smoking cessation PRPF4B intron 24665060 rs10485172 chr6 4069133 T A,C 9.41E-05 Creatinine levels FAM217A missense pha003069 rs77132955 chr6 4074822 C A 0.00024 Prostate cancer FAM217A missense 23555315 rs634114 chr6 4086920 G C 3.79E-04 Aortic root size C6orf201 intron 21223598 rs3177253 chr6 4133855 C T 9.18E-05 Bone mineral density ECI2 missense 19181680 rs9392556 chr6 4146198 T C 4.00E-38 Blood metabolite levels LOC100507506 intron 24816252 rs583807 chr6 4155792 G A 3.70E-05 Anger / / 24489884 rs2810793 chr6 4228049 G A 7.72E-05 Cognitive test performance / / 20125193 rs2810793 chr6 4228049 G A 1.90E-04 Rheumatoid arthritis / / 21452313 rs9504023 chr6 4269667 A G 9.45E-04 Multiple complex diseases / / 17554300 rs6904215 chr6 4283692 A G 3.42E-06 Uric acid levels / / 21294900 rs1999022 chr6 4297286 A G 1.80E-06 Uric acid levels / / 21294900 rs10900955 chr6 4323299 T C 4.96E-04 Multiple complex diseases / / 17554300 rs4959277 chr6 4354439 G A 3.11E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17138098 chr6 4364141 A G 3.38E-06 Obesity-related traits / / 23251661 rs17138114 chr6 4379511 A G 1.00E-06 Obesity-related traits / / 23251661 rs17138114 chr6 4379511 A G 4.52E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs170949 chr6 4395749 T C 5.30E-05 Hypothyroidism / / 22493691 rs1265290 chr6 4464135 A G 1.51E-04 Insulin resistance / / 21901158 rs1265283 chr6 4465188 G C 7.90E-06 Urinary metabolites / / 21572414 rs1265273 chr6 4469641 G A 2.30E-04 Breast cancer / / 20852631 rs1265270 chr6 4470378 T C 8.75E-05 Insulin resistance / / 21901158 rs2145910 chr6 4479146 A G 9.26E-04 Multiple complex diseases / / 17554300 rs4959990 chr6 4480510 G C 5.20E-04 Multiple complex diseases / / 17554300 rs4959295 chr6 4480742 C T 8.26E-04 Multiple complex diseases / / 17554300 rs6914063 chr6 4482102 C T 6.27E-04 Multiple complex diseases / / 17554300 rs1009603 chr6 4484350 A T 2.80E-05 Urinary metabolites / / 21572414 rs2150232 chr6 4490506 T C 4.63E-04 Multiple complex diseases / / 17554300 rs1265248 chr6 4491515 T C 2.59E-04 Multiple complex diseases / / 17554300 rs4959299 chr6 4492079 A G 4.42E-04 Smoking initiation / / 24665060 rs1265235 chr6 4500682 C T 1.06E-05 Suicidal ideation / / 22030708 rs4959999 chr6 4508960 A G 9.14E-05 Cognitive test performance / / 20125193 rs6915400 chr6 4512953 C T 1.96E-06 Uric acid levels / / 21294900 rs6942328 chr6 4512979 T C 1.00E-06 Uric acid levels / / 21294900 rs1265214 chr6 4520511 A G 1.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1923313 chr6 4547573 G A 9.06E-06 Aortic root size / / 21223598 rs6908122 chr6 4548562 C A 6.50E-06 Urinary metabolites / / 21572414 rs10484836 chr6 4553691 C T 1.57E-04 Blood pressure / / 17255346 rs10484836 chr6 4553691 C T 2.00E-05 Asthma / / pha003127 rs434509 chr6 4561830 G A 4.10E-04 Heart Failure / / pha002884 rs441034 chr6 4564117 C T 7.49E-04 Multiple complex diseases / / 17554300 rs441034 chr6 4564117 C T 2.50E-05 Urinary metabolites / / 21572414 rs415223 chr6 4568283 T C 5.85E-04 Multiple complex diseases / / 17554300 rs11242959 chr6 4574440 C T 2.27E-04 Aortic root size / / 21223598 rs9504162 chr6 4599442 C T 5.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs9328262 chr6 4600394 G A 2.88E-04 Alzheimer's disease / / 17998437 rs11965481 chr6 4600758 C T 1.70E-05 Urinary metabolites / / 21572414 rs234427 chr6 4629654 A C 3.01E-04 Alzheimer's disease / / 22005930 rs371778 chr6 4655490 A G 8.61E-05 Coronary heart disease / / pha003030 rs400478 chr6 4655679 C T 8.50E-07 Urinary metabolites / / 21572414 rs13191293 chr6 4662666 A G 3.12E-04 Birth weight / / 17255346 rs1971444 chr6 4664262 T C 2.02E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs429909 chr6 4665135 C T 2.61E-04 Birth weight / / 17255346 rs9328267 chr6 4665855 A G 4.49E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2063677 chr6 4666589 G T 2.02E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs408884 chr6 4671240 A G 5.94E-04 Multiple complex diseases / / 17554300 rs2073041 chr6 4674858 C T 3.75E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2073042 chr6 4677960 T C 1.12E-06 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs6918242 chr6 4678260 C T 2.63E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs3812179 chr6 4716016 A G 4.42E-05 Potassium levels / / pha003086 rs3812178 chr6 4716037 T C 4.42E-05 Potassium levels / / pha003086 rs7767658 chr6 4721046 C T 5.56E-05 Orofacial clefts CDYL intron 19270707 rs4502986 chr6 4762144 T C 3.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDYL intron 20877124 rs9504238 chr6 4763028 G A 3.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDYL intron 20877124 rs110284 chr6 4769767 T C 9.83E-05 Blood Pressure CDYL intron pha003040 rs12197283 chr6 4823231 C T 9.22E-04 Type 2 diabetes CDYL intron 17463246 rs808601 chr6 4864581 C T 4.82E-04 Multiple complex diseases CDYL intron 17554300 rs73717741 chr6 4874759 C G 3.00E-07 Chronic obstructive pulmonary disease CDYL intron 21685187 rs808627 chr6 4881615 G A 6.29E-04 Multiple complex diseases CDYL intron 17554300 rs808626 chr6 4882018 G A 6.27E-04 Multiple complex diseases CDYL intron 17554300 rs808620 chr6 4883663 G A,T 3.67E-05 Multiple complex diseases CDYL intron 17554300 rs9405785 chr6 4915028 G A 8.30E-05 Orofacial clefts CDYL intron 22863734 rs4144547 chr6 4915423 T A 2.17E-05 Asthma CDYL intron 23181788 rs3789793 chr6 4945774 C T 4.89E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CDYL intron 24023788 rs1246936 chr6 4961165 A G 4.65E-04 Smoking initiation / / 24665060 rs1246938 chr6 4962641 G A 7.57E-04 Depression (quantitative trait) / / 20800221 rs17285799 chr6 4973677 C T 4.40E-04 Depression (quantitative trait) / / 20800221 rs2793222 chr6 4978209 A G 4.94E-05 Body mass index / / 21701565 rs2793222 chr6 4978209 A G 6.83E-05 Body mass index / / 21701565 rs2793222 chr6 4978209 A G 8.39E-04 Body mass index / / 21701565 rs707966 chr6 5006839 C T 4.47E-06 Intelligence / / 21826061 rs2764126 chr6 5017118 T G 6.75E-04 Myocardial Infarction / / pha002873 rs2764142 chr6 5024363 G A 3.53E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs2326574 chr6 5041470 T G 7.99E-04 Myocardial Infarction / / pha002873 rs2764114 chr6 5051183 C T 6.83E-04 Body mass index / / 21701565 rs1246996 chr6 5059245 T C 1.93E-04 White matter integrity / / 22425255 rs1247000 chr6 5061594 C T 0.00000729 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1749133 chr6 5063893 T A 0.0000549 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11963503 chr6 5064140 G T 0.0000515 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9392653 chr6 5071492 C T 2.00E-09 Venous thromboembolism (gene x gene interaction) / / 23509962 rs1265351 chr6 5080904 C T 9.09E-05 Cognitive impairment induced by topiramate / / 22091778 rs1065500 chr6 5087422 G T 0.00000812 Nonsyndromic striae distensae (stretch marks) PPP1R3G UTR-3 23633020 rs394683 chr6 5098413 C T 0.000022 Primary sclerosing cholangitis / / 22521342 rs17139431 chr6 5106379 C G 2.85E-05 Multiple complex diseases / / 17554300 rs388597 chr6 5124190 T C 3.30E-06 Urinary metabolites LYRM4 intron 21572414 rs464606 chr6 5130429 G A 8.39E-06 C-Reactive Protein LYRM4 intron pha003070 rs10484845 chr6 5147040 T C 9.09E-04 Multiple complex diseases LYRM4 intron 17554300 rs12529198 chr6 5151247 A G 1.65E-05 Multiple complex diseases LYRM4 intron 17554300 rs12529198 chr6 5151247 A G 3.48E-07 Crohn's disease LYRM4 intron 18587394 rs6917194 chr6 5157420 C G 6.39E-04 Coronary Artery Disease LYRM4 intron 17634449 rs6917194 chr6 5157420 C G 1.30E-05 Urinary metabolites LYRM4 intron 21572414 rs6917225 chr6 5157471 C T 2.00E-04 Body mass index LYRM4 intron 24827717 rs12661523 chr6 5172009 T G 8.59E-05 ldl cholesterol LYRM4 intron pha003077 rs12661523 chr6 5172009 T G 8.12E-05 Cholesterol LYRM4 intron pha003083 rs4959334 chr6 5206776 T C 7.67E-16 Multiple complex diseases LYRM4 intron 17554300 rs4246073 chr6 5214983 T G 1.90E-05 Urinary metabolites LYRM4 intron 21572414 rs13212749 chr6 5246118 T C 1.71E-27 Narcolepsy LYRM4 intron 19629137 rs2753235 chr6 5252182 A G 6.68E-04 QT interval LYRM4 intron 22726844 rs2224391 chr6 5260936 A C 3.00E-06 Height LYRM4 missense 21998595 rs2326584 chr6 5289206 G A 2.90E-04 Type 2 diabetes and 6 quantitative traits FARS2 intron 17848626 rs9405828 chr6 5364290 C T 1.12E-04 Heart Failure FARS2 intron pha002884 rs708037 chr6 5366604 A C 6.26E-04 Amyotrophic lateral sclerosis (sporadic) FARS2 intron 24529757 rs11243007 chr6 5379058 G A 2.00E-06 Urinary metabolites FARS2 intron 21572414 rs12197914 chr6 5383589 C T 8.79E-04 Acute lung injury FARS2 intron 22295056 rs7770766 chr6 5385326 A G 7.77E-04 Acute lung injury FARS2 intron 22295056 rs6925333 chr6 5387077 C G 7.54E-04 Acute lung injury FARS2 intron 22295056 rs9392680 chr6 5387330 G A 7.54E-04 Acute lung injury FARS2 intron 22295056 rs11243009 chr6 5391286 G T 1.50E-06 Urinary metabolites FARS2 intron 21572414 rs2432789 chr6 5393305 T G 1.50E-06 Urinary metabolites FARS2 intron 21572414 rs2032989 chr6 5395285 T C 2.20E-05 Urinary metabolites FARS2 intron 21572414 rs6900391 chr6 5395873 C T 2.20E-06 Urinary metabolites FARS2 intron 21572414 rs11243010 chr6 5396596 G T 1.80E-07 Urinary metabolites FARS2 intron 21572414 rs12200334 chr6 5397070 G A 5.40E-07 Urinary metabolites FARS2 intron 21572414 rs2250354 chr6 5398252 A C 5.60E-06 Urinary metabolites FARS2 intron 21572414 rs2432778 chr6 5403926 C T 7.70E-07 Urinary metabolites FARS2 intron 21572414 rs200196 chr6 5445347 C A 7.40E-06 Urinary metabolites FARS2 intron 21572414 rs200194 chr6 5447754 G A 4.20E-06 Urinary metabolites FARS2 intron 21572414 rs414830 chr6 5452658 G A 1.88E-04 Amyotrophic lateral sclerosis (sporadic) FARS2 intron 24529757 rs2791458 chr6 5455161 T C 2.70E-06 Urinary metabolites FARS2 intron 21572414 rs11969624 chr6 5460085 G C 6.75E-05 Personality dimensions FARS2 intron 18957941 rs6597129 chr6 5482653 G T 4.80E-04 Multiple complex diseases FARS2 intron 17554300 rs9502305 chr6 5484829 A G 8.66E-04 Type 2 diabetes FARS2 intron 17463246 rs9502305 chr6 5484829 A G 1.61E-04 Multiple complex diseases FARS2 intron 17554300 rs9502305 chr6 5484829 A G 1.24E-05 Bladder cancer (smoking interaction) FARS2 intron 24662972 rs7774359 chr6 5486254 A G 4.43E-04 Spine bone size FARS2 intron 23207799 rs12199468 chr6 5502552 G T 3.13E-05 Fibrinogen FARS2 intron pha003068 rs9328308 chr6 5513491 T C 6.60E-05 Alcohol dependence FARS2 intron 20201924 rs9328308 chr6 5513491 T C 7.60E-04 Alcohol dependence FARS2 intron 20201924 rs9328308 chr6 5513491 T C 4.43E-06 Telomere length FARS2 intron 23001564 rs9328308 chr6 5513491 T C 6.57E-05 Alcoholism FARS2 intron pha002893 rs12204218 chr6 5513550 A G 9.30E-06 Urinary metabolites FARS2 intron 21572414 rs17140735 chr6 5516774 C T 6.72E-04 Type 2 diabetes FARS2 intron 17463246 rs6910841 chr6 5520850 C T 2.83E-04 Type 2 diabetes FARS2 intron 17463246 rs7763423 chr6 5523888 G T 2.79E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FARS2 intron 24023788 rs9405273 chr6 5524393 G A 2.12E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FARS2 intron 24023788 rs9405273 chr6 5524393 G A 3.50E-04 Smoking cessation FARS2 intron 24665060 rs12213022 chr6 5532008 C T 1.40E-05 Urinary metabolites FARS2 intron 21572414 rs9405842 chr6 5536180 T C 2.20E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FARS2 intron 24023788 rs2326613 chr6 5545046 T G 5.82E-05 Fibrinogen FARS2 intron pha003068 rs9378428 chr6 5548558 T C 6.24E-06 Serum metabolites FARS2 intron 19043545 rs10484312 chr6 5557149 T C 9.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) FARS2 intron 23233662 rs4960099 chr6 5557960 C G 7.14E-04 Multiple complex diseases FARS2 intron 17554300 rs9405847 chr6 5558173 C T 9.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) FARS2 intron 23233662 rs9378968 chr6 5581224 A G 8.60E-07 Lipid levels FARS2 intron 18193043 rs9405852 chr6 5587708 G A 6.10E-06 Urinary metabolites FARS2 intron 21572414 rs4960108 chr6 5589242 T C 1.40E-05 Urinary metabolites FARS2 intron 21572414 rs2142736 chr6 5592246 G A 6.40E-06 Urinary metabolites FARS2 intron 21572414 rs1985346 chr6 5593965 C G 6.40E-06 Urinary metabolites FARS2 intron 21572414 rs9502320 chr6 5595323 G C 1.80E-05 Urinary metabolites FARS2 intron 21572414 rs9328318 chr6 5595955 G C 2.90E-05 Urinary metabolites FARS2 intron 21572414 rs9328321 chr6 5600438 G A 5.00E-07 Obesity (early onset extreme) FARS2 intron 23563609 rs10484314 chr6 5648087 A G 6.10E-04 Alcohol dependence FARS2 intron 20201924 rs1977057 chr6 5661403 C T 8.03E-05 Acute lymphoblastic leukemia (childhood) FARS2 intron 19684603 rs11757961 chr6 5708735 G A 9.85E-04 Type 2 diabetes FARS2 intron 17463246 rs6918658 chr6 5717397 G A 4.77E-04 Response to cytadine analogues (cytosine arabinoside) FARS2 intron 24483146 rs7741438 chr6 5723118 A G 6.47E-04 Response to cytadine analogues (cytosine arabinoside) FARS2 intron 24483146 rs6923842 chr6 5723181 C T 5.50E-06 Urinary metabolites FARS2 intron 21572414 rs1569464 chr6 5723400 C T 9.18E-04 Response to cytadine analogues (cytosine arabinoside) FARS2 intron 24483146 rs1009606 chr6 5726369 A G 4.60E-04 Sudden cardiac arrest FARS2 intron 21658281 rs6933902 chr6 5730686 G A 2.14E-04 Multiple complex diseases FARS2 intron 17554300 rs7740019 chr6 5744992 G A 3.11E-04 Type 2 diabetes FARS2 intron 17463246 rs9504505 chr6 5746943 T C 4.35E-04 Type 2 diabetes FARS2 intron 17463246 rs7760017 chr6 5753906 G C 6.49E-04 Type 2 diabetes FARS2 intron 17463246 rs2326673 chr6 5757650 C A 9.96E-04 Type 2 diabetes FARS2 intron 17463246 rs7748744 chr6 5758827 G C 6.49E-04 Type 2 diabetes FARS2 intron 17463246 rs6919521 chr6 5780867 C T 6.05E-04 Type 2 diabetes / / 17463246 rs4960138 chr6 5788022 G T 4.33E-04 Obesity (extreme) / / 21935397 rs4604310 chr6 5822232 T C 0.000000629 Tuberculosis with early age of onset / / 22551897 rs7763309 chr6 5839085 T C 5.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6901736 chr6 5867862 G A 1.26E-04 Multiple complex diseases / / 17554300 rs17141353 chr6 5883721 A G 0.0000549 Panic disorder / / 23149450 rs17141353 chr6 5883721 A G 5.49E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs1407793 chr6 5884859 A G 1.80E-05 Urinary metabolites / / 21572414 rs12195664 chr6 5896461 G A 2.74E-04 Alzheimer's disease / / 24755620 rs12191107 chr6 5896552 T C 4.52E-04 Alzheimer's disease / / 24755620 rs11243038 chr6 5897768 T C 2.13E-04 Cognitive decline / / 23732972 rs11243038 chr6 5897768 T C 6.10E-04 Smoking initiation / / 24665060 rs11243038 chr6 5897768 T C 2.95E-04 Alzheimer's disease / / 24755620 rs12199406 chr6 5898358 G A 3.04E-04 Alzheimer's disease / / 24755620 rs12193326 chr6 5898375 A G 2.45E-04 Cognitive decline / / 23732972 rs12193326 chr6 5898375 A G 3.54E-04 Alzheimer's disease / / 24755620 rs1590328 chr6 5900268 G A 7.79E-05 Alzheimer's disease / / 24755620 rs10155777 chr6 5902668 C G 2.13E-04 Cognitive decline / / 23732972 rs7744130 chr6 5903994 G A 2.13E-04 Cognitive decline / / 23732972 rs7744130 chr6 5903994 G A 1.93E-04 Alzheimer's disease / / 24755620 rs7769375 chr6 5904322 A G 2.13E-04 Cognitive decline / / 23732972 rs10155695 chr6 5904791 T C 5.87E-05 Cognitive decline / / 23732972 rs10155695 chr6 5904791 T C 7.91E-04 Alzheimer's disease / / 24755620 rs7755613 chr6 5905606 C T 4.53E-05 Telomere length / / 23001564 rs12191669 chr6 5906529 C T 3.72E-06 Telomere length / / 23001564 rs7775306 chr6 5909164 G A 9.84E-04 Alzheimer's disease / / 24755620 rs1001289 chr6 5910305 C T 5.87E-05 Cognitive decline / / 23732972 rs1001289 chr6 5910305 C T 1.92E-04 Alzheimer's disease / / 24755620 rs1001290 chr6 5910329 T C 5.81E-04 Prostate cancer mortality / / 20978177 rs12213320 chr6 5919702 A G 2.08E-04 Cognitive decline / / 23732972 rs12213320 chr6 5919702 A G 6.72E-05 Alzheimer's disease / / 24755620 rs12193231 chr6 5928289 A G 1.57E-04 Alzheimer's disease / / 24755620 rs4960147 chr6 5952591 C T 0.000841337 Hypertension (early onset hypertension) / / 22479346 rs2146448 chr6 5982090 A G 4.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17363340 chr6 5989082 G A 5.97E-04 Type 2 diabetes / / 17463246 rs7748174 chr6 5995651 A G 4.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9405284 chr6 6013003 C T 3.21E-05 adolescent idiopathic scoliosis / / 24023777 rs1475157 chr6 6017169 A G 5.63E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs667875 chr6 6019942 A G 4.26E-05 Hemoglobin / / pha003098 rs680965 chr6 6020515 T C 8.28E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9328341 chr6 6027082 C T 7.53E-04 Rheumatoid arthritis / / 21452313 rs17298948 chr6 6034281 A C 1.15E-05 Heart Rate / / pha003053 rs629744 chr6 6037120 C A 7.57E-04 Alzheimer's disease / / 24755620 rs1409544 chr6 6040933 A G 9.09E-05 Heart Rate / / pha003053 rs6597183 chr6 6042429 T G 4.88E-04 Alzheimer's disease / / 24755620 rs7745950 chr6 6062392 G A 3.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1905212 chr6 6073966 C T 4.32E-05 Mammographic density / / 22532574 rs9504664 chr6 6092876 G A 4.68E-04 Taste perception / / 22132133 rs9405900 chr6 6093220 A G 5.31E-04 Mammographic density / / 22532574 rs55725325 chr6 6108849 C A 5.03E-04 Taste perception / / 22132133 rs2876006 chr6 6114382 T G 5.15E-04 Taste perception / / 22132133 rs11243060 chr6 6123280 G T 6.83E-04 Alzheimer's disease / / 22005930 rs13201744 chr6 6126845 C A 1.12E-06 Blood pressure / / 21378095 rs13201744 chr6 6126845 C A 7.30E-08 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs10484321 chr6 6136283 T G 3.13E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs9504681 chr6 6138154 A G 6.95E-04 Type 2 diabetes / / 17463246 rs3024466 chr6 6144857 C A 7.94E-04 Suicide attempts in bipolar disorder F13A1 UTR-3 21041247 rs1050783 chr6 6145692 C T 7.23E-04 Suicide attempts in bipolar disorder F13A1 UTR-3 21041247 rs7748218 chr6 6147369 C T 6.96E-04 Suicide attempts in bipolar disorder F13A1 intron 21041247 rs7748376 chr6 6147416 C G 2.68E-04 Suicide attempts in bipolar disorder F13A1 intron 21041247 rs7772909 chr6 6147905 T C 6.95E-04 Suicide attempts in bipolar disorder F13A1 intron 21041247 rs4960167 chr6 6150763 C T 5.35E-04 Suicide attempts in bipolar disorder F13A1 intron 21041247 rs2274394 chr6 6152211 C G 6.39E-04 Type 2 diabetes F13A1 intron 17463246 rs3024457 chr6 6152408 C A 4.58E-04 Type 2 diabetes F13A1 intron 17463246 rs3024457 chr6 6152408 C A 7.31E-04 Suicide attempts in bipolar disorder F13A1 intron 21041247 rs13203312 chr6 6153100 A G 8.88E-04 Type 2 diabetes F13A1 intron 17463246 rs6914953 chr6 6153443 C T 9.54E-04 Type 2 diabetes F13A1 intron 17463246 rs440330 chr6 6165782 T C 2.00E-04 Cognitive impairment induced by topiramate F13A1 intron 22091778 rs7769202 chr6 6169656 T C 6.18E-04 Multiple complex diseases F13A1 intron 17554300 rs6934608 chr6 6169890 T G 1.00E-06 Antibody status in Tripanosoma cruzi seropositivity F13A1 intron 24324551 rs7774391 chr6 6176625 A G 9.03E-06 Triglycerides F13A1 intron pha003081 rs7774391 chr6 6176625 A G 2.37E-06 Lipid levels F13A1 intron pha003082 rs426158 chr6 6199915 T C 4.80E-04 Acute lung injury F13A1 intron 22295056 rs1742929 chr6 6228025 G A 8.13E-04 Obesity (extreme) F13A1 intron 21935397 rs1742930 chr6 6228406 G A 1.07E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) F13A1 intron 24023788 rs9504730 chr6 6237117 C T 1.10E-05 Parkinson's disease (age of onset) F13A1 intron 19772629 rs1742923 chr6 6241008 G A 9.65E-04 Obesity (extreme) F13A1 intron 21935397 rs1781795 chr6 6241281 C T 9.52E-04 Obesity (extreme) F13A1 intron 21935397 rs17376901 chr6 6242593 G T 8.67E-04 Alzheimer's disease F13A1 intron 17998437 rs3024371 chr6 6250912 T A 7.03E-12 End-stage coagulation F13A1 intron 23381943 rs3024370 chr6 6250967 G A 8.76E-14 End-stage coagulation F13A1 intron 23381943 rs9504732 chr6 6252111 A G 1.49E-12 End-stage coagulation F13A1 intron 23381943 rs7766109 chr6 6256833 G A 5.61E-17 End-stage coagulation F13A1 intron 23381943 rs9504737 chr6 6258604 G A 1.69E-10 End-stage coagulation F13A1 intron 23381943 rs9504738 chr6 6258630 A G 1.51E-04 Multiple complex diseases F13A1 intron 17554300 rs9504738 chr6 6258630 A G 1.65E-10 End-stage coagulation F13A1 intron 23381943 rs3863221 chr6 6259582 T A 1.39E-11 End-stage coagulation F13A1 intron 23381943 rs12333289 chr6 6263446 C T 2.05E-10 End-stage coagulation F13A1 intron 23381943 rs140712764 chr6 6266854 C T 0.00000083 Prostate cancer (non-advanced prostate cancer) F13A1 missense 23555315 rs140712764 chr6 6266854 C T 0.00000091 Prostate cancer F13A1 missense 23555315 rs140712764 chr6 6266854 C T 0.000068 Breast cancer F13A1 missense 23555315 rs3024358 chr6 6267304 G T 3.40E-04 Type 2 diabetes F13A1 intron 17463246 rs10484323 chr6 6272186 T C 1.52E-04 Multiple complex diseases F13A1 intron 17554300 rs10484323 chr6 6272186 T C 7.85E-11 End-stage coagulation F13A1 intron 23381943 rs17141966 chr6 6272625 T C 1.79E-10 End-stage coagulation F13A1 intron 23381943 rs3851514 chr6 6274570 T C 4.14E-11 End-stage coagulation F13A1 intron 23381943 rs9328347 chr6 6274947 G A 2.13E-04 Type 2 diabetes F13A1 intron 17463246 rs9328347 chr6 6274947 G A 4.87E-04 Coronary heart disease F13A1 intron 21606135 rs9328347 chr6 6274947 G A 1.53E-16 End-stage coagulation F13A1 intron 23381943 rs9328347 chr6 6274947 G A 2.34E-04 Iron levels F13A1 intron pha002876 rs4959377 chr6 6280288 C T 3.75E-11 End-stage coagulation F13A1 intron 23381943 rs9405911 chr6 6282778 A G 1.23E-08 End-stage coagulation F13A1 intron 23381943 rs12664620 chr6 6282943 A G 2.37E-16 End-stage coagulation F13A1 intron 23381943 rs749005 chr6 6283666 G T 3.00E-07 MRI atrophy measures F13A1 intron 21116278 rs1742932 chr6 6304531 G A 2.47E-16 End-stage coagulation F13A1 intron 23381943 rs2295753 chr6 6305477 C A 6.45E-05 Lymphocyte counts F13A1 intron pha003094 rs714408 chr6 6306405 A G 2.21E-37 End-stage coagulation F13A1 intron 23381943 rs17378819 chr6 6307443 T C 2.73E-82 End-stage coagulation F13A1 intron 23381943 rs7758057 chr6 6307578 C G 2.25E-125 End-stage coagulation F13A1 intron 23381943 rs6922262 chr6 6307947 C G 4.14E-87 End-stage coagulation F13A1 intron 23381943 rs1742934 chr6 6308750 A C 1.47E-38 End-stage coagulation F13A1 intron 23381943 rs1742937 chr6 6309698 G A 5.86E-120 End-stage coagulation F13A1 intron 23381943 rs2755413 chr6 6310536 T C 2.21E-25 End-stage coagulation F13A1 intron 23381943 rs1674043 chr6 6310616 T A 1.23E-27 End-stage coagulation F13A1 intron 23381943 rs1674045 chr6 6311188 A G 1.98E-27 End-stage coagulation F13A1 intron 23381943 rs2755416 chr6 6311701 A G 1.14E-28 End-stage coagulation F13A1 intron 23381943 rs1475072 chr6 6313497 C T 4.99E-29 End-stage coagulation F13A1 intron 23381943 rs1781790 chr6 6314582 G C 2.37E-18 End-stage coagulation F13A1 intron 23381943 rs3024342 chr6 6314643 T C 5.24E-05 Body mass (lean) F13A1 intron 19268274 rs3024342 chr6 6314643 T C 6.54E-104 End-stage coagulation F13A1 intron 23381943 rs3024339 chr6 6314893 T C 6.43E-36 End-stage coagulation F13A1 intron 23381943 rs11243078 chr6 6316802 T G 5.35E-15 End-stage coagulation F13A1 intron 23381943 rs3024321 chr6 6318126 A G 8.00E-142 End-stage coagulation F13A1 intron 23381943 rs5985 chr6 6318795 C A 3.00E-186 End-stage coagulation F13A1 missense 23381943 rs3024317 chr6 6319379 G A 4.98E-36 End-stage coagulation F13A1 intron 23381943 rs6938914 chr6 6324038 A T 1.00E-11 End-stage coagulation / / 23381943 rs3844195 chr6 6325513 C G 1.32E-11 End-stage coagulation / / 23381943 rs3844196 chr6 6325739 T C 1.60E-11 End-stage coagulation / / 23381943 rs11752195 chr6 6326311 C G 1.59E-12 End-stage coagulation / / 23381943 rs11754589 chr6 6326592 A T 1.75E-12 End-stage coagulation / / 23381943 rs1781789 chr6 6326858 C T 1.58E-08 End-stage coagulation / / 23381943 rs11755846 chr6 6328146 A G 8.09E-22 End-stage coagulation / / 23381943 rs12199357 chr6 6331245 A G 4.50E-17 End-stage coagulation / / 23381943 rs927332 chr6 6331873 T C 1.38E-22 End-stage coagulation / / 23381943 rs1318606 chr6 6331936 T C 4.00E-17 End-stage coagulation / / 23381943 rs1318606 chr6 6331936 T C 9.35E-05 Body Mass Index / / pha003014 rs3851517 chr6 6334644 G A 1.45E-17 End-stage coagulation / / 23381943 rs1674072 chr6 6335427 G A 5.81E-09 End-stage coagulation / / 23381943 rs3863223 chr6 6336922 G T 1.05E-19 End-stage coagulation / / 23381943 rs11243081 chr6 6337506 C T 5.00E-18 End-stage coagulation / / 23381943 rs4960189 chr6 6338761 G A 6.19E-18 End-stage coagulation / / 23381943 rs17142067 chr6 6341287 A C 1.00E-17 End-stage coagulation / / 23381943 rs9328354 chr6 6344007 C A 1.42E-08 End-stage coagulation / / 23381943 rs13192814 chr6 6345311 T C 2.70E-08 End-stage coagulation / / 23381943 rs6901377 chr6 6346762 C T 2.48E-11 End-stage coagulation / / 23381943 rs11753672 chr6 6346966 G C 2.43E-08 End-stage coagulation / / 23381943 rs9504770 chr6 6347347 C T 2.43E-08 End-stage coagulation / / 23381943 rs13201655 chr6 6350139 G T 2.77E-08 End-stage coagulation LY86-AS1 intron 23381943 rs13201814 chr6 6350271 G T 2.77E-08 End-stage coagulation LY86-AS1 intron 23381943 rs9392770 chr6 6350381 C T 2.45E-11 End-stage coagulation LY86-AS1 intron 23381943 rs13206706 chr6 6351730 G A 2.68E-04 Aortic root size LY86-AS1 intron 21223598 rs13198304 chr6 6356482 C T 7.04E-07 Biliary atresia LY86-AS1 intron 20460270 rs7774436 chr6 6361816 G A 9.59E-05 Waist Circumference LY86-AS1 intron pha003024 rs7774436 chr6 6361816 G A 4.61E-05 Waist-Hip Ratio LY86-AS1 intron pha003029 rs1156061 chr6 6367428 C T 1.50E-05 Urinary metabolites LY86-AS1 intron 21572414 rs12198109 chr6 6369189 C T 7.50E-05 Body Mass Index LY86-AS1 intron pha003006 rs12198109 chr6 6369189 C T 7.64E-06 Waist Circumference LY86-AS1 intron pha003024 rs12198109 chr6 6369189 C T 5.91E-06 Waist-Hip Ratio LY86-AS1 intron pha003029 rs13206136 chr6 6376547 T C 6.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LY86-AS1 intron 20877124 rs4438996 chr6 6382616 T A 3.04E-04 Multiple complex diseases LY86-AS1 intron 17554300 rs9328360 chr6 6400149 G A 3.36E-05 Type 2 diabetes LY86-AS1 intron 17463246 rs12200621 chr6 6402127 A G 5.68E-05 Waist-Hip Ratio LY86-AS1 intron pha003029 rs17142175 chr6 6410104 T C 2.06E-05 Cognitive impairment induced by topiramate LY86-AS1 intron 22091778 rs4455715 chr6 6410663 A G 5.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LY86-AS1 intron 20877124 rs2774511 chr6 6433911 C T 3.91E-04 Alzheimer's disease LY86-AS1 intron 17998437 rs849056 chr6 6505111 C T 3.23E-04 Myopia (pathological) LY86-AS1 intron 21095009 rs849050 chr6 6516047 T C 1.00E-04 Myopia (pathological) LY86-AS1 intron 21095009 rs708064 chr6 6531361 G T 9.97E-04 Myopia (pathological) LY86-AS1 intron 21095009 rs17142289 chr6 6550749 A G 4.00E-06 Response to radiotherapy in cancer (late toxicity) LY86-AS1 intron 24785509 rs623810 chr6 6555051 C T 5.75E-05 Prion diseases LY86-AS1 intron 22210626 rs636574 chr6 6555641 G A 1.38E-04 Prion diseases LY86-AS1 intron 22210626 rs581403 chr6 6556120 A G 6.49E-04 Multiple complex diseases LY86-AS1 intron 17554300 rs681505 chr6 6558761 G A 3.79E-04 Lung function (forced expiratory volume in 1 second) LY86-AS1 intron 24023788 rs146115427 chr6 6563152 C T 0.0000701 Nonsyndromic striae distensae (stretch marks) LY86-AS1 intron 23633020 rs9379042 chr6 6565712 T A 1.68E-05 Lymphocyte counts LY86-AS1 intron 22286170 rs9504848 chr6 6566290 T C 1.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LY86-AS1 intron 20877124 rs1999652 chr6 6574384 T G 6.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LY86-AS1 intron 20877124 rs4959388 chr6 6582123 A G 0.0000185 Central corneal thickness in patients with an IOP <= 21mmHg and no history of IOP>= 21mmHg LY86-AS1 intron 22661486 rs977785 chr6 6588881 A C 3.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LY86-AS1 intron 20877124 rs6597220 chr6 6589477 C T 3.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LY86 intron 20877124 rs9328374 chr6 6591629 G A 2.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LY86 intron 20877124 rs7740529 chr6 6610609 C T 7.71E-04 Response to cytidine analogues (gemcitabine) LY86 intron 24483146 rs2326810 chr6 6612467 G C 7.00E-06 Major depressive disorder (broad) LY86 intron 20038947 rs2294461 chr6 6614501 A C 0.000108 Coronary artery disease LY86 intron 23202125 rs9392815 chr6 6614742 G T 2.46E-05 Major depressive disorder (broad) LY86 intron 20038947 rs932364 chr6 6616590 T C 7.41E-04 Type 2 diabetes LY86 intron 17463246 rs3804474 chr6 6621508 C T 2.65E-04 Longevity LY86 intron 22279548 rs7770797 chr6 6621962 G A 3.54E-04 Type 2 diabetes LY86 intron 17463246 rs1076673 chr6 6627184 G T 6.17E-04 Type 2 diabetes LY86 intron 17463246 rs1076673 chr6 6627184 G T 3.80E-05 Coronary heart disease LY86 intron pha003030 rs3804477 chr6 6628721 C T 8.76E-04 Response to taxane treatment (placlitaxel) LY86 intron 23006423 rs3761986 chr6 6680510 T C 4.94E-04 Alzheimer's disease (late onset) / / 21379329 rs3449 chr6 6730230 C G 2.30E-05 Cognitive function / / 24684796 rs201061 chr6 6730512 G A 7.87E-06 Hemoglobin / / pha003096 rs201061 chr6 6730512 G A 2.98E-05 Hematocrit / / pha003097 rs1294410 chr6 6738752 T C 1.00E-06 Waist-hip ratio / / 23966867 rs1294416 chr6 6741327 A G 2.92E-07 Hemoglobin / / pha003096 rs1294416 chr6 6741327 A G 2.05E-06 Hematocrit / / pha003097 rs1294421 chr6 6743149 T G 2.00E-17 Waist-hip ratio / / 20935629 rs1294421 chr6 6743149 T G 2.00E-10 Waist-hip ratio / / 23563607 rs1294433 chr6 6745163 G A 7.14E-06 Hemoglobin / / pha003096 rs1294433 chr6 6745163 G A 2.58E-05 Hematocrit / / pha003097 rs4959406 chr6 6784140 C A 1.04E-06 Waist-hip ratio / / 20935629 rs9502509 chr6 6816332 G A 7.96E-04 Multiple complex diseases / / 17554300 rs9502509 chr6 6816332 G A 9.71E-04 Aortic root size / / 21223598 rs13209867 chr6 6818779 G A,C 5.80E-06 Urinary metabolites / / 21572414 rs17142602 chr6 6819227 A G 1.25E-04 Multiple complex diseases / / 17554300 rs9504940 chr6 6823174 C T 2.51E-05 Personality dimensions / / 22628180 rs1892458 chr6 6826108 G A 5.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs1286053 chr6 6829312 T C 2.60E-04 Stroke / / pha002886 rs943613 chr6 6832811 C T 4.61E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs13215298 chr6 6833987 A G 0.0000456 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs1286046 chr6 6834674 G A 2.23E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1286045 chr6 6836121 C G 5.17E-05 Serum metabolites / / 19043545 rs1286037 chr6 6843733 A G 7.82E-05 Suicide attempts in bipolar disorder / / 21423239 rs4960250 chr6 6846098 G A 2.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs10900995 chr6 6848893 T C 5.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs4960252 chr6 6851439 A C 4.13E-05 Suicide attempts in bipolar disorder / / 21423239 rs2105454 chr6 6851538 A G 9.33E-05 Suicide attempts in bipolar disorder / / 21423239 rs7772595 chr6 6852974 G A 4.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs11243123 chr6 6853392 T C 2.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs12660428 chr6 6853441 A C 4.75E-05 Suicide attempts in bipolar disorder / / 21423239 rs4960254 chr6 6854396 T C 3.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs11758918 chr6 6864231 C G 1.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs4960257 chr6 6865244 A C 6.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs2148979 chr6 6883659 A C 6.36E-05 Serum metabolites / / 19043545 rs13199355 chr6 6886210 G A 6.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs1887507 chr6 6887857 C T 0.00000065 Salmonella-induced pyroptosis / / 22837397 rs3748061 chr6 6901235 C G 5.24E-05 Cognitive decline / / 22054870 rs7755797 chr6 6905093 A G 2.20E-05 Urinary metabolites / / 21572414 rs9392131 chr6 6909328 T C 2.39E-05 Creutzfeldt-Jakob disease (variant) / / 22137330 rs17142699 chr6 6933182 A G 8.62E-04 Type 2 diabetes / / 17463246 rs2148975 chr6 6938928 C T 3.14E-05 Sudden cardiac arrest / / 21658281 rs2765350 chr6 6956241 G A 3.22E-04 Type 2 diabetes / / 17463246 rs1536241 chr6 6960310 A G 2.42E-05 Elbow pain / / pha003008 rs814174 chr6 7025868 A G 1.06E-09 Urate levels / / 23263486 rs12201780 chr6 7026277 G A 1.60E-05 Type 2 diabetes / / 17460697 rs3863225 chr6 7032317 G A 8.64E-11 Urate levels / / 23263486 rs9505008 chr6 7033860 C T 7.75E-11 Urate levels / / 23263486 rs1611819 chr6 7034675 A T 9.13E-04 Alzheimer's disease / / 22005930 rs13212734 chr6 7037637 G A 1.06E-10 Urate levels / / 23263486 rs10458103 chr6 7037738 G A 6.87E-11 Urate levels / / 23263486 rs13202703 chr6 7038265 A G 8.09E-11 Urate levels / / 23263486 rs13207230 chr6 7041700 G A 3.36E-11 Urate levels / / 23263486 rs17584570 chr6 7044167 C T 7.72E-12 Urate levels / / 23263486 rs1286005 chr6 7046452 T C 1.87E-13 Urate levels / / 23263486 rs6929119 chr6 7046594 G C 1.58E-12 Urate levels / / 23263486 rs9328398 chr6 7046763 C T 1.01E-11 Urate levels / / 23263486 rs1286003 chr6 7046998 A G 1.80E-09 Urate levels / / 23263486 rs560131 chr6 7047411 T G 1.19E-11 Urate levels / / 23263486 rs7743312 chr6 7049929 G C 4.73E-09 Urate levels / / 23263486 rs7769136 chr6 7052225 C T 1.46E-08 Urate levels / / 23263486 rs592377 chr6 7060902 C T 5.23E-10 Urate levels / / 23263486 rs2148088 chr6 7061912 G T 1.55E-09 Urate levels / / 23263486 rs6936076 chr6 7063271 G A 4.61E-04 Alcohol dependence / / 21314694 rs6936076 chr6 7063271 G A 3.16E-09 Urate levels / / 23263486 rs2326878 chr6 7075094 C A 7.85E-17 Urate levels / / 23263486 rs611555 chr6 7075822 T C 1.00E-08 Urate levels / / 20884846 rs611555 chr6 7075822 T C 2.37E-17 Urate levels / / 23263486 rs6912908 chr6 7080522 A G 2.37E-17 Urate levels / / 23263486 rs501510 chr6 7081840 T A 2.40E-07 Urate levels / / 20884846 rs501510 chr6 7081840 T A 3.40E-17 Urate levels / / 23263486 rs9405325 chr6 7082633 T C 4.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9405325 chr6 7082633 T C 9.78E-18 Urate levels / / 23263486 rs13213992 chr6 7083218 C T 1.70E-08 Urate levels / / 20884846 rs13213992 chr6 7083218 C T 1.66E-17 Urate levels / / 23263486 rs4959424 chr6 7084857 G T 1.08E-16 Urate levels / / 23263486 rs482079 chr6 7086901 T C 6.52E-08 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs495261 chr6 7096070 G C 2.50E-05 Urinary metabolites / / 21572414 rs9502551 chr6 7099908 G A 1.20E-04 Multiple complex diseases / / 17554300 rs675209 chr6 7102084 T C 1.00E-09 Urate levels / / 20884846 rs675209 chr6 7102084 T C 1.00E-23 Urate levels / / 23263486 rs2842895 chr6 7106316 G C 4.00E-06 Visceral adipose tissue adjusted for BMI RREB1 nearGene-5 22589738 rs2842895 chr6 7106316 G C 8.66E-17 Urate levels RREB1 nearGene-5 23263486 rs1285874 chr6 7115533 T A 4.84E-13 Urate levels RREB1 intron 23263486 rs1285875 chr6 7115927 G C 9.30E-08 Urate levels RREB1 intron 20884846 rs1285875 chr6 7115927 G C 7.79E-15 Urate levels RREB1 intron 23263486 rs11755724 chr6 7118990 A G 1.00E-06 Age-related macular degeneration RREB1 intron 20385826 rs11755724 chr6 7118990 A G 1.40E-08 Urate levels RREB1 intron 20884846 rs11755724 chr6 7118990 A G 3.00E-06 Multiple sclerosis RREB1 intron 21833088 rs11755724 chr6 7118990 A G 6.03E-19 Urate levels RREB1 intron 23263486 rs3863227 chr6 7125371 G T 2.46E-04 Multiple complex diseases RREB1 intron 17554300 rs6933716 chr6 7125709 T C 2.80E-07 Urate levels RREB1 intron 20884846 rs6933716 chr6 7125709 T C 6.31E-14 Urate levels RREB1 intron 23263486 rs687467 chr6 7128076 A G 3.60E-08 Urate levels RREB1 intron 20884846 rs687467 chr6 7128076 A G 1.05E-16 Urate levels RREB1 intron 23263486 rs622404 chr6 7130596 A G 3.80E-08 Urate levels RREB1 intron 20884846 rs622404 chr6 7130596 A G 1.47E-17 Urate levels RREB1 intron 23263486 rs630258 chr6 7134401 T C 4.00E-08 Urate levels RREB1 intron 20884846 rs630258 chr6 7134401 T C 4.05E-17 Urate levels RREB1 intron 23263486 rs1285879 chr6 7137363 T C 4.20E-08 Urate levels RREB1 intron 20884846 rs1285879 chr6 7137363 T C 9.22E-17 Urate levels RREB1 intron 23263486 rs665723 chr6 7139064 C T 4.60E-08 Urate levels RREB1 intron 20884846 rs665723 chr6 7139064 C T 3.20E-17 Urate levels RREB1 intron 23263486 rs557074 chr6 7145191 T G 5.02E-08 Parkinson's disease RREB1 intron 17052657 rs4585612 chr6 7153152 C T 1.93E-16 Urate levels RREB1 intron 23263486 rs9405328 chr6 7166238 A G 3.73E-08 Metabolite levels RREB1 intron 23281178 rs9505057 chr6 7171407 T G 3.73E-08 Metabolite levels RREB1 intron 23281178 rs9502560 chr6 7177140 T G 3.73E-08 Metabolite levels RREB1 intron 23281178 rs6935691 chr6 7178539 T A 5.10E-08 Metabolite levels RREB1 intron 23281178 rs9406002 chr6 7181735 A G 3.02E-08 Metabolite levels RREB1 intron 23281178 rs9392863 chr6 7195009 G A 8.10E-04 Alcohol dependence RREB1 intron 20201924 rs1334577 chr6 7211751 G A 2.30E-07 Urate levels RREB1 intron 20884846 rs1334577 chr6 7211751 G A 2.11E-18 Urate levels RREB1 intron 23263486 rs17762454 chr6 7213200 C T 9.57E-09 Fasting blood glucose RREB1 intron 22885924 rs17762454 chr6 7213200 C T 8.07E-17 Urate levels RREB1 intron 23263486 rs6931262 chr6 7217517 C T 3.00E-08 Waist-hip ratio RREB1 intron 23966867 rs2714348 chr6 7222813 G C 9.47E-04 Suicide attempts in bipolar disorder RREB1 intron 21423239 rs2714348 chr6 7222813 G C 4.77E-04 Alzheimer's disease RREB1 intron 22005930 rs2714357 chr6 7225995 G T 3.81E-04 Alzheimer's disease RREB1 intron 22005930 rs2714315 chr6 7229346 T C 2.58E-04 Alzheimer's disease RREB1 cds-synon 22005930 rs201520366 chr6 7231754 C G 0.000054 Prostate cancer (advanced) RREB1 missense 23555315 rs2714337 chr6 7240577 A T 3.00E-07 Fasting glucose-related traits (interaction with BMI) RREB1 intron 22581228 rs3799504 chr6 7248212 G A 8.50E-05 Memory performance RREB1 intron 22105620 rs2094012 chr6 7248459 C T 7.87E-04 Major depressive disorder RREB1 intron 22472876 rs3778321 chr6 7250270 G A 0.000000129 Fasting blood glucose RREB1 UTR-3 22885924 rs2714338 chr6 7250960 G A 1.80E-04 Alzheimer's disease RREB1 UTR-3 22005930 rs2714341 chr6 7253731 G T 3.15E-05 Socioeconomic Factors / / pha003067 rs9502570 chr6 7258617 C T 1.00E-09 Type 2 diabetes / / 24509480 rs2842362 chr6 7266055 G T 4.15E-05 Meningococcal disease / / 20694013 rs9968917 chr6 7267002 C A 9.20E-05 White blood cell types / / 21738478 rs2842363 chr6 7267582 A G 1.75E-04 Epilepsy / / 22116939 rs11243149 chr6 7275926 A G 4.26E-04 Multiple complex diseases / / 17554300 rs11243150 chr6 7275941 T C 5.57E-04 Multiple complex diseases / / 17554300 rs9505117 chr6 7290282 C T 7.06E-04 Multiple complex diseases SSR1 intron 17554300 rs9505118 chr6 7290437 A G 6.30E-04 Multiple complex diseases SSR1 intron 17554300 rs9505118 chr6 7290437 A G 1.40E-09 Type 2 diabetes SSR1 intron 24509480 rs2714309 chr6 7298287 G A 9.88E-04 Suicide attempts in bipolar disorder SSR1 intron 21423239 rs11243152 chr6 7303665 G A 2.00E-04 Cognitive impairment induced by topiramate SSR1 intron 22091778 rs3778333 chr6 7309150 A G 7.80E-15 Leukemia(T-cell recognition in patients) SSR1 intron 21062987 rs10004 chr6 7310259 A G 7.80E-15 Leukemia(T-cell recognition in patients) SSR1 missense 21062987 rs1886568 chr6 7311474 A G 7.80E-15 Leukemia(T-cell recognition in patients) SSR1 intron 21062987 rs9379089 chr6 7330169 T C 2.69E-04 Celiac disease CAGE1 intron 23936387 rs2764097 chr6 7332074 C G 3.60E-05 Personality dimensions CAGE1 intron 18957941 rs1325031 chr6 7332556 C T 2.93E-05 Mammographic density CAGE1 intron 22532574 rs1325030 chr6 7332845 A G 4.64E-04 Suicide attempts in bipolar disorder CAGE1 intron 21423239 rs2038828 chr6 7336518 A G 4.86E-04 Alzheimer's disease (late onset) CAGE1 intron 21379329 rs13216713 chr6 7339371 C T 4.11E-04 Suicide attempts in bipolar disorder CAGE1 intron 21423239 rs9505189 chr6 7386000 T C 1.88E-04 Suicide attempts in bipolar disorder CAGE1 intron 21423239 rs4959432 chr6 7391921 G A 4.64E-05 Interstitial lung disease RIOK1 intron 23583980 rs9505195 chr6 7393786 T C 8.77E-04 Suicide attempts in bipolar disorder RIOK1 intron 21423239 rs6921373 chr6 7407858 A G 9.66E-04 Suicide attempts in bipolar disorder RIOK1 intron 21423239 rs6925903 chr6 7413995 A G 9.68E-04 Suicide attempts in bipolar disorder RIOK1 intron 21423239 rs9392887 chr6 7427474 G A 2.50E-05 Urinary metabolites / / 21572414 rs9379104 chr6 7431759 C T 6.63E-05 Pancreatic cancer / / pha002889 rs11753111 chr6 7445997 A G 1.08E-05 Smoking cessation / / 24665060 rs11756237 chr6 7470321 T C 8.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs11755831 chr6 7470873 A C 9.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs11243186 chr6 7473810 G A 9.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs17763231 chr6 7474343 C T 8.55E-05 Orofacial clefts / / 22863734 rs2806192 chr6 7476908 C T 9.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs2763119 chr6 7477213 C T 9.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs2763123 chr6 7484005 T C 8.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs4960327 chr6 7495756 G A 5.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs4960328 chr6 7495948 C A 5.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs751569 chr6 7502990 C T 2.80E-06 Urinary metabolites / / 21572414 rs9392162 chr6 7522598 C G 5.85E-05 Serum metabolites / / 19043545 rs9392903 chr6 7536115 A G 2.20E-05 Urinary metabolites / / 21572414 rs9392904 chr6 7555854 G C 2.83E-04 Bipolar disorder DSP intron 18317468 rs12198780 chr6 7556544 C G 6.53E-05 Neuroticism DSP intron 23229837 rs10484325 chr6 7557048 T C 2.92E-05 Interstitial lung disease DSP intron 23583980 rs10484326 chr6 7558318 T C 3.41E-07 Interstitial lung disease DSP intron 23583980 rs2076295 chr6 7563232 T G 1.00E-19 Interstitial lung disease DSP intron 23583980 rs2076295 chr6 7563232 T G 1.14E-16 Interstitial lung disease DSP intron 23583980 rs2076295 chr6 7563232 T G 3.13E-18 Interstitial lung disease DSP intron 23583980 rs1358904 chr6 7564461 C T 5.81E-10 Interstitial lung disease DSP intron 23583980 rs3778337 chr6 7565885 G A 1.53E-09 Interstitial lung disease DSP intron 23583980 rs3778337 chr6 7565885 G A 6.41E-09 Interstitial lung disease DSP intron 23583980 rs2076302 chr6 7570963 A G 1.54E-05 Interstitial lung disease DSP intron 23583980 rs6597271 chr6 7600469 A G 9.69E-05 Meningococcal disease SNRNP48 intron 20694013 rs17398289 chr6 7601436 T C 9.04E-06 Meningococcal disease SNRNP48 intron 20694013 rs12527897 chr6 7632243 A G 4.99E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs9502630 chr6 7633658 G A 4.99E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs9406044 chr6 7641836 A C 7.66E-04 Taste perception / / 22132133 rs9392164 chr6 7643033 C T 5.90E-06 Urinary metabolites / / 21572414 rs7739678 chr6 7652717 A G 9.00E-06 Obesity-related traits / / 23251661 rs11755444 chr6 7654163 T C 8.65E-05 Hypertension (essential hypertension) / / 22184326 rs1555479 chr6 7654391 T C 6.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4959447 chr6 7654694 G A 9.22E-06 Obesity-related traits / / 23251661 rs1885487 chr6 7668923 G A 2.13E-07 Schizophrenia / / 21926974 rs4959451 chr6 7685326 A G 6.67E-04 Multiple complex diseases / / 17554300 rs1322243 chr6 7690468 A T 5.93E-04 Multiple complex diseases / / 17554300 rs1885486 chr6 7695973 G A 5.00E-17 Height / / 23563607 rs9379130 chr6 7702659 G C 2.85E-04 Multiple complex diseases / / 17554300 rs9392918 chr6 7708631 T C 3.06E-04 Multiple complex diseases / / 17554300 rs7769495 chr6 7712702 C G 3.73E-04 Multiple complex diseases / / 17554300 rs1322239 chr6 7714191 C T 8.99E-04 Multiple complex diseases / / 17554300 rs2327010 chr6 7717073 T G 1.31E-04 Multiple complex diseases / / 17554300 rs12198986 chr6 7720059 G A 2.00E-11 Height / / 18391951 rs3812163 chr6 7725760 A T 1.00E-23 Height / / 20881960 rs1107495 chr6 7726057 A G 8.65E-04 Multiple complex diseases / / 17554300 rs6910759 chr6 7733862 G A 9.04E-05 Heart Failure BMP6 intron pha002884 rs2068361 chr6 7736743 C T 7.97E-04 Response to statin treatment (atorvastatin),change in cholesterol levels BMP6 intron 20031582 rs2068361 chr6 7736743 C T 5.00E-06 Orofacial clefts BMP6 intron 22419666 rs9505270 chr6 7743663 G A 4.00E-07 Myopia (pathological) BMP6 intron 23049088 rs270374 chr6 7764173 C T 7.98E-04 Type 2 diabetes BMP6 intron 17463246 rs270398 chr6 7765840 A C 8.91E-04 Type 2 diabetes BMP6 intron 17463246 rs270383 chr6 7775681 C T 5.23E-04 Type 2 diabetes BMP6 intron 17463246 rs189727 chr6 7776017 G A 8.26E-04 Suicide attempts in bipolar disorder BMP6 intron 21423239 rs11243205 chr6 7780436 A G 7.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BMP6 intron 20877124 rs1150890 chr6 7797113 A T 3.58E-04 Suicide attempts in bipolar disorder BMP6 intron 21423239 rs6923462 chr6 7801112 T C 6.00E-13 Lung function (forced vital capacity) BMP6 intron 24929828 rs6913143 chr6 7824236 T C 5.44E-04 Testicular dysgenesis syndrome BMP6 intron 22140272 rs12215656 chr6 7829209 G A 4.98E-08 Metabolite levels BMP6 intron 23281178 rs13192135 chr6 7831972 A G 0.00000382 Colorectal cancer (males) BMP6 intron 22532847 rs267184 chr6 7833429 G A 1.06E-04 Type 2 diabetes BMP6 intron 17463246 rs267186 chr6 7834019 G A 9.43E-05 Type 2 diabetes BMP6 intron 17463246 rs267196 chr6 7849335 T A 9.71E-05 Type 2 diabetes BMP6 intron 17463246 rs267202 chr6 7854236 G A 1.71E-04 Type 2 diabetes BMP6 intron 17463246 rs1225929 chr6 7874233 T A 2.70E-05 Urinary metabolites BMP6 intron 21572414 rs7740227 chr6 7939864 C T 2.60E-05 Urinary metabolites MUTED-TXNDC5 intron 21572414 rs2748364 chr6 7972477 G C 8.15E-05 Sudden cardiac arrest MUTED-TXNDC5 intron 21658281 rs7769739 chr6 7974867 A G 3.70E-04 Type 2 diabetes MUTED-TXNDC5 intron 17463246 rs197119 chr6 7976745 G A 2.54E-04 Prostate cancer mortality MUTED-TXNDC5 intron 20978177 rs197123 chr6 7981671 A C 2.90E-04 Alzheimer's disease (late onset) MUTED-TXNDC5 intron 21379329 rs6926213 chr6 7994513 C T 8.66E-04 Type 2 diabetes MUTED-TXNDC5 intron 17463246 rs9328448 chr6 8001117 A G 3.00E-06 Coronary artery calcification MUTED-TXNDC5 intron 23870195 rs910552 chr6 8001278 A C 1.72E-04 Type 2 diabetes MUTED-TXNDC5 intron 17463246 rs910553 chr6 8001337 G A 3.33E-04 Type 2 diabetes MUTED-TXNDC5 intron 17463246 rs2207720 chr6 8019197 T C 6.31E-04 Smoking initiation MUTED intron 24665060 rs7762614 chr6 8049760 G A 2.15E-04 Smoking cessation MUTED intron 24665060 rs9379163 chr6 8084877 C T 3.51E-05 Soluble levels of adhesion molecules EEF1E1 intron pha003072 rs12526001 chr6 8091525 C G 4.93E-04 Type 2 diabetes EEF1E1 intron 17463246 rs12526001 chr6 8091525 C G 7.81E-05 Schizophrenia EEF1E1 intron 19571811 rs1316319 chr6 8106028 T C 3.27E-04 Coronary heart disease / / 21971053 rs9392963 chr6 8109207 C A 5.67E-04 Type 2 diabetes / / 17463246 rs1537656 chr6 8115392 C T 7.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9378524 chr6 8125408 G A 3.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12200068 chr6 8129573 G A 7.20E-05 Lung adenocarcinoma / / 22797724 rs12201622 chr6 8143156 T A 6.36E-04 Smoking cessation / / 24665060 rs11243235 chr6 8152417 T C 5.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11243235 chr6 8152417 T C 9.06E-05 Soluble levels of adhesion molecules / / pha003072 rs1115608 chr6 8157968 G A 1.12E-05 Adverse response to lamotrigine and phenytoin / / 22379998 rs11962257 chr6 8168952 T C 8.55E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs11964561 chr6 8169800 G A 8.00E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs6930720 chr6 8171106 C T 1.12E-05 Vascular dementia / / 22116812 rs6930720 chr6 8171106 C T 9.75E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs4959471 chr6 8209898 C T 1.43E-04 Type 2 diabetes / / 17463246 rs4959471 chr6 8209898 C T 8.34E-04 Multiple complex diseases / / 17554300 rs2327036 chr6 8211191 G A 8.30E-04 Type 2 diabetes / / 17463246 rs9406109 chr6 8221425 T C 2.89E-04 Type 2 diabetes / / 17463246 rs12200008 chr6 8222599 C A 3.85E-05 Type 2 diabetes / / 17463246 rs9379174 chr6 8222774 C T 6.08E-06 Type 2 diabetes / / 17463246 rs9379174 chr6 8222774 C T 3.72E-04 Multiple complex diseases / / 17554300 rs9379174 chr6 8222774 C T 3.98E-05 HIV-1 progression to AIDS and death / / 21811574 rs2327037 chr6 8228490 G A 4.79E-06 Coronary artery calcification / / 23870195 rs6929568 chr6 8228942 T G 3.00E-06 Coronary artery calcification / / 23870195 rs9406110 chr6 8237195 G A 8.57E-04 Multiple complex diseases / / 17554300 rs9392201 chr6 8241801 A T 2.80E-05 Urinary metabolites / / 21572414 rs591705 chr6 8273873 G A 1.42E-05 Leukocyte Counts / / pha003091 rs663716 chr6 8278455 T C 1.58E-05 Leukocyte Counts / / pha003091 rs2245446 chr6 8293737 A G 1.20E-05 Urinary metabolites / / 21572414 rs2652855 chr6 8327711 G A 1.61E-04 Multiple complex diseases / / 17554300 rs2652854 chr6 8329434 A C 1.50E-05 Urinary metabolites / / 21572414 rs871727 chr6 8344434 G C 2.80E-05 Urinary metabolites / / 21572414 rs6900613 chr6 8351628 C T 6.07E-05 Lipoproteins / / pha003079 rs13216353 chr6 8353148 C T 5.89E-05 Lipoproteins / / pha003079 rs6920684 chr6 8361391 A G 1.52E-05 Lipoproteins / / pha003079 rs1934784 chr6 8370053 T C 1.90E-06 Urinary metabolites / / 21572414 rs1199388 chr6 8390967 A G 4.81E-05 Major depressive disorder (broad) / / 20038947 rs1199389 chr6 8391116 T C 7.25E-06 Erythrocyte counts / / pha003101 rs969421 chr6 8451949 A C 8.70E-04 Type 2 diabetes LOC100506207 intron 17846125 rs1335639 chr6 8483819 A G 1.01E-04 Autism spectrum disorders (language delay) LOC100506207 intron 21519539 rs1854412 chr6 8545975 T C 9.67E-05 Non-alcoholic fatty liver disease histology (other) LOC100506207 intron 20708005 rs850189 chr6 8561740 C T 6.93E-05 Multiple complex diseases LOC100506207 intron 17554300 rs17188761 chr6 8579951 G A 3.10E-06 Urinary metabolites LOC100506207 intron 21572414 rs1328883 chr6 8590447 G T 5.42E-05 Multiple complex diseases LOC100506207 intron 17554300 rs3005153 chr6 8605786 A T 3.81E-05 Multiple complex diseases LOC100506207 intron 17554300 rs9405400 chr6 8607128 A G 3.50E-04 Major depressive disorder LOC100506207 intron 21042317 rs6597343 chr6 8620503 T C 3.10E-04 Major depressive disorder LOC100506207 intron 21042317 rs1022720 chr6 8628041 C T 7.46E-05 Multiple complex diseases LOC100506207 intron 17554300 rs12192533 chr6 8632173 G A 3.59E-04 Alzheimer's disease LOC100506207 intron 22005930 rs7765238 chr6 8632793 C G 3.80E-04 Major depressive disorder LOC100506207 intron 21042317 rs7762631 chr6 8635572 A G 3.70E-04 Major depressive disorder LOC100506207 intron 21042317 rs7753781 chr6 8637501 C T 3.60E-04 Major depressive disorder LOC100506207 intron 21042317 rs1328870 chr6 8638036 G A 2.50E-04 Major depressive disorder LOC100506207 intron 21042317 rs9406183 chr6 8639771 G T 3.10E-04 Major depressive disorder LOC100506207 intron 21042317 rs7763881 chr6 8653247 A C 3.50E-04 Major depressive disorder HULC intron 21042317 rs9328500 chr6 8659071 G C 4.00E-04 Major depressive disorder LOC100506207 intron 21042317 rs7739573 chr6 8659904 C T 3.60E-04 Major depressive disorder LOC100506207 intron 21042317 rs11243268 chr6 8662608 G A,T 3.30E-04 Major depressive disorder LOC100506207 intron 21042317 rs4959496 chr6 8682166 C T 5.40E-04 Type 2 diabetes and 6 quantitative traits LOC100506207 intron 17848626 rs1328860 chr6 8706005 G A 5.72E-04 Multiple complex diseases LOC100506207 intron 17554300 rs7765012 chr6 8803042 G A 2.44E-05 Cognitive test performance / / 20125193 rs7765012 chr6 8803042 G A 3.17E-04 Smoking initiation / / 24665060 rs9688405 chr6 8840918 A G 4.30E-05 Cognitive test performance / / 20125193 rs9393068 chr6 8849275 A G 2.11E-05 Pancreatic cancer / / pha002874 rs7741799 chr6 8853850 C T 6.26E-05 Blood Pressure / / pha003049 rs13203778 chr6 8859077 G A 1.20E-05 Urinary metabolites / / 21572414 rs4566922 chr6 8871713 C T 2.90E-06 Asthma / / 24406073 rs4132732 chr6 8882315 C G 7.69E-04 Aortic root size / / 21223598 rs9393075 chr6 8910646 G A 5.48E-05 Coronary heart disease / / 21971053 rs4351309 chr6 8917897 A G 1.06E-04 Amyotrophic lateral sclerosis / / 20801718 rs9393078 chr6 8922190 C A 1.73E-04 Type 2 diabetes / / 17463246 rs12665086 chr6 8932455 T C 1.94E-04 Cholesterol / / 17255346 rs12665086 chr6 8932455 T C 9.70E-06 Urinary metabolites / / 21572414 rs9405429 chr6 8932890 C G 4.65E-04 Type 2 diabetes / / 17463246 rs9406226 chr6 8945690 G A 5.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs10458233 chr6 8948459 C T 9.83E-04 Depression (quantitative trait) / / 20800221 rs12208641 chr6 8949924 T G 9.73E-04 Depression (quantitative trait) / / 20800221 rs13211231 chr6 8950441 A G 9.70E-04 Depression (quantitative trait) / / 20800221 rs13211231 chr6 8950441 A G 1.60E-04 Amyotrophic lateral sclerosis / / 20801718 rs4316043 chr6 8951083 C T 2.53E-04 Cholesterol / / 17255346 rs4316043 chr6 8951083 C T 4.10E-06 Urinary metabolites / / 21572414 rs17145045 chr6 8974989 G A 2.10E-06 Urinary metabolites / / 21572414 rs9378579 chr6 8983242 G A 2.90E-06 Urinary metabolites / / 21572414 rs2327112 chr6 8999646 G A 7.00E-06 Type 2 diabetes / / 17293876 rs2327112 chr6 8999646 G A 7.00E-06 Type 2 diabetes / / 19184112 rs438259 chr6 9030336 G A 4.00E-06 Attention deficit hyperactivity disorder / / 20732626 rs9505597 chr6 9044593 T C 0.0000293 Migraine / / 22678113 rs9505597 chr6 9044593 T C 2.93E-05 Migraine / / 22683712 rs1886066 chr6 9057578 A G 0.0000556 Migraine / / 22678113 rs1886066 chr6 9057578 A G 5.56E-05 Migraine / / 22683712 rs2093745 chr6 9062461 T C 4.55E-04 Multiple complex diseases / / 17554300 rs7744460 chr6 9065215 G T 0.0000556 Migraine / / 22678113 rs7744460 chr6 9065215 G T 5.56E-05 Migraine / / 22683712 rs2209123 chr6 9068628 A G 4.86E-04 Multiple complex diseases / / 17554300 rs4626470 chr6 9102386 G A 5.77E-06 Glycemic traits (pregnancy) / / 23903356 rs4626470 chr6 9102386 G A 6.93E-06 Glycemic traits (pregnancy) / / 23903356 rs2146959 chr6 9116357 A G 2.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs17145407 chr6 9121141 A G 6.24E-04 Insulin resistance / / 21901158 rs17145441 chr6 9138310 T G 4.08E-05 Schizophrenia LOC100506288 intron 19571809 rs17145441 chr6 9138310 T G 1.12E-05 Schizophrenia LOC100506288 intron pha002859 rs17145445 chr6 9138488 A G 3.02E-04 Aortic root size LOC100506288 intron 21223598 rs11243305 chr6 9138798 C T 9.69E-04 Coronary Artery Disease LOC100506288 intron 17634449 rs2038702 chr6 9140658 G A 8.51E-04 Coronary Artery Disease LOC100506288 intron 17634449 rs2038702 chr6 9140658 G A 1.45E-04 Insulin resistance LOC100506288 intron 21901158 rs4260747 chr6 9265748 A G 4.74E-04 Multiple complex diseases / / 17554300 rs9358817 chr6 9300312 A G 0.000026 Salmonella-induced pyroptosis / / 22837397 rs7772742 chr6 9314354 G A 7.45E-04 Alcohol dependence / / 20201924 rs1107896 chr6 9334214 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1107896 chr6 9334214 T C 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs79304364 chr6 9381569 A C 0.0000956 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs75025617 chr6 9382051 A G 0.000096 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs214434 chr6 9391468 C T 8.03E-05 Tunica Media / / pha003037 rs214441 chr6 9394888 C A 9.61E-05 Tunica Media / / pha003037 rs214443 chr6 9398094 T C 9.61E-05 Tunica Media / / pha003037 rs214447 chr6 9401979 A G 3.50E-05 Type 2 diabetes / / 17460697 rs16892185 chr6 9405559 T C 3.24E-04 Self-reported allergy / / 23817569 rs16892199 chr6 9413108 C G 0.000534 Salmonella-induced pyroptosis / / 22837397 rs957122 chr6 9413488 C T 2.85E-05 Serum metabolites / / 19043545 rs9470710 chr6 9427516 C T 3.10E-06 Multiple complex diseases / / 17554300 rs10484246 chr6 9451197 T A 8.00E-08 Morbidity-free survival / / 17903295 rs742513 chr6 9457140 G T 9.26E-05 Calcium levels / / pha003085 rs1003063 chr6 9487676 G A 2.50E-05 Urinary metabolites / / 21572414 rs9357440 chr6 9492393 C G 8.01E-04 Multiple complex diseases / / 17554300 rs12525984 chr6 9515447 T A 2.00E-06 Urinary metabolites / / 21572414 rs2294732 chr6 9517257 T C 1.40E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs1997770 chr6 9530019 C T 0.0000355 Menopause (age at onset) / / 23424626 rs4715102 chr6 9537611 T C 2.06E-05 Rheumatoid arthritis / / 17804836 rs4386821 chr6 9553237 C T 4.33E-05 Serum albumin level / / pha003084 rs980414 chr6 9558460 G A 8.22E-05 Rheumatoid arthritis / / 17804836 rs9395670 chr6 9561817 T C 6.13E-05 Serum albumin level / / pha003084 rs9349592 chr6 9565483 T C 2.08E-05 Serum albumin level / / pha003084 rs7750180 chr6 9566248 A C 2.08E-05 Serum albumin level / / pha003084 rs9349607 chr6 9567341 A G 2.90E-05 Rheumatoid arthritis / / 17804836 rs9349607 chr6 9567341 A G 3.15E-05 Serum albumin level / / pha003084 rs10807451 chr6 9575334 T C 4.28E-05 Serum albumin level / / pha003084 rs855250 chr6 9608887 A C 9.94E-05 Alcohol dependence OFCC1 intron 21703634 rs61160737 chr6 9618787 G T 1.01E-21 Metabolite levels OFCC1 intron 22286219 rs6941642 chr6 9748363 C T 3.68E-04 Amyotrophic lateral sclerosis (sporadic) OFCC1 intron 24529757 rs1410360 chr6 9765238 C T 2.08E-05 Calcium levels OFCC1 intron pha003085 rs1206914 chr6 9770501 A G 1.47E-04 Acute lung injury OFCC1 intron 22295056 rs1206916 chr6 9772267 G C 6.43E-04 Acute lung injury OFCC1 intron 22295056 rs1206917 chr6 9773164 G A 6.26E-06 Acute lung injury OFCC1 intron 22295056 rs1206918 chr6 9773693 C G 1.14E-04 Multiple complex diseases OFCC1 intron 17554300 rs12208751 chr6 9774694 C T 1.54E-06 Tunica Media OFCC1 intron pha003034 rs16892538 chr6 9783516 G A 3.24E-05 Personality dimensions OFCC1 intron 18957941 rs12662884 chr6 9788600 T C 7.94E-04 Response to statin treatment (atorvastatin),change in cholesterol levels OFCC1 intron 20031582 rs12662524 chr6 9788659 A G 8.11E-05 Chronic obstructive pulmonary disease OFCC1 intron 19300482 rs12662524 chr6 9788659 A G 8.11E-05 Response to statin treatment (atorvastatin),change in cholesterol levels OFCC1 intron 20031582 rs9383066 chr6 9788897 C T 3.61E-06 Post-operative nausea and vomiting OFCC1 intron 21694509 rs16892581 chr6 9806865 A G 2.54E-04 Multiple complex diseases OFCC1 intron 17554300 rs9464844 chr6 9821182 A G 5.26E-05 Calcium levels OFCC1 intron pha003085 rs6459434 chr6 9823784 G T 2.40E-05 Tooth agenesis (third molar) OFCC1 intron 24172245 rs6459434 chr6 9823784 G T 9.70E-05 Tooth agenesis (maxillary third molar) OFCC1 intron 24172245 rs13196422 chr6 9825154 T C 7.90E-04 Type 2 diabetes OFCC1 intron 23209189 rs4716055 chr6 9853919 G T 4.00E-06 Adiponectin levels OFCC1 intron 22479202 rs7739081 chr6 9895130 A G 3.63E-04 Type 2 diabetes OFCC1 intron 17463246 rs4716094 chr6 9903068 C G 2.28E-04 Type 2 diabetes OFCC1 intron 17463246 rs9283926 chr6 9910238 A G 2.17E-04 Type 2 diabetes OFCC1 intron 17463246 rs9283926 chr6 9910238 A G 7.26E-04 Multiple complex diseases OFCC1 intron 17554300 rs9367929 chr6 9911750 G A 2.25E-05 Post-operative nausea and vomiting OFCC1 intron 21694509 rs9396715 chr6 9914294 T C 2.46E-05 Body mass (lean) OFCC1 intron 19268274 rs7771234 chr6 9920051 C A 2.70E-04 Type 2 diabetes OFCC1 intron 17463246 rs6459512 chr6 9933670 G A 2.55E-08 LDL cholesterol OFCC1 intron 23063622 rs149747749 chr6 9937360 G A 3.55E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) OFCC1 intron 24159190 rs149747749 chr6 9937360 G A 8.00E-06 Serum dimethylarginine levels (asymmetric) OFCC1 intron 24159190 rs9396752 chr6 9941223 G A 3.42E-05 Body mass (lean) OFCC1 intron 19268274 rs9297028 chr6 9941445 A C 4.39E-04 Multiple complex diseases OFCC1 intron 17554300 rs9297028 chr6 9941445 A C 2.17E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) OFCC1 intron 24023788 rs116201121 chr6 9993737 G A 1.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs201250 chr6 10013636 T C 3.90E-06 Urinary metabolites / / 21572414 rs6930386 chr6 10015220 G A 3.85E-04 Multiple complex diseases / / 17554300 rs9396814 chr6 10018524 C T 8.06E-04 Coronary heart disease / / 21606135 rs9383331 chr6 10018754 A G 8.74E-04 Coronary heart disease / / 21606135 rs12209628 chr6 10033326 T C 8.67E-05 Depression (quantitative trait) / / 23290196 rs10484258 chr6 10033355 A G 8.76E-04 Type 2 diabetes / / 17846125 rs12205387 chr6 10033433 C T 8.72E-05 Depression (quantitative trait) / / 23290196 rs2327221 chr6 10035875 G A 4.19E-05 Post-operative nausea and vomiting / / 21694509 rs855407 chr6 10039854 A G 6.10E-07 Urinary metabolites / / 21572414 rs9297055 chr6 10041880 T C 6.62E-07 Post-operative nausea and vomiting / / 21694509 rs855399 chr6 10047472 A G 9.40E-07 Urinary metabolites / / 21572414 rs855397 chr6 10048422 A G 2.10E-05 Urinary metabolites / / 21572414 rs855384 chr6 10054296 T A 7.26E-04 Multiple complex diseases / / 17554300 rs4716305 chr6 10106082 T C 2.08E-04 Smoking initiation / / 24665060 rs4716306 chr6 10106467 G A 8.98E-05 Smoking initiation / / 24665060 rs1207009 chr6 10112415 C T 7.72E-04 Rheumatoid arthritis / / 21452313 rs1209347 chr6 10112580 T G 2.59E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs541539 chr6 10130280 T C 5.44E-04 Alzheimer's disease / / 22005930 rs1590307 chr6 10132602 G A 5.43E-04 Alzheimer's disease / / 22005930 rs4418196 chr6 10133585 A G 5.55E-04 Alzheimer's disease / / 22005930 rs7754250 chr6 10135572 C T 4.54E-04 Alzheimer's disease / / 22005930 rs4712359 chr6 10136242 C T 4.73E-04 Alzheimer's disease / / 22005930 rs9465252 chr6 10137112 A G 6.80E-04 Alzheimer's disease / / 22005930 rs9465254 chr6 10137855 C T 7.64E-04 Alzheimer's disease / / 22005930 rs7764736 chr6 10139823 G C 3.94E-04 Alzheimer's disease / / 22005930 rs4710886 chr6 10141789 T G 2.77E-04 Alzheimer's disease / / 22005930 rs17554792 chr6 10147121 G A 2.68E-04 Alzheimer's disease / / 22005930 rs4710890 chr6 10147411 C A 2.62E-04 Alzheimer's disease / / 22005930 rs6936850 chr6 10160723 C G 9.38E-04 Alzheimer's disease / / 22005930 rs7753668 chr6 10162702 C A 9.77E-04 Alzheimer's disease / / 22005930 rs13195786 chr6 10163968 A G 7.00E-06 Calcium levels / / 20705733 rs6903082 chr6 10167137 C T 9.70E-04 Alzheimer's disease / / 22005930 rs6899391 chr6 10171763 G C 9.07E-04 Alzheimer's disease / / 22005930 rs9460357 chr6 10174652 C T 8.23E-04 Alzheimer's disease / / 22005930 rs9460358 chr6 10174735 T C 7.68E-04 Alzheimer's disease / / 22005930 rs12210761 chr6 10176036 G A 6.00E-06 Major depressive disorder / / 23377640 rs2327252 chr6 10177613 A G 2.15E-05 Post-operative nausea and vomiting / / 21694509 rs9465426 chr6 10178094 A C 2.23E-04 Rheumatoid arthritis / / 21452313 rs1029123 chr6 10179035 G T 7.83E-04 Multiple complex diseases / / 17554300 rs1029123 chr6 10179035 G T 5.89E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1029124 chr6 10179366 T C 6.46E-04 Myocardial Infarction / / pha002883 rs9368096 chr6 10186253 C T 5.50E-04 Smoking initiation / / 24665060 rs6922759 chr6 10201937 A G 6.83E-04 Acute lung injury / / 22295056 rs6899608 chr6 10201975 G A 6.13E-04 Acute lung injury / / 22295056 rs6926380 chr6 10206722 C T 4.91E-04 Acute lung injury / / 22295056 rs9460420 chr6 10211332 A G 2.13E-05 Blood Pressure / / pha003043 rs6906943 chr6 10240259 C T 7.27E-05 Blood Pressure / / pha003050 rs9358305 chr6 10241822 C T 8.20E-06 Urinary metabolites / / 21572414 rs9358307 chr6 10242206 C A 8.96E-05 Blood Pressure / / pha003050 rs1999563 chr6 10247659 C G 2.34E-04 Multiple complex diseases / / 17554300 rs1413189 chr6 10249758 A G 8.41E-04 Multiple complex diseases / / 17554300 rs1889210 chr6 10252225 G T 3.81E-04 Multiple complex diseases / / 17554300 rs6940110 chr6 10269064 T C 9.37E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs6940110 chr6 10269064 T C 8.42E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs1556547 chr6 10270377 G A 1.55E-08 Common traits (Other) / / 20585627 rs1556548 chr6 10270386 T C 2.88E-08 Common traits (Other) / / 20585627 rs1333652 chr6 10273963 T C 2.88E-08 Common traits (Other) / / 20585627 rs7757564 chr6 10295815 T C 3.49E-05 Cognitive test performance / / 20125193 rs1333657 chr6 10296336 C T 3.80E-08 Common traits (Other) / / 20585627 rs9465867 chr6 10298095 T C 5.70E-05 White matter hyperintensity burden / / 21681796 rs4710948 chr6 10305925 G A 8.02E-04 Multiple complex diseases / / 17554300 rs10456010 chr6 10324531 G A 1.06E-04 Vaspin levels / / 22907691 rs10456010 chr6 10324531 G A 0.0001055 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs12190178 chr6 10355723 G A 5.52E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs667342 chr6 10356484 G T 8.89E-05 Cognitive impairment induced by topiramate / / 22091778 rs10484886 chr6 10369675 C T 0.0000998 Panic disorder / / 23149450 rs10484886 chr6 10369675 C T 9.98E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs616879 chr6 10392500 T G 4.30E-05 Orofacial clefts / / 22863734 rs616879 chr6 10392500 T G 8.16E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs533558 chr6 10395572 A G 8.16E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3798696 chr6 10403650 C T 3.00E-06 Amyotrophic lateral sclerosis (sporadic) TFAP2A intron 24529757 rs4710998 chr6 10433825 A G 2.81E-04 Taste perception LINC00518 intron 22132133 rs9358532 chr6 10458926 A C 3.00E-04 Smoking initiation / / 24665060 rs9348513 chr6 10460373 C T 6.09E-05 Smoking initiation / / 24665060 rs470790 chr6 10460560 T C 7.75E-04 Alcohol dependence / / 20201924 rs9348516 chr6 10460738 T A 5.60E-05 Smoking initiation / / 24665060 rs594162 chr6 10467433 T A 5.80E-06 Urinary metabolites / / 21572414 rs796102 chr6 10467695 C T 2.42E-04 Age-related macular degeneration / / 22125219 rs629027 chr6 10472224 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs611542 chr6 10474840 C T 1.60E-05 Urinary metabolites / / 21572414 rs470382 chr6 10474951 T A 5.59E-05 Response to citalopram treatment / / 19846067 rs470153 chr6 10482862 A C 7.94E-05 Cognitive impairment induced by topiramate / / 22091778 rs511155 chr6 10483813 A G 1.80E-04 Glycosylated haemoglobin levels / / 17255346 rs667924 chr6 10484860 T C 1.42E-04 Glycosylated haemoglobin levels / / 17255346 rs496082 chr6 10487302 G A 1.77E-04 Glycosylated haemoglobin levels / / 17255346 rs3798745 chr6 10513955 G A 6.82E-06 Height / / pha003010 rs3798745 chr6 10513955 G A 2.58E-06 Height / / pha003011 rs3798748 chr6 10514492 G A 6.82E-06 Height / / pha003010 rs3798748 chr6 10514492 G A 2.58E-06 Height / / pha003011 rs511871 chr6 10514698 C T 6.04E-06 Height / / pha003010 rs511871 chr6 10514698 C T 2.01E-06 Height / / pha003011 rs504117 chr6 10518350 G A 3.87E-04 Parkinson's disease / / 17052657 rs1087924 chr6 10523826 G C 3.20E-04 Parkinson's disease GCNT2 intron 17052657 rs631299 chr6 10528434 A G 1.84E-04 Parkinson's disease GCNT2 intron 17052657 rs560194 chr6 10528794 T C 3.05E-04 Parkinson's disease GCNT2 intron 17052657 rs1226003 chr6 10548517 G A,C,T 8.09E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GCNT2 intron 20031582 rs9366500 chr6 10567115 C T 2.00E-06 Urinary metabolites GCNT2 intron 21572414 rs1318748 chr6 10574312 T C 1.70E-05 Urinary metabolites GCNT2 intron 21572414 rs13218560 chr6 10575346 T C 2.99E-04 Response to cytadine analogues (cytosine arabinoside) GCNT2 intron 24483146 rs13204330 chr6 10594260 G A 1.72E-04 Response to cytidine analogues (gemcitabine) GCNT2 intron 24483146 rs13204330 chr6 10594260 G A 1.94E-05 Response to cytadine analogues (cytosine arabinoside) GCNT2 intron 24483146 rs9466910 chr6 10599279 T G 1.72E-04 Response to cytidine analogues (gemcitabine) GCNT2 intron 24483146 rs9466910 chr6 10599279 T G 1.94E-05 Response to cytadine analogues (cytosine arabinoside) GCNT2 intron 24483146 rs9466912 chr6 10599320 G A 1.72E-04 Response to cytidine analogues (gemcitabine) GCNT2 intron 24483146 rs9466912 chr6 10599320 G A 1.94E-05 Response to cytadine analogues (cytosine arabinoside) GCNT2 intron 24483146 rs942631 chr6 10615078 G T 3.65E-04 Smoking quantity GCNT2 intron 24665060 rs942631 chr6 10615078 G T 7.70E-05 Cholesterol GCNT2 intron pha003083 rs9460985 chr6 10653976 C T 6.72E-04 Aortic root size / / 21223598 rs3737278 chr6 10671764 G A 2.71E-05 Lymphocyte counts C6orf52 cds-synon 22286170 rs474519 chr6 10794536 T C 2.20E-04 Glycosylated haemoglobin levels MAK intron 17255346 rs522793 chr6 10802955 T C 7.79E-05 Platelet counts MAK intron pha003100 rs2009118 chr6 10817505 A G 2.48E-05 IgE levels MAK intron 17255346 rs9379840 chr6 10856101 G A 1.47E-04 Glycosylated haemoglobin levels / / 17255346 rs6456719 chr6 10863325 A C 1.35E-04 Glycosylated haemoglobin levels / / 17255346 rs11754036 chr6 10868902 T C 6.49E-05 Glycosylated haemoglobin levels / / 17255346 rs9368446 chr6 10892220 G A 6.56E-08 Phospholipid levels (plasma) SYCP2L intron 21829377 rs9366664 chr6 10892499 T C 4.18E-10 Phospholipid levels (plasma) SYCP2L intron 21829377 rs946350 chr6 10892953 G C 4.39E-10 Phospholipid levels (plasma) SYCP2L intron 21829377 rs9368452 chr6 10893679 G T 6.09E-08 Phospholipid levels (plasma) SYCP2L intron 21829377 rs9368453 chr6 10894255 G A 5.90E-08 Phospholipid levels (plasma) SYCP2L intron 21829377 rs6456745 chr6 10894268 A G 1.54E-08 Phospholipid levels (plasma) SYCP2L intron 21829377 rs2153157 chr6 10897488 G A 5.00E-08 Menarche and menopause (age at onset) SYCP2L intron 19448621 rs2153157 chr6 10897488 G A 8.00E-12 Menopause (age at onset) SYCP2L intron 22267201 rs12234119 chr6 10902332 A G 3.50E-06 Phospholipid levels (plasma) SYCP2L intron 21829377 rs6910232 chr6 10902439 A G 0.00013 Prostate cancer SYCP2L intron 23555315 rs6910232 chr6 10902439 A G 0.00038 Prostate cancer (non-advanced prostate cancer) SYCP2L intron 23555315 rs9357021 chr6 10906154 A G 6.18E-07 Phospholipid levels (plasma) SYCP2L intron 21829377 rs4713039 chr6 10906256 A G 1.85E-04 Alcohol dependence SYCP2L cds-synon 21314694 rs9366669 chr6 10908869 G A 1.10E-13 Phospholipid levels (plasma) SYCP2L intron 21829377 rs6928281 chr6 10908917 G T 8.04E-13 Phospholipid levels (plasma) SYCP2L intron 21829377 rs9467921 chr6 10910619 C G 1.43E-10 Phospholipid levels (plasma) SYCP2L intron 21829377 rs4713044 chr6 10911282 G A 9.07E-13 Phospholipid levels (plasma) SYCP2L intron 21829377 rs9461310 chr6 10920196 A G 4.13E-14 Phospholipid levels (plasma) SYCP2L intron 21829377 rs190994806 chr6 10921531 G A 3.00E-06 Serum dimethylarginine levels (symmetric) SYCP2L intron 24159190 rs190994806 chr6 10921531 G A 9.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SYCP2L intron 24159190 rs12190237 chr6 10922638 G A 8.53E-04 Multiple complex diseases SYCP2L intron 17554300 rs12190237 chr6 10922638 G A 1.58E-12 Phospholipid levels (plasma) SYCP2L intron 21829377 rs1225763 chr6 10924243 G A 2.53E-06 Phospholipid levels (plasma) SYCP2L intron 21829377 rs1767777 chr6 10925803 A G 1.87E-06 Phospholipid levels (plasma) SYCP2L intron 21829377 rs12213249 chr6 10926942 C T 7.55E-14 Phospholipid levels (plasma) SYCP2L intron 21829377 rs1225731 chr6 10932493 C T 3.40E-06 Phospholipid levels (plasma) SYCP2L intron 21829377 rs12199131 chr6 10932569 G A 7.69E-16 Phospholipid levels (plasma) SYCP2L intron 21829377 rs12214825 chr6 10933378 C T 1.05E-15 Phospholipid levels (plasma) SYCP2L intron 21829377 rs2327323 chr6 10933813 C G 2.26E-13 Phospholipid levels (plasma) SYCP2L intron 21829377 rs1359159 chr6 10934371 C G 3.30E-08 Phospholipid levels (plasma) SYCP2L intron 21829377 rs1225732 chr6 10934570 A G 3.24E-06 Phospholipid levels (plasma) SYCP2L intron 21829377 rs1578068 chr6 10938104 T G 2.32E-13 Phospholipid levels (plasma) SYCP2L intron 21829377 rs1225736 chr6 10939389 A G 5.33E-07 Phospholipid levels (plasma) SYCP2L intron 21829377 rs12200867 chr6 10939824 C G 1.30E-13 Phospholipid levels (plasma) SYCP2L intron 21829377 rs9393800 chr6 10951737 A G 6.10E-15 Phospholipid levels (plasma) SYCP2L intron 21829377 rs1225741 chr6 10952243 G A 2.35E-11 Phospholipid levels (plasma) SYCP2L intron 21829377 rs12207488 chr6 10952336 G A 4.87E-16 Phospholipid levels (plasma) SYCP2L intron 21829377 rs9379969 chr6 10952636 T A 5.39E-16 Phospholipid levels (plasma) SYCP2L intron 21829377 rs1007323 chr6 10953244 T G 8.04E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SYCP2L intron 20031582 rs1007323 chr6 10953244 T G 2.20E-11 Phospholipid levels (plasma) SYCP2L intron 21829377 rs1225744 chr6 10954540 C T 1.28E-10 Phospholipid levels (plasma) SYCP2L intron 21829377 rs9393804 chr6 10956130 T G 2.33E-13 Phospholipid levels (plasma) SYCP2L intron 21829377 rs7759825 chr6 10956649 T C 1.18E-12 Phospholipid levels (plasma) SYCP2L intron 21829377 rs1225753 chr6 10956689 G A 7.10E-11 Phospholipid levels (plasma) SYCP2L intron 21829377 rs7773173 chr6 10956703 G C 5.42E-11 Phospholipid levels (plasma) SYCP2L intron 21829377 rs9368506 chr6 10958472 G T 7.38E-09 Phospholipid levels (plasma) SYCP2L intron 21829377 rs6918936 chr6 10960158 G C 3.00E-08 Phospholipid levels (plasma) SYCP2L intron 21829377 rs6920247 chr6 10960173 C G 2.92E-13 Phospholipid levels (plasma) SYCP2L intron 21829377 rs4711146 chr6 10961405 T C 2.84E-13 Phospholipid levels (plasma) SYCP2L intron 21829377 rs9791208 chr6 10961649 T C 9.81E-09 Phospholipid levels (plasma) SYCP2L intron 21829377 rs2295600 chr6 10962250 A G 1.99E-13 Phospholipid levels (plasma) SYCP2L intron 21829377 rs7774711 chr6 10965021 A G,T 1.25E-13 Phospholipid levels (plasma) SYCP2L intron 21829377 rs9295733 chr6 10965447 T A 1.34E-13 Phospholipid levels (plasma) SYCP2L intron 21829377 rs2327325 chr6 10965654 G A 7.24E-09 Phospholipid levels (plasma) SYCP2L intron 21829377 rs9348766 chr6 10968582 C T 9.03E-09 Phospholipid levels (plasma) SYCP2L intron 21829377 rs4713103 chr6 10969141 G T 3.00E-36 Phospholipid levels (plasma) SYCP2L intron 21829377 rs4713103 chr6 10969141 G T 8.00E-14 Phospholipid levels (plasma) SYCP2L intron 21829377 rs17674802 chr6 10969519 T A 8.21E-09 Phospholipid levels (plasma) SYCP2L intron 21829377 rs1225717 chr6 10978240 A G 7.13E-14 Phospholipid levels (plasma) / / 21829377 rs8523 chr6 10981053 G A 3.94E-14 Phospholipid levels (plasma) ELOVL2 UTR-3 21829377 rs17606561 chr6 10982359 G A 5.05E-09 Phospholipid levels (plasma) ELOVL2 UTR-3 21829377 rs17606561 chr6 10982359 G A 1.00E-11 Phospholipid levels (plasma) ELOVL2 UTR-3 22359512 rs1225737 chr6 10982652 C T 3.63E-15 Phospholipid levels (plasma) ELOVL2 UTR-3 21829377 rs3734397 chr6 10982848 G A 3.00E-06 Phospholipid levels (plasma) ELOVL2 UTR-3 21829377 rs3734398 chr6 10982973 T C 1.00E-43 Phospholipid levels (plasma) ELOVL2 UTR-3 21829377 rs3734398 chr6 10982973 T C 1.17E-06 Plasma omega-6 polyunsaturated fatty acid levels ELOVL2 UTR-3 24823311 rs4532436 chr6 10983971 C G 3.17E-15 Phospholipid levels (plasma) ELOVL2 UTR-3 21829377 rs4532436 chr6 10983971 C G 3.65E-06 Plasma omega-6 polyunsaturated fatty acid levels ELOVL2 UTR-3 24823311 rs12195587 chr6 10989942 G A 4.51E-10 Phospholipid levels (plasma) ELOVL2 cds-synon 21829377 rs2281591 chr6 10990493 A G 7.82E-09 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs911196 chr6 10990751 T G 2.08E-08 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs3798707 chr6 10991935 C T 3.27E-15 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs3798707 chr6 10991935 C T 2.70E-06 Plasma omega-6 polyunsaturated fatty acid levels ELOVL2 intron 24823311 rs2236212 chr6 10995015 G C 1.00E-15 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs2236212 chr6 10995015 G C 7.00E-07 Plasma omega-6 polyunsaturated fatty acid levels ELOVL2 intron 24823311 rs3798709 chr6 11001276 A G 8.37E-09 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs3798710 chr6 11002783 G C 6.45E-09 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs3798711 chr6 11002810 T C 3.54E-15 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs3798711 chr6 11002810 T C 3.24E-06 Plasma omega-6 polyunsaturated fatty acid levels ELOVL2 intron 24823311 rs17764592 chr6 11003144 A C 6.52E-09 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs976081 chr6 11003875 G T 2.39E-06 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs1323739 chr6 11004561 C G 2.00E-14 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs1323739 chr6 11004561 C G 1.02E-06 Plasma omega-6 polyunsaturated fatty acid levels ELOVL2 intron 24823311 rs2295601 chr6 11005686 G A 8.20E-09 Phospholipid levels (plasma) ELOVL2 cds-synon 21829377 rs2295602 chr6 11005842 T C 3.30E-15 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs2295602 chr6 11005842 T C 3.44E-06 Plasma omega-6 polyunsaturated fatty acid levels ELOVL2 intron 24823311 rs3798713 chr6 11008622 G C 2.00E-12 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs3798713 chr6 11008622 G C 1.03E-06 Plasma omega-6 polyunsaturated fatty acid levels ELOVL2 intron 24823311 rs17675073 chr6 11008649 G A 3.54E-10 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs953413 chr6 11012859 G A 1.10E-06 Triglycerides ELOVL2 intron 19074352 rs953413 chr6 11012859 G A 1.10E-06 Polyunsaturated fatty acid levels,in plasma ELOVL2 intron 19148276 rs953413 chr6 11012859 G A 7.00E-04 Polyunsaturated fatty acid levels,in plasma ELOVL2 intron 19148276 rs953413 chr6 11012859 G A 2.98E-15 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs953413 chr6 11012859 G A 5.54E-06 Plasma omega-6 polyunsaturated fatty acid levels ELOVL2 intron 24823311 rs7743830 chr6 11014220 A G 3.65E-15 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs7743830 chr6 11014220 A G 3.54E-06 Plasma omega-6 polyunsaturated fatty acid levels ELOVL2 intron 24823311 rs1570069 chr6 11017825 A G 3.61E-15 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs1570069 chr6 11017825 A G 3.47E-06 Plasma omega-6 polyunsaturated fatty acid levels ELOVL2 intron 24823311 rs1321536 chr6 11018812 T A,C,G 6.04E-15 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs1321536 chr6 11018812 T A,C,G 5.01E-06 Plasma omega-6 polyunsaturated fatty acid levels ELOVL2 intron 24823311 rs3756963 chr6 11022154 T C 1.26E-08 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs2180725 chr6 11025420 T C 6.66E-09 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs10498676 chr6 11026999 G A 5.79E-09 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs3778166 chr6 11033164 G A 1.16E-08 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs9295757 chr6 11033625 G T 8.59E-09 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs6936315 chr6 11035972 T C 1.34E-08 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs3846851 chr6 11036584 T A 1.05E-06 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs3798719 chr6 11036825 C T 2.40E-08 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs7744440 chr6 11038511 T G 1.77E-08 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs3798721 chr6 11040183 A C 9.51E-04 Multiple complex diseases ELOVL2 intron 17554300 rs3798721 chr6 11040183 A C 2.32E-12 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs3798722 chr6 11040423 A G 1.20E-11 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs3798722 chr6 11040423 A G 4.00E-09 Metabolite levels (atherosclerosis) ELOVL2 intron 22916037 rs3798723 chr6 11041720 G A 1.60E-08 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs9468304 chr6 11042165 G A 5.11E-09 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs9393903 chr6 11042909 G A 2.30E-42 Serum metabolites ELOVL2 intron 20037589 rs9393903 chr6 11042909 G A 1.54E-08 Phospholipid levels (plasma) ELOVL2 intron 21829377 rs9393903 chr6 11042909 G A 2.00E-14 Metabolic traits ELOVL2 intron 21886157 rs9295763 chr6 11045192 G C 9.87E-15 Phospholipid levels (plasma) LOC100506409 intron 21829377 rs9295764 chr6 11045196 A G 1.00E-14 Phospholipid levels (plasma) LOC100506409 intron 21829377 rs2147041 chr6 11050523 A G 5.02E-14 Phospholipid levels (plasma) LOC100506409 intron 21829377 rs17764682 chr6 11058815 A C 2.60E-09 Phospholipid levels (plasma) LOC100506409 intron 21829377 rs17675322 chr6 11059185 T A 3.50E-14 Phospholipid levels (plasma) LOC100506409 intron 21829377 rs9368564 chr6 11060283 A G 1.41E-09 Phospholipid levels (plasma) LOC100506409 intron 21829377 rs6900220 chr6 11065138 T C 4.50E-14 Phospholipid levels (plasma) LOC100506409 intron 21829377 rs4711170 chr6 11070434 C A 1.24E-09 Phospholipid levels (plasma) LOC100506409 intron 21829377 rs9393915 chr6 11072322 C T 3.38E-09 Phospholipid levels (plasma) LOC100506409 intron 21829377 rs9393915 chr6 11072322 C T 1.00E-22 Blood metabolite ratios LOC100506409 intron 24816252 rs12662634 chr6 11074191 G A 2.68E-10 Phospholipid levels (plasma) LOC100506409 intron 21829377 rs4713165 chr6 11074302 T C 7.23E-13 Phospholipid levels (plasma) LOC100506409 intron 21829377 rs4711171 chr6 11074347 C T 5.00E-13 Phospholipid levels (plasma) LOC100506409 intron 21829377 rs1321535 chr6 11076026 T G 1.00E-38 Phospholipid levels (plasma) LOC100506409 intron 21829377 rs1321535 chr6 11076026 T G 5.00E-11 Phospholipid levels (plasma) LOC100506409 intron 21829377 rs12665478 chr6 11080825 G A 7.12E-13 Phospholipid levels (plasma) / / 21829377 rs12526913 chr6 11082924 A G 7.36E-13 Phospholipid levels (plasma) / / 21829377 rs4713169 chr6 11084554 G C 7.48E-13 Phospholipid levels (plasma) / / 21829377 rs4713169 chr6 11084554 G C 3.00E-14 Blood metabolite levels / / 24816252 rs10484447 chr6 11143569 G A 1.91E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16870998 chr6 11150102 G A 5.33E-04 Multiple complex diseases / / 17554300 rs7452101 chr6 11153852 G A 9.39E-04 Multiple complex diseases / / 17554300 rs4713212 chr6 11161408 C T 9.25E-05 Postoperative ventricular dysfunction / / 21980348 rs9468537 chr6 11173821 T C 0.0000469 Major depressive disorder / / 23149448 rs9295808 chr6 11182079 G A 3.50E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11751998 chr6 11189087 C T 3.42E-05 Alzheimer's disease NEDD9 intron 17998437 rs11751998 chr6 11189087 C T 6.75E-05 Alzheimer's disease NEDD9 intron pha002879 rs3798731 chr6 11199234 A G 8.34E-05 Tunica Media NEDD9 intron pha003036 rs9368612 chr6 11214092 A T 1.40E-06 Urinary metabolites NEDD9 intron 21572414 rs9366751 chr6 11229497 A G 9.31E-05 Alcohol dependence NEDD9 intron 21314694 rs11970705 chr6 11229953 G A 4.64E-04 Obesity (extreme) NEDD9 intron 21935397 rs9380152 chr6 11234035 C T 2.39E-04 Obesity (extreme) NEDD9 intron 21935397 rs9468690 chr6 11239119 G A 1.60E-05 Urinary metabolites NEDD9 intron 21572414 rs744970 chr6 11243857 A G 1.90E-05 Urinary metabolites NEDD9 intron 21572414 rs6932615 chr6 11264612 T G 2.07E-04 Dental caries NEDD9 intron 21940522 rs10947075 chr6 11269466 A C 6.22E-04 Response to taxane treatment (placlitaxel) NEDD9 intron 23006423 rs4713334 chr6 11270935 C T 3.68E-04 Response to taxane treatment (placlitaxel) NEDD9 intron 23006423 rs16871186 chr6 11271992 T C 8.73E-04 Response to taxane treatment (placlitaxel) NEDD9 intron 23006423 rs11961171 chr6 11276028 G A 5.14E-04 Multiple complex diseases NEDD9 intron 17554300 rs11961171 chr6 11276028 G A 8.55E-13 Glaucoma (primary open-angle) NEDD9 intron 22605921 rs2072834 chr6 11297661 G A 4.30E-04 Type 2 diabetes and 6 quantitative traits NEDD9 intron 17848626 rs4713379 chr6 11305230 A G 9.88E-04 Alzheimer's disease NEDD9 intron 24755620 rs4437462 chr6 11310419 C T 2.00E-06 HIV-1 susceptibility NEDD9 intron 22174851 rs9295935 chr6 11316780 T C 1.32E-05 Multiple complex diseases NEDD9 intron 17554300 rs6918108 chr6 11328806 T C 2.00E-04 Type 2 diabetes NEDD9 intron 17463246 rs967473 chr6 11329423 G A 1.67E-04 Glaucoma (primary open-angle) NEDD9 intron 22605921 rs6940151 chr6 11335478 C T 9.01E-04 Multiple complex diseases NEDD9 intron 17554300 rs17507623 chr6 11401519 G A 6.18E-06 Stroke (ischemic) / / 21957438 rs9394080 chr6 11422923 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10498677 chr6 11466011 T G 4.77E-04 Premature ovarian failure / / 19508998 rs10947294 chr6 11470114 G A 4.50E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6899820 chr6 11476635 C A 2.34E-05 Odorant perception / / 23910658 rs6941700 chr6 11491130 T C 4.19E-05 Serum metabolites / / 19043545 rs6914208 chr6 11491480 G A 5.40E-04 Type 2 diabetes / / 17463246 rs6901328 chr6 11494337 C G 4.90E-05 Serum metabolites / / 19043545 rs12192094 chr6 11495136 C T 4.90E-05 Serum metabolites / / 19043545 rs12200454 chr6 11495324 T C 2.48E-05 Serum metabolites / / 19043545 rs9348896 chr6 11496300 A G 4.90E-05 Serum metabolites / / 19043545 rs538827 chr6 11509323 C T 1.72E-04 Myocardial Infarction / / pha002883 rs6927244 chr6 11510858 G A 4.00E-04 Alcohol dependence / / 21314694 rs17608111 chr6 11520033 A G 6.38E-04 Multiple complex diseases / / 17554300 rs6900578 chr6 11589656 G A 1.48E-10 Adiponectin levels / / 20887962 rs12215876 chr6 11601134 G A 8.58E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs515145 chr6 11612975 T G 6.09E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs479526 chr6 11618167 T C 3.00E-06 Reading and spelling / / 23738518 rs9469712 chr6 11627487 G A 8.74E-06 Reading and spelling / / 23738518 rs9469713 chr6 11627539 G A 4.76E-06 Cognitive impairment induced by topiramate / / 22091778 rs9469713 chr6 11627539 G A 8.74E-06 Reading and spelling / / 23738518 rs9469715 chr6 11629164 G T 8.06E-06 Reading and spelling / / 23738518 rs9469717 chr6 11630302 C T 2.29E-05 Cognitive impairment induced by topiramate / / 22091778 rs9469717 chr6 11630302 C T 8.74E-06 Reading and spelling / / 23738518 rs17398769 chr6 11630685 T C 8.74E-06 Reading and spelling / / 23738518 rs1150571 chr6 11638437 T G 8.44E-04 Multiple complex diseases / / 17554300 rs1150579 chr6 11653479 G A 9.36E-04 Type 2 diabetes / / 17463246 rs9469853 chr6 11689312 A G 9.81E-05 Cognitive test performance / / 20125193 rs2327459 chr6 11700438 C A 3.93E-05 HIV-1 viral setpoint / / 22174851 rs9366868 chr6 11703500 G A,C,T 2.59E-05 Glaucoma (primary open-angle) / / 22605921 rs210920 chr6 11710554 G A 1.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs210918 chr6 11711815 T A 2.40E-06 Urinary metabolites / / 21572414 rs210914 chr6 11715150 A C 5.10E-07 Urinary metabolites ADTRP intron 21572414 rs210913 chr6 11715751 G C 6.30E-07 Urinary metabolites ADTRP intron 21572414 rs9394270 chr6 11721301 C A 2.00E-05 Urinary metabolites ADTRP intron 21572414 rs210903 chr6 11724542 A G 1.00E-05 Urinary metabolites ADTRP intron 21572414 rs2294426 chr6 11730082 A G 4.00E-08 Orofacial clefts (interaction) ADTRP intron 21618603 rs2235418 chr6 11732823 C T 2.84E-07 Lymphocyte counts ADTRP intron 22286170 rs9462058 chr6 11736117 A G 7.48E-05 Body mass index ADTRP intron 17255346 rs17402850 chr6 11742589 A G 8.49E-04 Alzheimer's disease ADTRP intron 24755620 rs2235412 chr6 11743975 C T 2.92E-04 Multiple complex diseases ADTRP intron 17554300 rs172405 chr6 11746576 G A 1.72E-04 Schizophrenia ADTRP intron 20832056 rs2294424 chr6 11752551 C T 1.22E-04 Schizophrenia ADTRP intron 20832056 rs2294423 chr6 11752628 C G 1.49E-04 Schizophrenia ADTRP intron 20832056 rs2235401 chr6 11755803 G A 2.06E-04 Schizophrenia ADTRP intron 20832056 rs2235398 chr6 11756013 C T 2.06E-04 Schizophrenia ADTRP intron 20832056 rs6457825 chr6 11767620 G A 1.30E-05 Urinary metabolites ADTRP intron 21572414 rs760788 chr6 11770705 C T 5.50E-05 Cleft lip ADTRP intron 20436469 rs6903956 chr6 11774583 A G 1.21E-07 Coronary heart disease ADTRP intron 21378986 rs6903956 chr6 11774583 A G 1.90E-13 Coronary heart disease ADTRP intron 21378986 rs6903956 chr6 11774583 A G 2.55E-13 Coronary heart disease ADTRP intron 21378986 rs6903956 chr6 11774583 A G 3.17E-07 Coronary heart disease ADTRP intron 21378986 rs6903956 chr6 11774583 A G 3.56E-04 Coronary heart disease ADTRP intron 21378986 rs7743245 chr6 11808064 C T 1.94E-04 Vaspin levels / / 22907691 rs7743245 chr6 11808064 C T 0.0001942 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs3950186 chr6 11811314 C T 8.00E-06 Anxiety and major depressive disorder / / 24047446 rs10947579 chr6 11811589 T C 2.67E-04 Self-reported allergy / / 23817569 rs1883326 chr6 11818316 C T 1.96E-04 Vaspin levels / / 22907691 rs1883326 chr6 11818316 C T 0.0001963 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs1883326 chr6 11818316 C T 2.38E-04 Self-reported allergy / / 23817569 rs6899747 chr6 11825097 G A 2.92E-04 Self-reported allergy / / 23817569 rs1569731 chr6 11825414 A G 2.20E-04 Vaspin levels / / 22907691 rs1569731 chr6 11825414 A G 0.0002197 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs1569731 chr6 11825414 A G 2.78E-04 Self-reported allergy / / 23817569 rs1569732 chr6 11825666 C T 4.19E-04 Self-reported allergy / / 23817569 rs6457906 chr6 11855615 T G 5.45E-04 Heart Failure / / pha002884 rs6457952 chr6 11898806 A G 2.26E-05 Erythrocyte counts / / pha003090 rs6937349 chr6 11902591 T C 2.33E-05 Erythrocyte counts / / pha003090 rs169713 chr6 11920517 T C 8.00E-05 Prostate cancer / / 21743057 rs209780 chr6 11923194 C T 8.00E-05 Prostate cancer / / 21743057 rs864244 chr6 11929602 C A 6.00E-05 Prostate cancer / / 21743057 rs9394412 chr6 11931887 A C 1.90E-05 Urinary metabolites / / 21572414 rs9394412 chr6 11931887 A C 5.26E-04 Insulin resistance / / 21901158 rs10947661 chr6 11934964 G A 1.50E-05 Urinary metabolites / / 21572414 rs864245 chr6 11943505 T C 1.40E-05 Urinary metabolites / / 21572414 rs1205863 chr6 11943526 T G 6.00E-06 Disc degeneration (lumbar) / / 22993228 rs1205883 chr6 11947911 A G 1.80E-05 Urinary metabolites / / 21572414 rs209814 chr6 11951861 G C 1.90E-05 Urinary metabolites / / 21572414 rs209812 chr6 11953887 G A 1.20E-05 Urinary metabolites / / 21572414 rs12193434 chr6 11962746 T C 5.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12193434 chr6 11962746 T C 1.54E-04 Common variable immunodeficiency / / 21497890 rs12530006 chr6 11976776 G A 1.25E-06 Left ventricular mass / / 21212386 rs1570989 chr6 12048827 A G 7.61E-04 Alcohol dependence HIVEP1 intron 20201924 rs1570989 chr6 12048827 A G 2.00E-06 Alcohol and nictotine co-dependence HIVEP1 intron 22488850 rs17608729 chr6 12067809 G A 3.44E-05 Post-operative nausea and vomiting HIVEP1 intron 21694509 rs9296258 chr6 12084445 C G 1.95E-04 Multiple complex diseases HIVEP1 intron 17554300 rs4467769 chr6 12086759 G A 9.56E-05 Cholesterol HIVEP1 intron pha003078 rs17608937 chr6 12087988 G T 8.79E-05 Post-operative nausea and vomiting HIVEP1 intron 21694509 rs6939913 chr6 12089905 C T 4.39E-08 Post-operative nausea and vomiting HIVEP1 intron 21694509 rs3734271 chr6 12129936 T G 3.04E-05 Multiple complex diseases HIVEP1 intron 17554300 rs1040994 chr6 12197213 C A 2.00E-06 Response to antipsychotic treatment / / 19721433 rs2012560 chr6 12200727 C G 5.11E-04 Multiple complex diseases / / 17554300 rs1022848 chr6 12200772 A G 4.60E-04 Multiple complex diseases / / 17554300 rs1023483 chr6 12200946 A G 5.58E-04 Multiple complex diseases / / 17554300 rs9367034 chr6 12214326 G A 2.12E-04 Stroke / / pha002886 rs3021344 chr6 12216288 A G 5.26E-04 Multiple complex diseases / / 17554300 rs3021344 chr6 12216288 A G 5.25E-08 Metabolite levels / / 23281178 rs1794856 chr6 12216646 G A 1.25E-04 Multiple complex diseases / / 17554300 rs1794856 chr6 12216646 G A 8.38E-05 Blood Pressure / / pha003039 rs9380917 chr6 12217263 A G 1.72E-05 Multiple complex diseases / / 17554300 rs6908010 chr6 12217999 T G 3.33E-05 Multiple complex diseases / / 17554300 rs6938133 chr6 12221764 A G 7.65E-04 Acute lung injury / / 22295056 rs2180030 chr6 12223629 A G 2.53E-04 Multiple complex diseases / / 17554300 rs17592421 chr6 12223922 G A 3.33E-04 Multiple complex diseases / / 17554300 rs9296319 chr6 12226500 G A 1.67E-04 Multiple complex diseases / / 17554300 rs6458133 chr6 12226686 C T 5.00E-04 Multiple complex diseases / / 17554300 rs6458133 chr6 12226686 C T 4.25E-04 Acute lung injury / / 22295056 rs6458134 chr6 12226801 G A 4.31E-04 Acute lung injury / / 22295056 rs4711617 chr6 12230369 T A 6.69E-04 Acute lung injury / / 22295056 rs1028716 chr6 12230804 T C 6.06E-04 Acute lung injury / / 22295056 rs1922942 chr6 12231751 T C 6.60E-04 Acute lung injury / / 22295056 rs9394696 chr6 12262514 C T 6.73E-05 Cognitive impairment induced by topiramate / / 22091778 rs1626492 chr6 12295503 A G 7.90E-04 Coronary heart disease EDN1 intron 21966275 rs5370 chr6 12296255 G T 1.00E-27 Circulating vasoactive peptide levels EDN1 missense 23381795 rs10478730 chr6 12297509 C T 0.000000668 HDL cholesterol EDN1 nearGene-3 23063622 rs10478730 chr6 12297509 C T 2.46E-14 Cholesterol,total EDN1 nearGene-3 23063622 rs10478730 chr6 12297509 C T 3.46E-09 LDL cholesterol EDN1 nearGene-3 23063622 rs9296345 chr6 12298333 C T 3.93E-04 Hemoglobin concentration / / 20534544 rs7356986 chr6 12301462 G A 1.40E-04 Hemoglobin concentration / / 20534544 rs16872601 chr6 12302898 G T 1.40E-04 Hemoglobin concentration / / 20534544 rs6925906 chr6 12359302 G A 4.29E-04 Hemoglobin concentration / / 20534544 rs1931550 chr6 12362219 G A 9.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs994565 chr6 12388165 C T 1.50E-04 IgE levels in asthmatics / / 23967269 rs2050289 chr6 12401910 C T 1.72E-04 Type 2 diabetes / / 17463246 rs9471753 chr6 12426579 T C 7.10E-04 Multiple complex diseases / / 17554300 rs13203590 chr6 12429862 C T 7.71E-05 HDL cholesterol / / pha003075 rs4714566 chr6 12430130 T C 7.71E-05 HDL cholesterol / / pha003075 rs9471890 chr6 12482290 G A 2.00E-05 Urinary metabolites / / 21572414 rs1334306 chr6 12490082 A G 0.000023 Salmonella-induced pyroptosis / / 22837397 rs7753779 chr6 12491467 A G 1.90E-05 Urinary metabolites / / 21572414 rs12198798 chr6 12510127 T C 1.00E-06 Obesity-related traits / / 23251661 rs9369394 chr6 12512344 A G 9.53E-04 Parkinson's disease / / 17052657 rs6458320 chr6 12519432 A G 6.06E-05 Glycosylated haemoglobin levels / / 17255346 rs12212807 chr6 12520658 G T 4.57E-04 Hemoglobin concentration / / 20534544 rs6458324 chr6 12529622 T C 1.77E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2504899 chr6 12531551 G T 9.80E-05 Alcohol dependence / / 21703634 rs10948084 chr6 12585111 G A 5.84E-04 Multiple complex diseases / / 17554300 rs16873023 chr6 12585656 T C 2.77E-04 Multiple complex diseases / / 17554300 rs11754568 chr6 12587013 A G 3.37E-05 Personality dimensions / / 22628180 rs2516234 chr6 12593554 G C 6.12E-04 Multiple complex diseases / / 17554300 rs2516225 chr6 12604455 G A 2.31E-04 Hemoglobin concentration / / 20534544 rs499627 chr6 12614022 A G 4.60E-06 Glucose levels / / pha003061 rs1331478 chr6 12646680 C T 4.50E-04 Type 2 diabetes / / 17463246 rs763517 chr6 12651249 C T 2.36E-04 Type 2 diabetes / / 17463246 rs2516252 chr6 12654539 G A 2.91E-04 Type 2 diabetes / / 17463246 rs1360468 chr6 12656715 G T 2.76E-04 Type 2 diabetes / / 17463246 rs12524361 chr6 12656894 C T 3.21E-04 Type 2 diabetes / / 17463246 rs6936516 chr6 12657518 T C 3.52E-04 Type 2 diabetes / / 17463246 rs1548309 chr6 12660550 C A 3.63E-04 Type 2 diabetes / / 17463246 rs10948174 chr6 12703170 T A 7.00E-06 Personality dimensions / / 21173776 rs16873301 chr6 12715593 C T 4.70E-06 Personality dimensions / / 21173776 rs9472428 chr6 12722173 G A 0.00000415 Coronary artery disease PHACTR1 intron 23202125 rs12526812 chr6 12763839 A G 2.05E-05 Stroke PHACTR1 intron 22306652 rs883947 chr6 12787714 C T 0.00000211 Coronary artery disease PHACTR1 intron 23202125 rs10807323 chr6 12795031 G A 1.17E-05 Multiple complex diseases PHACTR1 intron 17554300 rs10807323 chr6 12795031 G A 3.54E-07 Coronary artery calcification PHACTR1 intron 22144573 rs10807323 chr6 12795031 G A 0.00000534 Coronary artery calcification PHACTR1 intron 23394302 rs10807323 chr6 12795031 G A 9.99E-05 Coronary heart disease PHACTR1 intron pha003031 rs17679107 chr6 12796033 T G 1.43E-04 Birth weight PHACTR1 intron 17255346 rs9472566 chr6 12797940 C T 2.92E-05 Stroke PHACTR1 intron 22306652 rs17617207 chr6 12800332 G A 1.69E-04 Amyotrophic lateral sclerosis (sporadic) PHACTR1 intron 24529757 rs9381401 chr6 12801967 A C 0.0000076 Coronary artery calcification PHACTR1 intron 23394302 rs7768030 chr6 12822973 A C 1.00E-04 Stroke PHACTR1 intron 22306652 rs2026458 chr6 12825874 C T 5.11E-05 Multiple complex diseases PHACTR1 intron 17554300 rs2026458 chr6 12825874 C T 1.78E-07 Coronary artery calcification PHACTR1 intron 22144573 rs2026458 chr6 12825874 C T 0.0000284 Coronary artery calcification PHACTR1 intron 23394302 rs3945322 chr6 12841306 G A 7.38E-05 Creatinine levels PHACTR1 intron pha003069 rs9296486 chr6 12848969 T G 5.44E-05 Creatinine levels PHACTR1 intron pha003069 rs13191496 chr6 12851625 G A 7.51E-04 Type 2 diabetes PHACTR1 intron 17463246 rs9395185 chr6 12856827 A G 5.71E-05 Creatinine levels PHACTR1 intron pha003069 rs6458503 chr6 12859556 T C 6.59E-04 Response to taxane treatment (placlitaxel) PHACTR1 intron 23006423 rs9381462 chr6 12873775 A G 2.70E-04 Migraine PHACTR1 intron 22683712 rs1332841 chr6 12875054 G T 7.55E-04 Response to taxane treatment (placlitaxel) PHACTR1 intron 23006423 rs8180628 chr6 12881163 A G 6.46E-05 Cognitive test performance PHACTR1 intron 20125193 rs1537340 chr6 12881855 G A 2.77E-06 Coronary heart disease PHACTR1 intron 22319020 rs1537340 chr6 12881855 G A 1.95E-05 Coronary heart disease PHACTR1 intron pha003031 rs1332844 chr6 12889004 C T 6.00E-08 Coronary heart disease PHACTR1 intron 21378988 rs1332844 chr6 12889004 C T 2.61E-06 Coronary artery calcification PHACTR1 intron 22144573 rs1332844 chr6 12889004 C T 1.08E-06 Coronary heart disease PHACTR1 intron pha003031 rs7750679 chr6 12891301 T C 2.34E-06 Coronary artery calcification PHACTR1 intron 22144573 rs7750679 chr6 12891301 T C 1.08E-06 Coronary heart disease PHACTR1 intron pha003031 rs1332847 chr6 12892754 C T 1.30E-04 Migraine PHACTR1 intron 22683712 rs9296512 chr6 12894904 G C 2.97E-06 Coronary artery calcification PHACTR1 intron 22144573 rs9395214 chr6 12898884 C G 2.73E-06 Coronary artery calcification PHACTR1 intron 22144573 rs7751826 chr6 12900977 C T 2.75E-06 Coronary artery calcification PHACTR1 intron 22144573 rs9369640 chr6 12901441 C A 2.84E-06 Coronary artery calcification PHACTR1 intron 22144573 rs9369640 chr6 12901441 C A 0.00000229 Coronary artery disease (CAD) (females) PHACTR1 intron 23202125 rs9369640 chr6 12901441 C A 0.000501 2-hour glucose tolerance test PHACTR1 intron 23202125 rs9369640 chr6 12901441 C A 1.17E-08 Coronary artery disease (CAD) age <=50 PHACTR1 intron 23202125 rs9369640 chr6 12901441 C A 1.49E-10 Coronary artery disease (CAD) age >50 PHACTR1 intron 23202125 rs9369640 chr6 12901441 C A 2.96E-18 Coronary artery disease (CAD) (males) PHACTR1 intron 23202125 rs9369640 chr6 12901441 C A 8.55E-20 Coronary artery disease with myocardial infarction PHACTR1 intron 23202125 rs9369640 chr6 12901441 C A 3.00E-11 Coronary artery disease PHACTR1 intron 24262325 rs4714955 chr6 12903435 C T 2.73E-06 Coronary artery calcification PHACTR1 intron 22144573 rs4714955 chr6 12903435 C T 2.00E-11 Coronary artery disease or large artery stroke PHACTR1 intron 24262325 rs4714955 chr6 12903435 C T 4.00E-11 Coronary artery disease or ischemic stroke PHACTR1 intron 24262325 rs9349379 chr6 12903957 A G 9.00E-26 Coronary heart disease PHACTR1 intron 21378988 rs9349379 chr6 12903957 A G 9.00E-26 Coronary heart disease PHACTR1 intron 21846871 rs9349379 chr6 12903957 A G 4.00E-22 Coronary artery calcification PHACTR1 intron 22144573 rs9349379 chr6 12903957 A G 3.00E-08 Migraine PHACTR1 intron 22683712 rs9349379 chr6 12903957 A G 4.00E-07 Coronary heart disease PHACTR1 intron 22745674 rs9349379 chr6 12903957 A G 6.00E-12 Coronary heart disease PHACTR1 intron 22745674 rs9349379 chr6 12903957 A G 8.00E-10 Coronary heart disease PHACTR1 intron 22745674 rs9349379 chr6 12903957 A G 2.00E-09 Coronary heart disease PHACTR1 intron 22751097 rs9349379 chr6 12903957 A G 0.000000035 Coronary artery calcification (males) PHACTR1 intron 23394302 rs9349379 chr6 12903957 A G 3.48E-11 Coronary artery calcification PHACTR1 intron 23394302 rs9349379 chr6 12903957 A G 2.00E-06 Migraine - clinic-based PHACTR1 intron 23793025 rs9349379 chr6 12903957 A G 2.22E-06 Migraine - clinic-based PHACTR1 intron 23793025 rs9349379 chr6 12903957 A G 2.81E-10 Migraine without aura PHACTR1 intron 23793025 rs9349379 chr6 12903957 A G 3.00E-10 Migraine without aura PHACTR1 intron 23793025 rs9349379 chr6 12903957 A G 4.60E-08 Migraine PHACTR1 intron 23793025 rs9349379 chr6 12903957 A G 5.00E-08 Migraine PHACTR1 intron 23793025 rs9349379 chr6 12903957 A G 5.28E-08 Coronary heart disease PHACTR1 intron pha003030 rs9349379 chr6 12903957 A G 7.66E-10 Coronary heart disease PHACTR1 intron pha003031 rs9349379 chr6 12903957 A G 3.33E-05 Coronary heart disease PHACTR1 intron pha003056 rs2327620 chr6 12907591 A G 1.16E-06 Coronary artery calcification PHACTR1 intron 22144573 rs2327620 chr6 12907591 A G 1.02E-06 Coronary heart disease PHACTR1 intron pha003031 rs7454157 chr6 12909874 G A 1.14E-06 Coronary artery calcification PHACTR1 intron 22144573 rs4711863 chr6 12915417 G C 9.31E-07 Coronary artery calcification PHACTR1 intron 22144573 rs2876303 chr6 12919867 G A 4.78E-06 Coronary artery calcification PHACTR1 intron 22144573 rs2876303 chr6 12919867 G A 3.49E-04 Myocardial infarction PHACTR1 intron 24916648 rs2876303 chr6 12919867 G A 3.99E-06 Coronary heart disease PHACTR1 intron pha003031 rs8180558 chr6 12919989 T C 4.81E-06 Coronary artery calcification PHACTR1 intron 22144573 rs9381500 chr6 12922535 G A 4.81E-06 Coronary artery calcification PHACTR1 intron 22144573 rs2327621 chr6 12922689 G A 3.95E-06 Coronary artery calcification PHACTR1 intron 22144573 rs1014342 chr6 12923157 T C 4.71E-06 Coronary artery calcification PHACTR1 intron 22144573 rs1953088 chr6 12925936 C A 4.97E-06 Coronary artery calcification PHACTR1 intron 22144573 rs12526453 chr6 12927544 C G 1.00E-09 Myocardial infarction (early onset) PHACTR1 intron 19198609 rs12526453 chr6 12927544 C G 8.06E-06 Cardiovascular disease risk factors PHACTR1 intron 21239051 rs12526453 chr6 12927544 C G 1.00E-09 Coronary heart disease PHACTR1 intron 21347282 rs12526453 chr6 12927544 C G 1.00E-09 Coronary heart disease PHACTR1 intron 21378990 rs12526453 chr6 12927544 C G 1.15E-09 Pericardial fat PHACTR1 intron 22589742 rs12526453 chr6 12927544 C G 1.84E-13 Coronary artery disease PHACTR1 intron 23202125 rs12526453 chr6 12927544 C G 0.00029 Coronary artery calcification PHACTR1 intron 23394302 rs4714990 chr6 12927845 T A,C 1.18E-05 Coronary heart disease PHACTR1 intron pha003031 rs2210514 chr6 12930061 A C 6.84E-04 Multiple complex diseases PHACTR1 intron 17554300 rs9381511 chr6 12931448 C T 9.77E-04 Multiple complex diseases PHACTR1 intron 17554300 rs9381512 chr6 12931992 T C 5.53E-04 Multiple complex diseases PHACTR1 intron 17554300 rs7739181 chr6 12934687 G A 7.60E-06 Migraine PHACTR1 intron 22683712 rs7775710 chr6 12951578 G C 0.0000435 Coronary artery calcification PHACTR1 intron 23394302 rs62386820 chr6 12954012 G A 0.0000602 Coronary artery calcification PHACTR1 intron 23394302 rs9473086 chr6 12957035 C T 7.05E-04 Multiple complex diseases PHACTR1 intron 17554300 rs9473086 chr6 12957035 C T 0.0000694 Coronary artery calcification PHACTR1 intron 23394302 rs66820937 chr6 12957412 A T 0.0000477 Coronary artery calcification PHACTR1 intron 23394302 rs11756003 chr6 12957621 G A 0.0000398 Coronary artery calcification PHACTR1 intron 23394302 rs4236093 chr6 12957825 C G 0.0000724 Coronary artery calcification PHACTR1 intron 23394302 rs13194360 chr6 12959815 T C 0.0000971 Coronary artery calcification PHACTR1 intron 23394302 rs6906890 chr6 12961220 A G 0.000099 Coronary artery calcification PHACTR1 intron 23394302 rs10948372 chr6 12982423 T C 0.0000651 Coronary artery calcification PHACTR1 intron 23394302 rs6901563 chr6 12983504 A C 3.95E-05 Insulin resistance PHACTR1 intron 21901158 rs35713382 chr6 12998889 C T 0.0000841 Coronary artery calcification PHACTR1 intron 23394302 rs4331981 chr6 13017916 G A 0.0000857 Coronary artery calcification PHACTR1 intron 23394302 rs4331981 chr6 13017916 G A 8.96E-05 Coronary heart disease PHACTR1 intron pha003031 rs4236098 chr6 13020317 A T 0.0000598 Coronary artery calcification PHACTR1 intron 23394302 rs4129937 chr6 13023788 T C 0.0000276 Coronary artery calcification PHACTR1 intron 23394302 rs9349439 chr6 13024536 G A 0.0000323 Coronary artery calcification PHACTR1 intron 23394302 rs9395336 chr6 13024606 C T 0.0000276 Coronary artery calcification PHACTR1 intron 23394302 rs4132045 chr6 13025564 T C 0.0000306 Coronary artery calcification PHACTR1 intron 23394302 rs190274417 chr6 13027789 C A,T 0.0000725 Coronary artery calcification PHACTR1 intron 23394302 rs9369762 chr6 13030256 G A 1.96E-05 Coronary heart disease PHACTR1 intron pha003031 rs6907651 chr6 13030594 C T 5.87E-05 Coronary heart disease PHACTR1 intron pha003031 rs6912487 chr6 13030993 C T 0.000053 Coronary artery calcification PHACTR1 intron 23394302 rs6936052 chr6 13031740 A C 0.0000779 Coronary artery calcification PHACTR1 intron 23394302 rs9369768 chr6 13035947 G A 8.86E-04 Insulin resistance PHACTR1 intron 21901158 rs4131857 chr6 13038879 G C 0.0000315 Coronary artery calcification PHACTR1 intron 23394302 rs7775901 chr6 13052693 T C 0.000014 Coronary artery calcification PHACTR1 intron 23394302 rs6920793 chr6 13068959 A G 0.0000396 Coronary artery calcification PHACTR1 intron 23394302 rs4329096 chr6 13086650 A G 0.000099 Coronary artery calcification PHACTR1 intron 23394302 rs4273676 chr6 13093634 C T 6.32E-04 Insulin resistance PHACTR1 intron 21901158 rs4537139 chr6 13097840 C G 3.82E-04 Insulin resistance PHACTR1 intron 21901158 rs9369815 chr6 13098495 A G 1.33E-04 Insulin resistance PHACTR1 intron 21901158 rs1937774 chr6 13100821 A G 0.0000914 Coronary artery calcification PHACTR1 intron 23394302 rs17375084 chr6 13104581 C T 0.0000859 Coronary artery calcification PHACTR1 intron 23394302 rs1223531 chr6 13147535 A G 8.00E-05 Kidney function and endocine traits PHACTR1 intron 17903292 rs73725617 chr6 13170302 A G 0.0000311 Menopause (age at onset) PHACTR1 intron 23424626 rs11760186 chr6 13196011 A G 6.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PHACTR1 intron 20877124 rs201554952 chr6 13196011 A AG 6.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PHACTR1 intron 20877124 rs3864314 chr6 13196576 T C 4.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PHACTR1 intron 20877124 rs4715166 chr6 13216058 A G 3.00E-06 Hip geometry PHACTR1 intron 17903296 rs12195574 chr6 13225971 G A 4.00E-06 QT interval in Tripanosoma cruzi seropositivity PHACTR1 intron 24324551 rs12660392 chr6 13232481 A G 2.70E-05 Urinary metabolites PHACTR1 intron 21572414 rs202062 chr6 13240272 A G 3.61E-06 Sickle cell anemia (severity) PHACTR1 intron 20029952 rs182148 chr6 13267547 G A 3.56E-05 Prostate cancer PHACTR1 intron 22923026 rs366904 chr6 13267681 T C 1.86E-04 Parkinson's disease PHACTR1 intron 21248740 rs1223397 chr6 13270945 G C 1.00E-07 Blood pressure PHACTR1 intron 22763476 rs117124693 chr6 13274664 A G 0.0000562 Menopause (age at onset) PHACTR1 intron 23424626 rs1512414 chr6 13276415 A G 6.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PHACTR1 intron 20877124 rs449321 chr6 13282092 G A 2.20E-05 Urinary metabolites PHACTR1 intron 21572414 rs202040 chr6 13288535 C T 9.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100130357 intron 23233662 rs202038 chr6 13288648 A G 9.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100130357 intron 23233662 rs8541 chr6 13290238 T C 9.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100130357 intron 23233662 rs543645 chr6 13293110 C T 9.53E-07 Gaucher disease severity LOC100130357 intron 22388998 rs76294174 chr6 13293570 G C 0.0000217 Menopause (age at onset) LOC100130357 intron 23424626 rs4602719 chr6 13295502 T C 9.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100130357 intron 23233662 rs1550526 chr6 13295515 A C 9.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100130357 missense 23233662 rs454563 chr6 13295536 C T 9.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100130357 missense 23233662 rs9296642 chr6 13298184 A C 3.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2002961 chr6 13298898 A G 3.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs202020 chr6 13301917 C G 2.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2439538 chr6 13308083 T C 2.03E-06 Gaucher disease severity TBC1D7 intron 22388998 rs2439538 chr6 13308083 T C 7.30E-05 Tunica Media TBC1D7 intron pha003037 rs2496144 chr6 13311941 A G 1.46E-04 Lymphocyte counts TBC1D7 intron 22286170 rs2458304 chr6 13323895 A G 3.74E-04 Tourette syndrome TBC1D7 intron 22889924 rs2439554 chr6 13329466 A G 8.44E-04 Type 2 diabetes / / 17463246 rs1512411 chr6 13331097 T C 1.55E-05 Cardiovascular disease / / 17903304 rs507369 chr6 13332060 G T 6.23E-05 Cardiovascular disease / / 17903304 rs499818 chr6 13332467 G A 7.00E-06 Major CVD / / 17903304 rs1866863 chr6 13336815 A G 6.09E-04 Tourette syndrome / / 22889924 rs9357720 chr6 13406499 A G 1.29E-04 Age-related macular degeneration GFOD1 intron 22125219 rs10807437 chr6 13414584 A C 0.0000548 Salmonella-induced pyroptosis GFOD1 intron 22837397 rs519758 chr6 13414600 G A 7.02E-34 Multiple complex diseases GFOD1 intron 17554300 rs6936420 chr6 13417746 G A 2.07E-04 Alzheimer's disease GFOD1 intron 17998437 rs16874136 chr6 13420685 C G 8.51E-05 Gallstones GFOD1 intron 17632509 rs16874145 chr6 13422162 A T 6.77E-04 Alzheimer's disease GFOD1 intron 17998437 rs9296672 chr6 13425532 C T 1.20E-04 Age-related macular degeneration GFOD1 intron 22125219 rs9357738 chr6 13457789 C G 9.42E-05 Alzheimer's disease GFOD1 intron 17998437 rs2560814 chr6 13471445 C T 8.43E-04 Type 2 diabetes GFOD1 intron 17463246 rs2560812 chr6 13472642 C T 1.35E-05 Tuberculosis GFOD1 intron 20694014 rs2841548 chr6 13490584 A C 2.90E-05 Urinary metabolites / / 21572414 rs2560770 chr6 13529708 A G 6.54E-05 Panic disorder / / 19165232 rs2841573 chr6 13548165 A G 7.35E-05 Alzheimer's disease / / 17998437 rs10498683 chr6 13560834 C T 2.80E-04 Height / / 17255346 rs16874223 chr6 13562277 G T 9.20E-05 HIV-1 viral setpoint / / 22174851 rs12663015 chr6 13564003 C T 8.84E-05 Major depressive disorder (broad) / / 20038947 rs707816 chr6 13634982 C T 2.99E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy RANBP9 intron 23834954 rs4715512 chr6 13716767 T A 6.84E-05 Type 2 diabetes / / 17463246 rs204247 chr6 13722523 G A 8.00E-09 Breast cancer / / 23535729 rs1204175 chr6 13838637 T G 8.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs7753981 chr6 13864271 A G 1.97E-04 Type 2 diabetes / / 17463246 rs1204224 chr6 13866326 C T 4.79E-04 Type 2 diabetes / / 17463246 rs9382651 chr6 13867230 A G 1.78E-04 Type 2 diabetes / / 17463246 rs1204250 chr6 13877123 A G 0.000536 Salmonella-induced pyroptosis / / 22837397 rs2274088 chr6 13897986 C T 3.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs280143 chr6 13929502 A G 8.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RNF182 intron 20877124 rs9382713 chr6 13943955 C T 5.86E-04 Multiple complex diseases RNF182 intron 17554300 rs280171 chr6 13954632 G A 6.20E-04 Myocardial Infarction RNF182 intron pha002873 rs280181 chr6 13961994 A T 6.63E-04 Cognition,early reading ability RNF182 intron 17684495 rs1003024 chr6 13995112 C T 0.0000743 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs742211 chr6 14004979 T G 8.10E-04 Myocardial Infarction / / pha002873 rs16874593 chr6 14040009 G A 6.02E-04 Alzheimer's disease / / 17998437 rs11967453 chr6 14040269 G C 7.07E-04 Alzheimer's disease / / 17998437 rs6924356 chr6 14045170 G A 3.45E-04 Alzheimer's disease / / 24755620 rs6915882 chr6 14046411 T C 3.82E-04 Alzheimer's disease / / 24755620 rs9476478 chr6 14065237 C A 8.73E-04 Alzheimer's disease / / 24755620 rs7744485 chr6 14072395 G T 1.39E-05 Schizophrenia(age at onset) / / 21688384 rs9296918 chr6 14073320 A G 2.52E-05 Schizophrenia(age at onset) / / 21688384 rs9476484 chr6 14074359 C G 1.15E-05 Schizophrenia(age at onset) / / 21688384 rs9382937 chr6 14083063 G A 2.02E-05 Schizophrenia(age at onset) / / 21688384 rs9476489 chr6 14085161 T C 5.78E-04 Multiple complex diseases / / 17554300 rs17430541 chr6 14085980 G A 8.58E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12529514 chr6 14096658 T C 2.00E-08 Rheumatoid arthritis / / 22446963 rs9296922 chr6 14129756 C T 4.72E-04 Multiple complex diseases CD83 intron 17554300 rs853372 chr6 14143961 G A 5.20E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs853356 chr6 14173428 G A 3.00E-06 Height / / 21998595 rs853382 chr6 14179776 G A 2.00E-05 Height / / 21998595 rs12214546 chr6 14180087 T C 1.83E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs12191763 chr6 14188742 A G 4.55E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7758616 chr6 14200147 G A 4.00E-06 Obesity-related traits / / 23251661 rs944488 chr6 14261558 C T 7.07E-05 Multiple complex diseases / / 17554300 rs6917540 chr6 14278169 A G 2.88E-05 Major depressive disorder (broad) / / 20038947 rs12526133 chr6 14282023 C T 5.87E-05 Major depressive disorder (broad) / / 20038947 rs2094923 chr6 14289082 T G 4.20E-05 Major depressive disorder / / 19065144 rs2094923 chr6 14289082 T G 3.14E-05 Major depressive disorder (broad) / / 20038947 rs2094923 chr6 14289082 T G 2.89E-05 Major depressive disorder / / pha002850 rs2274822 chr6 14291089 T C 7.00E-06 Major depressive disorder / / 19065144 rs2274822 chr6 14291089 T C 1.57E-05 Major depressive disorder / / 21621269 rs2274822 chr6 14291089 T C 1.56E-05 Major depressive disorder / / pha002850 rs17436946 chr6 14341801 G T 7.50E-06 Urinary metabolites / / 21572414 rs6459351 chr6 14354005 T C 0.0000043 Mean arterial pressure / / 22510845 rs4715888 chr6 14354147 A G 0.00019 Salmonella-induced pyroptosis / / 22837397 rs4715889 chr6 14358016 A T 8.17E-06 Glaucoma (primary open-angle) / / 22605921 rs4715890 chr6 14358168 G A 5.58E-05 Blood Pressure / / pha003049 rs7748589 chr6 14381484 G A 7.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs4715891 chr6 14396349 A C 5.68E-05 Lung function (forced vital capacity) / / pha003104 rs9370742 chr6 14451276 T C 4.49E-04 Heart Failure / / pha002884 rs3761987 chr6 14475527 A T 7.00E-04 Hypertension / / 18003638 rs16875088 chr6 14505886 C T 5.07E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs9396501 chr6 14524588 G A 1.76E-04 Smoking cessation / / 24665060 rs7774975 chr6 14539376 C T 2.83E-04 Multiple complex diseases / / 17554300 rs10080807 chr6 14551209 C T 1.02E-04 Smoking cessation / / 24665060 rs9370751 chr6 14558753 A T 7.82E-06 Metabolite levels (MHPG) / / 23319000 rs9370752 chr6 14558920 T C 2.40E-04 Multiple complex diseases / / 17554300 rs9370752 chr6 14558920 T C 6.55E-06 Metabolite levels (MHPG) / / 23319000 rs9349946 chr6 14559125 C T 7.82E-06 Metabolite levels (MHPG) / / 23319000 rs1984252 chr6 14559575 T C 7.82E-06 Metabolite levels (MHPG) / / 23319000 rs1984251 chr6 14559621 G A 1.93E-06 Metabolite levels (MHPG) / / 23319000 rs9396510 chr6 14560180 C T 7.82E-06 Metabolite levels (MHPG) / / 23319000 rs9370753 chr6 14560233 A G 7.82E-06 Metabolite levels (MHPG) / / 23319000 rs9396512 chr6 14560320 T G 7.82E-06 Metabolite levels (MHPG) / / 23319000 rs6914991 chr6 14560845 A G 7.82E-06 Metabolite levels (MHPG) / / 23319000 rs6459362 chr6 14573435 C G 5.38E-06 Metabolite levels (MHPG) / / 23319000 rs16875249 chr6 14582444 G A 7.75E-06 Uric acid levels / / 21294900 rs12213875 chr6 14587003 A G 3.00E-07 Ovarian reserve / / 22116950 rs7451206 chr6 14587734 C T 8.36E-06 Metabolite levels (MHPG) / / 23319000 rs113256482 chr6 14591869 C A 4.44E-06 Metabolite levels (MHPG) / / 23319000 rs6914079 chr6 14596365 A G 2.00E-06 Cognitive test performance / / 17903297 rs6940298 chr6 14597572 G T 4.00E-06 Metabolite levels (MHPG) / / 23319000 rs9296949 chr6 14597982 C T 2.00E-06 Metabolite levels (HVA/MHPG ratio) / / 23319000 rs7770731 chr6 14598820 T C 1.00E-06 Response to antipsychotic treatment in schizophrenia (working memory) / / 21107309 rs865671 chr6 14627157 G A 8.70E-07 Urinary metabolites / / 21572414 rs707824 chr6 14636963 T C 9.30E-05 Personality dimensions / / 18957941 rs707824 chr6 14636963 T C 6.00E-07 Lymphoma / / 23349640 rs707824 chr6 14636963 T C 5.99E-05 Smoking initiation / / 24665060 rs1267505 chr6 14714195 C T 5.83E-04 Coronary heart disease / / 21606135 rs1267500 chr6 14715825 C T 7.99E-04 Coronary heart disease / / 21606135 rs1267496 chr6 14716017 G C 3.10E-04 Coronary heart disease / / 21606135 rs1267495 chr6 14716037 C T 3.55E-04 Coronary heart disease / / 21606135 rs1267494 chr6 14716210 G C,T 7.17E-04 Coronary heart disease / / 21606135 rs17119 chr6 14719496 G A 2.98E-04 Coronary heart disease / / 21606135 rs17119 chr6 14719496 G A 3.00E-11 Inflammatory bowel disease / / 23128233 rs1267488 chr6 14719994 G A 9.71E-04 Coronary heart disease / / 21606135 rs2038016 chr6 14737509 A G 1.90E-05 Bone mineral density (BMD),in women / / 20164292 rs6459375 chr6 14741306 G T 1.10E-05 Bone mineral density (BMD),in women / / 20164292 rs2472793 chr6 14748675 T C 3.20E-05 Bone mineral density (BMD),in women / / 20164292 rs4712240 chr6 14752873 C T 3.60E-05 Bone mineral density (BMD),in women / / 20164292 rs7739370 chr6 14851102 G A 3.57E-04 Multiple complex diseases / / 17554300 rs1408254 chr6 14904327 A C 9.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10485309 chr6 14906120 A C 4.89E-05 Cognitive impairment induced by topiramate / / 22091778 rs367602 chr6 14922575 T G 2.56E-04 Alzheimer's disease / / 24755620 rs7759942 chr6 14953537 C T 9.20E-04 Multiple complex diseases / / 17554300 rs6902553 chr6 14977206 T G 8.78E-05 Orofacial clefts / / 22419666 rs9476703 chr6 14996169 T C 1.79E-04 Alzheimer's disease (late onset) / / 21379329 rs9476703 chr6 14996169 T C 3.78E-04 Alzheimer's disease / / 24755620 rs1259061 chr6 14999452 A G 1.48E-04 Alzheimer's disease (late onset) / / 21379329 rs1259061 chr6 14999452 A G 1.27E-04 Alzheimer's disease / / 24755620 rs724626 chr6 15009137 A G 1.09E-04 Alzheimer's disease / / 24755620 rs9296962 chr6 15035417 G A 4.12E-04 Fibrinogen / / 17255346 rs2791615 chr6 15062945 C G 9.78E-05 Bipolar disorder / / 20451256 rs7755465 chr6 15072927 T C 1.34E-05 Triglycerides / / pha003080 rs6941421 chr6 15089151 T C 6.00E-06 Multiple sclerosis (severity) / / 19010793 rs6906466 chr6 15093021 C A 0.0000049 Asthma (exacerbation) / / 23706709 rs2747496 chr6 15136433 G C 1.73E-04 Multiple complex diseases / / 17554300 rs13210652 chr6 15205208 T A 6.49E-04 Alzheimer's disease / / 22005930 rs12664987 chr6 15215150 C T 5.95E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs2295954 chr6 15250052 G A 2.90E-04 Coronary heart disease JARID2 intron 21971053 rs10949286 chr6 15256571 A C 5.24E-04 Multiple complex diseases JARID2 intron 17554300 rs11962776 chr6 15260153 C A 3.94E-05 Behcet's disease JARID2 intron pha002888 rs6459404 chr6 15281420 T C 4.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) JARID2 intron 20877124 rs16876210 chr6 15307884 C T 2.80E-05 Neuroblastoma JARID2 intron pha002895 rs7765425 chr6 15328073 G A 5.07E-05 Neuroblastoma JARID2 intron pha002895 rs707838 chr6 15352243 G T 3.26E-04 Alcohol consumption (maxi-drinks) JARID2 intron 24277619 rs12195286 chr6 15365977 C T 4.04E-04 Response to cytidine analogues (gemcitabine) JARID2 intron 24483146 rs2299059 chr6 15376994 A G 2.22E-04 Response to taxane treatment (placlitaxel) JARID2 intron 23006423 rs9383054 chr6 15397635 A G 7.00E-04 Systemic lupus erythematosus JARID2 intron 24871463 rs2299054 chr6 15398849 C T 6.60E-04 Systemic lupus erythematosus JARID2 intron 24871463 rs17619975 chr6 15402752 T G 1.49E-05 Schizophrenia JARID2 intron 19571809 rs10484354 chr6 15410108 C T 4.11E-11 Multiple complex diseases JARID2 intron 17554300 rs2237148 chr6 15412164 C T 3.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) JARID2 intron 20877124 rs11760101 chr6 15430608 G A 2.02E-05 Cognitive performance JARID2 intron 19734545 rs2237113 chr6 15500687 A G 8.51E-05 Non-alcoholic fatty liver disease histology (other) JARID2 intron 20708005 rs2282815 chr6 15503919 C A 2.56E-04 Amyotrophic Lateral Sclerosis JARID2 intron 17362836 rs760659 chr6 15504589 T C 7.78E-04 Alcohol consumption (maxi-drinks) JARID2 intron 24277619 rs909626 chr6 15517684 C T 5.19E-05 Parkinson's disease JARID2 intron 21738487 rs1047631 chr6 15523101 T C 2.50E-05 Myasthenia gravis DTNBP1 UTR-3 23055271 rs16876575 chr6 15525157 C T 6.90E-04 Type 2 diabetes DTNBP1 intron 17463246 rs16876575 chr6 15525157 C T 4.79E-05 Schizophrenia DTNBP1 intron 19571809 rs10456773 chr6 15537325 T C 9.54E-04 Alcohol dependence DTNBP1 intron 21314694 rs875462 chr6 15538436 C T 7.27E-05 Blood Pressure DTNBP1 intron pha003048 rs9296983 chr6 15555426 A G 8.03E-05 Blood Pressure DTNBP1 intron pha003040 rs9296983 chr6 15555426 A G 5.44E-05 Blood Pressure DTNBP1 intron pha003046 rs9296983 chr6 15555426 A G 8.72E-06 Blood Pressure DTNBP1 intron pha003048 rs742105 chr6 15573074 C T 1 Drug response to Clozapine DTNBP1 intron 19369910 rs9296985 chr6 15590015 T C 1.07E-04 Stroke DTNBP1 intron pha002887 rs9396593 chr6 15592559 A G 4.72E-05 Blood Pressure DTNBP1 intron pha003048 rs2619539 chr6 15620855 C G 1 Drug response to Methamphetamine DTNBP1 intron 17192893 rs2619539 chr6 15620855 C G 1 Drug response to Methamphetamine DTNBP1 intron 17555717 rs2619539 chr6 15620855 C G 1 Drug response to Methamphetamine DTNBP1 intron 18162312 rs3213207 chr6 15628102 T C 1 Drug response to Methamphetamine DTNBP1 intron 17192893 rs3213207 chr6 15628102 T C 1 Drug response to Methamphetamine DTNBP1 intron 17555717 rs3213207 chr6 15628102 T C 1 Drug response to Methamphetamine DTNBP1 intron 18162312 rs1474605 chr6 15658212 T C 5.40E-05 Myasthenia gravis DTNBP1 intron 23055271 rs1474605 chr6 15658212 T C 7.44E-05 Stroke DTNBP1 intron pha002887 rs909706 chr6 15660871 T C 1 Drug response to Haloperidol DTNBP1 intron 19369910 rs2619538 chr6 15665209 A T 1 Drug response to Methamphetamine DTNBP1 nearGene-5 15820225 rs2619538 chr6 15665209 A T 1 Drug response to Methamphetamine DTNBP1 nearGene-5 17192893 rs2619538 chr6 15665209 A T 1 Drug response to Methamphetamine DTNBP1 nearGene-5 17555717 rs2619538 chr6 15665209 A T 1 Drug response to Methamphetamine DTNBP1 nearGene-5 18162312 rs6937887 chr6 15688611 G T 4.07E-05 Blood Pressure / / pha003043 rs6906528 chr6 15690314 G A 8.43E-05 Blood Pressure / / pha003043 rs9283925 chr6 15696615 G A 2.09E-04 Multiple complex diseases / / 17554300 rs9283925 chr6 15696615 G A 9.04E-05 Serum metabolites / / 19043545 rs9464816 chr6 15698404 G C 1.10E-05 Urinary metabolites / / 21572414 rs748589 chr6 15716262 A T 3.99E-04 Multiple complex diseases / / 17554300 rs748589 chr6 15716262 A T 7.15E-05 Serum metabolites / / 19043545 rs9476899 chr6 15725478 C T 6.60E-05 Blood Pressure / / pha003043 rs7738190 chr6 15751845 C T 6.06E-05 Blood Pressure / / pha003043 rs1109287 chr6 15760644 G A 2.17E-05 Blood Pressure / / pha003043 rs420350 chr6 15763793 A C 4.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs420350 chr6 15763793 A C 3.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs220896 chr6 15769538 G A 8.56E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7739977 chr6 15777670 G A 9.87E-06 Odorant perception / / 23910658 rs74111 chr6 15786602 G T 7.36E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2007855 chr6 15788380 T C 1.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs440691 chr6 15820872 A G 8.70E-06 Urinary metabolites / / 21572414 rs13190874 chr6 15827242 T C 3.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs4712260 chr6 15827984 G A 4.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs191985 chr6 15828051 T C 6.60E-06 Urinary metabolites / / 21572414 rs13218971 chr6 15830901 C T 4.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs4712261 chr6 15835856 C T 4.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs424417 chr6 15836881 C T 7.90E-06 Urinary metabolites / / 21572414 rs13211010 chr6 15837290 T C 4.37E-04 Suicide attempts in bipolar disorder / / 21041247 rs4716002 chr6 15839255 G T 6.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs16877105 chr6 15840433 G A 6.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs16877108 chr6 15840679 A G 6.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs16877113 chr6 15840912 C A 6.63E-04 Suicide attempts in bipolar disorder / / 21041247 rs1927587 chr6 15845108 C T 6.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs220933 chr6 15845797 C T 2.40E-05 Urinary metabolites / / 21572414 rs9396607 chr6 15855428 G T 7.07E-07 Insulin-related traits / / 22791750 rs9370836 chr6 15856619 T C 3.95E-06 Glycemic traits (pregnancy) / / 23903356 rs10484350 chr6 15869055 G A 3.07E-04 Multiple complex diseases / / 17554300 rs10484349 chr6 15873951 A C 6.58E-04 Parkinson's disease / / 17052657 rs16877320 chr6 15923026 T C 3.42E-09 Blood pressure / / 21378095 rs16877320 chr6 15923026 T C 2.80E-08 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs9296994 chr6 15931538 T C 4.28E-04 Taste perception / / 22132133 rs1539422 chr6 15950027 T C 3.05E-04 Parkinson's disease / / 17052657 rs9358075 chr6 15958117 A C 2.00E-05 Urinary metabolites / / 21572414 rs6924791 chr6 15992308 C T 9.06E-04 Parkinson's disease / / 17052657 rs9296999 chr6 15996046 G T 3.25E-04 Parkinson's disease / / 17052657 rs1935784 chr6 16032433 G A 4.56E-05 Orofacial clefts / / 22419666 rs2876407 chr6 16078479 A G 4.83E-04 Myopia (pathological) / / 21095009 rs2294270 chr6 16087234 G A 4.83E-04 Myopia (pathological) / / 21095009 rs7768105 chr6 16091394 T C 2.39E-06 Venous thromboembolism / / 22672568 rs9358083 chr6 16092072 G A 2.34E-06 Venous thromboembolism / / 22672568 rs9358084 chr6 16092525 G A 2.33E-06 Venous thromboembolism / / 22672568 rs9396643 chr6 16092993 T G 2.28E-06 Venous thromboembolism / / 22672568 rs12192563 chr6 16093462 A T 2.28E-06 Venous thromboembolism / / 22672568 rs4716045 chr6 16096596 C T 2.49E-06 Venous thromboembolism / / 22672568 rs12201671 chr6 16097962 A C 2.60E-06 Venous thromboembolism / / 22672568 rs6459448 chr6 16098290 G A 2.66E-06 Venous thromboembolism / / 22672568 rs6921677 chr6 16098944 C T 5.80E-04 Schizophrenia / / 19197363 rs6921677 chr6 16098944 C T 1.19E-04 Insulin resistance / / 21901158 rs9383114 chr6 16099280 T A 2.88E-06 Venous thromboembolism / / 22672568 rs6928267 chr6 16100153 C G 2.94E-06 Venous thromboembolism / / 22672568 rs6912988 chr6 16100654 T C 3.00E-06 Venous thromboembolism / / 22672568 rs10949343 chr6 16101257 T C 2.94E-06 Venous thromboembolism / / 22672568 rs12192575 chr6 16102302 C T 3.34E-06 Venous thromboembolism / / 22672568 rs7745965 chr6 16102742 G A 3.47E-06 Venous thromboembolism / / 22672568 rs7749877 chr6 16102802 G A 3.70E-06 Venous thromboembolism / / 22672568 rs2480 chr6 16113733 C T 5.80E-11 Lipid levels / / 19936222 rs3757354 chr6 16127407 C T 6.40E-05 Longevity and age-related phenotypes / / 17903295 rs3757354 chr6 16127407 C T 1.00E-11 LDL cholesterol / / 20686565 rs3757354 chr6 16127407 C T 3.00E-09 Cholesterol,total / / 20686565 rs3757354 chr6 16127407 C T 2.00E-15 Cholesterol,total / / 24097068 rs3757354 chr6 16127407 C T 2.00E-17 LDL cholesterol / / 24097068 rs17580572 chr6 16153962 G A 1.64E-05 Brain structure / / 22504417 rs17641827 chr6 16157119 C G 1.14E-04 Brain structure / / 22504417 rs6924995 chr6 16161425 A G 5.00E-07 Response to statin therapy (LDL-C) / / 22331829 rs7739312 chr6 16174028 T G 8.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs9477049 chr6 16177688 G A 3.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs16877694 chr6 16185339 C T 1.24E-04 Multiple complex diseases / / 17554300 rs2142672 chr6 16197194 G A 2.00E-08 LDL cholesterol / / 20864672 rs4712277 chr6 16209635 T G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6926128 chr6 16218457 G A 9.87E-07 Red blood cell traits / / 23222517 rs9396650 chr6 16223268 G T 5.50E-08 Red blood cell traits / / 23222517 rs9367903 chr6 16226268 A G 9.88E-06 Paget's disease / / 20436471 rs9367903 chr6 16226268 A G 4.47E-08 Red blood cell traits / / 23222517 rs6459463 chr6 16228750 A G 1.24E-08 Red blood cell traits / / 23222517 rs9383137 chr6 16231486 G A 8.65E-07 Red blood cell traits / / 23222517 rs114353847 chr6 16232556 A C 1.06E-04 Acne (severe) / / 24927181 rs3814453 chr6 16236837 T G 6.53E-07 Red blood cell traits GMPR nearGene-5 23222517 rs9383138 chr6 16239779 G A 4.91E-07 Red blood cell traits GMPR intron 23222517 rs6459465 chr6 16248130 G C 1.49E-12 Red blood cell traits GMPR intron 23222517 rs9396658 chr6 16252853 T C 1.99E-15 Red blood cell traits GMPR intron 23222517 rs7763322 chr6 16254095 T C 3.00E-16 Red blood cell traits GMPR intron 23222517 rs10484358 chr6 16256043 G T 1.00E-06 Major depressive disorder GMPR intron 23377640 rs7742883 chr6 16258216 A G 2.33E-13 Red blood cell traits GMPR intron 23222517 rs9367907 chr6 16268059 C T 2.07E-05 Schizophrenia GMPR intron 24253340 rs6933491 chr6 16268408 A G 9.59E-14 Red blood cell traits GMPR intron 23222517 rs9477074 chr6 16269363 T C 8.98E-15 Red blood cell traits GMPR intron 23222517 rs9396661 chr6 16274791 G A 2.98E-08 Red blood cell traits GMPR intron 23222517 rs6922229 chr6 16275700 C T 1.96E-09 Red blood cell traits GMPR intron 23222517 rs4716056 chr6 16278390 A G 5.26E-12 Red blood cell traits GMPR intron 23222517 rs739473 chr6 16279097 T C 2.02E-05 Schizophrenia GMPR cds-synon 24253340 rs6914805 chr6 16281187 C T 1.24E-19 Red blood cell traits GMPR intron 23222517 rs6459467 chr6 16288192 G A 1.21E-17 Red blood cell traits GMPR intron 23222517 rs6459467 chr6 16288192 G A 2.00E-16 Blood metabolite levels GMPR intron 24816252 rs9350003 chr6 16289311 T A 1.79E-09 Red blood cell traits GMPR intron 23222517 rs11969354 chr6 16289328 G A 2.51E-09 Red blood cell traits GMPR intron 23222517 rs11969354 chr6 16289328 G A 2.51E-04 Smoking initiation GMPR intron 24665060 rs1042391 chr6 16290761 T A 1.41E-18 Red blood cell traits GMPR missense 23222517 rs6926552 chr6 16290862 T C 1.30E-09 Red blood cell traits GMPR intron 23222517 rs6926552 chr6 16290862 T C 2.08E-05 Smoking initiation GMPR intron 24665060 rs4716058 chr6 16292175 C T 1.83E-10 Red blood cell traits GMPR intron 23222517 rs4716059 chr6 16292760 C T 6.44E-09 Red blood cell traits GMPR intron 23222517 rs7765828 chr6 16294722 C G 6.80E-19 Red blood cell traits GMPR intron 23222517 rs13215954 chr6 16295038 C A 1.06E-08 Red blood cell traits GMPR intron 23222517 rs6723 chr6 16295589 C G 1.00E-16 Red blood cell traits GMPR UTR-3 23222517 rs16885 chr6 16306751 G A,C 5.69E-05 Smoking initiation ATXN1 missense 24665060 rs16877885 chr6 16333408 G A 2.41E-05 Multiple complex diseases ATXN1 intron 17554300 rs179989 chr6 16334419 A T 2.38E-04 Multiple complex diseases ATXN1 intron 17554300 rs9383153 chr6 16343056 A G 5.00E-06 Gambling ATXN1 intron 22780124 rs7738608 chr6 16384665 C T 7.97E-07 Schizophrenia ATXN1 intron 21926974 rs9383156 chr6 16394282 A C 1.10E-06 Urinary metabolites ATXN1 intron 21572414 rs421172 chr6 16401797 G A 4.81E-04 Obesity (extreme) ATXN1 intron 21935397 rs395065 chr6 16404580 T A 3.74E-04 Obesity (extreme) ATXN1 intron 21935397 rs9370893 chr6 16418562 C T 3.11E-04 Multiple complex diseases ATXN1 intron 17554300 rs2282840 chr6 16423649 T C 0.0004762 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ATXN1 intron 23233654 rs2282840 chr6 16423649 T C 4.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) ATXN1 intron 23233662 rs2237204 chr6 16424956 G T 0.0005021 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ATXN1 intron 23233654 rs2237204 chr6 16424956 G T 5.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) ATXN1 intron 23233662 rs6933822 chr6 16425370 C G 7.71E-04 Insulin resistance ATXN1 intron 21901158 rs2237202 chr6 16425946 A G 0.0004835 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ATXN1 intron 23233654 rs2237202 chr6 16425946 A G 4.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) ATXN1 intron 23233662 rs4716069 chr6 16427264 T C 6.26E-04 Insulin resistance ATXN1 intron 21901158 rs2237199 chr6 16430021 G A 0.0004125 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ATXN1 intron 23233654 rs2237199 chr6 16430021 G A 4.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) ATXN1 intron 23233662 rs4716071 chr6 16433223 G A 5.15E-04 Body mass index ATXN1 intron 21701565 rs4716071 chr6 16433223 G A 1.90E-04 Celiac disease ATXN1 intron 23936387 rs1737844 chr6 16441704 A G 1.01E-04 Alzheimer's disease ATXN1 intron 24755620 rs12525391 chr6 16458043 C T 1.50E-05 Iron levels ATXN1 intron 21208937 rs9396677 chr6 16466221 G A 1.57E-04 Stroke ATXN1 intron pha002887 rs7766262 chr6 16479778 T C 9.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) ATXN1 intron 23233662 rs2237189 chr6 16488356 G A 4.82E-04 Stroke ATXN1 intron pha002887 rs12332862 chr6 16492307 C G 4.88E-04 Insulin resistance ATXN1 intron 21901158 rs59302766 chr6 16492698 A C 0.00000676 Nonsyndromic striae distensae (stretch marks) ATXN1 intron 23633020 rs2237188 chr6 16495008 T C 4.42E-04 Alzheimer's disease (late onset) ATXN1 intron 21379329 rs3806136 chr6 16511362 T C 9.95E-05 Brain derived neurotrophic factor levels,in serum ATXN1 intron 22047184 rs2237187 chr6 16513846 T C 0.000653172 Hypertension (early onset hypertension) ATXN1 intron 22479346 rs16878358 chr6 16520065 A G 2.74E-05 Bipolar disorder ATXN1 intron 20451256 rs2327982 chr6 16531881 C A 7.03E-04 Myopia (pathological) ATXN1 intron 21095009 rs9464918 chr6 16552503 C T 1.00E-04 Prostate cancer ATXN1 intron 21743057 rs2237182 chr6 16553926 C T 2.60E-04 Insulin resistance ATXN1 intron 21901158 rs9477163 chr6 16559980 C A 1.00E-04 Prostate cancer ATXN1 intron 21743057 rs9477166 chr6 16565192 A G 6.90E-05 Colorectal cancer ATXN1 intron 19723657 rs236932 chr6 16595948 G A 0.0000655 Nonsyndromic striae distensae (stretch marks) ATXN1 intron 23633020 rs3806141 chr6 16607777 T C 5.45E-04 Amyotrophic Lateral Sclerosis ATXN1 intron 17362836 rs12198838 chr6 16639979 T C 4.37E-05 Lipoproteins ATXN1 intron pha003079 rs720006 chr6 16647991 A G 5.81E-04 Type 2 diabetes ATXN1 intron 17463246 rs2299063 chr6 16649641 A C 1.10E-04 Myocardial Infarction ATXN1 intron pha002873 rs2299063 chr6 16649641 A C 5.07E-04 Heart Failure ATXN1 intron pha002884 rs2237165 chr6 16654023 T G 6.68E-04 Type 2 diabetes ATXN1 intron 17463246 rs2237164 chr6 16654050 C T 6.25E-04 Type 2 diabetes ATXN1 intron 17463246 rs3812189 chr6 16664565 C T 6.58E-05 Myocardial Infarction ATXN1 intron pha002873 rs9367924 chr6 16669367 T C 7.40E-06 Urinary metabolites ATXN1 intron 21572414 rs9367924 chr6 16669367 T C 3.76E-05 Weight ATXN1 intron pha003027 rs719316 chr6 16672760 C T 2.52E-05 Bipolar disorder and schizophrenia ATXN1 intron 20889312 rs7739556 chr6 16673598 G A 5.98E-05 Bipolar disorder ATXN1 intron 19488044 rs7739556 chr6 16673598 G A 7.17E-05 Schizophrenia ATXN1 intron 19571809 rs7760476 chr6 16673629 A G 1.74E-05 Schizophrenia ATXN1 intron 19571809 rs7760476 chr6 16673629 A G 5.50E-04 Lymphocyte counts ATXN1 intron 22286170 rs12196785 chr6 16679824 A T 7.00E-06 Urinary metabolites ATXN1 intron 21572414 rs1570488 chr6 16683930 T C 5.56E-05 Schizophrenia ATXN1 intron 19571809 rs2327995 chr6 16685520 T G 2.00E-05 Urinary metabolites ATXN1 intron 21572414 rs6903850 chr6 16686066 G T 6.39E-05 Cardiovascular disease ATXN1 intron pha003065 rs17669102 chr6 16687493 G T 9.87E-05 Serum metabolites ATXN1 intron 19043545 rs9370920 chr6 16692186 G A 8.97E-06 Body Mass Index ATXN1 intron pha003009 rs3812200 chr6 16695530 C T 4.85E-06 Body Mass Index ATXN1 intron pha003009 rs3812200 chr6 16695530 C T 2.56E-05 Height ATXN1 intron pha003010 rs3812200 chr6 16695530 C T 1.51E-05 Height ATXN1 intron pha003011 rs3793113 chr6 16695912 G C 1.20E-05 Response to statin therapy ATXN1 intron 20339536 rs3812205 chr6 16699949 C T 2.44E-04 Alzheimer's disease ATXN1 intron pha002879 rs73725220 chr6 16700060 G A 3.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity ATXN1 intron 24324551 rs3812207 chr6 16700833 G A 7.21E-05 Bipolar disorder and schizophrenia ATXN1 intron 20889312 rs531089 chr6 16706041 T C 4.93E-04 Age-related macular degeneration ATXN1 intron 22125219 rs707850 chr6 16724555 C T 2.50E-05 Urinary metabolites ATXN1 intron 21572414 rs697739 chr6 16742033 C T 4.00E-06 Amyotrophic lateral sclerosis ATXN1 intron 19451621 rs697739 chr6 16742033 C T 5.05E-05 Longevity ATXN1 intron 21612516 rs1144696 chr6 16742925 A G 6.94E-04 Multiple complex diseases ATXN1 intron 17554300 rs1144700 chr6 16744687 C T 3.51E-04 Multiple complex diseases ATXN1 intron 17554300 rs607138 chr6 16749567 A G 1.69E-05 Attention deficit hyperactivity disorder ATXN1 intron 20732625 rs649266 chr6 16750901 T C 1.52E-05 Attention deficit hyperactivity disorder ATXN1 intron 20732625 rs2301594 chr6 16754366 G A 3.89E-04 Multiple complex diseases ATXN1 intron 17554300 rs647750 chr6 16758345 G C 2.69E-04 Alzheimer's disease ATXN1 intron 24755620 rs628059 chr6 16772225 T C 7.20E-04 Major depressive disorder / / 21042317 rs628021 chr6 16772252 C T 7.40E-04 Major depressive disorder / / 21042317 rs602206 chr6 16773382 C T 4.30E-05 Major depressive disorder / / 21042317 rs598948 chr6 16774161 C T 6.40E-05 Major depressive disorder / / 21042317 rs649395 chr6 16776326 C T 7.89E-05 Lactate dehydrogenase levels / / 20981236 rs528785 chr6 16777131 A G 2.10E-04 Major depressive disorder / / 21042317 rs7745346 chr6 16791976 C G 2.16E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs642859 chr6 16796614 G A 5.54E-05 Alzheimer's disease (late onset) / / 21379329 rs11752823 chr6 16806220 G T 5.30E-05 Eosinophil counts / / pha003088 rs7740575 chr6 16806573 T C 6.70E-07 Height / / 19729412 rs1150644 chr6 16814304 C A 8.00E-06 Urinary metabolites / / 21572414 rs9396712 chr6 16818625 C T 2.50E-05 Urinary metabolites / / 21572414 rs6942123 chr6 16833106 C T 1.99E-05 Brain structure / / 22504417 rs16879290 chr6 16833699 T C 2.03E-05 Brain structure / / 22504417 rs770939 chr6 16836322 T A,C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs770940 chr6 16838006 T C 6.43E-06 Brain structure / / 22504417 rs12204538 chr6 16841508 G A 4.13E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs1240829 chr6 16866948 G T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1573134 chr6 16875468 C T 5.35E-05 Age-related macular degeneration / / pha000002 rs4074661 chr6 16901138 G A 8.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1473730 chr6 16918550 T C 9.91E-05 Alcohol dependence / / 19581569 rs927366 chr6 16927529 C T 2.50E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs927366 chr6 16927529 C T 3.93E-05 Serum metabolites / / 19043545 rs6459492 chr6 16940518 T C 1.38E-04 Multiple complex diseases / / 17554300 rs9464966 chr6 16945864 C A 6.69E-04 Multiple complex diseases / / 17554300 rs6912394 chr6 16945997 G T 5.83E-04 Multiple complex diseases / / 17554300 rs6459495 chr6 16949970 T G 4.00E-04 Adverse response to radiation therapy / / 23719583 rs4716102 chr6 16959610 T C 8.78E-04 Type 2 diabetes / / 17463246 rs6903672 chr6 16962713 G A 2.65E-04 Multiple complex diseases / / 17554300 rs6903672 chr6 16962713 G A 1.45E-04 Insulin resistance / / 21901158 rs9358118 chr6 16989325 G A 1.48E-05 Coronary heart disease / / pha003030 rs1885366 chr6 17021468 A G 6.04E-04 Multiple complex diseases / / 17554300 rs10456205 chr6 17035875 G C 3.80E-06 Urinary metabolites / / 21572414 rs7738857 chr6 17044268 C G 5.20E-06 Urinary metabolites / / 21572414 rs10949397 chr6 17048176 G A 7.15E-05 Coronary heart disease / / pha003030 rs10949397 chr6 17048176 G A 3.69E-05 Coronary heart disease / / pha003031 rs4360123 chr6 17066353 C A 9.68E-04 Multiple complex diseases / / 17554300 rs4360123 chr6 17066353 C A 8.25E-06 Coronary heart disease / / pha003031 rs4496808 chr6 17067041 T G 6.95E-05 Cognitive performance / / 19734545 rs4610573 chr6 17080623 T C 7.79E-06 Coronary heart disease / / pha003031 rs4236170 chr6 17083865 A G 1.24E-05 Blood pressure / / 17255346 rs1408300 chr6 17154856 C T 7.88E-05 IgE levels / / 22075330 rs9367945 chr6 17180299 G C 8.90E-04 Multiple complex diseases / / 17554300 rs9370968 chr6 17226021 T C 8.21E-05 Waist-Hip Ratio / / pha003028 rs1322846 chr6 17241154 T C 6.00E-07 Immune response to smallpox vaccine (IL-6) / / 22542470 rs13206076 chr6 17251453 T C 6.10E-06 Parkinson's disease (familial) / / 18985386 rs6459530 chr6 17254901 A C 1.85E-06 Tunica Media / / pha003037 rs3886378 chr6 17268236 G T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs13212769 chr6 17302983 C T 8.22E-05 Blood Pressure / / pha003043 rs1745069 chr6 17311516 A G 4.93E-04 Coronary heart disease / / 21971053 rs1745074 chr6 17315838 T G 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs12526082 chr6 17330855 A G 3.46E-05 HIV-1 viral setpoint / / 22174851 rs4440469 chr6 17333338 C T 3.68E-05 Acute lung injury / / 22295056 rs4587177 chr6 17333372 T C 5.79E-05 Acute lung injury / / 22295056 rs9465016 chr6 17334641 T C 8.15E-05 Acute lung injury / / 22295056 rs12525145 chr6 17338225 C T 8.15E-05 Acute lung injury / / 22295056 rs12529404 chr6 17340172 G T 1.29E-04 Acute lung injury / / 22295056 rs13208157 chr6 17342553 C T 1.16E-04 Acute lung injury / / 22295056 rs13196666 chr6 17342848 A G 1.15E-04 Acute lung injury / / 22295056 rs7745401 chr6 17349508 T C 1.96E-04 Acute lung injury / / 22295056 rs4467778 chr6 17350073 A G 1.14E-04 Acute lung injury / / 22295056 rs9465019 chr6 17350499 T C 6.68E-05 Acute lung injury / / 22295056 rs12526619 chr6 17352429 T G 6.16E-05 Acute lung injury / / 22295056 rs9477397 chr6 17352445 A G 6.08E-05 Acute lung injury / / 22295056 rs947209 chr6 17353497 T C 5.59E-05 Acute lung injury / / 22295056 rs13195890 chr6 17355385 A C 5.80E-05 Acute lung injury / / 22295056 rs13215291 chr6 17356656 C A 9.83E-05 Acute lung injury / / 22295056 rs13218797 chr6 17357052 C T 9.83E-05 Acute lung injury / / 22295056 rs2328097 chr6 17367892 C A 1.20E-04 Acute lung injury / / 22295056 rs4716138 chr6 17368972 A G 4.96E-05 Acute lung injury / / 22295056 rs1575046 chr6 17369194 G A 4.96E-05 Acute lung injury / / 22295056 rs7771454 chr6 17369570 G C 7.62E-05 Acute lung injury / / 22295056 rs7758198 chr6 17369614 T G 6.80E-05 Acute lung injury / / 22295056 rs9465032 chr6 17405178 T A 4.42E-05 Brain structure CAP2 intron 22504417 rs9477420 chr6 17411585 C T 2.97E-05 Brain structure CAP2 intron 22504417 rs17379883 chr6 17416064 G A 4.39E-05 Brain structure CAP2 intron 22504417 rs9370988 chr6 17438635 T G 7.01E-04 Suicide attempts in bipolar disorder CAP2 intron 21423239 rs9350045 chr6 17440252 T C 7.81E-04 Suicide attempts in bipolar disorder CAP2 intron 21423239 rs9350046 chr6 17440381 T C 7.56E-04 Suicide attempts in bipolar disorder CAP2 intron 21423239 rs6918762 chr6 17441419 T C 6.65E-04 Suicide attempts in bipolar disorder CAP2 intron 21423239 rs9370990 chr6 17442190 A G 7.70E-04 Suicide attempts in bipolar disorder CAP2 intron 21423239 rs3777686 chr6 17442326 A G 8.50E-04 Suicide attempts in bipolar disorder CAP2 intron 21423239 rs2143451 chr6 17443625 C G 7.10E-04 Suicide attempts in bipolar disorder CAP2 intron 21423239 rs1320998 chr6 17444328 A G 9.64E-04 Suicide attempts in bipolar disorder CAP2 intron 21423239 rs9383284 chr6 17444905 G T 3.99E-04 Suicide attempts in bipolar disorder CAP2 intron 21423239 rs4993729 chr6 17445241 T A 4.63E-04 Suicide attempts in bipolar disorder CAP2 intron 21423239 rs910040 chr6 17445252 T C 6.28E-04 Suicide attempts in bipolar disorder CAP2 intron 21423239 rs9383285 chr6 17445727 C T 6.83E-04 Suicide attempts in bipolar disorder CAP2 intron 21423239 rs910041 chr6 17446263 C T 6.59E-04 Suicide attempts in bipolar disorder CAP2 intron 21423239 rs910042 chr6 17446523 G A 8.02E-04 Suicide attempts in bipolar disorder CAP2 intron 21423239 rs9477430 chr6 17446598 A T 7.46E-04 Suicide attempts in bipolar disorder CAP2 intron 21423239 rs7745495 chr6 17447095 G A 8.46E-04 Suicide attempts in bipolar disorder CAP2 intron 21423239 rs926584 chr6 17447251 G A 8.67E-04 Suicide attempts in bipolar disorder CAP2 intron 21423239 rs926585 chr6 17447265 A T 7.33E-04 Suicide attempts in bipolar disorder CAP2 intron 21423239 rs3777694 chr6 17458580 A G 4.80E-06 Age-related macular degeneration CAP2 intron pha000001 rs3798280 chr6 17491742 C T 3.89E-04 Blood pressure CAP2 intron 17255346 rs16879770 chr6 17512120 G T 5.06E-04 Multiple complex diseases CAP2 intron 17554300 rs16879771 chr6 17520055 T C 0.000000627 Anxiety Composite (ARBQ) in children CAP2 intron 23565138 rs4712300 chr6 17531409 G A 7.40E-04 Prostate cancer mortality CAP2 intron 20978177 rs4712300 chr6 17531409 G A 1.91E-04 Lung function (forced vital capacity) CAP2 intron 24023788 rs9465045 chr6 17535019 T C 2.08E-05 Blood pressure CAP2 intron 17255346 rs9465045 chr6 17535019 T C 4.50E-06 Urinary metabolites CAP2 intron 21572414 rs2274136 chr6 17633061 C T 3.00E-06 Obesity-related traits NUP153 missense 23251661 rs2274136 chr6 17633061 C T 5.00E-06 Obesity-related traits NUP153 missense 23251661 rs9396787 chr6 17670499 A T 7.54E-04 Multiple complex diseases NUP153 intron 17554300 rs12199222 chr6 17699322 G T 7.00E-07 Height NUP153 intron 18391951 rs6926745 chr6 17744329 G A 7.75E-05 Waist Circumference / / pha003023 rs17714754 chr6 17754961 C T 6.14E-04 Myopia (pathological) / / 21095009 rs9396802 chr6 17755884 T C 1.05E-04 Celiac disease / / 23936387 rs12524859 chr6 17770235 A G 5.18E-04 Multiple complex diseases KIF13A intron 17554300 rs3734234 chr6 17794494 G A 7.00E-06 Prostate cancer (early onset) KIF13A cds-synon 24740154 rs7341276 chr6 17797607 C T 2.66E-04 Multiple complex diseases KIF13A intron 17554300 rs12526840 chr6 17806748 G A 9.70E-04 Obesity (extreme) KIF13A intron 21935397 rs10456809 chr6 17813825 C T 5.00E-06 Prostate cancer (gene x gene interaction) KIF13A intron 22219177 rs6918261 chr6 17815431 G A 7.44E-04 Obesity (extreme) KIF13A intron 21935397 rs9396812 chr6 17845161 A G 6.78E-04 Suicide attempts in bipolar disorder KIF13A intron 21041247 rs676754 chr6 17850037 A G 7.31E-04 Obesity (extreme) KIF13A intron 21935397 rs2064187 chr6 17879218 T A 1.75E-04 Obesity (extreme) KIF13A intron 21935397 rs9367972 chr6 17881217 G A 1.85E-04 Obesity (extreme) KIF13A intron 21935397 rs724915 chr6 17885351 G A 1.92E-04 Obesity (extreme) KIF13A intron 21935397 rs1014535 chr6 17899646 G A 3.13E-04 Obesity (extreme) KIF13A intron 21935397 rs1014146 chr6 17913077 G T 8.78E-05 Major depressive disorder KIF13A intron 21621269 rs13198614 chr6 17938785 G C 1.38E-04 Response to radiotherapy in cancer (late toxicity) KIF13A intron 24785509 rs5007121 chr6 18072259 C T 2.70E-05 Urinary metabolites / / 21572414 rs16870039 chr6 18080365 G C 1.93E-09 Multiple complex diseases / / 17554300 rs6459591 chr6 18085650 G A 1.75E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6459591 chr6 18085650 G A 9.37E-06 Diabetes Mellitus / / pha003060 rs9477617 chr6 18099951 A C 2.81E-05 Diabetes Mellitus / / pha003060 rs9477617 chr6 18099951 A C 2.44E-05 Calcium levels / / pha003085 rs6929672 chr6 18100246 C A 7.04E-04 Diabetic retinopathy / / 20871662 rs9358148 chr6 18100865 G A 1.58E-05 Calcium levels / / pha003085 rs1142345 chr6 18130918 T C 1 Drug response to Thiopurines TPMT missense 11304783 rs1142345 chr6 18130918 T C 1 Drug response to Azathioprine TPMT missense 15228163 rs1142345 chr6 18130918 T C 1 Drug response to Mercaptopurine TPMT missense 15228163 rs1142345 chr6 18130918 T C 1 Drug response to Thiopurines TPMT missense 15352906 rs1142345 chr6 18130918 T C 1 Drug response to Thiopurines TPMT missense 18506437 rs1142345 chr6 18130918 T C 4.50E-21 Health and aging,CVD and cancer age of onset TPMT missense 22174011 rs1142345 chr6 18130918 T C 7.40E-14 Health and aging,CVD and cancer age of onset TPMT missense 22174011 rs112339338 chr6 18139201 G A 0.000051 Breast cancer (ER positive) TPMT missense 23555315 rs1800460 chr6 18139228 C T 1 Drug response to Thiopurines TPMT missense 11304783 rs1800460 chr6 18139228 C T 1 Drug response to Thiopurines TPMT missense 15352906 rs1800460 chr6 18139228 C T 1 Drug response to Thiopurines TPMT missense 18506437 rs1800462 chr6 18143955 C G 1 Drug response to Thiopurines TPMT missense 11304783 rs1800462 chr6 18143955 C G 1 Drug response to Azathioprine TPMT missense 15228163 rs1800462 chr6 18143955 C G 1 Drug response to Mercaptopurine TPMT missense 15228163 rs1800462 chr6 18143955 C G 1 Drug response to Thiopurines TPMT missense 15352906 rs1800462 chr6 18143955 C G 1 Drug response to Thiopurines TPMT missense 18506437 rs1800462 chr6 18143955 C G 1 Drug response to Mercaptopurine TPMT missense 7862671 rs9396834 chr6 18164073 T C 5.81E-04 Type 2 diabetes KDM1B intron 17463246 rs7754932 chr6 18174012 C T 1.80E-05 Urinary metabolites KDM1B intron 21572414 rs365237 chr6 18186697 A G 7.68E-05 Multiple complex diseases KDM1B intron 17554300 rs214621 chr6 18197475 A G 9.30E-05 Response to statin therapy KDM1B intron 20339536 rs6902280 chr6 18204345 T G 6.37E-04 Multiple complex diseases KDM1B intron 17554300 rs214598 chr6 18207876 G C 6.82E-05 Bipolar disorder and schizophrenia KDM1B intron 20889312 rs4712329 chr6 18235776 G A 2.10E-04 Smoking initiation DEK intron 24665060 rs9367983 chr6 18240002 T C 2.74E-04 Smoking initiation DEK intron 24665060 rs214544 chr6 18284716 C T 9.98E-04 Multiple complex diseases / / 17554300 rs7747741 chr6 18301503 A G 8.51E-05 Hemoglobin / / pha003098 rs6931265 chr6 18309605 T A 1.20E-05 Urinary metabolites / / 21572414 rs10949492 chr6 18318114 A G 8.20E-06 Urinary metabolites / / 21572414 rs11967050 chr6 18340298 C T 3.10E-06 Urinary metabolites / / 21572414 rs1408445 chr6 18349366 C T 2.31E-05 Blood Pressure / / pha002903 rs1951924 chr6 18352976 A C 1.60E-05 Urinary metabolites / / 21572414 rs12663043 chr6 18384387 C G 1.80E-06 Urinary metabolites / / 21572414 rs17626544 chr6 18404450 C T 7.79E-05 White matter integrity RNF144B intron 22425255 rs1408263 chr6 18407743 T C 2.43E-05 Blood Pressure and Arterial Stiffness RNF144B intron 17903302 rs4712334 chr6 18438962 G A 7.96E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines RNF144B intron 21844884 rs12197074 chr6 18442490 A C 6.26E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines RNF144B intron 21844884 rs577287 chr6 18445794 A G 5.89E-05 Bipolar disorder RNF144B intron 18317468 rs7741953 chr6 18445892 A G 2.39E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines RNF144B intron 21844884 rs494248 chr6 18455614 G C 1.03E-04 Bipolar disorder RNF144B intron 18317468 rs531481 chr6 18460203 T A 8.92E-05 Bipolar disorder RNF144B intron 18317468 rs527984 chr6 18466750 C T 1.05E-04 Bipolar disorder RNF144B UTR-3 18317468 rs532347 chr6 18476660 A G 1.26E-05 Attention deficit hyperactivity disorder / / 20732627 rs477588 chr6 18478116 C T 2.46E-05 Self-employment / / 23593239 rs567621 chr6 18481019 C T 1.25E-05 Attention deficit hyperactivity disorder / / 20732627 rs510367 chr6 18483512 G A 3.20E-05 Self-employment / / 23593239 rs477710 chr6 18484572 A G 3.43E-04 Multiple complex diseases / / 17554300 rs532048 chr6 18485886 T A 9.76E-04 Multiple complex diseases / / 17554300 rs536700 chr6 18486418 G C 1.42E-05 Attention deficit hyperactivity disorder / / 20732627 rs490618 chr6 18486487 T A 1.32E-05 Attention deficit hyperactivity disorder / / 20732627 rs9383398 chr6 18486862 C T 6.64E-05 Personality dimensions / / 18957941 rs9350075 chr6 18487112 C A 2.63E-05 Self-employment / / 23593239 rs3920593 chr6 18487133 C T 2.68E-05 Self-employment / / 23593239 rs6906622 chr6 18488308 T C 2.54E-05 Self-employment / / 23593239 rs6928004 chr6 18489642 G A 2.71E-05 Self-employment / / 23593239 rs4716268 chr6 18490495 A C 2.76E-05 Self-employment / / 23593239 rs6899634 chr6 18492986 A C 3.19E-05 Self-employment / / 23593239 rs9371065 chr6 18493130 A T 4.84E-05 Self-employment / / 23593239 rs4716269 chr6 18493389 G A 9.71E-04 Type 2 diabetes / / 17463246 rs2057556 chr6 18494377 C T 4.88E-05 Self-employment / / 23593239 rs1324564 chr6 18495449 C T 4.97E-05 Self-employment / / 23593239 rs10498690 chr6 18498347 G A 2.80E-05 Attention deficit hyperactivity disorder / / 20732627 rs1359339 chr6 18498528 T G 2.20E-05 Blood Phenotypes / / 17903294 rs1359339 chr6 18498528 T G 5.24E-05 Self-employment / / 23593239 rs1324572 chr6 18500427 A T 9.41E-05 Type 2 diabetes / / 17463246 rs6900274 chr6 18500606 A G 1.16E-04 Type 2 diabetes / / 17463246 rs6900274 chr6 18500606 A G 9.75E-04 Multiple complex diseases / / 17554300 rs4716274 chr6 18500884 A G 3.44E-04 Multiple complex diseases / / 17554300 rs10456831 chr6 18506764 C T 3.74E-05 Attention deficit hyperactivity disorder / / 20732627 rs6459623 chr6 18526812 G T 1.50E-04 Longevity and age-related phenotypes / / 17903295 rs9297082 chr6 18534338 T C 2.54E-04 Multiple complex diseases / / 17554300 rs722736 chr6 18535526 C G 6.96E-04 Multiple complex diseases / / 17554300 rs1324559 chr6 18539800 A G 4.16E-04 Multiple complex diseases / / 17554300 rs1408494 chr6 18542956 C T 2.53E-04 Multiple complex diseases / / 17554300 rs2142952 chr6 18545021 G A 2.51E-04 Multiple complex diseases / / 17554300 rs760825 chr6 18552036 T G 0.00000821 Femoral neck bone mineral density (premenopausal) / / 23074152 rs960270 chr6 18557074 T A 2.30E-05 Urinary metabolites / / 21572414 rs9396878 chr6 18559445 T C 2.80E-06 Urinary metabolites / / 21572414 rs9396879 chr6 18559565 C G 1.20E-05 Urinary metabolites / / 21572414 rs6927709 chr6 18559748 C T 3.09E-04 Multiple complex diseases / / 17554300 rs1569531 chr6 18571525 A G 1.79E-04 Multiple complex diseases / / 17554300 rs760827 chr6 18573670 A G 7.10E-05 Tunica Media / / pha003038 rs1983569 chr6 18577458 A G 5.07E-05 Tunica Media / / pha003038 rs7762184 chr6 18588949 C G 7.30E-04 Type 2 diabetes / / 17463246 rs9396888 chr6 18601456 C T 4.38E-04 Blood pressure (response to calcium channel blocker) / / 24192120 rs6921309 chr6 18618735 C A 8.70E-05 Height / / 19396169 rs10949532 chr6 18622008 A T 2.26E-04 Multiple complex diseases / / 17554300 rs7748349 chr6 18629070 G A 7.30E-04 Systemic lupus erythematosus / / 24871463 rs11965040 chr6 18644345 T C 4.60E-05 Multiple complex diseases / / 17554300 rs2206081 chr6 18644933 A T 7.43E-04 Type 2 diabetes / / 17463246 rs2064172 chr6 18645358 A G 2.86E-04 Blood pressure (response to calcium channel blocker) / / 24192120 rs2206082 chr6 18647084 G A 2.06E-04 Blood pressure (response to calcium channel blocker) / / 24192120 rs12206684 chr6 18653323 A G 2.34E-04 Blood pressure (response to calcium channel blocker) / / 24192120 rs7771382 chr6 18654349 G A 4.52E-04 Blood pressure (response to calcium channel blocker) / / 24192120 rs9465181 chr6 18663606 T G 2.90E-04 Blood pressure (response to calcium channel blocker) / / 24192120 rs9465198 chr6 18715417 C T 0.000348 Salmonella-induced pyroptosis / / 22837397 rs9477838 chr6 18717194 T C 0.000632 Salmonella-induced pyroptosis / / 22837397 rs9358176 chr6 18736583 T C 1.39E-05 Tunica Media / / pha003038 rs16881147 chr6 18742880 T A 3.32E-04 Birth weight / / 17255346 rs6941968 chr6 18780110 G T 8.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1418959 chr6 18782019 G A 2.82E-05 Intracerebral hemorrhage / / 24656865 rs41441749 chr6 18791723 C T 1.00E-06 Hyperactive-impulsive symptoms / / 18821565 rs17654008 chr6 18816027 G A 1.73E-05 Intracerebral hemorrhage / / 24656865 rs17654741 chr6 18834656 C T 1.95E-05 Intracerebral hemorrhage / / 24656865 rs113961379 chr6 18836430 G A 1.89E-05 Intracerebral hemorrhage / / 24656865 rs6903728 chr6 18837098 A G 2.07E-05 Tunica Media / / pha003038 rs4716312 chr6 18861242 G A 5.19E-04 Multiple complex diseases / / 17554300 rs1334788 chr6 18862556 A T 4.38E-04 Multiple complex diseases / / 17554300 rs6910109 chr6 18904764 C T 9.73E-04 Multiple complex diseases / / 17554300 rs1413810 chr6 18907389 A G 8.01E-04 Multiple complex diseases / / 17554300 rs6913666 chr6 18908672 T C 9.42E-04 Multiple complex diseases / / 17554300 rs988458 chr6 18914624 T C 8.86E-05 Alzheimer's disease / / 22832961 rs1413809 chr6 18916565 A G 7.29E-04 Multiple complex diseases / / 17554300 rs1983879 chr6 18918855 T C 9.76E-04 Multiple complex diseases / / 17554300 rs12190000 chr6 18919637 A G 3.55E-04 Multiple complex diseases / / 17554300 rs513776 chr6 18920029 A T 7.41E-04 Multiple complex diseases / / 17554300 rs16881502 chr6 18933419 A G 3.02E-04 Iron levels / / pha002876 rs17658562 chr6 18957829 C T 5.29E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1040931 chr6 19000114 A G 4.16E-04 Multiple complex diseases / / 17554300 rs9368028 chr6 19038132 T G 3.88E-06 Insulin-related traits / / 22791750 rs2742989 chr6 19084034 C T 8.14E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs2742989 chr6 19084034 C T 8.14E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs1322531 chr6 19087736 G A 2.32E-04 Multiple complex diseases / / 17554300 rs2742991 chr6 19088208 T A 1.74E-04 Multiple complex diseases / / 17554300 rs2842390 chr6 19093706 T A 5.56E-04 Multiple complex diseases / / 17554300 rs12194016 chr6 19093854 G A 9.51E-04 Multiple complex diseases / / 17554300 rs2743014 chr6 19124689 G A 2.80E-05 Urinary metabolites / / 21572414 rs9396937 chr6 19125680 G A 2.87E-04 Insulin resistance / / 21901158 rs9350103 chr6 19150494 G T 8.53E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4582372 chr6 19171741 T C 8.23E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9784816 chr6 19193980 G A 7.52E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7770854 chr6 19212170 C T 7.06E-04 Type 2 diabetes / / 17463246 rs9460308 chr6 19213073 C G 8.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs9465279 chr6 19213227 G A 4.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs1858504 chr6 19214889 C T 7.67E-05 Alcohol dependence / / 19581569 rs4712363 chr6 19219168 T A 5.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs1858513 chr6 19228938 C T 4.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs1858512 chr6 19229950 C T 6.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs9460319 chr6 19245298 C A 2.99E-04 Myocardial Infarction / / pha002873 rs9295427 chr6 19287493 A G 7.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs12205836 chr6 19297457 G A 8.30E-06 Asthma / / pha003128 rs9358214 chr6 19375078 T C 2.90E-05 Urinary metabolites / / 21572414 rs11755216 chr6 19381355 T C 8.77E-05 Cognitive performance / / 19734545 rs11755216 chr6 19381355 T C 9.04E-06 Hypertension / / pha003041 rs1495980 chr6 19386230 A G 1.69E-05 Kawasaki disease / / 22446961 rs1495983 chr6 19390255 C G 1.16E-05 Kawasaki disease / / 22446961 rs9366292 chr6 19390622 A G 4.26E-05 Longevity / / 21612516 rs10946315 chr6 19398333 T C 1.27E-05 Kawasaki disease / / 22446961 rs6917862 chr6 19399401 C G 8.12E-05 Kawasaki disease / / 22446961 rs9465383 chr6 19419004 A G 8.66E-05 Information processing speed / / 21130836 rs7765596 chr6 19431583 C T 7.00E-08 Metabolite levels / / 23281178 rs2172963 chr6 19437583 A G 7.30E-05 Bipolar disorder and schizophrenia / / 20889312 rs16882214 chr6 19443935 C G 2.00E-06 Breast cancer / / 23354978 rs4435931 chr6 19449968 C T 6.28E-05 Bipolar disorder and schizophrenia / / 20889312 rs4599622 chr6 19450017 C A 8.27E-05 Bipolar disorder and schizophrenia / / 20889312 rs9295438 chr6 19452664 T C 1.61E-04 Stroke / / pha002887 rs9465428 chr6 19515200 C T 7.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs718899 chr6 19519180 G A 7.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs9460373 chr6 19520219 T C 7.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs9295440 chr6 19520904 C T 8.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs4710908 chr6 19521412 A G 8.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs10456223 chr6 19522774 T G 8.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs4712413 chr6 19523598 G A 8.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs4712414 chr6 19523608 T C 8.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs13215285 chr6 19525408 A G 8.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs13201049 chr6 19525425 T G 9.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs9460374 chr6 19526240 T G 8.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs12198316 chr6 19531190 A G 9.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs9460376 chr6 19532627 T C 8.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs9465433 chr6 19532649 G A 8.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs4712418 chr6 19532819 T C 8.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs12205829 chr6 19533526 C T 8.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs12213020 chr6 19533619 T C 8.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs4710911 chr6 19549868 A C 2.22E-04 Celiac disease / / 23936387 rs9465436 chr6 19556807 T A 3.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs760669 chr6 19561987 T C 5.88E-05 Vitiligo / / 19890347 rs1883233 chr6 19566284 T C 4.80E-05 Kawasaki disease / / 22446962 rs6909115 chr6 19582625 T A,C 2.35E-04 Multiple complex diseases / / 17554300 rs10806896 chr6 19602973 C G 7.17E-05 Multiple complex diseases / / 17554300 rs6910563 chr6 19610835 A C 2.21E-04 Multiple complex diseases / / 17554300 rs9295444 chr6 19611375 A G 2.56E-04 Multiple complex diseases / / 17554300 rs2328483 chr6 19628340 A G 1.16E-04 Vaspin levels / / 22907691 rs2328483 chr6 19628340 A G 0.0001162 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs6930954 chr6 19628633 T G 1.41E-04 Vaspin levels / / 22907691 rs6930954 chr6 19628633 T G 0.0001413 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs4452635 chr6 19629346 T C 1.01E-04 Vaspin levels / / 22907691 rs4452635 chr6 19629346 T C 0.0001008 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs1936900 chr6 19631215 T G 1.71E-27 Narcolepsy / / 19629137 rs6456256 chr6 19651463 C T 7.21E-06 C-reactive protein / / 22492993 rs2876555 chr6 19653999 C T 9.99E-04 Myopia (pathological) / / 21095009 rs6931563 chr6 19656557 T A 2.24E-06 C-reactive protein / / 22492993 rs7756468 chr6 19657782 G A 5.83E-06 C-reactive protein / / 22492993 rs7756553 chr6 19658108 A G 5.83E-06 C-reactive protein / / 22492993 rs16882440 chr6 19665547 T G 1.70E-05 Urinary metabolites / / 21572414 rs9366306 chr6 19667184 C T 7.09E-06 C-reactive protein / / 22492993 rs9358265 chr6 19706407 C T 7.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs1016251 chr6 19706761 A G 6.30E-06 Endometriosis / / 23104006 rs9366312 chr6 19708481 G A 4.30E-06 Endometriosis / / 23104006 rs9356708 chr6 19729003 T G 1.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs9356708 chr6 19729003 T G 3.10E-07 Endometriosis / / 23104006 rs10484640 chr6 19759897 T G 5.87E-09 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs6916251 chr6 19761215 T C 3.40E-06 Endometriosis / / 23104006 rs6908034 chr6 19773930 G A 7.20E-05 Parkinson's disease (age of onset) / / 19772629 rs9465523 chr6 19780956 G A 7.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs7739264 chr6 19785588 C T 4.50E-05 Endometriosis / / 21151130 rs7739264 chr6 19785588 C T 8.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs7739264 chr6 19785588 C T 4.00E-10 Endometriosis / / 23104006 rs2223361 chr6 19790809 C T 7.30E-07 Endometriosis / / 23104006 rs12110613 chr6 19793675 G A 6.31E-05 Schizophrenia / / 19571809 rs6907340 chr6 19803768 C T 5.90E-07 Endometriosis / / 23104006 rs6907340 chr6 19803768 C T 2.00E-07 Endometriosis / / 23472165 rs9350190 chr6 19811660 A G 2.47E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9368127 chr6 19811991 G A 2.41E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs4140624 chr6 19818560 C T 2.18E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs4712433 chr6 19818707 A G 1.65E-05 Personality dimensions / / 18957941 rs12206194 chr6 19819908 T C 3.15E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs6910773 chr6 19820658 T C 1.42E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs12527834 chr6 19821781 A G 8.24E-05 Alcohol dependence / / 19581569 rs7773456 chr6 19823238 T G 7.00E-07 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9358278 chr6 19824971 C A 7.27E-04 Multiple complex diseases / / 17554300 rs973244 chr6 19826630 A G 7.04E-04 Type 2 diabetes / / 17463246 rs1980461 chr6 19835009 G C 3.21E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs1047014 chr6 19841493 T C 2.00E-13 Height ID4 UTR-3 20881960 rs1047014 chr6 19841493 T C 4.51E-05 HDL cholesterol ID4 UTR-3 pha003074 rs12528660 chr6 19876533 G A 8.70E-04 Endometrial cancer / / 24096698 rs2056954 chr6 19892586 T C 6.48E-04 Obesity (extreme) / / 21935397 rs9350195 chr6 19899405 T C 7.25E-04 Alcohol dependence / / 21314694 rs7759843 chr6 19903688 T C 6.30E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6936399 chr6 19909241 A G 1.10E-05 Response to statin therapy / / 20339536 rs1931773 chr6 19909736 G A 1.10E-05 Response to statin therapy / / 20339536 rs16882922 chr6 19911852 C T 1.30E-06 Response to statin therapy / / 20339536 rs12661503 chr6 19915326 T A 6.00E-06 Response to statin therapy / / 20339536 rs12110662 chr6 19918799 G A 1.61E-04 Type 2 diabetes / / 17463246 rs7768737 chr6 19920904 C T 9.50E-05 Response to statin therapy / / 20339536 rs994646 chr6 19922050 A T 1.44E-04 Type 2 diabetes / / 17463246 rs994646 chr6 19922050 A T 9.50E-05 Response to statin therapy / / 20339536 rs1202292 chr6 19933160 T C 4.65E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2782205 chr6 19937023 A G 8.73E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1079801 chr6 19945285 C T 1.32E-04 Glycosylated haemoglobin levels / / 17255346 rs1079801 chr6 19945285 C T 8.57E-05 Type 2 diabetes / / 17463246 rs1079801 chr6 19945285 C T 6.30E-05 Response to statin therapy / / 20339536 rs6917226 chr6 19946615 A T 6.60E-05 Response to statin therapy / / 20339536 rs2143046 chr6 19948028 G A 3.40E-05 Response to statin therapy / / 20339536 rs2782202 chr6 19948570 C T 8.89E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2744344 chr6 19954698 T C 2.40E-04 Type 2 diabetes / / 17463246 rs2744344 chr6 19954698 T C 1.40E-05 Response to statin therapy / / 20339536 rs9348403 chr6 19955306 C T 7.60E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2744338 chr6 19957282 G A 2.20E-06 Response to statin therapy / / 20339536 rs2782187 chr6 19959784 A G 7.26E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1931778 chr6 19961474 G C 1.40E-06 Response to statin therapy / / 20339536 rs2782192 chr6 19965966 A G 6.79E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2782195 chr6 19966110 T C 6.75E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs494483 chr6 19969130 G A 1.81E-20 Multiple complex diseases / / 17554300 rs11756396 chr6 19969304 G A 3.49E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs16883016 chr6 19969480 G A 7.90E-07 Response to statin therapy / / 20339536 rs16883019 chr6 19969638 T C 7.00E-07 Response to statin therapy / / 20339536 rs16883021 chr6 19969712 G A 6.60E-07 Response to statin therapy / / 20339536 rs727165 chr6 19971817 G C 3.09E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9348404 chr6 19988653 A C 6.38E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs965036 chr6 19991043 G T 8.60E-05 Longevity and age-related phenotypes / / 17903295 rs965036 chr6 19991043 G T 3.69E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs965036 chr6 19991043 G T 3.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9295456 chr6 19991446 T C 6.38E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs520188 chr6 19992265 G A 3.25E-04 Gallstones / / 17632509 rs9358292 chr6 19995731 G A 7.14E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7755724 chr6 20001699 C A 3.24E-04 Smoking initiation / / 24665060 rs7755724 chr6 20001699 C A 9.20E-05 Smoking quantity / / 24665060 rs11753077 chr6 20015205 T G 5.00E-04 Alcohol dependence / / 20201924 rs492591 chr6 20018376 A G 1.51E-05 Multiple complex diseases / / 17554300 rs7763815 chr6 20021842 T C 9.74E-04 Multiple complex diseases / / 17554300 rs662751 chr6 20027638 A G 8.40E-04 Alcohol dependence / / 20201924 rs532229 chr6 20046162 A T 6.28E-04 Type 2 diabetes / / 17463246 rs572550 chr6 20065970 G A 1.81E-04 Multiple complex diseases / / 17554300 rs667203 chr6 20066608 C T 4.10E-04 Multiple complex diseases / / 17554300 rs2472764 chr6 20090000 A G 2.12E-04 Multiple complex diseases / / 17554300 rs1812333 chr6 20099162 C T 7.81E-04 Myocardial Infarction / / pha002873 rs1889399 chr6 20105277 A C 4.80E-04 Type 2 diabetes and 6 quantitative traits MBOAT1 intron 17848626 rs2457335 chr6 20109592 G A 2.00E-06 Obesity-related traits MBOAT1 intron 23251661 rs2457334 chr6 20109696 A C 6.67E-05 Insulin Resistance MBOAT1 intron pha003062 rs2457334 chr6 20109696 A C 7.27E-05 Insulin-related traits MBOAT1 intron pha003063 rs2472756 chr6 20120469 G T 7.02E-04 Smoking quantity MBOAT1 intron 24665060 rs949550 chr6 20124860 G A 2.91E-04 Alzheimer's disease (late onset) MBOAT1 intron 21379329 rs2483767 chr6 20128557 A G 2.10E-04 Alcohol dependence MBOAT1 intron 20201924 rs16883399 chr6 20131035 A G 1.62E-04 Alzheimer's disease (late onset) MBOAT1 intron 21379329 rs4712455 chr6 20137841 A G 2.67E-04 Alzheimer's disease (late onset) MBOAT1 intron 21379329 rs2151837 chr6 20143736 T C 4.79E-04 Insulin resistance MBOAT1 intron 21901158 rs1202199 chr6 20156174 T C 9.00E-06 Hyperactive-impulsive symptoms MBOAT1 intron 18821565 rs1202199 chr6 20156174 T C 0.00077 Breast cancer MBOAT1 intron 23555315 rs1999625 chr6 20164940 C A 6.73E-06 Insulin Resistance MBOAT1 intron pha003062 rs1999625 chr6 20164940 C A 1.09E-05 Insulin-related traits MBOAT1 intron pha003063 rs9465643 chr6 20171056 G A 7.18E-04 Insulin resistance MBOAT1 intron 21901158 rs586124 chr6 20171926 C T 3.27E-05 Cognitive impairment induced by topiramate MBOAT1 intron 22091778 rs586124 chr6 20171926 C T 0.0000371 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes MBOAT1 intron 22628534 rs9465645 chr6 20178969 C T 3.65E-04 Multiple complex diseases MBOAT1 intron 17554300 rs552231 chr6 20184735 T C 4.20E-04 Type 2 diabetes MBOAT1 intron 22158537 rs555017 chr6 20185051 A G 4.00E-06 Anger MBOAT1 intron 24489884 rs9460467 chr6 20192373 T C 3.91E-04 Response to cytadine analogues (cytosine arabinoside) MBOAT1 intron 24483146 rs2182786 chr6 20197702 G A 4.00E-04 Multiple complex diseases MBOAT1 intron 17554300 rs11752473 chr6 20201181 G A 3.05E-04 Multiple complex diseases MBOAT1 intron 17554300 rs11752473 chr6 20201181 G A 7.47E-05 Serum metabolites MBOAT1 intron 19043545 rs9350223 chr6 20209792 A G 4.20E-05 Lymphocyte counts MBOAT1 intron 22286170 rs11753226 chr6 20253392 C A 4.08E-04 Multiple complex diseases / / 17554300 rs11753228 chr6 20253427 C T 7.89E-04 Multiple complex diseases / / 17554300 rs1327658 chr6 20254975 C T 5.17E-04 Multiple complex diseases / / 17554300 rs9295460 chr6 20261048 A C 3.75E-04 Multiple complex diseases / / 17554300 rs1887476 chr6 20265965 T C 6.27E-04 Multiple complex diseases / / 17554300 rs6907152 chr6 20271926 T C 5.58E-04 Multiple complex diseases / / 17554300 rs1590700 chr6 20272761 T C 7.94E-04 Multiple complex diseases / / 17554300 rs9368182 chr6 20343431 G T 3.70E-05 Pericardial fat / / 22589742 rs6937778 chr6 20374128 A G 2.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs6937778 chr6 20374128 A G 1.76E-05 Body Mass Index / / pha003009 rs6937778 chr6 20374128 A G 9.04E-05 Height / / pha003011 rs1570155 chr6 20382600 G A 4.00E-06 Obesity-related traits / / 23251661 rs6915426 chr6 20395257 C T 2.50E-04 Iron levels / / pha002876 rs10806918 chr6 20396953 G T 3.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs9465729 chr6 20400538 C T 7.82E-06 Obesity-related traits E2F3 nearGene-5 23251661 rs6456349 chr6 20405019 G A 5.02E-04 Gallstones E2F3 intron 17632509 rs6456350 chr6 20405539 A G 9.24E-04 Suicide attempts in bipolar disorder E2F3 intron 21423239 rs4712494 chr6 20408919 T C 1.52E-04 Attention deficit hyperactivity disorder E2F3 intron 22420046 rs9465733 chr6 20409775 A C 5.66E-04 Suicide attempts in bipolar disorder E2F3 intron 21423239 rs746720 chr6 20417976 G T 1.06E-04 Lung function (forced expiratory volume in 1 second) E2F3 intron 24023788 rs744143 chr6 20418718 G A 2.45E-04 Celiac disease E2F3 intron 23936387 rs7752992 chr6 20425458 G A 1.46E-04 Lung function (forced expiratory volume in 1 second) E2F3 intron 24023788 rs874448 chr6 20432729 G A 3.88E-09 Multiple complex diseases E2F3 intron 17554300 rs7760528 chr6 20442354 C T 4.35E-04 Heart Failure E2F3 intron pha002884 rs9366350 chr6 20511886 A G 4.25E-04 Lung function (forced vital capacity) / / 24023788 rs7772956 chr6 20529542 G T 3.37E-04 Stroke / / pha002886 rs2206578 chr6 20531530 T C 2.99E-05 Personality dimensions / / 23903073 rs6909467 chr6 20533162 T C 1.14E-04 Amyotrophic Lateral Sclerosis CDKAL1 nearGene-5 17362836 rs7758851 chr6 20542221 G A 6.91E-05 Hearing function CDKAL1 intron 17255346 rs7756211 chr6 20553785 G A 9.92E-05 Hearing function CDKAL1 intron 17255346 rs17584626 chr6 20560435 A T 1.36E-04 Hearing function CDKAL1 intron 17255346 rs9460521 chr6 20567541 G A 8.00E-06 Obesity-related traits CDKAL1 intron 23251661 rs4291090 chr6 20570039 C T 5.62E-04 Multiple complex diseases CDKAL1 intron 17554300 rs4291090 chr6 20570039 C T 5.01E-06 Diabetes (gestational) CDKAL1 intron 22233651 rs368819141 chr6 20582143 AG AAG,ACT 4.35E-06 Type 2 diabetes CDKAL1 intron 22158537 rs9460523 chr6 20582143 A C 4.35E-06 Type 2 diabetes CDKAL1 intron 22158537 rs13212326 chr6 20598303 G A 7.92E-05 Heart Failure CDKAL1 intron pha002885 rs9366357 chr6 20599628 C T 8.97E-05 Multiple complex diseases CDKAL1 intron 17554300 rs9366357 chr6 20599628 C T 2.96E-06 Diabetes (gestational) CDKAL1 intron 22233651 rs2294809 chr6 20599888 C T 1.90E-06 Diabetes (gestational) CDKAL1 intron 22233651 rs2294809 chr6 20599888 C T 9.57E-04 Lymphocyte counts CDKAL1 intron 22286170 rs7771052 chr6 20613151 T C 9.73E-04 Alzheimer's disease CDKAL1 intron 22005930 rs7739405 chr6 20618197 A G 9.99E-06 Scoliosis CDKAL1 intron 21216876 rs7763304 chr6 20624034 T C 1.73E-04 Self-reported allergy CDKAL1 intron 23817569 rs9465838 chr6 20625491 G T 1.74E-04 Self-reported allergy CDKAL1 intron 23817569 rs7771213 chr6 20629491 G A 2.31E-04 Self-reported allergy CDKAL1 intron 23817569 rs2328529 chr6 20631953 C A 1.45E-05 Multiple complex diseases CDKAL1 intron 17554300 rs2328529 chr6 20631953 C A 1.12E-14 Type 2 diabetes CDKAL1 intron 22158537 rs2328529 chr6 20631953 C A 3.54E-10 Glycated hemoglobin levels CDKAL1 intron 22290723 rs7768642 chr6 20633907 G A 1.14E-16 Type 2 diabetes CDKAL1 intron 22158537 rs9465846 chr6 20634341 C T 1.17E-16 Type 2 diabetes CDKAL1 intron 22158537 rs9465847 chr6 20634428 G T 1.14E-16 Type 2 diabetes CDKAL1 intron 22158537 rs7755830 chr6 20634886 T C 2.28E-11 Type 2 diabetes CDKAL1 intron 22158537 rs6940200 chr6 20635262 C T 9.16E-17 Type 2 diabetes CDKAL1 intron 22158537 rs9465848 chr6 20635820 C T 0.000000112 HDL cholesterol CDKAL1 intron 23063622 rs9465848 chr6 20635820 C T 0.000000241 LDL cholesterol CDKAL1 intron 23063622 rs7751957 chr6 20638009 C G 6.64E-17 Type 2 diabetes CDKAL1 intron 22158537 rs6921014 chr6 20638978 G A 1.77E-04 Self-reported allergy CDKAL1 intron 23817569 rs9465850 chr6 20639409 C T 6.18E-14 Type 2 diabetes CDKAL1 intron 22158537 rs7758612 chr6 20639604 G A 1.32E-05 Diabetes (gestational) CDKAL1 intron 22233651 rs9460538 chr6 20640537 G A 5.98E-12 Type 2 diabetes CDKAL1 intron 22158537 rs4710938 chr6 20640904 A G 2.61E-11 Type 2 diabetes CDKAL1 intron 22158537 rs9348440 chr6 20641336 C T 2.47E-04 Glycosylated haemoglobin levels CDKAL1 intron 17255346 rs9348440 chr6 20641336 C T 1.50E-06 Multiple complex diseases CDKAL1 intron 17554300 rs9348440 chr6 20641336 C T 1.61E-10 Type 2 diabetes CDKAL1 intron 20818381 rs9348440 chr6 20641336 C T 2.77E-20 Type 2 diabetes CDKAL1 intron 22158537 rs9348440 chr6 20641336 C T 4.01E-10 Diabetes (gestational) CDKAL1 intron 22233651 rs9348440 chr6 20641336 C T 1.26E-11 Glycated hemoglobin levels CDKAL1 intron 22290723 rs9348440 chr6 20641336 C T 3.00E-19 Glycemic traits CDKAL1 intron 23575436 rs9348440 chr6 20641336 C T 3.22E-05 Lung function (forced expiratory volume in 1 second) CDKAL1 intron 24023788 rs9465852 chr6 20641900 G A 2.13E-10 Type 2 diabetes CDKAL1 intron 22158537 rs6925328 chr6 20642785 A G 3.93E-12 Type 2 diabetes CDKAL1 intron 22158537 rs4235999 chr6 20643222 C G 7.53E-12 Type 2 diabetes CDKAL1 intron 22158537 rs2328531 chr6 20643752 A G 1.21E-08 Type 2 diabetes CDKAL1 intron 20818381 rs2328531 chr6 20643752 A G 3.95E-12 Type 2 diabetes CDKAL1 intron 22158537 rs2328531 chr6 20643752 A G 0.00041 Coronary artery calcification CDKAL1 intron 23727086 rs4710939 chr6 20644944 A G 1.42E-11 Type 2 diabetes CDKAL1 intron 22158537 rs9460540 chr6 20648762 A G 1.92E-08 Type 2 diabetes CDKAL1 intron 20818381 rs9460540 chr6 20648762 A G 4.01E-12 Type 2 diabetes CDKAL1 intron 22158537 rs6456364 chr6 20649254 A T 2.64E-19 Type 2 diabetes CDKAL1 intron 22158537 rs9295474 chr6 20652717 C G 9.00E-06 Type 2 diabetes CDKAL1 intron 21490949 rs9295474 chr6 20652717 C G 4.17E-19 Type 2 diabetes CDKAL1 intron 22158537 rs9295475 chr6 20652765 A G 6.28E-05 Nicotine smoking CDKAL1 intron 19268276 rs9295475 chr6 20652765 A G 4.22E-09 Type 2 diabetes CDKAL1 intron 20818381 rs9295475 chr6 20652765 A G 1.54E-19 Type 2 diabetes CDKAL1 intron 22158537 rs9295475 chr6 20652765 A G 3.18E-04 Lung function (forced expiratory volume in 1 second) CDKAL1 intron 24023788 rs2328545 chr6 20653550 G C 9.90E-20 Type 2 diabetes CDKAL1 intron 22158537 rs9358355 chr6 20654897 T C 9.60E-20 Type 2 diabetes CDKAL1 intron 22158537 rs9368216 chr6 20655110 A G 1.19E-19 Type 2 diabetes CDKAL1 intron 22158537 rs4712522 chr6 20656800 C G 1.17E-19 Type 2 diabetes CDKAL1 intron 22158537 rs4712523 chr6 20657564 A G 7.00E-20 Type 2 diabetes CDKAL1 intron 19401414 rs4712523 chr6 20657564 A G 2.00E-12 Type 2 diabetes and other traits CDKAL1 intron 19734900 rs4712523 chr6 20657564 A G 2.23E-08 Type 2 diabetes CDKAL1 intron 20818381 rs4712523 chr6 20657564 A G 7.00E-20 Coronary heart disease CDKAL1 intron 21347282 rs4712523 chr6 20657564 A G 1.64E-19 Type 2 diabetes CDKAL1 intron 22158537 rs4712524 chr6 20657865 A G 3.00E-10 Type 2 diabetes CDKAL1 intron 18711366 rs4712524 chr6 20657865 A G 3.00E-10 Coronary heart disease CDKAL1 intron 21347282 rs4710940 chr6 20658012 A C 8.57E-20 Type 2 diabetes CDKAL1 intron 22158537 rs6906327 chr6 20659459 G A 1.03E-19 Type 2 diabetes CDKAL1 intron 22158537 rs6456367 chr6 20659587 T A 8.75E-20 Type 2 diabetes CDKAL1 intron 22158537 rs6456368 chr6 20659806 T C 2.30E-09 Multiple complex diseases CDKAL1 intron 17554300 rs6456368 chr6 20659806 T C 4.08E-19 Type 2 diabetes CDKAL1 intron 22158537 rs6456368 chr6 20659806 T C 3.46E-11 Diabetes (gestational) CDKAL1 intron 22233651 rs6456368 chr6 20659806 T C 1.09E-11 Glycated hemoglobin levels CDKAL1 intron 22290723 rs6456369 chr6 20660365 T C 1.70E-12 Type 2 diabetes CDKAL1 intron 22158537 rs10946398 chr6 20661034 A C 1.00E-08 Type 2 diabetes CDKAL1 intron 17463249 rs10946398 chr6 20661034 A C 7.53E-08 Multiple complex diseases CDKAL1 intron 17554300 rs10946398 chr6 20661034 A C 7.00E-07 Type 2 diabetes CDKAL1 intron 19056611 rs10946398 chr6 20661034 A C 1.00E-08 Coronary heart disease CDKAL1 intron 21347282 rs10946398 chr6 20661034 A C 9.58E-20 Type 2 diabetes CDKAL1 intron 22158537 rs10946398 chr6 20661034 A C 1.76E-10 Diabetes (gestational) CDKAL1 intron 22233651 rs10946398 chr6 20661034 A C 5.16E-12 Glycated hemoglobin levels CDKAL1 intron 22290723 rs7774594 chr6 20661143 T A 6.50E-04 Type 2 diabetes CDKAL1 intron 17460697 rs7774594 chr6 20661143 T A 8.75E-20 Type 2 diabetes CDKAL1 intron 22158537 rs7754840 chr6 20661250 G C 4.00E-11 Type 2 diabetes CDKAL1 intron 17463246 rs7754840 chr6 20661250 G C 4.00E-11 Type 2 diabetes CDKAL1 intron 17463248 rs7754840 chr6 20661250 G C 1.37E-07 Multiple complex diseases CDKAL1 intron 17554300 rs7754840 chr6 20661250 G C 4.00E-11 Coronary heart disease CDKAL1 intron 21347282 rs7754840 chr6 20661250 G C 4.00E-11 Type 2 diabetes CDKAL1 intron 21647700 rs7754840 chr6 20661250 G C 2.94E-20 Type 2 diabetes CDKAL1 intron 22158537 rs7754840 chr6 20661250 G C 7.00E-16 Diabetes (gestational) CDKAL1 intron 22233651 rs7754840 chr6 20661250 G C 8.43E-12 Glycated hemoglobin levels CDKAL1 intron 22290723 rs7754840 chr6 20661250 G C 4.58E-19 Type 2 diabetes CDKAL1 intron 22325160 rs7754840 chr6 20661250 G C 7.00E-10 Type 2 diabetes CDKAL1 intron 22961080 rs7754840 chr6 20661250 G C 4.10E-11 Type 2 diabetes CDKAL1 intron 23300278 rs7754840 chr6 20661250 G C 2.00E-13 Type 2 diabetes CDKAL1 intron 23945395 rs9460544 chr6 20661529 G T 9.03E-20 Type 2 diabetes CDKAL1 intron 22158537 rs9460545 chr6 20661550 T C 9.03E-20 Type 2 diabetes CDKAL1 intron 22158537 rs979614 chr6 20662123 A G 1.67E-08 Type 2 diabetes CDKAL1 intron 20818381 rs979614 chr6 20662123 A G 4.91E-12 Type 2 diabetes CDKAL1 intron 22158537 rs4712525 chr6 20662966 C T 1.63E-19 Type 2 diabetes CDKAL1 intron 22158537 rs4712526 chr6 20663035 T A 1.58E-19 Type 2 diabetes CDKAL1 intron 22158537 rs4712526 chr6 20663035 T A 1.75E-04 Body mass index CDKAL1 intron 22344219 rs4712527 chr6 20663335 G A 7.01E-04 Smoking initiation CDKAL1 intron 24665060 rs9460546 chr6 20663632 T G 3.10E-07 Type 2 diabetes CDKAL1 intron 17463249 rs9460546 chr6 20663632 T G 1.18E-07 Multiple complex diseases CDKAL1 intron 17554300 rs9460546 chr6 20663632 T G 5.65E-20 Type 2 diabetes CDKAL1 intron 22158537 rs9460546 chr6 20663632 T G 4.06E-12 Glycated hemoglobin levels CDKAL1 intron 22290723 rs742642 chr6 20665081 G A 6.65E-20 Type 2 diabetes CDKAL1 intron 22158537 rs7748382 chr6 20665549 G A 2.37E-19 Type 2 diabetes CDKAL1 intron 22158537 rs145494032 chr6 20665946 T TC 5.20E-20 Type 2 diabetes CDKAL1 intron 22158537 rs145494032 chr6 20665946 T TC 4.00E-08 Glycated hemoglobin levels CDKAL1 intron 24647736 rs7772603 chr6 20665946 T C 5.20E-20 Type 2 diabetes CDKAL1 intron 22158537 rs7772603 chr6 20665946 T C 4.00E-08 Glycated hemoglobin levels CDKAL1 intron 24647736 rs7752780 chr6 20666022 G A 1.25E-19 Type 2 diabetes CDKAL1 intron 22158537 rs7752906 chr6 20666055 G A 6.50E-07 Type 2 diabetes CDKAL1 intron 17460697 rs7752906 chr6 20666055 G A 2.60E-16 Type 2 diabetes CDKAL1 intron 22158537 rs9358356 chr6 20667382 T C 6.60E-04 Type 2 diabetes CDKAL1 intron 17460697 rs9358356 chr6 20667382 T C 9.31E-20 Type 2 diabetes CDKAL1 intron 22158537 rs9356743 chr6 20667688 C T 2.06E-04 Glycosylated haemoglobin levels CDKAL1 intron 17255346 rs9356743 chr6 20667688 C T 2.44E-04 Lung function (forced expiratory volume in 1 second) CDKAL1 intron 24023788 rs9350270 chr6 20667799 A G 2.32E-09 Type 2 diabetes CDKAL1 intron 22158537 rs9350270 chr6 20667799 A G 5.46E-05 Lung function (forced expiratory volume in 1 second) CDKAL1 intron 24023788 rs9368219 chr6 20674691 C T 4.10E-18 Type 2 diabetes CDKAL1 intron 22158537 rs9368219 chr6 20674691 C T 1.42E-09 Body mass index CDKAL1 intron 22344219 rs1569699 chr6 20679310 T G 1.40E-07 Type 2 diabetes CDKAL1 intron 17460697 rs1569699 chr6 20679310 T G 7.44E-12 Type 2 diabetes CDKAL1 intron 20818381 rs1569699 chr6 20679310 T G 3.56E-16 Type 2 diabetes CDKAL1 intron 22158537 rs7756992 chr6 20679709 A G 8.00E-09 Type 2 diabetes CDKAL1 intron 17460697 rs7756992 chr6 20679709 A G 1.93E-12 Type 2 diabetes CDKAL1 intron 20818381 rs7756992 chr6 20679709 A G 8.00E-09 Coronary heart disease CDKAL1 intron 21347282 rs7756992 chr6 20679709 A G 5.10E-13 Type 2 diabetes CDKAL1 intron 22158537 rs7756992 chr6 20679709 A G 0.00051 Fasting insulin-related traits CDKAL1 intron 22885922 rs7756992 chr6 20679709 A G 1.50E-22 Type 2 diabetes (males) CDKAL1 intron 22885922 rs7756992 chr6 20679709 A G 1.80E-09 Fasting blood glucose CDKAL1 intron 22885922 rs7756992 chr6 20679709 A G 1.90E-20 Type 2 diabetes (females) CDKAL1 intron 22885922 rs7756992 chr6 20679709 A G 7.00E-35 Type 2 diabetes CDKAL1 intron 22885922 rs7756992 chr6 20679709 A G 2.00E-04 Cystic fibrosis-related diabetes CDKAL1 intron 23670970 rs7756992 chr6 20679709 A G 3.29E-04 Lung function (forced expiratory volume in 1 second) CDKAL1 intron 24023788 rs7756992 chr6 20679709 A G 3.84E-04 Lung function (forced vital capacity) CDKAL1 intron 24023788 rs7756992 chr6 20679709 A G 2.00E-26 Type 2 diabetes CDKAL1 intron 24509480 rs6931254 chr6 20680962 A G 8.68E-05 Cognitive impairment induced by topiramate CDKAL1 intron 22091778 rs9350271 chr6 20683164 G A 9.60E-07 Type 2 diabetes CDKAL1 intron 17460697 rs9350271 chr6 20683164 G A 1.65E-16 Type 2 diabetes CDKAL1 intron 22158537 rs9356744 chr6 20685486 T C 7.90E-07 Type 2 diabetes CDKAL1 intron 17460697 rs9356744 chr6 20685486 T C 2.10E-19 Type 2 diabetes CDKAL1 intron 22158537 rs9356744 chr6 20685486 T C 2.00E-11 Body mass index CDKAL1 intron 22344219 rs9356744 chr6 20685486 T C 5.00E-13 Body mass index CDKAL1 intron 24861553 rs7766070 chr6 20686573 C A 4.59E-19 Type 2 diabetes CDKAL1 intron 22158537 rs7766070 chr6 20686573 C A 1.42E-09 Body mass index CDKAL1 intron 22344219 rs7766070 chr6 20686573 C A 6.00E-11 Type 2 diabetes CDKAL1 intron 22693455 rs7766070 chr6 20686573 C A 7.00E-10 Type 2 diabetes CDKAL1 intron 22693455 rs9368222 chr6 20686996 C A 4.80E-07 Type 2 diabetes CDKAL1 intron 17460697 rs9368222 chr6 20686996 C A 4.01E-11 Type 2 diabetes CDKAL1 intron 22158537 rs9368222 chr6 20686996 C A 5.37E-21 Type 2 diabetes CDKAL1 intron 22325160 rs9368222 chr6 20686996 C A 1.70E-09 Body mass index CDKAL1 intron 22344219 rs9368222 chr6 20686996 C A 7.00E-34 Type 2 diabetes CDKAL1 intron 22885922 rs9368222 chr6 20686996 C A 4.54E-11 Fasting blood glucose CDKAL1 intron 22885924 rs9368222 chr6 20686996 C A 1.01E-04 Glycemic traits (pregnancy) CDKAL1 intron 23903356 rs9368222 chr6 20686996 C A 1.92E-04 Glycemic traits (pregnancy) CDKAL1 intron 23903356 rs10440833 chr6 20688121 T A 1.40E-06 Type 2 diabetes CDKAL1 intron 17460697 rs10440833 chr6 20688121 T A 2.00E-22 Type 2 diabetes CDKAL1 intron 20581827 rs10440833 chr6 20688121 T A 2.80E-05 Type 2 diabetes CDKAL1 intron 21874001 rs10440833 chr6 20688121 T A 4.08E-19 Type 2 diabetes CDKAL1 intron 22158537 rs10440833 chr6 20688121 T A 3.60E-22 Type 2 diabetes CDKAL1 intron 22885922 rs10440833 chr6 20688121 T A 1.80E-22 Type 2 diabetes CDKAL1 intron 23300278 rs7748720 chr6 20689945 G A 1.64E-07 Crohn's disease CDKAL1 intron 18587394 rs2206734 chr6 20694884 C T 1.34E-04 Glycosylated haemoglobin levels CDKAL1 intron 17255346 rs2206734 chr6 20694884 C T 2.20E-04 Type 2 diabetes CDKAL1 intron 17460697 rs2206734 chr6 20694884 C T 1.86E-13 Type 2 diabetes CDKAL1 intron 20818381 rs2206734 chr6 20694884 C T 8.00E-06 Ileal carcinoids CDKAL1 intron 21139019 rs2206734 chr6 20694884 C T 2.72E-19 Type 2 diabetes CDKAL1 intron 22158537 rs2206734 chr6 20694884 C T 1.00E-11 Body mass index CDKAL1 intron 22344221 rs2206734 chr6 20694884 C T 1.33E-04 Lung function (forced expiratory volume in 1 second) CDKAL1 intron 24023788 rs2206734 chr6 20694884 C T 5.05E-04 Myocardial Infarction CDKAL1 intron pha002883 rs114158228 chr6 20700123 T A 0.000000712 Menopause (age at onset) CDKAL1 intron 23424626 rs6931514 chr6 20703952 A G 7.80E-07 Type 2 diabetes CDKAL1 intron 17460697 rs6931514 chr6 20703952 A G 1.00E-11 Type 2 diabetes CDKAL1 intron 18372903 rs6931514 chr6 20703952 A G 1.00E-11 Coronary heart disease CDKAL1 intron 21347282 rs6931514 chr6 20703952 A G 2.00E-18 Birth weight CDKAL1 intron 23202124 rs11753081 chr6 20705590 T G 4.47E-16 Type 2 diabetes CDKAL1 intron 22158537 rs1040558 chr6 20713706 A G 9.69E-13 Type 2 diabetes CDKAL1 intron 22158537 rs9295478 chr6 20716253 G A 2.10E-04 Type 2 diabetes CDKAL1 intron 17460697 rs9295478 chr6 20716253 G A 3.04E-17 Type 2 diabetes CDKAL1 intron 22158537 rs2328548 chr6 20716958 G A 1.70E-16 Type 2 diabetes CDKAL1 intron 22158537 rs2328548 chr6 20716958 G A 1.90E-23 Type 2 diabetes CDKAL1 intron 22885922 rs6935599 chr6 20717095 A G 1.51E-16 Type 2 diabetes CDKAL1 intron 22158537 rs13216165 chr6 20717121 A G 1.47E-04 Hearing function CDKAL1 intron 17255346 rs9465871 chr6 20717255 T C 2.40E-04 Glycosylated haemoglobin levels CDKAL1 intron 17255346 rs9465871 chr6 20717255 T C 4.20E-08 Type 2 diabetes CDKAL1 intron 17463249 rs9465871 chr6 20717255 T C 3.00E-07 Type 2 diabetes CDKAL1 intron 17554300 rs9465871 chr6 20717255 T C 3.00E-07 Coronary heart disease CDKAL1 intron 21347282 rs9465871 chr6 20717255 T C 4.19E-13 Type 2 diabetes CDKAL1 intron 22158537 rs9465871 chr6 20717255 T C 1.14E-07 Diabetes (gestational) CDKAL1 intron 22233651 rs9465871 chr6 20717255 T C 4.25E-11 Glycated hemoglobin levels CDKAL1 intron 22290723 rs10946403 chr6 20717404 A G 1.60E-04 Glycosylated haemoglobin levels CDKAL1 intron 17255346 rs10946403 chr6 20717404 A G 8.81E-12 Type 2 diabetes CDKAL1 intron 20818381 rs10946403 chr6 20717404 A G 2.56E-16 Type 2 diabetes CDKAL1 intron 22158537 rs10946403 chr6 20717404 A G 1.21E-04 Lung function (forced expiratory volume in 1 second) CDKAL1 intron 24023788 rs2328549 chr6 20718240 A T 1.20E-05 Multiple complex diseases CDKAL1 intron 17554300 rs2328549 chr6 20718240 A T 4.78E-08 Diabetes (gestational) CDKAL1 intron 22233651 rs2328549 chr6 20718240 A T 7.79E-09 Glycated hemoglobin levels CDKAL1 intron 22290723 rs9358357 chr6 20719145 A G 1.60E-16 Type 2 diabetes CDKAL1 intron 22158537 rs9368224 chr6 20719232 T A 1.55E-16 Type 2 diabetes CDKAL1 intron 22158537 rs9358358 chr6 20719393 A C 2.31E-16 Type 2 diabetes CDKAL1 intron 22158537 rs9460550 chr6 20719561 G A 1.95E-16 Type 2 diabetes CDKAL1 intron 22158537 rs9356746 chr6 20720279 T C 2.18E-16 Type 2 diabetes CDKAL1 intron 22158537 rs9368226 chr6 20723057 T C 2.33E-17 Type 2 diabetes CDKAL1 intron 22158537 rs12111351 chr6 20724558 T G 1.18E-17 Type 2 diabetes CDKAL1 intron 22158537 rs9356747 chr6 20725007 T A 1.91E-17 Type 2 diabetes CDKAL1 intron 22158537 rs9356748 chr6 20725097 T A 2.30E-17 Type 2 diabetes CDKAL1 intron 22158537 rs7767391 chr6 20725240 T C 4.80E-06 Type 2 diabetes CDKAL1 intron 17463249 rs7767391 chr6 20725240 T C 1.91E-07 Multiple complex diseases CDKAL1 intron 17554300 rs7767391 chr6 20725240 T C 1.96E-13 Type 2 diabetes CDKAL1 intron 22158537 rs7767391 chr6 20725240 T C 8.25E-09 Diabetes (gestational) CDKAL1 intron 22233651 rs7767391 chr6 20725240 T C 2.00E-11 Glycated hemoglobin levels CDKAL1 intron 22290723 rs7747752 chr6 20725423 G C 2.67E-04 Multiple complex diseases CDKAL1 intron 17554300 rs7747752 chr6 20725423 G C 2.94E-18 Type 2 diabetes CDKAL1 intron 22158537 rs7747752 chr6 20725423 G C 1.00E-11 Glycated Hemoglobin levels CDKAL1 intron 22290723 rs6928012 chr6 20728513 C T 4.55E-05 Multiple complex diseases CDKAL1 intron 17554300 rs6928012 chr6 20728513 C T 1.65E-07 Type 2 diabetes CDKAL1 intron 20818381 rs6928012 chr6 20728513 C T 4.54E-11 Type 2 diabetes CDKAL1 intron 22158537 rs6908425 chr6 20728731 T C 5.13E-06 Multiple complex diseases CDKAL1 intron 17554300 rs6908425 chr6 20728731 T C 9.00E-10 Crohn's disease CDKAL1 intron 18587394 rs6908425 chr6 20728731 T C 1.00E-08 Crohn's disease CDKAL1 intron 21102463 rs6908425 chr6 20728731 T C 9.00E-10 Asthma CDKAL1 intron 21150878 rs6908425 chr6 20728731 T C 8.96E-10 Multiple sclerosis CDKAL1 intron 22190364 rs7741604 chr6 20731524 A C 3.46E-11 Type 2 diabetes CDKAL1 intron 20818381 rs7741604 chr6 20731524 A C 8.81E-07 Autism CDKAL1 intron 22843504 rs9350276 chr6 20740296 C T 1.27E-07 Type 2 diabetes CDKAL1 intron 22158537 rs9688952 chr6 20741383 G A 1.53E-07 Type 2 diabetes CDKAL1 intron 22158537 rs4710944 chr6 20744727 C T 4.03E-04 Multiple complex diseases CDKAL1 intron 17554300 rs2745933 chr6 20750714 T C 6.74E-04 Smoking cessation CDKAL1 intron 24665060 rs7747724 chr6 20751315 T C 1.00E-06 Bladder cancer CDKAL1 intron 24163127 rs16901574 chr6 20756976 C G 6.49E-08 Metabolite levels CDKAL1 intron 23281178 rs2819997 chr6 20758347 A G 6.07E-04 Smoking cessation CDKAL1 intron 24665060 rs2820000 chr6 20758704 A G 3.58E-04 Smoking cessation CDKAL1 intron 24665060 rs10946406 chr6 20758760 A G 4.33E-07 Type 2 diabetes CDKAL1 intron 22158537 rs2820001 chr6 20758943 G T 3.84E-07 Type 2 diabetes CDKAL1 intron 22158537 rs6909558 chr6 20760177 C T 2.89E-07 Type 2 diabetes CDKAL1 intron 22158537 rs12664021 chr6 20761080 C T 8.90E-04 Nicotine smoking CDKAL1 intron 19268276 rs12664021 chr6 20761080 C T 2.79E-07 Type 2 diabetes CDKAL1 intron 22158537 rs4510656 chr6 20766697 C A 7.00E-07 Bladder cancer CDKAL1 intron 24163127 rs7452218 chr6 20767471 C T 2.10E-07 Type 2 diabetes CDKAL1 intron 22158537 rs9368232 chr6 20771863 C T 9.56E-04 Alzheimer's disease CDKAL1 intron 22005930 rs9358366 chr6 20773560 G A 9.43E-04 Alzheimer's disease CDKAL1 intron 22005930 rs4712545 chr6 20774410 T C 9.26E-04 Alzheimer's disease CDKAL1 intron 22005930 rs4712545 chr6 20774410 T C 5.87E-04 Smoking cessation CDKAL1 intron 24665060 rs9465890 chr6 20774759 G A 8.86E-04 Multiple complex diseases CDKAL1 intron 17554300 rs6936300 chr6 20775221 A G 8.85E-04 Alzheimer's disease CDKAL1 intron 22005930 rs6936840 chr6 20775451 A G 8.80E-04 Alzheimer's disease CDKAL1 intron 22005930 rs4493738 chr6 20775660 A G 6.38E-08 Type 2 diabetes CDKAL1 intron 22158537 rs9465891 chr6 20778559 T C 8.60E-04 Alzheimer's disease CDKAL1 intron 22005930 rs4478387 chr6 20782893 A G 3.04E-04 Alzheimer's disease CDKAL1 intron 22005930 rs9348443 chr6 20785165 A G 3.01E-04 Alzheimer's disease CDKAL1 intron 22005930 rs9460557 chr6 20794625 T C 0.00000138 Cholesterol,total CDKAL1 intron 23063622 rs9465900 chr6 20811620 C T 9.88E-05 Smoking cessation CDKAL1 intron 24665060 rs9358372 chr6 20812588 G A 9.00E-14 Inflammatory bowel disease CDKAL1 intron 23128233 rs9358372 chr6 20812588 G A 5.91E-04 Smoking cessation CDKAL1 intron 24665060 rs7747989 chr6 20813375 G C 2.63E-04 Smoking cessation CDKAL1 intron 24665060 rs12661606 chr6 20815260 C T 3.67E-04 Smoking cessation CDKAL1 intron 24665060 rs9465904 chr6 20821662 T C 9.81E-05 Smoking cessation CDKAL1 intron 24665060 rs9465909 chr6 20824421 A G 3.32E-04 Smoking cessation CDKAL1 intron 24665060 rs9460563 chr6 20825018 T C 8.92E-05 Smoking cessation CDKAL1 intron 24665060 rs4395717 chr6 20826281 C A 2.13E-04 Smoking cessation CDKAL1 intron 24665060 rs9465914 chr6 20836213 G A 1.48E-06 Type 2 diabetes CDKAL1 intron 22158537 rs11967047 chr6 20841480 T C 1.97E-06 Type 2 diabetes CDKAL1 intron 22158537 rs11967068 chr6 20841593 T C 6.34E-04 HIV-1 viral setpoint CDKAL1 intron 17641165 rs11967068 chr6 20841593 T C 2.26E-06 Type 2 diabetes CDKAL1 intron 22158537 rs7751431 chr6 20845074 T A 1.83E-05 Type 2 diabetes CDKAL1 intron 22158537 rs6920045 chr6 20846026 T C 3.99E-04 Type 2 diabetes CDKAL1 intron 22158537 rs7742468 chr6 20847388 C T 3.54E-05 Type 2 diabetes CDKAL1 intron 22158537 rs7753271 chr6 20849412 C T 4.23E-06 Type 2 diabetes CDKAL1 intron 22158537 rs12663147 chr6 20850380 T A 4.57E-05 Type 2 diabetes CDKAL1 intron 22158537 rs16884229 chr6 20857925 T C 3.08E-05 Type 2 diabetes CDKAL1 intron 22158537 rs9366363 chr6 20858852 T G 2.56E-06 Type 2 diabetes CDKAL1 intron 22158537 rs16901585 chr6 20861152 G A 2.83E-05 Type 2 diabetes CDKAL1 intron 22158537 rs5007237 chr6 20861226 A T 3.54E-05 Type 2 diabetes CDKAL1 intron 22158537 rs9356757 chr6 20862611 A G 1.87E-05 Type 2 diabetes CDKAL1 intron 22158537 rs9465922 chr6 20865597 C A 5.50E-07 Stroke (ischemic) CDKAL1 intron 22384361 rs4077403 chr6 20876510 G T 5.12E-05 Type 2 diabetes CDKAL1 intron 22158537 rs4077405 chr6 20876683 G A 2.25E-04 Smoking cessation CDKAL1 intron 24665060 rs9368248 chr6 20877503 A C 4.41E-05 Serum metabolites CDKAL1 intron 19043545 rs10946415 chr6 20881386 C T 5.59E-05 Bipolar disorder CDKAL1 intron 21771265 rs9358376 chr6 20898249 T G 6.50E-05 Response to statin therapy CDKAL1 intron 20339536 rs6456381 chr6 20901232 A T 6.90E-05 Response to statin therapy CDKAL1 intron 20339536 rs6456382 chr6 20901311 A G 8.80E-05 Response to statin therapy CDKAL1 intron 20339536 rs12214079 chr6 20905231 G A 2.78E-05 Insulin resistance CDKAL1 intron 21901158 rs9465931 chr6 20905861 C T 4.80E-06 Serum metabolites CDKAL1 intron 19043545 rs9350298 chr6 20910936 G A 2.51E-04 Stroke CDKAL1 intron pha002887 rs12190631 chr6 20912672 C G 0.0001 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 CDKAL1 intron 21873659 rs6938184 chr6 20918251 A G 2.72E-04 Insulin resistance CDKAL1 intron 21901158 rs4712564 chr6 20920123 A G 8.79E-05 Chronic obstructive pulmonary disease CDKAL1 intron 19300482 rs6939250 chr6 20939734 T A 1.06E-09 LDL cholesterol CDKAL1 intron 23063622 rs9350301 chr6 20940761 T G 8.93E-05 Chronic obstructive pulmonary disease CDKAL1 intron 19300482 rs2015426 chr6 20953611 C A 3.88E-33 Narcolepsy CDKAL1 intron 19629137 rs7775523 chr6 20955332 T C 5.12E-05 Chronic obstructive pulmonary disease CDKAL1 intron 19300482 rs17236645 chr6 20959335 T C 0.00014 Coronary artery calcification CDKAL1 intron 23727086 rs1548145 chr6 21010568 A T 5.68E-04 Type 2 diabetes CDKAL1 intron 17463246 rs10946425 chr6 21018655 C T 2.29E-04 Multiple complex diseases CDKAL1 intron 17554300 rs10946425 chr6 21018655 C T 1.33E-04 Alzheimer's disease CDKAL1 intron 17998437 rs10946425 chr6 21018655 C T 1.70E-04 Alzheimer's disease CDKAL1 intron 22005930 rs16884396 chr6 21023748 A G 3.12E-05 Progressive supranuclear palsy CDKAL1 intron 21685912 rs4710961 chr6 21031079 A G 5.07E-04 Alzheimer's disease CDKAL1 intron 22005930 rs4710962 chr6 21031435 C T 1.88E-04 Multiple complex diseases CDKAL1 intron 17554300 rs4710962 chr6 21031435 C T 2.89E-05 Alzheimer's disease CDKAL1 intron 17998437 rs12198160 chr6 21034747 A G 5.10E-06 Urinary metabolites CDKAL1 intron 21572414 rs7766970 chr6 21034765 G A 1.27E-12 Cholesterol,total CDKAL1 intron 23063622 rs9295489 chr6 21039951 A G 0.0000072 Asthma (exacerbation) CDKAL1 intron 23706709 rs11963640 chr6 21077544 T C 9.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDKAL1 intron 23233662 rs4310041 chr6 21079631 C A 8.93E-04 Response to cytadine analogues (cytosine arabinoside) CDKAL1 intron 24483146 rs4130033 chr6 21086047 T C 9.01E-04 Type 2 diabetes CDKAL1 intron 17463246 rs6904348 chr6 21090622 C A 0.000841823 Hypertension (early onset hypertension) CDKAL1 intron 22479346 rs4454125 chr6 21094954 A G 0.0005398 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDKAL1 intron 23233654 rs4454125 chr6 21094954 A G 5.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDKAL1 intron 23233662 rs4401656 chr6 21095142 T G 0.0005423 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDKAL1 intron 23233654 rs4401656 chr6 21095142 T G 5.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDKAL1 intron 23233662 rs9986662 chr6 21131143 G A 6.67E-04 Smoking cessation CDKAL1 intron 24665060 rs2493869 chr6 21135158 A T 0.0001981 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDKAL1 intron 23233654 rs2493869 chr6 21135158 A T 1.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDKAL1 intron 23233662 rs2446489 chr6 21136120 G A 0.0001773 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDKAL1 intron 23233654 rs2446489 chr6 21136120 G A 1.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDKAL1 intron 23233662 rs2446487 chr6 21137390 G A 0.0002181 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDKAL1 intron 23233654 rs2446484 chr6 21140486 A G 0.000425 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDKAL1 intron 23233654 rs2446484 chr6 21140486 A G 4.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDKAL1 intron 23233662 rs1459047 chr6 21200390 T C 4.40E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) CDKAL1 intron 17982456 rs1459047 chr6 21200390 T C 6.06E-05 Lipid levels CDKAL1 intron 19913121 rs10456242 chr6 21205388 T C 4.63E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CDKAL1 intron 24023788 rs898165 chr6 21208429 G A 3.77E-04 Alzheimer's disease CDKAL1 intron 17998437 rs9368288 chr6 21209123 G A 4.16E-04 Alzheimer's disease CDKAL1 intron 17998437 rs9368288 chr6 21209123 G A 6.20E-04 Prostate cancer mortality CDKAL1 intron 20978177 rs16884681 chr6 21219875 C T 0.00000222 LDL cholesterol CDKAL1 intron 23063622 rs16884688 chr6 21220376 A T 7.66E-08 LDL cholesterol CDKAL1 intron 23063622 rs16884693 chr6 21222751 T C 2.69E-04 Multiple complex diseases CDKAL1 intron 17554300 rs16884693 chr6 21222751 T C 0.00000225 LDL cholesterol CDKAL1 intron 23063622 rs11964983 chr6 21224509 A C 0.00000217 LDL cholesterol CDKAL1 intron 23063622 rs6942273 chr6 21225577 G A 9.52E-06 Colorectal cancer CDKAL1 intron 21242260 rs4710966 chr6 21228888 A G 3.96E-04 Lung function (forced vital capacity) CDKAL1 intron 24023788 rs10755611 chr6 21233903 A G 6.57E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs11755275 chr6 21237370 C T 1.29E-04 Lymphocyte counts / / 22286170 rs6925942 chr6 21245429 G A 1.50E-04 Multiple complex diseases / / 17554300 rs6935795 chr6 21259328 G T 5.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs9368292 chr6 21279204 C G 2.15E-04 Cognitive decline / / 23732972 rs807836 chr6 21279280 C T 1.30E-05 Urinary metabolites / / 21572414 rs807837 chr6 21279488 T C 1.70E-05 Urinary metabolites / / 21572414 rs9348464 chr6 21282089 A G 2.65E-04 Cognitive decline / / 23732972 rs9466024 chr6 21286834 G A 2.15E-04 Cognitive decline / / 23732972 rs717512 chr6 21287993 C T 9.53E-04 Multiple complex diseases / / 17554300 rs717512 chr6 21287993 C T 4.15E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6456414 chr6 21330133 A G 5.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs10946449 chr6 21331247 C T 3.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs17622252 chr6 21331907 T C 2.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs2073001 chr6 21332936 C T 6.31E-05 Relative hand skill / / 24068947 rs6918245 chr6 21333958 C G 8.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs10456011 chr6 21334968 A G 6.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs10456012 chr6 21335141 G C 6.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs10946454 chr6 21335443 C T 4.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs11753776 chr6 21335527 C T 6.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs9368297 chr6 21337024 A G 4.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs12203023 chr6 21337783 C T 7.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs9366393 chr6 21338448 T C 3.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs13211048 chr6 21338933 T C 8.07E-04 Multiple complex diseases / / 17554300 rs17695594 chr6 21352381 G A 3.94E-05 Suicide attempts in bipolar disorder / / 21423239 rs17695674 chr6 21355095 C A 3.53E-05 Suicide attempts in bipolar disorder / / 21423239 rs12524874 chr6 21356199 A G 3.65E-05 Suicide attempts in bipolar disorder / / 21423239 rs9466040 chr6 21357289 C A 4.40E-05 Suicide attempts in bipolar disorder / / 21423239 rs17623091 chr6 21369139 G A 2.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs2328601 chr6 21372634 A G 1.25E-05 Coronary heart disease / / pha003031 rs9366399 chr6 21375995 A G 5.34E-04 Type 2 diabetes / / 17463246 rs9366399 chr6 21375995 A G 2.70E-05 Coronary heart disease / / pha003031 rs4712613 chr6 21378155 G T 8.60E-06 Urinary metabolites / / 21572414 rs17701487 chr6 21382897 G A 5.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs9466055 chr6 21384457 G A 7.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs9466056 chr6 21384613 A G 4.00E-06 Bone mineral density / / 21533022 rs9466056 chr6 21384613 A G 3.00E-13 Bone mineral density / / 22504420 rs9466056 chr6 21384613 A G 1.55E-05 Bone mineral density / / 24249740 rs9466056 chr6 21384613 A G 7.97E-04 Bone mineral density / / 24249740 rs6920208 chr6 21386879 A G 3.77E-04 Bone mineral density / / 24249740 rs6920208 chr6 21386879 A G 4.40E-06 Bone mineral density / / 24249740 rs6456423 chr6 21397120 G A 9.04E-05 Cognitive test performance / / 20125193 rs6456425 chr6 21413856 C T 6.27E-04 Multiple complex diseases / / 17554300 rs12663356 chr6 21430728 T C 4.00E-12 Crohn's disease / / 23128233 rs6904446 chr6 21439343 C A 3.09E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7752847 chr6 21444533 A T 1.97E-05 Multiple complex diseases / / 17554300 rs7752847 chr6 21444533 A T 5.80E-06 Urinary metabolites / / 21572414 rs9460635 chr6 21455153 T C 7.00E-06 Metabolite levels (HVA-5-HIAA Factor score) / / 23319000 rs7751132 chr6 21456425 G A 6.96E-06 Metabolite levels (MHPG) / / 23319000 rs11758376 chr6 21457762 G A 6.96E-06 Metabolite levels (MHPG) / / 23319000 rs11758386 chr6 21457950 C T 8.72E-05 Multiple complex diseases / / 17554300 rs11758386 chr6 21457950 C T 3.40E-05 Crohn's disease / / 18587394 rs7759649 chr6 21470419 C T 2.61E-06 Multiple complex diseases / / 17554300 rs7759649 chr6 21470419 C T 5.02E-06 Crohn's disease / / 18587394 rs4236005 chr6 21489747 A C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6456431 chr6 21503218 A G 9.95E-06 Periodontitis (DPAL) / / 24024966 rs1740852 chr6 21608979 C T 4.63E-04 Type 2 diabetes / / 17463246 rs1744885 chr6 21670816 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LINC00340 intron 22628534 rs4712625 chr6 21699342 A G 8.03E-04 Coronary heart disease LINC00340 intron 21606135 rs4712626 chr6 21701841 G A 8.89E-05 stroke (ischemic) LINC00340 intron 17434096 rs7739131 chr6 21727148 C T 6.32E-05 Hepatocellular carcinoma LINC00340 intron 22807686 rs1322884 chr6 21753645 T G 4.79E-05 Coronary heart disease LINC00340 intron pha003056 rs7740168 chr6 21755214 G A 7.92E-05 Iron levels LINC00340 intron 19880490 rs7740168 chr6 21755214 G A 7.92E-05 Iron levels LINC00340 intron pha002876 rs17197845 chr6 21759736 G A 1.04E-05 Coronary heart disease LINC00340 intron pha003056 rs9466179 chr6 21766998 C A 5.98E-05 Iron levels LINC00340 intron 19880490 rs9466179 chr6 21766998 C A 5.98E-05 Iron levels LINC00340 intron pha002876 rs4710984 chr6 21771990 G A 9.05E-05 Coronary heart disease LINC00340 intron pha003056 rs9466182 chr6 21786171 C T 1.00E-04 Cognitive impairment induced by topiramate LINC00340 intron 22091778 rs6917811 chr6 21800645 C T 2.55E-07 Platelet aggregation(pre- and post-aspirin) LINC00340 intron 20529293 rs16901621 chr6 21813153 A G 0.000000322 Cognitive impairment (no dementia) LINC00340 intron 23042215 rs6918975 chr6 21817965 G C 1.61E-05 Parkinson's disease LINC00340 intron 17052657 rs2479808 chr6 21824394 C T 4.95E-04 Alcohol dependence LINC00340 intron 20201924 rs912026 chr6 21827104 T C 4.56E-05 Intelligence LINC00340 intron 21826061 rs2094571 chr6 21847532 T C 5.17E-04 Smoking cessation LINC00340 intron 24665060 rs12199148 chr6 21853108 C T 1.46E-04 Bladder cancer LINC00340 intron 24163127 rs9366415 chr6 21863899 C T 6.90E-05 Hypothyroidism LINC00340 intron 22493691 rs9366415 chr6 21863899 C T 7.21E-05 Lipoproteins LINC00340 intron pha003079 rs952579 chr6 21884440 G A 2.96E-04 Smoking initiation LINC00340 intron 24665060 rs12213632 chr6 21922708 T G 9.35E-04 Multiple complex diseases LINC00340 intron 17554300 rs7767393 chr6 21938584 C G 6.94E-04 Multiple complex diseases LINC00340 intron 17554300 rs13204006 chr6 21946612 A G 7.85E-05 Response to acetaminophen (hepatotoxicity) LINC00340 intron 21177773 rs913568 chr6 21947118 C T 2.05E-04 Body mass index LINC00340 intron 17255346 rs6940927 chr6 21955544 A G 9.82E-04 Alzheimer's disease LINC00340 intron 17998437 rs9350403 chr6 21977571 C T 4.20E-05 Lipoproteins LINC00340 intron pha003079 rs6922362 chr6 21982253 G A 3.69E-06 Lipoproteins LINC00340 intron pha003079 rs12202475 chr6 21985247 G A 1.25E-05 Lipoproteins LINC00340 intron pha003079 rs1023056 chr6 21988752 G T 3.07E-04 Multiple complex diseases LINC00340 intron 17554300 rs140664025 chr6 21994684 G GTGTGTT 8.63E-04 Alzheimer's disease LINC00340 intron 24755620 rs9295532 chr6 21994684 G T 8.63E-04 Alzheimer's disease LINC00340 intron 24755620 rs9350404 chr6 21994744 A G 4.94E-05 Pulmonary function LINC00340 intron 20010835 rs9350404 chr6 21994744 A G 6.26E-05 Alcohol consumption LINC00340 intron 23953852 rs2025977 chr6 21995041 A C 3.70E-05 Pulmonary function LINC00340 intron 20010835 rs6926620 chr6 21995546 G C 4.48E-05 Pulmonary function LINC00340 intron 20010835 rs7766354 chr6 21995759 A T 3.67E-04 Multiple complex diseases LINC00340 intron 17554300 rs726730 chr6 21996108 A G 5.73E-05 Alcohol consumption LINC00340 intron 23953852 rs1928161 chr6 21996361 T C 8.10E-05 Pulmonary function LINC00340 intron 20010835 rs1410523 chr6 21996738 T C 8.29E-05 Pulmonary function LINC00340 intron 20010835 rs2078543 chr6 21996860 A G 6.32E-05 Pulmonary function LINC00340 intron 20010835 rs2078543 chr6 21996860 A G 2.00E-07 Pulmonary function (interaction) LINC00340 intron 23284291 rs9466231 chr6 21998442 C T 1.94E-04 Multiple complex diseases LINC00340 intron 17554300 rs4712647 chr6 21998459 T A 1.30E-05 Urinary metabolites LINC00340 intron 21572414 rs10946495 chr6 21999300 T C 3.11E-05 Pulmonary function LINC00340 intron 20010835 rs10946495 chr6 21999300 T C 4.70E-04 Heart Failure LINC00340 intron pha002885 rs1928160 chr6 22006676 G A 1.69E-05 Pulmonary function LINC00340 intron 20010835 rs1928168 chr6 22017738 T C 2.42E-05 Pulmonary function LINC00340 intron 20010835 rs1928168 chr6 22017738 T C 2.00E-07 Pulmonary function LINC00340 intron 21946350 rs1928168 chr6 22017738 T C 2.00E-07 Pulmonary function (interaction) LINC00340 intron 23284291 rs9366421 chr6 22018038 G C 1.86E-05 Pulmonary function LINC00340 intron 20010835 rs9356791 chr6 22018581 G A 1.94E-05 Pulmonary function LINC00340 intron 20010835 rs1928167 chr6 22020066 C T 5.46E-05 Pulmonary function LINC00340 intron 20010835 rs9350408 chr6 22021373 C T 2.40E-05 Pulmonary function LINC00340 intron 20010835 rs9368393 chr6 22022591 T G 6.82E-04 Alzheimer's disease LINC00340 intron 24755620 rs9368394 chr6 22025002 C T 8.97E-04 Multiple complex diseases LINC00340 intron 17554300 rs17261417 chr6 22034957 C T 9.82E-04 Alzheimer's disease LINC00340 intron 24755620 rs196033 chr6 22043658 T G 5.91E-04 Suicide attempts in bipolar disorder LINC00340 intron 21423239 rs993599 chr6 22045719 G T 3.49E-04 Suicide attempts in bipolar disorder LINC00340 intron 21423239 rs1736512 chr6 22046317 A G 9.57E-04 Suicide attempts in bipolar disorder LINC00340 intron 21423239 rs1736512 chr6 22046317 A G 1.10E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) LINC00340 intron 23648065 rs1736512 chr6 22046317 A G 2.95E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LINC00340 intron 23648065 rs1736511 chr6 22046374 A G 6.18E-04 Suicide attempts in bipolar disorder LINC00340 intron 21423239 rs610499 chr6 22046530 T C 5.84E-04 Suicide attempts in bipolar disorder LINC00340 intron 21423239 rs447800 chr6 22046757 C T 8.53E-04 Suicide attempts in bipolar disorder LINC00340 intron 21423239 rs12196515 chr6 22046786 G A 6.01E-06 Personality dimensions LINC00340 intron 23658558 rs196051 chr6 22056131 A G 1.86E-04 Attention deficit hyperactivity disorder LINC00340 intron 22420046 rs885769 chr6 22060582 T C 6.55E-06 Neuroblastoma LINC00340 intron pha002895 rs4712652 chr6 22078615 G A 1.00E-06 Smoking behavior LINC00340 intron 20418888 rs196048 chr6 22096361 C T 5.05E-06 Neuroblastoma LINC00340 intron pha002895 rs9393227 chr6 22100912 G A 3.85E-05 Neuroblastoma LINC00340 intron pha002895 rs12207718 chr6 22109567 T G 2.84E-05 Neuroblastoma LINC00340 intron pha002895 rs4712653 chr6 22125964 T C 1.16E-09 Neuroblastoma LINC00340 intron 18463370 rs4712653 chr6 22125964 T C 8.00E-17 Neuroblastoma LINC00340 intron 21124317 rs4712653 chr6 22125964 T C 2.46E-14 Neuroblastoma LINC00340 intron pha002895 rs9295536 chr6 22131929 C A 1.71E-09 Neuroblastoma LINC00340 intron 18463370 rs9295536 chr6 22131929 C A 8.00E-16 Neuroblastoma LINC00340 intron 22941191 rs9295536 chr6 22131929 C A 3.25E-13 Neuroblastoma LINC00340 intron pha002895 rs9466269 chr6 22136409 T C 1.30E-05 Urinary metabolites LINC00340 intron 21572414 rs9466269 chr6 22136409 T C 5.45E-05 Neuroblastoma LINC00340 intron pha002895 rs6939340 chr6 22140004 A G 9.00E-15 Neuroblastoma LINC00340 intron 18463370 rs6939340 chr6 22140004 A G 9.00E-15 Nasopharyngeal carcinoma LINC00340 intron 20512145 rs6939340 chr6 22140004 A G 3.58E-14 Neuroblastoma LINC00340 intron pha002895 rs16885715 chr6 22155441 T C 4.69E-04 Multiple complex diseases LINC00340 intron 17554300 rs3734231 chr6 22191966 C T 6.86E-05 Erythrocyte counts LINC00340 intron pha003090 rs7757198 chr6 22195333 C G 7.21E-04 Multiple complex diseases / / 17554300 rs7739417 chr6 22195500 T C 2.85E-05 Erythrocyte counts / / pha003090 rs7749084 chr6 22202679 T C 8.92E-04 Substance dependence / / 21818250 rs4236016 chr6 22246604 C T 4.00E-06 Cardiac hypertrophy / / 21348951 rs2455931 chr6 22265981 G A 6.12E-05 Orofacial clefts / / 22419666 rs1205961 chr6 22286012 A G 3.65E-05 Celiac disease / / 23936387 rs1341239 chr6 22304204 A C 4.00E-06 Paget's disease PRL nearGene-5 21623375 rs11970435 chr6 22316369 C T 3.00E-05 Alzheimer's disease (late onset) / / 21379329 rs11970435 chr6 22316369 C T 6.65E-04 Acute lung injury / / 22295056 rs11970435 chr6 22316369 C T 0.000839 Height (Pygmy height) / / 22570615 rs9358533 chr6 22322004 C T 7.91E-05 Acute lung injury / / 22295056 rs9358533 chr6 22322004 C T 0.0000638 Height (Pygmy height) / / 22570615 rs9393275 chr6 22325938 C T 7.97E-05 Acute lung injury / / 22295056 rs1205896 chr6 22341469 G A 9.99E-05 Coronary heart disease / / pha003030 rs1205918 chr6 22365762 A G 3.43E-04 Alzheimer's disease (late onset) / / 21379329 rs1205918 chr6 22365762 A G 5.40E-05 Epilepsy / / 22116939 rs1205918 chr6 22365762 A G 8.12E-04 Acute lung injury / / 22295056 rs9393280 chr6 22368828 G A 3.22E-04 Acute lung injury / / 22295056 rs10946553 chr6 22388887 T C 3.23E-04 Type 2 diabetes / / 17463246 rs12110752 chr6 22393475 T C 7.66E-06 Type 2 diabetes / / 17463246 rs7768473 chr6 22431621 T C 6.73E-05 Type 2 diabetes / / 17463246 rs10456018 chr6 22448778 T C 6.31E-04 Type 2 diabetes / / 17463246 rs4560628 chr6 22451820 A G 7.89E-04 Insulin resistance / / 21901158 rs12207880 chr6 22465317 A G 0.00008006 Sarcoidosis / / 22952805 rs4563703 chr6 22471152 G A 2.40E-05 Urinary metabolites / / 21572414 rs13209309 chr6 22472559 C T 0.00005806 Sarcoidosis / / 22952805 rs35713974 chr6 22473574 C T 0.0000776 Sarcoidosis / / 22952805 rs9393296 chr6 22474756 G A 2.30E-05 Urinary metabolites / / 21572414 rs9358551 chr6 22474777 A G 8.80E-06 Urinary metabolites / / 21572414 rs9356824 chr6 22480823 G A 3.80E-05 Personality dimensions / / 18957941 rs2185732 chr6 22491997 A G 8.50E-06 Urinary metabolites / / 21572414 rs2185732 chr6 22491997 A G 6.93E-04 Heart Failure / / pha002885 rs2000191 chr6 22504748 A C 6.68E-05 Schizophrenia / / 19197363 rs12195428 chr6 22507985 A G 3.34E-05 HIV-1 viral setpoint / / 22174851 rs9460753 chr6 22517187 C A 5.36E-04 Multiple complex diseases / / 17554300 rs9295552 chr6 22540765 C T 2.70E-05 Urinary metabolites / / 21572414 rs2294827 chr6 22597840 G A 1.00E-05 Urinary metabolites / / 21572414 rs10485011 chr6 22606942 C A 5.18E-04 Schizophrenia / / 19197363 rs9466410 chr6 22614730 C T 7.12E-04 Acute lung injury / / 22295056 rs728544 chr6 22615484 C T 7.12E-04 Acute lung injury / / 22295056 rs10456261 chr6 22623471 C T 5.10E-06 Urinary metabolites / / 21572414 rs12193608 chr6 22624817 G A 1.96E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs4538699 chr6 22625804 C T 6.28E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4538699 chr6 22625804 C T 9.14E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2179558 chr6 22647622 T C 1.57E-05 Multiple complex diseases / / 17554300 rs2057019 chr6 22686841 C T 3.20E-04 Alcohol dependence / / 20201924 rs1555108 chr6 22694829 G T 3.70E-04 Alzheimer's disease / / 22005930 rs4712709 chr6 22709739 C G,T 6.00E-06 Metabolite levels (Pyroglutamine) / / 23934736 rs4712710 chr6 22710041 A C 1.70E-05 Urinary metabolites / / 21572414 rs9358581 chr6 22711757 A T 1.00E-04 Prostate cancer / / 21743057 rs6456503 chr6 22720361 T C 9.31E-04 Alzheimer's disease / / 22005930 rs41526348 chr6 22732400 G A 2.03E-04 Insulin resistance / / 21901158 rs13214385 chr6 22741451 A G 8.57E-04 Insulin resistance / / 21901158 rs17272619 chr6 22741874 C T 7.84E-04 Coronary Artery Disease / / 17634449 rs10498712 chr6 22743403 A G 9.00E-06 Quantitative traits / / 19197348 rs9460779 chr6 22747137 T C 7.33E-04 Multiple complex diseases / / 17554300 rs7356884 chr6 22753047 A G 8.00E-06 Obesity-related traits / / 23251661 rs12154136 chr6 22755579 G A 9.06E-05 Substance dependence / / 21818250 rs4607423 chr6 22757260 C T 2.55E-04 Stroke / / pha002887 rs6456505 chr6 22776453 G A 4.67E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4594936 chr6 22792759 T A 9.90E-06 Urinary metabolites / / 21572414 rs6933879 chr6 22799700 A G 3.82E-04 Alzheimer's disease / / 17998437 rs6933879 chr6 22799700 A G 4.50E-06 Urinary metabolites / / 21572414 rs41510145 chr6 22805867 C G 5.90E-06 Urinary metabolites / / 21572414 rs9379447 chr6 22862034 A T 1.80E-06 Urinary metabolites / / 21572414 rs2480001 chr6 22890101 G A 1.42E-04 HIV-1 viral setpoint / / 17641165 rs4711037 chr6 22907994 G A 9.34E-05 Cognitive performance / / 19734545 rs16887045 chr6 22909333 G C 5.82E-04 Multiple complex diseases / / 17554300 rs9379455 chr6 22926459 A G 1.26E-05 Serum metabolites / / 19043545 rs4712728 chr6 22942213 G A 5.90E-04 Multiple complex diseases / / 17554300 rs6903116 chr6 22947194 C T 3.04E-04 Multiple complex diseases / / 17554300 rs6912706 chr6 22953911 A T 1.51E-04 Multiple complex diseases / / 17554300 rs6456514 chr6 22956627 T C 5.14E-04 Multiple complex diseases / / 17554300 rs17605739 chr6 22962798 A G 7.48E-04 Multiple complex diseases / / 17554300 rs17605766 chr6 22962827 A G 3.31E-04 Multiple complex diseases / / 17554300 rs2473700 chr6 22992322 C T 2.66E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2473700 chr6 22992322 C T 8.28E-05 Lung function (forced vital capacity) / / 24023788 rs7774154 chr6 22997063 T C 6.26E-05 HIV-1 viral setpoint / / 17641165 rs2473707 chr6 23002332 C T 2.23E-05 HIV-1 viral setpoint / / 17641165 rs2473710 chr6 23019225 G A 1.17E-05 HIV-1 viral setpoint / / 17641165 rs2498253 chr6 23025825 G T 4.19E-04 HIV-1 viral setpoint / / 17641165 rs2498254 chr6 23025981 T G 4.19E-04 HIV-1 viral setpoint / / 17641165 rs17670031 chr6 23034890 C T 1.44E-04 HIV-1 viral setpoint / / 17641165 rs2498259 chr6 23035333 G A 6.48E-04 HIV-1 viral setpoint / / 17641165 rs7753085 chr6 23067673 A G 6.69E-04 HIV-1 viral setpoint / / 17641165 rs7753085 chr6 23067673 A G 1.23E-04 Stroke / / pha002886 rs4345386 chr6 23077124 C T 7.30E-04 HIV-1 viral setpoint / / 17641165 rs9393366 chr6 23077311 G A 8.00E-06 Tourette syndrome / / 22889924 rs13208193 chr6 23077452 T C 6.99E-04 HIV-1 viral setpoint / / 17641165 rs9466615 chr6 23085982 C T 5.72E-04 HIV-1 viral setpoint / / 17641165 rs11752678 chr6 23127186 C T 4.53E-05 Serum metabolites / / 19043545 rs4626416 chr6 23135926 T C 8.36E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4626416 chr6 23135926 T C 1.35E-04 HIV-1 viral setpoint / / 17641165 rs7754121 chr6 23173613 G A 9.61E-06 Menarche (age at onset) / / 23599027 rs12524736 chr6 23184825 C T 7.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9460842 chr6 23200888 C T 7.97E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs10080831 chr6 23209127 A G 6.53E-04 Multiple complex diseases / / 17554300 rs4502928 chr6 23214230 A G 8.63E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs7740800 chr6 23237776 A C 3.38E-05 Psoriasis / / 18364390 rs9358623 chr6 23241944 A G 7.00E-04 Coronary heart disease / / 21971053 rs13200531 chr6 23242826 A G 3.71E-04 HIV-1 viral setpoint / / 17641165 rs4236026 chr6 23243562 T G 5.06E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9356854 chr6 23245281 A G 5.54E-05 Body mass index / / 22446040 rs10080544 chr6 23269960 A G 9.35E-05 Serum albumin level / / pha003084 rs1925439 chr6 23315977 T C 6.67E-05 Lung adenocarcinoma / / 19836008 rs12195633 chr6 23316593 C T 4.77E-04 Prostate cancer mortality / / 20978177 rs9379494 chr6 23318780 G A 2.15E-05 Lung adenocarcinoma / / 19836008 rs6902688 chr6 23325833 A G 7.82E-04 Prostate cancer mortality / / 20978177 rs17274691 chr6 23337844 G A 8.92E-04 Acute lung injury / / 22295056 rs17274705 chr6 23338268 G A 9.16E-05 Relative hand skill / / 24068947 rs1886703 chr6 23342714 C G 4.57E-04 Coronary Artery Disease / / 17634449 rs17274817 chr6 23343918 A T 8.89E-04 Type 2 diabetes / / 17463246 rs9295585 chr6 23347639 A G 1.16E-04 Multiple complex diseases / / 17554300 rs6912380 chr6 23350433 C T 7.35E-04 Multiple complex diseases / / 17554300 rs1925453 chr6 23365820 G A 9.88E-04 Coronary Artery Disease / / 17634449 rs9356861 chr6 23366140 T C 6.34E-04 Coronary Artery Disease / / 17634449 rs6918629 chr6 23374214 G A 8.50E-06 Triglycerides / / 19074352 rs6918629 chr6 23374214 G A 8.50E-06 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs6899580 chr6 23378165 A G 4.83E-04 Coronary Artery Disease / / 17634449 rs7771911 chr6 23437676 C A 2.00E-12 Immune reponse to smallpox (secreted IL-12p40) / / 22610502 rs199031 chr6 23439477 G C 5.02E-04 Multiple complex diseases / / 17554300 rs199026 chr6 23443834 A G 5.82E-04 Multiple complex diseases / / 17554300 rs199026 chr6 23443834 A G 2.63E-04 Coronary Artery Disease / / 17634449 rs9295589 chr6 23445330 A G 0.0000688 Skin naphthyl-keratin adduct (NKA) levels in workers exposed to naphthalene / / 22391508 rs199018 chr6 23454721 A G 7.96E-04 Alzheimer's disease / / 22005930 rs199067 chr6 23483286 T C 7.01E-04 Type 2 diabetes / / 17463246 rs199059 chr6 23487857 C T 7.18E-05 Serum metabolites / / 19043545 rs9295592 chr6 23518271 T C 1.33E-04 Body mass index / / 21701565 rs9295592 chr6 23518271 T C 8.90E-05 Body mass index / / 21701565 rs2143144 chr6 23520862 A G 6.77E-05 Body mass index / / 21701565 rs2143144 chr6 23520862 A G 9.57E-05 Body mass index / / 21701565 rs199090 chr6 23533622 C T 3.40E-04 Body mass index / / 21701565 rs199090 chr6 23533622 C T 3.60E-04 Body mass index / / 21701565 rs12197748 chr6 23558528 G A,T 4.01E-04 Body mass index / / 21701565 rs12197748 chr6 23558528 G A,T 7.59E-04 Body mass index / / 21701565 rs2328765 chr6 23559114 C G 2.79E-04 Body mass index / / 21701565 rs2328765 chr6 23559114 C G 8.51E-04 Body mass index / / 21701565 rs199126 chr6 23560815 G A 7.04E-04 Multiple complex diseases / / 17554300 rs7738058 chr6 23560889 C A 2.95E-04 Body mass index / / 21701565 rs7738058 chr6 23560889 C A 4.83E-04 Body mass index / / 21701565 rs7739213 chr6 23561434 G T 4.79E-04 Body mass index / / 21701565 rs7739213 chr6 23561434 G T 8.01E-04 Body mass index / / 21701565 rs199124 chr6 23562269 T C 7.42E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs199122 chr6 23563723 T A 7.06E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs126539 chr6 23566414 C T 6.56E-04 Tourette syndrome / / 22889924 rs75522 chr6 23566794 T C 9.06E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9466823 chr6 23572933 G T 5.22E-04 Multiple complex diseases / / 17554300 rs1321914 chr6 23574913 C T 9.99E-04 Tourette syndrome / / 22889924 rs561071 chr6 23655053 T C 8.07E-04 Type 2 diabetes / / 17463246 rs561071 chr6 23655053 T C 5.25E-04 Myopia (pathological) / / 21095009 rs497733 chr6 23672259 G A 0.0000005 Diabetic nephropathy in Type 1 diabetes / / 22721967 rs2181941 chr6 23672330 C T 6.15E-04 Type 2 diabetes / / 17463246 rs574167 chr6 23687090 G T 6.87E-04 Type 2 diabetes / / 17463246 rs12202337 chr6 23687744 T C 1.48E-04 Parkinson's disease / / 16252231 rs12205517 chr6 23694538 T C 1.50E-04 Parkinson's disease / / 16252231 rs1886565 chr6 23703294 T C 8.30E-04 Type 2 diabetes / / 17463246 rs2181938 chr6 23716153 C T 6.65E-05 Myopia (pathological) / / 21640322 rs12525796 chr6 23785745 T G 3.30E-05 HIV-1 control / / 20041166 rs12661929 chr6 23789334 C G 7.30E-04 Body mass index / / 21701565 rs1408744 chr6 23790115 A G 8.06E-07 Autism / / 22843504 rs9466930 chr6 23841132 C G 4.00E-06 Major depressive disorder / / 23377640 rs12192397 chr6 23850803 G A 2.07E-04 Parkinson's disease / / 16252231 rs16888247 chr6 23880358 T C 1.90E-05 Amyotrophic lateral sclerosis / / 19193627 rs953377 chr6 23890691 G A 1.50E-05 Blood Phenotypes / / 17903294 rs11757520 chr6 23900335 G T 6.98E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1883618 chr6 23915225 C T 4.96E-04 Multiple complex diseases / / 17554300 rs474923 chr6 23915899 T C 5.27E-05 Body Composition / / pha003012 rs518587 chr6 23934445 A G 8.95E-04 Alcohol dependence / / 20201924 rs499466 chr6 23961431 T C 5.46E-05 HDL cholesterol / / pha003074 rs537835 chr6 23967123 A G 3.04E-04 Schizophrenia / / 19197363 rs508584 chr6 23984030 G A 0.0002908 Sarcoidosis / / 22952805 rs16888503 chr6 24022898 T C 2.57E-04 Vaspin levels / / 22907691 rs16888503 chr6 24022898 T C 0.0002566 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs7761213 chr6 24028403 T C 3.38E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs10946659 chr6 24042393 T G 9.26E-05 Celiac disease / / 23936387 rs9348626 chr6 24052526 C T 8.90E-04 Type 2 diabetes / / 17463246 rs9358744 chr6 24053169 A G 5.54E-04 Alzheimer's disease / / 17998437 rs9467027 chr6 24059407 C T 2.10E-04 Celiac disease / / 23936387 rs146696563 chr6 24062788 T C 4.00E-06 Periodontitis (Mean PAL) / / 24024966 rs9460965 chr6 24078258 C T 1.63E-04 Celiac disease / / 23936387 rs2176933 chr6 24094140 A G 2.09E-04 Breast cancer / / pha002853 rs6922632 chr6 24107093 C A 4.00E-06 Information processing speed / / 21130836 rs1419229 chr6 24112537 A G 4.07E-05 Bipolar disorder,affective / / 20528957 rs9467044 chr6 24116423 T C 8.20E-05 Information processing speed / / 21130836 rs10484657 chr6 24116850 T C 6.00E-04 Volumetric brain MRI / / 17903297 rs10946673 chr6 24123314 T G 5.92E-05 Psoriasis / / 18364390 rs10946673 chr6 24123314 T G 3.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4449613 chr6 24130821 G A 1.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NRSN1 intron 20877124 rs12210008 chr6 24133472 T C 2.49E-04 Response to alcohol consumption (flushing response) NRSN1 intron 24277619 rs12210008 chr6 24133472 T C 4.70E-05 Neuroblastoma NRSN1 intron pha002895 rs16888718 chr6 24146454 C T 5.88E-04 Coronary Artery Disease NRSN1 UTR-3 17634449 rs6925917 chr6 24148142 G A 8.79E-04 Alzheimer's disease / / 22005930 rs13191953 chr6 24151043 G A 1.50E-04 Type 2 diabetes / / 17463246 rs4582376 chr6 24167807 G A 3.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9460973 chr6 24175021 T A 2.85E-04 Blood pressure DCDC2 missense 17255346 rs4052671 chr6 24223579 T C 6.83E-05 Aspirin exacerbated respiratory disease in asthmatics DCDC2 intron 23180272 rs793842 chr6 24224488 T C 1.11E-05 Information processing speed DCDC2 intron 21130836 rs793842 chr6 24224488 T C 6.47E-04 Stroke DCDC2 intron pha002887 rs9295616 chr6 24233032 G T 5.61E-04 Type 2 diabetes DCDC2 intron 17463246 rs9460980 chr6 24233288 G A 4.34E-06 Information processing speed DCDC2 intron 21130836 rs793834 chr6 24234933 A G 3.00E-06 Information processing speed DCDC2 intron 21130836 rs793834 chr6 24234933 A G 2.68E-04 Reading disability and language impairment DCDC2 intron 24024963 rs9460984 chr6 24247248 C T 6.96E-04 Type 2 diabetes DCDC2 intron 17463246 rs9460984 chr6 24247248 C T 5.60E-05 Pulmonary function DCDC2 intron 23932459 rs9295618 chr6 24248620 T C 1.31E-04 Multiple complex diseases DCDC2 intron 17554300 rs9295619 chr6 24250511 T C 1.05E-05 Information processing speed DCDC2 intron 21130836 rs870601 chr6 24261060 T C 7.90E-05 Information processing speed DCDC2 intron 21130836 rs870601 chr6 24261060 T C 3.88E-04 Aspirin exacerbated respiratory disease in asthmatics DCDC2 intron 23180272 rs6456601 chr6 24266739 C T 3.96E-04 Aspirin exacerbated respiratory disease in asthmatics DCDC2 intron 23180272 rs12055879 chr6 24274117 C A 5.88E-04 Aspirin exacerbated respiratory disease in asthmatics DCDC2 intron 23180272 rs807722 chr6 24279935 G C 8.66E-05 Multiple complex diseases DCDC2 intron 17554300 rs3789224 chr6 24280101 G A 3.07E-04 Aspirin exacerbated respiratory disease in asthmatics DCDC2 intron 23180272 rs2328208 chr6 24285571 C T 8.61E-04 Multiple complex diseases DCDC2 intron 17554300 rs2328208 chr6 24285571 C T 5.11E-04 Aspirin exacerbated respiratory disease in asthmatics DCDC2 intron 23180272 rs9379650 chr6 24286952 T C 3.63E-04 Aspirin exacerbated respiratory disease in asthmatics DCDC2 intron 23180272 rs17302729 chr6 24288724 G A 6.61E-04 Aspirin exacerbated respiratory disease in asthmatics DCDC2 intron 23180272 rs3804327 chr6 24292282 C T 1.80E-06 Asthma DCDC2 intron 24406073 rs16889038 chr6 24306387 T G 8.00E-07 Airflow obstruction DCDC2 intron 22837378 rs12196880 chr6 24313747 C T 3.52E-05 Type 2 diabetes DCDC2 intron 17463246 rs10806987 chr6 24315743 T C 1.59E-05 Information processing speed DCDC2 intron 21130836 rs10456303 chr6 24317399 C T 6.18E-06 Uric acid levels DCDC2 intron 21294900 rs12192947 chr6 24318570 A G 4.56E-06 Uric acid levels DCDC2 intron 21294900 rs9356933 chr6 24321213 A G 6.11E-04 Multiple complex diseases DCDC2 intron 17554300 rs11966126 chr6 24322287 G A 3.14E-04 Age-related macular degeneration DCDC2 intron 22125219 rs4504468 chr6 24333744 T G 9.38E-05 Left ventricular hypertrophy DCDC2 intron pha003052 rs16889092 chr6 24334379 C G 6.60E-06 Personality dimensions DCDC2 intron 21173776 rs10806988 chr6 24341769 C T 3.37E-04 Multiple complex diseases DCDC2 intron 17554300 rs1277351 chr6 24346056 A G 9.56E-05 Information processing speed DCDC2 intron 21130836 rs793674 chr6 24347883 G A 1.54E-05 Information processing speed DCDC2 intron 21130836 rs793650 chr6 24395765 A T 8.52E-04 Alzheimer's disease / / 17998437 rs9467160 chr6 24441746 G A 1.00E-11 Liver enzyme levels GPLD1 intron 18940312 rs2744591 chr6 24463461 G A,C,T 1.14E-04 Coronary heart disease GPLD1 intron 21971053 rs6901703 chr6 24475300 A T 8.09E-05 Lymphocyte counts GPLD1 intron 22286170 rs2760145 chr6 24478813 T C 5.38E-04 Smoking initiation GPLD1 intron 24665060 rs6911965 chr6 24480295 T C 2.00E-11 Blood cell counts and other traits GPLD1 intron 20139978 rs6911965 chr6 24480295 T C 2.13E-11 Blood cell counts and other traits GPLD1 intron 20139978 rs1126617 chr6 24489652 C T 1.80E-14 Liver enzyme levels (gamma-glutamyl transferase) GPLD1 missense 22001757 rs1883415 chr6 24491475 A C 6.00E-26 Liver enzyme levels (alkaline phosphatase) GPLD1 nearGene-5 22001757 rs7775073 chr6 24499551 A G 5.10E-06 Coronary Artery Disease ALDH5A1 intron 17634449 rs4646834 chr6 24501129 T G 1.95E-04 Amyotrophic lateral sclerosis (sporadic) ALDH5A1 intron 24529757 rs2760117 chr6 24504189 C T 4.09E-05 Coronary Artery Disease ALDH5A1 intron 17634449 rs807515 chr6 24519886 G T 1.12E-05 Sleep duration ALDH5A1 intron 22105623 rs807518 chr6 24526243 C A 1.59E-05 Sleep duration ALDH5A1 intron 22105623 rs2817232 chr6 24538113 A G 2.14E-05 Sleep duration / / 22105623 rs2744604 chr6 24540539 T C 4.21E-05 Job-related exhaustion / / 23620144 rs2744604 chr6 24540539 T C 8.99E-04 Alzheimer's disease / / 24755620 rs807511 chr6 24540715 A G 9.91E-05 Alzheimer's disease / / 24755620 rs16889440 chr6 24544967 C T 2.00E-06 Radiation response KIAA0319 UTR-3 20923822 rs807541 chr6 24559281 A G 6.47E-05 Alzheimer's disease KIAA0319 cds-synon 24755620 rs17311358 chr6 24580036 G A 4.80E-06 Personality dimensions KIAA0319 intron 21173776 rs6902039 chr6 24584181 T C 3.22E-04 Coronary heart disease KIAA0319 intron 21971053 rs2817200 chr6 24584366 A G 9.12E-04 Iron levels KIAA0319 intron pha002876 rs4576240 chr6 24596478 T G 3.94E-07 Coronary heart disease KIAA0319 missense 21971053 rs4236031 chr6 24605424 C A 2.60E-05 Coronary heart disease KIAA0319 intron 21971053 rs4236032 chr6 24606727 G A 3.52E-05 Coronary heart disease KIAA0319 intron 21971053 rs7763790 chr6 24615063 G A 2.91E-04 Celiac disease KIAA0319 intron 23936387 rs9467239 chr6 24624857 C G 3.12E-05 Schizophrenia KIAA0319 intron 19571809 rs12194307 chr6 24625562 A T 1.80E-05 Response to statin therapy KIAA0319 intron 20339536 rs9379678 chr6 24640615 G C 3.41E-05 Personality dimensions KIAA0319 intron 22628180 rs16889556 chr6 24641605 C T 4.90E-05 Response to statin therapy KIAA0319 intron 20339536 rs3756821 chr6 24646821 C T 7.35E-04 Suicide attempts in bipolar disorder KIAA0319 nearGene-5 21423239 rs3181245 chr6 24651320 C G 4.82E-04 Suicide attempts in bipolar disorder TDP2 intron 21423239 rs9295629 chr6 24654266 G A 9.00E-06 Left ventricular hypertrophy TDP2 intron 21828061 rs3756819 chr6 24665340 A C 5.55E-05 Left ventricular hypertrophy TDP2 intron pha003052 rs3777663 chr6 24700235 A G 3.54E-06 Cognitive test performance ACOT13 intron 20125193 rs3777663 chr6 24700235 A G 8.01E-05 Waist-Hip Ratio ACOT13 intron pha003013 rs3777663 chr6 24700235 A G 6.88E-05 Waist-Hip Ratio ACOT13 intron pha003028 rs9467267 chr6 24716221 C A 8.51E-05 Cognitive impairment induced by topiramate C6orf62 intron 22091778 rs9379687 chr6 24721787 C A 2.57E-04 Cognitive decline / / 23732972 rs10946724 chr6 24735308 G T 1.10E-05 Urinary metabolites / / 21572414 rs12190789 chr6 24746739 C T 3.32E-06 Lipid traits / / 21777205 rs17419851 chr6 24749413 C T 9.00E-06 Neutrophil count / / 21507922 rs3813680 chr6 24848086 A G 3.35E-04 Coronary heart disease FAM65B intron 21971053 rs4256430 chr6 24863075 G A 8.00E-06 Electroencephalographic traits in alcoholism FAM65B intron 22554406 rs12194442 chr6 24866495 A G 2.08E-07 Red blood cell traits FAM65B intron 23222517 rs10946732 chr6 24872443 T C 8.74E-04 Type 2 diabetes FAM65B intron 17463246 rs10946732 chr6 24872443 T C 9.20E-07 Urinary metabolites FAM65B intron 21572414 rs10946734 chr6 24872898 T C 2.28E-04 Multiple complex diseases FAM65B intron 17554300 rs16889761 chr6 24875339 G A 5.33E-04 Pulmonary function FAM65B intron 20010834 rs13192978 chr6 24885300 T C 2.10E-05 Urinary metabolites FAM65B intron 21572414 rs2817723 chr6 24899568 C A 3.53E-06 Height FAM65B intron 20400458 rs2064524 chr6 24919115 A G 2.45E-05 Serum metabolites / / 19043545 rs2747672 chr6 24933115 A G 2.19E-04 Multiple complex diseases / / 17554300 rs419288 chr6 24941436 C T 4.09E-06 Rheumatoid arthritis / / 19503088 rs419288 chr6 24941436 C T 4.41E-06 Height / / pha003010 rs419288 chr6 24941436 C T 3.33E-05 Height / / pha003011 rs419288 chr6 24941436 C T 5.76E-05 Lung function (forced vital capacity) / / pha003104 rs415025 chr6 24942506 T C 5.10E-07 Height / / pha003010 rs415025 chr6 24942506 T C 8.57E-06 Height / / pha003011 rs415025 chr6 24942506 T C 2.46E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs415025 chr6 24942506 T C 1.84E-05 Lung function (forced vital capacity) / / pha003104 rs644748 chr6 24943775 C T 1.18E-06 Height / / pha003010 rs644748 chr6 24943775 C T 2.69E-05 Height / / pha003011 rs644748 chr6 24943775 C T 5.19E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs644748 chr6 24943775 C T 7.80E-05 Lung function (forced vital capacity) / / pha003104 rs421817 chr6 24943900 G A 1.18E-06 Height / / pha003010 rs421817 chr6 24943900 G A 3.23E-05 Height / / pha003011 rs421817 chr6 24943900 G A 5.19E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs421817 chr6 24943900 G A 7.80E-05 Lung function (forced vital capacity) / / pha003104 rs16889835 chr6 24947772 C T 4.49E-06 Squamous cell carcinoma / / 23341777 rs680009 chr6 24950829 A G 8.20E-08 Rheumatoid arthritis / / 19503088 rs11752037 chr6 24953195 G A 0.0007613 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11752037 chr6 24953195 G A 7.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs621948 chr6 24958935 G T 8.14E-04 Smoking initiation / / 24665060 rs401671 chr6 24960647 C T 7.43E-04 Smoking initiation / / 24665060 rs401671 chr6 24960647 C T 7.55E-05 Triglycerides / / pha002904 rs391652 chr6 24963255 G A 1.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs365630 chr6 24967115 G T 8.72E-04 Multiple complex diseases / / 17554300 rs400592 chr6 24967294 C G 5.00E-05 Nephrolithiasis / / 21283782 rs7773555 chr6 24979164 T A 7.00E-05 Nephrolithiasis / / 21283782 rs7773555 chr6 24979164 T A 9.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7773555 chr6 24979164 T A 5.33E-05 Smoking initiation / / 24665060 rs9467373 chr6 24981223 T C 9.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13209866 chr6 24986330 A G 8.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs9379703 chr6 24992226 T C 2.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs1410689 chr6 25006785 A G 5.49E-05 Height / / pha003010 rs10946741 chr6 25010999 G A 9.00E-05 Nephrolithiasis / / 21283782 rs441342 chr6 25023189 T C 3.17E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9393607 chr6 25023253 A G 6.65E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs303031 chr6 25036980 A G 2.93E-05 Alzheimer's disease (late onset) / / 21379329 rs303031 chr6 25036980 A G 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs950877 chr6 25070377 G C 5.17E-07 Multiple complex diseases / / 17554300 rs303010 chr6 25082105 T C 1.25E-04 Multiple complex diseases / / 17554300 rs12197057 chr6 25082262 T G 9.34E-04 Multiple complex diseases CMAHP intron 17554300 rs9461103 chr6 25099116 G A 2.98E-05 Multiple complex diseases CMAHP intron 17554300 rs7774557 chr6 25106663 G A 1.31E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs16890104 chr6 25114809 T G 2.33E-10 Lymphocyte counts CMAHP intron 22286170 rs916539 chr6 25122715 G T 3.99E-04 Lung function (forced expiratory volume in 1 second) CMAHP intron 17255346 rs302971 chr6 25122737 G A 9.13E-05 Coronary heart disease CMAHP intron 21971053 rs303020 chr6 25137516 G C 7.39E-09 Multiple complex diseases CMAHP intron 17554300 rs9379723 chr6 25145712 C T 8.69E-04 Suicide attempts in bipolar disorder / / 21041247 rs12663706 chr6 25148966 C G 1.70E-04 Suicide attempts in bipolar disorder / / 21041247 rs6941417 chr6 25152674 G A 5.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs11752102 chr6 25154396 A G 5.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs1900554 chr6 25157617 T C 4.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs16890179 chr6 25169786 T C 5.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs6910965 chr6 25172034 C G 1.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs13198274 chr6 25178990 A C 6.65E-07 Red blood cell traits / / 23222517 rs6938383 chr6 25185361 T G 6.82E-08 Red blood cell traits / / 23222517 rs4711080 chr6 25189192 A C 2.30E-07 Red blood cell traits / / 23222517 rs4144129 chr6 25193064 A G 3.44E-05 Coronary heart disease / / pha003035 rs1815096 chr6 25200468 A T 1.78E-04 Multiple complex diseases / / 17554300 rs2876687 chr6 25212558 C T 3.20E-06 Urinary metabolites / / 21572414 rs2328869 chr6 25216159 T C 3.91E-05 Alzheimer's disease (late onset) / / 21379329 rs2328869 chr6 25216159 T C 3.73E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6939460 chr6 25219205 C T 0.0004135 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6939460 chr6 25219205 C T 4.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6939764 chr6 25219230 G A 0.0004461 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6939764 chr6 25219230 G A 4.46E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs77006546 chr6 25219582 T C 9.60E-06 Post-traumatic stress disorder / / 24677629 rs1996971 chr6 25222058 A C 0.0004488 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1996971 chr6 25222058 A C 4.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9467445 chr6 25234884 A G 1.30E-05 Urinary metabolites / / 21572414 rs2064207 chr6 25239809 T C 1.10E-05 Urinary metabolites / / 21572414 rs2690121 chr6 25255277 G C 4.48E-04 Multiple complex diseases / / 17554300 rs2690121 chr6 25255277 G C 4.79E-04 Schizophrenia / / 21926974 rs9379751 chr6 25292214 G A 9.48E-05 Receptive language ability LRRC16A intron 24687471 rs1883393 chr6 25297497 T G 4.01E-04 Intracranial aneurysm LRRC16A intron 20613766 rs2690129 chr6 25297658 A C,T 5.07E-05 Platelet counts LRRC16A intron 23263863 rs6938281 chr6 25312488 A G 4.54E-05 Educational attainment LRRC16A intron 21694764 rs7759796 chr6 25322301 C T 2.69E-15 Red blood cell traits LRRC16A intron 23222517 rs7764111 chr6 25322759 A C 1.96E-13 Red blood cell traits LRRC16A intron 23222517 rs9366617 chr6 25327270 T C 5.69E-07 Red blood cell traits LRRC16A intron 23222517 rs17678510 chr6 25327853 A G 4.92E-04 Smoking initiation LRRC16A intron 24665060 rs9295655 chr6 25328153 C T 3.62E-12 Red blood cell traits LRRC16A intron 23222517 rs2690107 chr6 25330538 T C 7.82E-09 Red blood cell traits LRRC16A intron 23222517 rs7769912 chr6 25331237 A G 9.33E-17 Red blood cell traits LRRC16A intron 23222517 rs7770388 chr6 25331472 A C 4.46E-13 Red blood cell traits LRRC16A intron 23222517 rs7746360 chr6 25331928 C G 7.96E-07 Red blood cell traits LRRC16A intron 23222517 rs12192951 chr6 25332605 C T 9.08E-13 Red blood cell traits LRRC16A intron 23222517 rs12207748 chr6 25332910 A G 2.16E-07 Red blood cell traits LRRC16A intron 23222517 rs5009712 chr6 25333071 G A 6.76E-10 Red blood cell traits LRRC16A intron 23222517 rs5009711 chr6 25333090 C T 1.19E-12 Red blood cell traits LRRC16A intron 23222517 rs10456321 chr6 25334038 T C 6.24E-13 Red blood cell traits LRRC16A intron 23222517 rs7762537 chr6 25334967 A C 2.05E-07 Red blood cell traits LRRC16A intron 23222517 rs2690078 chr6 25336567 T G 7.66E-08 Red blood cell traits LRRC16A intron 23222517 rs115178932 chr6 25337838 G A 0.0000507 Menopause (age at onset) LRRC16A intron 23424626 rs9379759 chr6 25343823 T C 4.00E-04 Acute lymphoblastic leukemia (childhood) LRRC16A intron 20189245 rs2690097 chr6 25346742 T C 4.80E-08 Red blood cell traits LRRC16A intron 23222517 rs6456671 chr6 25347646 T G 5.18E-20 Red blood cell traits LRRC16A intron 23222517 rs11491476 chr6 25351263 G C 7.70E-11 Multiple complex diseases LRRC16A intron 17554300 rs16890454 chr6 25352244 C T 4.63E-11 Multiple complex diseases LRRC16A intron 17554300 rs11967836 chr6 25352637 T C 1.24E-20 Red blood cell traits LRRC16A intron 23222517 rs2744236 chr6 25353374 A G 3.00E-04 Acute lymphoblastic leukemia (childhood) LRRC16A intron 20189245 rs1883392 chr6 25354122 G T 5.84E-07 Red blood cell traits LRRC16A intron 23222517 rs7748771 chr6 25355099 A G 5.82E-07 Red blood cell traits LRRC16A intron 23222517 rs11759648 chr6 25359637 C G 2.40E-05 Urinary metabolites LRRC16A intron 21572414 rs10946764 chr6 25361014 C G 7.00E-04 Acute lymphoblastic leukemia (childhood) LRRC16A intron 20189245 rs10456044 chr6 25367710 G C,T 1.00E-04 Cognitive impairment induced by topiramate LRRC16A intron 22091778 rs9467476 chr6 25368978 T G 3.63E-05 Parent of origin effect on language impairment (child trend) LRRC16A intron 24571439 rs9467477 chr6 25370066 T A 3.91E-08 Other erythrocyte phenotypes LRRC16A intron 19862010 rs9467477 chr6 25370066 T A 3.36E-09 Red blood cell traits LRRC16A intron 23222517 rs9467478 chr6 25370970 T G 4.60E-08 Red blood cell traits LRRC16A intron 23222517 rs9461146 chr6 25371044 C T 3.41E-16 Red blood cell traits LRRC16A intron 23222517 rs9461147 chr6 25371177 C T 3.33E-07 Red blood cell traits LRRC16A intron 23222517 rs1927695 chr6 25378113 A G 5.61E-07 Red blood cell traits LRRC16A intron 23222517 rs9461149 chr6 25383401 C G 8.16E-08 Red blood cell traits LRRC16A intron 23222517 rs9467481 chr6 25383435 T G 3.70E-09 Red blood cell traits LRRC16A intron 23222517 rs215010 chr6 25385648 A G 1.77E-08 Red blood cell traits LRRC16A intron 23222517 rs10946767 chr6 25387664 G C 9.72E-13 Red blood cell traits LRRC16A intron 23222517 rs12529416 chr6 25388089 C T 1.03E-13 Red blood cell traits LRRC16A intron 23222517 rs4711083 chr6 25391947 C T 3.81E-16 Red blood cell traits LRRC16A intron 23222517 rs10498723 chr6 25392345 A G 2.78E-12 Red blood cell traits LRRC16A intron 23222517 rs10498724 chr6 25392371 A G 8.48E-16 Red blood cell traits LRRC16A intron 23222517 rs716797 chr6 25393306 G A 1.19E-07 Red blood cell traits LRRC16A intron 23222517 rs17316893 chr6 25394439 C T 4.96E-08 Other erythrocyte phenotypes LRRC16A intron 19862010 rs17316893 chr6 25394439 C T 1.72E-18 Red blood cell traits LRRC16A intron 23222517 rs7751391 chr6 25394462 T C 1.22E-18 Red blood cell traits LRRC16A intron 23222517 rs2149228 chr6 25394673 A T 4.38E-16 Red blood cell traits LRRC16A intron 23222517 rs2328880 chr6 25394841 A G 7.01E-07 Red blood cell traits LRRC16A intron 23222517 rs2328882 chr6 25395277 T C 2.24E-18 Red blood cell traits LRRC16A intron 23222517 rs1328264 chr6 25396181 G A 6.10E-08 Red blood cell traits LRRC16A intron 23222517 rs12524380 chr6 25396890 G A 3.56E-19 Red blood cell traits LRRC16A intron 23222517 rs2182931 chr6 25397246 G A 1.04E-07 Red blood cell traits LRRC16A intron 23222517 rs2149227 chr6 25397289 T C 2.40E-07 Red blood cell traits LRRC16A intron 23222517 rs2149226 chr6 25397449 C A 4.17E-19 Red blood cell traits LRRC16A intron 23222517 rs17251430 chr6 25398003 A G 4.84E-08 Other erythrocyte phenotypes LRRC16A intron 19862010 rs17251430 chr6 25398003 A G 1.44E-19 Red blood cell traits LRRC16A intron 23222517 rs985984 chr6 25402179 C G 1.18E-08 Other erythrocyte phenotypes LRRC16A intron 19862010 rs985984 chr6 25402179 C G 2.98E-20 Red blood cell traits LRRC16A intron 23222517 rs4712930 chr6 25403707 A G 6.03E-17 Red blood cell traits LRRC16A intron 23222517 rs12173289 chr6 25407778 A G 1.20E-06 Nephrolithiasis LRRC16A intron 21283782 rs6912426 chr6 25409785 G A 5.05E-04 HIV-1 viral setpoint LRRC16A intron 17641165 rs6912426 chr6 25409785 G A 1.00E-05 Nephrolithiasis LRRC16A intron 21283782 rs9379762 chr6 25411414 G A 5.88E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LRRC16A intron 20031582 rs1543603 chr6 25413922 A G 1.60E-05 Multiple sclerosis (brain glutamate levels) LRRC16A intron 20802204 rs9467504 chr6 25414325 A G 1.47E-07 Stroke LRRC16A intron 22306652 rs12206709 chr6 25415117 C A 8.63E-12 Red blood cell traits LRRC16A intron 23222517 rs7752195 chr6 25419094 T C 1.01E-07 Multiple complex diseases LRRC16A intron 17554300 rs9295657 chr6 25419318 A G 2.63E-05 Multiple complex diseases LRRC16A intron 17554300 rs2076890 chr6 25420744 G T 1.43E-10 Coronary heart disease LRRC16A intron 21971053 rs2076890 chr6 25420744 G T 1.33E-10 Red blood cell traits LRRC16A intron 23222517 rs11968423 chr6 25422353 C T 4.05E-06 Multiple sclerosis LRRC16A intron 17660530 rs12153885 chr6 25424003 T A 4.82E-11 Red blood cell traits LRRC16A intron 23222517 rs7774567 chr6 25425526 A G 7.72E-08 Multiple complex diseases LRRC16A intron 17554300 rs7774567 chr6 25425526 A G 1.50E-04 Systemic lupus erythematosus LRRC16A intron 24871463 rs969645 chr6 25426858 T G 4.87E-08 Red blood cell traits LRRC16A intron 23222517 rs969645 chr6 25426858 T G 0.0003252 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LRRC16A intron 23233654 rs969645 chr6 25426858 T G 3.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) LRRC16A intron 23233662 rs6456681 chr6 25429762 T C 7.62E-04 Suicide attempts in bipolar disorder LRRC16A intron 21423239 rs1028885 chr6 25434518 G A 6.06E-04 Suicide attempts in bipolar disorder LRRC16A intron 21423239 rs9467515 chr6 25435758 A G 4.27E-09 Red blood cell traits LRRC16A cds-synon 23222517 rs6900224 chr6 25437986 C T 7.08E-04 Suicide attempts in bipolar disorder LRRC16A intron 21423239 rs6900224 chr6 25437986 C T 3.72E-05 Schizophrenia LRRC16A intron 21926974 rs6900224 chr6 25437986 C T 1.68E-08 Red blood cell traits LRRC16A intron 23222517 rs6900224 chr6 25437986 C T 0.0008015 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LRRC16A intron 23233654 rs6900224 chr6 25437986 C T 8.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) LRRC16A intron 23233662 rs6900224 chr6 25437986 C T 8.10E-05 Erythrocyte counts LRRC16A intron pha003090 rs9295661 chr6 25450026 C A 1.90E-08 Multiple complex diseases LRRC16A intron 17554300 rs10498725 chr6 25455015 C T 5.32E-06 Iron status biomarkers LRRC16A intron 19084217 rs10498725 chr6 25455015 C T 1.33E-08 Other erythrocyte phenotypes LRRC16A intron 19862010 rs10498725 chr6 25455015 C T 8.65E-07 Coronary heart disease LRRC16A intron 21971053 rs10498725 chr6 25455015 C T 5.66E-21 Red blood cell traits LRRC16A intron 23222517 rs41368745 chr6 25457788 C T 9.80E-04 Multiple complex diseases LRRC16A intron 17554300 rs4320355 chr6 25462824 T C 3.61E-04 Common variable immunodeficiency LRRC16A intron 21497890 rs16890640 chr6 25469331 T A 2.32E-07 Red blood cell traits LRRC16A intron 23222517 rs4712943 chr6 25484295 T G 3.10E-07 Red blood cell traits LRRC16A intron 23222517 rs301395 chr6 25486626 C A 3.10E-07 Urate levels LRRC16A intron 20884846 rs301395 chr6 25486626 C A 7.76E-17 Urate levels LRRC16A intron 23263486 rs9295663 chr6 25486800 T C 5.99E-06 Lung adenocarcinoma LRRC16A intron 19836008 rs4712944 chr6 25488265 C A 2.70E-07 Urate levels LRRC16A intron 20884846 rs4712944 chr6 25488265 C A 5.23E-07 Red blood cell traits LRRC16A intron 23222517 rs4712944 chr6 25488265 C A 1.24E-16 Urate levels LRRC16A intron 23263486 rs2274089 chr6 25488583 C T 3.00E-07 Iron status biomarkers LRRC16A intron 19084217 rs2274089 chr6 25488583 C T 5.00E-06 Iron status biomarkers LRRC16A intron 19084217 rs2274089 chr6 25488583 C T 8.00E-07 Iron status biomarkers LRRC16A intron 19084217 rs2274089 chr6 25488583 C T 4.38E-09 Other erythrocyte phenotypes LRRC16A intron 19862010 rs2274089 chr6 25488583 C T 0.000000001 Mean corpuscular hemoglobin LRRC16A intron 22560525 rs2274089 chr6 25488583 C T 0.000000006 Mean corpuscular volume LRRC16A intron 22560525 rs2274089 chr6 25488583 C T 1.26E-30 Red blood cell traits LRRC16A intron 23222517 rs12528639 chr6 25491807 C G 1.50E-07 Urate levels LRRC16A intron 20884846 rs12528639 chr6 25491807 C G 8.08E-07 Red blood cell traits LRRC16A intron 23222517 rs12528639 chr6 25491807 C G 1.93E-15 Urate levels LRRC16A intron 23263486 rs1034050 chr6 25492364 A G 1.30E-07 Urate levels LRRC16A intron 20884846 rs1034050 chr6 25492364 A G 5.47E-08 Red blood cell traits LRRC16A intron 23222517 rs1034050 chr6 25492364 A G 1.34E-17 Urate levels LRRC16A intron 23263486 rs17318575 chr6 25493238 C G 8.24E-11 Other erythrocyte phenotypes LRRC16A intron 19862010 rs17318575 chr6 25493238 C G 6.72E-33 Red blood cell traits LRRC16A intron 23222517 rs12526321 chr6 25494503 A G 2.04E-08 Red blood cell traits LRRC16A intron 23222517 rs12526321 chr6 25494503 A G 1.51E-10 Urate levels LRRC16A intron 23263486 rs17252870 chr6 25494666 G T 2.36E-08 Red blood cell traits LRRC16A intron 23222517 rs17252870 chr6 25494666 G T 4.42E-11 Urate levels LRRC16A intron 23263486 rs301393 chr6 25500709 T G 3.77E-08 Red blood cell traits LRRC16A intron 23222517 rs301393 chr6 25500709 T G 1.47E-10 Urate levels LRRC16A intron 23263486 rs17253044 chr6 25503735 C T 3.11E-08 Red blood cell traits LRRC16A intron 23222517 rs17253044 chr6 25503735 C T 6.87E-11 Urate levels LRRC16A intron 23263486 rs407934 chr6 25504562 C T 1.02E-04 Coronary heart disease LRRC16A intron 21971053 rs407934 chr6 25504562 C T 2.52E-07 Red blood cell traits LRRC16A intron 23222517 rs407934 chr6 25504562 C T 6.45E-09 Urate levels LRRC16A intron 23263486 rs1747568 chr6 25506072 T G 9.11E-04 Multiple complex diseases LRRC16A intron 17554300 rs1747568 chr6 25506072 T G 3.44E-08 Urate levels LRRC16A intron 23263486 rs572657 chr6 25513147 T C 4.57E-08 Urate levels LRRC16A intron 23263486 rs1408280 chr6 25513240 C T 4.66E-08 Urate levels LRRC16A intron 23263486 rs1830798 chr6 25513276 G A 4.61E-08 Urate levels LRRC16A intron 23263486 rs301390 chr6 25514216 A C 3.61E-08 Urate levels LRRC16A intron 23263486 rs301383 chr6 25515234 G A 4.46E-08 Urate levels LRRC16A intron 23263486 rs301382 chr6 25515450 C A 4.34E-08 Urate levels LRRC16A intron 23263486 rs301381 chr6 25515576 T A 4.05E-08 Urate levels LRRC16A intron 23263486 rs16890706 chr6 25520094 G A 2.50E-05 Urinary metabolites LRRC16A intron 21572414 rs184202 chr6 25520125 G A 9.95E-05 Kawasaki disease LRRC16A intron 22446961 rs212938 chr6 25522443 A G 2.69E-04 Acute lung injury LRRC16A intron 22295056 rs212941 chr6 25526702 T C 2.56E-04 Acute lung injury LRRC16A intron 22295056 rs391629 chr6 25529649 A G 2.56E-04 Acute lung injury LRRC16A intron 22295056 rs12526480 chr6 25533534 T G 9.00E-09 Mean platelet volume LRRC16A intron 22423221 rs150551 chr6 25533930 A G 2.13E-08 Uric acid levels LRRC16A intron 19503597 rs150551 chr6 25533930 A G 2.62E-08 Red blood cell traits LRRC16A intron 23222517 rs150551 chr6 25533930 A G 2.31E-08 Urate levels LRRC16A intron 23263486 rs212930 chr6 25535636 A G 2.44E-04 Acute lung injury LRRC16A intron 22295056 rs212936 chr6 25538860 C A 2.68E-04 Acute lung injury LRRC16A intron 22295056 rs969297 chr6 25543639 G A 2.61E-04 Acute lung injury LRRC16A intron 22295056 rs969297 chr6 25543639 G A 7.68E-07 Red blood cell traits LRRC16A intron 23222517 rs969297 chr6 25543639 G A 4.52E-60 Urate levels LRRC16A intron 23263486 rs441460 chr6 25548288 G A 9.00E-18 Platelet counts LRRC16A intron 22139419 rs2064128 chr6 25550139 A G 3.03E-12 Red blood cell traits LRRC16A intron 23222517 rs2064128 chr6 25550139 A G 1.66E-10 Urate levels LRRC16A intron 23263486 rs169946 chr6 25552143 G C 3.02E-04 Acute lung injury LRRC16A intron 22295056 rs169946 chr6 25552143 G C 9.00E-07 Red blood cell traits LRRC16A intron 23222517 rs169946 chr6 25552143 G C 4.39E-08 Urate levels LRRC16A intron 23263486 rs3804133 chr6 25552868 C T 5.28E-12 Red blood cell traits LRRC16A intron 23222517 rs3804133 chr6 25552868 C T 3.10E-10 Urate levels LRRC16A intron 23263486 rs214049 chr6 25554180 C G 3.02E-04 Acute lung injury LRRC16A intron 22295056 rs214050 chr6 25556249 G A 3.02E-04 Acute lung injury LRRC16A intron 22295056 rs214050 chr6 25556249 G A 9.18E-07 Red blood cell traits LRRC16A intron 23222517 rs214055 chr6 25560264 C T 5.53E-11 Red blood cell traits LRRC16A intron 23222517 rs214055 chr6 25560264 C T 2.33E-10 Urate levels LRRC16A intron 23263486 rs214066 chr6 25566528 A G 2.40E-05 Urinary metabolites LRRC16A intron 21572414 rs214066 chr6 25566528 A G 2.80E-04 Acute lung injury LRRC16A intron 22295056 rs4576241 chr6 25572082 C G 2.92E-04 Acute lung injury LRRC16A intron 22295056 rs9358860 chr6 25572245 A G 7.36E-07 Red blood cell traits LRRC16A intron 23222517 rs9379772 chr6 25573168 A C 2.50E-05 Urinary metabolites LRRC16A intron 21572414 rs926326 chr6 25575402 A G 3.40E-04 Acute lung injury LRRC16A intron 22295056 rs10434845 chr6 25582757 C G 4.99E-08 Other erythrocyte phenotypes LRRC16A intron 19862010 rs10434845 chr6 25582757 C G 8.08E-07 Red blood cell traits LRRC16A intron 23222517 rs13203202 chr6 25582771 T C 2.03E-08 Red blood cell traits LRRC16A intron 23222517 rs2328879 chr6 25583103 C T 1.10E-05 Urinary metabolites LRRC16A intron 21572414 rs2328879 chr6 25583103 C T 0.00000001 Mean corpuscular volume LRRC16A intron 22560525 rs2328879 chr6 25583103 C T 1.14E-07 Red blood cell traits LRRC16A intron 23222517 rs3788994 chr6 25587836 C A 1.52E-09 Red blood cell traits LRRC16A intron 23222517 rs3788994 chr6 25587836 C A 6.27E-11 Urate levels LRRC16A intron 23263486 rs13212936 chr6 25588815 C T 2.37E-08 Urate levels LRRC16A intron 23263486 rs1028318 chr6 25590224 T C 1.40E-08 Uric acid levels LRRC16A intron 19503597 rs1028318 chr6 25590224 T C 2.79E-07 Red blood cell traits LRRC16A intron 23222517 rs1028318 chr6 25590224 T C 9.47E-09 Urate levels LRRC16A intron 23263486 rs17492120 chr6 25590311 C T 3.75E-12 Other erythrocyte phenotypes LRRC16A intron 19862010 rs17492120 chr6 25590311 C T 2.68E-08 Red blood cell traits LRRC16A intron 23222517 rs9348687 chr6 25592489 A G 2.96E-19 Red blood cell traits LRRC16A intron 23222517 rs6903257 chr6 25600191 T C 3.38E-04 Acute lung injury LRRC16A intron 22295056 rs6903257 chr6 25600191 T C 4.46E-07 Red blood cell traits LRRC16A intron 23222517 rs3804114 chr6 25602604 C T 1.88E-07 Red blood cell traits LRRC16A intron 23222517 rs3804112 chr6 25602775 T C 3.25E-08 Red blood cell traits LRRC16A intron 23222517 rs1012898 chr6 25604715 G A 6.42E-07 Red blood cell traits LRRC16A intron 23222517 rs7740510 chr6 25605512 T C 2.55E-07 Red blood cell traits LRRC16A intron 23222517 rs2077393 chr6 25607365 C T 1.32E-08 Uric acid levels LRRC16A intron 19503597 rs2077393 chr6 25607365 C T 9.96E-07 Red blood cell traits LRRC16A intron 23222517 rs742132 chr6 25607571 A G 9.00E-09 Uric acid levels LRRC16A intron 19503597 rs742132 chr6 25607571 A G 7.84E-08 Red blood cell traits LRRC16A intron 23222517 rs742132 chr6 25607571 A G 1.90E-08 Urate levels LRRC16A intron 23263486 rs6903765 chr6 25609738 A G 1.55E-08 Uric acid levels LRRC16A intron 19503597 rs6903765 chr6 25609738 A G 3.42E-08 Red blood cell traits LRRC16A intron 23222517 rs6903765 chr6 25609738 A G 1.92E-08 Urate levels LRRC16A intron 23263486 rs6908390 chr6 25609756 C T 1.83E-08 Uric acid levels LRRC16A intron 19503597 rs6908390 chr6 25609756 C T 2.37E-08 Red blood cell traits LRRC16A intron 23222517 rs6908390 chr6 25609756 C T 2.75E-08 Urate levels LRRC16A intron 23263486 rs3804105 chr6 25612683 A C 1.53E-08 Uric acid levels LRRC16A intron 19503597 rs3804105 chr6 25612683 A C 3.23E-08 Red blood cell traits LRRC16A intron 23222517 rs3804105 chr6 25612683 A C 2.42E-08 Urate levels LRRC16A intron 23263486 rs10946785 chr6 25617068 G T 1.98E-08 Uric acid levels LRRC16A intron 19503597 rs10946785 chr6 25617068 G T 3.40E-08 Red blood cell traits LRRC16A intron 23222517 rs10946785 chr6 25617068 G T 2.68E-08 Urate levels LRRC16A intron 23263486 rs3804103 chr6 25617291 G A 1.42E-11 Other erythrocyte phenotypes LRRC16A intron 19862010 rs3804103 chr6 25617291 G A 0.00000001 Mean corpuscular hemoglobin LRRC16A intron 22560525 rs3804103 chr6 25617291 G A 1.06E-08 Red blood cell traits LRRC16A intron 23222517 rs1997672 chr6 25617544 T G 2.00E-08 Uric acid levels LRRC16A intron 19503597 rs1997672 chr6 25617544 T G 5.06E-08 Red blood cell traits LRRC16A intron 23222517 rs1997672 chr6 25617544 T G 3.20E-08 Urate levels LRRC16A intron 23263486 rs7761700 chr6 25618191 G C 1.89E-08 Uric acid levels LRRC16A intron 19503597 rs7761700 chr6 25618191 G C 3.94E-08 Red blood cell traits LRRC16A intron 23222517 rs7761700 chr6 25618191 G C 2.79E-08 Urate levels LRRC16A intron 23263486 rs2281070 chr6 25622116 C T 6.54E-08 Red blood cell traits / / 23222517 rs2281070 chr6 25622116 C T 1.60E-08 Urate levels / / 23263486 rs7765813 chr6 25624395 G T 1.51E-13 Other erythrocyte phenotypes / / 19862010 rs7765813 chr6 25624395 G T 1.51E-11 Red blood cell traits / / 23222517 rs12183240 chr6 25624416 G A 8.13E-08 Red blood cell traits / / 23222517 rs12183240 chr6 25624416 G A 2.07E-08 Urate levels / / 23263486 rs12201186 chr6 25625595 A C 1.77E-07 Red blood cell traits / / 23222517 rs12201186 chr6 25625595 A C 2.65E-08 Urate levels / / 23263486 rs6456685 chr6 25626549 T C 9.52E-04 Acute lung injury / / 22295056 rs6456685 chr6 25626549 T C 3.27E-07 Red blood cell traits / / 23222517 rs4383809 chr6 25626967 T C 9.41E-04 Acute lung injury / / 22295056 rs4383809 chr6 25626967 T C 3.75E-07 Red blood cell traits / / 23222517 rs10223506 chr6 25627216 T G 7.26E-08 Red blood cell traits / / 23222517 rs10223506 chr6 25627216 T G 2.41E-08 Urate levels / / 23263486 rs990850 chr6 25628511 G A 1.65E-13 Other erythrocyte phenotypes / / 19862010 rs990850 chr6 25628511 G A 1.77E-08 Red blood cell traits / / 23222517 rs9467538 chr6 25628688 G A 4.38E-08 Red blood cell traits / / 23222517 rs9467538 chr6 25628688 G A 2.62E-08 Urate levels / / 23263486 rs2223323 chr6 25628852 T A 5.61E-08 Red blood cell traits / / 23222517 rs2223323 chr6 25628852 T A 2.71E-08 Urate levels / / 23263486 rs2205933 chr6 25628924 C A 5.47E-08 Red blood cell traits / / 23222517 rs2205933 chr6 25628924 C A 2.73E-08 Urate levels / / 23263486 rs1980449 chr6 25629658 T C 5.87E-10 Urate levels / / 23263486 rs1980450 chr6 25629747 A G 4.39E-07 Red blood cell traits / / 23222517 rs1980450 chr6 25629747 A G 5.00E-08 Urate levels / / 23263486 rs1980451 chr6 25630091 G A 6.52E-08 Red blood cell traits / / 23222517 rs1980451 chr6 25630091 G A 2.77E-08 Urate levels / / 23263486 rs1980452 chr6 25630136 T C 4.79E-08 Red blood cell traits / / 23222517 rs1980452 chr6 25630136 T C 3.18E-08 Urate levels / / 23263486 rs9467541 chr6 25630549 C T 1.64E-08 Red blood cell traits / / 23222517 rs9467541 chr6 25630549 C T 3.11E-08 Urate levels / / 23263486 rs9467542 chr6 25631053 G C 1.26E-07 Red blood cell traits / / 23222517 rs2072844 chr6 25632041 G A 3.60E-08 Red blood cell traits / / 23222517 rs2072844 chr6 25632041 G A 4.20E-08 Urate levels / / 23263486 rs1321251 chr6 25632751 A G 3.76E-08 Red blood cell traits / / 23222517 rs4140641 chr6 25635400 C T 2.41E-11 Red blood cell traits / / 23222517 rs4140641 chr6 25635400 C T 2.10E-10 Urate levels / / 23263486 rs16890878 chr6 25636915 T C 7.82E-08 Red blood cell traits / / 23222517 rs1406926 chr6 25637117 A G 7.66E-08 Red blood cell traits / / 23222517 rs1406925 chr6 25637468 C T 1.71E-07 Red blood cell traits / / 23222517 rs7774036 chr6 25638211 A G 3.15E-08 Red blood cell traits / / 23222517 rs714563 chr6 25640166 C T 2.86E-08 Red blood cell traits / / 23222517 rs932316 chr6 25641200 T C 9.00E-06 Iron status biomarkers / / 19084217 rs932316 chr6 25641200 T C 2.09E-09 Other erythrocyte phenotypes / / 19862010 rs932316 chr6 25641200 T C 6.00E-11 Mean corpuscular hemoglobin / / 22560525 rs932316 chr6 25641200 T C 6.00E-11 Mean corpuscular volume / / 22560525 rs932316 chr6 25641200 T C 2.06E-08 Red blood cell traits / / 23222517 rs6456687 chr6 25641636 A T 2.73E-08 Red blood cell traits / / 23222517 rs10447387 chr6 25642100 A G 1.45E-07 Red blood cell traits / / 23222517 rs4712949 chr6 25644203 C T 6.19E-09 Red blood cell traits / / 23222517 rs909663 chr6 25645314 A C 3.09E-08 Red blood cell traits / / 23222517 rs876239 chr6 25645362 C T 2.15E-07 Red blood cell traits / / 23222517 rs909665 chr6 25646145 G A 1.40E-07 Red blood cell traits / / 23222517 rs1923027 chr6 25647354 A T 2.74E-11 Other erythrocyte phenotypes / / 19862010 rs1923027 chr6 25647354 A T 2.55E-26 Red blood cell traits / / 23222517 rs2328890 chr6 25647572 G A 1.09E-07 Red blood cell traits / / 23222517 rs11969981 chr6 25650817 T A 1.41E-09 Red blood cell traits / / 23222517 rs11969981 chr6 25650817 T A 1.02E-09 Urate levels / / 23263486 rs12528182 chr6 25651197 C G 1.72E-08 Red blood cell traits / / 23222517 rs12528182 chr6 25651197 C G 4.51E-08 Urate levels / / 23263486 rs12524760 chr6 25651263 A G 1.80E-08 Red blood cell traits / / 23222517 rs12524760 chr6 25651263 A G 4.70E-08 Urate levels / / 23263486 rs4140640 chr6 25651650 C G 1.83E-08 Red blood cell traits / / 23222517 rs4140640 chr6 25651650 C G 4.76E-08 Urate levels / / 23263486 rs2294344 chr6 25652225 C A 9.35E-09 Red blood cell traits / / 23222517 rs2294344 chr6 25652225 C A 1.47E-09 Urate levels / / 23263486 rs9467550 chr6 25653401 A G 9.10E-14 Other erythrocyte phenotypes SCGN intron 19862010 rs9467550 chr6 25653401 A G 2.95E-07 Red blood cell traits SCGN intron 23222517 rs1406927 chr6 25653842 T G 1.68E-07 Red blood cell traits SCGN intron 23222517 rs1884575 chr6 25654089 C G 7.24E-05 Kawasaki disease SCGN intron 22446961 rs2072846 chr6 25655104 T C 9.92E-08 Red blood cell traits SCGN intron 23222517 rs2072846 chr6 25655104 T C 4.96E-08 Urate levels SCGN intron 23263486 rs10484591 chr6 25656661 C G 1.38E-08 Red blood cell traits SCGN intron 23222517 rs10484591 chr6 25656661 C G 3.24E-08 Urate levels SCGN intron 23263486 rs2011472 chr6 25657463 A C 3.97E-08 Red blood cell traits SCGN intron 23222517 rs4712950 chr6 25657590 A G 1.78E-10 Red blood cell traits SCGN intron 23222517 rs4712950 chr6 25657590 A G 2.68E-10 Urate levels SCGN intron 23263486 rs1003688 chr6 25659172 G A 1.73E-11 Other erythrocyte phenotypes SCGN intron 19862010 rs1003688 chr6 25659172 G A 1.12E-07 Red blood cell traits SCGN intron 23222517 rs9467552 chr6 25659219 G A 7.40E-08 Red blood cell traits SCGN intron 23222517 rs9461189 chr6 25661064 G A 9.57E-08 Red blood cell traits SCGN intron 23222517 rs2072847 chr6 25661887 A T 1.41E-08 Red blood cell traits SCGN intron 23222517 rs2072851 chr6 25662332 G C 1.15E-07 Red blood cell traits SCGN intron 23222517 rs7754155 chr6 25662686 G A 2.51E-07 Red blood cell traits SCGN intron 23222517 rs1321248 chr6 25662803 T C 3.20E-11 Other erythrocyte phenotypes SCGN intron 19862010 rs1321248 chr6 25662803 T C 2.01E-07 Red blood cell traits SCGN intron 23222517 rs1321247 chr6 25662873 A T 8.01E-14 Other erythrocyte phenotypes SCGN intron 19862010 rs1321247 chr6 25662873 A T 2.35E-07 Red blood cell traits SCGN intron 23222517 rs10946789 chr6 25663903 A G 2.01E-08 Red blood cell traits SCGN intron 23222517 rs9467556 chr6 25664185 T C 7.05E-11 Other erythrocyte phenotypes SCGN intron 19862010 rs9467556 chr6 25664185 T C 0.00000002 Mean corpuscular hemoglobin SCGN intron 22560525 rs9467556 chr6 25664185 T C 2.74E-07 Red blood cell traits SCGN intron 23222517 rs12529390 chr6 25664679 C T 1.95E-08 Red blood cell traits SCGN intron 23222517 rs9393654 chr6 25664981 T A 9.44E-08 Red blood cell traits SCGN intron 23222517 rs12213891 chr6 25665041 C T 1.19E-05 Triglycerides SCGN intron pha003081 rs12213891 chr6 25665041 C T 9.72E-05 Lipid levels SCGN intron pha003082 rs7775000 chr6 25666164 G A 1.50E-07 Red blood cell traits SCGN intron 23222517 rs12525376 chr6 25666684 T G 1.95E-07 Red blood cell traits SCGN intron 23222517 rs2064126 chr6 25669496 A G 2.45E-07 Red blood cell traits SCGN intron 23222517 rs2876691 chr6 25669525 G A 3.01E-11 Other erythrocyte phenotypes SCGN intron 19862010 rs2876691 chr6 25669525 G A 1.78E-07 Red blood cell traits SCGN intron 23222517 rs2064127 chr6 25669636 A T 4.44E-08 Red blood cell traits SCGN intron 23222517 rs2328891 chr6 25669669 G A 2.98E-11 Other erythrocyte phenotypes SCGN intron 19862010 rs2328891 chr6 25669669 G A 1.84E-07 Red blood cell traits SCGN intron 23222517 rs4712952 chr6 25670792 T C 1.31E-07 Red blood cell traits SCGN intron 23222517 rs4712953 chr6 25671846 A T 2.42E-08 Red blood cell traits SCGN intron 23222517 rs4712954 chr6 25671873 C T 2.69E-08 Red blood cell traits SCGN intron 23222517 rs2010291 chr6 25675764 T G 2.33E-08 Red blood cell traits SCGN intron 23222517 rs932319 chr6 25676114 T C 2.30E-08 Red blood cell traits SCGN intron 23222517 rs1074706 chr6 25676740 T C 2.51E-08 Red blood cell traits SCGN intron 23222517 rs6932536 chr6 25677315 G A 3.29E-08 Red blood cell traits SCGN intron 23222517 rs6900762 chr6 25679044 A G 2.64E-08 Red blood cell traits SCGN intron 23222517 rs2049968 chr6 25681753 G A 4.42E-08 Red blood cell traits SCGN intron 23222517 rs1883259 chr6 25683280 A C 2.30E-05 Urinary metabolites SCGN intron 21572414 rs1883259 chr6 25683280 A C 8.65E-09 Red blood cell traits SCGN intron 23222517 rs4712955 chr6 25684279 A G 1.66E-07 Red blood cell traits SCGN intron 23222517 rs4711092 chr6 25684405 T C 3.37E-12 Red blood cell traits SCGN intron 23222517 rs9348689 chr6 25684653 G T 9.70E-12 Other erythrocyte phenotypes SCGN intron 19862010 rs9348689 chr6 25684653 G T 1.36E-10 Red blood cell traits SCGN intron 23222517 rs2205936 chr6 25685492 G C 5.93E-10 Other erythrocyte phenotypes SCGN intron 19862010 rs2205936 chr6 25685492 G C 1.30E-09 Urate levels SCGN intron 20884846 rs2205936 chr6 25685492 G C 4.99E-14 Red blood cell traits SCGN intron 23222517 rs2205936 chr6 25685492 G C 6.22E-27 Urate levels SCGN intron 23263486 rs9366627 chr6 25686405 C T 5.91E-09 Red blood cell traits SCGN intron 23222517 rs9366627 chr6 25686405 C T 1.19E-11 Urate levels SCGN intron 23263486 rs9379778 chr6 25687579 T C 6.03E-08 Red blood cell traits SCGN intron 23222517 rs9379778 chr6 25687579 T C 1.56E-09 Urate levels SCGN intron 23263486 rs4711093 chr6 25687895 T C 5.27E-08 Red blood cell traits SCGN intron 23222517 rs4711093 chr6 25687895 T C 1.68E-09 Urate levels SCGN intron 23263486 rs74918542 chr6 25688046 T C 0.0000217 Menopause (age at onset) SCGN intron 23424626 rs2294346 chr6 25689487 G C 1.48E-09 Other erythrocyte phenotypes SCGN intron 19862010 rs2294346 chr6 25689487 G C 3.60E-10 Urate levels SCGN intron 20884846 rs2294346 chr6 25689487 G C 2.39E-14 Red blood cell traits SCGN intron 23222517 rs2294346 chr6 25689487 G C 5.63E-28 Urate levels SCGN intron 23263486 rs17492659 chr6 25691362 C T 6.60E-11 Red blood cell traits SCGN intron 23222517 rs17492659 chr6 25691362 C T 7.98E-15 Urate levels SCGN intron 23263486 rs4419666 chr6 25693274 C T 4.30E-10 Urate levels SCGN intron 20884846 rs4419666 chr6 25693274 C T 5.10E-07 Red blood cell traits SCGN intron 23222517 rs4419666 chr6 25693274 C T 2.66E-22 Urate levels SCGN intron 23263486 rs4409177 chr6 25694491 T G 1.80E-10 Urate levels SCGN intron 20884846 rs4409177 chr6 25694491 T G 1.41E-08 Red blood cell traits SCGN intron 23222517 rs4409177 chr6 25694491 T G 1.99E-21 Urate levels SCGN intron 23263486 rs3922681 chr6 25698481 C T 3.10E-10 Urate levels SCGN intron 23263486 rs9467570 chr6 25699283 C A 1.70E-10 Urate levels SCGN intron 20884846 rs9467570 chr6 25699283 C A 4.94E-08 Red blood cell traits SCGN intron 23222517 rs9467570 chr6 25699283 C A 9.52E-22 Urate levels SCGN intron 23263486 rs11794 chr6 25701718 G A 1.02E-07 Red blood cell traits SCGN UTR-3 23222517 rs11794 chr6 25701718 G A 1.19E-09 Urate levels SCGN UTR-3 23263486 rs6908713 chr6 25703611 G A 8.31E-08 Red blood cell traits / / 23222517 rs6908713 chr6 25703611 G A 9.35E-10 Urate levels / / 23263486 rs9467573 chr6 25704190 C A 1.60E-10 Urate levels / / 20884846 rs9467573 chr6 25704190 C A 2.98E-08 Red blood cell traits / / 23222517 rs9467573 chr6 25704190 C A 4.53E-23 Urate levels / / 23263486 rs9467574 chr6 25705718 C G 1.60E-10 Urate levels / / 20884846 rs9467574 chr6 25705718 C G 1.76E-08 Red blood cell traits / / 23222517 rs9467574 chr6 25705718 C G 3.49E-23 Urate levels / / 23263486 rs4711094 chr6 25706174 T A 1.38E-08 Urate levels / / 23263486 rs9379780 chr6 25707171 G A 3.02E-07 Schizophrenia / / 21926974 rs9379780 chr6 25707171 G A 0.00000378 Schizophrenia / / 23637625 rs4395714 chr6 25708714 G T 4.14E-10 Red blood cell traits / / 23222517 rs4395714 chr6 25708714 G T 2.06E-14 Urate levels / / 23263486 rs6456688 chr6 25708960 T C 7.20E-09 Urate levels / / 20884846 rs6456688 chr6 25708960 T C 3.31E-09 Red blood cell traits / / 23222517 rs6456688 chr6 25708960 T C 4.01E-21 Urate levels / / 23263486 rs6456693 chr6 25710087 C G 7.69E-09 Other erythrocyte phenotypes / / 19862010 rs6456693 chr6 25710087 C G 7.90E-11 Urate levels / / 20884846 rs6456693 chr6 25710087 C G 1.37E-08 Red blood cell traits / / 23222517 rs6456693 chr6 25710087 C G 1.74E-23 Urate levels / / 23263486 rs6912391 chr6 25710763 C G 1.21E-09 Other erythrocyte phenotypes / / 19862010 rs6912391 chr6 25710763 C G 5.40E-10 Urate levels / / 20884846 rs6912391 chr6 25710763 C G 2.13E-09 Red blood cell traits / / 23222517 rs6912391 chr6 25710763 C G 6.95E-25 Urate levels / / 23263486 rs6456694 chr6 25712894 G A 1.13E-08 Urate levels / / 23263486 rs4236036 chr6 25712985 G A 1.47E-11 Red blood cell traits / / 23222517 rs4236036 chr6 25712985 G A 9.32E-15 Urate levels / / 23263486 rs10946795 chr6 25714739 A G 5.09E-08 Red blood cell traits / / 23222517 rs9379782 chr6 25715023 G A 1.31E-07 Red blood cell traits / / 23222517 rs9379782 chr6 25715023 G A 5.79E-10 Urate levels / / 23263486 rs4132072 chr6 25717843 C T 1.16E-07 Red blood cell traits / / 23222517 rs4132072 chr6 25717843 C T 6.59E-10 Urate levels / / 23263486 rs9461204 chr6 25718466 A G 6.10E-11 Urate levels / / 20884846 rs9461204 chr6 25718466 A G 1.04E-08 Red blood cell traits / / 23222517 rs9461204 chr6 25718466 A G 5.96E-23 Urate levels / / 23263486 rs7450798 chr6 25719280 T A 1.29E-07 Red blood cell traits / / 23222517 rs7450798 chr6 25719280 T A 5.94E-10 Urate levels / / 23263486 rs9348692 chr6 25720812 A G 1.25E-07 Red blood cell traits / / 23222517 rs9348692 chr6 25720812 A G 4.48E-10 Urate levels / / 23263486 rs9379783 chr6 25725207 C T 8.76E-08 Red blood cell traits / / 23222517 rs9379783 chr6 25725207 C T 4.88E-10 Urate levels / / 23263486 rs9379784 chr6 25725506 A G 1.20E-07 Red blood cell traits / / 23222517 rs9379784 chr6 25725506 A G 4.81E-10 Urate levels / / 23263486 rs12215823 chr6 25726074 G C 1.21E-10 Other erythrocyte phenotypes / / 19862010 rs12215823 chr6 25726074 G C 9.00E-11 Urate levels / / 20884846 rs12215823 chr6 25726074 G C 1.49E-14 Red blood cell traits / / 23222517 rs12215823 chr6 25726074 G C 1.17E-28 Urate levels / / 23263486 rs9379785 chr6 25726213 G A 1.33E-07 Red blood cell traits / / 23222517 rs9379785 chr6 25726213 G A 4.63E-10 Urate levels / / 23263486 rs9467583 chr6 25726621 C T 2.12E-07 Red blood cell traits HIST1H2AA cds-synon 23222517 rs9358871 chr6 25726675 G A 1.40E-07 Red blood cell traits HIST1H2AA cds-synon 23222517 rs9358871 chr6 25726675 G A 4.71E-10 Urate levels HIST1H2AA cds-synon 23263486 rs4711095 chr6 25726774 A C 1.30E-07 Red blood cell traits HIST1H2AA UTR-5 23222517 rs4711095 chr6 25726774 A C 4.78E-10 Urate levels HIST1H2AA UTR-5 23263486 rs4711096 chr6 25727054 A G 1.11E-07 Red blood cell traits / / 23222517 rs4711096 chr6 25727054 A G 4.84E-10 Urate levels / / 23263486 rs4712959 chr6 25727057 C T 4.30E-08 Red blood cell traits / / 23222517 rs4712959 chr6 25727057 C T 2.29E-10 Urate levels / / 23263486 rs4712960 chr6 25727265 C T 1.33E-07 Red blood cell traits HIST1H2BA cds-synon 23222517 rs4712960 chr6 25727265 C T 5.30E-10 Urate levels HIST1H2BA cds-synon 23263486 rs4712961 chr6 25727334 C T 1.31E-07 Red blood cell traits HIST1H2BA cds-synon 23222517 rs4712961 chr6 25727334 C T 5.33E-10 Urate levels HIST1H2BA cds-synon 23263486 rs9358872 chr6 25727517 G A 1.24E-07 Red blood cell traits HIST1H2BA cds-synon 23222517 rs9358872 chr6 25727517 G A 6.11E-10 Urate levels HIST1H2BA cds-synon 23263486 rs17320558 chr6 25727527 T A 3.15E-11 Red blood cell traits HIST1H2BA UTR-3 23222517 rs17320558 chr6 25727527 T A 5.84E-15 Urate levels HIST1H2BA UTR-3 23263486 rs17320614 chr6 25727921 C T 9.67E-05 Femoral neck bone geometry / / 22087292 rs17267614 chr6 25730027 T G 9.51E-08 Red blood cell traits / / 23222517 rs17267614 chr6 25730027 T G 1.16E-09 Urate levels / / 23263486 rs9379786 chr6 25730255 T C 1.11E-07 Red blood cell traits / / 23222517 rs9379786 chr6 25730255 T C 5.63E-10 Urate levels / / 23263486 rs9358873 chr6 25731783 C T 1.22E-07 Red blood cell traits / / 23222517 rs9358873 chr6 25731783 C T 4.25E-10 Urate levels / / 23263486 rs4711097 chr6 25732314 C T 1.81E-08 Red blood cell traits / / 23222517 rs4711097 chr6 25732314 C T 3.57E-10 Urate levels / / 23263486 rs4464787 chr6 25733558 G C 2.32E-07 Red blood cell traits / / 23222517 rs4464787 chr6 25733558 G C 1.53E-09 Urate levels / / 23263486 rs9461210 chr6 25734073 A G 4.80E-11 Urate levels / / 20884846 rs9461210 chr6 25734073 A G 1.13E-08 Red blood cell traits / / 23222517 rs9461210 chr6 25734073 A G 2.06E-23 Urate levels / / 23263486 rs4360128 chr6 25734558 A C,G 1.09E-07 Red blood cell traits / / 23222517 rs4360128 chr6 25734558 A C,G 4.58E-10 Urate levels / / 23263486 rs3923725 chr6 25734920 C A 1.34E-07 Red blood cell traits / / 23222517 rs3923725 chr6 25734920 C A 4.54E-10 Urate levels / / 23263486 rs3922699 chr6 25734969 A G 1.20E-07 Red blood cell traits / / 23222517 rs3922699 chr6 25734969 A G 4.88E-10 Urate levels / / 23263486 rs6924794 chr6 25735874 A G 1.15E-07 Red blood cell traits / / 23222517 rs6924794 chr6 25735874 A G 5.10E-10 Urate levels / / 23263486 rs6924948 chr6 25735966 A G 9.45E-07 Red blood cell traits / / 23222517 rs3922842 chr6 25736564 T C 1.34E-07 Red blood cell traits / / 23222517 rs3922842 chr6 25736564 T C 7.31E-10 Urate levels / / 23263486 rs9358875 chr6 25738008 G A 1.23E-08 Urate levels / / 23263486 rs16890987 chr6 25738020 C T 1.41E-09 Multiple complex diseases / / 17554300 rs9358876 chr6 25738956 A G 1.32E-08 Urate levels / / 23263486 rs9393661 chr6 25739080 C T 1.32E-07 Red blood cell traits / / 23222517 rs9393661 chr6 25739080 C T 1.03E-09 Urate levels / / 23263486 rs9356986 chr6 25739119 T C 1.69E-07 Red blood cell traits / / 23222517 rs9356986 chr6 25739119 T C 1.04E-09 Urate levels / / 23263486 rs9356987 chr6 25739187 C A,T 1.85E-07 Red blood cell traits / / 23222517 rs9356987 chr6 25739187 C A,T 1.04E-09 Urate levels / / 23263486 rs9358877 chr6 25739228 A G 1.31E-07 Red blood cell traits / / 23222517 rs9358877 chr6 25739228 A G 9.05E-10 Urate levels / / 23263486 rs12663099 chr6 25739518 C T 1.33E-07 Red blood cell traits / / 23222517 rs12663099 chr6 25739518 C T 9.04E-10 Urate levels / / 23263486 rs9393662 chr6 25739670 T C 1.86E-07 Red blood cell traits / / 23222517 rs9393662 chr6 25739670 T C 8.77E-10 Urate levels / / 23263486 rs9358878 chr6 25740273 C T 1.31E-07 Red blood cell traits / / 23222517 rs9358878 chr6 25740273 C T 9.41E-10 Urate levels / / 23263486 rs4712963 chr6 25740502 C T 1.07E-07 Red blood cell traits / / 23222517 rs4712963 chr6 25740502 C T 5.48E-10 Urate levels / / 23263486 rs9467590 chr6 25741110 C T 5.96E-07 Red blood cell traits / / 23222517 rs9366629 chr6 25741216 G A 1.81E-07 Red blood cell traits / / 23222517 rs9366629 chr6 25741216 G A 1.03E-09 Urate levels / / 23263486 rs6456697 chr6 25741434 A G 1.44E-07 Red blood cell traits / / 23222517 rs6456697 chr6 25741434 A G 9.85E-10 Urate levels / / 23263486 rs4711103 chr6 25742224 C T 6.75E-10 Urate levels / / 23263486 rs9467591 chr6 25742699 A G 1.60E-09 Urate levels / / 20884846 rs9467591 chr6 25742699 A G 1.04E-07 Red blood cell traits / / 23222517 rs9467591 chr6 25742699 A G 2.08E-19 Urate levels / / 23263486 rs9358880 chr6 25743161 C T 1.56E-07 Red blood cell traits / / 23222517 rs9358880 chr6 25743161 C T 8.92E-10 Urate levels / / 23263486 rs9393665 chr6 25744284 G A 2.01E-07 Red blood cell traits / / 23222517 rs9393665 chr6 25744284 G A 8.57E-10 Urate levels / / 23263486 rs1937131 chr6 25744831 T A 2.00E-07 Red blood cell traits / / 23222517 rs1937131 chr6 25744831 T A 8.50E-10 Urate levels / / 23263486 rs7754296 chr6 25744878 A G 1.37E-07 Red blood cell traits / / 23222517 rs7754296 chr6 25744878 A G 1.15E-09 Urate levels / / 23263486 rs7754733 chr6 25745049 C G 1.77E-07 Red blood cell traits / / 23222517 rs7754733 chr6 25745049 C G 9.30E-10 Urate levels / / 23263486 rs7754814 chr6 25745243 A T 1.77E-07 Red blood cell traits / / 23222517 rs7754814 chr6 25745243 A T 9.59E-10 Urate levels / / 23263486 rs7775354 chr6 25745266 T A 2.61E-07 Red blood cell traits / / 23222517 rs7775354 chr6 25745266 T A 1.43E-09 Urate levels / / 23263486 rs9379789 chr6 25745579 A G 1.78E-07 Red blood cell traits / / 23222517 rs9379789 chr6 25745579 A G 9.83E-10 Urate levels / / 23263486 rs6941933 chr6 25745702 T C 1.82E-07 Red blood cell traits / / 23222517 rs6941933 chr6 25745702 T C 1.02E-09 Urate levels / / 23263486 rs6923367 chr6 25745852 A T 1.24E-14 Other erythrocyte phenotypes / / 19862010 rs6923367 chr6 25745852 A T 4.42E-14 Red blood cell traits / / 23222517 rs6923367 chr6 25745852 A T 3.78E-08 Urate levels / / 23263486 rs2154219 chr6 25749957 A G 3.40E-08 Urate levels / / 23263486 rs10498728 chr6 25751320 T A 9.00E-11 Urate levels / / 20884846 rs10498728 chr6 25751320 T A 2.71E-08 Red blood cell traits / / 23222517 rs10498728 chr6 25751320 T A 1.41E-23 Urate levels / / 23263486 rs12207270 chr6 25751721 G A 9.00E-11 Urate levels / / 20884846 rs12207270 chr6 25751721 G A 1.73E-08 Red blood cell traits / / 23222517 rs12207270 chr6 25751721 G A 7.92E-24 Urate levels / / 23263486 rs9348694 chr6 25753640 C T 2.14E-08 Red blood cell traits / / 23222517 rs9348694 chr6 25753640 C T 8.37E-10 Urate levels / / 23263486 rs1892256 chr6 25754271 C T 1.00E-10 Urate levels / / 20884846 rs1892256 chr6 25754271 C T 1.29E-08 Red blood cell traits / / 23222517 rs1892256 chr6 25754271 C T 9.15E-24 Urate levels / / 23263486 rs13194155 chr6 25755508 C T 1.20E-10 Urate levels SLC17A4 intron 20884846 rs13194155 chr6 25755508 C T 5.28E-08 Red blood cell traits SLC17A4 intron 23222517 rs13194155 chr6 25755508 C T 6.01E-21 Urate levels SLC17A4 intron 23263486 rs16890999 chr6 25755583 A G 1.30E-10 Urate levels SLC17A4 intron 20884846 rs16890999 chr6 25755583 A G 2.71E-08 Red blood cell traits SLC17A4 intron 23222517 rs16890999 chr6 25755583 A G 2.16E-23 Urate levels SLC17A4 intron 23263486 rs9358886 chr6 25758253 T A 1.91E-08 Red blood cell traits SLC17A4 intron 23222517 rs9358886 chr6 25758253 T A 1.01E-09 Urate levels SLC17A4 intron 23263486 rs17268697 chr6 25758448 G T 2.35E-11 Red blood cell traits SLC17A4 intron 23222517 rs17268697 chr6 25758448 G T 1.58E-16 Urate levels SLC17A4 intron 23263486 rs2000351 chr6 25759783 T C 4.01E-09 Red blood cell traits SLC17A4 intron 23222517 rs2000351 chr6 25759783 T C 1.63E-12 Urate levels SLC17A4 intron 23263486 rs7770037 chr6 25760591 G A 3.70E-09 Red blood cell traits SLC17A4 intron 23222517 rs7770037 chr6 25760591 G A 1.68E-12 Urate levels SLC17A4 intron 23263486 rs4236040 chr6 25761209 T C 6.29E-11 Urate levels SLC17A4 intron 23263486 rs4712969 chr6 25764192 A G 3.78E-10 Multiple complex diseases SLC17A4 intron 17554300 rs4712969 chr6 25764192 A G 5.59E-11 Urate levels SLC17A4 intron 23263486 rs2186087 chr6 25764842 G C 8.69E-10 Red blood cell traits SLC17A4 intron 23222517 rs2186087 chr6 25764842 G C 3.48E-12 Urate levels SLC17A4 intron 23263486 rs1317816 chr6 25765390 T C 1.58E-08 Red blood cell traits SLC17A4 intron 23222517 rs1317816 chr6 25765390 T C 8.44E-12 Urate levels SLC17A4 intron 23263486 rs6937800 chr6 25765943 A G 4.67E-11 Urate levels SLC17A4 intron 23263486 rs6902211 chr6 25767437 G A 5.46E-11 Urate levels SLC17A4 intron 23263486 rs3778272 chr6 25767661 G A 1.21E-10 Urate levels SLC17A4 intron 23263486 rs2275904 chr6 25768085 T C 1.36E-09 Urate levels SLC17A4 intron 23263486 rs2275905 chr6 25768106 G A 1.48E-08 Red blood cell traits SLC17A4 intron 23222517 rs2275905 chr6 25768106 G A 3.96E-12 Urate levels SLC17A4 intron 23263486 rs1892248 chr6 25768914 C T 5.87E-08 Red blood cell traits SLC17A4 intron 23222517 rs1892248 chr6 25768914 C T 9.31E-13 Urate levels SLC17A4 intron 23263486 rs1892250 chr6 25769024 T C 6.57E-11 Urate levels SLC17A4 intron 23263486 rs1892251 chr6 25769349 T C 2.09E-08 Urate levels SLC17A4 cds-synon 23263486 rs2328892 chr6 25769510 A G 2.58E-10 Red blood cell traits SLC17A4 intron 23222517 rs2328892 chr6 25769510 A G 4.75E-12 Urate levels SLC17A4 intron 23263486 rs1937127 chr6 25769872 A C 4.59E-12 Urate levels SLC17A4 intron 23263486 rs2328893 chr6 25770239 A G 1.00E-12 Urate levels SLC17A4 intron 20884846 rs2328893 chr6 25770239 A G 4.67E-07 Coronary heart disease SLC17A4 intron 21971053 rs2328893 chr6 25770239 A G 1.56E-24 Urate levels SLC17A4 intron 23263486 rs4712970 chr6 25770707 G A 6.95E-12 Urate levels SLC17A4 intron 23263486 rs4712971 chr6 25771900 T C 9.77E-11 Urate levels SLC17A4 intron 23263486 rs4712972 chr6 25772047 A G 1.82E-07 Multiple complex diseases SLC17A4 intron 17554300 rs4712972 chr6 25772047 A G 8.00E-08 Carotid intima media thickness SLC17A4 intron 21909108 rs4712972 chr6 25772047 A G 9.74E-10 Urate levels SLC17A4 intron 23263486 rs1892252 chr6 25772639 G C 7.22E-07 Red blood cell traits SLC17A4 intron 23222517 rs1892252 chr6 25772639 G C 9.68E-10 Urate levels SLC17A4 intron 23263486 rs2275906 chr6 25773809 A G 8.90E-08 Urate levels SLC17A4 cds-synon 20884846 rs2275906 chr6 25773809 A G 1.65E-16 Urate levels SLC17A4 cds-synon 23263486 rs6456701 chr6 25774130 C T 3.33E-10 Urate levels SLC17A4 intron 23263486 rs17269374 chr6 25775242 C A 4.74E-10 Red blood cell traits SLC17A4 intron 23222517 rs17269374 chr6 25775242 C A 3.01E-12 Urate levels SLC17A4 intron 23263486 rs1954598 chr6 25776060 T C 2.03E-10 Urate levels SLC17A4 intron 23263486 rs2154218 chr6 25776290 T C 2.13E-08 Red blood cell traits SLC17A4 intron 23222517 rs2154218 chr6 25776290 T C 2.77E-13 Urate levels SLC17A4 intron 23263486 rs11754288 chr6 25776949 G A 4.38E-12 Uric acid levels SLC17A4 missense 19503597 rs11754288 chr6 25776949 G A 2.20E-22 Urate levels SLC17A4 missense 20884846 rs11754288 chr6 25776949 G A 4.00E-09 Cardiovascular disease risk factors SLC17A4 missense 21943158 rs11754288 chr6 25776949 G A 9.45E-49 Urate levels SLC17A4 missense 23263486 rs11754288 chr6 25776949 G A 2.00E-12 Blood metabolite levels SLC17A4 missense 24816252 rs9356988 chr6 25777481 G A 1.61E-08 Red blood cell traits SLC17A4 intron 23222517 rs9356988 chr6 25777481 G A 3.70E-12 Urate levels SLC17A4 intron 23263486 rs3949215 chr6 25777497 A T 2.25E-10 Urate levels SLC17A4 intron 23263486 rs12201071 chr6 25778055 C T 2.70E-12 Urate levels SLC17A4 intron 20884846 rs12201071 chr6 25778055 C T 2.48E-24 Urate levels SLC17A4 intron 23263486 rs1317510 chr6 25778924 T C 1.52E-08 Red blood cell traits SLC17A4 intron 23222517 rs1317510 chr6 25778924 T C 1.20E-13 Urate levels SLC17A4 intron 23263486 rs3734526 chr6 25779736 A C 1.69E-11 Coronary heart disease SLC17A4 UTR-3 21971053 rs1141034 chr6 25780332 C T 5.09E-07 Red blood cell traits SLC17A4 UTR-3 23222517 rs1141034 chr6 25780332 C T 3.88E-13 Urate levels SLC17A4 UTR-3 23263486 rs6910549 chr6 25780811 A G 6.67E-10 Urate levels SLC17A4 UTR-3 23263486 rs7749149 chr6 25781139 G A 2.50E-07 Red blood cell traits SLC17A4 UTR-3 23222517 rs7749149 chr6 25781139 G A 1.95E-14 Urate levels SLC17A4 UTR-3 23263486 rs10946798 chr6 25781853 T G 2.40E-12 Urate levels / / 20884846 rs10946798 chr6 25781853 T G 1.74E-28 Urate levels / / 23263486 rs1892253 chr6 25782314 T G 1.15E-09 Multiple complex diseases / / 17554300 rs1892253 chr6 25782314 T G 1.80E-07 Red blood cell traits / / 23222517 rs1892253 chr6 25782314 T G 6.47E-10 Urate levels / / 23263486 rs3923 chr6 25783315 T C 3.10E-11 Urate levels SLC17A1 UTR-3 20884846 rs3923 chr6 25783315 T C 1.00E-26 Urate levels SLC17A1 UTR-3 23263486 rs3757131 chr6 25783909 C T 3.67E-12 Uric acid levels SLC17A1 intron 19503597 rs3757131 chr6 25783909 C T 2.30E-22 Urate levels SLC17A1 intron 20884846 rs3757131 chr6 25783909 C T 1.37E-07 Red blood cell traits SLC17A1 intron 23222517 rs3757131 chr6 25783909 C T 3.26E-49 Urate levels SLC17A1 intron 23263486 rs12662869 chr6 25784481 C A 1.62E-07 Red blood cell traits SLC17A1 intron 23222517 rs12662869 chr6 25784481 C A 1.76E-14 Urate levels SLC17A1 intron 23263486 rs13197601 chr6 25785935 G A 1.11E-11 Uric acid levels SLC17A1 intron 19503597 rs13197601 chr6 25785935 G A 2.20E-22 Urate levels SLC17A1 intron 20884846 rs13197601 chr6 25785935 G A 9.33E-07 Red blood cell traits SLC17A1 intron 23222517 rs13197601 chr6 25785935 G A 3.08E-49 Urate levels SLC17A1 intron 23263486 rs13213957 chr6 25786226 T C 2.24E-09 Urate levels SLC17A1 intron 23263486 rs3799344 chr6 25786993 C T 3.53E-12 Uric acid levels SLC17A1 intron 19503597 rs3799344 chr6 25786993 C T 1.40E-20 Urate levels SLC17A1 intron 20884846 rs3799344 chr6 25786993 C T 9.40E-04 Coronary heart disease SLC17A1 intron 21971053 rs3799344 chr6 25786993 C T 8.55E-07 Red blood cell traits SLC17A1 intron 23222517 rs3799344 chr6 25786993 C T 1.43E-47 Urate levels SLC17A1 intron 23263486 rs2096386 chr6 25787817 G A 1.30E-10 Urate levels SLC17A1 intron 20884846 rs2096386 chr6 25787817 G A 2.46E-26 Urate levels SLC17A1 intron 23263486 rs9393670 chr6 25789061 A G 2.70E-13 Urate levels SLC17A1 intron 20884846 rs9393670 chr6 25789061 A G 1.91E-28 Urate levels SLC17A1 intron 23263486 rs9393671 chr6 25789189 G C 2.73E-13 Urate levels SLC17A1 intron 23263486 rs10214468 chr6 25789390 T A 3.90E-08 Urate levels SLC17A1 intron 20884846 rs10214468 chr6 25789390 T A 3.46E-11 Urate levels SLC17A1 intron 23263486 rs13200921 chr6 25790378 T C 2.76E-10 Urate levels SLC17A1 intron 23263486 rs3799346 chr6 25791354 C T 3.82E-08 Uric acid levels SLC17A1 intron 19503597 rs3799346 chr6 25791354 C T 2.70E-14 Urate levels SLC17A1 intron 20884846 rs3799346 chr6 25791354 C T 4.26E-31 Urate levels SLC17A1 intron 23263486 rs1165157 chr6 25792250 A G 1.66E-13 Urate levels SLC17A1 intron 23263486 rs942377 chr6 25792292 T C 2.60E-14 Urate levels SLC17A1 intron 20884846 rs942377 chr6 25792292 T C 3.92E-31 Urate levels SLC17A1 intron 23263486 rs1165156 chr6 25792978 T C 1.92E-13 Urate levels SLC17A1 intron 23263486 rs12209856 chr6 25793673 G A 2.36E-13 Urate levels SLC17A1 intron 23263486 rs2762353 chr6 25794431 A G 1.19E-13 Uric acid levels SLC17A1 intron 19503597 rs2762353 chr6 25794431 A G 6.20E-24 Urate levels SLC17A1 intron 20884846 rs2762353 chr6 25794431 A G 1.52E-07 Red blood cell traits SLC17A1 intron 23222517 rs2762353 chr6 25794431 A G 4.23E-56 Urate levels SLC17A1 intron 23263486 rs2762353 chr6 25794431 A G 3.00E-13 Blood metabolite levels SLC17A1 intron 24816252 rs1165155 chr6 25795577 A T 2.94E-13 Urate levels SLC17A1 intron 23263486 rs1165215 chr6 25798932 G A 7.12E-14 Uric acid levels SLC17A1 intron 19503597 rs1165215 chr6 25798932 G A 5.90E-25 Urate levels SLC17A1 intron 20884846 rs1165215 chr6 25798932 G A 7.33E-07 Red blood cell traits SLC17A1 intron 23222517 rs1165215 chr6 25798932 G A 3.42E-57 Urate levels SLC17A1 intron 23263486 rs3823151 chr6 25800197 A C 0.000263622 Hypertension (early onset hypertension) SLC17A1 intron 22479346 rs1165211 chr6 25800922 T C 1.64E-13 Urate levels SLC17A1 intron 23263486 rs1165209 chr6 25801319 G A 7.81E-14 Uric acid levels SLC17A1 intron 19503597 rs1165209 chr6 25801319 G A 5.10E-25 Urate levels SLC17A1 intron 20884846 rs1165209 chr6 25801319 G A 2.85E-07 Red blood cell traits SLC17A1 intron 23222517 rs1165209 chr6 25801319 G A 1.98E-57 Urate levels SLC17A1 intron 23263486 rs1324082 chr6 25801971 C T 3.42E-04 Multiple complex diseases SLC17A1 intron 17554300 rs1324082 chr6 25801971 C T 2.34E-08 Uric acid levels SLC17A1 intron 19503597 rs1324082 chr6 25801971 C T 2.60E-14 Urate levels SLC17A1 intron 20884846 rs1324082 chr6 25801971 C T 3.52E-31 Urate levels SLC17A1 intron 23263486 rs12191655 chr6 25803095 G T 2.82E-09 Other erythrocyte phenotypes SLC17A1 intron 19862010 rs12191655 chr6 25803095 G T 4.21E-07 Red blood cell traits SLC17A1 intron 23222517 rs12191655 chr6 25803095 G T 3.59E-10 Urate levels SLC17A1 intron 23263486 rs1165208 chr6 25803904 G A 1.94E-13 Urate levels SLC17A1 intron 23263486 rs9467604 chr6 25805002 A T 1.96E-08 Uric acid levels SLC17A1 intron 19503597 rs9467604 chr6 25805002 A T 1.50E-14 Urate levels SLC17A1 intron 20884846 rs9467604 chr6 25805002 A T 2.76E-25 Urate levels SLC17A1 intron 23263486 rs9461216 chr6 25808743 A T 4.27E-10 Urate levels SLC17A1 intron 23263486 rs9467606 chr6 25809218 A G 2.90E-07 Urate levels SLC17A1 intron 20884846 rs9467606 chr6 25809218 A G 1.84E-13 Urate levels SLC17A1 intron 23263486 rs9467609 chr6 25809751 A G 1.22E-11 Urate levels SLC17A1 intron 23263486 rs1359231 chr6 25809798 G T 6.20E-13 Red blood cell traits SLC17A1 intron 23222517 rs1359231 chr6 25809798 G T 1.52E-17 Urate levels SLC17A1 intron 23263486 rs1575535 chr6 25809909 G A 2.61E-07 Red blood cell traits SLC17A1 intron 23222517 rs1575535 chr6 25809909 G A 1.98E-13 Urate levels SLC17A1 intron 23263486 rs1575534 chr6 25811404 C T 2.28E-05 Bilirubin levels,in serum SLC17A1 intron 19389676 rs1575534 chr6 25811404 C T 7.30E-15 Urate levels SLC17A1 intron 20884846 rs1575534 chr6 25811404 C T 5.93E-31 Urate levels SLC17A1 intron 23263486 rs10498730 chr6 25812069 A G 6.97E-09 Uric acid levels SLC17A1 intron 19503597 rs10498730 chr6 25812069 A G 1.30E-10 Urate levels SLC17A1 intron 23263486 rs942378 chr6 25812459 G A 3.09E-08 Uric acid levels SLC17A1 intron 19503597 rs942378 chr6 25812459 G A 7.40E-15 Urate levels SLC17A1 intron 20884846 rs942378 chr6 25812459 G A 4.41E-31 Urate levels SLC17A1 intron 23263486 rs9467613 chr6 25812641 T C 6.22E-10 Urate levels SLC17A1 intron 23263486 rs1165196 chr6 25813150 G A 7.69E-04 Multiple complex diseases SLC17A1 missense 17554300 rs1165196 chr6 25813150 G A 2.51E-13 Uric acid levels SLC17A1 missense 19503597 rs1165196 chr6 25813150 G A 5.00E-25 Urate levels SLC17A1 missense 20884846 rs1165196 chr6 25813150 G A 1.30E-04 Urate (in serum),gout SLC17A1 missense 21983786 rs1165196 chr6 25813150 G A 2.80E-06 Urate (in serum),gout SLC17A1 missense 21983786 rs1165196 chr6 25813150 G A 2.83E-08 Red blood cell traits SLC17A1 missense 23222517 rs1165196 chr6 25813150 G A 2.08E-57 Urate levels SLC17A1 missense 23263486 rs10498731 chr6 25816355 T C 9.01E-04 Type 2 diabetes SLC17A1 intron 17463246 rs7753366 chr6 25817518 G A 1.96E-08 Uric acid levels SLC17A1 intron 19503597 rs7753366 chr6 25817518 G A 7.00E-15 Urate levels SLC17A1 intron 20884846 rs7753366 chr6 25817518 G A 7.38E-31 Urate levels SLC17A1 intron 23263486 rs1165153 chr6 25817789 A G 2.04E-13 Uric acid levels SLC17A1 intron 19503597 rs1165153 chr6 25817789 A G 6.30E-25 Urate levels SLC17A1 intron 20884846 rs1165153 chr6 25817789 A G 2.17E-07 Red blood cell traits SLC17A1 intron 23222517 rs1165153 chr6 25817789 A G 1.16E-57 Urate levels SLC17A1 intron 23263486 rs1185567 chr6 25818588 A G 2.48E-13 Uric acid levels SLC17A1 intron 19503597 rs1185567 chr6 25818588 A G 6.80E-25 Urate levels SLC17A1 intron 20884846 rs1185567 chr6 25818588 A G 1.98E-07 Red blood cell traits SLC17A1 intron 23222517 rs1185567 chr6 25818588 A G 2.39E-57 Urate levels SLC17A1 intron 23263486 rs1185567 chr6 25818588 A G 1.00E-26 Blood metabolite ratios SLC17A1 intron 24816252 rs1183200 chr6 25818646 G C 2.32E-13 Uric acid levels SLC17A1 intron 19503597 rs1183200 chr6 25818646 G C 7.30E-25 Urate levels SLC17A1 intron 20884846 rs1183200 chr6 25818646 G C 3.16E-07 Red blood cell traits SLC17A1 intron 23222517 rs1183200 chr6 25818646 G C 3.31E-57 Urate levels SLC17A1 intron 23263486 rs9461218 chr6 25818755 G A 3.28E-09 Uric acid levels SLC17A1 intron 19503597 rs9461218 chr6 25818755 G A 2.77E-05 Lung adenocarcinoma SLC17A1 intron 19836008 rs9461218 chr6 25818755 G A 1.50E-13 Urate levels SLC17A1 intron 20884846 rs9461218 chr6 25818755 G A 1.01E-31 Urate levels SLC17A1 intron 23263486 rs1165152 chr6 25818766 A G 3.34E-13 Uric acid levels SLC17A1 intron 19503597 rs1165152 chr6 25818766 A G 8.30E-25 Urate levels SLC17A1 intron 20884846 rs1165152 chr6 25818766 A G 2.09E-07 Red blood cell traits SLC17A1 intron 23222517 rs1165152 chr6 25818766 A G 2.96E-57 Urate levels SLC17A1 intron 23263486 rs6913879 chr6 25820428 T C 4.36E-04 Multiple complex diseases SLC17A1 intron 17554300 rs6913879 chr6 25820428 T C 3.52E-08 Uric acid levels SLC17A1 intron 19503597 rs6913879 chr6 25820428 T C 8.70E-15 Urate levels SLC17A1 intron 20884846 rs6913879 chr6 25820428 T C 1.79E-31 Urate levels SLC17A1 intron 23263486 rs17270561 chr6 25820439 C A 5.00E-07 Iron status biomarkers SLC17A1 intron 19084217 rs17270561 chr6 25820439 C A 4.45E-09 Red blood cell traits SLC17A1 intron 23222517 rs17270561 chr6 25820439 C A 1.60E-09 Urate levels SLC17A1 intron 23263486 rs6939997 chr6 25821224 C T 4.90E-07 Schizophrenia SLC17A1 intron 19571809 rs6939997 chr6 25821224 C T 1.90E-07 Schizophrenia (treatment refractory) SLC17A1 intron 22479419 rs6939997 chr6 25821224 C T 4.16E-10 Urate levels SLC17A1 intron 23263486 rs6940698 chr6 25821580 C T 7.83E-10 Urate levels SLC17A1 intron 23263486 rs1165151 chr6 25821616 T G 4.84E-14 Uric acid levels SLC17A1 intron 19503597 rs1165151 chr6 25821616 T G 1.10E-23 Urate levels SLC17A1 intron 20884846 rs1165151 chr6 25821616 T G 5.89E-10 Red blood cell traits SLC17A1 intron 23222517 rs1165151 chr6 25821616 T G 7.00E-70 Urate levels SLC17A1 intron 23263486 rs17342717 chr6 25821770 C T 2.71E-20 Other erythrocyte phenotypes SLC17A1 intron 19862010 rs17342717 chr6 25821770 C T 5.00E-08 Red blood cell traits SLC17A1 intron 20927387 rs17342717 chr6 25821770 C T 9.00E-10 Iron status biomarkers SLC17A1 intron 21149283 rs17342717 chr6 25821770 C T 5.00E-09 Iron levels SLC17A1 intron 21208937 rs17342717 chr6 25821770 C T 4.00E-15 Mean corpuscular volume SLC17A1 intron 22560525 rs17342717 chr6 25821770 C T 8.00E-19 Mean corpuscular hemoglobin SLC17A1 intron 22560525 rs17342717 chr6 25821770 C T 5.82E-11 Red blood cell traits SLC17A1 intron 23222517 rs1185976 chr6 25822363 C T 1.67E-12 Urate levels SLC17A1 intron 23263486 rs3799352 chr6 25822620 C T 4.51E-14 Uric acid levels SLC17A1 intron 19503597 rs3799352 chr6 25822620 C T 1.30E-23 Urate levels SLC17A1 intron 20884846 rs3799352 chr6 25822620 C T 8.68E-07 Red blood cell traits SLC17A1 intron 23222517 rs3799352 chr6 25822620 C T 9.69E-60 Urate levels SLC17A1 intron 23263486 rs13201341 chr6 25822661 C T 2.47E-09 Urate levels SLC17A1 intron 23263486 rs1183201 chr6 25823444 A T 3.00E-14 Uric acid levels SLC17A1 intron 19503597 rs1183201 chr6 25823444 A T 1.40E-23 Urate levels SLC17A1 intron 20884846 rs1183201 chr6 25823444 A T 1.00E-04 Urate (in serum),gout SLC17A1 intron 21983786 rs1183201 chr6 25823444 A T 6.40E-06 Urate (in serum),gout SLC17A1 intron 21983786 rs1183201 chr6 25823444 A T 4.63E-07 Red blood cell traits SLC17A1 intron 23222517 rs1183201 chr6 25823444 A T 3.79E-55 Urate levels SLC17A1 intron 23263486 rs12211184 chr6 25823774 G A 1.87E-08 Other erythrocyte phenotypes SLC17A1 intron 19862010 rs12211184 chr6 25823774 G A 1.31E-08 Red blood cell traits SLC17A1 intron 23222517 rs12211184 chr6 25823774 G A 1.94E-08 Urate levels SLC17A1 intron 23263486 rs1165181 chr6 25825390 T A 4.61E-12 Urate levels SLC17A1 intron 23263486 rs6456703 chr6 25826119 C T 1.36E-09 Uric acid levels SLC17A1 intron 19503597 rs6456703 chr6 25826119 C T 6.00E-15 Urate levels SLC17A1 intron 20884846 rs6456703 chr6 25826119 C T 1.40E-08 Urate levels SLC17A1 intron 21768215 rs6456703 chr6 25826119 C T 5.46E-31 Urate levels SLC17A1 intron 23263486 rs1408268 chr6 25826986 T A 2.08E-09 Uric acid levels SLC17A1 intron 19503597 rs1408268 chr6 25826986 T A 6.60E-15 Urate levels SLC17A1 intron 20884846 rs1408268 chr6 25826986 T A 1.36E-08 Urate levels SLC17A1 intron 21768215 rs1408268 chr6 25826986 T A 4.26E-31 Urate levels SLC17A1 intron 23263486 rs1165178 chr6 25827516 A G 4.05E-14 Uric acid levels SLC17A1 intron 19503597 rs1165178 chr6 25827516 A G 1.60E-23 Urate levels SLC17A1 intron 20884846 rs1165178 chr6 25827516 A G 5.02E-07 Red blood cell traits SLC17A1 intron 23222517 rs1165178 chr6 25827516 A G 2.46E-59 Urate levels SLC17A1 intron 23263486 rs765285 chr6 25828242 G C 4.72E-14 Uric acid levels SLC17A1 intron 19503597 rs765285 chr6 25828242 G C 6.10E-23 Urate levels SLC17A1 intron 20884846 rs765285 chr6 25828242 G C 1.02E-07 Red blood cell traits SLC17A1 intron 23222517 rs765285 chr6 25828242 G C 5.92E-52 Urate levels SLC17A1 intron 23263486 rs13199775 chr6 25828782 A T 1.19E-07 Schizophrenia SLC17A1 intron 19571809 rs13199775 chr6 25828782 A T 1.20E-07 Schizophrenia (treatment refractory) SLC17A1 intron 22479419 rs13199775 chr6 25828782 A T 2.00E-10 Urate levels SLC17A1 intron 23263486 rs12200962 chr6 25828986 T C 1.26E-08 Other erythrocyte phenotypes SLC17A1 intron 19862010 rs12200962 chr6 25828986 T C 2.92E-08 Red blood cell traits SLC17A1 intron 23222517 rs12200962 chr6 25828986 T C 2.92E-08 Urate levels SLC17A1 intron 23263486 rs13200784 chr6 25829633 A T 2.22E-09 Uric acid levels SLC17A1 intron 19503597 rs13200784 chr6 25829633 A T 1.30E-14 Urate levels SLC17A1 intron 20884846 rs13200784 chr6 25829633 A T 1.45E-08 Urate levels SLC17A1 intron 21768215 rs13200784 chr6 25829633 A T 1.35E-30 Urate levels SLC17A1 intron 23263486 rs1165177 chr6 25829659 T A 6.60E-14 Uric acid levels SLC17A1 intron 19503597 rs1165177 chr6 25829659 T A 7.60E-23 Urate levels SLC17A1 intron 20884846 rs1165177 chr6 25829659 T A 2.50E-10 Red blood cell traits SLC17A1 intron 23222517 rs1165177 chr6 25829659 T A 4.52E-55 Urate levels SLC17A1 intron 23263486 rs1165176 chr6 25830298 A G 3.94E-14 Uric acid levels SLC17A1 intron 19503597 rs1165176 chr6 25830298 A G 8.70E-23 Urate levels SLC17A1 intron 20884846 rs1165176 chr6 25830298 A G 5.10E-07 Red blood cell traits SLC17A1 intron 23222517 rs1165176 chr6 25830298 A G 3.76E-57 Urate levels SLC17A1 intron 23263486 rs2070642 chr6 25831212 G A 3.81E-12 Urate levels SLC17A1 intron 23263486 rs1185569 chr6 25831603 A G 1.23E-08 Uric acid levels SLC17A1 intron 19503597 rs1185569 chr6 25831603 A G 4.10E-16 Urate levels SLC17A1 intron 20884846 rs1185569 chr6 25831603 A G 4.75E-07 Red blood cell traits SLC17A1 intron 23222517 rs1185569 chr6 25831603 A G 1.13E-50 Urate levels SLC17A1 intron 23263486 rs1185568 chr6 25834428 T A 4.40E-14 Uric acid levels / / 19503597 rs1185568 chr6 25834428 T A 9.20E-23 Urate levels / / 20884846 rs1185568 chr6 25834428 T A 2.12E-10 Red blood cell traits / / 23222517 rs1185568 chr6 25834428 T A 4.07E-57 Urate levels / / 23263486 rs1184803 chr6 25834658 T C 4.92E-14 Uric acid levels / / 19503597 rs1184803 chr6 25834658 T C 9.50E-23 Urate levels / / 20884846 rs1184803 chr6 25834658 T C 7.71E-08 Red blood cell traits / / 23222517 rs1184803 chr6 25834658 T C 3.53E-50 Urate levels / / 23263486 rs1185978 chr6 25835895 A G 1.14E-12 Uric acid levels / / 19503597 rs1185978 chr6 25835895 A G 9.70E-23 Urate levels / / 20884846 rs1185978 chr6 25835895 A G 5.53E-47 Urate levels / / 23263486 rs9461219 chr6 25836927 C G 4.72E-07 Schizophrenia / / 19571809 rs9461219 chr6 25836927 C G 4.70E-07 Schizophrenia (treatment refractory) / / 22479419 rs9461219 chr6 25836927 C G 5.33E-10 Urate levels / / 23263486 rs1165182 chr6 25837829 A G 3.78E-14 Uric acid levels / / 19503597 rs1165182 chr6 25837829 A G 1.00E-22 Urate levels / / 20884846 rs1165182 chr6 25837829 A G 4.29E-07 Red blood cell traits / / 23222517 rs1165182 chr6 25837829 A G 1.74E-58 Urate levels / / 23263486 rs6905614 chr6 25840485 C A 1.79E-12 Uric acid levels / / 19503597 rs6905614 chr6 25840485 C A 3.80E-21 Urate levels / / 20884846 rs6905614 chr6 25840485 C A 4.59E-11 Red blood cell traits / / 23222517 rs6905614 chr6 25840485 C A 2.12E-56 Urate levels / / 23263486 rs1408273 chr6 25840946 A G 1.91E-13 Uric acid levels / / 19503597 rs1408273 chr6 25840946 A G 1.10E-22 Urate levels / / 20884846 rs1408273 chr6 25840946 A G 1.41E-50 Urate levels / / 23263486 rs1324088 chr6 25841122 G A 7.79E-13 Multiple complex diseases / / 17554300 rs1324088 chr6 25841122 G A 1.40E-07 Urate levels / / 20884846 rs1324088 chr6 25841122 G A 9.72E-10 Urate levels / / 23263486 rs1324087 chr6 25841408 G A 1.06E-13 Multiple complex diseases / / 17554300 rs1324087 chr6 25841408 G A 1.50E-07 Urate levels / / 20884846 rs1324087 chr6 25841408 G A 0.000452347 Hypertension (early onset hypertension) / / 22479346 rs1324087 chr6 25841408 G A 6.49E-10 Urate levels / / 23263486 rs4712976 chr6 25842203 C T 4.76E-12 Urate levels / / 23263486 rs9393672 chr6 25842605 T G 4.27E-14 Uric acid levels / / 19503597 rs9393672 chr6 25842605 T G 1.40E-22 Urate levels / / 20884846 rs9393672 chr6 25842605 T G 1.63E-09 Red blood cell traits / / 23222517 rs9393672 chr6 25842605 T G 4.25E-58 Urate levels / / 23263486 rs1408272 chr6 25842951 T G 1.00E-11 Hematology traits / / 19853236 rs1408272 chr6 25842951 T G 4.00E-39 Mean corpuscular hemoglobin / / 19862010 rs1408272 chr6 25842951 T G 9.00E-09 Iron status biomarkers / / 21149283 rs1408272 chr6 25842951 T G 5.00E-67 Red blood cell traits / / 23222517 rs1408272 chr6 25842951 T G 1.70E-04 Red blood cell traits / / 23935956 rs3887266 chr6 25843746 C T 1.73E-08 Other erythrocyte phenotypes / / 19862010 rs3887266 chr6 25843746 C T 4.00E-12 Mean corpuscular hemoglobin / / 22560525 rs3887266 chr6 25843746 C T 6.00E-10 Mean corpuscular volume / / 22560525 rs3887266 chr6 25843746 C T 2.21E-07 Red blood cell traits / / 23222517 rs3887266 chr6 25843746 C T 1.33E-18 Urate levels / / 23263486 rs726836 chr6 25843926 C T 3.25E-17 Multiple complex diseases / / 17554300 rs1165148 chr6 25844710 G T 5.53E-10 Uric acid levels / / 19503597 rs1165148 chr6 25844710 G T 2.70E-14 Urate levels / / 20884846 rs1165148 chr6 25844710 G T 5.69E-09 Urate levels / / 21768215 rs1165148 chr6 25844710 G T 2.03E-29 Urate levels / / 23263486 rs942379 chr6 25849620 A G 7.99E-14 Uric acid levels SLC17A3 cds-synon 19503597 rs942379 chr6 25849620 A G 4.02E-06 Bicuspid aortic valve SLC17A3 cds-synon 20098615 rs942379 chr6 25849620 A G 9.90E-22 Urate levels SLC17A3 cds-synon 20884846 rs942379 chr6 25849620 A G 1.73E-07 Red blood cell traits SLC17A3 cds-synon 23222517 rs942379 chr6 25849620 A G 6.24E-58 Urate levels SLC17A3 cds-synon 23263486 rs1165189 chr6 25849779 A C 8.20E-10 Uric acid levels SLC17A3 intron 19503597 rs1165189 chr6 25849779 A C 2.60E-14 Urate levels SLC17A3 intron 20884846 rs1165189 chr6 25849779 A C 5.10E-09 Urate levels SLC17A3 intron 21768215 rs1165189 chr6 25849779 A C 2.11E-29 Urate levels SLC17A3 intron 23263486 rs9467621 chr6 25851338 G A 5.18E-10 Urate levels SLC17A3 intron 23263486 rs1165187 chr6 25851369 T C 1.46E-09 Uric acid levels SLC17A3 intron 19503597 rs1165187 chr6 25851369 T C 2.60E-14 Urate levels SLC17A3 intron 20884846 rs1165187 chr6 25851369 T C 4.92E-09 Urate levels SLC17A3 intron 21768215 rs1165187 chr6 25851369 T C 1.71E-29 Urate levels SLC17A3 intron 23263486 rs9467622 chr6 25854644 C A 5.13E-10 Urate levels SLC17A3 intron 23263486 rs116645668 chr6 25855404 G A 0.00036 Prostate cancer SLC17A3 missense 23555315 rs717551 chr6 25855624 T C 2.22E-08 Other erythrocyte phenotypes SLC17A3 intron 19862010 rs717551 chr6 25855624 T C 1.33E-08 Red blood cell traits SLC17A3 intron 23222517 rs1780969 chr6 25858432 C A 5.66E-10 Uric acid levels SLC17A3 intron 19503597 rs1780969 chr6 25858432 C A 2.10E-14 Urate levels SLC17A3 intron 20884846 rs1780969 chr6 25858432 C A 7.56E-24 Urate levels SLC17A3 intron 23263486 rs1179087 chr6 25858704 G T 3.46E-09 Uric acid levels SLC17A3 intron 19503597 rs1179087 chr6 25858704 G T 3.40E-13 Urate levels SLC17A3 intron 20884846 rs1179087 chr6 25858704 G T 1.72E-08 Urate levels SLC17A3 intron 21768215 rs1179087 chr6 25858704 G T 2.66E-27 Urate levels SLC17A3 intron 23263486 rs1177441 chr6 25859413 A G 1.90E-07 Urate levels SLC17A3 intron 20884846 rs1177441 chr6 25859413 A G 1.14E-09 Urate levels SLC17A3 intron 23263486 rs1165168 chr6 25859508 A C 1.90E-07 Urate levels SLC17A3 intron 20884846 rs1165168 chr6 25859508 A C 7.15E-10 Urate levels SLC17A3 intron 23263486 rs1182814 chr6 25859554 T C 5.95E-06 Multiple complex diseases SLC17A3 intron 17554300 rs1182814 chr6 25859554 T C 7.90E-10 Uric acid levels SLC17A3 intron 19503597 rs1182814 chr6 25859554 T C 2.40E-14 Urate levels SLC17A3 intron 20884846 rs1182814 chr6 25859554 T C 4.25E-09 Urate levels SLC17A3 intron 21768215 rs1182814 chr6 25859554 T C 4.44E-29 Urate levels SLC17A3 intron 23263486 rs1408271 chr6 25859621 T A 1.12E-10 Urate levels SLC17A3 intron 23263486 rs1165167 chr6 25860688 A G 1.25E-09 Uric acid levels SLC17A3 intron 19503597 rs1165167 chr6 25860688 A G 2.90E-14 Urate levels SLC17A3 intron 20884846 rs1165167 chr6 25860688 A G 4.05E-09 Urate levels SLC17A3 intron 21768215 rs1165167 chr6 25860688 A G 3.18E-29 Urate levels SLC17A3 intron 23263486 rs1165165 chr6 25862466 C T 1.68E-05 Multiple complex diseases SLC17A3 missense 17554300 rs1165165 chr6 25862466 C T 5.71E-09 Uric acid levels SLC17A3 missense 19503597 rs1165165 chr6 25862466 C T 4.20E-13 Urate levels SLC17A3 missense 20884846 rs1165165 chr6 25862466 C T 7.47E-09 Urate levels SLC17A3 missense 21768215 rs1165165 chr6 25862466 C T 1.32E-27 Urate levels SLC17A3 missense 23263486 rs1165164 chr6 25863481 G A 9.45E-09 Uric acid levels SLC17A3 intron 19503597 rs1165164 chr6 25863481 G A 2.50E-13 Urate levels SLC17A3 intron 20884846 rs1165164 chr6 25863481 G A 7.38E-09 Urate levels SLC17A3 intron 21768215 rs1165164 chr6 25863481 G A 9.11E-28 Urate levels SLC17A3 intron 23263486 rs1165162 chr6 25863605 C T 3.06E-06 Multiple complex diseases SLC17A3 intron 17554300 rs1165162 chr6 25863605 C T 4.83E-10 Uric acid levels SLC17A3 intron 19503597 rs1165162 chr6 25863605 C T 3.10E-14 Urate levels SLC17A3 intron 20884846 rs1165162 chr6 25863605 C T 3.85E-09 Urate levels SLC17A3 intron 21768215 rs1165162 chr6 25863605 C T 1.76E-29 Urate levels SLC17A3 intron 23263486 rs17271121 chr6 25863650 T C 6.66E-09 Other erythrocyte phenotypes SLC17A3 intron 19862010 rs17271121 chr6 25863650 T C 8.47E-09 Red blood cell traits SLC17A3 intron 23222517 rs17271121 chr6 25863650 T C 1.13E-17 Urate levels SLC17A3 intron 23263486 rs1165161 chr6 25864362 C T 1.40E-06 Multiple complex diseases SLC17A3 intron 17554300 rs1165161 chr6 25864362 C T 1.09E-10 Uric acid levels SLC17A3 intron 19503597 rs1165161 chr6 25864362 C T 2.20E-14 Urate levels SLC17A3 intron 20884846 rs1165161 chr6 25864362 C T 3.74E-09 Urate levels SLC17A3 intron 21768215 rs1165161 chr6 25864362 C T 1.09E-29 Urate levels SLC17A3 intron 23263486 rs1165160 chr6 25864456 A G 4.44E-14 Uric acid levels SLC17A3 intron 19503597 rs1165160 chr6 25864456 A G 2.20E-21 Urate levels SLC17A3 intron 20884846 rs1165160 chr6 25864456 A G 8.97E-08 Red blood cell traits SLC17A3 intron 23222517 rs1165160 chr6 25864456 A G 6.12E-53 Urate levels SLC17A3 intron 23263486 rs1165159 chr6 25864625 A G 7.28E-10 Uric acid levels SLC17A3 intron 19503597 rs1165159 chr6 25864625 A G 1.80E-14 Urate levels SLC17A3 intron 20884846 rs1165159 chr6 25864625 A G 3.71E-09 Urate levels SLC17A3 intron 21768215 rs1165159 chr6 25864625 A G 3.37E-28 Urate levels SLC17A3 intron 23263486 rs13211947 chr6 25864818 C T 3.34E-09 Urate levels SLC17A3 intron 23263486 rs1184498 chr6 25864882 G A,C 9.20E-08 Urate levels SLC17A3 intron 20884846 rs1184498 chr6 25864882 G A,C 6.69E-07 Red blood cell traits SLC17A3 intron 23222517 rs1184498 chr6 25864882 G A,C 4.65E-10 Urate levels SLC17A3 intron 23263486 rs1165158 chr6 25864898 C A 3.04E-06 Multiple complex diseases SLC17A3 intron 17554300 rs1165158 chr6 25864898 C A 5.58E-10 Uric acid levels SLC17A3 intron 19503597 rs1165158 chr6 25864898 C A 1.30E-14 Urate levels SLC17A3 intron 20884846 rs1165158 chr6 25864898 C A 3.45E-09 Urate levels SLC17A3 intron 21768215 rs1165158 chr6 25864898 C A 3.84E-29 Urate levels SLC17A3 intron 23263486 rs1165207 chr6 25865266 T C 2.92E-04 Multiple complex diseases SLC17A3 intron 17554300 rs1165207 chr6 25865266 T C 1.01E-13 Uric acid levels SLC17A3 intron 19503597 rs1165207 chr6 25865266 T C 9.30E-22 Urate levels SLC17A3 intron 20884846 rs1165207 chr6 25865266 T C 6.28E-11 Red blood cell traits SLC17A3 intron 23222517 rs1165207 chr6 25865266 T C 1.28E-56 Urate levels SLC17A3 intron 23263486 rs1165206 chr6 25867566 G A 4.30E-11 Urate levels SLC17A3 intron 20884846 rs1165206 chr6 25867566 G A 3.25E-25 Urate levels SLC17A3 intron 23263486 rs1184804 chr6 25868226 T C 1.60E-13 Uric acid levels SLC17A3 intron 19503597 rs1184804 chr6 25868226 T C 7.20E-22 Urate levels SLC17A3 intron 20884846 rs1184804 chr6 25868226 T C 3.16E-07 Red blood cell traits SLC17A3 intron 23222517 rs1184804 chr6 25868226 T C 6.48E-50 Urate levels SLC17A3 intron 23263486 rs548987 chr6 25869371 G C 9.23E-14 Multiple complex diseases SLC17A3 intron 17554300 rs548987 chr6 25869371 G C 2.60E-08 Urate levels SLC17A3 intron 20884846 rs548987 chr6 25869371 G C 3.85E-07 Red blood cell traits SLC17A3 intron 23222517 rs548987 chr6 25869371 G C 2.51E-09 Urate levels SLC17A3 intron 23263486 rs548987 chr6 25869371 G C 1.00E-08 Homocysteine levels SLC17A3 intron 23824729 rs548987 chr6 25869371 G C 1.12E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) SLC17A3 intron 24192120 rs523383 chr6 25869848 A G 1.95E-07 Multiple complex diseases SLC17A3 intron 17554300 rs523383 chr6 25869848 A G 2.60E-08 Urate levels SLC17A3 intron 20884846 rs523383 chr6 25869848 A G 5.75E-10 Urate levels SLC17A3 intron 23263486 rs1165205 chr6 25870542 T A 3.69E-04 Multiple complex diseases SLC17A3 intron 17554300 rs1165205 chr6 25870542 T A 4.00E-29 Urate levels SLC17A3 intron 18834626 rs1165205 chr6 25870542 T A 1.60E-13 Uric acid levels SLC17A3 intron 19503597 rs1165205 chr6 25870542 T A 5.04E-04 Blood cell counts and other traits SLC17A3 intron 20139978 rs1165205 chr6 25870542 T A 6.00E-22 Urate levels SLC17A3 intron 20884846 rs1165205 chr6 25870542 T A 3.28E-07 Red blood cell traits SLC17A3 intron 23222517 rs1165205 chr6 25870542 T A 6.46E-57 Urate levels SLC17A3 intron 23263486 rs555460 chr6 25870655 C T 2.80E-08 Urate levels SLC17A3 intron 20884846 rs555460 chr6 25870655 C T 1.01E-09 Urate levels SLC17A3 intron 23263486 rs556339 chr6 25870745 C T 3.25E-09 Uric acid levels SLC17A3 intron 19503597 rs556339 chr6 25870745 C T 2.20E-15 Urate levels SLC17A3 intron 20884846 rs556339 chr6 25870745 C T 2.97E-09 Urate levels SLC17A3 intron 21768215 rs556339 chr6 25870745 C T 1.15E-29 Urate levels SLC17A3 intron 23263486 rs579996 chr6 25871044 G A 1.64E-04 Multiple complex diseases SLC17A3 intron 17554300 rs972087 chr6 25872579 A G 2.00E-07 Urate levels SLC17A3 intron 20884846 rs972087 chr6 25872579 A G 6.59E-10 Urate levels SLC17A3 intron 23263486 rs501220 chr6 25873025 C A 2.80E-08 Urate levels SLC17A3 intron 20884846 rs501220 chr6 25873025 C A 4.97E-08 Coronary heart disease SLC17A3 intron 21971053 rs501220 chr6 25873025 C A 0.000752544 Hypertension (early onset hypertension) SLC17A3 intron 22479346 rs501220 chr6 25873025 C A 3.16E-08 Red blood cell traits SLC17A3 intron 23222517 rs501220 chr6 25873025 C A 1.95E-09 Urate levels SLC17A3 intron 23263486 rs9467626 chr6 25873746 C A 1.65E-07 Schizophrenia SLC17A3 intron 19571809 rs9467626 chr6 25873746 C A 1.70E-07 Schizophrenia (treatment refractory) SLC17A3 intron 22479419 rs9467626 chr6 25873746 C A 8.19E-07 Red blood cell traits SLC17A3 intron 23222517 rs9467626 chr6 25873746 C A 5.32E-10 Urate levels SLC17A3 intron 23263486 rs13198474 chr6 25874423 G A 6.30E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SLC17A3 UTR-5 20031582 rs13198474 chr6 25874423 G A 3.00E-06 Ankylosing spondylitis SLC17A3 UTR-5 20062062 rs13198474 chr6 25874423 G A 1.81E-09 Urate levels SLC17A3 UTR-5 23263486 rs13198474 chr6 25874423 G A 1.40E-04 Systemic lupus erythematosus SLC17A3 UTR-5 24871463 rs1165201 chr6 25874823 A C 1.30E-08 Urate levels / / 20884846 rs1165201 chr6 25874823 A C 1.67E-08 Red blood cell traits / / 23222517 rs1165201 chr6 25874823 A C 6.87E-17 Urate levels / / 23263486 rs1165200 chr6 25875212 G A 1.09E-07 Red blood cell traits / / 23222517 rs12664474 chr6 25876089 A G 1.50E-05 Urinary metabolites / / 21572414 rs12664474 chr6 25876089 A G 1.22E-08 Red blood cell traits / / 23222517 rs12664474 chr6 25876089 A G 1.95E-20 Urate levels / / 23263486 rs603089 chr6 25877970 G A 2.50E-10 Urate levels / / 20884846 rs603089 chr6 25877970 G A 5.17E-09 Urate levels / / 21768215 rs603089 chr6 25877970 G A 6.24E-18 Urate levels / / 23263486 rs566530 chr6 25878361 T C 1.10E-07 Urate levels / / 20884846 rs566530 chr6 25878361 T C 4.90E-05 Renal function-related traits (urea) / / 22797727 rs11964886 chr6 25878379 C T 1.72E-16 Urate levels / / 23263486 rs11969868 chr6 25878506 A G 4.71E-16 Urate levels / / 23263486 rs629835 chr6 25879330 T C 9.90E-09 Urate levels / / 20884846 rs629835 chr6 25879330 T C 1.22E-08 Red blood cell traits / / 23222517 rs629835 chr6 25879330 T C 8.27E-17 Urate levels / / 23263486 rs645279 chr6 25880494 T C 1.20E-07 Urate levels / / 20884846 rs645279 chr6 25880494 T C 2.43E-09 Red blood cell traits / / 23222517 rs645279 chr6 25880494 T C 8.87E-16 Urate levels / / 23263486 rs12192635 chr6 25880907 A T 2.60E-05 Urinary metabolites / / 21572414 rs12192635 chr6 25880907 A T 1.99E-08 Red blood cell traits / / 23222517 rs531750 chr6 25882642 C G 1.30E-07 Urate levels / / 20884846 rs531750 chr6 25882642 C G 8.87E-10 Red blood cell traits / / 23222517 rs531750 chr6 25882642 C G 3.15E-16 Urate levels / / 23263486 rs599444 chr6 25883714 A G 6.98E-04 Multiple complex diseases / / 17554300 rs599444 chr6 25883714 A G 1.30E-07 Urate levels / / 20884846 rs599444 chr6 25883714 A G 7.05E-10 Red blood cell traits / / 23222517 rs599444 chr6 25883714 A G 6.61E-16 Urate levels / / 23263486 rs504576 chr6 25885181 A G 6.47E-05 Multiple complex diseases / / 17554300 rs504576 chr6 25885181 A G 1.10E-05 Cognitive function / / 24684796 rs2575174 chr6 25885552 T C 7.00E-05 Multiple complex diseases / / 17554300 rs2575174 chr6 25885552 T C 1.60E-05 Cognitive function / / 24684796 rs629444 chr6 25885814 C T 3.52E-09 Multiple complex diseases / / 17554300 rs629444 chr6 25885814 C T 7.40E-08 Urate levels / / 20884846 rs629444 chr6 25885814 C T 3.50E-07 Red blood cell traits / / 23222517 rs629444 chr6 25885814 C T 7.17E-10 Urate levels / / 23263486 rs537581 chr6 25886497 C A 1.18E-07 Red blood cell traits / / 23222517 rs537581 chr6 25886497 C A 9.33E-15 Urate levels / / 23263486 rs483906 chr6 25888094 C G 3.32E-08 Red blood cell traits / / 23222517 rs483906 chr6 25888094 C G 1.08E-14 Urate levels / / 23263486 rs9379800 chr6 25889099 C G 2.75E-08 Red blood cell traits / / 23222517 rs9379800 chr6 25889099 C G 2.70E-19 Urate levels / / 23263486 rs518700 chr6 25889553 T A 2.40E-07 Red blood cell traits / / 23222517 rs518700 chr6 25889553 T A 1.17E-12 Urate levels / / 23263486 rs181947983 chr6 25889699 G A 0.0000562 Menopause (age at onset) / / 23424626 rs9467632 chr6 25889706 A G 4.91E-09 Urate levels / / 23263486 rs9348697 chr6 25890834 C T 9.55E-07 Red blood cell traits / / 23222517 rs574933 chr6 25891131 C G 6.62E-11 Other erythrocyte phenotypes / / 19862010 rs574933 chr6 25891131 C G 8.90E-12 Red blood cell traits / / 23222517 rs6910741 chr6 25895575 T C 4.08E-05 Cognitive impairment induced by topiramate / / 22091778 rs6910741 chr6 25895575 T C 1.90E-08 Red blood cell traits / / 23222517 rs6910741 chr6 25895575 T C 3.95E-13 Urate levels / / 23263486 rs6910741 chr6 25895575 T C 2.00E-06 Blood pressure / / 24954895 rs13220488 chr6 25896907 A G 1.52E-08 Urate levels / / 23263486 rs428469 chr6 25898624 G A 2.03E-08 Red blood cell traits / / 23222517 rs428469 chr6 25898624 G A 1.34E-11 Urate levels / / 23263486 rs16891142 chr6 25899139 G A 2.51E-13 Urate levels / / 23263486 rs13207673 chr6 25901133 C T 3.54E-08 Urate levels / / 23263486 rs9379801 chr6 25901711 T C 3.47E-08 Uric acid levels / / 19503597 rs9379801 chr6 25901711 T C 3.00E-12 Urate levels / / 20884846 rs9379801 chr6 25901711 T C 4.86E-07 Red blood cell traits / / 23222517 rs9379801 chr6 25901711 T C 1.50E-24 Urate levels / / 23263486 rs9356991 chr6 25901758 C A 2.03E-10 Other erythrocyte phenotypes / / 19862010 rs9356991 chr6 25901758 C A 1.05E-17 Red blood cell traits / / 23222517 rs9356991 chr6 25901758 C A 1.17E-17 Urate levels / / 23263486 rs6910138 chr6 25904352 C G 2.02E-10 Other erythrocyte phenotypes / / 19862010 rs6910138 chr6 25904352 C G 5.10E-18 Red blood cell traits / / 23222517 rs6910138 chr6 25904352 C G 2.16E-17 Urate levels / / 23263486 rs7748167 chr6 25904652 A C 4.19E-08 Urate levels / / 23263486 rs9461222 chr6 25905111 G A 6.97E-07 Red blood cell traits / / 23222517 rs9461222 chr6 25905111 G A 2.10E-08 Urate levels / / 23263486 rs9467635 chr6 25909166 A C 2.25E-08 Urate levels / / 23263486 rs3799371 chr6 25912816 C T 2.03E-10 Other erythrocyte phenotypes / / 19862010 rs3799371 chr6 25912816 C T 7.78E-19 Red blood cell traits / / 23222517 rs3799371 chr6 25912816 C T 2.38E-17 Urate levels / / 23263486 rs6932113 chr6 25913098 C T 6.66E-10 Other erythrocyte phenotypes SLC17A2 UTR-3 19862010 rs6932113 chr6 25913098 C T 5.53E-16 Red blood cell traits SLC17A2 UTR-3 23222517 rs6932113 chr6 25913098 C T 1.24E-16 Urate levels SLC17A2 UTR-3 23263486 rs6938233 chr6 25914077 C T 2.10E-10 Other erythrocyte phenotypes SLC17A2 intron 19862010 rs6938233 chr6 25914077 C T 8.67E-19 Red blood cell traits SLC17A2 intron 23222517 rs6938233 chr6 25914077 C T 3.75E-17 Urate levels SLC17A2 intron 23263486 rs2071301 chr6 25914263 C A 2.13E-10 Other erythrocyte phenotypes SLC17A2 intron 19862010 rs2071301 chr6 25914263 C A 3.18E-18 Red blood cell traits SLC17A2 intron 23222517 rs2071301 chr6 25914263 C A 1.96E-17 Urate levels SLC17A2 intron 23263486 rs2071300 chr6 25914572 C T 2.27E-07 Red blood cell traits SLC17A2 intron 23222517 rs1865760 chr6 25916979 C T 3.41E-08 Other erythrocyte phenotypes SLC17A2 cds-synon 19862010 rs1865760 chr6 25916979 C T 3.12E-16 Red blood cell traits SLC17A2 cds-synon 23222517 rs1865760 chr6 25916979 C T 2.24E-17 Urate levels SLC17A2 cds-synon 23263486 rs9295675 chr6 25918473 C T 2.39E-08 Urate levels SLC17A2 intron 23263486 rs3752421 chr6 25918688 G A 2.06E-10 Other erythrocyte phenotypes SLC17A2 intron 19862010 rs3752421 chr6 25918688 G A 1.84E-17 Red blood cell traits SLC17A2 intron 23222517 rs3752421 chr6 25918688 G A 1.72E-17 Urate levels SLC17A2 intron 23263486 rs17526722 chr6 25918855 G A 4.52E-08 Urate levels SLC17A2 intron 23263486 rs13195279 chr6 25919431 T A 3.79E-07 Red blood cell traits SLC17A2 intron 23222517 rs13195279 chr6 25919431 T A 3.36E-08 Urate levels SLC17A2 intron 23263486 rs9467636 chr6 25919549 A C 1.93E-10 Other erythrocyte phenotypes SLC17A2 intron 19862010 rs9467636 chr6 25919549 A C 8.45E-18 Red blood cell traits SLC17A2 intron 23222517 rs9467636 chr6 25919549 A C 1.76E-17 Urate levels SLC17A2 intron 23263486 rs7749342 chr6 25920265 T C 1.70E-10 Urate levels SLC17A2 intron 20884846 rs7749342 chr6 25920265 T C 2.33E-09 Urate levels SLC17A2 intron 21768215 rs7749342 chr6 25920265 T C 1.60E-07 Red blood cell traits SLC17A2 intron 23222517 rs7749342 chr6 25920265 T C 9.10E-29 Urate levels SLC17A2 intron 23263486 rs9358893 chr6 25921761 A G 1.82E-10 Other erythrocyte phenotypes SLC17A2 intron 19862010 rs9358893 chr6 25921761 A G 9.15E-18 Red blood cell traits SLC17A2 intron 23222517 rs9358893 chr6 25921761 A G 1.83E-17 Urate levels SLC17A2 intron 23263486 rs3799372 chr6 25922311 A G 1.79E-10 Other erythrocyte phenotypes SLC17A2 intron 19862010 rs3799372 chr6 25922311 A G 1.15E-17 Red blood cell traits SLC17A2 intron 23222517 rs3799372 chr6 25922311 A G 1.87E-17 Urate levels SLC17A2 intron 23263486 rs1540273 chr6 25924158 T C 1.77E-10 Other erythrocyte phenotypes SLC17A2 intron 19862010 rs1540273 chr6 25924158 T C 3.03E-17 Red blood cell traits SLC17A2 intron 23222517 rs1540273 chr6 25924158 T C 1.85E-17 Urate levels SLC17A2 intron 23263486 rs2071297 chr6 25924513 G C 1.72E-10 Other erythrocyte phenotypes SLC17A2 intron 19862010 rs2071297 chr6 25924513 G C 1.14E-17 Red blood cell traits SLC17A2 intron 23222517 rs2071297 chr6 25924513 G C 2.32E-17 Urate levels SLC17A2 intron 23263486 rs7770139 chr6 25925823 A G 1.91E-15 Red blood cell traits SLC17A2 intron 23222517 rs7770139 chr6 25925823 A G 1.79E-16 Urate levels SLC17A2 intron 23263486 rs3734523 chr6 25925987 G A 6.54E-05 Lung cancer SLC17A2 intron 18978787 rs3734523 chr6 25925987 G A 1.60E-08 Ankylosing spondylitis SLC17A2 intron 20062062 rs3734523 chr6 25925987 G A 1.51E-07 Red blood cell traits SLC17A2 intron 23222517 rs3734523 chr6 25925987 G A 3.18E-08 Urate levels SLC17A2 intron 23263486 rs10484431 chr6 25926674 A G 1.92E-04 Alzheimer's disease SLC17A2 intron 17998437 rs10484431 chr6 25926674 A G 8.64E-13 Urate levels SLC17A2 intron 23263486 rs17586553 chr6 25928775 G A,C,T 7.39E-07 Red blood cell traits SLC17A2 intron 23222517 rs17586553 chr6 25928775 G A,C,T 2.50E-08 Urate levels SLC17A2 intron 23263486 rs3799373 chr6 25929173 A C 1.87E-10 Other erythrocyte phenotypes SLC17A2 intron 19862010 rs3799373 chr6 25929173 A C 1.08E-17 Red blood cell traits SLC17A2 intron 23222517 rs3799373 chr6 25929173 A C 3.04E-17 Urate levels SLC17A2 intron 23263486 rs199741 chr6 25931577 A G 1.74E-08 Red blood cell traits / / 23222517 rs199741 chr6 25931577 A G 2.84E-10 Urate levels / / 23263486 rs199737 chr6 25933538 A T 1.50E-09 Uric acid levels / / 19503597 rs199737 chr6 25933538 A T 3.99E-08 Other erythrocyte phenotypes / / 19862010 rs199737 chr6 25933538 A T 3.41E-07 Red blood cell traits / / 23222517 rs199737 chr6 25933538 A T 3.09E-19 Urate levels / / 23263486 rs442601 chr6 25934524 G A 3.06E-09 Uric acid levels / / 19503597 rs442601 chr6 25934524 G A 2.16E-09 Other erythrocyte phenotypes / / 19862010 rs442601 chr6 25934524 G A 3.50E-10 Red blood cell traits / / 23222517 rs442601 chr6 25934524 G A 3.61E-18 Urate levels / / 23263486 rs9461224 chr6 25936402 G T 3.01E-10 Other erythrocyte phenotypes / / 19862010 rs9461224 chr6 25936402 G T 5.75E-19 Red blood cell traits / / 23222517 rs9461224 chr6 25936402 G T 8.93E-18 Urate levels / / 23263486 rs199736 chr6 25936787 C T 2.96E-09 Uric acid levels / / 19503597 rs199736 chr6 25936787 C T 2.18E-09 Other erythrocyte phenotypes / / 19862010 rs199736 chr6 25936787 C T 9.66E-07 Red blood cell traits / / 23222517 rs199736 chr6 25936787 C T 2.83E-18 Urate levels / / 23263486 rs9393676 chr6 25936944 G A 1.42E-08 Uric acid levels / / 19503597 rs9393676 chr6 25936944 G A 9.20E-12 Urate levels / / 20884846 rs9393676 chr6 25936944 G A 3.60E-10 Urate levels / / 21768215 rs9393676 chr6 25936944 G A 6.63E-09 Red blood cell traits / / 23222517 rs9393676 chr6 25936944 G A 2.06E-31 Urate levels / / 23263486 rs9295678 chr6 25937033 G A 1.15E-08 Uric acid levels / / 19503597 rs9295678 chr6 25937033 G A 9.40E-12 Urate levels / / 20884846 rs9295678 chr6 25937033 G A 3.62E-10 Urate levels / / 21768215 rs9295678 chr6 25937033 G A 6.78E-09 Red blood cell traits / / 23222517 rs9295678 chr6 25937033 G A 2.13E-31 Urate levels / / 23263486 rs1436307 chr6 25939723 C T 3.27E-10 Other erythrocyte phenotypes / / 19862010 rs1436307 chr6 25939723 C T 6.07E-18 Red blood cell traits / / 23222517 rs1436307 chr6 25939723 C T 1.06E-17 Urate levels / / 23263486 rs199734 chr6 25940393 G C 2.46E-09 Uric acid levels / / 19503597 rs199734 chr6 25940393 G C 1.88E-08 Other erythrocyte phenotypes / / 19862010 rs199734 chr6 25940393 G C 6.56E-10 Red blood cell traits / / 23222517 rs199734 chr6 25940393 G C 1.94E-19 Urate levels / / 23263486 rs9379806 chr6 25940958 G A 2.92E-10 Other erythrocyte phenotypes / / 19862010 rs9379806 chr6 25940958 G A 4.74E-18 Red blood cell traits / / 23222517 rs9379806 chr6 25940958 G A 6.13E-18 Urate levels / / 23263486 rs9358896 chr6 25943197 C A 2.93E-10 Other erythrocyte phenotypes / / 19862010 rs9358896 chr6 25943197 C A 7.39E-14 Red blood cell traits / / 23222517 rs9358896 chr6 25943197 C A 1.69E-17 Urate levels / / 23263486 rs13192713 chr6 25943234 C A 1.03E-07 Red blood cell traits / / 23222517 rs9295680 chr6 25944103 T C 1.76E-10 Other erythrocyte phenotypes / / 19862010 rs9295680 chr6 25944103 T C 6.52E-18 Red blood cell traits / / 23222517 rs9295680 chr6 25944103 T C 1.03E-18 Urate levels / / 23263486 rs9295681 chr6 25944117 T G 1.83E-10 Other erythrocyte phenotypes / / 19862010 rs9295681 chr6 25944117 T G 2.25E-17 Red blood cell traits / / 23222517 rs9295681 chr6 25944117 T G 5.00E-20 Urate levels / / 23263486 rs7746105 chr6 25944278 A C 6.66E-06 Alzheimer's disease / / 17998437 rs2051541 chr6 25945211 A G 1.02E-09 Uric acid levels / / 19503597 rs2051541 chr6 25945211 A G 5.90E-12 Urate levels / / 20884846 rs2051541 chr6 25945211 A G 1.40E-11 Urate levels / / 21768215 rs2051541 chr6 25945211 A G 1.11E-09 Red blood cell traits / / 23222517 rs2051541 chr6 25945211 A G 7.44E-31 Urate levels / / 23263486 rs1436306 chr6 25948421 A G 2.51E-10 Other erythrocyte phenotypes / / 19862010 rs1436306 chr6 25948421 A G 2.29E-17 Red blood cell traits / / 23222517 rs1436306 chr6 25948421 A G 6.17E-20 Urate levels / / 23263486 rs1541987 chr6 25950397 C T 2.52E-10 Other erythrocyte phenotypes / / 19862010 rs1541987 chr6 25950397 C T 2.14E-18 Red blood cell traits / / 23222517 rs1541987 chr6 25950397 C T 3.85E-20 Urate levels / / 23263486 rs9348699 chr6 25951709 C T 1.99E-05 Multiple complex diseases / / 17554300 rs199726 chr6 25953360 G A 3.42E-09 Uric acid levels / / 19503597 rs199726 chr6 25953360 G A 2.23E-09 Other erythrocyte phenotypes / / 19862010 rs199726 chr6 25953360 G A 3.67E-10 Red blood cell traits / / 23222517 rs199726 chr6 25953360 G A 2.16E-18 Urate levels / / 23263486 rs2876693 chr6 25954434 C G 3.23E-10 Other erythrocyte phenotypes / / 19862010 rs2876693 chr6 25954434 C G 3.30E-18 Red blood cell traits / / 23222517 rs2876693 chr6 25954434 C G 1.52E-17 Urate levels / / 23263486 rs169219 chr6 25957392 C A 1.54E-04 Coronary heart disease / / 21971053 rs169219 chr6 25957392 C A 0.000000001 Mean corpuscular volume / / 22560525 rs169219 chr6 25957392 C A 1.00E-11 Mean corpuscular hemoglobin / / 22560525 rs169219 chr6 25957392 C A 1.54E-09 Red blood cell traits / / 23222517 rs9467646 chr6 25957408 A G 3.26E-10 Other erythrocyte phenotypes / / 19862010 rs9467646 chr6 25957408 A G 5.28E-19 Red blood cell traits / / 23222517 rs9467646 chr6 25957408 A G 1.04E-17 Urate levels / / 23263486 rs9467647 chr6 25957642 A G 2.46E-10 Other erythrocyte phenotypes / / 19862010 rs9467647 chr6 25957642 A G 5.43E-17 Red blood cell traits / / 23222517 rs9467647 chr6 25957642 A G 5.69E-20 Urate levels / / 23263486 rs10946800 chr6 25957773 C T 2.43E-10 Other erythrocyte phenotypes / / 19862010 rs10946800 chr6 25957773 C T 4.77E-17 Red blood cell traits / / 23222517 rs10946800 chr6 25957773 C T 6.36E-20 Urate levels / / 23263486 rs12195653 chr6 25958621 A G 3.04E-10 Other erythrocyte phenotypes / / 19862010 rs12195653 chr6 25958621 A G 6.07E-18 Red blood cell traits / / 23222517 rs12195653 chr6 25958621 A G 7.51E-18 Urate levels / / 23263486 rs9467652 chr6 25959127 A G 2.28E-10 Other erythrocyte phenotypes / / 19862010 rs9467652 chr6 25959127 A G 1.02E-17 Red blood cell traits / / 23222517 rs9467652 chr6 25959127 A G 6.56E-19 Urate levels / / 23263486 rs199739 chr6 25960509 A C 1.92E-09 Uric acid levels / / 19503597 rs199739 chr6 25960509 A C 1.73E-08 Other erythrocyte phenotypes / / 19862010 rs199739 chr6 25960509 A C 1.42E-07 Red blood cell traits / / 23222517 rs199739 chr6 25960509 A C 9.81E-20 Urate levels / / 23263486 rs129129 chr6 25961029 A G 2.23E-09 Uric acid levels / / 19503597 rs129129 chr6 25961029 A G 2.15E-09 Other erythrocyte phenotypes / / 19862010 rs129129 chr6 25961029 A G 1.21E-08 Red blood cell traits / / 23222517 rs129129 chr6 25961029 A G 3.85E-18 Urate levels / / 23263486 rs17587226 chr6 25962304 C T 8.41E-07 Red blood cell traits / / 23222517 rs12210098 chr6 25963966 C T 1.09E-13 Other erythrocyte phenotypes TRIM38 intron 19862010 rs12210098 chr6 25963966 C T 2.80E-06 Urinary metabolites TRIM38 intron 21572414 rs12210098 chr6 25963966 C T 9.60E-18 Red blood cell traits TRIM38 intron 23222517 rs12210098 chr6 25963966 C T 2.73E-13 Urate levels TRIM38 intron 23263486 rs1436310 chr6 25969958 G C 3.72E-13 Other erythrocyte phenotypes TRIM38 intron 19862010 rs1436310 chr6 25969958 G C 7.49E-18 Red blood cell traits TRIM38 intron 23222517 rs1436310 chr6 25969958 G C 8.79E-20 Urate levels TRIM38 intron 23263486 rs1436309 chr6 25970109 T A 5.99E-13 Other erythrocyte phenotypes TRIM38 intron 19862010 rs1436309 chr6 25970109 T A 1.29E-18 Red blood cell traits TRIM38 intron 23222517 rs1436309 chr6 25970109 T A 8.26E-20 Urate levels TRIM38 intron 23263486 rs12192649 chr6 25974450 G A 1.83E-07 Red blood cell traits TRIM38 intron 23222517 rs115810 chr6 25975883 G C 8.92E-10 Uric acid levels TRIM38 intron 19503597 rs115810 chr6 25975883 G C 1.06E-09 Other erythrocyte phenotypes TRIM38 intron 19862010 rs115810 chr6 25975883 G C 1.30E-07 Urate levels TRIM38 intron 20884846 rs115810 chr6 25975883 G C 1.35E-10 Urate levels TRIM38 intron 21768215 rs115810 chr6 25975883 G C 6.24E-12 Red blood cell traits TRIM38 intron 23222517 rs115810 chr6 25975883 G C 6.40E-20 Urate levels TRIM38 intron 23263486 rs1130000 chr6 25985396 A G 3.84E-13 Other erythrocyte phenotypes / / 19862010 rs1130000 chr6 25985396 A G 6.73E-21 Red blood cell traits / / 23222517 rs1130000 chr6 25985396 A G 4.92E-16 Urate levels / / 23263486 rs2032450 chr6 25993114 C G 3.78E-13 Other erythrocyte phenotypes / / 19862010 rs2032450 chr6 25993114 C G 1.11E-20 Red blood cell traits / / 23222517 rs2032450 chr6 25993114 C G 5.80E-16 Urate levels / / 23263486 rs9467656 chr6 25993559 G A 2.15E-13 Other erythrocyte phenotypes / / 19862010 rs9467656 chr6 25993559 G A 2.66E-14 Red blood cell traits / / 23222517 rs9467656 chr6 25993559 G A 4.48E-16 Urate levels / / 23263486 rs2013063 chr6 25994098 C T 9.27E-11 Other erythrocyte phenotypes / / 19862010 rs2013063 chr6 25994098 C T 4.48E-05 Orofacial clefts / / 20023658 rs2013063 chr6 25994098 C T 4.21E-20 Red blood cell traits / / 23222517 rs2013063 chr6 25994098 C T 3.56E-16 Urate levels / / 23263486 rs12216125 chr6 25997458 C T 4.00E-06 Iron status biomarkers / / 19084217 rs12216125 chr6 25997458 C T 1.42E-12 Other erythrocyte phenotypes / / 19862010 rs12216125 chr6 25997458 C T 1.90E-05 Urinary metabolites / / 21572414 rs12216125 chr6 25997458 C T 0.00000005 Mean corpuscular hemoglobin concentration / / 22560525 rs12216125 chr6 25997458 C T 6.00E-12 Mean corpuscular hemoglobin / / 22560525 rs12216125 chr6 25997458 C T 4.61E-20 Red blood cell traits / / 23222517 rs12216125 chr6 25997458 C T 1.32E-11 Urate levels / / 23263486 rs6901039 chr6 26000885 T G 4.73E-05 Bipolar disorder / / 19488044 rs6901039 chr6 26000885 T G 7.23E-05 Bipolar disorder and schizophrenia / / 20889312 rs199753 chr6 26001888 G A 8.36E-10 Uric acid levels / / 19503597 rs199753 chr6 26001888 G A 1.14E-09 Other erythrocyte phenotypes / / 19862010 rs199753 chr6 26001888 G A 1.10E-07 Urate levels / / 20884846 rs199753 chr6 26001888 G A 1.50E-10 Urate levels / / 21768215 rs199753 chr6 26001888 G A 1.14E-12 Red blood cell traits / / 23222517 rs199753 chr6 26001888 G A 1.27E-14 Urate levels / / 23263486 rs9393681 chr6 26008260 T C 9.20E-05 Height / / 19396169 rs9393681 chr6 26008260 T C 2.05E-13 Other erythrocyte phenotypes / / 19862010 rs9393681 chr6 26008260 T C 1.70E-19 Red blood cell traits / / 23222517 rs9393681 chr6 26008260 T C 1.36E-15 Urate levels / / 23263486 rs10484432 chr6 26008876 G A 1.43E-08 Red blood cell traits / / 23222517 rs9467658 chr6 26010881 T A,C,G 1.56E-13 Other erythrocyte phenotypes / / 19862010 rs9467658 chr6 26010881 T A,C,G 2.97E-18 Red blood cell traits / / 23222517 rs9467658 chr6 26010881 T A,C,G 2.25E-17 Urate levels / / 23263486 rs199752 chr6 26012875 C T 1.40E-09 Uric acid levels / / 19503597 rs199752 chr6 26012875 C T 1.82E-09 Other erythrocyte phenotypes / / 19862010 rs199752 chr6 26012875 C T 1.60E-07 Urate levels / / 20884846 rs199752 chr6 26012875 C T 1.51E-10 Urate levels / / 21768215 rs199752 chr6 26012875 C T 4.82E-09 Red blood cell traits / / 23222517 rs199752 chr6 26012875 C T 3.28E-16 Urate levels / / 23263486 rs199751 chr6 26015583 T C 5.53E-10 Uric acid levels / / 19503597 rs199751 chr6 26015583 T C 1.52E-09 Other erythrocyte phenotypes / / 19862010 rs199751 chr6 26015583 T C 5.40E-08 Urate levels / / 20884846 rs199751 chr6 26015583 T C 1.61E-10 Urate levels / / 21768215 rs199751 chr6 26015583 T C 7.25E-12 Red blood cell traits / / 23222517 rs199751 chr6 26015583 T C 2.89E-17 Urate levels / / 23263486 rs199750 chr6 26016462 C T 4.91E-10 Uric acid levels / / 19503597 rs199750 chr6 26016462 C T 5.20E-08 Urate levels / / 20884846 rs199750 chr6 26016462 C T 1.61E-10 Urate levels / / 21768215 rs199750 chr6 26016462 C T 5.55E-09 Red blood cell traits / / 23222517 rs199750 chr6 26016462 C T 2.86E-17 Urate levels / / 23263486 rs9461230 chr6 26019240 G C 1.59E-12 Other erythrocyte phenotypes / / 19862010 rs9461230 chr6 26019240 G C 9.23E-18 Red blood cell traits / / 23222517 rs9461230 chr6 26019240 G C 4.66E-16 Urate levels / / 23263486 rs2157050 chr6 26020431 C T 5.69E-10 Other erythrocyte phenotypes / / 19862010 rs2157050 chr6 26020431 C T 1.46E-11 Red blood cell traits / / 23222517 rs2157050 chr6 26020431 C T 4.36E-12 Urate levels / / 23263486 rs9467664 chr6 26021813 A T 2.34E-09 Uric acid levels / / 19503597 rs9467664 chr6 26021813 A T 7.17E-09 Other erythrocyte phenotypes / / 19862010 rs9467664 chr6 26021813 A T 2.80E-07 Urate levels / / 20884846 rs9467664 chr6 26021813 A T 1.70E-10 Urate levels / / 21768215 rs9467664 chr6 26021813 A T 3.38E-08 Red blood cell traits / / 23222517 rs9467664 chr6 26021813 A T 1.60E-16 Urate levels / / 23263486 rs9379818 chr6 26023206 G T 6.68E-06 Iron status biomarkers / / 19084217 rs9379818 chr6 26023206 G T 3.00E-10 Other erythrocyte phenotypes / / 19862010 rs9379818 chr6 26023206 G T 9.24E-05 Orofacial clefts / / 20023658 rs9379818 chr6 26023206 G T 0.000000004 Mean corpuscular hemoglobin / / 22560525 rs9379818 chr6 26023206 G T 1.58E-18 Red blood cell traits / / 23222517 rs9379818 chr6 26023206 G T 1.13E-13 Urate levels / / 23263486 rs9358901 chr6 26024436 G T 1.26E-09 Uric acid levels / / 19503597 rs9358901 chr6 26024436 G T 2.66E-09 Other erythrocyte phenotypes / / 19862010 rs9358901 chr6 26024436 G T 8.54E-10 Urate levels / / 21768215 rs9358901 chr6 26024436 G T 6.37E-09 Red blood cell traits / / 23222517 rs9358901 chr6 26024436 G T 2.91E-15 Urate levels / / 23263486 rs2032449 chr6 26026599 G C 4.81E-13 Other erythrocyte phenotypes / / 19862010 rs2032449 chr6 26026599 G C 7.12E-21 Red blood cell traits / / 23222517 rs2032449 chr6 26026599 G C 7.20E-11 Urate levels / / 23263486 rs3752419 chr6 26027433 G A 5.27E-13 Other erythrocyte phenotypes HIST1H4B cds-synon 19862010 rs3752419 chr6 26027433 G A 4.69E-16 Red blood cell traits HIST1H4B cds-synon 23222517 rs3752419 chr6 26027433 G A 1.48E-11 Urate levels HIST1H4B cds-synon 23263486 rs1540276 chr6 26028819 T G 9.91E-10 Uric acid levels / / 19503597 rs1540276 chr6 26028819 T G 6.48E-09 Other erythrocyte phenotypes / / 19862010 rs1540276 chr6 26028819 T G 4.00E-07 Urate levels / / 20884846 rs1540276 chr6 26028819 T G 1.74E-10 Urate levels / / 21768215 rs1540276 chr6 26028819 T G 4.74E-13 Red blood cell traits / / 23222517 rs1540276 chr6 26028819 T G 2.11E-17 Urate levels / / 23263486 rs10484433 chr6 26030492 C A 5.73E-07 Red blood cell traits / / 23222517 rs10484434 chr6 26031613 G A 1.00E-06 HIV-1 viral setpoint / / 22174851 rs10484435 chr6 26031811 T G 9.71E-10 Multiple complex diseases / / 17554300 rs10484435 chr6 26031811 T G 6.58E-07 Red blood cell traits / / 23222517 rs2213284 chr6 26031868 G A 1.16E-09 Uric acid levels HIST1H3B UTR-3 19503597 rs2213284 chr6 26031868 G A 1.91E-10 Urate levels HIST1H3B UTR-3 21768215 rs2213284 chr6 26031868 G A 3.34E-11 Red blood cell traits HIST1H3B UTR-3 23222517 rs2213284 chr6 26031868 G A 1.09E-16 Urate levels HIST1H3B UTR-3 23263486 rs2230655 chr6 26033506 G A 4.69E-10 Uric acid levels HIST1H2AB cds-synon 19503597 rs2230655 chr6 26033506 G A 1.82E-10 Urate levels HIST1H2AB cds-synon 21768215 rs2230655 chr6 26033506 G A 6.33E-07 Red blood cell traits HIST1H2AB cds-synon 23222517 rs2230655 chr6 26033506 G A 5.76E-17 Urate levels HIST1H2AB cds-synon 23263486 rs4401650 chr6 26035208 G A 1.18E-09 Uric acid levels / / 19503597 rs4401650 chr6 26035208 G A 2.94E-09 Other erythrocyte phenotypes / / 19862010 rs4401650 chr6 26035208 G A 9.34E-10 Urate levels / / 21768215 rs4401650 chr6 26035208 G A 4.92E-07 Red blood cell traits / / 23222517 rs4401650 chr6 26035208 G A 1.05E-15 Urate levels / / 23263486 rs1540275 chr6 26036476 T C 6.74E-10 Uric acid levels / / 19503597 rs1540275 chr6 26036476 T C 1.94E-10 Urate levels / / 21768215 rs1540275 chr6 26036476 T C 3.86E-11 Red blood cell traits / / 23222517 rs1540275 chr6 26036476 T C 6.01E-17 Urate levels / / 23263486 rs7753826 chr6 26042239 T A 2.54E-09 Other erythrocyte phenotypes / / 19862010 rs7753826 chr6 26042239 T A 3.30E-13 Red blood cell traits / / 23222517 rs7753826 chr6 26042239 T A 2.10E-09 Urate levels / / 23263486 rs2032447 chr6 26044369 A G 2.08E-08 Uric acid levels / / 19503597 rs2032447 chr6 26044369 A G 8.70E-10 Other erythrocyte phenotypes / / 19862010 rs2032447 chr6 26044369 A G 7.83E-09 Urate levels / / 21768215 rs2032447 chr6 26044369 A G 4.61E-04 Coronary heart disease / / 21971053 rs2032447 chr6 26044369 A G 7.74E-07 Red blood cell traits / / 23222517 rs2032447 chr6 26044369 A G 2.26E-13 Urate levels / / 23263486 rs11755492 chr6 26046158 T C 1.75E-06 HIV-1 viral setpoint / / 22174851 rs7756117 chr6 26046565 G A 7.86E-10 Uric acid levels / / 19503597 rs7756117 chr6 26046565 G A 2.35E-09 Other erythrocyte phenotypes / / 19862010 rs7756117 chr6 26046565 G A 1.01E-09 Urate levels / / 21768215 rs7756117 chr6 26046565 G A 4.40E-07 Red blood cell traits / / 23222517 rs7756117 chr6 26046565 G A 9.17E-16 Urate levels / / 23263486 rs7772312 chr6 26049616 G C 4.56E-13 Other erythrocyte phenotypes / / 19862010 rs7772312 chr6 26049616 G C 2.03E-20 Red blood cell traits / / 23222517 rs7772312 chr6 26049616 G C 2.10E-10 Urate levels / / 23263486 rs9379820 chr6 26049924 T C 4.26E-13 Other erythrocyte phenotypes / / 19862010 rs9379820 chr6 26049924 T C 1.39E-20 Red blood cell traits / / 23222517 rs9379820 chr6 26049924 T C 1.85E-10 Urate levels / / 23263486 rs13220395 chr6 26055368 G A 9.63E-07 Red blood cell traits / / 23222517 rs8384 chr6 26056072 G C 1.14E-08 Red blood cell traits HIST1H1C cds-synon 23222517 rs10425 chr6 26056549 A G 3.23E-08 Uric acid levels HIST1H1C cds-synon 19503597 rs10425 chr6 26056549 A G 7.68E-09 Urate levels HIST1H1C cds-synon 21768215 rs10425 chr6 26056549 A G 1.03E-08 Red blood cell traits HIST1H1C cds-synon 23222517 rs10425 chr6 26056549 A G 2.62E-18 Urate levels HIST1H1C cds-synon 23263486 rs807214 chr6 26061769 G C 8.43E-10 Uric acid levels / / 19503597 rs807214 chr6 26061769 G C 3.80E-07 Urate levels / / 20884846 rs807214 chr6 26061769 G C 1.86E-09 Urate levels / / 21768215 rs807214 chr6 26061769 G C 1.43E-08 Red blood cell traits / / 23222517 rs807214 chr6 26061769 G C 6.24E-21 Urate levels / / 23263486 rs9358903 chr6 26061949 A C 3.85E-13 Other erythrocyte phenotypes / / 19862010 rs9358903 chr6 26061949 A C 3.08E-20 Red blood cell traits / / 23222517 rs9358903 chr6 26061949 A C 3.44E-13 Urate levels / / 23263486 rs807212 chr6 26065621 A G 1.39E-09 Uric acid levels / / 19503597 rs807212 chr6 26065621 A G 4.15E-09 Other erythrocyte phenotypes / / 19862010 rs807212 chr6 26065621 A G 3.80E-07 Urate levels / / 20884846 rs807212 chr6 26065621 A G 2.20E-10 Urate levels / / 21768215 rs807212 chr6 26065621 A G 7.12E-08 Red blood cell traits / / 23222517 rs807212 chr6 26065621 A G 3.18E-18 Urate levels / / 23263486 rs9358904 chr6 26068566 G A 2.25E-13 Red blood cell traits / / 23222517 rs9295684 chr6 26069669 T C 1.00E-14 Other erythrocyte phenotypes / / 19862010 rs9295684 chr6 26069669 T C 6.96E-05 Orofacial clefts / / 20023658 rs9295684 chr6 26069669 T C 0.00000002 Mean corpuscular hemoglobin / / 22560525 rs9295684 chr6 26069669 T C 2.55E-21 Red blood cell traits / / 23222517 rs9295684 chr6 26069669 T C 6.23E-13 Urate levels / / 23263486 rs9295685 chr6 26071725 G C 1.72E-16 Other erythrocyte phenotypes / / 19862010 rs9295685 chr6 26071725 G C 2.96E-19 Red blood cell traits / / 23222517 rs9295685 chr6 26071725 G C 2.43E-08 Urate levels / / 23263486 rs9366634 chr6 26072396 C G 1.92E-08 Red blood cell traits / / 23222517 rs16891264 chr6 26072445 T C 1.88E-10 Multiple complex diseases / / 17554300 rs16891264 chr6 26072445 T C 9.46E-07 Red blood cell traits / / 23222517 rs9295687 chr6 26082710 T C 2.76E-13 Other erythrocyte phenotypes / / 19862010 rs9295687 chr6 26082710 T C 1.18E-20 Red blood cell traits / / 23222517 rs9295687 chr6 26082710 T C 5.83E-11 Urate levels / / 23263486 rs4529296 chr6 26083135 C G 2.72E-13 Other erythrocyte phenotypes / / 19862010 rs4529296 chr6 26083135 C G 5.82E-21 Red blood cell traits / / 23222517 rs4529296 chr6 26083135 C G 6.07E-11 Urate levels / / 23263486 rs9379825 chr6 26083871 C A 2.70E-13 Other erythrocyte phenotypes / / 19862010 rs9379825 chr6 26083871 C A 1.73E-20 Red blood cell traits / / 23222517 rs9379825 chr6 26083871 C A 5.30E-11 Urate levels / / 23263486 rs9467672 chr6 26083904 C T 2.66E-13 Other erythrocyte phenotypes / / 19862010 rs9467672 chr6 26083904 C T 6.47E-21 Red blood cell traits / / 23222517 rs9467672 chr6 26083904 C T 5.25E-11 Urate levels / / 23263486 rs9295688 chr6 26084217 G A 3.10E-13 Other erythrocyte phenotypes / / 19862010 rs9295688 chr6 26084217 G A 1.73E-20 Red blood cell traits / / 23222517 rs9295688 chr6 26084217 G A 5.15E-11 Urate levels / / 23263486 rs2006736 chr6 26086017 C T 3.05E-13 Other erythrocyte phenotypes HFE nearGene-5 19862010 rs2006736 chr6 26086017 C T 4.90E-21 Red blood cell traits HFE nearGene-5 23222517 rs2006736 chr6 26086017 C T 5.74E-11 Urate levels HFE nearGene-5 23263486 rs1800702 chr6 26086463 C G 2.99E-13 Other erythrocyte phenotypes HFE nearGene-5 19862010 rs1800702 chr6 26086463 C G 5.72E-21 Red blood cell traits HFE nearGene-5 23222517 rs1800702 chr6 26086463 C G 5.30E-11 Urate levels HFE nearGene-5 23263486 rs2794720 chr6 26087202 G C 1.80E-10 Other erythrocyte phenotypes HFE nearGene-5 19862010 rs2794720 chr6 26087202 G C 4.94E-17 Red blood cell traits HFE nearGene-5 23222517 rs2794720 chr6 26087202 G C 1.62E-10 Urate levels HFE nearGene-5 23263486 rs2794719 chr6 26088890 T G 2.93E-13 Other erythrocyte phenotypes HFE intron 19862010 rs2794719 chr6 26088890 T G 6.39E-05 Orofacial clefts HFE intron 20023658 rs2794719 chr6 26088890 T G 0.00000002 Mean corpuscular hemoglobin HFE intron 22560525 rs2794719 chr6 26088890 T G 1.52E-20 Red blood cell traits HFE intron 23222517 rs2794719 chr6 26088890 T G 5.41E-11 Urate levels HFE intron 23263486 rs1799945 chr6 26091179 C G 1 Drug response to Epoetin Alfa HFE missense 18025780 rs1799945 chr6 26091179 C G 4.34E-08 Hemoglobin HFE missense 19820698 rs1799945 chr6 26091179 C G 1.78E-24 Other erythrocyte phenotypes HFE missense 19862010 rs1799945 chr6 26091179 C G 3.00E-09 Iron levels HFE missense 21208937 rs1799945 chr6 26091179 C G 6.55E-12 Blood pressure HFE missense 21909110 rs1799945 chr6 26091179 C G 2.00E-10 Hypertension HFE missense 21909115 rs1799945 chr6 26091179 C G 2.00E-15 Diastolic blood pressure HFE missense 21909115 rs1799945 chr6 26091179 C G 8.00E-12 Systolic blood pressure HFE missense 21909115 rs1799945 chr6 26091179 C G 1.10E-08 Blood pressure HFE missense 22100073 rs1799945 chr6 26091179 C G 1.97E-09 Blood pressure HFE missense 22100073 rs1799945 chr6 26091179 C G 2.12E-06 Blood pressure HFE missense 22100073 rs1799945 chr6 26091179 C G 2.89E-08 Blood pressure HFE missense 22100073 rs1799945 chr6 26091179 C G 2.90E-04 Blood pressure HFE missense 22100073 rs1799945 chr6 26091179 C G 3.60E-26 Red blood cell traits HFE missense 23222517 rs2071303 chr6 26091336 T C 2.50E-07 Urate levels HFE intron 20884846 rs2071303 chr6 26091336 T C 9.68E-08 Urate levels HFE intron 21768215 rs2071303 chr6 26091336 T C 4.57E-04 Lymphocyte counts HFE intron 22286170 rs2071303 chr6 26091336 T C 4.67E-07 Red blood cell traits HFE intron 23222517 rs2071303 chr6 26091336 T C 9.80E-17 Urate levels HFE intron 23263486 rs1800562 chr6 26093141 G A 1 Drug response to Epoetin Alfa HFE missense 18025780 rs1800562 chr6 26093141 G A 1.00E-10 Iron status biomarkers HFE missense 19084217 rs1800562 chr6 26093141 G A 4.00E-11 Iron status biomarkers HFE missense 19084217 rs1800562 chr6 26093141 G A 4.00E-15 Iron status biomarkers HFE missense 19084217 rs1800562 chr6 26093141 G A 1.00E-23 Hematological parameters HFE missense 19820697 rs1800562 chr6 26093141 G A 2.00E-08 Iron status biomarkers HFE missense 19820699 rs1800562 chr6 26093141 G A 5.00E-07 Iron status biomarkers HFE missense 19820699 rs1800562 chr6 26093141 G A 1.00E-46 Mean corpuscular volume HFE missense 19862010 rs1800562 chr6 26093141 G A 2.00E-09 Hematocrit HFE missense 19862010 rs1800562 chr6 26093141 G A 6.00E-19 Hemoglobin HFE missense 19862010 rs1800562 chr6 26093141 G A 2.00E-08 Cholesterol,total HFE missense 20686565 rs1800562 chr6 26093141 G A 6.00E-10 LDL cholesterol HFE missense 20686565 rs1800562 chr6 26093141 G A 3.00E-20 Glycated Hemoglobin levels HFE missense 20858683 rs1800562 chr6 26093141 G A 3.00E-09 Red blood cell traits HFE missense 20927387 rs1800562 chr6 26093141 G A 6.00E-07 Red blood cell traits HFE missense 20927387 rs1800562 chr6 26093141 G A 1.17E-09 Iron status biomarkers HFE missense 21149283 rs1800562 chr6 26093141 G A 1.40E-15 Blood cell counts and traits,in red and white blood cells HFE missense 21153663 rs1800562 chr6 26093141 G A 2.50E-10 Blood cell counts and traits,in red and white blood cells HFE missense 21153663 rs1800562 chr6 26093141 G A 6.80E-16 Blood cell counts and traits,in red and white blood cells HFE missense 21153663 rs1800562 chr6 26093141 G A 3.00E-08 Iron status biomarkers HFE missense 21483845 rs1800562 chr6 26093141 G A 6.00E-10 Iron status biomarkers HFE missense 21483845 rs1800562 chr6 26093141 G A 2.00E-32 Alcohol consumption (transferrin glycosylation) HFE missense 21665994 rs1800562 chr6 26093141 G A 3.00E-07 Hepcidin levels HFE missense 21785125 rs1800562 chr6 26093141 G A 3.00E-15 Hepcidin levels HFE missense 21785125 rs1800562 chr6 26093141 G A 4.00E-09 Hepcidin levels HFE missense 21785125 rs1800562 chr6 26093141 G A 5.00E-11 Hepcidin levels HFE missense 21785125 rs1800562 chr6 26093141 G A 7.26E-07 Systolic blood pressure HFE missense 21909115 rs1800562 chr6 26093141 G A 5.00E-12 Cardiovascular disease risk factors HFE missense 21943158 rs1800562 chr6 26093141 G A 0.000000002 Hemoglobin HFE missense 22560525 rs1800562 chr6 26093141 G A 1.00E-10 Mean corpuscular hemoglobin concentration HFE missense 22560525 rs1800562 chr6 26093141 G A 2.00E-21 Mean corpuscular volume HFE missense 22560525 rs1800562 chr6 26093141 G A 2.00E-27 Mean corpuscular hemoglobin HFE missense 22560525 rs1800562 chr6 26093141 G A 2.59E-20 Glycated hemoglobin levels HFE missense 22885924 rs1800562 chr6 26093141 G A 5.57E-13 Red blood cell traits HFE missense 23222517 rs1800562 chr6 26093141 G A 2.00E-06 Hematology traits HFE missense 23263863 rs1800562 chr6 26093141 G A 7.00E-09 Mean corpuscular hemoglobin HFE missense 23263863 rs1800562 chr6 26093141 G A 4.00E-06 Red blood cell traits HFE missense 23446634 rs1800562 chr6 26093141 G A 2.00E-12 Cholesterol,total HFE missense 24097068 rs1800562 chr6 26093141 G A 8.00E-14 LDL cholesterol HFE missense 24097068 rs1800562 chr6 26093141 G A 5.92E-05 Hemoglobin HFE missense pha003098 rs1800758 chr6 26093236 G A 1.70E-04 Coronary heart disease HFE intron 21966275 rs1572982 chr6 26094367 G A 4.26E-09 Urate levels HFE intron 23263486 rs707889 chr6 26095931 G A 1.45E-08 Red blood cell traits HFE nearGene-3 23222517 rs12346 chr6 26097046 T C 2.04E-10 Urate levels / / 21768215 rs12346 chr6 26097046 T C 8.51E-11 Red blood cell traits / / 23222517 rs12346 chr6 26097046 T C 1.24E-16 Urate levels / / 23263486 rs17596719 chr6 26097194 G A 2.16E-05 HIV-1 viral setpoint / / 22174851 rs6918586 chr6 26097384 T C 2.73E-07 Urate levels / / 21768215 rs6918586 chr6 26097384 T C 2.12E-09 Urate levels / / 23263486 rs1150659 chr6 26100023 G A 1.97E-08 Red blood cell traits / / 23222517 rs1150660 chr6 26101440 A C 2.87E-09 Uric acid levels / / 19503597 rs1150660 chr6 26101440 A C 4.87E-10 Other erythrocyte phenotypes / / 19862010 rs1150660 chr6 26101440 A C 1.98E-10 Urate levels / / 21768215 rs1150660 chr6 26101440 A C 5.98E-09 Red blood cell traits / / 23222517 rs1150660 chr6 26101440 A C 2.50E-16 Urate levels / / 23263486 rs35385468 chr6 26101440 A AC 2.87E-09 Uric acid levels / / 19503597 rs35385468 chr6 26101440 A AC 4.87E-10 Other erythrocyte phenotypes / / 19862010 rs35385468 chr6 26101440 A AC 1.98E-10 Urate levels / / 21768215 rs35385468 chr6 26101440 A AC 5.98E-09 Red blood cell traits / / 23222517 rs35385468 chr6 26101440 A AC 2.50E-16 Urate levels / / 23263486 rs386406569 chr6 26101440 A AC 2.87E-09 Uric acid levels / / 19503597 rs386406569 chr6 26101440 A AC 4.87E-10 Other erythrocyte phenotypes / / 19862010 rs386406569 chr6 26101440 A AC 1.98E-10 Urate levels / / 21768215 rs386406569 chr6 26101440 A AC 5.98E-09 Red blood cell traits / / 23222517 rs386406569 chr6 26101440 A AC 2.50E-16 Urate levels / / 23263486 rs198857 chr6 26102417 G C 5.71E-09 Urate levels / / 23263486 rs198856 chr6 26102708 G A 6.72E-10 Urate levels / / 23263486 rs1543680 chr6 26103177 G A 2.97E-08 Red blood cell traits / / 23222517 rs1543680 chr6 26103177 G A 7.60E-05 Blood Pressure / / pha003039 rs198855 chr6 26103398 A T 2.70E-12 Other erythrocyte phenotypes / / 19862010 rs198855 chr6 26103398 A T 1.42E-19 Red blood cell traits / / 23222517 rs198854 chr6 26104057 T C 1.13E-09 Urate levels / / 23263486 rs198853 chr6 26104096 T C 6.99E-05 Bipolar disorder / / 17486107 rs198853 chr6 26104096 T C 5.67E-10 Uric acid levels / / 19503597 rs198853 chr6 26104096 T C 4.72E-10 Other erythrocyte phenotypes / / 19862010 rs198853 chr6 26104096 T C 1.99E-10 Urate levels / / 21768215 rs198853 chr6 26104096 T C 5.25E-13 Red blood cell traits / / 23222517 rs198853 chr6 26104096 T C 8.16E-21 Urate levels / / 23263486 rs2229768 chr6 26104280 T C 3.51E-08 Red blood cell traits HIST1H4C cds-synon 23222517 rs198852 chr6 26104448 A G 2.61E-08 Urate levels HIST1H4C cds-synon 21768215 rs198852 chr6 26104448 A G 4.44E-15 Urate levels HIST1H4C cds-synon 23263486 rs198851 chr6 26104632 T G 3.50E-08 Hemoglobin / / 19820698 rs198851 chr6 26104632 T G 7.18E-25 Other erythrocyte phenotypes / / 19862010 rs198851 chr6 26104632 T G 6.06E-25 Red blood cell traits / / 23222517 rs198848 chr6 26106325 C T 2.62E-08 Urate levels / / 21768215 rs198848 chr6 26106325 C T 6.26E-15 Urate levels / / 23263486 rs198846 chr6 26107463 A G 1.00E-08 Hemoglobin / / 19820698 rs198846 chr6 26107463 A G 1.13E-24 Other erythrocyte phenotypes / / 19862010 rs198846 chr6 26107463 A G 1.55E-06 Blood cell counts and other traits / / 20139978 rs198846 chr6 26107463 A G 2.00E-06 Blood cell counts and other traits / / 20139978 rs198846 chr6 26107463 A G 2.00E-12 Blood pressure / / 21909110 rs198846 chr6 26107463 A G 1.42E-30 Red blood cell traits / / 23222517 rs198845 chr6 26107790 G T 2.62E-08 Urate levels HIST1H1T missense 21768215 rs198845 chr6 26107790 G T 2.09E-14 Urate levels HIST1H1T missense 23263486 rs198844 chr6 26108282 C A,G 8.72E-09 Urate levels HIST1H1T missense 23263486 rs707892 chr6 26109233 T G 5.57E-08 Red blood cell traits / / 23222517 rs198839 chr6 26112620 T G 2.72E-12 Other erythrocyte phenotypes / / 19862010 rs198839 chr6 26112620 T G 1.27E-15 Red blood cell traits / / 23222517 rs933199 chr6 26112893 T C 3.96E-06 Dilated cardiomyopathy / / 23853074 rs198838 chr6 26113340 T C 1.12E-08 Urate levels / / 23263486 rs198837 chr6 26113398 T A 6.69E-09 Urate levels / / 23263486 rs198836 chr6 26113616 T A 1.60E-09 Urate levels / / 23263486 rs198834 chr6 26114372 G A 2.50E-08 Urate levels / / 21768215 rs198834 chr6 26114372 G A 8.76E-14 Urate levels / / 23263486 rs198833 chr6 26114508 G A 1.36E-08 Hemoglobin / / 19820698 rs198833 chr6 26114508 G A 1.30E-24 Other erythrocyte phenotypes / / 19862010 rs198833 chr6 26114508 G A 8.54E-26 Red blood cell traits / / 23222517 rs13161 chr6 26114702 C T 1.47E-09 Urate levels / / 23263486 rs707896 chr6 26116424 G A 0.000000004 Mean corpuscular hemoglobin / / 22560525 rs707896 chr6 26116424 G A 0.00000002 Mean corpuscular volume / / 22560525 rs707896 chr6 26116424 G A 6.65E-07 Red blood cell traits / / 23222517 rs12206204 chr6 26116982 C T 8.00E-07 Bilirubin levels / / 19414484 rs16891325 chr6 26118667 T C 4.15E-10 Red blood cell traits / / 23222517 rs198829 chr6 26118893 A G 0.0000218 Schizophrenia / / 23637625 rs198828 chr6 26119459 G A 8.59E-09 Urate levels / / 23263486 rs198827 chr6 26121002 C T 4.11E-09 Urate levels / / 23263486 rs198826 chr6 26121153 C T 1.94E-10 Urate levels / / 23263486 rs1773284 chr6 26122453 C A 8.04E-07 Red blood cell traits / / 23222517 rs198825 chr6 26122502 A G 2.11E-09 Urate levels / / 23263486 rs198823 chr6 26122933 G T 7.36E-10 Other erythrocyte phenotypes / / 19862010 rs198823 chr6 26122933 G T 1.59E-14 Red blood cell traits / / 23222517 rs198823 chr6 26122933 G T 0.0002567 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs198823 chr6 26122933 G T 2.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs198821 chr6 26123629 T C 9.23E-10 Urate levels / / 23263486 rs198820 chr6 26124243 G A 2.56E-08 Urate levels / / 21768215 rs198820 chr6 26124243 G A 9.21E-11 Urate levels / / 23263486 rs129128 chr6 26125342 C T 9.84E-04 Multiple complex diseases / / 17554300 rs129128 chr6 26125342 C T 3.34E-08 Hemoglobin / / 19820698 rs129128 chr6 26125342 C T 4.71E-20 Other erythrocyte phenotypes / / 19862010 rs129128 chr6 26125342 C T 8.10E-05 Blood pressure / / 22100073 rs129128 chr6 26125342 C T 8.50E-05 Blood pressure / / 22100073 rs129128 chr6 26125342 C T 1.00E-19 Mean corpuscular hemoglobin / / 22560525 rs129128 chr6 26125342 C T 2.00E-14 Mean corpuscular volume / / 22560525 rs129128 chr6 26125342 C T 4.00E-10 Mean corpuscular hemoglobin concentration / / 22560525 rs129128 chr6 26125342 C T 9.00E-27 Red blood cell traits / / 23222517 rs198817 chr6 26126524 A G 3.66E-07 Schizophrenia / / 21926974 rs1150663 chr6 26127252 A G 5.09E-10 Red blood cell traits / / 23222517 rs198815 chr6 26127271 A G 2.57E-08 Urate levels / / 21768215 rs198815 chr6 26127271 A G 9.82E-12 Urate levels / / 23263486 rs198814 chr6 26127759 A G 7.78E-09 Urate levels / / 23263486 rs198809 chr6 26128766 G A 8.81E-09 Urate levels / / 23263486 rs707899 chr6 26129948 C T 7.07E-04 White matter integrity / / 22425255 rs707899 chr6 26129948 C T 7.13E-11 Red blood cell traits / / 23222517 rs707901 chr6 26132664 C T 2.18E-11 Red blood cell traits / / 23222517 rs198806 chr6 26133616 A G 6.70E-05 HIV-1 control / / 20041166 rs198806 chr6 26133616 A G 2.46E-07 Urate levels / / 21768215 rs198806 chr6 26133616 A G 2.16E-07 Red blood cell traits / / 23222517 rs16891344 chr6 26134110 G T 3.14E-11 Red blood cell traits / / 23222517 rs2856646 chr6 26135498 A G 3.66E-11 Other erythrocyte phenotypes / / 19862010 rs2856646 chr6 26135498 A G 8.26E-04 Type 2 diabetes / / 22158537 rs2856646 chr6 26135498 A G 2.00E-15 Mean corpuscular hemoglobin / / 22560525 rs2856646 chr6 26135498 A G 5.00E-13 Mean corpuscular volume / / 22560525 rs2856646 chr6 26135498 A G 1.65E-20 Red blood cell traits / / 23222517 rs67250268 chr6 26135498 AT AAT,AGG 3.66E-11 Other erythrocyte phenotypes / / 19862010 rs67250268 chr6 26135498 AT AAT,AGG 8.26E-04 Type 2 diabetes / / 22158537 rs67250268 chr6 26135498 AT AAT,AGG 2.00E-15 Mean corpuscular hemoglobin / / 22560525 rs67250268 chr6 26135498 AT AAT,AGG 5.00E-13 Mean corpuscular volume / / 22560525 rs67250268 chr6 26135498 AT AAT,AGG 1.65E-20 Red blood cell traits / / 23222517 rs2856645 chr6 26135499 T G 1.14E-11 Other erythrocyte phenotypes / / 19862010 rs2856645 chr6 26135499 T G 9.65E-04 Type 2 diabetes / / 22158537 rs2856645 chr6 26135499 T G 2.43E-17 Red blood cell traits / / 23222517 rs806970 chr6 26141375 C T 6.51E-08 Red blood cell traits / / 23222517 rs806971 chr6 26144791 T G 1.24E-10 Multiple complex diseases / / 17554300 rs806973 chr6 26148326 A G 3.58E-06 Coronary heart disease / / 21971053 rs806973 chr6 26148326 A G 3.81E-07 Red blood cell traits / / 23222517 rs9379827 chr6 26153335 C A 7.57E-05 Type 2 diabetes / / 17463246 rs9379827 chr6 26153335 C A 7.03E-04 Multiple complex diseases / / 17554300 rs7749823 chr6 26158079 A C 0.000000132 Schizophrenia / / 23637625 rs1009181 chr6 26158993 T C 3.31E-06 Coronary heart disease HIST1H2BD intron 21971053 rs9366639 chr6 26167613 C G 4.42E-08 Red blood cell traits HIST1H2BD intron 23222517 rs4486004 chr6 26167710 G T 9.69E-07 Red blood cell traits HIST1H2BD intron 23222517 rs2066295 chr6 26168903 A G 9.20E-07 Red blood cell traits HIST1H2BD intron 23222517 rs9379829 chr6 26172219 C T 7.42E-04 White matter integrity / / 22425255 rs9379831 chr6 26175852 C A 3.90E-08 Ankylosing spondylitis / / 20062062 rs9379831 chr6 26175852 C A 2.60E-04 Coronary heart disease / / 21971053 rs16891375 chr6 26184041 A G 1.17E-07 Red blood cell traits HIST1H2BE cds-synon 23222517 rs6906367 chr6 26187125 C T 3.88E-07 Red blood cell traits / / 23222517 rs11751812 chr6 26187334 G T 8.25E-07 Red blood cell traits / / 23222517 rs1543681 chr6 26187783 C A 5.91E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs806977 chr6 26189615 A G 8.28E-06 Lung adenocarcinoma / / 19836008 rs806792 chr6 26198916 A G 5.86E-10 Multiple complex diseases HIST1H3D intron 17554300 rs806794 chr6 26200677 A G 1.00E-39 Height / / 20881960 rs806794 chr6 26200677 A G 1.94E-13 Red blood cell traits / / 23222517 rs806794 chr6 26200677 A G 1.00E-25 Height / / 23563607 rs3757135 chr6 26200707 G A 8.74E-04 Coronary heart disease / / 21971053 rs2069018 chr6 26205718 T C 9.56E-04 Coronary heart disease / / 21971053 rs16891407 chr6 26206299 T A 7.80E-07 Red blood cell traits / / 23222517 rs11755943 chr6 26211368 A G 8.24E-04 Coronary heart disease / / 21971053 rs16891417 chr6 26211395 C T 6.86E-05 Multiple complex diseases / / 17554300 rs11755618 chr6 26215802 A G 2.61E-07 Red blood cell traits / / 23222517 rs11751062 chr6 26216165 C T 1.45E-07 Red blood cell traits / / 23222517 rs811041 chr6 26226032 C G 4.52E-15 Red blood cell traits / / 23222517 rs3818947 chr6 26227104 C T 1.03E-04 Multiple complex diseases / / 17554300 rs10946808 chr6 26233387 A G 4.00E-17 Height / / 18391950 rs10946808 chr6 26233387 A G 6.00E-10 Height / / 18391951 rs10946808 chr6 26233387 A G 2.58E-05 Lung cancer / / 18978787 rs10946808 chr6 26233387 A G 6.00E-12 Height / / 19343178 rs10946808 chr6 26233387 A G 4.50E-07 Ankylosing spondylitis / / 20062062 rs10946808 chr6 26233387 A G 3.47E-05 Coronary heart disease / / 21971053 rs10946808 chr6 26233387 A G 4.81E-12 Red blood cell traits / / 23222517 rs16891464 chr6 26235300 A G 1.25E-08 Red blood cell traits / / 23222517 rs9358913 chr6 26239404 A G 2.69E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9358913 chr6 26239404 A G 1.80E-12 Red blood cell traits / / 23222517 rs3734533 chr6 26240624 A G 1.48E-07 Red blood cell traits / / 23222517 rs3734534 chr6 26240649 C T 1.79E-12 Red blood cell traits / / 23222517 rs11751286 chr6 26241361 C G 2.62E-09 Red blood cell traits / / 23222517 rs16891484 chr6 26242930 G A 4.28E-09 Red blood cell traits / / 23222517 rs11759720 chr6 26250254 C G 2.39E-07 Red blood cell traits / / 23222517 rs11753610 chr6 26251601 T C 1.53E-08 Red blood cell traits / / 23222517 rs6935954 chr6 26255451 A G 4.52E-04 Alzheimer's disease / / 22005930 rs6935954 chr6 26255451 A G 9.71E-08 Red blood cell traits / / 23222517 rs6935954 chr6 26255451 A G 4.45E-04 Stroke / / pha002887 rs809871 chr6 26256526 C G 3.70E-05 Multiple complex diseases / / 17554300 rs809871 chr6 26256526 C G 4.24E-04 Alzheimer's disease / / 22005930 rs809871 chr6 26256526 C G 8.10E-08 Red blood cell traits / / 23222517 rs3999543 chr6 26259807 G A 6.57E-13 Red blood cell traits / / 23222517 rs9358914 chr6 26262063 G T 4.98E-15 Red blood cell traits / / 23222517 rs7761779 chr6 26262306 T G 3.76E-08 Red blood cell traits / / 23222517 rs11962642 chr6 26263912 C T 4.10E-07 Red blood cell traits / / 23222517 rs11754746 chr6 26267579 G A 1.86E-08 Red blood cell traits / / 23222517 rs11757214 chr6 26267679 T C 2.46E-08 Red blood cell traits / / 23222517 rs7773004 chr6 26267755 A G,T 2.11E-05 Alzheimer's disease / / 22005930 rs7773004 chr6 26267755 A G,T 1.13E-10 Red blood cell traits / / 23222517 rs7773163 chr6 26267800 C T 3.55E-06 Coronary heart disease / / 21971053 rs11759682 chr6 26270961 T C 8.14E-07 Red blood cell traits / / 23222517 rs9393690 chr6 26271713 A T 3.86E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9393691 chr6 26272829 T C 4.54E-16 Red blood cell traits / / 23222517 rs6901243 chr6 26274498 C T 1.80E-07 Red blood cell traits / / 23222517 rs12665035 chr6 26275649 T C 1.89E-14 Red blood cell traits / / 23222517 rs9393692 chr6 26276650 A G 1.81E-05 Lung adenocarcinoma / / 19836008 rs9393692 chr6 26276650 A G 5.93E-04 Taste perception / / 22132133 rs2393592 chr6 26285560 A G 8.03E-04 Multiple complex diseases HIST1H4H cds-synon 17554300 rs2393593 chr6 26285683 T C 1.77E-04 Taste perception HIST1H4H cds-synon 22132133 rs3999544 chr6 26285867 C T 2.36E-04 Taste perception / / 22132133 rs9358918 chr6 26286744 C T 5.10E-05 Celiac disease / / 23936387 rs10946810 chr6 26288055 G A 6.00E-15 Red blood cell traits / / 23222517 rs6916289 chr6 26289122 A T 4.60E-06 Urinary metabolites / / 21572414 rs6939589 chr6 26289203 T C 5.65E-04 Multiple complex diseases / / 17554300 rs6916643 chr6 26289219 C A 3.31E-07 Red blood cell traits / / 23222517 rs9379842 chr6 26289310 T C 4.56E-16 Red blood cell traits / / 23222517 rs9379843 chr6 26289435 A G 5.17E-04 Multiple complex diseases / / 17554300 rs4412192 chr6 26290377 G A 3.70E-06 Urinary metabolites / / 21572414 rs9379844 chr6 26291527 G A 6.26E-07 Red blood cell traits / / 23222517 rs62396224 chr6 26292926 A G 1.44E-05 Taste perception / / 22132133 rs7746807 chr6 26293338 C A 2.28E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9393697 chr6 26293841 C T 6.48E-07 Red blood cell traits / / 23222517 rs2893820 chr6 26295686 G A 5.45E-16 Red blood cell traits / / 23222517 rs6456711 chr6 26302572 A C 3.70E-04 Taste perception / / 22132133 rs994379 chr6 26305407 G C 4.78E-05 Alzheimer's disease / / 22005930 rs994379 chr6 26305407 G C 5.18E-09 Red blood cell traits / / 23222517 rs9366648 chr6 26306282 T C 4.34E-14 Red blood cell traits / / 23222517 rs1883214 chr6 26306684 C A 6.36E-05 Coronary heart disease / / 21971053 rs11758318 chr6 26307970 C T 1.41E-07 Red blood cell traits / / 23222517 rs11751564 chr6 26308272 T A 1.22E-08 Red blood cell traits / / 23222517 rs10484438 chr6 26308287 T C 1.68E-07 Red blood cell traits / / 23222517 rs11751567 chr6 26308317 T G 1.10E-08 Red blood cell traits / / 23222517 rs9393700 chr6 26309380 G A 5.02E-05 Alzheimer's disease / / 22005930 rs9393700 chr6 26309380 G A 4.36E-10 Red blood cell traits / / 23222517 rs10484439 chr6 26309908 G A 2.85E-04 Celiac disease / / 23936387 rs16891525 chr6 26311321 T A 1.05E-07 Red blood cell traits / / 23222517 rs4145910 chr6 26313305 T C 1.51E-08 Red blood cell traits / / 23222517 rs6923139 chr6 26313348 C T 2.91E-04 Celiac disease / / 23936387 rs6923139 chr6 26313348 C T 7.70E-04 Systemic lupus erythematosus / / 24871463 rs11751978 chr6 26313936 T C 3.30E-07 Red blood cell traits / / 23222517 rs9467703 chr6 26318903 A G 3.06E-08 Red blood cell traits / / 23222517 rs9467704 chr6 26319486 C T 5.10E-13 Multiple complex diseases / / 17554300 rs766407 chr6 26319534 T C 1.82E-08 Red blood cell traits / / 23222517 rs766406 chr6 26319588 G T 1.16E-04 Taste perception / / 22132133 rs766406 chr6 26319588 G T 1.79E-08 Red blood cell traits / / 23222517 rs9358925 chr6 26322768 C G 1.50E-15 Red blood cell traits / / 23222517 rs11754384 chr6 26322985 T G 3.24E-07 Coronary heart disease / / 21971053 rs11754384 chr6 26322985 T G 3.86E-09 Red blood cell traits / / 23222517 rs11756569 chr6 26323026 A T 5.30E-08 Red blood cell traits / / 23222517 rs9358926 chr6 26323132 C G 1.71E-15 Red blood cell traits / / 23222517 rs6914596 chr6 26324032 G T 5.85E-08 Red blood cell traits / / 23222517 rs4631273 chr6 26324149 A G 5.45E-08 Red blood cell traits / / 23222517 rs1053860 chr6 26325228 C T 6.25E-05 Alzheimer's disease / / 22005930 rs1053860 chr6 26325228 C T 9.89E-10 Red blood cell traits / / 23222517 rs3778279 chr6 26325463 T C 7.59E-05 Alzheimer's disease / / 22005930 rs3778279 chr6 26325463 T C 5.75E-09 Red blood cell traits / / 23222517 rs2179152 chr6 26325888 T C 2.12E-08 Red blood cell traits / / 23222517 rs6932584 chr6 26327081 A C 6.10E-05 Alzheimer's disease / / 22005930 rs6932584 chr6 26327081 A C 5.93E-07 Red blood cell traits / / 23222517 rs6939048 chr6 26327953 G A 9.77E-07 Red blood cell traits / / 23222517 rs1155207 chr6 26328365 A G 6.45E-05 Alzheimer's disease / / 22005930 rs1155207 chr6 26328365 A G 6.36E-08 Red blood cell traits / / 23222517 rs9366649 chr6 26329103 T A 4.80E-06 Urinary metabolites / / 21572414 rs9358927 chr6 26330492 T G 9.87E-04 Coronary heart disease / / 21971053 rs9358927 chr6 26330492 T G 1.51E-15 Red blood cell traits / / 23222517 rs11755795 chr6 26334339 G A 7.11E-08 Red blood cell traits / / 23222517 rs2893842 chr6 26338434 T G 2.10E-05 Ankylosing spondylitis / / 20062062 rs2893842 chr6 26338434 T G 4.35E-13 Red blood cell traits / / 23222517 rs2893843 chr6 26338697 A G 9.76E-07 Red blood cell traits / / 23222517 rs9467714 chr6 26340785 G A 1.36E-10 Multiple complex diseases / / 17554300 rs9358928 chr6 26341030 C T 4.76E-07 Red blood cell traits / / 23222517 rs9358929 chr6 26341062 G A 8.10E-05 Major depressive disorder / / 21042317 rs9358929 chr6 26341062 G A 5.61E-07 Red blood cell traits / / 23222517 rs10946813 chr6 26345141 G A 2.34E-08 Multiple complex diseases / / 17554300 rs10946813 chr6 26345141 G A 8.34E-07 Red blood cell traits / / 23222517 rs9461245 chr6 26354572 G A 7.87E-05 Multiple complex diseases / / 17554300 rs9379851 chr6 26354780 A C 1.61E-13 Multiple complex diseases / / 17554300 rs9379851 chr6 26354780 A C 8.30E-13 Lymphocyte counts / / 22286170 rs9379851 chr6 26354780 A C 4.79E-07 Red blood cell traits / / 23222517 rs6933583 chr6 26355283 A C 7.15E-11 Multiple complex diseases / / 17554300 rs4712980 chr6 26355758 T G 2.32E-10 Multiple complex diseases / / 17554300 rs9393708 chr6 26362643 T C 5.02E-13 Multiple complex diseases / / 17554300 rs9393708 chr6 26362643 T C 5.15E-07 Red blood cell traits / / 23222517 rs9358932 chr6 26362705 C T 3.83E-13 Multiple complex diseases / / 17554300 rs9358932 chr6 26362705 C T 8.39E-07 Red blood cell traits / / 23222517 rs9379855 chr6 26364930 T C 6.00E-13 Multiple complex diseases / / 17554300 rs9379855 chr6 26364930 T C 5.24E-07 Red blood cell traits / / 23222517 rs3734536 chr6 26365346 G C 1.87E-10 Multiple complex diseases / / 17554300 rs3734536 chr6 26365346 G C 1.18E-05 Schizophrenia / / 19571811 rs12203176 chr6 26365595 T C 2.36E-04 Multiple complex diseases BTN3A2 intron 17554300 rs9348712 chr6 26366511 T A 7.71E-07 Red blood cell traits BTN3A2 intron 23222517 rs9379857 chr6 26367654 G C 7.40E-07 Red blood cell traits BTN3A2 intron 23222517 rs9379858 chr6 26367689 T C 1.42E-08 Schizophrenia,schizoaffective disorder or bipolar disorder BTN3A2 intron 24166486 rs9379858 chr6 26367689 T C 1.60E-05 Systemic lupus erythematosus BTN3A2 intron 24871463 rs9379859 chr6 26369549 C T 2.50E-05 Systemic lupus erythematosus BTN3A2 intron 24871463 rs12176317 chr6 26372786 A G 2.40E-05 Systemic lupus erythematosus BTN3A2 intron 24871463 rs9393713 chr6 26373678 G A 7.64E-14 Multiple complex diseases BTN3A2 intron 17554300 rs13218591 chr6 26376832 T C 6.64E-06 Schizophrenia BTN3A2 UTR-3 21926974 rs13218591 chr6 26376832 T C 5.39E-05 Celiac disease BTN3A2 UTR-3 23936387 rs1977 chr6 26377546 A G 1.66E-08 Multiple complex diseases BTN3A2 UTR-3 17554300 rs4712984 chr6 26379537 C T 9.80E-04 Coronary heart disease / / 21971053 rs569442616 chr6 26379537 CG C 9.80E-04 Coronary heart disease / / 21971053 rs71544680 chr6 26379537 CG C 9.80E-04 Coronary heart disease / / 21971053 rs3757142 chr6 26380545 A G 1.20E-04 Multiple complex diseases / / 17554300 rs3757146 chr6 26381125 A T 7.58E-05 Multiple complex diseases / / 17554300 rs3757148 chr6 26381206 T C 8.62E-05 Multiple complex diseases / / 17554300 rs3757149 chr6 26381316 T C 1.70E-05 Urinary metabolites / / 21572414 rs9461246 chr6 26381660 G A 2.10E-05 Urinary metabolites / / 21572414 rs9461249 chr6 26383386 T C 4.03E-07 Coronary heart disease BTN2A2 UTR-5 21971053 rs2072806 chr6 26385093 C G 9.27E-07 Schizophrenia BTN2A2 intron 19571809 rs2072806 chr6 26385093 C G 9.30E-07 Schizophrenia (treatment refractory) BTN2A2 intron 22479419 rs1796518 chr6 26388672 C T 1.36E-04 Depression (quantitative trait) BTN2A2 intron 20800221 rs7756881 chr6 26389926 C T 7.47E-08 Coronary heart disease BTN2A2 intron 21971053 rs2072803 chr6 26392515 G C 8.19E-07 Schizophrenia BTN2A2 missense 19571809 rs2072803 chr6 26392515 G C 8.20E-07 Schizophrenia (treatment refractory) BTN2A2 missense 22479419 rs1131936 chr6 26394320 A G 8.60E-04 Multiple complex diseases BTN2A2 UTR-3 17554300 rs7356849 chr6 26396739 T C 9.10E-10 Coronary heart disease / / 21971053 rs12208788 chr6 26398555 T A 8.66E-04 Multiple complex diseases / / 17554300 rs6912853 chr6 26401438 C T 6.89E-05 Multiple complex diseases / / 17554300 rs12200782 chr6 26403036 C G 8.30E-06 Urinary metabolites BTN3A1 intron 21572414 rs10456045 chr6 26404958 G A 2.03E-10 Multiple complex diseases BTN3A1 intron 17554300 rs10807008 chr6 26405264 G C 2.53E-04 Multiple complex diseases BTN3A1 intron 17554300 rs742090 chr6 26415637 A C 1.68E-11 Multiple complex diseases / / 17554300 rs12208390 chr6 26437106 C T 5.19E-06 Rheumatoid arthritis / / 19503088 rs2281027 chr6 26446705 A G 3.91E-10 Coronary heart disease BTN3A3 intron 21971053 rs2237236 chr6 26451553 A G 3.59E-10 Multiple complex diseases BTN3A3 intron 17554300 rs10484440 chr6 26453742 A G 1.84E-08 Red blood cell traits / / 23222517 rs6456724 chr6 26456443 T C 7.41E-04 Taste perception / / 22132133 rs6929846 chr6 26458265 T C 1.30E-23 Progranulin levels BTN2A1 UTR-5 21087763 rs6929846 chr6 26458265 T C 1.30E-23 Myocardial infarction BTN2A1 UTR-5 21211798 rs6912934 chr6 26459244 C T 7.41E-04 Taste perception BTN2A1 intron 22132133 rs2893856 chr6 26460721 T C 7.41E-04 Taste perception BTN2A1 intron 22132133 rs13195509 chr6 26463660 G A 3.75E-04 Schizophrenia BTN2A1 missense 19197363 rs13195509 chr6 26463660 G A 2.31E-04 Celiac disease BTN2A1 missense 23936387 rs13195509 chr6 26463660 G A 6.90E-08 Systemic lupus erythematosus BTN2A1 missense 24871463 rs13195509 chr6 26463660 G A 7.66E-06 Systemic lupus erythematosus BTN2A1 missense pha002867 rs6916321 chr6 26464789 A G 4.20E-04 Multiple complex diseases BTN2A1 intron 17554300 rs3799380 chr6 26467182 T C 1.20E-12 Multiple complex diseases BTN2A1 intron 17554300 rs3799380 chr6 26467182 T C 1.20E-06 Ankylosing spondylitis BTN2A1 intron 20062062 rs3799380 chr6 26467182 T C 2.80E-08 Schizophrenia,schizoaffective disorder or bipolar disorder BTN2A1 intron 24166486 rs9358945 chr6 26472114 A G 1.64E-12 Multiple complex diseases BTN2A1 intron 17554300 rs7763910 chr6 26472655 A G 3.85E-13 Multiple complex diseases BTN2A1 intron 17554300 rs7763910 chr6 26472655 A G 4.10E-04 Systemic lupus erythematosus BTN2A1 intron 24871463 rs7773938 chr6 26474044 C T 2.60E-08 Multiple complex diseases BTN2A1 intron 17554300 rs2893857 chr6 26474061 C A 4.85E-04 Multiple complex diseases BTN2A1 intron 17554300 rs10484441 chr6 26474742 G C 4.27E-04 Multiple complex diseases BTN2A1 intron 17554300 rs1407045 chr6 26476155 A G 3.20E-04 Systemic lupus erythematosus BTN2A1 intron 24871463 rs3757150 chr6 26476782 T A 8.02E-05 Pulmonary function BTN2A1 UTR-3 20010835 rs6456728 chr6 26477779 G A 6.69E-05 Pulmonary function LOC285819 intron 20010835 rs6456728 chr6 26477779 G A 2.36E-08 Schizophrenia,schizoaffective disorder or bipolar disorder LOC285819 intron 24166486 rs9358946 chr6 26478927 G A 5.25E-05 Pulmonary function / / 20010835 rs16891725 chr6 26479150 C T 2.02E-05 Pulmonary function / / 20010835 rs9357008 chr6 26479891 G T 6.63E-04 Multiple complex diseases LOC285819 intron 17554300 rs9357008 chr6 26479891 G T 8.47E-06 Rheumatoid arthritis LOC285819 intron 19503088 rs7756567 chr6 26481642 T G 5.22E-05 Pulmonary function LOC285819 intron 20010835 rs6456730 chr6 26484376 T C 1.45E-09 Coronary heart disease / / 21971053 rs4713001 chr6 26487310 G A 5.50E-04 Multiple complex diseases / / 17554300 rs2093169 chr6 26495099 C T 5.74E-05 Pulmonary function / / 20010835 rs2093169 chr6 26495099 C T 5.50E-06 Ankylosing spondylitis / / 20062062 rs9467772 chr6 26496578 A T 5.38E-05 Pulmonary function / / 20010835 rs13194984 chr6 26500563 G T 6.00E-08 Iron status biomarkers / / 19084217 rs1056667 chr6 26510564 T C 2.00E-08 Educational attainment BTN1A1 UTR-3 23722424 rs7765920 chr6 26514771 C T 7.59E-04 Multiple complex diseases / / 17554300 rs9357010 chr6 26527945 C G 1.31E-04 Multiple complex diseases / / 17554300 rs9295695 chr6 26528250 T C 1.67E-04 Multiple complex diseases / / 17554300 rs9467779 chr6 26536687 A T 1.00E-04 Multiple complex diseases / / 17554300 rs9467783 chr6 26542894 C T 7.89E-05 Multiple complex diseases HMGN4 intron 17554300 rs9461270 chr6 26544110 A G 5.65E-04 Suicide attempts in bipolar disorder HMGN4 intron 21041247 rs9461270 chr6 26544110 A G 4.73E-07 Red blood cell traits HMGN4 intron 23222517 rs4573 chr6 26546808 T C 2.44E-08 Multiple complex diseases HMGN4 UTR-3 17554300 rs1884947 chr6 26553273 G T 1.29E-08 Multiple complex diseases / / 17554300 rs6922824 chr6 26553815 C G 8.48E-05 Multiple complex diseases / / 17554300 rs16901784 chr6 26555433 C A 4.43E-05 Pulmonary function / / 20010835 rs9295697 chr6 26558531 T C 7.41E-05 Atopic dermatitis / / 23042114 rs9467791 chr6 26562486 G A 8.32E-05 Multiple complex diseases / / 17554300 rs13214027 chr6 26573631 C G 1.92E-05 Pulmonary function / / 20010835 rs9393735 chr6 26582327 A G 1.47E-05 Pulmonary function / / 20010835 rs9379892 chr6 26582414 G A 9.28E-06 Rheumatoid arthritis / / 19503088 rs9379893 chr6 26584668 C T 2.77E-05 Pulmonary function / / 20010835 rs9379895 chr6 26592707 A G 2.72E-05 Pulmonary function / / 20010835 rs9379895 chr6 26592707 A G 1.20E-07 Ankylosing spondylitis / / 20062062 rs9379895 chr6 26592707 A G 7.79E-04 White matter integrity / / 22425255 rs4634439 chr6 26598004 A G 2.37E-08 Multiple complex diseases ABT1 intron 17554300 rs12204145 chr6 26600156 G A 2.80E-05 Urinary metabolites ABT1 UTR-3 21572414 rs9379897 chr6 26601526 T C 1.60E-05 Systemic lupus erythematosus / / 24871463 rs6911476 chr6 26612363 C T 3.76E-11 Coronary heart disease / / 21971053 rs9393737 chr6 26617306 G A 2.95E-05 Pulmonary function / / 20010835 rs2451738 chr6 26618459 T A 9.88E-05 Multiple complex diseases / / 17554300 rs7754159 chr6 26620312 G A 3.13E-05 Pulmonary function / / 20010835 rs9393738 chr6 26620658 G A 3.14E-05 Pulmonary function / / 20010835 rs2101582 chr6 26622734 C T 3.30E-05 Multiple complex diseases / / 17554300 rs2451732 chr6 26622904 T A 4.52E-05 Multiple complex diseases / / 17554300 rs2451741 chr6 26629404 A G 4.73E-05 Multiple complex diseases / / 17554300 rs2451741 chr6 26629404 A G 7.48E-09 Other erythrocyte phenotypes / / 19862010 rs9295702 chr6 26634040 T C 4.64E-05 Pulmonary function / / 20010835 rs2504571 chr6 26643435 C T 4.62E-05 Multiple complex diseases ZNF322 intron 17554300 rs2498380 chr6 26643996 G C 8.13E-04 Multiple complex diseases ZNF322 intron 17554300 rs2498380 chr6 26643996 G C 1.54E-08 Other erythrocyte phenotypes ZNF322 intron 19862010 rs2498380 chr6 26643996 G C 9.92E-07 Red blood cell traits ZNF322 intron 23222517 rs9379907 chr6 26654318 C T 5.09E-05 Pulmonary function ZNF322 intron 20010835 rs13210025 chr6 26654817 A C 4.79E-05 Pulmonary function ZNF322 intron 20010835 rs2504567 chr6 26662920 G C 6.17E-05 Multiple complex diseases / / 17554300 rs7759969 chr6 26663096 T A 5.91E-05 Pulmonary function / / 20010835 rs7740197 chr6 26663478 A G 6.39E-05 Pulmonary function / / 20010835 rs1104871 chr6 26665235 T G 6.11E-05 Pulmonary function / / 20010835 rs7755721 chr6 26686889 T C 7.26E-04 Suicide attempts in bipolar disorder LOC100507100 intron 21041247 rs111173643 chr6 26704972 G A 7.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs12202849 chr6 26704972 G A 7.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs545019110 chr6 26704972 G A 7.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs386622790 chr6 26709591 T C 7.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs386622790 chr6 26709591 T C 8.48E-05 Coronary heart disease / / 21971053 rs533979848 chr6 26709591 T C 7.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs533979848 chr6 26709591 T C 8.48E-05 Coronary heart disease / / 21971053 rs9467847 chr6 26709591 T C 7.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs9467847 chr6 26709591 T C 8.48E-05 Coronary heart disease / / 21971053 rs9393754 chr6 26753131 G T 8.91E-05 Pulmonary function / / 20010835 rs2504586 chr6 26754650 G C 8.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs4711122 chr6 26758479 C T 6.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs3004050 chr6 26761646 C T 2.23E-08 Other erythrocyte phenotypes / / 19862010 rs2504527 chr6 26798531 A G 1.66E-08 Other erythrocyte phenotypes / / 19862010 rs9393777 chr6 26942027 T C 1.70E-04 Systemic lupus erythematosus LINC00240 intron 24871463 rs12212302 chr6 26947474 T G 1.57E-05 Major depressive disorder (broad) LINC00240 intron 20038947 rs10946885 chr6 26948174 A G 8.80E-06 Major depressive disorder (broad) LINC00240 intron 20038947 rs4713062 chr6 26948195 C T 2.87E-13 Multiple complex diseases LINC00240 intron 17554300 rs4713062 chr6 26948195 C T 7.35E-05 Major depressive disorder (broad) LINC00240 intron 20038947 rs10946888 chr6 26951678 T C 6.62E-06 Major depressive disorder (broad) LINC00240 intron 20038947 rs10946888 chr6 26951678 T C 6.31E-05 Elbow pain LINC00240 intron pha003008 rs2754603 chr6 26965139 T C 4.62E-05 Major depressive disorder (broad) LINC00240 intron 20038947 rs12201034 chr6 26965897 T C 5.89E-06 Major depressive disorder (broad) LINC00240 intron 20038947 rs10946891 chr6 26973215 T C 5.85E-06 Major depressive disorder (broad) LINC00240 intron 20038947 rs12201393 chr6 26975690 C A 5.84E-06 Major depressive disorder (broad) LINC00240 intron 20038947 rs6932003 chr6 26990191 T C 5.21E-12 Coronary heart disease LINC00240 intron 21971053 rs10456352 chr6 26990358 A T 5.75E-06 Major depressive disorder (broad) LINC00240 intron 20038947 rs6913271 chr6 26996131 C G 7.21E-04 Multiple complex diseases / / 17554300 rs4358615 chr6 26998567 A G 2.20E-09 Multiple complex diseases / / 17554300 rs4358615 chr6 26998567 A G 4.46E-05 Major depressive disorder (broad) / / 20038947 rs4358615 chr6 26998567 A G 4.69E-04 Coronary heart disease / / 21971053 rs6937880 chr6 27000236 C T 6.05E-06 Major depressive disorder (broad) / / 20038947 rs6937880 chr6 27000236 C T 5.62E-05 Elbow pain / / pha003008 rs12527111 chr6 27006475 C T 5.99E-06 Major depressive disorder (broad) / / 20038947 rs12527111 chr6 27006475 C T 4.22E-05 Elbow pain / / pha003008 rs11756275 chr6 27007113 G T 3.82E-11 Multiple complex diseases / / 17554300 rs11756275 chr6 27007113 G T 6.39E-06 Major depressive disorder (broad) / / 20038947 rs7775041 chr6 27009512 T A 5.51E-05 Major depressive disorder (broad) / / 20038947 rs6918835 chr6 27017827 T G 5.43E-05 Major depressive disorder (broad) / / 20038947 rs12190473 chr6 27024687 C T 1.16E-11 Multiple complex diseases / / 17554300 rs12190473 chr6 27024687 C T 5.70E-05 Systemic lupus erythematosus / / 24871463 rs4424065 chr6 27036456 C T 1.00E-05 Major depressive disorder (broad) / / 20038947 rs13194491 chr6 27037080 C T 1.00E-08 Iron status biomarkers / / 19084217 rs13194491 chr6 27037080 C T 1.52E-09 Other erythrocyte phenotypes / / 19862010 rs13194491 chr6 27037080 C T 0.00000004 Mean corpuscular volume / / 22560525 rs13194491 chr6 27037080 C T 5.00E-10 Mean corpuscular hemoglobin / / 22560525 rs13194491 chr6 27037080 C T 7.86E-07 Red blood cell traits / / 23222517 rs13194491 chr6 27037080 C T 1.40E-04 Systemic lupus erythematosus / / 24871463 rs6916301 chr6 27042258 C T 2.27E-04 Coronary heart disease / / 21971053 rs6904071 chr6 27047256 G A 1.78E-08 Schizophrenia / / 19571809 rs6904071 chr6 27047256 G A 1.02E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6904071 chr6 27047256 G A 4.06E-04 Major depressive disorder / / 22472876 rs6904071 chr6 27047256 G A 1.80E-08 Schizophrenia (treatment refractory) / / 22479419 rs994691 chr6 27047713 A T 5.88E-06 Major depressive disorder (broad) / / 20038947 rs994690 chr6 27047916 T C 3.31E-04 Coronary heart disease / / 21971053 rs6930508 chr6 27053142 T C 4.73E-06 Major depressive disorder (broad) / / 20038947 rs7451149 chr6 27057518 T C 4.94E-11 Multiple complex diseases / / 17554300 rs7451149 chr6 27057518 T C 4.92E-06 Major depressive disorder (broad) / / 20038947 rs926300 chr6 27059443 A T 1.06E-08 Schizophrenia / / 19571809 rs926300 chr6 27059443 A T 1.10E-08 Schizophrenia (treatment refractory) / / 22479419 rs926300 chr6 27059443 A T 9.12E-05 Depression (quantitative trait) / / 23290196 rs9379958 chr6 27066163 A C 2.56E-05 Major depressive disorder (broad) / / 20038947 rs6456767 chr6 27070543 C T 5.80E-06 Major depressive disorder (broad) / / 20038947 rs2393915 chr6 27080460 A C 1.36E-12 Multiple complex diseases / / 17554300 rs2393915 chr6 27080460 A C 7.07E-06 Major depressive disorder (broad) / / 20038947 rs7745603 chr6 27090404 C T 1.78E-12 Multiple complex diseases / / 17554300 rs7745603 chr6 27090404 C T 3.30E-04 Coronary heart disease / / 21971053 rs6913660 chr6 27091425 C A 2.36E-08 Schizophrenia / / 19571809 rs6913660 chr6 27091425 C A 1.70E-11 Schizophrenia / / 21791550 rs6913660 chr6 27091425 C A 0.000000016 Psychosis / / 23164818 rs6913660 chr6 27091425 C A 0.000023 Schizophrenia / / 23164818 rs6456768 chr6 27093821 G C 7.38E-06 Major depressive disorder (broad) / / 20038947 rs1321578 chr6 27104783 G T 3.43E-04 Hearing function / / 17255346 rs16894325 chr6 27114022 A G,T 4.42E-04 Insulin resistance HIST1H2BK intron 21901158 rs13219181 chr6 27136225 A G 1.29E-08 Schizophrenia / / 19571809 rs13219181 chr6 27136225 A G 1.30E-08 Schizophrenia (treatment refractory) / / 22479419 rs13194053 chr6 27143883 T C 1.00E-08 Schizophrenia / / 19571809 rs13194053 chr6 27143883 T C 1.00E-08 Schizophrenia / / 19571811 rs13194053 chr6 27143883 T C 4.21E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs13194053 chr6 27143883 T C 3.64E-04 Major depressive disorder / / 22472876 rs13194053 chr6 27143883 T C 9.50E-09 Schizophrenia (treatment refractory) / / 22479419 rs7755577 chr6 27171437 T C 8.92E-05 Coronary heart disease / / 21971053 rs858986 chr6 27178523 C A 8.01E-07 Red blood cell traits / / 23222517 rs12153912 chr6 27179829 G A 2.60E-05 Urinary metabolites / / 21572414 rs13219354 chr6 27185664 T C 1.12E-07 Schizophrenia / / 19571809 rs13219354 chr6 27185664 T C 5.50E-06 Systemic lupus erythematosus / / 24871463 rs3800307 chr6 27185792 T A 5.03E-10 Multiple complex diseases / / 17554300 rs3800307 chr6 27185792 T A 4.35E-08 Schizophrenia / / 19571809 rs3800307 chr6 27185792 T A 4.40E-08 Schizophrenia (treatment refractory) / / 22479419 rs6918423 chr6 27194072 T G 3.10E-05 Coronary heart disease / / 21971053 rs13212921 chr6 27205422 C T 1.28E-07 Schizophrenia / / 19571809 rs13212921 chr6 27205422 C T 5.04E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs13212921 chr6 27205422 C T 1.30E-07 Schizophrenia (treatment refractory) / / 22479419 rs3800312 chr6 27210614 C A 9.52E-06 Rheumatoid arthritis / / 19503088 rs3800312 chr6 27210614 C A 3.98E-05 Coronary heart disease / / 21971053 rs5030956 chr6 27213969 G C 2.77E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10946904 chr6 27217236 C T 3.16E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PRSS16 intron 20031582 rs9393795 chr6 27217719 G C 9.19E-05 Major depressive disorder (broad) PRSS16 intron 20038947 rs4546474 chr6 27224633 T C 3.35E-09 Multiple complex diseases / / 17554300 rs4452638 chr6 27229265 G A 9.05E-12 Multiple complex diseases / / 17554300 rs4452638 chr6 27229265 G A 2.68E-07 Schizophrenia / / 19571809 rs4452638 chr6 27229265 G A 2.70E-07 Schizophrenia (treatment refractory) / / 22479419 rs6938200 chr6 27231150 A G 3.02E-07 Schizophrenia / / 19571809 rs6938200 chr6 27231150 A G 3.00E-07 Schizophrenia (treatment refractory) / / 22479419 rs6902012 chr6 27243767 T C 1.50E-05 Urinary metabolites / / 21572414 rs9379968 chr6 27244590 G A 2.59E-06 Parkinson's disease / / 21738487 rs9379968 chr6 27244590 G A 8.59E-04 Coronary heart disease / / 21971053 rs6932590 chr6 27248931 T C 1.00E-12 Schizophrenia / / 19571808 rs6932590 chr6 27248931 T C 7.13E-08 Schizophrenia / / 19571809 rs6932590 chr6 27248931 T C 8.73E-06 HIV-1 control / / 20041166 rs6932590 chr6 27248931 T C 1.60E-10 Schizophrenia / / 21791550 rs6932590 chr6 27248931 T C 0.000000009 Psychosis / / 23164818 rs6932590 chr6 27248931 T C 0.000025 Schizophrenia / / 23164818 rs3800316 chr6 27256102 A C 3.81E-08 Schizophrenia / / 19571809 rs3800316 chr6 27256102 A C 1.57E-08 Schizophrenia / / 21926974 rs3800316 chr6 27256102 A C 3.80E-08 Schizophrenia (treatment refractory) / / 22479419 rs7746199 chr6 27261324 C T 2.96E-08 Multiple complex diseases / / 17554300 rs7746199 chr6 27261324 C T 4.91E-04 Schizophrenia / / 19197363 rs7746199 chr6 27261324 C T 5.03E-08 Schizophrenia / / 19571809 rs7746199 chr6 27261324 C T 8.87E-05 HIV-1 control / / 20041166 rs7746199 chr6 27261324 C T 5.00E-08 Schizophrenia (treatment refractory) / / 22479419 rs3800318 chr6 27263641 A T 6.38E-08 Schizophrenia / / 19571809 rs3800318 chr6 27263641 A T 6.40E-08 Schizophrenia (treatment refractory) / / 22479419 rs7771953 chr6 27271343 G A 1.07E-05 Multiple complex diseases / / 17554300 rs7771953 chr6 27271343 G A 1.19E-05 Parkinson's disease / / 21738487 rs16897515 chr6 27278020 C A 1.80E-08 Multiple complex diseases POM121L2 missense 17554300 rs16897515 chr6 27278020 C A 1.83E-07 Schizophrenia POM121L2 missense 19571809 rs16897515 chr6 27278020 C A 1.80E-07 Schizophrenia (treatment refractory) POM121L2 missense 22479419 rs16897515 chr6 27278020 C A 4.00E-07 Schizophrenia POM121L2 missense 23894747 rs17688097 chr6 27279774 C T 7.70E-04 Response to statin treatment (atorvastatin),change in cholesterol levels POM121L2 missense 20031582 rs61736098 chr6 27279805 G T 0.0002 Breast cancer POM121L2 missense 23555315 rs12174489 chr6 27287800 C T 2.65E-05 Major depressive disorder (broad) / / 20038947 rs9348759 chr6 27290888 C T 3.51E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs61746402 chr6 27293107 G A 0.000092 Breast cancer / / 23555315 rs61743950 chr6 27293114 T A 0.000092 Breast cancer / / 23555315 rs200789956 chr6 27293272 G A 0.0000017 Breast cancer(er negative) / / 23555315 rs9379976 chr6 27298200 T C 3.35E-05 Coronary heart disease / / 21971053 rs9379976 chr6 27298200 T C 9.56E-07 Left ventricular hypertrophy / / pha003052 rs9379977 chr6 27298279 T C 1.09E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9379977 chr6 27298279 T C 4.71E-05 Coronary heart disease / / 21971053 rs9379977 chr6 27298279 T C 7.90E-07 Left ventricular hypertrophy / / pha003052 rs721600 chr6 27298905 C T 1.60E-05 Coronary heart disease / / 21971053 rs721600 chr6 27298905 C T 3.44E-07 Left ventricular hypertrophy / / pha003052 rs1156457 chr6 27300580 A G 8.00E-04 Multiple complex diseases / / 17554300 rs9461362 chr6 27303927 C T 2.26E-05 Parkinson's disease / / 21738487 rs9461362 chr6 27303927 C T 9.09E-11 Coronary heart disease / / 21971053 rs9461366 chr6 27310533 G A 5.86E-08 Multiple complex diseases / / 17554300 rs9461366 chr6 27310533 G A 2.72E-04 Alzheimer's disease / / 17998437 rs9461366 chr6 27310533 G A 2.47E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs9461366 chr6 27310533 G A 1.01E-10 Coronary heart disease / / 21971053 rs9468076 chr6 27338890 C T 6.80E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ZNF204P intron 20031582 rs9468076 chr6 27338890 C T 1.28E-11 Coronary heart disease ZNF204P intron 21971053 rs9468076 chr6 27338890 C T 3.45E-06 Left ventricular hypertrophy ZNF204P intron pha003052 rs12529458 chr6 27361681 T C 1.19E-04 Multiple complex diseases ZNF391 intron 17554300 rs13207689 chr6 27369704 C G 4.57E-05 Pulmonary function / / 20010835 rs2076305 chr6 27375611 A C 6.50E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2064219 chr6 27376001 G A 7.11E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs13196692 chr6 27379119 C T 3.90E-05 Pulmonary function / / 20010835 rs4713096 chr6 27379409 G A 4.30E-04 Multiple complex diseases / / 17554300 rs9368509 chr6 27379422 G A 1.90E-05 Urinary metabolites / / 21572414 rs4711152 chr6 27380202 T C 1.08E-04 Multiple complex diseases / / 17554300 rs7753569 chr6 27389150 T G 5.32E-04 Multiple complex diseases / / 17554300 rs7771598 chr6 27389258 A C 4.83E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs13191227 chr6 27390115 G C 3.89E-05 Pulmonary function / / 20010835 rs16899778 chr6 27390150 T C 3.94E-12 Multiple complex diseases / / 17554300 rs6926142 chr6 27395764 T C 3.30E-04 Systemic lupus erythematosus / / 24871463 rs12200018 chr6 27406156 A G 1.91E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs760880 chr6 27408181 G A,C,T 9.00E-04 Systemic lupus erythematosus / / 24871463 rs76439045 chr6 27411729 A C 5.00E-08 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs7772160 chr6 27412386 C T 3.20E-04 Systemic lupus erythematosus / / 24871463 rs13195040 chr6 27413924 A G 2.50E-07 Schizophrenia / / 19571809 rs13195040 chr6 27413924 A G 3.85E-05 Pulmonary function / / 20010835 rs13195040 chr6 27413924 A G 2.50E-07 Schizophrenia (treatment refractory) / / 22479419 rs12199110 chr6 27423568 G A 2.36E-05 Response to statin treatment (atorvastatin),change in cholesterol levels ZNF184 intron 20031582 rs1883216 chr6 27425185 C A 4.39E-05 Response to statin treatment (atorvastatin),change in cholesterol levels ZNF184 missense 20031582 rs10807024 chr6 27428705 T C 7.31E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ZNF184 intron 20031582 rs10946920 chr6 27428991 C T 1.11E-04 Multiple complex diseases ZNF184 intron 17554300 rs7761966 chr6 27445703 C T 5.90E-05 Systemic lupus erythematosus / / 24871463 rs7749305 chr6 27446566 T C 2.57E-08 Schizophrenia,schizoaffective disorder or bipolar disorder / / 24166486 rs16867808 chr6 27463684 T C 4.72E-11 Coronary heart disease / / 21971053 rs2294309 chr6 27483816 G T 6.01E-04 Multiple complex diseases / / 17554300 rs6904596 chr6 27491299 G A 1.54E-05 Lung cancer / / 18978787 rs6904596 chr6 27491299 G A 6.19E-06 Lung adenocarcinoma / / 19836008 rs6904596 chr6 27491299 G A 5.28E-05 Pulmonary function / / 20010835 rs6904596 chr6 27491299 G A 6.77E-05 HIV-1 control / / 20041166 rs6904596 chr6 27491299 G A 4.70E-08 Lung cancer / / 22899653 rs6904596 chr6 27491299 G A 3.06E-08 Schizophrenia,schizoaffective disorder or bipolar disorder / / 24166486 rs6904596 chr6 27491299 G A 1.90E-08 Systemic lupus erythematosus / / 24871463 rs2064092 chr6 27511371 C A 2.09E-11 Coronary heart disease / / 21971053 rs13209332 chr6 27520752 T A 6.69E-05 Pulmonary function / / 20010835 rs10484399 chr6 27534528 A G 5.64E-11 Multiple complex diseases / / 17554300 rs10484399 chr6 27534528 A G 9.42E-06 AIDS progression / / 19115949 rs10484399 chr6 27534528 A G 3.50E-07 Schizophrenia / / 19571809 rs10484399 chr6 27534528 A G 2.96E-05 Lung adenocarcinoma / / 19836008 rs10484399 chr6 27534528 A G 2.20E-06 HIV-1 control / / 20041166 rs10484399 chr6 27534528 A G 3.50E-07 Schizophrenia (treatment refractory) / / 22479419 rs10484399 chr6 27534528 A G 3.10E-08 Lung cancer / / 22899653 rs10484399 chr6 27534528 A G 8.90E-09 Systemic lupus erythematosus / / 24871463 rs10484399 chr6 27534528 A G 8.53E-06 Systemic lupus erythematosus / / pha002867 rs6903982 chr6 27545744 T C 4.29E-12 Coronary heart disease / / 21971053 rs10946940 chr6 27560587 A G 8.00E-09 Systemic lupus erythematosus / / 24871463 rs10946940 chr6 27560587 A G 1.11E-06 Systemic lupus erythematosus / / pha002867 rs7749985 chr6 27568221 A G 8.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs13217599 chr6 27586230 T C 2.42E-09 Other erythrocyte phenotypes / / 19862010 rs13217599 chr6 27586230 T C 2.50E-15 Red blood cell traits / / 23222517 rs16867901 chr6 27656076 G A 1.25E-14 Multiple complex diseases / / 17554300 rs16867901 chr6 27656076 G A 4.88E-07 Red blood cell traits / / 23222517 rs9348772 chr6 27656090 G T 2.17E-09 Multiple complex diseases / / 17554300 rs9348772 chr6 27656090 G T 3.44E-05 Coronary heart disease / / 21971053 rs9380007 chr6 27660508 T C 4.77E-05 Coronary heart disease / / 21971053 rs17749927 chr6 27669976 A G 2.41E-06 HIV-1 control LOC100507173 intron 20041166 rs9380010 chr6 27683572 A G 1.65E-07 Coronary heart disease / / 21971053 rs9380010 chr6 27683572 A G 4.70E-06 Systemic lupus erythematosus / / 24871463 rs9393848 chr6 27688369 G A 1.72E-11 Multiple complex diseases / / 17554300 rs9468203 chr6 27688667 A G 2.06E-11 Multiple complex diseases / / 17554300 rs9348774 chr6 27688930 C T 7.87E-04 Acute lung injury / / 22295056 rs9295740 chr6 27689502 G A 2.80E-05 Blood Phenotypes / / 17903294 rs9295740 chr6 27689502 G A 3.63E-07 Lung cancer / / 18978787 rs9295740 chr6 27689502 G A 3.41E-06 Lung cancer / / 19654303 rs9295740 chr6 27689502 G A 2.50E-07 Coronary heart disease / / 21971053 rs9295740 chr6 27689502 G A 8.63E-04 Acute lung injury / / 22295056 rs9295740 chr6 27689502 G A 1.70E-06 Systemic lupus erythematosus / / 24871463 rs9468209 chr6 27694421 C T 2.51E-05 Coronary heart disease / / 21971053 rs9468209 chr6 27694421 C T 2.10E-05 Systemic lupus erythematosus / / 24871463 rs17750424 chr6 27701122 T C 1.99E-08 Schizophrenia,schizoaffective disorder or bipolar disorder / / 24166486 rs7740062 chr6 27705598 T C 4.85E-15 Multiple complex diseases / / 17554300 rs9468213 chr6 27706180 G A 2.01E-05 Coronary heart disease / / 21971053 rs17693963 chr6 27710165 A C 2.81E-07 Schizophrenia / / 19571809 rs17693963 chr6 27710165 A C 1.56E-10 Schizophrenia / / 21926974 rs17693963 chr6 27710165 A C 2.80E-07 Schizophrenia (treatment refractory) / / 22479419 rs17693963 chr6 27710165 A C 3.00E-11 Schizophrenia / / 22688191 rs17693963 chr6 27710165 A C 0.000000187 Schizophrenia / / 23637625 rs17693963 chr6 27710165 A C 2.00E-09 Schizophrenia,schizoaffective disorder or bipolar disorder / / 24166486 rs17693963 chr6 27710165 A C 3.00E-09 Bipolar disorder and schizophrenia / / 24280982 rs17693963 chr6 27710165 A C 3.00E-11 Bipolar disorder and schizophrenia / / 24280982 rs17693963 chr6 27710165 A C 4.28E-04 Bipolar disorder and schizophrenia / / 24280982 rs9283880 chr6 27715243 A C 3.06E-07 Coronary heart disease / / 21971053 rs9283880 chr6 27715243 A C 5.90E-06 Systemic lupus erythematosus / / 24871463 rs9283880 chr6 27715243 A C 5.34E-06 Systemic lupus erythematosus / / pha002867 rs9461405 chr6 27719375 G T 2.53E-11 Multiple complex diseases / / 17554300 rs4713120 chr6 27721835 C A 2.76E-05 Coronary heart disease / / 21971053 rs4713120 chr6 27721835 C A 1.80E-05 Systemic lupus erythematosus / / 24871463 rs7776351 chr6 27726731 C T 5.85E-12 Multiple complex diseases / / 17554300 rs7776351 chr6 27726731 C T 3.22E-07 Schizophrenia / / 19571809 rs7776351 chr6 27726731 C T 6.93E-07 Coronary heart disease / / 21971053 rs7776351 chr6 27726731 C T 3.20E-07 Schizophrenia (treatment refractory) / / 22479419 rs7776351 chr6 27726731 C T 2.30E-06 Systemic lupus erythematosus / / 24871463 rs9295746 chr6 27730064 T C 9.27E-07 Coronary heart disease LOC100131289 intron 21971053 rs742047 chr6 27739380 A G 5.68E-07 Coronary heart disease / / 21971053 rs742047 chr6 27739380 A G 9.40E-07 Systemic lupus erythematosus / / 24871463 rs9461407 chr6 27745738 G A 4.77E-07 Schizophrenia / / 19571809 rs9461407 chr6 27745738 G A 4.80E-07 Schizophrenia (treatment refractory) / / 22479419 rs10484401 chr6 27746590 A T 7.17E-08 Multiple complex diseases / / 17554300 rs2179095 chr6 27750858 C T 6.04E-12 Multiple complex diseases / / 17554300 rs200470 chr6 27762187 C T 9.23E-14 Multiple complex diseases / / 17554300 rs9295749 chr6 27767395 C T 1.48E-11 Coronary heart disease / / 21971053 rs200480 chr6 27773664 T C 3.99E-09 Multiple complex diseases / / 17554300 rs200481 chr6 27773832 T A 1.16E-06 Multiple complex diseases / / 17554300 rs201005 chr6 27804160 A C 5.25E-15 Multiple complex diseases / / 17554300 rs34706883 chr6 27805255 A C 3.14E-08 Schizophrenia,schizoaffective disorder or bipolar disorder / / 24166486 rs13212651 chr6 27806985 A G 3.34E-08 Schizophrenia,schizoaffective disorder or bipolar disorder / / 24166486 rs201002 chr6 27808192 A G 1.45E-06 Multiple complex diseases / / 17554300 rs175597 chr6 27810626 T C 5.31E-08 Type 1 diabetes / / 17632545 rs175597 chr6 27810626 T C 9.41E-05 Lung cancer / / 18978787 rs175597 chr6 27810626 T C 6.80E-05 Lung adenocarcinoma / / 19836008 rs175597 chr6 27810626 T C 6.00E-09 Systemic lupus erythematosus / / 24871463 rs200997 chr6 27811815 G A 6.70E-07 Systemic lupus erythematosus / / 24871463 rs200995 chr6 27813694 T C 2.01E-06 Multiple complex diseases / / 17554300 rs200991 chr6 27815494 C A 6.72E-13 Multiple complex diseases / / 17554300 rs200991 chr6 27815494 C A 0.00000883 Carotid intima media thickness / / 23152477 rs200991 chr6 27815494 C A 7.60E-08 Systemic lupus erythematosus / / 24871463 rs13194781 chr6 27815639 A G 1.51E-05 AIDS progression / / 19115949 rs13194781 chr6 27815639 A G 4.05E-05 Lung adenocarcinoma / / 19836008 rs13194781 chr6 27815639 A G 5.05E-06 HIV-1 control / / 20041166 rs13194781 chr6 27815639 A G 3.51E-08 Schizophrenia,schizoaffective disorder or bipolar disorder / / 24166486 rs13194781 chr6 27815639 A G 5.80E-09 Systemic lupus erythematosus / / 24871463 rs13194781 chr6 27815639 A G 6.28E-06 Systemic lupus erythematosus / / pha002867 rs13199772 chr6 27834085 A G 3.40E-08 Schizophrenia,schizoaffective disorder or bipolar disorder / / 24166486 rs200951 chr6 27835930 A G 1.10E-06 Systemic lupus erythematosus / / 24871463 rs200953 chr6 27837267 T C 1.30E-08 Systemic lupus erythematosus / / 24871463 rs200955 chr6 27839312 T C 1.29E-11 Multiple complex diseases / / 17554300 rs200959 chr6 27842047 C T 3.91E-14 Multiple complex diseases / / 17554300 rs200979 chr6 27852357 G A 3.55E-07 Red blood cell traits / / 23222517 rs200969 chr6 27859453 T C 6.48E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs200969 chr6 27859453 T C 1.00E-05 Systemic lupus erythematosus / / 24871463 rs200968 chr6 27859568 T C 3.33E-09 Type 1 diabetes / / 17632545 rs200968 chr6 27859568 T C 2.18E-07 Red blood cell traits / / 23222517 rs13219787 chr6 27861670 G A,T 6.46E-09 Other erythrocyte phenotypes / / 19862010 rs13219787 chr6 27861670 G A,T 1.05E-08 Red blood cell traits / / 23222517 rs200965 chr6 27866384 G A 4.61E-07 Red blood cell traits / / 23222517 rs6900413 chr6 27866823 G A 1.18E-05 Depression (quantitative trait) / / 23290196 rs1873213 chr6 27869321 T G 6.05E-06 Depression (quantitative trait) / / 23290196 rs9468252 chr6 27870772 A G 8.42E-06 Depression (quantitative trait) / / 23290196 rs6933825 chr6 27890631 A G 1.13E-04 Coronary heart disease / / 21971053 rs9468256 chr6 27895504 G A 9.84E-05 Coronary heart disease / / 21971053 rs6910968 chr6 27904181 C T 2.92E-06 Rheumatoid arthritis / / 19503088 rs6910968 chr6 27904181 C T 5.59E-10 Coronary heart disease / / 21971053 rs839777 chr6 27909657 T A 6.72E-14 Multiple complex diseases / / 17554300 rs2116984 chr6 27932762 C A 1.09E-04 Coronary heart disease / / 21971053 rs16893533 chr6 27933709 A T 1.59E-04 Multiple complex diseases / / 17554300 rs276361 chr6 27939409 G A 2.20E-14 Multiple complex diseases / / 17554300 rs13214703 chr6 27941387 T C 8.81E-08 Red blood cell traits / / 23222517 rs16893540 chr6 27958111 C A 2.02E-04 Multiple complex diseases / / 17554300 rs156741 chr6 27962384 T C 1.58E-13 Multiple complex diseases / / 17554300 rs156742 chr6 27963192 G A 2.25E-15 Multiple complex diseases / / 17554300 rs149946 chr6 27970031 G T 3.84E-11 Multiple complex diseases / / 17554300 rs149969 chr6 27977737 T C 6.31E-11 Multiple complex diseases / / 17554300 rs4141691 chr6 27979188 A G 1.65E-05 Multiple complex diseases / / 17554300 rs149970 chr6 27980220 G A 4.61E-10 Multiple complex diseases / / 17554300 rs149971 chr6 27982152 G A 9.75E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs149971 chr6 27982152 G A 0.0000457 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs6456804 chr6 27985388 G T 7.96E-06 Rheumatoid arthritis / / 19503088 rs6456804 chr6 27985388 G T 4.02E-04 Coronary heart disease / / 21971053 rs9357056 chr6 27987650 A G 3.40E-04 Multiple complex diseases / / 17554300 rs149976 chr6 27987776 A G 4.80E-11 Multiple complex diseases / / 17554300 rs149990 chr6 27998258 G A 1.10E-05 Systemic lupus erythematosus / / 24871463 rs16893573 chr6 27999421 C T 8.93E-05 Response to methylphenidate treatment / / 21130132 rs17709097 chr6 28002963 A G 1.09E-04 Multiple complex diseases / / 17554300 rs202906 chr6 28011652 T C 6.49E-13 Multiple complex diseases / / 17554300 rs149900 chr6 28014597 C T 6.19E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs149900 chr6 28014597 C T 7.20E-05 Systemic lupus erythematosus / / 24871463 rs172166 chr6 28020820 C G 5.00E-06 Cardiac Troponin-T levels / / 23247143 rs203887 chr6 28021269 C A,G,T 4.16E-10 Multiple complex diseases / / 17554300 rs203888 chr6 28021589 G A 5.36E-11 Multiple complex diseases / / 17554300 rs203888 chr6 28021589 G A 1.50E-05 Systemic lupus erythematosus / / 24871463 rs203890 chr6 28022248 T C 7.36E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs203890 chr6 28022248 T C 4.80E-05 Systemic lupus erythematosus / / 24871463 rs9393881 chr6 28023751 C G 7.93E-11 Multiple complex diseases / / 17554300 rs9393881 chr6 28023751 C G 5.90E-06 Cardiac Troponin-T levels / / 23247143 rs41375446 chr6 28024408 C G 7.81E-05 Multiple complex diseases / / 17554300 rs9468276 chr6 28027688 A C 1.60E-05 Systemic lupus erythematosus / / 24871463 rs149951 chr6 28033087 T C 2.60E-05 Systemic lupus erythematosus / / 24871463 rs9295755 chr6 28033174 A G 2.48E-10 Multiple complex diseases / / 17554300 rs9295756 chr6 28033396 C A 4.65E-10 Multiple complex diseases / / 17554300 rs10484403 chr6 28033523 A G 6.11E-10 Multiple complex diseases / / 17554300 rs149957 chr6 28037020 G T 7.74E-05 Glucose levels / / pha003061 rs203877 chr6 28048624 T C 3.90E-05 Systemic lupus erythematosus ZNF165 UTR-5 24871463 rs17767294 chr6 28054198 A G 6.96E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ZNF165 intron 20031582 rs16893666 chr6 28054707 T C 2.23E-10 Multiple complex diseases ZNF165 intron 17554300 rs10484404 chr6 28055495 C T 1.55E-05 Height ZNF165 intron 17255346 rs10484404 chr6 28055495 C T 3.55E-07 Multiple complex diseases ZNF165 intron 17554300 rs10484404 chr6 28055495 C T 1.07E-06 Rheumatoid arthritis ZNF165 intron 19503088 rs10484404 chr6 28055495 C T 9.88E-10 Coronary heart disease ZNF165 intron 21971053 rs175955 chr6 28059734 A C 1.67E-08 Multiple complex diseases ZSCAN12P1 intron 17554300 rs13197574 chr6 28060239 T C 2.34E-05 HIV-1 control / / 20041166 rs9380052 chr6 28064623 T C 2.21E-10 Multiple complex diseases / / 17554300 rs203885 chr6 28076886 C T 1.22E-12 Multiple complex diseases / / 17554300 rs203884 chr6 28077374 C A 1.40E-07 Multiple complex diseases / / 17554300 rs17711344 chr6 28077602 G A 1.82E-10 Multiple complex diseases / / 17554300 rs6932109 chr6 28078303 G A 1.45E-10 Multiple complex diseases / / 17554300 rs6931858 chr6 28078411 A T 2.73E-10 Multiple complex diseases / / 17554300 rs1654774 chr6 28096280 A G 8.30E-05 Non-alcoholic fatty liver disease histology (other) ZSCAN16 intron 20708005 rs1225710 chr6 28100640 T C 4.65E-09 Multiple complex diseases LOC100129195 intron 17554300 rs1225709 chr6 28103648 T C 2.79E-12 Multiple complex diseases LOC100129195 intron 17554300 rs1340004 chr6 28103691 C T 3.76E-10 Multiple complex diseases LOC100129195 intron 17554300 rs1871695 chr6 28109960 A G 4.67E-12 Multiple complex diseases ZNF192 intron 17554300 rs868987 chr6 28110148 C T 1.50E-10 Multiple complex diseases ZNF192 intron 17554300 rs1890809 chr6 28110478 A G 3.55E-05 Height ZNF192 intron 17255346 rs2791333 chr6 28111114 A G 0.0000148 HIV-1 infection (natural long-term nonprogression) ZNF192 intron 22238471 rs1225715 chr6 28113373 A G 1.13E-08 Multiple complex diseases ZNF192 intron 17554300 rs4711165 chr6 28115184 T G 1.59E-11 Multiple complex diseases ZNF192 intron 17554300 rs1150668 chr6 28129789 T G 2.00E-07 Pubertal anthropometrics ZNF192P1 intron 23449627 rs6929559 chr6 28134106 T C 1.79E-05 Height ZNF192P1 intron 17255346 rs6929559 chr6 28134106 T C 2.07E-06 Rheumatoid arthritis ZNF192P1 intron 19503088 rs9283884 chr6 28135660 G C 1.84E-10 Multiple complex diseases ZNF192P1 intron 17554300 rs9380064 chr6 28143118 A G 9.70E-07 Systemic lupus erythematosus / / 24871463 rs9380064 chr6 28143118 A G 3.75E-06 Systemic lupus erythematosus / / pha002867 rs1225593 chr6 28150519 C A 2.04E-08 Multiple complex diseases / / 17554300 rs1150683 chr6 28155314 C T 8.50E-12 Multiple complex diseases / / 17554300 rs1237873 chr6 28158954 A G 4.60E-06 Urinary metabolites / / 21572414 rs1233704 chr6 28166923 C T 6.19E-10 Multiple complex diseases / / 17554300 rs1233701 chr6 28168726 C G 1.05E-09 Multiple complex diseases / / 17554300 rs1233699 chr6 28169158 T A 8.86E-10 Multiple complex diseases / / 17554300 rs1237875 chr6 28173010 C T 9.25E-10 Multiple complex diseases / / 17554300 rs1233708 chr6 28173219 G A 1.12E-06 Multiple complex diseases / / 17554300 rs1233708 chr6 28173219 G A 2.00E-05 Systemic lupus erythematosus / / 24871463 rs1233665 chr6 28178512 T C 2.41E-04 Height / / 17255346 rs1233665 chr6 28178512 T C 8.20E-07 Rheumatoid arthritis / / 19503088 rs1150699 chr6 28181675 G A 2.41E-04 Height / / 17255346 rs1150699 chr6 28181675 G A 1.24E-04 Coronary heart disease / / 21971053 rs1150699 chr6 28181675 G A 6.38E-04 Smoking initiation / / 24665060 rs1150704 chr6 28184371 T G 2.18E-04 Height / / 17255346 rs1150704 chr6 28184371 T G 6.85E-05 Coronary heart disease / / 21971053 rs1233664 chr6 28185726 C T 3.17E-04 Height / / 17255346 rs1233664 chr6 28185726 C T 9.62E-05 Coronary heart disease / / 21971053 rs1736894 chr6 28186554 C A 6.56E-05 Height / / 17255346 rs1736894 chr6 28186554 C A 6.33E-07 Rheumatoid arthritis / / 19503088 rs1736894 chr6 28186554 C A 4.93E-05 Post-operative nausea and vomiting / / 21694509 rs1736894 chr6 28186554 C A 8.93E-05 Coronary heart disease / / 21971053 rs1736890 chr6 28189389 A G 2.17E-04 Height / / 17255346 rs1736890 chr6 28189389 A G 1.02E-04 Coronary heart disease / / 21971053 rs993619 chr6 28189663 G C 1.56E-04 Multiple complex diseases / / 17554300 rs9380069 chr6 28203300 A G 6.37E-04 Schizophrenia / / 19197363 rs9380069 chr6 28203300 A G 4.20E-07 Systemic lupus erythematosus / / 24871463 rs9380069 chr6 28203300 A G 1.38E-06 Systemic lupus erythematosus / / pha002867 rs11752073 chr6 28204793 G T 3.63E-04 Height / / 17255346 rs11752073 chr6 28204793 G T 2.71E-07 Multiple complex diseases / / 17554300 rs11752073 chr6 28204793 G T 6.75E-07 Rheumatoid arthritis / / 19503088 rs1150709 chr6 28207363 T C 1.39E-08 Multiple complex diseases / / 17554300 rs1150711 chr6 28208535 T C 4.79E-04 Suicide attempts in bipolar disorder / / 21041247 rs9295768 chr6 28209102 G A 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs9295768 chr6 28209102 G A 1.70E-06 Systemic lupus erythematosus / / 24871463 rs967005 chr6 28210688 C T 2.50E-07 Systemic lupus erythematosus / / 24871463 rs967005 chr6 28210688 C T 3.38E-05 Systemic lupus erythematosus / / pha002867 rs17720293 chr6 28214698 C T 7.46E-10 Multiple complex diseases ZKSCAN4 intron 17554300 rs1233710 chr6 28215446 C T 4.76E-11 Schizophrenia ZKSCAN4 intron 22037552 rs2235359 chr6 28215641 T G 1.13E-04 Height ZKSCAN4 intron 17255346 rs2235359 chr6 28215641 T G 5.28E-08 Rheumatoid arthritis ZKSCAN4 intron 19503088 rs2235358 chr6 28216027 A G 8.50E-05 Major depressive disorder ZKSCAN4 intron 21042317 rs2185955 chr6 28222980 A G 8.12E-04 Height / / 17255346 rs1531681 chr6 28226878 G A 1.67E-06 Multiple complex diseases / / 17554300 rs12000 chr6 28227436 A G 7.63E-08 Rheumatoid arthritis NKAPL missense 19503088 rs1635 chr6 28227604 C A 7.00E-12 Schizophrenia NKAPL missense 22037552 rs2179174 chr6 28238969 A G 8.43E-08 Rheumatoid arthritis ZNF187 intron 19503088 rs1419183 chr6 28242794 A C 1.30E-07 Systemic lupus erythematosus ZNF187 intron 24871463 rs1419183 chr6 28242794 A C 5.14E-07 Systemic lupus erythematosus ZNF187 intron pha002867 rs1150726 chr6 28243042 G A 1.05E-05 Multiple complex diseases ZNF187 intron 17554300 rs1150724 chr6 28250236 C T 3.03E-07 Rheumatoid arthritis PGBD1 intron 19503088 rs2142731 chr6 28250913 A G 5.14E-10 Schizophrenia PGBD1 intron 22037552 rs6901575 chr6 28250984 G A 3.06E-06 Pulmonary function PGBD1 intron 20010835 rs13211507 chr6 28257377 T C 9.60E-05 Lung cancer PGBD1 intron 18978787 rs13211507 chr6 28257377 T C 5.00E-05 Lung cancer PGBD1 intron 18978790 rs13211507 chr6 28257377 T C 6.15E-06 Lung adenocarcinoma PGBD1 intron 19836008 rs13211507 chr6 28257377 T C 1.40E-13 Schizophrenia PGBD1 intron 21791550 rs13211507 chr6 28257377 T C 8.30E-11 Schizophrenia (treatment refractory) PGBD1 intron 22479419 rs13211507 chr6 28257377 T C 8.20E-07 Lung cancer PGBD1 intron 22899653 rs13211507 chr6 28257377 T C 2.20E-10 Psychosis PGBD1 intron 23164818 rs13211507 chr6 28257377 T C 5.20E-09 Schizophrenia PGBD1 intron 23164818 rs13211507 chr6 28257377 T C 2.30E-08 Systemic lupus erythematosus PGBD1 intron 24871463 rs13211507 chr6 28257377 T C 8.18E-06 Systemic lupus erythematosus PGBD1 intron pha002867 rs3800324 chr6 28264681 G A 3.20E-04 Alzheimer's disease (late onset) PGBD1 missense 21460841 rs3800325 chr6 28264692 C G 6.71E-04 Height PGBD1 missense 17255346 rs2281043 chr6 28268497 C T 1.70E-04 Height PGBD1 intron 17255346 rs2281043 chr6 28268497 C T 1.38E-04 Coronary heart disease PGBD1 intron 21971053 rs1997660 chr6 28269663 A G 6.86E-04 Suicide attempts in bipolar disorder PGBD1 missense 21041247 rs853693 chr6 28282648 G A 1.60E-07 Multiple complex diseases / / 17554300 rs853693 chr6 28282648 G A 7.06E-04 Suicide attempts in bipolar disorder / / 21041247 rs707907 chr6 28291240 A G 7.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs853684 chr6 28294550 T C 0.0000234 HIV-1 infection (natural long-term nonprogression) ZNF323 missense 22238471 rs853683 chr6 28295039 A G 1.02E-07 Multiple complex diseases ZNF323 intron 17554300 rs853683 chr6 28295039 A G 7.61E-04 Suicide attempts in bipolar disorder ZNF323 intron 21041247 rs853679 chr6 28296863 C A 9.50E-07 Urate levels ZNF323 intron 23263486 rs853676 chr6 28299687 C T 5.70E-07 Systemic lupus erythematosus ZNF323 intron 24871463 rs853676 chr6 28299687 C T 6.14E-06 Systemic lupus erythematosus ZNF323 intron pha002867 rs7752448 chr6 28301099 A G 4.69E-06 Pulmonary function ZNF323 intron 20010835 rs1416920 chr6 28302784 A G 9.46E-05 Pulmonary function in asthmatics ZNF323 intron 23541324 rs9295769 chr6 28304569 A G 3.05E-10 Coronary heart disease ZNF323 UTR-5 21971053 rs17301128 chr6 28308034 C G 8.55E-08 Multiple complex diseases ZNF323 intron 17554300 rs1119211 chr6 28309136 G C 1.59E-08 Multiple complex diseases ZNF323 intron 17554300 rs6912584 chr6 28309590 T C 5.83E-04 Smoking initiation ZNF323 intron 24665060 rs6918631 chr6 28312456 C T 3.18E-10 Coronary heart disease ZNF323 intron 21971053 rs213240 chr6 28315875 T C 0.00000971 HIV-1 infection (natural long-term nonprogression) ZNF323 intron 22238471 rs12180820 chr6 28316478 C T 2.97E-08 Multiple complex diseases ZNF323 intron 17554300 rs12180820 chr6 28316478 C T 3.13E-04 Lymphocyte counts ZNF323 intron 22286170 rs1474589 chr6 28321544 G T 2.63E-06 Multiple complex diseases ZNF323 intron 17554300 rs6903823 chr6 28322296 A G 2.00E-10 Pulmonary function ZNF323 intron 21946350 rs6903823 chr6 28322296 A G 3.71E-04 Pulmonary function (interaction) ZNF323 intron 23284291 rs213228 chr6 28331252 A C 7.80E-04 Systemic lupus erythematosus ZKSCAN3 intron 24871463 rs9468355 chr6 28341877 T C 1.03E-07 Multiple complex diseases / / 17554300 rs7774981 chr6 28346910 T C 7.40E-04 Systemic lupus erythematosus / / 24871463 rs3799499 chr6 28354250 G T 6.20E-04 Systemic lupus erythematosus ZSCAN12 intron 24871463 rs7764722 chr6 28354533 C T 1.19E-07 Multiple complex diseases ZSCAN12 intron 17554300 rs2859379 chr6 28358195 C T 1.79E-04 Major depressive disorder ZSCAN12 UTR-3 22472876 rs1361385 chr6 28358320 A G 8.10E-04 Systemic lupus erythematosus ZSCAN12 missense 24871463 rs2041230 chr6 28365515 T C 1.22E-07 Multiple complex diseases ZSCAN12 intron 17554300 rs2232422 chr6 28366262 G A 9.20E-05 Height ZSCAN12 intron 17255346 rs9468370 chr6 28368940 C T 1.08E-07 Multiple complex diseases / / 17554300 rs6907950 chr6 28370246 C T 1.38E-07 Multiple complex diseases / / 17554300 rs2859365 chr6 28391465 A G 4.93E-09 Multiple complex diseases / / 17554300 rs2859365 chr6 28391465 A G 0.0000156 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs2859365 chr6 28391465 A G 9.80E-04 Systemic lupus erythematosus / / 24871463 rs1339898 chr6 28395506 C T 2.71E-08 Schizophrenia / / 21926974 rs11752919 chr6 28403603 T C 7.30E-04 Type 2 diabetes ZSCAN23 intron 17463246 rs11752919 chr6 28403603 T C 7.13E-05 Multiple complex diseases ZSCAN23 intron 17554300 rs11752919 chr6 28403603 T C 0.00004 HIV-1 infection (natural long-term nonprogression) ZSCAN23 intron 22238471 rs6917130 chr6 28406821 A G 7.91E-07 Red blood cell traits ZSCAN23 intron 23222517 rs916403 chr6 28408258 A G 9.67E-05 Non-alcoholic fatty liver disease histology (other) ZSCAN23 intron 20708005 rs916403 chr6 28408258 A G 0.00000176 HIV-1 infection (natural long-term nonprogression) ZSCAN23 intron 22238471 rs13190937 chr6 28411244 G A 7.56E-05 Rheumatoid arthritis ZSCAN23 UTR-5 17804836 rs13190937 chr6 28411244 G A 0.000123 Schizophrenia ZSCAN23 UTR-5 23637625 rs13215804 chr6 28415572 A G 1.87E-04 Multiple complex diseases / / 17554300 rs13215804 chr6 28415572 A G 1.27E-07 Red blood cell traits / / 23222517 rs11755387 chr6 28416034 C A 4.14E-07 Red blood cell traits / / 23222517 rs6903535 chr6 28417222 A G 7.43E-04 Type 2 diabetes / / 17463246 rs6903535 chr6 28417222 A G 3.84E-05 Multiple complex diseases / / 17554300 rs6903535 chr6 28417222 A G 0.0000393 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs2531809 chr6 28421368 G A 8.70E-04 Coronary heart disease / / 21971053 rs2859369 chr6 28421567 C T 3.54E-04 Coronary heart disease / / 21971053 rs2859374 chr6 28428145 C T 6.43E-04 Coronary heart disease / / 21971053 rs2531815 chr6 28436060 C T 2.90E-07 Coronary heart disease / / 21971053 rs16894128 chr6 28444165 A G 5.54E-09 Red blood cell traits / / 23222517 rs1029328 chr6 28447915 T C 3.85E-04 Multiple complex diseases / / 17554300 rs12661782 chr6 28466442 A G 3.07E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs2191037 chr6 28466988 T C 4.93E-04 Coronary heart disease / / 21971053 rs35701070 chr6 28472172 A G 1.73E-12 LDL cholesterol GPX6 missense 23063622 rs2071966 chr6 28473325 T G 3.07E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) GPX6 intron 23648065 rs11757000 chr6 28484869 T C 2.78E-05 Attention deficit hyperactivity disorder GPX6 nearGene-5 22012869 rs11757235 chr6 28489279 C T 1.93E-12 Red blood cell traits / / 23222517 rs769189 chr6 28500235 T C 5.21E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) GPX5 intron 23648065 rs380879 chr6 28500449 T G 6.96E-04 Coronary heart disease GPX5 intron 21971053 rs448450 chr6 28501006 A C 5.53E-04 Coronary heart disease GPX5 intron 21971053 rs454182 chr6 28511164 G C 2.34E-04 Multiple complex diseases / / 17554300 rs2394102 chr6 28512017 A G 2.94E-04 Height / / 17255346 rs2394102 chr6 28512017 A G 1.42E-07 Multiple complex diseases / / 17554300 rs4711174 chr6 28532960 G A 2.40E-05 Urinary metabolites / / 21572414 rs418092 chr6 28533946 C T 1.48E-07 Multiple complex diseases / / 17554300 rs138676911 chr6 28540989 T G 0.000021 Breast cancer SCAND3 missense 23555315 rs370520 chr6 28542520 C T 6.81E-04 Multiple complex diseases SCAND3 cds-synon 17554300 rs370520 chr6 28542520 C T 9.09E-06 Schizophrenia SCAND3 cds-synon 19571811 rs411538 chr6 28555450 C T 2.17E-06 Sickle cell anemia (severity) SCAND3 nearGene-5 20029952 rs411538 chr6 28555450 C T 1.18E-09 Coronary heart disease SCAND3 nearGene-5 21971053 rs911178 chr6 28574415 T C 1.34E-09 Coronary heart disease / / 21971053 rs1474986 chr6 28575172 T A 9.95E-06 Multiple complex diseases / / 17554300 rs4947336 chr6 28576143 T A 1.07E-11 Multiple complex diseases / / 17554300 rs13209646 chr6 28600128 T A 6.76E-08 Red blood cell traits / / 23222517 rs6925972 chr6 28601934 A G,T 2.83E-11 Multiple complex diseases / / 17554300 rs16894171 chr6 28602272 G A 1.10E-04 Multiple complex diseases / / 17554300 rs9295775 chr6 28627469 A G 2.04E-04 Multiple complex diseases / / 17554300 rs16894180 chr6 28628466 C G 8.85E-12 Multiple complex diseases / / 17554300 rs13194504 chr6 28630691 G A 2.60E-04 HIV-1 viral setpoint / / 17641165 rs13194504 chr6 28630691 G A 9.79E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs13194504 chr6 28630691 G A 9.60E-06 Lung cancer / / 18385738 rs13194504 chr6 28630691 G A 5.84E-05 Lung cancer / / 18978787 rs13194504 chr6 28630691 G A 5.00E-05 Lung cancer / / 18978790 rs13194504 chr6 28630691 G A 3.79E-07 AIDS progression / / 19115949 rs13194504 chr6 28630691 G A 7.34E-06 Lung adenocarcinoma / / 19836008 rs13194504 chr6 28630691 G A 4.66E-05 HIV-1 control / / 20041166 rs13194504 chr6 28630691 G A 3.60E-06 Lung cancer / / 22899653 rs13194504 chr6 28630691 G A 7.70E-09 Systemic lupus erythematosus / / 24871463 rs13194504 chr6 28630691 G A 1.01E-05 Systemic lupus erythematosus / / pha002867 rs7767008 chr6 28630793 T G 9.33E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs16894184 chr6 28631731 T C 9.18E-07 Telomere length / / 23900074 rs16894189 chr6 28641134 C T 1.04E-06 Telomere length / / 23900074 rs16894191 chr6 28641689 A G 1.59E-08 Multiple complex diseases / / 17554300 rs6939576 chr6 28669315 G A 3.48E-04 Coronary heart disease / / 21971053 rs6939576 chr6 28669315 G A 5.70E-04 Systemic lupus erythematosus / / 24871463 rs9295777 chr6 28669698 G T 5.77E-04 Alzheimer's disease / / 22005930 rs1107160 chr6 28671422 G T 1.45E-06 Multiple complex diseases / / 17554300 rs9368571 chr6 28677758 C G 6.93E-05 Multiple complex diseases / / 17554300 rs9366725 chr6 28685981 C T 2.85E-04 Coronary heart disease / / 21971053 rs9468413 chr6 28689672 C A 7.90E-05 Systemic lupus erythematosus / / 24871463 rs2893973 chr6 28697086 C T 6.96E-06 Amyotrophic Lateral Sclerosis / / 17827064 rs7755641 chr6 28699369 T C 2.88E-04 Height / / 17255346 rs6456834 chr6 28700352 T G 1.00E-04 Systemic lupus erythematosus / / 24871463 rs1233579 chr6 28712663 A G 2.60E-04 HIV-1 viral setpoint / / 17641165 rs1233579 chr6 28712663 A G 5.81E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1233579 chr6 28712663 A G 3.60E-05 Lung cancer / / 18385738 rs1233579 chr6 28712663 A G 4.22E-05 Lung cancer / / 18978787 rs1233579 chr6 28712663 A G 9.28E-07 AIDS progression / / 19115949 rs1233579 chr6 28712663 A G 2.05E-06 Lung cancer / / 19654303 rs1233579 chr6 28712663 A G 3.82E-06 Lung adenocarcinoma / / 19836008 rs1233579 chr6 28712663 A G 3.29E-05 HIV-1 control / / 20041166 rs1233579 chr6 28712663 A G 2.70E-08 Lung cancer / / 22899653 rs1233579 chr6 28712663 A G 5.40E-08 Systemic lupus erythematosus / / 24871463 rs1233579 chr6 28712663 A G 2.44E-05 Systemic lupus erythematosus / / pha002867 rs17398081 chr6 28724852 G C 9.84E-07 Multiple complex diseases / / 17554300 rs9257144 chr6 28729981 T C 1.38E-04 Multiple complex diseases / / 17554300 rs1233602 chr6 28733403 G A 1.96E-04 Coronary heart disease / / 21971053 rs1233604 chr6 28734676 G A 2.22E-12 Multiple complex diseases / / 17554300 rs1233615 chr6 28739584 C A 4.94E-04 Coronary heart disease / / 21971053 rs1233621 chr6 28747643 T C,G 3.66E-04 Coronary heart disease / / 21971053 rs1233627 chr6 28751727 T C 1.79E-09 Multiple complex diseases / / 17554300 rs1233627 chr6 28751727 T C 2.15E-04 Coronary heart disease / / 21971053 rs9257181 chr6 28754520 C T 1.39E-04 Coronary heart disease / / 21971053 rs9257181 chr6 28754520 C T 4.90E-05 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) / / 24325915 rs3131343 chr6 28775564 G A 1.01E-05 Pulmonary function / / 20010835 rs4324798 chr6 28776117 G A 2.60E-04 HIV-1 viral setpoint / / 17641165 rs4324798 chr6 28776117 G A 6.13E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs4324798 chr6 28776117 G A 5.60E-06 Lung cancer / / 18385738 rs4324798 chr6 28776117 G A 8.40E-06 Lung cancer / / 18978787 rs4324798 chr6 28776117 G A 4.00E-05 Lung cancer / / 18978790 rs4324798 chr6 28776117 G A 6.77E-07 AIDS progression / / 19115949 rs4324798 chr6 28776117 G A 2.98E-07 Lung cancer / / 19654303 rs4324798 chr6 28776117 G A 2.00E-08 Lung adenocarcinoma / / 19836008 rs4324798 chr6 28776117 G A 7.43E-05 HIV-1 control / / 20041166 rs4324798 chr6 28776117 G A 2.00E-08 Nasopharyngeal carcinoma / / 20512145 rs4324798 chr6 28776117 G A 1.60E-07 Lung cancer / / 22899653 rs4324798 chr6 28776117 G A 5.40E-09 Systemic lupus erythematosus / / 24871463 rs4324798 chr6 28776117 G A 1.89E-05 Systemic lupus erythematosus / / pha002867 rs9257223 chr6 28776317 T C 1.50E-07 Multiple complex diseases / / 17554300 rs377392 chr6 28784741 A C 6.05E-09 Multiple complex diseases / / 17554300 rs3118362 chr6 28785085 C T 5.56E-13 Red blood cell traits / / 23222517 rs10484543 chr6 28791202 A T 9.36E-06 Crohn's disease / / 17684544 rs209181 chr6 28792477 G A 3.41E-05 Lung adenocarcinoma / / 19836008 rs209181 chr6 28792477 G A 2.00E-04 Systemic lupus erythematosus / / 24871463 rs3135296 chr6 28795856 A T 3.07E-12 Multiple complex diseases / / 17554300 rs1002925 chr6 28801383 C T 9.20E-09 Multiple complex diseases / / 17554300 rs9257248 chr6 28803291 C T 3.15E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs422331 chr6 28810817 C T 3.70E-05 Lung cancer / / 18385738 rs422331 chr6 28810817 C T 1.63E-05 Lung cancer / / 18978787 rs422331 chr6 28810817 C T 6.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs176461 chr6 28826405 A G 3.35E-07 Multiple complex diseases / / 17554300 rs176461 chr6 28826405 A G 3.46E-04 Bipolar disorder / / 18317468 rs9257280 chr6 28833507 C T 7.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs209163 chr6 28836817 T C 1.35E-08 Multiple complex diseases / / 17554300 rs3131093 chr6 28837437 C T 2.60E-04 HIV-1 viral setpoint / / 17641165 rs3131093 chr6 28837437 C T 6.17E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs3131093 chr6 28837437 C T 1.60E-05 Lung cancer / / 18385738 rs3131093 chr6 28837437 C T 1.56E-05 Lung cancer / / 18978787 rs3131093 chr6 28837437 C T 6.78E-07 AIDS progression / / 19115949 rs3131093 chr6 28837437 C T 4.20E-07 Lung cancer / / 19654303 rs3131093 chr6 28837437 C T 1.80E-06 Lung adenocarcinoma / / 19836008 rs3131093 chr6 28837437 C T 8.19E-05 HIV-1 control / / 20041166 rs3131093 chr6 28837437 C T 3.10E-09 Lung cancer / / 22899653 rs3131093 chr6 28837437 C T 9.30E-09 Systemic lupus erythematosus / / 24871463 rs3131093 chr6 28837437 C T 1.67E-05 Systemic lupus erythematosus / / pha002867 rs209160 chr6 28839879 A G 1.48E-04 Coronary heart disease / / 21971053 rs209152 chr6 28846462 A G 4.30E-04 Coronary heart disease / / 21971053 rs1016472 chr6 28851367 T C 4.63E-06 Amyotrophic Lateral Sclerosis / / 17827064 rs1016472 chr6 28851367 T C 6.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1016472 chr6 28851367 T C 6.77E-05 Coronary heart disease / / 21971053 rs9257319 chr6 28851637 T G 1.37E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs9257319 chr6 28851637 T G 6.10E-05 Coronary heart disease / / 21971053 rs2032500 chr6 28854269 A G 2.56E-08 Multiple complex diseases / / 17554300 rs3135309 chr6 28855805 A C 1.89E-12 Multiple complex diseases / / 17554300 rs2148008 chr6 28855831 T C 1.15E-06 Multiple complex diseases / / 17554300 rs2148008 chr6 28855831 T C 4.37E-07 Red blood cell traits / / 23222517 rs209126 chr6 28872446 T C 2.44E-08 Multiple complex diseases TRIM27 intron 17554300 rs2269553 chr6 28876509 G A 1.23E-06 Amyotrophic Lateral Sclerosis TRIM27 intron 17827064 rs2269553 chr6 28876509 G A 5.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRIM27 intron 20877124 rs2269553 chr6 28876509 G A 3.66E-05 Coronary heart disease TRIM27 intron 21971053 rs209121 chr6 28881660 T C 7.67E-04 Multiple complex diseases TRIM27 intron 17554300 rs3131102 chr6 28891839 G A 1.97E-07 Multiple complex diseases TRIM27 nearGene-5 17554300 rs2894066 chr6 28893927 G A 2.49E-06 Multiple complex diseases / / 17554300 rs2894066 chr6 28893927 G A 6.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2894066 chr6 28893927 G A 7.08E-06 Coronary heart disease / / 21971053 rs3763338 chr6 28894311 G A 2.15E-06 Rheumatoid arthritis / / 17804836 rs3763338 chr6 28894311 G A 5.14E-06 Rheumatoid arthritis / / 19503088 rs1233508 chr6 28897633 G T 7.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRIM27 nearGene-5 20877124 rs3135318 chr6 28897980 T C 8.07E-06 Pulmonary function TRIM27 nearGene-5 20010835 rs7762289 chr6 28910235 A C 5.54E-05 Multiple complex diseases / / 17554300 rs2071790 chr6 28911802 G A 1.44E-04 Coronary heart disease / / 21971053 rs2071789 chr6 28912076 C T 1.85E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs2071789 chr6 28912076 C T 1.50E-05 Coronary heart disease / / 21971053 rs2071788 chr6 28912307 C T 2.85E-05 Rheumatoid arthritis / / 17804836 rs4947339 chr6 28916252 C T 2.00E-06 Platelet aggregation / / 20526338 rs9257403 chr6 28916972 C T 2.61E-04 Coronary heart disease / / 21971053 rs1476016 chr6 28922719 G A 1.33E-04 Coronary heart disease / / 21971053 rs3131074 chr6 28924530 T C 1.46E-08 Multiple complex diseases / / 17554300 rs9257425 chr6 28936556 A G 1.02E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs9257425 chr6 28936556 A G 1.56E-04 Coronary heart disease / / 21971053 rs6933672 chr6 28941688 G A 1.65E-07 Multiple complex diseases / / 17554300 rs3135322 chr6 28946920 T C 3.64E-08 Multiple complex diseases / / 17554300 rs3135322 chr6 28946920 T C 1.36E-04 Coronary heart disease / / 21971053 rs3130837 chr6 28948092 G T 4.79E-08 Type 1 diabetes / / 17632545 rs3130837 chr6 28948092 G T 2.60E-04 HIV-1 viral setpoint / / 17641165 rs3130837 chr6 28948092 G T 8.47E-05 HIV-1 control / / 20041166 rs9257445 chr6 28949206 G C 1.38E-07 Telomere length / / 23900074 rs3129791 chr6 28954293 G A 6.98E-08 Type 1 diabetes / / 17632545 rs3129791 chr6 28954293 G A 1.20E-05 Lung cancer / / 18385738 rs3129791 chr6 28954293 G A 1.61E-05 Lung cancer / / 18978787 rs3129791 chr6 28954293 G A 4.00E-05 Lung cancer / / 18978790 rs3129791 chr6 28954293 G A 4.59E-07 Lung cancer / / 19654303 rs3129791 chr6 28954293 G A 7.45E-07 Lung adenocarcinoma / / 19836008 rs3129791 chr6 28954293 G A 7.10E-08 Lung cancer / / 22899653 rs3129791 chr6 28954293 G A 2.30E-09 Systemic lupus erythematosus / / 24871463 rs3129791 chr6 28954293 G A 1.10E-05 Systemic lupus erythematosus / / pha002867 rs569105839 chr6 28958458 C A 6.53E-04 Multiple complex diseases / / 17554300 rs7776164 chr6 28958458 C A 6.53E-04 Multiple complex diseases / / 17554300 rs6456880 chr6 28963248 T G 2.18E-05 Migraine ZNF311 missense 20802479 rs6456880 chr6 28963248 T G 1.60E-04 Coronary heart disease ZNF311 missense 21971053 rs9257453 chr6 28968930 A G 1.73E-06 Multiple complex diseases ZNF311 intron 17554300 rs9257453 chr6 28968930 A G 3.10E-04 Crohn's disease ZNF311 intron 17684544 rs9257453 chr6 28968930 A G 3.74E-04 Alzheimer's disease (late onset) ZNF311 intron 21379329 rs3130891 chr6 28977217 G C 7.97E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs3130893 chr6 28980707 A G 1.70E-05 Lung cancer / / 18385738 rs3130893 chr6 28980707 A G 1.12E-05 Lung cancer / / 18978787 rs3130893 chr6 28980707 A G 4.00E-05 Lung cancer / / 18978790 rs3130893 chr6 28980707 A G 2.68E-07 Lung cancer / / 19654303 rs3130893 chr6 28980707 A G 7.39E-07 Lung adenocarcinoma / / 19836008 rs3130893 chr6 28980707 A G 5.80E-08 Lung cancer / / 22899653 rs3130893 chr6 28980707 A G 0.00000383 Schizophrenia / / 23637625 rs3130893 chr6 28980707 A G 1.30E-09 Systemic lupus erythematosus / / 24871463 rs3130893 chr6 28980707 A G 9.64E-06 Systemic lupus erythematosus / / pha002867 rs9357075 chr6 28982287 G A 5.49E-05 Multiple complex diseases / / 17554300 rs9357075 chr6 28982287 G A 3.44E-05 Telomere length / / 23900074 rs9366734 chr6 28987058 A G 1.16E-04 Multiple complex diseases / / 17554300 rs3129797 chr6 28992159 C G 6.97E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2394512 chr6 28992184 A G 1.27E-04 Coronary heart disease / / 21971053 rs7741520 chr6 28994570 A G 5.09E-07 Telomere length / / 23900074 rs2269554 chr6 28994989 G A 9.47E-05 Multiple complex diseases / / 17554300 rs10484544 chr6 28995719 T C 9.81E-05 Multiple complex diseases / / 17554300 rs10484544 chr6 28995719 T C 1.33E-07 Rheumatoid arthritis / / 19503088 rs6914501 chr6 28996177 A G 5.56E-05 Multiple complex diseases / / 17554300 rs16894557 chr6 28999826 G A 6.58E-04 Coronary heart disease / / 21971053 rs16894557 chr6 28999826 G A 2.25E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs41424052 chr6 29010003 T C 1.36E-06 Multiple complex diseases LOC100129636 intron 17554300 rs7341218 chr6 29012116 G A 5.33E-06 Rheumatoid arthritis OR2W1 cds-synon 19503088 rs2143574 chr6 29014026 C T 1.10E-04 Coronary heart disease LOC100129636 intron 21971053 rs3117143 chr6 29031142 C A 5.95E-13 Multiple complex diseases LOC100129636 intron 17554300 rs3117143 chr6 29031142 C A 2.60E-04 HIV-1 viral setpoint LOC100129636 intron 17641165 rs3117143 chr6 29031142 C A 7.44E-04 Amyotrophic Lateral Sclerosis LOC100129636 intron 17827064 rs3117143 chr6 29031142 C A 1.70E-05 Lung cancer LOC100129636 intron 18385738 rs3117143 chr6 29031142 C A 3.00E-05 Lung cancer LOC100129636 intron 18978790 rs3117143 chr6 29031142 C A 9.11E-07 AIDS progression LOC100129636 intron 19115949 rs3117143 chr6 29031142 C A 3.50E-08 Lung cancer LOC100129636 intron 19654303 rs3117143 chr6 29031142 C A 8.21E-07 Lung adenocarcinoma LOC100129636 intron 19836008 rs3117143 chr6 29031142 C A 3.56E-05 HIV-1 control LOC100129636 intron 20041166 rs3117143 chr6 29031142 C A 6.90E-05 Lung cancer LOC100129636 intron 22899653 rs3117143 chr6 29031142 C A 3.30E-11 Systemic lupus erythematosus LOC100129636 intron 24871463 rs7752270 chr6 29053998 G A 2.95E-06 Multiple complex diseases OR2B3 UTR-3 17554300 rs7752270 chr6 29053998 G A 3.03E-04 Alzheimer's disease (late onset) OR2B3 UTR-3 21379329 rs3129788 chr6 29057639 G A 5.41E-13 Multiple complex diseases / / 17554300 rs3131091 chr6 29073094 A G 4.65E-08 Multiple complex diseases / / 17554300 rs3130764 chr6 29080349 A G 9.08E-04 Amyotrophic Lateral Sclerosis OR2J3 missense 17827064 rs3129109 chr6 29084232 T C 2.00E-17 Height / / 20881960 rs9295791 chr6 29096033 A G 5.95E-04 Multiple complex diseases / / 17554300 rs3130778 chr6 29099579 T C 1.21E-04 Coronary heart disease / / 21971053 rs9295794 chr6 29104935 G A 3.28E-05 Rheumatoid arthritis / / 17804836 rs9393945 chr6 29108291 C G 6.71E-04 Multiple complex diseases / / 17554300 rs3130718 chr6 29114621 G A 1.49E-04 Coronary heart disease / / 21971053 rs3129126 chr6 29121631 G A 1.13E-07 Multiple complex diseases / / 17554300 rs3116817 chr6 29149561 G A 1.63E-04 Coronary heart disease / / 21971053 rs3116817 chr6 29149561 G A 3.70E-04 Systemic lupus erythematosus / / 24871463 rs3116830 chr6 29167575 G A 8.03E-13 Multiple complex diseases / / 17554300 rs1883329 chr6 29177102 T C 2.01E-04 Coronary heart disease / / 21971053 rs2206040 chr6 29178514 T C 5.77E-08 Multiple complex diseases / / 17554300 rs2206040 chr6 29178514 T C 6.33E-04 Coronary heart disease / / 21971053 rs2206041 chr6 29178606 T C 4.20E-04 Coronary heart disease / / 21971053 rs3130817 chr6 29179237 T G 7.42E-08 Type 1 diabetes / / 17632545 rs3130817 chr6 29179237 T G 5.32E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs3130817 chr6 29179237 T G 2.50E-07 Systemic lupus erythematosus / / 24871463 rs9257616 chr6 29180721 G A 1.21E-08 Multiple complex diseases / / 17554300 rs9257616 chr6 29180721 G A 3.00E-07 Social communication problems / / 24047820 rs3130826 chr6 29181314 G A 1.46E-04 Coronary heart disease / / 21971053 rs3116837 chr6 29184660 T C 3.51E-05 Coronary heart disease / / 21971053 rs3130813 chr6 29195011 C T 4.36E-09 Multiple complex diseases / / 17554300 rs3129103 chr6 29207570 C T 2.36E-07 Multiple complex diseases / / 17554300 rs3117337 chr6 29211556 T A 5.63E-08 Multiple complex diseases / / 17554300 rs3117330 chr6 29225795 T C 9.25E-07 Multiple complex diseases / / 17554300 rs3130827 chr6 29230683 T C 3.20E-06 Schizophrenia / / 21926974 rs3130827 chr6 29230683 T C 1.10E-04 Systemic lupus erythematosus / / 24871463 rs16894681 chr6 29232072 T G 8.62E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10484545 chr6 29234510 C G 2.84E-07 Crohn's disease / / 17684544 rs7766902 chr6 29236645 G T 6.60E-04 Multiple complex diseases / / 17554300 rs3117326 chr6 29240378 C T 7.94E-08 Type 1 diabetes / / 17632545 rs3117326 chr6 29240378 C T 2.60E-04 HIV-1 viral setpoint / / 17641165 rs3117326 chr6 29240378 C T 6.65E-05 HIV-1 control / / 20041166 rs1884123 chr6 29256420 A G 3.17E-06 Multiple complex diseases / / 17554300 rs1884123 chr6 29256420 A G 2.80E-05 Systemic lupus erythematosus / / 24871463 rs3117425 chr6 29260431 C T 2.96E-07 Multiple complex diseases / / 17554300 rs1884294 chr6 29262956 G A 9.88E-04 Multiple complex diseases / / 17554300 rs6925072 chr6 29263357 A G 6.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs3117426 chr6 29272012 C T 1.61E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs3117426 chr6 29272012 C T 8.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs3117426 chr6 29272012 C T 8.62E-10 Common variable immunodeficiency / / 21497890 rs3117426 chr6 29272012 C T 1.60E-09 Systemic lupus erythematosus / / 24871463 rs3117431 chr6 29280638 A G 4.41E-07 Red blood cell traits / / 23222517 rs720831 chr6 29284518 A G 5.00E-04 Systemic lupus erythematosus / / 24871463 rs3129683 chr6 29286670 C G 1.19E-09 Multiple complex diseases / / 17554300 rs12660111 chr6 29296148 C T 4.86E-05 Coronary heart disease / / 21971053 rs9357078 chr6 29297666 C T 5.27E-05 Rheumatoid arthritis / / 17804836 rs9357078 chr6 29297666 C T 9.74E-06 Rheumatoid arthritis / / 19503088 rs3130802 chr6 29299503 T C 7.16E-07 Red blood cell traits / / 23222517 rs6930435 chr6 29301222 A G 0.0000358 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs3130805 chr6 29306456 G A 3.00E-05 Lung cancer / / 18978790 rs3130805 chr6 29306456 G A 0.0000428 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs3130806 chr6 29306484 G A 5.54E-07 Red blood cell traits / / 23222517 rs9257745 chr6 29306656 C T 6.98E-04 Multiple complex diseases / / 17554300 rs3117436 chr6 29315419 A G 5.51E-08 Red blood cell traits / / 23222517 rs10447393 chr6 29316852 T C 6.81E-06 Multiple complex diseases / / 17554300 rs6930033 chr6 29323905 A C 2.39E-05 Coronary heart disease OR5V1 missense 21971053 rs10484546 chr6 29324599 A C 1.55E-05 Coronary heart disease OR5V1 nearGene-5 21971053 rs3129684 chr6 29325160 G C 1.58E-07 Red blood cell traits OR5V1 nearGene-5 23222517 rs3129685 chr6 29325602 G A 2.01E-07 Red blood cell traits OR5V1 nearGene-5 23222517 rs9380120 chr6 29335537 T C 4.45E-05 Rheumatoid arthritis / / 17804836 rs9380120 chr6 29335537 T C 9.33E-06 Rheumatoid arthritis / / 19503088 rs9257794 chr6 29335661 C T 6.62E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4713211 chr6 29336054 G A 4.41E-06 Rheumatoid arthritis / / 17804836 rs4713211 chr6 29336054 G A 6.04E-08 Rheumatoid arthritis / / 19503088 rs6934993 chr6 29337500 A G 5.30E-07 Multiple complex diseases / / 17554300 rs6934993 chr6 29337500 A G 6.61E-05 Lung cancer / / 18978787 rs6934993 chr6 29337500 A G 3.00E-04 Schizophrenia / / 19197363 rs7753474 chr6 29341308 G A 1.17E-07 Rheumatoid arthritis OR12D3 UTR-3 19503088 rs7753474 chr6 29341308 G A 1.70E-05 Telomere length OR12D3 UTR-3 23900074 rs3117440 chr6 29341666 T A 4.25E-07 Red blood cell traits OR12D3 UTR-3 23222517 rs3749971 chr6 29342775 G A 4.86E-08 Multiple complex diseases OR12D3 missense 17554300 rs3749971 chr6 29342775 G A 8.31E-05 HIV-1 viral setpoint OR12D3 missense 17641165 rs3749971 chr6 29342775 G A 1.90E-05 Lung cancer OR12D3 missense 18385738 rs3749971 chr6 29342775 G A 3.62E-05 Lung cancer OR12D3 missense 18978787 rs3749971 chr6 29342775 G A 5.00E-05 Lung cancer OR12D3 missense 18978790 rs3749971 chr6 29342775 G A 4.66E-07 AIDS progression OR12D3 missense 19115949 rs3749971 chr6 29342775 G A 4.02E-06 Lung cancer OR12D3 missense 19654303 rs3749971 chr6 29342775 G A 2.13E-06 Lung adenocarcinoma OR12D3 missense 19836008 rs3749971 chr6 29342775 G A 4.10E-06 HIV-1 control OR12D3 missense 20041166 rs3749971 chr6 29342775 G A 1.40E-07 Lung cancer OR12D3 missense 22899653 rs3749971 chr6 29342775 G A 1.20E-08 Systemic lupus erythematosus OR12D3 missense 24871463 rs3749970 chr6 29342825 G A 9.02E-06 Multiple complex diseases OR12D3 cds-synon 17554300 rs9257802 chr6 29343355 C T 7.88E-05 HIV-1 control OR12D3 nearGene-5 20041166 rs9378134 chr6 29351784 G A,C,T 3.00E-06 Retinopathy in non-diabetics / / 23393555 rs238872 chr6 29351873 C T 1.23E-06 Multiple complex diseases / / 17554300 rs238872 chr6 29351873 C T 2.71E-04 Coronary heart disease / / 21971053 rs3094556 chr6 29353408 T C 3.15E-04 Coronary heart disease / / 21971053 rs3094551 chr6 29354799 A G 2.19E-04 Coronary heart disease / / 21971053 rs3094551 chr6 29354799 A G 2.70E-08 HIV-1 susceptibility / / 23935489 rs3094550 chr6 29354809 C A 2.23E-04 Coronary heart disease / / 21971053 rs3094550 chr6 29354809 C A 2.60E-08 HIV-1 susceptibility / / 23935489 rs3094549 chr6 29355148 C A 7.49E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs3094548 chr6 29355202 G C 1.00E-07 Pulmonary function / / 21946350 rs4711185 chr6 29356046 G A 6.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9257809 chr6 29356331 A G 3.09E-10 Type 1 diabetes / / 17632545 rs9257809 chr6 29356331 A G 7.64E-05 HIV-1 viral setpoint / / 17641165 rs9257809 chr6 29356331 A G 1.15E-05 HIV-1 control / / 20041166 rs9257809 chr6 29356331 A G 4.00E-09 Barrett's esophagus / / 22961001 rs9257809 chr6 29356331 A G 4.00E-09 Body mass index / / 22982992 rs379157 chr6 29356587 G A 1.44E-06 Narcolepsy / / 20711174 rs9257816 chr6 29359112 C A 3.13E-12 Multiple complex diseases / / 17554300 rs9257834 chr6 29364615 G T 5.48E-12 Multiple complex diseases OR12D2 missense 17554300 rs2073151 chr6 29364951 G A 1.30E-11 Multiple complex diseases OR12D2 missense 17554300 rs2073149 chr6 29365423 A T 7.07E-08 Multiple complex diseases OR12D2 UTR-3 17554300 rs9257837 chr6 29368021 C T 3.80E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2394604 chr6 29369268 C A 4.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10946988 chr6 29371884 T A 3.85E-04 Multiple complex diseases / / 17554300 rs406511 chr6 29376385 C G 2.26E-08 Multiple complex diseases / / 17554300 rs1419643 chr6 29391936 T G 4.14E-10 Multiple complex diseases / / 17554300 rs2074470 chr6 29394427 G A 1.08E-06 Multiple complex diseases OR11A1 UTR-3 17554300 rs16894899 chr6 29395104 G A 7.93E-15 Multiple complex diseases OR11A1 cds-synon 17554300 rs16894900 chr6 29395499 C G 2.98E-11 Multiple complex diseases OR11A1 UTR-5 17554300 rs7770592 chr6 29395747 C A 6.72E-04 Multiple complex diseases OR11A1 nearGene-5 17554300 rs9295805 chr6 29397779 C T 1.36E-04 Multiple complex diseases / / 17554300 rs3131025 chr6 29398815 A G 2.23E-06 Multiple complex diseases / / 17554300 rs16894909 chr6 29402687 C T 1.88E-04 Multiple complex diseases / / 17554300 rs16894932 chr6 29415075 A G 8.09E-05 Multiple complex diseases / / 17554300 rs2523443 chr6 29415464 C A 1.19E-09 Multiple complex diseases / / 17554300 rs6906897 chr6 29415636 C T 2.81E-05 Multiple complex diseases / / 17554300 rs2107193 chr6 29420000 G T 1.53E-04 Multiple complex diseases / / 17554300 rs6456951 chr6 29426203 T A 1.74E-05 Multiple complex diseases OR2H1 nearGene-5 17554300 rs2107192 chr6 29433942 G A 8.62E-05 Multiple complex diseases / / 17554300 rs2107191 chr6 29434295 C T 2.50E-09 Multiple complex diseases / / 17554300 rs4713226 chr6 29434414 G A 2.40E-07 Rheumatoid arthritis / / 19503088 rs4713226 chr6 29434414 G A 4.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4713226 chr6 29434414 G A 2.00E-08 Immune reponse to smallpox (secreted IFN-alpha) / / 22610502 rs4713226 chr6 29434414 G A 1.37E-06 Nasopharyngeal carcinoma / / 23209447 rs4713226 chr6 29434414 G A 1.37E-06 Schizophrenia / / 23212062 rs2746149 chr6 29435355 T C 9.17E-10 Multiple complex diseases / / 17554300 rs16894948 chr6 29440257 G A 1.89E-04 Multiple complex diseases / / 17554300 rs1362076 chr6 29441169 G T 2.03E-09 Coronary heart disease / / 21971053 rs2746150 chr6 29442701 C T 1.77E-09 Type 1 diabetes / / 17632545 rs2746150 chr6 29442701 C T 2.25E-04 HIV-1 viral setpoint / / 17641165 rs2746150 chr6 29442701 C T 1.60E-05 Lung cancer / / 18385738 rs2746150 chr6 29442701 C T 1.45E-05 Lung cancer / / 18978787 rs2746150 chr6 29442701 C T 1.00E-05 Lung cancer / / 18978790 rs2746150 chr6 29442701 C T 2.80E-06 AIDS progression / / 19115949 rs2746150 chr6 29442701 C T 1.21E-06 Lung cancer / / 19654303 rs2746150 chr6 29442701 C T 4.71E-08 Lung adenocarcinoma / / 19836008 rs2746150 chr6 29442701 C T 8.95E-06 HIV-1 control / / 20041166 rs2746150 chr6 29442701 C T 3.60E-09 Lung cancer / / 22899653 rs2746150 chr6 29442701 C T 2.90E-09 Systemic lupus erythematosus / / 24871463 rs2746150 chr6 29442701 C T 3.42E-05 Systemic lupus erythematosus / / pha002867 rs1233495 chr6 29444121 G A 8.22E-09 Multiple complex diseases / / 17554300 rs1233493 chr6 29458241 A G 5.68E-07 Multiple complex diseases / / 17554300 rs1233491 chr6 29461730 G C 1.97E-07 Multiple complex diseases / / 17554300 rs1233490 chr6 29461914 A G 3.30E-05 Multiple complex diseases / / 17554300 rs1233487 chr6 29468809 A G 3.67E-08 Multiple complex diseases / / 17554300 rs1233487 chr6 29468809 A G 2.96E-05 Lung adenocarcinoma / / 19836008 rs1233487 chr6 29468809 A G 5.60E-06 Systemic lupus erythematosus / / 24871463 rs757256 chr6 29472916 C T 2.23E-08 Type 1 diabetes / / 17632545 rs757256 chr6 29472916 C T 9.55E-05 Coronary heart disease / / 21971053 rs3130858 chr6 29473501 C A 1.78E-07 Red blood cell traits / / 23222517 rs734961 chr6 29475039 G T 4.48E-09 Multiple complex diseases / / 17554300 rs734960 chr6 29475142 C T 9.82E-09 Multiple complex diseases / / 17554300 rs3131020 chr6 29475902 C T 1.67E-04 Coronary heart disease / / 21971053 rs3094572 chr6 29480993 T C 1.60E-12 Multiple complex diseases / / 17554300 rs3094572 chr6 29480993 T C 4.25E-06 Rheumatoid arthritis / / 19503088 rs9257879 chr6 29483019 C G 4.95E-07 Multiple complex diseases / / 17554300 rs3094564 chr6 29486345 C T 3.50E-07 Rheumatoid arthritis / / 19503088 rs2745400 chr6 29488249 A G 9.00E-09 Graves' disease / / 21900946 rs3131023 chr6 29493144 C T 8.38E-07 Red blood cell traits / / 23222517 rs6913746 chr6 29495815 T C 4.43E-05 Multiple complex diseases LOC100507362 nearGene-5 17554300 rs9501677 chr6 29497002 G A 3.15E-04 Coronary heart disease LOC100507362 nearGene-5 21971053 rs362514 chr6 29507310 C T 2.46E-04 Smoking initiation / / 24665060 rs362540 chr6 29510325 G A 5.84E-08 Multiple complex diseases / / 17554300 rs362540 chr6 29510325 G A 8.20E-09 Graves' disease / / 21900946 rs362538 chr6 29510630 G C 1.68E-07 Red blood cell traits / / 23222517 rs9368606 chr6 29518665 A C 4.29E-04 Multiple complex diseases / / 17554300 rs446145 chr6 29520787 G C 2.10E-06 Graves' disease / / 21900946 rs562085911 chr6 29520787 G GCCAC 2.10E-06 Graves' disease / / 21900946 rs16895057 chr6 29520877 T C 3.00E-06 Height / / 23456168 rs6915177 chr6 29522588 C T 1.50E-04 Multiple complex diseases / / 17554300 rs444013 chr6 29523646 G C 7.90E-04 Alzheimer's disease (late onset) UBD UTR-3 21460841 rs2272991 chr6 29527599 T C 2.62E-04 Coronary heart disease UBD UTR-5 21971053 rs1233405 chr6 29529754 A G 4.14E-05 Multiple complex diseases / / 17554300 rs459970 chr6 29531253 G A 5.26E-07 Coronary heart disease / / 21971053 rs1235162 chr6 29537224 A G 8.05E-09 Type 1 diabetes / / 17632545 rs1235162 chr6 29537224 A G 3.07E-05 HIV-1 viral setpoint / / 17641165 rs1235162 chr6 29537224 A G 5.13E-06 Lung cancer / / 18978787 rs1235162 chr6 29537224 A G 2.00E-05 Lung cancer / / 18978790 rs1235162 chr6 29537224 A G 6.65E-07 AIDS progression / / 19115949 rs1235162 chr6 29537224 A G 8.74E-07 Lung cancer / / 19654303 rs1235162 chr6 29537224 A G 1.09E-09 Lung adenocarcinoma / / 19836008 rs1235162 chr6 29537224 A G 1.86E-06 HIV-1 control / / 20041166 rs1235162 chr6 29537224 A G 2.30E-13 Lung cancer / / 22899653 rs1235162 chr6 29537224 A G 1.80E-49 Myasthenia gravis / / 23055271 rs1235162 chr6 29537224 A G 8.10E-09 Systemic lupus erythematosus / / 24871463 rs1233400 chr6 29537975 G A 8.64E-05 Multiple complex diseases / / 17554300 rs1233400 chr6 29537975 G A 7.10E-11 Rheumatoid arthritis / / 19503088 rs1233399 chr6 29539482 G A 1.99E-09 Rheumatoid arthritis / / 19503088 rs3025652 chr6 29539765 G A 6.81E-05 Behcet's disease / / pha002888 rs1003581 chr6 29540204 G A 4.99E-05 Coronary heart disease / / 21971053 rs362525 chr6 29543646 T G 3.00E-07 Multiple complex diseases / / 17554300 rs1233397 chr6 29545715 A G 2.19E-04 Multiple complex diseases / / 17554300 rs1233397 chr6 29545715 A G 2.03E-05 HIV-1 control / / 20041166 rs1233396 chr6 29546799 G A 5.77E-07 Multiple complex diseases / / 17554300 rs1233396 chr6 29546799 G A 5.43E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs926552 chr6 29548089 G A 6.56E-13 Multiple complex diseases SNORD32B nearGene-5 17554300 rs1233391 chr6 29550618 T C 3.51E-05 HIV-1 control / / 20041166 rs1233386 chr6 29558190 C T 2.71E-08 Rheumatoid arthritis / / 19503088 rs1233384 chr6 29559295 C T 9.37E-09 Rheumatoid arthritis / / 19503088 rs17508548 chr6 29563067 T G 7.86E-10 Multiple complex diseases / / 17554300 rs17508548 chr6 29563067 T G 5.39E-05 Nasopharyngeal carcinoma / / 19664746 rs3095273 chr6 29566369 A G 2.04E-06 Narcolepsy / / 20711174 rs3025645 chr6 29567621 T A 8.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs362518 chr6 29567638 T C 5.64E-05 Nasopharyngeal carcinoma / / 19664746 rs3025643 chr6 29569955 A G 9.76E-04 Hypothyroidism GABBR1 nearGene-3 21981779 rs2267633 chr6 29570841 A G 2.36E-07 Rheumatoid arthritis GABBR1 UTR-3 19503088 rs2267633 chr6 29570841 A G 2.82E-05 Nasopharyngeal carcinoma GABBR1 UTR-3 19664746 rs2267633 chr6 29570841 A G 1.20E-12 Nasopharyngeal carcinoma GABBR1 UTR-3 20512145 rs2267633 chr6 29570841 A G 2.19E-06 Nasopharyngeal carcinoma GABBR1 UTR-3 23209447 rs2076483 chr6 29571545 A G 7.59E-07 Rheumatoid arthritis GABBR1 intron 19503088 rs2076483 chr6 29571545 A G 3.13E-05 Nasopharyngeal carcinoma GABBR1 intron 19664746 rs2076483 chr6 29571545 A G 1.30E-12 Nasopharyngeal carcinoma GABBR1 intron 20512145 rs28359963 chr6 29574476 T C 6.61E-05 Nasopharyngeal carcinoma GABBR1 intron 19664746 rs29267 chr6 29575003 G A 2.30E-05 Nasopharyngeal carcinoma GABBR1 intron 19664746 rs740883 chr6 29575405 A T 7.05E-04 Multiple complex diseases GABBR1 intron 17554300 rs740882 chr6 29575456 C T 6.66E-05 Multiple complex diseases GABBR1 intron 17554300 rs29230 chr6 29576393 A G 4.03E-05 Nasopharyngeal carcinoma GABBR1 cds-synon 19664746 rs29230 chr6 29576393 A G 1.30E-12 Nasopharyngeal carcinoma GABBR1 cds-synon 20512145 rs29230 chr6 29576393 A G 9.48E-09 Nasopharyngeal carcinoma GABBR1 cds-synon 23209447 rs29259 chr6 29577938 A G 3.83E-05 Nasopharyngeal carcinoma GABBR1 intron 19664746 rs29255 chr6 29579544 A C 1.06E-10 Multiple complex diseases GABBR1 intron 17554300 rs29227 chr6 29580588 G T 1.35E-04 Multiple complex diseases GABBR1 intron 17554300 rs29226 chr6 29581011 T G 2.40E-04 Multiple complex diseases GABBR1 intron 17554300 rs29225 chr6 29581041 A G 1.03E-04 Multiple complex diseases GABBR1 cds-synon 17554300 rs29224 chr6 29581343 T A 1.20E-04 Multiple complex diseases GABBR1 intron 17554300 rs16867690 chr6 29585383 C T 1.50E-04 Multiple complex diseases GABBR1 intron 17554300 rs17842396 chr6 29586384 T C 1.15E-04 Multiple complex diseases GABBR1 intron 17554300 rs29221 chr6 29589124 C G 6.22E-05 Multiple complex diseases GABBR1 intron 17554300 rs29220 chr6 29589666 C G 6.08E-06 Nasopharyngeal carcinoma GABBR1 intron 19664746 rs9461540 chr6 29604264 T G 2.97E-04 Nasopharyngeal carcinoma / / 19664746 rs3095267 chr6 29607046 G C 4.15E-07 Nasopharyngeal carcinoma / / 19664746 rs3095267 chr6 29607046 G C 9.00E-06 Migraine without aura / / 23793025 rs29218 chr6 29607429 A G 1.10E-07 Multiple complex diseases / / 17554300 rs29218 chr6 29607429 A G 4.03E-07 Nasopharyngeal carcinoma / / 19664746 rs29240 chr6 29607476 A G 2.01E-05 Multiple complex diseases / / 17554300 rs62392946 chr6 29609600 T C 2.95E-04 Nasopharyngeal carcinoma / / 19664746 rs29273 chr6 29610989 G C 3.26E-04 Multiple complex diseases / / 17554300 rs29233 chr6 29611229 C G 1.10E-04 Nasopharyngeal carcinoma / / 19664746 rs29232 chr6 29611431 C T 5.47E-07 Rheumatoid arthritis / / 19503088 rs29232 chr6 29611431 C T 9.00E-17 Nasopharyngeal carcinoma / / 19664746 rs29232 chr6 29611431 C T 3.10E-05 HIV-1 control / / 20041166 rs29232 chr6 29611431 C T 9.00E-17 Nasopharyngeal carcinoma / / 20512145 rs29232 chr6 29611431 C T 4.35E-06 Nasopharyngeal carcinoma / / 23209447 rs29232 chr6 29611431 C T 1.90E-04 Systemic lupus erythematosus / / 24871463 rs3131854 chr6 29611885 T C 2.54E-08 Behcet's disease / / pha002888 rs3129073 chr6 29615822 A G 4.01E-05 Lung adenocarcinoma / / 19836008 rs3129073 chr6 29615822 A G 1.90E-08 Lung cancer / / 22899653 rs29254 chr6 29623594 T C 2.95E-09 Multiple complex diseases MOG nearGene-5 17554300 rs29228 chr6 29623739 G A 2.18E-07 Multiple complex diseases MOG nearGene-5 17554300 rs29228 chr6 29623739 G A 0.00048 Coronary artery calcification MOG nearGene-5 23727086 rs2252711 chr6 29626321 T C 4.00E-07 Pulmonary function (interaction) MOG intron 23284291 rs16895223 chr6 29626949 C G 4.60E-05 Personality dimensions MOG intron 18957941 rs371558780 chr6 29626949 C CAAG 4.60E-05 Personality dimensions MOG intron 18957941 rs3135050 chr6 29628437 T C 2.42E-11 Behcet's disease MOG intron pha002888 rs2535260 chr6 29628883 C G 1.17E-08 Multiple complex diseases MOG intron 17554300 rs3117286 chr6 29629774 T C 9.81E-05 Multiple complex diseases MOG intron 17554300 rs3117286 chr6 29629774 T C 5.78E-05 Personality dimensions MOG intron 18957941 rs2535255 chr6 29631690 G A 6.76E-07 Multiple complex diseases MOG intron 17554300 rs3130252 chr6 29631744 C T 3.46E-06 Multiple sclerosis MOG intron 17660530 rs3130253 chr6 29634012 A G 6.84E-05 Rheumatoid arthritis MOG missense 17804836 rs3130253 chr6 29634012 A G 4.04E-09 Red blood cell traits MOG missense 23222517 rs2071652 chr6 29635317 C T 1.80E-10 Graves' disease MOG intron 21900946 rs2071653 chr6 29635928 T C 2.34E-07 Behcet's disease MOG intron pha002888 rs9257936 chr6 29639776 C T 5.60E-05 HIV-1 control MOG UTR-3 20041166 rs378596 chr6 29643287 A C 6.97E-07 Multiple complex diseases ZFP57 intron 17554300 rs2535238 chr6 29645038 C A 5.28E-05 Rheumatoid arthritis ZFP57 nearGene-5 17804836 rs2535238 chr6 29645038 C A 7.32E-06 Lung adenocarcinoma ZFP57 nearGene-5 19836008 rs2535238 chr6 29645038 C A 7.07E-05 Orofacial clefts ZFP57 nearGene-5 22863734 rs2535238 chr6 29645038 C A 2.70E-09 Lung cancer ZFP57 nearGene-5 22899653 rs387603 chr6 29645578 C A 6.77E-07 Multiple complex diseases ZFP57 nearGene-5 17554300 rs3129063 chr6 29645613 C A 7.86E-09 Multiple complex diseases ZFP57 nearGene-5 17554300 rs387642 chr6 29645634 C T 3.23E-09 Multiple complex diseases ZFP57 nearGene-5 17554300 rs3129054 chr6 29649056 C T 7.20E-07 Rheumatoid arthritis / / 19503088 rs3129054 chr6 29649056 C T 1.46E-05 Lung adenocarcinoma / / 19836008 rs3131847 chr6 29649105 G A 5.67E-10 Multiple complex diseases / / 17554300 rs3129051 chr6 29650122 T A 5.27E-07 Multiple complex diseases / / 17554300 rs398931 chr6 29651492 G C 1.26E-06 Multiple complex diseases / / 17554300 rs2747436 chr6 29651935 T C 5.53E-10 Multiple complex diseases / / 17554300 rs3117292 chr6 29652199 A G 3.12E-05 Lung adenocarcinoma / / 19836008 rs3129045 chr6 29652576 C A 1.74E-12 Multiple complex diseases / / 17554300 rs2747442 chr6 29653186 A G 2.27E-09 Multiple complex diseases / / 17554300 rs3117294 chr6 29653329 T G 3.58E-13 Multiple complex diseases / / 17554300 rs3117294 chr6 29653329 T G 4.71E-07 Rheumatoid arthritis / / 19503088 rs3117295 chr6 29653377 T C 6.43E-09 Multiple complex diseases / / 17554300 rs2747445 chr6 29653695 C A 2.62E-07 Multiple complex diseases / / 17554300 rs2747454 chr6 29655113 G A 5.50E-12 Rheumatoid arthritis / / 19503088 rs2747454 chr6 29655113 G A 2.00E-06 Asthma / / 21790008 rs2747457 chr6 29656417 T G 2.25E-05 Rheumatoid arthritis / / 17804836 rs2747457 chr6 29656417 T G 5.11E-06 Lung adenocarcinoma / / 19836008 rs2747457 chr6 29656417 T G 5.68E-05 Orofacial clefts / / 22863734 rs2747457 chr6 29656417 T G 5.50E-09 Lung cancer / / 22899653 rs3131888 chr6 29663889 T C 5.03E-09 Rheumatoid arthritis / / 17804836 rs3131888 chr6 29663889 T C 1.22E-14 Rheumatoid arthritis / / 19503088 rs7776082 chr6 29667273 G A 1.17E-06 Rheumatoid arthritis / / 17804836 rs7776082 chr6 29667273 G A 1.32E-09 Rheumatoid arthritis / / 19503088 rs3129055 chr6 29670261 A G 7.00E-11 Nasopharyngeal carcinoma / / 19664746 rs3129055 chr6 29670261 A G 1.92E-05 Lung adenocarcinoma / / 19836008 rs3129055 chr6 29670261 A G 7.00E-11 Nasopharyngeal carcinoma / / 20512145 rs3129047 chr6 29670573 C T 6.15E-08 Multiple complex diseases / / 17554300 rs3129046 chr6 29670652 G A 1.47E-12 Multiple complex diseases / / 17554300 rs3131866 chr6 29671740 G A 7.32E-07 Nasopharyngeal carcinoma / / 19664746 rs3131866 chr6 29671740 G A 2.40E-07 Nasopharyngeal carcinoma / / 20512145 rs2394660 chr6 29672686 A G 8.46E-04 Alcohol dependence / / 20201924 rs3131863 chr6 29673483 G A 8.45E-04 Alcohol dependence / / 20201924 rs3131863 chr6 29673483 G A 8.80E-06 Nasopharyngeal carcinoma / / 20512145 rs3131863 chr6 29673483 G A 2.74E-04 Coronary heart disease / / 21971053 rs3131863 chr6 29673483 G A 5.63E-06 Behcet's disease / / pha002888 rs3116788 chr6 29674197 C T 4.60E-04 Multiple complex diseases / / 17554300 rs56918232 chr6 29674700 G A 5.14E-06 Stroke (ischemic) / / 21957438 rs1476572 chr6 29674741 G T 5.89E-04 Alcohol dependence / / 20201924 rs1610585 chr6 29675676 C G 8.29E-04 Multiple complex diseases / / 17554300 rs1610585 chr6 29675676 C G 8.10E-05 Multiple sclerosis / / 17660530 rs1610585 chr6 29675676 C G 4.50E-04 Coronary heart disease / / 21606135 rs9258126 chr6 29675791 T C 1.85E-04 Multiple complex diseases / / 17554300 rs1610586 chr6 29676316 T C 8.35E-04 Multiple complex diseases / / 17554300 rs1610586 chr6 29676316 T C 5.45E-04 Coronary heart disease / / 21606135 rs1610588 chr6 29676716 C T 5.34E-07 Nasopharyngeal carcinoma / / 19664746 rs1610591 chr6 29677835 A C,G,T 1.10E-08 Graves' disease / / 21900946 rs1736931 chr6 29677877 A T 7.36E-04 Alcohol dependence / / 20201924 rs1610742 chr6 29677952 T C 2.00E-12 Multiple complex diseases / / 17554300 rs1610742 chr6 29677952 T C 8.25E-07 Nasopharyngeal carcinoma / / 19664746 rs4098873 chr6 29678150 C T 6.18E-07 Multiple complex diseases / / 17554300 rs1610593 chr6 29678520 A C,G,T 6.05E-04 Multiple complex diseases / / 17554300 rs1610593 chr6 29678520 A C,G,T 8.54E-05 Multiple sclerosis / / 17660530 rs1611356 chr6 29679016 C G 6.44E-04 Multiple complex diseases / / 17554300 rs1611356 chr6 29679016 C G 7.27E-04 Coronary heart disease / / 21606135 rs1610594 chr6 29679047 C T 6.13E-04 Alcohol dependence / / 20201924 rs1610594 chr6 29679047 C T 1.10E-05 Nasopharyngeal carcinoma / / 20512145 rs1610594 chr6 29679047 C T 2.12E-04 Coronary heart disease / / 21971053 rs73410967 chr6 29679908 T C 3.91E-06 Stroke (ischemic) / / 21957438 rs1611371 chr6 29680021 C T 3.52E-04 Alcohol dependence / / 20201924 rs1611371 chr6 29680021 C T 5.19E-05 Coronary heart disease / / 21971053 rs1611371 chr6 29680021 C T 1.97E-05 Body Composition / / pha003012 rs1611371 chr6 29680021 C T 2.05E-05 Body Mass Index / / pha003021 rs1611381 chr6 29680492 T C 5.90E-04 Multiple complex diseases / / 17554300 rs1611381 chr6 29680492 T C 7.08E-04 Coronary heart disease / / 21606135 rs528375841 chr6 29680492 T C 5.90E-04 Multiple complex diseases / / 17554300 rs528375841 chr6 29680492 T C 7.08E-04 Coronary heart disease / / 21606135 rs570138622 chr6 29680657 G C 5.30E-04 Multiple complex diseases / / 17554300 rs7741807 chr6 29680657 G C 5.30E-04 Multiple complex diseases / / 17554300 rs1611388 chr6 29680789 C T 5.45E-04 Multiple complex diseases / / 17554300 rs535304218 chr6 29680789 C T 5.45E-04 Multiple complex diseases / / 17554300 rs557729411 chr6 29681161 C A 2.76E-06 Stroke (ischemic) / / 21957438 rs73410989 chr6 29681161 C A 2.76E-06 Stroke (ischemic) / / 21957438 rs533550179 chr6 29682239 C T 5.56E-07 Nasopharyngeal carcinoma / / 19664746 rs1627465 chr6 29682901 G A 4.07E-04 Multiple complex diseases / / 17554300 rs577078190 chr6 29683808 G A 7.34E-07 Nasopharyngeal carcinoma / / 19664746 rs9391658 chr6 29688828 G A 7.52E-04 Nasopharyngeal carcinoma / / 19664746 rs9258170 chr6 29689590 T G 3.20E-05 Nasopharyngeal carcinoma / / 20512145 rs1362126 chr6 29691019 G A 7.54E-06 Behcet's disease HLA-F nearGene-5 pha002888 rs1632953 chr6 29692305 A G 2.30E-05 Multiple complex diseases HLA-F intron 17554300 rs1632953 chr6 29692305 A G 6.74E-07 Multiple sclerosis HLA-F intron 17660530 rs9258186 chr6 29692334 A G 6.00E-05 Nasopharyngeal carcinoma HLA-F intron 20512145 rs2072898 chr6 29692729 T G 5.85E-07 Multiple complex diseases HLA-F intron 17554300 rs2235383 chr6 29693499 A G 4.00E-05 Nasopharyngeal carcinoma HLA-F intron 20512145 rs1059174 chr6 29694427 C T 1.21E-05 Multiple complex diseases HLA-F intron 17554300 rs1059174 chr6 29694427 C T 7.46E-08 Multiple sclerosis HLA-F intron 17660530 rs2523405 chr6 29695305 T G 1.51E-05 Multiple complex diseases HLA-F-AS1 intron 17554300 rs2523405 chr6 29695305 T G 3.84E-08 Narcolepsy HLA-F-AS1 intron 19629137 rs2523404 chr6 29695713 C T 1.09E-05 Multiple complex diseases HLA-F-AS1 intron 17554300 rs1736921 chr6 29696209 G A 6.46E-06 Multiple complex diseases HLA-F-AS1 intron 17554300 rs1736921 chr6 29696209 G A 1.12E-07 Multiple sclerosis HLA-F-AS1 intron 17660530 rs2272874 chr6 29696245 T C 8.07E-04 Coronary heart disease HLA-F-AS1 intron 21606135 rs2735057 chr6 29698031 G C 1.37E-04 Multiple complex diseases HLA-F-AS1 intron 17554300 rs2735057 chr6 29698031 G C 2.46E-06 Multiple sclerosis HLA-F-AS1 intron 17660530 rs2735057 chr6 29698031 G C 9.31E-10 Narcolepsy HLA-F-AS1 intron 19629137 rs1611350 chr6 29698821 T C 1.33E-11 Multiple complex diseases HLA-F-AS1 intron 17554300 rs3909134 chr6 29699253 A G 2.90E-06 Multiple complex diseases HLA-F-AS1 intron 17554300 rs2523399 chr6 29700079 C T 1.45E-05 Rheumatoid arthritis HLA-F-AS1 intron 17804836 rs2523399 chr6 29700079 C T 2.37E-06 Behcet's disease HLA-F-AS1 intron pha002888 rs2523399 chr6 29700079 C T 8.05E-05 Eosinophil counts HLA-F-AS1 intron pha003088 rs1610601 chr6 29700183 C A 2.22E-13 Multiple complex diseases HLA-F-AS1 intron 17554300 rs1610601 chr6 29700183 C A 4.76E-05 Rheumatoid arthritis HLA-F-AS1 intron 17804836 rs2844833 chr6 29702206 C G 2.59E-04 Suicide attempts in bipolar disorder HLA-F-AS1 intron 21041247 rs2523395 chr6 29702510 G A 2.00E-06 Prostate cancer (gene x gene interaction) HLA-F-AS1 intron 22219177 rs2394160 chr6 29703262 A G 8.21E-06 Rheumatoid arthritis HLA-F-AS1 intron 17804836 rs2394160 chr6 29703262 A G 7.92E-05 Behcet's disease HLA-F-AS1 intron pha002888 rs9258205 chr6 29703823 T C 2.18E-07 Multiple complex diseases HLA-F-AS1 intron 17554300 rs9258205 chr6 29703823 T C 1.58E-04 Alzheimer's disease HLA-F-AS1 intron 17998437 rs1736916 chr6 29704083 C T 2.68E-05 Multiple complex diseases HLA-F-AS1 intron 17554300 rs1736916 chr6 29704083 C T 1.05E-06 Multiple sclerosis HLA-F-AS1 intron 17660530 rs1736915 chr6 29704316 G A 3.73E-05 Schizophrenia HLA-F-AS1 intron 21926974 rs1736913 chr6 29704400 T C 1.89E-12 Multiple complex diseases HLA-F-AS1 intron 17554300 rs1736913 chr6 29704400 T C 4.63E-05 Multiple sclerosis HLA-F-AS1 intron 17660530 rs2523393 chr6 29705659 A G 1.00E-17 Multiple sclerosis HLA-F-AS1 intron 19525953 rs9258215 chr6 29707307 A G 4.57E-07 Multiple complex diseases HLA-F-AS1 intron 17554300 rs9258215 chr6 29707307 A G 7.26E-04 Alzheimer's disease HLA-F-AS1 intron 17998437 rs9258218 chr6 29708028 G A 3.76E-05 Coronary heart disease HLA-F-AS1 intron 21971053 rs1610603 chr6 29708222 T C 3.91E-05 Multiple complex diseases HLA-F-AS1 intron 17554300 rs1610603 chr6 29708222 T C 2.54E-07 Multiple sclerosis HLA-F-AS1 intron 17660530 rs1610603 chr6 29708222 T C 1.24E-08 Behcet's disease HLA-F-AS1 intron pha002888 rs2517941 chr6 29708417 C G 4.39E-04 Suicide attempts in bipolar disorder HLA-F-AS1 intron 21041247 rs2743950 chr6 29709286 C T 4.23E-04 Suicide attempts in bipolar disorder HLA-F-AS1 intron 21041247 rs2517938 chr6 29709840 T C 4.16E-04 Suicide attempts in bipolar disorder HLA-F-AS1 intron 21041247 rs730858 chr6 29710628 G A 4.12E-04 Suicide attempts in bipolar disorder HLA-F-AS1 intron 21041247 rs4713240 chr6 29710726 A G 5.79E-05 Behcet's disease HLA-F-AS1 intron pha002888 rs1610613 chr6 29710963 T C 2.40E-05 Multiple complex diseases HLA-F-AS1 intron 17554300 rs2523386 chr6 29711747 G A 4.03E-04 Suicide attempts in bipolar disorder HLA-F-AS1 intron 21041247 rs9258223 chr6 29712175 C G 5.01E-07 Multiple complex diseases HLA-F-AS1 intron 17554300 rs2844845 chr6 29712759 T A 2.16E-04 Multiple complex diseases HLA-F-AS1 intron 17554300 rs2844845 chr6 29712759 T A 4.78E-04 Suicide attempts in bipolar disorder HLA-F-AS1 intron 21041247 rs2844845 chr6 29712759 T A 6.47E-04 Suicide attempts in bipolar disorder HLA-F-AS1 intron 21041247 rs1633091 chr6 29712866 T C 1.94E-08 Behcet's disease HLA-F-AS1 intron pha002888 rs34260811 chr6 29715332 C A 7.25E-05 Behcet's disease HLA-F-AS1 intron pha002888 rs1633085 chr6 29715997 T C 6.32E-06 Multiple complex diseases HLA-F-AS1 intron 17554300 rs1737084 chr6 29717339 T A 3.66E-04 Multiple complex diseases / / 17554300 rs4713244 chr6 29721146 G A 5.46E-05 Behcet's disease / / pha002888 rs2523407 chr6 29721305 C G 3.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs2523407 chr6 29721305 C G 6.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs1611297 chr6 29721755 C T 1.20E-08 Behcet's disease / / pha002888 rs9258260 chr6 29723161 C T 2.00E-10 Crohn's disease / / 22412388 rs1633070 chr6 29724147 T C 1.66E-05 Multiple complex diseases / / 17554300 rs1633070 chr6 29724147 T C 1.11E-07 Multiple sclerosis / / 17660530 rs1633069 chr6 29724201 C G 2.24E-05 Multiple complex diseases / / 17554300 rs1633069 chr6 29724201 C G 8.70E-08 Multiple sclerosis / / 17660530 rs1633068 chr6 29724310 T C 1.28E-08 Behcet's disease / / pha002888 rs1737078 chr6 29724939 G T 1.63E-06 Rheumatoid arthritis / / 17804836 rs1737078 chr6 29724939 G T 7.31E-10 Rheumatoid arthritis / / 19503088 rs1737076 chr6 29725321 A G 5.41E-07 Multiple complex diseases / / 17554300 rs1737076 chr6 29725321 A G 2.52E-05 Multiple sclerosis / / 17660530 rs1737076 chr6 29725321 A G 9.85E-07 Esophageal cancer (squamous cell) / / 22960999 rs1633063 chr6 29726046 C T 5.98E-13 Multiple complex diseases / / 17554300 rs113795410 chr6 29728209 C A 1.28E-08 Behcet's disease / / pha002888 rs1610630 chr6 29729286 C T 1.91E-05 Multiple complex diseases / / 17554300 rs1610630 chr6 29729286 C T 1.96E-07 Multiple sclerosis / / 17660530 rs1610630 chr6 29729286 C T 1.18E-08 Behcet's disease / / pha002888 rs1737070 chr6 29730546 C A 2.17E-06 Multiple complex diseases / / 17554300 rs1737070 chr6 29730546 C A 4.45E-22 Narcolepsy / / 19629137 rs1633048 chr6 29730642 A G 5.53E-09 Behcet's disease / / pha002888 rs1737068 chr6 29730923 C A 2.48E-05 Multiple complex diseases / / 17554300 rs1737068 chr6 29730923 C A 7.46E-08 Multiple sclerosis / / 17660530 rs7759482 chr6 29731687 A G 4.90E-11 Graves' disease / / 21900946 rs1737060 chr6 29732969 G C 2.53E-05 Multiple complex diseases / / 17554300 rs1737060 chr6 29732969 G C 8.31E-08 Multiple sclerosis / / 17660530 rs1737060 chr6 29732969 G C 2.43E-09 Behcet's disease / / pha002888 rs1737055 chr6 29733742 A G 1.54E-04 Multiple complex diseases / / 17554300 rs1737055 chr6 29733742 A G 4.27E-05 Multiple sclerosis / / 17660530 rs12660712 chr6 29734634 C A 2.33E-04 Taste perception / / 22132133 rs1737046 chr6 29735693 A G 1.12E-05 Behcet's disease / / pha002888 rs11753872 chr6 29736942 C A 6.49E-10 Coronary heart disease / / 21971053 rs6932033 chr6 29737846 A G 7.31E-07 Multiple complex diseases / / 17554300 rs3888722 chr6 29739000 C G 3.18E-09 Multiple complex diseases / / 17554300 rs1614309 chr6 29745884 G A 8.10E-04 Multiple complex diseases / / 17554300 rs1633021 chr6 29746869 T C 5.43E-04 Schizophrenia / / 19197363 rs1633021 chr6 29746869 T C 1.18E-13 Carbamazepine ADRs / / 21149285 rs2743941 chr6 29755451 T C 4.45E-08 Coronary heart disease / / 21971053 rs2743941 chr6 29755451 T C 0.000068 Breast cancer(er negative) / / 23555315 rs2743941 chr6 29755451 T C 4.43E-07 Behcet's disease / / pha002888 rs2735036 chr6 29756871 C T 1.55E-05 IgE levels / / 22075330 rs2735035 chr6 29757715 C T 3.83E-12 Multiple complex diseases / / 17554300 rs16895757 chr6 29762178 C T 4.60E-07 Multiple complex diseases LOC554223 intron 17554300 rs11758087 chr6 29764443 G A 2.49E-09 Coronary heart disease LOC554223 intron 21971053 rs2523755 chr6 29766082 A G 1.51E-05 IgE levels / / 22075330 rs2523755 chr6 29766082 A G 1.58E-04 Self-reported allergy / / 23817569 rs7741100 chr6 29768123 C A 6.90E-06 HIV-1 control / / 20041166 rs1611185 chr6 29768344 T C 1.86E-06 Rheumatoid arthritis / / 17804836 rs2894117 chr6 29768801 C G 7.55E-07 Multiple complex diseases / / 17554300 rs9258447 chr6 29773852 C T 4.68E-05 Creatinine levels / / pha003069 rs3998759 chr6 29775904 G T 1.48E-05 IgE levels / / 22075330 rs1736971 chr6 29776322 G T 1.04E-05 Rheumatoid arthritis / / 17804836 rs1736971 chr6 29776322 G T 1.49E-09 Carbamazepine ADRs / / 21149285 rs4098859 chr6 29777199 A G 3.82E-06 Multiple complex diseases / / 17554300 rs1632971 chr6 29777911 T C 9.76E-06 Multiple sclerosis / / 17660530 rs9357086 chr6 29778029 G C 2.54E-11 Multiple complex diseases / / 17554300 rs1611174 chr6 29778282 T A,C,G 1.45E-05 IgE levels / / 22075330 rs753544 chr6 29780529 C T 3.15E-07 Esophageal cancer (squamous cell) / / 22960999 rs11753654 chr6 29782621 C T 1.87E-05 HIV-1 control / / 20041166 rs2743934 chr6 29784517 C T 1.34E-05 IgE levels / / 22075330 rs2743934 chr6 29784517 C T 1.87E-04 Self-reported allergy / / 23817569 rs1619379 chr6 29785235 C T 7.08E-05 Rheumatoid arthritis / / 17804836 rs2743933 chr6 29786220 T C 1.26E-05 IgE levels / / 22075330 rs2743932 chr6 29786243 C T 1.25E-05 IgE levels / / 22075330 rs2743931 chr6 29787072 C T 3.71E-11 Behcet's disease / / pha002888 rs2246283 chr6 29787237 C T 1.24E-05 IgE levels / / 22075330 rs2246283 chr6 29787237 C T 1.98E-04 Self-reported allergy / / 23817569 rs1610677 chr6 29789171 T C 7.91E-09 Multiple complex diseases / / 17554300 rs1610677 chr6 29789171 T C 4.00E-15 Rheumatoid arthritis / / 21653640 rs1610677 chr6 29789171 T C 5.71E-06 Lymphocyte counts / / 22286170 rs1611146 chr6 29789523 T C 1.22E-05 IgE levels / / 22075330 rs1611146 chr6 29789523 T C 1.61E-04 Self-reported allergy / / 23817569 rs1632948 chr6 29794049 T C 2.30E-09 Rheumatoid arthritis / / 17804836 rs915668 chr6 29798459 C G 6.55E-07 Multiple complex diseases HLA-G intron 17554300 rs1063320 chr6 29798749 C G 5.38E-07 Multiple complex diseases HLA-G UTR-3 17554300 rs2517898 chr6 29799746 C G 7.99E-05 Schizophrenia / / 20185149 rs2517897 chr6 29800101 C A 5.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs2517892 chr6 29801474 T C 3.90E-13 Graves' disease / / 21900946 rs2253981 chr6 29805922 G A 2.31E-05 Multiple complex diseases / / 17554300 rs2254071 chr6 29806062 T C 1.20E-05 Multiple complex diseases / / 17554300 rs2254071 chr6 29806062 T C 8.39E-05 Schizophrenia / / 20185149 rs2254071 chr6 29806062 T C 3.90E-12 Graves' disease / / 21900946 rs9258525 chr6 29806341 T C 1.20E-05 HIV-1 control / / 20041166 rs9258525 chr6 29806341 T C 2.53E-05 Hodgkin's lymphoma / / 24149102 rs2743937 chr6 29807923 T C 3.67E-04 Multiple complex diseases / / 17554300 rs1233320 chr6 29808032 C G 9.14E-04 Multiple complex diseases / / 17554300 rs1233320 chr6 29808032 C G 1.00E-05 IgE levels / / 22075330 rs1611133 chr6 29809382 C T 1.00E-06 Rheumatoid arthritis / / 17804836 rs1611133 chr6 29809382 C T 1.90E-09 Carbamazepine ADRs / / 21149285 rs1611133 chr6 29809382 C T 1.18E-06 Post-traumatic stress disorder / / 24080187 rs4607472 chr6 29810543 A G 6.08E-05 HIV-1 control / / 20041166 rs4607472 chr6 29810543 A G 4.27E-05 HIV-1 viral setpoint / / 21490045 rs1611135 chr6 29810740 T C 9.92E-06 IgE levels / / 22075330 rs16896081 chr6 29811709 C T 3.66E-08 Multiple complex diseases / / 17554300 rs4084097 chr6 29811750 T C 1.77E-08 Multiple complex diseases / / 17554300 rs2734990 chr6 29812505 A T 9.86E-07 Multiple complex diseases / / 17554300 rs2523767 chr6 29812807 A G 3.25E-07 Multiple complex diseases / / 17554300 rs2523766 chr6 29812834 A G 1.59E-04 Multiple complex diseases / / 17554300 rs9258555 chr6 29813016 G C 2.31E-04 Multiple complex diseases / / 17554300 rs9258555 chr6 29813016 G C 5.29E-04 Coronary Artery Disease / / 17634449 rs2734986 chr6 29818568 T C 2.53E-05 Lung cancer / / 18978787 rs2734986 chr6 29818568 T C 5.00E-05 Lung cancer / / 18978790 rs2734986 chr6 29818568 T C 2.59E-07 Lung cancer / / 19654303 rs2734986 chr6 29818568 T C 1.72E-08 Lung adenocarcinoma / / 19836008 rs2734986 chr6 29818568 T C 2.50E-10 Hodgkin's lymphoma / / 22286212 rs2734986 chr6 29818568 T C 2.20E-10 Lung cancer / / 22899653 rs2734986 chr6 29818568 T C 3.00E-07 Hodgkin's lymphoma / / 24920014 rs2734985 chr6 29818662 T C 1.56E-06 Rheumatoid arthritis / / 17804836 rs2734985 chr6 29818662 T C 2.02E-06 Lung adenocarcinoma / / 19836008 rs2508052 chr6 29820002 C A 5.52E-06 Multiple complex diseases / / 17554300 rs2508050 chr6 29820047 T C 2.17E-05 IgE levels / / 22075330 rs2247726 chr6 29821434 G A 9.51E-06 IgE levels / / 22075330 rs2734982 chr6 29821567 G T 4.30E-06 IgE levels / / 22075330 rs2517861 chr6 29821982 C T 9.13E-06 Rheumatoid arthritis / / 17804836 rs2517861 chr6 29821982 C T 1.17E-05 Lung adenocarcinoma / / 19836008 rs2517861 chr6 29821982 C T 1.80E-06 Lung cancer / / 22899653 rs2975033 chr6 29822261 G A 3.23E-10 Rheumatoid arthritis / / 17804836 rs2975033 chr6 29822261 G A 8.96E-13 Rheumatoid arthritis / / 19503088 rs2975033 chr6 29822261 G A 1.29E-04 Vitiligo / / 20410501 rs2975033 chr6 29822261 G A 4.27E-06 IgE levels / / 22075330 rs2517859 chr6 29822571 G A 3.70E-06 Urinary metabolites / / 21572414 rs3132726 chr6 29823606 A G 2.93E-06 Behcet's disease / / pha002888 rs2508049 chr6 29823883 A G 2.50E-08 Lung cancer / / 22899653 rs1611697 chr6 29827385 A C 9.10E-06 IgE levels / / 22075330 rs1611697 chr6 29827385 A C 1.26E-04 Self-reported allergy / / 23817569 rs1611699 chr6 29827753 T A 3.73E-05 Multiple complex diseases / / 17554300 rs1611701 chr6 29827956 C T 1.91E-05 Multiple complex diseases / / 17554300 rs1611703 chr6 29828435 A C,G,T 1.78E-06 Multiple complex diseases / / 17554300 rs1611704 chr6 29828467 C T 4.35E-06 Multiple complex diseases / / 17554300 rs2523822 chr6 29828660 A G 2.00E-10 Drug-induced liver injury (amoxicillin-clavulanate) / / 21570397 rs2523822 chr6 29828660 A G 4.12E-06 IgE levels / / 22075330 rs9295822 chr6 29828880 C T 3.52E-08 Vitiligo / / 20526339 rs1611710 chr6 29828916 C T 1.05E-04 Multiple complex diseases / / 17554300 rs1611710 chr6 29828916 C T 5.08E-10 Rheumatoid arthritis / / 17804836 rs1611710 chr6 29828916 C T 5.68E-11 Rheumatoid arthritis / / 19503088 rs9258750 chr6 29828972 A G 7.42E-05 Multiple complex diseases / / 17554300 rs9258750 chr6 29828972 A G 2.06E-09 Positivity for ZnT8A in Type 1 diabetes / / 22526605 rs1611711 chr6 29829108 G A,C,T 4.40E-05 Multiple complex diseases / / 17554300 rs3094170 chr6 29829265 T C 5.38E-04 Hypothyroidism / / 21981779 rs1611714 chr6 29829407 G A,C,T 2.68E-06 Multiple complex diseases / / 17554300 rs2517830 chr6 29829566 T G 5.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs7760172 chr6 29830074 T C 6.07E-09 Carbamazepine ADRs / / 21149285 rs7760172 chr6 29830074 T C 4.03E-05 Coronary heart disease / / 21971053 rs2517829 chr6 29830529 C G 2.54E-05 IgE levels / / 22075330 rs1611732 chr6 29831008 C T 7.35E-10 Rheumatoid arthritis / / 17804836 rs1611732 chr6 29831008 C T 2.46E-10 Rheumatoid arthritis / / 19503088 rs2524035 chr6 29832332 A G 8.90E-07 Red blood cell traits / / 23222517 rs9468645 chr6 29832867 A C 6.42E-05 Multiple complex diseases / / 17554300 rs3094165 chr6 29833541 A G 3.83E-07 Multiple complex diseases / / 17554300 rs3094165 chr6 29833541 A G 6.70E-05 HIV-1 control / / 20041166 rs2734973 chr6 29833948 C T 1.18E-11 Multiple complex diseases / / 17554300 rs2734973 chr6 29833948 C T 4.93E-06 IgE levels / / 22075330 rs2734973 chr6 29833948 C T 3.28E-06 Lymphocyte counts / / 22286170 rs2734971 chr6 29834449 A G 1.92E-05 Sudden cardiac arrest / / 21658281 rs2734970 chr6 29834472 C T 2.09E-06 Multiple complex diseases / / 17554300 rs1611631 chr6 29835654 C T 2.21E-08 Multiple complex diseases / / 17554300 rs1611631 chr6 29835654 C T 9.59E-06 IgE levels / / 22075330 rs3094159 chr6 29835834 G A 1.92E-04 Multiple complex diseases / / 17554300 rs3094159 chr6 29835834 G A 2.38E-05 Multiple sclerosis / / 17660530 rs3094159 chr6 29835834 G A 7.84E-08 Narcolepsy / / 19629137 rs3094157 chr6 29836239 C G 2.19E-06 Multiple sclerosis / / 17660530 rs1611634 chr6 29836366 C T 8.17E-06 IgE levels / / 22075330 rs1611635 chr6 29836463 C T 4.39E-06 Multiple complex diseases / / 17554300 rs9258866 chr6 29836524 C A 6.50E-06 HIV-1 control / / 20041166 rs3132718 chr6 29836577 T C 3.16E-04 Multiple complex diseases / / 17554300 rs3132718 chr6 29836577 T C 1.65E-05 Multiple sclerosis / / 17660530 rs3132718 chr6 29836577 T C 7.47E-08 Narcolepsy / / 19629137 rs1611636 chr6 29836703 A C 9.49E-06 IgE levels / / 22075330 rs1611637 chr6 29836741 A G 4.94E-09 Multiple complex diseases / / 17554300 rs1611638 chr6 29836853 G C 9.58E-06 IgE levels / / 22075330 rs577545656 chr6 29837142 G A 1.19E-05 Multiple complex diseases / / 17554300 rs577545656 chr6 29837142 G A 8.26E-09 Narcolepsy / / 19629137 rs9258881 chr6 29837142 G A 1.19E-05 Multiple complex diseases / / 17554300 rs9258881 chr6 29837142 G A 8.26E-09 Narcolepsy / / 19629137 rs9258883 chr6 29837188 C T 4.56E-05 Coronary heart disease / / 21971053 rs2844821 chr6 29838642 T C 2.24E-06 IgE levels / / 22075330 rs886398 chr6 29839268 C T 1.41E-05 IgE levels / / 22075330 rs3094654 chr6 29839816 T C 1.17E-05 Behcet's disease / / pha002888 rs9258966 chr6 29840382 C T 1.02E-05 Behcet's disease / / pha002888 rs3132712 chr6 29841021 A G 4.40E-04 Multiple complex diseases / / 17554300 rs3132712 chr6 29841021 A G 1.52E-05 Multiple sclerosis / / 17660530 rs3132712 chr6 29841021 A G 9.32E-08 Narcolepsy / / 19629137 rs2523809 chr6 29849619 G T 9.08E-06 Rheumatoid arthritis / / 19503088 rs2523809 chr6 29849619 G T 4.10E-05 HIV-1 control / / 20041166 rs2523809 chr6 29849619 G T 4.00E-08 IgE levels / / 22075330 rs2523807 chr6 29850274 A G 1.38E-05 IgE levels / / 22075330 rs1054175 chr6 29854795 G C 1.74E-05 IgE levels HLA-H nearGene-5 22075330 rs1611610 chr6 29855818 G T 9.02E-06 IgE levels / / 22075330 rs1611628 chr6 29857772 T C 9.34E-06 IgE levels HLA-H intron 22075330 rs2517817 chr6 29859517 C T 6.13E-06 IgE levels / / 22075330 rs1611567 chr6 29866200 G T 3.33E-05 IgE levels / / 22075330 rs1611575 chr6 29867809 T C 3.92E-06 IgE levels / / 22075330 rs2517905 chr6 29868833 T C 3.88E-06 IgE levels / / 22075330 rs2517904 chr6 29868984 A G 3.87E-06 IgE levels / / 22075330 rs9468653 chr6 29871636 C A 2.50E-05 Urinary metabolites / / 21572414 rs433518 chr6 29873809 G C 3.80E-06 IgE levels / / 22075330 rs9259594 chr6 29873963 G A 9.38E-06 IgE levels / / 22075330 rs2571410 chr6 29881464 C G 9.33E-06 IgE levels / / 22075330 rs2734922 chr6 29882798 G A 5.16E-05 IgE levels / / 22075330 rs422055 chr6 29885546 C T 6.13E-04 Multiple complex diseases / / 17554300 rs422055 chr6 29885546 C T 6.60E-05 IgE levels / / 22075330 rs2517774 chr6 29893982 C T 4.26E-06 IgE levels / / 22075330 rs386014 chr6 29894629 G C 2.50E-06 IgE levels / / 22075330 rs2517754 chr6 29896680 A G 3.59E-07 IgE levels / / 22075330 rs404655 chr6 29896968 G A 2.46E-06 IgE levels / / 22075330 rs389600 chr6 29896999 C T 4.63E-05 Multiple complex diseases / / 17554300 rs2517749 chr6 29897259 T A 2.20E-05 IgE levels / / 22075330 rs1655927 chr6 29899493 T C 8.79E-06 Multiple complex diseases / / 17554300 rs2524005 chr6 29899677 G A 7.66E-05 Lung cancer / / 18978787 rs2524005 chr6 29899677 G A 5.00E-05 Lung cancer / / 18978790 rs2524005 chr6 29899677 G A 1.33E-06 Lung adenocarcinoma / / 19836008 rs2524005 chr6 29899677 G A 1.28E-08 Carbamazepine ADRs / / 21149285 rs2524005 chr6 29899677 G A 4.04E-05 Coronary heart disease / / 21971053 rs2524005 chr6 29899677 G A 5.00E-07 Bipolar disorder and schizophrenia / / 22688191 rs2524005 chr6 29899677 G A 1.30E-06 Lung cancer / / 22899653 rs2524005 chr6 29899677 G A 3.50E-51 Myasthenia gravis / / 23055271 rs2860580 chr6 29906691 A C,G,T 5.00E-67 Nasopharyngeal carcinoma / / 20512145 rs2860580 chr6 29906691 A C,G,T 5.70E-04 Systemic lupus erythematosus / / 24871463 rs3094141 chr6 29909807 T G 4.54E-08 Red blood cell traits HLA-A nearGene-5 23222517 rs2517725 chr6 29911326 A G 1.89E-05 IgE levels HLA-A intron 22075330 rs2571381 chr6 29912830 T C 3.73E-08 Red blood cell traits HLA-A intron 23222517 rs3823343 chr6 29913111 A G 6.12E-07 IgE levels HLA-A intron 22075330 rs1061235 chr6 29913298 A T 1.00E-07 Adverse response to carbamapezine HLA-A UTR-3 21428769 rs2499 chr6 29913542 T G 3.43E-08 Red blood cell traits HLA-A UTR-3 23222517 rs2975046 chr6 29915149 A G 2.57E-04 Multiple complex diseases / / 17554300 rs2735097 chr6 29915301 C A 3.63E-04 IgE levels / / 17255346 rs2735096 chr6 29915751 G A 9.33E-05 Multiple sclerosis / / 17660530 rs1632883 chr6 29915993 C A 1.44E-07 Red blood cell traits / / 23222517 rs9260285 chr6 29916098 T C 3.22E-05 IgE levels / / 22075330 rs2517719 chr6 29916253 G C 1.11E-08 Multiple complex diseases / / 17554300 rs2517719 chr6 29916253 G C 1.43E-06 IgE levels / / 22075330 rs417162 chr6 29916505 C T 3.37E-06 Multiple sclerosis / / 17660530 rs417162 chr6 29916505 C T 6.77E-10 Nasopharyngeal carcinoma / / 19664746 rs417162 chr6 29916505 C T 5.47E-11 Lymphocyte counts / / 22286170 rs417162 chr6 29916505 C T 2.00E-07 Nasopharyngeal carcinoma / / 23209447 rs1655900 chr6 29916618 G A 2.96E-06 Multiple complex diseases / / 17554300 rs1655900 chr6 29916618 G A 2.27E-07 Esophageal cancer (squamous cell) / / 22960999 rs1655902 chr6 29916855 G A 4.59E-08 Lung cancer / / 21725308 rs1655904 chr6 29917146 T C 7.76E-05 Multiple sclerosis / / 17660530 rs1655904 chr6 29917146 T C 6.52E-08 Red blood cell traits / / 23222517 rs2517715 chr6 29917439 T C 1.55E-04 Vitiligo / / 20410501 rs2517715 chr6 29917439 T C 1.44E-06 Behcet's disease / / pha002888 rs1632879 chr6 29917703 G A 1.02E-07 Red blood cell traits / / 23222517 rs2517713 chr6 29918099 G T 4.00E-20 Nasopharyngeal carcinoma / / 19664746 rs2517713 chr6 29918099 G T 4.00E-20 Nasopharyngeal carcinoma / / 20512145 rs2517713 chr6 29918099 G T 1.92E-11 Nasopharyngeal carcinoma / / 23209447 rs2517713 chr6 29918099 G T 5.30E-04 Systemic lupus erythematosus / / 24871463 rs2508037 chr6 29918436 T C 8.60E-06 Multiple sclerosis / / 17660530 rs2508037 chr6 29918436 T C 8.43E-19 Lymphocyte counts / / 22286170 rs3115637 chr6 29918453 A G 5.62E-08 Multiple complex diseases / / 17554300 rs3115637 chr6 29918453 A G 3.59E-06 IgE levels / / 22075330 rs3094674 chr6 29918538 C G 1.42E-07 Multiple complex diseases / / 17554300 rs3094674 chr6 29918538 C G 3.58E-06 IgE levels / / 22075330 rs9260484 chr6 29920253 A C 1.07E-09 Nasopharyngeal carcinoma / / 19664746 rs9260489 chr6 29920332 T G 1.00E-11 Multiple sclerosis / / 22190364 rs9260489 chr6 29920332 T G 2.00E-22 Beta-2 microglubulin plasma levels / / 23417110 rs2975042 chr6 29920536 G T 7.78E-10 Nasopharyngeal carcinoma / / 19664746 rs2517703 chr6 29921700 C T 7.77E-07 IgE levels / / 22075330 rs9260587 chr6 29922492 A G 2.95E-06 IgE levels / / 22075330 rs16896742 chr6 29922740 A G 4.28E-05 IgE levels / / 17255346 rs16896742 chr6 29922740 A G 1.48E-05 IgE levels / / 22075330 rs9260607 chr6 29922856 T C 2.93E-06 IgE levels / / 22075330 rs9260622 chr6 29923128 G A,C 8.30E-06 IgE levels / / 22075330 rs9260632 chr6 29923290 G T 9.98E-06 Migraine without aura / / 23793025 rs2904758 chr6 29923351 G A 4.07E-05 IgE levels / / 22075330 rs2571391 chr6 29923838 A C 1.00E-15 IgE levels / / 22075330 rs12665039 chr6 29924779 T C 4.19E-08 Carbamazepine ADRs / / 21149285 rs12665039 chr6 29924779 T C 1.03E-04 Coronary heart disease / / 21971053 rs2523942 chr6 29925086 T G 3.32E-06 IgE levels / / 22075330 rs2905760 chr6 29926461 A C 2.96E-06 Multiple complex diseases / / 17554300 rs441808 chr6 29928137 T C 8.19E-05 Orofacial clefts / / 22419666 rs2517688 chr6 29930323 C T 3.33E-06 IgE levels / / 22075330 rs7739434 chr6 29930619 G A 8.58E-11 Red blood cell traits / / 23222517 rs9260734 chr6 29932666 G A 6.14E-10 Nasopharyngeal carcinoma / / 19664746 rs9260734 chr6 29932666 G A 9.80E-22 Nasopharyngeal carcinoma / / 20512145 rs9260734 chr6 29932666 G A 6.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs9260734 chr6 29932666 G A 2.63E-11 Nasopharyngeal carcinoma / / 23209447 rs3903160 chr6 29932897 G A 1.38E-04 Vitiligo / / 20410501 rs3873283 chr6 29933000 A G 6.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs6457109 chr6 29933261 T C 2.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs6457109 chr6 29933261 T C 5.81E-04 Suicide attempts in bipolar disorder / / 21041247 rs6457109 chr6 29933261 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9260742 chr6 29933549 T G 2.27E-07 Red blood cell traits / / 23222517 rs6457110 chr6 29933881 T A 5.44E-04 IgE levels / / 17255346 rs6457110 chr6 29933881 T A 1.88E-07 Behcet's disease / / pha002888 rs6935053 chr6 29934163 A C 2.00E-06 Ulcerative colitis / / 23511034 rs4713270 chr6 29934697 G A 2.37E-06 Behcet's disease / / pha002888 rs3869062 chr6 29934891 A G 6.47E-09 Nasopharyngeal carcinoma / / 19664746 rs3869062 chr6 29934891 A G 2.90E-20 Nasopharyngeal carcinoma / / 20512145 rs3869062 chr6 29934891 A G 7.03E-08 Nasopharyngeal carcinoma / / 23209447 rs3893464 chr6 29935250 G A 2.31E-05 Rheumatoid arthritis / / 17804836 rs3893464 chr6 29935250 G A 1.10E-06 Rheumatoid arthritis / / 19503088 rs3893464 chr6 29935250 G A 6.84E-05 Lung adenocarcinoma / / 19836008 rs3893464 chr6 29935250 G A 2.00E-20 Graves' disease / / 21900946 rs9260761 chr6 29935469 T C 5.75E-09 Red blood cell traits / / 23222517 rs12193110 chr6 29937104 C T 1.42E-09 Multiple complex diseases / / 17554300 rs12206499 chr6 29937127 A G 4.50E-05 Vitiligo / / 20410501 rs12206499 chr6 29937127 A G 1.24E-19 Vitiligo / / 21326295 rs12206499 chr6 29937127 A G 2.55E-30 Vitiligo / / 22561518 rs2517673 chr6 29937242 G A 6.61E-09 Carbamazepine ADRs / / 21149285 rs2517673 chr6 29937242 G A 1.01E-04 Coronary heart disease / / 21971053 rs2517673 chr6 29937242 G A 2.92E-05 IgE levels / / 22075330 rs2517672 chr6 29937262 A G 3.36E-08 Multiple complex diseases / / 17554300 rs1061539 chr6 29937555 T C 2.18E-07 Red blood cell traits / / 23222517 rs2256543 chr6 29937833 T C 1.09E-06 Rheumatoid arthritis / / 17804836 rs2256543 chr6 29937833 T C 4.44E-06 Lung cancer / / 18978787 rs2256543 chr6 29937833 T C 9.00E-06 Lung cancer / / 18978790 rs2256543 chr6 29937833 T C 6.34E-06 Rheumatoid arthritis / / 19503088 rs2256543 chr6 29937833 T C 8.73E-08 Lung cancer / / 19654303 rs2256543 chr6 29937833 T C 2.37E-07 Lung adenocarcinoma / / 19836008 rs2256543 chr6 29937833 T C 2.70E-04 Lung cancer / / 22899653 rs1061535 chr6 29937924 T C 7.07E-07 Red blood cell traits / / 23222517 rs2523969 chr6 29938777 A T 1.78E-10 Multiple complex diseases / / 17554300 rs5009448 chr6 29940488 T C 1.38E-09 Nasopharyngeal carcinoma / / 19664746 rs5009448 chr6 29940488 T C 3.92E-05 HIV-1 control / / 20041166 rs5009448 chr6 29940488 T C 2.00E-18 Nasopharyngeal carcinoma / / 20512145 rs5009448 chr6 29940488 T C 6.40E-11 Nasopharyngeal carcinoma / / 23209447 rs2256919 chr6 29940750 C A 3.71E-05 HIV-1 control / / 20041166 rs2256919 chr6 29940750 C A 5.25E-04 Coronary heart disease / / 21971053 rs2256919 chr6 29940750 C A 2.67E-05 Behcet's disease / / pha002888 rs2523946 chr6 29941943 C T 8.65E-12 Rheumatoid arthritis / / 17804836 rs2523946 chr6 29941943 C T 1.43E-12 Rheumatoid arthritis / / 19503088 rs2523946 chr6 29941943 C T 1.72E-05 Lung adenocarcinoma / / 19836008 rs2523946 chr6 29941943 C T 2.00E-11 IgA nephropathy / / 22197929 rs3823355 chr6 29942083 C T 4.42E-05 Vitiligo / / 20410501 rs3823355 chr6 29942083 C T 9.00E-23 Vitiligo / / 20410501 rs2523943 chr6 29942927 T G 7.24E-05 IgE levels / / 22075330 rs400488 chr6 29943035 G A 9.80E-06 Coronary heart disease / / 21971053 rs6904029 chr6 29943067 G A 1.30E-10 Rheumatoid arthritis / / 17804836 rs6904029 chr6 29943067 G A 4.10E-13 Rheumatoid arthritis / / 19503088 rs6904029 chr6 29943067 G A 1.00E-21 Vitiligo / / 20410501 rs6904029 chr6 29943067 G A 2.60E-06 Hodgkin's lymphoma / / 22286212 rs6904029 chr6 29943067 G A 2.06E-06 Behcet's disease / / pha002888 rs2735076 chr6 29943490 A G 7.67E-09 Coronary heart disease HCG9 intron 21971053 rs2735076 chr6 29943490 A G 3.61E-04 Hypothyroidism HCG9 intron 21981779 rs2735076 chr6 29943490 A G 5.19E-09 Red blood cell traits HCG9 intron 23222517 rs2394250 chr6 29943656 G T 3.11E-05 Orofacial clefts HCG9 intron 22419666 rs2245961 chr6 29944004 C A 9.16E-06 Coronary heart disease HCG9 intron 21971053 rs2735071 chr6 29944979 G C 4.76E-05 IgE levels HCG9 intron 22075330 rs2571375 chr6 29945270 A G 3.82E-11 Carbamazepine ADRs HCG9 intron 21149285 rs3132685 chr6 29945949 G A,C,T 4.05E-09 Type 1 diabetes HCG9 intron 17632545 rs3132685 chr6 29945949 G A,C,T 6.73E-05 HIV-1 viral setpoint HCG9 intron 17641165 rs3132685 chr6 29945949 G A,C,T 1.00E-05 Lung cancer HCG9 intron 18978790 rs3132685 chr6 29945949 G A,C,T 8.98E-06 AIDS progression HCG9 intron 19115949 rs3132685 chr6 29945949 G A,C,T 1.38E-07 Lung cancer HCG9 intron 19654303 rs3132685 chr6 29945949 G A,C,T 3.39E-09 Lung adenocarcinoma HCG9 intron 19836008 rs3132685 chr6 29945949 G A,C,T 6.23E-05 HIV-1 control HCG9 intron 20041166 rs3132685 chr6 29945949 G A,C,T 7.37E-05 HIV-1 viral setpoint HCG9 intron 21490045 rs3132685 chr6 29945949 G A,C,T 1.60E-11 Lung cancer HCG9 intron 22899653 rs3132685 chr6 29945949 G A,C,T 1.00E-54 Myasthenia gravis HCG9 intron 23055271 rs3132685 chr6 29945949 G A,C,T 2.50E-10 Systemic lupus erythematosus HCG9 intron 24871463 rs3132685 chr6 29945949 G A,C,T 1.14E-05 Systemic lupus erythematosus HCG9 intron pha002867 rs2517808 chr6 29951011 C T 5.01E-05 Multiple complex diseases / / 17554300 rs2517808 chr6 29951011 C T 9.61E-06 IgE levels / / 22075330 rs2517808 chr6 29951011 C T 1.39E-04 Self-reported allergy / / 23817569 rs4947244 chr6 29954364 C G 1.11E-10 Multiple complex diseases / / 17554300 rs4947244 chr6 29954364 C G 3.87E-04 Vitiligo / / 20410501 rs4947244 chr6 29954364 C G 1.07E-05 IgE levels / / 22075330 rs4947244 chr6 29954364 C G 1.92E-06 Behcet's disease / / pha002888 rs5025708 chr6 29955199 G T 3.95E-04 Hypothyroidism / / 21981779 rs5025708 chr6 29955199 G T 1.46E-07 Red blood cell traits / / 23222517 rs5025708 chr6 29955199 G T 9.16E-11 Behcet's disease / / pha002888 rs4959039 chr6 29957069 A G 4.19E-04 Vitiligo / / 20410501 rs4959039 chr6 29957069 A G 1.04E-05 IgE levels / / 22075330 rs9260954 chr6 29959935 C G 1.04E-07 Multiple complex diseases / / 17554300 rs9260968 chr6 29961439 C A 8.67E-06 Multiple complex diseases / / 17554300 rs9260973 chr6 29961580 A G 2.55E-07 Red blood cell traits / / 23222517 rs9261013 chr6 29964948 A G 1.86E-05 Multiple complex diseases / / 17554300 rs6911737 chr6 29965501 C A 2.81E-05 Multiple complex diseases / / 17554300 rs9261043 chr6 29966726 C T 2.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs9261043 chr6 29966726 C T 6.30E-05 Suicide attempts in bipolar disorder / / 21041247 rs356960 chr6 29968275 C T 2.67E-05 Multiple complex diseases / / 17554300 rs7758512 chr6 29970589 T G 1.78E-04 Schizophrenia ZNRD1-AS1 intron 19197363 rs7758512 chr6 29970589 T G 2.00E-08 HIV-1 control ZNRD1-AS1 intron 20041166 rs9295826 chr6 29970927 C T 1.04E-05 IgE levels ZNRD1-AS1 intron 22075330 rs6905157 chr6 29971548 A G 1.30E-05 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs9393986 chr6 29973526 T C 1.07E-05 IgE levels ZNRD1-AS1 intron 22075330 rs4313034 chr6 29973925 C T 2.00E-15 Graves' disease HLA-J intron 21900946 rs4313034 chr6 29973925 C T 2.52E-08 Red blood cell traits HLA-J intron 23222517 rs2275855 chr6 29976789 T C 4.48E-09 Multiple complex diseases HLA-J intron 17554300 rs2275855 chr6 29976789 T C 1.18E-05 IgE levels HLA-J intron 22075330 rs4713281 chr6 29978352 G A 1.14E-05 IgE levels ZNRD1-AS1 intron 22075330 rs9261129 chr6 29979579 T C 3.84E-04 Schizophrenia ZNRD1-AS1 intron 19197363 rs9261129 chr6 29979579 T C 1.80E-08 HIV-1 control ZNRD1-AS1 intron 20041166 rs9357092 chr6 29984252 G A 2.74E-10 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs9357092 chr6 29984252 G A 3.00E-04 Vitiligo ZNRD1-AS1 intron 20410501 rs9357092 chr6 29984252 G A 9.55E-06 IgE levels ZNRD1-AS1 intron 22075330 rs9357092 chr6 29984252 G A 3.85E-07 Behcet's disease ZNRD1-AS1 intron pha002888 rs9348835 chr6 29985630 A G 9.40E-06 IgE levels ZNRD1-AS1 intron 22075330 rs6926792 chr6 29985849 G A 2.39E-05 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs3115631 chr6 29986324 T A 4.43E-09 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs6931776 chr6 29986427 A G 2.11E-05 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs4711206 chr6 29987184 G A 9.40E-06 IgE levels ZNRD1-AS1 intron 22075330 rs9261151 chr6 29987738 G A 1.06E-07 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs3129012 chr6 29988642 G A 6.88E-05 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs9261154 chr6 29990937 C T 3.10E-05 HIV-1 control ZNRD1-AS1 intron 20041166 rs1150743 chr6 29992261 C T 9.01E-09 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs6925061 chr6 29992286 C T 6.97E-07 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs6925061 chr6 29992286 C T 1.00E-05 HIV-1 control ZNRD1-AS1 intron 20041166 rs6925061 chr6 29992286 C T 3.39E-05 Hodgkin's lymphoma ZNRD1-AS1 intron 24149102 rs259925 chr6 29992737 G A 3.97E-05 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs166325 chr6 29993196 G C 1.41E-05 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs9261174 chr6 29996855 T C 3.89E-07 HIV-1 viral setpoint ZNRD1-AS1 intron 17641165 rs9261174 chr6 29996855 T C 1.80E-08 HIV-1 control ZNRD1-AS1 intron 20041166 rs9261189 chr6 30000280 C T 1.68E-05 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs16896923 chr6 30000687 T C 2.66E-05 Nasopharyngeal carcinoma ZNRD1-AS1 intron 19664746 rs16896923 chr6 30000687 T C 4.20E-11 Nasopharyngeal carcinoma ZNRD1-AS1 intron 20512145 rs16896923 chr6 30000687 T C 2.57E-05 Nasopharyngeal carcinoma ZNRD1-AS1 intron 23209447 rs166327 chr6 30002881 T C 1.76E-06 Rheumatoid arthritis / / 17804836 rs166327 chr6 30002881 T C 5.35E-07 Rheumatoid arthritis / / 19503088 rs166327 chr6 30002881 T C 3.80E-05 HIV-1 control / / 20041166 rs3869068 chr6 30004052 C T 1.01E-05 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs3869068 chr6 30004052 C T 3.84E-04 Schizophrenia ZNRD1-AS1 intron 19197363 rs3869068 chr6 30004052 C T 1.80E-08 HIV-1 control ZNRD1-AS1 intron 20041166 rs4711207 chr6 30005754 C A 3.57E-11 Rheumatoid arthritis ZNRD1-AS1 intron 17804836 rs4711207 chr6 30005754 C A 4.68E-14 Rheumatoid arthritis ZNRD1-AS1 intron 19503088 rs4711207 chr6 30005754 C A 1.55E-05 IgE levels ZNRD1-AS1 intron 22075330 rs9405044 chr6 30006765 G A 2.43E-09 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs9405044 chr6 30006765 G A 1.21E-05 IgE levels ZNRD1-AS1 intron 22075330 rs259934 chr6 30006876 C T 2.44E-12 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs9261212 chr6 30008996 C T 2.95E-10 Behcet's disease ZNRD1-AS1 intron pha002888 rs9393987 chr6 30009169 C T 1.45E-05 IgE levels ZNRD1-AS1 intron 22075330 rs9261216 chr6 30010139 A G 9.18E-06 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs9380150 chr6 30010492 T C 1.30E-05 IgE levels ZNRD1-AS1 intron 22075330 rs9261217 chr6 30010508 T C 2.30E-05 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs259940 chr6 30011934 A G 3.33E-12 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs259940 chr6 30011934 A G 7.06E-05 Lung cancer ZNRD1-AS1 intron 18978787 rs259940 chr6 30011934 A G 7.00E-05 Lung cancer ZNRD1-AS1 intron 18978790 rs259940 chr6 30011934 A G 5.05E-07 Lung adenocarcinoma ZNRD1-AS1 intron 19836008 rs259940 chr6 30011934 A G 2.20E-07 Lung cancer ZNRD1-AS1 intron 22899653 rs259942 chr6 30015167 C T 2.99E-04 Coronary heart disease ZNRD1-AS1 intron 21971053 rs6917603 chr6 30017071 T C 3.00E-29 Lipid metabolism phenotypes ZNRD1-AS1 intron 22286219 rs6917603 chr6 30017071 T C 6.80E-20 Gender ZNRD1-AS1 intron 22362730 rs259945 chr6 30019206 T A 1.51E-06 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs259919 chr6 30025503 G A 4.03E-07 Lung adenocarcinoma ZNRD1-AS1 intron 19836008 rs259919 chr6 30025503 G A 3.00E-07 HIV-1 control ZNRD1-AS1 intron 20041166 rs259919 chr6 30025503 G A 6.20E-10 Lung cancer ZNRD1-AS1 intron 22899653 rs259920 chr6 30025759 G A 4.46E-05 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs6917477 chr6 30025984 G C 2.69E-06 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs12208867 chr6 30026236 G A 6.83E-05 Suicide attempts in bipolar disorder ZNRD1-AS1 intron 21041247 rs10484549 chr6 30026290 T C 1.20E-08 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs9261265 chr6 30026350 T C 7.92E-07 Multiple complex diseases ZNRD1-AS1 intron 17554300 rs3757333 chr6 30028606 C A 8.18E-10 Coronary heart disease / / 21971053 rs9295829 chr6 30028800 A G 5.16E-05 IgE levels ZNRD1-AS1 intron 22075330 rs9261277 chr6 30031091 T C 4.30E-05 HIV-1 control ZNRD1 intron 20041166 rs9261277 chr6 30031091 T C 2.50E-04 Coronary heart disease ZNRD1 intron 21971053 rs8321 chr6 30032522 A C 4.29E-11 Type 1 diabetes ZNRD1 UTR-3 17632545 rs8321 chr6 30032522 A C 6.68E-05 HIV-1 viral setpoint ZNRD1 UTR-3 17641165 rs8321 chr6 30032522 A C 5.91E-06 Lung cancer ZNRD1 UTR-3 18978787 rs8321 chr6 30032522 A C 2.00E-05 Lung cancer ZNRD1 UTR-3 18978790 rs8321 chr6 30032522 A C 5.00E-07 AIDS progression ZNRD1 UTR-3 19115949 rs8321 chr6 30032522 A C 1.44E-07 Lung cancer ZNRD1 UTR-3 19654303 rs8321 chr6 30032522 A C 5.75E-10 Lung adenocarcinoma ZNRD1 UTR-3 19836008 rs8321 chr6 30032522 A C 4.72E-07 HIV-1 control ZNRD1 UTR-3 20041166 rs8321 chr6 30032522 A C 5.96E-05 HIV-1 viral setpoint ZNRD1 UTR-3 21490045 rs8321 chr6 30032522 A C 3.90E-14 Lung cancer ZNRD1 UTR-3 22899653 rs8321 chr6 30032522 A C 6.50E-57 Myasthenia gravis ZNRD1 UTR-3 23055271 rs8321 chr6 30032522 A C 8.00E-09 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) ZNRD1 UTR-3 23453885 rs8321 chr6 30032522 A C 3.80E-11 Systemic lupus erythematosus ZNRD1 UTR-3 24871463 rs8321 chr6 30032522 A C 6.18E-06 Systemic lupus erythematosus ZNRD1 UTR-3 pha002867 rs3807030 chr6 30033690 G T 8.09E-07 Multiple complex diseases PPP1R11 nearGene-5 17554300 rs3807031 chr6 30033884 C A 1.35E-12 Rheumatoid arthritis PPP1R11 nearGene-5 17804836 rs3807031 chr6 30033884 C A 7.17E-19 Rheumatoid arthritis PPP1R11 nearGene-5 19503088 rs3807031 chr6 30033884 C A 1.20E-05 Alzheimer's disease (late onset) PPP1R11 nearGene-5 20885792 rs3807031 chr6 30033884 C A 1.20E-05 Alzheimer's disease (late onset) PPP1R11 nearGene-5 21460841 rs9261282 chr6 30035457 T G 1.72E-06 Multiple complex diseases PPP1R11 intron 17554300 rs9261285 chr6 30036083 C A 1.00E-05 HIV-1 control PPP1R11 intron 20041166 rs2074482 chr6 30036471 C A 2.17E-05 Multiple complex diseases PPP1R11 cds-synon 17554300 rs1245371 chr6 30038352 A G 1.38E-06 Lung adenocarcinoma RNF39 UTR-3 19836008 rs1245371 chr6 30038352 A G 6.00E-08 Lung cancer RNF39 UTR-3 22899653 rs9261290 chr6 30038647 T C 1.22E-12 Type 1 diabetes RNF39 UTR-3 17632545 rs9261290 chr6 30038647 T C 1.00E-04 HIV-1 viral setpoint RNF39 UTR-3 17641165 rs9261290 chr6 30038647 T C 1.84E-05 Lung cancer RNF39 UTR-3 18978787 rs9261290 chr6 30038647 T C 3.00E-05 Lung cancer RNF39 UTR-3 18978790 rs9261290 chr6 30038647 T C 5.11E-07 AIDS progression RNF39 UTR-3 19115949 rs9261290 chr6 30038647 T C 4.76E-07 Lung cancer RNF39 UTR-3 19654303 rs9261290 chr6 30038647 T C 2.18E-09 Lung adenocarcinoma RNF39 UTR-3 19836008 rs9261290 chr6 30038647 T C 1.24E-04 Response to statin treatment (atorvastatin),change in cholesterol levels RNF39 UTR-3 20031582 rs9261290 chr6 30038647 T C 3.26E-07 HIV-1 control RNF39 UTR-3 20041166 rs9261290 chr6 30038647 T C 2.40E-12 Lung cancer RNF39 UTR-3 22899653 rs9261290 chr6 30038647 T C 2.60E-58 Myasthenia gravis RNF39 UTR-3 23055271 rs9261290 chr6 30038647 T C 3.80E-10 Systemic lupus erythematosus RNF39 UTR-3 24871463 rs9261290 chr6 30038647 T C 1.73E-05 Systemic lupus erythematosus RNF39 UTR-3 pha002867 rs2301753 chr6 30039240 G T 3.84E-04 Schizophrenia RNF39 missense 19197363 rs2301753 chr6 30039240 G T 1.80E-08 HIV-1 control RNF39 missense 20041166 rs2074480 chr6 30040810 T G 3.84E-04 Schizophrenia RNF39 intron 19197363 rs2074480 chr6 30040810 T G 1.80E-08 HIV-1 control RNF39 intron 20041166 rs2074479 chr6 30041009 A G 3.84E-04 Schizophrenia RNF39 missense 19197363 rs2074479 chr6 30041009 A G 1.80E-08 HIV-1 control RNF39 missense 20041166 rs3807034 chr6 30043992 T C 8.17E-04 Schizophrenia RNF39 nearGene-5 19197363 rs3807034 chr6 30043992 T C 6.40E-06 HIV-1 control RNF39 nearGene-5 20041166 rs3132682 chr6 30044388 G C 8.19E-07 Multiple complex diseases RNF39 nearGene-5 17554300 rs3807035 chr6 30044827 C T 8.17E-04 Schizophrenia RNF39 nearGene-5 19197363 rs3807035 chr6 30044827 C T 3.60E-06 HIV-1 control RNF39 nearGene-5 20041166 rs1150735 chr6 30045199 G A 3.46E-06 Rheumatoid arthritis RNF39 nearGene-5 17804836 rs1150735 chr6 30045199 G A 9.45E-08 Rheumatoid arthritis RNF39 nearGene-5 19503088 rs1150735 chr6 30045199 G A 9.50E-06 Lung adenocarcinoma RNF39 nearGene-5 19836008 rs1150735 chr6 30045199 G A 3.80E-08 Lung cancer RNF39 nearGene-5 22899653 rs2394734 chr6 30046246 G A 5.60E-05 HIV-1 control / / 20041166 rs4711209 chr6 30047403 G A 3.06E-04 Vitiligo / / 20410501 rs4711209 chr6 30047403 G A 1.03E-06 Behcet's disease / / pha002888 rs9261317 chr6 30048305 A T 1.08E-07 Multiple complex diseases / / 17554300 rs6909253 chr6 30055643 G T 2.01E-09 Rheumatoid arthritis / / 17804836 rs6909253 chr6 30055643 G T 6.35E-13 Rheumatoid arthritis / / 19503088 rs6909253 chr6 30055643 G T 6.80E-05 HIV-1 control / / 20041166 rs6909253 chr6 30055643 G T 1.31E-04 Vitiligo / / 20410501 rs6909253 chr6 30055643 G T 4.10E-10 Graves' disease / / 21900946 rs1264708 chr6 30057154 A G 1.34E-08 Rheumatoid arthritis / / 19503088 rs9261371 chr6 30058988 C T 4.70E-05 HIV-1 control / / 20041166 rs7753935 chr6 30060783 C A 3.30E-05 Coronary heart disease / / 21971053 rs9261389 chr6 30061555 C G 1.44E-10 Multiple complex diseases / / 17554300 rs6923832 chr6 30062058 G A 1.20E-05 HIV-1 control / / 20041166 rs6923832 chr6 30062058 G A 3.17E-05 Hodgkin's lymphoma / / 24149102 rs6457144 chr6 30063368 T A 5.14E-07 Multiple complex diseases / / 17554300 rs7765810 chr6 30063496 C A 7.69E-06 Coronary heart disease / / 21971053 rs9261394 chr6 30064562 A G 3.04E-07 Multiple complex diseases / / 17554300 rs9261394 chr6 30064562 A G 5.00E-05 HIV-1 control / / 20041166 rs9261394 chr6 30064562 A G 1.50E-04 Vitiligo / / 20410501 rs1264704 chr6 30065319 G A 2.07E-06 Multiple complex diseases / / 17554300 rs1264704 chr6 30065319 G A 6.72E-05 Height / / pha003011 rs1264702 chr6 30065575 T C 7.80E-06 Coronary heart disease / / 21971053 rs916570 chr6 30066031 A G 2.77E-05 Coronary heart disease / / 21971053 rs1264701 chr6 30066358 G T 3.69E-08 Rheumatoid arthritis / / 19503088 rs1264695 chr6 30067892 A G 3.15E-05 Coronary heart disease / / 21971053 rs1116221 chr6 30071330 C T 1.35E-10 Carbamazepine ADRs TRIM31 STOP-GAIN 21149285 rs11964542 chr6 30071760 T C 1.28E-08 Vitiligo TRIM31 intron 20526339 rs2844796 chr6 30072511 G A 1.58E-10 Carbamazepine ADRs TRIM31 intron 21149285 rs3132680 chr6 30073195 A C 6.84E-12 Rheumatoid arthritis TRIM31 intron 17804836 rs3132680 chr6 30073195 A C 4.04E-16 Rheumatoid arthritis TRIM31 intron 19503088 rs2844795 chr6 30073847 C T 1.05E-06 Rheumatoid arthritis TRIM31 intron 17804836 rs2844795 chr6 30073847 C T 2.75E-15 Rheumatoid arthritis TRIM31 intron 19503088 rs2844795 chr6 30073847 C T 5.10E-07 HIV-1 control TRIM31 intron 20041166 rs2844795 chr6 30073847 C T 1.10E-06 Coronary heart disease TRIM31 intron 21971053 rs2844795 chr6 30073847 C T 2.40E-05 Systemic lupus erythematosus TRIM31 intron 24871463 rs3132679 chr6 30075843 T C 2.38E-04 Coronary heart disease TRIM31 cds-synon 21971053 rs2023472 chr6 30075864 A G 3.00E-15 Beta-2 microglubulin plasma levels TRIM31 missense 23417110 rs2523990 chr6 30077229 A G 4.88E-13 Multiple complex diseases TRIM31 intron 17554300 rs2523990 chr6 30077229 A G 1.31E-06 Multiple sclerosis TRIM31 intron 17660530 rs2523990 chr6 30077229 A G 9.02E-07 Rheumatoid arthritis TRIM31 intron 17804836 rs4959041 chr6 30077967 T C 2.11E-10 Rheumatoid arthritis TRIM31 intron 17804836 rs4959041 chr6 30077967 T C 3.71E-10 Rheumatoid arthritis TRIM31 intron 19503088 rs4959041 chr6 30077967 T C 6.50E-13 Ankylosing spondylitis TRIM31 intron 21743469 rs4959041 chr6 30077967 T C 7.89E-05 IgE levels TRIM31 intron 22075330 rs2523989 chr6 30078275 C T 8.05E-11 Type 1 diabetes TRIM31 missense 17632545 rs2523989 chr6 30078275 C T 5.14E-06 Lung adenocarcinoma TRIM31 missense 19836008 rs2523989 chr6 30078275 C T 8.60E-07 Lung cancer TRIM31 missense 22899653 rs2523989 chr6 30078275 C T 1.10E-57 Myasthenia gravis TRIM31 missense 23055271 rs2523989 chr6 30078275 C T 3.00E-07 Systemic lupus erythematosus TRIM31 missense 24871463 rs2523987 chr6 30079993 A C 3.38E-10 Type 1 diabetes TRIM31 intron 17632545 rs2523987 chr6 30079993 A C 5.61E-07 Lung adenocarcinoma TRIM31 intron 19836008 rs2523987 chr6 30079993 A C 5.40E-07 Lung cancer TRIM31 intron 22899653 rs2523987 chr6 30079993 A C 8.70E-61 Myasthenia gravis TRIM31 intron 23055271 rs2523987 chr6 30079993 A C 5.30E-08 Systemic lupus erythematosus TRIM31 intron 24871463 rs2517598 chr6 30080274 G A 3.59E-09 Type 1 diabetes TRIM31 cds-synon 17632545 rs2517598 chr6 30080274 G A 7.49E-06 Lung adenocarcinoma TRIM31 cds-synon 19836008 rs2517598 chr6 30080274 G A 1.50E-08 Lung cancer TRIM31 cds-synon 22899653 rs2517598 chr6 30080274 G A 1.40E-55 Myasthenia gravis TRIM31 cds-synon 23055271 rs2517598 chr6 30080274 G A 1.00E-06 Systemic lupus erythematosus TRIM31 cds-synon 24871463 rs34704616 chr6 30080369 G A 6.00E-06 Cognitive performance TRIM31 missense 20125193 rs2517595 chr6 30084549 G A 3.95E-09 Multiple complex diseases / / 17554300 rs1015465 chr6 30086340 T C 3.69E-15 Psoriasis / / pha002855 rs9261434 chr6 30087776 G C 1.75E-06 Behcet's disease / / pha002888 rs1419675 chr6 30092707 G T 2.06E-10 Type 1 diabetes / / 17632545 rs1419675 chr6 30092707 G T 1.05E-06 Rheumatoid arthritis / / 19503088 rs1419675 chr6 30092707 G T 1.06E-04 Coronary heart disease / / 21971053 rs1419675 chr6 30092707 G T 4.50E-07 Red blood cell traits / / 23222517 rs2517592 chr6 30093137 C T 1.53E-07 Multiple complex diseases / / 17554300 rs10947055 chr6 30093364 T C 2.86E-13 Multiple complex diseases / / 17554300 rs10947055 chr6 30093364 T C 2.79E-04 Suicide attempts in bipolar disorder / / 21041247 rs10947055 chr6 30093364 T C 2.00E-07 Cardiac hypertrophy / / 21348951 rs10947055 chr6 30093364 T C 3.94E-07 Red blood cell traits / / 23222517 rs10947056 chr6 30095603 C G 3.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs10947056 chr6 30095603 C G 6.16E-07 Red blood cell traits / / 23222517 rs1362104 chr6 30101656 G A 5.45E-05 Rheumatoid arthritis / / 17804836 rs1362104 chr6 30101656 G A 7.42E-05 Coronary heart disease / / 21971053 rs2523995 chr6 30102184 C T 3.71E-10 Multiple complex diseases / / 17554300 rs2517591 chr6 30103049 T A 8.90E-12 Multiple complex diseases TRIM40 nearGene-5 17554300 rs1541270 chr6 30103331 G T 1.55E-12 Multiple complex diseases TRIM40 nearGene-5 17554300 rs1541269 chr6 30103360 G A 4.07E-07 Multiple complex diseases TRIM40 nearGene-5 17554300 rs2021723 chr6 30103923 G A 1.10E-09 Rheumatoid arthritis TRIM40 nearGene-5 19503088 rs2021723 chr6 30103923 G A 5.71E-04 Coronary heart disease TRIM40 nearGene-5 21971053 rs2021723 chr6 30103923 G A 8.69E-15 Psoriasis TRIM40 nearGene-5 pha002855 rs9261471 chr6 30105349 T C 2.27E-12 Multiple complex diseases TRIM40 intron 17554300 rs2107202 chr6 30105743 T C 1.23E-10 Type 1 diabetes TRIM40 intron 17632545 rs2107202 chr6 30105743 T C 2.22E-06 Rheumatoid arthritis TRIM40 intron 19503088 rs2107202 chr6 30105743 T C 1.19E-04 Coronary heart disease TRIM40 intron 21971053 rs2107202 chr6 30105743 T C 1.39E-07 Red blood cell traits TRIM40 intron 23222517 rs2857435 chr6 30106024 A T 7.16E-13 Multiple complex diseases TRIM40 intron 17554300 rs2857436 chr6 30106070 C T 8.55E-12 Multiple complex diseases TRIM40 intron 17554300 rs2857439 chr6 30106296 G A 3.73E-12 Multiple complex diseases TRIM40 intron 17554300 rs9261485 chr6 30108751 G A 6.74E-13 Multiple complex diseases TRIM40 intron 17554300 rs9261487 chr6 30109207 C A 5.74E-05 HIV-1 control TRIM40 intron 20041166 rs9261488 chr6 30109412 C T 3.89E-12 Multiple complex diseases TRIM40 intron 17554300 rs9261489 chr6 30109482 A G 1.78E-11 Multiple complex diseases TRIM40 intron 17554300 rs9261491 chr6 30109861 A C 2.44E-11 Multiple complex diseases TRIM40 intron 17554300 rs12202131 chr6 30113550 T A 3.70E-04 Suicide attempts in bipolar disorder TRIM40 intron 21041247 rs757262 chr6 30114955 C T 1.89E-12 Multiple complex diseases TRIM40 missense 17554300 rs757262 chr6 30114955 C T 2.65E-15 Rheumatoid arthritis TRIM40 missense 17804836 rs757262 chr6 30114955 C T 1.59E-23 Rheumatoid arthritis TRIM40 missense 19503088 rs757260 chr6 30115204 C T 2.94E-08 Multiple complex diseases TRIM40 intron 17554300 rs757259 chr6 30115542 G A 2.57E-12 Multiple complex diseases TRIM40 missense 17554300 rs757259 chr6 30115542 G A 2.27E-15 Rheumatoid arthritis TRIM40 missense 17804836 rs757259 chr6 30115542 G A 8.46E-23 Rheumatoid arthritis TRIM40 missense 19503088 rs3132676 chr6 30116078 A G 9.39E-07 Multiple complex diseases TRIM40 UTR-3 17554300 rs1573298 chr6 30116160 G C 5.46E-12 Multiple complex diseases TRIM40 UTR-3 17554300 rs9261518 chr6 30116985 G A 1.55E-11 Multiple complex diseases TRIM40 nearGene-3 17554300 rs9261519 chr6 30117101 T C 9.26E-12 Multiple complex diseases / / 17554300 rs9468692 chr6 30119890 G A,T 1.00E-06 HIV-1 control TRIM10 UTR-3 20041166 rs9468692 chr6 30119890 G A,T 4.18E-04 Suicide attempts in bipolar disorder TRIM10 UTR-3 21041247 rs2257914 chr6 30120563 C A 4.23E-08 Rheumatoid arthritis TRIM10 UTR-3 19503088 rs2257914 chr6 30120563 C A 2.94E-07 Lung cancer TRIM10 UTR-3 21725308 rs2257914 chr6 30120563 C A 4.77E-04 Coronary heart disease TRIM10 UTR-3 21971053 rs2257914 chr6 30120563 C A 9.00E-04 Systemic lupus erythematosus TRIM10 UTR-3 24871463 rs9468693 chr6 30120637 T C 4.28E-04 Suicide attempts in bipolar disorder TRIM10 UTR-3 21041247 rs2022065 chr6 30121460 C T 2.54E-09 Rheumatoid arthritis TRIM10 UTR-3 17804836 rs2022065 chr6 30121460 C T 9.70E-13 Rheumatoid arthritis TRIM10 UTR-3 19503088 rs12210298 chr6 30121525 G A 1.25E-07 Red blood cell traits TRIM10 cds-synon 23222517 rs2517646 chr6 30122575 C T 2.87E-11 Multiple complex diseases TRIM10 intron 17554300 rs2517646 chr6 30122575 C T 1.23E-05 Multiple sclerosis TRIM10 intron 17660530 rs9261535 chr6 30127323 G A 2.46E-16 Rheumatoid arthritis TRIM10 intron 17804836 rs9261535 chr6 30127323 G A 9.39E-25 Rheumatoid arthritis TRIM10 intron 19503088 rs1318638 chr6 30127873 C T 2.09E-04 Type 2 diabetes TRIM10 intron 17463246 rs1318638 chr6 30127873 C T 3.27E-13 Multiple complex diseases TRIM10 intron 17554300 rs1318638 chr6 30127873 C T 5.50E-04 Suicide attempts in bipolar disorder TRIM10 intron 21041247 rs1318638 chr6 30127873 C T 1.27E-07 Red blood cell traits TRIM10 intron 23222517 rs12212092 chr6 30128442 C T 5.54E-04 Suicide attempts in bipolar disorder TRIM10 missense 21041247 rs561051318 chr6 30131349 T TCTCTCTCTCTGTCTCTC 1.13E-05 Multiple complex diseases TRIM15 UTR-5 17554300 rs9261536 chr6 30131349 T C 1.13E-05 Multiple complex diseases TRIM15 UTR-5 17554300 rs17188127 chr6 30135102 C T 1.24E-08 Vitiligo TRIM15 intron 20526339 rs1018846 chr6 30137649 G A 5.83E-04 Suicide attempts in bipolar disorder TRIM15 intron 21041247 rs2107195 chr6 30137866 A G 1.68E-17 Psoriasis TRIM15 intron pha002855 rs2074475 chr6 30137890 T C 5.60E-09 Carbamazepine ADRs TRIM15 intron 21149285 rs929156 chr6 30139699 G A 2.95E-13 Rheumatoid arthritis TRIM15 missense 17804836 rs929156 chr6 30139699 G A 8.99E-19 Rheumatoid arthritis TRIM15 missense 19503088 rs929156 chr6 30139699 G A 2.38E-04 Alzheimer's disease (late onset) TRIM15 missense 20885792 rs929156 chr6 30139699 G A 1.70E-05 Alzheimer's disease (late onset) TRIM15 missense 21460841 rs6905949 chr6 30140525 T C 8.33E-06 Rheumatoid arthritis TRIM15 nearGene-3 19503088 rs6905949 chr6 30140525 T C 1.02E-05 HIV-1 control TRIM15 nearGene-3 20041166 rs6905949 chr6 30140525 T C 2.30E-04 HIV-1 control TRIM15 nearGene-3 21051598 rs6905949 chr6 30140525 T C 7.58E-05 Parkinson's disease TRIM15 nearGene-3 21738487 rs6905949 chr6 30140525 T C 6.30E-05 Hypothyroidism TRIM15 nearGene-3 22493691 rs6905949 chr6 30140525 T C 9.40E-04 Systemic lupus erythematosus TRIM15 nearGene-3 24871463 rs13212414 chr6 30140540 A C,T 7.80E-04 Suicide attempts in bipolar disorder TRIM15 nearGene-3 21041247 rs2844787 chr6 30140913 G T 1.65E-07 Red blood cell traits TRIM15 nearGene-3 23222517 rs957765 chr6 30142690 G A 4.21E-15 Rheumatoid arthritis / / 21156761 rs2844786 chr6 30144420 C A 2.04E-11 Rheumatoid arthritis / / 17804836 rs2844786 chr6 30144420 C A 7.56E-13 Rheumatoid arthritis / / 19503088 rs9261539 chr6 30145083 G A 4.35E-13 Multiple complex diseases / / 17554300 rs11158 chr6 30152467 G A,C,T 1.39E-09 Multiple complex diseases TRIM26 UTR-3 17554300 rs9261547 chr6 30154928 G A 5.94E-05 Behcet's disease TRIM26 intron pha002888 rs2517618 chr6 30158127 G A 1.27E-11 Multiple complex diseases TRIM26 intron 17554300 rs4711211 chr6 30162809 A G 4.17E-16 Rheumatoid arthritis TRIM26 intron 17804836 rs4711211 chr6 30162809 A G 1.82E-24 Rheumatoid arthritis TRIM26 intron 19503088 rs2517614 chr6 30163955 G A 4.98E-05 IgE levels TRIM26 intron 22075330 rs2523722 chr6 30165273 C T 4.96E-05 IgE levels TRIM26 intron 22075330 rs2523722 chr6 30165273 C T 1.00E-16 Schizophrenia TRIM26 intron 22883433 rs2523722 chr6 30165273 C T 0.000000254 Schizophrenia TRIM26 intron 23637625 rs2523721 chr6 30166266 C T 4.92E-05 IgE levels TRIM26 cds-synon 22075330 rs2072107 chr6 30166935 G A 1.90E-08 HIV-1 control TRIM26 UTR-5 21051598 rs2072107 chr6 30166935 G A 5.97E-04 Major depressive disorder TRIM26 UTR-5 22472876 rs2517611 chr6 30169327 A G 2.39E-09 Multiple complex diseases TRIM26 intron 17554300 rs2517611 chr6 30169327 A G 4.80E-05 IgE levels TRIM26 intron 22075330 rs1117490 chr6 30170510 T C 4.65E-05 IgE levels TRIM26 intron 22075330 rs2523716 chr6 30170525 C T 4.43E-05 IgE levels TRIM26 intron 22075330 rs2844776 chr6 30171827 T C 4.04E-05 IgE levels TRIM26 intron 22075330 rs2284169 chr6 30172385 A C 1.30E-04 HIV-1 control TRIM26 intron 21051598 rs971570 chr6 30172513 A C 3.14E-05 IgE levels TRIM26 UTR-5 22075330 rs2523713 chr6 30173330 G A 2.87E-05 IgE levels TRIM26 intron 22075330 rs2021722 chr6 30174131 C A,T 2.00E-12 Schizophrenia TRIM26 intron 21926974 rs2021722 chr6 30174131 C A,T 2.80E-05 IgE levels TRIM26 intron 22075330 rs2021722 chr6 30174131 C A,T 2.00E-12 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) TRIM26 intron 23453885 rs885912 chr6 30174633 C A 2.60E-05 IgE levels TRIM26 intron 22075330 rs10947058 chr6 30176122 C T 2.60E-06 Behcet's disease TRIM26 intron pha002888 rs3132671 chr6 30178287 C T 1.37E-10 Multiple complex diseases TRIM26 intron 17554300 rs3132671 chr6 30178287 C T 5.21E-05 Multiple sclerosis TRIM26 intron 17660530 rs11967808 chr6 30179188 G C 4.26E-08 Vitiligo TRIM26 intron 20526339 rs2844775 chr6 30179422 G A 1.86E-12 Multiple complex diseases TRIM26 intron 17554300 rs2844775 chr6 30179422 G A 8.00E-07 Anger TRIM26 intron 24489884 rs9295837 chr6 30184704 G A 3.67E-04 Type 2 diabetes / / 17463246 rs9261567 chr6 30185244 T C 6.00E-08 HIV-1 control / / 21051598 rs9261567 chr6 30185244 T C 8.33E-05 Major depressive disorder / / 22472876 rs3130391 chr6 30190640 C T 5.74E-11 Multiple complex diseases / / 17554300 rs3130391 chr6 30190640 C T 5.45E-06 Multiple sclerosis / / 17660530 rs3132666 chr6 30193513 A G 2.47E-13 Multiple complex diseases / / 17554300 rs3132666 chr6 30193513 A G 5.75E-05 Multiple sclerosis / / 17660530 rs3129690 chr6 30196855 T C 3.39E-05 Rheumatoid arthritis / / 17804836 rs3129690 chr6 30196855 T C 7.50E-10 Rheumatoid arthritis / / 19503088 rs3094138 chr6 30199016 C T 2.98E-06 Coronary heart disease / / 21971053 rs17188268 chr6 30199358 G A 4.57E-08 Vitiligo / / 20526339 rs1013518 chr6 30199512 G A 2.74E-13 Multiple complex diseases / / 17554300 rs1013518 chr6 30199512 G A 2.49E-05 Multiple sclerosis / / 17660530 rs916571 chr6 30201955 G A 8.64E-13 Multiple complex diseases / / 17554300 rs885916 chr6 30202571 C T 1.61E-11 Multiple complex diseases / / 17554300 rs885916 chr6 30202571 C T 8.91E-05 Pulmonary function / / 20010835 rs2517589 chr6 30204008 T C 7.53E-05 Pulmonary function / / 20010835 rs2523742 chr6 30204399 C G 4.63E-12 Multiple complex diseases / / 17554300 rs2844780 chr6 30204526 G T 4.86E-07 Multiple complex diseases / / 17554300 rs2844780 chr6 30204526 G T 1.86E-05 Multiple sclerosis / / 17660530 rs2844779 chr6 30205407 G T 1.25E-10 Rheumatoid arthritis / / 17804836 rs2844779 chr6 30205407 G T 1.64E-12 Rheumatoid arthritis / / 19503088 rs10456378 chr6 30206186 G A 1.04E-06 Behcet's disease / / pha002888 rs2844773 chr6 30207495 C A 1.41E-11 Type 1 diabetes / / 17632545 rs2844773 chr6 30207495 C A 1.30E-05 Lung adenocarcinoma / / 19836008 rs2844773 chr6 30207495 C A 8.05E-05 Pulmonary function / / 20010835 rs2844773 chr6 30207495 C A 1.50E-09 Lung cancer / / 22899653 rs2844773 chr6 30207495 C A 2.50E-07 Systemic lupus erythematosus / / 24871463 rs2844773 chr6 30207495 C A 1.17E-05 Systemic lupus erythematosus / / pha002867 rs1362089 chr6 30209802 T G 7.58E-05 Rheumatoid arthritis / / 17804836 rs1362089 chr6 30209802 T G 1.03E-10 Rheumatoid arthritis / / 19503088 rs1362088 chr6 30209836 T C 9.86E-08 Carbamazepine ADRs / / 21149285 rs2188099 chr6 30209918 A G 9.39E-05 Pulmonary function / / 20010835 rs9261588 chr6 30210807 T G 1.28E-11 Coronary heart disease / / 21971053 rs9261588 chr6 30210807 T G 3.46E-05 Behcet's disease / / pha002888 rs1579220 chr6 30224238 G T 4.00E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs928824 chr6 30224889 C T 3.98E-05 Schizophrenia / / 24253340 rs2516712 chr6 30227340 C A 8.80E-05 Schizophrenia HLA-L nearGene-5 24253340 rs2516711 chr6 30227399 A G 4.33E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs2523747 chr6 30228938 T C 6.74E-04 Multiple complex diseases HLA-L intron 17554300 rs2523747 chr6 30228938 T C 9.62E-05 Serum metabolites HLA-L intron 19043545 rs3094073 chr6 30231224 G A 1.67E-11 Type 1 diabetes / / 17632545 rs3094073 chr6 30231224 G A 1.30E-05 Lung adenocarcinoma / / 19836008 rs3094073 chr6 30231224 G A 3.90E-09 Lung cancer / / 22899653 rs3094073 chr6 30231224 G A 1.70E-07 Systemic lupus erythematosus / / 24871463 rs3094073 chr6 30231224 G A 7.68E-06 Systemic lupus erythematosus / / pha002867 rs3094070 chr6 30231829 G C 1.50E-10 Multiple complex diseases / / 17554300 rs3130404 chr6 30232250 A G 1.27E-10 Multiple complex diseases / / 17554300 rs3094629 chr6 30232953 G A 1.50E-10 Multiple complex diseases / / 17554300 rs3130405 chr6 30234152 C T 1.42E-10 Multiple complex diseases / / 17554300 rs2844764 chr6 30234668 T A 1.02E-07 Multiple complex diseases / / 17554300 rs3129705 chr6 30234721 G A 2.37E-11 Multiple complex diseases / / 17554300 rs2844762 chr6 30236754 T C 1.48E-07 Multiple complex diseases / / 17554300 rs2844754 chr6 30246212 C A 8.76E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2844753 chr6 30248424 T C 6.27E-05 Schizophrenia / / 24253340 rs4713305 chr6 30252836 A T 7.73E-13 Multiple complex diseases / / 17554300 rs10484551 chr6 30256838 G A 4.22E-04 Type 2 diabetes / / 17463246 rs1264622 chr6 30256936 C T 5.17E-12 Type 1 diabetes / / 17632545 rs1264622 chr6 30256936 C T 6.33E-04 HIV-1 viral setpoint / / 17641165 rs11752362 chr6 30260982 C T 2.64E-07 Multiple complex diseases HCG18 intron 17554300 rs1048664 chr6 30262512 A G 8.76E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1264616 chr6 30264307 C T 5.19E-04 Multiple complex diseases HCG18 intron 17554300 rs1264616 chr6 30264307 C T 9.62E-05 Serum metabolites HCG18 intron 19043545 rs1264616 chr6 30264307 C T 5.45E-06 Esophageal cancer (squamous cell) HCG18 intron 22960999 rs1264616 chr6 30264307 C T 3.70E-05 Height HCG18 intron pha003010 rs261950 chr6 30269561 A T 3.76E-05 Multiple complex diseases HCG18 intron 17554300 rs261949 chr6 30270080 G A 4.15E-10 Rheumatoid arthritis HCG18 intron 19503088 rs261949 chr6 30270080 G A 1.95E-05 Height HCG18 intron pha003010 rs261948 chr6 30270609 C T 3.16E-04 Multiple complex diseases HCG18 intron 17554300 rs261948 chr6 30270609 C T 5.67E-05 Serum metabolites HCG18 intron 19043545 rs261947 chr6 30271144 T C 6.88E-05 Multiple complex diseases HCG18 intron 17554300 rs261946 chr6 30271334 A G 6.34E-12 Multiple complex diseases HCG18 intron 17554300 rs261943 chr6 30273371 G A 4.57E-04 Multiple complex diseases HCG18 intron 17554300 rs9380167 chr6 30274461 A G 1.44E-12 Rheumatoid arthritis HCG18 intron 19503088 rs9380167 chr6 30274461 A G 1.33E-04 Coronary heart disease HCG18 intron 21971053 rs928822 chr6 30275246 G T 2.69E-09 Rheumatoid arthritis HCG18 intron 17804836 rs928822 chr6 30275246 G T 2.77E-16 Rheumatoid arthritis HCG18 intron 19503088 rs928822 chr6 30275246 G T 1.25E-05 Coronary heart disease HCG18 intron 21971053 rs1264608 chr6 30278112 C T 7.13E-05 Schizophrenia HCG18 intron 24253340 rs1268447 chr6 30279059 C T 6.23E-05 Schizophrenia HCG18 intron 24253340 rs3130380 chr6 30279130 G A 9.89E-14 Type 1 diabetes HCG18 intron 17632545 rs3130380 chr6 30279130 G A 8.27E-05 HIV-1 viral setpoint HCG18 intron 17641165 rs3130380 chr6 30279130 G A 1.27E-05 Lung cancer HCG18 intron 18978787 rs3130380 chr6 30279130 G A 5.64E-07 AIDS progression HCG18 intron 19115949 rs3130380 chr6 30279130 G A 9.42E-07 Lung cancer HCG18 intron 19654303 rs3130380 chr6 30279130 G A 6.07E-10 Lung adenocarcinoma HCG18 intron 19836008 rs3130380 chr6 30279130 G A 5.40E-07 HIV-1 control HCG18 intron 20041166 rs3130380 chr6 30279130 G A 5.37E-05 HIV-1 viral setpoint HCG18 intron 21490045 rs3130380 chr6 30279130 G A 1.20E-13 Lung cancer HCG18 intron 22899653 rs3130380 chr6 30279130 G A 1.80E-62 Myasthenia gravis HCG18 intron 23055271 rs3130380 chr6 30279130 G A 1.30E-09 Systemic lupus erythematosus HCG18 intron 24871463 rs9295843 chr6 30281234 T A 3.67E-04 Multiple complex diseases HCG18 intron 17554300 rs9295843 chr6 30281234 T A 9.62E-05 Serum metabolites HCG18 intron 19043545 rs9295844 chr6 30281402 G C 5.72E-05 Multiple complex diseases HCG18 intron 17554300 rs3094065 chr6 30282332 T C 8.88E-10 Coronary heart disease HCG18 intron 21971053 rs3094065 chr6 30282332 T C 1.81E-06 Behcet's disease HCG18 intron pha002888 rs6912771 chr6 30284375 C A 5.21E-05 Multiple complex diseases HCG18 intron 17554300 rs9357097 chr6 30285121 C T 3.75E-12 Rheumatoid arthritis HCG18 intron 19503088 rs1473102 chr6 30285405 C A 4.01E-04 Multiple complex diseases HCG18 intron 17554300 rs6924453 chr6 30285955 G A 9.32E-05 Multiple complex diseases HCG18 intron 17554300 rs9366755 chr6 30286729 C T 4.22E-06 Height HCG18 intron pha003010 rs9366755 chr6 30286729 C T 8.43E-05 Height HCG18 intron pha003011 rs17194824 chr6 30293186 G A 8.76E-05 Non-alcoholic fatty liver disease histology (other) HCG18 intron 20708005 rs1264583 chr6 30293483 C T 6.50E-05 Schizophrenia HCG18 intron 24253340 rs12663184 chr6 30301600 C T 4.99E-04 HIV-1 viral setpoint TRIM39 intron 17641165 rs12663184 chr6 30301600 C T 2.50E-04 Systemic lupus erythematosus TRIM39 intron 24871463 rs3778624 chr6 30302600 T G 1.21E-12 Rheumatoid arthritis TRIM39 intron 19503088 rs3778624 chr6 30302600 T G 5.16E-04 Coronary heart disease TRIM39 intron 21971053 rs9380173 chr6 30309105 G A 3.71E-04 Multiple complex diseases TRIM39 intron 17554300 rs2240058 chr6 30310500 T C 1.17E-06 Height TRIM39 UTR-3 pha003010 rs2240058 chr6 30310500 T C 4.26E-05 Height TRIM39 UTR-3 pha003011 rs974962 chr6 30314607 A G 8.08E-07 Height RPP21 UTR-3 pha003010 rs974962 chr6 30314607 A G 3.94E-05 Height RPP21 UTR-3 pha003011 rs6905389 chr6 30319930 C A 1.29E-04 Multiple complex diseases / / 17554300 rs6905389 chr6 30319930 C A 1.76E-05 IgE levels / / 22075330 rs3132649 chr6 30321057 G A 1.47E-07 Multiple complex diseases / / 17554300 rs3132649 chr6 30321057 G A 2.85E-08 Vitiligo / / 20526339 rs3094061 chr6 30321189 A C 6.89E-08 Multiple complex diseases / / 17554300 rs3094061 chr6 30321189 A C 3.75E-12 Type 1 diabetes / / 17632545 rs3094061 chr6 30321189 A C 3.00E-05 Lung adenocarcinoma / / 19836008 rs3094061 chr6 30321189 A C 2.85E-08 Vitiligo / / 20526339 rs3130374 chr6 30321336 C T 9.50E-08 Multiple complex diseases / / 17554300 rs984802 chr6 30321361 G T 3.15E-05 Multiple complex diseases / / 17554300 rs3094627 chr6 30321482 T C 1.16E-07 Multiple complex diseases / / 17554300 rs3130375 chr6 30321732 C A 4.02E-08 Multiple complex diseases / / 17554300 rs3130375 chr6 30321732 C A 3.66E-07 Schizophrenia / / 19571811 rs3094626 chr6 30323623 T C 4.73E-04 Depression (quantitative trait) / / 20800221 rs3130379 chr6 30325531 T C 4.80E-08 Red blood cell traits / / 23222517 rs2523726 chr6 30327753 G A 5.80E-04 Multiple complex diseases / / 17554300 rs3130350 chr6 30327839 G T 8.74E-10 Multiple complex diseases / / 17554300 rs3130350 chr6 30327839 G T 8.43E-11 Type 1 diabetes / / 17632545 rs3130350 chr6 30327839 G T 4.00E-05 Lung cancer / / 18978790 rs3130350 chr6 30327839 G T 8.70E-08 Lung cancer / / 19654303 rs3130350 chr6 30327839 G T 8.62E-11 Lung adenocarcinoma / / 19836008 rs3130350 chr6 30327839 G T 1.15E-05 HIV-1 control / / 20041166 rs3130350 chr6 30327839 G T 2.70E-14 Lung cancer / / 22899653 rs3130350 chr6 30327839 G T 3.40E-63 Myasthenia gravis / / 23055271 rs3130350 chr6 30327839 G T 2.40E-12 Systemic lupus erythematosus / / 24871463 rs3130351 chr6 30328192 C T 5.67E-10 Multiple complex diseases / / 17554300 rs3130352 chr6 30328357 C T 5.75E-10 Multiple complex diseases / / 17554300 rs3094621 chr6 30328753 T C 3.08E-14 Type 1 diabetes / / 17632545 rs3094621 chr6 30328753 T C 8.25E-04 HIV-1 viral setpoint / / 17641165 rs3094621 chr6 30328753 T C 1.93E-05 Orofacial clefts / / 22863734 rs3094057 chr6 30329966 G A 7.34E-10 Multiple complex diseases / / 17554300 rs3094055 chr6 30332146 C G 1.45E-06 Multiple complex diseases / / 17554300 rs3094055 chr6 30332146 C G 4.93E-05 Multiple sclerosis / / 17660530 rs3094055 chr6 30332146 C G 1.11E-07 Red blood cell traits / / 23222517 rs1012411 chr6 30332555 T G 2.84E-05 Multiple complex diseases / / 17554300 rs1012411 chr6 30332555 T G 1.21E-09 Type 1 diabetes / / 17632545 rs1012411 chr6 30332555 T G 1.40E-04 Systemic lupus erythematosus / / 24871463 rs3094054 chr6 30333505 G T 3.18E-09 Type 1 diabetes / / 17632545 rs3094054 chr6 30333505 G T 2.87E-05 Rheumatoid arthritis / / 17804836 rs3094054 chr6 30333505 G T 1.13E-07 Lung cancer / / 19654303 rs3094054 chr6 30333505 G T 2.70E-10 Lung adenocarcinoma / / 19836008 rs3094054 chr6 30333505 G T 9.27E-06 HIV-1 control / / 20041166 rs3094054 chr6 30333505 G T 7.70E-14 Lung cancer / / 22899653 rs3094054 chr6 30333505 G T 1.90E-61 Myasthenia gravis / / 23055271 rs3094054 chr6 30333505 G T 7.20E-11 Systemic lupus erythematosus / / 24871463 rs3094054 chr6 30333505 G T 3.65E-05 Systemic lupus erythematosus / / pha002867 rs2040450 chr6 30334339 C T 9.99E-05 Behcet's disease / / pha002888 rs2057726 chr6 30335350 C T 1.93E-09 Red blood cell traits / / 23222517 rs3129808 chr6 30335554 G T 3.42E-08 Red blood cell traits / / 23222517 rs3129811 chr6 30337916 G A 6.66E-08 Red blood cell traits / / 23222517 rs3130361 chr6 30339564 A G 3.93E-10 Type 1 diabetes / / 17632545 rs3130361 chr6 30339564 A G 9.14E-12 Coronary heart disease / / 21971053 rs3130361 chr6 30339564 A G 6.82E-09 Red blood cell traits / / 23222517 rs2844746 chr6 30339602 T C 2.04E-05 Height / / 17255346 rs2844746 chr6 30339602 T C 1.46E-09 Type 1 diabetes / / 17632545 rs2844746 chr6 30339602 T C 5.26E-09 Rheumatoid arthritis / / 19503088 rs3132644 chr6 30340086 T C 5.70E-12 Multiple complex diseases / / 17554300 rs3130362 chr6 30340397 A G 2.26E-11 Multiple complex diseases / / 17554300 rs3132636 chr6 30342512 T G 4.24E-12 Multiple complex diseases / / 17554300 rs3129818 chr6 30342966 G T 3.27E-47 Multiple complex diseases / / 17554300 rs3129819 chr6 30343251 G C 9.00E-12 Multiple complex diseases / / 17554300 rs2844745 chr6 30343703 C T 9.02E-06 Coronary heart disease / / 21971053 rs3132631 chr6 30344645 C T 1.44E-15 Type 1 diabetes / / 17632545 rs3132631 chr6 30344645 C T 7.28E-07 Lung adenocarcinoma / / 19836008 rs3132631 chr6 30344645 C T 9.95E-05 HIV-1 control / / 20041166 rs3132630 chr6 30345118 C T 1.11E-16 Type 1 diabetes / / 17632545 rs3132630 chr6 30345118 C T 1.28E-06 Lung adenocarcinoma / / 19836008 rs3132630 chr6 30345118 C T 9.66E-05 HIV-1 control / / 20041166 rs970269 chr6 30347239 A G 5.82E-12 Multiple complex diseases / / 17554300 rs3132625 chr6 30347720 A G 1.06E-46 Multiple complex diseases / / 17554300 rs9404964 chr6 30347833 T C 3.57E-05 Multiple complex diseases / / 17554300 rs9404964 chr6 30347833 T C 7.65E-05 Serum metabolites / / 19043545 rs1245218 chr6 30348042 G A 4.24E-06 Multiple complex diseases / / 17554300 rs1245218 chr6 30348042 G A 2.06E-07 Red blood cell traits / / 23222517 rs3129828 chr6 30348340 G A 1.91E-12 Multiple complex diseases / / 17554300 rs3132622 chr6 30348674 C T 7.37E-05 Lung adenocarcinoma / / 19836008 rs3132622 chr6 30348674 C T 2.02E-04 Coronary heart disease / / 21971053 rs3094623 chr6 30349201 G A 1.57E-11 Multiple complex diseases / / 17554300 rs9261700 chr6 30349294 G A 1.14E-11 Multiple complex diseases / / 17554300 rs28780099 chr6 30351417 A G 8.00E-10 HIV-1 control / / 21051598 rs2097775 chr6 30354303 A T 1.39E-10 Multiple complex diseases / / 17554300 rs2097775 chr6 30354303 A T 3.11E-04 Lymphocyte counts / / 22286170 rs2097775 chr6 30354303 A T 1.33E-10 Red blood cell traits / / 23222517 rs3130139 chr6 30357176 T C 2.28E-05 Non-obstructive azoospermia / / 22541561 rs3094050 chr6 30358591 A G 2.98E-48 Multiple complex diseases / / 17554300 rs3094703 chr6 30358957 C T 1.19E-47 Multiple complex diseases / / 17554300 rs3094045 chr6 30360602 G A 4.99E-12 Multiple complex diseases / / 17554300 rs2516685 chr6 30361608 G A 8.30E-06 Coronary heart disease / / 21971053 rs3094035 chr6 30363136 G T 3.79E-43 Multiple complex diseases / / 17554300 rs3094034 chr6 30363351 A T 4.57E-11 Multiple complex diseases / / 17554300 rs2524202 chr6 30363373 A C 7.97E-04 Multiple complex diseases / / 17554300 rs3130112 chr6 30363428 T G 2.67E-12 Multiple complex diseases / / 17554300 rs3130113 chr6 30363945 C T 2.11E-04 Height / / 17255346 rs3130113 chr6 30363945 C T 7.10E-13 Multiple complex diseases / / 17554300 rs17475879 chr6 30364508 C T 1.90E-09 HIV-1 control / / 21051598 rs17475879 chr6 30364508 C T 1.58E-10 Coronary heart disease / / 21971053 rs2516688 chr6 30364524 T C 2.48E-07 Multiple complex diseases / / 17554300 rs2516687 chr6 30364587 A T 5.62E-06 Multiple complex diseases / / 17554300 rs2516687 chr6 30364587 A T 7.61E-05 IgE levels / / 22075330 rs1264569 chr6 30365320 C T 1.35E-07 Red blood cell traits / / 23222517 rs1264568 chr6 30366076 G C 2.19E-07 Red blood cell traits / / 23222517 rs35118048 chr6 30367227 C A 7.20E-05 Multiple complex diseases / / 17554300 rs9261739 chr6 30367535 T C 9.66E-08 Multiple complex diseases / / 17554300 rs1264563 chr6 30368092 C T 9.22E-09 Multiple complex diseases / / 17554300 rs1264563 chr6 30368092 C T 1.30E-05 Personality dimensions / / 18957941 rs1264563 chr6 30368092 C T 1.10E-05 Urinary metabolites / / 21572414 rs1034325 chr6 30368457 T C 1.09E-10 Multiple complex diseases / / 17554300 rs1034323 chr6 30368635 C T 9.51E-12 Rheumatoid arthritis / / 17804836 rs1034323 chr6 30368635 C T 8.02E-13 Rheumatoid arthritis / / 19503088 rs7741364 chr6 30372570 G A 3.60E-11 Rheumatoid arthritis / / 17804836 rs7741364 chr6 30372570 G A 4.55E-16 Rheumatoid arthritis / / 19503088 rs9261761 chr6 30372987 G A 1.34E-08 Vitiligo / / 20526339 rs9261799 chr6 30376487 C T 3.72E-07 Multiple complex diseases / / 17554300 rs1264551 chr6 30377173 A G 1.87E-05 Coronary heart disease / / 21971053 rs1079991 chr6 30377860 G A 2.58E-04 Acute lung injury / / 22295056 rs1264547 chr6 30378447 A G 1.89E-05 Coronary heart disease / / 21971053 rs1264547 chr6 30378447 A G 4.49E-07 Red blood cell traits / / 23222517 rs9261817 chr6 30378601 A C 1.34E-08 Vitiligo / / 20526339 rs9261821 chr6 30379074 T C 2.22E-07 Multiple complex diseases / / 17554300 rs9261821 chr6 30379074 T C 2.59E-08 Vitiligo / / 20526339 rs9261846 chr6 30382440 G C 1.45E-08 Vitiligo / / 20526339 rs9261850 chr6 30383412 T C 8.59E-08 Multiple complex diseases / / 17554300 rs4713325 chr6 30383442 C G 4.93E-05 Multiple complex diseases / / 17554300 rs9261854 chr6 30383675 T C 7.34E-08 Multiple complex diseases / / 17554300 rs4713327 chr6 30383768 A G 3.32E-11 Multiple complex diseases / / 17554300 rs9261855 chr6 30383799 G A 4.29E-08 Multiple complex diseases / / 17554300 rs4713328 chr6 30383876 C T 6.15E-05 Multiple complex diseases / / 17554300 rs9261858 chr6 30384317 G A 1.38E-08 Vitiligo / / 20526339 rs9261862 chr6 30384738 C G 1.38E-08 Vitiligo / / 20526339 rs9261871 chr6 30385894 A G 1.22E-08 Vitiligo / / 20526339 rs1548515 chr6 30387403 T G 2.03E-07 Multiple complex diseases / / 17554300 rs1548514 chr6 30387468 G T 9.99E-09 Vitiligo / / 20526339 rs1548513 chr6 30387687 A G 1.20E-07 Multiple complex diseases / / 17554300 rs1264539 chr6 30388701 C T 1.96E-07 Red blood cell traits / / 23222517 rs1264537 chr6 30390199 A T 2.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs9261919 chr6 30391723 G A 9.99E-09 Vitiligo / / 20526339 rs9261923 chr6 30392160 G A 9.99E-09 Vitiligo / / 20526339 rs9261925 chr6 30392248 T C 2.06E-07 Multiple complex diseases / / 17554300 rs9261926 chr6 30392406 C A 2.35E-07 Multiple complex diseases / / 17554300 rs9261926 chr6 30392406 C A 9.33E-09 Vitiligo / / 20526339 rs9261947 chr6 30394628 C T 1.36E-08 Vitiligo / / 20526339 rs9501447 chr6 30397840 A G 1.43E-08 Vitiligo / / 20526339 rs1264521 chr6 30405956 A G 2.39E-09 Red blood cell traits / / 23222517 rs1079541 chr6 30406756 C A 9.99E-09 Vitiligo / / 20526339 rs17476793 chr6 30410988 G C 1.26E-17 Psoriasis / / pha002855 rs9295871 chr6 30411089 T C 9.99E-09 Vitiligo / / 20526339 rs1264510 chr6 30414011 T C 7.48E-10 Red blood cell traits / / 23222517 rs9295873 chr6 30414235 A G 9.01E-08 Multiple complex diseases / / 17554300 rs9295873 chr6 30414235 A G 1.36E-08 Vitiligo / / 20526339 rs9461607 chr6 30414574 C A,T 1.73E-07 Multiple complex diseases / / 17554300 rs2524201 chr6 30415904 T C 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2844731 chr6 30416985 G A 1.98E-07 Multiple complex diseases / / 17554300 rs2844731 chr6 30416985 G A 5.90E-04 Acute lung injury / / 22295056 rs9295878 chr6 30417149 G A 5.03E-07 Multiple complex diseases / / 17554300 rs9295881 chr6 30417459 C T 1.36E-06 Multiple complex diseases / / 17554300 rs4947284 chr6 30418662 C A 1.86E-04 Age-related macular degeneration / / 22125219 rs1078792 chr6 30419620 T G 2.48E-07 Red blood cell traits / / 23222517 rs1076832 chr6 30419831 C A 1.21E-13 Rheumatoid arthritis / / 17804836 rs1076832 chr6 30419831 C A 6.45E-19 Rheumatoid arthritis / / 19503088 rs2516671 chr6 30420764 A G 3.25E-07 Red blood cell traits / / 23222517 rs9295886 chr6 30421397 C T 4.07E-08 Vitiligo / / 20526339 rs9295888 chr6 30422481 G A 2.44E-07 Multiple complex diseases / / 17554300 rs2844729 chr6 30422632 A G 9.71E-06 Rheumatoid arthritis / / 17804836 rs17411480 chr6 30423117 C G 1.27E-07 Multiple complex diseases / / 17554300 rs35407515 chr6 30423223 A G 1.36E-08 Vitiligo / / 20526339 rs34101875 chr6 30423358 G A 1.87E-08 Vitiligo / / 20526339 rs33986393 chr6 30424074 A G 1.34E-08 Vitiligo / / 20526339 rs9501336 chr6 30427510 G A 1.50E-08 Vitiligo / / 20526339 rs11966619 chr6 30429033 T G 9.99E-09 Vitiligo / / 20526339 rs1833080 chr6 30429440 A G 5.94E-08 Red blood cell traits / / 23222517 rs2516676 chr6 30430482 G C 4.49E-10 Red blood cell traits / / 23222517 rs2516676 chr6 30430482 G C 2.06E-06 Behcet's disease / / pha002888 rs2516675 chr6 30430520 T C 1.64E-07 Multiple complex diseases / / 17554300 rs2516675 chr6 30430520 T C 9.85E-05 Multiple sclerosis / / 17660530 rs2516675 chr6 30430520 T C 4.50E-05 Coronary heart disease / / 21971053 rs35792611 chr6 30430875 C G 1.32E-08 Vitiligo / / 20526339 rs2524172 chr6 30433611 A G 2.29E-09 Red blood cell traits / / 23222517 rs2524172 chr6 30433611 A G 4.65E-06 Behcet's disease / / pha002888 rs2516670 chr6 30434999 G A 3.11E-07 Multiple complex diseases / / 17554300 rs2516670 chr6 30434999 G A 5.93E-10 Red blood cell traits / / 23222517 rs6930977 chr6 30435288 A G 2.15E-13 Rheumatoid arthritis / / 17804836 rs6930977 chr6 30435288 A G 5.51E-19 Rheumatoid arthritis / / 19503088 rs9461612 chr6 30438556 G A 2.11E-08 Vitiligo / / 20526339 rs28780106 chr6 30451515 G A 7.40E-10 HIV-1 control LOC100653026 intron 21051598 rs3094694 chr6 30451904 T C 3.65E-08 Multiple complex diseases LOC100653026 intron 17554300 rs3094694 chr6 30451904 T C 2.60E-10 Type 1 diabetes LOC100653026 intron 17632545 rs3094694 chr6 30451904 T C 1.03E-06 Lung adenocarcinoma LOC100653026 intron 19836008 rs3094694 chr6 30451904 T C 9.20E-08 Lung cancer LOC100653026 intron 22899653 rs3094694 chr6 30451904 T C 7.80E-06 Systemic lupus erythematosus LOC100653026 intron 24871463 rs2157605 chr6 30454076 T C 3.39E-04 Multiple complex diseases LOC100653026 intron 17554300 rs1264459 chr6 30455920 G A 4.22E-08 Red blood cell traits LOC100653026 intron 23222517 rs1264459 chr6 30455920 G A 4.51E-06 Behcet's disease LOC100653026 intron pha002888 rs2429657 chr6 30471520 A G 6.66E-05 Cholesterol / / 17255346 rs2429657 chr6 30471520 A G 4.67E-06 Schizophrenia / / 21926974 rs996589 chr6 30477235 G A 6.04E-05 Serum metabolites / / 19043545 rs975195 chr6 30477947 G A 1.82E-04 Non-obstructive azoospermia / / 22541561 rs10484552 chr6 30484036 G C 7.49E-19 Psoriasis / / pha002855 rs2524222 chr6 30511170 C T 1.40E-07 HIV-1 control GNL1 UTR-3 21051598 rs2844713 chr6 30519258 A G 1.66E-07 Rheumatoid arthritis GNL1 intron 17804836 rs2844713 chr6 30519258 A G 8.97E-07 Rheumatoid arthritis GNL1 intron 19503088 rs2074504 chr6 30530245 T C 2.28E-07 Red blood cell traits PRR3 cds-synon 23222517 rs3132613 chr6 30537606 C G 1.00E-13 Graves' disease ABCF1 nearGene-5 21900946 rs3132610 chr6 30544401 A G 3.25E-12 Type 1 diabetes ABCF1 intron 17632545 rs3132610 chr6 30544401 A G 8.22E-04 HIV-1 viral setpoint ABCF1 intron 17641165 rs3132610 chr6 30544401 A G 2.21E-05 Lung cancer ABCF1 intron 18978787 rs3132610 chr6 30544401 A G 5.00E-05 Lung cancer ABCF1 intron 18978790 rs3132610 chr6 30544401 A G 4.92E-07 Lung cancer ABCF1 intron 19654303 rs3132610 chr6 30544401 A G 3.39E-09 Lung adenocarcinoma ABCF1 intron 19836008 rs3132610 chr6 30544401 A G 2.47E-06 HIV-1 control ABCF1 intron 20041166 rs3132610 chr6 30544401 A G 1.20E-13 Lung cancer ABCF1 intron 22899653 rs3132610 chr6 30544401 A G 2.80E-63 Myasthenia gravis ABCF1 intron 23055271 rs3132610 chr6 30544401 A G 1.90E-08 Systemic lupus erythematosus ABCF1 intron 24871463 rs7749109 chr6 30561724 A G 4.84E-04 Multiple complex diseases / / 17554300 rs1264432 chr6 30562021 G A 3.30E-09 Rheumatoid arthritis / / 17804836 rs1264432 chr6 30562021 G A 8.23E-09 Rheumatoid arthritis / / 19503088 rs7759666 chr6 30569489 C T 3.38E-04 Acute lung injury PPP1R10 intron 22295056 rs7759666 chr6 30569489 C T 3.61E-05 Behcet's disease PPP1R10 intron pha002888 rs1264423 chr6 30571471 T C 0.00000052 Joint damage severity in rheumatoid arthritis PPP1R10 intron 23696630 rs1264423 chr6 30571471 T C 3.19E-04 Smoking quantity PPP1R10 intron 24665060 rs9262122 chr6 30573842 T C 4.72E-05 Behcet's disease PPP1R10 intron pha002888 rs1264419 chr6 30576781 G C 0.00000052 Joint damage severity in rheumatoid arthritis PPP1R10 intron 23696630 rs2267637 chr6 30578335 C T 8.50E-08 Rheumatoid arthritis PPP1R10 intron 19503088 rs6919835 chr6 30580597 G A 1.65E-06 Coronary heart disease PPP1R10 intron 21971053 rs6904236 chr6 30596135 A G 9.68E-04 Multiple complex diseases ATAT1 cds-synon 17554300 rs2517564 chr6 30597337 T C 1.67E-04 Self-reported allergy ATAT1 intron 23817569 rs4713340 chr6 30599702 G A 5.79E-05 Rheumatoid arthritis ATAT1 intron 19503088 rs4713340 chr6 30599702 G A 2.34E-04 Acute lung injury ATAT1 intron 22295056 rs17195551 chr6 30601395 C T 5.11E-09 Vitiligo ATAT1 intron 20526339 rs2394390 chr6 30601821 T C 8.60E-04 Type 2 diabetes ATAT1 intron 17463246 rs2394390 chr6 30601821 T C 3.87E-07 Multiple complex diseases ATAT1 intron 17554300 rs1140809 chr6 30611676 C A 6.91E-17 Rheumatoid arthritis ATAT1 UTR-3 17804836 rs1140809 chr6 30611676 C A 5.21E-16 Rheumatoid arthritis ATAT1 UTR-3 19503088 rs1140809 chr6 30611676 C A 0.00000031 Joint damage severity in rheumatoid arthritis ATAT1 UTR-3 23696630 rs1140809 chr6 30611676 C A 1.91E-04 Smoking quantity ATAT1 UTR-3 24665060 rs542566633 chr6 30627867 T C 6.81E-07 Rheumatoid arthritis DHX16 missense 19503088 rs542566633 chr6 30627867 T C 4.36E-05 Hodgkin's lymphoma DHX16 missense 24149102 rs542566633 chr6 30627867 T C 2.81E-06 Schizophrenia DHX16 missense 24253340 rs9262138 chr6 30627867 T C 6.81E-07 Rheumatoid arthritis DHX16 missense 19503088 rs9262138 chr6 30627867 T C 4.36E-05 Hodgkin's lymphoma DHX16 missense 24149102 rs9262138 chr6 30627867 T C 2.81E-06 Schizophrenia DHX16 missense 24253340 rs3130000 chr6 30628082 A G 1.18E-06 Multiple complex diseases DHX16 intron 17554300 rs3130000 chr6 30628082 A G 2.38E-09 Multiple sclerosis DHX16 intron 17660530 rs3130000 chr6 30628082 A G 5.78E-07 Dilated cardiomyopathy DHX16 intron 23853074 rs1076828 chr6 30628252 G A 1.96E-10 Rheumatoid arthritis DHX16 intron 17804836 rs1076828 chr6 30628252 G A 3.85E-07 Rheumatoid arthritis DHX16 intron 19503088 rs3094097 chr6 30633875 A G 1.97E-04 Coronary heart disease DHX16 intron 21971053 rs566158921 chr6 30635593 T C 1.70E-04 Coronary heart disease DHX16 intron 21971053 rs7749235 chr6 30635593 T C 1.70E-04 Coronary heart disease DHX16 intron 21971053 rs2394392 chr6 30650318 T G 5.43E-05 Coronary heart disease PPP1R18 intron 21971053 rs9262143 chr6 30652781 C T 3.61E-10 Type 1 diabetes PPP1R18 missense 17632545 rs9262143 chr6 30652781 C T 8.28E-04 HIV-1 viral setpoint PPP1R18 missense 17641165 rs9262143 chr6 30652781 C T 1.45E-06 Lung cancer PPP1R18 missense 18978787 rs9262143 chr6 30652781 C T 6.00E-05 Lung cancer PPP1R18 missense 18978790 rs9262143 chr6 30652781 C T 3.55E-08 Lung cancer PPP1R18 missense 19654303 rs9262143 chr6 30652781 C T 7.97E-10 Lung adenocarcinoma PPP1R18 missense 19836008 rs9262143 chr6 30652781 C T 3.72E-06 HIV-1 control PPP1R18 missense 20041166 rs9262143 chr6 30652781 C T 9.56E-05 HIV-1 viral setpoint PPP1R18 missense 21490045 rs9262143 chr6 30652781 C T 1.00E-12 Lung cancer PPP1R18 missense 22899653 rs9262143 chr6 30652781 C T 4.60E-11 Systemic lupus erythematosus PPP1R18 missense 24871463 rs2269706 chr6 30652872 G A 6.34E-06 Rheumatoid arthritis PPP1R18 missense 19503088 rs1075496 chr6 30658239 C A 2.44E-05 Multiple complex diseases NRM intron 17554300 rs1075496 chr6 30658239 C A 8.35E-07 Rheumatoid arthritis NRM intron 17804836 rs1075496 chr6 30658239 C A 7.01E-06 Rheumatoid arthritis NRM intron 19503088 rs1075496 chr6 30658239 C A 2.06E-04 Coronary heart disease NRM intron 21971053 rs1075496 chr6 30658239 C A 0.00000001 Joint damage severity in rheumatoid arthritis NRM intron 23696630 rs3130663 chr6 30666594 A G 8.93E-05 Myopia (pathological) / / 23049088 rs9468811 chr6 30666669 C G 2.00E-06 IgG glycosylation / / 23382691 rs9468811 chr6 30666669 C G 3.00E-06 IgG glycosylation / / 23382691 rs9468811 chr6 30666669 C G 3.00E-06 IgG glycosylation / / 23382691 rs9468811 chr6 30666669 C G 5.00E-07 IgG glycosylation / / 23382691 rs9468811 chr6 30666669 C G 6.00E-07 IgG glycosylation / / 23382691 rs3094093 chr6 30679628 T A 3.00E-06 IgG glycosylation MDC1 intron 23382691 rs3094093 chr6 30679628 T A 8.00E-06 IgG glycosylation MDC1 intron 23382691 rs9262152 chr6 30680916 C T 2.77E-08 Multiple complex diseases MDC1 missense 17554300 rs9262152 chr6 30680916 C T 4.20E-07 Rheumatoid arthritis MDC1 missense 19503088 rs9262152 chr6 30680916 C T 9.37E-05 Acute lung injury MDC1 missense 22295056 rs9262152 chr6 30680916 C T 3.62E-05 Behcet's disease MDC1 missense pha002888 rs2253802 chr6 30684686 C T 1.07E-05 Multiple complex diseases MDC1 intron 17554300 rs2253802 chr6 30684686 C T 5.96E-07 Body mass index MDC1 intron 19584900 rs2253802 chr6 30684686 C T 8.43E-09 Body mass index MDC1 intron 19584900 rs2253802 chr6 30684686 C T 2.46E-04 Self-reported allergy MDC1 intron 23817569 rs9295910 chr6 30687714 T A 1.23E-04 Amyotrophic lateral sclerosis TUBB nearGene-5 20801718 rs3132584 chr6 30688427 G T 1.25E-05 HIV-1 control TUBB intron 20041166 rs1061397 chr6 30692539 C T 9.89E-04 Multiple complex diseases TUBB UTR-3 17554300 rs11546742 chr6 30692768 C G 1.20E-04 Alcohol dependence TUBB UTR-3 20201924 rs11546742 chr6 30692768 C G 3.60E-04 Alcohol dependence TUBB UTR-3 20201924 rs8233 chr6 30692965 G A 4.22E-42 Multiple complex diseases TUBB UTR-3 17554300 rs8233 chr6 30692965 G A 8.30E-05 HIV-1 control TUBB UTR-3 20041166 rs3095329 chr6 30693816 A G 2.88E-41 Multiple complex diseases / / 17554300 rs3095329 chr6 30693816 A G 4.20E-13 Type 1 diabetes / / 17632545 rs3095329 chr6 30693816 A G 2.65E-06 HIV-1 control / / 20041166 rs3095329 chr6 30693816 A G 1.63E-04 Coronary heart disease / / 21971053 rs3094127 chr6 30697447 A G 9.41E-45 Multiple complex diseases FLOT1 intron 17554300 rs3094127 chr6 30697447 A G 2.58E-14 Type 1 diabetes FLOT1 intron 17632545 rs3094127 chr6 30697447 A G 2.20E-06 Lung adenocarcinoma FLOT1 intron 19836008 rs3094127 chr6 30697447 A G 1.19E-05 HIV-1 control FLOT1 intron 20041166 rs3094127 chr6 30697447 A G 3.69E-04 Coronary heart disease FLOT1 intron 21971053 rs3094127 chr6 30697447 A G 8.00E-09 Lung cancer FLOT1 intron 22899653 rs3094127 chr6 30697447 A G 8.20E-05 Systemic lupus erythematosus FLOT1 intron 24871463 rs9501028 chr6 30697561 T C 6.75E-05 Coronary heart disease FLOT1 intron 21971053 rs1064627 chr6 30698541 A G 3.17E-05 HIV-1 control FLOT1 intron 20041166 rs1064627 chr6 30698541 A G 8.39E-07 Schizophrenia FLOT1 intron 21926974 rs3909184 chr6 30699384 G C 1 Drug response to Carbamazepine FLOT1 intron 10392983 rs3909184 chr6 30699384 G C 1 Drug response to Carbamazepine FLOT1 intron 15057820 rs3909184 chr6 30699384 G C 1 Drug response to Phenytoin FLOT1 intron 15057820 rs3909184 chr6 30699384 G C 1 Drug response to Carbamazepine FLOT1 intron 16415921 rs3909184 chr6 30699384 G C 1 Drug response to Phenytoin FLOT1 intron 16415921 rs3909184 chr6 30699384 G C 1 Drug response to Carbamazepine FLOT1 intron 16538176 rs3909184 chr6 30699384 G C 1 Drug response to Phenytoin FLOT1 intron 16538176 rs3909184 chr6 30699384 G C 1 Drug response to Carbamazepine FLOT1 intron 16981842 rs3909184 chr6 30699384 G C 1 Drug response to Carbamazepine FLOT1 intron 16998491 rs3909184 chr6 30699384 G C 1 Drug response to Phenytoin FLOT1 intron 16998491 rs3909184 chr6 30699384 G C 1 Drug response to Carbamazepine FLOT1 intron 18370849 rs3909184 chr6 30699384 G C 1 Drug response to Phenytoin FLOT1 intron 18370849 rs3909184 chr6 30699384 G C 1 Drug response to Carbamazepine FLOT1 intron 18637831 rs3909184 chr6 30699384 G C 1 Drug response to Phenytoin FLOT1 intron 18637831 rs3909184 chr6 30699384 G C 1 Drug response to Carbamazepine FLOT1 intron 7477195 rs3909184 chr6 30699384 G C 1 Drug response to Carbamazepine FLOT1 intron 8781718 rs3909184 chr6 30699384 G C 1 Drug response to Carbamazepine FLOT1 intron 9679693 rs8512 chr6 30711357 G A 9.36E-04 Acute lung injury IER3 UTR-3 22295056 rs2535319 chr6 30714479 T C 4.62E-05 Lung adenocarcinoma LOC100294307 intron 19836008 rs2535323 chr6 30718180 A G 7.00E-08 HIV-1 control LOC100294307 intron 21051598 rs562932852 chr6 30718180 A G 7.00E-08 HIV-1 control LOC100294307 intron 21051598 rs2394401 chr6 30724430 T C 7.99E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3095341 chr6 30726748 T C 1.50E-08 Nasopharyngeal carcinoma / / 20512145 rs3095341 chr6 30726748 T C 5.53E-04 Coronary heart disease / / 21971053 rs3095341 chr6 30726748 T C 0.000502 Salmonella-induced pyroptosis / / 22837397 rs3095340 chr6 30726939 A C 6.12E-07 Multiple complex diseases / / 17554300 rs3095340 chr6 30726939 A C 2.89E-12 Type 1 diabetes / / 17632545 rs3095340 chr6 30726939 A C 2.67E-05 HIV-1 control / / 20041166 rs3094122 chr6 30728360 T G 1.27E-12 Multiple complex diseases / / 17554300 rs3094122 chr6 30728360 T G 4.70E-09 Type 1 diabetes / / 17632545 rs3094121 chr6 30730960 C T 6.56E-13 Multiple complex diseases / / 17554300 rs13214831 chr6 30731505 G A 6.23E-05 HIV-1 control / / 20041166 rs3129975 chr6 30732054 T C 3.10E-09 Systemic lupus erythematosus / / 24871463 rs3129975 chr6 30732054 T C 2.40E-07 Systemic lupus erythematosus / / pha002867 rs12210947 chr6 30735105 A G 1.22E-08 Rheumatoid arthritis / / 17804836 rs12210947 chr6 30735105 A G 5.27E-15 Rheumatoid arthritis / / 19503088 rs12526186 chr6 30736151 C T 3.00E-06 Response to antipsychotic treatment / / 19721433 rs12526186 chr6 30736151 C T 1.27E-12 Psoriasis / / pha002855 rs3094117 chr6 30737486 A C 2.00E-06 Migraine without aura / / 23793025 rs6911628 chr6 30739846 C T 2.36E-10 Type 1 diabetes / / 17632545 rs3132605 chr6 30739972 A C 3.56E-40 Multiple complex diseases / / 17554300 rs3130666 chr6 30740160 G A 8.33E-07 Multiple complex diseases / / 17554300 rs3130666 chr6 30740160 G A 9.91E-05 Self-reported allergy / / 23817569 rs4248148 chr6 30742134 G A 7.33E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17481190 chr6 30743014 C T 1.90E-07 HIV-1 control / / 21051598 rs11757629 chr6 30744529 A C 3.11E-04 Smoking initiation / / 24665060 rs12526481 chr6 30746633 C A 6.63E-05 Cognitive test performance / / 20125193 rs12526481 chr6 30746633 C A 3.10E-12 HIV-1 control / / 21051598 rs10947091 chr6 30747216 C T 2.00E-12 Multiple complex diseases / / 17554300 rs10947091 chr6 30747216 C T 2.60E-12 HIV-1 control / / 21051598 rs13220225 chr6 30747802 G A 1.70E-07 HIV-1 control / / 21051598 rs9468829 chr6 30749233 T G 4.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9468830 chr6 30749712 T G 1.80E-09 HIV-1 control / / 21051598 rs12527415 chr6 30754540 C T 9.33E-12 Multiple complex diseases / / 17554300 rs12527415 chr6 30754540 C T 1.80E-09 HIV-1 control / / 21051598 rs16897900 chr6 30755893 C A 1.90E-09 HIV-1 control / / 21051598 rs13201769 chr6 30756066 G A 1.01E-06 HIV-1 control / / 20041166 rs13201769 chr6 30756066 G A 1.90E-09 HIV-1 control / / 21051598 rs4713366 chr6 30756361 C T 2.40E-05 HIV-1 control / / 20041166 rs4711229 chr6 30756744 G T 1.80E-09 HIV-1 control / / 21051598 rs4711229 chr6 30756744 G T 5.43E-14 Psoriasis / / pha002855 rs4713367 chr6 30756822 G A 1.80E-09 HIV-1 control / / 21051598 rs10947095 chr6 30757575 C T 1.50E-09 HIV-1 control / / 21051598 rs11758688 chr6 30758348 C T 6.98E-12 Multiple complex diseases / / 17554300 rs11758688 chr6 30758348 C T 2.20E-09 HIV-1 control / / 21051598 rs3131043 chr6 30758466 A G 9.63E-04 Multiple complex diseases / / 17554300 rs3131043 chr6 30758466 A G 1.76E-04 Breast cancer / / pha002853 rs3131043 chr6 30758466 A G 1.81E-11 Psoriasis / / pha002855 rs3131050 chr6 30760025 T C 3.48E-39 Multiple complex diseases / / 17554300 rs34682678 chr6 30760639 A C 1.68E-05 Behcet's disease / / pha002888 rs3131060 chr6 30763291 G A 4.49E-39 Multiple complex diseases / / 17554300 rs6930444 chr6 30763632 A G 8.00E-07 Multiple complex diseases / / 17554300 rs3131063 chr6 30763756 G A 6.97E-09 Type 1 diabetes / / 17632545 rs3131064 chr6 30763893 T C 7.21E-06 HIV-1 control / / 20041166 rs3130641 chr6 30764081 C T 1.71E-39 Multiple complex diseases / / 17554300 rs12660860 chr6 30764241 T C 2.40E-12 Multiple complex diseases / / 17554300 rs12660883 chr6 30764420 T C 3.42E-13 Multiple complex diseases / / 17554300 rs12660883 chr6 30764420 T C 8.08E-10 Rheumatoid arthritis / / 19503088 rs12660883 chr6 30764420 T C 4.09E-05 HIV-1 control / / 20041166 rs1264377 chr6 30764907 G A 3.89E-08 Vitiligo / / 20526339 rs10947096 chr6 30765895 G A 7.18E-13 Multiple complex diseases / / 17554300 rs3129987 chr6 30766204 T C 2.28E-08 Chronic hepatitis B infection / / 23760081 rs6905957 chr6 30766740 A G 3.30E-11 HIV-1 control / / 21051598 rs4587207 chr6 30766945 A G 1.80E-10 Multiple complex diseases / / 17554300 rs4587207 chr6 30766945 A G 3.40E-12 HIV-1 control / / 21051598 rs4483030 chr6 30767129 C T 2.59E-08 Multiple complex diseases / / 17554300 rs4483030 chr6 30767129 C T 2.50E-10 HIV-1 control / / 21051598 rs4248149 chr6 30767627 T C 2.61E-11 Multiple complex diseases / / 17554300 rs4248149 chr6 30767627 T C 9.50E-12 HIV-1 control / / 21051598 rs2394403 chr6 30767869 C T 1.20E-10 Multiple complex diseases / / 17554300 rs2394403 chr6 30767869 C T 6.90E-12 HIV-1 control / / 21051598 rs2394403 chr6 30767869 C T 0.00036 Endometrial cancer / / 22426144 rs4711235 chr6 30768636 T C 1.76E-05 Rheumatoid arthritis / / 17804836 rs1264373 chr6 30769273 G A 0.0000413 Sarcoidosis / / 22952805 rs3129988 chr6 30769478 T C 3.67E-04 Smoking initiation / / 24665060 rs9295917 chr6 30769772 C G 5.09E-13 Psoriasis / / pha002855 rs13198118 chr6 30770732 T G 1.31E-04 HIV-1 viral setpoint / / 17641165 rs13198118 chr6 30770732 T G 1.43E-09 HIV-1 control / / 20041166 rs13198118 chr6 30770732 T G 1.30E-11 HIV-1 control / / 21051598 rs13198118 chr6 30770732 T G 1.41E-05 HIV-1 viral setpoint / / 21490045 rs13198118 chr6 30770732 T G 2.07E-12 Psoriasis / / pha002855 rs3094123 chr6 30772378 A G 5.85E-13 Multiple complex diseases / / 17554300 rs3094123 chr6 30772378 A G 8.07E-10 Multiple sclerosis / / 17660530 rs3094123 chr6 30772378 A G 6.60E-04 Coronary heart disease / / 21971053 rs4713376 chr6 30773314 A C 4.73E-09 Multiple complex diseases / / 17554300 rs3130783 chr6 30774357 G A 2.00E-11 Age-related macular degeneration / / 23455636 rs9378109 chr6 30774474 C A 4.76E-04 HIV-1 viral setpoint / / 17641165 rs9378109 chr6 30774474 C A 4.73E-06 AIDS progression / / 19115949 rs9378109 chr6 30774474 C A 4.97E-08 Rheumatoid arthritis / / 19503088 rs9378109 chr6 30774474 C A 4.58E-07 HIV-1 control / / 20041166 rs9404974 chr6 30776483 T C 1.94E-05 HIV-1 control / / 20041166 rs9404974 chr6 30776483 T C 2.80E-11 HIV-1 control / / 21051598 rs1264362 chr6 30776590 C G 1.31E-05 Behcet's disease / / pha002888 rs9391696 chr6 30778786 A G 5.90E-10 HIV-1 control / / 21051598 rs2524266 chr6 30780568 C T 0.00005866 Sarcoidosis / / 22952805 rs886424 chr6 30782002 C T 3.31E-14 Type 1 diabetes / / 17632545 rs886424 chr6 30782002 C T 5.41E-06 Lung cancer / / 19654303 rs886424 chr6 30782002 C T 9.99E-08 Lung adenocarcinoma / / 19836008 rs886424 chr6 30782002 C T 6.39E-05 HIV-1 control / / 20041166 rs886424 chr6 30782002 C T 7.21E-05 HIV-1 viral setpoint / / 21490045 rs886424 chr6 30782002 C T 9.00E-07 Bipolar disorder and schizophrenia / / 22688191 rs886424 chr6 30782002 C T 6.60E-11 Lung cancer / / 22899653 rs886424 chr6 30782002 C T 4.10E-69 Myasthenia gravis / / 23055271 rs886424 chr6 30782002 C T 6.70E-12 Systemic lupus erythematosus / / 24871463 rs2894046 chr6 30782105 T C 7.23E-06 Rheumatoid arthritis / / 17804836 rs2894046 chr6 30782105 T C 5.57E-05 HIV-1 control / / 20041166 rs886423 chr6 30782205 G C 9.58E-04 Parkinson's disease / / 17052657 rs2394412 chr6 30782235 G A 8.09E-06 Rheumatoid arthritis / / 17804836 rs2394412 chr6 30782235 G A 4.64E-05 HIV-1 control / / 20041166 rs9295924 chr6 30782361 G A 4.92E-04 HIV-1 viral setpoint / / 17641165 rs9295924 chr6 30782361 G A 1.78E-06 AIDS progression / / 19115949 rs9295924 chr6 30782361 G A 8.83E-09 Rheumatoid arthritis / / 19503088 rs9295924 chr6 30782361 G A 2.66E-07 HIV-1 control / / 20041166 rs9295924 chr6 30782361 G A 2.69E-12 Psoriasis / / pha002855 rs4713380 chr6 30785273 T C 4.48E-04 HIV-1 viral setpoint / / 17641165 rs4713380 chr6 30785273 T C 1.61E-06 AIDS progression / / 19115949 rs4713380 chr6 30785273 T C 8.15E-09 Rheumatoid arthritis / / 19503088 rs4713380 chr6 30785273 T C 6.45E-10 HIV-1 control / / 20041166 rs4713380 chr6 30785273 T C 2.30E-11 HIV-1 control / / 21051598 rs4713380 chr6 30785273 T C 2.09E-05 HIV-1 viral setpoint / / 21490045 rs4713380 chr6 30785273 T C 6.51E-13 Psoriasis / / pha002855 rs9380198 chr6 30785886 G T 1.94E-05 HIV-1 control / / 20041166 rs9380198 chr6 30785886 G T 2.30E-11 HIV-1 control / / 21051598 rs4713382 chr6 30787175 G A 7.08E-10 Multiple complex diseases / / 17554300 rs4713382 chr6 30787175 G A 1.94E-05 HIV-1 control / / 20041166 rs4713383 chr6 30787241 G A 1.94E-05 HIV-1 control / / 20041166 rs4713383 chr6 30787241 G A 3.50E-11 HIV-1 control / / 21051598 rs4713385 chr6 30787593 G A 4.48E-04 HIV-1 viral setpoint / / 17641165 rs4713385 chr6 30787593 G A 1.55E-06 AIDS progression / / 19115949 rs4713385 chr6 30787593 G A 2.21E-09 Rheumatoid arthritis / / 19503088 rs4713385 chr6 30787593 G A 8.96E-10 HIV-1 control / / 20041166 rs4713385 chr6 30787593 G A 3.70E-11 HIV-1 control / / 21051598 rs4713385 chr6 30787593 G A 2.51E-05 HIV-1 viral setpoint / / 21490045 rs1264353 chr6 30787762 C A 9.91E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs12195469 chr6 30789608 T A 8.35E-09 Multiple complex diseases / / 17554300 rs4713389 chr6 30790604 G T 1.94E-05 HIV-1 control / / 20041166 rs4713389 chr6 30790604 G T 2.90E-11 HIV-1 control / / 21051598 rs6901761 chr6 30790798 C T 1.94E-05 HIV-1 control / / 20041166 rs6901761 chr6 30790798 C T 3.00E-11 HIV-1 control / / 21051598 rs4947289 chr6 30791409 C T 1.94E-05 HIV-1 control / / 20041166 rs1264351 chr6 30792117 G C 0.00003693 Sarcoidosis / / 22952805 rs4713391 chr6 30792235 T C 8.76E-15 Rheumatoid arthritis / / 17804836 rs4713391 chr6 30792235 T C 3.70E-24 Rheumatoid arthritis / / 19503088 rs12192704 chr6 30792270 G A 1.79E-14 Rheumatoid arthritis / / 17804836 rs12192704 chr6 30792270 G A 2.05E-23 Rheumatoid arthritis / / 19503088 rs7751869 chr6 30793314 A G 1.94E-05 HIV-1 control / / 20041166 rs7751869 chr6 30793314 A G 2.90E-11 HIV-1 control / / 21051598 rs4947290 chr6 30794405 G A 1.94E-05 HIV-1 control / / 20041166 rs4947290 chr6 30794405 G A 3.10E-11 HIV-1 control / / 21051598 rs915664 chr6 30794617 T C 0.000359439 Hypertension (early onset hypertension) / / 22479346 rs915664 chr6 30794617 T C 8.45E-05 Behcet's disease / / pha002888 rs7772131 chr6 30795171 A C 3.00E-06 Response to angiotensin II receptor blocker therapy / / 22566498 rs12215119 chr6 30795328 C A 5.85E-09 Multiple complex diseases / / 17554300 rs9380199 chr6 30796271 A G 8.28E-04 Type 2 diabetes / / 17463246 rs1264350 chr6 30796545 T C 1.00E-10 Type 1 diabetes / / 17632545 rs1264350 chr6 30796545 T C 1.96E-09 Vitiligo / / 20526339 rs3130785 chr6 30796738 T C 2.75E-05 Post-operative nausea and vomiting / / 21694509 rs3130785 chr6 30796738 T C 4.92E-04 Coronary heart disease / / 21971053 rs9368644 chr6 30797083 C T 2.39E-10 Multiple complex diseases / / 17554300 rs9368644 chr6 30797083 C T 1.10E-10 HIV-1 control / / 21051598 rs7749924 chr6 30797991 C T 3.00E-09 HIV-1 control / / 21051598 rs7749924 chr6 30797991 C T 5.94E-04 Major depressive disorder / / 22472876 rs7749924 chr6 30797991 C T 8.00E-06 IgG glycosylation / / 23382691 rs7749924 chr6 30797991 C T 2.25E-12 Psoriasis / / pha002855 rs1264347 chr6 30798697 C T 0.00001161 Sarcoidosis / / 22952805 rs9501030 chr6 30799399 T A 4.00E-06 Ulcerative colitis / / 20848476 rs3130648 chr6 30800326 C T 1.78E-08 Chronic hepatitis B infection / / 23760081 rs1264344 chr6 30800577 C T 3.27E-06 Multiple complex diseases / / 17554300 rs1264344 chr6 30800577 C T 1.19E-09 Rheumatoid arthritis / / 17804836 rs1264344 chr6 30800577 C T 2.04E-09 Rheumatoid arthritis / / 19503088 rs3130649 chr6 30803254 A T 9.40E-09 Multiple complex diseases / / 17554300 rs3130649 chr6 30803254 A T 3.92E-06 Multiple sclerosis / / 17660530 rs3095352 chr6 30805921 C T 4.59E-04 Parkinson's disease / / 16252231 rs3095352 chr6 30805921 C T 4.09E-06 Rheumatoid arthritis / / 17804836 rs3095352 chr6 30805921 C T 7.56E-10 Rheumatoid arthritis / / 19503088 rs3095352 chr6 30805921 C T 3.12E-06 Systemic sclerosis / / 20383147 rs3095352 chr6 30805921 C T 1.90E-04 Systemic lupus erythematosus / / 24871463 rs11752162 chr6 30809952 A G 5.33E-05 Smoking initiation / / 24665060 rs2517578 chr6 30811265 G C 0.00002551 Sarcoidosis / / 22952805 rs7759803 chr6 30812519 G A 2.31E-08 Vitiligo / / 20526339 rs2535334 chr6 30812996 G A 0.00002379 Sarcoidosis / / 22952805 rs2535332 chr6 30813249 C T 0.00002551 Sarcoidosis / / 22952805 rs2535331 chr6 30816270 G A 3.74E-06 Behcet's disease / / pha002888 rs3095350 chr6 30817866 A G 8.72E-10 Multiple complex diseases / / 17554300 rs3095350 chr6 30817866 A G 3.97E-06 Multiple sclerosis / / 17660530 rs2263298 chr6 30820373 C T 0.00001741 Sarcoidosis / / 22952805 rs2250264 chr6 30821187 G A 1.69E-04 Glycosylated haemoglobin levels / / 17255346 rs2250264 chr6 30821187 G A 8.16E-09 Behcet's disease / / pha002888 rs2844661 chr6 30821522 C T 0.00002267 Sarcoidosis / / 22952805 rs3095345 chr6 30822413 C T 2.50E-08 Multiple complex diseases / / 17554300 rs3095345 chr6 30822413 C T 6.37E-10 Multiple sclerosis / / 17660530 rs3095345 chr6 30822413 C T 3.28E-05 Hepatitis B / / 21750111 rs3130653 chr6 30822771 C A 5.40E-04 Parkinson's disease / / 16252231 rs3130653 chr6 30822771 C A 7.31E-05 Rheumatoid arthritis / / 17804836 rs3130653 chr6 30822771 C A 1.07E-08 Rheumatoid arthritis / / 19503088 rs3130653 chr6 30822771 C A 3.40E-04 Systemic lupus erythematosus / / 24871463 rs17840009 chr6 30823122 C T 3.17E-05 Smoking initiation / / 24665060 rs9295928 chr6 30823630 T C 4.28E-10 HIV-1 control / / 20041166 rs9295928 chr6 30823630 T C 8.30E-08 HIV-1 control / / 21051598 rs9295928 chr6 30823630 T C 1.62E-06 HIV-1 viral setpoint / / 21490045 rs2844659 chr6 30824532 C T 6.12E-09 Type 1 diabetes / / 17632545 rs2844659 chr6 30824532 C T 2.26E-05 Lung adenocarcinoma / / 19836008 rs2844659 chr6 30824532 C T 4.40E-07 Lung cancer / / 22899653 rs2844659 chr6 30824532 C T 1.30E-68 Myasthenia gravis / / 23055271 rs2844659 chr6 30824532 C T 2.20E-11 Systemic lupus erythematosus / / 24871463 rs7772269 chr6 30825220 C A 4.00E-05 Smoking initiation / / 24665060 rs2535328 chr6 30825994 C T 0.00002588 Sarcoidosis / / 22952805 rs2535327 chr6 30826904 T C 1.30E-07 Behcet's disease / / pha002888 rs2844657 chr6 30829522 A G 4.20E-09 Type 1 diabetes / / 17632545 rs2844657 chr6 30829522 A G 3.49E-05 Lung adenocarcinoma / / 19836008 rs2844657 chr6 30829522 A G 3.00E-69 Myasthenia gravis / / 23055271 rs2844657 chr6 30829522 A G 9.30E-08 Systemic lupus erythematosus / / 24871463 rs7761138 chr6 30830292 C A 4.00E-05 Smoking initiation / / 24665060 rs3132577 chr6 30831195 G A 0.00003059 Sarcoidosis / / 22952805 rs2844656 chr6 30834331 A G 0.00003209 Sarcoidosis / / 22952805 rs10947109 chr6 30836225 T C 9.65E-05 Smoking initiation / / 24665060 rs2535340 chr6 30838497 T C 0.00002551 Sarcoidosis / / 22952805 rs2844654 chr6 30838688 T G 4.51E-12 Rheumatoid arthritis / / 17804836 rs2844654 chr6 30838688 T G 3.45E-14 Rheumatoid arthritis / / 19503088 rs2844654 chr6 30838688 T G 0.00084 Breast cancer / / 23555315 rs2844654 chr6 30838688 T G 4.43E-06 Behcet's disease / / pha002888 rs7746003 chr6 30842894 T A 5.74E-10 Vitiligo / / 20526339 rs1264333 chr6 30844314 T C 4.19E-12 Rheumatoid arthritis / / 17804836 rs1264333 chr6 30844314 T C 6.56E-14 Rheumatoid arthritis / / 19503088 rs1264333 chr6 30844314 T C 4.42E-06 Behcet's disease / / pha002888 rs1264332 chr6 30845563 G C 4.98E-06 Behcet's disease / / pha002888 rs1264331 chr6 30846830 G T 4.47E-06 Behcet's disease / / pha002888 rs7756521 chr6 30848253 T C 1.99E-04 HIV-1 viral setpoint / / 17641165 rs7756521 chr6 30848253 T C 8.03E-07 AIDS progression / / 19115949 rs7756521 chr6 30848253 T C 1.00E-06 HIV-1 control / / 20041166 rs7756521 chr6 30848253 T C 5.70E-05 HIV-1 control / / 21051598 rs7756521 chr6 30848253 T C 5.23E-08 HIV-1 viral setpoint / / 21490045 rs7756521 chr6 30848253 T C 7.70E-04 Systemic lupus erythematosus / / 24871463 rs7756521 chr6 30848253 T C 7.58E-19 Psoriasis / / pha002855 rs9295930 chr6 30849822 G A 1.19E-05 HIV-1 control / / 20041166 rs9295930 chr6 30849822 G A 4.30E-08 HIV-1 control / / 21051598 rs9501032 chr6 30850191 T C 1.18E-05 HIV-1 control DDR1 nearGene-5 20041166 rs9501032 chr6 30850191 T C 4.70E-05 HIV-1 control DDR1 nearGene-5 21051598 rs1264327 chr6 30850582 G A 1.68E-07 Behcet's disease DDR1 nearGene-5 pha002888 rs9461638 chr6 30851305 G C 1.22E-05 HIV-1 control DDR1 nearGene-5 20041166 rs7757648 chr6 30851933 G A 0.00086 Prostate cancer DDR1 intron 23555315 rs1264325 chr6 30851989 G A 0.00003102 Sarcoidosis DDR1 intron 22952805 rs9468842 chr6 30852747 C T 1.81E-05 HIV-1 control DDR1 intron 20041166 rs9468842 chr6 30852747 C T 2.90E-05 HIV-1 control DDR1 intron 21051598 rs3131034 chr6 30853796 G A 3.20E-08 HIV-1 control DDR1 intron 21051598 rs3131034 chr6 30853796 G A 2.08E-08 Chronic hepatitis B infection DDR1 intron 23760081 rs6901464 chr6 30854090 G T 1.22E-05 HIV-1 control DDR1 intron 20041166 rs6901464 chr6 30854090 G T 5.80E-05 HIV-1 control DDR1 intron 21051598 rs4618569 chr6 30855251 G A 1.22E-05 HIV-1 control DDR1 intron 20041166 rs4618569 chr6 30855251 G A 4.10E-05 HIV-1 control DDR1 intron 21051598 rs1264323 chr6 30855907 G A 6.49E-05 HIV-1 control DDR1 intron 20041166 rs2229933 chr6 30857072 G C 1.42E-05 HIV-1 control DDR1 cds-synon 20041166 rs6924600 chr6 30857542 G A 2.13E-09 Multiple complex diseases DDR1 intron 17554300 rs6924600 chr6 30857542 G A 1.22E-05 HIV-1 control DDR1 intron 20041166 rs6924600 chr6 30857542 G A 6.00E-05 HIV-1 control DDR1 intron 21051598 rs6457282 chr6 30857988 T C 2.44E-09 Multiple complex diseases DDR1 intron 17554300 rs6457282 chr6 30857988 T C 3.60E-05 HIV-1 control DDR1 intron 21051598 rs7743661 chr6 30858254 T C 1.15E-05 HIV-1 control DDR1 intron 20041166 rs7743661 chr6 30858254 T C 5.80E-05 HIV-1 control DDR1 intron 21051598 rs1049622 chr6 30858857 C T 6.90E-05 HIV-1 control DDR1 cds-synon 21051598 rs3213644 chr6 30861225 G A 8.38E-06 HIV-1 control DDR1 intron 20041166 rs886422 chr6 30864279 C T 6.40E-06 Pulmonary function DDR1 intron 20010835 rs886422 chr6 30864279 C T 0.00002551 Sarcoidosis DDR1 intron 22952805 rs1049623 chr6 30864829 T C 6.30E-05 HIV-1 control DDR1 cds-synon 20041166 rs2239517 chr6 30865115 G A 1.22E-05 HIV-1 control DDR1 intron 20041166 rs2239517 chr6 30865115 G A 6.30E-05 HIV-1 control DDR1 intron 21051598 rs2239518 chr6 30865725 C T 1.21E-05 HIV-1 control DDR1 intron 20041166 rs2239518 chr6 30865725 C T 9.80E-06 HIV-1 control DDR1 intron 21051598 rs2239518 chr6 30865725 C T 3.45E-12 Psoriasis DDR1 intron pha002855 rs1049628 chr6 30867106 C T 1.22E-05 HIV-1 control DDR1 UTR-3 20041166 rs1049628 chr6 30867106 C T 6.00E-05 HIV-1 control DDR1 UTR-3 21051598 rs1049633 chr6 30867527 G A 6.05E-06 Pulmonary function DDR1 UTR-3 20010835 rs1049633 chr6 30867527 G A 0.00001651 Sarcoidosis DDR1 UTR-3 22952805 rs8408 chr6 30867666 T C 1.22E-05 HIV-1 control DDR1 UTR-3 20041166 rs8408 chr6 30867666 T C 5.60E-05 HIV-1 control DDR1 UTR-3 21051598 rs9468843 chr6 30867958 T C 9.77E-06 HIV-1 control DDR1 nearGene-3 20041166 rs9468843 chr6 30867958 T C 6.90E-08 HIV-1 control DDR1 nearGene-3 21051598 rs9468843 chr6 30867958 T C 9.01E-14 Psoriasis DDR1 nearGene-3 pha002855 rs2894055 chr6 30868628 T C 9.75E-06 HIV-1 control / / 20041166 rs2894055 chr6 30868628 T C 6.40E-05 HIV-1 control / / 21051598 rs9295931 chr6 30869714 C T 6.01E-09 Multiple complex diseases / / 17554300 rs9295931 chr6 30869714 C T 1.22E-05 HIV-1 control / / 20041166 rs9295931 chr6 30869714 C T 6.00E-05 HIV-1 control / / 21051598 rs3869086 chr6 30870168 G T 1.08E-05 HIV-1 control / / 20041166 rs3869086 chr6 30870168 G T 6.20E-05 HIV-1 control / / 21051598 rs9468846 chr6 30870763 T C 1.22E-05 HIV-1 control / / 20041166 rs9468846 chr6 30870763 T C 6.10E-05 HIV-1 control / / 21051598 rs12206075 chr6 30871000 T C 1.22E-05 HIV-1 control / / 20041166 rs12206075 chr6 30871000 T C 1.00E-04 HIV-1 control / / 21051598 rs13215409 chr6 30871619 C A 1.22E-05 HIV-1 control / / 20041166 rs13215409 chr6 30871619 C A 6.00E-05 HIV-1 control / / 21051598 rs3130779 chr6 30872203 A G 1.80E-08 HIV-1 control / / 21051598 rs3130779 chr6 30872203 A G 4.06E-08 Chronic hepatitis B infection / / 23760081 rs2894054 chr6 30872274 G A 4.34E-05 Smoking initiation / / 24665060 rs3909130 chr6 30874165 T C 7.82E-06 HIV-1 control GTF2H4 nearGene-5 20041166 rs3909130 chr6 30874165 T C 5.80E-05 HIV-1 control GTF2H4 nearGene-5 21051598 rs3130780 chr6 30874308 T G 5.22E-08 Chronic hepatitis B infection GTF2H4 nearGene-5 23760081 rs2284175 chr6 30875145 T C 8.56E-06 HIV-1 control GTF2H4 nearGene-5 20041166 rs2284175 chr6 30875145 T C 5.80E-05 HIV-1 control GTF2H4 nearGene-5 21051598 rs2284176 chr6 30875622 T C 9.22E-06 HIV-1 control GTF2H4 nearGene-5 20041166 rs1264309 chr6 30875899 A G 0.00072 Breast cancer GTF2H4 nearGene-5 23555315 rs2074510 chr6 30876034 G T 8.56E-06 HIV-1 control GTF2H4 UTR-5 20041166 rs2074510 chr6 30876034 G T 6.10E-05 HIV-1 control GTF2H4 UTR-5 21051598 rs1052693 chr6 30876152 C T 8.56E-06 HIV-1 control GTF2H4 UTR-5 20041166 rs1052693 chr6 30876152 C T 5.90E-05 HIV-1 control GTF2H4 UTR-5 21051598 rs1052693 chr6 30876152 C T 3.00E-48 Complement C3 and C4 levels GTF2H4 UTR-5 23028341 rs2074508 chr6 30876438 G A 3.27E-09 Multiple complex diseases GTF2H4 intron 17554300 rs2074508 chr6 30876438 G A 5.90E-05 HIV-1 control GTF2H4 intron 21051598 rs916920 chr6 30877202 T C 8.56E-06 HIV-1 control GTF2H4 intron 20041166 rs916920 chr6 30877202 T C 5.80E-05 HIV-1 control GTF2H4 intron 21051598 rs3218815 chr6 30878769 C T 3.18E-09 Multiple complex diseases GTF2H4 intron 17554300 rs3218815 chr6 30878769 C T 8.56E-06 HIV-1 control GTF2H4 intron 20041166 rs3218815 chr6 30878769 C T 5.30E-05 HIV-1 control GTF2H4 intron 21051598 rs2074512 chr6 30878919 T C 1.74E-09 Multiple complex diseases GTF2H4 intron 17554300 rs2074512 chr6 30878919 T C 8.56E-06 HIV-1 control GTF2H4 intron 20041166 rs2074512 chr6 30878919 T C 5.30E-05 HIV-1 control GTF2H4 intron 21051598 rs1264308 chr6 30879987 C T 8.37E-06 Pulmonary function GTF2H4 intron 20010835 rs1264308 chr6 30879987 C T 0.00002551 Sarcoidosis GTF2H4 intron 22952805 rs3218822 chr6 30880336 T C 2.18E-09 Vitiligo GTF2H4 intron 20526339 rs3218822 chr6 30880336 T C 7.71E-04 Smoking quantity GTF2H4 intron 24665060 rs1264303 chr6 30882513 A G 1.74E-09 Multiple complex diseases VARS2 intron 17554300 rs1264303 chr6 30882513 A G 3.12E-12 Rheumatoid arthritis VARS2 intron 17804836 rs1264303 chr6 30882513 A G 1.76E-13 Rheumatoid arthritis VARS2 intron 19503088 rs1264303 chr6 30882513 A G 0.00075 Breast cancer VARS2 intron 23555315 rs1264303 chr6 30882513 A G 7.62E-06 Behcet's disease VARS2 intron pha002888 rs1264302 chr6 30882634 C T 1.15E-10 Rheumatoid arthritis VARS2 cds-synon 17804836 rs1264302 chr6 30882634 C T 5.75E-11 Rheumatoid arthritis VARS2 cds-synon 19503088 rs1264302 chr6 30882634 C T 7.39E-06 Behcet's disease VARS2 cds-synon pha002888 rs6926224 chr6 30882689 C T 8.09E-05 Smoking initiation VARS2 missense 24665060 rs1264301 chr6 30882781 G T 7.62E-06 Behcet's disease VARS2 cds-synon pha002888 rs6926723 chr6 30882803 G A 1.02E-04 Smoking initiation VARS2 missense 24665060 rs1264298 chr6 30884436 A G 7.62E-06 Behcet's disease VARS2 intron pha002888 rs9262288 chr6 30885639 A G 6.65E-06 Behcet's disease VARS2 intron pha002888 rs9262293 chr6 30886350 C G 8.03E-06 Behcet's disease VARS2 intron pha002888 rs7738138 chr6 30887344 T C 9.66E-10 Multiple complex diseases VARS2 intron 17554300 rs7738138 chr6 30887344 T C 0.00072 Breast cancer VARS2 intron 23555315 rs2285319 chr6 30887972 C T 1.50E-04 HIV-1 control VARS2 cds-synon 21051598 rs2517467 chr6 30889260 G A 8.78E-06 Leprosy VARS2 intron pha002872 rs2517467 chr6 30889260 G A 2.25E-05 Behcet's disease VARS2 intron pha002888 rs2074511 chr6 30889389 T C 1.24E-05 HIV-1 control VARS2 cds-synon 20041166 rs2074511 chr6 30889389 T C 1.00E-05 HIV-1 control VARS2 cds-synon 21051598 rs2074506 chr6 30890483 G T 1.68E-12 Rheumatoid arthritis VARS2 missense 17804836 rs2074506 chr6 30890483 G T 2.89E-13 Rheumatoid arthritis VARS2 missense 19503088 rs2074506 chr6 30890483 G T 5.71E-06 Behcet's disease VARS2 missense pha002888 rs753725 chr6 30890871 T C 2.95E-07 Multiple complex diseases VARS2 intron 17554300 rs753725 chr6 30890871 T C 9.11E-11 Rheumatoid arthritis VARS2 intron 17804836 rs753725 chr6 30890871 T C 2.01E-08 Rheumatoid arthritis VARS2 intron 19503088 rs753725 chr6 30890871 T C 9.10E-04 Coronary heart disease VARS2 intron 21971053 rs753725 chr6 30890871 T C 4.98E-05 Lymphocyte counts VARS2 intron 22286170 rs753725 chr6 30890871 T C 4.10E-05 Systemic lupus erythematosus VARS2 intron 24871463 rs753725 chr6 30890871 T C 1.05E-05 Leprosy VARS2 intron pha002872 rs753725 chr6 30890871 T C 2.01E-05 Behcet's disease VARS2 intron pha002888 rs2252760 chr6 30892377 G C 0.00075 Breast cancer VARS2 intron 23555315 rs2532938 chr6 30893831 G A 7.71E-06 Behcet's disease VARS2 intron pha002888 rs4678 chr6 30893941 G A 1.75E-09 Type 1 diabetes VARS2 missense 17632545 rs4678 chr6 30893941 G A 2.55E-06 Lung adenocarcinoma VARS2 missense 19836008 rs4678 chr6 30893941 G A 4.50E-05 Lung cancer VARS2 missense 22899653 rs4678 chr6 30893941 G A 4.60E-68 Myasthenia gravis VARS2 missense 23055271 rs2532934 chr6 30894759 G A 2.69E-10 Rheumatoid arthritis / / 17804836 rs2532934 chr6 30894759 G A 6.92E-09 Rheumatoid arthritis / / 19503088 rs2532934 chr6 30894759 G A 7.10E-05 HIV-1 control / / 20041166 rs2532934 chr6 30894759 G A 3.70E-05 Systemic lupus erythematosus / / 24871463 rs2532934 chr6 30894759 G A 8.78E-06 Leprosy / / pha002872 rs2532934 chr6 30894759 G A 2.37E-05 Behcet's disease / / pha002888 rs3094088 chr6 30894965 T A 0.00001407 Sarcoidosis / / 22952805 rs2532932 chr6 30895444 A G 7.26E-09 Chronic hepatitis B infection / / 23760081 rs4711247 chr6 30895680 C T 1.96E-11 Multiple complex diseases / / 17554300 rs3873332 chr6 30895990 A G 7.45E-12 HIV-1 control / / 20041166 rs3873332 chr6 30895990 A G 9.60E-06 HIV-1 control / / 21051598 rs3873332 chr6 30895990 A G 9.10E-07 HIV-1 viral setpoint / / 21490045 rs3873334 chr6 30896147 G A 2.82E-11 HIV-1 control / / 20041166 rs3873334 chr6 30896147 G A 1.60E-04 HIV-1 control / / 21051598 rs3873334 chr6 30896147 G A 9.20E-07 HIV-1 viral setpoint / / 21490045 rs3873334 chr6 30896147 G A 4.60E-04 Systemic lupus erythematosus / / 24871463 rs3873334 chr6 30896147 G A 6.85E-05 Sodium levels / / pha003093 rs2517459 chr6 30897022 T C 7.84E-05 Rheumatoid arthritis / / 17804836 rs2517459 chr6 30897022 T C 6.65E-06 Rheumatoid arthritis / / 19503088 rs2517459 chr6 30897022 T C 9.80E-05 HIV-1 control / / 20041166 rs2517459 chr6 30897022 T C 3.00E-08 HIV-1 control / / 21051598 rs2517459 chr6 30897022 T C 8.98E-06 Hepatitis B / / 21750111 rs2517459 chr6 30897022 T C 3.28E-08 Chronic hepatitis B infection / / 23760081 rs2532929 chr6 30897774 A G 6.90E-04 Type 2 diabetes / / 23209189 rs2532929 chr6 30897774 A G 0.00081 Breast cancer / / 23555315 rs2532929 chr6 30897774 A G 1.51E-05 Behcet's disease / / pha002888 rs2844652 chr6 30898687 C T 7.62E-06 Behcet's disease SFTA2 nearGene-3 pha002888 rs3095155 chr6 30899051 G C 0.00002779 Sarcoidosis SFTA2 nearGene-3 22952805 rs2532925 chr6 30899163 G A 5.60E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SFTA2 UTR-3 20031582 rs2286656 chr6 30899571 C T 1.38E-05 HIV-1 control SFTA2 cds-synon 20041166 rs2286656 chr6 30899571 C T 5.30E-06 HIV-1 control SFTA2 cds-synon 21051598 rs3095152 chr6 30899650 G A 0.00007672 Sarcoidosis SFTA2 intron 22952805 rs2286655 chr6 30899746 G A 1.21E-05 HIV-1 control SFTA2 intron 20041166 rs2286655 chr6 30899746 G A 1.40E-05 HIV-1 control SFTA2 intron 21051598 rs2253705 chr6 30900094 T C 3.13E-08 Chronic hepatitis B infection SFTA2 nearGene-5 23760081 rs2844651 chr6 30900664 T C 6.24E-04 Coronary heart disease SFTA2 nearGene-5 21971053 rs3131785 chr6 30901895 C G 2.96E-05 Multiple complex diseases SFTA2 nearGene-5 17554300 rs10947114 chr6 30902181 C T 8.80E-06 HIV-1 control / / 21051598 rs3131784 chr6 30903948 C T 3.32E-05 Multiple complex diseases / / 17554300 rs12697941 chr6 30904714 G A 8.34E-12 HIV-1 control / / 20041166 rs12697941 chr6 30904714 G A 5.20E-06 HIV-1 control / / 21051598 rs12697941 chr6 30904714 G A 1.97E-06 HIV-1 viral setpoint / / 21490045 rs3132571 chr6 30905313 A G 2.33E-11 Type 1 diabetes / / 17632545 rs3132571 chr6 30905313 A G 7.12E-07 Rheumatoid arthritis / / 19503088 rs3132571 chr6 30905313 A G 1.25E-06 Coronary heart disease / / 21971053 rs3132571 chr6 30905313 A G 3.80E-05 Systemic lupus erythematosus / / 24871463 rs6933400 chr6 30907176 C T 5.33E-05 Rheumatoid arthritis DPCR1 nearGene-5 19503088 rs6933400 chr6 30907176 C T 7.16E-07 Coronary heart disease DPCR1 nearGene-5 21971053 rs3131921 chr6 30907335 T C 4.80E-04 Alcohol dependence DPCR1 nearGene-5 20201924 rs3131921 chr6 30907335 T C 0.0000738 Sarcoidosis DPCR1 nearGene-5 22952805 rs4711249 chr6 30908266 G A 6.39E-06 HIV-1 control DPCR1 nearGene-5 20041166 rs4711249 chr6 30908266 G A 1.20E-05 HIV-1 control DPCR1 nearGene-5 21051598 rs9501035 chr6 30912414 G A 6.39E-06 HIV-1 control DPCR1 intron 20041166 rs9501035 chr6 30912414 G A 1.20E-05 HIV-1 control DPCR1 intron 21051598 rs3132581 chr6 30913458 G A 7.00E-41 Multiple complex diseases DPCR1 intron 17554300 rs3132581 chr6 30913458 G A 0.00004672 Sarcoidosis DPCR1 intron 22952805 rs3132581 chr6 30913458 G A 2.00E-07 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) DPCR1 intron 23453885 rs2517451 chr6 30914751 C T 1.85E-06 Multiple sclerosis DPCR1 intron 20598377 rs3130782 chr6 30914843 C T 0.00001075 Sarcoidosis DPCR1 intron 22952805 rs3130782 chr6 30914843 C T 5.00E-05 Smoking initiation DPCR1 intron 24665060 rs3094086 chr6 30919391 G A 6.80E-04 Alcohol dependence DPCR1 cds-synon 20201924 rs3094086 chr6 30919391 G A 0.00004767 Sarcoidosis DPCR1 cds-synon 22952805 rs3132580 chr6 30920124 G A 1.87E-12 Type 1 diabetes DPCR1 missense 17632545 rs3132580 chr6 30920124 G A 4.00E-08 Lung adenocarcinoma DPCR1 missense 19836008 rs3132580 chr6 30920124 G A 6.10E-04 Alcohol dependence DPCR1 missense 20201924 rs3132580 chr6 30920124 G A 5.43E-09 Vitiligo DPCR1 missense 20526339 rs3132580 chr6 30920124 G A 5.40E-06 Alopecia areata DPCR1 missense 22027810 rs3132580 chr6 30920124 G A 1.40E-10 Lung cancer DPCR1 missense 22899653 rs3132580 chr6 30920124 G A 0.00004767 Sarcoidosis DPCR1 missense 22952805 rs3132580 chr6 30920124 G A 1.90E-70 Myasthenia gravis DPCR1 missense 23055271 rs3132580 chr6 30920124 G A 3.60E-12 Systemic lupus erythematosus DPCR1 missense 24871463 rs3132580 chr6 30920124 G A 1.66E-05 Systemic lupus erythematosus DPCR1 missense pha002867 rs2240804 chr6 30920890 G A 4.87E-12 Rheumatoid arthritis DPCR1 missense 17804836 rs2240804 chr6 30920890 G A 9.35E-15 Rheumatoid arthritis DPCR1 missense 19503088 rs2240804 chr6 30920890 G A 2.09E-07 Behcet's disease DPCR1 missense pha002888 rs2240803 chr6 30920957 G A 1.37E-05 HIV-1 control DPCR1 UTR-3 20041166 rs2240803 chr6 30920957 G A 8.19E-13 Psoriasis DPCR1 UTR-3 pha002855 rs12190030 chr6 30921364 C T 1.33E-06 HIV-1 control DPCR1 UTR-3 20041166 rs12190030 chr6 30921364 C T 2.00E-10 HIV-1 control DPCR1 UTR-3 21051598 rs3757340 chr6 30921882 T C 6.33E-06 Multiple complex diseases DPCR1 UTR-3 17554300 rs3757340 chr6 30921882 T C 1.10E-08 Rheumatoid arthritis DPCR1 UTR-3 19503088 rs3757340 chr6 30921882 T C 5.00E-04 Systemic lupus erythematosus DPCR1 UTR-3 24871463 rs3757340 chr6 30921882 T C 4.63E-05 Sodium levels DPCR1 UTR-3 pha003093 rs2532921 chr6 30922570 C G 3.26E-10 Multiple complex diseases / / 17554300 rs11753326 chr6 30925985 T C 4.47E-06 Rheumatoid arthritis / / 19503088 rs11753326 chr6 30925985 T C 1.52E-04 Smoking initiation / / 24665060 rs199700573 chr6 30926517 CG C 0.00001311 Sarcoidosis / / 22952805 rs3095156 chr6 30926517 C T 0.00001311 Sarcoidosis / / 22952805 rs3131934 chr6 30931844 T C 0.000004943 Sarcoidosis / / 22952805 rs2844697 chr6 30932309 C T 1.00E-16 Type 1 diabetes / / 17632545 rs2844697 chr6 30932309 C T 2.69E-06 Coronary heart disease / / 21971053 rs2844697 chr6 30932309 C T 1.70E-06 Systemic lupus erythematosus / / 24871463 rs2844697 chr6 30932309 C T 6.16E-08 Behcet's disease / / pha002888 rs2532924 chr6 30932682 T C 1.76E-04 Amyotrophic lateral sclerosis / / 20801718 rs3095089 chr6 30933794 G T 4.56E-09 Type 1 diabetes / / 17632545 rs3095089 chr6 30933794 G T 1.59E-05 Rheumatoid arthritis / / 17804836 rs3095089 chr6 30933794 G T 1.42E-05 Lung adenocarcinoma / / 19836008 rs3095089 chr6 30933794 G T 1.80E-79 Myasthenia gravis / / 23055271 rs3095089 chr6 30933794 G T 4.80E-11 Systemic lupus erythematosus / / 24871463 rs3095089 chr6 30933794 G T 2.09E-05 Systemic lupus erythematosus / / pha002867 rs3095089 chr6 30933794 G T 1.03E-05 Behcet's disease / / pha002888 rs2532919 chr6 30933975 A C 3.87E-10 Rheumatoid arthritis / / 19503088 rs2532919 chr6 30933975 A C 1.21E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs3131781 chr6 30937732 A G 0.00001897 Sarcoidosis / / 22952805 rs554543329 chr6 30938883 A G 5.50E-05 Schizophrenia / / 19571809 rs554543329 chr6 30938883 A G 4.85E-05 Bipolar disorder and schizophrenia / / 20889312 rs554543329 chr6 30938883 A G 5.40E-12 HIV-1 control / / 21051598 rs554543329 chr6 30938883 A G 1.00E-07 Pulmonary function (interaction) / / 23284291 rs554543329 chr6 30938883 A G 1.00E-07 Pulmonary function (interaction) / / 23284291 rs9368649 chr6 30938883 A G 5.50E-05 Schizophrenia / / 19571809 rs9368649 chr6 30938883 A G 4.85E-05 Bipolar disorder and schizophrenia / / 20889312 rs9368649 chr6 30938883 A G 5.40E-12 HIV-1 control / / 21051598 rs9368649 chr6 30938883 A G 1.00E-07 Pulmonary function (interaction) / / 23284291 rs9368649 chr6 30938883 A G 1.00E-07 Pulmonary function (interaction) / / 23284291 rs2844690 chr6 30940032 C T 5.12E-05 Orofacial clefts / / 22419666 rs2530710 chr6 30940387 T C 1.03E-11 Multiple complex diseases / / 17554300 rs2530710 chr6 30940387 T C 3.01E-11 Multiple sclerosis / / 17660530 rs2530709 chr6 30940569 G C 1.75E-04 Multiple complex diseases / / 17554300 rs2530709 chr6 30940569 G C 7.87E-07 Multiple sclerosis / / 17660530 rs2517446 chr6 30940945 A G 1.67E-04 Multiple complex diseases / / 17554300 rs2530705 chr6 30944982 T C 2.23E-04 Multiple complex diseases / / 17554300 rs2844682 chr6 30946148 G A 1 Drug response to Carbamazepine / / 10392983 rs2844682 chr6 30946148 G A 1 Drug response to Carbamazepine / / 15057820 rs2844682 chr6 30946148 G A 1 Drug response to Phenytoin / / 15057820 rs2844682 chr6 30946148 G A 1 Drug response to Carbamazepine / / 16415921 rs2844682 chr6 30946148 G A 1 Drug response to Phenytoin / / 16415921 rs2844682 chr6 30946148 G A 1 Drug response to Carbamazepine / / 16538176 rs2844682 chr6 30946148 G A 1 Drug response to Phenytoin / / 16538176 rs2844682 chr6 30946148 G A 1 Drug response to Carbamazepine / / 16981842 rs2844682 chr6 30946148 G A 1 Drug response to Carbamazepine / / 16998491 rs2844682 chr6 30946148 G A 1 Drug response to Phenytoin / / 16998491 rs2844682 chr6 30946148 G A 1 Drug response to Carbamazepine / / 18370849 rs2844682 chr6 30946148 G A 1 Drug response to Phenytoin / / 18370849 rs2844682 chr6 30946148 G A 1 Drug response to Carbamazepine / / 18637831 rs2844682 chr6 30946148 G A 1 Drug response to Phenytoin / / 18637831 rs2844682 chr6 30946148 G A 1 Drug response to Carbamazepine / / 7477195 rs2844682 chr6 30946148 G A 1 Drug response to Carbamazepine / / 8781718 rs2844682 chr6 30946148 G A 1 Drug response to Carbamazepine / / 9679693 rs2844680 chr6 30946496 T G 6.72E-06 Rheumatoid arthritis / / 19503088 rs2844680 chr6 30946496 T G 7.00E-05 HIV-1 control / / 20041166 rs2844680 chr6 30946496 T G 6.06E-07 Behcet's disease / / pha002888 rs9394023 chr6 30947042 C A 2.71E-05 HIV-1 control / / 20041166 rs2844678 chr6 30950050 G A 8.16E-05 Multiple complex diseases MUC21 nearGene-5 17554300 rs2844678 chr6 30950050 G A 4.39E-05 Multiple sclerosis MUC21 nearGene-5 17660530 rs2523929 chr6 30950306 G A 5.59E-05 Multiple complex diseases MUC21 nearGene-5 17554300 rs9295938 chr6 30953105 G A 5.60E-05 HIV-1 control MUC21 intron 20041166 rs9295938 chr6 30953105 G A 1.90E-08 HIV-1 control MUC21 intron 21051598 rs9295938 chr6 30953105 G A 3.95E-04 Schizophrenia MUC21 intron 21926974 rs9295938 chr6 30953105 G A 9.16E-18 Psoriasis MUC21 intron pha002855 rs2530699 chr6 30953240 A T 8.53E-05 Multiple complex diseases MUC21 intron 17554300 rs1634731 chr6 30955681 G A 6.54E-10 Type 1 diabetes MUC21 intron 17632545 rs1634731 chr6 30955681 G A 4.41E-05 Rheumatoid arthritis MUC21 intron 17804836 rs1634731 chr6 30955681 G A 6.05E-05 Multiple sclerosis MUC21 intron 20598377 rs1634731 chr6 30955681 G A 2.45E-05 Crohn's disease MUC21 intron 23266558 rs886403 chr6 30957618 T C 4.60E-60 Myasthenia gravis MUC21 UTR-3 23055271 rs886403 chr6 30957618 T C 1.00E-06 Systemic lupus erythematosus MUC21 UTR-3 24871463 rs886403 chr6 30957618 T C 5.60E-07 Systemic lupus erythematosus MUC21 UTR-3 pha002867 rs3873342 chr6 30957766 T C 6.07E-04 Type 2 diabetes MUC21 nearGene-3 17463246 rs2517411 chr6 30960267 T C 1.47E-04 Multiple complex diseases / / 17554300 rs2517411 chr6 30960267 T C 0.000000825 Behcet's disease / / 23041938 rs2844673 chr6 30961926 C T 1.41E-04 Multiple complex diseases / / 17554300 rs2844673 chr6 30961926 C T 6.13E-10 Rheumatoid arthritis / / 19503088 rs2844673 chr6 30961926 C T 3.24E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2252925 chr6 30966282 A G 2.13E-04 Multiple complex diseases / / 17554300 rs2252926 chr6 30966304 A G 1.24E-04 Multiple complex diseases / / 17554300 rs2252926 chr6 30966304 A G 8.38E-10 Rheumatoid arthritis / / 19503088 rs2252926 chr6 30966304 A G 4.36E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2530690 chr6 30967202 G A 1.16E-04 Multiple complex diseases / / 17554300 rs1634716 chr6 30969754 G A 0.00002357 Sarcoidosis / / 22952805 rs2844668 chr6 30972121 T A 9.65E-05 Schizophrenia (cytomegalovirus infection interaction) MUC22 nearGene-5 23358160 rs436376 chr6 30972390 G T 1.12E-04 Multiple complex diseases MUC22 nearGene-5 17554300 rs2256514 chr6 30972471 G A 3.18E-04 Multiple complex diseases MUC22 nearGene-5 17554300 rs1634717 chr6 30972589 G T 5.52E-07 Multiple complex diseases MUC22 nearGene-5 17554300 rs1634717 chr6 30972589 G T 1.15E-06 Rheumatoid arthritis MUC22 nearGene-5 17804836 rs1634717 chr6 30972589 G T 1.26E-13 Rheumatoid arthritis MUC22 nearGene-5 19503088 rs1634717 chr6 30972589 G T 1.00E-05 Systemic lupus erythematosus MUC22 nearGene-5 24871463 rs1634718 chr6 30972865 A G 3.00E-05 Multiple complex diseases MUC22 nearGene-5 17554300 rs1634718 chr6 30972865 A G 8.20E-61 Myasthenia gravis MUC22 nearGene-5 23055271 rs1634718 chr6 30972865 A G 6.10E-08 Systemic lupus erythematosus MUC22 nearGene-5 24871463 rs1634718 chr6 30972865 A G 2.64E-08 Systemic lupus erythematosus MUC22 nearGene-5 pha002867 rs2523915 chr6 30973358 T A 2.68E-04 Multiple complex diseases MUC22 nearGene-5 17554300 rs1632854 chr6 30975649 T A 7.39E-07 Multiple complex diseases MUC22 intron 17554300 rs28360974 chr6 30976219 G A 3.00E-06 Preeclampsia MUC22 intron 23551011 rs1634721 chr6 30977680 G A 0.0000337 Sarcoidosis MUC22 intron 22952805 rs13191258 chr6 30978717 C T 3.95E-33 Psoriasis MUC22 intron pha002855 rs9366764 chr6 30979793 G A 8.10E-18 Psoriasis MUC22 intron pha002855 rs7755802 chr6 30982209 A G 1.40E-06 Bipolar disorder MUC22 intron 21738484 rs9394026 chr6 30982544 G A 4.90E-06 Major depressive disorder MUC22 intron 21042317 rs9394026 chr6 30982544 G A 2.20E-05 HIV-1 control MUC22 intron 21051598 rs9391701 chr6 30983263 G A 1.37E-08 HIV-1 control MUC22 intron 20041166 rs9391701 chr6 30983263 G A 1.10E-12 HIV-1 control MUC22 intron 21051598 rs1619376 chr6 30983326 A G 8.48E-10 Rheumatoid arthritis MUC22 intron 19503088 rs1619376 chr6 30983326 A G 6.42E-05 Schizophrenia (cytomegalovirus infection interaction) MUC22 intron 23358160 rs3871466 chr6 30983683 T C 7.12E-05 Rheumatoid arthritis MUC22 intron 17804836 rs3871466 chr6 30983683 T C 4.90E-07 Rheumatoid arthritis MUC22 intron 19503088 rs3871466 chr6 30983683 T C 4.71E-09 HIV-1 control MUC22 intron 20041166 rs3871466 chr6 30983683 T C 4.60E-13 HIV-1 control MUC22 intron 21051598 rs3871466 chr6 30983683 T C 4.36E-06 HIV-1 viral setpoint MUC22 intron 21490045 rs3871466 chr6 30983683 T C 8.80E-05 Systemic lupus erythematosus MUC22 intron 24871463 rs3871466 chr6 30983683 T C 7.90E-17 Psoriasis MUC22 intron pha002855 rs3871466 chr6 30983683 T C 3.74E-05 Systemic lupus erythematosus MUC22 intron pha002867 rs3869096 chr6 30984404 T G 1.10E-12 HIV-1 control MUC22 intron 21051598 rs1634726 chr6 30985828 G A 0.00004087 Sarcoidosis MUC22 intron 22952805 rs9262492 chr6 30986015 A G 2.99E-11 Psoriasis MUC22 intron pha002855 rs2894176 chr6 30986038 G C 9.71E-12 Psoriasis MUC22 intron pha002855 rs9262494 chr6 30986504 C T 5.57E-05 Multiple complex diseases MUC22 intron 17554300 rs9262495 chr6 30986527 T C 5.10E-05 Multiple complex diseases MUC22 intron 17554300 rs9262495 chr6 30986527 T C 2.85E-11 Rheumatoid arthritis MUC22 intron 19503088 rs9262499 chr6 30987098 G T 5.96E-07 Urate levels MUC22 intron 23263486 rs4713411 chr6 30987176 C A 8.50E-05 Systemic lupus erythematosus MUC22 intron 24871463 rs4713412 chr6 30987211 A G 1.60E-04 Systemic lupus erythematosus MUC22 intron 24871463 rs7758976 chr6 30987786 A G 1.20E-05 Systemic lupus erythematosus MUC22 intron 24871463 rs6903912 chr6 30991559 G A 3.73E-05 Multiple sclerosis MUC22 intron 20598377 rs9394031 chr6 30991643 T C 8.25E-18 Psoriasis MUC22 intron pha002855 rs9262546 chr6 30993128 G A 1.42E-04 Multiple complex diseases MUC22 intron 17554300 rs4713419 chr6 30993236 A G 5.63E-05 Schizophrenia MUC22 intron 19571809 rs4713419 chr6 30993236 A G 2.10E-17 HIV-1 control MUC22 intron 21051598 rs2523898 chr6 30993533 A G 6.03E-04 IgE levels MUC22 missense 17255346 rs2523898 chr6 30993533 A G 4.00E-05 Systemic lupus erythematosus MUC22 missense 24871463 rs12179536 chr6 30993590 A G 3.69E-05 Rheumatoid arthritis MUC22 missense 19503088 rs12179536 chr6 30993590 A G 6.00E-05 Major depressive disorder MUC22 missense 21042317 rs12179536 chr6 30993590 A G 1.92E-06 Triglycerides MUC22 missense pha002904 rs2523897 chr6 30993958 A G 6.80E-06 Rheumatoid arthritis MUC22 cds-synon 17804836 rs2523897 chr6 30993958 A G 3.09E-04 Insulin resistance MUC22 cds-synon 21901158 rs564732150 chr6 30996132 C T 7.25E-07 Systemic sclerosis MUC22 missense 20383147 rs9262549 chr6 30997692 G C 0.00004878 Sarcoidosis MUC22 missense 22952805 rs17190071 chr6 30999703 G A 1.55E-05 Behcet's disease MUC22 intron pha002888 rs13210132 chr6 31001143 A G 5.35E-06 HIV-1 viral setpoint MUC22 intron 17641165 rs13210132 chr6 31001143 A G 1.99E-16 HIV-1 control MUC22 intron 20041166 rs13210132 chr6 31001143 A G 3.80E-20 HIV-1 control MUC22 intron 21051598 rs13210132 chr6 31001143 A G 3.90E-08 HIV-1 viral setpoint MUC22 intron 21490045 rs6933349 chr6 31002013 G A 3.65E-07 Rheumatoid arthritis MUC22 intron 17804836 rs6933349 chr6 31002013 G A 6.50E-07 Rheumatoid arthritis MUC22 intron 19503088 rs4248154 chr6 31002616 C T 4.16E-09 Rheumatoid arthritis MUC22 cds-synon 17804836 rs4248154 chr6 31002616 C T 2.93E-11 Rheumatoid arthritis MUC22 cds-synon 19503088 rs4248154 chr6 31002616 C T 1.00E-13 Graves' disease MUC22 cds-synon 21900946 rs4248154 chr6 31002616 C T 2.52E-04 Coronary heart disease MUC22 cds-synon 21971053 rs28732082 chr6 31004521 G A 1.50E-14 HIV-1 control / / 21051598 rs11753208 chr6 31005432 C T 1.40E-10 HIV-1 control / / 21051598 rs2844670 chr6 31005726 G A 1.04E-10 Multiple complex diseases / / 17554300 rs2844670 chr6 31005726 G A 1.61E-05 Multiple sclerosis / / 20598377 rs2844670 chr6 31005726 G A 8.48E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs2844665 chr6 31006855 T C 3.00E-07 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) / / 21801394 rs2844665 chr6 31006855 T C 5.00E-07 Hypothyroidism / / 22493691 rs4711253 chr6 31007081 C A 0.000593 Salmonella-induced pyroptosis / / 22837397 rs12201301 chr6 31007557 G A 4.96E-05 Alzheimer's disease / / 19734903 rs12201301 chr6 31007557 G A 2.71E-09 Vitiligo / / 20526339 rs2517552 chr6 31007590 C T 1.80E-06 Hypothyroidism / / 22493691 rs2517552 chr6 31007590 C T 8.16E-12 Psoriasis / / pha002855 rs9262560 chr6 31008626 C T 1.98E-09 Coronary heart disease / / 21971053 rs2517546 chr6 31009055 C T 0.0000185 Sarcoidosis / / 22952805 rs2517544 chr6 31009508 C G 9.27E-05 Self-reported allergy / / 23817569 rs2508015 chr6 31010200 G A 2.78E-13 Type 1 diabetes / / 17632545 rs2508015 chr6 31010200 G A 1.53E-09 Coronary heart disease / / 21971053 rs2508015 chr6 31010200 G A 3.09E-06 Behcet's disease / / pha002888 rs2523877 chr6 31010683 C T 0.0002547 Sarcoidosis / / 22952805 rs2844647 chr6 31011013 G A 0.0002416 Sarcoidosis / / 22952805 rs2248386 chr6 31011247 C T 0.0003041 Sarcoidosis / / 22952805 rs2517540 chr6 31011892 T A 0.0002547 Sarcoidosis / / 22952805 rs7756294 chr6 31012356 G A 5.00E-09 HIV-1 control / / 21051598 rs2844646 chr6 31012466 G A 0.0002547 Sarcoidosis / / 22952805 rs3131927 chr6 31012996 T C 6.10E-05 Hypothyroidism / / 22493691 rs3131926 chr6 31013085 C T 0.0002881 Sarcoidosis / / 22952805 rs2517538 chr6 31013541 C G 2.31E-09 Multiple complex diseases / / 17554300 rs2517538 chr6 31013541 C G 1.80E-06 Multiple sclerosis / / 17660530 rs2517538 chr6 31013541 C G 2.60E-05 Height / / 19396169 rs2517538 chr6 31013541 C G 2.07E-21 Lymphocyte counts / / 22286170 rs2523870 chr6 31014116 C T 2.73E-12 Psoriasis / / pha002855 rs2844645 chr6 31015182 G A 7.29E-19 Psoriasis / / pha002855 rs3130574 chr6 31016550 A G 0.000005347 Sarcoidosis / / 22952805 rs2251830 chr6 31016978 C A 2.52E-06 Behcet's disease / / pha002888 rs2517534 chr6 31017334 A G 1.70E-06 Hypothyroidism / / 22493691 rs2517532 chr6 31018407 A G 1.33E-10 Type 1 diabetes / / 17632545 rs2517532 chr6 31018407 A G 1.00E-08 Hypothyroidism / / 22493691 rs2523865 chr6 31018448 A C 6.71E-11 Multiple complex diseases / / 17554300 rs2523864 chr6 31018546 C T 2.54E-14 Type 1 diabetes / / 17632545 rs2523864 chr6 31018546 C T 8.51E-04 Coronary heart disease / / 21971053 rs2523864 chr6 31018546 C T 1.96E-06 Behcet's disease / / pha002888 rs3131920 chr6 31018908 T G 0.000005757 Sarcoidosis / / 22952805 rs9262602 chr6 31020271 A G 3.83E-04 Self-reported allergy HCG22 nearGene-5 23817569 rs4713429 chr6 31021017 C G 9.74E-05 Multiple complex diseases HCG22 nearGene-5 17554300 rs4713429 chr6 31021017 C G 6.71E-07 Multiple sclerosis HCG22 nearGene-5 17660530 rs4713429 chr6 31021017 C G 0.00004107 Sarcoidosis HCG22 nearGene-5 22952805 rs4713429 chr6 31021017 C G 3.31E-07 Dilated cardiomyopathy HCG22 nearGene-5 23853074 rs9262615 chr6 31021161 C G 2.01E-07 Multiple complex diseases HCG22 nearGene-5 17554300 rs9262615 chr6 31021161 C G 2.83E-07 Multiple sclerosis HCG22 nearGene-5 17660530 rs9262615 chr6 31021161 C G 0.00005349 Sarcoidosis HCG22 nearGene-5 22952805 rs9262615 chr6 31021161 C G 4.49E-08 Dilated cardiomyopathy HCG22 nearGene-5 23853074 rs2517527 chr6 31021547 A G 9.50E-06 Hypothyroidism HCG22 nearGene-5 22493691 rs2517527 chr6 31021547 A G 1.83E-11 Psoriasis HCG22 nearGene-5 pha002855 rs17190134 chr6 31021860 C G 8.04E-09 Vitiligo HCG22 nearGene-5 20526339 rs2523855 chr6 31022158 G C 0.000001323 Sarcoidosis / / 22952805 rs3915966 chr6 31022274 C T 0.00001553 Sarcoidosis / / 22952805 rs2905757 chr6 31022828 C T 0.00001061 Sarcoidosis / / 22952805 rs9262626 chr6 31023024 T C 0.00009848 Sarcoidosis / / 22952805 rs7744253 chr6 31023524 T C 8.40E-04 Systemic lupus erythematosus / / 24871463 rs16898614 chr6 31023840 A G 7.30E-09 HIV-1 control / / 21051598 rs3764808 chr6 31024673 T C 1.30E-05 Hypothyroidism / / 22493691 rs2523851 chr6 31024712 C T 1.88E-04 Obesity (extreme) / / 21935397 rs2523850 chr6 31024748 C T 3.54E-04 Obesity (extreme) / / 21935397 rs3131788 chr6 31024796 G A 0.00001665 Sarcoidosis / / 22952805 rs9262632 chr6 31024808 A G 1.00E-08 HIV-1 control / / 21051598 rs2523849 chr6 31025051 T C 3.18E-07 Rheumatoid arthritis / / 17804836 rs2523849 chr6 31025051 T C 1.98E-10 Rheumatoid arthritis / / 19503088 rs2523849 chr6 31025051 T C 6.99E-05 HIV-1 control / / 20041166 rs2523849 chr6 31025051 T C 0.0000753 Gains in maximal O2 uptake response / / 21183627 rs2523849 chr6 31025051 T C 2.76E-04 Obesity (extreme) / / 21935397 rs2523848 chr6 31025104 G A 0.0000753 Gains in maximal O2 uptake response / / 21183627 rs2523848 chr6 31025104 G A 2.76E-04 Obesity (extreme) / / 21935397 rs9262635 chr6 31025479 A G 7.97E-07 Multiple sclerosis / / 17660530 rs9262635 chr6 31025479 A G 6.44E-09 Dilated cardiomyopathy / / 23853074 rs2517524 chr6 31025713 C A 6.97E-10 Multiple complex diseases / / 17554300 rs9262636 chr6 31025848 A G 9.11E-07 Multiple sclerosis / / 17660530 rs9262636 chr6 31025848 A G 4.90E-09 Dilated cardiomyopathy / / 23853074 rs9262638 chr6 31025989 C T 2.36E-05 Cognitive test performance / / 20125193 rs9262638 chr6 31025989 C T 5.77E-05 Coronary heart disease / / 21971053 rs9262638 chr6 31025989 C T 2.40E-07 Hypothyroidism / / 22493691 rs9262639 chr6 31026009 C T 2.94E-05 Cognitive test performance / / 20125193 rs9262639 chr6 31026009 C T 2.43E-05 Coronary heart disease / / 21971053 rs9262639 chr6 31026009 C T 2.10E-07 Hypothyroidism / / 22493691 rs2517523 chr6 31026434 A G 7.40E-06 Hypothyroidism / / 22493691 rs2523845 chr6 31027393 A C 1.95E-04 Obesity (extreme) / / 21935397 rs2428514 chr6 31027516 G A 1.59E-06 Rheumatoid arthritis / / 17804836 rs2428514 chr6 31027516 G A 2.56E-07 Rheumatoid arthritis / / 19503088 rs2428514 chr6 31027516 G A 4.72E-04 Obesity (extreme) / / 21935397 rs2517518 chr6 31028345 C T 0.0000753 Gains in maximal O2 uptake response / / 21183627 rs2517516 chr6 31028920 T C 8.50E-06 Hypothyroidism / / 22493691 rs9262648 chr6 31029173 C A 4.11E-05 Behcet's disease / / pha002888 rs9262651 chr6 31029455 C T 7.50E-05 Behcet's disease / / pha002888 rs2517512 chr6 31029685 C T 4.72E-04 Obesity (extreme) / / 21935397 rs2517511 chr6 31029918 A C 6.90E-06 Hypothyroidism / / 22493691 rs2517510 chr6 31030122 T G 2.88E-04 Multiple complex diseases / / 17554300 rs2517510 chr6 31030122 T G 4.00E-13 White blood cell count / / 21738480 rs2517510 chr6 31030122 T G 8.20E-06 Hypothyroidism / / 22493691 rs2523841 chr6 31030283 G A 5.76E-07 Multiple complex diseases / / 17554300 rs2523841 chr6 31030283 G A 1.95E-04 Obesity (extreme) / / 21935397 rs2523840 chr6 31030425 G A 1.05E-06 Multiple complex diseases / / 17554300 rs2523840 chr6 31030425 G A 0.0000753 Gains in maximal O2 uptake response / / 21183627 rs2523840 chr6 31030425 G A 1.95E-04 Obesity (extreme) / / 21935397 rs2256436 chr6 31031381 A G 9.10E-06 Hypothyroidism / / 22493691 rs2394423 chr6 31032042 G A 4.84E-05 Behcet's disease / / pha002888 rs2517504 chr6 31032370 T G 8.10E-06 Hypothyroidism / / 22493691 rs2517502 chr6 31032937 C T 8.00E-06 Hypothyroidism / / 22493691 rs2517500 chr6 31033509 C T 7.30E-06 Hypothyroidism / / 22493691 rs9262656 chr6 31034264 A G 4.80E-05 Behcet's disease / / pha002888 rs2517497 chr6 31036783 A G 8.20E-06 Hypothyroidism / / 22493691 rs2523891 chr6 31038976 C T 9.50E-06 Hypothyroidism / / 22493691 rs9263450 chr6 31039428 C T 0.00005922 Sarcoidosis / / 22952805 rs12175179 chr6 31040264 C T 3.72E-04 Self-reported allergy / / 23817569 rs2523884 chr6 31041155 C T 6.50E-06 Hypothyroidism / / 22493691 rs2246330 chr6 31041493 G A 3.32E-04 Multiple complex diseases / / 17554300 rs2523883 chr6 31042070 C T 3.69E-04 Multiple complex diseases / / 17554300 rs2523883 chr6 31042070 C T 2.58E-06 Dilated cardiomyopathy / / 23853074 rs2523882 chr6 31042217 C T 7.58E-04 Self-reported allergy / / 23817569 rs2517489 chr6 31042306 G A 4.87E-04 Multiple complex diseases / / 17554300 rs2517489 chr6 31042306 G A 6.80E-06 Hypothyroidism / / 22493691 rs2523881 chr6 31042608 T G 2.39E-04 Multiple complex diseases / / 17554300 rs2523881 chr6 31042608 T G 9.87E-05 Multiple sclerosis / / 17660530 rs2523881 chr6 31042608 T G 8.62E-08 Narcolepsy / / 19629137 rs2523881 chr6 31042608 T G 6.90E-06 Hypothyroidism / / 22493691 rs2523880 chr6 31042769 C G 3.10E-04 Multiple complex diseases / / 17554300 rs2523880 chr6 31042769 C G 9.08E-05 Multiple sclerosis / / 17660530 rs2249231 chr6 31043232 G A 1.00E-05 Hypothyroidism / / 22493691 rs3094671 chr6 31044463 T C 0.00001931 Sarcoidosis / / 22952805 rs2905759 chr6 31044468 C T 8.80E-06 Hypothyroidism / / 22493691 rs2517478 chr6 31044802 G T 8.30E-06 Hypothyroidism / / 22493691 rs2517477 chr6 31044863 G A 7.50E-06 Hypothyroidism / / 22493691 rs9378152 chr6 31045554 C G 0.0000492 post-traumatic stress disorder / / 22869035 rs9378152 chr6 31045554 C G 4.92E-05 Schizophrenia / / 22883433 rs2523843 chr6 31046528 A G 7.60E-06 Hypothyroidism / / 22493691 rs2523836 chr6 31047145 C T 8.30E-06 Hypothyroidism / / 22493691 rs2523895 chr6 31047471 A C 1.30E-05 Hypothyroidism / / 22493691 rs3132564 chr6 31047620 G A 2.73E-05 Relative hand skill / / 24068947 rs2106067 chr6 31048263 T C 6.20E-06 Hypothyroidism / / 22493691 rs2249876 chr6 31048387 G A 4.30E-07 Hypothyroidism / / 22493691 rs6941772 chr6 31048916 C G 1.00E-05 Hypothyroidism / / 22493691 rs9380215 chr6 31049655 G A 0.0000374 post-traumatic stress disorder / / 22869035 rs9380215 chr6 31049655 G A 3.74E-05 Schizophrenia / / 22883433 rs9380215 chr6 31049655 G A 1.71E-04 Smoking quantity / / 24665060 rs9380215 chr6 31049655 G A 6.13E-23 Behcet's disease / / pha002888 rs9263473 chr6 31050179 A G 9.50E-06 Hypothyroidism / / 22493691 rs9263474 chr6 31050244 A C 9.20E-06 Hypothyroidism / / 22493691 rs2535318 chr6 31051388 C T 3.27E-04 Multiple complex diseases / / 17554300 rs2535318 chr6 31051388 C T 1.00E-05 Hypothyroidism / / 22493691 rs9380217 chr6 31051553 C T 1.98E-11 Behcet's disease / / 23001997 rs3095311 chr6 31051675 A G 0.000009266 Sarcoidosis / / 22952805 rs2517471 chr6 31052098 C G 4.42E-04 Multiple complex diseases / / 17554300 rs2517471 chr6 31052098 C G 1.20E-05 Hypothyroidism / / 22493691 rs2535315 chr6 31052127 C T 4.28E-04 Multiple complex diseases / / 17554300 rs2535315 chr6 31052127 C T 2.70E-07 Hypothyroidism / / 22493691 rs2535315 chr6 31052127 C T 6.10E-04 Systemic lupus erythematosus / / 24871463 rs2535311 chr6 31052684 A G 8.05E-04 Pemphigus vulgaris / / 22437316 rs2535311 chr6 31052684 A G 3.00E-07 Hypothyroidism / / 22493691 rs2535311 chr6 31052684 A G 6.20E-04 Systemic lupus erythematosus / / 24871463 rs2535310 chr6 31053257 A C 2.70E-06 Hypothyroidism / / 22493691 rs2535306 chr6 31053867 A G 5.18E-04 Multiple complex diseases / / 17554300 rs2535306 chr6 31053867 A G 8.80E-06 Hypothyroidism / / 22493691 rs3130955 chr6 31054511 C A 2.46E-08 Multiple complex diseases / / 17554300 rs3130955 chr6 31054511 C A 9.31E-05 HIV-1 control / / 20041166 rs3130955 chr6 31054511 C A 1.31E-20 Psoriasis / / pha002855 rs2535304 chr6 31054687 T C 1.40E-05 Hypothyroidism / / 22493691 rs12527394 chr6 31055018 G A 0.0000376 post-traumatic stress disorder / / 22869035 rs12527394 chr6 31055018 G A 3.76E-05 Schizophrenia / / 22883433 rs2535303 chr6 31055423 G A 2.20E-06 Hypothyroidism / / 22493691 rs4947296 chr6 31058178 T C 5.81E-04 Multiple complex diseases / / 17554300 rs4947296 chr6 31058178 T C 4.00E-51 Graves' disease / / 21841780 rs4947296 chr6 31058178 T C 0.0000374 post-traumatic stress disorder / / 22869035 rs4947296 chr6 31058178 T C 3.74E-05 Schizophrenia / / 22883433 rs4947296 chr6 31058178 T C 1.00E-11 Behcet's disease / / 23001997 rs4947296 chr6 31058178 T C 4.01E-13 Behcet's disease / / 23041938 rs4947296 chr6 31058178 T C 5.81E-07 Dilated cardiomyopathy / / 23853074 rs4947296 chr6 31058178 T C 2.37E-23 Behcet's disease / / pha002888 rs3130544 chr6 31058340 C A 2.18E-63 Multiple complex diseases / / 17554300 rs3130544 chr6 31058340 C A 1.00E-16 Type 1 diabetes / / 17632545 rs3130544 chr6 31058340 C A 2.16E-04 HIV-1 viral setpoint / / 17641165 rs3130544 chr6 31058340 C A 1.94E-08 Lung adenocarcinoma / / 19836008 rs3130544 chr6 31058340 C A 1.06E-06 HIV-1 control / / 20041166 rs3130544 chr6 31058340 C A 2.10E-12 Lung cancer / / 22899653 rs3130544 chr6 31058340 C A 0.00001043 Sarcoidosis / / 22952805 rs3130544 chr6 31058340 C A 2.00E-90 Myasthenia gravis / / 23055271 rs3130544 chr6 31058340 C A 5.00E-07 Hematology traits / / 23263863 rs3130544 chr6 31058340 C A 2.30E-15 Systemic lupus erythematosus / / 24871463 rs3130544 chr6 31058340 C A 1.62E-04 Breast cancer / / pha002853 rs3130544 chr6 31058340 C A 1.95E-06 Systemic lupus erythematosus / / pha002867 rs2517453 chr6 31060115 C T 2.30E-06 Hypothyroidism / / 22493691 rs2517452 chr6 31060162 T C 8.00E-05 Upper aerodigestive tract cancers / / 21437268 rs2517452 chr6 31060162 T C 1.80E-08 Hypothyroidism / / 22493691 rs3094087 chr6 31061561 T C 0.000001315 Sarcoidosis / / 22952805 rs2535294 chr6 31062133 A G 1.70E-08 Hypothyroidism / / 22493691 rs2535294 chr6 31062133 A G 4.33E-07 Red blood cell traits / / 23222517 rs2535293 chr6 31062363 A G 2.50E-05 Urinary metabolites / / 21572414 rs2535293 chr6 31062363 A G 3.80E-08 Hypothyroidism / / 22493691 rs2517448 chr6 31062667 T C 2.59E-07 Rheumatoid arthritis / / 19503088 rs2517448 chr6 31062667 T C 4.80E-06 Hypothyroidism / / 22493691 rs2517448 chr6 31062667 T C 8.97E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2535291 chr6 31062899 G A 3.70E-06 Hypothyroidism / / 22493691 rs2535289 chr6 31063233 G A 4.50E-06 Hypothyroidism / / 22493691 rs3130968 chr6 31065071 C T 5.75E-07 Sarcoidosis / / 22952805 rs9263509 chr6 31066419 C T 3.02E-05 Bipolar disorder and schizophrenia / / 20889312 rs2517403 chr6 31067009 T C 2.08E-09 Type 1 diabetes / / 17632545 rs2517403 chr6 31067009 T C 2.69E-06 Rheumatoid arthritis / / 17804836 rs2517403 chr6 31067009 T C 1.18E-06 Rheumatoid arthritis / / 19503088 rs2517403 chr6 31067009 T C 2.53E-05 HIV-1 control / / 20041166 rs2517403 chr6 31067009 T C 2.90E-07 Systemic lupus erythematosus / / 24871463 rs2517403 chr6 31067009 T C 3.96E-06 Systemic lupus erythematosus / / pha002867 rs2517403 chr6 31067009 T C 3.72E-06 Behcet's disease / / pha002888 rs2535283 chr6 31068420 A G 2.90E-06 Hypothyroidism / / 22493691 rs9263567 chr6 31069527 T A 1.82E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9263567 chr6 31069527 T A 5.11E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9394037 chr6 31070522 G A 0.0000241 post-traumatic stress disorder / / 22869035 rs9394037 chr6 31070522 G A 2.41E-05 Schizophrenia / / 22883433 rs2508011 chr6 31071058 A C 3.21E-06 Behcet's disease / / pha002888 rs9263597 chr6 31071547 A G 1.43E-06 Multiple complex diseases / / 17554300 rs9263597 chr6 31071547 A G 2.52E-06 Multiple sclerosis / / 17660530 rs9263597 chr6 31071547 A G 2.40E-05 Urinary metabolites / / 21572414 rs7381897 chr6 31073903 A G 3.50E-06 Hypothyroidism / / 22493691 rs6457327 chr6 31074030 A C 3.91E-07 Rheumatoid arthritis / / 19503088 rs6457327 chr6 31074030 A C 5.00E-11 Follicular lymphoma / / 19620980 rs6457327 chr6 31074030 A C 5.00E-11 Nasopharyngeal carcinoma / / 20512145 rs6457327 chr6 31074030 A C 7.00E-06 Follicular lymphoma / / 20639881 rs6457327 chr6 31074030 A C 4.20E-06 Hypothyroidism / / 22493691 rs6457327 chr6 31074030 A C 8.97E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6457327 chr6 31074030 A C 1.85E-04 Smoking initiation / / 24665060 rs2517485 chr6 31074101 C T 4.18E-08 Type 1 diabetes / / 17632545 rs4947302 chr6 31074128 C T 0.0000526 post-traumatic stress disorder / / 22869035 rs4947302 chr6 31074128 C T 5.26E-05 Schizophrenia / / 22883433 rs2517484 chr6 31074129 G A 5.60E-05 Hypothyroidism / / 22493691 rs4947246 chr6 31074148 G T 0.0000511 post-traumatic stress disorder / / 22869035 rs4947246 chr6 31074148 G T 5.11E-05 Schizophrenia / / 22883433 rs1064191 chr6 31075375 T C 2.20E-08 Hypothyroidism / / 22493691 rs2844635 chr6 31075481 A G 1.42E-09 Type 1 diabetes / / 17632545 rs2844635 chr6 31075481 A G 2.76E-06 Rheumatoid arthritis / / 17804836 rs2844635 chr6 31075481 A G 3.77E-07 Rheumatoid arthritis / / 19503088 rs2844635 chr6 31075481 A G 2.75E-05 HIV-1 control / / 20041166 rs2844635 chr6 31075481 A G 5.90E-07 Systemic lupus erythematosus / / 24871463 rs2844635 chr6 31075481 A G 6.41E-06 Systemic lupus erythematosus / / pha002867 rs2844635 chr6 31075481 A G 2.76E-06 Behcet's disease / / pha002888 rs9391709 chr6 31077405 G C 0.0000511 post-traumatic stress disorder / / 22869035 rs9391709 chr6 31077405 G C 5.11E-05 Schizophrenia / / 22883433 rs9391709 chr6 31077405 G C 1.38E-20 Behcet's disease / / pha002888 rs1265063 chr6 31077938 A G 3.10E-06 Hypothyroidism / / 22493691 rs1265062 chr6 31078005 C T 5.95E-06 Behcet's disease / / pha002888 rs3132556 chr6 31078809 A T 0.000004239 Sarcoidosis C6orf15 nearGene-3 22952805 rs3734854 chr6 31078836 G A 4.76E-04 Smoking quantity C6orf15 nearGene-3 24665060 rs2233985 chr6 31079242 A G 7.08E-04 Smoking quantity C6orf15 cds-synon 24665060 rs2233984 chr6 31079264 C T 7.32E-04 Coronary heart disease C6orf15 missense 21971053 rs2233984 chr6 31079264 C T 0.0000511 post-traumatic stress disorder C6orf15 missense 22869035 rs2233984 chr6 31079264 C T 5.11E-05 Schizophrenia C6orf15 missense 22883433 rs2233984 chr6 31079264 C T 3.70E-04 Smoking quantity C6orf15 missense 24665060 rs1265054 chr6 31079643 T C 3.00E-06 Hypothyroidism C6orf15 missense 22493691 rs2233980 chr6 31079644 G A 0.000005172 Sarcoidosis C6orf15 cds-synon 22952805 rs2233976 chr6 31079994 C T 4.40E-08 HIV-1 control C6orf15 missense 21051598 rs2233976 chr6 31079994 C T 2.88E-05 Self-reported allergy C6orf15 missense 23817569 rs2233969 chr6 31080432 A G 1.23E-10 Multiple complex diseases C6orf15 nearGene-5 17554300 rs2233969 chr6 31080432 A G 2.71E-05 Multiple sclerosis C6orf15 nearGene-5 17660530 rs2233969 chr6 31080432 A G 5.10E-05 Height C6orf15 nearGene-5 19396169 rs1265052 chr6 31080471 T C 1.06E-12 Multiple complex diseases C6orf15 nearGene-5 17554300 rs1265052 chr6 31080471 T C 2.22E-06 Multiple sclerosis C6orf15 nearGene-5 17660530 rs4495304 chr6 31080718 T C 6.62E-04 Coronary heart disease C6orf15 nearGene-5 21971053 rs2233967 chr6 31080828 C G 4.23E-07 Multiple complex diseases C6orf15 nearGene-5 17554300 rs2233967 chr6 31080828 C G 1.73E-05 Multiple sclerosis C6orf15 nearGene-5 17660530 rs2233967 chr6 31080828 C G 9.71E-11 Behcet's disease C6orf15 nearGene-5 pha002888 rs2233966 chr6 31080859 A G 3.50E-05 Hypothyroidism C6orf15 nearGene-5 22493691 rs2233965 chr6 31080899 T G 1.23E-10 Behcet's disease C6orf15 nearGene-5 pha002888 rs2233956 chr6 31081205 T C 1.00E-16 Type 1 diabetes C6orf15 nearGene-5 17632545 rs2233956 chr6 31081205 T C 1.47E-06 Lung adenocarcinoma C6orf15 nearGene-5 19836008 rs2233956 chr6 31081205 T C 2.40E-08 Lung cancer C6orf15 nearGene-5 22899653 rs2233956 chr6 31081205 T C 6.10E-68 Myasthenia gravis C6orf15 nearGene-5 23055271 rs2233956 chr6 31081205 T C 3.40E-06 Systemic lupus erythematosus C6orf15 nearGene-5 24871463 rs2233955 chr6 31081251 G A 0.00002158 Sarcoidosis C6orf15 nearGene-5 22952805 rs1265048 chr6 31081409 T C 3.14E-08 Multiple complex diseases C6orf15 nearGene-5 17554300 rs1265048 chr6 31081409 T C 2.57E-07 Rheumatoid arthritis C6orf15 nearGene-5 17804836 rs1265048 chr6 31081409 T C 1.07E-05 Self-reported allergy C6orf15 nearGene-5 23817569 rs1265048 chr6 31081409 T C 5.92E-06 Leprosy C6orf15 nearGene-5 pha002872 rs3094222 chr6 31081434 A G 0.00001662 Sarcoidosis C6orf15 nearGene-5 22952805 rs3130975 chr6 31081838 C T 6.16E-10 Multiple complex diseases C6orf15 nearGene-5 17554300 rs3130975 chr6 31081838 C T 8.82E-04 Coronary Artery Disease C6orf15 nearGene-5 17634449 rs3130975 chr6 31081838 C T 1.79E-08 Multiple sclerosis C6orf15 nearGene-5 17660530 rs3130975 chr6 31081838 C T 1.90E-08 HIV-1 control C6orf15 nearGene-5 21051598 rs3130977 chr6 31081989 T C 4.80E-05 Hypothyroidism C6orf15 nearGene-5 22493691 rs17190526 chr6 31082081 G A 8.55E-06 Behcet's disease C6orf15 nearGene-5 pha002888 rs3130553 chr6 31082285 A G 7.30E-05 Hypothyroidism C6orf15 nearGene-5 22493691 rs6917517 chr6 31082361 C T 1.64E-08 Rheumatoid arthritis PSORS1C1 nearGene-5 19503088 rs6917517 chr6 31082361 C T 1.51E-05 Coronary heart disease PSORS1C1 nearGene-5 21971053 rs6917517 chr6 31082361 C T 3.74E-04 Alcohol consumption (maxi-drinks) PSORS1C1 nearGene-5 24277619 rs6917517 chr6 31082361 C T 4.73E-12 Behcet's disease PSORS1C1 nearGene-5 pha002888 rs1042147 chr6 31083156 A G 6.13E-05 HIV-1 control CDSN UTR-3 20041166 rs1042147 chr6 31083156 A G 8.70E-14 HIV-1 control CDSN UTR-3 21051598 rs3094217 chr6 31083656 G A 4.48E-05 HIV-1 control CDSN UTR-3 20041166 rs3094217 chr6 31083656 G A 8.80E-14 HIV-1 control CDSN UTR-3 21051598 rs1042134 chr6 31083664 G A 4.48E-05 HIV-1 control CDSN UTR-3 20041166 rs1042134 chr6 31083664 G A 9.20E-14 HIV-1 control CDSN UTR-3 21051598 rs3130981 chr6 31083813 T C 3.29E-08 Multiple complex diseases CDSN missense 17554300 rs3130981 chr6 31083813 T C 5.07E-11 Multiple sclerosis CDSN missense 17660530 rs3130981 chr6 31083813 T C 1.09E-07 HIV-1 control CDSN missense 20041166 rs3130981 chr6 31083813 T C 3.90E-14 HIV-1 control CDSN missense 21051598 rs3130982 chr6 31084075 G C,T 9.47E-04 Type 2 diabetes CDSN cds-synon 17463246 rs3130982 chr6 31084075 G C,T 9.92E-04 Multiple complex diseases CDSN cds-synon 17554300 rs3130982 chr6 31084075 G C,T 4.20E-14 HIV-1 control CDSN cds-synon 21051598 rs1042127 chr6 31084170 A C 6.86E-08 Rheumatoid arthritis CDSN missense 19503088 rs1042127 chr6 31084170 A C 4.35E-05 Coronary heart disease CDSN missense 21971053 rs1042126 chr6 31084288 T C 4.48E-05 HIV-1 control CDSN cds-synon 20041166 rs1042126 chr6 31084288 T C 8.90E-14 HIV-1 control CDSN cds-synon 21051598 rs1062470 chr6 31084435 G A 7.36E-05 HIV-1 viral setpoint CDSN cds-synon 17641165 rs1062470 chr6 31084435 G A 2.13E-08 HIV-1 control CDSN cds-synon 20041166 rs1062470 chr6 31084435 G A 4.80E-04 HIV-1 control CDSN cds-synon 21051598 rs1062470 chr6 31084435 G A 4.10E-04 Pemphigus vulgaris CDSN cds-synon 22437316 rs1062470 chr6 31084435 G A 8.99E-05 Behcet's disease CDSN cds-synon pha002888 rs3130983 chr6 31084792 C T 4.48E-05 HIV-1 control CDSN cds-synon 20041166 rs3130983 chr6 31084792 C T 9.00E-14 HIV-1 control CDSN cds-synon 21051598 rs3130984 chr6 31084964 T C 3.50E-14 HIV-1 control PSORS1C1 intron 21051598 rs575513907 chr6 31084964 T C 3.50E-14 HIV-1 control PSORS1C1 intron 21051598 rs3132553 chr6 31085200 A G 3.60E-14 HIV-1 control PSORS1C1 intron 21051598 rs386580037 chr6 31085200 A G 3.60E-14 HIV-1 control PSORS1C1 intron 21051598 rs3132552 chr6 31085269 A G 3.40E-14 HIV-1 control PSORS1C1 intron 21051598 rs386580036 chr6 31085269 A G 3.40E-14 HIV-1 control PSORS1C1 intron 21051598 rs3130985 chr6 31085356 C T 0.00001186 Sarcoidosis CDSN intron 22952805 rs3094214 chr6 31085382 C A 4.48E-05 HIV-1 control CDSN intron 20041166 rs3094214 chr6 31085382 C A 8.60E-14 HIV-1 control CDSN intron 21051598 rs3094214 chr6 31085382 C A 5.20E-08 Graves' disease CDSN intron 21900946 rs540385376 chr6 31085382 C A 4.48E-05 HIV-1 control CDSN intron 20041166 rs540385376 chr6 31085382 C A 8.60E-14 HIV-1 control CDSN intron 21051598 rs540385376 chr6 31085382 C A 5.20E-08 Graves' disease CDSN intron 21900946 rs3094212 chr6 31085770 G A 7.09E-05 HIV-1 viral setpoint CDSN intron 17641165 rs3094212 chr6 31085770 G A 3.23E-12 HIV-1 control CDSN intron 20041166 rs3094212 chr6 31085770 G A 6.76E-09 Blood cell counts and other traits CDSN intron 20139978 rs3094212 chr6 31085770 G A 7.00E-09 Blood cell counts and other traits CDSN intron 20139978 rs3094212 chr6 31085770 G A 1.10E-13 HIV-1 control CDSN intron 21051598 rs3094212 chr6 31085770 G A 1.07E-05 HIV-1 viral setpoint CDSN intron 21490045 rs3094212 chr6 31085770 G A 1.16E-05 Crohn's disease CDSN intron 23266558 rs551894425 chr6 31085770 G A 7.09E-05 HIV-1 viral setpoint CDSN intron 17641165 rs551894425 chr6 31085770 G A 3.23E-12 HIV-1 control CDSN intron 20041166 rs551894425 chr6 31085770 G A 6.76E-09 Blood cell counts and other traits CDSN intron 20139978 rs551894425 chr6 31085770 G A 7.00E-09 Blood cell counts and other traits CDSN intron 20139978 rs551894425 chr6 31085770 G A 1.10E-13 HIV-1 control CDSN intron 21051598 rs551894425 chr6 31085770 G A 1.07E-05 HIV-1 viral setpoint CDSN intron 21490045 rs551894425 chr6 31085770 G A 1.16E-05 Crohn's disease CDSN intron 23266558 rs3132551 chr6 31085882 A G 6.70E-16 HIV-1 control CDSN intron 21051598 rs546583999 chr6 31085882 A G 6.70E-16 HIV-1 control CDSN intron 21051598 rs3094211 chr6 31086402 G A 2.50E-16 HIV-1 control CDSN intron 21051598 rs555542204 chr6 31086402 G A 2.50E-16 HIV-1 control CDSN intron 21051598 rs12207756 chr6 31086682 C T 1.90E-07 HIV-1 control CDSN intron 21051598 rs541134362 chr6 31086682 C T 1.90E-07 HIV-1 control CDSN intron 21051598 rs3095324 chr6 31087133 C T 5.43E-12 Multiple complex diseases CDSN intron 17554300 rs3095324 chr6 31087133 C T 2.36E-06 Multiple sclerosis CDSN intron 17660530 rs3095324 chr6 31087133 C T 4.24E-08 Behcet's disease CDSN intron 23001997 rs386579334 chr6 31087133 C T 5.43E-12 Multiple complex diseases CDSN intron 17554300 rs386579334 chr6 31087133 C T 2.36E-06 Multiple sclerosis CDSN intron 17660530 rs386579334 chr6 31087133 C T 4.24E-08 Behcet's disease CDSN intron 23001997 rs3130991 chr6 31087354 C T 4.05E-05 Multiple complex diseases CDSN intron 17554300 rs3130991 chr6 31087354 C T 8.19E-06 Serum metabolites CDSN intron 19043545 rs3130991 chr6 31087354 C T 4.80E-04 HIV-1 control CDSN intron 21051598 rs541820233 chr6 31087354 C T 4.05E-05 Multiple complex diseases CDSN intron 17554300 rs541820233 chr6 31087354 C T 8.19E-06 Serum metabolites CDSN intron 19043545 rs541820233 chr6 31087354 C T 4.80E-04 HIV-1 control CDSN intron 21051598 rs3095320 chr6 31087934 G A 9.87E-08 HIV-1 control CDSN intron 20041166 rs3095320 chr6 31087934 G A 3.60E-16 HIV-1 control CDSN intron 21051598 rs562436976 chr6 31087934 G A 9.87E-08 HIV-1 control CDSN intron 20041166 rs562436976 chr6 31087934 G A 3.60E-16 HIV-1 control CDSN intron 21051598 rs3132546 chr6 31088579 A G 3.90E-14 HIV-1 control PSORS1C1 intron 21051598 rs540151006 chr6 31088579 A G 3.90E-14 HIV-1 control PSORS1C1 intron 21051598 rs2239519 chr6 31088856 T C 3.40E-16 HIV-1 control PSORS1C1 intron 21051598 rs573422310 chr6 31088856 T C 3.40E-16 HIV-1 control PSORS1C1 intron 21051598 rs3132545 chr6 31089125 A G 5.00E-16 HIV-1 control PSORS1C1 intron 21051598 rs553317370 chr6 31089125 A G 5.00E-16 HIV-1 control PSORS1C1 intron 21051598 rs111199278 chr6 31089631 C T 2.82E-12 Multiple complex diseases PSORS1C1 intron 17554300 rs111199278 chr6 31089631 C T 5.15E-06 Multiple sclerosis PSORS1C1 intron 17660530 rs111199278 chr6 31089631 C T 2.03E-04 Orofacial clefts PSORS1C1 intron 22863734 rs111199278 chr6 31089631 C T 9.30E-04 Systemic lupus erythematosus PSORS1C1 intron 24871463 rs111199278 chr6 31089631 C T 8.15E-05 Body Composition PSORS1C1 intron pha003012 rs3095314 chr6 31089631 C T 2.82E-12 Multiple complex diseases PSORS1C1 intron 17554300 rs3095314 chr6 31089631 C T 5.15E-06 Multiple sclerosis PSORS1C1 intron 17660530 rs3095314 chr6 31089631 C T 2.03E-04 Orofacial clefts PSORS1C1 intron 22863734 rs3095314 chr6 31089631 C T 9.30E-04 Systemic lupus erythematosus PSORS1C1 intron 24871463 rs3095314 chr6 31089631 C T 8.15E-05 Body Composition PSORS1C1 intron pha003012 rs574266188 chr6 31090552 G A 4.80E-04 HIV-1 control PSORS1C1 intron 21051598 rs542150497 chr6 31090583 C T 2.87E-06 Leprosy PSORS1C1 intron pha002872 rs9295953 chr6 31090583 C T 2.87E-06 Leprosy PSORS1C1 intron pha002872 rs3095312 chr6 31090837 G C 4.77E-07 Red blood cell traits PSORS1C1 intron 23222517 rs560052000 chr6 31090837 G C 4.77E-07 Red blood cell traits PSORS1C1 intron 23222517 rs3131000 chr6 31091273 G C 2.60E-09 Graves' disease PSORS1C1 intron 21900946 rs3131000 chr6 31091273 G C 5.66E-07 Red blood cell traits PSORS1C1 intron 23222517 rs534526282 chr6 31091273 G C 2.60E-09 Graves' disease PSORS1C1 intron 21900946 rs534526282 chr6 31091273 G C 5.66E-07 Red blood cell traits PSORS1C1 intron 23222517 rs3094205 chr6 31091862 A G 7.84E-05 HIV-1 viral setpoint PSORS1C1 intron 17641165 rs3094205 chr6 31091862 A G 1.31E-08 HIV-1 control PSORS1C1 intron 20041166 rs3094205 chr6 31091862 A G 4.60E-04 HIV-1 control PSORS1C1 intron 21051598 rs3094205 chr6 31091862 A G 4.11E-04 Pemphigus vulgaris PSORS1C1 intron 22437316 rs3094205 chr6 31091862 A G 1.73E-15 Psoriasis PSORS1C1 intron pha002855 rs560839399 chr6 31091862 A G 7.84E-05 HIV-1 viral setpoint PSORS1C1 intron 17641165 rs560839399 chr6 31091862 A G 1.31E-08 HIV-1 control PSORS1C1 intron 20041166 rs560839399 chr6 31091862 A G 4.60E-04 HIV-1 control PSORS1C1 intron 21051598 rs560839399 chr6 31091862 A G 4.11E-04 Pemphigus vulgaris PSORS1C1 intron 22437316 rs560839399 chr6 31091862 A G 1.73E-15 Psoriasis PSORS1C1 intron pha002855 rs537435650 chr6 31091967 A G 8.67E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PSORS1C1 intron 21844884 rs3094204 chr6 31091992 A G 6.16E-05 HIV-1 viral setpoint PSORS1C1 intron 17641165 rs3094204 chr6 31091992 A G 1.34E-08 HIV-1 control PSORS1C1 intron 20041166 rs3094204 chr6 31091992 A G 2.50E-04 Systemic lupus erythematosus PSORS1C1 intron 24871463 rs545914110 chr6 31091992 A G 6.16E-05 HIV-1 viral setpoint PSORS1C1 intron 17641165 rs545914110 chr6 31091992 A G 1.34E-08 HIV-1 control PSORS1C1 intron 20041166 rs545914110 chr6 31091992 A G 2.50E-04 Systemic lupus erythematosus PSORS1C1 intron 24871463 rs3778638 chr6 31092124 G A 4.51E-04 Pemphigus vulgaris PSORS1C1 intron 22437316 rs3778638 chr6 31092124 G A 7.58E-05 Behcet's disease PSORS1C1 intron pha002888 rs527680481 chr6 31092124 G A 4.51E-04 Pemphigus vulgaris PSORS1C1 intron 22437316 rs527680481 chr6 31092124 G A 7.58E-05 Behcet's disease PSORS1C1 intron pha002888 rs6909321 chr6 31093190 G A 5.29E-05 HIV-1 control PSORS1C1 intron 20041166 rs6909321 chr6 31093190 G A 1.40E-07 HIV-1 control PSORS1C1 intron 21051598 rs3131003 chr6 31093482 G A 1.38E-05 HIV-1 viral setpoint PSORS1C1 UTR-5 17641165 rs3131003 chr6 31093482 G A 1.80E-10 HIV-1 control PSORS1C1 UTR-5 20041166 rs3815087 chr6 31093587 G A 7.09E-06 HIV-1 viral setpoint PSORS1C1 UTR-5 17641165 rs3815087 chr6 31093587 G A 2.68E-06 Rheumatoid arthritis PSORS1C1 UTR-5 17804836 rs3815087 chr6 31093587 G A 1.46E-07 AIDS progression PSORS1C1 UTR-5 19115949 rs3815087 chr6 31093587 G A 4.00E-15 Rheumatoid arthritis PSORS1C1 UTR-5 19503088 rs3815087 chr6 31093587 G A 8.00E-08 HIV-1 control PSORS1C1 UTR-5 20041166 rs3815087 chr6 31093587 G A 3.10E-07 HIV-1 control PSORS1C1 UTR-5 21051598 rs3815087 chr6 31093587 G A 9.17E-07 HIV-1 viral setpoint PSORS1C1 UTR-5 21490045 rs3815087 chr6 31093587 G A 6.70E-05 Schizophrenia PSORS1C1 UTR-5 21791550 rs3815087 chr6 31093587 G A 3.00E-07 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) PSORS1C1 UTR-5 21801394 rs3815087 chr6 31093587 G A 0.000067 Psychosis PSORS1C1 UTR-5 23164818 rs9263699 chr6 31093699 G A 8.60E-06 HIV-1 control PSORS1C1 intron 21051598 rs3778639 chr6 31093776 A G 9.76E-06 HIV-1 control PSORS1C1 intron 20041166 rs3778639 chr6 31093776 A G 1.10E-07 HIV-1 control PSORS1C1 intron 21051598 rs9263702 chr6 31094195 C T 1.88E-13 Multiple complex diseases PSORS1C1 intron 17554300 rs9263702 chr6 31094195 C T 3.01E-05 Biliary atresia PSORS1C1 intron 20460270 rs3130557 chr6 31094703 C T 0.00001796 Sarcoidosis PSORS1C1 intron 22952805 rs3130557 chr6 31094703 C T 3.33E-07 Rheumatoid arthritis (ACPA-negative) PSORS1C1 intron 24532677 rs6931921 chr6 31095003 G C 4.63E-06 HIV-1 control PSORS1C1 intron 20041166 rs9263715 chr6 31095801 G A 4.38E-08 Multiple complex diseases PSORS1C1 intron 17554300 rs9263715 chr6 31095801 G A 7.09E-06 HIV-1 viral setpoint PSORS1C1 intron 17641165 rs9263715 chr6 31095801 G A 5.94E-13 HIV-1 control PSORS1C1 intron 20041166 rs9263715 chr6 31095801 G A 1.00E-05 HIV-1 control PSORS1C1 intron 21051598 rs9263715 chr6 31095801 G A 9.81E-07 HIV-1 viral setpoint PSORS1C1 intron 21490045 rs9263716 chr6 31095816 A T 3.38E-08 Multiple complex diseases PSORS1C1 intron 17554300 rs9263716 chr6 31095816 A T 9.60E-06 HIV-1 control PSORS1C1 intron 21051598 rs3909109 chr6 31096367 A G 3.80E-06 HIV-1 control PSORS1C1 intron 21051598 rs3130558 chr6 31097183 C G 1.10E-08 Multiple complex diseases PSORS1C1 intron 17554300 rs3130558 chr6 31097183 C G 7.43E-11 Multiple sclerosis PSORS1C1 intron 17660530 rs3130558 chr6 31097183 C G 1.40E-08 HIV-1 control PSORS1C1 intron 21051598 rs3130559 chr6 31097301 C T 1.81E-07 Rheumatoid arthritis PSORS1C1 intron 17804836 rs3130559 chr6 31097301 C T 7.72E-08 Rheumatoid arthritis PSORS1C1 intron 19503088 rs3130559 chr6 31097301 C T 8.00E-09 Chronic obstructive pulmonary disease-related biomarkers PSORS1C1 intron 23144326 rs3130560 chr6 31097453 T G 6.80E-09 HIV-1 control PSORS1C1 intron 21051598 rs6929464 chr6 31097918 T C 7.00E-04 HIV-1 control PSORS1C1 intron 21051598 rs3132541 chr6 31098734 A C 0.00001876 Sarcoidosis PSORS1C1 intron 22952805 rs3131009 chr6 31098832 G A 7.39E-10 Multiple complex diseases PSORS1C1 intron 17554300 rs3131009 chr6 31098832 G A 1.26E-10 Multiple sclerosis PSORS1C1 intron 17660530 rs3131009 chr6 31098832 G A 7.70E-09 HIV-1 control PSORS1C1 intron 21051598 rs528878831 chr6 31098832 G A 7.39E-10 Multiple complex diseases PSORS1C1 intron 17554300 rs528878831 chr6 31098832 G A 1.26E-10 Multiple sclerosis PSORS1C1 intron 17660530 rs528878831 chr6 31098832 G A 7.70E-09 HIV-1 control PSORS1C1 intron 21051598 rs13200022 chr6 31098957 C T 3.79E-07 Multiple complex diseases PSORS1C1 intron 17554300 rs13200022 chr6 31098957 C T 8.70E-04 HIV-1 control PSORS1C1 intron 21051598 rs4959053 chr6 31099577 G A 3.14E-303 Multiple complex diseases PSORS1C1 intron 17554300 rs4959053 chr6 31099577 G A 2.00E-20 Behcet's disease PSORS1C1 intron 23001997 rs4959053 chr6 31099577 G A 2.08E-11 Behcet's disease PSORS1C1 intron 23041938 rs4959053 chr6 31099577 G A 9.70E-04 Type 2 diabetes PSORS1C1 intron 23209189 rs3823417 chr6 31100869 G A 8.30E-08 HIV-1 control PSORS1C1 intron 21051598 rs3823417 chr6 31100869 G A 4.41E-05 Response to mTOR inhibitor (everolimus) PSORS1C1 intron 24009623 rs559951725 chr6 31100869 G A 8.30E-08 HIV-1 control PSORS1C1 intron 21051598 rs559951725 chr6 31100869 G A 4.41E-05 Response to mTOR inhibitor (everolimus) PSORS1C1 intron 24009623 rs3823418 chr6 31100942 G A 1.11E-05 HIV-1 viral setpoint PSORS1C1 intron 17641165 rs3823418 chr6 31100942 G A 1.40E-08 AIDS progression PSORS1C1 intron 19115949 rs3823418 chr6 31100942 G A 2.10E-10 Rheumatoid arthritis PSORS1C1 intron 19503088 rs3823418 chr6 31100942 G A 7.46E-10 HIV-1 control PSORS1C1 intron 20041166 rs3823418 chr6 31100942 G A 6.00E-06 HIV-1 control PSORS1C1 intron 21051598 rs3823418 chr6 31100942 G A 1.11E-16 Psoriasis risk prediction PSORS1C1 intron 21214922 rs3823418 chr6 31100942 G A 7.29E-06 HIV-1 viral setpoint PSORS1C1 intron 21490045 rs3823418 chr6 31100942 G A 6.96E-04 White matter integrity PSORS1C1 intron 22425255 rs3823418 chr6 31100942 G A 4.16E-05 Response to mTOR inhibitor (everolimus) PSORS1C1 intron 24009623 rs3823418 chr6 31100942 G A 1.17E-33 Psoriasis PSORS1C1 intron pha002855 rs527476195 chr6 31100942 G A 1.11E-05 HIV-1 viral setpoint PSORS1C1 intron 17641165 rs527476195 chr6 31100942 G A 1.40E-08 AIDS progression PSORS1C1 intron 19115949 rs527476195 chr6 31100942 G A 2.10E-10 Rheumatoid arthritis PSORS1C1 intron 19503088 rs527476195 chr6 31100942 G A 7.46E-10 HIV-1 control PSORS1C1 intron 20041166 rs527476195 chr6 31100942 G A 6.00E-06 HIV-1 control PSORS1C1 intron 21051598 rs527476195 chr6 31100942 G A 1.11E-16 Psoriasis risk prediction PSORS1C1 intron 21214922 rs527476195 chr6 31100942 G A 7.29E-06 HIV-1 viral setpoint PSORS1C1 intron 21490045 rs527476195 chr6 31100942 G A 6.96E-04 White matter integrity PSORS1C1 intron 22425255 rs527476195 chr6 31100942 G A 4.16E-05 Response to mTOR inhibitor (everolimus) PSORS1C1 intron 24009623 rs527476195 chr6 31100942 G A 1.17E-33 Psoriasis PSORS1C1 intron pha002855 rs3130562 chr6 31100974 T C 0.00002006 Sarcoidosis PSORS1C1 intron 22952805 rs3823419 chr6 31101001 G A 8.10E-06 HIV-1 control PSORS1C1 intron 21051598 rs3823419 chr6 31101001 G A 3.55E-05 Response to mTOR inhibitor (everolimus) PSORS1C1 intron 24009623 rs529345691 chr6 31101001 G A 8.10E-06 HIV-1 control PSORS1C1 intron 21051598 rs529345691 chr6 31101001 G A 3.55E-05 Response to mTOR inhibitor (everolimus) PSORS1C1 intron 24009623 rs4084091 chr6 31101401 C T 1.90E-06 HIV-1 control PSORS1C1 intron 21051598 rs555916934 chr6 31101401 C T 1.90E-06 HIV-1 control PSORS1C1 intron 21051598 rs4294047 chr6 31101583 G A 3.40E-08 HIV-1 control PSORS1C1 intron 21051598 rs542420252 chr6 31101583 G A 3.40E-08 HIV-1 control PSORS1C1 intron 21051598 rs3130564 chr6 31101674 C T 1.19E-34 Multiple complex diseases PSORS1C1 intron 17554300 rs3130564 chr6 31101674 C T 5.46E-11 Type 1 diabetes PSORS1C1 intron 17632545 rs3130564 chr6 31101674 C T 2.09E-07 Multiple sclerosis PSORS1C1 intron 17660530 rs3130564 chr6 31101674 C T 2.37E-06 Rheumatoid arthritis PSORS1C1 intron 19503088 rs3130564 chr6 31101674 C T 8.15E-06 Lung cancer PSORS1C1 intron 19654303 rs3130564 chr6 31101674 C T 1.21E-05 Lung adenocarcinoma PSORS1C1 intron 19836008 rs3130564 chr6 31101674 C T 4.65E-05 HIV-1 control PSORS1C1 intron 20041166 rs3130564 chr6 31101674 C T 3.00E-08 Lung cancer PSORS1C1 intron 22899653 rs3130564 chr6 31101674 C T 1.60E-56 Myasthenia gravis PSORS1C1 intron 23055271 rs3130564 chr6 31101674 C T 1.40E-07 Systemic lupus erythematosus PSORS1C1 intron 24871463 rs3130566 chr6 31102618 C G 0.00005152 Sarcoidosis PSORS1C1 intron 22952805 rs3132566 chr6 31102790 G T 0.00002815 Sarcoidosis PSORS1C1 intron 22952805 rs3094669 chr6 31103195 C G 0.00001771 Sarcoidosis PSORS1C1 intron 22952805 rs28732100 chr6 31104593 C T 1.53E-06 HIV-1 control PSORS1C1 intron 20041166 rs28732100 chr6 31104593 C T 6.59E-05 Cognitive test performance PSORS1C1 intron 20125193 rs28732100 chr6 31104593 C T 3.10E-19 HIV-1 control PSORS1C1 intron 21051598 rs3131010 chr6 31105147 C T 0.00002226 Sarcoidosis PSORS1C1 intron 22952805 rs1265099 chr6 31105413 A G 3.93E-06 AIDS progression PSORS1C2 UTR-3 19115949 rs1265099 chr6 31105413 A G 3.77E-05 HIV-1 control PSORS1C2 UTR-3 20041166 rs1265099 chr6 31105413 A G 3.19E-06 Schizophrenia PSORS1C2 UTR-3 21926974 rs1265099 chr6 31105413 A G 9.90E-06 Type 2 diabetes PSORS1C2 UTR-3 22158537 rs2074478 chr6 31105633 C T 3.39E-05 Multiple sclerosis PSORS1C2 UTR-3 20598377 rs2074478 chr6 31105633 C T 1.09E-07 Behcet's disease PSORS1C2 UTR-3 pha002888 rs2233952 chr6 31105891 A G 3.07E-05 Multiple sclerosis PSORS1C2 missense 20598377 rs2233950 chr6 31106065 C T 5.00E-05 Diabetic retinopathy PSORS1C2 missense 21441570 rs3130573 chr6 31106268 A G 1.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PSORS1C1 intron 20877124 rs3130573 chr6 31106268 A G 6.00E-10 Systemic sclerosis PSORS1C1 intron 21750679 rs3130573 chr6 31106268 A G 2.20E-04 Systemic lupus erythematosus PSORS1C1 intron 24871463 rs3130573 chr6 31106268 A G 6.21E-15 Psoriasis PSORS1C1 intron pha002855 rs1265097 chr6 31106459 C A 2.37E-04 Self-reported allergy PSORS1C1 missense 23817569 rs3094663 chr6 31107087 T C 1.10E-05 Breast cancer (survival) PSORS1C2 UTR-5 20332263 rs3094663 chr6 31107087 T C 4.00E-08 Multiple myeloma PSORS1C2 UTR-5 23955597 rs1265093 chr6 31107187 G A 4.22E-05 Parkinson's disease PSORS1C1 intron 21738487 rs1265093 chr6 31107187 G A 6.00E-09 Chronic obstructive pulmonary disease-related biomarkers PSORS1C1 intron 23144326 rs2285803 chr6 31107258 T C 1.00E-10 Multiple myeloma PSORS1C1 intron 23955597 rs1966 chr6 31107733 C T 5.77E-09 Rheumatoid arthritis PSORS1C1 UTR-3 17804836 rs1966 chr6 31107733 C T 9.09E-09 Rheumatoid arthritis PSORS1C1 UTR-3 19503088 rs3130454 chr6 31108485 G A 7.00E-08 Multiple myeloma PSORS1C2 nearGene-5 23955597 rs9263733 chr6 31108829 C T 3.63E-09 Behcet's disease PSORS1C2 nearGene-5 pha002888 rs1265087 chr6 31109810 G A 1.21E-08 Nevirapine-induced rash CCHCR1 nearGene-3 21810746 rs1265086 chr6 31109882 G T 2.24E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1265086 chr6 31109882 G T 2.69E-11 Psoriasis / / pha002855 rs386525443 chr6 31109882 G T 2.24E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs386525443 chr6 31109882 G T 2.69E-11 Psoriasis / / pha002855 rs2523834 chr6 31109946 T A 1.21E-08 Nevirapine-induced rash CCHCR1 nearGene-3 21810746 rs2523833 chr6 31109947 C T 1.21E-08 Nevirapine-induced rash CCHCR1 nearGene-3 21810746 rs1576 chr6 31110391 G C 1.21E-08 Nevirapine-induced rash CCHCR1 missense 21810746 rs9263739 chr6 31111356 C T 4.00E-67 Ulcerative colitis CCHCR1 intron 19915573 rs9263739 chr6 31111356 C T 7.11E-04 Crohn's disease CCHCR1 intron 23266558 rs9263740 chr6 31111400 T C 8.23E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCHCR1 intron 20877124 rs1265079 chr6 31112108 G T 1.21E-08 Nevirapine-induced rash CCHCR1 intron 21810746 rs11967883 chr6 31112354 C T 3.15E-06 Behcet's disease CCHCR1 intron pha002888 rs130072 chr6 31112484 C T 4.73E-05 HIV-1 control CCHCR1 missense 20041166 rs130072 chr6 31112484 C T 1.10E-08 HIV-1 control CCHCR1 missense 21051598 rs130072 chr6 31112484 C T 7.42E-06 Self-reported allergy CCHCR1 missense 23817569 rs1265078 chr6 31112602 G C 3.44E-12 Psoriasis risk prediction CCHCR1 intron 21214922 rs1265078 chr6 31112602 G C 1.21E-08 Nevirapine-induced rash CCHCR1 intron 21810746 rs1265078 chr6 31112602 G C 2.04E-21 Psoriasis CCHCR1 intron pha002855 rs3094225 chr6 31113052 G A 2.30E-06 Urinary metabolites CCHCR1 cds-synon 21572414 rs1265076 chr6 31113083 G A 1.21E-08 Nevirapine-induced rash CCHCR1 intron 21810746 rs1265074 chr6 31113214 C A 7.44E-05 Multiple complex diseases CCHCR1 intron 17554300 rs1265074 chr6 31113214 C A 2.14E-05 Multiple sclerosis CCHCR1 intron 17660530 rs1265074 chr6 31113214 C A 3.75E-05 Rheumatoid arthritis CCHCR1 intron 17804836 rs1265074 chr6 31113214 C A 2.81E-06 Rheumatoid arthritis CCHCR1 intron 19503088 rs17196989 chr6 31113703 A G 3.96E-10 Behcet's disease CCHCR1 intron pha002888 rs746646 chr6 31113940 T C 1.21E-08 Nevirapine-induced rash CCHCR1 intron 21810746 rs746647 chr6 31114182 A G 1.21E-08 Nevirapine-induced rash CCHCR1 intron 21810746 rs746647 chr6 31114182 A G 3.63E-06 Dengue shock syndrome CCHCR1 intron 22001756 rs746647 chr6 31114182 A G 9.00E-04 Systemic lupus erythematosus CCHCR1 intron 24871463 rs2240066 chr6 31114335 A G 9.61E-04 Multiple complex diseases CCHCR1 intron 17554300 rs9263749 chr6 31114515 G A 5.60E-05 Behcet's disease CCHCR1 intron pha002888 rs2240064 chr6 31114573 G A 1.40E-05 Graves' disease CCHCR1 intron 21900946 rs2240064 chr6 31114573 G A 5.23E-04 Crohn's disease CCHCR1 intron 23266558 rs2240064 chr6 31114573 G A 8.00E-06 Multiple myeloma CCHCR1 intron 23955597 rs2240064 chr6 31114573 G A 8.73E-07 Hodgkin's lymphoma CCHCR1 intron 24149102 rs2240063 chr6 31114745 T C 9.33E-05 Multiple complex diseases CCHCR1 intron 17554300 rs3131012 chr6 31115441 T C 3.00E-06 Multiple myeloma CCHCR1 intron 23955597 rs1265069 chr6 31115700 A G 1.21E-08 Nevirapine-induced rash CCHCR1 intron 21810746 rs9263758 chr6 31115874 A G 5.40E-07 Urinary metabolites CCHCR1 intron 21572414 rs1265067 chr6 31116142 G A 1.21E-08 Nevirapine-induced rash CCHCR1 intron 21810746 rs3131014 chr6 31116627 G A 8.56E-14 Behcet's disease CCHCR1 intron pha002888 rs1265115 chr6 31117075 C A 1.74E-05 HIV-1 control CCHCR1 intron 20041166 rs1265115 chr6 31117075 C A 2.50E-08 HIV-1 control CCHCR1 intron 21051598 rs1265115 chr6 31117075 C A 1.98E-08 Chronic hepatitis B infection CCHCR1 intron 23760081 rs1265114 chr6 31117188 C T 8.60E-06 Urinary metabolites CCHCR1 intron 21572414 rs1265114 chr6 31117188 C T 1.21E-08 Nevirapine-induced rash CCHCR1 intron 21810746 rs1265112 chr6 31118019 T C 1.00E-08 Nevirapine-induced rash CCHCR1 intron 21810746 rs1265112 chr6 31118019 T C 7.61E-06 Dengue shock syndrome CCHCR1 intron 22001756 rs130067 chr6 31118511 T G 9.07E-09 Rheumatoid arthritis CCHCR1 missense 17804836 rs130067 chr6 31118511 T G 4.99E-08 Rheumatoid arthritis CCHCR1 missense 19503088 rs130067 chr6 31118511 T G 3.00E-08 Prostate cancer CCHCR1 missense 21743467 rs130078 chr6 31118565 C G 3.90E-14 Graves' disease CCHCR1 cds-synon 21900946 rs2517985 chr6 31118942 T C 1.21E-08 Nevirapine-induced rash CCHCR1 intron 21810746 rs1265111 chr6 31119380 G A 1.21E-08 Nevirapine-induced rash CCHCR1 intron 21810746 rs1265110 chr6 31119422 C T 3.96E-10 Rheumatoid arthritis CCHCR1 intron 17804836 rs1265110 chr6 31119422 C T 7.90E-12 Rheumatoid arthritis CCHCR1 intron 19503088 rs1265109 chr6 31119589 G T 2.05E-04 Crohn's disease CCHCR1 intron 23266558 rs130065 chr6 31122500 G A 2.22E-09 Vitiligo CCHCR1 missense 20526339 rs130065 chr6 31122500 G A 3.13E-08 Asthma CCHCR1 missense 20860503 rs2073716 chr6 31122997 C G 7.08E-04 Multiple complex diseases CCHCR1 intron 17554300 rs2073716 chr6 31122997 C G 4.56E-09 Behcet's disease CCHCR1 intron 23001997 rs3130453 chr6 31124849 C T 4.39E-05 HIV-1 control CCHCR1 STOP-GAIN 20041166 rs3130453 chr6 31124849 C T 6.70E-08 HIV-1 control CCHCR1 STOP-GAIN 21051598 rs3130453 chr6 31124849 C T 2.06E-12 Psoriasis CCHCR1 STOP-GAIN pha002855 rs2239524 chr6 31125569 T G 3.03E-04 Crohn's disease CCHCR1 intron 23266558 rs720465 chr6 31125777 C A 4.53E-07 HIV-1 control CCHCR1 intron 20041166 rs720465 chr6 31125777 C A 1.50E-09 HIV-1 control CCHCR1 intron 21051598 rs720467 chr6 31125799 G A,C,T 1.14E-05 Self-reported allergy CCHCR1 intron 23817569 rs3130455 chr6 31125978 A T 4.45E-09 Vitiligo CCHCR1 UTR-5 20526339 rs720468 chr6 31125993 C G 1.16E-05 Self-reported allergy CCHCR1 UTR-5 23817569 rs3095239 chr6 31126790 A G 5.30E-06 HIV-1 control TCF19 UTR-5 21051598 rs3094187 chr6 31126944 C T 8.22E-07 HIV-1 control TCF19 UTR-5 20041166 rs3094187 chr6 31126944 C T 1.50E-06 HIV-1 control TCF19 UTR-5 21051598 rs3094187 chr6 31126944 C T 2.80E-09 Graves' disease TCF19 UTR-5 21900946 rs3094187 chr6 31126944 C T 1.37E-04 Crohn's disease TCF19 UTR-5 23266558 rs3094187 chr6 31126944 C T 3.73E-13 Psoriasis TCF19 UTR-5 pha002855 rs1150765 chr6 31127562 C T 1.50E-04 HIV-1 control TCF19 intron 21051598 rs7750641 chr6 31129310 C T 1.00E-16 Type 1 diabetes TCF19 missense 17632545 rs7750641 chr6 31129310 C T 2.59E-06 Lung cancer TCF19 missense 18978787 rs7750641 chr6 31129310 C T 7.00E-05 Lung cancer TCF19 missense 18978790 rs7750641 chr6 31129310 C T 6.77E-08 Lung cancer TCF19 missense 19654303 rs7750641 chr6 31129310 C T 5.87E-09 Lung adenocarcinoma TCF19 missense 19836008 rs7750641 chr6 31129310 C T 3.56E-05 HIV-1 control TCF19 missense 20041166 rs7750641 chr6 31129310 C T 2.40E-11 Lung cancer TCF19 missense 22899653 rs7750641 chr6 31129310 C T 0.00002128 Sarcoidosis TCF19 missense 22952805 rs7750641 chr6 31129310 C T 1.20E-92 Myasthenia gravis TCF19 missense 23055271 rs7750641 chr6 31129310 C T 1.50E-13 Systemic lupus erythematosus TCF19 missense 24871463 rs7750641 chr6 31129310 C T 5.60E-06 Systemic lupus erythematosus TCF19 missense pha002867 rs2073721 chr6 31129616 A G 5.00E-06 Multiple myeloma TCF19 missense 23955597 rs2073722 chr6 31129642 A C,G 1.90E-05 Urinary metabolites TCF19 cds-synon 21572414 rs2073724 chr6 31129707 C T 2.05E-09 Multiple complex diseases TCF19 missense 17554300 rs2073724 chr6 31129707 C T 7.42E-07 Rheumatoid arthritis TCF19 missense 19503088 rs2073724 chr6 31129707 C T 8.30E-05 HIV-1 control TCF19 missense 20041166 rs2073724 chr6 31129707 C T 4.57E-07 Longevity,exceptional TCF19 missense 20595579 rs2073724 chr6 31129707 C T 1.10E-05 Self-reported allergy TCF19 missense 23817569 rs9263794 chr6 31130019 A G 9.89E-04 Multiple complex diseases TCF19 intron 17554300 rs9263794 chr6 31130019 A G 9.83E-05 Behcet's disease TCF19 intron pha002888 rs2073723 chr6 31130078 T C 2.27E-06 Multiple complex diseases TCF19 intron 17554300 rs2073723 chr6 31130078 T C 2.69E-10 Multiple sclerosis TCF19 intron 17660530 rs2073723 chr6 31130078 T C 1.20E-05 Urinary metabolites TCF19 intron 21572414 rs2073723 chr6 31130078 T C 1.00E-14 Graves' disease TCF19 intron 21900946 rs2073723 chr6 31130078 T C 5.00E-06 Multiple myeloma TCF19 intron 23955597 rs1419881 chr6 31130593 G A 5.72E-05 HIV-1 control TCF19 UTR-3 20041166 rs1419881 chr6 31130593 G A 2.36E-04 Crohn's disease TCF19 UTR-3 23266558 rs1419881 chr6 31130593 G A 1.00E-18 Chronic hepatitis B infection TCF19 UTR-3 23760081 rs3130933 chr6 31132085 T C 1.60E-08 Type 1 diabetes POU5F1 nearGene-3 17632545 rs3130933 chr6 31132085 T C 1.27E-05 Rheumatoid arthritis POU5F1 nearGene-3 17804836 rs3130933 chr6 31132085 T C 3.21E-07 Multiple sclerosis POU5F1 nearGene-3 20598377 rs2394882 chr6 31132649 A C 2.70E-06 HIV-1 control POU5F1 intron 21051598 rs2394882 chr6 31132649 A C 1.80E-04 Self-reported allergy POU5F1 intron 23817569 rs2106074 chr6 31133509 G A 7.81E-11 Multiple complex diseases POU5F1 intron 17554300 rs2106074 chr6 31133509 G A 1.33E-06 Multiple sclerosis POU5F1 intron 17660530 rs2106074 chr6 31133509 G A 1.30E-06 HIV-1 control POU5F1 intron 21051598 rs2106074 chr6 31133509 G A 1.90E-04 Self-reported allergy POU5F1 intron 23817569 rs9501063 chr6 31133894 G C 1.50E-05 Multiple complex diseases POU5F1 UTR-5 17554300 rs9501063 chr6 31133894 G C 2.29E-05 Behcet's disease POU5F1 UTR-5 pha002888 rs3130932 chr6 31133943 C A 2.19E-05 Orofacial clefts POU5F1 UTR-5 20023658 rs3130932 chr6 31133943 C A 3.00E-06 HIV-1 control POU5F1 UTR-5 21051598 rs3130932 chr6 31133943 C A 9.90E-05 Crohn's disease POU5F1 UTR-5 23266558 rs3130932 chr6 31133943 C A 1.98E-04 Self-reported allergy POU5F1 UTR-5 23817569 rs9263800 chr6 31134599 G A 8.12E-04 Multiple complex diseases POU5F1 UTR-5 17554300 rs9263800 chr6 31134599 G A 6.55E-05 Behcet's disease POU5F1 UTR-5 pha002888 rs3130931 chr6 31134888 T C 3.43E-04 Crohn's disease POU5F1 intron 23266558 rs3130931 chr6 31134888 T C 1.14E-05 Behcet's disease POU5F1 intron pha002888 rs9263804 chr6 31135706 C T 2.65E-06 Multiple complex diseases POU5F1 intron 17554300 rs9263804 chr6 31135706 C T 7.48E-11 Multiple sclerosis POU5F1 intron 17660530 rs9263804 chr6 31135706 C T 9.60E-06 Urinary metabolites POU5F1 intron 21572414 rs200484944 chr6 31135735 A AC 2.97E-05 Behcet's disease POU5F1 intron pha002888 rs9263805 chr6 31135735 A C 2.97E-05 Behcet's disease POU5F1 intron pha002888 rs3130501 chr6 31136453 A G 2.11E-06 Multiple complex diseases POU5F1 intron 17554300 rs3130501 chr6 31136453 A G 2.13E-10 Multiple sclerosis POU5F1 intron 17660530 rs3130501 chr6 31136453 A G 2.29E-05 Orofacial clefts POU5F1 intron 20023658 rs3130501 chr6 31136453 A G 9.60E-06 Urinary metabolites POU5F1 intron 21572414 rs3130501 chr6 31136453 A G 2.00E-08 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) POU5F1 intron 21801394 rs3130501 chr6 31136453 A G 2.22E-04 Crohn's disease POU5F1 intron 23266558 rs3130501 chr6 31136453 A G 6.00E-06 Multiple myeloma POU5F1 intron 23955597 rs3130501 chr6 31136453 A G 4.20E-09 Type 2 diabetes POU5F1 intron 24509480 rs3130502 chr6 31136666 A G 2.00E-06 Multiple myeloma POU5F1 intron 23955597 rs3132524 chr6 31136714 T C 2.66E-06 Multiple complex diseases POU5F1 intron 17554300 rs3132524 chr6 31136714 T C 9.05E-11 Multiple sclerosis POU5F1 intron 17660530 rs3132524 chr6 31136714 T C 9.60E-06 Urinary metabolites POU5F1 intron 21572414 rs3132524 chr6 31136714 T C 4.00E-09 Type 2 diabetes POU5F1 intron 24509480 rs3132523 chr6 31136832 T C 1.00E-06 Multiple myeloma POU5F1 intron 23955597 rs879882 chr6 31139452 T C 2.00E-07 Height POU5F1 nearGene-5 20881960 rs879882 chr6 31139452 T C 5.00E-07 Multiple myeloma POU5F1 nearGene-5 23955597 rs1265159 chr6 31140047 G A 1.24E-06 HIV-1 control POU5F1 nearGene-5 20041166 rs1265159 chr6 31140047 G A 7.15E-09 Vitiligo POU5F1 nearGene-5 20526339 rs1265159 chr6 31140047 G A 1.40E-57 Myasthenia gravis POU5F1 nearGene-5 23055271 rs1265159 chr6 31140047 G A 1.70E-05 Type 2 diabetes POU5F1 nearGene-5 23209189 rs1265159 chr6 31140047 G A 9.50E-06 Systemic lupus erythematosus POU5F1 nearGene-5 24871463 rs885948 chr6 31140532 A G 1.30E-04 HIV-1 control / / 21051598 rs1265158 chr6 31140741 C G 6.92E-05 HIV-1 control / / 20041166 rs1265158 chr6 31140741 C G 0.000008627 Sarcoidosis / / 22952805 rs887468 chr6 31141523 C T 6.20E-05 HIV-1 control / / 21051598 rs887468 chr6 31141523 C T 0.00007144 Sarcoidosis / / 22952805 rs3132517 chr6 31141836 C T 1.50E-06 HIV-1 control PSORS1C3 intron 21051598 rs3094188 chr6 31142245 C A 7.00E-07 Crohn's disease PSORS1C3 intron 23266558 rs9468877 chr6 31142903 G A 2.80E-09 HIV-1 control PSORS1C3 intron 21051598 rs887466 chr6 31143511 G A 7.46E-06 Multiple complex diseases PSORS1C3 intron 17554300 rs887466 chr6 31143511 G A 5.29E-07 Red blood cell traits PSORS1C3 intron 23222517 rs3131018 chr6 31143582 A C 3.21E-05 HIV-1 control PSORS1C3 intron 20041166 rs3131018 chr6 31143582 A C 4.00E-16 HIV-1 control PSORS1C3 intron 21051598 rs887465 chr6 31143652 C G 9.48E-10 Multiple complex diseases PSORS1C3 intron 17554300 rs3868542 chr6 31145839 T C 4.40E-07 Rheumatoid arthritis PSORS1C3 nearGene-5 17804836 rs887464 chr6 31145920 C T 7.75E-41 Multiple complex diseases PSORS1C3 nearGene-5 17554300 rs887464 chr6 31145920 C T 7.17E-08 Type 1 diabetes PSORS1C3 nearGene-5 17632545 rs887464 chr6 31145920 C T 2.45E-06 Rheumatoid arthritis PSORS1C3 nearGene-5 19503088 rs887464 chr6 31145920 C T 2.50E-52 Myasthenia gravis PSORS1C3 nearGene-5 23055271 rs887464 chr6 31145920 C T 3.80E-06 Systemic lupus erythematosus PSORS1C3 nearGene-5 24871463 rs887464 chr6 31145920 C T 8.80E-05 Left ventricular hypertrophy PSORS1C3 nearGene-5 pha003052 rs3130457 chr6 31147194 T C 9.53E-09 Vitiligo PSORS1C3 nearGene-5 20526339 rs3130457 chr6 31147194 T C 9.90E-05 Type 2 diabetes PSORS1C3 nearGene-5 23209189 rs9263827 chr6 31149045 C T 1.39E-07 Behcet's disease / / pha002888 rs7760698 chr6 31150225 T A 4.92E-05 Behcet's disease / / pha002888 rs1128175 chr6 31150435 A G 6.17E-04 Type 2 diabetes / / 17463246 rs1128175 chr6 31150435 A G 2.10E-12 HIV-1 control / / 21051598 rs6921663 chr6 31154620 T C 9.83E-04 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9263844 chr6 31155186 C T 8.05E-11 Behcet's disease / / pha002888 rs1265181 chr6 31155785 G C 5.28E-12 Multiple complex diseases / / 17554300 rs1265181 chr6 31155785 G C 5.85E-09 Vitiligo / / 20526339 rs1265181 chr6 31155785 G C 2.70E-05 Type 2 diabetes / / 23209189 rs9405015 chr6 31155803 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9263850 chr6 31156188 A G 0.00001431 Sarcoidosis / / 22952805 rs9263851 chr6 31156195 C T 0.00003059 Sarcoidosis / / 22952805 rs9295957 chr6 31157593 G A 3.11E-06 Multiple complex diseases / / 17554300 rs9295957 chr6 31157593 G A 1.58E-14 Rheumatoid arthritis / / 17804836 rs9295957 chr6 31157593 G A 8.10E-17 Rheumatoid arthritis / / 19503088 rs9295957 chr6 31157593 G A 0.0000827 Carotid intima media thickness / / 23152477 rs9295957 chr6 31157593 G A 8.88E-05 Triglycerides / / pha002904 rs9263856 chr6 31157707 C T 0.00003331 Sarcoidosis / / 22952805 rs9263857 chr6 31158086 C A 0.00003294 Sarcoidosis / / 22952805 rs9263860 chr6 31158136 C G 0.00003331 Sarcoidosis / / 22952805 rs7759224 chr6 31158468 A G 0.00003175 Sarcoidosis / / 22952805 rs7759909 chr6 31158689 G T 0.00003067 Sarcoidosis / / 22952805 rs28362323 chr6 31159414 T C 0.00003067 Sarcoidosis / / 22952805 rs3915965 chr6 31160117 C T 0.0000276 Sarcoidosis / / 22952805 rs28362328 chr6 31160678 G A 0.00003067 Sarcoidosis / / 22952805 rs3095238 chr6 31161210 T G 9.79E-07 Multiple complex diseases / / 17554300 rs3095238 chr6 31161210 T G 1.14E-18 Multiple sclerosis / / 17660530 rs28362331 chr6 31161897 A T 0.00003208 Sarcoidosis / / 22952805 rs576308474 chr6 31161897 A AT 0.00003208 Sarcoidosis / / 22952805 rs28362332 chr6 31162154 G A 3.37E-06 Cognitive test performance / / 20125193 rs28362332 chr6 31162154 G A 5.40E-10 HIV-1 control / / 21051598 rs28362332 chr6 31162154 G A 0.00003 Sarcoidosis / / 22952805 rs28362332 chr6 31162154 G A 1.02E-05 Behcet's disease / / pha002888 rs6899874 chr6 31162328 C A 3.06E-05 Multiple complex diseases / / 17554300 rs7762933 chr6 31162520 T C 4.88E-07 Lung cancer / / 21725308 rs4713447 chr6 31162963 A G 3.98E-07 Rheumatoid arthritis / / 17804836 rs4713447 chr6 31162963 A G 1.44E-04 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs17191118 chr6 31163133 T C 0.00002675 Sarcoidosis / / 22952805 rs9501510 chr6 31163667 G A,T 0.00002747 Sarcoidosis HCG27 nearGene-5 22952805 rs28742573 chr6 31164009 G T 0.00002739 Sarcoidosis HCG27 nearGene-5 22952805 rs28362334 chr6 31164828 C A 0.00002834 Sarcoidosis HCG27 nearGene-5 22952805 rs28362338 chr6 31165089 T C 0.00002834 Sarcoidosis HCG27 nearGene-5 22952805 rs28362339 chr6 31165269 G A 0.00002834 Sarcoidosis HCG27 nearGene-5 22952805 rs28362340 chr6 31165359 G C 0.00002834 Sarcoidosis HCG27 nearGene-5 22952805 rs28362341 chr6 31165361 C G 0.00002834 Sarcoidosis HCG27 nearGene-5 22952805 rs28362343 chr6 31165527 G A 2.83E-06 Cognitive test performance HCG27 nearGene-5 20125193 rs28362343 chr6 31165527 G A 5.40E-10 HIV-1 control HCG27 nearGene-5 21051598 rs28362343 chr6 31165527 G A 0.0000356 Sarcoidosis HCG27 nearGene-5 22952805 rs28362343 chr6 31165527 G A 1.38E-05 Behcet's disease HCG27 nearGene-5 pha002888 rs3094609 chr6 31165566 T C 6.24E-06 Rheumatoid arthritis / / 17804836 rs3094609 chr6 31165566 T C 1.64E-07 Multiple sclerosis / / 20598377 rs3094609 chr6 31165566 T C 3.40E-07 HIV-1 control / / 21051598 rs9404982 chr6 31166539 G A 1.90E-04 Lupus nephritis in systemic lupus erythematosus HCG27 intron 24925725 rs28362349 chr6 31166598 G A 0.00002692 Sarcoidosis HCG27 intron 22952805 rs28362350 chr6 31166625 G C 0.00002692 Sarcoidosis HCG27 intron 22952805 rs9295961 chr6 31167498 T C 2.46E-04 Multiple complex diseases HCG27 intron 17554300 rs28362351 chr6 31167760 C T 0.00003093 Sarcoidosis HCG27 intron 22952805 rs3868075 chr6 31167815 A G 4.64E-07 Rheumatoid arthritis HCG27 intron 17804836 rs3868075 chr6 31167815 A G 2.23E-04 Lupus nephritis in systemic lupus erythematosus HCG27 intron 24925725 rs4122189 chr6 31167927 C T 1.39E-08 Rheumatoid arthritis HCG27 intron 17804836 rs4122189 chr6 31167927 C T 5.33E-08 Rheumatoid arthritis HCG27 intron 19503088 rs4122189 chr6 31167927 C T 7.07E-05 Lung adenocarcinoma HCG27 intron 19836008 rs4122189 chr6 31167927 C T 1.70E-05 Triglycerides HCG27 intron pha002904 rs6903896 chr6 31168029 G A 6.00E-07 Common traits (Other) HCG27 intron 20585627 rs6903896 chr6 31168029 G A 4.08E-05 Coronary heart disease HCG27 intron 21971053 rs28362352 chr6 31168387 G A 0.00005277 Sarcoidosis HCG27 intron 22952805 rs28362353 chr6 31168571 C T 0.00004893 Sarcoidosis HCG27 intron 22952805 rs28362354 chr6 31168624 C T 0.00005034 Sarcoidosis HCG27 intron 22952805 rs28362361 chr6 31169933 A G 0.00007997 Sarcoidosis HCG27 intron 22952805 rs9263870 chr6 31170514 A G 7.14E-07 HIV-1 control / / 20041166 rs9263870 chr6 31170514 A G 2.48E-06 Cognitive test performance / / 20125193 rs9263870 chr6 31170514 A G 6.60E-11 HIV-1 control / / 21051598 rs9263870 chr6 31170514 A G 0.0000926 Sarcoidosis / / 22952805 rs9263871 chr6 31170528 A G 3.99E-06 HIV-1 control / / 20041166 rs9263871 chr6 31170528 A G 2.10E-10 HIV-1 control / / 21051598 rs9263871 chr6 31170528 A G 9.00E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9263873 chr6 31170713 T C 2.47E-04 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9263875 chr6 31170914 A G 1.89E-14 Rheumatoid arthritis / / 21156761 rs9263876 chr6 31171167 C G 0.00008984 Sarcoidosis / / 22952805 rs6921948 chr6 31171257 A C 5.09E-09 Rheumatoid arthritis / / 21156761 rs6921948 chr6 31171257 A C 0.00006519 Sarcoidosis / / 22952805 rs9263878 chr6 31171486 T C 0.00007844 Sarcoidosis / / 22952805 rs9263879 chr6 31171581 G A 0.00007844 Sarcoidosis / / 22952805 rs9263880 chr6 31171830 C T 0.00007844 Sarcoidosis HCG27 nearGene-3 22952805 rs3132510 chr6 31172151 T C 0.000001351 Sarcoidosis HCG27 nearGene-3 22952805 rs2894180 chr6 31172655 G A 0.0000827 Sarcoidosis / / 22952805 rs4446605 chr6 31173096 A G 3.37E-06 Cognitive test performance / / 20125193 rs4446605 chr6 31173096 A G 3.40E-11 HIV-1 control / / 21051598 rs4446605 chr6 31173096 A G 0.0000827 Sarcoidosis / / 22952805 rs4446605 chr6 31173096 A G 1.42E-05 Behcet's disease / / pha002888 rs3998077 chr6 31173433 G A 0.00006705 Sarcoidosis / / 22952805 rs9263893 chr6 31173906 G A 0.00008668 Sarcoidosis / / 22952805 rs6930462 chr6 31173933 T G 0.0000735 Sarcoidosis / / 22952805 rs9263895 chr6 31173939 T C 0.00008668 Sarcoidosis / / 22952805 rs6930643 chr6 31174035 T C 0.00007254 Sarcoidosis / / 22952805 rs9263897 chr6 31174385 A G 0.00008668 Sarcoidosis / / 22952805 rs2894181 chr6 31174527 A G 3.32E-06 Parkinson's disease / / 21738487 rs2894181 chr6 31174527 A G 0.00007178 Sarcoidosis / / 22952805 rs2894181 chr6 31174527 A G 4.06E-06 Age-related macular degeneration / / pha002869 rs2894181 chr6 31174527 A G 5.46E-05 Blood Pressure / / pha003050 rs6936825 chr6 31175044 T C 0.00007178 Sarcoidosis / / 22952805 rs9263904 chr6 31175126 C T 0.00008917 Sarcoidosis / / 22952805 rs9263907 chr6 31175283 C T 0.00008917 Sarcoidosis / / 22952805 rs4249311 chr6 31175608 T C 0.00007225 Sarcoidosis / / 22952805 rs9263910 chr6 31175662 A G 0.00008917 Sarcoidosis / / 22952805 rs545040429 chr6 31175667 A G 3.00E-09 HIV-1 control / / 21051598 rs9263911 chr6 31175667 A G 3.00E-09 HIV-1 control / / 21051598 rs6919603 chr6 31175912 A G 0.00002748 Sarcoidosis / / 22952805 rs1619179 chr6 31175946 A C 0.000007734 Sarcoidosis / / 22952805 rs3132506 chr6 31176226 T C 4.10E-04 HIV-1 control / / 21051598 rs3132506 chr6 31176226 T C 0.0000838 Sarcoidosis / / 22952805 rs4410769 chr6 31176246 C T 0.000005506 Sarcoidosis / / 22952805 rs3887152 chr6 31176335 C T 7.09E-05 Age-related macular degeneration / / pha002890 rs4516988 chr6 31176602 A G 4.28E-07 Multiple complex diseases / / 17554300 rs4516988 chr6 31176602 A G 7.37E-07 Multiple sclerosis / / 17660530 rs9263916 chr6 31176928 T C 3.37E-06 Cognitive test performance / / 20125193 rs9263916 chr6 31176928 T C 6.10E-11 HIV-1 control / / 21051598 rs9263916 chr6 31176928 T C 0.00008435 Sarcoidosis / / 22952805 rs3130511 chr6 31176948 C T 0.00003256 Sarcoidosis / / 22952805 rs3130953 chr6 31177094 G A 7.83E-08 Multiple complex diseases / / 17554300 rs3130953 chr6 31177094 G A 0.00003171 Sarcoidosis / / 22952805 rs4457201 chr6 31177372 T C 0.000002698 Sarcoidosis / / 22952805 rs3132505 chr6 31177503 G T 5.40E-04 HIV-1 control / / 21051598 rs3132505 chr6 31177503 G T 0.00008548 Sarcoidosis / / 22952805 rs3130952 chr6 31177915 G A 1.13E-07 Multiple complex diseases / / 17554300 rs3130952 chr6 31177915 G A 1.19E-18 Multiple sclerosis / / 17660530 rs9263928 chr6 31178324 T G 0.000002659 Sarcoidosis / / 22952805 rs9263929 chr6 31178328 G A 0.000002659 Sarcoidosis / / 22952805 rs9263930 chr6 31178376 A G 0.00008654 Sarcoidosis / / 22952805 rs9263931 chr6 31178547 A G 0.000002659 Sarcoidosis / / 22952805 rs9263932 chr6 31178613 C A 0.00008654 Sarcoidosis / / 22952805 rs9263933 chr6 31178626 A G 0.000002659 Sarcoidosis / / 22952805 rs9295965 chr6 31179033 T C 4.43E-07 Multiple complex diseases / / 17554300 rs9295965 chr6 31179033 T C 1.58E-05 Multiple sclerosis / / 17660530 rs9263936 chr6 31179159 A C 0.000002586 Sarcoidosis / / 22952805 rs3134785 chr6 31179193 G A 0.00009101 Sarcoidosis / / 22952805 rs9263938 chr6 31179378 C T 0.000002586 Sarcoidosis / / 22952805 rs9263940 chr6 31179492 C T 0.000002504 Sarcoidosis / / 22952805 rs9263941 chr6 31180055 G A 0.00008654 Sarcoidosis / / 22952805 rs9263943 chr6 31180339 G A 0.00008654 Sarcoidosis / / 22952805 rs9263944 chr6 31180423 A G 0.000002504 Sarcoidosis / / 22952805 rs9263946 chr6 31180642 T C 0.0000889 Sarcoidosis / / 22952805 rs9263947 chr6 31180680 T G 0.000002491 Sarcoidosis / / 22952805 rs9263948 chr6 31181025 C T 3.37E-06 Cognitive test performance / / 20125193 rs9263948 chr6 31181025 C T 6.10E-11 HIV-1 control / / 21051598 rs9263948 chr6 31181025 C T 0.00008435 Sarcoidosis / / 22952805 rs9263948 chr6 31181025 C T 8.67E-06 Behcet's disease / / pha002888 rs9263949 chr6 31181092 T C 0.00008435 Sarcoidosis / / 22952805 rs9263950 chr6 31181196 G C 0.00008435 Sarcoidosis / / 22952805 rs9263951 chr6 31181270 C T 0.00007368 Sarcoidosis / / 22952805 rs9263952 chr6 31181346 G A 0.000002753 Sarcoidosis / / 22952805 rs9263953 chr6 31181708 T C 0.000002756 Sarcoidosis / / 22952805 rs9263954 chr6 31182021 T A 0.00007368 Sarcoidosis / / 22952805 rs9263955 chr6 31182059 G A 0.00007368 Sarcoidosis / / 22952805 rs9468898 chr6 31182383 A G 7.68E-257 Ankylosing spondylitis / / 22138694 rs9468898 chr6 31182383 A G 2.51E-06 Behcet's disease / / pha002888 rs9263956 chr6 31182971 C T 0.000002283 Sarcoidosis / / 22952805 rs3132502 chr6 31183509 G A 0.00003742 Sarcoidosis / / 22952805 rs9295967 chr6 31184020 A G 5.62E-07 Multiple complex diseases / / 17554300 rs9263957 chr6 31184175 G A 6.70E-11 HIV-1 control / / 21051598 rs9263957 chr6 31184175 G A 0.00009784 Sarcoidosis / / 22952805 rs3869109 chr6 31184196 A G 1.34E-04 Multiple complex diseases / / 17554300 rs3869109 chr6 31184196 A G 1.20E-11 Rheumatoid arthritis / / 17804836 rs3869109 chr6 31184196 A G 2.70E-05 Rheumatoid arthritis / / 19503088 rs3869109 chr6 31184196 A G 5.62E-08 Rheumatoid arthritis / / 21156761 rs3869109 chr6 31184196 A G 7.33E-06 Parkinson's disease / / 21738487 rs3869109 chr6 31184196 A G 1.00E-09 Coronary heart disease / / 22319020 rs3869109 chr6 31184196 A G 0.000002504 Sarcoidosis / / 22952805 rs3869109 chr6 31184196 A G 2.40E-04 Systemic lupus erythematosus / / 24871463 rs3130514 chr6 31184524 C G 0.00009062 Sarcoidosis / / 22952805 rs9263959 chr6 31184553 G C 0.0000872 Sarcoidosis / / 22952805 rs9263960 chr6 31184877 T C 0.000002934 Sarcoidosis / / 22952805 rs9263961 chr6 31184903 C T 0.0000872 Sarcoidosis / / 22952805 rs9263962 chr6 31185803 G A 0.00001955 Sarcoidosis / / 22952805 rs9263963 chr6 31186026 A T 0.00008435 Sarcoidosis / / 22952805 rs9263963 chr6 31186026 A T 1.00E-06 IgG glycosylation / / 23382691 rs9263964 chr6 31186039 C T 0.000009938 Sarcoidosis / / 22952805 rs9263965 chr6 31186083 G C 0.00008435 Sarcoidosis / / 22952805 rs9263966 chr6 31186230 C A,T 0.00008264 Sarcoidosis / / 22952805 rs9263967 chr6 31186245 A G 8.95E-08 Rheumatoid arthritis / / 21156761 rs9263967 chr6 31186245 A G 0.000002312 Sarcoidosis / / 22952805 rs9263967 chr6 31186245 A G 7.30E-15 Psoriasis / / pha002855 rs9263968 chr6 31186368 G A 0.000001942 Sarcoidosis / / 22952805 rs9263971 chr6 31186647 C T 0.00008115 Sarcoidosis / / 22952805 rs9263972 chr6 31186837 G A 0.00001538 Sarcoidosis / / 22952805 rs9263974 chr6 31186869 G A 0.00001538 Sarcoidosis / / 22952805 rs3130467 chr6 31187075 C T 2.84E-05 HIV-1 control / / 20041166 rs3130467 chr6 31187075 C T 2.80E-05 HIV-1 control / / 21051598 rs3130467 chr6 31187075 C T 1.11E-16 Psoriasis risk prediction / / 21214922 rs3130467 chr6 31187075 C T 0.00003247 Sarcoidosis / / 22952805 rs3130467 chr6 31187075 C T 7.90E-05 Crohn's disease / / 23266558 rs3130467 chr6 31187075 C T 1.34E-27 Psoriasis / / pha002855 rs3130467 chr6 31187075 C T 5.92E-06 Behcet's disease / / pha002888 rs9263976 chr6 31187414 G A 0.00001664 Sarcoidosis / / 22952805 rs9263977 chr6 31187529 T C 0.00001664 Sarcoidosis / / 22952805 rs9263978 chr6 31187568 A G 0.000002273 Sarcoidosis / / 22952805 rs9263980 chr6 31188397 A G 0.00000183 Sarcoidosis / / 22952805 rs3130517 chr6 31190303 T C 4.33E-15 Psoriasis risk prediction / / 21214922 rs3130517 chr6 31190303 T C 0.00007934 Sarcoidosis / / 22952805 rs3130517 chr6 31190303 T C 1.43E-28 Psoriasis / / pha002855 rs12662501 chr6 31190850 C T 1.95E-04 Self-reported allergy / / 23817569 rs9263986 chr6 31191070 A G 0.000002483 Sarcoidosis / / 22952805 rs1793895 chr6 31192192 G T 1.20E-09 Multiple complex diseases / / 17554300 rs6904669 chr6 31192796 A G 9.80E-09 Rheumatoid arthritis / / 21156761 rs4997405 chr6 31193211 C T 0.00000814 Sarcoidosis / / 22952805 rs7758178 chr6 31193966 A T 1.98E-05 Self-reported allergy / / 23817569 rs6928399 chr6 31195218 C T 3.80E-08 HIV-1 control / / 21051598 rs7769059 chr6 31195996 G A 0.000002958 Sarcoidosis / / 22952805 rs1639108 chr6 31196554 T C 0.00001396 Sarcoidosis / / 22952805 rs3130944 chr6 31196671 C G 2.15E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs3130944 chr6 31196671 C G 4.41E-12 Multiple complex diseases / / 17554300 rs3130944 chr6 31196671 C G 0.00000142 Behcet's disease / / 23041938 rs1793894 chr6 31196862 G A 0.00002592 Sarcoidosis / / 22952805 rs3134783 chr6 31197263 G A,T 3.50E-10 HIV-1 control / / 21051598 rs3130942 chr6 31197293 C T 2.50E-08 HIV-1 control / / 21051598 rs3130941 chr6 31197514 C G 1.00E-10 IgE levels / / 24324648 rs6908994 chr6 31198709 C T 1.55E-05 Multiple complex diseases / / 17554300 rs3130473 chr6 31199208 C T 5.00E-08 HIV-1 control / / 20041166 rs3130473 chr6 31199208 C T 1.04E-08 Vitiligo / / 20526339 rs3130473 chr6 31199208 C T 6.00E-08 HIV-1 control / / 21051598 rs3130473 chr6 31199208 C T 1.50E-55 Myasthenia gravis / / 23055271 rs3130473 chr6 31199208 C T 5.40E-06 Systemic lupus erythematosus / / 24871463 rs3130473 chr6 31199208 C T 1.86E-08 Behcet's disease / / pha002888 rs7757622 chr6 31200764 C T 0.000009821 Sarcoidosis / / 22952805 rs9264086 chr6 31201684 G A 0.00001257 Sarcoidosis / / 22952805 rs6927080 chr6 31201772 C G 0.00001411 Sarcoidosis / / 22952805 rs6457349 chr6 31203886 A T 5.10E-08 Graves' disease / / 21900946 rs7745906 chr6 31204008 G A 2.03E-14 Rheumatoid arthritis / / 17804836 rs7745906 chr6 31204008 G A 1.47E-16 Rheumatoid arthritis / / 19503088 rs3130713 chr6 31205617 G T 2.54E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs3130713 chr6 31205617 G T 6.54E-12 Multiple complex diseases / / 17554300 rs3130713 chr6 31205617 G T 5.55E-16 Psoriasis risk prediction / / 21214922 rs3130713 chr6 31205617 G T 9.81E-28 Psoriasis / / pha002855 rs3130685 chr6 31206206 C T 2.86E-06 HIV-1 control / / 20041166 rs3130685 chr6 31206206 C T 8.58E-14 Psoriasis / / pha002855 rs3130531 chr6 31206616 A G 2.31E-04 Multiple complex diseases / / 17554300 rs3130531 chr6 31206616 A G 7.53E-06 Multiple sclerosis / / 17660530 rs3134768 chr6 31206844 G C 5.04E-05 Parkinson's disease / / 21738487 rs2894186 chr6 31206868 G C 0.00000408 Behcet's disease / / 23041938 rs2394894 chr6 31206920 T C 1.40E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2394894 chr6 31206920 T C 1.47E-07 Multiple complex diseases / / 17554300 rs2394894 chr6 31206920 T C 1.00E-07 HIV-1 control / / 21051598 rs2394895 chr6 31206979 T C 2.28E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2394895 chr6 31206979 T C 1.36E-07 Multiple complex diseases / / 17554300 rs2394895 chr6 31206979 T C 1.60E-07 HIV-1 control / / 21051598 rs2394895 chr6 31206979 T C 1.13E-14 Psoriasis risk prediction / / 21214922 rs2394895 chr6 31206979 T C 2.59E-29 Psoriasis / / pha002855 rs3868082 chr6 31207692 A G 0.00003853 Sarcoidosis / / 22952805 rs3095250 chr6 31208340 C T 1.56E-07 Multiple complex diseases / / 17554300 rs3095250 chr6 31208340 C T 6.83E-07 Multiple sclerosis / / 17660530 rs3095250 chr6 31208340 C T 1.22E-05 HIV-1 control / / 20041166 rs3095250 chr6 31208340 C T 3.57E-06 Multiple sclerosis / / 20598377 rs3095250 chr6 31208340 C T 1.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3095250 chr6 31208340 C T 2.89E-12 Psoriasis / / pha002855 rs3130532 chr6 31208453 A G 1.06E-07 Multiple complex diseases / / 17554300 rs3130532 chr6 31208453 A G 2.82E-18 Multiple sclerosis / / 17660530 rs3132496 chr6 31208610 G T 2.90E-12 Psoriasis / / pha002855 rs3130534 chr6 31209045 G A 4.76E-09 Multiple complex diseases / / 17554300 rs3130534 chr6 31209045 G A 1.20E-07 Multiple sclerosis / / 17660530 rs3130712 chr6 31209510 C T 6.46E-05 HIV-1 control / / 20041166 rs3130712 chr6 31209510 C T 6.18E-06 Multiple sclerosis / / 20598377 rs3130712 chr6 31209510 C T 9.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3130712 chr6 31209510 C T 7.24E-05 Crohn's disease / / 23266558 rs3130688 chr6 31210216 C T 1.43E-05 HIV-1 control / / 20041166 rs3134762 chr6 31210866 T C 1.48E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs3134762 chr6 31210866 T C 1.96E-07 Multiple complex diseases / / 17554300 rs3134762 chr6 31210866 T C 1.00E-07 HIV-1 control / / 21051598 rs3130409 chr6 31213811 G A 1.39E-05 Relative hand skill / / 24068947 rs3899471 chr6 31215037 T C 4.08E-09 Multiple complex diseases / / 17554300 rs3130424 chr6 31218239 A C 6.60E-07 HIV-1 control / / 20041166 rs3130424 chr6 31218239 A C 3.23E-09 Vitiligo / / 20526339 rs3130424 chr6 31218239 A C 1.30E-07 HIV-1 control / / 21051598 rs3130425 chr6 31218327 T C 1.81E-12 Psoriasis / / pha002855 rs4084090 chr6 31218835 A G 2.86E-09 Behcet's disease / / pha002888 rs4084262 chr6 31218889 C T 1.36E-04 Self-reported allergy / / 23817569 rs2394944 chr6 31220450 C T 2.90E-07 HIV-1 control / / 21051598 rs4416711 chr6 31221039 C T 4.00E-05 HIV-1 control / / 20041166 rs3095254 chr6 31221668 C G 6.00E-11 White blood cell types / / 21738478 rs1793891 chr6 31221698 C T 2.40E-05 HIV-1 control / / 21051598 rs1793891 chr6 31221698 C T 0.00002864 Sarcoidosis / / 22952805 rs9264219 chr6 31221914 C T 5.50E-05 HIV-1 control / / 20041166 rs9264219 chr6 31221914 C T 6.30E-10 HIV-1 control / / 21051598 rs9264227 chr6 31222119 G A 8.62E-06 Hepatitis B / / 24162738 rs2524130 chr6 31226591 C T 0.0000244 Sarcoidosis / / 22952805 rs2844630 chr6 31228084 G T 0.00001057 Sarcoidosis / / 22952805 rs2428535 chr6 31228214 C T 0.000008793 Sarcoidosis / / 22952805 rs4570007 chr6 31228282 C T 0.000008531 Sarcoidosis / / 22952805 rs1986997 chr6 31228410 T C 0.00002078 Sarcoidosis / / 22952805 rs3130443 chr6 31228600 C T 0.00001087 Sarcoidosis / / 22952805 rs3130444 chr6 31228634 T C 0.000009862 Sarcoidosis / / 22952805 rs2524122 chr6 31228860 C A 0.000009633 Sarcoidosis / / 22952805 rs9264393 chr6 31229279 G A 1.33E-07 Sarcoidosis / / 22952805 rs9264396 chr6 31229307 C T 0.000004836 Sarcoidosis / / 22952805 rs2844627 chr6 31229462 C T 0.000009633 Sarcoidosis / / 22952805 rs2844627 chr6 31229462 C T 2.31E-36 Psoriasis / / pha002855 rs2844626 chr6 31229552 A T 0.00003273 Sarcoidosis / / 22952805 rs11966319 chr6 31229678 C T 2.14E-23 Rheumatoid arthritis / / 21156761 rs11966319 chr6 31229678 C T 6.97E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11966319 chr6 31229678 C T 2.79E-04 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs11966332 chr6 31229701 C T 2.14E-23 Rheumatoid arthritis / / 21156761 rs11966332 chr6 31229701 C T 2.77E-04 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9264411 chr6 31229845 C T 3.10E-06 Hepatitis B / / 24162738 rs9264412 chr6 31229921 G C 3.10E-06 Hepatitis B / / 24162738 rs9264413 chr6 31229930 C T 1.63E-06 Hepatitis B / / 24162738 rs9264414 chr6 31229942 T C 3.10E-06 Hepatitis B / / 24162738 rs2245731 chr6 31229966 T C 0.000007687 Sarcoidosis / / 22952805 rs9264417 chr6 31230078 A G 3.10E-06 Hepatitis B / / 24162738 rs2245738 chr6 31230221 A C 0.00001615 Sarcoidosis / / 22952805 rs9264427 chr6 31230356 G A 3.10E-06 Hepatitis B / / 24162738 rs9264428 chr6 31230452 C A 3.10E-06 Hepatitis B / / 24162738 rs9264429 chr6 31230498 G A 3.46E-06 Hepatitis B / / 24162738 rs4995903 chr6 31230605 C T 2.90E-06 Hepatitis B / / 24162738 rs4995902 chr6 31230645 C T 3.46E-06 Hepatitis B / / 24162738 rs4995901 chr6 31230651 G C 3.10E-06 Hepatitis B / / 24162738 rs2394950 chr6 31230701 G A 5.79E-06 HIV-1 control / / 20041166 rs2394951 chr6 31230759 A G 3.10E-06 Hepatitis B / / 24162738 rs2245822 chr6 31230800 G A 0.00003956 Sarcoidosis / / 22952805 rs2524117 chr6 31230869 T C 0.00001939 Sarcoidosis / / 22952805 rs2394952 chr6 31230882 G A 3.10E-06 Hepatitis B / / 24162738 rs7747738 chr6 31230924 C T 7.53E-05 Self-reported allergy / / 23817569 rs2524116 chr6 31231176 C T 0.00003956 Sarcoidosis / / 22952805 rs9264450 chr6 31231193 A G 3.13E-06 Hepatitis B / / 24162738 rs9264451 chr6 31231199 C T 2.80E-06 Hepatitis B / / 24162738 rs9264452 chr6 31231232 G A 3.29E-06 Hepatitis B / / 24162738 rs9264455 chr6 31231382 T A 4.48E-06 Hepatitis B / / 24162738 rs2524114 chr6 31231454 A G 0.00002309 Sarcoidosis / / 22952805 rs3888070 chr6 31231644 C G,T 0.0000302 Sarcoidosis / / 22952805 rs9264466 chr6 31231688 T C 4.00E-06 Hepatitis B / / 24162738 rs2524113 chr6 31231692 T G 0.00003327 Sarcoidosis / / 22952805 rs4365966 chr6 31231718 C A 9.60E-07 Hepatitis B / / 24162738 rs2524112 chr6 31231780 A G 0.00001086 Sarcoidosis / / 22952805 rs2524111 chr6 31231784 A T 0.0000346 Sarcoidosis / / 22952805 rs3130445 chr6 31231809 T C 2.05E-06 Hepatitis B / / 24162738 rs2853961 chr6 31231989 G A 0.00003294 Sarcoidosis / / 22952805 rs3130542 chr6 31232111 A G 2.05E-08 HIV-1 control / / 20041166 rs3130542 chr6 31232111 A G 2.33E-05 Multiple sclerosis / / 20598377 rs3130542 chr6 31232111 A G 6.04E-05 HIV-1 viral setpoint / / 21490045 rs3130542 chr6 31232111 A G 4.56E-06 Hodgkin's lymphoma / / 24149102 rs3130542 chr6 31232111 A G 9.00E-14 Hepatitis B / / 24162738 rs3130543 chr6 31232147 C T 2.88E-06 Hepatitis B / / 24162738 rs2844624 chr6 31232247 T C 0.00001577 Sarcoidosis / / 22952805 rs9264481 chr6 31232318 T C 1.66E-06 Hepatitis B / / 24162738 rs9264482 chr6 31232412 T G 4.34E-06 Hepatitis B / / 24162738 rs9264483 chr6 31232446 T C 4.25E-06 Hepatitis B / / 24162738 rs2524108 chr6 31232451 C G 0.000004428 Sarcoidosis / / 22952805 rs2853960 chr6 31232484 G A 0.00003683 Sarcoidosis / / 22952805 rs2844623 chr6 31232543 C T 4.40E-05 HIV-1 control / / 20041166 rs2844623 chr6 31232543 C T 5.91E-08 Hepatitis B vaccine response / / 21764829 rs9264489 chr6 31232563 C G 4.21E-06 Hepatitis B / / 24162738 rs9264490 chr6 31232578 A G 0.00003683 Sarcoidosis / / 22952805 rs2524107 chr6 31232590 C T 0.00001376 Sarcoidosis / / 22952805 rs9264492 chr6 31232676 T A,G 4.61E-06 Hepatitis B / / 24162738 rs9264493 chr6 31232697 A G 5.44E-06 Hepatitis B / / 24162738 rs9264494 chr6 31232703 A G 4.88E-06 Hepatitis B / / 24162738 rs9264497 chr6 31232769 G A 4.34E-06 Hepatitis B / / 24162738 rs9264498 chr6 31232789 A T 4.34E-06 Hepatitis B / / 24162738 rs9264500 chr6 31232825 G A 4.25E-06 Hepatitis B / / 24162738 rs2524105 chr6 31232910 G C 0.000009674 Sarcoidosis / / 22952805 rs9264502 chr6 31232913 C T 4.34E-06 Hepatitis B / / 24162738 rs9264505 chr6 31233121 T C 4.34E-06 Hepatitis B / / 24162738 rs9264506 chr6 31233143 C T 4.83E-06 Hepatitis B / / 24162738 rs9264507 chr6 31233152 A G 4.34E-06 Hepatitis B / / 24162738 rs9264508 chr6 31233214 T C 4.34E-06 Hepatitis B / / 24162738 rs9264508 chr6 31233214 T C 1.33E-06 HIV-1 control / / 20041166 rs9264508 chr6 31233214 T C 1.43E-05 Hodgkin's lymphoma / / 24149102 rs549189246 chr6 31233258 G C 4.34E-06 Hepatitis B / / 24162738 rs9264511 chr6 31233258 G C 4.34E-06 Hepatitis B / / 24162738 rs2894202 chr6 31233270 T G 4.34E-06 Hepatitis B / / 24162738 rs2394953 chr6 31233353 G A 4.83E-06 Hepatitis B / / 24162738 rs2394953 chr6 31233353 G A 1.60E-04 HIV-1 control / / 21051598 rs2394956 chr6 31233456 C T 4.34E-06 Hepatitis B / / 24162738 rs112229878 chr6 31233510 T C 2.02E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs112229878 chr6 31233510 T C 2.08E-12 Multiple complex diseases / / 17554300 rs2394957 chr6 31233521 T C 4.34E-06 Hepatitis B / / 24162738 rs2394958 chr6 31233529 T C 5.10E-06 Hepatitis B / / 24162738 rs560512392 chr6 31233529 T C 5.10E-06 Hepatitis B / / 24162738 rs571519400 chr6 31233643 T C 4.83E-06 Hepatitis B / / 24162738 rs9264522 chr6 31233643 T C 4.83E-06 Hepatitis B / / 24162738 rs9264523 chr6 31233758 T A 4.34E-06 Hepatitis B / / 24162738 rs9264524 chr6 31233845 T G 4.83E-06 Hepatitis B / / 24162738 rs9264526 chr6 31233988 G T 4.83E-06 Hepatitis B / / 24162738 rs9264527 chr6 31233992 C T 4.83E-06 Hepatitis B / / 24162738 rs9264528 chr6 31234058 A G 3.61E-06 Hepatitis B / / 24162738 rs9264529 chr6 31234074 G A 3.61E-06 Hepatitis B / / 24162738 rs2248902 chr6 31234114 G A 7.06E-09 Vitiligo / / 20526339 rs2248902 chr6 31234114 G A 0.00003955 Sarcoidosis / / 22952805 rs2248902 chr6 31234114 G A 3.70E-04 Type 2 diabetes / / 23209189 rs115799091 chr6 31234569 C T 0.000009616 Sarcoidosis / / 22952805 rs9264548 chr6 31234771 A G 7.41E-06 Hepatitis B / / 24162738 rs9264559 chr6 31235127 T C 4.65E-06 Hepatitis B / / 24162738 rs9264560 chr6 31235139 T C 5.71E-06 Hepatitis B / / 24162738 rs6929779 chr6 31235276 C T 1.37E-06 Hepatitis B / / 24162738 rs9264570 chr6 31235421 C T 1.93E-06 Hepatitis B / / 24162738 rs571022361 chr6 31235502 T TA 6.09E-06 Hepatitis B / / 24162738 rs9264572 chr6 31235502 T A 6.09E-06 Hepatitis B / / 24162738 rs2853953 chr6 31235505 G A 0.00004423 Sarcoidosis / / 22952805 rs6907910 chr6 31235558 A G 5.10E-06 Hepatitis B / / 24162738 rs9264575 chr6 31235576 G C 5.10E-06 Hepatitis B / / 24162738 rs6907622 chr6 31235610 C A 2.14E-06 Hepatitis B / / 24162738 rs9264578 chr6 31235708 C G 4.43E-06 Hepatitis B / / 24162738 rs9264581 chr6 31235786 C T 4.22E-06 Hepatitis B / / 24162738 rs3873372 chr6 31235798 G T 1.61E-07 Behcet's disease / / pha002888 rs9264582 chr6 31235816 A G 3.80E-06 Hepatitis B / / 24162738 rs2853952 chr6 31235869 T C 0.00007759 Sarcoidosis / / 22952805 rs2853951 chr6 31236115 C T 0.00002453 Sarcoidosis HLA-C nearGene-3 22952805 rs2853950 chr6 31236175 C T 1.76E-14 Psoriasis HLA-C nearGene-3 pha002855 rs2524098 chr6 31236316 G T 5.16E-06 Hepatitis B HLA-C nearGene-3 24162738 rs2524098 chr6 31236316 G T 0.000007832 Sarcoidosis HLA-C nearGene-3 22952805 rs2524097 chr6 31236339 T C 5.20E-06 Hepatitis B HLA-C nearGene-3 24162738 rs2524097 chr6 31236339 T C 0.000006827 Sarcoidosis HLA-C nearGene-3 22952805 rs9264586 chr6 31236523 A G 0.000009655 Sarcoidosis HLA-C nearGene-3 22952805 rs9264587 chr6 31236524 A G 0.00000566 Sarcoidosis HLA-C nearGene-3 22952805 rs1049281 chr6 31236567 T C 1.44E-07 Rheumatoid arthritis HLA-C UTR-3 21156761 rs1049281 chr6 31236567 T C 0.00001773 Sarcoidosis HLA-C UTR-3 22952805 rs9264594 chr6 31237048 A G 0.000004572 Sarcoidosis HLA-C intron 22952805 rs2894204 chr6 31237061 C T 3.64E-07 Sarcoidosis HLA-C intron 22952805 rs1130838 chr6 31237124 T C 0.000004572 Sarcoidosis HLA-C missense 22952805 rs1130838 chr6 31237124 T C 8.31E-06 Hepatitis B HLA-C missense 24162738 rs35708511 chr6 31237162 C G 8.31E-06 Hepatitis B HLA-C missense 24162738 rs35708511 chr6 31237162 C G 0.000004572 Sarcoidosis HLA-C missense 22952805 rs9264596 chr6 31237230 A G 0.000003975 Sarcoidosis HLA-C intron 22952805 rs9264597 chr6 31237233 A G 0.000004923 Sarcoidosis HLA-C intron 22952805 rs2523609 chr6 31237255 G A 0.00002168 Sarcoidosis HLA-C intron 22952805 rs68094471 chr6 31237323 A G 8.31E-06 Hepatitis B HLA-C intron 24162738 rs68094471 chr6 31237323 A G 0.000004873 Sarcoidosis HLA-C intron 22952805 rs66772001 chr6 31237333 T A 6.93E-06 Hepatitis B HLA-C intron 24162738 rs66772001 chr6 31237333 T A 0.000004873 Sarcoidosis HLA-C intron 22952805 rs67827555 chr6 31237353 T C 7.29E-06 Hepatitis B HLA-C intron 24162738 rs56010430 chr6 31237405 C T 8.31E-06 Hepatitis B HLA-C intron 24162738 rs56010430 chr6 31237405 C T 0.00001034 Sarcoidosis HLA-C intron 22952805 rs9264602 chr6 31237406 G C,T 5.38E-06 HIV-1 control HLA-C intron 20041166 rs9264602 chr6 31237406 G C,T 2.20E-06 HIV-1 control HLA-C intron 21051598 rs9264602 chr6 31237406 G C,T 3.27E-07 Rheumatoid arthritis HLA-C intron 21156761 rs66459704 chr6 31237437 T C 8.31E-06 Hepatitis B HLA-C intron 24162738 rs66459704 chr6 31237437 T C 0.0000108 Sarcoidosis HLA-C intron 22952805 rs9264603 chr6 31237438 G A,C,T 2.90E-07 Rheumatoid arthritis HLA-C intron 21156761 rs68037221 chr6 31237449 T C 3.48E-06 Hepatitis B HLA-C intron 24162738 rs68037221 chr6 31237449 T C 0.00003753 Sarcoidosis HLA-C intron 22952805 rs66620546 chr6 31237463 C G 8.31E-06 Hepatitis B HLA-C intron 24162738 rs66620546 chr6 31237463 C G 0.0000108 Sarcoidosis HLA-C intron 22952805 rs3819287 chr6 31237563 C T 6.84E-06 Hepatitis B HLA-C intron 24162738 rs3819287 chr6 31237563 C T 0.0000108 Sarcoidosis HLA-C intron 22952805 rs9264606 chr6 31237592 A C 6.84E-06 Hepatitis B HLA-C intron 24162738 rs9264606 chr6 31237592 A C 2.90E-07 Rheumatoid arthritis HLA-C intron 21156761 rs9264606 chr6 31237592 A C 0.0000108 Sarcoidosis HLA-C intron 22952805 rs9264608 chr6 31237660 A C,G,T 8.31E-06 Hepatitis B HLA-C intron 24162738 rs9264608 chr6 31237660 A C,G,T 2.90E-07 Rheumatoid arthritis HLA-C intron 21156761 rs9264608 chr6 31237660 A C,G,T 0.0000108 Sarcoidosis HLA-C intron 22952805 rs9264609 chr6 31237664 C T 8.31E-06 Hepatitis B HLA-C intron 24162738 rs9264609 chr6 31237664 C T 0.0000108 Sarcoidosis HLA-C intron 22952805 rs41556617 chr6 31237786 A T 3.81E-06 Hepatitis B HLA-C cds-synon 24162738 rs1050147 chr6 31237802 A G 0.000007441 Sarcoidosis HLA-C missense 22952805 rs9264622 chr6 31237876 A G 0.000006058 Sarcoidosis HLA-C intron 22952805 rs2308622 chr6 31238029 T C 0.00001321 Sarcoidosis HLA-C missense 22952805 rs707908 chr6 31238053 G C,T 0.000009054 Sarcoidosis HLA-C missense 22952805 rs1050317 chr6 31238135 G A 0.00001781 Sarcoidosis HLA-C cds-synon 22952805 rs1050320 chr6 31238138 C T 0.00001803 Sarcoidosis HLA-C cds-synon 22952805 rs1050716 chr6 31238230 G C,T 0.00001096 Sarcoidosis HLA-C missense 22952805 rs1050716 chr6 31238230 G C,T 6.80E-06 Hepatitis B HLA-C missense 24162738 rs1050344 chr6 31238234 G A 0.00001135 Sarcoidosis HLA-C cds-synon 22952805 rs1050344 chr6 31238234 G A 2.34E-06 Hepatitis B HLA-C cds-synon 24162738 rs1131096 chr6 31238259 G C,T 0.0000146 Sarcoidosis HLA-C missense 22952805 rs1131096 chr6 31238259 G C,T 2.47E-06 Hepatitis B HLA-C missense 24162738 rs9264636 chr6 31238297 C T 2.83E-06 Hepatitis B HLA-C intron 24162738 rs9264636 chr6 31238297 C T 4.40E-07 Rheumatoid arthritis HLA-C intron 21156761 rs9264636 chr6 31238297 C T 0.00001096 Sarcoidosis HLA-C intron 22952805 rs9264637 chr6 31238308 G C 2.83E-06 Hepatitis B HLA-C intron 24162738 rs9264637 chr6 31238308 G C 0.00001096 Sarcoidosis HLA-C intron 22952805 rs9264638 chr6 31238318 G A 2.94E-06 Hepatitis B HLA-C intron 24162738 rs9264638 chr6 31238318 G A 0.00001301 Sarcoidosis HLA-C intron 22952805 rs9264638 chr6 31238318 G A 2.00E-23 Beta-2 microglubulin plasma levels HLA-C intron 23417110 rs9264640 chr6 31238372 C G 8.28E-06 Hepatitis B HLA-C intron 24162738 rs9264640 chr6 31238372 C G 0.00001096 Sarcoidosis HLA-C intron 22952805 rs9264642 chr6 31238490 T C 9.18E-06 Hepatitis B HLA-C intron 24162738 rs9264643 chr6 31238492 C A 7.72E-06 Hepatitis B HLA-C intron 24162738 rs9264643 chr6 31238492 C A 0.00001096 Sarcoidosis HLA-C intron 22952805 rs9264645 chr6 31238524 G A 8.02E-06 Hepatitis B HLA-C intron 24162738 rs9264645 chr6 31238524 G A 0.00001301 Sarcoidosis HLA-C intron 22952805 rs9264646 chr6 31238535 T C 9.39E-06 Hepatitis B HLA-C intron 24162738 rs9264646 chr6 31238535 T C 0.00001324 Sarcoidosis HLA-C intron 22952805 rs9264647 chr6 31238613 A G 4.87E-07 Rheumatoid arthritis HLA-C intron 21156761 rs9264647 chr6 31238613 A G 0.00001096 Sarcoidosis HLA-C intron 22952805 rs9264652 chr6 31238762 T C 6.64E-06 Hepatitis B HLA-C intron 24162738 rs9264652 chr6 31238762 T C 0.00001012 Sarcoidosis HLA-C intron 22952805 rs9264653 chr6 31238814 T C 0.00001411 Sarcoidosis HLA-C intron 22952805 rs2308604 chr6 31238851 T A,C 0.00003552 Sarcoidosis HLA-C cds-synon 22952805 rs9264663 chr6 31239205 C T 3.17E-06 Hepatitis B HLA-C intron 24162738 rs9264663 chr6 31239205 C T 0.00001458 Sarcoidosis HLA-C intron 22952805 rs9264664 chr6 31239227 C T 4.87E-07 Rheumatoid arthritis HLA-C intron 21156761 rs9264664 chr6 31239227 C T 0.00001761 Sarcoidosis HLA-C intron 22952805 rs2308557 chr6 31239417 C A,G,T 0.000009467 Sarcoidosis HLA-C missense 22952805 rs41543814 chr6 31239430 C T 0.00009341 Sarcoidosis HLA-C missense 22952805 rs9264671 chr6 31239752 C A,T 0.000009393 Sarcoidosis HLA-C intron 22952805 rs1050451 chr6 31239802 C A,G 0.00001165 Sarcoidosis HLA-C missense 22952805 rs2308525 chr6 31239827 C T 0.00001522 Sarcoidosis HLA-C missense 22952805 rs7767581 chr6 31239855 C G 5.45E-06 Hepatitis B HLA-C UTR-5 24162738 rs7767581 chr6 31239855 C G 4.87E-07 Rheumatoid arthritis HLA-C UTR-5 21156761 rs7767581 chr6 31239855 C G 0.00001286 Sarcoidosis HLA-C UTR-5 22952805 rs9264674 chr6 31239868 G C 0.00001286 Sarcoidosis HLA-C UTR-5 22952805 rs2524094 chr6 31240041 C T 1.45E-08 Rheumatoid arthritis HLA-C nearGene-5 21156761 rs2844622 chr6 31240060 A G 0.00004538 Sarcoidosis HLA-C nearGene-5 22952805 rs2074489 chr6 31240128 C T 6.55E-11 Rheumatoid arthritis HLA-C nearGene-5 21156761 rs2074489 chr6 31240128 C T 6.25E-05 Self-reported allergy HLA-C nearGene-5 23817569 rs2074489 chr6 31240128 C T 4.40E-04 Lupus nephritis in systemic lupus erythematosus HLA-C nearGene-5 24925725 rs2524093 chr6 31240180 A C 4.60E-06 Hepatitis B HLA-C nearGene-5 24162738 rs2524093 chr6 31240180 A C 0.00001232 Sarcoidosis HLA-C nearGene-5 22952805 rs2524091 chr6 31240293 C A,G,T 5.16E-06 Hepatitis B HLA-C nearGene-5 24162738 rs2524091 chr6 31240293 C A,G,T 4.33E-07 Rheumatoid arthritis HLA-C nearGene-5 21156761 rs2074488 chr6 31240431 G T 6.65E-22 Rheumatoid arthritis HLA-C nearGene-5 17804836 rs2074488 chr6 31240431 G T 9.61E-30 Rheumatoid arthritis HLA-C nearGene-5 19503088 rs2074488 chr6 31240431 G T 6.65E-24 Rheumatoid arthritis HLA-C nearGene-5 21156761 rs2074488 chr6 31240431 G T 2.00E-10 Chronic obstructive pulmonary disease-related biomarkers HLA-C nearGene-5 23144326 rs2074488 chr6 31240431 G T 2.58E-04 Lupus nephritis in systemic lupus erythematosus HLA-C nearGene-5 24925725 rs4361609 chr6 31240635 G C 6.93E-05 Self-reported allergy HLA-C nearGene-5 23817569 rs2395471 chr6 31240692 G A 5.77E-15 Type 1 diabetes HLA-C nearGene-5 17632545 rs2395471 chr6 31240692 G A 2.36E-04 HIV-1 viral setpoint HLA-C nearGene-5 17641165 rs2395471 chr6 31240692 G A 3.01E-16 HIV-1 control HLA-C nearGene-5 20041166 rs2395471 chr6 31240692 G A 1.73E-07 HIV-1 viral setpoint HLA-C nearGene-5 21490045 rs2395471 chr6 31240692 G A 4.28E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) HLA-C nearGene-5 24023788 rs2395471 chr6 31240692 G A 8.84E-18 Psoriasis HLA-C nearGene-5 pha002855 rs2249741 chr6 31240712 A C,G,T 3.34E-12 Psoriasis HLA-C nearGene-5 pha002855 rs2249742 chr6 31240721 C T 3.48E-09 Type 1 diabetes HLA-C nearGene-5 17632545 rs2249742 chr6 31240721 C T 5.09E-06 HIV-1 viral setpoint HLA-C nearGene-5 17641165 rs2249742 chr6 31240721 C T 1.56E-17 HIV-1 control HLA-C nearGene-5 20041166 rs2249742 chr6 31240721 C T 1.00E-15 HIV-1 control HLA-C nearGene-5 21051598 rs2249742 chr6 31240721 C T 3.35E-09 Hepatitis B vaccine response HLA-C nearGene-5 21764829 rs2249742 chr6 31240721 C T 6.35E-18 Psoriasis HLA-C nearGene-5 pha002855 rs9264681 chr6 31240871 G C 1.82E-15 Rheumatoid arthritis HLA-C nearGene-5 21156761 rs7773175 chr6 31240959 C G 4.77E-30 Psoriasis HLA-C nearGene-5 pha002855 rs7759127 chr6 31240988 T G 1.50E-07 Leprosy HLA-C nearGene-5 20018961 rs7759127 chr6 31240988 T G 6.30E-12 HIV-1 control HLA-C nearGene-5 21051598 rs7759127 chr6 31240988 T G 1.50E-07 Leprosy HLA-C nearGene-5 pha002872 rs5010528 chr6 31241032 A G 5.94E-05 Height HLA-C nearGene-5 17255346 rs5010528 chr6 31241032 A G 4.80E-12 HIV-1 control HLA-C nearGene-5 21051598 rs2523599 chr6 31241092 C G 0.000002342 Sarcoidosis HLA-C nearGene-5 22952805 rs13191343 chr6 31241109 C T 2.00E-72 Psoriatic arthritis HLA-C nearGene-5 20953186 rs13207315 chr6 31241127 T C 3.79E-07 HIV-1 viral setpoint HLA-C nearGene-5 17641165 rs13207315 chr6 31241127 T C 7.06E-17 HIV-1 control HLA-C nearGene-5 20041166 rs13207315 chr6 31241127 T C 6.72E-04 Crohn's disease HLA-C nearGene-5 23266558 rs2844621 chr6 31241537 C T 9.49E-07 Red blood cell traits HLA-C nearGene-5 23222517 rs2524083 chr6 31241737 C T 8.20E-12 HIV-1 control HLA-C nearGene-5 21051598 rs2524082 chr6 31241761 A T 2.22E-11 Psoriasis HLA-C nearGene-5 pha002855 rs9264699 chr6 31241933 A C 7.30E-07 Red blood cell traits / / 23222517 rs2524080 chr6 31242089 A T 1.91E-06 Hepatitis B / / 24162738 rs2524080 chr6 31242089 A T 0.000006387 Sarcoidosis / / 22952805 rs2844620 chr6 31242151 C T 1.11E-06 Hepatitis B / / 24162738 rs2524079 chr6 31242174 G A 1.00E-11 White blood cell count / / 21738480 rs12111032 chr6 31242191 A G 2.72E-06 HIV-1 control / / 20041166 rs2844619 chr6 31242223 C G 0.00003747 Sarcoidosis / / 22952805 rs2844618 chr6 31242439 C T 1.73E-07 Red blood cell traits / / 23222517 rs3132490 chr6 31242560 G A 2.98E-06 Hepatitis B / / 24162738 rs3132488 chr6 31242695 G T 5.20E-09 HIV-1 control / / 21051598 rs3134745 chr6 31242762 C T 6.90E-06 HIV-1 control / / 21051598 rs28481932 chr6 31242900 A G 5.30E-09 HIV-1 control / / 21051598 rs2844615 chr6 31242959 C T 8.10E-12 HIV-1 control / / 21051598 rs2844615 chr6 31242959 C T 5.94E-08 Red blood cell traits / / 23222517 rs3132486 chr6 31243170 G A 3.31E-63 Multiple complex diseases / / 17554300 rs3132486 chr6 31243170 G A 1.11E-16 Type 1 diabetes / / 17632545 rs3132486 chr6 31243170 G A 2.92E-09 Multiple sclerosis / / 17660530 rs3132486 chr6 31243170 G A 1.14E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs3132486 chr6 31243170 G A 9.60E-05 Systemic lupus erythematosus / / 24871463 rs3132486 chr6 31243170 G A 6.66E-13 Psoriasis / / pha002855 rs3132486 chr6 31243170 G A 6.12E-79 Type 1 diabetes / / pha002862 rs3132485 chr6 31243389 C A 2.62E-12 Psoriasis / / pha002855 rs6913377 chr6 31243495 G A 8.17E-05 Self-reported allergy / / 23817569 rs2524077 chr6 31243603 C T 3.11E-07 Red blood cell traits / / 23222517 rs2524076 chr6 31243830 G A 0.00001048 Sarcoidosis / / 22952805 rs3130696 chr6 31243884 G A 7.62E-05 Behcet's disease / / pha002888 rs3130696 chr6 31243884 G A 1.65E-04 Crohn's disease / / 23266558 rs3130696 chr6 31243884 G A 7.34E-05 Pulmonary function in asthmatics / / 23541324 rs3094680 chr6 31243895 C T 0.00001009 Sarcoidosis / / 22952805 rs2844612 chr6 31243971 A G 1.32E-06 Hepatitis B / / 24162738 rs2844612 chr6 31243971 A G 0.00003389 Sarcoidosis / / 22952805 rs2844611 chr6 31243979 T A 1.32E-06 Hepatitis B / / 24162738 rs2844611 chr6 31243979 T A 0.00003273 Sarcoidosis / / 22952805 rs2524074 chr6 31244021 G A 2.79E-05 HIV-1 control / / 20041166 rs2524074 chr6 31244021 G A 2.70E-05 HIV-1 control / / 21051598 rs2524074 chr6 31244021 G A 0.00003714 Sarcoidosis / / 22952805 rs2524074 chr6 31244021 G A 1.32E-06 Hepatitis B / / 24162738 rs9264733 chr6 31244214 C G 4.21E-06 Retinopathy in non-diabetics / / 23393555 rs2524073 chr6 31244235 G A 6.00E-12 HIV-1 control / / 21051598 rs2524073 chr6 31244235 G A 2.71E-07 Leprosy / / pha002872 rs9264740 chr6 31244331 C T 4.21E-06 Retinopathy in non-diabetics / / 23393555 rs2524070 chr6 31244520 G A 1.97E-06 Leprosy / / 20018961 rs2524070 chr6 31244520 G A 3.90E-13 HIV-1 control / / 21051598 rs2524070 chr6 31244520 G A 1.97E-06 Leprosy / / pha002872 rs6919908 chr6 31244960 T C 5.67E-06 Retinopathy in non-diabetics / / 23393555 rs2524068 chr6 31245061 G T 5.00E-13 HIV-1 control / / 21051598 rs2524068 chr6 31245061 G T 2.40E-06 Leprosy / / pha002872 rs9391714 chr6 31245080 G A 5.24E-04 Intracranial aneurysm / / 22286173 rs10456057 chr6 31245534 A G 7.34E-12 Multiple complex diseases / / 17554300 rs10456057 chr6 31245534 A G 6.80E-13 HIV-1 control / / 21051598 rs2853948 chr6 31245573 G C 7.00E-12 HIV-1 control / / 21051598 rs6906846 chr6 31245736 A G 2.03E-04 Type 2 diabetes / / 17463246 rs6906846 chr6 31245736 A G 1.13E-09 Multiple complex diseases / / 17554300 rs6906846 chr6 31245736 A G 1.18E-10 Type 1 diabetes / / 17632545 rs6906846 chr6 31245736 A G 1.15E-09 Multiple sclerosis / / 17660530 rs6906846 chr6 31245736 A G 1.70E-12 HIV-1 control / / 21051598 rs6906846 chr6 31245736 A G 2.52E-04 Crohn's disease / / 23266558 rs6906846 chr6 31245736 A G 6.23E-06 Retinopathy in non-diabetics / / 23393555 rs2524067 chr6 31245821 A G 1.71E-65 Multiple complex diseases / / 17554300 rs7381988 chr6 31246703 G A 9.60E-09 HIV-1 control / / 21051598 rs7382297 chr6 31247067 T G 3.50E-08 Multiple complex diseases / / 17554300 rs7382297 chr6 31247067 T G 9.76E-19 Multiple sclerosis / / 17660530 rs7382297 chr6 31247067 T G 5.67E-06 Rheumatoid arthritis / / 17804836 rs7382297 chr6 31247067 T G 4.68E-08 Multiple sclerosis / / 20598377 rs7382297 chr6 31247067 T G 6.20E-08 HIV-1 control / / 21051598 rs4386816 chr6 31247135 T C 2.60E-04 Height / / 17255346 rs4386816 chr6 31247135 T C 3.86E-09 Type 1 diabetes / / 17632545 rs4386816 chr6 31247135 T C 5.59E-06 Rheumatoid arthritis / / 19503088 rs4386816 chr6 31247135 T C 1.20E-10 HIV-1 control / / 21051598 rs6917363 chr6 31247169 G A 1.16E-05 HIV-1 control / / 20041166 rs2853946 chr6 31247203 A T 0.000001466 Sarcoidosis / / 22952805 rs2844608 chr6 31247414 C T 9.12E-07 Sarcoidosis / / 22952805 rs2853944 chr6 31247758 T C 0.00006223 Sarcoidosis / / 22952805 rs2853943 chr6 31247871 T C 4.50E-10 HIV-1 control / / 21051598 rs2844606 chr6 31248432 A G 0.000001899 Sarcoidosis / / 22952805 rs9264758 chr6 31248434 A G 1.24E-06 Hepatitis B / / 24162738 rs9368669 chr6 31248493 T C 1.68E-04 Multiple complex diseases / / 17554300 rs2844605 chr6 31248591 A C 3.33E-09 Rheumatoid arthritis / / 21156761 rs2844605 chr6 31248591 A C 0.000001809 Sarcoidosis / / 22952805 rs9264759 chr6 31248678 T C 3.15E-07 Rheumatoid arthritis / / 21156761 rs9264761 chr6 31249132 A T 4.40E-06 Hepatitis B / / 24162738 rs9264763 chr6 31249196 A C 4.47E-06 Hepatitis B / / 24162738 rs2253491 chr6 31249217 G A 0.0000204 Sarcoidosis / / 22952805 rs7766089 chr6 31249593 G A 5.41E-08 Sarcoidosis / / 22952805 rs9468914 chr6 31250606 A C 1.60E-09 HIV-1 control / / 21051598 rs9468914 chr6 31250606 A C 1.37E-13 Behcet's disease / / pha002888 rs2853939 chr6 31250642 T C 2.38E-07 Rheumatoid arthritis / / 21156761 rs2853939 chr6 31250642 T C 3.01E-07 Sarcoidosis / / 22952805 rs2524059 chr6 31250823 C G 3.01E-07 Sarcoidosis / / 22952805 rs2844603 chr6 31250854 A G 3.01E-07 Sarcoidosis / / 22952805 rs3873374 chr6 31251311 T C 3.50E-10 HIV-1 control / / 21051598 rs3873375 chr6 31251360 C T 1.07E-11 Multiple complex diseases / / 17554300 rs3873375 chr6 31251360 C T 1.30E-10 HIV-1 control / / 21051598 rs2394963 chr6 31251462 C T 5.84E-04 Multiple complex diseases / / 17554300 rs2394963 chr6 31251462 C T 2.40E-10 HIV-1 control / / 21051598 rs2394963 chr6 31251462 C T 5.63E-04 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2853938 chr6 31251477 T C 3.02E-07 Sarcoidosis / / 22952805 rs2524055 chr6 31252237 A C 6.89E-08 Red blood cell traits / / 23222517 rs2524054 chr6 31252396 A C 2.00E-28 CD4:CD8 lymphocyte ratio / / 20045101 rs2524054 chr6 31252396 A C 6.00E-21 CD4:CD8 lymphocyte ratio / / 20045101 rs2524053 chr6 31252469 T G 3.11E-07 Rheumatoid arthritis / / 21156761 rs386568878 chr6 31252469 T G 3.11E-07 Rheumatoid arthritis / / 21156761 rs12191877 chr6 31252925 C T 1.00E-100 Psoriasis / / 19169254 rs12191877 chr6 31252925 C T 1.57E-07 HIV-1 control / / 20041166 rs12191877 chr6 31252925 C T 4.00E-32 Psoriasis / / 20953188 rs12191877 chr6 31252925 C T 5.80E-13 HIV-1 control / / 21051598 rs12191877 chr6 31252925 C T 2.02E-51 Psoriasis / / pha002855 rs9461684 chr6 31253444 C T 4.46E-05 Height / / 17255346 rs9461684 chr6 31253444 C T 1.10E-11 HIV-1 control / / 21051598 rs9461684 chr6 31253444 C T 3.05E-06 Dengue shock syndrome / / 22001756 rs2844600 chr6 31253771 G T 1.16E-07 Red blood cell traits / / 23222517 rs2853935 chr6 31253878 C T 4.27E-07 Sarcoidosis / / 22952805 rs2853934 chr6 31253928 A T 9.84E-08 Red blood cell traits / / 23222517 rs2524052 chr6 31253996 A G 2.71E-07 Rheumatoid arthritis / / 21156761 rs2524052 chr6 31253996 A G 4.23E-07 Sarcoidosis / / 22952805 rs2853933 chr6 31254088 T C 2.71E-07 Rheumatoid arthritis / / 21156761 rs2853933 chr6 31254088 T C 4.23E-07 Sarcoidosis / / 22952805 rs2853933 chr6 31254088 T C 3.70E-04 Type 2 diabetes / / 23209189 rs2853933 chr6 31254088 T C 9.13E-07 Behcet's disease / / pha002888 rs7754443 chr6 31254263 G A 1.20E-10 HIV-1 control / / 21051598 rs7754443 chr6 31254263 G A 6.34E-04 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9380236 chr6 31254664 A G 1.50E-11 Graves' disease / / 21900946 rs9468920 chr6 31254936 G A 2.50E-10 HIV-1 control / / 21051598 rs9468920 chr6 31254936 G A 6.26E-04 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2853931 chr6 31255007 C T 4.16E-07 Sarcoidosis / / 22952805 rs2853930 chr6 31255424 A C 4.74E-07 Leprosy / / 20018961 rs2853930 chr6 31255424 A C 5.00E-07 Red blood cell traits / / 23222517 rs2853930 chr6 31255424 A C 4.74E-07 Leprosy / / pha002872 rs2524051 chr6 31255500 A G 5.52E-04 Multiple complex diseases / / 17554300 rs2524051 chr6 31255500 A G 4.29E-08 Red blood cell traits / / 23222517 rs2524050 chr6 31255541 T C 4.74E-07 Leprosy / / pha002872 rs2524047 chr6 31256591 A G 1.50E-07 Red blood cell traits / / 23222517 rs2524044 chr6 31256753 T G 1.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2524044 chr6 31256753 T G 7.30E-05 Hypothyroidism / / 22493691 rs2524044 chr6 31256753 T G 1.93E-05 Behcet's disease / / pha002888 rs2524043 chr6 31257012 A G 1.38E-07 Red blood cell traits / / 23222517 rs4628144 chr6 31257104 T C 6.19E-04 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2853927 chr6 31257591 C T 1.50E-07 Red blood cell traits / / 23222517 rs3900938 chr6 31257622 T C 1.70E-13 HIV-1 control / / 21051598 rs2524040 chr6 31257625 T C 3.14E-07 Sarcoidosis / / 22952805 rs28367594 chr6 31258141 G A 7.32E-08 Behcet's disease / / pha002888 rs2844595 chr6 31258255 G C 2.94E-07 Sarcoidosis / / 22952805 rs9468925 chr6 31258837 G A 7.30E-05 HIV-1 control / / 20041166 rs9468925 chr6 31258837 G A 2.00E-33 Vitiligo / / 20526339 rs9468925 chr6 31258837 G A 7.60E-06 Type 2 diabetes / / 23209189 rs2256583 chr6 31258846 T C 7.70E-05 Hypothyroidism / / 22493691 rs3906269 chr6 31258968 G A 6.21E-04 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1819788 chr6 31259137 T C 3.16E-06 Leprosy / / pha002872 rs2524163 chr6 31259579 C T 1.77E-07 Rheumatoid arthritis / / 21156761 rs2524163 chr6 31259579 C T 3.14E-07 Sarcoidosis / / 22952805 rs2524163 chr6 31259579 C T 5.33E-20 Psoriasis / / pha002855 rs2524162 chr6 31259750 C T 9.62E-08 Red blood cell traits / / 23222517 rs2524161 chr6 31259798 C G 1.77E-07 Rheumatoid arthritis / / 21156761 rs2524161 chr6 31259798 C G 3.14E-07 Sarcoidosis / / 22952805 rs2524159 chr6 31259930 A G 1.77E-07 Rheumatoid arthritis / / 21156761 rs2524159 chr6 31259930 A G 3.14E-07 Sarcoidosis / / 22952805 rs2524157 chr6 31260331 G C 3.58E-07 Sarcoidosis / / 22952805 rs2524156 chr6 31260397 A G 1.77E-07 Rheumatoid arthritis / / 21156761 rs2524156 chr6 31260397 A G 3.14E-07 Sarcoidosis / / 22952805 rs2524155 chr6 31260739 A G 1.27E-07 Red blood cell traits / / 23222517 rs2213140 chr6 31261185 T C 3.33E-07 Sarcoidosis / / 22952805 rs2243866 chr6 31261196 G A 3.33E-07 Sarcoidosis / / 22952805 rs2243868 chr6 31261276 A G 6.58E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2243868 chr6 31261276 A G 2.09E-12 Rheumatoid arthritis / / 17804836 rs2243868 chr6 31261276 A G 8.01E-06 Rheumatoid arthritis / / 19503088 rs2243868 chr6 31261276 A G 1.69E-07 Rheumatoid arthritis / / 21156761 rs2243868 chr6 31261276 A G 0.000000323 Sarcoidosis / / 22952805 rs2243868 chr6 31261276 A G 2.70E-04 Type 2 diabetes / / 23209189 rs2243868 chr6 31261276 A G 4.80E-05 Systemic lupus erythematosus / / 24871463 rs2243868 chr6 31261276 A G 2.80E-19 Psoriasis / / pha002855 rs2243868 chr6 31261276 A G 9.44E-07 Behcet's disease / / pha002888 rs3873379 chr6 31262169 T C 4.02E-09 Rheumatoid arthritis / / 17804836 rs3873379 chr6 31262169 T C 2.00E-10 HIV-1 control / / 21051598 rs3873379 chr6 31262169 T C 6.21E-04 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs3873380 chr6 31262438 C T 7.00E-06 HIV-1 control / / 20041166 rs3873380 chr6 31262438 C T 3.10E-15 HIV-1 control / / 21051598 rs3873380 chr6 31262438 C T 4.97E-05 Parkinson's disease / / 21738487 rs2853926 chr6 31263051 A G 1.30E-14 HIV-1 control / / 21051598 rs2524143 chr6 31263510 T C 4.97E-06 Hepatitis B / / 24162738 rs2524143 chr6 31263510 T C 5.02E-07 Sarcoidosis / / 22952805 rs2524142 chr6 31263522 C G 4.97E-06 Hepatitis B / / 24162738 rs2524142 chr6 31263522 C G 4.47E-07 Sarcoidosis / / 22952805 rs2894207 chr6 31263751 T C 1.82E-06 HIV-1 viral setpoint / / 17641165 rs2894207 chr6 31263751 T C 5.23E-07 AIDS progression / / 19115949 rs2894207 chr6 31263751 T C 7.66E-12 HIV-1 control / / 20041166 rs2894207 chr6 31263751 T C 3.00E-33 Nasopharyngeal carcinoma / / 20512145 rs2894207 chr6 31263751 T C 2.00E-07 HIV-1 control / / 21051598 rs2894207 chr6 31263751 T C 1.11E-16 Psoriasis risk prediction / / 21214922 rs2894207 chr6 31263751 T C 0.000028 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs2894207 chr6 31263751 T C 2.90E-05 Crohn's disease (time to surgery) / / 23665963 rs2894207 chr6 31263751 T C 3.77E-38 Psoriasis / / pha002855 rs2524139 chr6 31264133 G C 4.97E-06 Hepatitis B / / 24162738 rs2524139 chr6 31264133 G C 4.97E-07 Sarcoidosis / / 22952805 rs9380237 chr6 31264392 G A 2.58E-28 Psoriasis / / pha002855 rs3094682 chr6 31264461 A C 1.12E-08 Type 1 diabetes / / 17632545 rs2524137 chr6 31264582 C T 1.25E-06 Hepatitis B / / 24162738 rs2524137 chr6 31264582 C T 0.000001159 Sarcoidosis / / 22952805 rs9468932 chr6 31264823 G A 1.26E-05 HIV-1 viral setpoint / / 17641165 rs9468932 chr6 31264823 G A 1.07E-14 HIV-1 control / / 20041166 rs9468932 chr6 31264823 G A 1.80E-06 HIV-1 control / / 21051598 rs9468932 chr6 31264823 G A 1.78E-07 HIV-1 viral setpoint / / 21490045 rs2524132 chr6 31264912 G A 4.13E-04 Multiple complex diseases / / 17554300 rs2524132 chr6 31264912 G A 1.95E-07 Leprosy / / 20018961 rs2524132 chr6 31264912 G A 1.95E-07 Leprosy / / pha002872 rs2853925 chr6 31264922 A G 3.01E-08 Red blood cell traits / / 23222517 rs9468933 chr6 31265057 T A 1.62E-46 Psoriasis / / pha002855 rs2524129 chr6 31265135 C G 1.26E-06 Hepatitis B / / 24162738 rs2524129 chr6 31265135 C G 0.000000794 Sarcoidosis / / 22952805 rs2853924 chr6 31265146 A T 2.31E-07 Leprosy / / pha002872 rs2246954 chr6 31265262 A G 2.83E-08 Rheumatoid arthritis / / 21156761 rs2246954 chr6 31265262 A G 3.60E-07 Sarcoidosis / / 22952805 rs2524123 chr6 31265314 T C 1.53E-05 HIV-1 viral setpoint / / 17641165 rs2524123 chr6 31265314 T C 3.06E-08 HIV-1 control / / 20041166 rs2524123 chr6 31265314 T C 2.04E-09 Vitiligo / / 20526339 rs2524123 chr6 31265314 T C 2.00E-18 HIV-1 control / / 21051598 rs2524123 chr6 31265314 T C 1.60E-05 Type 2 diabetes / / 23209189 rs2247056 chr6 31265490 T C 4.53E-09 Type 1 diabetes / / 17632545 rs2247056 chr6 31265490 T C 3.07E-04 HIV-1 viral setpoint / / 17641165 rs2247056 chr6 31265490 T C 9.57E-11 HIV-1 control / / 20041166 rs2247056 chr6 31265490 T C 2.00E-15 Triglycerides / / 20686565 rs2247056 chr6 31265490 T C 1.70E-05 HIV-1 control / / 21051598 rs2247056 chr6 31265490 T C 1.65E-05 HIV-1 viral setpoint / / 21490045 rs2247056 chr6 31265490 T C 7.38E-07 Sarcoidosis / / 22952805 rs2247056 chr6 31265490 T C 4.00E-12 Height / / 23563607 rs2247056 chr6 31265490 T C 1.24E-06 Hepatitis B / / 24162738 rs2247056 chr6 31265490 T C 7.09E-05 Blood Pressure / / pha003050 rs3905495 chr6 31265539 G A 2.40E-04 Multiple complex diseases / / 17554300 rs3905495 chr6 31265539 G A 1.50E-14 HIV-1 control / / 21051598 rs3905495 chr6 31265539 G A 2.01E-05 Parkinson's disease / / 21738487 rs2524115 chr6 31265554 C A 5.11E-04 Multiple complex diseases / / 17554300 rs2524115 chr6 31265554 C A 3.82E-07 Red blood cell traits / / 23222517 rs2853923 chr6 31265737 A G 0.000003687 Sarcoidosis / / 22952805 rs2853923 chr6 31265737 A G 2.70E-15 Psoriasis / / pha002855 rs13191519 chr6 31265752 T C 1.51E-06 HIV-1 viral setpoint / / 17641165 rs13191519 chr6 31265752 T C 1.57E-17 HIV-1 control / / 20041166 rs13191519 chr6 31265752 T C 9.91E-08 HIV-1 viral setpoint / / 21490045 rs4406273 chr6 31266090 G A 4.5E-723 Psoriasis / / 23143594 rs2524095 chr6 31266117 A C 2.31E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2524095 chr6 31266117 A C 7.41E-05 Multiple complex diseases / / 17554300 rs2524095 chr6 31266117 A C 1.32E-09 Multiple sclerosis / / 17660530 rs2524095 chr6 31266117 A C 2.96E-07 Rheumatoid arthritis / / 21156761 rs2853922 chr6 31266190 A G 3.13E-07 Sarcoidosis / / 22952805 rs16899202 chr6 31266299 G C 5.26E-06 Leprosy / / pha002872 rs16899203 chr6 31266335 T C 6.08E-04 Multiple complex diseases / / 17554300 rs16899205 chr6 31266361 A G 1.00E-15 HIV-1 control / / 21051598 rs16899207 chr6 31266387 A G 1.00E-15 HIV-1 control / / 21051598 rs2524089 chr6 31266522 G T 3.64E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2524089 chr6 31266522 G T 6.86E-05 Multiple complex diseases / / 17554300 rs2524089 chr6 31266522 G T 5.95E-10 Multiple sclerosis / / 17660530 rs2524089 chr6 31266522 G T 2.18E-12 Rheumatoid arthritis / / 17804836 rs2524089 chr6 31266522 G T 3.27E-07 Rheumatoid arthritis / / 21156761 rs2524089 chr6 31266522 G T 1.82E-10 Lymphocyte counts / / 22286170 rs2524089 chr6 31266522 G T 3.40E-04 Type 2 diabetes / / 23209189 rs2524089 chr6 31266522 G T 4.30E-05 Systemic lupus erythematosus / / 24871463 rs2853921 chr6 31267061 A G 3.06E-07 Sarcoidosis / / 22952805 rs2524060 chr6 31267422 A C 6.69E-07 Hepatitis B / / 24162738 rs2524060 chr6 31267422 A C 7.38E-07 Sarcoidosis / / 22952805 rs9380238 chr6 31267618 A G 1.00E-11 HIV-1 control / / 21051598 rs9380238 chr6 31267618 A G 8.76E-05 Intracranial aneurysm / / 22286173 rs9380238 chr6 31267618 A G 2.78E-08 Red blood cell traits / / 23222517 rs2524046 chr6 31268114 C T 0.00005507 Sarcoidosis / / 22952805 rs2524045 chr6 31268115 T G 0.00004359 Sarcoidosis / / 22952805 rs28367646 chr6 31268332 A C 5.10E-15 HIV-1 control / / 21051598 rs2853918 chr6 31268620 C T 2.93E-07 Rheumatoid arthritis / / 21156761 rs2853918 chr6 31268620 C T 3.13E-07 Sarcoidosis / / 22952805 rs2524145 chr6 31268747 A C 1.84E-07 Red blood cell traits / / 23222517 rs9380240 chr6 31268832 T C 3.87E-07 Red blood cell traits / / 23222517 rs9380240 chr6 31268832 T C 4.41E-14 Psoriasis / / pha002855 rs2524135 chr6 31268930 G A 8.08E-07 Red blood cell traits / / 23222517 rs2394967 chr6 31269129 G A 6.00E-08 HIV-1 control / / 21051598 rs2524066 chr6 31269154 T C 2.93E-07 Rheumatoid arthritis / / 21156761 rs2524066 chr6 31269154 T C 3.13E-07 Sarcoidosis / / 22952805 rs9366778 chr6 31269173 G A 1.30E-04 Multiple complex diseases / / 17554300 rs9366778 chr6 31269173 G A 2.66E-07 Rheumatoid arthritis / / 17804836 rs9366778 chr6 31269173 G A 4.42E-07 HIV-1 control / / 20041166 rs9366778 chr6 31269173 G A 1.30E-09 HIV-1 control / / 21051598 rs9366778 chr6 31269173 G A 8.43E-05 Parkinson's disease / / 21738487 rs9366778 chr6 31269173 G A 1.25E-07 Red blood cell traits / / 23222517 rs3873385 chr6 31269308 C T 3.91E-04 Multiple complex diseases / / 17554300 rs4523128 chr6 31269382 T C 1.60E-04 Multiple complex diseases / / 17554300 rs4523128 chr6 31269382 T C 5.60E-08 HIV-1 control / / 21051598 rs1960278 chr6 31269874 C G 7.23E-07 Rheumatoid arthritis / / 21156761 rs1960278 chr6 31269874 C G 4.08E-07 Sarcoidosis / / 22952805 rs9468937 chr6 31270118 C A 4.83E-12 Psoriasis / / pha002855 rs9264842 chr6 31271007 C T 6.12E-07 Red blood cell traits / / 23222517 rs13216197 chr6 31271018 T C 3.46E-06 HIV-1 viral setpoint / / 17641165 rs13216197 chr6 31271018 T C 6.85E-09 HIV-1 control / / 20041166 rs7750269 chr6 31271157 A G 5.52E-04 Crohn's disease / / 23266558 rs11967472 chr6 31271285 G A 2.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7750963 chr6 31271567 A G 9.36E-07 Hepatitis B / / 24162738 rs9264867 chr6 31271585 G A 5.95E-07 Red blood cell traits / / 23222517 rs9264868 chr6 31271601 A G 1.18E-07 Leprosy / / 20018961 rs9264868 chr6 31271601 A G 1.18E-07 Leprosy / / pha002872 rs9264869 chr6 31271630 A G 1.95E-07 Leprosy / / pha002872 rs9264870 chr6 31271662 G A 1.95E-07 Leprosy / / pha002872 rs9264873 chr6 31271700 T C 0.000000318 Sarcoidosis / / 22952805 rs9461688 chr6 31271716 A G 4.00E-06 Protein quantitative trait loci / / 18464913 rs9461688 chr6 31271716 A G 4.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9461688 chr6 31271716 A G 3.70E-16 HIV-1 control / / 21051598 rs9264875 chr6 31271735 G C 4.44E-07 Red blood cell traits / / 23222517 rs9264879 chr6 31271775 A C 7.11E-07 Red blood cell traits / / 23222517 rs9264880 chr6 31271852 T C 4.77E-07 Red blood cell traits / / 23222517 rs9264883 chr6 31271894 A G 8.20E-07 Red blood cell traits / / 23222517 rs9264884 chr6 31271921 C T 7.81E-07 Red blood cell traits / / 23222517 rs9264885 chr6 31271958 G C,T 6.30E-07 Leprosy / / pha002872 rs9368675 chr6 31272157 G A 5.47E-04 Crohn's disease / / 23266558 rs6457374 chr6 31272261 C T 1.20E-06 Hepatitis B / / 24162738 rs6457374 chr6 31272261 C T 1.78E-09 Type 1 diabetes / / 17632545 rs6457374 chr6 31272261 C T 4.42E-08 HIV-1 viral setpoint / / 17641165 rs6457374 chr6 31272261 C T 2.98E-07 Rheumatoid arthritis / / 17804836 rs6457374 chr6 31272261 C T 2.85E-06 AIDS progression / / 19115949 rs6457374 chr6 31272261 C T 2.00E-04 Schizophrenia / / 19197363 rs6457374 chr6 31272261 C T 7.79E-06 Lung adenocarcinoma / / 19836008 rs6457374 chr6 31272261 C T 4.38E-11 HIV-1 control / / 20041166 rs6457374 chr6 31272261 C T 2.77E-05 Multiple sclerosis / / 20598377 rs6457374 chr6 31272261 C T 1.20E-12 HIV-1 control / / 21051598 rs6457374 chr6 31272261 C T 8.63E-06 HIV-1 viral setpoint / / 21490045 rs6457374 chr6 31272261 C T 1.70E-11 Systemic lupus erythematosus / / 24871463 rs6457374 chr6 31272261 C T 7.97E-05 Blood Pressure / / pha003050 rs9368677 chr6 31272321 G A 7.12E-05 HIV-1 control / / 20041166 rs9368677 chr6 31272321 G A 1.00E-17 Atopic dermatitis / / 23042114 rs9264896 chr6 31272369 G A 1.23E-07 Red blood cell traits / / 23222517 rs9264899 chr6 31272421 T C 9.44E-08 Red blood cell traits / / 23222517 rs9264900 chr6 31272447 C T 6.02E-07 Red blood cell traits / / 23222517 rs9368678 chr6 31272463 T C 9.76E-08 Behcet's disease / / 23041938 rs9264901 chr6 31272490 T C 2.22E-07 Red blood cell traits / / 23222517 rs9264904 chr6 31272553 G A 1.50E-06 Hypothyroidism / / 22493691 rs9264904 chr6 31272553 G A 0.000001852 Sarcoidosis / / 22952805 rs9264904 chr6 31272553 G A 8.24E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9264906 chr6 31272590 A G 6.23E-07 Red blood cell traits / / 23222517 rs6457375 chr6 31272612 G A 1.98E-09 Sarcoidosis / / 22952805 rs9264910 chr6 31272648 A C 6.58E-07 Red blood cell traits / / 23222517 rs9264916 chr6 31272774 G A 4.00E-07 HIV-1 control / / 21051598 rs9264917 chr6 31272808 A G 5.93E-07 Red blood cell traits / / 23222517 rs396337 chr6 31272915 C A 1.83E-07 Red blood cell traits / / 23222517 rs396038 chr6 31272980 C T 6.64E-04 Multiple complex diseases / / 17554300 rs396038 chr6 31272980 C T 1.86E-07 Red blood cell traits / / 23222517 rs393225 chr6 31273268 A G 5.55E-07 Red blood cell traits / / 23222517 rs9264924 chr6 31273301 G A 1.78E-07 Red blood cell traits / / 23222517 rs9264927 chr6 31273422 T C 1.68E-07 Red blood cell traits / / 23222517 rs9264928 chr6 31273455 T C 2.03E-07 Red blood cell traits / / 23222517 rs3873386 chr6 31273745 T C 1.64E-12 Rheumatoid arthritis / / 17804836 rs3873386 chr6 31273745 T C 7.84E-07 Rheumatoid arthritis / / 19503088 rs3873386 chr6 31273745 T C 0.00009872 Sarcoidosis / / 22952805 rs3873386 chr6 31273745 T C 1.17E-12 Psoriasis / / pha002855 rs3873386 chr6 31273745 T C 1.00E-05 Behcet's disease / / pha002888 rs1634761 chr6 31274027 C T 8.99E-09 Rheumatoid arthritis / / 21156761 rs9264929 chr6 31274137 A G 2.58E-07 Red blood cell traits / / 23222517 rs9264932 chr6 31274206 T A 3.11E-07 Red blood cell traits / / 23222517 rs9264933 chr6 31274218 C T 2.52E-07 Red blood cell traits / / 23222517 rs6931332 chr6 31274245 A G 1.21E-06 Multiple sclerosis / / 20598377 rs6931332 chr6 31274245 A G 6.42E-07 Sarcoidosis / / 22952805 rs9264936 chr6 31274257 G C 9.52E-07 Red blood cell traits / / 23222517 rs9264942 chr6 31274380 T C 3.77E-09 HIV-1 viral setpoint / / 17641165 rs9264942 chr6 31274380 T C 6.00E-12 HIV-1 control / / 20041166 rs9264942 chr6 31274380 T C 6.00E-32 HIV-1 control / / 20041166 rs9264942 chr6 31274380 T C 3.00E-35 HIV-1 control / / 21051598 rs9264942 chr6 31274380 T C 1.09E-12 HIV-1 viral setpoint / / 21490045 rs9264942 chr6 31274380 T C 8.24E-08 IgA nephropathy / / 22197929 rs9264942 chr6 31274380 T C 5.00E-28 Crohn's disease / / 23128233 rs9264942 chr6 31274380 T C 2.20E-05 Type 2 diabetes / / 23209189 rs9264943 chr6 31274521 G A 7.77E-07 Red blood cell traits / / 23222517 rs10484554 chr6 31274555 C T 8.06E-07 HIV-1 viral setpoint / / 17641165 rs10484554 chr6 31274555 C T 2.00E-39 Psoriasis / / 18369459 rs10484554 chr6 31274555 C T 6.00E-08 AIDS progression / / 19115949 rs10484554 chr6 31274555 C T 7.40E-08 Rheumatoid arthritis / / 19503088 rs10484554 chr6 31274555 C T 8.39E-18 HIV-1 control / / 20041166 rs10484554 chr6 31274555 C T 2.31E-09 Vitiligo / / 20526339 rs10484554 chr6 31274555 C T 4.00E-214 Psoriasis / / 20953190 rs10484554 chr6 31274555 C T 8.40E-13 HIV-1 control / / 21051598 rs10484554 chr6 31274555 C T 1.33E-07 HIV-1 viral setpoint / / 21490045 rs10484554 chr6 31274555 C T 0.00000136 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs10484554 chr6 31274555 C T 2.70E-04 Type 2 diabetes / / 23209189 rs3094691 chr6 31274693 G A 2.87E-09 Type 1 diabetes / / 17632545 rs3094691 chr6 31274693 G A 0.000004526 Sarcoidosis / / 22952805 rs3132479 chr6 31274752 A G 0.00003817 Sarcoidosis / / 22952805 rs9264951 chr6 31275100 C T 5.20E-07 Red blood cell traits / / 23222517 rs396243 chr6 31275174 T C 1.20E-09 HIV-1 control / / 21051598 rs396243 chr6 31275174 T C 5.63E-04 Crohn's disease / / 23266558 rs1634788 chr6 31277686 T A 4.68E-05 Bipolar disorder and schizophrenia / / 20889312 rs7755852 chr6 31277988 A G 1.98E-20 Type 1 diabetes / / 17632545 rs1634747 chr6 31281876 G A 1.17E-12 Type 1 diabetes / / 17632545 rs3130690 chr6 31285935 G T 1 Drug response to Carbamazepine / / 16538176 rs7748141 chr6 31288877 T C 0.000004563 Sarcoidosis / / 22952805 rs114046333 chr6 31296388 G C 0.00001354 Sarcoidosis / / 22952805 rs9265645 chr6 31300197 G A 0.000000986 Sarcoidosis / / 22952805 rs4947307 chr6 31302265 A G 0.000002599 Sarcoidosis / / 22952805 rs6914104 chr6 31302470 G A 7.44E-04 Acute lung injury / / 22295056 rs9500887 chr6 31302591 T G 9.92E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1634775 chr6 31303236 A G 3.58E-08 Sarcoidosis / / 22952805 rs1634767 chr6 31304648 G A 0.00002113 Sarcoidosis / / 22952805 rs1634764 chr6 31305043 G T 0.00002152 Sarcoidosis / / 22952805 rs1631951 chr6 31305641 C T 0.00001871 Sarcoidosis / / 22952805 rs1625792 chr6 31306420 G A 0.000001003 Sarcoidosis / / 22952805 rs1634753 chr6 31306639 C T 0.000001003 Sarcoidosis / / 22952805 rs2854022 chr6 31306816 T C 0.000001034 Sarcoidosis / / 22952805 rs1634734 chr6 31307885 G A,C,T 0.00007275 Sarcoidosis / / 22952805 rs2854019 chr6 31308476 T A 0.000001264 Sarcoidosis / / 22952805 rs2854018 chr6 31308562 C T 0.000001641 Sarcoidosis / / 22952805 rs9265797 chr6 31308630 G A 2.11E-15 Type 1 diabetes / / 17632545 rs9265797 chr6 31308630 G A 7.00E-05 HIV-1 control / / 21051598 rs9265797 chr6 31308630 G A 5.06E-04 Crohn's disease / / 23266558 rs402175 chr6 31308717 G A 0.000001641 Sarcoidosis / / 22952805 rs1634776 chr6 31308988 C T 0.000001641 Sarcoidosis / / 22952805 rs34244713 chr6 31309015 G C 0.0004585 Sarcoidosis / / 22952805 rs3132474 chr6 31309785 G A 0.000008454 Sarcoidosis / / 22952805 rs9265811 chr6 31310372 C T 0.00001222 Sarcoidosis / / 22952805 rs2854011 chr6 31311211 G A 0.000009104 Sarcoidosis / / 22952805 rs9265827 chr6 31311318 A G 0.000008906 Sarcoidosis / / 22952805 rs9265830 chr6 31311376 A G 0.00000228 Sarcoidosis / / 22952805 rs9265831 chr6 31311449 T A 0.000009338 Sarcoidosis / / 22952805 rs2394976 chr6 31311912 G T 6.82E-07 Sarcoidosis / / 22952805 rs2256747 chr6 31311950 T C 0.000001734 Sarcoidosis / / 22952805 rs2256750 chr6 31312020 G A 0.000001955 Sarcoidosis / / 22952805 rs2394977 chr6 31312058 C G 0.000000997 Sarcoidosis / / 22952805 rs2844589 chr6 31312259 G A 0.000001955 Sarcoidosis / / 22952805 rs3134792 chr6 31312326 T G 3.77E-09 Psoriasis / / 17587057 rs3134792 chr6 31312326 T G 1.00E-16 Type 1 diabetes / / 17632545 rs3134792 chr6 31312326 T G 1.00E-09 Psoriasis / / 18364390 rs3134792 chr6 31312326 T G 1.90E-05 HIV-1 control / / 20041166 rs3134792 chr6 31312326 T G 1.00E-09 Asthma / / 21907864 rs3134792 chr6 31312326 T G 0.000001955 Sarcoidosis / / 22952805 rs2854010 chr6 31312492 A G 0.000001955 Sarcoidosis / / 22952805 rs9265857 chr6 31312607 G C 0.000002096 Sarcoidosis / / 22952805 rs2394978 chr6 31312656 C T 0.000002096 Sarcoidosis / / 22952805 rs2394979 chr6 31312729 G A 0.000002096 Sarcoidosis / / 22952805 rs2394980 chr6 31312941 C T 0.000002232 Sarcoidosis / / 22952805 rs2394981 chr6 31313029 G T 0.000001579 Sarcoidosis / / 22952805 rs9265882 chr6 31313101 T C 1.40E-07 HIV-1 control / / 21051598 rs9265882 chr6 31313101 T C 1.23E-50 Ankylosing spondylitis / / 22138694 rs9265886 chr6 31313221 A C 0.000003222 Sarcoidosis / / 22952805 rs7450305 chr6 31313367 T C 0.000001574 Sarcoidosis / / 22952805 rs9265908 chr6 31313677 C T 0.000001393 Sarcoidosis / / 22952805 rs9265910 chr6 31313722 C T 0.000001393 Sarcoidosis / / 22952805 rs9265912 chr6 31313733 T C 0.00001129 Sarcoidosis / / 22952805 rs7749555 chr6 31314274 A G 0.000001393 Sarcoidosis / / 22952805 rs2507998 chr6 31314652 A G 0.000001393 Sarcoidosis / / 22952805 rs9265937 chr6 31314938 C T 0.000001572 Sarcoidosis / / 22952805 rs9265938 chr6 31315005 C T 0.000001572 Sarcoidosis / / 22952805 rs9265939 chr6 31315027 A G 0.000001572 Sarcoidosis / / 22952805 rs9265942 chr6 31315058 C G 0.000001572 Sarcoidosis / / 22952805 rs9265946 chr6 31315138 G A 0.000001654 Sarcoidosis / / 22952805 rs9265948 chr6 31315193 C T 0.000001281 Sarcoidosis / / 22952805 rs9265949 chr6 31315229 C T 0.000002323 Sarcoidosis / / 22952805 rs9265954 chr6 31315339 C T 0.000001393 Sarcoidosis / / 22952805 rs9265961 chr6 31315501 A G 8.42E-08 Sarcoidosis / / 22952805 rs9265964 chr6 31315618 A G 0.000001393 Sarcoidosis / / 22952805 rs9265965 chr6 31315629 T C 0.000001393 Sarcoidosis / / 22952805 rs9265968 chr6 31315663 A T 0.000001393 Sarcoidosis / / 22952805 rs9265969 chr6 31315706 G A 3.60E-07 Sarcoidosis / / 22952805 rs9265971 chr6 31315792 T C 0.000001393 Sarcoidosis / / 22952805 rs9265972 chr6 31315805 G C 0.000001393 Sarcoidosis / / 22952805 rs9265973 chr6 31315861 G A 0.000001393 Sarcoidosis / / 22952805 rs9265974 chr6 31315879 T G 0.000001393 Sarcoidosis / / 22952805 rs9265976 chr6 31315933 A G 0.000001393 Sarcoidosis / / 22952805 rs9265979 chr6 31316044 C T 0.000001503 Sarcoidosis / / 22952805 rs9265982 chr6 31316080 C T 0.000001536 Sarcoidosis / / 22952805 rs9265985 chr6 31316234 A C 0.000001503 Sarcoidosis / / 22952805 rs9265990 chr6 31316448 T A 0.000001079 Sarcoidosis / / 22952805 rs9265993 chr6 31316520 G A 0.000001079 Sarcoidosis / / 22952805 rs9265994 chr6 31316526 T C 0.000001509 Sarcoidosis / / 22952805 rs9265998 chr6 31316613 G A 0.000001162 Sarcoidosis / / 22952805 rs9266001 chr6 31316695 C A 0.000001752 Sarcoidosis / / 22952805 rs5014817 chr6 31316764 A G 0.00002876 Sarcoidosis / / 22952805 rs4530905 chr6 31316880 C T 0.00003939 Sarcoidosis / / 22952805 rs2923008 chr6 31316911 G T 0.000001964 Sarcoidosis / / 22952805 rs3016017 chr6 31317063 A G 0.000001406 Sarcoidosis / / 22952805 rs2923007 chr6 31317065 T C 0.000001406 Sarcoidosis / / 22952805 rs4409218 chr6 31317115 C A 0.00003895 Sarcoidosis / / 22952805 rs4540292 chr6 31317182 T G 2.07E-08 Rheumatoid arthritis / / 21156761 rs4540292 chr6 31317182 T G 0.00003755 Sarcoidosis / / 22952805 rs2156875 chr6 31317347 C T 1.04E-10 Type 1 diabetes / / 17632545 rs2156875 chr6 31317347 C T 2.76E-10 Rheumatoid arthritis / / 17804836 rs2156875 chr6 31317347 C T 4.72E-11 Rheumatoid arthritis / / 19503088 rs2156875 chr6 31317347 C T 4.75E-08 HIV-1 control / / 20041166 rs2156875 chr6 31317347 C T 2.80E-05 HIV-1 control / / 21051598 rs2156875 chr6 31317347 C T 1.00E-05 Multiple myeloma / / 23955597 rs2156875 chr6 31317347 C T 8.30E-05 Systemic lupus erythematosus / / 24871463 rs2156875 chr6 31317347 C T 3.71E-12 Psoriasis / / pha002855 rs9266022 chr6 31317446 G A 0.00004156 Sarcoidosis / / 22952805 rs529559634 chr6 31317697 G A 8.41E-04 Multiple complex diseases / / 17554300 rs9295984 chr6 31317697 G A 8.41E-04 Multiple complex diseases / / 17554300 rs9266030 chr6 31317820 G A 0.00004218 Sarcoidosis / / 22952805 rs4469339 chr6 31317976 T A 0.000038 Sarcoidosis / / 22952805 rs2523619 chr6 31318144 T C 6.33E-06 HIV-1 viral setpoint / / 17641165 rs2523619 chr6 31318144 T C 2.31E-07 Rheumatoid arthritis / / 17804836 rs2523619 chr6 31318144 T C 7.25E-06 AIDS progression / / 19115949 rs2523619 chr6 31318144 T C 8.10E-14 Rheumatoid arthritis / / 19503088 rs2523619 chr6 31318144 T C 1.52E-13 HIV-1 control / / 20041166 rs2523619 chr6 31318144 T C 4.60E-04 HIV-1 control / / 21051598 rs2523619 chr6 31318144 T C 7.51E-06 HIV-1 viral setpoint / / 21490045 rs2523619 chr6 31318144 T C 0.00000785 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs2523619 chr6 31318144 T C 6.30E-04 Type 2 diabetes / / 23209189 rs2523619 chr6 31318144 T C 4.40E-05 Systemic lupus erythematosus / / 24871463 rs4394274 chr6 31318164 C A 0.00003939 Sarcoidosis / / 22952805 rs4394274 chr6 31318164 C A 1.40E-08 Behcet's disease / / 23001997 rs4394275 chr6 31318177 G A 1.03E-04 Multiple complex diseases / / 17554300 rs4394275 chr6 31318177 G A 1.20E-13 HIV-1 control / / 21051598 rs4394275 chr6 31318177 G A 3.56E-11 Rheumatoid arthritis / / 21156761 rs4394275 chr6 31318177 G A 0.0000584 Triglycerides / / 23063622 rs4394275 chr6 31318177 G A 3.52E-05 Self-reported allergy / / 23817569 rs2596510 chr6 31318308 G T 0.000001467 Sarcoidosis / / 22952805 rs2596508 chr6 31318432 T C 0.000002278 Sarcoidosis / / 22952805 rs9266042 chr6 31318621 T A 0.00007901 Sarcoidosis / / 22952805 rs9266043 chr6 31318630 A G 0.00003508 Sarcoidosis / / 22952805 rs9266046 chr6 31318978 G C 0.00003329 Sarcoidosis / / 22952805 rs9266047 chr6 31318985 G A 0.00002896 Sarcoidosis / / 22952805 rs4992477 chr6 31319007 C T 0.00009716 Sarcoidosis / / 22952805 rs9266057 chr6 31319176 G A,C,T 0.00004878 Sarcoidosis / / 22952805 rs9391846 chr6 31319281 A G 3.60E-07 HIV-1 control / / 21051598 rs9266069 chr6 31319604 A G,T 0.00003226 Sarcoidosis / / 22952805 rs9266071 chr6 31319620 C T 0.00008038 Sarcoidosis / / 22952805 rs9266076 chr6 31319785 A G 0.00003565 Sarcoidosis / / 22952805 rs2442719 chr6 31320538 C T 2.69E-08 Type 1 diabetes / / 17632545 rs2442719 chr6 31320538 C T 2.28E-05 HIV-1 control / / 20041166 rs2442719 chr6 31320538 C T 7.10E-06 HIV-1 control / / 21051598 rs2442719 chr6 31320538 C T 4.03E-06 Self-reported allergy / / 23817569 rs2442719 chr6 31320538 C T 2.81E-13 Psoriasis / / pha002855 rs2596503 chr6 31320810 A G 4.06E-06 HIV-1 control / / 20041166 rs2596503 chr6 31320810 A G 9.78E-06 Multiple sclerosis / / 20598377 rs2596503 chr6 31320810 A G 2.49E-04 Coronary heart disease / / 21971053 rs2596503 chr6 31320810 A G 2.93E-05 IgE levels / / 22075330 rs2523612 chr6 31321123 G T 5.30E-09 HIV-1 control / / 21051598 rs2596501 chr6 31321211 C T 6.66E-15 Type 1 diabetes HLA-B nearGene-3 17632545 rs2596501 chr6 31321211 C T 3.06E-08 Rheumatoid arthritis HLA-B nearGene-3 19503088 rs2596501 chr6 31321211 C T 1.68E-06 Bicuspid aortic valve HLA-B nearGene-3 20098615 rs2596501 chr6 31321211 C T 3.50E-09 Systemic lupus erythematosus HLA-B nearGene-3 24871463 rs2596500 chr6 31321267 A C 0.000002975 Sarcoidosis HLA-B nearGene-3 22952805 rs1058026 chr6 31321685 A C 1.71E-09 Type 1 diabetes HLA-B UTR-3 17632545 rs1058026 chr6 31321685 A C 2.70E-12 HIV-1 control HLA-B UTR-3 21051598 rs1058026 chr6 31321685 A C 1.31E-27 Behcet's disease HLA-B UTR-3 pha002888 rs1057387 chr6 31321753 T G 4.40E-08 HIV-1 susceptibility HLA-B UTR-3 23935489 rs563209172 chr6 31321753 T G 4.40E-08 HIV-1 susceptibility HLA-B UTR-3 23935489 rs1057151 chr6 31321776 T C 4.40E-08 HIV-1 susceptibility HLA-B UTR-3 23935489 rs3819299 chr6 31322367 T G 4.29E-05 HIV-1 control HLA-B intron 20041166 rs3819299 chr6 31322367 T G 1.80E-13 HIV-1 control HLA-B intron 21051598 rs3819299 chr6 31322367 T G 9.00E-10 Platelet counts HLA-B intron 22139419 rs3819299 chr6 31322367 T G 5.00E-04 Platelet counts HLA-B intron 24026423 rs3819294 chr6 31322487 G A 3.34E-18 Rheumatoid arthritis HLA-B intron 21156761 rs3819294 chr6 31322487 G A 5.90E-04 Lupus nephritis in systemic lupus erythematosus HLA-B intron 24925725 rs2523608 chr6 31322559 G A 1.82E-05 AIDS progression HLA-B intron 19115949 rs2523608 chr6 31322559 G A 9.95E-08 HIV-1 control HLA-B intron 20041166 rs2523608 chr6 31322559 G A 3.00E-06 HIV-1 viral setpoint HLA-B intron 20205591 rs2523608 chr6 31322559 G A 9.00E-20 HIV-1 control HLA-B intron 21051598 rs2523608 chr6 31322559 G A 1.15E-04 HIV-1 viral setpoint HLA-B intron 21490045 rs2523608 chr6 31322559 G A 9.00E-09 Beta-2 microglubulin plasma levels HLA-B intron 23417110 rs2523608 chr6 31322559 G A 2.87E-05 Cervical cancer HLA-B intron 23817570 rs41543314 chr6 31322690 A G 2.30E-08 HIV-1 susceptibility HLA-B intron 23935489 rs2523607 chr6 31322790 T A 0.000003281 Sarcoidosis HLA-B intron 22952805 rs2596495 chr6 31323416 G C 0.000002995 Sarcoidosis HLA-B intron 22952805 rs41557415 chr6 31323455 A G 9.40E-09 HIV-1 susceptibility HLA-B intron 23935489 rs4990036 chr6 31323506 C T 0.000002995 Sarcoidosis HLA-B intron 22952805 rs2596494 chr6 31323838 C G 1.80E-06 Height HLA-B intron 21194676 rs2596494 chr6 31323838 C G 7.10E-05 Height HLA-B intron 21194676 rs9266214 chr6 31325049 G A,T 0.000000273 Sarcoidosis HLA-B nearGene-5 22952805 rs2596487 chr6 31325056 C T 0.00003915 Sarcoidosis HLA-B nearGene-5 22952805 rs9266230 chr6 31325341 G C 3.15E-07 Sarcoidosis HLA-B nearGene-5 22952805 rs9266231 chr6 31325380 C T 3.37E-07 Sarcoidosis HLA-B nearGene-5 22952805 rs9266232 chr6 31325424 G T 3.43E-07 Sarcoidosis HLA-B nearGene-5 22952805 rs9266242 chr6 31325620 T C 4.25E-07 Sarcoidosis HLA-B nearGene-5 22952805 rs9266243 chr6 31325623 T C 3.94E-07 Sarcoidosis HLA-B nearGene-5 22952805 rs9266244 chr6 31325692 G A 7.27E-07 Sarcoidosis HLA-B nearGene-5 22952805 rs9266245 chr6 31325702 A G 7.27E-07 Sarcoidosis HLA-B nearGene-5 22952805 rs9266247 chr6 31325756 G A 0.00001321 Sarcoidosis HLA-B nearGene-5 22952805 rs9266248 chr6 31325758 G A 0.00002399 Sarcoidosis HLA-B nearGene-5 22952805 rs9266250 chr6 31325792 A G 4.07E-08 Sarcoidosis HLA-B nearGene-5 22952805 rs9266257 chr6 31325886 G C 8.99E-09 Sarcoidosis HLA-B nearGene-5 22952805 rs2853999 chr6 31326074 A T 0.00002413 Sarcoidosis HLA-B nearGene-5 22952805 rs9266271 chr6 31326082 T C 1.70E-06 Hypothyroidism HLA-B nearGene-5 22493691 rs2523598 chr6 31326175 G T 0.000006699 Sarcoidosis HLA-B nearGene-5 22952805 rs2596475 chr6 31326324 C G,T 3.82E-08 Sarcoidosis HLA-B nearGene-5 22952805 rs2523595 chr6 31326618 G A 8.91E-07 Sarcoidosis HLA-B nearGene-5 22952805 rs2523594 chr6 31326629 C T 8.91E-07 Sarcoidosis HLA-B nearGene-5 22952805 rs2523593 chr6 31326703 T C 0.00005943 Sarcoidosis HLA-B nearGene-5 22952805 rs1894743 chr6 31326794 A T 0.00004242 Sarcoidosis HLA-B nearGene-5 22952805 rs2395475 chr6 31326920 G A 0.00000127 Sarcoidosis HLA-B nearGene-5 22952805 rs2523591 chr6 31326960 G A 4.54E-14 Behcet's disease HLA-B nearGene-5 pha002888 rs2523590 chr6 31327064 T C 2.00E-13 HIV-1 control / / 21051598 rs2523590 chr6 31327064 T C 9.10E-04 Major depressive disorder / / 22472876 rs2523589 chr6 31327334 G T 1.31E-08 Rheumatoid arthritis / / 17804836 rs2523589 chr6 31327334 G T 5.61E-04 Coronary heart disease / / 21971053 rs2523589 chr6 31327334 G T 3.24E-07 Sarcoidosis / / 22952805 rs2523589 chr6 31327334 G T 4.20E-07 Systemic lupus erythematosus / / 24871463 rs2523589 chr6 31327334 G T 1.77E-04 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2395476 chr6 31327382 G T 0.000001327 Sarcoidosis / / 22952805 rs2523587 chr6 31327400 T C 6.77E-07 Sarcoidosis / / 22952805 rs2523586 chr6 31327435 T G 9.89E-07 Self-reported allergy / / 23817569 rs1811197 chr6 31327660 G A 0.00003504 Sarcoidosis / / 22952805 rs9378249 chr6 31327701 T G 8.50E-09 Multiple complex diseases / / 17554300 rs9378249 chr6 31327701 T G 2.10E-18 Rheumatoid arthritis / / 21156761 rs9378249 chr6 31327701 T G 1.00E-08 Bipolar disorder / / 21254220 rs9378249 chr6 31327701 T G 6.19E-04 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2596477 chr6 31327723 G A 3.81E-09 Multiple complex diseases / / 17554300 rs2596477 chr6 31327723 G A 8.72E-09 Self-reported allergy / / 23817569 rs2523584 chr6 31327890 A G 0.00004606 Sarcoidosis / / 22952805 rs2523582 chr6 31328092 A G 0.000001656 Sarcoidosis / / 22952805 rs2523580 chr6 31328245 A G 2.90E-11 HIV-1 control / / 21051598 rs2523579 chr6 31328517 T C 0.00001411 Sarcoidosis / / 22952805 rs2523578 chr6 31328542 G A 7.30E-07 HIV-1 control / / 21051598 rs2523578 chr6 31328542 G A 0.000001568 Sarcoidosis / / 22952805 rs2523575 chr6 31328826 C G 4.55E-06 Multiple complex diseases / / 17554300 rs2523575 chr6 31328826 C G 1.31E-19 Cholesterol,total / / 23063622 rs2523575 chr6 31328826 C G 1.42E-47 LDL cholesterol / / 23063622 rs2523575 chr6 31328826 C G 3.17E-13 Triglycerides / / 23063622 rs2523573 chr6 31328988 C G 0.00002272 Sarcoidosis / / 22952805 rs112515516 chr6 31329100 A G 1.20E-08 HIV-1 susceptibility / / 23935489 rs2596545 chr6 31329374 A C 0.00008546 Sarcoidosis / / 22952805 rs113688927 chr6 31329447 A G 2.70E-08 HIV-1 susceptibility / / 23935489 rs76518703 chr6 31329466 A G 1.60E-08 HIV-1 susceptibility / / 23935489 rs2596547 chr6 31329642 C T 0.00007943 Sarcoidosis / / 22952805 rs2523571 chr6 31329691 T A 0.00007943 Sarcoidosis / / 22952805 rs9266327 chr6 31330619 G A 1.40E-06 HIV-1 control / / 21051598 rs2523560 chr6 31330844 C T 5.83E-04 Self-reported allergy / / 23817569 rs2523557 chr6 31331257 G A 5.47E-10 Self-reported allergy / / 23817569 rs2523554 chr6 31331829 C T 5.22E-05 Rheumatoid arthritis / / 17804836 rs2523554 chr6 31331829 C T 2.00E-06 Lung cancer / / 18978790 rs2523554 chr6 31331829 C T 1.67E-04 Schizophrenia / / 19197363 rs2523554 chr6 31331829 C T 8.98E-06 Lung adenocarcinoma / / 19836008 rs2523554 chr6 31331829 C T 6.48E-09 HIV-1 control / / 20041166 rs2523554 chr6 31331829 C T 1.92E-05 HIV-1 viral setpoint / / 21490045 rs2523554 chr6 31331829 C T 0.00005142 Sarcoidosis / / 22952805 rs2523554 chr6 31331829 C T 0.00000696 HIV-1-specific cross-reactive neutralizing activity / / 23372753 rs2523554 chr6 31331829 C T 3.10E-11 Systemic lupus erythematosus / / 24871463 rs2523554 chr6 31331829 C T 3.34E-11 Behcet's disease / / pha002888 rs2596551 chr6 31332239 A C 5.46E-11 Coronary heart disease / / 21971053 rs9501374 chr6 31332332 C T 1.57E-06 Self-reported allergy / / 23817569 rs2523546 chr6 31332920 G A 0.00001128 Sarcoidosis / / 22952805 rs2853993 chr6 31333191 T C 0.00007669 Sarcoidosis / / 22952805 rs2844580 chr6 31333303 T C 5.38E-05 Self-reported allergy / / 23817569 rs2523545 chr6 31333499 G A 4.76E-10 Self-reported allergy / / 23817569 rs2523545 chr6 31333499 G A 2.95E-06 Behcet's disease / / pha002888 rs2523544 chr6 31333562 G A 3.00E-54 Multiple complex diseases / / 17554300 rs2523544 chr6 31333562 G A 1.74E-08 Behcet's disease / / pha002888 rs9501571 chr6 31333610 C T 5.71E-06 Self-reported allergy / / 23817569 rs2844579 chr6 31333716 G A 2.55E-11 Self-reported allergy / / 23817569 rs9501572 chr6 31333820 A G 2.51E-06 Self-reported allergy / / 23817569 rs7761068 chr6 31333939 A G 2.32E-04 Multiple complex diseases / / 17554300 rs7761068 chr6 31333939 A G 3.33E-06 Lymphocyte counts / / 22286170 rs7761068 chr6 31333939 A G 2.26E-06 Self-reported allergy / / 23817569 rs2596574 chr6 31334174 G A 1.51E-06 Lung adenocarcinoma / / 19836008 rs2596574 chr6 31334174 G A 2.05E-08 Coronary heart disease / / 21971053 rs2596574 chr6 31334174 G A 9.93E-09 Self-reported allergy / / 23817569 rs2844577 chr6 31334422 T C 0.000009968 Sarcoidosis / / 22952805 rs2596428 chr6 31334731 G C 7.91E-09 Self-reported allergy / / 23817569 rs7766461 chr6 31334799 C T 1.13E-05 Self-reported allergy / / 23817569 rs6457401 chr6 31334852 G T 7.67E-07 Self-reported allergy / / 23817569 rs6457402 chr6 31334864 G T 7.67E-07 Self-reported allergy / / 23817569 rs2844575 chr6 31334945 T C 1.93E-06 Rheumatoid arthritis / / 17804836 rs2844575 chr6 31334945 T C 4.32E-05 Information processing speed / / 21130836 rs2844575 chr6 31334945 T C 0.00005982 Sarcoidosis / / 22952805 rs2844575 chr6 31334945 T C 2.60E-04 Systemic lupus erythematosus / / 24871463 rs7767216 chr6 31335096 G A 5.91E-06 Self-reported allergy / / 23817569 rs7767142 chr6 31335311 A T 3.28E-06 Self-reported allergy / / 23817569 rs2596430 chr6 31335431 T C 0.000008853 Sarcoidosis / / 22952805 rs2844573 chr6 31335454 A C 9.14E-05 Parkinson's disease / / 17052657 rs2844573 chr6 31335454 A C 3.80E-08 Lung cancer / / 22899653 rs2844573 chr6 31335454 A C 3.88E-07 Rheumatoid arthritis (ACPA-negative) / / 24532677 rs9266395 chr6 31335566 C T 1.18E-04 HIV-1 viral setpoint / / 17641165 rs9266395 chr6 31335566 C T 1.57E-13 HIV-1 control / / 20041166 rs9266395 chr6 31335566 C T 2.20E-06 HIV-1 control / / 21051598 rs2523538 chr6 31335623 A G 7.51E-09 Self-reported allergy / / 23817569 rs2523537 chr6 31335707 A G 1.98E-10 Multiple complex diseases / / 17554300 rs9266399 chr6 31335806 A T 3.04E-05 HIV-1 control / / 20041166 rs9266399 chr6 31335806 A T 1.55E-43 Behcet's disease / / pha002888 rs2922994 chr6 31335901 A G 0.000009267 Sarcoidosis / / 22952805 rs2156874 chr6 31335976 G C 0.000002559 Sarcoidosis / / 22952805 rs2523536 chr6 31336000 A G 2.85E-11 Multiple complex diseases / / 17554300 rs2523536 chr6 31336000 A G 7.09E-09 Self-reported allergy / / 23817569 rs7743761 chr6 31336100 C A 5.00E-304 Ankylosing spondylitis / / 20062062 rs7743761 chr6 31336100 C A 0.0000195 Cholesterol,total / / 23063622 rs7743761 chr6 31336100 C A 1.91E-06 Self-reported allergy / / 23817569 rs2523535 chr6 31336250 A G 1.13E-09 Multiple complex diseases / / 17554300 rs2523535 chr6 31336250 A G 9.98E-10 Type 1 diabetes / / 17632545 rs2523535 chr6 31336250 A G 5.24E-07 Multiple sclerosis / / 17660530 rs2523535 chr6 31336250 A G 7.20E-06 AIDS progression / / 19115949 rs2523535 chr6 31336250 A G 4.49E-08 HIV-1 control / / 20041166 rs2523535 chr6 31336250 A G 8.05E-10 Coronary heart disease / / 21971053 rs2523535 chr6 31336250 A G 0.00000189 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs2523535 chr6 31336250 A G 6.10E-05 Self-reported allergy / / 23817569 rs2523534 chr6 31336349 A G 1.82E-42 Multiple complex diseases / / 17554300 rs2523534 chr6 31336349 A G 1.17E-05 Multiple sclerosis / / 17660530 rs2523534 chr6 31336349 A G 5.88E-04 Self-reported allergy / / 23817569 rs9266406 chr6 31336418 G A 4.06E-07 Multiple complex diseases / / 17554300 rs9266406 chr6 31336418 G A 1.80E-06 HIV-1 control / / 21051598 rs9266406 chr6 31336418 G A 2.00E-10 Behcet's disease / / 23001997 rs9266406 chr6 31336418 G A 2.56E-10 Behcet's disease / / 23041938 rs9266409 chr6 31336568 T C 2.82E-07 Multiple complex diseases / / 17554300 rs9266409 chr6 31336568 T C 2.02E-04 HIV-1 viral setpoint / / 17641165 rs9266409 chr6 31336568 T C 4.86E-14 HIV-1 control / / 20041166 rs9266409 chr6 31336568 T C 2.20E-06 HIV-1 control / / 21051598 rs9266409 chr6 31336568 T C 5.65E-07 HIV-1 viral setpoint / / 21490045 rs9266409 chr6 31336568 T C 1.91E-10 Behcet's disease / / 23001997 rs9266409 chr6 31336568 T C 2.56E-10 Behcet's disease / / 23041938 rs2844567 chr6 31336644 G A 2.98E-08 Self-reported allergy / / 23817569 rs2253907 chr6 31336870 C T 1.70E-21 Behcet's disease / / pha002888 rs2253907 chr6 31336870 C T 8.10E-15 Type 1 diabetes / / 17632545 rs2253907 chr6 31336870 C T 6.57E-09 Rheumatoid arthritis / / 17804836 rs2253907 chr6 31336870 C T 4.60E-13 Rheumatoid arthritis / / 19503088 rs2253907 chr6 31336870 C T 1.78E-08 Behcet's disease / / 23001997 rs2253907 chr6 31336870 C T 5.87E-08 Behcet's disease / / 23041938 rs2253907 chr6 31336870 C T 1.50E-04 Systemic lupus erythematosus / / 24871463 rs2253907 chr6 31336870 C T 2.99E-71 Type 1 diabetes / / pha002862 rs2922997 chr6 31337281 G A 5.41E-04 Self-reported allergy / / 23817569 rs13215664 chr6 31337311 T C 1.22E-06 Self-reported allergy / / 23817569 rs2523530 chr6 31337654 A G 9.00E-09 Self-reported allergy / / 23817569 rs2523529 chr6 31337780 C G 8.48E-09 Self-reported allergy / / 23817569 rs9266440 chr6 31337815 C T 1.19E-05 HIV-1 control / / 20041166 rs9266440 chr6 31337815 C T 7.50E-04 Self-reported allergy / / 23817569 rs9295986 chr6 31338528 C T 2.67E-07 Rheumatoid arthritis / / 21156761 rs9295986 chr6 31338528 C T 3.60E-103 Ankylosing spondylitis / / 22138694 rs9295986 chr6 31338528 C T 2.54E-05 Self-reported allergy / / 23817569 rs2853986 chr6 31338844 T C 4.41E-77 Multiple complex diseases / / 17554300 rs2853986 chr6 31338844 T C 0.000007757 Sarcoidosis / / 22952805 rs41519045 chr6 31339086 G A 5.52E-34 Multiple complex diseases / / 17554300 rs41519045 chr6 31339086 G A 1.19E-18 Multiple sclerosis / / 17660530 rs2523527 chr6 31339334 T G 2.65E-08 Self-reported allergy / / 23817569 rs2523525 chr6 31339844 A G 6.49E-09 Self-reported allergy / / 23817569 rs2523524 chr6 31339996 G A 0.00000668 Sarcoidosis / / 22952805 rs2844559 chr6 31340075 C T 3.74E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2844559 chr6 31340075 C T 3.49E-80 Multiple complex diseases / / 17554300 rs2844559 chr6 31340075 C T 4.20E-26 Primary sclerosing cholangitis / / 19944697 rs2844559 chr6 31340075 C T 0.00000668 Sarcoidosis / / 22952805 rs9266490 chr6 31340158 A G 2.80E-08 Behcet's disease / / 23001997 rs2523522 chr6 31340328 T C 1.21E-04 Amyotrophic lateral sclerosis / / 20801718 rs2523522 chr6 31340328 T C 9.60E-196 Ankylosing spondylitis / / 22138694 rs2523522 chr6 31340328 T C 2.27E-13 Behcet's disease / / pha002888 rs2844558 chr6 31340433 C T 1.38E-54 Multiple complex diseases / / 17554300 rs2844558 chr6 31340433 C T 1.27E-09 Multiple sclerosis / / 17660530 rs2394990 chr6 31340559 C A 5.16E-12 Type 1 diabetes / / 17632545 rs2394990 chr6 31340559 C A 1.35E-04 Amyotrophic lateral sclerosis / / 20801718 rs2394990 chr6 31340559 C A 1.97E-13 Behcet's disease / / pha002888 rs7770216 chr6 31340611 G T 9.95E-04 HIV-1 viral setpoint / / 17641165 rs7770216 chr6 31340611 G T 4.80E-13 HIV-1 control / / 20041166 rs2263311 chr6 31340807 C T 2.24E-11 Multiple complex diseases / / 17554300 rs6936035 chr6 31341156 A G 3.90E-05 Response to statin therapy / / 20339536 rs6936035 chr6 31341156 A G 3.05E-04 Self-reported allergy / / 23817569 rs2844556 chr6 31341357 G A 3.56E-09 Self-reported allergy / / 23817569 rs2254549 chr6 31342436 C T 8.61E-09 Self-reported allergy / / 23817569 rs2254556 chr6 31342631 T C 8.05E-10 Type 1 diabetes / / 17632545 rs2254556 chr6 31342631 T C 4.31E-07 Rheumatoid arthritis / / 17804836 rs2254556 chr6 31342631 T C 3.80E-42 Ankylosing spondylitis / / 21743469 rs5025315 chr6 31343604 A G 1.54E-35 Multiple complex diseases / / 17554300 rs5025315 chr6 31343604 A G 4.59E-08 Multiple sclerosis / / 17660530 rs6933050 chr6 31343632 T C 1.06E-07 Multiple complex diseases / / 17554300 rs6933050 chr6 31343632 T C 3.74E-08 HIV-1 control / / 20041166 rs6933050 chr6 31343632 T C 2.20E-06 HIV-1 control / / 21051598 rs6933050 chr6 31343632 T C 1.64E-10 Behcet's disease / / 23041938 rs6910516 chr6 31343827 A G 3.01E-07 Multiple complex diseases / / 17554300 rs6910516 chr6 31343827 A G 2.60E-06 HIV-1 control / / 21051598 rs6910516 chr6 31343827 A G 2.56E-10 Behcet's disease / / 23041938 rs4959068 chr6 31343844 T A 2.56E-07 Multiple complex diseases / / 17554300 rs4959068 chr6 31343844 T A 6.80E-05 Response to statin therapy / / 20339536 rs5022119 chr6 31343862 T A 2.42E-35 Multiple complex diseases / / 17554300 rs5022119 chr6 31343862 T A 1.67E-08 Multiple sclerosis / / 17660530 rs2523640 chr6 31343919 G A 9.13E-09 Self-reported allergy / / 23817569 rs2523639 chr6 31344098 C T 9.00E-09 Self-reported allergy / / 23817569 rs13198903 chr6 31344157 C T 2.30E-11 HIV-1 control / / 21051598 rs2523638 chr6 31344273 T C 7.05E-56 Multiple complex diseases / / 17554300 rs2523638 chr6 31344273 T C 4.63E-09 Multiple sclerosis / / 17660530 rs3997982 chr6 31344294 T A 7.22E-04 Type 2 diabetes / / 17463246 rs3997982 chr6 31344294 T A 8.17E-34 Multiple complex diseases / / 17554300 rs3997982 chr6 31344294 T A 4.88E-19 Multiple sclerosis / / 17660530 rs3957110 chr6 31344348 T C 7.84E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2905719 chr6 31344390 A G 0.000007734 Sarcoidosis / / 22952805 rs3957111 chr6 31344490 G A 6.56E-08 Multiple complex diseases / / 17554300 rs3957111 chr6 31344490 G A 9.53E-09 Self-reported allergy / / 23817569 rs13202464 chr6 31344583 A G 8.70E-12 HIV-1 control / / 21051598 rs7382258 chr6 31345021 G A 1.58E-13 Behcet's disease / / pha002888 rs2844544 chr6 31345728 G T 7.85E-09 Self-reported allergy / / 23817569 rs2523632 chr6 31345844 G A 8.83E-09 Self-reported allergy / / 23817569 rs2523626 chr6 31346490 G A 5.83E-09 Self-reported allergy / / 23817569 rs6909636 chr6 31346599 G A 1.15E-12 Rheumatoid arthritis / / 21156761 rs2442735 chr6 31346653 A G 0.000007446 Sarcoidosis / / 22952805 rs9266629 chr6 31346822 T C 7.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9266629 chr6 31346822 T C 4.00E-10 Chronic obstructive pulmonary disease-related biomarkers / / 23144326 rs9501587 chr6 31346937 G A 2.48E-05 Coronary heart disease / / 21971053 rs9266634 chr6 31346978 A T 0.00001001 Sarcoidosis / / 22952805 rs9266636 chr6 31347033 A G 0.00003775 Sarcoidosis / / 22952805 rs9266637 chr6 31347045 C G 0.0000301 Sarcoidosis / / 22952805 rs9266638 chr6 31347057 C T 6.67E-05 Height / / 17255346 rs9266638 chr6 31347057 C T 0.00003524 Sarcoidosis / / 22952805 rs9266639 chr6 31347069 C T 0.00003114 Sarcoidosis / / 22952805 rs3094600 chr6 31347144 G A 0.00001109 Sarcoidosis / / 22952805 rs2244020 chr6 31347451 A G 1.22E-04 Height / / 17255346 rs4713462 chr6 31347816 G A 1.10E-05 HIV-1 control / / 20041166 rs2507980 chr6 31347877 G A 5.83E-09 Self-reported allergy / / 23817569 rs2596573 chr6 31347930 C T 5.56E-09 Lung cancer / / 21725308 rs2596573 chr6 31347930 C T 4.94E-06 Self-reported allergy / / 23817569 rs2596571 chr6 31348022 G C 3.95E-48 Multiple complex diseases / / 17554300 rs2596571 chr6 31348022 G C 1.57E-17 Multiple sclerosis / / 17660530 rs2596571 chr6 31348022 G C 4.70E-09 Lung cancer / / 21725308 rs2596571 chr6 31348022 G C 6.15E-06 Self-reported allergy / / 23817569 rs2596570 chr6 31348040 T C 2.21E-07 Sarcoidosis / / 22952805 rs9266669 chr6 31348077 G A 2.36E-07 Sarcoidosis / / 22952805 rs9266669 chr6 31348077 G A 2.27E-07 Rheumatoid arthritis (ACPA-negative) / / 24532677 rs4143332 chr6 31348365 G A 0.000003367 Sarcoidosis / / 22952805 rs9266684 chr6 31348505 T C 5.39E-05 Self-reported allergy / / 23817569 rs4143333 chr6 31348519 A G 0.00001379 Sarcoidosis / / 22952805 rs9266688 chr6 31348543 G A 5.85E-08 Rheumatoid arthritis / / 21156761 rs9266689 chr6 31348580 A G 1.50E-06 Hypothyroidism / / 22493691 rs9266689 chr6 31348580 A G 5.54E-05 Crohn's disease / / 23266558 rs9266689 chr6 31348580 A G 1.62E-05 Self-reported allergy / / 23817569 rs9266701 chr6 31349030 G T 5.85E-08 Rheumatoid arthritis / / 21156761 rs9266718 chr6 31349788 C T 5.93E-06 Self-reported allergy / / 23817569 rs9266719 chr6 31349805 C A 5.41E-06 Self-reported allergy / / 23817569 rs9295987 chr6 31349844 A G 1.88E-06 Self-reported allergy / / 23817569 rs9266722 chr6 31349922 C T 2.92E-10 Type 1 diabetes / / 17632545 rs9266722 chr6 31349922 C T 1.07E-11 Rheumatoid arthritis / / 17804836 rs9266722 chr6 31349922 C T 5.81E-09 Rheumatoid arthritis / / 19503088 rs9266722 chr6 31349922 C T 7.68E-08 Rheumatoid arthritis / / 21156761 rs9266722 chr6 31349922 C T 9.80E-05 Crohn's disease / / 23266558 rs2523547 chr6 31350154 C T 1.75E-08 Self-reported allergy / / 23817569 rs2596568 chr6 31350232 A G 6.33E-06 Self-reported allergy / / 23817569 rs2844535 chr6 31350303 T G 7.39E-07 Self-reported allergy / / 23817569 rs4293988 chr6 31350380 G T 5.85E-08 Rheumatoid arthritis / / 21156761 rs3094596 chr6 31350579 T C 6.21E-06 Self-reported allergy / / 23817569 rs1521 chr6 31350704 C T 8.96E-09 Systemic sclerosis / / 20383147 rs1521 chr6 31350704 C T 2.00E-65 Graves' disease / / 21841780 rs1521 chr6 31350704 C T 6.47E-06 Self-reported allergy / / 23817569 rs1521 chr6 31350704 C T 4.25E-08 Behcet's disease / / pha002888 rs2844533 chr6 31350802 G A 1.82E-08 Type 1 diabetes / / 17632545 rs2844533 chr6 31350802 G A 1.55E-11 Rheumatoid arthritis / / 17804836 rs2844533 chr6 31350802 G A 2.50E-11 Rheumatoid arthritis / / 19503088 rs2844533 chr6 31350802 G A 4.76E-06 Hepatitis B / / 21750111 rs2844533 chr6 31350802 G A 6.47E-06 Self-reported allergy / / 23817569 rs2523485 chr6 31351035 T C 6.81E-33 Multiple complex diseases / / 17554300 rs2523485 chr6 31351035 T C 5.80E-18 Multiple sclerosis / / 17660530 rs2523646 chr6 31351079 C T 9.44E-09 Self-reported allergy / / 23817569 rs2844532 chr6 31351175 G C 9.24E-08 Rheumatoid arthritis / / 21156761 rs2844532 chr6 31351175 G C 4.83E-05 Self-reported allergy / / 23817569 rs3016013 chr6 31351242 G A 2.74E-12 Multiple sclerosis / / 17660530 rs9266749 chr6 31351313 C T 1.53E-07 Rheumatoid arthritis / / 21156761 rs3099849 chr6 31351415 G A 2.99E-33 Multiple complex diseases / / 17554300 rs3099848 chr6 31351442 A T 1.45E-13 Multiple sclerosis / / 17660530 rs3020582 chr6 31351522 A C 0.00003735 Sarcoidosis / / 22952805 rs2905715 chr6 31351530 T C 6.39E-06 IgE levels / / 22075330 rs2507976 chr6 31351887 C A 4.39E-04 Multiple complex diseases / / 17554300 rs2507976 chr6 31351887 C A 2.00E-22 HIV-1 control / / 21051598 rs2442749 chr6 31352040 T C 1.62E-71 Multiple complex diseases / / 17554300 rs2442749 chr6 31352040 T C 1.00E-16 Type 1 diabetes / / 17632545 rs9266772 chr6 31352113 T C 3.00E-12 Self-reported allergy / / 23817569 rs7775759 chr6 31352446 G A 1.60E-07 HIV-1 control / / 21051598 rs7775759 chr6 31352446 G A 0.000000147 Behcet's disease / / 23041938 rs7775759 chr6 31352446 G A 3.09E-08 Self-reported allergy / / 23817569 rs7741091 chr6 31352631 A G 3.09E-08 Self-reported allergy / / 23817569 rs6903496 chr6 31352774 G A 7.67E-14 Type 1 diabetes / / 17632545 rs9266774 chr6 31352880 C T 4.02E-47 Multiple complex diseases / / 17554300 rs9266774 chr6 31352880 C T 1.82E-07 Rheumatoid arthritis / / 21156761 rs2844531 chr6 31353171 A G 0.000002584 Sarcoidosis / / 22952805 rs2596565 chr6 31353329 G A 0.000002045 Sarcoidosis / / 22952805 rs2596565 chr6 31353329 G A 0.00000933 Schizophrenia / / 23637625 rs2596565 chr6 31353329 G A 9.00E-09 Rheumatoid arthritis (ACPA-negative) / / 24532677 rs9266775 chr6 31353417 A G 7.75E-47 Multiple complex diseases / / 17554300 rs9266775 chr6 31353417 A G 2.08E-07 Rheumatoid arthritis / / 21156761 rs2844530 chr6 31353435 C G 0.000001878 Sarcoidosis / / 22952805 rs6927154 chr6 31353541 T G 3.00E-09 HIV-1 control / / 21051598 rs2844529 chr6 31353593 G A 3.34E-05 Rheumatoid arthritis / / 17804836 rs2844529 chr6 31353593 G A 3.93E-04 Schizophrenia / / 19197363 rs2844529 chr6 31353593 G A 2.50E-11 Rheumatoid arthritis / / 19503088 rs2844529 chr6 31353593 G A 1.60E-07 HIV-1 control / / 20041166 rs2844529 chr6 31353593 G A 2.70E-06 HIV-1 control / / 21051598 rs2844529 chr6 31353593 G A 4.20E-05 Dengue shock syndrome / / 22001756 rs2844529 chr6 31353593 G A 0.00000345 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs2844529 chr6 31353593 G A 0.00000868 HIV-1-specific cross-reactive neutralizing activity / / 23372753 rs2844529 chr6 31353593 G A 1.00E-05 Systemic lupus erythematosus / / 24871463 rs2844529 chr6 31353593 G A 7.10E-13 Behcet's disease / / pha002888 rs111182473 chr6 31353689 G A 1.64E-11 Multiple complex diseases / / 17554300 rs111182473 chr6 31353689 G A 1.40E-09 HIV-1 control / / 21051598 rs4081552 chr6 31353689 G A 1.64E-11 Multiple complex diseases / / 17554300 rs4081552 chr6 31353689 G A 1.40E-09 HIV-1 control / / 21051598 rs6909461 chr6 31353950 A C 5.38E-07 Self-reported allergy / / 23817569 rs2428486 chr6 31354104 T C 3.31E-05 Rheumatoid arthritis / / 17804836 rs2428486 chr6 31354104 T C 3.93E-04 Schizophrenia / / 19197363 rs2428486 chr6 31354104 T C 5.32E-10 Rheumatoid arthritis / / 19503088 rs2428486 chr6 31354104 T C 1.99E-07 HIV-1 control / / 20041166 rs2428486 chr6 31354104 T C 2.30E-06 HIV-1 control / / 21051598 rs2428486 chr6 31354104 T C 5.44E-05 Dengue shock syndrome / / 22001756 rs2428486 chr6 31354104 T C 0.00000345 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs2428486 chr6 31354104 T C 0.00000868 HIV-1-specific cross-reactive neutralizing activity / / 23372753 rs2428486 chr6 31354104 T C 7.20E-06 Systemic lupus erythematosus / / 24871463 rs2428486 chr6 31354104 T C 7.10E-13 Behcet's disease / / pha002888 rs6932730 chr6 31354182 T C 2.20E-08 HIV-1 control / / 20041166 rs6932730 chr6 31354182 T C 4.80E-04 HIV-1 control / / 21051598 rs6932730 chr6 31354182 T C 1.38E-05 HIV-1 viral setpoint / / 21490045 rs6932730 chr6 31354182 T C 3.86E-05 Self-reported allergy / / 23817569 rs6932730 chr6 31354182 T C 4.00E-08 Allergic sensitization / / 23817571 rs12524487 chr6 31354238 C T 2.80E-14 Rheumatoid arthritis / / 21156761 rs2853972 chr6 31354344 G A 9.43E-09 Self-reported allergy / / 23817569 rs4711268 chr6 31354504 C T 1.30E-10 HIV-1 control / / 20041166 rs4711268 chr6 31354504 C T 1.20E-09 HIV-1 control / / 21051598 rs4711268 chr6 31354504 C T 4.87E-06 HIV-1 viral setpoint / / 21490045 rs4711268 chr6 31354504 C T 1.87E-05 Dengue shock syndrome / / 22001756 rs4711268 chr6 31354504 C T 4.87E-07 Self-reported allergy / / 23817569 rs13437082 chr6 31354560 C T 3.63E-06 AIDS progression / / 19115949 rs13437082 chr6 31354560 C T 5.00E-08 Height / / 19343178 rs13437082 chr6 31354560 C T 4.89E-11 HIV-1 control / / 20041166 rs13437082 chr6 31354560 C T 4.50E-09 HIV-1 control / / 21051598 rs13437082 chr6 31354560 C T 6.10E-06 HIV-1 viral setpoint / / 21490045 rs13437082 chr6 31354560 C T 1.90E-05 Dengue shock syndrome / / 22001756 rs13437082 chr6 31354560 C T 8.70E-10 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs13437082 chr6 31354560 C T 0.000000768 HIV-1-specific cross-reactive neutralizing activity / / 23372753 rs13437082 chr6 31354560 C T 4.48E-07 Self-reported allergy / / 23817569 rs13437082 chr6 31354560 C T 7.20E-04 Systemic lupus erythematosus / / 24871463 rs13437082 chr6 31354560 C T 1.96E-07 Behcet's disease / / pha002888 rs2596562 chr6 31354595 T C 2.90E-06 HIV-1 control / / 21051598 rs2596562 chr6 31354595 T C 7.10E-13 Behcet's disease / / pha002888 rs4711269 chr6 31354819 C T 4.31E-06 AIDS progression / / 19115949 rs4711269 chr6 31354819 C T 6.00E-11 HIV-1 control / / 20041166 rs4711269 chr6 31354819 C T 3.30E-09 HIV-1 control / / 21051598 rs4711269 chr6 31354819 C T 5.23E-06 HIV-1 viral setpoint / / 21490045 rs4711269 chr6 31354819 C T 2.17E-05 Dengue shock syndrome / / 22001756 rs4711269 chr6 31354819 C T 1.10E-09 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs4711269 chr6 31354819 C T 0.000000768 HIV-1-specific cross-reactive neutralizing activity / / 23372753 rs4711269 chr6 31354819 C T 4.64E-07 Self-reported allergy / / 23817569 rs4711269 chr6 31354819 C T 6.80E-04 Systemic lupus erythematosus / / 24871463 rs13437092 chr6 31355056 G T 5.39E-07 Self-reported allergy / / 23817569 rs13437088 chr6 31355119 C T 5.30E-09 HIV-1 control / / 21051598 rs13437088 chr6 31355119 C T 5.47E-07 Self-reported allergy / / 23817569 rs13437088 chr6 31355119 C T 2.54E-13 Psoriasis / / pha002855 rs13437088 chr6 31355119 C T 2.36E-07 Behcet's disease / / pha002888 rs2596560 chr6 31355318 T C 2.83E-27 Type 1 diabetes / / 17632545 rs2596560 chr6 31355318 T C 5.90E-05 Rheumatoid arthritis / / 17804836 rs2596560 chr6 31355318 T C 4.10E-09 Rheumatoid arthritis / / 19503088 rs2596560 chr6 31355318 T C 7.28E-05 Pulmonary function / / 20010835 rs2596560 chr6 31355318 T C 1.00E-04 Prostate cancer / / 21743057 rs2596560 chr6 31355318 T C 3.10E-58 Myasthenia gravis / / 23055271 rs2596560 chr6 31355318 T C 4.70E-10 Systemic lupus erythematosus / / 24871463 rs2596560 chr6 31355318 T C 6.64E-134 Type 1 diabetes / / pha002862 rs2596560 chr6 31355318 T C 9.19E-05 Monocyte chemoattractant protein-1 / / pha003071 rs2853969 chr6 31356574 G A 9.54E-09 Self-reported allergy / / 23817569 rs2395485 chr6 31359648 T C 1.01E-08 Multiple complex diseases / / 17554300 rs2395485 chr6 31359648 T C 5.45E-05 Multiple sclerosis / / 17660530 rs2395485 chr6 31359648 T C 9.85E-05 Serum metabolites / / 19043545 rs2596517 chr6 31360095 G A 8.66E-34 Multiple complex diseases / / 17554300 rs2596517 chr6 31360095 G A 7.32E-18 Multiple sclerosis / / 17660530 rs7751505 chr6 31360255 A C 9.92E-06 HIV-1 control / / 20041166 rs7751505 chr6 31360255 A C 2.30E-09 HIV-1 control / / 21051598 rs7751505 chr6 31360255 A C 4.00E-06 Pubertal anthropometrics / / 23449627 rs7751505 chr6 31360255 A C 8.37E-07 Self-reported allergy / / 23817569 rs2523477 chr6 31360389 T C 5.04E-05 Rheumatoid arthritis / / 17804836 rs2523477 chr6 31360389 T C 3.77E-06 Lung adenocarcinoma / / 19836008 rs2523477 chr6 31360389 T C 1.94E-07 Systemic sclerosis / / 20383147 rs2523477 chr6 31360389 T C 2.07E-10 Coronary heart disease / / 21971053 rs2523477 chr6 31360389 T C 6.25E-09 Self-reported allergy / / 23817569 rs2523477 chr6 31360389 T C 1.30E-05 Behcet's disease / / pha002888 rs7751725 chr6 31360433 A G 1.00E-05 HIV-1 control / / 20041166 rs7751725 chr6 31360433 A G 1.90E-09 HIV-1 control / / 21051598 rs7751725 chr6 31360433 A G 3.93E-07 Self-reported allergy / / 23817569 rs7751725 chr6 31360433 A G 4.70E-07 Behcet's disease / / pha002888 rs7752021 chr6 31360526 C T 4.25E-07 Self-reported allergy / / 23817569 rs2428481 chr6 31360663 C T 0.000002238 Sarcoidosis / / 22952805 rs2428477 chr6 31361325 T A 5.50E-09 Self-reported allergy / / 23817569 rs10947206 chr6 31361397 A T 3.75E-07 Self-reported allergy / / 23817569 rs2523476 chr6 31361424 C T 5.04E-06 Lung adenocarcinoma / / 19836008 rs2523476 chr6 31361424 C T 1.98E-10 Coronary heart disease / / 21971053 rs2523476 chr6 31361424 C T 5.50E-09 Self-reported allergy / / 23817569 rs10947207 chr6 31361485 T C 4.71E-09 HIV-1 control / / 20041166 rs10947207 chr6 31361485 T C 2.70E-09 HIV-1 control / / 21051598 rs10947207 chr6 31361485 T C 3.77E-07 Self-reported allergy / / 23817569 rs2523475 chr6 31361710 A G 3.80E-06 HIV-1 control / / 21051598 rs2523475 chr6 31361710 A G 0.0000006 Cholesterol,total / / 23063622 rs10947208 chr6 31361837 A G 3.35E-07 Self-reported allergy / / 23817569 rs10947208 chr6 31361837 A G 2.18E-12 Psoriasis / / pha002855 rs16899524 chr6 31362310 C T 1.58E-08 Multiple complex diseases / / 17554300 rs16899524 chr6 31362310 C T 1.00E-08 Beta-2 microglubulin plasma levels / / 23417110 rs16899524 chr6 31362310 C T 1.33E-08 Self-reported allergy / / 23817569 rs2523467 chr6 31362930 C T 2.11E-31 Multiple complex diseases / / 17554300 rs2523467 chr6 31362930 C T 1.79E-05 Rheumatoid arthritis / / 17804836 rs2523467 chr6 31362930 C T 6.75E-05 Serum metabolites / / 19043545 rs2523467 chr6 31362930 C T 4.32E-04 Schizophrenia / / 19197363 rs2523467 chr6 31362930 C T 9.07E-10 Rheumatoid arthritis / / 19503088 rs2523467 chr6 31362930 C T 1.43E-07 HIV-1 control / / 20041166 rs2523467 chr6 31362930 C T 3.50E-06 HIV-1 control / / 21051598 rs2523467 chr6 31362930 C T 0.0000078 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs2523467 chr6 31362930 C T 0.00000868 HIV-1-specific cross-reactive neutralizing activity / / 23372753 rs2523467 chr6 31362930 C T 4.90E-06 Systemic lupus erythematosus / / 24871463 rs2523467 chr6 31362930 C T 5.16E-13 Behcet's disease / / pha002888 rs2251396 chr6 31364707 G A 1.00E-16 Type 1 diabetes / / 17632545 rs2251396 chr6 31364707 G A 2.49E-11 Rheumatoid arthritis / / 17804836 rs2251396 chr6 31364707 G A 4.36E-18 Rheumatoid arthritis / / 19503088 rs2251396 chr6 31364707 G A 1.28E-09 Atopic dermatitis / / 23886662 rs2251396 chr6 31364707 G A 7.90E-07 Systemic lupus erythematosus / / 24871463 rs7739560 chr6 31364790 C T 2.01E-05 Self-reported allergy / / 23817569 rs2523457 chr6 31365707 G A 1.00E-04 Prostate cancer / / 21743057 rs4349859 chr6 31365787 G A 1.00E-200 Ankylosing spondylitis / / 21743469 rs2596542 chr6 31366595 C T 4.78E-07 HIV-1 control MICA nearGene-5 20041166 rs2596542 chr6 31366595 C T 4.00E-13 Hepatocellular carcinoma MICA nearGene-5 21499248 rs2596542 chr6 31366595 C T 4.21E-13 Hepatocellular carcinoma (hepatitis B virus related) MICA nearGene-5 23242368 rs2523454 chr6 31367865 G A 3.33E-16 Type 1 diabetes MICA nearGene-5 17632545 rs2523454 chr6 31367865 G A 6.07E-09 Hepatitis B vaccine response MICA nearGene-5 21764829 rs2523454 chr6 31367865 G A 3.20E-93 Ankylosing spondylitis MICA nearGene-5 22138694 rs2523454 chr6 31367865 G A 0.00003 Placental abruption MICA nearGene-5 23205182 rs2523454 chr6 31367865 G A 4.46E-05 Platelet counts MICA nearGene-5 23263863 rs6911024 chr6 31368451 T C 2.50E-05 Response to statin therapy MICA nearGene-5 20339536 rs6911024 chr6 31368451 T C 2.92E-05 Self-reported allergy MICA nearGene-5 23817569 rs2844523 chr6 31368588 G A 6.43E-09 Self-reported allergy MICA intron 23817569 rs2844521 chr6 31368964 C T 2.40E-06 HIV-1 control MICA intron 21051598 rs2844521 chr6 31368964 C T 4.96E-13 Behcet's disease MICA intron pha002888 rs3763288 chr6 31370367 G A 5.04E-19 Rheumatoid arthritis MICA intron 21156761 rs6906175 chr6 31371101 G C 9.58E-09 Self-reported allergy MICA intron 23817569 rs2301750 chr6 31371342 C G 4.16E-05 Self-reported allergy MICA intron 23817569 rs2844519 chr6 31371430 T C,G 1.80E-05 IgE levels MICA missense 22075330 rs2252223 chr6 31371521 T C 6.63E-09 Self-reported allergy MICA intron 23817569 rs2301747 chr6 31371587 C G 9.10E-05 Response to statin therapy MICA intron 20339536 rs2301747 chr6 31371587 C G 1.86E-06 Self-reported allergy MICA intron 23817569 rs2844518 chr6 31372569 C T 2.00E-04 Self-reported allergy MICA intron 23817569 rs9295988 chr6 31373718 C G 1.65E-06 Self-reported allergy MICA intron 23817569 rs2857281 chr6 31374262 A C 4.31E-05 Behcet's disease MICA intron pha002888 rs12174396 chr6 31374579 A G 1.86E-13 Rheumatoid arthritis MICA intron 21156761 rs6910087 chr6 31377047 C T 7.50E-10 HIV-1 control MICA intron 21051598 rs6910087 chr6 31377047 C T 4.33E-05 Self-reported allergy MICA intron 23817569 rs12175489 chr6 31377587 G A 5.34E-06 Alopecia areata MICA intron 22027810 rs12175489 chr6 31377587 G A 2.00E-06 Visceral adipose tissue adjusted for BMI MICA intron 22589738 rs2523495 chr6 31377978 C T 0.000002309 Sarcoidosis MICA intron 22952805 rs9380254 chr6 31378335 G C 8.11E-13 Rheumatoid arthritis MICA missense 21156761 rs1051792 chr6 31378977 G A 6.42E-05 Self-reported allergy MICA missense 23817569 rs1051794 chr6 31379109 G A 3.25E-06 AIDS progression MICA missense 19115949 rs1051794 chr6 31379109 G A 3.55E-11 HIV-1 control MICA missense 20041166 rs1051794 chr6 31379109 G A 4.89E-05 HIV-1 viral setpoint MICA missense 21490045 rs1131896 chr6 31379115 G A 1.20E-04 Systemic lupus erythematosus MICA missense 24871463 rs3828875 chr6 31379168 C T 4.06E-04 Amyotrophic lateral sclerosis (sporadic) MICA intron 24529757 rs2256028 chr6 31379198 C A 2.15E-05 Rheumatoid arthritis MICA intron 17804836 rs2256028 chr6 31379198 C A 1.95E-06 Carotenoid and tocopherol levels MICA intron 19185284 rs2256028 chr6 31379198 C A 1.84E-12 Rheumatoid arthritis MICA intron 19503088 rs2256028 chr6 31379198 C A 3.80E-04 Systemic lupus erythematosus MICA intron 24871463 rs2853977 chr6 31379304 A T 0.00000403 Cholesterol,total MICA intron 23063622 rs3828881 chr6 31379549 A T 5.61E-05 Self-reported allergy MICA intron 23817569 rs1063635 chr6 31379931 G A 9.16E-13 Multiple complex diseases MICA missense 17554300 rs1063635 chr6 31379931 G A 1.00E-17 Rheumatoid arthritis MICA missense 21653640 rs2256175 chr6 31380449 C T 4.94E-07 HIV-1 control MICA intron 20041166 rs2256175 chr6 31380449 C T 0.000000188 Cholesterol,total MICA intron 23063622 rs2256183 chr6 31380529 A G 8.00E-29 Height MICA intron 20881960 rs9357133 chr6 31380897 C T 6.50E-21 Rheumatoid arthritis MICA intron 21156761 rs6934187 chr6 31380974 C G 3.90E-05 Self-reported allergy MICA intron 23817569 rs9266813 chr6 31381321 C G 2.11E-05 Self-reported allergy MICA intron 23817569 rs7775227 chr6 31382147 G C 8.32E-05 Self-reported allergy MICA intron 23817569 rs9266823 chr6 31382690 A G 0.0000487 Cholesterol,total MICA intron 23063622 rs9266823 chr6 31382690 A G 5.42E-05 Self-reported allergy MICA intron 23817569 rs2853975 chr6 31382717 A T 4.27E-04 Self-reported allergy MICA intron 23817569 rs9266825 chr6 31382882 C A 1.37E-07 HIV-1 control MICA missense 20041166 rs9266825 chr6 31382882 C A 5.81E-04 Self-reported allergy MICA missense 23817569 rs1131904 chr6 31383071 A G 1.20E-05 HIV-1 control MICA UTR-3 20041166 rs9266831 chr6 31383083 G A 0.0000165 Cholesterol,total MICA UTR-3 23063622 rs3094584 chr6 31383848 G A 8.12E-13 Multiple complex diseases / / 17554300 rs3094584 chr6 31383848 G A 0.00000019 Behcet's disease / / 23041938 rs9266844 chr6 31384331 G C 7.56E-04 Self-reported allergy / / 23817569 rs9266844 chr6 31384331 G C 1.02E-11 Psoriasis / / pha002855 rs2848713 chr6 31384479 G A 5.62E-45 Behcet's disease / / pha002888 rs9468992 chr6 31384578 G A 3.76E-05 Behcet's disease / / pha002888 rs9266845 chr6 31384792 T C 1.11E-07 HIV-1 control / / 20041166 rs9266845 chr6 31384792 T C 7.92E-04 Self-reported allergy / / 23817569 rs9266846 chr6 31384889 C G 3.03E-07 Psoriasis risk prediction / / 21214922 rs9266846 chr6 31384889 C G 7.30E-04 Self-reported allergy / / 23817569 rs9266846 chr6 31384889 C G 2.44E-11 Psoriasis / / pha002855 rs9295990 chr6 31386019 T G 2.83E-11 Multiple complex diseases / / 17554300 rs9295990 chr6 31386019 T G 3.69E-09 Self-reported allergy / / 23817569 rs3132472 chr6 31386131 G A 0.00000176 Sarcoidosis / / 22952805 rs2596530 chr6 31387373 G A 1.64E-05 HIV-1 control / / 20041166 rs2596530 chr6 31387373 G A 9.30E-05 HIV-1 control / / 21051598 rs2596530 chr6 31387373 G A 4.29E-08 Behcet's disease / / pha002888 rs2596531 chr6 31387557 C T 1.22E-10 HIV-1 control / / 20041166 rs2596531 chr6 31387557 C T 7.50E-05 HIV-1 control / / 21051598 rs2596532 chr6 31387871 G C 3.65E-21 Rheumatoid arthritis / / 21156761 rs3880459 chr6 31387912 T G 3.70E-09 Self-reported allergy / / 23817569 rs2848716 chr6 31387967 G C 1 Drug response to Carbamazepine / / 16538176 rs2848716 chr6 31387967 G C 2.77E-11 Rheumatoid arthritis / / 21156761 rs9501106 chr6 31388109 G A 4.84E-09 HIV-1 control / / 20041166 rs9501106 chr6 31388109 G A 1.51E-05 HIV-1 viral setpoint / / 21490045 rs9501106 chr6 31388109 G A 3.53E-16 Psoriasis / / pha002855 rs2844513 chr6 31388214 G A 2.40E-04 HIV-1 viral setpoint / / 17641165 rs2844513 chr6 31388214 G A 4.93E-09 Rheumatoid arthritis / / 17804836 rs2844513 chr6 31388214 G A 2.53E-07 AIDS progression / / 19115949 rs2844513 chr6 31388214 G A 3.60E-16 Rheumatoid arthritis / / 19503088 rs2844513 chr6 31388214 G A 5.09E-10 HIV-1 control / / 20041166 rs2844513 chr6 31388214 G A 3.50E-04 HIV-1 control / / 21051598 rs2844513 chr6 31388214 G A 0.00000125 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs2844513 chr6 31388214 G A 3.90E-06 Systemic lupus erythematosus / / 24871463 rs2844513 chr6 31388214 G A 1.69E-07 Behcet's disease / / pha002888 rs9283891 chr6 31388230 G A 6.90E-04 Self-reported allergy / / 23817569 rs9295991 chr6 31388277 C T 5.22E-04 Self-reported allergy / / 23817569 rs9295993 chr6 31388595 A G 5.09E-04 Self-reported allergy / / 23817569 rs9295993 chr6 31388595 A G 1.34E-15 Psoriasis / / pha002855 rs9295993 chr6 31388595 A G 8.35E-07 Behcet's disease / / pha002888 rs2844511 chr6 31389784 A G 4.72E-07 AIDS progression / / 19115949 rs2844511 chr6 31389784 A G 1.00E-04 Schizophrenia / / 19197363 rs2844511 chr6 31389784 A G 6.56E-08 Rheumatoid arthritis / / 19503088 rs2844511 chr6 31389784 A G 1.07E-10 HIV-1 control / / 20041166 rs2844511 chr6 31389784 A G 8.60E-05 HIV-1 control / / 21051598 rs2844511 chr6 31389784 A G 0.00000122 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs2844511 chr6 31389784 A G 0.0000127 HIV-1-specific cross-reactive neutralizing activity / / 23372753 rs2844511 chr6 31389784 A G 8.30E-08 Systemic lupus erythematosus / / 24871463 rs2844511 chr6 31389784 A G 5.36E-08 Behcet's disease / / pha002888 rs10223421 chr6 31390055 G T 7.37E-04 Self-reported allergy / / 23817569 rs10223568 chr6 31390203 T C 4.63E-05 Behcet's disease / / pha002888 rs2516448 chr6 31390410 T C 3.34E-07 HIV-1 control / / 20041166 rs2516448 chr6 31390410 T C 8.90E-05 HIV-1 control / / 21051598 rs2516448 chr6 31390410 T C 1.50E-06 Height / / 21194676 rs2516448 chr6 31390410 T C 3.20E-08 Height / / 21194676 rs2516448 chr6 31390410 T C 0.00000015 Cholesterol,total / / 23063622 rs2516448 chr6 31390410 T C 0.0000515 LDL cholesterol / / 23063622 rs2516448 chr6 31390410 T C 4.00E-18 Cervical cancer / / 23482656 rs4418214 chr6 31391401 T C 1.19E-14 HIV-1 control / / 20041166 rs4418214 chr6 31391401 T C 1.00E-34 HIV-1 control / / 21051598 rs4418214 chr6 31391401 T C 6.70E-08 Ankylosing spondylitis / / 22138694 rs4418214 chr6 31391401 T C 4.00E-11 HIV-1 susceptibility / / 23935489 rs2394994 chr6 31391618 A T 5.86E-05 IgE levels / / 22075330 rs9501109 chr6 31392118 A G 3.64E-10 Behcet's disease / / pha002888 rs2524279 chr6 31392906 A G 2.99E-19 Rheumatoid arthritis / / 17804836 rs2524279 chr6 31392906 A G 8.89E-21 Rheumatoid arthritis / / 19503088 rs2524279 chr6 31392906 A G 1.93E-20 Rheumatoid arthritis / / 21156761 rs2516472 chr6 31394700 A G 7.49E-06 Behcet's disease / / pha002888 rs2394999 chr6 31400935 A G 2.11E-06 Multiple complex diseases / / 17554300 rs4346874 chr6 31401374 C T 9.20E-05 Behcet's disease / / pha002888 rs2596466 chr6 31405617 T C 5.63E-21 Rheumatoid arthritis / / 21156761 rs2596466 chr6 31405617 T C 2.00E-12 Beta-2 microglubulin plasma levels / / 23417110 rs7772549 chr6 31407643 T C 1.59E-10 HIV-1 control / / 20041166 rs7772549 chr6 31407643 T C 0.000000606 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs7772549 chr6 31407643 T C 1.69E-04 Self-reported allergy / / 23817569 rs7772549 chr6 31407643 T C 1.03E-11 Psoriasis / / pha002855 rs7772549 chr6 31407643 T C 1.12E-08 Behcet's disease / / pha002888 rs2844520 chr6 31407758 G T 6.05E-10 Self-reported allergy / / 23817569 rs6915220 chr6 31407821 A T 1.29E-04 Self-reported allergy / / 23817569 rs9469003 chr6 31407828 T C 1.99E-09 HIV-1 control / / 20041166 rs9469003 chr6 31407828 T C 1.28E-05 HIV-1 viral setpoint / / 21490045 rs9469003 chr6 31407828 T C 2.00E-09 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) / / 21801394 rs9469003 chr6 31407828 T C 0.00000226 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs9469003 chr6 31407828 T C 4.39E-05 Behcet's disease / / pha002888 rs6938674 chr6 31408004 T C 6.67E-04 Iron levels / / pha002876 rs2524276 chr6 31408265 C A 6.00E-06 Capecitabine sensitivity / / 22864933 rs2524276 chr6 31408265 C A 6.03E-10 Self-reported allergy / / 23817569 rs3132473 chr6 31408329 T A 0.000004456 Sarcoidosis / / 22952805 rs9469007 chr6 31409024 T C 8.56E-05 HIV-1 control / / 20041166 rs9469007 chr6 31409024 T C 6.14E-09 Behcet's disease / / pha002888 rs9267084 chr6 31409605 G A 3.89E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs28575156 chr6 31409857 A G 3.76E-05 Behcet's disease / / pha002888 rs2844510 chr6 31410408 G T 1.01E-05 IgE levels / / 22075330 rs2844510 chr6 31410408 G T 1.10E-07 Self-reported allergy / / 23817569 rs3093958 chr6 31410521 A G 9.75E-07 Sarcoidosis / / 22952805 rs3899823 chr6 31410597 G A 3.47E-08 Behcet's disease / / pha002888 rs3869129 chr6 31410649 C T 1.31E-06 HIV-1 control / / 20041166 rs3869129 chr6 31410649 C T 3.53E-04 Coronary heart disease / / 21971053 rs9267088 chr6 31411213 T A 2.20E-05 Self-reported allergy / / 23817569 rs2395004 chr6 31412513 G C 3.66E-07 Self-reported allergy / / 23817569 rs2596464 chr6 31412961 T C 1.06E-11 Multiple complex diseases / / 17554300 rs2596464 chr6 31412961 T C 1.79E-06 Multiple sclerosis / / 17660530 rs2596464 chr6 31412961 T C 5.27E-37 Ankylosing spondylitis / / 22138694 rs2596464 chr6 31412961 T C 5.61E-05 Self-reported allergy / / 23817569 rs2516467 chr6 31413798 T C 7.65E-10 Self-reported allergy / / 23817569 rs12206131 chr6 31414010 A G 1.73E-09 Vitiligo / / 20526339 rs9267092 chr6 31414241 G T 0.000003137 Sarcoidosis / / 22952805 rs2516464 chr6 31416156 A G 2.21E-14 Behcet's disease / / pha002888 rs2516463 chr6 31416536 A G 8.34E-06 Behcet's disease / / pha002888 rs2524281 chr6 31416699 A C 1.88E-09 Self-reported allergy / / 23817569 rs16899646 chr6 31416920 C G 1.33E-05 HIV-1 progression / / 20064070 rs16899646 chr6 31416920 C G 4.70E-04 Cervical cancer / / 21716314 rs16899646 chr6 31416920 C G 1.25E-06 Behcet's disease / / pha002888 rs3128982 chr6 31417191 A G 5.62E-08 Rheumatoid arthritis / / 19503088 rs3128982 chr6 31417191 A G 2.00E-06 Systemic lupus erythematosus / / 24871463 rs9501129 chr6 31417396 T C 2.64E-06 Behcet's disease / / pha002888 rs2596460 chr6 31417510 A G 1.51E-11 Multiple complex diseases / / 17554300 rs2596460 chr6 31417510 A G 1.88E-09 Self-reported allergy / / 23817569 rs2596457 chr6 31418022 A G 4.12E-11 Multiple complex diseases / / 17554300 rs2596457 chr6 31418022 A G 1.88E-09 Self-reported allergy / / 23817569 rs2523693 chr6 31418124 C T 2.12E-04 Multiple complex diseases / / 17554300 rs2516460 chr6 31418700 T G 2.33E-05 Multiple complex diseases / / 17554300 rs2516460 chr6 31418700 T G 4.61E-11 Multiple sclerosis / / 17660530 rs2516458 chr6 31419387 T C 1.95E-14 Behcet's disease / / pha002888 rs2516456 chr6 31420018 T C 1.39E-14 Behcet's disease / / pha002888 rs3131622 chr6 31420500 T G 4.72E-13 Multiple complex diseases / / 17554300 rs3131622 chr6 31420500 T G 7.73E-10 Multiple sclerosis / / 17660530 rs2523691 chr6 31420687 G A 1.08E-10 Multiple complex diseases / / 17554300 rs2523691 chr6 31420687 G A 2.16E-09 Self-reported allergy / / 23817569 rs6919586 chr6 31421112 A G 1.11E-06 Behcet's disease / / pha002888 rs3093971 chr6 31424607 G A 0.00009725 Sarcoidosis / / 22952805 rs2254386 chr6 31425033 T C 1.54E-14 Behcet's disease / / pha002888 rs3131621 chr6 31425499 A G 1.02E-08 Multiple complex diseases / / 17554300 rs3131621 chr6 31425499 A G 3.12E-09 Multiple sclerosis / / 17660530 rs2596480 chr6 31425985 C T 1.97E-08 Rheumatoid arthritis / / 17804836 rs2596480 chr6 31425985 C T 6.55E-07 Systemic sclerosis / / 20383147 rs2596480 chr6 31425985 C T 5.49E-09 Self-reported allergy / / 23817569 rs2596480 chr6 31425985 C T 8.06E-06 Behcet's disease / / pha002888 rs2254618 chr6 31427139 A T 2.92E-05 IgE levels / / 22075330 rs9267123 chr6 31427395 G C 0.00005066 Sarcoidosis / / 22952805 rs6930572 chr6 31428169 A G 2.51E-04 Multiple complex diseases / / 17554300 rs3130477 chr6 31428920 T C 0.000001655 Sarcoidosis / / 22952805 rs2596472 chr6 31428967 G A 1.11E-16 Type 1 diabetes HCP5 nearGene-5 17632545 rs2596472 chr6 31428967 G A 8.37E-05 HIV-1 control HCP5 nearGene-5 20041166 rs2596472 chr6 31428967 G A 2.45E-05 Behcet's disease HCP5 nearGene-5 pha002888 rs3094228 chr6 31429927 T C 4.00E-07 Thyroid peroxidase antibody positivity / / 24586183 rs3094228 chr6 31429927 T C 5.80E-05 Thyroid peroxidase antibody levels / / 24586183 rs3094228 chr6 31429927 T C 6.35E-04 Heart Failure / / pha002885 rs3094228 chr6 31429927 T C 4.27E-12 Behcet's disease / / pha002888 rs3132089 chr6 31430010 G A 0.00001003 Sarcoidosis / / 22952805 rs3099839 chr6 31430065 C T 0.00001753 Sarcoidosis / / 22952805 rs3094605 chr6 31430694 G C 0.000009843 Sarcoidosis HCP5 nearGene-5 22952805 rs2255221 chr6 31431691 G T 4.00E-14 HIV-1 control HCP5 UTR-3 21051598 rs2395029 chr6 31431780 T G 1 Drug response to Abacavir HCP5 UTR-3 11888582 rs2395029 chr6 31431780 T G 1 Drug response to Abacavir HCP5 UTR-3 15024131 rs2395029 chr6 31431780 T G 1 Drug response to Abacavir HCP5 UTR-3 15247625 rs2395029 chr6 31431780 T G 1 Drug response to Floxacillin HCP5 UTR-3 15963097 rs2395029 chr6 31431780 T G 1 Drug response to Abacavir HCP5 UTR-3 16998491 rs2395029 chr6 31431780 T G 9.36E-12 HIV-1 viral setpoint HCP5 UTR-3 17641165 rs2395029 chr6 31431780 T G 1 Drug response to Abacavir HCP5 UTR-3 18256392 rs2395029 chr6 31431780 T G 2.00E-26 Psoriasis HCP5 UTR-3 18369459 rs2395029 chr6 31431780 T G 1 Drug response to Abacavir HCP5 UTR-3 18536095 rs2395029 chr6 31431780 T G 1 Drug response to Abacavir HCP5 UTR-3 18684101 rs2395029 chr6 31431780 T G 3.00E-19 AIDS progression HCP5 UTR-3 19115949 rs2395029 chr6 31431780 T G 9.00E-33 Drug-induced liver injury (flucloxacillin) HCP5 UTR-3 19483685 rs2395029 chr6 31431780 T G 1.00E-11 HIV-1 control HCP5 UTR-3 20041166 rs2395029 chr6 31431780 T G 5.00E-35 HIV-1 control HCP5 UTR-3 20041166 rs2395029 chr6 31431780 T G 1.00E-25 HIV-1 control HCP5 UTR-3 21051598 rs2395029 chr6 31431780 T G 3.21E-19 HIV-1 viral setpoint HCP5 UTR-3 21490045 rs2395029 chr6 31431780 T G 1.61E-11 HIV-1 infection (natural long-term nonprogression) HCP5 UTR-3 22238471 rs3130907 chr6 31431813 A G 0.000007557 Sarcoidosis HCP5 UTR-3 22952805 rs2284178 chr6 31432125 C T 1.00E-16 Type 1 diabetes HCP5 UTR-3 17632545 rs2284178 chr6 31432125 C T 5.30E-05 HIV-1 viral setpoint HCP5 UTR-3 17641165 rs2284178 chr6 31432125 C T 4.21E-07 AIDS progression HCP5 UTR-3 19115949 rs2284178 chr6 31432125 C T 6.46E-04 Schizophrenia HCP5 UTR-3 19197363 rs2284178 chr6 31432125 C T 5.01E-12 HIV-1 control HCP5 UTR-3 20041166 rs2284178 chr6 31432125 C T 4.60E-28 HIV-1 control HCP5 UTR-3 21051598 rs2284178 chr6 31432125 C T 6.30E-07 HIV-1 viral setpoint HCP5 UTR-3 21490045 rs2284178 chr6 31432125 C T 0.0000134 HIV-1-specific cross-reactive neutralizing activity HCP5 UTR-3 23372753 rs2284178 chr6 31432125 C T 0.000331 Schizophrenia HCP5 UTR-3 23637625 rs2284178 chr6 31432125 C T 3.50E-05 Systemic lupus erythematosus HCP5 UTR-3 24871463 rs2284178 chr6 31432125 C T 3.06E-10 Behcet's disease HCP5 UTR-3 pha002888 rs3128986 chr6 31433693 T C 0.000006518 Sarcoidosis HCP5 nearGene-3 22952805 rs3094604 chr6 31434111 A G 7.16E-06 Schizophrenia / / 21926974 rs3094604 chr6 31434111 A G 3.20E-09 Behcet's disease / / pha002888 rs3131619 chr6 31434331 A T 0.000008204 Sarcoidosis / / 22952805 rs3094013 chr6 31434366 G A 1.68E-05 Pulmonary function / / 20010835 rs3094013 chr6 31434366 G A 0.000008204 Sarcoidosis / / 22952805 rs3094012 chr6 31434520 G C 0.00001236 Sarcoidosis / / 22952805 rs3131618 chr6 31434621 A G 0.00005034 Sarcoidosis / / 22952805 rs3131618 chr6 31434621 A G 8.63E-08 Rheumatoid arthritis (ACPA-negative) / / 24532677 rs2516518 chr6 31435119 G A 8.71E-05 Cognitive test performance / / 20125193 rs2516518 chr6 31435119 G A 5.80E-09 HIV-1 control / / 21051598 rs2516518 chr6 31435119 G A 3.31E-06 Behcet's disease / / pha002888 rs4713466 chr6 31435869 C T 5.71E-04 Type 2 diabetes / / 17463246 rs4713466 chr6 31435869 C T 8.36E-07 Multiple complex diseases / / 17554300 rs4713466 chr6 31435869 C T 5.78E-04 HIV-1 viral setpoint / / 17641165 rs2518028 chr6 31436047 T C 1.20E-08 HIV-1 control / / 21051598 rs2518028 chr6 31436047 T C 4.41E-08 Behcet's disease / / pha002888 rs2518027 chr6 31436476 T G 1.01E-12 Multiple complex diseases / / 17554300 rs2844507 chr6 31436581 T C 8.44E-12 Multiple complex diseases / / 17554300 rs2844507 chr6 31436581 T C 1.59E-09 Multiple sclerosis / / 17660530 rs2844507 chr6 31436581 T C 1.74E-04 Lymphocyte counts / / 22286170 rs2244579 chr6 31436639 G C 9.83E-05 Height / / 17255346 rs2244579 chr6 31436639 G C 1.21E-12 Multiple complex diseases / / 17554300 rs3131617 chr6 31436738 A T 0.00003056 Sarcoidosis / / 22952805 rs2523674 chr6 31436789 A G 3.52E-12 Rheumatoid arthritis / / 17804836 rs2523674 chr6 31436789 A G 1.12E-13 Rheumatoid arthritis / / 19503088 rs2523674 chr6 31436789 A G 1.06E-07 HIV-1 control / / 20041166 rs2523674 chr6 31436789 A G 3.04E-04 Crohn's disease / / 23266558 rs2523674 chr6 31436789 A G 7.10E-09 HIV-1 susceptibility / / 23935489 rs2244839 chr6 31438368 G A 3.14E-04 Height HCG26 nearGene-5 17255346 rs2244839 chr6 31438368 G A 1.31E-08 Type 1 diabetes HCG26 nearGene-5 17632545 rs2244839 chr6 31438368 G A 1.82E-08 Rheumatoid arthritis HCG26 nearGene-5 17804836 rs2244839 chr6 31438368 G A 3.35E-14 Rheumatoid arthritis HCG26 nearGene-5 19503088 rs2244839 chr6 31438368 G A 8.31E-04 Coronary heart disease HCG26 nearGene-5 21971053 rs2244839 chr6 31438368 G A 1.22E-07 Pemphigus vulgaris HCG26 nearGene-5 22437316 rs7758090 chr6 31438794 C T 9.77E-05 Amyotrophic lateral sclerosis HCG26 nearGene-5 20801718 rs2844505 chr6 31439063 C T 2.40E-05 Multiple sclerosis / / 20598377 rs1055569 chr6 31440082 C T 2.48E-08 Type 1 diabetes / / 17632545 rs1055569 chr6 31440082 C T 2.00E-05 Rheumatoid arthritis / / 17804836 rs1055569 chr6 31440082 C T 2.20E-12 Rheumatoid arthritis / / 19503088 rs1055569 chr6 31440082 C T 1.09E-04 Coronary heart disease / / 21971053 rs1055569 chr6 31440082 C T 5.28E-05 Pemphigus vulgaris / / 22437316 rs1055569 chr6 31440082 C T 9.70E-04 Systemic lupus erythematosus / / 24871463 rs2516440 chr6 31440497 G A 9.58E-09 Type 1 diabetes HCG26 nearGene-3 17632545 rs2516440 chr6 31440497 G A 2.58E-05 Rheumatoid arthritis HCG26 nearGene-3 17804836 rs2516440 chr6 31440497 G A 5.48E-11 Rheumatoid arthritis HCG26 nearGene-3 19503088 rs2516440 chr6 31440497 G A 1.14E-04 Coronary heart disease HCG26 nearGene-3 21971053 rs2516440 chr6 31440497 G A 6.92E-05 Pemphigus vulgaris HCG26 nearGene-3 22437316 rs3828886 chr6 31440552 T G 5.44E-06 Multiple complex diseases HCG26 nearGene-3 17554300 rs3828886 chr6 31440552 T G 1.14E-04 Coronary heart disease HCG26 nearGene-3 21971053 rs3828890 chr6 31440669 C G 1.00E-09 Renal function-related traits (eGRFcrea) HCG26 nearGene-3 22797727 rs3828890 chr6 31440669 C G 3.00E-09 Renal function-related traits (sCR) HCG26 nearGene-3 22797727 rs4413654 chr6 31441349 G A 1.50E-04 Coronary heart disease / / 21971053 rs12665745 chr6 31441901 G A 3.13E-06 Hodgkin's lymphoma / / 24149102 rs6940467 chr6 31442137 A G 1.07E-10 Coronary heart disease / / 21971053 rs2844503 chr6 31442731 T A 0.0000771 Sarcoidosis / / 22952805 rs3131643 chr6 31442782 G A 6.47E-05 Behcet's disease / / pha002888 rs12660382 chr6 31443323 C T 1.11E-08 Type 1 diabetes / / 17632545 rs12660382 chr6 31443323 C T 4.15E-05 Rheumatoid arthritis / / 17804836 rs12660382 chr6 31443323 C T 2.01E-07 Rheumatoid arthritis / / 19503088 rs12660382 chr6 31443323 C T 5.60E-11 Pemphigus vulgaris / / 22437316 rs2516516 chr6 31443570 T C 3.01E-05 Multiple complex diseases / / 17554300 rs2395488 chr6 31445909 A G 1.33E-15 Type 1 diabetes / / 17632545 rs2395488 chr6 31445909 A G 9.22E-05 HIV-1 viral setpoint / / 17641165 rs2395488 chr6 31445909 A G 5.96E-06 HIV-1 control / / 20041166 rs2395488 chr6 31445909 A G 3.98E-12 Pemphigus vulgaris / / 22437316 rs2395488 chr6 31445909 A G 1.53E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2395488 chr6 31445909 A G 3.40E-08 Systemic lupus erythematosus / / 24871463 rs2395488 chr6 31445909 A G 1.05E-104 Type 1 diabetes / / pha002862 rs2395488 chr6 31445909 A G 5.72E-06 Systemic lupus erythematosus / / pha002867 rs2248372 chr6 31446466 G A 2.79E-11 Type 1 diabetes / / 17632545 rs2248372 chr6 31446466 G A 1.75E-07 HIV-1 control / / 20041166 rs2248372 chr6 31446466 G A 0.0000261 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs2248372 chr6 31446466 G A 1.90E-06 Pemphigus vulgaris / / 22437316 rs2248372 chr6 31446466 G A 6.80E-06 Systemic lupus erythematosus / / 24871463 rs2248373 chr6 31446546 T C 9.73E-11 Multiple complex diseases / / 17554300 rs2248373 chr6 31446546 T C 1.28E-06 Multiple sclerosis / / 17660530 rs2248373 chr6 31446546 T C 1.15E-06 Hepatitis B / / 21750111 rs2248373 chr6 31446546 T C 6.15E-08 Red blood cell traits / / 23222517 rs2248459 chr6 31446710 A G 7.77E-94 Multiple complex diseases / / 17554300 rs2248462 chr6 31446796 G A 9.47E-40 Multiple complex diseases / / 17554300 rs2248462 chr6 31446796 G A 4.34E-08 Type 1 diabetes / / 17632545 rs2248462 chr6 31446796 G A 3.61E-06 HIV-1 viral setpoint / / 17641165 rs2248462 chr6 31446796 G A 4.26E-08 AIDS progression / / 19115949 rs2248462 chr6 31446796 G A 5.12E-15 HIV-1 control / / 20041166 rs2248462 chr6 31446796 G A 4.51E-04 HIV-1 progression / / 20064070 rs2248462 chr6 31446796 G A 3.27E-07 Systemic sclerosis / / 20383147 rs2248462 chr6 31446796 G A 7.57E-07 HIV-1 viral setpoint / / 21490045 rs2248462 chr6 31446796 G A 0.00000133 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs2248462 chr6 31446796 G A 7.00E-16 Hodgkin's lymphoma / / 22286212 rs2516513 chr6 31447588 C T 3.61E-06 HIV-1 viral setpoint / / 17641165 rs2516513 chr6 31447588 C T 8.46E-15 HIV-1 control / / 20041166 rs2516513 chr6 31447588 C T 7.80E-14 HIV-1 control / / 21051598 rs2516513 chr6 31447588 C T 1.34E-06 HIV-1 viral setpoint / / 21490045 rs2516513 chr6 31447588 C T 8.58E-07 Hodgkin's lymphoma / / 24149102 rs2523651 chr6 31448154 A G 1.48E-07 Red blood cell traits / / 23222517 rs2516424 chr6 31448315 A G 3.90E-05 Type 2 diabetes / / 17460697 rs2516424 chr6 31448315 A G 4.44E-16 Type 1 diabetes / / 17632545 rs2516424 chr6 31448315 A G 9.22E-05 HIV-1 viral setpoint / / 17641165 rs2516424 chr6 31448315 A G 4.34E-06 HIV-1 control / / 20041166 rs2516424 chr6 31448315 A G 1.43E-12 Pemphigus vulgaris / / 22437316 rs2516424 chr6 31448315 A G 1.28E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2516424 chr6 31448315 A G 8.37E-105 Type 1 diabetes / / pha002862 rs2248617 chr6 31448533 C T 4.52E-93 Multiple complex diseases / / 17554300 rs2248617 chr6 31448533 C T 7.77E-16 Type 1 diabetes / / 17632545 rs2248617 chr6 31448533 C T 9.22E-05 HIV-1 viral setpoint / / 17641165 rs2248617 chr6 31448533 C T 6.09E-06 HIV-1 control / / 20041166 rs2248617 chr6 31448533 C T 1.53E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2248617 chr6 31448533 C T 1.68E-104 Type 1 diabetes / / pha002862 rs2516512 chr6 31448563 C T 7.80E-09 Graves' disease / / 21900946 rs2516511 chr6 31448625 C T 9.23E-06 HIV-1 control / / 20041166 rs3749946 chr6 31448862 C A 3.55E-08 Multiple complex diseases / / 17554300 rs3749946 chr6 31448862 C A 8.60E-07 Self-reported allergy / / 23817569 rs3749946 chr6 31448862 C A 2.00E-15 Ulcerative colitis / / 24837172 rs3099844 chr6 31448976 C A 2.23E-79 Multiple complex diseases / / 17554300 rs3099844 chr6 31448976 C A 1.00E-16 Type 1 diabetes / / 17632545 rs3099844 chr6 31448976 C A 3.85E-04 HIV-1 viral setpoint / / 17641165 rs3099844 chr6 31448976 C A 1.98E-05 Lung cancer / / 18978787 rs3099844 chr6 31448976 C A 2.00E-04 Schizophrenia / / 19197363 rs3099844 chr6 31448976 C A 9.10E-05 Schizophrenia / / 19571808 rs3099844 chr6 31448976 C A 8.88E-07 Lung cancer / / 19654303 rs3099844 chr6 31448976 C A 2.21E-07 Lung adenocarcinoma / / 19836008 rs3099844 chr6 31448976 C A 2.60E-26 Primary sclerosing cholangitis / / 19944697 rs3099844 chr6 31448976 C A 1.41E-05 HIV-1 control / / 20041166 rs3099844 chr6 31448976 C A 5.00E-10 Neonatal lupus / / 20662065 rs3099844 chr6 31448976 C A 9.52E-07 Alopecia areata / / 22027810 rs3099844 chr6 31448976 C A 2.00E-08 Metabolic syndrome / / 22399527 rs3099844 chr6 31448976 C A 1.80E-10 Lung cancer / / 22899653 rs3099844 chr6 31448976 C A 4.70E-85 Myasthenia gravis / / 23055271 rs3099844 chr6 31448976 C A 6.10E-16 Systemic lupus erythematosus / / 24871463 rs3099844 chr6 31448976 C A 7.98E-06 Systemic lupus erythematosus / / pha002867 rs2523650 chr6 31449022 T C 8.78E-08 Multiple complex diseases / / 17554300 rs2523650 chr6 31449022 T C 1.34E-05 Multiple sclerosis / / 17660530 rs2523650 chr6 31449022 T C 1.24E-07 Red blood cell traits / / 23222517 rs2904776 chr6 31449081 G C 9.29E-11 Multiple complex diseases / / 17554300 rs2904776 chr6 31449081 G C 6.52E-05 Multiple sclerosis / / 17660530 rs2516422 chr6 31449269 C T 3.42E-39 Multiple complex diseases / / 17554300 rs2905722 chr6 31449327 A G 2.02E-09 Type 1 diabetes / / 17632545 rs2905722 chr6 31449327 A G 3.10E-05 HIV-1 control / / 20041166 rs2905722 chr6 31449327 A G 1.40E-08 HIV-1 control / / 21051598 rs3130908 chr6 31449552 T C 0.00008108 Sarcoidosis / / 22952805 rs3130909 chr6 31449710 T C 0.00007446 Sarcoidosis / / 22952805 rs2523647 chr6 31449778 A G 3.88E-05 Rheumatoid arthritis / / 17804836 rs2523647 chr6 31449778 A G 8.98E-15 Pemphigus vulgaris / / 22437316 rs2516509 chr6 31449994 T C 6.02E-08 Type 1 diabetes / / 17632545 rs2516509 chr6 31449994 T C 3.61E-06 HIV-1 viral setpoint / / 17641165 rs2516509 chr6 31449994 T C 4.95E-08 AIDS progression / / 19115949 rs2516509 chr6 31449994 T C 1.35E-14 HIV-1 control / / 20041166 rs2516509 chr6 31449994 T C 4.19E-07 Systemic sclerosis / / 20383147 rs2516509 chr6 31449994 T C 1.75E-06 HIV-1 viral setpoint / / 21490045 rs2516509 chr6 31449994 T C 0.000000806 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs2523710 chr6 31450909 G A 3.36E-07 Hodgkin's lymphoma / / 24149102 rs2905747 chr6 31451476 A G 2.66E-09 Multiple complex diseases / / 17554300 rs2905747 chr6 31451476 A G 7.07E-17 Multiple sclerosis / / 17660530 rs2523705 chr6 31451680 C T 1.05E-05 HIV-1 control / / 20041166 rs2904602 chr6 31451847 G A 0.0000542 Sarcoidosis / / 22952805 rs9267202 chr6 31452602 G A 7.37E-04 Self-reported allergy / / 23817569 rs2904600 chr6 31453113 A C 1.06E-05 HIV-1 control / / 20041166 rs2428501 chr6 31453547 A G 3.49E-07 Red blood cell traits / / 23222517 rs9267247 chr6 31455834 A C 4.94E-05 Multiple complex diseases / / 17554300 rs9267247 chr6 31455834 A C 1.92E-06 Multiple sclerosis / / 17660530 rs9267247 chr6 31455834 A C 5.73E-08 Red blood cell traits / / 23222517 rs2904781 chr6 31457417 C G 2.83E-05 IgE levels / / 22075330 rs2395033 chr6 31458554 C T 5.37E-08 Red blood cell traits / / 23222517 rs2516415 chr6 31459742 G A 1.90E-11 Type 1 diabetes / / 17632545 rs2516415 chr6 31459742 G A 2.03E-04 HIV-1 viral setpoint / / 17641165 rs2516415 chr6 31459742 G A 3.14E-05 HIV-1 control / / 20041166 rs2516415 chr6 31459742 G A 3.75E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2516415 chr6 31459742 G A 4.45E-74 Type 1 diabetes / / pha002862 rs2395034 chr6 31460143 T C 4.56E-40 Multiple complex diseases / / 17554300 rs2395034 chr6 31460143 T C 2.10E-17 HIV-1 control / / 21051598 rs2395038 chr6 31460451 T G 2.37E-07 Red blood cell traits / / 23222517 rs3130922 chr6 31461089 A G 1.90E-05 Rheumatoid arthritis / / 17804836 rs3130923 chr6 31462135 G A 0.0000801 Sarcoidosis / / 22952805 rs3095235 chr6 31463170 G C 2.40E-05 Coronary heart disease / / 21966275 rs2534678 chr6 31463963 G T 8.10E-10 Type 1 diabetes MICB nearGene-5 17632545 rs2534678 chr6 31463963 G T 8.26E-06 HIV-1 viral setpoint MICB nearGene-5 17641165 rs2534678 chr6 31463963 G T 9.78E-07 HIV-1 control MICB nearGene-5 20041166 rs3095234 chr6 31464571 C T 5.85E-04 Type 2 diabetes MICB nearGene-5 17463246 rs3095234 chr6 31464571 C T 1.40E-10 HIV-1 control MICB nearGene-5 21051598 rs3828903 chr6 31464739 G A 7.23E-05 Schizophrenia (cytomegalovirus infection interaction) MICB nearGene-5 23358160 rs3094005 chr6 31465047 G T 0.00006857 Sarcoidosis MICB nearGene-5 22952805 rs3094005 chr6 31465047 G T 4.61E-07 Rheumatoid arthritis (ACPA-negative) MICB nearGene-5 24532677 rs3828914 chr6 31465819 C T 7.57E-06 HIV-1 control MICB nearGene-5 20041166 rs3828914 chr6 31465819 C T 9.70E-05 Schizophrenia (cytomegalovirus infection interaction) MICB nearGene-5 23358160 rs2516498 chr6 31465899 G C 0.0000487 Cholesterol,total MICB UTR-5 23063622 rs3828917 chr6 31465917 G T 1 Drug response to Abacavir MICB UTR-5 11675863 rs3828917 chr6 31465917 G T 1 Drug response to Abacavir MICB UTR-5 11888582 rs3828917 chr6 31465917 G T 1 Drug response to Abacavir MICB UTR-5 11943262 rs3828917 chr6 31465917 G T 1 Drug response to Abacavir MICB UTR-5 15024131 rs3828917 chr6 31465917 G T 1 Drug response to Abacavir MICB UTR-5 16758424 rs3828917 chr6 31465917 G T 1 Drug response to Abacavir MICB UTR-5 16758425 rs3828917 chr6 31465917 G T 1 Drug response to Abacavir MICB UTR-5 18256392 rs3828917 chr6 31465917 G T 1 Drug response to Abacavir MICB UTR-5 19115972 rs3828917 chr6 31465917 G T 5.11E-07 HIV-1 control MICB UTR-5 20041166 rs3828917 chr6 31465917 G T 3.80E-20 HIV-1 control MICB UTR-5 21051598 rs3134897 chr6 31466547 T C 5.85E-04 Type 2 diabetes MICB intron 17463246 rs3095233 chr6 31469774 A G 0.00003888 Sarcoidosis MICB intron 22952805 rs9267404 chr6 31470545 T G 7.65E-05 AIDS progression MICB intron 19115949 rs2534657 chr6 31472459 C T 3.56E-08 Type 1 diabetes MICB intron 17632545 rs2534657 chr6 31472459 C T 8.26E-06 HIV-1 viral setpoint MICB intron 17641165 rs2534657 chr6 31472459 C T 2.86E-07 HIV-1 control MICB intron 20041166 rs2534657 chr6 31472459 C T 3.25E-07 Hodgkin's lymphoma MICB intron 24149102 rs2855812 chr6 31472720 G T 1.00E-16 Type 1 diabetes MICB intron 17632545 rs2855812 chr6 31472720 G T 7.29E-04 HIV-1 viral setpoint MICB intron 17641165 rs2855812 chr6 31472720 G T 4.73E-05 Rheumatoid arthritis MICB intron 17804836 rs2855812 chr6 31472720 G T 1.01E-07 Rheumatoid arthritis MICB intron 19503088 rs2855812 chr6 31472720 G T 2.00E-07 Pulmonary function MICB intron 21946350 rs2855812 chr6 31472720 G T 0.0000225 Positivity for ZnT8A in Type 1 diabetes MICB intron 22526605 rs2855812 chr6 31472720 G T 4.20E-52 Myasthenia gravis MICB intron 23055271 rs2855812 chr6 31472720 G T 7.10E-09 Systemic lupus erythematosus MICB intron 24871463 rs2855812 chr6 31472720 G T 2.55E-96 Type 1 diabetes MICB intron pha002862 rs2855812 chr6 31472720 G T 4.14E-05 Blood Pressure MICB intron pha003050 rs3134899 chr6 31473286 C T 6.76E-07 HIV-1 control MICB intron 20041166 rs3134899 chr6 31473286 C T 2.60E-10 HIV-1 control MICB intron 21051598 rs3130616 chr6 31473746 G A 0.00003888 Sarcoidosis MICB intron 22952805 rs2242955 chr6 31474280 G A 1.56E-05 Behcet's disease MICB intron pha002888 rs3093953 chr6 31474688 T G 5.85E-04 Type 2 diabetes MICB intron 17463246 rs3093953 chr6 31474688 T G 3.45E-08 Behcet's disease MICB intron 23001997 rs3131638 chr6 31475127 A G 5.85E-04 Type 2 diabetes MICB intron 17463246 rs3132468 chr6 31475486 C T 4.00E-11 Dengue shock syndrome MICB intron 22001756 rs3132468 chr6 31475486 C T 1.85E-05 Triglycerides MICB intron pha003080 rs2844498 chr6 31476854 C T 9.35E-04 HIV-1 viral setpoint MICB intron 17641165 rs2844498 chr6 31476854 C T 1.70E-05 AIDS progression MICB intron 19115949 rs2844498 chr6 31476854 C T 7.25E-04 Schizophrenia MICB intron 19197363 rs2844498 chr6 31476854 C T 1.44E-05 Pemphigus vulgaris MICB intron 22437316 rs2844498 chr6 31476854 C T 1.50E-05 Systemic lupus erythematosus MICB intron 24871463 rs2246618 chr6 31478986 C T 9.61E-14 Type 1 diabetes MICB nearGene-3 17632545 rs2246618 chr6 31478986 C T 4.58E-11 Pemphigus vulgaris MICB nearGene-3 22437316 rs2246618 chr6 31478986 C T 1.65E-78 Type 1 diabetes MICB nearGene-3 pha002862 rs2516400 chr6 31481105 G A 3.66E-15 Type 1 diabetes / / 17632545 rs2516400 chr6 31481105 G A 9.74E-05 HIV-1 viral setpoint / / 17641165 rs2516400 chr6 31481105 G A 2.72E-06 AIDS progression / / 19115949 rs2516400 chr6 31481105 G A 8.75E-07 HIV-1 control / / 20041166 rs2516400 chr6 31481105 G A 8.40E-53 Myasthenia gravis / / 23055271 rs2516400 chr6 31481105 G A 4.45E-81 Type 1 diabetes / / pha002862 rs2516399 chr6 31481299 A G 2.91E-13 Multiple complex diseases / / 17554300 rs2516399 chr6 31481299 A G 6.43E-05 Rheumatoid arthritis / / 17804836 rs2516399 chr6 31481299 A G 9.50E-10 Rheumatoid arthritis / / 19503088 rs2516399 chr6 31481299 A G 6.27E-09 Systemic sclerosis / / 20383147 rs2516399 chr6 31481299 A G 2.00E-12 White blood cell types / / 21738478 rs2516398 chr6 31481526 G T 1.42E-10 Type 1 diabetes / / 17632545 rs2516398 chr6 31481526 G T 9.38E-08 Rheumatoid arthritis / / 17804836 rs2516398 chr6 31481526 G T 1.64E-07 Systemic sclerosis / / 20383147 rs2516398 chr6 31481526 G T 7.76E-78 Type 1 diabetes / / pha002862 rs3130612 chr6 31482097 T G 0.00003174 Sarcoidosis / / 22952805 rs2844494 chr6 31483415 C A 2.76E-09 Type 1 diabetes / / 17632545 rs2844494 chr6 31483415 C A 2.84E-06 Rheumatoid arthritis / / 17804836 rs2844494 chr6 31483415 C A 3.22E-08 Systemic sclerosis / / 20383147 rs2844494 chr6 31483415 C A 4.45E-80 Type 1 diabetes / / pha002862 rs9267444 chr6 31483458 G A 1.55E-15 Type 1 diabetes / / 17632545 rs9267444 chr6 31483458 G A 2.65E-05 Pulmonary function / / 20010835 rs9267445 chr6 31483481 G C 0.00007464 Sarcoidosis / / 22952805 rs3131631 chr6 31484683 G C 3.99E-33 Multiple complex diseases / / 17554300 rs3131631 chr6 31484683 G C 2.11E-18 Multiple sclerosis / / 17660530 rs3131631 chr6 31484683 G C 4.39E-05 Behcet's disease / / pha002888 rs3093998 chr6 31485174 C A 6.82E-08 Hodgkin's lymphoma / / 24149102 rs2516489 chr6 31488038 C T 2.11E-09 Rheumatoid arthritis / / 21156761 rs3130637 chr6 31488145 A G 8.26E-06 Rheumatoid arthritis / / 17804836 rs3130637 chr6 31488145 A G 4.98E-06 Multiple sclerosis / / 20598377 rs3130637 chr6 31488145 A G 3.00E-05 Behcet's disease / / pha002888 rs4959079 chr6 31488879 C T 3.72E-09 HIV-1 control / / 20041166 rs4959079 chr6 31488879 C T 3.00E-11 HIV-1 control / / 21051598 rs3132454 chr6 31489644 A G 1.09E-04 Crohn's disease / / 23266558 rs3132454 chr6 31489644 A G 6.20E-04 Systemic lupus erythematosus / / 24871463 rs9267463 chr6 31490480 G A 1.10E-23 Psoriasis / / pha002855 rs9267464 chr6 31490646 C T 1.81E-22 Psoriasis / / pha002855 rs3093993 chr6 31490725 C A 5.84E-06 Rheumatoid arthritis / / 17804836 rs3093993 chr6 31490725 C A 4.98E-06 Multiple sclerosis / / 20598377 rs3093993 chr6 31490725 C A 3.12E-05 Behcet's disease / / pha002888 rs3095227 chr6 31491000 A G 9.40E-06 Rheumatoid arthritis / / 17804836 rs3095227 chr6 31491000 A G 5.94E-06 Multiple sclerosis / / 20598377 rs3095227 chr6 31491000 A G 3.12E-05 Behcet's disease / / pha002888 rs3093988 chr6 31492453 G A 9.67E-05 Pulmonary function / / 20010835 rs3093986 chr6 31493421 T A 2.33E-06 Behcet's disease / / pha002888 rs2734573 chr6 31494738 C A 2.92E-05 Multiple complex diseases MCCD1 nearGene-5 17554300 rs2734573 chr6 31494738 C A 8.38E-11 Multiple sclerosis MCCD1 nearGene-5 17660530 rs2734573 chr6 31494738 C A 1.50E-12 Psoriasis MCCD1 nearGene-5 pha002855 rs2516480 chr6 31496791 C G 3.45E-09 Rheumatoid arthritis MCCD1 UTR-5 21156761 rs2259435 chr6 31496915 G A 2.79E-06 Rheumatoid arthritis MCCD1 missense 17804836 rs2259435 chr6 31496915 G A 4.12E-05 Information processing speed MCCD1 missense 21130836 rs2259435 chr6 31496915 G A 1.51E-09 Rheumatoid arthritis MCCD1 missense 21156761 rs3093983 chr6 31496925 G A 1.04E-05 HIV-1 control MCCD1 missense 20041166 rs3093983 chr6 31496925 G A 1.33E-05 Multiple sclerosis MCCD1 missense 20598377 rs2734586 chr6 31497342 G C 1.26E-09 Rheumatoid arthritis MCCD1 intron 21156761 rs3130055 chr6 31497399 C T 6.84E-04 HIV-1 viral setpoint MCCD1 intron 17641165 rs3130055 chr6 31497399 C T 3.74E-06 HIV-1 control MCCD1 intron 20041166 rs3130055 chr6 31497399 C T 1.03E-04 HIV-1 viral setpoint MCCD1 intron 21490045 rs3115537 chr6 31497835 G C 1.34E-06 Multiple complex diseases MCCD1 UTR-3 17554300 rs3115537 chr6 31497835 G C 1.74E-18 Multiple sclerosis MCCD1 UTR-3 17660530 rs3093978 chr6 31498497 C A 9.46E-06 HIV-1 control DDX39B intron 20041166 rs3093978 chr6 31498497 C A 9.28E-06 Multiple sclerosis DDX39B intron 20598377 rs3093978 chr6 31498497 C A 1.17E-04 HIV-1 viral setpoint DDX39B intron 21490045 rs3093978 chr6 31498497 C A 8.82E-07 Behcet's disease DDX39B intron pha002888 rs2516478 chr6 31498737 G A 4.04E-06 Multiple complex diseases DDX39B intron 17554300 rs2516478 chr6 31498737 G A 1.50E-09 Rheumatoid arthritis DDX39B intron 21156761 rs3853601 chr6 31499603 C G 2.20E-06 Asthma DDX39B intron 21790008 rs3853601 chr6 31499603 C G 3.82E-06 Asthma DDX39B intron 21790008 rs3853601 chr6 31499603 C G 5.57E-06 Asthma DDX39B intron 21790008 rs3853601 chr6 31499603 C G 5.73E-07 Asthma DDX39B intron 21790008 rs3853601 chr6 31499603 C G 2.00E-06 Atopic dermatitis DDX39B intron 22197932 rs3093948 chr6 31501413 A G 8.72E-07 Behcet's disease DDX39B intron pha002888 rs3093976 chr6 31502861 A G 1.03E-06 Behcet's disease DDX39B intron pha002888 rs929138 chr6 31503698 T C 5.37E-05 HIV-1 control DDX39B intron 20041166 rs929138 chr6 31503698 T C 1.40E-09 HIV-1 control DDX39B intron 21051598 rs2075580 chr6 31503975 G C 1.00E-09 Graves' disease DDX39B intron 21900946 rs3130057 chr6 31504587 G T 1.07E-06 Behcet's disease DDX39B intron pha002888 rs2734583 chr6 31505480 A G 1.00E-16 Type 1 diabetes DDX39B intron 17632545 rs2734583 chr6 31505480 A G 1.88E-05 Lung adenocarcinoma DDX39B intron 19836008 rs2734583 chr6 31505480 A G 3.66E-05 HIV-1 control DDX39B intron 20041166 rs2734583 chr6 31505480 A G 2.00E-08 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) DDX39B intron 21912425 rs2734583 chr6 31505480 A G 0.00005363 Sarcoidosis DDX39B intron 22952805 rs2734583 chr6 31505480 A G 4.46E-07 Rheumatoid arthritis (ACPA-negative) DDX39B intron 24532677 rs2734583 chr6 31505480 A G 5.29E-68 Type 1 diabetes DDX39B intron pha002862 rs3130058 chr6 31505887 T C 6.23E-07 Behcet's disease DDX39B intron pha002888 rs3093975 chr6 31506138 G A 6.21E-05 Pulmonary function DDX39B intron 20010835 rs933208 chr6 31506648 G T 2.10E-08 Graves' disease DDX39B intron 21900946 rs933208 chr6 31506648 G T 2.04E-05 Odorant perception DDX39B intron 23910658 rs2071596 chr6 31506691 G A 9.68E-07 Rheumatoid arthritis DDX39B intron 17804836 rs2071596 chr6 31506691 G A 1.75E-09 Rheumatoid arthritis DDX39B intron 19503088 rs2516393 chr6 31506744 A C 1.02E-05 HIV-1 control DDX39B intron 20041166 rs2516393 chr6 31506744 A C 1.14E-05 Multiple sclerosis DDX39B intron 20598377 rs2516393 chr6 31506744 A C 1.17E-04 HIV-1 viral setpoint DDX39B intron 21490045 rs2516393 chr6 31506744 A C 8.82E-07 Behcet's disease DDX39B intron pha002888 rs2523512 chr6 31506801 G A 1.69E-09 Rheumatoid arthritis DDX39B intron 21156761 rs2071595 chr6 31507062 G C 1.67E-07 Self-reported allergy DDX39B intron 23817569 rs2239709 chr6 31507447 C T 8.16E-08 Self-reported allergy DDX39B intron 23817569 rs2239709 chr6 31507447 C T 4.56E-05 Behcet's disease DDX39B intron pha002888 rs2239527 chr6 31509779 C G 1.30E-04 Myocardial infarction DDX39B UTR-5 12426569 rs2523506 chr6 31509967 G T 5.38E-09 Rheumatoid arthritis DDX39B UTR-5 21156761 rs2523506 chr6 31509967 G T 5.44E-04 Taste perception DDX39B UTR-5 22132133 rs2523505 chr6 31510002 C G 4.73E-10 Vitiligo DDX39B UTR-5 20526339 rs2844509 chr6 31510924 A G 8.49E-16 Rheumatoid arthritis ATP6V1G2-DDX39B intron 17804836 rs2844509 chr6 31510924 A G 5.52E-27 Rheumatoid arthritis ATP6V1G2-DDX39B intron 19503088 rs2844509 chr6 31510924 A G 6.40E-09 HIV-1 control ATP6V1G2-DDX39B intron 20041166 rs2844509 chr6 31510924 A G 1.20E-10 HIV-1 control ATP6V1G2-DDX39B intron 21051598 rs2844509 chr6 31510924 A G 4.33E-12 Atopic dermatitis ATP6V1G2-DDX39B intron 23886662 rs9267487 chr6 31511350 T C 2.30E-12 HIV-1 control ATP6V1G2-DDX39B intron 20041166 rs9267487 chr6 31511350 T C 5.00E-11 HIV-1 control ATP6V1G2-DDX39B intron 21051598 rs2251824 chr6 31511857 G A 1.70E-05 Information processing speed ATP6V1G2-DDX39B intron 21130836 rs2251824 chr6 31511857 G A 5.38E-09 Rheumatoid arthritis ATP6V1G2-DDX39B intron 21156761 rs2251824 chr6 31511857 G A 5.97E-06 Behcet's disease ATP6V1G2-DDX39B intron pha002888 rs2071593 chr6 31512799 G A 7.65E-08 Self-reported allergy ATP6V1G2 UTR-3 23817569 rs2071593 chr6 31512799 G A 4.56E-05 Behcet's disease ATP6V1G2 UTR-3 pha002888 rs2239705 chr6 31513402 G A 2.27E-05 Rheumatoid arthritis ATP6V1G2 intron 17804836 rs2239705 chr6 31513402 G A 2.65E-11 Rheumatoid arthritis ATP6V1G2 intron 19503088 rs2523503 chr6 31513559 C A 1.70E-05 Information processing speed ATP6V1G2 intron 21130836 rs2523503 chr6 31513559 C A 5.38E-09 Rheumatoid arthritis ATP6V1G2 intron 21156761 rs2523503 chr6 31513559 C A 5.59E-06 Behcet's disease ATP6V1G2 intron pha002888 rs9267488 chr6 31514247 A G 0.0000608 Sarcoidosis ATP6V1G2 intron 22952805 rs3219184 chr6 31515140 A G 8.69E-06 Self-reported allergy NFKBIL1 intron 23817569 rs2071592 chr6 31515340 T A 1.30E-04 Myocardial infarction NFKBIL1 intron 12426569 rs2071591 chr6 31515799 G A 3.50E-07 Systemic lupus erythematosus NFKBIL1 intron 24871463 rs2857607 chr6 31517248 C T 3.25E-05 Personality dimensions NFKBIL1 intron 22628180 rs2857607 chr6 31517248 C T 1.08E-08 Self-reported allergy NFKBIL1 intron 23817569 rs2523500 chr6 31518354 G A 8.31E-04 Response to taxane treatment (placlitaxel) NFKBIL1 intron 23006423 rs2523500 chr6 31518354 G A 2.64E-06 Behcet's disease NFKBIL1 intron pha002888 rs6916921 chr6 31520426 C T 1.15E-05 Hodgkin's lymphoma NFKBIL1 intron 24149102 rs2255798 chr6 31521302 G C 1.66E-06 Information processing speed NFKBIL1 intron 21130836 rs2255798 chr6 31521302 G C 8.43E-05 Behcet's disease NFKBIL1 intron pha002888 rs6929796 chr6 31522669 G A 7.32E-07 Rheumatoid arthritis NFKBIL1 intron 17804836 rs6929796 chr6 31522669 G A 4.40E-10 Rheumatoid arthritis NFKBIL1 intron 19503088 rs2230365 chr6 31525448 C T 8.25E-05 Rheumatoid arthritis NFKBIL1 cds-synon 17804836 rs2230365 chr6 31525448 C T 8.38E-05 Information processing speed NFKBIL1 cds-synon 21130836 rs2230365 chr6 31525448 C T 2.75E-08 Rheumatoid arthritis NFKBIL1 cds-synon 21156761 rs2230365 chr6 31525448 C T 2.52E-05 Behcet's disease NFKBIL1 cds-synon pha002888 rs4947324 chr6 31528130 C T 1.07E-04 AIDS progression / / 19115949 rs17200733 chr6 31528951 A G 2.98E-06 Asthma LOC100287329 intron 21790008 rs2516390 chr6 31529883 C T 2.62E-13 Type 1 diabetes LOC100287329 intron 17632545 rs2516390 chr6 31529883 C T 8.90E-06 Kawasaki disease LOC100287329 intron 22446962 rs2516390 chr6 31529883 C T 5.57E-04 Response to taxane treatment (placlitaxel) LOC100287329 intron 23006423 rs2516390 chr6 31529883 C T 1.04E-05 Hodgkin's lymphoma LOC100287329 intron 24149102 rs928815 chr6 31531215 T G 4.32E-13 Type 1 diabetes LOC100287329 intron 17632545 rs928815 chr6 31531215 T G 8.90E-06 Kawasaki disease LOC100287329 intron 22446962 rs928815 chr6 31531215 T G 3.07E-04 Response to taxane treatment (placlitaxel) LOC100287329 intron 23006423 rs928815 chr6 31531215 T G 9.45E-06 Hodgkin's lymphoma LOC100287329 intron 24149102 rs2857602 chr6 31533378 G A 1.83E-04 Response to taxane treatment (placlitaxel) LOC100287329 intron 23006423 rs2857708 chr6 31533606 C T 1.66E-06 Information processing speed LOC100287329 intron 21130836 rs2857708 chr6 31533606 C T 0.00000651 Triglycerides LOC100287329 intron 23063622 rs2844484 chr6 31536224 A G 3.14E-13 Type 1 diabetes LOC100287329 intron 17632545 rs2844484 chr6 31536224 A G 7.82E-07 Rheumatoid arthritis LOC100287329 intron 17804836 rs2844484 chr6 31536224 A G 2.70E-07 Rheumatoid arthritis LOC100287329 intron 19503088 rs2844484 chr6 31536224 A G 2.88E-04 Response to taxane treatment (placlitaxel) LOC100287329 intron 23006423 rs2844484 chr6 31536224 A G 7.56E-06 Hodgkin's lymphoma LOC100287329 intron 24149102 rs2009658 chr6 31538244 C G 1.39E-05 Information processing speed LOC100287329 intron 21130836 rs2009658 chr6 31538244 C G 1.92E-08 Rheumatoid arthritis LOC100287329 intron 21156761 rs2009658 chr6 31538244 C G 6.64E-05 Behcet's disease LOC100287329 intron pha002888 rs2844482 chr6 31539767 C T 2.07E-06 Rheumatoid arthritis LOC100287329 intron 17804836 rs2844482 chr6 31539767 C T 1.39E-05 Information processing speed LOC100287329 intron 21130836 rs2844482 chr6 31539767 C T 1.87E-08 Rheumatoid arthritis LOC100287329 intron 21156761 rs2071590 chr6 31539768 A G 5.76E-04 Response to taxane treatment (placlitaxel) LOC100287329 intron 23006423 rs1800683 chr6 31540071 G A 3.30E-06 Myocardial infarction LTA UTR-5 12426569 rs1800683 chr6 31540071 G A 1.91E-04 Hemoglobin concentration LTA UTR-5 20534544 rs2239704 chr6 31540141 A C 1.12E-04 Response to taxane treatment (placlitaxel) LTA UTR-5 23006423 rs909253 chr6 31540313 A G 1.80E-05 Myocardial infarction LTA intron 12426569 rs2229094 chr6 31540556 T C 5.01E-06 HIV-1 control LTA missense 20041166 rs2229094 chr6 31540556 T C 1.68E-06 Behcet's disease LTA missense pha002888 rs3093542 chr6 31540693 G C 1.70E-05 Self-reported allergy LTA intron 23817569 rs1041981 chr6 31540784 C A 3.30E-06 Myocardial infarction LTA missense 12426569 rs1041981 chr6 31540784 C A 4.14E-08 Type 1 diabetes LTA missense 17632545 rs1041981 chr6 31540784 C A 5.20E-07 Systemic lupus erythematosus LTA missense 24871463 rs1799964 chr6 31542308 T C 2.66E-09 Multiple complex diseases / / 17554300 rs1799964 chr6 31542308 T C 2.60E-04 HIV-1 control / / 21051598 rs1799964 chr6 31542308 T C 4.00E-11 Crohn's disease / / 21102463 rs1800630 chr6 31542476 C A 1.87E-08 Rheumatoid arthritis / / 21156761 rs1800629 chr6 31543031 G A 1 Drug response to Carbamazepine TNF nearGene-5 11294926 rs1800629 chr6 31543031 G A 1 Drug response to Adalimumab TNF nearGene-5 17638513 rs1800629 chr6 31543031 G A 1 Drug response to Etanercept TNF nearGene-5 17638513 rs1800629 chr6 31543031 G A 1 Drug response to Infliximab TNF nearGene-5 17638513 rs3093661 chr6 31543758 G A 1.33E-11 HIV-1 control TNF intron 20041166 rs3093661 chr6 31543758 G A 6.30E-18 HIV-1 control TNF intron 21051598 rs1800610 chr6 31543827 G A 8.00E-08 Graves' disease TNF intron 21900946 rs3093662 chr6 31544189 A G 1.34E-04 HIV-1 viral setpoint TNF intron 17641165 rs3093662 chr6 31544189 A G 2.49E-08 Rheumatoid arthritis TNF intron 17804836 rs3093662 chr6 31544189 A G 3.18E-07 AIDS progression TNF intron 19115949 rs3093662 chr6 31544189 A G 3.42E-14 HIV-1 control TNF intron 20041166 rs3093662 chr6 31544189 A G 6.50E-11 HIV-1 control TNF intron 21051598 rs3093662 chr6 31544189 A G 2.28E-05 HIV-1 viral setpoint TNF intron 21490045 rs3093662 chr6 31544189 A G 8.07E-06 Atopic dermatitis TNF intron 23886662 rs3093662 chr6 31544189 A G 4.75E-21 Psoriasis TNF intron pha002855 rs3093668 chr6 31546495 G C 1.33E-11 HIV-1 control TNF nearGene-3 20041166 rs3093726 chr6 31546789 T C 1 Drug response to Abacavir / / 11888582 rs3093726 chr6 31546789 T C 1 Drug response to Abacavir / / 15247625 rs3093726 chr6 31546789 T C 1 Drug response to Abacavir / / 16998491 rs3093726 chr6 31546789 T C 1 Drug response to Abacavir / / 18256392 rs3093726 chr6 31546789 T C 1 Drug response to Abacavir / / 18536095 rs1800628 chr6 31546850 G A 0.00004976 Sarcoidosis / / 22952805 rs3093553 chr6 31549556 T G 2.30E-09 HIV-1 control LTB intron 20041166 rs9267502 chr6 31553194 G A 8.22E-04 Atopic dermatitis LST1 nearGene-5 23886662 rs9267502 chr6 31553194 G A 3.79E-19 Psoriasis LST1 nearGene-5 pha002855 rs2256965 chr6 31555130 A G,T 4.55E-08 Type 1 diabetes LST1 intron 17632545 rs2256965 chr6 31555130 A G,T 4.62E-07 Rheumatoid arthritis LST1 intron 17804836 rs2256965 chr6 31555130 A G,T 1.28E-08 Rheumatoid arthritis LST1 intron 19503088 rs2256974 chr6 31555392 C A 6.51E-04 Response to taxane treatment (placlitaxel) LST1 intron 23006423 rs28732144 chr6 31556205 G A 2.77E-11 HIV-1 control LST1 intron 20041166 rs28732144 chr6 31556205 G A 4.10E-21 HIV-1 control LST1 intron 21051598 rs1052248 chr6 31556581 T A 1.13E-06 HIV-1 control LST1 UTR-3 20041166 rs1052248 chr6 31556581 T A 2.30E-05 HIV-1 control LST1 UTR-3 21051598 rs1052248 chr6 31556581 T A 3.48E-09 Rheumatoid arthritis LST1 UTR-3 21156761 rs3087617 chr6 31556656 A T 7.54E-05 Melanoma LST1 UTR-3 21926416 rs986475 chr6 31556709 A G 1.34E-05 Hodgkin's lymphoma NCR3 UTR-3 24149102 rs11575839 chr6 31557791 G A 1.00E-54 Complement C3 and C4 levels NCR3 cds-synon 23028341 rs3130063 chr6 31558702 C T 0.00006736 Sarcoidosis NCR3 intron 22952805 rs3130632 chr6 31562764 C T 0.000007379 Sarcoidosis NCR3 nearGene-5 22952805 rs2515919 chr6 31564167 A G 3.20E-07 HIV-1 control / / 21051598 rs2736189 chr6 31564728 G A 4.74E-06 Information processing speed / / 21130836 rs2736189 chr6 31564728 G A 3.13E-09 Rheumatoid arthritis / / 21156761 rs2844480 chr6 31564821 C T 9.64E-04 HIV-1 viral setpoint / / 17641165 rs2844480 chr6 31564821 C T 1.61E-05 Rheumatoid arthritis / / 17804836 rs2844480 chr6 31564821 C T 1.08E-04 AIDS progression / / 19115949 rs2844480 chr6 31564821 C T 1.72E-13 HIV-1 control / / 20041166 rs2844480 chr6 31564821 C T 6.80E-06 HIV-1 control / / 21051598 rs2844480 chr6 31564821 C T 2.00E-04 Information processing speed / / 21130836 rs2844480 chr6 31564821 C T 2.46E-07 HIV-1 viral setpoint / / 21490045 rs2844480 chr6 31564821 C T 4.62E-06 Behcet's disease / / pha002888 rs3130631 chr6 31566168 C G 0.00009269 Sarcoidosis / / 22952805 rs2509217 chr6 31566204 C T 5.70E-04 Crohn's disease / / 23266558 rs2857595 chr6 31568469 G A 3.47E-12 Type 1 diabetes / / 17632545 rs2857595 chr6 31568469 G A 5.61E-04 Schizophrenia / / 19197363 rs2857595 chr6 31568469 G A 2.00E-10 Pulmonary function / / 21946350 rs2857595 chr6 31568469 G A 6.95E-05 Cognitive impairment induced by topiramate / / 22091778 rs2857595 chr6 31568469 G A 0.000006747 Sarcoidosis / / 22952805 rs2857595 chr6 31568469 G A 1.00E-60 Myasthenia gravis / / 23055271 rs2857595 chr6 31568469 G A 8.00E-08 Pulmonary function (interaction) / / 23284291 rs2857595 chr6 31568469 G A 7.60E-15 Systemic lupus erythematosus / / 24871463 rs2857595 chr6 31568469 G A 6.48E-06 Systemic lupus erythematosus / / pha002867 rs17207190 chr6 31569520 G A 2.79E-11 HIV-1 control / / 20041166 rs17207190 chr6 31569520 G A 2.20E-24 HIV-1 control / / 21051598 rs9378200 chr6 31572927 T C 3.80E-10 Type 1 diabetes / / 17632545 rs9378200 chr6 31572927 T C 1.10E-04 HIV-1 viral setpoint / / 17641165 rs9378200 chr6 31572927 T C 1.88E-14 HIV-1 control / / 20041166 rs9378200 chr6 31572927 T C 1.80E-16 HIV-1 control / / 21051598 rs9378200 chr6 31572927 T C 5.86E-06 HIV-1 viral setpoint / / 21490045 rs9378200 chr6 31572927 T C 1.84E-05 Atopic dermatitis / / 23886662 rs2844479 chr6 31572956 A C 1.31E-16 Rheumatoid arthritis / / 17804836 rs2844479 chr6 31572956 A C 2.00E-08 Weight / / 19079260 rs2844479 chr6 31572956 A C 4.10E-11 Rheumatoid arthritis / / 19503088 rs2844479 chr6 31572956 A C 6.10E-05 Smoking behavior / / 20418888 rs2844479 chr6 31572956 A C 1.02E-18 Rheumatoid arthritis / / 21156761 rs2844479 chr6 31572956 A C 4.00E-06 IgG glycosylation / / 23382691 rs2844479 chr6 31572956 A C 4.00E-06 IgG glycosylation / / 23382691 rs2844479 chr6 31572956 A C 7.00E-06 IgG glycosylation / / 23382691 rs2844479 chr6 31572956 A C 9.00E-06 IgG glycosylation / / 23382691 rs2844479 chr6 31572956 A C 3.00E-10 Height / / 23563607 rs2844479 chr6 31572956 A C 9.30E-04 Systemic lupus erythematosus / / 24871463 rs9348876 chr6 31575276 C T 1.68E-11 Multiple complex diseases / / 17554300 rs9348876 chr6 31575276 C T 4.10E-05 HIV-1 viral setpoint / / 17641165 rs9348876 chr6 31575276 C T 2.07E-13 HIV-1 control / / 20041166 rs9348876 chr6 31575276 C T 4.50E-13 HIV-1 control / / 21051598 rs9348876 chr6 31575276 C T 1.49E-05 HIV-1 viral setpoint / / 21490045 rs9348876 chr6 31575276 C T 3.00E-06 Crohn's disease / / 22936669 rs2844477 chr6 31578772 T C 2.90E-08 HIV-1 control / / 21051598 rs2844477 chr6 31578772 T C 4.05E-17 Rheumatoid arthritis / / 21156761 rs3132451 chr6 31582025 G C 2.88E-12 Rheumatoid arthritis AIF1 nearGene-5 21156761 rs3132451 chr6 31582025 G C 2.78E-06 Epstein-Barr virus immune response (EBNA-1) AIF1 nearGene-5 23326239 rs2844475 chr6 31583155 G A 7.70E-10 HIV-1 control AIF1 intron 21051598 rs28732150 chr6 31583224 G A 2.56E-05 HIV-1 control AIF1 intron 20041166 rs28732150 chr6 31583224 G A 1.90E-14 HIV-1 control AIF1 intron 21051598 rs2259571 chr6 31583827 T G 1.10E-08 HIV-1 control AIF1 UTR-5 21051598 rs2269475 chr6 31583931 C T 3.65E-12 Rheumatoid arthritis AIF1 missense 17804836 rs2269475 chr6 31583931 C T 8.77E-33 Rheumatoid arthritis AIF1 missense 19503088 rs2269475 chr6 31583931 C T 4.35E-04 Longevity AIF1 missense 22279548 rs2269475 chr6 31583931 C T 4.48E-05 Age-related macular degeneration AIF1 missense pha002890 rs2857597 chr6 31585000 T A 3.15E-16 Rheumatoid arthritis AIF1 nearGene-3 21156761 rs2857597 chr6 31585000 T A 0.0000659 Follicular lymphoma AIF1 nearGene-3 23025665 rs2857697 chr6 31585219 C T 2.87E-06 Multiple complex diseases AIF1 nearGene-3 17554300 rs2857697 chr6 31585219 C T 6.30E-11 HIV-1 control AIF1 nearGene-3 21051598 rs2857697 chr6 31585219 C T 1.02E-16 Rheumatoid arthritis AIF1 nearGene-3 21156761 rs2736177 chr6 31586094 C T 2.23E-60 Multiple complex diseases / / 17554300 rs2736177 chr6 31586094 C T 3.15E-23 Multiple sclerosis / / 17660530 rs2736176 chr6 31587561 G C 1.81E-22 Rheumatoid arthritis PRRC2A nearGene-5 21156761 rs2857693 chr6 31588384 G T 1.02E-16 Rheumatoid arthritis PRRC2A nearGene-5 21156761 rs2844472 chr6 31589676 A G 3.60E-08 HIV-1 control PRRC2A intron 21051598 rs2844472 chr6 31589676 A G 1.56E-17 Rheumatoid arthritis PRRC2A intron 21156761 rs2736172 chr6 31590898 C T 1.28E-05 Multiple complex diseases PRRC2A intron 17554300 rs2736172 chr6 31590898 C T 1.08E-07 Multiple sclerosis PRRC2A intron 17660530 rs2736172 chr6 31590898 C T 3.40E-08 HIV-1 control PRRC2A intron 21051598 rs2736172 chr6 31590898 C T 2.22E-17 Rheumatoid arthritis PRRC2A intron 21156761 rs2736172 chr6 31590898 C T 3.37E-04 Lymphocyte counts PRRC2A intron 22286170 rs2736172 chr6 31590898 C T 4.00E-06 Psychosis (atypical) PRRC2A intron 24132900 rs3130070 chr6 31591808 A G 1.39E-09 Epstein-Barr virus immune response (EBNA-1) PRRC2A intron 23326239 rs2280801 chr6 31592064 C T 1.71E-05 HIV-1 control PRRC2A missense 20041166 rs2280801 chr6 31592064 C T 4.90E-14 HIV-1 control PRRC2A missense 21051598 rs3130622 chr6 31592524 G C 4.94E-06 Epstein-Barr virus immune response (EBNA-1) PRRC2A intron 23326239 rs2260000 chr6 31593476 A G 3.18E-08 Type 1 diabetes PRRC2A intron 17632545 rs2260000 chr6 31593476 A G 2.40E-16 Rheumatoid arthritis PRRC2A intron 17804836 rs2260000 chr6 31593476 A G 7.51E-10 Rheumatoid arthritis PRRC2A intron 19503088 rs2260000 chr6 31593476 A G 4.60E-04 Smoking behavior PRRC2A intron 20418888 rs2260000 chr6 31593476 A G 3.20E-08 HIV-1 control PRRC2A intron 21051598 rs2260000 chr6 31593476 A G 1.56E-17 Rheumatoid arthritis PRRC2A intron 21156761 rs2260000 chr6 31593476 A G 5.00E-05 Systemic lupus erythematosus PRRC2A intron 24871463 rs2736171 chr6 31595487 A G 7.50E-12 HIV-1 control PRRC2A intron 21051598 rs2736171 chr6 31595487 A G 1.26E-16 Rheumatoid arthritis PRRC2A intron 21156761 rs1046080 chr6 31595882 C A 4.41E-16 Rheumatoid arthritis PRRC2A missense 21156761 rs1046080 chr6 31595882 C A 1.00E-14 Blood metabolite ratios PRRC2A missense 24816252 rs3132450 chr6 31596138 A G 1.45E-09 Rheumatoid arthritis PRRC2A intron 21156761 rs3130623 chr6 31597700 C T 5.07E-09 Epstein-Barr virus immune response (EBNA-1) PRRC2A intron 23326239 rs2242660 chr6 31597753 G A 3.15E-09 Hodgkin's lymphoma PRRC2A intron 24149102 rs2242660 chr6 31597753 G A 3.70E-09 Systemic lupus erythematosus PRRC2A intron 24871463 rs2242660 chr6 31597753 G A 3.94E-109 Type 1 diabetes PRRC2A intron pha002862 rs3130625 chr6 31597915 A G 0.00008641 Sarcoidosis PRRC2A intron 22952805 rs3130626 chr6 31598489 A G 1.07E-12 Rheumatoid arthritis PRRC2A cds-synon 21156761 rs3130626 chr6 31598489 A G 1.07E-09 Epstein-Barr virus immune response (EBNA-1) PRRC2A cds-synon 23326239 rs2736157 chr6 31600820 A G 1.07E-12 Rheumatoid arthritis PRRC2A intron 21156761 rs2736157 chr6 31600820 A G 1.07E-09 Epstein-Barr virus immune response (EBNA-1) PRRC2A intron 23326239 rs2272593 chr6 31601344 T C 4.22E-16 Rheumatoid arthritis PRRC2A missense 21156761 rs3115663 chr6 31601843 T C 5.56E-25 Type 1 diabetes PRRC2A intron 17632545 rs3115663 chr6 31601843 T C 7.54E-12 Rheumatoid arthritis PRRC2A intron 17804836 rs3115663 chr6 31601843 T C 4.35E-05 Schizophrenia PRRC2A intron 19197363 rs3115663 chr6 31601843 T C 4.45E-10 Rheumatoid arthritis PRRC2A intron 19503088 rs3115663 chr6 31601843 T C 1.36E-06 Lung adenocarcinoma PRRC2A intron 19836008 rs3115663 chr6 31601843 T C 8.90E-13 Rheumatoid arthritis PRRC2A intron 21156761 rs3115663 chr6 31601843 T C 2.40E-67 Myasthenia gravis PRRC2A intron 23055271 rs3115663 chr6 31601843 T C 1.06E-09 Hematology traits PRRC2A intron 23303382 rs3115663 chr6 31601843 T C 1.06E-09 Epstein-Barr virus immune response (EBNA-1) PRRC2A intron 23326239 rs3115663 chr6 31601843 T C 3.69E-05 Hodgkin's lymphoma PRRC2A intron 24149102 rs3115663 chr6 31601843 T C 8.30E-14 Systemic lupus erythematosus PRRC2A intron 24871463 rs1046089 chr6 31602967 G A 4.07E-72 Multiple complex diseases PRRC2A missense 17554300 rs1046089 chr6 31602967 G A 6.95E-05 Alzheimer's disease PRRC2A missense 17998437 rs1046089 chr6 31602967 G A 1.18E-09 Hepatitis B vaccine response PRRC2A missense 21764829 rs1046089 chr6 31602967 G A 2.00E-16 Menopause (age at onset) PRRC2A missense 22267201 rs1046089 chr6 31602967 G A 7.76E-04 Lymphocyte counts PRRC2A missense 22286170 rs1046089 chr6 31602967 G A 4.00E-11 Menopause (age at onset) PRRC2A missense 23307926 rs1046089 chr6 31602967 G A 4.00E-06 Schizophrenia PRRC2A missense 23894747 rs1046089 chr6 31602967 G A 7.90E-09 Hodgkin's lymphoma PRRC2A missense 24149102 rs1046089 chr6 31602967 G A 2.70E-10 Systemic lupus erythematosus PRRC2A missense 24871463 rs1046089 chr6 31602967 G A 1.28E-124 Type 1 diabetes PRRC2A missense pha002862 rs1046089 chr6 31602967 G A 2.40E-05 Diabetic nephropathy PRRC2A missense pha002866 rs1046089 chr6 31602967 G A 1.30E-05 Systemic lupus erythematosus PRRC2A missense pha002867 rs2261033 chr6 31603591 A G 3.09E-42 Rheumatoid arthritis PRRC2A intron 17804836 rs2261033 chr6 31603591 A G 9.34E-50 Rheumatoid arthritis PRRC2A intron 19503088 rs2261033 chr6 31603591 A G 2.49E-06 Systemic sclerosis PRRC2A intron 20383147 rs2261033 chr6 31603591 A G 1.98E-30 Rheumatoid arthritis PRRC2A intron 21156761 rs2261033 chr6 31603591 A G 0.00001253 Sarcoidosis PRRC2A intron 22952805 rs2261033 chr6 31603591 A G 1.81E-08 Ulcerative colitis PRRC2A intron 24837172 rs11229 chr6 31603770 A G 3.89E-25 Type 1 diabetes PRRC2A cds-synon 17632545 rs11229 chr6 31603770 A G 1.12E-11 Rheumatoid arthritis PRRC2A cds-synon 17804836 rs11229 chr6 31603770 A G 6.75E-10 Rheumatoid arthritis PRRC2A cds-synon 19503088 rs11229 chr6 31603770 A G 1.77E-06 Lung adenocarcinoma PRRC2A cds-synon 19836008 rs11229 chr6 31603770 A G 3.92E-16 Hepatitis B vaccine response PRRC2A cds-synon 21764829 rs11229 chr6 31603770 A G 3.80E-67 Myasthenia gravis PRRC2A cds-synon 23055271 rs11229 chr6 31603770 A G 1.07E-09 Hematology traits PRRC2A cds-synon 23303382 rs11229 chr6 31603770 A G 1.07E-09 Epstein-Barr virus immune response (EBNA-1) PRRC2A cds-synon 23326239 rs11229 chr6 31603770 A G 7.80E-14 Systemic lupus erythematosus PRRC2A cds-synon 24871463 rs11229 chr6 31603770 A G 4.45E-05 Hodgkin's lymphoma PRRC2A cds-synon 24149102 rs3132453 chr6 31604044 T G 4.89E-15 Type 1 diabetes PRRC2A missense 17632545 rs3132453 chr6 31604044 T G 2.79E-06 Rheumatoid arthritis PRRC2A missense 17804836 rs3132453 chr6 31604044 T G 5.13E-06 Rheumatoid arthritis PRRC2A missense 19503088 rs3132453 chr6 31604044 T G 1.81E-05 Multiple sclerosis PRRC2A missense 20598377 rs3132453 chr6 31604044 T G 8.76E-05 Parkinson's disease PRRC2A missense 21738487 rs35502919 chr6 31604355 C A 1.90E-05 Major depressive disorder PRRC2A cds-synon 21042317 rs10885 chr6 31604591 C T 1.57E-09 Epstein-Barr virus immune response (EBNA-1) PRRC2A missense 23326239 rs2255741 chr6 31605167 G A 5.69E-04 Multiple complex diseases PRRC2A intron 17554300 rs2736155 chr6 31605199 G C 2.68E-09 Rheumatoid arthritis PRRC2A intron 21156761 rs2077537 chr6 31606522 C G 0.00001074 Sarcoidosis BAG6 nearGene-3 22952805 rs2178899 chr6 31606756 A T 6.27E-06 Self-reported allergy BAG6 nearGene-3 23817569 rs750332 chr6 31607050 C T 1 Drug response to Carbamazepine BAG6 intron 16538176 rs750332 chr6 31607050 C T 0.00003419 Sarcoidosis BAG6 intron 22952805 rs3130628 chr6 31609272 T C 1.07E-12 Rheumatoid arthritis BAG6 intron 21156761 rs3130628 chr6 31609272 T C 2.61E-09 Epstein-Barr virus immune response (EBNA-1) BAG6 intron 23326239 rs755714 chr6 31609813 C T 4.39E-23 Rheumatoid arthritis BAG6 intron 21156761 rs1077394 chr6 31610384 C T 3.66E-05 Multiple sclerosis BAG6 intron 20598377 rs3130047 chr6 31610479 C T 1.07E-12 Rheumatoid arthritis BAG6 intron 21156761 rs1077393 chr6 31610529 A G 1.00E-16 Type 1 diabetes BAG6 intron 17632545 rs1077393 chr6 31610529 A G 7.53E-09 Rheumatoid arthritis BAG6 intron 17804836 rs1077393 chr6 31610529 A G 4.70E-04 Smoking behavior BAG6 intron 20418888 rs1077393 chr6 31610529 A G 1.84E-09 Rheumatoid arthritis BAG6 intron 21156761 rs1077393 chr6 31610529 A G 1.40E-08 Systemic lupus erythematosus BAG6 intron 24871463 rs1052486 chr6 31610686 A G 1.00E-16 Type 1 diabetes BAG6 missense 17632545 rs2395047 chr6 31611158 T C 0.00001277 Sarcoidosis BAG6 intron 22952805 rs760293 chr6 31611777 T C 5.81E-54 Multiple complex diseases BAG6 intron 17554300 rs760293 chr6 31611777 T C 9.72E-20 Multiple sclerosis BAG6 intron 17660530 rs760293 chr6 31611777 T C 0.00003093 Sarcoidosis BAG6 intron 22952805 rs2077102 chr6 31611840 C A 1.94E-12 Multiple complex diseases BAG6 intron 17554300 rs3130048 chr6 31613739 T C 7.97E-53 Multiple complex diseases BAG6 intron 17554300 rs3130048 chr6 31613739 T C 1.00E-16 Type 1 diabetes BAG6 intron 17632545 rs3130048 chr6 31613739 T C 2.98E-11 Hepatitis B vaccine response BAG6 intron 21764829 rs3130048 chr6 31613739 T C 3.77E-12 Epstein-Barr virus immune response (EBNA-1) BAG6 intron 23326239 rs2844464 chr6 31613991 A G 0.00003074 Sarcoidosis BAG6 intron 22952805 rs2242656 chr6 31614102 C T 7.12E-05 Parkinson's disease BAG6 intron 21738487 rs2242656 chr6 31614102 C T 0.0000187 Sarcoidosis BAG6 intron 22952805 rs2844463 chr6 31615167 G A 6.92E-10 Multiple complex diseases BAG6 intron 17554300 rs2844463 chr6 31615167 G A 2.70E-10 Rheumatoid arthritis BAG6 intron 17804836 rs2844463 chr6 31615167 G A 2.89E-16 Rheumatoid arthritis BAG6 intron 19503088 rs2844463 chr6 31615167 G A 9.22E-06 Coronary heart disease BAG6 intron 21971053 rs805303 chr6 31616366 G A 2.08E-09 Hepatitis B vaccine response BAG6 intron 21764829 rs805303 chr6 31616366 G A 1.00E-10 Hypertension BAG6 intron 21909115 rs805303 chr6 31616366 G A 2.00E-11 Systolic blood pressure BAG6 intron 21909115 rs805303 chr6 31616366 G A 3.00E-11 Diastolic blood pressure BAG6 intron 21909115 rs805303 chr6 31616366 G A 5.93E-09 Hodgkin's lymphoma BAG6 intron 24149102 rs805303 chr6 31616366 G A 7.40E-08 Systemic lupus erythematosus BAG6 intron 24871463 rs805303 chr6 31616366 G A 2.79E-119 Type 1 diabetes BAG6 intron pha002862 rs805301 chr6 31618121 A C 2.59E-71 Multiple complex diseases BAG6 intron 17554300 rs805301 chr6 31618121 A C 3.54E-04 Alzheimer's disease BAG6 intron 17998437 rs805301 chr6 31618121 A C 5.44E-05 Blood pressure BAG6 intron 22100073 rs3130050 chr6 31618761 G A 2.76E-11 Type 1 diabetes BAG6 intron 17632545 rs3130050 chr6 31618761 G A 7.51E-10 Rheumatoid arthritis BAG6 intron 17804836 rs3130050 chr6 31618761 G A 1.75E-10 Rheumatoid arthritis BAG6 intron 19503088 rs3130050 chr6 31618761 G A 1.33E-07 Multiple sclerosis BAG6 intron 20598377 rs3130050 chr6 31618761 G A 9.00E-06 Multiple myeloma BAG6 intron 23955597 rs3130050 chr6 31618761 G A 1.52E-71 Type 1 diabetes BAG6 intron pha002862 rs3117583 chr6 31619576 A G 1.20E-24 Type 1 diabetes BAG6 intron 17632545 rs3117583 chr6 31619576 A G 1.07E-12 Rheumatoid arthritis BAG6 intron 21156761 rs3117583 chr6 31619576 A G 2.44E-16 Hepatitis B vaccine response BAG6 intron 21764829 rs3117583 chr6 31619576 A G 1.07E-09 Epstein-Barr virus immune response (EBNA-1) BAG6 intron 23326239 rs805299 chr6 31619652 T A 3.16E-23 Rheumatoid arthritis BAG6 intron 21156761 rs3117582 chr6 31620520 T G 1.00E-16 Type 1 diabetes APOM intron 17632545 rs3117582 chr6 31620520 T G 2.29E-07 Rheumatoid arthritis APOM intron 17804836 rs3117582 chr6 31620520 T G 5.00E-10 Lung cancer APOM intron 18978787 rs3117582 chr6 31620520 T G 5.00E-06 Lung cancer APOM intron 18978790 rs3117582 chr6 31620520 T G 2.71E-04 Schizophrenia APOM intron 19197363 rs3117582 chr6 31620520 T G 4.00E-10 Lung cancer APOM intron 19654303 rs3117582 chr6 31620520 T G 5.00E-12 Lung adenocarcinoma APOM intron 19836008 rs3117582 chr6 31620520 T G 5.00E-12 Nasopharyngeal carcinoma APOM intron 20512145 rs3117582 chr6 31620520 T G 1.31E-09 Rheumatoid arthritis APOM intron 21156761 rs3117582 chr6 31620520 T G 2.30E-14 Lung cancer APOM intron 22899653 rs3117582 chr6 31620520 T G 1.10E-20 Systemic lupus erythematosus APOM intron 24871463 rs3117582 chr6 31620520 T G 2.62E-83 Type 1 diabetes APOM intron pha002862 rs3117582 chr6 31620520 T G 4.53E-08 Systemic lupus erythematosus APOM intron pha002867 rs805297 chr6 31622606 C A 8.38E-12 Multiple complex diseases APOM intron 17554300 rs805297 chr6 31622606 C A 5.46E-05 Multiple sclerosis APOM intron 17660530 rs805297 chr6 31622606 C A 4.47E-23 Rheumatoid arthritis APOM intron 21156761 rs805297 chr6 31622606 C A 3.00E-10 Rheumatoid arthritis APOM intron 21844665 rs707921 chr6 31625541 C A 2.38E-04 Multiple complex diseases APOM intron 17554300 rs2242655 chr6 31627449 C G 1.74E-12 Multiple complex diseases C6orf47 missense 17554300 rs3130617 chr6 31627523 C T 1.00E-16 Type 1 diabetes C6orf47 missense 17632545 rs3130617 chr6 31627523 C T 3.60E-15 Rheumatoid arthritis C6orf47 missense 17804836 rs3130617 chr6 31627523 C T 6.39E-19 Rheumatoid arthritis C6orf47 missense 19503088 rs3130617 chr6 31627523 C T 7.86E-16 Rheumatoid arthritis C6orf47 missense 21156761 rs3130617 chr6 31627523 C T 2.90E-05 Coronary heart disease C6orf47 missense 21966275 rs3130617 chr6 31627523 C T 0.0000163 Follicular lymphoma C6orf47 missense 23025665 rs3130617 chr6 31627523 C T 1.00E-05 Multiple myeloma C6orf47 missense 23955597 rs3130617 chr6 31627523 C T 6.29E-135 Type 1 diabetes C6orf47 missense pha002862 rs28732157 chr6 31628216 C T 9.78E-06 HIV-1 control C6orf47 UTR-5 20041166 rs28732157 chr6 31628216 C T 1.90E-14 HIV-1 control C6orf47 UTR-5 21051598 rs805262 chr6 31628733 C T 3.84E-07 Rheumatoid arthritis / / 17804836 rs805262 chr6 31628733 C T 2.40E-08 Rheumatoid arthritis / / 19503088 rs805262 chr6 31628733 C T 5.50E-14 Rheumatoid arthritis / / 21156761 rs707974 chr6 31629499 A G 4.72E-37 Multiple complex diseases GPANK1 UTR-3 17554300 rs3130618 chr6 31632134 C A 1.56E-24 Type 1 diabetes GPANK1 missense 17632545 rs3130618 chr6 31632134 C A 9.07E-12 Rheumatoid arthritis GPANK1 missense 17804836 rs3130618 chr6 31632134 C A 4.35E-05 Schizophrenia GPANK1 missense 19197363 rs3130618 chr6 31632134 C A 5.83E-09 Rheumatoid arthritis GPANK1 missense 19503088 rs3130618 chr6 31632134 C A 1.68E-06 Lung adenocarcinoma GPANK1 missense 19836008 rs3130618 chr6 31632134 C A 1.27E-12 Rheumatoid arthritis GPANK1 missense 21156761 rs3130618 chr6 31632134 C A 8.22E-16 Hepatitis B vaccine response GPANK1 missense 21764829 rs3130618 chr6 31632134 C A 2.00E-67 Myasthenia gravis GPANK1 missense 23055271 rs3130618 chr6 31632134 C A 1.51E-09 Hematology traits GPANK1 missense 23303382 rs3130618 chr6 31632134 C A 1.51E-09 Epstein-Barr virus immune response (EBNA-1) GPANK1 missense 23326239 rs3130618 chr6 31632134 C A 3.25E-05 Hodgkin's lymphoma GPANK1 missense 24149102 rs3130618 chr6 31632134 C A 6.50E-14 Systemic lupus erythematosus GPANK1 missense 24871463 rs3117579 chr6 31633496 G T 1.07E-12 Rheumatoid arthritis GPANK1 UTR-5 21156761 rs9267531 chr6 31636742 A G 1.45E-09 Rheumatoid arthritis CSNK2B intron 21156761 rs805268 chr6 31638178 A C 4.19E-04 Multiple complex diseases / / 17554300 rs2142234 chr6 31639129 G A 8.52E-13 Multiple complex diseases LY6G5B intron 17554300 rs3131377 chr6 31639420 A G 0.00007274 Sarcoidosis LY6G5B intron 22952805 rs805267 chr6 31639757 G A 2.55E-04 Multiple complex diseases LY6G5B missense 17554300 rs9267532 chr6 31639979 C T 4.86E-11 Type 1 diabetes LY6G5B missense 17632545 rs9267532 chr6 31639979 C T 8.98E-17 Hepatitis B vaccine response LY6G5B missense 21764829 rs9267532 chr6 31639979 C T 1.40E-07 Epstein-Barr virus immune response (EBNA-1) LY6G5B missense 23326239 rs707919 chr6 31641139 A G 2.70E-23 Rheumatoid arthritis / / 21156761 rs3115668 chr6 31641485 T C 0.00008569 Sarcoidosis / / 22952805 rs3115667 chr6 31643399 T C 2.07E-15 Rheumatoid arthritis / / 21156761 rs9378164 chr6 31643522 G A 4.15E-09 Multiple complex diseases / / 17554300 rs9378164 chr6 31643522 G A 1.30E-13 HIV-1 control / / 21051598 rs2280800 chr6 31646398 C A 2.30E-08 Type 1 diabetes LY6G5C intron 17632545 rs2280800 chr6 31646398 C A 2.76E-12 Rheumatoid arthritis LY6G5C intron 17804836 rs2280800 chr6 31646398 C A 3.05E-33 Rheumatoid arthritis LY6G5C intron 19503088 rs2280800 chr6 31646398 C A 4.75E-05 Age-related macular degeneration LY6G5C intron pha002890 rs3131376 chr6 31646683 A G 0.00009877 Sarcoidosis LY6G5C intron 22952805 rs9267536 chr6 31651194 A C 7.65E-08 Epstein-Barr virus immune response (EBNA-1) / / 23326239 rs707918 chr6 31654732 T A 1.66E-12 Multiple complex diseases ABHD16A UTR-3 17554300 rs1475865 chr6 31657413 T C 9.00E-06 Multiple myeloma ABHD16A cds-synon 23955597 rs760294 chr6 31657701 C A 0.00007728 Sarcoidosis ABHD16A intron 22952805 rs805274 chr6 31665194 T C 1.91E-13 Type 1 diabetes ABHD16A intron 17632545 rs805274 chr6 31665194 T C 1.20E-05 Hodgkin's lymphoma ABHD16A intron 24149102 rs2295663 chr6 31669295 A G 4.10E-05 HIV-1 control ABHD16A intron 20041166 rs2295663 chr6 31669295 A G 2.20E-14 HIV-1 control ABHD16A intron 21051598 rs2295663 chr6 31669295 A G 8.40E-24 Psoriasis ABHD16A intron pha002855 rs1266071 chr6 31669496 C T 7.18E-05 Parkinson's disease ABHD16A intron 21738487 rs1266071 chr6 31669496 C T 4.47E-05 Bipolar disorder ABHD16A intron 21771265 rs9267546 chr6 31673436 G A 1.11E-06 Rheumatoid arthritis LY6G6F nearGene-5 17804836 rs9267546 chr6 31673436 G A 8.38E-11 Rheumatoid arthritis LY6G6F nearGene-5 19503088 rs9267546 chr6 31673436 G A 2.56E-15 Hepatitis B vaccine response LY6G6F nearGene-5 21764829 rs9267546 chr6 31673436 G A 1.67E-10 Coronary heart disease LY6G6F nearGene-5 21971053 rs2242653 chr6 31675765 G A 6.17E-11 Rheumatoid arthritis LY6G6F missense 17804836 rs2242653 chr6 31675765 G A 4.82E-31 Rheumatoid arthritis LY6G6F missense 19503088 rs2242653 chr6 31675765 G A 3.15E-04 Longevity LY6G6F missense 22279548 rs2242653 chr6 31675765 G A 1.63E-06 Age-related macular degeneration LY6G6F missense pha002869 rs2242653 chr6 31675765 G A 3.23E-06 Age-related macular degeneration LY6G6F missense pha002890 rs6916278 chr6 31678774 G A 5.89E-11 Rheumatoid arthritis LY6G6F nearGene-3 21156761 rs805286 chr6 31679307 A G 9.00E-08 Hodgkin's lymphoma LY6G6E nearGene-3 24149102 rs385306 chr6 31681160 G A 1.91E-10 Type 1 diabetes LY6G6E intron 17632545 rs385306 chr6 31681160 G A 2.34E-06 Hodgkin's lymphoma LY6G6E intron 24149102 rs805284 chr6 31682029 G A 7.77E-07 Pulmonary function LY6G6D nearGene-5 20010835 rs805284 chr6 31682029 G A 8.20E-06 Major depressive disorder LY6G6D nearGene-5 21042317 rs3749952 chr6 31683157 T G 2.05E-05 Rheumatoid arthritis LY6G6D missense 17804836 rs1065356 chr6 31687008 G A 2.55E-10 Type 1 diabetes LY6G6C cds-synon 17632545 rs1065356 chr6 31687008 G A 1.01E-14 Hepatitis B vaccine response LY6G6C cds-synon 21764829 rs376510 chr6 31688200 C T 4.45E-06 Multiple complex diseases LY6G6C intron 17554300 rs376510 chr6 31688200 C T 7.11E-12 Type 1 diabetes LY6G6C intron 17632545 rs805294 chr6 31688217 A G 4.79E-106 Multiple complex diseases LY6G6C intron 17554300 rs805294 chr6 31688217 A G 7.28E-25 Type 1 diabetes LY6G6C intron 17632545 rs805294 chr6 31688217 A G 5.45E-05 Rheumatoid arthritis LY6G6C intron 17804836 rs805294 chr6 31688217 A G 0.000111 Schizophrenia LY6G6C intron 23637625 rs805294 chr6 31688217 A G 1.28E-09 Hodgkin's lymphoma LY6G6C intron 24149102 rs805294 chr6 31688217 A G 4.10E-08 Systemic lupus erythematosus LY6G6C intron 24871463 rs805294 chr6 31688217 A G 5.69E-06 Systemic lupus erythematosus LY6G6C intron pha002867 rs805293 chr6 31688518 T A 1.10E-13 Rheumatoid arthritis LY6G6C intron 21156761 rs805292 chr6 31690009 G A 3.00E-04 Multiple complex diseases C6orf25 nearGene-5 17554300 rs805304 chr6 31698088 T G 6.71E-04 Blood pressure / / 22100073 rs3131383 chr6 31704294 G T 1.57E-09 Rheumatoid arthritis CLIC1 UTR-5 21156761 rs3101018 chr6 31705864 C T 1.57E-09 Rheumatoid arthritis CLIC1 nearGene-5 21156761 rs707915 chr6 31710968 T A 5.28E-06 Multiple complex diseases MSH5 intron 17554300 rs3132445 chr6 31712196 G A 3.79E-07 Rheumatoid arthritis (ACPA-negative) MSH5 intron 24532677 rs3749953 chr6 31713124 A G 7.62E-05 Rheumatoid arthritis MSH5 intron 17804836 rs3749953 chr6 31713124 A G 3.15E-11 Rheumatoid arthritis MSH5 intron 19503088 rs3749953 chr6 31713124 A G 2.36E-05 Age-related macular degeneration MSH5 intron pha002890 rs3130484 chr6 31715882 T C 1.04E-04 Lung function (forced expiratory volume in 1 second) MSH5 intron 17255346 rs3130484 chr6 31715882 T C 7.50E-95 Multiple complex diseases MSH5 intron 17554300 rs3130484 chr6 31715882 T C 5.63E-04 Alzheimer's disease MSH5 intron 17998437 rs3130484 chr6 31715882 T C 1.63E-09 Rheumatoid arthritis MSH5 intron 21156761 rs3130484 chr6 31715882 T C 3.89E-07 Rheumatoid arthritis (ACPA-negative) MSH5 intron 24532677 rs2299851 chr6 31718602 G A 8.47E-09 Multiple complex diseases MSH5 intron 17554300 rs2299851 chr6 31718602 G A 4.77E-06 Rheumatoid arthritis MSH5 intron 19503088 rs2299851 chr6 31718602 G A 6.00E-06 Upper aerodigestive tract cancers MSH5 intron 21437268 rs3131379 chr6 31721033 G A 7.57E-05 Lung function (forced expiratory volume in 1 second) MSH5 intron 17255346 rs3131379 chr6 31721033 G A 4.84E-93 Multiple complex diseases MSH5 intron 17554300 rs3131379 chr6 31721033 G A 1.00E-16 Type 1 diabetes MSH5 intron 17632545 rs3131379 chr6 31721033 G A 5.64E-07 Rheumatoid arthritis MSH5 intron 17804836 rs3131379 chr6 31721033 G A 2.00E-52 Systemic lupus erythematosus MSH5 intron 18204446 rs3131379 chr6 31721033 G A 1.91E-07 Lung cancer MSH5 intron 18978787 rs3131379 chr6 31721033 G A 6.00E-06 Lung cancer MSH5 intron 18978790 rs3131379 chr6 31721033 G A 2.41E-04 Schizophrenia MSH5 intron 19197363 rs3131379 chr6 31721033 G A 1.02E-08 Lung cancer MSH5 intron 19654303 rs3131379 chr6 31721033 G A 1.43E-10 Lung adenocarcinoma MSH5 intron 19836008 rs3131379 chr6 31721033 G A 1.91E-09 Rheumatoid arthritis MSH5 intron 21156761 rs3131379 chr6 31721033 G A 6.80E-12 Lung cancer MSH5 intron 22899653 rs3131379 chr6 31721033 G A 9.70E-84 Myasthenia gravis MSH5 intron 23055271 rs3131379 chr6 31721033 G A 3.05E-07 Rheumatoid arthritis (ACPA-negative) MSH5 intron 24532677 rs3131379 chr6 31721033 G A 2.60E-20 Systemic lupus erythematosus MSH5 intron 24871463 rs3131379 chr6 31721033 G A 7.24E-85 Type 1 diabetes MSH5 intron pha002862 rs3131379 chr6 31721033 G A 4.89E-08 Systemic lupus erythematosus MSH5 intron pha002867 rs9267560 chr6 31722740 A G 0.0001095 Sarcoidosis MSH5 intron 22952805 rs3130487 chr6 31723389 C T 0.00008683 Sarcoidosis MSH5 intron 22952805 rs3117574 chr6 31725230 G A 1.91E-09 Rheumatoid arthritis MSH5 intron 21156761 rs3117574 chr6 31725230 G A 3.80E-07 Rheumatoid arthritis (ACPA-negative) MSH5 intron 24532677 rs3131378 chr6 31725285 A G 1.91E-09 Rheumatoid arthritis MSH5 intron 21156761 rs3131378 chr6 31725285 A G 3.90E-07 Rheumatoid arthritis (ACPA-negative) MSH5 intron 24532677 rs3117575 chr6 31726253 T C 1.91E-09 Rheumatoid arthritis MSH5 intron 21156761 rs3117575 chr6 31726253 T C 3.96E-07 Rheumatoid arthritis (ACPA-negative) MSH5 intron 24532677 rs707939 chr6 31726688 C A 1.88E-41 Multiple complex diseases MSH5 intron 17554300 rs707939 chr6 31726688 C A 7.33E-30 Rheumatoid arthritis MSH5 intron 17804836 rs707939 chr6 31726688 C A 7.85E-35 Rheumatoid arthritis MSH5 intron 19503088 rs707939 chr6 31726688 C A 6.55E-07 Systemic sclerosis MSH5 intron 20383147 rs707939 chr6 31726688 C A 9.73E-31 Rheumatoid arthritis MSH5 intron 21156761 rs707939 chr6 31726688 C A 2.07E-05 Pemphigus vulgaris MSH5 intron 22437316 rs707939 chr6 31726688 C A 7.02E-10 Ulcerative colitis MSH5 intron 24837172 rs707939 chr6 31726688 C A 3.00E-04 Systemic lupus erythematosus MSH5 intron 24871463 rs3117577 chr6 31727474 A G 9.96E-06 Pulmonary function MSH5 intron 20010835 rs3117577 chr6 31727474 A G 1.36E-08 Rheumatoid arthritis MSH5 intron 21156761 rs3117577 chr6 31727474 A G 3.89E-07 Rheumatoid arthritis (ACPA-negative) MSH5 intron 24532677 rs3115672 chr6 31727897 C T 1.78E-04 Lung function (forced expiratory volume in 1 second) MSH5 cds-synon 17255346 rs3115672 chr6 31727897 C T 4.92E-75 Multiple complex diseases MSH5 cds-synon 17554300 rs3115672 chr6 31727897 C T 1.54E-09 Rheumatoid arthritis MSH5 cds-synon 21156761 rs3115672 chr6 31727897 C T 4.22E-07 Rheumatoid arthritis (ACPA-negative) MSH5 cds-synon 24532677 rs707938 chr6 31729359 A G 5.50E-05 Response to statin therapy MSH5 cds-synon 20339536 rs707938 chr6 31729359 A G 2.62E-06 Schizophrenia MSH5 cds-synon 21926974 rs707937 chr6 31731014 C G 1.95E-04 Response to ximelagatran treatment SAPCD1 intron 17505501 rs707937 chr6 31731014 C G 1.40E-08 Multiple complex diseases SAPCD1 intron 17554300 rs6905572 chr6 31731881 C T 1.50E-05 Age-related macular degeneration SAPCD1 missense pha002890 rs3115671 chr6 31734345 G T 1.60E-09 Rheumatoid arthritis VWA7 cds-synon 21156761 rs707929 chr6 31742067 A G 1.99E-08 Rheumatoid arthritis VWA7 intron 21156761 rs707928 chr6 31742590 A G 1.00E-22 Type 1 diabetes VWA7 intron 17632545 rs707928 chr6 31742590 A G 6.33E-05 Rheumatoid arthritis VWA7 intron 17804836 rs707928 chr6 31742590 A G 1.46E-08 Rheumatoid arthritis VWA7 intron 21156761 rs707928 chr6 31742590 A G 1.84E-08 Hodgkin's lymphoma VWA7 intron 24149102 rs707928 chr6 31742590 A G 1.40E-07 Systemic lupus erythematosus VWA7 intron 24871463 rs707928 chr6 31742590 A G 8.89E-111 Type 1 diabetes VWA7 intron pha002862 rs707928 chr6 31742590 A G 3.39E-05 Systemic lupus erythematosus VWA7 intron pha002867 rs707926 chr6 31748820 G A 4.86E-05 Self-reported allergy VARS cds-synon 23817569 rs2607015 chr6 31762843 G C 3.38E-15 Rheumatoid arthritis VARS missense 21156761 rs480092 chr6 31764899 T C 2.44E-05 Multiple complex diseases / / 17554300 rs480092 chr6 31764899 T C 1.11E-12 Type 1 diabetes / / 17632545 rs480092 chr6 31764899 T C 5.95E-13 Hepatitis B vaccine response / / 21764829 rs480092 chr6 31764899 T C 0.0000875 Triglycerides / / 23063622 rs480092 chr6 31764899 T C 4.92E-05 Self-reported allergy / / 23817569 rs2242668 chr6 31773821 C T 5.68E-04 Type 2 diabetes LSM2 intron 22158537 rs2075800 chr6 31777946 C T 9.50E-42 Multiple complex diseases HSPA1L missense 17554300 rs2075800 chr6 31777946 C T 1.98E-29 Rheumatoid arthritis HSPA1L missense 17804836 rs2075800 chr6 31777946 C T 8.30E-36 Rheumatoid arthritis HSPA1L missense 19503088 rs2075800 chr6 31777946 C T 1.58E-07 Systemic sclerosis HSPA1L missense 20383147 rs2075800 chr6 31777946 C T 1.29E-31 Rheumatoid arthritis HSPA1L missense 21156761 rs2075800 chr6 31777946 C T 2.88E-05 Pemphigus vulgaris HSPA1L missense 22437316 rs2075800 chr6 31777946 C T 2.44E-10 Ulcerative colitis HSPA1L missense 24837172 rs2075800 chr6 31777946 C T 2.00E-04 Systemic lupus erythematosus HSPA1L missense 24871463 rs2227956 chr6 31778272 G A 1 Drug response to Carbamazepine HSPA1L missense 16538175 rs2227956 chr6 31778272 G A 8.19E-18 Type 1 diabetes HSPA1L missense 17632545 rs2227956 chr6 31778272 G A 2.37E-12 Rheumatoid arthritis HSPA1L missense 17804836 rs2227956 chr6 31778272 G A 4.92E-15 Rheumatoid arthritis HSPA1L missense 19503088 rs2227956 chr6 31778272 G A 1.89E-07 Multiple sclerosis HSPA1L missense 20598377 rs2227956 chr6 31778272 G A 1.23E-115 Type 1 diabetes HSPA1L missense pha002862 rs2075799 chr6 31778529 C T 8.19E-04 Type 2 diabetes HSPA1L cds-synon 22158537 rs2075799 chr6 31778529 C T 6.00E-97 Complement C3 and C4 levels HSPA1L cds-synon 23028341 rs1043620 chr6 31783755 T C 1 Drug response to Carbamazepine HSPA1A cds-synon 16538175 rs506770 chr6 31785228 G C 1 Drug response to Carbamazepine HSPA1A cds-synon 16538175 rs9469058 chr6 31788050 T A 4.20E-06 Plasminogen activator inhibitor-1 (PAI1) levels,in plasma / / 20558613 rs2763979 chr6 31794592 C T 1.76E-94 Multiple complex diseases HSPA1B nearGene-5 17554300 rs2763979 chr6 31794592 C T 8.74E-23 Type 1 diabetes HSPA1B nearGene-5 17632545 rs2763979 chr6 31794592 C T 4.25E-10 Hodgkin's lymphoma HSPA1B nearGene-5 24149102 rs2763979 chr6 31794592 C T 2.90E-07 Systemic lupus erythematosus HSPA1B nearGene-5 24871463 rs2763979 chr6 31794592 C T 3.26E-99 Type 1 diabetes HSPA1B nearGene-5 pha002862 rs2763979 chr6 31794592 C T 8.14E-06 Systemic lupus erythematosus HSPA1B nearGene-5 pha002867 rs17207559 chr6 31794963 T G 7.29E-05 Cognitive test performance HSPA1B nearGene-5 20125193 rs539689 chr6 31797587 C G 0.000005971 Sarcoidosis HSPA1B cds-synon 22952805 rs7769158 chr6 31799494 G T 3.12E-08 Rheumatoid arthritis / / 21156761 rs4711279 chr6 31802465 C G 1.00E-06 IgG glycosylation SNORD48 nearGene-5 23382691 rs4711279 chr6 31802465 C G 3.00E-07 IgG glycosylation SNORD48 nearGene-5 23382691 rs4711279 chr6 31802465 C G 4.00E-06 IgG glycosylation SNORD48 nearGene-5 23382691 rs4711279 chr6 31802465 C G 1.06E-05 Age-related macular degeneration SNORD48 nearGene-5 pha002890 rs9368699 chr6 31802541 T C 7.04E-08 Type 1 diabetes SNORD48 nearGene-5 17632545 rs9368699 chr6 31802541 T C 1.20E-06 HIV-1 viral setpoint SNORD48 nearGene-5 17641165 rs9368699 chr6 31802541 T C 1.84E-11 AIDS progression SNORD48 nearGene-5 19115949 rs9368699 chr6 31802541 T C 5.00E-08 HIV-1 control SNORD48 nearGene-5 20041166 rs9368699 chr6 31802541 T C 2.60E-16 HIV-1 control SNORD48 nearGene-5 21051598 rs9368699 chr6 31802541 T C 5.20E-06 HIV-1 viral setpoint SNORD48 nearGene-5 21490045 rs9368699 chr6 31802541 T C 2.99E-10 HIV-1 infection (natural long-term nonprogression) SNORD48 nearGene-5 22238471 rs9368699 chr6 31802541 T C 3.19E-08 Atopic dermatitis SNORD48 nearGene-5 23886662 rs17201248 chr6 31803130 C T 1.42E-04 Alzheimer's disease (late onset) C6orf48 intron 21379329 rs17207629 chr6 31804610 G A 3.36E-05 Age-related macular degeneration C6orf48 intron pha002890 rs733539 chr6 31807489 C T 4.64E-06 Age-related macular degeneration C6orf48 UTR-3 pha002869 rs733539 chr6 31807489 C T 5.49E-06 Age-related macular degeneration C6orf48 UTR-3 pha002890 rs3130679 chr6 31807540 A G 2.33E-09 Rheumatoid arthritis C6orf48 UTR-3 21156761 rs3130679 chr6 31807540 A G 4.57E-07 Rheumatoid arthritis (ACPA-negative) C6orf48 UTR-3 24532677 rs599707 chr6 31808436 C T 3.01E-09 Rheumatoid arthritis / / 21156761 rs3115673 chr6 31810085 G T 8.46E-14 Type 1 diabetes / / 17632545 rs9267576 chr6 31812038 T G 7.00E-06 Multiple myeloma / / 23955597 rs12210887 chr6 31815723 G T 3.36E-06 Hepatitis B / / 21750111 rs12210887 chr6 31815723 G T 3.05E-11 Coronary heart disease / / 21971053 rs9501157 chr6 31819123 G A 1.60E-04 Smoking initiation / / 24665060 rs9267649 chr6 31824828 A G 6.41E-21 Type 1 diabetes / / 17632545 rs9267649 chr6 31824828 A G 7.10E-12 Rheumatoid arthritis / / 17804836 rs9267649 chr6 31824828 A G 5.81E-15 Rheumatoid arthritis / / 19503088 rs9267649 chr6 31824828 A G 1.07E-07 Multiple sclerosis / / 20598377 rs9267649 chr6 31824828 A G 3.11E-126 Type 1 diabetes / / pha002862 rs13118 chr6 31827286 A T 4.29E-08 Vitiligo NEU1 UTR-3 20526339 rs11965547 chr6 31836151 G A 5.23E-04 Multiple complex diseases SLC44A4 intron 17554300 rs521977 chr6 31836827 T G 6.97E-04 Coronary heart disease SLC44A4 intron 21606135 rs521977 chr6 31836827 T G 0.000003322 Sarcoidosis SLC44A4 intron 22952805 rs11966200 chr6 31837066 C T 1.00E-48 Vitiligo SLC44A4 intron 20526339 rs660594 chr6 31837250 G A 8.37E-05 Non-alcoholic fatty liver disease histology (other) SLC44A4 intron 20708005 rs660550 chr6 31837277 C A 3.40E-10 Rheumatoid arthritis SLC44A4 intron 17804836 rs660550 chr6 31837277 C A 3.94E-09 Rheumatoid arthritis SLC44A4 intron 19503088 rs660550 chr6 31837277 C A 6.01E-07 Multiple sclerosis SLC44A4 intron 20598377 rs660550 chr6 31837277 C A 8.37E-05 Non-alcoholic fatty liver disease histology (other) SLC44A4 intron 20708005 rs660550 chr6 31837277 C A 1.74E-11 Hepatitis B vaccine response SLC44A4 intron 21764829 rs660550 chr6 31837277 C A 3.20E-10 Systemic lupus erythematosus SLC44A4 intron 24871463 rs577272 chr6 31837963 G A 8.37E-05 Non-alcoholic fatty liver disease histology (other) SLC44A4 intron 20708005 rs644827 chr6 31838441 T C 2.81E-10 Rheumatoid arthritis SLC44A4 missense 17804836 rs644827 chr6 31838441 T C 9.90E-10 Rheumatoid arthritis SLC44A4 missense 19503088 rs644827 chr6 31838441 T C 7.30E-07 Multiple sclerosis SLC44A4 missense 20598377 rs644827 chr6 31838441 T C 8.37E-05 Non-alcoholic fatty liver disease histology (other) SLC44A4 missense 20708005 rs644827 chr6 31838441 T C 4.10E-10 Systemic lupus erythematosus SLC44A4 missense 24871463 rs494620 chr6 31838713 G A 1.10E-22 Rheumatoid arthritis SLC44A4 cds-synon 17804836 rs494620 chr6 31838713 G A 5.00E-07 Menopause (age at onset) SLC44A4 cds-synon 19448619 rs494620 chr6 31838713 G A 3.98E-25 Rheumatoid arthritis SLC44A4 cds-synon 19503088 rs494620 chr6 31838713 G A 4.10E-04 Pemphigus vulgaris SLC44A4 cds-synon 22437316 rs494620 chr6 31838713 G A 2.20E-07 Systemic lupus erythematosus SLC44A4 cds-synon 24871463 rs9267652 chr6 31838940 C T 0.00000635 Sarcoidosis SLC44A4 intron 22952805 rs2242665 chr6 31839309 C T 4.84E-10 Rheumatoid arthritis SLC44A4 missense 17804836 rs2242665 chr6 31839309 C T 9.94E-09 Rheumatoid arthritis SLC44A4 missense 19503088 rs2242665 chr6 31839309 C T 5.74E-07 Multiple sclerosis SLC44A4 missense 20598377 rs2242665 chr6 31839309 C T 8.37E-05 Non-alcoholic fatty liver disease histology (other) SLC44A4 missense 20708005 rs2242665 chr6 31839309 C T 4.80E-10 Systemic lupus erythematosus SLC44A4 missense 24871463 rs2763981 chr6 31840021 T A 0.00003531 Sarcoidosis SLC44A4 intron 22952805 rs62395845 chr6 31840408 C T 0.000029 Sarcoidosis SLC44A4 intron 22952805 rs9267655 chr6 31841055 G A 2.37E-07 Sarcoidosis SLC44A4 intron 22952805 rs9267656 chr6 31841450 C T 0.00001412 Sarcoidosis SLC44A4 intron 22952805 rs2736428 chr6 31843924 C T 1.67E-26 Rheumatoid arthritis SLC44A4 intron 17804836 rs2736428 chr6 31843924 C T 2.49E-31 Rheumatoid arthritis SLC44A4 intron 19503088 rs2736428 chr6 31843924 C T 3.00E-06 Telomere length SLC44A4 intron 20421499 rs2736428 chr6 31843924 C T 1.96E-04 Pemphigus vulgaris SLC44A4 intron 22437316 rs2736428 chr6 31843924 C T 4.86E-11 Ulcerative colitis SLC44A4 intron 24837172 rs2736428 chr6 31843924 C T 3.40E-05 Systemic lupus erythematosus SLC44A4 intron 24871463 rs6907185 chr6 31844684 A G 2.13E-09 Rheumatoid arthritis SLC44A4 intron 21156761 rs9267658 chr6 31845985 T C 1.00E-16 Type 1 diabetes SLC44A4 intron 17632545 rs9267658 chr6 31845985 T C 1.32E-10 Rheumatoid arthritis SLC44A4 intron 17804836 rs9267658 chr6 31845985 T C 2.17E-12 Rheumatoid arthritis SLC44A4 intron 19503088 rs9267658 chr6 31845985 T C 3.17E-08 Multiple sclerosis SLC44A4 intron 20598377 rs9267658 chr6 31845985 T C 4.00E-06 Multiple myeloma SLC44A4 intron 23955597 rs9267658 chr6 31845985 T C 2.51E-84 Type 1 diabetes SLC44A4 intron pha002862 rs2075798 chr6 31846741 C A 6.73E-04 Hearing function SLC44A4 missense 17255346 rs605203 chr6 31847012 C A 4.03E-14 Rheumatoid arthritis SLC44A4 nearGene-5 21156761 rs605203 chr6 31847012 C A 0.00009371 Sarcoidosis SLC44A4 nearGene-5 22952805 rs570263 chr6 31847196 T C 0.0000915 Sarcoidosis / / 22952805 rs589428 chr6 31848220 T G 3.67E-14 Rheumatoid arthritis EHMT2 intron 21156761 rs652888 chr6 31851234 A G 1.00E-16 Type 1 diabetes EHMT2 intron 17632545 rs652888 chr6 31851234 A G 6.45E-11 Rheumatoid arthritis EHMT2 intron 17804836 rs652888 chr6 31851234 A G 2.20E-12 Rheumatoid arthritis EHMT2 intron 19503088 rs652888 chr6 31851234 A G 2.58E-08 Rheumatoid arthritis EHMT2 intron 21156761 rs652888 chr6 31851234 A G 3.15E-11 Hepatitis B vaccine response EHMT2 intron 21764829 rs652888 chr6 31851234 A G 8.70E-04 Age-related macular degeneration EHMT2 intron 22694956 rs652888 chr6 31851234 A G 6.12E-11 Hematology traits EHMT2 intron 23303382 rs652888 chr6 31851234 A G 6.12E-11 Epstein-Barr virus immune response (EBNA-1) EHMT2 intron 23326239 rs652888 chr6 31851234 A G 7.00E-13 Chronic hepatitis B infection EHMT2 intron 23760081 rs652888 chr6 31851234 A G 1.00E-10 Systemic lupus erythematosus EHMT2 intron 24871463 rs652888 chr6 31851234 A G 1.56E-05 Systemic lupus erythematosus EHMT2 intron pha002867 rs652888 chr6 31851234 A G 4.73E-06 Age-related macular degeneration EHMT2 intron pha002869 rs3869145 chr6 31851354 G A 7.63E-05 Self-reported allergy EHMT2 intron 23817569 rs7743807 chr6 31854543 C T 8.56E-11 Rheumatoid arthritis EHMT2 intron 21156761 rs7743807 chr6 31854543 C T 8.09E-05 Age-related macular degeneration EHMT2 intron pha002890 rs486416 chr6 31856070 G A 1.79E-10 Multiple complex diseases EHMT2 intron 17554300 rs486416 chr6 31856070 G A 7.87E-17 Multiple sclerosis EHMT2 intron 17660530 rs486416 chr6 31856070 G A 3.39E-12 Rheumatoid arthritis EHMT2 intron 21156761 rs486416 chr6 31856070 G A 2.73E-04 Coronary heart disease EHMT2 intron 21606135 rs535586 chr6 31860337 T C 8.30E-21 Rheumatoid arthritis EHMT2 cds-synon 17804836 rs535586 chr6 31860337 T C 9.42E-18 Rheumatoid arthritis EHMT2 cds-synon 19503088 rs535586 chr6 31860337 T C 3.30E-05 Lung adenocarcinoma EHMT2 cds-synon 19836008 rs535586 chr6 31860337 T C 7.26E-07 Multiple sclerosis EHMT2 cds-synon 20598377 rs535586 chr6 31860337 T C 8.76E-05 Non-alcoholic fatty liver disease histology (other) EHMT2 cds-synon 20708005 rs535586 chr6 31860337 T C 4.37E-11 Rheumatoid arthritis EHMT2 cds-synon 21156761 rs535586 chr6 31860337 T C 8.54E-06 Parkinson's disease EHMT2 cds-synon 21738487 rs535586 chr6 31860337 T C 8.47E-06 Alopecia areata EHMT2 cds-synon 22027810 rs535586 chr6 31860337 T C 0.00009108 Sarcoidosis EHMT2 cds-synon 22952805 rs535586 chr6 31860337 T C 5.60E-11 Systemic lupus erythematosus EHMT2 cds-synon 24871463 rs535586 chr6 31860337 T C 1.21E-06 Age-related macular degeneration EHMT2 cds-synon pha002869 rs9267661 chr6 31860576 C T 0.00001478 Sarcoidosis EHMT2 intron 22952805 rs2243873 chr6 31863433 C A 1.65E-08 Chronic hepatitis B infection EHMT2 intron 23760081 rs659445 chr6 31864304 G A 6.56E-21 Rheumatoid arthritis EHMT2 intron 17804836 rs659445 chr6 31864304 G A 1.56E-18 Rheumatoid arthritis EHMT2 intron 19503088 rs659445 chr6 31864304 G A 3.26E-05 Lung adenocarcinoma EHMT2 intron 19836008 rs659445 chr6 31864304 G A 7.73E-07 Multiple sclerosis EHMT2 intron 20598377 rs659445 chr6 31864304 G A 8.76E-05 Non-alcoholic fatty liver disease histology (other) EHMT2 intron 20708005 rs659445 chr6 31864304 G A 2.68E-12 Rheumatoid arthritis EHMT2 intron 21156761 rs659445 chr6 31864304 G A 7.20E-06 Parkinson's disease EHMT2 intron 21738487 rs659445 chr6 31864304 G A 0.00009371 Sarcoidosis EHMT2 intron 22952805 rs659445 chr6 31864304 G A 4.30E-11 Systemic lupus erythematosus EHMT2 intron 24871463 rs659445 chr6 31864304 G A 1.45E-06 Age-related macular degeneration EHMT2 intron pha002869 rs115884658 chr6 31864538 G A 0.0004 Prostate cancer (non-advanced prostate cancer) EHMT2 missense 23555315 rs9267663 chr6 31867253 C T 6.00E-06 Economic and political preferences (environmentalism) / / 22566634 rs12525922 chr6 31869135 G A 3.44E-04 Amyotrophic lateral sclerosis (sporadic) C2 intron 24529757 rs558702 chr6 31870326 G A 1.00E-16 Type 1 diabetes C2 intron 17632545 rs558702 chr6 31870326 G A 7.78E-07 Rheumatoid arthritis C2 intron 17804836 rs558702 chr6 31870326 G A 6.96E-07 Lung cancer C2 intron 18978787 rs558702 chr6 31870326 G A 1.00E-05 Lung cancer C2 intron 18978790 rs558702 chr6 31870326 G A 2.85E-04 Schizophrenia C2 intron 19197363 rs558702 chr6 31870326 G A 6.89E-06 Lung cancer C2 intron 19654303 rs558702 chr6 31870326 G A 2.37E-10 Lung adenocarcinoma C2 intron 19836008 rs558702 chr6 31870326 G A 1.03E-09 Rheumatoid arthritis C2 intron 21156761 rs558702 chr6 31870326 G A 9.90E-13 Lung cancer C2 intron 22899653 rs558702 chr6 31870326 G A 5.20E-82 Myasthenia gravis C2 intron 23055271 rs558702 chr6 31870326 G A 8.00E-21 Systemic lupus erythematosus C2 intron 24871463 rs558702 chr6 31870326 G A 1.60E-86 Type 1 diabetes C2 intron pha002862 rs558702 chr6 31870326 G A 4.20E-08 Systemic lupus erythematosus C2 intron pha002867 rs9267665 chr6 31870856 C T 1.48E-10 Type 1 diabetes C2 intron 17632545 rs9267665 chr6 31870856 C T 1.00E-17 Hepatitis B vaccine response C2 intron 21764829 rs9267665 chr6 31870856 C T 1.24E-17 Hepatocellular carcinoma (hepatitis B virus related) C2 intron 23242368 rs519417 chr6 31878433 G A 8.67E-08 Rheumatoid arthritis (ACPA-negative) C2 intron 24532677 rs3128761 chr6 31879158 A T 0.00009036 Sarcoidosis C2 intron 22952805 rs2844452 chr6 31882024 A G 0.00041 Breast cancer C2 intron 23555315 rs9267673 chr6 31883679 C T 4.54E-09 Multiple complex diseases C2 intron 17554300 rs9267673 chr6 31883679 C T 3.20E-09 HIV-1 control C2 intron 21051598 rs9267673 chr6 31883679 C T 2.00E-06 Hepatocellular carcinoma C2 intron 21105107 rs9267673 chr6 31883679 C T 0.00012 Salmonella-induced pyroptosis C2 intron 22837397 rs9267673 chr6 31883679 C T 2.00E-06 Hepatocellular carcinoma (hepatitis B virus related) C2 intron 23242368 rs9267673 chr6 31883679 C T 2.30E-33 Psoriasis C2 intron pha002855 rs644045 chr6 31883957 A G 5.70E-14 Multiple complex diseases C2 intron 17554300 rs644045 chr6 31883957 A G 1.84E-16 Multiple sclerosis C2 intron 17660530 rs644045 chr6 31883957 A G 1.23E-17 Rheumatoid arthritis C2 intron 21156761 rs644045 chr6 31883957 A G 3.03E-04 Self-reported allergy C2 intron 23817569 rs3128759 chr6 31885930 C T 0.0000209 Sarcoidosis C2 intron 22952805 rs511294 chr6 31888869 T G 2.71E-10 Rheumatoid arthritis C2 intron 21156761 rs511294 chr6 31888869 T G 1.45E-13 Age-related macular degeneration C2 intron pha002869 rs511294 chr6 31888869 T G 6.27E-13 Age-related macular degeneration C2 intron pha002890 rs544167 chr6 31890158 T G 2.44E-10 Rheumatoid arthritis C2 intron 21156761 rs544167 chr6 31890158 T G 2.56E-09 Age-related macular degeneration C2 intron 23577725 rs544167 chr6 31890158 T G 2.93E-06 Age-related macular degeneration (extreme sampling) C2 intron 23577725 rs544167 chr6 31890158 T G 2.48E-13 Age-related macular degeneration C2 intron pha002869 rs544167 chr6 31890158 T G 7.79E-13 Age-related macular degeneration C2 intron pha002890 rs9267676 chr6 31890460 A T 0.00000285 Sarcoidosis C2 intron 22952805 rs497309 chr6 31892484 A C 1.38E-04 Lung function (forced expiratory volume in 1 second) C2 intron 17255346 rs497309 chr6 31892484 A C 7.61E-10 Rheumatoid arthritis C2 intron 21156761 rs497309 chr6 31892484 A C 1.44E-07 Rheumatoid arthritis (ACPA-negative) C2 intron 24532677 rs498240 chr6 31892592 G A 2.17E-11 Rheumatoid arthritis C2 intron 21156761 rs2734335 chr6 31893944 G A 3.65E-26 Rheumatoid arthritis C2 intron 17804836 rs2734335 chr6 31893944 G A 6.46E-29 Rheumatoid arthritis C2 intron 19503088 rs2734335 chr6 31893944 G A 2.41E-06 Multiple sclerosis C2 intron 20598377 rs2734335 chr6 31893944 G A 1.20E-18 Rheumatoid arthritis C2 intron 21156761 rs2734335 chr6 31893944 G A 0.00045 Breast cancer C2 intron 23555315 rs2734335 chr6 31893944 G A 1.14E-04 Self-reported allergy C2 intron 23817569 rs2734335 chr6 31893944 G A 2.60E-06 Systemic lupus erythematosus C2 intron 24871463 rs3020644 chr6 31894626 A G 2.00E-05 Rheumatoid arthritis C2 intron 17159887 rs3020644 chr6 31894626 A G 0.00017 Breast cancer C2 intron 23555315 rs3020644 chr6 31894626 A G 0.00027 Coronary artery calcification C2 intron 23727086 rs7746553 chr6 31895973 C G 0.00027 Breast cancer (ER positive) C2 intron 23555315 rs7746553 chr6 31895973 C G 0.00084 Breast cancer C2 intron 23555315 rs11752672 chr6 31896874 G C 8.12E-05 Acne (severe) C2 intron 24927181 rs621701 chr6 31903121 G A 9.07E-12 Rheumatoid arthritis C2 intron 21156761 rs9332739 chr6 31903804 G C 2.00E-23 Age-related macular degeneration C2 missense 21665990 rs9332739 chr6 31903804 G C 1.00E-06 Age-related macular degeneration (GA) C2 missense 22705344 rs9332739 chr6 31903804 G C 2.00E-08 Age-related macular degeneration (CNV) C2 missense 22705344 rs9332739 chr6 31903804 G C 4.83E-10 Circulating myeloperoxidase levels (serum) C2 missense 23620142 rs1042663 chr6 31905130 G A 2.00E-04 Rheumatoid arthritis C2 cds-synon 17159887 rs1042663 chr6 31905130 G A 1.12E-19 Rheumatoid arthritis C2 cds-synon 17804836 rs1042663 chr6 31905130 G A 9.34E-18 Rheumatoid arthritis C2 cds-synon 19503088 rs1042663 chr6 31905130 G A 7.42E-14 Rheumatoid arthritis C2 cds-synon 21156761 rs1042663 chr6 31905130 G A 1.69E-04 Longevity C2 cds-synon 22279548 rs1042663 chr6 31905130 G A 9.50E-09 Age-related macular degeneration C2 cds-synon 22694956 rs1042663 chr6 31905130 G A 0.00028 Coronary artery calcification C2 cds-synon 23727086 rs1042663 chr6 31905130 G A 3.14E-19 Age-related macular degeneration C2 cds-synon pha002869 rs1042663 chr6 31905130 G A 2.97E-18 Age-related macular degeneration C2 cds-synon pha002890 rs9380272 chr6 31906010 G A 2.00E-08 Age-related macular degeneration C2 intron 20385819 rs550605 chr6 31907147 T C 6.40E-15 Rheumatoid arthritis C2 intron 17804836 rs550605 chr6 31907147 T C 1.63E-15 Rheumatoid arthritis C2 intron 19503088 rs550605 chr6 31907147 T C 7.37E-14 Rheumatoid arthritis C2 intron 21156761 rs550605 chr6 31907147 T C 7.70E-09 Age-related macular degeneration C2 intron 22694956 rs550605 chr6 31907147 T C 0.00026 Coronary artery calcification C2 intron 23727086 rs550605 chr6 31907147 T C 4.98E-19 Age-related macular degeneration C2 intron pha002869 rs550605 chr6 31907147 T C 4.38E-18 Age-related macular degeneration C2 intron pha002890 rs653414 chr6 31907168 C T 2.00E-04 Rheumatoid arthritis C2 intron 17159887 rs638383 chr6 31908224 C T 4.76E-05 Age-related macular degeneration C2 intron pha002890 rs497239 chr6 31908761 T C 7.85E-14 Rheumatoid arthritis C2 intron 21156761 rs497239 chr6 31908761 T C 7.82E-19 Age-related macular degeneration C2 intron pha002869 rs497239 chr6 31908761 T C 6.02E-18 Age-related macular degeneration C2 intron pha002890 rs609061 chr6 31910162 G A 4.79E-14 Rheumatoid arthritis C2 intron 21156761 rs547154 chr6 31910938 G T 0.00023 Coronary artery calcification C2 intron 23727086 rs547154 chr6 31910938 G T 2.90E-19 Age-related macular degeneration C2 intron pha002869 rs547154 chr6 31910938 G T 2.70E-18 Age-related macular degeneration C2 intron pha002890 rs12614 chr6 31914179 C T 8.99E-13 Non-obstructive azoospermia CFB missense 22541561 rs641153 chr6 31914180 G A,T 2.00E-20 Age-related macular degeneration CFB missense 20385826 rs641153 chr6 31914180 G A,T 6.00E-31 Age-related macular degeneration CFB missense 21665990 rs641153 chr6 31914180 G A,T 1.00E-17 Age-related macular degeneration (CNV) CFB missense 22705344 rs641153 chr6 31914180 G A,T 2.00E-09 Age-related macular degeneration (GA) CFB missense 22705344 rs1048709 chr6 31914935 A G 6.00E-06 Type 2 diabetes CFB cds-synon 21647700 rs17201431 chr6 31916013 T C 9.93E-04 Multiple complex diseases CFB intron 17554300 rs512559 chr6 31916062 A G 4.99E-05 Age-related macular degeneration CFB intron pha002890 rs537160 chr6 31916400 A G 1.11E-12 Rheumatoid arthritis CFB intron 21156761 rs537160 chr6 31916400 A G 3.40E-04 Coronary heart disease CFB intron 21966275 rs541862 chr6 31916951 T C 2.00E-04 Rheumatoid arthritis CFB intron 17159887 rs541862 chr6 31916951 T C 2.16E-12 Multiple complex diseases CFB intron 17554300 rs541862 chr6 31916951 T C 2.02E-15 Rheumatoid arthritis CFB intron 17804836 rs541862 chr6 31916951 T C 4.53E-16 Rheumatoid arthritis CFB intron 19503088 rs541862 chr6 31916951 T C 3.00E-05 Age-related macular degeneration CFB intron 20861866 rs541862 chr6 31916951 T C 1.35E-13 Rheumatoid arthritis CFB intron 21156761 rs541862 chr6 31916951 T C 9.00E-17 Age-related macular degeneration CFB intron 22694956 rs541862 chr6 31916951 T C 2.99E-10 Age-related macular degeneration CFB intron 23577725 rs541862 chr6 31916951 T C 3.96E-07 Age-related macular degeneration (extreme sampling) CFB intron 23577725 rs541862 chr6 31916951 T C 1.38E-05 Age-related macular degeneration CFB intron pha000001 rs541862 chr6 31916951 T C 8.34E-05 Age-related macular degeneration CFB intron pha002856 rs541862 chr6 31916951 T C 3.78E-19 Age-related macular degeneration CFB intron pha002869 rs541862 chr6 31916951 T C 3.41E-18 Age-related macular degeneration CFB intron pha002890 rs4151657 chr6 31917540 T C 7.42E-29 Rheumatoid arthritis CFB intron 17804836 rs4151657 chr6 31917540 T C 1.01E-35 Rheumatoid arthritis CFB intron 19503088 rs4151657 chr6 31917540 T C 3.88E-04 Crohn's disease CFB intron 23266558 rs4151657 chr6 31917540 T C 0.00049 Coronary artery calcification CFB intron 23727086 rs4151657 chr6 31917540 T C 5.00E-14 Ulcerative colitis CFB intron 24837172 rs4151657 chr6 31917540 T C 4.70E-05 Systemic lupus erythematosus CFB intron 24871463 rs149101394 chr6 31918154 A G 0.0000035 Breast cancer CFB missense 23555315 rs149101394 chr6 31918154 A G 0.0001 Breast cancer (ER positive) CFB missense 23555315 rs1270942 chr6 31918860 A G 4.76E-17 Type 1 diabetes CFB intron 17632545 rs1270942 chr6 31918860 A G 1.25E-07 Rheumatoid arthritis CFB intron 17804836 rs1270942 chr6 31918860 A G 1.27E-51 Systemic lupus erythematosus CFB intron 18204446 rs1270942 chr6 31918860 A G 2.16E-06 Lung cancer CFB intron 18978787 rs1270942 chr6 31918860 A G 2.00E-05 Lung cancer CFB intron 18978790 rs1270942 chr6 31918860 A G 2.70E-04 Schizophrenia CFB intron 19197363 rs1270942 chr6 31918860 A G 8.66E-06 Lung cancer CFB intron 19654303 rs1270942 chr6 31918860 A G 7.07E-10 Lung adenocarcinoma CFB intron 19836008 rs1270942 chr6 31918860 A G 7.82E-10 Rheumatoid arthritis CFB intron 21156761 rs1270942 chr6 31918860 A G 1.40E-13 Lung cancer CFB intron 22899653 rs1270942 chr6 31918860 A G 1.20E-79 Myasthenia gravis CFB intron 23055271 rs1270942 chr6 31918860 A G 4.20E-20 Systemic lupus erythematosus CFB intron 24871463 rs1270942 chr6 31918860 A G 4.69E-86 Type 1 diabetes CFB intron pha002862 rs1270942 chr6 31918860 A G 7.82E-08 Systemic lupus erythematosus CFB intron pha002867 rs2072633 chr6 31919578 A G 3.81E-12 Multiple complex diseases CFB intron 17554300 rs2072633 chr6 31919578 A G 1.31E-14 Multiple sclerosis CFB intron 17660530 rs2072633 chr6 31919578 A G 3.44E-41 Rheumatoid arthritis CFB intron 17804836 rs2072633 chr6 31919578 A G 3.88E-37 Rheumatoid arthritis CFB intron 19503088 rs2072633 chr6 31919578 A G 6.32E-25 Rheumatoid arthritis CFB intron 21156761 rs2072633 chr6 31919578 A G 6.60E-06 Graves' disease CFB intron 21900946 rs2072633 chr6 31919578 A G 8.80E-05 Type 2 diabetes CFB intron 23209189 rs2072633 chr6 31919578 A G 2.90E-06 Systemic lupus erythematosus CFB intron 24871463 rs4151672 chr6 31919830 C T 1.59E-05 Rheumatoid arthritis CFB UTR-3 17804836 rs4151672 chr6 31919830 C T 6.10E-10 Age-related macular degeneration CFB UTR-3 pha002869 rs4151672 chr6 31919830 C T 1.74E-09 Age-related macular degeneration CFB UTR-3 pha002890 rs522162 chr6 31919917 T C 3.78E-11 Multiple complex diseases RDBP UTR-3 17554300 rs522162 chr6 31919917 T C 1.27E-13 Rheumatoid arthritis RDBP UTR-3 21156761 rs522162 chr6 31919917 T C 2.07E-04 Cervical cancer RDBP UTR-3 21716314 rs522162 chr6 31919917 T C 2.00E-10 Age-related macular degeneration RDBP UTR-3 23577725 rs522162 chr6 31919917 T C 3.00E-07 Age-related macular degeneration (extreme sampling) RDBP UTR-3 23577725 rs760070 chr6 31919956 T C 2.00E-04 Rheumatoid arthritis RDBP UTR-3 17159887 rs760070 chr6 31919956 T C 5.50E-05 Age-related macular degeneration RDBP UTR-3 20861866 rs760070 chr6 31919956 T C 1.27E-13 Rheumatoid arthritis RDBP UTR-3 21156761 rs550513 chr6 31920687 C T 5.14E-09 Multiple complex diseases RDBP intron 17554300 rs550513 chr6 31920687 C T 1.27E-13 Rheumatoid arthritis RDBP intron 21156761 rs550513 chr6 31920687 C T 2.00E-04 Cervical cancer RDBP intron 21716314 rs550513 chr6 31920687 C T 1.69E-06 Age-related macular degeneration (extreme sampling) RDBP intron 23577725 rs550513 chr6 31920687 C T 2.75E-09 Age-related macular degeneration RDBP intron 23577725 rs4151664 chr6 31920873 C T 1.10E-08 HIV-1 control RDBP intron 20041166 rs4151664 chr6 31920873 C T 3.50E-04 HIV-1 control RDBP intron 21051598 rs4151664 chr6 31920873 C T 4.89E-16 Hepatitis B vaccine response RDBP intron 21764829 rs4151664 chr6 31920873 C T 0.00084 Breast cancer RDBP intron 23555315 rs630379 chr6 31922254 A C 5.50E-05 Lung adenocarcinoma RDBP intron 19836008 rs630379 chr6 31922254 A C 1.78E-05 HIV-1 control RDBP intron 20041166 rs630379 chr6 31922254 A C 2.30E-04 Alcohol dependence RDBP intron 20201924 rs630379 chr6 31922254 A C 6.20E-04 Alcohol dependence RDBP intron 20201924 rs630379 chr6 31922254 A C 4.85E-07 Multiple sclerosis RDBP intron 20598377 rs630379 chr6 31922254 A C 2.40E-07 Graves' disease RDBP intron 21900946 rs630379 chr6 31922254 A C 0.00002026 Sarcoidosis RDBP intron 22952805 rs630379 chr6 31922254 A C 5.50E-14 Systemic lupus erythematosus RDBP intron 24871463 rs9501161 chr6 31924327 G A 2.08E-09 Multiple complex diseases RDBP intron 17554300 rs403569 chr6 31924880 G A 1.27E-13 Rheumatoid arthritis RDBP intron 21156761 rs440454 chr6 31927342 A G 6.25E-11 Rheumatoid arthritis SKIV2L intron 21156761 rs440454 chr6 31927342 A G 0.00001939 Sarcoidosis SKIV2L intron 22952805 rs438999 chr6 31928306 A G 2.00E-04 Rheumatoid arthritis SKIV2L missense 17159887 rs438999 chr6 31928306 A G 2.62E-14 Rheumatoid arthritis SKIV2L missense 17804836 rs438999 chr6 31928306 A G 4.81E-15 Rheumatoid arthritis SKIV2L missense 19503088 rs438999 chr6 31928306 A G 5.50E-05 Age-related macular degeneration SKIV2L missense 20861866 rs438999 chr6 31928306 A G 1.46E-13 Rheumatoid arthritis SKIV2L missense 21156761 rs438999 chr6 31928306 A G 8.20E-09 Age-related macular degeneration SKIV2L missense 22694956 rs438999 chr6 31928306 A G 5.68E-19 Age-related macular degeneration SKIV2L missense pha002869 rs438999 chr6 31928306 A G 4.89E-18 Age-related macular degeneration SKIV2L missense pha002890 rs419788 chr6 31928799 T C 3.30E-04 Alcohol dependence SKIV2L intron 20201924 rs419788 chr6 31928799 T C 5.27E-12 Rheumatoid arthritis SKIV2L intron 21156761 rs419788 chr6 31928799 T C 0.00002126 Sarcoidosis SKIV2L intron 22952805 rs437179 chr6 31929014 A C 6.15E-20 Rheumatoid arthritis SKIV2L missense 17804836 rs437179 chr6 31929014 A C 6.63E-17 Rheumatoid arthritis SKIV2L missense 19503088 rs437179 chr6 31929014 A C 3.50E-04 Alcohol dependence SKIV2L missense 20201924 rs437179 chr6 31929014 A C 2.49E-07 Multiple sclerosis SKIV2L missense 20598377 rs437179 chr6 31929014 A C 9.47E-05 Non-alcoholic fatty liver disease histology (other) SKIV2L missense 20708005 rs437179 chr6 31929014 A C 0.00002126 Sarcoidosis SKIV2L missense 22952805 rs437179 chr6 31929014 A C 4.80E-11 Systemic lupus erythematosus SKIV2L missense 24871463 rs437179 chr6 31929014 A C 8.61E-06 Systemic lupus erythematosus SKIV2L missense pha002867 rs2734331 chr6 31930351 A G 1.69E-04 Self-reported allergy SKIV2L cds-synon 23817569 rs2734331 chr6 31930351 A G 7.00E-13 Blood metabolite levels SKIV2L cds-synon 24816252 rs592229 chr6 31930441 G T 1.34E-04 Type 2 diabetes SKIV2L intron 22158537 rs592229 chr6 31930441 G T 2.80E-06 Age-related macular degeneration SKIV2L intron 22694956 rs592229 chr6 31930441 G T 4.00E-06 IgG glycosylation SKIV2L intron 23382691 rs592229 chr6 31930441 G T 9.00E-06 IgG glycosylation SKIV2L intron 23382691 rs592229 chr6 31930441 G T 1.70E-07 Systemic lupus erythematosus SKIV2L intron 24871463 rs592229 chr6 31930441 G T 4.34E-05 Age-related macular degeneration SKIV2L intron pha002890 rs429608 chr6 31930462 G A 3.00E-21 Age-related macular degeneration SKIV2L intron 20385819 rs429608 chr6 31930462 G A 5.00E-15 Age-related macular degeneration SKIV2L intron 20861866 rs429608 chr6 31930462 G A 2.49E-06 Age-related macular degeneration SKIV2L intron 21197116 rs429608 chr6 31930462 G A 2.24E-07 Age-related macular degeneration SKIV2L intron 21909106 rs429608 chr6 31930462 G A 1.00E-06 Age-related macular degeneration SKIV2L intron 22694956 rs429608 chr6 31930462 G A 4.00E-89 Age-related macular degeneration SKIV2L intron 23455636 rs429608 chr6 31930462 G A 0.0004 Coronary artery calcification SKIV2L intron 23727086 rs429608 chr6 31930462 G A 2.63E-06 Age-related macular degeneration SKIV2L intron pha000001 rs429608 chr6 31930462 G A 1.37E-05 Age-related macular degeneration SKIV2L intron pha002856 rs429608 chr6 31930462 G A 1.29E-22 Age-related macular degeneration SKIV2L intron pha002869 rs429608 chr6 31930462 G A 2.03E-21 Age-related macular degeneration SKIV2L intron pha002890 rs401775 chr6 31931137 T C 9.04E-05 HIV-1 control SKIV2L intron 20041166 rs401775 chr6 31931137 T C 2.30E-08 HIV-1 control SKIV2L intron 21051598 rs406936 chr6 31933161 G A 8.84E-38 Multiple complex diseases SKIV2L intron 17554300 rs406936 chr6 31933161 G A 3.23E-11 Type 1 diabetes SKIV2L intron 17632545 rs406936 chr6 31933161 G A 3.19E-13 Rheumatoid arthritis SKIV2L intron 17804836 rs406936 chr6 31933161 G A 5.37E-05 Multiple sclerosis (age of onset) SKIV2L intron 19010793 rs406936 chr6 31933161 G A 6.72E-14 Rheumatoid arthritis SKIV2L intron 19503088 rs406936 chr6 31933161 G A 3.37E-06 Lung adenocarcinoma SKIV2L intron 19836008 rs406936 chr6 31933161 G A 1.61E-10 Rheumatoid arthritis SKIV2L intron 21156761 rs406936 chr6 31933161 G A 5.50E-06 Age-related macular degeneration SKIV2L intron 22694956 rs406936 chr6 31933161 G A 7.00E-07 Age-related macular degeneration SKIV2L intron 23577725 rs406936 chr6 31933161 G A 5.68E-09 Age-related macular degeneration SKIV2L intron pha002869 rs406936 chr6 31933161 G A 1.64E-08 Age-related macular degeneration SKIV2L intron pha002890 rs492899 chr6 31933518 T C 2.18E-11 Multiple complex diseases SKIV2L intron 17554300 rs492899 chr6 31933518 T C 1.00E-16 Type 1 diabetes SKIV2L intron 17632545 rs492899 chr6 31933518 T C 7.80E-06 Hepatitis B SKIV2L intron 21750111 rs492899 chr6 31933518 T C 5.17E-10 Coronary heart disease SKIV2L intron 21971053 rs454212 chr6 31934372 C T 5.12E-11 Type 1 diabetes SKIV2L intron 17632545 rs454212 chr6 31934372 C T 3.58E-13 Rheumatoid arthritis SKIV2L intron 17804836 rs454212 chr6 31934372 C T 5.37E-05 Multiple sclerosis (age of onset) SKIV2L intron 19010793 rs454212 chr6 31934372 C T 3.91E-13 Rheumatoid arthritis SKIV2L intron 19503088 rs454212 chr6 31934372 C T 3.56E-06 Lung adenocarcinoma SKIV2L intron 19836008 rs454212 chr6 31934372 C T 1.61E-10 Rheumatoid arthritis SKIV2L intron 21156761 rs454212 chr6 31934372 C T 4.80E-05 Age-related macular degeneration SKIV2L intron 22694956 rs454212 chr6 31934372 C T 5.99E-09 Age-related macular degeneration SKIV2L intron pha002869 rs454212 chr6 31934372 C T 2.13E-08 Age-related macular degeneration SKIV2L intron pha002890 rs454212 chr6 31934372 C T 3.78E-05 Neuroblastoma SKIV2L intron pha002895 rs453821 chr6 31935311 C T 5.48E-09 Age-related macular degeneration SKIV2L intron pha002869 rs453821 chr6 31935311 C T 1.58E-08 Age-related macular degeneration SKIV2L intron pha002890 rs106287 chr6 31935750 G A 1.70E-05 Self-reported allergy SKIV2L missense 23817569 rs34241101 chr6 31936057 G T 2.49E-05 HIV-1 control SKIV2L intron 20041166 rs34241101 chr6 31936057 G T 1.20E-16 HIV-1 control SKIV2L intron 21051598 rs34241101 chr6 31936057 G T 0.000261 Salmonella-induced pyroptosis SKIV2L intron 22837397 rs410851 chr6 31936668 T C 1.70E-04 Alcohol dependence SKIV2L cds-synon 20201924 rs410851 chr6 31936668 T C 5.80E-04 Alcohol dependence SKIV2L cds-synon 20201924 rs410851 chr6 31936668 T C 0.00002048 Sarcoidosis SKIV2L cds-synon 22952805 rs416002 chr6 31938635 G C 9.33E-05 Age-related macular degeneration DOM3Z intron pha002890 rs389884 chr6 31940897 A G 3.61E-04 Lung function (forced expiratory volume in 1 second) STK19 intron 17255346 rs389884 chr6 31940897 A G 7.86E-17 Type 1 diabetes STK19 intron 17632545 rs389884 chr6 31940897 A G 7.75E-08 Rheumatoid arthritis STK19 intron 17804836 rs389884 chr6 31940897 A G 2.84E-06 Lung cancer STK19 intron 18978787 rs389884 chr6 31940897 A G 1.00E-05 Lung cancer STK19 intron 18978790 rs389884 chr6 31940897 A G 1.81E-04 Schizophrenia STK19 intron 19197363 rs389884 chr6 31940897 A G 9.30E-06 Lung cancer STK19 intron 19654303 rs389884 chr6 31940897 A G 7.21E-10 Lung adenocarcinoma STK19 intron 19836008 rs389884 chr6 31940897 A G 6.24E-10 Rheumatoid arthritis STK19 intron 21156761 rs389884 chr6 31940897 A G 1.30E-13 Lung cancer STK19 intron 22899653 rs389884 chr6 31940897 A G 1.80E-79 Myasthenia gravis STK19 intron 23055271 rs389884 chr6 31940897 A G 2.00E-08 Hematology traits STK19 intron 23263863 rs389884 chr6 31940897 A G 8.32E-08 Rheumatoid arthritis (ACPA-negative) STK19 intron 24532677 rs389884 chr6 31940897 A G 1.30E-19 Systemic lupus erythematosus STK19 intron 24871463 rs389884 chr6 31940897 A G 9.98E-05 Lupus nephritis in systemic lupus erythematosus STK19 intron 24925725 rs389884 chr6 31940897 A G 8.47E-87 Type 1 diabetes STK19 intron pha002862 rs389884 chr6 31940897 A G 9.42E-08 Systemic lupus erythematosus STK19 intron pha002867 rs387608 chr6 31941557 G A 1.38E-10 Type 1 diabetes STK19 intron 17632545 rs387608 chr6 31941557 G A 8.52E-13 Rheumatoid arthritis STK19 intron 17804836 rs387608 chr6 31941557 G A 4.57E-05 Multiple sclerosis (age of onset) STK19 intron 19010793 rs387608 chr6 31941557 G A 7.15E-14 Rheumatoid arthritis STK19 intron 19503088 rs387608 chr6 31941557 G A 3.08E-06 Lung adenocarcinoma STK19 intron 19836008 rs387608 chr6 31941557 G A 1.71E-10 Rheumatoid arthritis STK19 intron 21156761 rs387608 chr6 31941557 G A 8.50E-06 Age-related macular degeneration STK19 intron 22694956 rs387608 chr6 31941557 G A 1.44E-06 Age-related macular degeneration STK19 intron 23577725 rs387608 chr6 31941557 G A 6.95E-09 Age-related macular degeneration STK19 intron pha002869 rs387608 chr6 31941557 G A 1.91E-08 Age-related macular degeneration STK19 intron pha002890 rs2734325 chr6 31945646 C T 0.00003416 Sarcoidosis STK19 intron 22952805 rs6941112 chr6 31946614 G A 7.10E-26 Rheumatoid arthritis STK19 intron 17804836 rs6941112 chr6 31946614 G A 8.87E-18 Rheumatoid arthritis STK19 intron 19503088 rs6941112 chr6 31946614 G A 2.29E-07 Systemic sclerosis STK19 intron 20383147 rs6941112 chr6 31946614 G A 1.90E-07 Pemphigus vulgaris STK19 intron 22437316 rs6941112 chr6 31946614 G A 0.0001 Migraine STK19 intron 22678113 rs6941112 chr6 31946614 G A 1.95E-05 Atopic dermatitis STK19 intron 23886662 rs6941112 chr6 31946614 G A 2.40E-04 Systemic lupus erythematosus STK19 intron 24871463 rs386480 chr6 31946837 C G 1.00E-04 Alcohol dependence STK19 intron 20201924 rs386480 chr6 31946837 C G 3.20E-04 Alcohol dependence STK19 intron 20201924 rs386480 chr6 31946837 C G 9.47E-05 Non-alcoholic fatty liver disease histology (other) STK19 intron 20708005 rs386480 chr6 31946837 C G 0.00002338 Sarcoidosis STK19 intron 22952805 rs389883 chr6 31947460 G T 4.74E-21 Rheumatoid arthritis STK19 intron 17804836 rs389883 chr6 31947460 G T 4.96E-18 Rheumatoid arthritis STK19 intron 19503088 rs389883 chr6 31947460 G T 1.40E-04 Alcohol dependence STK19 intron 20201924 rs389883 chr6 31947460 G T 3.90E-04 Alcohol dependence STK19 intron 20201924 rs389883 chr6 31947460 G T 1.83E-07 Multiple sclerosis STK19 intron 20598377 rs389883 chr6 31947460 G T 9.47E-05 Non-alcoholic fatty liver disease histology (other) STK19 intron 20708005 rs389883 chr6 31947460 G T 5.50E-04 Coronary heart disease STK19 intron 21966275 rs389883 chr6 31947460 G T 0.00003511 Sarcoidosis STK19 intron 22952805 rs389883 chr6 31947460 G T 0.000000863 Triglycerides STK19 intron 23063622 rs389883 chr6 31947460 G T 9.90E-19 Triglycerides STK19 intron 23063622 rs389883 chr6 31947460 G T 7.00E-11 Systemic lupus erythematosus STK19 intron 24871463 rs389883 chr6 31947460 G T 1.56E-05 Systemic lupus erythematosus STK19 intron pha002867 rs389512 chr6 31947594 G C 1.93E-10 Rheumatoid arthritis STK19 intron 21156761 rs389512 chr6 31947594 G C 9.00E-09 Age-related macular degeneration STK19 intron pha002869 rs389512 chr6 31947594 G C 2.34E-08 Age-related macular degeneration STK19 intron pha002890 rs34214527 chr6 32014456 C T 2.47E-05 HIV-1 control TNXB intron 20041166 rs34214527 chr6 32014456 C T 1.88E-10 Vitiligo TNXB intron 20526339 rs34214527 chr6 32014456 C T 8.10E-17 HIV-1 control TNXB intron 21051598 rs2856448 chr6 32014575 A G 2.00E-10 HIV-1 control TNXB intron 21051598 rs433061 chr6 32014828 G A 4.64E-10 Rheumatoid arthritis TNXB intron 21156761 rs433061 chr6 32014828 G A 9.08E-05 Lupus nephritis in systemic lupus erythematosus TNXB intron 24925725 rs140530599 chr6 32015775 G A 0.0001 Breast cancer TNXB missense 23555315 rs2857009 chr6 32019746 G C 1.00E-22 Complement C3 and C4 levels TNXB intron 23028341 rs12333245 chr6 32019769 G A 4.47E-06 Rheumatoid arthritis TNXB intron 17804836 rs12333245 chr6 32019769 G A 4.37E-05 Multiple sclerosis (age of onset) TNXB intron 19010793 rs12333245 chr6 32019769 G A 7.35E-08 Rheumatoid arthritis TNXB intron 19503088 rs2077580 chr6 32020844 G A 7.45E-32 Psoriasis TNXB intron pha002855 rs1009382 chr6 32026107 C T 5.18E-06 Systemic lupus erythematosus TNXB missense 18058064 rs12198173 chr6 32026808 G A 6.66E-08 Type 1 diabetes TNXB intron 17632545 rs12198173 chr6 32026808 G A 3.34E-04 HIV-1 viral setpoint TNXB intron 17641165 rs12198173 chr6 32026808 G A 9.50E-07 Rheumatoid arthritis TNXB intron 17804836 rs12198173 chr6 32026808 G A 3.95E-07 AIDS progression TNXB intron 19115949 rs12198173 chr6 32026808 G A 8.42E-10 Rheumatoid arthritis TNXB intron 19503088 rs12198173 chr6 32026808 G A 3.00E-06 HIV-1 control TNXB intron 20041166 rs12198173 chr6 32026808 G A 2.55E-10 Vitiligo TNXB intron 20526339 rs12198173 chr6 32026808 G A 1.40E-16 HIV-1 control TNXB intron 21051598 rs12198173 chr6 32026808 G A 1.08E-10 Hepatitis B vaccine response TNXB intron 21764829 rs12198173 chr6 32026808 G A 0.0000727 HIV-1 infection (natural long-term nonprogression) TNXB intron 22238471 rs12198173 chr6 32026808 G A 1.40E-06 Age-related macular degeneration TNXB intron 22694956 rs12198173 chr6 32026808 G A 1.33E-10 Atopic dermatitis TNXB intron 23886662 rs12198173 chr6 32026808 G A 8.39E-05 Age-related macular degeneration TNXB intron pha002890 rs2269429 chr6 32029183 C T 3.12E-08 Rheumatoid arthritis TNXB missense 17804836 rs2269429 chr6 32029183 C T 3.16E-05 Multiple sclerosis (age of onset) TNXB missense 19010793 rs2269429 chr6 32029183 C T 1.70E-10 Rheumatoid arthritis TNXB missense 19503088 rs2239689 chr6 32030284 G A 7.21E-37 Rheumatoid arthritis TNXB intron 17804836 rs2239689 chr6 32030284 G A 4.98E-47 Rheumatoid arthritis TNXB intron 19503088 rs2239689 chr6 32030284 G A 4.64E-09 Systemic sclerosis TNXB intron 20383147 rs2239689 chr6 32030284 G A 1.36E-32 Rheumatoid arthritis TNXB intron 21156761 rs2239689 chr6 32030284 G A 1.44E-05 Pemphigus vulgaris TNXB intron 22437316 rs2239689 chr6 32030284 G A 7.50E-05 Systemic lupus erythematosus TNXB intron 24871463 rs204883 chr6 32032743 G A 2.75E-04 Type 2 diabetes TNXB cds-synon 17463246 rs204883 chr6 32032743 G A 2.92E-22 Rheumatoid arthritis TNXB cds-synon 21156761 rs7766862 chr6 32033007 G A 4.24E-34 Rheumatoid arthritis TNXB intron 21156761 rs7766862 chr6 32033007 G A 3.40E-05 Alcoholism (heaviness of drinking) TNXB intron 21529783 rs3117189 chr6 32033944 A G 4.63E-06 Phospholipid levels (plasma) TNXB intron 21829377 rs1150755 chr6 32038550 C T 2.31E-05 Lupus nephritis in systemic lupus erythematosus TNXB intron 24925725 rs2071295 chr6 32038700 C T 2.88E-37 Rheumatoid arthritis TNXB intron 17804836 rs2071295 chr6 32038700 C T 8.87E-48 Rheumatoid arthritis TNXB intron 19503088 rs2071295 chr6 32038700 C T 2.71E-09 Systemic sclerosis TNXB intron 20383147 rs2071295 chr6 32038700 C T 1.16E-34 Rheumatoid arthritis TNXB intron 21156761 rs2071295 chr6 32038700 C T 1.03E-05 Pemphigus vulgaris TNXB intron 22437316 rs2071295 chr6 32038700 C T 5.50E-05 Systemic lupus erythematosus TNXB intron 24871463 rs11751545 chr6 32041043 A C 6.29E-05 Acne (severe) TNXB intron 24927181 rs204878 chr6 32045226 T A 1.21E-05 Age-related macular degeneration TNXB intron pha002890 rs17201560 chr6 32047268 T C 8.14E-09 Age-related macular degeneration TNXB intron pha002869 rs17201560 chr6 32047268 T C 1.56E-08 Age-related macular degeneration TNXB intron pha002890 rs12211410 chr6 32049423 C T 3.75E-05 HIV-1 control TNXB missense 20041166 rs12211410 chr6 32049423 C T 4.50E-17 HIV-1 control TNXB missense 21051598 rs12211410 chr6 32049423 C T 5.78E-10 Atopic dermatitis TNXB missense 23886662 rs185819 chr6 32050067 T C 1.52E-08 Type 1 diabetes TNXB missense 17632545 rs185819 chr6 32050067 T C 9.88E-15 Rheumatoid arthritis TNXB missense 17804836 rs185819 chr6 32050067 T C 3.00E-08 Height TNXB missense 18391951 rs185819 chr6 32050067 T C 3.43E-16 Rheumatoid arthritis TNXB missense 19503088 rs185819 chr6 32050067 T C 1.83E-06 HIV-1 control TNXB missense 20041166 rs185819 chr6 32050067 T C 2.50E-10 HIV-1 control TNXB missense 21051598 rs185819 chr6 32050067 T C 4.58E-05 HIV-1 viral setpoint TNXB missense 21490045 rs185819 chr6 32050067 T C 8.40E-04 Age-related macular degeneration TNXB missense 22694956 rs185819 chr6 32050067 T C 2.08E-04 Crohn's disease TNXB missense 23266558 rs185819 chr6 32050067 T C 2.90E-08 Systemic lupus erythematosus TNXB missense 24871463 rs3130287 chr6 32050544 C T 6.47E-91 Multiple complex diseases TNXB intron 17554300 rs3130287 chr6 32050544 C T 2.26E-28 Multiple sclerosis TNXB intron 17660530 rs1150754 chr6 32050758 C T 7.91E-20 Type 1 diabetes TNXB intron 17632545 rs1150754 chr6 32050758 C T 6.00E-29 Systemic lupus erythematosus TNXB intron 21408207 rs1150754 chr6 32050758 C T 2.30E-05 Lupus nephritis in systemic lupus erythematosus TNXB intron 24925725 rs1150754 chr6 32050758 C T 1.96E-106 Type 1 diabetes TNXB intron pha002862 rs169496 chr6 32052983 C T 7.19E-06 Rheumatoid arthritis TNXB intron 17804836 rs169496 chr6 32052983 C T 3.89E-05 Multiple sclerosis (age of onset) TNXB intron 19010793 rs169496 chr6 32052983 C T 7.62E-08 Rheumatoid arthritis TNXB intron 19503088 rs204899 chr6 32057627 C T 1.54E-06 Rheumatoid arthritis TNXB intron 17804836 rs204899 chr6 32057627 C T 5.13E-05 Multiple sclerosis (age of onset) TNXB intron 19010793 rs204899 chr6 32057627 C T 3.66E-08 Rheumatoid arthritis TNXB intron 19503088 rs1150753 chr6 32059867 A G 3.10E-05 Lung function (forced expiratory volume in 1 second) TNXB intron 17255346 rs1150753 chr6 32059867 A G 6.21E-101 Multiple complex diseases TNXB intron 17554300 rs1150753 chr6 32059867 A G 3.12E-10 Rheumatoid arthritis TNXB intron 21156761 rs1150753 chr6 32059867 A G 1.77E-07 Rheumatoid arthritis (ACPA-negative) TNXB intron 24532677 rs1150753 chr6 32059867 A G 8.42E-05 Lupus nephritis in systemic lupus erythematosus TNXB intron 24925725 rs2071293 chr6 32062687 G A 1.44E-34 Rheumatoid arthritis TNXB intron 21156761 rs2071293 chr6 32062687 G A 5.20E-05 Alcoholism (heaviness of drinking) TNXB intron 21529783 rs1150752 chr6 32064726 T C 3.98E-04 Lung function (forced expiratory volume in 1 second) TNXB missense 17255346 rs1150752 chr6 32064726 T C 1.00E-16 Type 1 diabetes TNXB missense 17632545 rs1150752 chr6 32064726 T C 1.97E-05 Rheumatoid arthritis TNXB missense 17804836 rs1150752 chr6 32064726 T C 1.93E-06 Lung cancer TNXB missense 19654303 rs1150752 chr6 32064726 T C 2.10E-08 Lung adenocarcinoma TNXB missense 19836008 rs1150752 chr6 32064726 T C 9.80E-11 Rheumatoid arthritis TNXB missense 21156761 rs1150752 chr6 32064726 T C 8.30E-05 Lupus nephritis in systemic lupus erythematosus TNXB missense 24925725 rs1150752 chr6 32064726 T C 3.64E-86 Type 1 diabetes TNXB missense pha002862 rs17421624 chr6 32066177 T C 1.01E-48 Multiple complex diseases TNXB intron 17554300 rs17421624 chr6 32066177 T C 2.51E-11 Multiple sclerosis TNXB intron 17660530 rs17421624 chr6 32066177 T C 2.13E-34 Rheumatoid arthritis TNXB intron 21156761 rs13199524 chr6 32066765 C T 1.72E-08 Type 1 diabetes TNXB intron 17632545 rs13199524 chr6 32066765 C T 8.23E-04 HIV-1 viral setpoint TNXB intron 17641165 rs13199524 chr6 32066765 C T 5.79E-07 Rheumatoid arthritis TNXB intron 17804836 rs13199524 chr6 32066765 C T 1.10E-06 AIDS progression TNXB intron 19115949 rs13199524 chr6 32066765 C T 3.71E-10 Rheumatoid arthritis TNXB intron 19503088 rs13199524 chr6 32066765 C T 1.96E-09 HIV-1 control TNXB intron 20041166 rs13199524 chr6 32066765 C T 2.55E-10 Vitiligo TNXB intron 20526339 rs13199524 chr6 32066765 C T 6.00E-17 HIV-1 control TNXB intron 21051598 rs13199524 chr6 32066765 C T 1.70E-11 Hepatitis B vaccine response TNXB intron 21764829 rs13199524 chr6 32066765 C T 0.0000653 HIV-1 infection (natural long-term nonprogression) TNXB intron 22238471 rs13199524 chr6 32066765 C T 3.60E-06 Age-related macular degeneration TNXB intron 22694956 rs13199524 chr6 32066765 C T 8.01E-12 Atopic dermatitis TNXB intron 23886662 rs3117182 chr6 32066819 T A 3.14E-06 Phospholipid levels (plasma) TNXB intron 21829377 rs1269854 chr6 32070838 T C 7.53E-06 Age-related macular degeneration TNXB intron pha002869 rs1269854 chr6 32070838 T C 1.08E-05 Age-related macular degeneration TNXB intron pha002890 rs3117181 chr6 32071017 C G 9.20E-04 Type 2 diabetes TNXB intron 17463246 rs3117181 chr6 32071017 C G 5.00E-07 Phospholipid levels (plasma) TNXB intron 21829377 rs4711286 chr6 32071637 T C 0.00001522 Sarcoidosis TNXB intron 22952805 rs3134954 chr6 32071893 C T 1.39E-19 Type 1 diabetes TNXB intron 17632545 rs3134954 chr6 32071893 C T 2.57E-12 Rheumatoid arthritis TNXB intron 17804836 rs3134954 chr6 32071893 C T 7.55E-13 Rheumatoid arthritis TNXB intron 19503088 rs3134954 chr6 32071893 C T 3.19E-09 Multiple sclerosis TNXB intron 20598377 rs3134954 chr6 32071893 C T 1.11E-06 Phospholipid levels (plasma) TNXB intron 21829377 rs3134954 chr6 32071893 C T 5.42E-05 Crohn's disease TNXB intron 23266558 rs3134954 chr6 32071893 C T 1.40E-108 Type 1 diabetes TNXB intron pha002862 rs12153855 chr6 32074804 T C 1.24E-11 Type 1 diabetes TNXB intron 17632545 rs12153855 chr6 32074804 T C 6.62E-10 Rheumatoid arthritis TNXB intron 17804836 rs12153855 chr6 32074804 T C 3.06E-15 Rheumatoid arthritis TNXB intron 19503088 rs12153855 chr6 32074804 T C 6.35E-08 HIV-1 control TNXB intron 20041166 rs12153855 chr6 32074804 T C 5.08E-08 Systemic sclerosis TNXB intron 20383147 rs12153855 chr6 32074804 T C 3.84E-10 Vitiligo TNXB intron 20526339 rs12153855 chr6 32074804 T C 3.50E-09 HIV-1 control TNXB intron 21051598 rs12153855 chr6 32074804 T C 0.0002 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer TNXB intron 21245432 rs12153855 chr6 32074804 T C 2.09E-11 Hepatitis B vaccine response TNXB intron 21764829 rs12153855 chr6 32074804 T C 1.00E-09 Age-related macular degeneration TNXB intron 22694956 rs12153855 chr6 32074804 T C 3.00E-14 Atopic dermatitis TNXB intron 23886662 rs429150 chr6 32075563 T C 6.20E-09 HIV-1 control TNXB intron 21051598 rs429150 chr6 32075563 T C 1.93E-07 Blood pressure TNXB intron 21909110 rs2269426 chr6 32076499 G A 3.50E-13 Type 1 diabetes TNXB intron 17632545 rs2269426 chr6 32076499 G A 2.09E-12 Rheumatoid arthritis TNXB intron 17804836 rs2269426 chr6 32076499 G A 3.00E-06 Eosinophil counts TNXB intron 19198610 rs2269426 chr6 32076499 G A 3.60E-09 Rheumatoid arthritis TNXB intron 19503088 rs2269426 chr6 32076499 G A 2.00E-08 HIV-1 control TNXB intron 21051598 rs2269426 chr6 32076499 G A 1.00E-06 Age-related macular degeneration TNXB intron 22694956 rs2269426 chr6 32076499 G A 4.90E-07 Systemic lupus erythematosus TNXB intron 24871463 rs411337 chr6 32077380 C T 1.02E-10 Rheumatoid arthritis TNXB nearGene-5 21156761 rs3807039 chr6 32078373 A C 0.00001248 Sarcoidosis TNXB nearGene-5 22952805 rs17207986 chr6 32079567 T C 1.00E-16 Ulcerative colitis / / 20848476 rs3130342 chr6 32080146 A C 9.30E-07 Systemic lupus erythematosus / / 18058064 rs3130342 chr6 32080146 A C 1.61E-06 Phospholipid levels (plasma) / / 21829377 rs1269852 chr6 32080191 G C 1.56E-09 Rheumatoid arthritis / / 21156761 rs9469084 chr6 32080383 C T 6.20E-10 Rheumatoid arthritis / / 21156761 rs8111 chr6 32083175 C T 2.32E-26 Rheumatoid arthritis ATF6B UTR-3 17804836 rs8111 chr6 32083175 C T 5.40E-27 Rheumatoid arthritis ATF6B UTR-3 19503088 rs8111 chr6 32083175 C T 7.06E-24 Rheumatoid arthritis ATF6B UTR-3 21156761 rs8111 chr6 32083175 C T 1.44E-05 Pemphigus vulgaris ATF6B UTR-3 22437316 rs8111 chr6 32083175 C T 7.70E-05 Systemic lupus erythematosus ATF6B UTR-3 24871463 rs8111 chr6 32083175 C T 8.51E-05 Coronary heart disease ATF6B UTR-3 pha003033 rs8283 chr6 32083300 A G 2.20E-09 HIV-1 control ATF6B UTR-3 21051598 rs28732175 chr6 32085278 C T 4.90E-15 HIV-1 control ATF6B intron 21051598 rs1269851 chr6 32092207 T C 5.17E-08 Multiple complex diseases ATF6B intron 17554300 rs3830076 chr6 32096244 C T 9.73E-22 Rheumatoid arthritis / / 17804836 rs3830076 chr6 32096244 C T 3.07E-20 Rheumatoid arthritis / / 19503088 rs9391734 chr6 32097983 G A 4.87E-05 HIV-1 control FKBPL UTR-5 20041166 rs9391734 chr6 32097983 G A 2.20E-09 HIV-1 control FKBPL UTR-5 21051598 rs9267803 chr6 32101762 C T 4.70E-24 Rheumatoid arthritis / / 21156761 rs9267803 chr6 32101762 C T 0.0001 Migraine / / 22678113 rs13211318 chr6 32102680 A C 4.87E-05 HIV-1 control / / 20041166 rs13211318 chr6 32102680 A C 3.84E-10 Vitiligo / / 20526339 rs13211318 chr6 32102680 A C 2.50E-09 HIV-1 control / / 21051598 rs4713505 chr6 32105001 G T 1.47E-23 Rheumatoid arthritis / / 21156761 rs388629 chr6 32105512 G A 6.78E-12 Multiple complex diseases / / 17554300 rs388629 chr6 32105512 G A 6.93E-06 Age-related macular degeneration / / 23577725 rs7383258 chr6 32106931 C T 1.51E-05 Age-related macular degeneration / / pha002890 rs17208000 chr6 32109938 G C,T 0.00002298 Sarcoidosis / / 22952805 rs204999 chr6 32109979 A G 1.90E-09 Type 1 diabetes / / 17632545 rs204999 chr6 32109979 A G 3.53E-29 Rheumatoid arthritis / / 17804836 rs204999 chr6 32109979 A G 2.30E-09 Systemic sclerosis / / 20383147 rs204999 chr6 32109979 A G 6.62E-24 Rheumatoid arthritis / / 21156761 rs204999 chr6 32109979 A G 3.76E-07 Hepatitis B / / 21750111 rs204999 chr6 32109979 A G 1.69E-15 Hepatitis B vaccine response / / 21764829 rs204999 chr6 32109979 A G 2.46E-12 Coronary heart disease / / 21971053 rs204999 chr6 32109979 A G 2.00E-07 Nodular sclerosis Hodgkin lymphoma / / 22086417 rs204999 chr6 32109979 A G 3.00E-09 Serum total protein level / / 23022100 rs204999 chr6 32109979 A G 4.00E-11 Serum total protein level / / 23022100 rs204999 chr6 32109979 A G 6.30E-15 Hematology traits / / 23303382 rs204999 chr6 32109979 A G 6.30E-15 Epstein-Barr virus immune response (EBNA-1) / / 23326239 rs204999 chr6 32109979 A G 6.28E-07 Self-reported allergy / / 23817569 rs204999 chr6 32109979 A G 7.95E-21 Celiac disease / / 23936387 rs204999 chr6 32109979 A G 3.10E-05 Systemic lupus erythematosus / / 24871463 rs204999 chr6 32109979 A G 2.00E-07 Hodgkin's lymphoma / / 24920014 rs3134952 chr6 32113571 A T 1.35E-15 Rheumatoid arthritis / / 21156761 rs3134952 chr6 32113571 A T 1.08E-04 Self-reported allergy / / 23817569 rs4713506 chr6 32113980 G A 3.16E-23 Rheumatoid arthritis / / 21156761 rs4713506 chr6 32113980 G A 0.00000178 Body mass index / / 22885924 rs9296009 chr6 32114515 A T 9.00E-05 Rheumatoid arthritis / / 17159887 rs9296009 chr6 32114515 A T 1.78E-57 Multiple complex diseases / / 17554300 rs9296009 chr6 32114515 A T 1.85E-08 Multiple sclerosis / / 17660530 rs9296009 chr6 32114515 A T 7.00E-08 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs9296009 chr6 32114515 A T 2.70E-06 Urinary metabolites / / 21572414 rs9296009 chr6 32114515 A T 4.00E-06 IgG glycosylation / / 23382691 rs9296009 chr6 32114515 A T 4.00E-08 IgG glycosylation / / 23382691 rs9296009 chr6 32114515 A T 1.19E-05 Age-related macular degeneration / / pha002890 rs28732178 chr6 32115222 G A 2.30E-14 HIV-1 control / / 21051598 rs3134608 chr6 32117971 T G 1.10E-15 Rheumatoid arthritis PRRT1 intron 21156761 rs3134608 chr6 32117971 T G 1.09E-04 Self-reported allergy PRRT1 intron 23817569 rs3131283 chr6 32119898 T C 1.41E-06 Phospholipid levels (plasma) PPT2 nearGene-5 21829377 rs1053924 chr6 32120715 T C 1.88E-11 Type 1 diabetes / / 17632545 rs2269425 chr6 32123639 G A 1.72E-05 stroke (ischemic) PPT2 intron 17434096 rs2269425 chr6 32123639 G A 8.16E-07 Rheumatoid arthritis PPT2 intron 17804836 rs2269425 chr6 32123639 G A 7.04E-20 Rheumatoid arthritis PPT2 intron 19503088 rs2269425 chr6 32123639 G A 0.000009473 Sarcoidosis PPT2 intron 22952805 rs10947233 chr6 32124424 G T 4.71E-08 Pulmonary function PPT2 intron 20010835 rs10947233 chr6 32124424 G T 2.31E-32 Rheumatoid arthritis PPT2 intron 21156761 rs10947233 chr6 32124424 G T 3.20E-08 Pulmonary emphysema PPT2 intron 24383474 rs3134603 chr6 32126002 A G 1.82E-17 Type 1 diabetes PPT2 intron 17632545 rs3134603 chr6 32126002 A G 8.85E-11 Rheumatoid arthritis PPT2 intron 17804836 rs3134603 chr6 32126002 A G 6.08E-12 Rheumatoid arthritis PPT2 intron 19503088 rs3134603 chr6 32126002 A G 8.36E-10 Multiple sclerosis PPT2 intron 20598377 rs3134603 chr6 32126002 A G 2.38E-06 Phospholipid levels (plasma) PPT2 intron 21829377 rs3134603 chr6 32126002 A G 4.73E-05 Interstitial lung disease PPT2 intron 23583980 rs3134603 chr6 32126002 A G 3.00E-07 Multiple myeloma PPT2 intron 23955597 rs3134603 chr6 32126002 A G 3.36E-116 Type 1 diabetes PPT2 intron pha002862 rs3134950 chr6 32127477 C A 1.00E-06 Oleic acid (18:1n-9) plasma levels PPT2 intron 23362303 rs3134950 chr6 32127477 C A 1.18E-05 Self-reported allergy PPT2 intron 23817569 rs3134950 chr6 32127477 C A 6.00E-06 Plasma omega-6 polyunsaturated fatty acid levels PPT2 intron 24823311 rs12524510 chr6 32129434 G A 0.000006021 Sarcoidosis PPT2 intron 22952805 rs2849013 chr6 32132590 A G 9.03E-08 Rheumatoid arthritis EGFL8 intron 21156761 rs3096697 chr6 32134510 G A 6.44E-23 Rheumatoid arthritis EGFL8 missense 17804836 rs3096697 chr6 32134510 G A 9.35E-24 Rheumatoid arthritis EGFL8 missense 19503088 rs3096697 chr6 32134510 G A 5.59E-06 Lung cancer EGFL8 missense 19654303 rs3096697 chr6 32134510 G A 1.09E-05 Lung adenocarcinoma EGFL8 missense 19836008 rs3096697 chr6 32134510 G A 6.31E-09 Vitiligo EGFL8 missense 20526339 rs3096697 chr6 32134510 G A 6.10E-06 Age-related macular degeneration EGFL8 missense 22694956 rs3096697 chr6 32134510 G A 1.27E-04 Self-reported allergy EGFL8 missense 23817569 rs3096697 chr6 32134510 G A 2.16E-08 Age-related macular degeneration EGFL8 missense pha002869 rs3096697 chr6 32134510 G A 5.66E-06 Age-related macular degeneration EGFL8 missense pha002890 rs3130347 chr6 32134656 T C 4.64E-10 Vitiligo EGFL8 intron 20526339 rs3130347 chr6 32134656 T C 3.62E-08 Age-related macular degeneration EGFL8 intron pha002869 rs3130347 chr6 32134656 T C 1.22E-05 Age-related macular degeneration EGFL8 intron pha002890 rs1061808 chr6 32136547 T G 8.00E-10 Phospholipid levels (plasma) AGPAT1 UTR-3 22359512 rs1061808 chr6 32136547 T G 5.94E-06 Self-reported allergy AGPAT1 UTR-3 23817569 rs1061808 chr6 32136547 T G 7.28E-06 Plasma omega-6 polyunsaturated fatty acid levels AGPAT1 UTR-3 24823311 rs11553430 chr6 32136771 C T 2.45E-05 Age-related macular degeneration AGPAT1 UTR-3 pha002890 rs1269839 chr6 32136930 G T 6.34E-08 Rheumatoid arthritis AGPAT1 UTR-3 21156761 rs3130283 chr6 32138545 A C 9.20E-04 Type 2 diabetes AGPAT1 intron 17463246 rs3130283 chr6 32138545 A C 1.46E-06 Phospholipid levels (plasma) AGPAT1 intron 21829377 rs3130348 chr6 32140277 C A 5.54E-12 Multiple complex diseases AGPAT1 intron 17554300 rs3130348 chr6 32140277 C A 7.47E-16 Rheumatoid arthritis AGPAT1 intron 21156761 rs3130348 chr6 32140277 C A 1.15E-04 Self-reported allergy AGPAT1 intron 23817569 rs3130284 chr6 32140487 T C 2.16E-12 Multiple complex diseases AGPAT1 intron 17554300 rs3130284 chr6 32140487 T C 3.57E-10 Vitiligo AGPAT1 intron 20526339 rs3130284 chr6 32140487 T C 7.47E-16 Rheumatoid arthritis AGPAT1 intron 21156761 rs3130284 chr6 32140487 T C 1.21E-04 Self-reported allergy AGPAT1 intron 23817569 rs3130284 chr6 32140487 T C 4.39E-08 Age-related macular degeneration AGPAT1 intron pha002869 rs3130284 chr6 32140487 T C 1.39E-05 Age-related macular degeneration AGPAT1 intron pha002890 rs3131297 chr6 32141005 A T 7.47E-16 Rheumatoid arthritis AGPAT1 intron 21156761 rs3131297 chr6 32141005 A T 1.27E-04 Self-reported allergy AGPAT1 intron 23817569 rs408359 chr6 32141883 G A 1.58E-04 Multiple complex diseases AGPAT1 intron 17554300 rs408359 chr6 32141883 G A 5.04E-13 Type 1 diabetes AGPAT1 intron 17632545 rs16869385 chr6 32143991 G A,C 0.00001022 Sarcoidosis AGPAT1 intron 22952805 rs2071290 chr6 32144530 C T 8.61E-05 Crohn's disease AGPAT1 intron 23266558 rs3134947 chr6 32145205 C T 5.08E-05 Lipid levels AGPAT1 intron 19913121 rs3134947 chr6 32145205 C T 4.02E-10 Vitiligo AGPAT1 intron 20526339 rs3134947 chr6 32145205 C T 6.33E-16 Rheumatoid arthritis AGPAT1 intron 21156761 rs3134947 chr6 32145205 C T 1.82E-14 Hepatitis B vaccine response AGPAT1 intron 21764829 rs3134947 chr6 32145205 C T 1.44E-04 Self-reported allergy AGPAT1 intron 23817569 rs2269423 chr6 32145707 A C 8.14E-05 Multiple sclerosis AGPAT1 intron 20598377 rs3134946 chr6 32145993 C G 5.59E-16 Rheumatoid arthritis RNF5 nearGene-5 21156761 rs3134946 chr6 32145993 C G 1.52E-04 Self-reported allergy RNF5 nearGene-5 23817569 rs3096689 chr6 32145999 C G 1.52E-04 Self-reported allergy RNF5 nearGene-5 23817569 rs3134945 chr6 32146492 C A 1.10E-20 Rheumatoid arthritis RNF5 intron 17804836 rs3134945 chr6 32146492 C A 5.59E-22 Rheumatoid arthritis RNF5 intron 19503088 rs3134945 chr6 32146492 C A 4.93E-10 Vitiligo RNF5 intron 20526339 rs3134945 chr6 32146492 C A 1.65E-16 Rheumatoid arthritis RNF5 intron 21156761 rs3134945 chr6 32146492 C A 1.21E-13 Hepatitis B vaccine response RNF5 intron 21764829 rs3134945 chr6 32146492 C A 1.20E-05 Age-related macular degeneration RNF5 intron 22694956 rs3134945 chr6 32146492 C A 1.34E-04 Self-reported allergy RNF5 intron 23817569 rs3134945 chr6 32146492 C A 3.20E-08 Systemic lupus erythematosus RNF5 intron 24871463 rs3134945 chr6 32146492 C A 4.06E-08 Age-related macular degeneration RNF5 intron pha002869 rs3134945 chr6 32146492 C A 1.24E-05 Age-related macular degeneration RNF5 intron pha002890 rs9469089 chr6 32146657 G C 0.000007271 Sarcoidosis RNF5 intron 22952805 rs9469089 chr6 32146657 G C 0.0000619 Rate of forced expiratory volume in 1 second (FEV1) decline (young adult women) RNF5 intron 23527081 rs3132965 chr6 32146997 A G 4.21E-16 Rheumatoid arthritis RNF5 intron 21156761 rs3132965 chr6 32146997 A G 1.28E-04 Self-reported allergy RNF5 intron 23817569 rs3132965 chr6 32146997 A G 8.39E-16 Psoriasis RNF5 intron pha002855 rs3130349 chr6 32147696 G A 1.07E-10 Rheumatoid arthritis RNF5 cds-synon 21156761 rs3130349 chr6 32147696 G A 2.19E-12 Hepatitis B vaccine response RNF5 cds-synon 21764829 rs3130349 chr6 32147696 G A 8.58E-05 Crohn's disease RNF5 cds-synon 23266558 rs3130349 chr6 32147696 G A 7.76E-04 Self-reported allergy RNF5 cds-synon 23817569 rs3130349 chr6 32147696 G A 9.28E-08 Age-related macular degeneration RNF5 cds-synon pha002869 rs3130349 chr6 32147696 G A 5.68E-05 Age-related macular degeneration RNF5 cds-synon pha002890 rs3134943 chr6 32147761 T C 9.20E-04 Type 2 diabetes RNF5 intron 17463246 rs3134943 chr6 32147761 T C 1.00E-16 Type 1 diabetes RNF5 intron 17632545 rs3134943 chr6 32147761 T C 2.51E-12 Rheumatoid arthritis RNF5 intron 17804836 rs3134943 chr6 32147761 T C 5.59E-16 Rheumatoid arthritis RNF5 intron 19503088 rs3134943 chr6 32147761 T C 4.88E-10 Multiple sclerosis RNF5 intron 20598377 rs3134943 chr6 32147761 T C 3.70E-06 Phospholipid levels (plasma) RNF5 intron 21829377 rs3134943 chr6 32147761 T C 2.76E-05 Interstitial lung disease RNF5 intron 23583980 rs3134943 chr6 32147761 T C 2.82E-105 Type 1 diabetes RNF5 intron pha002862 rs8365 chr6 32148403 G C 1.07E-10 Rheumatoid arthritis RNF5 UTR-3 21156761 rs8365 chr6 32148403 G C 1.09E-17 Psoriasis RNF5 UTR-3 pha002855 rs3134940 chr6 32149816 T C 2.23E-10 Type 1 diabetes AGER intron 17632545 rs3134940 chr6 32149816 T C 1.58E-10 Rheumatoid arthritis AGER intron 21156761 rs3134940 chr6 32149816 T C 1.45E-04 Crohn's disease AGER intron 23266558 rs3134940 chr6 32149816 T C 7.26E-04 Self-reported allergy AGER intron 23817569 rs1035798 chr6 32151222 G A 1.37E-04 Multiple complex diseases AGER intron 17554300 rs1035798 chr6 32151222 G A 7.02E-05 Rheumatoid arthritis AGER intron 17804836 rs1035798 chr6 32151222 G A 2.66E-09 Systemic sclerosis AGER intron 20383147 rs1035798 chr6 32151222 G A 2.10E-04 Blood pressure AGER intron 21060006 rs1035798 chr6 32151222 G A 3.80E-05 Blood pressure AGER intron 21060006 rs1035798 chr6 32151222 G A 8.50E-04 Systemic lupus erythematosus AGER intron 24871463 rs2070600 chr6 32151443 C T 1.20E-29 Rheumatoid arthritis AGER missense 17804836 rs2070600 chr6 32151443 C T 2.76E-05 Pulmonary function AGER missense 19300500 rs2070600 chr6 32151443 C T 3.00E-15 Pulmonary function AGER missense 20010834 rs2070600 chr6 32151443 C T 3.00E-14 Pulmonary function AGER missense 20010835 rs2070600 chr6 32151443 C T 7.62E-37 Rheumatoid arthritis AGER missense 21156761 rs2070600 chr6 32151443 C T 3.90E-05 Hypothyroidism AGER missense 22493691 rs2070600 chr6 32151443 C T 1.00E-21 Pulmonary function (interaction) AGER missense 23284291 rs2070600 chr6 32151443 C T 2.18E-04 Stroke AGER missense pha002887 rs3131300 chr6 32151934 A G 1.13E-11 Rheumatoid arthritis AGER intron 21156761 rs3131300 chr6 32151934 A G 7.28E-04 Self-reported allergy AGER intron 23817569 rs1800684 chr6 32151994 A T 3.14E-06 Phospholipid levels (plasma) AGER cds-synon 21829377 rs1800624 chr6 32152387 A T 5.40E-05 Alcoholism (heaviness of drinking) / / 21529783 rs1800625 chr6 32152442 A G 1.47E-11 Rheumatoid arthritis / / 21156761 rs1800625 chr6 32152442 A G 6.15E-04 Self-reported allergy / / 23817569 rs999 chr6 32153886 C G 1.42E-05 Nicotine dependence PBX2 UTR-3 17158188 rs204995 chr6 32154285 A G 1.08E-15 Rheumatoid arthritis PBX2 intron 21156761 rs204995 chr6 32154285 A G 4.14E-10 Epstein-Barr virus immune response (EBNA-1) PBX2 intron 23326239 rs204995 chr6 32154285 A G 2.98E-06 Self-reported allergy PBX2 intron 23817569 rs204994 chr6 32154998 C T 2.81E-23 Rheumatoid arthritis PBX2 intron 17804836 rs204994 chr6 32154998 C T 4.38E-15 Rheumatoid arthritis PBX2 intron 21156761 rs204994 chr6 32154998 C T 6.28E-10 Epstein-Barr virus immune response (EBNA-1) PBX2 intron 23326239 rs204994 chr6 32154998 C T 3.90E-07 Systemic lupus erythematosus PBX2 intron 24871463 rs204993 chr6 32155581 A G 7.25E-06 Hepatitis B PBX2 intron 21750111 rs204993 chr6 32155581 A G 2.00E-15 Asthma PBX2 intron 21804548 rs204993 chr6 32155581 A G 7.32E-07 Self-reported allergy PBX2 intron 23817569 rs204993 chr6 32155581 A G 4.78E-12 Hodgkin's lymphoma PBX2 intron 24149102 rs2022059 chr6 32156489 G C 5.33E-05 Pulmonary function PBX2 intron 19300500 rs2022059 chr6 32156489 G C 7.90E-05 Pulmonary function PBX2 intron 20010835 rs204992 chr6 32156908 G A 9.12E-10 Epstein-Barr virus immune response (EBNA-1) PBX2 intron 23326239 rs2856437 chr6 32157364 G A 5.36E-05 Pulmonary function PBX2 intron 19300500 rs2856437 chr6 32157364 G A 2.15E-07 Pulmonary function PBX2 intron 20010835 rs2856437 chr6 32157364 G A 2.18E-36 Rheumatoid arthritis PBX2 intron 21156761 rs176095 chr6 32158319 A G 6.84E-16 Rheumatoid arthritis / / 21156761 rs176095 chr6 32158319 A G 8.00E-20 Atopic dermatitis / / 23042114 rs176095 chr6 32158319 A G 9.60E-07 Self-reported allergy / / 23817569 rs176095 chr6 32158319 A G 4.63E-04 Atopic dermatitis / / 23886662 rs176095 chr6 32158319 A G 2.18E-12 Psoriasis / / pha002855 rs2269420 chr6 32160153 C A,G,T 8.45E-06 Crohn's disease GPSM3 intron 23266558 rs12663103 chr6 32161324 T C 2.36E-12 Type 1 diabetes GPSM3 intron 17632545 rs12663103 chr6 32161324 T C 7.00E-13 HIV-1 control GPSM3 intron 21051598 rs12663103 chr6 32161324 T C 6.09E-08 Hepatitis B GPSM3 intron 21750111 rs12663103 chr6 32161324 T C 5.54E-12 Coronary heart disease GPSM3 intron 21971053 rs204991 chr6 32161366 T C 1.74E-35 Multiple complex diseases GPSM3 intron 17554300 rs204991 chr6 32161366 T C 1.53E-10 Type 1 diabetes GPSM3 intron 17632545 rs204991 chr6 32161366 T C 3.74E-19 Rheumatoid arthritis GPSM3 intron 17804836 rs204991 chr6 32161366 T C 1.18E-04 Schizophrenia GPSM3 intron 19197363 rs204991 chr6 32161366 T C 2.68E-12 Rheumatoid arthritis GPSM3 intron 21156761 rs204991 chr6 32161366 T C 5.16E-04 Intracranial aneurysm GPSM3 intron 22286173 rs204991 chr6 32161366 T C 0.00001035 Sarcoidosis GPSM3 intron 22952805 rs204991 chr6 32161366 T C 1.06E-05 Self-reported allergy GPSM3 intron 23817569 rs3132940 chr6 32161396 T G 5.73E-04 Type 2 diabetes GPSM3 intron 17463246 rs3132940 chr6 32161396 T G 8.00E-06 Multiple myeloma GPSM3 intron 23955597 rs204990 chr6 32161430 C A 3.07E-36 Multiple complex diseases GPSM3 intron 17554300 rs204990 chr6 32161430 C A 3.08E-10 Type 1 diabetes GPSM3 intron 17632545 rs204990 chr6 32161430 C A 4.32E-20 Rheumatoid arthritis GPSM3 intron 17804836 rs204990 chr6 32161430 C A 8.68E-05 Schizophrenia GPSM3 intron 19197363 rs204990 chr6 32161430 C A 3.13E-12 Rheumatoid arthritis GPSM3 intron 21156761 rs204990 chr6 32161430 C A 7.00E-49 Myasthenia gravis GPSM3 intron 23055271 rs204990 chr6 32161430 C A 1.02E-05 Self-reported allergy GPSM3 intron 23817569 rs204990 chr6 32161430 C A 4.40E-09 Systemic lupus erythematosus GPSM3 intron 24871463 rs204989 chr6 32161852 G A 5.42E-36 Multiple complex diseases GPSM3 intron 17554300 rs204989 chr6 32161852 G A 2.53E-12 Rheumatoid arthritis GPSM3 intron 21156761 rs204989 chr6 32161852 G A 1.28E-06 Schizophrenia GPSM3 intron 21926974 rs204989 chr6 32161852 G A 1.21E-05 Self-reported allergy GPSM3 intron 23817569 rs8192583 chr6 32163274 G A 8.40E-14 HIV-1 control NOTCH4 cds-synon 21051598 rs8192583 chr6 32163274 G A 2.25E-20 Psoriasis NOTCH4 cds-synon pha002855 rs13215567 chr6 32163748 C T 1.00E-06 Obesity-related traits NOTCH4 cds-synon 23251661 rs2071278 chr6 32165444 A G 2.45E-05 Lung function (forced expiratory volume in 1 second) NOTCH4 intron 17255346 rs2071278 chr6 32165444 A G 1.96E-82 Multiple complex diseases NOTCH4 intron 17554300 rs2071278 chr6 32165444 A G 9.90E-04 Alzheimer's disease NOTCH4 intron 17998437 rs2071278 chr6 32165444 A G 1.28E-09 Rheumatoid arthritis NOTCH4 intron 21156761 rs2071278 chr6 32165444 A G 4.00E-72 Complement C3 and C4 levels NOTCH4 intron 23028341 rs8192575 chr6 32166384 C G 6.16E-07 Pulmonary function NOTCH4 intron 20010835 rs8192575 chr6 32166384 C G 7.92E-37 Rheumatoid arthritis NOTCH4 intron 21156761 rs3134942 chr6 32168771 G T 1.40E-04 Lung function (forced expiratory volume in 1 second) NOTCH4 cds-synon 17255346 rs3134942 chr6 32168771 G T 1.00E-16 Type 1 diabetes NOTCH4 cds-synon 17632545 rs3134942 chr6 32168771 G T 1.57E-05 Schizophrenia NOTCH4 cds-synon 19197363 rs3134942 chr6 32168771 G T 5.73E-06 Lung cancer NOTCH4 cds-synon 19654303 rs3134942 chr6 32168771 G T 7.17E-08 Lung adenocarcinoma NOTCH4 cds-synon 19836008 rs3134942 chr6 32168771 G T 2.12E-11 Vitiligo NOTCH4 cds-synon 20526339 rs3134942 chr6 32168771 G T 3.19E-10 Rheumatoid arthritis NOTCH4 cds-synon 21156761 rs3134942 chr6 32168771 G T 1.19E-10 Hepatitis B vaccine response NOTCH4 cds-synon 21764829 rs3134942 chr6 32168771 G T 3.00E-07 Lung cancer NOTCH4 cds-synon 22899653 rs3134942 chr6 32168771 G T 5.94E-04 Self-reported allergy NOTCH4 cds-synon 23817569 rs3134942 chr6 32168771 G T 1.10E-18 Systemic lupus erythematosus NOTCH4 cds-synon 24871463 rs3134942 chr6 32168771 G T 1.92E-85 Type 1 diabetes NOTCH4 cds-synon pha002862 rs3134942 chr6 32168771 G T 1.86E-08 Systemic lupus erythematosus NOTCH4 cds-synon pha002867 rs9267822 chr6 32170407 C G 0.00006564 Sarcoidosis NOTCH4 intron 22952805 rs3132935 chr6 32171075 A G 4.84E-13 Rheumatoid arthritis NOTCH4 intron 21156761 rs3132935 chr6 32171075 A G 3.00E-07 Schizophrenia NOTCH4 intron 23894747 rs3132935 chr6 32171075 A G 5.00E-07 Schizophrenia NOTCH4 intron 23894747 rs2071277 chr6 32171683 T C 7.77E-06 Rheumatoid arthritis NOTCH4 intron 17804836 rs2071277 chr6 32171683 T C 9.46E-12 Rheumatoid arthritis NOTCH4 intron 19503088 rs2071277 chr6 32171683 T C 2.00E-11 Age-related macular degeneration NOTCH4 intron 22694956 rs2071277 chr6 32171683 T C 1.58E-06 Age-related macular degeneration NOTCH4 intron pha002869 rs2071277 chr6 32171683 T C 8.14E-06 Age-related macular degeneration NOTCH4 intron pha002890 rs1044506 chr6 32172065 T G 6.96E-04 Type 2 diabetes NOTCH4 cds-synon 17463246 rs1044506 chr6 32172065 T G 9.00E-06 Multiple myeloma NOTCH4 cds-synon 23955597 rs3131296 chr6 32172993 C T 1.00E-16 Type 1 diabetes NOTCH4 intron 17632545 rs3131296 chr6 32172993 C T 6.28E-13 Rheumatoid arthritis NOTCH4 intron 17804836 rs3131296 chr6 32172993 C T 1.57E-05 Schizophrenia NOTCH4 intron 19197363 rs3131296 chr6 32172993 C T 7.86E-12 Rheumatoid arthritis NOTCH4 intron 19503088 rs3131296 chr6 32172993 C T 2.00E-10 Schizophrenia NOTCH4 intron 19571808 rs3131296 chr6 32172993 C T 4.44E-11 Vitiligo NOTCH4 intron 20526339 rs3131296 chr6 32172993 C T 3.17E-10 Rheumatoid arthritis NOTCH4 intron 21156761 rs3131296 chr6 32172993 C T 5.10E-11 Schizophrenia NOTCH4 intron 21791550 rs3131296 chr6 32172993 C T 2.30E-10 Schizophrenia (treatment refractory) NOTCH4 intron 22479419 rs3131296 chr6 32172993 C T 7.10E-61 Myasthenia gravis NOTCH4 intron 23055271 rs3131296 chr6 32172993 C T 5.73E-04 Self-reported allergy NOTCH4 intron 23817569 rs3131296 chr6 32172993 C T 1.90E-17 Systemic lupus erythematosus NOTCH4 intron 24871463 rs3131296 chr6 32172993 C T 5.53E-85 Type 1 diabetes NOTCH4 intron pha002862 rs3131296 chr6 32172993 C T 1.09E-08 Systemic lupus erythematosus NOTCH4 intron pha002867 rs3130292 chr6 32176208 G C 9.10E-08 Age-related macular degeneration NOTCH4 intron pha002869 rs3130292 chr6 32176208 G C 4.00E-05 Age-related macular degeneration NOTCH4 intron pha002890 rs3132947 chr6 32176782 G T 6.82E-13 Rheumatoid arthritis NOTCH4 intron 21156761 rs9267833 chr6 32177900 T C 2.33E-04 Lung function (forced vital capacity) NOTCH4 intron 24023788 rs9267833 chr6 32177900 T C 6.10E-04 Systemic lupus erythematosus NOTCH4 intron 24871463 rs2854047 chr6 32179432 G T 1.59E-06 Pulmonary function NOTCH4 intron 20010835 rs2854047 chr6 32179432 G T 2.34E-36 Rheumatoid arthritis NOTCH4 intron 21156761 rs3132956 chr6 32179438 G A 2.18E-10 Rheumatoid arthritis NOTCH4 intron 21156761 rs3132956 chr6 32179438 G A 4.21E-04 Self-reported allergy NOTCH4 intron 23817569 rs3132956 chr6 32179438 G A 9.62E-05 Lupus nephritis in systemic lupus erythematosus NOTCH4 intron 24925725 rs2555469 chr6 32179494 C G 1.59E-06 Pulmonary function NOTCH4 intron 20010835 rs2555469 chr6 32179494 C G 2.34E-36 Rheumatoid arthritis NOTCH4 intron 21156761 rs2071286 chr6 32179896 C T 9.67E-04 Type 2 diabetes NOTCH4 intron 17463246 rs2071286 chr6 32179896 C T 4.79E-06 Multiple complex diseases NOTCH4 intron 17554300 rs2071286 chr6 32179896 C T 5.05E-06 Rheumatoid arthritis NOTCH4 intron 17804836 rs2071286 chr6 32179896 C T 1.67E-10 Systemic sclerosis NOTCH4 intron 20383147 rs2071286 chr6 32179896 C T 3.25E-04 Schizophrenia NOTCH4 intron 20832056 rs2071286 chr6 32179896 C T 5.21E-08 Pemphigus vulgaris NOTCH4 intron 22437316 rs2269418 chr6 32180120 T G 4.43E-04 Substance dependence NOTCH4 intron 21818250 rs3131294 chr6 32180146 A G 6.69E-04 Type 2 diabetes NOTCH4 intron 17463246 rs3131294 chr6 32180146 A G 1.75E-88 Multiple complex diseases NOTCH4 intron 17554300 rs3131294 chr6 32180146 A G 4.04E-32 Multiple sclerosis NOTCH4 intron 17660530 rs2071285 chr6 32180431 A T 1.65E-06 Pulmonary function NOTCH4 intron 20010835 rs2071285 chr6 32180431 A T 1.45E-35 Rheumatoid arthritis NOTCH4 intron 21156761 rs206016 chr6 32181182 G A 7.73E-05 Pulmonary function NOTCH4 intron 20010835 rs206016 chr6 32181182 G A 2.83E-12 Rheumatoid arthritis NOTCH4 intron 21156761 rs206015 chr6 32182759 G A 4.27E-12 Multiple complex diseases NOTCH4 intron 17554300 rs206015 chr6 32182759 G A 6.10E-06 Gallstones NOTCH4 intron 17632509 rs206015 chr6 32182759 G A 3.78E-09 Type 1 diabetes NOTCH4 intron 17632545 rs206015 chr6 32182759 G A 8.34E-09 Rheumatoid arthritis NOTCH4 intron 17804836 rs206015 chr6 32182759 G A 7.94E-13 Rheumatoid arthritis NOTCH4 intron 19503088 rs206015 chr6 32182759 G A 7.62E-05 Type 2 diabetes NOTCH4 intron 20818381 rs206015 chr6 32182759 G A 4.28E-12 Rheumatoid arthritis NOTCH4 intron 21156761 rs206015 chr6 32182759 G A 8.40E-05 Systemic lupus erythematosus NOTCH4 intron 24871463 rs206015 chr6 32182759 G A 7.69E-06 Systemic lupus erythematosus NOTCH4 intron pha002867 rs9267836 chr6 32183965 A G 0.00004805 Sarcoidosis NOTCH4 intron 22952805 rs404860 chr6 32184345 T C 9.16E-12 Type 1 diabetes NOTCH4 intron 17632545 rs404860 chr6 32184345 T C 9.58E-06 Rheumatoid arthritis NOTCH4 intron 19503088 rs404860 chr6 32184345 T C 3.80E-05 Pulmonary function NOTCH4 intron 20010835 rs404860 chr6 32184345 T C 4.00E-23 Asthma NOTCH4 intron 21804548 rs404860 chr6 32184345 T C 9.05E-06 Hodgkin's lymphoma NOTCH4 intron 24149102 rs384247 chr6 32184574 G A 3.57E-05 Pulmonary function NOTCH4 intron 20010835 rs3134798 chr6 32184705 G A 1.95E-04 Response to cytadine analogues (cytosine arabinoside) NOTCH4 intron 24483146 rs2854050 chr6 32185605 G A 2.87E-06 Pulmonary function NOTCH4 intron 20010835 rs2854050 chr6 32185605 G A 9.02E-36 Rheumatoid arthritis NOTCH4 intron 21156761 rs2854050 chr6 32185605 G A 2.76E-05 Hepatitis B NOTCH4 intron 21750111 rs8192591 chr6 32185796 C T 3.16E-12 Type 1 diabetes NOTCH4 missense 17632545 rs8192591 chr6 32185796 C T 5.29E-06 AIDS progression NOTCH4 missense 19115949 rs8192591 chr6 32185796 C T 9.02E-09 HIV-1 control NOTCH4 missense 20041166 rs8192591 chr6 32185796 C T 3.40E-24 Psoriasis NOTCH4 missense pha002855 rs431541 chr6 32186193 T C 4.15E-05 Pulmonary function NOTCH4 intron 20010835 rs438475 chr6 32186245 G A 9.53E-10 Multiple complex diseases NOTCH4 intron 17554300 rs438475 chr6 32186245 G A 1.13E-09 Multiple sclerosis NOTCH4 intron 17660530 rs438475 chr6 32186245 G A 2.29E-05 Pulmonary function NOTCH4 intron 20010835 rs379464 chr6 32186348 C T 6.37E-07 Multiple complex diseases NOTCH4 intron 17554300 rs379464 chr6 32186348 C T 1.14E-09 Rheumatoid arthritis NOTCH4 intron 21156761 rs2256594 chr6 32186872 A G 5.91E-13 Type 1 diabetes NOTCH4 intron 17632545 rs2256594 chr6 32186872 A G 4.38E-05 Pulmonary function NOTCH4 intron 20010835 rs2256594 chr6 32186872 A G 6.10E-04 Crohn's disease NOTCH4 intron 23266558 rs2256594 chr6 32186872 A G 1.25E-05 Hodgkin's lymphoma NOTCH4 intron 24149102 rs394657 chr6 32187023 A G 8.07E-08 Rheumatoid arthritis NOTCH4 intron 19503088 rs394657 chr6 32187023 A G 5.10E-06 Age-related macular degeneration NOTCH4 intron 22694956 rs394657 chr6 32187023 A G 1.53E-06 Age-related macular degeneration NOTCH4 intron pha002869 rs394657 chr6 32187023 A G 1.04E-05 Age-related macular degeneration NOTCH4 intron pha002890 rs8192590 chr6 32187783 C G 1.66E-34 Narcolepsy NOTCH4 intron 19629137 rs422951 chr6 32188383 T C 2.14E-12 Rheumatoid arthritis NOTCH4 missense 19503088 rs422951 chr6 32188383 T C 4.77E-04 Coronary heart disease NOTCH4 missense 21971053 rs422951 chr6 32188383 T C 2.00E-07 Age-related macular degeneration NOTCH4 missense 22694956 rs422951 chr6 32188383 T C 3.28E-07 Age-related macular degeneration NOTCH4 missense pha002869 rs422951 chr6 32188383 T C 2.31E-06 Age-related macular degeneration NOTCH4 missense pha002890 rs8192585 chr6 32188823 G A 6.12E-04 Crohn's disease NOTCH4 missense 23266558 rs415929 chr6 32189032 T C 6.73E-09 Multiple complex diseases NOTCH4 cds-synon 17554300 rs415929 chr6 32189032 T C 2.30E-10 Type 1 diabetes NOTCH4 cds-synon 17632545 rs415929 chr6 32189032 T C 6.91E-05 Multiple sclerosis NOTCH4 cds-synon 17660530 rs415929 chr6 32189032 T C 1.91E-11 Narcolepsy NOTCH4 cds-synon 19629137 rs415929 chr6 32189032 T C 3.18E-06 Non-obstructive azoospermia NOTCH4 cds-synon 22541561 rs8192584 chr6 32189192 G A 9.96E-05 Age-related macular degeneration NOTCH4 intron pha002890 rs715299 chr6 32189841 T G 6.51E-10 Sarcoidosis NOTCH4 intron 22952805 rs3132946 chr6 32190028 A G 2.31E-18 Type 1 diabetes NOTCH4 intron 17632545 rs3132946 chr6 32190028 A G 1.34E-11 Rheumatoid arthritis NOTCH4 intron 17804836 rs3132946 chr6 32190028 A G 8.93E-18 Rheumatoid arthritis NOTCH4 intron 19503088 rs3132946 chr6 32190028 A G 6.73E-11 Multiple sclerosis NOTCH4 intron 20598377 rs3132946 chr6 32190028 A G 2.58E-05 Interstitial lung disease NOTCH4 intron 23583980 rs3132946 chr6 32190028 A G 8.00E-06 Interstitial lung disease NOTCH4 intron 23583980 rs3132946 chr6 32190028 A G 4.92E-126 Type 1 diabetes NOTCH4 intron pha002862 rs443198 chr6 32190406 A G 6.82E-12 Systemic sclerosis NOTCH4 cds-synon 20383147 rs443198 chr6 32190406 A G 9.00E-21 Systemic sclerosis NOTCH4 cds-synon 21779181 rs443198 chr6 32190406 A G 1.08E-08 Pemphigus vulgaris NOTCH4 cds-synon 22437316 rs443198 chr6 32190406 A G 1.53E-11 Psoriasis NOTCH4 cds-synon pha002855 rs3134931 chr6 32190620 T C 4.68E-06 Multiple sclerosis NOTCH4 intron 20598377 rs3134931 chr6 32190620 T C 6.82E-05 Pemphigus vulgaris NOTCH4 intron 22437316 rs3134931 chr6 32190620 T C 1.00E-08 Circulating myeloperoxidase levels (serum) NOTCH4 intron 23620142 rs3134931 chr6 32190620 T C 5.00E-05 Systemic lupus erythematosus NOTCH4 intron 24871463 rs3134931 chr6 32190620 T C 5.63E-05 Triglycerides NOTCH4 intron pha003080 rs434841 chr6 32191041 G A 1.00E-16 Type 1 diabetes NOTCH4 intron 17632545 rs434841 chr6 32191041 G A 6.88E-05 Pemphigus vulgaris NOTCH4 intron 22437316 rs434841 chr6 32191041 G A 3.80E-96 Type 1 diabetes NOTCH4 intron pha002862 rs3830041 chr6 32191339 C T 1.15E-10 Type 1 diabetes NOTCH4 intron 17632545 rs3830041 chr6 32191339 C T 1.52E-11 Rheumatoid arthritis NOTCH4 intron 17804836 rs3830041 chr6 32191339 C T 1.11E-18 Rheumatoid arthritis NOTCH4 intron 19503088 rs3830041 chr6 32191339 C T 3.30E-06 HIV-1 control NOTCH4 intron 20041166 rs3830041 chr6 32191339 C T 4.26E-05 Crohn's disease NOTCH4 intron 23266558 rs3134929 chr6 32192107 C G 4.43E-06 Venous thromboembolism NOTCH4 nearGene-5 22672568 rs3134929 chr6 32192107 C G 7.06E-06 Atopic dermatitis NOTCH4 nearGene-5 23886662 rs3096702 chr6 32192331 A G 5.00E-09 Prostate cancer NOTCH4 nearGene-5 23535732 rs3096702 chr6 32192331 A G 2.98E-04 Response to cytadine analogues (cytosine arabinoside) NOTCH4 nearGene-5 24483146 rs391755 chr6 32192436 A C,G,T 4.37E-11 Multiple complex diseases NOTCH4 nearGene-5 17554300 rs391755 chr6 32192436 A C,G,T 5.72E-11 Rheumatoid arthritis NOTCH4 nearGene-5 21156761 rs391755 chr6 32192436 A C,G,T 1.87E-08 Self-reported allergy NOTCH4 nearGene-5 23817569 rs2267644 chr6 32192560 G A 4.33E-15 Type 1 diabetes NOTCH4 nearGene-5 17632545 rs2267644 chr6 32192560 G A 8.71E-13 Rheumatoid arthritis NOTCH4 nearGene-5 17804836 rs2267644 chr6 32192560 G A 2.56E-04 Crohn's disease NOTCH4 nearGene-5 23266558 rs397081 chr6 32192617 T C 4.67E-08 Rheumatoid arthritis NOTCH4 nearGene-5 21156761 rs397081 chr6 32192617 T C 4.98E-07 Self-reported allergy NOTCH4 nearGene-5 23817569 rs2395106 chr6 32193220 A G 4.00E-04 Self-reported allergy NOTCH4 nearGene-5 23817569 rs479536 chr6 32193678 G A 1.56E-10 Type 1 diabetes NOTCH4 nearGene-5 17632545 rs479536 chr6 32193678 G A 2.25E-15 Rheumatoid arthritis NOTCH4 nearGene-5 17804836 rs479536 chr6 32193678 G A 3.76E-05 Lung adenocarcinoma NOTCH4 nearGene-5 19836008 rs479536 chr6 32193678 G A 1.50E-08 Systemic sclerosis NOTCH4 nearGene-5 20383147 rs479536 chr6 32193678 G A 1.45E-05 Self-reported allergy NOTCH4 nearGene-5 23817569 rs479536 chr6 32193678 G A 1.55E-06 Hodgkin's lymphoma NOTCH4 nearGene-5 24149102 rs9267845 chr6 32193698 A T 3.03E-04 Self-reported allergy NOTCH4 nearGene-5 23817569 rs499691 chr6 32194339 C T 7.48E-07 Self-reported allergy / / 23817569 rs1475961 chr6 32194609 A G 3.12E-04 Self-reported allergy / / 23817569 rs3096690 chr6 32194630 G C 1.08E-11 Rheumatoid arthritis / / 21156761 rs3096691 chr6 32194854 G A 3.12E-04 Self-reported allergy / / 23817569 rs3096691 chr6 32194854 G A 4.51E-05 Eosinophil counts / / pha003088 rs526945 chr6 32194982 T A 1.40E-05 Self-reported allergy / / 23817569 rs482759 chr6 32195017 A G 7.92E-10 Pemphigus vulgaris / / 22437316 rs482759 chr6 32195017 A G 3.00E-04 Systemic lupus erythematosus / / 24871463 rs532385 chr6 32195359 G A 4.90E-05 AIDS progression / / 19115949 rs428947 chr6 32195786 G A 2.34E-05 Self-reported allergy / / 23817569 rs399950 chr6 32196940 C T 4.29E-05 Self-reported allergy / / 23817569 rs495089 chr6 32197463 A G 4.29E-05 Self-reported allergy / / 23817569 rs9267866 chr6 32198329 C T 0.00006583 Sarcoidosis / / 22952805 rs404890 chr6 32198867 C A 1.66E-24 Rheumatoid arthritis / / 17804836 rs404890 chr6 32198867 C A 2.68E-39 Rheumatoid arthritis / / 19503088 rs404890 chr6 32198867 C A 3.69E-08 Multiple sclerosis / / 20598377 rs404890 chr6 32198867 C A 2.17E-22 Rheumatoid arthritis / / 21156761 rs2849015 chr6 32198936 G A 3.71E-25 Rheumatoid arthritis / / 17804836 rs2849015 chr6 32198936 G A 5.11E-39 Rheumatoid arthritis / / 19503088 rs2849015 chr6 32198936 G A 5.58E-08 Multiple sclerosis / / 20598377 rs2849015 chr6 32198936 G A 6.57E-23 Rheumatoid arthritis / / 21156761 rs6457499 chr6 32198948 T C 4.08E-23 Rheumatoid arthritis / / 21156761 rs3130297 chr6 32198981 C T 9.31E-12 Rheumatoid arthritis / / 21156761 rs377763 chr6 32199144 C A 3.14E-80 Multiple complex diseases / / 17554300 rs377763 chr6 32199144 C A 1.36E-25 Type 1 diabetes / / 17632545 rs377763 chr6 32199144 C A 1.55E-12 Rheumatoid arthritis / / 21156761 rs377763 chr6 32199144 C A 9.18E-04 Crohn's disease / / 23266558 rs377763 chr6 32199144 C A 9.90E-05 Diabetic nephropathy / / pha002866 rs9267873 chr6 32199352 C T 1.04E-29 Rheumatoid arthritis / / 17804836 rs9267873 chr6 32199352 C T 1.15E-59 Rheumatoid arthritis / / 19503088 rs9267873 chr6 32199352 C T 2.32E-07 Multiple sclerosis / / 20598377 rs3134926 chr6 32200147 C G 4.10E-34 Multiple complex diseases / / 17554300 rs3134926 chr6 32200147 C G 1.16E-09 Multiple sclerosis / / 17660530 rs3134926 chr6 32200147 C G 7.26E-12 Narcolepsy / / 19629137 rs3134926 chr6 32200147 C G 1.43E-23 Rheumatoid arthritis / / 21156761 rs6936346 chr6 32200754 C T 0.0002 Migraine / / 22678113 rs9501398 chr6 32202597 G T 1.40E-08 HIV-1 control / / 21051598 rs508445 chr6 32203347 G A 1.14E-08 Rheumatoid arthritis / / 21156761 rs508445 chr6 32203347 G A 2.07E-07 Self-reported allergy / / 23817569 rs3130299 chr6 32203537 A G 1.00E-16 Type 1 diabetes / / 17632545 rs3130299 chr6 32203537 A G 2.74E-13 Rheumatoid arthritis / / 17804836 rs3130299 chr6 32203537 A G 7.79E-31 Rheumatoid arthritis / / 19503088 rs3130299 chr6 32203537 A G 5.39E-07 Multiple sclerosis / / 20598377 rs3130299 chr6 32203537 A G 3.10E-07 Systemic lupus erythematosus / / 24871463 rs3130299 chr6 32203537 A G 1.19E-71 Type 1 diabetes / / pha002862 rs549182 chr6 32205045 G A 7.61E-14 Type 1 diabetes / / 17632545 rs549182 chr6 32205045 G A 3.28E-04 Taste perception / / 22132133 rs549182 chr6 32205045 G A 6.43E-04 Crohn's disease / / 23266558 rs549182 chr6 32205045 G A 2.72E-04 Lung function (forced vital capacity) / / 24023788 rs549182 chr6 32205045 G A 8.00E-10 Ulcerative colitis / / 24837172 rs9267911 chr6 32205110 T C 4.95E-34 Rheumatoid arthritis / / 21156761 rs9267911 chr6 32205110 T C 3.00E-07 Crohn's disease / / 23266558 rs6901158 chr6 32205942 C T 6.55E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6901158 chr6 32205942 C T 6.12E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs6906128 chr6 32206304 A C 1.41E-23 Rheumatoid arthritis / / 21156761 rs3130304 chr6 32207181 G A 5.68E-13 Rheumatoid arthritis / / 21156761 rs416352 chr6 32207393 G T 7.91E-31 Rheumatoid arthritis / / 21156761 rs4947337 chr6 32207512 T C,G 4.20E-11 Rheumatoid arthritis / / 21156761 rs4947337 chr6 32207512 T C,G 8.46E-05 Self-reported allergy / / 23817569 rs424232 chr6 32208324 C T 1.95E-54 Multiple complex diseases / / 17554300 rs424232 chr6 32208324 C T 1.52E-22 Rheumatoid arthritis / / 21156761 rs424232 chr6 32208324 C T 9.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs424232 chr6 32208324 C T 8.57E-05 Sudden cardiac arrest / / 21658281 rs424232 chr6 32208324 C T 5.00E-21 Celiac disease / / 23936387 rs382259 chr6 32209027 T C 1.06E-17 Rheumatoid arthritis / / 17804836 rs382259 chr6 32209027 T C 1.99E-26 Rheumatoid arthritis / / 21156761 rs382259 chr6 32209027 T C 1.83E-04 Crohn's disease / / 23266558 rs382259 chr6 32209027 T C 6.80E-06 Systemic lupus erythematosus / / 24871463 rs507778 chr6 32209861 C T 2.19E-13 Type 1 diabetes / / 17632545 rs507778 chr6 32209861 C T 1.29E-33 Rheumatoid arthritis / / 21156761 rs371156 chr6 32209963 T C 3.02E-26 Rheumatoid arthritis / / 21156761 rs419132 chr6 32210799 A G 7.15E-26 Rheumatoid arthritis / / 21156761 rs412657 chr6 32211085 T G 4.68E-10 Type 1 diabetes / / 17632545 rs412657 chr6 32211085 T G 2.34E-40 Rheumatoid arthritis / / 21156761 rs412657 chr6 32211085 T G 4.33E-07 Sarcoidosis / / 22952805 rs9267947 chr6 32211218 A G 3.77E-15 Hodgkin's lymphoma / / 24149102 rs411326 chr6 32211317 C T 9.00E-05 Systemic lupus erythematosus / / 24871463 rs9267948 chr6 32212233 G A 5.68E-06 Narcolepsy / / 20711174 rs9267948 chr6 32212233 G A 7.83E-36 Rheumatoid arthritis / / 21156761 rs427037 chr6 32212264 A G 4.04E-10 Multiple complex diseases / / 17554300 rs427037 chr6 32212264 A G 1.07E-17 Rheumatoid arthritis / / 21156761 rs9267951 chr6 32212655 C T 9.08E-07 Sarcoidosis / / 22952805 rs17576984 chr6 32212985 C T 2.55E-10 Rheumatoid arthritis / / 21156761 rs9267954 chr6 32213052 A T 1.64E-63 Multiple complex diseases / / 17554300 rs9267954 chr6 32213052 A T 9.16E-08 Multiple sclerosis / / 17660530 rs9267954 chr6 32213052 A T 6.39E-41 Narcolepsy / / 19629137 rs9267954 chr6 32213052 A T 9.93E-49 Rheumatoid arthritis / / 21156761 rs454748 chr6 32213210 G A 1.31E-04 Type 2 diabetes / / 17463246 rs454748 chr6 32213210 G A 2.45E-19 Rheumatoid arthritis / / 21156761 rs9267956 chr6 32213638 A G 4.82E-05 Type 2 diabetes / / 17463246 rs9267956 chr6 32213638 A G 8.15E-29 Rheumatoid arthritis / / 21156761 rs440169 chr6 32213788 G A 2.13E-20 Rheumatoid arthritis / / 21156761 rs453275 chr6 32213810 G C 2.12E-20 Rheumatoid arthritis / / 21156761 rs412492 chr6 32213831 A T 2.93E-20 Rheumatoid arthritis / / 21156761 rs9267958 chr6 32214616 A C 2.31E-20 Rheumatoid arthritis / / 21156761 rs563412 chr6 32215063 G A 2.32E-20 Rheumatoid arthritis / / 21156761 rs405875 chr6 32215188 T C 2.34E-20 Rheumatoid arthritis / / 21156761 rs405875 chr6 32215188 T C 1.40E-07 Alopecia areata / / 22027810 rs405875 chr6 32215188 T C 4.73E-05 Heart Rate / / pha003051 rs410283 chr6 32215198 G T 2.34E-20 Rheumatoid arthritis / / 21156761 rs2515892 chr6 32215252 G T 2.40E-20 Rheumatoid arthritis / / 21156761 rs3130309 chr6 32215472 A G 1.91E-19 Rheumatoid arthritis / / 21156761 rs3130309 chr6 32215472 A G 0.00001224 Sarcoidosis / / 22952805 rs3130309 chr6 32215472 A G 4.83E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1559876 chr6 32215769 G C 4.82E-05 Type 2 diabetes / / 17463246 rs1559876 chr6 32215769 G C 1.22E-30 Rheumatoid arthritis / / 21156761 rs2894239 chr6 32215796 T G 7.66E-20 Rheumatoid arthritis / / 21156761 rs2395111 chr6 32215964 T C 7.51E-20 Rheumatoid arthritis / / 21156761 rs6914780 chr6 32216529 T A 4.28E-11 Rheumatoid arthritis / / 21156761 rs3115576 chr6 32216850 T A 1.14E-04 Type 2 diabetes / / 17463246 rs3115576 chr6 32216850 T A 7.65E-11 Multiple complex diseases / / 17554300 rs3115576 chr6 32216850 T A 2.29E-14 Multiple sclerosis / / 17660530 rs3115576 chr6 32216850 T A 5.47E-15 Narcolepsy / / 19629137 rs3115576 chr6 32216850 T A 8.70E-20 Rheumatoid arthritis / / 21156761 rs3115575 chr6 32216891 T G 1.64E-19 Rheumatoid arthritis / / 21156761 rs3130310 chr6 32216911 C G 7.61E-20 Rheumatoid arthritis / / 21156761 rs6457508 chr6 32216963 C T 7.61E-20 Rheumatoid arthritis / / 21156761 rs6457509 chr6 32217018 G C 7.61E-20 Rheumatoid arthritis / / 21156761 rs6457510 chr6 32217046 C T 7.61E-20 Rheumatoid arthritis / / 21156761 rs6936204 chr6 32217092 T C 4.66E-13 Multiple complex diseases / / 17554300 rs6936204 chr6 32217092 T C 2.98E-22 Multiple sclerosis / / 17660530 rs6936204 chr6 32217092 T C 2.94E-31 Rheumatoid arthritis / / 21156761 rs6936204 chr6 32217092 T C 2.92E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9267970 chr6 32217160 A C,G 7.61E-20 Rheumatoid arthritis / / 21156761 rs9267971 chr6 32217185 T C 8.53E-05 Type 2 diabetes / / 17463246 rs9267971 chr6 32217185 T C 1.20E-10 Multiple complex diseases / / 17554300 rs9267971 chr6 32217185 T C 6.12E-16 Multiple sclerosis / / 17660530 rs9267971 chr6 32217185 T C 1.87E-14 Narcolepsy / / 19629137 rs9267971 chr6 32217185 T C 1.60E-19 Rheumatoid arthritis / / 21156761 rs9267972 chr6 32217232 A G 2.28E-16 Rheumatoid arthritis / / 21156761 rs9267972 chr6 32217232 A G 0.000009395 Sarcoidosis / / 22952805 rs9267972 chr6 32217232 A G 2.00E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs3130311 chr6 32217367 A G 7.26E-05 Type 2 diabetes / / 17463246 rs3130311 chr6 32217367 A G 1.14E-10 Multiple complex diseases / / 17554300 rs3130311 chr6 32217367 A G 5.76E-15 Multiple sclerosis / / 17660530 rs3130311 chr6 32217367 A G 3.11E-14 Narcolepsy / / 19629137 rs3130311 chr6 32217367 A G 1.20E-19 Rheumatoid arthritis / / 21156761 rs2894240 chr6 32217846 G A 7.00E-20 Rheumatoid arthritis / / 21156761 rs3115573 chr6 32218843 A G 2.19E-30 Rheumatoid arthritis / / 17804836 rs3115573 chr6 32218843 A G 5.89E-42 Rheumatoid arthritis / / 19503088 rs3115573 chr6 32218843 A G 1.00E-09 Nephropathy / / 20595679 rs3115573 chr6 32218843 A G 5.17E-05 Multiple sclerosis / / 20598377 rs3115573 chr6 32218843 A G 7.00E-20 Rheumatoid arthritis / / 21156761 rs3115573 chr6 32218843 A G 8.06E-06 Pemphigus vulgaris / / 22437316 rs3115573 chr6 32218843 A G 1.50E-04 Systemic lupus erythematosus / / 24871463 rs3115573 chr6 32218843 A G 3.84E-05 Heart Rate / / pha003051 rs9296015 chr6 32218989 G A 8.28E-10 Type 1 diabetes / / 17632545 rs9296015 chr6 32218989 G A 2.00E-38 Rheumatoid arthritis / / 21505073 rs9296015 chr6 32218989 G A 1.00E-08 Systemic sclerosis / / 21779181 rs9296015 chr6 32218989 G A 0.00011 Prostate cancer / / 23555315 rs9296015 chr6 32218989 G A 1.04E-07 Hodgkin's lymphoma / / 24149102 rs9296015 chr6 32218989 G A 4.30E-05 Systemic lupus erythematosus / / 24871463 rs6916062 chr6 32219041 C T 2.40E-13 HIV-1 control / / 21051598 rs6916062 chr6 32219041 C T 2.52E-22 Psoriasis / / pha002855 rs9267989 chr6 32219320 G A,T 3.67E-09 Sarcoidosis / / 22952805 rs4959089 chr6 32219725 A G 1.75E-10 Type 1 diabetes / / 17632545 rs4959089 chr6 32219725 A G 0.00011 Prostate cancer / / 23555315 rs4959089 chr6 32219725 A G 1.12E-07 Hodgkin's lymphoma / / 24149102 rs4959089 chr6 32219725 A G 6.30E-05 Systemic lupus erythematosus / / 24871463 rs4959090 chr6 32219962 G A 5.86E-08 Multiple complex diseases / / 17554300 rs9267992 chr6 32220397 G A 7.57E-20 Type 1 diabetes / / 17632545 rs9267992 chr6 32220397 G A 1.20E-15 Rheumatoid arthritis / / 17804836 rs9267992 chr6 32220397 G A 2.35E-21 Rheumatoid arthritis / / 19503088 rs9267992 chr6 32220397 G A 1.18E-14 Multiple sclerosis / / 20598377 rs9267992 chr6 32220397 G A 3.38E-05 Interstitial lung disease / / 23583980 rs9267992 chr6 32220397 G A 2.98E-161 Type 1 diabetes / / pha002862 rs3115572 chr6 32220484 C G 3.90E-19 Rheumatoid arthritis / / 21156761 rs3115572 chr6 32220484 C G 9.46E-04 Coronary heart disease / / 21606135 rs3115572 chr6 32220484 C G 0.00001791 Sarcoidosis / / 22952805 rs3130315 chr6 32220685 G A 1.91E-30 Rheumatoid arthritis / / 17804836 rs3130315 chr6 32220685 G A 4.02E-42 Rheumatoid arthritis / / 19503088 rs3130315 chr6 32220685 G A 5.17E-05 Multiple sclerosis / / 20598377 rs3130315 chr6 32220685 G A 5.05E-20 Rheumatoid arthritis / / 21156761 rs3130315 chr6 32220685 G A 8.06E-06 Pemphigus vulgaris / / 22437316 rs3130315 chr6 32220685 G A 1.50E-04 Systemic lupus erythematosus / / 24871463 rs3130315 chr6 32220685 G A 3.84E-05 Heart Rate / / pha003051 rs3115571 chr6 32220918 A G 5.58E-19 Rheumatoid arthritis / / 21156761 rs3115571 chr6 32220918 A G 0.000009395 Sarcoidosis / / 22952805 rs3115571 chr6 32220918 A G 3.93E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs3130316 chr6 32221228 T C 9.86E-19 Rheumatoid arthritis / / 21156761 rs3130316 chr6 32221228 T C 0.000009395 Sarcoidosis / / 22952805 rs3130316 chr6 32221228 T C 3.93E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9267995 chr6 32221552 G A 0.000007151 Sarcoidosis / / 22952805 rs41264786 chr6 32221645 C T 0.000000532 Sarcoidosis / / 22952805 rs3096700 chr6 32221782 A C 1.08E-18 Rheumatoid arthritis / / 21156761 rs3096700 chr6 32221782 A C 2.05E-04 Coronary heart disease / / 21971053 rs3096700 chr6 32221782 A C 5.21E-06 Alopecia areata / / 22027810 rs3096700 chr6 32221782 A C 8.57E-05 Kawasaki disease / / 22081228 rs3096700 chr6 32221782 A C 0.000009395 Sarcoidosis / / 22952805 rs3096700 chr6 32221782 A C 4.01E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs3130320 chr6 32223258 T C 2.80E-45 Rheumatoid arthritis / / 17804836 rs3130320 chr6 32223258 T C 1.39E-56 Rheumatoid arthritis / / 19503088 rs3130320 chr6 32223258 T C 4.22E-08 Multiple sclerosis / / 20598377 rs3130320 chr6 32223258 T C 2.55E-29 Rheumatoid arthritis / / 21156761 rs3130320 chr6 32223258 T C 3.00E-06 Systemic lupus erythematosus / / 21408207 rs3130320 chr6 32223258 T C 8.98E-05 Coronary heart disease / / 21971053 rs3130320 chr6 32223258 T C 3.41E-07 Alopecia areata / / 22027810 rs3130320 chr6 32223258 T C 8.80E-14 Systemic lupus erythematosus / / 24871463 rs3130320 chr6 32223258 T C 9.30E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9268000 chr6 32223531 A C 2.05E-44 Rheumatoid arthritis / / 21156761 rs6457515 chr6 32223785 G C 8.87E-25 Rheumatoid arthritis / / 21156761 rs6457516 chr6 32223830 A T 8.87E-25 Rheumatoid arthritis / / 21156761 rs3130322 chr6 32223925 T C 8.87E-25 Rheumatoid arthritis / / 21156761 rs3130322 chr6 32223925 T C 4.39E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs3132967 chr6 32223947 T A 8.87E-25 Rheumatoid arthritis / / 21156761 rs3115569 chr6 32224139 G A 8.87E-25 Rheumatoid arthritis / / 21156761 rs3115569 chr6 32224139 G A 4.40E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs3115568 chr6 32224319 G T 8.87E-25 Rheumatoid arthritis / / 21156761 rs3115568 chr6 32224319 G T 4.42E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs28895018 chr6 32224378 T C 7.37E-05 HIV-1 control / / 20041166 rs28895018 chr6 32224378 T C 3.80E-11 HIV-1 control / / 21051598 rs9268005 chr6 32224388 C A 8.73E-26 Type 1 diabetes / / 17632545 rs9268005 chr6 32224388 C A 6.93E-161 Type 1 diabetes / / pha002862 rs6908927 chr6 32224489 G A 8.87E-25 Rheumatoid arthritis / / 21156761 rs6908927 chr6 32224489 G A 4.40E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs78885616 chr6 32226992 G A 0.000001829 Sarcoidosis / / 22952805 rs3132972 chr6 32230354 A G 0.000002581 Sarcoidosis / / 22952805 rs1150762 chr6 32230665 G A 4.61E-05 Self-reported allergy / / 23817569 rs3115563 chr6 32233638 T A 2.65E-24 Rheumatoid arthritis / / 21156761 rs3115562 chr6 32233814 C T 4.48E-05 Self-reported allergy / / 23817569 rs7767325 chr6 32233886 G C 5.39E-25 Rheumatoid arthritis / / 21156761 rs3132928 chr6 32234015 G A 5.39E-25 Rheumatoid arthritis / / 21156761 rs3132928 chr6 32234015 G A 7.99E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9268082 chr6 32234953 G T 2.73E-44 Rheumatoid arthritis / / 21156761 rs9268082 chr6 32234953 G T 2.20E-07 Red blood cell traits / / 23222517 rs2114436 chr6 32235384 C G 4.61E-05 Self-reported allergy / / 23817569 rs17201917 chr6 32235757 A G 0.000001432 Sarcoidosis / / 22952805 rs3132931 chr6 32235895 T G 1.12E-24 Rheumatoid arthritis / / 21156761 rs3132931 chr6 32235895 T G 5.73E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs3132933 chr6 32236054 G T 3.15E-05 Self-reported allergy / / 23817569 rs3115560 chr6 32236142 G A 6.23E-13 Multiple complex diseases / / 17554300 rs3115560 chr6 32236142 G A 1.12E-24 Rheumatoid arthritis / / 21156761 rs3115560 chr6 32236142 G A 5.75E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs3096673 chr6 32238013 T C 1.12E-24 Rheumatoid arthritis / / 21156761 rs3096673 chr6 32238013 T C 5.76E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs28366168 chr6 32238427 A G 0.00000154 Sarcoidosis / / 22952805 rs28366170 chr6 32238510 G A 0.000003369 Sarcoidosis / / 22952805 rs3132945 chr6 32238680 A G 1.12E-24 Rheumatoid arthritis / / 21156761 rs3132945 chr6 32238680 A G 5.76E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs4713515 chr6 32240875 A G 6.17E-08 Sarcoidosis / / 22952805 rs28752481 chr6 32242894 C G 0.000001384 Sarcoidosis / / 22952805 rs1559873 chr6 32243129 T C 9.73E-11 Multiple complex diseases / / 17554300 rs1559873 chr6 32243129 T C 1.12E-24 Rheumatoid arthritis / / 21156761 rs1559873 chr6 32243129 T C 5.29E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1559874 chr6 32243155 G A 3.03E-12 Multiple complex diseases / / 17554300 rs1559874 chr6 32243155 G A 1.12E-24 Rheumatoid arthritis / / 21156761 rs1559874 chr6 32243155 G A 5.22E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs28752482 chr6 32244093 T C 0.000001384 Sarcoidosis / / 22952805 rs3130340 chr6 32244627 T C 2.46E-08 Type 1 diabetes / / 17632545 rs3130340 chr6 32244627 T C 1.75E-26 Rheumatoid arthritis / / 17804836 rs3130340 chr6 32244627 T C 1.00E-07 Bone mineral density (spine) / / 18445777 rs3130340 chr6 32244627 T C 8.26E-30 Rheumatoid arthritis / / 19503088 rs3130340 chr6 32244627 T C 1.12E-24 Rheumatoid arthritis / / 21156761 rs3130340 chr6 32244627 T C 5.51E-05 Coronary heart disease / / 21971053 rs3130340 chr6 32244627 T C 7.20E-10 Systemic lupus erythematosus / / 24871463 rs3130340 chr6 32244627 T C 5.15E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9268103 chr6 32245370 A G 1.13E-05 Parkinson's disease (motor and cognition) / / 22658654 rs9268103 chr6 32245370 A G 1.13E-05 Immune response to anthrax vaccine / / 22658931 rs3115553 chr6 32245827 C T 2.68E-08 Type 1 diabetes / / 17632545 rs3115553 chr6 32245827 C T 1.93E-26 Rheumatoid arthritis / / 17804836 rs3115553 chr6 32245827 C T 9.35E-30 Rheumatoid arthritis / / 19503088 rs3115553 chr6 32245827 C T 1.12E-24 Rheumatoid arthritis / / 21156761 rs3115553 chr6 32245827 C T 4.24E-05 Coronary heart disease / / 21971053 rs3115553 chr6 32245827 C T 5.84E-09 Alopecia areata / / 22027810 rs3115553 chr6 32245827 C T 8.70E-10 Systemic lupus erythematosus / / 24871463 rs3115553 chr6 32245827 C T 4.91E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs28366171 chr6 32246573 C T 0.000001425 Sarcoidosis / / 22952805 rs28752483 chr6 32250247 A G 0.000002945 Sarcoidosis / / 22952805 rs555826822 chr6 32254654 A G 1.51E-59 Rheumatoid arthritis / / 17804836 rs555826822 chr6 32254654 A G 1.07E-84 Rheumatoid arthritis / / 19503088 rs555826822 chr6 32254654 A G 2.30E-44 Rheumatoid arthritis / / 21156761 rs555826822 chr6 32254654 A G 4.47E-05 Alopecia areata / / 22027810 rs555826822 chr6 32254654 A G 1.44E-07 Red blood cell traits / / 23222517 rs9268142 chr6 32256418 T C 1.12E-24 Rheumatoid arthritis / / 21156761 rs9268142 chr6 32256418 T C 5.19E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9268143 chr6 32256473 A G 1.12E-24 Rheumatoid arthritis / / 21156761 rs9268143 chr6 32256473 A G 5.19E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9268144 chr6 32257199 T C 2.72E-12 Rheumatoid arthritis / / 21156761 rs9268144 chr6 32257199 T C 1.11E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9268145 chr6 32257284 T G 6.95E-93 Rheumatoid arthritis / / 21156761 rs9268145 chr6 32257284 T G 6.30E-10 Sarcoidosis / / 22952805 rs4713518 chr6 32257337 A G 2.73E-44 Rheumatoid arthritis / / 21156761 rs4713518 chr6 32257337 A G 1.45E-07 Red blood cell traits / / 23222517 rs926070 chr6 32257566 G A 7.95E-27 Type 1 diabetes / / 17632545 rs926070 chr6 32257566 G A 8.41E-12 Rheumatoid arthritis / / 17804836 rs926070 chr6 32257566 G A 9.10E-22 Rheumatoid arthritis / / 19503088 rs926070 chr6 32257566 G A 1.13E-07 Multiple sclerosis / / 20598377 rs926070 chr6 32257566 G A 0.00088 Prostate cancer / / 23555315 rs926070 chr6 32257566 G A 4.00E-08 Chronic lymphocytic leukemia / / 24292274 rs926070 chr6 32257566 G A 3.19E-161 Type 1 diabetes / / pha002862 rs9268148 chr6 32259527 G A 3.66E-06 Phospholipid levels (plasma) / / 21829377 rs9268148 chr6 32259527 G A 1.57E-05 Parkinson's disease (motor and cognition) / / 22658654 rs9268148 chr6 32259527 G A 1.57E-05 Immune response to anthrax vaccine / / 22658931 rs17422727 chr6 32259923 C G 0.000002406 Sarcoidosis / / 22952805 rs565448 chr6 32260270 G C 5.98E-05 Self-reported allergy C6orf10 nearGene-3 23817569 rs6935269 chr6 32260350 T C 2.25E-26 Rheumatoid arthritis C6orf10 nearGene-3 17804836 rs6935269 chr6 32260350 T C 2.16E-29 Rheumatoid arthritis C6orf10 nearGene-3 19503088 rs6935269 chr6 32260350 T C 1.43E-24 Rheumatoid arthritis C6orf10 nearGene-3 21156761 rs6935269 chr6 32260350 T C 5.38E-05 Coronary heart disease C6orf10 nearGene-3 21971053 rs6935269 chr6 32260350 T C 5.00E-10 Systemic lupus erythematosus C6orf10 nearGene-3 24871463 rs6935269 chr6 32260350 T C 3.43E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 nearGene-3 24925725 rs6935269 chr6 32260350 T C 1.42E-05 Systemic lupus erythematosus C6orf10 nearGene-3 pha002867 rs482194 chr6 32260559 A G 2.00E-07 Rheumatoid arthritis C6orf10 UTR-3 17159887 rs16870005 chr6 32261153 C T 0.00018 Prostate cancer C6orf10 missense 23555315 rs7775397 chr6 32261252 T G 4.63E-04 Lung function (forced expiratory volume in 1 second) C6orf10 missense 17255346 rs7775397 chr6 32261252 T G 4.98E-20 Type 1 diabetes C6orf10 missense 17632545 rs7775397 chr6 32261252 T G 3.96E-13 Rheumatoid arthritis C6orf10 missense 17804836 rs7775397 chr6 32261252 T G 8.00E-47 Systemic lupus erythematosus C6orf10 missense 18204446 rs7775397 chr6 32261252 T G 7.73E-06 Lung cancer C6orf10 missense 18978787 rs7775397 chr6 32261252 T G 6.00E-06 Lung cancer C6orf10 missense 18978790 rs7775397 chr6 32261252 T G 1.38E-04 Schizophrenia C6orf10 missense 19197363 rs7775397 chr6 32261252 T G 1.61E-13 Rheumatoid arthritis C6orf10 missense 19503088 rs7775397 chr6 32261252 T G 9.94E-08 Lung cancer C6orf10 missense 19654303 rs7775397 chr6 32261252 T G 1.86E-10 Lung adenocarcinoma C6orf10 missense 19836008 rs7775397 chr6 32261252 T G 2.56E-12 Rheumatoid arthritis C6orf10 missense 21156761 rs7775397 chr6 32261252 T G 3.10E-09 Lung cancer C6orf10 missense 22899653 rs7775397 chr6 32261252 T G 2.60E-75 Myasthenia gravis C6orf10 missense 23055271 rs7775397 chr6 32261252 T G 1.80E-17 Systemic lupus erythematosus C6orf10 missense 24871463 rs7775397 chr6 32261252 T G 1.16E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 missense 24925725 rs7775397 chr6 32261252 T G 2.58E-96 Type 1 diabetes C6orf10 missense pha002862 rs3749966 chr6 32261507 T C 1.12E-24 Rheumatoid arthritis C6orf10 missense 21156761 rs3749966 chr6 32261507 T C 4.30E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 missense 24925725 rs560505 chr6 32261771 A G 1.17E-44 Rheumatoid arthritis C6orf10 missense 21156761 rs560505 chr6 32261771 A G 4.15E-07 Red blood cell traits C6orf10 missense 23222517 rs6457535 chr6 32262406 A G 4.50E-06 Phospholipid levels (plasma) C6orf10 intron 21829377 rs6910668 chr6 32263458 T G 2.56E-18 Rheumatoid arthritis C6orf10 intron 21156761 rs9268153 chr6 32264179 C T 2.56E-18 Rheumatoid arthritis C6orf10 intron 21156761 rs17422797 chr6 32265528 C T 2.10E-05 Self-reported allergy C6orf10 intron 23817569 rs518374 chr6 32265710 A C 3.69E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs518374 chr6 32265710 A C 8.94E-08 Red blood cell traits C6orf10 intron 23222517 rs9268154 chr6 32266021 T A 3.54E-06 Phospholipid levels (plasma) C6orf10 intron 21829377 rs28366174 chr6 32266490 T A,C,G 7.81E-05 Systemic sclerosis C6orf10 intron 21750679 rs6906662 chr6 32266506 G A 2.78E-15 Type 1 diabetes C6orf10 intron 17632545 rs6906662 chr6 32266506 G A 1.32E-08 HIV-1 control C6orf10 intron 20041166 rs6906662 chr6 32266506 G A 1.00E-10 HIV-1 control C6orf10 intron 21051598 rs6906662 chr6 32266506 G A 2.10E-11 Rheumatoid arthritis C6orf10 intron 21156761 rs6906662 chr6 32266506 G A 2.11E-14 Psoriasis C6orf10 intron pha002855 rs565571 chr6 32266535 G A 9.60E-45 Rheumatoid arthritis C6orf10 intron 21156761 rs565571 chr6 32266535 G A 8.61E-08 Red blood cell traits C6orf10 intron 23222517 rs7750783 chr6 32268080 C T 2.07E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs7750783 chr6 32268080 C T 3.77E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs537757 chr6 32268501 A T 2.00E-07 Rheumatoid arthritis C6orf10 intron 17159887 rs6909427 chr6 32268701 T G 2.07E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs6909427 chr6 32268701 T G 3.77E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs7775592 chr6 32270283 G A 2.07E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs7775592 chr6 32270283 G A 3.76E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs7775332 chr6 32270363 A T 2.07E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs477005 chr6 32270500 A G 2.00E-07 Rheumatoid arthritis C6orf10 intron 17159887 rs477005 chr6 32270500 A G 2.26E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs477005 chr6 32270500 A G 3.19E-07 Red blood cell traits C6orf10 intron 23222517 rs9268163 chr6 32270875 C T 2.07E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs9268163 chr6 32270875 C T 3.57E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs9268164 chr6 32271263 A T 2.07E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs7742654 chr6 32271443 C G 2.07E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs491870 chr6 32271450 T A 6.20E-05 Self-reported allergy C6orf10 intron 23817569 rs3864300 chr6 32271807 G T 3.59E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs3864300 chr6 32271807 G T 3.40E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs3864301 chr6 32271955 C T 3.59E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs3864301 chr6 32271955 C T 3.40E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs9268170 chr6 32272711 A G 4.52E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs9268170 chr6 32272711 A G 3.40E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs544358 chr6 32273158 G C 7.73E-05 Type 2 diabetes C6orf10 intron 17463246 rs544358 chr6 32273158 G C 7.71E-64 Multiple complex diseases C6orf10 intron 17554300 rs544358 chr6 32273158 G C 2.18E-14 Multiple sclerosis C6orf10 intron 17660530 rs544358 chr6 32273158 G C 2.81E-35 Narcolepsy C6orf10 intron 19629137 rs6457536 chr6 32273765 A G 1.60E-09 Type 1 diabetes C6orf10 intron 17632545 rs6457536 chr6 32273765 A G 3.65E-23 Rheumatoid arthritis C6orf10 intron 17804836 rs6457536 chr6 32273765 A G 1.55E-25 Rheumatoid arthritis C6orf10 intron 19503088 rs6457536 chr6 32273765 A G 4.18E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs6457536 chr6 32273765 A G 6.02E-05 Coronary heart disease C6orf10 intron 21971053 rs6457536 chr6 32273765 A G 2.20E-09 Systemic lupus erythematosus C6orf10 intron 24871463 rs6457536 chr6 32273765 A G 6.68E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs9268176 chr6 32274079 C T 2.54E-22 Rheumatoid arthritis C6orf10 intron 21156761 rs9268176 chr6 32274079 C T 4.95E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs9268177 chr6 32274882 C A 3.68E-12 Rheumatoid arthritis C6orf10 intron 21156761 rs9268177 chr6 32274882 C A 9.08E-06 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs7341300 chr6 32275027 C T 4.52E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs7341300 chr6 32275027 C T 3.32E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs7341328 chr6 32275194 G A 4.52E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs7341328 chr6 32275194 G A 3.32E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs28366176 chr6 32275565 T G 0.000001667 Sarcoidosis C6orf10 intron 22952805 rs9268181 chr6 32276009 T C 4.52E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs9268181 chr6 32276009 T C 3.32E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs9268182 chr6 32276027 T G 4.52E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs9268182 chr6 32276027 T G 3.32E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs28366177 chr6 32276192 G A 0.000003156 Sarcoidosis C6orf10 intron 22952805 rs28366178 chr6 32276275 T C 7.81E-08 Sarcoidosis C6orf10 intron 22952805 rs9268197 chr6 32277934 C A 4.52E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs9268197 chr6 32277934 C A 3.32E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs502626 chr6 32278266 A G 4.80E-43 Rheumatoid arthritis C6orf10 intron 21156761 rs502626 chr6 32278266 A G 1.09E-07 Red blood cell traits C6orf10 intron 23222517 rs9268199 chr6 32278635 G A 4.39E-05 Type 2 diabetes C6orf10 intron 17463246 rs9268199 chr6 32278635 G A 1.11E-20 Rheumatoid arthritis C6orf10 intron 21156761 rs9268200 chr6 32278670 C T 4.52E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs9268200 chr6 32278670 C T 3.32E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs3864302 chr6 32278792 C T 4.52E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs3864302 chr6 32278792 C T 3.32E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs9268201 chr6 32279284 G A 4.52E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs9268201 chr6 32279284 G A 3.32E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs9268202 chr6 32279340 C T 4.52E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs9268202 chr6 32279340 C T 3.32E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs9268204 chr6 32279500 C T 4.52E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs9268204 chr6 32279500 C T 3.32E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs6934429 chr6 32279622 G T 4.52E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs6934429 chr6 32279622 G T 3.32E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs9268205 chr6 32279938 A G 2.71E-06 Phospholipid levels (plasma) C6orf10 intron 21829377 rs9268207 chr6 32280462 C T 2.24E-10 Multiple complex diseases C6orf10 intron 17554300 rs9268207 chr6 32280462 C T 4.52E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs9268207 chr6 32280462 C T 3.25E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs9268208 chr6 32280591 T C 7.59E-98 Multiple complex diseases C6orf10 intron 17554300 rs9268208 chr6 32280591 T C 3.68E-12 Rheumatoid arthritis C6orf10 intron 21156761 rs9268208 chr6 32280591 T C 9.40E-06 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs9268209 chr6 32280620 A C 9.41E-24 Rheumatoid arthritis C6orf10 intron 21156761 rs9268209 chr6 32280620 A C 2.52E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs1018434 chr6 32281360 T C 8.24E-25 Rheumatoid arthritis C6orf10 intron 21156761 rs1018434 chr6 32281360 T C 3.96E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs28366179 chr6 32281412 C A 0.000001636 Sarcoidosis C6orf10 intron 22952805 rs1018433 chr6 32281510 A T 1.07E-10 Multiple complex diseases C6orf10 intron 17554300 rs1018433 chr6 32281510 A T 6.61E-25 Rheumatoid arthritis C6orf10 intron 21156761 rs3864303 chr6 32281621 A G 6.61E-25 Rheumatoid arthritis C6orf10 intron 21156761 rs3864303 chr6 32281621 A G 4.08E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs1018431 chr6 32281676 G A 6.61E-25 Rheumatoid arthritis C6orf10 intron 21156761 rs1018431 chr6 32281676 G A 4.08E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs1018430 chr6 32281688 C T 6.61E-25 Rheumatoid arthritis C6orf10 intron 21156761 rs1018430 chr6 32281688 C T 4.08E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs2069026 chr6 32281958 C T 6.61E-25 Rheumatoid arthritis C6orf10 intron 21156761 rs2069026 chr6 32281958 C T 4.05E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs6903871 chr6 32282019 A C 6.61E-25 Rheumatoid arthritis C6orf10 intron 21156761 rs6903871 chr6 32282019 A C 4.08E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs547261 chr6 32282033 G A 2.20E-59 Rheumatoid arthritis C6orf10 intron 17804836 rs547261 chr6 32282033 G A 3.76E-85 Rheumatoid arthritis C6orf10 intron 19503088 rs547261 chr6 32282033 G A 6.05E-06 Multiple sclerosis C6orf10 intron 20598377 rs547261 chr6 32282033 G A 6.90E-07 Red blood cell traits C6orf10 intron 23222517 rs2395141 chr6 32282068 G A 1.03E-05 Type 2 diabetes C6orf10 intron 17463246 rs6910071 chr6 32282854 A G 3.44E-15 Type 1 diabetes C6orf10 intron 17632545 rs6910071 chr6 32282854 A G 7.19E-103 Rheumatoid arthritis C6orf10 intron 17804836 rs6910071 chr6 32282854 A G 1.00E-299 Rheumatoid arthritis C6orf10 intron 20453842 rs6910071 chr6 32282854 A G 6.09E-95 Rheumatoid arthritis C6orf10 intron 21156761 rs6910071 chr6 32282854 A G 6.91E-10 Sarcoidosis C6orf10 intron 22952805 rs6910071 chr6 32282854 A G 2.00E-124 Rheumatoid arthritis C6orf10 intron 24449572 rs6909790 chr6 32282979 A G 6.61E-25 Rheumatoid arthritis C6orf10 intron 21156761 rs6909790 chr6 32282979 A G 4.22E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs493136 chr6 32283394 A G 5.68E-05 Self-reported allergy C6orf10 intron 23817569 rs6915455 chr6 32283494 G A 3.83E-22 Rheumatoid arthritis C6orf10 intron 21156761 rs6915455 chr6 32283494 G A 8.16E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs9268218 chr6 32283699 A G 6.61E-25 Rheumatoid arthritis C6orf10 intron 21156761 rs9268218 chr6 32283699 A G 4.51E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs9268219 chr6 32284108 T G 3.68E-12 Rheumatoid arthritis C6orf10 intron 21156761 rs9268219 chr6 32284108 T G 9.83E-06 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs9268220 chr6 32284340 C T 4.41E-18 Rheumatoid arthritis C6orf10 intron 21156761 rs12661557 chr6 32284657 C T 0.000001891 Sarcoidosis C6orf10 intron 22952805 rs531094 chr6 32286102 T A 3.50E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs531094 chr6 32286102 T A 5.07E-08 Red blood cell traits C6orf10 intron 23222517 rs503042 chr6 32286252 G A 3.34E-05 Self-reported allergy C6orf10 intron 23817569 rs500279 chr6 32286562 C T 3.34E-05 Self-reported allergy C6orf10 intron 23817569 rs498422 chr6 32286761 T G 6.40E-09 Rheumatoid arthritis C6orf10 intron 17804836 rs498422 chr6 32286761 T G 2.60E-05 Kawasaki disease C6orf10 intron 22446962 rs498422 chr6 32286761 T G 1.53E-11 Non-obstructive azoospermia C6orf10 intron 22541561 rs498422 chr6 32286761 T G 6.17E-05 Self-reported allergy C6orf10 intron 23817569 rs566241495 chr6 32287119 G A 4.70E-36 Rheumatoid arthritis C6orf10 intron 21156761 rs9268230 chr6 32287567 G A 4.35E-91 Multiple complex diseases C6orf10 intron 17554300 rs9268231 chr6 32287754 T C 5.31E-18 Rheumatoid arthritis C6orf10 intron 21156761 rs513095 chr6 32287876 T G 3.57E-07 Multiple complex diseases C6orf10 intron 17554300 rs513095 chr6 32287876 T G 4.97E-05 Self-reported allergy C6orf10 intron 23817569 rs6920338 chr6 32288089 C T 3.14E-05 Parkinson's disease (motor and cognition) C6orf10 intron 22658654 rs6920338 chr6 32288089 C T 3.13E-05 Immune response to anthrax vaccine C6orf10 intron 22658931 rs574710 chr6 32288190 T C 3.00E-04 Type 2 diabetes C6orf10 intron 17463246 rs574710 chr6 32288190 T C 4.18E-62 Multiple complex diseases C6orf10 intron 17554300 rs574710 chr6 32288190 T C 6.03E-15 Multiple sclerosis C6orf10 intron 17660530 rs574710 chr6 32288190 T C 2.48E-32 Narcolepsy C6orf10 intron 19629137 rs574710 chr6 32288190 T C 3.50E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs574710 chr6 32288190 T C 6.14E-08 Red blood cell traits C6orf10 intron 23222517 rs539703 chr6 32288462 A C 7.43E-05 Type 2 diabetes C6orf10 intron 17463246 rs539703 chr6 32288462 A C 2.38E-63 Multiple complex diseases C6orf10 intron 17554300 rs539703 chr6 32288462 A C 2.14E-14 Multiple sclerosis C6orf10 intron 17660530 rs539703 chr6 32288462 A C 8.58E-34 Narcolepsy C6orf10 intron 19629137 rs539703 chr6 32288462 A C 3.50E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs539703 chr6 32288462 A C 1.45E-07 Red blood cell traits C6orf10 intron 23222517 rs547077 chr6 32289318 T C 8.09E-61 Rheumatoid arthritis C6orf10 intron 17804836 rs547077 chr6 32289318 T C 1.15E-85 Rheumatoid arthritis C6orf10 intron 19503088 rs547077 chr6 32289318 T C 1.08E-05 Multiple sclerosis C6orf10 intron 20598377 rs547077 chr6 32289318 T C 7.65E-46 Rheumatoid arthritis C6orf10 intron 21156761 rs547077 chr6 32289318 T C 4.05E-08 Red blood cell traits C6orf10 intron 23222517 rs7756177 chr6 32289358 G A,C,T 1.26E-18 Rheumatoid arthritis C6orf10 intron 21156761 rs570963 chr6 32289594 A G 5.11E-14 Rheumatoid arthritis C6orf10 intron 21156761 rs570963 chr6 32289594 A G 4.09E-07 Self-reported allergy C6orf10 intron 23817569 rs572730 chr6 32289764 C T 6.32E-41 Rheumatoid arthritis C6orf10 intron 21156761 rs572730 chr6 32289764 C T 2.58E-07 Red blood cell traits C6orf10 intron 23222517 rs9268235 chr6 32290208 C T 4.97E-12 Rheumatoid arthritis C6orf10 intron 21156761 rs9268235 chr6 32290208 C T 1.03E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs485774 chr6 32290954 A G 6.53E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs485774 chr6 32290954 A G 2.10E-10 Alopecia areata C6orf10 intron 22027810 rs485774 chr6 32290954 A G 7.05E-07 Red blood cell traits C6orf10 intron 23222517 rs496360 chr6 32291190 A G 5.49E-05 Self-reported allergy C6orf10 intron 23817569 rs521828 chr6 32291643 C T 9.35E-29 Rheumatoid arthritis C6orf10 intron 21156761 rs521828 chr6 32291643 C T 4.45E-06 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs523627 chr6 32291837 G T 7.29E-41 Rheumatoid arthritis C6orf10 intron 21156761 rs536693 chr6 32292818 C A 5.68E-05 Self-reported allergy C6orf10 intron 23817569 rs533885 chr6 32293152 A G 4.91E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs533885 chr6 32293152 A G 1.71E-07 Red blood cell traits C6orf10 intron 23222517 rs9268246 chr6 32294549 A T 1.17E-18 Rheumatoid arthritis C6orf10 intron 21156761 rs476885 chr6 32294712 A G 4.94E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs476885 chr6 32294712 A G 5.74E-08 Red blood cell traits C6orf10 intron 23222517 rs505274 chr6 32294992 G A 4.94E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs505274 chr6 32294992 G A 6.79E-08 Red blood cell traits C6orf10 intron 23222517 rs508805 chr6 32295350 G A 4.99E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs508805 chr6 32295350 G A 6.63E-08 Red blood cell traits C6orf10 intron 23222517 rs524578 chr6 32295357 G A 4.99E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs524578 chr6 32295357 G A 4.97E-07 Red blood cell traits C6orf10 intron 23222517 rs9348880 chr6 32296780 C T 5.04E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs9348880 chr6 32296780 C T 6.00E-08 Red blood cell traits C6orf10 intron 23222517 rs9368711 chr6 32297156 T C 5.04E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs9368711 chr6 32297156 T C 5.86E-08 Red blood cell traits C6orf10 intron 23222517 rs12524063 chr6 32297310 T A 7.46E-05 Multiple complex diseases C6orf10 intron 17554300 rs12524063 chr6 32297310 T A 1.04E-06 Coronary Artery Disease C6orf10 intron 17634449 rs12524063 chr6 32297310 T A 2.58E-05 Multiple sclerosis C6orf10 intron 17660530 rs9368712 chr6 32297328 G A 5.04E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs9368712 chr6 32297328 G A 5.73E-08 Red blood cell traits C6orf10 intron 23222517 rs9368714 chr6 32297341 G A 2.76E-06 Obesity-related traits C6orf10 intron 23251661 rs9296021 chr6 32297690 C T 4.00E-05 Rheumatoid arthritis C6orf10 intron 17159887 rs9296021 chr6 32297690 C T 1.90E-19 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) C6orf10 intron 17982456 rs9296021 chr6 32297690 C T 5.04E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs9296021 chr6 32297690 C T 6.17E-08 Red blood cell traits C6orf10 intron 23222517 rs3132958 chr6 32297901 A G 3.00E-05 Rheumatoid arthritis C6orf10 intron 17159887 rs3132958 chr6 32297901 A G 1.68E-04 Self-reported allergy C6orf10 intron 23817569 rs9296022 chr6 32297955 G A 5.04E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs9296022 chr6 32297955 G A 5.55E-08 Red blood cell traits C6orf10 intron 23222517 rs10484560 chr6 32298137 G A 1.86E-06 Rheumatoid arthritis C6orf10 intron 17804836 rs10484560 chr6 32298137 G A 4.60E-11 Rheumatoid arthritis C6orf10 intron 19503088 rs10484560 chr6 32298137 G A 3.93E-04 Schizophrenia C6orf10 intron 21674006 rs9405090 chr6 32298372 A G 2.00E-07 Rheumatoid arthritis C6orf10 missense 17159887 rs9405090 chr6 32298372 A G 1.31E-59 Rheumatoid arthritis C6orf10 missense 17804836 rs9405090 chr6 32298372 A G 6.97E-84 Rheumatoid arthritis C6orf10 missense 19503088 rs9405090 chr6 32298372 A G 3.40E-05 Multiple sclerosis C6orf10 missense 20598377 rs9405090 chr6 32298372 A G 8.30E-07 Red blood cell traits C6orf10 missense 23222517 rs3129949 chr6 32298814 C A 1.62E-22 Rheumatoid arthritis C6orf10 intron 21156761 rs3129949 chr6 32298814 C A 1.36E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs3132959 chr6 32298942 G A 1.75E-05 Type 2 diabetes C6orf10 intron 17463246 rs3132959 chr6 32298942 G A 2.91E-96 Multiple complex diseases C6orf10 intron 17554300 rs3132959 chr6 32298942 G A 1.84E-29 Rheumatoid arthritis C6orf10 intron 21156761 rs3132959 chr6 32298942 G A 1.70E-04 Self-reported allergy C6orf10 intron 23817569 rs3132959 chr6 32298942 G A 3.20E-05 Diabetic nephropathy C6orf10 intron pha002866 rs1003879 chr6 32299592 G A 3.34E-30 Rheumatoid arthritis C6orf10 intron 21156761 rs742582 chr6 32299715 G A 4.97E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs742582 chr6 32299715 G A 4.76E-08 Red blood cell traits C6orf10 intron 23222517 rs1003878 chr6 32299822 G A 1.00E-16 Type 1 diabetes C6orf10 missense 17632545 rs1003878 chr6 32299822 G A 7.31E-27 Rheumatoid arthritis C6orf10 missense 17804836 rs1003878 chr6 32299822 G A 4.11E-28 Rheumatoid arthritis C6orf10 missense 19503088 rs1003878 chr6 32299822 G A 4.49E-23 Rheumatoid arthritis C6orf10 missense 21156761 rs1003878 chr6 32299822 G A 6.60E-07 Systemic lupus erythematosus C6orf10 missense 24871463 rs1003878 chr6 32299822 G A 1.72E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 missense 24925725 rs1076712 chr6 32300152 T C 8.26E-08 Red blood cell traits C6orf10 intron 23222517 rs9366793 chr6 32301289 T C 4.97E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs9366793 chr6 32301289 T C 4.92E-08 Red blood cell traits C6orf10 intron 23222517 rs1474728 chr6 32302067 C T 4.97E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs1474728 chr6 32302067 C T 7.63E-08 Red blood cell traits C6orf10 intron 23222517 rs6929776 chr6 32303511 G A 4.97E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs6929776 chr6 32303511 G A 5.84E-08 Red blood cell traits C6orf10 intron 23222517 rs1265754 chr6 32303692 T A 4.97E-04 Lung function (forced expiratory volume in 1 second) C6orf10 missense 17255346 rs1265754 chr6 32303692 T A 4.97E-12 Rheumatoid arthritis C6orf10 missense 21156761 rs28361060 chr6 32303848 G A 7.19E-10 Sarcoidosis C6orf10 intron 22952805 rs926591 chr6 32305690 C A 4.33E-05 Type 2 diabetes C6orf10 intron 17463246 rs926591 chr6 32305690 C A 3.61E-63 Multiple complex diseases C6orf10 intron 17554300 rs926591 chr6 32305690 C A 7.12E-15 Multiple sclerosis C6orf10 intron 17660530 rs926591 chr6 32305690 C A 3.44E-34 Narcolepsy C6orf10 intron 19629137 rs926591 chr6 32305690 C A 4.97E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs926591 chr6 32305690 C A 1.17E-07 Red blood cell traits C6orf10 intron 23222517 rs3129900 chr6 32305979 G T 1.45E-05 Type 2 diabetes C6orf10 intron 17463246 rs3129900 chr6 32305979 G T 1.28E-71 Multiple complex diseases C6orf10 intron 17554300 rs3129900 chr6 32305979 G T 2.63E-37 Multiple sclerosis C6orf10 intron 17660530 rs3129900 chr6 32305979 G T 7.00E-25 Lumiracoxib-related liver injury C6orf10 intron 20639878 rs3129900 chr6 32305979 G T 1.14E-07 Narcolepsy C6orf10 intron 20711174 rs3129900 chr6 32305979 G T 3.90E-06 Phospholipid levels (plasma) C6orf10 intron 21829377 rs3129900 chr6 32305979 G T 9.81E-05 Parkinson's disease (motor and cognition) C6orf10 intron 22658654 rs3129900 chr6 32305979 G T 9.81E-05 Immune response to anthrax vaccine C6orf10 intron 22658931 rs9368716 chr6 32306090 G A 8.49E-13 Multiple complex diseases C6orf10 intron 17554300 rs9368716 chr6 32306090 G A 5.06E-16 Multiple sclerosis C6orf10 intron 17660530 rs9368716 chr6 32306090 G A 2.20E-39 Narcolepsy C6orf10 intron 19629137 rs9368716 chr6 32306090 G A 3.09E-28 Rheumatoid arthritis C6orf10 intron 21156761 rs9368716 chr6 32306090 G A 3.39E-08 Red blood cell traits C6orf10 intron 23222517 rs9368716 chr6 32306090 G A 2.21E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs3817982 chr6 32306262 T C 4.97E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs3817982 chr6 32306262 T C 3.57E-08 Red blood cell traits C6orf10 intron 23222517 rs2273019 chr6 32306419 C T 1.40E-18 Rheumatoid arthritis C6orf10 intron 21156761 rs28732193 chr6 32306922 T C 2.40E-13 HIV-1 control C6orf10 intron 21051598 rs2022534 chr6 32307137 T C 4.77E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs2022534 chr6 32307137 T C 6.19E-08 Red blood cell traits C6orf10 intron 23222517 rs1033500 chr6 32307382 G A 1.80E-59 Rheumatoid arthritis C6orf10 missense 17804836 rs1033500 chr6 32307382 G A 3.52E-85 Rheumatoid arthritis C6orf10 missense 19503088 rs1033500 chr6 32307382 G A 3.09E-05 Multiple sclerosis C6orf10 missense 20598377 rs1033500 chr6 32307382 G A 3.78E-44 Rheumatoid arthritis C6orf10 missense 21156761 rs1033500 chr6 32307382 G A 4.18E-08 Red blood cell traits C6orf10 missense 23222517 rs9469099 chr6 32308908 G A 5.00E-19 Atopic dermatitis C6orf10 intron 23042114 rs2143465 chr6 32309352 T C 4.77E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs2143465 chr6 32309352 T C 5.04E-08 Red blood cell traits C6orf10 intron 23222517 rs3129904 chr6 32310396 A G 4.06E-29 Rheumatoid arthritis C6orf10 intron 21156761 rs3129904 chr6 32310396 A G 1.78E-04 Self-reported allergy C6orf10 intron 23817569 rs6904320 chr6 32312082 A G 4.06E-29 Rheumatoid arthritis C6orf10 intron 21156761 rs6904320 chr6 32312082 A G 1.19E-04 Self-reported allergy C6orf10 intron 23817569 rs4576282 chr6 32312796 A G 4.77E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs4576282 chr6 32312796 A G 9.89E-08 Red blood cell traits C6orf10 intron 23222517 rs4959092 chr6 32313011 T G 4.77E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs4959092 chr6 32313011 T G 5.80E-08 Red blood cell traits C6orf10 intron 23222517 rs4959093 chr6 32313097 T C 6.23E-05 Type 2 diabetes C6orf10 intron 17463246 rs4959093 chr6 32313097 T C 9.77E-63 Multiple complex diseases C6orf10 intron 17554300 rs4959093 chr6 32313097 T C 8.11E-15 Multiple sclerosis C6orf10 intron 17660530 rs4959093 chr6 32313097 T C 3.05E-33 Narcolepsy C6orf10 intron 19629137 rs4959093 chr6 32313097 T C 4.77E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs4959093 chr6 32313097 T C 7.92E-08 Red blood cell traits C6orf10 intron 23222517 rs4959096 chr6 32314676 G A 1.39E-05 Sleep duration C6orf10 intron 22105623 rs3132964 chr6 32314738 T C 2.04E-29 Rheumatoid arthritis C6orf10 intron 21156761 rs3132964 chr6 32314738 T C 1.93E-04 Self-reported allergy C6orf10 intron 23817569 rs9268283 chr6 32315173 T C 4.82E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs3117127 chr6 32315507 A C 1.98E-05 Parkinson's disease (motor and cognition) C6orf10 intron 22658654 rs3117127 chr6 32315507 A C 1.98E-05 Immune response to anthrax vaccine C6orf10 intron 22658931 rs910050 chr6 32315654 G C 9.09E-09 Multiple complex diseases C6orf10 intron 17554300 rs910050 chr6 32315654 G C 9.99E-10 Multiple sclerosis C6orf10 intron 17660530 rs910050 chr6 32315654 G C 1.07E-31 Narcolepsy C6orf10 intron 19629137 rs910049 chr6 32315727 T C 5.00E-07 Type 2 diabetes C6orf10 intron 17463246 rs910049 chr6 32315727 T C 3.02E-93 Multiple complex diseases C6orf10 intron 17554300 rs910049 chr6 32315727 T C 5.42E-27 Type 1 diabetes C6orf10 intron 17632545 rs910049 chr6 32315727 T C 7.65E-04 Coronary Artery Disease C6orf10 intron 17634449 rs910049 chr6 32315727 T C 1.97E-23 Multiple sclerosis C6orf10 intron 17660530 rs910049 chr6 32315727 T C 9.52E-07 Lung adenocarcinoma C6orf10 intron 19836008 rs910049 chr6 32315727 T C 1.05E-28 Rheumatoid arthritis C6orf10 intron 21156761 rs910049 chr6 32315727 T C 5.44E-06 Crohn's disease C6orf10 intron 23266558 rs910049 chr6 32315727 T C 9.00E-11 Hepatitis C induced liver cirrhosis C6orf10 intron 23321320 rs910049 chr6 32315727 T C 2.85E-04 Self-reported allergy C6orf10 intron 23817569 rs910049 chr6 32315727 T C 1.38E-188 Type 1 diabetes C6orf10 intron pha002862 rs3117126 chr6 32315975 C T 2.04E-29 Rheumatoid arthritis C6orf10 intron 21156761 rs3117126 chr6 32315975 C T 1.98E-04 Self-reported allergy C6orf10 intron 23817569 rs3117124 chr6 32316240 G T 2.04E-29 Rheumatoid arthritis C6orf10 intron 21156761 rs3117124 chr6 32316240 G T 2.09E-04 Self-reported allergy C6orf10 intron 23817569 rs969891 chr6 32316415 T C 7.73E-19 Rheumatoid arthritis C6orf10 intron 21156761 rs3117120 chr6 32316804 G C 7.73E-19 Rheumatoid arthritis C6orf10 intron 21156761 rs2076542 chr6 32317127 G A 4.82E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs2076540 chr6 32317276 T C 3.10E-05 Intelligence (childhood) C6orf10 intron 23358156 rs2076538 chr6 32317471 A C 4.77E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs2076538 chr6 32317471 A C 8.71E-08 Red blood cell traits C6orf10 intron 23222517 rs2076537 chr6 32317635 G A 2.01E-12 Type 1 diabetes C6orf10 intron 17632545 rs2076537 chr6 32317635 G A 7.85E-14 Rheumatoid arthritis C6orf10 intron 17804836 rs2076537 chr6 32317635 G A 7.17E-17 Rheumatoid arthritis C6orf10 intron 19503088 rs2076537 chr6 32317635 G A 8.23E-19 Rheumatoid arthritis C6orf10 intron 21156761 rs2076537 chr6 32317635 G A 2.60E-05 Schizophrenia C6orf10 intron 21791550 rs2076537 chr6 32317635 G A 0.000055 Psychosis C6orf10 intron 23164818 rs2076537 chr6 32317635 G A 4.90E-04 Systemic lupus erythematosus C6orf10 intron 24871463 rs761188 chr6 32317973 A G 7.73E-19 Rheumatoid arthritis C6orf10 intron 21156761 rs761187 chr6 32318036 A G 3.97E-45 Rheumatoid arthritis C6orf10 intron 21156761 rs761187 chr6 32318036 A G 3.57E-07 Red blood cell traits C6orf10 intron 23222517 rs3117119 chr6 32318610 G A 2.63E-05 Parkinson's disease (motor and cognition) C6orf10 intron 22658654 rs3117119 chr6 32318610 G A 2.63E-05 Immune response to anthrax vaccine C6orf10 intron 22658931 rs1265763 chr6 32319364 C T 6.30E-10 Self-reported allergy C6orf10 intron 23817569 rs3117118 chr6 32319387 C T 4.07E-31 Rheumatoid arthritis C6orf10 intron 21156761 rs3117118 chr6 32319387 C T 1.29E-04 Self-reported allergy C6orf10 intron 23817569 rs9268301 chr6 32319637 G A 2.55E-54 Rheumatoid arthritis C6orf10 intron 21156761 rs9268301 chr6 32319637 G A 2.00E-06 Obesity-related traits C6orf10 intron 23251661 rs3132963 chr6 32320153 G A 2.63E-05 Parkinson's disease (motor and cognition) C6orf10 intron 22658654 rs3132963 chr6 32320153 G A 2.63E-05 Immune response to anthrax vaccine C6orf10 intron 22658931 rs2022544 chr6 32321004 C T 1.68E-05 Self-reported allergy C6orf10 intron 23817569 rs1265762 chr6 32321115 C A 2.49E-04 Type 2 diabetes C6orf10 intron 17463246 rs3117117 chr6 32321272 C A 3.18E-06 Phospholipid levels (plasma) C6orf10 intron 21829377 rs2395148 chr6 32321554 G T 2.00E-10 Arthritis (juvenile idiopathic) C6orf10 intron 18576341 rs2395148 chr6 32321554 G T 1.00E-10 Primary biliary cirrhosis C6orf10 intron 19458352 rs2395148 chr6 32321554 G T 2.39E-05 Vascular dementia C6orf10 intron 22116812 rs1265761 chr6 32321597 A G 1.94E-09 Type 1 diabetes C6orf10 intron 17632545 rs1265761 chr6 32321597 A G 6.12E-04 Crohn's disease C6orf10 intron 23266558 rs1265761 chr6 32321597 A G 5.02E-05 Self-reported allergy C6orf10 intron 23817569 rs1265760 chr6 32321872 T C 6.24E-04 Type 2 diabetes C6orf10 intron 17463246 rs1265759 chr6 32322393 C T 2.57E-04 Type 2 diabetes C6orf10 intron 17463246 rs1265759 chr6 32322393 C T 1.00E-16 Type 1 diabetes C6orf10 intron 17632545 rs1265759 chr6 32322393 C T 8.91E-105 Type 1 diabetes C6orf10 intron pha002862 rs3132962 chr6 32322433 T C 4.07E-31 Rheumatoid arthritis C6orf10 intron 21156761 rs3132962 chr6 32322433 T C 1.28E-04 Self-reported allergy C6orf10 intron 23817569 rs1265758 chr6 32323529 A G 4.56E-04 Type 2 diabetes C6orf10 intron 17463246 rs1265758 chr6 32323529 A G 1.00E-16 Type 1 diabetes C6orf10 intron 17632545 rs1265758 chr6 32323529 A G 7.66E-98 Type 1 diabetes C6orf10 intron pha002862 rs3129907 chr6 32323745 G A 4.07E-31 Rheumatoid arthritis C6orf10 intron 21156761 rs3129907 chr6 32323745 G A 1.25E-04 Self-reported allergy C6orf10 intron 23817569 rs2206618 chr6 32324544 A G 6.99E-10 Self-reported allergy C6orf10 intron 23817569 rs9268302 chr6 32324817 C T 9.11E-04 Coronary Artery Disease C6orf10 intron 17634449 rs9268302 chr6 32324817 C T 1.05E-06 Multiple sclerosis C6orf10 intron 17660530 rs9268302 chr6 32324817 C T 9.87E-32 Narcolepsy C6orf10 intron 19629137 rs9268302 chr6 32324817 C T 7.62E-10 Self-reported allergy C6orf10 intron 23817569 rs6907322 chr6 32324945 G A 1.19E-04 Multiple complex diseases C6orf10 intron 17554300 rs6907322 chr6 32324945 G A 2.56E-06 Multiple sclerosis C6orf10 intron 17660530 rs6907322 chr6 32324945 G A 6.89E-29 Narcolepsy C6orf10 intron 19629137 rs6907322 chr6 32324945 G A 7.13E-10 Self-reported allergy C6orf10 intron 23817569 rs6907226 chr6 32325138 A G 5.93E-10 Self-reported allergy C6orf10 intron 23817569 rs6907757 chr6 32325358 C T 1.19E-05 Self-reported allergy C6orf10 intron 23817569 rs13196329 chr6 32325371 A C 3.00E-06 Visceral fat C6orf10 intron 22589738 rs2395149 chr6 32325562 G A 5.17E-12 Rheumatoid arthritis C6orf10 intron 21156761 rs2395149 chr6 32325562 G A 1.22E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs3129909 chr6 32325710 G A 7.89E-05 Type 2 diabetes C6orf10 intron 17463246 rs2894249 chr6 32325835 C T 3.64E-06 Type 2 diabetes C6orf10 intron 17463246 rs2894249 chr6 32325835 C T 2.74E-91 Multiple complex diseases C6orf10 intron 17554300 rs2894249 chr6 32325835 C T 7.15E-04 Coronary Artery Disease C6orf10 intron 17634449 rs2894249 chr6 32325835 C T 3.49E-20 Multiple sclerosis C6orf10 intron 17660530 rs2894249 chr6 32325835 C T 4.07E-31 Rheumatoid arthritis C6orf10 intron 21156761 rs2894249 chr6 32325835 C T 1.25E-04 Self-reported allergy C6orf10 intron 23817569 rs2894249 chr6 32325835 C T 1.50E-05 Diabetic nephropathy C6orf10 intron pha002866 rs2395150 chr6 32326045 G A 6.24E-04 Type 2 diabetes C6orf10 intron 17463246 rs2395150 chr6 32326045 G A 1.00E-16 Type 1 diabetes C6orf10 intron 17632545 rs2395150 chr6 32326045 G A 1.65E-21 Rheumatoid arthritis C6orf10 intron 17804836 rs2395150 chr6 32326045 G A 6.55E-37 Rheumatoid arthritis C6orf10 intron 19503088 rs2395150 chr6 32326045 G A 1.40E-06 Multiple sclerosis C6orf10 intron 20598377 rs2395150 chr6 32326045 G A 6.15E-98 Type 1 diabetes C6orf10 intron pha002862 rs9268303 chr6 32326165 G A 1.69E-10 Self-reported allergy C6orf10 intron 23817569 rs6904608 chr6 32327727 C T 2.07E-04 Type 2 diabetes C6orf10 intron 17463246 rs6904636 chr6 32327781 C T 3.60E-04 Type 2 diabetes C6orf10 intron 17463246 rs9268314 chr6 32327839 A G 5.72E-10 Self-reported allergy C6orf10 intron 23817569 rs9268315 chr6 32327969 C T 1.80E-10 Self-reported allergy C6orf10 intron 23817569 rs3117112 chr6 32330705 A T 5.87E-31 Rheumatoid arthritis C6orf10 intron 21156761 rs3117112 chr6 32330705 A T 1.33E-04 Self-reported allergy C6orf10 intron 23817569 rs9268346 chr6 32331927 C G 2.62E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs9268346 chr6 32331927 C G 2.15E-07 Red blood cell traits C6orf10 intron 23222517 rs9268347 chr6 32331998 G A 1.00E-09 Self-reported allergy C6orf10 intron 23817569 rs3129916 chr6 32332322 G A 6.97E-20 Rheumatoid arthritis C6orf10 intron 21156761 rs9268357 chr6 32332996 C G 2.62E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs9268357 chr6 32332996 C G 3.56E-07 Red blood cell traits C6orf10 intron 23222517 rs9268361 chr6 32333243 G A 5.10E-10 Self-reported allergy C6orf10 intron 23817569 rs9268362 chr6 32333341 A G 1.64E-89 Rheumatoid arthritis C6orf10 intron 21156761 rs9268362 chr6 32333341 A G 6.18E-10 Sarcoidosis C6orf10 intron 22952805 rs9268365 chr6 32333439 G T 5.50E-10 Self-reported allergy C6orf10 intron 23817569 rs9268367 chr6 32333542 A G 5.72E-10 Self-reported allergy C6orf10 intron 23817569 rs3129927 chr6 32333827 A C 5.00E-12 Rheumatoid arthritis C6orf10 intron 21156761 rs3129927 chr6 32333827 A C 1.24E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs9268368 chr6 32333955 T C 2.00E-07 Rheumatoid arthritis C6orf10 missense 17159887 rs9268368 chr6 32333955 T C 3.26E-59 Rheumatoid arthritis C6orf10 missense 17804836 rs9268368 chr6 32333955 T C 2.82E-83 Rheumatoid arthritis C6orf10 missense 19503088 rs9268368 chr6 32333955 T C 3.40E-05 Multiple sclerosis C6orf10 missense 20598377 rs9268368 chr6 32333955 T C 6.33E-44 Rheumatoid arthritis C6orf10 missense 21156761 rs9268369 chr6 32334224 C G 2.62E-44 Rheumatoid arthritis C6orf10 intron 21156761 rs9268369 chr6 32334224 C G 4.50E-07 Red blood cell traits C6orf10 intron 23222517 rs3129928 chr6 32334241 G T 4.07E-31 Rheumatoid arthritis C6orf10 intron 21156761 rs3129928 chr6 32334241 G T 1.25E-04 Self-reported allergy C6orf10 intron 23817569 rs2143462 chr6 32335204 G A 9.31E-20 Rheumatoid arthritis C6orf10 intron 21156761 rs2143461 chr6 32335347 G A 1.92E-08 Multiple complex diseases C6orf10 intron 17554300 rs2073048 chr6 32335433 G A 1.28E-05 Self-reported allergy C6orf10 intron 23817569 rs3129931 chr6 32335516 C T 1.25E-04 Self-reported allergy C6orf10 intron 23817569 rs3129932 chr6 32336127 G C 1.06E-05 Type 2 diabetes C6orf10 intron 17463246 rs3129932 chr6 32336127 G C 1.86E-96 Multiple complex diseases C6orf10 intron 17554300 rs3129932 chr6 32336127 G C 7.06E-04 Coronary Artery Disease C6orf10 intron 17634449 rs3129932 chr6 32336127 G C 5.76E-28 Multiple sclerosis C6orf10 intron 17660530 rs3129932 chr6 32336127 G C 4.07E-31 Rheumatoid arthritis C6orf10 intron 21156761 rs3129932 chr6 32336127 G C 3.34E-23 Lymphocyte counts C6orf10 intron 22286170 rs3129932 chr6 32336127 G C 1.25E-04 Self-reported allergy C6orf10 intron 23817569 rs3129932 chr6 32336127 G C 1.50E-05 Diabetic nephropathy C6orf10 intron pha002866 rs3129933 chr6 32336161 G A 1.11E-09 Multiple complex diseases C6orf10 intron 17554300 rs3129933 chr6 32336161 G A 1.66E-19 Rheumatoid arthritis C6orf10 intron 21156761 rs3129934 chr6 32336187 T C 1.34E-05 Type 2 diabetes C6orf10 intron 17463246 rs3129934 chr6 32336187 T C 2.00E-72 Multiple complex diseases C6orf10 intron 17554300 rs3129934 chr6 32336187 T C 3.23E-22 Type 1 diabetes C6orf10 intron 17632545 rs3129934 chr6 32336187 T C 2.60E-40 Multiple sclerosis C6orf10 intron 17660530 rs3129934 chr6 32336187 T C 9.00E-11 Multiple sclerosis C6orf10 intron 18941528 rs3129934 chr6 32336187 T C 3.01E-06 Phospholipid levels (plasma) C6orf10 intron 21829377 rs3129934 chr6 32336187 T C 7.00E-16 Multiple sclerosis C6orf10 intron 22457343 rs3129934 chr6 32336187 T C 2.62E-05 Parkinson's disease (motor and cognition) C6orf10 intron 22658654 rs3129934 chr6 32336187 T C 2.62E-05 Immune response to anthrax vaccine C6orf10 intron 22658931 rs3129937 chr6 32336364 C A 1.66E-19 Rheumatoid arthritis C6orf10 intron 21156761 rs3129938 chr6 32336495 T A 2.98E-06 Phospholipid levels (plasma) C6orf10 intron 21829377 rs3129938 chr6 32336495 T A 2.63E-05 Parkinson's disease (motor and cognition) C6orf10 intron 22658654 rs3129938 chr6 32336495 T A 2.63E-05 Immune response to anthrax vaccine C6orf10 intron 22658931 rs9268384 chr6 32336586 A G 2.00E-07 Rheumatoid arthritis C6orf10 missense 17159887 rs9268384 chr6 32336586 A G 5.22E-60 Rheumatoid arthritis C6orf10 missense 17804836 rs9268384 chr6 32336586 A G 6.11E-85 Rheumatoid arthritis C6orf10 missense 19503088 rs9268384 chr6 32336586 A G 3.50E-05 Multiple sclerosis C6orf10 missense 20598377 rs9268384 chr6 32336586 A G 2.25E-44 Rheumatoid arthritis C6orf10 missense 21156761 rs9268384 chr6 32336586 A G 4.32E-07 Red blood cell traits C6orf10 missense 23222517 rs3129939 chr6 32336766 A G 2.22E-13 Type 1 diabetes C6orf10 intron 17632545 rs3129939 chr6 32336766 A G 6.97E-20 Rheumatoid arthritis C6orf10 intron 17804836 rs3129939 chr6 32336766 A G 7.38E-19 Rheumatoid arthritis C6orf10 intron 19503088 rs3129939 chr6 32336766 A G 6.95E-05 Lung adenocarcinoma C6orf10 intron 19836008 rs3129939 chr6 32336766 A G 5.48E-19 Rheumatoid arthritis C6orf10 intron 21156761 rs3129939 chr6 32336766 A G 1.10E-49 Myasthenia gravis C6orf10 intron 23055271 rs3129939 chr6 32336766 A G 1.29E-06 Crohn's disease C6orf10 intron 23266558 rs3129939 chr6 32336766 A G 6.90E-11 Systemic lupus erythematosus C6orf10 intron 24871463 rs2273017 chr6 32337630 G A 2.00E-22 Graves' disease C6orf10 intron 21900946 rs3129941 chr6 32337686 A G 3.00E-05 Rheumatoid arthritis C6orf10 missense 17159887 rs3129941 chr6 32337686 A G 4.78E-28 Type 1 diabetes C6orf10 missense 17632545 rs3129941 chr6 32337686 A G 2.11E-33 Rheumatoid arthritis C6orf10 missense 17804836 rs3129941 chr6 32337686 A G 9.18E-49 Rheumatoid arthritis C6orf10 missense 19503088 rs3129941 chr6 32337686 A G 2.22E-06 Lung adenocarcinoma C6orf10 missense 19836008 rs3129941 chr6 32337686 A G 1.43E-06 Systemic sclerosis C6orf10 missense 20383147 rs3129941 chr6 32337686 A G 4.00E-10 Multiple sclerosis C6orf10 missense 20598377 rs3129941 chr6 32337686 A G 3.00E-31 Rheumatoid arthritis C6orf10 missense 21156761 rs3129941 chr6 32337686 A G 1.28E-04 Self-reported allergy C6orf10 missense 23817569 rs3129941 chr6 32337686 A G 1.37E-197 Type 1 diabetes C6orf10 missense pha002862 rs3129943 chr6 32338695 A G 1.00E-16 Type 1 diabetes C6orf10 intron 17632545 rs3129943 chr6 32338695 A G 4.96E-28 Rheumatoid arthritis C6orf10 intron 17804836 rs3129943 chr6 32338695 A G 2.54E-28 Rheumatoid arthritis C6orf10 intron 19503088 rs3129943 chr6 32338695 A G 1.55E-27 Rheumatoid arthritis C6orf10 intron 21156761 rs3129943 chr6 32338695 A G 3.00E-15 Asthma C6orf10 intron 21804548 rs3129943 chr6 32338695 A G 9.80E-04 Asthma C6orf10 intron 24406073 rs3129943 chr6 32338695 A G 3.80E-07 Systemic lupus erythematosus C6orf10 intron 24871463 rs3129943 chr6 32338695 A G 3.60E-06 Lupus nephritis in systemic lupus erythematosus C6orf10 intron 24925725 rs2050191 chr6 32338901 A T 4.50E-30 Rheumatoid arthritis C6orf10 intron 21156761 rs2050191 chr6 32338901 A T 1.32E-04 Self-reported allergy C6orf10 intron 23817569 rs2050190 chr6 32339076 A G 1.14E-29 Rheumatoid arthritis C6orf10 intron 17804836 rs2050190 chr6 32339076 A G 2.36E-47 Rheumatoid arthritis C6orf10 intron 19503088 rs2050190 chr6 32339076 A G 7.51E-11 Hepatitis B vaccine response C6orf10 intron 21764829 rs2050190 chr6 32339076 A G 7.00E-07 Activated partial thromboplastin time C6orf10 intron 22703881 rs2050190 chr6 32339076 A G 2.00E-05 Systemic lupus erythematosus C6orf10 intron 24871463 rs2076536 chr6 32339348 C T 0.00003428 Sarcoidosis C6orf10 intron 22952805 rs2076536 chr6 32339348 C T 3.20E-10 Joint damage severity in rheumatoid arthritis C6orf10 intron 23696630 rs2073045 chr6 32339548 G A,C,T 5.00E-10 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) C6orf10 UTR-5 17982456 rs2073045 chr6 32339548 G A,C,T 3.48E-10 Self-reported allergy C6orf10 UTR-5 23817569 rs2050189 chr6 32339647 T C 2.64E-14 Type 1 diabetes C6orf10 UTR-5 17632545 rs2050189 chr6 32339647 T C 3.24E-05 Rheumatoid arthritis C6orf10 UTR-5 17804836 rs2050189 chr6 32339647 T C 3.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) C6orf10 UTR-5 17982456 rs2050189 chr6 32339647 T C 7.92E-07 Rheumatoid arthritis C6orf10 UTR-5 19503088 rs2050189 chr6 32339647 T C 2.89E-05 Schizophrenia C6orf10 UTR-5 21926974 rs2050189 chr6 32339647 T C 2.00E-06 Systemic lupus erythematosus C6orf10 UTR-5 24871463 rs6913309 chr6 32339840 T A 5.25E-08 Sarcoidosis C6orf10 nearGene-5 22952805 rs2050188 chr6 32339897 C T 7.00E-06 Multiple myeloma C6orf10 nearGene-5 23955597 rs111625658 chr6 32339988 C T 0.0000125 Sarcoidosis C6orf10 nearGene-5 22952805 rs2281276 chr6 32340106 A G 1.54E-08 Sarcoidosis C6orf10 nearGene-5 22952805 rs9268399 chr6 32340236 G A 0.00001966 Sarcoidosis C6orf10 nearGene-5 22952805 rs9268400 chr6 32340654 G A 4.40E-07 Sarcoidosis C6orf10 nearGene-5 22952805 rs9378202 chr6 32341208 T C 0.00009395 Sarcoidosis C6orf10 nearGene-5 22952805 rs9268401 chr6 32341318 A G 4.51E-07 Sarcoidosis C6orf10 nearGene-5 22952805 rs9268402 chr6 32341353 G A 4.32E-69 Multiple complex diseases C6orf10 nearGene-5 17554300 rs9268402 chr6 32341353 G A 9.92E-18 Multiple sclerosis C6orf10 nearGene-5 17660530 rs9268402 chr6 32341353 G A 1.20E-11 Sarcoidosis C6orf10 nearGene-5 19165924 rs9268402 chr6 32341353 G A 3.83E-19 Narcolepsy C6orf10 nearGene-5 19629137 rs9268402 chr6 32341353 G A 3.00E-15 Coronary heart disease C6orf10 nearGene-5 22751097 rs9268402 chr6 32341353 G A 7.04E-08 Sarcoidosis C6orf10 nearGene-5 22952805 rs9268402 chr6 32341353 G A 3.47E-05 Lupus nephritis in systemic lupus erythematosus C6orf10 nearGene-5 24925725 rs9391858 chr6 32341398 A G 8.93E-05 Multiple complex diseases C6orf10 nearGene-5 17554300 rs9391858 chr6 32341398 A G 8.38E-10 Multiple sclerosis C6orf10 nearGene-5 17660530 rs9391858 chr6 32341398 A G 7.60E-06 HIV-1 control C6orf10 nearGene-5 20041166 rs9391858 chr6 32341398 A G 2.20E-08 HIV-1 control C6orf10 nearGene-5 21051598 rs9391858 chr6 32341398 A G 7.67E-04 Parkinson's disease C6orf10 nearGene-5 21248740 rs9391858 chr6 32341398 A G 0.00003844 Sarcoidosis C6orf10 nearGene-5 22952805 rs9391858 chr6 32341398 A G 3.25E-09 Self-reported allergy C6orf10 nearGene-5 23817569 rs9391858 chr6 32341398 A G 8.68E-06 Hodgkin's lymphoma C6orf10 nearGene-5 24149102 rs9268403 chr6 32341473 T C 1.36E-76 Multiple complex diseases C6orf10 nearGene-5 17554300 rs9268403 chr6 32341473 T C 2.91E-08 Multiple sclerosis C6orf10 nearGene-5 17660530 rs9268403 chr6 32341473 T C 9.27E-59 Rheumatoid arthritis C6orf10 nearGene-5 21156761 rs9268403 chr6 32341473 T C 4.21E-07 Sarcoidosis C6orf10 nearGene-5 22952805 rs9268403 chr6 32341473 T C 1.82E-05 Asthma C6orf10 nearGene-5 23181788 rs9268403 chr6 32341473 T C 3.53E-05 Self-reported allergy C6orf10 nearGene-5 23817569 rs9268404 chr6 32341719 C T 1.62E-07 Sarcoidosis / / 22952805 rs9268405 chr6 32342087 C T 4.51E-07 Sarcoidosis / / 22952805 rs9268406 chr6 32342129 C T 4.51E-07 Sarcoidosis / / 22952805 rs9268407 chr6 32342166 T C 4.51E-07 Sarcoidosis / / 22952805 rs3129945 chr6 32342537 G A 2.61E-06 Podoconiosis / / 22455414 rs9268409 chr6 32342639 A C 4.51E-07 Sarcoidosis / / 22952805 rs7746327 chr6 32342691 C A 8.16E-08 Sarcoidosis / / 22952805 rs3117108 chr6 32342822 C G 0.00003738 Sarcoidosis / / 22952805 rs9268412 chr6 32343018 T A 5.52E-07 Sarcoidosis / / 22952805 rs9268413 chr6 32343095 T C 4.93E-07 Sarcoidosis / / 22952805 rs9268414 chr6 32343096 G A 0.000006652 Sarcoidosis / / 22952805 rs9268415 chr6 32343267 G C 3.85E-07 Sarcoidosis / / 22952805 rs3117106 chr6 32343369 T C 8.74E-06 Podoconiosis / / 22455414 rs3117106 chr6 32343369 T C 8.77E-08 Leprosy / / pha002872 rs9268416 chr6 32343384 A G 7.00E-07 Sarcoidosis / / 22952805 rs9268417 chr6 32343616 A G 0.00007532 Sarcoidosis / / 22952805 rs9268418 chr6 32343686 T C 1.52E-76 Multiple complex diseases / / 17554300 rs9268418 chr6 32343686 T C 7.04E-08 Multiple sclerosis / / 17660530 rs9268418 chr6 32343686 T C 0.00006568 Sarcoidosis / / 22952805 rs3117105 chr6 32343714 T C 0.00004531 Sarcoidosis / / 22952805 rs9268420 chr6 32343796 C T 3.54E-07 Sarcoidosis / / 22952805 rs9268421 chr6 32343869 A G 0.000000536 Sarcoidosis / / 22952805 rs9268422 chr6 32343873 G A 3.54E-07 Sarcoidosis / / 22952805 rs9268423 chr6 32343882 C T 0.000000536 Sarcoidosis / / 22952805 rs9268424 chr6 32343985 T C 0.00000038 Sarcoidosis / / 22952805 rs9268425 chr6 32344376 C T 3.47E-07 Sarcoidosis / / 22952805 rs9268426 chr6 32344731 A G 3.47E-07 Sarcoidosis / / 22952805 rs9268427 chr6 32344808 C T 3.47E-07 Sarcoidosis / / 22952805 rs9268428 chr6 32344973 G T 3.47E-07 Sarcoidosis / / 22952805 rs9268429 chr6 32345052 A G 7.95E-70 Multiple complex diseases / / 17554300 rs9268429 chr6 32345052 A G 9.73E-09 Multiple sclerosis / / 17660530 rs9268429 chr6 32345052 A G 4.75E-55 Rheumatoid arthritis / / 21156761 rs9268429 chr6 32345052 A G 0.00009472 Sarcoidosis / / 22952805 rs12528797 chr6 32345086 A G 9.05E-07 Multiple complex diseases / / 17554300 rs12528797 chr6 32345086 A G 8.70E-05 Coronary Artery Disease / / 17634449 rs12528797 chr6 32345086 A G 4.28E-05 Multiple sclerosis / / 17660530 rs12528797 chr6 32345086 A G 1.94E-06 Self-reported allergy / / 23817569 rs7757831 chr6 32345183 A G 9.32E-08 Multiple complex diseases / / 17554300 rs7757831 chr6 32345183 A G 2.14E-12 Rheumatoid arthritis / / 21156761 rs7758128 chr6 32345283 C A 8.00E-11 Vitiligo / / 21326295 rs9268431 chr6 32345514 T G 3.47E-07 Sarcoidosis / / 22952805 rs2894253 chr6 32345540 T G 0.000000437 Follicular lymphoma / / 23025665 rs2395153 chr6 32345595 C G 2.12E-71 Rheumatoid arthritis / / 21156761 rs2395153 chr6 32345595 C G 5.01E-10 Sarcoidosis / / 22952805 rs9268432 chr6 32345667 A G 3.47E-07 Sarcoidosis / / 22952805 rs2894254 chr6 32345689 T G 3.66E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2894254 chr6 32345689 T G 5.47E-111 Multiple complex diseases / / 17554300 rs2894254 chr6 32345689 T G 3.81E-04 Alzheimer's disease / / 17998437 rs2894254 chr6 32345689 T G 2.03E-11 Rheumatoid arthritis / / 21156761 rs2894254 chr6 32345689 T G 3.25E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs111877852 chr6 32346408 T TGATA 0.00000032 Sarcoidosis / / 22952805 rs565188555 chr6 32346408 T TGATA,TGATAGATAGATAGATA,TGATAGGTA 0.00000032 Sarcoidosis / / 22952805 rs9405094 chr6 32346408 T A 0.00000032 Sarcoidosis / / 22952805 rs9268434 chr6 32346452 A T 0.000002413 Sarcoidosis / / 22952805 rs9268435 chr6 32346491 G A 1.12E-07 Sarcoidosis / / 22952805 rs9268436 chr6 32346637 A G 0.00006568 Sarcoidosis / / 22952805 rs9268439 chr6 32346701 G A 0.00006568 Sarcoidosis / / 22952805 rs3129946 chr6 32346772 A G 0.0000538 Sarcoidosis / / 22952805 rs1980495 chr6 32346794 A C 1.00E-16 Type 1 diabetes / / 17632545 rs1980495 chr6 32346794 A C 3.02E-09 Pemphigus vulgaris / / 22437316 rs1980495 chr6 32346794 A C 0.00004685 Sarcoidosis / / 22952805 rs1980495 chr6 32346794 A C 6.49E-05 Self-reported allergy / / 23817569 rs1980494 chr6 32347016 A G 3.47E-07 Sarcoidosis / / 22952805 rs8180664 chr6 32347490 C T 1.25E-59 Rheumatoid arthritis / / 21156761 rs8180664 chr6 32347490 C T 4.35E-05 Self-reported allergy / / 23817569 rs9268446 chr6 32347749 A G 3.47E-07 Sarcoidosis / / 22952805 rs9268447 chr6 32347831 T C 0.00006568 Sarcoidosis / / 22952805 rs2395155 chr6 32347897 C T 3.47E-07 Sarcoidosis / / 22952805 rs2395156 chr6 32348098 C A 0.00006568 Sarcoidosis / / 22952805 rs2395157 chr6 32348145 A G 1.00E-16 Type 1 diabetes / / 17632545 rs2395157 chr6 32348145 A G 1.76E-70 Rheumatoid arthritis / / 17804836 rs2395157 chr6 32348145 A G 3.85E-59 Rheumatoid arthritis / / 21156761 rs2395157 chr6 32348145 A G 7.12E-05 Parkinson's disease / / 21738487 rs2395157 chr6 32348145 A G 4.72E-17 Hepatitis B vaccine response / / 21764829 rs2395157 chr6 32348145 A G 5.24E-07 Alopecia areata / / 22027810 rs2395157 chr6 32348145 A G 1.52E-08 Pemphigus vulgaris / / 22437316 rs2395157 chr6 32348145 A G 0.000000404 Sarcoidosis / / 22952805 rs2395157 chr6 32348145 A G 4.36E-05 Self-reported allergy / / 23817569 rs2395157 chr6 32348145 A G 2.33E-05 Blood Pressure / / pha003048 rs3117104 chr6 32348309 T A 4.00E-06 Parkinson's disease / / 20711177 rs3117104 chr6 32348309 T A 0.0000487 Sarcoidosis / / 22952805 rs9268448 chr6 32348463 C G 0.00008687 Sarcoidosis / / 22952805 rs9268449 chr6 32348467 G A 0.00008065 Sarcoidosis / / 22952805 rs9268450 chr6 32348690 G A 3.47E-07 Sarcoidosis / / 22952805 rs9268452 chr6 32349494 A G 0.00006568 Sarcoidosis / / 22952805 rs3117103 chr6 32349557 A T 1.82E-11 Rheumatoid arthritis / / 21156761 rs9268453 chr6 32349571 T C 0.00006568 Sarcoidosis / / 22952805 rs9268454 chr6 32349711 A G 0.00006568 Sarcoidosis / / 22952805 rs9268456 chr6 32349946 C A 0.00006568 Sarcoidosis / / 22952805 rs9268457 chr6 32350036 A G 0.00004417 Sarcoidosis / / 22952805 rs3117102 chr6 32350107 C T 3.90E-06 Parkinson's disease / / 20711177 rs3117102 chr6 32350107 C T 0.00005132 Sarcoidosis / / 22952805 rs9268458 chr6 32350384 C A 0.00009273 Sarcoidosis / / 22952805 rs9268459 chr6 32350776 G A 0.0000652 Sarcoidosis / / 22952805 rs4373382 chr6 32350868 A C 3.60E-07 Sarcoidosis / / 22952805 rs9268460 chr6 32351283 T C 0.000002227 Sarcoidosis / / 22952805 rs6930777 chr6 32351566 C T 1.27E-06 Multiple complex diseases / / 17554300 rs6930777 chr6 32351566 C T 4.87E-04 Coronary Artery Disease / / 17634449 rs6930777 chr6 32351566 C T 1.64E-06 Self-reported allergy / / 23817569 rs9268461 chr6 32351901 C A 4.48E-07 Sarcoidosis / / 22952805 rs9268462 chr6 32351991 C A 4.48E-07 Sarcoidosis / / 22952805 rs7767173 chr6 32352294 A T 0.00009129 Sarcoidosis / / 22952805 rs9268468 chr6 32353166 A G 0.00005265 Sarcoidosis / / 22952805 rs4424066 chr6 32354428 A G 2.16E-10 Type 1 diabetes / / 17632545 rs4424066 chr6 32354428 A G 1.23E-69 Rheumatoid arthritis / / 17804836 rs4424066 chr6 32354428 A G 3.83E-61 Rheumatoid arthritis / / 21156761 rs4424066 chr6 32354428 A G 6.04E-05 Follicular lymphoma / / 21533074 rs4424066 chr6 32354428 A G 1.24E-17 Hepatitis B vaccine response / / 21764829 rs4424066 chr6 32354428 A G 8.68E-06 Pemphigus vulgaris / / 22437316 rs4424066 chr6 32354428 A G 5.00E-05 Kawasaki disease / / 22446962 rs4424066 chr6 32354428 A G 0.000001145 Sarcoidosis / / 22952805 rs4424066 chr6 32354428 A G 1.79E-05 Hodgkin's lymphoma / / 24149102 rs4424066 chr6 32354428 A G 7.70E-05 Systemic lupus erythematosus / / 24871463 rs4424066 chr6 32354428 A G 7.34E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1555115 chr6 32354520 C G 8.62E-07 Narcolepsy / / 20711174 rs1555115 chr6 32354520 C G 2.45E-05 Self-reported allergy / / 23817569 rs3129948 chr6 32354644 C A 4.20E-06 Parkinson's disease / / 20711177 rs3129948 chr6 32354644 C A 4.64E-31 Rheumatoid arthritis / / 21156761 rs3129948 chr6 32354644 C A 0.00005702 Sarcoidosis / / 22952805 rs9268472 chr6 32355605 G A 0.000001785 Sarcoidosis / / 22952805 rs9268473 chr6 32355683 A G 5.68E-61 Rheumatoid arthritis / / 21156761 rs9268473 chr6 32355683 A G 0.000001154 Sarcoidosis / / 22952805 rs9268473 chr6 32355683 A G 6.24E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs17423649 chr6 32357133 C T 1.22E-09 Multiple complex diseases / / 17554300 rs17423649 chr6 32357133 C T 0.0000214 Follicular lymphoma / / 23025665 rs17423649 chr6 32357133 C T 4.17E-05 Self-reported allergy / / 23817569 rs9268474 chr6 32357165 T C 3.15E-55 Rheumatoid arthritis / / 21156761 rs9268474 chr6 32357165 T C 4.20E-07 Sarcoidosis / / 22952805 rs9268474 chr6 32357165 T C 4.32E-05 Self-reported allergy / / 23817569 rs17202259 chr6 32357489 T G 4.11E-05 Parkinson's disease / / 21248740 rs12529049 chr6 32357715 C T 5.08E-05 Parkinson's disease / / 21248740 rs12529049 chr6 32357715 C T 0.00000792 Follicular lymphoma / / 23025665 rs12529049 chr6 32357715 C T 3.90E-05 Self-reported allergy / / 23817569 rs12525722 chr6 32358163 A G 6.32E-06 Self-reported allergy / / 23817569 rs3129950 chr6 32358201 G C 8.30E-12 Rheumatoid arthritis / / 21156761 rs9268475 chr6 32358231 C T 4.70E-07 Sarcoidosis / / 22952805 rs3117099 chr6 32358270 G A 1.59E-24 Rheumatoid arthritis / / 21156761 rs3117099 chr6 32358270 G A 1.72E-10 Hepatitis B vaccine response / / 21764829 rs3117099 chr6 32358270 G A 8.35E-06 Podoconiosis / / 22455414 rs3117099 chr6 32358270 G A 3.00E-06 Bipolar disorder and schizophrenia / / 22688191 rs3117099 chr6 32358270 G A 5.44E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs3129951 chr6 32358286 T C 5.23E-31 Rheumatoid arthritis / / 21156761 rs3129951 chr6 32358286 T C 0.00005605 Sarcoidosis / / 22952805 rs17423691 chr6 32358345 C A 3.81E-05 Self-reported allergy / / 23817569 rs17423698 chr6 32358368 T C 1.10E-04 Self-reported allergy / / 23817569 rs3117098 chr6 32358513 G A 1.00E-16 Type 1 diabetes / / 17632545 rs3117098 chr6 32358513 G A 6.22E-24 Rheumatoid arthritis / / 17804836 rs3117098 chr6 32358513 G A 1.07E-50 Rheumatoid arthritis / / 19503088 rs3117098 chr6 32358513 G A 2.19E-07 Multiple sclerosis / / 20598377 rs3117098 chr6 32358513 G A 2.90E-06 Parkinson's disease / / 20711177 rs3117098 chr6 32358513 G A 7.77E-31 Rheumatoid arthritis / / 21156761 rs3117098 chr6 32358513 G A 5.00E-12 Asthma / / 21804548 rs3117098 chr6 32358513 G A 0.00005563 Sarcoidosis / / 22952805 rs3117098 chr6 32358513 G A 1.69E-106 Type 1 diabetes / / pha002862 rs17495592 chr6 32358533 A G 9.05E-07 Self-reported allergy HCG23 intron 23817569 rs3117097 chr6 32358689 A G 1.61E-17 Rheumatoid arthritis HCG23 intron 21156761 rs9268476 chr6 32358942 T A 1.66E-08 Sarcoidosis HCG23 intron 22952805 rs9268477 chr6 32359121 G A 2.86E-55 Rheumatoid arthritis HCG23 intron 21156761 rs9268477 chr6 32359121 G A 4.48E-07 Sarcoidosis HCG23 intron 22952805 rs9268477 chr6 32359121 G A 4.21E-05 Self-reported allergy HCG23 intron 23817569 rs17495612 chr6 32359431 T C 8.30E-11 Multiple complex diseases / / 17554300 rs17495612 chr6 32359431 T C 7.67E-10 Narcolepsy / / 19629137 rs17495612 chr6 32359431 T C 1.22E-05 Self-reported allergy / / 23817569 rs16870123 chr6 32359460 G A 0.0000174 Follicular lymphoma / / 23025665 rs16870123 chr6 32359460 G A 2.82E-05 Self-reported allergy / / 23817569 rs3129952 chr6 32359763 G C 3.62E-35 Rheumatoid arthritis HCG23 intron 21156761 rs3129952 chr6 32359763 G C 0.00006577 Sarcoidosis HCG23 intron 22952805 rs75476410 chr6 32360223 C T 0.00007137 Sarcoidosis HCG23 intron 22952805 rs9268478 chr6 32360258 G A 4.81E-07 Sarcoidosis HCG23 intron 22952805 rs17423753 chr6 32360341 C A 9.61E-07 Self-reported allergy HCG23 intron 23817569 rs3817976 chr6 32361003 C T 1.29E-05 Self-reported allergy HCG23 intron 23817569 rs3817973 chr6 32361111 C T 2.73E-10 Type 1 diabetes HCG23 intron 17632545 rs3817973 chr6 32361111 C T 7.41E-70 Rheumatoid arthritis HCG23 intron 17804836 rs3817973 chr6 32361111 C T 1.67E-61 Rheumatoid arthritis HCG23 intron 21156761 rs3817973 chr6 32361111 C T 5.41E-05 Follicular lymphoma HCG23 intron 21533074 rs3817973 chr6 32361111 C T 8.68E-06 Pemphigus vulgaris HCG23 intron 22437316 rs3817973 chr6 32361111 C T 5.00E-05 Kawasaki disease HCG23 intron 22446962 rs3817973 chr6 32361111 C T 0.000001145 Sarcoidosis HCG23 intron 22952805 rs3817973 chr6 32361111 C T 1.54E-05 Hodgkin's lymphoma HCG23 intron 24149102 rs3817973 chr6 32361111 C T 8.50E-05 Systemic lupus erythematosus HCG23 intron 24871463 rs3817973 chr6 32361111 C T 9.28E-05 Blood Pressure HCG23 intron pha003048 rs3817969 chr6 32361388 C T 1.95E-06 Self-reported allergy / / 23817569 rs3129953 chr6 32361821 C T 1.42E-70 Multiple complex diseases / / 17554300 rs3129953 chr6 32361821 C T 4.34E-19 Rheumatoid arthritis / / 21156761 rs1980493 chr6 32363215 T C 1.00E-16 Type 1 diabetes BTNL2 intron 17632545 rs1980493 chr6 32363215 T C 1.01E-28 Rheumatoid arthritis BTNL2 intron 17804836 rs1980493 chr6 32363215 T C 5.00E-07 Anti-cyclic Citrullinated Peptide Antibody BTNL2 intron 19287509 rs1980493 chr6 32363215 T C 2.53E-29 Rheumatoid arthritis BTNL2 intron 19503088 rs1980493 chr6 32363215 T C 9.06E-19 Rheumatoid arthritis BTNL2 intron 21156761 rs1980493 chr6 32363215 T C 5.90E-70 Myasthenia gravis BTNL2 intron 23055271 rs1980493 chr6 32363215 T C 1.70E-12 Systemic lupus erythematosus BTNL2 intron 24871463 rs1980493 chr6 32363215 T C 1.57E-08 Frontotemporal dementia BTNL2 intron 24943344 rs1980493 chr6 32363215 T C 4.90E-69 Type 1 diabetes BTNL2 intron pha002862 rs2076533 chr6 32363527 C T 9.80E-76 Multiple complex diseases BTNL2 intron 17554300 rs2076533 chr6 32363527 C T 4.01E-13 Multiple sclerosis BTNL2 intron 17660530 rs2076533 chr6 32363527 C T 2.74E-17 Narcolepsy BTNL2 intron 19629137 rs2076533 chr6 32363527 C T 1.94E-61 Rheumatoid arthritis BTNL2 intron 21156761 rs2076533 chr6 32363527 C T 0.000001434 Sarcoidosis BTNL2 intron 22952805 rs2076533 chr6 32363527 C T 6.60E-05 Lupus nephritis in systemic lupus erythematosus BTNL2 intron 24925725 rs2076532 chr6 32363639 T G 4.74E-05 Multiple complex diseases BTNL2 intron 17554300 rs2076531 chr6 32363712 A G 1.00E-09 Non-obstructive azoospermia BTNL2 intron 22541561 rs2076530 chr6 32363816 T C 3.00E-08 Rheumatoid arthritis BTNL2 missense 17159887 rs2076530 chr6 32363816 T C 6.70E-74 Multiple complex diseases BTNL2 missense 17554300 rs2076530 chr6 32363816 T C 3.21E-10 Type 1 diabetes BTNL2 missense 17632545 rs2076530 chr6 32363816 T C 2.46E-13 Multiple sclerosis BTNL2 missense 17660530 rs2076530 chr6 32363816 T C 3.20E-68 Rheumatoid arthritis BTNL2 missense 17804836 rs2076530 chr6 32363816 T C 4.21E-24 Narcolepsy BTNL2 missense 19629137 rs2076530 chr6 32363816 T C 1.30E-09 Lipid levels BTNL2 missense 19936222 rs2076530 chr6 32363816 T C 3.40E-08 Lipid levels BTNL2 missense 19936222 rs2076530 chr6 32363816 T C 5.40E-07 Lipid levels BTNL2 missense 19936222 rs2076530 chr6 32363816 T C 1.78E-59 Rheumatoid arthritis BTNL2 missense 21156761 rs2076530 chr6 32363816 T C 7.74E-05 Follicular lymphoma BTNL2 missense 21533074 rs2076530 chr6 32363816 T C 8.16E-05 Parkinson's disease BTNL2 missense 21738487 rs2076530 chr6 32363816 T C 5.28E-05 Pemphigus vulgaris BTNL2 missense 22437316 rs2076530 chr6 32363816 T C 3.00E-11 Sarcoidosis BTNL2 missense 22936702 rs2076530 chr6 32363816 T C 0.00000144 Sarcoidosis BTNL2 missense 22952805 rs2076530 chr6 32363816 T C 1.56E-05 Hodgkin's lymphoma BTNL2 missense 24149102 rs2076530 chr6 32363816 T C 1.30E-04 Systemic lupus erythematosus BTNL2 missense 24871463 rs9268480 chr6 32363844 C T 1.38E-75 Multiple complex diseases BTNL2 cds-synon 17554300 rs9268480 chr6 32363844 C T 8.00E-08 Multiple sclerosis BTNL2 cds-synon 17660530 rs9268480 chr6 32363844 C T 3.00E-06 Ulcerative colitis BTNL2 cds-synon 19915573 rs9268480 chr6 32363844 C T 1.81E-54 Rheumatoid arthritis BTNL2 cds-synon 21156761 rs9268480 chr6 32363844 C T 4.93E-07 Sarcoidosis BTNL2 cds-synon 22952805 rs9268480 chr6 32363844 C T 2.79E-05 Self-reported allergy BTNL2 cds-synon 23817569 rs2076529 chr6 32363955 T C 3.00E-08 Rheumatoid arthritis BTNL2 cds-synon 17159887 rs2076529 chr6 32363955 T C 4.00E-07 Waist-hip ratio BTNL2 cds-synon 20935629 rs2076529 chr6 32363955 T C 0.000001145 Sarcoidosis BTNL2 cds-synon 22952805 rs9268481 chr6 32364356 A G 4.20E-07 Sarcoidosis BTNL2 intron 22952805 rs3117139 chr6 32364667 A G 0.00001486 Sarcoidosis BTNL2 intron 22952805 rs3129954 chr6 32365580 A G 3.90E-06 Parkinson's disease BTNL2 intron 20711177 rs3129954 chr6 32365580 A G 5.89E-31 Rheumatoid arthritis BTNL2 intron 21156761 rs3129954 chr6 32365580 A G 0.00005563 Sarcoidosis BTNL2 intron 22952805 rs3129955 chr6 32365840 T C 3.80E-06 Parkinson's disease BTNL2 intron 20711177 rs3129955 chr6 32365840 T C 0.00005461 Sarcoidosis BTNL2 intron 22952805 rs4713523 chr6 32365971 G A 2.67E-08 Self-reported allergy BTNL2 intron 23817569 rs4248166 chr6 32366421 T C 3.89E-05 Parkinson's disease BTNL2 intron 21248740 rs4248166 chr6 32366421 T C 2.37E-17 Hepatitis B vaccine response BTNL2 intron 21764829 rs4248166 chr6 32366421 T C 2.13E-13 Epstein-Barr virus immune response (EBNA-1) BTNL2 intron 23326239 rs3117116 chr6 32367017 G A 9.41E-07 Sarcoidosis BTNL2 intron 22952805 rs3117116 chr6 32367017 G A 2.85E-08 Interstitial lung disease BTNL2 intron 23583980 rs2294884 chr6 32367259 T G 6.86E-05 Parkinson's disease BTNL2 intron 21248740 rs2294884 chr6 32367259 T G 3.44E-12 Epstein-Barr virus immune response (EBNA-1) BTNL2 intron 23326239 rs2294884 chr6 32367259 T G 1.11E-06 Self-reported allergy BTNL2 intron 23817569 rs2294883 chr6 32367451 T A 1.64E-08 Self-reported allergy BTNL2 intron 23817569 rs2294882 chr6 32367515 T C 1.83E-12 Epstein-Barr virus immune response (EBNA-1) BTNL2 intron 23326239 rs2294882 chr6 32367515 T C 1.93E-08 Self-reported allergy BTNL2 intron 23817569 rs2294881 chr6 32367604 T C 1.83E-12 Epstein-Barr virus immune response (EBNA-1) BTNL2 intron 23326239 rs2294881 chr6 32367604 T C 2.44E-08 Self-reported allergy BTNL2 intron 23817569 rs2294880 chr6 32367722 A G 5.14E-07 Sarcoidosis BTNL2 intron 22952805 rs2294880 chr6 32367722 A G 4.06E-05 Self-reported allergy BTNL2 intron 23817569 rs9268482 chr6 32367777 A T 3.31E-07 Sarcoidosis BTNL2 intron 22952805 rs2294878 chr6 32367795 G T 1.13E-09 Sarcoidosis BTNL2 intron 22952805 rs3817966 chr6 32367847 T C 0.00009085 Sarcoidosis BTNL2 intron 22952805 rs3817966 chr6 32367847 T C 5.96E-04 Self-reported allergy BTNL2 intron 23817569 rs3817963 chr6 32368087 T C 1.00E-16 Type 1 diabetes BTNL2 intron 17632545 rs3817963 chr6 32368087 T C 4.43E-67 Rheumatoid arthritis BTNL2 intron 17804836 rs3817963 chr6 32368087 T C 7.74E-109 Rheumatoid arthritis BTNL2 intron 19503088 rs3817963 chr6 32368087 T C 3.88E-55 Rheumatoid arthritis BTNL2 intron 21156761 rs3817963 chr6 32368087 T C 9.20E-18 Hepatitis B vaccine response BTNL2 intron 21764829 rs3817963 chr6 32368087 T C 1.50E-05 Alopecia areata BTNL2 intron 22027810 rs3817963 chr6 32368087 T C 1.91E-06 Pemphigus vulgaris BTNL2 intron 22437316 rs3817963 chr6 32368087 T C 8.90E-05 Hypothyroidism BTNL2 intron 22493691 rs3817963 chr6 32368087 T C 3.00E-10 Lung adenocarcinoma BTNL2 intron 22797724 rs3817963 chr6 32368087 T C 5.69E-07 Sarcoidosis BTNL2 intron 22952805 rs3817963 chr6 32368087 T C 1.00E-08 Hepatitis C induced liver cirrhosis BTNL2 intron 23321320 rs3817963 chr6 32368087 T C 6.00E-10 Multiple sclerosis (OCB status) BTNL2 intron 23472185 rs3817963 chr6 32368087 T C 8.00E-06 Multiple sclerosis (OCB status) BTNL2 intron 23472185 rs3817963 chr6 32368087 T C 5.71E-05 Self-reported allergy BTNL2 intron 23817569 rs3817963 chr6 32368087 T C 5.10E-04 Systemic lupus erythematosus BTNL2 intron 24871463 rs3817963 chr6 32368087 T C 6.09E-05 Blood Pressure BTNL2 intron pha003048 rs3817962 chr6 32368314 C A 0.0000917 Sarcoidosis BTNL2 intron 22952805 rs3817962 chr6 32368314 C A 4.39E-05 Self-reported allergy BTNL2 intron 23817569 rs9268489 chr6 32368709 G A,T 0.0000376 Sarcoidosis BTNL2 intron 22952805 rs3763305 chr6 32369488 G A 2.03E-08 Rheumatoid arthritis BTNL2 intron 17804836 rs3763305 chr6 32369488 G A 9.33E-26 Rheumatoid arthritis BTNL2 intron 19503088 rs3763305 chr6 32369488 G A 4.51E-05 Longevity BTNL2 intron 22279548 rs2076525 chr6 32370616 T C 4.00E-07 Rheumatoid arthritis BTNL2 intron 17159887 rs2076525 chr6 32370616 T C 4.20E-07 Sarcoidosis BTNL2 intron 22952805 rs2076525 chr6 32370616 T C 4.41E-05 Self-reported allergy BTNL2 intron 23817569 rs2076524 chr6 32370684 A G 6.07E-55 Rheumatoid arthritis BTNL2 intron 21156761 rs2076524 chr6 32370684 A G 5.27E-07 Sarcoidosis BTNL2 intron 22952805 rs2076524 chr6 32370684 A G 4.28E-05 Self-reported allergy BTNL2 intron 23817569 rs28362680 chr6 32370816 G A 1.48E-06 Vitiligo BTNL2 missense 21326295 rs28362680 chr6 32370816 G A 2.97E-11 Epstein-Barr virus immune response (EBNA-1) BTNL2 missense 23326239 rs2076523 chr6 32370835 T C 4.00E-04 Rheumatoid arthritis BTNL2 missense 17159887 rs2076523 chr6 32370835 T C 5.14E-36 Rheumatoid arthritis BTNL2 missense 21156761 rs2076523 chr6 32370835 T C 2.77E-05 Response to mTOR inhibitor (rapamycin) BTNL2 missense 24009623 rs2076522 chr6 32371179 G C 6.17E-55 Rheumatoid arthritis BTNL2 intron 21156761 rs2076522 chr6 32371179 G C 4.34E-07 Sarcoidosis BTNL2 intron 22952805 rs2076522 chr6 32371179 G C 4.17E-05 Self-reported allergy BTNL2 intron 23817569 rs2076520 chr6 32371269 C T 3.53E-07 Sarcoidosis BTNL2 intron 22952805 rs3793126 chr6 32371619 A G 1.00E-16 Type 1 diabetes BTNL2 intron 17632545 rs3793126 chr6 32371619 A G 1.01E-53 Rheumatoid arthritis BTNL2 intron 21156761 rs3793126 chr6 32371619 A G 3.16E-07 Sarcoidosis BTNL2 intron 22952805 rs3793126 chr6 32371619 A G 3.03E-05 Self-reported allergy BTNL2 intron 23817569 rs3793126 chr6 32371619 A G 8.33E-05 Lupus nephritis in systemic lupus erythematosus BTNL2 intron 24925725 rs3793127 chr6 32371915 C T 1.24E-87 Rheumatoid arthritis BTNL2 intron 21156761 rs28362683 chr6 32372963 G A 1.09E-07 Vitiligo BTNL2 cds-synon 21326295 rs28362683 chr6 32372963 G A 4.56E-11 Epstein-Barr virus immune response (EBNA-1) BTNL2 cds-synon 23326239 rs28362683 chr6 32372963 G A 5.96E-04 Response to cytadine analogues (cytosine arabinoside) BTNL2 cds-synon 24483146 rs10947260 chr6 32373185 T C 2.03E-09 Multiple complex diseases BTNL2 intron 17554300 rs10947260 chr6 32373185 T C 6.94E-18 Rheumatoid arthritis BTNL2 intron 21156761 rs10947260 chr6 32373185 T C 9.20E-04 Response to cytadine analogues (cytosine arabinoside) BTNL2 intron 24483146 rs10947260 chr6 32373185 T C 9.79E-04 Response to cytidine analogues (gemcitabine) BTNL2 intron 24483146 rs10947261 chr6 32373232 G T 4.34E-11 Multiple complex diseases BTNL2 intron 17554300 rs10947261 chr6 32373232 G T 5.66E-11 Narcolepsy BTNL2 intron 19629137 rs10947261 chr6 32373232 G T 6.94E-18 Rheumatoid arthritis BTNL2 intron 21156761 rs10947261 chr6 32373232 G T 2.37E-11 Epstein-Barr virus immune response (EBNA-1) BTNL2 intron 23326239 rs10947261 chr6 32373232 G T 3.00E-12 Crohn's disease BTNL2 intron 23850713 rs10947262 chr6 32373312 C T 5.00E-09 Knee osteoarthritis BTNL2 intron 20305777 rs10947262 chr6 32373312 C T 1.48E-06 Vitiligo BTNL2 intron 21326295 rs10947262 chr6 32373312 C T 5.41E-11 Epstein-Barr virus immune response (EBNA-1) BTNL2 intron 23326239 rs10947262 chr6 32373312 C T 8.84E-04 Myocardial infarction BTNL2 intron 24916648 rs3806156 chr6 32373698 G T 4.65E-46 Multiple complex diseases BTNL2 intron 17554300 rs3806156 chr6 32373698 G T 5.12E-12 Type 1 diabetes BTNL2 intron 17632545 rs3806156 chr6 32373698 G T 4.56E-09 Multiple sclerosis BTNL2 intron 17660530 rs3806156 chr6 32373698 G T 7.00E-40 Rheumatoid arthritis BTNL2 intron 17804836 rs3806156 chr6 32373698 G T 1.31E-73 Rheumatoid arthritis BTNL2 intron 19503088 rs3806156 chr6 32373698 G T 5.86E-18 Narcolepsy BTNL2 intron 19629137 rs3806156 chr6 32373698 G T 7.00E-19 Vitiligo BTNL2 intron 20410501 rs3806156 chr6 32373698 G T 1.20E-35 Rheumatoid arthritis BTNL2 intron 21156761 rs3806156 chr6 32373698 G T 4.29E-06 Pemphigus vulgaris BTNL2 intron 22437316 rs3806156 chr6 32373698 G T 4.00E-05 Hypothyroidism BTNL2 intron 22493691 rs3806156 chr6 32373698 G T 1.59E-25 Vitiligo BTNL2 intron 22561518 rs3806156 chr6 32373698 G T 4.31E-05 Response to mTOR inhibitor (rapamycin) BTNL2 intron 24009623 rs3806156 chr6 32373698 G T 2.44E-05 Blood Pressure BTNL2 intron pha003048 rs3806157 chr6 32373801 T G 1.20E-35 Rheumatoid arthritis BTNL2 intron 21156761 rs3806157 chr6 32373801 T G 0.00004909 Sarcoidosis BTNL2 intron 22952805 rs3806157 chr6 32373801 T G 2.62E-04 Self-reported allergy BTNL2 intron 23817569 rs9268491 chr6 32374131 C G 1.13E-48 Rheumatoid arthritis BTNL2 intron 21156761 rs9268491 chr6 32374131 C G 3.22E-07 Sarcoidosis BTNL2 intron 22952805 rs9268491 chr6 32374131 C G 3.13E-05 Self-reported allergy BTNL2 intron 23817569 rs3763307 chr6 32374622 A T 5.09E-76 Multiple complex diseases BTNL2 intron 17554300 rs3763307 chr6 32374622 A T 1.37E-07 Multiple sclerosis BTNL2 intron 17660530 rs3763307 chr6 32374622 A T 7.22E-55 Rheumatoid arthritis BTNL2 intron 21156761 rs3763307 chr6 32374622 A T 3.79E-07 Sarcoidosis BTNL2 intron 22952805 rs3763307 chr6 32374622 A T 7.23E-05 Self-reported allergy BTNL2 intron 23817569 rs3763308 chr6 32374640 G A 5.43E-11 Multiple complex diseases BTNL2 intron 17554300 rs3763308 chr6 32374640 G A 2.08E-12 Rheumatoid arthritis BTNL2 intron 21156761 rs9268492 chr6 32375280 C G 4.00E-07 Rheumatoid arthritis BTNL2 nearGene-5 17159887 rs9268492 chr6 32375280 C G 7.65E-49 Rheumatoid arthritis BTNL2 nearGene-5 21156761 rs9268492 chr6 32375280 C G 0.000003077 Sarcoidosis BTNL2 nearGene-5 22952805 rs9268492 chr6 32375280 C G 3.34E-04 Self-reported allergy BTNL2 nearGene-5 23817569 rs9268493 chr6 32375330 G A 1.00E-48 Rheumatoid arthritis BTNL2 nearGene-5 21156761 rs9268493 chr6 32375330 G A 0.000003329 Sarcoidosis BTNL2 nearGene-5 22952805 rs9268493 chr6 32375330 G A 2.59E-04 Self-reported allergy BTNL2 nearGene-5 23817569 rs9268493 chr6 32375330 G A 9.20E-05 Lupus nephritis in systemic lupus erythematosus BTNL2 nearGene-5 24925725 rs9268494 chr6 32375352 A C 4.00E-07 Rheumatoid arthritis BTNL2 nearGene-5 17159887 rs9268494 chr6 32375352 A C 5.80E-49 Rheumatoid arthritis BTNL2 nearGene-5 21156761 rs9268494 chr6 32375352 A C 0.000004317 Sarcoidosis BTNL2 nearGene-5 22952805 rs9268494 chr6 32375352 A C 0.00000008 Joint damage severity in rheumatoid arthritis BTNL2 nearGene-5 23696630 rs9268494 chr6 32375352 A C 9.25E-05 Lupus nephritis in systemic lupus erythematosus BTNL2 nearGene-5 24925725 rs9268495 chr6 32375371 A T 0.000004317 Sarcoidosis BTNL2 nearGene-5 22952805 rs9268496 chr6 32375374 G A 0.000003902 Sarcoidosis BTNL2 nearGene-5 22952805 rs9268497 chr6 32375424 G A 4.00E-07 Rheumatoid arthritis BTNL2 nearGene-5 17159887 rs9268497 chr6 32375424 G A 0.000004622 Sarcoidosis BTNL2 nearGene-5 22952805 rs9268497 chr6 32375424 G A 0.00000008 Joint damage severity in rheumatoid arthritis BTNL2 nearGene-5 23696630 rs9268499 chr6 32375695 G A 8.03E-49 Rheumatoid arthritis BTNL2 nearGene-5 21156761 rs9268499 chr6 32375695 G A 0.000001149 Sarcoidosis BTNL2 nearGene-5 22952805 rs9268499 chr6 32375695 G A 9.90E-04 Self-reported allergy BTNL2 nearGene-5 23817569 rs9268499 chr6 32375695 G A 9.49E-05 Lupus nephritis in systemic lupus erythematosus BTNL2 nearGene-5 24925725 rs6926737 chr6 32375745 G A 3.10E-08 Sarcoidosis BTNL2 nearGene-5 22952805 rs3129959 chr6 32375796 A T 4.60E-20 Rheumatoid arthritis BTNL2 nearGene-5 21156761 rs3763309 chr6 32375973 C A 1.17E-102 Rheumatoid arthritis BTNL2 nearGene-5 17804836 rs3763309 chr6 32375973 C A 9.91E-88 Rheumatoid arthritis BTNL2 nearGene-5 21156761 rs3763309 chr6 32375973 C A 4.70E-06 Parkinson's disease BTNL2 nearGene-5 21738487 rs3763309 chr6 32375973 C A 2.80E-07 Asthma BTNL2 nearGene-5 21907864 rs3763309 chr6 32375973 C A 6.69E-06 Alopecia areata BTNL2 nearGene-5 22027810 rs3763309 chr6 32375973 C A 1.03E-16 Pemphigus vulgaris BTNL2 nearGene-5 22437316 rs3763311 chr6 32376176 C T 0.000001218 Sarcoidosis BTNL2 nearGene-5 22952805 rs3763311 chr6 32376176 C T 9.66E-05 Self-reported allergy BTNL2 nearGene-5 23817569 rs3763312 chr6 32376348 G A 5.62E-06 Parkinson's disease BTNL2 nearGene-5 21738487 rs17208853 chr6 32376360 T C 0.00000241 Sarcoidosis BTNL2 nearGene-5 22952805 rs3763313 chr6 32376471 A C 6.01E-08 Type 1 diabetes BTNL2 nearGene-5 17632545 rs3763313 chr6 32376471 A C 2.60E-09 Crohn's disease BTNL2 nearGene-5 18587394 rs3763313 chr6 32376471 A C 2.00E-06 HIV-1 control BTNL2 nearGene-5 20041166 rs3763313 chr6 32376471 A C 7.30E-05 Follicular lymphoma BTNL2 nearGene-5 21533074 rs3763313 chr6 32376471 A C 0.000000463 Follicular lymphoma BTNL2 nearGene-5 23025665 rs3763313 chr6 32376471 A C 4.48E-08 Self-reported allergy BTNL2 nearGene-5 23817569 rs3763313 chr6 32376471 A C 8.40E-07 Hodgkin's lymphoma BTNL2 nearGene-5 24149102 rs3763314 chr6 32376618 C T 3.52E-08 Sarcoidosis BTNL2 nearGene-5 22952805 rs3763316 chr6 32376746 C T 2.52E-51 Rheumatoid arthritis BTNL2 nearGene-5 21156761 rs3763316 chr6 32376746 C T 3.91E-07 Sarcoidosis BTNL2 nearGene-5 22952805 rs3763316 chr6 32376746 C T 4.63E-05 Self-reported allergy BTNL2 nearGene-5 23817569 rs3763316 chr6 32376746 C T 3.75E-13 Hepatitis B vaccine response BTNL2 nearGene-5 24282030 rs3763317 chr6 32376788 C T 0.00001928 Sarcoidosis BTNL2 nearGene-5 22952805 rs3763317 chr6 32376788 C T 9.00E-66 Complement C3 and C4 levels BTNL2 nearGene-5 23028341 rs9268501 chr6 32376882 T G 1.97E-08 Sarcoidosis BTNL2 nearGene-5 22952805 rs9268502 chr6 32376932 C T 0.000000016 Sarcoidosis / / 22952805 rs9268503 chr6 32377061 C T 2.20E-08 Sarcoidosis / / 22952805 rs9268504 chr6 32377116 C G 0.000000021 Sarcoidosis / / 22952805 rs9268506 chr6 32377470 C T 3.62E-08 Sarcoidosis / / 22952805 rs9268507 chr6 32377539 A G 3.23E-08 Sarcoidosis / / 22952805 rs9268508 chr6 32377588 T A 0.000000032 Sarcoidosis / / 22952805 rs9268513 chr6 32378787 T C 3.43E-08 Sarcoidosis / / 22952805 rs5007266 chr6 32378834 T C 3.23E-08 Sarcoidosis / / 22952805 rs5007265 chr6 32378866 T G 3.23E-08 Sarcoidosis / / 22952805 rs5007264 chr6 32378877 C T 3.23E-08 Sarcoidosis / / 22952805 rs3129961 chr6 32378940 C T 0.0000473 Sarcoidosis / / 22952805 rs9268514 chr6 32378945 T A 8.04E-07 Sarcoidosis / / 22952805 rs5007263 chr6 32378982 A G 3.23E-08 Sarcoidosis / / 22952805 rs5007262 chr6 32379011 A G 3.64E-08 Sarcoidosis / / 22952805 rs5007261 chr6 32379031 G A 3.23E-08 Sarcoidosis / / 22952805 rs5007260 chr6 32379047 G A 3.72E-08 Sarcoidosis / / 22952805 rs5007259 chr6 32379101 T C 3.23E-08 Sarcoidosis / / 22952805 rs5007258 chr6 32379239 A G 2.61E-08 Sarcoidosis / / 22952805 rs3129962 chr6 32379383 G A,C 2.20E-18 Type 1 diabetes / / 17632545 rs3129962 chr6 32379383 G A,C 1.70E-05 Lung adenocarcinoma / / 19836008 rs3129962 chr6 32379383 G A,C 1.12E-13 Rheumatoid arthritis / / 21156761 rs3129962 chr6 32379383 G A,C 5.23E-98 Type 1 diabetes / / pha002862 rs6906730 chr6 32379445 T C 3.23E-08 Sarcoidosis / / 22952805 rs9268516 chr6 32379489 C T 1.54E-55 Rheumatoid arthritis / / 21156761 rs9268516 chr6 32379489 C T 8.77E-07 Sarcoidosis / / 22952805 rs9268516 chr6 32379489 C T 1.00E-08 Asthma / / 23028483 rs9268516 chr6 32379489 C T 4.16E-05 Self-reported allergy / / 23817569 rs17208888 chr6 32379506 G A 6.34E-20 Type 1 diabetes / / 17632545 rs6911383 chr6 32379682 T C 3.23E-08 Sarcoidosis / / 22952805 rs9405098 chr6 32379736 G A 7.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9405098 chr6 32379736 G A 1.30E-05 Kawasaki disease / / 22446962 rs9405098 chr6 32379736 G A 1.00E-10 Hepatitis C induced liver cirrhosis / / 23321320 rs6932810 chr6 32380190 G A 3.23E-08 Sarcoidosis / / 22952805 rs3129963 chr6 32380208 A G 5.40E-14 Type 1 diabetes / / 17632545 rs3129963 chr6 32380208 A G 1.30E-33 Rheumatoid arthritis / / 17804836 rs3129963 chr6 32380208 A G 7.51E-35 Rheumatoid arthritis / / 19503088 rs3129963 chr6 32380208 A G 2.74E-29 Rheumatoid arthritis / / 21156761 rs3129963 chr6 32380208 A G 2.50E-64 Myasthenia gravis / / 23055271 rs3129963 chr6 32380208 A G 1.40E-12 Systemic lupus erythematosus / / 24871463 rs3129963 chr6 32380208 A G 6.53E-06 Systemic lupus erythematosus / / pha002867 rs6932542 chr6 32380262 A G 9.25E-70 Rheumatoid arthritis / / 17804836 rs6932542 chr6 32380262 A G 1.30E-05 HIV-1 control / / 20041166 rs6932542 chr6 32380262 A G 3.43E-07 Follicular lymphoma / / 21533074 rs6932542 chr6 32380262 A G 2.89E-08 Sarcoidosis / / 22952805 rs6932542 chr6 32380262 A G 2.64E-10 Hodgkin's lymphoma / / 24149102 rs6932542 chr6 32380262 A G 1.50E-07 Systemic lupus erythematosus / / 24871463 rs968155 chr6 32380715 C T 2.54E-08 Sarcoidosis / / 22952805 rs3129964 chr6 32380717 C G 0.00006546 Sarcoidosis / / 22952805 rs4502931 chr6 32380782 T A 3.23E-08 Sarcoidosis / / 22952805 rs968154 chr6 32380785 G A 3.23E-08 Sarcoidosis / / 22952805 rs9268518 chr6 32380818 A G 3.96E-08 Sarcoidosis / / 22952805 rs9268519 chr6 32380826 G A 3.89E-08 Sarcoidosis / / 22952805 rs9268520 chr6 32380860 C A 3.89E-08 Sarcoidosis / / 22952805 rs9469108 chr6 32380892 C T 0.00004246 Sarcoidosis / / 22952805 rs6938337 chr6 32381041 C G 2.94E-08 Sarcoidosis / / 22952805 rs6918317 chr6 32381210 T C 2.21E-08 Sarcoidosis / / 22952805 rs7759742 chr6 32381736 T A 2.32E-08 Sarcoidosis / / 22952805 rs743862 chr6 32381939 T C 9.54E-16 Rheumatoid arthritis / / 21156761 rs743862 chr6 32381939 T C 7.72E-04 Self-reported allergy / / 23817569 rs743862 chr6 32381939 T C 9.40E-04 Systemic lupus erythematosus / / 24871463 rs4959027 chr6 32383050 A G 2.44E-30 Rheumatoid arthritis / / 21156761 rs4959027 chr6 32383050 A G 9.00E-07 Pubertal anthropometrics / / 23449627 rs9268528 chr6 32383108 A G 8.18E-19 Type 1 diabetes / / 17632545 rs9268528 chr6 32383108 A G 2.14E-47 Rheumatoid arthritis / / 21156761 rs9268528 chr6 32383108 A G 8.30E-12 Hepatitis B vaccine response / / 21764829 rs9268528 chr6 32383108 A G 1.56E-08 Alopecia areata / / 22027810 rs9268528 chr6 32383108 A G 1.90E-05 Kawasaki disease / / 22446962 rs9268528 chr6 32383108 A G 3.12E-06 Leprosy / / pha002872 rs6930571 chr6 32383208 G T 6.99E-29 Rheumatoid arthritis / / 21156761 rs9268530 chr6 32383223 T C 1.00E-16 Type 1 diabetes / / 17632545 rs9268530 chr6 32383223 T C 6.99E-29 Rheumatoid arthritis / / 21156761 rs9268534 chr6 32383307 T G 4.98E-29 Rheumatoid arthritis / / 21156761 rs6908065 chr6 32383341 A C 3.54E-28 Rheumatoid arthritis / / 21156761 rs6908056 chr6 32383360 G A 4.98E-29 Rheumatoid arthritis / / 21156761 rs6930933 chr6 32383410 G T 1.55E-59 Multiple complex diseases / / 17554300 rs6930933 chr6 32383410 G T 4.98E-29 Rheumatoid arthritis / / 21156761 rs3135382 chr6 32383441 T G 4.98E-29 Rheumatoid arthritis / / 21156761 rs2001100 chr6 32383488 T A 4.98E-29 Rheumatoid arthritis / / 21156761 rs2001099 chr6 32383633 G C 2.48E-58 Multiple complex diseases / / 17554300 rs2001099 chr6 32383633 G C 4.98E-29 Rheumatoid arthritis / / 21156761 rs2001098 chr6 32383837 G A 4.98E-29 Rheumatoid arthritis / / 21156761 rs2001097 chr6 32383858 G T 8.01E-60 Multiple complex diseases / / 17554300 rs2001097 chr6 32383858 G T 4.98E-29 Rheumatoid arthritis / / 21156761 rs2395159 chr6 32384077 C T 4.98E-29 Rheumatoid arthritis / / 21156761 rs3135381 chr6 32384343 G A 4.98E-29 Rheumatoid arthritis / / 21156761 rs2227138 chr6 32384500 C T 6.43E-19 Rheumatoid arthritis / / 21156761 rs9268541 chr6 32384527 T C 3.49E-14 Multiple complex diseases / / 17554300 rs9268541 chr6 32384527 T C 1.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs3135380 chr6 32384677 A C 4.98E-29 Rheumatoid arthritis / / 21156761 rs9268542 chr6 32384721 A G 1.00E-04 Rheumatoid arthritis / / 17159887 rs9268542 chr6 32384721 A G 7.19E-18 Type 1 diabetes / / 17632545 rs9268542 chr6 32384721 A G 4.33E-67 Rheumatoid arthritis / / 17804836 rs9268542 chr6 32384721 A G 8.17E-82 Rheumatoid arthritis / / 19503088 rs9268542 chr6 32384721 A G 8.55E-05 Asthma / / 20159242 rs9268542 chr6 32384721 A G 3.94E-45 Rheumatoid arthritis / / 21156761 rs9268542 chr6 32384721 A G 5.43E-12 Hepatitis B vaccine response / / 21764829 rs9268542 chr6 32384721 A G 4.91E-09 Pemphigus vulgaris / / 22437316 rs9268542 chr6 32384721 A G 1.80E-05 Kawasaki disease / / 22446962 rs9268542 chr6 32384721 A G 1.40E-05 Systemic lupus erythematosus / / 24871463 rs9268542 chr6 32384721 A G 3.12E-06 Leprosy / / pha002872 rs9268543 chr6 32384801 A T 7.36E-06 IgE levels / / 22075330 rs9268543 chr6 32384801 A T 0.00000248 Sarcoidosis / / 22952805 rs3135378 chr6 32385099 G A 3.76E-59 Multiple complex diseases / / 17554300 rs3135378 chr6 32385099 G A 1.00E-28 Rheumatoid arthritis / / 21156761 rs3135377 chr6 32385399 A G 1.38E-04 Type 2 diabetes / / 17463246 rs3135377 chr6 32385399 A G 1.96E-97 Multiple complex diseases / / 17554300 rs3135377 chr6 32385399 A G 6.32E-28 Multiple sclerosis / / 17660530 rs3135377 chr6 32385399 A G 3.69E-30 Rheumatoid arthritis / / 21156761 rs3135377 chr6 32385399 A G 4.30E-05 Diabetic nephropathy / / pha002866 rs9268544 chr6 32385453 G A 6.34E-45 Rheumatoid arthritis / / 21156761 rs3135376 chr6 32385470 A G 1.96E-59 Multiple complex diseases / / 17554300 rs3135376 chr6 32385470 A G 1.00E-28 Rheumatoid arthritis / / 21156761 rs3135375 chr6 32385573 G A 1.00E-28 Rheumatoid arthritis / / 21156761 rs3135374 chr6 32385605 C A 1.00E-28 Rheumatoid arthritis / / 21156761 rs3135373 chr6 32385653 A G 1.00E-28 Rheumatoid arthritis / / 21156761 rs3135372 chr6 32385782 C A 1.00E-28 Rheumatoid arthritis / / 21156761 rs2187820 chr6 32385873 C T 1.00E-28 Rheumatoid arthritis / / 21156761 rs2157336 chr6 32386061 C T 1.00E-28 Rheumatoid arthritis / / 21156761 rs9268556 chr6 32386964 T C 6.34E-45 Rheumatoid arthritis / / 21156761 rs3135368 chr6 32387278 T A 1.00E-28 Rheumatoid arthritis / / 21156761 rs2395161 chr6 32387752 A C 2.46E-59 Multiple complex diseases / / 17554300 rs2395161 chr6 32387752 A C 1.10E-28 Rheumatoid arthritis / / 21156761 rs2395162 chr6 32387780 G T 1.00E-16 Type 1 diabetes / / 17632545 rs2395162 chr6 32387780 G T 1.10E-28 Rheumatoid arthritis / / 21156761 rs2395163 chr6 32387809 T C 4.21E-109 Rheumatoid arthritis / / 17804836 rs2395163 chr6 32387809 T C 1.62E-92 Rheumatoid arthritis / / 21156761 rs2395163 chr6 32387809 T C 3.40E-06 Parkinson's disease / / 21738487 rs2395163 chr6 32387809 T C 3.01E-14 Pemphigus vulgaris / / 22437316 rs2395163 chr6 32387809 T C 3.00E-11 Parkinson's disease / / 22451204 rs2395163 chr6 32387809 T C 2.00E-04 Parkinson's disease / / 24511991 rs2395163 chr6 32387809 T C 9.00E-05 Parkinson's disease / / 24511991 rs2395164 chr6 32387860 C T 4.40E-58 Multiple complex diseases / / 17554300 rs2395164 chr6 32387860 C T 1.10E-28 Rheumatoid arthritis / / 21156761 rs2395167 chr6 32388308 C T 1.20E-59 Multiple complex diseases / / 17554300 rs2395167 chr6 32388308 C T 0.000404 Breast cancer early age of onset / / 18463975 rs2395167 chr6 32388308 C T 1.10E-28 Rheumatoid arthritis / / 21156761 rs2213580 chr6 32388574 T C 1.20E-58 Multiple complex diseases / / 17554300 rs2213580 chr6 32388574 T C 1.10E-28 Rheumatoid arthritis / / 21156761 rs3135366 chr6 32388709 T C 1.94E-58 Multiple complex diseases / / 17554300 rs3135366 chr6 32388709 T C 2.81E-28 Rheumatoid arthritis / / 21156761 rs9268557 chr6 32389305 T C 2.17E-82 Multiple complex diseases / / 17554300 rs9268557 chr6 32389305 T C 7.37E-17 Multiple sclerosis / / 17660530 rs9268557 chr6 32389305 T C 5.81E-21 Narcolepsy / / 19629137 rs9268557 chr6 32389305 T C 7.08E-72 Rheumatoid arthritis / / 21156761 rs12524667 chr6 32389334 C T 7.07E-07 Sarcoidosis / / 22952805 rs9268560 chr6 32389512 C G 2.25E-84 Multiple complex diseases / / 17554300 rs9268560 chr6 32389512 C G 1.83E-16 Multiple sclerosis / / 17660530 rs9268560 chr6 32389512 C G 9.24E-05 Serum metabolites / / 19043545 rs9268560 chr6 32389512 C G 2.69E-17 Narcolepsy / / 19629137 rs9268560 chr6 32389512 C G 8.46E-65 Rheumatoid arthritis / / 21156761 rs3135363 chr6 32389648 A G 9.81E-12 Multiple complex diseases / / 17554300 rs3135363 chr6 32389648 A G 8.24E-39 Rheumatoid arthritis / / 17804836 rs3135363 chr6 32389648 A G 1.00E-10 Primary biliary cirrhosis / / 19458352 rs3135363 chr6 32389648 A G 7.33E-62 Rheumatoid arthritis / / 19503088 rs3135363 chr6 32389648 A G 8.62E-07 Multiple sclerosis / / 20598377 rs3135363 chr6 32389648 A G 1.77E-33 Rheumatoid arthritis / / 21156761 rs3135363 chr6 32389648 A G 7.94E-05 Follicular lymphoma / / 21533074 rs3135363 chr6 32389648 A G 2.17E-05 Hepatitis B / / 21750111 rs3135363 chr6 32389648 A G 7.00E-22 Hepatitis B vaccine response / / 21764829 rs3135363 chr6 32389648 A G 6.53E-22 Hepatocellular carcinoma (hepatitis B virus related) / / 23242368 rs3135363 chr6 32389648 A G 1.00E-10 Hepatitis C induced liver cirrhosis / / 23321320 rs3135363 chr6 32389648 A G 8.00E-07 Hepatitis B vaccine response / / 24282030 rs3135363 chr6 32389648 A G 6.00E-04 Systemic lupus erythematosus / / 24871463 rs2157332 chr6 32392661 C T 2.06E-08 Sarcoidosis / / 22952805 rs3135353 chr6 32392877 C T 1.00E-16 Type 1 diabetes / / 17632545 rs3135353 chr6 32392877 C T 1.78E-25 Rheumatoid arthritis / / 17804836 rs3135353 chr6 32392877 C T 7.95E-26 Rheumatoid arthritis / / 19503088 rs3135353 chr6 32392877 C T 8.96E-06 Lung adenocarcinoma / / 19836008 rs3135353 chr6 32392877 C T 6.30E-18 Rheumatoid arthritis / / 21156761 rs3135353 chr6 32392877 C T 1.80E-72 Myasthenia gravis / / 23055271 rs3135353 chr6 32392877 C T 1.15E-84 Type 1 diabetes / / pha002862 rs3135353 chr6 32392877 C T 1.43E-05 Systemic lupus erythematosus / / pha002867 rs3135351 chr6 32392945 C A 9.48E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6457580 chr6 32393141 G T 5.35E-04 Intracranial aneurysm / / 22286173 rs28452472 chr6 32394048 G A 0.000002386 Sarcoidosis / / 22952805 rs2395171 chr6 32394537 C T 1.11E-27 Rheumatoid arthritis / / 21156761 rs2187818 chr6 32395568 G T 1.50E-43 Rheumatoid arthritis / / 21156761 rs2187818 chr6 32395568 G T 4.39E-08 Sarcoidosis / / 22952805 rs9268576 chr6 32395641 T C 0.00005444 Sarcoidosis / / 22952805 rs9268577 chr6 32395942 C T 0.00005959 Sarcoidosis / / 22952805 rs9268578 chr6 32396057 A G 4.39E-08 Sarcoidosis / / 22952805 rs3129845 chr6 32396277 A G 2.70E-05 Self-reported allergy / / 23817569 rs9268579 chr6 32396450 G A 4.39E-08 Sarcoidosis / / 22952805 rs3129847 chr6 32396506 A G 1.05E-07 Multiple complex diseases / / 17554300 rs3129847 chr6 32396506 A G 3.68E-11 Rheumatoid arthritis / / 21156761 rs3129847 chr6 32396506 A G 1.61E-05 Self-reported allergy / / 23817569 rs3129847 chr6 32396506 A G 7.28E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs3135342 chr6 32396615 G T 8.09E-08 Multiple complex diseases / / 17554300 rs3135342 chr6 32396615 G T 2.48E-10 Multiple sclerosis / / 17660530 rs3135342 chr6 32396615 G T 3.68E-11 Rheumatoid arthritis / / 21156761 rs3135342 chr6 32396615 G T 1.61E-05 Self-reported allergy / / 23817569 rs3135342 chr6 32396615 G T 7.24E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9268580 chr6 32396905 G C 0.00003824 Sarcoidosis / / 22952805 rs9268582 chr6 32396964 C T 2.19E-08 Sarcoidosis / / 22952805 rs3129848 chr6 32397049 G A 1.60E-05 Self-reported allergy / / 23817569 rs9268583 chr6 32397266 T G 4.39E-08 Sarcoidosis / / 22952805 rs3129849 chr6 32397309 A G 1.14E-08 Sarcoidosis / / 22952805 rs9268585 chr6 32397403 T G 4.39E-08 Sarcoidosis / / 22952805 rs9268585 chr6 32397403 T G 9.27E-06 Leprosy / / pha002872 rs201097158 chr6 32397575 A G 0.00001388 Sarcoidosis / / 22952805 rs3129852 chr6 32397784 G A 1.18E-08 Sarcoidosis / / 22952805 rs9268588 chr6 32397794 C G 0.0008646 Sarcoidosis / / 22952805 rs9268589 chr6 32398202 G A 0.0008995 Sarcoidosis / / 22952805 rs9268589 chr6 32398202 G A 6.43E-08 Chronic hepatitis B infection / / 23760081 rs9268589 chr6 32398202 G A 1.45E-06 Leprosy / / pha002872 rs7774047 chr6 32398563 C A 0.0008995 Sarcoidosis / / 22952805 rs7774047 chr6 32398563 C A 6.43E-08 Chronic hepatitis B infection / / 23760081 rs7756262 chr6 32398675 T A 5.02E-90 Multiple complex diseases / / 17554300 rs7756262 chr6 32398675 T A 1.42E-10 Multiple sclerosis / / 17660530 rs7756262 chr6 32398675 T A 1.25E-11 Narcolepsy / / 19629137 rs7756262 chr6 32398675 T A 1.38E-43 Rheumatoid arthritis / / 21156761 rs3135341 chr6 32398748 C A 1.03E-08 Sarcoidosis / / 22952805 rs3135340 chr6 32398872 T G 3.68E-11 Rheumatoid arthritis / / 21156761 rs3135340 chr6 32398872 T G 1.60E-05 Self-reported allergy / / 23817569 rs3135340 chr6 32398872 T G 7.21E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs4988822 chr6 32398975 C T 3.68E-11 Rheumatoid arthritis / / 21156761 rs4988822 chr6 32398975 C T 1.19E-05 Self-reported allergy / / 23817569 rs4988822 chr6 32398975 C T 7.21E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs4348358 chr6 32399092 G A 0.0008995 Sarcoidosis / / 22952805 rs4504509 chr6 32399159 T C 1.03E-08 Sarcoidosis / / 22952805 rs4321864 chr6 32399187 C A 1.00E-52 Rheumatoid arthritis / / 21156761 rs4321864 chr6 32399187 C A 8.18E-06 Self-reported allergy / / 23817569 rs3135339 chr6 32399261 C G 4.86E-11 Rheumatoid arthritis / / 21156761 rs3135339 chr6 32399261 C G 1.70E-05 Self-reported allergy / / 23817569 rs9501624 chr6 32399286 A G 0.0006786 Sarcoidosis / / 22952805 rs9501624 chr6 32399286 A G 2.36E-12 Psoriasis / / pha002855 rs3129856 chr6 32399337 T C 6.03E-13 Rheumatoid arthritis / / 21156761 rs3129856 chr6 32399337 T C 5.27E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9268605 chr6 32399833 G A 9.78E-44 Rheumatoid arthritis / / 21156761 rs9268605 chr6 32399833 G A 0.0008853 Sarcoidosis / / 22952805 rs2395172 chr6 32399842 T C 4.86E-11 Rheumatoid arthritis / / 21156761 rs2395172 chr6 32399842 T C 1.62E-05 Self-reported allergy / / 23817569 rs2395172 chr6 32399842 T C 6.80E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9268606 chr6 32400070 G A 9.78E-44 Rheumatoid arthritis / / 21156761 rs9268606 chr6 32400070 G A 0.0008748 Sarcoidosis / / 22952805 rs9268606 chr6 32400070 G A 6.63E-08 Chronic hepatitis B infection / / 23760081 rs984778 chr6 32400088 C T 2.63E-43 Rheumatoid arthritis / / 21156761 rs7762370 chr6 32400190 T C 5.13E-19 Psoriasis / / pha002855 rs9501626 chr6 32400344 C A 2.56E-13 Type 1 diabetes / / 17632545 rs9501626 chr6 32400344 C A 1.42E-19 Rheumatoid arthritis / / 17804836 rs9501626 chr6 32400344 C A 1.41E-28 Rheumatoid arthritis / / 19503088 rs9501626 chr6 32400344 C A 5.00E-17 Rheumatoid arthritis / / 21156761 rs9501626 chr6 32400344 C A 1.39E-09 Leprosy / / pha002872 rs9501626 chr6 32400344 C A 1.00E-04 Coronary heart disease / / pha003033 rs3129858 chr6 32400520 G A 4.86E-11 Rheumatoid arthritis / / 21156761 rs3129858 chr6 32400520 G A 1.61E-05 Self-reported allergy / / 23817569 rs3129858 chr6 32400520 G A 6.70E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9268607 chr6 32400538 A G 9.78E-44 Rheumatoid arthritis / / 21156761 rs9268607 chr6 32400538 A G 0.0008995 Sarcoidosis / / 22952805 rs9268607 chr6 32400538 A G 6.43E-08 Chronic hepatitis B infection / / 23760081 rs9268608 chr6 32400865 C T 0.0008456 Sarcoidosis / / 22952805 rs9268608 chr6 32400865 C T 6.43E-08 Chronic hepatitis B infection / / 23760081 rs3129859 chr6 32400939 G C 3.44E-11 Rheumatoid arthritis / / 21156761 rs17496307 chr6 32401036 A T 2.24E-09 Self-reported allergy / / 23817569 rs3129860 chr6 32401079 A G 3.84E-25 Type 1 diabetes / / 17632545 rs3129860 chr6 32401079 A G 2.06E-06 Phospholipid levels (plasma) / / 21829377 rs3129860 chr6 32401079 A G 9.80E-07 Kawasaki disease / / 22446962 rs3129860 chr6 32401079 A G 1.00E-09 Hepatitis C induced liver cirrhosis / / 23321320 rs3129860 chr6 32401079 A G 2.26E-06 Interstitial lung disease / / 23583980 rs3129860 chr6 32401079 A G 8.62E-192 Type 1 diabetes / / pha002862 rs3135338 chr6 32401217 C T 5.55E-47 Type 1 diabetes / / 17632545 rs3135338 chr6 32401217 C T 6.85E-47 Rheumatoid arthritis / / 17804836 rs3135338 chr6 32401217 C T 3.53E-61 Rheumatoid arthritis / / 19503088 rs3135338 chr6 32401217 C T 2.00E-25 Multiple sclerosis / / 20159113 rs3135338 chr6 32401217 C T 9.46E-10 Multiple sclerosis / / 20598377 rs3135338 chr6 32401217 C T 2.63E-43 Rheumatoid arthritis / / 21156761 rs3135338 chr6 32401217 C T 1.40E-06 Kawasaki disease / / 22446962 rs3135338 chr6 32401217 C T 1.59E-280 Type 1 diabetes / / pha002862 rs3135338 chr6 32401217 C T 1.31E-09 Leprosy / / pha002872 rs9268609 chr6 32401261 G A 0.0008995 Sarcoidosis / / 22952805 rs9268610 chr6 32401263 T C 0.0008995 Sarcoidosis / / 22952805 rs7356880 chr6 32401327 C T 1.11E-15 Type 1 diabetes / / 17632545 rs7356880 chr6 32401327 C T 9.61E-04 HIV-1 viral setpoint / / 17641165 rs7356880 chr6 32401327 C T 5.13E-06 Rheumatoid arthritis / / 17804836 rs7356880 chr6 32401327 C T 1.16E-06 HIV-1 control / / 20041166 rs7356880 chr6 32401327 C T 2.20E-04 HIV-1 control / / 21051598 rs3129861 chr6 32401532 T A 3.17E-17 Rheumatoid arthritis / / 21156761 rs3135335 chr6 32401845 C G 5.37E-43 Rheumatoid arthritis / / 21156761 rs17202745 chr6 32401889 G A,T 2.55E-08 Sarcoidosis / / 22952805 rs7753264 chr6 32402440 A G 0.0007525 Sarcoidosis / / 22952805 rs7753264 chr6 32402440 A G 6.43E-08 Chronic hepatitis B infection / / 23760081 rs7773756 chr6 32402464 T C 0.0008497 Sarcoidosis / / 22952805 rs3135334 chr6 32402686 C T 1.03E-08 Sarcoidosis / / 22952805 rs9268613 chr6 32402692 C T 0.0008995 Sarcoidosis / / 22952805 rs9268613 chr6 32402692 C T 6.43E-08 Chronic hepatitis B infection / / 23760081 rs2027856 chr6 32402705 G A 3.32E-13 Type 1 diabetes / / 17632545 rs2027856 chr6 32402705 G A 2.25E-21 Rheumatoid arthritis / / 21156761 rs2027856 chr6 32402705 G A 1.12E-05 Common variable immunodeficiency / / 21497890 rs2027856 chr6 32402705 G A 1.11E-09 Leprosy / / pha002872 rs9268614 chr6 32402778 T G 5.40E-15 Rheumatoid arthritis / / 17159887 rs9268614 chr6 32402778 T G 1.00E-30 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs9268614 chr6 32402778 T G 1.01E-91 Rheumatoid arthritis / / 21156761 rs9268615 chr6 32402889 G A 9.07E-22 Type 1 diabetes / / 17632545 rs9268615 chr6 32402889 G A 4.81E-45 Rheumatoid arthritis / / 21156761 rs9268615 chr6 32402889 G A 7.90E-05 Alopecia areata / / 22027810 rs9268615 chr6 32402889 G A 0.0005349 Sarcoidosis / / 22952805 rs9268615 chr6 32402889 G A 6.43E-08 Chronic hepatitis B infection / / 23760081 rs9268615 chr6 32402889 G A 1.46E-06 Leprosy / / pha002872 rs983561 chr6 32403655 T A,C,G 5.23E-11 Rheumatoid arthritis / / 21156761 rs983561 chr6 32403655 T A,C,G 1.55E-05 Self-reported allergy / / 23817569 rs983561 chr6 32403655 T A,C,G 7.62E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs3129866 chr6 32404065 G C 7.23E-43 Rheumatoid arthritis / / 21156761 rs4612206 chr6 32404093 C T 8.82E-44 Rheumatoid arthritis / / 21156761 rs5000563 chr6 32404135 A G 9.26E-08 Multiple complex diseases / / 17554300 rs5000563 chr6 32404135 A G 2.31E-10 Multiple sclerosis / / 17660530 rs5000563 chr6 32404135 A G 5.23E-11 Rheumatoid arthritis / / 21156761 rs5000563 chr6 32404135 A G 5.60E-10 Hepatitis B / / 21750111 rs5000563 chr6 32404135 A G 1.86E-05 Self-reported allergy / / 23817569 rs5000563 chr6 32404135 A G 7.94E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs3129867 chr6 32404220 G C 5.57E-43 Rheumatoid arthritis / / 21156761 rs3129868 chr6 32404377 A C 3.06E-06 Phospholipid levels (plasma) / / 21829377 rs3129868 chr6 32404377 A C 0.000799 Triglycerides / / 23063622 rs3129868 chr6 32404377 A C 3.79E-08 Interstitial lung disease / / 23583980 rs2395173 chr6 32404859 A G 8.00E-07 Rheumatoid arthritis / / 17159887 rs2395173 chr6 32404859 A G 2.35E-52 Type 1 diabetes / / 17632545 rs2395173 chr6 32404859 A G 6.46E-48 Rheumatoid arthritis / / 17804836 rs2395173 chr6 32404859 A G 7.00E-10 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs2395173 chr6 32404859 A G 5.31E-66 Rheumatoid arthritis / / 19503088 rs2395173 chr6 32404859 A G 1.02E-09 Multiple sclerosis / / 20598377 rs2395173 chr6 32404859 A G 2.46E-43 Rheumatoid arthritis / / 21156761 rs2395173 chr6 32404859 A G 1.30E-06 Kawasaki disease / / 22446962 rs2395173 chr6 32404859 A G 1.19E-281 Type 1 diabetes / / pha002862 rs2395173 chr6 32404859 A G 1.31E-09 Leprosy / / pha002872 rs2395174 chr6 32404878 T G 2.02E-10 Type 1 diabetes / / 17632545 rs2395174 chr6 32404878 T G 1.97E-06 Rheumatoid arthritis / / 17804836 rs2395174 chr6 32404878 T G 2.37E-06 Rheumatoid arthritis / / 19503088 rs2395174 chr6 32404878 T G 3.48E-11 Rheumatoid arthritis / / 21156761 rs2395174 chr6 32404878 T G 4.44E-07 Hepatitis B / / 21750111 rs2395174 chr6 32404878 T G 7.70E-17 Hepatitis B vaccine response / / 21764829 rs2395174 chr6 32404878 T G 2.49E-07 Coronary heart disease / / 21971053 rs2395174 chr6 32404878 T G 4.50E-05 Alopecia areata / / 22027810 rs2395174 chr6 32404878 T G 1.55E-05 Self-reported allergy / / 23817569 rs2395174 chr6 32404878 T G 8.50E-08 Systemic lupus erythematosus / / 24871463 rs2395174 chr6 32404878 T G 8.65E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2395175 chr6 32405026 G A 4.82E-19 Type 1 diabetes / / 17632545 rs2395175 chr6 32405026 G A 3.87E-122 Rheumatoid arthritis / / 17804836 rs2395175 chr6 32405026 G A 2.71E-06 IgE levels / / 22075330 rs9268626 chr6 32405044 G C 0.00001648 Sarcoidosis / / 22952805 rs9268626 chr6 32405044 G C 5.90E-05 Self-reported allergy / / 23817569 rs2395176 chr6 32405062 G T 1.86E-05 Self-reported allergy / / 23817569 rs2395177 chr6 32405076 G C 3.82E-11 Rheumatoid arthritis / / 21156761 rs2395177 chr6 32405076 G C 1.56E-05 Self-reported allergy / / 23817569 rs3135395 chr6 32405192 T G 6.60E-43 Rheumatoid arthritis / / 21156761 rs2395178 chr6 32405362 G C 8.00E-07 Rheumatoid arthritis / / 17159887 rs2395178 chr6 32405362 G C 1.25E-10 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs2395178 chr6 32405362 G C 6.60E-43 Rheumatoid arthritis / / 21156761 rs3129869 chr6 32405671 A C 4.89E-43 Rheumatoid arthritis HLA-DRA nearGene-5 21156761 rs9268629 chr6 32406085 G T 0.00005845 Sarcoidosis HLA-DRA nearGene-5 22952805 rs3129871 chr6 32406342 A C 1.87E-57 Type 1 diabetes HLA-DRA nearGene-5 17632545 rs3129871 chr6 32406342 A C 1.13E-55 Rheumatoid arthritis HLA-DRA nearGene-5 17804836 rs3129871 chr6 32406342 A C 4.95E-08 Systemic sclerosis HLA-DRA nearGene-5 20383147 rs3129871 chr6 32406342 A C 5.26E-08 Multiple sclerosis HLA-DRA nearGene-5 20598377 rs3129871 chr6 32406342 A C 6.06E-50 Rheumatoid arthritis HLA-DRA nearGene-5 21156761 rs3129871 chr6 32406342 A C 5.30E-07 Kawasaki disease HLA-DRA nearGene-5 22446962 rs3129871 chr6 32406342 A C 0.00004393 Sarcoidosis HLA-DRA nearGene-5 22952805 rs3129871 chr6 32406342 A C 1.00E-16 Multiple sclerosis (OCB status) HLA-DRA nearGene-5 23472185 rs3129871 chr6 32406342 A C 6.00E-15 Multiple sclerosis (OCB status) HLA-DRA nearGene-5 23472185 rs3129871 chr6 32406342 A C 1.15E-299 Type 1 diabetes HLA-DRA nearGene-5 pha002862 rs3129871 chr6 32406342 A C 1.75E-07 Leprosy HLA-DRA nearGene-5 pha002872 rs9268633 chr6 32406473 A G 8.22E-04 Type 2 diabetes HLA-DRA nearGene-5 17463246 rs9268633 chr6 32406473 A G 5.47E-23 Rheumatoid arthritis HLA-DRA nearGene-5 21156761 rs9268633 chr6 32406473 A G 7.58E-09 Sarcoidosis HLA-DRA nearGene-5 22952805 rs9268634 chr6 32406530 G A 4.60E-44 Rheumatoid arthritis HLA-DRA nearGene-5 21156761 rs3763321 chr6 32406704 T G 3.59E-08 Sarcoidosis HLA-DRA nearGene-5 22952805 rs3763322 chr6 32406807 G A 0.0002521 Sarcoidosis HLA-DRA nearGene-5 22952805 rs9268641 chr6 32406887 C T 3.52E-11 Rheumatoid arthritis HLA-DRA nearGene-5 21156761 rs9268641 chr6 32406887 C T 1.93E-05 Self-reported allergy HLA-DRA nearGene-5 23817569 rs9405035 chr6 32407068 G A 1.22E-06 Multiple complex diseases HLA-DRA nearGene-5 17554300 rs3129872 chr6 32407153 A T 9.93E-08 Multiple complex diseases HLA-DRA nearGene-5 17554300 rs3129872 chr6 32407153 A T 2.64E-10 Multiple sclerosis HLA-DRA nearGene-5 17660530 rs3129872 chr6 32407153 A T 3.94E-11 Rheumatoid arthritis HLA-DRA nearGene-5 21156761 rs3129872 chr6 32407153 A T 2.00E-05 Self-reported allergy HLA-DRA nearGene-5 23817569 rs2395179 chr6 32407302 A G 3.17E-05 Self-reported allergy HLA-DRA nearGene-5 23817569 rs2395180 chr6 32407310 T G 3.68E-05 Self-reported allergy HLA-DRA nearGene-5 23817569 rs2395181 chr6 32407404 G C 4.82E-11 Rheumatoid arthritis HLA-DRA nearGene-5 21156761 rs2395181 chr6 32407404 G C 3.22E-05 Self-reported allergy HLA-DRA nearGene-5 23817569 rs3129875 chr6 32407468 T C 3.88E-05 Self-reported allergy HLA-DRA nearGene-5 23817569 rs14004 chr6 32407709 C A 5.00E-04 Rheumatoid arthritis HLA-DRA UTR-5 17159887 rs14004 chr6 32407709 C A 7.95E-44 Rheumatoid arthritis HLA-DRA UTR-5 21156761 rs14004 chr6 32407709 C A 0.0002487 Sarcoidosis HLA-DRA UTR-5 22952805 rs3129876 chr6 32408012 G A 3.99E-05 Self-reported allergy HLA-DRA intron 23817569 rs9268644 chr6 32408044 A C 6.19E-17 Rheumatoid arthritis HLA-DRA intron 21156761 rs3135394 chr6 32408497 A G 6.47E-13 Rheumatoid arthritis HLA-DRA intron 21156761 rs3135394 chr6 32408497 A G 7.11E-05 Lupus nephritis in systemic lupus erythematosus HLA-DRA intron 24925725 rs9268645 chr6 32408527 C G 6.56E-95 Multiple complex diseases HLA-DRA intron 17554300 rs9268645 chr6 32408527 C G 1.96E-11 Multiple sclerosis HLA-DRA intron 17660530 rs9268645 chr6 32408527 C G 2.80E-05 Serum metabolites HLA-DRA intron 19043545 rs9268645 chr6 32408527 C G 1.00E-100 Type 1 diabetes HLA-DRA intron 19430480 rs9268645 chr6 32408527 C G 2.72E-15 Narcolepsy HLA-DRA intron 19629137 rs9268645 chr6 32408527 C G 1.02E-43 Rheumatoid arthritis HLA-DRA intron 21156761 rs9268645 chr6 32408527 C G 2.87E-08 Chronic hepatitis B infection HLA-DRA intron 23760081 rs3129877 chr6 32408597 G A 1.01E-33 Multiple complex diseases HLA-DRA intron 17554300 rs3129877 chr6 32408597 G A 9.12E-11 Multiple sclerosis HLA-DRA intron 17660530 rs3129877 chr6 32408597 G A 4.82E-11 Rheumatoid arthritis HLA-DRA intron 21156761 rs3129877 chr6 32408597 G A 1.72E-05 Self-reported allergy HLA-DRA intron 23817569 rs3129878 chr6 32408735 A C 4.82E-11 Rheumatoid arthritis HLA-DRA intron 21156761 rs3129878 chr6 32408735 A C 1.03E-12 Non-obstructive azoospermia HLA-DRA intron 22541561 rs3129878 chr6 32408735 A C 1.41E-06 Self-reported allergy HLA-DRA intron 23817569 rs3135393 chr6 32408842 A G 4.13E-56 Multiple complex diseases HLA-DRA intron 17554300 rs3135393 chr6 32408842 A G 8.94E-04 Alzheimer's disease HLA-DRA intron 17998437 rs3135393 chr6 32408842 A G 3.25E-27 Rheumatoid arthritis HLA-DRA intron 21156761 rs3129880 chr6 32408917 T C 3.87E-08 Sarcoidosis HLA-DRA intron 22952805 rs9268651 chr6 32409046 G A 0.000007987 Sarcoidosis HLA-DRA intron 22952805 rs3135392 chr6 32409242 C A 1.69E-12 Multiple complex diseases HLA-DRA intron 17554300 rs3135392 chr6 32409242 C A 2.87E-13 Multiple sclerosis HLA-DRA intron 17660530 rs3135392 chr6 32409242 C A 5.07E-23 Rheumatoid arthritis HLA-DRA intron 21156761 rs3135392 chr6 32409242 C A 2.44E-06 Self-reported allergy HLA-DRA intron 23817569 rs6926374 chr6 32409305 A G 1.68E-28 Rheumatoid arthritis HLA-DRA intron 21156761 rs6926374 chr6 32409305 A G 2.84E-11 Sarcoidosis HLA-DRA intron 22952805 rs6926374 chr6 32409305 A G 3.75E-05 Self-reported allergy HLA-DRA intron 23817569 rs3129881 chr6 32409484 C T 2.99E-11 Rheumatoid arthritis HLA-DRA intron 21156761 rs3129881 chr6 32409484 C T 3.82E-05 Self-reported allergy HLA-DRA intron 23817569 rs3129882 chr6 32409530 G A 1.54E-38 Rheumatoid arthritis HLA-DRA intron 17804836 rs3129882 chr6 32409530 G A 5.18E-75 Rheumatoid arthritis HLA-DRA intron 19503088 rs3129882 chr6 32409530 G A 1.70E-09 Lipid levels HLA-DRA intron 19936222 rs3129882 chr6 32409530 G A 1.80E-08 Lipid levels HLA-DRA intron 19936222 rs3129882 chr6 32409530 G A 2.10E-07 Lipid levels HLA-DRA intron 19936222 rs3129882 chr6 32409530 G A 5.90E-04 Lipid levels HLA-DRA intron 19936222 rs3129882 chr6 32409530 G A 1.53E-07 Multiple sclerosis HLA-DRA intron 20598377 rs3129882 chr6 32409530 G A 2.00E-10 Parkinson's disease HLA-DRA intron 20711177 rs3129882 chr6 32409530 G A 2.88E-45 Rheumatoid arthritis HLA-DRA intron 21156761 rs3129882 chr6 32409530 G A 2.00E-27 Systemic sclerosis HLA-DRA intron 21779181 rs3129882 chr6 32409530 G A 4.79E-04 Crohn's disease HLA-DRA intron 23266558 rs3129882 chr6 32409530 G A 5.26E-12 Hodgkin's lymphoma HLA-DRA intron 24149102 rs3129882 chr6 32409530 G A 3.00E-08 Parkinson's disease HLA-DRA intron 24511991 rs3129882 chr6 32409530 G A 3.00E-08 Parkinson's disease HLA-DRA intron 24511991 rs3129882 chr6 32409530 G A 5.00E-10 Parkinson's disease HLA-DRA intron 24511991 rs3129882 chr6 32409530 G A 5.00E-10 Parkinson's disease HLA-DRA intron 24511991 rs3129882 chr6 32409530 G A 1.39E-178 Type 1 diabetes HLA-DRA intron pha002862 rs9268657 chr6 32409656 G A 6.67E-44 Rheumatoid arthritis HLA-DRA intron 21156761 rs9268657 chr6 32409656 G A 0.00002078 Sarcoidosis HLA-DRA intron 22952805 rs17496549 chr6 32409708 C T 0.0000139 LDL cholesterol HLA-DRA intron 23063622 rs17496549 chr6 32409708 C T 1.18E-09 Cholesterol,total HLA-DRA intron 23063622 rs17496549 chr6 32409708 C T 1.49E-09 Self-reported allergy HLA-DRA intron 23817569 rs6931646 chr6 32409781 C T 3.43E-11 Sarcoidosis HLA-DRA intron 22952805 rs6911419 chr6 32409787 T C 2.84E-11 Sarcoidosis HLA-DRA intron 22952805 rs6911419 chr6 32409787 T C 6.83E-06 Self-reported allergy HLA-DRA intron 23817569 rs6911777 chr6 32409996 T C 5.65E-06 Self-reported allergy HLA-DRA intron 23817569 rs3129883 chr6 32410137 T C 2.07E-28 Rheumatoid arthritis HLA-DRA intron 21156761 rs3129883 chr6 32410137 T C 1.57E-08 Sarcoidosis HLA-DRA intron 22952805 rs3129886 chr6 32410576 T C 2.07E-28 Rheumatoid arthritis HLA-DRA intron 21156761 rs3129886 chr6 32410576 T C 1.57E-08 Sarcoidosis HLA-DRA intron 22952805 rs3129887 chr6 32410691 G A 1.48E-27 Rheumatoid arthritis HLA-DRA intron 21156761 rs9268658 chr6 32410716 G A 2.84E-11 Sarcoidosis HLA-DRA intron 22952805 rs9268658 chr6 32410716 G A 3.02E-09 Epstein-Barr virus immune response (EBNA-1) HLA-DRA intron 23326239 rs9268659 chr6 32410941 T C 2.18E-53 Rheumatoid arthritis HLA-DRA intron 21156761 rs9268659 chr6 32410941 T C 2.43E-12 Sarcoidosis HLA-DRA intron 22952805 rs3135391 chr6 32410987 A G 3.60E-06 Phospholipid levels (plasma) HLA-DRA cds-synon 21829377 rs8084 chr6 32411035 A C 1.72E-53 Rheumatoid arthritis HLA-DRA cds-synon 21156761 rs8084 chr6 32411035 A C 2.64E-09 Epstein-Barr virus immune response (EBNA-1) HLA-DRA cds-synon 23326239 rs8084 chr6 32411035 A C 3.10E-04 Response to cytadine analogues (cytosine arabinoside) HLA-DRA cds-synon 24483146 rs8084 chr6 32411035 A C 3.29E-04 Response to cytidine analogues (gemcitabine) HLA-DRA cds-synon 24483146 rs2239806 chr6 32411307 C T 1.48E-27 Rheumatoid arthritis HLA-DRA intron 21156761 rs13218331 chr6 32411362 A C 1.08E-09 Self-reported allergy HLA-DRA intron 23817569 rs2239805 chr6 32411376 T G 1.48E-27 Rheumatoid arthritis HLA-DRA intron 21156761 rs2239804 chr6 32411523 T C 5.69E-12 Type 1 diabetes HLA-DRA intron 17632545 rs2239804 chr6 32411523 T C 1.37E-44 Rheumatoid arthritis HLA-DRA intron 17804836 rs2239804 chr6 32411523 T C 8.34E-49 Rheumatoid arthritis HLA-DRA intron 19503088 rs2239804 chr6 32411523 T C 2.80E-05 Asthma HLA-DRA intron 20159242 rs2239804 chr6 32411523 T C 5.48E-05 Multiple sclerosis HLA-DRA intron 20598377 rs2239804 chr6 32411523 T C 5.86E-29 Rheumatoid arthritis HLA-DRA intron 21156761 rs2239804 chr6 32411523 T C 3.45E-11 Sarcoidosis HLA-DRA intron 22952805 rs2239804 chr6 32411523 T C 8.86E-04 Crohn's disease HLA-DRA intron 23266558 rs2239804 chr6 32411523 T C 4.05E-09 Epstein-Barr virus immune response (EBNA-1) HLA-DRA intron 23326239 rs2239804 chr6 32411523 T C 3.66E-05 Self-reported allergy HLA-DRA intron 23817569 rs2239804 chr6 32411523 T C 1.50E-09 Systemic lupus erythematosus HLA-DRA intron 24871463 rs2239804 chr6 32411523 T C 1.89E-06 Systemic lupus erythematosus HLA-DRA intron pha002867 rs7192 chr6 32411646 T G 7.00E-05 Rheumatoid arthritis HLA-DRA missense 17159887 rs7192 chr6 32411646 T G 1.85E-75 Rheumatoid arthritis HLA-DRA missense 17804836 rs7192 chr6 32411646 T G 6.20E-40 Systemic lupus erythematosus HLA-DRA missense 18204446 rs7192 chr6 32411646 T G 2.14E-06 Multiple sclerosis HLA-DRA missense 20598377 rs7192 chr6 32411646 T G 8.56E-51 Rheumatoid arthritis HLA-DRA missense 21156761 rs7192 chr6 32411646 T G 1.15E-04 Coronary heart disease HLA-DRA missense 21971053 rs7192 chr6 32411646 T G 3.00E-06 Non-obstructive azoospermia HLA-DRA missense 22541561 rs7192 chr6 32411646 T G 6.10E-11 Epstein-Barr virus immune response (EBNA-1) HLA-DRA missense 23326239 rs7192 chr6 32411646 T G 4.10E-05 Response to cytadine analogues (cytosine arabinoside) HLA-DRA missense 24483146 rs7192 chr6 32411646 T G 5.51E-05 Response to cytidine analogues (gemcitabine) HLA-DRA missense 24483146 rs7192 chr6 32411646 T G 8.00E-15 Systemic lupus erythematosus HLA-DRA missense 24871463 rs7192 chr6 32411646 T G 5.43E-10 Systemic lupus erythematosus HLA-DRA missense pha002867 rs3129888 chr6 32411726 G A 4.44E-27 Rheumatoid arthritis HLA-DRA intron 21156761 rs3129888 chr6 32411726 G A 2.82E-09 Sarcoidosis HLA-DRA intron 22952805 rs3129888 chr6 32411726 G A 4.32E-08 Epstein-Barr virus immune response (EBNA-1) HLA-DRA intron 23326239 rs3129888 chr6 32411726 G A 8.78E-04 Response to cytadine analogues (cytosine arabinoside) HLA-DRA intron 24483146 rs2239803 chr6 32411833 C T 5.87E-29 Rheumatoid arthritis HLA-DRA intron 21156761 rs2239803 chr6 32411833 C T 1.18E-11 Sarcoidosis HLA-DRA intron 22952805 rs2239803 chr6 32411833 C T 1.93E-10 Epstein-Barr virus immune response (EBNA-1) HLA-DRA intron 23326239 rs2239802 chr6 32411846 C G 4.44E-27 Rheumatoid arthritis HLA-DRA intron 21156761 rs2239802 chr6 32411846 C G 5.22E-10 Sarcoidosis HLA-DRA intron 22952805 rs2239802 chr6 32411846 C G 3.15E-08 Epstein-Barr virus immune response (EBNA-1) HLA-DRA intron 23326239 rs2239802 chr6 32411846 C G 1.30E-04 Response to cytadine analogues (cytosine arabinoside) HLA-DRA intron 24483146 rs4935356 chr6 32412388 T A,G 3.02E-09 Epstein-Barr virus immune response (EBNA-1) HLA-DRA intron 23326239 rs3135390 chr6 32412395 C A 2.16E-09 Sarcoidosis HLA-DRA intron 22952805 rs4935354 chr6 32412398 C T 5.28E-14 Sarcoidosis HLA-DRA intron 22952805 rs3177928 chr6 32412435 G A 6.81E-05 Multiple complex diseases HLA-DRA UTR-3 17554300 rs3177928 chr6 32412435 G A 2.24E-09 Multiple sclerosis HLA-DRA UTR-3 17660530 rs3177928 chr6 32412435 G A 2.00E-15 LDL cholesterol HLA-DRA UTR-3 20686565 rs3177928 chr6 32412435 G A 4.00E-19 Cholesterol,total HLA-DRA UTR-3 20686565 rs3177928 chr6 32412435 G A 1.00E-09 Self-reported allergy HLA-DRA UTR-3 23817569 rs3177928 chr6 32412435 G A 1.00E-21 Cholesterol,total HLA-DRA UTR-3 24097068 rs3177928 chr6 32412435 G A 3.00E-17 LDL cholesterol HLA-DRA UTR-3 24097068 rs7194 chr6 32412480 G A 8.87E-55 Multiple complex diseases HLA-DRA UTR-3 17554300 rs7194 chr6 32412480 G A 6.01E-25 Multiple sclerosis HLA-DRA UTR-3 17660530 rs7194 chr6 32412480 G A 3.58E-05 Serum metabolites HLA-DRA UTR-3 19043545 rs7194 chr6 32412480 G A 9.80E-07 Sarcoidosis HLA-DRA UTR-3 19165924 rs7194 chr6 32412480 G A 6.93E-09 Narcolepsy HLA-DRA UTR-3 19629137 rs7194 chr6 32412480 G A 7.25E-51 Rheumatoid arthritis HLA-DRA UTR-3 21156761 rs7194 chr6 32412480 G A 5.28E-14 Sarcoidosis HLA-DRA UTR-3 22952805 rs7194 chr6 32412480 G A 4.27E-11 Epstein-Barr virus immune response (EBNA-1) HLA-DRA UTR-3 23326239 rs7194 chr6 32412480 G A 4.10E-05 Response to cytadine analogues (cytosine arabinoside) HLA-DRA UTR-3 24483146 rs7194 chr6 32412480 G A 5.51E-05 Response to cytidine analogues (gemcitabine) HLA-DRA UTR-3 24483146 rs7195 chr6 32412539 A G 7.00E-05 Rheumatoid arthritis HLA-DRA UTR-3 17159887 rs7195 chr6 32412539 A G 5.28E-14 Sarcoidosis HLA-DRA UTR-3 22952805 rs7195 chr6 32412539 A G 4.27E-11 Epstein-Barr virus immune response (EBNA-1) HLA-DRA UTR-3 23326239 rs7195 chr6 32412539 A G 4.10E-05 Response to cytadine analogues (cytosine arabinoside) HLA-DRA UTR-3 24483146 rs7195 chr6 32412539 A G 5.51E-05 Response to cytidine analogues (gemcitabine) HLA-DRA UTR-3 24483146 rs7196 chr6 32412571 A T 6.30E-10 Sarcoidosis HLA-DRA UTR-3 22952805 rs7197 chr6 32412580 T C 6.43E-28 Rheumatoid arthritis HLA-DRA UTR-3 21156761 rs7197 chr6 32412580 T C 1.98E-09 Sarcoidosis HLA-DRA UTR-3 22952805 rs1051336 chr6 32412592 G A,C,T 2.79E-54 Multiple complex diseases HLA-DRA UTR-3 17554300 rs1051336 chr6 32412592 G A,C,T 6.23E-04 Alzheimer's disease HLA-DRA UTR-3 17998437 rs1051336 chr6 32412592 G A,C,T 1.48E-27 Rheumatoid arthritis HLA-DRA UTR-3 21156761 rs1041885 chr6 32412809 T A 5.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) HLA-DRA UTR-3 17982456 rs1041885 chr6 32412809 T A 1.48E-27 Rheumatoid arthritis HLA-DRA UTR-3 21156761 rs3135388 chr6 32413051 A G 9.00E-81 Multiple sclerosis HLA-DRA nearGene-3 17660530 rs3135388 chr6 32413051 A G 4.00E-225 Multiple sclerosis HLA-DRA nearGene-3 19525953 rs3135388 chr6 32413051 A G 2.51E-06 Phospholipid levels (plasma) HLA-DRA nearGene-3 21829377 rs2213586 chr6 32413094 A G 5.28E-14 Sarcoidosis HLA-DRA nearGene-3 22952805 rs2213586 chr6 32413094 A G 4.27E-11 Epstein-Barr virus immune response (EBNA-1) HLA-DRA nearGene-3 23326239 rs2213586 chr6 32413094 A G 5.44E-05 Response to cytadine analogues (cytosine arabinoside) HLA-DRA nearGene-3 24483146 rs2213586 chr6 32413094 A G 6.29E-05 Response to cytidine analogues (gemcitabine) HLA-DRA nearGene-3 24483146 rs2213585 chr6 32413150 G A 5.28E-14 Sarcoidosis HLA-DRA nearGene-3 22952805 rs2213585 chr6 32413150 G A 4.27E-11 Epstein-Barr virus immune response (EBNA-1) HLA-DRA nearGene-3 23326239 rs2213585 chr6 32413150 G A 5.44E-05 Response to cytadine analogues (cytosine arabinoside) HLA-DRA nearGene-3 24483146 rs2213585 chr6 32413150 G A 6.29E-05 Response to cytidine analogues (gemcitabine) HLA-DRA nearGene-3 24483146 rs2213584 chr6 32413259 A G 5.28E-14 Sarcoidosis HLA-DRA nearGene-3 22952805 rs2395182 chr6 32413317 G T 2.00E-05 Rheumatoid arthritis HLA-DRA nearGene-3 17159887 rs2395182 chr6 32413317 G T 8.86E-28 Type 1 diabetes HLA-DRA nearGene-3 17632545 rs2395182 chr6 32413317 G T 2.74E-27 Rheumatoid arthritis HLA-DRA nearGene-3 17804836 rs2395182 chr6 32413317 G T 9.30E-37 Rheumatoid arthritis HLA-DRA nearGene-3 19503088 rs2395182 chr6 32413317 G T 9.03E-15 Multiple sclerosis HLA-DRA nearGene-3 20598377 rs2395182 chr6 32413317 G T 5.90E-27 Rheumatoid arthritis HLA-DRA nearGene-3 21156761 rs2395182 chr6 32413317 G T 5.74E-10 Sarcoidosis HLA-DRA nearGene-3 22952805 rs2395182 chr6 32413317 G T 3.41E-09 Epstein-Barr virus immune response (EBNA-1) HLA-DRA nearGene-3 23326239 rs2395182 chr6 32413317 G T 8.89E-05 Response to cytadine analogues (cytosine arabinoside) HLA-DRA nearGene-3 24483146 rs2227139 chr6 32413459 G A 3.00E-04 Rheumatoid arthritis / / 17159887 rs2227139 chr6 32413459 G A 6.73E-29 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs2227139 chr6 32413459 G A 1.00E-07 Hematological parameters / / 19820697 rs2227139 chr6 32413459 G A 2.75E-50 Rheumatoid arthritis / / 21156761 rs2227139 chr6 32413459 G A 3.77E-14 Sarcoidosis / / 22952805 rs2227139 chr6 32413459 G A 4.27E-11 Epstein-Barr virus immune response (EBNA-1) / / 23326239 rs2227139 chr6 32413459 G A 5.44E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2227139 chr6 32413459 G A 6.29E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs3129889 chr6 32413545 G A 2.63E-05 Type 2 diabetes / / 17463246 rs3129889 chr6 32413545 G A 2.41E-06 Phospholipid levels (plasma) / / 21829377 rs3129889 chr6 32413545 G A 1.00E-206 Multiple sclerosis / / 22190364 rs3129889 chr6 32413545 G A 7.38E-05 Parkinson's disease (motor and cognition) / / 22658654 rs3129889 chr6 32413545 G A 7.38E-05 Immune response to anthrax vaccine / / 22658931 rs3763326 chr6 32413557 T C 6.81E-13 Rheumatoid arthritis / / 21156761 rs3763327 chr6 32413830 G C 4.19E-50 Rheumatoid arthritis / / 21156761 rs3763327 chr6 32413830 G C 4.04E-14 Sarcoidosis / / 22952805 rs9268668 chr6 32413889 C A 1.66E-13 Sarcoidosis / / 22952805 rs3129890 chr6 32414273 T C 4.36E-43 Rheumatoid arthritis / / 17804836 rs3129890 chr6 32414273 T C 3.46E-44 Rheumatoid arthritis / / 19503088 rs3129890 chr6 32414273 T C 5.00E-13 Asthma / / 21804548 rs3129890 chr6 32414273 T C 5.81E-05 Coronary heart disease / / 21971053 rs3129890 chr6 32414273 T C 1.13E-10 Sarcoidosis / / 22952805 rs3129890 chr6 32414273 T C 3.40E-51 Myasthenia gravis / / 23055271 rs3129890 chr6 32414273 T C 2.67E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs3129890 chr6 32414273 T C 6.60E-09 Systemic lupus erythematosus / / 24871463 rs9268670 chr6 32414287 T C 1.17E-10 Sarcoidosis / / 22952805 rs9268671 chr6 32414290 A G 5.49E-07 Sarcoidosis / / 22952805 rs7382085 chr6 32414420 G A 0.000001759 Sarcoidosis / / 22952805 rs9268673 chr6 32414433 C T 0.00001275 Sarcoidosis / / 22952805 rs7382354 chr6 32414639 G A 0.000002137 Sarcoidosis / / 22952805 rs9268677 chr6 32414668 G A 0.00003646 Sarcoidosis / / 22952805 rs3129891 chr6 32415080 G A 9.58E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs3135387 chr6 32415109 T G 0.00002625 Sarcoidosis / / 22952805 rs9268681 chr6 32415386 G A 0.00001833 Sarcoidosis / / 22952805 rs9268682 chr6 32415422 G T 0.000009177 Sarcoidosis / / 22952805 rs9268684 chr6 32415457 G A 0.00001022 Sarcoidosis / / 22952805 rs9268685 chr6 32415464 A T 0.00001097 Sarcoidosis / / 22952805 rs9268686 chr6 32415522 C T 9.66E-11 Sarcoidosis / / 22952805 rs9268687 chr6 32415540 G T 0.00001238 Sarcoidosis / / 22952805 rs2894256 chr6 32415585 C A 0.00001318 Sarcoidosis / / 22952805 rs12529093 chr6 32415858 A G 2.06E-09 Self-reported allergy / / 23817569 rs13209234 chr6 32415975 G A 4.14E-05 Follicular lymphoma / / 21533074 rs13209234 chr6 32415975 G A 1.14E-09 Self-reported allergy / / 23817569 rs3135385 chr6 32416366 A G 0.000004199 Sarcoidosis / / 22952805 rs7762488 chr6 32416469 G C 0.00002203 Sarcoidosis / / 22952805 rs9268693 chr6 32416826 C T 0.00001615 Sarcoidosis / / 22952805 rs9268759 chr6 32417704 C T 0.00001735 Sarcoidosis / / 22952805 rs28895078 chr6 32417891 C G 0.000000343 Follicular lymphoma / / 23025665 rs6937696 chr6 32418018 C T 0.00002464 Sarcoidosis / / 22952805 rs6937545 chr6 32418031 A C 0.00002464 Sarcoidosis / / 22952805 rs6937545 chr6 32418031 A C 4.29E-06 Leprosy / / pha002872 rs9268765 chr6 32418579 A C 0.0001089 Sarcoidosis / / 22952805 rs9268766 chr6 32418710 C A 0.00001885 Sarcoidosis / / 22952805 rs9268766 chr6 32418710 C A 1.13E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs28895095 chr6 32418848 G A 0.00000418 Follicular lymphoma / / 23025665 rs12528026 chr6 32419116 A G 0.0005611 Sarcoidosis / / 22952805 rs12524661 chr6 32419204 G A 0.0005592 Sarcoidosis / / 22952805 rs28895103 chr6 32419464 G A 0.00000037 Follicular lymphoma / / 23025665 rs7754768 chr6 32420179 C T 3.71E-10 Sarcoidosis / / 22952805 rs7754768 chr6 32420179 C T 3.82E-11 Epstein-Barr virus immune response (EBNA-1) / / 23326239 rs7754768 chr6 32420179 C T 1.76E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7754768 chr6 32420179 C T 9.93E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7754768 chr6 32420179 C T 1.21E-06 Leprosy / / pha002872 rs7775108 chr6 32420238 T C 3.71E-10 Sarcoidosis / / 22952805 rs9268781 chr6 32420497 T C 0.00002528 Sarcoidosis / / 22952805 rs9268783 chr6 32420715 T C 0.0001127 Sarcoidosis / / 22952805 rs9268791 chr6 32421073 T C 0.0002323 Sarcoidosis / / 22952805 rs6457590 chr6 32421798 G T 1.90E-11 Rheumatoid arthritis / / 21156761 rs28895171 chr6 32423021 G A 0.000000113 Follicular lymphoma / / 23025665 rs113928914 chr6 32423195 G A 0.000389 Sarcoidosis / / 22952805 rs7776297 chr6 32424108 C T 3.14E-08 Sarcoidosis / / 22952805 rs28895187 chr6 32424380 G A 0.000000135 Follicular lymphoma / / 23025665 rs9268812 chr6 32424568 A G,T 0.00001916 Sarcoidosis / / 22952805 rs9268814 chr6 32424616 C G 0.00002 Sarcoidosis / / 22952805 rs9268815 chr6 32424677 A T 9.50E-11 Sarcoidosis / / 22952805 rs7763262 chr6 32424882 T C 0.00002131 Sarcoidosis / / 22952805 rs7763262 chr6 32424882 T C 4.29E-06 Leprosy / / pha002872 rs115080784 chr6 32424888 C T 3.09E-09 Sarcoidosis / / 22952805 rs7743662 chr6 32425049 G A 0.000008556 Sarcoidosis / / 22952805 rs7743415 chr6 32425135 C T 6.70E-11 Sarcoidosis / / 22952805 rs7744304 chr6 32425487 G T 0.00002214 Sarcoidosis / / 22952805 rs7748310 chr6 32425605 G A 0.000004088 Sarcoidosis / / 22952805 rs13198610 chr6 32425672 G T 0.000000141 Follicular lymphoma / / 23025665 rs7748085 chr6 32425742 A G 0.000004088 Sarcoidosis / / 22952805 rs7748825 chr6 32425914 G C 0.000004313 Sarcoidosis / / 22952805 rs9767620 chr6 32426100 T C 0.0003618 Sarcoidosis / / 22952805 rs113320073 chr6 32426355 G A 0.0008854 Sarcoidosis / / 22952805 rs7769693 chr6 32426458 T G 2.63E-11 Sarcoidosis / / 22952805 rs9268828 chr6 32426540 A G 0.000004482 Sarcoidosis / / 22952805 rs9268829 chr6 32426602 A G 0.000003961 Sarcoidosis / / 22952805 rs4632888 chr6 32426873 T C 0.0006817 Sarcoidosis / / 22952805 rs1548306 chr6 32427179 A T 0.00001276 Sarcoidosis / / 22952805 rs9268831 chr6 32427748 C T 2.21E-35 Multiple complex diseases / / 17554300 rs9268831 chr6 32427748 C T 3.03E-13 Multiple sclerosis / / 17660530 rs9268831 chr6 32427748 C T 6.17E-05 Serum metabolites / / 19043545 rs9268831 chr6 32427748 C T 1.22E-19 Narcolepsy / / 19629137 rs9268831 chr6 32427748 C T 1.31E-20 Rheumatoid arthritis / / 21156761 rs9268831 chr6 32427748 C T 7.23E-06 Asthma / / 23181788 rs9268831 chr6 32427748 C T 9.00E-06 Self-reported allergy / / 23817569 rs9268832 chr6 32427789 T C 2.00E-04 Rheumatoid arthritis / / 17159887 rs9268832 chr6 32427789 T C 4.56E-75 Rheumatoid arthritis / / 17804836 rs9268832 chr6 32427789 T C 1.09E-07 Multiple sclerosis / / 20598377 rs9268832 chr6 32427789 T C 0.00004346 Sarcoidosis / / 22952805 rs9268832 chr6 32427789 T C 0.0000432 Follicular lymphoma / / 23025665 rs9268832 chr6 32427789 T C 3.11E-11 Epstein-Barr virus immune response (EBNA-1) / / 23326239 rs9268832 chr6 32427789 T C 6.23E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9268832 chr6 32427789 T C 7.20E-15 Systemic lupus erythematosus / / 24871463 rs9268832 chr6 32427789 T C 3.14E-10 Systemic lupus erythematosus / / pha002867 rs9268833 chr6 32428062 C T 0.00007105 Sarcoidosis / / 22952805 rs9268834 chr6 32428079 C A 0.00007457 Sarcoidosis / / 22952805 rs9268835 chr6 32428115 G A 0.00007457 Sarcoidosis / / 22952805 rs9268835 chr6 32428115 G A 0.00000003 Joint damage severity in rheumatoid arthritis / / 23696630 rs6923504 chr6 32428186 G C 0.00007696 Sarcoidosis / / 22952805 rs6923504 chr6 32428186 G C 1.10E-11 Joint damage severity in rheumatoid arthritis / / 23696630 rs6903608 chr6 32428285 C T 1.61E-17 Type 1 diabetes / / 17632545 rs6903608 chr6 32428285 C T 4.55E-42 Rheumatoid arthritis / / 17804836 rs6903608 chr6 32428285 C T 4.47E-05 Amyotrophic lateral sclerosis / / 19193627 rs6903608 chr6 32428285 C T 3.13E-80 Rheumatoid arthritis / / 19503088 rs6903608 chr6 32428285 C T 2.15E-07 Multiple sclerosis / / 20598377 rs6903608 chr6 32428285 C T 3.00E-50 Hodgkin's lymphoma / / 21037568 rs6903608 chr6 32428285 C T 9.72E-49 Rheumatoid arthritis / / 21156761 rs6903608 chr6 32428285 C T 5.12E-24 Graves' disease / / 21841780 rs6903608 chr6 32428285 C T 2.70E-21 Hodgkin's lymphoma / / 22286212 rs6903608 chr6 32428285 C T 0.00007696 Sarcoidosis / / 22952805 rs6903608 chr6 32428285 C T 0.0000908 Follicular lymphoma / / 23025665 rs6903608 chr6 32428285 C T 1.10E-11 Joint damage severity in rheumatoid arthritis / / 23696630 rs6903608 chr6 32428285 C T 7.00E-06 Multiple myeloma / / 23955597 rs6903608 chr6 32428285 C T 5.00E-27 Hodgkin's lymphoma / / 24149102 rs6903608 chr6 32428285 C T 7.00E-31 Hodgkin's lymphoma / / 24920014 rs6903608 chr6 32428285 C T 1.55E-144 Type 1 diabetes / / pha002862 rs9268838 chr6 32428715 G A 0.00001412 Sarcoidosis / / 22952805 rs9268838 chr6 32428715 G A 0.00000003 Joint damage severity in rheumatoid arthritis / / 23696630 rs9268839 chr6 32428772 A G 2.13E-13 Sarcoidosis / / 22952805 rs9268839 chr6 32428772 A G 1.00E-250 Rheumatoid arthritis / / 24390342 rs9268839 chr6 32428772 A G 1.00E-250 Rheumatoid arthritis / / 24390342 rs9268839 chr6 32428772 A G 2.00E-145 Rheumatoid arthritis / / 24390342 rs9268840 chr6 32428804 C T 0.00005949 Sarcoidosis / / 22952805 rs9791280 chr6 32428994 G C 9.59E-08 Sarcoidosis / / 22952805 rs6919855 chr6 32429011 C T 0.00007191 Sarcoidosis / / 22952805 rs72843939 chr6 32429077 T C 9.10E-08 Sarcoidosis / / 22952805 rs11346111 chr6 32429153 A AT 0.00001982 Sarcoidosis / / 22952805 rs9268844 chr6 32429153 A G 0.00001982 Sarcoidosis / / 22952805 rs9268846 chr6 32429245 C G 0.00004582 Sarcoidosis / / 22952805 rs9268849 chr6 32429327 C T 0.000001924 Sarcoidosis / / 22952805 rs9268853 chr6 32429643 T C 1.48E-75 Multiple complex diseases / / 17554300 rs9268853 chr6 32429643 T C 7.40E-10 Multiple sclerosis / / 17660530 rs9268853 chr6 32429643 T C 1.90E-09 Narcolepsy / / 19629137 rs9268853 chr6 32429643 T C 8.90E-05 Major depressive disorder / / 21042317 rs9268853 chr6 32429643 T C 1.19E-64 Rheumatoid arthritis / / 21156761 rs9268853 chr6 32429643 T C 1.00E-55 Ulcerative colitis / / 21297633 rs9268853 chr6 32429643 T C 5.00E-109 Rheumatoid arthritis / / 21653640 rs9268853 chr6 32429643 T C 9.16E-08 Inflammatory biomarkers / / 22291609 rs9268853 chr6 32429643 T C 0.000002389 Sarcoidosis / / 22952805 rs9268853 chr6 32429643 T C 9.55E-07 Asthma / / 23181788 rs9268853 chr6 32429643 T C 3.32E-14 Epstein-Barr virus immune response (EBNA-1) / / 23326239 rs9268853 chr6 32429643 T C 2.00E-10 Lymphoma / / 23349640 rs9268853 chr6 32429643 T C 3.00E-06 Ulcerative colitis / / 23511034 rs9268853 chr6 32429643 T C 0.00000002 Joint damage severity in rheumatoid arthritis / / 23696630 rs9268853 chr6 32429643 T C 4.75E-06 Self-reported allergy / / 23817569 rs9268853 chr6 32429643 T C 8.87E-13 Psoriasis / / pha002855 rs12527323 chr6 32429694 C A 3.25E-07 Sarcoidosis / / 22952805 rs9268856 chr6 32429719 C A 1.06E-09 Narcolepsy / / 19629137 rs9268856 chr6 32429719 C A 2.78E-41 Rheumatoid arthritis / / 21156761 rs9268856 chr6 32429719 C A 8.64E-08 Schizophrenia / / 21926974 rs9268856 chr6 32429719 C A 5.21E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9268856 chr6 32429719 C A 5.51E-09 Frontotemporal dementia / / 24943344 rs9268856 chr6 32429719 C A 6.00E-09 Frontotemporal dementia / / 24943344 rs9268858 chr6 32429758 T C 2.48E-74 Multiple complex diseases / / 17554300 rs9268858 chr6 32429758 T C 6.17E-09 Multiple sclerosis / / 17660530 rs9268858 chr6 32429758 T C 1.10E-09 Narcolepsy / / 19629137 rs9268858 chr6 32429758 T C 8.60E-05 Major depressive disorder / / 21042317 rs9268858 chr6 32429758 T C 1.13E-64 Rheumatoid arthritis / / 21156761 rs9268858 chr6 32429758 T C 6.96E-12 Lymphocyte counts / / 22286170 rs9268858 chr6 32429758 T C 7.68E-08 Inflammatory biomarkers / / 22291609 rs9268858 chr6 32429758 T C 0.000001799 Sarcoidosis / / 22952805 rs9268858 chr6 32429758 T C 0.0000859 Major depressive disorder / / 23149448 rs9268858 chr6 32429758 T C 1.13E-06 Asthma / / 23181788 rs9268858 chr6 32429758 T C 0.0000166 Schizophrenia / / 23637625 rs9268858 chr6 32429758 T C 4.58E-06 Self-reported allergy / / 23817569 rs9268860 chr6 32429825 C T 0.000001784 Sarcoidosis / / 22952805 rs9268861 chr6 32429894 C A 1.62E-40 Multiple complex diseases / / 17554300 rs9268861 chr6 32429894 C A 5.12E-04 Alzheimer's disease / / 17998437 rs9268861 chr6 32429894 C A 5.55E-37 Rheumatoid arthritis / / 21156761 rs9268861 chr6 32429894 C A 9.00E-04 Rheumatoid arthritis / / 21156761 rs9268861 chr6 32429894 C A 0.000000666 Behcet's disease / / 23041938 rs9268862 chr6 32430167 A C 2.07E-41 Rheumatoid arthritis / / 21156761 rs9268862 chr6 32430167 A C 0.000000621 Schizophrenia / / 23637625 rs9268862 chr6 32430167 A C 6.22E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9268864 chr6 32430326 T A 0.0000017 Sarcoidosis / / 22952805 rs13193827 chr6 32430337 C A 3.99E-07 Sarcoidosis / / 22952805 rs4428528 chr6 32430362 C G 1.67E-37 Multiple complex diseases / / 17554300 rs4428528 chr6 32430362 C G 1.32E-08 Narcolepsy / / 19629137 rs4434496 chr6 32430508 C T 4.26E-28 Rheumatoid arthritis / / 21156761 rs7766843 chr6 32430729 C T 9.45E-10 Narcolepsy / / 19629137 rs7766843 chr6 32430729 C T 1.61E-41 Rheumatoid arthritis / / 21156761 rs7766843 chr6 32430729 C T 5.66E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7766854 chr6 32430752 C T 0.0000926 Sarcoidosis / / 22952805 rs7746922 chr6 32430975 C A 4.11E-31 Multiple complex diseases / / 17554300 rs7746922 chr6 32430975 C A 1.01E-09 Narcolepsy / / 19629137 rs7746922 chr6 32430975 C A 2.84E-41 Rheumatoid arthritis / / 21156761 rs7747521 chr6 32431105 A G 2.00E-09 Non-obstructive azoospermia / / 22541561 rs7747521 chr6 32431105 A G 6.78E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7747529 chr6 32431124 G A 0.000001803 Sarcoidosis / / 22952805 rs9268877 chr6 32431147 A G 3.82E-78 Multiple complex diseases / / 17554300 rs9268877 chr6 32431147 A G 2.87E-16 Multiple sclerosis / / 17660530 rs9268877 chr6 32431147 A G 6.00E-18 Ulcerative colitis / / 18836448 rs9268877 chr6 32431147 A G 1.41E-30 Narcolepsy / / 19629137 rs9268877 chr6 32431147 A G 4.00E-23 Ulcerative colitis / / 19915572 rs9268877 chr6 32431147 A G 3.31E-04 Self-reported allergy / / 23817569 rs9268877 chr6 32431147 A G 1.05E-08 Frontotemporal dementia / / 24943344 rs35458464 chr6 32431239 A G 0.000000735 Sarcoidosis / / 22952805 rs9268878 chr6 32431292 T A 1.01E-09 Narcolepsy / / 19629137 rs9268878 chr6 32431292 T A 3.21E-41 Rheumatoid arthritis / / 21156761 rs9268878 chr6 32431292 T A 5.07E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9268880 chr6 32431358 T G 0.00004593 Sarcoidosis / / 22952805 rs9268882 chr6 32431623 T C 0.00002856 Sarcoidosis / / 22952805 rs9268882 chr6 32431623 T C 1.10E-11 Joint damage severity in rheumatoid arthritis / / 23696630 rs9268884 chr6 32431640 T A 0.00000191 Sarcoidosis / / 22952805 rs9268889 chr6 32431886 A G 0.000001928 Sarcoidosis / / 22952805 rs9268895 chr6 32431962 A G 9.00E-14 Schizophrenia / / 23974872 rs9268905 chr6 32432077 G C 1.00E-07 Cystic fibrosis severity / / 21602797 rs9268905 chr6 32432077 G C 0.000001928 Sarcoidosis / / 22952805 rs9268906 chr6 32432181 A G 0.000001894 Sarcoidosis / / 22952805 rs9268909 chr6 32432340 T C 0.0000732 Sarcoidosis / / 22952805 rs9268911 chr6 32432406 A G 6.59E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9268914 chr6 32432556 C T 2.19E-47 Rheumatoid arthritis / / 21156761 rs9268914 chr6 32432556 C T 0.00003487 Sarcoidosis / / 22952805 rs2395184 chr6 32432646 G A 7.42E-05 IgE levels / / 22075330 rs28377518 chr6 32432650 C T 7.45E-07 Sarcoidosis / / 22952805 rs9268923 chr6 32432835 C T 4.00E-15 Ulcerative colitis / / 20228798 rs9268923 chr6 32432835 C T 9.85E-08 Inflammatory biomarkers / / 22291609 rs9268923 chr6 32432835 C T 0.000001996 Sarcoidosis / / 22952805 rs9268923 chr6 32432835 C T 0.00000002 Joint damage severity in rheumatoid arthritis / / 23696630 rs9268923 chr6 32432835 C T 1.71E-06 Self-reported allergy / / 23817569 rs9268926 chr6 32433067 A G 0.00001418 Sarcoidosis / / 22952805 rs9268927 chr6 32433085 A T 0.00006991 Sarcoidosis / / 22952805 rs113585425 chr6 32433125 A C 0.000000153 Sarcoidosis / / 22952805 rs2395185 chr6 32433167 G T 1.00E-16 Type 1 diabetes / / 17632545 rs2395185 chr6 32433167 G T 1.15E-83 Rheumatoid arthritis / / 17804836 rs2395185 chr6 32433167 G T 1.00E-16 Ulcerative colitis / / 19122664 rs2395185 chr6 32433167 G T 4.42E-125 Rheumatoid arthritis / / 19503088 rs2395185 chr6 32433167 G T 5.00E-22 Ulcerative colitis / / 19915573 rs2395185 chr6 32433167 G T 8.73E-05 Asthma / / 20159242 rs2395185 chr6 32433167 G T 5.20E-08 Vitiligo / / 20410501 rs2395185 chr6 32433167 G T 6.80E-05 Major depressive disorder / / 21042317 rs2395185 chr6 32433167 G T 2.61E-66 Rheumatoid arthritis / / 21156761 rs2395185 chr6 32433167 G T 4.00E-31 Hodgkin's lymphoma / / 22286212 rs2395185 chr6 32433167 G T 8.38E-08 Inflammatory biomarkers / / 22291609 rs2395185 chr6 32433167 G T 2.80E-06 Hypothyroidism / / 22493691 rs2395185 chr6 32433167 G T 0.00077 Asthma / / 22694930 rs2395185 chr6 32433167 G T 0.000001996 Sarcoidosis / / 22952805 rs2395185 chr6 32433167 G T 1.00E-08 Lung cancer / / 23143601 rs2395185 chr6 32433167 G T 5.30E-14 Epstein-Barr virus immune response (EBNA-1) / / 23326239 rs2395185 chr6 32433167 G T 0.00000002 Joint damage severity in rheumatoid arthritis / / 23696630 rs2395185 chr6 32433167 G T 4.52E-06 Self-reported allergy / / 23817569 rs2395185 chr6 32433167 G T 4.44E-16 Hodgkin's lymphoma / / 24149102 rs2395185 chr6 32433167 G T 1.10E-04 Systemic lupus erythematosus / / 24871463 rs2395186 chr6 32433192 C G 0.000002029 Sarcoidosis / / 22952805 rs2395188 chr6 32433256 T C 0.00009843 Sarcoidosis / / 22952805 rs34014061 chr6 32433508 T C 0.00000151 Sarcoidosis / / 22952805 rs35385757 chr6 32433565 C T 0.000001114 Sarcoidosis / / 22952805 rs9268965 chr6 32434240 G A 0.000001572 Sarcoidosis / / 22952805 rs9268969 chr6 32434349 C T 9.38E-08 Inflammatory biomarkers / / 22291609 rs9268969 chr6 32434349 C T 0.000002059 Sarcoidosis / / 22952805 rs9268969 chr6 32434349 C T 0.000000005 Joint damage severity in rheumatoid arthritis / / 23696630 rs9268970 chr6 32434361 C A 0.000001898 Sarcoidosis / / 22952805 rs17202892 chr6 32434479 C A 8.78E-07 Sarcoidosis / / 22952805 rs9268971 chr6 32434639 G A 0.0000853 Sarcoidosis / / 22952805 rs28377109 chr6 32434716 C A 7.70E-07 Sarcoidosis / / 22952805 rs369688458 chr6 32434716 C CTT 7.70E-07 Sarcoidosis / / 22952805 rs372346302 chr6 32434716 C CTT 7.70E-07 Sarcoidosis / / 22952805 rs9281838 chr6 32434716 C CTT 7.70E-07 Sarcoidosis / / 22952805 rs9268973 chr6 32434778 T C 0.00009843 Sarcoidosis / / 22952805 rs9268974 chr6 32434830 C T 0.00009843 Sarcoidosis / / 22952805 rs9268975 chr6 32434844 A T 0.00009644 Sarcoidosis / / 22952805 rs9391781 chr6 32434850 G C 0.000002027 Sarcoidosis / / 22952805 rs9268976 chr6 32434874 A T 0.00009843 Sarcoidosis / / 22952805 rs9268977 chr6 32434939 T C 6.22E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9268978 chr6 32434978 A G 0.00009861 Sarcoidosis / / 22952805 rs9268979 chr6 32435044 T C 7.52E-07 Inflammatory biomarkers / / 22291609 rs9268980 chr6 32435123 A G 3.15E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs35421268 chr6 32435196 C T 7.29E-07 Sarcoidosis / / 22952805 rs4947340 chr6 32435338 C T 0.00001297 Sarcoidosis / / 22952805 rs28654725 chr6 32435542 A G 0.000002605 Sarcoidosis / / 22952805 rs28831180 chr6 32435921 C G 0.00001204 Sarcoidosis / / 22952805 rs77244909 chr6 32436240 A C 0.000001788 Sarcoidosis / / 22952805 rs76914018 chr6 32436250 A T 0.000001982 Sarcoidosis / / 22952805 rs28895234 chr6 32437050 A G 0.00002622 Sarcoidosis / / 22952805 rs28895235 chr6 32437160 T A 0.000003326 Sarcoidosis / / 22952805 rs9269026 chr6 32437433 G A 0.00004876 Sarcoidosis / / 22952805 rs9405038 chr6 32437614 G T 0.000002039 Sarcoidosis / / 22952805 rs191785247 chr6 32437813 G A 0.000005843 Sarcoidosis / / 22952805 rs9368725 chr6 32438159 C T 0.000002166 Sarcoidosis / / 22952805 rs9380306 chr6 32438298 A G 0.000002092 Sarcoidosis / / 22952805 rs12524496 chr6 32438513 G C 0.00001146 Sarcoidosis / / 22952805 rs9368726 chr6 32438542 T C 7.50E-05 Major depressive disorder / / 21042317 rs9368726 chr6 32438542 T C 0.00000187 Sarcoidosis / / 22952805 rs9368726 chr6 32438542 T C 3.32E-14 Epstein-Barr virus immune response (EBNA-1) / / 23326239 rs12525692 chr6 32438546 A T 6.91E-07 Sarcoidosis / / 22952805 rs9269043 chr6 32438598 T C 2.52E-40 Rheumatoid arthritis / / 21156761 rs9269043 chr6 32438598 T C 0.00009843 Sarcoidosis / / 22952805 rs9269043 chr6 32438598 T C 3.19E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9405108 chr6 32438648 C T 7.50E-05 Major depressive disorder / / 21042317 rs9405108 chr6 32438648 C T 0.000001996 Sarcoidosis / / 22952805 rs9405108 chr6 32438648 C T 3.32E-14 Epstein-Barr virus immune response (EBNA-1) / / 23326239 rs9405108 chr6 32438648 C T 0.00000002 Joint damage severity in rheumatoid arthritis / / 23696630 rs34200087 chr6 32438691 G A 6.98E-07 Sarcoidosis / / 22952805 rs9391877 chr6 32438867 G T 0.000002204 Sarcoidosis / / 22952805 rs9405109 chr6 32439029 T C 0.000002288 Sarcoidosis / / 22952805 rs7452864 chr6 32439077 T C 0.00004598 Sarcoidosis / / 22952805 rs9405110 chr6 32439108 A C 0.000002143 Sarcoidosis / / 22952805 rs2157338 chr6 32439323 C T 0.00009458 Sarcoidosis / / 22952805 rs2157338 chr6 32439323 C T 5.66E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9405040 chr6 32439393 A C 2.61E-66 Rheumatoid arthritis / / 21156761 rs9405040 chr6 32439393 A C 9.19E-08 Inflammatory biomarkers / / 22291609 rs2187823 chr6 32439508 G A 0.00009843 Sarcoidosis / / 22952805 rs2187823 chr6 32439508 G A 5.66E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs5026740 chr6 32439753 T A 2.35E-40 Rheumatoid arthritis / / 21156761 rs5026740 chr6 32439753 T A 0.0000921 Sarcoidosis / / 22952805 rs67209722 chr6 32439782 T C 7.14E-07 Sarcoidosis / / 22952805 rs9286790 chr6 32439828 G A 2.01E-63 Rheumatoid arthritis / / 21156761 rs9286790 chr6 32439828 G A 9.25E-08 Inflammatory biomarkers / / 22291609 rs9286790 chr6 32439828 G A 0.000001996 Sarcoidosis / / 22952805 rs5026742 chr6 32439915 T C 0.00009029 Sarcoidosis / / 22952805 rs35954087 chr6 32440049 C T 7.14E-07 Sarcoidosis / / 22952805 rs35954087 chr6 32440049 C T 0.00000115 Follicular lymphoma / / 23025665 rs9269078 chr6 32440879 C T 3.56E-46 Rheumatoid arthritis / / 21156761 rs9348886 chr6 32441008 C T 0.000001996 Sarcoidosis / / 22952805 rs9269081 chr6 32441100 A C 4.06E-45 Rheumatoid arthritis / / 21156761 rs9269081 chr6 32441100 A C 0.00002042 Sarcoidosis / / 22952805 rs9269081 chr6 32441100 A C 1.60E-11 Joint damage severity in rheumatoid arthritis / / 23696630 rs9269081 chr6 32441100 A C 2.87E-08 Chronic hepatitis B infection / / 23760081 rs13217979 chr6 32441126 C T 7.14E-07 Sarcoidosis / / 22952805 rs12215261 chr6 32441150 C T 0.000001996 Sarcoidosis / / 22952805 rs12215313 chr6 32441276 C T 0.000001996 Sarcoidosis / / 22952805 rs13191565 chr6 32441577 G C 7.14E-07 Sarcoidosis / / 22952805 rs9269094 chr6 32441934 T C 0.00009843 Sarcoidosis / / 22952805 rs34442410 chr6 32442086 C G 0.00005206 Sarcoidosis / / 22952805 rs6901541 chr6 32442261 T C 4.00E-04 Rheumatoid arthritis / / 21156761 rs6901541 chr6 32442261 T C 4.40E-36 Rheumatoid arthritis / / 21156761 rs6901541 chr6 32442261 T C 2.77E-10 Epstein-Barr virus immune response (EBNA-1) / / 23326239 rs6924267 chr6 32442296 C T 0.0000968 Sarcoidosis / / 22952805 rs35168843 chr6 32442408 G A 7.01E-07 Sarcoidosis / / 22952805 rs9269101 chr6 32442711 A C 4.00E-04 Rheumatoid arthritis / / 21156761 rs9269101 chr6 32442711 A C 4.40E-36 Rheumatoid arthritis / / 21156761 rs9269101 chr6 32442711 A C 0.00009843 Sarcoidosis / / 22952805 rs9269106 chr6 32443131 C T 0.00009843 Sarcoidosis / / 22952805 rs9391879 chr6 32443172 C T 3.97E-13 Sarcoidosis / / 22952805 rs9269107 chr6 32443210 G A 0.00009843 Sarcoidosis / / 22952805 rs9269110 chr6 32443269 A C 0.00004593 Sarcoidosis / / 22952805 rs9269110 chr6 32443269 A C 1.10E-11 Joint damage severity in rheumatoid arthritis / / 23696630 rs9269112 chr6 32443368 C G 0.00009843 Sarcoidosis / / 22952805 rs9269113 chr6 32443387 T A 0.00009843 Sarcoidosis / / 22952805 rs9391881 chr6 32443432 C G 3.97E-13 Sarcoidosis / / 22952805 rs9378264 chr6 32443451 G A 2.88E-13 Sarcoidosis / / 22952805 rs9269116 chr6 32443458 T C 0.00004351 Sarcoidosis / / 22952805 rs9269118 chr6 32443641 G A 0.00004593 Sarcoidosis / / 22952805 rs28895241 chr6 32443665 T C 9.07E-13 Sarcoidosis / / 22952805 rs28895242 chr6 32443666 G C 1.32E-12 Sarcoidosis / / 22952805 rs28732242 chr6 32444078 G A 9.72E-07 Sarcoidosis / / 22952805 rs28732244 chr6 32444096 C T 5.34E-12 Sarcoidosis / / 22952805 rs12194148 chr6 32444198 G T 1.57E-100 Rheumatoid arthritis / / 21156761 rs12194148 chr6 32444198 G T 3.97E-13 Sarcoidosis / / 22952805 rs12207473 chr6 32444330 A C 1.51E-12 Sarcoidosis / / 22952805 rs6457597 chr6 32444455 T C 0.00009843 Sarcoidosis / / 22952805 rs6457598 chr6 32444475 T C 0.00004562 Sarcoidosis / / 22952805 rs34468823 chr6 32444493 C T 0.000005255 Sarcoidosis / / 22952805 rs12195589 chr6 32444584 C T 3.97E-13 Sarcoidosis / / 22952805 rs7776032 chr6 32444896 C T 0.00007678 Sarcoidosis / / 22952805 rs7755770 chr6 32444968 G A 0.00009843 Sarcoidosis / / 22952805 rs7755918 chr6 32444971 A C 0.00009843 Sarcoidosis / / 22952805 rs9269135 chr6 32445030 T C 0.00003423 Sarcoidosis / / 22952805 rs28895255 chr6 32445079 C T 4.15E-13 Sarcoidosis / / 22952805 rs28895257 chr6 32445114 A G 4.15E-13 Sarcoidosis / / 22952805 rs28895258 chr6 32445117 C T 4.15E-13 Sarcoidosis / / 22952805 rs9269137 chr6 32445147 C T 0.0000242 Sarcoidosis / / 22952805 rs28895261 chr6 32445306 G A 4.38E-11 Sarcoidosis / / 22952805 rs147716103 chr6 32445319 G C 3.75E-07 Sarcoidosis / / 22952805 rs9269142 chr6 32445423 G A 0.00004593 Sarcoidosis / / 22952805 rs9269144 chr6 32445519 A G 0.0000394 Sarcoidosis / / 22952805 rs9405112 chr6 32445600 G A 8.88E-68 Rheumatoid arthritis / / 21156761 rs9405112 chr6 32445600 G A 6.43E-08 Inflammatory biomarkers / / 22291609 rs9405112 chr6 32445600 G A 0.000002318 Sarcoidosis / / 22952805 rs201207765 chr6 32445660 T TTGC 0.00009969 Sarcoidosis / / 22952805 rs9269149 chr6 32445660 T C 0.00009969 Sarcoidosis / / 22952805 rs9378212 chr6 32445691 C T 1.57E-100 Rheumatoid arthritis / / 21156761 rs9378212 chr6 32445691 C T 3.97E-13 Sarcoidosis / / 22952805 rs6924676 chr6 32445727 T C 0.00004593 Sarcoidosis / / 22952805 rs28895264 chr6 32445792 C T 8.20E-12 Sarcoidosis / / 22952805 rs17209866 chr6 32445992 G A 8.84E-13 Sarcoidosis / / 22952805 rs17209873 chr6 32446010 T C 2.27E-07 Sarcoidosis / / 22952805 rs6925041 chr6 32446025 G A 0.00009843 Sarcoidosis / / 22952805 rs17209887 chr6 32446051 A C 2.70E-12 Sarcoidosis / / 22952805 rs17203514 chr6 32446071 C G 4.01E-13 Sarcoidosis / / 22952805 rs17203521 chr6 32446078 C A 7.01E-07 Sarcoidosis / / 22952805 rs17203549 chr6 32446307 T C 3.65E-08 Sarcoidosis / / 22952805 rs17203563 chr6 32446459 G A 2.65E-12 Sarcoidosis / / 22952805 rs9269158 chr6 32446518 C T 0.0000969 Sarcoidosis / / 22952805 rs17209950 chr6 32446588 G A 0.000002315 Sarcoidosis / / 22952805 rs9269163 chr6 32446833 A G 0.00004311 Sarcoidosis / / 22952805 rs17203612 chr6 32446853 A T 2.80E-13 Sarcoidosis / / 22952805 rs17203626 chr6 32446994 G A 2.34E-07 Sarcoidosis / / 22952805 rs17203636 chr6 32447014 G A 4.01E-13 Sarcoidosis / / 22952805 rs2395191 chr6 32447085 T C 0.000003377 Sarcoidosis / / 22952805 rs29001652 chr6 32447111 A G 4.42E-13 Sarcoidosis / / 22952805 rs9269172 chr6 32447154 C G 0.00004311 Sarcoidosis / / 22952805 rs29001478 chr6 32447162 G A 4.29E-13 Sarcoidosis / / 22952805 rs29001620 chr6 32447216 A T 4.73E-13 Sarcoidosis / / 22952805 rs28732246 chr6 32447219 G A 4.73E-13 Sarcoidosis / / 22952805 rs29001568 chr6 32447341 G A 4.29E-13 Sarcoidosis / / 22952805 rs9269174 chr6 32447364 T C 0.00004311 Sarcoidosis / / 22952805 rs35007143 chr6 32447518 T A 1.41E-12 Sarcoidosis / / 22952805 rs9269177 chr6 32447574 G A 0.00009705 Sarcoidosis / / 22952805 rs2395193 chr6 32447709 A G 0.00009705 Sarcoidosis / / 22952805 rs4994859 chr6 32447715 A G 4.29E-13 Sarcoidosis / / 22952805 rs4078374 chr6 32447740 G A 8.20E-07 Sarcoidosis / / 22952805 rs2894261 chr6 32447769 C T 0.00004358 Sarcoidosis / / 22952805 rs2894262 chr6 32447816 A G 0.00004247 Sarcoidosis / / 22952805 rs4078373 chr6 32447832 G A 8.20E-07 Sarcoidosis / / 22952805 rs4994855 chr6 32447873 A G 4.24E-13 Sarcoidosis / / 22952805 rs4994854 chr6 32447900 T C 4.24E-13 Sarcoidosis / / 22952805 rs2395194 chr6 32447953 G A 0.00009286 Sarcoidosis / / 22952805 rs4999342 chr6 32448098 T C 8.21E-24 Narcolepsy / / 19629137 rs9378266 chr6 32448189 G T 1.57E-100 Rheumatoid arthritis / / 21156761 rs28735118 chr6 32448360 T A 0.000001198 Sarcoidosis / / 22952805 rs9378213 chr6 32448398 T G 1.57E-100 Rheumatoid arthritis / / 21156761 rs9378213 chr6 32448398 T G 5.94E-13 Sarcoidosis / / 22952805 rs9269186 chr6 32448416 C A,G 1.01E-40 Rheumatoid arthritis / / 21156761 rs9269187 chr6 32448440 C T 2.63E-27 Rheumatoid arthritis / / 21156761 rs9269190 chr6 32448500 T C 5.11E-49 Rheumatoid arthritis / / 21156761 rs9391786 chr6 32448561 A G 1.57E-100 Rheumatoid arthritis / / 21156761 rs7748270 chr6 32448599 C A,G,T 2.74E-05 Schizophrenia / / 19571811 rs7748270 chr6 32448599 C A,G,T 1.00E-16 Rheumatoid arthritis / / 24782177 rs7748270 chr6 32448599 C A,G,T 4.00E-13 Rheumatoid arthritis / / 24782177 rs7748472 chr6 32448763 A G 3.02E-04 Alzheimer's disease (late onset) / / 21379329 rs7749057 chr6 32448904 A G 4.36E-06 Pulmonary function / / 20010834 rs7749057 chr6 32448904 A G 2.99E-25 Rheumatoid arthritis / / 21156761 rs71565330 chr6 32448962 T A 0.00001809 Sarcoidosis / / 22952805 rs7749242 chr6 32449030 A G 2.08E-48 Rheumatoid arthritis / / 21156761 rs7749092 chr6 32449050 T C 4.65E-82 Multiple complex diseases / / 17554300 rs7749092 chr6 32449050 T C 1.14E-26 Narcolepsy / / 19629137 rs9394098 chr6 32449138 C T 4.78E-13 Sarcoidosis / / 22952805 rs9394099 chr6 32449160 G T 6.92E-13 Sarcoidosis / / 22952805 rs67505275 chr6 32449386 C A 0.0000307 Sarcoidosis / / 22952805 rs1964995 chr6 32449411 T C 3.40E-13 Sarcoidosis / / 22952805 rs1964995 chr6 32449411 T C 9.20E-14 Joint damage severity in rheumatoid arthritis / / 23696630 rs9380309 chr6 32449820 A G 4.95E-12 Sarcoidosis / / 22952805 rs7754119 chr6 32449858 T C 2.53E-08 Rheumatoid arthritis / / 21156761 rs5020947 chr6 32450033 C T 4.21E-13 Sarcoidosis / / 22952805 rs5020946 chr6 32450089 G T 6.44E-101 Rheumatoid arthritis / / 21156761 rs5020946 chr6 32450089 G T 6.03E-13 Sarcoidosis / / 22952805 rs5020944 chr6 32450140 C G 5.96E-13 Sarcoidosis / / 22952805 rs113653545 chr6 32450203 C T 6.68E-07 Sarcoidosis / / 22952805 rs34452456 chr6 32450678 T C 4.79E-13 Sarcoidosis / / 22952805 rs12191360 chr6 32451361 C A 6.77E-48 Rheumatoid arthritis / / 21156761 rs28437337 chr6 32451484 C T 0.000002184 Sarcoidosis / / 22952805 rs13194770 chr6 32451570 C T 5.14E-13 Sarcoidosis / / 22952805 rs28619202 chr6 32451650 T C 0.00001375 Sarcoidosis / / 22952805 rs78279385 chr6 32451758 G A 9.05E-07 Sarcoidosis / / 22952805 rs71565333 chr6 32451902 C T 0.000002355 Sarcoidosis / / 22952805 rs2395202 chr6 32451906 T C 0.000003913 Sarcoidosis / / 22952805 rs71565334 chr6 32451947 C T 0.000007647 Sarcoidosis / / 22952805 rs71565336 chr6 32451963 G A 0.000003333 Sarcoidosis / / 22952805 rs62405565 chr6 32452281 C G 0.000002355 Sarcoidosis / / 22952805 rs71543453 chr6 32452361 C T 4.81E-13 Sarcoidosis / / 22952805 rs71565339 chr6 32452378 C A 0.000001335 Sarcoidosis / / 22952805 rs71543454 chr6 32452399 G A 8.88E-13 Sarcoidosis / / 22952805 rs71543455 chr6 32452409 G C 8.88E-13 Sarcoidosis / / 22952805 rs28599891 chr6 32452470 C G 0.00009946 Sarcoidosis / / 22952805 rs71565340 chr6 32452506 C T 0.000002355 Sarcoidosis / / 22952805 rs28368843 chr6 32452587 C T 0.00000148 Sarcoidosis / / 22952805 rs62405566 chr6 32453095 C T 5.71E-13 Sarcoidosis / / 22952805 rs67037615 chr6 32453163 T C 0.00000314 Sarcoidosis / / 22952805 rs527369852 chr6 32453191 T C 1.60E-05 Hypothyroidism / / 22493691 rs6916742 chr6 32453191 T C 1.60E-05 Hypothyroidism / / 22493691 rs72849247 chr6 32453194 T C 0.000002034 Sarcoidosis / / 22952805 rs34036879 chr6 32453336 G T 0.000003457 Sarcoidosis / / 22952805 rs75259234 chr6 32453338 C T 1.37E-12 Sarcoidosis / / 22952805 rs77469652 chr6 32453532 T C 2.15E-12 Sarcoidosis / / 22952805 rs114060570 chr6 32453568 C T 2.02E-07 Sarcoidosis / / 22952805 rs79251508 chr6 32453632 A G 1.62E-12 Sarcoidosis / / 22952805 rs9269254 chr6 32454327 C T 6.85E-09 Sarcoidosis / / 22952805 rs76209082 chr6 32501127 C T 0.0000618 Sarcoidosis / / 22952805 rs67170736 chr6 32504571 T C 0.00008561 Sarcoidosis / / 22952805 rs28568890 chr6 32505767 G A 0.00003897 Sarcoidosis / / 22952805 rs28772724 chr6 32509357 G T 1.34E-08 Ulcerative colitis,refractory / / 20848476 rs66857824 chr6 32512539 C T 0.00008144 Sarcoidosis / / 22952805 rs35571839 chr6 32512613 C T 9.77E-08 Follicular lymphoma / / 23025665 rs71534541 chr6 32513076 C T 0.00007217 Sarcoidosis / / 22952805 rs35997662 chr6 32513575 G T 0.00008144 Sarcoidosis / / 22952805 rs34791134 chr6 32513714 A C 0.00003837 Sarcoidosis / / 22952805 rs33998225 chr6 32513883 T C 0.00008144 Sarcoidosis / / 22952805 rs28880026 chr6 32517398 G A 0.00002982 Sarcoidosis / / 22952805 rs113356426 chr6 32517878 C T 0.000002593 Sarcoidosis / / 22952805 rs66884109 chr6 32518369 G A 0.00007839 Sarcoidosis / / 22952805 rs113566030 chr6 32519000 T C 0.000008523 Sarcoidosis / / 22952805 rs28490179 chr6 32519005 C T 1.42E-13 Leprosy / / 20018961 rs28490179 chr6 32519005 C T 1.42E-13 Leprosy / / pha002872 rs67077728 chr6 32520338 A G 0.00004094 Sarcoidosis HLA-DRB4 nearGene-3 22952805 rs61615404 chr6 32520785 T G 0.00005963 Sarcoidosis HLA-DRB4 UTR-3 22952805 rs58495148 chr6 32520816 G C 0.00005963 Sarcoidosis HLA-DRB4 UTR-3 22952805 rs3828840 chr6 32520907 T C 5.00E-15 Multiple sclerosis (OCB status) HLA-DRB4 intron 23472185 rs3828828 chr6 32521243 T C 0.000002229 Sarcoidosis HLA-DRB4 intron 22952805 rs28530648 chr6 32527079 A C 0.000000564 Follicular lymphoma HLA-DRB6 intron 23025665 rs139707193 chr6 32534429 T C 0.000007505 Sarcoidosis / / 22952805 rs9269329 chr6 32540041 T C 1.94E-16 Leprosy / / pha002872 rs35204106 chr6 32543848 T C 7.80E-10 Sarcoidosis / / 22952805 rs35445101 chr6 32546879 A G 5.56E-09 Sarcoidosis HLA-DRB1 missense 22952805 rs113132500 chr6 32547136 T C 0.0006074 Sarcoidosis HLA-DRB1 intron 22952805 rs9269749 chr6 32548136 T G 5.77E-09 Sarcoidosis HLA-DRB1 intron 22952805 rs9269761 chr6 32548280 G A,C,T 1.97E-09 Sarcoidosis HLA-DRB1 intron 22952805 rs34309628 chr6 32549331 C A,T 7.15E-09 Sarcoidosis HLA-DRB1 intron 22952805 rs1059615 chr6 32549557 G A,C,T 2.20E-12 Urinary metabolites HLA-DRB1 cds-synon 21572414 rs9269821 chr6 32549808 G A 7.06E-06 Parkinson's disease (motor and cognition) HLA-DRB1 intron 22658654 rs9269821 chr6 32549808 G A 7.06E-06 Immune response to anthrax vaccine HLA-DRB1 intron 22658931 rs28724008 chr6 32550550 C G 8.70E-09 Sarcoidosis HLA-DRB1 intron 22952805 rs28724031 chr6 32550819 C A 6.53E-08 Sarcoidosis HLA-DRB1 intron 22952805 rs28724033 chr6 32550905 C A,T 9.35E-09 Sarcoidosis HLA-DRB1 intron 22952805 rs113520250 chr6 32554885 C T 6.18E-08 Sarcoidosis HLA-DRB1 intron 22952805 rs28986206 chr6 32555411 C CAT 1.84E-09 Sarcoidosis HLA-DRB1 intron 22952805 rs9270157 chr6 32555411 C T 1.84E-09 Sarcoidosis HLA-DRB1 intron 22952805 rs9270187 chr6 32555965 T G 0.00004034 Sarcoidosis HLA-DRB1 intron 22952805 rs9270189 chr6 32556030 C T 0.00008216 Sarcoidosis HLA-DRB1 intron 22952805 rs9270352 chr6 32558041 G A,T 0.00008409 Sarcoidosis / / 22952805 rs9270467 chr6 32558946 G A 7.00E-17 Leprosy / / pha002872 rs77122291 chr6 32559019 G A 8.67E-09 Sarcoidosis / / 22952805 rs9270504 chr6 32559184 C A 2.81E-08 Sarcoidosis / / 22952805 rs9270505 chr6 32559216 A G 0.0005033 Sarcoidosis / / 22952805 rs114258010 chr6 32559284 A G 0.00000455 Sarcoidosis / / 22952805 rs9270520 chr6 32559493 A T 6.38E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366267 chr6 32559781 A C 7.14E-09 Sarcoidosis LOC100507709 intron 22952805 rs11756331 chr6 32559929 A G 0.000008007 Sarcoidosis LOC100507709 intron 22952805 rs28366270 chr6 32559934 A G 8.80E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366288 chr6 32560432 C T 4.38E-09 Sarcoidosis LOC100507709 intron 22952805 rs11752229 chr6 32560478 C T 0.000003488 Sarcoidosis LOC100507709 intron 22952805 rs115740813 chr6 32560534 A T 0.000003488 Sarcoidosis LOC100507709 intron 22952805 rs9270555 chr6 32560584 C T 0.0002157 Sarcoidosis LOC100507709 intron 22952805 rs9270556 chr6 32560606 G A 3.44E-09 Sarcoidosis LOC100507709 intron 22952805 rs9270558 chr6 32560667 G A 2.22E-09 Sarcoidosis LOC100507709 intron 22952805 rs9270559 chr6 32560698 T G 1.11E-08 Sarcoidosis LOC100507709 intron 22952805 rs28366296 chr6 32560727 C A 3.60E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366296 chr6 32560727 C A 2.17E-05 IgE levels LOC100507709 intron 24324648 rs9270567 chr6 32560801 T G 2.50E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366297 chr6 32560829 G C 4.20E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366298 chr6 32560859 A C 5.76E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366298 chr6 32560859 A C 1.00E-08 Lung cancer LOC100507709 intron 23143601 rs28366298 chr6 32560859 A C 1.08E-14 Epstein-Barr virus immune response (EBNA-1) LOC100507709 intron 23326239 rs28366298 chr6 32560859 A C 1.67E-14 Hepatitis B vaccine response LOC100507709 intron 24282030 rs28366301 chr6 32560883 G A 4.92E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366302 chr6 32560934 G C 6.41E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366303 chr6 32560963 C G 4.96E-09 Sarcoidosis LOC100507709 intron 22952805 rs9270570 chr6 32560978 A G 2.61E-09 Sarcoidosis LOC100507709 intron 22952805 rs9270574 chr6 32561028 G T 3.83E-09 Sarcoidosis LOC100507709 intron 22952805 rs9270580 chr6 32561123 T C 2.47E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366312 chr6 32561175 T C 5.39E-09 Sarcoidosis / / 22952805 rs28366313 chr6 32561186 G A 3.96E-09 Sarcoidosis / / 22952805 rs28366314 chr6 32561201 A G 4.70E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366315 chr6 32561207 C T 4.70E-09 Sarcoidosis LOC100507709 intron 22952805 rs9270583 chr6 32561229 A G 2.48E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366316 chr6 32561246 T C 4.70E-09 Sarcoidosis LOC100507709 intron 22952805 rs75976095 chr6 32561250 A G 0.000004034 Sarcoidosis LOC100507709 intron 22952805 rs35139284 chr6 32561370 C T 4.22E-08 Sarcoidosis LOC100507709 intron 22952805 rs9270589 chr6 32561390 C T 2.59E-09 Sarcoidosis LOC100507709 intron 22952805 rs9270590 chr6 32561392 G A 2.59E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366317 chr6 32561411 C T 4.70E-09 Sarcoidosis LOC100507709 intron 22952805 rs9270592 chr6 32561429 A T 2.59E-09 Sarcoidosis LOC100507709 intron 22952805 rs9270593 chr6 32561445 A G 2.59E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366319 chr6 32561495 G A 3.36E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366320 chr6 32561551 G A 1.16E-14 Sarcoidosis LOC100507709 intron 22952805 rs9270597 chr6 32561598 T G 2.22E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366323 chr6 32561609 A G 3.11E-09 Sarcoidosis LOC100507709 intron 22952805 rs9270598 chr6 32561618 T C 2.22E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366327 chr6 32561678 G A 4.04E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366328 chr6 32561766 A G 4.32E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366330 chr6 32561846 G C 5.41E-09 Sarcoidosis / / 22952805 rs28366331 chr6 32561880 T G 8.19E-09 Sarcoidosis / / 22952805 rs28366334 chr6 32561895 A C 7.18E-08 Sarcoidosis / / 22952805 rs28366335 chr6 32561911 A G 1.04E-07 Sarcoidosis / / 22952805 rs17191234 chr6 32564681 A C 1.65E-08 Sarcoidosis LOC100507709 intron 22952805 rs28366341 chr6 32564784 G C 1.66E-09 Sarcoidosis LOC100507709 intron 22952805 rs9270604 chr6 32564800 T C 4.97E-11 Sarcoidosis LOC100507709 intron 22952805 rs28366344 chr6 32564813 T C 1.63E-08 Sarcoidosis LOC100507709 intron 22952805 rs9270606 chr6 32564869 C T 6.07E-11 Sarcoidosis LOC100507709 intron 22952805 rs35372932 chr6 32564985 C T 0.000004153 Sarcoidosis LOC100507709 intron 22952805 rs28366351 chr6 32564990 G A 1.66E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366352 chr6 32564993 T C 1.66E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366353 chr6 32565004 A G 1.71E-09 Sarcoidosis LOC100507709 intron 22952805 rs28366356 chr6 32565091 G T 1.66E-09 Sarcoidosis LOC100507709 intron 22952805 rs9270614 chr6 32565115 C A 5.01E-11 Sarcoidosis LOC100507709 intron 22952805 rs28366357 chr6 32565138 C T 1.66E-09 Sarcoidosis LOC100507709 intron 22952805 rs9270616 chr6 32565154 C G 4.97E-11 Sarcoidosis LOC100507709 intron 22952805 rs28366362 chr6 32565213 T C 1.66E-09 Sarcoidosis LOC100507709 intron 22952805 rs9270618 chr6 32565236 C T 4.45E-11 Sarcoidosis LOC100507709 intron 22952805 rs9270621 chr6 32565283 G A 4.97E-11 Sarcoidosis LOC100507709 intron 22952805 rs9270632 chr6 32565533 G A 1.22E-10 Sarcoidosis LOC100507709 intron 22952805 rs9270642 chr6 32565707 G T 7.00E-11 Sarcoidosis LOC100507709 intron 22952805 rs9270651 chr6 32565884 C T 4.54E-11 Sarcoidosis LOC100507709 intron 22952805 rs9270652 chr6 32565905 C T 4.70E-11 Sarcoidosis LOC100507709 intron 22952805 rs9270653 chr6 32565940 G A 4.63E-11 Sarcoidosis LOC100507709 intron 22952805 rs9270654 chr6 32565946 T G 4.63E-11 Sarcoidosis LOC100507709 intron 22952805 rs9270655 chr6 32565966 A T 4.63E-11 Sarcoidosis LOC100507709 intron 22952805 rs9270657 chr6 32566021 T G 7.49E-48 Rheumatoid arthritis LOC100507709 intron 21156761 rs9270657 chr6 32566021 T G 2.73E-10 Sarcoidosis LOC100507709 intron 22952805 rs2647078 chr6 32566096 C G 0.00009414 Sarcoidosis LOC100507709 intron 22952805 rs11754183 chr6 32566156 G A 0.000004475 Sarcoidosis LOC100507709 intron 22952805 rs9270665 chr6 32566232 G T 0.0000476 Cholesterol,total LOC100507709 intron 23063622 rs9270665 chr6 32566232 G T 0.0000113 Interleukin-6 (IL-6) levels LOC100507709 intron 23505291 rs4343959 chr6 32566284 T A 2.01E-07 Sarcoidosis LOC100507709 intron 22952805 rs9270667 chr6 32566306 T C 4.93E-11 Sarcoidosis LOC100507709 intron 22952805 rs74729707 chr6 32566501 C T 0.00007948 Sarcoidosis LOC100507709 intron 22952805 rs2647079 chr6 32566502 G A 0.00007003 Sarcoidosis LOC100507709 intron 22952805 rs75783927 chr6 32566712 T C 1.52E-09 Sarcoidosis LOC100507709 intron 22952805 rs71542417 chr6 32566892 A G 0.00008781 Sarcoidosis LOC100507709 intron 22952805 rs9689836 chr6 32567603 A T 0.00008703 Sarcoidosis LOC100507709 intron 22952805 rs9689437 chr6 32567650 T C 0.00008703 Sarcoidosis LOC100507709 intron 22952805 rs74587827 chr6 32567757 G A 9.43E-11 Sarcoidosis LOC100507709 intron 22952805 rs28752490 chr6 32567897 G A 2.49E-09 Sarcoidosis LOC100507709 intron 22952805 rs28752491 chr6 32568127 G C 0.00007735 Sarcoidosis / / 22952805 rs35117964 chr6 32568146 A G 0.00008382 Sarcoidosis / / 22952805 rs28752493 chr6 32568165 G C 9.56E-10 Sarcoidosis LOC100507709 intron 22952805 rs28752497 chr6 32568481 T A 2.75E-09 Sarcoidosis LOC100507709 intron 22952805 rs9270769 chr6 32568907 T A 9.81E-11 Sarcoidosis LOC100507709 intron 22952805 rs9270770 chr6 32568910 T A 9.81E-11 Sarcoidosis LOC100507709 intron 22952805 rs10947315 chr6 32568937 T C 0.0001029 Sarcoidosis LOC100507709 intron 22952805 rs9270771 chr6 32568964 G T 9.81E-11 Sarcoidosis LOC100507709 intron 22952805 rs9270772 chr6 32568967 T C 5.85E-11 Sarcoidosis LOC100507709 intron 22952805 rs9270773 chr6 32568990 A G 9.81E-11 Sarcoidosis LOC100507709 intron 22952805 rs28752501 chr6 32568995 G A 2.75E-09 Sarcoidosis LOC100507709 intron 22952805 rs11752754 chr6 32569500 C T 0.000004153 Sarcoidosis LOC100507709 intron 22952805 rs9270806 chr6 32569563 C T 8.96E-10 Sarcoidosis LOC100507709 intron 22952805 rs9270807 chr6 32569572 G A 7.67E-10 Sarcoidosis LOC100507709 intron 22952805 rs28605404 chr6 32569687 A G 1.88E-08 Follicular lymphoma LOC100507709 intron 23025665 rs477515 chr6 32569691 G A 1.00E-16 Type 1 diabetes LOC100507709 intron 17632545 rs477515 chr6 32569691 G A 1.00E-08 Inflammatory bowel disease LOC100507709 intron 18758464 rs477515 chr6 32569691 G A 6.44E-15 Hepatitis B vaccine response LOC100507709 intron 21764829 rs477515 chr6 32569691 G A 7.70E-07 Hypothyroidism LOC100507709 intron 22493691 rs477515 chr6 32569691 G A 4.04E-09 Sarcoidosis LOC100507709 intron 22952805 rs477515 chr6 32569691 G A 2.28E-07 Crohn's disease LOC100507709 intron 23266558 rs477515 chr6 32569691 G A 3.00E-13 Epstein-Barr virus immune response (EBNA-1) LOC100507709 intron 23326239 rs477515 chr6 32569691 G A 0.00000053 Joint damage severity in rheumatoid arthritis LOC100507709 intron 23696630 rs477515 chr6 32569691 G A 9.99E-15 Hodgkin's lymphoma LOC100507709 intron 24149102 rs477515 chr6 32569691 G A 3.00E-19 Hepatitis B vaccine response LOC100507709 intron 24282030 rs476602 chr6 32569792 T C 7.87E-10 Sarcoidosis LOC100507709 intron 22952805 rs622137 chr6 32569852 G A 4.17E-09 Sarcoidosis LOC100507709 intron 22952805 rs13191764 chr6 32570110 T A 3.58E-07 Sarcoidosis LOC100507709 intron 22952805 rs2516050 chr6 32570352 G A 4.26E-10 Sarcoidosis LOC100507709 intron 22952805 rs2516049 chr6 32570400 T C 1.00E-16 Type 1 diabetes LOC100507709 intron 17632545 rs2516049 chr6 32570400 T C 1.43E-79 Rheumatoid arthritis LOC100507709 intron 17804836 rs2516049 chr6 32570400 T C 5.77E-123 Rheumatoid arthritis LOC100507709 intron 19503088 rs2516049 chr6 32570400 T C 2.62E-05 Asthma LOC100507709 intron 20159242 rs2516049 chr6 32570400 T C 2.02E-09 Vitiligo LOC100507709 intron 20410501 rs2516049 chr6 32570400 T C 4.35E-65 Rheumatoid arthritis LOC100507709 intron 21156761 rs2516049 chr6 32570400 T C 3.60E-31 Rheumatoid arthritis LOC100507709 intron 21673997 rs2516049 chr6 32570400 T C 2.90E-15 Hepatitis B vaccine response LOC100507709 intron 21764829 rs2516049 chr6 32570400 T C 1.11E-05 Alopecia areata LOC100507709 intron 22027810 rs2516049 chr6 32570400 T C 1.85E-07 Pemphigus vulgaris LOC100507709 intron 22437316 rs2516049 chr6 32570400 T C 6.00E-07 Hypothyroidism LOC100507709 intron 22493691 rs2516049 chr6 32570400 T C 4.04E-09 Sarcoidosis LOC100507709 intron 22952805 rs2516049 chr6 32570400 T C 2.33E-07 Crohn's disease LOC100507709 intron 23266558 rs2516049 chr6 32570400 T C 6.45E-06 Hepatitis C induced liver cirrhosis LOC100507709 intron 23321320 rs2516049 chr6 32570400 T C 1.37E-15 Epstein-Barr virus immune response (EBNA-1) LOC100507709 intron 23326239 rs2516049 chr6 32570400 T C 3.29E-14 Hodgkin's lymphoma LOC100507709 intron 24149102 rs2516049 chr6 32570400 T C 7.00E-04 Systemic lupus erythematosus LOC100507709 intron 24871463 rs2454138 chr6 32570401 G A 4.26E-09 Sarcoidosis LOC100507709 intron 22952805 rs9270856 chr6 32570839 A G 3.56E-17 Leprosy LOC100507709 intron 20018961 rs9270856 chr6 32570839 A G 3.56E-17 Leprosy LOC100507709 intron pha002872 rs556025 chr6 32570880 C T 1.62E-07 Sarcoidosis LOC100507709 intron 22952805 rs679243 chr6 32570959 C T 7.99E-10 Sarcoidosis LOC100507709 intron 22952805 rs680151 chr6 32571166 A G 3.95E-11 Sarcoidosis LOC100507709 intron 22952805 rs526784 chr6 32572030 T A 3.33E-08 Sarcoidosis LOC100507709 intron 22952805 rs585305 chr6 32572048 G T 3.11E-08 Sarcoidosis LOC100507709 intron 22952805 rs2858870 chr6 32572251 T C 5.54E-18 Type 1 diabetes LOC100507709 intron 17632545 rs2858870 chr6 32572251 T C 4.46E-05 HIV-1 control LOC100507709 intron 20041166 rs2858870 chr6 32572251 T C 1.18E-10 Vitiligo LOC100507709 intron 20526339 rs2858870 chr6 32572251 T C 3.01E-13 Hepatitis B vaccine response LOC100507709 intron 21764829 rs2858870 chr6 32572251 T C 0.00005158 Sarcoidosis LOC100507709 intron 22952805 rs2858870 chr6 32572251 T C 6.07E-83 Type 1 diabetes LOC100507709 intron pha002862 rs2858869 chr6 32572666 A G 6.00E-06 Response to ximelagatran treatment LOC100507709 intron 17505501 rs115673262 chr6 32572742 C G 4.54E-07 Sarcoidosis LOC100507709 intron 22952805 rs144453041 chr6 32573025 A G 3.37E-07 Sarcoidosis LOC100507709 intron 22952805 rs601945 chr6 32573415 A G 1.53E-57 Type 1 diabetes LOC100507709 intron 17632545 rs9270965 chr6 32573471 A G 5.00E-12 Narcolepsy (onset before 2009 H1N1 influenza pandemic) LOC100507709 intron 24204295 rs602457 chr6 32573562 T C 2.86E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines LOC100507709 intron 21844884 rs614348 chr6 32573877 T C 7.59E-09 Sarcoidosis LOC100507709 intron 22952805 rs2647071 chr6 32573910 C T 7.21E-09 Sarcoidosis LOC100507709 intron 22952805 rs614437 chr6 32573941 A G 3.29E-10 Sarcoidosis LOC100507709 intron 22952805 rs9270984 chr6 32573991 T G 5.00E-24 Systemic lupus erythematosus LOC100507709 intron 23273568 rs9270984 chr6 32573991 T G 2.73E-15 Leprosy LOC100507709 intron pha002872 rs2647073 chr6 32574014 A C 6.00E-05 Hepatocellular carcinoma (hepatitis B virus related) LOC100507709 intron 23242368 rs9270986 chr6 32574060 A C 1.71E-05 Type 2 diabetes LOC100507709 intron 17463246 rs9270986 chr6 32574060 A C 2.30E-122 Multiple complex diseases LOC100507709 intron 17554300 rs9270986 chr6 32574060 A C 2.38E-39 Multiple sclerosis LOC100507709 intron 17660530 rs9270986 chr6 32574060 A C 1.18E-43 Narcolepsy LOC100507709 intron 19629137 rs9270986 chr6 32574060 A C 2.00E-06 Multiple myeloma LOC100507709 intron 23955597 rs34107399 chr6 32574108 G A 6.39E-07 Sarcoidosis LOC100507709 intron 22952805 rs615672 chr6 32574171 G C 8.00E-27 Rheumatoid arthritis LOC100507709 nearGene-5 17554300 rs615672 chr6 32574171 G C 7.54E-07 Multiple sclerosis LOC100507709 nearGene-5 17660530 rs615672 chr6 32574171 G C 6.60E-05 Personality dimensions LOC100507709 nearGene-5 18957941 rs615672 chr6 32574171 G C 6.75E-20 Narcolepsy LOC100507709 nearGene-5 19629137 rs615672 chr6 32574171 G C 1.48E-43 Rheumatoid arthritis LOC100507709 nearGene-5 21156761 rs615672 chr6 32574171 G C 9.97E-10 Sarcoidosis LOC100507709 nearGene-5 22952805 rs615672 chr6 32574171 G C 2.10E-07 Red blood cell traits LOC100507709 nearGene-5 23222517 rs615698 chr6 32574190 A G 8.78E-11 Sarcoidosis LOC100507709 nearGene-5 22952805 rs616187 chr6 32574305 G A 6.87E-10 Sarcoidosis LOC100507709 nearGene-5 22952805 rs2760994 chr6 32574308 C T 0.0001766 Sarcoidosis LOC100507709 nearGene-5 22952805 rs2760995 chr6 32574358 G A 0.000466 Sarcoidosis LOC100507709 nearGene-5 22952805 rs618095 chr6 32574736 G A 7.94E-11 Sarcoidosis LOC100507709 nearGene-5 22952805 rs9271055 chr6 32575369 G T 7.40E-24 Systemic lupus erythematosus LOC100507709 nearGene-5 23273568 rs9271055 chr6 32575369 G T 2.22E-15 Leprosy LOC100507709 nearGene-5 pha002872 rs2858866 chr6 32575391 G C 6.39E-11 Sarcoidosis LOC100507709 nearGene-5 22952805 rs486912 chr6 32575493 C G 6.39E-11 Sarcoidosis LOC100507709 nearGene-5 22952805 rs9271065 chr6 32575619 C G 0.00003618 Sarcoidosis LOC100507709 nearGene-5 22952805 rs9271069 chr6 32575700 A G 0.00003701 Sarcoidosis / / 22952805 rs115736757 chr6 32575724 T C 1.53E-07 Sarcoidosis LOC100507709 nearGene-5 22952805 rs116119619 chr6 32575725 G A 2.44E-08 Sarcoidosis LOC100507709 nearGene-5 22952805 rs9461776 chr6 32575735 A G 1.21E-10 Sarcoidosis LOC100507709 nearGene-5 22952805 rs3021303 chr6 32575746 G T 7.39E-11 Sarcoidosis LOC100507709 nearGene-5 22952805 rs643889 chr6 32575918 A T 1.52E-09 Sarcoidosis LOC100507709 nearGene-5 22952805 rs482205 chr6 32576009 T G 1.76E-09 Sarcoidosis LOC100507709 nearGene-5 22952805 rs482162 chr6 32576019 T C 1.76E-09 Sarcoidosis LOC100507709 nearGene-5 22952805 rs482044 chr6 32576064 G C 9.80E-06 Parkinson's disease (motor and cognition) LOC100507709 nearGene-5 22658654 rs482044 chr6 32576064 G C 9.80E-06 Immune response to anthrax vaccine LOC100507709 nearGene-5 22658931 rs481245 chr6 32576114 A C 5.58E-11 Sarcoidosis LOC100507709 nearGene-5 22952805 rs481139 chr6 32576145 C A 1.69E-09 Sarcoidosis / / 22952805 rs646159 chr6 32576446 C T 7.01E-11 Sarcoidosis / / 22952805 rs9271100 chr6 32576478 T C 1.00E-12 Systemic lupus erythematosus / / 19838193 rs9271100 chr6 32576478 T C 1.31E-05 Parkinson's disease (motor and cognition) / / 22658654 rs9271100 chr6 32576478 T C 1.31E-05 Immune response to anthrax vaccine / / 22658931 rs9271100 chr6 32576478 T C 1.00E-22 Systemic lupus erythematosus / / 23273568 rs9271100 chr6 32576478 T C 4.92E-17 Leprosy / / pha002872 rs566861 chr6 32576538 T C 1.14E-10 Sarcoidosis / / 22952805 rs646984 chr6 32576592 A C 3.93E-06 Waist-hip ratio / / 20935629 rs646984 chr6 32576592 A C 6.19E-04 Self-reported allergy / / 23817569 rs647035 chr6 32576626 G A 1.08E-08 Sarcoidosis / / 22952805 rs647467 chr6 32576726 C T 1.45E-10 Sarcoidosis / / 22952805 rs9271117 chr6 32576795 C T 6.00E-14 Narcolepsy (onset before 2009 H1N1 influenza pandemic) / / 24204295 rs660895 chr6 32577380 A G 1.28E-43 Type 1 diabetes / / 17632545 rs660895 chr6 32577380 A G 1.00E-108 Rheumatoid arthritis / / 17804836 rs660895 chr6 32577380 A G 1.40E-108 Rheumatoid arthritis / / 21156761 rs660895 chr6 32577380 A G 2.13E-06 Parkinson's disease / / 21738487 rs660895 chr6 32577380 A G 1.79E-14 Hepatitis B vaccine response / / 21764829 rs660895 chr6 32577380 A G 3.46E-06 IgE levels / / 22075330 rs660895 chr6 32577380 A G 4.00E-20 IgA nephropathy / / 22197929 rs660895 chr6 32577380 A G 2.70E-19 Pemphigus vulgaris / / 22437316 rs660895 chr6 32577380 A G 1.00E-300 Rheumatoid arthritis (CCP positive) / / 23143596 rs660895 chr6 32577380 A G 1.00E-300 Rheumatoid arthritis / / 23143596 rs660895 chr6 32577380 A G 1.54E-08 Rheumatoid arthritis (CCP negative) / / 23143596 rs660895 chr6 32577380 A G 2.04E-10 Crohn's disease / / 23266558 rs660895 chr6 32577380 A G 1.30E-13 Systemic lupus erythematosus / / 23273568 rs660895 chr6 32577380 A G 0.00000021 Joint damage severity in rheumatoid arthritis / / 23696630 rs536810 chr6 32577497 C T 7.55E-09 Sarcoidosis / / 22952805 rs535852 chr6 32577604 C T 6.10E-09 Sarcoidosis / / 22952805 rs17840121 chr6 32577693 G C 0.0001619 Sarcoidosis / / 22952805 rs673002 chr6 32577814 G C,T 1.03E-10 Sarcoidosis / / 22952805 rs9271170 chr6 32577889 T C 4.92E-17 Leprosy / / pha002872 rs532098 chr6 32578052 G A 1.90E-10 Vitiligo / / 20410501 rs532098 chr6 32578052 G A 2.03E-06 Vitiligo / / 21326295 rs532098 chr6 32578052 G A 1.60E-52 Vitiligo / / 22561518 rs532098 chr6 32578052 G A 9.16E-07 Sarcoidosis / / 22952805 rs532098 chr6 32578052 G A 5.43E-08 Crohn's disease / / 23266558 rs674313 chr6 32578082 C T 7.00E-09 Chronic lymphocytic leukemia / / 21131588 rs674313 chr6 32578082 C T 0.000001246 Sarcoidosis / / 22952805 rs1281937 chr6 32578143 T C 1.05E-07 Sarcoidosis / / 22952805 rs2858864 chr6 32578229 C T 2.73E-10 Sarcoidosis / / 22952805 rs17211342 chr6 32578323 A G 8.99E-07 Sarcoidosis / / 22952805 rs17204995 chr6 32578328 G A 0.000000893 Sarcoidosis / / 22952805 rs9461778 chr6 32578352 A G 3.85E-10 Sarcoidosis / / 22952805 rs9271190 chr6 32578369 C A 8.52E-10 Sarcoidosis / / 22952805 rs5021726 chr6 32578481 T C 9.16E-07 Sarcoidosis / / 22952805 rs9271192 chr6 32578530 C A 3.00E-12 Alzheimer's disease (late onset) / / 24162737 rs5021727 chr6 32578633 A G 0.000001124 Sarcoidosis / / 22952805 rs77064057 chr6 32578653 A G 7.27E-10 Sarcoidosis / / 22952805 rs75639337 chr6 32578656 C T 7.27E-10 Sarcoidosis / / 22952805 rs112485576 chr6 32578772 C A 0.00008079 Sarcoidosis / / 22952805 rs76946723 chr6 32578917 A T 1.45E-09 Sarcoidosis / / 22952805 rs502803 chr6 32578958 G A 9.19E-07 Sarcoidosis / / 22952805 rs502771 chr6 32578970 T C 7.54E-10 Sarcoidosis / / 22952805 rs502771 chr6 32578970 T C 0.0000297 Schizophrenia / / 23637625 rs502055 chr6 32579003 T C 7.45E-50 Multiple complex diseases / / 17554300 rs502055 chr6 32579003 T C 4.00E-06 Personality dimensions / / 18957941 rs502055 chr6 32579003 T C 1.82E-09 Narcolepsy / / 19629137 rs502055 chr6 32579003 T C 6.26E-10 Sarcoidosis / / 22952805 rs9271209 chr6 32579035 G A 1.31E-05 Parkinson's disease (motor and cognition) / / 22658654 rs9271209 chr6 32579035 G A 1.31E-05 Immune response to anthrax vaccine / / 22658931 rs583177 chr6 32579567 C A 4.56E-10 Sarcoidosis / / 22952805 rs28752509 chr6 32579623 C T 6.91E-07 Sarcoidosis / / 22952805 rs28752510 chr6 32579626 G A 6.91E-07 Sarcoidosis / / 22952805 rs13191975 chr6 32579671 C T 5.66E-07 Sarcoidosis / / 22952805 rs9271238 chr6 32579702 C T 4.12E-10 Sarcoidosis / / 22952805 rs13207945 chr6 32579708 T C 6.84E-07 Sarcoidosis / / 22952805 rs13208027 chr6 32579743 T A 2.86E-07 Sarcoidosis / / 22952805 rs12523808 chr6 32579775 A T 6.92E-07 Sarcoidosis / / 22952805 rs150165719 chr6 32579868 G T 0.000004485 Sarcoidosis / / 22952805 rs3104421 chr6 32580007 G A 6.08E-10 Sarcoidosis / / 22952805 rs3104420 chr6 32580028 G A 6.27E-10 Sarcoidosis / / 22952805 rs3104419 chr6 32580136 C T 0.000000695 Sarcoidosis / / 22952805 rs2858862 chr6 32580321 C T 5.20E-10 Sarcoidosis / / 22952805 rs2647094 chr6 32580322 A G 4.33E-10 Sarcoidosis / / 22952805 rs2858861 chr6 32580331 C T 0.00000276 Sarcoidosis / / 22952805 rs9271255 chr6 32580357 C T 1.55E-05 Parkinson's disease (motor and cognition) / / 22658654 rs9271255 chr6 32580357 C T 1.55E-05 Immune response to anthrax vaccine / / 22658931 rs2858860 chr6 32580366 G T 6.64E-07 Sarcoidosis / / 22952805 rs80243928 chr6 32580571 C T 4.94E-10 Sarcoidosis / / 22952805 rs13212015 chr6 32580580 T C 0.0001414 Sarcoidosis / / 22952805 rs28383216 chr6 32580596 T C 0.0001456 Sarcoidosis / / 22952805 rs3997872 chr6 32580617 T A 0.00005392 Sarcoidosis / / 22952805 rs3997872 chr6 32580617 T A 2.00E-05 Hepatocellular carcinoma (hepatitis B virus related) / / 23242368 rs79838044 chr6 32580632 T C 5.68E-10 Sarcoidosis / / 22952805 rs3997873 chr6 32580723 G T 0.00008839 Sarcoidosis / / 22952805 rs77568742 chr6 32580790 T C 4.94E-10 Sarcoidosis / / 22952805 rs76662008 chr6 32580869 C G 4.94E-10 Sarcoidosis / / 22952805 rs9271280 chr6 32581047 T A 5.23E-10 Sarcoidosis / / 22952805 rs75765164 chr6 32581157 G A 2.40E-07 Sarcoidosis / / 22952805 rs12212951 chr6 32581233 T C 0.0001574 Sarcoidosis / / 22952805 rs9271301 chr6 32581614 C T 6.04E-10 Sarcoidosis / / 22952805 rs9271303 chr6 32581647 A G 1.26E-09 Chronic hepatitis B infection / / 23760081 rs1966002 chr6 32581684 T G 0.000007575 Sarcoidosis / / 22952805 rs201621006 chr6 32581684 T TG 0.000007575 Sarcoidosis / / 22952805 rs2395223 chr6 32581778 C T 1.26E-09 Chronic hepatitis B infection / / 23760081 rs4530903 chr6 32581889 C T 8.29E-09 Multiple complex diseases / / 17554300 rs4530903 chr6 32581889 C T 5.00E-06 Schizophrenia / / 23212062 rs4530903 chr6 32581889 C T 2.00E-08 Lymphoma / / 23349640 rs4530903 chr6 32581889 C T 3.00E-06 Lymphoma / / 23349640 rs4530903 chr6 32581889 C T 3.00E-12 Lymphoma / / 23349640 rs522308 chr6 32581922 C T 2.45E-08 Sarcoidosis / / 22952805 rs521539 chr6 32581973 G A 0.00000021 Joint damage severity in rheumatoid arthritis / / 23696630 rs642093 chr6 32582075 G A 2.75E-07 Red blood cell traits / / 23222517 rs642093 chr6 32582075 G A 1.10E-08 Leprosy / / pha002872 rs3129751 chr6 32582189 A C 0.00004966 Sarcoidosis / / 22952805 rs2858859 chr6 32582275 G A 1.41E-09 Chronic hepatitis B infection / / 23760081 rs5004276 chr6 32582332 G A 1.26E-09 Chronic hepatitis B infection / / 23760081 rs5004278 chr6 32582401 G C 0.00003442 Sarcoidosis / / 22952805 rs5004279 chr6 32582406 G C 0.00003442 Sarcoidosis / / 22952805 rs7451962 chr6 32582435 G A 8.33E-64 Rheumatoid arthritis / / 21156761 rs7451962 chr6 32582435 G A 2.49E-06 Parkinson's disease / / 21738487 rs7451962 chr6 32582435 G A 6.65E-05 IgE levels / / 22075330 rs9271325 chr6 32582513 C G 4.20E-08 Chronic hepatitis B infection / / 23760081 rs9271326 chr6 32582527 C T 1.35E-09 Sarcoidosis / / 22952805 rs9271328 chr6 32582548 A G 0.00007332 Sarcoidosis / / 22952805 rs3104415 chr6 32582577 A C 0.000000195 Sarcoidosis / / 22952805 rs3129752 chr6 32582627 G C 0.000003187 Sarcoidosis / / 22952805 rs9271330 chr6 32582640 G A 1.50E-09 Sarcoidosis / / 22952805 rs3104413 chr6 32582650 C G 0.00000005 Joint damage severity in rheumatoid arthritis / / 23696630 rs9271333 chr6 32582678 C T 1.40E-09 Sarcoidosis / / 22952805 rs9271334 chr6 32582711 A C 5.28E-10 Sarcoidosis / / 22952805 rs13204672 chr6 32582796 A G 5.89E-06 HIV-1 control / / 20041166 rs13204672 chr6 32582796 A G 2.18E-10 Vitiligo / / 20526339 rs13204672 chr6 32582796 A G 0.0001549 Sarcoidosis / / 22952805 rs13204672 chr6 32582796 A G 1.45E-13 Hepatitis B vaccine response / / 24282030 rs7756647 chr6 32582843 A G,T 3.79E-08 Sarcoidosis / / 22952805 rs9271340 chr6 32582932 T C 0.00003423 Sarcoidosis / / 22952805 rs13204933 chr6 32583026 A G 0.0001549 Sarcoidosis / / 22952805 rs3129753 chr6 32583027 G C 0.00005699 Sarcoidosis / / 22952805 rs3129755 chr6 32583057 A G 3.13E-07 Sarcoidosis / / 22952805 rs6605556 chr6 32583099 A G 0.00005699 Sarcoidosis / / 22952805 rs4959106 chr6 32583159 T C 8.26E-07 Sarcoidosis / / 22952805 rs28383221 chr6 32583212 A G 3.54E-13 Sarcoidosis / / 22952805 rs34850435 chr6 32583299 C T 8.18E-07 Sarcoidosis / / 22952805 rs6931277 chr6 32583357 A T 0.00007433 Sarcoidosis / / 22952805 rs6931277 chr6 32583357 A T 0.00000003 Joint damage severity in rheumatoid arthritis / / 23696630 rs28383222 chr6 32583405 G A 0.0001549 Sarcoidosis / / 22952805 rs35029150 chr6 32583426 T G 7.13E-07 Sarcoidosis / / 22952805 rs9271346 chr6 32583468 C T 5.28E-07 Sarcoidosis / / 22952805 rs9271347 chr6 32583543 A G 0.00008656 Sarcoidosis / / 22952805 rs34599306 chr6 32583557 C G 7.13E-07 Sarcoidosis / / 22952805 rs28752514 chr6 32583576 T C 3.07E-13 Sarcoidosis / / 22952805 rs28383224 chr6 32583653 A G 3.09E-13 Sarcoidosis / / 22952805 rs36124427 chr6 32583677 T C 7.57E-07 Sarcoidosis / / 22952805 rs34136174 chr6 32583682 A C 7.57E-07 Sarcoidosis / / 22952805 rs9271348 chr6 32583742 G A 1.71E-15 Leprosy / / 20018961 rs9271348 chr6 32583742 G A 5.00E-07 Rheumatoid arthritis (ACPA-negative) / / 24532677 rs9271348 chr6 32583742 G A 1.71E-15 Leprosy / / pha002872 rs28383225 chr6 32583824 T C 0.0001549 Sarcoidosis / / 22952805 rs9271351 chr6 32583860 C G 0.00009701 Sarcoidosis / / 22952805 rs28383227 chr6 32583982 G A 0.0001549 Sarcoidosis / / 22952805 rs28383228 chr6 32583993 T A 0.0001549 Sarcoidosis / / 22952805 rs9271353 chr6 32584014 T C 0.00009701 Sarcoidosis / / 22952805 rs9271354 chr6 32584066 C T 0.00008781 Sarcoidosis / / 22952805 rs28383230 chr6 32584088 T C 7.86E-12 Sarcoidosis / / 22952805 rs28383231 chr6 32584099 C T 7.86E-12 Sarcoidosis / / 22952805 rs28383233 chr6 32584153 G A 7.86E-12 Sarcoidosis / / 22952805 rs6930731 chr6 32584237 C T 0.000000255 Sarcoidosis / / 22952805 rs28383243 chr6 32584410 T G 0.0001417 Sarcoidosis / / 22952805 rs28752518 chr6 32584588 A G 0.0001726 Sarcoidosis / / 22952805 rs3129757 chr6 32584609 A C 0.00008781 Sarcoidosis / / 22952805 rs28752519 chr6 32584705 T C 0.0001417 Sarcoidosis / / 22952805 rs28752524 chr6 32584862 G A 0.0001834 Sarcoidosis / / 22952805 rs28752525 chr6 32584868 G C 0.0001834 Sarcoidosis / / 22952805 rs28752534 chr6 32585068 T C 0.000005002 Sarcoidosis / / 22952805 rs146146117 chr6 32585288 C T 2.37E-11 Sarcoidosis / / 22952805 rs28383251 chr6 32585567 C T 0.0001998 Sarcoidosis / / 22952805 rs28383254 chr6 32585638 A C 0.0001117 Sarcoidosis / / 22952805 rs28383255 chr6 32585641 G A 0.0001117 Sarcoidosis / / 22952805 rs28383256 chr6 32585675 G C 0.0000998 Sarcoidosis / / 22952805 rs28383257 chr6 32585680 C T 0.0000998 Sarcoidosis / / 22952805 rs13217507 chr6 32585681 A T 0.000000255 Sarcoidosis / / 22952805 rs13217512 chr6 32585696 A C 0.000000255 Sarcoidosis / / 22952805 rs3129762 chr6 32585755 T A 0.00008781 Sarcoidosis / / 22952805 rs28383262 chr6 32585773 A T 0.0001589 Sarcoidosis / / 22952805 rs28383263 chr6 32585843 C G,T 0.0001589 Sarcoidosis / / 22952805 rs3135005 chr6 32586019 A G 3.89E-05 Type 2 diabetes / / 17463246 rs3135005 chr6 32586019 A G 0.00008781 Sarcoidosis / / 22952805 rs28383271 chr6 32586134 C T 0.0001589 Sarcoidosis / / 22952805 rs28383272 chr6 32586207 T A 0.0001098 Sarcoidosis / / 22952805 rs28383273 chr6 32586221 C T 0.0001839 Sarcoidosis / / 22952805 rs28383274 chr6 32586246 A G 0.0001098 Sarcoidosis / / 22952805 rs13191494 chr6 32586432 G C 0.000000255 Sarcoidosis / / 22952805 rs34598287 chr6 32586465 A T 0.000000255 Sarcoidosis / / 22952805 rs28383308 chr6 32586782 C T 0.0001054 Sarcoidosis / / 22952805 rs28383309 chr6 32586783 G T 0.0001054 Sarcoidosis / / 22952805 rs9271364 chr6 32586787 A G 0.00009606 Sarcoidosis / / 22952805 rs13191810 chr6 32586831 C T 0.00001074 Sarcoidosis / / 22952805 rs9271366 chr6 32586854 G A 1.92E-05 Type 2 diabetes / / 17463246 rs9271366 chr6 32586854 G A 5.57E-19 Rheumatoid arthritis / / 17804836 rs9271366 chr6 32586854 G A 6.64E-23 Rheumatoid arthritis / / 19503088 rs9271366 chr6 32586854 G A 7.00E-184 Multiple sclerosis / / 19525955 rs9271366 chr6 32586854 G A 1.46E-17 Leprosy / / 20018961 rs9271366 chr6 32586854 G A 4.00E-17 Multiple sclerosis / / 20598377 rs9271366 chr6 32586854 G A 3.00E-33 Immunoglobulin A / / 20694011 rs9271366 chr6 32586854 G A 2.00E-70 Inflammatory bowel disease / / 21699788 rs9271366 chr6 32586854 G A 3.00E-31 Inflammatory bowel disease / / 21699788 rs9271366 chr6 32586854 G A 8.00E-11 Inflammatory bowel disease / / 21699788 rs9271366 chr6 32586854 G A 0.00009701 Sarcoidosis / / 22952805 rs9271366 chr6 32586854 G A 2.80E-09 Crohn's disease / / 23266558 rs9271366 chr6 32586854 G A 2.40E-18 Systemic lupus erythematosus / / 23273568 rs9271366 chr6 32586854 G A 1.00E-18 Ulcerative colitis / / 23511034 rs9271366 chr6 32586854 G A 6.72E-06 Interstitial lung disease / / 23583980 rs9271366 chr6 32586854 G A 5.00E-12 Crohn's disease / / 23850713 rs9271366 chr6 32586854 G A 1.46E-17 Leprosy / / pha002872 rs114812135 chr6 32586961 A T 4.31E-08 Sarcoidosis / / 22952805 rs28383311 chr6 32587011 A T 1.80E-07 Sarcoidosis / / 22952805 rs28383312 chr6 32587090 C T 5.94E-10 Sarcoidosis / / 22952805 rs28383313 chr6 32587117 C G 1.27E-09 Sarcoidosis / / 22952805 rs28383314 chr6 32587213 T C 4.64E-07 Sarcoidosis / / 22952805 rs28411161 chr6 32587384 C G 0.0004332 Sarcoidosis / / 22952805 rs28391139 chr6 32587390 T C 0.0004332 Sarcoidosis / / 22952805 rs9271401 chr6 32587525 A G 0.00008816 Sarcoidosis / / 22952805 rs9271405 chr6 32587584 T C 0.00003267 Sarcoidosis / / 22952805 rs9271406 chr6 32587588 A G 1.64E-13 Sarcoidosis / / 22952805 rs9271407 chr6 32587605 C T 0.00003267 Sarcoidosis / / 22952805 rs9271408 chr6 32587613 C T 5.62E-09 Sarcoidosis / / 22952805 rs9271409 chr6 32587628 G C 1.06E-08 Sarcoidosis / / 22952805 rs9271410 chr6 32587645 A G 0.00003199 Sarcoidosis / / 22952805 rs9271411 chr6 32587661 G A 1.06E-08 Sarcoidosis / / 22952805 rs9271412 chr6 32587685 C T 0.00003199 Sarcoidosis / / 22952805 rs28718904 chr6 32587687 A G 0.00007 Sarcoidosis / / 22952805 rs28589559 chr6 32587716 G T 0.00009149 Sarcoidosis / / 22952805 rs9271413 chr6 32587768 G A 0.00009701 Sarcoidosis / / 22952805 rs9271416 chr6 32587812 G A 1.06E-08 Sarcoidosis / / 22952805 rs9271417 chr6 32587818 T C 0.00003199 Sarcoidosis / / 22952805 rs71542418 chr6 32587820 G A,C 0.00002583 Sarcoidosis / / 22952805 rs9271423 chr6 32587897 G T 0.00009701 Sarcoidosis / / 22952805 rs9271426 chr6 32587973 G A 1.06E-08 Sarcoidosis / / 22952805 rs9271430 chr6 32588002 T C 1.06E-08 Sarcoidosis / / 22952805 rs35372933 chr6 32588080 T C 0.000000248 Sarcoidosis / / 22952805 rs9271437 chr6 32588166 G A 0.00005019 Sarcoidosis / / 22952805 rs9271438 chr6 32588193 A G 8.23E-09 Sarcoidosis / / 22952805 rs35945734 chr6 32588201 A G 0.00002583 Sarcoidosis / / 22952805 rs71542420 chr6 32588216 A G 0.000000248 Sarcoidosis / / 22952805 rs9271439 chr6 32588234 A G 0.00005019 Sarcoidosis / / 22952805 rs9271442 chr6 32588260 T A 3.46E-09 Sarcoidosis / / 22952805 rs28644259 chr6 32588272 C G 0.000000248 Sarcoidosis / / 22952805 rs34697429 chr6 32588432 A T 0.00002583 Sarcoidosis / / 22952805 rs28456694 chr6 32588449 G T 0.00002583 Sarcoidosis / / 22952805 rs9271459 chr6 32588457 T C 0.00004232 Sarcoidosis / / 22952805 rs28592295 chr6 32588460 G A 0.00002583 Sarcoidosis / / 22952805 rs9271461 chr6 32588500 G A 1.76E-08 Sarcoidosis / / 22952805 rs9271464 chr6 32588544 A T 0.000000011 Sarcoidosis / / 22952805 rs9271465 chr6 32588554 C T 8.64E-09 Sarcoidosis / / 22952805 rs9271469 chr6 32588630 T C 9.97E-09 Sarcoidosis / / 22952805 rs9271470 chr6 32588662 C T 9.76E-09 Sarcoidosis / / 22952805 rs9271472 chr6 32588700 C T 9.76E-09 Sarcoidosis / / 22952805 rs9271474 chr6 32588707 G A 9.76E-09 Sarcoidosis / / 22952805 rs9271481 chr6 32588877 A G 0.00009701 Sarcoidosis / / 22952805 rs9271484 chr6 32588905 G T 0.0000569 Sarcoidosis / / 22952805 rs28699237 chr6 32588939 A T 2.87E-07 Sarcoidosis / / 22952805 rs9271485 chr6 32588953 A G 9.97E-09 Sarcoidosis / / 22952805 rs200688486 chr6 32589000 G GT 7.54E-14 Epstein-Barr virus immune response (EBNA-1) / / 23326239 rs200688486 chr6 32589000 G GT 0.00000002 Joint damage severity in rheumatoid arthritis / / 23696630 rs9271488 chr6 32589000 G T 7.54E-14 Epstein-Barr virus immune response (EBNA-1) / / 23326239 rs9271488 chr6 32589000 G T 0.00000002 Joint damage severity in rheumatoid arthritis / / 23696630 rs28669773 chr6 32589095 A G 0.00002937 Sarcoidosis / / 22952805 rs34846487 chr6 32589101 T G 3.28E-07 Sarcoidosis / / 22952805 rs9271492 chr6 32589122 A C 2.06E-10 Sarcoidosis / / 22952805 rs34104805 chr6 32589217 A T 0.000003586 Sarcoidosis / / 22952805 rs35597309 chr6 32589266 G A 3.28E-07 Sarcoidosis / / 22952805 rs9271498 chr6 32589282 G A 1.06E-08 Sarcoidosis / / 22952805 rs9271503 chr6 32589326 C A 1.08E-08 Sarcoidosis / / 22952805 rs28664035 chr6 32589372 T A 0.00004619 Sarcoidosis / / 22952805 rs9271509 chr6 32589415 G A 0.00005059 Sarcoidosis / / 22952805 rs9271511 chr6 32589483 G A 9.58E-09 Sarcoidosis / / 22952805 rs35990832 chr6 32589495 G A 0.000000328 Sarcoidosis / / 22952805 rs9271516 chr6 32589668 C A 9.58E-09 Sarcoidosis / / 22952805 rs77875016 chr6 32589700 C T 3.28E-07 Sarcoidosis / / 22952805 rs9271520 chr6 32589771 A G 1.08E-08 Sarcoidosis / / 22952805 rs9271523 chr6 32589806 A G 1.08E-08 Sarcoidosis / / 22952805 rs9271524 chr6 32589820 A C 0.00008551 Sarcoidosis / / 22952805 rs9271526 chr6 32589862 G A 0.00002095 Sarcoidosis / / 22952805 rs9271537 chr6 32589982 C T 0.0000494 Sarcoidosis / / 22952805 rs9271544 chr6 32590120 C A 1.08E-08 Sarcoidosis / / 22952805 rs9271545 chr6 32590153 C T 0.00008551 Sarcoidosis / / 22952805 rs9271549 chr6 32590248 T C 1.08E-08 Sarcoidosis / / 22952805 rs9271550 chr6 32590274 T A 0.00004493 Sarcoidosis / / 22952805 rs71542421 chr6 32590315 C T 3.28E-07 Sarcoidosis / / 22952805 rs9271560 chr6 32590381 A T 1.08E-08 Sarcoidosis / / 22952805 rs9271561 chr6 32590393 T G 1.08E-08 Sarcoidosis / / 22952805 rs9271562 chr6 32590411 G A 0.00005722 Sarcoidosis / / 22952805 rs9271568 chr6 32590463 G A 1.00E-16 Type 1 diabetes / / 17632545 rs9271568 chr6 32590463 G A 2.95E-08 Hepatocellular carcinoma (hepatitis B virus related) / / 23242368 rs9271573 chr6 32590501 A C 0.0000129 Sarcoidosis / / 22952805 rs35407883 chr6 32590529 A G 3.28E-07 Sarcoidosis / / 22952805 rs9271574 chr6 32590590 T G 0.000000011 Sarcoidosis / / 22952805 rs9271576 chr6 32590612 T C 1.27E-08 Sarcoidosis / / 22952805 rs2395225 chr6 32590624 T C 6.10E-37 Rheumatoid arthritis / / 21156761 rs373094430 chr6 32590624 T TC 6.10E-37 Rheumatoid arthritis / / 21156761 rs17533090 chr6 32590722 G T 6.78E-08 Type 1 diabetes / / 17632545 rs17533090 chr6 32590722 G T 2.00E-04 Parkinson's disease / / 21248740 rs17533090 chr6 32590722 G T 2.17E-13 Self-reported allergy / / 23817569 rs2097432 chr6 32590771 T C 7.93E-08 Red blood cell traits / / 23222517 rs17533167 chr6 32590844 G C 7.95E-11 Self-reported allergy / / 23817569 rs9271584 chr6 32590870 T C 0.000000011 Sarcoidosis / / 22952805 rs9271585 chr6 32590879 C A 1.08E-08 Sarcoidosis / / 22952805 rs9271586 chr6 32590899 G T 0.000001874 Sarcoidosis / / 22952805 rs9271587 chr6 32590916 A G 0.000001884 Sarcoidosis / / 22952805 rs3129763 chr6 32590925 G A 3.41E-12 Type 1 diabetes / / 17632545 rs3129763 chr6 32590925 G A 2.72E-27 Rheumatoid arthritis / / 17804836 rs3129763 chr6 32590925 G A 1.85E-04 Schizophrenia / / 19197363 rs3129763 chr6 32590925 G A 3.64E-07 Lung adenocarcinoma / / 19836008 rs3129763 chr6 32590925 G A 1.17E-30 Rheumatoid arthritis / / 21156761 rs3129763 chr6 32590925 G A 1.00E-11 Systemic sclerosis / / 21779181 rs3129763 chr6 32590925 G A 1.50E-08 Lung cancer / / 22899653 rs3129763 chr6 32590925 G A 9.12E-08 Red blood cell traits / / 23222517 rs3129763 chr6 32590925 G A 1.92E-05 Self-reported allergy / / 23817569 rs9271588 chr6 32590953 T C 0.000001874 Sarcoidosis / / 22952805 rs9271588 chr6 32590953 T C 9.90E-11 Joint damage severity in rheumatoid arthritis / / 23696630 rs9271588 chr6 32590953 T C 9.00E-37 Sjogren's syndrome / / 24097066 rs35399661 chr6 32590990 T C 0.0000235 Follicular lymphoma / / 23025665 rs17599077 chr6 32591058 A C 1.66E-10 Self-reported allergy / / 23817569 rs9271589 chr6 32591128 G A 5.10E-09 Sarcoidosis / / 22952805 rs9271591 chr6 32591141 G A 0.000001925 Sarcoidosis / / 22952805 rs35765065 chr6 32591151 C T 1.84E-07 Sarcoidosis / / 22952805 rs9271592 chr6 32591173 C T 1.08E-08 Sarcoidosis / / 22952805 rs9271593 chr6 32591198 C T 0.00001275 Sarcoidosis / / 22952805 rs9271594 chr6 32591213 A G 0.0000564 Sarcoidosis / / 22952805 rs9271595 chr6 32591235 A G 1.21E-08 Sarcoidosis / / 22952805 rs9271596 chr6 32591237 A G 1.21E-08 Sarcoidosis / / 22952805 rs9271597 chr6 32591291 T A 9.67E-07 Sarcoidosis / / 22952805 rs9271600 chr6 32591332 T G 0.000001014 Sarcoidosis / / 22952805 rs9271601 chr6 32591337 A T 0.000001309 Sarcoidosis / / 22952805 rs114480004 chr6 32591360 G C 4.59E-07 Sarcoidosis / / 22952805 rs9271602 chr6 32591383 T G 0.00001725 Sarcoidosis / / 22952805 rs9271605 chr6 32591448 G A 1.16E-08 Sarcoidosis / / 22952805 rs9271607 chr6 32591566 A G 1.16E-08 Sarcoidosis / / 22952805 rs9271608 chr6 32591588 A G 0.00006041 Sarcoidosis / / 22952805 rs9271609 chr6 32591597 T C 1.16E-08 Sarcoidosis / / 22952805 rs9271612 chr6 32591654 A G 4.14E-29 Rheumatoid arthritis / / 21156761 rs9271612 chr6 32591654 A G 7.64E-07 Red blood cell traits / / 23222517 rs9271612 chr6 32591654 A G 3.59E-05 Self-reported allergy / / 23817569 rs9271613 chr6 32591666 C T 4.14E-29 Rheumatoid arthritis / / 21156761 rs9271613 chr6 32591666 C T 1.36E-07 Red blood cell traits / / 23222517 rs9271613 chr6 32591666 C T 3.02E-05 Self-reported allergy / / 23817569 rs4959030 chr6 32591751 A G 3.63E-07 Sarcoidosis / / 22952805 rs9271620 chr6 32591777 G T 0.000001895 Sarcoidosis / / 22952805 rs9271624 chr6 32591921 G T 1.22E-08 Sarcoidosis / / 22952805 rs4959108 chr6 32591922 G A 2.68E-07 Sarcoidosis / / 22952805 rs9271628 chr6 32591971 T G 9.62E-09 Sarcoidosis / / 22952805 rs9271637 chr6 32592124 A G 1.05E-08 Sarcoidosis / / 22952805 rs9271640 chr6 32592200 T C 5.82E-08 Sarcoidosis / / 22952805 rs9271640 chr6 32592200 T C 2.00E-20 Multiple sclerosis (OCB status) / / 23472185 rs9271641 chr6 32592209 A G 3.75E-08 Sarcoidosis / / 22952805 rs9271642 chr6 32592219 A G 0.00001358 Sarcoidosis / / 22952805 rs9271643 chr6 32592229 G A 9.16E-09 Sarcoidosis / / 22952805 rs9271644 chr6 32592337 G A 9.16E-09 Sarcoidosis / / 22952805 rs4246055 chr6 32592360 C T 7.06E-09 Sarcoidosis / / 22952805 rs9271650 chr6 32592383 T C 1.72E-07 Sarcoidosis / / 22952805 rs9271655 chr6 32592567 G A 3.13E-07 Sarcoidosis / / 22952805 rs9271660 chr6 32592602 T G 1.57E-08 Sarcoidosis / / 22952805 rs9271661 chr6 32592605 T A 1.57E-08 Sarcoidosis / / 22952805 rs9271664 chr6 32592656 T C 6.85E-07 Sarcoidosis / / 22952805 rs28421666 chr6 32592737 A G 2.00E-18 Nasopharyngeal carcinoma / / 20512145 rs9271674 chr6 32592845 T C 1.22E-08 Sarcoidosis / / 22952805 rs9271675 chr6 32592862 T C 2.03E-08 Sarcoidosis / / 22952805 rs9271676 chr6 32592868 T C 1.98E-08 Sarcoidosis / / 22952805 rs9271685 chr6 32592970 T C 1.22E-08 Sarcoidosis / / 22952805 rs9271687 chr6 32592985 A G 4.11E-07 Sarcoidosis / / 22952805 rs9271693 chr6 32593033 C T 1.22E-08 Sarcoidosis / / 22952805 rs4587163 chr6 32593167 C T 0.000007481 Sarcoidosis / / 22952805 rs9271718 chr6 32593465 A T 1.37E-08 Sarcoidosis / / 22952805 rs9271722 chr6 32593522 C G 8.01E-09 Sarcoidosis / / 22952805 rs9271726 chr6 32593566 T G 0.0000467 Sarcoidosis / / 22952805 rs9271734 chr6 32593639 C A,T 5.29E-08 Sarcoidosis / / 22952805 rs9271735 chr6 32593649 G A 2.35E-08 Sarcoidosis / / 22952805 rs9271736 chr6 32593688 T A 6.34E-08 Sarcoidosis / / 22952805 rs9271737 chr6 32593690 T C 7.21E-12 Sarcoidosis / / 22952805 rs9271761 chr6 32594022 C A,T 1.99E-07 Sarcoidosis / / 22952805 rs9271762 chr6 32594028 T G 1.71E-08 Sarcoidosis / / 22952805 rs9271763 chr6 32594061 A G 0.000001293 Sarcoidosis / / 22952805 rs9271767 chr6 32594176 G T 2.85E-08 Sarcoidosis / / 22952805 rs9271769 chr6 32594217 G T 3.57E-08 Sarcoidosis / / 22952805 rs9271770 chr6 32594248 G A 6.36E-08 Sarcoidosis / / 22952805 rs9271775 chr6 32594328 C T 2.13E-20 Rheumatoid arthritis / / 21156761 rs9271775 chr6 32594328 C T 0.000000031 Sarcoidosis / / 22952805 rs9271776 chr6 32594341 T C 1.06E-08 Sarcoidosis / / 22952805 rs3104393 chr6 32594403 C T 2.37E-08 Sarcoidosis / / 22952805 rs3104392 chr6 32594425 C T 2.45E-07 Sarcoidosis / / 22952805 rs3129766 chr6 32594441 A G 1.58E-08 Sarcoidosis / / 22952805 rs3104391 chr6 32594901 T A,C,G 4.40E-06 Phospholipid levels (plasma) / / 21829377 rs3104391 chr6 32594901 T A,C,G 2.52E-07 Sarcoidosis / / 22952805 rs3104390 chr6 32595031 A T 6.22E-08 Sarcoidosis / / 22952805 rs34217071 chr6 32595042 G A,C,T 0.0000284 Sarcoidosis / / 22952805 rs9271850 chr6 32595060 A G 7.53E-51 Multiple complex diseases / / 17554300 rs9271850 chr6 32595060 A G 8.34E-06 Schizophrenia / / 19571811 rs9271850 chr6 32595060 A G 1.90E-44 Rheumatoid arthritis / / 21156761 rs3129768 chr6 32595083 G T 1.62E-04 Type 2 diabetes / / 17463246 rs3129768 chr6 32595083 G T 1.36E-79 Multiple complex diseases / / 17554300 rs3129768 chr6 32595083 G T 3.37E-35 Multiple sclerosis / / 17660530 rs3129768 chr6 32595083 G T 7.05E-36 Narcolepsy / / 19629137 rs3129768 chr6 32595083 G T 2.50E-21 Rheumatoid arthritis / / 21156761 rs3129768 chr6 32595083 G T 6.35E-08 Sarcoidosis / / 22952805 rs9271858 chr6 32595223 A G 3.00E-17 Leishmaniasis (visceral) / / 23291585 rs13207922 chr6 32596247 G T 0.000000974 Sarcoidosis / / 22952805 rs2036202 chr6 32596309 C T 1.33E-07 Sarcoidosis / / 22952805 rs2133035 chr6 32596475 C A 3.76E-08 Sarcoidosis / / 22952805 rs114420104 chr6 32596533 G T 0.00009741 Sarcoidosis / / 22952805 rs3104386 chr6 32596937 G T 0.000001696 Sarcoidosis / / 22952805 rs3129769 chr6 32597022 G A 0.00000004 Joint damage severity in rheumatoid arthritis / / 23696630 rs74927567 chr6 32597064 G A 0.00001515 Sarcoidosis / / 22952805 rs9271956 chr6 32597313 T C 0.000001388 Sarcoidosis / / 22952805 rs114798579 chr6 32597341 G A 2.15E-07 Sarcoidosis / / 22952805 rs9272025 chr6 32598581 C A 2.75E-08 Sarcoidosis / / 22952805 rs3104380 chr6 32599042 G T 0.000001815 Sarcoidosis / / 22952805 rs3104379 chr6 32599114 G T 0.00000173 Sarcoidosis / / 22952805 rs34680078 chr6 32599904 G A 0.00000032 Sarcoidosis / / 22952805 rs9272105 chr6 32599999 G A 9.30E-05 Major depressive disorder / / 21042317 rs9272105 chr6 32599999 G A 4.00E-10 Response to interferon beta therapy / / 21502966 rs9272105 chr6 32599999 G A 1.27E-08 Schizophrenia / / 21926974 rs9272105 chr6 32599999 G A 5.00E-22 Hepatocellular carcinoma / / 22807686 rs3104376 chr6 32600003 T C 0.00005997 Sarcoidosis / / 22952805 rs3104373 chr6 32600375 T C 5.77E-07 Sarcoidosis / / 22952805 rs13211715 chr6 32600468 G A 2.87E-08 Sarcoidosis / / 22952805 rs9272143 chr6 32600803 T C 3.00E-22 Cervical cancer / / 23482656 rs13215343 chr6 32601054 C A 6.17E-08 Sarcoidosis / / 22952805 rs9272159 chr6 32601129 A T 0.000003595 Sarcoidosis / / 22952805 rs114549185 chr6 32601204 C G 3.50E-07 Sarcoidosis / / 22952805 rs2002779 chr6 32601684 T G 0.00000449 Sarcoidosis / / 22952805 rs9272219 chr6 32602269 G T 3.40E-70 Multiple complex diseases / / 17554300 rs9272219 chr6 32602269 G T 2.96E-05 Personality dimensions / / 18957941 rs9272219 chr6 32602269 G T 7.00E-08 Schizophrenia / / 19571809 rs9272219 chr6 32602269 G T 8.80E-05 Major depressive disorder / / 21042317 rs9272219 chr6 32602269 G T 5.37E-36 Rheumatoid arthritis / / 21156761 rs9272219 chr6 32602269 G T 1.00E-45 Rheumatoid arthritis / / 21653640 rs9272219 chr6 32602269 G T 2.10E-17 Lymphocyte counts / / 22286170 rs9272219 chr6 32602269 G T 6.90E-08 Schizophrenia (treatment refractory) / / 22479419 rs9272219 chr6 32602269 G T 1.66E-05 Hepatocellular carcinoma / / 22807686 rs9272219 chr6 32602269 G T 4.06E-08 Red blood cell traits / / 23222517 rs9272219 chr6 32602269 G T 1.52E-05 Self-reported allergy / / 23817569 rs3104370 chr6 32602341 G A 0.00000205 Sarcoidosis / / 22952805 rs17211510 chr6 32602430 C A 2.00E-15 Type 1 diabetes / / 17632545 rs17211510 chr6 32602430 C A 6.69E-04 Taste perception / / 22132133 rs17211510 chr6 32602430 C A 3.77E-06 Podoconiosis / / 22455414 rs17211510 chr6 32602430 C A 0.00000216 Triglycerides / / 23063622 rs17211510 chr6 32602430 C A 0.0000175 LDL cholesterol / / 23063622 rs17211510 chr6 32602430 C A 1.55E-08 Cholesterol,total / / 23063622 rs3104369 chr6 32602482 T C 0.000003676 Sarcoidosis / / 22952805 rs3104369 chr6 32602482 T C 7.03E-09 Epstein-Barr virus immune response (EBNA-1) / / 23326239 rs3104369 chr6 32602482 T C 9.94E-09 Leprosy / / pha002872 rs2040406 chr6 32603007 A G 1.00E-20 Multiple sclerosis / / 20453840 rs2040406 chr6 32603007 A G 2.10E-15 Rheumatoid arthritis / / 21156761 rs2040406 chr6 32603007 A G 1.45E-20 Hepatocellular carcinoma (hepatitis B virus related) / / 23242368 rs3104367 chr6 32603487 T C 0.00001281 Sarcoidosis HLA-DQA1 nearGene-5 22952805 rs1391373 chr6 32603660 T C 0.00001974 Sarcoidosis HLA-DQA1 nearGene-5 22952805 rs3104364 chr6 32603968 A G 0.000009244 Sarcoidosis HLA-DQA1 nearGene-5 22952805 rs9272319 chr6 32604108 T C 1.93E-07 Sarcoidosis HLA-DQA1 nearGene-5 22952805 rs9272320 chr6 32604124 G A 1.01E-10 Sarcoidosis HLA-DQA1 nearGene-5 22952805 rs9272323 chr6 32604151 C T 0.000000146 Sarcoidosis HLA-DQA1 nearGene-5 22952805 rs9272335 chr6 32604259 C T 2.31E-07 Sarcoidosis HLA-DQA1 nearGene-5 22952805 rs9272346 chr6 32604372 G A 5.00E-134 Type 1 diabetes HLA-DQA1 nearGene-5 17554300 rs9272346 chr6 32604372 G A 4.43E-13 Multiple sclerosis HLA-DQA1 nearGene-5 17660530 rs9272346 chr6 32604372 G A 6.00E-129 Type 1 diabetes HLA-DQA1 nearGene-5 18978792 rs9272346 chr6 32604372 G A 1.71E-19 Narcolepsy HLA-DQA1 nearGene-5 19629137 rs9272346 chr6 32604372 G A 1.19E-14 Rheumatoid arthritis HLA-DQA1 nearGene-5 21156761 rs9272346 chr6 32604372 G A 8.14E-26 Lymphocyte counts HLA-DQA1 nearGene-5 22286170 rs9272346 chr6 32604372 G A 2.00E-06 Hypothyroidism HLA-DQA1 nearGene-5 22493691 rs9272346 chr6 32604372 G A 2.00E-08 Asthma HLA-DQA1 nearGene-5 23181788 rs9272349 chr6 32604402 G A 0.000006735 Sarcoidosis HLA-DQA1 nearGene-5 22952805 rs28619112 chr6 32604588 C G 6.03E-07 Sarcoidosis HLA-DQA1 nearGene-5 22952805 rs9272364 chr6 32604599 G A 0.00000116 Sarcoidosis HLA-DQA1 nearGene-5 22952805 rs9272367 chr6 32604625 T C 0.000004053 Sarcoidosis HLA-DQA1 nearGene-5 22952805 rs9272410 chr6 32604969 A G 0.000009613 Sarcoidosis HLA-DQA1 nearGene-5 22952805 rs28383344 chr6 32605067 C G 8.63E-06 HIV-1 control HLA-DQA1 nearGene-5 20041166 rs28383344 chr6 32605067 C G 1.28E-10 Vitiligo HLA-DQA1 nearGene-5 20526339 rs9272420 chr6 32605101 A G 1.74E-07 Sarcoidosis HLA-DQA1 nearGene-5 22952805 rs9272435 chr6 32605336 G A 1.35E-07 Sarcoidosis HLA-DQA1 intron 22952805 rs9272443 chr6 32605418 G A 0.000000182 Sarcoidosis HLA-DQA1 intron 22952805 rs199889539 chr6 32605419 G GT 2.25E-07 Sarcoidosis HLA-DQA1 intron 22952805 rs9272444 chr6 32605419 G C 2.25E-07 Sarcoidosis HLA-DQA1 intron 22952805 rs9272460 chr6 32605583 A G 0.000008239 Sarcoidosis HLA-DQA1 intron 22952805 rs9272463 chr6 32605646 T G 1.81E-07 Sarcoidosis HLA-DQA1 intron 22952805 rs2187668 chr6 32605884 C T 1.00E-19 Celiac disease HLA-DQA1 intron 17558408 rs2187668 chr6 32605884 C T 2.39E-55 Type 1 diabetes HLA-DQA1 intron 17632545 rs2187668 chr6 32605884 C T 7.68E-16 Rheumatoid arthritis HLA-DQA1 intron 17804836 rs2187668 chr6 32605884 C T 3.00E-21 Systemic lupus erythematosus HLA-DQA1 intron 18204098 rs2187668 chr6 32605884 C T 2.32E-06 Lung cancer HLA-DQA1 intron 18978787 rs2187668 chr6 32605884 C T 1.56E-04 Schizophrenia HLA-DQA1 intron 19197363 rs2187668 chr6 32605884 C T 6.79E-23 Rheumatoid arthritis HLA-DQA1 intron 19503088 rs2187668 chr6 32605884 C T 1.92E-07 Lung cancer HLA-DQA1 intron 19654303 rs2187668 chr6 32605884 C T 6.91E-10 Lung adenocarcinoma HLA-DQA1 intron 19836008 rs2187668 chr6 32605884 C T 1.00E-50 Celiac disease HLA-DQA1 intron 20190752 rs2187668 chr6 32605884 C T 2.00E-33 Immunoglobulin A HLA-DQA1 intron 20694011 rs2187668 chr6 32605884 C T 1.00E-50 Asthma HLA-DQA1 intron 21150878 rs2187668 chr6 32605884 C T 1.68E-13 Rheumatoid arthritis HLA-DQA1 intron 21156761 rs2187668 chr6 32605884 C T 8.00E-93 Nephropathy (idiopathic membranous) HLA-DQA1 intron 21323541 rs2187668 chr6 32605884 C T 6.00E-28 Systemic lupus erythematosus HLA-DQA1 intron 21408207 rs2187668 chr6 32605884 C T 2.70E-13 Lung cancer HLA-DQA1 intron 22899653 rs2187668 chr6 32605884 C T 1.30E-67 Myasthenia gravis HLA-DQA1 intron 23055271 rs2187668 chr6 32605884 C T 2.00E-78 Autoimmune hepatitis type-1 HLA-DQA1 intron 24768677 rs2187668 chr6 32605884 C T 7.70E-17 Systemic lupus erythematosus HLA-DQA1 intron 24871463 rs2187668 chr6 32605884 C T 7.27E-07 Systemic lupus erythematosus HLA-DQA1 intron pha002867 rs9272482 chr6 32605920 G A 0.00001122 Sarcoidosis HLA-DQA1 intron 22952805 rs9272484 chr6 32605943 G A 0.00001147 Sarcoidosis HLA-DQA1 intron 22952805 rs9272485 chr6 32605972 A G 9.14E-08 Sarcoidosis HLA-DQA1 intron 22952805 rs147897616 chr6 32605982 T TTA 0.000000126 Sarcoidosis HLA-DQA1 intron 22952805 rs9272486 chr6 32605982 T G 0.000000126 Sarcoidosis HLA-DQA1 intron 22952805 rs9272492 chr6 32606052 T G 0.00000011 Sarcoidosis HLA-DQA1 intron 22952805 rs9272498 chr6 32606217 G A 3.80E-07 Sarcoidosis HLA-DQA1 intron 22952805 rs9272535 chr6 32606756 G A 8.87E-08 Schizophrenia HLA-DQA1 intron 19571809 rs9272535 chr6 32606756 G A 9.00E-08 Chronic lymphocytic leukemia HLA-DQA1 intron 21131588 rs9272535 chr6 32606756 G A 1.91E-34 Rheumatoid arthritis HLA-DQA1 intron 21156761 rs9272535 chr6 32606756 G A 8.90E-08 Schizophrenia (treatment refractory) HLA-DQA1 intron 22479419 rs9272535 chr6 32606756 G A 8.60E-07 Red blood cell traits HLA-DQA1 intron 23222517 rs9272535 chr6 32606756 G A 9.31E-08 Hepatocellular carcinoma (hepatitis B virus related) HLA-DQA1 intron 23242368 rs28383362 chr6 32606864 T C 5.85E-07 Sarcoidosis HLA-DQA1 intron 22952805 rs28383363 chr6 32606868 T C 1.89E-07 Sarcoidosis HLA-DQA1 intron 22952805 rs28383365 chr6 32606942 G A 2.59E-07 Sarcoidosis HLA-DQA1 intron 22952805 rs77888377 chr6 32607055 T C 3.10E-09 Sarcoidosis HLA-DQA1 intron 22952805 rs28383380 chr6 32607253 C A 0.00000175 Sarcoidosis HLA-DQA1 intron 22952805 rs28383381 chr6 32607288 G A 1.91E-07 Sarcoidosis HLA-DQA1 intron 22952805 rs28383384 chr6 32607414 C A 0.00003957 Sarcoidosis HLA-DQA1 intron 22952805 rs28383385 chr6 32607416 G A 0.000003077 Sarcoidosis HLA-DQA1 intron 22952805 rs28383389 chr6 32607596 G A 0.000002592 Sarcoidosis HLA-DQA1 intron 22952805 rs28383403 chr6 32608035 T C 1.63E-07 Sarcoidosis HLA-DQA1 intron 22952805 rs17426593 chr6 32608077 T C 3.58E-06 Esophageal cancer (squamous cell) HLA-DQA1 intron 22960999 rs28383405 chr6 32608108 C T 1.63E-07 Sarcoidosis HLA-DQA1 intron 22952805 rs28383408 chr6 32608251 C G 1.65E-07 Sarcoidosis HLA-DQA1 intron 22952805 rs28383413 chr6 32608417 G A 7.91E-08 Sarcoidosis HLA-DQA1 intron 22952805 rs28383415 chr6 32608473 G A 2.14E-07 Sarcoidosis HLA-DQA1 intron 22952805 rs28383416 chr6 32608483 T C 2.88E-07 Sarcoidosis HLA-DQA1 intron 22952805 rs28383418 chr6 32608537 A C 4.59E-07 Sarcoidosis HLA-DQA1 intron 22952805 rs28383420 chr6 32608707 T C 8.59E-07 Sarcoidosis HLA-DQA1 intron 22952805 rs28383428 chr6 32608809 T C 9.99E-07 Sarcoidosis HLA-DQA1 intron 22952805 rs28621855 chr6 32608817 T C 4.96E-09 Sarcoidosis HLA-DQA1 intron 22952805 rs9272723 chr6 32609427 T C 2.20E-75 Multiple complex diseases HLA-DQA1 intron 17554300 rs9272723 chr6 32609427 T C 2.22E-28 Narcolepsy HLA-DQA1 intron 19629137 rs9272723 chr6 32609427 T C 1.69E-09 Rheumatoid arthritis HLA-DQA1 intron 21156761 rs9272723 chr6 32609427 T C 9.10E-05 Hypothyroidism HLA-DQA1 intron 22493691 rs28383457 chr6 32609456 C T 6.84E-07 Sarcoidosis HLA-DQA1 intron 22952805 rs28383460 chr6 32609586 A G 7.59E-07 Sarcoidosis HLA-DQA1 intron 22952805 rs9272731 chr6 32609645 T C 0.00001853 Sarcoidosis HLA-DQA1 intron 22952805 rs9272744 chr6 32609746 C T 4.18E-07 Sarcoidosis HLA-DQA1 intron 22952805 rs9272853 chr6 32610705 G C,T 3.41E-33 Rheumatoid arthritis HLA-DQA1 intron 21156761 rs9272865 chr6 32610736 G A,T 0.000002024 Sarcoidosis HLA-DQA1 UTR-3 22952805 rs9272957 chr6 32611152 G A 0.000005505 Sarcoidosis HLA-DQA1 UTR-3 22952805 rs1064993 chr6 32611181 G A 0.00000419 Sarcoidosis HLA-DQA1 UTR-3 22952805 rs1065043 chr6 32611234 C T 0.000003994 Sarcoidosis HLA-DQA1 UTR-3 22952805 rs1065044 chr6 32611243 C T 0.000005271 Sarcoidosis HLA-DQA1 UTR-3 22952805 rs1065047 chr6 32611260 A G 0.000004825 Sarcoidosis HLA-DQA1 UTR-3 22952805 rs1065048 chr6 32611265 C T 0.000005499 Sarcoidosis HLA-DQA1 UTR-3 22952805 rs9272973 chr6 32611312 G T 0.00000549 Sarcoidosis HLA-DQA1 UTR-3 22952805 rs9272980 chr6 32611357 C T 0.00000225 Sarcoidosis HLA-DQA1 UTR-3 22952805 rs9272998 chr6 32611474 G A 0.000006644 Sarcoidosis / / 22952805 rs9273002 chr6 32611513 A G 0.0000992 Sarcoidosis / / 22952805 rs9273007 chr6 32611537 C T 8.49E-07 Sarcoidosis HLA-DQA1 nearGene-3 22952805 rs9273008 chr6 32611572 T A 0.000000956 Sarcoidosis HLA-DQA1 nearGene-3 22952805 rs9273009 chr6 32611579 A G 0.000000956 Sarcoidosis HLA-DQA1 nearGene-3 22952805 rs9273012 chr6 32611641 A G 8.80E-05 Major depressive disorder HLA-DQA1 nearGene-3 21042317 rs9273012 chr6 32611641 A G 1.73E-05 Hepatocellular carcinoma HLA-DQA1 nearGene-3 22807686 rs9273012 chr6 32611641 A G 3.51E-06 Chronic lymphocytic leukemia HLA-DQA1 nearGene-3 23770605 rs28566533 chr6 32611647 G C 4.42E-08 Sarcoidosis HLA-DQA1 nearGene-3 22952805 rs36214157 chr6 32611764 T C 4.42E-08 Sarcoidosis HLA-DQA1 nearGene-3 22952805 rs9273031 chr6 32611849 A C 0.000002963 Sarcoidosis / / 22952805 rs9273036 chr6 32611898 A G 0.000001363 Sarcoidosis / / 22952805 rs9273040 chr6 32611958 C G 0.000004372 Sarcoidosis / / 22952805 rs9273062 chr6 32612161 C A 0.000003398 Sarcoidosis / / 22952805 rs9273063 chr6 32612166 C T 0.000003085 Sarcoidosis / / 22952805 rs9273070 chr6 32612241 A T 0.00001228 Sarcoidosis / / 22952805 rs6927022 chr6 32612397 A G 6.10E-06 Hypothyroidism / / 22493691 rs6927022 chr6 32612397 A G 5.00E-133 Ulcerative colitis / / 23128233 rs34276369 chr6 32614037 C T 0.000000545 Sarcoidosis / / 22952805 rs28452520 chr6 32615272 C G 3.82E-09 Sarcoidosis / / 22952805 rs28609302 chr6 32615346 C G 0.0002099 Sarcoidosis / / 22952805 rs17612633 chr6 32615710 G C 2.90E-04 Bladder cancer / / 21824976 rs17612633 chr6 32615710 G C 3.61E-06 Podoconiosis / / 22455414 rs17612633 chr6 32615710 G C 6.97E-13 Leprosy / / pha002872 rs17843604 chr6 32620283 C T 1.55E-10 Asthma / / 20860503 rs17843604 chr6 32620283 C T 5.54E-06 Podoconiosis / / 22455414 rs17843604 chr6 32620283 C T 1.21E-10 Sarcoidosis / / 22952805 rs17843604 chr6 32620283 C T 2.52E-10 Leprosy / / pha002872 rs17612858 chr6 32620622 A T 2.21E-05 Podoconiosis / / 22455414 rs17612858 chr6 32620622 A T 1.24E-10 Leprosy / / pha002872 rs9273349 chr6 32625869 T C 7.00E-14 Asthma / / 20860503 rs9273349 chr6 32625869 T C 7.00E-14 Asthma / / 21907864 rs9273349 chr6 32625869 T C 5.41E-06 Podoconiosis / / 22455414 rs9273349 chr6 32625869 T C 8.40E-05 Hypothyroidism / / 22493691 rs9273349 chr6 32625869 T C 7.00E-14 Asthma / / 22561531 rs9273349 chr6 32625869 T C 0.00000881 Sarcoidosis / / 22952805 rs9273349 chr6 32625869 T C 8.31E-13 Leprosy / / pha002872 rs7744001 chr6 32626086 G A 1.73E-05 Hepatocellular carcinoma / / 22807686 rs7744001 chr6 32626086 G A 2.11E-11 Self-reported allergy / / 23817569 rs7744020 chr6 32626130 G A 8.00E-09 Narcolepsy (age of onset) / / 24204295 rs6928482 chr6 32626249 T C 1.54E-27 Rheumatoid arthritis / / 21156761 rs6928482 chr6 32626249 T C 3.40E-05 Hypothyroidism / / 22493691 rs6928482 chr6 32626249 T C 1.09E-11 Self-reported allergy / / 23817569 rs9273363 chr6 32626272 C A 1.12E-307 Multiple complex diseases / / 17554300 rs9273363 chr6 32626272 C A 2.39E-04 Alzheimer's disease / / 17998437 rs9273363 chr6 32626272 C A 3.13E-19 Narcolepsy / / 19629137 rs9273363 chr6 32626272 C A 0.000000011 Type 2 diabetes / / 22325160 rs9273363 chr6 32626272 C A 0.000009802 Sarcoidosis / / 22952805 rs9273363 chr6 32626272 C A 0.00000499 Cholesterol,total / / 23063622 rs9273363 chr6 32626272 C A 0.0000564 LDL cholesterol / / 23063622 rs9273363 chr6 32626272 C A 0.00000035 Joint damage severity in rheumatoid arthritis / / 23696630 rs9273363 chr6 32626272 C A 0.000007 Coronary artery calcification / / 23727086 rs9273363 chr6 32626272 C A 2.00E-10 Chronic lymphocytic leukemia / / 23770605 rs9273364 chr6 32626302 T G 0.000009481 Sarcoidosis / / 22952805 rs6906021 chr6 32626311 T C 1.33E-05 IgE levels / / 22075330 rs6906021 chr6 32626311 T C 6.99E-08 Chronic hepatitis B infection / / 23760081 rs6906021 chr6 32626311 T C 7.00E-15 Self-reported allergy / / 23817569 rs6906021 chr6 32626311 T C 2.00E-12 Allergic sensitization / / 23817571 rs9273367 chr6 32626438 A T 0.00001022 Sarcoidosis / / 22952805 rs9273368 chr6 32626475 G A 0.000009802 Sarcoidosis / / 22952805 rs9273373 chr6 32626601 A G 0.00001087 Sarcoidosis / / 22952805 rs9273373 chr6 32626601 A G 4.00E-14 Asthma and hay fever / / 24388013 rs9273374 chr6 32626614 A G 0.00001245 Sarcoidosis / / 22952805 rs9273394 chr6 32627082 A G 0.00001247 Sarcoidosis / / 22952805 rs1063355 chr6 32627714 T G 3.39E-18 Rheumatoid arthritis HLA-DQB1 UTR-3 17804836 rs1063355 chr6 32627714 T G 4.70E-23 Rheumatoid arthritis HLA-DQB1 UTR-3 19503088 rs1063355 chr6 32627714 T G 9.55E-06 Asthma HLA-DQB1 UTR-3 20159242 rs1063355 chr6 32627714 T G 5.41E-06 Podoconiosis HLA-DQB1 UTR-3 22455414 rs1063355 chr6 32627714 T G 2.50E-06 Hypothyroidism HLA-DQB1 UTR-3 22493691 rs1063355 chr6 32627714 T G 0.00000881 Sarcoidosis HLA-DQB1 UTR-3 22952805 rs1063355 chr6 32627714 T G 2.65E-07 Crohn's disease HLA-DQB1 UTR-3 23266558 rs1063355 chr6 32627714 T G 1.33E-219 Type 1 diabetes HLA-DQB1 UTR-3 pha002862 rs1063355 chr6 32627714 T G 8.09E-13 Leprosy HLA-DQB1 UTR-3 pha002872 rs1049225 chr6 32627747 A G 3.04E-11 Leprosy HLA-DQB1 UTR-3 pha002872 rs1049225 chr6 32627747 A G 0.00000315 Follicular lymphoma HLA-DQB1 UTR-3 23025665 rs1049225 chr6 32627747 A G 0.00000008 Joint damage severity in rheumatoid arthritis HLA-DQB1 UTR-3 23696630 rs78372297 chr6 32627784 C T 0.0003232 Sarcoidosis HLA-DQB1 UTR-3 22952805 rs1766 chr6 32627795 A G 0.00004607 Sarcoidosis HLA-DQB1 UTR-3 22952805 rs1063349 chr6 32627906 T C 0.00000881 Sarcoidosis HLA-DQB1 UTR-3 22952805 rs9273481 chr6 32628122 G C 0.0006179 Sarcoidosis HLA-DQB1 intron 22952805 rs9273490 chr6 32628193 G A 0.0005536 Sarcoidosis HLA-DQB1 intron 22952805 rs9273504 chr6 32628407 T C 0.0003181 Sarcoidosis HLA-DQB1 intron 22952805 rs2854275 chr6 32628428 C A 4.24E-05 Lipid levels HLA-DQB1 intron 19913121 rs2854275 chr6 32628428 C A 2.00E-10 Epstein-Barr virus immune response (EBNA-1) HLA-DQB1 intron 23326239 rs9273527 chr6 32628621 T C,G 0.0007661 Sarcoidosis HLA-DQB1 intron 22952805 rs9273529 chr6 32628698 C T 0.000232 Sarcoidosis HLA-DQB1 intron 22952805 rs9273530 chr6 32628699 A G 0.0002256 Sarcoidosis HLA-DQB1 intron 22952805 rs9273549 chr6 32628873 C T 0.0004075 Sarcoidosis HLA-DQB1 intron 22952805 rs2515895 chr6 32628960 T C 3.84E-08 Sarcoidosis HLA-DQB1 intron 22952805 rs2854272 chr6 32629680 A G 3.94E-08 Sarcoidosis HLA-DQB1 intron 22952805 rs9282114 chr6 32629680 A AC 3.94E-08 Sarcoidosis HLA-DQB1 intron 22952805 rs9274079 chr6 32630131 C A,G,T 0.0003192 Sarcoidosis HLA-DQB1 intron 22952805 rs9274134 chr6 32630242 T A,C 0.0003763 Sarcoidosis HLA-DQB1 intron 22952805 rs9274407 chr6 32632832 A T 5.00E-14 Drug-induced liver injury (amoxicillin-clavulanate) HLA-DQB1 missense 21570397 rs9274407 chr6 32632832 A T 4.80E-14 Hepatocellular carcinoma (hepatitis B virus related) HLA-DQB1 missense 23242368 rs9274407 chr6 32632832 A T 6.72E-08 Leprosy HLA-DQB1 missense pha002872 rs9274477 chr6 32633713 A G 0.0008534 Sarcoidosis HLA-DQB1 intron 22952805 rs9274477 chr6 32633713 A G 2.00E-08 Narcolepsy (age of onset) HLA-DQB1 intron 24204295 rs9274484 chr6 32633818 C A,G 0.0008908 Sarcoidosis HLA-DQB1 intron 22952805 rs9274490 chr6 32633879 A G,T 0.0008079 Sarcoidosis HLA-DQB1 intron 22952805 rs9274500 chr6 32634024 T A,C 0.0007955 Sarcoidosis HLA-DQB1 intron 22952805 rs1049058 chr6 32634331 G A,C 0.0000797 Sarcoidosis HLA-DQB1 cds-synon 22952805 rs3189152 chr6 32634341 A G,T 0.0004141 Sarcoidosis HLA-DQB1 missense 22952805 rs3189152 chr6 32634341 A G,T 1.55E-09 Chronic hepatitis B infection HLA-DQB1 missense 23760081 rs3891175 chr6 32634467 C T 1.67E-27 Rheumatoid arthritis HLA-DQB1 nearGene-5 21156761 rs3891175 chr6 32634467 C T 5.37E-05 IgE levels HLA-DQB1 nearGene-5 22075330 rs3891175 chr6 32634467 C T 0.0007725 Sarcoidosis HLA-DQB1 nearGene-5 22952805 rs3891175 chr6 32634467 C T 1.68E-09 Self-reported allergy HLA-DQB1 nearGene-5 23817569 rs9274536 chr6 32634634 C T 0.000007225 Sarcoidosis HLA-DQB1 nearGene-5 22952805 rs4988888 chr6 32635197 T C 4.81E-08 Sarcoidosis HLA-DQB1 nearGene-5 22952805 rs77296290 chr6 32635296 C T 0.0006558 Sarcoidosis HLA-DQB1 nearGene-5 22952805 rs114544105 chr6 32635629 G A 0.0002 Sarcoidosis HLA-DQB1 nearGene-5 22952805 rs9274606 chr6 32635687 T C 0.0008127 Sarcoidosis HLA-DQB1 nearGene-5 22952805 rs9274614 chr6 32635846 C G 0.000000137 Follicular lymphoma HLA-DQB1 nearGene-5 23025665 rs9274620 chr6 32635965 G T 0.0007372 Sarcoidosis HLA-DQB1 nearGene-5 22952805 rs9274622 chr6 32635990 T C 0.0007914 Sarcoidosis HLA-DQB1 nearGene-5 22952805 rs201386475 chr6 32636063 G GCA 7.91E-37 Rheumatoid arthritis HLA-DQB1 nearGene-5 21156761 rs201386475 chr6 32636063 G GCA 1.59E-05 IgE levels HLA-DQB1 nearGene-5 22075330 rs201386475 chr6 32636063 G GCA 0.00000004 Joint damage severity in rheumatoid arthritis HLA-DQB1 nearGene-5 23696630 rs3828800 chr6 32636063 G A 7.91E-37 Rheumatoid arthritis HLA-DQB1 nearGene-5 21156761 rs3828800 chr6 32636063 G A 1.59E-05 IgE levels HLA-DQB1 nearGene-5 22075330 rs3828800 chr6 32636063 G A 0.00000004 Joint damage severity in rheumatoid arthritis HLA-DQB1 nearGene-5 23696630 rs3134996 chr6 32636866 A T 8.40E-06 Hypothyroidism / / 22493691 rs3134996 chr6 32636866 A T 3.78E-09 Chronic hepatitis B infection / / 23760081 rs9274689 chr6 32636930 T C 6.50E-09 Leprosy / / pha002872 rs9274741 chr6 32637994 T C 4.72E-10 Leprosy / / pha002872 rs9274759 chr6 32638315 G A 7.24E-10 Leprosy / / pha002872 rs9274810 chr6 32639510 C G,T 1.61E-10 Sarcoidosis / / 22952805 rs28891406 chr6 32640336 G A 1.62E-09 Leprosy / / pha002872 rs149288329 chr6 32642794 T C 1.55E-10 Sarcoidosis / / 22952805 rs17205696 chr6 32650587 C T 4.66E-06 Hepatitis B / / 24162738 rs9275134 chr6 32650612 C G 4.56E-91 Multiple complex diseases / / 17554300 rs9275134 chr6 32650612 C G 5.41E-17 Narcolepsy / / 19629137 rs9275134 chr6 32650612 C G 1.69E-21 Rheumatoid arthritis / / 21156761 rs9275134 chr6 32650612 C G 5.81E-04 Self-reported allergy / / 23817569 rs17212090 chr6 32650809 C T 7.46E-10 Leprosy / / pha002872 rs9275141 chr6 32651117 T G 2.00E-07 Response to ximelagatran treatment / / 17505501 rs9275141 chr6 32651117 T G 3.90E-16 Celiac disease / / 17558408 rs9275141 chr6 32651117 T G 2.17E-39 Rheumatoid arthritis / / 17804836 rs9275141 chr6 32651117 T G 3.57E-52 Rheumatoid arthritis / / 19503088 rs9275141 chr6 32651117 T G 1.15E-25 Rheumatoid arthritis / / 21156761 rs9275141 chr6 32651117 T G 1.42E-08 Hepatitis B / / 21750111 rs9275141 chr6 32651117 T G 1.58E-07 Alopecia areata / / 22027810 rs9275141 chr6 32651117 T G 4.70E-06 Hypothyroidism / / 22493691 rs9275141 chr6 32651117 T G 5.80E-09 Self-reported allergy / / 23817569 rs9275141 chr6 32651117 T G 4.30E-10 Systemic lupus erythematosus / / 24871463 rs9275141 chr6 32651117 T G 6.80E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9275141 chr6 32651117 T G 7.42E-06 Systemic lupus erythematosus / / pha002867 rs9275141 chr6 32651117 T G 2.61E-10 Leprosy / / pha002872 rs17212223 chr6 32651540 C T 3.00E-08 Narcolepsy (age of onset) / / 24204295 rs3021061 chr6 32651839 C G 2.02E-04 Self-reported allergy / / 23817569 rs2856695 chr6 32651894 A G 7.66E-08 Leprosy / / pha002872 rs6457614 chr6 32651900 T G 5.74E-10 Self-reported allergy / / 23817569 rs7755224 chr6 32652317 A G,T 4.70E-04 Parkinson's disease / / 21248740 rs7755224 chr6 32652317 A G,T 1.39E-04 Follicular lymphoma / / 21533074 rs7755224 chr6 32652317 A G,T 2.24E-05 Hepatitis B / / 21750111 rs7755224 chr6 32652317 A G,T 9.93E-04 Crohn's disease / / 23266558 rs17212420 chr6 32652400 C T 1.11E-09 Leprosy / / pha002872 rs3134975 chr6 32652581 T C 6.77E-38 Rheumatoid arthritis / / 21156761 rs3134975 chr6 32652581 T C 8.80E-07 Hypothyroidism / / 22493691 rs3134974 chr6 32652865 T C,G 0.00000382 Interleukin-6 (IL-6) levels / / 23505291 rs28371251 chr6 32653018 T C 5.50E-06 Hepatitis B / / 24162738 rs4947342 chr6 32653070 G A 1.02E-21 Rheumatoid arthritis / / 21156761 rs547905023 chr6 32653608 T C 9.40E-10 Self-reported allergy / / 23817569 rs12528368 chr6 32653643 T C 1.16E-09 Self-reported allergy / / 23817569 rs2856688 chr6 32654640 G T 5.94E-91 Multiple complex diseases / / 17554300 rs2856688 chr6 32654640 G T 3.80E-18 Narcolepsy / / 19629137 rs2856688 chr6 32654640 G T 1.11E-21 Rheumatoid arthritis / / 21156761 rs2856688 chr6 32654640 G T 3.21E-04 Self-reported allergy / / 23817569 rs9275184 chr6 32654714 T C 4.50E-72 Type 1 diabetes / / 17632545 rs9275184 chr6 32654714 T C 5.94E-67 Rheumatoid arthritis / / 17804836 rs9275184 chr6 32654714 T C 4.66E-47 Rheumatoid arthritis / / 21156761 rs9275184 chr6 32654714 T C 1.09E-05 Parkinson's disease / / 21738487 rs9275184 chr6 32654714 T C 4.03E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9275184 chr6 32654714 T C 7.69E-21 Pemphigus vulgaris / / 22437316 rs145291666 chr6 32654919 C T 2.90E-10 Sarcoidosis / / 22952805 rs2856683 chr6 32655218 T G 1.24E-22 Type 1 diabetes / / 17632545 rs2856683 chr6 32655218 T G 1.00E-10 Primary biliary cirrhosis / / 19458352 rs2856683 chr6 32655218 T G 9.91E-21 Rheumatoid arthritis / / 21156761 rs2856683 chr6 32655218 T G 4.02E-04 Parkinson's disease / / 21248740 rs2856683 chr6 32655218 T G 2.30E-06 Pemphigus vulgaris / / 22437316 rs2856683 chr6 32655218 T G 1.78E-19 Hepatocellular carcinoma (hepatitis B virus related) / / 23242368 rs2856683 chr6 32655218 T G 3.64E-04 Self-reported allergy / / 23817569 rs28747043 chr6 32655508 A G 1.05E-06 Prostate cancer / / 24185611 rs4538747 chr6 32657334 T A 6.53E-10 Leprosy / / pha002872 rs2395535 chr6 32657351 A C 1.01E-08 Chronic hepatitis B infection / / 23760081 rs4538748 chr6 32657505 T C 1.01E-08 Chronic hepatitis B infection / / 23760081 rs7774434 chr6 32657578 T C 3.33E-16 Type 1 diabetes / / 17632545 rs7774434 chr6 32657578 T C 3.00E-26 Primary biliary cirrhosis / / 20639880 rs7774434 chr6 32657578 T C 3.30E-26 Rheumatoid arthritis / / 21156761 rs7774434 chr6 32657578 T C 4.00E-34 Primary biliary cirrhosis / / 21399635 rs7774434 chr6 32657578 T C 5.88E-11 Hepatitis B vaccine response / / 21764829 rs7774434 chr6 32657578 T C 5.46E-05 Coronary heart disease / / 21971053 rs7774434 chr6 32657578 T C 1.30E-48 Primary biliary cirrhosis / / 22961000 rs7774434 chr6 32657578 T C 2.38E-26 Hepatocellular carcinoma (hepatitis B virus related) / / 23242368 rs7774434 chr6 32657578 T C 0.0000011 Joint damage severity in rheumatoid arthritis / / 23696630 rs7774434 chr6 32657578 T C 1.10E-04 IgE levels in asthmatics (D.f. specific) / / 23967269 rs7774434 chr6 32657578 T C 3.43E-09 Hodgkin's lymphoma / / 24149102 rs9275207 chr6 32657710 A G 3.84E-54 Rheumatoid arthritis / / 21156761 rs9275207 chr6 32657710 A G 9.57E-05 IgE levels / / 22075330 rs7775055 chr6 32657916 T C 1.11E-33 Primary biliary cirrhosis / / 22936693 rs7775055 chr6 32657916 T C 1.84E-25 Primary biliary cirrhosis in females / / 22936693 rs7775055 chr6 32657916 T C 6.76E-36 Primary biliary cirrhosis (anti-mitochondrial antibody positive) / / 22936693 rs7775055 chr6 32657916 T C 2.24E-162 Oligoarticular juvenile idiopathic arthritis / / 23603761 rs7775055 chr6 32657916 T C 3.14E-174 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs7775055 chr6 32657916 T C 6.64E-52 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis / / 23603761 rs7775228 chr6 32658079 T C 8.59E-10 Multiple complex diseases / / 17554300 rs7775228 chr6 32658079 T C 1.00E-16 Type 1 diabetes / / 17632545 rs7775228 chr6 32658079 T C 8.83E-23 Rheumatoid arthritis / / 17804836 rs7775228 chr6 32658079 T C 7.29E-30 Rheumatoid arthritis / / 19503088 rs7775228 chr6 32658079 T C 6.18E-09 Narcolepsy / / 19629137 rs7775228 chr6 32658079 T C 1.81E-20 Rheumatoid arthritis / / 21156761 rs7775228 chr6 32658079 T C 5.00E-15 Asthma / / 21804548 rs7775228 chr6 32658079 T C 2.00E-09 IgE grass sensitization / / 22036096 rs7775228 chr6 32658079 T C 1.21E-04 Self-reported allergy / / 23817569 rs9469220 chr6 32658310 G A 2.00E-06 Crohn's disease / / 17554300 rs9469220 chr6 32658310 G A 4.45E-18 Multiple sclerosis / / 17660530 rs9469220 chr6 32658310 G A 7.19E-38 Narcolepsy / / 19629137 rs9469220 chr6 32658310 G A 2.00E-07 IgE levels / / 23146381 rs9469220 chr6 32658310 G A 6.02E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9469220 chr6 32658310 G A 2.50E-05 Diabetic nephropathy / / pha002866 rs9368737 chr6 32658429 T C 6.55E-06 Hepatitis B / / 24162738 rs9368737 chr6 32658429 T C 5.84E-09 Self-reported allergy / / 23817569 rs2157051 chr6 32658624 G A 1.50E-07 Multiple sclerosis / / 20598377 rs2157051 chr6 32658624 G A 5.96E-27 Rheumatoid arthritis / / 21156761 rs2157051 chr6 32658624 G A 0.00000271 Follicular lymphoma / / 23025665 rs2157051 chr6 32658624 G A 1.32E-252 Type 1 diabetes / / pha002862 rs2858330 chr6 32658715 T C 2.19E-26 Rheumatoid arthritis / / 21156761 rs2858330 chr6 32658715 T C 4.47E-09 Self-reported allergy / / 23817569 rs2858330 chr6 32658715 T C 3.59E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2858328 chr6 32658911 C T 0.00008897 Sarcoidosis / / 22952805 rs9275219 chr6 32659077 C T 1.37E-55 Rheumatoid arthritis / / 21156761 rs9275219 chr6 32659077 C T 0.000009177 Sarcoidosis / / 22952805 rs9275219 chr6 32659077 C T 1.95E-05 Self-reported allergy / / 23817569 rs9275220 chr6 32659087 T C 1.37E-55 Rheumatoid arthritis / / 21156761 rs9275220 chr6 32659087 T C 0.00001925 Sarcoidosis / / 22952805 rs9275220 chr6 32659087 T C 1.95E-05 Self-reported allergy / / 23817569 rs9275221 chr6 32659099 T C 3.84E-54 Rheumatoid arthritis / / 21156761 rs9275221 chr6 32659099 T C 9.53E-05 IgE levels / / 22075330 rs5002702 chr6 32659158 G A 4.62E-80 Rheumatoid arthritis / / 21156761 rs5002702 chr6 32659158 G A 8.16E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1794523 chr6 32659192 C A,G,T 9.95E-07 Self-reported allergy / / 23817569 rs2856674 chr6 32659645 A G 7.50E-14 Rheumatoid arthritis / / 21156761 rs2856674 chr6 32659645 A G 8.79E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs4248168 chr6 32659743 G C 4.62E-80 Rheumatoid arthritis / / 21156761 rs2856673 chr6 32659822 G T 4.69E-05 IgE levels / / 22075330 rs2856673 chr6 32659822 G T 2.82E-06 Self-reported allergy / / 23817569 rs9275224 chr6 32659878 A G 6.21E-79 Rheumatoid arthritis / / 21156761 rs9275224 chr6 32659878 A G 2.60E-10 Nephropathy / / 21399633 rs9275224 chr6 32659878 A G 9.18E-08 Systemic sclerosis / / 21750679 rs9275224 chr6 32659878 A G 2.48E-04 Crohn's disease / / 23266558 rs9275224 chr6 32659878 A G 0.0000001 Joint damage severity in rheumatoid arthritis / / 23696630 rs9275224 chr6 32659878 A G 7.23E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9275224 chr6 32659878 A G 2.32E-10 Leprosy / / pha002872 rs4713581 chr6 32660023 T C 7.29E-100 Rheumatoid arthritis / / 21156761 rs4713582 chr6 32660051 T C 5.68E-80 Rheumatoid arthritis / / 21156761 rs4713582 chr6 32660051 T C 7.99E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs4713583 chr6 32660153 T G 5.68E-80 Rheumatoid arthritis / / 21156761 rs4713583 chr6 32660153 T G 7.97E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2858324 chr6 32660375 A G 0.00000038 Joint damage severity in rheumatoid arthritis / / 23696630 rs9275245 chr6 32660943 A G 1.39E-07 Systemic sclerosis / / 21750679 rs9275245 chr6 32660943 A G 0.000000362 Follicular lymphoma / / 23025665 rs9275245 chr6 32660943 A G 2.28E-10 Leprosy / / pha002872 rs2647009 chr6 32661615 T A 4.65E-05 IgE levels / / 22075330 rs2647009 chr6 32661615 T A 2.43E-06 Self-reported allergy / / 23817569 rs3129719 chr6 32661779 T G 9.37E-38 Rheumatoid arthritis / / 21156761 rs1794520 chr6 32662338 T A 2.56E-11 Rheumatoid arthritis / / 21156761 rs9275292 chr6 32663289 C A 1.41E-79 Rheumatoid arthritis / / 21156761 rs9275292 chr6 32663289 C A 7.29E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9275293 chr6 32663308 T C 3.84E-54 Rheumatoid arthritis / / 21156761 rs9275293 chr6 32663308 T C 9.49E-05 IgE levels / / 22075330 rs9275295 chr6 32663391 A G 1.76E-79 Rheumatoid arthritis / / 21156761 rs9275295 chr6 32663391 A G 7.29E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs5000634 chr6 32663564 A G 2.16E-68 Rheumatoid arthritis / / 17804836 rs5000634 chr6 32663564 A G 1.28E-100 Rheumatoid arthritis / / 19503088 rs5000634 chr6 32663564 A G 9.16E-05 Asthma / / 20159242 rs5000634 chr6 32663564 A G 9.13E-13 Systemic sclerosis / / 20383147 rs5000634 chr6 32663564 A G 1.01E-47 Rheumatoid arthritis / / 21156761 rs5000634 chr6 32663564 A G 1.03E-06 Alopecia areata / / 22027810 rs5000634 chr6 32663564 A G 1.87E-06 Pemphigus vulgaris / / 22437316 rs5000634 chr6 32663564 A G 3.88E-11 Hepatocellular carcinoma (hepatitis B virus related) / / 23242368 rs5000634 chr6 32663564 A G 6.99E-08 Crohn's disease / / 23266558 rs5000634 chr6 32663564 A G 2.60E-06 Systemic lupus erythematosus / / 24871463 rs5000634 chr6 32663564 A G 7.40E-12 Leprosy / / pha002872 rs3129720 chr6 32663631 T C 5.85E-38 Rheumatoid arthritis / / 21156761 rs3129720 chr6 32663631 T C 5.00E-07 Hypothyroidism / / 22493691 rs3129720 chr6 32663631 T C 5.00E-15 Multiple sclerosis (OCB status) / / 23472185 rs3129720 chr6 32663631 T C 5.58E-08 Chronic hepatitis B infection / / 23760081 rs3129720 chr6 32663631 T C 4.91E-11 Leprosy / / pha002872 rs17427431 chr6 32663644 G A 3.34E-09 Self-reported allergy / / 23817569 rs17427445 chr6 32663764 G A 1.87E-09 Self-reported allergy / / 23817569 rs2647017 chr6 32663772 T G 4.57E-05 IgE levels / / 22075330 rs2647017 chr6 32663772 T G 2.56E-06 Self-reported allergy / / 23817569 rs6457617 chr6 32663851 C T 5.00E-75 Rheumatoid arthritis / / 17554300 rs6457617 chr6 32663851 C T 9.47E-15 Multiple sclerosis / / 17660530 rs6457617 chr6 32663851 C T 5.28E-111 Rheumatoid arthritis / / 17804836 rs6457617 chr6 32663851 C T 1.00E-09 Rheumatoid arthritis / / 18668548 rs6457617 chr6 32663851 C T 3.41E-28 Narcolepsy / / 19629137 rs6457617 chr6 32663851 C T 4.00E-17 Systemic sclerosis / / 20383147 rs6457617 chr6 32663851 C T 3.34E-79 Rheumatoid arthritis / / 21156761 rs6457617 chr6 32663851 C T 2.94E-05 Follicular lymphoma / / 21533074 rs6457617 chr6 32663851 C T 2.00E-37 Systemic sclerosis / / 21750679 rs6457617 chr6 32663851 C T 7.00E-33 Graves' disease / / 21841780 rs6457617 chr6 32663851 C T 3.98E-17 Hepatocellular carcinoma (hepatitis B virus related) / / 23242368 rs6457617 chr6 32663851 C T 7.41E-05 Crohn's disease / / 23266558 rs6457617 chr6 32663851 C T 0.00000046 Joint damage severity in rheumatoid arthritis / / 23696630 rs6457617 chr6 32663851 C T 6.73E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs6457617 chr6 32663851 C T 1.31E-08 Leprosy / / pha002872 rs6457620 chr6 32663999 G C 1.92E-102 Multiple complex diseases / / 17554300 rs6457620 chr6 32663999 G C 3.41E-13 Multiple sclerosis / / 17660530 rs6457620 chr6 32663999 G C 4.00E-186 Rheumatoid arthritis / / 18794853 rs6457620 chr6 32663999 G C 3.22E-28 Narcolepsy / / 19629137 rs6457620 chr6 32663999 G C 2.00E-16 Height / / 20881960 rs6457620 chr6 32663999 G C 4.87E-80 Rheumatoid arthritis / / 21156761 rs2647015 chr6 32664093 T G 8.28E-40 Multiple complex diseases / / 17554300 rs2647015 chr6 32664093 T G 4.58E-05 IgE levels / / 22075330 rs2647015 chr6 32664093 T G 2.45E-06 Self-reported allergy / / 23817569 rs6457622 chr6 32664163 A C 1.12E-51 Rheumatoid arthritis / / 21156761 rs7745040 chr6 32664332 T C 7.21E-48 Rheumatoid arthritis / / 21156761 rs2647012 chr6 32664458 T C 2.07E-76 Rheumatoid arthritis / / 17804836 rs2647012 chr6 32664458 T C 7.96E-99 Rheumatoid arthritis / / 19503088 rs2647012 chr6 32664458 T C 5.29E-05 HIV-1 control / / 20041166 rs2647012 chr6 32664458 T C 3.08E-51 Rheumatoid arthritis / / 21156761 rs2647012 chr6 32664458 T C 8.00E-06 Systemic lupus erythematosus / / 21408207 rs2647012 chr6 32664458 T C 2.00E-21 Follicular lymphoma / / 21533074 rs2647012 chr6 32664458 T C 1.49E-04 Coronary heart disease / / 21971053 rs2647012 chr6 32664458 T C 2.00E-21 Hepatocellular carcinoma (hepatitis B virus related) / / 23242368 rs2647012 chr6 32664458 T C 0.00000062 Joint damage severity in rheumatoid arthritis / / 23696630 rs2647012 chr6 32664458 T C 2.18E-05 Hodgkin's lymphoma / / 24149102 rs2647012 chr6 32664458 T C 1.20E-14 Systemic lupus erythematosus / / 24871463 rs2647012 chr6 32664458 T C 3.00E-07 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2647012 chr6 32664458 T C 2.19E-07 Systemic lupus erythematosus / / pha002867 rs2647012 chr6 32664458 T C 3.97E-08 Leprosy / / pha002872 rs142451601 chr6 32664698 C A 3.79E-10 Sarcoidosis / / 22952805 rs2395522 chr6 32664722 A T 7.13E-80 Rheumatoid arthritis / / 21156761 rs2647003 chr6 32664880 T G 3.08E-51 Rheumatoid arthritis / / 21156761 rs2647003 chr6 32664880 T G 3.62E-07 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9357152 chr6 32664960 A G 5.20E-14 Celiac disease / / 17558408 rs9357152 chr6 32664960 A G 7.47E-08 Rheumatoid arthritis / / 17804836 rs9357152 chr6 32664960 A G 1.00E-10 Primary biliary cirrhosis / / 19458352 rs9357152 chr6 32664960 A G 8.35E-10 Rheumatoid arthritis / / 19503088 rs9357152 chr6 32664960 A G 1.00E-14 HPV seropositivity / / 21896673 rs9357152 chr6 32664960 A G 3.51E-06 Alopecia areata / / 22027810 rs9357152 chr6 32664960 A G 1.80E-09 Systemic lupus erythematosus / / 24871463 rs9357152 chr6 32664960 A G 1.91E-141 Type 1 diabetes / / pha002862 rs9357152 chr6 32664960 A G 1.80E-08 Leprosy / / pha002872 rs9275307 chr6 32664990 A T 8.13E-54 Rheumatoid arthritis / / 21156761 rs9275307 chr6 32664990 A T 9.04E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9275307 chr6 32664990 A T 9.08E-05 IgE levels / / 22075330 rs17499411 chr6 32665002 C G 5.82E-10 Self-reported allergy / / 23817569 rs9275309 chr6 32665258 G T 0.00002339 Sarcoidosis / / 22952805 rs17206147 chr6 32665311 T C 0.0002129 Sarcoidosis / / 22952805 rs10484561 chr6 32665420 T G 1.00E-29 Follicular lymphoma / / 20639881 rs10484561 chr6 32665420 T G 1.63E-04 Parkinson's disease / / 21248740 rs10484561 chr6 32665420 T G 5.77E-05 Follicular lymphoma / / 21533074 rs10484561 chr6 32665420 T G 1.12E-29 Hepatocellular carcinoma (hepatitis B virus related) / / 23242368 rs10484561 chr6 32665420 T G 2.00E-09 Self-reported allergy / / 23817569 rs2856665 chr6 32665597 A G 7.42E-05 IgE levels / / 22075330 rs2856665 chr6 32665597 A G 1.39E-07 Self-reported allergy / / 23817569 rs2856664 chr6 32665616 G T 2.84E-09 Chronic hepatitis B infection / / 23760081 rs9275311 chr6 32665640 G T 8.00E-54 Rheumatoid arthritis / / 21156761 rs9275312 chr6 32665728 A G 9.90E-60 Type 1 diabetes / / 17632545 rs9275312 chr6 32665728 A G 1.09E-53 Rheumatoid arthritis / / 17804836 rs9275312 chr6 32665728 A G 5.05E-93 Rheumatoid arthritis / / 19503088 rs9275312 chr6 32665728 A G 1.13E-05 Asthma / / 20159242 rs9275312 chr6 32665728 A G 3.70E-08 Systemic sclerosis / / 20383147 rs9275312 chr6 32665728 A G 7.42E-44 Rheumatoid arthritis / / 21156761 rs9275312 chr6 32665728 A G 9.25E-04 Atopy / / 21625490 rs9275312 chr6 32665728 A G 2.12E-19 Pemphigus vulgaris / / 22437316 rs9275312 chr6 32665728 A G 8.04E-09 Hepatocellular carcinoma (hepatitis B virus related) / / 23242368 rs9275312 chr6 32665728 A G 7.20E-09 Crohn's disease / / 23266558 rs2646996 chr6 32665741 A G 2.84E-09 Chronic hepatitis B infection / / 23760081 rs148735424 chr6 32665759 G GCTTCGT 7.06E-67 Type 1 diabetes / / 17632545 rs148735424 chr6 32665759 G GCTTCGT 4.20E-09 Joint damage severity in rheumatoid arthritis / / 23696630 rs9275313 chr6 32665759 G T 7.06E-67 Type 1 diabetes / / 17632545 rs9275313 chr6 32665759 G T 4.20E-09 Joint damage severity in rheumatoid arthritis / / 23696630 rs2646994 chr6 32665813 C T 7.82E-05 IgE levels / / 22075330 rs2646994 chr6 32665813 C T 2.55E-06 Self-reported allergy / / 23817569 rs9275316 chr6 32665916 T C 0.00002339 Sarcoidosis / / 22952805 rs9275319 chr6 32666295 A G 3.00E-17 Hepatocellular carcinoma (hepatitis B virus related) / / 23242368 rs9275320 chr6 32666469 A C 0.00002032 Sarcoidosis / / 22952805 rs1794282 chr6 32666526 C T 1.65E-19 Type 1 diabetes / / 17632545 rs1794282 chr6 32666526 C T 6.90E-16 Rheumatoid arthritis / / 17804836 rs1794282 chr6 32666526 C T 2.60E-46 Systemic lupus erythematosus / / 18204446 rs1794282 chr6 32666526 C T 7.15E-05 Lung cancer / / 18978787 rs1794282 chr6 32666526 C T 6.00E-05 Lung cancer / / 18978790 rs1794282 chr6 32666526 C T 2.00E-04 Schizophrenia / / 19197363 rs1794282 chr6 32666526 C T 5.74E-17 Rheumatoid arthritis / / 19503088 rs1794282 chr6 32666526 C T 6.68E-10 Lung adenocarcinoma / / 19836008 rs1794282 chr6 32666526 C T 2.99E-13 Rheumatoid arthritis / / 21156761 rs1794282 chr6 32666526 C T 7.10E-13 Lung cancer / / 22899653 rs1794282 chr6 32666526 C T 1.40E-73 Myasthenia gravis / / 23055271 rs1794282 chr6 32666526 C T 9.60E-18 Systemic lupus erythematosus / / 24871463 rs1794282 chr6 32666526 C T 2.77E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1794282 chr6 32666526 C T 2.48E-103 Type 1 diabetes / / pha002862 rs1794282 chr6 32666526 C T 2.21E-07 Systemic lupus erythematosus / / pha002867 rs9275322 chr6 32666560 C G 0.00002064 Sarcoidosis / / 22952805 rs9275323 chr6 32666609 T C 5.13E-56 Rheumatoid arthritis / / 21156761 rs9275323 chr6 32666609 T C 0.0000202 Sarcoidosis / / 22952805 rs9275323 chr6 32666609 T C 1.30E-05 Self-reported allergy / / 23817569 rs9275324 chr6 32666635 C T 2.20E-53 Rheumatoid arthritis / / 21156761 rs2856726 chr6 32666721 A T 2.83E-09 Chronic hepatitis B infection / / 23760081 rs2856726 chr6 32666721 A T 1.83E-09 Self-reported allergy / / 23817569 rs2856726 chr6 32666721 A T 5.09E-12 Psoriasis / / pha002855 rs2856725 chr6 32666738 C T 5.48E-05 HIV-1 control / / 20041166 rs2856725 chr6 32666738 C T 1.11E-04 Coronary heart disease / / 21971053 rs2856725 chr6 32666738 C T 1.82E-05 Hodgkin's lymphoma / / 24149102 rs2856725 chr6 32666738 C T 2.05E-08 Leprosy / / pha002872 rs1794281 chr6 32666817 A G 1.32E-06 Self-reported allergy / / 23817569 rs9275328 chr6 32666822 C T 1.02E-59 Type 1 diabetes / / 17632545 rs9275328 chr6 32666822 C T 4.59E-43 Rheumatoid arthritis / / 21156761 rs9275328 chr6 32666822 C T 9.40E-04 Atopy / / 21625490 rs9275328 chr6 32666822 C T 8.28E-09 Crohn's disease / / 23266558 rs9275329 chr6 32666831 G T 5.13E-56 Rheumatoid arthritis / / 21156761 rs9275329 chr6 32666831 G T 0.00002339 Sarcoidosis / / 22952805 rs9275329 chr6 32666831 G T 1.10E-05 Self-reported allergy / / 23817569 rs9275330 chr6 32666875 A G 0.00000004 Joint damage severity in rheumatoid arthritis / / 23696630 rs9275332 chr6 32666943 G A 5.13E-56 Rheumatoid arthritis / / 21156761 rs9275332 chr6 32666943 G A 0.00002339 Sarcoidosis / / 22952805 rs9275332 chr6 32666943 G A 5.50E-10 Joint damage severity in rheumatoid arthritis / / 23696630 rs9275332 chr6 32666943 G A 1.30E-05 Self-reported allergy / / 23817569 rs35998847 chr6 32666997 G A 6.08E-08 Follicular lymphoma / / 23025665 rs17427564 chr6 32667067 T C 1.63E-09 Self-reported allergy / / 23817569 rs9275334 chr6 32667107 T C 5.94E-49 Rheumatoid arthritis / / 21156761 rs9275334 chr6 32667107 T C 9.06E-05 IgE levels / / 22075330 rs9275334 chr6 32667107 T C 4.50E-09 Joint damage severity in rheumatoid arthritis / / 23696630 rs3135006 chr6 32667119 T C 1.23E-37 Rheumatoid arthritis / / 21156761 rs3135006 chr6 32667119 T C 9.60E-07 Hypothyroidism / / 22493691 rs2858312 chr6 32667230 G C 4.51E-09 Chronic hepatitis B infection / / 23760081 rs2858312 chr6 32667230 G C 4.46E-11 Self-reported allergy / / 23817569 rs2647040 chr6 32667280 A G 4.72E-52 Rheumatoid arthritis / / 21156761 rs2647040 chr6 32667280 A G 6.09E-07 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9275337 chr6 32667318 G T 0.00002393 Sarcoidosis / / 22952805 rs9275338 chr6 32667343 A T 5.78E-39 Rheumatoid arthritis / / 21156761 rs9275338 chr6 32667343 A T 0.00000007 Joint damage severity in rheumatoid arthritis / / 23696630 rs17427599 chr6 32667364 C T 0.0003807 Sarcoidosis / / 22952805 rs17427599 chr6 32667364 C T 7.47E-04 Self-reported allergy / / 23817569 rs9275351 chr6 32667793 C A 6.14E-47 Rheumatoid arthritis / / 21156761 rs9275351 chr6 32667793 C A 9.10E-05 IgE levels / / 22075330 rs9275352 chr6 32667807 C T 0.00001594 Sarcoidosis / / 22952805 rs9275353 chr6 32667815 T G 0.00002062 Sarcoidosis / / 22952805 rs9275354 chr6 32667820 T G 0.00002339 Sarcoidosis / / 22952805 rs9275354 chr6 32667820 T G 4.61E-05 Self-reported allergy / / 23817569 rs9275355 chr6 32667829 T C 0.00002045 Sarcoidosis / / 22952805 rs9275356 chr6 32667850 C G 9.13E-05 IgE levels / / 22075330 rs9275357 chr6 32667891 A C 0.00003707 Sarcoidosis / / 22952805 rs2647044 chr6 32667910 G A 1.00E-16 Type 1 diabetes / / 17632545 rs2647044 chr6 32667910 G A 4.03E-13 Rheumatoid arthritis / / 21156761 rs2647044 chr6 32667910 G A 6.00E-06 Pulmonary function / / 21946350 rs2647044 chr6 32667910 G A 7.75E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9275364 chr6 32668027 A G 0.00003629 Sarcoidosis / / 22952805 rs2647045 chr6 32668100 G A 4.00E-10 Lymphoma / / 23349640 rs2647045 chr6 32668100 G A 4.05E-04 Self-reported allergy / / 23817569 rs9275366 chr6 32668171 A C 0.00003629 Sarcoidosis / / 22952805 rs9275367 chr6 32668182 A G 0.00002501 Sarcoidosis / / 22952805 rs9275368 chr6 32668183 C G 0.00002302 Sarcoidosis / / 22952805 rs9275369 chr6 32668255 C T 0.00003629 Sarcoidosis / / 22952805 rs9275370 chr6 32668258 C T 0.00003629 Sarcoidosis / / 22952805 rs9275371 chr6 32668296 T C 3.07E-39 Type 1 diabetes / / 17632545 rs9275371 chr6 32668296 T C 5.23E-56 Rheumatoid arthritis / / 21156761 rs9275371 chr6 32668296 T C 0.00003629 Sarcoidosis / / 22952805 rs9275371 chr6 32668296 T C 1.10E-04 Crohn's disease / / 23266558 rs9275371 chr6 32668296 T C 5.40E-10 Joint damage severity in rheumatoid arthritis / / 23696630 rs9275371 chr6 32668296 T C 1.30E-05 Self-reported allergy / / 23817569 rs2858310 chr6 32668323 G A 2.95E-52 Rheumatoid arthritis / / 21156761 rs2858310 chr6 32668323 G A 7.67E-07 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2647046 chr6 32668336 A C 1.89E-59 Multiple complex diseases / / 17554300 rs2647046 chr6 32668336 A C 1.04E-20 Multiple sclerosis / / 17660530 rs2647046 chr6 32668336 A C 1.04E-46 Narcolepsy / / 19629137 rs2647046 chr6 32668336 A C 1.96E-51 Rheumatoid arthritis / / 21156761 rs2647046 chr6 32668336 A C 2.00E-06 Lymphoma / / 23349640 rs2647046 chr6 32668336 A C 8.04E-07 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9275372 chr6 32668388 C T 0.00003492 Sarcoidosis / / 22952805 rs9275373 chr6 32668411 G A 1.47E-09 Chronic hepatitis B infection / / 23760081 rs9275374 chr6 32668526 C T 0.00002339 Sarcoidosis / / 22952805 rs9275374 chr6 32668526 C T 9.55E-05 Crohn's disease / / 23266558 rs9275375 chr6 32668632 G A 0.00002339 Sarcoidosis / / 22952805 rs9275376 chr6 32668633 G T 0.00002234 Sarcoidosis / / 22952805 rs2856720 chr6 32668657 C T 7.13E-09 Chronic hepatitis B infection / / 23760081 rs9275377 chr6 32668667 A G 0.00002327 Sarcoidosis / / 22952805 rs2647047 chr6 32668704 C G 6.40E-09 Chronic hepatitis B infection / / 23760081 rs9275378 chr6 32668729 C G 0.00002761 Sarcoidosis / / 22952805 rs9275379 chr6 32668804 C T 0.00002761 Sarcoidosis / / 22952805 rs9275379 chr6 32668804 C T 3.65E-06 Self-reported allergy / / 23817569 rs9275381 chr6 32668819 A C 0.00002093 Sarcoidosis / / 22952805 rs9275383 chr6 32668846 G T 3.28E-69 Type 1 diabetes / / 17632545 rs9275384 chr6 32668898 T C 0.00002339 Sarcoidosis / / 22952805 rs9275384 chr6 32668898 T C 3.24E-06 Self-reported allergy / / 23817569 rs9275385 chr6 32668917 C T 0.00002339 Sarcoidosis / / 22952805 rs9275386 chr6 32668960 A T 0.00002339 Sarcoidosis / / 22952805 rs1612904 chr6 32669018 C A 7.30E-05 Hypothyroidism / / 22493691 rs9275388 chr6 32669084 T C 6.04E-39 Type 1 diabetes / / 17632545 rs9275388 chr6 32669084 T C 0.00002339 Sarcoidosis / / 22952805 rs9275390 chr6 32669156 T C 9.20E-70 Rheumatoid arthritis / / 17804836 rs9275390 chr6 32669156 T C 6.77E-107 Rheumatoid arthritis / / 19503088 rs9275390 chr6 32669156 T C 1.87E-10 Systemic sclerosis / / 20383147 rs9275390 chr6 32669156 T C 1.00E-07 Systemic sclerosis / / 21779181 rs9275390 chr6 32669156 T C 3.00E-54 Systemic sclerosis / / 21779181 rs9275390 chr6 32669156 T C 8.32E-04 Coronary heart disease / / 21971053 rs9275390 chr6 32669156 T C 2.63E-08 Pemphigus vulgaris / / 22437316 rs9275390 chr6 32669156 T C 0.00002339 Sarcoidosis / / 22952805 rs9275390 chr6 32669156 T C 8.88E-05 Crohn's disease / / 23266558 rs9275390 chr6 32669156 T C 5.40E-10 Joint damage severity in rheumatoid arthritis / / 23696630 rs9275390 chr6 32669156 T C 1.26E-05 Self-reported allergy / / 23817569 rs11752643 chr6 32669373 C T 1.26E-10 Hepatitis B / / 21750111 rs11752643 chr6 32669373 C T 5.00E-07 Coronary heart disease / / 21971053 rs11752643 chr6 32669373 C T 9.93E-05 Myocardial infarction / / 24916648 rs9275392 chr6 32669425 A T 0.00002422 Sarcoidosis / / 22952805 rs9275393 chr6 32669439 G A 0.00002339 Sarcoidosis / / 22952805 rs9275393 chr6 32669439 G A 8.69E-05 Crohn's disease / / 23266558 rs9275393 chr6 32669439 G A 2.30E-10 Joint damage severity in rheumatoid arthritis / / 23696630 rs9275393 chr6 32669439 G A 1.30E-05 Self-reported allergy / / 23817569 rs9275396 chr6 32669528 T A 0.00002549 Sarcoidosis / / 22952805 rs9275396 chr6 32669528 T A 4.22E-06 Self-reported allergy / / 23817569 rs9275399 chr6 32669712 A G 0.00002327 Sarcoidosis / / 22952805 rs2647050 chr6 32669767 T C 1.02E-55 Type 1 diabetes / / 17632545 rs2647050 chr6 32669767 T C 4.71E-10 Hepatitis B / / 21750111 rs2647050 chr6 32669767 T C 4.29E-06 Pemphigus vulgaris / / 22437316 rs2647050 chr6 32669767 T C 9.10E-05 Hypothyroidism / / 22493691 rs2647050 chr6 32669767 T C 5.95E-04 Crohn's disease / / 23266558 rs2647050 chr6 32669767 T C 6.12E-10 Chronic hepatitis B infection / / 23760081 rs2647050 chr6 32669767 T C 2.31E-09 Self-reported allergy / / 23817569 rs2647050 chr6 32669767 T C 7.60E-13 Systemic lupus erythematosus / / 24871463 rs2647050 chr6 32669767 T C 5.59E-05 Myocardial infarction / / 24916648 rs9275401 chr6 32669827 C G 0.00002339 Sarcoidosis / / 22952805 rs9275404 chr6 32669878 T C 0.00002339 Sarcoidosis / / 22952805 rs9275405 chr6 32669883 A G 0.00002339 Sarcoidosis / / 22952805 rs9275406 chr6 32669955 G T 0.00002339 Sarcoidosis / / 22952805 rs9275406 chr6 32669955 G T 8.69E-05 Crohn's disease / / 23266558 rs9275406 chr6 32669955 G T 3.00E-12 Rheumatoid arthritis / / 23918589 rs2858308 chr6 32670000 G T 6.25E-40 Multiple complex diseases / / 17554300 rs2858308 chr6 32670000 G T 1.00E-16 Type 1 diabetes / / 17632545 rs2858308 chr6 32670000 G T 3.36E-05 Hepatitis B / / 21750111 rs2858308 chr6 32670000 G T 4.76E-05 Systemic sclerosis / / 21750679 rs2858308 chr6 32670000 G T 7.14E-05 Crohn's disease / / 23266558 rs2858308 chr6 32670000 G T 4.02E-06 Self-reported allergy / / 23817569 rs9275407 chr6 32670037 G T 0.00002339 Sarcoidosis / / 22952805 rs9275407 chr6 32670037 G T 8.69E-05 Crohn's disease / / 23266558 rs9275407 chr6 32670037 G T 5.40E-10 Joint damage severity in rheumatoid arthritis / / 23696630 rs9275407 chr6 32670037 G T 1.30E-05 Self-reported allergy / / 23817569 rs9275408 chr6 32670110 T C 5.47E-39 Type 1 diabetes / / 17632545 rs9275408 chr6 32670110 T C 0.00002339 Sarcoidosis / / 22952805 rs9275408 chr6 32670110 T C 8.14E-05 Crohn's disease / / 23266558 rs9275417 chr6 32670214 A C 0.00002339 Sarcoidosis / / 22952805 rs9275417 chr6 32670214 A C 1.50E-05 Self-reported allergy / / 23817569 rs9275418 chr6 32670244 A G 8.23E-69 Multiple complex diseases / / 17554300 rs9275418 chr6 32670244 A G 6.35E-08 Multiple sclerosis / / 17660530 rs9275418 chr6 32670244 A G 2.15E-10 Narcolepsy / / 19629137 rs9275418 chr6 32670244 A G 3.06E-56 Rheumatoid arthritis / / 21156761 rs9275418 chr6 32670244 A G 0.00002339 Sarcoidosis / / 22952805 rs9275418 chr6 32670244 A G 8.44E-05 Crohn's disease / / 23266558 rs9275418 chr6 32670244 A G 1.29E-05 Self-reported allergy / / 23817569 rs2856718 chr6 32670255 C T 1.59E-55 Type 1 diabetes / / 17632545 rs2856718 chr6 32670255 C T 4.00E-37 Hepatitis B / / 21750111 rs2856718 chr6 32670255 C T 4.29E-06 Pemphigus vulgaris / / 22437316 rs2856718 chr6 32670255 C T 8.50E-05 Hypothyroidism / / 22493691 rs2856718 chr6 32670255 C T 3.99E-37 Hepatocellular carcinoma (hepatitis B virus related) / / 23242368 rs2856718 chr6 32670255 C T 6.26E-04 Crohn's disease / / 23266558 rs2856718 chr6 32670255 C T 2.00E-24 Chronic hepatitis B infection / / 23760081 rs2856718 chr6 32670255 C T 2.31E-09 Self-reported allergy / / 23817569 rs2856718 chr6 32670255 C T 1.10E-12 Systemic lupus erythematosus / / 24871463 rs2856717 chr6 32670308 A G 3.30E-08 Nephropathy / / 21399633 rs2856717 chr6 32670308 A G 1.72E-04 Coronary heart disease / / 21971053 rs2856717 chr6 32670308 A G 0.00000062 Joint damage severity in rheumatoid arthritis / / 23696630 rs2856717 chr6 32670308 A G 2.40E-05 Hodgkin's lymphoma / / 24149102 rs2856717 chr6 32670308 A G 1.70E-07 Leprosy / / pha002872 rs35406540 chr6 32670368 A G 0.0001968 Sarcoidosis / / 22952805 rs66709408 chr6 32670414 C T 0.0001968 Sarcoidosis / / 22952805 rs2858305 chr6 32670464 G T 1.38E-04 Coronary heart disease / / 21971053 rs2858305 chr6 32670464 G T 1.70E-05 Hodgkin's lymphoma / / 24149102 rs2858305 chr6 32670464 G T 1.70E-07 Leprosy / / pha002872 rs9275421 chr6 32670477 C A 0.00002339 Sarcoidosis / / 22952805 rs9275421 chr6 32670477 C A 1.26E-05 Self-reported allergy / / 23817569 rs35120848 chr6 32670495 C T 1.83E-05 Multiple complex diseases / / 17554300 rs35120848 chr6 32670495 C T 1.92E-06 Non-obstructive azoospermia / / 22541561 rs35120848 chr6 32670495 C T 0.0001968 Sarcoidosis / / 22952805 rs9275423 chr6 32670564 G T 0.00002412 Sarcoidosis / / 22952805 rs9275423 chr6 32670564 G T 1.26E-05 Self-reported allergy / / 23817569 rs9275424 chr6 32670576 A G 1.70E-08 Nephropathy / / 21399633 rs9275424 chr6 32670576 A G 0.00002412 Sarcoidosis / / 22952805 rs9275424 chr6 32670576 A G 8.69E-05 Crohn's disease / / 23266558 rs9275424 chr6 32670576 A G 1.26E-05 Self-reported allergy / / 23817569 rs9275425 chr6 32670874 C A 0.00001373 Sarcoidosis / / 22952805 rs9275425 chr6 32670874 C A 8.60E-05 Crohn's disease / / 23266558 rs9275425 chr6 32670874 C A 6.60E-06 Self-reported allergy / / 23817569 rs9275427 chr6 32670915 C T 0.00002339 Sarcoidosis / / 22952805 rs9275427 chr6 32670915 C T 8.41E-05 Crohn's disease / / 23266558 rs9275427 chr6 32670915 C T 8.44E-06 Self-reported allergy / / 23817569 rs2856705 chr6 32670956 C T 2.22E-16 Type 1 diabetes / / 17632545 rs2856705 chr6 32670956 C T 4.34E-20 Rheumatoid arthritis / / 17804836 rs2856705 chr6 32670956 C T 7.34E-28 Rheumatoid arthritis / / 19503088 rs2856705 chr6 32670956 C T 3.71E-14 Systemic sclerosis / / 20383147 rs2856705 chr6 32670956 C T 3.47E-05 Hepatitis B / / 21750111 rs2856705 chr6 32670956 C T 4.76E-05 Systemic sclerosis / / 21750679 rs2856705 chr6 32670956 C T 7.03E-05 Crohn's disease / / 23266558 rs2856705 chr6 32670956 C T 4.19E-06 Self-reported allergy / / 23817569 rs9275428 chr6 32670978 A G 0.00002207 Sarcoidosis / / 22952805 rs9275428 chr6 32670978 A G 8.60E-05 Crohn's disease / / 23266558 rs9275428 chr6 32670978 A G 5.30E-10 Joint damage severity in rheumatoid arthritis / / 23696630 rs9275428 chr6 32670978 A G 1.30E-05 Self-reported allergy / / 23817569 rs2856704 chr6 32671014 C A 5.75E-09 Chronic hepatitis B infection / / 23760081 rs13192471 chr6 32671103 T C 2.00E-58 Rheumatoid arthritis / / 20453841 rs13192471 chr6 32671103 T C 5.38E-04 Parkinson's disease / / 21248740 rs13192471 chr6 32671103 T C 1.81E-05 Systemic sclerosis / / 21750679 rs13192471 chr6 32671103 T C 0.0001968 Sarcoidosis / / 22952805 rs13192471 chr6 32671103 T C 5.67E-08 Crohn's disease / / 23266558 rs13192471 chr6 32671103 T C 3.82E-09 Self-reported allergy / / 23817569 rs9275431 chr6 32671140 G A 0.00002536 Sarcoidosis / / 22952805 rs9275431 chr6 32671140 G A 3.01E-05 Self-reported allergy / / 23817569 rs9275432 chr6 32671185 G T 0.00002163 Sarcoidosis / / 22952805 rs9275432 chr6 32671185 G T 4.53E-05 Self-reported allergy / / 23817569 rs9275433 chr6 32671206 G C 0.00002163 Sarcoidosis / / 22952805 rs1794275 chr6 32671248 G A 3.00E-13 IgA nephropathy / / 22197929 rs1794275 chr6 32671248 G A 3.02E-14 Self-reported allergy / / 23817569 rs9275436 chr6 32671399 C G 0.00001669 Sarcoidosis / / 22952805 rs9275436 chr6 32671399 C G 2.43E-05 Self-reported allergy / / 23817569 rs9275438 chr6 32671508 C T 0.00001887 Sarcoidosis / / 22952805 rs9275438 chr6 32671508 C T 3.86E-05 Self-reported allergy / / 23817569 rs9275439 chr6 32671521 T C 0.00002339 Sarcoidosis / / 22952805 rs9275439 chr6 32671521 T C 8.69E-05 Crohn's disease / / 23266558 rs9275439 chr6 32671521 T C 2.10E-10 Joint damage severity in rheumatoid arthritis / / 23696630 rs9275439 chr6 32671521 T C 3.85E-05 Self-reported allergy / / 23817569 rs9275440 chr6 32671596 C T 0.00002339 Sarcoidosis / / 22952805 rs28451714 chr6 32671601 G T 0.0002401 Sarcoidosis / / 22952805 rs9275441 chr6 32671676 C A 0.00002412 Sarcoidosis / / 22952805 rs9275441 chr6 32671676 C A 3.63E-05 Self-reported allergy / / 23817569 rs9275464 chr6 32672082 A G 0.00002653 Sarcoidosis / / 22952805 rs17499655 chr6 32672135 C T 0.0001968 Sarcoidosis / / 22952805 rs4568495 chr6 32672246 A C 0.00002327 Sarcoidosis / / 22952805 rs4568494 chr6 32672361 A G 0.000207 Sarcoidosis / / 22952805 rs1794529 chr6 32672383 G C 1.25E-06 Self-reported allergy / / 23817569 rs9275468 chr6 32672412 G A 0.00002456 Sarcoidosis / / 22952805 rs9275468 chr6 32672412 G A 2.29E-05 Self-reported allergy / / 23817569 rs9275469 chr6 32672430 A G 0.0000246 Sarcoidosis / / 22952805 rs9275471 chr6 32672491 G A 0.0000246 Sarcoidosis / / 22952805 rs9275472 chr6 32672494 G A 0.0000246 Sarcoidosis / / 22952805 rs9275473 chr6 32672523 C T 0.0000246 Sarcoidosis / / 22952805 rs9275474 chr6 32672529 C T 0.0000246 Sarcoidosis / / 22952805 rs9275475 chr6 32672556 A G 0.00002327 Sarcoidosis / / 22952805 rs9275478 chr6 32672654 G T 0.00002436 Sarcoidosis / / 22952805 rs9275479 chr6 32672659 C T 0.00002436 Sarcoidosis / / 22952805 rs9275480 chr6 32672668 G A 0.00002436 Sarcoidosis / / 22952805 rs35030589 chr6 32672903 G A 0.0002249 Sarcoidosis / / 22952805 rs9275481 chr6 32672913 T A 0.0000246 Sarcoidosis / / 22952805 rs9275482 chr6 32672932 G T 0.0000246 Sarcoidosis / / 22952805 rs9275482 chr6 32672932 G T 4.07E-05 Self-reported allergy / / 23817569 rs9275483 chr6 32673051 T C 0.00002327 Sarcoidosis / / 22952805 rs9275485 chr6 32673077 G A 0.0000246 Sarcoidosis / / 22952805 rs9275488 chr6 32673269 G A 0.00002537 Sarcoidosis / / 22952805 rs9275489 chr6 32673272 C T 0.00002537 Sarcoidosis / / 22952805 rs9275491 chr6 32673424 C T 0.00002378 Sarcoidosis / / 22952805 rs9275492 chr6 32673446 C T 0.00001002 Sarcoidosis / / 22952805 rs9275492 chr6 32673446 C T 1.30E-05 Self-reported allergy / / 23817569 rs9275494 chr6 32673479 G C 0.000004839 Sarcoidosis / / 22952805 rs112214454 chr6 32673569 A G 0.0002141 Sarcoidosis / / 22952805 rs9275495 chr6 32673574 A T 0.00000002 Joint damage severity in rheumatoid arthritis / / 23696630 rs9275496 chr6 32673714 T C 0.00001904 Sarcoidosis / / 22952805 rs9275497 chr6 32673726 A G 0.00008188 Sarcoidosis / / 22952805 rs71565343 chr6 32673729 T C 8.44E-09 Sarcoidosis / / 22952805 rs9275501 chr6 32673920 C T 0.00002916 Sarcoidosis / / 22952805 rs9275502 chr6 32673921 A G 0.00003158 Sarcoidosis / / 22952805 rs71565345 chr6 32673968 C G 3.56E-08 Sarcoidosis / / 22952805 rs9275504 chr6 32673986 C T 0.00002464 Sarcoidosis / / 22952805 rs9275507 chr6 32674130 G A 0.00001883 Sarcoidosis / / 22952805 rs9275508 chr6 32674159 C G 0.00002411 Sarcoidosis / / 22952805 rs9275516 chr6 32674643 A G 3.14E-55 Rheumatoid arthritis / / 21156761 rs9275517 chr6 32674649 A G 4.02E-58 Rheumatoid arthritis / / 21156761 rs9275517 chr6 32674649 A G 4.03E-11 Follicular lymphoma / / 23025665 rs9275517 chr6 32674649 A G 1.92E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1794265 chr6 32674737 C A,G,T 1.00E-06 IgG glycosylation / / 23382691 rs1794265 chr6 32674737 C A,G,T 3.00E-07 IgG glycosylation / / 23382691 rs1794265 chr6 32674737 C A,G,T 8.00E-06 IgG glycosylation / / 23382691 rs9275521 chr6 32674952 T C 8.14E-53 Rheumatoid arthritis / / 21156761 rs9275521 chr6 32674952 T C 1.28E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9275522 chr6 32674970 C T 2.22E-62 Rheumatoid arthritis / / 21156761 rs9275522 chr6 32674970 C T 2.33E-05 Self-reported allergy / / 23817569 rs9275523 chr6 32674994 C A 2.27E-82 Multiple complex diseases / / 17554300 rs9275523 chr6 32674994 C A 9.69E-07 Multiple sclerosis / / 17660530 rs9275523 chr6 32674994 C A 2.22E-62 Rheumatoid arthritis / / 21156761 rs17206350 chr6 32675067 T C 3.73E-06 Hepatitis B / / 24162738 rs9275524 chr6 32675109 T C 3.55E-58 Rheumatoid arthritis / / 21156761 rs9275524 chr6 32675109 T C 2.00E-07 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs9275524 chr6 32675109 T C 2.09E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs12525220 chr6 32675470 G A 2.00E-13 Rheumatoid arthritis / / 24782177 rs12525220 chr6 32675470 G A 3.00E-12 Rheumatoid arthritis / / 24782177 rs12525220 chr6 32675470 G A 7.00E-14 Rheumatoid arthritis / / 24782177 rs9275530 chr6 32675523 G C 0.00000002 Joint damage severity in rheumatoid arthritis / / 23696630 rs9275532 chr6 32675634 C G 0.00000002 Joint damage severity in rheumatoid arthritis / / 23696630 rs9275555 chr6 32677088 C T 2.54E-42 Type 1 diabetes / / 17632545 rs9275555 chr6 32677088 C T 2.04E-61 Rheumatoid arthritis / / 21156761 rs9275555 chr6 32677088 C T 2.83E-05 Self-reported allergy / / 23817569 rs16898264 chr6 32677152 G A 3.06E-55 Type 1 diabetes / / 17632545 rs16898264 chr6 32677152 G A 8.74E-06 Alopecia areata / / 22027810 rs16898264 chr6 32677152 G A 2.33E-09 Self-reported allergy / / 23817569 rs16898262 chr6 32677397 A G 1.59E-06 Self-reported allergy / / 23817569 rs10947332 chr6 32677440 G A 2.56E-09 Self-reported allergy / / 23817569 rs536833125 chr6 32677669 C T 3.28E-58 Rheumatoid arthritis / / 21156761 rs536833125 chr6 32677669 C T 2.11E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9275561 chr6 32677789 C T 7.49E-63 Rheumatoid arthritis / / 21156761 rs9275561 chr6 32677789 C T 2.63E-05 Self-reported allergy / / 23817569 rs4947344 chr6 32677846 T C 0.00006106 Sarcoidosis / / 22952805 rs9275563 chr6 32677912 C T 2.30E-06 Hypothyroidism / / 22493691 rs9275563 chr6 32677912 C T 0.0003085 Sarcoidosis / / 22952805 rs9275563 chr6 32677912 C T 1.63E-04 Crohn's disease / / 23266558 rs9275563 chr6 32677912 C T 6.00E-11 Multiple sclerosis (OCB status) / / 23472185 rs9275565 chr6 32677938 T C 2.09E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9275566 chr6 32678087 T A 7.49E-63 Rheumatoid arthritis / / 21156761 rs3998157 chr6 32678477 C A 3.28E-58 Rheumatoid arthritis / / 21156761 rs3998157 chr6 32678477 C A 2.09E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs4273729 chr6 32678597 C G 3.28E-58 Rheumatoid arthritis / / 21156761 rs4273729 chr6 32678597 C G 5.00E-17 Chronic Hepatitis C infection / / 23420232 rs17581326 chr6 32678753 A G 1.61E-09 Self-reported allergy / / 23817569 rs3135191 chr6 32678896 C A 2.22E-06 Self-reported allergy / / 23817569 rs9275572 chr6 32678999 A G 1.58E-67 Multiple complex diseases / / 17554300 rs9275572 chr6 32678999 A G 1.74E-20 Multiple sclerosis / / 17660530 rs9275572 chr6 32678999 A G 2.61E-82 Rheumatoid arthritis / / 17804836 rs9275572 chr6 32678999 A G 7.00E-48 Systemic lupus erythematosus / / 18204446 rs9275572 chr6 32678999 A G 1.14E-33 Narcolepsy / / 19629137 rs9275572 chr6 32678999 A G 4.92E-05 HIV-1 control / / 20041166 rs9275572 chr6 32678999 A G 1.00E-35 Alopecia areata / / 20596022 rs9275572 chr6 32678999 A G 5.99E-58 Rheumatoid arthritis / / 21156761 rs9275572 chr6 32678999 A G 6.00E-09 Hepatocellular carcinoma / / 21499248 rs9275572 chr6 32678999 A G 8.43E-07 Follicular lymphoma / / 21533074 rs9275572 chr6 32678999 A G 1.87E-08 Alopecia areata / / 22027810 rs9275572 chr6 32678999 A G 5.97E-09 Hepatocellular carcinoma (hepatitis B virus related) / / 23242368 rs9275572 chr6 32678999 A G 1.38E-09 Crohn's disease / / 23266558 rs9275572 chr6 32678999 A G 1.51E-05 Hodgkin's lymphoma / / 24149102 rs9275572 chr6 32678999 A G 4.00E-16 Chronic hepatitis C infection / / 24376798 rs9275572 chr6 32678999 A G 5.00E-16 Systemic lupus erythematosus / / 24871463 rs9275572 chr6 32678999 A G 2.45E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9275572 chr6 32678999 A G 1.37E-09 Systemic lupus erythematosus / / pha002867 rs17427887 chr6 32679107 G T 1.68E-04 Self-reported allergy / / 23817569 rs9275573 chr6 32679146 C G 3.28E-58 Rheumatoid arthritis / / 21156761 rs9275576 chr6 32679326 C T 8.74E-13 Rheumatoid arthritis / / 21156761 rs9275576 chr6 32679326 C T 8.33E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9275578 chr6 32679384 G T 3.07E-63 Rheumatoid arthritis / / 21156761 rs9275578 chr6 32679384 G T 8.40E-10 Joint damage severity in rheumatoid arthritis / / 23696630 rs9275578 chr6 32679384 G T 2.39E-05 Self-reported allergy / / 23817569 rs9275580 chr6 32679462 A G 1.80E-10 Joint damage severity in rheumatoid arthritis / / 23696630 rs9275580 chr6 32679462 A G 2.34E-05 Self-reported allergy / / 23817569 rs12203586 chr6 32679591 G C 3.00E-09 Self-reported allergy / / 23817569 rs12203586 chr6 32679591 G C 5.74E-12 Psoriasis / / pha002855 rs3129727 chr6 32679690 C T 4.71E-04 Crohn's disease / / 23266558 rs3129727 chr6 32679690 C T 1.63E-06 Self-reported allergy / / 23817569 rs2647083 chr6 32679722 C G 2.94E-09 Self-reported allergy / / 23817569 rs9275582 chr6 32680070 C T 5.00E-06 Smoking behavior / / 20418888 rs9275582 chr6 32680070 C T 2.13E-63 Rheumatoid arthritis / / 21156761 rs9275582 chr6 32680070 C T 8.40E-10 Joint damage severity in rheumatoid arthritis / / 23696630 rs9275582 chr6 32680070 C T 2.13E-05 Self-reported allergy / / 23817569 rs3129728 chr6 32680149 G A 1.43E-06 Self-reported allergy / / 23817569 rs9391744 chr6 32680227 C T 6.31E-05 IgE levels / / 22075330 rs9391744 chr6 32680227 C T 1.69E-06 Self-reported allergy / / 23817569 rs3129729 chr6 32680277 A C 1.94E-06 Self-reported allergy / / 23817569 rs9275585 chr6 32680350 T C 3.56E-63 Rheumatoid arthritis / / 21156761 rs9275585 chr6 32680350 T C 1.52E-05 Self-reported allergy / / 23817569 rs9275588 chr6 32680423 G A 9.61E-23 Rheumatoid arthritis / / 21156761 rs9275590 chr6 32680480 T C 3.56E-63 Rheumatoid arthritis / / 21156761 rs9275590 chr6 32680480 T C 1.61E-05 Self-reported allergy / / 23817569 rs7764819 chr6 32680576 T G 4.00E-09 Pulmonary function (interaction) / / 23284291 rs7764819 chr6 32680576 T G 4.00E-09 Pulmonary function (interaction) / / 23284291 rs17581425 chr6 32680585 T C 6.35E-05 IgE levels / / 22075330 rs17581425 chr6 32680585 T C 1.72E-06 Self-reported allergy / / 23817569 rs9275592 chr6 32680620 G T 1.16E-53 Rheumatoid arthritis / / 21156761 rs7764856 chr6 32680640 T A 0.00001287 Sarcoidosis / / 22952805 rs7764856 chr6 32680640 T A 8.00E-10 Joint damage severity in rheumatoid arthritis / / 23696630 rs9275593 chr6 32680843 G A 3.02E-63 Rheumatoid arthritis / / 21156761 rs9275593 chr6 32680843 G A 1.70E-05 Self-reported allergy / / 23817569 rs7765379 chr6 32680928 T G 5.32E-08 Type 1 diabetes / / 17632545 rs7765379 chr6 32680928 T G 5.00E-23 Rheumatoid arthritis / / 21452313 rs7765379 chr6 32680928 T G 9.00E-59 Crohn's disease / / 23266558 rs7745656 chr6 32680970 G T 3.60E-44 Type 1 diabetes / / 17632545 rs7745656 chr6 32680970 G T 5.02E-28 Rheumatoid arthritis / / 17804836 rs7745656 chr6 32680970 G T 7.51E-51 Rheumatoid arthritis / / 19503088 rs7745656 chr6 32680970 G T 1.26E-05 Hepatitis B / / 21750111 rs7745656 chr6 32680970 G T 6.41E-05 IgE levels / / 22075330 rs7745656 chr6 32680970 G T 5.28E-05 Pemphigus vulgaris / / 22437316 rs7745656 chr6 32680970 G T 1.53E-04 Crohn's disease / / 23266558 rs7745656 chr6 32680970 G T 2.22E-06 Self-reported allergy / / 23817569 rs7745656 chr6 32680970 G T 1.30E-08 Systemic lupus erythematosus / / 24871463 rs7745656 chr6 32680970 G T 3.18E-161 Type 1 diabetes / / pha002862 rs2647087 chr6 32681049 A C 1.21E-08 Psoriasis risk prediction / / 21214922 rs2647087 chr6 32681049 A C 6.39E-05 IgE levels / / 22075330 rs2647087 chr6 32681049 A C 2.22E-06 Self-reported allergy / / 23817569 rs2647087 chr6 32681049 A C 1.87E-16 Psoriasis / / pha002855 rs2858333 chr6 32681085 A G 1.23E-08 Psoriasis risk prediction / / 21214922 rs2858333 chr6 32681085 A G 6.38E-05 IgE levels / / 22075330 rs2858333 chr6 32681085 A G 2.22E-06 Self-reported allergy / / 23817569 rs2858333 chr6 32681085 A G 8.55E-16 Psoriasis / / pha002855 rs2858332 chr6 32681161 G T 2.27E-06 HIV-1 control / / 20041166 rs2858332 chr6 32681161 G T 1.57E-10 Crohn's disease / / 23266558 rs2858331 chr6 32681277 A G 5.32E-45 Type 1 diabetes / / 17632545 rs2858331 chr6 32681277 A G 3.92E-06 Rheumatoid arthritis / / 17804836 rs2858331 chr6 32681277 A G 2.17E-09 Crohn's disease / / 18587394 rs2858331 chr6 32681277 A G 6.70E-16 Rheumatoid arthritis / / 19503088 rs2858331 chr6 32681277 A G 2.52E-05 HIV-1 control / / 20041166 rs2858331 chr6 32681277 A G 1.09E-04 Follicular lymphoma / / 21533074 rs2858331 chr6 32681277 A G 1.00E-08 IgE levels / / 22075330 rs2858331 chr6 32681277 A G 3.95E-10 Pemphigus vulgaris / / 22437316 rs2858331 chr6 32681277 A G 6.00E-06 IgE levels / / 23146381 rs2858331 chr6 32681277 A G 2.02E-07 Crohn's disease / / 23266558 rs2858331 chr6 32681277 A G 8.60E-11 Systemic lupus erythematosus / / 24871463 rs2858331 chr6 32681277 A G 3.49E-160 Type 1 diabetes / / pha002862 rs9275595 chr6 32681355 T C 1.72E-41 Type 1 diabetes / / 17632545 rs9275595 chr6 32681355 T C 1.69E-62 Rheumatoid arthritis / / 21156761 rs9275595 chr6 32681355 T C 1.47E-05 Self-reported allergy / / 23817569 rs7454108 chr6 32681483 T C 8.78E-54 Rheumatoid arthritis / / 21156761 rs7454108 chr6 32681483 T C 0.00000002 Joint damage severity in rheumatoid arthritis / / 23696630 rs2647088 chr6 32681518 A G 6.42E-05 IgE levels / / 22075330 rs2647088 chr6 32681518 A G 2.32E-06 Self-reported allergy / / 23817569 rs3957146 chr6 32681530 T C 5.13E-78 Multiple complex diseases / / 17554300 rs3957146 chr6 32681530 T C 8.78E-54 Rheumatoid arthritis / / 21156761 rs3957146 chr6 32681530 T C 0.00000002 Joint damage severity in rheumatoid arthritis / / 23696630 rs2647089 chr6 32681568 T C 6.42E-05 IgE levels / / 22075330 rs2647089 chr6 32681568 T C 2.41E-06 Self-reported allergy / / 23817569 rs9275596 chr6 32681631 C T 2.05E-08 Type 1 diabetes / / 17632545 rs9275596 chr6 32681631 C T 7.82E-46 Rheumatoid arthritis / / 21156761 rs9275596 chr6 32681631 C T 2.00E-26 Nephropathy / / 21399633 rs9275596 chr6 32681631 C T 1.70E-06 Hepatitis B / / 21750111 rs9275596 chr6 32681631 C T 2.43E-06 Coronary heart disease / / 21971053 rs9275596 chr6 32681631 C T 6.40E-05 Hypothyroidism / / 22493691 rs9275596 chr6 32681631 C T 3.22E-05 Hodgkin's lymphoma / / 24149102 rs9275596 chr6 32681631 C T 2.01E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9275596 chr6 32681631 C T 1.21E-07 Leprosy / / pha002872 rs3916766 chr6 32681645 T A 6.42E-05 IgE levels / / 22075330 rs3916766 chr6 32681645 T A 2.42E-06 Self-reported allergy / / 23817569 rs6935723 chr6 32681669 T C 6.81E-05 IgE levels / / 22075330 rs6935723 chr6 32681669 T C 2.96E-06 Self-reported allergy / / 23817569 rs3104402 chr6 32681676 T G 1.00E-16 Type 1 diabetes / / 17632545 rs3104402 chr6 32681676 T G 5.83E-06 Parkinson's disease (motor and cognition) / / 22658654 rs3104402 chr6 32681676 T G 6.00E-06 Immune response to anthrax vaccine / / 22658931 rs3129730 chr6 32681839 A G 4.00E-09 Self-reported allergy / / 23817569 rs3998158 chr6 32681992 T C 2.30E-10 Joint damage severity in rheumatoid arthritis / / 23696630 rs3998158 chr6 32681992 T C 2.18E-05 Self-reported allergy / / 23817569 rs3998159 chr6 32682019 A C 3.38E-52 Rheumatoid arthritis / / 21156761 rs3998159 chr6 32682019 A C 1.06E-05 Parkinson's disease / / 21738487 rs3998159 chr6 32682019 A C 0.00000004 Joint damage severity in rheumatoid arthritis / / 23696630 rs3957148 chr6 32682137 A G 1.20E-66 Type 1 diabetes / / 17632545 rs3957148 chr6 32682137 A G 8.83E-06 Parkinson's disease / / 21738487 rs3957148 chr6 32682137 A G 6.40E-05 IgE levels / / 22075330 rs3957148 chr6 32682137 A G 0.00000001 Joint damage severity in rheumatoid arthritis / / 23696630 rs3104404 chr6 32682174 C A 1.99E-79 Multiple complex diseases / / 17554300 rs3104404 chr6 32682174 C A 3.11E-12 Narcolepsy / / 19629137 rs3104404 chr6 32682174 C A 2.63E-07 Hepatitis B / / 21750111 rs3104405 chr6 32682308 C A 1.81E-06 Hepatitis B / / 21750111 rs3104405 chr6 32682308 C A 6.30E-05 Hypothyroidism / / 22493691 rs3104405 chr6 32682308 C A 7.69E-07 Self-reported allergy / / 23817569 rs3104405 chr6 32682308 C A 3.47E-06 Leprosy / / pha002872 rs3997848 chr6 32682394 T G 1.41E-05 Self-reported allergy / / 23817569 rs3997849 chr6 32682402 C T 1.19E-05 Self-reported allergy / / 23817569 rs9275599 chr6 32682429 C T 0.00000033 Joint damage severity in rheumatoid arthritis / / 23696630 rs3873444 chr6 32682724 C T 1.06E-18 Rheumatoid arthritis / / 17804836 rs3873444 chr6 32682724 C T 1.61E-33 Rheumatoid arthritis / / 19503088 rs9275602 chr6 32682812 C A 5.62E-12 Type 1 diabetes / / 17632545 rs9275602 chr6 32682812 C A 9.06E-04 Self-reported allergy / / 23817569 rs3892710 chr6 32682862 C T 1.00E-16 Type 1 diabetes / / 17632545 rs3892710 chr6 32682862 C T 2.30E-07 Rheumatoid arthritis / / 17804836 rs3892710 chr6 32682862 C T 3.21E-10 Rheumatoid arthritis / / 19503088 rs3892710 chr6 32682862 C T 3.95E-04 Hepatitis B / / 21750111 rs3892710 chr6 32682862 C T 2.77E-12 Coronary heart disease / / 21971053 rs3892710 chr6 32682862 C T 3.39E-09 Pemphigus vulgaris / / 22437316 rs3873448 chr6 32683055 C T 0.0005601 Sarcoidosis / / 22952805 rs6936863 chr6 32684029 C G 1.17E-87 Multiple complex diseases / / 17554300 rs6936863 chr6 32684029 C G 3.20E-13 Narcolepsy / / 19629137 rs9275614 chr6 32684257 A G 1.51E-29 Rheumatoid arthritis / / 21156761 rs9275615 chr6 32684272 T A 3.90E-30 Rheumatoid arthritis / / 21156761 rs9275615 chr6 32684272 T A 4.14E-04 Alzheimer's disease (late onset) / / 21379329 rs6916779 chr6 32684317 T C 3.90E-30 Rheumatoid arthritis / / 21156761 rs5024431 chr6 32684344 G A 0.0000559 Sarcoidosis / / 22952805 rs5024432 chr6 32684468 C T 2.43E-05 Self-reported allergy / / 23817569 rs3916765 chr6 32685550 G A 5.19E-92 Multiple complex diseases / / 17554300 rs3916765 chr6 32685550 G A 1.72E-33 Rheumatoid arthritis / / 17804836 rs3916765 chr6 32685550 G A 7.53E-61 Rheumatoid arthritis / / 19503088 rs3916765 chr6 32685550 G A 1.16E-29 Rheumatoid arthritis / / 21156761 rs3916765 chr6 32685550 G A 1.95E-04 Alzheimer's disease (late onset) / / 21379329 rs3916765 chr6 32685550 G A 4.50E-04 Coronary heart disease / / 21971053 rs3916765 chr6 32685550 G A 9.54E-05 Lymphocyte counts / / 22286170 rs3916765 chr6 32685550 G A 3.39E-17 Pemphigus vulgaris / / 22437316 rs3916765 chr6 32685550 G A 1.00E-06 Type 2 diabetes / / 22693455 rs3104398 chr6 32685685 G A 2.81E-07 Systemic sclerosis / / 20383147 rs3104398 chr6 32685685 G A 3.19E-05 Crohn's disease / / 23266558 rs3104398 chr6 32685685 G A 5.10E-05 Waist Circumference / / pha003023 rs9275652 chr6 32685822 G C 4.57E-17 Rheumatoid arthritis / / 21156761 rs9275653 chr6 32685865 G A 2.54E-10 Type 1 diabetes / / 17632545 rs9275653 chr6 32685865 G A 4.33E-04 Crohn's disease / / 23266558 rs3104399 chr6 32685911 T A 6.64E-08 Chronic hepatitis B infection / / 23760081 rs3129736 chr6 32685953 C T 4.80E-09 Rheumatoid arthritis / / 21156761 rs12177980 chr6 32686084 G A 1.00E-16 Type 1 diabetes / / 17632545 rs12177980 chr6 32686084 G A 1.39E-08 Rheumatoid arthritis / / 17804836 rs12177980 chr6 32686084 G A 6.86E-12 Rheumatoid arthritis / / 19503088 rs12177980 chr6 32686084 G A 5.87E-92 Type 1 diabetes / / pha002862 rs9275659 chr6 32686103 C A,G,T 2.23E-18 Rheumatoid arthritis / / 21156761 rs9275686 chr6 32687570 G A 3.28E-17 Rheumatoid arthritis / / 21156761 rs9275690 chr6 32687720 G A 4.57E-17 Rheumatoid arthritis / / 21156761 rs9275698 chr6 32687973 A G 3.12E-24 Rheumatoid arthritis / / 21156761 rs9275698 chr6 32687973 A G 5.00E-12 Asthma / / 21804548 rs9275716 chr6 32688302 T C 2.93E-09 Rheumatoid arthritis / / 21156761 rs9275738 chr6 32688839 C T 4.57E-17 Rheumatoid arthritis / / 21156761 rs9275741 chr6 32688872 G A 4.57E-17 Rheumatoid arthritis / / 21156761 rs9275765 chr6 32689324 A T 4.46E-57 Multiple complex diseases / / 17554300 rs9275765 chr6 32689324 A T 3.30E-21 Multiple sclerosis / / 17660530 rs9275765 chr6 32689324 A T 2.93E-09 Rheumatoid arthritis / / 21156761 rs9275772 chr6 32689503 T C 8.17E-57 Multiple complex diseases / / 17554300 rs9275772 chr6 32689503 T C 7.53E-22 Multiple sclerosis / / 17660530 rs9275772 chr6 32689503 T C 2.93E-09 Rheumatoid arthritis / / 21156761 rs9461799 chr6 32689529 T C 8.82E-62 Multiple complex diseases / / 17554300 rs9461799 chr6 32689529 T C 1.00E-16 Type 1 diabetes / / 17632545 rs9461799 chr6 32689529 T C 3.86E-13 Multiple sclerosis / / 17660530 rs9461799 chr6 32689529 T C 1.42E-08 Rheumatoid arthritis / / 17804836 rs9461799 chr6 32689529 T C 9.09E-12 Rheumatoid arthritis / / 19503088 rs9461799 chr6 32689529 T C 2.28E-13 Narcolepsy / / 19629137 rs9461799 chr6 32689529 T C 4.85E-92 Type 1 diabetes / / pha002862 rs9469240 chr6 32690001 C T 8.12E-61 Multiple complex diseases / / 17554300 rs9469240 chr6 32690001 C T 7.16E-13 Multiple sclerosis / / 17660530 rs9469240 chr6 32690001 C T 2.18E-12 Narcolepsy / / 19629137 rs9275793 chr6 32690027 G A 9.91E-57 Multiple complex diseases / / 17554300 rs9275793 chr6 32690027 G A 3.13E-21 Multiple sclerosis / / 17660530 rs9275793 chr6 32690027 G A 2.93E-09 Rheumatoid arthritis / / 21156761 rs763026 chr6 32691745 C T 1.37E-17 Rheumatoid arthritis / / 21156761 rs9275936 chr6 32692933 G A 1.37E-17 Rheumatoid arthritis / / 21156761 rs9275970 chr6 32693615 T C 1.37E-17 Rheumatoid arthritis / / 21156761 rs9276013 chr6 32694724 T A 4.27E-09 Rheumatoid arthritis / / 21156761 rs9276014 chr6 32694738 T C 4.27E-09 Rheumatoid arthritis / / 21156761 rs5029394 chr6 32695082 A G 4.27E-09 Rheumatoid arthritis / / 21156761 rs5029393 chr6 32695168 G A 4.32E-09 Rheumatoid arthritis / / 21156761 rs9276132 chr6 32697755 A G 1.37E-17 Rheumatoid arthritis / / 21156761 rs2859113 chr6 32697785 C G 6.00E-08 IgG glycosylation / / 23382691 rs9276149 chr6 32698156 C T 1.37E-17 Rheumatoid arthritis / / 21156761 rs9276160 chr6 32698421 T C 5.05E-09 Rheumatoid arthritis / / 21156761 rs9276162 chr6 32698457 G A 4.69E-10 Type 1 diabetes / / 17632545 rs9276162 chr6 32698457 G A 4.50E-09 Rheumatoid arthritis / / 21156761 rs9276162 chr6 32698457 G A 5.78E-09 Hepatitis B / / 21750111 rs7771946 chr6 32698800 C T 5.05E-09 Rheumatoid arthritis / / 21156761 rs7751699 chr6 32698899 G A 3.89E-09 Rheumatoid arthritis / / 21156761 rs7751699 chr6 32698899 G A 6.39E-08 Chronic hepatitis B infection / / 23760081 rs9276171 chr6 32698918 A G 7.23E-18 Rheumatoid arthritis / / 21156761 rs9276172 chr6 32698947 G C 1.37E-17 Rheumatoid arthritis / / 21156761 rs7751842 chr6 32698960 C A 5.05E-09 Rheumatoid arthritis / / 21156761 rs2859102 chr6 32699054 G C 3.89E-09 Rheumatoid arthritis / / 21156761 rs9276180 chr6 32699116 T C 5.05E-09 Rheumatoid arthritis / / 21156761 rs9276181 chr6 32699125 G C 5.05E-09 Rheumatoid arthritis / / 21156761 rs9276185 chr6 32699179 A C 5.05E-09 Rheumatoid arthritis / / 21156761 rs9276186 chr6 32699197 G A 5.05E-09 Rheumatoid arthritis / / 21156761 rs9276190 chr6 32699350 C T 1.37E-17 Rheumatoid arthritis / / 21156761 rs2859099 chr6 32699515 C T 2.94E-06 Crohn's disease / / 23266558 rs2858884 chr6 32700083 A C 3.00E-08 Narcolepsy / / 20711174 rs2858884 chr6 32700083 A C 1.37E-17 Rheumatoid arthritis / / 21156761 rs9276227 chr6 32700684 C T 1.22E-10 Multiple complex diseases / / 17554300 rs9276228 chr6 32700700 T C 6.36E-09 Rheumatoid arthritis / / 21156761 rs2859090 chr6 32700833 G A 2.65E-09 Multiple complex diseases / / 17554300 rs2859090 chr6 32700833 G A 1.37E-17 Rheumatoid arthritis / / 21156761 rs9276239 chr6 32701083 G C 7.05E-09 Rheumatoid arthritis / / 21156761 rs9276240 chr6 32701098 T G 7.05E-09 Rheumatoid arthritis / / 21156761 rs2859078 chr6 32702449 A G 8.33E-20 Rheumatoid arthritis / / 21156761 rs2859078 chr6 32702449 A G 6.49E-05 Crohn's disease / / 23266558 rs9276278 chr6 32702470 C T 9.07E-09 Rheumatoid arthritis / / 21156761 rs9276279 chr6 32702498 C T 4.78E-09 Rheumatoid arthritis / / 21156761 rs9276279 chr6 32702498 C T 5.20E-08 Chronic hepatitis B infection / / 23760081 rs9276280 chr6 32702527 C T 9.07E-09 Rheumatoid arthritis / / 21156761 rs2859077 chr6 32702562 A G 9.07E-09 Rheumatoid arthritis / / 21156761 rs2859076 chr6 32702586 T A 4.94E-18 Rheumatoid arthritis / / 21156761 rs9276287 chr6 32702745 A C 9.07E-09 Rheumatoid arthritis / / 21156761 rs9276288 chr6 32702769 G C 9.07E-09 Rheumatoid arthritis / / 21156761 rs9276291 chr6 32702813 T C 7.21E-10 Type 1 diabetes / / 17632545 rs9276291 chr6 32702813 T C 9.49E-09 Rheumatoid arthritis / / 21156761 rs9276291 chr6 32702813 T C 7.70E-05 Coronary heart disease / / 21971053 rs9276295 chr6 32702891 A G 1.60E-08 Rheumatoid arthritis / / 21156761 rs9276296 chr6 32702930 C T 1.56E-08 Rheumatoid arthritis / / 21156761 rs9276297 chr6 32702946 G C 1.41E-08 Rheumatoid arthritis / / 21156761 rs9276298 chr6 32703021 G A 1.19E-08 Rheumatoid arthritis / / 21156761 rs9276298 chr6 32703021 G A 5.56E-08 Chronic hepatitis B infection / / 23760081 rs9276299 chr6 32703108 C G 8.46E-04 Type 2 diabetes / / 17463246 rs9276299 chr6 32703108 C G 2.12E-10 Multiple complex diseases / / 17554300 rs10484563 chr6 32703162 A G 4.26E-05 Self-reported allergy / / 23817569 rs9276302 chr6 32703206 A G 4.22E-10 Chronic hepatitis B infection / / 23760081 rs7744593 chr6 32704326 A T 1.25E-08 Rheumatoid arthritis / / 21156761 rs9276313 chr6 32704706 G A 5.54E-17 Rheumatoid arthritis / / 21156761 rs9276319 chr6 32705002 C T 1.25E-08 Rheumatoid arthritis / / 21156761 rs9276319 chr6 32705002 C T 5.48E-08 Chronic hepatitis B infection / / 23760081 rs13199787 chr6 32705276 C T 1.00E-16 Type 1 diabetes / / 17632545 rs13199787 chr6 32705276 C T 2.53E-08 Hepatitis B / / 21750111 rs13199787 chr6 32705276 C T 2.00E-05 Kawasaki disease / / 22446962 rs13199787 chr6 32705276 C T 2.51E-96 Type 1 diabetes / / pha002862 rs9276348 chr6 32706209 A G 2.16E-05 Blood pressure / / 21909110 rs7773068 chr6 32706234 G A 1.25E-08 Rheumatoid arthritis / / 21156761 rs7773068 chr6 32706234 G A 4.85E-08 Chronic hepatitis B infection / / 23760081 rs7773694 chr6 32706334 A G 3.01E-10 Type 1 diabetes / / 17632545 rs7773694 chr6 32706334 A G 1.25E-08 Rheumatoid arthritis / / 21156761 rs7773694 chr6 32706334 A G 3.83E-10 Hepatitis B / / 21750111 rs7773694 chr6 32706334 A G 2.44E-04 Coronary heart disease / / 21971053 rs7773694 chr6 32706334 A G 5.48E-08 Chronic hepatitis B infection / / 23760081 rs9276351 chr6 32706416 C A 1.44E-17 Rheumatoid arthritis / / 21156761 rs7755596 chr6 32706478 C T 3.54E-10 Type 1 diabetes / / 17632545 rs7755596 chr6 32706478 C T 1.25E-08 Rheumatoid arthritis / / 21156761 rs7755596 chr6 32706478 C T 2.58E-10 Hepatitis B / / 21750111 rs7755596 chr6 32706478 C T 2.59E-04 Coronary heart disease / / 21971053 rs7755597 chr6 32706480 C T 1.25E-08 Rheumatoid arthritis / / 21156761 rs7755597 chr6 32706480 C T 4.85E-08 Chronic hepatitis B infection / / 23760081 rs9276357 chr6 32706559 T G 3.35E-17 Rheumatoid arthritis / / 21156761 rs9276370 chr6 32707295 G T 1.00E-16 Type 1 diabetes HLA-DQA2 nearGene-5 17632545 rs9276370 chr6 32707295 G T 6.88E-10 Hepatitis B HLA-DQA2 nearGene-5 21750111 rs9276370 chr6 32707295 G T 1.23E-04 Coronary heart disease HLA-DQA2 nearGene-5 21971053 rs9276370 chr6 32707295 G T 2.10E-05 Kawasaki disease HLA-DQA2 nearGene-5 22446962 rs9276370 chr6 32707295 G T 2.00E-12 Chronic hepatitis B infection HLA-DQA2 nearGene-5 24940741 rs5021448 chr6 32707706 C T 7.54E-15 Rheumatoid arthritis HLA-DQA2 nearGene-5 21156761 rs9276394 chr6 32708467 T A 9.57E-09 Rheumatoid arthritis HLA-DQA2 nearGene-5 21156761 rs9276394 chr6 32708467 T A 5.48E-08 Chronic hepatitis B infection HLA-DQA2 nearGene-5 23760081 rs9276395 chr6 32708504 C G 9.57E-09 Rheumatoid arthritis HLA-DQA2 nearGene-5 21156761 rs9276395 chr6 32708504 C G 5.60E-09 Chronic hepatitis B infection HLA-DQA2 nearGene-5 23760081 rs9276396 chr6 32708736 T C 4.85E-08 Chronic hepatitis B infection HLA-DQA2 nearGene-5 23760081 rs2051600 chr6 32709309 A G 9.28E-09 Rheumatoid arthritis HLA-DQA2 intron 21156761 rs2051598 chr6 32709363 G A 4.53E-08 Chronic hepatitis B infection HLA-DQA2 intron 23760081 rs4403295 chr6 32710010 G T 4.87E-24 Rheumatoid arthritis HLA-DQA2 intron 21156761 rs5018343 chr6 32710119 A T 1.33E-08 Rheumatoid arthritis HLA-DQA2 intron 21156761 rs9276408 chr6 32710370 T G 1.33E-08 Rheumatoid arthritis HLA-DQA2 intron 21156761 rs9276425 chr6 32711050 C T 7.56E-14 Rheumatoid arthritis HLA-DQA2 intron 21156761 rs17500468 chr6 32711178 A G 1.00E-16 Type 1 diabetes HLA-DQA2 intron 17632545 rs17500468 chr6 32711178 A G 5.94E-04 Crohn's disease HLA-DQA2 intron 23266558 rs17500468 chr6 32711178 A G 8.90E-06 Hodgkin's lymphoma HLA-DQA2 intron 24149102 rs2227127 chr6 32711782 A G 1.66E-64 Multiple complex diseases HLA-DQA2 intron 17554300 rs2227127 chr6 32711782 A G 7.47E-13 Multiple sclerosis HLA-DQA2 intron 17660530 rs2227127 chr6 32711782 A G 5.63E-12 Narcolepsy HLA-DQA2 intron 19629137 rs9276427 chr6 32711857 T C 1.83E-09 Chronic hepatitis B infection HLA-DQA2 intron 23760081 rs9276429 chr6 32712104 G A 2.98E-77 Multiple complex diseases HLA-DQA2 intron 17554300 rs9276429 chr6 32712104 G A 5.39E-15 Multiple sclerosis HLA-DQA2 intron 17660530 rs9276431 chr6 32712247 T C 1.30E-77 Multiple complex diseases HLA-DQA2 intron 17554300 rs9276431 chr6 32712247 T C 3.40E-15 Multiple sclerosis HLA-DQA2 intron 17660530 rs9276431 chr6 32712247 T C 3.45E-06 Obesity (early onset extreme) HLA-DQA2 intron 18159244 rs9276432 chr6 32712384 T C 1.82E-77 Multiple complex diseases HLA-DQA2 intron 17554300 rs9276432 chr6 32712384 T C 4.28E-15 Multiple sclerosis HLA-DQA2 intron 17660530 rs2213565 chr6 32713188 C T 3.05E-08 Chronic hepatitis B infection HLA-DQA2 intron 23760081 rs2239800 chr6 32713267 A G 4.74E-07 Multiple complex diseases HLA-DQA2 intron 17554300 rs2239800 chr6 32713267 A G 5.60E-14 Type 1 diabetes HLA-DQA2 intron 17632545 rs2239800 chr6 32713267 A G 1.94E-05 Rheumatoid arthritis HLA-DQA2 intron 17804836 rs2239800 chr6 32713267 A G 1.46E-09 Rheumatoid arthritis HLA-DQA2 intron 19503088 rs2239800 chr6 32713267 A G 3.29E-34 Narcolepsy HLA-DQA2 intron 19629137 rs4398729 chr6 32713854 G A 1.08E-08 Multiple complex diseases HLA-DQA2 intron 17554300 rs9276435 chr6 32713867 C T 6.94E-14 Multiple complex diseases HLA-DQA2 intron 17554300 rs9276435 chr6 32713867 C T 1.05E-12 Rheumatoid arthritis HLA-DQA2 intron 21156761 rs2071800 chr6 32714143 G A 4.27E-14 Rheumatoid arthritis HLA-DQA2 missense 17804836 rs2071800 chr6 32714143 G A 7.80E-38 Rheumatoid arthritis HLA-DQA2 missense 21156761 rs9276440 chr6 32714783 A T 1.38E-75 Multiple complex diseases HLA-DQA2 nearGene-3 17554300 rs9276440 chr6 32714783 A T 6.34E-15 Multiple sclerosis HLA-DQA2 nearGene-3 17660530 rs9276440 chr6 32714783 A T 3.27E-09 Narcolepsy HLA-DQA2 nearGene-3 19629137 rs9276448 chr6 32715629 A G 5.73E-12 Multiple complex diseases / / 17554300 rs9276456 chr6 32715943 A G 1.15E-13 Rheumatoid arthritis / / 21156761 rs2213573 chr6 32716022 G A 2.35E-08 Rheumatoid arthritis / / 21156761 rs2213573 chr6 32716022 G A 4.59E-08 Chronic hepatitis B infection / / 23760081 rs9276472 chr6 32717224 A G 8.52E-05 Lung adenocarcinoma MIR3135B nearGene-3 19836008 rs9276482 chr6 32718162 C T 5.23E-06 Hepatitis B MIR3135B nearGene-5 24162738 rs9276482 chr6 32718162 C T 1.00E-08 Chronic hepatitis B infection MIR3135B nearGene-5 23760081 rs9276490 chr6 32718681 A G 7.59E-76 Multiple complex diseases MIR3135B nearGene-5 17554300 rs5014418 chr6 32719381 A C 1.00E-11 Multiple complex diseases MIR3135B nearGene-5 17554300 rs2213572 chr6 32719804 A G 5.71E-08 Narcolepsy / / 19629137 rs9276506 chr6 32719914 C T 2.27E-08 Rheumatoid arthritis / / 21156761 rs7774435 chr6 32721948 C T 5.23E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10807113 chr6 32722186 C A 1.00E-16 Type 1 diabetes / / 17632545 rs10807113 chr6 32722186 C A 8.65E-04 Crohn's disease / / 23266558 rs10807113 chr6 32722186 C A 7.00E-112 Type 1 diabetes / / pha002862 rs9276550 chr6 32722243 G T 5.93E-14 Rheumatoid arthritis / / 21156761 rs9276555 chr6 32722754 G A 5.93E-14 Rheumatoid arthritis / / 21156761 rs6934041 chr6 32722767 C G 1.34E-06 Hepatitis B / / 24162738 rs6933763 chr6 32722852 A G 9.70E-09 Multiple complex diseases / / 17554300 rs9276556 chr6 32723233 G C 5.93E-14 Rheumatoid arthritis / / 21156761 rs7756516 chr6 32723917 C T 1.00E-16 Type 1 diabetes HLA-DQB2 UTR-3 17632545 rs7756516 chr6 32723917 C T 5.27E-08 Rheumatoid arthritis HLA-DQB2 UTR-3 17804836 rs7756516 chr6 32723917 C T 7.06E-10 Rheumatoid arthritis HLA-DQB2 UTR-3 19503088 rs7756516 chr6 32723917 C T 0.0000172 Follicular lymphoma HLA-DQB2 UTR-3 23025665 rs7756516 chr6 32723917 C T 8.77E-04 Crohn's disease HLA-DQB2 UTR-3 23266558 rs7756516 chr6 32723917 C T 8.40E-05 Systemic lupus erythematosus HLA-DQB2 UTR-3 24871463 rs7756516 chr6 32723917 C T 1.48E-11 Chronic hepatitis B infection HLA-DQB2 UTR-3 24940741 rs7756516 chr6 32723917 C T 5.36E-112 Type 1 diabetes HLA-DQB2 UTR-3 pha002862 rs7774954 chr6 32724189 C A 4.78E-10 Rheumatoid arthritis HLA-DQB2 UTR-3 17804836 rs7774954 chr6 32724189 C A 3.06E-07 Systemic sclerosis HLA-DQB2 UTR-3 20383147 rs2301271 chr6 32725193 A G 1.00E-16 Type 1 diabetes HLA-DQB2 intron 17632545 rs2301271 chr6 32725193 A G 7.67E-05 Multiple sclerosis HLA-DQB2 intron 20598377 rs2301271 chr6 32725193 A G 2.00E-12 Systemic lupus erythematosus HLA-DQB2 intron 21408207 rs2301271 chr6 32725193 A G 5.59E-05 Follicular lymphoma HLA-DQB2 intron 21533074 rs2301271 chr6 32725193 A G 2.96E-09 Hepatitis B HLA-DQB2 intron 21750111 rs2301271 chr6 32725193 A G 6.16E-05 Coronary heart disease HLA-DQB2 intron 21971053 rs2301271 chr6 32725193 A G 4.00E-05 Kawasaki disease HLA-DQB2 intron 22446962 rs2301271 chr6 32725193 A G 7.70E-08 Systemic lupus erythematosus HLA-DQB2 intron 24871463 rs2301271 chr6 32725193 A G 2.38E-100 Type 1 diabetes HLA-DQB2 intron pha002862 rs1049110 chr6 32726803 C T 2.00E-08 IgG glycosylation HLA-DQB2 missense 23382691 rs1049110 chr6 32726803 C T 4.00E-08 IgG glycosylation HLA-DQB2 missense 23382691 rs2071551 chr6 32729459 C T 4.31E-09 Chronic hepatitis B infection HLA-DQB2 cds-synon 23760081 rs762815 chr6 32729642 G C 6.47E-06 Hepatitis B HLA-DQB2 cds-synon 24162738 rs762815 chr6 32729642 G C 2.62E-09 Chronic hepatitis B infection HLA-DQB2 cds-synon 23760081 rs7768538 chr6 32729821 C A 5.81E-06 Hepatitis B HLA-DQB2 intron 24162738 rs7768538 chr6 32729821 C A 2.27E-76 Multiple complex diseases HLA-DQB2 intron 17554300 rs7768538 chr6 32729821 C A 4.59E-15 Multiple sclerosis HLA-DQB2 intron 17660530 rs7768538 chr6 32729821 C A 4.08E-09 Chronic hepatitis B infection HLA-DQB2 intron 23760081 rs9276583 chr6 32729880 G A 5.81E-06 Hepatitis B HLA-DQB2 intron 24162738 rs9276583 chr6 32729880 G A 3.72E-08 Chronic hepatitis B infection HLA-DQB2 intron 23760081 rs7453920 chr6 32730012 A G 2.18E-76 Multiple complex diseases HLA-DQB2 intron 17554300 rs7453920 chr6 32730012 A G 1.00E-16 Type 1 diabetes HLA-DQB2 intron 17632545 rs7453920 chr6 32730012 A G 3.99E-15 Multiple sclerosis HLA-DQB2 intron 17660530 rs7453920 chr6 32730012 A G 7.01E-05 Multiple sclerosis HLA-DQB2 intron 20598377 rs7453920 chr6 32730012 A G 5.31E-05 Follicular lymphoma HLA-DQB2 intron 21533074 rs7453920 chr6 32730012 A G 6.00E-28 Hepatitis B HLA-DQB2 intron 21750111 rs7453920 chr6 32730012 A G 1.22E-05 Coronary heart disease HLA-DQB2 intron 21971053 rs7453920 chr6 32730012 A G 5.98E-28 Hepatocellular carcinoma (hepatitis B virus related) HLA-DQB2 intron 23242368 rs7453920 chr6 32730012 A G 5.00E-06 Lymphoma HLA-DQB2 intron 23349640 rs7453920 chr6 32730012 A G 7.00E-26 Chronic hepatitis B infection HLA-DQB2 intron 23760081 rs7453920 chr6 32730012 A G 5.00E-37 Hepatitis B HLA-DQB2 intron 24162738 rs7453920 chr6 32730012 A G 8.70E-08 Systemic lupus erythematosus HLA-DQB2 intron 24871463 rs7453920 chr6 32730012 A G 7.00E-15 Chronic hepatitis B infection HLA-DQB2 intron 24940741 rs7453920 chr6 32730012 A G 6.84E-100 Type 1 diabetes HLA-DQB2 intron pha002862 rs2051549 chr6 32730086 G A 5.81E-06 Hepatitis B HLA-DQB2 intron 24162738 rs2051549 chr6 32730086 G A 4.86E-79 Multiple complex diseases HLA-DQB2 intron 17554300 rs2051549 chr6 32730086 G A 1.00E-16 Type 1 diabetes HLA-DQB2 intron 17632545 rs2051549 chr6 32730086 G A 7.98E-15 Multiple sclerosis HLA-DQB2 intron 17660530 rs2051549 chr6 32730086 G A 8.70E-05 Multiple sclerosis HLA-DQB2 intron 20598377 rs2051549 chr6 32730086 G A 6.92E-05 Follicular lymphoma HLA-DQB2 intron 21533074 rs2051549 chr6 32730086 G A 6.38E-06 Coronary heart disease HLA-DQB2 intron 21971053 rs2051549 chr6 32730086 G A 3.00E-22 Systemic lupus erythematosus HLA-DQB2 intron 23053960 rs2051549 chr6 32730086 G A 4.67E-09 Chronic hepatitis B infection HLA-DQB2 intron 23760081 rs2051549 chr6 32730086 G A 5.40E-07 Systemic lupus erythematosus HLA-DQB2 intron 24871463 rs11759423 chr6 32730392 C T 2.30E-37 Rheumatoid arthritis HLA-DQB2 intron 21156761 rs2071550 chr6 32730940 C A 1.05E-20 Type 1 diabetes HLA-DQB2 intron 17632545 rs2071550 chr6 32730940 C A 1.29E-95 Type 1 diabetes HLA-DQB2 intron pha002862 rs1573649 chr6 32731258 G A 9.00E-13 Type 1 diabetes HLA-DQB2 UTR-5 17632545 rs1573649 chr6 32731258 G A 9.09E-05 Follicular lymphoma HLA-DQB2 UTR-5 21533074 rs1573649 chr6 32731258 G A 3.00E-06 Rheumatoid arthritis HLA-DQB2 UTR-5 23918589 rs1573649 chr6 32731258 G A 5.50E-04 Systemic lupus erythematosus HLA-DQB2 UTR-5 24871463 rs1573649 chr6 32731258 G A 1.03E-71 Type 1 diabetes HLA-DQB2 UTR-5 pha002862 rs6902723 chr6 32731960 G A 3.75E-49 Multiple complex diseases HLA-DQB2 nearGene-5 17554300 rs6902723 chr6 32731960 G A 2.40E-14 Multiple sclerosis HLA-DQB2 nearGene-5 17660530 rs6902723 chr6 32731960 G A 4.23E-13 Narcolepsy HLA-DQB2 nearGene-5 19629137 rs6903130 chr6 32732210 G A 3.75E-49 Multiple complex diseases HLA-DQB2 nearGene-5 17554300 rs6903130 chr6 32732210 G A 5.84E-13 Type 1 diabetes HLA-DQB2 nearGene-5 17632545 rs6903130 chr6 32732210 G A 1.40E-13 Multiple sclerosis HLA-DQB2 nearGene-5 17660530 rs6903130 chr6 32732210 G A 1.61E-14 Narcolepsy HLA-DQB2 nearGene-5 19629137 rs6903130 chr6 32732210 G A 6.65E-05 Follicular lymphoma HLA-DQB2 nearGene-5 21533074 rs6903130 chr6 32732210 G A 8.10E-04 Systemic lupus erythematosus HLA-DQB2 nearGene-5 24871463 rs6903130 chr6 32732210 G A 6.43E-72 Type 1 diabetes HLA-DQB2 nearGene-5 pha002862 rs6919798 chr6 32732890 A G 1.20E-10 Multiple complex diseases HLA-DQB2 nearGene-5 17554300 rs9276601 chr6 32734304 A G 1.02E-12 Rheumatoid arthritis / / 21156761 rs9296043 chr6 32736103 T C 1.02E-55 Multiple complex diseases / / 17554300 rs9296044 chr6 32736144 T A 1.43E-56 Multiple complex diseases / / 17554300 rs9296044 chr6 32736144 T A 2.00E-12 Multiple sclerosis / / 17660530 rs9276606 chr6 32736695 A T 3.00E-22 Complement C3 and C4 levels / / 23028341 rs6901084 chr6 32736936 C T 1.00E-16 Type 1 diabetes / / 17632545 rs6901084 chr6 32736936 C T 1.55E-06 Hepatitis B / / 21750111 rs6901084 chr6 32736936 C T 2.45E-04 Coronary heart disease / / 21971053 rs6901084 chr6 32736936 C T 2.60E-05 Kawasaki disease / / 22446962 rs6901084 chr6 32736936 C T 1.21E-85 Type 1 diabetes / / pha002862 rs9368741 chr6 32737507 G A 1.51E-20 Type 1 diabetes / / 17632545 rs9368741 chr6 32737507 G A 3.26E-95 Type 1 diabetes / / pha002862 rs1015575 chr6 32738115 G A 1.42E-64 Multiple complex diseases / / 17554300 rs1383265 chr6 32739888 T C 2.42E-08 Type 1 diabetes / / 17632545 rs1383265 chr6 32739888 T C 3.77E-07 Hepatitis B / / 21750111 rs1383264 chr6 32739967 A T 8.42E-04 Self-reported allergy / / 23817569 rs1383264 chr6 32739967 A T 6.75E-04 Smoking quantity / / 24665060 rs2857212 chr6 32740411 A G 1.66E-68 Multiple complex diseases / / 17554300 rs2857212 chr6 32740411 A G 8.19E-09 Multiple sclerosis / / 17660530 rs2857212 chr6 32740411 A G 1.27E-04 Self-reported allergy / / 23817569 rs1480383 chr6 32740856 A C 8.84E-08 Rheumatoid arthritis / / 21156761 rs2621419 chr6 32741006 T C 2.17E-10 Multiple complex diseases / / 17554300 rs2857210 chr6 32741742 A G 2.90E-07 Multiple complex diseases / / 17554300 rs2857210 chr6 32741742 A G 4.10E-14 Multiple sclerosis / / 17660530 rs2857210 chr6 32741742 A G 7.01E-04 Crohn's disease / / 23266558 rs28724890 chr6 32741844 G A 3.90E-05 HIV-1 control / / 20041166 rs28724890 chr6 32741844 G A 1.30E-08 HIV-1 control / / 21051598 rs2621416 chr6 32741868 T C 1.80E-07 Multiple complex diseases / / 17554300 rs2621416 chr6 32741868 T C 6.44E-09 Narcolepsy / / 19629137 rs2621416 chr6 32741868 T C 6.26E-09 Rheumatoid arthritis / / 21156761 rs2621416 chr6 32741868 T C 2.00E-09 Lymphoma / / 23349640 rs9276615 chr6 32743217 C T 1.90E-05 Kawasaki disease / / 22446962 rs13195441 chr6 32743298 G A 2.07E-06 HIV-1 control / / 20041166 rs13195441 chr6 32743298 G A 5.93E-09 Rheumatoid arthritis / / 21156761 rs13195441 chr6 32743298 G A 4.22E-07 Hodgkin's lymphoma / / 24149102 rs2857204 chr6 32744347 G T 1.98E-06 HIV-1 control / / 20041166 rs13203429 chr6 32744852 G C 2.60E-04 Self-reported allergy / / 23817569 rs13203438 chr6 32744869 G C 2.58E-04 Self-reported allergy / / 23817569 rs9276644 chr6 32745043 T C 2.04E-06 Leprosy / / pha002872 rs12661352 chr6 32745527 G T 1.66E-07 Multiple complex diseases / / 17554300 rs4947258 chr6 32747502 A G 2.55E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs4947349 chr6 32747790 G T 7.91E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs17429127 chr6 32751614 G C 5.38E-11 Multiple complex diseases / / 17554300 rs9276689 chr6 32751962 C T 7.89E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs10484564 chr6 32752049 G C 1.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10484564 chr6 32752049 G C 7.84E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs719654 chr6 32752139 G A 1.98E-09 Type 1 diabetes / / 17632545 rs719654 chr6 32752139 G A 3.31E-07 HIV-1 control / / 20041166 rs719654 chr6 32752139 G A 0.0000504 Follicular lymphoma / / 23025665 rs719654 chr6 32752139 G A 1.33E-05 Hodgkin's lymphoma / / 24149102 rs719653 chr6 32752566 C T 1.33E-08 Rheumatoid arthritis / / 17804836 rs2621396 chr6 32752913 A T 5.27E-09 Rheumatoid arthritis / / 21156761 rs2261566 chr6 32754081 T C 3.53E-11 Rheumatoid arthritis / / 21156761 rs7762279 chr6 32755290 T C 1.00E-16 Type 1 diabetes / / 17632545 rs7762279 chr6 32755290 T C 1.99E-12 Rheumatoid arthritis / / 17804836 rs7762279 chr6 32755290 T C 1.00E-04 Schizophrenia / / 19197363 rs7762279 chr6 32755290 T C 3.05E-15 Rheumatoid arthritis / / 19503088 rs7762279 chr6 32755290 T C 2.69E-06 Lung adenocarcinoma / / 19836008 rs7762279 chr6 32755290 T C 1.30E-08 Rheumatoid arthritis / / 21156761 rs7762279 chr6 32755290 T C 3.35E-08 Schizophrenia / / 21926974 rs7762279 chr6 32755290 T C 1.00E-08 Lung cancer / / 22899653 rs7762279 chr6 32755290 T C 1.60E-58 Myasthenia gravis / / 23055271 rs7762279 chr6 32755290 T C 3.10E-12 Systemic lupus erythematosus / / 24871463 rs7762279 chr6 32755290 T C 3.72E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs7762279 chr6 32755290 T C 2.40E-06 Systemic lupus erythematosus / / pha002867 rs2621389 chr6 32757532 C A 3.90E-11 Rheumatoid arthritis / / 21156761 rs2621387 chr6 32757971 C A 4.25E-11 Rheumatoid arthritis / / 21156761 rs2857164 chr6 32758219 C A 4.25E-11 Rheumatoid arthritis / / 21156761 rs2621386 chr6 32758268 C A 4.25E-11 Rheumatoid arthritis / / 21156761 rs7758736 chr6 32758394 G A 1.52E-09 Type 1 diabetes / / 17632545 rs7758736 chr6 32758394 G A 2.03E-17 Rheumatoid arthritis / / 17804836 rs7758736 chr6 32758394 G A 9.72E-19 Rheumatoid arthritis / / 19503088 rs7758736 chr6 32758394 G A 9.60E-12 Rheumatoid arthritis / / 21156761 rs7758736 chr6 32758394 G A 1.60E-07 Systemic lupus erythematosus / / 24871463 rs7758736 chr6 32758394 G A 3.07E-05 Systemic lupus erythematosus / / pha002867 rs1158785 chr6 32758571 T C 4.25E-11 Rheumatoid arthritis / / 21156761 rs2261684 chr6 32758667 A T 4.25E-11 Rheumatoid arthritis / / 21156761 rs9276712 chr6 32759252 A C 3.61E-10 Multiple complex diseases / / 17554300 rs2621384 chr6 32759273 C T 5.03E-11 Multiple complex diseases / / 17554300 rs2621384 chr6 32759273 C T 4.64E-14 Multiple sclerosis / / 17660530 rs2621384 chr6 32759273 C T 5.03E-11 Rheumatoid arthritis / / 21156761 rs2857161 chr6 32759297 G A 1.15E-12 Multiple complex diseases / / 17554300 rs2857161 chr6 32759297 G A 5.42E-20 Multiple sclerosis / / 17660530 rs2857161 chr6 32759297 G A 3.40E-11 Rheumatoid arthritis / / 21156761 rs2621383 chr6 32759335 C A 9.87E-12 Multiple complex diseases / / 17554300 rs2621383 chr6 32759335 C A 5.42E-20 Multiple sclerosis / / 17660530 rs2621383 chr6 32759335 C A 6.44E-11 Rheumatoid arthritis / / 21156761 rs2621382 chr6 32760445 G T 1.92E-12 Multiple complex diseases / / 17554300 rs2621382 chr6 32760445 G T 6.43E-15 Multiple sclerosis / / 17660530 rs2157082 chr6 32760714 G T 2.07E-15 Multiple sclerosis / / 17660530 rs2067578 chr6 32762461 G A 2.42E-22 Rheumatoid arthritis / / 21156761 rs2857154 chr6 32762616 A G 1.15E-04 Multiple complex diseases / / 17554300 rs2857154 chr6 32762616 A G 2.18E-15 Multiple sclerosis / / 17660530 rs2621377 chr6 32763110 C T 4.77E-05 Hepatitis B / / 21750111 rs2621377 chr6 32763110 C T 5.30E-06 Kawasaki disease / / 22446962 rs2857151 chr6 32763514 A G 5.00E-11 Kawasaki disease / / 22446962 rs9276726 chr6 32763888 T C 1.28E-71 Type 1 diabetes / / pha002862 rs2621373 chr6 32765130 T C 1.55E-15 Type 1 diabetes / / 17632545 rs2621373 chr6 32765130 T C 2.49E-07 HIV-1 control / / 20041166 rs7767167 chr6 32765182 G A 9.33E-68 Type 1 diabetes / / pha002862 rs9276731 chr6 32765585 G T 1.56E-08 Rheumatoid arthritis / / 21156761 rs9276731 chr6 32765585 G T 3.04E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2219893 chr6 32769663 T C 8.88E-16 Type 1 diabetes / / 17632545 rs2219893 chr6 32769663 T C 2.24E-08 HIV-1 control / / 20041166 rs2219893 chr6 32769663 T C 2.56E-68 Type 1 diabetes / / pha002862 rs2199874 chr6 32769926 A G 6.45E-05 HIV-1 control / / 20041166 rs2857136 chr6 32775686 A G 1.17E-04 Multiple complex diseases / / 17554300 rs2857136 chr6 32775686 A G 2.17E-14 Multiple sclerosis / / 17660530 rs2857129 chr6 32776623 A T 1.78E-04 Multiple complex diseases / / 17554300 rs2857129 chr6 32776623 A T 3.44E-14 Multiple sclerosis / / 17660530 rs2621332 chr6 32780317 G A 2.30E-05 Kawasaki disease HLA-DOB nearGene-3 22446962 rs11244 chr6 32780724 G A 8.01E-08 Type 1 diabetes HLA-DOB UTR-3 17632545 rs11244 chr6 32780724 G A 1.20E-102 Type 1 diabetes HLA-DOB UTR-3 pha002862 rs2071479 chr6 32781112 C T 4.39E-23 Rheumatoid arthritis HLA-DOB intron 21156761 rs2621330 chr6 32781524 C T 4.45E-10 Multiple complex diseases HLA-DOB missense 17554300 rs2621330 chr6 32781524 C T 1.06E-08 Type 1 diabetes HLA-DOB missense 17632545 rs2621330 chr6 32781524 C T 6.33E-06 Rheumatoid arthritis HLA-DOB missense 17804836 rs2070121 chr6 32781554 G A 1.96E-10 Multiple complex diseases HLA-DOB missense 17554300 rs2856997 chr6 32781776 C A 5.43E-09 Type 1 diabetes HLA-DOB intron 17632545 rs2856997 chr6 32781776 C A 3.87E-07 Rheumatoid arthritis HLA-DOB intron 17804836 rs2856997 chr6 32781776 C A 6.59E-08 HIV-1 control HLA-DOB intron 20041166 rs16870880 chr6 32782018 C T 8.35E-10 Multiple complex diseases HLA-DOB intron 17554300 rs11575907 chr6 32782112 C T 5.96E-19 Psoriasis HLA-DOB missense pha002855 rs17501267 chr6 32782149 G A 1.34E-06 Multiple complex diseases HLA-DOB cds-synon 17554300 rs2071474 chr6 32782582 C T 1.42E-47 Multiple complex diseases HLA-DOB intron 17554300 rs2071474 chr6 32782582 C T 1.11E-16 Type 1 diabetes HLA-DOB intron 17632545 rs2071474 chr6 32782582 C T 4.02E-08 HIV-1 control HLA-DOB intron 20041166 rs2071474 chr6 32782582 C T 6.65E-70 Type 1 diabetes HLA-DOB intron pha002862 rs2071473 chr6 32782605 C T 8.36E-08 HIV-1 control HLA-DOB intron 20041166 rs2071473 chr6 32782605 C T 8.40E-06 Kawasaki disease HLA-DOB intron 22446962 rs2071473 chr6 32782605 C T 1.49E-04 Self-reported allergy HLA-DOB intron 23817569 rs7383287 chr6 32783086 A G 1.17E-14 Rheumatoid arthritis HLA-DOB cds-synon 17804836 rs7383287 chr6 32783086 A G 2.41E-19 Rheumatoid arthritis HLA-DOB cds-synon 19503088 rs7383287 chr6 32783086 A G 2.59E-10 Rheumatoid arthritis HLA-DOB cds-synon 21156761 rs7383287 chr6 32783086 A G 5.15E-06 Schizophrenia HLA-DOB cds-synon 21926974 rs7383287 chr6 32783086 A G 1.80E-06 Systemic lupus erythematosus HLA-DOB cds-synon 24871463 rs1383258 chr6 32783405 C T 6.90E-18 Rheumatoid arthritis HLA-DOB intron 21156761 rs2071472 chr6 32784620 C T 3.33E-16 Type 1 diabetes HLA-DOB intron 17632545 rs2071472 chr6 32784620 C T 4.10E-08 HIV-1 control HLA-DOB intron 20041166 rs2071472 chr6 32784620 C T 1.89E-69 Type 1 diabetes HLA-DOB intron pha002862 rs2071554 chr6 32784676 C T 4.92E-08 Type 1 diabetes HLA-DOB missense 17632545 rs2071554 chr6 32784676 C T 1.37E-22 Rheumatoid arthritis HLA-DOB missense 17804836 rs2071554 chr6 32784676 C T 8.85E-22 Rheumatoid arthritis HLA-DOB missense 19503088 rs2071554 chr6 32784676 C T 1.15E-17 Rheumatoid arthritis HLA-DOB missense 21156761 rs2071554 chr6 32784676 C T 3.20E-06 Crohn's disease HLA-DOB missense 23266558 rs2071554 chr6 32784676 C T 9.90E-81 Type 1 diabetes HLA-DOB missense pha002862 rs2071554 chr6 32784676 C T 2.30E-07 Leprosy HLA-DOB missense pha002872 rs2071469 chr6 32784783 C T 1.00E-16 Type 1 diabetes HLA-DOB UTR-5 17632545 rs2071469 chr6 32784783 C T 6.17E-06 HIV-1 control HLA-DOB UTR-5 20041166 rs2071469 chr6 32784783 C T 1.32E-84 Type 1 diabetes HLA-DOB UTR-5 pha002862 rs2857107 chr6 32785515 C T 2.18E-12 Rheumatoid arthritis HLA-DOB nearGene-5 17804836 rs2857107 chr6 32785515 C T 9.93E-19 Rheumatoid arthritis HLA-DOB nearGene-5 19503088 rs17429444 chr6 32786068 A G 0.00000027 Joint damage severity in rheumatoid arthritis HLA-DOB nearGene-5 23696630 rs3763355 chr6 32786882 T C 5.10E-11 Rheumatoid arthritis / / 21156761 rs3763355 chr6 32786882 T C 3.25E-09 Chronic hepatitis B infection / / 23760081 rs3763354 chr6 32786917 G A 4.08E-10 Chronic hepatitis B infection / / 23760081 rs1894407 chr6 32787036 C A 5.24E-07 Multiple complex diseases / / 17554300 rs1894407 chr6 32787036 C A 1.00E-07 Thyroid peroxidase antibody positivity / / 24586183 rs1894406 chr6 32787056 C T 1.00E-16 Type 1 diabetes / / 17632545 rs1894406 chr6 32787056 C T 5.21E-07 HIV-1 control / / 20041166 rs1894406 chr6 32787056 C T 9.40E-88 Type 1 diabetes / / pha002862 rs9784858 chr6 32787175 G C 5.14E-09 Multiple complex diseases / / 17554300 rs9784858 chr6 32787175 G C 7.77E-31 Narcolepsy / / 19629137 rs9784858 chr6 32787175 G C 7.86E-13 Rheumatoid arthritis / / 21156761 rs17220136 chr6 32787337 C T 2.66E-06 Multiple complex diseases / / 17554300 rs2857106 chr6 32787570 T C 4.58E-11 Type 1 diabetes / / 17632545 rs2857106 chr6 32787570 T C 1.87E-08 HIV-1 control / / 20041166 rs2857106 chr6 32787570 T C 0.00000243 Follicular lymphoma / / 23025665 rs2857106 chr6 32787570 T C 2.39E-05 Behcet's disease / / pha002888 rs9784758 chr6 32788511 T C 6.58E-08 Type 1 diabetes / / 17632545 rs9784758 chr6 32788511 T C 1.41E-14 Rheumatoid arthritis / / 21156761 rs9784758 chr6 32788511 T C 3.01E-06 Crohn's disease / / 23266558 rs9784758 chr6 32788511 T C 6.79E-77 Type 1 diabetes / / pha002862 rs9784758 chr6 32788511 T C 2.30E-07 Leprosy / / pha002872 rs2621323 chr6 32788707 A G 4.10E-04 Alcohol dependence / / 20201924 rs2621323 chr6 32788707 A G 2.45E-04 Self-reported allergy / / 23817569 rs9784876 chr6 32788878 C A 1.41E-14 Rheumatoid arthritis / / 21156761 rs2621321 chr6 32789480 A G 7.66E-05 HIV-1 control TAP2 nearGene-3 20041166 rs16870907 chr6 32789807 C T 2.46E-06 Leprosy TAP2 UTR-3 pha002872 rs2857103 chr6 32791299 C A 8.30E-04 Alcohol dependence TAP2 intron 20201924 rs13209654 chr6 32792659 T C 9.85E-05 Cognitive test performance TAP2 intron 20125193 rs1894411 chr6 32792973 T C 9.50E-05 Hypothyroidism TAP2 intron 22493691 rs1044043 chr6 32793981 A C 9.50E-07 Graves' disease TAP2 UTR-3 21900946 rs2857101 chr6 32794676 T C 5.59E-05 HIV-1 control TAP2 UTR-3 20041166 rs10484565 chr6 32795032 G A 1.28E-10 Multiple complex diseases TAP2 UTR-3 17554300 rs10484565 chr6 32795032 G A 3.00E-26 Rheumatoid arthritis TAP2 UTR-3 17804836 rs10484565 chr6 32795032 G A 5.02E-25 Rheumatoid arthritis TAP2 UTR-3 19503088 rs10484565 chr6 32795032 G A 1.00E-38 Narcolepsy TAP2 UTR-3 19629137 rs10484565 chr6 32795032 G A 4.21E-21 Rheumatoid arthritis TAP2 UTR-3 21156761 rs241454 chr6 32796144 A G 9.11E-05 HIV-1 control TAP2 UTR-3 20041166 rs241453 chr6 32796226 G A 1.00E-16 Type 1 diabetes TAP2 UTR-3 17632545 rs241453 chr6 32796226 G A 5.59E-09 HIV-1 control TAP2 UTR-3 20041166 rs241453 chr6 32796226 G A 3.04E-71 Type 1 diabetes TAP2 UTR-3 pha002862 rs241452 chr6 32796346 T C 1.00E-16 Type 1 diabetes TAP2 UTR-3 17632545 rs241452 chr6 32796346 T C 2.97E-09 HIV-1 control TAP2 UTR-3 20041166 rs241452 chr6 32796346 T C 2.07E-72 Type 1 diabetes TAP2 UTR-3 pha002862 rs17034 chr6 32796521 C T 4.55E-05 HIV-1 control TAP2 UTR-3 20041166 rs241448 chr6 32796685 A G 1.00E-16 Type 1 diabetes TAP2 STOP-GAIN 17632545 rs241448 chr6 32796685 A G 4.04E-08 HIV-1 control TAP2 STOP-GAIN 20041166 rs241448 chr6 32796685 A G 5.50E-04 Systemic lupus erythematosus TAP2 STOP-GAIN 24871463 rs241448 chr6 32796685 A G 7.86E-70 Type 1 diabetes TAP2 STOP-GAIN pha002862 rs241447 chr6 32796751 T C 1.00E-16 Type 1 diabetes TAP2 missense 17632545 rs241447 chr6 32796751 T C 4.35E-09 HIV-1 control TAP2 missense 20041166 rs241447 chr6 32796751 T C 4.69E-71 Type 1 diabetes TAP2 missense pha002862 rs4148876 chr6 32796793 G A 9.19E-10 Chronic hepatitis B infection TAP2 missense 23760081 rs241446 chr6 32796967 G A 8.88E-05 HIV-1 control TAP2 intron 20041166 rs241440 chr6 32797361 C T 1.00E-16 Type 1 diabetes TAP2 intron 17632545 rs241440 chr6 32797361 C T 7.80E-09 HIV-1 control TAP2 intron 20041166 rs241440 chr6 32797361 C T 2.36E-71 Type 1 diabetes TAP2 intron pha002862 rs241438 chr6 32797620 C T 3.07E-09 Multiple complex diseases TAP2 intron 17554300 rs241437 chr6 32797684 A G 2.06E-12 Rheumatoid arthritis TAP2 intron 17804836 rs241437 chr6 32797684 A G 5.67E-16 Rheumatoid arthritis TAP2 intron 19503088 rs241437 chr6 32797684 A G 8.01E-05 HIV-1 control TAP2 intron 20041166 rs241437 chr6 32797684 A G 2.06E-04 Crohn's disease TAP2 intron 23266558 rs241436 chr6 32797876 A G 6.70E-04 Pemphigus vulgaris TAP2 intron 22437316 rs1042116 chr6 32798548 G A 4.52E-05 Hepatitis B TAP2 cds-synon 21750111 rs1015166 chr6 32798731 C T 3.94E-17 Type 1 diabetes TAP2 intron 17632545 rs1015166 chr6 32798731 C T 8.68E-107 Type 1 diabetes TAP2 intron pha002862 rs241433 chr6 32798795 C A 9.56E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TAP2 intron 20877124 rs2228397 chr6 32800224 C A 1.11E-16 Type 1 diabetes TAP2 cds-synon 17632545 rs2228397 chr6 32800224 C A 1.04E-05 Ulcerative colitis TAP2 cds-synon 24837172 rs1800454 chr6 32800412 C T 2.49E-12 Multiple complex diseases TAP2 missense 17554300 rs1800454 chr6 32800412 C T 1.59E-05 Multiple sclerosis TAP2 missense 17660530 rs241432 chr6 32802203 G T 2.44E-06 Multiple complex diseases TAP2 intron 17554300 rs4148872 chr6 32802807 C T 0.00009501 Sarcoidosis TAP2 intron 22952805 rs241430 chr6 32802820 T C 7.13E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TAP2 intron 20877124 rs140654840 chr6 32802938 C T 0.000033 Prostate cancer TAP2 missense 23555315 rs4148871 chr6 32803316 A G 3.60E-08 Chronic hepatitis B infection TAP2 intron 23760081 rs241429 chr6 32803840 A G 3.06E-10 Multiple complex diseases TAP2 intron 17554300 rs241429 chr6 32803840 A G 6.28E-06 Lymphocyte counts TAP2 intron 22286170 rs241428 chr6 32804070 T G 5.36E-05 Multiple complex diseases TAP2 intron 17554300 rs241428 chr6 32804070 T G 9.00E-83 Complement C3 and C4 levels TAP2 intron 23028341 rs3819715 chr6 32804219 G T 9.75E-10 Type 1 diabetes TAP2 intron 17632545 rs3819716 chr6 32804284 G A 3.58E-05 Orofacial clefts TAP2 intron 22419666 rs3819717 chr6 32804299 C T 4.70E-09 Joint damage severity in rheumatoid arthritis TAP2 intron 23696630 rs241427 chr6 32804414 A G 7.27E-86 Multiple complex diseases TAP2 intron 17554300 rs241427 chr6 32804414 A G 1.00E-16 Type 1 diabetes TAP2 intron 17632545 rs241427 chr6 32804414 A G 4.34E-19 Multiple sclerosis TAP2 intron 17660530 rs241427 chr6 32804414 A G 3.48E-82 Type 1 diabetes TAP2 intron pha002862 rs3819720 chr6 32804570 G A 0.000035 Coronary artery calcification TAP2 intron 23727086 rs3819721 chr6 32804798 G A 1.02E-37 Rheumatoid arthritis TAP2 intron 17804836 rs3819721 chr6 32804798 G A 9.61E-64 Rheumatoid arthritis TAP2 intron 19503088 rs3819721 chr6 32804798 G A 1.10E-09 Joint damage severity in rheumatoid arthritis TAP2 intron 23696630 rs241425 chr6 32804909 A G 1.31E-19 Type 1 diabetes TAP2 intron 17632545 rs241425 chr6 32804909 A G 9.90E-07 Asthma TAP2 intron 21907864 rs241425 chr6 32804909 A G 1.60E-94 Type 1 diabetes TAP2 intron pha002862 rs241424 chr6 32804934 G A 1.00E-16 Type 1 diabetes TAP2 intron 17632545 rs241424 chr6 32804934 G A 4.61E-08 Rheumatoid arthritis TAP2 intron 19503088 rs241424 chr6 32804934 G A 4.50E-05 Schizophrenia TAP2 intron 19571808 rs241424 chr6 32804934 G A 8.97E-04 Coronary heart disease TAP2 intron 21971053 rs241424 chr6 32804934 G A 7.96E-71 Type 1 diabetes TAP2 intron pha002862 rs3763349 chr6 32808232 A G 1.72E-10 Type 1 diabetes / / 17632545 rs9357155 chr6 32809848 G A 1.26E-12 Rheumatoid arthritis PSMB8 intron 17804836 rs9357155 chr6 32809848 G A 5.99E-13 Rheumatoid arthritis PSMB8 intron 19503088 rs9357155 chr6 32809848 G A 2.00E-12 Nephropathy PSMB8 intron 21399633 rs9357155 chr6 32809848 G A 8.90E-04 Coronary heart disease PSMB8 intron 21966275 rs6924102 chr6 32811383 A G 9.53E-11 Type 1 diabetes PSMB8 intron 17632545 rs6924102 chr6 32811383 A G 8.22E-05 Rheumatoid arthritis PSMB8 intron 17804836 rs6924102 chr6 32811383 A G 1.79E-04 Schizophrenia PSMB8 intron 19197363 rs6924102 chr6 32811383 A G 3.50E-08 Rheumatoid arthritis PSMB8 intron 19503088 rs6924102 chr6 32811383 A G 2.26E-04 Coronary heart disease PSMB8 intron 21971053 rs2071543 chr6 32811629 G T 1.52E-10 Rheumatoid arthritis PSMB8 missense 17804836 rs2071543 chr6 32811629 G T 6.46E-10 Rheumatoid arthritis PSMB8 missense 19503088 rs2071543 chr6 32811629 G T 7.20E-06 Nephropathy PSMB8 missense 21399633 rs2071540 chr6 32812916 T C 1.48E-13 Type 1 diabetes LOC100507463 intron 17632545 rs2071540 chr6 32812916 T C 9.90E-08 Rheumatoid arthritis LOC100507463 intron 19503088 rs2071540 chr6 32812916 T C 1.26E-69 Type 1 diabetes LOC100507463 intron pha002862 rs13215 chr6 32813852 C A 4.14E-04 Tourette syndrome TAP1 intron 22889924 rs4711312 chr6 32814659 A G 5.08E-04 Multiple complex diseases TAP1 intron 17554300 rs1057149 chr6 32814942 C T 0.00061 Prostate cancer TAP1 missense 23555315 rs1135216 chr6 32814975 T C 7.69E-05 Response to cholinesterase inhibitors in Alzheimer's disease TAP1 missense 23374588 rs735883 chr6 32816054 G A 4.59E-05 Coronary heart disease TAP1 intron 21971053 rs2071482 chr6 32816700 C A 5.14E-07 Multiple complex diseases TAP1 intron 17554300 rs41550019 chr6 32816772 C A 0.00053 Prostate cancer TAP1 missense 23555315 rs4148882 chr6 32816958 G A 6.07E-66 Multiple complex diseases TAP1 intron 17554300 rs4148882 chr6 32816958 G A 5.08E-08 Narcolepsy TAP1 intron 19629137 rs12529313 chr6 32817130 A G 9.31E-06 Multiple complex diseases TAP1 intron 17554300 rs2071538 chr6 32818678 G A 2.17E-11 Type 1 diabetes TAP1 intron 17632545 rs2071538 chr6 32818678 G A 2.00E-04 Schizophrenia TAP1 intron 19197363 rs2071538 chr6 32818678 G A 3.91E-09 Crohn's disease TAP1 intron 23266558 rs2071481 chr6 32819865 T C 8.63E-08 Type 1 diabetes TAP1 intron 17632545 rs2071481 chr6 32819865 T C 8.20E-05 Homocysteine levels,in plasma TAP1 intron 19525478 rs241420 chr6 32823393 C A,G,T 5.40E-05 Major depressive disorder (broad) PSMB9 intron 20038947 rs991760 chr6 32823567 G A 4.84E-10 Rheumatoid arthritis PSMB9 intron 19503088 rs17587 chr6 32825090 G A 1.52E-04 Coronary heart disease PSMB9 missense 21971053 rs20547 chr6 32826233 A G 1.75E-07 Multiple complex diseases PSMB9 cds-synon 17554300 rs9276825 chr6 32829714 G A 7.62E-10 Multiple complex diseases / / 17554300 rs9276825 chr6 32829714 G A 1.34E-05 Multiple sclerosis / / 17660530 rs9276825 chr6 32829714 G A 9.98E-04 Prostate cancer mortality / / 20978177 rs9276825 chr6 32829714 G A 2.20E-05 Urinary metabolites / / 21572414 rs9276826 chr6 32830568 A G 4.19E-04 Self-reported allergy / / 23817569 rs9276831 chr6 32832033 A G 4.67E-12 Type 1 diabetes / / 17632545 rs9276831 chr6 32832033 A G 6.73E-05 Lung function (forced vital capacity) / / pha003104 rs9276832 chr6 32832400 C T 1.20E-04 Multiple complex diseases / / 17554300 rs10484566 chr6 32835258 T G 3.82E-08 Type 1 diabetes / / 17632545 rs10484566 chr6 32835258 T G 8.22E-10 Rheumatoid arthritis / / 19503088 rs6931062 chr6 32835615 C A 6.32E-04 Myocardial Infarction / / pha002883 rs9276835 chr6 32837129 T A 3.73E-04 Myocardial Infarction / / pha002883 rs6929078 chr6 32838664 T C 3.54E-04 Myocardial Infarction / / pha002883 rs9276845 chr6 32840139 A G 3.54E-04 Myocardial Infarction / / pha002883 rs6903433 chr6 32842975 C T 0.00000095 Joint damage severity in rheumatoid arthritis / / 23696630 rs9276864 chr6 32843238 G T 7.12E-04 Myocardial Infarction / / pha002883 rs7757767 chr6 32845873 A G 6.16E-04 Myocardial Infarction / / pha002883 rs2187689 chr6 32852647 T C 3.00E-08 Disc degeneration (lumbar) / / 22993228 rs10046257 chr6 32854697 G A 3.00E-07 Disc degeneration (lumbar) / / 22993228 rs7740137 chr6 32855275 A G 1.36E-10 Multiple complex diseases / / 17554300 rs6457690 chr6 32855717 G A 9.00E-08 Disc degeneration (lumbar) / / 22993228 rs2018501 chr6 32856208 T C 2.50E-05 Urinary metabolites / / 21572414 rs1029296 chr6 32856381 T C 9.00E-08 Disc degeneration (lumbar) / / 22993228 rs1029295 chr6 32856482 T C 5.00E-07 Disc degeneration (lumbar) / / 22993228 rs6936004 chr6 32856934 T C 1.00E-07 Disc degeneration (lumbar) / / 22993228 rs10214886 chr6 32857419 T A 2.00E-07 Disc degeneration (lumbar) / / 22993228 rs7744666 chr6 32859712 T C 6.00E-08 Disc degeneration (lumbar) / / 22993228 rs11969002 chr6 32859748 G A 6.00E-08 Disc degeneration (lumbar) / / 22993228 rs9469300 chr6 32860752 G A 1.00E-07 Disc degeneration (lumbar) LOC100294145 nearGene-5 22993228 rs241409 chr6 32861920 A G 2.65E-10 Type 1 diabetes LOC100294145 nearGene-5 17632545 rs241409 chr6 32861920 A G 3.94E-15 Rheumatoid arthritis LOC100294145 nearGene-5 21156761 rs3749982 chr6 32862607 T A 1.00E-07 Disc degeneration (lumbar) / / 22993228 rs3749981 chr6 32862682 C T 9.28E-17 Rheumatoid arthritis / / 21156761 rs241407 chr6 32862740 C T 2.39E-10 Type 1 diabetes LOC100294145 intron 17632545 rs241407 chr6 32862740 C T 2.90E-15 Rheumatoid arthritis LOC100294145 intron 17804836 rs241407 chr6 32862740 C T 6.10E-13 Rheumatoid arthritis LOC100294145 intron 19503088 rs241407 chr6 32862740 C T 3.14E-15 Rheumatoid arthritis LOC100294145 intron 21156761 rs17508331 chr6 32865338 T C 8.83E-13 Multiple complex diseases LOC100294145 intron 17554300 rs241405 chr6 32865798 A G 1.60E-05 Urinary metabolites LOC100294145 intron 21572414 rs241404 chr6 32865997 T C 9.85E-05 Rheumatoid arthritis LOC100294145 intron 17804836 rs241404 chr6 32865997 T C 3.30E-04 Schizophrenia LOC100294145 intron 19197363 rs241404 chr6 32865997 T C 2.43E-10 Narcolepsy LOC100294145 intron 19629137 rs241403 chr6 32866992 T C 2.12E-70 Multiple complex diseases LOC100294145 intron 17554300 rs241403 chr6 32866992 T C 4.12E-07 Multiple sclerosis LOC100294145 intron 17660530 rs241403 chr6 32866992 T C 7.38E-11 Narcolepsy LOC100294145 intron 19629137 rs241403 chr6 32866992 T C 8.40E-06 Urinary metabolites LOC100294145 intron 21572414 rs241403 chr6 32866992 T C 1.60E-05 Diabetic nephropathy LOC100294145 intron pha002866 rs6912492 chr6 32869709 G A 2.23E-05 Non-obstructive azoospermia / / 22541561 rs9296057 chr6 32869915 A G 6.48E-07 Rheumatoid arthritis / / 19503088 rs3101942 chr6 32870057 G A 1.13E-94 Multiple complex diseases / / 17554300 rs3101942 chr6 32870057 G A 4.82E-17 Type 1 diabetes / / 17632545 rs3101942 chr6 32870057 G A 4.39E-07 Multiple sclerosis / / 17660530 rs3101942 chr6 32870057 G A 4.42E-11 Narcolepsy / / 19629137 rs3101942 chr6 32870057 G A 3.09E-110 Type 1 diabetes / / pha002862 rs3101942 chr6 32870057 G A 6.50E-05 Diabetic nephropathy / / pha002866 rs241400 chr6 32871536 G A 2.97E-48 Multiple complex diseases LOC100294145 nearGene-3 17554300 rs241400 chr6 32871536 G A 2.11E-11 Narcolepsy LOC100294145 nearGene-3 19629137 rs154986 chr6 32879233 G T 7.06E-07 Rheumatoid arthritis / / 19503088 rs154986 chr6 32879233 G T 7.60E-05 Homocysteine levels,in plasma / / 19525478 rs154982 chr6 32880545 C G 3.72E-11 Multiple complex diseases / / 17554300 rs154981 chr6 32880993 C T 1.11E-16 Type 1 diabetes / / 17632545 rs154981 chr6 32880993 C T 1.44E-06 Rheumatoid arthritis / / 17804836 rs154981 chr6 32880993 C T 1.00E-04 Schizophrenia / / 19197363 rs154981 chr6 32880993 C T 3.21E-11 Rheumatoid arthritis / / 19503088 rs154981 chr6 32880993 C T 3.14E-91 Type 1 diabetes / / pha002862 rs9501239 chr6 32895580 A G 1.18E-09 Type 1 diabetes / / 17632545 rs154978 chr6 32899296 C T 6.00E-15 Type 1 diabetes / / 17632545 rs154978 chr6 32899296 C T 4.49E-81 Type 1 diabetes / / pha002862 rs3132131 chr6 32899485 A G 2.22E-16 Type 1 diabetes / / 17632545 rs3132131 chr6 32899485 A G 2.34E-06 Hodgkin's lymphoma / / 24149102 rs154977 chr6 32900018 C G 6.32E-10 Chronic hepatitis B infection / / 23760081 rs154972 chr6 32900651 A G 1.46E-07 Hepatitis B / / 21750111 rs154972 chr6 32900651 A G 1.25E-10 Coronary heart disease / / 21971053 rs154972 chr6 32900651 A G 6.14E-06 Hodgkin's lymphoma / / 24149102 rs181997 chr6 32900718 G A 7.84E-06 Rheumatoid arthritis / / 19503088 rs181997 chr6 32900718 G A 1.13E-06 Hepatitis B / / 21750111 rs181997 chr6 32900718 G A 2.10E-08 Coronary heart disease / / 21971053 rs181997 chr6 32900718 G A 2.42E-07 Hodgkin's lymphoma / / 24149102 rs181997 chr6 32900718 G A 8.20E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3129299 chr6 32900787 C T 3.35E-05 Coronary heart disease / / 21971053 rs3129299 chr6 32900787 C T 8.76E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs3129299 chr6 32900787 C T 4.33E-05 Lung function (forced vital capacity) / / pha003104 rs3132132 chr6 32901934 G A 7.29E-04 Lymphocyte counts HLA-DMB nearGene-3 22286170 rs68600 chr6 32903724 C T 9.35E-04 Coronary heart disease HLA-DMB intron 21971053 rs151719 chr6 32903900 C T 7.57E-09 Multiple complex diseases HLA-DMB intron 17554300 rs151719 chr6 32903900 C T 1.43E-16 Multiple sclerosis HLA-DMB intron 17660530 rs151719 chr6 32903900 C T 1.97E-07 Rheumatoid arthritis HLA-DMB intron 17804836 rs151719 chr6 32903900 C T 4.10E-04 Alzheimer's disease HLA-DMB intron 17998437 rs151719 chr6 32903900 C T 1.19E-11 Rheumatoid arthritis HLA-DMB intron 19503088 rs151719 chr6 32903900 C T 2.20E-04 Coronary heart disease HLA-DMB intron 21971053 rs2071556 chr6 32904601 G T 1.11E-04 Lung function (forced expiratory volume in 1 second) HLA-DMB intron 24023788 rs1042337 chr6 32904981 G A 6.46E-07 Rheumatoid arthritis HLA-DMB missense 19503088 rs714289 chr6 32905811 A G 6.55E-06 Rheumatoid arthritis HLA-DMB intron 19503088 rs3101944 chr6 32911127 C T 0.00000005 Joint damage severity in rheumatoid arthritis / / 23696630 rs2395296 chr6 32911814 A G 7.53E-07 Rheumatoid arthritis / / 19503088 rs1480380 chr6 32913246 C T 1.00E-16 Type 1 diabetes BRD2 nearGene-5 17632545 rs1480380 chr6 32913246 C T 6.75E-11 Rheumatoid arthritis BRD2 nearGene-5 17804836 rs1480380 chr6 32913246 C T 1.19E-14 Rheumatoid arthritis BRD2 nearGene-5 19503088 rs1480380 chr6 32913246 C T 6.00E-07 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) BRD2 nearGene-5 23453885 rs1480380 chr6 32913246 C T 6.30E-07 Systemic lupus erythematosus BRD2 nearGene-5 24871463 rs3130595 chr6 32914297 G A 0.00000018 Joint damage severity in rheumatoid arthritis BRD2 nearGene-5 23696630 rs194682 chr6 32914613 C T 4.03E-07 Rheumatoid arthritis / / 17804836 rs194682 chr6 32914613 C T 3.28E-08 Rheumatoid arthritis / / 19503088 rs194682 chr6 32914613 C T 2.60E-05 Kawasaki disease / / 22446962 rs194682 chr6 32914613 C T 7.58E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs16871226 chr6 32915851 A G 2.00E-06 IgG glycosylation / / 23382691 rs1063478 chr6 32917544 C T 3.54E-05 HIV-1 control HLA-DMA missense 20041166 rs1050391 chr6 32917857 A G 1.18E-09 Multiple complex diseases HLA-DMA intron 17554300 rs1050391 chr6 32917857 A G 1.46E-11 Multiple sclerosis HLA-DMA intron 17660530 rs11539216 chr6 32917980 G A 7.35E-10 Multiple complex diseases HLA-DMA intron 17554300 rs11539216 chr6 32917980 G A 9.95E-11 Multiple sclerosis HLA-DMA intron 17660530 rs3135029 chr6 32921774 T G 4.88E-05 Rheumatoid arthritis HLA-DMA nearGene-5 17804836 rs9378127 chr6 32922459 G A 2.55E-06 HIV-1 control HLA-DMA nearGene-5 20041166 rs9378127 chr6 32922459 G A 0.0000121 HIV-1 infection (natural long-term nonprogression) HLA-DMA nearGene-5 22238471 rs209473 chr6 32922908 A C 2.42E-09 Type 1 diabetes / / 17632545 rs209473 chr6 32922908 A C 5.00E-05 Kawasaki disease / / 22446962 rs209473 chr6 32922908 A C 8.26E-05 Heart Rate / / pha003051 rs1431393 chr6 32923988 G A 0.00000018 Joint damage severity in rheumatoid arthritis / / 23696630 rs1431394 chr6 32923993 T G 0.00000018 Joint damage severity in rheumatoid arthritis / / 23696630 rs28724903 chr6 32924061 C T 3.21E-05 HIV-1 control / / 20041166 rs209474 chr6 32924584 A G 8.37E-06 Rheumatoid arthritis / / 17804836 rs209474 chr6 32924584 A G 8.30E-04 Coronary heart disease / / 21971053 rs209474 chr6 32924584 A G 2.70E-05 Kawasaki disease / / 22446962 rs209474 chr6 32924584 A G 0.0000429 C-reactive protein / / 23505291 rs580962 chr6 32925692 C T 1.55E-11 Type 1 diabetes / / 17632545 rs580962 chr6 32925692 C T 4.57E-05 Body Composition / / pha003012 rs580962 chr6 32925692 C T 5.12E-05 Body Mass Index / / pha003021 rs9276933 chr6 32930795 T C 2.76E-06 Schizophrenia / / 21926974 rs206783 chr6 32932150 C A 5.94E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs1367727 chr6 32934409 T C 0.00000018 Joint damage severity in rheumatoid arthritis / / 23696630 rs206786 chr6 32935179 A C 5.94E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) BRD2 nearGene-5 23648065 rs3918149 chr6 32936373 G A 3.87E-05 HIV-1 control BRD2 nearGene-5 20041166 rs9276935 chr6 32936441 T C 0.00000018 Joint damage severity in rheumatoid arthritis BRD2 UTR-5 23696630 rs17840186 chr6 32938199 G A 1.45E-11 Multiple complex diseases BRD2 intron 17554300 rs17840186 chr6 32938199 G A 4.94E-10 Multiple sclerosis BRD2 intron 17660530 rs3130597 chr6 32941191 T C 2.29E-05 Rheumatoid arthritis BRD2 intron 17804836 rs12196597 chr6 32941214 C A 6.21E-06 HIV-1 control BRD2 intron 20041166 rs620202 chr6 32941910 G T 1.68E-06 Rheumatoid arthritis BRD2 intron 17804836 rs620202 chr6 32941910 G T 2.08E-06 Rheumatoid arthritis BRD2 intron 19503088 rs620202 chr6 32941910 G T 3.88E-05 Crohn's disease BRD2 intron 23266558 rs15912 chr6 32944094 G C 0.00000018 Joint damage severity in rheumatoid arthritis BRD2 cds-synon 23696630 rs11908 chr6 32944746 G A 2.32E-05 Crohn's disease BRD2 intron 23266558 rs144861747 chr6 32948385 G A 0.00012 Breast cancer BRD2 missense 23555315 rs144861747 chr6 32948385 G A 0.0001 Breast cancer (ER positive) BRD2 missense 23555315 rs2071876 chr6 32948426 C A,G,T 0.00000066 Joint damage severity in rheumatoid arthritis BRD2 cds-synon 23696630 rs565876 chr6 32950050 G A 1.07E-06 Rheumatoid arthritis / / 17804836 rs565876 chr6 32950050 G A 1.15E-07 Rheumatoid arthritis / / 19503088 rs565876 chr6 32950050 G A 2.79E-05 Crohn's disease / / 23266558 rs3135034 chr6 32951662 T C 8.73E-19 Rheumatoid arthritis / / 17804836 rs3135034 chr6 32951662 T C 6.76E-39 Rheumatoid arthritis / / 19503088 rs3135034 chr6 32951662 T C 0.00000018 Joint damage severity in rheumatoid arthritis / / 23696630 rs206777 chr6 32952546 G A 2.18E-12 Type 1 diabetes / / 17632545 rs3097645 chr6 32953280 G C 2.00E-06 IgG glycosylation / / 23382691 rs3097645 chr6 32953280 G C 3.00E-06 IgG glycosylation / / 23382691 rs3097645 chr6 32953280 G C 5.00E-06 IgG glycosylation / / 23382691 rs3097645 chr6 32953280 G C 6.00E-06 IgG glycosylation / / 23382691 rs3097645 chr6 32953280 G C 6.00E-07 IgG glycosylation / / 23382691 rs3097645 chr6 32953280 G C 7.00E-06 IgG glycosylation / / 23382691 rs3097646 chr6 32954689 A C 0.00000018 Joint damage severity in rheumatoid arthritis / / 23696630 rs188245 chr6 32955976 A G 6.61E-59 Multiple complex diseases / / 17554300 rs188245 chr6 32955976 A G 1.18E-09 Type 1 diabetes / / 17632545 rs188245 chr6 32955976 A G 5.30E-05 Kawasaki disease / / 22446962 rs188245 chr6 32955976 A G 2.84E-05 Crohn's disease / / 23266558 rs188245 chr6 32955976 A G 7.00E-04 Systemic lupus erythematosus / / 24871463 rs3129305 chr6 32959180 G C 1.26E-10 Multiple complex diseases / / 17554300 rs3129305 chr6 32959180 G C 1.70E-11 Multiple sclerosis / / 17660530 rs206769 chr6 32961104 C T 1.58E-08 Type 1 diabetes / / 17632545 rs206769 chr6 32961104 C T 1.61E-05 Coronary heart disease / / 21971053 rs9500927 chr6 32961361 G A 8.61E-05 Chronic Hepatitis C infection / / 21725309 rs9500927 chr6 32961361 G A 4.00E-09 Asthma / / 21804548 rs172275 chr6 32961621 A G 7.68E-05 Cognitive test performance / / 20125193 rs206767 chr6 32962420 C A 6.40E-04 Crohn's disease / / 23266558 rs3128947 chr6 32965062 A G 3.63E-05 Multiple complex diseases / / 17554300 rs176248 chr6 32965942 G A 3.45E-08 Multiple complex diseases / / 17554300 rs2395300 chr6 32968276 G A 1.56E-07 Rheumatoid arthritis / / 17804836 rs2395300 chr6 32968276 G A 1.50E-09 Rheumatoid arthritis / / 19503088 rs2395300 chr6 32968276 G A 9.67E-05 Blood Pressure / / pha003039 rs172274 chr6 32969457 C T 1.19E-08 Rheumatoid arthritis / / 17804836 rs172274 chr6 32969457 C T 9.16E-11 Rheumatoid arthritis / / 19503088 rs172274 chr6 32969457 C T 6.42E-05 Blood Pressure / / pha003039 rs206762 chr6 32970450 G A 1.43E-06 Rheumatoid arthritis / / 17804836 rs206762 chr6 32970450 G A 3.88E-06 Rheumatoid arthritis / / 19503088 rs3130602 chr6 32972207 C T 5.00E-10 Multiple complex diseases HLA-DOA UTR-3 17554300 rs3128935 chr6 32972404 T C 9.00E-06 Periodontitis (CDC/AAP) HLA-DOA UTR-3 24024966 rs3129304 chr6 32973743 C T 6.58E-11 Multiple complex diseases HLA-DOA UTR-3 17554300 rs3129303 chr6 32973878 C T 5.77E-11 Multiple complex diseases HLA-DOA UTR-3 17554300 rs417812 chr6 32974081 C T 1.46E-10 Rheumatoid arthritis HLA-DOA UTR-3 21156761 rs408036 chr6 32974268 T C 1.17E-12 Rheumatoid arthritis HLA-DOA UTR-3 21156761 rs3129302 chr6 32974343 C T 3.90E-06 Multiple complex diseases HLA-DOA UTR-3 17554300 rs2581 chr6 32974401 G T 5.28E-10 Rheumatoid arthritis HLA-DOA UTR-3 17804836 rs2581 chr6 32974401 G T 4.82E-13 Rheumatoid arthritis HLA-DOA UTR-3 19503088 rs2581 chr6 32974401 G T 2.52E-10 Rheumatoid arthritis HLA-DOA UTR-3 21156761 rs378352 chr6 32974934 G A 4.26E-09 Rheumatoid arthritis HLA-DOA cds-synon 21156761 rs399604 chr6 32975014 T C 9.48E-09 Multiple complex diseases HLA-DOA intron 17554300 rs399604 chr6 32975014 T C 1.33E-10 Rheumatoid arthritis HLA-DOA intron 21156761 rs399604 chr6 32975014 T C 1.00E-10 Platelet counts HLA-DOA intron 22139419 rs365066 chr6 32975257 C T 1.32E-08 Multiple complex diseases HLA-DOA cds-synon 17554300 rs365066 chr6 32975257 C T 1.58E-10 Rheumatoid arthritis HLA-DOA cds-synon 21156761 rs453779 chr6 32975381 A G 2.84E-14 Rheumatoid arthritis HLA-DOA intron 21156761 rs6920363 chr6 32976572 C A 1.86E-04 Multiple complex diseases HLA-DOA intron 17554300 rs2284191 chr6 32976654 G A 4.47E-04 Parkinson's disease HLA-DOA intron 17052657 rs381218 chr6 32977420 G T 8.84E-04 Amyotrophic Lateral Sclerosis HLA-DOA nearGene-5 17362836 rs381218 chr6 32977420 G T 3.94E-08 Rheumatoid arthritis HLA-DOA nearGene-5 17804836 rs381218 chr6 32977420 G T 9.65E-08 Rheumatoid arthritis HLA-DOA nearGene-5 19503088 rs381218 chr6 32977420 G T 6.95E-07 Rheumatoid arthritis HLA-DOA nearGene-5 21156761 rs6911639 chr6 32978178 T C 3.25E-07 Rheumatoid arthritis HLA-DOA nearGene-5 19503088 rs6911639 chr6 32978178 T C 2.68E-07 Coronary heart disease HLA-DOA nearGene-5 21971053 rs429916 chr6 32978587 C A 4.15E-09 Multiple complex diseases HLA-DOA nearGene-5 17554300 rs429916 chr6 32978587 C A 1.12E-10 Rheumatoid arthritis HLA-DOA nearGene-5 17804836 rs429916 chr6 32978587 C A 8.96E-15 Rheumatoid arthritis HLA-DOA nearGene-5 19503088 rs429916 chr6 32978587 C A 8.89E-05 Self-reported allergy HLA-DOA nearGene-5 23817569 rs4713603 chr6 32979609 T C 1.74E-04 Multiple complex diseases / / 17554300 rs447088 chr6 32979980 A C 3.23E-09 Rheumatoid arthritis / / 21156761 rs9276991 chr6 32981848 A G 5.95E-08 Type 1 diabetes / / 17632545 rs9276991 chr6 32981848 A G 3.38E-08 Hepatitis B / / 21750111 rs9276991 chr6 32981848 A G 1.94E-12 Coronary heart disease / / 21971053 rs1367731 chr6 32985199 C G,T 2.68E-10 Multiple complex diseases / / 17554300 rs1367731 chr6 32985199 C G,T 6.46E-07 Rheumatoid arthritis / / 19503088 rs1367731 chr6 32985199 C G,T 7.78E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs435119 chr6 32986835 G C 6.68E-09 Rheumatoid arthritis / / 21156761 rs423639 chr6 32987774 C T 4.66E-09 Type 1 diabetes / / 17632545 rs423639 chr6 32987774 C T 3.38E-08 Hepatitis B / / 21750111 rs423639 chr6 32987774 C T 1.87E-12 Coronary heart disease / / 21971053 rs9296068 chr6 32988695 T G 7.01E-09 Rheumatoid arthritis / / 19503088 rs3135196 chr6 32997577 A C 5.15E-11 Multiple complex diseases / / 17554300 rs9277027 chr6 32998238 A G 7.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs9277029 chr6 32998806 C T 7.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs493158 chr6 33000150 C T 3.61E-09 Rheumatoid arthritis / / 21156761 rs380468 chr6 33001488 A G 4.56E-13 Rheumatoid arthritis / / 21156761 rs448733 chr6 33003687 C A 1.91E-07 Multiple complex diseases / / 17554300 rs141112 chr6 33004427 T C 3.76E-13 Rheumatoid arthritis / / 21156761 rs444821 chr6 33004935 C T 3.76E-13 Rheumatoid arthritis / / 21156761 rs439852 chr6 33005208 C T 2.86E-09 Multiple complex diseases / / 17554300 rs439852 chr6 33005208 C T 3.76E-13 Rheumatoid arthritis / / 21156761 rs412065 chr6 33005273 G A 3.76E-13 Rheumatoid arthritis / / 21156761 rs379569 chr6 33005600 G A 3.76E-13 Rheumatoid arthritis / / 21156761 rs406477 chr6 33005644 T C 3.56E-11 Rheumatoid arthritis / / 21156761 rs426523 chr6 33005689 C T 3.76E-13 Rheumatoid arthritis / / 21156761 rs9277052 chr6 33005932 T C 2.33E-11 Rheumatoid arthritis / / 21156761 rs9277053 chr6 33006222 G A 7.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs663310 chr6 33006869 T C 3.76E-13 Rheumatoid arthritis / / 21156761 rs375912 chr6 33016728 T C 8.13E-04 Suicide attempts in bipolar disorder / / 21041247 rs3130578 chr6 33018310 T C 1.44E-08 Multiple complex diseases / / 17554300 rs3130578 chr6 33018310 T C 7.03E-05 Multiple sclerosis / / 17660530 rs446853 chr6 33018377 C T 1.83E-11 Multiple complex diseases / / 17554300 rs3130179 chr6 33018459 A G 1.33E-08 Multiple complex diseases / / 17554300 rs3130179 chr6 33018459 A G 7.61E-05 Multiple sclerosis / / 17660530 rs9296069 chr6 33018957 C A,T 6.66E-12 Multiple complex diseases / / 17554300 rs440841 chr6 33019643 T G 3.51E-08 Multiple complex diseases / / 17554300 rs3128952 chr6 33019973 A T 2.92E-06 Multiple complex diseases / / 17554300 rs3130180 chr6 33020286 C G 3.56E-06 Multiple complex diseases / / 17554300 rs3097662 chr6 33020777 C T 6.13E-06 Multiple complex diseases / / 17554300 rs3128955 chr6 33021192 A T 2.84E-06 Multiple complex diseases / / 17554300 rs9277183 chr6 33023370 C T 4.33E-07 Multiple complex diseases / / 17554300 rs9277194 chr6 33023894 C T 8.19E-04 Multiple complex diseases / / 17554300 rs9277196 chr6 33023946 A G 9.77E-13 Multiple complex diseases / / 17554300 rs367645 chr6 33024499 G A 9.07E-06 Multiple complex diseases / / 17554300 rs376877 chr6 33024606 C G 1.11E-05 Multiple complex diseases / / 17554300 rs3135402 chr6 33024654 A C 3.01E-04 Alzheimer's disease (late onset) / / 21379329 rs3135402 chr6 33024654 A C 7.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3135402 chr6 33024654 A C 2.80E-09 Chronic hepatitis B infection / / 23760081 rs9380335 chr6 33025174 C G 4.31E-11 Chronic hepatitis B infection / / 23760081 rs2116260 chr6 33025440 T C 5.79E-16 Cervical cancer / / 23817570 rs7741912 chr6 33026087 C G 1.89E-11 Chronic hepatitis B infection / / 23760081 rs422544 chr6 33026110 A C 3.89E-06 IgE levels / / 22075330 rs422544 chr6 33026110 A C 6.34E-04 Acute lung injury / / 22295056 rs422544 chr6 33026110 A C 1.12E-10 Chronic hepatitis B infection / / 23760081 rs2395309 chr6 33026246 A G 3.45E-14 Rheumatoid arthritis / / 17804836 rs2395309 chr6 33026246 A G 1.16E-13 Hepatitis B / / 19349983 rs2395309 chr6 33026246 A G 9.30E-23 Rheumatoid arthritis / / 19503088 rs2395309 chr6 33026246 A G 1.28E-16 Hepatitis B / / 21750111 rs2395309 chr6 33026246 A G 1.26E-07 Hepatitis B vaccine response / / 21764829 rs2395309 chr6 33026246 A G 2.71E-11 Chronic hepatitis B infection / / 23760081 rs34937821 chr6 33026553 G A 3.88E-11 Chronic hepatitis B infection / / 23760081 rs6457710 chr6 33029437 A G 1.29E-06 Multiple complex diseases / / 17554300 rs9469325 chr6 33030441 C A 4.26E-11 Chronic hepatitis B infection / / 23760081 rs9469329 chr6 33031602 C T 2.52E-11 Chronic hepatitis B infection / / 23760081 rs17214519 chr6 33032188 G A 2.71E-11 Chronic hepatitis B infection HLA-DPA1 nearGene-3 23760081 rs7905 chr6 33032975 T C 5.53E-04 Self-reported allergy HLA-DPA1 UTR-3 23817569 rs3077 chr6 33033022 A G 3.23E-12 Multiple complex diseases HLA-DPA1 UTR-3 17554300 rs3077 chr6 33033022 A G 5.98E-14 Rheumatoid arthritis HLA-DPA1 UTR-3 17804836 rs3077 chr6 33033022 A G 1.59E-13 Hepatitis B HLA-DPA1 UTR-3 19349983 rs3077 chr6 33033022 A G 3.76E-22 Rheumatoid arthritis HLA-DPA1 UTR-3 19503088 rs3077 chr6 33033022 A G 2.00E-61 Hepatitis B HLA-DPA1 UTR-3 21750111 rs3077 chr6 33033022 A G 4.47E-08 Hepatitis B vaccine response HLA-DPA1 UTR-3 21764829 rs3077 chr6 33033022 A G 1.00E-09 Hepatitis B (viral clearance) HLA-DPA1 UTR-3 22737229 rs3077 chr6 33033022 A G 4.00E-45 Hepatitis B (viral clearance) HLA-DPA1 UTR-3 22737229 rs3077 chr6 33033022 A G 6.66E-06 Esophageal cancer (squamous cell) HLA-DPA1 UTR-3 22960999 rs3077 chr6 33033022 A G 1.87E-61 Hepatocellular carcinoma (hepatitis B virus related) HLA-DPA1 UTR-3 23242368 rs3077 chr6 33033022 A G 5.00E-39 Chronic hepatitis B infection HLA-DPA1 UTR-3 23760081 rs7751953 chr6 33033351 G T 2.71E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs2301226 chr6 33034596 G A 1.71E-09 Hepatitis B HLA-DPA1 intron 21750111 rs9469331 chr6 33034785 G A 2.71E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs1367728 chr6 33034815 G A 7.28E-09 Type 1 diabetes HLA-DPA1 intron 17632545 rs1367728 chr6 33034815 G A 2.44E-05 Hepatitis B HLA-DPA1 intron 21750111 rs9469332 chr6 33034876 T C 2.71E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs9469341 chr6 33035877 A G 1.28E-16 Hepatitis B HLA-DPA1 intron 21750111 rs9469341 chr6 33035877 A G 1.03E-07 Hepatitis B vaccine response HLA-DPA1 intron 21764829 rs9469341 chr6 33035877 A G 2.71E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs3179779 chr6 33035969 A G 2.44E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs3180554 chr6 33036177 A G 4.73E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs3180553 chr6 33036210 G T 3.53E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs1126769 chr6 33036435 T G 2.71E-11 Chronic hepatitis B infection HLA-DPA1 missense 23760081 rs1042190 chr6 33036999 T C 1.67E-11 Chronic hepatitis B infection HLA-DPA1 missense 23760081 rs3830066 chr6 33037187 C G 4.71E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs36081724 chr6 33037265 C A 2.71E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs1126542 chr6 33037424 T A,C,G 2.71E-11 Chronic hepatitis B infection HLA-DPA1 missense 23760081 rs2308911 chr6 33037580 T G 2.37E-11 Chronic hepatitis B infection HLA-DPA1 missense 23760081 rs10214910 chr6 33037675 C A 2.71E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs2301224 chr6 33038369 C A 1.02E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs2301220 chr6 33038766 C T 1.81E-13 Hepatitis B HLA-DPA1 intron 19349983 rs2301220 chr6 33038766 C T 1.38E-16 Hepatitis B HLA-DPA1 intron 21750111 rs2301220 chr6 33038766 C T 2.60E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs28452918 chr6 33039295 T A 4.26E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs9277341 chr6 33039625 T C 1.25E-06 Rheumatoid arthritis HLA-DPA1 intron 17804836 rs9277341 chr6 33039625 T C 1.84E-08 Hepatitis B HLA-DPA1 intron 19349983 rs9277341 chr6 33039625 T C 2.86E-15 Rheumatoid arthritis HLA-DPA1 intron 19503088 rs9277341 chr6 33039625 T C 1.47E-05 Hepatitis B HLA-DPA1 intron 21750111 rs9277341 chr6 33039625 T C 2.19E-11 Hepatitis B vaccine response HLA-DPA1 intron 21764829 rs9277341 chr6 33039625 T C 2.18E-39 Wegener's granulomatosis HLA-DPA1 intron 23740775 rs13213149 chr6 33039686 T C 1.64E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs4640928 chr6 33040596 A G 1.64E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs6914849 chr6 33040715 G A 8.96E-12 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs9380336 chr6 33040736 T C 1.12E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs6914995 chr6 33040744 G C 1.64E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs9380338 chr6 33040798 T C 1.64E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs9348904 chr6 33040835 A G 5.84E-13 Multiple complex diseases HLA-DPA1 intron 17554300 rs9348904 chr6 33040835 A G 1.94E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs1431399 chr6 33041034 A C,G,T 3.26E-16 Hepatitis B HLA-DPA1 intron 21750111 rs1431399 chr6 33041034 A C,G,T 1.12E-10 Hepatitis B vaccine response HLA-DPA1 intron 21764829 rs1431399 chr6 33041034 A C,G,T 1.02E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs9357156 chr6 33041073 A C 2.66E-09 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs1431400 chr6 33041176 C T 1.35E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs1431401 chr6 33041186 G A 9.15E-12 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs9296073 chr6 33042551 C T 1.64E-09 Multiple complex diseases HLA-DPA1 intron 17554300 rs987870 chr6 33042880 A G 4.68E-10 Rheumatoid arthritis HLA-DPA1 intron 17804836 rs987870 chr6 33042880 A G 4.53E-17 Rheumatoid arthritis HLA-DPA1 intron 19503088 rs987870 chr6 33042880 A G 2.00E-20 Systemic sclerosis HLA-DPA1 intron 21779181 rs987870 chr6 33042880 A G 2.00E-10 Asthma HLA-DPA1 intron 21814517 rs987870 chr6 33042880 A G 9.24E-05 Self-reported allergy HLA-DPA1 intron 23817569 rs2071351 chr6 33043930 A G 1.64E-11 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs2071352 chr6 33044188 T A 9.21E-05 Self-reported allergy HLA-DPA1 intron 23817569 rs2071353 chr6 33044257 T C 1.07E-10 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs2071353 chr6 33044257 T C 7.17E-04 Self-reported allergy HLA-DPA1 intron 23817569 rs2071354 chr6 33044388 T C 8.61E-05 Self-reported allergy HLA-DPA1 intron 23817569 rs2856816 chr6 33045500 T C 2.60E-09 Multiple complex diseases HLA-DPA1 intron 17554300 rs2856816 chr6 33045500 T C 2.32E-06 Esophageal cancer (squamous cell) HLA-DPA1 intron 22960999 rs3135021 chr6 33045558 G A 1.63E-08 Hepatitis B HLA-DPA1 intron 19349983 rs3135021 chr6 33045558 G A 7.24E-13 Hepatitis B HLA-DPA1 intron 21750111 rs3135021 chr6 33045558 G A 7.23E-07 IgE levels HLA-DPA1 intron 22075330 rs2567279 chr6 33046662 T C 1.74E-08 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs1431402 chr6 33046915 T A 1.11E-05 Aspirin exacerbated respiratory disease in asthmatics HLA-DPA1 intron 23180272 rs1431403 chr6 33047031 T C 1.12E-10 Multiple complex diseases HLA-DPA1 intron 17554300 rs1431403 chr6 33047031 T C 1.32E-09 Rheumatoid arthritis HLA-DPA1 intron 21156761 rs1431403 chr6 33047031 T C 7.40E-04 Cervical cancer HLA-DPA1 intron 21716314 rs1431403 chr6 33047031 T C 6.18E-05 IgE levels HLA-DPA1 intron 22075330 rs1431403 chr6 33047031 T C 8.97E-16 Hepatitis B (viral clearance) HLA-DPA1 intron 22737229 rs1431403 chr6 33047031 T C 3.95E-10 Chronic hepatitis B infection HLA-DPA1 intron 23760081 rs2856822 chr6 33047432 A C 3.62E-07 Hepatitis B HLA-DPA1 intron 24162738 rs3135024 chr6 33047466 T C 2.17E-05 IgE levels HLA-DPA1 intron 22075330 rs1042151 chr6 33048661 A G 5.00E-07 Aspirin exacerbated respiratory disease in asthmatics HLA-DPB1 missense 23180272 rs1042169 chr6 33048686 G A,T 7.77E-07 Hepatitis B HLA-DPB1 missense 24162738 rs1042169 chr6 33048686 G A,T 2.62E-11 Chronic hepatitis B infection HLA-DPB1 missense 23760081 rs553665868 chr6 33048694 A G 8.11E-07 Hepatitis B HLA-DPB1 missense 24162738 rs553665868 chr6 33048694 A G 2.17E-11 Chronic hepatitis B infection HLA-DPB1 missense 23760081 rs7770370 chr6 33048921 A G 2.56E-06 Hepatitis B HLA-DPB1 intron 24162738 rs7770370 chr6 33048921 A G 7.44E-09 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs7770370 chr6 33048921 A G 6.24E-07 Cervical cancer HLA-DPB1 intron 23817570 rs928976 chr6 33049211 C T 1.45E-06 Hepatitis B HLA-DPB1 intron 24162738 rs928976 chr6 33049211 C T 4.54E-09 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs928976 chr6 33049211 C T 4.68E-05 IgE levels HLA-DPB1 intron 22075330 rs928976 chr6 33049211 C T 1.33E-10 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs2567289 chr6 33049565 C G 6.16E-04 Self-reported allergy HLA-DPB1 intron 23817569 rs9277357 chr6 33049979 A G 2.31E-10 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277359 chr6 33050024 C A 1.97E-08 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277359 chr6 33050024 C A 2.77E-05 IgE levels HLA-DPB1 intron 22075330 rs9277359 chr6 33050024 C A 1.77E-10 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277377 chr6 33050203 C G 9.02E-07 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277378 chr6 33050279 A G 2.00E-10 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) HLA-DPB1 intron 17982456 rs9277378 chr6 33050279 A G 5.84E-09 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277378 chr6 33050279 A G 4.17E-05 IgE levels HLA-DPB1 intron 22075330 rs9277378 chr6 33050279 A G 7.59E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277386 chr6 33050499 A G 1.68E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs3128960 chr6 33050654 G A 2.00E-08 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs3097674 chr6 33050683 A G 2.00E-08 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs3128961 chr6 33050742 G A 2.00E-08 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs3128961 chr6 33050742 G A 9.05E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs3128961 chr6 33050742 G A 5.03E-06 Cervical cancer HLA-DPB1 intron 23817570 rs9277392 chr6 33050829 G C 5.90E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277392 chr6 33050829 G C 2.14E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277393 chr6 33050877 A G 5.90E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277394 chr6 33050970 A T 5.90E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277394 chr6 33050970 A T 2.39E-09 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277394 chr6 33050970 A T 5.64E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277394 chr6 33050970 A T 2.03E-05 IgE levels HLA-DPB1 intron 22075330 rs9277394 chr6 33050970 A T 1.61E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277395 chr6 33051051 A G 5.90E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277395 chr6 33051051 A G 2.17E-09 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277395 chr6 33051051 A G 5.62E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277395 chr6 33051051 A G 2.02E-05 IgE levels HLA-DPB1 intron 22075330 rs9277395 chr6 33051051 A G 1.48E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277396 chr6 33051139 G A 2.17E-09 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277396 chr6 33051139 G A 5.61E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277396 chr6 33051139 G A 2.01E-05 IgE levels HLA-DPB1 intron 22075330 rs9277396 chr6 33051139 G A 1.48E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277397 chr6 33051277 A G 9.71E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277398 chr6 33051280 T C 9.71E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277401 chr6 33051394 C T 8.83E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277406 chr6 33051554 T C 4.30E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277408 chr6 33051562 G A 4.85E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277409 chr6 33051624 C G 4.74E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277409 chr6 33051624 C G 2.17E-09 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277409 chr6 33051624 C G 5.61E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277409 chr6 33051624 C G 2.01E-05 IgE levels HLA-DPB1 intron 22075330 rs9277409 chr6 33051624 C G 1.48E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277410 chr6 33051640 G A 5.90E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277410 chr6 33051640 G A 2.17E-09 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277410 chr6 33051640 G A 5.61E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277410 chr6 33051640 G A 2.00E-05 IgE levels HLA-DPB1 intron 22075330 rs9277410 chr6 33051640 G A 1.48E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277411 chr6 33051683 C T 5.90E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277412 chr6 33051689 C T 5.90E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277412 chr6 33051689 C T 4.88E-09 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277412 chr6 33051689 C T 6.00E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277412 chr6 33051689 C T 2.39E-05 IgE levels HLA-DPB1 intron 22075330 rs9277419 chr6 33051777 A G 1.48E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277420 chr6 33051790 C A 5.77E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277421 chr6 33051820 G A 2.17E-09 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277421 chr6 33051820 G A 5.61E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277421 chr6 33051820 G A 1.98E-05 IgE levels HLA-DPB1 intron 22075330 rs9277423 chr6 33051845 T A 3.22E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277424 chr6 33051865 A C 5.14E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277424 chr6 33051865 A C 2.17E-09 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277424 chr6 33051865 A C 5.61E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277424 chr6 33051865 A C 1.98E-05 IgE levels HLA-DPB1 intron 22075330 rs9277426 chr6 33051910 C A,G,T 6.23E-10 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277426 chr6 33051910 C A,G,T 5.63E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277426 chr6 33051910 C A,G,T 2.86E-05 IgE levels HLA-DPB1 intron 22075330 rs9277426 chr6 33051910 C A,G,T 1.48E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277427 chr6 33051969 A T 5.53E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277428 chr6 33051976 T A 4.02E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277428 chr6 33051976 T A 2.11E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277431 chr6 33052028 C T 5.08E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277431 chr6 33052028 C T 2.17E-09 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277431 chr6 33052028 C T 5.61E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277431 chr6 33052028 C T 1.89E-05 IgE levels HLA-DPB1 intron 22075330 rs9277432 chr6 33052072 A T 4.53E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277432 chr6 33052072 A T 2.17E-09 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277432 chr6 33052072 A T 5.63E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277432 chr6 33052072 A T 2.83E-05 IgE levels HLA-DPB1 intron 22075330 rs9277432 chr6 33052072 A T 1.48E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277433 chr6 33052128 C T 4.53E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277434 chr6 33052186 A G 2.17E-09 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277434 chr6 33052186 A G 5.63E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277434 chr6 33052186 A G 2.83E-05 IgE levels HLA-DPB1 intron 22075330 rs9277437 chr6 33052250 A G 4.64E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277437 chr6 33052250 A G 2.17E-09 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277437 chr6 33052250 A G 5.63E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277437 chr6 33052250 A G 2.82E-05 IgE levels HLA-DPB1 intron 22075330 rs9277437 chr6 33052250 A G 1.48E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277438 chr6 33052303 C T 2.66E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277439 chr6 33052315 C A 2.97E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277440 chr6 33052327 C T 2.63E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277441 chr6 33052354 C A 4.91E-06 Hepatitis B HLA-DPB1 intron 24162738 rs1811359 chr6 33052382 G C 5.28E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277443 chr6 33052414 A G 3.49E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277444 chr6 33052439 A G 5.20E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277446 chr6 33052498 G C 7.86E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277450 chr6 33052695 T G 2.17E-09 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277450 chr6 33052695 T G 5.63E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277450 chr6 33052695 T G 2.81E-05 IgE levels HLA-DPB1 intron 22075330 rs1042187 chr6 33052768 T A,C,G 5.90E-06 Hepatitis B HLA-DPB1 missense 24162738 rs1042212 chr6 33052803 G A 5.90E-06 Hepatitis B HLA-DPB1 cds-synon 24162738 rs1042331 chr6 33052950 T C 5.90E-06 Hepatitis B HLA-DPB1 cds-synon 24162738 rs1042335 chr6 33052958 C T 5.90E-06 Hepatitis B HLA-DPB1 missense 24162738 rs1071597 chr6 33052986 T C 5.90E-06 Hepatitis B HLA-DPB1 cds-synon 24162738 rs9277458 chr6 33053167 A C 5.90E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277458 chr6 33053167 A C 2.17E-09 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277458 chr6 33053167 A C 5.61E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277458 chr6 33053167 A C 1.86E-05 IgE levels HLA-DPB1 intron 22075330 rs9277458 chr6 33053167 A C 1.48E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277459 chr6 33053248 A G 5.90E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277460 chr6 33053252 G A 5.90E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277460 chr6 33053252 G A 2.17E-09 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277460 chr6 33053252 G A 5.63E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277460 chr6 33053252 G A 2.80E-05 IgE levels HLA-DPB1 intron 22075330 rs9277462 chr6 33053271 T C 1.48E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277463 chr6 33053307 C T 5.90E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277463 chr6 33053307 C T 2.93E-10 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) HLA-DPB1 intron 17982456 rs9277463 chr6 33053307 C T 5.24E-10 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277463 chr6 33053307 C T 5.63E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277463 chr6 33053307 C T 2.79E-05 IgE levels HLA-DPB1 intron 22075330 rs9277463 chr6 33053307 C T 1.48E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277464 chr6 33053352 C T 3.54E-05 IgE levels HLA-DPB1 intron 22075330 rs9277464 chr6 33053352 C T 3.29E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277465 chr6 33053396 A G 7.25E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277466 chr6 33053399 T C 5.90E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277467 chr6 33053444 G A,C 4.79E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277468 chr6 33053455 C T 5.90E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277468 chr6 33053455 C T 1.81E-09 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277468 chr6 33053455 C T 5.63E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277468 chr6 33053455 C T 2.78E-05 IgE levels HLA-DPB1 intron 22075330 rs9277468 chr6 33053455 C T 1.56E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277469 chr6 33053468 G T 1.96E-09 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277469 chr6 33053468 G T 5.63E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277469 chr6 33053468 G T 2.78E-05 IgE levels HLA-DPB1 intron 22075330 rs9277469 chr6 33053468 G T 1.48E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277470 chr6 33053477 G C 5.90E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277470 chr6 33053477 G C 5.60E-10 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277470 chr6 33053477 G C 5.63E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277470 chr6 33053477 G C 2.78E-05 IgE levels HLA-DPB1 intron 22075330 rs9277471 chr6 33053682 G A 1.48E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277472 chr6 33053723 T C 1.62E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277477 chr6 33053772 G A 6.49E-10 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277477 chr6 33053772 G A 5.63E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277477 chr6 33053772 G A 2.78E-05 IgE levels HLA-DPB1 intron 22075330 rs9277477 chr6 33053772 G A 1.53E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277479 chr6 33053789 A G 6.49E-10 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277479 chr6 33053789 A G 5.63E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277479 chr6 33053789 A G 2.78E-05 IgE levels HLA-DPB1 intron 22075330 rs9277479 chr6 33053789 A G 1.15E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277480 chr6 33053812 A G 3.54E-05 IgE levels HLA-DPB1 intron 22075330 rs9277480 chr6 33053812 A G 3.39E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277488 chr6 33053906 G T 1.48E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277489 chr6 33053942 T C 3.54E-05 IgE levels HLA-DPB1 intron 22075330 rs9277490 chr6 33053968 T A 1.55E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277492 chr6 33053982 G C 4.06E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277492 chr6 33053982 G C 6.49E-10 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277492 chr6 33053982 G C 5.63E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277492 chr6 33053982 G C 2.78E-05 IgE levels HLA-DPB1 intron 22075330 rs9277492 chr6 33053982 G C 1.48E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277494 chr6 33054057 G A 3.17E-06 Hepatitis B HLA-DPB1 intron 24162738 rs9277495 chr6 33054071 G C 8.55E-12 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277497 chr6 33054091 C T 6.49E-10 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277497 chr6 33054091 C T 5.63E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277497 chr6 33054091 C T 2.78E-05 IgE levels HLA-DPB1 intron 22075330 rs9277515 chr6 33054268 C A 6.49E-10 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277515 chr6 33054268 C A 5.63E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277515 chr6 33054268 C A 2.78E-05 IgE levels HLA-DPB1 intron 22075330 rs9277515 chr6 33054268 C A 3.10E-11 Chronic hepatitis B infection HLA-DPB1 intron 23760081 rs9277518 chr6 33054302 T C 2.61E-09 Rheumatoid arthritis HLA-DPB1 intron 21156761 rs9277518 chr6 33054302 T C 5.61E-04 Obesity (extreme) HLA-DPB1 intron 21935397 rs9277518 chr6 33054302 T C 1.85E-05 IgE levels HLA-DPB1 intron 22075330 rs1042448 chr6 33054342 T A 6.49E-10 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs1042448 chr6 33054342 T A 5.63E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs1042448 chr6 33054342 T A 2.78E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs1042544 chr6 33054457 A G 6.49E-10 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs1042544 chr6 33054457 A G 5.63E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs1042544 chr6 33054457 A G 2.77E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs1042544 chr6 33054457 A G 1.22E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs1042544 chr6 33054457 A G 2.88E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs929 chr6 33054619 G A 7.70E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs929 chr6 33054619 G A 6.49E-10 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs929 chr6 33054619 G A 5.63E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs929 chr6 33054619 G A 2.77E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs9277532 chr6 33054711 G T 5.90E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs9277533 chr6 33054721 C T 6.49E-10 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs9277533 chr6 33054721 C T 5.63E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs9277533 chr6 33054721 C T 2.77E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs9277533 chr6 33054721 C T 1.48E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs9277534 chr6 33054807 A G 5.90E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs9277534 chr6 33054807 A G 6.49E-10 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs9277534 chr6 33054807 A G 5.62E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs9277534 chr6 33054807 A G 2.77E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs9277534 chr6 33054807 A G 1.48E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs9277535 chr6 33054861 A G 7.25E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs9277535 chr6 33054861 A G 9.05E-12 Rheumatoid arthritis HLA-DPB1 UTR-3 17804836 rs9277535 chr6 33054861 A G 6.00E-39 Hepatitis B HLA-DPB1 UTR-3 19349983 rs9277535 chr6 33054861 A G 7.55E-12 Rheumatoid arthritis HLA-DPB1 UTR-3 19503088 rs9277535 chr6 33054861 A G 3.00E-54 Hepatitis B HLA-DPB1 UTR-3 21750111 rs9277535 chr6 33054861 A G 3.00E-12 Hepatitis B vaccine response HLA-DPB1 UTR-3 21764829 rs9277535 chr6 33054861 A G 3.55E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs9277535 chr6 33054861 A G 2.00E-17 Hepatitis B (viral clearance) HLA-DPB1 UTR-3 22737229 rs9277535 chr6 33054861 A G 2.00E-21 Hepatitis B (viral clearance) HLA-DPB1 UTR-3 22737229 rs9277535 chr6 33054861 A G 2.55E-54 Hepatocellular carcinoma (hepatitis B virus related) HLA-DPB1 UTR-3 23242368 rs9277535 chr6 33054861 A G 4.00E-40 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs9277535 chr6 33054861 A G 3.36E-07 Cervical cancer HLA-DPB1 UTR-3 23817570 rs9277535 chr6 33054861 A G 5.00E-14 Chronic hepatitis B infection HLA-DPB1 UTR-3 24940741 rs9277536 chr6 33054890 C T 5.90E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs9277537 chr6 33055009 C A 5.90E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs9277538 chr6 33055047 A G 6.49E-10 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs9277538 chr6 33055047 A G 5.63E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs9277538 chr6 33055047 A G 2.77E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs9277538 chr6 33055047 A G 1.74E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs9277540 chr6 33055123 A G 5.90E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs9277540 chr6 33055123 A G 6.49E-10 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs9277540 chr6 33055123 A G 5.63E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs9277540 chr6 33055123 A G 2.77E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs9277540 chr6 33055123 A G 1.09E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs9277541 chr6 33055158 A G 5.90E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs9277541 chr6 33055158 A G 6.49E-10 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs9277541 chr6 33055158 A G 5.63E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs9277541 chr6 33055158 A G 2.77E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs9277541 chr6 33055158 A G 1.82E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs9277542 chr6 33055247 T C 5.90E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs9277542 chr6 33055247 T C 2.10E-12 Multiple complex diseases HLA-DPB1 UTR-3 17554300 rs9277542 chr6 33055247 T C 4.14E-09 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs9277542 chr6 33055247 T C 8.40E-05 Cervical cancer HLA-DPB1 UTR-3 21716314 rs9277542 chr6 33055247 T C 5.63E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs9277542 chr6 33055247 T C 2.77E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs9277542 chr6 33055247 T C 3.98E-15 Hepatitis B (viral clearance) HLA-DPB1 UTR-3 22737229 rs9277542 chr6 33055247 T C 9.60E-05 Hematology traits HLA-DPB1 UTR-3 23303382 rs9277542 chr6 33055247 T C 1.73E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs9277542 chr6 33055247 T C 5.07E-06 Cervical cancer HLA-DPB1 UTR-3 23817570 rs9277544 chr6 33055308 C T 6.01E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs9277545 chr6 33055323 C T 3.34E-07 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs9277545 chr6 33055323 C T 7.63E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs9277546 chr6 33055346 T G 6.49E-10 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs9277546 chr6 33055346 T G 5.63E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs9277546 chr6 33055346 T G 2.77E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs9277546 chr6 33055346 T G 1.48E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs9277547 chr6 33055367 C A 6.49E-10 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs9277547 chr6 33055367 C A 5.63E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs9277547 chr6 33055367 C A 2.77E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs9277547 chr6 33055367 C A 1.48E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs9277548 chr6 33055390 C T 6.49E-10 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs9277548 chr6 33055390 C T 5.63E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs9277548 chr6 33055390 C T 2.77E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs9277549 chr6 33055419 A G 1.48E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs9277550 chr6 33055487 T C 5.86E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs9277550 chr6 33055487 T C 6.49E-10 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs9277550 chr6 33055487 T C 1.48E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs9277551 chr6 33055494 G T 5.86E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs9277551 chr6 33055494 G T 2.05E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs9277553 chr6 33055516 T C 5.90E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs9277553 chr6 33055516 T C 6.49E-10 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs9277553 chr6 33055516 T C 5.63E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs9277553 chr6 33055516 T C 2.77E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs9277554 chr6 33055538 C T 8.17E-08 Type 1 diabetes HLA-DPB1 UTR-3 17632545 rs9277554 chr6 33055538 C T 3.42E-15 Rheumatoid arthritis HLA-DPB1 UTR-3 17804836 rs9277554 chr6 33055538 C T 3.01E-16 Rheumatoid arthritis HLA-DPB1 UTR-3 19503088 rs9277554 chr6 33055538 C T 4.64E-08 Systemic sclerosis HLA-DPB1 UTR-3 20383147 rs9277554 chr6 33055538 C T 6.07E-10 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs9277554 chr6 33055538 C T 1.12E-04 Follicular lymphoma HLA-DPB1 UTR-3 21533074 rs9277554 chr6 33055538 C T 1.87E-17 Hepatitis B HLA-DPB1 UTR-3 21750111 rs9277554 chr6 33055538 C T 3.08E-11 Hepatitis B vaccine response HLA-DPB1 UTR-3 21764829 rs9277554 chr6 33055538 C T 5.63E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs9277554 chr6 33055538 C T 2.77E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs9277554 chr6 33055538 C T 1.46E-04 IgA nephropathy HLA-DPB1 UTR-3 22197929 rs9277554 chr6 33055538 C T 2.00E-50 Wegener's granulomatosis HLA-DPB1 UTR-3 23740775 rs9277554 chr6 33055538 C T 1.48E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs9277555 chr6 33055605 G A 5.79E-10 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs9277555 chr6 33055605 G A 6.44E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs9277555 chr6 33055605 G A 2.77E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs9277555 chr6 33055605 G A 6.00E-07 Thyroid peroxidase antibody levels HLA-DPB1 UTR-3 24586183 rs3128963 chr6 33055780 C T 5.90E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs3128963 chr6 33055780 C T 4.87E-11 Multiple complex diseases HLA-DPB1 UTR-3 17554300 rs3128963 chr6 33055780 C T 2.61E-10 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs3128963 chr6 33055780 C T 2.50E-04 Cervical cancer HLA-DPB1 UTR-3 21716314 rs3128963 chr6 33055780 C T 6.44E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs3128963 chr6 33055780 C T 2.77E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs3128963 chr6 33055780 C T 9.40E-05 Hematology traits HLA-DPB1 UTR-3 23303382 rs3128963 chr6 33055780 C T 1.53E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs3128964 chr6 33055818 A G 5.90E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs3128964 chr6 33055818 A G 1.48E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs201709182 chr6 33055844 T TTATC 1.48E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs3128965 chr6 33055899 G A 2.10E-10 Multiple complex diseases HLA-DPB1 UTR-3 17554300 rs3128965 chr6 33055899 G A 1.07E-07 Systemic sclerosis HLA-DPB1 UTR-3 19950302 rs3128965 chr6 33055899 G A 1.09E-04 Systemic sclerosis HLA-DPB1 UTR-3 19950302 rs3128965 chr6 33055899 G A 1.29E-05 Systemic sclerosis HLA-DPB1 UTR-3 19950302 rs3128965 chr6 33055899 G A 1.71E-05 Systemic sclerosis HLA-DPB1 UTR-3 19950302 rs3128965 chr6 33055899 G A 4.37E-06 Systemic sclerosis HLA-DPB1 UTR-3 19950302 rs3128965 chr6 33055899 G A 4.47E-05 Systemic sclerosis HLA-DPB1 UTR-3 19950302 rs3128965 chr6 33055899 G A 6.28E-09 Systemic sclerosis HLA-DPB1 UTR-3 19950302 rs3128965 chr6 33055899 G A 3.10E-04 Cervical cancer HLA-DPB1 UTR-3 21716314 rs3128966 chr6 33055946 G A 2.13E-10 Multiple complex diseases HLA-DPB1 UTR-3 17554300 rs3128966 chr6 33055946 G A 3.02E-30 Primary biliary cirrhosis HLA-DPB1 UTR-3 21399635 rs3128966 chr6 33055946 G A 4.90E-05 Cervical cancer HLA-DPB1 UTR-3 21716314 rs3117229 chr6 33056069 G A 1.35E-08 Multiple complex diseases HLA-DPB1 UTR-3 17554300 rs3117229 chr6 33056069 G A 1.30E-04 Cervical cancer HLA-DPB1 UTR-3 21716314 rs3117229 chr6 33056069 G A 3.55E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs3117229 chr6 33056069 G A 8.70E-05 Hematology traits HLA-DPB1 UTR-3 23303382 rs3117229 chr6 33056069 G A 3.29E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs3128967 chr6 33056097 T A,G 3.52E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs3130186 chr6 33056207 C T 7.25E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs3130186 chr6 33056207 C T 3.50E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs3130186 chr6 33056207 C T 3.29E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs3128968 chr6 33056253 T A 7.25E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs3128968 chr6 33056253 T A 3.47E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs3128968 chr6 33056253 T A 1.08E-10 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs3130187 chr6 33056405 C T 7.25E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs3117228 chr6 33056435 G T 5.58E-10 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs3117228 chr6 33056435 G T 6.47E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs3117228 chr6 33056435 G T 2.67E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs3117228 chr6 33056435 G T 1.48E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs3091281 chr6 33056566 T C 7.25E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs3091281 chr6 33056566 T C 3.41E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs3091281 chr6 33056566 T C 3.29E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs9277557 chr6 33056694 T C 1.15E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs9277557 chr6 33056694 T C 3.29E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs9277558 chr6 33056711 C T 6.98E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs9277558 chr6 33056711 C T 3.36E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs9277558 chr6 33056711 C T 2.84E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs9296075 chr6 33056788 G A 4.50E-05 Coffee consumption HLA-DPB1 UTR-3 21357676 rs9277565 chr6 33056897 C T 2.26E-06 Rheumatoid arthritis HLA-DPB1 UTR-3 17804836 rs9277565 chr6 33056897 C T 3.51E-06 Rheumatoid arthritis HLA-DPB1 UTR-3 19503088 rs9277565 chr6 33056897 C T 2.81E-15 Hepatitis B HLA-DPB1 UTR-3 21750111 rs9277565 chr6 33056897 C T 0.0000176 Follicular lymphoma HLA-DPB1 UTR-3 23025665 rs9277566 chr6 33056916 G T 5.90E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs9277566 chr6 33056916 G T 3.60E-07 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs9277566 chr6 33056916 G T 8.87E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs9277566 chr6 33056916 G T 5.03E-12 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs9277568 chr6 33057055 T C 8.67E-06 Hepatitis B HLA-DPB1 UTR-3 24162738 rs9277568 chr6 33057055 T C 2.93E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs9277568 chr6 33057055 T C 1.80E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs3130188 chr6 33057176 T C 5.58E-10 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs3130188 chr6 33057176 T C 5.88E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs3130188 chr6 33057176 T C 2.24E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs3130188 chr6 33057176 T C 1.53E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs3091282 chr6 33057198 G C 5.58E-10 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs3091282 chr6 33057198 G C 5.83E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs3091282 chr6 33057198 G C 2.22E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs3091282 chr6 33057198 G C 1.37E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs3091283 chr6 33057213 C T 3.60E-07 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs3091283 chr6 33057213 C T 7.95E-04 Obesity (extreme) HLA-DPB1 UTR-3 21935397 rs3091283 chr6 33057213 C T 9.46E-05 IgE levels HLA-DPB1 UTR-3 22075330 rs3091284 chr6 33057244 T G 6.40E-07 Rheumatoid arthritis HLA-DPB1 UTR-3 21156761 rs3097650 chr6 33057440 C T 8.83E-11 Chronic hepatitis B infection HLA-DPB1 UTR-3 23760081 rs3117226 chr6 33057659 G A 6.40E-07 Rheumatoid arthritis HLA-DPB1 nearGene-3 21156761 rs3117225 chr6 33057711 G A 5.38E-04 Obesity (extreme) HLA-DPB1 nearGene-3 21935397 rs3117225 chr6 33057711 G A 2.11E-05 IgE levels HLA-DPB1 nearGene-3 22075330 rs3117225 chr6 33057711 G A 1.48E-11 Chronic hepatitis B infection HLA-DPB1 nearGene-3 23760081 rs3097652 chr6 33057835 C T 5.58E-10 Rheumatoid arthritis HLA-DPB1 nearGene-3 21156761 rs3097652 chr6 33057835 C T 5.28E-04 Obesity (extreme) HLA-DPB1 nearGene-3 21935397 rs3097652 chr6 33057835 C T 2.10E-05 IgE levels HLA-DPB1 nearGene-3 22075330 rs3097652 chr6 33057835 C T 1.48E-11 Chronic hepatitis B infection HLA-DPB1 nearGene-3 23760081 rs1367730 chr6 33058114 C T 3.55E-07 Rheumatoid arthritis / / 21156761 rs1367730 chr6 33058114 C T 6.59E-04 Obesity (extreme) / / 21935397 rs1367730 chr6 33058114 C T 8.52E-05 IgE levels / / 22075330 rs574503121 chr6 33058114 C CTATT 3.55E-07 Rheumatoid arthritis / / 21156761 rs574503121 chr6 33058114 C CTATT 6.59E-04 Obesity (extreme) / / 21935397 rs574503121 chr6 33058114 C CTATT 8.52E-05 IgE levels / / 22075330 rs2068204 chr6 33058718 G A 4.31E-04 Multiple complex diseases / / 17554300 rs2068204 chr6 33058718 G A 4.30E-05 Hematology traits / / 23303382 rs3128972 chr6 33058774 T C 3.55E-07 Rheumatoid arthritis / / 21156761 rs3128972 chr6 33058774 T C 6.42E-04 Obesity (extreme) / / 21935397 rs3128972 chr6 33058774 T C 8.46E-05 IgE levels / / 22075330 rs2179920 chr6 33058874 C T 1.19E-12 Multiple complex diseases / / 17554300 rs10484569 chr6 33058952 G A 2.34E-08 Hepatitis B / / 19349983 rs10484569 chr6 33058952 G A 2.14E-10 Hepatitis B / / 21750111 rs10484569 chr6 33058952 G A 2.38E-05 Crohn's disease / / 23266558 rs2179919 chr6 33059262 T C 6.16E-04 Obesity (extreme) / / 21935397 rs2179919 chr6 33059262 T C 8.51E-05 IgE levels / / 22075330 rs2395313 chr6 33059336 A C 6.12E-04 Obesity (extreme) / / 21935397 rs2395313 chr6 33059336 A C 8.55E-05 IgE levels / / 22075330 rs3117224 chr6 33059625 G A,C 4.90E-06 IgE levels / / 22075330 rs2281390 chr6 33059669 G T 2.97E-09 Type 1 diabetes / / 17632545 rs2281389 chr6 33059796 A G 4.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs2281389 chr6 33059796 A G 6.98E-07 Aspirin exacerbated respiratory disease in asthmatics / / 23180272 rs3128917 chr6 33059996 T G 1.05E-11 Rheumatoid arthritis / / 17804836 rs3128917 chr6 33059996 T G 1.98E-10 Hepatitis B / / 19349983 rs3128917 chr6 33059996 T G 8.66E-12 Rheumatoid arthritis / / 19503088 rs3128917 chr6 33059996 T G 3.13E-07 Rheumatoid arthritis / / 21156761 rs3128917 chr6 33059996 T G 2.81E-15 Hepatitis B / / 21750111 rs3128917 chr6 33059996 T G 4.68E-04 Obesity (extreme) / / 21935397 rs3128917 chr6 33059996 T G 8.84E-05 IgE levels / / 22075330 rs3128917 chr6 33059996 T G 0.00000583 Follicular lymphoma / / 23025665 rs3117223 chr6 33060064 G A 3.13E-07 Rheumatoid arthritis / / 21156761 rs3117223 chr6 33060064 G A 4.68E-04 Obesity (extreme) / / 21935397 rs3117223 chr6 33060064 G A 8.91E-05 IgE levels / / 22075330 rs2281388 chr6 33060118 G A 3.62E-08 Hepatitis B / / 19349983 rs2281388 chr6 33060118 G A 2.72E-09 Hepatitis B / / 21750111 rs2281388 chr6 33060118 G A 2.00E-65 Graves' disease / / 21841780 rs2281388 chr6 33060118 G A 3.25E-05 Crohn's disease / / 23266558 rs2281388 chr6 33060118 G A 3.71E-04 Lung function (forced vital capacity) / / 24023788 rs7763822 chr6 33060428 C T 1.57E-06 Multiple complex diseases / / 17554300 rs7763822 chr6 33060428 C T 1.77E-12 Systemic sclerosis / / 19950302 rs7763822 chr6 33060428 C T 5.28E-10 Systemic sclerosis / / 19950302 rs7763822 chr6 33060428 C T 5.60E-04 Systemic sclerosis / / 19950302 rs7763822 chr6 33060428 C T 7.64E-08 Systemic sclerosis / / 19950302 rs7763822 chr6 33060428 C T 8.24E-09 Systemic sclerosis / / 19950302 rs7763822 chr6 33060428 C T 8.61E-19 Systemic sclerosis / / 19950302 rs2295120 chr6 33060769 G A 4.18E-04 Multiple complex diseases / / 17554300 rs2295120 chr6 33060769 G A 9.60E-05 Hematology traits / / 23303382 rs6928954 chr6 33060822 C T 8.57E-10 Bilirubin levels,in serum / / 20639394 rs7764491 chr6 33060840 C G 3.66E-06 Multiple complex diseases / / 17554300 rs7764491 chr6 33060840 C G 1.77E-12 Systemic sclerosis / / 19950302 rs7764491 chr6 33060840 C G 2.86E-18 Systemic sclerosis / / 19950302 rs7764491 chr6 33060840 C G 5.28E-10 Systemic sclerosis / / 19950302 rs7764491 chr6 33060840 C G 7.64E-08 Systemic sclerosis / / 19950302 rs7764491 chr6 33060840 C G 8.24E-09 Systemic sclerosis / / 19950302 rs2295118 chr6 33060892 C T 3.58E-06 Hepatitis B / / 24162738 rs2295118 chr6 33060892 C T 1.00E-10 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs2295118 chr6 33060892 C T 4.80E-10 Rheumatoid arthritis / / 21156761 rs2295118 chr6 33060892 C T 3.41E-04 Obesity (extreme) / / 21935397 rs2295118 chr6 33060892 C T 2.32E-05 IgE levels / / 22075330 rs3117222 chr6 33060949 C T 9.08E-12 Rheumatoid arthritis / / 17804836 rs3117222 chr6 33060949 C T 2.57E-08 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs3117222 chr6 33060949 C T 1.29E-10 Hepatitis B / / 19349983 rs3117222 chr6 33060949 C T 7.84E-12 Rheumatoid arthritis / / 19503088 rs3117222 chr6 33060949 C T 3.13E-07 Rheumatoid arthritis / / 21156761 rs3117222 chr6 33060949 C T 5.23E-15 Hepatitis B / / 21750111 rs3117222 chr6 33060949 C T 4.67E-04 Obesity (extreme) / / 21935397 rs3117222 chr6 33060949 C T 8.17E-05 IgE levels / / 22075330 rs3117222 chr6 33060949 C T 0.000000145 Follicular lymphoma / / 23025665 rs3128918 chr6 33061098 T C 2.33E-09 Type 1 diabetes / / 17632545 rs3128918 chr6 33061098 T C 2.05E-05 Hepatitis B / / 21750111 rs3128919 chr6 33061626 T A 3.85E-04 Obesity (extreme) / / 21935397 rs3128919 chr6 33061626 T A 7.24E-05 IgE levels / / 22075330 rs3130190 chr6 33061690 T C 8.00E-10 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs3130190 chr6 33061690 T C 2.28E-04 Obesity (extreme) / / 21935397 rs3130190 chr6 33061690 T C 7.37E-05 IgE levels / / 22075330 rs3130191 chr6 33061871 T C 3.15E-07 Rheumatoid arthritis / / 21156761 rs3130191 chr6 33061871 T C 2.44E-04 Obesity (extreme) / / 21935397 rs3130191 chr6 33061871 T C 6.75E-05 IgE levels / / 22075330 rs3130192 chr6 33061930 C T 1.43E-05 Rheumatoid arthritis / / 19503088 rs2395314 chr6 33062673 G T 2.42E-04 Obesity (extreme) / / 21935397 rs2395314 chr6 33062673 G T 5.36E-05 IgE levels / / 22075330 rs3117217 chr6 33063271 G A 4.89E-07 Rheumatoid arthritis / / 21156761 rs3117217 chr6 33063271 G A 2.23E-04 Obesity (extreme) / / 21935397 rs3117217 chr6 33063271 G A 6.24E-05 IgE levels / / 22075330 rs3117216 chr6 33063403 A G 3.58E-06 Hepatitis B / / 24162738 rs3117216 chr6 33063403 A G 2.11E-11 Chronic hepatitis B infection / / 23760081 rs6914651 chr6 33063699 A G 2.14E-04 Obesity (extreme) / / 21935397 rs6914651 chr6 33063699 A G 5.86E-05 IgE levels / / 22075330 rs3117213 chr6 33064605 G T 4.89E-07 Rheumatoid arthritis / / 21156761 rs3117213 chr6 33064605 G T 2.10E-04 Obesity (extreme) / / 21935397 rs3117213 chr6 33064605 G T 5.72E-05 IgE levels / / 22075330 rs2144014 chr6 33065813 G A 4.89E-07 Rheumatoid arthritis / / 21156761 rs2144014 chr6 33065813 G A 2.09E-04 Obesity (extreme) / / 21935397 rs2144014 chr6 33065813 G A 5.53E-05 IgE levels / / 22075330 rs569253080 chr6 33065813 G A 4.89E-07 Rheumatoid arthritis / / 21156761 rs569253080 chr6 33065813 G A 2.09E-04 Obesity (extreme) / / 21935397 rs569253080 chr6 33065813 G A 5.53E-05 IgE levels / / 22075330 rs2894316 chr6 33066594 A G 7.66E-07 Hepatitis B / / 24162738 rs559802496 chr6 33066594 A G 7.66E-07 Hepatitis B / / 24162738 rs3117242 chr6 33069893 A G 6.05E-09 Multiple complex diseases / / 17554300 rs3117242 chr6 33069893 A G 4.89E-07 Rheumatoid arthritis / / 21156761 rs3117242 chr6 33069893 A G 2.07E-04 Obesity (extreme) / / 21935397 rs3117242 chr6 33069893 A G 5.36E-05 IgE levels / / 22075330 rs3117242 chr6 33069893 A G 1.00E-71 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs3128921 chr6 33070749 C A 2.39E-13 Multiple complex diseases / / 17554300 rs3128921 chr6 33070749 C A 5.52E-07 Rheumatoid arthritis / / 21156761 rs3128921 chr6 33070749 C A 3.40E-04 Cervical cancer / / 21716314 rs3128921 chr6 33070749 C A 2.91E-04 Obesity (extreme) / / 21935397 rs3128921 chr6 33070749 C A 2.12E-05 IgE levels / / 22075330 rs3128923 chr6 33071322 C G 7.14E-09 Multiple complex diseases / / 17554300 rs3128923 chr6 33071322 C G 4.89E-07 Rheumatoid arthritis / / 21156761 rs3128923 chr6 33071322 C G 5.40E-04 Cervical cancer / / 21716314 rs3128923 chr6 33071322 C G 2.01E-04 Obesity (extreme) / / 21935397 rs3128923 chr6 33071322 C G 5.37E-05 IgE levels / / 22075330 rs3128924 chr6 33071424 A G 1.73E-04 Alzheimer's disease (late onset) / / 21379329 rs4282438 chr6 33072172 T G 5.00E-27 Cervical cancer / / 23817570 rs4282438 chr6 33072172 T G 9.00E-25 Sjogren's syndrome / / 24097066 rs2064478 chr6 33072266 C T 1.71E-09 Type 1 diabetes / / 17632545 rs2064478 chr6 33072266 C T 5.40E-08 Rheumatoid arthritis / / 17804836 rs2064478 chr6 33072266 C T 4.31E-08 Rheumatoid arthritis / / 19503088 rs2064478 chr6 33072266 C T 4.53E-04 Obesity (extreme) / / 21935397 rs9296079 chr6 33072539 G T 2.18E-08 Multiple complex diseases / / 17554300 rs9296079 chr6 33072539 G T 5.10E-05 Hematology traits / / 23303382 rs3130210 chr6 33072729 G T 3.82E-04 Obesity (extreme) / / 21935397 rs3117236 chr6 33073068 A G 3.08E-04 Obesity (extreme) / / 21935397 rs3130211 chr6 33073076 G A 3.06E-04 Obesity (extreme) / / 21935397 rs2064476 chr6 33073322 A G 3.97E-10 Rheumatoid arthritis / / 21156761 rs2064476 chr6 33073322 A G 1.74E-04 Obesity (extreme) / / 21935397 rs2064476 chr6 33073322 A G 2.65E-05 IgE levels / / 22075330 rs2064476 chr6 33073322 A G 1.73E-11 Chronic hepatitis B infection / / 23760081 rs2064475 chr6 33073440 G A 4.14E-04 Obesity (extreme) / / 21935397 rs2064474 chr6 33073463 G A 2.92E-04 Obesity (extreme) / / 21935397 rs3117234 chr6 33073984 A G 2.86E-04 Obesity (extreme) / / 21935397 rs3128927 chr6 33074288 C T 5.48E-08 Rheumatoid arthritis / / 21156761 rs3128927 chr6 33074288 C T 2.81E-04 Obesity (extreme) / / 21935397 rs3128927 chr6 33074288 C T 5.86E-06 Aspirin exacerbated respiratory disease in asthmatics / / 23180272 rs3117233 chr6 33074348 T C 3.93E-04 Obesity (extreme) / / 21935397 rs3130212 chr6 33074389 G C 2.79E-04 Obesity (extreme) / / 21935397 rs3117232 chr6 33074569 A G 2.76E-04 Obesity (extreme) / / 21935397 rs3128928 chr6 33074612 C A 7.42E-04 Obesity (extreme) / / 21935397 rs3128928 chr6 33074612 C A 1.29E-05 IgE levels / / 22075330 rs3130214 chr6 33074712 G C 6.57E-07 IgE levels / / 22075330 rs3128929 chr6 33074853 C T 2.62E-04 Obesity (extreme) / / 21935397 rs3117231 chr6 33074908 A G 5.89E-07 Rheumatoid arthritis / / 21156761 rs3117231 chr6 33074908 A G 2.03E-04 Obesity (extreme) / / 21935397 rs3117231 chr6 33074908 A G 7.54E-05 IgE levels / / 22075330 rs3130215 chr6 33074963 A G 1.03E-09 Rheumatoid arthritis / / 17804836 rs3130215 chr6 33074963 A G 4.08E-07 Hepatitis B / / 21750111 rs3130215 chr6 33074963 A G 1.32E-10 Coronary heart disease / / 21971053 rs910320 chr6 33075443 C T 2.32E-04 Obesity (extreme) / / 21935397 rs910320 chr6 33075443 C T 1.01E-06 Aspirin exacerbated respiratory disease in asthmatics / / 23180272 rs3117230 chr6 33075635 A G 4.07E-13 Multiple complex diseases / / 17554300 rs3117230 chr6 33075635 A G 1.60E-09 Type 1 diabetes / / 17632545 rs3117230 chr6 33075635 A G 7.02E-08 Rheumatoid arthritis / / 17804836 rs3117230 chr6 33075635 A G 7.14E-08 Rheumatoid arthritis / / 19503088 rs3117230 chr6 33075635 A G 1.04E-05 Systemic sclerosis / / 19950302 rs3117230 chr6 33075635 A G 3.37E-06 Systemic sclerosis / / 19950302 rs3117230 chr6 33075635 A G 3.52E-05 Systemic sclerosis / / 19950302 rs3117230 chr6 33075635 A G 4.51E-09 Systemic sclerosis / / 19950302 rs3117230 chr6 33075635 A G 4.77E-04 Systemic sclerosis / / 19950302 rs3117230 chr6 33075635 A G 6.90E-04 Systemic sclerosis / / 19950302 rs3117230 chr6 33075635 A G 9.24E-05 Systemic sclerosis / / 19950302 rs3117230 chr6 33075635 A G 2.80E-04 Cervical cancer / / 21716314 rs3117230 chr6 33075635 A G 3.52E-04 Obesity (extreme) / / 21935397 rs3117230 chr6 33075635 A G 1.21E-06 Aspirin exacerbated respiratory disease in asthmatics / / 23180272 rs3128930 chr6 33075666 C T 2.06E-10 Multiple complex diseases / / 17554300 rs3128930 chr6 33075666 C T 1.15E-11 Systemic sclerosis / / 19950302 rs3128930 chr6 33075666 C T 1.67E-07 Systemic sclerosis / / 19950302 rs3128930 chr6 33075666 C T 3.33E-16 Systemic sclerosis / / 19950302 rs3128930 chr6 33075666 C T 4.38E-15 Systemic sclerosis / / 19950302 rs3128930 chr6 33075666 C T 8.16E-13 Systemic sclerosis / / 19950302 rs3128930 chr6 33075666 C T 8.26E-22 Systemic sclerosis / / 19950302 rs3128930 chr6 33075666 C T 6.55E-07 Rheumatoid arthritis / / 21156761 rs3128930 chr6 33075666 C T 4.30E-05 Cervical cancer / / 21716314 rs3128930 chr6 33075666 C T 2.39E-04 Obesity (extreme) / / 21935397 rs3128930 chr6 33075666 C T 6.09E-15 Lymphocyte counts / / 22286170 rs872956 chr6 33076090 T A 1.47E-11 Multiple complex diseases / / 17554300 rs872956 chr6 33076090 T A 7.30E-04 Cervical cancer / / 21716314 rs872956 chr6 33076090 T A 2.58E-04 Obesity (extreme) / / 21935397 rs6924377 chr6 33077588 A G 4.17E-04 Self-reported allergy / / 23817569 rs6457713 chr6 33077776 C T 4.21E-05 Cognitive test performance / / 20125193 rs6457713 chr6 33077776 C T 2.39E-10 Hepatitis B / / 21750111 rs6457713 chr6 33077776 C T 2.38E-05 Crohn's disease / / 23266558 rs9380343 chr6 33079166 C T 8.43E-04 Multiple complex diseases HLA-DPB2 nearGene-5 17554300 rs9380343 chr6 33079166 C T 1.66E-08 Hepatitis B HLA-DPB2 nearGene-5 19349983 rs9380343 chr6 33079166 C T 1.66E-09 Hepatitis B HLA-DPB2 nearGene-5 21750111 rs9380343 chr6 33079166 C T 5.94E-05 Crohn's disease HLA-DPB2 nearGene-5 23266558 rs733208 chr6 33082308 G A 1.51E-10 Multiple complex diseases / / 17554300 rs733208 chr6 33082308 G A 4.00E-07 Thyroid peroxidase antibody positivity / / 24722205 rs1810472 chr6 33083121 T C 5.03E-05 Tunica Media / / pha003036 rs3129294 chr6 33084671 A C 2.09E-06 Aspirin exacerbated respiratory disease in asthmatics / / 23180272 rs3117039 chr6 33085851 C T 6.80E-07 Hepatitis B / / 21750111 rs3117039 chr6 33085851 C T 1.37E-04 Coronary heart disease / / 21971053 rs3117039 chr6 33085851 C T 1.32E-10 Cervical cancer / / 23817570 rs3117035 chr6 33086249 C T 1.00E-06 RR interval (heart rate) / / 20031603 rs3117035 chr6 33086249 C T 2.43E-09 Hepatitis B vaccine response / / 21764829 rs3117035 chr6 33086249 C T 8.66E-05 Coronary heart disease / / 21971053 rs1883414 chr6 33086448 G A 2.74E-06 Rheumatoid arthritis / / 17804836 rs1883414 chr6 33086448 G A 3.37E-08 Rheumatoid arthritis / / 19503088 rs1883414 chr6 33086448 G A 5.00E-09 Nephropathy / / 21399633 rs1883414 chr6 33086448 G A 9.00E-04 Coronary heart disease / / 21971053 rs1883414 chr6 33086448 G A 9.43E-06 Aspirin exacerbated respiratory disease in asthmatics / / 23180272 rs1883414 chr6 33086448 G A 6.11E-04 Crohn's disease / / 23266558 rs3129286 chr6 33089196 G A 3.58E-04 Aspirin exacerbated respiratory disease in asthmatics / / 23180272 rs3117027 chr6 33089623 C A 1.00E-07 Cervical cancer / / 23482656 rs4713607 chr6 33090836 G A 5.60E-04 Schizophrenia / / 19197363 rs4713607 chr6 33090836 G A 6.66E-07 Longevity,exceptional / / 20595579 rs4713607 chr6 33090836 G A 2.01E-15 Cervical cancer / / 23817570 rs3129275 chr6 33094258 C T 2.47E-15 Cervical cancer / / 23817570 rs3129274 chr6 33094869 C T 1.16E-05 Creatinine levels / / pha003069 rs9277758 chr6 33095162 A G 2.20E-05 Urinary metabolites / / 21572414 rs3130233 chr6 33095176 T C 7.78E-15 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs3117016 chr6 33095516 G A 2.42E-07 Multiple complex diseases HLA-DPB2 nearGene-5 17554300 rs3117016 chr6 33095516 G A 6.41E-24 Antineutrophil cytoplasmic antibody-associated vasculitis HLA-DPB2 nearGene-5 22808956 rs3117008 chr6 33096274 G A 5.60E-04 Schizophrenia / / 19197363 rs3117008 chr6 33096274 G A 1.64E-21 Cervical cancer / / 23817570 rs3129270 chr6 33097423 C T 1.76E-06 Aspirin exacerbated respiratory disease in asthmatics / / 23180272 rs3130237 chr6 33097561 T C 1.06E-11 Hodgkin's lymphoma / / 24149102 rs3129269 chr6 33097614 C A 1.30E-05 Nephropathy / / 21399633 rs3129269 chr6 33097614 C A 8.52E-04 Coronary heart disease / / 21971053 rs3129269 chr6 33097614 C A 1.93E-04 Aspirin exacerbated respiratory disease in asthmatics / / 23180272 rs3129269 chr6 33097614 C A 2.48E-05 Crohn's disease / / 23266558 rs3129269 chr6 33097614 C A 3.17E-06 Hodgkin's lymphoma / / 24149102 rs3116996 chr6 33097964 T A 8.33E-05 Multiple complex diseases / / 17554300 rs3116996 chr6 33097964 T A 8.70E-04 Cervical cancer / / 21716314 rs6901221 chr6 33098276 A C 2.98E-06 Rheumatoid arthritis / / 17804836 rs6901221 chr6 33098276 A C 1.19E-07 Systemic sclerosis / / 20383147 rs6901221 chr6 33098276 A C 1.41E-06 Aspirin exacerbated respiratory disease in asthmatics / / 23180272 rs6901221 chr6 33098276 A C 1.13E-11 Hodgkin's lymphoma / / 24149102 rs2294478 chr6 33098966 C A 1.12E-04 Crohn's disease / / 23266558 rs2294472 chr6 33099210 A G 8.25E-04 Coronary heart disease / / 21971053 rs2294472 chr6 33099210 A G 2.09E-05 Crohn's disease / / 23266558 rs2395351 chr6 33100427 T C 1.81E-12 Multiple complex diseases / / 17554300 rs3116985 chr6 33100590 G A 3.73E-11 Multiple complex diseases / / 17554300 rs2395352 chr6 33100732 A G 4.57E-04 Alzheimer's disease (late onset) / / 21379329 rs2395352 chr6 33100732 A G 3.60E-04 Coronary heart disease / / 21971053 rs9366816 chr6 33104175 T C 8.77E-04 Coronary heart disease / / 21971053 rs9366816 chr6 33104175 T C 3.00E-10 Chronic hepatitis B infection / / 24940741 rs3129249 chr6 33109556 C T 6.02E-04 Type 2 diabetes / / 17463246 rs3129249 chr6 33109556 C T 3.16E-04 Multiple complex diseases / / 17554300 rs3129248 chr6 33109658 A G 2.79E-05 Type 2 diabetes / / 17463246 rs3129248 chr6 33109658 A G 2.19E-11 Multiple complex diseases / / 17554300 rs3129248 chr6 33109658 A G 5.00E-05 Hematology traits / / 23303382 rs7754200 chr6 33110933 A G 9.04E-05 Alzheimer's disease (late onset) / / 21379329 rs7754200 chr6 33110933 A G 5.63E-09 Coronary heart disease / / 21971053 rs7754200 chr6 33110933 A G 1.82E-08 Hodgkin's lymphoma / / 24149102 rs3129234 chr6 33111347 C T 9.04E-05 Alzheimer's disease (late onset) / / 21379329 rs3129234 chr6 33111347 C T 8.13E-09 Coronary heart disease / / 21971053 rs3129234 chr6 33111347 C T 2.16E-08 Hodgkin's lymphoma / / 24149102 rs3129223 chr6 33113197 C T 9.16E-05 Alzheimer's disease (late onset) / / 21379329 rs3129223 chr6 33113197 C T 5.25E-09 Coronary heart disease / / 21971053 rs3129223 chr6 33113197 C T 1.96E-08 Hodgkin's lymphoma / / 24149102 rs1003979 chr6 33114171 T C 8.12E-07 Multiple complex diseases / / 17554300 rs1003979 chr6 33114171 T C 1.09E-04 Crohn's disease / / 23266558 rs9391756 chr6 33115794 C A 6.10E-21 Cervical cancer / / 23817570 rs2395365 chr6 33116222 A C 1.27E-05 Rheumatoid arthritis / / 17804836 rs3129214 chr6 33117258 C T 1.04E-04 Alzheimer's disease (late onset) / / 21379329 rs3129214 chr6 33117258 C T 7.22E-09 Coronary heart disease / / 21971053 rs3129214 chr6 33117258 C T 2.79E-08 Hodgkin's lymphoma / / 24149102 rs721394 chr6 33117818 C T 9.35E-04 Coronary heart disease / / 21971053 rs756441 chr6 33122171 A G 1.86E-05 Rheumatoid arthritis / / 17804836 rs756441 chr6 33122171 A G 1.92E-06 Hodgkin's lymphoma / / 24149102 rs756440 chr6 33122331 A G 1.03E-04 Alzheimer's disease (late onset) / / 21379329 rs756440 chr6 33122331 A G 8.13E-09 Coronary heart disease / / 21971053 rs756440 chr6 33122331 A G 2.06E-08 Hodgkin's lymphoma / / 24149102 rs3130159 chr6 33124693 G C 5.97E-05 Multiple complex diseases / / 17554300 rs9277920 chr6 33125725 G A 3.12E-05 Hepatitis B / / 21750111 rs9277920 chr6 33125725 G A 3.91E-05 Hodgkin's lymphoma / / 24149102 rs4713614 chr6 33127987 C A 7.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs4713614 chr6 33127987 C A 8.41E-05 Creatinine levels / / pha003069 rs2235498 chr6 33130430 G A 9.49E-06 Hodgkin's lymphoma COL11A2 nearGene-3 24149102 rs986522 chr6 33135962 C G 1.20E-05 Urinary metabolites COL11A2 intron 21572414 rs986521 chr6 33136145 G A 1.67E-07 Rheumatoid arthritis COL11A2 intron 17804836 rs986521 chr6 33136145 G A 2.31E-09 Rheumatoid arthritis COL11A2 intron 19503088 rs986521 chr6 33136145 G A 5.92E-05 Creatinine levels COL11A2 intron pha003069 rs9368758 chr6 33138021 G A 1.69E-07 Rheumatoid arthritis COL11A2 intron 19503088 rs9368758 chr6 33138021 G A 4.82E-04 Crohn's disease COL11A2 intron 23266558 rs9277932 chr6 33141253 T G 2.29E-04 Crohn's disease COL11A2 intron 23266558 rs2855430 chr6 33141280 G A 3.76E-05 Crohn's disease COL11A2 missense 23266558 rs2855430 chr6 33141280 G A 4.47E-09 Hodgkin's lymphoma COL11A2 missense 24149102 rs3762013 chr6 33142539 G A 2.38E-04 Crohn's disease COL11A2 intron 23266558 rs2071025 chr6 33143756 A G 1.70E-04 Multiple complex diseases COL11A2 intron 17554300 rs2071025 chr6 33143756 A G 9.96E-05 Formal thought disorder in schizophrenia COL11A2 intron 22648509 rs2254287 chr6 33143948 C G 5.00E-08 LDL cholesterol COL11A2 intron 18193043 rs2254287 chr6 33143948 C G 5.00E-08 Coronary heart disease COL11A2 intron 21347282 rs2855425 chr6 33144373 G A 2.34E-06 Rheumatoid arthritis COL11A2 intron 19503088 rs2855425 chr6 33144373 G A 4.42E-05 Creatinine levels COL11A2 intron pha003069 rs16868943 chr6 33147727 G A 1.90E-04 Self-reported allergy COL11A2 intron 23817569 rs7382464 chr6 33150268 T C 1.85E-07 Multiple complex diseases COL11A2 intron 17554300 rs2855459 chr6 33154656 G A 6.72E-10 Multiple complex diseases COL11A2 intron 17554300 rs2855459 chr6 33154656 G A 3.47E-05 Crohn's disease COL11A2 intron 23266558 rs2269346 chr6 33158898 C T 1.63E-07 Rheumatoid arthritis COL11A2 intron 19503088 rs2269346 chr6 33158898 C T 4.82E-04 Crohn's disease COL11A2 intron 23266558 rs2744537 chr6 33162215 A C 3.19E-06 Multiple complex diseases RXRB UTR-3 17554300 rs6531 chr6 33163451 G A 5.23E-06 Multiple complex diseases RXRB cds-synon 17554300 rs6531 chr6 33163451 G A 6.88E-05 Creatinine levels RXRB cds-synon pha003069 rs1547387 chr6 33169895 C G 2.20E-04 Lipid levels SLC39A7 cds-synon 19802338 rs439205 chr6 33173842 G A 4.03E-08 Rheumatoid arthritis HSD17B8 intron 17804836 rs439205 chr6 33173842 G A 3.43E-09 Rheumatoid arthritis HSD17B8 intron 19503088 rs439205 chr6 33173842 G A 2.55E-08 Hepatitis B HSD17B8 intron 21750111 rs439205 chr6 33173842 G A 0.0000188 Follicular lymphoma HSD17B8 intron 23025665 rs421446 chr6 33174783 A G 1.50E-09 Rheumatoid arthritis / / 17804836 rs421446 chr6 33174783 A G 6.17E-13 Rheumatoid arthritis / / 19503088 rs421446 chr6 33174783 A G 1.02E-08 Hepatitis B / / 21750111 rs213210 chr6 33175824 A G 1.19E-15 Cervical cancer / / 23817570 rs213208 chr6 33178010 G T 2.48E-04 Multiple complex diseases RING1 intron 17554300 rs2854028 chr6 33179689 C T 1.48E-07 Hepatitis B RING1 cds-synon 21750111 rs2854028 chr6 33179689 C T 3.33E-04 Coronary heart disease RING1 cds-synon 21971053 rs2854028 chr6 33179689 C T 8.90E-05 Systemic lupus erythematosus RING1 cds-synon 24871463 rs9277937 chr6 33184894 T C 1.90E-06 Hepatitis B / / 21750111 rs9277937 chr6 33184894 T C 1.01E-08 Coronary heart disease / / 21971053 rs1977090 chr6 33185578 C T 7.38E-09 Type 1 diabetes / / 17632545 rs213212 chr6 33185918 C A 7.76E-05 Creatinine levels / / pha003069 rs213220 chr6 33202640 C T 1.92E-05 Rheumatoid arthritis / / 19503088 rs213220 chr6 33202640 C T 1.32E-04 Crohn's disease / / 23266558 rs213220 chr6 33202640 C T 6.64E-05 Cholesterol / / pha003078 rs9277952 chr6 33204274 G A 2.00E-09 Cervical cancer / / 23817570 rs461338 chr6 33218180 T C 1.39E-12 Multiple complex diseases VPS52 UTR-3 17554300 rs462618 chr6 33222163 G T 5.55E-10 Multiple complex diseases VPS52 intron 17554300 rs213199 chr6 33235755 G A 2.79E-07 Rheumatoid arthritis VPS52 cds-synon 17804836 rs213199 chr6 33235755 G A 4.90E-13 Rheumatoid arthritis VPS52 cds-synon 19503088 rs464921 chr6 33240506 A G 4.49E-07 Rheumatoid arthritis RPS18 intron 19503088 rs213207 chr6 33241169 C T 4.12E-06 Rheumatoid arthritis RPS18 intron 19503088 rs213207 chr6 33241169 C T 4.49E-05 Cholesterol RPS18 intron pha003078 rs458679 chr6 33242492 C G 1.78E-11 Multiple complex diseases RPS18 intron 17554300 rs455567 chr6 33252115 G A 8.29E-12 Multiple complex diseases WDR46 intron 17554300 rs455567 chr6 33252115 G A 9.02E-04 Crohn's disease WDR46 intron 23266558 rs14398 chr6 33254665 A G 5.17E-08 Multiple complex diseases WDR46 missense 17554300 rs3130257 chr6 33256471 T C 4.97E-05 Orofacial clefts WDR46 missense 22419666 rs1059288 chr6 33267672 A G 6.49E-07 Rheumatoid arthritis TAPBP UTR-3 21156761 rs138516982 chr6 33271971 C T 0.000018 Prostate cancer (advanced) TAPBP missense 23555315 rs2071888 chr6 33272855 G C 6.87E-07 Rheumatoid arthritis TAPBP missense 21156761 rs3135408 chr6 33275013 T C 5.18E-07 Rheumatoid arthritis TAPBP intron 21156761 rs2282851 chr6 33280309 C T 3.24E-06 Rheumatoid arthritis TAPBP intron 17804836 rs2282851 chr6 33280309 C T 5.61E-06 Rheumatoid arthritis TAPBP intron 19503088 rs2282851 chr6 33280309 C T 4.30E-05 Cholesterol TAPBP intron pha003078 rs3106190 chr6 33280629 C G 8.50E-07 Rheumatoid arthritis TAPBP intron 21156761 rs3106189 chr6 33282002 C T 8.50E-07 Rheumatoid arthritis TAPBP UTR-5 21156761 rs3130100 chr6 33283766 T C 1.83E-09 Rheumatoid arthritis ZBTB22 missense 17804836 rs3130100 chr6 33283766 T C 3.13E-08 Rheumatoid arthritis ZBTB22 missense 19503088 rs3130100 chr6 33283766 T C 5.00E-07 Rheumatoid arthritis ZBTB22 missense 21156761 rs2239839 chr6 33288075 C A 3.03E-06 Rheumatoid arthritis DAXX intron 17804836 rs2239839 chr6 33288075 C A 8.97E-06 Rheumatoid arthritis DAXX intron 19503088 rs2239839 chr6 33288075 C A 4.11E-05 Cholesterol DAXX intron pha003078 rs2073524 chr6 33290547 T A 3.13E-07 Rheumatoid arthritis DAXX intron 21156761 rs2395379 chr6 33298478 A G 3.55E-07 Rheumatoid arthritis / / 21156761 rs3130266 chr6 33303989 G A 6.02E-07 Rheumatoid arthritis / / 21156761 rs3130267 chr6 33306794 T A,G 3.87E-11 Multiple complex diseases / / 17554300 rs3130267 chr6 33306794 T A,G 8.62E-07 Rheumatoid arthritis / / 21156761 rs113652681 chr6 33307400 T TG 8.15E-07 Rheumatoid arthritis / / 21156761 rs3130268 chr6 33307400 T G 8.15E-07 Rheumatoid arthritis / / 21156761 rs3130014 chr6 33312308 A G 5.00E-05 Multiple complex diseases / / 17554300 rs3130014 chr6 33312308 A G 2.57E-05 Rheumatoid arthritis / / 17804836 rs3130014 chr6 33312308 A G 4.78E-07 Rheumatoid arthritis / / 19503088 rs3130010 chr6 33318571 C T 3.65E-05 Suicide attempts in bipolar disorder / / 21423239 rs3117324 chr6 33324527 G T 8.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs3106192 chr6 33326250 A G 3.41E-05 Suicide attempts in bipolar disorder / / 21423239 rs9278019 chr6 33326434 C T 1.03E-06 Rheumatoid arthritis / / 19503088 rs9278019 chr6 33326434 C T 6.60E-04 Systemic lupus erythematosus / / 24871463 rs211455 chr6 33328518 G A 8.88E-07 Multiple complex diseases / / 17554300 rs211455 chr6 33328518 G A 1.45E-06 Rheumatoid arthritis / / 17804836 rs211455 chr6 33328518 G A 3.95E-11 Rheumatoid arthritis / / 19503088 rs211455 chr6 33328518 G A 1.94E-05 Cognitive test performance / / 20125193 rs211453 chr6 33330131 T G 1.21E-06 Multiple complex diseases / / 17554300 rs211452 chr6 33330981 A G 2.32E-08 Rheumatoid arthritis / / 17804836 rs211452 chr6 33330981 A G 7.67E-15 Rheumatoid arthritis / / 19503088 rs211452 chr6 33330981 A G 1.49E-06 Cognitive test performance / / 20125193 rs3130275 chr6 33332137 A G 5.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs3130276 chr6 33336930 C T 4.50E-06 Rheumatoid arthritis / / 17804836 rs3130276 chr6 33336930 C T 3.02E-06 Rheumatoid arthritis / / 19503088 rs3130276 chr6 33336930 C T 2.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs2747476 chr6 33351251 C G 4.65E-04 Multiple complex diseases / / 17554300 rs465877 chr6 33356073 C T 2.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs456993 chr6 33358278 T C 2.75E-04 Suicide attempts in bipolar disorder KIFC1 nearGene-5 21423239 rs465506 chr6 33359008 A G 2.06E-04 Suicide attempts in bipolar disorder KIFC1 nearGene-5 21423239 rs465474 chr6 33359142 A G 2.21E-04 Suicide attempts in bipolar disorder KIFC1 nearGene-5 21423239 rs465223 chr6 33359716 G C 2.13E-04 Suicide attempts in bipolar disorder KIFC1 UTR-5 21423239 rs461964 chr6 33360574 T G 2.04E-04 Suicide attempts in bipolar disorder KIFC1 intron 21423239 rs461887 chr6 33360787 T C 2.18E-04 Suicide attempts in bipolar disorder KIFC1 intron 21423239 rs211457 chr6 33365640 T C 1.07E-04 Multiple complex diseases KIFC1 intron 17554300 rs376006 chr6 33370774 A C 1.55E-04 Suicide attempts in bipolar disorder KIFC1 intron 21423239 rs459927 chr6 33373532 G C 1.59E-04 Suicide attempts in bipolar disorder KIFC1 intron 21423239 rs442745 chr6 33382241 T C 1.13E-04 Suicide attempts in bipolar disorder PHF1 intron 21423239 rs3116713 chr6 33382288 G A 5.29E-05 Orofacial clefts PHF1 missense 22419666 rs211456 chr6 33389381 G T 6.05E-06 Rheumatoid arthritis SYNGAP1 intron 17804836 rs211456 chr6 33389381 G T 6.25E-10 Rheumatoid arthritis SYNGAP1 intron 19503088 rs211456 chr6 33389381 G T 6.53E-06 Cognitive test performance SYNGAP1 intron 20125193 rs10807124 chr6 33404064 G A 2.63E-09 Multiple complex diseases SYNGAP1 intron 17554300 rs10807124 chr6 33404064 G A 4.49E-05 Schizophrenia SYNGAP1 intron 19571811 rs411136 chr6 33408542 G A 5.31E-06 Multiple complex diseases SYNGAP1 cds-synon 17554300 rs12204193 chr6 33415307 C G 1.35E-04 Suicide attempts in bipolar disorder SYNGAP1 intron 21423239 rs1755044 chr6 33416818 C T 1.68E-04 Amyotrophic lateral sclerosis (sporadic) SYNGAP1 intron 24529757 rs2247385 chr6 33421577 T C 1.72E-06 Rheumatoid arthritis / / 17804836 rs2247385 chr6 33421577 T C 2.22E-10 Rheumatoid arthritis / / 19503088 rs2247385 chr6 33421577 T C 4.75E-06 Cognitive test performance / / 20125193 rs2274730 chr6 33422545 C G 3.46E-04 Suicide attempts in bipolar disorder ZBTB9 UTR-5 21423239 rs9380355 chr6 33426699 G A 5.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs2772373 chr6 33429672 A G 1.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs3119021 chr6 33429952 A G 5.89E-04 Multiple complex diseases / / 17554300 rs1755047 chr6 33431319 G C 1.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs3130028 chr6 33442738 C T 1.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs2772387 chr6 33451578 G C 4.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs9394152 chr6 33465482 C T 7.00E-08 Chronic obstructive pulmonary disease / / 21685187 rs4713630 chr6 33472941 T C 1.56E-04 Multiple complex diseases / / 17554300 rs769051 chr6 33473894 T A,C,G 8.40E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs4713633 chr6 33477140 G A 8.05E-05 Multiple complex diseases / / 17554300 rs9296092 chr6 33478496 A G 6.00E-07 Chronic obstructive pulmonary disease / / 21685187 rs9296092 chr6 33478496 A G 6.92E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs86715 chr6 33480435 A G 3.27E-04 Intracranial aneurysm / / 20613766 rs86715 chr6 33480435 A G 8.08E-09 Hepatitis B / / 21750111 rs86715 chr6 33480435 A G 9.44E-06 Coronary heart disease / / 21971053 rs68191 chr6 33480738 T C 1.51E-06 Hepatitis B / / 21750111 rs68191 chr6 33480738 T C 8.01E-12 Coronary heart disease / / 21971053 rs6457730 chr6 33486732 G A 1.00E-06 Self-reported allergy / / 23817569 rs6929647 chr6 33488549 T C 1.21E-06 Self-reported allergy / / 23817569 rs9469457 chr6 33489882 G A 9.00E-06 Obesity-related traits / / 23251661 rs9469457 chr6 33489882 G A 1.21E-06 Self-reported allergy / / 23817569 rs6924409 chr6 33491057 G C 4.17E-04 Multiple complex diseases / / 17554300 rs6924409 chr6 33491057 G C 2.73E-06 Self-reported allergy / / 23817569 rs10452588 chr6 33493071 A G 1.25E-06 Self-reported allergy / / 23817569 rs9469465 chr6 33496201 A G 1.29E-06 Self-reported allergy / / 23817569 rs435945 chr6 33496632 C T 1.07E-04 Multiple complex diseases / / 17554300 rs449242 chr6 33496714 T G 6.20E-08 Blood cell counts and traits,in red and white blood cells / / 21153663 rs449242 chr6 33496714 T G 2.66E-05 Coronary heart disease / / 21971053 rs449242 chr6 33496714 T G 6.20E-08 Mean platelet volume / / 22423221 rs6929336 chr6 33497517 C A 4.05E-06 Self-reported allergy / / 23817569 rs368716 chr6 33505981 T C 3.64E-05 Coronary heart disease / / 21971053 rs6910233 chr6 33534726 G T 7.50E-06 Urinary metabolites / / 21572414 rs6910233 chr6 33534726 G T 4.00E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs17627049 chr6 33537802 C A 3.09E-05 Multiple complex diseases / / 17554300 rs210134 chr6 33540209 A G 4.05E-04 Coronary heart disease / / 21971053 rs210134 chr6 33540209 A G 7.00E-36 Platelet counts / / 22139419 rs210134 chr6 33540209 A G 2.00E-15 Mean platelet volume / / 22423221 rs210134 chr6 33540209 A G 2.00E-08 Platelet counts / / 23263863 rs210134 chr6 33540209 A G 3.37E-05 Self-reported allergy / / 23817569 rs210134 chr6 33540209 A G 6.00E-08 Platelet counts / / 24026423 rs210134 chr6 33540209 A G 3.00E-06 Chronic lymphocytic leukemia / / 24292274 rs513349 chr6 33541719 A G 1.16E-08 Testicular germ cell cancer BAK1 intron 20543847 rs513349 chr6 33541719 A G 2.00E-12 Platelet counts BAK1 intron 23263863 rs210138 chr6 33542538 A G 1.00E-13 Testicular germ cell tumor BAK1 intron 19483681 rs210138 chr6 33542538 A G 1.00E-13 Nasopharyngeal carcinoma BAK1 intron 20512145 rs210138 chr6 33542538 A G 3.77E-12 Testicular germ cell cancer BAK1 intron 20543847 rs210138 chr6 33542538 A G 6.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BAK1 intron 20877124 rs210138 chr6 33542538 A G 3.00E-07 Testicular germ cell tumor BAK1 intron 23666239 rs210138 chr6 33542538 A G 2.00E-24 Testicular germ cell tumor BAK1 intron 23666240 rs210139 chr6 33543409 A C 2.80E-14 Testicular germ cell cancer BAK1 intron 20543847 rs210142 chr6 33546837 T C 9.00E-16 Chronic lymphocytic leukemia BAK1 intron 22700719 rs210142 chr6 33546837 T C 5.00E-08 Chronic lymphocytic leukemia BAK1 intron 23770605 rs5745571 chr6 33548166 G A 0.000000407 HDL cholesterol / / 23063622 rs5745568 chr6 33548394 G T 6.66E-11 Blood cell counts and other traits / / 20139978 rs5745568 chr6 33548394 G T 7.00E-11 Blood cell counts and other traits / / 20139978 rs5745568 chr6 33548394 G T 6.66E-11 Hepatitis B / / 21750111 rs420361 chr6 33555904 T C 3.18E-06 Cognitive test performance LINC00336 intron 20125193 rs375555 chr6 33557741 T C 1.94E-12 Testicular germ cell cancer LINC00336 intron 20543847 rs6457733 chr6 33561962 T C 5.80E-04 Systemic lupus erythematosus / / 18219441 rs10947410 chr6 33562709 T C 5.80E-04 Systemic lupus erythematosus / / 18219441 rs12206050 chr6 33564296 A T 1.68E-05 Systemic lupus erythematosus / / 18219441 rs510153 chr6 33570075 G A 1.42E-05 Major depression (suicidal thoughts and behavior) / / 21750702 rs76108243 chr6 33573994 G A 2.01E-07 Sarcoidosis / / 22952805 rs112668322 chr6 33574199 G A 1.71E-07 Sarcoidosis / / 22952805 rs77459368 chr6 33574238 C T 1.71E-07 Sarcoidosis / / 22952805 rs444697 chr6 33575009 G A 7.87E-06 Multiple complex diseases / / 17554300 rs16869280 chr6 33575395 C T 2.18E-07 Sarcoidosis / / 22952805 rs75468179 chr6 33578391 A T 9.55E-05 Epilepsy (remission after treatment) / / 23962720 rs1794681 chr6 33579661 C T 3.18E-04 Multiple complex diseases / / 17554300 rs494654 chr6 33581566 G C 0.00004082 Sarcoidosis / / 22952805 rs113162166 chr6 33583558 C T 0.00005294 Sarcoidosis / / 22952805 rs9469529 chr6 33587443 G A 3.63E-04 Multiple complex diseases MNF1 nearGene-5 17554300 rs9469529 chr6 33587443 G A 7.96E-04 Type 2 diabetes MNF1 nearGene-5 22158537 rs3748079 chr6 33588147 C T 1.11E-08 Systemic lupus erythematosus MNF1 nearGene-5 18219441 rs3748079 chr6 33588147 C T 3.60E-04 Systemic lupus erythematosus MNF1 nearGene-5 18219441 rs3748079 chr6 33588147 C T 4.55E-04 Alzheimer's disease (late onset) MNF1 nearGene-5 21379329 rs9368768 chr6 33588610 G A 8.60E-04 Systemic lupus erythematosus MNF1 nearGene-5 18219441 rs116351191 chr6 33590998 T A 7.46E-05 Epilepsy (remission after treatment) ITPR3 intron 23962720 rs115743807 chr6 33591043 G A 7.46E-05 Epilepsy (remission after treatment) ITPR3 intron 23962720 rs6903502 chr6 33593687 C G 1.10E-04 Systemic lupus erythematosus ITPR3 intron 18219441 rs4711332 chr6 33595399 A G 1.66E-04 Multiple complex diseases ITPR3 intron 17554300 rs4711332 chr6 33595399 A G 2.17E-04 Intracranial aneurysm ITPR3 intron 20613766 rs4711332 chr6 33595399 A G 6.44E-08 Hepatitis B ITPR3 intron 21750111 rs4711332 chr6 33595399 A G 8.60E-09 Graves' disease ITPR3 intron 21900946 rs4711332 chr6 33595399 A G 3.71E-06 Coronary heart disease ITPR3 intron 21971053 rs7769019 chr6 33598642 G A 4.30E-05 Melanoma ITPR3 intron 21926416 rs9469531 chr6 33599495 A G 7.38E-05 Epilepsy (remission after treatment) ITPR3 intron 23962720 rs9469533 chr6 33601172 C A 7.43E-05 Epilepsy (remission after treatment) ITPR3 intron 23962720 rs80106788 chr6 33602123 T C 7.86E-05 Epilepsy (remission after treatment) ITPR3 intron 23962720 rs9469536 chr6 33604913 T G 9.39E-05 Epilepsy (remission after treatment) ITPR3 intron 23962720 rs4713646 chr6 33606523 C T 4.10E-04 Systemic lupus erythematosus ITPR3 intron 18219441 rs4713646 chr6 33606523 C T 2.41E-12 Testicular germ cell cancer ITPR3 intron 20543847 rs4713646 chr6 33606523 C T 5.95E-05 Glucose levels ITPR3 intron pha002899 rs10947421 chr6 33611278 G T 1.10E-04 Systemic lupus erythematosus ITPR3 intron 18219441 rs12205634 chr6 33611667 C G 5.86E-05 Multiple complex diseases ITPR3 intron 17554300 rs12205634 chr6 33611667 C G 2.00E-05 Urinary metabolites ITPR3 intron 21572414 rs9357162 chr6 33613344 G A 3.10E-04 Systemic lupus erythematosus ITPR3 intron 18219441 rs9394158 chr6 33613367 G T 2.60E-04 Systemic lupus erythematosus ITPR3 intron 18219441 rs6935686 chr6 33614127 C T 8.84E-07 Rheumatoid arthritis ITPR3 intron 17804836 rs6935686 chr6 33614127 C T 1.25E-04 Systemic lupus erythematosus ITPR3 intron 18219441 rs6457738 chr6 33617464 C T 2.40E-04 Systemic lupus erythematosus ITPR3 intron 18219441 rs9348923 chr6 33617924 C T 8.90E-04 Systemic lupus erythematosus ITPR3 intron 18219441 rs9394159 chr6 33618162 A T 9.48E-06 Systemic lupus erythematosus ITPR3 intron 18219441 rs9394159 chr6 33618162 A T 4.00E-12 Graves' disease ITPR3 intron 21900946 rs9366826 chr6 33619184 G C 8.47E-04 Multiple complex diseases ITPR3 intron 17554300 rs9366826 chr6 33619184 G C 3.00E-04 Systemic lupus erythematosus ITPR3 intron 18219441 rs62407648 chr6 33622436 C G 1.62E-06 Systemic lupus erythematosus ITPR3 intron 18219441 rs4259245 chr6 33624221 A G 3.53E-05 Rheumatoid arthritis ITPR3 intron 17804836 rs4259245 chr6 33624221 A G 8.55E-04 Suicide attempts in bipolar disorder ITPR3 intron 21423239 rs999943 chr6 33624733 A G 1.00E-06 Obesity (extreme) ITPR3 intron 19553259 rs999942 chr6 33624902 G C 2.10E-04 Systemic lupus erythematosus ITPR3 intron 18219441 rs2296343 chr6 33626717 T C 5.60E-04 Suicide attempts in bipolar disorder ITPR3 intron 21423239 rs2296340 chr6 33630472 G A 3.08E-06 Hepatitis B ITPR3 intron 21750111 rs2296340 chr6 33630472 G A 4.68E-12 Coronary heart disease ITPR3 intron 21971053 rs2296339 chr6 33630624 C T 8.31E-05 Systemic lupus erythematosus ITPR3 intron 18219441 rs2296337 chr6 33631696 G A 3.73E-04 Suicide attempts in bipolar disorder ITPR3 intron 21423239 rs6901411 chr6 33633527 A G 4.75E-04 Suicide attempts in bipolar disorder ITPR3 intron 21423239 rs12662536 chr6 33635407 T A 2.67E-04 Suicide attempts in bipolar disorder ITPR3 intron 21423239 rs2296336 chr6 33636660 C G 3.20E-04 Systemic lupus erythematosus ITPR3 intron 18219441 rs2296336 chr6 33636660 C G 8.71E-04 Suicide attempts in bipolar disorder ITPR3 intron 21423239 rs2229634 chr6 33638180 C T 4.20E-04 Systemic lupus erythematosus ITPR3 cds-synon 18219441 rs2229634 chr6 33638180 C T 8.29E-04 Suicide attempts in bipolar disorder ITPR3 cds-synon 21423239 rs1803831 chr6 33641379 T C 1.70E-04 Systemic lupus erythematosus ITPR3 missense 18219441 rs9368771 chr6 33641721 C T 5.56E-04 Suicide attempts in bipolar disorder ITPR3 intron 21423239 rs6913517 chr6 33642682 C T 2.70E-07 Urinary metabolites ITPR3 intron 21572414 rs6913517 chr6 33642682 C T 6.07E-05 Smoking initiation ITPR3 intron 24665060 rs2229637 chr6 33643558 G A 3.07E-05 Multiple complex diseases ITPR3 cds-synon 17554300 rs2229637 chr6 33643558 G A 2.34E-04 Self-reported allergy ITPR3 cds-synon 23817569 rs10947427 chr6 33644253 G A 1.63E-06 Multiple complex diseases ITPR3 intron 17554300 rs2274197 chr6 33645115 G T 4.40E-04 Systemic lupus erythematosus ITPR3 intron 18219441 rs10947428 chr6 33647058 T C 4.43E-06 Self-reported allergy ITPR3 intron 23817569 rs4713653 chr6 33647594 C A 2.27E-09 Rheumatoid arthritis ITPR3 intron 17804836 rs4713653 chr6 33647594 C A 5.82E-07 Rheumatoid arthritis ITPR3 intron 19503088 rs4713653 chr6 33647594 C A 2.45E-05 Alzheimer's disease (late onset) ITPR3 intron 21379329 rs4713653 chr6 33647594 C A 3.47E-08 Coronary heart disease ITPR3 intron 21971053 rs4713654 chr6 33647651 A G 3.09E-09 Rheumatoid arthritis ITPR3 intron 17804836 rs4713654 chr6 33647651 A G 7.19E-07 Rheumatoid arthritis ITPR3 intron 19503088 rs4713654 chr6 33647651 A G 9.92E-05 Lung adenocarcinoma ITPR3 intron 19836008 rs4713654 chr6 33647651 A G 2.73E-05 Alzheimer's disease (late onset) ITPR3 intron 21379329 rs2296329 chr6 33650743 A G 4.36E-05 Systemic lupus erythematosus ITPR3 intron 18219441 rs942636 chr6 33651129 C T 1.98E-06 Systemic lupus erythematosus ITPR3 cds-synon 18219441 rs2296328 chr6 33651277 C T 3.67E-04 Alzheimer's disease (late onset) ITPR3 intron 21379329 rs2296328 chr6 33651277 C T 8.48E-08 Coronary heart disease ITPR3 intron 21971053 rs4711336 chr6 33659046 G A 1.09E-05 Multiple complex diseases ITPR3 intron 17554300 rs4711336 chr6 33659046 G A 3.00E-08 Height ITPR3 intron 20881960 rs2296742 chr6 33659793 G A 2.15E-07 Rheumatoid arthritis ITPR3 intron 21156761 rs9296097 chr6 33660143 G A 9.50E-08 Coronary heart disease ITPR3 intron 21971053 rs4711338 chr6 33660188 T C 2.54E-04 Coronary heart disease ITPR3 intron 21971053 rs3818523 chr6 33660371 G A 2.15E-07 Rheumatoid arthritis ITPR3 intron 21156761 rs3818527 chr6 33661035 G A 1.50E-04 Multiple complex diseases ITPR3 intron 17554300 rs3818527 chr6 33661035 G A 3.76E-07 Rheumatoid arthritis ITPR3 intron 21156761 rs3818528 chr6 33661091 G A 2.60E-09 Rheumatoid arthritis ITPR3 intron 17804836 rs3818528 chr6 33661091 G A 7.08E-07 Rheumatoid arthritis ITPR3 intron 19503088 rs3818530 chr6 33661222 C G 2.75E-04 Multiple complex diseases ITPR3 intron 17554300 rs3818530 chr6 33661222 C G 2.85E-07 Rheumatoid arthritis ITPR3 intron 21156761 rs3227 chr6 33662295 G C 3.00E-07 Educational attainment ITPR3 intron 23722424 rs658087 chr6 33665020 T A 3.45E-04 Multiple complex diseases / / 17554300 rs4711339 chr6 33667199 A G 3.21E-07 Rheumatoid arthritis MNF1 intron 21156761 rs9469566 chr6 33667605 C A 2.45E-07 Rheumatoid arthritis MNF1 intron 21156761 rs4713659 chr6 33667839 A G 1.01E-04 Multiple complex diseases MNF1 intron 17554300 rs4713659 chr6 33667839 A G 2.45E-07 Rheumatoid arthritis MNF1 intron 21156761 rs594223 chr6 33667965 G T 7.05E-04 Multiple complex diseases MNF1 intron 17554300 rs594223 chr6 33667965 G T 5.74E-04 Coronary Artery Disease MNF1 intron 17634449 rs594223 chr6 33667965 G T 2.74E-06 Rheumatoid arthritis MNF1 intron 17804836 rs594223 chr6 33667965 G T 2.19E-06 Rheumatoid arthritis MNF1 intron 19503088 rs942643 chr6 33668370 A G 2.85E-07 Rheumatoid arthritis MNF1 intron 21156761 rs7739505 chr6 33670370 G A 2.44E-07 Rheumatoid arthritis MNF1 intron 21156761 rs7759668 chr6 33670406 T C 1.01E-04 Multiple complex diseases MNF1 intron 17554300 rs7759668 chr6 33670406 T C 2.44E-07 Rheumatoid arthritis MNF1 intron 21156761 rs654682 chr6 33672226 G A 4.69E-04 Multiple complex diseases MNF1 intron 17554300 rs6457739 chr6 33673831 A G 1.63E-07 Rheumatoid arthritis MNF1 intron 21156761 rs2281829 chr6 33675642 A G 1.88E-12 Rheumatoid arthritis MNF1 intron 17804836 rs2281829 chr6 33675642 A G 2.36E-08 Rheumatoid arthritis MNF1 intron 19503088 rs2281829 chr6 33675642 A G 1.91E-07 Rheumatoid arthritis MNF1 intron 21156761 rs2281829 chr6 33675642 A G 2.37E-05 Coronary heart disease MNF1 intron 21971053 rs542441 chr6 33675851 A C 4.94E-05 Rheumatoid arthritis MNF1 intron 17804836 rs542441 chr6 33675851 A C 2.09E-04 Coronary heart disease MNF1 intron 21971053 rs6904816 chr6 33676156 G A 2.52E-07 Rheumatoid arthritis MNF1 intron 21156761 rs6928010 chr6 33676590 T C 2.74E-07 Rheumatoid arthritis MNF1 intron 21156761 rs3818532 chr6 33679807 A G 2.51E-06 Hepatitis B / / 21750111 rs3818532 chr6 33679807 A G 1.65E-10 Coronary heart disease / / 21971053 rs9394163 chr6 33682414 T C 9.52E-05 Multiple complex diseases / / 17554300 rs2966 chr6 33689520 C T 7.49E-12 Rheumatoid arthritis IP6K3 UTR-3 17804836 rs2966 chr6 33689520 C T 4.59E-07 Rheumatoid arthritis IP6K3 UTR-3 19503088 rs2966 chr6 33689520 C T 4.98E-05 Coronary heart disease IP6K3 UTR-3 21971053 rs2967 chr6 33689534 A G 6.12E-04 Multiple complex diseases IP6K3 UTR-3 17554300 rs4713668 chr6 33690796 C T 1.93E-12 Rheumatoid arthritis IP6K3 missense 17804836 rs4713668 chr6 33690796 C T 5.88E-08 Rheumatoid arthritis IP6K3 missense 19503088 rs4713668 chr6 33690796 C T 2.28E-05 Coronary heart disease IP6K3 missense 21971053 rs10947434 chr6 33691501 G T 6.39E-07 Rheumatoid arthritis IP6K3 intron 21156761 rs2281830 chr6 33695130 G A 2.70E-04 Systemic lupus erythematosus IP6K3 intron 18219441 rs6457740 chr6 33697125 A G 2.54E-09 Rheumatoid arthritis IP6K3 intron 17804836 rs6457740 chr6 33697125 A G 1.53E-05 Rheumatoid arthritis IP6K3 intron 19503088 rs6457740 chr6 33697125 A G 5.60E-04 Myocardial Infarction IP6K3 intron pha002883 rs4713670 chr6 33699882 T C 6.65E-05 Multiple complex diseases IP6K3 intron 17554300 rs4713671 chr6 33699899 T C 3.05E-05 Multiple complex diseases IP6K3 intron 17554300 rs791903 chr6 33702645 G C 4.81E-04 Obesity (extreme) IP6K3 intron 21935397 rs622917 chr6 33702869 C T 5.32E-05 Coronary heart disease IP6K3 intron 21971053 rs4713672 chr6 33705066 G A 1.35E-08 Rheumatoid arthritis IP6K3 intron 21156761 rs9469578 chr6 33706479 C T 1.00E-11 Phosphorus levels IP6K3 intron 20558539 rs4713674 chr6 33708169 A G 7.46E-06 Multiple complex diseases IP6K3 intron 17554300 rs4713674 chr6 33708169 A G 1.35E-08 Rheumatoid arthritis IP6K3 intron 21156761 rs652049 chr6 33711420 C T 1.39E-06 Rheumatoid arthritis IP6K3 intron 17804836 rs9469583 chr6 33717770 T C 1.12E-13 Rheumatoid arthritis / / 17804836 rs9469583 chr6 33717770 T C 1.62E-10 Rheumatoid arthritis / / 19503088 rs9469583 chr6 33717770 T C 3.08E-05 Coronary heart disease / / 21971053 rs10947435 chr6 33718075 G A 4.73E-05 Coronary heart disease / / 21971053 rs4304152 chr6 33723290 G A 1.03E-04 Coronary heart disease / / 21971053 rs1536500 chr6 33723383 T C 1.51E-06 Rheumatoid arthritis / / 17804836 rs6919321 chr6 33724004 G A 1.45E-09 Rheumatoid arthritis / / 17804836 rs6919321 chr6 33724004 G A 4.67E-06 Rheumatoid arthritis / / 19503088 rs6919321 chr6 33724004 G A 9.46E-07 Coronary heart disease / / 21971053 rs9380376 chr6 33724794 C T 1.18E-05 Rheumatoid arthritis / / 17804836 rs12211490 chr6 33725528 G T 1.89E-07 Coronary heart disease / / 21971053 rs1536501 chr6 33727885 T C 5.57E-04 Multiple complex diseases / / 17554300 rs4711345 chr6 33730954 G A 5.63E-04 Coronary heart disease / / 21971053 rs943472 chr6 33738442 T C 7.95E-05 Alzheimer's disease (age of onset) / / 22005931 rs10947436 chr6 33739960 A G 7.82E-05 Alzheimer's disease (age of onset) LEMD2 UTR-3 22005931 rs2296743 chr6 33740025 C T 8.00E-06 Obesity-related traits LEMD2 UTR-3 23251661 rs2296744 chr6 33740382 G A 8.99E-05 Alcohol and nictotine co-dependence LEMD2 UTR-3 20158304 rs4711350 chr6 33741716 A G 8.34E-05 Alzheimer's disease (age of onset) LEMD2 intron 22005931 rs2296748 chr6 33745071 C T 5.48E-06 Rheumatoid arthritis LEMD2 intron 17804836 rs2296748 chr6 33745071 C T 3.12E-06 Rheumatoid arthritis LEMD2 intron 19503088 rs111606296 chr6 33747892 T C 0.00048 Prostate cancer (non-advanced prostate cancer) LEMD2 missense 23555315 rs2182658 chr6 33748831 T G 9.45E-04 Multiple complex diseases LEMD2 intron 17554300 rs943475 chr6 33749978 T C 2.86E-04 Multiple complex diseases LEMD2 intron 17554300 rs943476 chr6 33750086 A G 7.47E-04 Multiple complex diseases LEMD2 intron 17554300 rs2182659 chr6 33751767 A G 8.39E-05 Alzheimer's disease (age of onset) LEMD2 intron 22005931 rs9394167 chr6 33754396 A G 9.70E-04 Hypothyroidism LEMD2 intron 21981779 rs6929696 chr6 33759290 T C 2.04E-04 Multiple complex diseases / / 17554300 rs2395401 chr6 33759471 T C 8.25E-05 Alzheimer's disease (age of onset) / / 22005931 rs2274459 chr6 33762242 G A 6.00E-06 Obesity (extreme) / / 19553259 rs2274459 chr6 33762242 G A 1.93E-07 Coronary heart disease / / 21971053 rs751728 chr6 33764033 C T 1.00E-08 Crohn's disease MLN intron 23850713 rs751727 chr6 33764158 A G 7.62E-05 Alzheimer's disease (age of onset) MLN intron 22005931 rs3806109 chr6 33770370 T G 4.76E-06 Rheumatoid arthritis MLN intron 17804836 rs3806109 chr6 33770370 T G 3.64E-06 Rheumatoid arthritis MLN intron 19503088 rs9366829 chr6 33773199 A G 3.08E-05 Multiple complex diseases / / 17554300 rs2894342 chr6 33774394 C A 1 Drug response to Carbamazepine / / 16538176 rs1547668 chr6 33775446 A G 1.44E-05 Alzheimer's disease (age of onset) / / 22005931 rs1547669 chr6 33775641 A G 1.58E-04 Coronary heart disease / / 21971053 rs9394169 chr6 33778964 A G 1.27E-09 Rheumatoid arthritis / / 17804836 rs9394169 chr6 33778964 A G 5.42E-06 Rheumatoid arthritis / / 19503088 rs9394169 chr6 33778964 A G 4.45E-05 Coronary heart disease / / 21971053 rs3957165 chr6 33784864 C T 9.61E-05 Alzheimer's disease (age of onset) / / 22005931 rs1535950 chr6 33785827 A G 1.76E-06 Rheumatoid arthritis / / 17804836 rs1535950 chr6 33785827 A G 9.13E-06 Obesity-related traits / / 23251661 rs13203745 chr6 33787746 T C 3.81E-05 Hepatitis B / / 21750111 rs13203745 chr6 33787746 T C 1.04E-10 Coronary heart disease / / 21971053 rs12195485 chr6 33790877 C T 3.62E-06 Coronary heart disease / / 21971053 rs9469598 chr6 33794167 G T 6.37E-04 Parkinson's disease / / 17052657 rs9461918 chr6 33799632 G C 1.76E-04 Multiple complex diseases / / 17554300 rs6901216 chr6 33807091 T C 7.31E-04 Multiple complex diseases / / 17554300 rs4713692 chr6 33807638 C T 7.84E-04 Multiple complex diseases / / 17554300 rs4713692 chr6 33807638 C T 4.40E-06 Urinary metabolites / / 21572414 rs6905353 chr6 33813043 T G 3.02E-05 Coronary heart disease / / 21971053 rs6931760 chr6 33813971 G C 9.31E-04 Type 2 diabetes / / 17463246 rs6931760 chr6 33813971 G C 1.46E-04 Multiple complex diseases / / 17554300 rs9469615 chr6 33816933 T C 1.40E-05 Multiple complex diseases / / 17554300 rs4713693 chr6 33817929 T C 7.00E-13 Graves' disease / / 21900946 rs11753213 chr6 33819582 A G 3.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9296100 chr6 33822865 C T 3.51E-04 Coronary heart disease / / 21971053 rs2104362 chr6 33825358 G A 7.00E-06 Alzheimer's disease (age of onset) / / 22005931 rs4713697 chr6 33826590 T C 1.29E-05 Alzheimer's disease (age of onset) / / 22005931 rs9469619 chr6 33828178 A G 7.02E-05 Coronary heart disease / / 21971053 rs9469619 chr6 33828178 A G 6.75E-05 Triglycerides / / pha003080 rs10947460 chr6 33828234 G A 1.13E-05 Hepatitis B / / 21750111 rs10947460 chr6 33828234 G A 4.91E-10 Coronary heart disease / / 21971053 rs6934013 chr6 33830362 T C 1.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6934013 chr6 33830362 T C 7.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1555685 chr6 33830804 T C 2.16E-05 Alzheimer's disease (age of onset) / / 22005931 rs9394174 chr6 33831672 T C 2.21E-05 Alzheimer's disease (age of onset) / / 22005931 rs3998107 chr6 33833005 G A 2.29E-05 Alzheimer's disease (age of onset) / / 22005931 rs4713699 chr6 33833433 T C 1.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4713699 chr6 33833433 T C 7.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1535937 chr6 33834431 T C 2.59E-05 Alzheimer's disease (age of onset) / / 22005931 rs1555687 chr6 33835210 C T 2.59E-05 Alzheimer's disease (age of onset) / / 22005931 rs4713704 chr6 33836691 A G 8.04E-05 Alzheimer's disease (age of onset) / / 22005931 rs1555688 chr6 33837242 G A 1.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1555688 chr6 33837242 G A 7.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6457744 chr6 33837316 A G 8.92E-05 Coronary heart disease / / 21971053 rs10947461 chr6 33840121 G A 5.00E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9348927 chr6 33840657 G A 2.08E-05 Coronary heart disease / / 21971053 rs4713711 chr6 33846143 T C 4.01E-05 Rheumatoid arthritis / / 17804836 rs4713711 chr6 33846143 T C 1.18E-06 Rheumatoid arthritis / / 19503088 rs4713711 chr6 33846143 T C 1.94E-06 Coronary heart disease / / 21971053 rs10947463 chr6 33847077 G A 3.55E-06 Hepatitis B / / 21750111 rs10947463 chr6 33847077 G A 1.19E-12 Coronary heart disease / / 21971053 rs6926599 chr6 33850861 G A 1.61E-05 Multiple complex diseases / / 17554300 rs11759059 chr6 33851052 C A 3.76E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs16869652 chr6 33851173 G A 5.00E-06 Schizophrenia / / 22885689 rs2274154 chr6 33857525 C T 2.18E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6941621 chr6 33858199 A G 3.82E-08 Multiple complex diseases / / 17554300 rs6457748 chr6 33872149 G A 2.96E-06 Heart Rate / / pha003053 rs9380389 chr6 33903076 A G 8.13E-04 Alcohol dependence / / 21314694 rs7740698 chr6 33904769 A C 1.55E-04 Multiple complex diseases / / 17554300 rs9368787 chr6 33906104 A C 6.52E-04 Body mass index / / 21701565 rs9368787 chr6 33906104 A C 8.39E-04 Body mass index / / 21701565 rs10947469 chr6 33917711 G A 0.0000889 post-traumatic stress disorder / / 22869035 rs10947469 chr6 33917711 G A 8.89E-05 Schizophrenia / / 22883433 rs2495971 chr6 33929065 G T 7.51E-05 Melanoma / / 21926416 rs9461937 chr6 33940663 T C 4.92E-05 Coronary heart disease / / 21971053 rs2499762 chr6 33948624 C T 0.000248134 Hypertension (early onset hypertension) / / 22479346 rs2451374 chr6 33959996 G A 2.49E-04 Type 2 diabetes / / 17463246 rs7745522 chr6 33965434 C T 6.17E-04 Multiple complex diseases / / 17554300 rs6900980 chr6 33971226 G T 1.62E-05 Amyotrophic lateral sclerosis / / 20801717 rs3778045 chr6 33999991 T C 6.11E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GRM4 intron 20031582 rs2228623 chr6 34003685 T C 2.05E-05 Taste perception GRM4 cds-synon 22132133 rs2499677 chr6 34007054 G A 1.55E-04 Taste perception GRM4 intron 22132133 rs1906953 chr6 34036446 C T 5.97E-04 Coronary heart disease GRM4 intron 21971053 rs1906953 chr6 34036446 C T 8.00E-09 Osteosarcoma GRM4 intron 23727862 rs937039 chr6 34043652 A G 3.19E-04 Height GRM4 intron 17255346 rs937039 chr6 34043652 A G 1.09E-05 Coronary heart disease GRM4 intron 21971053 rs9394187 chr6 34046840 A G 1.00E-05 Serum metabolites GRM4 intron 19043545 rs12211633 chr6 34050917 C T 1.13E-05 Serum metabolites GRM4 intron 19043545 rs12211633 chr6 34050917 C T 8.22E-05 Coronary heart disease GRM4 intron 21971053 rs1873249 chr6 34053424 A G 2.40E-04 Coronary heart disease GRM4 intron 21971053 rs12206652 chr6 34065982 A G 9.32E-04 Myopia (pathological) GRM4 intron 21095009 rs16894846 chr6 34068923 G A 7.09E-04 Response to cytidine analogues (gemcitabine) GRM4 intron 24483146 rs3887555 chr6 34069062 T C 9.05E-05 Creatinine levels GRM4 intron pha003069 rs2499714 chr6 34072215 C T 3.64E-05 Type 2 diabetes GRM4 intron 17463246 rs7763695 chr6 34072561 T C 2.24E-05 Creatinine levels GRM4 intron pha003069 rs1109654 chr6 34074463 A G 9.48E-04 Type 2 diabetes GRM4 intron 17463246 rs2029461 chr6 34105790 C T 1.55E-04 Height GRM4 intron 17255346 rs2029461 chr6 34105790 C T 9.90E-04 Type 2 diabetes GRM4 intron 17463246 rs2029459 chr6 34106454 G A 1.38E-04 Height GRM4 intron 17255346 rs9380416 chr6 34142506 C T 4.18E-05 Schizophrenia / / 20185149 rs9366841 chr6 34142755 T C 7.05E-05 Schizophrenia / / 20185149 rs1106280 chr6 34144073 C T 4.38E-05 Schizophrenia / / 20185149 rs7742369 chr6 34165721 A G 1.00E-13 Height / / 20189936 rs1759645 chr6 34194866 C T 5.00E-15 Height / / 23563607 rs1776897 chr6 34195011 G T 1.00E-08 Height / / 18391951 rs1776897 chr6 34195011 G T 8.00E-11 Height / / 19343178 rs1776897 chr6 34195011 G T 2.07E-06 Height / / 19570815 rs1776897 chr6 34195011 G T 2.07E-08 Height / / 19893584 rs1776897 chr6 34195011 G T 7.00E-06 Height / / 20397748 rs2780226 chr6 34199092 C T 8.00E-28 Height / / 20881960 rs1150781 chr6 34214322 C G 2.00E-39 Height C6orf1 missense 21194676 rs1150781 chr6 34214322 C G 2.40E-22 Height C6orf1 missense 21194676 rs1150781 chr6 34214322 C G 7.40E-12 Height C6orf1 missense 21194676 rs1150781 chr6 34214322 C G 2.00E-08 Height C6orf1 missense 21998595 rs9366846 chr6 34222939 A G 7.58E-04 Smoking initiation / / 24665060 rs6918981 chr6 34238514 G A 3.00E-08 Height / / 19396169 rs6918981 chr6 34238514 G A 2.00E-08 Height / / 19893584 rs4713766 chr6 34244245 C A 5.49E-05 Body mass index / / 24861553 rs16883137 chr6 34249546 G A 4.76E-04 Hemoglobin concentration / / 20534544 rs16883137 chr6 34249546 G A 1.40E-05 Urinary metabolites / / 21572414 rs6691 chr6 34252352 C A,G,T 1.63E-04 Body mass index / / 21701565 rs6691 chr6 34252352 C A,G,T 8.09E-04 Body mass index / / 21701565 rs1057691 chr6 34299232 A G 4.76E-04 Hemoglobin concentration NUDT3 intron 20534544 rs206936 chr6 34302869 A G 3.00E-08 Body mass index NUDT3 intron 20935630 rs206936 chr6 34302869 A G 3.02E-08 Body mass index NUDT3 intron 23001569 rs206937 chr6 34332179 T C 7.24E-05 Response to mTOR inhibitor (everolimus) NUDT3 intron 24009623 rs4713784 chr6 34403234 T C 1.19E-04 Multiple complex diseases / / 17554300 rs4713797 chr6 34458533 A G 9.36E-04 Alcohol consumption (maxi-drinks) PACSIN1 intron 24277619 rs4713806 chr6 34474629 C T 3.48E-04 Alcohol consumption (maxi-drinks) PACSIN1 intron 24277619 rs10947508 chr6 34480637 C T 8.75E-04 Type 2 diabetes PACSIN1 intron 17463246 rs3800472 chr6 34481092 G A 4.27E-05 QT interval PACSIN1 intron 16648850 rs3800471 chr6 34481140 T G 1.25E-05 Parent of origin effect on language impairment (paternal) PACSIN1 intron 24571439 rs11753634 chr6 34482267 C A 6.32E-05 Parent of origin effect on language impairment (paternal) PACSIN1 intron 24571439 rs11758326 chr6 34482498 A G 2.18E-05 Parent of origin effect on language impairment (paternal) PACSIN1 intron 24571439 rs4713808 chr6 34483015 T C 5.11E-05 Erythrocyte counts PACSIN1 intron pha003099 rs2233637 chr6 34512195 G C 0.00011 Breast cancer SPDEF missense 23555315 rs3756929 chr6 34527019 G A 1.91E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4713812 chr6 34528955 T C 0.0007852 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4713812 chr6 34528955 T C 7.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4713813 chr6 34530165 C T 0.0007857 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4713813 chr6 34530165 C T 7.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4713815 chr6 34530433 A G 0.0007823 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4713815 chr6 34530433 A G 7.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10947510 chr6 34531300 T C 5.33E-07 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13197699 chr6 34532836 G A 0.0006728 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13197699 chr6 34532836 G A 6.73E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13194133 chr6 34532922 T G 0.0006736 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13194133 chr6 34532922 T G 6.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4713817 chr6 34532977 G A 0.0007793 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4713817 chr6 34532977 G A 7.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11755671 chr6 34535986 C T 0.0006343 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11755671 chr6 34535986 C T 6.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2395597 chr6 34542662 T C 4.23E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2395597 chr6 34542662 T C 0.0004218 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2395597 chr6 34542662 T C 4.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6917350 chr6 34544384 G A 0.0007182 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6917350 chr6 34544384 G A 7.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2814982 chr6 34546560 C T 5.00E-11 Cholesterol,total / / 20686565 rs2814982 chr6 34546560 C T 4.00E-15 Cholesterol,total / / 24097068 rs451603 chr6 34549107 G A 8.90E-06 Urinary metabolites / / 21572414 rs205284 chr6 34551912 C T 2.80E-12 Systemic lupus erythematosus / / 23273568 rs2814944 chr6 34552797 G A 4.00E-09 HDL cholesterol / / 20686565 rs2814944 chr6 34552797 G A 1.37E-05 Waist Circumference / / pha003023 rs205262 chr6 34563164 A G 8.10E-06 Systemic lupus erythematosus C6orf106 intron 24871463 rs2744971 chr6 34581636 T G 8.00E-13 Height C6orf106 intron 23563607 rs182503338 chr6 34582274 T G 1.00E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity C6orf106 intron 24324551 rs182503338 chr6 34582274 T G 8.00E-07 QRS duration in Tripanosoma cruzi seropositivity C6orf106 intron 24324551 rs7764921 chr6 34604335 C A 8.70E-12 Systemic lupus erythematosus C6orf106 intron 23273568 rs17644393 chr6 34607958 G T 6.50E-05 Endometriosis C6orf106 intron 21151130 rs2814993 chr6 34618893 G A 4.00E-12 Height C6orf106 intron 18391952 rs2814993 chr6 34618893 G A 8.46E-06 Waist Circumference C6orf106 intron pha003023 rs6938239 chr6 34683635 G A 6.00E-12 Height / / 20881960 rs2814966 chr6 34712232 C T 2.00E-04 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs2764208 chr6 34714322 A G 7.00E-06 Systemic lupus erythematosus / / 24871463 rs9462007 chr6 34715341 C T 2.67E-05 Waist Circumference / / pha003023 rs9462015 chr6 34739726 T G 7.80E-06 Systemic lupus erythematosus SNRPC intron 24871463 rs1555773 chr6 34758133 C G 2.42E-05 Heart rate / / 23583979 rs9469890 chr6 34763982 C T 9.00E-08 Pubertal anthropometrics UHRF1BP1 intron 23449627 rs6912327 chr6 34764922 T C 2.26E-08 Fasting insulin-related traits UHRF1BP1 intron 22885924 rs2395607 chr6 34773727 C T 1.13E-06 Odorant perception UHRF1BP1 intron 23910658 rs7774697 chr6 34791027 A G 9.40E-06 Systemic lupus erythematosus UHRF1BP1 intron 24871463 rs9462027 chr6 34797241 G A 5.00E-06 Systemic lupus erythematosus UHRF1BP1 intron 24871463 rs3734266 chr6 34823187 T C 1.00E-12 Systemic lupus erythematosus UHRF1BP1 intron 23273568 rs16894959 chr6 34825662 T C 2.11E-05 Waist Circumference UHRF1BP1 cds-synon pha003023 rs13205210 chr6 34831856 T C 1.20E-11 Systemic lupus erythematosus UHRF1BP1 missense 23273568 rs3734262 chr6 34838577 C T 2.74E-05 Multiple complex diseases UHRF1BP1 intron 17554300 rs16895035 chr6 34839097 A G 9.07E-04 Multiple complex diseases UHRF1BP1 intron 17554300 rs9296137 chr6 34839236 T C 6.92E-04 Suicide attempts in bipolar disorder UHRF1BP1 intron 21423239 rs3734261 chr6 34840398 G A 6.20E-12 Systemic lupus erythematosus UHRF1BP1 UTR-3 23273568 rs3822923 chr6 34840515 C T 7.92E-04 Multiple complex diseases UHRF1BP1 UTR-3 17554300 rs4646949 chr6 34845449 T G 4.00E-08 Fasting insulin-related traits (interaction with BMI) / / 22581228 rs2273006 chr6 34851134 T C 3.20E-05 Alcoholism (heaviness of drinking) TAF11 intron 21529783 rs9368834 chr6 34860764 T G 4.26E-05 Multiple complex diseases ANKS1A intron 17554300 rs9380466 chr6 34869224 C T 8.23E-04 Multiple complex diseases ANKS1A intron 17554300 rs9380467 chr6 34873783 G C 6.26E-04 Multiple complex diseases ANKS1A intron 17554300 rs16895362 chr6 34874175 C T 6.07E-05 Multiple complex diseases ANKS1A intron 17554300 rs3800449 chr6 34880392 T A 7.60E-05 Multiple complex diseases ANKS1A intron 17554300 rs12173920 chr6 34887316 C T 6.17E-05 Multiple complex diseases ANKS1A intron 17554300 rs12205331 chr6 34898455 C T 0.000143 Coronary artery disease (CAD) (males) ANKS1A intron 23202125 rs12205331 chr6 34898455 C T 0.000644 Coronary artery disease with myocardial infarction ANKS1A intron 23202125 rs12205331 chr6 34898455 C T 0.000884 HDL cholesterol ANKS1A intron 23202125 rs12205331 chr6 34898455 C T 6.00E-06 Coronary artery disease ANKS1A intron 24262325 rs847852 chr6 34904092 G A 4.70E-06 Systemic lupus erythematosus ANKS1A intron 24871463 rs1737727 chr6 34904488 T C 5.50E-05 Alcoholism (heaviness of drinking) ANKS1A intron 21529783 rs847851 chr6 34904584 G A 9.30E-06 Alcoholism (heaviness of drinking) ANKS1A intron 21529783 rs847851 chr6 34904584 G A 3.80E-05 Systemic lupus erythematosus ANKS1A intron 24871463 rs847848 chr6 34906168 T C 1.80E-05 Alcoholism (heaviness of drinking) ANKS1A intron 21529783 rs9348954 chr6 34906891 T A 4.24E-05 Multiple complex diseases ANKS1A intron 17554300 rs847845 chr6 34923864 G A 6.00E-06 Non-small cell lung cancer ANKS1A intron 23144319 rs1535001 chr6 34927280 A G 3.00E-07 Systemic lupus erythematosus and Systemic sclerosis ANKS1A intron 23740937 rs6457799 chr6 34960744 A G 7.49E-04 Suicide attempts in bipolar disorder ANKS1A intron 21423239 rs3800440 chr6 34961360 G A 1.70E-04 Crohn's disease ANKS1A intron 23266558 rs2140418 chr6 34975415 T C 4.00E-06 Alcoholism (alcohol use disorder factor score) ANKS1A intron 21529783 rs10947535 chr6 34975969 A T 1.50E-05 Urinary metabolites ANKS1A intron 21572414 rs2395601 chr6 34977222 A G 1.50E-05 Urinary metabolites ANKS1A intron 21572414 rs1880090 chr6 34990968 C T 1.40E-04 Systemic lupus erythematosus ANKS1A intron 24871463 rs1996913 chr6 35000453 T C 3.13E-05 Multiple complex diseases ANKS1A intron 17554300 rs3800433 chr6 35001136 G A 2.11E-05 Triglycerides ANKS1A intron 19074352 rs3800433 chr6 35001136 G A 2.11E-05 Polyunsaturated fatty acid levels,in plasma ANKS1A intron 19148276 rs2820232 chr6 35003603 G T 3.50E-04 Systemic lupus erythematosus ANKS1A intron 24871463 rs12525532 chr6 35004819 C T 8.95E-08 Body mass index ANKS1A intron 22885924 rs12525532 chr6 35004819 C T 0.000012 Fasting insulin-related traits ANKS1A intron 23202125 rs12525532 chr6 35004819 C T 0.0000183 HOMA-IR ANKS1A intron 23202125 rs13210323 chr6 35005084 A C 4.66E-04 Gallstones ANKS1A intron 17632509 rs13210323 chr6 35005084 A C 8.00E-12 Height ANKS1A intron 23563607 rs2049316 chr6 35009153 T C 3.45E-04 Multiple complex diseases ANKS1A intron 17554300 rs2049316 chr6 35009153 T C 6.51E-04 Coronary Artery Disease ANKS1A intron 17634449 rs2820223 chr6 35009295 T C 3.50E-04 Systemic lupus erythematosus(serologic and cytokine profiles in serum) ANKS1A intron 20659327 rs3800424 chr6 35011446 G A 0.0000427 Primary sclerosing cholangitis ANKS1A intron 23603763 rs820082 chr6 35031441 C T 4.08E-04 Parkinson's disease ANKS1A intron 17052657 rs17609940 chr6 35034800 G C 1.00E-08 Coronary heart disease ANKS1A intron 21378990 rs17609940 chr6 35034800 G C 1.36E-08 Pericardial fat ANKS1A intron 22589742 rs820099 chr6 35045835 C T 9.73E-04 Type 2 diabetes ANKS1A intron 17463246 rs2005 chr6 35056443 A G 7.00E-06 Obesity-related traits ANKS1A UTR-3 23251661 rs3822921 chr6 35057331 G A 0.00000261 Cholesterol,total ANKS1A UTR-3 23202125 rs3822921 chr6 35057331 G A 0.0000165 HDL cholesterol ANKS1A UTR-3 23202125 rs3822921 chr6 35057331 G A 0.000275 LDL cholesterol ANKS1A UTR-3 23202125 rs2057537 chr6 35090279 G A 2.19E-04 Breast cancer TCP11 intron 21060860 rs12661389 chr6 35104018 C A 1.76E-04 Glycosylated haemoglobin levels TCP11 intron 17255346 rs6923951 chr6 35117363 G A 2.89E-04 Type 2 diabetes / / 17463246 rs1886243 chr6 35117399 A C 2.22E-04 Type 2 diabetes / / 17463246 rs16872293 chr6 35117996 G C 7.00E-04 Type 2 diabetes / / 17463246 rs9394277 chr6 35130421 G A 5.47E-04 Multiple complex diseases / / 17554300 rs3800405 chr6 35133228 T G 5.17E-04 Multiple complex diseases / / 17554300 rs6934246 chr6 35154495 C A 4.21E-05 Type 2 diabetes / / 17463246 rs3800397 chr6 35160008 G A 1.59E-10 Coronary heart disease / / 21971053 rs11755266 chr6 35162141 C T 8.47E-05 Crohn's disease / / 23266558 rs11755266 chr6 35162141 C T 3.66E-05 Waist Circumference / / pha003023 rs968828 chr6 35168613 G A 1.73E-04 Multiple complex diseases / / 17554300 rs6928769 chr6 35174858 T G 2.12E-04 Multiple complex diseases / / 17554300 rs914547 chr6 35176547 C T 1.56E-04 Multiple complex diseases / / 17554300 rs914547 chr6 35176547 C T 9.93E-04 Lymphocyte counts / / 22286170 rs3800385 chr6 35189999 G T 2.74E-04 Multiple complex diseases SCUBE3 intron 17554300 rs4713843 chr6 35203745 T C 4.19E-04 Multiple complex diseases SCUBE3 intron 17554300 rs732594 chr6 35206553 C A 7.65E-04 Crohn's disease SCUBE3 intron 23266558 rs9394288 chr6 35222010 T C 8.94E-05 Multiple complex diseases / / 17554300 rs16874062 chr6 35251195 A G 4.60E-11 Height ZNF76 intron 21998595 rs16874262 chr6 35265711 C T 3.00E-10 Height DEF6 cds-synon 21998595 rs1888823 chr6 35268410 A G 3.54E-04 Multiple complex diseases DEF6 intron 17554300 rs6938946 chr6 35280697 C T 3.76E-05 Coronary heart disease DEF6 intron pha003031 rs6920432 chr6 35298662 T C 0.0000957 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs7744392 chr6 35322763 A G 2.34E-05 Femoral neck bone geometry PPARD intron 22087292 rs7744392 chr6 35322763 A G 0.00000391 Body mass index PPARD intron 22885924 rs7744392 chr6 35322763 A G 3.00E-06 Cataracts in type 2 diabetes PPARD intron 23137000 rs6901410 chr6 35330030 T C 0.0000209 HIV-1 infection (natural long-term nonprogression) PPARD intron 22238471 rs9470003 chr6 35337931 G C,T 1.30E-09 Height PPARD intron 21998595 rs9470004 chr6 35341850 C T 1.00E-11 Height PPARD intron 21998595 rs6922548 chr6 35353523 A G 1 Drug response to Docetaxel PPARD intron 20038957 rs6922548 chr6 35353523 A G 1 Drug response to Thalidomide PPARD intron 20038957 rs16868709 chr6 35354471 C G 9.90E-05 Height PPARD intron 21998595 rs9658100 chr6 35356640 T G 0.0000239 HIV-1 infection (natural long-term nonprogression) PPARD intron 22238471 rs9462078 chr6 35357974 A G 4.90E-08 Height PPARD intron 21998595 rs7769719 chr6 35362525 G A 1 Drug response to Docetaxel PPARD intron 20038957 rs7769719 chr6 35362525 G A 1 Drug response to Thalidomide PPARD intron 20038957 rs9658108 chr6 35363757 C G 5.00E-07 Response to antipsychotic treatment PPARD intron 20195266 rs9658113 chr6 35364794 C T 8.21E-13 HDL cholesterol PPARD intron 23063622 rs1883322 chr6 35369806 C T 1 Drug response to Docetaxel PPARD intron 20038957 rs1883322 chr6 35369806 C T 1 Drug response to Thalidomide PPARD intron 20038957 rs2267666 chr6 35370728 A T 5.10E-06 Urinary metabolites PPARD intron 21572414 rs2267667 chr6 35372524 G C 7.10E-06 Urinary metabolites PPARD intron 21572414 rs2038068 chr6 35374461 A G 9.60E-05 Pericardial fat PPARD intron 22589742 rs9658131 chr6 35378735 G T 0.000000177 Triglycerides PPARD intron 23063622 rs2016520 chr6 35378778 C T 1 Drug response to Docetaxel PPARD UTR-5 20038957 rs2016520 chr6 35378778 C T 1 Drug response to Thalidomide PPARD UTR-5 20038957 rs2299869 chr6 35383432 C T 2.06E-08 HDL cholesterol PPARD intron 23063622 rs9462082 chr6 35386041 A G 8.65E-04 Multiple complex diseases PPARD intron 17554300 rs9462082 chr6 35386041 A G 1.30E-06 Urinary metabolites PPARD intron 21572414 rs9658150 chr6 35387900 G A 1.46E-08 LDL cholesterol PPARD intron 23063622 rs9658150 chr6 35387900 G A 3.59E-12 Triglycerides PPARD intron 23063622 rs2076169 chr6 35388479 A G 2.20E-05 Urinary metabolites PPARD intron 21572414 rs3734254 chr6 35395010 C T 1 Drug response to Docetaxel PPARD UTR-3 20038957 rs3734254 chr6 35395010 C T 1 Drug response to Thalidomide PPARD UTR-3 20038957 rs3734254 chr6 35395010 C T 1.10E-13 Height PPARD UTR-3 21194676 rs3734254 chr6 35395010 C T 4.00E-06 Height PPARD UTR-3 21194676 rs3734254 chr6 35395010 C T 4.10E-09 Height PPARD UTR-3 21194676 rs1053049 chr6 35395618 C T 8.38E-06 Coronary heart disease PPARD UTR-3 pha003031 rs1053049 chr6 35395618 C T 5.55E-05 Left ventricular hypertrophy PPARD UTR-3 pha003052 rs4713858 chr6 35402785 A G 4.00E-08 Height / / 18391951 rs4713858 chr6 35402785 A G 1.50E-06 Urinary metabolites / / 21572414 rs6457821 chr6 35402805 C A 2.00E-12 Height / / 20881960 rs2206030 chr6 35404354 T C 5.00E-07 Pulmonary function (interaction) / / 23284291 rs4713859 chr6 35406153 T C 0.000053 Primary sclerosing cholangitis / / 22521342 rs12212952 chr6 35407374 C G 0.0000148 Body mass index / / 22885924 rs4713865 chr6 35416308 C G 5.27E-08 HDL cholesterol / / 23063622 rs7758978 chr6 35418442 C G 3.68E-05 Serum metabolites FANCE nearGene-5 19043545 rs6907678 chr6 35418954 T C 1.91E-04 Smoking initiation FANCE nearGene-5 24665060 rs2395626 chr6 35422754 G T 5.30E-05 Serum metabolites FANCE intron 19043545 rs11962317 chr6 35431932 T A 1.91E-05 Odorant perception FANCE intron 23910658 rs2076173 chr6 35442397 A G 3.77E-04 Stroke TEAD3 UTR-3 pha002887 rs9394299 chr6 35449326 C T 2.40E-04 Stroke TEAD3 intron pha002887 rs9366886 chr6 35457842 G A 3.90E-05 Response to statin therapy TEAD3 intron 20339536 rs7757174 chr6 35460722 A G 4.30E-05 Response to statin therapy TEAD3 intron 20339536 rs2075611 chr6 35474467 A G 5.80E-05 Response to statin therapy TULP1 intron 20339536 rs11754612 chr6 35476562 T A 7.60E-05 Response to statin therapy TULP1 intron 20339536 rs9296155 chr6 35477303 T C 2.22E-04 Type 2 diabetes TULP1 intron 17463246 rs4267954 chr6 35484790 G A 5.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4267954 chr6 35484790 G A 6.95E-05 Waist Circumference / / pha003023 rs4711420 chr6 35495811 G T 8.37E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9380516 chr6 35502202 T C 5.00E-07 Hepatitis C induced liver fibrosis / / 22841784 rs9470055 chr6 35521961 G A 4.68E-05 Coronary heart disease / / 21971053 rs9470055 chr6 35521961 G A 9.22E-05 Waist Circumference / / pha003023 rs1413896 chr6 35522907 T C 2.50E-04 Type 2 diabetes / / 17463246 rs6911621 chr6 35529025 C T 7.79E-06 Interstitial lung disease / / 23583980 rs3800374 chr6 35537406 T C 6.81E-05 Coronary heart disease / / 21971053 rs3800374 chr6 35537406 T C 6.88E-06 Waist Circumference / / pha003023 rs3800373 chr6 35542476 C A 1 Drug response to Desipramine FKBP5 UTR-3 15565110 rs3800373 chr6 35542476 C A 1 Drug response to Fluoxetine FKBP5 UTR-3 15565110 rs3800373 chr6 35542476 C A 1 Drug response to Mirtazapine FKBP5 UTR-3 15565110 rs3800373 chr6 35542476 C A 1 Drug response to Venlafaxine FKBP5 UTR-3 15565110 rs3800373 chr6 35542476 C A 1 Drug response to Desipramine FKBP5 UTR-3 18349090 rs3800373 chr6 35542476 C A 1 Drug response to Fluoxetine FKBP5 UTR-3 18349090 rs3800373 chr6 35542476 C A 1 Drug response to Mirtazapine FKBP5 UTR-3 18349090 rs3800373 chr6 35542476 C A 1 Drug response to Venlafaxine FKBP5 UTR-3 18349090 rs3800373 chr6 35542476 C A 1 Drug response to Desipramine FKBP5 UTR-3 18597649 rs3800373 chr6 35542476 C A 1 Drug response to Fluoxetine FKBP5 UTR-3 18597649 rs3800373 chr6 35542476 C A 1 Drug response to Mirtazapine FKBP5 UTR-3 18597649 rs3800373 chr6 35542476 C A 1 Drug response to Venlafaxine FKBP5 UTR-3 18597649 rs992105 chr6 35555183 C A 4.25E-04 Coronary heart disease FKBP5 intron 21971053 rs7748266 chr6 35592744 T C 9.23E-05 Cortisol secretion,in saliva FKBP5 intron 21316860 rs1360780 chr6 35607571 T C 1 Drug response to Desipramine FKBP5 intron 15565111 rs1360780 chr6 35607571 T C 1 Drug response to Fluoxetine FKBP5 intron 15565111 rs1360780 chr6 35607571 T C 1 Drug response to Mirtazapine FKBP5 intron 15565111 rs1360780 chr6 35607571 T C 1 Drug response to Venlafaxine FKBP5 intron 15565111 rs1360780 chr6 35607571 T C 1 Drug response to Desipramine FKBP5 intron 18349090 rs1360780 chr6 35607571 T C 1 Drug response to Fluoxetine FKBP5 intron 18349090 rs1360780 chr6 35607571 T C 1 Drug response to Mirtazapine FKBP5 intron 18349090 rs1360780 chr6 35607571 T C 1 Drug response to Venlafaxine FKBP5 intron 18349090 rs1360780 chr6 35607571 T C 1 Drug response to Desipramine FKBP5 intron 18597649 rs1360780 chr6 35607571 T C 1 Drug response to Fluoxetine FKBP5 intron 18597649 rs1360780 chr6 35607571 T C 1 Drug response to Mirtazapine FKBP5 intron 18597649 rs1360780 chr6 35607571 T C 1 Drug response to Venlafaxine FKBP5 intron 18597649 rs9394309 chr6 35621781 G A 1.58E-05 Cortisol secretion,in saliva FKBP5 intron 21316860 rs9368881 chr6 35634288 A G 3.50E-04 Pulmonary function FKBP5 intron 23932459 rs9470080 chr6 35646435 T C 1.00E-05 Cortisol secretion,in saliva FKBP5 intron 21316860 rs2766534 chr6 35685714 G T 7.27E-05 Intelligence FKBP5 intron 21826061 rs2766535 chr6 35691782 A G 8.43E-05 Interstitial lung disease FKBP5 intron 23583980 rs7752049 chr6 35723417 A C 1.82E-05 HDL particle features / / pha002900 rs2817056 chr6 35734051 C A 8.16E-05 HDL particle features / / pha002900 rs6908914 chr6 35759518 G A 1.96E-04 Taste perception / / 22132133 rs2817027 chr6 35778719 C A 4.41E-04 Bipolar disorder,schizoaffective LHFPL5 intron 19567891 rs879493 chr6 35787417 C T 5.76E-05 Prion diseases LHFPL5 intron 22210626 rs2859420 chr6 35803283 C T 8.26E-04 Bipolar disorder,schizoaffective SRPK1 intron 19567891 rs17704843 chr6 35805133 G A 4.95E-04 Crohn's disease SRPK1 intron 23266558 rs17704843 chr6 35805133 G A 7.75E-05 Blood Pressure SRPK1 intron pha003039 rs6923015 chr6 35807181 G A 8.39E-04 Bipolar disorder,schizoaffective SRPK1 intron 19567891 rs17705020 chr6 35809776 C T 5.76E-05 Prion diseases SRPK1 intron 22210626 rs17705020 chr6 35809776 C T 5.22E-05 Body Mass Index SRPK1 intron pha003015 rs7752551 chr6 35818768 C T 5.76E-05 Prion diseases SRPK1 intron 22210626 rs7752551 chr6 35818768 C T 6.18E-05 Body Mass Index SRPK1 intron pha003015 rs9470144 chr6 35829144 A G 8.97E-04 Bipolar disorder,schizoaffective SRPK1 intron 19567891 rs9462141 chr6 35835038 G A 6.25E-04 Bipolar disorder,schizoaffective SRPK1 intron 19567891 rs7755022 chr6 35861319 A G 5.76E-05 Prion diseases SRPK1 intron 22210626 rs9470162 chr6 35863886 C T 8.39E-04 Bipolar disorder,schizoaffective SRPK1 intron 19567891 rs9470172 chr6 35880155 A G 4.74E-05 Prion diseases SRPK1 intron 22210626 rs9470172 chr6 35880155 A G 7.31E-05 Body Mass Index SRPK1 intron pha003015 rs639421 chr6 35887466 C T 8.97E-04 Bipolar disorder,schizoaffective SRPK1 intron 19567891 rs612262 chr6 35891608 C T 8.31E-04 Bipolar disorder,schizoaffective / / 19567891 rs668438 chr6 35901378 A G 4.74E-05 Prion diseases / / 22210626 rs17707124 chr6 35942313 C T 2.98E-04 Multiple complex diseases SLC26A8 intron 17554300 rs17714205 chr6 36019336 C T 8.45E-04 Multiple complex diseases MAPK14 intron 17554300 rs2237093 chr6 36035354 C T 2.30E-04 Multiple complex diseases MAPK14 intron 17554300 rs2237093 chr6 36035354 C T 1.01E-05 Type 1 diabetes MAPK14 intron 18978792 rs851006 chr6 36065185 T C 3.79E-04 Premature ovarian failure MAPK14 intron 19508998 rs7752459 chr6 36084672 C T 8.10E-05 Eating disorders (purging via substances) / / 23568457 rs2815808 chr6 36113035 G C 3.09E-04 Type 2 diabetes / / 17463246 rs9470224 chr6 36140636 T C 9.25E-05 Lung cancer / / 18978787 rs6906612 chr6 36151177 T C 2.38E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4713936 chr6 36165213 C T 1.50E-05 Inflammatory demyelinating disease BRPF3 intron 19850125 rs9470238 chr6 36228600 T G 4.11E-06 Coronary heart disease PNPLA1 intron 21971053 rs6903663 chr6 36230664 A C 5.51E-04 Bipolar disorder,schizoaffective PNPLA1 intron 19567891 rs9368920 chr6 36242317 C T 1.87E-04 Bipolar disorder,schizoaffective PNPLA1 intron 19567891 rs12526665 chr6 36246707 C A,G,T 6.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PNPLA1 intron 20877124 rs12526665 chr6 36246707 C A,G,T 8.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PNPLA1 intron 20877124 rs6914153 chr6 36258667 T G 7.05E-04 Multiple complex diseases PNPLA1 intron 17554300 rs2239795 chr6 36260858 C T 5.83E-04 Multiple complex diseases PNPLA1 cds-synon 17554300 rs9470247 chr6 36262483 G A 5.27E-04 Multiple complex diseases PNPLA1 intron 17554300 rs4713951 chr6 36262991 C T 4.01E-04 Bipolar disorder,schizoaffective PNPLA1 intron 19567891 rs11754972 chr6 36267519 T C 2.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PNPLA1 intron 20877124 rs10947600 chr6 36269603 G A 9.76E-04 Response to taxane treatment (placlitaxel) PNPLA1 intron 23006423 rs4713955 chr6 36270668 G A 8.31E-05 Waist-Hip Ratio PNPLA1 intron pha003028 rs13203654 chr6 36273317 G A 7.20E-06 Urinary metabolites PNPLA1 intron 21572414 rs4713956 chr6 36275458 T C 5.63E-04 Smoking initiation PNPLA1 missense 24665060 rs41272160 chr6 36297893 C T 0.000071 Breast cancer (ER positive) C6orf222 missense 23555315 rs73406941 chr6 36301205 C T 0.000000369 Nonsyndromic striae distensae (stretch marks) C6orf222 intron 23633020 rs11965295 chr6 36301553 C A 0.0000551 Nonsyndromic striae distensae (stretch marks) C6orf222 intron 23633020 rs11965968 chr6 36302109 C T 0.000000259 Nonsyndromic striae distensae (stretch marks) C6orf222 intron 23633020 rs9462173 chr6 36302210 T C 8.03E-04 Multiple complex diseases C6orf222 intron 17554300 rs11968573 chr6 36302213 T C 0.00000025 Nonsyndromic striae distensae (stretch marks) C6orf222 intron 23633020 rs113093358 chr6 36308105 T C 0.000000154 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs16887986 chr6 36308285 C T 0.000000141 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs73406950 chr6 36311047 C T 0.000000097 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11969921 chr6 36316800 A G 0.000000109 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs113770204 chr6 36330140 T C 0.000000633 Nonsyndromic striae distensae (stretch marks) ETV7 intron 23633020 rs73407000 chr6 36341153 C T 0.0000536 Nonsyndromic striae distensae (stretch marks) ETV7 intron 23633020 rs9470263 chr6 36341693 A G 7.34E-05 Psoriasis ETV7 intron 18364390 rs146204139 chr6 36342002 C T 0.0000864 Nonsyndromic striae distensae (stretch marks) ETV7 intron 23633020 rs9470265 chr6 36345977 G A 7.73E-04 Multiple complex diseases ETV7 intron 17554300 rs1076929 chr6 36348800 C T 3.19E-05 Parent of origin effect on language impairment (child trend) ETV7 intron 24571439 rs879036 chr6 36349890 T C 5.77E-05 Rheumatoid arthritis ETV7 intron 21452313 rs2234067 chr6 36355654 A C 1.60E-09 Rheumatoid arthritis ETV7 nearGene-5 24390342 rs2234067 chr6 36355654 A C 4.10E-08 Rheumatoid arthritis ETV7 nearGene-5 24390342 rs7747099 chr6 36370254 T C 1.58E-04 Rheumatoid arthritis PXT1 intron 21452313 rs941816 chr6 36375304 G A 2.45E-04 Rheumatoid arthritis PXT1 intron 21452313 rs12190911 chr6 36378487 A G 1.50E-04 Insulin response PXT1 intron 19430760 rs7741260 chr6 36399120 T C 8.17E-04 Amyotrophic lateral sclerosis (sporadic) PXT1 intron 24529757 rs6923993 chr6 36427276 C T 6.42E-04 Type 2 diabetes KCTD20 intron 17463246 rs16888603 chr6 36432705 C T 1.46E-09 Multiple complex diseases KCTD20 intron 17554300 rs1061632 chr6 36457484 T C 1.50E-04 Insulin response KCTD20 UTR-3 19430760 rs374999674 chr6 36457484 T TC 1.50E-04 Insulin response KCTD20 UTR-3 19430760 rs595954 chr6 36464834 G C,T 8.00E-04 Type 2 diabetes STK38 intron 17463246 rs626516 chr6 36465380 C T 7.29E-04 HIV-1 viral setpoint STK38 intron 17641165 rs2300064 chr6 36474141 G A 1.10E-04 Insulin response STK38 intron 19430760 rs12203115 chr6 36490733 A G 3.17E-04 Alzheimer's disease STK38 intron 24755620 rs7741729 chr6 36524075 A G 2.10E-04 Systemic lupus erythematosus / / 24871463 rs684482 chr6 36528536 A G 4.72E-04 Multiple complex diseases / / 17554300 rs600382 chr6 36529031 C T 1.71E-09 Multiple complex diseases / / 17554300 rs596907 chr6 36534854 T C 8.43E-05 Multiple complex diseases / / 17554300 rs9394363 chr6 36558964 T C 9.82E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs9368942 chr6 36566513 G C 4.91E-04 Type 2 diabetes SRSF3 intron 17463246 rs9366911 chr6 36589340 G C 5.80E-04 Type 2 diabetes / / 17463246 rs4713989 chr6 36604198 C T 7.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4713992 chr6 36612205 G A 5.70E-05 Type 2 diabetes / / 17463248 rs1321313 chr6 36618821 C T 4.60E-04 Alcohol dependence / / 20201924 rs1321313 chr6 36618821 C T 6.40E-04 Alcohol dependence / / 20201924 rs1321313 chr6 36618821 C T 3.81E-04 Myopia (pathological) / / 21095009 rs1321313 chr6 36618821 C T 5.00E-25 Electrocardiographic conduction measures / / 23463857 rs1321311 chr6 36622900 C A 3.00E-10 Electrocardiographic traits / / 20062063 rs1321311 chr6 36622900 C A 6.20E-04 Alcohol dependence / / 20201924 rs1321311 chr6 36622900 C A 7.70E-04 Alcohol dependence / / 20201924 rs1321311 chr6 36622900 C A 2.37E-04 Myopia (pathological) / / 21095009 rs1321311 chr6 36622900 C A 1.00E-10 Colorectal cancer / / 22634755 rs9470361 chr6 36623379 G A 3.00E-27 Ventricular conduction / / 21076409 rs9368950 chr6 36627872 T C 5.41E-04 Myopia (pathological) / / 21095009 rs9462209 chr6 36628042 T G 7.10E-04 Myopia (pathological) / / 21095009 rs1321309 chr6 36638636 G A 0.00000411 Coronary artery disease / / 23202125 rs10947623 chr6 36642836 G A 9.48E-04 Alzheimer's disease / / 17998437 rs3829963 chr6 36644386 C A 6.26E-05 Basophils CDKN1A intron pha003087 rs2395655 chr6 36645696 A G 3.30E-06 Response to lithium treatment in bipolar disorder CDKN1A UTR-5 19448189 rs3176326 chr6 36647289 G A 3.00E-04 Atrial fibrillation CDKN1A intron 21846873 rs3176353 chr6 36652605 C T 3.86E-28 Triglycerides CDKN1A intron 23063622 rs3176353 chr6 36652605 C T 7.46E-11 Cholesterol,total CDKN1A intron 23063622 rs876581 chr6 36655445 C T 7.89E-05 Sudden cardiac arrest CDKN1A nearGene-3 21658281 rs12191972 chr6 36658742 T C 4.89E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9394373 chr6 36665639 T C 3.53E-04 Response to taxane treatment (placlitaxel) LOC100652802 UTR-5 23006423 rs6906101 chr6 36667610 A G 3.00E-05 Myopia (pathological) LOC100652802 intron 21095009 rs6906101 chr6 36667610 A G 6.49E-05 Myopia (severe) LOC100652802 intron 23933737 rs9380590 chr6 36673510 A G 1.87E-04 Myopia (pathological) LOC100652802 intron 21095009 rs9380590 chr6 36673510 A G 4.92E-04 Response to taxane treatment (placlitaxel) LOC100652802 intron 23006423 rs236459 chr6 36700899 T G 2.20E-05 Urinary metabolites / / 21572414 rs236449 chr6 36702843 G A 9.40E-05 Pancreatic cancer / / pha002874 rs236448 chr6 36703095 A C 9.39E-05 Pancreatic cancer / / pha002874 rs1894560 chr6 36704787 G A 1.64E-04 Pancreatic cancer / / pha002874 rs13216190 chr6 36705684 C T 1.76E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs12196180 chr6 36706157 T C 6.02E-04 Multiple complex diseases / / 17554300 rs10456444 chr6 36722842 T C 1.92E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer CPNE5 intron 21483023 rs236446 chr6 36722951 T C 2.70E-05 Urinary metabolites CPNE5 intron 21572414 rs11757761 chr6 36727707 G A 5.65E-04 Myopia (pathological) CPNE5 intron 21095009 rs7769970 chr6 36735480 C G 1.49E-04 Alcohol dependence CPNE5 intron 21314694 rs12198605 chr6 36741266 G A 1.10E-05 Urinary metabolites CPNE5 intron 21572414 rs16889125 chr6 36749072 C T 8.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CPNE5 intron 20877124 rs236414 chr6 36753140 T A 3.28E-04 Acute lung injury CPNE5 intron 22295056 rs236410 chr6 36755402 T G 8.59E-04 Coronary heart disease CPNE5 intron 21971053 rs236410 chr6 36755402 T G 1.29E-05 Acute lung injury CPNE5 intron 22295056 rs4711465 chr6 36757803 A G 4.93E-05 Acute lung injury CPNE5 intron 22295056 rs9366916 chr6 36759741 G A 3.86E-04 Acute lung injury CPNE5 intron 22295056 rs9349011 chr6 36759768 C A,G,T 1.06E-04 Acute lung injury CPNE5 intron 22295056 rs9366917 chr6 36790666 G A 1.53E-04 Coronary heart disease CPNE5 intron 21606135 rs9366917 chr6 36790666 G A 4.93E-04 Acute lung injury CPNE5 intron 22295056 rs236375 chr6 36791835 T C 5.58E-04 Lymphocyte counts CPNE5 intron 22286170 rs236374 chr6 36792006 C A 2.83E-04 Acute lung injury CPNE5 intron 22295056 rs236373 chr6 36792057 C T 5.60E-04 Acute lung injury CPNE5 intron 22295056 rs236373 chr6 36792057 C T 9.00E-07 Heart rate CPNE5 intron 23583979 rs9368965 chr6 36814105 A G 7.02E-05 Cognitive test performance / / 20125193 rs9380614 chr6 36819210 T C 4.57E-05 Cognitive test performance / / 20125193 rs9380618 chr6 36853543 A G 2.01E-05 Breast cancer / / 21060860 rs9357230 chr6 36855382 G C 4.32E-04 Response to taxane treatment (placlitaxel) C6orf89 intron 23006423 rs140986907 chr6 36867372 C A 0.00052 Breast cancer C6orf89 missense 23555315 rs6931297 chr6 36871931 A G 1.00E-04 Prostate cancer C6orf89 intron 21743057 rs6932579 chr6 36872657 A G 6.00E-05 Prostate cancer C6orf89 intron 21743057 rs1224499 chr6 36873787 T G 8.43E-04 Multiple complex diseases C6orf89 intron 17554300 rs9462242 chr6 36875883 C T 6.00E-05 Prostate cancer C6orf89 intron 21743057 rs6900068 chr6 36879464 G A 1.68E-05 Cognitive test performance C6orf89 intron 20125193 rs1405069 chr6 36922684 A C 6.00E-06 Chemerin levels PI16 missense 20237162 rs1046279 chr6 36932571 T C 1.60E-04 IgE levels in asthmatics PI16 UTR-3 23967269 rs708006 chr6 36934244 C A 1.09E-06 Alcohol dependence / / 19581569 rs2293381 chr6 36938432 G A 4.40E-04 Sarcoidosis MTCH1 cds-synon 19165924 rs9296204 chr6 36944479 T C 3.20E-05 Celiac disease MTCH1 intron 23936387 rs708010 chr6 36963372 C A 7.35E-05 Nonalcoholic fatty liver disease / / 21423719 rs708010 chr6 36963372 C A 0.0000163 LDL cholesterol particle diameter / / 23263444 rs4714031 chr6 36971011 C T 4.94E-05 Acute lung injury / / 22295056 rs831494 chr6 36982947 C T 6.50E-04 Multiple complex diseases FGD2 intron 17554300 rs940920 chr6 36985516 T C 6.55E-06 Bipolar disorder FGD2 intron 19488044 rs6457974 chr6 37021260 T A 1.13E-11 Lymphocyte counts / / 22286170 rs2395670 chr6 37082809 A G 3.70E-05 Nicotine smoking / / 19268276 rs9380645 chr6 37102822 G A 7.53E-04 Schizophrenia / / 19197363 rs262902 chr6 37116078 G T 6.91E-04 Lymphocyte counts / / 22286170 rs262908 chr6 37130282 A G 6.91E-04 Multiple complex diseases / / 17554300 rs3957240 chr6 37154223 C T 4.57E-04 Insulin resistance / / 21901158 rs1757008 chr6 37173475 A G 4.05E-04 Type 2 diabetes / / 17463246 rs1757009 chr6 37173505 C T 4.16E-04 Type 2 diabetes / / 17463246 rs1680005 chr6 37174745 A G 7.00E-06 Bipolar disorder (mood-incongruent) / / 23092984 rs1224310 chr6 37186929 C T 2.62E-05 Multiple complex diseases TMEM217 intron 17554300 rs195753 chr6 37250112 A G 1.13E-04 Type 2 diabetes / / 17463246 rs149709 chr6 37278933 T C 2.00E-06 Acne (severe) TBC1D22B intron 24927181 rs195403 chr6 37295630 A G 2.17E-06 Acne (severe) TBC1D22B intron 24927181 rs195411 chr6 37301117 A G 3.73E-05 Alcohol dependence / / 21314694 rs6940938 chr6 37308594 G C 4.25E-04 Nicotine smoking / / 19268276 rs13203701 chr6 37329800 A G 3.24E-05 Glucose levels RNF8 intron pha003061 rs195386 chr6 37333318 G A 1.90E-04 Blood pressure RNF8 intron 21228793 rs195385 chr6 37333796 C T 7.32E-04 Stroke RNF8 intron pha002887 rs195379 chr6 37345704 T C 7.90E-05 Multiple complex diseases RNF8 intron 17554300 rs9394433 chr6 37380324 T C 1.30E-05 Suicide attempts in depression or bipolar disorder / / 24964207 rs2173314 chr6 37394873 G A 7.96E-05 Post-operative nausea and vomiting / / 21694509 rs1224127 chr6 37417556 G A 5.84E-05 Cognitive performance FTSJD2 intron 19734545 rs1224127 chr6 37417556 G A 5.03E-04 Myocardial Infarction FTSJD2 intron pha002883 rs904251 chr6 37451696 G T 7.00E-06 Cognitive performance CCDC167 intron 19734545 rs6940323 chr6 37456564 A G 4.57E-06 Multiple complex diseases CCDC167 intron 17554300 rs756202 chr6 37460350 C A 7.22E-05 Cognitive performance CCDC167 intron 19734545 rs2646937 chr6 37469537 C T 4.36E-04 Alcohol dependence / / 21314694 rs2797793 chr6 37477262 T C 5.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11969056 chr6 37484285 C T 5.05E-04 Nicotine dependence / / 17158188 rs1757171 chr6 37487044 T C 7.00E-06 Cognitive performance / / 19734545 rs11754662 chr6 37492336 G A 1.74E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2153945 chr6 37496291 A C 4.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12527264 chr6 37499842 G A 6.67E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs6921307 chr6 37509000 T C 4.13E-05 Alzheimer's disease (late onset) / / 21460841 rs2797777 chr6 37510932 G T 4.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9296225 chr6 37514461 T C 1.51E-04 Heart Failure / / pha002884 rs2776892 chr6 37528469 T C 2.10E-06 Urinary metabolites / / 21572414 rs2776892 chr6 37528469 T C 6.04E-05 Body Mass Index / / pha003014 rs9394438 chr6 37532103 G A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs9394438 chr6 37532103 G A 7.00E-06 IgG glycosylation / / 23382691 rs11751671 chr6 37533294 G A 2.96E-04 Major depressive disorder / / 22472876 rs9470630 chr6 37548456 A G 9.37E-04 Alzheimer's disease / / 22005930 rs6458003 chr6 37556555 C T 1.50E-05 Urinary metabolites / / 21572414 rs6458004 chr6 37562703 T C 8.78E-05 Psoriasis / / 18364390 rs6458004 chr6 37562703 T C 8.29E-04 Alcohol dependence / / 20201924 rs9380691 chr6 37574852 C T 8.59E-05 Cognitive impairment induced by topiramate / / 22091778 rs804853 chr6 37578630 A T 5.20E-05 Diabetic retinopathy / / 21441570 rs804854 chr6 37578883 A T 5.10E-05 Diabetic retinopathy / / 21441570 rs809251 chr6 37579781 T A 6.40E-05 Diabetic retinopathy / / 21441570 rs804820 chr6 37584451 T C 8.20E-05 Diabetic retinopathy / / 21441570 rs4714082 chr6 37585054 A G 6.20E-05 Epilepsy (remission after treatment) / / 23962720 rs4714083 chr6 37585129 C A 6.22E-05 Epilepsy (remission after treatment) / / 23962720 rs4711505 chr6 37585139 G C 6.22E-05 Epilepsy (remission after treatment) / / 23962720 rs4714084 chr6 37585221 C T 5.13E-05 Epilepsy (remission after treatment) / / 23962720 rs7751500 chr6 37589797 G T 7.50E-05 Diabetic retinopathy / / 21441570 rs6923013 chr6 37596215 A G 3.94E-04 Multiple complex diseases / / 17554300 rs9366943 chr6 37602406 C A 1.84E-04 Multiple complex diseases MDGA1 UTR-3 17554300 rs12191311 chr6 37603707 C T 1.78E-05 Suicidal ideation MDGA1 UTR-3 20877300 rs11963879 chr6 37619161 A G 0.0000965 Nonsyndromic striae distensae (stretch marks) MDGA1 intron 23633020 rs35787789 chr6 37619192 C T 0.0000956 Nonsyndromic striae distensae (stretch marks) MDGA1 intron 23633020 rs61749283 chr6 37623584 A G 0.0000965 Nonsyndromic striae distensae (stretch marks) MDGA1 cds-synon 23633020 rs16890045 chr6 37625389 T A 1.15E-04 Multiple complex diseases MDGA1 intron 17554300 rs6903441 chr6 37633072 G A 9.70E-05 Bipolar disorder MDGA1 intron 22925353 rs7760531 chr6 37652730 T C 1.31E-05 Parent of origin effect on language impairment (child trend) MDGA1 intron 24571439 rs17639988 chr6 37680592 A C 2.88E-04 Multiple complex diseases / / 17554300 rs742787 chr6 37691626 T C 4.11E-04 Rheumatoid arthritis / / 21452313 rs10947698 chr6 37723353 G A 3.68E-05 Age-related macular degeneration / / 22125219 rs10947698 chr6 37723353 G A 4.53E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6929224 chr6 37746848 T C 1.89E-04 Type 2 diabetes / / 22158537 rs13198558 chr6 37746921 A G 1.82E-04 Type 2 diabetes / / 22158537 rs4329108 chr6 37756871 G A 4.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs9357255 chr6 37761373 A C 7.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs7750445 chr6 37764977 C G 2.00E-05 Type 2 diabetes / / 17463248 rs16890175 chr6 37767791 T C 1.20E-05 Urinary metabolites / / 21572414 rs2274090 chr6 37820968 T C 8.07E-05 Type 2 diabetes ZFAND3 intron 22158537 rs7747199 chr6 37847013 G C 1.70E-05 Urinary metabolites ZFAND3 intron 21572414 rs6901928 chr6 37937302 T C 9.73E-05 Alcohol dependence ZFAND3 intron 20201924 rs6901928 chr6 37937302 T C 9.73E-05 Alcoholism ZFAND3 intron pha002891 rs752110 chr6 37953988 A G 1.46E-04 Type 2 diabetes ZFAND3 intron 22158537 rs2645117 chr6 37954153 G T 7.35E-04 Coronary Artery Disease ZFAND3 intron 17634449 rs2645117 chr6 37954153 G T 1.60E-05 Urinary metabolites ZFAND3 intron 21572414 rs16890299 chr6 37960055 A G 6.76E-04 Type 2 diabetes ZFAND3 intron 22158537 rs12661480 chr6 37963308 T C 2.62E-04 Type 2 diabetes ZFAND3 intron 22158537 rs16890307 chr6 37972892 C A 3.42E-04 Type 2 diabetes ZFAND3 intron 22158537 rs16890309 chr6 37973613 A G 9.62E-04 Type 2 diabetes ZFAND3 intron 22158537 rs11750950 chr6 37979180 T C 7.26E-06 Type 2 diabetes ZFAND3 intron 22158537 rs12660773 chr6 37986564 T C 1.18E-05 Type 2 diabetes ZFAND3 intron 22158537 rs11753054 chr6 37991800 C T 6.66E-05 Type 2 diabetes ZFAND3 intron 22158537 rs10947710 chr6 38002748 T A 8.25E-05 Type 2 diabetes ZFAND3 intron 22158537 rs11757072 chr6 38018628 C T 9.44E-05 Type 2 diabetes ZFAND3 intron 22158537 rs2055208 chr6 38018921 C T 2.27E-04 Type 2 diabetes ZFAND3 intron 22158537 rs12660732 chr6 38022989 A G 3.07E-04 Type 2 diabetes ZFAND3 intron 22158537 rs12664900 chr6 38026003 G A 8.61E-05 Type 2 diabetes ZFAND3 intron 22158537 rs16890341 chr6 38033254 A G 1.67E-04 Type 2 diabetes ZFAND3 intron 22158537 rs17589516 chr6 38036420 A G 4.00E-06 Insulin resistance ZFAND3 intron 21901158 rs12661073 chr6 38036574 G C 6.48E-04 Type 2 diabetes ZFAND3 intron 22158537 rs12663427 chr6 38038538 T A 6.21E-04 Type 2 diabetes ZFAND3 intron 22158537 rs17589683 chr6 38045836 C T 4.44E-05 Insulin resistance ZFAND3 intron 21901158 rs4524602 chr6 38050367 A G 1.06E-04 Type 2 diabetes ZFAND3 intron 22158537 rs17589955 chr6 38060879 C T 1.91E-05 Insulin resistance ZFAND3 intron 21901158 rs9470772 chr6 38063070 A C 1.11E-04 Type 2 diabetes ZFAND3 intron 22158537 rs9470777 chr6 38071455 G A 2.17E-04 Type 2 diabetes ZFAND3 intron 22158537 rs16890362 chr6 38074723 G A 7.12E-04 Type 2 diabetes ZFAND3 intron 22158537 rs16890370 chr6 38080431 A G 8.25E-04 Type 2 diabetes ZFAND3 intron 22158537 rs9470784 chr6 38083640 A G 1.92E-04 Type 2 diabetes ZFAND3 intron 22158537 rs2295791 chr6 38084569 C A 2.10E-05 Urinary metabolites ZFAND3 intron 21572414 rs11758095 chr6 38085449 C G 7.17E-06 Type 2 diabetes ZFAND3 intron 22158537 rs11759483 chr6 38087679 C A 7.46E-06 Type 2 diabetes ZFAND3 intron 22158537 rs2145887 chr6 38097774 G A 7.56E-06 Type 2 diabetes ZFAND3 intron 22158537 rs9470794 chr6 38106844 T C 2.00E-10 Type 2 diabetes ZFAND3 intron 22158537 rs9470794 chr6 38106844 T C 2.06E-10 Type 2 diabetes ZFAND3 intron 23300278 rs9470798 chr6 38111339 C G 8.18E-06 Type 2 diabetes ZFAND3 intron 22158537 rs9470798 chr6 38111339 C G 7.45E-04 Smoking quantity ZFAND3 intron 24665060 rs11756902 chr6 38118638 G C 7.32E-06 Type 2 diabetes ZFAND3 intron 22158537 rs7748392 chr6 38118755 A G 7.52E-06 Type 2 diabetes ZFAND3 intron 22158537 rs876818 chr6 38120660 C T 9.43E-06 Type 2 diabetes ZFAND3 UTR-3 22158537 rs3800364 chr6 38121211 A G 1.20E-05 Type 2 diabetes ZFAND3 UTR-3 22158537 rs2395692 chr6 38124079 A G 1.30E-05 Type 2 diabetes / / 22158537 rs2395693 chr6 38124219 G A 1.53E-05 Type 2 diabetes / / 22158537 rs3749926 chr6 38137814 G A 8.44E-05 Telomere length BTBD9 UTR-3 21573004 rs17678747 chr6 38145965 A G 4.42E-04 Coronary Artery Disease BTBD9 intron 17634449 rs13205068 chr6 38162180 G A 5.04E-04 Coronary Artery Disease BTBD9 intron 17634449 rs926564 chr6 38199259 T G 9.40E-05 Post-operative nausea and vomiting BTBD9 intron 21694509 rs726160 chr6 38221639 A G 1.44E-04 Amyotrophic lateral sclerosis (sporadic) BTBD9 intron 24529757 rs726160 chr6 38221639 A G 1.75E-04 Smoking initiation BTBD9 intron 24665060 rs13194038 chr6 38230229 A G 4.81E-05 Fibrinogen BTBD9 intron 17255346 rs16890541 chr6 38247391 C G 8.01E-04 Type 2 diabetes BTBD9 intron 17463246 rs6905637 chr6 38277910 C T 2.00E-04 Restless legs syndrome BTBD9 intron 17634447 rs228181 chr6 38300140 A G 8.00E-05 Restless legs syndrome BTBD9 intron 17634447 rs12660215 chr6 38305770 A C 3.75E-04 Multiple complex diseases BTBD9 intron 17554300 rs9394492 chr6 38332610 C T 4.07E-04 Restless legs syndrome BTBD9 intron 17637780 rs4714156 chr6 38361112 C T 6.50E-07 Restless legs syndrome BTBD9 intron 17637780 rs9296249 chr6 38365841 T C 4.00E-18 Restless legs syndrome BTBD9 intron 17637780 rs9357271 chr6 38365873 T C 2.00E-07 Restless legs syndrome BTBD9 intron 17634447 rs9357271 chr6 38365873 T C 6.31E-18 Restless legs syndrome BTBD9 intron 17637780 rs9357271 chr6 38365873 T C 8.00E-22 Restless legs syndrome BTBD9 intron 21779176 rs4711546 chr6 38366186 A G 2.00E-06 Restless legs syndrome BTBD9 intron 17634447 rs4711546 chr6 38366186 A G 8.70E-05 Basophils BTBD9 intron pha003087 rs4565302 chr6 38400139 T C 2.00E-04 Restless legs syndrome BTBD9 intron 17634447 rs12208647 chr6 38408223 G A 2.00E-04 Restless legs syndrome BTBD9 intron 17634447 rs12208647 chr6 38408223 G A 6.32E-04 Premature ovarian failure BTBD9 intron 19508998 rs4623233 chr6 38414387 C G 6.70E-04 Suicide attempts in bipolar disorder BTBD9 intron 21423239 rs6904723 chr6 38436317 A C 7.00E-07 Restless legs syndrome BTBD9 intron 17634447 rs3923809 chr6 38440970 A G 1.00E-17 Restless legs syndrome BTBD9 intron 17634447 rs3923809 chr6 38440970 A G 1.75E-09 Restless legs syndrome BTBD9 intron 17637780 rs4316001 chr6 38468887 T C 7.99E-04 Multiple complex diseases BTBD9 intron 17554300 rs4236060 chr6 38470087 C T 1.00E-08 Restless legs syndrome BTBD9 intron 17637780 rs7740763 chr6 38478267 C T 5.59E-05 Basophils BTBD9 intron pha003087 rs6923737 chr6 38483564 T C 1.00E-07 Restless legs syndrome BTBD9 intron 17634447 rs13219695 chr6 38505703 A G 0.00000814 Colorectal cancer BTBD9 intron 22532847 rs2814889 chr6 38519761 C T 8.21E-04 Alcohol dependence BTBD9 intron 21314694 rs1321056 chr6 38535576 G A 4.00E-05 Restless legs syndrome BTBD9 intron 17634447 rs17543178 chr6 38543377 A G 3.00E-04 Restless legs syndrome BTBD9 intron 17634447 rs2814894 chr6 38544497 A G 3.00E-05 Restless legs syndrome BTBD9 intron 17634447 rs1739626 chr6 38599566 C A 5.00E-05 Restless legs syndrome BTBD9 intron 17634447 rs7775968 chr6 38618247 C T 2.60E-04 Multiple complex diseases / / 17554300 rs1781738 chr6 38627279 T C 6.00E-05 Restless legs syndrome / / 17634447 rs12198212 chr6 38679147 T A 3.37E-04 Insulin resistance / / 21901158 rs1699012 chr6 38680943 G A 8.10E-06 Urinary metabolites / / 21572414 rs9296260 chr6 38692437 C T 6.63E-30 Narcolepsy D/H8 intron 19629137 rs2654444 chr6 38715678 T C 6.95E-04 Multiple complex diseases D/H8 intron 17554300 rs4714177 chr6 38720239 A G 1.30E-05 Multiple complex diseases D/H8 intron 17554300 rs2206860 chr6 38723161 T G 7.09E-06 Cortisol secretion,in saliva D/H8 intron 21316860 rs7749015 chr6 38738537 A G 6.87E-06 Type 1 diabetes D/H8 intron 21980299 rs7769812 chr6 38738834 T G 9.13E-05 Tuberculosis D/H8 intron 20694014 rs7756191 chr6 38757378 C T 5.81E-05 Celiac disease D/H8 intron 23936387 rs4714183 chr6 38762865 A G 0.00007803 Sarcoidosis D/H8 intron 22952805 rs9380777 chr6 38764346 G A 0.0000941 Sarcoidosis D/H8 intron 22952805 rs9394539 chr6 38764459 G A 0.00009934 Sarcoidosis D/H8 intron 22952805 rs12211963 chr6 38767450 T C 9.14E-05 Tuberculosis D/H8 intron 20694014 rs9380779 chr6 38771401 A G 0.00009838 Sarcoidosis D/H8 intron 22952805 rs12665115 chr6 38773146 T C 0.00009318 Sarcoidosis D/H8 intron 22952805 rs9380780 chr6 38773709 G A 0.00007546 Sarcoidosis D/H8 intron 22952805 rs6901200 chr6 38784563 A G 0.00004128 Sarcoidosis D/H8 intron 22952805 rs12194119 chr6 38786528 G A 6.59E-05 Hypertension D/H8 intron pha003041 rs1738211 chr6 38790149 C T 5.56E-05 Rheumatoid arthritis D/H8 intron 17804836 rs9380782 chr6 38794912 C G 0.00002784 Sarcoidosis D/H8 intron 22952805 rs9357283 chr6 38800164 G A 0.000096 Prostate cancer (advanced) D/H8 missense 23555315 rs9296264 chr6 38800901 T C 1.03E-05 Rheumatoid arthritis D/H8 intron 17804836 rs9296264 chr6 38800901 T C 0.00008314 Sarcoidosis D/H8 intron 22952805 rs71571354 chr6 38842276 G T 0.00003766 Sarcoidosis D/H8 intron 22952805 rs862432 chr6 38850809 C A 7.90E-04 Multiple complex diseases D/H8 missense 17554300 rs4714192 chr6 38851669 C T 2.13E-04 Response to statin treatment (atorvastatin),change in cholesterol levels D/H8 cds-synon 20031582 rs116401640 chr6 38854645 A G 0.00069 Breast cancer D/H8 missense 23555315 rs9470944 chr6 38861151 G T 0.00004741 Sarcoidosis D/H8 intron 22952805 rs62398569 chr6 38861879 G T 0.00006661 Sarcoidosis D/H8 intron 22952805 rs75351853 chr6 38864378 C A 0.00005358 Sarcoidosis D/H8 intron 22952805 rs62398571 chr6 38868774 C T 0.00006326 Sarcoidosis D/H8 intron 22952805 rs11753074 chr6 38874911 A G 0.00009217 Sarcoidosis D/H8 intron 22952805 rs4714198 chr6 38877605 C A 6.65E-04 Alcohol dependence D/H8 intron 21314694 rs11753138 chr6 38882425 C T 0.00009217 Sarcoidosis D/H8 intron 22952805 rs9470949 chr6 38884151 A G 0.00008952 Sarcoidosis D/H8 intron 22952805 rs9462464 chr6 38886122 T C 0.00008681 Sarcoidosis D/H8 intron 22952805 rs77109846 chr6 38891419 T G 0.00006824 Sarcoidosis D/H8 intron 22952805 rs9462466 chr6 38901358 G A 0.00006484 Sarcoidosis D/H8 intron 22952805 rs6905467 chr6 38904004 T C 8.87E-04 Response to statin treatment (atorvastatin),change in cholesterol levels D/H8 intron 20031582 rs522327 chr6 38913177 A G 2.27E-04 Body mass index D/H8 intron 23669352 rs1537230 chr6 38944196 G A 0.000038 Type 2 diabetes (females) D/H8 intron 22885922 rs17337012 chr6 38964657 G A 2.31E-04 Amyotrophic lateral sclerosis (sporadic) D/H8 intron 24529757 rs1412269 chr6 38965333 A C 9.86E-05 Cytomegalovirus antibody response D/H8 intron 21993531 rs910171 chr6 39018874 G C 6.66E-04 Multiple complex diseases GLP1R intron 17554300 rs10305438 chr6 39024448 G A 7.43E-04 Multiple complex diseases GLP1R intron 17554300 rs2268650 chr6 39030401 G A 5.92E-05 Orofacial clefts GLP1R intron 22419666 rs2300615 chr6 39039503 T G 3.29E-07 Fasting blood glucose GLP1R intron 22885924 rs10305518 chr6 39055012 T G 4.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GLP1R UTR-3 20877124 rs2746303 chr6 39091869 C T 2.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs411827 chr6 39091922 A G 2.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs228808 chr6 39092039 T C 2.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs6905394 chr6 39098344 G A 9.84E-05 Bipolar disorder / / 17486107 rs10947782 chr6 39106907 G A 9.09E-05 Suicide attempts in bipolar disorder / / 21423239 rs7757873 chr6 39110904 G A 3.45E-05 Suicide attempts in bipolar disorder / / 21423239 rs1593917 chr6 39111533 C T 6.33E-05 Scoliosis / / 21216876 rs2115200 chr6 39117698 T G 3.44E-05 Cognitive test performance / / 20125193 rs2115200 chr6 39117698 T G 2.00E-06 Eating disorders / / 23568457 rs1366323 chr6 39121828 C T 7.67E-04 Myocardial infarction / / 24916648 rs2815074 chr6 39124008 C T 3.40E-06 Urinary metabolites / / 21572414 rs1544935 chr6 39124448 T G 8.76E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9942541 chr6 39124682 C T 5.00E-06 Social communication problems / / 24564958 rs9470983 chr6 39127045 C T 3.83E-04 Prostate cancer mortality / / 20978177 rs9470986 chr6 39128424 C T 3.83E-04 Prostate cancer mortality / / 20978177 rs6899384 chr6 39132435 C T 4.04E-04 Smoking initiation / / 24665060 rs12214118 chr6 39136651 A G 9.99E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2815090 chr6 39136818 G A 1.90E-05 Urinary metabolites / / 21572414 rs9380833 chr6 39139464 C T 1.60E-05 Bilirubin levels / / 19414484 rs6921231 chr6 39141213 A G 9.88E-06 Triglycerides / / 19074352 rs6921231 chr6 39141213 A G 9.88E-06 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs1428373 chr6 39150098 G A 5.06E-05 Blood Pressure / / pha003039 rs10456468 chr6 39151425 G T 3.14E-04 Multiple complex diseases / / 17554300 rs3778448 chr6 39163201 A G 8.87E-08 Coronary artery disease KCNK5 intron 23202125 rs10947788 chr6 39174612 C T 5.30E-05 Leukocyte Counts KCNK5 intron pha003091 rs10947789 chr6 39174922 T C 0.00000686 Coronary artery disease (CAD) (males) KCNK5 intron 23202125 rs10947789 chr6 39174922 T C 0.000114 Coronary artery disease (CAD) age >50 KCNK5 intron 23202125 rs10947789 chr6 39174922 T C 0.000205 Coronary artery disease (CAD) age <=50 KCNK5 intron 23202125 rs10947789 chr6 39174922 T C 3.65E-08 Coronary artery disease with myocardial infarction KCNK5 intron 23202125 rs10947789 chr6 39174922 T C 6.62E-09 Coronary artery disease KCNK5 intron 23202125 rs10456100 chr6 39183470 C T 2.06E-04 Migraine without aura KCNK5 intron 23793025 rs10456100 chr6 39183470 C T 2.50E-05 Migraine - clinic-based KCNK5 intron 23793025 rs10456100 chr6 39183470 C T 5.00E-07 Migraine KCNK5 intron 23793025 rs9369107 chr6 39201171 T A 2.30E-06 Urinary metabolites / / 21572414 rs9366999 chr6 39202157 G A 7.00E-06 Obesity-related traits / / 23251661 rs16868846 chr6 39207558 G C 3.71E-06 Stroke (ischemic) / / 21957438 rs60637107 chr6 39211825 G A 3.80E-06 Stroke (ischemic) / / 21957438 rs1744415 chr6 39215601 T C 2.50E-06 Urinary metabolites / / 21572414 rs1651110 chr6 39218008 T A 5.60E-06 Urinary metabolites / / 21572414 rs1651107 chr6 39218584 A G 5.20E-06 Urinary metabolites / / 21572414 rs1744403 chr6 39218651 T C 2.80E-06 Urinary metabolites / / 21572414 rs1651106 chr6 39219300 G A 2.80E-06 Urinary metabolites / / 21572414 rs1744416 chr6 39221803 C T 3.00E-06 Urinary metabolites / / 21572414 rs1744417 chr6 39221920 T C 2.00E-07 Urinary metabolites / / 21572414 rs1651114 chr6 39223000 T C 6.20E-07 Urinary metabolites / / 21572414 rs116181858 chr6 39229421 C G 4.32E-06 Stroke (ischemic) / / 21957438 rs114566901 chr6 39229743 A C 4.39E-06 Stroke (ischemic) / / 21957438 rs1182864 chr6 39230307 G A 4.04E-05 Vaspin levels / / 22907691 rs1182864 chr6 39230307 G A 0.0000404 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs4711589 chr6 39230571 A C 3.82E-05 Vaspin levels / / 22907691 rs4711589 chr6 39230571 A C 0.0000382 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs2758862 chr6 39239122 C T 1.10E-04 Breast cancer / / 22452962 rs2758871 chr6 39244377 T G 4.00E-05 Cognitive test performance / / 20125193 rs2758886 chr6 39250837 G A 3.00E-08 Cholesterol,total / / 24097068 rs115057884 chr6 39256986 T C 2.46E-06 Stroke (ischemic) / / 21957438 rs2815063 chr6 39262535 C A 5.55E-07 Stroke (ischemic) / / 21957438 rs2815067 chr6 39266636 G A 4.05E-05 Height / / pha003010 rs2815067 chr6 39266636 G A 4.45E-05 Height / / pha003011 rs10807204 chr6 39273426 C G 6.70E-04 stroke (ischemic) KCNK17 intron 17434096 rs10807204 chr6 39273426 C G 4.33E-04 Multiple complex diseases KCNK17 intron 17554300 rs1544050 chr6 39279131 G A 3.37E-05 Glycosylated haemoglobin levels KCNK17 intron 17255346 rs11756091 chr6 39282806 G T 1.74E-04 Alzheimer's disease KCNK16 missense 22005930 rs11756091 chr6 39282806 G T 1.78E-06 Type 2 diabetes KCNK16 missense 22158537 rs2146262 chr6 39283793 G A 1.62E-04 Alzheimer's disease KCNK16 intron 22005930 rs1535500 chr6 39284050 G T 2.97E-04 Alzheimer's disease KCNK16 missense 22005930 rs1535500 chr6 39284050 G T 2.00E-08 Type 2 diabetes KCNK16 missense 22158537 rs1535500 chr6 39284050 G T 8.00E-06 Type 2 diabetes KCNK16 missense 24509480 rs3734618 chr6 39284184 A G 1.16E-04 Alzheimer's disease KCNK16 cds-synon 22005930 rs3734618 chr6 39284184 A G 8.45E-07 Type 2 diabetes KCNK16 cds-synon 22158537 rs1109798 chr6 39289875 G A 2.14E-04 Alzheimer's disease KCNK16 intron 22005930 rs1109798 chr6 39289875 G A 1.93E-04 Vaspin levels KCNK16 intron 22907691 rs1109798 chr6 39289875 G A 0.0001932 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks KCNK16 intron 22907730 rs3807045 chr6 39290653 G A 6.00E-04 Alzheimer's disease / / 22005930 rs3807042 chr6 39290834 T G 7.40E-05 Alzheimer's disease / / 22005930 rs1328384 chr6 39291807 C A 4.38E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1328384 chr6 39291807 C A 3.06E-04 Colorectal cancer / / 24737748 rs4714239 chr6 39301442 T C 4.10E-05 Cognitive decline / / 22054870 rs11756848 chr6 39301460 A G 5.21E-05 Multiple complex diseases / / 17554300 rs16891940 chr6 39301670 C G 7.53E-06 Multiple complex diseases / / 17554300 rs7774046 chr6 39302432 T C 7.45E-07 Left ventricular mass / / 21212386 rs11756686 chr6 39303966 G A 2.37E-05 Multiple complex diseases KIF6 UTR-3 17554300 rs3734621 chr6 39304211 A C 1.04E-06 Smooth-surface caries KIF6 UTR-3 24556642 rs9471075 chr6 39307032 A C 1.00E-06 Smooth-surface caries KIF6 intron 24556642 rs9471075 chr6 39307032 A C 9.71E-07 Smooth-surface caries KIF6 intron 24556642 rs3818308 chr6 39307514 T G 3.45E-04 Parkinson's disease KIF6 intron 17052657 rs20455 chr6 39325078 A G 1 Drug response to Statins KIF6 missense 17443022 rs20455 chr6 39325078 A G 1 Drug response to Pravastatin KIF6 missense 18073581 rs20455 chr6 39325078 A G 1 Drug response to Statins KIF6 missense 18073581 rs20455 chr6 39325078 A G 1 Drug response to Pravastatin KIF6 missense 18222353 rs20455 chr6 39325078 A G 1 Drug response to Statins KIF6 missense 18222353 rs20455 chr6 39325078 A G 1 Drug response to Pravastatin KIF6 missense 18222354 rs20455 chr6 39325078 A G 1 Drug response to Statins KIF6 missense 18222354 rs20455 chr6 39325078 A G 1 Drug response to Pravastatin KIF6 missense 18222355 rs20455 chr6 39325078 A G 1 Drug response to Statins KIF6 missense 18222355 rs20455 chr6 39325078 A G 7.20E-06 Urinary metabolites KIF6 missense 21572414 rs1885615 chr6 39338435 A G 2.40E-05 Urinary metabolites KIF6 intron 21572414 rs6924789 chr6 39339891 T C 1.80E-05 Urinary metabolites KIF6 intron 21572414 rs1927777 chr6 39344590 T C 1.70E-05 Urinary metabolites KIF6 intron 21572414 rs716952 chr6 39349365 G A 3.68E-05 Orofacial clefts KIF6 intron 20023658 rs9462540 chr6 39354375 G A 1.46E-04 Lung function (forced expiratory volume in 1 second) KIF6 intron 24023788 rs12175497 chr6 39356438 T C 6.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KIF6 intron 20877124 rs9380854 chr6 39357257 A G 9.50E-06 Urinary metabolites KIF6 intron 21572414 rs9380857 chr6 39359065 G A 6.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KIF6 intron 20877124 rs9296295 chr6 39361854 C A 6.00E-06 Obesity-related traits KIF6 intron 23251661 rs9369114 chr6 39370670 G A 2.79E-04 Multiple complex diseases KIF6 intron 17554300 rs7759557 chr6 39384111 G A 4.35E-04 Insulin resistance KIF6 intron 21901158 rs9394591 chr6 39389992 A G 7.84E-04 Type 2 diabetes KIF6 intron 17463246 rs4142117 chr6 39392718 T A 7.87E-04 Type 2 diabetes KIF6 intron 17463246 rs4142117 chr6 39392718 T A 4.11E-04 Multiple complex diseases KIF6 intron 17554300 rs10484825 chr6 39399454 A G 4.80E-04 Smoking quantity KIF6 intron 24665060 rs4236064 chr6 39414027 G T 1.80E-04 Schizophrenia KIF6 intron 19197363 rs4236064 chr6 39414027 G T 4.10E-05 Alcoholism (heaviness of drinking) KIF6 intron 21529783 rs722250 chr6 39428480 C G 9.10E-04 Type 2 diabetes and 6 quantitative traits KIF6 intron 17848626 rs9380874 chr6 39486517 T C 2.30E-04 Schizophrenia KIF6 intron 19197363 rs6901155 chr6 39500579 C A 2.76E-05 Nicotine smoking KIF6 intron 19268276 rs1520 chr6 39526867 A G 3.00E-04 Schizophrenia KIF6 intron 19197363 rs6458117 chr6 39526895 T C 3.44E-06 Serum metabolites KIF6 intron 19043545 rs9380880 chr6 39528982 G A 1.00E-07 Immune response to smallpox vaccine (IL-6) KIF6 intron 22542470 rs2092524 chr6 39529692 G A 4.90E-04 Schizophrenia KIF6 intron 19197363 rs4714261 chr6 39539207 C T 2.00E-06 Attention deficit hyperactivity disorder symptoms (interaction) KIF6 intron 18846501 rs4302661 chr6 39564229 C T 6.57E-04 Coronary heart disease KIF6 intron 21606135 rs9394619 chr6 39574377 T C 5.19E-04 Alcohol consumption (maxi-drinks) KIF6 intron 24277619 rs1026526 chr6 39587757 A G 2.32E-04 Alcohol consumption (maxi-drinks) KIF6 intron 24277619 rs10456473 chr6 39596070 C T 2.93E-06 Serum metabolites KIF6 intron 19043545 rs11752716 chr6 39599328 T C 7.53E-04 Acute lung injury KIF6 intron 22295056 rs11758109 chr6 39607551 C T 5.72E-04 Acute lung injury KIF6 intron 22295056 rs1018155 chr6 39732432 G A 8.99E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs455674 chr6 39736402 C T 7.08E-08 Narcolepsy / / 19629137 rs9380893 chr6 39745436 C G 4.98E-04 Bipolar disorder,schizoaffective / / 19567891 rs16892594 chr6 39757257 G T 8.37E-04 Multiple complex diseases / / 17554300 rs2395730 chr6 39784365 C A 8.00E-08 Pulmonary function DAAM2 intron 20010834 rs11756622 chr6 39790043 C T 2.96E-04 Orofacial clefts DAAM2 intron 22419666 rs2504804 chr6 39822219 G A 5.72E-04 Body mass index DAAM2 intron 21701565 rs2504804 chr6 39822219 G A 6.75E-04 Body mass index DAAM2 intron 21701565 rs2504804 chr6 39822219 G A 8.57E-05 Serum albumin level DAAM2 intron pha003084 rs2504100 chr6 39827804 A G 8.96E-04 Body mass index DAAM2 intron 21701565 rs2504789 chr6 39834314 A G 3.24E-04 Taste perception DAAM2 intron 22132133 rs2504796 chr6 39844718 T C 3.66E-05 Body Mass Index DAAM2 intron pha003009 rs2504800 chr6 39850298 T C 4.16E-08 Metabolite levels DAAM2 intron 23281178 rs2504082 chr6 39851679 A G 7.93E-08 Metabolite levels DAAM2 intron 23281178 rs2504082 chr6 39851679 A G 3.98E-05 Erythrocyte counts DAAM2 intron pha003101 rs3003929 chr6 39851818 G A 7.93E-08 Metabolite levels DAAM2 cds-synon 23281178 rs3003930 chr6 39852037 T C 7.74E-08 Metabolite levels DAAM2 intron 23281178 rs3003932 chr6 39852438 A G 7.93E-08 Metabolite levels DAAM2 intron 23281178 rs3003938 chr6 39853190 A G 7.93E-08 Metabolite levels DAAM2 intron 23281178 rs3003942 chr6 39854425 A G 6.66E-08 Metabolite levels DAAM2 intron 23281178 rs3003945 chr6 39855112 T G 8.13E-05 Erythrocyte counts DAAM2 intron pha003101 rs2504805 chr6 39861595 G A 4.70E-04 Alzheimer's disease DAAM2 intron 24755620 rs2984659 chr6 39890267 A C 7.19E-05 Myopia (pathological) MOCS1 intron 23049088 rs10947842 chr6 39915349 C T 2.52E-05 Bone mineral density / / 19181680 rs16892750 chr6 39920674 G C 4.41E-04 Coronary Artery Disease / / 17634449 rs880919 chr6 39925922 G A 4.82E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2984436 chr6 39955366 C A 8.69E-04 Alzheimer's disease / / 24755620 rs2894387 chr6 39962200 T A 1.32E-04 Multiple complex diseases / / 17554300 rs10807222 chr6 39974339 G A 1.04E-04 Multiple complex diseases / / 17554300 rs1546965 chr6 39999149 T C 3.20E-04 Fibrinogen / / 17255346 rs10947854 chr6 40066516 G A 4.63E-04 Multiple complex diseases / / 17554300 rs10807224 chr6 40072712 C T 2.87E-04 Multiple complex diseases / / 17554300 rs6912289 chr6 40079519 G A 3.02E-04 Multiple complex diseases / / 17554300 rs9369170 chr6 40083496 G T 2.18E-04 Multiple complex diseases / / 17554300 rs115899206 chr6 40084864 A G 1.59E-06 Prostate cancer / / 24185611 rs761798 chr6 40087514 T C 4.70E-04 Multiple complex diseases / / 17554300 rs9471244 chr6 40092331 C T 5.85E-04 Multiple complex diseases / / 17554300 rs10947855 chr6 40096889 G A 1.47E-04 Multiple complex diseases / / 17554300 rs10947855 chr6 40096889 G A 5.41E-05 Bone mineral density / / 19181680 rs6936016 chr6 40097013 T C 4.39E-04 Multiple complex diseases / / 17554300 rs10947856 chr6 40111427 G T 2.43E-04 Multiple complex diseases / / 17554300 rs10947857 chr6 40111515 T C 1.33E-04 Multiple complex diseases / / 17554300 rs7751650 chr6 40125459 A G 6.95E-04 Alzheimer's disease / / 24755620 rs6930375 chr6 40132914 G A 9.64E-05 Personality dimensions / / 18957941 rs6930375 chr6 40132914 G A 6.66E-04 Esophageal adenocarcinoma / / 24121790 rs819944 chr6 40165431 A C,G,T 8.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs9367046 chr6 40166385 T G 1.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs9369178 chr6 40178333 G T 4.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs866036 chr6 40178353 T C 4.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs1325557 chr6 40184894 T C 1.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs1325558 chr6 40185078 A G 1.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs10807228 chr6 40188351 T A 4.44E-05 Suicide attempts in bipolar disorder / / 21423239 rs71537482 chr6 40188351 TC TAA,TTC 4.44E-05 Suicide attempts in bipolar disorder / / 21423239 rs11969625 chr6 40188482 A G 4.07E-05 Suicide attempts in bipolar disorder / / 21423239 rs7772688 chr6 40189205 C T 2.09E-05 Suicide attempts in bipolar disorder / / 21423239 rs9349142 chr6 40191579 T C 5.98E-05 Suicide attempts in bipolar disorder / / 21423239 rs1555799 chr6 40193032 G A 6.31E-05 Suicide attempts in bipolar disorder / / 21423239 rs7770511 chr6 40193960 A G 6.38E-05 Suicide attempts in bipolar disorder / / 21423239 rs2147927 chr6 40195566 C T 6.60E-05 Suicide attempts in bipolar disorder / / 21423239 rs9367047 chr6 40195954 T C 6.83E-05 Suicide attempts in bipolar disorder / / 21423239 rs9357320 chr6 40196306 C T 8.68E-05 Suicide attempts in bipolar disorder / / 21423239 rs4714311 chr6 40196518 T C 7.82E-05 Suicide attempts in bipolar disorder / / 21423239 rs4714312 chr6 40196582 C T 6.51E-05 Suicide attempts in bipolar disorder / / 21423239 rs10807230 chr6 40198930 A C 6.88E-05 Suicide attempts in bipolar disorder / / 21423239 rs974476 chr6 40199229 C T 7.70E-05 Suicide attempts in bipolar disorder / / 21423239 rs972258 chr6 40200774 C T 6.77E-05 Suicide attempts in bipolar disorder / / 21423239 rs972259 chr6 40200846 C T 7.20E-05 Suicide attempts in bipolar disorder / / 21423239 rs9369183 chr6 40203437 T C 8.27E-05 Personality dimensions / / 18957941 rs9369183 chr6 40203437 T C 5.26E-05 Suicide attempts in bipolar disorder / / 21423239 rs1575764 chr6 40204713 A G 4.84E-05 Suicide attempts in bipolar disorder / / 21423239 rs1575765 chr6 40205890 G C 9.16E-05 Suicide attempts in bipolar disorder / / 21423239 rs2395733 chr6 40207231 G C 1.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs4377782 chr6 40210387 A T 2.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs6458144 chr6 40212623 C T 9.23E-04 Alzheimer's disease / / 24755620 rs6458146 chr6 40218128 C T 5.01E-05 Telomere length / / 21573004 rs10498746 chr6 40224268 T C 3.01E-04 Coronary Artery Disease / / 17634449 rs1077330 chr6 40225869 A G 3.39E-04 Alzheimer's disease / / 24755620 rs1325545 chr6 40232327 C T 2.31E-04 Alzheimer's disease / / 24755620 rs1325546 chr6 40232471 C T 2.19E-04 Alzheimer's disease / / 24755620 rs10947867 chr6 40237576 C T 7.04E-04 Multiple complex diseases / / 17554300 rs2038864 chr6 40269309 T A 6.37E-04 Multiple complex diseases / / 17554300 rs2038864 chr6 40269309 T A 1.15E-04 Diabetic nephropathy / / pha002866 rs7762056 chr6 40270047 C A 1.15E-04 Diabetic nephropathy / / pha002866 rs9349149 chr6 40280873 C T 1.15E-04 Diabetic nephropathy / / pha002866 rs13194396 chr6 40282507 T C 1.90E-05 Urinary metabolites / / 21572414 rs912821 chr6 40297847 C T 9.01E-05 Body mass index / / 17255346 rs10498748 chr6 40298297 C T 5.83E-04 Alzheimer's disease / / 17998437 rs2504824 chr6 40313456 A T 1.34E-04 Multiple complex diseases FLJ41649 intron 17554300 rs16868911 chr6 40317469 T C 1.29E-04 Multiple complex diseases FLJ41649 intron 17554300 rs2477757 chr6 40321778 T C 1.17E-04 Multiple complex diseases / / 17554300 rs4714336 chr6 40322250 C T 1.17E-04 Multiple complex diseases / / 17554300 rs7767512 chr6 40325586 T C 5.26E-04 Multiple complex diseases / / 17554300 rs2038868 chr6 40328378 A G 9.00E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs1575758 chr6 40338061 A C 4.84E-04 Multiple complex diseases / / 17554300 rs4145199 chr6 40351841 G A 9.06E-06 LDL lipoproteins / / pha002902 rs9462616 chr6 40356181 T G 9.23E-06 LDL lipoproteins / / pha002902 rs2436728 chr6 40365601 G A 4.17E-04 Type 2 diabetes LRFN2 intron 17463246 rs2436728 chr6 40365601 G A 3.20E-05 Alcoholism (heaviness of drinking) LRFN2 intron 21529783 rs2436728 chr6 40365601 G A 6.57E-05 Odorant perception LRFN2 intron 23910658 rs13196792 chr6 40392369 C T 1.62E-04 Multiple complex diseases LRFN2 intron 17554300 rs13196792 chr6 40392369 C T 5.90E-04 Primary sclerosing cholangitis LRFN2 intron 19944697 rs9394694 chr6 40406359 T C 8.75E-04 Suicide attempts in bipolar disorder LRFN2 intron 21423239 rs6910503 chr6 40407980 C T 9.61E-04 Multiple complex diseases LRFN2 intron 17554300 rs919875 chr6 40411700 A G 5.78E-04 Multiple complex diseases LRFN2 intron 17554300 rs17626141 chr6 40435536 A C 3.46E-04 Multiple complex diseases LRFN2 intron 17554300 rs9296335 chr6 40440500 G A 3.00E-06 Obesity-related traits LRFN2 intron 23251661 rs9296335 chr6 40440500 G A 8.00E-06 Obesity-related traits LRFN2 intron 23251661 rs4711637 chr6 40452054 G A 2.36E-04 Alzheimer's disease (late onset) LRFN2 intron 21379329 rs9357329 chr6 40453008 C T 7.60E-04 Multiple complex diseases LRFN2 intron 17554300 rs9349157 chr6 40472177 C T 2.30E-04 Primary sclerosing cholangitis LRFN2 intron 19944697 rs12663853 chr6 40477173 T G 3.86E-04 Alzheimer's disease LRFN2 intron 22005930 rs9462631 chr6 40479802 C T 3.36E-05 Acute lung injury LRFN2 intron 22295056 rs403319 chr6 40490906 A G 2.80E-04 Primary sclerosing cholangitis LRFN2 intron 19944697 rs382047 chr6 40491278 G A 1.18E-04 Acute lung injury LRFN2 intron 22295056 rs7356878 chr6 40494855 T G 1.80E-04 Vaspin levels LRFN2 intron 22907691 rs7356878 chr6 40494855 T G 0.0001796 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit LRFN2 intron 22907730 rs1433742 chr6 40503796 G T 1.81E-04 Vaspin levels LRFN2 intron 22907691 rs1433742 chr6 40503796 G T 0.0001812 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit LRFN2 intron 22907730 rs7775867 chr6 40522176 T C 1.02E-04 White matter integrity LRFN2 intron 22425255 rs2494938 chr6 40536128 G A 1.00E-12 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) LRFN2 intron 23103227 rs2494938 chr6 40536128 G A 2.00E-06 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) LRFN2 intron 23103227 rs2494938 chr6 40536128 G A 5.00E-09 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) LRFN2 intron 23103227 rs1340862 chr6 40561705 C T 7.59E-04 Alzheimer's disease / / 17998437 rs1771294 chr6 40587787 A G 8.17E-04 Alzheimer's disease / / 17998437 rs10498750 chr6 40616890 T C 4.67E-04 Type 2 diabetes / / 17463246 rs11752851 chr6 40622140 A G 2.91E-04 Type 2 diabetes / / 17463246 rs11967079 chr6 40626617 G A 2.94E-04 Taste perception / / 22132133 rs16893884 chr6 40635410 G A 2.91E-04 Type 2 diabetes / / 17463246 rs6901833 chr6 40637653 G A 8.81E-04 Suicide attempts in bipolar disorder / / 21041247 rs9380975 chr6 40640295 T C 7.73E-04 Type 2 diabetes / / 17463246 rs4714357 chr6 40641293 A G 6.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs4714358 chr6 40641396 C A 6.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs16893894 chr6 40641508 T C 6.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs4580847 chr6 40641633 G A 1.75E-05 Attention deficit hyperactivity disorder / / 23728934 rs7766099 chr6 40641973 C A 2.68E-04 Type 2 diabetes / / 17463246 rs10947907 chr6 40642643 T C 6.31E-04 Type 2 diabetes / / 17463246 rs11962303 chr6 40644284 C A 5.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs12660870 chr6 40644344 G T 7.05E-04 Type 2 diabetes / / 17463246 rs12660870 chr6 40644344 G T 2.56E-05 Attention deficit hyperactivity disorder / / 23728934 rs12662449 chr6 40644699 T C 4.00E-04 Type 2 diabetes / / 17463246 rs9394717 chr6 40645099 C G 7.62E-04 Type 2 diabetes / / 17463246 rs9394717 chr6 40645099 C G 2.01E-05 Attention deficit hyperactivity disorder / / 23728934 rs7759444 chr6 40646039 G A 4.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs9471398 chr6 40652255 A G 2.14E-05 Attention deficit hyperactivity disorder / / 23728934 rs9471400 chr6 40653510 G A 9.19E-04 Type 2 diabetes / / 17463246 rs9471400 chr6 40653510 G A 1.68E-05 Attention deficit hyperactivity disorder / / 23728934 rs9471401 chr6 40653779 T C 6.98E-04 Type 2 diabetes / / 17463246 rs9471401 chr6 40653779 T C 2.64E-05 Attention deficit hyperactivity disorder / / 23728934 rs9369223 chr6 40656746 A G 5.13E-04 Type 2 diabetes / / 17463246 rs9369223 chr6 40656746 A G 6.32E-05 Serum metabolites / / 19043545 rs9367072 chr6 40664388 C T 9.30E-04 Multiple complex diseases / / 17554300 rs6931798 chr6 40665415 C T 4.66E-05 Glioma / / 19578367 rs9369226 chr6 40670716 A G 4.08E-06 Glioma / / 19578367 rs9369226 chr6 40670716 A G 9.63E-05 Meningococcal disease / / 20694013 rs66563568 chr6 40688829 T G 0.00008887 Sarcoidosis / / 22952805 rs4541736 chr6 40689997 C A 7.73E-04 Schizophrenia / / 19197363 rs13209441 chr6 40713216 T G 2.82E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs9471419 chr6 40720703 T C 4.95E-04 Response to TNF antagonist treatment / / 21061259 rs9380991 chr6 40725975 C T 6.16E-05 Waist-Hip Ratio / / pha003013 rs9367077 chr6 40727512 G T 7.86E-05 Waist-Hip Ratio / / pha003013 rs16894035 chr6 40742985 A G 8.25E-04 Multiple complex diseases / / 17554300 rs16894035 chr6 40742985 A G 2.68E-04 Body mass index / / 21701565 rs16894035 chr6 40742985 A G 6.09E-04 Body mass index / / 21701565 rs4714381 chr6 40752126 C A 2.92E-04 Multiple complex diseases / / 17554300 rs9394732 chr6 40753185 A G 0.0001575 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9394732 chr6 40753185 A G 1.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9369235 chr6 40759957 G A 3.05E-05 Waist-Hip Ratio / / pha003013 rs9369236 chr6 40764060 T C 0.0002224 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9369236 chr6 40764060 T C 2.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4714387 chr6 40768517 T C 0.0002046 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4714387 chr6 40768517 T C 2.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs914513 chr6 40769212 G C 0.0002046 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs914513 chr6 40769212 G C 2.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9394734 chr6 40769901 G T 0.0002021 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9394734 chr6 40769901 G T 2.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11966183 chr6 40770955 T C 0.0001997 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11966183 chr6 40770955 T C 2.00E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9369238 chr6 40772971 C T 9.65E-06 Waist-Hip Ratio / / pha003013 rs9369238 chr6 40772971 C T 4.75E-05 Waist Circumference / / pha003025 rs9369238 chr6 40772971 C T 4.26E-05 Waist-Hip Ratio / / pha003028 rs9369238 chr6 40772971 C T 9.49E-05 Hemoglobin / / pha003096 rs9369238 chr6 40772971 C T 3.38E-05 Hematocrit / / pha003097 rs9367079 chr6 40776593 A G 8.93E-04 Schizophrenia / / 19197363 rs9367079 chr6 40776593 A G 1.31E-05 Erythrocyte counts / / pha003101 rs10738088 chr6 40787459 C T 2.90E-05 Urinary metabolites / / 21572414 rs6923463 chr6 40792491 T A 6.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs12193490 chr6 40799633 G A 7.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs9381001 chr6 40800494 A T 3.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs12664598 chr6 40801731 A G 5.29E-05 Cognitive test performance / / 20125193 rs12664598 chr6 40801731 A G 3.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs10484761 chr6 40802261 T C 7.00E-12 Esophageal cancer / / 21642993 rs9394737 chr6 40804862 A G 2.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs1929784 chr6 40808835 A C 2.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs6910188 chr6 40809806 A G 2.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs9369240 chr6 40810012 A G 5.29E-05 Cognitive test performance / / 20125193 rs9369240 chr6 40810012 A G 2.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs1929774 chr6 40810735 A G 1.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs1929774 chr6 40810735 A G 1.70E-05 Urinary metabolites / / 21572414 rs6901893 chr6 40811578 T C 5.81E-04 Rheumatoid arthritis / / 21452313 rs9369241 chr6 40816440 C T 2.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs7770499 chr6 40822140 T C 4.27E-04 Multiple complex diseases / / 17554300 rs9394740 chr6 40824416 G A 5.58E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9367085 chr6 40848013 G A 3.07E-05 Cognitive test performance / / 20125193 rs882922 chr6 40859320 C G 7.33E-04 Multiple complex diseases / / 17554300 rs9394745 chr6 40907124 T C 6.96E-04 Smoking quantity / / 24665060 rs1883595 chr6 40935728 G A 0.00000811 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment / / 23392654 rs1883595 chr6 40935728 G A 8.11E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs9381017 chr6 40949933 T C 2.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9471456 chr6 40952263 A G 9.56E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs9471456 chr6 40952263 A G 0.000659646 Hypertension (early onset hypertension) / / 22479346 rs714051 chr6 40963113 T C 2.60E-07 Urinary metabolites / / 21572414 rs9369250 chr6 40964595 T C 4.20E-07 Urinary metabolites / / 21572414 rs6458195 chr6 40972498 A T 3.70E-04 Type 2 diabetes / / 17463246 rs9381024 chr6 40984262 G T 0.00000625 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment / / 23392654 rs9381024 chr6 40984262 G T 6.25E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs742493 chr6 40998167 T C 5.69E-04 Fibrinogen UNC5CL missense 17255346 rs9394755 chr6 41006680 T C 0.00000252 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment UNC5CL intron 23392654 rs9394755 chr6 41006680 T C 2.52E-06 Thiazide-induced adverse metabolic effects in hypertensive patients UNC5CL intron 23400010 rs9369260 chr6 41010368 C G 0.00000713 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment TSPO2 UTR-5 23392654 rs9369260 chr6 41010368 C G 7.13E-06 Thiazide-induced adverse metabolic effects in hypertensive patients TSPO2 UTR-5 23400010 rs11963445 chr6 41013724 T G 5.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs6932226 chr6 41015088 T C 5.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs11963598 chr6 41017567 G A 5.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs1014737 chr6 41022717 T A 7.11E-04 Suicide attempts in bipolar disorder APOBEC2 intron 21423239 rs6938220 chr6 41032397 C T 7.97E-04 Suicide attempts in bipolar disorder APOBEC2 UTR-3 21423239 rs11280 chr6 41034858 T C 3.23E-05 Osteoarthritis (knee and hip) C6orf130 UTR-3 21177295 rs11280 chr6 41034858 T C 5.94E-05 Osteoarthritis (knee and hip) C6orf130 UTR-3 21177295 rs7775972 chr6 41038116 A C 8.74E-04 Acute lung injury C6orf130 intron 22295056 rs6921430 chr6 41047022 G A 9.20E-04 Suicide attempts in bipolar disorder NFYA intron 21423239 rs6912013 chr6 41061593 T C 2.97E-04 Multiple complex diseases NFYA intron 17554300 rs12189634 chr6 41068423 G T 4.41E-05 Schizophrenia NFYA UTR-3 24253340 rs6900025 chr6 41068789 C A 7.46E-04 Suicide attempts in bipolar disorder NFYA UTR-3 21423239 rs11964892 chr6 41079634 G A 6.14E-04 Suicide attempts in bipolar disorder LOC221442 intron 21423239 rs878998 chr6 41080001 C T 5.36E-04 Multiple complex diseases LOC221442 intron 17554300 rs878998 chr6 41080001 C T 5.62E-04 Suicide attempts in bipolar disorder LOC221442 intron 21423239 rs10456499 chr6 41083352 G A 1.80E-05 Type 2 diabetes LOC221442 intron 17460697 rs11968153 chr6 41089310 G A 4.36E-04 Suicide attempts in bipolar disorder LOC221442 intron 21423239 rs6905117 chr6 41090249 T C 8.52E-04 Suicide attempts in bipolar disorder LOC221442 intron 21423239 rs6926079 chr6 41090682 C T 1.66E-04 Suicide attempts in bipolar disorder LOC221442 intron 21423239 rs11969526 chr6 41091307 C A 3.64E-04 Suicide attempts in bipolar disorder LOC221442 intron 21423239 rs2234255 chr6 41127543 G A 5.09E-04 Smoking initiation TREM2 missense 24665060 rs7748513 chr6 41127972 A G 1.00E-10 C-reactive protein TREM2 intron 22939635 rs75932628 chr6 41129252 C T 2.00E-12 Alzheimer's disease TREM2 missense 23150908 rs9381040 chr6 41154650 C T 6.00E-07 Alzheimer's disease (late onset) / / 24162737 rs2093395 chr6 41155026 G C 9.59E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs3747742 chr6 41162518 T C 5.53E-05 Lymphocyte counts TREML2 missense 22286170 rs1968871 chr6 41185430 T C 6.00E-05 Ankylosing spondylitis / / 20062062 rs9296359 chr6 41205690 G A 6.12E-05 Serum metabolites TREML4 UTR-3 19043545 rs4714443 chr6 41220384 G A 8.52E-04 Alzheimer's disease / / 22005930 rs16894387 chr6 41240171 A C 4.73E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs6910730 chr6 41246633 A G 8.22E-04 HIV-1 viral setpoint TREM1 intron 17641165 rs6910730 chr6 41246633 A G 3.26E-04 Iron levels TREM1 intron pha002876 rs3789204 chr6 41254741 G T 5.50E-04 Systemic lupus erythematosus TREM1 nearGene-5 24871463 rs9357353 chr6 41277855 T C 1.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs612399 chr6 41287803 T C 2.10E-04 Insulin response / / 19430760 rs6458214 chr6 41289493 T G 9.10E-04 Lymphocyte counts / / 22286170 rs7772334 chr6 41289850 T G 5.70E-04 Insulin response / / 19430760 rs9471555 chr6 41290769 T C 3.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs9471555 chr6 41290769 T C 3.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs9462696 chr6 41291124 T A 3.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs9462696 chr6 41291124 T A 3.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs9471557 chr6 41291779 C T 4.70E-04 Suicide attempts in bipolar disorder / / 21041247 rs9471557 chr6 41291779 C T 6.14E-05 Suicide attempts in bipolar disorder / / 21041247 rs9471560 chr6 41292008 G A 4.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs9471560 chr6 41292008 G A 6.14E-05 Suicide attempts in bipolar disorder / / 21041247 rs12198812 chr6 41293326 T C 4.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs12198812 chr6 41293326 T C 6.16E-05 Suicide attempts in bipolar disorder / / 21041247 rs9462699 chr6 41294063 A G 4.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs9462699 chr6 41294063 A G 6.18E-05 Suicide attempts in bipolar disorder / / 21041247 rs13219519 chr6 41294915 T A 4.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs13219519 chr6 41294915 T A 6.22E-05 Suicide attempts in bipolar disorder / / 21041247 rs13203392 chr6 41294946 C T 4.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs13203392 chr6 41294946 C T 6.23E-05 Suicide attempts in bipolar disorder / / 21041247 rs2395773 chr6 41295612 C T 4.06E-04 Suicide attempts in bipolar disorder / / 21041247 rs2395773 chr6 41295612 C T 6.24E-05 Suicide attempts in bipolar disorder / / 21041247 rs2395774 chr6 41295625 A G 4.06E-04 Suicide attempts in bipolar disorder / / 21041247 rs2395774 chr6 41295625 A G 6.27E-05 Suicide attempts in bipolar disorder / / 21041247 rs4605877 chr6 41295778 T G 4.13E-04 Suicide attempts in bipolar disorder / / 21041247 rs4605877 chr6 41295778 T G 6.27E-05 Suicide attempts in bipolar disorder / / 21041247 rs9471566 chr6 41296090 C A 2.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs9471568 chr6 41296381 C T 4.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs9471568 chr6 41296381 C T 6.31E-05 Suicide attempts in bipolar disorder / / 21041247 rs13208294 chr6 41296452 A G 4.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs13208294 chr6 41296452 A G 6.32E-05 Suicide attempts in bipolar disorder / / 21041247 rs13208406 chr6 41296510 A C 4.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs13208406 chr6 41296510 A C 6.35E-05 Suicide attempts in bipolar disorder / / 21041247 rs12525710 chr6 41296679 C T 4.37E-04 Suicide attempts in bipolar disorder / / 21041247 rs12525710 chr6 41296679 C T 6.35E-05 Suicide attempts in bipolar disorder / / 21041247 rs9471573 chr6 41297383 G A 1.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs9471573 chr6 41297383 G A 6.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs1905568 chr6 41297947 C T 5.20E-04 Suicide attempts in bipolar disorder / / 21041247 rs1905568 chr6 41297947 C T 6.76E-05 Suicide attempts in bipolar disorder / / 21041247 rs2395775 chr6 41298015 C G 4.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs2395775 chr6 41298015 C G 6.99E-05 Suicide attempts in bipolar disorder / / 21041247 rs7771870 chr6 41298764 A T 5.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs7771870 chr6 41298764 A T 7.74E-05 Suicide attempts in bipolar disorder / / 21041247 rs9471576 chr6 41303805 G A 2.00E-06 Total ventricular volume NCR2 intron 21116278 rs6939396 chr6 41305075 T C 1.57E-05 Bipolar disorder NCR2 intron 17486107 rs6939396 chr6 41305075 T C 1.65E-06 Total ventricular volume NCR2 intron 21116278 rs10947963 chr6 41305976 G A 1.13E-04 Celiac disease NCR2 intron 23936387 rs6929418 chr6 41307594 A G 3.15E-04 Alcohol dependence NCR2 intron 21314694 rs6922617 chr6 41336101 G A 4.00E-08 Alzheimer's disease biomarkers / / 23562540 rs6922692 chr6 41336319 C G 2.42E-04 Type 2 diabetes / / 17463246 rs11966476 chr6 41340572 G A 1.59E-05 Alzheimer's disease biomarkers / / 23562540 rs11966476 chr6 41340572 G A 4.97E-08 Alzheimer's disease biomarkers / / 23562540 rs584301 chr6 41351077 A G 2.18E-04 Type 2 diabetes / / 17463246 rs4141938 chr6 41356635 A G 5.94E-05 Coronary heart disease / / pha003030 rs4141938 chr6 41356635 A G 1.31E-05 Coronary heart disease / / pha003031 rs4141938 chr6 41356635 A G 7.08E-05 Heart Rate / / pha003051 rs640399 chr6 41361012 G A 2.55E-04 Type 2 diabetes / / 17463246 rs640399 chr6 41361012 G A 5.56E-04 Major depressive disorder / / 22472876 rs13194139 chr6 41370497 C T 6.21E-04 Type 2 diabetes / / 17463246 rs17538671 chr6 41371118 C T 2.70E-05 Parkinson's disease (familial) / / 18985386 rs7762544 chr6 41379315 G A 8.00E-08 Periodontitis / / 23459936 rs596917 chr6 41388344 G T 3.45E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs596917 chr6 41388344 G T 6.44E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs814836 chr6 41389328 G A 0.0002 Migraine / / 22678113 rs9369279 chr6 41404666 G A 6.70E-06 Urinary metabolites / / 21572414 rs912881 chr6 41415737 C A 5.07E-04 Smoking initiation / / 24665060 rs2477829 chr6 41430550 T G 3.48E-04 Body mass index / / 21701565 rs2477829 chr6 41430550 T G 3.53E-04 Body mass index / / 21701565 rs9471595 chr6 41430572 C T 3.21E-04 Multiple complex diseases / / 17554300 rs7762551 chr6 41437259 C T 1.24E-04 Blood pressure / / 17255346 rs4714468 chr6 41452996 G A 7.00E-04 Chronic fatigue syndrome / / 21912186 rs4711676 chr6 41461395 T C 1.07E-04 Multiple complex diseases / / 17554300 rs2477839 chr6 41485594 C T 9.31E-04 Multiple complex diseases / / 17554300 rs2477842 chr6 41489441 C T 7.60E-06 Lung adenocarcinoma / / 22797724 rs2477842 chr6 41489441 C T 2.49E-04 Stroke / / pha002886 rs41435745 chr6 41490382 G C 9.40E-04 Multiple complex diseases / / 17554300 rs2495239 chr6 41490488 A G 5.40E-07 Lung adenocarcinoma / / 22797724 rs1983891 chr6 41536427 C T 1.74E-04 Multiple complex diseases FOXP4 intron 17554300 rs1983891 chr6 41536427 C T 8.00E-08 Prostate cancer FOXP4 intron 20676098 rs1983891 chr6 41536427 C T 0.00033 Prostate cancer FOXP4 intron 23555315 rs1983891 chr6 41536427 C T 0.00053 Prostate cancer (non-advanced prostate cancer) FOXP4 intron 23555315 rs16894837 chr6 41574164 A G 6.40E-06 Urinary metabolites / / 21572414 rs2765943 chr6 41582464 G A 8.00E-06 Urinary metabolites / / 21572414 rs2143678 chr6 41623033 G T 4.00E-07 Cardiovascular disease risk factors / / 21779381 rs2746183 chr6 41625429 A C 5.50E-04 Alcohol dependence / / 20201924 rs2746183 chr6 41625429 A C 8.60E-04 Alcohol dependence / / 20201924 rs2746182 chr6 41626625 T C 1.23E-04 Multiple complex diseases / / 17554300 rs1474761 chr6 41627063 G A 3.21E-04 Body mass index / / 21701565 rs2746178 chr6 41639294 G C 1.80E-05 Alcohol consumption / / 23743675 rs2746177 chr6 41639575 G A 1.80E-05 Alcohol consumption / / 23743675 rs1883816 chr6 41644441 C T 4.18E-04 Myopia (pathological) / / 21095009 rs9462735 chr6 41646839 C T 4.87E-07 Red blood cell traits / / 23222517 rs2842643 chr6 41650736 C T 3.00E-06 Attention deficit hyperactivity disorder / / 18839057 rs2842643 chr6 41650736 C T 2.00E-07 Red blood cell traits / / 23222517 rs1015149 chr6 41658889 C T 1.16E-09 Red blood cell traits TFEB cds-synon 23222517 rs1015150 chr6 41659304 C T 2.96E-08 Red blood cell traits TFEB intron 23222517 rs7761800 chr6 41662843 G C 7.99E-08 Red blood cell traits TFEB intron 23222517 rs7775136 chr6 41662890 C G 1.59E-09 Red blood cell traits TFEB intron 23222517 rs4541741 chr6 41664032 C A 1.68E-09 Red blood cell traits TFEB intron 23222517 rs9462738 chr6 41664501 G T 3.18E-09 Red blood cell traits TFEB intron 23222517 rs9349200 chr6 41684390 A G 5.76E-13 Other erythrocyte phenotypes TFEB intron 19862010 rs9349200 chr6 41684390 A G 6.18E-11 Red blood cell traits TFEB intron 23222517 rs9349200 chr6 41684390 A G 3.70E-05 Coronary heart disease TFEB intron pha003056 rs4711689 chr6 41692812 G A 8.10E-04 Bipolar disorder,schizoaffective TFEB intron 19567891 rs4711689 chr6 41692812 G A 1.37E-05 Body mass index TFEB intron 21701565 rs4711689 chr6 41692812 G A 3.82E-05 Body mass index TFEB intron 21701565 rs1858584 chr6 41694772 C T 5.23E-05 Cardiovascular disease TFEB intron pha003065 rs6907935 chr6 41717855 C T 4.27E-08 Red blood cell traits / / 23222517 rs6912200 chr6 41717908 C T 7.24E-09 Red blood cell traits / / 23222517 rs9471643 chr6 41718915 G C 2.91E-08 Other erythrocyte phenotypes / / 19862010 rs9471643 chr6 41718915 G C 5.54E-08 Red blood cell traits / / 23222517 rs2395788 chr6 41726339 G A 4.34E-15 Other erythrocyte phenotypes / / 19862010 rs2395788 chr6 41726339 G A 2.95E-15 Red blood cell traits / / 23222517 rs12661968 chr6 41729406 T C 4.28E-19 Other erythrocyte phenotypes / / 19862010 rs12661968 chr6 41729406 T C 7.13E-16 Red blood cell traits / / 23222517 rs13197439 chr6 41735468 C T 8.68E-09 Other erythrocyte phenotypes / / 19862010 rs13197439 chr6 41735468 C T 1.93E-09 Red blood cell traits / / 23222517 rs11962743 chr6 41736456 C G 6.19E-20 Other erythrocyte phenotypes / / 19862010 rs11962743 chr6 41736456 C G 3.50E-16 Red blood cell traits / / 23222517 rs3761781 chr6 41744948 G A 6.82E-21 Other erythrocyte phenotypes FRS3 intron 19862010 rs3761781 chr6 41744948 G A 1.14E-23 Red blood cell traits FRS3 intron 23222517 rs3804281 chr6 41745989 A G 5.02E-09 Red blood cell traits FRS3 intron 23222517 rs13193974 chr6 41749896 T C 3.08E-07 Red blood cell traits PRICKLE4 intron 23222517 rs6905726 chr6 41750812 T C 3.74E-11 Other erythrocyte phenotypes PRICKLE4 intron 19862010 rs6905726 chr6 41750812 T C 2.46E-10 Red blood cell traits PRICKLE4 intron 23222517 rs6925777 chr6 41750822 C T 4.56E-11 Other erythrocyte phenotypes PRICKLE4 intron 19862010 rs6925777 chr6 41750822 C T 2.75E-09 Red blood cell traits PRICKLE4 intron 23222517 rs9394831 chr6 41753084 C T 1.06E-17 Other erythrocyte phenotypes PRICKLE4 cds-synon 19862010 rs9394831 chr6 41753084 C T 4.35E-16 Red blood cell traits PRICKLE4 cds-synon 23222517 rs8393 chr6 41757836 C A 4.20E-11 Other erythrocyte phenotypes / / 19862010 rs8393 chr6 41757836 C A 1.34E-10 Red blood cell traits / / 23222517 rs3747751 chr6 41758583 G A 3.59E-05 Intracerebral hemorrhage / / 24656865 rs3747750 chr6 41760372 C G 3.83E-20 Other erythrocyte phenotypes / / 19862010 rs3747750 chr6 41760372 C G 8.78E-22 Red blood cell traits / / 23222517 rs2282444 chr6 41762808 C G 8.39E-08 Red blood cell traits / / 23222517 rs6902650 chr6 41764080 G A 3.45E-11 Other erythrocyte phenotypes / / 19862010 rs6902650 chr6 41764080 G A 9.21E-09 Red blood cell traits / / 23222517 rs1891453 chr6 41765265 T C 3.89E-20 Other erythrocyte phenotypes / / 19862010 rs1891453 chr6 41765265 T C 3.66E-22 Red blood cell traits / / 23222517 rs10498752 chr6 41768510 T C 4.82E-11 Other erythrocyte phenotypes USP49 intron 19862010 rs10498752 chr6 41768510 T C 8.42E-09 Red blood cell traits USP49 intron 23222517 rs9367112 chr6 41769920 T C 3.89E-20 Other erythrocyte phenotypes USP49 intron 19862010 rs9367112 chr6 41769920 T C 1.18E-21 Red blood cell traits USP49 intron 23222517 rs3747749 chr6 41770604 G A 3.83E-20 Other erythrocyte phenotypes USP49 intron 19862010 rs3747749 chr6 41770604 G A 1.18E-21 Red blood cell traits USP49 intron 23222517 rs2153878 chr6 41773322 G A 4.69E-16 Other erythrocyte phenotypes USP49 intron 19862010 rs2153878 chr6 41773322 G A 3.33E-24 Red blood cell traits USP49 intron 23222517 rs2185798 chr6 41773576 G C 3.98E-11 Other erythrocyte phenotypes / / 19862010 rs2185798 chr6 41773576 G C 5.45E-07 Red blood cell traits / / 23222517 rs6926173 chr6 41773735 G A 8.03E-08 Red blood cell traits USP49 cds-synon 23222517 rs7753507 chr6 41784094 C T 2.92E-08 Other erythrocyte phenotypes USP49 intron 19862010 rs7753507 chr6 41784094 C T 0.00000002 Mean corpuscular volume USP49 intron 22560525 rs7753507 chr6 41784094 C T 1.65E-08 Red blood cell traits USP49 intron 23222517 rs9357366 chr6 41786976 T G 3.04E-20 Other erythrocyte phenotypes USP49 intron 19862010 rs9357366 chr6 41786976 T G 1.09E-21 Red blood cell traits USP49 intron 23222517 rs9394833 chr6 41787740 C A 7.34E-07 Red blood cell traits USP49 intron 23222517 rs11753329 chr6 41788380 T G 5.01E-22 Other erythrocyte phenotypes USP49 intron 19862010 rs11753329 chr6 41788380 T G 1.19E-26 Red blood cell traits USP49 intron 23222517 rs12661667 chr6 41792545 C T 1.54E-15 Other erythrocyte phenotypes USP49 intron 19862010 rs12661667 chr6 41792545 C T 0.000000003 Mean corpuscular hemoglobin USP49 intron 22560525 rs12661667 chr6 41792545 C T 4.00E-14 Mean corpuscular volume USP49 intron 22560525 rs12661667 chr6 41792545 C T 1.23E-23 Red blood cell traits USP49 intron 23222517 rs12661667 chr6 41792545 C T 7.87E-04 Stroke USP49 intron pha002887 rs4714516 chr6 41796817 A G 1.69E-04 Lymphocyte counts USP49 intron 22286170 rs4714516 chr6 41796817 A G 6.74E-08 Red blood cell traits USP49 intron 23222517 rs6899876 chr6 41796970 T C 9.77E-21 Other erythrocyte phenotypes USP49 intron 19862010 rs6899876 chr6 41796970 T C 3.00E-12 Mean corpuscular volume USP49 intron 22560525 rs6899876 chr6 41796970 T C 1.30E-21 Red blood cell traits USP49 intron 23222517 rs11756454 chr6 41798578 T A 4.72E-09 Other erythrocyte phenotypes USP49 intron 19862010 rs9381094 chr6 41800629 T C 2.55E-22 Other erythrocyte phenotypes USP49 intron 19862010 rs9381094 chr6 41800629 T C 8.28E-24 Red blood cell traits USP49 intron 23222517 rs9394834 chr6 41806793 G A 2.53E-22 Other erythrocyte phenotypes USP49 intron 19862010 rs9394834 chr6 41806793 G A 9.40E-24 Red blood cell traits USP49 intron 23222517 rs2488338 chr6 41808351 A G 2.91E-12 Other erythrocyte phenotypes USP49 intron 19862010 rs2488338 chr6 41808351 A G 2.17E-09 Red blood cell traits USP49 intron 23222517 rs2249703 chr6 41814760 A G 1.70E-08 Other erythrocyte phenotypes USP49 intron 19862010 rs2249703 chr6 41814760 A G 3.40E-08 Red blood cell traits USP49 intron 23222517 rs9381096 chr6 41821137 G A 3.32E-20 Other erythrocyte phenotypes USP49 intron 19862010 rs9381096 chr6 41821137 G A 6.19E-19 Red blood cell traits USP49 intron 23222517 rs6901756 chr6 41825590 T C 5.94E-10 Red blood cell traits USP49 intron 23222517 rs2253961 chr6 41827011 A G 5.75E-09 Other erythrocyte phenotypes USP49 intron 19862010 rs2253961 chr6 41827011 A G 3.94E-10 Red blood cell traits USP49 intron 23222517 rs2025951 chr6 41827193 A G 8.43E-04 Type 2 diabetes USP49 intron 17463246 rs2025951 chr6 41827193 A G 2.69E-12 Other erythrocyte phenotypes USP49 intron 19862010 rs2025951 chr6 41827193 A G 3.63E-07 Red blood cell traits USP49 intron 23222517 rs2254479 chr6 41831143 G A 6.25E-10 Other erythrocyte phenotypes USP49 intron 19862010 rs2251084 chr6 41838119 T C 2.32E-12 Other erythrocyte phenotypes USP49 intron 19862010 rs2251084 chr6 41838119 T C 2.94E-09 Red blood cell traits USP49 intron 23222517 rs9369312 chr6 41841535 A T 2.13E-22 Other erythrocyte phenotypes USP49 intron 19862010 rs9369312 chr6 41841535 A T 1.88E-23 Red blood cell traits USP49 intron 23222517 rs2254474 chr6 41843044 T G 2.33E-12 Other erythrocyte phenotypes USP49 intron 19862010 rs2254474 chr6 41843044 T G 5.72E-09 Red blood cell traits USP49 intron 23222517 rs2254805 chr6 41846110 T G 2.27E-12 Other erythrocyte phenotypes USP49 intron 19862010 rs2254805 chr6 41846110 T G 5.74E-09 Red blood cell traits USP49 intron 23222517 rs9381097 chr6 41847800 G A 2.19E-22 Other erythrocyte phenotypes USP49 intron 19862010 rs9381097 chr6 41847800 G A 1.26E-23 Red blood cell traits USP49 intron 23222517 rs1536703 chr6 41852755 G A 7.34E-10 Other erythrocyte phenotypes USP49 intron 19862010 rs1887718 chr6 41857691 C T 2.96E-12 Other erythrocyte phenotypes USP49 intron 19862010 rs1887718 chr6 41857691 C T 1.75E-07 Red blood cell traits USP49 intron 23222517 rs1536701 chr6 41869924 G A 9.28E-04 Nicotine dependence / / 17158188 rs1536701 chr6 41869924 G A 7.98E-08 Red blood cell traits / / 23222517 rs6899659 chr6 41870957 C A 7.72E-08 Red blood cell traits / / 23222517 rs3806113 chr6 41876335 C T 2.82E-05 Hirschsprung's disease MED20 intron 19196962 rs3806113 chr6 41876335 C T 4.31E-16 Other erythrocyte phenotypes MED20 intron 19862010 rs3806113 chr6 41876335 C T 1.00E-14 Mean corpuscular volume MED20 intron 22560525 rs3806113 chr6 41876335 C T 8.00E-10 Mean corpuscular hemoglobin MED20 intron 22560525 rs3806113 chr6 41876335 C T 5.43E-21 Red blood cell traits MED20 intron 23222517 rs7746198 chr6 41881073 T C 4.90E-05 Intracerebral hemorrhage MED20 intron 24656865 rs11969866 chr6 41882123 C T 4.69E-15 Other erythrocyte phenotypes MED20 intron 19862010 rs11969866 chr6 41882123 C T 2.11E-20 Red blood cell traits MED20 intron 23222517 rs9357371 chr6 41885319 A C 4.76E-16 Other erythrocyte phenotypes MED20 intron 19862010 rs9357371 chr6 41885319 A C 0.000000002 Mean corpuscular hemoglobin MED20 intron 22560525 rs9357371 chr6 41885319 A C 3.00E-14 Mean corpuscular volume MED20 intron 22560525 rs9357371 chr6 41885319 A C 9.06E-22 Red blood cell traits MED20 intron 23222517 rs9357371 chr6 41885319 A C 4.23E-05 Waist-Hip Ratio MED20 intron pha003029 rs2274578 chr6 41888827 C G 2.92E-12 Other erythrocyte phenotypes MED20 UTR-5 19862010 rs2479724 chr6 41890982 T C 2.31E-10 Other erythrocyte phenotypes BYSL intron 19862010 rs10947996 chr6 41892809 G T 3.11E-09 Red blood cell traits BYSL intron 23222517 rs12661819 chr6 41898564 C T 4.10E-08 Red blood cell traits BYSL intron 23222517 rs3218108 chr6 41902655 C T 1.46E-22 Other erythrocyte phenotypes / / 19862010 rs3218108 chr6 41902655 C T 2.98E-23 Red blood cell traits / / 23222517 rs1051130 chr6 41903782 A C,G,T 1.70E-09 Other erythrocyte phenotypes CCND3 missense 19862010 rs3218097 chr6 41905275 G A 7.97E-17 Other erythrocyte phenotypes CCND3 intron 19862010 rs3218097 chr6 41905275 G A 1.09E-10 Blood cell counts and other traits CCND3 intron 20139978 rs3218097 chr6 41905275 G A 1.80E-20 Blood cell counts and other traits CCND3 intron 20139978 rs3218097 chr6 41905275 G A 2.00E-20 Blood cell counts and other traits CCND3 intron 20139978 rs3218097 chr6 41905275 G A 3.62E-27 Blood cell counts and other traits CCND3 intron 20139978 rs3218097 chr6 41905275 G A 1.00E-18 Mean corpuscular volume CCND3 intron 22560525 rs3218097 chr6 41905275 G A 6.00E-12 Mean corpuscular hemoglobin CCND3 intron 22560525 rs3218097 chr6 41905275 G A 3.66E-23 Red blood cell traits CCND3 intron 23222517 rs3218097 chr6 41905275 G A 9.00E-08 Mean corpuscular volume CCND3 intron 23263863 rs3218097 chr6 41905275 G A 6.69E-05 Waist-Hip Ratio CCND3 intron pha003029 rs3218086 chr6 41910064 C T 8.66E-24 Other erythrocyte phenotypes CCND3 intron 19862010 rs3218086 chr6 41910064 C T 9.80E-28 Red blood cell traits CCND3 intron 23222517 rs9381100 chr6 41911185 A G 5.50E-10 Red blood cell traits CCND3 intron 23222517 rs4714520 chr6 41913778 G A 3.95E-13 Red blood cell traits CCND3 intron 23222517 rs9349204 chr6 41914378 A G 7.76E-22 Other erythrocyte phenotypes CCND3 intron 19862010 rs9349204 chr6 41914378 A G 2.00E-40 Red blood cell traits CCND3 intron 23222517 rs6934551 chr6 41915519 G A 6.25E-07 Red blood cell traits CCND3 intron 23222517 rs2479720 chr6 41915704 G C 1.07E-07 Red blood cell traits CCND3 intron 23222517 rs7766960 chr6 41918190 T G 1.43E-09 Other erythrocyte phenotypes CCND3 intron 19862010 rs10947997 chr6 41921241 G T 9.27E-19 Other erythrocyte phenotypes CCND3 intron 19862010 rs10947997 chr6 41921241 G T 0.00000002 Mean corpuscular volume CCND3 intron 22560525 rs10947997 chr6 41921241 G T 2.11E-24 Red blood cell traits CCND3 intron 23222517 rs10947997 chr6 41921241 G T 3.78E-05 Platelet counts CCND3 intron 23263863 rs16895128 chr6 41924369 G A 6.00E-24 Other erythrocyte phenotypes CCND3 intron 19862010 rs16895128 chr6 41924369 G A 1.60E-31 Red blood cell traits CCND3 intron 23222517 rs4623235 chr6 41924853 G A 2.74E-07 Red blood cell traits CCND3 intron 23222517 rs4623235 chr6 41924853 G A 2.78E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CCND3 intron 24023788 rs16895130 chr6 41924931 A G 6.31E-07 Red blood cell traits CCND3 intron 23222517 rs9349205 chr6 41925159 G A 1.00E-31 Mean corpuscular volume CCND3 intron 19862010 rs9349205 chr6 41925159 G A 8.00E-20 Mean corpuscular hemoglobin CCND3 intron 19862010 rs9349205 chr6 41925159 G A 2.07E-21 Blood cell counts and other traits CCND3 intron 20139978 rs9349205 chr6 41925159 G A 6.28E-29 Blood cell counts and other traits CCND3 intron 20139978 rs9349205 chr6 41925159 G A 1.02E-21 Red blood cell traits CCND3 intron 23222517 rs11970772 chr6 41925290 T A 7.00E-19 Hematological parameters CCND3 intron 19820697 rs11970772 chr6 41925290 T A 7.96E-23 Other erythrocyte phenotypes CCND3 intron 19862010 rs11970772 chr6 41925290 T A 1.51E-15 Blood cell counts and other traits CCND3 intron 20139978 rs11970772 chr6 41925290 T A 1.21E-32 Red blood cell traits CCND3 intron 23222517 rs11968166 chr6 41925304 G A 4.94E-24 Other erythrocyte phenotypes CCND3 intron 19862010 rs11968166 chr6 41925304 G A 8.00E-06 Neutrophil count CCND3 intron 21507922 rs11968166 chr6 41925304 G A 9.35E-34 Red blood cell traits CCND3 intron 23222517 rs4478405 chr6 41927813 T C 9.89E-18 Other erythrocyte phenotypes CCND3 intron 19862010 rs4478405 chr6 41927813 T C 2.24E-24 Red blood cell traits CCND3 intron 23222517 rs9349206 chr6 41928382 C A 1.19E-09 Red blood cell traits CCND3 intron 23222517 rs9381101 chr6 41928548 C G 9.11E-10 Red blood cell traits CCND3 intron 23222517 rs9381102 chr6 41929356 A G 1.10E-09 Red blood cell traits CCND3 intron 23222517 rs7745210 chr6 41930294 G A 3.82E-10 Red blood cell traits CCND3 intron 23222517 rs9349208 chr6 41933482 C T 2.22E-09 Red blood cell traits CCND3 intron 23222517 rs9357372 chr6 41933554 G A 5.14E-08 Red blood cell traits CCND3 intron 23222517 rs4607432 chr6 41934647 A C 2.11E-08 Red blood cell traits CCND3 intron 23222517 rs6920885 chr6 41941169 T C 6.36E-10 Other erythrocyte phenotypes CCND3 intron 19862010 rs6920885 chr6 41941169 T C 7.34E-09 Red blood cell traits CCND3 intron 23222517 rs4415146 chr6 41941980 A C 3.19E-04 Type 2 diabetes CCND3 intron 17463246 rs4415146 chr6 41941980 A C 7.04E-09 Red blood cell traits CCND3 intron 23222517 rs9394842 chr6 41943290 G C 6.69E-10 Red blood cell traits CCND3 intron 23222517 rs9357377 chr6 41962671 G A 5.00E-06 Metabolite levels (5-HIAA/ MHPG Ratio) CCND3 intron 23319000 rs11756584 chr6 41977937 G A 1.27E-11 Red blood cell traits CCND3 intron 23222517 rs4445045 chr6 41978412 C T 3.88E-09 Other erythrocyte phenotypes CCND3 intron 19862010 rs4445045 chr6 41978412 C T 4.80E-12 Red blood cell traits CCND3 intron 23222517 rs6921368 chr6 41980666 C A 9.49E-13 Red blood cell traits CCND3 intron 23222517 rs6922061 chr6 41980871 G A 3.62E-15 Red blood cell traits CCND3 intron 23222517 rs9349211 chr6 41981077 A G 1.77E-16 Red blood cell traits CCND3 intron 23222517 rs9349212 chr6 41981392 A G 9.81E-16 Red blood cell traits CCND3 intron 23222517 rs6906330 chr6 41982957 C A 9.08E-17 Other erythrocyte phenotypes CCND3 intron 19862010 rs6906330 chr6 41982957 C A 2.07E-21 Red blood cell traits CCND3 intron 23222517 rs7770391 chr6 41993167 G T 1.27E-09 Red blood cell traits CCND3 intron 23222517 rs4714556 chr6 41993229 A G 2.01E-12 Red blood cell traits CCND3 intron 23222517 rs12214723 chr6 41993688 G A 5.87E-09 Red blood cell traits CCND3 intron 23222517 rs7753265 chr6 41993861 T C 6.60E-11 Red blood cell traits CCND3 intron 23222517 rs9369325 chr6 41995297 T C 1.47E-17 Other erythrocyte phenotypes CCND3 intron 19862010 rs9369325 chr6 41995297 T C 2.53E-11 Red blood cell traits CCND3 intron 23222517 rs9381120 chr6 41996607 T A 1.73E-12 Other erythrocyte phenotypes CCND3 intron 19862010 rs9381120 chr6 41996607 T A 1.63E-15 Red blood cell traits CCND3 intron 23222517 rs9367126 chr6 41997698 T C 1.34E-12 Other erythrocyte phenotypes CCND3 intron 19862010 rs9367126 chr6 41997698 T C 2.09E-09 Red blood cell traits CCND3 intron 23222517 rs9357384 chr6 41997926 G A 1.80E-10 Other erythrocyte phenotypes CCND3 intron 19862010 rs9357384 chr6 41997926 G A 6.88E-15 Red blood cell traits CCND3 intron 23222517 rs4711703 chr6 41999125 A C 2.41E-05 Body Mass Index CCND3 intron pha003015 rs4711703 chr6 41999125 A C 3.99E-07 Body Fat Distribution CCND3 intron pha003016 rs4711703 chr6 41999125 A C 4.28E-07 Body Fat Distribution CCND3 intron pha003017 rs4711703 chr6 41999125 A C 6.93E-07 Body Fat Distribution CCND3 intron pha003018 rs4711703 chr6 41999125 A C 4.70E-05 Waist Circumference CCND3 intron pha003024 rs4711703 chr6 41999125 A C 6.93E-06 Waist Circumference CCND3 intron pha003025 rs4711703 chr6 41999125 A C 6.27E-05 Weight CCND3 intron pha003027 rs13194688 chr6 42002867 A G 6.25E-05 Body Mass Index CCND3 intron pha003015 rs13194688 chr6 42002867 A G 3.52E-06 Body Fat Distribution CCND3 intron pha003016 rs13194688 chr6 42002867 A G 3.05E-06 Body Fat Distribution CCND3 intron pha003017 rs13194688 chr6 42002867 A G 8.53E-06 Body Fat Distribution CCND3 intron pha003018 rs13194688 chr6 42002867 A G 9.87E-05 Body Mass Index CCND3 intron pha003022 rs13194688 chr6 42002867 A G 7.59E-05 Waist Circumference CCND3 intron pha003025 rs13194688 chr6 42002867 A G 7.99E-05 Weight CCND3 intron pha003027 rs10948007 chr6 42003084 C T 3.34E-06 Body Mass Index CCND3 intron pha003006 rs10948007 chr6 42003084 C T 7.39E-05 Waist Circumference CCND3 intron pha003024 rs10948007 chr6 42003084 C T 6.22E-05 Weight CCND3 intron pha003026 rs4554318 chr6 42012159 C T 1.70E-10 Other erythrocyte phenotypes CCND3 intron 19862010 rs4554318 chr6 42012159 C T 4.51E-09 Red blood cell traits CCND3 intron 23222517 rs12208813 chr6 42025318 G A 7.37E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) TAF8 intron 23648065 rs2492943 chr6 42033440 C T 4.66E-07 Red blood cell traits TAF8 intron 23222517 rs12194513 chr6 42037167 C T 7.37E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) TAF8 intron 23648065 rs7763360 chr6 42039572 A G 2.21E-05 Nephrolithiasis TAF8 intron 22396660 rs2492937 chr6 42054346 G A 6.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7764771 chr6 42057325 A G 8.04E-06 Multiple complex diseases / / 17554300 rs7749023 chr6 42061733 A C 2.58E-04 Acute lung injury / / 22295056 rs10456507 chr6 42084146 C A 4.65E-04 Multiple complex diseases C6orf132 intron 17554300 rs13203733 chr6 42134409 T C 9.61E-05 Smoking quantity GUCA1A intron 24665060 rs12201777 chr6 42134517 A G 1.11E-04 Smoking quantity GUCA1A intron 24665060 rs9471799 chr6 42153609 C T 3.80E-04 Smoking quantity GUCA1B intron 24665060 rs9369346 chr6 42159132 C G 1.82E-04 Smoking quantity GUCA1B intron 24665060 rs3749921 chr6 42162388 A G 3.72E-04 Smoking quantity GUCA1B cds-synon 24665060 rs1474867 chr6 42162575 A G 4.05E-04 Smoking quantity / / 24665060 rs13217993 chr6 42164401 C T 2.00E-04 Smoking quantity GUCA1B nearGene-5 24665060 rs6912658 chr6 42167161 A T 3.27E-04 Smoking quantity / / 24665060 rs6936388 chr6 42167486 T C 9.20E-06 Parkinson's disease (age of onset) / / 19772629 rs1065236 chr6 42167888 A G 7.23E-04 Multiple complex diseases / / 17554300 rs1065236 chr6 42167888 A G 6.47E-04 Smoking quantity / / 24665060 rs2180174 chr6 42167970 T C 9.70E-13 Lymphocyte counts / / 22286170 rs2180174 chr6 42167970 T C 3.50E-04 Smoking quantity / / 24665060 rs2180172 chr6 42168542 T C 2.73E-04 Smoking quantity / / 24665060 rs7749339 chr6 42170662 T C 4.99E-04 Smoking quantity / / 24665060 rs4714579 chr6 42174478 A G 1.19E-04 Smoking quantity / / 24665060 rs4714580 chr6 42174558 A G 3.55E-04 Multiple complex diseases MRPS10 UTR-3 17554300 rs4714580 chr6 42174558 A G 4.99E-04 Smoking quantity MRPS10 UTR-3 24665060 rs8850 chr6 42174611 G T 2.46E-04 Smoking quantity MRPS10 UTR-3 24665060 rs9369350 chr6 42179091 G A 2.46E-04 Smoking quantity MRPS10 intron 24665060 rs1884317 chr6 42182183 C T 6.51E-04 Smoking quantity MRPS10 intron 24665060 rs9471809 chr6 42185564 A C 1.46E-04 Parkinson's disease MRPS10 cds-synon 17052657 rs9471810 chr6 42185712 A T 1.33E-04 Parkinson's disease / / 17052657 rs7757788 chr6 42186305 C T 1.33E-04 Parkinson's disease / / 17052657 rs10452607 chr6 42190446 G A 1.27E-04 Parkinson's disease / / 17052657 rs4714584 chr6 42190556 T G 6.37E-04 Smoking quantity / / 24665060 rs4424082 chr6 42194235 T A 2.27E-04 Smoking quantity TRERF1 UTR-3 24665060 rs9471815 chr6 42203748 A G 6.47E-07 Lymphocyte counts TRERF1 intron 22286170 rs12195244 chr6 42286006 C T 4.68E-04 Aortic root size TRERF1 intron 21223598 rs4714608 chr6 42391331 T A,C,G 9.40E-04 Alzheimer's disease TRERF1 intron 17998437 rs260263 chr6 42428156 G C 1.21E-05 Type 2 diabetes / / 17463246 rs9349233 chr6 42447008 C T 5.56E-05 Type 2 diabetes / / 17463246 rs2941397 chr6 42447132 C G 6.66E-06 Type 2 diabetes / / 17463246 rs9462805 chr6 42450392 T C 5.27E-05 Multiple complex diseases / / 17554300 rs16895812 chr6 42495278 T C 3.00E-06 Obesity-related traits / / 23251661 rs9381199 chr6 42561972 C T 2.00E-06 Smoking initiation UBR2 missense 24665060 rs16895871 chr6 42605532 T C 5.76E-04 Multiple complex diseases UBR2 intron 17554300 rs3736745 chr6 42630107 A G 0.000753 Salmonella-induced pyroptosis UBR2 intron 22837397 rs11751656 chr6 42643068 A G 1.72E-06 Ankle-brachial index UBR2 intron 22199011 rs422717 chr6 42668404 T G 1.22E-05 Common variable immunodeficiency PRPH2 intron 21497890 rs12202031 chr6 42722290 T G 5.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11759402 chr6 42723809 C T 5.04E-05 Cognitive test performance / / 20125193 rs6908950 chr6 42726349 G C 7.85E-05 Multiple complex diseases / / 17554300 rs10484911 chr6 42730289 T G 5.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6458307 chr6 42731115 C T 4.00E-06 Bipolar disorder / / 17554300 rs9296399 chr6 42778467 A G 5.84E-05 Cognitive impairment induced by topiramate / / 22091778 rs9462840 chr6 42824756 A G 2.36E-05 Brain structure KIAA0240 intron 22504417 rs685096 chr6 42845778 C G,T 2.80E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs9394931 chr6 42873245 C T 2.00E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs6901007 chr6 42892834 G T 4.88E-04 Premature ovarian failure PTCRA intron 19508998 rs4711731 chr6 42897712 C T 5.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CNPY3 intron 20877124 rs4714634 chr6 42901120 G A 9.86E-05 Partial epilepsies CNPY3 intron 20522523 rs3763236 chr6 42902508 T C 2.15E-05 Heart rate CNPY3 intron 23583979 rs6941212 chr6 42915920 T C 1.30E-04 Response to antidepressants / / 19736353 rs9296404 chr6 42925803 T C 2.00E-63 Plasma homocysteine levels (post-methionine load test) / / 24651765 rs2274517 chr6 42932715 C T 1.19E-20 Lymphocyte counts PEX6 intron 22286170 rs3793023 chr6 42982759 A C 8.25E-04 Alcohol consumption (maxi-drinks) KLHDC3 intron 24277619 rs3805944 chr6 43045462 G T 8.26E-04 Alcohol consumption (maxi-drinks) PTK7 intron 24277619 rs2007950 chr6 43049461 A G 3.42E-05 Lipid levels PTK7 intron pha003082 rs3805941 chr6 43057581 A G 2.10E-06 Bone mineral density (BMD),in women PTK7 intron 20164292 rs16896326 chr6 43153409 G A 7.16E-05 Schizophrenia CUL9 intron 24253340 rs61743561 chr6 43153787 G A 9.00E-06 Obesity-related traits CUL9 missense 23251661 rs9462875 chr6 43168117 A G 1.20E-21 Progranulin levels CUL9 intron 21087763 rs9462875 chr6 43168117 A G 1.20E-21 Myocardial infarction CUL9 intron 21211798 rs9462875 chr6 43168117 A G 1.46E-06 Schizophrenia CUL9 intron 21926974 rs9462875 chr6 43168117 A G 0.000161 Schizophrenia CUL9 intron 23637625 rs2273709 chr6 43184132 A C 2.60E-06 Schizophrenia CUL9 missense 21791550 rs2273709 chr6 43184132 A C 0.0000082 Psychosis CUL9 missense 23164818 rs115842765 chr6 43193318 G T 3.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs114326925 chr6 43193320 A G 3.10E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs12204749 chr6 43221896 G T 2.31E-04 Body mass index TTBK1 intron 21701565 rs7764257 chr6 43224755 A G 7.48E-04 Body mass index TTBK1 intron 21701565 rs7769182 chr6 43225117 G C 1.19E-04 Body mass index TTBK1 intron 21701565 rs7769094 chr6 43225284 A G 1.20E-04 Body mass index TTBK1 intron 21701565 rs7769094 chr6 43225284 A G 5.64E-04 Body mass index TTBK1 intron 21701565 rs12202445 chr6 43226255 G C 2.50E-05 Urinary metabolites TTBK1 intron 21572414 rs12202445 chr6 43226255 G C 2.24E-04 Body mass index TTBK1 intron 21701565 rs2756173 chr6 43246384 T C 3.70E-04 Primary sclerosing cholangitis TTBK1 intron 19944697 rs6458330 chr6 43252211 G C 2.80E-06 Urinary metabolites TTBK1 intron 21572414 rs4149178 chr6 43272188 A G 1.00E-06 Urate levels SLC22A7 intron 23263486 rs4714675 chr6 43287893 T C 5.52E-05 Schizophrenia / / 19197363 rs6933055 chr6 43325793 A G 5.14E-05 Tuberculosis ZNF318 intron 20694014 rs2125738 chr6 43327750 A G 1.95E-04 Multiple complex diseases ZNF318 intron 17554300 rs6915659 chr6 43347394 A G 1.75E-04 Multiple complex diseases / / 17554300 rs7750647 chr6 43359265 C T 4.45E-05 Tuberculosis / / 20694014 rs9394952 chr6 43401105 G A 8.59E-05 Cognitive impairment induced by topiramate ABCC10 intron 22091778 rs2487663 chr6 43409418 A G 3.94E-05 Alzheimer's disease ABCC10 intron 17998437 rs9357412 chr6 43416342 G C 3.60E-04 Lymphocyte counts ABCC10 intron 22286170 rs1674870 chr6 43434222 A C 6.68E-05 Alzheimer's disease (late onset) / / 21379329 rs1150798 chr6 43448821 G A 2.50E-05 Urinary metabolites TJAP1 intron 21572414 rs61018535 chr6 43449230 C A 2.00E-07 PR interval in Tripanosoma cruzi seropositivity TJAP1 intron 24324551 rs9462897 chr6 43454962 A G 3.83E-06 PR interval in Tripanosoma cruzi seropositivity TJAP1 intron 24324551 rs1096699 chr6 43528441 C T 4.80E-04 Type 2 diabetes XPO5 intron 17463246 rs1096699 chr6 43528441 C T 2.95E-05 HIV-1 control XPO5 intron 20041166 rs1617105 chr6 43613180 G A 6.90E-05 HIV-1 control RSPH9 intron 20041166 rs2277125 chr6 43640099 A G 9.43E-05 Glucose levels MRPS18A intron pha003058 rs3807024 chr6 43657127 T G 1.51E-06 AIDS progression / / 19115949 rs1761769 chr6 43679047 T G 8.10E-05 Nasopharyngeal carcinoma / / 20512145 rs752073 chr6 43682990 T C 2.96E-04 Type 2 diabetes / / 17463246 rs752073 chr6 43682990 T C 7.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4711748 chr6 43694598 T C 4.11E-05 Cognitive test performance / / 20125193 rs9472113 chr6 43695564 A C 1.70E-05 Cognitive test performance / / 20125193 rs9394963 chr6 43719391 G T 8.49E-05 Orofacial clefts / / 22419666 rs9394963 chr6 43719391 G T 9.60E-05 Prostate cancer / / 22923026 rs699947 chr6 43736389 A C 1 Drug response to Capecitabine VEGFA nearGene-5 20125120 rs699947 chr6 43736389 A C 1 Drug response to Oxaliplatin VEGFA nearGene-5 20125120 rs833061 chr6 43737486 C T 1 Drug response to Capecitabine VEGFA nearGene-5 20125120 rs833061 chr6 43737486 C T 1 Drug response to Oxaliplatin VEGFA nearGene-5 20125120 rs2010963 chr6 43738350 C G 1 Drug response to Capecitabine VEGFA UTR-5 20125120 rs2010963 chr6 43738350 C G 1 Drug response to Oxaliplatin VEGFA UTR-5 20125120 rs3024994 chr6 43743507 C T 2.46E-04 Multiple complex diseases VEGFA intron 17554300 rs3778497 chr6 43744177 C T 0.0000017 LDL cholesterol VEGFA intron 23063622 rs998584 chr6 43757896 C A 3.00E-08 Adiponectin levels / / 22479202 rs998584 chr6 43757896 C A 2.00E-11 HDL cholesterol / / 24097068 rs998584 chr6 43757896 C A 3.00E-15 Triglycerides / / 24097068 rs6905288 chr6 43758873 G A 2.00E-26 Waist-hip ratio / / 20935629 rs6905288 chr6 43758873 G A 7.00E-08 Coronary heart disease / / 22319020 rs1358980 chr6 43764551 C T 2.00E-11 Sexual dimorphism in anthropometric traits / / 23754948 rs4507587 chr6 43775838 T C 9.10E-04 Type 2 diabetes / / 23209189 rs6458351 chr6 43791080 T C 1.39E-05 Attention deficit hyperactivity disorder / / 22012869 rs6458351 chr6 43791080 T C 1.69E-04 Celiac disease / / 23936387 rs943072 chr6 43795968 G T 2.00E-10 Ulcerative colitis / / 21297633 rs943072 chr6 43795968 G T 8.02E-04 Tourette syndrome / / 22889924 rs2894536 chr6 43801878 C T 3.35E-04 Lung function (forced vital capacity) / / 24023788 rs729761 chr6 43804571 T G 5.37E-10 Red blood cell traits / / 23222517 rs729761 chr6 43804571 T G 8.00E-16 Urate levels / / 23263486 rs2396083 chr6 43804808 G C 1.93E-10 Red blood cell traits / / 23222517 rs2396083 chr6 43804808 G C 1.23E-11 Urate levels / / 23263486 rs744103 chr6 43805362 T A 1.62E-10 Red blood cell traits / / 23222517 rs744103 chr6 43805362 T A 8.31E-12 Urate levels / / 23263486 rs881858 chr6 43806609 G A 9.00E-14 Chronic kidney disease / / 20383146 rs881858 chr6 43806609 G A 9.90E-06 Nephrolithiasis / / 22396660 rs881858 chr6 43806609 G A 1.60E-10 Chronic kidney disease / / 22479191 rs881858 chr6 43806609 G A 2.65E-11 Red blood cell traits / / 23222517 rs881858 chr6 43806609 G A 1.50E-11 Urate levels / / 23263486 rs881858 chr6 43806609 G A 2.30E-04 Glomerular filtration rate / / 23535967 rs881858 chr6 43806609 G A 2.70E-04 Glomerular filtration rate / / 23535967 rs881858 chr6 43806609 G A 3.10E-04 Glomerular filtration rate / / 23535967 rs9472135 chr6 43809802 T C 2.94E-10 Red blood cell traits / / 23222517 rs9472135 chr6 43809802 T C 6.80E-11 Urate levels / / 23263486 rs9369425 chr6 43810974 G A 2.00E-04 Type 2 diabetes / / 17463249 rs9369425 chr6 43810974 G A 8.57E-04 Multiple complex diseases / / 17554300 rs9369425 chr6 43810974 G A 1.18E-06 Chronic kidney disease / / 21931561 rs9369425 chr6 43810974 G A 2.68E-11 Red blood cell traits / / 23222517 rs9369425 chr6 43810974 G A 1.09E-09 Urate levels / / 23263486 rs9369427 chr6 43811430 C A 5.63E-12 Red blood cell traits / / 23222517 rs9369427 chr6 43811430 C A 1.63E-09 Urate levels / / 23263486 rs9472138 chr6 43811762 C T 5.96E-04 Multiple complex diseases / / 17554300 rs9472138 chr6 43811762 C T 4.00E-06 Type 2 diabetes / / 18372903 rs9472138 chr6 43811762 C T 4.00E-06 Coronary heart disease / / 21347282 rs9472138 chr6 43811762 C T 4.00E-06 Type 2 diabetes / / 21647700 rs9472138 chr6 43811762 C T 2.00E-04 Coronary heart disease / / 21966275 rs9472138 chr6 43811762 C T 5.27E-10 Red blood cell traits / / 23222517 rs9472138 chr6 43811762 C T 1.50E-09 Urate levels / / 23263486 rs9472138 chr6 43811762 C T 5.00E-06 Thyroid hormone levels / / 23408906 rs9472138 chr6 43811762 C T 6.00E-12 Thyroid hormone levels / / 23408906 rs9472138 chr6 43811762 C T 7.00E-16 Thyroid hormone levels / / 23408906 rs9472138 chr6 43811762 C T 2.00E-07 Type 2 diabetes / / 24509480 rs10456526 chr6 43814625 G A 1.25E-11 Red blood cell traits / / 23222517 rs10456526 chr6 43814625 G A 3.74E-09 Urate levels / / 23263486 rs6937438 chr6 43815364 G A 5.48E-09 Red blood cell traits / / 23222517 rs6937438 chr6 43815364 G A 4.09E-08 Urate levels / / 23263486 rs9472142 chr6 43818942 C T 1.77E-09 Red blood cell traits / / 23222517 rs943080 chr6 43826627 C T 9.00E-16 Age-related macular degeneration / / 23455636 rs4711751 chr6 43828582 T C 9.00E-09 Age-related macular degeneration / / 21665990 rs6458356 chr6 43829251 C T 1.50E-05 Urinary metabolites / / 21572414 rs7747095 chr6 43829941 C A 4.92E-07 Red blood cell traits / / 23222517 rs4714706 chr6 43832177 A G 7.30E-04 Premature ovarian failure / / 19508998 rs943081 chr6 43880667 C A 2.24E-05 Multiple complex diseases LOC100132354 intron 17554300 rs9472153 chr6 43882612 G A 1.28E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) LOC100132354 intron 23648065 rs721640 chr6 43886159 G A 3.46E-05 Erythrocyte counts LOC100132354 intron pha003099 rs1750571 chr6 43890856 G A 5.00E-04 Chronic kidney disease LOC100132354 intron 21931561 rs1776721 chr6 43890983 G T 1.30E-26 Vascular endothelial growth factor levels LOC100132354 intron 21757650 rs9472155 chr6 43897727 C T 2.00E-26 Vascular endothelial growth factor levels LOC100132354 intron 21757650 rs10948107 chr6 43898232 G A 9.57E-04 Thyroid stimulating hormone LOC100132354 intron 24852370 rs7767550 chr6 43899252 G A 8.34E-04 Multiple complex diseases LOC100132354 intron 17554300 rs833621 chr6 43900443 T C 0.0000206 post-traumatic stress disorder LOC100132354 intron 22869035 rs833621 chr6 43900443 T C 2.06E-05 Schizophrenia LOC100132354 intron 22883433 rs844294 chr6 43900707 T C 1.20E-18 Vascular endothelial growth factor levels LOC100132354 intron 21757650 rs1326141 chr6 43903277 G A 6.53E-04 Multiple complex diseases LOC100132354 intron 17554300 rs11755845 chr6 43904780 C T 2.00E-10 Thyroid hormone levels / / 23408906 rs11755845 chr6 43904780 C T 3.00E-07 Thyroid hormone levels / / 23408906 rs1886979 chr6 43904901 G A 7.07E-25 Vascular endothelial growth factor levels / / 21757650 rs1886979 chr6 43904901 G A 5.85E-05 Insulin resistance / / 21901158 rs4513773 chr6 43925526 A G 1E-584 Vascular endothelial growth factor levels / / 21757650 rs7755431 chr6 43937518 A G 8.76E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4416670 chr6 43950453 T C 3.14E-15 Vascular endothelial growth factor levels / / 21757650 rs910611 chr6 43950851 T C 8.62E-15 Vascular endothelial growth factor levels / / 21757650 rs1776717 chr6 43951336 G A 8.47E-27 Vascular endothelial growth factor levels / / 21757650 rs910609 chr6 43951656 G A 3.34E-05 Monocyte chemoattractant protein-1 / / pha003071 rs9367181 chr6 43956615 A G 5.14E-05 Monocyte chemoattractant protein-1 / / pha003071 rs9381275 chr6 43980128 A G 5.76E-04 Type 2 diabetes / / 17463246 rs9472189 chr6 43980879 T G 7.30E-06 Urinary metabolites / / 21572414 rs926959 chr6 43982132 C A 3.61E-04 Multiple complex diseases / / 17554300 rs9381279 chr6 43999697 A C 8.61E-04 Multiple complex diseases / / 17554300 rs9381279 chr6 43999697 A C 5.34E-04 Body mass index / / 21701565 rs9381282 chr6 44008325 C A 1.39E-04 Body mass index / / 21701565 rs9381282 chr6 44008325 C A 8.89E-06 Body mass index / / 21701565 rs833802 chr6 44026734 A C 6.97E-06 Alzheimer's disease / / 17998437 rs13210320 chr6 44035374 T C 9.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9381286 chr6 44035804 T G 9.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9381287 chr6 44040640 G C 9.00E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9357429 chr6 44046143 C T 9.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs881934 chr6 44050269 T C 2.52E-04 Body mass index / / 21701565 rs881934 chr6 44050269 T C 8.85E-04 Body mass index / / 21701565 rs6458368 chr6 44051221 T C 8.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs4714738 chr6 44056585 C T 0.000853 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4714738 chr6 44056585 C T 8.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10948121 chr6 44057452 C T 0.0008548 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10948121 chr6 44057452 C T 8.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12191873 chr6 44060576 A C 0.0008621 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12191873 chr6 44060576 A C 8.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7742824 chr6 44065311 G A 9.00E-06 Major depressive disorder / / 23377640 rs4711764 chr6 44074229 T C 9.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7756283 chr6 44076780 T G 9.35E-04 Type 2 diabetes / / 17463246 rs1321097 chr6 44077356 A G 9.66E-04 Type 2 diabetes / / 17463246 rs6883 chr6 44081718 G A 7.33E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) MRPL14 cds-synon 23648065 rs4711767 chr6 44081987 T C 8.90E-04 Type 2 diabetes MRPL14 intron 17463246 rs1935611 chr6 44093742 C T 7.94E-04 Type 2 diabetes MRPL14 intron 17463246 rs1935611 chr6 44093742 C T 1.16E-06 Lymphocyte counts MRPL14 intron 22286170 rs4714759 chr6 44115169 G A 0.0007558 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMEM63B missense 23233654 rs4714759 chr6 44115169 G A 7.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMEM63B missense 23233662 rs4711777 chr6 44154325 C T 5.07E-04 Lymphocyte counts / / 22286170 rs7773444 chr6 44171484 A T 1.90E-05 Urinary metabolites / / 21572414 rs35131064 chr6 44172063 C T 6.00E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs1057985 chr6 44185901 T C 6.72E-05 Age-related macular degeneration / / 22125219 rs693955 chr6 44191920 A C 5.65E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) SLC29A1 intron 23648065 rs1128870 chr6 44198315 G A 1 Drug response to Gemcitabine SLC29A1 cds-synon 15224082 rs9381299 chr6 44211867 T C 1.00E-05 Urinary metabolites / / 21572414 rs9367190 chr6 44217654 C A 2.60E-05 Urinary metabolites HSP90AB1 intron 21572414 rs9381303 chr6 44217667 C T 2.60E-05 Urinary metabolites HSP90AB1 intron 21572414 rs9381303 chr6 44217667 C T 3.74E-05 Odorant perception HSP90AB1 intron 23910658 rs730775 chr6 44232074 A G 0.00026 Coronary artery calcification NFKBIE intron 23727086 rs2233434 chr6 44232920 A G 6.00E-19 Rheumatoid arthritis NFKBIE missense 22446963 rs2233434 chr6 44232920 A G 1.00E-15 Rheumatoid arthritis NFKBIE missense 23028356 rs2233433 chr6 44232977 G A 1.30E-06 Rheumatoid arthritis NFKBIE missense 23028356 rs2233424 chr6 44233921 C T 2.30E-06 Rheumatoid arthritis / / 23028356 rs2233424 chr6 44233921 C T 1.00E-19 Rheumatoid arthritis / / 24390342 rs2233424 chr6 44233921 C T 2.00E-13 Rheumatoid arthritis / / 24390342 rs2233424 chr6 44233921 C T 3.00E-08 Rheumatoid arthritis / / 24390342 rs524533 chr6 44240559 C T 7.33E-04 Longevity TMEM151B intron 22279548 rs12664825 chr6 44252253 C T 7.20E-05 Lung function (forced expiratory volume in 1 second) TCTE1 intron pha003102 rs557373 chr6 44258324 G A 7.56E-04 Type 2 diabetes TCTE1 intron 17463246 rs139372744 chr6 44274257 G A 0.0000042 Breast cancer (ER positive) AARS2 missense 23555315 rs4714776 chr6 44282316 T G 7.85E-05 Lipoproteins AARS2 nearGene-5 pha003079 rs4714776 chr6 44282316 T G 5.53E-05 Lung function (forced expiratory volume in 1 second) AARS2 nearGene-5 pha003102 rs11962379 chr6 44288847 T G 5.82E-04 Myocardial Infarction / / pha002873 rs9472250 chr6 44297772 C T 1.30E-05 Urinary metabolites / / 21572414 rs9472250 chr6 44297772 C T 2.42E-04 Lymphocyte counts / / 22286170 rs9369476 chr6 44297871 G A 1.39E-05 Erythrocyte counts / / pha003090 rs1571773 chr6 44303728 C T 5.55E-05 Hemoglobin / / pha003098 rs7769148 chr6 44304376 A G 1.30E-05 Systolic blood pressure in sickle cell anemia / / 24058526 rs7757993 chr6 44309346 C T 7.13E-06 Hemoglobin / / pha003098 rs10948132 chr6 44310854 G A 9.80E-06 Urinary metabolites SPATS1 missense 21572414 rs10948134 chr6 44324199 A T 1.50E-05 Urinary metabolites SPATS1 intron 21572414 rs4714784 chr6 44324600 A G 3.50E-05 Erythrocyte counts SPATS1 intron pha003090 rs2221224 chr6 44330556 C T 2.97E-05 Erythrocyte counts SPATS1 intron pha003090 rs7769100 chr6 44334252 G A 9.10E-05 Type 2 diabetes SPATS1 intron 17463246 rs7769100 chr6 44334252 G A 7.20E-06 Urinary metabolites SPATS1 intron 21572414 rs6918742 chr6 44341980 T C 6.24E-05 Type 2 diabetes SPATS1 intron 17463246 rs11571943 chr6 44371690 T C 9.40E-07 Fasting plasma glucose CDC5L cds-synon 19060907 rs543844 chr6 44424800 A G 1.35E-04 Migraine without aura / / 23793025 rs543844 chr6 44424800 A G 3.00E-06 Migraine / / 23793025 rs9395021 chr6 44440722 C T 5.74E-05 HIV-1 viral setpoint / / 21490045 rs6458389 chr6 44452011 T G 1.20E-07 Urinary metabolites / / 21572414 rs2396253 chr6 44454017 G A 1.30E-05 Urinary metabolites / / 21572414 rs116755262 chr6 44455133 A G 8.00E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs114761004 chr6 44457273 G A 1.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs115317167 chr6 44457274 C T 8.55E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs6458390 chr6 44469029 T C 4.32E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6919522 chr6 44469505 C A 2.47E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1322667 chr6 44470006 A G 9.89E-05 Cognitive performance / / 19734545 rs1322667 chr6 44470006 A G 2.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17390094 chr6 44471348 G A 7.00E-06 Urinary metabolites / / 21572414 rs6931981 chr6 44471673 A C 2.05E-04 Multiple complex diseases / / 17554300 rs9296440 chr6 44472854 A G 4.89E-05 Stroke (ischemic) / / 22941190 rs1322669 chr6 44479176 G A 6.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9369494 chr6 44498472 C T 3.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs932680 chr6 44501873 G T 3.36E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs911982 chr6 44523643 G T 3.11E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs7739888 chr6 44524173 C T 2.59E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs13196428 chr6 44525198 G A 5.14E-04 Type 2 diabetes / / 17463246 rs6923772 chr6 44533311 A G 8.17E-04 Alcohol dependence / / 20201924 rs326798 chr6 44541936 G A 4.69E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1283946 chr6 44572155 A G 9.87E-05 Height / / pha003011 rs4714797 chr6 44573454 C G 9.89E-06 Stroke (ischemic) / / 22941190 rs4711790 chr6 44573822 C T 7.10E-07 Stroke (ischemic) / / 22941190 rs13202385 chr6 44574614 C A 9.49E-06 Stroke (ischemic) / / 22941190 rs1283944 chr6 44576607 T C 8.89E-04 Multiple complex diseases / / 17554300 rs9395035 chr6 44576665 A G 8.86E-06 Stroke (ischemic) / / 22941190 rs12526438 chr6 44577322 G A 8.53E-06 Stroke (ischemic) / / 22941190 rs9381341 chr6 44578074 C G 8.63E-06 Stroke (ischemic) / / 22941190 rs561160 chr6 44579789 A G 5.74E-05 Height / / pha003011 rs9472309 chr6 44580743 C T 2.20E-05 Urinary metabolites / / 21572414 rs4714801 chr6 44584387 A G 7.64E-08 Stroke (ischemic) / / 22941190 rs6913259 chr6 44586363 C T 8.31E-05 Height / / pha003011 rs900403 chr6 44591850 G A 3.19E-06 Stroke (ischemic) / / 22941190 rs9472313 chr6 44592706 G A 5.43E-08 Stroke (ischemic) / / 22941190 rs556621 chr6 44594159 T G 5.00E-08 Stroke (ischemic) / / 22941190 rs556512 chr6 44594192 A G 4.25E-08 Stroke (ischemic) / / 22941190 rs658726 chr6 44595142 G T 8.12E-06 Stroke (ischemic) / / 22941190 rs504615 chr6 44595212 G A 4.58E-07 Stroke (ischemic) / / 22941190 rs1767788 chr6 44595393 C T 5.42E-07 Stroke (ischemic) / / 22941190 rs646977 chr6 44595443 C T 9.12E-06 Stroke (ischemic) / / 22941190 rs497177 chr6 44596053 T G 2.57E-07 Stroke (ischemic) / / 22941190 rs632728 chr6 44596341 T C 1.15E-06 Stroke (ischemic) / / 22941190 rs632728 chr6 44596341 T C 2.00E-07 Large artery stroke / / 24262325 rs1680900 chr6 44596354 A C 1.41E-06 Stroke (ischemic) / / 22941190 rs4714805 chr6 44601207 G A 1.27E-04 Schizophrenia / / 20832056 rs638598 chr6 44615861 C T 2.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs6937562 chr6 44617898 C T 7.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs900404 chr6 44621993 C A 2.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs7741085 chr6 44636919 C T 7.25E-04 Multiple complex diseases / / 17554300 rs11755164 chr6 44639184 T C 6.00E-11 Bone mineral density / / 22504420 rs13206206 chr6 44684124 T C 1.60E-05 Urinary metabolites / / 21572414 rs10948155 chr6 44687957 T C 7.04E-05 Hypertension / / 21082022 rs10948155 chr6 44687957 T C 7.70E-07 Osteoarthritis / / 22566624 rs1342371 chr6 44739949 C T 2.00E-06 Obesity-related traits / / 23251661 rs1293457 chr6 44758098 T C 4.79E-04 Stroke (ischemic) / / 21940970 rs720988 chr6 44765660 C T 8.41E-05 Cognitive impairment induced by topiramate / / 22091778 rs7770848 chr6 44769237 T G 2.00E-07 Asthma (childhood onset) / / 23829686 rs7766901 chr6 44772113 G A 1.00E-04 Prostate cancer / / 21743057 rs6912535 chr6 44774828 C T 6.00E-05 Prostate cancer / / 21743057 rs10948172 chr6 44777691 A G 6.00E-07 Osteoarthritis / / 22763110 rs10948172 chr6 44777691 A G 6.00E-07 Cortical thickness / / 22792071 rs7349931 chr6 44783674 A G 7.83E-05 Serum metabolites / / 19043545 rs3799965 chr6 44798617 G T 8.41E-05 Cognitive impairment induced by topiramate SUPT3H intron 22091778 rs9463046 chr6 44802718 T C 1.62E-05 Alcohol consumption SUPT3H intron 23953852 rs9472381 chr6 44808110 C T 2.00E-05 Prostate cancer SUPT3H intron 21743057 rs672098 chr6 44810249 A G 9.34E-04 Multiple complex diseases SUPT3H intron 17554300 rs13436998 chr6 44813340 C T 2.00E-05 Prostate cancer SUPT3H intron 21743057 rs9472384 chr6 44817557 A T 1.00E-04 Prostate cancer SUPT3H intron 21743057 rs9296447 chr6 44822936 C T 6.00E-05 Prostate cancer SUPT3H intron 21743057 rs16872751 chr6 44827696 T C 6.00E-05 Prostate cancer SUPT3H intron 21743057 rs3799977 chr6 44837356 T G 5.00E-06 Attention deficit hyperactivity disorder SUPT3H intron 18839057 rs3857587 chr6 44884538 G A 7.13E-04 Multiple complex diseases SUPT3H intron 17554300 rs3778507 chr6 44896803 G A 1.38E-04 Stroke (ischemic) SUPT3H intron 21940970 rs12210292 chr6 44925293 T C 1.97E-05 Serum albumin level SUPT3H intron pha003084 rs9472414 chr6 44946506 T A 2.00E-09 Height SUPT3H intron 20881960 rs10948197 chr6 44967490 T C 8.00E-06 Height SUPT3H intron 19893584 rs9395066 chr6 45095163 A C 8.00E-06 Height SUPT3H intron 18391951 rs10948222 chr6 45244415 T C 5.00E-11 Height SUPT3H intron 23563607 rs17209741 chr6 45292438 A T 8.50E-05 Serum metabolites SUPT3H intron 19043545 rs12199720 chr6 45307443 C T 0.0000177 Transmission distortion RUNX2 intron 22377632 rs3763190 chr6 45347644 G A 2.00E-04 Cognitive impairment induced by topiramate RUNX2 intron 22091778 rs4510673 chr6 45350107 A G 1.66E-04 Lymphocyte counts RUNX2 intron 22286170 rs717987 chr6 45356983 A G 8.00E-05 Lipid traits RUNX2 intron 17903299 rs11968177 chr6 45359876 A C 7.66E-04 Type 2 diabetes RUNX2 intron 20818381 rs1321075 chr6 45391943 T G 9.20E-05 Alcoholism (heaviness of drinking) RUNX2 intron 21529783 rs16873429 chr6 45449798 G A 4.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RUNX2 intron 20877124 rs7750470 chr6 45473256 T C 3.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RUNX2 intron 20877124 rs6930053 chr6 45488758 T C 6.00E-05 Type 2 diabetes RUNX2 intron 17463246 rs10485422 chr6 45489192 T A 9.16E-05 Pancreatic cancer RUNX2 intron 23180869 rs6458444 chr6 45490182 C A 1.00E-04 Pancreatic cancer RUNX2 intron 23180869 rs6458445 chr6 45490218 C T 9.76E-05 Pancreatic cancer RUNX2 intron 23180869 rs7755257 chr6 45490292 A G 7.00E-05 Pancreatic cancer RUNX2 intron 23180869 rs12195878 chr6 45490753 C T 8.47E-05 Pancreatic cancer RUNX2 intron 23180869 rs2031966 chr6 45495736 A G 7.16E-05 Pancreatic cancer RUNX2 intron 23180869 rs4438954 chr6 45495748 C G 7.16E-05 Pancreatic cancer RUNX2 intron 23180869 rs13207392 chr6 45496456 C T 6.16E-05 Pancreatic cancer RUNX2 intron 23180869 rs11756145 chr6 45500266 C T 7.93E-05 Pancreatic cancer RUNX2 intron 23180869 rs6458446 chr6 45500470 G A 6.20E-05 Pancreatic cancer RUNX2 intron 23180869 rs6905181 chr6 45500666 G A 6.88E-05 Pancreatic cancer RUNX2 intron 23180869 rs12208240 chr6 45501937 G A 4.40E-04 Lung function (forced expiratory volume in 1 second) RUNX2 intron 24023788 rs12209785 chr6 45506122 A G 4.47E-05 Pancreatic cancer RUNX2 intron 23180869 rs4714860 chr6 45529755 A G 9.99E-05 Schizophrenia / / 19571809 rs4714860 chr6 45529755 A G 7.86E-05 Schizophrenia / / pha002859 rs1928529 chr6 45534165 C T 4.40E-07 Fasting glucose-related traits / / 20152958 rs16873520 chr6 45541177 A G 8.11E-05 Multiple complex diseases / / 17554300 rs2280229 chr6 45543338 C T 9.15E-05 Asthma / / 20159242 rs16873629 chr6 45625610 C T 6.08E-05 Multiple complex diseases / / 17554300 rs1388244 chr6 45650154 T C 7.54E-04 Type 2 diabetes / / 17463246 rs6458458 chr6 45665697 A G 8.38E-04 Type 2 diabetes / / 17463246 rs9395112 chr6 45682806 A G 8.25E-04 Multiple complex diseases / / 17554300 rs1932040 chr6 45696788 A G 1.00E-06 Periodontal microbiota / / 22699663 rs829930 chr6 45710553 G A 1.05E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs829930 chr6 45710553 G A 2.08E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10498761 chr6 45742506 G T 3.58E-04 Type 2 diabetes / / 17846124 rs10498764 chr6 45770388 A G 3.64E-04 Multiple complex diseases / / 17554300 rs9463121 chr6 45772397 G T 2.96E-04 Multiple complex diseases / / 17554300 rs4714873 chr6 45772603 G T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7746680 chr6 45777347 A G 1.14E-05 Attention deficit hyperactivity disorder / / 22420046 rs4714874 chr6 45777475 A G 8.83E-05 Orofacial clefts / / 22419666 rs4714874 chr6 45777475 A G 6.15E-05 Relative hand skill / / 24068947 rs4714875 chr6 45777794 G A 1.81E-05 Relative hand skill / / 24068947 rs9395123 chr6 45779732 G A 6.46E-04 Multiple complex diseases / / 17554300 rs9472585 chr6 45783479 G A 7.58E-04 Multiple complex diseases / / 17554300 rs2894651 chr6 45787468 T C 7.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs2894651 chr6 45787468 T C 1.38E-05 Relative hand skill / / 24068947 rs7738064 chr6 45793603 A T 2.67E-04 Obesity (extreme) / / 21935397 rs9369581 chr6 45806986 A G 2.20E-05 Urinary metabolites / / 21572414 rs9463130 chr6 45809850 C T 2.10E-04 Obesity (extreme) / / 21935397 rs9463132 chr6 45810806 A G 2.11E-04 Obesity (extreme) / / 21935397 rs9369584 chr6 45824539 C T 2.70E-05 Urinary metabolites / / 21572414 rs1475781 chr6 45833255 T A 7.10E-05 Immunoglobulin A / / 20694011 rs10948262 chr6 45840604 G A 3.91E-04 Type 2 diabetes / / 17463246 rs10948262 chr6 45840604 G A 2.00E-04 Lipid levels / / 18193043 rs928613 chr6 45845801 A G 7.60E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs873053 chr6 45847115 C T 0.00009047 Sarcoidosis / / 22952805 rs2396559 chr6 45847678 C G 5.13E-04 Type 2 diabetes / / 17463246 rs10948263 chr6 45852320 G A 0.00005238 Sarcoidosis / / 22952805 rs6936314 chr6 45857604 A G 0.000027274 Hypertension (early onset hypertension) / / 22479346 rs9463147 chr6 45863826 A G 1.33E-05 Hypertension (early onset hypertension) / / 22479346 rs9369588 chr6 45864505 G A 1.41E-05 Hypertension (early onset hypertension) / / 22479346 rs3814071 chr6 45867872 C A 7.71E-04 HIV-1 viral setpoint CLIC5 UTR-3 17641165 rs6458477 chr6 45880311 T C 2.00E-05 Urinary metabolites CLIC5 UTR-3 21572414 rs6458478 chr6 45880937 T G 3.05E-05 Hypertension (early onset hypertension) CLIC5 intron 22479346 rs4714888 chr6 45885061 G T 8.00E-06 Age-related macular degeneration CLIC5 intron 23326517 rs3777542 chr6 45885642 T A 6.73E-04 Multiple complex diseases CLIC5 intron 17554300 rs6904888 chr6 45889375 A G 9.59E-04 Multiple complex diseases CLIC5 intron 17554300 rs3777566 chr6 45898002 C G 1.00E-04 Prostate cancer CLIC5 intron 21743057 rs3777582 chr6 45914028 A T 2.58E-29 Multiple complex diseases CLIC5 intron 17554300 rs1999908 chr6 45917819 G C 2.79E-04 Multiple complex diseases CLIC5 intron 17554300 rs3777585 chr6 45918969 C T 2.00E-05 Urinary metabolites CLIC5 intron 21572414 rs4714892 chr6 45924967 A G 5.78E-04 Substance dependence CLIC5 intron 21818250 rs1555214 chr6 45928400 C T 1.32E-05 Leukocyte Counts CLIC5 intron pha003091 rs2057148 chr6 45937610 G C 4.63E-04 Multiple complex diseases CLIC5 intron 17554300 rs3777599 chr6 45942950 G T 5.70E-05 Alcohol and nictotine co-dependence CLIC5 intron 20158304 rs4714899 chr6 45947467 G A 6.54E-05 Alcohol and nictotine co-dependence CLIC5 intron 20158304 rs4714899 chr6 45947467 G A 5.73E-04 Suicide attempts in bipolar disorder CLIC5 intron 21423239 rs7772905 chr6 45961515 T C 7.94E-04 Multiple complex diseases CLIC5 intron 17554300 rs7772905 chr6 45961515 T C 3.63E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CLIC5 intron 24578207 rs7772905 chr6 45961515 T C 3.63E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CLIC5 intron 24578207 rs7773297 chr6 45961770 T C 3.42E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CLIC5 intron 24578207 rs7773297 chr6 45961770 T C 3.42E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CLIC5 intron 24578207 rs10948268 chr6 45962471 G A 8.47E-04 Type 2 diabetes CLIC5 intron 22158537 rs3777612 chr6 45965608 G A 7.37E-05 Multiple complex diseases CLIC5 intron 17554300 rs3777625 chr6 45978236 G A 9.71E-04 Type 2 diabetes CLIC5 intron 22158537 rs10484840 chr6 46027152 C G 8.51E-04 Alzheimer's disease CLIC5 intron 17998437 rs1338463 chr6 46030130 C T 8.30E-05 Alzheimer's disease CLIC5 intron 22005930 rs9381423 chr6 46047269 T C 6.32E-04 Iron levels CLIC5 intron pha002876 rs3734207 chr6 46047458 C T 8.61E-04 Iron levels CLIC5 cds-synon pha002876 rs9395152 chr6 46050835 A G 9.99E-04 Iron levels / / pha002876 rs9357499 chr6 46057309 T A 2.75E-04 Multiple complex diseases / / 17554300 rs9463178 chr6 46057386 A G 9.68E-04 Multiple complex diseases / / 17554300 rs995564 chr6 46082810 C T 4.84E-04 Multiple complex diseases / / 17554300 rs995564 chr6 46082810 C T 3.37E-05 Serum metabolites / / 19043545 rs3756804 chr6 46096777 T C 2.71E-04 Iron levels / / pha002876 rs2143747 chr6 46105419 T C 5.82E-04 Multiple complex diseases ENPP4 intron 17554300 rs2143747 chr6 46105419 T C 5.69E-05 Serum metabolites ENPP4 intron 19043545 rs910179 chr6 46105497 A T 4.99E-04 Multiple complex diseases ENPP4 intron 17554300 rs2179760 chr6 46106405 G A 5.69E-04 Multiple complex diseases ENPP4 intron 17554300 rs2179760 chr6 46106405 G A 3.89E-05 Serum metabolites ENPP4 intron 19043545 rs11752816 chr6 46107312 G A,C,T 4.35E-04 Multiple complex diseases ENPP4 UTR-5 17554300 rs1048076 chr6 46112372 T C 6.87E-04 Multiple complex diseases ENPP4 UTR-3 17554300 rs1048076 chr6 46112372 T C 3.67E-05 Serum metabolites ENPP4 UTR-3 19043545 rs1048077 chr6 46112389 A G 8.55E-06 Serum metabolites ENPP4 UTR-3 19043545 rs3777632 chr6 46112887 A G 4.02E-04 Coronary heart disease ENPP4 UTR-3 21971053 rs3777632 chr6 46112887 A G 5.50E-04 Iron levels ENPP4 UTR-3 pha002876 rs9472700 chr6 46116332 A G 3.29E-04 Multiple complex diseases / / 17554300 rs9472700 chr6 46116332 A G 3.80E-05 Serum metabolites / / 19043545 rs9472701 chr6 46116449 G A 4.78E-05 Serum metabolites / / 19043545 rs9472702 chr6 46117304 C T 2.92E-04 Iron levels / / pha002876 rs9472707 chr6 46119669 T C 3.50E-04 Multiple complex diseases / / 17554300 rs9472707 chr6 46119669 T C 3.89E-05 Serum metabolites / / 19043545 rs9349348 chr6 46120103 A G 4.42E-04 Multiple complex diseases / / 17554300 rs9349348 chr6 46120103 A G 5.15E-05 Serum metabolites / / 19043545 rs6930766 chr6 46127626 C T 5.19E-04 Multiple complex diseases / / 17554300 rs6930766 chr6 46127626 C T 1.91E-05 Serum metabolites / / 19043545 rs2295018 chr6 46127807 T G 1.43E-04 Type 2 diabetes ENPP5 UTR-3 17463246 rs2295017 chr6 46127836 T A 1.43E-04 Type 2 diabetes ENPP5 UTR-3 17463246 rs2295017 chr6 46127836 T A 5.00E-05 Asthma (aspirin-intolerant) ENPP5 UTR-3 21072201 rs2235882 chr6 46128794 C T 1.97E-04 Vaspin levels ENPP5 UTR-3 22907691 rs2235882 chr6 46128794 C T 0.0001967 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks ENPP5 UTR-3 22907730 rs9472709 chr6 46130385 A G 6.20E-04 Coronary heart disease ENPP5 intron 21971053 rs7748442 chr6 46130906 C G 6.37E-04 Multiple complex diseases ENPP5 intron 17554300 rs7748442 chr6 46130906 C G 6.02E-05 Serum metabolites ENPP5 intron 19043545 rs9472714 chr6 46134641 G A 7.08E-05 Type 2 diabetes ENPP5 intron 17463246 rs6926570 chr6 46135489 T C 3.68E-04 Multiple complex diseases ENPP5 missense 17554300 rs6926570 chr6 46135489 T C 3.86E-05 Serum metabolites ENPP5 missense 19043545 rs6926570 chr6 46135489 T C 7.08E-04 Coronary heart disease ENPP5 missense 21971053 rs5011271 chr6 46142439 G A 2.49E-05 Serum metabolites / / 19043545 rs2799359 chr6 46144252 G T 1.51E-05 Breast cancer / / 21060860 rs2223776 chr6 46145461 C G 3.85E-06 Serum metabolites / / 19043545 rs6925476 chr6 46151231 C T 5.25E-04 Iron levels / / pha002876 rs879014 chr6 46158310 A G 3.73E-04 Multiple complex diseases / / 17554300 rs2277121 chr6 46293328 G A 6.22E-04 Smoking initiation RCAN2 UTR-5 24665060 rs6911147 chr6 46307628 C T 7.26E-05 Body mass index RCAN2 intron 19079261 rs6911147 chr6 46307628 C T 6.90E-05 Smoking behavior RCAN2 intron 20418888 rs4711853 chr6 46457836 A G 1.90E-05 Glaucoma (primary open-angle) RCAN2 intron 20835238 rs9369624 chr6 46484995 C T 3.90E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs9357509 chr6 46485635 G T 2.22E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs4714942 chr6 46489208 G A 9.09E-04 Obesity (extreme) / / 21935397 rs6458510 chr6 46505465 G A 4.07E-04 Alzheimer's disease (late onset) / / 21379329 rs9472780 chr6 46507446 G T 9.61E-04 Obesity (extreme) / / 21935397 rs806511 chr6 46515565 A C 9.53E-04 Obesity (extreme) / / 21935397 rs806509 chr6 46517163 G A 5.30E-04 Multiple complex diseases CYP39A1 nearGene-3 17554300 rs806509 chr6 46517163 G A 4.13E-04 Alzheimer's disease (late onset) CYP39A1 nearGene-3 21379329 rs806506 chr6 46520256 T C 9.34E-04 Obesity (extreme) CYP39A1 intron 21935397 rs699941 chr6 46527016 A T 8.69E-04 Obesity (extreme) CYP39A1 intron 21935397 rs1534357 chr6 46533772 C G 5.15E-04 Multiple complex diseases CYP39A1 intron 17554300 rs806489 chr6 46536415 G T 8.69E-04 Obesity (extreme) CYP39A1 intron 21935397 rs699945 chr6 46541261 G T 2.36E-05 Panic disorder CYP39A1 intron 19165232 rs806484 chr6 46547502 C A 9.92E-04 Obesity (extreme) CYP39A1 intron 21935397 rs1727595 chr6 46549970 C T 9.96E-04 Obesity (extreme) CYP39A1 intron 21935397 rs737011 chr6 46555401 G A 9.99E-04 Obesity (extreme) CYP39A1 intron 21935397 rs6458511 chr6 46570783 C G 1.49E-05 Lipoprotein-associated phospholipase A2 activity and mass CYP39A1 intron 20442857 rs3799872 chr6 46580382 G A 1.46E-05 Major depressive disorder CYP39A1 intron 19107115 rs7758684 chr6 46582156 G T 5.71E-05 Major depressive disorder CYP39A1 intron 19107115 rs16874867 chr6 46590885 T C 3.11E-04 Acute lung injury CYP39A1 intron 22295056 rs6936750 chr6 46595117 C G 3.19E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers CYP39A1 intron 21775533 rs6907129 chr6 46597608 G T 7.83E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers CYP39A1 intron 21775533 rs666240 chr6 46607708 C T 1.49E-08 Lipoprotein-associated phospholipase A2 activity and mass CYP39A1 intron 22003152 rs681513 chr6 46608766 G C 1.47E-08 Lipoprotein-associated phospholipase A2 activity and mass CYP39A1 intron 22003152 rs2277119 chr6 46609905 C T 6.87E-09 Lipoprotein-associated phospholipase A2 activity and mass CYP39A1 missense 22003152 rs952884 chr6 46613083 T C 3.28E-11 Lipoprotein-associated phospholipase A2 activity and mass CYP39A1 intron 22003152 rs12215229 chr6 46614439 T G 1.94E-09 Lipoprotein-associated phospholipase A2 activity and mass CYP39A1 intron 22003152 rs12192544 chr6 46620252 C G 4.09E-11 Lipoprotein-associated phospholipase A2 activity and mass CYP39A1 missense 20442857 rs12192544 chr6 46620252 C G 2.76E-17 Lipoprotein-associated phospholipase A2 activity and mass CYP39A1 missense 22003152 rs3757241 chr6 46623698 T C 6.74E-10 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 cds-synon 22003152 rs9381468 chr6 46625274 A G 2.75E-12 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 intron 22003152 rs10807344 chr6 46625635 C T 3.60E-04 Alcohol dependence SLC25A27 intron 20201924 rs10807344 chr6 46625635 C T 1.31E-10 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 intron 20442857 rs10807344 chr6 46625635 C T 1.58E-16 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 intron 22003152 rs6907892 chr6 46625886 C T 2.19E-12 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 intron 22003152 rs953062 chr6 46626353 A G 2.31E-12 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 intron 22003152 rs3778483 chr6 46627100 C G 4.96E-11 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 intron 22003152 rs6904373 chr6 46628067 T C 6.65E-10 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 intron 22003152 rs6924489 chr6 46628111 A G 6.26E-10 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 intron 22003152 rs9296504 chr6 46629505 T C 9.91E-11 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 intron 22003152 rs9296505 chr6 46629841 A G 3.84E-10 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 intron 20442857 rs9296505 chr6 46629841 A G 2.49E-11 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 intron 22003152 rs7767605 chr6 46629857 G A 5.05E-10 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 intron 22003152 rs9381469 chr6 46630068 G A 4.61E-11 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 intron 22003152 rs6901132 chr6 46631801 A G 4.62E-08 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 intron 20442857 rs6901132 chr6 46631801 A G 1.94E-12 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 intron 22003152 rs6901178 chr6 46631886 A G 4.45E-10 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 intron 22003152 rs6928546 chr6 46632006 T C 4.79E-09 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 intron 22003152 rs9395206 chr6 46638422 T A 3.79E-10 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 intron 22003152 rs9472817 chr6 46640992 C G 8.32E-13 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 intron 22003152 rs9357512 chr6 46642875 T C 3.31E-10 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 intron 22003152 rs2270450 chr6 46644875 C T 6.22E-19 Lipoprotein-associated phospholipase A2 activity and mass SLC25A27 UTR-3 22003152 rs7740677 chr6 46649231 C T 2.84E-10 Lipoprotein-associated phospholipase A2 activity and mass LOC100131283 intron 22003152 rs9472819 chr6 46653789 A G 2.64E-10 Lipoprotein-associated phospholipase A2 activity and mass LOC100131283 intron 22003152 rs10948299 chr6 46653858 G T 5.68E-09 Lipoprotein-associated phospholipase A2 activity and mass LOC100131283 intron 22003152 rs11961117 chr6 46654246 G A 8.40E-04 Alcohol dependence LOC100131283 intron 20201924 rs13196132 chr6 46655603 C T 9.53E-13 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs3799277 chr6 46657057 A G 1.91E-10 Lipoprotein-associated phospholipase A2 activity and mass TDRD6 missense 22003152 rs9381472 chr6 46658905 C G 1.44E-11 Lipoprotein-associated phospholipase A2 activity and mass TDRD6 missense 22003152 rs2216464 chr6 46662577 C T 1.88E-10 Lipoprotein-associated phospholipase A2 activity and mass TDRD6 intron 22003152 rs974670 chr6 46667343 C T 2.60E-08 Lipoprotein-associated phospholipase A2 activity and mass TDRD6 intron 22003152 rs12528857 chr6 46669936 C A 5.40E-04 Alcohol dependence TDRD6 UTR-3 20201924 rs12528857 chr6 46669936 C A 4.33E-11 Lipoprotein-associated phospholipase A2 activity and mass TDRD6 UTR-3 20442857 rs12528857 chr6 46669936 C A 3.21E-18 Lipoprotein-associated phospholipase A2 activity and mass TDRD6 UTR-3 22003152 rs1051931 chr6 46672943 A G 1.85E-10 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 missense 22003152 rs7756935 chr6 46675025 C A 1.00E-10 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 intron 22003152 rs2216465 chr6 46676019 C G 4.72E-11 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 intron 22003152 rs4498351 chr6 46676783 T A 3.45E-12 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 intron 22003152 rs1421372 chr6 46681403 A G 4.36E-10 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 intron 22003152 rs1362931 chr6 46682079 A C 3.80E-10 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 intron 22003152 rs1362931 chr6 46682079 A C 3.00E-19 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 intron 23118302 rs1805017 chr6 46684222 C T 6.00E-14 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 missense 20442857 rs1805017 chr6 46684222 C T 2.00E-23 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 missense 22003152 rs1805017 chr6 46684222 C T 0.0002 Prostate cancer PLA2G7 missense 23555315 rs6929105 chr6 46685286 T C 7.66E-10 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 intron 22003152 rs12195701 chr6 46687419 C T 4.17E-23 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 intron 22003152 rs3799862 chr6 46687931 C T 7.52E-10 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 intron 22003152 rs3799861 chr6 46689529 T C 3.39E-10 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 intron 22003152 rs3799861 chr6 46689529 T C 7.49E-04 Alcohol dependence PLA2G7 intron 24277619 rs9472830 chr6 46689762 T C 5.48E-09 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 intron 22003152 rs1421368 chr6 46696593 G A 4.88E-08 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 intron 22003152 rs9381474 chr6 46697380 G T 4.26E-21 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 intron 22003152 rs9381475 chr6 46699292 C T 3.90E-19 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 intron 22003152 rs9395208 chr6 46703319 G C 1.00E-16 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 UTR-5 22003152 rs1421378 chr6 46703513 A G 8.96E-05 Personality dimensions PLA2G7 nearGene-5 18957941 rs1421378 chr6 46703513 A G 5.35E-07 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 nearGene-5 20442857 rs1421378 chr6 46703513 A G 4.05E-09 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 nearGene-5 22003152 rs1421378 chr6 46703513 A G 0.000051 Coronary artery calcification PLA2G7 nearGene-5 23727086 rs10948301 chr6 46704467 C T 1.27E-10 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 nearGene-5 20442857 rs10948301 chr6 46704467 C T 7.11E-19 Lipoprotein-associated phospholipase A2 activity and mass PLA2G7 nearGene-5 22003152 rs1421379 chr6 46705994 G A 5.79E-19 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs9349373 chr6 46706593 G A 5.65E-19 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs9369631 chr6 46707519 A G 9.53E-11 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs9369631 chr6 46707519 A G 3.80E-19 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs9381477 chr6 46707580 G A 1.62E-10 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs9381477 chr6 46707580 G A 7.19E-19 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs1862008 chr6 46710279 A G 1.06E-10 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs1862008 chr6 46710279 A G 1.03E-18 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs12211537 chr6 46711024 C G 8.85E-09 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs12211537 chr6 46711024 C G 1.34E-10 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs9395210 chr6 46711962 A G 4.29E-19 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs9369632 chr6 46713394 A G 4.44E-19 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs9296510 chr6 46713805 T C 1.27E-10 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs9296510 chr6 46713805 T C 2.68E-19 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs9349374 chr6 46714598 C T 4.88E-19 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs1421373 chr6 46715067 C T 1.40E-09 Lipoprotein-associated phospholipase A2 activity and mass LOC100287718 intron 22003152 rs1592704 chr6 46715761 T A 5.85E-19 Lipoprotein-associated phospholipase A2 activity and mass LOC100287718 intron 22003152 rs1362932 chr6 46716079 A G 4.71E-19 Lipoprotein-associated phospholipase A2 activity and mass LOC100287718 intron 22003152 rs9367256 chr6 46723267 C T 9.17E-19 Lipoprotein-associated phospholipase A2 activity and mass LOC100287718 intron 22003152 rs9381480 chr6 46724131 A G 9.32E-19 Lipoprotein-associated phospholipase A2 activity and mass LOC100287718 intron 22003152 rs9395211 chr6 46724247 T C 2.87E-08 Lipoprotein-associated phospholipase A2 activity and mass LOC100287718 intron 22003152 rs9395212 chr6 46726441 G C 2.30E-05 Urinary metabolites LOC100287718 intron 21572414 rs13191618 chr6 46733069 T G 2.61E-04 Type 2 diabetes / / 17463246 rs6458516 chr6 46741903 G A 6.39E-04 Type 2 diabetes / / 17463246 rs872019 chr6 46766468 G C 1.15E-05 Acute lung injury MEP1A intron 22295056 rs3799859 chr6 46767645 A G 1.15E-05 Acute lung injury MEP1A intron 22295056 rs3799858 chr6 46767688 G A 3.57E-04 Multiple complex diseases MEP1A intron 17554300 rs9357516 chr6 46772534 T G 1.15E-05 Acute lung injury MEP1A intron 22295056 rs3799857 chr6 46776337 G T 1.15E-05 Acute lung injury MEP1A intron 22295056 rs1833460 chr6 46777377 T C 4.94E-04 Suicide attempts in bipolar disorder MEP1A intron 21423239 rs6458518 chr6 46779818 T G 7.70E-04 Acute lung injury MEP1A intron 22295056 rs1410826 chr6 46781182 A G 1.15E-05 Acute lung injury MEP1A intron 22295056 rs3778481 chr6 46785050 G A 1.91E-05 Acute lung injury MEP1A intron 22295056 rs7748263 chr6 46786183 G T 9.72E-04 Obesity (extreme) MEP1A intron 21935397 rs6903045 chr6 46797515 G A 1.40E-05 Urinary metabolites MEP1A intron 21572414 rs2297019 chr6 46803102 A G 2.59E-05 Acute lung injury MEP1A missense 22295056 rs12199610 chr6 46804986 G A 2.60E-05 Urinary metabolites MEP1A intron 21572414 rs9349377 chr6 46806383 G A 1.15E-05 Acute lung injury MEP1A intron 22295056 rs148186379 chr6 46806939 G GTGGGGCAGCTTT 1.90E-05 Urinary metabolites MEP1A UTR-3 21572414 rs17468190 chr6 46806939 G T 1.90E-05 Urinary metabolites MEP1A UTR-3 21572414 rs1059276 chr6 46807040 C A 1.30E-04 Iris characteristics MEP1A UTR-3 21835309 rs220687 chr6 46814991 C T 3.78E-04 Blood pressure / / 17255346 rs9357517 chr6 46815322 C G 5.32E-06 Acute lung injury / / 22295056 rs7759681 chr6 46816473 A C 1.01E-05 Acute lung injury / / 22295056 rs1819371 chr6 46817274 T A 1.13E-05 Acute lung injury / / 22295056 rs6458525 chr6 46817982 C T 4.95E-06 Acute lung injury / / 22295056 rs9367258 chr6 46822589 A C 1.46E-05 Acute lung injury GPR116 intron 22295056 rs9395217 chr6 46824165 T A 8.52E-05 Acute lung injury GPR116 intron 22295056 rs2281443 chr6 46825595 G A 1.38E-05 Acute lung injury GPR116 intron 22295056 rs9395218 chr6 46827239 C T 1.16E-05 Acute lung injury GPR116 missense 22295056 rs508818 chr6 46829816 T C 8.27E-05 Acute lung injury GPR116 intron 22295056 rs614826 chr6 46832813 G A 8.27E-05 Acute lung injury GPR116 cds-synon 22295056 rs614826 chr6 46832813 G A 4.57E-04 Lung function (forced vital capacity) GPR116 cds-synon 24023788 rs1928274 chr6 46837390 C T 6.34E-04 Amyotrophic Lateral Sclerosis GPR116 intron 17362836 rs1928274 chr6 46837390 C T 9.35E-05 Cognitive test performance GPR116 intron 20125193 rs1928274 chr6 46837390 C T 1.18E-05 Acute lung injury GPR116 intron 22295056 rs11760108 chr6 46849057 G T 8.74E-04 Multiple complex diseases GPR116 intron 17554300 rs220665 chr6 46850169 T G 7.09E-04 Alzheimer's disease GPR116 intron 17998437 rs11753137 chr6 46854163 T C 9.89E-04 Multiple complex diseases GPR116 intron 17554300 rs1004018 chr6 46854403 G A 5.23E-04 Nicotine smoking GPR116 intron 19268276 rs3065 chr6 46860928 T G 7.53E-06 Post-operative nausea and vomiting GPR116 intron 21694509 rs220704 chr6 46865758 T A 4.06E-05 Multiple complex diseases GPR116 intron 17554300 rs6910089 chr6 46871985 T C 6.13E-04 Nicotine smoking GPR116 intron 19268276 rs1234121 chr6 46873470 C T 3.99E-04 Lung function (forced expiratory volume in 1 second) GPR116 intron 24023788 rs13203899 chr6 46891009 T C 4.89E-04 Obesity (extreme) GPR116 intron 21935397 rs9381489 chr6 46911748 C A 4.05E-04 Body mass index GPR116 intron 21701565 rs2021916 chr6 46914521 G T 3.15E-05 Multiple complex diseases GPR116 intron 17554300 rs761748 chr6 46918018 T C 9.23E-04 Suicide attempts in bipolar disorder GPR116 intron 21423239 rs1028495 chr6 46925176 C T 8.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs9472920 chr6 46926129 A G 6.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs9472921 chr6 46926134 T C 6.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs1889577 chr6 46929805 T C 7.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2105027 chr6 46930537 C G 8.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs4714970 chr6 46930890 C A 7.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs1334972 chr6 46942554 G T 7.06E-05 Hemoglobin / / pha003098 rs6458533 chr6 46951248 A G 1.17E-04 Multiple complex diseases / / 17554300 rs1932033 chr6 46953541 A G 1.67E-05 Hemoglobin / / pha003098 rs1226498 chr6 46957625 G A 2.72E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1226500 chr6 46961952 C A 5.27E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1226478 chr6 46979403 T C 0.0000725 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes GPR110 intron 22628534 rs1226479 chr6 46980115 G A 0.000853 Salmonella-induced pyroptosis GPR110 intron 22837397 rs1226493 chr6 46988648 C T 2.09E-05 Post-operative nausea and vomiting GPR110 intron 21694509 rs1226485 chr6 46996218 C G 5.36E-04 Response to cytidine analogues (gemcitabine) GPR110 intron 24483146 rs143669522 chr6 46996760 G A 0.000038 Breast cancer(er negative) GPR110 missense 23555315 rs6941183 chr6 46997110 C T 8.57E-05 Post-operative nausea and vomiting GPR110 intron 21694509 rs16875546 chr6 47028451 G A 4.20E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1226534 chr6 47030351 G A,C,T 5.00E-05 Bilirubin levels / / 19414484 rs1226537 chr6 47034842 A T 5.00E-05 Bilirubin levels / / 19414484 rs10498772 chr6 47045015 G T 1.67E-05 Intelligence / / 21826061 rs7757633 chr6 47064147 C T 1.20E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs960718 chr6 47064338 T C 6.77E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2396805 chr6 47066294 G A 6.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs1532137 chr6 47069291 C T 8.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs937055 chr6 47086952 T C 1.99E-05 Depression (quantitative trait) / / 23290196 rs1687119 chr6 47089544 A G 4.51E-05 Depression (quantitative trait) / / 23290196 rs1687128 chr6 47094118 G T 4.05E-05 Depression (quantitative trait) / / 23290196 rs1738819 chr6 47094552 C T 9.57E-05 Depression (quantitative trait) / / 23290196 rs1738820 chr6 47095197 C T 7.20E-05 Diabetic retinopathy / / 21441570 rs1738822 chr6 47095744 A G 2.19E-04 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs1687135 chr6 47101137 A G 3.54E-04 Type 2 diabetes / / 17463246 rs1617315 chr6 47102342 C G 9.89E-05 Diabetic nephropathy / / 21150874 rs1627116 chr6 47104451 A G 7.40E-04 Taste perception / / 22132133 rs1738829 chr6 47109623 G A 3.48E-08 Metabolite levels / / 23281178 rs995641 chr6 47113039 C G 3.66E-08 Metabolite levels / / 23281178 rs16875681 chr6 47119155 T A 7.09E-04 Multiple complex diseases / / 17554300 rs10484958 chr6 47121186 G A 1.62E-04 Multiple complex diseases / / 17554300 rs9381514 chr6 47124056 A C 9.66E-09 Metabolite levels / / 23281178 rs7774223 chr6 47124987 G A 2.10E-04 Alzheimer's disease (late onset) / / 21379329 rs9395236 chr6 47128649 A C 3.71E-04 Multiple complex diseases / / 17554300 rs9296534 chr6 47128729 A G 1.07E-08 Metabolite levels / / 23281178 rs9296536 chr6 47130988 A G 8.04E-04 Multiple complex diseases / / 17554300 rs2396819 chr6 47136513 C G 7.43E-04 Alzheimer's disease / / 17998437 rs9473023 chr6 47137996 A C 0.000889 Salmonella-induced pyroptosis / / 22837397 rs7748298 chr6 47152278 A G 2.14E-06 Left ventricular mass / / 21212386 rs7764020 chr6 47153497 G T 9.41E-05 Personality dimensions / / 18957941 rs4629675 chr6 47187915 T C 6.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs4482973 chr6 47213859 G T 4.33E-04 Depression (quantitative trait) TNFRSF21 intron 20800221 rs1884311 chr6 47214413 A G 8.39E-05 Personality dimensions TNFRSF21 intron 18957941 rs2295270 chr6 47216562 G A 8.39E-05 Personality dimensions TNFRSF21 intron 18957941 rs2103868 chr6 47230615 A G 5.00E-06 Panic disorder TNFRSF21 intron 19165232 rs2103868 chr6 47230615 A G 4.69E-05 Glucose levels TNFRSF21 intron pha002899 rs7744364 chr6 47287769 C T 4.14E-05 Suicidal ideation / / 20877300 rs12210004 chr6 47295025 G T 6.19E-04 Obesity (extreme) / / 21935397 rs12198405 chr6 47296227 A G 7.60E-04 Obesity (extreme) / / 21935397 rs10948347 chr6 47311898 T C 4.01E-06 Personality dimensions / / 22628180 rs10948347 chr6 47311898 T C 4.33E-05 HDL particle features / / pha002900 rs9381534 chr6 47313491 G A 2.88E-06 Personality dimensions / / 22628180 rs9369675 chr6 47314809 C A 3.45E-06 Personality dimensions / / 22628180 rs6918220 chr6 47317312 C T 3.62E-06 Personality dimensions / / 22628180 rs9357529 chr6 47317432 C A 3.61E-06 Personality dimensions / / 22628180 rs3905310 chr6 47318818 G A 3.94E-04 Multiple complex diseases / / 17554300 rs3905310 chr6 47318818 G A 4.96E-05 Alcohol dependence / / 21314694 rs3905310 chr6 47318818 G A 3.73E-06 Personality dimensions / / 22628180 rs537723700 chr6 47318847 C CG 3.73E-06 Personality dimensions / / 22628180 rs9395248 chr6 47318847 C G,T 3.73E-06 Personality dimensions / / 22628180 rs7761581 chr6 47318885 G A 2.14E-04 Type 2 diabetes / / 17463246 rs6938470 chr6 47338091 G A 2.51E-04 Parkinson's disease / / 17052657 rs12197270 chr6 47348061 G A 9.30E-06 Urinary metabolites / / 21572414 rs4374821 chr6 47355493 G A 1.07E-06 Personality dimensions / / 22628180 rs4236095 chr6 47368687 G A 9.06E-04 Type 2 diabetes / / 17463246 rs1931833 chr6 47427281 T A 1.64E-05 Alzheimer's disease (late onset) / / 21460841 rs9381563 chr6 47432637 C T 3.59E-05 Alzheimer's disease (late onset) / / 21460841 rs1004173 chr6 47445017 C T 2.03E-05 Alzheimer's disease (late onset) CD2AP nearGene-5 21460841 rs4715019 chr6 47447041 T A 1.19E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs9367279 chr6 47448336 A G 1.31E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs9296558 chr6 47451883 C T 1.29E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs9296559 chr6 47452270 T C 4.26E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs9349407 chr6 47453378 G C 9.00E-09 Alzheimer's disease (late onset) CD2AP intron 21460841 rs9349407 chr6 47453378 G C 8.60E-09 Prion diseases CD2AP intron 22210626 rs7738044 chr6 47469273 A G 1.33E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs1872505 chr6 47480975 C G 1.36E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs17289198 chr6 47482456 C T 6.81E-04 Alzheimer's disease CD2AP intron 22005930 rs4715025 chr6 47483653 C G 1.40E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs10948363 chr6 47487762 A G 1.60E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs10948363 chr6 47487762 A G 5.00E-11 Alzheimer's disease (late onset) CD2AP intron 24162737 rs9296561 chr6 47488938 G A 1.89E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs7749167 chr6 47493940 G A 2.05E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs7754282 chr6 47502024 G C 2.09E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs17289226 chr6 47504513 A G 6.72E-04 Alzheimer's disease CD2AP intron 22005930 rs9349413 chr6 47511491 A G 2.13E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs4715031 chr6 47528817 T G 4.99E-04 Multiple complex diseases CD2AP intron 17554300 rs9296566 chr6 47549126 C T 2.27E-04 Bone mass and geometry CD2AP intron 17903296 rs9395283 chr6 47551444 T C 1.99E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs9349416 chr6 47551938 G A 1.98E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs9369716 chr6 47552180 A T 1.97E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs9395285 chr6 47554177 G A 1.95E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs9369717 chr6 47554468 T G 1.95E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs1485780 chr6 47556630 A C 1.97E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs9381578 chr6 47556634 C T 1.93E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs2396825 chr6 47568696 A G 1.94E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs9395286 chr6 47575332 T C 1.88E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs10948367 chr6 47585615 A G 1.81E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs2171086 chr6 47590104 C T 1.77E-05 Alzheimer's disease (late onset) CD2AP intron 21460841 rs719856 chr6 47594722 G A 1.21E-05 Blood Pressure and Arterial Stiffness CD2AP UTR-3 17903302 rs9395288 chr6 47598125 C T 5.63E-06 Alzheimer's disease (late onset) / / 21460841 rs16876120 chr6 47599978 T C 1.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12202615 chr6 47618171 T C 1.69E-04 Alzheimer's disease (late onset) / / 21460841 rs7740538 chr6 47633098 C T 0.0004171 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) GPR111 intron 23233654 rs7740538 chr6 47633098 C T 4.17E-04 Methotrexate clearance (acute lymphoblastic leukemia) GPR111 intron 23233662 rs869002 chr6 47640097 T C 6.61E-04 Alzheimer's disease GPR111 intron 24755620 rs9296571 chr6 47653898 T C 4.93E-04 Response to cytidine analogues (gemcitabine) GPR111 intron 24483146 rs1890667 chr6 47660777 A C 9.19E-04 Alzheimer's disease GPR111 intron 22005930 rs4715044 chr6 47662710 G A 5.72E-04 Multiple complex diseases GPR111 intron 17554300 rs1329536 chr6 47663326 T C 6.20E-06 Prostate cancer GPR111 UTR-3 24185611 rs12198900 chr6 47685655 C A 1.96E-04 Response to cytidine analogues (gemcitabine) GPR115 intron 24483146 rs1329523 chr6 47690613 G A 7.08E-05 Multiple complex diseases / / 17554300 rs1329524 chr6 47690634 A G 2.01E-19 Multiple complex diseases / / 17554300 rs1360156 chr6 47691208 G A 5.08E-05 Rheumatoid arthritis / / 17804836 rs1928461 chr6 47696865 G A 6.78E-04 Multiple complex diseases / / 17554300 rs9369741 chr6 47702934 T G 6.22E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2026734 chr6 47705042 A G 7.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9381607 chr6 47708879 A T 9.54E-04 Alzheimer's disease / / 22005930 rs9381607 chr6 47708879 A T 6.75E-04 Alzheimer's disease / / 24755620 rs12215131 chr6 47709696 C A 2.38E-04 Alzheimer's disease (late onset) / / 21379329 rs2149779 chr6 47719839 G A 3.72E-04 Multiple complex diseases / / 17554300 rs2149779 chr6 47719839 G A 0.0000032 Mean arterial pressure / / 22510845 rs9395320 chr6 47749539 A G 1.76E-04 Response to alcohol consumption (flushing response) / / 24277619 rs7764303 chr6 47750439 C T 8.37E-08 Metabolite levels OPN5 intron 23281178 rs9367304 chr6 47750894 C T 8.18E-08 Metabolite levels OPN5 intron 23281178 rs9296582 chr6 47755080 T C 4.89E-05 Alzheimer's disease (late onset) OPN5 intron 21379329 rs9296583 chr6 47757853 A C 1.62E-04 Alzheimer's disease (late onset) OPN5 intron 21379329 rs16876536 chr6 47760306 A C 1.76E-04 Response to alcohol consumption (flushing response) OPN5 intron 24277619 rs7743905 chr6 47771214 C T 5.92E-05 Cognitive impairment induced by topiramate OPN5 intron 22091778 rs7752425 chr6 47774597 T A 7.64E-04 Smoking cessation OPN5 intron 24665060 rs10485320 chr6 47776901 T C 3.28E-05 Blood Pressure and Arterial Stiffness OPN5 intron 17903302 rs9381618 chr6 47780081 T C 5.80E-04 Smoking cessation OPN5 intron 24665060 rs506816 chr6 47782969 G T 5.44E-05 Alzheimer's disease (late onset) OPN5 intron 21379329 rs563587 chr6 47810381 C T 4.78E-04 Alzheimer's disease (late onset) / / 21379329 rs4715047 chr6 47841953 G T 2.97E-04 Alzheimer's disease (late onset) / / 21379329 rs1571444 chr6 47880620 C T 4.47E-06 Plasma omega-6 polyunsaturated fatty acid levels PTCHD4 intron 24823311 rs9357565 chr6 47881668 A G 3.89E-06 Plasma omega-6 polyunsaturated fatty acid levels PTCHD4 intron 24823311 rs12209011 chr6 47882340 T C 2.79E-06 Plasma omega-6 polyunsaturated fatty acid levels PTCHD4 intron 24823311 rs12209128 chr6 47882548 T G 3.00E-06 Plasma omega-6 polyunsaturated fatty acid levels PTCHD4 intron 24823311 rs12209190 chr6 47882650 T A 3.77E-06 Plasma omega-6 polyunsaturated fatty acid levels PTCHD4 intron 24823311 rs10807382 chr6 47882737 T C 3.60E-06 Plasma omega-6 polyunsaturated fatty acid levels PTCHD4 intron 24823311 rs10807383 chr6 47882808 A G 1.97E-04 Cognitive decline PTCHD4 intron 23732972 rs10807383 chr6 47882808 A G 3.53E-06 Plasma omega-6 polyunsaturated fatty acid levels PTCHD4 intron 24823311 rs10807385 chr6 47882936 T A 3.44E-06 Plasma omega-6 polyunsaturated fatty acid levels PTCHD4 intron 24823311 rs1328969 chr6 47883382 A G 5.01E-06 Plasma omega-6 polyunsaturated fatty acid levels PTCHD4 intron 24823311 rs7750802 chr6 47883656 G A 3.49E-06 Plasma omega-6 polyunsaturated fatty acid levels PTCHD4 intron 24823311 rs9349435 chr6 47887732 G A 2.33E-04 Alzheimer's disease (late onset) PTCHD4 intron 21379329 rs9381631 chr6 47888700 C T 3.30E-05 Body Fat Distribution PTCHD4 intron pha003017 rs16876853 chr6 47914995 T C 9.76E-04 Alzheimer's disease PTCHD4 intron 22005930 rs1974051 chr6 47916225 A G 5.12E-05 Celiac disease PTCHD4 intron 23936387 rs1974051 chr6 47916225 A G 1.02E-04 Amyotrophic lateral sclerosis (sporadic) PTCHD4 intron 24529757 rs10485047 chr6 47923245 T C 9.21E-04 Alzheimer's disease PTCHD4 intron 22005930 rs10485047 chr6 47923245 T C 2.73E-05 Celiac disease PTCHD4 intron 23936387 rs1325713 chr6 47949493 T C 8.16E-04 Alzheimer's disease PTCHD4 intron 17998437 rs1325709 chr6 47962767 C T 4.11E-04 Alzheimer's disease PTCHD4 intron 17998437 rs10456573 chr6 47968236 A C 2.00E-04 Cognitive impairment induced by topiramate PTCHD4 intron 22091778 rs1570077 chr6 47981073 T C 4.93E-04 Alzheimer's disease (late onset) PTCHD4 intron 21379329 rs2814473 chr6 47990857 G A 8.19E-04 Suicide attempts in bipolar disorder PTCHD4 intron 21423239 rs13197345 chr6 48002761 G T 9.69E-04 Suicide attempts in bipolar disorder PTCHD4 intron 21423239 rs10456131 chr6 48008899 G T 7.01E-04 Insulin resistance PTCHD4 intron 21901158 rs674227 chr6 48009426 C T 5.69E-05 Serum metabolites PTCHD4 intron 19043545 rs10456575 chr6 48011568 A G 4.63E-04 Acute lung injury PTCHD4 intron 22295056 rs10485049 chr6 48029847 C T 6.20E-04 Acute lung injury PTCHD4 intron 22295056 rs12196066 chr6 48031994 A G 1.96E-04 Acute lung injury PTCHD4 intron 22295056 rs4715063 chr6 48079018 T C 5.64E-04 Body mass index / / 21701565 rs6908563 chr6 48083008 G A 1.58E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs6908563 chr6 48083008 G A 4.10E-04 Body mass index / / 21701565 rs12198093 chr6 48086158 C T 8.90E-05 Body Mass Index / / pha003021 rs3945413 chr6 48088140 T G 1.72E-04 Body mass index / / 21701565 rs10738102 chr6 48089517 G C 1.58E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs10738102 chr6 48089517 G C 2.61E-04 Body mass index / / 21701565 rs2894746 chr6 48090032 G A 2.77E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs2894746 chr6 48090032 G A 2.26E-04 Body mass index / / 21701565 rs1952975 chr6 48095846 G A 2.72E-04 Body mass index / / 21701565 rs12204829 chr6 48112608 A G 2.69E-05 Nonalcoholic fatty liver disease / / 21423719 rs2503674 chr6 48228338 T C 1.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs2503674 chr6 48228338 T C 6.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs603284 chr6 48282352 T G 6.28E-04 Prostate cancer mortality / / 20978177 rs615396 chr6 48282842 G A 5.38E-04 Smoking cessation / / 24665060 rs482581 chr6 48284790 C G 7.01E-04 Prostate cancer mortality / / 20978177 rs659675 chr6 48285824 G A 6.28E-04 Prostate cancer mortality / / 20978177 rs673410 chr6 48286594 C A 6.25E-04 Prostate cancer mortality / / 20978177 rs973094 chr6 48286611 G T 6.28E-04 Prostate cancer mortality / / 20978177 rs973093 chr6 48286655 T C 6.28E-04 Prostate cancer mortality / / 20978177 rs676219 chr6 48287248 A G 7.46E-05 Schizophrenia / / 19197363 rs584557 chr6 48288536 G A 7.46E-05 Schizophrenia / / 19197363 rs9296594 chr6 48344746 C G 2.61E-04 Schizophrenia / / 21674006 rs325286 chr6 48387129 T C 7.99E-04 Schizophrenia / / 19197363 rs7739101 chr6 48474714 T C 9.93E-04 Parkinson's disease / / 16252231 rs9463425 chr6 48513035 A G 9.70E-06 Asthma / / 20698975 rs12176541 chr6 48530298 G A 3.12E-05 Kawasaki disease / / 22081228 rs16877558 chr6 48533769 T C 1.58E-04 Type 2 diabetes / / 17463246 rs85679 chr6 48654869 T A 6.85E-04 Type 2 diabetes / / 17463246 rs1555281 chr6 48660713 G A 3.10E-04 Type 2 diabetes / / 17463246 rs2207999 chr6 48665857 G C 4.05E-04 Type 2 diabetes / / 17463246 rs9395398 chr6 48667665 A C 1.79E-04 Type 2 diabetes / / 17463246 rs2474496 chr6 48670675 T C 5.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs7771117 chr6 48695407 A C,G,T 5.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs9395402 chr6 48696010 A G 7.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs9473470 chr6 48700354 G C 2.32E-04 Multiple complex diseases / / 17554300 rs4715097 chr6 48700646 C T 6.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs9473472 chr6 48700995 T C 5.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs9473474 chr6 48701367 C T 6.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs9349458 chr6 48820253 T C 8.50E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs9349458 chr6 48820253 T C 4.77E-04 Type 2 diabetes / / 17463246 rs1938212 chr6 48840782 G C 1.70E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1938212 chr6 48840782 G C 4.63E-04 Type 2 diabetes / / 17463246 rs1938218 chr6 48858479 T C 8.27E-04 Alcohol dependence / / 20201924 rs9357585 chr6 48862878 G A 6.89E-04 Alcohol dependence / / 20201924 rs10948466 chr6 48923009 T C 7.10E-05 Schizophrenia / / 19571808 rs7766357 chr6 48942707 A G 2.70E-04 Statin-induced myopathy / / 21826682 rs9367338 chr6 48949938 C T 2.39E-04 Alcohol dependence / / 20201924 rs7772532 chr6 48957842 T G 1.90E-04 Alcohol dependence / / 20201924 rs11758627 chr6 49017502 A G 5.60E-05 Cognitive function / / 24684796 rs2032553 chr6 49132793 T C 7.30E-05 Cognitive function / / 24684796 rs2051643 chr6 49146592 A G 3.70E-05 Cognitive function / / 24684796 rs2496363 chr6 49184770 T C 3.33E-05 Socioeconomic Factors / / pha003067 rs497734 chr6 49211631 T G 3.36E-05 Socioeconomic Factors / / pha003067 rs476144 chr6 49212102 T C 3.33E-05 Socioeconomic Factors / / pha003067 rs4711926 chr6 49225804 T G 4.96E-05 Socioeconomic Factors / / pha003067 rs491715 chr6 49238515 T C 6.65E-04 Multiple complex diseases / / 17554300 rs531102 chr6 49263042 C G 6.53E-04 Multiple complex diseases / / 17554300 rs1924989 chr6 49330805 C T 1.66E-05 Response to hepatitis C treatment / / 19684573 rs12528625 chr6 49378668 G T 8.00E-09 Lymphocyte counts / / 22286170 rs9369898 chr6 49382193 G A 2.00E-10 Homocysteine levels / / 23824729 rs8589 chr6 49403282 T C 3.45E-05 Coronary heart disease MUT missense pha003030 rs9473555 chr6 49409487 G C 5.00E-08 Folate pathway vitamin levels MUT intron 19744961 rs3806988 chr6 49431569 A G 2.03E-07 Lymphocyte counts CENPQ intron 22286170 rs2501968 chr6 49459978 A G 1.77E-06 Hodgkin's lymphoma CENPQ missense 24149102 rs2501968 chr6 49459978 A G 9.76E-06 Coronary heart disease CENPQ missense pha003030 rs9395500 chr6 49479930 A G 3.27E-04 Smoking initiation GLYATL3 intron 24665060 rs9473582 chr6 49488908 A C 8.00E-07 Brain structure GLYATL3 intron 20171287 rs9473583 chr6 49491305 C T 1.08E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) GLYATL3 intron 24023788 rs9473583 chr6 49491305 C T 2.51E-04 Smoking initiation GLYATL3 intron 24665060 rs9395504 chr6 49494933 C T 5.20E-05 Personality dimensions GLYATL3 UTR-3 18957941 rs4715136 chr6 49515525 T C 6.47E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7761928 chr6 49520083 C A 8.91E-04 Type 2 diabetes / / 17463246 rs7742891 chr6 49525360 T C 9.11E-04 Type 2 diabetes / / 17463246 rs7753655 chr6 49536564 A G 4.29E-06 Migraine / / 20802479 rs13198157 chr6 49602760 A G 8.21E-04 Alzheimer's disease RHAG intron 22005930 rs11757820 chr6 49636941 A C 5.09E-04 Alzheimer's disease / / 22005930 rs527461 chr6 49725341 A C 5.70E-06 Stroke (ischemic) / / 21957438 rs489184 chr6 49747462 T C 3.57E-06 Stroke (ischemic) / / 21957438 rs4715153 chr6 49891258 T C 7.13E-05 Asthma / / pha003127 rs41334350 chr6 49893260 G A 8.70E-06 Urinary metabolites / / 21572414 rs6927196 chr6 49902734 T C 7.60E-05 Asthma / / pha003127 rs1361121 chr6 49924070 A C 0.000000967 Amyotrophic lateral sclerosis / / 23587638 rs1361121 chr6 49924070 A C 0.00000102 Amyotrophic lateral sclerosis / / 23587638 rs12196609 chr6 49985939 A G 3.48E-05 Tunica Media DEFB110 intron pha003034 rs12208674 chr6 50020423 G A 3.83E-05 Tunica Media / / pha003034 rs7761173 chr6 50083282 T C 4.60E-05 Cervical cancer / / 24700089 rs41402445 chr6 50086239 G A 7.73E-05 Cervical cancer / / 24700089 rs6458722 chr6 50100827 A G 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7750808 chr6 50125321 G A 8.74E-05 Tunica Media / / pha003034 rs9381845 chr6 50140671 A G 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12210112 chr6 50142856 T C 6.51E-05 Tunica Media / / pha003034 rs1572887 chr6 50159392 T C 7.21E-05 Tunica Media / / pha003034 rs11965925 chr6 50160119 A G 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6916083 chr6 50198125 A G 9.66E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs28712294 chr6 50242679 T C 2.80E-04 Urinary metabolites / / 21572414 rs1126287 chr6 50267833 C T 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs9357655 chr6 50279484 A G 6.09E-05 Tunica Media / / pha003034 rs1845031 chr6 50322944 C T 1.52E-06 Stroke (ischemic) / / 22941190 rs6921059 chr6 50352136 C T 4.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs200247 chr6 50401480 T A 9.40E-05 Aging (time to event) / / 21782286 rs6915141 chr6 50444807 G A 8.90E-06 Urinary metabolites / / 21572414 rs1008297 chr6 50458021 C T 1.43E-04 Multiple complex diseases / / 17554300 rs9463613 chr6 50467830 G C 4.95E-04 Multiple complex diseases / / 17554300 rs2225204 chr6 50479739 G A 5.32E-06 Lipid levels / / 19016617 rs6919902 chr6 50496338 T C 2.10E-05 Urinary metabolites / / 21572414 rs984329 chr6 50522228 C T 1.27E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs984329 chr6 50522228 C T 3.42E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs280344 chr6 50528436 T C 3.40E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs9367402 chr6 50548918 C T 1.25E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs9367402 chr6 50548918 C T 2.88E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs1161444 chr6 50576468 C T 4.36E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs12528623 chr6 50633619 A G 9.43E-04 Obesity (extreme) / / 21935397 rs187190790 chr6 50654400 T C 0.0000638 Menopause (age at onset) / / 23424626 rs12528998 chr6 50664180 A C 6.82E-04 Obesity (extreme) / / 21935397 rs12527048 chr6 50666968 C T 6.32E-04 Obesity (extreme) / / 21935397 rs6928472 chr6 50712508 A G 2.16E-04 Type 2 diabetes TFAP2D intron 23945395 rs9349553 chr6 50715407 C T 7.60E-05 Endometriosis TFAP2D intron 21151130 rs186129489 chr6 50734367 C T 0.0000712 Menopause (age at onset) TFAP2D intron 23424626 rs2206272 chr6 50765352 A G 3.07E-04 Alzheimer's disease / / 24755620 rs2206271 chr6 50786008 T A 2.00E-07 Renal function-related traits (BUN) TFAP2B nearGene-5 22797727 rs2272903 chr6 50786571 G A 0.000186 Body mass index (males) TFAP2B UTR-5 23001569 rs2272903 chr6 50786571 G A 4.53E-09 Body mass index TFAP2B UTR-5 23001569 rs2272903 chr6 50786571 G A 2.11E-05 Parent of origin effect on language impairment (paternal) TFAP2B UTR-5 24571439 rs62405419 chr6 50787459 G T 6.00E-04 Type 2 diabetes TFAP2B intron 15940393 rs3798519 chr6 50788778 A C 4.00E-04 Type 2 diabetes TFAP2B intron 15940393 rs2076308 chr6 50791640 G C 5.00E-05 Type 2 diabetes TFAP2B intron 15940393 rs2206277 chr6 50798526 C T 4.25E-06 Body mass index TFAP2B intron 19557197 rs2206277 chr6 50798526 C T 1.00E-07 Metabolic syndrome (bivariate traits) TFAP2B intron 21386085 rs2206277 chr6 50798526 C T 3.37E-05 Obesity (extreme) TFAP2B intron 21935397 rs2206277 chr6 50798526 C T 5.00E-22 Obesity TFAP2B intron 23563607 rs2206277 chr6 50798526 C T 7.00E-16 Obesity TFAP2B intron 23563607 rs987237 chr6 50803050 A G 2.00E-11 Adiposity TFAP2B intron 19557161 rs987237 chr6 50803050 A G 4.47E-06 Body mass index TFAP2B intron 19557197 rs987237 chr6 50803050 A G 3.00E-20 Body mass index TFAP2B intron 20935630 rs987237 chr6 50803050 A G 7.80E-04 Menarche (age at onset) TFAP2B intron 21102462 rs987237 chr6 50803050 A G 2.66E-05 Obesity (extreme) TFAP2B intron 21935397 rs987237 chr6 50803050 A G 2.90E-20 Body mass index TFAP2B intron 23001569 rs987237 chr6 50803050 A G 2.00E-11 Body mass index TFAP2B intron 23563607 rs987237 chr6 50803050 A G 7.37E-07 Body Mass Index TFAP2B intron pha002896 rs1569777 chr6 50808745 C T 4.58E-05 Parent of origin effect on language impairment (paternal) TFAP2B intron 24571439 rs2817419 chr6 50812906 G A 3.78E-10 Obesity TFAP2B UTR-3 23563607 rs2817419 chr6 50812906 G A 6.89E-10 Obesity TFAP2B UTR-3 23563607 rs9473924 chr6 50834157 G T 8.49E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs9473924 chr6 50834157 G T 4.00E-07 Body mass index / / 24861553 rs9349560 chr6 50834379 T C 9.06E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs9463654 chr6 50835607 C T 2.61E-04 Alzheimer's disease / / 24755620 rs9473926 chr6 50835815 G A 2.35E-04 Alzheimer's disease / / 24755620 rs734597 chr6 50836279 G A 3.00E-08 Obesity (extreme) / / 21935397 rs16880741 chr6 50837708 A G 4.03E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs2207139 chr6 50845490 A G 2.86E-05 Obesity (extreme) / / 21935397 rs2207139 chr6 50845490 A G 3.00E-19 Obesity / / 23563607 rs9473931 chr6 50851411 C G 2.20E-05 Urinary metabolites / / 21572414 rs2143881 chr6 50852887 C A 2.10E-05 Volumetric brain MRI / / 17903297 rs9473932 chr6 50857995 G A 3.26E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs7745565 chr6 50860083 T C 1.30E-05 Urinary metabolites / / 21572414 rs943005 chr6 50865820 C T 7.78E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs943005 chr6 50865820 C T 2.83E-05 Obesity (extreme) / / 21935397 rs9381913 chr6 50874822 T C 3.02E-04 Alzheimer's disease / / 24755620 rs12529728 chr6 50896630 A G 2.83E-05 Obesity (extreme) / / 21935397 rs4715210 chr6 50897251 C T 7.75E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs4715210 chr6 50897251 C T 2.83E-05 Obesity (extreme) / / 21935397 rs4715210 chr6 50897251 C T 1.61E-07 Body mass index / / 22344219 rs2223869 chr6 50904239 G A 2.20E-05 Urinary metabolites / / 21572414 rs3857596 chr6 50905067 C T 7.75E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs3857596 chr6 50905067 C T 2.80E-05 Obesity (extreme) / / 21935397 rs4715213 chr6 50911091 C T 2.77E-05 Obesity (extreme) / / 21935397 rs9381917 chr6 50911334 G A 4.03E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs9369988 chr6 50921271 G T 2.72E-04 Alzheimer's disease / / 24755620 rs6904450 chr6 50921602 A T 6.96E-05 Obesity (extreme) / / 21935397 rs9473953 chr6 50925331 A T 2.81E-04 Alzheimer's disease / / 24755620 rs6924593 chr6 50926154 T C 2.50E-04 Alzheimer's disease / / 24755620 rs3857599 chr6 50938247 C A 2.97E-05 Obesity (extreme) / / 21935397 rs10484665 chr6 50942550 T G 4.90E-06 Body Mass Index / / pha002896 rs11759809 chr6 50955081 C T 4.94E-04 Alzheimer's disease (late onset) / / 21379329 rs11759809 chr6 50955081 C T 4.42E-06 Body Mass Index / / pha002896 rs4715215 chr6 50960316 T C 1.44E-05 Adiposity / / 19557161 rs283552 chr6 50963997 A G 2.23E-04 Alzheimer's disease / / 17998437 rs190759 chr6 50987768 A G 5.00E-06 Sudden cardiac arrest / / 21658281 rs912714 chr6 50992143 C T 4.30E-04 Alzheimer's disease (late onset) / / 21379329 rs912714 chr6 50992143 C T 8.00E-06 Body mass index (non-asthmatics) / / 23517042 rs12526832 chr6 50992865 C T 2.77E-04 Alzheimer's disease (late onset) / / 21379329 rs12526832 chr6 50992865 C T 1.10E-05 Body mass index (non-asthmatics) / / 23517042 rs2770664 chr6 50998135 T G 9.53E-06 Obesity-related traits / / 23251661 rs10484664 chr6 51016523 G A 2.81E-04 Alzheimer's disease (late onset) / / 21379329 rs10484664 chr6 51016523 G A 1.20E-05 Body mass index (non-asthmatics) / / 23517042 rs10484664 chr6 51016523 G A 3.59E-05 Body Mass Index / / pha002896 rs9395656 chr6 51029764 G T 4.40E-04 Alzheimer's disease / / 22005930 rs1184437 chr6 51044524 A T 6.85E-04 Alzheimer's disease / / 22005930 rs1925217 chr6 51049650 T C 5.96E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1925216 chr6 51049681 G A 7.40E-04 Alzheimer's disease / / 22005930 rs2505292 chr6 51052203 T A 7.16E-04 Alzheimer's disease / / 22005930 rs188191 chr6 51052310 C T 6.69E-04 Alzheimer's disease / / 22005930 rs927716 chr6 51052686 C T 8.03E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs12211338 chr6 51053722 G A 3.08E-05 Sudden cardiac arrest / / 21658281 rs283566 chr6 51058721 C G 9.00E-06 Electrocardiographic conduction measures / / 19389651 rs283566 chr6 51058721 C G 6.47E-04 Alzheimer's disease / / 22005930 rs283559 chr6 51061789 A G 6.41E-04 Alzheimer's disease / / 22005930 rs7775861 chr6 51068717 C T 8.60E-08 Body mass index (non-asthmatics) / / 23517042 rs7775861 chr6 51068717 C T 9.00E-08 Body mass index (non-asthmatics) / / 23517042 rs1886570 chr6 51084931 C T 8.69E-05 Glucose levels / / pha003058 rs2505276 chr6 51087831 C T 8.11E-05 Body Mass Index / / pha003014 rs2505276 chr6 51087831 C T 4.63E-06 Glucose levels / / pha003058 rs7762246 chr6 51099256 T C 6.00E-06 Obesity-related traits / / 23251661 rs4615388 chr6 51147020 T A 3.86E-06 Body mass index / / 19557197 rs4615388 chr6 51147020 T A 6.47E-10 Obesity / / 23563607 rs2397026 chr6 51157533 C T 3.43E-06 Waist circumference / / 19557197 rs1555967 chr6 51159995 G A 3.00E-06 Waist circumference / / 19557197 rs947725 chr6 51166486 T C 6.94E-05 Hemoglobin / / pha003096 rs947725 chr6 51166486 T C 1.18E-05 Erythrocyte counts / / pha003101 rs947724 chr6 51166730 T C 8.65E-05 Hemoglobin / / pha003096 rs947724 chr6 51166730 T C 1.11E-05 Erythrocyte counts / / pha003101 rs1003225 chr6 51167704 G A 4.71E-04 Smoking initiation / / 24665060 rs1327268 chr6 51172469 G C 8.60E-05 Pericardial fat / / 22589742 rs13211684 chr6 51175486 T C 7.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs2465043 chr6 51180765 G A 8.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs9474014 chr6 51314245 A C 7.56E-06 Alzheimer's disease / / 17998437 rs4435937 chr6 51318134 G T 2.55E-05 Serum metabolites / / 19043545 rs9367433 chr6 51318566 A G 5.80E-04 Multiple complex diseases / / 17554300 rs9367433 chr6 51318566 A G 4.05E-04 Alzheimer's disease / / 17998437 rs4715222 chr6 51359852 T C 2.54E-05 Multiple sclerosis / / 17660530 rs10807424 chr6 51365011 C T 5.75E-04 Alzheimer's disease / / 17998437 rs6902578 chr6 51370293 A C 2.26E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs11962312 chr6 51373205 T C 6.30E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11962312 chr6 51373205 T C 7.60E-04 Stroke / / pha002887 rs4506044 chr6 51374975 T C 4.49E-04 Multiple complex diseases / / 17554300 rs4506044 chr6 51374975 T C 6.14E-04 Alzheimer's disease / / 17998437 rs2397049 chr6 51431253 T G 1.27E-05 Femoral neck bone geometry / / 22087292 rs10948634 chr6 51448806 A T 8.15E-04 Alzheimer's disease / / 17998437 rs10948634 chr6 51448806 A T 2.20E-05 Urinary metabolites / / 21572414 rs2784231 chr6 51459621 C T 1.60E-05 Urinary metabolites / / 21572414 rs2579989 chr6 51460154 T G 2.92E-04 Alzheimer's disease / / 17998437 rs6930919 chr6 51468044 A G 1.30E-05 Urinary metabolites / / 21572414 rs1108202 chr6 51469221 T C 1.50E-05 Urinary metabolites / / 21572414 rs9296658 chr6 51489948 G C 3.93E-04 Sudden cardiac arrest PKHD1 intron 21658281 rs2580009 chr6 51512707 T C 7.10E-06 Urinary metabolites PKHD1 intron 21572414 rs624699 chr6 51514608 T C 8.86E-04 Type 2 diabetes PKHD1 intron 17463246 rs9395707 chr6 51572515 G A 6.10E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) PKHD1 intron 23648065 rs1750961 chr6 51617677 C T 2.60E-05 Urinary metabolites PKHD1 intron 21572414 rs2025751 chr6 51622449 T C 7.00E-07 Intraocular pressure PKHD1 intron 24002674 rs728996 chr6 51643014 C T 5.00E-07 Weight loss (gastric bypass surgery) PKHD1 intron 23633212 rs728996 chr6 51643014 C T 5.00E-08 Weight loss (gastric bypass surgery) PKHD1 intron 23633212 rs2894788 chr6 51643268 C T 9.16E-07 Weight loss (gastric bypass surgery) PKHD1 intron 23633212 rs6458777 chr6 51655407 A G 3.70E-06 Weight loss (gastric bypass surgery) PKHD1 intron 23633212 rs4715233 chr6 51656388 A G 2.14E-06 Weight loss (gastric bypass surgery) PKHD1 intron 23633212 rs10498792 chr6 51666631 T C 3.00E-06 Prostate cancer PKHD1 intron 17903305 rs10498792 chr6 51666631 T C 3.00E-06 Nasopharyngeal carcinoma PKHD1 intron 20512145 rs1326580 chr6 51669599 G A 9.05E-04 Multiple complex diseases PKHD1 intron 17554300 rs6458791 chr6 51670542 T C 9.96E-04 Multiple complex diseases PKHD1 intron 17554300 rs9395726 chr6 51673301 A G 5.69E-04 Multiple complex diseases PKHD1 intron 17554300 rs9296661 chr6 51673439 C T 3.90E-04 Multiple complex diseases PKHD1 intron 17554300 rs9296661 chr6 51673439 C T 4.82E-05 Weight loss (gastric bypass surgery) PKHD1 intron 23633212 rs1326589 chr6 51674161 T C 5.58E-04 Multiple complex diseases PKHD1 intron 17554300 rs1326589 chr6 51674161 T C 3.30E-05 Weight loss (gastric bypass surgery) PKHD1 intron 23633212 rs9296662 chr6 51675610 C T 5.74E-04 Cognition,early reading ability PKHD1 intron 17684495 rs6935608 chr6 51687277 A C 6.65E-04 Type 2 diabetes PKHD1 intron 17463246 rs9474094 chr6 51689626 C G 4.52E-04 Type 2 diabetes PKHD1 intron 17463246 rs12194557 chr6 51696268 A G 4.45E-04 Type 2 diabetes PKHD1 intron 17463246 rs1321508 chr6 51731773 C T 2.51E-05 Triglycerides PKHD1 intron pha003081 rs1321508 chr6 51731773 C T 5.90E-05 Lipid levels PKHD1 intron pha003082 rs7449744 chr6 51734163 C T 8.37E-05 Response to mTOR inhibitor (rapamycin) PKHD1 intron 24009623 rs6458801 chr6 51747589 T C 9.55E-06 Triglycerides PKHD1 intron pha003081 rs6458801 chr6 51747589 T C 3.18E-05 Lipid levels PKHD1 intron pha003082 rs4715254 chr6 51748554 A C 9.88E-04 Multiple complex diseases PKHD1 intron 17554300 rs12206267 chr6 51760454 C T 7.64E-04 Suicide attempts in bipolar disorder PKHD1 intron 21041247 rs12196767 chr6 51776535 T C 4.87E-04 Suicide attempts in bipolar disorder PKHD1 intron 21041247 rs1266890 chr6 51800445 A G 5.55E-05 ldl cholesterol PKHD1 intron pha003076 rs927188 chr6 51809617 T G 4.35E-05 ldl cholesterol PKHD1 intron pha003076 rs12194995 chr6 51810499 T C 4.62E-04 Suicide attempts in bipolar disorder PKHD1 intron 21041247 rs1266922 chr6 51822297 A G 3.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PKHD1 intron 20877124 rs927185 chr6 51826782 T C 4.25E-04 Smoking cessation PKHD1 intron 24665060 rs12212158 chr6 51865376 T C 7.18E-04 Response to cytadine analogues (cytosine arabinoside) PKHD1 intron 24483146 rs1896974 chr6 51876267 G A 0.00017 Erectile dysfunction after radiotherapy for prostate cancer PKHD1 intron 23021708 rs956511 chr6 51884842 T C 9.60E-05 Personality dimensions PKHD1 intron 18957941 rs9382062 chr6 51896417 C T 0.00064 Erectile dysfunction after radiotherapy for prostate cancer PKHD1 intron 23021708 rs10948669 chr6 51941459 G C 8.54E-04 Multiple complex diseases PKHD1 intron 17554300 rs1896978 chr6 51948935 G T 1.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PKHD1 intron 20877124 rs6906409 chr6 51953524 C A 8.42E-04 Multiple complex diseases PKHD1 nearGene-5 17554300 rs6458810 chr6 51974474 A G 6.16E-04 Smoking cessation / / 24665060 rs12527406 chr6 51986236 T C 6.68E-04 Schizophrenia / / 19197363 rs12527406 chr6 51986236 T C 4.10E-06 Urinary metabolites / / 21572414 rs16882131 chr6 52008933 C T 0.0000256 Migraine / / 22678113 rs16882131 chr6 52008933 C T 2.56E-05 Migraine / / 22683712 rs1537670 chr6 52009600 A G 3.14E-04 Type 2 diabetes / / 17463246 rs10484882 chr6 52011469 G A 0.0002 Migraine / / 22678113 rs10948679 chr6 52012873 C T 3.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7766405 chr6 52022832 A C 1.21E-04 Multiple complex diseases / / 17554300 rs1937142 chr6 52023133 C T 9.15E-05 Multiple complex diseases / / 17554300 rs4711998 chr6 52050353 A G 1.43E-04 Bipolar disorder,schizoaffective / / 19567891 rs10484879 chr6 52051957 G T 7.39E-04 Type 2 diabetes IL17A intron 17463246 rs10484879 chr6 52051957 G T 5.10E-04 Alzheimer's disease IL17A intron 22005930 rs7747909 chr6 52054249 G A 4.31E-04 Alzheimer's disease IL17A UTR-3 22005930 rs2154225 chr6 52063101 C T 3.90E-06 Alcohol and nictotine co-dependence / / 20158304 rs2064332 chr6 52094056 C T 8.39E-04 Type 2 diabetes / / 17463246 rs763780 chr6 52101739 T C 3.00E-08 Response to gemcitabine in pancreatic cancer IL17F missense 22142827 rs7771466 chr6 52104109 C A 3.58E-06 Response to gemcitabine in pancreatic cancer IL17F intron 22142827 rs9395772 chr6 52122014 G A 8.32E-04 Type 2 diabetes / / 17463246 rs16882270 chr6 52122884 G A 6.50E-04 Insulin resistance / / 21901158 rs13210985 chr6 52145277 A C 5.21E-04 Alzheimer's disease MCM3 intron 22005930 rs12191519 chr6 52196117 A G 6.25E-05 Arthritis (juvenile idiopathic) / / 22354554 rs6912417 chr6 52213010 A G 5.58E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9382099 chr6 52220793 C T 5.12E-04 Lymphocyte counts / / 22286170 rs4712003 chr6 52224245 C T 6.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs10807443 chr6 52242105 T C 9.14E-04 Suicide attempts in bipolar disorder PAQR8 intron 21423239 rs722101 chr6 52261566 C T 8.09E-05 Suicide attempts in bipolar disorder PAQR8 intron 21423239 rs2397086 chr6 52261671 A C 6.63E-05 Suicide attempts in bipolar disorder PAQR8 intron 21423239 rs1408258 chr6 52265818 T C 4.54E-05 Suicide attempts in bipolar disorder PAQR8 intron 21423239 rs6901937 chr6 52266051 C T 5.92E-05 Suicide attempts in bipolar disorder PAQR8 intron 21423239 rs17591255 chr6 52266334 G A 4.36E-05 Suicide attempts in bipolar disorder PAQR8 intron 21423239 rs3748066 chr6 52268008 T G 9.85E-05 Suicide attempts in bipolar disorder PAQR8 UTR-5 21423239 rs3799274 chr6 52269046 C G 4.19E-05 Suicide attempts in bipolar disorder PAQR8 cds-synon 21423239 rs1297 chr6 52272313 A G 2.61E-05 Suicide attempts in bipolar disorder PAQR8 UTR-3 21423239 rs617318 chr6 52279901 T A 4.23E-05 Suicide attempts in bipolar disorder / / 21423239 rs3804506 chr6 52303291 C G,T 6.25E-05 Suicide attempts in bipolar disorder EFHC1 missense 21423239 rs7757573 chr6 52327367 A C 1.44E-04 Suicide attempts in bipolar disorder EFHC1 intron 21423239 rs4715301 chr6 52349822 C G 7.50E-05 Suicide attempts in bipolar disorder EFHC1 intron 21423239 rs7757370 chr6 52357260 C A 4.98E-04 Suicide attempts in bipolar disorder EFHC1 UTR-3 21423239 rs6458841 chr6 52364270 G A 6.65E-04 Suicide attempts in bipolar disorder TRAM2 UTR-3 21423239 rs6900141 chr6 52365988 G A 4.05E-04 Suicide attempts in bipolar disorder TRAM2 UTR-3 21423239 rs9474232 chr6 52368478 C T 5.54E-04 Suicide attempts in bipolar disorder TRAM2 intron 21423239 rs2207062 chr6 52371158 A G 3.67E-04 Suicide attempts in bipolar disorder TRAM2 intron 21423239 rs2067002 chr6 52371419 G A 4.70E-04 Suicide attempts in bipolar disorder TRAM2 intron 21423239 rs6917841 chr6 52374823 C T 3.20E-04 Suicide attempts in bipolar disorder TRAM2 intron 21423239 rs1033541 chr6 52383067 A G 8.56E-04 Suicide attempts in bipolar disorder TRAM2 intron 21423239 rs2064438 chr6 52383231 T C 4.73E-04 Suicide attempts in bipolar disorder TRAM2 intron 21423239 rs4712009 chr6 52385064 C A 4.98E-04 Tourette syndrome TRAM2 intron 22889924 rs941969 chr6 52388875 G A 1.97E-05 Suicide attempts in bipolar disorder TRAM2 intron 21423239 rs1060912 chr6 52389711 C T 1.91E-05 Suicide attempts in bipolar disorder TRAM2 intron 21423239 rs2092625 chr6 52395510 A G 6.51E-04 Suicide attempts in bipolar disorder TRAM2 intron 21423239 rs4715302 chr6 52396167 T A 6.59E-04 Suicide attempts in bipolar disorder TRAM2 intron 21423239 rs1883930 chr6 52400889 C T 9.43E-05 Oral cancers (chewing tobacco related) TRAM2 intron 22503698 rs2268722 chr6 52405415 A G 7.42E-04 Suicide attempts in bipolar disorder TRAM2 intron 21423239 rs910244 chr6 52411122 A C 8.39E-05 Suicide attempts in bipolar disorder TRAM2 intron 21423239 rs2268718 chr6 52415023 C T 9.95E-04 Tourette syndrome TRAM2 intron 22889924 rs2268718 chr6 52415023 C T 4.85E-04 Lung function (forced vital capacity) TRAM2 intron 24023788 rs10484874 chr6 52436648 G A 7.13E-04 Multiple complex diseases TRAM2 intron 17554300 rs2268705 chr6 52437025 G C 5.36E-04 Type 2 diabetes TRAM2 intron 17463246 rs7746685 chr6 52450447 C T 2.86E-04 Hearing function / / 17255346 rs2057350 chr6 52452233 G C 6.93E-05 Serum metabolites / / 19043545 rs9370134 chr6 52453608 G C 1.56E-04 Hearing function / / 17255346 rs6936059 chr6 52465451 G T 1.80E-05 Celiac disease / / 17558408 rs9463802 chr6 52469904 A G 9.17E-04 Myocardial Infarction / / pha002883 rs17602312 chr6 52476054 T C 1.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs2063643 chr6 52478364 A G 4.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs2063643 chr6 52478364 A G 6.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9474254 chr6 52478524 A G 3.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs9474257 chr6 52481678 T G 2.82E-04 Suicide attempts in bipolar disorder / / 21041247 rs9463804 chr6 52483626 A T 2.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs16882812 chr6 52486401 A G 2.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs9474262 chr6 52491686 T C 1.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs9474264 chr6 52492594 T A 2.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs1884456 chr6 52505030 G A 2.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs9474269 chr6 52507285 T C 2.41E-04 Type 2 diabetes / / 17463246 rs9463810 chr6 52507605 G T 4.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs7752356 chr6 52509348 C T 2.56E-05 Acute lung injury / / 22295056 rs13205411 chr6 52509965 A C 3.33E-04 Acute lung injury / / 22295056 rs10948708 chr6 52510442 C T 3.33E-04 Acute lung injury / / 22295056 rs10948709 chr6 52510497 A G 3.16E-05 Acute lung injury / / 22295056 rs10948710 chr6 52510573 T C 3.16E-05 Acute lung injury / / 22295056 rs10948711 chr6 52510665 A G 2.10E-05 Acute lung injury / / 22295056 rs9296688 chr6 52526489 G A 6.11E-04 Multiple complex diseases / / 17554300 rs10948714 chr6 52529666 A C 6.23E-04 Coronary heart disease / / 21606135 rs6923338 chr6 52549322 T C 4.06E-05 Calcium intake levels and metabolic syndrome TMEM14A intron 22170361 rs6923338 chr6 52549322 T C 4.51E-05 Brain structure TMEM14A intron 22504417 rs2180323 chr6 52557627 A G 7.42E-05 Type 2 diabetes / / 17463246 rs9357742 chr6 52560377 G C 1.50E-04 Type 2 diabetes / / 17463246 rs2670134 chr6 52561774 T C 5.64E-05 Body mass index / / 21701565 rs2670134 chr6 52561774 T C 8.91E-06 Body mass index / / 21701565 rs10484873 chr6 52564490 A G 9.89E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1884458 chr6 52565035 A G 7.42E-05 Type 2 diabetes / / 17463246 rs1884459 chr6 52565211 A G 1.30E-04 Type 2 diabetes / / 17463246 rs4637643 chr6 52565427 T G 1.50E-04 Type 2 diabetes / / 17463246 rs6907248 chr6 52573274 G C 2.28E-04 Type 2 diabetes / / 17463246 rs6458861 chr6 52595017 G A 3.63E-05 Type 2 diabetes / / 17463246 rs9474312 chr6 52598501 C T 2.18E-05 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs7747120 chr6 52598582 G A 3.92E-04 Alzheimer's disease / / 22005930 rs9474314 chr6 52602360 T C 2.14E-04 Alzheimer's disease / / 22005930 rs6913696 chr6 52660631 T C 4.82E-13 LDL cholesterol GSTA1 intron 23063622 rs6917325 chr6 52666273 T C 0.0000666 Triglycerides GSTA1 intron 23063622 rs3957357 chr6 52668687 A G 1 Drug response to Cisplatin / / 19786980 rs3957357 chr6 52668687 A G 1 Drug response to Cyclophosphamide / / 19786980 rs6415165 chr6 52689508 G A 6.53E-04 Multiple complex diseases / / 17554300 rs4715352 chr6 52703396 C T 1.79E-04 Body mass index GSTA5 intron 21701565 rs4715352 chr6 52703396 C T 7.67E-05 Body mass index GSTA5 intron 21701565 rs7775877 chr6 52737093 C T 5.65E-04 Multiple complex diseases / / 17554300 rs641019 chr6 52751593 T A 4.24E-04 Alzheimer's disease / / 22005930 rs510179 chr6 52752162 C T 3.32E-04 Alzheimer's disease / / 22005930 rs668163 chr6 52753034 G A 3.98E-04 Alzheimer's disease / / 22005930 rs2295605 chr6 52761898 T C 9.30E-04 Alzheimer's disease GSTA3 intron 22005930 rs557135 chr6 52765760 A G 1.73E-04 Alzheimer's disease GSTA3 intron 22005930 rs6916414 chr6 52766805 T C 6.73E-04 Alzheimer's disease GSTA3 intron 22005930 rs567832 chr6 52785776 T C 8.62E-04 Alzheimer's disease / / 22005930 rs651733 chr6 52789828 C T 6.12E-04 Alzheimer's disease / / 22005930 rs547362 chr6 52795274 G T 3.57E-04 Alzheimer's disease / / 22005930 rs650296 chr6 52795985 C T 5.96E-04 Alzheimer's disease / / 22005930 rs6917307 chr6 52800648 A T 5.10E-04 Major depressive disorder / / 21042317 rs364932 chr6 52801687 C T 5.10E-04 Major depressive disorder / / 21042317 rs371403 chr6 52802244 A G 7.78E-04 Alcohol dependence / / 21314694 rs550022 chr6 52805002 A T 7.17E-04 Alzheimer's disease / / 22005930 rs487642 chr6 52818053 A G 1.10E-05 Urinary metabolites / / 21572414 rs594614 chr6 52819451 A C 1.30E-05 Urinary metabolites / / 21572414 rs560788 chr6 52830861 T C 4.98E-06 Epilepsy (remission after treatment) / / 23962720 rs615060 chr6 52834000 C G 3.24E-06 Epilepsy (remission after treatment) / / 23962720 rs375872 chr6 52834917 C T 4.66E-07 Epilepsy (remission after treatment) / / 23962720 rs384505 chr6 52835572 G A 2.82E-07 Epilepsy (remission after treatment) / / 23962720 rs5028437 chr6 52835674 T C 4.40E-07 Epilepsy (remission after treatment) / / 23962720 rs492146 chr6 52835895 G A 2.00E-07 Epilepsy (remission after treatment) / / 23962720 rs693733 chr6 52836756 T C 2.18E-07 Epilepsy (remission after treatment) / / 23962720 rs400804 chr6 52837090 G C 2.23E-07 Epilepsy (remission after treatment) / / 23962720 rs677636 chr6 52837307 G A 5.22E-07 Epilepsy (remission after treatment) / / 23962720 rs13219629 chr6 52837551 C A 1.06E-04 Body mass index / / 21701565 rs13219629 chr6 52837551 C A 8.14E-04 Body mass index / / 21701565 rs13219629 chr6 52837551 C A 8.37E-04 Body mass index / / 21701565 rs380646 chr6 52837640 G A 2.31E-07 Epilepsy (remission after treatment) / / 23962720 rs419833 chr6 52837985 G C 2.36E-07 Epilepsy (remission after treatment) / / 23962720 rs449690 chr6 52838158 C T 2.39E-07 Epilepsy (remission after treatment) / / 23962720 rs584124 chr6 52838196 G A 5.54E-07 Epilepsy (remission after treatment) / / 23962720 rs428957 chr6 52839185 T C 2.38E-07 Epilepsy (remission after treatment) / / 23962720 rs426169 chr6 52839888 G A 3.44E-04 Multiple complex diseases / / 17554300 rs426169 chr6 52839888 G A 2.35E-07 Epilepsy (remission after treatment) / / 23962720 rs612483 chr6 52839958 T C 5.58E-07 Epilepsy (remission after treatment) / / 23962720 rs613764 chr6 52840235 C T 5.79E-07 Epilepsy (remission after treatment) / / 23962720 rs387853 chr6 52840254 C T 2.26E-07 Epilepsy (remission after treatment) / / 23962720 rs426013 chr6 52840745 T C 2.20E-06 Epilepsy (remission after treatment) / / 23962720 rs374275 chr6 52840797 G C 2.20E-06 Epilepsy (remission after treatment) / / 23962720 rs385636 chr6 52840937 C T 9.34E-07 Epilepsy (remission after treatment) / / 23962720 rs378775 chr6 52841479 C G 3.51E-05 Epilepsy (remission after treatment) / / 23962720 rs419129 chr6 52841995 A C 9.25E-07 Epilepsy (remission after treatment) / / 23962720 rs369381148 chr6 52842106 AT AAT,ACA 2.18E-06 Epilepsy (remission after treatment) / / 23962720 rs642851 chr6 52842106 A C 2.18E-06 Epilepsy (remission after treatment) / / 23962720 rs642853 chr6 52842107 T A 9.25E-07 Epilepsy (remission after treatment) / / 23962720 rs644100 chr6 52842371 A C 2.18E-06 Epilepsy (remission after treatment) / / 23962720 rs405729 chr6 52842781 T C 6.48E-07 Epilepsy (remission after treatment) GSTA4 UTR-3 23962720 rs367836 chr6 52843131 G T 1.97E-06 Epilepsy (remission after treatment) GSTA4 UTR-3 23962720 rs375887 chr6 52843477 A G 9.21E-07 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs670960 chr6 52843796 A G 1.96E-06 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs672281 chr6 52844045 G A 1.96E-06 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs673197 chr6 52844257 A G 1.97E-06 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs423475 chr6 52844583 G T 1.97E-06 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs419427 chr6 52844886 T A 1.97E-06 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs597295 chr6 52845351 T C 1.97E-06 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs492825 chr6 52845393 C T 9.21E-07 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs597348 chr6 52845397 C G 1.97E-06 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs316141 chr6 52846158 A G 4.00E-04 Type 2 diabetes and 6 quantitative traits GSTA4 intron 17848626 rs316141 chr6 52846158 A G 1.97E-06 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs316140 chr6 52846188 C T 1.97E-06 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs316139 chr6 52846372 G T 9.21E-07 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs316138 chr6 52846419 T C 1.97E-06 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs622902 chr6 52846474 G A 1.97E-06 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs316137 chr6 52846680 C A 9.21E-07 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs316136 chr6 52846769 T C 9.21E-07 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs316135 chr6 52846777 C T 9.21E-07 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs316133 chr6 52847551 G C 5.50E-04 Type 2 diabetes and 6 quantitative traits GSTA4 intron 17848626 rs316133 chr6 52847551 G C 1.66E-06 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs316132 chr6 52847966 C T 1.97E-06 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs316131 chr6 52848149 A G 1.97E-06 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs316130 chr6 52848200 G A 1.97E-06 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs316129 chr6 52848905 C T 1.97E-06 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs316128 chr6 52849146 G T 4.60E-04 Type 2 diabetes and 6 quantitative traits GSTA4 intron 17848626 rs316128 chr6 52849146 G T 9.21E-07 Epilepsy (remission after treatment) GSTA4 intron 23962720 rs4986947 chr6 52849230 G A 1.96E-04 Alzheimer's disease (late onset) GSTA4 intron 21379329 rs1802061 chr6 52849325 C T 4.56E-04 Alzheimer's disease (late onset) GSTA4 cds-synon 21379329 rs3756980 chr6 52851979 A G 8.84E-04 Body mass index GSTA4 intron 21701565 rs6904771 chr6 52856179 A G 6.23E-05 Asthma GSTA4 intron pha003128 rs3756979 chr6 52861204 T G 1.56E-08 Hepatitis B / / 24162738 rs10456665 chr6 52905592 C T 7.36E-06 Post-operative nausea and vomiting ICK intron 21694509 rs9474372 chr6 52906738 T C 0.00043 Salmonella-induced pyroptosis ICK intron 22837397 rs4129429 chr6 53007050 C A 8.86E-04 Alzheimer's disease GCM1 intron 22005930 rs9367511 chr6 53010182 A G 4.48E-04 Iron levels GCM1 intron pha002876 rs9382181 chr6 53044379 A G 6.32E-04 Multiple complex diseases / / 17554300 rs2816369 chr6 53088181 A C 1.18E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2816369 chr6 53088181 A C 3.86E-05 Elbow pain / / pha003008 rs735860 chr6 53123118 T C 4.00E-06 Glaucoma / / 20363506 rs715441 chr6 53124501 T C 7.90E-04 Multiple complex diseases / / 17554300 rs2281274 chr6 53143554 T C 3.10E-05 Alcohol dependence ELOVL5 intron 20201924 rs2281274 chr6 53143554 T C 2.30E-05 Response to statin therapy ELOVL5 intron 20339536 rs2281274 chr6 53143554 T C 3.14E-05 Alcoholism ELOVL5 intron pha002892 rs209512 chr6 53203577 T C 4.31E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ELOVL5 intron 20877124 rs209512 chr6 53203577 T C 7.03E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ELOVL5 intron 20877124 rs10948748 chr6 53220825 A G 3.89E-04 Esophageal adenocarcinoma / / 24121790 rs9463908 chr6 53241240 T G 3.39E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1401160 chr6 53281511 T C 9.51E-05 Major depressive disorder (broad) / / 20038947 rs6458934 chr6 53291466 G A 4.73E-05 Major depressive disorder (broad) / / 20038947 rs7744451 chr6 53291576 T A 3.12E-05 Major depressive disorder (broad) / / 20038947 rs4715392 chr6 53292013 A T 5.05E-05 Major depressive disorder (broad) / / 20038947 rs1401159 chr6 53292425 T C 6.31E-05 Major depressive disorder (broad) / / 20038947 rs4440459 chr6 53293410 T G 5.21E-05 Major depressive disorder (broad) / / 20038947 rs1401158 chr6 53294553 A T 3.68E-05 Major depressive disorder (broad) / / 20038947 rs9395864 chr6 53295907 G A 5.18E-05 Major depressive disorder (broad) / / 20038947 rs9370209 chr6 53296156 A G 5.55E-05 Major depressive disorder (broad) / / 20038947 rs1377392 chr6 53298485 T C 1.65E-05 Post-operative nausea and vomiting / / 21694509 rs9395865 chr6 53307694 C T 6.00E-06 Electroencephalographic traits in alcoholism / / 22554406 rs9367532 chr6 53310839 G A 1.08E-14 Multiple complex diseases / / 17554300 rs9367532 chr6 53310839 G A 0.000081 Prostate cancer / / 23555315 rs7758711 chr6 53326981 T C 6.77E-05 Cholesterol / / pha003073 rs2397146 chr6 53360119 G A 3.70E-05 Personality dimensions / / 18957941 rs2397146 chr6 53360119 G A 4.32E-05 Serum metabolites / / 19043545 rs2397146 chr6 53360119 G A 5.03E-04 Body mass index / / 21701565 rs7742367 chr6 53361276 T C 6.48E-04 Body mass index / / 21701565 rs661603 chr6 53370107 T C 4.40E-04 Obesity (extreme) GCLC intron 21935397 rs9474576 chr6 53373105 A G 1.86E-04 Body mass index GCLC intron 21701565 rs2235707 chr6 53373197 G C 1.26E-04 Body mass index GCLC intron 21701565 rs542914 chr6 53376648 C A 4.71E-04 Obesity (extreme) GCLC intron 21935397 rs546726 chr6 53377122 C T 2.73E-04 Obesity (extreme) GCLC intron 21935397 rs634657 chr6 53377550 A G 2.76E-04 Obesity (extreme) GCLC intron 21935397 rs572496 chr6 53377619 C T 2.78E-04 Obesity (extreme) GCLC intron 21935397 rs574389 chr6 53377834 C T 2.83E-04 Obesity (extreme) GCLC intron 21935397 rs574389 chr6 53377834 C T 1.67E-04 Stroke GCLC intron pha002887 rs648595 chr6 53378369 T G 2.88E-04 Obesity (extreme) GCLC intron 21935397 rs3736729 chr6 53379405 A C 5.21E-05 Body mass index GCLC intron 21701565 rs3736729 chr6 53379405 A C 3.09E-04 Obesity (extreme) GCLC intron 21935397 rs84933 chr6 53380390 G A 3.46E-04 Obesity (extreme) GCLC intron 21935397 rs512827 chr6 53382260 A T 3.47E-04 Obesity (extreme) GCLC intron 21935397 rs600033 chr6 53382370 G C 3.46E-04 Obesity (extreme) GCLC intron 21935397 rs570818 chr6 53384030 A C 6.02E-04 Obesity (extreme) GCLC intron 21935397 rs13212365 chr6 53385084 C T 5.16E-04 Body mass index GCLC intron 21701565 rs13212365 chr6 53385084 C T 5.83E-06 Body mass index GCLC intron 21701565 rs13212365 chr6 53385084 C T 7.94E-04 Obesity (extreme) GCLC intron 21935397 rs2300422 chr6 53388525 G A 6.60E-06 Body mass index GCLC intron 21701565 rs2300422 chr6 53388525 G A 8.68E-04 Body mass index GCLC intron 21701565 rs1555907 chr6 53390720 C T 9.61E-05 Body mass index GCLC intron 21701565 rs2268329 chr6 53395363 T C 4.44E-04 Body mass index GCLC intron 21701565 rs2268329 chr6 53395363 T C 6.06E-06 Body mass index GCLC intron 21701565 rs7758764 chr6 53396162 G A 2.51E-06 Body mass index GCLC intron 21701565 rs7758764 chr6 53396162 G A 6.70E-05 Body mass index GCLC intron 21701565 rs3799698 chr6 53401903 C T 4.44E-04 Body mass index GCLC intron 21701565 rs3799698 chr6 53401903 C T 6.06E-06 Body mass index GCLC intron 21701565 rs3799699 chr6 53401999 C T 4.00E-04 Body mass index GCLC intron 21701565 rs3799699 chr6 53401999 C T 6.04E-06 Body mass index GCLC intron 21701565 rs6926440 chr6 53403880 T C 3.81E-04 Multiple complex diseases GCLC intron 17554300 rs9349677 chr6 53448040 T G 7.61E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2179545 chr6 53461965 T C 4.73E-04 Alcohol dependence / / 20201924 rs9474614 chr6 53514946 A G 6.00E-06 Obesity-related traits KLHL31 UTR-3 23251661 rs3823111 chr6 53517035 G A 2.10E-04 Lung adenocarcinoma KLHL31 cds-synon 21242121 rs6914160 chr6 53560062 G A 9.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs4425583 chr6 53560828 T A 1.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs6933157 chr6 53586515 A C 1.50E-04 Type 2 diabetes / / 22158537 rs6933301 chr6 53586549 C T 6.68E-04 Type 2 diabetes / / 22158537 rs4715418 chr6 53600045 G A 1.84E-05 Serum metabolites / / 19043545 rs7759593 chr6 53600708 T C 7.91E-04 Type 2 diabetes / / 17463246 rs9474643 chr6 53613433 C A 7.29E-04 Type 2 diabetes / / 17463246 rs12213392 chr6 53617730 T C 6.33E-05 Hypertension / / pha003041 rs6921605 chr6 53619575 G A 4.75E-04 Type 2 diabetes / / 17463246 rs10456674 chr6 53620831 C T 3.95E-05 Hypertension / / pha003041 rs12216441 chr6 53633422 C T 4.50E-05 Hypertension / / pha003041 rs3813850 chr6 53658211 C T 1.90E-04 Multiple complex diseases / / 17554300 rs6906921 chr6 53689624 C A 6.28E-05 Serum metabolites LRRC1 intron 19043545 rs4612163 chr6 53693292 C G 7.40E-05 Serum metabolites LRRC1 intron 19043545 rs4331986 chr6 53693395 T C 7.50E-05 Serum metabolites LRRC1 intron 19043545 rs4273680 chr6 53703425 T A 8.76E-05 Serum metabolites LRRC1 intron 19043545 rs10948783 chr6 53705374 T C 7.50E-05 Serum metabolites LRRC1 intron 19043545 rs7763081 chr6 53708315 C T 6.50E-04 Volumetric brain MRI LRRC1 intron 17903297 rs7453639 chr6 53721602 G A 7.50E-05 Serum metabolites LRRC1 intron 19043545 rs12193567 chr6 53721818 T G 7.50E-05 Serum metabolites LRRC1 intron 19043545 rs2473600 chr6 53792822 C T 7.02E-04 Acute lung injury / / 22295056 rs742525 chr6 53823579 C T 3.87E-05 Receptive language ability / / 24687471 rs761136 chr6 53823767 C T 5.09E-05 Cognitive impairment induced by topiramate / / 22091778 rs9395894 chr6 53828391 T C 4.48E-05 Receptive language ability / / 24687471 rs2206574 chr6 53831461 A G 3.39E-05 Receptive language ability / / 24687471 rs9367546 chr6 53831734 T C 3.12E-05 Receptive language ability / / 24687471 rs9357779 chr6 53831829 G A 3.23E-05 Receptive language ability / / 24687471 rs2397150 chr6 53834379 A C 2.91E-05 Receptive language ability / / 24687471 rs1325826 chr6 53839730 C T 5.93E-05 Hypertension / / pha003041 rs12206936 chr6 53848634 G A 9.35E-05 Body Mass Index / / pha003009 rs12206936 chr6 53848634 G A 6.28E-05 Height / / pha003010 rs12206936 chr6 53848634 G A 2.87E-05 Height / / pha003011 rs1409101 chr6 53876547 T C 2.38E-04 Type 2 diabetes / / 17463246 rs16884583 chr6 53883490 C T 2.72E-04 Type 2 diabetes / / 17463246 rs17625497 chr6 53883843 G A 2.75E-05 Brain derived neurotrophic factor levels,in serum MLIP missense 22047184 rs10484653 chr6 53884126 C T 8.47E-04 Type 2 diabetes MLIP intron 17463246 rs17555505 chr6 53892401 T C 2.83E-06 Kawasaki disease MLIP intron 21221998 rs1409110 chr6 53894318 G A 9.28E-04 Tourette syndrome MLIP intron 22889924 rs9637973 chr6 53903152 G A 5.57E-04 Type 2 diabetes MLIP intron 17463246 rs9637973 chr6 53903152 G A 2.70E-05 Major depressive disorder MLIP intron 21042317 rs1325831 chr6 53904347 T C 3.89E-04 Type 2 diabetes MLIP intron 17463246 rs1325831 chr6 53904347 T C 2.40E-05 Major depressive disorder MLIP intron 21042317 rs9474718 chr6 53917787 A C 2.00E-04 Information processing speed MLIP intron 21130836 rs7739196 chr6 53920024 T G 2.92E-04 Tourette syndrome MLIP intron 22889924 rs9474720 chr6 53921127 A C 7.80E-05 Major depressive disorder MLIP intron 21042317 rs9296736 chr6 53924697 T C 9.53E-05 Type 2 diabetes MLIP intron 17463246 rs9296736 chr6 53924697 T C 3.20E-05 Major depressive disorder MLIP intron 21042317 rs9296736 chr6 53924697 T C 3.00E-09 Liver enzyme levels (gamma-glutamyl transferase) MLIP intron 22001757 rs7742515 chr6 53942185 A T 1.58E-04 Blood pressure MLIP intron 24001895 rs673471 chr6 53953392 A G 9.18E-04 Type 2 diabetes MLIP intron 17463246 rs689298 chr6 53954579 C T 8.48E-04 Type 2 diabetes MLIP intron 17463246 rs685893 chr6 53961784 A G 5.79E-05 Triglycerides MLIP intron pha002904 rs519777 chr6 53989038 C T 4.45E-04 Multiple complex diseases MLIP intron 17554300 rs1321884 chr6 54003344 A G 7.79E-04 Multiple complex diseases MLIP intron 17554300 rs816376 chr6 54007349 C G 8.29E-04 Type 2 diabetes MLIP intron 17463246 rs816376 chr6 54007349 C G 4.14E-04 Multiple complex diseases MLIP intron 17554300 rs2797424 chr6 54007820 C A 5.25E-04 Multiple complex diseases MLIP intron 17554300 rs4715446 chr6 54010651 A T 4.97E-04 Multiple complex diseases MLIP intron 17554300 rs4715447 chr6 54010681 G A 4.23E-04 Multiple complex diseases MLIP intron 17554300 rs2797425 chr6 54012352 G C 9.27E-04 Type 2 diabetes MLIP intron 17463246 rs864642 chr6 54025859 T A 8.30E-04 Type 2 diabetes MLIP intron 17463246 rs6934690 chr6 54054686 T A 7.68E-06 Bronchopulmonary dysplasia MLIP missense 23897914 rs7741347 chr6 54123118 A T 1.90E-07 Urinary metabolites MLIP intron 21572414 rs9357795 chr6 54125839 C T 2.80E-07 Urinary metabolites MLIP intron 21572414 rs9885789 chr6 54129147 A G 2.80E-07 Urinary metabolites MLIP intron 21572414 rs6913087 chr6 54137049 G A 1.70E-07 Urinary metabolites / / 21572414 rs10456680 chr6 54137424 T G 1.80E-07 Urinary metabolites / / 21572414 rs10447407 chr6 54151514 G A 6.70E-08 Urinary metabolites / / 21572414 rs12206200 chr6 54154189 G T 3.00E-07 Urinary metabolites / / 21572414 rs12215705 chr6 54159146 G A 1.30E-06 Urinary metabolites / / 21572414 rs12191165 chr6 54160851 G A 8.20E-07 Urinary metabolites / / 21572414 rs4415156 chr6 54164079 C T 5.36E-04 Body mass index / / 21701565 rs991286 chr6 54166054 G A 8.84E-05 Glycosylated haemoglobin levels / / 17255346 rs2202802 chr6 54167681 C T 5.93E-05 Body mass index / / 21701565 rs2202802 chr6 54167681 C T 6.35E-04 Body mass index / / 21701565 rs4712061 chr6 54168401 A T 3.68E-04 Body mass index / / 21701565 rs12212836 chr6 54169957 A G 5.70E-07 Urinary metabolites / / 21572414 rs6458994 chr6 54170056 A T 2.46E-04 Body mass index / / 21701565 rs3756808 chr6 54171624 C T 6.29E-04 Body mass index / / 21701565 rs16885209 chr6 54179040 T C 1.94E-04 Multiple complex diseases TI/G intron 17554300 rs1995768 chr6 54181882 G A 4.76E-04 Body mass index TI/G intron 21701565 rs6909083 chr6 54182303 T C 1.62E-04 Body mass index TI/G intron 21701565 rs2297983 chr6 54185689 G T 8.07E-04 Body mass index TI/G intron 21701565 rs1508642 chr6 54185864 G A 2.53E-04 Body mass index TI/G intron 21701565 rs1058768 chr6 54186147 T C 1.30E-04 Body mass index TI/G missense 21701565 rs6928234 chr6 54187793 C A 5.82E-04 Multiple complex diseases TI/G intron 17554300 rs9395944 chr6 54228413 G A 8.52E-05 Lung function (forced expiratory volume in 1 second) TI/G intron pha003103 rs17748851 chr6 54239163 C A 9.96E-04 Multiple complex diseases TI/G intron 17554300 rs1508635 chr6 54247467 A C 2.73E-05 Diabetes (gestational) TI/G intron 22233651 rs487474 chr6 54256214 A G 6.90E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs16885294 chr6 54265396 T C 4.00E-07 Radiation response / / 20923822 rs9474851 chr6 54276380 G A 5.66E-05 Insulin resistance / / 21901158 rs9395961 chr6 54278358 T A 8.10E-05 Insulin resistance / / 21901158 rs631269 chr6 54309237 T C 5.05E-06 Statin-induced myopathy / / 21826682 rs243799 chr6 54310853 C T 1.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs6459009 chr6 54424937 T G 3.32E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs9464097 chr6 54428460 T C 2.21E-04 Type 2 diabetes / / 17463246 rs1853335 chr6 54441359 G A 5.86E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs9474919 chr6 54467633 T C 4.13E-04 Alzheimer's disease / / 22005930 rs9395986 chr6 54477002 T G 2.00E-04 Information processing speed / / 21130836 rs9474935 chr6 54483722 T C 3.79E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs534685 chr6 54503147 A T 4.95E-04 Type 2 diabetes / / 17463246 rs9474943 chr6 54507683 T C 7.51E-06 Type 2 diabetes / / 17463246 rs971199 chr6 54508401 C T 5.19E-05 Bipolar disorder and schizophrenia / / 20889312 rs16885649 chr6 54509794 A T 6.99E-04 Type 2 diabetes / / 17463246 rs12215844 chr6 54509812 T A 7.62E-06 Type 2 diabetes / / 17463246 rs147209429 chr6 54516607 C T 0.00001617 Sarcoidosis / / 22952805 rs33961304 chr6 54523828 C A 4.98E-06 Type 2 diabetes / / 17463246 rs884027 chr6 54525251 C T 0.00001606 Sarcoidosis / / 22952805 rs931890 chr6 54528364 T C 0.000003257 Sarcoidosis / / 22952805 rs6925402 chr6 54528801 C T 0.000004522 Sarcoidosis / / 22952805 rs73440046 chr6 54529782 C T 0.000003225 Sarcoidosis / / 22952805 rs73440053 chr6 54531352 T C 0.000003225 Sarcoidosis / / 22952805 rs73440056 chr6 54531666 A T 0.000003225 Sarcoidosis / / 22952805 rs73440059 chr6 54532259 G A 0.000003225 Sarcoidosis / / 22952805 rs73440062 chr6 54533517 A G 0.000003225 Sarcoidosis / / 22952805 rs6923484 chr6 54533834 A G 0.000003225 Sarcoidosis / / 22952805 rs6928647 chr6 54534296 A T 0.000003225 Sarcoidosis / / 22952805 rs113554147 chr6 54542591 G A 0.000005813 Sarcoidosis / / 22952805 rs17445948 chr6 54545066 C T 6.63E-04 Alzheimer's disease / / 22005930 rs7744009 chr6 54546026 T C 0.000003259 Sarcoidosis / / 22952805 rs59251337 chr6 54548674 T C 0.000003259 Sarcoidosis / / 22952805 rs7740523 chr6 54549231 G A 0.000003259 Sarcoidosis / / 22952805 rs1395625 chr6 54551781 T G 6.91E-04 Alzheimer's disease / / 22005930 rs17446535 chr6 54554082 T C 7.73E-04 Alzheimer's disease / / 22005930 rs1395633 chr6 54557664 G A 5.46E-04 Alzheimer's disease / / 22005930 rs78992731 chr6 54559285 G A 0.00001104 Sarcoidosis / / 22952805 rs78540819 chr6 54565109 C T 0.00002174 Sarcoidosis / / 22952805 rs112544501 chr6 54576449 G A 0.00001333 Sarcoidosis / / 22952805 rs151157333 chr6 54580419 C A,T 0.00001333 Sarcoidosis / / 22952805 rs7739592 chr6 54584702 G C 8.68E-05 Suicide attempts in bipolar disorder / / 21423239 rs12198783 chr6 54585379 T C 1.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs9474972 chr6 54586637 C T 5.82E-05 Type 2 diabetes / / 17463246 rs6459021 chr6 54588069 G A 6.91E-05 Bipolar disorder / / 17486107 rs113394167 chr6 54592768 C A 0.000009752 Sarcoidosis / / 22952805 rs16869519 chr6 54594179 A G 8.14E-04 Type 2 diabetes / / 17463246 rs12209646 chr6 54603171 A G 2.97E-05 Suicide attempts in bipolar disorder / / 21423239 rs10948847 chr6 54604517 A G 6.79E-05 Type 2 diabetes / / 17463246 rs13220672 chr6 54615504 T G 2.60E-05 Suicide attempts in bipolar disorder / / 21423239 rs1890239 chr6 54615835 A C 9.39E-04 Type 2 diabetes / / 17463246 rs1354830 chr6 54616000 A G 1.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs2397166 chr6 54617773 G T 9.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs4094394 chr6 54620103 C T 1.87E-04 Type 2 diabetes / / 17463246 rs13220641 chr6 54622762 T G 6.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs6942314 chr6 54624647 G T 7.89E-05 Suicide attempts in bipolar disorder / / 21423239 rs17545576 chr6 54626318 G A 5.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs17545776 chr6 54630795 T C 5.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs16869530 chr6 54633035 A G 5.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs6909269 chr6 54638866 C A 7.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs6913881 chr6 54638991 G A 6.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs10948852 chr6 54656673 C T 8.50E-04 Type 2 diabetes / / 17463246 rs1395634 chr6 54667989 C T 2.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs12661022 chr6 54669411 A G 4.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs13195757 chr6 54671663 T C 2.07E-04 Response to alcohol consumption (flushing response) / / 24277619 rs6918855 chr6 54682824 C A 2.07E-04 Response to alcohol consumption (flushing response) / / 24277619 rs9464141 chr6 54690036 T C 2.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs6926482 chr6 54701685 A G 3.62E-05 HIV-1 viral setpoint / / 22174851 rs9370332 chr6 54727075 A G 7.70E-04 Alzheimer's disease FAM83B intron 22005930 rs16886072 chr6 54727815 C T 2.48E-05 Coronary heart disease FAM83B intron pha003030 rs7739951 chr6 54732039 A G 4.61E-05 Coronary heart disease FAM83B intron pha003030 rs9370349 chr6 54849161 G A 3.50E-05 Multiple complex diseases / / 17554300 rs9370355 chr6 54864756 C T 5.77E-04 Insulin resistance / / 21901158 rs6907460 chr6 54881047 A G 8.30E-04 Smoking behavior / / 20418888 rs9396029 chr6 54885290 T C 8.72E-04 Multiple complex diseases / / 17554300 rs4715520 chr6 54995995 T C 3.66E-04 Type 2 diabetes / / 17463246 rs7767652 chr6 55006797 C T 0.000522272 Hypertension (early onset hypertension) / / 22479346 rs7756097 chr6 55034424 C T 2.58E-04 Hearing function / / 17255346 rs7771743 chr6 55036920 G A 6.93E-05 Hearing function / / 17255346 rs3134708 chr6 55080894 A C 2.34E-04 Body mass index HCRTR2 intron 21701565 rs10214854 chr6 55115679 T A 1.70E-25 Health and aging,CVD and cancer age of onset HCRTR2 intron 22174011 rs10214854 chr6 55115679 T A 3.00E-08 Health and aging,CVD and cancer age of onset HCRTR2 intron 22174011 rs10214854 chr6 55115679 T A 9.60E-19 Health and aging,CVD and cancer age of onset HCRTR2 intron 22174011 rs9367630 chr6 55148103 G A 1.00E-07 HIV-1 control / / 20041166 rs2653352 chr6 55149600 A C 6.39E-04 Multiple complex diseases / / 17554300 rs2653354 chr6 55152655 G A 9.79E-04 Multiple complex diseases / / 17554300 rs2811231 chr6 55155704 C A 8.14E-04 Multiple complex diseases / / 17554300 rs6937228 chr6 55185043 G A 8.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs6937228 chr6 55185043 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs958626 chr6 55191223 T G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12210212 chr6 55202199 C T 4.30E-06 Urinary metabolites GFRAL intron 21572414 rs11752897 chr6 55213731 T A 1.97E-04 Self-reported allergy GFRAL intron 23817569 rs9396082 chr6 55215868 A G 2.40E-05 Urinary metabolites GFRAL intron 21572414 rs2102164 chr6 55217813 T C 2.43E-05 Multiple complex diseases GFRAL intron 17554300 rs7452656 chr6 55218271 G T 7.84E-04 Type 2 diabetes GFRAL intron 17463246 rs7452656 chr6 55218271 G T 3.15E-05 Multiple complex diseases GFRAL intron 17554300 rs7452656 chr6 55218271 G T 2.00E-05 Urinary metabolites GFRAL intron 21572414 rs11756296 chr6 55252487 G A 4.02E-04 Suicide attempts in bipolar disorder GFRAL intron 21423239 rs11759316 chr6 55255071 A C 5.28E-04 Suicide attempts in bipolar disorder GFRAL intron 21423239 rs1032769 chr6 55263387 G A 4.22E-04 Suicide attempts in bipolar disorder GFRAL intron 21423239 rs7776329 chr6 55265150 T C 4.47E-04 Suicide attempts in bipolar disorder GFRAL intron 21423239 rs12203074 chr6 55272581 T C 4.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs10948918 chr6 55277002 C A 1.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs1979875 chr6 55277167 C T 9.82E-04 Multiple complex diseases / / 17554300 rs12211679 chr6 55291190 C T 3.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs13215064 chr6 55292633 C T 6.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs7749561 chr6 55297641 T C 1.87E-05 ldl cholesterol / / pha003077 rs1546298 chr6 55298959 C T 2.00E-06 Urinary metabolites / / 21572414 rs12195882 chr6 55302377 G A 6.86E-04 Suicide attempts in bipolar disorder HMGCLL1 intron 21423239 rs7776283 chr6 55302486 T G 3.19E-04 Suicide attempts in bipolar disorder HMGCLL1 intron 21423239 rs10948922 chr6 55303448 G A 3.46E-04 Suicide attempts in bipolar disorder HMGCLL1 intron 21423239 rs4715548 chr6 55305291 T C 4.15E-04 Suicide attempts in bipolar disorder HMGCLL1 intron 21423239 rs6918642 chr6 55312698 G T 2.68E-04 Suicide attempts in bipolar disorder HMGCLL1 intron 21423239 rs9464247 chr6 55313379 G A 2.26E-04 Suicide attempts in bipolar disorder HMGCLL1 intron 21423239 rs4236130 chr6 55318527 C A 7.61E-04 Suicide attempts in bipolar disorder HMGCLL1 intron 21423239 rs4256438 chr6 55319485 T C 2.09E-04 Suicide attempts in bipolar disorder HMGCLL1 intron 21423239 rs4256438 chr6 55319485 T C 3.89E-04 Acute lung injury HMGCLL1 intron 22295056 rs9382494 chr6 55325559 G T 3.86E-04 Common variable immunodeficiency HMGCLL1 intron 21497890 rs6928695 chr6 55333415 T C 3.44E-04 Suicide attempts in bipolar disorder HMGCLL1 intron 21423239 rs4712105 chr6 55344782 A G 3.39E-04 Suicide attempts in bipolar disorder HMGCLL1 intron 21423239 rs3807018 chr6 55354613 A G 2.90E-04 Suicide attempts in bipolar disorder HMGCLL1 intron 21423239 rs12528088 chr6 55355591 T A 3.26E-04 Coronary Artery Disease HMGCLL1 intron 17634449 rs10456715 chr6 55356693 A G 2.48E-04 Multiple complex diseases HMGCLL1 intron 17554300 rs10456715 chr6 55356693 A G 2.28E-04 Suicide attempts in bipolar disorder HMGCLL1 intron 21423239 rs9475319 chr6 55361878 T C 3.25E-04 Coronary Artery Disease HMGCLL1 intron 17634449 rs6917354 chr6 55364966 G T 3.18E-05 Cognitive test performance HMGCLL1 intron 20125193 rs12208624 chr6 55365000 C A 2.06E-05 Cognitive test performance HMGCLL1 intron 20125193 rs12193408 chr6 55371268 G A 2.78E-04 Suicide attempts in bipolar disorder HMGCLL1 intron 21423239 rs12202230 chr6 55374178 A T 3.25E-04 Suicide attempts in bipolar disorder HMGCLL1 intron 21423239 rs6907772 chr6 55379442 T A 2.25E-04 Suicide attempts in bipolar disorder HMGCLL1 intron 21423239 rs12200439 chr6 55380308 G A 3.23E-04 Suicide attempts in bipolar disorder HMGCLL1 intron 21423239 rs12525326 chr6 55383610 C T 2.29E-04 Suicide attempts in bipolar disorder HMGCLL1 intron 21423239 rs9357865 chr6 55386477 A G 7.63E-04 Suicide attempts in bipolar disorder HMGCLL1 intron 21041247 rs12189728 chr6 55390692 T C 2.31E-04 Multiple complex diseases HMGCLL1 intron 17554300 rs9296792 chr6 55393687 G A 5.12E-04 Suicide attempts in bipolar disorder HMGCLL1 intron 21423239 rs9475342 chr6 55395820 A C 2.79E-04 Type 2 diabetes HMGCLL1 intron 17463246 rs9396103 chr6 55397800 G A 3.77E-05 Cognitive test performance HMGCLL1 intron 20125193 rs11754509 chr6 55473294 A G 3.00E-07 Obesity-related traits / / 23251661 rs4509122 chr6 55480911 T C 7.06E-04 Alzheimer's disease / / 22005930 rs9382519 chr6 55486126 A C 7.01E-04 Alzheimer's disease / / 22005930 rs6915090 chr6 55565836 G A 3.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs9370450 chr6 55566578 G C 3.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs9370451 chr6 55566842 G A 3.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs9382529 chr6 55571671 T C 4.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs2065026 chr6 55573769 T C 3.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs17732188 chr6 55574726 A G 3.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs17732224 chr6 55574792 A T 3.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs9382531 chr6 55576602 A G 3.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs2208603 chr6 55577214 T C 5.70E-07 Carotenoid and tocopherol levels / / 19185284 rs17732324 chr6 55578612 C T 3.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs9396140 chr6 55579345 G A 4.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs9349789 chr6 55581902 A G 4.40E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11970729 chr6 55582225 A G 4.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs9370454 chr6 55582827 A G 4.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs9357873 chr6 55586693 C G 3.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs9357874 chr6 55586881 T C 3.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs9357875 chr6 55590730 A C 2.90E-05 Major depressive disorder / / 21042317 rs1159020 chr6 55593390 C T 3.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs9382546 chr6 55593871 T A 3.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs9382547 chr6 55593985 C A 3.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs9382548 chr6 55594083 C T 3.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs9367661 chr6 55594317 C T 3.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs9382550 chr6 55596618 C T 3.40E-05 Major depressive disorder / / 21042317 rs9382551 chr6 55597908 A C 3.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs9349791 chr6 55598297 A C 3.70E-05 Major depressive disorder / / 21042317 rs2145900 chr6 55607255 A G 3.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs2145898 chr6 55607390 T C 3.40E-05 Major depressive disorder / / 21042317 rs9370464 chr6 55610447 G C 3.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs6910005 chr6 55617362 A G 5.51E-05 Receptive language ability / / 24687471 rs11537721 chr6 55620017 G A 5.40E-05 Receptive language ability / / 24687471 rs3756991 chr6 55620218 C A 1.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs228139 chr6 55628283 G T 3.21E-04 Suicide attempts in bipolar disorder BMP5 intron 21423239 rs228140 chr6 55628344 C T 7.50E-05 Personality dimensions BMP5 intron 18957941 rs228140 chr6 55628344 C T 5.76E-05 Receptive language ability BMP5 intron 24687471 rs228144 chr6 55631762 G A 0.00000986 Child behavior checklist/1.5-5 pervasive developmental problems BMP5 intron 23049896 rs228146 chr6 55636255 C A 3.89E-05 Information processing speed BMP5 intron 21130836 rs228146 chr6 55636255 C A 5.20E-05 Post-operative nausea and vomiting BMP5 intron 21694509 rs10948955 chr6 55687414 C T 1.74E-05 Post-operative nausea and vomiting BMP5 intron 21694509 rs9475417 chr6 55688361 A G 4.51E-04 Response to taxane treatment (placlitaxel) BMP5 intron 23006423 rs3823039 chr6 55689305 A G 0.0003227 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BMP5 intron 23233654 rs3823039 chr6 55689305 A G 3.23E-04 Methotrexate clearance (acute lymphoblastic leukemia) BMP5 intron 23233662 rs1447133 chr6 55694267 C T 0.000339 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BMP5 intron 23233654 rs1447133 chr6 55694267 C T 3.39E-04 Methotrexate clearance (acute lymphoblastic leukemia) BMP5 intron 23233662 rs17734678 chr6 55695376 A G 0.0003437 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BMP5 intron 23233654 rs17734678 chr6 55695376 A G 3.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) BMP5 intron 23233662 rs17678251 chr6 55708204 C A 0.000387 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BMP5 intron 23233654 rs17678251 chr6 55708204 C A 3.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) BMP5 intron 23233662 rs921126 chr6 55709741 C T 0.0005158 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BMP5 intron 23233654 rs921126 chr6 55709741 C T 5.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) BMP5 intron 23233662 rs9475436 chr6 55734220 C T 2.06E-04 Alzheimer's disease (late onset) BMP5 intron 21379329 rs3734444 chr6 55739553 A G 4.13E-05 Alzheimer's disease (late onset) BMP5 cds-synon 21379329 rs4715571 chr6 55809047 T A 5.90E-05 Obesity-related traits / / 17903300 rs4312989 chr6 55810482 C T 4.20E-05 Obesity-related traits / / 17903300 rs12209568 chr6 55837287 C A 2.89E-04 Smoking initiation / / 24665060 rs12195241 chr6 55884758 G A 9.88E-04 Myocardial Infarction / / pha002873 rs2223662 chr6 55893797 G A 5.10E-06 Obesity-related traits / / 17903300 rs2206682 chr6 55893979 A G 4.20E-06 Obesity-related traits / / 17903300 rs17817377 chr6 55916978 C G 7.44E-05 Sudden cardiac arrest / / 21658281 rs12196860 chr6 55950374 G A 2.00E-07 Psychosis (atypical) COL21A1 intron 24132900 rs12207650 chr6 55952234 T C 2.60E-06 Lung function (forced vital capacity) COL21A1 intron pha003104 rs9296832 chr6 56100909 C G 5.46E-07 Blood pressure COL21A1 intron 21909110 rs7768520 chr6 56110642 A G 3.58E-04 Type 2 diabetes COL21A1 intron 17463246 rs4119564 chr6 56123758 T C 3.41E-04 Stroke / / pha002887 rs12663282 chr6 56130126 G A 4.56E-05 Schizophrenia / / pha002859 rs9464371 chr6 56152943 G A 8.73E-05 Aging (time to event) / / 21782286 rs4529301 chr6 56159808 A G 6.86E-04 Type 2 diabetes / / 17463246 rs9475671 chr6 56186443 G A 8.55E-06 Bipolar disorder / / 19488044 rs9475671 chr6 56186443 G A 1.49E-05 Bipolar disorder and schizophrenia / / 20889312 rs9475671 chr6 56186443 G A 1.07E-05 Bipolar Disorder / / pha002858 rs9464379 chr6 56203674 G T 1.58E-04 Hearing function / / 17255346 rs6931260 chr6 56203830 G A 4.64E-05 Soluble levels of adhesion molecules / / pha003072 rs6459154 chr6 56207337 C T 2.15E-05 Disc degeneration (lumbar) / / 24216480 rs16887812 chr6 56210764 C T 7.00E-06 Allergic sensitization / / 23817571 rs17823624 chr6 56212819 G A 8.05E-05 Cognitive test performance / / 20125193 rs2397220 chr6 56217207 T C 9.45E-05 Alzheimer's disease / / 22005930 rs6915291 chr6 56220394 C T 5.82E-04 Alzheimer's disease / / 22005930 rs601783 chr6 56273680 G A 8.88E-04 Multiple complex diseases / / 17554300 rs633348 chr6 56277853 C T 5.11E-04 Multiple complex diseases / / 17554300 rs657057 chr6 56294282 C T 3.40E-05 Breast cancer and prostate cancer / / 17903305 rs6927258 chr6 56333130 A G 3.50E-04 Type 2 diabetes and 6 quantitative traits DST intron 17848626 rs41439750 chr6 56388799 C T 6.22E-04 Body mass index DST intron 21701565 rs4715634 chr6 56424421 A G 4.66E-05 Body Mass Index DST intron pha003019 rs973089 chr6 56435357 T C 6.33E-04 Multiple complex diseases DST intron 17554300 rs973089 chr6 56435357 T C 9.52E-06 Height DST intron 20400458 rs9349832 chr6 56445051 G A 3.95E-05 Body Fat Distribution DST intron pha003016 rs9349832 chr6 56445051 G A 9.98E-06 Body Fat Distribution DST intron pha003017 rs9349832 chr6 56445051 G A 2.20E-05 Body Fat Distribution DST intron pha003018 rs6929091 chr6 56446035 A G 5.98E-05 Body Fat Distribution DST intron pha003016 rs6929091 chr6 56446035 A G 1.30E-05 Body Fat Distribution DST intron pha003017 rs6929091 chr6 56446035 A G 2.90E-05 Body Fat Distribution DST intron pha003018 rs9382658 chr6 56471402 G A 5.33E-05 Body Fat Distribution DST intron pha003016 rs9382658 chr6 56471402 G A 8.85E-06 Body Fat Distribution DST intron pha003017 rs9382658 chr6 56471402 G A 2.20E-05 Body Fat Distribution DST intron pha003018 rs16888118 chr6 56552636 C T 5.56E-05 Multiple sclerosis LOC100652766 intron 17660530 rs1870639 chr6 56726819 C T 2.12E-05 Lung function (forced expiratory volume in 1 second) LOC100652827 intron 17255346 rs9396247 chr6 56846334 A G 3.24E-04 Multiple complex diseases BEND6 intron 17554300 rs2167460 chr6 56884451 T C 5.45E-05 Angioedema in response to angiotensin-converting enzyme inhibitor BEND6 intron 23838604 rs4715646 chr6 56900340 T C 1.17E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs4236146 chr6 56960612 T G 1.72E-05 Type 1 diabetes ZNF451 intron 21980299 rs4236146 chr6 56960612 T G 8.05E-04 Circulating vasoactive peptide levels ZNF451 intron 23381795 rs10484410 chr6 56996688 T C 2.64E-04 Sarcoidosis ZNF451 intron 21540310 rs16888392 chr6 57076552 G A 5.98E-15 Lymphocyte counts RAB23 intron 22286170 rs223287 chr6 57104266 C T 7.23E-08 Body Mass Index / / pha003009 rs223287 chr6 57104266 C T 4.55E-06 Coronary heart disease / / pha003031 rs16888410 chr6 57110862 C T 1.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs2064245 chr6 57117624 C G 6.56E-04 Multiple complex diseases / / 17554300 rs16888420 chr6 57121359 C T 2.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs10080526 chr6 57122994 C T 3.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs9475804 chr6 57127760 G A 2.64E-04 Suicide attempts in bipolar disorder LOC100506188 intron 21423239 rs9464425 chr6 57128426 A G 2.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs16888439 chr6 57129124 A T 2.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs9367716 chr6 57160572 G T 1.29E-04 Multiple complex diseases / / 17554300 rs9367716 chr6 57160572 G T 1.72E-05 Serum metabolites / / 19043545 rs2397232 chr6 57161932 G T 8.97E-04 Multiple complex diseases / / 17554300 rs2397232 chr6 57161932 G T 0.0000935 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9464432 chr6 57162703 G A 3.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs9382699 chr6 57169715 T C 3.74E-04 Multiple complex diseases / / 17554300 rs9382699 chr6 57169715 T C 8.73E-05 Serum metabolites / / 19043545 rs1013893 chr6 57184113 A G 3.81E-04 Type 2 diabetes PRIM2 intron 22158537 rs1741910 chr6 57186515 A T 3.36E-05 Bipolar disorder and schizophrenia PRIM2 intron 20889312 rs1741916 chr6 57189636 A G 2.00E-05 Endometriosis PRIM2 intron 21151130 rs9357943 chr6 57195666 G A 9.26E-05 Type 2 diabetes PRIM2 intron 22158537 rs2098172 chr6 57196372 A G 5.39E-05 Type 2 diabetes PRIM2 intron 22158537 rs3800015 chr6 57208396 G C 6.62E-05 Type 2 diabetes PRIM2 intron 22158537 rs9396278 chr6 57215494 T C 5.86E-05 Type 2 diabetes PRIM2 intron 22158537 rs12209200 chr6 57217336 C T 1.80E-05 Crohn's disease PRIM2 intron 20570966 rs17705499 chr6 57226182 C T 9.06E-05 Bipolar disorder and schizophrenia PRIM2 intron 20889312 rs1988981 chr6 57282076 A G 5.42E-04 Multiple complex diseases PRIM2 intron 17554300 rs2191651 chr6 57299092 A G 6.70E-07 Type 2 diabetes PRIM2 intron 22158537 rs2191651 chr6 57299092 A G 6.73E-05 Coronary heart disease PRIM2 intron pha003031 rs7738502 chr6 57344762 G C 8.47E-04 Multiple complex diseases PRIM2 intron 17554300 rs9476059 chr6 57381003 G A 3.94E-06 Plasma omega-6 polyunsaturated fatty acid levels PRIM2 intron 24823311 rs9476082 chr6 57401058 T A 4.00E-06 Plasma omega-6 polyunsaturated fatty acid levels PRIM2 intron 24823311 rs7764828 chr6 57437428 A G 6.60E-06 Response to statin therapy PRIM2 intron 20339536 rs4715784 chr6 57444641 T C 4.50E-05 Response to statin therapy PRIM2 intron 20339536 rs7759896 chr6 57591840 C T 2.55E-04 Celiac disease / / 23936387 rs4715853 chr6 57652860 T A 1.28E-04 Multiple complex diseases / / 17554300 rs10949189 chr6 57880892 T C 1.60E-05 Age-related macular degeneration / / 20861866 rs6459316 chr6 57991660 A C 4.92E-05 Cognitive test performance / / 20125193 rs41380951 chr6 58035974 T C 3.28E-04 Multiple complex diseases / / 17554300 rs4598117 chr6 58146054 C T 3.81E-12 Narcolepsy / / 19629137 rs9500256 chr6 58308955 G A 5.00E-06 Eosinophilic esophagitis (pediatric) / / 20208534 rs6588685 chr6 58319653 A G,T 7.82E-04 Type 2 diabetes / / 22158537 rs10458024 chr6 58324089 T C 6.47E-04 Type 2 diabetes / / 22158537 rs12210275 chr6 58331759 C T 7.21E-04 Type 2 diabetes / / 22158537 rs12209098 chr6 58340472 A C 5.14E-06 Meningococcal disease / / 20694013 rs12209098 chr6 58340472 A C 5.69E-04 Type 2 diabetes / / 22158537 rs12209098 chr6 58340472 A C 0.0000874 Primary sclerosing cholangitis / / 23603763 rs4928437 chr6 58385830 G A 3.84E-05 Cognitive impairment induced by topiramate / / 22091778 rs4928437 chr6 58385830 G A 7.68E-05 Cognitive impairment induced by topiramate / / 22091778 rs1224763 chr6 58431621 A C 7.56E-05 Cognitive impairment induced by topiramate / / 22091778 rs1224760 chr6 58432574 T C 8.30E-04 Type 2 diabetes / / 17463246 rs1224753 chr6 58436484 T C 4.20E-04 Type 2 diabetes / / 22158537 rs1224752 chr6 58436650 T C 4.34E-04 Type 2 diabetes / / 22158537 rs1224742 chr6 58442711 G A 3.29E-04 Type 2 diabetes / / 22158537 rs1224739 chr6 58448292 T G 3.10E-04 Type 2 diabetes / / 22158537 rs1224728 chr6 58454677 G A 2.82E-04 Type 2 diabetes / / 22158537 rs1224726 chr6 58455395 C T 2.94E-04 Type 2 diabetes / / 22158537 rs1020866 chr6 58466815 T A 3.04E-04 Type 2 diabetes / / 22158537 rs1585503 chr6 58499904 G T 4.36E-04 Type 2 diabetes / / 22158537 rs4144870 chr6 58504614 G A 4.92E-05 Type 2 diabetes / / 22158537 rs3862295 chr6 58514721 G T 4.46E-05 Type 2 diabetes / / 22158537 rs7773120 chr6 58516551 A G 4.99E-05 Type 2 diabetes / / 22158537 rs3125353 chr6 58521604 T G 1.29E-04 Type 2 diabetes / / 22158537 rs6921458 chr6 58558689 A G 8.38E-05 Type 2 diabetes / / 22158537 rs4144869 chr6 58565091 A G 8.11E-05 Type 2 diabetes / / 22158537 rs1914347 chr6 58567162 C T 2.18E-04 Type 2 diabetes / / 22158537 rs1829211 chr6 58588092 C A 2.50E-04 Type 2 diabetes / / 22158537 rs2063944 chr6 58595586 C A 1.76E-04 Type 2 diabetes / / 22158537 rs35986449 chr6 58600549 A AT 8.44E-05 Type 2 diabetes / / 22158537 rs9377715 chr6 58600549 A G 8.44E-05 Type 2 diabetes / / 22158537 rs1517231 chr6 58614100 T C 9.82E-04 Type 2 diabetes / / 17463246 rs1517231 chr6 58614100 T C 4.80E-04 Type 2 diabetes / / 22158537 rs1517229 chr6 58616843 A C 1.69E-05 Type 2 diabetes / / 22158537 rs10498816 chr6 58619927 T C 8.94E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs2462785 chr6 58622318 C A 1.69E-05 Type 2 diabetes / / 22158537 rs2693079 chr6 58641933 G A 2.55E-05 Type 2 diabetes / / 22158537 rs2459566 chr6 58666731 A G 6.99E-05 Cognitive test performance / / 20125193 rs9391303 chr6 58701896 C T 6.20E-05 Cognitive test performance / / 20125193 rs4928472 chr6 58711541 G A 1.34E-05 Cognitive test performance / / 20125193 rs6900393 chr6 58727179 G A 2.40E-04 Multiple complex diseases / / 17554300 rs2880516 chr6 58762891 C T 7.06E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs4513829 chr6 58764531 A G 6.00E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs2342002 chr6 61951860 G A 7.00E-06 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs2342002 chr6 61951860 G A 9.00E-07 Esophageal adenocarcinoma / / 24121790 rs2152599 chr6 62004761 C A 8.60E-05 Multiple complex diseases / / 17554300 rs4710348 chr6 62270449 G C 3.23E-04 Multiple complex diseases / / 17554300 rs4710691 chr6 62273698 G A 7.40E-04 Multiple complex diseases / / 17554300 rs3799935 chr6 62338385 A G 3.27E-04 Multiple complex diseases / / 17554300 rs1204116 chr6 62404096 C A 7.30E-04 Volumetric brain MRI KHDRBS2 intron 17903297 rs17239464 chr6 62409551 T C 2.20E-05 Urinary metabolites KHDRBS2 intron 21572414 rs17240267 chr6 62425171 A T 9.40E-06 Urinary metabolites KHDRBS2 intron 21572414 rs1938395 chr6 62478217 T G 3.70E-06 Urinary metabolites KHDRBS2 intron 21572414 rs16899598 chr6 62491355 C A 2.48E-04 Multiple complex diseases KHDRBS2 intron 17554300 rs4710493 chr6 62507427 G A 6.76E-04 Multiple complex diseases KHDRBS2 intron 17554300 rs1547073 chr6 62545593 G A 7.60E-05 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) KHDRBS2 intron 24121790 rs1547073 chr6 62545593 G A 9.99E-06 Esophageal adenocarcinoma KHDRBS2 intron 24121790 rs4513770 chr6 62550428 C T 8.40E-04 Response to taxane treatment (placlitaxel) KHDRBS2 intron 23006423 rs6925549 chr6 62559728 G T 7.15E-04 Response to taxane treatment (placlitaxel) KHDRBS2 intron 23006423 rs511137 chr6 62563667 T C 7.71E-05 Partial epilepsies KHDRBS2 intron 20522523 rs1931814 chr6 62589167 A G 3.83E-05 Response to taxane treatment (placlitaxel) KHDRBS2 intron 23006423 rs10498817 chr6 62589325 G A 9.47E-04 Response to taxane treatment (placlitaxel) KHDRBS2 intron 23006423 rs16900514 chr6 62611579 T C 1.69E-04 Multiple complex diseases KHDRBS2 intron 17554300 rs16900514 chr6 62611579 T C 1.67E-04 Alzheimer's disease KHDRBS2 intron 17998437 rs16900631 chr6 62630645 A G 1.54E-04 Multiple complex diseases KHDRBS2 intron 17554300 rs1931805 chr6 62630863 T C 4.50E-04 Response to taxane treatment (placlitaxel) KHDRBS2 intron 23006423 rs9453572 chr6 62633416 T C 2.02E-04 Response to taxane treatment (placlitaxel) KHDRBS2 intron 23006423 rs16900658 chr6 62635287 C T 7.55E-04 Multiple complex diseases KHDRBS2 intron 17554300 rs16900658 chr6 62635287 C T 1.91E-04 Alzheimer's disease KHDRBS2 intron 17998437 rs16900673 chr6 62638176 A G 5.83E-04 Multiple complex diseases KHDRBS2 intron 17554300 rs16900673 chr6 62638176 A G 1.71E-04 Alzheimer's disease KHDRBS2 intron 17998437 rs16900674 chr6 62638493 A G 7.05E-04 Multiple complex diseases KHDRBS2 intron 17554300 rs16900674 chr6 62638493 A G 2.31E-04 Alzheimer's disease KHDRBS2 intron 17998437 rs905383 chr6 62649173 A T 9.24E-04 Aortic root size KHDRBS2 intron 21223598 rs16867909 chr6 62668135 C T 8.54E-04 Multiple complex diseases KHDRBS2 intron 17554300 rs1516709 chr6 62682069 T C 9.92E-04 Response to taxane treatment (placlitaxel) KHDRBS2 intron 23006423 rs12524852 chr6 62683123 T G 1.90E-06 Urinary metabolites KHDRBS2 intron 21572414 rs4607412 chr6 62685091 T C 4.21E-04 Multiple complex diseases KHDRBS2 intron 17554300 rs6455128 chr6 62697746 A C 3.00E-07 Protein quantitative trait loci KHDRBS2 intron 18464913 rs9342639 chr6 62759859 A G 2.17E-04 Multiple complex diseases KHDRBS2 intron 17554300 rs10484620 chr6 62775875 A G 7.40E-05 Memory performance KHDRBS2 intron 22105620 rs208976 chr6 62805160 G T 1.20E-04 Multiple complex diseases KHDRBS2 intron 17554300 rs209003 chr6 62834273 A G 8.08E-05 Multiple complex diseases KHDRBS2 intron 17554300 rs17458901 chr6 62850877 A G 6.10E-05 Memory performance KHDRBS2 intron 22105620 rs208987 chr6 62855519 C T 6.80E-04 Type 2 diabetes and 6 quantitative traits KHDRBS2 intron 17848626 rs482102 chr6 62902837 C T 1.15E-04 Multiple complex diseases KHDRBS2 intron 17554300 rs485617 chr6 62922474 A T 1.36E-04 Multiple complex diseases KHDRBS2 intron 17554300 rs577542 chr6 62925642 G A 6.27E-04 Multiple complex diseases KHDRBS2 intron 17554300 rs574036 chr6 62931836 C G 1.28E-04 Multiple complex diseases KHDRBS2 intron 17554300 rs176620 chr6 62939279 A G 1.68E-04 Multiple complex diseases KHDRBS2 intron 17554300 rs176612 chr6 62952000 T A 2.22E-05 Multiple complex diseases KHDRBS2 intron 17554300 rs855409 chr6 62967960 T C 6.40E-05 Multiple complex diseases KHDRBS2 intron 17554300 rs2679573 chr6 62970477 T C 8.70E-04 Type 2 diabetes and 6 quantitative traits KHDRBS2 intron 17848626 rs7770793 chr6 62971265 A C 2.29E-04 Multiple complex diseases KHDRBS2 intron 17554300 rs9354868 chr6 62985206 T C 0.0000484 Tuberculosis with late age of onset KHDRBS2 intron 22551897 rs603987 chr6 63033690 C T 7.19E-04 Multiple complex diseases / / 17554300 rs606199 chr6 63034181 G A 4.54E-04 Multiple complex diseases / / 17554300 rs721423 chr6 63034767 T G 5.88E-05 Tunica Media / / pha003038 rs590059 chr6 63038560 G A 3.33E-04 Multiple complex diseases / / 17554300 rs604017 chr6 63039345 C T 5.50E-04 Multiple complex diseases / / 17554300 rs577751 chr6 63039709 C T 7.63E-04 Multiple complex diseases / / 17554300 rs649940 chr6 63042698 G A 4.21E-04 Multiple complex diseases / / 17554300 rs515188 chr6 63042889 C T 2.99E-04 Multiple complex diseases / / 17554300 rs651370 chr6 63042987 G C 4.68E-04 Multiple complex diseases / / 17554300 rs1023471 chr6 63045767 T A 8.16E-04 Multiple complex diseases / / 17554300 rs7762267 chr6 63045976 T C 7.14E-04 Multiple complex diseases / / 17554300 rs7758390 chr6 63046463 A G 6.75E-04 Multiple complex diseases / / 17554300 rs2814653 chr6 63067695 A T 6.86E-04 Type 2 diabetes / / 17463246 rs2814652 chr6 63067982 T C 7.77E-04 Multiple complex diseases / / 17554300 rs2842809 chr6 63069946 A G 9.39E-04 Multiple complex diseases / / 17554300 rs2814650 chr6 63070614 A T 9.60E-06 Calcium levels / / 20705733 rs2814649 chr6 63070663 T G 9.60E-06 Calcium levels / / 20705733 rs2842804 chr6 63074182 G A 9.43E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11758619 chr6 63074388 G C 6.70E-06 Calcium levels / / 20705733 rs2345331 chr6 63075694 T C 3.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2345331 chr6 63075694 T C 6.70E-06 Calcium levels / / 20705733 rs10498818 chr6 63076170 G T 5.25E-05 Pulmonary function / / 17903307 rs12662273 chr6 63076831 T C 6.60E-06 Calcium levels / / 20705733 rs2814680 chr6 63077973 A T 6.60E-06 Calcium levels / / 20705733 rs2842802 chr6 63078319 T C 6.60E-06 Calcium levels / / 20705733 rs2814681 chr6 63078424 T C 6.00E-06 Calcium levels / / 20705733 rs2639415 chr6 63078904 T C 5.30E-06 Calcium levels / / 20705733 rs16884169 chr6 63080465 T C 5.30E-06 Calcium levels / / 20705733 rs12663464 chr6 63081095 G C 5.71E-04 Multiple complex diseases / / 17554300 rs12663464 chr6 63081095 G C 5.40E-06 Calcium levels / / 20705733 rs876854 chr6 63081673 T C 5.70E-06 Calcium levels / / 20705733 rs2842798 chr6 63082734 G A 6.00E-06 Calcium levels / / 20705733 rs2814660 chr6 63082948 G A 4.90E-06 Calcium levels / / 20705733 rs2814658 chr6 63083366 A T 4.90E-06 Calcium levels / / 20705733 rs2639447 chr6 63085970 C A 4.90E-06 Calcium levels / / 20705733 rs2639448 chr6 63086002 T A 4.90E-06 Calcium levels / / 20705733 rs2639449 chr6 63086197 T G 4.90E-06 Calcium levels / / 20705733 rs2639450 chr6 63086240 T A 4.90E-06 Calcium levels / / 20705733 rs2639400 chr6 63090188 T A 4.80E-06 Calcium levels / / 20705733 rs2639427 chr6 63098091 G A 6.99E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2639421 chr6 63100190 T G 3.97E-04 Bipolar disorder / / 19259986 rs2260966 chr6 63102796 T C 4.70E-06 Calcium levels / / 20705733 rs2639419 chr6 63104240 A C 3.20E-06 Calcium levels / / 20705733 rs2492805 chr6 63117685 T C 1.88E-04 Multiple complex diseases / / 17554300 rs2492805 chr6 63117685 T C 4.40E-06 Calcium levels / / 20705733 rs2639396 chr6 63135909 A G 3.50E-06 Calcium levels / / 20705733 rs2452462 chr6 63138227 A G 1.70E-04 Multiple complex diseases / / 17554300 rs2452462 chr6 63138227 A G 3.60E-06 Calcium levels / / 20705733 rs581435 chr6 63153926 A G 4.20E-06 Calcium levels / / 20705733 rs675484 chr6 63154495 T C 4.40E-06 Calcium levels / / 20705733 rs682238 chr6 63160147 C G 3.00E-06 Calcium levels / / 20705733 rs674193 chr6 63160790 T C 1.97E-04 Multiple complex diseases / / 17554300 rs674193 chr6 63160790 T C 3.00E-06 Calcium levels / / 20705733 rs596571 chr6 63162908 T G 3.10E-06 Calcium levels / / 20705733 rs584274 chr6 63174417 C G 2.26E-10 Alcohol consumption / / pha001398 rs9351812 chr6 63174910 C T 1.61E-04 Celiac disease / / 23936387 rs6912542 chr6 63186449 A G 3.93E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1334728 chr6 63196072 T A 3.87E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2345981 chr6 63209941 G A 1.76E-04 Celiac disease / / 23936387 rs6910728 chr6 63224998 G A 8.90E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs756344 chr6 63244061 T C 6.62E-04 Multiple complex diseases / / 17554300 rs756344 chr6 63244061 T C 1.40E-05 Urinary metabolites / / 21572414 rs9341362 chr6 63244978 C T 9.20E-06 Urinary metabolites / / 21572414 rs12525202 chr6 63249463 C T 3.80E-06 Urinary metabolites / / 21572414 rs953435 chr6 63254174 T A 1.30E-05 Urinary metabolites / / 21572414 rs9446610 chr6 63257354 C T 3.24E-05 Telomere length / / 23001564 rs6453614 chr6 63330876 G A 1.10E-05 Urinary metabolites / / 21572414 rs2843124 chr6 63352863 C T 1.43E-04 Multiple complex diseases / / 17554300 rs2843115 chr6 63432083 G T 9.18E-04 Multiple complex diseases / / 17554300 rs1856123 chr6 63475320 A G 1.76E-04 Multiple complex diseases / / 17554300 rs553713 chr6 63502215 C A 2.00E-05 Urinary metabolites / / 21572414 rs1577822 chr6 63585140 T G 1.65E-04 Opioid sensitivity / / 23183491 rs12192467 chr6 63601482 G A 2.57E-04 Type 2 diabetes / / 22158537 rs4435924 chr6 63609424 T C 7.38E-04 Type 2 diabetes / / 22158537 rs12214838 chr6 63610793 C T 6.88E-04 Type 2 diabetes / / 22158537 rs10943290 chr6 63613349 C G 8.51E-04 Multiple complex diseases / / 17554300 rs573245251 chr6 63613349 CT C 8.51E-04 Multiple complex diseases / / 17554300 rs9448077 chr6 63769553 A G 3.90E-04 Type 2 diabetes / / 17463246 rs1341193 chr6 63769671 A G 0.0002398 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1341193 chr6 63769671 A G 2.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9294075 chr6 63771225 G A 3.90E-04 Type 2 diabetes / / 17463246 rs9343612 chr6 63771395 T A 3.82E-04 Type 2 diabetes / / 17463246 rs1341188 chr6 63771994 A G 3.91E-04 Type 2 diabetes / / 17463246 rs4710403 chr6 63774961 A C,G,T 4.14E-04 Type 2 diabetes / / 17463246 rs4710405 chr6 63775030 G A 5.80E-04 Type 2 diabetes / / 17463246 rs789964 chr6 63775888 A T 3.85E-04 Type 2 diabetes / / 17463246 rs789943 chr6 63802355 T A 4.16E-04 Type 2 diabetes / / 17463246 rs789942 chr6 63803188 C A 5.00E-06 Obesity-related traits / / 23251661 rs810967 chr6 63826982 A G 6.15E-04 Type 2 diabetes / / 17463246 rs6454050 chr6 63864982 T C 2.57E-05 Alcohol and nictotine co-dependence / / 20158304 rs12195233 chr6 63871248 T C 9.03E-04 Multiple complex diseases / / 17554300 rs7739721 chr6 63900708 G A 2.31E-04 White matter integrity / / 22425255 rs9350790 chr6 63918433 C T 3.08E-04 White matter integrity / / 22425255 rs1870488 chr6 63933079 C T 3.08E-04 White matter integrity / / 22425255 rs9352692 chr6 63939938 T A 1.10E-05 Urinary metabolites / / 21572414 rs1504377 chr6 63947422 T C 9.25E-04 White matter integrity / / 22425255 rs10755383 chr6 63956367 G A 5.49E-04 White matter integrity / / 22425255 rs12195405 chr6 63975596 C T 7.54E-04 Parkinson's disease / / 16252231 rs2459572 chr6 63993375 C T 2.47E-04 Opioid sensitivity LGSN intron 23183491 rs9352774 chr6 64014812 A C 9.53E-05 Major depressive disorder LGSN intron 21621269 rs1741797 chr6 64058565 T C 5.20E-05 Malaria / / 19465909 rs1525361 chr6 64094892 T C 4.62E-04 Major depressive disorder / / 22472876 rs1525361 chr6 64094892 T C 9.70E-04 Myocardial Infarction / / pha002873 rs1723527 chr6 64101818 A G 3.67E-05 Major depressive disorder (broad) / / 20038947 rs9449291 chr6 64162953 G A 7.80E-06 Alcohol dependence / / 22096494 rs6942342 chr6 64176447 T C 4.10E-06 Alcohol dependence / / 22096494 rs9353016 chr6 64186032 G A 1.00E-05 Alcohol dependence / / 22096494 rs4299811 chr6 64190446 C T 7.00E-06 Alcohol dependence / / 22096494 rs4557499 chr6 64190547 G T 1.00E-05 Alcohol dependence / / 22096494 rs2758259 chr6 64193107 C T 1.10E-05 Alcohol dependence / / 22096494 rs1744140 chr6 64212831 T C 1.20E-05 Alcohol dependence / / 22096494 rs2984458 chr6 64215163 T C 1.10E-05 Alcohol dependence / / 22096494 rs1681957 chr6 64223145 T C 9.10E-06 Alcohol dependence / / 22096494 rs1197905 chr6 64235006 T C 9.10E-06 Alcohol dependence / / 22096494 rs1322416 chr6 64254019 T G 7.50E-06 Alcohol dependence / / 22096494 rs1744163 chr6 64288210 G A 6.90E-05 Schizophrenia PTP4A1 intron 21791550 rs1744163 chr6 64288210 G A 0.000069 Psychosis PTP4A1 intron 23164818 rs9294269 chr6 64337297 A C 3.70E-06 Alcohol dependence / / 22096494 rs10485358 chr6 64386060 C T 3.20E-04 Alcohol dependence PHF3 intron 22096494 rs10755432 chr6 64397853 A C 3.40E-04 Alcohol dependence PHF3 intron 22096494 rs4710437 chr6 64426894 A G 1.25E-04 Weight loss (gastric bypass surgery) / / 23643386 rs319924 chr6 64487247 A G 6.40E-04 Alcohol dependence EYS intron 22096494 rs319924 chr6 64487247 A G 7.74E-04 Alzheimer's disease EYS intron 24755620 rs319920 chr6 64504252 A G 2.90E-04 Alcohol dependence EYS intron 22096494 rs319920 chr6 64504252 A G 8.18E-04 Alzheimer's disease EYS intron 24755620 rs756274 chr6 64505213 A G 5.00E-04 Alcohol dependence EYS intron 22096494 rs6921058 chr6 64524151 G T 8.00E-04 Alcohol dependence EYS intron 22096494 rs1482463 chr6 64589465 C T 0.0000813 Major depressive disorder EYS intron 23149448 rs729291 chr6 64595074 T C 3.68E-04 Alzheimer's disease EYS intron 24755620 rs1482451 chr6 64597086 G A 8.01E-04 Alzheimer's disease EYS intron 24755620 rs6936580 chr6 64616909 T C 4.67E-05 Serum metabolites EYS intron 19043545 rs12529599 chr6 64618911 G T 4.20E-04 Lung function (forced expiratory volume in 1 second) EYS intron 17255346 rs12529599 chr6 64618911 G T 9.65E-05 Tunica Media EYS intron pha003036 rs16879841 chr6 64619805 G A 2.81E-04 Coronary heart disease EYS intron 21606135 rs4535528 chr6 64623199 C T 3.01E-04 Coronary heart disease EYS intron 21606135 rs452975 chr6 64625328 T C 1.15E-04 Lung function (forced expiratory volume in 1 second) EYS intron 17255346 rs397228 chr6 64626592 C T 3.64E-04 Coronary heart disease EYS intron 21606135 rs1552165 chr6 64639465 C T 4.56E-04 Lung function (forced expiratory volume in 1 second) EYS intron 17255346 rs7757616 chr6 64654533 C A 1.52E-04 Coronary heart disease EYS intron 21606135 rs7753314 chr6 64658652 G T 1.89E-04 Coronary heart disease EYS intron 21606135 rs9353441 chr6 64731015 A G 9.83E-05 Non-alcoholic fatty liver disease histology (other) EYS intron 20708005 rs3003672 chr6 64831120 A C 5.50E-04 Alcohol dependence EYS intron 20201924 rs4573063 chr6 64850803 C A 9.68E-04 Multiple complex diseases EYS intron 17554300 rs9353533 chr6 64855302 A C 7.95E-04 Multiple complex diseases EYS intron 17554300 rs3013162 chr6 64863870 G C 1.11E-04 Multiple complex diseases EYS intron 17554300 rs3013162 chr6 64863870 G C 8.93E-04 Response to cytidine analogues (gemcitabine) EYS intron 24483146 rs9344825 chr6 64882930 C G 2.85E-04 Multiple complex diseases EYS intron 17554300 rs4235967 chr6 64885284 A G 1.15E-04 Multiple complex diseases EYS intron 17554300 rs9362531 chr6 64889898 G A 6.75E-04 Response to cytidine analogues (gemcitabine) EYS intron 24483146 rs4326220 chr6 64896909 T C 1.28E-04 Multiple complex diseases EYS intron 17554300 rs5002649 chr6 64896964 G A 9.44E-04 Multiple complex diseases EYS intron 17554300 rs12174860 chr6 64916432 C T 1.39E-04 Multiple complex diseases EYS intron 17554300 rs12175881 chr6 64916780 A G 7.91E-04 Multiple complex diseases EYS intron 17554300 rs12175881 chr6 64916780 A G 7.96E-04 Response to cytidine analogues (gemcitabine) EYS intron 24483146 rs4710471 chr6 64925611 C G 1.55E-04 Multiple complex diseases EYS intron 17554300 rs4391246 chr6 64952475 C T 3.67E-04 Response to cytidine analogues (gemcitabine) EYS intron 24483146 rs9344917 chr6 64955968 G A 4.32E-04 Response to cytidine analogues (gemcitabine) EYS intron 24483146 rs4710476 chr6 64961573 G A 4.67E-04 Response to cytidine analogues (gemcitabine) EYS intron 24483146 rs9344924 chr6 64963796 T C 7.76E-04 Multiple complex diseases EYS intron 17554300 rs9362642 chr6 64967203 T C 1.79E-04 Response to cytidine analogues (gemcitabine) EYS intron 24483146 rs9451209 chr6 64967888 T G 3.91E-04 Multiple complex diseases EYS intron 17554300 rs2057161 chr6 64968189 C T 5.32E-04 Multiple complex diseases EYS intron 17554300 rs9362651 chr6 64971436 G A 8.99E-04 Multiple complex diseases EYS intron 17554300 rs9362651 chr6 64971436 G A 8.93E-04 Response to cytidine analogues (gemcitabine) EYS intron 24483146 rs9344936 chr6 64971602 A T 2.56E-04 Response to cytidine analogues (gemcitabine) EYS intron 24483146 rs2180038 chr6 64971885 C A 2.84E-04 Response to cytidine analogues (gemcitabine) EYS intron 24483146 rs10806410 chr6 64983718 T C 4.76E-04 Response to cytidine analogues (gemcitabine) EYS intron 24483146 rs7747074 chr6 64989092 T C 6.18E-04 Response to cytidine analogues (gemcitabine) EYS intron 24483146 rs1922955 chr6 64996226 C A,G 5.24E-04 Multiple complex diseases EYS intron 17554300 rs9344951 chr6 64997807 T C 4.57E-04 Multiple complex diseases EYS intron 17554300 rs1922956 chr6 64998321 G A 5.12E-04 Response to cytidine analogues (gemcitabine) EYS intron 24483146 rs1028484 chr6 65003904 C T 2.30E-04 Multiple complex diseases EYS intron 17554300 rs7774545 chr6 65034184 G A,T 4.23E-04 Multiple complex diseases EYS intron 17554300 rs7774545 chr6 65034184 G A,T 1.83E-06 Testicular cancer EYS intron 19483682 rs7774545 chr6 65034184 G A,T 7.46E-04 Response to cytidine analogues (gemcitabine) EYS intron 24483146 rs7757305 chr6 65034280 A C 1.05E-04 Multiple complex diseases EYS intron 17554300 rs7757305 chr6 65034280 A C 3.02E-04 Response to cytidine analogues (gemcitabine) EYS intron 24483146 rs648766 chr6 65039769 T C 4.52E-04 Multiple complex diseases EYS intron 17554300 rs593493 chr6 65056811 G T 6.18E-04 Response to cytidine analogues (gemcitabine) EYS intron 24483146 rs1922945 chr6 65065008 A G 1.50E-04 Statin-induced myopathy EYS intron 21826682 rs661287 chr6 65073683 C T 7.30E-04 Multiple complex diseases EYS intron 17554300 rs671938 chr6 65073876 G T 5.05E-04 Multiple complex diseases EYS intron 17554300 rs673676 chr6 65074128 C T 3.11E-04 Multiple complex diseases EYS intron 17554300 rs609098 chr6 65085510 C T 1.86E-04 Multiple complex diseases EYS intron 17554300 rs609098 chr6 65085510 C T 3.51E-04 Response to cytidine analogues (gemcitabine) EYS intron 24483146 rs6454814 chr6 65090443 A C 4.42E-04 Multiple complex diseases EYS intron 17554300 rs9359927 chr6 65147829 G T 1.51E-04 Multiple complex diseases EYS intron 17554300 rs1337515 chr6 65164326 G C 2.12E-04 Multiple complex diseases EYS intron 17554300 rs9359943 chr6 65180260 G A 6.96E-04 Multiple complex diseases EYS intron 17554300 rs9342288 chr6 65187046 G A 6.98E-04 Multiple complex diseases EYS intron 17554300 rs9342288 chr6 65187046 G A 8.00E-04 Statin-induced myopathy EYS intron 21826682 rs1337512 chr6 65193820 T G 5.28E-04 Multiple complex diseases EYS intron 17554300 rs1337512 chr6 65193820 T G 8.00E-04 Statin-induced myopathy EYS intron 21826682 rs3857532 chr6 65233665 G A 3.00E-04 Statin-induced myopathy EYS intron 21826682 rs1337518 chr6 65238937 C A 1.22E-04 Statin-induced myopathy EYS intron 21826682 rs17217924 chr6 65288688 T C 6.60E-04 Multiple complex diseases EYS intron 17554300 rs12660387 chr6 65291644 A G 4.05E-04 Multiple complex diseases EYS intron 17554300 rs12660680 chr6 65292039 A G 7.09E-04 Multiple complex diseases EYS intron 17554300 rs10944599 chr6 65292620 C T 6.15E-04 Multiple complex diseases EYS intron 17554300 rs34148654 chr6 65295448 G A 7.71E-04 Multiple complex diseases EYS intron 17554300 rs12663622 chr6 65301787 G C 7.27E-04 Multiple complex diseases EYS missense 17554300 rs12662610 chr6 65301824 T C 6.48E-04 Multiple complex diseases EYS cds-synon 17554300 rs12661208 chr6 65302728 C G 6.90E-04 Multiple complex diseases EYS intron 17554300 rs9353962 chr6 65321389 A G 8.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EYS intron 20877124 rs604490 chr6 65321689 A G 8.05E-05 Prostate cancer EYS intron pha002878 rs9353967 chr6 65325793 T G 6.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EYS intron 20877124 rs7761723 chr6 65330390 A G 3.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EYS intron 20877124 rs7740016 chr6 65342354 C T 8.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EYS intron 20877124 rs9354006 chr6 65366564 A G 3.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EYS intron 20877124 rs7740229 chr6 65394975 G A 3.44E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) EYS intron 24023788 rs1495531 chr6 65422320 G T 1.56E-04 Multiple complex diseases EYS intron 17554300 rs1495528 chr6 65422772 A C 1.75E-04 Multiple complex diseases EYS intron 17554300 rs1889497 chr6 65432283 A T 2.00E-06 Melanoma EYS intron 24980573 rs7753225 chr6 65435625 T C 0.000454809 Hypertension (early onset hypertension) EYS intron 22479346 rs6934929 chr6 65453785 C T 3.61E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) EYS intron 24023788 rs6911837 chr6 65496953 G A 1.99E-04 Alcohol dependence EYS intron 20201924 rs16895833 chr6 65539557 G A 6.45E-04 Type 2 diabetes EYS intron 17463246 rs9294631 chr6 65622463 A G 8.05E-04 Parkinson's disease EYS missense 17052657 rs2350001 chr6 65628676 A G 5.96E-05 Parkinson's disease EYS intron 17052657 rs11754641 chr6 65635923 C G 8.00E-06 Disc degeneration (lumbar) EYS intron 22993228 rs16896055 chr6 65636981 G A 8.77E-04 Multiple complex diseases EYS intron 17554300 rs7767572 chr6 65662621 A G 8.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) EYS intron 23934736 rs2882373 chr6 65770749 T C 1.90E-04 Response to alcohol consumption (flushing response) EYS intron 24277619 rs17495347 chr6 65779431 G T 3.17E-04 Smoking initiation EYS intron 24665060 rs975618 chr6 65824579 G A 4.93E-07 Duodenal ulcer EYS intron 22387998 rs6455027 chr6 65842061 G A 2.40E-05 Glycemic traits (pregnancy) EYS intron 23903356 rs6924505 chr6 65856804 A T 8.77E-05 Serum metabolites EYS intron 19043545 rs7775478 chr6 65861193 G T 4.31E-07 Duodenal ulcer EYS intron 22387998 rs12198932 chr6 65871821 C T 1.80E-05 Duodenal ulcer EYS intron 22387998 rs531101 chr6 65886480 C T 1.94E-05 Duodenal ulcer EYS intron 22387998 rs841528 chr6 65899528 G A 7.83E-05 Serum metabolites EYS intron 19043545 rs16896391 chr6 65905998 T C 4.10E-07 Duodenal ulcer EYS intron 22387998 rs16896392 chr6 65906179 T C 8.30E-05 Serum metabolites EYS intron 19043545 rs686041 chr6 65906722 T C 3.09E-05 Multiple complex diseases EYS intron 17554300 rs12212207 chr6 65920352 A G 9.76E-04 Multiple complex diseases EYS intron 17554300 rs2788907 chr6 65940233 G A 8.36E-06 Duodenal ulcer EYS intron 22387998 rs533110 chr6 65952526 G T 3.65E-06 Duodenal ulcer EYS intron 22387998 rs6905713 chr6 65957304 C T 3.66E-06 Duodenal ulcer EYS intron 22387998 rs536372 chr6 65969239 T C 3.65E-06 Duodenal ulcer EYS intron 22387998 rs536372 chr6 65969239 T C 5.19E-04 Smoking quantity EYS intron 24665060 rs656486 chr6 65977842 C T 4.67E-04 Multiple complex diseases EYS intron 17554300 rs13197839 chr6 65989292 A C 2.22E-05 Duodenal ulcer EYS intron 22387998 rs13197839 chr6 65989292 A C 2.98E-04 Response to cytadine analogues (cytosine arabinoside) EYS intron 24483146 rs11962234 chr6 65989747 A G 5.19E-04 Response to cytadine analogues (cytosine arabinoside) EYS intron 24483146 rs9354219 chr6 66009103 G T 2.71E-05 Duodenal ulcer EYS intron 22387998 rs6937429 chr6 66021416 T G 1.80E-05 Duodenal ulcer EYS intron 22387998 rs7754286 chr6 66030650 T G 1.52E-05 Duodenal ulcer EYS intron 22387998 rs9354228 chr6 66039601 G A 1.61E-05 Duodenal ulcer EYS UTR-3 22387998 rs9453294 chr6 66106319 T C 3.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) EYS intron 23648065 rs974110 chr6 66112409 A G 3.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) EYS cds-synon 23648065 rs11968993 chr6 66115654 A G 4.71E-05 Intelligence EYS intron 21826061 rs2753977 chr6 66119463 C T 8.47E-04 Response to taxane treatment (placlitaxel) EYS intron 23006423 rs148215303 chr6 66127607 T C 0.0000832 Nonsyndromic striae distensae (stretch marks) EYS intron 23633020 rs10944796 chr6 66133281 T C 4.54E-05 Smoking quantity EYS intron 24665060 rs1393700 chr6 66136936 C T 6.76E-05 Smoking quantity EYS intron 24665060 rs2036475 chr6 66154647 T G 1.78E-04 Response to taxane treatment (placlitaxel) EYS intron 23006423 rs9445549 chr6 66157091 C T 6.55E-05 Platelet counts EYS intron pha003100 rs12208109 chr6 66168229 A G 0.0000207 Breast cancer early age of onset EYS intron 18463975 rs4710520 chr6 66178480 T C 3.00E-06 IgG glycosylation EYS intron 23382691 rs4710520 chr6 66178480 T C 5.00E-06 IgG glycosylation EYS intron 23382691 rs4710520 chr6 66178480 T C 6.00E-06 IgG glycosylation EYS intron 23382691 rs7751898 chr6 66226339 A G 9.72E-06 Platelet counts EYS intron pha003100 rs9445554 chr6 66233548 G C 3.53E-04 Suicide attempts in bipolar disorder EYS intron 21423239 rs9363384 chr6 66234737 A T 6.93E-04 Suicide attempts in bipolar disorder EYS intron 21423239 rs9363384 chr6 66234737 A T 4.10E-06 Urinary metabolites EYS intron 21572414 rs9354260 chr6 66234821 G A 7.83E-04 Suicide attempts in bipolar disorder EYS intron 21423239 rs9363385 chr6 66235215 C G 4.48E-04 Suicide attempts in bipolar disorder EYS intron 21423239 rs9453319 chr6 66235307 C T 5.11E-04 Suicide attempts in bipolar disorder EYS intron 21423239 rs7742748 chr6 66236110 T A 4.48E-04 Suicide attempts in bipolar disorder EYS intron 21423239 rs1929328 chr6 66237260 G C 4.48E-04 Suicide attempts in bipolar disorder EYS intron 21423239 rs7768271 chr6 66238320 C T 2.95E-04 Suicide attempts in bipolar disorder EYS intron 21423239 rs9453321 chr6 66240717 C T 5.64E-04 Suicide attempts in bipolar disorder EYS intron 21423239 rs7775434 chr6 66241186 A T 3.18E-04 Suicide attempts in bipolar disorder EYS intron 21423239 rs7756463 chr6 66241582 C G 8.36E-04 Suicide attempts in bipolar disorder EYS intron 21423239 rs7776123 chr6 66241604 A G 4.13E-04 Suicide attempts in bipolar disorder EYS intron 21423239 rs1831476 chr6 66244123 C T 7.06E-04 Suicide attempts in bipolar disorder EYS intron 21423239 rs1929330 chr6 66246610 C T 8.33E-04 Suicide attempts in bipolar disorder EYS intron 21423239 rs1411850 chr6 66248424 T C 8.30E-04 Suicide attempts in bipolar disorder EYS intron 21423239 rs1331200 chr6 66249824 C A 8.36E-04 Suicide attempts in bipolar disorder EYS intron 21423239 rs9363388 chr6 66252000 T C 8.39E-04 Suicide attempts in bipolar disorder EYS intron 21423239 rs7767793 chr6 66259309 A G 1.18E-04 Multiple complex diseases EYS intron 17554300 rs9342486 chr6 66277416 G A 4.30E-06 Urinary metabolites EYS intron 21572414 rs9351510 chr6 66283800 C T 5.10E-06 Urinary metabolites EYS intron 21572414 rs1929338 chr6 66289183 T C 2.00E-06 Urinary metabolites EYS intron 21572414 rs354362 chr6 66301907 A C 2.63E-04 Type 2 diabetes EYS intron 17463246 rs354364 chr6 66304163 T C 7.80E-06 Urinary metabolites EYS intron 21572414 rs971620 chr6 66325019 T A 8.07E-05 Multiple complex diseases EYS intron 17554300 rs2130493 chr6 66340432 C T 2.74E-04 Alzheimer's disease (late onset) EYS intron 21379329 rs9354270 chr6 66340589 G T 4.71E-04 Coronary heart disease EYS intron 21971053 rs6910313 chr6 66435543 G A 1.20E-05 Urinary metabolites / / 21572414 rs9453396 chr6 66471880 T G 2.40E-05 Urinary metabolites / / 21572414 rs1938105 chr6 66510926 C T 8.84E-06 HIV-1 viral setpoint / / 22174851 rs2814111 chr6 66514251 C T 2.60E-05 Urinary metabolites / / 21572414 rs2814094 chr6 66536275 T G 2.94E-06 Serum metabolites / / 19043545 rs2351729 chr6 66537291 A G 1.12E-05 Serum metabolites / / 19043545 rs2882754 chr6 66537341 G A 5.57E-05 Serum metabolites / / 19043545 rs9354305 chr6 66542891 T C 4.25E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12529685 chr6 66544648 C T 4.07E-05 HIV-1 viral setpoint / / 22174851 rs6907911 chr6 66555683 T C 2.20E-05 Serum metabolites / / 19043545 rs9354308 chr6 66565353 G A 3.00E-07 Metabolite levels / / 19043545 rs9342503 chr6 66565436 A G 3.12E-07 Serum metabolites / / 19043545 rs9360161 chr6 66565457 T C 3.12E-07 Serum metabolites / / 19043545 rs1604019 chr6 66571977 G A 9.02E-05 Triglycerides / / pha003080 rs9453460 chr6 66577382 G C 5.86E-05 Serum metabolites / / 19043545 rs9345701 chr6 66577992 C T 6.01E-05 Coronary heart disease / / pha003030 rs1938072 chr6 66583328 T C 1.45E-06 Serum metabolites / / 19043545 rs1938073 chr6 66583387 C G 1.33E-06 Serum metabolites / / 19043545 rs9453462 chr6 66583491 C T 1.33E-06 Serum metabolites / / 19043545 rs9354319 chr6 66583656 T C 1.33E-06 Serum metabolites / / 19043545 rs9294660 chr6 66585334 C T 9.02E-05 Triglycerides / / pha003080 rs10944852 chr6 66589863 T G 5.64E-05 Blood Pressure / / pha003040 rs9360166 chr6 66590974 C T 1.15E-06 Serum metabolites / / 19043545 rs9345711 chr6 66591447 A G 1.08E-06 Serum metabolites / / 19043545 rs16897334 chr6 66591791 T C 1.20E-05 Urinary metabolites / / 21572414 rs1499706 chr6 66593415 A G 1.33E-06 Serum metabolites / / 19043545 rs4464770 chr6 66594482 T C 6.60E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs9294661 chr6 66595971 A C 3.44E-06 Serum metabolites / / 19043545 rs2211636 chr6 66596815 A G 3.25E-06 Serum metabolites / / 19043545 rs10455590 chr6 66598194 G A 2.00E-06 HIV-1 viral setpoint / / 22174851 rs9445610 chr6 66598938 A C,G,T 5.53E-06 Serum metabolites / / 19043545 rs9445610 chr6 66598938 A C,G,T 8.81E-05 Triglycerides / / pha003080 rs9453471 chr6 66598984 G T 2.09E-06 Serum metabolites / / 19043545 rs4031876 chr6 66604261 A G 1.74E-06 Serum metabolites / / 19043545 rs1938065 chr6 66608617 T A,C,G 5.85E-07 Serum metabolites / / 19043545 rs9453479 chr6 66610017 C A 3.91E-04 Lung function (forced vital capacity) / / 24023788 rs1587434 chr6 66615355 T C 3.61E-04 Multiple complex diseases / / 17554300 rs9363486 chr6 66615551 G A 2.69E-06 Serum metabolites / / 19043545 rs6939062 chr6 66633781 C T 2.73E-04 Multiple complex diseases / / 17554300 rs9453519 chr6 66648288 T C 2.06E-04 Multiple complex diseases / / 17554300 rs9294677 chr6 66652620 G C 8.16E-04 Bipolar disorder / / 19259986 rs9345745 chr6 66689252 G A 4.18E-06 Triglycerides / / pha003080 rs1466554 chr6 66702268 G A 5.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs9354370 chr6 66808209 T C 8.23E-04 Type 2 diabetes / / 17463246 rs1100950 chr6 66827285 A C 6.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) / / 24554482 rs208482 chr6 66923129 G A 3.23E-04 Multiple complex diseases / / 17554300 rs3857536 chr6 66929048 C T 4.00E-06 Blood trace element (Cu levels) / / 23720494 rs9351552 chr6 66998589 T A,G 2.84E-05 Alzheimer's disease / / 22832961 rs9354411 chr6 67019930 A G 1.00E-04 Information processing speed / / 21130836 rs1634222 chr6 67038021 C T 8.94E-04 Obesity (extreme) / / 21935397 rs851860 chr6 67054884 A G 4.94E-04 Alcohol dependence / / 24277619 rs17702764 chr6 67060771 C A 6.04E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs1634186 chr6 67070064 G A 7.65E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9453749 chr6 67105476 G A 6.74E-04 Alzheimer's disease / / 17998437 rs1464074 chr6 67123344 A G 1.79E-04 Alzheimer's disease / / 17998437 rs1464072 chr6 67123755 C T 8.61E-04 Alzheimer's disease / / 17998437 rs1567793 chr6 67123794 T C 2.96E-04 Alzheimer's disease / / 17998437 rs10223721 chr6 67126456 G A 2.80E-05 Urinary metabolites / / 21572414 rs4710604 chr6 67149979 A C 3.56E-05 Aging (time to event) / / 21782286 rs1513498 chr6 67171922 G A 7.74E-05 Major depressive disorder / / 22472876 rs9445732 chr6 67248410 G T 2.00E-06 Corneal astigmatism / / 23322567 rs10806538 chr6 67249077 A G 6.92E-08 Metabolite levels / / 23281178 rs9354439 chr6 67249103 G T 6.92E-08 Metabolite levels / / 23281178 rs12176231 chr6 67259979 T C 9.71E-08 Metabolite levels / / 23281178 rs12662737 chr6 67274700 A G 9.68E-04 White matter integrity / / 22425255 rs2504156 chr6 67335224 C T 3.09E-05 Heart Failure / / pha002885 rs12194460 chr6 67335614 A G 9.17E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1563301 chr6 67348139 G A 1.22E-05 Longevity / / 21612516 rs9294714 chr6 67348446 T C 2.89E-04 Bipolar disorder / / 19259986 rs12208629 chr6 67350044 G A 7.39E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1869677 chr6 67350269 C T 1.59E-04 Bipolar disorder / / 19259986 rs9294715 chr6 67353438 T C 9.86E-05 Bipolar disorder and schizophrenia / / 20889312 rs17527707 chr6 67368150 T C 4.91E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1037576 chr6 67372927 C A 5.65E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs7740653 chr6 67391027 A T 6.80E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9294716 chr6 67391355 A G 5.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs994377 chr6 67391578 A G 7.40E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4639316 chr6 67402281 G A 2.78E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9354464 chr6 67408526 C T 3.92E-05 Cognitive test performance / / 20125193 rs12200993 chr6 67423526 C A 9.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4629669 chr6 67435826 G T 9.09E-05 Cognitive test performance / / 20125193 rs6935468 chr6 67453417 C T 2.22E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12211123 chr6 67454402 T C 8.24E-05 Alzheimer's disease (age of onset) / / 22005931 rs12213144 chr6 67455452 T C 8.24E-05 Alzheimer's disease (age of onset) / / 22005931 rs12190949 chr6 67455466 G T 8.21E-05 Alzheimer's disease (age of onset) / / 22005931 rs12192940 chr6 67456596 G A 8.21E-05 Alzheimer's disease (age of onset) / / 22005931 rs12215287 chr6 67457078 A T 8.16E-05 Alzheimer's disease (age of onset) / / 22005931 rs10447347 chr6 67458231 T C 8.15E-05 Alzheimer's disease (age of onset) / / 22005931 rs4710624 chr6 67462564 A G 8.07E-05 Alzheimer's disease (age of onset) / / 22005931 rs1869682 chr6 67463990 T A 8.06E-05 Alzheimer's disease (age of onset) / / 22005931 rs12195065 chr6 67465262 T C 4.82E-05 Bone mineral density / / 19181680 rs12195065 chr6 67465262 T C 8.03E-05 Alzheimer's disease (age of onset) / / 22005931 rs4235980 chr6 67469995 C T 7.90E-05 Alzheimer's disease (age of onset) / / 22005931 rs12204007 chr6 67475294 T G 8.58E-05 Alzheimer's disease (age of onset) / / 22005931 rs12203111 chr6 67479089 C T 4.40E-05 Alzheimer's disease (age of onset) / / 22005931 rs12202727 chr6 67482667 G A 6.19E-05 Alzheimer's disease (age of onset) / / 22005931 rs12206424 chr6 67484419 G A 6.91E-05 Alzheimer's disease (age of onset) / / 22005931 rs12201073 chr6 67488602 C T 3.52E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12201163 chr6 67488728 C T 8.54E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs4446548 chr6 67496741 A T 9.61E-05 Alzheimer's disease (age of onset) / / 22005931 rs4710625 chr6 67497830 C G 8.39E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs12212990 chr6 67505032 C T 2.54E-05 Alzheimer's disease (age of onset) / / 22005931 rs12203012 chr6 67507305 G T 7.52E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12209528 chr6 67519114 A G 7.05E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4298331 chr6 67520962 T A 7.05E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7756661 chr6 67521259 G A 1.83E-05 Alzheimer's disease (age of onset) / / 22005931 rs4301287 chr6 67526987 A T 1.80E-05 Alzheimer's disease (age of onset) / / 22005931 rs4394199 chr6 67536400 A G 1.73E-05 Alzheimer's disease (age of onset) / / 22005931 rs11753204 chr6 67541579 T C 7.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12200302 chr6 67544661 A G 1.75E-05 Alzheimer's disease (age of onset) / / 22005931 rs12201841 chr6 67545058 A T 1.73E-05 Alzheimer's disease (age of onset) / / 22005931 rs9445792 chr6 67628858 T A 5.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs4257844 chr6 67635684 T C 7.38E-05 Response to citalopram treatment / / 19846067 rs4257844 chr6 67635684 T C 4.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs6912709 chr6 67641300 A G 7.06E-04 Endometrial cancer / / 24096698 rs11970254 chr6 67649216 G T 6.00E-07 Brain structure / / 20171287 rs12529449 chr6 67653117 G A 9.00E-06 Urinary metabolites / / 21572414 rs28631020 chr6 67653279 G A 3.00E-06 Bulimia nervosa / / 23568457 rs10214441 chr6 67658860 A G 2.15E-04 Alzheimer's disease (late onset) / / 21379329 rs9354514 chr6 67680571 A G 3.47E-05 Alzheimer's disease (late onset) / / 21379329 rs9345943 chr6 67681572 T C 3.47E-05 Alzheimer's disease (late onset) / / 21379329 rs12203791 chr6 67721488 T C 8.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs935997 chr6 67737658 G T 4.82E-05 Multiple complex diseases / / 17554300 rs4235984 chr6 67738061 A G 1.52E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2502273 chr6 67753307 A C 2.08E-04 Smoking initiation / / 24665060 rs2502286 chr6 67769601 A T 7.27E-04 Smoking initiation / / 24665060 rs1947413 chr6 67787699 G C 9.05E-04 Alzheimer's disease / / 17998437 rs2444666 chr6 67787889 G A 6.16E-04 Type 2 diabetes / / 17463246 rs1377705 chr6 67790773 G C 4.05E-04 Alzheimer's disease / / 17998437 rs13202756 chr6 67799924 A C 0.00000164 Antisocial behavior / / 23077488 rs1349813 chr6 67801858 G A 8.14E-04 Smoking initiation / / 24665060 rs9351629 chr6 67803212 G A 6.10E-05 Alcohol dependence / / 20201924 rs9351629 chr6 67803212 G A 6.08E-05 Alcoholism / / pha002892 rs7757164 chr6 67836893 T C 4.20E-04 Smoking initiation / / 24665060 rs12665811 chr6 67843093 C T 6.44E-04 Alzheimer's disease / / 17998437 rs2503967 chr6 67848659 A T 7.92E-04 Alzheimer's disease / / 22005930 rs1901928 chr6 67851244 A C 9.38E-04 Alzheimer's disease / / 22005930 rs2444686 chr6 67851436 T C 9.42E-04 Alzheimer's disease / / 22005930 rs1453904 chr6 67851938 A G 9.25E-04 Alzheimer's disease / / 22005930 rs1453900 chr6 67853047 G A 9.33E-04 Alzheimer's disease / / 22005930 rs2503962 chr6 67853484 T G 8.43E-04 Alzheimer's disease / / 22005930 rs2444679 chr6 67853613 C G 9.22E-04 Alzheimer's disease / / 22005930 rs2444621 chr6 67855340 G T 9.14E-04 Alzheimer's disease / / 22005930 rs1377692 chr6 67855735 C A 9.16E-04 Alzheimer's disease / / 22005930 rs1377694 chr6 67856009 G A 9.05E-04 Alzheimer's disease / / 22005930 rs1377695 chr6 67856164 A G 8.22E-04 Alzheimer's disease / / 22005930 rs1453881 chr6 67857011 A G 8.14E-04 Alzheimer's disease / / 22005930 rs2444633 chr6 67857500 T C 8.92E-04 Alzheimer's disease / / 22005930 rs1901924 chr6 67858214 G C 7.99E-04 Alzheimer's disease / / 22005930 rs1901925 chr6 67858366 A G 5.06E-04 Alzheimer's disease / / 22005930 rs1453883 chr6 67859251 A T 7.74E-04 Alzheimer's disease / / 22005930 rs2924591 chr6 67859490 C G 7.77E-04 Alzheimer's disease / / 22005930 rs2034702 chr6 67859720 A G 7.79E-04 Alzheimer's disease / / 22005930 rs2444636 chr6 67859837 C T 5.63E-04 Alzheimer's disease / / 22005930 rs2503958 chr6 67860311 G T 7.90E-04 Alzheimer's disease / / 22005930 rs1377698 chr6 67860965 T C 4.65E-04 Alzheimer's disease / / 22005930 rs1377700 chr6 67861155 T G 7.97E-04 Alzheimer's disease / / 22005930 rs2444637 chr6 67861180 A T 8.02E-04 Alzheimer's disease / / 22005930 rs601460 chr6 67861654 C G 7.99E-04 Alzheimer's disease / / 22005930 rs480251 chr6 67863919 A C 8.12E-04 Alzheimer's disease / / 22005930 rs10498848 chr6 67865255 A G 8.19E-04 Alzheimer's disease / / 22005930 rs10498849 chr6 67865364 G A 4.70E-04 Alzheimer's disease / / 22005930 rs532920 chr6 67865611 T G 8.23E-04 Alzheimer's disease / / 22005930 rs659986 chr6 67865651 C T 8.23E-04 Alzheimer's disease / / 22005930 rs500744 chr6 67867193 G A 8.00E-04 Alzheimer's disease / / 22005930 rs583466 chr6 67868021 C A 8.31E-04 Alzheimer's disease / / 22005930 rs2444657 chr6 67868566 C T 8.16E-04 Alzheimer's disease / / 22005930 rs686589 chr6 67873569 C T 8.34E-04 Alzheimer's disease / / 22005930 rs17539557 chr6 67876490 C T 6.04E-04 Type 2 diabetes / / 17463246 rs9345971 chr6 67876895 C T 8.07E-04 Alzheimer's disease / / 22005930 rs9363706 chr6 67879171 G A 8.22E-04 Alzheimer's disease / / 22005930 rs12055569 chr6 67879219 C T 8.22E-04 Alzheimer's disease / / 22005930 rs9345972 chr6 67880898 G C 8.28E-04 Alzheimer's disease / / 22005930 rs9354551 chr6 67881640 A G 8.38E-04 Alzheimer's disease / / 22005930 rs9342616 chr6 67885919 A G 5.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9342616 chr6 67885919 A G 1.00E-06 QT interval / / 23534349 rs9294750 chr6 67904039 C T 8.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12215896 chr6 67930937 G A 6.17E-05 Formal thought disorder in schizophrenia / / 22648509 rs9454109 chr6 67947988 C T 5.69E-06 Melanoma / / 21926416 rs9360281 chr6 67955735 T G 2.60E-05 Urinary metabolites / / 21572414 rs9363732 chr6 67959832 C T 1.71E-04 Alzheimer's disease / / 17998437 rs12209656 chr6 67960771 T A 3.55E-05 Formal thought disorder in schizophrenia / / 22648509 rs10498853 chr6 67967125 G T 4.01E-04 Multiple complex diseases / / 17554300 rs10498853 chr6 67967125 G T 6.47E-04 Alzheimer's disease / / 17998437 rs7743494 chr6 68057505 C T 5.73E-04 Myocardial Infarction / / pha002873 rs1447136 chr6 68112095 C A 7.07E-04 Multiple complex diseases / / 17554300 rs4710341 chr6 68116872 C A 1.74E-04 Glycosylated haemoglobin levels / / 17255346 rs9351662 chr6 68140783 G T 4.44E-05 Serum metabolites / / 19043545 rs9454147 chr6 68151868 A C 3.67E-06 Response to amphetamines / / 22952603 rs9454149 chr6 68156538 A G 8.83E-05 Cognitive impairment induced by topiramate / / 22091778 rs9294768 chr6 68161428 A C 7.00E-05 Serum metabolites / / 19043545 rs9294768 chr6 68161428 A C 3.61E-06 Response to amphetamines / / 22952603 rs4142595 chr6 68170032 G C 3.20E-06 Response to amphetamines / / 22952603 rs4710654 chr6 68181697 T C 8.00E-07 Response to amphetamines / / 22952603 rs4710655 chr6 68181772 T C 3.46E-06 Response to amphetamines / / 22952603 rs9351666 chr6 68277530 A C 1.75E-04 Glycosylated haemoglobin levels / / 17255346 rs856818 chr6 68278150 A G 3.59E-04 Multiple complex diseases / / 17554300 rs2747146 chr6 68298774 G C 1.58E-05 Serum metabolites / / 19043545 rs41388347 chr6 68314406 C T 1.80E-05 Cognitive function / / 24684796 rs41397544 chr6 68323096 T C 7.28E-04 Type 2 diabetes / / 17463246 rs875033 chr6 68327030 C T 8.00E-06 Response to amphetamines / / 22952603 rs2818113 chr6 68341629 A G 1.05E-05 Insulin-related traits / / 19902172 rs9346050 chr6 68341686 A G 7.68E-06 Lipid traits / / 21777205 rs41334445 chr6 68342496 G C 9.26E-04 Type 2 diabetes / / 17463246 rs12200729 chr6 68384198 C T 6.65E-04 Type 2 diabetes / / 17463246 rs12207706 chr6 68384242 A G 5.08E-04 Type 2 diabetes / / 17463246 rs17546195 chr6 68388068 A C 1.10E-04 Multiple complex diseases / / 17554300 rs2493374 chr6 68398230 G A 7.00E-04 Obesity,menopause / / 21424828 rs2818114 chr6 68407962 G A 4.45E-04 HIV-1 viral setpoint / / 17641165 rs9454239 chr6 68410039 C T 2.95E-04 White matter integrity / / 22425255 rs9454257 chr6 68435871 G T 4.09E-04 White matter integrity / / 22425255 rs9454263 chr6 68446055 A G 9.08E-04 White matter integrity / / 22425255 rs4132510 chr6 68465910 G A 5.59E-05 Multiple complex diseases / / 17554300 rs4541731 chr6 68475531 T C 5.20E-05 Malaria / / 19465909 rs13212559 chr6 68479981 A C 6.69E-04 Multiple complex diseases / / 17554300 rs9363804 chr6 68485750 C T 5.81E-05 Serum metabolites / / 19043545 rs4131870 chr6 68492448 T C 1.41E-04 Multiple complex diseases / / 17554300 rs4131872 chr6 68492620 C T 5.83E-04 Multiple complex diseases / / 17554300 rs12198555 chr6 68499138 A G 9.27E-04 HIV-1 viral setpoint / / 17641165 rs12203654 chr6 68506715 T G 7.35E-05 Serum metabolites / / 19043545 rs7752297 chr6 68532752 A G 7.99E-04 HIV-1 viral setpoint / / 17641165 rs7760466 chr6 68532965 T C 3.56E-04 White matter integrity / / 22425255 rs2203381 chr6 68548907 C T 1.20E-05 Urinary metabolites / / 21572414 rs9454352 chr6 68601405 A G 3.70E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1877779 chr6 68687348 C T 9.18E-04 Multiple complex diseases / / 17554300 rs1567904 chr6 68697721 G A 0.00069131 Hypertension (early onset hypertension) / / 22479346 rs1122626 chr6 68704380 G T 2.40E-05 Urinary metabolites / / 21572414 rs9354655 chr6 68722068 G A 7.29E-05 Body Mass Index / / pha003021 rs1020689 chr6 68728797 G A 7.38E-05 Diabetes Mellitus / / pha003060 rs4707479 chr6 68731109 C T 7.44E-04 Type 2 diabetes / / 17463246 rs4707479 chr6 68731109 C T 1.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2340741 chr6 68731635 C A 1.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9351689 chr6 68739602 T C 5.05E-06 Height / / pha003010 rs9351689 chr6 68739602 T C 1.67E-06 Height / / pha003011 rs9351689 chr6 68739602 T C 6.20E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs9454418 chr6 68746668 A G 0.0006455 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9454418 chr6 68746668 A G 6.46E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1378456 chr6 68747349 C T 0.0003994 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1378456 chr6 68747349 C T 3.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1378455 chr6 68747569 A G 1.72E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs4311477 chr6 68749320 T G 0.0004231 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4311477 chr6 68749320 T G 4.23E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4495242 chr6 68749729 G C 0.0004242 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4495242 chr6 68749729 G C 4.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1531064 chr6 68751515 T C 0.0003886 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1531064 chr6 68751515 T C 3.89E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10945052 chr6 68752614 T C 0.0004976 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10945052 chr6 68752614 T C 4.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1378451 chr6 68753031 A G 0.000386 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1378451 chr6 68753031 A G 3.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1378451 chr6 68753031 A G 1.80E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs7743527 chr6 68755949 A T 0.0003561 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7743527 chr6 68755949 A T 3.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9445968 chr6 68759067 G T 7.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs7751480 chr6 68761973 T C 0.0003502 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7751480 chr6 68761973 T C 3.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9454421 chr6 68763734 G T 1.78E-04 Alzheimer's disease / / 22005930 rs9454422 chr6 68764690 G T 5.11E-04 Alzheimer's disease / / 22005930 rs1455444 chr6 68765185 A G 0.0003448 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1455444 chr6 68765185 A G 3.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7768996 chr6 68765982 A G 3.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7768996 chr6 68765982 A G 9.60E-05 Height / / pha003010 rs7768996 chr6 68765982 A G 2.23E-05 Height / / pha003011 rs7768996 chr6 68765982 A G 8.69E-07 Lung function (forced expiratory volume in 1 second) / / pha003102 rs7768996 chr6 68765982 A G 5.43E-05 Lung function (forced vital capacity) / / pha003104 rs1350023 chr6 68766313 A G 0.0003796 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1350023 chr6 68766313 A G 3.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs990017 chr6 68768576 T C 7.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs990019 chr6 68768950 G A 0.0003762 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs990019 chr6 68768950 G A 3.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7767069 chr6 68770563 T A 0.00002283 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7767069 chr6 68770563 T A 3.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13204707 chr6 68775710 T G 4.98E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs12664094 chr6 68779481 C T 8.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs6900918 chr6 68783499 A G 9.17E-04 Alzheimer's disease / / 22005930 rs9294787 chr6 68790482 T A 6.58E-04 Alzheimer's disease / / 22005930 rs7753361 chr6 68800495 G A 8.00E-05 Prostate cancer / / 21743057 rs13219267 chr6 68804067 G T 1.40E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs13219267 chr6 68804067 G T 2.74E-05 Lung function (forced vital capacity) / / pha003104 rs9354671 chr6 68804218 A G 7.16E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs9354671 chr6 68804218 A G 5.67E-05 Lung function (forced vital capacity) / / pha003104 rs9454429 chr6 68823251 G A 6.65E-05 Cognitive impairment induced by topiramate / / 22091778 rs9454429 chr6 68823251 G A 7.19E-06 Cognitive impairment induced by topiramate / / 22091778 rs2340743 chr6 68859372 C T 9.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs9294788 chr6 68862498 G A 9.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs9363857 chr6 68863414 C A 8.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs12211024 chr6 68873924 G T 5.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs9360320 chr6 68875075 G T 5.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs701663 chr6 68891683 G T 2.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs777625 chr6 68898262 T C 1.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs701667 chr6 68901218 A G 9.59E-05 Suicide attempts in bipolar disorder / / 21423239 rs801128 chr6 68915929 G C 8.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs1993329 chr6 68936060 C T 9.26E-04 Acute lung injury / / 22295056 rs10498861 chr6 68957840 C T 2.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9294790 chr6 68958213 T G 7.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10455657 chr6 68984930 T G 6.00E-06 Cannabis use (initiation) / / 22823124 rs12665496 chr6 68988833 T C 5.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs10945072 chr6 68992928 T C 2.65E-05 Multiple complex diseases / / 17554300 rs1388051 chr6 69029424 G A 6.61E-04 Type 2 diabetes / / 17463246 rs16899907 chr6 69051816 C T 6.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs16899910 chr6 69054787 T G 5.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs2029516 chr6 69077987 T C 1.11E-05 Bipolar disorder / / 21771265 rs1907149 chr6 69082145 G A 0.000757153 Hypertension (early onset hypertension) / / 22479346 rs12190456 chr6 69118608 G A 2.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs10455661 chr6 69125714 T C 8.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs10455220 chr6 69125903 T C 5.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs9363918 chr6 69142008 T G 1.00E-06 Pancreatic cancer / / 22158540 rs3011917 chr6 69146027 A C 5.05E-06 Schizophrenia(age at onset) / / 21688384 rs352537 chr6 69168139 G A 6.64E-05 Hemoglobin / / pha003096 rs352537 chr6 69168139 G A 8.86E-05 Hematocrit / / pha003097 rs981146 chr6 69170908 C T 7.70E-04 Nicotine dependence / / 17158188 rs4708157 chr6 69185660 G A 6.50E-05 Response to statin therapy / / 20339536 rs7741993 chr6 69272000 G A 5.49E-05 Myocardial Infarction / / pha002883 rs9351730 chr6 69294485 G A 3.98E-05 Bipolar disorder / / 17486107 rs9351730 chr6 69294485 G A 5.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs2585617 chr6 69337787 A G 6.00E-07 Phospholipid levels (plasma) / / 21829377 rs2802684 chr6 69397597 G A 6.72E-05 Cognitive test performance BAI3 intron 20125193 rs2206835 chr6 69421464 G A 2.10E-06 Lung function (forced expiratory volume in 1 second) BAI3 intron pha003102 rs2206835 chr6 69421464 G A 3.02E-05 Lung function (forced vital capacity) BAI3 intron pha003104 rs715294 chr6 69426396 A G 9.88E-05 Personality dimensions BAI3 intron 18957941 rs2802676 chr6 69426869 A T 1.81E-05 Personality dimensions BAI3 intron 18957941 rs9342730 chr6 69435506 A G 1.22E-05 Personality dimensions BAI3 intron 18957941 rs10484792 chr6 69467243 G C 2.03E-06 Phospholipid levels (plasma) BAI3 intron 21829377 rs1403920 chr6 69474672 A G 2.06E-06 Phospholipid levels (plasma) BAI3 intron 21829377 rs13220538 chr6 69475139 A G 2.08E-06 Phospholipid levels (plasma) BAI3 intron 21829377 rs9346240 chr6 69487880 T G 8.34E-04 Multiple complex diseases BAI3 intron 17554300 rs1033521 chr6 69504861 T C 4.05E-06 Phospholipid levels (plasma) BAI3 intron 21829377 rs10806605 chr6 69512348 A T 2.35E-05 Telomere length BAI3 intron 20139977 rs568360 chr6 69540590 T A 6.41E-04 Obesity (extreme) BAI3 intron 21935397 rs570379 chr6 69540836 G A 6.44E-04 Obesity (extreme) BAI3 intron 21935397 rs571299 chr6 69540950 G A 6.58E-04 Obesity (extreme) BAI3 intron 21935397 rs577328 chr6 69541331 G A 4.39E-04 Obesity (extreme) BAI3 intron 21935397 rs497240 chr6 69542291 C T 4.36E-04 Obesity (extreme) BAI3 intron 21935397 rs551876 chr6 69545429 A G 4.35E-04 Obesity (extreme) BAI3 intron 21935397 rs482005 chr6 69545793 T G 3.76E-04 Obesity (extreme) BAI3 intron 21935397 rs555588 chr6 69545855 C T 3.76E-04 Obesity (extreme) BAI3 intron 21935397 rs483875 chr6 69545996 T G 3.74E-04 Obesity (extreme) BAI3 intron 21935397 rs580073 chr6 69546221 C T 3.73E-04 Obesity (extreme) BAI3 intron 21935397 rs510779 chr6 69546639 T C 3.73E-04 Obesity (extreme) BAI3 intron 21935397 rs540974 chr6 69547642 T G 3.72E-04 Obesity (extreme) BAI3 intron 21935397 rs483942 chr6 69549203 T A,C 3.76E-04 Obesity (extreme) BAI3 intron 21935397 rs2224011 chr6 69555181 A C 3.78E-04 Obesity (extreme) BAI3 intron 21935397 rs16900274 chr6 69564053 A G 3.88E-04 Insulin resistance BAI3 intron 21901158 rs547423 chr6 69564830 G A 5.28E-04 Obesity (extreme) BAI3 intron 21935397 rs556592 chr6 69576000 A G 2.76E-04 Multiple complex diseases BAI3 intron 17554300 rs558452 chr6 69589587 G A 5.25E-04 Obesity (extreme) BAI3 intron 21935397 rs478789 chr6 69592536 G A 5.24E-04 Obesity (extreme) BAI3 intron 21935397 rs4706061 chr6 69596592 T C 5.24E-04 Obesity (extreme) BAI3 intron 21935397 rs4706712 chr6 69597897 T A 5.24E-04 Obesity (extreme) BAI3 intron 21935397 rs6906092 chr6 69601104 C A 5.24E-04 Obesity (extreme) BAI3 intron 21935397 rs1523936 chr6 69605682 C T 5.24E-04 Obesity (extreme) BAI3 intron 21935397 rs1523938 chr6 69608492 A C 2.35E-04 Obesity (extreme) BAI3 intron 21935397 rs2342761 chr6 69610281 G A 1.64E-04 Suicide attempts in bipolar disorder BAI3 intron 21423239 rs9689807 chr6 69611665 G A 2.25E-04 Obesity (extreme) BAI3 intron 21935397 rs10485435 chr6 69615615 G T 8.15E-04 Suicide attempts in bipolar disorder BAI3 intron 21423239 rs10485435 chr6 69615615 G T 3.44E-04 Alzheimer's disease BAI3 intron 24755620 rs9294812 chr6 69618124 C G 8.08E-04 Suicide attempts in bipolar disorder BAI3 intron 21423239 rs10485434 chr6 69637928 C T 4.54E-04 Type 2 diabetes BAI3 intron 17846124 rs556992272 chr6 69637928 CG C 4.54E-04 Type 2 diabetes BAI3 intron 17846124 rs2184723 chr6 69647086 G A 4.16E-04 Type 2 diabetes BAI3 intron 17846124 rs1932614 chr6 69656950 G A 7.12E-04 Suicide attempts in bipolar disorder BAI3 intron 21423239 rs3823061 chr6 69667472 A G 4.86E-04 Intracranial aneurysm BAI3 intron 22286173 rs12191480 chr6 69675867 T C 3.96E-05 Asthma BAI3 intron pha003128 rs1006997 chr6 69677322 T C 2.91E-04 Multiple complex diseases BAI3 intron 17554300 rs1415033 chr6 69680063 C A 7.23E-04 Suicide attempts in bipolar disorder BAI3 intron 21423239 rs9454664 chr6 69683474 G T 0.0000904 Circulating PCSK9 levels BAI3 intron 22460556 rs1336645 chr6 69697406 G A 1.60E-05 Urinary metabolites BAI3 intron 21572414 rs3798997 chr6 69708219 A G 1.07E-04 Amyotrophic lateral sclerosis (sporadic) BAI3 intron 24529757 rs13191563 chr6 69713057 G A 8.61E-05 Body Composition BAI3 intron pha003012 rs2785575 chr6 69725582 G T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes BAI3 intron 22628534 rs1415035 chr6 69730452 C T 8.95E-04 Multiple complex diseases BAI3 intron 17554300 rs2225803 chr6 69745723 G A 2.67E-05 Body Composition BAI3 intron pha003012 rs9446089 chr6 69767587 A G 8.25E-04 Response to cytadine analogues (cytosine arabinoside) BAI3 intron 24483146 rs2046251 chr6 69813713 A G 8.28E-05 Obesity (extreme) BAI3 intron 21935397 rs314194 chr6 69822586 A G 3.47E-05 Obesity (extreme) BAI3 intron 21935397 rs9294819 chr6 69836379 C T 0.000061 Circulating PCSK9 levels BAI3 intron 22460556 rs1482327 chr6 69838394 C A 7.26E-05 Obesity (extreme) BAI3 intron 21935397 rs67807 chr6 69847967 G A 7.11E-05 Obesity (extreme) BAI3 intron 21935397 rs1912988 chr6 69851816 T C 6.70E-05 Obesity (extreme) BAI3 intron 21935397 rs1912987 chr6 69851870 T G 6.70E-05 Obesity (extreme) BAI3 intron 21935397 rs7739401 chr6 69858930 A T 6.76E-05 Obesity (extreme) BAI3 intron 21935397 rs7741707 chr6 69880777 A G 6.57E-04 Insulin resistance BAI3 intron 21901158 rs1083694 chr6 69885135 C T 9.70E-05 Response to mTOR inhibitor (everolimus) BAI3 intron 24009623 rs1877427 chr6 69928269 A G 6.36E-04 Insulin resistance BAI3 intron 21901158 rs971564 chr6 69937179 C T 5.05E-04 Insulin resistance BAI3 intron 21901158 rs9454723 chr6 69983102 G A 3.63E-04 Obesity (extreme) BAI3 intron 21935397 rs10485252 chr6 69994361 T C 4.55E-06 Response to tocilizumab in rheumatoid arthritis BAI3 intron 22491018 rs11751520 chr6 70002111 C T 8.66E-05 Schizophrenia(age at onset) BAI3 intron 21688384 rs9454727 chr6 70003389 A G 0.0000104 Circulating PCSK9 levels BAI3 intron 22460556 rs1885331 chr6 70007550 G T 2.83E-04 Obesity (extreme) BAI3 intron 21935397 rs1321982 chr6 70023164 T C 2.50E-05 Response to statin therapy BAI3 intron 20339536 rs2145889 chr6 70024534 T A 2.90E-05 Response to statin therapy BAI3 intron 20339536 rs10485251 chr6 70029389 A C 9.60E-05 stroke (ischemic) BAI3 intron 17434096 rs3757053 chr6 70033536 G A 1.50E-05 Response to statin therapy BAI3 intron 20339536 rs3757054 chr6 70037944 A G 9.00E-06 Response to statin therapy BAI3 intron 20339536 rs16900648 chr6 70038567 A G 5.90E-06 Response to statin therapy BAI3 intron 20339536 rs1321974 chr6 70045101 C G 5.20E-06 Response to statin therapy BAI3 intron 20339536 rs3737019 chr6 70049070 A T 5.80E-06 Response to statin therapy BAI3 intron 20339536 rs3757057 chr6 70074232 A T 4.00E-06 Response to statin therapy BAI3 intron 20339536 rs10485249 chr6 70105187 G C 7.96E-05 Type 2 diabetes / / 17846126 rs6911011 chr6 70106360 T G 5.51E-04 Multiple complex diseases / / 17554300 rs1928055 chr6 70127704 A G 3.41E-04 Stroke / / pha002886 rs12211885 chr6 70144566 T C 3.93E-04 Stroke / / pha002886 rs2094596 chr6 70176916 A G 1.83E-05 Neuroblastoma / / pha002895 rs78536982 chr6 70182710 C T 7.62E-06 Triglycerides / / 24886709 rs149826766 chr6 70185897 G T 1.69E-04 Acne (severe) / / 24927181 rs9454820 chr6 70241869 T C 3.48E-04 Multiple complex diseases / / 17554300 rs4707218 chr6 70312551 C T 9.41E-04 Alzheimer's disease / / 24755620 rs9364034 chr6 70314809 C T 0.0005537 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9364034 chr6 70314809 C T 5.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9354870 chr6 70315247 C T 0.0005509 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9354870 chr6 70315247 C T 5.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10455692 chr6 70315559 T C 0.0005311 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10455692 chr6 70315559 T C 5.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10455225 chr6 70315758 T C 0.0005284 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10455225 chr6 70315758 T C 5.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6910099 chr6 70319717 T G 0.0005181 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6910099 chr6 70319717 T G 5.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12196517 chr6 70320251 A G 0.0004328 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12196517 chr6 70320251 A G 4.33E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9454842 chr6 70322234 T A 0.000508 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9454842 chr6 70322234 T A 5.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13198249 chr6 70322288 G C 0.0005055 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13198249 chr6 70322288 G C 5.06E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12210052 chr6 70323942 G C 0.0004814 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12210052 chr6 70323942 G C 4.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12205685 chr6 70324351 T G 0.0004744 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12205685 chr6 70324351 T G 4.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12204227 chr6 70324397 A G 0.0004717 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12204227 chr6 70324397 A G 4.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12205802 chr6 70324536 T C 0.0005073 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12205802 chr6 70324536 T C 5.07E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12204388 chr6 70324650 A G 0.0005116 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12204388 chr6 70324650 A G 5.12E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12206366 chr6 70325727 A G 0.0005147 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12206366 chr6 70325727 A G 5.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10455693 chr6 70326025 A T 0.0005176 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10455693 chr6 70326025 A T 5.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs16867833 chr6 70331197 T C 0.0006104 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16867833 chr6 70331197 T C 6.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10455226 chr6 70331651 A G 0.0006134 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10455226 chr6 70331651 A G 6.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9454846 chr6 70335262 C A 0.0006352 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9454846 chr6 70335262 C A 6.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13201075 chr6 70335332 G C 0.0005511 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13201075 chr6 70335332 G C 5.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9454849 chr6 70335495 T C 0.0006645 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9454849 chr6 70335495 T C 6.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9454852 chr6 70336437 T A 0.0006831 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9454852 chr6 70336437 T A 6.83E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7774239 chr6 70339326 C T 0.0006983 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7774239 chr6 70339326 C T 6.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9446145 chr6 70339936 T G 0.0007011 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9446145 chr6 70339936 T G 7.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7761366 chr6 70342762 G C 0.0007057 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7761366 chr6 70342762 G C 7.06E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9446149 chr6 70353034 T C 0.0007736 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9446149 chr6 70353034 T C 7.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4706258 chr6 70353136 A G 5.27E-04 Alzheimer's disease / / 24755620 rs7761673 chr6 70357368 T A 0.0008275 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7761673 chr6 70357368 T A 8.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17503505 chr6 70398402 T C 9.56E-04 Suicide attempts in bipolar disorder LMBRD1 intron 21423239 rs1031631 chr6 70442866 C T 6.20E-06 Iron levels LMBRD1 intron 21208937 rs2502543 chr6 70477319 A G 8.16E-04 Suicide attempts in bipolar disorder LMBRD1 intron 21423239 rs7765774 chr6 70522555 A G 6.28E-05 Body mass index / / 17255346 rs7739024 chr6 70533804 C T 3.70E-05 Socioeconomic Factors / / pha003067 rs2487398 chr6 70537290 G T 2.71E-05 Suicide attempts in bipolar disorder / / 21423239 rs2487399 chr6 70537434 T G 2.15E-05 Suicide attempts in bipolar disorder / / 21423239 rs1340970 chr6 70537975 T A 2.20E-06 Suicide attempts in bipolar disorder / / 21423239 rs2487402 chr6 70539224 A G,T 2.16E-06 Suicide attempts in bipolar disorder / / 21423239 rs2502593 chr6 70539805 T A 2.29E-06 Suicide attempts in bipolar disorder / / 21423239 rs9351777 chr6 70540610 C T 2.29E-06 Suicide attempts in bipolar disorder / / 21423239 rs1340969 chr6 70541265 C T 1.45E-06 Suicide attempts in bipolar disorder / / 21423239 rs1340968 chr6 70542310 T C 2.71E-06 Suicide attempts in bipolar disorder / / 21423239 rs2487404 chr6 70543753 T G 5.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs2502592 chr6 70544211 C G 2.14E-06 Suicide attempts in bipolar disorder / / 21423239 rs2487406 chr6 70544408 G C 2.40E-06 Suicide attempts in bipolar disorder / / 21423239 rs2487407 chr6 70545027 C A 5.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs1934900 chr6 70546236 T A 2.69E-06 Suicide attempts in bipolar disorder / / 21423239 rs2487409 chr6 70546781 A G 1.98E-06 Suicide attempts in bipolar disorder / / 21423239 rs2502590 chr6 70546899 A G 2.64E-06 Suicide attempts in bipolar disorder / / 21423239 rs2066244 chr6 70547075 G A 2.50E-06 Suicide attempts in bipolar disorder / / 21423239 rs2066243 chr6 70547567 G A 3.20E-06 Suicide attempts in bipolar disorder / / 21423239 rs2487410 chr6 70547652 T C 1.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs2487411 chr6 70548624 T C 1.74E-06 Suicide attempts in bipolar disorder / / 21423239 rs2487412 chr6 70548710 T A 3.28E-06 Suicide attempts in bipolar disorder / / 21423239 rs2487413 chr6 70550464 C T 7.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs9351778 chr6 70550975 A G 4.15E-06 Suicide attempts in bipolar disorder / / 21423239 rs2502586 chr6 70551688 C T 2.42E-06 Suicide attempts in bipolar disorder / / 21423239 rs2487416 chr6 70551846 A G 5.13E-06 Suicide attempts in bipolar disorder / / 21423239 rs1891013 chr6 70552259 T C 3.99E-06 Suicide attempts in bipolar disorder / / 21423239 rs2502584 chr6 70554925 C T 3.32E-06 Suicide attempts in bipolar disorder / / 21423239 rs2487418 chr6 70555588 G A 3.51E-06 Suicide attempts in bipolar disorder / / 21423239 rs2487419 chr6 70556265 G C 3.52E-06 Suicide attempts in bipolar disorder / / 21423239 rs2502583 chr6 70556295 A G 3.74E-06 Suicide attempts in bipolar disorder / / 21423239 rs2502582 chr6 70556763 G C 5.05E-06 Suicide attempts in bipolar disorder / / 21423239 rs2502580 chr6 70558562 C T 7.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs2502579 chr6 70559305 G A 5.45E-06 Suicide attempts in bipolar disorder / / 21423239 rs2502575 chr6 70561100 A G 5.14E-06 Suicide attempts in bipolar disorder / / 21423239 rs2502574 chr6 70561155 T C 5.19E-06 Suicide attempts in bipolar disorder / / 21423239 rs2066242 chr6 70561763 T C 8.55E-06 Suicide attempts in bipolar disorder / / 21423239 rs2066241 chr6 70561815 G A 6.54E-06 Suicide attempts in bipolar disorder / / 21423239 rs2502573 chr6 70561894 C T 9.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs1361517 chr6 70563502 C T 1.06E-05 Suicide attempts in bipolar disorder / / 21423239 rs2502571 chr6 70564734 T C 1.46E-05 Suicide attempts in bipolar disorder / / 21423239 rs2502570 chr6 70566269 A G 1.74E-05 Suicide attempts in bipolar disorder / / 21423239 rs883090 chr6 70568611 A G 9.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs883091 chr6 70568647 C T 1.23E-05 Suicide attempts in bipolar disorder / / 21423239 rs883092 chr6 70568866 A G 1.66E-05 Suicide attempts in bipolar disorder / / 21423239 rs884116 chr6 70569157 C T 8.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs2487428 chr6 70572354 T C 5.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs1538968 chr6 70572454 G A 6.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs2487429 chr6 70572961 T C 4.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs2502559 chr6 70573133 G C 7.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs2487430 chr6 70573606 C T 2.00E-05 Suicide attempts in bipolar disorder / / 21423239 rs1538966 chr6 70574081 G T 8.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs1934898 chr6 70574189 T C 9.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs1340960 chr6 70575948 T C 2.26E-05 Suicide attempts in bipolar disorder / / 21423239 rs9354896 chr6 70576244 C T 5.01E-04 Multiple complex diseases / / 17554300 rs2298017 chr6 70577824 G A 3.46E-05 Suicide attempts in bipolar disorder COL19A1 intron 21423239 rs2487433 chr6 70581412 A G 4.27E-05 Suicide attempts in bipolar disorder COL19A1 intron 21423239 rs1934897 chr6 70586816 T C 7.38E-05 Glucose levels COL19A1 intron pha003058 rs1934897 chr6 70586816 T C 4.02E-05 Glucose levels COL19A1 intron pha003061 rs12201139 chr6 70590638 G A 6.98E-04 Suicide attempts in bipolar disorder COL19A1 intron 21423239 rs12189777 chr6 70591331 C T 6.11E-04 Suicide attempts in bipolar disorder COL19A1 intron 21423239 rs7750029 chr6 70593586 C A 6.22E-04 Suicide attempts in bipolar disorder COL19A1 intron 21423239 rs7757078 chr6 70597502 T C 3.59E-04 Suicide attempts in bipolar disorder COL19A1 intron 21423239 rs10755538 chr6 70597721 C T 2.47E-04 Suicide attempts in bipolar disorder COL19A1 intron 21423239 rs12191461 chr6 70599710 G A 4.25E-04 Suicide attempts in bipolar disorder COL19A1 intron 21423239 rs17689448 chr6 70622425 T C 7.60E-05 HDL cholesterol COL19A1 intron pha003075 rs9360410 chr6 70652566 G A 7.59E-04 Suicide attempts in bipolar disorder COL19A1 intron 21423239 rs3805963 chr6 70654658 G A 7.61E-04 Suicide attempts in bipolar disorder COL19A1 intron 21423239 rs3793032 chr6 70681159 G T 4.07E-04 Alzheimer's disease COL19A1 intron 24755620 rs1156404 chr6 70740306 C T 5.37E-05 Response to hepatitis C treatment COL19A1 intron 19684573 rs1156404 chr6 70740306 C T 9.43E-05 Monocyte chemoattractant protein-1 COL19A1 intron pha003071 rs3793039 chr6 70741209 A G 2.00E-06 IgG glycosylation COL19A1 intron 23382691 rs3828767 chr6 70743251 G A 5.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL19A1 intron 20877124 rs12194223 chr6 70794142 C T 4.20E-04 Response to cytadine analogues (cytosine arabinoside) COL19A1 intron 24483146 rs1983761 chr6 70794208 C T 2.63E-05 Cognitive test performance COL19A1 intron 20125193 rs6918625 chr6 70795108 G C 4.90E-04 Multiple complex diseases COL19A1 intron 17554300 rs12530055 chr6 70798109 G A 6.48E-04 Smoking initiation COL19A1 intron 24665060 rs716410 chr6 70799492 A G 3.56E-04 Response to cytadine analogues (cytosine arabinoside) COL19A1 intron 24483146 rs3806022 chr6 70803453 G A 5.01E-05 Response to cytadine analogues (cytosine arabinoside) COL19A1 intron 24483146 rs12190849 chr6 70808224 A T 1.90E-04 Response to cytadine analogues (cytosine arabinoside) COL19A1 intron 24483146 rs3806033 chr6 70828336 T C 3.75E-05 Lung adenocarcinoma COL19A1 intron 19836008 rs3806033 chr6 70828336 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) COL19A1 intron 20708005 rs2181011 chr6 70839436 A G 3.65E-04 Type 2 diabetes COL19A1 intron 17463246 rs2181011 chr6 70839436 A G 8.83E-07 Serum metabolites COL19A1 intron 19043545 rs9342783 chr6 70852493 A G 9.05E-04 Parkinson's disease COL19A1 intron 17052657 rs9342783 chr6 70852493 A G 6.77E-04 Type 2 diabetes COL19A1 intron 17463246 rs3806040 chr6 70860725 A G 8.45E-04 Amyotrophic Lateral Sclerosis COL19A1 intron 17362836 rs3806041 chr6 70860739 C A 6.41E-04 Parkinson's disease COL19A1 intron 17052657 rs7756657 chr6 70872851 G A 4.59E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) COL19A1 intron 22566498 rs802172 chr6 70874168 A G 8.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL19A1 intron 20877124 rs802173 chr6 70875234 T C 7.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL19A1 intron 20877124 rs3806052 chr6 70886784 A C 8.43E-05 Personality dimensions COL19A1 intron 18957941 rs802182 chr6 70888744 A G 7.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL19A1 intron 20877124 rs10945200 chr6 70891740 G A 3.05E-05 Personality dimensions COL19A1 intron 18957941 rs10945200 chr6 70891740 G A 3.10E-05 Personality dimensions COL19A1 intron 21173776 rs1753258 chr6 70899247 G A 7.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL19A1 intron 20877124 rs671910 chr6 70902529 A G 7.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL19A1 intron 20877124 rs16868656 chr6 70910980 C G 3.20E-04 Smoking initiation COL19A1 intron 24665060 rs10498871 chr6 70912835 C T 5.10E-04 Crohn's disease COL19A1 intron 17684544 rs13208888 chr6 70914298 G A 9.60E-05 Diabetic retinopathy COL19A1 intron 21441570 rs529805 chr6 70919597 C T 5.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL19A1 UTR-3 20877124 rs3793071 chr6 70958346 C T 4.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL9A1 intron 20877124 rs16868818 chr6 70960010 G A 2.93E-05 Cognitive performance COL9A1 intron 19734545 rs510423 chr6 70965827 G A 9.84E-05 Serum metabolites COL9A1 intron 19043545 rs558485 chr6 70975512 C T 2.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL9A1 intron 20877124 rs558485 chr6 70975512 C T 3.48E-04 Alzheimer's disease (late onset) COL9A1 intron 21379329 rs883707 chr6 70976803 G T 3.97E-08 LDL cholesterol COL9A1 intron 23063622 rs550675 chr6 70979193 C T 7.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL9A1 intron 20877124 rs518558 chr6 70980388 G A 4.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL9A1 intron 20877124 rs592121 chr6 70984436 A G 7.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL9A1 missense 20877124 rs3806095 chr6 70987976 G A 8.70E-04 Coronary heart disease COL9A1 intron 21606135 rs9455020 chr6 70994969 T C 9.39E-09 Metabolite levels COL9A1 intron 23281178 rs17649310 chr6 70995286 C T 9.39E-09 Metabolite levels COL9A1 intron 23281178 rs1406844 chr6 70996682 C T 2.40E-05 Urinary metabolites COL9A1 intron 21572414 rs1406844 chr6 70996682 C T 3.72E-09 Metabolite levels COL9A1 intron 23281178 rs1406845 chr6 70996792 C A 9.39E-09 Metabolite levels COL9A1 intron 23281178 rs1321061 chr6 70998563 A G 9.39E-09 Metabolite levels COL9A1 intron 23281178 rs9455022 chr6 70998823 A T 9.39E-09 Metabolite levels COL9A1 intron 23281178 rs3806104 chr6 70999796 G A 9.39E-09 Metabolite levels COL9A1 intron 23281178 rs9294862 chr6 71000814 C A 9.39E-09 Metabolite levels COL9A1 intron 23281178 rs9455026 chr6 71001369 C T 9.39E-09 Metabolite levels COL9A1 intron 23281178 rs3793075 chr6 71002769 A G 7.72E-09 Metabolite levels COL9A1 intron 23281178 rs9455027 chr6 71003444 A T 9.39E-09 Metabolite levels COL9A1 intron 23281178 rs9455029 chr6 71004931 G A 1.80E-05 Urinary metabolites COL9A1 intron 21572414 rs9455031 chr6 71006375 T C 9.39E-09 Metabolite levels COL9A1 intron 23281178 rs3806105 chr6 71006718 G A 9.39E-09 Metabolite levels COL9A1 intron 23281178 rs9446219 chr6 71009310 C T 9.39E-09 Metabolite levels COL9A1 intron 23281178 rs600179 chr6 71018411 G A 8.01E-06 Pulmonary function / / 20010835 rs696990 chr6 71022226 T C 2.50E-05 Urinary metabolites / / 21572414 rs667857 chr6 71023622 T C 2.50E-05 Urinary metabolites / / 21572414 rs17650115 chr6 71023774 A G 4.26E-05 Pulmonary function / / 20010835 rs4706434 chr6 71060696 A G 9.56E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs9346382 chr6 71076351 A G 2.01E-04 Alzheimer's disease (late onset) / / 21379329 rs12529984 chr6 71104467 G T 1.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2346889 chr6 71116172 C G 5.64E-04 Multiple complex diseases / / 17554300 rs7752409 chr6 71186281 T A 6.83E-05 Multiple complex diseases FAM135A intron 17554300 rs7769582 chr6 71229659 G A 1.15E-04 Multiple complex diseases FAM135A intron 17554300 rs16869370 chr6 71267566 G A 1.59E-04 Multiple complex diseases FAM135A intron 17554300 rs9455160 chr6 71273819 C G 1.52E-04 Multiple complex diseases / / 17554300 rs12216376 chr6 71278224 G T 3.71E-04 Multiple complex diseases C6orf57 intron 17554300 rs12203298 chr6 71278236 C T 5.35E-04 Multiple complex diseases C6orf57 intron 17554300 rs1048886 chr6 71289189 A G 2.65E-04 Multiple complex diseases C6orf57 missense 17554300 rs1048886 chr6 71289189 A G 3.00E-08 Type 2 diabetes C6orf57 missense 21490949 rs10945231 chr6 71297763 A G 6.73E-04 Multiple complex diseases C6orf57 intron 17554300 rs2842079 chr6 71304786 A G 2.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11754144 chr6 71337296 A G 7.14E-04 Multiple complex diseases / / 17554300 rs782000 chr6 71351812 G T 2.92E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs782000 chr6 71351812 G T 1.40E-05 Anger / / 24489884 rs10498877 chr6 71457737 A G 6.95E-04 Smoking initiation SMAP1 intron 24665060 rs4707851 chr6 71468674 G T 6.50E-04 Type 2 diabetes SMAP1 intron 17463246 rs2347624 chr6 71500873 C T 2.59E-04 Multiple complex diseases SMAP1 intron 17554300 rs12215835 chr6 71523951 G T 7.17E-04 Insulin resistance SMAP1 intron 21901158 rs13174 chr6 71568130 G C 8.27E-04 Suicide attempts in bipolar disorder SMAP1 intron 21423239 rs3734369 chr6 71569129 C T 2.20E-05 Urinary metabolites SMAP1 intron 21572414 rs1716007 chr6 71577875 A G 8.98E-04 Suicide attempts in bipolar disorder B3GAT2 intron 21423239 rs651984 chr6 71599887 A G 0.0002 Migraine B3GAT2 intron 22678113 rs2504742 chr6 71602068 C G 7.92E-05 Suicide attempts in bipolar disorder B3GAT2 intron 21423239 rs568993 chr6 71602169 G A 1.70E-05 Lipid traits B3GAT2 intron 24386095 rs495433 chr6 71606987 C T 4.22E-04 Hemoglobin concentration B3GAT2 intron 20534544 rs473861 chr6 71613651 T C 8.93E-06 Obesity-related traits B3GAT2 intron 23251661 rs2460691 chr6 71613855 G C 2.40E-06 Urinary metabolites B3GAT2 intron 21572414 rs6922893 chr6 71660111 A G 7.00E-06 Obesity-related traits B3GAT2 intron 23251661 rs1111994 chr6 71676933 T C 0.0000102 HDL cholesterol particle diameter / / 23263444 rs10455718 chr6 71681044 G A 0.0000101 HDL cholesterol particle diameter / / 23263444 rs10455231 chr6 71683478 C A 0.00001 HDL cholesterol particle diameter / / 23263444 rs9455286 chr6 71705162 A G 2.01E-04 Smoking initiation / / 24665060 rs16869647 chr6 71707217 T C 2.25E-04 Type 2 diabetes / / 17463246 rs6910674 chr6 71722821 T C 1.30E-05 Urinary metabolites / / 21572414 rs9351798 chr6 71723119 T C 2.60E-04 Lung function (forced vital capacity) / / 24023788 rs1158058 chr6 71726539 A T 5.00E-06 Metabolite levels (MHPG) / / 23319000 rs6925100 chr6 71743144 A G 9.60E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs16880776 chr6 71749173 T C 8.02E-04 Parkinson's disease / / 16252231 rs9364126 chr6 71752702 A G 2.85E-04 Birth weight / / 17255346 rs7743868 chr6 71761504 C T 1.10E-05 Urinary metabolites / / 21572414 rs11968814 chr6 71776971 G A 9.00E-07 F-cell distribution / / 21326311 rs1418677 chr6 71788265 C T 7.10E-06 Urinary metabolites / / 21572414 rs4707892 chr6 71812630 A G 6.30E-06 Urinary metabolites / / 21572414 rs9364129 chr6 71814944 A G 1.90E-05 Urinary metabolites / / 21572414 rs1857224 chr6 71835518 A G 4.88E-05 Creutzfeldt-Jakob disease (variant) / / 22137330 rs4707900 chr6 71872252 T A,G 2.51E-05 Multiple complex diseases / / 17554300 rs1418688 chr6 71878869 A G 9.33E-08 Panic disorder / / 19165232 rs6914937 chr6 71979329 A C 1.15E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs9455408 chr6 71979875 C G 6.58E-04 Multiple complex diseases / / 17554300 rs6907281 chr6 71988210 A G 9.79E-06 Response to mTOR inhibitor (rapamycin) / / 24009623 rs9346458 chr6 72010963 G A 1.25E-05 Response to mTOR inhibitor (rapamycin) OGFRL1 intron 24009623 rs1885677 chr6 72024133 A G 1.92E-05 Response to mTOR inhibitor (rapamycin) LOC100507367 intron 24009623 rs1885676 chr6 72033126 T C 1.99E-05 Response to mTOR inhibitor (rapamycin) LOC100507367 intron 24009623 rs9364166 chr6 72106622 C T 3.90E-06 Kawasaki disease / / 21221998 rs1527710 chr6 72115581 T G 2.35E-04 Multiple complex diseases / / 17554300 rs763354 chr6 72115621 C T 6.64E-06 Kawasaki disease / / 21221998 rs7349905 chr6 72118716 G C 5.41E-06 Kawasaki disease / / 21221998 rs9346470 chr6 72136315 T C 9.56E-06 Kawasaki disease / / 21221998 rs9346471 chr6 72137905 T G 5.64E-04 Multiple complex diseases / / 17554300 rs1727638 chr6 72139572 G A 1.00E-06 AB1-42 levels / / 20932310 rs852935 chr6 72155027 A G 9.19E-04 Type 2 diabetes / / 17463246 rs852928 chr6 72181115 T C 8.35E-04 Multiple complex diseases / / 17554300 rs9351814 chr6 72193707 A C 5.00E-08 Coronary artery disease or ischemic stroke / / 24262325 rs493265 chr6 72195981 A G 4.09E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1527708 chr6 72198638 C T 2.87E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs35663023 chr6 72202025 T A 3.00E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs12190423 chr6 72202711 G C 5.42E-05 Coronary heart disease / / 21378990 rs547136 chr6 72210423 T C 5.44E-05 Pancreatic cancer / / pha002874 rs9360456 chr6 72218629 C T 4.21E-04 Multiple complex diseases / / 17554300 rs199619 chr6 72218776 T G 7.64E-04 Multiple complex diseases / / 17554300 rs12173424 chr6 72227746 C T 6.05E-04 Multiple complex diseases / / 17554300 rs9342838 chr6 72234743 C G 6.01E-04 Multiple complex diseases / / 17554300 rs12193019 chr6 72300534 T C 2.27E-05 Chronic obstructive pulmonary disease / / 19300482 rs1889276 chr6 72330088 C T 1.44E-04 Celiac disease / / 23936387 rs10942957 chr6 72337017 C T 3.15E-05 Chronic obstructive pulmonary disease / / 19300482 rs10942957 chr6 72337017 C T 1.96E-05 Hypertension (early onset hypertension) / / 22479346 rs1575208 chr6 72346472 C T 1.46E-05 Chronic obstructive pulmonary disease / / 19300482 rs1575208 chr6 72346472 C T 1.96E-05 Hypertension (early onset hypertension) / / 22479346 rs9446432 chr6 72356760 T C 2.84E-06 Type 2 diabetes and other traits / / 19734900 rs9446432 chr6 72356760 T C 2.84E-06 Alzheimer's disease (late onset) / / 21460841 rs6938557 chr6 72356780 G A 2.35E-04 Celiac disease / / 23936387 rs9342864 chr6 72366851 G A 2.98E-05 Hypertension (early onset hypertension) / / 22479346 rs272226 chr6 72375097 G A 8.80E-05 White matter hyperintensity burden / / 21681796 rs10455242 chr6 72383139 A G 2.40E-05 Urinary metabolites / / 21572414 rs175360 chr6 72392227 T C 2.10E-05 Tuberculosis / / 20694014 rs1552418 chr6 72392503 G C 8.37E-04 Tuberculosis / / 22239941 rs2754042 chr6 72401403 A G 5.54E-05 LDL lipoproteins / / pha002902 rs4707930 chr6 72406319 T G 6.00E-06 Response to anti-TNF alpha therapy in inflammatory bowel disease / / 20014019 rs829465 chr6 72431453 T C 2.20E-04 Multiple complex diseases / / 17554300 rs829467 chr6 72432977 A C 1.87E-04 Multiple complex diseases / / 17554300 rs9342868 chr6 72440800 C T 0.000117736 Hypertension (early onset hypertension) / / 22479346 rs9360487 chr6 72440854 A C 0.000117736 Hypertension (early onset hypertension) / / 22479346 rs829473 chr6 72440951 A C 9.38E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs1204331 chr6 72443369 G A 2.61E-04 Multiple complex diseases / / 17554300 rs9351848 chr6 72445024 A G 2.63E-04 Multiple complex diseases / / 17554300 rs1932327 chr6 72454176 T C 3.89E-04 Alzheimer's disease (late onset) / / 21379329 rs1328702 chr6 72469364 G A 5.31E-04 Type 2 diabetes / / 17463246 rs4707940 chr6 72470319 A G 6.30E-04 Type 2 diabetes / / 17463246 rs1328698 chr6 72476648 C A 0.000733 Common carotid artery thickness (average of near and far wall measures) / / 23487405 rs17779253 chr6 72477412 T C 8.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10455248 chr6 72482458 C T 4.00E-06 Cognitive performance / / 20125193 rs2149446 chr6 72492346 C T 7.06E-04 Type 2 diabetes / / 17463246 rs9350437 chr6 72515891 T C 6.21E-04 Type 2 diabetes / / 17463246 rs4354106 chr6 72516838 C T 3.04E-04 Multiple complex diseases / / 17554300 rs4706494 chr6 72580090 T C 8.29E-04 Heart Failure / / pha002885 rs13206808 chr6 72582426 G C 5.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1147523 chr6 72583571 C G 6.40E-06 Urinary metabolites / / 21572414 rs1147522 chr6 72583600 C T 0.000000043 Confectionary intake / / 23408455 rs2040055 chr6 72603664 C T 3.34E-05 Meningococcal disease RIMS1 intron 20694013 rs9446506 chr6 72604260 T C 1.30E-05 Urinary metabolites RIMS1 intron 21572414 rs9341356 chr6 72620787 G T 6.92E-05 Schizophrenia RIMS1 intron 19571809 rs12215297 chr6 72627481 G A 2.00E-04 Cognitive impairment induced by topiramate RIMS1 intron 22091778 rs1891698 chr6 72633028 C T 4.29E-06 Multiple complex diseases RIMS1 intron 17554300 rs6924133 chr6 72651482 T C 2.49E-04 Glycosylated haemoglobin levels RIMS1 intron 17255346 rs10214880 chr6 72662508 C T 7.87E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RIMS1 intron 20877124 rs1936022 chr6 72666352 C T 4.93E-04 Smoking initiation RIMS1 intron 24665060 rs13206801 chr6 72666847 C T 1.75E-04 Glycosylated haemoglobin levels RIMS1 intron 17255346 rs9293858 chr6 72666867 A G 2.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RIMS1 intron 20877124 rs1482567 chr6 72671565 C T 1.81E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RIMS1 intron 20877124 rs9358988 chr6 72674265 A T 4.66E-05 Smoking initiation RIMS1 intron 24665060 rs9350450 chr6 72674436 T C 5.81E-05 Smoking initiation RIMS1 intron 24665060 rs17568100 chr6 72674853 A T 5.20E-05 Response to statin therapy RIMS1 intron 20339536 rs17568100 chr6 72674853 A T 3.95E-05 Personality dimensions RIMS1 intron 22628180 rs9446518 chr6 72676757 G A 1.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RIMS1 intron 20877124 rs9446521 chr6 72682023 G A 8.05E-04 Coronary Artery Disease RIMS1 intron 17634449 rs1482571 chr6 72682255 A G 7.40E-04 Coronary Artery Disease RIMS1 intron 17634449 rs9342908 chr6 72682483 A C 4.51E-04 Smoking initiation RIMS1 intron 24665060 rs9341358 chr6 72683914 T C 8.58E-05 Smoking initiation RIMS1 intron 24665060 rs17568315 chr6 72689500 A T 5.20E-05 Response to statin therapy RIMS1 intron 20339536 rs7743295 chr6 72692125 A G 4.93E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) RIMS1 intron 24023788 rs9442725 chr6 72693502 T C 6.58E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RIMS1 intron 20877124 rs12528110 chr6 72693648 G C 5.30E-05 Response to statin therapy RIMS1 intron 20339536 rs17568434 chr6 72698830 T C 5.40E-05 Response to statin therapy RIMS1 intron 20339536 rs1384390 chr6 72699513 C T 5.20E-05 Response to statin therapy RIMS1 intron 20339536 rs12524886 chr6 72705884 G A 4.40E-05 Response to statin therapy RIMS1 intron 20339536 rs2057021 chr6 72706219 A G 4.20E-05 Response to statin therapy RIMS1 intron 20339536 rs2057022 chr6 72706488 G A 3.60E-05 Response to statin therapy RIMS1 intron 20339536 rs9442728 chr6 72707175 C T 3.20E-05 Response to statin therapy RIMS1 intron 20339536 rs9446532 chr6 72708688 G C 3.00E-05 Response to statin therapy RIMS1 intron 20339536 rs12524322 chr6 72710364 G A 3.50E-05 Response to statin therapy RIMS1 intron 20339536 rs17568677 chr6 72711050 C T 3.20E-05 Response to statin therapy RIMS1 intron 20339536 rs10942990 chr6 72717431 T C 3.50E-05 Response to statin therapy RIMS1 intron 20339536 rs9446545 chr6 72724632 G T 3.50E-05 Response to statin therapy RIMS1 intron 20339536 rs9446546 chr6 72725012 A T 3.50E-05 Response to statin therapy RIMS1 intron 20339536 rs17568838 chr6 72730978 A T 3.30E-05 Response to statin therapy RIMS1 intron 20339536 rs7761468 chr6 72734047 T C 3.40E-05 Response to statin therapy RIMS1 intron 20339536 rs9446549 chr6 72736482 A G 3.20E-05 Response to statin therapy RIMS1 intron 20339536 rs17569061 chr6 72740626 G A 3.50E-05 Response to statin therapy RIMS1 intron 20339536 rs17569172 chr6 72741747 A T 3.70E-05 Response to statin therapy RIMS1 intron 20339536 rs575472 chr6 72742390 G A 9.00E-06 Urinary metabolites RIMS1 intron 21572414 rs6926634 chr6 72743714 G A 3.50E-05 Response to statin therapy RIMS1 intron 20339536 rs12529960 chr6 72750269 A T 3.30E-05 Response to statin therapy RIMS1 intron 20339536 rs12526614 chr6 72750392 C G 3.40E-05 Response to statin therapy RIMS1 intron 20339536 rs9446553 chr6 72751600 C T 7.52E-04 Type 2 diabetes RIMS1 intron 17463246 rs17569339 chr6 72752312 A G 3.50E-05 Response to statin therapy RIMS1 intron 20339536 rs12530391 chr6 72754763 T C 3.60E-05 Response to statin therapy RIMS1 intron 20339536 rs17491332 chr6 72756823 T C 4.00E-05 Response to statin therapy RIMS1 intron 20339536 rs11754917 chr6 72757619 A G 6.20E-05 Response to statin therapy RIMS1 intron 20339536 rs6919752 chr6 72763339 T C 2.54E-05 Coronary heart disease RIMS1 intron pha003031 rs17569784 chr6 72769390 T C 3.70E-05 Response to statin therapy RIMS1 intron 20339536 rs10942994 chr6 72775842 G A 2.20E-05 Urinary metabolites RIMS1 intron 21572414 rs12528112 chr6 72781730 A G 1.45E-05 Personality dimensions RIMS1 intron 22628180 rs9446563 chr6 72803906 A G 3.63E-05 Cognitive impairment induced by topiramate RIMS1 intron 22091778 rs11758304 chr6 72813547 A C 1.08E-05 Personality dimensions RIMS1 intron 22628180 rs2496551 chr6 72851032 T C 8.32E-05 Coronary heart disease RIMS1 intron pha003031 rs17725217 chr6 72851788 G A 2.11E-05 Personality dimensions RIMS1 intron 22628180 rs2349095 chr6 72875873 G T 1.10E-05 Urinary metabolites RIMS1 intron 21572414 rs11756194 chr6 72877052 C T 2.11E-05 Personality dimensions RIMS1 intron 22628180 rs12526524 chr6 72885609 G A 2.13E-05 Personality dimensions RIMS1 intron 22628180 rs9442750 chr6 72886012 A G 2.14E-05 Personality dimensions RIMS1 intron 22628180 rs9446589 chr6 72888264 T G 8.91E-05 Coronary heart disease RIMS1 intron pha003031 rs2496515 chr6 72905741 A G 5.63E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) RIMS1 intron 24236485 rs2249625 chr6 72906753 A G 2.17E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) RIMS1 intron 24236485 rs2249625 chr6 72906753 A G 5.00E-06 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) RIMS1 intron 24236485 rs1852702 chr6 72908366 T C 8.51E-05 Cognitive impairment induced by topiramate RIMS1 intron 22091778 rs2463749 chr6 72918148 G C 6.80E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) RIMS1 intron 24236485 rs2254147 chr6 72920943 C G 5.04E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) RIMS1 intron 24236485 rs10498881 chr6 72942606 C G 2.00E-04 Type 2 diabetes RIMS1 intron 17846126 rs1883822 chr6 73036365 C G 1.41E-04 Alzheimer's disease RIMS1 intron 17998437 rs17746778 chr6 73055271 G A 4.14E-04 Alzheimer's disease RIMS1 intron 17998437 rs1339226 chr6 73056548 T C 3.81E-04 Alzheimer's disease RIMS1 intron 17998437 rs1546914 chr6 73057643 C T 2.02E-04 Alzheimer's disease RIMS1 intron 17998437 rs17690774 chr6 73072401 G A 3.40E-04 Alzheimer's disease RIMS1 intron 17998437 rs2807510 chr6 73090537 G A 3.42E-06 Asthma (childhood onset) RIMS1 intron 23829686 rs2815743 chr6 73091378 A T 9.59E-04 Alzheimer's disease RIMS1 intron 17998437 rs1548335 chr6 73135430 A G 0.00029 Erectile dysfunction after radiotherapy for prostate cancer / / 23021708 rs2789588 chr6 73143697 A C 1.60E-05 Schizophrenia / / 21791550 rs2789588 chr6 73143697 A C 0.00000021 Psychosis / / 23164818 rs1572208 chr6 73171594 T C 1.55E-04 Cognitive decline / / 23732972 rs2781564 chr6 73177863 A C 7.89E-04 Schizophrenia / / 21674006 rs2781564 chr6 73177863 A C 7.50E-06 Personality dimensions / / 23658558 rs2781564 chr6 73177863 A C 8.42E-06 Response to mTOR inhibitor (rapamycin) / / 24009623 rs2815715 chr6 73186272 A C 4.20E-06 Cognitive impairment induced by topiramate / / 22091778 rs1334346 chr6 73193151 C A 2.54E-04 Multiple complex diseases / / 17554300 rs1334346 chr6 73193151 C A 8.00E-06 Response to mTOR inhibitor (rapamycin) / / 24009623 rs9442813 chr6 73244928 G A 1.58E-04 Osteoarthritis / / 19508968 rs6929554 chr6 73263598 G T 3.71E-04 Aortic root size / / 21223598 rs1209049 chr6 73270044 C A 6.60E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs9442829 chr6 73325524 A G 4.03E-04 Cocaine dependence / / 23958962 rs9442829 chr6 73325524 A G 8.61E-05 Cocaine dependence / / 23958962 rs867520 chr6 73330586 T G 0.000391 Salmonella-induced pyroptosis / / 22837397 rs12200468 chr6 73351870 A G 1.47E-05 Asthma KCNQ5 intron 22561531 rs17749408 chr6 73358340 G A 8.93E-04 Suicide attempts in bipolar disorder KCNQ5 intron 21041247 rs12194741 chr6 73376868 T C 0.0000018 Chronic obstructive pulmonary disease (moderate to severe) KCNQ5 intron 22986903 rs17729195 chr6 73405265 T C 1.00E-06 Asthma KCNQ5 intron 21790008 rs719830 chr6 73431969 A G 5.31E-04 Parkinson's disease KCNQ5 intron 17052657 rs719830 chr6 73431969 A G 4.00E-06 Asthma KCNQ5 intron 21790008 rs6910780 chr6 73443379 C T 9.29E-04 Acute lymphoblastic leukemia (childhood) KCNQ5 intron 22076464 rs4235869 chr6 73449742 G T 1.50E-05 Urinary metabolites KCNQ5 intron 21572414 rs910355 chr6 73450321 A G 1.22E-04 Multiple complex diseases KCNQ5 intron 17554300 rs7758723 chr6 73475153 C T 1.90E-05 Urinary metabolites KCNQ5 intron 21572414 rs16882872 chr6 73490084 A C 2.10E-05 Urinary metabolites KCNQ5 intron 21572414 rs4421163 chr6 73492028 A G 7.26E-07 Serum metabolites KCNQ5 intron 19043545 rs4707991 chr6 73493822 T C 2.13E-06 Serum metabolites KCNQ5 intron 19043545 rs4293967 chr6 73504798 T C 1.10E-06 Serum metabolites KCNQ5 intron 19043545 rs4707995 chr6 73526074 A G 3.94E-05 Serum metabolites KCNQ5 intron 19043545 rs6912655 chr6 73526348 A G 4.94E-05 Serum metabolites KCNQ5 intron 19043545 rs4615346 chr6 73529940 C G 2.81E-04 Type 2 diabetes KCNQ5 intron 17463246 rs2185766 chr6 73531697 A G 1.41E-04 Multiple complex diseases KCNQ5 intron 17554300 rs1935521 chr6 73573771 A G 7.10E-06 Asthma (childhood onset) KCNQ5 intron 23829686 rs10498886 chr6 73622234 A C 2.38E-04 Coronary heart disease KCNQ5 intron 21971053 rs7744813 chr6 73643289 C A 4.00E-09 Refractive error KCNQ5 intron 23396134 rs7744813 chr6 73643289 C A 6.60E-22 Myopia (Age of onset) KCNQ5 intron 23468642 rs1317538 chr6 73649411 G A 3.00E-05 Lipid traits KCNQ5 intron 17903299 rs11758798 chr6 73652005 C T 3.39E-04 Coronary heart disease KCNQ5 intron 21971053 rs885247 chr6 73660234 T C 1.99E-06 Alcohol dependence KCNQ5 intron 23089632 rs1891395 chr6 73660344 T C 5.14E-04 Multiple complex diseases KCNQ5 intron 17554300 rs13206617 chr6 73663745 G T 5.98E-05 Calcium levels KCNQ5 intron pha003085 rs2226133 chr6 73679577 A G 6.33E-04 Multiple complex diseases KCNQ5 intron 17554300 rs9360623 chr6 73681783 G A 3.55E-04 Iron levels KCNQ5 intron pha002876 rs10943075 chr6 73719982 A G 7.93E-06 Alcohol dependence KCNQ5 intron 23089632 rs10498887 chr6 73740864 G A,C 5.09E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) KCNQ5 intron 23648065 rs6453619 chr6 73743509 C A 2.13E-04 Cholesterol KCNQ5 intron 17255346 rs2051024 chr6 73814756 C T 5.21E-04 Multiple complex diseases KCNQ5 intron 17554300 rs6911409 chr6 73853370 T A 9.70E-05 Weight loss (gastric bypass surgery) KCNQ5 intron 23643386 rs12662682 chr6 73889797 A G 2.81E-05 Alcohol dependence KCNQ5 intron 21314694 rs10498891 chr6 73891434 T A,C,G 3.00E-05 Response to statin therapy KCNQ5 intron 20339536 rs16883476 chr6 73895541 A G 1.81E-04 Multiple complex diseases KCNQ5 intron 17554300 rs7740791 chr6 73913780 G A 4.23E-04 Multiple complex diseases / / 17554300 rs9688431 chr6 73922654 T C 3.00E-05 Response to statin therapy / / 20339536 rs2282448 chr6 73933401 T G 3.50E-05 Response to statin therapy KHDC1L UTR-3 20339536 rs2350753 chr6 73948140 C T 4.40E-05 Response to statin therapy / / 20339536 rs6911421 chr6 73948431 T C 1.56E-04 Multiple complex diseases / / 17554300 rs16883544 chr6 74001420 G A 5.21E-05 Multiple complex diseases KHDC1 intron 17554300 rs9360664 chr6 74041424 G A 5.28E-05 Parkinson's disease / / 17052657 rs578701 chr6 74048823 A G 2.95E-04 Age-related macular degeneration / / 22125219 rs12190522 chr6 74052755 T G 6.15E-04 Obesity (extreme) / / 21935397 rs12198600 chr6 74053742 A C 6.06E-04 Obesity (extreme) / / 21935397 rs6906976 chr6 74062007 G A 6.72E-06 Blood Pressure / / pha003043 rs7740005 chr6 74080010 T G 4.17E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6917933 chr6 74104299 G T 6.62E-04 Self-reported allergy DDX43 UTR-5 23817569 rs610913 chr6 74155346 G T 7.86E-05 Blood Pressure MB21D1 missense pha003047 rs7453831 chr6 74179395 A G 5.87E-05 Blood Pressure MTO1 intron pha003048 rs12529857 chr6 74179788 G A 8.80E-05 Blood Pressure MTO1 intron pha003048 rs4708059 chr6 74209463 T C 8.80E-05 Blood Pressure MTO1 intron pha003048 rs11755449 chr6 74226353 C T 2.31E-05 Blood Pressure EEF1A1 UTR-3 pha003048 rs2073466 chr6 74229258 G T 6.98E-05 Hypertension EEF1A1 intron pha003042 rs2073465 chr6 74229792 A G 5.86E-05 Blood Pressure EEF1A1 intron pha003048 rs606263 chr6 74279910 A G 2.02E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9442924 chr6 74280026 C A 3.50E-05 Coffee consumption / / 21357676 rs364734 chr6 74309401 G T 3.10E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs364734 chr6 74309401 G T 9.12E-04 Response to cytidine analogues (gemcitabine) SLC17A5 intron 24483146 rs4079357 chr6 74315241 A G 3.10E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs4079357 chr6 74315241 A G 4.92E-04 Response to cytidine analogues (gemcitabine) SLC17A5 intron 24483146 rs1874231 chr6 74315281 C T 3.10E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs1741895 chr6 74316107 C A 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs1741895 chr6 74316107 C A 5.75E-04 Response to cytidine analogues (gemcitabine) SLC17A5 intron 24483146 rs543642 chr6 74316593 C T 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs543642 chr6 74316593 C T 4.64E-04 Response to cytidine analogues (gemcitabine) SLC17A5 intron 24483146 rs636166 chr6 74316996 A G 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs636166 chr6 74316996 A G 4.64E-04 Response to cytidine analogues (gemcitabine) SLC17A5 intron 24483146 rs476838 chr6 74317842 G A 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs476838 chr6 74317842 G A 4.64E-04 Response to cytidine analogues (gemcitabine) SLC17A5 intron 24483146 rs473078 chr6 74318265 T C 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs473078 chr6 74318265 T C 4.64E-04 Response to cytidine analogues (gemcitabine) SLC17A5 intron 24483146 rs1691341 chr6 74319303 A G 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs1691341 chr6 74319303 A G 4.64E-04 Response to cytidine analogues (gemcitabine) SLC17A5 intron 24483146 rs549852 chr6 74324403 A C 6.27E-08 Metabolite levels SLC17A5 intron 23281178 rs615956 chr6 74324901 T C 8.22E-08 Metabolite levels SLC17A5 intron 23281178 rs657212 chr6 74327075 C T 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs673511 chr6 74328384 A T 5.89E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs686317 chr6 74328932 T A 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs570050 chr6 74329361 C T 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs506262 chr6 74330303 G A 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs506157 chr6 74330345 G A 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs609790 chr6 74331314 C T 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs609829 chr6 74331345 T C 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs474661 chr6 74331439 G A 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs610260 chr6 74331457 C T 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs611580 chr6 74331736 G C 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs580531 chr6 74331918 G A 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs1848523 chr6 74332267 C T 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs555840 chr6 74332344 G A 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs625512 chr6 74332493 T C 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs1741886 chr6 74332695 A G 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs584571 chr6 74335497 C G 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs584078 chr6 74335621 C A,G 4.56E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs583149 chr6 74335824 G A 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs678054 chr6 74336401 T C 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs6930349 chr6 74337302 C T 0.00000157 Cholesterol,total SLC17A5 intron 23063622 rs9446952 chr6 74338986 C T 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs9446955 chr6 74339192 T C 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs685491 chr6 74341221 C A 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs687210 chr6 74341589 C A 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs9446957 chr6 74342244 T C 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs7764560 chr6 74342632 A T 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs7764983 chr6 74342686 G T 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs9446964 chr6 74342696 T G 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs9293932 chr6 74343128 C T 3.64E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs9293933 chr6 74343319 G T 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs1703461 chr6 74344099 G A 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs494841 chr6 74344499 G T 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs636605 chr6 74344976 C T 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs520589 chr6 74345053 C T 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs527606 chr6 74346172 C T 3.09E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs7772556 chr6 74346857 T A 6.72E-05 Cytomegalovirus antibody response SLC17A5 intron 21993531 rs495385 chr6 74352365 A G 9.21E-04 Response to cytidine analogues (gemcitabine) SLC17A5 intron 24483146 rs472294 chr6 74354175 C A,G,T 3.09E-05 Cytomegalovirus antibody response SLC17A5 cds-synon 21993531 rs472294 chr6 74354175 C A,G,T 4.64E-04 Response to cytidine analogues (gemcitabine) SLC17A5 cds-synon 24483146 rs3757108 chr6 74365178 T G 3.01E-05 Cytomegalovirus antibody response SLC17A5 nearGene-5 21993531 rs3757108 chr6 74365178 T G 5.83E-04 Response to cytidine analogues (gemcitabine) SLC17A5 nearGene-5 24483146 rs4708072 chr6 74371910 C T 2.92E-05 Cytomegalovirus antibody response / / 21993531 rs4708073 chr6 74371936 T C 2.92E-05 Cytomegalovirus antibody response / / 21993531 rs9442947 chr6 74406977 C T 9.25E-05 Iron levels CD109 intron 19880490 rs9442947 chr6 74406977 C T 9.25E-05 Iron levels CD109 intron pha002876 rs72955210 chr6 74436256 G A 0.0000741 Nonsyndromic striae distensae (stretch marks) CD109 intron 23633020 rs138959924 chr6 74439438 T C 0.0000426 Nonsyndromic striae distensae (stretch marks) CD109 intron 23633020 rs10805974 chr6 74440514 G C 5.11E-04 Alzheimer's disease CD109 intron 17998437 rs72955215 chr6 74444612 T C 0.0000733 Nonsyndromic striae distensae (stretch marks) CD109 intron 23633020 rs10498894 chr6 74451229 T C 4.44E-04 Multiple complex diseases CD109 intron 17554300 rs9447004 chr6 74458737 A G 3.00E-06 Calcium levels CD109 intron 24068962 rs1501192 chr6 74521787 T C 8.72E-05 Depression (quantitative trait) CD109 intron 23290196 rs10943133 chr6 74525643 T C 8.45E-05 Telomere length CD109 intron 21573004 rs3764240 chr6 74530075 C T 5.83E-05 Platelet counts CD109 intron pha003100 rs3005511 chr6 74605806 A G 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1124748 chr6 74646516 C G 3.20E-05 Cognitive function / / 24684796 rs3003181 chr6 74677830 G A 5.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs3012539 chr6 74692160 G A 1.09E-04 Cognitive function / / 24684796 rs9359049 chr6 74701929 T A 3.19E-05 Multiple complex diseases / / 17554300 rs9443001 chr6 74725363 T C 6.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs9447105 chr6 74728642 G C 9.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs7765933 chr6 74756191 C G 3.20E-06 Urinary metabolites / / 21572414 rs4386774 chr6 74764272 G T 5.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs6916906 chr6 74766609 C T 5.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs7745718 chr6 74769947 A T 4.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs13200840 chr6 74770939 C T 3.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6926832 chr6 74773413 C T 8.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs9341446 chr6 74780589 T C 1.40E-06 Urinary metabolites / / 21572414 rs4706570 chr6 74795428 C T 2.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs12213921 chr6 74809690 G T 4.58E-04 Schizophrenia / / 19197363 rs4469252 chr6 74852508 C T 1.00E-06 Urinary metabolites / / 21572414 rs7775575 chr6 74858456 C T 3.90E-05 Alcoholism (heaviness of drinking) / / 21529783 rs6933348 chr6 74862264 G C 4.60E-06 Urinary metabolites / / 21572414 rs6453739 chr6 74870820 G A 2.43E-05 Response to methylphenidate treatment / / 21130132 rs6912405 chr6 74871231 A G 9.00E-06 Obesity-related traits / / 23251661 rs4708135 chr6 74877900 A G 8.39E-04 Multiple complex diseases / / 17554300 rs9360745 chr6 74879308 A G 1.80E-04 Type 2 diabetes / / 17463246 rs9359077 chr6 74982166 T C 3.58E-05 Major depressive disorder (broad) / / 20038947 rs9360769 chr6 74998457 T C 9.00E-05 Prostate cancer / / 21743057 rs4708146 chr6 75031230 G C 6.18E-05 Major depressive disorder (broad) / / 20038947 rs1552568 chr6 75035349 G T 1.70E-04 Multiple complex diseases / / 17554300 rs527658 chr6 75073037 A T 6.28E-05 Serum metabolites / / 19043545 rs9360790 chr6 75120834 A G 2.11E-04 Multiple complex diseases / / 17554300 rs7774793 chr6 75125541 T G 8.12E-05 Cognitive performance / / 19734545 rs1853182 chr6 75129384 T A 9.76E-05 Panic disorder / / 19165232 rs9343163 chr6 75155303 G A 3.53E-06 Cognitive test performance / / 20125193 rs72960926 chr6 75158266 C A 2.00E-06 Metabolite levels (MHPG) / / 23319000 rs9350550 chr6 75160914 A G 8.91E-05 Cognitive test performance / / 20125193 rs9343167 chr6 75166903 A G 3.53E-06 Cognitive test performance / / 20125193 rs6912037 chr6 75191133 T C 9.21E-05 HIV-1 viral setpoint / / 22174851 rs6904268 chr6 75211546 C T 4.35E-05 Cognitive test performance / / 20125193 rs6902731 chr6 75217944 C A 2.96E-04 Type 2 diabetes / / 17463246 rs1577217 chr6 75264996 T C 8.35E-05 Cognitive performance / / 19734545 rs2785691 chr6 75327919 C T 2.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2502497 chr6 75342363 G T 1.00E-04 Type 2 diabetes / / 17846126 rs6910395 chr6 75351505 T C 4.55E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs2502481 chr6 75363233 C T 9.00E-04 Coronary Artery Disease / / 17634449 rs2485093 chr6 75366837 G A 2.06E-04 Coronary Artery Disease / / 17634449 rs2502521 chr6 75409434 T C 3.29E-04 Nicotine dependence / / 17158188 rs4235888 chr6 75432861 C T 6.31E-05 Body mass index / / 22446040 rs7741861 chr6 75454263 C T 0.00000734 HDL cholesterol particle diameter / / 23263444 rs16885523 chr6 75454968 G C 2.20E-05 Coffee consumption / / 21357676 rs2502465 chr6 75455385 C T 3.10E-05 Body mass index / / 22446040 rs2502467 chr6 75461769 C T 1.00E-04 Prostate cancer / / 21743057 rs9343222 chr6 75469916 T C 8.78E-04 Multiple complex diseases / / 17554300 rs2152826 chr6 75525927 A T 1.33E-04 Multiple complex diseases / / 17554300 rs12664807 chr6 75660292 T C 6.36E-04 Multiple complex diseases / / 17554300 rs554152 chr6 75789526 C T 2.10E-05 Urinary metabolites / / 21572414 rs240727 chr6 75843360 G A 3.33E-05 Tuberculosis COL12A1 intron 24057671 rs9360895 chr6 75882769 A G 1.31E-04 Multiple complex diseases COL12A1 intron 17554300 rs151068918 chr6 75994198 T C 0.0000021 Breast cancer(er negative) TMEM30A missense 23555315 rs2842463 chr6 76009426 T C 0.0000695 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4708179 chr6 76025603 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FILIP1 intron 22628534 rs6453825 chr6 76050367 G A 9.06E-05 Relative hand skill in reading disability FILIP1 intron 24068947 rs6929270 chr6 76053386 G T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FILIP1 intron 22628534 rs13211961 chr6 76077948 A G 6.50E-06 Urinary metabolites FILIP1 intron 21572414 rs2808203 chr6 76125691 T G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FILIP1 intron 22628534 rs9359122 chr6 76127504 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FILIP1 intron 22628534 rs2808207 chr6 76130215 C T 7.08E-04 Alzheimer's disease FILIP1 intron 22005930 rs2703702 chr6 76147294 G A 7.27E-04 Alzheimer's disease FILIP1 intron 22005930 rs2703714 chr6 76160101 G A 7.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FILIP1 intron 20877124 rs2703714 chr6 76160101 G A 8.96E-04 Alzheimer's disease FILIP1 intron 22005930 rs2951922 chr6 76162850 A G 6.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FILIP1 intron 20877124 rs2951922 chr6 76162850 A G 7.74E-04 Alzheimer's disease FILIP1 intron 22005930 rs12212816 chr6 76166164 C T 1.46E-04 Response to cytadine analogues (cytosine arabinoside) FILIP1 intron 24483146 rs2951916 chr6 76174857 A G 3.87E-16 Leprosy FILIP1 intron 22019778 rs2808186 chr6 76183202 C T 5.93E-04 Alzheimer's disease FILIP1 intron 22005930 rs1932523 chr6 76194895 T C 3.00E-05 Asthma (aspirin-intolerant) FILIP1 intron 21072201 rs9350591 chr6 76241527 C T 2.49E-06 Osteoarthritis / / 22763110 rs9360921 chr6 76265642 T G 3.00E-13 Height / / 20881960 rs6453835 chr6 76306750 A G 3.70E-04 Type 2 diabetes / / 17463246 rs6453835 chr6 76306750 A G 6.95E-06 Lipid traits / / 24023261 rs569731 chr6 76357593 G A 1.64E-06 Osteoarthritis SENP6 intron 22763110 rs6936085 chr6 76401210 A G 5.37E-04 Type 2 diabetes SENP6 intron 17463246 rs6936085 chr6 76401210 A G 1.55E-05 Lipid traits SENP6 intron 24023261 rs276685 chr6 76429164 C T 6.33E-04 Multiple complex diseases / / 17554300 rs276699 chr6 76456048 G C 9.37E-05 Multiple complex diseases / / 17554300 rs276693 chr6 76461184 A G 9.31E-04 Multiple complex diseases MYO6 intron 17554300 rs1280038 chr6 76513415 C T 1.76E-05 Lipid traits MYO6 intron 24023261 rs12196105 chr6 76518704 A T 2.10E-05 Urinary metabolites MYO6 intron 21572414 rs10943292 chr6 76533481 G A 6.19E-04 Type 2 diabetes MYO6 intron 17463246 rs1280054 chr6 76540988 A G 8.00E-05 White matter hyperintensity burden MYO6 intron 21681796 rs1280054 chr6 76540988 A G 7.35E-04 Alzheimer's disease MYO6 intron 24755620 rs12207159 chr6 76552776 C A,G,T 7.98E-05 Coronary heart disease MYO6 intron 21606135 rs3798440 chr6 76556619 C T 3.00E-10 Hypertension MYO6 intron 21626137 rs6453843 chr6 76558485 T G 7.94E-08 Metabolite levels MYO6 intron 23281178 rs9350602 chr6 76560498 C T 2.70E-05 Urinary metabolites MYO6 intron 21572414 rs9350602 chr6 76560498 C T 3.00E-10 Hypertension MYO6 intron 21626137 rs9352244 chr6 76571630 G A 1.90E-05 Urinary metabolites MYO6 intron 21572414 rs9360946 chr6 76572972 G A 2.00E-05 Urinary metabolites MYO6 intron 21572414 rs2312933 chr6 76577665 C T 7.94E-08 Metabolite levels MYO6 intron 23281178 rs2208798 chr6 76583643 G A 2.00E-05 Urinary metabolites MYO6 intron 21572414 rs13202519 chr6 76584271 T C 7.74E-04 Alzheimer's disease MYO6 intron 24755620 rs9359145 chr6 76588190 G A 7.94E-08 Metabolite levels MYO6 intron 23281178 rs2295938 chr6 76601992 G A 7.94E-08 Metabolite levels MYO6 intron 23281178 rs3798430 chr6 76603852 A G 2.10E-05 Urinary metabolites MYO6 intron 21572414 rs9294004 chr6 76606056 T C 7.94E-08 Metabolite levels MYO6 intron 23281178 rs9359149 chr6 76638950 T A 3.35E-04 Type 2 diabetes IMPG1 intron 17463246 rs1540999 chr6 76695323 T C 4.09E-05 Waist-Hip Ratio IMPG1 intron pha003028 rs17802413 chr6 76710341 C A 4.09E-05 Waist-Hip Ratio IMPG1 intron pha003028 rs1886985 chr6 76716742 C T 7.96E-04 Bipolar disorder IMPG1 intron 19259986 rs1575856 chr6 76717763 G A 3.07E-05 Bipolar disorder IMPG1 intron 19259986 rs947340 chr6 76747944 A C 8.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IMPG1 intron 20877124 rs1416471 chr6 76854848 T G 4.86E-05 Body mass (lean) / / 19268274 rs4708220 chr6 76861486 C G 5.24E-05 Body mass (lean) / / 19268274 rs6453855 chr6 76862529 C G 5.52E-05 Body mass (lean) / / 19268274 rs6453860 chr6 76890811 A T 4.94E-04 Multiple complex diseases / / 17554300 rs9352266 chr6 76901651 T C 5.32E-05 Body mass (lean) / / 19268274 rs4467744 chr6 76904136 A G 5.63E-05 Body mass (lean) / / 19268274 rs1825651 chr6 76926454 A G 3.93E-04 Bipolar disorder / / 19259986 rs4706607 chr6 76930997 C G 1.73E-04 Bipolar disorder / / 19259986 rs10943319 chr6 76933542 C T 3.80E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7760923 chr6 76943515 G T 9.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs2220249 chr6 76946814 G A 9.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs6912202 chr6 76948675 A G 6.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs4708237 chr6 76949831 G C 7.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs6921190 chr6 76954909 C T 8.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs9352282 chr6 76961159 T G 9.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs12213728 chr6 76962641 G A 9.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs1960557 chr6 76973027 G T 8.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs1843572 chr6 76973548 C A 7.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs7766063 chr6 76974585 C A 6.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs972408 chr6 76974947 T C 7.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs1385894 chr6 76975040 G A 7.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs972407 chr6 76975045 C T 7.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs6921404 chr6 76975931 T C 9.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs6919801 chr6 77000777 G A 8.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504982 chr6 77033984 C T 9.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504983 chr6 77034997 C A 6.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504984 chr6 77035130 A T 6.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs1490219 chr6 77035434 G A 6.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504985 chr6 77035951 C T 5.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504986 chr6 77036639 C T 5.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504987 chr6 77037058 C A 6.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504988 chr6 77037678 G T 6.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs2451582 chr6 77042177 A G 3.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs2451583 chr6 77046416 C T 4.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs1490221 chr6 77048315 T C 5.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs2451588 chr6 77050376 T C 4.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs1490224 chr6 77051438 T C 6.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs923553 chr6 77052331 A G 6.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs923553 chr6 77052331 A G 0.000188 Salmonella-induced pyroptosis / / 22837397 rs2054950 chr6 77056061 G C 5.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs2054951 chr6 77056195 A G 5.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs2451590 chr6 77056952 C T 5.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs2260529 chr6 77058484 C A 4.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs2451593 chr6 77059861 C T 5.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs2451594 chr6 77061239 G A 4.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs2451594 chr6 77061239 G A 0.000228 Salmonella-induced pyroptosis / / 22837397 rs2504995 chr6 77063769 A C 4.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504623 chr6 77064998 T C 7.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504996 chr6 77066322 A G 5.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs1160652 chr6 77067306 A C 4.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs1160653 chr6 77067387 G A 4.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504999 chr6 77067958 C T 4.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs1021366 chr6 77068380 G A 4.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs2451523 chr6 77068563 T C 4.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs2505000 chr6 77069490 G A 4.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs2261162 chr6 77070503 T C 4.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs2505002 chr6 77071132 A C 4.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs2261333 chr6 77071374 A G 3.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs2262304 chr6 77085331 G A 4.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs1490200 chr6 77088201 A C 4.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs2101563 chr6 77088890 T C 4.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504634 chr6 77088987 A T 3.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs2171926 chr6 77089590 G A 4.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs2505020 chr6 77092687 A C 3.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs2505024 chr6 77097008 C T 3.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504640 chr6 77105446 A G 4.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs1907044 chr6 77109009 T A 4.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs2451554 chr6 77111136 C T 4.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504647 chr6 77113510 A C 4.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs2451563 chr6 77114087 G A 4.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs1586665 chr6 77114719 T C 4.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs2314935 chr6 77115110 T A 4.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504649 chr6 77115525 A G 4.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs2451568 chr6 77115909 G A 4.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs1586666 chr6 77116848 T C 4.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504652 chr6 77117653 A G 3.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504653 chr6 77118114 A G 4.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504654 chr6 77118132 A T 4.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504967 chr6 77118219 C T 4.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504970 chr6 77118680 G T 4.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs35627656 chr6 77118680 GT G 4.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504971 chr6 77118760 C T 3.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs6931027 chr6 77120135 G T 3.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504974 chr6 77121158 T C 3.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs2451573 chr6 77121907 T C 4.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs2451574 chr6 77121933 T A 3.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504662 chr6 77122674 C T 3.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504663 chr6 77122762 C T 3.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504664 chr6 77122872 A G 3.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504975 chr6 77122907 T C 3.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs2451575 chr6 77123003 G A 3.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504665 chr6 77123236 T G 3.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs2451576 chr6 77123667 A G 2.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504668 chr6 77123803 A G 4.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504977 chr6 77123958 T C 3.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs2504978 chr6 77123973 T C 3.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs1490206 chr6 77124675 T C 4.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs9447693 chr6 77128955 T C 3.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs6903382 chr6 77131798 T C 3.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs9343441 chr6 77133082 G T 3.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs1490207 chr6 77134940 G C 3.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs4583941 chr6 77135100 A G 6.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs10455318 chr6 77135331 C T 5.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs1490223 chr6 77142524 T C 2.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs923549 chr6 77144095 C T 2.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs5009482 chr6 77145573 T C 2.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs1490220 chr6 77149485 C G 2.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs1038749 chr6 77151212 C T 2.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs6453899 chr6 77154643 C T 2.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs1387843 chr6 77156038 T C 3.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs9352336 chr6 77156554 T C 2.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs9443242 chr6 77157446 C T 2.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs9447698 chr6 77157625 C G 2.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs4706618 chr6 77158618 C T 2.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs6453900 chr6 77161277 G A 2.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs9359202 chr6 77169168 A G 3.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs6924853 chr6 77170414 T C 2.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs1490209 chr6 77172081 T C 3.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs1038750 chr6 77174067 T C 2.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs1490210 chr6 77174967 C T 2.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs9447705 chr6 77193221 G A 1.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs12055559 chr6 77198194 C A 1.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs4489120 chr6 77208726 C T 6.70E-05 Suicide attempts in bipolar disorder / / 21423239 rs12193144 chr6 77212059 A G 8.74E-05 Suicide attempts in bipolar disorder / / 21423239 rs9447718 chr6 77217750 G C 3.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs4478374 chr6 77221400 A C 4.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs4475297 chr6 77223839 G A 4.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs4467745 chr6 77224236 C T 4.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs4513750 chr6 77226819 T C 4.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs9443250 chr6 77227275 A G 4.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs7768715 chr6 77228581 C T 4.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs4492169 chr6 77233124 G A 3.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs9352345 chr6 77236543 A G 4.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs10046429 chr6 77242394 T C 4.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs4329074 chr6 77243034 A G 4.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs9447726 chr6 77247004 A C 4.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs9343463 chr6 77247867 T C 3.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs7745942 chr6 77250804 T G 3.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs7773888 chr6 77252081 G C 3.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs4336415 chr6 77253367 T C 2.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs7747109 chr6 77254635 C T 2.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs6453912 chr6 77259118 C T 3.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs4235898 chr6 77266188 G A 1.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs4441926 chr6 77280443 A G 7.33E-05 Alzheimer's disease / / 24755620 rs4291070 chr6 77286644 G A 7.19E-05 Iron levels / / 19880490 rs4291070 chr6 77286644 G A 5.58E-05 Alzheimer's disease / / 24755620 rs4291070 chr6 77286644 G A 7.19E-05 Iron levels / / pha002876 rs12198063 chr6 77290799 A G 8.00E-06 Capecitabine sensitivity / / 22864933 rs4706623 chr6 77291161 C T 8.19E-04 Alzheimer's disease / / 24755620 rs4706623 chr6 77291161 C T 5.49E-04 Iron levels / / pha002876 rs11755314 chr6 77340148 C T 4.16E-04 Myocardial Infarction / / pha002883 rs1457938 chr6 77365406 T C 7.36E-05 Bipolar disorder and schizophrenia / / 20889312 rs1350401 chr6 77369378 T A 3.32E-05 Bipolar disorder and schizophrenia / / 20889312 rs2504430 chr6 77377283 C A 2.51E-04 Parkinson's disease / / 17052657 rs6919990 chr6 77384675 A C 4.62E-04 Iron levels / / pha002876 rs7760381 chr6 77390412 G A 2.63E-05 Iron levels / / 19880490 rs7760381 chr6 77390412 G A 2.63E-05 Iron levels / / pha002876 rs12529543 chr6 77391826 C T 4.94E-04 Multiple complex diseases / / 17554300 rs12529543 chr6 77391826 C T 1.98E-04 Iron levels / / pha002876 rs17763139 chr6 77406237 C T 4.89E-04 Fibrinogen / / 17255346 rs9359218 chr6 77407991 T C 3.35E-04 Acute lung injury / / 22295056 rs7745028 chr6 77412199 C T 3.45E-04 Acute lung injury / / 22295056 rs961243 chr6 77419099 T C 8.96E-05 Intelligence / / 21826061 rs10498907 chr6 77419782 A G 2.09E-06 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs1457974 chr6 77424462 A G 9.10E-06 Dietary macronutrient intake / / 23372041 rs9352377 chr6 77436710 C A 6.19E-05 Major depressive disorder (broad) / / 20038947 rs9447791 chr6 77462539 A G 9.64E-04 Parkinson's disease / / 17052657 rs9447791 chr6 77462539 A G 7.56E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2125215 chr6 77470251 T C 1.03E-04 Nonalcoholic fatty liver disease / / 21423719 rs987008 chr6 77476663 G A 4.85E-04 Multiple complex diseases / / 17554300 rs1457946 chr6 77478249 G A 0.000251 Salmonella-induced pyroptosis / / 22837397 rs374103273 chr6 77478712 TC T 5.90E-08 Height,pubertal growth in / / 20398887 rs374103273 chr6 77478712 TC T 0.0000835 Salmonella-induced pyroptosis / / 22837397 rs7759939 chr6 77478712 T G 5.90E-08 Height,pubertal growth in / / 20398887 rs7759939 chr6 77478712 T G 0.0000835 Salmonella-induced pyroptosis / / 22837397 rs1156082 chr6 77501140 G A 9.40E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs1156081 chr6 77501580 C T 9.71E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs13219726 chr6 77523671 C A 6.44E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs936498 chr6 77529907 G A 2.46E-04 Alcohol dependence / / 20201924 rs4706636 chr6 77566201 C T 3.14E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs1462475 chr6 77570661 G A 1.39E-05 Bilirubin levels,in serum / / 19389676 rs9294040 chr6 77596958 G A 8.28E-05 Schizophrenia / / 19197363 rs7772268 chr6 77623152 A G 7.22E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs323222 chr6 77660387 C A 6.80E-04 Multiple complex diseases / / 17554300 rs323254 chr6 77677175 T C 0.000703 Salmonella-induced pyroptosis / / 22837397 rs323256 chr6 77679931 T C 0.000807 Salmonella-induced pyroptosis / / 22837397 rs323259 chr6 77681574 C T 0.000451 Salmonella-induced pyroptosis / / 22837397 rs9341629 chr6 77734250 T C 3.57E-04 Multiple complex diseases / / 17554300 rs6900885 chr6 77772275 A G 6.46E-04 Multiple complex diseases / / 17554300 rs1590262 chr6 77787815 C T 2.33E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs9343557 chr6 77788834 T C 4.02E-04 Antisocial behavior / / 20345837 rs7738636 chr6 77789808 A C 6.00E-06 Acute lymphoblastic leukemia (childhood) / / 22076464 rs1548240 chr6 77820495 A G 8.80E-05 Parkinson's disease / / 21812969 rs4706646 chr6 77859890 G A 7.56E-04 Multiple complex diseases / / 17554300 rs4235902 chr6 77882940 A G 1.75E-05 Multiple complex diseases / / 17554300 rs9343582 chr6 77898301 C T 8.43E-05 Cognitive test performance / / 20125193 rs4075570 chr6 77903809 G A 9.34E-04 Tourette syndrome / / 22889924 rs4075571 chr6 77903893 G A 6.23E-04 Tourette syndrome / / 22889924 rs4311481 chr6 77934037 A G 6.80E-04 Tourette syndrome / / 22889924 rs6453970 chr6 77993870 C T 6.33E-04 Amyotrophic lateral sclerosis / / 23624525 rs6924517 chr6 77999640 C A 2.37E-04 Multiple complex diseases / / 17554300 rs9294071 chr6 78024630 T A,G 2.32E-04 Multiple complex diseases / / 17554300 rs6910130 chr6 78032434 C T 2.40E-05 Urinary metabolites / / 21572414 rs1361845 chr6 78074083 G A 7.25E-04 Type 2 diabetes / / 17846124 rs9443406 chr6 78092636 C A 2.95E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs7769433 chr6 78094062 G A 2.95E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs6920118 chr6 78095157 T C 2.99E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1936166 chr6 78098653 G A 9.00E-07 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1419085 chr6 78100404 T C 9.34E-07 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1419084 chr6 78100688 G A 3.07E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1342631 chr6 78101576 T C 3.07E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1777822 chr6 78102380 G T 3.03E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1738535 chr6 78102499 C T 3.06E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1738534 chr6 78102549 T A 3.06E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1615713 chr6 78102849 T G 3.93E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1592315 chr6 78102854 A G 4.12E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1614775 chr6 78102964 C T 3.06E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1419083 chr6 78102988 C A 3.06E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1613126 chr6 78103116 G C 3.06E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs546347602 chr6 78103116 G GA 3.06E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1626310 chr6 78103283 G T 3.66E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1738532 chr6 78103562 C T 3.06E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1738531 chr6 78103588 T C 2.60E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1738530 chr6 78104417 T C 3.07E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1738529 chr6 78104655 T G 3.07E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1738528 chr6 78104711 A T 5.55E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs2746595 chr6 78105177 A G 3.07E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1738527 chr6 78105318 T C 3.07E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1738526 chr6 78105486 C A 3.41E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1777820 chr6 78105741 G A 3.06E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1777819 chr6 78105797 A G 3.07E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1738525 chr6 78105825 C T 3.61E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1738524 chr6 78106449 T C 2.97E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1777818 chr6 78106537 C T 2.99E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1777817 chr6 78106600 G A 3.84E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1777815 chr6 78107052 A G 3.02E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1777814 chr6 78107195 C A 3.02E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1777813 chr6 78107322 G A 3.03E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1777812 chr6 78107344 T A 2.83E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1738523 chr6 78107599 C T 3.03E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1777811 chr6 78107827 T G 3.03E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1738522 chr6 78107854 T C 3.03E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1777810 chr6 78107896 C G 3.00E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1738521 chr6 78107959 G A 3.03E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1777809 chr6 78108355 G A 3.03E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1777808 chr6 78108624 A G 3.03E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1777807 chr6 78108747 A G 2.88E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs2746594 chr6 78108825 G A 3.60E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs2746593 chr6 78108829 G A 3.59E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1777806 chr6 78108843 A G 3.55E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1777805 chr6 78108859 A C 3.61E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs74566120 chr6 78108958 C T 3.62E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1777803 chr6 78109222 A G 3.65E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs113832082 chr6 78109886 A G 3.65E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs115040360 chr6 78109888 T C 8.12E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs114186984 chr6 78109889 G A 8.08E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs2746592 chr6 78110081 C T 3.10E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs2798523 chr6 78110498 A C 3.10E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs2746591 chr6 78110556 C T 3.10E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs2746590 chr6 78110692 G C 1.06E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs59227895 chr6 78110943 T C 3.56E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs10943455 chr6 78110971 A G 4.26E-04 Alzheimer's disease / / 17998437 rs1738519 chr6 78111780 C A 0.0000607 Major depressive disorder / / 23149448 rs1738519 chr6 78111780 C A 3.65E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1738518 chr6 78111923 A G 3.70E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1777800 chr6 78112291 G A 3.65E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs2798525 chr6 78112717 A G 3.65E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs2798526 chr6 78112763 A G 3.65E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1738516 chr6 78113822 G C 2.96E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1623132 chr6 78116508 A G 7.96E-04 Alzheimer's disease / / 17998437 rs9359267 chr6 78129122 A G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1228806 chr6 78132749 T C 7.38E-05 Alzheimer's disease / / 17998437 rs4708340 chr6 78138724 A C 5.90E-05 Alzheimer's disease / / 17998437 rs6453980 chr6 78140843 T G 8.71E-04 Alzheimer's disease / / 17998437 rs1145831 chr6 78160573 C T 1.66E-05 Tunica Media / / pha003036 rs1343485 chr6 78160933 A C 7.90E-04 Alcohol dependence / / 20201924 rs1936158 chr6 78184375 G T 6.89E-05 Vaspin levels / / 22907691 rs1936158 chr6 78184375 G T 0.0000689 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs1936158 chr6 78184375 G T 0.0001893 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs994952 chr6 78262955 A G 2.00E-04 Type 2 diabetes / / 17846126 rs1458405 chr6 78264479 C A 2.00E-04 Type 2 diabetes / / 17846126 rs10484725 chr6 78269161 A G 2.00E-04 Type 2 diabetes / / 17846126 rs733015 chr6 78272819 T A 5.03E-04 Type 2 diabetes / / 17463246 rs73761504 chr6 78285902 C T 1.69E-11 Metabolite levels / / 22286219 rs1902970 chr6 78294880 G A 1.21E-04 Vaspin levels / / 22907691 rs1902970 chr6 78294880 G A 0.0001209 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs2125381 chr6 78298676 G A 9.37E-04 Multiple complex diseases / / 17554300 rs12527916 chr6 78328078 G A 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2504298 chr6 78332893 A G 1.74E-05 Coronary heart disease / / pha003035 rs1379887 chr6 78350842 C T 9.05E-06 Vaspin levels / / 22907691 rs1379887 chr6 78350842 C T 0.00000788 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs1379887 chr6 78350842 C T 0.00000905 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs1379887 chr6 78350842 C T 0.00000905 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at minimum 6 weeks / / 22907730 rs898040 chr6 78351916 G A 1.32E-05 Progressive supranuclear palsy / / 21685912 rs898040 chr6 78351916 G A 1.69E-05 Vaspin levels / / 22907691 rs898040 chr6 78351916 G A 0.0000167 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) / / 22907730 rs898040 chr6 78351916 G A 0.0000169 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs898040 chr6 78351916 G A 0.0000181 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs12206237 chr6 78354757 T C 6.29E-04 Alzheimer's disease / / 24755620 rs7752338 chr6 78355600 T G 7.31E-04 Alzheimer's disease / / 24755620 rs9343638 chr6 78381834 G A 4.99E-05 Vaspin levels / / 22907691 rs9343638 chr6 78381834 G A 0.0000499 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs9343638 chr6 78381834 G A 0.0000717 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs7761742 chr6 78420432 T C 1.66E-05 Opioid sensitivity / / 23183491 rs12660344 chr6 78450475 G T 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs17777705 chr6 78494764 C T 7.62E-05 Vaspin levels / / 22907691 rs17777705 chr6 78494764 C T 0.0000762 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs17777705 chr6 78494764 C T 0.000124 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs17777705 chr6 78494764 C T 6.67E-05 Waist Circumference / / pha003023 rs9361293 chr6 78526642 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs9359294 chr6 78531689 A G 8.61E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs12528041 chr6 78534702 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4706658 chr6 78545637 C A 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs9361296 chr6 78547147 A C 1.44E-04 Vaspin levels / / 22907691 rs9361296 chr6 78547147 A C 0.0000912 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs9361296 chr6 78547147 A C 0.0001435 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs9343676 chr6 78549277 C T 1.46E-08 Lung cancer / / 21725308 rs1877531 chr6 78562076 T C 8.65E-05 Vaspin levels / / 22907691 rs1877531 chr6 78562076 T C 0.0000624 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs1877531 chr6 78562076 T C 0.0000865 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs7738598 chr6 78614862 C A 1.67E-05 Vaspin levels / / 22907691 rs7738598 chr6 78614862 C A 0.0000162 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) / / 22907730 rs7738598 chr6 78614862 C A 0.0000166 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs7738598 chr6 78614862 C A 0.0000167 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs7738598 chr6 78614862 C A 0.0000167 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at minimum 6 weeks / / 22907730 rs12189558 chr6 78620417 G A 2.31E-04 Vaspin levels / / 22907691 rs12189558 chr6 78620417 G A 0.0002311 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs2207343 chr6 78639575 T A,G 2.99E-05 Response to citalopram treatment / / 19846067 rs9294091 chr6 78655699 C T 1.74E-04 Vaspin levels / / 22907691 rs9294091 chr6 78655699 C T 0.0000573 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs9294091 chr6 78655699 C T 0.0001741 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs9294092 chr6 78655840 G C 1.85E-05 Response to citalopram treatment / / 19846067 rs6941223 chr6 78678184 T C 1.27E-05 Response to citalopram treatment / / 19846067 rs9343705 chr6 78695490 C T 3.75E-05 Cocaine dependence / / 23958962 rs9352550 chr6 78697736 G A 1.01E-04 Vaspin levels / / 22907691 rs9352550 chr6 78697736 G A 0.000101 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs12206418 chr6 78699746 G T 2.84E-05 Response to citalopram treatment / / 19846067 rs12192878 chr6 78699763 A G 5.35E-05 Response to citalopram treatment / / 19846067 rs6932080 chr6 78708695 C T 2.23E-05 Response to citalopram treatment / / 19846067 rs9350746 chr6 78719322 G A 1.50E-04 Vaspin levels / / 22907691 rs9350746 chr6 78719322 G A 0.0000752 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs9350746 chr6 78719322 G A 0.0001499 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs9343714 chr6 78723311 A C 3.10E-05 Orofacial clefts / / 22419666 rs2207350 chr6 78726755 A G 8.18E-05 Relative hand skill / / 24068947 rs9359307 chr6 78727796 A G 8.14E-05 Relative hand skill / / 24068947 rs9359308 chr6 78727813 A G 8.14E-05 Relative hand skill / / 24068947 rs9352555 chr6 78729843 T C 8.11E-05 Relative hand skill / / 24068947 rs1412171 chr6 78733161 A G 8.08E-05 Relative hand skill / / 24068947 rs1412172 chr6 78733261 A G 9.91E-05 Relative hand skill / / 24068947 rs1888779 chr6 78735673 G T 8.01E-05 Relative hand skill / / 24068947 rs9359309 chr6 78737335 C A 8.00E-05 Relative hand skill / / 24068947 rs10943508 chr6 78741610 G C 1.12E-04 Multiple complex diseases / / 17554300 rs9361337 chr6 78744833 A G 7.97E-05 Relative hand skill / / 24068947 rs10943509 chr6 78746760 C A 7.95E-05 Relative hand skill / / 24068947 rs9448274 chr6 78747488 G A 7.95E-05 Relative hand skill / / 24068947 rs9361340 chr6 78749184 T A 7.94E-05 Relative hand skill / / 24068947 rs4706676 chr6 78749689 G A 7.93E-05 Relative hand skill / / 24068947 rs1590999 chr6 78751523 G A 7.90E-05 Relative hand skill / / 24068947 rs9448277 chr6 78752798 C G 7.90E-05 Relative hand skill / / 24068947 rs1412174 chr6 78753249 A G 7.90E-05 Relative hand skill / / 24068947 rs1412175 chr6 78753259 T C 7.90E-05 Relative hand skill / / 24068947 rs2223968 chr6 78753675 T C 7.90E-05 Relative hand skill / / 24068947 rs2144169 chr6 78761382 C G 7.90E-05 Relative hand skill / / 24068947 rs2150822 chr6 78766809 G A 8.02E-05 Relative hand skill / / 24068947 rs1331789 chr6 78767855 T A 8.08E-05 Relative hand skill / / 24068947 rs12524999 chr6 78769197 T A,C 8.87E-05 Relative hand skill / / 24068947 rs944579 chr6 78772661 G A 8.27E-05 Relative hand skill / / 24068947 rs7746269 chr6 78786978 A G 9.26E-05 Relative hand skill / / 24068947 rs2210391 chr6 78789277 C T 9.27E-05 Relative hand skill / / 24068947 rs9443509 chr6 78789877 G T 9.28E-05 Relative hand skill / / 24068947 rs1331809 chr6 78797141 G A 9.31E-05 Relative hand skill / / 24068947 rs9448288 chr6 78798865 C T 9.43E-05 Relative hand skill / / 24068947 rs9448292 chr6 78811692 G T 8.82E-04 Multiple complex diseases / / 17554300 rs9294101 chr6 78832557 G A 3.83E-04 Multiple complex diseases / / 17554300 rs9294101 chr6 78832557 G A 4.51E-04 Myocardial Infarction / / pha002873 rs7775561 chr6 78833101 A G 8.31E-04 HIV-1 viral setpoint / / 17641165 rs9352565 chr6 78834120 A T 3.18E-04 Multiple complex diseases / / 17554300 rs9352566 chr6 78834161 A G 9.27E-04 Multiple complex diseases / / 17554300 rs7763627 chr6 78834453 T C 2.37E-04 Multiple complex diseases / / 17554300 rs6454038 chr6 78835789 T C 7.90E-04 HIV-1 viral setpoint / / 17641165 rs6914630 chr6 78840944 C G 4.74E-04 Multiple complex diseases / / 17554300 rs12212103 chr6 78867891 C T 6.04E-04 Multiple complex diseases / / 17554300 rs9361377 chr6 78868438 A G 2.58E-04 Multiple complex diseases / / 17554300 rs9343745 chr6 78874114 C T 2.01E-05 Relative hand skill / / 24068947 rs9343746 chr6 78874656 C A 2.01E-05 Relative hand skill / / 24068947 rs4706690 chr6 78875167 T C 3.10E-05 Relative hand skill / / 24068947 rs9359321 chr6 78875660 C G 2.04E-05 Relative hand skill / / 24068947 rs6920828 chr6 78879490 A G 1.12E-04 Multiple complex diseases / / 17554300 rs4129963 chr6 78882209 G A 4.46E-05 Relative hand skill / / 24068947 rs1933510 chr6 78906675 A C 5.00E-05 Personality dimensions / / 18957941 rs2050689 chr6 78934100 C T 5.04E-04 Type 2 diabetes / / 17463246 rs9448335 chr6 78934437 T C 9.69E-04 Type 2 diabetes / / 17463246 rs946138 chr6 78944894 G A 6.99E-04 Type 2 diabetes / / 17463246 rs5004383 chr6 78954412 T C 9.01E-04 Acute lung injury / / 22295056 rs7741242 chr6 78955138 T G 9.01E-04 Acute lung injury / / 22295056 rs9448340 chr6 78955473 C T 9.01E-04 Acute lung injury / / 22295056 rs17728780 chr6 78962293 C T 8.83E-05 Hypertension (essential hypertension) / / 22184326 rs7751252 chr6 78962626 T C 5.49E-05 Hypertension (essential hypertension) / / 22184326 rs818262 chr6 78979398 T C 1.50E-06 Parkinson's disease (familial) / / 18985386 rs9443553 chr6 79042157 C A 7.46E-05 Information processing speed / / 21130836 rs818314 chr6 79042990 T C 5.42E-05 Information processing speed / / 21130836 rs9361394 chr6 79048526 A G 2.20E-05 Cytomegalovirus antibody response / / 21993531 rs16889893 chr6 79055191 A T 6.38E-04 Multiple complex diseases / / 17554300 rs766797 chr6 79059790 G A 6.34E-04 Multiple complex diseases / / 17554300 rs1452528 chr6 79098360 T C 4.37E-06 Bilirubin levels,in serum / / 19389676 rs236225 chr6 79115935 G C 2.62E-05 Bilirubin levels,in serum / / 19389676 rs12193017 chr6 79141693 A C 1.40E-04 Adiposity / / 19461586 rs12193017 chr6 79141693 A C 2.80E-05 Adiposity / / 19461586 rs7738834 chr6 79158987 C A 3.47E-04 Schizophrenia / / 21674006 rs11970012 chr6 79185919 A T 6.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs10943541 chr6 79190083 T C 6.06E-04 Multiple complex diseases / / 17554300 rs1474755 chr6 79190209 T C 7.04E-04 HIV-1 viral setpoint / / 17641165 rs4632856 chr6 79212957 G A 8.14E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4706060 chr6 79232161 C T 7.73E-04 Multiple complex diseases / / 17554300 rs6414995 chr6 79238604 A G 6.52E-04 HIV-1 viral setpoint / / 17641165 rs1395451 chr6 79272439 T G 5.84E-05 Body Mass Index / / pha003021 rs16890184 chr6 79300379 C T 6.00E-04 Multiple complex diseases / / 17554300 rs12191138 chr6 79341123 G C 4.96E-04 Multiple complex diseases / / 17554300 rs12530352 chr6 79369972 G A 8.08E-04 Multiple complex diseases / / 17554300 rs10485129 chr6 79371183 G A 4.89E-04 Diabetic retinopathy / / 20871662 rs16890254 chr6 79378422 G T 1.65E-07 Blood pressure measurement (high sodium intervention) / / 24165912 rs16890254 chr6 79378422 G T 3.81E-05 Blood pressure measurement (high sodium intervention) / / 24165912 rs17235125 chr6 79380836 A G 8.00E-05 Type 2 diabetes / / 17463248 rs17235167 chr6 79380895 C G 7.80E-05 Type 2 diabetes / / 17463248 rs17235209 chr6 79380917 C T 7.60E-05 Type 2 diabetes / / 17463248 rs17826801 chr6 79381022 A G 7.80E-05 Type 2 diabetes / / 17463248 rs1938551 chr6 79385469 C T 2.00E-05 Biomarkers / / 17903293 rs631308 chr6 79399775 C T 3.70E-05 Multiple complex diseases / / 17554300 rs496269 chr6 79400375 T C 1.05E-04 Multiple complex diseases / / 17554300 rs496269 chr6 79400375 T C 9.40E-06 Biomarkers / / 17903293 rs237109 chr6 79414694 T A 1.27E-04 Multiple complex diseases / / 17554300 rs1180825 chr6 79433850 G T 4.28E-07 Facial morphology / / 22341974 rs2321769 chr6 79437960 G T 4.27E-07 Facial morphology / / 22341974 rs7740607 chr6 79441290 C T 4.28E-07 Facial morphology / / 22341974 rs9448542 chr6 79444365 C A 4.29E-07 Facial morphology / / 22341974 rs7743640 chr6 79454075 A G 4.29E-07 Facial morphology / / 22341974 rs9352627 chr6 79455586 T C 4.29E-07 Facial morphology / / 22341974 rs9359343 chr6 79456731 G A 4.28E-07 Facial morphology / / 22341974 rs9352628 chr6 79457447 T G 4.28E-07 Facial morphology / / 22341974 rs3918524 chr6 79459097 G A 4.28E-07 Facial morphology / / 22341974 rs9350774 chr6 79461603 A G 4.27E-07 Facial morphology / / 22341974 rs9350776 chr6 79463845 A G 4.27E-07 Facial morphology / / 22341974 rs2321772 chr6 79476190 T G 4.31E-07 Facial morphology / / 22341974 rs6454082 chr6 79487282 T C 2.15E-04 Multiple complex diseases / / 17554300 rs570982868 chr6 79497569 A AG 1.85E-05 Orofacial clefts / / 20023658 rs9343824 chr6 79497569 A G 1.85E-05 Orofacial clefts / / 20023658 rs906319 chr6 79520689 A G 4.74E-04 Multiple complex diseases / / 17554300 rs6454088 chr6 79537679 T C 6.39E-04 Multiple complex diseases / / 17554300 rs16890330 chr6 79546204 A C 2.12E-12 Multiple complex diseases / / 17554300 rs1507150 chr6 79548597 T A 4.50E-04 Multiple complex diseases / / 17554300 rs16890334 chr6 79556166 T C 1.00E-10 Blood pressure measurement (high sodium and potassium intervention) / / 24165912 rs16890334 chr6 79556166 T C 1.13E-05 Blood pressure measurement (low sodium intervention) / / 24165912 rs16890334 chr6 79556166 T C 2.00E-06 Blood pressure measurement (high sodium intervention) / / 24165912 rs16890334 chr6 79556166 T C 2.00E-07 Blood pressure measurement (low sodium intervention) / / 24165912 rs16890334 chr6 79556166 T C 4.00E-09 Blood pressure measurement (high sodium intervention) / / 24165912 rs16890334 chr6 79556166 T C 5.00E-07 Blood pressure measurement (high sodium and potassium intervention) / / 24165912 rs16890334 chr6 79556166 T C 5.02E-04 Blood pressure measurement (high sodium and potassium intervention) / / 24165912 rs16890334 chr6 79556166 T C 8.43E-04 Blood pressure measurement (high sodium intervention) / / 24165912 rs12209235 chr6 79688366 T C 1.70E-05 Iron levels PHIP cds-synon 21208937 rs9359363 chr6 79746891 C T 2.62E-04 Multiple complex diseases PHIP intron 17554300 rs7744876 chr6 79783037 G A 1.10E-06 Multiple complex diseases PHIP intron 17554300 rs1577792 chr6 79886077 A G 9.60E-06 Osteoarthritis (hip) / / 23989986 rs3920792 chr6 79901340 C T 1.20E-05 Urinary metabolites / / 21572414 rs9352704 chr6 79910318 T C 9.96E-04 Alcohol dependence / / 21314694 rs9343884 chr6 79922278 C A 4.61E-04 Lung function (forced vital capacity) HMGN3 intron 24023788 rs4706756 chr6 79935629 A G 1.34E-04 Multiple complex diseases HMGN3 intron 17554300 rs1335539 chr6 79979365 G A 4.14E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs4706769 chr6 80020537 T C 2.69E-04 Coronary Artery Disease / / 17634449 rs4706776 chr6 80054021 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4706778 chr6 80065225 G A 4.50E-06 Phospholipid levels (plasma) / / 21829377 rs9294142 chr6 80066239 G T 9.27E-05 Multiple complex diseases / / 17554300 rs2038297 chr6 80081376 C T 9.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs725750 chr6 80082927 C T 9.42E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7773764 chr6 80107104 C T 5.69E-05 Coronary heart disease / / 21971053 rs17743190 chr6 80107679 C T 7.65E-04 Type 2 diabetes / / 17463246 rs11754426 chr6 80109143 T C 9.29E-06 Glaucoma (primary open-angle) / / 22605921 rs9294143 chr6 80111104 C T 2.00E-04 Information processing speed / / 21130836 rs196670 chr6 80113595 G A 3.00E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs196676 chr6 80115863 T C 3.05E-04 Type 2 diabetes / / 17463246 rs196676 chr6 80115863 T C 1.66E-04 Coronary heart disease / / 21971053 rs10484943 chr6 80124758 G A 6.52E-04 Type 2 diabetes / / 17463246 rs3843505 chr6 80126245 C T 2.49E-04 Coronary heart disease / / 21971053 rs196686 chr6 80129933 A C 3.21E-04 Coronary heart disease LOC100506851 nearGene-5 21971053 rs3846739 chr6 80136466 A G 4.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs10498920 chr6 80143500 G A 2.68E-04 Type 2 diabetes / / 17846124 rs9294146 chr6 80147506 C T 4.51E-04 Type 2 diabetes / / 17846124 rs12204683 chr6 80156259 C T 7.00E-06 Presence of antiphospholipid antibodies / / 23509613 rs9448722 chr6 80168035 C G 3.68E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs3747767 chr6 80257281 C A 7.00E-07 Hoarding / / 21302353 rs12204955 chr6 80297314 A G 2.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1394289 chr6 80311361 T C 7.90E-04 Alcohol dependence / / 20201924 rs1062793 chr6 80411396 A G 2.80E-05 Attention deficit hyperactivity disorder / / pha002875 rs9352760 chr6 80441913 G A 8.64E-04 Tourette syndrome / / 22889924 rs9352760 chr6 80441913 G A 2.26E-04 Alcohol dependence / / 24277619 rs2057155 chr6 80448393 A C 8.62E-04 HIV-1 viral setpoint / / 17641165 rs6925255 chr6 80466124 A G 1.00E-06 Aging / / 22773346 rs6925597 chr6 80466264 A G 2.20E-05 Urinary metabolites / / 21572414 rs9341793 chr6 80495689 C A 9.51E-05 Serum albumin level / / pha003084 rs12527733 chr6 80512054 T G 6.42E-04 Parkinson's disease / / 16252231 rs9448824 chr6 80512765 G T 4.25E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs10806179 chr6 80527555 A C 2.75E-05 Major depressive disorder C6orf7 intron 20516156 rs1321847 chr6 80533187 A G 2.00E-06 Body mass index C6orf7 intron 23669352 rs1321838 chr6 80538489 T A 1.98E-04 Response to platinum-based chemotherapy in small-cell lung cancer C6orf7 intron 20463552 rs10755388 chr6 80540728 G C 4.70E-05 Response to platinum-based chemotherapy in small-cell lung cancer C6orf7 intron 20463552 rs9343942 chr6 80542904 A G 2.94E-04 Response to platinum-based chemotherapy in small-cell lung cancer C6orf7 intron 20463552 rs4706803 chr6 80562589 A G 1.00E-04 Prostate cancer C6orf7 intron 21743057 rs9341799 chr6 80564519 T C 4.82E-07 Partial epilepsies C6orf7 intron 20522523 rs9341799 chr6 80564519 T C 2.08E-06 Epilepsy C6orf7 intron 22116939 rs9341799 chr6 80564519 T C 7.18E-05 Hepatocellular carcinoma C6orf7 intron 22807686 rs346291 chr6 80564836 C T 3.00E-07 Partial epilepsies C6orf7 intron 20522523 rs346291 chr6 80564836 C T 2.51E-06 Epilepsy C6orf7 intron 22116939 rs1120229 chr6 80597212 C T 2.23E-05 Partial epilepsies / / 20522523 rs16891209 chr6 80604428 C A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10943676 chr6 80606507 G T 4.20E-04 Response to antidepressants / / 19736353 rs4706814 chr6 80610573 T C 9.45E-05 Personality dimensions / / 18957941 rs2164166 chr6 80610839 G A 9.45E-05 Personality dimensions / / 18957941 rs1887571 chr6 80611616 G A 7.76E-05 Body Mass Index / / pha003015 rs12528948 chr6 80724666 C T 3.56E-05 Erythrocyte counts TTK intron pha003090 rs9341802 chr6 80731675 A G 0.000706167 Hypertension (early onset hypertension) TTK intron 22479346 rs608962 chr6 80750290 C T 3.60E-20 Leukemia(T-cell recognition in patients) TTK intron 21062987 rs3828761 chr6 80777467 C T 9.16E-05 Erythrocyte counts / / pha003090 rs9448881 chr6 80786375 A G 7.29E-05 Erythrocyte counts / / pha003090 rs12526331 chr6 80796148 A G 3.71E-05 Erythrocyte counts / / pha003090 rs12529764 chr6 80796581 C T 2.11E-05 Erythrocyte counts / / pha003090 rs7453746 chr6 80810013 T G 7.10E-05 Alcohol dependence / / 20201924 rs7453746 chr6 80810013 T G 7.90E-06 Alcohol dependence / / 20201924 rs7453746 chr6 80810013 T G 7.12E-05 Alcoholism / / pha002892 rs7453746 chr6 80810013 T G 7.86E-06 Alcoholism / / pha002893 rs2490232 chr6 80814802 T C 4.07E-04 Multiple complex diseases BCKDHB nearGene-5 17554300 rs2298307 chr6 80816296 T C 1.20E-04 Alcohol dependence BCKDHB nearGene-5 20201924 rs2298307 chr6 80816296 T C 1.20E-04 Alcohol dependence BCKDHB nearGene-5 20201924 rs4437429 chr6 80828592 A G 1.00E-05 Alcohol dependence BCKDHB intron 20201924 rs4437429 chr6 80828592 A G 4.30E-06 Alcohol dependence BCKDHB intron 20201924 rs4437429 chr6 80828592 A G 1.00E-05 Alcoholism BCKDHB intron pha002892 rs4437429 chr6 80828592 A G 4.34E-06 Alcoholism BCKDHB intron pha002893 rs9448894 chr6 80837253 G A,C,T 7.10E-05 Alcohol dependence BCKDHB intron 20201924 rs9448894 chr6 80837253 G A,C,T 7.30E-05 Alcohol dependence BCKDHB intron 20201924 rs9448894 chr6 80837253 G A,C,T 7.28E-05 Alcoholism BCKDHB intron pha002892 rs9448894 chr6 80837253 G A,C,T 7.14E-05 Alcoholism BCKDHB intron pha002893 rs4706113 chr6 80839315 C T 7.10E-05 Alcohol dependence BCKDHB intron 20201924 rs4706113 chr6 80839315 C T 7.30E-05 Alcohol dependence BCKDHB intron 20201924 rs4706113 chr6 80839315 C T 7.28E-05 Alcoholism BCKDHB intron pha002892 rs4706113 chr6 80839315 C T 7.14E-05 Alcoholism BCKDHB intron pha002893 rs2322631 chr6 80843956 A C 4.10E-06 Alcohol dependence BCKDHB intron 20201924 rs2322631 chr6 80843956 A C 9.70E-06 Alcohol dependence BCKDHB intron 20201924 rs2322631 chr6 80843956 A C 1.14E-04 Vaspin levels BCKDHB intron 22907691 rs2322631 chr6 80843956 A C 0.0001139 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks BCKDHB intron 22907730 rs2322631 chr6 80843956 A C 9.67E-06 Alcoholism BCKDHB intron pha002892 rs2322631 chr6 80843956 A C 4.13E-06 Alcoholism BCKDHB intron pha002893 rs2322633 chr6 80845989 T C 1.20E-04 Alcohol dependence BCKDHB intron 20201924 rs2322633 chr6 80845989 T C 1.40E-04 Alcohol dependence BCKDHB intron 20201924 rs2322633 chr6 80845989 T C 3.00E-09 Height BCKDHB intron 23563607 rs10080237 chr6 80854470 T C 4.10E-06 Alcohol dependence BCKDHB intron 20201924 rs10080237 chr6 80854470 T C 9.70E-06 Alcohol dependence BCKDHB intron 20201924 rs10080237 chr6 80854470 T C 1.14E-04 Vaspin levels BCKDHB intron 22907691 rs10080237 chr6 80854470 T C 0.0001139 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks BCKDHB intron 22907730 rs10080237 chr6 80854470 T C 9.67E-06 Alcoholism BCKDHB intron pha002892 rs10080237 chr6 80854470 T C 4.13E-06 Alcoholism BCKDHB intron pha002893 rs942381 chr6 80880150 T G 1.20E-04 Alcohol dependence BCKDHB intron 20201924 rs942381 chr6 80880150 T G 1.50E-04 Alcohol dependence BCKDHB intron 20201924 rs9343974 chr6 80924645 A G 1.40E-04 Alcohol dependence BCKDHB intron 20201924 rs9343974 chr6 80924645 A G 1.50E-04 Alcohol dependence BCKDHB intron 20201924 rs600843 chr6 80952028 C T 4.86E-04 White matter integrity BCKDHB intron 22425255 rs806781 chr6 80958915 T C 9.48E-04 Multiple complex diseases BCKDHB intron 17554300 rs978814 chr6 80959912 C A 1.90E-05 Alcohol dependence BCKDHB intron 20201924 rs978814 chr6 80959912 C A 3.00E-05 Alcohol dependence BCKDHB intron 20201924 rs978814 chr6 80959912 C A 3.82E-05 Vaspin levels BCKDHB intron 22907691 rs978814 chr6 80959912 C A 0.0000382 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks BCKDHB intron 22907730 rs978814 chr6 80959912 C A 0.0002081 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit BCKDHB intron 22907730 rs978814 chr6 80959912 C A 3.03E-05 Alcoholism BCKDHB intron pha002892 rs978814 chr6 80959912 C A 1.91E-05 Alcoholism BCKDHB intron pha002893 rs590641 chr6 80966483 C T 4.08E-05 Calcium levels BCKDHB intron pha003085 rs9343977 chr6 80967001 C T 2.80E-04 Alcohol dependence BCKDHB intron 20201924 rs9343977 chr6 80967001 C T 3.60E-04 Alcohol dependence BCKDHB intron 20201924 rs3812121 chr6 80968727 A G 2.10E-05 Alcohol dependence BCKDHB intron 20201924 rs3812121 chr6 80968727 A G 4.00E-05 Alcohol dependence BCKDHB intron 20201924 rs3812121 chr6 80968727 A G 4.94E-05 Vaspin levels BCKDHB intron 22907691 rs3812121 chr6 80968727 A G 0.0000494 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks BCKDHB intron 22907730 rs3812121 chr6 80968727 A G 4.03E-05 Alcoholism BCKDHB intron pha002892 rs3812121 chr6 80968727 A G 2.07E-05 Alcoholism BCKDHB intron pha002893 rs16891609 chr6 80978104 G C 4.35E-04 Multiple complex diseases BCKDHB intron 17554300 rs2179842 chr6 80979053 T C 2.60E-05 Alcohol dependence BCKDHB intron 20201924 rs2179842 chr6 80979053 T C 3.50E-05 Alcohol dependence BCKDHB intron 20201924 rs2179842 chr6 80979053 T C 3.51E-05 Alcoholism BCKDHB intron pha002892 rs2179842 chr6 80979053 T C 2.61E-05 Alcoholism BCKDHB intron pha002893 rs16891629 chr6 80983354 A C 1.80E-05 Urinary metabolites BCKDHB intron 21572414 rs627240 chr6 80985885 C A 0.0000904 Uterine leiomyomata BCKDHB intron 23040493 rs676311 chr6 80989750 T G 5.78E-04 White matter integrity BCKDHB intron 22425255 rs4706834 chr6 81012605 G T 1.20E-04 Alcohol dependence BCKDHB intron 20201924 rs4706834 chr6 81012605 G T 1.50E-04 Alcohol dependence BCKDHB intron 20201924 rs9352817 chr6 81025879 T G 8.20E-05 Alcohol dependence BCKDHB intron 20201924 rs9352817 chr6 81025879 T G 8.90E-05 Alcohol dependence BCKDHB intron 20201924 rs9352817 chr6 81025879 T G 6.70E-05 Vaspin levels BCKDHB intron 22907691 rs9352817 chr6 81025879 T G 0.000067 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks BCKDHB intron 22907730 rs9352817 chr6 81025879 T G 8.91E-05 Alcoholism BCKDHB intron pha002892 rs9352817 chr6 81025879 T G 8.23E-05 Alcoholism BCKDHB intron pha002893 rs806851 chr6 81030831 T G 3.05E-04 White matter integrity BCKDHB intron 22425255 rs806846 chr6 81034777 G A 3.10E-04 Type 2 diabetes BCKDHB intron 17463246 rs1341278 chr6 81038921 T G 3.21E-04 Obesity (extreme) BCKDHB intron 21935397 rs10455370 chr6 81040867 C T 7.70E-04 Alcohol dependence BCKDHB intron 20201924 rs9352828 chr6 81059998 T A 9.97E-04 Obesity (extreme) / / 21935397 rs1595245 chr6 81087676 A G 3.76E-04 Multiple complex diseases / / 17554300 rs9344001 chr6 81136301 G C 8.20E-04 Obesity (extreme) / / 21935397 rs536598 chr6 81156003 A G 5.83E-04 Multiple complex diseases / / 17554300 rs12207977 chr6 81228174 T C 7.89E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs16891947 chr6 81237839 G A 8.98E-04 Multiple complex diseases / / 17554300 rs6907126 chr6 81239298 T A 8.36E-04 Multiple complex diseases / / 17554300 rs4706121 chr6 81246170 C A 9.68E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs10943724 chr6 81302805 C A 7.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs10943725 chr6 81302983 A T 7.19E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs10943726 chr6 81303910 G T 7.20E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs10943727 chr6 81305244 T A 0.00000662 HDL cholesterol particle diameter / / 23263444 rs1840334 chr6 81306495 T C 0.00000641 HDL cholesterol particle diameter / / 23263444 rs6926124 chr6 81309680 C A 0.00000623 HDL cholesterol particle diameter / / 23263444 rs10943730 chr6 81313494 T C 6.38E-04 Alzheimer's disease / / 17998437 rs13207647 chr6 81314168 C T 0.000015 HDL cholesterol particle diameter / / 23263444 rs9443804 chr6 81315597 A G 9.22E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2061040 chr6 81318355 G T 0.0000137 HDL cholesterol particle diameter / / 23263444 rs2444796 chr6 81332877 A G 7.20E-05 Malaria / / 19465909 rs2444831 chr6 81340865 T C 5.30E-05 Multiple complex diseases / / 17554300 rs9294177 chr6 81352515 T C 5.80E-04 Type 2 diabetes / / 17463246 rs3937697 chr6 81374150 G C 7.94E-04 Multiple complex diseases / / 17554300 rs16892113 chr6 81374182 G T 5.32E-04 Multiple complex diseases / / 17554300 rs1454460 chr6 81380133 A T 4.90E-04 Multiple complex diseases / / 17554300 rs6920092 chr6 81387426 T C 2.39E-04 Multiple complex diseases / / 17554300 rs1454455 chr6 81388499 T C 3.42E-04 Multiple complex diseases / / 17554300 rs7757271 chr6 81417782 T C 2.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs985737 chr6 81428748 A C 2.08E-05 Personality dimensions / / 18957941 rs1339377 chr6 81447367 C T 8.43E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12664845 chr6 81466059 T C 5.28E-04 Alzheimer's disease / / 24755620 rs13201732 chr6 81473184 C G 8.32E-06 Crohn's disease / / 17804789 rs10485285 chr6 81478607 G A 6.75E-05 Vaspin levels / / 22907691 rs10485285 chr6 81478607 G A 0.0000675 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs6902257 chr6 81481354 G A 7.00E-06 Obesity-related traits / / 23251661 rs16892247 chr6 81482659 A G 5.45E-04 Alzheimer's disease / / 24755620 rs35052062 chr6 81500133 C A 5.08E-04 Alzheimer's disease / / 24755620 rs1416641 chr6 81504236 A G 5.15E-04 Alzheimer's disease / / 24755620 rs13213247 chr6 81516036 A C 2.40E-05 Alzheimer's disease (late onset) / / 21460841 rs13213247 chr6 81516036 A C 5.09E-04 Alzheimer's disease / / 24755620 rs10485282 chr6 81547853 A G 7.88E-04 Alzheimer's disease / / 24755620 rs534800 chr6 81648445 A G 2.02E-04 Vaspin levels / / 22907691 rs534800 chr6 81648445 A G 0.0002016 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs9294187 chr6 81670272 A G 3.18E-05 Bilirubin levels,in serum / / 19389676 rs10485279 chr6 81672097 A T 1.90E-05 Bilirubin levels,in serum / / 19389676 rs11969591 chr6 81682916 T C 8.32E-04 Type 2 diabetes / / 17463246 rs9361709 chr6 81704749 T C 5.57E-04 Type 2 diabetes / / 17463246 rs310405 chr6 81800362 G A 2.00E-13 Height / / 20881960 rs310405 chr6 81800362 G A 1.00E-10 Height / / 23563607 rs9344121 chr6 81902287 T G 9.30E-05 Allergic sensitization / / 23817571 rs9361786 chr6 82007541 G A 8.88E-05 Cognitive decline / / 22054870 rs10455382 chr6 82020990 G T 0.000094 Asthma / / 22607992 rs962983 chr6 82064465 C T 2.56E-05 Reading and spelling / / 23738518 rs1343255 chr6 82065819 C G 2.56E-05 Reading and spelling / / 23738518 rs1343252 chr6 82067893 C T 2.56E-05 Reading and spelling / / 23738518 rs9344163 chr6 82068407 T C 9.85E-06 Reading and spelling / / 23738518 rs9352999 chr6 82068775 A C 9.85E-06 Reading and spelling / / 23738518 rs1343250 chr6 82069574 T C 2.56E-05 Reading and spelling / / 23738518 rs915169 chr6 82071151 C G 2.56E-05 Reading and spelling / / 23738518 rs6935610 chr6 82071645 G A 2.56E-05 Reading and spelling / / 23738518 rs4706889 chr6 82072436 A G 0.00064 Asthma / / 22607992 rs1015917 chr6 82072900 T G 2.65E-05 Reading and spelling / / 23738518 rs9341883 chr6 82091661 T G 0.00048 Asthma / / 22607992 rs2120535 chr6 82093262 G A 3.94E-04 Insulin resistance / / 21901158 rs2323252 chr6 82099191 A C 0.00035 Asthma / / 22607992 rs9359489 chr6 82120647 T C 1.00E-04 Information processing speed / / 21130836 rs724931 chr6 82129371 C T 1.30E-05 Urinary metabolites / / 21572414 rs1343232 chr6 82130332 A G 3.82E-05 Height / / pha003010 rs16893155 chr6 82155864 T A 1.38E-05 Height / / 22021425 rs17530068 chr6 82193109 T C 3.00E-07 Breast cancer / / 22976474 rs17530068 chr6 82193109 T C 8.00E-09 Breast cancer / / 23535729 rs17530068 chr6 82193109 T C 3.00E-06 Breast cancer / / 23535733 rs6924906 chr6 82220552 T C 6.00E-07 Blood pressure / / 23972371 rs6924906 chr6 82220552 T C 6.20E-05 Blood pressure / / 23972371 rs1361549 chr6 82287685 G A 0.00000187 Asthma / / 22607992 rs1361549 chr6 82287685 G A 5.24E-05 Asthma / / pha003128 rs2323435 chr6 82308619 T C 5.06E-05 Varicose Veins / / pha001411 rs16893251 chr6 82319418 T C 2.77E-05 Type 2 diabetes / / 17463246 rs16893263 chr6 82321973 T C 7.46E-04 Type 2 diabetes / / 17463246 rs16893284 chr6 82331106 A C 4.99E-04 Type 2 diabetes / / 17463246 rs1341219 chr6 82342007 T A 9.67E-04 Multiple complex diseases / / 17554300 rs4706902 chr6 82344812 T A 6.57E-04 Type 2 diabetes / / 17463246 rs16893308 chr6 82357304 T C 6.84E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10943829 chr6 82399911 A G 1.74E-04 Multiple complex diseases / / 17554300 rs10943829 chr6 82399911 A G 1.06E-04 Coronary heart disease / / 21606135 rs194877 chr6 82406877 T C 6.43E-05 Coronary heart disease / / 21606135 rs6911841 chr6 82417140 G A 4.58E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs194933 chr6 82441337 T C 2.85E-05 Heart Rate / / pha003051 rs194941 chr6 82442277 T G 9.40E-06 Urinary metabolites / / 21572414 rs915125 chr6 82463376 C T 6.39E-04 Coronary heart disease / / 21606135 rs9361858 chr6 82464216 T G 1.07E-05 Coronary heart disease / / 21606135 rs1034241 chr6 82473953 T A 8.43E-04 Coronary heart disease / / 21606135 rs194636 chr6 82488988 T C 8.33E-04 Type 2 diabetes / / 17463246 rs194615 chr6 82496434 T C 8.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs16893523 chr6 82504179 G A 2.99E-04 Coronary heart disease / / 21606135 rs16893526 chr6 82515315 G A 5.00E-06 Coronary heart disease / / 21606135 rs999567 chr6 82522971 T C 2.49E-05 Breast cancer / / 24143190 rs194601 chr6 82524209 G A 3.45E-05 Blood Pressure / / pha003044 rs9344225 chr6 82524543 G C 3.55E-04 Coronary heart disease / / 21606135 rs6900421 chr6 82554618 T C 1.01E-04 Multiple complex diseases / / 17554300 rs12663436 chr6 82564601 G A 2.43E-05 Blood Pressure LOC100506867 intron pha003044 rs13197670 chr6 82569884 G C 1.98E-04 Coronary heart disease LOC100506867 intron 21606135 rs9361866 chr6 82592568 T G 5.30E-06 Urinary metabolites LOC100506867 intron 21572414 rs9361874 chr6 82610327 G A 6.70E-07 Urinary metabolites LOC100506867 intron 21572414 rs885582 chr6 82612197 T C 1.40E-05 Urinary metabolites LOC100506867 intron 21572414 rs4613862 chr6 82612271 A C 0.0000017 Coronary artery disease LOC100506867 intron 23202125 rs1931619 chr6 82625669 G A 1.00E-04 Kidney function and endocine traits LOC100506867 intron 17903292 rs9294239 chr6 82637934 C T 2.35E-05 Osteoarthritis (knee and hip) LOC100506867 intron 21177295 rs9294239 chr6 82637934 C T 2.53E-05 Osteoarthritis (knee and hip) LOC100506867 intron 21177295 rs9294240 chr6 82647162 C T 5.35E-05 Osteoarthritis (knee and hip) LOC100506867 intron 21177295 rs9294240 chr6 82647162 C T 5.99E-05 Osteoarthritis (knee and hip) LOC100506867 intron 21177295 rs9449384 chr6 82670520 C T 2.19E-06 Osteoarthritis / / 22763110 rs10806234 chr6 82685299 A G 9.92E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12525526 chr6 82686159 T C 9.92E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs16893747 chr6 82726897 C T 8.93E-05 Femoral neck bone geometry / / 22087292 rs16893762 chr6 82728686 T A 1.30E-04 Acute lymphoblastic leukemia (childhood) / / 22076464 rs1538138 chr6 82794594 T C 1.00E-12 Corneal structure / / 23291589 rs9443958 chr6 82828838 C T 9.77E-04 Alcohol dependence / / 21314694 rs13208556 chr6 82831311 C T 1.95E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs117339193 chr6 82870318 T C 0.0000307 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9449444 chr6 82900811 G A 2.09E-05 Coronary heart disease IBTK missense pha003031 rs4706937 chr6 82908034 C T 9.86E-04 Bipolar disorder IBTK intron 19259986 rs2273194 chr6 82927491 C T 1.54E-05 Coronary heart disease IBTK intron pha003031 rs9361904 chr6 82933309 C T 0.0000795 post-traumatic stress disorder IBTK cds-synon 22869035 rs9361904 chr6 82933309 C T 7.95E-05 Schizophrenia IBTK cds-synon 22883433 rs9361904 chr6 82933309 C T 1.54E-05 Coronary heart disease IBTK cds-synon pha003031 rs6939987 chr6 82946661 G A 1.54E-05 Coronary heart disease IBTK intron pha003031 rs9294253 chr6 82950899 C T 6.21E-05 Coronary heart disease IBTK intron pha003031 rs9344262 chr6 82954394 C T 9.77E-05 Coronary heart disease IBTK intron pha003031 rs473472 chr6 82962125 T C 1.31E-05 Coronary heart disease / / pha003031 rs507500 chr6 83010602 C T 8.93E-05 Cognitive impairment induced by topiramate / / 22091778 rs507500 chr6 83010602 C T 9.00E-04 Cardiovascular heart disease in diabetics / / 23982368 rs6454267 chr6 83041140 A G 3.31E-05 Multiple sclerosis (age of onset) / / 19010793 rs6907015 chr6 83041610 A T 1.50E-05 Urinary metabolites / / 21572414 rs6930014 chr6 83041633 T C 1.50E-05 Urinary metabolites / / 21572414 rs9361923 chr6 83115610 G A 3.00E-04 Cardiovascular heart disease in diabetics / / 23982368 rs927253 chr6 83203074 G T 3.03E-04 Body mass index / / 21701565 rs9361928 chr6 83204071 C T 2.37E-04 Heart Failure / / pha002885 rs9344283 chr6 83204488 T C 4.83E-04 Body mass index / / 21701565 rs9361930 chr6 83217056 C T 2.65E-04 Body mass index / / 17255346 rs9361930 chr6 83217056 C T 1.09E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs9361930 chr6 83217056 C T 7.79E-04 Heart Failure / / pha002885 rs2917468 chr6 83238771 C T 7.59E-04 Type 2 diabetes / / 17463246 rs3011881 chr6 83242302 C A 7.59E-04 Type 2 diabetes / / 17463246 rs9449500 chr6 83281761 T G 5.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs16885899 chr6 83282692 G A 5.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs9361943 chr6 83285055 A G 4.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs6904410 chr6 83285700 T C 4.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs9443987 chr6 83289789 T C 5.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs1999411 chr6 83292182 C T 5.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs1999412 chr6 83292274 A C 5.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs6939695 chr6 83292939 A C 5.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs7758218 chr6 83297452 A G 6.66E-05 Blood Pressure / / pha003045 rs1369869 chr6 83366282 C T 1.29E-05 Body Mass Index / / pha003009 rs1369869 chr6 83366282 C T 9.95E-06 Height / / pha003010 rs1369869 chr6 83366282 C T 3.03E-06 Height / / pha003011 rs1369869 chr6 83366282 C T 1.07E-05 Weight / / pha003027 rs10498930 chr6 83366352 T C 7.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1473879 chr6 83368897 T G 7.30E-05 Height / / pha003011 rs376096 chr6 83370452 T C 4.04E-05 Alcohol and nictotine co-dependence / / 20158304 rs1318150 chr6 83372325 G A 1.19E-05 Body Mass Index / / pha003009 rs1318150 chr6 83372325 G A 1.89E-05 Height / / pha003010 rs1318150 chr6 83372325 G A 1.32E-06 Height / / pha003011 rs1318150 chr6 83372325 G A 2.53E-05 Weight / / pha003027 rs992014 chr6 83380203 A C 8.23E-06 Body Mass Index / / pha003009 rs992014 chr6 83380203 A C 2.94E-05 Height / / pha003010 rs992014 chr6 83380203 A C 2.55E-06 Height / / pha003011 rs992014 chr6 83380203 A C 1.06E-05 Weight / / pha003027 rs1369867 chr6 83385150 C T 2.06E-05 Body Mass Index / / pha003009 rs1369867 chr6 83385150 C T 6.76E-07 Height / / pha003010 rs1369867 chr6 83385150 C T 1.18E-07 Height / / pha003011 rs1369867 chr6 83385150 C T 1.45E-05 Weight / / pha003027 rs287822 chr6 83397096 C T 8.01E-05 Body Mass Index / / pha003009 rs287822 chr6 83397096 C T 8.15E-05 Height / / pha003011 rs287831 chr6 83401424 A G 1.14E-05 Height / / pha003011 rs2253003 chr6 83423397 C T 7.44E-06 Body Mass Index / / pha003009 rs2253003 chr6 83423397 C T 8.42E-05 Height / / pha003010 rs2253003 chr6 83423397 C T 1.47E-05 Height / / pha003011 rs2253003 chr6 83423397 C T 8.28E-06 Weight / / pha003027 rs7770091 chr6 83440724 G A 1.42E-04 Alzheimer's disease (late onset) / / 21460841 rs1412166 chr6 83442261 T C 1.45E-04 Alzheimer's disease (late onset) / / 21460841 rs6901940 chr6 83454538 G A 7.40E-05 Coffee consumption / / 21357676 rs10498934 chr6 83459847 A G 2.00E-04 Type 2 diabetes / / 17846126 rs1040046 chr6 83473573 C A 9.50E-04 Heart Failure / / pha002885 rs1040046 chr6 83473573 C A 2.71E-05 Coronary heart disease / / pha003030 rs700496 chr6 83483355 C G 6.38E-04 Multiple complex diseases / / 17554300 rs700496 chr6 83483355 C G 4.63E-04 Non-small cell lung cancer (recurrence rate) / / 24737549 rs700496 chr6 83483355 C G 4.63E-04 Non-small cell lung cancer (recurrence rate) / / 24737549 rs4706172 chr6 83493985 C T 7.72E-04 Multiple complex diseases / / 17554300 rs9359543 chr6 83536070 C T 6.20E-05 Thyroid peroxidase antibody positivity / / 24586183 rs209411 chr6 83541333 C A 2.49E-05 Coronary heart disease / / pha003030 rs176596 chr6 83541486 A G 2.49E-05 Coronary heart disease / / pha003030 rs2783169 chr6 83545840 C A 6.44E-05 Coronary heart disease / / pha003030 rs1932217 chr6 83550056 A G 6.40E-06 Urinary metabolites / / 21572414 rs9294264 chr6 83551624 C T 1.73E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1932215 chr6 83559409 T C 3.35E-06 Coronary heart disease / / pha003030 rs6938924 chr6 83571520 G A 7.40E-06 Urinary metabolites / / 21572414 rs16876998 chr6 83576274 C T 1.30E-05 Multiple complex diseases / / 17554300 rs9688767 chr6 83582258 T C 9.50E-06 Urinary metabolites / / 21572414 rs744436 chr6 83588229 C T 1.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4317380 chr6 83588696 C T 1.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16877440 chr6 83590026 T G 2.30E-05 Urinary metabolites / / 21572414 rs13206195 chr6 83590891 C T 9.60E-07 Glaucoma (primary open-angle) / / 22605921 rs159046 chr6 83591286 A T 4.70E-06 Telomere length / / 23001564 rs159050 chr6 83606157 C G 0.00001 Endometrial cancer UBE3D intron 22426144 rs9294266 chr6 83610065 T G 5.32E-04 Bone mass and geometry UBE3D intron 17903296 rs9444024 chr6 83683593 A G 2.24E-05 Telomere length UBE3D intron 23001564 rs6934537 chr6 83748563 C T 9.13E-04 Alzheimer's disease UBE3D intron 24755620 rs13218698 chr6 83779028 A C 0.0000666 Cognitive impairment (no dementia) DOPEY1 intron 23042215 rs4515348 chr6 83782301 C T 2.00E-04 Information processing speed DOPEY1 intron 21130836 rs4437440 chr6 83795119 A G 7.00E-05 Prostate cancer DOPEY1 intron 21743057 rs9294271 chr6 83803769 G C 7.00E-05 Prostate cancer DOPEY1 intron 21743057 rs7742531 chr6 83808673 A G 7.00E-05 Prostate cancer DOPEY1 intron 21743057 rs13216745 chr6 83845150 T C 6.90E-04 Telomere length DOPEY1 intron 23900074 rs686786 chr6 83890642 T C 5.72E-04 Multiple complex diseases PGM3 intron 17554300 rs474075 chr6 83897565 C T 7.28E-04 Multiple complex diseases PGM3 intron 17554300 rs1180241 chr6 83932070 G A 5.26E-04 Bipolar disorder,schizoaffective ME1 intron 19567891 rs1145909 chr6 84003291 G T 0.0000462 Cognitive impairment (no dementia) ME1 intron 23042215 rs1145908 chr6 84014398 A G 2.68E-04 Alzheimer's disease ME1 intron 17998437 rs10943930 chr6 84060858 T A 8.91E-04 Alzheimer's disease ME1 intron 17998437 rs12529407 chr6 84062581 T C 8.70E-04 Alzheimer's disease ME1 intron 17998437 rs6917851 chr6 84064190 C A 8.39E-04 Alzheimer's disease ME1 intron 17998437 rs6937193 chr6 84095331 C T 8.75E-04 Alzheimer's disease ME1 intron 17998437 rs2152183 chr6 84102879 C A 5.76E-04 Alzheimer's disease ME1 intron 17998437 rs4706990 chr6 84108065 A T 1.41E-04 Alzheimer's disease ME1 intron 17998437 rs7750443 chr6 84112468 T C 7.88E-04 Alzheimer's disease ME1 intron 17998437 rs6935296 chr6 84121294 T A 6.62E-04 Alzheimer's disease ME1 intron 17998437 rs3798889 chr6 84121512 C A 6.98E-04 Alzheimer's disease ME1 intron 17998437 rs3798887 chr6 84121713 C G 7.96E-04 Alzheimer's disease ME1 intron 17998437 rs16885184 chr6 84128786 A C 5.61E-04 Multiple complex diseases ME1 intron 17554300 rs945238 chr6 84165856 C T 2.81E-04 Multiple complex diseases / / 17554300 rs945238 chr6 84165856 C T 5.21E-04 Alzheimer's disease / / 17998437 rs945238 chr6 84165856 C T 5.89E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6454329 chr6 84171532 A T 7.98E-04 Alzheimer's disease / / 17998437 rs9444075 chr6 84171930 A G 4.34E-04 Alzheimer's disease / / 17998437 rs13196054 chr6 84174943 A G 2.96E-04 Bipolar disorder,schizoaffective / / 19567891 rs6454330 chr6 84175552 A C 2.09E-04 Bipolar disorder,schizoaffective / / 19567891 rs13201274 chr6 84176481 G A 2.33E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9449623 chr6 84180355 A T 5.40E-04 Alzheimer's disease / / 17998437 rs13207536 chr6 84188476 A G 1.11E-05 Bipolar disorder,schizoaffective / / 19567891 rs4707006 chr6 84216117 C T 4.49E-04 Bipolar disorder / / 19259986 rs9341961 chr6 84220770 C T 6.83E-05 Cognitive test performance / / 20125193 rs9341961 chr6 84220770 C T 0.00000891 Sarcoidosis / / 22952805 rs1171113 chr6 84226595 C T 1.00E-07 Bipolar disorder (mood-incongruent) PRSS35 intron 23092984 rs1171115 chr6 84229623 C T 5.77E-04 Multiple complex diseases PRSS35 intron 17554300 rs1171115 chr6 84229623 C T 8.36E-06 Bipolar disorder,schizoaffective PRSS35 intron 19567891 rs512140 chr6 84230653 A G 5.88E-04 Multiple complex diseases PRSS35 intron 17554300 rs512140 chr6 84230653 A G 9.64E-06 Bipolar disorder,schizoaffective PRSS35 intron 19567891 rs3812141 chr6 84234144 C T 6.25E-04 Type 2 diabetes PRSS35 cds-synon 17463246 rs7741310 chr6 84250330 C T 5.36E-05 Hypertension / / pha003041 rs798395 chr6 84269317 T C 1.30E-05 Bipolar disorder,schizoaffective S/P91 intron 19567891 rs9341963 chr6 84287238 T C 7.79E-04 Multiple complex diseases S/P91 intron 17554300 rs9341963 chr6 84287238 T C 1.03E-05 Bipolar disorder,schizoaffective S/P91 intron 19567891 rs9341963 chr6 84287238 T C 2.68E-04 Alzheimer's disease S/P91 intron 22005930 rs11752615 chr6 84380660 C T 7.18E-04 Type 2 diabetes S/P91 intron 17463246 rs2924667 chr6 84426446 C G 9.32E-04 Multiple complex diseases / / 17554300 rs586661 chr6 84428280 C T 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs965208 chr6 84650364 G T 5.64E-04 Smoking cessation CYB5R4 intron 24665060 rs1325470 chr6 84665379 A G 1.33E-05 Multiple complex diseases CYB5R4 intron 17554300 rs9359576 chr6 84670804 A G 3.93E-09 Multiple complex diseases / / 17554300 rs1928280 chr6 84703588 T C 4.14E-05 Multiple complex diseases LOC100506908 intron 17554300 rs16874200 chr6 84769110 C T 5.82E-04 Multiple complex diseases MRAP2 intron 17554300 rs2480196 chr6 84796363 G A 6.66E-05 Information processing speed MRAP2 intron 21130836 rs2875382 chr6 84799185 C T 2.98E-05 Coronary heart disease MRAP2 cds-synon pha003031 rs2497129 chr6 84799673 T C 8.59E-05 Information processing speed MRAP2 UTR-3 21130836 rs2497129 chr6 84799673 T C 8.86E-07 Coronary heart disease MRAP2 UTR-3 pha003031 rs2480199 chr6 84802323 C T 8.31E-05 Information processing speed / / 21130836 rs2480199 chr6 84802323 C T 1.45E-06 Coronary heart disease / / pha003031 rs2476900 chr6 84849717 G A 6.71E-07 Coronary heart disease KIAA1009 intron pha003031 rs9449802 chr6 84853623 T C 4.00E-07 Coronary heart disease KIAA1009 intron pha003031 rs9449804 chr6 84856409 T C 6.87E-05 Smoking quantity KIAA1009 cds-synon 24665060 rs6905922 chr6 84877816 C T 6.44E-05 Coronary heart disease KIAA1009 intron pha003031 rs16874323 chr6 84903394 C G 9.33E-04 Type 2 diabetes KIAA1009 missense 17463246 rs2277090 chr6 84937530 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1408274 chr6 84972805 G T 1.95E-04 Multiple complex diseases / / 17554300 rs1408274 chr6 84972805 G T 4.19E-06 Gallstones / / 17632509 rs1535821 chr6 84978327 A G 7.09E-05 Cognitive impairment induced by topiramate / / 22091778 rs12174666 chr6 84982208 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2324570 chr6 84997747 T G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6923103 chr6 85001736 C T 2.20E-04 Multiple complex diseases / / 17554300 rs2223793 chr6 85034682 C T 6.58E-05 Blood Pressure / / pha002898 rs12208987 chr6 85055653 C T 1.20E-05 Coronary heart disease / / pha003033 rs10455426 chr6 85056975 G T 1.20E-05 Coronary heart disease / / pha003033 rs9449868 chr6 85060287 G A 1.29E-05 Coronary heart disease / / pha003033 rs9449869 chr6 85062937 T A 2.84E-04 Type 2 diabetes / / 17463246 rs6934412 chr6 85063254 G A 3.03E-04 Type 2 diabetes / / 17463246 rs1555173 chr6 85064458 C T 1.00E-05 Lipid traits / / 17903299 rs4527671 chr6 85067377 T A 2.68E-04 Type 2 diabetes / / 17463246 rs7745556 chr6 85071341 A G 1.18E-05 Coronary heart disease / / pha003033 rs9449880 chr6 85073642 A G 1.17E-05 Coronary heart disease / / pha003033 rs9444163 chr6 85073731 A C 4.15E-04 Type 2 diabetes / / 17463246 rs10080471 chr6 85079851 T A 2.12E-04 Type 2 diabetes / / 17463246 rs9449881 chr6 85080575 A G 8.65E-04 Type 2 diabetes / / 17463246 rs2021910 chr6 85085016 A C 2.22E-04 Type 2 diabetes / / 17463246 rs1010437 chr6 85098237 G A 1.09E-05 Coronary heart disease / / pha003033 rs2143787 chr6 85114881 C G 7.50E-04 Type 2 diabetes / / 17463246 rs1012958 chr6 85122962 C G 7.83E-05 Postoperative ventricular dysfunction / / 21980348 rs16874544 chr6 85127929 A G 6.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7742127 chr6 85153476 A T 2.90E-05 Urinary metabolites / / 21572414 rs4618489 chr6 85173502 A G 5.43E-05 Serum metabolites / / 19043545 rs9362053 chr6 85178017 G A 5.80E-05 Serum metabolites / / 19043545 rs9362054 chr6 85178268 T C 8.68E-05 Pulmonary function in asthmatics / / 23541324 rs9344399 chr6 85197356 G A 1.16E-04 Multiple complex diseases / / 17554300 rs7765620 chr6 85203739 G A 5.43E-05 Serum metabolites / / 19043545 rs6940283 chr6 85210634 C T 1.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs7741380 chr6 85211340 G A 4.28E-05 Cognitive performance / / 19734545 rs13193461 chr6 85211666 C T 2.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs13193467 chr6 85211681 C T 2.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs6911365 chr6 85228752 T A 8.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs6936385 chr6 85228896 G T 8.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs10943999 chr6 85229506 T C 6.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs10944000 chr6 85229514 G T 4.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs9449952 chr6 85229751 C G 7.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs9449954 chr6 85230345 C T 9.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs10944025 chr6 85314871 C T 4.51E-06 Lipid traits / / 24023261 rs9444205 chr6 85327630 A G 2.70E-06 Lipid traits / / 24023261 rs9444205 chr6 85327630 A G 5.04E-04 Lipid traits / / 24023261 rs10806277 chr6 85328459 T G 8.89E-06 Lipid traits / / 24023261 rs4707075 chr6 85332242 G C 5.10E-06 Lipid traits / / 24023261 rs7772920 chr6 85334902 C T 5.53E-06 Lipid traits / / 24023261 rs7755292 chr6 85335098 T A 9.52E-04 Type 2 diabetes / / 17463246 rs7755292 chr6 85335098 T A 2.33E-06 Lipid traits / / 24023261 rs4707082 chr6 85342772 G T 5.68E-06 Lipid traits / / 24023261 rs12523671 chr6 85344801 T C 2.84E-05 Lipid traits / / 24023261 rs9449990 chr6 85345955 T C 1.88E-05 Lipid traits / / 24023261 rs4706211 chr6 85349264 A G 7.21E-06 Lipid traits / / 24023261 rs16874923 chr6 85350479 A G 8.79E-04 Type 2 diabetes / / 17463246 rs6938512 chr6 85355872 T G 2.28E-04 Type 2 diabetes / / 17846125 rs9344414 chr6 85373520 A G 3.87E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs6454393 chr6 85381928 C T 9.21E-05 Blood Pressure / / pha002898 rs9294310 chr6 85435275 G T 1.50E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs9362099 chr6 85439432 T G 4.04E-05 Lipid traits / / 24023261 rs215939 chr6 85466286 A C 3.40E-04 Intracranial aneurysm TBX18 intron 20613766 rs215939 chr6 85466286 A C 9.84E-05 Aging (time to event) TBX18 intron 21782286 rs141127 chr6 85489234 C T 9.13E-05 Vascular dementia / / 22116812 rs215935 chr6 85489616 C T 4.26E-05 Cardiovascular disease / / 22029572 rs9353222 chr6 85515813 T G 3.82E-05 Lipid traits / / 24023261 rs72912698 chr6 85591861 C T 1.42E-11 Blood pressure / / 21909110 rs9444253 chr6 85625729 T C 9.07E-05 Common variable immunodeficiency / / 21497890 rs12333263 chr6 85639941 A C 9.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs9359617 chr6 85688541 G T 7.37E-05 Coronary heart disease / / pha003030 rs10485066 chr6 85689003 T C 2.90E-04 Smoking initiation / / 24665060 rs17521560 chr6 85690875 G A 1.40E-05 Urinary metabolites / / 21572414 rs17521560 chr6 85690875 G A 5.97E-04 Smoking initiation / / 24665060 rs10485067 chr6 85696163 G T 5.70E-06 Urinary metabolites / / 21572414 rs1322867 chr6 85696272 A G 6.32E-04 Smoking initiation / / 24665060 rs9444276 chr6 85707337 G A 6.76E-05 Orofacial clefts / / 22419666 rs6919160 chr6 85724163 T A 1.72E-05 Cognitive decline / / 22054870 rs17695342 chr6 85730991 C G 1.90E-05 Urinary metabolites / / 21572414 rs10498949 chr6 85744722 G A 4.28E-04 Multiple complex diseases / / 17554300 rs7765284 chr6 85777822 C A 9.37E-07 Renal cell carcinoma / / 23184150 rs10498951 chr6 85782095 C T 1.33E-05 Bipolar disorder / / 20451256 rs9450148 chr6 85800720 A G 1.80E-04 Alcohol dependence / / 20201924 rs1325975 chr6 85818620 G C 1.48E-06 Stevens-Johnson syndrome / / 20947153 rs10485304 chr6 85824323 A G 3.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10485305 chr6 85825144 G A 6.80E-05 Iron levels / / 21208937 rs16875678 chr6 85828033 T C 1.85E-08 Metabolite levels / / 23281178 rs6454423 chr6 85837808 T C 2.00E-05 Urinary metabolites / / 21572414 rs1321723 chr6 85846502 G C 8.49E-04 Multiple complex diseases / / 17554300 rs7741178 chr6 85873400 A C 9.85E-05 Serum metabolites / / 19043545 rs4707130 chr6 85877043 G A 2.02E-04 Multiple complex diseases / / 17554300 rs6919048 chr6 85879372 T C 1.45E-04 Multiple complex diseases / / 17554300 rs1321742 chr6 85881189 A C 0.000046 Endometrial cancer / / 22426144 rs1321744 chr6 85891744 T C 3.55E-04 Multiple complex diseases / / 17554300 rs16875837 chr6 85896793 T C 9.01E-05 Multiple complex diseases / / 17554300 rs1853135 chr6 85898746 T C 4.32E-04 Multiple complex diseases / / 17554300 rs13206561 chr6 85934442 G A 4.40E-04 Alcohol dependence / / 20201924 rs944666 chr6 85941000 C T 2.85E-04 Type 2 diabetes / / 17463246 rs4706229 chr6 85953860 A G 4.06E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1575188 chr6 85957696 A G,T 3.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1885015 chr6 85963538 G A 1.82E-05 Lung function (forced vital capacity) / / pha003104 rs9353292 chr6 85970663 T C 0.000046 Endometrial cancer / / 22426144 rs1885016 chr6 85982579 A G 2.24E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7749042 chr6 85985075 G A 9.55E-04 Obesity (extreme) / / 21935397 rs11752804 chr6 86028681 G A 1.30E-05 Alcohol dependence / / 20201924 rs11752804 chr6 86028681 G A 3.10E-04 Alcohol dependence / / 20201924 rs11752804 chr6 86028681 G A 1.30E-05 Alcoholism / / pha002892 rs987892 chr6 86049870 A G 1.10E-04 Type 2 diabetes / / 17463246 rs4707202 chr6 86091724 C T 6.83E-05 Bone mineral density / / 19181680 rs494562 chr6 86117129 A G 7.00E-13 Metabolic traits / / 21886157 rs494562 chr6 86117129 A G 1.00E-12 Blood metabolite levels / / 24816252 rs4593336 chr6 86181931 A G 0.000331 fMRI brain tests in schizophrenia NT5E intron 22440650 rs1059307 chr6 86387888 G T 2.63E-26 Lymphocyte counts / / 22286170 rs2475792 chr6 86392102 C T 3.01E-04 Multiple complex diseases / / 17554300 rs9344542 chr6 86393905 C T 1.91E-04 Multiple complex diseases / / 17554300 rs9353327 chr6 86394066 T C 2.39E-04 Multiple complex diseases / / 17554300 rs2484355 chr6 86394403 A G 4.03E-04 Multiple complex diseases / / 17554300 rs6454486 chr6 86433587 C T 3.41E-04 Multiple complex diseases / / 17554300 rs6454487 chr6 86446868 C T 8.60E-04 Multiple complex diseases / / 17554300 rs12192546 chr6 86476484 G A 4.62E-04 Multiple complex diseases / / 17554300 rs9353339 chr6 86504198 A G 3.88E-04 Multiple complex diseases / / 17554300 rs17442622 chr6 86521582 G T 4.42E-04 Alzheimer's disease / / 22005930 rs7757175 chr6 86566463 C G 5.89E-04 Response to TNF antagonist treatment / / 21061259 rs1995688 chr6 86632319 G A 9.55E-04 Type 2 diabetes / / 17846125 rs806606 chr6 86683779 T C 7.32E-05 Parkinson's disease / / 17052657 rs1577917 chr6 86691940 C T 3.00E-06 Response to antipsychotic treatment / / 20195266 rs1577917 chr6 86691940 C T 8.82E-05 Bipolar Disorder / / pha002863 rs9344563 chr6 86759985 C A 1.35E-04 Alzheimer's disease / / 22005930 rs6913709 chr6 86781618 C T 6.50E-04 Multiple complex diseases / / 17554300 rs220420 chr6 86861879 T A,G 2.00E-04 Schizophrenia / / 19197363 rs220419 chr6 86862204 C T 2.47E-06 Serum metabolites / / 19043545 rs220411 chr6 86869506 A G 2.43E-05 Multiple complex diseases / / 17554300 rs66504230 chr6 86871444 T C 1.77E-07 Prostate cancer / / 24185611 rs1855590 chr6 86873757 G A 0.0006147 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1855590 chr6 86873757 G A 6.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs220394 chr6 86885509 G A 5.53E-04 Coronary Artery Disease / / 17634449 rs220394 chr6 86885509 G A 6.85E-04 Alcohol dependence / / 24277619 rs9359682 chr6 86896768 T C 6.17E-07 Serum metabolites / / 19043545 rs7765374 chr6 86944599 G A 7.34E-06 Asthma / / 20698975 rs17541873 chr6 87001570 G A 1.13E-05 Adverse response to lamotrigine and phenytoin / / 22379998 rs17541873 chr6 87001570 G A 4.31E-04 Alcohol dependence / / 24277619 rs2816583 chr6 87023751 A G 3.48E-04 Multiple complex diseases / / 17554300 rs12208821 chr6 87060779 A G 8.87E-04 Bipolar disorder,schizoaffective / / 19567891 rs1954406 chr6 87084763 C T 2.40E-05 Urinary metabolites / / 21572414 rs13203149 chr6 87086122 T C 1.60E-05 Urinary metabolites / / 21572414 rs12193553 chr6 87094486 G T 9.30E-05 Alcohol dependence / / 24277619 rs6919366 chr6 87113172 G T 9.30E-07 Bone mineral density and osteoporosis-related phenotypes / / 22072498 rs6936075 chr6 87121412 C T 6.93E-04 Multiple complex diseases / / 17554300 rs3857481 chr6 87124569 G A 5.00E-07 Breast cancer / / 17529967 rs9362320 chr6 87136164 C T 6.00E-07 Bone mineral density and osteoporosis-related phenotypes / / 22072498 rs9362321 chr6 87136247 C T 5.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs9362321 chr6 87136247 C T 4.30E-08 Bone mineral density and osteoporosis-related phenotypes / / 22072498 rs9351097 chr6 87138115 G T 3.81E-04 Suicide attempts in bipolar disorder / / 21041247 rs9351097 chr6 87138115 G T 3.40E-08 Bone mineral density and osteoporosis-related phenotypes / / 22072498 rs9362322 chr6 87140425 T A 2.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs9362322 chr6 87140425 T A 9.30E-08 Bone mineral density and osteoporosis-related phenotypes / / 22072498 rs9344613 chr6 87153668 T C 1.52E-04 Smoking cessation / / 24665060 rs13202860 chr6 87155254 A T 1.00E-07 Sexual dysfunction (female) / / 22509378 rs9450458 chr6 87174156 C T 0.0000981 Polycystic ovary syndrome / / 22951595 rs9450458 chr6 87174156 C T 9.81E-05 Intracranial aneurysm / / 22961961 rs994732 chr6 87178252 C T 2.10E-05 Coffee consumption / / 21357676 rs10455463 chr6 87211767 C T 4.78E-04 Multiple complex diseases / / 17554300 rs12525980 chr6 87245400 G A 2.39E-05 Type 2 diabetes / / 17463246 rs12661195 chr6 87264702 T C 7.46E-08 Narcolepsy / / 19629137 rs2211074 chr6 87349163 G A 8.43E-05 Serum metabolites / / 19043545 rs2211074 chr6 87349163 G A 2.80E-05 Urinary metabolites / / 21572414 rs1954290 chr6 87351573 A G 9.97E-05 Bipolar disorder and schizophrenia / / 20889312 rs1954291 chr6 87352034 T C 2.94E-05 Bipolar disorder and schizophrenia / / 20889312 rs10485360 chr6 87352141 C G 3.96E-05 Bipolar disorder and schizophrenia / / 20889312 rs1935601 chr6 87352507 G A 4.81E-05 Bipolar disorder and schizophrenia / / 20889312 rs1935596 chr6 87368368 T C 2.90E-05 Urinary metabolites / / 21572414 rs1325183 chr6 87395567 A G 5.12E-05 Serum metabolites / / 19043545 rs1325183 chr6 87395567 A G 1.60E-05 Urinary metabolites / / 21572414 rs671837 chr6 87410024 A G 4.87E-06 Bipolar disorder and schizophrenia / / 20889312 rs592728 chr6 87420652 C T 7.30E-04 Coronary heart disease / / 21606135 rs641422 chr6 87423256 C T 3.13E-05 Bipolar disorder and schizophrenia / / 20889312 rs689367 chr6 87427426 G T 5.36E-06 Bipolar disorder and schizophrenia / / 20889312 rs517706 chr6 87434076 A G 6.67E-04 Type 2 diabetes / / 17846125 rs616174 chr6 87438888 G A 7.47E-06 Bipolar disorder and schizophrenia / / 20889312 rs670510 chr6 87448174 G A 6.14E-06 Bipolar disorder and schizophrenia / / 20889312 rs493187 chr6 87466492 A G 3.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs668111 chr6 87474096 A C 3.10E-05 Bipolar disorder and schizophrenia / / 20889312 rs12665525 chr6 87496480 T C 3.20E-05 Bone mineral density and osteoporosis-related phenotypes / / 22072498 rs6911565 chr6 87500866 C A 1.10E-05 Bone mineral density and osteoporosis-related phenotypes / / 22072498 rs7768894 chr6 87547049 C T 7.51E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LOC643962 intron 20031582 rs1321317 chr6 87556038 C G 4.37E-04 Multiple complex diseases LOC643962 intron 17554300 rs1853639 chr6 87606842 G A 8.00E-06 IgG glycosylation LOC643962 intron 23382691 rs10944288 chr6 87651742 C T 2.19E-04 Type 2 diabetes HTR1E intron 17463246 rs6935195 chr6 87693355 C T 0.00039 Coronary artery calcification HTR1E intron 23727086 rs10485177 chr6 87702335 A G 2.46E-04 Multiple complex diseases HTR1E intron 17554300 rs6926547 chr6 87704125 G A 8.95E-04 Myocardial Infarction HTR1E intron pha002883 rs17822183 chr6 87739154 C T 3.90E-05 Malaria / / 19465909 rs17448801 chr6 87749625 T A 9.30E-05 Tuberculosis / / 20694014 rs17448899 chr6 87750566 A G 9.30E-05 Tuberculosis / / 20694014 rs17448940 chr6 87750843 T C 9.30E-05 Tuberculosis / / 20694014 rs17546090 chr6 87751047 A C 9.30E-05 Tuberculosis / / 20694014 rs9359725 chr6 87753317 A C 3.80E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1590428 chr6 87756580 A T 9.19E-05 Serum metabolites / / 19043545 rs6631 chr6 87795259 A T 2.96E-04 Suicide attempts in bipolar disorder CGA UTR-3 21423239 rs9342104 chr6 87798512 A G 1.56E-04 Smoking initiation CGA intron 24665060 rs6926846 chr6 87799514 C A 1.14E-04 Smoking initiation CGA intron 24665060 rs1983841 chr6 87799885 T A 2.72E-04 Smoking initiation CGA intron 24665060 rs9444470 chr6 87801536 T C 5.50E-05 Smoking initiation CGA intron 24665060 rs9344674 chr6 87802423 A G 3.90E-04 Smoking initiation CGA intron 24665060 rs1075068 chr6 87825309 T A 3.99E-04 Smoking initiation / / 24665060 rs6454587 chr6 87857882 A G 5.88E-04 Smoking initiation / / 24665060 rs1925690 chr6 87867063 T C 3.00E-08 MRI atrophy measures ZNF292 intron 21116278 rs16878570 chr6 87874872 T C 3.94E-04 Type 2 diabetes ZNF292 intron 17463246 rs3857487 chr6 87963688 A G 7.88E-04 Nicotine smoking ZNF292 intron 19268276 rs7341237 chr6 88032390 G C 2.00E-06 PR interval in Tripanosoma cruzi seropositivity C6orf162 intron 24324551 rs190262 chr6 88070607 T G 0.00043 Endometrial cancer C6orf163 intron 22426144 rs242287 chr6 88071825 G A 3.40E-04 Smoking initiation C6orf163 intron 24665060 rs1203156 chr6 88079694 T C 5.91E-04 Lymphocyte counts / / 22286170 rs61731441 chr6 88125542 G A 0.00026 Prostate cancer C6orf165 missense 23555315 rs10944312 chr6 88171627 G T 1.68E-04 Amyotrophic lateral sclerosis (sporadic) C6orf165 intron 24529757 rs2268993 chr6 88184111 G A 2.20E-05 HIV(mother-to-child transmission) SLC35A1 intron 20487506 rs2268993 chr6 88184111 G A 4.26E-04 HIV(mother-to-child transmission) SLC35A1 intron 20487506 rs2273130 chr6 88219037 C T 4.16E-06 Obesity-related traits SLC35A1 intron 23251661 rs6900057 chr6 88273969 A C 9.15E-06 Obesity-related traits RARS2 intron 23251661 rs13213285 chr6 88329942 C T 4.00E-06 Obesity-related traits ORC3 intron 23251661 rs13206957 chr6 88353696 G A 7.93E-06 Obesity-related traits ORC3 intron 23251661 rs2307393 chr6 88362943 C T 5.08E-06 Obesity-related traits ORC3 cds-synon 23251661 rs2307373 chr6 88366708 C T 0.00000482 LDL cholesterol particle diameter ORC3 intron 23263444 rs6454640 chr6 88370352 A C 5.30E-04 Smoking initiation ORC3 intron 24665060 rs715207 chr6 88370957 C A 9.65E-04 Alzheimer's disease ORC3 intron 24755620 rs28381552 chr6 88377049 T C 4.00E-06 Obesity-related traits ORC3 UTR-3 23251661 rs2754244 chr6 88381221 C G 9.90E-06 Urinary metabolites / / 21572414 rs2754244 chr6 88381221 C G 9.09E-04 Alzheimer's disease / / 24755620 rs2250795 chr6 88393705 T C 1.83E-04 Alzheimer's disease AKIRIN2 intron 24755620 rs9294385 chr6 88393958 C A 3.30E-05 Allergic sensitization AKIRIN2 intron 23817571 rs2250276 chr6 88397755 T C 2.04E-05 Common variable immunodeficiency AKIRIN2 intron 21497890 rs2787933 chr6 88420902 G A 3.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16879736 chr6 88423165 C T 7.83E-04 Multiple complex diseases / / 17554300 rs16879736 chr6 88423165 C T 8.25E-05 Prostate cancer / / pha002877 rs2245777 chr6 88424509 T C 3.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2754273 chr6 88433865 T C 8.17E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs2185065 chr6 88496641 C T 6.72E-05 Tunica Media / / pha003036 rs718220 chr6 88549795 T C 0.000728985 Hypertension (early onset hypertension) / / 22479346 rs6454660 chr6 88607147 A C 6.10E-05 Parkinson's disease (motor and cognition) / / 22658654 rs6454660 chr6 88607147 A C 6.10E-05 Immune response to anthrax vaccine / / 22658931 rs9353510 chr6 88612652 T G 5.01E-04 Smoking initiation / / 24665060 rs6930073 chr6 88613150 C T 2.95E-05 Parkinson's disease (motor and cognition) / / 22658654 rs6930073 chr6 88613150 C T 2.95E-05 Immune response to anthrax vaccine / / 22658931 rs12528790 chr6 88620665 T C 3.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9450828 chr6 88621625 T G 3.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9344741 chr6 88622319 G A 1.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9353512 chr6 88629753 C T 3.10E-05 Body Mass Index / / pha003006 rs9344744 chr6 88630632 A G 0.00009956 Sarcoidosis / / 22952805 rs9342128 chr6 88630757 C T 0.00009956 Sarcoidosis / / 22952805 rs4428477 chr6 88633009 A G 6.67E-04 Alzheimer's disease / / 24755620 rs2509458 chr6 88652580 T C 7.00E-06 Blood pressure / / 17903302 rs1940893 chr6 88660007 G A 2.85E-04 Multiple complex diseases / / 17554300 rs1940893 chr6 88660007 G A 5.91E-04 Prostate cancer mortality / / 20978177 rs4707427 chr6 88663533 G A 3.88E-06 Malignant mesothelioma / / 23827383 rs1940890 chr6 88663964 G A 4.29E-04 Type 2 diabetes / / 17463246 rs16879998 chr6 88671201 C T 7.25E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1321501 chr6 88676599 A G 1.89E-07 Schizophrenia / / 21926974 rs663878 chr6 88679785 T C 2.06E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2466413 chr6 88680458 C T 3.87E-04 Premature ovarian failure / / 19508998 rs366676 chr6 88717766 A G 2.00E-06 Echocardiographic traits / / 17903301 rs366676 chr6 88717766 A G 0.00024 Prostate cancer / / 23555315 rs366676 chr6 88717766 A G 0.00056 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs806435 chr6 88769878 T C 2.50E-04 Lung adenocarcinoma SPACA1 intron 21242121 rs806438 chr6 88776981 T A 1.00E-07 Crohn's disease / / 18587394 rs6938321 chr6 88836054 T C 9.49E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16880248 chr6 88851687 G T 1.19E-10 LDL cholesterol CNR1 UTR-3 23063622 rs16880248 chr6 88851687 G T 3.93E-18 HDL cholesterol CNR1 UTR-3 23063622 rs16880248 chr6 88851687 G T 8.47E-09 Triglycerides CNR1 UTR-3 23063622 rs6454676 chr6 88877455 G A 0.000029 Aging / / 22445811 rs6454676 chr6 88877455 G A 9.27E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9344757 chr6 88879928 T G 6.35E-04 Common variable immunodeficiency / / 21497890 rs9450901 chr6 88880120 G A 7.52E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9450902 chr6 88880224 C G 7.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs9444586 chr6 88881642 G C 7.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs9444586 chr6 88881642 G C 5.66E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs9450903 chr6 88882193 A G 7.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs9450903 chr6 88882193 A G 5.78E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs9450904 chr6 88882493 C T 5.84E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs9450905 chr6 88882562 A G 7.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs10485170 chr6 88882652 T C 8.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs10485170 chr6 88882652 T C 0.0000367 Aging / / 22445811 rs10485170 chr6 88882652 T C 7.52E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9450906 chr6 88883324 C T 8.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs9450906 chr6 88883324 C T 6.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs9444587 chr6 88883356 T C 8.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs9450907 chr6 88883522 C A 5.67E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs11966501 chr6 88883547 T A 5.68E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs11968764 chr6 88883569 A C 5.69E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs11963892 chr6 88883571 G A 6.14E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs9444588 chr6 88884166 C A 5.84E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs12213790 chr6 88902564 G A 1.52E-05 Cognitive performance / / 19734545 rs9450916 chr6 88907388 G A 7.16E-05 Information processing speed / / 21130836 rs9450917 chr6 88907598 C T 2.00E-04 Information processing speed / / 21130836 rs7738812 chr6 88916603 A T 8.52E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs964647 chr6 88936392 A T 1.34E-05 Attention deficit hyperactivity disorder / / 18980221 rs964647 chr6 88936392 A T 2.09E-05 Attention deficit hyperactivity disorder / / pha002875 rs1408700 chr6 88936439 T C 3.61E-05 AIDS / / 19754311 rs12202794 chr6 88975832 C G 9.91E-05 Longevity / / 20304771 rs16880441 chr6 88975977 C G 9.00E-06 Conduct disorder (interaction) / / 18846501 rs9344790 chr6 89060277 A G 3.25E-05 Hemoglobin / / pha003098 rs990060 chr6 89074336 T C 6.16E-05 Hemoglobin / / pha003098 rs10485166 chr6 89075687 T C 4.86E-05 Hemoglobin / / pha003098 rs10485166 chr6 89075687 T C 9.65E-05 Erythrocyte counts / / pha003099 rs723787 chr6 89086152 A G 3.88E-05 Elbow pain / / pha003008 rs9344795 chr6 89096817 A G 1.65E-05 Tunica Media / / pha003034 rs12110782 chr6 89111138 T A 8.58E-04 Insulin resistance / / 21901158 rs10485165 chr6 89112817 C T 1.00E-06 Select biomarker traits / / 17903293 rs936495 chr6 89152479 G T 1.20E-05 Urinary metabolites / / 21572414 rs936495 chr6 89152479 G T 2.46E-05 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs1359431 chr6 89164698 C G 2.10E-05 Urinary metabolites / / 21572414 rs16880592 chr6 89168472 C T 5.12E-04 Type 2 diabetes / / 17463246 rs7763511 chr6 89169157 C T 4.94E-05 stroke (ischemic) / / 17434096 rs11757661 chr6 89183580 G A 8.00E-06 Subcutaneous adipose tissue / / 22589738 rs1408734 chr6 89186177 T G 5.53E-05 Height / / pha003011 rs10944385 chr6 89188694 C A 9.23E-04 Multiple complex diseases / / 17554300 rs16880618 chr6 89190332 T C 5.61E-06 Multiple complex diseases / / 17554300 rs9353563 chr6 89190579 A G 5.53E-05 Height / / pha003011 rs12197916 chr6 89193448 T G 8.19E-05 Scoliosis / / 21216876 rs959186 chr6 89193994 G A 9.22E-05 Heart Rate / / pha003053 rs6650988 chr6 89195922 G A 8.83E-04 Bipolar disorder / / 19259986 rs6650988 chr6 89195922 G A 7.93E-05 Information processing speed / / 21130836 rs1325008 chr6 89211957 T C 7.93E-05 Information processing speed / / 21130836 rs1325010 chr6 89216149 A G 7.93E-05 Information processing speed / / 21130836 rs7769477 chr6 89221793 C T 6.94E-04 Bipolar disorder / / 19259986 rs4707485 chr6 89237691 C T 2.10E-05 Urinary metabolites / / 21572414 rs4707486 chr6 89237770 G A 2.10E-05 Urinary metabolites / / 21572414 rs7763299 chr6 89250297 G A 9.15E-04 Alzheimer's disease / / 22005930 rs964888 chr6 89252152 C T 5.67E-05 Heart Rate / / pha003053 rs2610739 chr6 89253649 G A 4.00E-06 IgG glycosylation / / 23382691 rs9444628 chr6 89255077 G A 8.79E-04 Acne (severe) / / 24927181 rs2610725 chr6 89265657 C T 6.47E-05 Heart Rate / / pha003053 rs9294403 chr6 89266528 C T 2.10E-05 Response to statin therapy / / 20339536 rs2246529 chr6 89284739 C T 9.77E-04 Multiple complex diseases / / 17554300 rs12527253 chr6 89293745 A G 1.00E-06 Response to statin therapy / / 20339536 rs12527253 chr6 89293745 A G 4.31E-04 Depression (quantitative trait) / / 20800221 rs2325138 chr6 89298590 T C 2.07E-04 Type 2 diabetes / / 17463246 rs16879934 chr6 89304760 A G 2.63E-04 Type 2 diabetes / / 17463246 rs2610769 chr6 89317596 T C 3.06E-04 Multiple complex diseases / / 17554300 rs2236287 chr6 89323961 T G 1.76E-04 Amyotrophic lateral sclerosis RNGTT intron 23624525 rs2756368 chr6 89325645 A C 4.60E-04 Amyotrophic Lateral Sclerosis RNGTT intron 17362836 rs2756368 chr6 89325645 A C 5.69E-04 Multiple complex diseases RNGTT intron 17554300 rs16880995 chr6 89362020 A T 5.15E-25 Narcolepsy RNGTT intron 19629137 rs9342170 chr6 89562222 A G 6.37E-04 Smoking initiation RNGTT intron 24665060 rs10944415 chr6 89641507 T C 0.00007432 Sarcoidosis RNGTT intron 22952805 rs9359829 chr6 89642071 C A 0.00001133 Sarcoidosis RNGTT intron 22952805 rs9451108 chr6 89650922 C A 0.00003675 Sarcoidosis RNGTT intron 22952805 rs12055577 chr6 89652959 A T 0.00007432 Sarcoidosis RNGTT intron 22952805 rs12173779 chr6 89661266 G C 0.00008882 Sarcoidosis RNGTT intron 22952805 rs12665654 chr6 89677955 G A 3.68E-05 Serum metabolites / / 19043545 rs12665654 chr6 89677955 G A 2.80E-05 Urinary metabolites / / 21572414 rs9342175 chr6 89692400 G A 6.37E-06 Serum metabolites / / 19043545 rs9342175 chr6 89692400 G A 6.60E-06 Urinary metabolites / / 21572414 rs4707509 chr6 89696044 A G 1.60E-05 Urinary metabolites / / 21572414 rs2325167 chr6 89697159 T C 7.96E-06 Post-operative nausea and vomiting / / 21694509 rs12198521 chr6 89704358 C T 8.10E-05 Bipolar disorder and schizophrenia / / 20889312 rs205199 chr6 89723277 T A 1.50E-04 Type 2 diabetes / / 17463246 rs205204 chr6 89724418 T C 8.45E-05 Aging (time to event) / / 21782286 rs12527359 chr6 89728221 T A 7.75E-07 Bipolar disorder and schizophrenia / / 20889312 rs2748178 chr6 89730740 C T 8.27E-05 Cognitive test performance / / 20125193 rs12201676 chr6 89732101 T C 6.38E-05 Bipolar disorder / / 19488044 rs12201676 chr6 89732101 T C 4.00E-08 Bipolar disorder and schizophrenia / / 20889312 rs205229 chr6 89740659 C T 5.13E-05 Serum metabolites / / 19043545 rs205217 chr6 89749105 G A 1.18E-04 Type 2 diabetes / / 17463246 rs6932023 chr6 89770216 G T 2.20E-05 Cognitive test performance / / 20125193 rs9451150 chr6 89810210 A G 8.29E-04 Type 2 diabetes SRSF12 intron 17463246 rs693932 chr6 89830374 G C 8.15E-05 Type 2 diabetes / / 17463246 rs10223547 chr6 89853696 A T 1.93E-04 Alzheimer's disease / / pha002879 rs2150820 chr6 89872976 C T 1.73E-07 Lymphocyte counts PM20D2 UTR-3 22286170 rs7775554 chr6 89879168 A C 1.00E-15 Blood metabolite levels / / 24816252 rs1796740 chr6 89882849 G A 4.74E-05 Kawasaki disease / / 22081228 rs375565 chr6 89884115 A G 4.05E-06 Serum metabolites / / 19043545 rs7758562 chr6 89886430 A G 1.61E-05 Serum metabolites / / 19043545 rs9359845 chr6 89889461 G A 6.46E-05 Serum metabolites GABRR1 intron 19043545 rs368873 chr6 89893162 G A 5.87E-05 Serum metabolites GABRR1 intron 19043545 rs368873 chr6 89893162 G A 3.39E-05 Kawasaki disease GABRR1 intron 22081228 rs2183648 chr6 89894016 C G 6.70E-04 Type 2 diabetes GABRR1 intron 17463246 rs2297391 chr6 89915404 C A 8.33E-05 Cognitive test performance GABRR1 intron 20125193 rs13215160 chr6 89918386 C T 4.69E-05 Heart Rate GABRR1 intron pha003053 rs282123 chr6 89960222 C T 5.66E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs282123 chr6 89960222 C T 8.37E-05 Lung function (forced vital capacity) / / pha003104 rs9451192 chr6 89976372 G A 7.23E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GABRR2 intron 22566498 rs4707535 chr6 89977906 T C 6.00E-05 Alcohol dependence GABRR2 intron 20201924 rs4707535 chr6 89977906 T C 5.97E-05 Alcoholism GABRR2 intron pha002892 rs964626 chr6 89999296 T C 3.17E-05 IgE levels GABRR2 intron 22075330 rs9344921 chr6 90006421 G A 3.91E-04 Type 2 diabetes GABRR2 intron 17463246 rs9344921 chr6 90006421 G A 1.50E-05 Urinary metabolites GABRR2 intron 21572414 rs2325202 chr6 90011510 G T 5.34E-05 Bipolar disorder GABRR2 intron 19488044 rs2325202 chr6 90011510 G T 2.65E-05 Bipolar Disorder GABRR2 intron pha002863 rs3777514 chr6 90020581 G T 9.29E-05 Bone mineral density GABRR2 intron 19181680 rs7744352 chr6 90026794 A G 7.29E-06 Bone mineral density / / 19181680 rs2064831 chr6 90032942 T C 7.20E-05 Creatinine levels / / 20222955 rs1998576 chr6 90043137 G A 8.60E-05 Creatinine levels UBE2J1 intron 20222955 rs1062108 chr6 90075359 A G 9.69E-04 Response to TNF antagonist treatment RRAGD UTR-3 21061259 rs7762955 chr6 90096683 T C 9.75E-05 Schizophrenia RRAGD intron 19571809 rs854917 chr6 90127390 C T 1.70E-04 Multiple sclerosis / / 21833088 rs12201016 chr6 90149275 A G 2.54E-04 Myocardial Infarction ANKRD6 intron pha002873 rs7451687 chr6 90204153 C G 5.29E-04 Smoking quantity ANKRD6 intron 24665060 rs6940797 chr6 90208120 C A 2.30E-04 Smoking quantity ANKRD6 intron 24665060 rs9444693 chr6 90238738 A G 6.42E-04 Smoking quantity ANKRD6 intron 24665060 rs2026651 chr6 90244235 G A 6.42E-04 Smoking quantity ANKRD6 intron 24665060 rs12664754 chr6 90281402 G A 1.92E-04 Smoking quantity ANKRD6 intron 24665060 rs1328015 chr6 90283864 A T 2.63E-04 Smoking quantity ANKRD6 intron 24665060 rs1328016 chr6 90284136 C T 4.40E-05 Serum metabolites ANKRD6 intron 19043545 rs1328016 chr6 90284136 C T 5.41E-04 Smoking quantity ANKRD6 intron 24665060 rs7745254 chr6 90285588 C A 3.83E-04 Smoking quantity ANKRD6 intron 24665060 rs9444699 chr6 90287331 G A 9.80E-05 Hematology traits ANKRD6 intron 23303382 rs6939321 chr6 90299210 T C 4.00E-06 Metabolite levels (Pyroglutamine) ANKRD6 intron 23934736 rs6454764 chr6 90310966 T C 5.00E-06 vWF and FVIII levels ANKRD6 intron 21810271 rs3748085 chr6 90315789 A G 8.67E-04 Type 2 diabetes ANKRD6 missense 17463246 rs6934804 chr6 90316020 T C 7.66E-04 Smoking quantity ANKRD6 intron 24665060 rs6454765 chr6 90316178 C T 3.91E-04 Smoking quantity ANKRD6 intron 24665060 rs4706346 chr6 90322507 C T 1.43E-04 Type 2 diabetes ANKRD6 intron 17463246 rs2273238 chr6 90326360 C T 6.60E-06 Urinary metabolites ANKRD6 missense 21572414 rs2273238 chr6 90326360 C T 6.06E-04 Stroke ANKRD6 missense pha002886 rs9362672 chr6 90405993 C G 7.37E-04 Alcohol dependence MDN1 intron 21314694 rs12530146 chr6 90408742 C T 1.40E-06 Iron levels MDN1 missense 21208937 rs9344954 chr6 90416006 T G 6.62E-04 Tourette syndrome MDN1 intron 22889924 rs764108 chr6 90432621 A G 8.90E-04 Type 2 diabetes and 6 quantitative traits MDN1 intron 17848626 rs764108 chr6 90432621 A G 6.16E-04 Tourette syndrome MDN1 intron 22889924 rs6942026 chr6 90465626 T G 4.39E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) MDN1 intron 23648065 rs9451268 chr6 90471000 T C 2.89E-04 Suicide attempts in bipolar disorder MDN1 intron 21423239 rs12110451 chr6 90482397 T C 9.09E-04 Tourette syndrome MDN1 missense 22889924 rs4707569 chr6 90497589 A C 9.05E-04 Tourette syndrome MDN1 missense 22889924 rs292263 chr6 90549490 T C 7.89E-05 Lupus nephritis in systemic lupus erythematosus CASP8AP2 intron 24925725 rs441577 chr6 90592223 T C 6.32E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs292246 chr6 90595849 A G 3.26E-04 Schizophrenia / / 19197363 rs1055403 chr6 90638963 G A 2.23E-04 Multiple complex diseases BACH2 UTR-3 17554300 rs2289577 chr6 90640491 C T 9.00E-06 Cognitive performance BACH2 UTR-3 20125193 rs10455512 chr6 90641522 T C 3.79E-04 Response to platinum-based chemotherapy in non-small-cell lung cancer BACH2 UTR-3 21483023 rs292257 chr6 90642998 T C 1.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BACH2 intron 20877124 rs292255 chr6 90643281 T C 1.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BACH2 intron 20877124 rs17708487 chr6 90643949 T C 5.11E-04 Response to cytadine analogues (cytosine arabinoside) BACH2 intron 24483146 rs292251 chr6 90646226 G A 4.62E-04 Suicide attempts in bipolar disorder BACH2 intron 21041247 rs292250 chr6 90647154 G A 4.53E-04 Suicide attempts in bipolar disorder BACH2 intron 21041247 rs182382 chr6 90647759 G C 4.53E-04 Suicide attempts in bipolar disorder BACH2 intron 21041247 rs3734662 chr6 90651086 C T 8.32E-04 Suicide attempts in bipolar disorder BACH2 intron 21041247 rs3734662 chr6 90651086 C T 1.15E-04 Major depression (suicidal thoughts and behavior) BACH2 intron 21750702 rs210052 chr6 90651785 T C 4.44E-04 Suicide attempts in bipolar disorder BACH2 intron 21041247 rs210051 chr6 90652100 A G 3.45E-04 Suicide attempts in bipolar disorder BACH2 intron 21041247 rs404256 chr6 90657783 T C 7.56E-05 Prion diseases BACH2 intron 22210626 rs404256 chr6 90657783 T C 5.00E-06 IgG glycosylation BACH2 intron 23382691 rs404256 chr6 90657783 T C 7.00E-09 IgG glycosylation BACH2 intron 23382691 rs9451298 chr6 90660319 T C 2.51E-05 Coronary heart disease BACH2 cds-synon pha003030 rs9451298 chr6 90660319 T C 2.51E-05 Coronary heart disease BACH2 cds-synon pha003056 rs176713 chr6 90671114 T C 5.31E-05 Type 2 diabetes BACH2 intron 17463246 rs176713 chr6 90671114 T C 2.73E-04 Stroke BACH2 intron pha002886 rs16882302 chr6 90674451 C T 2.28E-07 Alcohol and nictotine co-dependence BACH2 intron 20158304 rs6917758 chr6 90681466 A C 3.00E-06 Obesity-related traits BACH2 intron 23251661 rs12204127 chr6 90698274 C T 6.00E-07 Visceral adipose tissue/subcutaneous adipose tissue ratio BACH2 intron 22589738 rs16882337 chr6 90706217 C G 5.57E-04 Body mass index BACH2 intron 21701565 rs16882357 chr6 90731445 T C 1.38E-04 Body mass index BACH2 intron 21701565 rs16882357 chr6 90731445 T C 4.37E-04 Body mass index BACH2 intron 21701565 rs16882357 chr6 90731445 T C 5.16E-04 Body mass index BACH2 intron 21701565 rs12664550 chr6 90732877 T C 5.75E-04 Body mass index BACH2 intron 21701565 rs12664550 chr6 90732877 T C 7.05E-04 Body mass index BACH2 intron 21701565 rs12664550 chr6 90732877 T C 9.72E-05 Body mass index BACH2 intron 21701565 rs9444730 chr6 90733337 T G 1.00E-05 Hepatocellular carcinoma (hepatitis B virus related) BACH2 intron 23242368 rs9444730 chr6 90733337 T G 6.09E-08 Metabolite levels BACH2 intron 23281178 rs12663434 chr6 90734082 C A 3.00E-05 Hepatocellular carcinoma (hepatitis B virus related) BACH2 intron 23242368 rs4388268 chr6 90734908 G A 9.74E-08 Metabolite levels BACH2 intron 23281178 rs7749730 chr6 90734984 A G 1.00E-05 Hepatocellular carcinoma (hepatitis B virus related) BACH2 intron 23242368 rs4141551 chr6 90743965 G A 1.63E-04 Body mass index BACH2 intron 21701565 rs12662903 chr6 90745320 A G 1.92E-04 Body mass index BACH2 intron 21701565 rs12662903 chr6 90745320 A G 7.41E-04 Body mass index BACH2 intron 21701565 rs9353713 chr6 90745875 C T 3.60E-04 Body mass index BACH2 intron 21701565 rs17766774 chr6 90755352 C G 4.60E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma BACH2 intron 22205395 rs4707589 chr6 90755887 G C 1.39E-04 Body mass index BACH2 intron 21701565 rs4707589 chr6 90755887 G C 5.77E-04 Body mass index BACH2 intron 21701565 rs9342219 chr6 90756453 C T 4.20E-04 Body mass index BACH2 intron 21701565 rs9342219 chr6 90756453 C T 8.80E-05 Body mass index BACH2 intron 21701565 rs9342220 chr6 90771812 G A 1.39E-06 Body mass index BACH2 intron 21701565 rs9342220 chr6 90771812 G A 3.22E-05 Body mass index BACH2 intron 21701565 rs4707593 chr6 90785351 G A 3.16E-04 Body mass index BACH2 intron 21701565 rs4707595 chr6 90797100 C T 3.82E-04 Body mass index BACH2 intron 21701565 rs4707597 chr6 90797349 A G 6.12E-04 Body mass index BACH2 intron 21701565 rs4707599 chr6 90800254 T C 7.45E-04 Body mass index BACH2 intron 21701565 rs7753008 chr6 90809639 T C 2.70E-07 Celiac disease BACH2 intron 22057235 rs7753008 chr6 90809639 T C 0.00000027 Celiac disease BACH2 intron 23143596 rs6454802 chr6 90814199 C T 2.65E-04 Self-reported allergy BACH2 intron 23817569 rs12202119 chr6 90815190 A T 2.94E-04 Self-reported allergy BACH2 intron 23817569 rs11753332 chr6 90819153 G A 2.53E-04 Self-reported allergy BACH2 intron 23817569 rs12196749 chr6 90819815 G A 4.39E-04 Self-reported allergy BACH2 intron 23817569 rs12194007 chr6 90823159 G T 2.41E-04 Self-reported allergy BACH2 intron 23817569 rs2501721 chr6 90845036 T C 2.32E-04 Self-reported allergy BACH2 intron 23817569 rs12199079 chr6 90852258 T G 4.81E-05 Self-reported allergy BACH2 intron 23817569 rs1010473 chr6 90856878 G T 7.33E-05 Self-reported allergy BACH2 intron 23817569 rs1010474 chr6 90857028 T C 6.14E-05 Self-reported allergy BACH2 intron 23817569 rs17711850 chr6 90864870 T C 7.09E-05 Self-reported allergy BACH2 intron 23817569 rs7774138 chr6 90866227 T A 8.13E-05 Self-reported allergy BACH2 intron 23817569 rs2474618 chr6 90876844 T C 1.26E-05 Graves' disease BACH2 intron 21841780 rs2474619 chr6 90880035 C A 1.07E-05 Graves' disease BACH2 intron 21841780 rs2474619 chr6 90880035 C A 2.00E-08 Celiac disease BACH2 intron 24999842 rs10944479 chr6 90880393 G A 2.51E-04 Response to taxane treatment (placlitaxel) BACH2 intron 23006423 rs10944479 chr6 90880393 G A 4.00E-08 Thyroid peroxidase antibody positivity BACH2 intron 24586183 rs10455168 chr6 90883525 T C 1.88E-04 Self-reported allergy BACH2 intron 23817569 rs10806423 chr6 90886824 C T 2.04E-04 Self-reported allergy BACH2 intron 23817569 rs2501716 chr6 90892399 C G 7.45E-06 Type 1 diabetes BACH2 intron 18978792 rs2501720 chr6 90899561 G A 4.49E-05 Graves' disease BACH2 intron 21841780 rs2064870 chr6 90903990 T C 3.59E-04 Self-reported allergy BACH2 intron 23817569 rs766153 chr6 90905047 A G 5.52E-04 Self-reported allergy BACH2 intron 23817569 rs4997561 chr6 90908057 C T 2.70E-04 Self-reported allergy BACH2 intron 23817569 rs17712288 chr6 90909157 G A 3.86E-04 Self-reported allergy BACH2 intron 23817569 rs12209546 chr6 90912594 C T 1.48E-05 Graves' disease BACH2 intron 21841780 rs3734660 chr6 90916345 T C 7.61E-05 Serum metabolites BACH2 UTR-5 19043545 rs3734660 chr6 90916345 T C 4.66E-04 Self-reported allergy BACH2 UTR-5 23817569 rs10944481 chr6 90917314 G A 4.90E-04 Self-reported allergy BACH2 intron 23817569 rs370409 chr6 90921740 C A 2.00E-06 Graves' disease BACH2 intron 21841780 rs1319433 chr6 90921988 G A 4.08E-04 Self-reported allergy BACH2 intron 23817569 rs10806425 chr6 90926612 C A 4.00E-10 Celiac disease BACH2 intron 20190752 rs10806425 chr6 90926612 C A 4.00E-10 Asthma BACH2 intron 21150878 rs10806425 chr6 90926612 C A 3.89E-10 Celiac disease and Rheumatoid arthritis BACH2 intron 21383967 rs10806425 chr6 90926612 C A 3.89E-10 Multiple sclerosis BACH2 intron 22190364 rs10806425 chr6 90926612 C A 3.46E-04 Self-reported allergy BACH2 intron 23817569 rs206916 chr6 90927728 T C 3.60E-05 Graves' disease BACH2 intron 21841780 rs9344996 chr6 90929301 T C 7.68E-06 Graves' disease BACH2 intron 21841780 rs9344996 chr6 90929301 T C 1.90E-05 Graves' disease BACH2 intron 23612905 rs206913 chr6 90936894 C A 2.85E-05 Graves' disease BACH2 intron 21841780 rs11757155 chr6 90941240 C T 5.04E-04 Self-reported allergy BACH2 intron 23817569 rs2021716 chr6 90941289 C T 3.90E-04 Self-reported allergy BACH2 intron 23817569 rs4707609 chr6 90946479 T C 8.19E-04 Self-reported allergy BACH2 intron 23817569 rs2655387 chr6 90947998 T C 2.54E-06 Graves' disease BACH2 intron 21841780 rs16882569 chr6 90950391 C T 1.78E-04 Multiple complex diseases BACH2 intron 17554300 rs2875584 chr6 90950628 C T 5.17E-04 Self-reported allergy BACH2 intron 23817569 rs17513531 chr6 90951239 C T 5.75E-04 Self-reported allergy BACH2 intron 23817569 rs3757247 chr6 90957463 C T 1.00E-06 Type 1 diabetes BACH2 intron 18840781 rs3757247 chr6 90957463 C T 8.18E-05 Graves' disease BACH2 intron 21841780 rs3757247 chr6 90957463 C T 3.00E-08 Vitiligo BACH2 intron 22561518 rs11755527 chr6 90958231 C G 3.36E-05 Multiple complex diseases BACH2 intron 17554300 rs11755527 chr6 90958231 C G 5.00E-12 Type 1 diabetes BACH2 intron 18978792 rs11755527 chr6 90958231 C G 5.00E-08 Type 1 diabetes BACH2 intron 19430480 rs11755527 chr6 90958231 C G 3.00E-08 Type 1 diabetes autoantibodies BACH2 intron 21829393 rs11755527 chr6 90958231 C G 5.00E-12 Multiple sclerosis BACH2 intron 22190364 rs905670 chr6 90958502 G A 6.67E-04 Self-reported allergy BACH2 intron 23817569 rs619192 chr6 90968949 C T 1.40E-04 Multiple complex diseases BACH2 intron 17554300 rs619192 chr6 90968949 C T 3.98E-06 Type 1 diabetes BACH2 intron 18978792 rs1847472 chr6 90973159 C A 6.24E-05 Type 1 diabetes BACH2 intron 18978792 rs1847472 chr6 90973159 C A 5.00E-09 Crohn's disease BACH2 intron 21102463 rs1847472 chr6 90973159 C A 5.00E-09 Asthma BACH2 intron 21907864 rs1847472 chr6 90973159 C A 2.00E-10 Inflammatory bowel disease BACH2 intron 23128233 rs1847472 chr6 90973159 C A 3.03E-04 Self-reported allergy BACH2 intron 23817569 rs661713 chr6 90975999 G A 1.26E-05 Graves' disease BACH2 intron 21841780 rs72928038 chr6 90976768 G A 0.000000123 Graves' disease and Hashimoto's thyroiditis BACH2 intron 22922229 rs72928038 chr6 90976768 G A 0.00000363 Graves' disease BACH2 intron 22922229 rs72928038 chr6 90976768 G A 0.000000823 Rheumatoid arthritis BACH2 intron 23143596 rs72928038 chr6 90976768 G A 0.000112 Rheumatoid arthritis (CCP positive) BACH2 intron 23143596 rs943689 chr6 90984035 C T 3.28E-04 Self-reported allergy BACH2 intron 23817569 rs604912 chr6 90986320 A G 1.68E-04 Multiple complex diseases BACH2 intron 17554300 rs604912 chr6 90986320 A G 9.13E-06 Type 1 diabetes BACH2 intron 18978792 rs953233 chr6 90995817 C T 7.86E-06 Graves' disease BACH2 intron 21841780 rs12212193 chr6 90996769 A G 4.00E-08 Multiple sclerosis BACH2 intron 21833088 rs10498965 chr6 90999602 A G 1.03E-05 Graves' disease BACH2 intron 21841780 rs597325 chr6 91002494 A G 1.02E-04 Graves' disease BACH2 intron 21841780 rs597325 chr6 91002494 A G 3.38E-10 Type 1 diabetes BACH2 intron 21980299 rs1504215 chr6 91006227 G A 2.58E-04 Self-reported allergy BACH2 UTR-5 23817569 rs6925032 chr6 91008027 C A 1.78E-04 Self-reported allergy / / 23817569 rs1321859 chr6 91011673 C T 1.71E-04 Self-reported allergy / / 23817569 rs12529935 chr6 91015039 C T 9.00E-06 Systemic lupus erythematosus / / 23273568 rs1394220 chr6 91019304 A C 5.30E-07 Celiac disease / / 24999842 rs12195431 chr6 91019654 C T 1.79E-04 Multiple complex diseases / / 17554300 rs56258221 chr6 91030441 T C 8.36E-12 Primary sclerosing cholangitis / / 23603763 rs6926330 chr6 91038726 G A 0.000037 Asthma / / 22607992 rs10755490 chr6 91061321 A G 1.40E-05 Alzheimer's disease / / 17998437 rs4707614 chr6 91082136 G A 7.80E-04 Crohn's disease / / 17684544 rs6915865 chr6 91082281 C T 7.00E-04 Chronic fatigue syndrome / / 21912186 rs10498968 chr6 91083880 C G 5.00E-04 Chronic fatigue syndrome / / 21912186 rs12530177 chr6 91098611 A T 8.47E-04 Multiple complex diseases / / 17554300 rs12530177 chr6 91098611 A T 1.10E-04 Body mass index / / 21701565 rs725351 chr6 91118921 C T 4.70E-05 Rheumatoid arthritis / / 22446963 rs10944485 chr6 91129879 A G 8.01E-04 Multiple complex diseases / / 17554300 rs1451075 chr6 91138957 T C 7.11E-04 Multiple complex diseases / / 17554300 rs1782449 chr6 91150188 T C 2.40E-05 Psoriasis / / 20953190 rs7772355 chr6 91151093 C T 2.20E-05 Urinary metabolites / / 21572414 rs12664489 chr6 91173423 G A 6.69E-04 Smoking cessation / / 24665060 rs1145724 chr6 91187510 T C 4.14E-05 Pancreatic cancer / / pha002889 rs366103 chr6 91202459 C T 1.50E-05 Urinary metabolites / / 21572414 rs806276 chr6 91207351 A G 3.00E-07 Attention deficit hyperactivity disorder (time to onset) / / 18937294 rs284509 chr6 91208376 T G 6.24E-05 HIV-1 viral setpoint / / 21490045 rs284513 chr6 91208693 C T 7.70E-04 Multiple complex diseases / / 17554300 rs9451437 chr6 91209886 A C 3.08E-06 Attention deficit hyperactivity disorder (time to onset) / / 18937294 rs157695 chr6 91218473 A C 7.11E-05 Blood Pressure / / pha003040 rs157705 chr6 91225135 C T 9.67E-05 Non-alcoholic fatty liver disease histology (other) MAP3K7 nearGene-3 20708005 rs205339 chr6 91231979 G A 1.32E-05 Serum metabolites MAP3K7 intron 19043545 rs791062 chr6 91238926 T C 9.60E-05 Non-alcoholic fatty liver disease histology (other) MAP3K7 intron 20708005 rs205352 chr6 91249218 G A 5.82E-05 Serum metabolites MAP3K7 intron 19043545 rs10944489 chr6 91264093 G A 3.57E-27 Narcolepsy MAP3K7 intron 19629137 rs282064 chr6 91303512 G T 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs282427 chr6 91310855 C T 3.98E-04 Multiple complex diseases / / 17554300 rs4707633 chr6 91327743 T C 9.71E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs4707640 chr6 91343657 G A 9.34E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs2750451 chr6 91352508 C T 7.92E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2616039 chr6 91353037 C T 7.91E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1923080 chr6 91354865 A G 7.79E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9353750 chr6 91359440 A G 2.02E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs13217057 chr6 91399141 G A 5.51E-04 Tourette syndrome / / 22889924 rs6916490 chr6 91401234 A G 2.60E-04 Hearing function / / 17255346 rs1145739 chr6 91409940 A G 5.15E-05 Cognitive impairment induced by topiramate / / 22091778 rs1145744 chr6 91414247 A C 5.15E-05 Cognitive impairment induced by topiramate / / 22091778 rs1145746 chr6 91415679 A C 8.45E-05 Lipoproteins / / pha003079 rs713155 chr6 91417752 G A,T 5.00E-07 Brain structure / / 20171287 rs1231499 chr6 91435263 T A 2.60E-05 Urinary metabolites / / 21572414 rs9451480 chr6 91472016 A G 4.50E-04 Multiple complex diseases / / 17554300 rs1504278 chr6 91488935 T C 8.90E-04 Multiple complex diseases / / 17554300 rs7775444 chr6 91493282 A G 4.41E-04 Tourette syndrome / / 22889924 rs11759332 chr6 91504562 C T 6.26E-04 Depression (quantitative trait) / / 20800221 rs9444785 chr6 91504822 T C 6.95E-04 Tourette syndrome / / 22889924 rs10485409 chr6 91505411 C T 1.00E-05 Kidney function and endocine traits / / 17903292 rs1504291 chr6 91522589 C T 7.76E-05 Heart Rate / / pha003053 rs9362786 chr6 91526500 G A 1.54E-05 Height / / pha003011 rs9359908 chr6 91533460 C T 1.59E-05 Height / / pha003011 rs4305691 chr6 91545010 T C 4.81E-05 Type 2 diabetes / / 17463246 rs1528982 chr6 91545554 A C 3.96E-04 Type 2 diabetes / / 17463246 rs6913163 chr6 91567851 C T 5.39E-04 Type 2 diabetes / / 17463246 rs2797450 chr6 91568654 C T 7.01E-05 Heart Rate / / pha003053 rs2062358 chr6 91575816 A G 5.99E-04 Type 2 diabetes / / 17463246 rs698162 chr6 91584932 C T 0.00072 Salmonella-induced pyroptosis / / 22837397 rs1775876 chr6 91588112 C T 6.99E-05 Type 2 diabetes / / 17463246 rs1699477 chr6 91588183 A G 2.87E-04 Type 2 diabetes / / 17463246 rs1342840 chr6 91596456 G A 0.000226 Salmonella-induced pyroptosis / / 22837397 rs12207515 chr6 91601534 G A 1.25E-04 Iron levels / / pha002876 rs12191179 chr6 91611925 G T 2.97E-04 Iron levels / / pha002876 rs1145796 chr6 91629740 T G 9.32E-04 Myocardial Infarction / / pha002873 rs711281 chr6 91650198 C T 4.67E-04 Myopia (pathological) / / 21095009 rs1220444 chr6 91655762 C G 7.85E-04 Type 2 diabetes / / 17463246 rs1220445 chr6 91656112 A G 5.44E-04 Type 2 diabetes / / 17463246 rs7775358 chr6 91669341 T G 1.00E-07 Multiple complex diseases / / 17554300 rs12205556 chr6 91716559 T C 1.19E-04 Parkinson's disease / / 17052657 rs9345075 chr6 91743110 A G 0.0000161 Asthma / / 22607992 rs9294476 chr6 91752411 T C 2.12E-04 Body mass index / / 21701565 rs9294476 chr6 91752411 T C 5.43E-04 Body mass index / / 21701565 rs10944512 chr6 91752473 A G 3.60E-05 Personality dimensions / / 22628180 rs6928845 chr6 91792042 A C 8.86E-04 Alzheimer's disease / / 17998437 rs4424056 chr6 91845407 T G 5.00E-07 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4707657 chr6 91865681 T C 4.63E-05 Lung function (forced vital capacity) / / pha003104 rs6925314 chr6 91876805 A G 3.32E-06 Asthma / / 21790008 rs6925314 chr6 91876805 A G 5.25E-06 Asthma / / 21790008 rs2820350 chr6 91909164 C A 1.00E-04 Information processing speed / / 21130836 rs7758604 chr6 91942743 T C 9.56E-05 Response to hepatitis C treatment / / 19684573 rs4235846 chr6 91944598 A T 7.52E-04 Multiple complex diseases / / 17554300 rs2811670 chr6 91956663 T C 7.00E-06 Response to inhaled corticosteroid treatment in asthma (percentage change of FEV1) / / 24792382 rs7740461 chr6 91975997 T C 7.59E-04 Depression (quantitative trait) / / 20800221 rs7758710 chr6 91976164 A G 8.81E-04 Depression (quantitative trait) / / 20800221 rs2811650 chr6 91977107 A G 9.44E-05 Coronary heart disease / / pha003032 rs9294485 chr6 91978493 A G 4.14E-04 Type 2 diabetes / / 17846125 rs12174540 chr6 92010992 A G 2.19E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9345126 chr6 92011208 T C 1.65E-04 Body mass index / / 21701565 rs9345126 chr6 92011208 T C 7.39E-04 Body mass index / / 21701565 rs4707672 chr6 92011531 T C 1.86E-04 Body mass index / / 21701565 rs4707672 chr6 92011531 T C 7.30E-04 Body mass index / / 21701565 rs2748276 chr6 92014180 C T 8.18E-05 Attention deficit hyperactivity disorder / / 23728934 rs2748276 chr6 92014180 C T 3.23E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7751503 chr6 92014849 C G 2.27E-04 Body mass index / / 21701565 rs9342272 chr6 92022715 C T 3.42E-04 Depression (quantitative trait) / / 20800221 rs9353821 chr6 92024031 C A 3.41E-04 Depression (quantitative trait) / / 20800221 rs6906049 chr6 92031699 G A 3.22E-04 Depression (quantitative trait) / / 20800221 rs2144363 chr6 92041904 A C 2.70E-04 Depression (quantitative trait) / / 20800221 rs2144363 chr6 92041904 A C 5.30E-05 Alcohol consumption (maxi-drinks) / / 24277619 rs9294486 chr6 92042794 C T 2.68E-04 Depression (quantitative trait) / / 20800221 rs9353823 chr6 92045007 G C 2.64E-04 Depression (quantitative trait) / / 20800221 rs9353824 chr6 92061701 A G 6.21E-05 Suicide attempts in bipolar disorder / / 21041247 rs9353824 chr6 92061701 A G 8.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs7762541 chr6 92068101 T C 6.13E-05 Suicide attempts in bipolar disorder / / 21041247 rs7762541 chr6 92068101 T C 8.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs6910080 chr6 92069148 A G 4.32E-05 Suicide attempts in bipolar disorder / / 21041247 rs6910080 chr6 92069148 A G 8.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs9345131 chr6 92076041 G C 4.12E-05 Depression (quantitative trait) / / 20800221 rs9362869 chr6 92076091 T C 4.06E-05 Depression (quantitative trait) / / 20800221 rs2180130 chr6 92077314 A G 3.00E-05 Suicide attempts in bipolar disorder / / 21041247 rs2180130 chr6 92077314 A G 8.57E-04 Suicide attempts in bipolar disorder / / 21041247 rs9342276 chr6 92086552 G A 3.79E-05 Depression (quantitative trait) / / 20800221 rs17555739 chr6 92255747 G A,C 9.50E-06 Urinary metabolites / / 21572414 rs9362886 chr6 92256671 G C 5.08E-04 Insulin resistance / / 21901158 rs9342290 chr6 92263628 T C 7.20E-04 Suicide attempts in bipolar disorder / / 21041247 rs9345149 chr6 92263757 T A 7.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs9362888 chr6 92265165 A G 7.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs9345152 chr6 92270124 G A 6.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs9342293 chr6 92271821 A T 6.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs9353859 chr6 92313979 T G 1.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9353859 chr6 92313979 T G 4.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2039500 chr6 92316225 A G 2.26E-04 HIV-1 viral setpoint / / 17641165 rs9359954 chr6 92318594 T G 2.49E-04 HIV-1 viral setpoint / / 17641165 rs4112305 chr6 92321000 A C 2.05E-04 HIV-1 viral setpoint / / 17641165 rs9451755 chr6 92369315 C T 4.92E-05 Cognitive decline / / 22054870 rs10485100 chr6 92377905 G A 3.05E-04 Diabetic retinopathy / / 20871662 rs559663 chr6 92393049 C G 5.47E-04 Alzheimer's disease / / 17998437 rs512950 chr6 92405901 C T 6.65E-04 Aortic root size / / 21223598 rs539526 chr6 92406092 G A 2.66E-04 Aortic root size / / 21223598 rs437932 chr6 92429905 C T 6.34E-04 Prostate cancer mortality / / 20978177 rs437932 chr6 92429905 C T 8.27E-05 Aortic root size / / 21223598 rs1334627 chr6 92445508 T C 8.19E-05 Personality dimensions / / 18957941 rs7747766 chr6 92447161 A G 9.18E-05 Personality dimensions / / 18957941 rs2325399 chr6 92450136 G C 9.54E-05 Personality dimensions / / 18957941 rs6454882 chr6 92530585 C A 5.60E-04 Aortic root size / / 21223598 rs9362911 chr6 92532877 G A 8.00E-04 Type 2 diabetes / / 17463246 rs1542838 chr6 92533816 T G 3.86E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2454268 chr6 92560593 G C 1.51E-05 Type 2 diabetes / / 17463246 rs16884981 chr6 92565414 G A 7.13E-04 Aortic root size / / 21223598 rs9342302 chr6 92572932 C A 5.54E-04 Type 2 diabetes / / 17463246 rs1546210 chr6 92576591 C A 4.20E-04 Crohn's disease / / 17684544 rs1546210 chr6 92576591 C A 7.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9359960 chr6 92589873 A T 5.98E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4318847 chr6 92590109 A G 2.42E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9444920 chr6 92600947 G A 1.01E-04 Aortic root size / / 21223598 rs9451852 chr6 92603229 T C 8.99E-06 Aortic root size / / 21223598 rs1603728 chr6 92617115 A G 3.00E-05 Aortic root size / / 21223598 rs9362923 chr6 92638995 C T 9.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs9342307 chr6 92643232 C T 5.59E-05 Amyotrophic lateral sclerosis / / 20801717 rs9342307 chr6 92643232 C T 0.0000399 Amyotrophic lateral sclerosis / / 23587638 rs9342307 chr6 92643232 C T 0.000072 Amyotrophic lateral sclerosis / / 23587638 rs9342307 chr6 92643232 C T 6.98E-05 Platelet counts / / pha003100 rs9294517 chr6 92646964 T A 3.24E-04 Body mass index / / 21701565 rs13194247 chr6 92687070 A G 1.46E-04 Coronary heart disease / / 21606135 rs7768073 chr6 92814956 A G 0.00007364 Sarcoidosis / / 22952805 rs13217394 chr6 92820925 C A 0.00008828 Sarcoidosis / / 22952805 rs2452941 chr6 92822555 G A 6.16E-05 Multiple complex diseases / / 17554300 rs2452940 chr6 92822870 G A 1.55E-04 Multiple complex diseases / / 17554300 rs4571541 chr6 92828724 G A 2.80E-05 Celiac disease / / 17558408 rs4571541 chr6 92828724 G A 3.59E-05 Prostate cancer / / 22923026 rs4446534 chr6 92829488 G A 3.30E-05 Celiac disease / / 17558408 rs4334953 chr6 92830228 C T 8.78E-04 Type 2 diabetes / / 17463246 rs7758700 chr6 92834690 T A 3.07E-04 Multiple complex diseases / / 17554300 rs7738591 chr6 92834715 G A 3.74E-04 Multiple complex diseases / / 17554300 rs7738449 chr6 92834762 C T 2.30E-04 Multiple complex diseases / / 17554300 rs11751556 chr6 92835169 C G 5.02E-04 Type 2 diabetes / / 17463246 rs6908539 chr6 92840842 C T 3.13E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6908539 chr6 92840842 C T 8.00E-05 Prostate cancer / / 21743057 rs7747255 chr6 92841275 G T 1.25E-04 Multiple complex diseases / / 17554300 rs7773056 chr6 92849774 T C 9.18E-04 Type 2 diabetes / / 17463246 rs12193981 chr6 92919470 A G 6.24E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1470359 chr6 92923205 A G 3.19E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1822589 chr6 92965297 T C 7.90E-04 Substance dependence / / 21818250 rs9351314 chr6 92983291 G A 2.10E-05 Urinary metabolites / / 21572414 rs1020320 chr6 92999553 T C 7.00E-04 Substance dependence / / 21818250 rs678303 chr6 93081848 T A 6.55E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs582808 chr6 93099728 C A 3.41E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2555773 chr6 93183933 A G 2.76E-05 Body Mass Index / / pha003006 rs2555773 chr6 93183933 A G 4.61E-05 Body Mass Index / / pha003007 rs13207034 chr6 93197300 G A 1.00E-06 Metabolite levels (HVA-5-HIAA Factor score) / / 23319000 rs13207034 chr6 93197300 G A 4.00E-06 Metabolite levels (HVA) / / 23319000 rs2730835 chr6 93279039 T C 5.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6918777 chr6 93369655 G T 7.00E-06 Amyotrophic lateral sclerosis / / 22959728 rs6937258 chr6 93393323 C T 7.90E-04 Type 2 diabetes / / 17463246 rs1342007 chr6 93396506 C T 6.94E-05 Aging (time to event) / / 21782286 rs1380490 chr6 93425595 G C 7.89E-04 Type 2 diabetes / / 17463246 rs1563798 chr6 93455495 G T 8.95E-05 Serum metabolites / / 19043545 rs12211463 chr6 93467158 T G 5.80E-04 Pain relief with opioid treatment / / 21622719 rs1515786 chr6 93475558 C T 2.94E-05 Serum metabolites / / 19043545 rs6899693 chr6 93518927 G A 9.98E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6909753 chr6 93556066 C T 5.67E-05 Multiple complex diseases / / 17554300 rs10485365 chr6 93574113 T A 2.44E-04 Multiple complex diseases / / 17554300 rs9363009 chr6 93578359 A G 9.48E-04 Tourette syndrome / / 22889924 rs2066012 chr6 93605453 A G 0.000243 Breast cancer early age of onset / / 18463975 rs2506933 chr6 93615450 T C 6.00E-06 Cognitive performance / / 20125193 rs1416017 chr6 93618316 A G 5.94E-04 Multiple complex diseases / / 17554300 rs17527547 chr6 93622828 G C 9.79E-04 Multiple complex diseases / / 17554300 rs9363019 chr6 93628360 T G 8.14E-05 Cognitive test performance / / 20125193 rs1122046 chr6 93639896 A G 1.28E-05 Post-operative nausea and vomiting / / 21694509 rs6923057 chr6 93646679 A G 3.16E-05 Soluble levels of adhesion molecules / / pha003072 rs4409157 chr6 93656050 C T 3.69E-05 Soluble levels of adhesion molecules / / pha003072 rs17437983 chr6 93674832 T C 5.75E-05 Alcohol dependence / / 19581569 rs12530327 chr6 93689648 G A 1.20E-05 Urinary metabolites / / 21572414 rs7765676 chr6 93696809 T G 5.09E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs677242 chr6 93702141 C T 3.79E-04 Myocardial Infarction / / pha002873 rs585369 chr6 93711683 T C 7.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs652520 chr6 93713805 T C 2.00E-06 Chronic obstructive pulmonary disease-related biomarkers / / 23144326 rs652520 chr6 93713805 T C 2.20E-04 Myocardial Infarction / / pha002873 rs9918467 chr6 93718600 G A 9.54E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1590392 chr6 93735074 T G 1.71E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1324132 chr6 93748699 T A,G 1.42E-13 Multiple complex diseases / / 17554300 rs12216260 chr6 93760118 G A 2.78E-04 Smoking initiation / / 24665060 rs9452225 chr6 93766609 C A 5.74E-04 Myopia (pathological) / / 21095009 rs9452232 chr6 93773302 C T 6.00E-05 ldl cholesterol / / pha003077 rs9452232 chr6 93773302 C T 3.30E-05 Cholesterol / / pha003083 rs1324115 chr6 93790248 G T 7.46E-04 Alzheimer's disease / / 24755620 rs9353982 chr6 93802038 G A 1.21E-04 Myopia (pathological) / / 21095009 rs6454939 chr6 93813414 C T 3.00E-05 Telomere length / / 23001564 rs2224854 chr6 93814357 G A 5.45E-05 ldl cholesterol / / pha003077 rs2224854 chr6 93814357 G A 3.37E-05 Cholesterol / / pha003083 rs10485372 chr6 93821238 T C 7.46E-05 ldl cholesterol / / pha003077 rs10485372 chr6 93821238 T C 8.36E-05 Cholesterol / / pha003083 rs9294559 chr6 93821257 G A 2.90E-05 ldl cholesterol / / pha003077 rs9294559 chr6 93821257 G A 3.70E-05 Cholesterol / / pha003083 rs9294560 chr6 93823182 G A 1.84E-04 Myopia (pathological) / / 21095009 rs16870789 chr6 93827963 C T 2.50E-06 Urinary metabolites / / 21572414 rs6922405 chr6 93842847 T C 1.40E-06 Urinary metabolites / / 21572414 rs594442 chr6 93847884 A T 1.00E-06 Dialysis-related mortality / / 21546767 rs1408282 chr6 93852252 G A 1.00E-06 C-reactive protein / / 21647738 rs4707785 chr6 93861788 A G 9.20E-07 C-reactive protein / / 21647738 rs9353992 chr6 93869122 A G 9.43E-05 Cognitive impairment induced by topiramate / / 22091778 rs1930936 chr6 93869208 G A 2.80E-05 Urinary metabolites / / 21572414 rs9342352 chr6 93871532 G T 9.60E-07 C-reactive protein / / 21647738 rs1998578 chr6 93872068 C T 9.60E-07 C-reactive protein / / 21647738 rs6929495 chr6 93888496 A C 1.69E-05 Cognitive impairment induced by topiramate / / 22091778 rs6901416 chr6 93892412 T G 4.10E-06 Non-small cell lung cancer (survival) / / 23704207 rs1324103 chr6 93901016 A G 2.95E-04 Stroke / / pha002887 rs6931820 chr6 93906373 G A 5.03E-04 Stroke / / pha002887 rs1575536 chr6 93909926 A G 3.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12527818 chr6 93911119 T C 7.00E-06 Response to hepatitis C treatment / / 22095909 rs1486756 chr6 93942185 A G 1.85E-04 Epilepsy / / 22116939 rs373675 chr6 93962032 C G 2.46E-04 Multiple complex diseases EPHA7 intron 17554300 rs3799821 chr6 93962293 G C 2.90E-05 Urinary metabolites EPHA7 intron 21572414 rs17447037 chr6 93962762 C T 2.70E-05 Urinary metabolites EPHA7 intron 21572414 rs345717 chr6 93985029 A G 8.55E-04 Multiple complex diseases EPHA7 intron 17554300 rs17447791 chr6 93995454 A G 7.49E-05 Hemoglobin EPHA7 intron pha003096 rs967520 chr6 94000513 A C 7.40E-05 Cognitive test performance EPHA7 intron 20125193 rs9363058 chr6 94008535 C T 8.00E-06 Response to cytadine analogues (cytosine arabinoside) EPHA7 intron 24483146 rs164301 chr6 94029815 T G 4.37E-04 Hemoglobin concentration EPHA7 intron 20534544 rs1492967 chr6 94069681 G A 3.01E-05 Schizophrenia EPHA7 intron 21926974 rs625822 chr6 94112802 C T 4.80E-04 Alcohol dependence EPHA7 intron 20201924 rs625822 chr6 94112802 C T 7.50E-05 Alcohol dependence EPHA7 intron 20201924 rs625822 chr6 94112802 C T 7.50E-05 Alcoholism EPHA7 intron pha002892 rs9445111 chr6 94178128 G A,T 3.26E-04 Multiple complex diseases / / 17554300 rs6915701 chr6 94210134 A G 1.00E-05 Urinary metabolites / / 21572414 rs1602160 chr6 94220472 T C 9.70E-06 Urinary metabolites / / 21572414 rs9445122 chr6 94221770 A G 9.60E-06 Urinary metabolites / / 21572414 rs9445138 chr6 94300090 A G 1.90E-06 Urinary metabolites / / 21572414 rs2022156 chr6 94302093 T G 4.40E-06 Urinary metabolites / / 21572414 rs9342368 chr6 94307346 G T 6.60E-06 Urinary metabolites / / 21572414 rs9363099 chr6 94327480 G A 3.40E-06 Urinary metabolites / / 21572414 rs1906980 chr6 94348038 A G 8.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13208357 chr6 94389460 C T 2.20E-04 Alcohol dependence / / 20201924 rs13208357 chr6 94389460 C T 6.17E-05 Depression (quantitative trait) / / 20800221 rs1577598 chr6 94394828 G A 4.68E-05 Height / / 17255346 rs10944690 chr6 94404170 T A 5.34E-04 Depression (quantitative trait) / / 20800221 rs6933279 chr6 94408714 G A 4.30E-04 Depression (quantitative trait) / / 20800221 rs937044 chr6 94412252 G A 1.26E-04 Height / / 17255346 rs937044 chr6 94412252 G A 1.17E-05 Coronary restenosis / / 21878436 rs6454977 chr6 94419927 C T 6.34E-05 Height TSG1 intron 17255346 rs6454977 chr6 94419927 C T 1.17E-05 Coronary restenosis TSG1 intron 21878436 rs1414614 chr6 94460497 T C 0.00062 Asthma TSG1 intron 22607992 rs9363108 chr6 94461990 C T 0.00062 Asthma TSG1 intron 22607992 rs7765319 chr6 94473157 C T 6.82E-04 Alcohol dependence TSG1 intron 20201924 rs9345399 chr6 94493290 C T 2.00E-05 Prostate cancer / / 21743057 rs1984151 chr6 94529099 A G 7.60E-04 Suicidal ideation / / 22030708 rs1937367 chr6 94572785 T C 2.88E-04 Multiple complex diseases / / 17554300 rs1488304 chr6 94592955 T C 2.27E-04 Multiple complex diseases / / 17554300 rs7449883 chr6 94660447 T G 7.26E-04 Multiple complex diseases / / 17554300 rs1463675 chr6 94676283 T C 3.95E-04 Multiple complex diseases / / 17554300 rs1488307 chr6 94715324 C T 1.67E-05 Suicide attempts in bipolar disorder / / 21041247 rs1488307 chr6 94715324 C T 7.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs2129857 chr6 94718496 C T 3.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs10806484 chr6 94720340 A C 7.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs4707818 chr6 94722101 G C 5.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs1352380 chr6 94726087 C T 6.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs9345421 chr6 94728423 C T 4.91E-05 Heart Rate / / pha003054 rs582835 chr6 94728619 T C 1.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs582835 chr6 94728619 T C 2.19E-05 Suicide attempts in bipolar disorder / / 21041247 rs10944710 chr6 94732089 C T 7.53E-04 Suicide attempts in bipolar disorder / / 21041247 rs1586510 chr6 94733175 C T 1.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs1586510 chr6 94733175 C T 2.33E-05 Suicide attempts in bipolar disorder / / 21041247 rs1488324 chr6 94735555 A C,G,T 1.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs1488324 chr6 94735555 A C,G,T 3.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs2129859 chr6 94742138 A C,G,T 5.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs2129859 chr6 94742138 A C,G,T 9.79E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs2171518 chr6 94742277 T C 5.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs679881 chr6 94743025 A G 1.53E-04 Suicide attempts in bipolar disorder / / 21041247 rs679881 chr6 94743025 A G 2.66E-05 Suicide attempts in bipolar disorder / / 21041247 rs1463678 chr6 94743997 A G 1.95E-04 Suicide attempts in bipolar disorder / / 21041247 rs1463678 chr6 94743997 A G 2.68E-05 Suicide attempts in bipolar disorder / / 21041247 rs2875662 chr6 94751020 T C 2.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs2875662 chr6 94751020 T C 3.02E-05 Suicide attempts in bipolar disorder / / 21041247 rs12663518 chr6 94756060 T G 2.30E-04 Smoking initiation / / 24665060 rs16871825 chr6 94756403 C A 8.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs678036 chr6 94757398 G C 3.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs678036 chr6 94757398 G C 3.24E-05 Suicide attempts in bipolar disorder / / 21041247 rs9363138 chr6 94757658 G T 6.57E-04 Suicide attempts in bipolar disorder / / 21041247 rs16871829 chr6 94757719 A G 5.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs6919516 chr6 94759892 A G 3.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs6919516 chr6 94759892 A G 3.12E-05 Suicide attempts in bipolar disorder / / 21041247 rs10944713 chr6 94761440 A T 5.71E-04 Suicide attempts in bipolar disorder / / 21041247 rs667243 chr6 94761761 A G 2.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs667243 chr6 94761761 A G 2.56E-05 Suicide attempts in bipolar disorder / / 21041247 rs590701 chr6 94763117 G T 5.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs2787944 chr6 94765030 C T 1.28E-05 Suicide attempts in bipolar disorder / / 21041247 rs2787944 chr6 94765030 C T 2.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs1538283 chr6 94767468 G A 1.18E-05 Suicide attempts in bipolar disorder / / 21041247 rs1538283 chr6 94767468 G A 1.79E-04 Suicide attempts in bipolar disorder / / 21041247 rs1416058 chr6 94768457 A T 1.43E-05 Suicide attempts in bipolar disorder / / 21041247 rs1416058 chr6 94768457 A T 1.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs12664815 chr6 94768721 C T 4.09E-04 Smoking initiation / / 24665060 rs16871876 chr6 94769403 T C 8.73E-05 Smoking initiation / / 24665060 rs1338341 chr6 94773306 G A 1.18E-05 Suicide attempts in bipolar disorder / / 21041247 rs1338341 chr6 94773306 G A 2.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs9354082 chr6 94773711 T C 1.21E-05 Suicide attempts in bipolar disorder / / 21041247 rs9354082 chr6 94773711 T C 2.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs9354083 chr6 94773950 T C 1.48E-05 Suicide attempts in bipolar disorder / / 21041247 rs9354083 chr6 94773950 T C 2.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs9445199 chr6 94774235 G A 1.24E-05 Suicide attempts in bipolar disorder / / 21041247 rs9445199 chr6 94774235 G A 2.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs9351405 chr6 94777317 G A 1.32E-05 Suicide attempts in bipolar disorder / / 21041247 rs9351405 chr6 94777317 G A 2.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs2535660 chr6 94781543 T C 5.71E-04 Suicide attempts in bipolar disorder / / 21041247 rs583000 chr6 94789360 C T 5.95E-04 Suicide attempts in bipolar disorder / / 21041247 rs2535672 chr6 94789940 G A 6.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs658208 chr6 94793255 A G 6.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs606061 chr6 94796278 A G 6.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs694170 chr6 94797641 A G 6.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs591551 chr6 94798191 C T 6.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs471348 chr6 94798785 G A 6.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs669021 chr6 94799070 C T 1.92E-05 Suicide attempts in bipolar disorder / / 21041247 rs669021 chr6 94799070 C T 3.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs682644 chr6 94799797 C T 7.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs2787948 chr6 94800160 C T 7.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs2787950 chr6 94803148 C A 6.48E-04 Suicide attempts in bipolar disorder / / 21041247 rs546100 chr6 94803806 A C 6.53E-04 Suicide attempts in bipolar disorder / / 21041247 rs546226 chr6 94803847 G A 6.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs596498 chr6 94840873 A G 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs537092 chr6 94842774 G A 5.25E-04 Smoking initiation / / 24665060 rs682365 chr6 94869742 G A 8.78E-04 Multiple complex diseases / / 17554300 rs1639417 chr6 94876830 G C 6.79E-04 Type 2 diabetes / / 17463246 rs1750607 chr6 94920887 G T 8.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs1750608 chr6 94921682 G A 1.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs1548760 chr6 94922112 C G 1.34E-04 Bipolar disorder / / 18317468 rs452930 chr6 94922837 C T 3.57E-04 Type 2 diabetes / / 17463246 rs416145 chr6 94925228 A G 9.15E-04 Alzheimer's disease / / 24755620 rs1613035 chr6 94926752 A T 4.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs1639414 chr6 94928611 C T 5.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs2021314 chr6 94937733 C T 4.52E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs6454990 chr6 94939515 A G 3.50E-05 Alzheimer's disease (late onset) / / 21379329 rs6454990 chr6 94939515 A G 8.07E-06 Parent of origin effect on language impairment (maternal) / / 24571439 rs9360055 chr6 94940269 G A 1.26E-05 Alcohol and nictotine co-dependence / / 20158304 rs9452602 chr6 94945292 G A 4.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs9445219 chr6 94947263 A G 3.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs1558592 chr6 94956556 T C 7.95E-04 Type 2 diabetes / / 17463246 rs220944 chr6 94958322 T C 2.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs220946 chr6 94959110 G A 2.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs220948 chr6 94960398 T A 1.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs220952 chr6 94963667 T C 1.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs220953 chr6 94965328 C A 1.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs220954 chr6 94965717 T C 2.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs220956 chr6 94966002 T A 1.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs1028795 chr6 94967014 C T 2.93E-04 Alzheimer's disease / / 24755620 rs65552 chr6 94967613 C T 2.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs220957 chr6 94967773 G A 2.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs220960 chr6 94971757 G A 2.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs220968 chr6 94977716 G A 2.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs220970 chr6 94980573 A G 3.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs397178 chr6 94994082 G A 2.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs424717 chr6 94995487 C T 9.24E-05 Suicide attempts in bipolar disorder / / 21423239 rs452854 chr6 94996521 G A 1.26E-04 Alzheimer's disease (late onset) / / 21379329 rs376040 chr6 94996541 G T 1.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs1359504 chr6 94997850 C T 3.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs389972 chr6 94998630 T C 1.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs391568 chr6 94999081 T C 1.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs9345457 chr6 95000401 A G 6.69E-04 Acute lung injury / / 22295056 rs419342 chr6 95003348 A G 1.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs420786 chr6 95003974 A G 1.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs434310 chr6 95004561 G A 6.59E-07 Bilirubin levels,in serum / / 19389676 rs434310 chr6 95004561 G A 4.13E-04 Alzheimer's disease / / 22005930 rs442124 chr6 95004698 C T 8.34E-05 Alzheimer's disease (late onset) / / 21379329 rs524391 chr6 95005854 A G 4.16E-04 Alzheimer's disease / / 22005930 rs383736 chr6 95007019 G A 1.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs417343 chr6 95008024 T C 8.34E-05 Alzheimer's disease (late onset) / / 21379329 rs1235816 chr6 95013549 A G 5.00E-04 Alzheimer's disease / / 22005930 rs422906 chr6 95014649 T C 3.81E-04 Alzheimer's disease / / 22005930 rs366115 chr6 95014933 T G 1.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs428082 chr6 95015266 G A 5.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs431852 chr6 95016416 T A 4.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs446469 chr6 95020338 A G 5.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs422693 chr6 95021588 G T 5.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs428609 chr6 95022811 A G 6.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs385900 chr6 95022844 T C 5.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs386272 chr6 95022980 T G 4.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs442750 chr6 95023402 A G 5.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs396560 chr6 95023865 T G 5.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs376819 chr6 95024380 A T 5.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs404648 chr6 95024608 C G 5.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs372396 chr6 95024637 G A 5.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs372761 chr6 95024725 G A 5.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs441859 chr6 95025022 G C 3.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs1235830 chr6 95025391 T C 6.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs398381 chr6 95025462 C T 2.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs394508 chr6 95025625 T C 2.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs414214 chr6 95025647 T C 3.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs385157 chr6 95025994 C A 2.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs421900 chr6 95026342 T C 4.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs441057 chr6 95026399 G A 2.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs489102 chr6 95026641 A G 2.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs428967 chr6 95027321 T C 3.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs417946 chr6 95027402 G A 2.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs453736 chr6 95028303 G A 2.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs1325478 chr6 95028476 A G 8.91E-04 Tourette syndrome / / 22889924 rs453873 chr6 95028615 G A 2.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs440350 chr6 95029337 T A 2.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs1325479 chr6 95035288 G A 8.19E-04 Tourette syndrome / / 22889924 rs9342406 chr6 95043459 G A 0.000642 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs412502 chr6 95043627 G A 5.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs7770845 chr6 95045878 A G 7.15E-04 Tourette syndrome / / 22889924 rs397771 chr6 95046365 A G 4.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs6911960 chr6 95049245 A G 6.22E-04 Multiple complex diseases / / 17554300 rs459253 chr6 95049341 A C 4.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs9363184 chr6 95050754 A C 1.03E-04 Type 2 diabetes / / 17463246 rs16872554 chr6 95051448 T C 1.09E-04 Multiple complex diseases / / 17554300 rs462001 chr6 95057247 C G 6.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs457558 chr6 95057602 A G 9.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs461185 chr6 95057655 G A 6.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs460365 chr6 95057693 C T 6.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs459545 chr6 95058699 A G 6.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs457175 chr6 95058801 C A 6.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs464492 chr6 95059333 T G 6.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs885717 chr6 95060183 A G 4.82E-05 Relative hand skill in reading disability / / 24068947 rs458523 chr6 95061602 T C 5.80E-04 Lung adenocarcinoma / / 21242121 rs13203547 chr6 95072929 A G 7.32E-04 Prostate cancer mortality / / 20978177 rs9342409 chr6 95098682 A C 2.00E-04 Information processing speed / / 21130836 rs16872925 chr6 95100315 A G 9.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs9445243 chr6 95103580 G A 3.58E-05 Alzheimer's disease (late onset) / / 21379329 rs9445243 chr6 95103580 G A 1.10E-05 Orofacial clefts / / 22419666 rs9354118 chr6 95147902 C T 1.85E-04 Cognitive decline / / 23732972 rs2207428 chr6 95152928 G A 0.000042 Asthma / / 22607992 rs2224003 chr6 95156418 C T 1.00E-09 Brain connectivity / / 23471985 rs10485022 chr6 95156454 G A 5.00E-09 Brain connectivity / / 23471985 rs9342418 chr6 95197387 C T 6.40E-06 Urinary metabolites / / 21572414 rs1022787 chr6 95202197 G A 9.44E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs9445305 chr6 95205713 G C 3.20E-06 Urinary metabolites / / 21572414 rs9452812 chr6 95211042 T C 3.40E-06 Urinary metabolites / / 21572414 rs9452816 chr6 95213956 A T 8.00E-06 Urinary metabolites / / 21572414 rs2145067 chr6 95256763 C T 1.41E-07 Blood pressure / / 21996601 rs2750024 chr6 95303185 C T 6.75E-04 Myocardial Infarction / / pha002873 rs2750023 chr6 95304525 A C 6.46E-04 Myocardial Infarction / / pha002873 rs16873405 chr6 95334164 C T 2.40E-05 Urinary metabolites / / 21572414 rs4282379 chr6 95341309 T C 8.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10806489 chr6 95352842 T C 1.19E-04 Heart rate / / 23583979 rs9363229 chr6 95358968 G T 0.0000167 Asthma / / 22607992 rs2493975 chr6 95377376 G T 1.40E-05 Urinary metabolites / / 21572414 rs2493984 chr6 95383492 A G 3.25E-06 Osteoarthritis / / 22763110 rs10498989 chr6 95390186 C T 0.00000856 Asthma / / 22607992 rs4145130 chr6 95422618 A T 1.00E-07 Methotrexate phramacokinetics (acute lymphoblastic leukemia) / / 19901119 rs12524279 chr6 95513192 C T 4.54E-04 HIV-1 viral setpoint / / 17641165 rs16873774 chr6 95552875 T C 1.10E-04 Multiple complex diseases / / 17554300 rs12195016 chr6 95597741 A G 8.38E-04 Multiple complex diseases / / 17554300 rs2716054 chr6 95842444 G T 3.37E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2613557 chr6 95845966 G A 4.32E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6905412 chr6 95896515 C T 9.06E-04 Multiple complex diseases / / 17554300 rs9386595 chr6 95945014 T C 2.54E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2380220 chr6 95967412 T C 3.60E-04 Behavioural disinhibition (generation interaction) / / 23942779 rs2380220 chr6 95967412 T C 3.70E-04 Behavioural disinhibition (generation interaction) / / 23942779 rs2380220 chr6 95967412 T C 4.00E-06 Behavioural disinhibition (generation interaction) / / 23942779 rs2380220 chr6 95967412 T C 4.30E-05 Behavioural disinhibition (generation interaction) / / 23942779 rs2380220 chr6 95967412 T C 4.60E-04 Behavioural disinhibition (generation interaction) / / 23942779 rs2380222 chr6 95975395 C T 2.50E-04 Behavioural disinhibition (generation interaction) / / 23942779 rs2380222 chr6 95975395 C T 3.00E-04 Behavioural disinhibition (generation interaction) / / 23942779 rs2380222 chr6 95975395 C T 3.30E-04 Behavioural disinhibition (generation interaction) / / 23942779 rs2380222 chr6 95975395 C T 5.00E-06 Behavioural disinhibition (generation interaction) / / 23942779 rs2380222 chr6 95975395 C T 5.20E-05 Behavioural disinhibition (generation interaction) / / 23942779 rs7748108 chr6 96008082 T C 7.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs4308568 chr6 96009525 G T 5.55E-04 Alzheimer's disease / / 17998437 rs11153964 chr6 96082712 T G 9.00E-04 Body mass index / / 21701565 rs4388292 chr6 96083087 T G 1.52E-05 Multiple sclerosis / / 20598377 rs4342432 chr6 96089153 G A 2.96E-05 Neuroticism / / 23229837 rs4510687 chr6 96112861 T C 2.49E-05 Neuroticism / / 23229837 rs139591835 chr6 96128910 C G 8.48E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs143247165 chr6 96179004 T A 8.00E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs7743203 chr6 96202862 C T 2.92E-04 Glycemic traits (pregnancy) / / 23903356 rs9321480 chr6 96223953 A G 9.70E-04 Multiple complex diseases / / 17554300 rs6935338 chr6 96275925 T A 3.20E-05 Bilirubin levels / / 19414484 rs6570428 chr6 96283669 C T 6.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs6570428 chr6 96283669 C T 6.39E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2799652 chr6 96333852 A C 0.0000235 Colorectal cancer / / 22532847 rs7763885 chr6 96365166 C A 8.54E-04 Body mass index / / 21701565 rs6925466 chr6 96376843 C T 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs494801 chr6 96380731 G T 3.38E-04 Multiple complex diseases / / 17554300 rs4839793 chr6 96382578 A G 2.74E-04 Multiple complex diseases / / 17554300 rs10484742 chr6 96409150 A C 4.66E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs632630 chr6 96417975 T G 8.80E-04 Testosterone levels / / 22675492 rs477272 chr6 96418654 A G 8.90E-04 Testosterone levels / / 22675492 rs11962981 chr6 96420417 A G 4.07E-04 Acute lung injury / / 22295056 rs608475 chr6 96424790 C T 0.000716732 Hypertension (early onset hypertension) / / 22479346 rs655865 chr6 96427122 T C 0.000736694 Hypertension (early onset hypertension) / / 22479346 rs567149 chr6 96435678 C T 3.28E-07 Corneal structure / / 22003120 rs6913319 chr6 96462712 C G 1.55E-04 Schizophrenia / / 20832056 rs6934593 chr6 96464414 T C 1.14E-04 Schizophrenia FUT9 intron 20832056 rs9404150 chr6 96474372 A G 4.33E-05 Schizophrenia FUT9 intron 19571809 rs2224951 chr6 96493143 G A 9.40E-04 Insulin resistance FUT9 intron 21901158 rs2248641 chr6 96493233 G A 8.90E-04 Insulin resistance FUT9 intron 21901158 rs17055974 chr6 96496552 A C 2.88E-35 Multiple complex diseases FUT9 intron 17554300 rs4002794 chr6 96511945 C G 1.19E-05 Bipolar disorder FUT9 intron 22925353 rs4598084 chr6 96530099 T C 2.78E-04 Smoking initiation FUT9 intron 24665060 rs17056048 chr6 96532690 C A 4.70E-04 Smoking initiation FUT9 intron 24665060 rs12200614 chr6 96544414 A C 1.06E-04 AIDS progression FUT9 intron 19115949 rs12200614 chr6 96544414 A C 7.30E-05 Smoking initiation FUT9 intron 24665060 rs9499225 chr6 96562987 G A 9.53E-04 Multiple complex diseases FUT9 intron 17554300 rs9499225 chr6 96562987 G A 2.46E-04 Smoking initiation FUT9 intron 24665060 rs4452646 chr6 96567853 T C 7.57E-05 AIDS progression FUT9 intron 19115949 rs4452646 chr6 96567853 T C 2.46E-04 Smoking initiation FUT9 intron 24665060 rs7772067 chr6 96569905 G A 9.26E-05 AIDS progression FUT9 intron 19115949 rs7772067 chr6 96569905 G A 2.81E-04 Smoking initiation FUT9 intron 24665060 rs17722911 chr6 96569930 G C 5.74E-04 Smoking initiation FUT9 intron 24665060 rs9485739 chr6 96571137 T C 8.09E-04 Insulin resistance FUT9 intron 21901158 rs9485739 chr6 96571137 T C 7.00E-05 Cognitive impairment induced by topiramate FUT9 intron 22091778 rs11967141 chr6 96583909 C T 3.21E-05 Smoking initiation FUT9 intron 24665060 rs12214860 chr6 96586116 T C 7.41E-06 Coronary heart disease FUT9 intron pha003030 rs12214860 chr6 96586116 T C 6.00E-05 Coronary heart disease FUT9 intron pha003031 rs4144272 chr6 96590228 T C 7.42E-04 Smoking initiation FUT9 intron 24665060 rs4132260 chr6 96595020 C T 1.12E-05 Alcohol dependence FUT9 intron 23089632 rs10499001 chr6 96598066 C T 9.00E-05 HIV-1 control FUT9 intron 20041166 rs6571086 chr6 96606573 C T 6.80E-05 HIV-1 control FUT9 intron 20041166 rs9404334 chr6 96610748 T C 8.73E-05 Coronary heart disease FUT9 intron pha003030 rs9399799 chr6 96612930 A G 9.92E-05 Coronary heart disease FUT9 intron pha003030 rs9404338 chr6 96614392 C T 3.50E-04 Multiple complex diseases FUT9 intron 17554300 rs11156259 chr6 96616566 A T 9.83E-04 Multiple complex diseases FUT9 intron 17554300 rs7745505 chr6 96617081 C T 4.37E-04 Multiple complex diseases FUT9 intron 17554300 rs4133133 chr6 96635467 C T 3.13E-04 Smoking initiation FUT9 intron 24665060 rs7745248 chr6 96660114 G A 6.63E-04 Multiple complex diseases FUT9 UTR-3 17554300 rs11156354 chr6 96696786 G T 5.00E-04 Multiple complex diseases / / 17554300 rs2263190 chr6 96739393 T C 6.78E-06 Alcohol dependence / / 23089632 rs7754354 chr6 96746620 C T 2.95E-05 Coronary heart disease / / pha003030 rs7744810 chr6 96749691 T C 2.95E-05 Coronary heart disease / / pha003030 rs2387154 chr6 96751756 G A 2.99E-05 Coronary heart disease / / pha003030 rs9391221 chr6 96758925 G T 5.62E-08 Metabolite levels / / 23281178 rs9391221 chr6 96758925 G T 5.59E-06 Coronary heart disease / / pha003030 rs9386424 chr6 96759465 T C 5.62E-08 Metabolite levels / / 23281178 rs9404611 chr6 96808410 C T 6.82E-08 Metabolite levels / / 23281178 rs9399905 chr6 96809884 A T 6.82E-08 Metabolite levels / / 23281178 rs2499797 chr6 96848669 G A 5.70E-04 Migraine / / 22683712 rs2472908 chr6 96875998 A T 3.26E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11757063 chr6 96884886 G A 6.00E-08 Migraine / / 22683712 rs11759769 chr6 97065212 G A 1.00E-11 Migraine / / 23793025 rs11759769 chr6 97065212 G A 2.00E-12 Migraine without aura / / 23793025 rs11759769 chr6 97065212 G A 4.00E-07 Migraine - clinic-based / / 23793025 rs6899647 chr6 97065661 A G 2.00E-04 Information processing speed / / 21130836 rs211170 chr6 97070100 C A 5.19E-04 Multiple complex diseases / / 17554300 rs12200560 chr6 97080198 A G 6.00E-07 Coronary heart disease / / 22319020 rs4839693 chr6 97131684 A G 1.40E-05 Urinary metabolites / / 21572414 rs9386770 chr6 97191923 G T 8.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs11153162 chr6 97204294 C A 3.48E-05 Job-related exhaustion / / 23620144 rs399454 chr6 97237453 G A 9.54E-04 Multiple complex diseases / / 17554300 rs213843 chr6 97244612 C G 7.81E-04 Multiple complex diseases GPR63 UTR-3 17554300 rs7759611 chr6 97288437 A G 2.29E-04 Multiple complex diseases / / 17554300 rs6932754 chr6 97288664 T C 2.72E-04 Multiple complex diseases / / 17554300 rs9400365 chr6 97292630 A G 6.59E-04 Multiple complex diseases / / 17554300 rs9400365 chr6 97292630 A G 5.87E-05 Serum metabolites / / 19043545 rs7744614 chr6 97312531 G A 4.37E-04 Multiple complex diseases / / 17554300 rs7744614 chr6 97312531 G A 6.73E-05 Serum metabolites / / 19043545 rs9374164 chr6 97314345 T C 2.38E-04 Alcohol dependence / / 21314694 rs974417 chr6 97419598 C T 6.00E-06 Body mass index KLHL32 intron 23583978 rs1206100 chr6 97469390 G A 1.00E-05 Prostate cancer KLHL32 intron 21743057 rs12195230 chr6 97500047 G C 8.66E-04 Depression (quantitative trait) KLHL32 intron 20800221 rs12195230 chr6 97500047 G C 5.00E-07 Blood pressure KLHL32 intron 24954895 rs1737659 chr6 97501957 T C 9.09E-04 Depression (quantitative trait) KLHL32 intron 20800221 rs1737660 chr6 97502496 T A 9.04E-04 Depression (quantitative trait) KLHL32 intron 20800221 rs12206420 chr6 97503734 C T 7.65E-04 Depression (quantitative trait) KLHL32 intron 20800221 rs1737661 chr6 97504652 C T 7.46E-04 Depression (quantitative trait) KLHL32 intron 20800221 rs9320403 chr6 97504706 G A 6.17E-04 Depression (quantitative trait) KLHL32 intron 20800221 rs1206118 chr6 97508981 T C 5.93E-04 Depression (quantitative trait) KLHL32 intron 20800221 rs946117 chr6 97509164 G A 5.33E-04 Depression (quantitative trait) KLHL32 intron 20800221 rs9320409 chr6 97530846 T C 8.00E-04 Chronic fatigue syndrome KLHL32 intron 21912186 rs9320409 chr6 97530846 T C 1.86E-04 Smoking quantity KLHL32 intron 24665060 rs879382 chr6 97536333 C A 1.09E-04 Bipolar disorder KLHL32 intron 17486107 rs879382 chr6 97536333 C A 1.39E-05 Cognitive impairment induced by topiramate KLHL32 intron 22091778 rs3822908 chr6 97599612 T C 2.43E-04 Diabetic nephropathy MMS22L intron 21150874 rs3822908 chr6 97599612 T C 3.63E-04 Type 2 diabetes MMS22L intron 22238593 rs1206129 chr6 97622500 G A 3.27E-04 Smoking quantity MMS22L intron 24665060 rs1474620 chr6 97645628 C T 3.40E-04 Body mass index MMS22L intron 21701565 rs2500505 chr6 97649821 T G 4.40E-04 Body mass index MMS22L intron 21701565 rs1569532 chr6 97651583 C T 5.93E-04 Body mass index MMS22L intron 21701565 rs9400692 chr6 97688091 T C 3.15E-05 Myocardial Infarction MMS22L intron pha002883 rs4363042 chr6 97694800 C T 7.57E-04 Body mass index MMS22L intron 21701565 rs7740887 chr6 97724718 C G 1.23E-04 Body mass index MMS22L intron 21701565 rs9387218 chr6 97734271 G A 1.40E-04 Body mass index / / 21701565 rs4839709 chr6 97737422 T C 6.01E-04 Alzheimer's disease / / 17998437 rs4839709 chr6 97737422 T C 1.60E-04 Body mass index / / 21701565 rs4839903 chr6 97742108 G T 1.25E-04 Body mass index / / 21701565 rs17806588 chr6 97744036 G A 7.94E-04 Stroke (pediatric) / / 22990015 rs9400737 chr6 97746730 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2388037 chr6 97747124 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2388039 chr6 97747244 T C 6.70E-05 Body mass index / / 21701565 rs9320505 chr6 97749332 G C 9.17E-04 Alzheimer's disease / / 17998437 rs9320505 chr6 97749332 G C 1.34E-04 Body mass index / / 21701565 rs9387228 chr6 97749609 A G 6.14E-04 Alzheimer's disease / / 17998437 rs9387228 chr6 97749609 A G 1.95E-04 Body mass index / / 21701565 rs9387246 chr6 97755248 C G 7.90E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs9320518 chr6 97763117 G A 7.90E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs10457310 chr6 97983877 G A 3.79E-04 Body mass index / / 21701565 rs9398455 chr6 98015352 G A 1.50E-05 Urinary metabolites / / 21572414 rs9398455 chr6 98015352 G A 4.23E-05 Brain structure / / 22504417 rs9320598 chr6 98019080 A G 9.00E-07 Multiple sclerosis (OCB status) / / 23785401 rs7356837 chr6 98033236 A G 1.90E-04 Body mass index / / 21701565 rs7757567 chr6 98169886 G A 6.44E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6569077 chr6 98212409 C T 4.79E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11153822 chr6 98214814 C T 7.28E-05 Smoking initiation / / 24665060 rs595074 chr6 98240442 A C 3.18E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs1338555 chr6 98253424 C A 1.17E-04 Multiple complex diseases / / 17554300 rs4839713 chr6 98263613 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1933720 chr6 98297832 T C 1.00E-04 Information processing speed / / 21130836 rs10484868 chr6 98332622 C T 5.99E-04 Smoking initiation / / 24665060 rs6928545 chr6 98337903 A G 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6934784 chr6 98361795 A C 3.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs6940021 chr6 98379027 G A 3.40E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs12529874 chr6 98462501 G A 3.00E-07 Oleic acid (18:1n-9) plasma levels / / 23362303 rs17813462 chr6 98470233 T C 2.14E-05 Cognitive test performance / / 20125193 rs17813462 chr6 98470233 T C 4.49E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs4839936 chr6 98489654 C T 1.03E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs2505059 chr6 98495952 A G 5.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs4466255 chr6 98517095 C A 1.61E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs901630 chr6 98539519 C T 4.19E-04 Smoking initiation / / 24665060 rs9385269 chr6 98547979 C T 8.74E-07 Bipolar disorder / / 24618891 rs1906252 chr6 98550289 C A 2.08E-05 Information processing speed / / 21130836 rs1906252 chr6 98550289 C A 3.39E-08 Bipolar disorder / / 24618891 rs1487441 chr6 98553894 G A 3.22E-10 Educational attainment / / 23722424 rs1487441 chr6 98553894 G A 3.57E-08 Bipolar disorder / / 24618891 rs1906251 chr6 98560826 C A 9.48E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs9375195 chr6 98562720 G A 3.00E-05 Bone mineral density (spine) / / 19079262 rs9375195 chr6 98562720 G A 7.62E-05 Information processing speed / / 21130836 rs9375195 chr6 98562720 G A 1.46E-06 Bipolar disorder / / 24618891 rs10457441 chr6 98572120 T C 4.99E-07 Bipolar disorder / / 24618891 rs9388171 chr6 98575726 C G 4.66E-07 Bipolar disorder / / 24618891 rs12202969 chr6 98576223 G A 1.00E-08 Bipolar disorder / / 24618891 rs1872841 chr6 98576688 C A 4.61E-07 Bipolar disorder / / 24618891 rs9401634 chr6 98578511 T C 5.11E-07 Bipolar disorder / / 24618891 rs12204181 chr6 98579481 T C 5.53E-07 Bipolar disorder / / 24618891 rs12206087 chr6 98582900 G A 1.64E-08 Bipolar disorder / / 24618891 rs9320913 chr6 98584733 C A 4.00E-10 Educational attainment / / 23722424 rs9375225 chr6 98588754 G T 6.00E-06 QT interval (interaction) / / 23459443 rs9375225 chr6 98588754 G T 6.83E-07 Bipolar disorder / / 24618891 rs1487452 chr6 98597689 C T 7.61E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs1487439 chr6 98611300 A G 5.56E-06 Bipolar disorder / / 24618891 rs12203165 chr6 98613744 T A 8.50E-06 Bipolar disorder / / 24618891 rs12203171 chr6 98613792 T A 5.51E-06 Bipolar disorder / / 24618891 rs6569342 chr6 98613835 C T 7.93E-05 Bipolar disorder / / 19488044 rs12215368 chr6 98617582 G A 6.64E-06 Bipolar disorder / / 24618891 rs9372752 chr6 98626561 G A 1.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs9320942 chr6 98628831 A G 5.98E-06 Bipolar disorder / / 24618891 rs9385308 chr6 98632010 G T 5.17E-06 Bipolar disorder / / 24618891 rs1487447 chr6 98632082 A G 6.51E-06 Bipolar disorder / / 24618891 rs9388268 chr6 98633802 A G 6.56E-06 Bipolar disorder / / 24618891 rs2505081 chr6 98634277 C T 6.95E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs12195240 chr6 98636905 G A 6.65E-06 Bipolar disorder / / 24618891 rs12216178 chr6 98637119 A G 8.34E-06 Bipolar disorder / / 24618891 rs1376499 chr6 98652595 C A 2.25E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs9388292 chr6 98669276 A C 1.05E-05 Bipolar disorder / / 24618891 rs12192372 chr6 98673904 A G 1.05E-05 Bipolar disorder / / 24618891 rs10499016 chr6 98678145 A G 4.00E-05 Cognitive test performance / / 20125193 rs9388303 chr6 98687387 A G 9.69E-06 Bipolar disorder / / 24618891 rs1376503 chr6 98704423 G A 5.41E-06 Bipolar disorder / / 24618891 rs9375321 chr6 98706822 A C 9.89E-06 Bipolar disorder / / 24618891 rs6569382 chr6 98709685 C T 8.28E-06 Bipolar disorder / / 24618891 rs12205529 chr6 98713048 G T 8.01E-06 Bipolar disorder / / 24618891 rs2063144 chr6 98713238 C A 8.50E-06 Bipolar disorder / / 24618891 rs9320990 chr6 98713523 T G 7.49E-06 Bipolar disorder / / 24618891 rs9320990 chr6 98713523 T G 4.55E-04 Smoking initiation / / 24665060 rs4565311 chr6 98714495 C T 6.13E-06 Bipolar disorder / / 24618891 rs1868885 chr6 98719233 C T 7.23E-06 Bipolar disorder / / 24618891 rs6911443 chr6 98722903 G A 6.56E-06 Bipolar disorder / / 24618891 rs10499017 chr6 98724638 G C 6.83E-06 Bipolar disorder / / 24618891 rs9320996 chr6 98726528 G C 3.11E-04 Multiple complex diseases / / 17554300 rs9320996 chr6 98726528 G C 6.76E-06 Bipolar disorder / / 24618891 rs1451346 chr6 98729160 G A 7.16E-06 Bipolar disorder / / 24618891 rs9401757 chr6 98733864 T C 6.32E-06 Bipolar disorder / / 24618891 rs9388349 chr6 98734648 T G 6.59E-06 Bipolar disorder / / 24618891 rs9375350 chr6 98739311 G A 7.49E-06 Bipolar disorder / / 24618891 rs6909430 chr6 98739774 G A 8.00E-06 Quantitative traits / / 19197348 rs9375351 chr6 98739867 A G 7.30E-06 Bipolar disorder / / 24618891 rs9375352 chr6 98739938 T A 7.63E-06 Bipolar disorder / / 24618891 rs9388352 chr6 98739949 T A 6.92E-06 Bipolar disorder / / 24618891 rs717296 chr6 98741067 C A 8.26E-06 Bipolar disorder / / 24618891 rs6927284 chr6 98741419 G A 8.38E-06 Bipolar disorder / / 24618891 rs2892512 chr6 98744946 T C 9.00E-06 Bipolar disorder / / 24618891 rs1562865 chr6 98747312 T C 6.84E-06 Bipolar disorder / / 24618891 rs9385344 chr6 98748500 C T 5.58E-06 Bipolar disorder / / 24618891 rs7754741 chr6 98749329 T C 6.23E-06 Bipolar disorder / / 24618891 rs6939461 chr6 98750517 G A 5.98E-06 Bipolar disorder / / 24618891 rs9375371 chr6 98751680 G A 5.33E-06 Bipolar disorder / / 24618891 rs11968196 chr6 98793832 A G 4.16E-04 Multiple complex diseases / / 17554300 rs13437130 chr6 98798280 G A 9.56E-04 Multiple complex diseases / / 17554300 rs980899 chr6 98819800 C T 2.88E-05 Cleft lip / / 20436469 rs1507774 chr6 98824077 G A 4.06E-05 Cleft lip / / 20436469 rs2047179 chr6 98878812 A G 3.00E-04 Chronic fatigue syndrome / / 21912186 rs9321063 chr6 98896667 A G 5.66E-05 Brain imaging in schizophrenia (interaction) / / 19023125 rs9321063 chr6 98896667 A G 2.00E-06 Metabolite levels (X-11787) / / 23934736 rs9321063 chr6 98896667 A G 8.21E-04 Stroke / / pha002887 rs9491608 chr6 98898903 G A 1.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs3123337 chr6 98899247 C T 1.63E-04 Suicide attempts in bipolar disorder / / 21041247 rs9491610 chr6 98900019 A G 8.91E-05 Suicide attempts in bipolar disorder / / 21041247 rs9482736 chr6 98900621 C T 8.09E-05 Suicide attempts in bipolar disorder / / 21041247 rs12200527 chr6 98902531 A T 8.03E-05 Suicide attempts in bipolar disorder / / 21041247 rs12208539 chr6 98903461 G T 6.87E-05 Suicide attempts in bipolar disorder / / 21041247 rs3104078 chr6 98904002 A T 8.98E-05 Suicide attempts in bipolar disorder / / 21041247 rs12213284 chr6 98908289 T G 3.97E-05 Suicide attempts in bipolar disorder / / 21041247 rs3125579 chr6 98908958 G A 8.62E-05 Suicide attempts in bipolar disorder / / 21041247 rs9491625 chr6 98909707 G A 3.95E-05 Suicide attempts in bipolar disorder / / 21041247 rs9491625 chr6 98909707 G A 8.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs9388491 chr6 98913361 A C 3.92E-05 Suicide attempts in bipolar disorder / / 21041247 rs9401880 chr6 98913784 C G 3.94E-05 Suicide attempts in bipolar disorder / / 21041247 rs9491631 chr6 98914471 C T 3.93E-05 Suicide attempts in bipolar disorder / / 21041247 rs9482746 chr6 98914482 T C 3.95E-05 Suicide attempts in bipolar disorder / / 21041247 rs9491632 chr6 98914569 T A 3.94E-05 Suicide attempts in bipolar disorder / / 21041247 rs9491633 chr6 98914680 C A 3.90E-05 Suicide attempts in bipolar disorder / / 21041247 rs1908399 chr6 98915046 A G 3.83E-05 Suicide attempts in bipolar disorder / / 21041247 rs9482747 chr6 98916468 C T 3.75E-05 Suicide attempts in bipolar disorder / / 21041247 rs9491637 chr6 98917369 A G 3.71E-05 Suicide attempts in bipolar disorder / / 21041247 rs9491640 chr6 98919264 C A 9.00E-06 Brain imaging in schizophrenia (interaction) / / 19023125 rs9491640 chr6 98919264 C A 3.66E-05 Suicide attempts in bipolar disorder / / 21041247 rs1494770 chr6 98920237 T C 3.65E-05 Suicide attempts in bipolar disorder / / 21041247 rs1494770 chr6 98920237 T C 6.63E-04 Suicide attempts in bipolar disorder / / 21041247 rs9482751 chr6 98921305 C T 3.65E-05 Suicide attempts in bipolar disorder / / 21041247 rs9482752 chr6 98922227 C A 3.66E-05 Suicide attempts in bipolar disorder / / 21041247 rs9482753 chr6 98922805 A G 1.59E-05 Suicide attempts in bipolar disorder / / 21041247 rs6941388 chr6 98924533 T A 8.16E-05 Suicide attempts in bipolar disorder / / 21041247 rs9491644 chr6 98925800 A G 3.49E-05 Suicide attempts in bipolar disorder / / 21041247 rs9491645 chr6 98925823 C T 3.48E-05 Suicide attempts in bipolar disorder / / 21041247 rs9491646 chr6 98927363 G A 1.59E-05 Brain imaging in schizophrenia (interaction) / / 19023125 rs9491646 chr6 98927363 G A 3.47E-05 Suicide attempts in bipolar disorder / / 21041247 rs210406 chr6 98928272 T C 8.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7450747 chr6 98936809 A G 7.09E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2213553 chr6 98937146 T G 5.00E-06 Response to amphetamines / / 22952603 rs158777 chr6 98959605 C T 4.34E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs150398 chr6 98963513 G T 1.92E-05 Serum metabolites / / 19043545 rs4546492 chr6 98963927 T C 2.76E-04 Multiple complex diseases / / 17554300 rs211211 chr6 98973368 G A 2.50E-05 Serum metabolites / / 19043545 rs211214 chr6 98975506 A G 2.98E-05 Serum metabolites / / 19043545 rs9388545 chr6 98979105 G A 5.31E-04 Multiple complex diseases / / 17554300 rs211221 chr6 98980113 C G 1.04E-05 Serum metabolites / / 19043545 rs183317 chr6 98981611 T C 1.04E-05 Serum metabolites / / 19043545 rs638458 chr6 98982001 A C 6.49E-05 Serum metabolites / / 19043545 rs211191 chr6 98985615 C G 3.05E-05 Serum metabolites / / 19043545 rs6904416 chr6 98990489 T C 9.00E-10 C-reactive protein and white blood cell count / / 22788528 rs2086512 chr6 99011501 A G 9.00E-06 Cytomegalovirus antibody response / / 21993531 rs6931766 chr6 99014744 C T 1.58E-04 Rheumatoid arthritis / / 21452313 rs1383808 chr6 99028866 C T 9.00E-06 Obesity-related traits / / 23251661 rs17762161 chr6 99028910 G C 2.46E-04 Multiple complex diseases / / 17554300 rs9402081 chr6 99156223 C A 6.65E-04 Heart Failure / / pha002885 rs11154467 chr6 99195548 T C 6.17E-04 Smoking quantity / / 24665060 rs7762570 chr6 99214884 G A 7.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9385493 chr6 99221669 T C 7.53E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9385494 chr6 99221705 G A 7.50E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6931205 chr6 99228209 G C 1.85E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs371533997 chr6 99228445 C CA 3.93E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6932982 chr6 99228445 C A 3.93E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4240568 chr6 99229261 G T 1.87E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4839977 chr6 99229574 G A 1.90E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9372939 chr6 99230183 G A 1.91E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9388713 chr6 99230519 T C 1.99E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4839978 chr6 99231487 A T 5.89E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4451139 chr6 99232481 C T 6.41E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4839731 chr6 99232632 T C 7.48E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9492351 chr6 99233987 A G 8.84E-05 Schizophrenia / / 19571809 rs9492351 chr6 99233987 A G 7.64E-05 Bipolar disorder and schizophrenia / / 20889312 rs4131463 chr6 99257831 T C 1.50E-71 Multiple complex diseases / / 17554300 rs2444932 chr6 99301320 C A 1.71E-04 Acute lung injury / / 22295056 rs2604065 chr6 99301511 C T 1.71E-04 Acute lung injury / / 22295056 rs2604066 chr6 99303615 A T 1.71E-04 Acute lung injury / / 22295056 rs2038051 chr6 99304776 C G 1.71E-04 Acute lung injury / / 22295056 rs195856 chr6 99306950 T C 1.71E-04 Acute lung injury / / 22295056 rs195833 chr6 99324963 A G 2.20E-04 Acute lung injury FBXL4 intron 22295056 rs12110702 chr6 99336136 T C 9.62E-04 Acute lung injury FBXL4 intron 22295056 rs10484609 chr6 99336279 A G 9.62E-04 Acute lung injury FBXL4 intron 22295056 rs3823035 chr6 99342518 T C 9.62E-04 Acute lung injury FBXL4 intron 22295056 rs195822 chr6 99352338 A G 1.99E-04 Acute lung injury FBXL4 intron 22295056 rs195829 chr6 99388940 C T 2.89E-04 Acute lung injury FBXL4 intron 22295056 rs11964185 chr6 99418852 G A 3.82E-04 Smoking quantity / / 24665060 rs17058986 chr6 99431200 A C 6.23E-04 Smoking quantity / / 24665060 rs2747734 chr6 99437566 G T 4.30E-06 Urinary metabolites / / 21572414 rs190624773 chr6 99440919 A G 0.000006686 Sarcoidosis / / 22952805 rs11154646 chr6 99461627 C T 3.76E-04 Acute lung injury / / 22295056 rs192988303 chr6 99467370 A G 0.000002704 Sarcoidosis / / 22952805 rs6569770 chr6 99471885 T C 0.0000118 VLDL cholesterol particle diameter / / 23263444 rs9483374 chr6 99476311 G C 0.0000108 VLDL cholesterol particle diameter / / 23263444 rs4839737 chr6 99478304 G T 0.0000104 VLDL cholesterol particle diameter / / 23263444 rs9483378 chr6 99479941 A G 0.00000997 VLDL cholesterol particle diameter / / 23263444 rs9483379 chr6 99480090 A T 0.0000099 VLDL cholesterol particle diameter / / 23263444 rs9483380 chr6 99480292 T G 0.00000981 VLDL cholesterol particle diameter / / 23263444 rs10484613 chr6 99480905 T A 2.45E-04 Smoking quantity / / 24665060 rs9321324 chr6 99482883 A G 0.00000926 VLDL cholesterol particle diameter / / 23263444 rs9321325 chr6 99483028 G A 8.70E-04 Multiple complex diseases / / 17554300 rs9321325 chr6 99483028 G A 0.00000919 VLDL cholesterol particle diameter / / 23263444 rs6938048 chr6 99483410 T C 0.00000903 VLDL cholesterol particle diameter / / 23263444 rs9493177 chr6 99483590 G T 0.00000889 VLDL cholesterol particle diameter / / 23263444 rs9483382 chr6 99483699 T G 0.00000428 VLDL cholesterol particle diameter / / 23263444 rs17059069 chr6 99483896 C T 1.70E-05 Urinary metabolites / / 21572414 rs148909396 chr6 99489174 G A 0.00000476 Sarcoidosis / / 22952805 rs6925042 chr6 99497948 G A 0.0000136 VLDL cholesterol particle diameter / / 23263444 rs2252933 chr6 99500622 A G 8.37E-04 Multiple complex diseases / / 17554300 rs9483434 chr6 99504838 G A 0.0000139 VLDL cholesterol particle diameter / / 23263444 rs117465767 chr6 99513439 C A 0.000007322 Sarcoidosis / / 22952805 rs1884184 chr6 99515956 A G 7.51E-05 Multiple complex diseases / / 17554300 rs1158653 chr6 99530312 C A 1.92E-04 Multiple complex diseases / / 17554300 rs12191555 chr6 99537716 C T 6.36E-04 Type 2 diabetes / / 17463246 rs17059155 chr6 99549296 G T 0.0000155 Panic disorder / / 23149450 rs17059155 chr6 99549296 G T 1.55E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs10457592 chr6 99551970 G A 5.27E-04 Major depressive disorder / / 22472876 rs6905786 chr6 99555756 A G 1.41E-05 Periodontitis (Chronic) / / 25008200 rs4454147 chr6 99575874 C T 5.79E-04 Acute lung injury / / 22295056 rs12190591 chr6 99593258 T C 7.88E-04 Aortic root size / / 21223598 rs9321394 chr6 99600083 G A 2.30E-05 Urinary metabolites / / 21572414 rs4839999 chr6 99610074 G T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4314508 chr6 99629096 A G 6.93E-04 Multiple complex diseases / / 17554300 rs7745052 chr6 99640610 G A 8.44E-05 Celiac disease / / 23936387 rs2132683 chr6 99672014 T C 1.00E-06 Brain structure / / 20171287 rs2132683 chr6 99672014 T C 1.45E-04 Attention deficit hyperactivity disorder / / 22420046 rs9402564 chr6 99679902 C T 3.03E-04 Smoking cessation / / 24665060 rs12193060 chr6 99690449 A G 5.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs1353588 chr6 99693276 C A 5.75E-04 Suicide attempts in bipolar disorder / / 21041247 rs12194369 chr6 99696449 A G 5.20E-04 Suicide attempts in bipolar disorder / / 21041247 rs2132678 chr6 99715097 C A 5.62E-05 IgE levels / / 22075330 rs1045731 chr6 99721003 C T 5.70E-05 IgE levels FAXC UTR-3 22075330 rs1045728 chr6 99721049 G A 5.70E-05 IgE levels FAXC UTR-3 22075330 rs12660321 chr6 99727653 C T 9.32E-05 Orofacial clefts FAXC UTR-3 22419666 rs12660321 chr6 99727653 C T 9.50E-05 Heart Rate FAXC UTR-3 pha003053 rs6933093 chr6 99729901 G A 4.58E-05 IgE levels FAXC intron 22075330 rs1496980 chr6 99734185 A G 7.55E-05 Alzheimer's disease (late onset) FAXC intron 21379329 rs721150 chr6 99735012 A G 5.02E-05 IgE levels FAXC intron 22075330 rs4840026 chr6 99737100 G C 5.30E-05 IgE levels FAXC intron 22075330 rs221530 chr6 99753499 G A 5.73E-05 Orofacial clefts FAXC intron 22419666 rs17053610 chr6 99765784 T G 1.46E-04 Sudden cardiac arrest FAXC intron 21658281 rs6925577 chr6 99769036 G A 9.41E-05 IgE levels FAXC intron 22075330 rs6912685 chr6 99770319 A C 9.39E-05 IgE levels FAXC intron 22075330 rs13206094 chr6 99772374 T C 4.75E-05 IgE levels FAXC intron 22075330 rs17059400 chr6 99782879 A C 2.00E-06 Illicit drug use FAXC intron 23942779 rs9483838 chr6 99817928 G A 9.73E-05 Serum metabolites COQ3 intron 19043545 rs7745110 chr6 99878619 G C 1.00E-04 Prostate cancer / / 21743057 rs6915401 chr6 99880839 T A 4.00E-05 Prostate cancer USP45 UTR-3 21743057 rs6570064 chr6 99883137 A G 1.00E-04 Prostate cancer USP45 UTR-3 21743057 rs4840044 chr6 99888013 A G 4.00E-05 Prostate cancer USP45 intron 21743057 rs4504482 chr6 99893938 T C 2.66E-05 Glucose levels USP45 cds-synon pha002899 rs994198 chr6 99960761 C T 7.00E-05 Orofacial clefts USP45 intron 22419666 rs6912892 chr6 99972609 C T 5.59E-05 Orofacial clefts LOC100130890 intron 22419666 rs10223892 chr6 99973893 G A 8.64E-05 Tunica Media LOC100130890 intron pha003037 rs9389578 chr6 100112101 C T 9.94E-04 Multiple complex diseases / / 17554300 rs6927984 chr6 100118321 C T 7.88E-04 Multiple complex diseases / / 17554300 rs6927984 chr6 100118321 C T 1.00E-05 Urinary metabolites / / 21572414 rs946427 chr6 100126590 C T 6.45E-04 Multiple complex diseases / / 17554300 rs946427 chr6 100126590 C T 3.70E-07 Urinary metabolites / / 21572414 rs576231 chr6 100138561 C T 0.0000167 Asthma / / 22607992 rs2894889 chr6 100161940 A T 5.60E-07 Urinary metabolites / / 21572414 rs6917474 chr6 100176760 T C 2.64E-05 Serum metabolites / / 19043545 rs117002627 chr6 100187167 T G 0.00002324 Sarcoidosis / / 22952805 rs151254356 chr6 100187361 G C 0.00002324 Sarcoidosis / / 22952805 rs6902345 chr6 100199777 A G 7.80E-07 Urinary metabolites / / 21572414 rs10485227 chr6 100207327 A G 3.00E-07 Urinary metabolites / / 21572414 rs4388294 chr6 100207838 C T 2.70E-05 Urinary metabolites / / 21572414 rs4840086 chr6 100208438 A G 2.00E-08 Menarche (age at onset) / / 21102462 rs4431442 chr6 100213515 A G 5.59E-05 Parkinson's disease / / pha002865 rs10457694 chr6 100232528 A G 4.22E-04 Multiple complex diseases / / 17554300 rs4840091 chr6 100278633 C A 7.40E-06 Urinary metabolites / / 21572414 rs7453200 chr6 100281681 G A 8.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs12215849 chr6 100283304 A G 4.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs9403180 chr6 100319031 G T 2.88E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4840097 chr6 100328198 C T 5.00E-07 Age-related macular degeneration (smoking status interaction) / / 23577725 rs12717189 chr6 100406446 C T 3.86E-04 Obesity (extreme) MCHR2 intron 21935397 rs9389906 chr6 100407196 T A 3.79E-04 Obesity (extreme) MCHR2 intron 21935397 rs9376634 chr6 100429917 G A 8.97E-05 Prion diseases MCHR2 intron 22210626 rs9496085 chr6 100430803 G A 7.70E-05 Lung adenocarcinoma MCHR2 intron 19836008 rs2001456 chr6 100439009 G A 4.33E-05 Prion diseases MCHR2 intron 22210626 rs4357143 chr6 100469407 C T 7.69E-04 Response to alcohol consumption (flushing response) LOC728012 intron 24277619 rs4840117 chr6 100564829 T C 5.94E-04 Schizophrenia / / 21674006 rs7746675 chr6 100574390 C T 5.72E-04 Alzheimer's disease / / 22005930 rs4839772 chr6 100583430 G A 4.81E-04 Alzheimer's disease / / 22005930 rs2474267 chr6 100609124 A G 6.38E-04 Type 2 diabetes / / 17463246 rs2503099 chr6 100610101 A G 6.38E-04 Type 2 diabetes / / 17463246 rs13205707 chr6 100627435 G T 7.10E-04 Type 2 diabetes / / 17463246 rs13195365 chr6 100627492 T C 5.27E-04 Type 2 diabetes / / 17463246 rs12201659 chr6 100633338 G A 5.01E-04 Smoking cessation / / 24665060 rs961918 chr6 100655668 T C 1.38E-05 Interstitial lung disease / / 23583980 rs9399465 chr6 100661466 C T 3.73E-04 Response to alcohol consumption (flushing response) / / 24277619 rs730223 chr6 100676593 C T 5.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs761710 chr6 100695905 A G 1.33E-05 Post-operative nausea and vomiting / / 21694509 rs9390162 chr6 100698564 A C,G,T 4.66E-05 Bipolar disorder and schizophrenia / / 20889312 rs9496988 chr6 100723680 A C 5.32E-05 Bipolar disorder and schizophrenia / / 20889312 rs4840124 chr6 100729007 T C 2.90E-05 Bipolar disorder and schizophrenia / / 20889312 rs9321981 chr6 100732279 A G 6.02E-05 Bipolar disorder and schizophrenia / / 20889312 rs3934920 chr6 100740293 C G 4.65E-05 Bipolar disorder and schizophrenia / / 20889312 rs10499029 chr6 100744264 T C 2.07E-05 Bipolar disorder and schizophrenia / / 20889312 rs2841307 chr6 100756687 C T 1.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs17792460 chr6 100763922 C G 3.43E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9390276 chr6 100779692 T C 7.09E-04 Alcohol dependence / / 24277619 rs1395118 chr6 100791267 G T 4.18E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1876155 chr6 100797890 G T 1.90E-05 Urinary metabolites / / 21572414 rs10872573 chr6 100810622 T C 3.26E-05 Intracranial aneurysm / / 20613766 rs17793103 chr6 100820791 C T 4.25E-05 Alzheimer's disease / / 17998437 rs3798502 chr6 100859189 A G 2.37E-04 Intracranial aneurysm SIM1 intron 20613766 rs3798502 chr6 100859189 A G 5.42E-04 Oral cancers (chewing tobacco related) SIM1 intron 22503698 rs17060530 chr6 100859947 T C 4.50E-05 Pancreatic cancer SIM1 intron pha002889 rs17241549 chr6 100864280 C G 4.02E-05 Obesity (extreme) SIM1 intron 21935397 rs1395122 chr6 100865806 G T 1.89E-04 Oral cancers (chewing tobacco related) SIM1 intron 22503698 rs9386144 chr6 100873257 T C 6.31E-08 Metabolite levels SIM1 intron 23281178 rs3778033 chr6 100875516 T C 2.50E-08 Metabolite levels SIM1 intron 23281178 rs1847912 chr6 100880696 A G 8.53E-04 Multiple complex diseases SIM1 intron 17554300 rs17060652 chr6 100928767 C T 6.85E-04 Tourette syndrome / / 22889924 rs6570772 chr6 100936361 T C 3.15E-05 Type 2 diabetes / / 21799836 rs7751526 chr6 100949822 A G 5.76E-05 Type 2 diabetes / / 21799836 rs240766 chr6 100954036 G A 5.72E-05 Type 2 diabetes / / 21799836 rs240768 chr6 100957344 T C 2.00E-06 Economic and political preferences (immigration/crime) ASCC3 missense 22566634 rs4461738 chr6 100977940 T C 2.31E-05 Brain structure ASCC3 intron 22504417 rs2398132 chr6 100981200 A C 2.00E-05 Brain structure ASCC3 intron 22504417 rs11155496 chr6 100988939 T C 2.27E-05 Brain structure ASCC3 intron 22504417 rs12201157 chr6 101147095 G T 7.80E-07 Urinary metabolites ASCC3 intron 21572414 rs1414733 chr6 101201981 C G 6.74E-05 Obesity (extreme) ASCC3 intron 21935397 rs9390697 chr6 101294431 G A 8.64E-04 Obesity (extreme) ASCC3 intron 21935397 rs9399696 chr6 101295873 A G 8.64E-04 Obesity (extreme) ASCC3 intron 21935397 rs9390698 chr6 101296389 G A 0.00049 Coronary artery calcification ASCC3 missense 23727086 rs9498409 chr6 101299966 G A 8.64E-04 Obesity (extreme) ASCC3 intron 21935397 rs9485417 chr6 101300038 T C 7.01E-04 Obesity (extreme) ASCC3 intron 21935397 rs3734351 chr6 101307131 C T 8.56E-05 Orofacial clefts ASCC3 intron 20023658 rs3734351 chr6 101307131 C T 8.64E-04 Obesity (extreme) ASCC3 intron 21935397 rs10485299 chr6 101313501 T G 2.21E-04 Obesity (extreme) ASCC3 intron 21935397 rs9498414 chr6 101322976 C T 8.90E-04 Obesity (extreme) ASCC3 intron 21935397 rs9404058 chr6 101323078 T C 8.92E-04 Obesity (extreme) ASCC3 intron 21935397 rs9498419 chr6 101337611 A G 7.76E-06 Systemic sclerosis / / 21750679 rs9390700 chr6 101338808 T A 6.68E-06 Stroke / / pha002887 rs6919745 chr6 101338978 T C 8.21E-06 Systemic sclerosis / / 21750679 rs7771570 chr6 101339400 C T 1.82E-05 Systemic sclerosis / / 21750679 rs10485300 chr6 101371187 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs657915 chr6 101379666 G A 1.90E-05 Urinary metabolites / / 21572414 rs596601 chr6 101380020 G T 1.32E-04 Alzheimer's disease / / 17998437 rs11969893 chr6 101395407 G A 6.66E-04 Obesity (extreme) / / 21935397 rs11969893 chr6 101395407 G A 4.00E-06 Economic and political preferences (immigration/crime) / / 22566634 rs1406893 chr6 101454788 T C 7.68E-04 Alzheimer's disease / / 22005930 rs1321204 chr6 101468591 A G 7.01E-05 Orofacial clefts / / 20023658 rs1415468 chr6 101468785 A C 7.55E-04 Type 2 diabetes / / 17463246 rs2764273 chr6 101660659 T G 8.56E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2797369 chr6 101674290 C T 1.00E-07 Renal function-related traits (eGRFcrea) / / 22797727 rs406541 chr6 101714615 T G 5.30E-05 Creatinine levels / / pha003069 rs649371 chr6 101795378 T C 1.86E-05 Multiple complex diseases / / 17554300 rs7755912 chr6 101855808 G A 6.92E-05 Cognitive test performance GRIK2 intron 20125193 rs1856309 chr6 101866368 G A 1.44E-04 Amyotrophic Lateral Sclerosis GRIK2 intron 17362836 rs6911953 chr6 101867394 G A 6.06E-05 Bipolar disorder GRIK2 intron 19488044 rs1361168 chr6 101870167 T C 1.28E-04 Amyotrophic Lateral Sclerosis GRIK2 intron 17362836 rs1832413 chr6 101873533 A G 1.07E-05 Bipolar disorder GRIK2 intron 19488044 rs1832413 chr6 101873533 A G 4.34E-04 Schizophrenia GRIK2 intron 20832056 rs2787566 chr6 101878734 G A 2.80E-04 Schizophrenia GRIK2 intron 20832056 rs6918619 chr6 101882084 A G 4.93E-04 Schizophrenia GRIK2 intron 20832056 rs1856310 chr6 101897534 G T 3.39E-05 Bipolar disorder GRIK2 intron 19488044 rs2518224 chr6 101906652 A C 1 Drug response to Citalopram GRIK2 intron 17898344 rs2518224 chr6 101906652 A C 3.60E-05 Triglycerides GRIK2 intron pha003080 rs13205777 chr6 101947367 C T 6.07E-05 Blood Pressure GRIK2 intron pha003050 rs2224201 chr6 101951502 T C 6.00E-05 Blood Pressure GRIK2 intron pha003050 rs7747072 chr6 101957291 T C 1.56E-05 Epilepsy GRIK2 intron 22116939 rs6570989 chr6 101957413 G A 7.73E-05 Nicotine smoking GRIK2 intron 19268276 rs7760831 chr6 101964843 T C 1.62E-06 Diabetic nephropathy GRIK2 intron 21150874 rs7760831 chr6 101964843 T C 2.55E-04 Type 2 diabetes GRIK2 intron 22238593 rs9390754 chr6 101964914 A G 5.46E-06 Epilepsy GRIK2 intron 22116939 rs10485270 chr6 101966333 G A 4.00E-04 Schizophrenia GRIK2 intron 19197363 rs10485270 chr6 101966333 G A 3.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRIK2 intron 20877124 rs2247215 chr6 101966454 A G 5.00E-04 Chronic fatigue syndrome GRIK2 intron 21912186 rs2247218 chr6 101966553 T C 7.00E-05 Chronic fatigue syndrome GRIK2 intron 21912186 rs2518251 chr6 101976291 T G 6.92E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) GRIK2 intron 23648065 rs2255306 chr6 101987410 A C 2.66E-05 Suicide attempts in bipolar disorder GRIK2 intron 21423239 rs2518300 chr6 101988538 T C 2.15E-05 Suicide attempts in bipolar disorder GRIK2 intron 21423239 rs2518216 chr6 101988652 C A 4.73E-05 Hemoglobin GRIK2 intron pha003098 rs2023169 chr6 101990259 T C 5.14E-04 Response to cytadine analogues (cytosine arabinoside) GRIK2 intron 24483146 rs2518220 chr6 101991728 A G 3.32E-04 Schizophrenia GRIK2 intron 19197363 rs2518220 chr6 101991728 A G 1.98E-05 Suicide attempts in bipolar disorder GRIK2 intron 21423239 rs2518289 chr6 101997494 A G 4.19E-05 Suicide attempts in bipolar disorder GRIK2 intron 21423239 rs2852570 chr6 102000287 T A 2.59E-05 Suicide attempts in bipolar disorder GRIK2 intron 21423239 rs2749072 chr6 102001948 A G 8.46E-04 Response to cytadine analogues (cytosine arabinoside) GRIK2 intron 24483146 rs2245825 chr6 102002591 A C 3.36E-05 Suicide attempts in bipolar disorder GRIK2 intron 21423239 rs2518302 chr6 102002868 A C 3.18E-05 Suicide attempts in bipolar disorder GRIK2 intron 21423239 rs2518221 chr6 102006568 G C 3.92E-05 Suicide attempts in bipolar disorder GRIK2 intron 21423239 rs2852577 chr6 102007227 G A 1.16E-04 Schizophrenia GRIK2 intron 19197363 rs2852577 chr6 102007227 G A 2.67E-05 Gout GRIK2 intron pha001405 rs2852578 chr6 102007254 G C 5.46E-04 Suicide attempts in bipolar disorder GRIK2 intron 21423239 rs9386284 chr6 102009047 G C 4.83E-04 Alzheimer's disease GRIK2 intron 17998437 rs599545 chr6 102029409 T C 4.80E-05 Cognitive function GRIK2 intron 24684796 rs6936552 chr6 102037684 A G 2.96E-04 Suicide attempts in bipolar disorder GRIK2 intron 21423239 rs1415484 chr6 102042953 C A 4.54E-04 Suicide attempts in bipolar disorder GRIK2 intron 21423239 rs9404120 chr6 102043286 T C 9.61E-04 Suicide attempts in bipolar disorder GRIK2 intron 21423239 rs471128 chr6 102047689 G T 4.27E-04 Suicide attempts in bipolar disorder GRIK2 intron 21423239 rs608729 chr6 102048504 A G 4.37E-04 Suicide attempts in bipolar disorder GRIK2 intron 21423239 rs9377284 chr6 102050173 G T 6.99E-04 Suicide attempts in bipolar disorder GRIK2 intron 21423239 rs685686 chr6 102050780 T C 3.04E-04 Suicide attempts in bipolar disorder GRIK2 intron 21423239 rs543196 chr6 102051349 G A 3.08E-04 Suicide attempts in bipolar disorder GRIK2 intron 21423239 rs611348 chr6 102054465 A C 3.44E-06 Personality dimensions GRIK2 intron 22628180 rs478344 chr6 102057438 T A 2.24E-04 Multiple complex diseases GRIK2 intron 17554300 rs520257 chr6 102062571 G A 1.11E-04 Insulin resistance GRIK2 intron 21901158 rs2518288 chr6 102090079 G A 4.28E-05 Hemoglobin GRIK2 intron pha003098 rs12193068 chr6 102102237 A C 6.50E-04 Iron levels GRIK2 intron pha002876 rs9485528 chr6 102114780 A G 4.63E-06 Ankle-brachial index GRIK2 intron 22199011 rs9498669 chr6 102145638 T C 5.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRIK2 intron 20877124 rs9404129 chr6 102163043 C T 1.74E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) GRIK2 intron 24023788 rs1222955 chr6 102165329 A G 1.91E-06 Triglycerides GRIK2 intron 19074352 rs1222955 chr6 102165329 A G 1.91E-06 Polyunsaturated fatty acid levels,in plasma GRIK2 intron 19148276 rs1925227 chr6 102183265 C T 9.59E-04 Acute lung injury GRIK2 intron 22295056 rs9377299 chr6 102202511 G A 2.50E-05 Urinary metabolites GRIK2 intron 21572414 rs9390779 chr6 102209081 T A 1.27E-05 Type 1 diabetes GRIK2 intron 18978792 rs1325060 chr6 102218731 A G 9.77E-04 Depression (quantitative trait) GRIK2 intron 20800221 rs11156157 chr6 102244334 A G 8.21E-04 Smoking cessation GRIK2 intron 24665060 rs4839801 chr6 102246628 T C 9.60E-04 Pulmonary function GRIK2 intron 23932459 rs9377308 chr6 102255073 C A 7.35E-04 Smoking cessation GRIK2 intron 24665060 rs2852573 chr6 102259114 T C 2.04E-04 Smoking cessation GRIK2 intron 24665060 rs2518266 chr6 102260840 G A 3.19E-04 Smoking cessation GRIK2 intron 24665060 rs12333317 chr6 102261917 G A 6.35E-04 Suicide attempts in bipolar disorder GRIK2 intron 21041247 rs2852576 chr6 102265623 T C 3.24E-04 Smoking cessation GRIK2 intron 24665060 rs9498719 chr6 102267086 C T 5.82E-04 Suicide attempts in bipolar disorder GRIK2 intron 21041247 rs2764229 chr6 102267593 T C 2.68E-04 Smoking cessation GRIK2 intron 24665060 rs2518191 chr6 102270322 C T 2.55E-04 Smoking cessation GRIK2 intron 24665060 rs2764226 chr6 102270991 A G 5.73E-04 Smoking cessation GRIK2 intron 24665060 rs2764225 chr6 102273820 A G 2.70E-04 Smoking cessation GRIK2 intron 24665060 rs2764218 chr6 102279200 G A 4.46E-04 Smoking cessation GRIK2 intron 24665060 rs2764236 chr6 102282457 G A 4.46E-04 Smoking cessation GRIK2 intron 24665060 rs2246394 chr6 102283963 A G 2.67E-04 Smoking cessation GRIK2 intron 24665060 rs2791819 chr6 102286281 G A 4.98E-04 Smoking cessation GRIK2 intron 24665060 rs2791827 chr6 102293189 A G 2.64E-04 Smoking cessation GRIK2 intron 24665060 rs2518201 chr6 102303080 C T 3.15E-04 Smoking cessation GRIK2 intron 24665060 rs9404153 chr6 102303369 C T 3.27E-04 Smoking cessation GRIK2 intron 24665060 rs2518203 chr6 102305195 A T 5.72E-04 Smoking cessation GRIK2 intron 24665060 rs9390790 chr6 102307069 G A 6.00E-04 Epilepsy GRIK2 intron 22116939 rs9485549 chr6 102308598 T C 4.20E-04 Smoking cessation GRIK2 intron 24665060 rs4840200 chr6 102327303 T C 1.42E-04 Epilepsy GRIK2 intron 22116939 rs4840200 chr6 102327303 T C 0.000656857 Hypertension (early onset hypertension) GRIK2 intron 22479346 rs12207601 chr6 102355867 A G 2.00E-06 Biochemical measures GRIK2 intron 19260141 rs1475919 chr6 102358855 A G 1.99E-04 Prion diseases GRIK2 intron 22210626 rs12192251 chr6 102394185 G C 1.11E-04 Multiple complex diseases GRIK2 intron 17554300 rs6570999 chr6 102399335 G A 2.72E-05 Prion diseases GRIK2 intron 22210626 rs6928180 chr6 102409781 A G 6.64E-05 Amyotrophic lateral sclerosis (sporadic) GRIK2 intron 24529757 rs11156164 chr6 102411548 A C 3.99E-05 Prion diseases GRIK2 intron 22210626 rs2248800 chr6 102413176 T G 2.20E-06 Urinary metabolites GRIK2 intron 21572414 rs2852605 chr6 102432398 G T 2.20E-06 Urinary metabolites GRIK2 intron 21572414 rs1335022 chr6 102466397 C T 1.38E-05 Oral cancers (chewing tobacco related) GRIK2 intron 22503698 rs1335024 chr6 102471903 A G 7.07E-05 Oral cancers (chewing tobacco related) GRIK2 intron 22503698 rs1335033 chr6 102489410 A G 5.29E-04 Oral cancers (chewing tobacco related) GRIK2 intron 22503698 rs12198351 chr6 102515450 C G 2.86E-05 Multiple complex diseases GRIK2 intron 17554300 rs17062886 chr6 102629300 G A 1.72E-04 Type 2 diabetes / / 17463246 rs6937225 chr6 102642021 G A 1.96E-04 Type 2 diabetes / / 17463246 rs9377344 chr6 102655432 C T 1.87E-04 Type 2 diabetes / / 17463246 rs12175716 chr6 102727552 C T 4.46E-04 Multiple complex diseases / / 17554300 rs954551 chr6 102779335 G A 5.33E-06 Longevity / / 20304771 rs12663507 chr6 102795501 C A 7.34E-04 Myopia (pathological) / / 21095009 rs7768616 chr6 102813806 C A 8.27E-04 Myopia (pathological) / / 21095009 rs1338657 chr6 102849336 C T 2.57E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs1338657 chr6 102849336 C T 6.82E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9377361 chr6 102865390 A G 5.61E-05 Longevity / / 20304771 rs9377363 chr6 102868636 C T 4.23E-05 Longevity / / 20304771 rs7771560 chr6 102870087 T C 4.50E-05 Longevity / / 20304771 rs9285551 chr6 102873089 C T 4.45E-05 Longevity / / 20304771 rs1416280 chr6 102886643 C G 4.39E-05 Longevity / / 20304771 rs9377366 chr6 102891638 G A 3.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs9377366 chr6 102891638 G A 2.77E-04 Coronary heart disease / / 21606135 rs4475333 chr6 102896943 A G 3.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs537534 chr6 102910292 A G 3.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs638319 chr6 102913637 C T 3.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs685072 chr6 102917110 C T 3.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs559731 chr6 102918686 T A 3.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs601907 chr6 102922642 A G 3.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs479856 chr6 102940480 G C 3.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs9399749 chr6 102943062 C T 4.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs484457 chr6 102950477 T C 4.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs662991 chr6 102959138 G A 3.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs2142338 chr6 102965635 A C 3.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs7762734 chr6 102966177 C G 3.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs9390844 chr6 102966628 G A 2.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs17430337 chr6 102971246 G A 5.00E-06 Obesity-related traits / / 23251661 rs2205396 chr6 102972812 G T 1.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs9404214 chr6 102974128 A G 1.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs9404214 chr6 102974128 A G 7.07E-04 Coronary heart disease / / 21606135 rs12203272 chr6 102977378 C T 1.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs6933454 chr6 102981477 A T 1.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs1934009 chr6 103015795 C T 5.28E-05 Lung adenocarcinoma / / 19836008 rs7752919 chr6 103018974 C T 4.77E-05 Lung adenocarcinoma / / 19836008 rs12110754 chr6 103025155 T C 9.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs9485729 chr6 103136031 C T 5.43E-07 Kawasaki disease / / 21221998 rs9377381 chr6 103146074 T G 3.49E-04 Myocardial Infarction / / pha002873 rs1983428 chr6 103165407 G A 9.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs2399850 chr6 103166026 A G 9.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs6902640 chr6 103169903 G T 9.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs1403687 chr6 103179061 A G 8.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs9390870 chr6 103183734 A T 8.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs9404237 chr6 103186051 C A 7.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs1431213 chr6 103198856 T C 2.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs13205979 chr6 103199393 G C 3.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs951197 chr6 103210765 C A 5.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs11156219 chr6 103218355 A G 3.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs9390875 chr6 103218711 A T 8.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs1594462 chr6 103219703 T C 8.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs6939739 chr6 103221891 G A 3.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs1367643 chr6 103223780 A C,G,T 8.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs6900311 chr6 103225137 T G 8.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs12201024 chr6 103226815 T C 8.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs1431210 chr6 103229346 C T 9.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs17063646 chr6 103243032 C T 4.73E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11966481 chr6 103284564 C T 2.70E-05 Urinary metabolites / / 21572414 rs11963159 chr6 103319490 T C 7.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs9377407 chr6 103325998 T G 5.32E-04 Smoking initiation / / 24665060 rs9390914 chr6 103354385 A G 1.12E-04 Alzheimer's disease / / 17998437 rs12212546 chr6 103354421 T C 2.58E-04 Alzheimer's disease / / 17998437 rs9404279 chr6 103354524 C T 8.89E-05 Alzheimer's disease / / 17998437 rs7774430 chr6 103371434 A G 5.74E-04 Multiple complex diseases / / 17554300 rs1323204 chr6 103375824 A T 5.26E-04 Multiple complex diseases / / 17554300 rs724389 chr6 103417615 C T 7.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs2157534 chr6 103443756 G T 8.68E-05 Potassium levels / / pha003086 rs6900581 chr6 103475623 G A 9.59E-04 Obesity (extreme) / / 21935397 rs6900275 chr6 103481466 G A 2.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9377426 chr6 103482088 C T 4.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9485765 chr6 103482619 T G 8.55E-04 Obesity (extreme) / / 21935397 rs6571078 chr6 103497909 A G 1.63E-04 Multiple complex diseases / / 17554300 rs522447 chr6 103612659 C T 8.26E-04 Stroke / / pha002887 rs7775385 chr6 103646294 G A 1.15E-08 Schizophrenia / / 22037555 rs501241 chr6 103652391 T C 5.43E-04 Multiple complex diseases / / 17554300 rs7740569 chr6 103712337 G T 2.45E-04 Multiple complex diseases / / 17554300 rs7768059 chr6 103775306 G T 8.60E-05 Alcoholism (heaviness of drinking) / / 21529783 rs10782355 chr6 103788853 A T 1.83E-04 Multiple complex diseases / / 17554300 rs994988 chr6 103799046 C T 2.00E-07 Palmitic acid (16:0) plasma levels / / 23362303 rs1155126 chr6 103801640 C A 4.00E-04 Response to antidepressants / / 19736353 rs724846 chr6 103837748 A G 0.000815 Salmonella-induced pyroptosis / / 22837397 rs11156278 chr6 103889182 C A 8.79E-05 Psoriasis / / 20953190 rs2207016 chr6 103895135 C T 5.47E-05 Psoriasis / / 20953190 rs2207021 chr6 103899170 C T 6.99E-04 Multiple complex diseases / / 17554300 rs9373696 chr6 103900570 T C 8.46E-04 Type 2 diabetes / / 22158537 rs9404382 chr6 103902932 G A 6.99E-04 Type 2 diabetes / / 22158537 rs9404383 chr6 103903144 C T 6.67E-04 Type 2 diabetes / / 22158537 rs9391020 chr6 103904709 G A 1.93E-04 Type 2 diabetes / / 22158537 rs9391021 chr6 103904742 C A 2.11E-04 Type 2 diabetes / / 22158537 rs7452892 chr6 103916778 G A 6.84E-05 Type 2 diabetes / / 22158537 rs9391023 chr6 103924200 G A 3.88E-04 Type 2 diabetes / / 17463246 rs6903018 chr6 103938853 A C 8.37E-04 Type 2 diabetes / / 22158537 rs9399823 chr6 103961070 G A 9.39E-04 Type 2 diabetes / / 22158537 rs9399827 chr6 103968992 T C 2.68E-04 Alzheimer's disease (late onset) / / 21379329 rs9399827 chr6 103968992 T C 1.83E-04 Type 2 diabetes / / 22158537 rs2506739 chr6 104003082 C T 7.49E-05 Serum metabolites / / 19043545 rs7452689 chr6 104016969 G T 9.01E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs9391062 chr6 104023650 C T 6.71E-04 Smoking initiation / / 24665060 rs9399834 chr6 104040669 T G 2.42E-04 Bipolar disorder,schizoaffective / / 19567891 rs6571130 chr6 104042691 A G 3.50E-05 Cognitive function / / 24684796 rs2501194 chr6 104048526 G A 1.21E-04 Bipolar disorder,schizoaffective / / 19567891 rs9377537 chr6 104057380 A G 7.82E-05 Serum metabolites / / 19043545 rs9386374 chr6 104057539 C T 6.53E-05 Serum metabolites / / 19043545 rs4945900 chr6 104057615 C T 4.90E-05 Serum metabolites / / 19043545 rs9499589 chr6 104059214 G C 4.35E-05 Serum metabolites / / 19043545 rs7452930 chr6 104060114 T C 7.77E-04 Multiple complex diseases / / 17554300 rs9391078 chr6 104060760 C G 4.35E-05 Serum metabolites / / 19043545 rs9499594 chr6 104060812 G A 1.88E-05 Serum metabolites / / 19043545 rs7744535 chr6 104062116 T G 5.44E-05 Serum metabolites / / 19043545 rs9499598 chr6 104062475 A T 4.35E-05 Serum metabolites / / 19043545 rs9499614 chr6 104071171 G A 2.36E-05 Serum metabolites / / 19043545 rs9499615 chr6 104071191 G A 2.36E-05 Serum metabolites / / 19043545 rs9377543 chr6 104071301 C T 2.36E-05 Serum metabolites / / 19043545 rs7764933 chr6 104071467 T G 2.36E-05 Serum metabolites / / 19043545 rs2501185 chr6 104072481 T G 1.84E-04 Multiple complex diseases / / 17554300 rs2501184 chr6 104072649 G C 1.16E-04 Bipolar disorder,schizoaffective / / 19567891 rs2501182 chr6 104072971 A G 8.99E-05 Multiple complex diseases / / 17554300 rs9373718 chr6 104074113 T A 5.30E-05 Serum metabolites / / 19043545 rs9373718 chr6 104074113 T A 2.73E-04 Bipolar disorder,schizoaffective / / 19567891 rs9377558 chr6 104121701 T C 2.82E-04 Bipolar disorder,schizoaffective / / 19567891 rs7743180 chr6 104128743 T G 4.84E-05 Major depressive disorder / / 22472876 rs6917911 chr6 104144452 G A 4.46E-04 Multiple complex diseases / / 17554300 rs9373729 chr6 104214242 A G 3.12E-04 Alzheimer's disease (late onset) / / 21379329 rs7760658 chr6 104222812 G A 2.31E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs4610597 chr6 104223877 G A 2.13E-04 Iron levels / / pha002876 rs9485899 chr6 104279864 T G 8.50E-04 Bipolar I disorder / / 24444492 rs10214527 chr6 104352616 G T 2.00E-05 Cortisol secretion,in saliva / / 21316860 rs9404493 chr6 104371747 A T 6.91E-04 Alzheimer's disease / / 17998437 rs4520040 chr6 104432165 G A 3.00E-06 Cardiac hypertrophy / / 21348951 rs9499708 chr6 104445367 C T 7.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9499708 chr6 104445367 C T 3.00E-06 Obsessive-compulsive disorder / / 22889921 rs2205748 chr6 104462555 A G 4.57E-04 Parkinson's disease / / 17052657 rs1883176 chr6 104463297 G A 8.79E-04 Alzheimer's disease / / 22005930 rs2205747 chr6 104466213 A G 8.57E-04 Alzheimer's disease / / 22005930 rs2205746 chr6 104466287 G A 8.90E-04 Alzheimer's disease / / 22005930 rs6571153 chr6 104467385 C T 7.67E-04 Alzheimer's disease / / 22005930 rs6571154 chr6 104467623 C G 7.52E-04 Alzheimer's disease / / 22005930 rs990396 chr6 104468451 A G 7.45E-04 Alzheimer's disease / / 22005930 rs9499725 chr6 104469371 G A 6.48E-04 Alzheimer's disease / / 22005930 rs6915190 chr6 104469545 C T 7.45E-04 Alzheimer's disease / / 22005930 rs2895561 chr6 104471603 C T 7.40E-04 Alzheimer's disease / / 22005930 rs13207301 chr6 104479248 G C 7.88E-04 Alzheimer's disease / / 22005930 rs859981 chr6 104500957 G A 4.40E-04 Type 2 diabetes / / 17463246 rs859966 chr6 104515705 C T 8.12E-04 Type 2 diabetes / / 17463246 rs9386402 chr6 104519786 C T 5.59E-04 Parkinson's disease / / 17052657 rs9377619 chr6 104593867 A G 2.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs9377619 chr6 104593867 A G 6.60E-05 Cognitive function / / 24684796 rs9377619 chr6 104593867 A G 1.44E-05 Schizophrenia / / pha002857 rs2744203 chr6 104663778 G C 7.00E-06 IgG glycosylation / / 23382691 rs9391179 chr6 104745414 T G 6.04E-04 Body mass index / / 21701565 rs559295 chr6 104751488 C T 4.20E-05 Cognitive function / / 24684796 rs270666 chr6 104753237 A C 6.19E-06 Schizophrenia / / pha002857 rs1341118 chr6 104754646 C G,T 1.12E-05 Schizophrenia / / pha002857 rs9391181 chr6 104759143 C T 1.19E-05 Schizophrenia / / pha002857 rs13213851 chr6 104760123 A G 1.86E-06 Chronic kidney disease / / 21931561 rs169282 chr6 104765744 A G 7.76E-06 Schizophrenia / / pha002857 rs17456339 chr6 104765822 C T 4.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs447871 chr6 104765867 C T 1.90E-05 Schizophrenia / / pha002857 rs404900 chr6 104765922 G T 2.77E-05 Schizophrenia / / pha002857 rs6571178 chr6 104766876 T C 9.84E-06 Schizophrenia / / pha002857 rs17516082 chr6 104768201 A G 5.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs814372 chr6 104768833 C T 1.37E-05 Schizophrenia / / pha002857 rs549374 chr6 104768977 C T 2.00E-05 Schizophrenia / / pha002857 rs4945639 chr6 104772168 C T 5.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs13197557 chr6 104773749 A G 5.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs7764670 chr6 104774231 A G 2.19E-05 Schizophrenia / / pha002857 rs9391184 chr6 104780499 C T 2.39E-05 Schizophrenia / / pha002857 rs10499040 chr6 104782345 C G 4.36E-05 Bipolar disorder and schizophrenia / / 20889312 rs10499040 chr6 104782345 C G 6.80E-04 Alzheimer's disease / / 22005930 rs10499040 chr6 104782345 C G 2.04E-06 Schizophrenia / / pha002857 rs270675 chr6 104783463 C T 2.59E-04 Alzheimer's disease / / 22005930 rs270678 chr6 104784819 C T 4.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs270678 chr6 104784819 C T 1.94E-04 Major depression (suicidal thoughts and behavior) / / 21750702 rs270678 chr6 104784819 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs17064894 chr6 104786345 C G 3.96E-04 Alzheimer's disease / / 22005930 rs17064895 chr6 104786511 A C 3.79E-04 Alzheimer's disease / / 22005930 rs10872798 chr6 104788441 G T 3.70E-04 Alzheimer's disease / / 22005930 rs1341113 chr6 104792340 C T 9.56E-05 Coronary heart disease / / pha003055 rs12215393 chr6 104792894 C T 7.47E-05 Coronary heart disease / / pha003055 rs9373757 chr6 104796518 T C 3.17E-04 Alzheimer's disease / / 22005930 rs9373758 chr6 104796636 G A 2.95E-04 Alzheimer's disease / / 22005930 rs17517558 chr6 104797578 A C 4.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs156153 chr6 104798065 G A 4.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs156151 chr6 104799007 C G 4.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs1417667 chr6 104803190 T C 8.19E-05 Alzheimer's disease / / 22005930 rs155510 chr6 104805862 G T 4.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs9391188 chr6 104808854 C T 2.91E-04 Alzheimer's disease / / 22005930 rs9399879 chr6 104809548 T C 2.87E-04 Alzheimer's disease / / 22005930 rs156126 chr6 104810083 T C 4.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs13219556 chr6 104810749 C T 5.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs156123 chr6 104811745 G A 5.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs17458588 chr6 104813497 T C 5.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs271880 chr6 104813766 A G 4.81E-04 Suicide attempts in bipolar disorder / / 21041247 rs271878 chr6 104814437 A C 4.94E-05 Bipolar disorder and schizophrenia / / 20889312 rs271878 chr6 104814437 A C 2.09E-04 Alzheimer's disease / / 22005930 rs271878 chr6 104814437 A C 2.75E-06 Schizophrenia / / pha002857 rs271876 chr6 104814799 C T 4.82E-04 Multiple complex diseases / / 17554300 rs271876 chr6 104814799 C T 7.10E-05 Bipolar disorder and schizophrenia / / 20889312 rs271876 chr6 104814799 C T 2.93E-04 Alzheimer's disease / / 22005930 rs271876 chr6 104814799 C T 1.47E-06 Schizophrenia / / pha002857 rs1341111 chr6 104815137 A G 6.48E-05 Coronary heart disease / / pha003055 rs1417665 chr6 104816944 T C 5.06E-04 Suicide attempts in bipolar disorder / / 21041247 rs443578 chr6 104817535 A G 3.87E-05 Cognitive impairment induced by topiramate / / 22091778 rs443578 chr6 104817535 A G 7.70E-05 Cognitive impairment induced by topiramate / / 22091778 rs17459015 chr6 104817775 T C 5.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs17459015 chr6 104817775 T C 1.63E-04 Major depression (suicidal thoughts and behavior) / / 21750702 rs467827 chr6 104820174 A T 4.43E-04 Alzheimer's disease / / 22005930 rs156120 chr6 104821805 T C 2.12E-04 Alzheimer's disease / / 22005930 rs4946463 chr6 104831503 A C 1.13E-06 Parkinson's disease / / 17052657 rs267333 chr6 104856640 A G 1.00E-04 Information processing speed / / 21130836 rs94577 chr6 104864877 A C 6.43E-05 Information processing speed / / 21130836 rs156232 chr6 104872816 C T 6.43E-05 Information processing speed / / 21130836 rs94802 chr6 104924823 C T 5.96E-04 Type 2 diabetes / / 17846124 rs94802 chr6 104924823 C T 5.32E-05 Information processing speed / / 21130836 rs271858 chr6 104951875 C G 5.77E-04 Type 2 diabetes / / 17463246 rs1416042 chr6 105067879 G A 3.69E-04 Body mass index / / 21701565 rs1416042 chr6 105067879 G A 7.03E-04 Body mass index / / 21701565 rs2895591 chr6 105070744 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9377660 chr6 105076512 T C 8.18E-04 Alzheimer's disease / / 22005930 rs2185061 chr6 105078118 A C 3.15E-04 Alzheimer's disease / / 22005930 rs9373777 chr6 105079634 T G 8.58E-04 Alzheimer's disease / / 22005930 rs884270 chr6 105080990 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6910034 chr6 105133622 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9499921 chr6 105137252 C G 4.94E-04 Multiple complex diseases / / 17554300 rs921855 chr6 105148481 A G 8.20E-04 Multiple complex diseases / / 17554300 rs9386426 chr6 105165367 A G 2.49E-04 Body mass index / / 17255346 rs9386427 chr6 105166802 G T 1.65E-04 Body mass index / / 17255346 rs9499937 chr6 105167260 C T 8.35E-04 Alzheimer's disease / / 17998437 rs4336470 chr6 105180785 C T 2.70E-04 Hemoglobin concentration HACE1 intron 20534544 rs4336470 chr6 105180785 C T 2.00E-04 Cognitive impairment induced by topiramate HACE1 intron 22091778 rs4336470 chr6 105180785 C T 3.00E-11 Neuroblastoma HACE1 intron 22941191 rs4336470 chr6 105180785 C T 7.91E-05 Neuroblastoma HACE1 intron pha002895 rs9404576 chr6 105184640 T G 1.62E-04 Hemoglobin concentration HACE1 intron 20534544 rs9404576 chr6 105184640 T G 2.00E-04 Cognitive impairment induced by topiramate HACE1 intron 22091778 rs9404576 chr6 105184640 T G 1.80E-10 Neuroblastoma HACE1 intron 22941191 rs6942231 chr6 105191814 C T 1.60E-04 Kidney function and endocine traits HACE1 intron 17903292 rs9322816 chr6 105216695 T C 3.71E-04 Hemoglobin concentration HACE1 intron 20534544 rs733724 chr6 105223864 G A 3.00E-07 Multiple sclerosis HACE1 intron 23412934 rs17065302 chr6 105229646 C G 0.0000048 Equol producers as measured by serum equol concentrations HACE1 intron 22477055 rs9322817 chr6 105232233 A C 7.00E-06 Thyroid stimulating hormone HACE1 intron 17903292 rs11759010 chr6 105236302 T G 0.0000038 Equol producers as measured by serum equol concentrations HACE1 intron 22477055 rs4079063 chr6 105266118 A G 1.30E-07 Neuroblastoma HACE1 intron 22941191 rs6927608 chr6 105288125 A C 0.0000025 Equol producers as measured by serum equol concentrations HACE1 intron 22477055 rs4946645 chr6 105295535 C G 0.000003 Equol producers as measured by serum equol concentrations HACE1 intron 22477055 rs2499663 chr6 105300570 C T 1.60E-07 Neuroblastoma HACE1 intron 22941191 rs4245525 chr6 105306144 C T 0.0000079 Equol producers as measured by serum equol concentrations HACE1 intron 22477055 rs6911031 chr6 105311616 C T 5.76E-05 Hemoglobin concentration / / 20534544 rs2499667 chr6 105319125 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2499667 chr6 105319125 G A 1.20E-07 Neuroblastoma / / 22941191 rs6928554 chr6 105332920 T C 2.06E-04 Hemoglobin concentration / / 20534544 rs7762076 chr6 105344836 T G 2.24E-04 Multiple complex diseases / / 17554300 rs2153127 chr6 105348544 T C 2.00E-04 Information processing speed / / 21130836 rs12193005 chr6 105355331 C A 1.00E-04 Information processing speed / / 21130836 rs11156429 chr6 105364421 T G 2.35E-05 Information processing speed / / 21130836 rs11156429 chr6 105364421 T G 2.00E-07 Pubertal anthropometrics / / 23449627 rs11156429 chr6 105364421 T G 1.22E-06 Menarche (age at onset) / / 23667675 rs9391253 chr6 105367616 A T 7.43E-09 Menarche (age at onset) / / 19448620 rs9391253 chr6 105367616 A T 5.00E-12 Height / / 23563607 rs9391253 chr6 105367616 A T 1.22E-06 Menarche (age at onset) / / 23667675 rs9391253 chr6 105367616 A T 3.00E-07 Puberty onset (breast development) / / 24770850 rs4946651 chr6 105369510 A G 1.60E-08 Menarche (age at onset) / / 19448622 rs4946651 chr6 105369510 A G 1.48E-06 Height,pubertal growth in / / 20398887 rs4946651 chr6 105369510 A G 2.80E-05 Information processing speed / / 21130836 rs4946651 chr6 105369510 A G 1.15E-06 Menarche (age at onset) / / 23667675 rs4946651 chr6 105369510 A G 4.98E-08 Waist Circumference / / pha003023 rs7759938 chr6 105378954 C T 7.00E-09 Menarche (age at onset) / / 19448620 rs7759938 chr6 105378954 C T 1.00E-05 Digit length ratio / / 20303062 rs7759938 chr6 105378954 C T 1.70E-04 Height,pubertal growth in / / 20398887 rs7759938 chr6 105378954 C T 1.80E-05 Height,pubertal growth in / / 20398887 rs7759938 chr6 105378954 C T 3.00E-05 Height,pubertal growth in / / 20398887 rs7759938 chr6 105378954 C T 4.40E-04 Height,pubertal growth in / / 20398887 rs7759938 chr6 105378954 C T 5.00E-04 Height,pubertal growth in / / 20398887 rs7759938 chr6 105378954 C T 5.00E-11 Height,pubertal growth in / / 20398887 rs7759938 chr6 105378954 C T 5.00E-11 Height,pubertal growth in / / 20398887 rs7759938 chr6 105378954 C T 6.65E-05 Height,pubertal growth in / / 20398887 rs7759938 chr6 105378954 C T 7.00E-05 Height,pubertal growth in / / 20398887 rs7759938 chr6 105378954 C T 8.20E-09 Height,pubertal growth in / / 20398887 rs7759938 chr6 105378954 C T 8.30E-08 Height,pubertal growth in / / 20398887 rs7759938 chr6 105378954 C T 8.00E-31 Height / / 20881960 rs7759938 chr6 105378954 C T 4.00E-09 Pubertal anthropometrics / / 23449627 rs7759938 chr6 105378954 C T 1.12E-06 Menarche (age at onset) / / 23667675 rs7759938 chr6 105378954 C T 5.60E-07 Puberty onset (breast development) / / 24770850 rs12200251 chr6 105382415 G A 1.00E-06 Menarche (age at onset) / / 23667675 rs2095812 chr6 105383978 C G 7.55E-09 Menarche (age at onset) / / 19448620 rs2095812 chr6 105383978 C G 1.08E-06 Menarche (age at onset) / / 23667675 rs2095812 chr6 105383978 C G 2.60E-07 Puberty onset (breast development) / / 24770850 rs314263 chr6 105392745 C T 9.79E-09 Menarche (age at onset) / / 19448620 rs314263 chr6 105392745 C T 2.00E-05 Digit length ratio / / 20303062 rs314263 chr6 105392745 C T 1.03E-06 Menarche (age at onset) / / 23667675 rs314263 chr6 105392745 C T 3.10E-07 Puberty onset (breast development) / / 24770850 rs314263 chr6 105392745 C T 3.43E-05 Height / / pha003010 rs314263 chr6 105392745 C T 2.75E-05 Height / / pha003011 rs314263 chr6 105392745 C T 3.78E-08 Waist Circumference / / pha003023 rs314262 chr6 105394621 G A 1.50E-08 Menarche (age at onset) / / 19448622 rs314262 chr6 105394621 G A 9.10E-07 Height,pubertal growth in / / 20398887 rs314262 chr6 105394621 G A 2.80E-05 Information processing speed / / 21130836 rs314262 chr6 105394621 G A 1.26E-06 Menarche (age at onset) / / 23667675 rs314262 chr6 105394621 G A 4.17E-08 Waist Circumference / / pha003023 rs395962 chr6 105397418 T G 8.34E-09 Menarche (age at onset) / / 19448620 rs395962 chr6 105397418 T G 1.26E-06 Menarche (age at onset) / / 23667675 rs395962 chr6 105397418 T G 3.00E-07 Puberty onset (breast development) / / 24770850 rs314280 chr6 105400837 A G 2.00E-14 Menarche (age at onset) / / 19448622 rs314280 chr6 105400837 A G 3.30E-07 Height,pubertal growth in / / 20398887 rs314280 chr6 105400837 A G 5.40E-07 Height,pubertal growth in / / 20398887 rs314280 chr6 105400837 A G 2.80E-05 Information processing speed / / 21130836 rs314280 chr6 105400837 A G 1.26E-06 Menarche (age at onset) / / 23667675 rs314280 chr6 105400837 A G 4.24E-08 Waist Circumference / / pha003023 rs9404590 chr6 105401013 T G 6.49E-06 Menarche (age at onset) / / 23667675 rs17065417 chr6 105406274 A C 1.00E-08 Neuroblastoma LIN28B intron 22941191 rs17065417 chr6 105406274 A C 6.85E-05 Neuroblastoma LIN28B intron pha002895 rs314277 chr6 105407662 A C 1.00E-08 Height LIN28B intron 18391950 rs314277 chr6 105407662 A C 3.00E-13 Menarche and menopause (age at onset) LIN28B intron 19448621 rs314277 chr6 105407662 A C 1.30E-07 Menarche (age at onset) LIN28B intron 19448622 rs314277 chr6 105407662 A C 2.00E-06 Digit length ratio LIN28B intron 20303062 rs314277 chr6 105407662 A C 2.10E-35 Menarche (age at onset) LIN28B intron 21102462 rs314276 chr6 105407999 A C 1.04E-08 Menarche (age at onset) LIN28B intron 19448620 rs314276 chr6 105407999 A C 4.00E-16 Menarche (age at onset) LIN28B intron 19448623 rs314276 chr6 105407999 A C 5.00E-05 Digit length ratio LIN28B intron 20303062 rs314276 chr6 105407999 A C 1.57E-06 Menarche (age at onset) LIN28B intron 23667675 rs314276 chr6 105407999 A C 3.70E-07 Puberty onset (breast development) LIN28B intron 24770850 rs167539 chr6 105410048 C A 1.06E-08 Menarche (age at onset) LIN28B intron 19448620 rs167539 chr6 105410048 C A 1.61E-06 Menarche (age at onset) LIN28B intron 23667675 rs167539 chr6 105410048 C A 4.30E-07 Puberty onset (breast development) LIN28B intron 24770850 rs314274 chr6 105412932 A C 1.28E-06 Menarche (age at onset) LIN28B intron 23667675 rs314268 chr6 105417978 G A 8.00E-07 Height LIN28B intron 18391951 rs314268 chr6 105417978 G A 1.12E-08 Menarche (age at onset) LIN28B intron 19448620 rs314268 chr6 105417978 G A 3.00E-08 Menarche (age at onset) LIN28B intron 19448622 rs314268 chr6 105417978 G A 1.42E-05 Height,pubertal growth in LIN28B intron 20398887 rs314268 chr6 105417978 G A 1.31E-06 Menarche (age at onset) LIN28B intron 23667675 rs314268 chr6 105417978 G A 9.60E-07 Puberty onset (breast development) LIN28B intron 24770850 rs314268 chr6 105417978 G A 9.98E-06 Height LIN28B intron pha003010 rs314268 chr6 105417978 G A 8.89E-06 Height LIN28B intron pha003011 rs314268 chr6 105417978 G A 2.40E-08 Waist Circumference LIN28B intron pha003023 rs314266 chr6 105421317 C T 2.90E-04 Menarche (age at onset) LIN28B intron 23599027 rs314266 chr6 105421317 C T 1.31E-06 Menarche (age at onset) LIN28B intron 23667675 rs1744206 chr6 105423931 G C 1.31E-06 Menarche (age at onset) LIN28B intron 23667675 rs314291 chr6 105424901 C T 1.34E-06 Menarche (age at onset) LIN28B intron 23667675 rs314290 chr6 105426994 A G 1.34E-06 Menarche (age at onset) LIN28B intron 23667675 rs314289 chr6 105430934 C T 1.39E-06 Menarche (age at onset) LIN28B intron 23667675 rs364663 chr6 105443189 T A 5.00E-07 Menarche (age at onset) LIN28B intron 23667675 rs369065 chr6 105444058 C T 1.06E-08 Menarche (age at onset) LIN28B intron 19448620 rs369065 chr6 105444058 C T 5.00E-05 Digit length ratio LIN28B intron 20303062 rs369065 chr6 105444058 C T 8.90E-05 Age at menarche,age at menopause LIN28B intron 22131368 rs369065 chr6 105444058 C T 7.92E-06 Menarche (age at onset) LIN28B intron 23667675 rs369065 chr6 105444058 C T 3.69E-05 Height LIN28B intron pha003010 rs369065 chr6 105444058 C T 2.31E-05 Height LIN28B intron pha003011 rs369065 chr6 105444058 C T 4.20E-08 Waist Circumference LIN28B intron pha003023 rs9377684 chr6 105445364 A G 0.0000603 Amyotrophic lateral sclerosis LIN28B intron 23587638 rs9377684 chr6 105445364 A G 6.19E-06 Waist Circumference LIN28B intron pha003023 rs9377684 chr6 105445364 A G 8.44E-05 Waist Circumference LIN28B intron pha003024 rs314273 chr6 105461882 T G 1.16E-08 Menarche (age at onset) LIN28B intron 19448620 rs314273 chr6 105461882 T G 2.31E-06 Menarche (age at onset) LIN28B intron 23667675 rs314273 chr6 105461882 T G 6.80E-07 Puberty onset (breast development) LIN28B intron 24770850 rs314272 chr6 105462004 G A 8.79E-04 Response to taxane treatment (placlitaxel) LIN28B intron 23006423 rs314272 chr6 105462004 G A 2.26E-06 Menarche (age at onset) LIN28B intron 23667675 rs314270 chr6 105462876 T C 2.10E-06 Menarche (age at onset) LIN28B intron 23667675 rs9404597 chr6 105520630 G A 7.70E-06 Urinary metabolites LIN28B intron 21572414 rs1149285 chr6 105525121 T C 4.08E-04 Multiple complex diseases LIN28B intron 17554300 rs1190472 chr6 105536491 C T 7.94E-05 Aortic root size / / 21223598 rs221645 chr6 105538504 G A 1.20E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12529519 chr6 105543354 A G 3.07E-04 Type 2 diabetes / / 17463246 rs13196925 chr6 105551229 T G 2.25E-05 Meningococcal disease BVES intron 20694013 rs11962089 chr6 105612220 A G 8.00E-06 Multiple sclerosis POPDC3 intron 21654844 rs1624675 chr6 105630330 T A,C,G 0.00032 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines / / 23204130 rs1624675 chr6 105630330 T A,C,G 9.44E-05 Monocyte chemoattractant protein-1 / / pha003071 rs1144610 chr6 105705710 G C 1.22E-04 Type 2 diabetes / / 17463246 rs3799992 chr6 105727864 T C 2.32E-04 Smoking initiation PREP intron 24665060 rs1190053 chr6 105745188 G A 8.48E-05 Panic disorder PREP intron 19165232 rs1149309 chr6 105749923 G T 4.90E-05 Pulmonary function PREP intron 23932459 rs1617445 chr6 105757070 C T 6.33E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) PREP intron 23648065 rs1190063 chr6 105769201 C T 8.72E-04 Suicide attempts in bipolar disorder PREP intron 21423239 rs1190065 chr6 105769900 A T 8.90E-04 Suicide attempts in bipolar disorder PREP intron 21423239 rs2793389 chr6 105771166 C A 5.78E-04 Suicide attempts in bipolar disorder PREP intron 21423239 rs6571228 chr6 105774061 T C 1.95E-05 Coronary heart disease PREP intron pha003031 rs11156437 chr6 105778067 C T 6.95E-04 Suicide attempts in bipolar disorder PREP intron 21423239 rs4512258 chr6 105783150 A C 1.38E-05 Coronary heart disease PREP intron pha003031 rs4585599 chr6 105795907 C T 9.90E-04 Suicide attempts in bipolar disorder PREP intron 21423239 rs11752450 chr6 105807821 A G 9.79E-04 Acute lung injury PREP intron 22295056 rs41382946 chr6 105809057 A C 9.63E-04 Multiple complex diseases PREP intron 17554300 rs17065860 chr6 105810523 C G 7.69E-04 Type 2 diabetes PREP intron 17463246 rs9486077 chr6 105849023 C T 1.85E-05 Relative hand skill PREP intron 24068947 rs6909720 chr6 105875614 A G 4.57E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs17065917 chr6 105879268 T C 7.19E-04 Alzheimer's disease / / 17998437 rs1998736 chr6 105886985 G A,T 7.67E-05 Alzheimer's disease (age of onset) / / 22005931 rs7765899 chr6 105896843 C T 7.36E-05 Alzheimer's disease (age of onset) / / 22005931 rs10080910 chr6 105898952 G A 8.82E-05 Monocyte counts / / pha003089 rs6927151 chr6 105914261 C A 2.44E-04 Alzheimer's disease / / 22005930 rs9486125 chr6 105948763 G A 1.18E-05 Monocyte counts / / pha003089 rs4946672 chr6 105991031 G A 5.43E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs714530 chr6 106042885 C T 9.48E-05 Coronary heart disease / / pha003035 rs9373794 chr6 106043635 A G 7.41E-05 Coronary heart disease / / pha003035 rs2027873 chr6 106059644 C T 8.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9372096 chr6 106065730 C T 2.19E-05 Alcohol consumption / / 23953852 rs2040431 chr6 106071251 A T 1.60E-05 Urinary metabolites / / 21572414 rs2213753 chr6 106083885 T C 8.08E-04 Multiple complex diseases / / 17554300 rs17066117 chr6 106084322 C T 8.85E-04 Multiple complex diseases / / 17554300 rs1011659 chr6 106091250 T C 5.15E-04 Multiple complex diseases / / 17554300 rs9386463 chr6 106094057 A G 6.00E-07 Primary tooth development (time to first tooth eruption) / / 20195514 rs13215959 chr6 106113144 G A 9.12E-05 Cognitive performance / / 19734545 rs4945721 chr6 106113443 G T 1.00E-05 Urinary metabolites / / 21572414 rs3749923 chr6 106115785 C A 6.94E-05 Cognitive performance / / 19734545 rs10457131 chr6 106130591 C T 2.50E-05 Urinary metabolites / / 21572414 rs7749157 chr6 106147299 C T 1.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7749157 chr6 106147299 C T 2.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2202768 chr6 106149846 A G 8.26E-06 Intracerebral hemorrhage / / 24656865 rs952063 chr6 106174929 T C 8.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1355025 chr6 106177758 T C 5.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1355025 chr6 106177758 T C 7.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6568401 chr6 106188818 C T 1.60E-05 Primary tooth development (number of teeth) / / 23704328 rs6568401 chr6 106188818 C T 2.00E-10 Primary tooth development (time to first tooth eruption) / / 23704328 rs6568402 chr6 106207093 A G 8.60E-05 Malaria / / 19465909 rs1876550 chr6 106213051 G A 3.59E-05 Taste perception / / 22132133 rs2202766 chr6 106237505 G A 2.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2202766 chr6 106237505 G A 7.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10499043 chr6 106247137 C T 0.00000393 Gains in maximal O2 uptake response / / 21183627 rs1355023 chr6 106252999 T C 6.00E-06 Age-related macular degeneration / / 23326517 rs7750345 chr6 106260128 A G 7.00E-06 Age-related macular degeneration / / 23326517 rs1876561 chr6 106269803 C T 2.74E-05 stroke (ischemic) / / 17434096 rs1355027 chr6 106287543 A G 0.0000674 Salmonella-induced pyroptosis / / 22837397 rs1876564 chr6 106292430 T C 5.01E-05 Fibrinogen / / 17255346 rs9386485 chr6 106329055 C T 1.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs9386485 chr6 106329055 C T 3.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs4072698 chr6 106330503 C T 3.04E-08 Metabolite levels / / 23281178 rs6902443 chr6 106333604 A T 6.08E-08 Metabolite levels / / 23281178 rs9399956 chr6 106336363 C T 2.68E-05 Sudden cardiac arrest / / 21658281 rs4530898 chr6 106339392 C T 9.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs9372114 chr6 106368296 T C 7.26E-04 Myopia (pathological) / / 21095009 rs4946713 chr6 106374015 C A 1.93E-04 Aortic root size / / 21223598 rs4245528 chr6 106374235 A G 3.00E-04 Amyotrophic lateral sclerosis / / 17671248 rs7772171 chr6 106374868 C A 1.26E-04 Arthritis (juvenile idiopathic) / / 22354554 rs9480620 chr6 106384529 T C 2.70E-06 Urinary metabolites / / 21572414 rs9320139 chr6 106387197 C T 5.80E-06 Urinary metabolites / / 21572414 rs9486222 chr6 106388245 A C 6.30E-07 Urinary metabolites / / 21572414 rs9486226 chr6 106392887 A C 2.00E-06 Urinary metabolites / / 21572414 rs12197969 chr6 106394642 C T 1.40E-06 Urinary metabolites / / 21572414 rs6926851 chr6 106397895 A G 2.50E-06 Urinary metabolites / / 21572414 rs6568421 chr6 106435025 A G 4.00E-08 Crohn's disease / / 21102463 rs6568421 chr6 106435025 A G 8.00E-20 Inflammatory bowel disease / / 23128233 rs7746082 chr6 106435269 G C 3.96E-04 Multiple complex diseases / / 17554300 rs7746082 chr6 106435269 G C 2.00E-10 Crohn's disease / / 18587394 rs7746082 chr6 106435269 G C 2.00E-10 Asthma / / 21150878 rs7746082 chr6 106435269 G C 2.44E-10 Multiple sclerosis / / 22190364 rs6938089 chr6 106470070 G A 2.69E-04 Hearing function / / 17255346 rs6911690 chr6 106470963 G A 0.00012 Rheumatoid arthritis / / 23143596 rs7769470 chr6 106487292 G A 1.31E-04 Smoking initiation / / 24665060 rs6911490 chr6 106522027 T C 1.00E-08 Ulcerative colitis / / 21297633 rs6923608 chr6 106537790 G A 3.20E-05 Alcohol and nictotine co-dependence PRDM1 intron 20158304 rs4946725 chr6 106540276 G A 2.99E-05 Elbow pain PRDM1 intron pha003008 rs811925 chr6 106547372 C G 9.52E-04 Type 2 diabetes PRDM1 missense 17463246 rs535780 chr6 106548730 T C 0.00000118 Primary sclerosing cholangitis PRDM1 intron 23603763 rs1934593 chr6 106559602 G A 1.37E-05 Elbow pain / / pha003008 rs548234 chr6 106568034 C T 6.58E-04 Multiple complex diseases / / 17554300 rs548234 chr6 106568034 C T 5.00E-12 Systemic lupus erythematosus / / 19838193 rs548234 chr6 106568034 C T 2.10E-08 Celiac disease and Rheumatoid arthritis / / 21383967 rs548234 chr6 106568034 C T 4.50E-08 Multiple sclerosis / / 22190364 rs548234 chr6 106568034 C T 1.30E-04 Rheumatoid arthritis / / 22446963 rs548234 chr6 106568034 C T 0.000097 Rheumatoid arthritis / / 23143596 rs548234 chr6 106568034 C T 5.20E-06 Systemic lupus erythematosus / / 23273568 rs693612 chr6 106568864 G A 2.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs504045 chr6 106570628 C G 2.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs11152965 chr6 106571543 G A 4.11E-05 Lipid levels / / pha003082 rs4946727 chr6 106573372 A T 2.88E-05 Alzheimer's disease / / 21098978 rs7761791 chr6 106576986 T C 1.73E-05 Alzheimer's disease / / 21098978 rs6903903 chr6 106577507 A G 1.87E-05 Alzheimer's disease / / 21098978 rs742108 chr6 106582920 G A 4.00E-06 Systemic lupus erythematosus / / 23273568 rs6568431 chr6 106588806 A C 1.74E-08 Systemic lupus erythematosus / / 18204446 rs6568431 chr6 106588806 A C 7.10E-10 Multiple sclerosis / / 22190364 rs6568431 chr6 106588806 A C 0.00000742 Sarcoidosis / / 22952805 rs6568431 chr6 106588806 A C 6.60E-06 Systemic lupus erythematosus / / 23273568 rs742109 chr6 106594224 T C 2.70E-06 Malignant pleural mesothelioma / / 23626673 rs1040411 chr6 106598023 G A 6.10E-05 Systemic lupus erythematosus / / 23273568 rs1018552 chr6 106598313 T C 6.56E-04 Multiple complex diseases / / 17554300 rs9386512 chr6 106599710 A G 3.53E-06 Acute lymphoblastic leukemia (childhood) / / 19684603 rs9373836 chr6 106616379 T C 9.29E-05 Blood Pressure / / pha003039 rs9372120 chr6 106667535 T G 4.00E-08 Rheumatoid arthritis ATG5 intron 24390342 rs9372120 chr6 106667535 T G 8.00E-10 Rheumatoid arthritis ATG5 intron 24390342 rs1769972 chr6 106675819 T C 1.57E-05 Soluble levels of adhesion molecules ATG5 intron pha003072 rs538557 chr6 106683876 T C 1.36E-26 Narcolepsy ATG5 intron 19629137 rs3827644 chr6 106685195 G C 5.00E-07 Systemic lupus erythematosus and Systemic sclerosis ATG5 intron 23740937 rs3851210 chr6 106718522 C T 5.80E-04 Schizophrenia ATG5 intron 19197363 rs3804333 chr6 106727215 C T 2.40E-05 Systemic lupus erythematosus ATG5 intron 24871463 rs633724 chr6 106734040 C T 1.19E-04 Arthritis (juvenile idiopathic) ATG5 intron 22354554 rs633724 chr6 106734040 C T 4.40E-04 Systemic lupus erythematosus ATG5 intron 23273568 rs12212740 chr6 106749308 G A 5.08E-04 Alzheimer's disease ATG5 intron 22005930 rs573775 chr6 106764866 G A 1.36E-07 Systemic lupus erythematosus ATG5 intron 18204446 rs3804338 chr6 106772773 C T 2.10E-04 Type 2 diabetes ATG5 intron 17463246 rs10457143 chr6 106791266 T C 1.73E-04 Alzheimer's disease / / 22005930 rs17066837 chr6 106791283 T C 5.48E-05 Type 2 diabetes / / 17463246 rs17066840 chr6 106792209 G A 1.40E-04 Type 2 diabetes / / 17463246 rs6924580 chr6 106795331 T C 7.13E-05 Sodium levels / / pha003093 rs533685 chr6 106819586 C T 1.26E-04 Arthritis (juvenile idiopathic) / / 22354554 rs17066908 chr6 106821193 C G 1.51E-04 Type 2 diabetes / / 17463246 rs17066910 chr6 106821393 G A 2.49E-04 Type 2 diabetes / / 17463246 rs17066916 chr6 106822546 A G 2.38E-04 Type 2 diabetes / / 17463246 rs654127 chr6 106822726 T G 1.96E-04 Multiple complex diseases / / 17554300 rs17066928 chr6 106823477 G T 3.42E-04 Type 2 diabetes / / 17463246 rs6568433 chr6 106829537 T C 1.00E-06 Longevity / / 20834067 rs7740539 chr6 106831666 T C 1.39E-05 Periodontitis (Chronic) / / 25008200 rs2749083 chr6 106836299 A C 3.00E-05 Nephrolithiasis / / 22396660 rs1884461 chr6 106879930 A G 7.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9373865 chr6 106893070 G C 3.85E-05 Personality dimensions / / 22628180 rs9398086 chr6 106895065 A C 3.58E-05 Personality dimensions / / 22628180 rs1417352 chr6 106899226 C T 2.00E-06 Select biomarker traits / / 17903293 rs12197698 chr6 106899726 T C 3.60E-05 Personality dimensions LOC100506165 intron 22628180 rs9398087 chr6 106905415 A C 2.35E-05 Personality dimensions / / 22628180 rs9400007 chr6 106905933 T C 1.47E-05 Personality dimensions / / 22628180 rs17067057 chr6 106918735 G T 4.82E-05 Personality dimensions / / 22628180 rs3814077 chr6 106919469 C G 4.69E-05 Personality dimensions / / 22628180 rs6926643 chr6 106926143 T G 1.96E-04 Type 2 diabetes / / 17463246 rs9400020 chr6 106936679 C T 1.34E-04 Type 2 diabetes / / 17463246 rs7751527 chr6 106937904 C T 7.72E-05 Cognitive test performance / / 20125193 rs1181557 chr6 106943311 C T 7.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs1417356 chr6 106957120 G T 7.00E-05 Coffee consumption / / 21357676 rs11153000 chr6 106975536 T G 8.96E-04 Myopia (pathological) AIM1 intron 21095009 rs13202942 chr6 106983546 C T 9.61E-05 Lymphocyte counts AIM1 intron 22286170 rs783402 chr6 106984120 G C 5.12E-04 Aortic root size AIM1 intron 21223598 rs9320174 chr6 106985408 A G 8.34E-05 Multiple complex diseases AIM1 intron 17554300 rs783396 chr6 106987370 A C 9.00E-06 Stroke / / 17434096 rs1770721 chr6 106993458 A G 1.00E-04 Information processing speed AIM1 intron 21130836 rs1770721 chr6 106993458 A G 2.40E-05 Urinary metabolites AIM1 intron 21572414 rs9480684 chr6 107012225 G A 9.90E-04 Suicidal ideation AIM1 intron 22030708 rs10499045 chr6 107085574 T C 5.84E-04 Multiple complex diseases QRSL1 intron 17554300 rs1026619 chr6 107114361 A G 3.54E-09 Lymphocyte counts QRSL1 UTR-3 22286170 rs3104037 chr6 107139657 C T 2.24E-04 Alzheimer's disease / / 22005930 rs10499044 chr6 107141295 T C 5.29E-17 Multiple complex diseases / / 17554300 rs2642465 chr6 107161532 G A 8.52E-05 Acne (severe) / / 24927181 rs2642467 chr6 107162648 A G 4.25E-04 Alzheimer's disease / / 22005930 rs2642467 chr6 107162648 A G 4.29E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6915445 chr6 107174515 A G 2.20E-05 Urinary metabolites LOC100422737 intron 21572414 rs6915469 chr6 107174569 A G 2.10E-05 Urinary metabolites LOC100422737 intron 21572414 rs2024742 chr6 107177500 T G 1.30E-05 Urinary metabolites LOC100422737 intron 21572414 rs10872009 chr6 107178504 A G 5.60E-06 Urinary metabolites LOC100422737 intron 21572414 rs9320189 chr6 107178542 C T 5.60E-06 Urinary metabolites LOC100422737 intron 21572414 rs9480703 chr6 107190424 A C 4.80E-05 Alcohol consumption LOC100422737 intron 23743675 rs7753899 chr6 107192081 C T 5.13E-05 Alcohol consumption LOC100422737 intron 23743675 rs9486459 chr6 107206929 G T 6.25E-04 Aortic root size LOC100422737 intron 21223598 rs7775079 chr6 107236494 G A 8.11E-05 Height / / pha003011 rs7763472 chr6 107294288 G T 4.08E-04 Smoking initiation / / 24665060 rs272583 chr6 107298061 T C 4.07E-05 Schizophrenia / / 24253340 rs272582 chr6 107298159 G A 2.05E-05 Cholesterol / / pha003073 rs908819 chr6 107307003 A G 2.31E-06 Cholesterol / / pha003073 rs908819 chr6 107307003 A G 2.25E-05 ldl cholesterol / / pha003076 rs908819 chr6 107307003 A G 2.81E-05 Cholesterol / / pha003078 rs1900601 chr6 107313977 C T 1.96E-05 Alzheimer's disease (age of onset) / / 22005931 rs7746539 chr6 107328319 C T 9.75E-05 Bipolar disorder and schizophrenia / / 20889312 rs1665913 chr6 107329420 C T 8.61E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2783030 chr6 107344359 T A 3.47E-06 Uric acid levels / / 21294900 rs12199744 chr6 107383411 T C 1.60E-05 Urinary metabolites / / 21572414 rs311255 chr6 107384896 A C 4.35E-05 Bipolar disorder and schizophrenia / / 20889312 rs3749872 chr6 107388504 C T 4.33E-04 Amyotrophic lateral sclerosis (sporadic) BEND3 UTR-3 24529757 rs1665910 chr6 107413164 A G 6.86E-06 Lipoprotein-associated phospholipase A2 activity and mass BEND3 intron 20442857 rs1665901 chr6 107433400 A T 2.50E-05 Type 2 diabetes BEND3 intron 17463249 rs1665901 chr6 107433400 A T 2.46E-05 Multiple complex diseases BEND3 intron 17554300 rs1665901 chr6 107433400 A T 5.90E-06 Urinary metabolites BEND3 intron 21572414 rs998593 chr6 107493140 G A 7.25E-05 Serum metabolites PDSS2 intron 19043545 rs998593 chr6 107493140 G A 6.08E-04 Smoking initiation PDSS2 intron 24665060 rs12199523 chr6 107508270 T C 8.00E-05 Basophils PDSS2 intron pha003087 rs3734678 chr6 107533160 T G 8.20E-06 Lipid traits PDSS2 intron 17903299 rs3734677 chr6 107533265 G A 4.73E-04 Alzheimer's disease PDSS2 intron 22005930 rs10456855 chr6 107538205 C T 3.83E-04 Alzheimer's disease PDSS2 intron 22005930 rs1861419 chr6 107539445 G A 9.39E-04 Alzheimer's disease PDSS2 intron 22005930 rs61315837 chr6 107542547 A G 5.71E-16 Metabolite levels PDSS2 intron 22286219 rs9480754 chr6 107549447 A G 2.23E-04 Alzheimer's disease PDSS2 intron 22005930 rs12194751 chr6 107551331 T C 2.63E-04 HIV-1 viral setpoint PDSS2 intron 17641165 rs17269207 chr6 107570481 G A 1.93E-05 Serum metabolites PDSS2 intron 19043545 rs7772518 chr6 107579380 A G 3.88E-10 Triglycerides PDSS2 intron 23063622 rs11967511 chr6 107596774 C T 2.88E-04 Response to cytadine analogues (cytosine arabinoside) PDSS2 intron 24483146 rs2430467 chr6 107635456 C A 8.90E-05 Parkinson's disease (familial) PDSS2 intron 18985386 rs2430467 chr6 107635456 C A 6.08E-05 Serum metabolites PDSS2 intron 19043545 rs763415 chr6 107638569 G A 1.60E-04 Response to cytadine analogues (cytosine arabinoside) PDSS2 intron 24483146 rs763415 chr6 107638569 G A 6.71E-04 Response to cytidine analogues (gemcitabine) PDSS2 intron 24483146 rs763416 chr6 107638780 G A 5.03E-04 Response to cytidine analogues (gemcitabine) PDSS2 intron 24483146 rs763416 chr6 107638780 G A 7.25E-05 Response to cytadine analogues (cytosine arabinoside) PDSS2 intron 24483146 rs2500584 chr6 107639608 T C 9.93E-05 Response to citalopram treatment PDSS2 intron 19846067 rs2500578 chr6 107650025 C T 7.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDSS2 intron 20877124 rs2500578 chr6 107650025 C T 8.00E-05 Blood Pressure PDSS2 intron pha003043 rs2500570 chr6 107659857 T C 6.99E-04 Rheumatoid arthritis PDSS2 intron 21452313 rs2430457 chr6 107660646 G A 5.00E-06 IgG glycosylation PDSS2 intron 23382691 rs8180652 chr6 107666030 C T 8.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDSS2 intron 20877124 rs2500561 chr6 107697101 A G 4.05E-05 Cognitive impairment induced by topiramate PDSS2 intron 22091778 rs9486619 chr6 107763996 C G 9.34E-04 Multiple complex diseases PDSS2 intron 17554300 rs3814451 chr6 107782894 T A 4.37E-04 Multiple complex diseases / / 17554300 rs12664555 chr6 107822074 A G 3.73E-04 Height SOBP intron 17255346 rs12664555 chr6 107822074 A G 8.41E-04 Multiple complex diseases SOBP intron 17554300 rs1407079 chr6 107822332 A G 1.61E-04 Height SOBP intron 17255346 rs1407079 chr6 107822332 A G 2.28E-04 Acute lung injury SOBP intron 22295056 rs9486632 chr6 107826391 G A 2.28E-04 Acute lung injury SOBP intron 22295056 rs6936145 chr6 107827233 G A 2.28E-04 Acute lung injury SOBP intron 22295056 rs7755026 chr6 107830698 T A 2.28E-04 Acute lung injury SOBP intron 22295056 rs12664365 chr6 107832069 G T 2.35E-04 Acute lung injury SOBP intron 22295056 rs9486637 chr6 107832661 G A 2.35E-04 Acute lung injury SOBP intron 22295056 rs7745939 chr6 107840020 G A 3.34E-04 Acute lung injury SOBP intron 22295056 rs1321550 chr6 107845684 T C 5.05E-04 Acute lung injury SOBP intron 22295056 rs9486641 chr6 107850518 G C 4.75E-04 Acute lung injury SOBP intron 22295056 rs13210582 chr6 107858160 A G 7.25E-04 Acute lung injury SOBP intron 22295056 rs9400125 chr6 107877202 G A 7.36E-04 Acute lung injury SOBP intron 22295056 rs6929555 chr6 107878826 A C 7.36E-04 Acute lung injury SOBP intron 22295056 rs6940398 chr6 107886003 A G 6.02E-04 HIV-1 viral setpoint SOBP intron 17641165 rs6940398 chr6 107886003 A G 4.78E-05 Triglycerides SOBP intron pha003081 rs6940398 chr6 107886003 A G 9.73E-05 Lipid levels SOBP intron pha003082 rs7775895 chr6 107886522 G A 5.60E-05 Alcoholism (heaviness of drinking) SOBP intron 21529783 rs4946839 chr6 107895418 G A 7.09E-04 HIV-1 viral setpoint SOBP intron 17641165 rs4946839 chr6 107895418 G A 6.39E-05 Triglycerides SOBP intron pha003081 rs4440495 chr6 107906652 G A 3.10E-04 White matter integrity SOBP intron 22425255 rs9373955 chr6 107918351 A G 9.57E-05 Triglycerides SOBP intron pha003081 rs12661385 chr6 107921995 A C 5.24E-05 Body Mass Index SOBP intron pha003022 rs7751374 chr6 107981856 G A 6.67E-04 Stroke SOBP UTR-3 pha002886 rs846987 chr6 107991893 C G 7.29E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2915 chr6 107992045 C A 2.25E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2914 chr6 107992074 C A 1.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7754879 chr6 107995121 A G 7.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12525668 chr6 108017671 A G 8.00E-11 Myopia (pathological) / / 23049088 rs846951 chr6 108018282 G A 7.51E-05 Bipolar disorder / / 18317468 rs4083443 chr6 108028842 A G 2.40E-05 Urinary metabolites SCML4 intron 21572414 rs3862834 chr6 108028879 C T 1.44E-05 Arthritis (juvenile idiopathic) SCML4 intron 22354554 rs1621495 chr6 108030088 A G 1.08E-04 Arthritis (juvenile idiopathic) SCML4 intron 22354554 rs1624055 chr6 108030405 C T 4.97E-04 Schizophrenia SCML4 intron 20832056 rs1624055 chr6 108030405 C T 8.41E-05 Arthritis (juvenile idiopathic) SCML4 intron 22354554 rs1728123 chr6 108033181 C T 1.57E-04 Arthritis (juvenile idiopathic) SCML4 intron 22354554 rs1629910 chr6 108033895 T C 2.73E-04 Schizophrenia SCML4 intron 20832056 rs1629910 chr6 108033895 T C 1.05E-04 Arthritis (juvenile idiopathic) SCML4 intron 22354554 rs3844149 chr6 108040446 G A 1.10E-05 Urinary metabolites SCML4 intron 21572414 rs6922304 chr6 108066144 A G 1.92E-04 Arthritis (juvenile idiopathic) SCML4 intron 22354554 rs6934505 chr6 108068003 C T 3.16E-04 Amyotrophic lateral sclerosis (sporadic) SCML4 missense 24529757 rs12664414 chr6 108069833 A G 1.79E-04 Arthritis (juvenile idiopathic) SCML4 intron 22354554 rs9320231 chr6 108070239 A G 1.16E-04 Arthritis (juvenile idiopathic) SCML4 intron 22354554 rs1850654 chr6 108095250 T C 5.51E-06 Statin-induced myopathy SCML4 intron 21826682 rs7758747 chr6 108096239 A G 6.46E-05 Gallstones SCML4 intron 17632509 rs7741285 chr6 108096529 T C 6.89E-05 Body Mass Index SCML4 intron pha003021 rs938971 chr6 108102004 A G 5.84E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SCML4 intron 20877124 rs9486692 chr6 108107761 T C 4.61E-05 Aging (time to event) SCML4 intron 21782286 rs1401171 chr6 108113248 G A 4.30E-05 Body Mass Index SCML4 intron pha003021 rs17528993 chr6 108114633 C G 6.40E-06 Urinary metabolites SCML4 intron 21572414 rs13220047 chr6 108145192 T C 2.63E-05 Body Mass Index SCML4 intron pha003021 rs632582 chr6 108175173 G A 9.74E-04 Alcohol dependence / / 21314694 rs527609 chr6 108185867 A G 8.22E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs847120 chr6 108189328 C T 5.30E-04 Myopia (pathological) SEC63 UTR-3 21095009 rs6933329 chr6 108189411 T C 1.75E-06 Lung adenocarcinoma SEC63 UTR-3 19836008 rs1001145 chr6 108294470 T C 1.36E-04 Myopia (pathological) / / 21095009 rs2008860 chr6 108312267 C G 4.93E-05 Diabetic nephropathy / / 21150874 rs2008860 chr6 108312267 C G 3.42E-04 Type 2 diabetes / / 22238593 rs17069122 chr6 108323759 G A 1.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs9480825 chr6 108331221 T A 1.46E-06 Bipolar disorder and schizophrenia / / 20889312 rs7770621 chr6 108332351 A G 3.47E-06 Bipolar disorder and schizophrenia / / 20889312 rs9374007 chr6 108358328 A G 3.45E-05 Cognitive test performance / / 20125193 rs1064346 chr6 108364951 T C 1.28E-06 Post-operative nausea and vomiting OSTM1 UTR-3 21694509 rs9374013 chr6 108381347 G A 1.32E-07 Post-operative nausea and vomiting OSTM1 intron 21694509 rs916395 chr6 108382401 G A 1.36E-04 Statin-induced myopathy OSTM1 intron 21826682 rs7769514 chr6 108412714 T G 2.65E-04 Premature ovarian failure / / 19508998 rs2227217 chr6 108427169 A G 4.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9486813 chr6 108437246 A G 9.79E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17069280 chr6 108448611 C T 8.78E-04 Response to taxane treatment (placlitaxel) OSTM1-AS1 intron 23006423 rs170125 chr6 108469920 G T 7.50E-06 Urinary metabolites OSTM1-AS1 intron 21572414 rs383319 chr6 108489462 G A 1.00E-05 Urinary metabolites NR2E1 intron 21572414 rs217526 chr6 108499725 G A 1.90E-05 Urinary metabolites NR2E1 intron 21572414 rs217528 chr6 108499945 A G 4.66E-04 Smoking initiation NR2E1 intron 24665060 rs630515 chr6 108626108 T C 6.48E-04 Insulin resistance LACE1 intron 21901158 rs12528572 chr6 108658974 C A 1.20E-04 Alzheimer's disease (late onset) LACE1 intron 21460841 rs12529330 chr6 108665932 C G 7.87E-05 Alzheimer's disease (late onset) LACE1 intron 21460841 rs12528220 chr6 108763854 C G 7.01E-05 Alzheimer's disease (late onset) LACE1 intron 21460841 rs9486892 chr6 108786063 C T 7.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LACE1 intron 20877124 rs9486893 chr6 108789853 A G 6.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LACE1 intron 20877124 rs1332027 chr6 108798498 A G 6.91E-05 Alzheimer's disease (late onset) LACE1 intron 21460841 rs17041 chr6 108853493 A G 6.00E-06 Obesity-related traits / / 23251661 rs9480861 chr6 108858460 C T 2.18E-05 Alzheimer's disease (late onset) / / 21460841 rs9384677 chr6 108863432 C A 7.35E-04 Multiple complex diseases / / 17554300 rs9384678 chr6 108863541 G C 9.37E-04 Multiple complex diseases / / 17554300 rs9384679 chr6 108864419 C T 1.74E-04 Multiple complex diseases / / 17554300 rs9384679 chr6 108864419 C T 7.43E-05 Serum metabolites / / 19043545 rs6911407 chr6 108867031 C A 8.80E-05 Intelligence / / 21826061 rs6911407 chr6 108867031 C A 9.90E-05 Monocyte counts / / pha003089 rs768024 chr6 108876108 G A 6.23E-04 Smoking quantity / / 24665060 rs7746906 chr6 108878813 G A 3.69E-04 Smoking quantity / / 24665060 rs2253310 chr6 108888593 C G 2.17E-04 Multiple complex diseases FOXO3 intron 17554300 rs9372190 chr6 108889822 T G 1.47E-04 Multiple complex diseases FOXO3 intron 17554300 rs2490272 chr6 108895386 C T 3.94E-04 Multiple complex diseases FOXO3 intron 17554300 rs2802288 chr6 108896215 A G 9.54E-05 Intelligence FOXO3 intron 21826061 rs2802290 chr6 108905680 G A 0.000041 Body mass index FOXO3 intron 23001569 rs12206094 chr6 108906200 C T 5.76E-05 Intelligence FOXO3 intron 21826061 rs13220810 chr6 108913201 T C 6.86E-05 Blood Pressure FOXO3 intron pha003040 rs9480865 chr6 108916573 T C 7.00E-06 Normalized brain volume FOXO3 intron 19010793 rs7341233 chr6 108940280 T C 7.07E-05 Creatinine levels FOXO3 intron pha003069 rs3813498 chr6 108944165 C T 2.22E-04 Alzheimer's disease (late onset) FOXO3 intron 21460841 rs4946932 chr6 108974746 A C 0.000067 Coronary artery calcification FOXO3 intron 23727086 rs9480867 chr6 108975646 G A 4.40E-06 Urinary metabolites FOXO3 intron 21572414 rs12212067 chr6 108981196 T G 3.64E-04 Alzheimer's disease FOXO3 intron 17998437 rs2153960 chr6 108988184 G A 5.00E-07 Insulin-like growth factors FOXO3 intron 21216879 rs3800227 chr6 108994161 A G 0.000025 Coronary artery calcification FOXO3 intron 23727086 rs9398172 chr6 108994826 G A 5.34E-04 Coronary Artery Disease FOXO3 intron 17634449 rs4946935 chr6 109000742 A G 6.82E-04 Coronary Artery Disease FOXO3 intron 17634449 rs9486917 chr6 109017038 C T 1.50E-05 Urinary metabolites / / 21572414 rs514293 chr6 109024278 C T 9.90E-05 Alcohol consumption / / 23953852 rs520942 chr6 109026566 C T 9.66E-04 Multiple complex diseases / / 17554300 rs556862 chr6 109031166 A C 0.0002638 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs556862 chr6 109031166 A C 2.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs564376 chr6 109032000 T C 5.32E-05 Alcohol consumption / / 23953852 rs17069794 chr6 109040488 C T 9.00E-05 Prostate cancer / / 21743057 rs484754 chr6 109042459 T C 4.90E-05 Tooth agenesis (third molar) / / 24172245 rs7751556 chr6 109052040 T C 1.00E-04 Prostate cancer / / 21743057 rs6910534 chr6 109055454 C G 3.00E-04 Longevity and age-related phenotypes / / 17903295 rs500108 chr6 109062964 T C 8.23E-04 Parkinson's disease / / 16252231 rs568064 chr6 109110096 T C 4.40E-05 Left ventricular hypertrophy / / pha003052 rs1268128 chr6 109116491 C A 3.51E-05 Left ventricular hypertrophy / / pha003052 rs514217 chr6 109123629 A G 2.01E-04 Longevity / / 22279548 rs9384688 chr6 109132221 T C 6.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9372196 chr6 109132237 G A 6.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs471422 chr6 109138491 C T 1.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11153132 chr6 109139055 G T 6.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1269178 chr6 109149087 A G 2.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1327470 chr6 109168234 C A,G,T 0.000863 Salmonella-induced pyroptosis / / 22837397 rs2806371 chr6 109221846 G A 7.23E-04 Multiple complex diseases ARMC2 intron 17554300 rs13219800 chr6 109240562 A G 1.19E-05 Left ventricular hypertrophy ARMC2 intron pha003052 rs13195372 chr6 109259375 G A 5.94E-05 Diabetes Mellitus ARMC2 intron pha003059 rs2798641 chr6 109268050 C T 5.00E-06 Pulmonary function ARMC2 intron 21946350 rs2798641 chr6 109268050 C T 8.00E-09 Pulmonary function ARMC2 intron 21946350 rs2798641 chr6 109268050 C T 2.00E-07 Pulmonary function (interaction) ARMC2 intron 23284291 rs12193858 chr6 109277908 A T 6.86E-07 Red blood cell traits ARMC2 intron 23222517 rs12195728 chr6 109278873 A G 2.20E-07 Red blood cell traits ARMC2 intron 23222517 rs12195848 chr6 109279105 A C 2.34E-07 Red blood cell traits ARMC2 intron 23222517 rs12195378 chr6 109284255 A G 5.56E-07 Red blood cell traits ARMC2 intron 23222517 rs2273669 chr6 109285189 A G 8.00E-09 Prostate cancer ARMC2 intron 23535732 rs11754955 chr6 109287459 A G 5.47E-07 Red blood cell traits ARMC2 intron 23222517 rs3734649 chr6 109294752 C T 3.73E-07 Red blood cell traits ARMC2 UTR-3 23222517 rs12196010 chr6 109302173 C A 5.72E-07 Red blood cell traits / / 23222517 rs12196024 chr6 109302258 C T 1.76E-07 Red blood cell traits / / 23222517 rs12196143 chr6 109302372 C T 1.87E-07 Red blood cell traits / / 23222517 rs12206834 chr6 109303967 T G 5.60E-07 Red blood cell traits / / 23222517 rs12210444 chr6 109305743 T C 5.81E-07 Red blood cell traits / / 23222517 rs12212402 chr6 109306681 T C 5.83E-07 Red blood cell traits / / 23222517 rs2145763 chr6 109306963 C A 5.51E-07 Red blood cell traits / / 23222517 rs16822 chr6 109307710 G A 5.90E-07 Red blood cell traits SESN1 UTR-3 23222517 rs4509156 chr6 109308952 C A 2.54E-07 Red blood cell traits SESN1 intron 23222517 rs12215614 chr6 109313629 T C 5.96E-07 Red blood cell traits SESN1 intron 23222517 rs10872028 chr6 109313728 C T 2.70E-04 Pulmonary function SESN1 intron 23932459 rs12153822 chr6 109315115 T C 5.98E-07 Red blood cell traits SESN1 intron 23222517 rs11153150 chr6 109316652 C G 2.02E-07 Red blood cell traits SESN1 intron 23222517 rs11153151 chr6 109316754 C G 2.02E-07 Red blood cell traits SESN1 intron 23222517 rs12214567 chr6 109317330 C T 2.00E-07 Red blood cell traits SESN1 intron 23222517 rs6918331 chr6 109317394 C G 7.63E-07 Red blood cell traits SESN1 intron 23222517 rs12216104 chr6 109317635 C T 2.00E-07 Red blood cell traits SESN1 intron 23222517 rs12198182 chr6 109318704 T G 5.77E-07 Red blood cell traits SESN1 intron 23222517 rs12204576 chr6 109318843 A G 1.98E-07 Red blood cell traits SESN1 intron 23222517 rs10457185 chr6 109322477 G C 5.33E-07 Red blood cell traits SESN1 intron 23222517 rs12214121 chr6 109322554 C T 8.81E-08 Red blood cell traits SESN1 cds-synon 23222517 rs2273668 chr6 109323519 G T 7.18E-07 Red blood cell traits SESN1 missense 23222517 rs7761290 chr6 109326621 T G 6.96E-07 Red blood cell traits SESN1 intron 23222517 rs12200578 chr6 109329473 G A 5.43E-07 Red blood cell traits SESN1 intron 23222517 rs6568555 chr6 109331777 A G 1.95E-07 Red blood cell traits SESN1 intron 23222517 rs11751295 chr6 109334458 C G 3.94E-07 Red blood cell traits SESN1 intron 23222517 rs12197912 chr6 109338147 C T 6.65E-07 Red blood cell traits SESN1 intron 23222517 rs12198088 chr6 109338433 C T 4.30E-07 Red blood cell traits SESN1 intron 23222517 rs12374597 chr6 109346184 A G 4.20E-07 Red blood cell traits SESN1 intron 23222517 rs7765732 chr6 109347057 A C 4.02E-07 Red blood cell traits SESN1 intron 23222517 rs7766248 chr6 109347262 C T 3.95E-07 Red blood cell traits SESN1 intron 23222517 rs7759014 chr6 109351125 A G 3.53E-07 Red blood cell traits SESN1 intron 23222517 rs12206423 chr6 109353216 C T 3.14E-07 Red blood cell traits SESN1 intron 23222517 rs1424479 chr6 109355790 G T 3.16E-07 Red blood cell traits SESN1 intron 23222517 rs11153154 chr6 109357324 G T 2.39E-07 Red blood cell traits SESN1 intron 23222517 rs17070139 chr6 109358345 C G 2.23E-07 Red blood cell traits SESN1 intron 23222517 rs12215381 chr6 109363217 C T 2.59E-07 Red blood cell traits SESN1 intron 23222517 rs2003315 chr6 109367169 C T 2.70E-07 Red blood cell traits SESN1 intron 23222517 rs6900472 chr6 109372120 G A 7.68E-07 Red blood cell traits SESN1 intron 23222517 rs12524627 chr6 109401045 G T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SESN1 intron 22628534 rs12524627 chr6 109401045 G T 4.59E-04 Response to cytadine analogues (cytosine arabinoside) SESN1 intron 24483146 rs1539596 chr6 109408428 C G 1.07E-07 Red blood cell traits SESN1 intron 23222517 rs10046283 chr6 109419070 A G 6.30E-05 Post-operative nausea and vomiting CEP57L1 intron 21694509 rs1260658 chr6 109420225 A G 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CEP57L1 intron 22628534 rs17070181 chr6 109428184 C A,T 7.65E-07 Red blood cell traits CEP57L1 intron 23222517 rs1547325 chr6 109461506 A C 1.25E-07 Red blood cell traits CEP57L1 intron 23222517 rs1998172 chr6 109483826 A C 1.38E-07 Red blood cell traits CEP57L1 intron 23222517 rs11962354 chr6 109496192 C T 1.11E-07 Red blood cell traits C6orf183 intron 23222517 rs3813499 chr6 109497085 G T 8.69E-07 Red blood cell traits C6orf183 intron 23222517 rs351739 chr6 109503976 A G 1.40E-06 Post-operative nausea and vomiting C6orf183 intron 21694509 rs351739 chr6 109503976 A G 3.68E-08 Red blood cell traits C6orf183 intron 23222517 rs351737 chr6 109505740 T C 1.69E-11 Red blood cell traits C6orf183 intron 23222517 rs351736 chr6 109505894 G A 1.58E-11 Red blood cell traits C6orf183 intron 23222517 rs566164 chr6 109506461 A G 5.78E-12 Red blood cell traits C6orf183 intron 23222517 rs1341272 chr6 109507533 C T 3.61E-14 Red blood cell traits C6orf183 intron 23222517 rs351730 chr6 109510766 C T 2.84E-11 Red blood cell traits C6orf183 intron 23222517 rs7757193 chr6 109510972 G A 4.53E-07 Red blood cell traits C6orf183 intron 23222517 rs1761608 chr6 109517706 G A 2.98E-14 Red blood cell traits C6orf183 missense 23222517 rs368467 chr6 109519451 T C 2.99E-14 Red blood cell traits C6orf183 intron 23222517 rs396000 chr6 109519611 G A 2.02E-14 Red blood cell traits C6orf183 missense 23222517 rs1741930 chr6 109519797 T A 2.87E-14 Red blood cell traits C6orf183 intron 23222517 rs1260596 chr6 109519847 T C 2.89E-14 Red blood cell traits C6orf183 intron 23222517 rs1260595 chr6 109519873 T G 2.79E-14 Red blood cell traits C6orf183 intron 23222517 rs419106 chr6 109520067 G C 1.18E-14 Red blood cell traits C6orf183 intron 23222517 rs386696 chr6 109520166 G A 3.02E-16 Red blood cell traits C6orf183 intron 23222517 rs463916 chr6 109520538 A G 9.23E-17 Red blood cell traits C6orf183 intron 23222517 rs1260593 chr6 109521400 C T 9.63E-17 Red blood cell traits C6orf183 intron 23222517 rs412754 chr6 109522057 G C 1.48E-11 Red blood cell traits C6orf183 intron 23222517 rs429534 chr6 109523256 A G 9.94E-12 Red blood cell traits C6orf183 intron 23222517 rs398944 chr6 109523444 T G 3.34E-16 Red blood cell traits C6orf183 intron 23222517 rs352834 chr6 109523821 C T 1.93E-05 Post-operative nausea and vomiting C6orf183 intron 21694509 rs458185 chr6 109524074 A G 9.04E-17 Red blood cell traits C6orf183 intron 23222517 rs455839 chr6 109524221 G A 3.44E-16 Red blood cell traits C6orf183 intron 23222517 rs449736 chr6 109524342 A T 2.71E-11 Red blood cell traits C6orf183 intron 23222517 rs422113 chr6 109524417 A G 8.48E-04 Amyotrophic Lateral Sclerosis C6orf183 intron 17827064 rs422113 chr6 109524417 A G 3.15E-11 Red blood cell traits C6orf183 intron 23222517 rs459956 chr6 109524760 A G 7.51E-17 Red blood cell traits C6orf183 intron 23222517 rs12660449 chr6 109524795 G A 3.76E-08 Red blood cell traits C6orf183 intron 23222517 rs427960 chr6 109524939 G A 3.76E-16 Red blood cell traits C6orf183 missense 23222517 rs399561 chr6 109524979 G A 5.67E-16 Red blood cell traits C6orf183 missense 23222517 rs449850 chr6 109525045 A G 6.94E-17 Red blood cell traits C6orf183 missense 23222517 rs371960 chr6 109525082 T C 1.07E-16 Red blood cell traits C6orf183 intron 23222517 rs461487 chr6 109525504 A G 3.92E-13 Red blood cell traits C6orf183 intron 23222517 rs458740 chr6 109525527 C T 3.37E-12 Red blood cell traits C6orf183 intron 23222517 rs446974 chr6 109525589 T G 3.30E-11 Red blood cell traits C6orf183 intron 23222517 rs463503 chr6 109525757 T C 3.47E-16 Red blood cell traits C6orf183 intron 23222517 rs442405 chr6 109526980 T G 3.74E-16 Red blood cell traits C6orf183 intron 23222517 rs377436 chr6 109527104 G A 4.20E-11 Red blood cell traits C6orf183 intron 23222517 rs351745 chr6 109529169 C T 4.88E-15 Red blood cell traits C6orf183 intron 23222517 rs351747 chr6 109531855 G T 4.14E-09 Red blood cell traits C6orf183 intron 23222517 rs351750 chr6 109533385 T C 4.35E-08 Red blood cell traits C6orf183 intron 23222517 rs351754 chr6 109537553 A G 3.87E-15 Red blood cell traits C6orf183 intron 23222517 rs351755 chr6 109538073 G A 9.32E-15 Red blood cell traits C6orf183 intron 23222517 rs410449 chr6 109539853 G A 4.92E-19 Red blood cell traits C6orf183 intron 23222517 rs448496 chr6 109540157 G T 1.20E-10 Red blood cell traits C6orf183 intron 23222517 rs830554 chr6 109543226 A G 1.12E-07 Red blood cell traits C6orf183 intron 23222517 rs830556 chr6 109544915 C A 2.23E-12 Red blood cell traits C6orf183 intron 23222517 rs351723 chr6 109545547 G A 5.54E-12 Red blood cell traits C6orf183 intron 23222517 rs351724 chr6 109546577 T C 2.20E-17 Red blood cell traits C6orf183 intron 23222517 rs351725 chr6 109547939 G A 2.20E-17 Red blood cell traits C6orf183 intron 23222517 rs351726 chr6 109548304 C T 3.78E-11 Red blood cell traits C6orf183 cds-synon 23222517 rs59673 chr6 109548713 C T 1.83E-11 Red blood cell traits C6orf183 missense 23222517 rs351727 chr6 109548837 A G 3.47E-11 Red blood cell traits C6orf183 cds-synon 23222517 rs351728 chr6 109549099 T C 1.44E-19 Red blood cell traits C6orf183 intron 23222517 rs830552 chr6 109549914 A G 3.52E-11 Red blood cell traits C6orf183 intron 23222517 rs351721 chr6 109551109 G T 3.64E-11 Red blood cell traits C6orf183 intron 23222517 rs351720 chr6 109551147 A G 3.73E-11 Red blood cell traits C6orf183 intron 23222517 rs351719 chr6 109552434 A G 8.35E-11 Red blood cell traits C6orf183 intron 23222517 rs351717 chr6 109553718 A T 2.00E-11 Red blood cell traits C6orf183 intron 23222517 rs351716 chr6 109553764 A G 4.16E-11 Red blood cell traits C6orf183 intron 23222517 rs9384701 chr6 109557542 C T 4.67E-10 Red blood cell traits C6orf183 intron 23222517 rs6919423 chr6 109558471 G A 1.86E-04 Ankylosing spondylitis C6orf183 intron 22138694 rs6919423 chr6 109558471 G A 2.66E-19 Red blood cell traits C6orf183 intron 23222517 rs6925339 chr6 109559416 G A 1.83E-11 Red blood cell traits C6orf183 intron 23222517 rs9386774 chr6 109561646 C T 1.50E-18 Red blood cell traits C6orf183 intron 23222517 rs9386775 chr6 109561779 T C 1.73E-13 Red blood cell traits C6orf183 intron 23222517 rs13196590 chr6 109561918 T C 3.98E-14 Red blood cell traits C6orf183 intron 23222517 rs11964178 chr6 109562035 A G 1.14E-18 Red blood cell traits C6orf183 intron 23222517 rs13211313 chr6 109562074 G C 3.46E-18 Red blood cell traits C6orf183 intron 23222517 rs884366 chr6 109574095 G A 4.12E-12 Red blood cell traits / / 23222517 rs4945826 chr6 109575070 G C 6.06E-12 Red blood cell traits / / 23222517 rs13190802 chr6 109581804 G A 6.76E-11 Red blood cell traits / / 23222517 rs4946953 chr6 109583631 A G 1.52E-14 Red blood cell traits / / 23222517 rs9374067 chr6 109584043 C T 2.00E-04 Smoking cessation / / 18519826 rs13199388 chr6 109584100 C T 1.38E-09 Red blood cell traits / / 23222517 rs9386780 chr6 109584410 A G 1.78E-19 Red blood cell traits / / 23222517 rs9386781 chr6 109584520 G A 1.07E-07 Red blood cell traits / / 23222517 rs13203020 chr6 109584645 C A 2.69E-11 Red blood cell traits / / 23222517 rs4427037 chr6 109585612 G C 1.14E-07 Red blood cell traits / / 23222517 rs949882 chr6 109586062 C T 9.59E-07 Red blood cell traits / / 23222517 rs949881 chr6 109586240 A G 7.09E-07 Red blood cell traits / / 23222517 rs9374069 chr6 109586334 A G 3.35E-07 Red blood cell traits / / 23222517 rs9374070 chr6 109586455 G A 1.89E-08 Red blood cell traits / / 23222517 rs9398191 chr6 109586561 C T 9.75E-07 Red blood cell traits / / 23222517 rs932223 chr6 109586656 T C 1.65E-19 Red blood cell traits / / 23222517 rs932223 chr6 109586656 T C 7.59E-06 Bilirubin levels / / 23371916 rs932222 chr6 109586678 G A 1.25E-05 Smoking cessation / / 18519826 rs932222 chr6 109586678 G A 3.03E-11 Red blood cell traits / / 23222517 rs9384703 chr6 109586803 T C 1.69E-07 Red blood cell traits / / 23222517 rs9384704 chr6 109587209 G A 2.15E-07 Red blood cell traits / / 23222517 rs9398192 chr6 109587236 C T 8.46E-07 Red blood cell traits / / 23222517 rs9374071 chr6 109588681 T C 9.39E-08 Red blood cell traits / / 23222517 rs9386784 chr6 109591208 C A 2.96E-07 Red blood cell traits / / 23222517 rs9374072 chr6 109591586 A G 7.20E-07 Red blood cell traits / / 23222517 rs6903107 chr6 109597711 A G 2.18E-19 Red blood cell traits / / 23222517 rs13210424 chr6 109598737 G A 1.10E-21 Red blood cell traits / / 23222517 rs13210693 chr6 109598964 G A 2.67E-08 Post-operative nausea and vomiting / / 21694509 rs13210693 chr6 109598964 G A 9.00E-07 Ankylosing spondylitis / / 22138694 rs13210693 chr6 109598964 G A 1.74E-20 Red blood cell traits / / 23222517 rs13210693 chr6 109598964 G A 9.62E-06 Bilirubin levels / / 23371916 rs2884013 chr6 109599952 C T 2.64E-17 Red blood cell traits / / 23222517 rs9386788 chr6 109600523 A G 2.88E-18 Red blood cell traits / / 23222517 rs9386788 chr6 109600523 A G 9.62E-06 Bilirubin levels / / 23371916 rs7773213 chr6 109601885 C T 3.21E-17 Red blood cell traits / / 23222517 rs7755970 chr6 109602359 T A,C,G 1.03E-17 Red blood cell traits / / 23222517 rs7774390 chr6 109602461 G C 9.24E-17 Red blood cell traits / / 23222517 rs13205489 chr6 109603410 C T 7.16E-10 Red blood cell traits / / 23222517 rs9487033 chr6 109605388 G C 6.16E-19 Red blood cell traits / / 23222517 rs9480921 chr6 109605668 G A 6.42E-16 Red blood cell traits / / 23222517 rs9487034 chr6 109605899 T C 7.81E-20 Red blood cell traits / / 23222517 rs9400269 chr6 109606065 C G 1.71E-17 Red blood cell traits / / 23222517 rs9480922 chr6 109607211 G A 8.98E-20 Red blood cell traits / / 23222517 rs9480923 chr6 109607369 G C 8.42E-20 Red blood cell traits / / 23222517 rs9487036 chr6 109607449 C T 1.75E-13 Red blood cell traits / / 23222517 rs9400271 chr6 109607556 G A 8.17E-20 Red blood cell traits / / 23222517 rs9386790 chr6 109608460 A C 4.11E-18 Red blood cell traits / / 23222517 rs9386791 chr6 109608497 C T 4.82E-16 Red blood cell traits / / 23222517 rs9386791 chr6 109608497 C T 1.00E-08 Red blood cell traits / / 23446634 rs7772602 chr6 109608661 G C 3.16E-19 Red blood cell traits / / 23222517 rs1111866 chr6 109610846 G T 1.59E-17 Red blood cell traits / / 23222517 rs1111865 chr6 109610863 C T 1.19E-17 Red blood cell traits / / 23222517 rs1111863 chr6 109611206 A G 3.17E-17 Red blood cell traits / / 23222517 rs4601178 chr6 109611246 G A 3.09E-19 Red blood cell traits / / 23222517 rs6924815 chr6 109612344 A G 3.12E-18 Red blood cell traits / / 23222517 rs6568571 chr6 109613252 A C,T 3.94E-08 Other erythrocyte phenotypes / / 19862010 rs6568571 chr6 109613252 A C,T 1.10E-25 Red blood cell traits / / 23222517 rs7748918 chr6 109613564 T C 1.15E-24 Red blood cell traits / / 23222517 rs1521908 chr6 109613986 T C 7.12E-20 Red blood cell traits / / 23222517 rs9487048 chr6 109615603 G T 1.49E-20 Red blood cell traits / / 23222517 rs9374080 chr6 109616420 T C 4.00E-10 Mean corpuscular volume CCDC162P intron 19862010 rs9374080 chr6 109616420 T C 4.82E-08 Blood cell counts and other traits CCDC162P intron 20139978 rs9374080 chr6 109616420 T C 2.96E-21 Red blood cell traits CCDC162P intron 23222517 rs9400272 chr6 109616762 A G 3.17E-24 Red blood cell traits / / 23222517 rs1341271 chr6 109617542 T A 5.00E-08 Other erythrocyte phenotypes CCDC162P intron 19862010 rs1341271 chr6 109617542 T A 1.28E-25 Red blood cell traits CCDC162P intron 23222517 rs9386796 chr6 109618704 C T 5.83E-06 Post-operative nausea and vomiting CCDC162P intron 21694509 rs9386796 chr6 109618704 C T 2.85E-23 Red blood cell traits CCDC162P intron 23222517 rs9320282 chr6 109619377 A G 6.39E-20 Red blood cell traits CCDC162P intron 23222517 rs9487053 chr6 109619697 T C 8.65E-18 Red blood cell traits CCDC162P intron 23222517 rs6927569 chr6 109621494 T C 7.36E-19 Red blood cell traits CCDC162P intron 23222517 rs11153165 chr6 109622159 G A 1.06E-11 Red blood cell traits CCDC162P intron 23222517 rs11153166 chr6 109622494 A G 1.14E-11 Red blood cell traits CCDC162P intron 23222517 rs11153167 chr6 109622582 A T 2.66E-11 Red blood cell traits CCDC162P intron 23222517 rs7773490 chr6 109623048 T C 1.04E-11 Red blood cell traits CCDC162P intron 23222517 rs13220206 chr6 109624481 G T 4.56E-08 Red blood cell traits CCDC162P intron 23222517 rs9784763 chr6 109624937 G A 3.66E-08 Red blood cell traits CCDC162P intron 23222517 rs9784763 chr6 109624937 G A 3.25E-04 Iron levels CCDC162P intron pha002876 rs13209277 chr6 109624963 T A 4.77E-22 Red blood cell traits CCDC162P intron 23222517 rs1006081 chr6 109625550 T C 2.39E-11 Red blood cell traits CCDC162P intron 23222517 rs1008084 chr6 109626965 G A 3.83E-08 Other erythrocyte phenotypes CCDC162P intron 19862010 rs1008084 chr6 109626965 G A 6.00E-26 Red blood cell traits CCDC162P intron 23222517 rs6902892 chr6 109627601 C A 6.72E-04 Type 2 diabetes CCDC162P intron 17463246 rs6902892 chr6 109627601 C A 5.60E-21 Red blood cell traits CCDC162P intron 23222517 rs11153168 chr6 109629420 A T 1.50E-17 Red blood cell traits / / 23222517 rs6903519 chr6 109631315 G T 7.35E-05 Serum metabolites / / 19043545 rs6903519 chr6 109631315 G T 2.01E-13 Red blood cell traits / / 23222517 rs6903695 chr6 109631422 G C 6.49E-04 Type 2 diabetes / / 17463246 rs6903695 chr6 109631422 G C 3.05E-15 Red blood cell traits / / 23222517 rs9374081 chr6 109631782 A G 1.24E-17 Red blood cell traits / / 23222517 rs9386797 chr6 109632520 C A 4.57E-22 Red blood cell traits / / 23222517 rs9400273 chr6 109632799 A G 4.69E-08 Other erythrocyte phenotypes / / 19862010 rs9400273 chr6 109632799 A G 2.02E-24 Red blood cell traits / / 23222517 rs13200047 chr6 109633244 T C 3.25E-16 Red blood cell traits / / 23222517 rs11966072 chr6 109634828 A G 1.00E-08 Blood cell counts and other traits / / 20139978 rs11966072 chr6 109634828 A G 1.49E-08 Blood cell counts and other traits / / 20139978 rs11966072 chr6 109634828 A G 2.51E-08 Blood cell counts and other traits / / 20139978 rs11966072 chr6 109634828 A G 6.92E-09 Blood cell counts and other traits / / 20139978 rs13196219 chr6 109635787 A T 3.95E-17 Red blood cell traits / / 23222517 rs7755798 chr6 109637154 T C 2.71E-05 Post-operative nausea and vomiting / / 21694509 rs7755798 chr6 109637154 T C 9.87E-06 Osteoarthritis / / 22763110 rs4945829 chr6 109638828 T C 2.41E-11 Red blood cell traits / / 23222517 rs4946954 chr6 109639656 C T 1.61E-11 Red blood cell traits / / 23222517 rs11759269 chr6 109640488 A G 6.27E-12 Red blood cell traits / / 23222517 rs4946956 chr6 109641115 G A 5.80E-11 Red blood cell traits / / 23222517 rs4946957 chr6 109641411 C T 8.11E-11 Red blood cell traits / / 23222517 rs4946959 chr6 109641563 A G 2.66E-09 Red blood cell traits / / 23222517 rs2884036 chr6 109642916 C T 1.01E-15 Red blood cell traits / / 23222517 rs9374083 chr6 109642957 C G 2.13E-11 Red blood cell traits / / 23222517 rs11153169 chr6 109643521 G T 2.40E-08 Red blood cell traits / / 23222517 rs9400276 chr6 109647405 G A 4.90E-07 Red blood cell traits / / 23222517 rs12191774 chr6 109648353 A G 7.25E-13 Red blood cell traits / / 23222517 rs13202939 chr6 109649655 A G 1.77E-15 Red blood cell traits / / 23222517 rs4301336 chr6 109650140 A T 9.41E-16 Red blood cell traits / / 23222517 rs12200757 chr6 109651220 C T 5.83E-10 Red blood cell traits / / 23222517 rs13220304 chr6 109652236 G A 9.50E-06 Urinary metabolites / / 21572414 rs13220304 chr6 109652236 G A 7.93E-08 Red blood cell traits / / 23222517 rs12528712 chr6 109660884 C A 6.50E-06 Urinary metabolites / / 21572414 rs12528712 chr6 109660884 C A 7.38E-08 Red blood cell traits / / 23222517 rs13199519 chr6 109709175 G A 2.68E-07 Red blood cell traits / / 23222517 rs9487082 chr6 109709536 C T 5.47E-08 Red blood cell traits / / 23222517 rs6904271 chr6 109716206 C G 4.34E-08 Type 2 diabetes PPIL6 intron 23300278 rs9487094 chr6 109742015 G A 4.00E-06 Height PPIL6 intron 18391951 rs1048197 chr6 109762332 C T 5.30E-04 Alzheimer's disease SMPD2 missense 24755620 rs1476387 chr6 109764535 G T 1.80E-04 Height SMPD2 missense 21194676 rs1476387 chr6 109764535 G T 1.90E-06 Height SMPD2 missense 21194676 rs1046943 chr6 109783941 A G 3.00E-08 Height ZBTB24 UTR-3 20881960 rs3734652 chr6 109786980 T C 6.20E-05 Tooth agenesis (mandibular third molar) ZBTB24 UTR-3 24172245 rs2236084 chr6 109797304 A G 6.20E-05 Tooth agenesis (mandibular third molar) ZBTB24 intron 24172245 rs1054607 chr6 109814411 C T 2.30E-05 Tooth agenesis (mandibular third molar) AKD1 UTR-3 24172245 rs6925886 chr6 109878515 A G 1.20E-05 Urinary metabolites AKD1 intron 21572414 rs10499052 chr6 109885475 G A 9.15E-07 Red blood cell traits AKD1 missense 23222517 rs13214717 chr6 109894354 C A 1.36E-07 Red blood cell traits AKD1 intron 23222517 rs12529505 chr6 109946561 G A 3.18E-07 Red blood cell traits AKD1 intron 23222517 rs1321329 chr6 109980796 C T 1.58E-04 Multiple complex diseases AKD1 intron 17554300 rs911022 chr6 109982605 C T 2.70E-05 Urinary metabolites AKD1 intron 21572414 rs6568591 chr6 109992884 C T 1.60E-05 Urinary metabolites AKD1 intron 21572414 rs9400317 chr6 110007647 A G 7.00E-06 Response to hepatitis C treatment AKD1 intron 19684573 rs9400317 chr6 110007647 A G 9.30E-05 White matter hyperintensity burden AKD1 intron 21681796 rs17070875 chr6 110049823 G A 8.88E-04 Multiple complex diseases FIG4 intron 17554300 rs12661287 chr6 110053250 T A 7.98E-05 Lymphocyte counts FIG4 intron 22286170 rs12192279 chr6 110055313 G A 1.94E-07 Red blood cell traits FIG4 intron 23222517 rs3799852 chr6 110057219 A G 4.55E-05 IgE levels in asthmatics (D.p. specific) FIG4 intron 23967269 rs17070915 chr6 110062551 G T 4.75E-04 Multiple complex diseases FIG4 intron 17554300 rs12206574 chr6 110067773 G A 1.75E-07 Red blood cell traits FIG4 intron 23222517 rs12526189 chr6 110089053 C T 0.00007045 Sarcoidosis FIG4 intron 22952805 rs4947019 chr6 110090049 C G 8.00E-06 Hematological parameters FIG4 intron 19820697 rs13207150 chr6 110092900 C A 8.43E-07 Red blood cell traits FIG4 intron 23222517 rs11968978 chr6 110096896 T C 3.46E-05 Lymphocyte counts FIG4 intron 22286170 rs11153219 chr6 110102628 A G 2.60E-06 Urinary metabolites FIG4 intron 21572414 rs11153219 chr6 110102628 A G 2.88E-04 Lung function (forced vital capacity) FIG4 intron 24023788 rs10499054 chr6 110106234 A G 7.40E-05 Personality dimensions FIG4 intron 18957941 rs10499054 chr6 110106234 A G 5.50E-05 Information processing speed FIG4 intron 21130836 rs2492979 chr6 110108855 G T 7.32E-06 Alzheimer's disease (late onset) FIG4 intron 21379329 rs4295520 chr6 110118439 T G 2.60E-05 Cognitive test performance FIG4 intron 20125193 rs4495300 chr6 110124528 C G 1.20E-05 Urinary metabolites FIG4 intron 21572414 rs4601174 chr6 110174645 C A 5.96E-04 Heart Failure / / pha002885 rs4245542 chr6 110231998 T C 1.13E-04 Alcohol dependence / / 20201924 rs6914221 chr6 110235126 G C 2.39E-05 Schizophrenia / / 19571809 rs6900525 chr6 110239670 C T 8.79E-05 Cognitive performance / / 19734545 rs4947035 chr6 110245755 G A 3.69E-05 Vaspin levels / / 22907691 rs4947035 chr6 110245755 G A 0.0000369 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs9374140 chr6 110250208 T C 2.47E-05 Leukocyte Counts / / pha003091 rs4245543 chr6 110261409 C T 8.06E-05 Longevity / / 22279548 rs11964097 chr6 110282108 A T 4.11E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2503772 chr6 110285415 T C 8.02E-05 Fibrinogen / / 17255346 rs4245544 chr6 110289593 T C 2.77E-04 Fibrinogen / / 17255346 rs6568622 chr6 110298307 A C 1.57E-05 Fibrinogen / / 17255346 rs4354185 chr6 110301661 A G 1.61E-04 Fibrinogen GPR6 UTR-3 17255346 rs17541919 chr6 110322543 G A 5.59E-04 Multiple complex diseases / / 17554300 rs879134 chr6 110359250 C T 9.85E-05 Multiple complex diseases / / 17554300 rs9372247 chr6 110389869 G C 5.11E-04 Type 2 diabetes / / 17463246 rs9372248 chr6 110389926 T C 4.58E-04 Type 2 diabetes / / 17463246 rs9372248 chr6 110389926 T C 1.41E-05 Lipoproteins / / pha003079 rs9400359 chr6 110392627 C A 2.59E-05 Lipoproteins / / pha003079 rs41381746 chr6 110400063 T C 2.57E-04 Type 2 diabetes / / 17463246 rs12660119 chr6 110405670 T C 7.28E-06 Cognitive decline / / 22054870 rs3828927 chr6 110424341 T C 2.48E-04 Vaspin levels WASF1 intron 22907691 rs3828927 chr6 110424341 T C 0.0002483 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit WASF1 intron 22907730 rs6931749 chr6 110443685 A G 7.88E-05 Multiple complex diseases WASF1 intron 17554300 rs11751590 chr6 110485943 G C 9.95E-06 Cognitive decline WASF1 intron 22054870 rs7761436 chr6 110502831 A G 2.50E-04 Vaspin levels CDC40 intron 22907691 rs7761436 chr6 110502831 A G 0.0002495 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit CDC40 intron 22907730 rs11757055 chr6 110504680 C T 3.37E-05 Cognitive decline CDC40 intron 22054870 rs12662559 chr6 110508696 A C 3.77E-04 Alzheimer's disease CDC40 intron 24755620 rs6918148 chr6 110532805 T C 8.12E-04 Alzheimer's disease CDC40 intron 24755620 rs4947058 chr6 110537685 A G 2.66E-05 Cognitive decline CDC40 intron 22054870 rs9487321 chr6 110555401 C T 3.38E-04 Type 2 diabetes / / 17463246 rs17071340 chr6 110569544 A C 8.31E-05 Multiple complex diseases METTL24 intron 17554300 rs7741277 chr6 110579632 T A 3.63E-04 Multiple complex diseases METTL24 intron 17554300 rs17071361 chr6 110590138 T G 1.47E-04 Multiple complex diseases METTL24 intron 17554300 rs17071372 chr6 110599164 A G 4.92E-05 Multiple complex diseases METTL24 intron 17554300 rs2878176 chr6 110620021 C T 1.21E-04 Multiple complex diseases METTL24 intron 17554300 rs714693 chr6 110642661 T C 1.41E-04 Multiple complex diseases METTL24 intron 17554300 rs9400374 chr6 110655911 G A 4.54E-04 Amyotrophic Lateral Sclerosis METTL24 intron 17362836 rs997865 chr6 110656665 C T 8.41E-04 Myopia (pathological) METTL24 intron 21095009 rs997865 chr6 110656665 C T 2.08E-04 Myocardial Infarction METTL24 intron pha002873 rs7745186 chr6 110659752 C T 3.71E-04 Myopia (pathological) METTL24 intron 21095009 rs7750080 chr6 110666384 C G 9.95E-04 Suicide attempts in bipolar disorder METTL24 intron 21423239 rs9384738 chr6 110669277 T C 0.0002 Migraine METTL24 intron 22678113 rs9386891 chr6 110692360 C A 3.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs9374168 chr6 110698852 G A 6.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs7748253 chr6 110701451 A G 6.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs4945856 chr6 110705847 G C 7.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs6939019 chr6 110711025 G A 1.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs2235989 chr6 110714584 A T 7.88E-04 Type 2 diabetes DDO intron 17463246 rs9384741 chr6 110732736 G A 1.90E-05 Body Mass Index DDO intron pha003007 rs9384741 chr6 110732736 G A 5.00E-05 Weight DDO intron pha003027 rs9481069 chr6 110750986 G A 5.74E-04 Response to taxane treatment (placlitaxel) SLC22A16 intron 23006423 rs12210538 chr6 110760008 A G 6.07E-04 Body mass index SLC22A16 missense 17255346 rs11153238 chr6 110818847 G A 4.66E-06 Orofacial clefts / / 22419666 rs12665517 chr6 110889332 T A 2.78E-04 Multiple complex diseases / / 17554300 rs4512259 chr6 110897030 T C 0.0000684 Panic disorder / / 23149450 rs4512259 chr6 110897030 T C 6.84E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs9374185 chr6 110902843 T C 0.0000317 Panic disorder / / 23149450 rs9374185 chr6 110902843 T C 3.17E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs4947082 chr6 110909500 G A 1.28E-05 Multiple complex diseases / / 17554300 rs7772441 chr6 110915293 T C 5.84E-04 Multiple complex diseases / / 17554300 rs1543991 chr6 110932032 T C 0.0000486 Panic disorder CDK19 UTR-3 23149450 rs1543991 chr6 110932032 T C 4.86E-05 Serum tamsulosin hydrochloride concentration CDK19 UTR-3 23151678 rs9386927 chr6 110946811 A G 0.0000655 Panic disorder CDK19 intron 23149450 rs9386927 chr6 110946811 A G 6.55E-05 Serum tamsulosin hydrochloride concentration CDK19 intron 23151678 rs1949817 chr6 110981076 T A 0.0000732 Panic disorder CDK19 intron 23149450 rs1949817 chr6 110981076 T A 7.32E-05 Serum tamsulosin hydrochloride concentration CDK19 intron 23151678 rs4383853 chr6 111064499 C T 0.0000256 Panic disorder CDK19 intron 23149450 rs4383853 chr6 111064499 C T 2.56E-05 Serum tamsulosin hydrochloride concentration CDK19 intron 23151678 rs802660 chr6 111106135 C T 0.0000381 Panic disorder CDK19 intron 23149450 rs802660 chr6 111106135 C T 3.81E-05 Serum tamsulosin hydrochloride concentration CDK19 intron 23151678 rs802661 chr6 111106687 G T 0.0000279 Panic disorder CDK19 intron 23149450 rs802661 chr6 111106687 G T 2.79E-05 Serum tamsulosin hydrochloride concentration CDK19 intron 23151678 rs802669 chr6 111171882 G A 0.0000122 Panic disorder / / 23149450 rs802669 chr6 111171882 G A 1.74E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs10484430 chr6 111178005 A G 1.21E-04 Multiple complex diseases / / 17554300 rs11153258 chr6 111222552 C T 6.11E-04 Amyotrophic lateral sclerosis / / 23624525 rs6914829 chr6 111273796 C T 7.20E-04 Type 2 diabetes / / 17463246 rs12207535 chr6 111277745 A G 7.10E-05 HIV-1 control / / 20041166 rs9400442 chr6 111298225 A G 3.42E-06 Mathematical ability / / 24801482 rs3862838 chr6 111303974 A G 9.06E-04 Amyotrophic lateral sclerosis RPF2 intron 23624525 rs9320354 chr6 111336435 A C 8.20E-05 HIV-1 control RPF2 intron 20041166 rs6935864 chr6 111390344 A C 0.0000226 Asthma / / 22694930 rs4947106 chr6 111421366 T C 8.39E-04 Multiple complex diseases SLC16A10 intron 17554300 rs6900781 chr6 111422856 T A 1.01E-13 Metabolite levels SLC16A10 intron 22286219 rs9400467 chr6 111424015 C T 2.04E-12 Metabolite levels SLC16A10 intron 22286219 rs9400467 chr6 111424015 C T 7.00E-14 Blood metabolite levels SLC16A10 intron 24816252 rs1022092 chr6 111427286 G A 9.90E-14 Metabolite levels SLC16A10 intron 22286219 rs9767473 chr6 111428095 G T 8.31E-14 Metabolite levels SLC16A10 intron 22286219 rs9384787 chr6 111434910 T A 8.89E-04 Multiple complex diseases SLC16A10 intron 17554300 rs6938986 chr6 111436452 C T 1.83E-12 Metabolite levels SLC16A10 intron 22286219 rs4947107 chr6 111442505 C T 1.05E-13 Metabolite levels SLC16A10 intron 22286219 rs12202418 chr6 111451467 A G 3.86E-12 Metabolite levels SLC16A10 intron 22286219 rs9387000 chr6 111459941 A C 1.29E-13 Metabolite levels SLC16A10 intron 22286219 rs9320360 chr6 111462272 G T 1.29E-13 Metabolite levels SLC16A10 intron 22286219 rs1040903 chr6 111470153 T G 1.16E-13 Metabolite levels SLC16A10 intron 22286219 rs9400470 chr6 111478131 T C 1.56E-13 Metabolite levels SLC16A10 intron 22286219 rs11153272 chr6 111479539 C T 1.19E-13 Metabolite levels SLC16A10 intron 22286219 rs1322214 chr6 111480045 T A 1.68E-13 Metabolite levels SLC16A10 intron 22286219 rs241768 chr6 111492119 T C 2.21E-12 Metabolite levels SLC16A10 intron 22286219 rs395564 chr6 111497379 G A 8.05E-04 Multiple complex diseases SLC16A10 intron 17554300 rs12211045 chr6 111498116 C T 3.69E-11 Metabolite levels SLC16A10 intron 22286219 rs12213248 chr6 111499394 G C 4.51E-11 Metabolite levels SLC16A10 intron 22286219 rs12214886 chr6 111500081 C T 3.73E-11 Metabolite levels SLC16A10 intron 22286219 rs9647629 chr6 111501484 C T 3.37E-11 Metabolite levels SLC16A10 intron 22286219 rs1216019 chr6 111503194 T C 4.62E-14 Metabolite levels SLC16A10 intron 22286219 rs354529 chr6 111504655 G A 1.03E-13 Metabolite levels SLC16A10 intron 22286219 rs17663278 chr6 111504881 A C 2.61E-11 Metabolite levels SLC16A10 intron 22286219 rs12214550 chr6 111505499 C T 2.54E-11 Metabolite levels SLC16A10 intron 22286219 rs168522 chr6 111506628 A G 8.92E-14 Metabolite levels SLC16A10 intron 22286219 rs354524 chr6 111508109 G A 1.60E-13 Metabolite levels SLC16A10 intron 22286219 rs354524 chr6 111508109 G A 7.63E-05 ldl cholesterol SLC16A10 intron pha003077 rs1150083 chr6 111510767 C T 1.40E-13 Metabolite levels SLC16A10 intron 22286219 rs2757571 chr6 111511124 T G 1.39E-13 Metabolite levels SLC16A10 intron 22286219 rs373526 chr6 111511464 A G 5.17E-04 Multiple complex diseases SLC16A10 intron 17554300 rs367734 chr6 111512378 C G 3.93E-13 Metabolite levels SLC16A10 intron 22286219 rs354539 chr6 111517829 T C 1.29E-13 Metabolite levels SLC16A10 intron 22286219 rs35253168 chr6 111521030 T TAA 4.43E-12 Metabolite levels SLC16A10 intron 22286219 rs354534 chr6 111521030 T A 4.43E-12 Metabolite levels SLC16A10 intron 22286219 rs386408250 chr6 111521030 T TAA 4.43E-12 Metabolite levels SLC16A10 intron 22286219 rs12212282 chr6 111524838 T C 3.48E-11 Metabolite levels SLC16A10 intron 22286219 rs9372297 chr6 111524954 T A 1.87E-12 Metabolite levels SLC16A10 intron 22286219 rs12207199 chr6 111525906 G A 1.96E-11 Metabolite levels SLC16A10 intron 22286219 rs402014 chr6 111527696 C T 7.89E-14 Metabolite levels SLC16A10 intron 22286219 rs12191266 chr6 111528041 T C 3.52E-11 Metabolite levels SLC16A10 intron 22286219 rs354544 chr6 111531159 T C 9.28E-14 Metabolite levels SLC16A10 intron 22286219 rs354545 chr6 111531412 G A 1.22E-13 Metabolite levels SLC16A10 intron 22286219 rs354547 chr6 111535122 G T 6.56E-04 Multiple complex diseases SLC16A10 intron 17554300 rs12210707 chr6 111538387 C T 3.80E-11 Metabolite levels SLC16A10 intron 22286219 rs369361 chr6 111539761 A G 7.90E-11 Metabolite levels SLC16A10 intron 22286219 rs405948 chr6 111540372 G A 1.40E-13 Metabolite levels SLC16A10 intron 22286219 rs17606481 chr6 111542388 A G 3.59E-11 Metabolite levels SLC16A10 intron 22286219 rs193282 chr6 111543067 G A 6.12E-14 Metabolite levels SLC16A10 intron 22286219 rs14399 chr6 111543944 C A 2.34E-14 Metabolite levels SLC16A10 UTR-3 22286219 rs12213673 chr6 111544839 C T 3.72E-11 Metabolite levels / / 22286219 rs191632 chr6 111544882 C T 4.13E-14 Metabolite levels / / 22286219 rs354550 chr6 111546484 G A 2.47E-12 Metabolite levels / / 22286219 rs17606672 chr6 111546833 G C 3.87E-11 Metabolite levels / / 22286219 rs1150076 chr6 111548430 T C 1.58E-04 Multiple complex diseases / / 17554300 rs354532 chr6 111548813 C T 2.73E-04 Pulmonary function / / 20010834 rs354532 chr6 111548813 C T 1.07E-13 Metabolite levels / / 22286219 rs354531 chr6 111548933 C T 2.57E-13 Metabolite levels / / 22286219 rs2297939 chr6 111549162 G A 4.88E-05 Multiple sclerosis / / 20598377 rs2297939 chr6 111549162 G A 3.83E-14 Metabolite levels / / 22286219 rs6901004 chr6 111554822 C G 5.98E-13 Metabolite levels / / 22286219 rs6901004 chr6 111554822 C G 1.00E-11 Blood metabolite levels / / 24816252 rs12214933 chr6 111558006 A G 1.04E-11 Metabolite levels / / 22286219 rs1150078 chr6 111560301 T C 1.67E-14 Metabolite levels / / 22286219 rs9487602 chr6 111560946 G A 3.28E-13 Metabolite levels / / 22286219 rs783086 chr6 111561713 G A 1.90E-13 Metabolite levels / / 22286219 rs391196 chr6 111563908 G A 4.49E-04 Type 2 diabetes / / 17463246 rs411604 chr6 111565847 A G 1.38E-11 Metabolite levels / / 22286219 rs12192718 chr6 111569151 T A 8.27E-12 Metabolite levels / / 22286219 rs12208141 chr6 111572138 G A 2.61E-11 Metabolite levels / / 22286219 rs12215396 chr6 111572395 T C 9.36E-12 Metabolite levels / / 22286219 rs241001 chr6 111579998 C T 4.17E-04 Type 2 diabetes / / 17463246 rs17756732 chr6 111580154 T C 6.38E-04 Multiple complex diseases / / 17554300 rs17756732 chr6 111580154 T C 2.19E-11 Metabolite levels / / 22286219 rs17678681 chr6 111582038 T A 1.05E-11 Metabolite levels KIAA1919 intron 22286219 rs12203093 chr6 111585382 T C 1.12E-11 Metabolite levels KIAA1919 intron 22286219 rs10456872 chr6 111586667 C T 1.15E-11 Metabolite levels KIAA1919 intron 22286219 rs11153280 chr6 111589293 A C 7.40E-12 Metabolite levels KIAA1919 UTR-3 22286219 rs240989 chr6 111591055 T C 2.32E-04 Type 2 diabetes / / 17463246 rs12199233 chr6 111592317 G A 1.32E-11 Metabolite levels / / 22286219 rs10872066 chr6 111593611 C G 8.03E-12 Metabolite levels / / 22286219 rs11153281 chr6 111594594 C T 1.42E-11 Metabolite levels / / 22286219 rs11153283 chr6 111597143 C T 2.69E-11 Metabolite levels / / 22286219 rs173287 chr6 111597439 G A 3.16E-04 Type 2 diabetes / / 17463246 rs12196873 chr6 111598058 A C 8.08E-04 Multiple complex diseases / / 17554300 rs12196873 chr6 111598058 A C 2.59E-11 Metabolite levels / / 22286219 rs6933627 chr6 111600809 C T 1.74E-11 Metabolite levels / / 22286219 rs12207616 chr6 111608797 A T 1.95E-11 Metabolite levels / / 22286219 rs12195578 chr6 111614786 C T 2.95E-11 Metabolite levels / / 22286219 rs12215049 chr6 111618384 A G 2.85E-11 Metabolite levels / / 22286219 rs465565 chr6 111619136 A T 1.12E-11 Metabolite levels / / 22286219 rs12205046 chr6 111619620 G A 2.90E-11 Metabolite levels / / 22286219 rs465796 chr6 111619725 T G 1.11E-11 Metabolite levels / / 22286219 rs1061388 chr6 111620294 A C 2.96E-11 Metabolite levels REV3L UTR-3 22286219 rs12200641 chr6 111622758 C T 2.98E-11 Metabolite levels REV3L intron 22286219 rs56827 chr6 111623203 C A,G,T 1.19E-11 Metabolite levels REV3L intron 22286219 rs3204954 chr6 111628597 C G 3.17E-11 Metabolite levels REV3L cds-synon 22286219 rs3204953 chr6 111628626 C T 2.98E-11 Metabolite levels REV3L missense 22286219 rs10485124 chr6 111631907 C G 3.28E-11 Metabolite levels REV3L intron 22286219 rs456865 chr6 111632928 T C 1.02E-11 Metabolite levels REV3L intron 22286219 rs1676863 chr6 111641590 C T 2.76E-12 Metabolite levels REV3L intron 22286219 rs457492 chr6 111641850 G A 1.30E-11 Metabolite levels REV3L intron 22286219 rs12209435 chr6 111643037 G A 3.13E-11 Metabolite levels REV3L intron 22286219 rs240965 chr6 111644524 C T 8.50E-06 Urinary metabolites REV3L intron 21572414 rs12215189 chr6 111646002 G C 2.54E-11 Metabolite levels REV3L intron 22286219 rs12192147 chr6 111648057 G C 2.28E-11 Metabolite levels REV3L intron 22286219 rs240974 chr6 111649316 C T 9.19E-11 Metabolite levels REV3L intron 22286219 rs459403 chr6 111653877 T C 9.03E-12 Metabolite levels REV3L intron 22286219 rs465969 chr6 111655530 G A 2.00E-16 Psoriasis REV3L intron 20953190 rs12197149 chr6 111656067 G A 2.76E-11 Metabolite levels REV3L intron 22286219 rs12207774 chr6 111657576 T C 2.81E-11 Metabolite levels REV3L intron 22286219 rs462432 chr6 111659755 G A 7.42E-12 Metabolite levels REV3L intron 22286219 rs240954 chr6 111659822 G A 7.42E-12 Metabolite levels REV3L intron 22286219 rs445349 chr6 111662102 A G 9.30E-06 Urinary metabolites REV3L intron 21572414 rs445349 chr6 111662102 A G 7.65E-12 Metabolite levels REV3L intron 22286219 rs12198556 chr6 111662338 C T 2.82E-11 Metabolite levels REV3L intron 22286219 rs466923 chr6 111662977 T C 3.70E-12 Metabolite levels REV3L intron 22286219 rs12200610 chr6 111663567 C G 2.82E-11 Metabolite levels REV3L intron 22286219 rs17539951 chr6 111664969 G A 3.11E-11 Metabolite levels REV3L intron 22286219 rs1623806 chr6 111665071 T C 8.46E-12 Metabolite levels REV3L intron 22286219 rs455247 chr6 111667799 G A 9.16E-12 Metabolite levels REV3L intron 22286219 rs12209969 chr6 111668167 G A 2.82E-11 Metabolite levels REV3L intron 22286219 rs464401 chr6 111669007 G A 2.47E-11 Metabolite levels REV3L intron 22286219 rs463854 chr6 111673207 C G 1.01E-11 Metabolite levels REV3L intron 22286219 rs463853 chr6 111673211 C G 1.01E-11 Metabolite levels REV3L intron 22286219 rs240993 chr6 111673714 T C 5.00E-20 Psoriasis REV3L intron 20953190 rs17539875 chr6 111674350 C T 2.79E-11 Metabolite levels REV3L intron 22286219 rs456569 chr6 111674801 T G 1.05E-11 Metabolite levels REV3L intron 22286219 rs12199656 chr6 111675143 A C 2.75E-11 Metabolite levels REV3L intron 22286219 rs455335 chr6 111675516 A G 9.14E-12 Metabolite levels REV3L intron 22286219 rs465795 chr6 111676443 C T 9.15E-12 Metabolite levels REV3L intron 22286219 rs12203741 chr6 111677544 A T 1.36E-04 Type 2 diabetes REV3L intron 17463246 rs12203741 chr6 111677544 A T 2.33E-11 Metabolite levels REV3L intron 22286219 rs110732 chr6 111679869 G T 9.14E-12 Metabolite levels REV3L intron 22286219 rs462493 chr6 111683740 T C 1.98E-14 Metabolite levels REV3L intron 22286219 rs12198788 chr6 111686791 C G 2.32E-11 Metabolite levels REV3L intron 22286219 rs456871 chr6 111687650 C T 1.31E-11 Metabolite levels REV3L intron 22286219 rs455732 chr6 111695268 C T 1.04E-11 Metabolite levels REV3L cds-synon 22286219 rs458017 chr6 111696091 T C 2.00E-16 Psoriasis REV3L missense 20953190 rs3218591 chr6 111696129 T A 2.25E-11 Metabolite levels REV3L cds-synon 22286219 rs458486 chr6 111696852 T C 9.73E-12 Metabolite levels REV3L cds-synon 22286219 rs12190135 chr6 111698204 T C 2.04E-11 Metabolite levels REV3L intron 22286219 rs455726 chr6 111699368 G A 9.06E-12 Metabolite levels REV3L intron 22286219 rs17510789 chr6 111702789 A G 2.03E-11 Metabolite levels REV3L intron 22286219 rs11153287 chr6 111704537 G A 9.62E-12 Metabolite levels REV3L intron 22286219 rs1002475 chr6 111709589 T C 7.28E-12 Metabolite levels REV3L intron 22286219 rs12200758 chr6 111710844 A G 2.01E-11 Metabolite levels REV3L intron 22286219 rs12191195 chr6 111712718 C G 2.00E-11 Metabolite levels REV3L intron 22286219 rs11153288 chr6 111715238 T A 9.17E-12 Metabolite levels REV3L intron 22286219 rs11153290 chr6 111718132 T C 8.73E-12 Metabolite levels REV3L intron 22286219 rs11153291 chr6 111720130 T C 9.18E-12 Metabolite levels REV3L intron 22286219 rs11153292 chr6 111722379 G A 9.18E-12 Metabolite levels REV3L intron 22286219 rs12190634 chr6 111725160 A G 9.19E-12 Metabolite levels REV3L intron 22286219 rs11153293 chr6 111725899 A T 1.10E-11 Metabolite levels REV3L intron 22286219 rs11756643 chr6 111726146 C T 4.14E-11 Metabolite levels REV3L intron 22286219 rs3218575 chr6 111726611 A T 5.84E-05 Type 2 diabetes REV3L intron 17463246 rs1989574 chr6 111728533 T C 1.04E-11 Metabolite levels REV3L intron 22286219 rs11153294 chr6 111730246 T C 8.27E-12 Metabolite levels REV3L intron 22286219 rs7451051 chr6 111744818 G A 9.75E-12 Metabolite levels REV3L intron 22286219 rs7760535 chr6 111747083 G C 8.40E-07 Urinary metabolites REV3L intron 21572414 rs7760535 chr6 111747083 G C 1.00E-12 Metabolic traits REV3L intron 21886157 rs7760535 chr6 111747083 G C 2.81E-12 Metabolite levels REV3L intron 22286219 rs62420437 chr6 111748780 T C 1.07E-11 Metabolite levels REV3L intron 22286219 rs10456875 chr6 111749725 A G 7.53E-12 Metabolite levels REV3L intron 22286219 rs4276544 chr6 111759699 A G 9.19E-12 Metabolite levels REV3L intron 22286219 rs10457238 chr6 111762593 C G 1.90E-11 Metabolite levels REV3L intron 22286219 rs12207339 chr6 111767012 C T 2.27E-11 Metabolite levels REV3L intron 22286219 rs12207557 chr6 111767459 C T 2.29E-11 Metabolite levels REV3L intron 22286219 rs17539197 chr6 111769171 C G 2.78E-12 Metabolite levels REV3L intron 22286219 rs12191726 chr6 111769524 T C 2.35E-11 Metabolite levels REV3L intron 22286219 rs17751426 chr6 111772223 T C 2.35E-11 Metabolite levels REV3L intron 22286219 rs6568680 chr6 111776164 C T 2.44E-12 Metabolite levels REV3L intron 22286219 rs7752361 chr6 111780705 A G 2.31E-12 Metabolite levels REV3L intron 22286219 rs7764591 chr6 111783414 G C 3.02E-12 Metabolite levels REV3L intron 22286219 rs7750792 chr6 111783759 T C 2.26E-12 Metabolite levels REV3L intron 22286219 rs12192837 chr6 111784240 C G 2.84E-11 Metabolite levels REV3L intron 22286219 rs12211763 chr6 111787156 A G 9.47E-12 Metabolite levels REV3L intron 22286219 rs10872067 chr6 111788391 T C 2.27E-12 Metabolite levels REV3L intron 22286219 rs7758483 chr6 111789148 G A 9.86E-05 Gallstones REV3L intron 17632509 rs6913769 chr6 111792897 G A 2.45E-12 Metabolite levels REV3L intron 22286219 rs12208482 chr6 111793646 T A 3.53E-11 Metabolite levels REV3L intron 22286219 rs6900341 chr6 111794409 T G 4.00E-15 Metabolite levels REV3L intron 22286219 rs17510381 chr6 111794658 C G 3.63E-11 Metabolite levels REV3L intron 22286219 rs9689727 chr6 111796563 T C 2.67E-12 Metabolite levels REV3L intron 22286219 rs12214380 chr6 111796937 T C 2.70E-12 Metabolite levels REV3L intron 22286219 rs61269242 chr6 111803059 T C 1.36E-11 Metabolite levels REV3L intron 22286219 rs7776184 chr6 111809918 G A 1.92E-06 Menopause (age at onset) TRAF3IP2-AS1 intron 22267201 rs7450789 chr6 111816975 G T 9.63E-05 Waist Circumference TRAF3IP2-AS1 intron pha003025 rs9481155 chr6 111829239 A G 9.63E-05 Waist Circumference TRAF3IP2-AS1 intron pha003025 rs12203434 chr6 111844290 T C 9.02E-11 Metabolite levels TRAF3IP2-AS1 intron 22286219 rs3851228 chr6 111848191 A T 6.70E-04 Iris characteristics TRAF3IP2-AS1 intron 21835309 rs3851228 chr6 111848191 A T 1.00E-13 Inflammatory bowel disease TRAF3IP2-AS1 intron 23128233 rs11757203 chr6 111850003 G T 7.45E-11 Metabolite levels TRAF3IP2-AS1 intron 22286219 rs7742244 chr6 111852662 T C 2.31E-11 Metabolite levels TRAF3IP2-AS1 intron 22286219 rs10872069 chr6 111861726 A C 1.22E-11 Metabolite levels TRAF3IP2-AS1 intron 22286219 rs9374262 chr6 111874975 G A 2.60E-05 Urinary metabolites TRAF3IP2-AS1 intron 21572414 rs4947127 chr6 111902798 T G 3.37E-04 Response to statin treatment (atorvastatin),change in cholesterol levels TRAF3IP2 intron 20031582 rs33980500 chr6 111913262 C T 1.00E-20 Psoriatic arthritis TRAF3IP2 missense 20953186 rs33980500 chr6 111913262 C T 1.00E-16 Psoriasis TRAF3IP2 missense 20953188 rs33980500 chr6 111913262 C T 4.20E-45 Psoriasis TRAF3IP2 missense 23143594 rs13210247 chr6 111922720 A G 7.31E-09 Psoriasis TRAF3IP2 intron 20953188 rs3777921 chr6 111924410 A G 7.06E-04 Taste perception TRAF3IP2 intron 22132133 rs9487680 chr6 111926848 T G 6.95E-06 Uric acid levels TRAF3IP2 intron 21294900 rs4947133 chr6 111940548 C T 4.58E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1476043 chr6 111944979 G A 8.56E-04 Taste perception / / 22132133 rs9400484 chr6 111949779 A G 2.61E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs9320373 chr6 111965272 G A 8.72E-04 Obesity (extreme) / / 21935397 rs2343601 chr6 111970699 T C 3.52E-05 Coronary heart disease / / pha003031 rs2343601 chr6 111970699 T C 1.58E-05 Insulin Resistance / / pha003062 rs2343601 chr6 111970699 T C 7.60E-05 Insulin-related traits / / pha003063 rs9320374 chr6 111983818 A G 2.90E-05 Breast cancer FYN intron 22452962 rs6919400 chr6 111991321 T C 7.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FYN intron 20877124 rs2237255 chr6 111992827 C T 1.14E-04 Response to statin treatment (atorvastatin),change in cholesterol levels FYN intron 20031582 rs9374274 chr6 111996419 G A 4.62E-05 Coronary heart disease FYN intron pha003031 rs9374274 chr6 111996419 G A 5.80E-06 Insulin Resistance FYN intron pha003062 rs9374274 chr6 111996419 G A 2.29E-05 Insulin-related traits FYN intron pha003063 rs2344706 chr6 111999020 A T 5.94E-04 Response to statin treatment (atorvastatin),change in cholesterol levels FYN intron 20031582 rs7746279 chr6 112000162 G A 4.99E-05 Coronary heart disease FYN intron pha003031 rs7746279 chr6 112000162 G A 1.35E-05 Insulin Resistance FYN intron pha003062 rs7746279 chr6 112000162 G A 5.61E-05 Insulin-related traits FYN intron pha003063 rs2237259 chr6 112006549 C T 3.31E-05 Waist-Hip Ratio FYN intron pha003029 rs2237259 chr6 112006549 C T 8.79E-05 Coronary heart disease FYN intron pha003031 rs2237259 chr6 112006549 C T 4.49E-06 Insulin Resistance FYN intron pha003062 rs2237259 chr6 112006549 C T 2.24E-05 Insulin-related traits FYN intron pha003063 rs1998038 chr6 112006995 C T 3.31E-05 Waist-Hip Ratio FYN intron pha003029 rs1998038 chr6 112006995 C T 8.79E-05 Coronary heart disease FYN intron pha003031 rs1998038 chr6 112006995 C T 4.49E-06 Insulin Resistance FYN intron pha003062 rs1998038 chr6 112006995 C T 2.24E-05 Insulin-related traits FYN intron pha003063 rs11153311 chr6 112009325 A G 1.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FYN intron 20877124 rs809193 chr6 112020414 T C 2.34E-04 Parkinson's disease FYN intron 17052657 rs1726124 chr6 112023493 T A 4.42E-04 Multiple complex diseases FYN intron 17554300 rs706892 chr6 112038640 C G 9.57E-04 Multiple complex diseases FYN intron 17554300 rs1740377 chr6 112043118 C A 2.74E-04 Parkinson's disease FYN intron 17052657 rs1726113 chr6 112043133 C A 2.95E-04 Parkinson's disease FYN intron 17052657 rs706907 chr6 112046409 G C 1.28E-04 Multiple complex diseases FYN intron 17554300 rs7746471 chr6 112049045 T C 9.63E-05 Multiple complex diseases FYN intron 17554300 rs697642 chr6 112053105 G A 2.20E-05 Urinary metabolites FYN intron 21572414 rs6930230 chr6 112063482 T C 8.00E-05 Systolic blood pressure FYN intron 19430483 rs2148710 chr6 112122226 C T 3.00E-08 Anger FYN intron 24489884 rs9487737 chr6 112175517 C T 7.26E-04 Endometrial cancer FYN intron 24096698 rs9372316 chr6 112203035 A G 9.72E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs9372316 chr6 112203035 A G 9.72E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs4373389 chr6 112212449 C T 9.72E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs4373389 chr6 112212449 C T 9.72E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs2026603 chr6 112215441 T G 9.72E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs2026603 chr6 112215441 T G 9.72E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs7773966 chr6 112231970 A T 1.45E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs7773966 chr6 112231970 A T 1.45E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs9487749 chr6 112232986 C T 3.13E-04 Cholesterol / / 17255346 rs9400515 chr6 112250110 A C 3.14E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs671271 chr6 112261385 G A 8.94E-04 Hodgkin's lymphoma / / 24149102 rs9487771 chr6 112281277 T C 1.51E-05 Hodgkin's lymphoma / / 24149102 rs571060 chr6 112296520 T C 7.44E-04 Coronary heart disease / / 21606135 rs2815787 chr6 112332393 C A 1.69E-04 Sudden cardiac arrest / / 21658281 rs1515333 chr6 112338958 G A 6.88E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2673307 chr6 112360196 G T 1.71E-04 Parkinson's disease / / 17052657 rs2345804 chr6 112413462 G A 1.83E-04 Multiple complex diseases C6orf225 intron 17554300 rs6914605 chr6 112420052 G A 7.77E-04 Multiple complex diseases C6orf225 intron 17554300 rs9384820 chr6 112437586 G C 4.33E-04 Suicide attempts in bipolar disorder LAMA4 intron 21423239 rs9487823 chr6 112451778 C T 6.93E-04 Multiple complex diseases LAMA4 intron 17554300 rs2072020 chr6 112460648 G A 8.33E-05 Body Mass Index LAMA4 intron pha003009 rs9374311 chr6 112524266 T C 5.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LAMA4 intron 20877124 rs2237245 chr6 112525132 A G 9.22E-04 Response to cytadine analogues (cytosine arabinoside) LAMA4 intron 24483146 rs7754329 chr6 112526404 C T 8.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LAMA4 intron 20877124 rs41375645 chr6 112536338 G A 4.51E-06 Multiple complex diseases LAMA4 intron 17554300 rs7450379 chr6 112543539 T C 1.18E-04 Response to platinum-based chemotherapy in small-cell lung cancer LAMA4 intron 20463552 rs3208829 chr6 112573289 C G 2.54E-05 Response to acetaminophen (hepatotoxicity) LAMA4 intron 21177773 rs11153350 chr6 112578384 G A 2.54E-05 Response to acetaminophen (hepatotoxicity) LOC100506430 intron 21177773 rs12195039 chr6 112580969 C T 7.24E-05 Insulin-related traits LOC100506430 intron pha003063 rs1891470 chr6 112596456 A G 1.77E-04 Amyotrophic Lateral Sclerosis LOC100506430 intron 17827064 rs6901099 chr6 112606123 G A 3.62E-04 Response to TNF antagonist treatment LOC100506430 intron 21061259 rs1935689 chr6 112612615 A G 3.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100506430 intron 20877124 rs9374315 chr6 112615438 T G 1.71E-04 Glycosylated haemoglobin levels LOC100506430 intron 17255346 rs1342593 chr6 112621834 C T 1.70E-05 Urinary metabolites LOC100506430 intron 21572414 rs6903594 chr6 112624550 C T 6.01E-04 Suicide attempts in bipolar disorder LOC100506430 intron 21423239 rs9320405 chr6 112629434 C T 3.80E-06 Urinary metabolites / / 21572414 rs1935683 chr6 112629554 T C 3.89E-05 Multiple complex diseases / / 17554300 rs9487885 chr6 112631064 C T 5.47E-04 Multiple complex diseases / / 17554300 rs2027532 chr6 112635196 T C 3.72E-06 Osteoarthritis / / 22763110 rs6940518 chr6 112651195 A G 6.90E-06 Urinary metabolites / / 21572414 rs1935681 chr6 112651206 G A 6.71E-04 Myocardial Infarction / / pha002873 rs9398305 chr6 112653890 C T 1.20E-05 Urinary metabolites / / 21572414 rs6933749 chr6 112656911 G T 1.10E-05 Urinary metabolites / / 21572414 rs1539403 chr6 112661896 T G 6.97E-05 Body mass index / / 17255346 rs13202473 chr6 112675606 G A 5.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs2881334 chr6 112697273 T C 8.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs7741290 chr6 112710075 T C 7.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs1935706 chr6 112714251 A G 8.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs9387074 chr6 112717989 T C 9.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs4945906 chr6 112720097 C T 8.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs1108967 chr6 112722413 A G 8.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs1935698 chr6 112730694 C T 6.50E-05 Suicide attempts in bipolar disorder / / 21423239 rs12202021 chr6 112749838 G T 2.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs1397935 chr6 112764338 C T 9.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10485414 chr6 112795277 C T 3.40E-04 Bipolar disorder / / 19259986 rs6900593 chr6 112819061 C T 2.10E-04 Insulin resistance / / 21901158 rs6926282 chr6 112861788 G A 0.0000855 Uterine leiomyomata / / 23040493 rs1276535 chr6 112882942 A C 4.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs6910169 chr6 112883987 G A 3.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1556973 chr6 112942941 T C 8.80E-05 Parkinson's disease (age of onset) / / 19772629 rs17074196 chr6 112957317 C A 9.73E-04 Alzheimer's disease / / 17998437 rs9387092 chr6 112964352 C T 6.50E-05 Parkinson's disease (age of onset) / / 19772629 rs9387092 chr6 112964352 C T 1.11E-04 Alcohol dependence / / 24277619 rs4947192 chr6 112967841 T C 1.23E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12194046 chr6 112989209 C T 9.10E-05 Bipolar Disorder / / pha002858 rs10499068 chr6 113082504 A G 4.90E-04 Obesity-related traits LOC100287612 intron 17903300 rs9487982 chr6 113111808 C T 1.40E-04 Endometriosis / / 21151130 rs9487982 chr6 113111808 C T 8.20E-06 Endometriosis / / 23104006 rs6934970 chr6 113124301 C T 9.74E-05 Bipolar disorder / / 22925353 rs6934970 chr6 113124301 C T 7.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs10782174 chr6 113134476 G A 2.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs17074473 chr6 113140879 C G 8.23E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs7739145 chr6 113140908 G T 1.50E-04 Endometriosis / / 21151130 rs6940920 chr6 113143682 T C 8.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13215654 chr6 113156392 A G 2.00E-04 Asperger disorder / / 21182207 rs62421103 chr6 113160344 G T 4.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs9320422 chr6 113197993 T C 4.60E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1481323 chr6 113346306 G T 4.86E-04 Multiple complex diseases / / 17554300 rs2185710 chr6 113377048 A G 5.95E-08 Prostate cancer / / 24185611 rs6921287 chr6 113405557 C G 6.89E-04 Multiple complex diseases / / 17554300 rs2502404 chr6 113449502 C T 5.00E-05 Lung adenocarcinoma / / 22797724 rs2502402 chr6 113457727 C T 9.13E-04 Multiple complex diseases / / 17554300 rs13218679 chr6 113463252 C T 7.00E-05 Asperger disorder / / 21182207 rs7763553 chr6 113464570 C T 7.91E-04 Multiple complex diseases / / 17554300 rs1321028 chr6 113478468 G T 8.22E-04 Multiple complex diseases / / 17554300 rs2473967 chr6 113479335 G T 8.10E-06 Pain relief with opioid treatment / / 21622719 rs2473967 chr6 113479335 G T 2.00E-06 Asthma (childhood onset) / / 23829686 rs1406832 chr6 113480927 C A 8.74E-04 Multiple complex diseases / / 17554300 rs7773871 chr6 113496218 C T 5.52E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs1406829 chr6 113496411 T C 9.43E-04 Alzheimer's disease / / 17998437 rs1406829 chr6 113496411 T C 7.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs926730 chr6 113497065 A C 3.00E-05 Asperger disorder / / 21182207 rs1883973 chr6 113502071 A G 1.22E-05 Left ventricular hypertrophy / / pha003052 rs1321023 chr6 113503020 A G 1.22E-05 Left ventricular hypertrophy / / pha003052 rs12154111 chr6 113509151 C T 5.00E-05 Asperger disorder / / 21182207 rs774568 chr6 113515814 A G 8.72E-04 Multiple complex diseases / / 17554300 rs774568 chr6 113515814 A G 9.00E-05 Asperger disorder / / 21182207 rs774564 chr6 113518365 A G 6.00E-05 Asperger disorder / / 21182207 rs4945934 chr6 113540548 T G 0.000435559 Hypertension (early onset hypertension) / / 22479346 rs9400601 chr6 113541196 T C 0.000226685 Hypertension (early onset hypertension) / / 22479346 rs706922 chr6 113542698 T C 5.00E-04 Spine bone size / / 21947420 rs1687806 chr6 113546637 A C 3.40E-05 Iron levels / / 21208937 rs9481326 chr6 113554511 A G 3.70E-05 Cholesterol / / pha003083 rs2842846 chr6 113636230 A C 8.13E-06 Triglycerides / / 19074352 rs2842846 chr6 113636230 A C 8.13E-06 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs7765175 chr6 113665327 C T 5.00E-06 Coronary artery calcification / / 23870195 rs9481344 chr6 113684429 C T 7.28E-05 Hypertension / / 19609347 rs10484461 chr6 113727330 C T 1.47E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10484461 chr6 113727330 C T 1.91E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9918379 chr6 113730180 G T 2.64E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9918379 chr6 113730180 G T 3.30E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2049924 chr6 113752301 G A 8.42E-06 Bone mineral traits,in men / / 21427758 rs1481432 chr6 113848999 A C 8.97E-05 Cognitive impairment induced by topiramate / / 22091778 rs2348305 chr6 113869058 A C 3.43E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs547797 chr6 113881630 G T 8.22E-04 Multiple complex diseases / / 17554300 rs6904910 chr6 113889837 T C 2.68E-04 Parkinson's disease / / 16252231 rs4945955 chr6 113893183 T G 8.95E-05 Cognitive test performance / / 20125193 rs7755236 chr6 113918650 C T 4.60E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10872099 chr6 113926484 G A 3.23E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs9384874 chr6 113937733 T C 9.90E-06 Urinary metabolites / / 21572414 rs986543 chr6 113953169 T C 5.60E-06 Urinary metabolites / / 21572414 rs6931833 chr6 113971591 G A 5.92E-06 Osteoarthritis / / 22763110 rs9387161 chr6 113972290 C T 1.58E-05 Brain lesion load / / 19010793 rs9387161 chr6 113972290 C T 1.10E-04 Asperger disorder / / 21182207 rs9481383 chr6 114007247 C G 1.54E-05 Suicide attempts in bipolar disorder LOC100652953 intron 21423239 rs9481384 chr6 114007383 A T 1.58E-05 Suicide attempts in bipolar disorder LOC100652953 intron 21423239 rs9488238 chr6 114017133 A G 5.00E-06 Disc degeneration (lumbar) LOC100652953 intron 22993228 rs17075374 chr6 114019594 T C 5.11E-04 Multiple complex diseases LOC100652953 intron 17554300 rs773682 chr6 114020940 A G 4.38E-04 Obesity (extreme) LOC100652953 intron 21935397 rs1880964 chr6 114029505 G A 1.90E-05 Urinary metabolites LOC100652953 intron 21572414 rs6938123 chr6 114030573 C T 8.40E-04 Multiple complex diseases LOC100652953 intron 17554300 rs9374425 chr6 114053992 C T 2.50E-05 Urinary metabolites LOC100652953 intron 21572414 rs13208937 chr6 114069916 G A 8.48E-05 Insulin resistance LOC100652953 intron 21901158 rs11153450 chr6 114145603 A G 1.42E-04 Type 2 diabetes LOC100652953 intron 17463246 rs594930 chr6 114170427 T C 1.38E-06 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs352081 chr6 114173871 T G 6.45E-04 Insulin resistance / / 21901158 rs11153451 chr6 114194523 A G 5.27E-05 Body Mass Index / / pha003015 rs503593 chr6 114206311 A G 1.65E-05 Osteoarthritis (knee and hip) / / 21177295 rs2146178 chr6 114207591 G T 4.38E-05 Body Mass Index / / pha003015 rs2348779 chr6 114209516 G T 9.59E-04 Multiple complex diseases / / 17554300 rs352080 chr6 114210411 A T 8.11E-04 Smoking initiation / / 24665060 rs352074 chr6 114216946 G T 8.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs541076 chr6 114220473 G C 2.82E-04 Multiple complex diseases / / 17554300 rs352099 chr6 114225811 A G 2.41E-05 Socioeconomic Factors / / pha003066 rs9320475 chr6 114243506 C T 2.10E-04 Alzheimer's disease (late onset) / / 21379329 rs717389 chr6 114308844 T C 3.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2499615 chr6 114319622 A G 4.31E-04 Multiple complex diseases / / 17554300 rs2282237 chr6 114378970 C T 1.35E-04 Alcohol dependence HS3ST5 cds-synon 21314694 rs715825 chr6 114392599 C G 6.16E-05 Personality dimensions / / 18957941 rs17075861 chr6 114403464 C T 9.80E-05 Personality dimensions / / 18957941 rs9488322 chr6 114408925 T C 1.00E-05 Major depressive disorder (broad) / / 20038947 rs1855625 chr6 114429171 G T 9.34E-06 Major depressive disorder (broad) / / 20038947 rs6900394 chr6 114440364 C A 3.66E-04 Smoking cessation / / 24665060 rs9488336 chr6 114465305 G A 5.96E-04 Alzheimer's disease / / 24755620 rs1889556 chr6 114479520 T G 1.05E-04 Stroke / / pha002887 rs9320481 chr6 114490281 T A 1.04E-06 Gray matter volume (schizophrenia interaction) / / 24086445 rs9320482 chr6 114492599 T C 1.14E-06 Gray matter volume (schizophrenia interaction) / / 24086445 rs9488340 chr6 114508475 A G 8.20E-07 Gray matter volume (schizophrenia interaction) / / 24086445 rs9374441 chr6 114513862 A G 8.25E-06 Gray matter volume (schizophrenia interaction) / / 24086445 rs6936717 chr6 114522082 A G 8.46E-07 Gray matter volume (schizophrenia interaction) / / 24086445 rs9400701 chr6 114522398 T C 8.46E-07 Gray matter volume (schizophrenia interaction) / / 24086445 rs1812872 chr6 114522515 G C 5.71E-04 Multiple complex diseases / / 17554300 rs2037336 chr6 114524473 T G 1.04E-04 Alzheimer's disease / / 24755620 rs9320486 chr6 114538983 C T 3.19E-06 Gray matter volume (schizophrenia interaction) / / 24086445 rs7746324 chr6 114547249 A C 2.74E-06 Gray matter volume (schizophrenia interaction) / / 24086445 rs9488343 chr6 114547981 G A 7.00E-07 Gray matter volume (schizophrenia interaction) / / 24086445 rs1474171 chr6 114553296 T C 8.48E-04 Stroke LOC441167 intron pha002887 rs6901267 chr6 114581460 G A 6.00E-05 Height / / pha003011 rs9488363 chr6 114591986 A G 2.00E-06 optic disc size (rim) / / 20395239 rs7758085 chr6 114593560 T A 9.72E-05 Cervical cancer / / 24700089 rs1323049 chr6 114596121 G A 8.90E-05 Personality dimensions / / 18957941 rs1323056 chr6 114653522 G A 6.54E-05 Height / / pha003011 rs1407728 chr6 114672954 G T 4.73E-04 Type 2 diabetes / / 17463246 rs6568842 chr6 114800377 A G 2.60E-05 Major depressive disorder / / 21042317 rs1324443 chr6 114817483 A T 2.93E-04 Multiple complex diseases / / 17554300 rs17076203 chr6 114865780 A G 5.00E-05 Prostate cancer / / pha002878 rs9285412 chr6 114922474 G A 5.63E-04 Type 2 diabetes / / 17463246 rs7761443 chr6 114939097 A C 6.01E-05 Prostate cancer / / pha002878 rs9481463 chr6 114966599 G A 8.03E-08 Narcolepsy / / 19629137 rs6906296 chr6 114971507 C T 2.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs3003879 chr6 114973810 A G 2.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs3003879 chr6 114973810 A G 2.35E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6928844 chr6 115069717 C G 4.00E-06 IgG glycosylation / / 23382691 rs6928844 chr6 115069717 C G 7.00E-06 IgG glycosylation / / 23382691 rs6935353 chr6 115084581 T C 3.67E-05 Bipolar disorder / / 18317468 rs4379324 chr6 115170045 G A 3.22E-06 Myopia (severe) / / 23933737 rs9488492 chr6 115180226 T C 9.31E-04 Alzheimer's disease / / 22005930 rs7743827 chr6 115184297 A G 1.88E-04 Body mass index / / 17255346 rs7743827 chr6 115184297 A G 9.18E-05 Myopia (severe) / / 23933737 rs9387262 chr6 115202602 G A 2.34E-05 Non-small cell lung cancer / / 21866343 rs6909459 chr6 115227127 G A 1.77E-04 Body mass index / / 17255346 rs4945528 chr6 115251728 G C 2.96E-04 Body mass index / / 17255346 rs365114 chr6 115327645 T C 4.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs934346 chr6 115457895 T C 7.28E-04 Type 2 diabetes / / 17463246 rs2017590 chr6 115457968 T C 7.31E-04 Type 2 diabetes / / 17463246 rs11153546 chr6 115635187 T C 3.36E-05 Serum metabolites / / 19043545 rs6917783 chr6 115639883 C T 9.80E-05 Serum metabolites / / 19043545 rs6940934 chr6 115640061 T C 4.01E-05 Serum metabolites / / 19043545 rs6918482 chr6 115654060 T C 5.03E-05 Serum metabolites / / 19043545 rs4624905 chr6 115698999 G A 8.48E-04 Stroke / / pha002886 rs4333447 chr6 115756918 G A 6.30E-05 Scoliosis / / 21216876 rs4398772 chr6 115763024 A G 5.33E-05 Scoliosis / / 21216876 rs6912194 chr6 115817157 G A 7.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17076905 chr6 115883912 C G 9.12E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9374544 chr6 115905297 G A 9.70E-06 Urinary metabolites / / 21572414 rs4540285 chr6 115907315 G C 4.48E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6934597 chr6 115938264 C T 2.57E-05 Body Mass Index / / pha003015 rs4386848 chr6 115964718 T C 1.00E-05 Urinary metabolites / / 21572414 rs9387348 chr6 115965195 C G 3.39E-04 Multiple complex diseases / / 17554300 rs12205135 chr6 115985492 G C 4.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs9387353 chr6 115987344 C T 4.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs9320545 chr6 115999839 C T 5.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs9374562 chr6 116004497 C T 5.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs9372446 chr6 116011927 G T 4.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9374564 chr6 116014608 C T 3.20E-06 Thyroid function / / 20826269 rs9374564 chr6 116014608 C T 7.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs9400871 chr6 116026846 A T 3.79E-04 Suicide attempts in bipolar disorder / / 21041247 rs9400871 chr6 116026846 A T 7.70E-05 Cognitive function / / 24684796 rs9372449 chr6 116029398 C G 3.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs9374567 chr6 116030178 C T 3.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs9320546 chr6 116030515 C T 6.59E-04 Schizophrenia / / 19197363 rs9320546 chr6 116030515 C T 1.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9320546 chr6 116030515 C T 3.95E-04 Suicide attempts in bipolar disorder / / 21041247 rs9320546 chr6 116030515 C T 4.84E-05 Diabetes Mellitus / / pha003059 rs9384957 chr6 116059352 T C 5.43E-04 Suicide attempts in bipolar disorder / / 21041247 rs1935414 chr6 116077361 G A 9.10E-05 Hemoglobin / / pha003098 rs1935414 chr6 116077361 G A 5.85E-05 Erythrocyte counts / / pha003099 rs6934225 chr6 116085882 G A 1.40E-05 Body mass index (non-asthmatics) / / 23517042 rs7751236 chr6 116095030 G A 2.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs4946118 chr6 116097510 C T 3.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs9387366 chr6 116098280 G T 3.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs10457298 chr6 116098598 G C 3.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs9374571 chr6 116099909 C T 1.00E-05 Body mass index / / 20818722 rs9374571 chr6 116099909 C T 3.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs4946120 chr6 116102412 G A 1.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs9488775 chr6 116102720 T C 2.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs2050989 chr6 116106784 C A 8.18E-05 Cognitive performance / / 19734545 rs10485114 chr6 116128906 C T 4.01E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs497064 chr6 116159306 T C 2.42E-05 Serum metabolites / / 19043545 rs195482 chr6 116169307 T G 3.31E-04 Birth weight / / 17255346 rs195482 chr6 116169307 T G 6.14E-05 Orofacial clefts / / 22419666 rs195506 chr6 116193934 C A 3.47E-05 Cytomegalovirus antibody response / / 21993531 rs195511 chr6 116197857 T C 3.30E-05 Cytomegalovirus antibody response / / 21993531 rs195512 chr6 116200457 C G 3.29E-05 Cytomegalovirus antibody response / / 21993531 rs195513 chr6 116202783 C T 3.30E-05 Cytomegalovirus antibody response / / 21993531 rs195513 chr6 116202783 C T 7.23E-04 Response to alcohol consumption (flushing response) / / 24277619 rs195465 chr6 116206270 A G 3.21E-05 Cytomegalovirus antibody response / / 21993531 rs195490 chr6 116219420 C T 3.01E-05 Cytomegalovirus antibody response / / 21993531 rs195488 chr6 116222200 T C 2.86E-05 Cytomegalovirus antibody response / / 21993531 rs195486 chr6 116224667 T C 2.76E-05 Cytomegalovirus antibody response / / 21993531 rs195485 chr6 116232098 C T 3.52E-05 Cytomegalovirus antibody response / / 21993531 rs195517 chr6 116241584 G A 5.41E-04 Alzheimer's disease / / 22005930 rs10485107 chr6 116243394 A G 9.15E-04 Alzheimer's disease / / 22005930 rs195521 chr6 116244114 T C 7.48E-04 Alzheimer's disease / / 22005930 rs195522 chr6 116245016 G A 7.28E-04 Alzheimer's disease / / 22005930 rs195524 chr6 116247480 G C 7.64E-04 Alzheimer's disease / / 22005930 rs195525 chr6 116248273 C T 1.46E-04 Alzheimer's disease / / 22005930 rs195531 chr6 116252551 T A 7.86E-04 Alzheimer's disease / / 22005930 rs195534 chr6 116254834 T C 7.86E-04 Alzheimer's disease / / 22005930 rs495565 chr6 116262976 G A 8.45E-04 Alzheimer's disease FRK UTR-3 22005930 rs580396 chr6 116263181 T C 8.38E-04 Alzheimer's disease FRK UTR-3 22005930 rs536160 chr6 116267166 T C 7.90E-04 Alzheimer's disease FRK intron 22005930 rs496311 chr6 116274730 C T 8.61E-04 Alzheimer's disease FRK intron 22005930 rs1193609 chr6 116298479 C T 1.09E-04 Cholesterol FRK intron 17255346 rs1193608 chr6 116298792 C T 1.12E-04 Cholesterol FRK intron 17255346 rs3822858 chr6 116305064 T C 9.10E-04 Alzheimer's disease FRK intron 22005930 rs3798236 chr6 116309649 T C 5.37E-04 Alzheimer's disease FRK intron 22005930 rs1933738 chr6 116310243 A G 7.87E-04 Alzheimer's disease FRK intron 22005930 rs1933737 chr6 116310287 T C 8.64E-04 Alzheimer's disease FRK intron 22005930 rs1933737 chr6 116310287 T C 7.00E-07 Urate levels FRK intron 23263486 rs9488822 chr6 116312893 A T 2.00E-10 Cholesterol,total FRK intron 20686565 rs9488822 chr6 116312893 A T 3.00E-09 LDL cholesterol FRK intron 20686565 rs9488822 chr6 116312893 A T 2.50E-04 Alzheimer's disease FRK intron 22005930 rs9488822 chr6 116312893 A T 1.00E-09 Cholesterol,total FRK intron 24097068 rs9488822 chr6 116312893 A T 2.00E-07 LDL cholesterol FRK intron 24097068 rs3822857 chr6 116313931 G C 5.77E-04 Alzheimer's disease FRK intron 22005930 rs3822856 chr6 116316103 C A 3.97E-05 Lymphocyte counts FRK intron 22286170 rs1999930 chr6 116387134 C T 1.00E-08 Age-related macular degeneration / / 21665990 rs1999659 chr6 116430382 G A 3.61E-05 Personality dimensions NT5DC1 intron 22628180 rs476330 chr6 116433265 C T 1.91E-05 Personality dimensions NT5DC1 intron 22628180 rs3812111 chr6 116443735 T A 2.00E-08 Age-related macular degeneration COL10A1 intron 23455636 rs11965969 chr6 116452203 T G 0.0000877 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs9488845 chr6 116452658 C A 0.000111 Salmonella-induced pyroptosis NT5DC1 intron 22837397 rs9488845 chr6 116452658 C A 0.0000295 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs549332 chr6 116454588 G A 4.72E-04 Type 2 diabetes NT5DC1 intron 17463246 rs7763110 chr6 116456335 G A 0.0000261 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs9481607 chr6 116459190 A G 0.0000316 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs471766 chr6 116461477 T C 7.61E-05 Serum metabolites NT5DC1 intron 19043545 rs9320557 chr6 116462083 A C 0.0000352 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs9481608 chr6 116464568 T C 0.0000262 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs4946138 chr6 116469584 A G 0.0000295 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs958738 chr6 116470561 A G 0.0000298 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs958738 chr6 116470561 A G 4.89E-05 Insulin Resistance NT5DC1 intron pha003062 rs958738 chr6 116470561 A G 5.85E-05 Insulin-related traits NT5DC1 intron pha003063 rs6915372 chr6 116475557 T G 0.0000256 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs4946140 chr6 116477278 C T 0.000033 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs9488853 chr6 116477518 C T 0.0000238 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs6910311 chr6 116478187 C T 0.0000281 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs12525805 chr6 116482947 G A 0.0000213 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs9488857 chr6 116485722 C T 0.0000211 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs7739793 chr6 116488577 G A 0.000022 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs9481609 chr6 116489854 T C 0.0000214 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs9488860 chr6 116495717 G T 0.0000643 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs1546943 chr6 116501503 G A 0.0000179 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs2351141 chr6 116501983 G A 0.0000125 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs1114228 chr6 116502011 T A 0.0000189 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs7758930 chr6 116503168 C T 0.0000194 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs9488865 chr6 116505795 G A 0.0000132 Nonsyndromic striae distensae (stretch marks) NT5DC1 intron 23633020 rs1204797 chr6 116541547 C T 0.00047 Coronary artery calcification NT5DC1 intron 23727086 rs1204798 chr6 116543847 A G 3.10E-04 Suicidal ideation NT5DC1 intron 22030708 rs1204798 chr6 116543847 A G 2.00E-06 Dental caries NT5DC1 intron 23064961 rs1204803 chr6 116546866 G T 1.82E-24 Narcolepsy NT5DC1 intron 19629137 rs149060725 chr6 116574940 C T 0.00036 Prostate cancer TSPYL4 missense 23555315 rs1204853 chr6 116577113 C T 8.54E-04 Type 2 diabetes / / 17463246 rs1045182 chr6 116598475 T C 1.44E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses TSPYL1 UTR-3 17903301 rs3749894 chr6 116600453 C T 2.42E-04 Cholesterol TSPYL1 missense 17255346 rs11965787 chr6 116615608 G C 3.85E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines DSE intron 21844884 rs6568927 chr6 116624402 T A 1.40E-04 Multiple complex diseases DSE intron 17554300 rs4286814 chr6 116627648 A G 1.39E-04 Multiple complex diseases DSE intron 17554300 rs6911873 chr6 116641641 A C 1.71E-04 Multiple complex diseases DSE intron 17554300 rs17077864 chr6 116672939 T G 1.33E-04 Multiple complex diseases DSE intron 17554300 rs7738448 chr6 116676685 G A 3.21E-04 Multiple complex diseases DSE intron 17554300 rs2227125 chr6 116721656 A G 1.21E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) DSE intron 24023788 rs508521 chr6 116747241 A G 5.10E-06 Height DSE intron 18391952 rs479454 chr6 116756667 G A 0.0000785 Narcolepsy (non-HLA narcolepsy) DSE intron 23459209 rs483981 chr6 116763077 T C 6.21E-04 Stroke / / pha002887 rs2858829 chr6 116768917 A G 3.45E-05 Hemoglobin concentration / / 20534544 rs9400918 chr6 116794528 C T 3.90E-05 Hemoglobin concentration / / 20534544 rs9384981 chr6 116803328 T C 2.55E-06 Lymphocyte counts / / 22286170 rs2858846 chr6 116814368 G A 9.69E-05 Femoral neck bone geometry / / 22087292 rs12526587 chr6 116820735 C A 1.40E-06 Urinary metabolites BET3L intron 21572414 rs7775839 chr6 116821146 T C 6.86E-05 Schizophrenia BET3L intron 20832056 rs9400929 chr6 116829323 C T 1.54E-04 Schizophrenia BET3L intron 20832056 rs2250263 chr6 116834007 T C 1.98E-04 Response to taxane treatment (placlitaxel) FAM26E intron 23006423 rs3734309 chr6 116837310 G A 7.98E-05 Schizophrenia FAM26E UTR-3 20832056 rs2064877 chr6 116859771 A G 8.78E-04 Type 2 diabetes FAM26D intron 17463246 rs2064877 chr6 116859771 A G 2.50E-04 Schizophrenia FAM26D intron 20832056 rs2064878 chr6 116859793 T C 1.11E-04 Schizophrenia FAM26D intron 20832056 rs2064878 chr6 116859793 T C 7.28E-04 Response to taxane treatment (placlitaxel) FAM26D intron 23006423 rs9372465 chr6 116861883 G C 2.44E-04 Schizophrenia FAM26D intron 20832056 rs9372465 chr6 116861883 G C 5.25E-04 Response to taxane treatment (placlitaxel) FAM26D intron 23006423 rs17078051 chr6 116866949 A G 1.74E-05 Femoral neck bone geometry FAM26D intron 22087292 rs9374611 chr6 116867514 C T 9.15E-04 Type 2 diabetes FAM26D intron 17463246 rs9374611 chr6 116867514 C T 3.00E-04 Schizophrenia FAM26D intron 20832056 rs6568947 chr6 116871496 C T 2.50E-04 Schizophrenia FAM26D intron 20832056 rs6568947 chr6 116871496 C T 2.80E-04 Response to taxane treatment (placlitaxel) FAM26D intron 23006423 rs6904837 chr6 116883953 C T 2.73E-05 Femoral neck bone geometry / / 22087292 rs980214 chr6 116889576 T G 2.32E-04 Schizophrenia / / 20832056 rs11961321 chr6 116893146 C A 5.52E-05 Femoral neck bone geometry RWDD1 intron 22087292 rs7757158 chr6 116898814 C G 5.21E-05 Femoral neck bone geometry RWDD1 intron 22087292 rs7757967 chr6 116899322 C G 1.53E-04 Schizophrenia RWDD1 intron 20832056 rs4946182 chr6 116903944 G A 6.68E-05 Femoral neck bone geometry RWDD1 intron 22087292 rs9374615 chr6 116937342 C T 5.43E-05 Femoral neck bone geometry RSPH4A nearGene-5 22087292 rs10485188 chr6 116951761 C G 9.38E-06 Odorant perception RSPH4A intron 23910658 rs784136 chr6 116954186 T C 7.45E-04 Response to taxane treatment (placlitaxel) RSPH4A nearGene-3 23006423 rs6568960 chr6 116990510 A G 1.56E-04 Hemoglobin concentration / / 20534544 rs11757332 chr6 117004240 T C 7.67E-05 Femoral neck bone geometry KP/5 intron 22087292 rs1177449 chr6 117016054 G A 5.00E-05 Response to statin therapy KP/5 intron 20339536 rs606242 chr6 117039223 T C 8.00E-05 Response to statin therapy KP/5 intron 20339536 rs598405 chr6 117053071 G A 9.50E-05 Response to statin therapy KP/5 intron 20339536 rs1577759 chr6 117065543 C G 1.76E-04 Schizophrenia / / 20832056 rs654128 chr6 117086378 C A 3.00E-06 Telomere length FAM162B missense 21460395 rs1567700 chr6 117092892 C T 8.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs6901250 chr6 117114025 G A 5.00E-08 C-reactive protein GPRC6A cds-synon 21300955 rs6901250 chr6 117114025 G A 7.95E-04 C-reactive protein GPRC6A cds-synon 23844046 rs140603319 chr6 117128107 A G 0.000095 Prostate cancer GPRC6A missense 23555315 rs2274911 chr6 117130704 G A 0.000013 Prostate cancer GPRC6A missense 23555315 rs2274911 chr6 117130704 G A 0.000041 Prostate cancer (non-advanced prostate cancer) GPRC6A missense 23555315 rs339331 chr6 117210052 T C 2.00E-12 Prostate cancer RFX6 intron 20676098 rs339331 chr6 117210052 T C 0.000021 Prostate cancer RFX6 intron 23555315 rs339331 chr6 117210052 T C 0.00019 Prostate cancer (non-advanced prostate cancer) RFX6 intron 23555315 rs1741662 chr6 117260956 T C 5.90E-05 Lipid traits / / 17903299 rs1741660 chr6 117261069 T C 6.00E-05 Lipid traits / / 17903299 rs17212273 chr6 117300789 T A 2.16E-04 IgE levels / / 17255346 rs1321365 chr6 117301614 C T 4.25E-04 White matter integrity / / 22425255 rs868855 chr6 117328708 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17291964 chr6 117347375 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs573837 chr6 117349993 A C 1.80E-04 White matter integrity / / 22425255 rs9320589 chr6 117350903 T C 4.57E-04 White matter integrity / / 22425255 rs1577245 chr6 117367652 C T 3.42E-04 White matter integrity / / 22425255 rs1577244 chr6 117385009 T C 2.04E-04 White matter integrity / / 22425255 rs1577244 chr6 117385009 T C 7.74E-05 Erythrocyte counts / / pha003101 rs6924937 chr6 117385496 T C 3.79E-04 White matter integrity / / 22425255 rs537350 chr6 117389059 A G 7.46E-05 IgE levels / / 22075330 rs2498924 chr6 117423253 C T 4.08E-04 White matter integrity / / 22425255 rs7749803 chr6 117487485 A C 6.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs998144 chr6 117488896 A G 6.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9400988 chr6 117514510 C A 2.18E-05 IgE levels / / 22075330 rs1526268 chr6 117518518 G C 9.72E-05 IgE levels / / 22075330 rs6904594 chr6 117521371 G C 2.04E-05 IgE levels / / 22075330 rs961764 chr6 117522156 C G 1.00E-11 Height / / 20881960 rs9387453 chr6 117536605 A G 8.27E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9387454 chr6 117536784 C T 2.12E-05 Cognitive decline / / 22054870 rs9372476 chr6 117540701 T C 8.15E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9400992 chr6 117542480 C T 7.74E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9387455 chr6 117543442 A G 7.93E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9385000 chr6 117545367 A G 5.30E-05 Cognitive decline / / 22054870 rs9385000 chr6 117545367 A G 7.94E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9385001 chr6 117546418 T C 7.94E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs954671 chr6 117546518 C T 7.94E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs954670 chr6 117546605 A G 5.03E-05 Cognitive decline / / 22054870 rs954670 chr6 117546605 A G 7.94E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9387456 chr6 117550347 T C 3.57E-05 Cognitive decline / / 22054870 rs783199 chr6 117550594 G A 9.16E-04 Multiple complex diseases / / 17554300 rs441184 chr6 117599632 T G 7.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs1724763 chr6 117603523 A G 3.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs13201929 chr6 117605991 T C 3.00E-06 Myopia (pathological) / / 23049088 rs2778 chr6 117609529 A G 3.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1013528 chr6 117636702 C T 4.31E-04 Taste perception ROS1 intron 22132133 rs501109 chr6 117639620 G T 1.20E-05 Urinary metabolites ROS1 intron 21572414 rs13211635 chr6 117699988 A G 4.20E-06 Urinary metabolites ROS1 intron 21572414 rs13203726 chr6 117721376 A T 1.80E-05 Urinary metabolites ROS1 intron 21572414 rs9385010 chr6 117723640 T C 4.10E-04 Colorectal cancer ROS1 intron 23266556 rs1407179 chr6 117724499 A C 3.44E-04 Colorectal cancer ROS1 intron 23266556 rs2243378 chr6 117725578 T A 3.96E-04 Colorectal cancer ROS1 cds-synon 23266556 rs1321802 chr6 117725912 G C 4.02E-04 Colorectal cancer ROS1 intron 23266556 rs7770923 chr6 117726980 C A 4.04E-04 Colorectal cancer ROS1 intron 23266556 rs7771211 chr6 117727025 G A 4.03E-04 Colorectal cancer ROS1 intron 23266556 rs7772046 chr6 117727485 G A 4.00E-04 Colorectal cancer ROS1 intron 23266556 rs7776244 chr6 117727949 C A 4.06E-04 Colorectal cancer ROS1 intron 23266556 rs765516 chr6 117728118 C T 4.66E-04 Colorectal cancer ROS1 intron 23266556 rs2273602 chr6 117730592 G A 2.71E-04 Colorectal cancer ROS1 intron 23266556 rs17634067 chr6 117730673 G A 1.30E-05 Urinary metabolites ROS1 intron 21572414 rs2273601 chr6 117730819 G A 8.00E-06 QT interval (interaction) ROS1 intron 23459443 rs9372479 chr6 117731107 G C 1.40E-05 Urinary metabolites ROS1 intron 21572414 rs1321799 chr6 117731177 G T 3.67E-04 Colorectal cancer ROS1 intron 23266556 rs1321798 chr6 117731192 A G 3.59E-04 Colorectal cancer ROS1 intron 23266556 rs3798393 chr6 117731968 G C 3.35E-04 Colorectal cancer ROS1 intron 23266556 rs3798394 chr6 117732362 A T 3.31E-04 Colorectal cancer ROS1 intron 23266556 rs9401006 chr6 117732924 T C 3.21E-04 Colorectal cancer ROS1 intron 23266556 rs3777980 chr6 117733973 G T 3.00E-04 Type 2 diabetes and 6 quantitative traits ROS1 intron 17848626 rs9489152 chr6 117734746 G A 1.63E-04 Colorectal cancer ROS1 intron 23266556 rs3777981 chr6 117735255 A C 1.34E-04 Myopia (pathological) ROS1 intron 21095009 rs3777981 chr6 117735255 A C 2.84E-04 Colorectal cancer ROS1 intron 23266556 rs17079156 chr6 117740268 A G 8.40E-06 Urinary metabolites ROS1 intron 21572414 rs9320601 chr6 117744939 T A 3.70E-06 Urinary metabolites ROS1 intron 21572414 rs6913494 chr6 117745663 C T 1.20E-05 Urinary metabolites ROS1 intron 21572414 rs17079163 chr6 117753730 C G 1.50E-05 Urinary metabolites / / 21572414 rs17090953 chr6 117753765 G A 2.30E-05 Urinary metabolites / / 21572414 rs36111427 chr6 117753834 C A 1.30E-05 Urinary metabolites / / 21572414 rs17079166 chr6 117754038 A G 8.50E-06 Urinary metabolites / / 21572414 rs17079171 chr6 117754723 C T 8.40E-06 Urinary metabolites / / 21572414 rs1358849 chr6 117760129 C T 1.00E-05 Urinary metabolites / / 21572414 rs7763010 chr6 117762218 T C 4.50E-04 Multiple complex diseases / / 17554300 rs9489193 chr6 117769728 T C 4.75E-05 Major depressive disorder / / 19107115 rs17635492 chr6 117771277 A T 4.00E-07 non-small cell lung cancer / / 23478653 rs10081005 chr6 117775205 A G 5.80E-06 Urinary metabolites / / 21572414 rs9374662 chr6 117777804 G A 3.54E-04 Colorectal cancer / / 23266556 rs2180811 chr6 117780158 T A 3.19E-04 Colorectal cancer / / 23266556 rs9374663 chr6 117782634 A G 3.03E-04 Colorectal cancer / / 23266556 rs6937083 chr6 117785308 A T 2.73E-04 Colorectal cancer / / 23266556 rs6942067 chr6 117785696 A G 6.02E-05 Body Mass Index / / pha003014 rs9387478 chr6 117786180 C A 4.00E-10 Lung cancer / / 23143601 rs9387478 chr6 117786180 C A 2.75E-04 Colorectal cancer / / 23266556 rs7749229 chr6 117787897 C T 7.38E-05 Major depressive disorder / / 19107115 rs2104064 chr6 117793798 T C 9.23E-06 Major depressive disorder / / 19107115 rs7746536 chr6 117799572 A C 1.06E-05 Major depressive disorder / / 19107115 rs6911915 chr6 117809031 T C 6.27E-05 Colorectal cancer DCBLD1 intron 23266556 rs13195478 chr6 117814437 G A 4.90E-05 Major depressive disorder DCBLD1 intron 19107115 rs4945586 chr6 117815020 T A 3.90E-06 Colorectal cancer DCBLD1 intron 23266556 rs17574179 chr6 117815859 A G 5.84E-04 Type 2 diabetes DCBLD1 intron 17463246 rs9320604 chr6 117816045 G A 3.92E-06 Colorectal cancer DCBLD1 intron 23266556 rs4946259 chr6 117816093 A G 1.41E-05 Colorectal cancer DCBLD1 intron 23266556 rs9481728 chr6 117817165 C T 4.06E-06 Colorectal cancer DCBLD1 intron 23266556 rs929057 chr6 117818911 T A 3.41E-06 Colorectal cancer DCBLD1 intron 23266556 rs2057314 chr6 117819357 A G 3.00E-06 Colorectal cancer DCBLD1 intron 23266556 rs4946260 chr6 117822993 C T 3.44E-06 Colorectal cancer DCBLD1 intron 23266556 rs10782186 chr6 117823508 T C 3.53E-06 Colorectal cancer DCBLD1 intron 23266556 rs1015130 chr6 117827493 C T 1.86E-04 Suicide attempts in bipolar disorder DCBLD1 intron 21423239 rs9688605 chr6 117831565 G A 9.05E-04 Heart Failure DCBLD1 intron pha002885 rs210648 chr6 117844072 A G 2.00E-06 Economic and political preferences DCBLD1 intron 22566634 rs3756894 chr6 117857488 T G 7.40E-05 Hypothyroidism DCBLD1 intron 22493691 rs9285425 chr6 117871836 G A 2.00E-08 Height DCBLD1 intron 23563607 rs916305 chr6 117879695 C T 1.28E-05 Alopecia areata DCBLD1 intron 22027810 rs12194183 chr6 117885959 C T 1.47E-05 Major depressive disorder GOPC intron 19107115 rs13211542 chr6 117994158 G A 1.63E-05 Major depressive disorder / / 19107115 rs41441047 chr6 118040684 T C 5.82E-04 Multiple complex diseases / / 17554300 rs509931 chr6 118098501 A G 4.33E-04 Acute lung injury / / 22295056 rs11755280 chr6 118117246 T C 9.09E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs6903494 chr6 118117602 A G 1.70E-05 Urinary metabolites / / 21572414 rs495662 chr6 118124150 G A 3.05E-16 Crohn's disease / / 18587394 rs1016083 chr6 118249495 A G 2.86E-04 Alzheimer's disease (late onset) SLC35F1 intron 21379329 rs9489288 chr6 118271405 C T 1.16E-06 Alzheimer's disease (late onset) SLC35F1 intron 21379329 rs1416412 chr6 118282848 C T 5.40E-06 Urinary metabolites SLC35F1 intron 21572414 rs17821187 chr6 118283331 C T 4.79E-04 Multiple complex diseases SLC35F1 intron 17554300 rs1416413 chr6 118286180 T C 9.70E-06 Urinary metabolites SLC35F1 intron 21572414 rs4373391 chr6 118341151 A G 2.50E-05 Urinary metabolites SLC35F1 intron 21572414 rs9398476 chr6 118343350 C T 1.20E-05 Urinary metabolites SLC35F1 intron 21572414 rs4332012 chr6 118366945 C T 7.10E-04 Tourette syndrome SLC35F1 intron 22889924 rs9320634 chr6 118368339 C T 1.40E-05 Urinary metabolites SLC35F1 intron 21572414 rs11153718 chr6 118372057 G A 1.10E-05 Urinary metabolites SLC35F1 intron 21572414 rs9374715 chr6 118415013 G T 9.85E-05 Heart Rate SLC35F1 intron pha003053 rs9374715 chr6 118415013 G T 1.55E-06 Heart Rate SLC35F1 intron pha003054 rs11153721 chr6 118424187 C T 4.19E-04 Smoking initiation SLC35F1 intron 24665060 rs12203615 chr6 118438261 C T 6.45E-04 Multiple complex diseases SLC35F1 intron 17554300 rs9320642 chr6 118439555 A G 1.03E-04 Type 2 diabetes SLC35F1 intron 17463246 rs2883773 chr6 118439794 T C 8.11E-05 Multiple complex diseases SLC35F1 intron 17554300 rs953412 chr6 118440018 A G 4.77E-04 Multiple complex diseases SLC35F1 intron 17554300 rs4479972 chr6 118444712 T C 1.34E-04 Multiple complex diseases SLC35F1 intron 17554300 rs1334834 chr6 118444863 C T 1.59E-04 Multiple complex diseases SLC35F1 intron 17554300 rs1334839 chr6 118446510 C T 1.33E-04 Multiple complex diseases SLC35F1 intron 17554300 rs1334840 chr6 118446571 T C 2.49E-04 Multiple complex diseases SLC35F1 intron 17554300 rs7743666 chr6 118447183 A C 1.55E-04 Multiple complex diseases SLC35F1 intron 17554300 rs4512262 chr6 118447326 T G 1.44E-04 Multiple complex diseases SLC35F1 intron 17554300 rs12110370 chr6 118455669 G T 1.65E-04 Multiple complex diseases SLC35F1 intron 17554300 rs10484290 chr6 118455740 A G 1.62E-04 Multiple complex diseases SLC35F1 intron 17554300 rs977793 chr6 118473766 C G 1.28E-04 Multiple complex diseases SLC35F1 intron 17554300 rs205966 chr6 118475798 G A 9.09E-04 Multiple complex diseases SLC35F1 intron 17554300 rs205966 chr6 118475798 G A 7.61E-04 Smoking initiation SLC35F1 intron 24665060 rs205959 chr6 118480795 T C 1.03E-04 Smoking initiation SLC35F1 intron 24665060 rs763098 chr6 118481215 G A 6.74E-04 Type 2 diabetes SLC35F1 intron 17463246 rs743928 chr6 118481811 C T 4.60E-04 Type 2 diabetes SLC35F1 intron 17463246 rs1894612 chr6 118482161 T C 8.92E-04 Type 2 diabetes SLC35F1 intron 17463246 rs11970553 chr6 118485317 G A 2.87E-05 Personality dimensions SLC35F1 intron 22628180 rs205946 chr6 118494825 A G 6.15E-04 Type 2 diabetes SLC35F1 intron 17463246 rs205945 chr6 118496349 A G 1.13E-04 Type 2 diabetes SLC35F1 intron 17463246 rs172239 chr6 118496388 A G 2.69E-05 Type 2 diabetes SLC35F1 intron 17463246 rs172239 chr6 118496388 A G 1.29E-04 Multiple complex diseases SLC35F1 intron 17554300 rs205941 chr6 118504523 G A 9.78E-05 Type 2 diabetes SLC35F1 intron 17463246 rs205940 chr6 118505635 C A 2.04E-04 Type 2 diabetes SLC35F1 intron 17463246 rs205939 chr6 118505752 A G 9.09E-05 Type 2 diabetes SLC35F1 intron 17463246 rs205928 chr6 118516498 A G 1.09E-04 Type 2 diabetes SLC35F1 intron 17463246 rs205924 chr6 118525699 C T 8.83E-04 Obesity (extreme) SLC35F1 intron 21935397 rs1413845 chr6 118528018 C T 9.39E-04 Heart Failure SLC35F1 intron pha002885 rs7768436 chr6 118541407 T C 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer SLC35F1 intron 21245432 rs2184365 chr6 118546256 G A 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer SLC35F1 intron 21245432 rs281868 chr6 118574061 G A 4.00E-10 Resting heart rate SLC35F1 intron 20639392 rs89107 chr6 118578043 G A 1.00E-09 Cardiac structure and function SLC35F1 intron 19584346 rs166881 chr6 118618981 T C 4.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients SLC35F1 intron 23400010 rs12210810 chr6 118653204 G C 2.00E-17 QT interval / / 19305409 rs11153730 chr6 118667522 T C 2.00E-29 QT interval / / 19587794 rs11153730 chr6 118667522 T C 1.00E-18 Ventricular conduction / / 21076409 rs11153730 chr6 118667522 T C 1.26E-18 QRS duration / / 23583979 rs11153730 chr6 118667522 T C 2.23E-67 QT duration / / 23583979 rs11153730 chr6 118667522 T C 5.19E-04 Atrial fibrillation / / 23583979 rs11153730 chr6 118667522 T C 8.00E-21 Heart rate / / 23583979 rs11970286 chr6 118680374 C T 2.00E-24 QT interval / / 19305409 rs11970286 chr6 118680374 C T 8.00E-07 Electrocardiographic traits / / 20062063 rs11970286 chr6 118680374 C T 2.20E-05 Personality dimensions / / 22628180 rs9320649 chr6 118693665 G A 6.61E-04 Multiple complex diseases / / 17554300 rs17226667 chr6 118721628 A G 1.97E-05 Personality dimensions / / 22628180 rs17226667 chr6 118721628 A G 4.33E-06 QT interval / / 23166209 rs17227124 chr6 118741382 T C 2.23E-05 Personality dimensions / / 22628180 rs17825393 chr6 118772583 T C 2.17E-05 Personality dimensions / / 22628180 rs17825393 chr6 118772583 T C 1.99E-06 QT interval / / 23166209 rs11752626 chr6 118788652 G T 2.32E-05 Personality dimensions CEP85L intron 22628180 rs11752626 chr6 118788652 G T 2.00E-06 QT interval CEP85L intron 23166209 rs12661338 chr6 118794690 C A 2.40E-05 Personality dimensions CEP85L intron 22628180 rs12661338 chr6 118794690 C A 3.99E-06 QT interval CEP85L intron 23166209 rs25422 chr6 118807847 C T 5.00E-06 Renal cell carcinoma CEP85L intron 22010048 rs4307206 chr6 118813320 C A 3.34E-06 QT interval CEP85L intron 23166209 rs11968176 chr6 118900940 C A 2.68E-05 Personality dimensions CEP85L intron 22628180 rs11968176 chr6 118900940 C A 3.92E-06 QT interval CEP85L intron 23166209 rs11968176 chr6 118900940 C A 1.35E-11 Heart rate CEP85L intron 23583979 rs9489468 chr6 118935682 A C 4.89E-04 Alzheimer's disease CEP85L intron 17998437 rs2356502 chr6 118945007 G A 9.72E-04 Multiple complex diseases CEP85L intron 17554300 rs6906287 chr6 118962740 T C 2.92E-05 Personality dimensions CEP85L intron 22628180 rs6906287 chr6 118962740 T C 6.00E-16 Electrocardiographic conduction measures CEP85L intron 23463857 rs9481842 chr6 118974798 T G 3.93E-04 Myopia (pathological) CEP85L intron 21095009 rs4945623 chr6 118980556 G C 1.86E-05 Personality dimensions CEP85L intron 22628180 rs11153768 chr6 118988152 C T 1.51E-05 Personality dimensions CEP85L intron 22628180 rs10872167 chr6 118988362 A G 1.76E-05 Personality dimensions CEP85L intron 22628180 rs11756438 chr6 118993632 C A 5.00E-22 QT interval CEP85L intron 19305408 rs1771754 chr6 119025257 G A 1.94E-05 Myopia (pathological) CEP85L intron 21095009 rs1688609 chr6 119035141 G T 2.45E-05 Parkinson's disease / / 21738487 rs1417613 chr6 119065289 C A 3.18E-04 Lymphocyte counts / / 22286170 rs11751221 chr6 119071671 T C 7.70E-06 Urinary metabolites / / 21572414 rs11968468 chr6 119071713 G A 2.00E-04 Body mass index / / 24827717 rs67456868 chr6 119079800 G A 0.0000307 Carotid intima media thickness / / 23152477 rs9489520 chr6 119080379 G A 3.20E-05 Kawasaki disease / / 22081228 rs7742473 chr6 119101740 G A 1.90E-05 Anger / / 24489884 rs9374751 chr6 119104706 T C 7.33E-06 Multiple complex diseases / / 17554300 rs902780 chr6 119108363 T C 3.68E-05 Kawasaki disease / / 22081228 rs12210027 chr6 119122746 T C 7.45E-05 Parkinson's disease / / 21738487 rs988098 chr6 119240226 A G 9.96E-04 Suicide attempts in bipolar disorder MCM9 intron 21423239 rs7381535 chr6 119262275 A G 3.49E-04 Multiple complex diseases / / 17554300 rs41292558 chr6 119297143 T A 0.00012 Breast cancer FAM184A missense 23555315 rs794266 chr6 119320313 A G 2.49E-04 Lung function (forced expiratory volume in 1 second) FAM184A intron 24023788 rs794266 chr6 119320313 A G 2.18E-05 Neutrophil count FAM184A intron pha003095 rs3822955 chr6 119326375 T C 7.25E-05 Fibrinogen FAM184A intron pha003068 rs1889561 chr6 119335865 A G 8.93E-05 Kawasaki disease FAM184A intron 22081228 rs6929403 chr6 119346912 G A 8.30E-05 Kawasaki disease FAM184A intron 22081228 rs954753 chr6 119363976 C T 6.30E-04 Multiple complex diseases FAM184A intron 17554300 rs192266016 chr6 119399385 G T 0.000062 Breast cancer FAM184A missense 23555315 rs192266016 chr6 119399385 G T 0.000089 Breast cancer(er negative) FAM184A missense 23555315 rs1535613 chr6 119421422 A C 7.28E-05 Fibrinogen FAM184A intron pha003068 rs4946395 chr6 119425969 C T 7.92E-05 Fibrinogen FAM184A intron pha003068 rs1360782 chr6 119434014 A G 4.81E-05 Fibrinogen FAM184A intron pha003068 rs706981 chr6 119451332 A G 4.32E-04 Depression (quantitative trait) FAM184A intron 20800221 rs10457349 chr6 119455554 A C 3.99E-04 Depression (quantitative trait) FAM184A intron 20800221 rs9385067 chr6 119460747 G A 3.30E-04 Depression (quantitative trait) FAM184A intron 20800221 rs9385067 chr6 119460747 G A 6.53E-05 Smoking quantity FAM184A intron 24665060 rs9387636 chr6 119462950 C A 3.12E-04 Depression (quantitative trait) FAM184A intron 20800221 rs706983 chr6 119463018 T C 3.21E-04 Depression (quantitative trait) FAM184A intron 20800221 rs9401129 chr6 119463757 G A 3.03E-04 Depression (quantitative trait) FAM184A intron 20800221 rs6934752 chr6 119465611 C G 7.99E-04 Depression (quantitative trait) FAM184A intron 20800221 rs7775389 chr6 119466590 G A 7.95E-04 Depression (quantitative trait) FAM184A intron 20800221 rs9387637 chr6 119466737 G A 8.07E-04 Depression (quantitative trait) FAM184A intron 20800221 rs9398502 chr6 119467331 C T 9.07E-04 Depression (quantitative trait) FAM184A intron 20800221 rs6928078 chr6 119468457 T G 5.10E-04 Depression (quantitative trait) FAM184A intron 20800221 rs11153794 chr6 119508989 G A 4.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAN1A1 intron 20877124 rs1008472 chr6 119509969 T C 4.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAN1A1 intron 20877124 rs3798603 chr6 119517239 T C 4.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAN1A1 intron 20877124 rs4590306 chr6 119517983 G A 8.32E-05 Basophils MAN1A1 intron pha003087 rs970181 chr6 119527394 T C 4.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAN1A1 intron 20877124 rs17514051 chr6 119534744 G A 7.78E-05 Alzheimer's disease MAN1A1 intron 21098978 rs7770777 chr6 119552205 T C 7.40E-05 Alzheimer's disease MAN1A1 intron 21098978 rs9481892 chr6 119554934 C G 4.68E-04 Multiple complex diseases MAN1A1 intron 17554300 rs12198667 chr6 119564160 A G 7.39E-05 Alzheimer's disease MAN1A1 intron 21098978 rs7753492 chr6 119565043 A G 7.39E-05 Alzheimer's disease MAN1A1 intron 21098978 rs12192420 chr6 119565900 A T 7.18E-05 Alzheimer's disease MAN1A1 intron 21098978 rs17080911 chr6 119570101 C A 3.48E-04 Alcohol dependence MAN1A1 intron 20201924 rs11751945 chr6 119573081 C T 6.75E-05 Alzheimer's disease MAN1A1 intron 21098978 rs7740993 chr6 119575001 G T 6.58E-05 Alzheimer's disease MAN1A1 intron 21098978 rs11153800 chr6 119580818 G A 4.40E-05 Alzheimer's disease MAN1A1 intron 21098978 rs12205826 chr6 119586804 T C 4.58E-05 Alzheimer's disease MAN1A1 intron 21098978 rs11153803 chr6 119590869 T C 5.28E-05 Alzheimer's disease MAN1A1 intron 21098978 rs11962211 chr6 119591307 A C 3.83E-04 Lung function (forced expiratory volume in 1 second) MAN1A1 intron 24023788 rs1005506 chr6 119600556 T C 1.50E-05 Glucose levels MAN1A1 intron pha003061 rs11153805 chr6 119611660 G C 5.16E-05 Alzheimer's disease MAN1A1 intron 21098978 rs1022869 chr6 119614081 T G 5.13E-05 Alzheimer's disease MAN1A1 intron 21098978 rs7760582 chr6 119617357 G A 5.07E-05 Alzheimer's disease MAN1A1 intron 21098978 rs6909928 chr6 119618207 T C 5.05E-05 Alzheimer's disease MAN1A1 intron 21098978 rs7743824 chr6 119621227 G A 5.00E-05 Alzheimer's disease MAN1A1 intron 21098978 rs10457352 chr6 119624058 C T 4.76E-05 Alzheimer's disease MAN1A1 intron 21098978 rs11153808 chr6 119626054 C T 4.69E-05 Alzheimer's disease MAN1A1 intron 21098978 rs10457353 chr6 119626357 C T 4.67E-05 Alzheimer's disease MAN1A1 intron 21098978 rs11759899 chr6 119629116 A C,G,T 4.63E-05 Alzheimer's disease MAN1A1 intron 21098978 rs6913654 chr6 119631176 T C 4.62E-05 Alzheimer's disease MAN1A1 intron 21098978 rs3778107 chr6 119633534 T C 6.10E-04 Multiple complex diseases MAN1A1 intron 17554300 rs10485001 chr6 119633625 T C 4.64E-05 Alzheimer's disease MAN1A1 intron 21098978 rs7767198 chr6 119634189 T G 4.68E-05 Alzheimer's disease MAN1A1 intron 21098978 rs12205260 chr6 119635739 G A 4.71E-05 Alzheimer's disease MAN1A1 intron 21098978 rs10456921 chr6 119637327 T C 4.77E-05 Alzheimer's disease MAN1A1 intron 21098978 rs11153812 chr6 119638232 T C 4.82E-05 Alzheimer's disease MAN1A1 intron 21098978 rs3798642 chr6 119640006 C T 4.46E-05 Multiple complex diseases MAN1A1 intron 17554300 rs11962938 chr6 119641060 T G 5.02E-05 Alzheimer's disease MAN1A1 intron 21098978 rs10872177 chr6 119642700 C T 5.04E-05 Alzheimer's disease MAN1A1 intron 21098978 rs195077 chr6 119655145 A C 4.00E-05 Glucose levels MAN1A1 intron pha003061 rs195078 chr6 119656946 G T 2.60E-04 Lung function (forced expiratory volume in 1 second) MAN1A1 intron 24023788 rs195079 chr6 119657640 C T 9.66E-04 Multiple complex diseases MAN1A1 intron 17554300 rs7765368 chr6 119678456 A G 5.11E-05 Schizophrenia / / 19571811 rs1295378 chr6 119685952 T C 2.52E-06 Asthma (childhood onset) / / 23829686 rs6920832 chr6 119689056 A C 4.91E-05 Alzheimer's disease / / 21098978 rs9489697 chr6 119699524 C T 5.66E-05 Alzheimer's disease / / 21098978 rs9372528 chr6 119704829 C T 3.39E-06 Glucose levels / / pha003061 rs6936790 chr6 119707418 A G 5.10E-05 Alzheimer's disease / / 21098978 rs6569076 chr6 119710290 A G 5.13E-05 Alzheimer's disease / / 21098978 rs9372532 chr6 119729710 T C 5.32E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs6904915 chr6 119738748 G A 5.62E-05 Alzheimer's disease / / 21098978 rs12527248 chr6 119747598 A G,T 5.73E-05 Alzheimer's disease / / 21098978 rs9372535 chr6 119748232 A G 1.81E-05 Serum metabolites / / 19043545 rs9401144 chr6 119748259 G A 2.05E-05 Serum metabolites / / 19043545 rs6925366 chr6 119750921 T C 4.38E-06 Glucose levels / / pha003061 rs6903310 chr6 119751316 A T 2.05E-05 Serum metabolites / / 19043545 rs2036257 chr6 119759401 G C 5.78E-05 Alzheimer's disease / / 21098978 rs9320690 chr6 119770906 G A 9.42E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10485003 chr6 119772946 A G 8.25E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10485006 chr6 119841070 T C 3.68E-04 Gallstones / / 17632509 rs17081391 chr6 119856817 C G 6.11E-04 Aortic root size / / 21223598 rs1392089 chr6 119866141 C T 4.00E-07 Immune reponse to smallpox (secreted IL-2) / / 22610502 rs6905827 chr6 119885481 T C 1.59E-05 Serum metabolites / / 19043545 rs12206925 chr6 119915150 G T 1.42E-05 Serum metabolites / / 19043545 rs807301 chr6 119928007 G A 2.40E-05 Multiple complex diseases / / 17554300 rs9398517 chr6 119930915 C G 1.50E-05 Urinary metabolites / / 21572414 rs9374809 chr6 119935496 G T 2.80E-05 Urinary metabolites / / 21572414 rs12212125 chr6 119946363 A G 8.53E-05 Cognitive impairment induced by topiramate / / 22091778 rs9489766 chr6 119998300 A G 8.78E-04 Multiple complex diseases / / 17554300 rs1341499 chr6 120015713 C T 6.36E-04 Multiple complex diseases / / 17554300 rs17081552 chr6 120017860 T C 8.89E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9489789 chr6 120055590 G A 8.40E-05 Smoking initiation / / 24665060 rs991356 chr6 120060051 A G 7.89E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9387681 chr6 120090415 G A 6.45E-04 Multiple complex diseases / / 17554300 rs4945648 chr6 120093867 A G 4.10E-05 Cognitive function / / 24684796 rs9372555 chr6 120111018 G T 9.40E-04 Multiple complex diseases / / 17554300 rs7752256 chr6 120142415 G A 8.63E-04 Body mass index / / 21701565 rs1994705 chr6 120153021 A G 5.58E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9401181 chr6 120155531 A G 8.56E-04 Body mass index / / 21701565 rs1330106 chr6 120165475 G A 2.95E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17630332 chr6 120174236 A T 5.14E-04 Body mass index / / 21701565 rs17630332 chr6 120174236 A T 8.23E-04 Body mass index / / 21701565 rs952213 chr6 120183578 C T 9.53E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1330108 chr6 120186039 T C 9.77E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7768469 chr6 120189416 T C 1.17E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17636773 chr6 120207151 G A 7.50E-05 Diabetes Mellitus / / pha003059 rs7773714 chr6 120278071 T A 9.63E-05 Serum metabolites / / 19043545 rs9401193 chr6 120284989 A C 3.23E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs9385104 chr6 120297444 G A 4.10E-06 Urinary metabolites / / 21572414 rs9320730 chr6 120312329 G T 2.19E-04 Breast cancer / / pha002853 rs1474780 chr6 120314863 T C 4.80E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs9320733 chr6 120323950 C T 6.00E-06 Urinary metabolites / / 21572414 rs4945655 chr6 120325575 G C 9.80E-06 Urinary metabolites / / 21572414 rs7758591 chr6 120336680 C T 7.36E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs6569099 chr6 120359702 T C 6.70E-06 Urinary metabolites / / 21572414 rs6569100 chr6 120359826 A T 1.36E-05 Serum metabolites / / 19043545 rs12661222 chr6 120452629 A G 8.88E-04 Alcohol dependence / / 20201924 rs262467 chr6 120455770 T C 6.39E-05 Cardiovascular disease / / 17903304 rs17081960 chr6 120484779 C T 4.25E-05 Alcohol dependence / / 20201924 rs17081960 chr6 120484779 C T 4.25E-05 Alcoholism / / pha002891 rs2357856 chr6 120485128 T G 1.78E-04 Multiple complex diseases / / 17554300 rs155155 chr6 120490336 A G 8.32E-05 Alcohol dependence / / 20201924 rs155155 chr6 120490336 A G 8.32E-05 Alcoholism / / pha002891 rs155162 chr6 120509191 T C 0.000206278 Hypertension (early onset hypertension) / / 22479346 rs155176 chr6 120535310 T C 3.73E-04 Multiple complex diseases / / 17554300 rs10499097 chr6 120539013 G A 9.83E-04 Diabetic retinopathy / / 20871662 rs9385117 chr6 120548834 A G 2.20E-06 Urinary metabolites / / 21572414 rs9372588 chr6 120598458 C G 3.34E-04 Multiple complex diseases / / 17554300 rs9489928 chr6 120606358 T C 5.89E-04 Type 2 diabetes / / 17463246 rs3013685 chr6 120644266 C T 2.23E-04 Multiple complex diseases / / 17554300 rs3013688 chr6 120645686 C G 2.14E-04 Multiple complex diseases / / 17554300 rs2927899 chr6 120645789 T C 3.90E-04 Multiple complex diseases / / 17554300 rs3013689 chr6 120645859 C T 2.77E-04 Multiple complex diseases / / 17554300 rs1486210 chr6 120670086 C T 9.60E-06 Urinary metabolites / / 21572414 rs3013713 chr6 120694559 G A 2.13E-04 Multiple complex diseases / / 17554300 rs7755882 chr6 120719882 G A 2.20E-05 Urinary metabolites / / 21572414 rs12204585 chr6 120726829 G T 5.22E-04 Multiple complex diseases / / 17554300 rs1385964 chr6 120735220 T C 1.95E-04 Mammographic density / / 22532574 rs4946483 chr6 120750709 T C 1.57E-05 Glaucoma (primary open-angle) / / 22605921 rs12660882 chr6 120775626 G A 1.13E-04 Multiple complex diseases / / 17554300 rs9489963 chr6 120790347 C T 4.59E-04 Mammographic density / / 22532574 rs1486200 chr6 120795089 C T 3.20E-04 Multiple complex diseases / / 17554300 rs9387798 chr6 120803246 G A 3.50E-04 Multiple complex diseases / / 17554300 rs1385966 chr6 120808032 C T 0.0003979 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1385966 chr6 120808032 C T 3.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6569128 chr6 120809500 T C 0.0001155 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6569128 chr6 120809500 T C 1.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7740004 chr6 120856203 T A 0.00000787 Bisphosphonate-induced osteonecrosis of the jaw / / 22267851 rs4543410 chr6 120859841 T C 4.64E-04 Multiple complex diseases / / 17554300 rs9482055 chr6 120892849 G A 7.36E-05 Major depressive disorder / / 19107115 rs1203070 chr6 120908695 G C 2.80E-05 Urinary metabolites / / 21572414 rs1933830 chr6 120908719 C T 8.00E-06 Urinary metabolites / / 21572414 rs7764151 chr6 120910362 C T 0.0007731 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7764151 chr6 120910362 C T 7.73E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs962312 chr6 120911731 A G 8.72E-05 Major depressive disorder / / 19107115 rs1203087 chr6 120929891 G A 0.0007954 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1203087 chr6 120929891 G A 7.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1203045 chr6 120941838 C T 2.50E-05 Urinary metabolites / / 21572414 rs7741833 chr6 121001047 A G 6.61E-06 Alcohol consumption / / pha001397 rs6929429 chr6 121028535 G A 7.46E-04 Multiple complex diseases / / 17554300 rs12215672 chr6 121056932 C T 5.01E-04 Multiple complex diseases / / 17554300 rs12194792 chr6 121084577 C T 1.24E-04 Premature ovarian failure / / 19508998 rs2817939 chr6 121087489 T C 8.66E-04 Premature ovarian failure / / 19508998 rs2817939 chr6 121087489 T C 5.66E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2817937 chr6 121098457 C T 3.00E-06 Primary tooth development (number of teeth) / / 20195514 rs2789066 chr6 121100137 G A 9.00E-06 HIV-1 viral setpoint / / 20205591 rs9387891 chr6 121100366 G T 1.45E-04 Multiple complex diseases / / 17554300 rs2789034 chr6 121172873 G A 7.97E-04 Multiple complex diseases / / 17554300 rs17699863 chr6 121175001 A G 2.80E-05 Urinary metabolites / / 21572414 rs2789052 chr6 121196068 A G 6.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10499100 chr6 121208345 T C 3.40E-05 Amyotrophic lateral sclerosis / / 17671248 rs4629724 chr6 121208892 T G 1.10E-05 Amyotrophic lateral sclerosis / / 17671248 rs9490068 chr6 121226570 G A 1.40E-05 Urinary metabolites / / 21572414 rs7760976 chr6 121258316 G A 7.24E-06 Cognitive test performance / / 20125193 rs1474015 chr6 121314717 C A 8.33E-04 Body mass index / / 21701565 rs1343075 chr6 121339179 A G 2.00E-06 Cognitive performance / / 20125193 rs6940566 chr6 121360996 C T 0.0007405 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6940566 chr6 121360996 C T 7.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs218862 chr6 121384062 C T 1.81E-04 Smoking initiation / / 24665060 rs218867 chr6 121398535 T C 4.21E-04 Smoking initiation / / 24665060 rs9401367 chr6 121404112 C T 3.58E-04 Suicide attempts in bipolar disorder C6orf170 intron 21041247 rs13199297 chr6 121436070 A G 5.90E-04 HIV-1 viral setpoint C6orf170 intron 17641165 rs12206641 chr6 121439560 T G 8.31E-04 HIV-1 viral setpoint C6orf170 intron 17641165 rs9401370 chr6 121453970 A T 3.07E-04 Suicide attempts in bipolar disorder C6orf170 intron 21041247 rs9375002 chr6 121456893 C A 3.08E-04 Suicide attempts in bipolar disorder C6orf170 intron 21041247 rs1273745 chr6 121465011 G C 3.52E-05 Smoking cessation C6orf170 intron 18519826 rs1273746 chr6 121465217 T C 9.98E-05 Smoking cessation C6orf170 intron 18519826 rs811484 chr6 121499580 G A 1.97E-04 Response to cytidine analogues (gemcitabine) C6orf170 intron 24483146 rs813068 chr6 121519579 G A 2.35E-04 Response to cytidine analogues (gemcitabine) C6orf170 intron 24483146 rs6926502 chr6 121524231 A G 4.58E-04 Smoking initiation C6orf170 intron 24665060 rs6569179 chr6 121530912 T C 2.39E-04 Response to cytidine analogues (gemcitabine) C6orf170 intron 24483146 rs9490138 chr6 121532376 C T 8.34E-04 Suicide attempts in bipolar disorder C6orf170 intron 21041247 rs12717175 chr6 121535031 C T 7.85E-05 Smoking cessation C6orf170 intron 18519826 rs4527742 chr6 121562084 A G 2.39E-04 Response to cytidine analogues (gemcitabine) C6orf170 intron 24483146 rs7452947 chr6 121584370 A C 6.87E-05 Lung function (forced expiratory volume in 1 second) C6orf170 intron 24023788 rs7452947 chr6 121584370 A C 5.76E-04 Response to cytidine analogues (gemcitabine) C6orf170 intron 24483146 rs4585603 chr6 121600538 A G 2.39E-04 Response to cytidine analogues (gemcitabine) C6orf170 intron 24483146 rs4245508 chr6 121601627 A G 2.97E-04 Response to cytidine analogues (gemcitabine) C6orf170 intron 24483146 rs6933489 chr6 121613541 A G 2.39E-04 Response to cytidine analogues (gemcitabine) C6orf170 intron 24483146 rs6569194 chr6 121619157 G A 2.39E-04 Response to cytidine analogues (gemcitabine) C6orf170 intron 24483146 rs9320803 chr6 121625087 C T 6.62E-04 Suicide attempts in bipolar disorder C6orf170 intron 21041247 rs10499105 chr6 121625832 T C 2.39E-04 Response to cytidine analogues (gemcitabine) C6orf170 intron 24483146 rs10499109 chr6 121637802 C T 4.64E-04 HIV-1 viral setpoint C6orf170 intron 17641165 rs17083420 chr6 121641574 T C 3.07E-14 Multiple complex diseases C6orf170 intron 17554300 rs9320808 chr6 121654596 A G 0.0000334 HIV-1 infection (natural long-term nonprogression) C6orf170 intron 22238471 rs9320809 chr6 121656844 A G 6.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs9398632 chr6 121661170 A C 6.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs1555772 chr6 121710583 A G 4.37E-05 Coronary heart disease / / pha003032 rs17083533 chr6 121730722 G A 1.00E-08 Heart rate / / 23583979 rs11154022 chr6 121748542 A G 7.00E-08 Resting heart rate / / 20639392 rs3805787 chr6 121758907 A G 9.68E-05 Relative hand skill GJA1 intron 24068947 rs3805787 chr6 121758907 A G 1.15E-04 Smoking initiation GJA1 intron 24665060 rs11961755 chr6 121766286 G A 3.00E-06 Asthma GJA1 intron 21790008 rs7753979 chr6 121774402 T C 6.55E-05 Attention deficit hyperactivity disorder / / 23728934 rs11154027 chr6 121781390 T C 7.00E-12 Heart rate / / 23583979 rs9490291 chr6 121796952 A G 2.19E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1408277 chr6 121811989 G A 2.00E-04 Information processing speed / / 21130836 rs9490306 chr6 121816879 C A 3.00E-07 Migraine without aura / / 23793025 rs9490306 chr6 121816879 C A 6.27E-05 Migraine - clinic-based / / 23793025 rs9490306 chr6 121816879 C A 7.00E-06 Migraine / / 23793025 rs6901013 chr6 121817075 T G 9.65E-05 Information processing speed / / 21130836 rs12201990 chr6 121817108 C T 1.59E-04 Smoking initiation / / 24665060 rs10499113 chr6 121836595 G C 3.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs9385199 chr6 121837314 A G 3.65E-04 Coronary heart disease / / 21606135 rs4541776 chr6 121902869 G A 2.00E-06 Protein quantitative trait loci / / 18464913 rs9490327 chr6 121903970 T C 4.79E-06 Bipolar disorder / / 19488044 rs9490327 chr6 121903970 T C 2.09E-06 Bipolar Disorder / / pha002863 rs11759649 chr6 121932660 T C 5.10E-04 Schizophrenia / / 19197363 rs10872226 chr6 121986316 T C 1.89E-05 Schizophrenia / / 19197363 rs11757506 chr6 122008684 G A 1.68E-04 Schizophrenia / / 19197363 rs9320841 chr6 122114451 A G 5.00E-15 Resting heart rate / / 23183192 rs2040424 chr6 122125094 T C 5.08E-04 Schizophrenia / / 19197363 rs2040424 chr6 122125094 T C 2.79E-04 Coronary heart disease / / 21606135 rs1015451 chr6 122131485 T C 1.00E-33 Heart rate / / 23583979 rs1015451 chr6 122131485 T C 1.58E-04 Atrial fibrillation / / 23583979 rs1015451 chr6 122131485 T C 6.51E-04 QRS duration / / 23583979 rs13219211 chr6 122136209 A G 8.20E-04 Schizophrenia / / 19197363 rs9398652 chr6 122146034 C A 4.00E-15 Resting heart rate / / 20639392 rs2269583 chr6 122157634 C T 4.60E-04 Type 2 diabetes / / 17463246 rs12110693 chr6 122158270 G A 2.00E-09 Biomedical quantitative traits / / 19396169 rs17083872 chr6 122165277 C T 7.29E-04 Multiple complex diseases / / 17554300 rs6916952 chr6 122224659 G A 7.95E-04 Type 2 diabetes / / 17463246 rs9398656 chr6 122238983 T A 2.23E-04 Type 2 diabetes / / 17463246 rs2679663 chr6 122300508 T C 2.40E-05 Urinary metabolites / / 21572414 rs2679684 chr6 122305408 G A 2.50E-05 Urinary metabolites / / 21572414 rs7738084 chr6 122405096 A G 7.43E-04 Multiple complex diseases / / 17554300 rs1474967 chr6 122607310 A G 1.83E-04 Amyotrophic lateral sclerosis / / 20801718 rs502071 chr6 122739062 T G 7.68E-06 Liver disease in chronic hepatitis B virus infection HSF2 intron 24065354 rs197686 chr6 122878720 T G 2.68E-04 Lung function (forced vital capacity) PKIB intron 24023788 rs1430816 chr6 122913123 G A 9.60E-05 Orofacial clefts PKIB intron 22419666 rs4554346 chr6 122918372 G A 3.25E-04 Alzheimer's disease (late onset) PKIB intron 21379329 rs13191198 chr6 122927060 A G 5.30E-06 Urinary metabolites PKIB intron 21572414 rs9398679 chr6 122941551 C T 4.39E-05 Lipoproteins PKIB intron pha003079 rs11154102 chr6 122967997 T C 2.22E-05 Lipoproteins PKIB intron pha003079 rs12200245 chr6 122974591 C T 2.83E-05 Lipoproteins PKIB intron pha003079 rs12209247 chr6 122981550 T C 9.49E-04 Celiac disease PKIB intron 23936387 rs9482269 chr6 123027861 A T 9.91E-04 Response to taxane treatment (placlitaxel) PKIB intron 23006423 rs9490529 chr6 123031388 G A 6.40E-04 Response to taxane treatment (placlitaxel) PKIB intron 23006423 rs7739343 chr6 123055140 G C 3.00E-04 Cholesterol / / 17255346 rs9401596 chr6 123104703 A G 9.45E-06 Heart Rate FABP7 intron pha003053 rs9401596 chr6 123104703 A G 2.49E-05 Heart Rate FABP7 intron pha003054 rs6904500 chr6 123109596 T C 0.000446 Salmonella-induced pyroptosis / / 22837397 rs7738249 chr6 123139281 T C 8.54E-04 Type 2 diabetes / / 17463246 rs9986482 chr6 123181158 G A 1.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs6569293 chr6 123182856 A T 5.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs6569294 chr6 123183020 C T 3.02E-04 Multiple complex diseases / / 17554300 rs6569294 chr6 123183020 C T 1.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs9401603 chr6 123188088 C T 7.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs9490566 chr6 123189265 T C 3.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs9490567 chr6 123189391 G A 3.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs9490568 chr6 123189470 T C 4.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs9388153 chr6 123224427 G T 3.05E-04 Bipolar disorder / / 18317468 rs13192613 chr6 123282941 G T 3.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs7774522 chr6 123364258 T C 4.45E-05 Coronary heart disease CLVS2 intron pha003035 rs6569332 chr6 123602485 G T 9.93E-04 Multiple complex diseases TRDN intron 17554300 rs991282 chr6 123642143 G A 1.41E-05 Parkinson's disease (motor and cognition) TRDN intron 22658654 rs991282 chr6 123642143 G A 1.41E-05 Immune response to anthrax vaccine TRDN intron 22658931 rs200243235 chr6 123673686 T C 0.000026 Breast cancer(er negative) TRDN missense 23555315 rs6901299 chr6 123775326 A G 3.13E-06 Multiple complex diseases TRDN intron 17554300 rs6901299 chr6 123775326 A G 9.70E-06 Bipolar disorder TRDN intron 19416921 rs9482391 chr6 123776501 T C 2.64E-04 Multiple complex diseases TRDN intron 17554300 rs13205992 chr6 123776893 T C 1.54E-04 Multiple complex diseases TRDN intron 17554300 rs4571590 chr6 123788232 A G 9.15E-04 Tourette syndrome TRDN intron 22889924 rs10499124 chr6 123799339 C A 5.21E-04 Multiple complex diseases TRDN intron 17554300 rs17739564 chr6 123814633 C T 4.28E-05 Multiple complex diseases TRDN intron 17554300 rs9375259 chr6 123830413 T C 3.30E-04 Multiple complex diseases TRDN intron 17554300 rs6939403 chr6 123853556 T C 6.87E-04 Response to taxane treatment (placlitaxel) TRDN intron 23006423 rs4307191 chr6 123860153 G A 2.70E-05 Triglycerides TRDN intron pha003081 rs4307191 chr6 123860153 G A 2.67E-05 Lipid levels TRDN intron pha003082 rs6905496 chr6 123868992 C T 8.13E-05 Lipid levels TRDN intron pha003082 rs9490852 chr6 123967785 C T 8.97E-04 Type 2 diabetes / / 17463246 rs979537 chr6 123983066 T C 6.80E-05 Alcoholism (heaviness of drinking) / / 21529783 rs9490860 chr6 123989741 A C 4.00E-06 IgG glycosylation / / 23382691 rs17703235 chr6 124023675 C T 2.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs342616 chr6 124110325 C A 8.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs928534 chr6 124141739 C T 3.97E-04 Multiple complex diseases NKAIN2 intron 17554300 rs17749667 chr6 124174336 A G 7.95E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs6569368 chr6 124178280 A G 7.81E-05 Waist Circumference NKAIN2 intron pha003024 rs2171970 chr6 124181547 G A 1.50E-06 Urinary metabolites NKAIN2 intron 21572414 rs2171970 chr6 124181547 G A 2.65E-04 Alzheimer's disease NKAIN2 intron 24755620 rs17693403 chr6 124183703 G A 6.34E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs7744173 chr6 124187969 A T 1.18E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs2318064 chr6 124189423 G A 2.34E-04 Response to cytidine analogues (gemcitabine) NKAIN2 intron 24483146 rs6924068 chr6 124190888 A G 8.98E-05 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs1490363 chr6 124194095 C A 2.85E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs11753061 chr6 124194354 G A 1.25E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs9320964 chr6 124195807 A T 3.35E-06 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs9320964 chr6 124195807 A T 8.00E-04 Type 2 diabetes NKAIN2 intron 22158537 rs9372760 chr6 124196345 T A 3.45E-06 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs9372761 chr6 124196412 C T 8.65E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs9372762 chr6 124196534 C A 4.49E-06 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs7742731 chr6 124197585 G A 4.24E-06 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs17625478 chr6 124198889 A G 3.75E-06 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs9490983 chr6 124200584 G A 7.70E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs9388287 chr6 124200765 G A 5.20E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs2130589 chr6 124201150 G A 3.46E-05 Alzheimer's disease NKAIN2 intron 17998437 rs2130589 chr6 124201150 G A 1.14E-05 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs1352676 chr6 124202548 C G 2.86E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs1352678 chr6 124202712 C T 4.98E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs9388288 chr6 124206586 G A 7.39E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs1490357 chr6 124206803 T A 4.81E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs2057081 chr6 124215440 G C 8.20E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs11963900 chr6 124216302 G T 4.34E-04 Multiple complex diseases NKAIN2 intron 17554300 rs11963900 chr6 124216302 G T 6.60E-26 Narcolepsy NKAIN2 intron 19629137 rs11154196 chr6 124217713 G A 8.69E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs7745476 chr6 124223375 G A 1.14E-04 Type 2 diabetes NKAIN2 intron 22158537 rs9490996 chr6 124230928 T C 2.62E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs1883870 chr6 124231022 G A 3.15E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs584050 chr6 124238200 C T 5.35E-04 Insulin resistance NKAIN2 intron 21901158 rs728017 chr6 124292594 A G 3.54E-04 Body mass index NKAIN2 intron 17255346 rs728017 chr6 124292594 A G 2.30E-05 Urinary metabolites NKAIN2 intron 21572414 rs9320967 chr6 124298718 C A 8.88E-04 Coronary Artery Disease NKAIN2 intron 17634449 rs12190776 chr6 124302543 C G 1 Drug response to Etoposide NKAIN2 intron 17537913 rs117780815 chr6 124326227 A T 6.00E-07 Alzheimer's disease (cognitive decline) NKAIN2 intron 23535033 rs1510295 chr6 124329313 G A 5.33E-04 Stroke NKAIN2 intron pha002887 rs9320970 chr6 124332260 A G 9.00E-04 Acute lymphoblastic leukemia (childhood) NKAIN2 intron 20189245 rs12203197 chr6 124336951 A G 5.19E-05 Cognitive test performance NKAIN2 intron 20125193 rs6917824 chr6 124342663 A G 4.00E-06 Schizophrenia NKAIN2 intron 23894747 rs6917824 chr6 124342663 A G 4.00E-06 Schizophrenia NKAIN2 intron 23894747 rs6902462 chr6 124388163 A G 9.12E-04 Amyotrophic Lateral Sclerosis NKAIN2 intron 17362836 rs17086573 chr6 124396177 T G 5.00E-05 Major depressive disorder NKAIN2 intron 21042317 rs17086573 chr6 124396177 T G 2.10E-04 Blood pressure (response to calcium channel blocker) NKAIN2 intron 24192120 rs9320975 chr6 124396731 T G 5.60E-05 Major depressive disorder NKAIN2 intron 21042317 rs13204086 chr6 124405155 C T 2.00E-06 Periodontitis (Mean PAL) NKAIN2 intron 24024966 rs13220639 chr6 124437412 C T 1.32E-06 Periodontitis (Mean PAL) NKAIN2 intron 24024966 rs35900954 chr6 124439410 G A 1.09E-06 Periodontitis (Mean PAL) NKAIN2 intron 24024966 rs594664 chr6 124442286 C T 2.63E-05 Alcohol and nictotine co-dependence NKAIN2 intron 20158304 rs9388306 chr6 124470054 G C 8.69E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21041247 rs2146252 chr6 124470761 T C 8.71E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21041247 rs2146253 chr6 124470796 G A 8.76E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21041247 rs2008699 chr6 124471208 T C 8.82E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21041247 rs2008708 chr6 124471337 A G 8.94E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21041247 rs802273 chr6 124481616 G T 7.88E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21041247 rs802274 chr6 124483459 A G 7.44E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21041247 rs749212 chr6 124483836 G A 7.11E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21041247 rs811418 chr6 124484988 A C 8.38E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21041247 rs802228 chr6 124526649 C T 7.48E-05 Cytomegalovirus antibody response NKAIN2 intron 21993531 rs9482518 chr6 124543314 A C 3.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NKAIN2 intron 20877124 rs9482518 chr6 124543314 A C 4.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NKAIN2 intron 20877124 rs722577 chr6 124546035 T C 4.71E-04 Multiple complex diseases NKAIN2 intron 17554300 rs77490164 chr6 124559732 C T 8.00E-07 Periodontitis (Mean PAL) NKAIN2 intron 24024966 rs1523979 chr6 124570477 C T 3.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NKAIN2 intron 20877124 rs2689887 chr6 124571367 T C 1.34E-05 Cytomegalovirus antibody response NKAIN2 intron 21993531 rs17557323 chr6 124573516 G A 2.33E-06 Multiple complex diseases NKAIN2 intron 17554300 rs2753138 chr6 124582245 A G 3.81E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) NKAIN2 intron 24023788 rs2626091 chr6 124589717 A G 9.91E-05 Cytomegalovirus antibody response NKAIN2 intron 21993531 rs7774290 chr6 124605179 A G 2.85E-04 Hearing function NKAIN2 intron 17255346 rs2753147 chr6 124608621 C T 6.38E-04 Response to cytadine analogues (cytosine arabinoside) NKAIN2 intron 24483146 rs802500 chr6 124610320 T C 6.00E-04 Polycystic ovary syndrome NKAIN2 intron 22178785 rs2753159 chr6 124617031 T G 1.71E-05 Tunica Media NKAIN2 intron pha003036 rs6926318 chr6 124632606 A G 4.95E-06 Multiple complex diseases NKAIN2 intron 17554300 rs2626130 chr6 124651358 A G 6.77E-04 Self-reported allergy NKAIN2 intron 23817569 rs11154212 chr6 124651861 C T 3.82E-05 Soluble levels of adhesion molecules NKAIN2 intron pha003072 rs719581 chr6 124657315 A G 6.97E-06 Body Mass Index NKAIN2 intron pha003015 rs12204812 chr6 124681503 C A 4.16E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) NKAIN2 intron 23648065 rs12204812 chr6 124681503 C A 5.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) NKAIN2 intron 23648065 rs911959 chr6 124688755 T C 3.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) NKAIN2 intron 23648065 rs9491140 chr6 124691237 C T 3.00E-07 Neuroticism NKAIN2 intron 20634892 rs9491141 chr6 124691352 C T 1.10E-05 Urinary metabolites NKAIN2 intron 21572414 rs332611 chr6 124713527 C T 1.53E-06 Body Mass Index NKAIN2 intron pha003007 rs332611 chr6 124713527 C T 3.85E-05 Body Mass Index NKAIN2 intron pha003009 rs332611 chr6 124713527 C T 1.06E-05 Body Mass Index NKAIN2 intron pha003015 rs332611 chr6 124713527 C T 9.92E-07 Weight NKAIN2 intron pha003027 rs6909328 chr6 124717781 G A 4.77E-04 Stroke NKAIN2 intron pha002886 rs616482 chr6 124728196 C A 0.00032 Endometrial cancer NKAIN2 intron 22426144 rs531930 chr6 124743507 A G 5.00E-07 Celiac disease NKAIN2 intron 24999842 rs9372777 chr6 124764559 A G 2.76E-05 Body Mass Index NKAIN2 intron pha003007 rs9372777 chr6 124764559 A G 7.79E-05 Body Mass Index NKAIN2 intron pha003009 rs9372777 chr6 124764559 A G 1.66E-05 Weight NKAIN2 intron pha003027 rs524235 chr6 124771166 C T 2.19E-05 Multiple sclerosis NKAIN2 intron 17660530 rs643630 chr6 124797902 G T 4.37E-04 IgE levels NKAIN2 intron 17255346 rs658410 chr6 124803552 G A 2.71E-04 IgE levels NKAIN2 intron 17255346 rs1832252 chr6 124825375 G C 2.25E-05 Mammographic density NKAIN2 intron 22532574 rs2785713 chr6 124837601 T C 3.06E-05 Personality dimensions NKAIN2 intron 23903073 rs643002 chr6 124841336 T C 3.59E-04 Multiple complex diseases NKAIN2 intron 17554300 rs11154244 chr6 124885670 C T 1.68E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs12234116 chr6 124887219 A G 2.28E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs145641727 chr6 124887219 A AT 2.28E-04 Suicide attempts in bipolar disorder NKAIN2 intron 21423239 rs611601 chr6 124896353 T C 6.52E-04 Aortic root size NKAIN2 intron 21223598 rs635837 chr6 124910739 A G 6.08E-04 Response to taxane treatment (placlitaxel) NKAIN2 intron 23006423 rs1871329 chr6 124911534 A G 5.24E-04 Response to statin treatment (atorvastatin),change in cholesterol levels NKAIN2 intron 20031582 rs472059 chr6 124917005 A G 6.52E-04 Aortic root size NKAIN2 intron 21223598 rs568892324 chr6 124917005 AT A 6.52E-04 Aortic root size NKAIN2 intron 21223598 rs10499128 chr6 124917584 G A 7.60E-19 Varicose Veins NKAIN2 intron pha001416 rs1031881 chr6 124921140 T G 4.26E-04 Response to taxane treatment (placlitaxel) NKAIN2 intron 23006423 rs9321003 chr6 124942850 A G 6.84E-05 Heart Rate NKAIN2 intron pha003051 rs504008 chr6 124951063 A C 3.00E-06 QRS duration NKAIN2 intron 23534349 rs9491205 chr6 124955517 A G 4.63E-05 HIV-1 viral setpoint NKAIN2 intron 22174851 rs781484 chr6 124977655 G A 1.83E-04 Breast cancer NKAIN2 intron pha002853 rs1479037 chr6 124978458 T C 0.0002847 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NKAIN2 intron 23233654 rs1479037 chr6 124978458 T C 2.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) NKAIN2 intron 23233662 rs6908208 chr6 125018981 C T 9.66E-04 Methotrexate clearance (acute lymphoblastic leukemia) NKAIN2 intron 23233662 rs4540279 chr6 125023343 C T 0.0007179 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NKAIN2 intron 23233654 rs4540279 chr6 125023343 C T 7.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) NKAIN2 intron 23233662 rs5006628 chr6 125024693 G A 2.26E-04 Amyotrophic lateral sclerosis NKAIN2 intron 23624525 rs870583 chr6 125055529 G A 7.30E-04 Adiposity NKAIN2 intron 19461586 rs1337863 chr6 125069337 T C 2.93E-04 Amyotrophic lateral sclerosis NKAIN2 intron 23624525 rs9398764 chr6 125072022 A G 9.00E-07 Political ideology NKAIN2 intron 24569950 rs9372792 chr6 125082498 C T 3.89E-05 Cholesterol NKAIN2 intron pha003073 rs9372792 chr6 125082498 C T 4.40E-05 Cholesterol NKAIN2 intron pha003078 rs6923265 chr6 125097304 C G 6.00E-05 Type 2 diabetes and 6 quantitative traits NKAIN2 intron 17848626 rs2065973 chr6 125098980 G A 7.13E-04 Response to cytadine analogues (cytosine arabinoside) NKAIN2 intron 24483146 rs2326102 chr6 125132040 A C 0.0000088 HDL cholesterol particle diameter NKAIN2 intron 23263444 rs1923728 chr6 125147538 G A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs11154271 chr6 125156449 C T 1.00E-06 Subcutaneous adipose tissue / / 22589738 rs1326156 chr6 125181691 T G 3.66E-04 Heart Failure / / pha002885 rs9401786 chr6 125252994 C A,T 3.53E-04 Alzheimer's disease STL intron 17998437 rs1889436 chr6 125253532 G A 6.00E-04 Multiple complex diseases STL intron 17554300 rs1889436 chr6 125253532 G A 5.36E-04 Response to cytidine analogues (gemcitabine) STL intron 24483146 rs4896606 chr6 125268385 A G 3.57E-04 Response to taxane treatment (placlitaxel) STL intron 23006423 rs1413600 chr6 125274128 G A 0.0000021 HDL cholesterol particle diameter STL intron 23263444 rs17720559 chr6 125287561 G A 2.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9321013 chr6 125330921 G A 4.95E-05 Nicotine smoking RNF217 intron 19268276 rs9388398 chr6 125332811 A G 0.00000102 HDL cholesterol particle diameter RNF217 intron 23263444 rs1413596 chr6 125334720 G A 1.19E-04 Multiple complex diseases RNF217 intron 17554300 rs1413598 chr6 125336799 T C 0.0000558 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes RNF217 intron 22628534 rs1413598 chr6 125336799 T C 0.00000153 HDL cholesterol particle diameter RNF217 intron 23263444 rs11154284 chr6 125338353 C T 9.91E-05 Insulin-related traits RNF217 intron pha002901 rs571846 chr6 125401564 C T 6.68E-04 Alcohol dependence RNF217 intron 21314694 rs3778463 chr6 125498512 T C 1.88E-05 Cognitive impairment induced by topiramate TPD52L1 intron 22091778 rs17052811 chr6 125500202 T G 2.59E-04 Multiple complex diseases TPD52L1 intron 17554300 rs1555373 chr6 125509459 C T 5.35E-04 Type 2 diabetes TPD52L1 intron 17463246 rs3799732 chr6 125574509 T C 6.49E-05 Response to acetaminophen (hepatotoxicity) TPD52L1 intron 21177773 rs9491352 chr6 125596750 T A 2.05E-05 Brain structure HDDC2 UTR-3 22504417 rs9482637 chr6 125607559 T A 3.18E-05 Brain structure HDDC2 intron 22504417 rs1417701 chr6 125614100 C A 2.63E-05 Brain structure HDDC2 intron 22504417 rs1417700 chr6 125614121 C A 2.60E-05 Brain structure HDDC2 intron 22504417 rs10223874 chr6 125614421 T C 2.63E-05 Brain structure HDDC2 intron 22504417 rs3734645 chr6 125615257 C T 2.50E-05 Brain structure HDDC2 intron 22504417 rs3799716 chr6 125618558 C A 2.48E-05 Brain structure HDDC2 intron 22504417 rs1934990 chr6 125666821 C A 6.54E-05 Alcohol dependence / / 21703634 rs10456957 chr6 125698805 G T 5.30E-05 Kawasaki disease / / 22081228 rs1006782 chr6 125746562 C T 2.80E-05 Urinary metabolites / / 21572414 rs17053174 chr6 125759664 T A 0.000029 Mean arterial pressure / / 22510845 rs7769904 chr6 125760955 C A 0.000011 Mean arterial pressure / / 22510845 rs1494137 chr6 125763226 G A 0.000016 Mean arterial pressure / / 22510845 rs6941500 chr6 125810710 T C 9.97E-05 Coronary Artery Disease / / 17634449 rs2131829 chr6 125835682 A G 5.62E-04 Body mass index / / 21701565 rs4895767 chr6 125845390 T C 8.27E-04 Body mass index / / 21701565 rs7769272 chr6 125899476 T G 9.71E-04 Endometrial cancer / / 24096698 rs9491468 chr6 125982848 C A 0.000609 Salmonella-induced pyroptosis / / 22837397 rs984040 chr6 126021277 T C 9.60E-04 Type 2 diabetes and 6 quantitative traits LOC643623 intron 17848626 rs1777220 chr6 126022602 G T 0.0000598 Asthma LOC643623 intron 22694930 rs1777220 chr6 126022602 G T 1.30E-05 Endometrial cancer LOC643623 intron 24096698 rs1777220 chr6 126022602 G T 2.00E-06 Endometrial cancer LOC643623 intron 24096698 rs1777220 chr6 126022602 G T 8.55E-05 Endometrial cancer LOC643623 intron 24096698 rs1268070 chr6 126041164 C T 5.13E-09 Brugada syndrome / / 23872634 rs4895799 chr6 126052729 C T 4.05E-04 Schizophrenia / / 19197363 rs9388451 chr6 126090377 T C 5.00E-17 Brugada syndrome / / 23872634 rs622936 chr6 126146711 A G 6.63E-05 Paget's disease NCOA7 intron 20436471 rs622936 chr6 126146711 A G 2.27E-04 Heart Failure NCOA7 intron pha002884 rs584032 chr6 126165003 G A 3.94E-04 Schizophrenia NCOA7 intron 19197363 rs481233 chr6 126165465 G A 7.20E-05 Sleep and circadian phenotypes NCOA7 intron 17903308 rs481233 chr6 126165465 G A 2.39E-05 Lung function (forced vital capacity) NCOA7 intron pha003104 rs7742064 chr6 126170617 G A 2.83E-04 Multiple complex diseases NCOA7 intron 17554300 rs9482712 chr6 126189659 A G 4.66E-05 Multiple complex diseases NCOA7 intron 17554300 rs4895801 chr6 126216403 C G 8.43E-04 Suicide attempts in bipolar disorder NCOA7 intron 21423239 rs1322756 chr6 126220223 A G 7.88E-04 Suicide attempts in bipolar disorder NCOA7 intron 21423239 rs1407592 chr6 126235316 G A 8.05E-04 Type 2 diabetes NCOA7 intron 17463246 rs9791366 chr6 126236806 A G 5.08E-05 Lung function (forced vital capacity) NCOA7 intron pha003104 rs9482716 chr6 126245644 C A 4.91E-05 Lung function (forced vital capacity) NCOA7 intron pha003104 rs1567 chr6 126249914 T G 7.14E-05 Lung function (forced vital capacity) NCOA7 missense pha003104 rs11759246 chr6 126266135 A G 4.80E-05 Response to statin therapy / / 20339536 rs17053722 chr6 126285333 A G 4.60E-23 Narcolepsy HINT3 intron 19629137 rs146575767 chr6 126329589 A G 0.00017 Breast cancer TRMT11 missense 23555315 rs1268121 chr6 126352586 A G 3.35E-05 Hearing function TRMT11 intron 17255346 rs17053767 chr6 126392441 A G 9.07E-04 Acute lung injury / / 22295056 rs7763104 chr6 126393517 A G 9.07E-04 Acute lung injury / / 22295056 rs9388472 chr6 126471447 C T 3.23E-04 White matter integrity / / 22425255 rs9375435 chr6 126661858 C T 1.71E-06 Type 1 diabetes CENPW intron 21980299 rs12202204 chr6 126686407 A G 9.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9388489 chr6 126698719 A G 4.00E-13 Type 1 diabetes / / 19430480 rs9388489 chr6 126698719 A G 4.20E-13 Multiple sclerosis / / 22190364 rs9388489 chr6 126698719 A G 9.80E-05 Type 2 diabetes / / 24509480 rs10457478 chr6 126704934 C G 0.0008764 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10457478 chr6 126704934 C G 8.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9321065 chr6 126744087 G A 1.60E-04 Height / / 21998595 rs9385399 chr6 126759033 G T 8.76E-04 Type 2 diabetes / / 17463246 rs1361108 chr6 126767600 C T 2.00E-08 Menarche (age at onset) / / 21102462 rs1361108 chr6 126767600 C T 9.00E-06 Height / / 21998595 rs7753563 chr6 126802598 A G 4.20E-10 Bone mineral density (paediatric,skull) / / 24945404 rs4422634 chr6 126806676 T C 3.60E-05 Height / / 21998595 rs10457480 chr6 126812609 C G 0.0006853 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10457480 chr6 126812609 C G 6.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10457481 chr6 126813721 G A 0.0006816 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10457481 chr6 126813721 G A 6.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4418209 chr6 126819699 T G 1.00E-06 Bone mineral density (paediatric,skull) / / 24945404 rs2130604 chr6 126820561 T G 3.00E-11 Bone mineral density (paediatric,skull) / / 24945404 rs2130604 chr6 126820561 T G 4.00E-11 Bone mineral density (paediatric,skull) / / 24945404 rs1490388 chr6 126835655 C T 6.00E-07 Height / / 18391951 rs1490384 chr6 126851160 C T 4.00E-21 Height / / 20881960 rs1490384 chr6 126851160 C T 1.00E-16 Height / / 23563607 rs9388501 chr6 126903011 T C 5.90E-08 Primary tooth development (time to first tooth eruption) / / 23704328 rs4273712 chr6 126964510 A G 2.00E-13 Intracranial volume / / 22504418 rs4273712 chr6 126964510 A G 3.00E-06 Type 2 diabetes / / 24509480 rs4549631 chr6 126966308 T C 3.49E-04 Gallstones / / 17632509 rs4549631 chr6 126966308 T C 5.00E-13 Height / / 18391952 rs4549631 chr6 126966308 T C 4.90E-07 Menarche (age at onset) / / 21102462 rs1262474 chr6 126976071 G C 0.0000533 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1262476 chr6 126986996 A G 0.0000647 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1262476 chr6 126986996 A G 3.00E-09 Bone mineral density (paediatric,upper limb) / / 24945404 rs1262476 chr6 126986996 A G 4.00E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs17054008 chr6 127002633 A G 1.52E-04 Multiple complex diseases / / 17554300 rs13212044 chr6 127025661 G T 0.0000294 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13212044 chr6 127025661 G T 3.40E-09 Bone mineral density (paediatric,upper limb) / / 24945404 rs10484759 chr6 127037042 C T 0.0000137 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10484759 chr6 127037042 C T 1.10E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs111743285 chr6 127048230 C T 0.0000664 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13220518 chr6 127048609 T A 0.0000848 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1262554 chr6 127079341 C T 4.30E-10 Bone mineral density (paediatric,skull) / / 24945404 rs9385403 chr6 127083941 C T 7.40E-05 Multiple complex diseases / / 17554300 rs4897189 chr6 127088550 A T 1.29E-04 Multiple complex diseases / / 17554300 rs9385404 chr6 127088591 A G 1.01E-04 Multiple complex diseases / / 17554300 rs4895815 chr6 127090469 A G 7.45E-05 Multiple complex diseases / / 17554300 rs983741 chr6 127096527 C A 8.31E-05 Multiple complex diseases / / 17554300 rs9388518 chr6 127103785 C A 6.19E-05 Multiple complex diseases / / 17554300 rs13209747 chr6 127115454 C A,G,T 2.00E-11 Blood pressure / / 23972371 rs13209747 chr6 127115454 C A,G,T 3.00E-10 Blood pressure / / 23972371 rs761356 chr6 127135132 T C 6.34E-05 Multiple complex diseases / / 17554300 rs2022476 chr6 127136222 C G 4.63E-04 Multiple complex diseases / / 17554300 rs13194508 chr6 127144683 T C 2.40E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs1105956 chr6 127146879 G A 4.31E-04 Multiple complex diseases / / 17554300 rs6569470 chr6 127158042 C T 6.79E-05 Multiple complex diseases / / 17554300 rs17563605 chr6 127164572 T C 1.90E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs9401916 chr6 127166454 T C 9.09E-05 Multiple complex diseases / / 17554300 rs13204965 chr6 127167072 A C 3.00E-08 Bone mineral density / / 21533022 rs13204965 chr6 127167072 A C 8.00E-12 Bone mineral density / / 22504420 rs13204965 chr6 127167072 A C 8.99E-04 Bone mineral density / / 24249740 rs13204965 chr6 127167072 A C 1.20E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs13204965 chr6 127167072 A C 1.25E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs13204965 chr6 127167072 A C 1.75E-06 Bone mineral density (paediatric,total body less head) / / 24945404 rs13204965 chr6 127167072 A C 2.00E-06 Bone mineral density (paediatric,total body less head) / / 24945404 rs13204965 chr6 127167072 A C 5.20E-05 Bone mineral density (paediatric,lower limb) / / 24945404 rs9375465 chr6 127167396 A G 1.04E-04 Multiple complex diseases / / 17554300 rs9375466 chr6 127167512 A G 1.07E-04 Multiple complex diseases / / 17554300 rs11154370 chr6 127167591 A T 4.40E-07 Waist-hip ratio / / 20935629 rs1361831 chr6 127181089 T C 6.47E-05 Multiple complex diseases / / 17554300 rs1361832 chr6 127187019 T C 7.70E-05 Multiple complex diseases / / 17554300 rs1930948 chr6 127187658 A G 9.89E-05 Multiple complex diseases / / 17554300 rs12663110 chr6 127219931 T C 3.97E-05 Multiple complex diseases / / 17554300 rs1930951 chr6 127231708 C T 3.04E-05 Multiple complex diseases / / 17554300 rs6908100 chr6 127262938 G A 7.69E-05 Multiple complex diseases / / 17554300 rs6907995 chr6 127263088 A G 8.27E-05 Multiple complex diseases / / 17554300 rs1343657 chr6 127263534 T C 6.57E-05 Multiple complex diseases / / 17554300 rs9385413 chr6 127268497 C T 7.40E-05 Multiple complex diseases / / 17554300 rs6906261 chr6 127275281 C T 1.47E-04 Multiple complex diseases / / 17554300 rs10872310 chr6 127276881 C T 2.62E-04 Multiple complex diseases / / 17554300 rs987763 chr6 127281547 C T 2.37E-07 Waist-hip ratio / / 20935629 rs4897197 chr6 127283784 G A 2.98E-04 Multiple complex diseases / / 17554300 rs1930958 chr6 127284568 G A 4.38E-04 Multiple complex diseases / / 17554300 rs1930959 chr6 127284605 A G 2.09E-04 Multiple complex diseases / / 17554300 rs9375479 chr6 127286233 C T 1.72E-04 Multiple complex diseases / / 17554300 rs4897198 chr6 127289089 C A 2.19E-04 Multiple complex diseases / / 17554300 rs4897199 chr6 127289168 G A 2.00E-04 Multiple complex diseases / / 17554300 rs6920351 chr6 127315767 C G 3.14E-04 Multiple complex diseases / / 17554300 rs997112 chr6 127321485 A G 3.21E-04 Multiple complex diseases / / 17554300 rs997112 chr6 127321485 A G 3.90E-05 Iron status biomarkers / / 19084217 rs17572870 chr6 127324914 T A 2.76E-04 Multiple complex diseases / / 17554300 rs9401934 chr6 127329967 C T 4.02E-04 Multiple complex diseases / / 17554300 rs1034207 chr6 127337699 C T 8.62E-07 Waist-hip ratio / / 20935629 rs17651529 chr6 127340068 T C 8.99E-04 Obesity (extreme) / / 21935397 rs972275 chr6 127391844 C G 2.00E-06 Iron status biomarkers / / 19084217 rs1936813 chr6 127392421 A G 6.09E-06 Iron status biomarkers / / 19084217 rs9321069 chr6 127392977 G A 5.72E-06 Iron status biomarkers / / 19084217 rs727330 chr6 127399325 A G 9.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4580892 chr6 127409882 C T 2.35E-09 Waist-hip ratio / / 20935629 rs2745347 chr6 127421520 A C 2.44E-04 Smoking cessation / / 24665060 rs11154383 chr6 127425457 A G 1.61E-04 Multiple complex diseases / / 17554300 rs1936800 chr6 127436064 C T 1.00E-11 Renal function-related traits (BUN) / / 22797727 rs1936800 chr6 127436064 C T 3.00E-08 Triglycerides / / 24097068 rs1936800 chr6 127436064 C T 3.00E-10 HDL cholesterol / / 24097068 rs1936806 chr6 127451665 C T 8.10E-04 Waist-hip ratio RSPO3 intron 23966867 rs9491696 chr6 127452639 C G 1.00E-11 Waist-hip ratio RSPO3 intron 20935629 rs9491696 chr6 127452639 C G 2.00E-32 Waist-hip ratio RSPO3 intron 20935629 rs2745353 chr6 127452935 C T 0.00000041 Body mass index RSPO3 intron 22885924 rs2745353 chr6 127452935 C T 5.48E-09 Fasting insulin-related traits RSPO3 intron 22885924 rs9491697 chr6 127456122 A G 4.00E-10 Crohn's disease RSPO3 intron 23128233 rs7741021 chr6 127468274 A C 1.00E-19 Bone properties (heel) RSPO3 intron 24430505 rs7741021 chr6 127468274 A C 4.00E-08 Bone properties (heel) RSPO3 intron 24430505 rs7741021 chr6 127468274 A C 9.00E-21 Bone properties (heel) RSPO3 intron 24430505 rs2489629 chr6 127476717 C T 9.34E-06 Triglycerides RSPO3 intron 19074352 rs2489629 chr6 127476717 C T 9.34E-06 Polyunsaturated fatty acid levels,in plasma RSPO3 intron 19148276 rs2326566 chr6 127492840 G T 4.68E-04 Schizophrenia RSPO3 intron 21747397 rs6569474 chr6 127493611 A T 1.00E-08 Metabolite levels RSPO3 intron 21909109 rs7745274 chr6 127509157 G A 9.00E-10 Waist-hip ratio RSPO3 intron 23563607 rs7774321 chr6 127546114 T C 3.95E-05 Multiple complex diseases / / 17554300 rs4371861 chr6 127568447 C A 6.45E-04 Myocardial Infarction / / pha002883 rs4895820 chr6 127572671 C T 3.46E-04 Multiple complex diseases / / 17554300 rs9375498 chr6 127595441 G A 4.03E-04 Suicide attempts in bipolar disorder RNF146 intron 21041247 rs9375498 chr6 127595441 G A 8.03E-04 Suicide attempts in bipolar disorder RNF146 intron 21041247 rs9388558 chr6 127596586 A T 3.79E-04 Suicide attempts in bipolar disorder RNF146 intron 21041247 rs9388558 chr6 127596586 A T 7.21E-04 Suicide attempts in bipolar disorder RNF146 intron 21041247 rs2180341 chr6 127600630 G A 3.00E-08 Breast cancer RNF146 intron 18326623 rs2180341 chr6 127600630 G A 3.00E-08 Nasopharyngeal carcinoma RNF146 intron 20512145 rs9372861 chr6 127601195 C T 3.73E-04 Suicide attempts in bipolar disorder RNF146 intron 21041247 rs9372861 chr6 127601195 C T 7.00E-04 Suicide attempts in bipolar disorder RNF146 intron 21041247 rs9372862 chr6 127601246 T C 3.69E-04 Suicide attempts in bipolar disorder RNF146 intron 21041247 rs9372862 chr6 127601246 T C 6.99E-04 Suicide attempts in bipolar disorder RNF146 intron 21041247 rs9388559 chr6 127601717 G A 3.68E-04 Suicide attempts in bipolar disorder RNF146 UTR-5 21041247 rs9388559 chr6 127601717 G A 6.99E-04 Suicide attempts in bipolar disorder RNF146 UTR-5 21041247 rs9401947 chr6 127602061 C T 3.99E-04 Suicide attempts in bipolar disorder RNF146 intron 21041247 rs9401947 chr6 127602061 C T 6.99E-04 Suicide attempts in bipolar disorder RNF146 intron 21041247 rs7764180 chr6 127605667 A C 3.76E-04 Suicide attempts in bipolar disorder RNF146 intron 21041247 rs7764180 chr6 127605667 A C 6.99E-04 Suicide attempts in bipolar disorder RNF146 intron 21041247 rs9321072 chr6 127606349 C T 4.50E-04 Suicide attempts in bipolar disorder RNF146 intron 21041247 rs9321072 chr6 127606349 C T 6.99E-04 Suicide attempts in bipolar disorder RNF146 intron 21041247 rs6936084 chr6 127614301 G A 3.64E-04 Suicide attempts in bipolar disorder ECHDC1 intron 21041247 rs6936084 chr6 127614301 G A 6.99E-04 Suicide attempts in bipolar disorder ECHDC1 intron 21041247 rs9372863 chr6 127618198 A G 3.76E-04 Suicide attempts in bipolar disorder ECHDC1 intron 21041247 rs9372863 chr6 127618198 A G 6.99E-04 Suicide attempts in bipolar disorder ECHDC1 intron 21041247 rs761842 chr6 127620870 A T 3.76E-04 Suicide attempts in bipolar disorder ECHDC1 intron 21041247 rs761842 chr6 127620870 A T 6.99E-04 Suicide attempts in bipolar disorder ECHDC1 intron 21041247 rs9401948 chr6 127624944 C T 3.18E-04 Suicide attempts in bipolar disorder ECHDC1 intron 21041247 rs9401948 chr6 127624944 C T 6.99E-04 Suicide attempts in bipolar disorder ECHDC1 intron 21041247 rs9401948 chr6 127624944 C T 4.41E-04 Smoking quantity ECHDC1 intron 24665060 rs9375500 chr6 127647206 T C 3.78E-04 Suicide attempts in bipolar disorder ECHDC1 intron 21041247 rs9375500 chr6 127647206 T C 7.00E-04 Suicide attempts in bipolar disorder ECHDC1 intron 21041247 rs4141423 chr6 127648646 C T 3.81E-04 Suicide attempts in bipolar disorder ECHDC1 intron 21041247 rs4141423 chr6 127648646 C T 7.00E-04 Suicide attempts in bipolar disorder ECHDC1 intron 21041247 rs3823043 chr6 127649319 A C 9.82E-06 Obesity-related traits ECHDC1 intron 23251661 rs9372865 chr6 127649384 C T 3.22E-04 Suicide attempts in bipolar disorder ECHDC1 intron 21041247 rs9372865 chr6 127649384 C T 7.00E-04 Suicide attempts in bipolar disorder ECHDC1 intron 21041247 rs9401949 chr6 127651116 T C 3.08E-04 Suicide attempts in bipolar disorder ECHDC1 intron 21041247 rs9401949 chr6 127651116 T C 6.99E-04 Suicide attempts in bipolar disorder ECHDC1 intron 21041247 rs9372866 chr6 127655427 T C 3.16E-04 Suicide attempts in bipolar disorder ECHDC1 intron 21041247 rs9372866 chr6 127655427 T C 7.01E-04 Suicide attempts in bipolar disorder ECHDC1 intron 21041247 rs9375502 chr6 127656792 G T 3.16E-04 Suicide attempts in bipolar disorder ECHDC1 intron 21041247 rs9375502 chr6 127656792 G T 7.04E-04 Suicide attempts in bipolar disorder ECHDC1 intron 21041247 rs13194280 chr6 127657099 T C 4.82E-04 Smoking initiation ECHDC1 intron 24665060 rs6569485 chr6 127676191 C T 3.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs6569485 chr6 127676191 C T 7.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs9401952 chr6 127677027 A C 4.64E-04 Birth weight / / 17255346 rs9375503 chr6 127677071 T C 4.92E-04 Birth weight / / 17255346 rs1964130 chr6 127677391 G C 3.70E-04 Birth weight / / 17255346 rs2073298 chr6 127678404 C T 3.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs2073298 chr6 127678404 C T 7.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs9375505 chr6 127697418 T C 3.81E-04 Suicide attempts in bipolar disorder / / 21041247 rs9375505 chr6 127697418 T C 7.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs2068981 chr6 127697992 A C 7.57E-05 Body Mass Index / / pha003009 rs9385420 chr6 127702335 A G 3.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs9385420 chr6 127702335 A G 7.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs9401954 chr6 127712351 A C 5.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs9401954 chr6 127712351 A C 7.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs9401954 chr6 127712351 A C 7.91E-04 Smoking quantity / / 24665060 rs11154403 chr6 127719108 T A 3.40E-04 Multiple complex diseases / / 17554300 rs9401956 chr6 127719901 A G 8.81E-04 Multiple complex diseases / / 17554300 rs6938872 chr6 127720556 G T 2.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs6938872 chr6 127720556 G T 7.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs6941233 chr6 127725733 A G 2.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs6941233 chr6 127725733 A G 8.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs2236026 chr6 127768472 G A 1.41E-04 Blood pressure KIAA0408 missense 17255346 rs2236026 chr6 127768472 G A 2.91E-04 Suicide attempts in bipolar disorder KIAA0408 missense 21423239 rs3757001 chr6 127774309 A G 3.32E-04 Suicide attempts in bipolar disorder KIAA0408 intron 21423239 rs9375513 chr6 127775166 T C 1.33E-04 Blood pressure KIAA0408 UTR-5 17255346 rs9375513 chr6 127775166 T C 3.15E-04 Suicide attempts in bipolar disorder KIAA0408 UTR-5 21423239 rs723642 chr6 127781820 T C 4.58E-04 Multiple complex diseases SOGA3 intron 17554300 rs1533186 chr6 127842055 C T 1.90E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9482815 chr6 127843776 T C 2.76E-04 Multiple complex diseases / / 17554300 rs7766541 chr6 127843873 G T 1.53E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1512454 chr6 127850966 G A 8.45E-04 Alcohol dependence / / 21314694 rs7743300 chr6 127852098 G T 1.28E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs34099566 chr6 127863487 A G 6.16E-04 Multiple complex diseases / / 17554300 rs938152 chr6 127869277 G A 7.88E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1512464 chr6 127875884 T C 2.07E-04 Multiple complex diseases / / 17554300 rs1913079 chr6 127879644 C T 2.27E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7746884 chr6 127888292 A G 3.55E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9401977 chr6 127895111 C G 8.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs6916511 chr6 127896109 T A 1.10E-06 Urinary metabolites / / 21572414 rs9388590 chr6 127898305 C T 1.30E-06 Urinary metabolites / / 21572414 rs9482826 chr6 127900557 A G 5.44E-05 Chronic obstructive pulmonary disease C6orf58 intron 19300482 rs9482826 chr6 127900557 A G 5.44E-05 Response to statin treatment (atorvastatin),change in cholesterol levels C6orf58 intron 20031582 rs1080436 chr6 127903054 C T 1.51E-04 Response to statin treatment (atorvastatin),change in cholesterol levels C6orf58 intron 20031582 rs2121881 chr6 127909977 C A 4.56E-04 Amyotrophic Lateral Sclerosis C6orf58 intron 17362836 rs2121881 chr6 127909977 C A 9.44E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) C6orf58 intron 24023788 rs721508 chr6 127910550 A G 3.51E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) C6orf58 intron 24023788 rs658838 chr6 128020485 C T 5.90E-06 Obesity-related traits / / 17658951 rs17299841 chr6 128021803 A C 2.00E-07 Immune response to smallpox vaccine (IL-6) / / 22610502 rs661254 chr6 128039966 T C 5.59E-04 Aortic root size THEMIS intron 21223598 rs476366 chr6 128044051 G A 4.11E-04 Aortic root size THEMIS intron 21223598 rs270010 chr6 128079888 C T 8.62E-04 Alzheimer's disease THEMIS intron 24755620 rs270012 chr6 128097770 T C 4.73E-04 Alzheimer's disease THEMIS intron 24755620 rs58702039 chr6 128106407 T TCTAC 4.63E-04 Alzheimer's disease THEMIS intron 24755620 rs623345 chr6 128106407 T C 4.63E-04 Alzheimer's disease THEMIS intron 24755620 rs920992 chr6 128129380 G T 4.19E-04 Lung function (forced vital capacity) THEMIS intron 24023788 rs4243492 chr6 128162928 T C 6.38E-04 Suicide attempts in bipolar disorder THEMIS intron 21423239 rs10484716 chr6 128175722 A G 6.80E-05 Celiac disease THEMIS intron 17558408 rs270041 chr6 128184738 T C 1.40E-05 Urinary metabolites THEMIS intron 21572414 rs270044 chr6 128186483 G C 1.40E-05 Urinary metabolites THEMIS intron 21572414 rs12194062 chr6 128194473 C T 5.67E-04 Suicide attempts in bipolar disorder THEMIS intron 21423239 rs12194062 chr6 128194473 C T 5.00E-06 QRS duration THEMIS intron 23534349 rs13204742 chr6 128245765 G T 8.00E-15 Crohn's disease / / 23128233 rs802734 chr6 128278798 A G 3.00E-14 Celiac disease / / 20190752 rs802734 chr6 128278798 A G 3.00E-14 Asthma / / 21150878 rs802734 chr6 128278798 A G 2.62E-14 Celiac disease and Rheumatoid arthritis / / 21383967 rs802734 chr6 128278798 A G 6.00E-09 Multiple sclerosis / / 21833088 rs802734 chr6 128278798 A G 3.00E-14 Asthma / / 21907864 rs802734 chr6 128278798 A G 2.62E-14 Multiple sclerosis / / 22190364 rs55743914 chr6 128293562 C T 1.10E-18 Celiac disease PTPRK intron 22057235 rs72975916 chr6 128294055 C T 1.20E-05 Celiac disease PTPRK intron 22057235 rs9402011 chr6 128305888 T C 1.00E-04 Schizophrenia PTPRK intron 19197363 rs9375543 chr6 128311140 T C 7.75E-05 Schizophrenia PTPRK intron 19197363 rs3903663 chr6 128313088 A G 2.52E-04 Schizophrenia PTPRK intron 19197363 rs2326671 chr6 128334236 T C 5.86E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PTPRK intron 21844884 rs17245411 chr6 128345371 T C 4.60E-06 Urinary metabolites PTPRK intron 21572414 rs7759323 chr6 128411176 T C 8.93E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PTPRK intron 21844884 rs6938199 chr6 128434932 A G 4.23E-04 Multiple complex diseases PTPRK intron 17554300 rs10499138 chr6 128492182 A T 2.00E-06 Hearing impairment PTPRK intron 20068591 rs1012049 chr6 128530307 G A 1.20E-05 Urinary metabolites PTPRK intron 21572414 rs6923988 chr6 128593134 A C 1.90E-04 Response to antidepressants PTPRK intron 19736353 rs17364090 chr6 128832425 T C 5.80E-05 HIV-1 control PTPRK intron 20041166 rs6923822 chr6 128839470 G A 9.11E-05 Alcohol consumption PTPRK intron 23743675 rs17056135 chr6 128949233 G T 2.30E-06 Urinary metabolites / / 21572414 rs17056140 chr6 128951307 T C 6.90E-04 Alcohol dependence / / 20201924 rs17056165 chr6 128965521 C T 1.70E-05 Urinary metabolites / / 21572414 rs575131 chr6 128979455 A C 0.00071 Salmonella-induced pyroptosis / / 22837397 rs562490 chr6 128983667 T C 0.000000684 Interventricular septal wall thickness / / 23275298 rs1508444 chr6 129079265 G T 7.42E-04 Multiple complex diseases / / 17554300 rs6569558 chr6 129141297 A G 2.26E-04 Vaspin levels / / 22907691 rs6569558 chr6 129141297 A G 0.0002262 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs12192613 chr6 129199783 C T 3.34E-05 Biliary atresia / / 20460270 rs11154452 chr6 129302280 T C 9.83E-04 Multiple complex diseases LAMA2 intron 17554300 rs1140366 chr6 129371106 C T 2.06E-04 Coronary Artery Disease LAMA2 cds-synon 17634449 rs4534007 chr6 129373689 G A 7.23E-05 Alcohol dependence LAMA2 intron 19581569 rs4895846 chr6 129384367 T C 8.71E-05 Alcohol dependence LAMA2 intron 19581569 rs9375615 chr6 129401222 A G 4.55E-05 Multiple complex diseases LAMA2 intron 17554300 rs1478800 chr6 129436996 A C 8.23E-04 Type 2 diabetes LAMA2 intron 17463246 rs12213754 chr6 129439995 A G 1.35E-04 Celiac disease LAMA2 intron 23936387 rs1478797 chr6 129460337 C T 0.000009 Salmonella-induced pyroptosis LAMA2 intron 22837397 rs1478796 chr6 129466315 C T 0.000013 Salmonella-induced pyroptosis LAMA2 intron 22837397 rs3778137 chr6 129486913 T C 8.88E-04 Type 2 diabetes LAMA2 intron 17463246 rs9492262 chr6 129505832 T C 8.23E-04 Type 2 diabetes LAMA2 intron 17463246 rs12210504 chr6 129520730 G A 9.98E-04 Type 2 diabetes LAMA2 intron 17463246 rs3778132 chr6 129527534 G A 9.98E-04 Type 2 diabetes LAMA2 intron 17463246 rs7739194 chr6 129550457 G A 1.07E-04 Multiple complex diseases LAMA2 intron 17554300 rs9385483 chr6 129551123 G T 7.08E-04 Multiple complex diseases LAMA2 intron 17554300 rs4280978 chr6 129619236 G A,C,T 5.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LAMA2 intron 20877124 rs3798662 chr6 129634426 G A 8.40E-04 Type 2 diabetes LAMA2 intron 17463246 rs9385488 chr6 129673689 T C 5.47E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) LAMA2 intron 23648065 rs3813367 chr6 129674757 G T 5.09E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) LAMA2 intron 23648065 rs17742838 chr6 129681346 C T 0.0006852 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LAMA2 intron 23233654 rs17742838 chr6 129681346 C T 6.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) LAMA2 intron 23233662 rs7758663 chr6 129695667 T C 9.00E-05 Prostate cancer LAMA2 intron 21743057 rs17057193 chr6 129697164 T C 9.00E-05 Prostate cancer LAMA2 intron 21743057 rs9492314 chr6 129697887 G A 9.00E-05 Prostate cancer LAMA2 intron 21743057 rs7356971 chr6 129699599 C T 9.36E-04 Type 2 diabetes LAMA2 intron 17463246 rs9483018 chr6 129699605 T A 9.00E-05 Prostate cancer LAMA2 intron 21743057 rs9483020 chr6 129700639 G A 9.00E-05 Prostate cancer LAMA2 intron 21743057 rs9483022 chr6 129700896 T C 9.00E-05 Prostate cancer LAMA2 intron 21743057 rs9483023 chr6 129700964 T C 9.00E-05 Prostate cancer LAMA2 intron 21743057 rs17057200 chr6 129700998 C T 5.09E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) LAMA2 intron 23648065 rs41524649 chr6 129718493 T A 9.76E-05 Response to citalopram treatment LAMA2 intron 19846067 rs7755729 chr6 129783642 C T 3.00E-06 Amyotrophic lateral sclerosis (sporadic) LAMA2 intron 24529757 rs6569603 chr6 129793717 C A 1.91E-04 Substance dependence LAMA2 intron 21818250 rs2571577 chr6 129798084 T C 7.05E-04 Alcohol dependence LAMA2 intron 21314694 rs2571577 chr6 129798084 T C 3.42E-05 Cognitive decline LAMA2 intron 22054870 rs2571584 chr6 129803485 A G 6.00E-06 Type 2 diabetes LAMA2 intron 19184112 rs12193446 chr6 129820038 A G 1.40E-45 Myopia (Age of onset) LAMA2 intron 23468642 rs12193446 chr6 129820038 A G 1.00E-08 Axial length LAMA2 intron 24144296 rs17752721 chr6 129820505 C T 7.39E-05 Partial epilepsies LAMA2 intron 20522523 rs12205363 chr6 129834629 T C 2.00E-12 Refractive error LAMA2 intron 23396134 rs875128 chr6 129849509 T G 1.83E-04 Alzheimer's disease (late onset) / / 21379329 rs2275215 chr6 129861392 T C 4.00E-07 Body mass index / / 20397748 rs10457525 chr6 129872966 G T 3.50E-06 Periodontal disease-related phenotypes / / 24347629 rs7749983 chr6 129874355 T A 2.00E-06 Periodontal disease-related phenotypes / / 24347629 rs17810534 chr6 129887299 T C 0.0000028 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs10457526 chr6 129896501 G T 6.00E-06 Periodontal disease-related phenotypes / / 24347629 rs10499161 chr6 129912799 A G 0.00000401 Change in depression severity with antidepressants (NRI or SRI) ARHGAP18 intron 23091423 rs10499162 chr6 129919010 T C 7.00E-04 Colorectal cancer ARHGAP18 intron 17618283 rs9321174 chr6 129921216 G A 2.40E-05 Cognitive function ARHGAP18 intron 24684796 rs4604290 chr6 129923552 A C 3.40E-05 Cognitive function ARHGAP18 intron 24684796 rs12530181 chr6 129925003 A G 3.26E-06 Cognitive impairment induced by topiramate ARHGAP18 intron 22091778 rs9375641 chr6 129948198 T C 7.48E-04 Smoking initiation ARHGAP18 intron 24665060 rs9375645 chr6 129955117 A C 9.50E-04 Myopia (pathological) ARHGAP18 intron 21095009 rs4310078 chr6 129957731 T C 1.47E-04 Alzheimer's disease ARHGAP18 intron pha002879 rs6931247 chr6 129961976 G A 3.68E-04 Multiple complex diseases ARHGAP18 intron 17554300 rs4479964 chr6 129971544 G A 4.44E-05 Multiple complex diseases ARHGAP18 intron 17554300 rs4479964 chr6 129971544 G A 7.07E-04 Myopia (pathological) ARHGAP18 intron 21095009 rs9388721 chr6 129971929 C T 1.80E-04 Type 2 diabetes ARHGAP18 intron 17463246 rs12197901 chr6 129973843 T C 1.38E-04 HIV-1 viral setpoint ARHGAP18 intron 17641165 rs9402156 chr6 129973962 A T 8.83E-04 Alzheimer's disease ARHGAP18 intron 17998437 rs17811901 chr6 129979762 C T 1.44E-04 Type 2 diabetes ARHGAP18 intron 17463246 rs6569617 chr6 129980436 T C 0.0002 Prostate cancer ARHGAP18 intron 23555315 rs13209334 chr6 129982914 C A 6.80E-04 Myopia (pathological) ARHGAP18 intron 21095009 rs6922711 chr6 129986792 T C 8.87E-04 Myopia (pathological) ARHGAP18 intron 21095009 rs6920979 chr6 130005667 G T 8.50E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) ARHGAP18 intron 23648065 rs12660691 chr6 130008445 A C 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) ARHGAP18 intron 23648065 rs1894642 chr6 130015331 T G 4.55E-05 Smoking cessation ARHGAP18 intron 18519826 rs1894642 chr6 130015331 T G 0.000275335 Hypertension (early onset hypertension) ARHGAP18 intron 22479346 rs17057640 chr6 130019354 T C 5.00E-06 Cognitive function ARHGAP18 intron 24684796 rs763132 chr6 130020347 A C 1.19E-04 Smoking cessation ARHGAP18 intron 18519826 rs2157460 chr6 130021128 A G 7.07E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) ARHGAP18 intron 23648065 rs12529067 chr6 130023213 A G 1.00E-04 Cognitive impairment induced by topiramate ARHGAP18 intron 22091778 rs2068685 chr6 130029839 G A 8.90E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) ARHGAP18 intron 23648065 rs17057678 chr6 130031493 T C 6.00E-07 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs12213388 chr6 130032745 T C 3.32E-04 Alcohol dependence / / 20201924 rs6914728 chr6 130055734 T G 4.40E-06 Urinary metabolites / / 21572414 rs6569625 chr6 130058210 C T 3.04E-05 Lymphocyte counts / / 22286170 rs10484282 chr6 130066078 G A 8.34E-05 Alzheimer's disease (late onset) / / 21379329 rs13210213 chr6 130071460 C T 6.45E-04 Aortic root size / / 21223598 rs208865 chr6 130072556 T C 2.60E-05 Diabetic nephropathy / / 21150874 rs208865 chr6 130072556 T C 2.14E-04 Type 2 diabetes / / 22238593 rs433351 chr6 130075541 T C 8.83E-05 Lymphocyte counts / / 22286170 rs4897336 chr6 130082061 G A 9.04E-04 Myocardial Infarction / / pha002883 rs12195685 chr6 130082258 G A 7.48E-04 Multiple complex diseases / / 17554300 rs9321180 chr6 130102959 C T 1.97E-04 Multiple complex diseases / / 17554300 rs9321180 chr6 130102959 C T 8.64E-06 Heart Rate / / pha003054 rs4256453 chr6 130106117 T C 3.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9321183 chr6 130113882 G T 9.68E-04 Multiple complex diseases / / 17554300 rs11968591 chr6 130116227 C T 3.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1480520 chr6 130134676 G A 8.60E-04 Insulin resistance / / 21901158 rs7776426 chr6 130152520 A C 9.71E-04 Myopia (pathological) TMEM244 missense 21095009 rs9492393 chr6 130154667 T C 1.90E-04 Alcohol dependence TMEM244 missense 20201924 rs9492393 chr6 130154667 T C 6.90E-04 Alcohol dependence TMEM244 missense 20201924 rs6912805 chr6 130155713 T C 1.40E-04 Alcohol dependence TMEM244 intron 20201924 rs6912805 chr6 130155713 T C 6.00E-04 Alcohol dependence TMEM244 intron 20201924 rs9402186 chr6 130171667 A G 1.46E-04 Multiple complex diseases TMEM244 intron 17554300 rs9492408 chr6 130187499 T G 9.55E-05 Brain lesion load / / 19010793 rs9492408 chr6 130187499 T G 5.98E-04 Heart Failure / / pha002885 rs2127706 chr6 130190985 G A 5.12E-06 Leprosy / / 22019778 rs7759872 chr6 130207074 A G 9.34E-04 Type 2 diabetes / / 17463246 rs13194029 chr6 130207695 C T 2.04E-05 Epilepsy (remission after treatment) / / 23962720 rs9375674 chr6 130216510 A G 6.00E-06 Renal sinus fat / / 22044751 rs9375674 chr6 130216510 A G 1.51E-04 Vaspin levels / / 22907691 rs9375674 chr6 130216510 A G 0.000151 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs2039683 chr6 130251793 C A 6.80E-05 Type 2 diabetes / / 17463246 rs10457532 chr6 130254961 A C 1.22E-04 Height / / 22216288 rs7767265 chr6 130263566 A G 2.86E-04 Smoking quantity / / 24665060 rs11757973 chr6 130275975 G A 7.70E-06 Urinary metabolites / / 21572414 rs4897357 chr6 130311011 C G 3.17E-04 Parkinson's disease / / 16252231 rs1415699 chr6 130315411 G A 6.63E-05 Suicide attempts in bipolar disorder / / 21041247 rs945889 chr6 130321244 T C 7.57E-05 Suicide attempts in bipolar disorder / / 21041247 rs2876066 chr6 130322179 C A 7.74E-05 Suicide attempts in bipolar disorder / / 21041247 rs1337775 chr6 130334365 A G 4.58E-04 Type 2 diabetes / / 17463246 rs1415701 chr6 130345835 G A 2.80E-04 Type 2 diabetes and 6 quantitative traits L3MBTL3 intron 17848626 rs1415701 chr6 130345835 G A 5.00E-13 Height L3MBTL3 intron 23563607 rs6569648 chr6 130349119 C T 1.00E-21 Height L3MBTL3 intron 20881960 rs9375694 chr6 130356608 G A 8.97E-05 Type 2 diabetes L3MBTL3 intron 17463246 rs6899976 chr6 130358428 G A 6.00E-06 Height L3MBTL3 intron 18391951 rs9375695 chr6 130358944 G T 3.97E-04 Type 2 diabetes L3MBTL3 intron 17463246 rs9388769 chr6 130379954 G A 8.07E-04 Type 2 diabetes L3MBTL3 intron 17463246 rs1932103 chr6 130420052 G A 6.11E-05 Interstitial lung disease L3MBTL3 intron 23583980 rs9492457 chr6 130438612 C T 2.27E-04 Multiple complex diseases L3MBTL3 intron 17554300 rs10485400 chr6 130444124 C T 6.89E-04 Multiple complex diseases L3MBTL3 intron 17554300 rs4897366 chr6 130458078 C A 9.23E-04 Multiple complex diseases L3MBTL3 intron 17554300 rs2152192 chr6 130469126 T C 0.0000277 Antithrombin SAMD3 intron 23705025 rs1932106 chr6 130474597 G T 9.35E-05 Cognitive test performance SAMD3 intron 20125193 rs6569657 chr6 130478834 G A 2.23E-04 Multiple complex diseases SAMD3 intron 17554300 rs10223341 chr6 130495883 G T 3.72E-05 Opioid sensitivity SAMD3 intron 23183491 rs1034263 chr6 130499476 C T 1.00E-04 Prostate cancer SAMD3 intron 21743057 rs6919001 chr6 130507474 G A 6.07E-04 Multiple complex diseases SAMD3 intron 17554300 rs7760764 chr6 130508557 A G 5.86E-05 Glucose levels SAMD3 intron pha003057 rs1932116 chr6 130520943 G A,T 8.64E-04 Type 2 diabetes SAMD3 intron 17463246 rs1932116 chr6 130520943 G A,T 9.09E-04 Multiple complex diseases SAMD3 intron 17554300 rs11154532 chr6 130525375 T C 1.10E-04 Mathematical ability SAMD3 intron 20039944 rs11154532 chr6 130525375 T C 5.00E-04 Mathematical ability SAMD3 intron 20039944 rs7747640 chr6 130525487 A G 1.80E-05 Urinary metabolites SAMD3 intron 21572414 rs6569665 chr6 130533734 C T 5.96E-04 Type 2 diabetes SAMD3 intron 17463246 rs6569665 chr6 130533734 C T 8.05E-04 Multiple complex diseases SAMD3 intron 17554300 rs17058525 chr6 130546950 C T 7.38E-04 Multiple complex diseases SAMD3 intron 17554300 rs10447419 chr6 130550063 C A 2.00E-06 PR interval SAMD3 intron 23534349 rs6909415 chr6 130642915 G A 7.14E-05 Response to methylphenidate treatment SAMD3 intron 21130132 rs6909986 chr6 130643221 G A 1.06E-04 Multiple complex diseases SAMD3 intron 17554300 rs2011841 chr6 130704033 T C 6.76E-04 Amyotrophic Lateral Sclerosis TMEM200A intron 17827064 rs6569682 chr6 130734782 T C 9.58E-04 Amyotrophic Lateral Sclerosis TMEM200A intron 17827064 rs10155668 chr6 130752428 C A 2.84E-04 Amyotrophic Lateral Sclerosis TMEM200A intron 17827064 rs11154581 chr6 130770833 T A 3.04E-05 Biliary atresia / / 20460270 rs2209151 chr6 130771125 T G 1.17E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs2069129 chr6 130779148 G A 1.33E-04 Type 2 diabetes / / 17463246 rs11751990 chr6 130787776 C T 4.30E-04 Alzheimer's disease / / 17998437 rs11751990 chr6 130787776 C T 4.97E-06 Asthma / / 20698975 rs9483132 chr6 130789807 C A 3.54E-05 Cognitive impairment induced by topiramate / / 22091778 rs17059127 chr6 130792769 T G 5.81E-04 Taste perception / / 22132133 rs12210827 chr6 130806316 A T 8.40E-04 Alcohol dependence / / 21314694 rs2876086 chr6 130818014 C T 6.26E-04 Type 2 diabetes / / 17463246 rs2876086 chr6 130818014 C T 2.56E-08 Lymphocyte counts / / 22286170 rs9402234 chr6 130827482 C T 1.37E-05 Celiac disease / / 23936387 rs17059212 chr6 130868894 A C 3.35E-05 Body Mass Index / / pha003019 rs17059212 chr6 130868894 A C 3.44E-05 Body Mass Index / / pha003020 rs11154594 chr6 130879168 T C 8.56E-04 Multiple complex diseases / / 17554300 rs9492645 chr6 130886437 G A 5.00E-06 IgG glycosylation / / 23382691 rs9492645 chr6 130886437 G A 7.00E-06 IgG glycosylation / / 23382691 rs7745661 chr6 130913854 A G 9.93E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17059277 chr6 130933034 A G 7.83E-04 Multiple complex diseases / / 17554300 rs9398953 chr6 130933340 C T 5.90E-06 Iron levels / / 21208937 rs4895890 chr6 130941233 C T 5.83E-05 Orofacial clefts / / 22863734 rs997732 chr6 130951351 A T 8.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs1532986 chr6 130962874 G T 7.58E-05 Cognitive decline / / 23732972 rs9492683 chr6 130967588 A G 3.69E-05 Cognitive decline / / 23732972 rs9492684 chr6 130969003 A C 8.51E-04 Nicotine dependence / / 17158188 rs2020202 chr6 130984945 T C 2.30E-04 Alcohol dependence / / 20201924 rs9483167 chr6 131030583 G A 6.08E-04 Depression (quantitative trait) / / 20800221 rs4897449 chr6 131046403 A G 2.78E-04 Depression (quantitative trait) / / 20800221 rs4897450 chr6 131046661 A C 2.77E-04 Depression (quantitative trait) / / 20800221 rs4897451 chr6 131046822 C T 2.76E-04 Depression (quantitative trait) / / 20800221 rs4897455 chr6 131047288 A G 2.41E-04 Depression (quantitative trait) / / 20800221 rs4112310 chr6 131052404 C A 1.30E-04 Depression (quantitative trait) / / 20800221 rs1497885 chr6 131052657 C A 1.86E-04 Depression (quantitative trait) / / 20800221 rs1497885 chr6 131052657 C A 5.68E-05 Major depressive disorder / / 21621269 rs10457556 chr6 131054125 A G 1.85E-04 Depression (quantitative trait) / / 20800221 rs9388836 chr6 131055104 G A 8.74E-05 Depression (quantitative trait) / / 20800221 rs6933145 chr6 131080130 T C 1.87E-04 Response to alcohol consumption (flushing response) / / 24277619 rs17059529 chr6 131090112 G A 5.42E-04 Alcohol dependence / / 21314694 rs728263 chr6 131095477 C T 1.51E-04 Depression (quantitative trait) / / 20800221 rs9375768 chr6 131097518 T G 3.49E-06 Glaucoma (primary open-angle) / / 22605921 rs1582055 chr6 131144363 T C 7.70E-05 Blood Phenotypes / / 17903294 rs9388856 chr6 131148863 A T 1.00E-04 Acute lymphoblastic leukemia (childhood) LOC100507203 intron 20189245 rs1360756 chr6 131149416 C T 1.00E-04 Acute lymphoblastic leukemia (childhood) LOC100507203 intron 20189245 rs9388857 chr6 131149878 T G 1.00E-04 Acute lymphoblastic leukemia (childhood) LOC100507203 intron 20189245 rs6908659 chr6 131149902 G T 2.00E-04 Acute lymphoblastic leukemia (childhood) LOC100507203 intron 20189245 rs9388858 chr6 131150127 T C 2.34E-06 Serum metabolites LOC100507203 intron 19043545 rs9388858 chr6 131150127 T C 2.00E-04 Acute lymphoblastic leukemia (childhood) LOC100507203 intron 20189245 rs1413754 chr6 131150626 A G 1.45E-06 Bilirubin levels,in serum LOC100507203 intron 19389676 rs6918160 chr6 131154822 T C 9.10E-05 HIV-1 control LOC100507203 intron 20041166 rs17059678 chr6 131162265 A G 1.70E-07 Urinary metabolites EPB41L2 intron 21572414 rs6569709 chr6 131182046 T C 3.87E-05 Serum metabolites EPB41L2 intron 19043545 rs17059736 chr6 131190838 G A 1.20E-05 Urinary metabolites EPB41L2 cds-synon 21572414 rs9285468 chr6 131192130 C T 2.70E-05 Serum metabolites EPB41L2 intron 19043545 rs9285468 chr6 131192130 C T 4.12E-05 Hematocrit EPB41L2 intron pha003097 rs10499177 chr6 131215821 A G 6.70E-07 Urinary metabolites EPB41L2 intron 21572414 rs17832366 chr6 131217024 G T 7.00E-07 Urinary metabolites EPB41L2 intron 21572414 rs9388867 chr6 131228767 A G 1.74E-05 Serum metabolites EPB41L2 intron 19043545 rs4897475 chr6 131232950 A G 1.60E-04 Blood Phenotypes EPB41L2 intron 17903294 rs1334689 chr6 131234008 A G 9.69E-06 Serum metabolites EPB41L2 intron 19043545 rs7766505 chr6 131246774 G T 1.90E-05 Serum metabolites EPB41L2 intron 19043545 rs3777456 chr6 131249824 C A 2.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EPB41L2 intron 20877124 rs3777457 chr6 131249887 G A 5.76E-04 Alzheimer's disease EPB41L2 intron 17998437 rs3798251 chr6 131255106 G A 2.80E-06 Urinary metabolites EPB41L2 intron 21572414 rs7769153 chr6 131256364 T G 2.00E-07 Response to statin therapy (LDL-C) EPB41L2 intron 22331829 rs9492762 chr6 131260784 G T 2.90E-06 Urinary metabolites EPB41L2 intron 21572414 rs9492764 chr6 131267066 T C 9.69E-06 Serum metabolites EPB41L2 intron 19043545 rs6941712 chr6 131282210 T C 5.00E-06 Lentiform nucleus volume EPB41L2 intron 22903471 rs12530288 chr6 131298399 A T 8.61E-05 Dietary macronutrient intake EPB41L2 intron 23636237 rs9375791 chr6 131313416 T C 7.46E-04 Amyotrophic lateral sclerosis (sporadic) EPB41L2 intron 24529757 rs9375797 chr6 131345517 G C 6.25E-06 Lymphocyte counts EPB41L2 intron 22286170 rs7742376 chr6 131349836 A C 2.60E-05 Urinary metabolites EPB41L2 intron 21572414 rs17059987 chr6 131349865 A C 2.96E-09 Multiple complex diseases EPB41L2 intron 17554300 rs6908917 chr6 131355864 G C 2.00E-06 IgG glycosylation EPB41L2 intron 23382691 rs1338905 chr6 131361935 C T 9.30E-06 Urinary metabolites EPB41L2 intron 21572414 rs9492803 chr6 131402416 A G 9.40E-06 Post-operative nausea and vomiting / / 21694509 rs13208443 chr6 131402814 G T 4.44E-05 Celiac disease / / 23936387 rs602848 chr6 131446791 C G 1.00E-06 Migraine - clinic-based / / 23793025 rs602848 chr6 131446791 C G 5.00E-06 Migraine with aura / / 23793025 rs6917207 chr6 131470236 C T 8.02E-05 Response to treatment for acute lymphoblastic leukemia AKAP7 intron 19176441 rs17787339 chr6 131473361 T C 7.77E-04 Type 2 diabetes AKAP7 intron 17463246 rs1569196 chr6 131481670 C T 8.75E-04 Response to taxane treatment (placlitaxel) AKAP7 intron 23006423 rs1881573 chr6 131483778 G A 8.28E-04 Heart Failure AKAP7 intron pha002885 rs9321275 chr6 131493218 A G 2.31E-04 Multiple complex diseases AKAP7 intron 17554300 rs1729549 chr6 131506165 C T 4.41E-04 Multiple complex diseases AKAP7 intron 17554300 rs3777474 chr6 131526505 A G 8.10E-05 Eating disorders (purging via substances) AKAP7 intron 23568457 rs12215812 chr6 131541438 G A 2.37E-05 Cognitive impairment induced by topiramate AKAP7 intron 22091778 rs4629710 chr6 131563577 G A 6.00E-06 Multiple myeloma (IgH translocation) AKAP7 intron 23502783 rs3777486 chr6 131584648 T C 5.37E-06 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines AKAP7 intron 21483694 rs3777487 chr6 131584810 G A 8.26E-04 Suicide attempts in bipolar disorder AKAP7 intron 21423239 rs6923644 chr6 131589237 G T 5.54E-05 Cognitive impairment induced by topiramate AKAP7 intron 22091778 rs6924196 chr6 131589506 G A 1.81E-04 Amyotrophic Lateral Sclerosis AKAP7 intron 17362836 rs6924196 chr6 131589506 G A 8.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) AKAP7 intron 20877124 rs1322596 chr6 131590957 A T 9.57E-04 Suicide attempts in bipolar disorder AKAP7 intron 21423239 rs6937607 chr6 131604844 T G 7.69E-04 Suicide attempts in bipolar disorder AKAP7 nearGene-3 21423239 rs7754007 chr6 131615814 A T 9.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs1407530 chr6 131624204 C A 1.90E-05 Urinary metabolites / / 21572414 rs6938891 chr6 131631588 A G 8.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs4897509 chr6 131673070 A G 8.45E-05 Meningococcal disease / / 20694013 rs9483254 chr6 131675201 A G 5.87E-05 Meningococcal disease / / 20694013 rs2206980 chr6 131712619 G C 2.25E-04 Response to TNF antagonist treatment / / 21061259 rs722027 chr6 131737654 G A 6.10E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2179771 chr6 131754930 T C 3.72E-08 C-reactive protein / / 24763700 rs9492976 chr6 131755998 C A 3.13E-08 C-reactive protein / / 24763700 rs9483280 chr6 131756636 A G 3.08E-08 C-reactive protein / / 24763700 rs9402328 chr6 131757051 T C 3.08E-08 C-reactive protein / / 24763700 rs9375813 chr6 131757247 C A 2.85E-08 C-reactive protein / / 24763700 rs9375813 chr6 131757247 C A 3.00E-08 C-reactive protein / / 24763700 rs2143779 chr6 131758785 G T 3.41E-08 C-reactive protein / / 24763700 rs9483281 chr6 131765179 G A 5.35E-08 C-reactive protein / / 24763700 rs6904726 chr6 131768697 G A 9.44E-08 C-reactive protein / / 24763700 rs6904733 chr6 131768709 G T 9.54E-08 C-reactive protein / / 24763700 rs6927792 chr6 131769107 T C 9.54E-08 C-reactive protein / / 24763700 rs17060292 chr6 131780576 G A 3.06E-05 Coronary heart disease / / pha003035 rs2491209 chr6 131781130 A G 4.01E-06 C-reactive protein / / 24763700 rs2608951 chr6 131783780 G C 5.79E-08 C-reactive protein / / 24763700 rs2608935 chr6 131789736 A G 6.56E-08 C-reactive protein / / 24763700 rs2807272 chr6 131791245 T C 1.30E-06 C-reactive protein / / 24763700 rs2608928 chr6 131791871 A C 6.27E-08 C-reactive protein / / 24763700 rs2807273 chr6 131792521 G T 1.45E-06 C-reactive protein / / 24763700 rs2608927 chr6 131794043 T C 6.85E-08 C-reactive protein / / 24763700 rs9321294 chr6 131795557 T C 6.70E-08 C-reactive protein / / 24763700 rs2491204 chr6 131797404 T A 6.73E-08 C-reactive protein / / 24763700 rs4443525 chr6 131798267 A G 1.79E-06 C-reactive protein / / 24763700 rs2608940 chr6 131798931 T C 1.79E-06 C-reactive protein / / 24763700 rs2608945 chr6 131802294 G C 4.76E-04 Response to TNF antagonist treatment / / 21061259 rs9492992 chr6 131802427 G T 1.05E-05 C-reactive protein / / 24763700 rs9493000 chr6 131808591 T C 4.56E-06 C-reactive protein / / 24763700 rs7740929 chr6 131808622 A G 4.56E-06 C-reactive protein / / 24763700 rs3861462 chr6 131809436 T C 4.06E-06 C-reactive protein / / 24763700 rs3861462 chr6 131809436 T C 2.31E-05 Coronary heart disease / / pha003035 rs17656494 chr6 131809785 T C 3.53E-05 Coronary heart disease / / pha003035 rs2807278 chr6 131809920 T C 3.00E-07 Obesity / / 21552555 rs3904567 chr6 131840255 C T 3.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs6900409 chr6 131847557 T G 9.23E-04 Obesity (extreme) / / 21935397 rs11759748 chr6 131854519 A G 5.30E-05 Alzheimer's disease (late onset) / / 21379329 rs4526224 chr6 131855503 T G 9.75E-05 Alzheimer's disease (late onset) / / 21379329 rs9493022 chr6 131857907 T C 4.14E-04 Alzheimer's disease (late onset) / / 21379329 rs17060362 chr6 131867261 G A 5.12E-04 Obesity (extreme) / / 21935397 rs2608912 chr6 131869783 T C 5.10E-05 C-reactive protein / / 24763700 rs2608913 chr6 131870261 T C 2.00E-05 C-reactive protein / / 24763700 rs2608914 chr6 131870611 T A 5.10E-05 C-reactive protein / / 24763700 rs2608915 chr6 131871314 A G 4.96E-05 C-reactive protein / / 24763700 rs2608916 chr6 131871605 T G 4.96E-05 C-reactive protein / / 24763700 rs2608917 chr6 131871956 A G 4.76E-05 C-reactive protein / / 24763700 rs2608918 chr6 131872892 C T 4.96E-05 C-reactive protein / / 24763700 rs2608919 chr6 131873335 A T 4.91E-05 C-reactive protein / / 24763700 rs2608921 chr6 131873735 C T 4.91E-05 C-reactive protein / / 24763700 rs2446213 chr6 131874031 T C 4.75E-05 C-reactive protein / / 24763700 rs2608982 chr6 131876200 G T 5.23E-05 C-reactive protein / / 24763700 rs2781650 chr6 131876721 A G 5.23E-05 C-reactive protein / / 24763700 rs2781651 chr6 131876943 A G 0.0000144 Fasting blood glucose / / 22885924 rs2781651 chr6 131876943 A G 5.23E-05 C-reactive protein / / 24763700 rs2749933 chr6 131877233 C T 5.23E-05 C-reactive protein / / 24763700 rs2608976 chr6 131878175 T C 5.23E-05 C-reactive protein / / 24763700 rs17060390 chr6 131883790 G A 6.19E-05 Suicide attempts in bipolar disorder / / 21423239 rs17060391 chr6 131884112 A G 6.29E-05 Suicide attempts in bipolar disorder / / 21423239 rs7753497 chr6 131888670 C T 6.13E-05 Suicide attempts in bipolar disorder / / 21423239 rs2781659 chr6 131891820 A G 1 Drug response to Budesonide / / 18617639 rs2781659 chr6 131891820 A G 1 Drug response to Fluticasone Propionate / / 18617639 rs2781659 chr6 131891820 A G 1 Drug response to Formoterol / / 18617639 rs2781659 chr6 131891820 A G 1 Drug response to Salmeterol / / 18617639 rs2781659 chr6 131891820 A G 4.40E-05 Lipid levels / / 19913121 rs3756780 chr6 131893052 T C 5.96E-04 Suicide attempts in bipolar disorder ARG1 nearGene-5 21423239 rs2608897 chr6 131893463 C T 1.07E-06 Post-operative nausea and vomiting ARG1 nearGene-5 21694509 rs2608897 chr6 131893463 C T 6.98E-05 Height ARG1 nearGene-5 pha003010 rs10484766 chr6 131899986 C T 0.000000759 HDL cholesterol ARG1 intron 23063622 rs10484766 chr6 131899986 C T 0.00000184 Cholesterol,total ARG1 intron 23063622 rs10484766 chr6 131899986 C T 1.08E-08 LDL cholesterol ARG1 intron 23063622 rs2297637 chr6 131900519 G T 3.29E-04 Suicide attempts in bipolar disorder ARG1 intron 21423239 rs17060430 chr6 131918737 G A 3.81E-04 Suicide attempts in bipolar disorder MED23 intron 21423239 rs17060430 chr6 131918737 G A 1.80E-07 Homoarginine levels MED23 intron 24047826 rs453639 chr6 132049657 C A 3.59E-07 Phosphorus levels ENPP3 intron 20558539 rs12199015 chr6 132058947 A G 5.00E-06 Response to fenofibrate (adiponectin levels) ENPP3 intron 23149075 rs17060697 chr6 132084833 A G 6.15E-04 Multiple complex diseases / / 17554300 rs10452621 chr6 132085401 C T 0.000123 Gains in maximal O2 uptake response / / 21183627 rs13212333 chr6 132089144 G A 1.00E-07 Urinary metabolites / / 21572414 rs9483341 chr6 132095668 T C 2.60E-06 Urinary metabolites / / 21572414 rs13198582 chr6 132096380 C A,G,T 1.70E-06 Urinary metabolites / / 21572414 rs13202409 chr6 132096993 C G 2.40E-05 Urinary metabolites / / 21572414 rs3908475 chr6 132098634 T A 5.40E-07 Urinary metabolites / / 21572414 rs7758525 chr6 132100610 G A 6.80E-08 Urinary metabolites / / 21572414 rs1800949 chr6 132128564 C T 8.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ENPP1 nearGene-5 20877124 rs6569759 chr6 132133116 A G 7.82E-04 Response to taxane treatment (placlitaxel) ENPP1 intron 23006423 rs2021966 chr6 132150439 A G 2.60E-04 Type 2 diabetes ENPP1 intron 17463248 rs2021966 chr6 132150439 A G 4.23E-04 Response to cytadine analogues (cytosine arabinoside) ENPP1 intron 24483146 rs858342 chr6 132160643 A G 0.000562401 Hypertension (early onset hypertension) ENPP1 intron 22479346 rs9375831 chr6 132164687 T A 8.42E-04 Type 2 diabetes ENPP1 intron 17463246 rs7768555 chr6 132168362 G A 8.24E-06 Alcohol and nictotine co-dependence ENPP1 intron 20158304 rs1044498 chr6 132172368 A C 0.000071 Stroke ENPP1 missense 23422753 rs9493114 chr6 132182584 A G 3.91E-04 Smoking initiation ENPP1 intron 24665060 rs7769712 chr6 132193395 A C 4.34E-05 Myopia (pathological) ENPP1 intron 21095009 rs7768480 chr6 132203432 A G 3.62E-05 Neutrophil count ENPP1 intron pha003095 rs7753048 chr6 132217687 C T 3.52E-04 Type 2 diabetes / / 17463246 rs6907728 chr6 132228769 A C 3.00E-06 Obesity-related traits / / 23251661 rs4897554 chr6 132262991 G A 9.35E-04 Heart Failure / / pha002884 rs9483364 chr6 132281798 A G 9.23E-05 Post-operative nausea and vomiting / / 21694509 rs12200142 chr6 132318165 G C 3.20E-05 White matter hyperintensity burden / / 21681796 rs2027035 chr6 132319751 C T 3.30E-05 White matter hyperintensity burden / / 21681796 rs7742135 chr6 132340824 C G 6.82E-04 Multiple complex diseases / / 17554300 rs12207504 chr6 132351866 G A 6.40E-05 White matter hyperintensity burden / / 21681796 rs6569772 chr6 132357671 C A 8.98E-04 Multiple complex diseases / / 17554300 rs9493173 chr6 132376018 G A 4.81E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9483377 chr6 132380668 A G 1.30E-05 Type 2 diabetes / / 17460697 rs9385594 chr6 132381115 G T 2.97E-05 Serum metabolites / / 19043545 rs7745875 chr6 132417564 G A 9.53E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1321267 chr6 132466452 A C 5.46E-05 Pulmonary function in asthmatics LOC100507254 intron 23541324 rs1321270 chr6 132466782 C A 1.37E-04 Arthritis (juvenile idiopathic) LOC100507254 intron 22354554 rs7756650 chr6 132537406 G A 9.80E-06 Obesity-related traits / / 23251661 rs9493262 chr6 132593433 C T 6.16E-04 Multiple complex diseases / / 17554300 rs9493264 chr6 132593480 G A 6.17E-04 Multiple complex diseases / / 17554300 rs1883339 chr6 132600984 G A 2.70E-04 Alcohol dependence / / 20201924 rs2092236 chr6 132607038 A G 5.20E-04 Alcohol dependence / / 20201924 rs11760080 chr6 132607796 G A 6.00E-04 Alcohol dependence / / 20201924 rs17718841 chr6 132611452 A G 4.01E-04 Multiple complex diseases / / 17554300 rs9388971 chr6 132611762 A G 3.34E-06 Obesity-related traits / / 23251661 rs17061146 chr6 132613798 C T 7.20E-04 Alcohol dependence / / 20201924 rs6902875 chr6 132617072 A G 8.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6903616 chr6 132617469 C T 6.80E-04 Alcohol dependence MOXD1 UTR-3 20201924 rs589756 chr6 132643117 C A 1.00E-06 Obesity-related traits MOXD1 intron 23251661 rs589756 chr6 132643117 C A 1.00E-07 Obesity-related traits MOXD1 intron 23251661 rs589756 chr6 132643117 C A 1.00E-07 Obesity-related traits MOXD1 intron 23251661 rs589756 chr6 132643117 C A 2.00E-06 Obesity-related traits MOXD1 intron 23251661 rs589756 chr6 132643117 C A 5.00E-06 Obesity-related traits MOXD1 intron 23251661 rs589756 chr6 132643117 C A 9.00E-06 Obesity-related traits MOXD1 intron 23251661 rs9373014 chr6 132687248 T C 1.00E-04 Information processing speed MOXD1 intron 21130836 rs9373014 chr6 132687248 T C 4.82E-04 Suicide attempts in bipolar disorder MOXD1 intron 21423239 rs17061204 chr6 132687293 T G 7.01E-06 Cortisol secretion,in saliva MOXD1 intron 21316860 rs6569792 chr6 132694751 A G 6.40E-05 Subclinical atherosclerosis MOXD1 intron 17903303 rs6569792 chr6 132694751 A G 2.47E-05 Soluble levels of adhesion molecules MOXD1 intron pha003072 rs9321341 chr6 132712426 T G 6.22E-04 Lipid levels MOXD1 intron 19016617 rs9321341 chr6 132712426 T G 7.87E-05 Lipid levels MOXD1 intron 19016617 rs6901304 chr6 132724298 G A 1.62E-22 Narcolepsy / / 19629137 rs6906574 chr6 132724996 C T 8.76E-05 Multiple complex diseases / / 17554300 rs6906574 chr6 132724996 C T 9.45E-04 Lymphocyte counts / / 22286170 rs7743622 chr6 132730372 C G 9.12E-04 Type 2 diabetes / / 17463246 rs2282315 chr6 132776734 A G 0.000016 Transmission distortion / / 22377632 rs9483454 chr6 132783865 C A 2.61E-04 Lymphocyte counts STX7 intron 22286170 rs2842891 chr6 132817897 C T 2.25E-04 Alcohol dependence STX7 intron 21314694 rs3813356 chr6 132834518 C T 5.87E-04 Amyotrophic lateral sclerosis / / 23624525 rs1001859 chr6 132845928 C T 9.42E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs1933988 chr6 132871653 A C 3.57E-05 Coronary heart disease / / pha003031 rs2840837 chr6 132883583 G A 2.43E-06 Coronary heart disease / / pha003031 rs9321351 chr6 132885423 C A 6.05E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9399032 chr6 132888939 T A 4.00E-06 Migraine without aura / / 23793025 rs12526035 chr6 132901735 C T 3.24E-04 Type 2 diabetes / / 17463246 rs9321354 chr6 132905187 C A 3.40E-05 Subclinical atherosclerosis / / 17903303 rs4458717 chr6 132908879 T C 2.64E-11 Peripartum cardiomyopathy / / 21665988 rs4631322 chr6 132917346 C T 9.11E-05 Bipolar disorder / / 20451256 rs12200430 chr6 132929084 T C 1.56E-04 Birth weight / / 17255346 rs1081076 chr6 132931359 C T 8.33E-05 Multiple complex diseases / / 17554300 rs9389020 chr6 132963053 T C 5.87E-04 Schizophrenia / / 19197363 rs2745438 chr6 132980067 G A 2.20E-05 Urinary metabolites / / 21572414 rs909975 chr6 133014991 G A 8.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VNN1 intron 20877124 rs12205095 chr6 133037306 T G 4.85E-04 Lymphocyte counts / / 22286170 rs7739368 chr6 133042840 A C 1.13E-04 Height / / 17255346 rs2294758 chr6 133045812 G A 4.60E-05 Parkinson's disease (age of onset) / / 19772629 rs767147 chr6 133057661 T C 2.86E-05 Multiple complex diseases / / 17554300 rs9321363 chr6 133068419 C A 3.23E-12 Multiple complex diseases VNN2 intron 17554300 rs7738071 chr6 133085116 G A 4.11E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs369717923 chr6 133085301 GT GCC,GGT 7.35E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7738400 chr6 133085301 G C 7.35E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7758703 chr6 133085417 T C 8.75E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9493435 chr6 133088205 T C 6.87E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7751879 chr6 133089557 T C 1.54E-04 Smoking initiation / / 24665060 rs7770081 chr6 133089569 G T 3.73E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1467404 chr6 133090141 C T 9.26E-04 Diabetic nephropathy / / 21150874 rs1467404 chr6 133090141 C T 9.22E-04 Type 2 diabetes / / 22238593 rs9493454 chr6 133144629 A C 2.35E-05 Diabetic nephropathy / / 21150874 rs9493454 chr6 133144629 A C 4.91E-04 Type 2 diabetes / / 22238593 rs7769051 chr6 133146796 C A 2.00E-06 Type 2 diabetes nephropathy / / 21150874 rs7769051 chr6 133146796 C A 4.06E-04 Type 2 diabetes / / 22238593 rs7774585 chr6 133154926 G A 5.10E-05 Cholesterol / / pha003073 rs7774585 chr6 133154926 G A 5.05E-05 Cholesterol / / pha003078 rs7768053 chr6 133159414 C G 1.30E-05 Formal thought disorder in schizophrenia / / 22648509 rs9389037 chr6 133171832 T C 5.49E-05 Cholesterol / / pha003073 rs9389037 chr6 133171832 T C 3.66E-05 Cholesterol / / pha003078 rs9375927 chr6 133187185 T G 8.42E-05 Cholesterol / / pha003078 rs718508 chr6 133204398 C T 7.84E-04 Type 2 diabetes / / 17846124 rs2764217 chr6 133234716 G A,C 0.0000382 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs271114 chr6 133235462 C T 0.0000519 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs271119 chr6 133237557 C T 0.0000567 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs271129 chr6 133245534 C G 5.59E-04 Lymphocyte counts / / 22286170 rs271145 chr6 133282058 G A 4.00E-08 Bone mineral density (paediatric,skull) / / 24945404 rs271146 chr6 133282147 A G 2.00E-14 Bone mineral density (paediatric,skull) / / 24945404 rs378273 chr6 133292440 G A 1.29E-04 Age-related macular degeneration / / 22125219 rs872249 chr6 133294702 A G 2.00E-08 Bone mineral density (paediatric,skull) / / 24945404 rs271177 chr6 133298964 A T 3.60E-08 Bone mineral density (paediatric,skull) / / 24945404 rs271173 chr6 133312222 C T 4.70E-09 Bone mineral density (paediatric,skull) / / 24945404 rs271170 chr6 133315804 T C 3.00E-12 Bone mineral density / / 23437003 rs271170 chr6 133315804 T C 3.10E-16 Bone mineral density (paediatric,skull) / / 24945404 rs3012463 chr6 133335493 C T 2.30E-16 Bone mineral density (paediatric,skull) / / 24945404 rs2926349 chr6 133340139 G A 2.90E-16 Bone mineral density (paediatric,skull) / / 24945404 rs3012465 chr6 133350936 A G 1.57E-04 Epilepsy / / 22116939 rs3012465 chr6 133350936 A G 2.00E-12 Bone mineral density (paediatric,skull) / / 24945404 rs3012465 chr6 133350936 A G 8.00E-17 Bone mineral density (paediatric,skull) / / 24945404 rs3012471 chr6 133356235 A T 2.90E-16 Bone mineral density (paediatric,skull) / / 24945404 rs4487594 chr6 133396480 A G 2.88E-06 Neuroblastoma / / pha002895 rs11966375 chr6 133408039 T C 0.0000022 Mean arterial pressure / / 22510845 rs9389047 chr6 133436307 C T 8.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs9389047 chr6 133436307 C T 1.00E-08 Bone mineral density (paediatric,skull) / / 24945404 rs7764524 chr6 133438126 T G 8.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs7764524 chr6 133438126 T G 2.20E-08 Bone mineral density (paediatric,skull) / / 24945404 rs6923702 chr6 133446565 G A 8.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs9389049 chr6 133447768 G A 6.90E-04 Multiple complex diseases / / 17554300 rs7751379 chr6 133447855 T G 9.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs7751379 chr6 133447855 T G 5.90E-09 Bone mineral density (paediatric,skull) / / 24945404 rs6569867 chr6 133450298 A G 7.90E-09 Bone mineral density (paediatric,skull) / / 24945404 rs9389050 chr6 133451476 T G 1.00E-08 Bone mineral density (paediatric,skull) / / 24945404 rs2050658 chr6 133479103 A G 3.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs546329 chr6 133495524 C T 3.80E-09 Bone mineral density (paediatric,skull) / / 24945404 rs509685 chr6 133517005 A G 3.90E-10 Bone mineral density (paediatric,skull) / / 24945404 rs509904 chr6 133517082 A T 6.10E-10 Bone mineral density (paediatric,skull) / / 24945404 rs569833 chr6 133527935 T C 1.60E-08 Bone mineral density (paediatric,skull) / / 24945404 rs71574647 chr6 133569517 G C 0.0000132 Nonsyndromic striae distensae (stretch marks) EYA4 intron 23633020 rs71574648 chr6 133571382 A G 0.0000184 Nonsyndromic striae distensae (stretch marks) EYA4 intron 23633020 rs34018528 chr6 133578639 C T 0.0000641 Nonsyndromic striae distensae (stretch marks) EYA4 intron 23633020 rs973714 chr6 133578733 G A 7.44E-05 Obsessive-compulsive disorder EYA4 intron 24821223 rs973714 chr6 133578733 G A 7.44E-05 Obsessive-compulsive disorder EYA4 intron 24821223 rs58707513 chr6 133596313 G A 0.0000182 Nonsyndromic striae distensae (stretch marks) EYA4 intron 23633020 rs11154720 chr6 133598239 G A 0.0000203 Nonsyndromic striae distensae (stretch marks) EYA4 intron 23633020 rs71574649 chr6 133601173 G C 0.0000181 Nonsyndromic striae distensae (stretch marks) EYA4 intron 23633020 rs34895585 chr6 133601339 T C 0.0000204 Nonsyndromic striae distensae (stretch marks) EYA4 intron 23633020 rs6940715 chr6 133601845 A C 0.0000229 Nonsyndromic striae distensae (stretch marks) EYA4 intron 23633020 rs211433 chr6 133610750 A G 0.000853 Salmonella-induced pyroptosis EYA4 intron 22837397 rs17301249 chr6 133612914 G C 3.37E-04 Response to TNF antagonist treatment EYA4 intron 21061259 rs9375955 chr6 133624410 T C 5.97E-04 Response to TNF antagonist treatment EYA4 intron 21061259 rs7454561 chr6 133636623 G T 4.92E-04 Multiple complex diseases EYA4 intron 17554300 rs10485232 chr6 133636811 G A 6.95E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) EYA4 intron 22566498 rs10485232 chr6 133636811 G A 1.50E-09 Bone mineral density (paediatric,skull) EYA4 intron 24945404 rs11759873 chr6 133641473 A G 7.03E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) EYA4 intron 22566498 rs11759873 chr6 133641473 A G 1.80E-09 Bone mineral density (paediatric,skull) EYA4 intron 24945404 rs12523816 chr6 133642013 A G 8.29E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) EYA4 intron 22566498 rs1336521 chr6 133645017 G C 7.06E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) EYA4 intron 22566498 rs1336521 chr6 133645017 G C 1.00E-08 Bone mineral density (paediatric,skull) EYA4 intron 24945404 rs439123 chr6 133663021 C T 6.27E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) EYA4 intron 22566498 rs439123 chr6 133663021 C T 4.60E-08 Bone mineral density (paediatric,skull) EYA4 intron 24945404 rs11753937 chr6 133663589 C T 6.00E-06 Response to angiotensin II receptor blocker therapy EYA4 intron 22566498 rs377962 chr6 133666904 A C 1.70E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) EYA4 intron 22566498 rs9373052 chr6 133698314 G A 9.30E-05 Lipid levels EYA4 intron pha003082 rs296422 chr6 133725776 G A 7.00E-04 Smoking initiation EYA4 intron 24665060 rs3777842 chr6 133740526 G A 3.63E-04 Multiple complex diseases EYA4 intron 17554300 rs9385647 chr6 133748381 T C 3.18E-04 Alzheimer's disease (late onset) EYA4 intron 21379329 rs9385647 chr6 133748381 T C 8.64E-05 Coronary heart disease EYA4 intron pha003035 rs1336534 chr6 133753825 C T 1.01E-05 Coronary heart disease EYA4 intron pha003035 rs3777860 chr6 133756500 G A 1.00E-05 Urinary metabolites EYA4 intron 21572414 rs12665690 chr6 133759487 G T 1.50E-05 Urinary metabolites EYA4 intron 21572414 rs17062561 chr6 133768525 A G 4.31E-06 Epilepsy EYA4 intron 22116939 rs4895967 chr6 133772170 A G 1.00E-05 Urinary metabolites EYA4 intron 21572414 rs212764 chr6 133790493 G A 1.12E-04 Obesity (extreme) EYA4 intron 21935397 rs212778 chr6 133794209 T G 1.42E-04 Obesity (extreme) EYA4 intron 21935397 rs509453 chr6 133796444 T C 1.08E-04 Obesity (extreme) EYA4 intron 21935397 rs6905892 chr6 133803682 C T 8.98E-05 Epilepsy EYA4 intron 22116939 rs6911807 chr6 133827595 A G 1.05E-04 Obesity (extreme) EYA4 intron 21935397 rs6929938 chr6 133834529 T A 4.97E-04 Multiple complex diseases EYA4 intron 17554300 rs3777887 chr6 133836330 C T 7.19E-04 Multiple complex diseases EYA4 intron 17554300 rs17643040 chr6 133847686 T C 9.93E-04 Multiple complex diseases EYA4 intron 17554300 rs17053540 chr6 133851810 C T 3.69E-05 Bipolar disorder and schizophrenia EYA4 UTR-3 20889312 rs9402515 chr6 133860345 A G 1.00E-06 Protein quantitative trait loci / / 18464913 rs9402515 chr6 133860345 A G 8.86E-04 Heart Failure / / pha002884 rs17062664 chr6 133866326 G A 4.41E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs9375969 chr6 133867802 G A 2.89E-04 Obesity (extreme) / / 21935397 rs9375969 chr6 133867802 G A 9.00E-06 Visceral fat / / 22589738 rs7759024 chr6 133872201 A C 9.85E-06 Multiple complex diseases / / 17554300 rs9285474 chr6 133873486 A C 3.15E-04 Multiple complex diseases / / 17554300 rs6569884 chr6 133885723 G T 8.13E-04 Heart Failure / / pha002884 rs10046269 chr6 133890195 A G 9.12E-04 Multiple complex diseases / / 17554300 rs1319087 chr6 133897107 T C 3.25E-05 Soluble levels of adhesion molecules / / pha003072 rs41518850 chr6 133909197 A T 5.17E-15 Multiple complex diseases / / 17554300 rs2677821 chr6 133922011 A G 1.06E-07 Multiple complex diseases / / 17554300 rs2677826 chr6 133926587 G A 9.68E-04 Type 2 diabetes / / 17463246 rs2677828 chr6 133927888 T C 9.58E-04 Type 2 diabetes / / 17463246 rs2636593 chr6 133927902 G T 9.74E-04 Type 2 diabetes / / 17463246 rs2327363 chr6 133956939 T C 8.04E-04 Heart Failure / / pha002885 rs6569890 chr6 133968745 C T 1.80E-05 Urinary metabolites / / 21572414 rs9483612 chr6 134053107 G A 1.80E-05 Urinary metabolites / / 21572414 rs1000025 chr6 134085319 C T 8.83E-04 Coronary Artery Disease / / 17634449 rs17062853 chr6 134101045 T G 0.00000173 Coronary artery disease / / 23202125 rs12203224 chr6 134101494 G T 2.16E-04 Smoking initiation / / 24665060 rs1414668 chr6 134108060 T C 9.09E-04 Type 2 diabetes / / 17463246 rs6909803 chr6 134111198 C T 2.84E-04 Type 2 diabetes / / 17463246 rs1041714 chr6 134141309 C T 7.06E-05 Glucose levels / / pha003058 rs9389106 chr6 134150456 A G 7.20E-18 Infantile hypertrophic pyloric stenosis MGC34034 intron 22306654 rs41406249 chr6 134155216 T C 3.56E-04 Type 2 diabetes MGC34034 intron 17463246 rs1208285 chr6 134158800 T C 6.00E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs1535616 chr6 134171132 C T 4.49E-04 Myocardial infarction MGC34034 intron 24916648 rs7752775 chr6 134172346 C G 7.83E-04 Multiple complex diseases / / 17554300 rs12524865 chr6 134196674 C A 2.29E-08 Coronary heart disease / / 21378990 rs12524865 chr6 134196674 C A 2.00E-07 Coronary heart disease / / 22751097 rs12524865 chr6 134196674 C A 7.17E-04 Myocardial infarction / / 24916648 rs1967917 chr6 134198175 G A 8.63E-04 Multiple complex diseases / / 17554300 rs12190287 chr6 134214525 C G 1.00E-12 Coronary heart disease TCF21 UTR-3 21378990 rs12190287 chr6 134214525 C G 1.07E-12 Pericardial fat TCF21 UTR-3 22589742 rs12190287 chr6 134214525 C G 0.000778 Coronary artery disease (CAD) age <=50 TCF21 UTR-3 23202125 rs12190287 chr6 134214525 C G 3.05E-10 Coronary artery disease with myocardial infarction TCF21 UTR-3 23202125 rs12190287 chr6 134214525 C G 3.51E-09 Coronary artery disease (CAD) (males) TCF21 UTR-3 23202125 rs12190287 chr6 134214525 C G 4.94E-13 Coronary artery disease TCF21 UTR-3 23202125 rs12190287 chr6 134214525 C G 5.34E-09 Coronary artery disease (CAD) age >50 TCF21 UTR-3 23202125 rs12190287 chr6 134214525 C G 2.00E-08 Coronary artery disease or ischemic stroke TCF21 UTR-3 24262325 rs12190287 chr6 134214525 C G 2.00E-08 Coronary artery disease or large artery stroke TCF21 UTR-3 24262325 rs12190287 chr6 134214525 C G 2.00E-09 Coronary artery disease TCF21 UTR-3 24262325 rs4896011 chr6 134214753 A T 4.90E-05 Heart rate TCF21 UTR-3 23583979 rs9385672 chr6 134215155 C T 0.0000349 Colorectal adenoma (excluding hyperplasic) TCF21 UTR-3 23677573 rs9385672 chr6 134215155 C T 0.0000349 Colorectal adenoma (including hyperplasic) TCF21 UTR-3 23677573 rs1336170 chr6 134219229 G A 0.0000426 Colorectal adenoma (excluding hyperplasic) / / 23677573 rs1336170 chr6 134219229 G A 0.0000426 Colorectal adenoma (including hyperplasic) / / 23677573 rs328455 chr6 134222253 C T 6.80E-05 Pericardial fat / / 22589742 rs162183 chr6 134225835 A C 6.20E-05 Pericardial fat / / 22589742 rs162186 chr6 134226255 C T 7.00E-05 Pericardial fat / / 22589742 rs162187 chr6 134226321 C T 5.90E-05 Pericardial fat / / 22589742 rs162188 chr6 134227223 G A 5.80E-05 Pericardial fat / / 22589742 rs229927 chr6 134235699 T C 3.23E-04 Multiple complex diseases / / 17554300 rs229928 chr6 134236143 C T 4.49E-04 Multiple complex diseases / / 17554300 rs229932 chr6 134241797 C T 7.48E-04 Multiple complex diseases / / 17554300 rs9373073 chr6 134288098 T G 8.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TBPL1 intron 20877124 rs117173630 chr6 134308216 C G 0.000094 Breast cancer TBPL1 UTR-3 23555315 rs2811673 chr6 134331737 G T 3.99E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SLC2A12 intron 24023788 rs9493805 chr6 134364211 C T 4.49E-06 White blood cell count SLC2A12 intron 21738479 rs2811686 chr6 134369424 T G 9.80E-05 Asthma (bronchodilator response) SLC2A12 intron 22792082 rs2627230 chr6 134379869 A T 2.99E-04 Multiple complex diseases / / 17554300 rs6905952 chr6 134399058 C T 7.07E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9385677 chr6 134405747 T C 3.40E-04 Type 2 diabetes / / 17463246 rs6569926 chr6 134420012 G A 6.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7749507 chr6 134430223 A G 1.10E-05 Urinary metabolites / / 21572414 rs12662210 chr6 134447959 A G 9.87E-04 Alzheimer's disease / / 22005930 rs7453135 chr6 134458872 T A,G 5.37E-05 Acne (severe) / / 24399259 rs9689446 chr6 134461443 T C 5.98E-05 Multiple complex diseases / / 17554300 rs6569930 chr6 134461880 A C,G,T 2.08E-04 Acne (severe) / / 24399259 rs2811690 chr6 134468423 G A 5.84E-04 Multiple complex diseases / / 17554300 rs2758150 chr6 134487214 G A 8.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs2758152 chr6 134488913 G T 7.76E-05 Glycosylated haemoglobin levels / / 17255346 rs4896028 chr6 134539179 G A 5.35E-05 Male-pattern baldness SGK1 intron 18849994 rs17053580 chr6 134539954 G A 2.72E-04 Aortic root size SGK1 intron 21223598 rs1763500 chr6 134544733 G A 2.00E-06 Body mass index (interaction) SGK1 intron 23192594 rs1009840 chr6 134546685 G A 6.13E-05 Type 2 diabetes SGK1 intron 17463246 rs1009840 chr6 134546685 G A 2.62E-07 Chronic kidney disease SGK1 intron 21931561 rs1009840 chr6 134546685 G A 2.62E-07 Chronic kidney disease SGK1 intron 21931561 rs1763509 chr6 134554338 G A 2.45E-04 Myocardial Infarction SGK1 intron pha002873 rs1743930 chr6 134571401 A G 1.02E-04 Acute lung injury SGK1 intron 22295056 rs9493873 chr6 134576511 T C 4.00E-07 Immune reponse to smallpox (secreted IFN-alpha) SGK1 intron 22610502 rs1763505 chr6 134581118 T C 9.57E-05 Alzheimer's disease SGK1 intron 24755620 rs4896035 chr6 134582344 C T 7.55E-04 Insulin resistance SGK1 intron 21901158 rs9483670 chr6 134589331 A G 1.00E-04 Prostate cancer SGK1 intron 21743057 rs7766493 chr6 134609390 A G 4.59E-04 Myocardial Infarction SGK1 intron pha002883 rs12202855 chr6 134615030 A G 5.63E-04 Response to taxane treatment (placlitaxel) SGK1 intron 23006423 rs12197956 chr6 134621071 T G 8.82E-06 Stroke (ischemic) SGK1 intron 21957438 rs7763911 chr6 134621107 A G 8.82E-06 Stroke (ischemic) SGK1 intron 21957438 rs12204317 chr6 134621215 A C 8.82E-06 Stroke (ischemic) SGK1 intron 21957438 rs12194586 chr6 134622943 C T 8.82E-06 Stroke (ischemic) SGK1 intron 21957438 rs9493891 chr6 134623840 G A 8.82E-06 Stroke (ischemic) SGK1 intron 21957438 rs9493891 chr6 134623840 G A 9.17E-04 Response to taxane treatment (placlitaxel) SGK1 intron 23006423 rs9493896 chr6 134630400 A T 1.50E-05 Urinary metabolites SGK1 intron 21572414 rs17063661 chr6 134659892 T C 1.54E-04 Multiple complex diseases / / 17554300 rs379977 chr6 134661885 A C 7.34E-05 Ulcerative colitis / / 19915573 rs2269566 chr6 134669083 G A 2.00E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7762833 chr6 134680598 A G 3.79E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7762833 chr6 134680598 A G 4.82E-05 Heart Failure / / pha002885 rs9402592 chr6 134720067 G A 3.00E-06 Dental caries / / 23259602 rs6932621 chr6 134721958 G A 8.84E-04 Major depressive disorder / / 22472876 rs4896044 chr6 134738088 G A 2.41E-06 Multiple complex diseases / / 17554300 rs9389176 chr6 134764036 C T 8.08E-04 Parkinson's disease LOC154092 intron 16252231 rs10457626 chr6 134773227 C T 8.12E-04 Coronary heart disease LOC154092 intron 21606135 rs9321453 chr6 134773554 T C 1.00E-09 Urate levels LOC154092 intron 21768215 rs4896049 chr6 134776146 A C 6.09E-04 Parkinson's disease LOC154092 intron 16252231 rs4896052 chr6 134782152 T A 6.54E-04 Parkinson's disease LOC154092 intron 16252231 rs9402608 chr6 134786163 A G 9.91E-04 Multiple complex diseases LOC154092 intron 17554300 rs1158967 chr6 134807018 A T 2.57E-05 Sleep duration LOC154092 intron 22105623 rs4895410 chr6 134809080 A C 2.45E-05 Sleep duration LOC154092 intron 22105623 rs9321459 chr6 134810476 T C 1.31E-05 Sleep duration LOC154092 intron 22105623 rs6929591 chr6 134818314 T C 7.36E-04 Parkinson's disease LOC154092 intron 17052657 rs6930961 chr6 134822264 C T 4.73E-04 Suicide attempts in bipolar disorder LOC154092 intron 21423239 rs1040637 chr6 134823919 A G 4.84E-04 Lung function (forced expiratory volume in 1 second) LOC154092 intron 24023788 rs6920474 chr6 134845350 C A 2.28E-05 Platelet counts / / pha003100 rs2273208 chr6 134852088 C T 2.19E-04 Acute lung injury / / 22295056 rs9483720 chr6 134854690 A G 2.99E-04 Multiple complex diseases / / 17554300 rs228437 chr6 134898456 C T 1.00E-07 Melanoma / / 21983787 rs7767262 chr6 134979397 T C 6.20E-04 Bladder cancer / / 21824976 rs9321466 chr6 134979983 C G 9.40E-04 Bladder cancer / / 21824976 rs6905115 chr6 135001201 A C 2.49E-04 Multiple complex diseases / / 17554300 rs4896094 chr6 135072288 G A 9.41E-07 Red blood cell traits / / 23222517 rs7749709 chr6 135079617 G A 1.16E-05 Alcohol and nictotine co-dependence / / 20158304 rs11760067 chr6 135094272 C T 7.00E-06 Coronary artery calcification / / 23870195 rs2049953 chr6 135138990 C A 4.00E-06 Non-alcoholic fatty liver disease histology (AST) / / 20708005 rs7744034 chr6 135143748 A G 7.56E-08 Red blood cell traits / / 23222517 rs9402655 chr6 135147968 T A 6.31E-07 Red blood cell traits / / 23222517 rs6904528 chr6 135148949 A T 2.34E-05 Alcohol dependence / / 21314694 rs11758776 chr6 135149958 A G 8.18E-10 Red blood cell traits / / 23222517 rs2876266 chr6 135150488 A G 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2876266 chr6 135150488 A G 7.46E-08 Red blood cell traits / / 23222517 rs9285479 chr6 135150516 T G 4.35E-07 Red blood cell traits / / 23222517 rs9321476 chr6 135150550 A C 3.08E-08 Red blood cell traits / / 23222517 rs4896107 chr6 135150869 A G 5.71E-08 Red blood cell traits / / 23222517 rs2049954 chr6 135152139 G C 5.60E-07 Red blood cell traits / / 23222517 rs1474989 chr6 135154572 C T 9.35E-08 Red blood cell traits / / 23222517 rs4896109 chr6 135157534 A C 2.91E-08 Red blood cell traits / / 23222517 rs9483757 chr6 135158533 C T 1.15E-04 Aortic root size / / 21223598 rs11756550 chr6 135158832 C G 3.03E-09 Red blood cell traits / / 23222517 rs11752655 chr6 135160309 A G 1.20E-04 Aortic root size / / 21223598 rs9494087 chr6 135163743 C T 2.12E-04 Aortic root size / / 21223598 rs4896112 chr6 135164851 G A 3.76E-07 Red blood cell traits / / 23222517 rs4896114 chr6 135164877 T C 2.87E-07 Red blood cell traits / / 23222517 rs9494089 chr6 135165518 T C 7.62E-07 Red blood cell traits / / 23222517 rs2327536 chr6 135165945 C T 1.29E-07 Red blood cell traits / / 23222517 rs7750144 chr6 135167877 C T 2.40E-08 Red blood cell traits / / 23222517 rs7750181 chr6 135167961 C T 2.65E-08 Red blood cell traits / / 23222517 rs9385707 chr6 135168474 T C 4.16E-09 Red blood cell traits / / 23222517 rs4896115 chr6 135168723 C T 1.34E-09 Red blood cell traits / / 23222517 rs9376069 chr6 135169378 G C 4.90E-09 Red blood cell traits / / 23222517 rs760661 chr6 135171146 T A,G 3.74E-10 Red blood cell traits / / 23222517 rs737153 chr6 135171263 A C 2.92E-09 Red blood cell traits / / 23222517 rs1883225 chr6 135172345 G A 1.38E-09 Red blood cell traits / / 23222517 rs9483760 chr6 135172515 T A 3.20E-08 Red blood cell traits / / 23222517 rs9494090 chr6 135172880 T G 8.12E-09 Red blood cell traits / / 23222517 rs1040806 chr6 135176176 T G 1.21E-08 Red blood cell traits / / 23222517 rs2327576 chr6 135177685 A G 7.95E-10 Red blood cell traits / / 23222517 rs742103 chr6 135183233 A C 7.90E-10 Red blood cell traits / / 23222517 rs9376070 chr6 135185868 C A 3.47E-10 Red blood cell traits / / 23222517 rs17776494 chr6 135187044 T G 1.04E-08 Red blood cell traits / / 23222517 rs10080880 chr6 135190028 G A 8.94E-12 Red blood cell traits / / 23222517 rs11968896 chr6 135191863 G C 6.76E-12 Red blood cell traits / / 23222517 rs9385708 chr6 135192075 C T 1.39E-11 Red blood cell traits / / 23222517 rs2876282 chr6 135194848 A C 4.53E-09 Red blood cell traits / / 23222517 rs2142727 chr6 135194861 G A 2.30E-05 Urinary metabolites / / 21572414 rs2103564 chr6 135195272 G C 4.40E-11 Red blood cell traits / / 23222517 rs9483768 chr6 135199287 A C 8.12E-10 Red blood cell traits / / 23222517 rs9494101 chr6 135199596 C T 0.000000005 Mean corpuscular hemoglobin / / 22560525 rs9494101 chr6 135199596 C T 0.000000005 Mean corpuscular volume / / 22560525 rs9494101 chr6 135199596 C T 8.09E-10 Red blood cell traits / / 23222517 rs9494102 chr6 135199710 T C 5.09E-12 Red blood cell traits / / 23222517 rs9483769 chr6 135199781 A G 0.000000004 Mean corpuscular hemoglobin / / 22560525 rs9483769 chr6 135199781 A G 0.000000005 Mean corpuscular volume / / 22560525 rs9483769 chr6 135199781 A G 3.75E-10 Red blood cell traits / / 23222517 rs9494104 chr6 135200146 T C 1.12E-08 Red blood cell traits / / 23222517 rs6900542 chr6 135200853 A T 6.39E-08 Red blood cell traits / / 23222517 rs6923527 chr6 135200950 T C 2.69E-08 Red blood cell traits / / 23222517 rs9389237 chr6 135203779 T C 8.60E-13 Red blood cell traits / / 23222517 rs7759398 chr6 135209834 C A 3.46E-09 Other erythrocyte phenotypes / / 19862010 rs7759398 chr6 135209834 C A 7.16E-11 Red blood cell traits / / 23222517 rs7759527 chr6 135209883 C T 1.91E-09 Other erythrocyte phenotypes / / 19862010 rs7759527 chr6 135209883 C T 3.01E-08 Red blood cell traits / / 23222517 rs962189 chr6 135210182 A G 0.000000008 Red blood cell count / / 22560525 rs962189 chr6 135210182 A G 0.00000004 Mean corpuscular hemoglobin / / 22560525 rs962189 chr6 135210182 A G 5.79E-10 Red blood cell traits / / 23222517 rs9373116 chr6 135224369 C G 1.21E-07 Red blood cell traits / / 23222517 rs4896117 chr6 135229400 T C 4.80E-10 Red blood cell traits / / 23222517 rs9321479 chr6 135233909 A G 9.67E-10 Red blood cell traits / / 23222517 rs4646880 chr6 135237686 G A 1.39E-07 Red blood cell traits / / 23222517 rs728030 chr6 135246294 C A 1.26E-11 Red blood cell traits ALDH8A1 intron 23222517 rs2064101 chr6 135250530 G A 1.14E-13 Red blood cell traits ALDH8A1 intron 23222517 rs2294321 chr6 135253048 T G 1.01E-13 Red blood cell traits ALDH8A1 intron 23222517 rs2072825 chr6 135253451 A G 7.10E-12 Red blood cell traits ALDH8A1 intron 23222517 rs2072826 chr6 135253558 G C 2.05E-10 Red blood cell traits ALDH8A1 intron 23222517 rs2072827 chr6 135253603 G A 4.11E-08 Red blood cell traits ALDH8A1 intron 23222517 rs3817776 chr6 135256756 C T 3.94E-10 Red blood cell traits ALDH8A1 intron 23222517 rs2142725 chr6 135258942 T G 4.53E-12 Red blood cell traits ALDH8A1 intron 23222517 rs1022491 chr6 135259366 C T 4.38E-09 Red blood cell traits ALDH8A1 intron 23222517 rs7772031 chr6 135259734 G A 3.14E-11 Red blood cell traits ALDH8A1 intron 23222517 rs7754722 chr6 135260303 T C 5.81E-13 Red blood cell traits ALDH8A1 intron 23222517 rs4646871 chr6 135265617 G A 1.86E-10 Red blood cell traits ALDH8A1 intron 23222517 rs4646870 chr6 135271328 C A 1.44E-07 Red blood cell traits ALDH8A1 nearGene-5 23222517 rs4646868 chr6 135271946 A G 2.37E-11 Red blood cell traits ALDH8A1 nearGene-5 23222517 rs4267967 chr6 135272477 T G 5.11E-11 Red blood cell traits ALDH8A1 nearGene-5 23222517 rs7771310 chr6 135272535 G A 6.44E-13 Red blood cell traits ALDH8A1 nearGene-5 23222517 rs4472368 chr6 135274232 A G 2.36E-12 Red blood cell traits / / 23222517 rs7768278 chr6 135274957 T C 9.18E-14 Red blood cell traits / / 23222517 rs4289677 chr6 135275485 T C 3.28E-14 Red blood cell traits / / 23222517 rs4896118 chr6 135276065 G A 1.79E-12 Red blood cell traits / / 23222517 rs4440481 chr6 135276696 T C 9.78E-11 Red blood cell traits / / 23222517 rs11753985 chr6 135280438 C T 9.72E-14 Red blood cell traits / / 23222517 rs1135205 chr6 135281795 C T 7.60E-11 Red blood cell traits HBS1L UTR-3 23222517 rs566152659 chr6 135282225 TTGC T 5.80E-14 Red blood cell traits HBS1L UTR-3 23222517 rs7739722 chr6 135282225 T C 5.80E-14 Red blood cell traits HBS1L UTR-3 23222517 rs9389248 chr6 135282656 T C 8.09E-11 Red blood cell traits HBS1L UTR-3 23222517 rs13196486 chr6 135283874 C G 4.88E-14 Red blood cell traits HBS1L UTR-3 23222517 rs9399129 chr6 135285148 C A 3.19E-07 Red blood cell traits HBS1L UTR-3 23222517 rs4594969 chr6 135285586 A T 3.64E-14 Red blood cell traits HBS1L UTR-3 23222517 rs13199205 chr6 135286505 T C 2.86E-07 Red blood cell traits HBS1L intron 23222517 rs12663810 chr6 135289782 G A,C 6.89E-12 Red blood cell traits HBS1L intron 23222517 rs4895434 chr6 135293365 G A 4.32E-07 Red blood cell traits HBS1L intron 23222517 rs4896119 chr6 135293391 C T 3.66E-07 Red blood cell traits HBS1L intron 23222517 rs4895435 chr6 135293463 C A 4.02E-07 Red blood cell traits HBS1L intron 23222517 rs4896120 chr6 135293512 C G 5.01E-07 Red blood cell traits HBS1L intron 23222517 rs7755680 chr6 135294259 A G 4.77E-07 Red blood cell traits HBS1L intron 23222517 rs4895436 chr6 135295001 G A 5.01E-07 Red blood cell traits HBS1L intron 23222517 rs9376075 chr6 135296963 A G 3.76E-07 Red blood cell traits HBS1L intron 23222517 rs10484496 chr6 135299682 T C 5.19E-15 Red blood cell traits HBS1L intron 23222517 rs13214669 chr6 135299959 T C 4.93E-15 Red blood cell traits HBS1L intron 23222517 rs11754021 chr6 135308375 A G 3.94E-15 Red blood cell traits HBS1L intron 23222517 rs13218642 chr6 135309940 A G 3.42E-07 Red blood cell traits HBS1L intron 23222517 rs4451151 chr6 135310546 C T 3.34E-07 Red blood cell traits HBS1L intron 23222517 rs13197750 chr6 135312380 G A 2.61E-15 Red blood cell traits HBS1L intron 23222517 rs6902954 chr6 135313994 C A 4.30E-07 Red blood cell traits HBS1L intron 23222517 rs7761964 chr6 135314265 T C 3.80E-14 Red blood cell traits HBS1L intron 23222517 rs6909975 chr6 135315570 C T 3.35E-07 Red blood cell traits HBS1L intron 23222517 rs12663447 chr6 135317026 A C 1.45E-15 Red blood cell traits HBS1L intron 23222517 rs4895438 chr6 135317665 G T 3.53E-07 Red blood cell traits HBS1L intron 23222517 rs7773126 chr6 135318390 A G 3.45E-07 Red blood cell traits HBS1L intron 23222517 rs4895439 chr6 135318854 A T 3.92E-07 Red blood cell traits HBS1L intron 23222517 rs12526055 chr6 135325918 C T 1.09E-07 Red blood cell traits HBS1L intron 23222517 rs6929661 chr6 135328792 G A 1.20E-07 Red blood cell traits HBS1L intron 23222517 rs2327578 chr6 135329969 C T 3.77E-07 Red blood cell traits HBS1L intron 23222517 rs9389256 chr6 135331254 A C 5.33E-07 Red blood cell traits HBS1L intron 23222517 rs1014021 chr6 135334600 A G 1.68E-07 Red blood cell traits HBS1L intron 23222517 rs6923765 chr6 135335176 G C 6.01E-07 Red blood cell traits HBS1L intron 23222517 rs6923512 chr6 135335268 C T 6.44E-15 Red blood cell traits HBS1L intron 23222517 rs6923827 chr6 135335382 C T 5.42E-07 Red blood cell traits HBS1L intron 23222517 rs6902438 chr6 135336587 C T 5.57E-07 Red blood cell traits HBS1L intron 23222517 rs6908681 chr6 135337733 A G 5.60E-07 Red blood cell traits HBS1L intron 23222517 rs3756799 chr6 135341011 A G 5.49E-07 Red blood cell traits HBS1L intron 23222517 rs4896125 chr6 135342569 C T 5.80E-07 Red blood cell traits HBS1L intron 23222517 rs949547 chr6 135343499 C G 6.18E-07 Red blood cell traits HBS1L intron 23222517 rs13209780 chr6 135344795 G C 4.97E-15 Red blood cell traits HBS1L intron 23222517 rs13192235 chr6 135346351 G A 6.12E-15 Other erythrocyte phenotypes HBS1L intron 19862010 rs13192235 chr6 135346351 G A 4.66E-18 Red blood cell traits HBS1L intron 23222517 rs9376082 chr6 135346389 T A 5.67E-07 Red blood cell traits HBS1L intron 23222517 rs11756988 chr6 135347595 A G 6.03E-07 Red blood cell traits HBS1L intron 23222517 rs12661423 chr6 135349570 C T 6.47E-07 Red blood cell traits HBS1L intron 23222517 rs4896128 chr6 135349756 G A 2.86E-15 Red blood cell traits HBS1L intron 23222517 rs4896129 chr6 135349845 C T 5.13E-15 Red blood cell traits HBS1L intron 23222517 rs7750574 chr6 135350932 G C 4.39E-15 Red blood cell traits HBS1L intron 23222517 rs7750300 chr6 135350950 C G 5.20E-07 Red blood cell traits HBS1L intron 23222517 rs1590975 chr6 135352088 C T 3.44E-07 Red blood cell traits HBS1L intron 23222517 rs6569988 chr6 135352303 C A 3.42E-07 Red blood cell traits HBS1L intron 23222517 rs6919862 chr6 135352443 C A 3.99E-07 Red blood cell traits HBS1L intron 23222517 rs10872427 chr6 135353452 T C 3.86E-07 Red blood cell traits HBS1L intron 23222517 rs7766189 chr6 135353851 A C 3.90E-07 Red blood cell traits HBS1L intron 23222517 rs4896130 chr6 135355118 C T 3.80E-07 Red blood cell traits HBS1L intron 23222517 rs7742542 chr6 135358567 T G 3.44E-07 Red blood cell traits HBS1L missense 23222517 rs9376084 chr6 135360046 C T 5.57E-07 Red blood cell traits HBS1L intron 23222517 rs6569990 chr6 135365818 C T 3.16E-07 Red blood cell traits HBS1L intron 23222517 rs6940258 chr6 135366132 C T 8.94E-13 Red blood cell traits HBS1L intron 23222517 rs9399135 chr6 135368314 G A 2.99E-07 Red blood cell traits HBS1L intron 23222517 rs6915770 chr6 135369214 G A 3.70E-07 Red blood cell traits HBS1L intron 23222517 rs11755229 chr6 135369913 A G 4.09E-07 Red blood cell traits HBS1L intron 23222517 rs9402677 chr6 135370708 A T 4.08E-07 Red blood cell traits HBS1L intron 23222517 rs9389261 chr6 135371148 C G 3.30E-07 Red blood cell traits HBS1L intron 23222517 rs9376085 chr6 135371224 T C 3.96E-07 Red blood cell traits HBS1L intron 23222517 rs9376086 chr6 135371329 T C 3.73E-07 Red blood cell traits HBS1L intron 23222517 rs1041480 chr6 135373076 G T 4.03E-07 Red blood cell traits HBS1L intron 23222517 rs9373122 chr6 135373534 G A 3.60E-07 Red blood cell traits HBS1L intron 23222517 rs2150681 chr6 135375232 C T 7.21E-07 Red blood cell traits HBS1L intron 23222517 rs2297338 chr6 135375762 G A 5.40E-07 Red blood cell traits HBS1L intron 23222517 rs2183709 chr6 135377091 C T 5.68E-07 Red blood cell traits HBS1L nearGene-5 23222517 rs4142299 chr6 135377186 G T 5.47E-07 Red blood cell traits HBS1L nearGene-5 23222517 rs11154791 chr6 135379148 A G 5.29E-12 Red blood cell traits / / 23222517 rs11759062 chr6 135381248 A C 8.46E-15 Red blood cell traits / / 23222517 rs11759077 chr6 135381351 A G 5.33E-15 Red blood cell traits / / 23222517 rs6904897 chr6 135382980 T G 1.20E-06 F-cell distribution / / 17767159 rs6904897 chr6 135382980 T G 1.20E-06 F-cell distribution / / 21326311 rs6904897 chr6 135382980 T G 4.36E-14 Red blood cell traits / / 23222517 rs11758774 chr6 135383789 T G 2.04E-15 Red blood cell traits / / 23222517 rs1547247 chr6 135390836 G A 5.40E-04 Multiple complex diseases / / 17554300 rs1547247 chr6 135390836 G A 9.79E-10 Fetal hemoglobin levels / / 18245381 rs1547247 chr6 135390836 G A 5.93E-12 Other erythrocyte phenotypes / / 19862010 rs1547247 chr6 135390836 G A 2.00E-13 Mean corpuscular volume / / 22560525 rs1547247 chr6 135390836 G A 2.00E-15 Mean corpuscular hemoglobin / / 22560525 rs1547247 chr6 135390836 G A 9.00E-11 Red blood cell count / / 22560525 rs1547247 chr6 135390836 G A 8.71E-39 Red blood cell traits / / 23222517 rs11757577 chr6 135391465 G A 2.31E-07 Red blood cell traits / / 23222517 rs11752907 chr6 135391495 A G 1.55E-07 Red blood cell traits / / 23222517 rs13220662 chr6 135395548 G A 1.17E-21 Other erythrocyte phenotypes / / 19862010 rs13220662 chr6 135395548 G A 0.00000001 Mean corpuscular volume / / 22560525 rs13220662 chr6 135395548 G A 1.00E-11 Mean corpuscular hemoglobin / / 22560525 rs13220662 chr6 135395548 G A 1.67E-31 Red blood cell traits / / 23222517 rs13220662 chr6 135395548 G A 5.00E-05 Hodgkin's lymphoma / / 24149102 rs7763587 chr6 135399065 C G 5.25E-14 Red blood cell traits / / 23222517 rs9483783 chr6 135401040 T C 2.65E-09 Other erythrocyte phenotypes / / 19862010 rs9483783 chr6 135401040 T C 5.32E-13 Red blood cell traits / / 23222517 rs9389264 chr6 135401112 C G 3.73E-14 Red blood cell traits / / 23222517 rs6914564 chr6 135403624 C T 1.12E-14 Red blood cell traits / / 23222517 rs1331308 chr6 135405122 A C 6.36E-14 Red blood cell traits / / 23222517 rs9402683 chr6 135406798 T A 8.09E-15 Red blood cell traits / / 23222517 rs6913541 chr6 135409116 A G 2.05E-14 Red blood cell traits / / 23222517 rs9376090 chr6 135411228 T C 1.17E-55 Other erythrocyte phenotypes / / 19862010 rs9376090 chr6 135411228 T C 9.34E-09 Red blood cell traits / / 23222517 rs9376090 chr6 135411228 T C 3.00E-09 Cholesterol,total / / 24097068 rs9389266 chr6 135411737 G T 2.31E-09 Other erythrocyte phenotypes / / 19862010 rs9389266 chr6 135411737 G T 1.53E-16 Red blood cell traits / / 23222517 rs9494139 chr6 135414793 A G 3.00E-09 Other erythrocyte phenotypes / / 19862010 rs9494139 chr6 135414793 A G 1.11E-11 Red blood cell traits / / 23222517 rs7745098 chr6 135415004 C T 5.10E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7745098 chr6 135415004 C T 7.13E-13 Red blood cell traits / / 23222517 rs7745098 chr6 135415004 C T 1.68E-07 Hodgkin's lymphoma / / 24149102 rs7745098 chr6 135415004 C T 3.00E-09 Hodgkin's lymphoma / / 24149102 rs2210366 chr6 135415208 G A 3.26E-23 Other erythrocyte phenotypes / / 19862010 rs2210366 chr6 135415208 G A 1.72E-45 Red blood cell traits / / 23222517 rs7775698 chr6 135418635 C T 5.00E-13 Hematology traits / / 19853236 rs7775698 chr6 135418635 C T 8.00E-18 Hematology traits / / 19853236 rs7775698 chr6 135418635 C T 3.46E-30 Other erythrocyte phenotypes / / 19862010 rs7775698 chr6 135418635 C T 1.00E-10 Blood cell counts and other traits / / 20139978 rs7775698 chr6 135418635 C T 2.54E-14 Blood cell counts and other traits / / 20139978 rs7775698 chr6 135418635 C T 2.82E-66 Blood cell counts and other traits / / 20139978 rs7775698 chr6 135418635 C T 3.44E-56 Blood cell counts and other traits / / 20139978 rs7775698 chr6 135418635 C T 6.22E-12 Blood cell counts and other traits / / 20139978 rs7775698 chr6 135418635 C T 7.31E-48 Blood cell counts and other traits / / 20139978 rs7775698 chr6 135418635 C T 9.52E-11 Blood cell counts and other traits / / 20139978 rs7775698 chr6 135418635 C T 1.00E-14 Red blood cell traits / / 20927387 rs7775698 chr6 135418635 C T 1.00E-15 Red blood cell traits / / 20927387 rs7775698 chr6 135418635 C T 2.54E-14 Hepatitis B / / 21750111 rs7775698 chr6 135418635 C T 2.54E-14 Mean platelet volume / / 22423221 rs7775698 chr6 135418635 C T 0.000000004 Mean corpuscular hemoglobin concentration / / 22560525 rs7775698 chr6 135418635 C T 0.00000001 Hematocrit / / 22560525 rs7775698 chr6 135418635 C T 3.00E-31 Red blood cell count / / 22560525 rs7775698 chr6 135418635 C T 5.00E-34 Mean corpuscular volume / / 22560525 rs7775698 chr6 135418635 C T 5.00E-38 Mean corpuscular hemoglobin / / 22560525 rs7775698 chr6 135418635 C T 2.14E-08 Red blood cell traits / / 23222517 rs7775698 chr6 135418635 C T 2.00E-09 Mean corpuscular volume / / 23263863 rs7775698 chr6 135418635 C T 4.00E-13 Mean corpuscular hemoglobin / / 23263863 rs7775698 chr6 135418635 C T 1.88E-05 Hemoglobin / / pha003098 rs7775698 chr6 135418635 C T 1.96E-05 Erythrocyte counts / / pha003099 rs7775698 chr6 135418635 C T 1.52E-05 Erythrocyte counts / / pha003101 rs7776054 chr6 135418916 A G 7.00E-69 Mean corpuscular hemoglobin / / 19862010 rs7776054 chr6 135418916 A G 2.38E-66 Blood cell counts and other traits / / 20139978 rs7776054 chr6 135418916 A G 1.60E-09 Red blood cell traits / / 23222517 rs7776054 chr6 135418916 A G 4.00E-06 Red blood cell traits / / 23935956 rs9399137 chr6 135419018 T C 3.00E-36 F-cell distribution / / 17767159 rs9399137 chr6 135419018 T C 1.00E-09 Hematology traits / / 19853236 rs9399137 chr6 135419018 T C 6.90E-57 Other erythrocyte phenotypes / / 19862010 rs9399137 chr6 135419018 T C 2.50E-36 F-cell distribution / / 21326311 rs9399137 chr6 135419018 T C 5.00E-47 Platelet counts / / 22139419 rs9399137 chr6 135419018 T C 1.17E-15 Fetal hemoglobin levels / / 22936743 rs9399137 chr6 135419018 T C 5.00E-09 HbA2 levels / / 23043469 rs9399137 chr6 135419018 T C 2.90E-09 Red blood cell traits / / 23222517 rs9399137 chr6 135419018 T C 1.00E-11 Mean corpuscular volume / / 23263863 rs9399137 chr6 135419018 T C 3.00E-06 Hematology traits / / 23263863 rs9399137 chr6 135419018 T C 4.00E-15 Mean corpuscular hemoglobin / / 23263863 rs9399137 chr6 135419018 T C 8.00E-10 Platelet counts / / 24026423 rs9399137 chr6 135419018 T C 9.00E-15 Glycated hemoglobin levels / / 24647736 rs9399137 chr6 135419018 T C 1.42E-05 Hemoglobin / / pha003098 rs9399137 chr6 135419018 T C 1.44E-05 Erythrocyte counts / / pha003099 rs9399137 chr6 135419018 T C 8.48E-06 Erythrocyte counts / / pha003101 rs9402684 chr6 135419305 T C 5.73E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9402684 chr6 135419305 T C 7.22E-15 Red blood cell traits / / 23222517 rs9402684 chr6 135419305 T C 5.40E-05 Hodgkin's lymphoma / / 24920014 rs9389268 chr6 135419631 A G 6.66E-57 Other erythrocyte phenotypes / / 19862010 rs9389268 chr6 135419631 A G 1.95E-09 Red blood cell traits / / 23222517 rs7743042 chr6 135419834 A G 2.58E-14 Red blood cell traits / / 23222517 rs11759553 chr6 135422296 A T 2.11E-57 Other erythrocyte phenotypes / / 19862010 rs11759553 chr6 135422296 A T 7.50E-10 Red blood cell traits / / 23222517 rs9373124 chr6 135423209 T C 7.00E-14 Other erythrocyte phenotypes / / 19862010 rs9373124 chr6 135423209 T C 7.44E-09 Blood cell counts and other traits / / 20139978 rs9373124 chr6 135423209 T C 1.00E-10 White blood cell types / / 21738478 rs9373124 chr6 135423209 T C 3.41E-10 Red blood cell traits / / 23222517 rs1074849 chr6 135423412 G A 1.01E-22 Other erythrocyte phenotypes / / 19862010 rs1074849 chr6 135423412 G A 4.94E-44 Red blood cell traits / / 23222517 rs6930223 chr6 135424203 G T 3.80E-16 Red blood cell traits / / 23222517 rs4895440 chr6 135426558 A T 4.95E-57 Other erythrocyte phenotypes / / 19862010 rs4895440 chr6 135426558 A T 7.91E-10 Red blood cell traits / / 23222517 rs4895441 chr6 135426573 A G 1.60E-20 Fetal hemoglobin levels / / 18245381 rs4895441 chr6 135426573 A G 7.00E-86 Mean corpuscular volume / / 19862010 rs4895441 chr6 135426573 A G 1.19E-31 Blood cell counts and other traits / / 20139978 rs4895441 chr6 135426573 A G 1.67E-09 Blood cell counts and other traits / / 20139978 rs4895441 chr6 135426573 A G 2.00E-09 Blood cell counts and other traits / / 20139978 rs4895441 chr6 135426573 A G 1.60E-20 F-cell distribution / / 21326311 rs4895441 chr6 135426573 A G 1.00E-30 Mean corpuscular volume / / 22560525 rs4895441 chr6 135426573 A G 3.00E-10 Mean corpuscular hemoglobin concentration / / 22560525 rs4895441 chr6 135426573 A G 6.00E-36 Mean corpuscular hemoglobin / / 22560525 rs4895441 chr6 135426573 A G 7.00E-27 Red blood cell count / / 22560525 rs4895441 chr6 135426573 A G 2.23E-15 Fetal hemoglobin levels / / 22936743 rs4895441 chr6 135426573 A G 9.22E-10 Red blood cell traits / / 23222517 rs4895441 chr6 135426573 A G 3.00E-06 Mean corpuscular hemoglobin concentration / / 23263863 rs4895441 chr6 135426573 A G 3.00E-06 Red blood cell traits / / 23935956 rs4895441 chr6 135426573 A G 9.00E-10 Platelet counts / / 24026423 rs4895441 chr6 135426573 A G 9.71E-05 Erythrocyte counts / / pha003101 rs9376092 chr6 135427144 C A 4.05E-16 Fetal hemoglobin levels / / 18245381 rs9376092 chr6 135427144 C A 1.49E-47 Other erythrocyte phenotypes / / 19862010 rs9376092 chr6 135427144 C A 2.00E-11 Beta thalassemia/Hemoglobin E disease / / 20183929 rs9376092 chr6 135427144 C A 1.00E-30 Mean corpuscular volume / / 22560525 rs9376092 chr6 135427144 C A 2.00E-35 Mean corpuscular hemoglobin / / 22560525 rs9376092 chr6 135427144 C A 4.00E-27 Red blood cell count / / 22560525 rs9376092 chr6 135427144 C A 7.00E-10 Mean corpuscular hemoglobin concentration / / 22560525 rs9376092 chr6 135427144 C A 8.34E-10 Red blood cell traits / / 23222517 rs9376092 chr6 135427144 C A 7.63E-05 Erythrocyte counts / / pha003101 rs9389269 chr6 135427159 T C 2.28E-57 Other erythrocyte phenotypes / / 19862010 rs9389269 chr6 135427159 T C 3.00E-19 Red blood cell traits / / 23222517 rs9402686 chr6 135427817 G A 7.00E-42 Hematological parameters / / 19820697 rs9402686 chr6 135427817 G A 1.96E-57 Other erythrocyte phenotypes / / 19862010 rs9402686 chr6 135427817 G A 8.87E-32 Blood cell counts and other traits / / 20139978 rs9402686 chr6 135427817 G A 2.20E-13 Mean platelet volume / / 22423221 rs9402686 chr6 135427817 G A 3.89E-10 Red blood cell traits / / 23222517 rs10484494 chr6 135430093 G A 1.08E-18 Other erythrocyte phenotypes / / 19862010 rs10484494 chr6 135430093 G A 3.62E-37 Red blood cell traits / / 23222517 rs6920211 chr6 135431318 T C 3.05E-49 Other erythrocyte phenotypes / / 19862010 rs6920211 chr6 135431318 T C 5.54E-09 Red blood cell traits / / 23222517 rs9494142 chr6 135431640 T C 2.02E-41 Other erythrocyte phenotypes / / 19862010 rs9494142 chr6 135431640 T C 5.54E-09 Red blood cell traits / / 23222517 rs1411919 chr6 135432061 A G 2.87E-20 Other erythrocyte phenotypes / / 19862010 rs1411919 chr6 135432061 A G 5.35E-43 Red blood cell traits / / 23222517 rs9494145 chr6 135432552 T C 1.73E-38 Other erythrocyte phenotypes / / 19862010 rs9494145 chr6 135432552 T C 3.00E-15 Red blood cell traits / / 20927387 rs9494145 chr6 135432552 T C 3.00E-09 Mean platelet volume / / 22423221 rs9494145 chr6 135432552 T C 0.00000002 Mean corpuscular hemoglobin concentration / / 22560525 rs9494145 chr6 135432552 T C 1.00E-24 Red blood cell count / / 22560525 rs9494145 chr6 135432552 T C 3.00E-29 Mean corpuscular volume / / 22560525 rs9494145 chr6 135432552 T C 8.00E-33 Mean corpuscular hemoglobin / / 22560525 rs9494145 chr6 135432552 T C 4.32E-17 Fetal hemoglobin levels / / 22936743 rs9494145 chr6 135432552 T C 3.18E-08 Red blood cell traits / / 23222517 rs9494145 chr6 135432552 T C 4.39E-05 Hemoglobin / / pha003098 rs9494145 chr6 135432552 T C 6.08E-05 Erythrocyte counts / / pha003101 rs7766963 chr6 135432883 T C 1.56E-07 Red blood cell traits / / 23222517 rs2223385 chr6 135435171 G A 3.51E-19 Other erythrocyte phenotypes / / 19862010 rs2223385 chr6 135435171 G A 8.56E-34 Red blood cell traits / / 23222517 rs9483788 chr6 135435501 T C 1.00E-47 Other erythrocyte phenotypes / / 19862010 rs9483788 chr6 135435501 T C 3.00E-15 Hematocrit / / 19862010 rs9483788 chr6 135435501 T C 1.59E-05 Blood cell counts and other traits / / 20139978 rs9483788 chr6 135435501 T C 6.19E-21 Blood cell counts and other traits / / 20139978 rs9483788 chr6 135435501 T C 3.75E-08 Red blood cell traits / / 23222517 rs9483788 chr6 135435501 T C 9.38E-04 Red blood cell traits / / 23935956 rs1320959 chr6 135437386 T C 2.62E-19 Other erythrocyte phenotypes / / 19862010 rs1320959 chr6 135437386 T C 2.10E-32 Red blood cell traits / / 23222517 rs2026937 chr6 135439263 A G 1.61E-06 Hodgkin's lymphoma / / 24149102 rs6924609 chr6 135440657 A G 6.39E-19 Other erythrocyte phenotypes / / 19862010 rs6924609 chr6 135440657 A G 1.23E-40 Red blood cell traits / / 23222517 rs6925841 chr6 135441245 C T 3.42E-19 Other erythrocyte phenotypes / / 19862010 rs6925841 chr6 135441245 C T 1.38E-38 Red blood cell traits / / 23222517 rs1320962 chr6 135443144 G A 3.39E-19 Other erythrocyte phenotypes / / 19862010 rs1320962 chr6 135443144 G A 1.36E-31 Red blood cell traits / / 23222517 rs1320963 chr6 135443212 A G 4.10E-15 F-cell distribution / / 17767159 rs1320963 chr6 135443212 A G 8.46E-17 Other erythrocyte phenotypes / / 19862010 rs1320963 chr6 135443212 A G 7.61E-05 Cognitive test performance / / 20125193 rs1320963 chr6 135443212 A G 3.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1320963 chr6 135443212 A G 4.10E-15 F-cell distribution / / 21326311 rs1320963 chr6 135443212 A G 3.00E-11 Red blood cell count / / 22560525 rs1320963 chr6 135443212 A G 5.00E-15 Mean corpuscular volume / / 22560525 rs1320963 chr6 135443212 A G 5.00E-16 Mean corpuscular hemoglobin / / 22560525 rs1320963 chr6 135443212 A G 2.79E-39 Red blood cell traits / / 23222517 rs2026938 chr6 135444009 G A 1.41E-17 Other erythrocyte phenotypes / / 19862010 rs2026938 chr6 135444009 G A 3.46E-29 Red blood cell traits / / 23222517 rs10457631 chr6 135445179 A C 3.45E-19 Other erythrocyte phenotypes / / 19862010 rs10457631 chr6 135445179 A C 9.07E-41 Red blood cell traits / / 23222517 rs10457632 chr6 135445202 A G 3.67E-19 Other erythrocyte phenotypes / / 19862010 rs10457632 chr6 135445202 A G 2.57E-40 Red blood cell traits / / 23222517 rs9376093 chr6 135445448 C T 6.48E-19 Other erythrocyte phenotypes / / 19862010 rs9376093 chr6 135445448 C T 3.22E-40 Red blood cell traits / / 23222517 rs9376094 chr6 135445814 T A 7.33E-19 Other erythrocyte phenotypes / / 19862010 rs9376094 chr6 135445814 T A 4.16E-31 Red blood cell traits / / 23222517 rs12191243 chr6 135446826 C G 7.34E-19 Other erythrocyte phenotypes / / 19862010 rs12191243 chr6 135446826 C G 8.57E-40 Red blood cell traits / / 23222517 rs9321485 chr6 135447773 T C 3.12E-19 Other erythrocyte phenotypes / / 19862010 rs9321485 chr6 135447773 T C 5.55E-31 Red blood cell traits / / 23222517 rs9321486 chr6 135447820 T C 6.12E-19 Other erythrocyte phenotypes / / 19862010 rs9321486 chr6 135447820 T C 4.93E-32 Red blood cell traits / / 23222517 rs9494149 chr6 135449315 C T 1.17E-18 Other erythrocyte phenotypes / / 19862010 rs9494149 chr6 135449315 C T 1.59E-37 Red blood cell traits / / 23222517 rs9376095 chr6 135450755 T C 5.20E-18 Other erythrocyte phenotypes / / 19862010 rs9376095 chr6 135450755 T C 1.67E-27 Red blood cell traits / / 23222517 rs6934903 chr6 135451564 T A 1.59E-25 Other erythrocyte phenotypes / / 19862010 rs6934903 chr6 135451564 T A 3.29E-08 Red blood cell traits / / 23222517 rs1569534 chr6 135451580 C T 1.84E-16 Other erythrocyte phenotypes / / 19862010 rs1569534 chr6 135451580 C T 1.00E-11 Mean corpuscular volume / / 22560525 rs1569534 chr6 135451580 C T 8.00E-13 Mean corpuscular hemoglobin / / 22560525 rs1569534 chr6 135451580 C T 9.00E-11 Red blood cell count / / 22560525 rs1569534 chr6 135451580 C T 4.66E-36 Red blood cell traits / / 23222517 rs6569992 chr6 135452152 G A 6.13E-26 Other erythrocyte phenotypes / / 19862010 rs6569992 chr6 135452152 G A 1.00E-08 Red blood cell traits / / 20927387 rs6569992 chr6 135452152 G A 3.00E-08 Red blood cell traits / / 20927387 rs6569992 chr6 135452152 G A 6.00E-09 Red blood cell traits / / 20927387 rs6569992 chr6 135452152 G A 1.00E-18 Mean corpuscular volume / / 22560525 rs6569992 chr6 135452152 G A 4.00E-17 Red blood cell count / / 22560525 rs6569992 chr6 135452152 G A 9.00E-20 Mean corpuscular hemoglobin / / 22560525 rs6569992 chr6 135452152 G A 7.52E-09 Red blood cell traits / / 23222517 rs6929404 chr6 135454027 C A 1.31E-16 Other erythrocyte phenotypes / / 19862010 rs6929404 chr6 135454027 C A 3.22E-28 Red blood cell traits / / 23222517 rs9385716 chr6 135455329 A G 1.48E-16 Other erythrocyte phenotypes / / 19862010 rs9385716 chr6 135455329 A G 3.94E-36 Red blood cell traits / / 23222517 rs2078213 chr6 135458071 T C 1.69E-16 Other erythrocyte phenotypes / / 19862010 rs2078213 chr6 135458071 T C 1.59E-27 Red blood cell traits / / 23222517 rs9385717 chr6 135458423 A G 1.80E-16 Other erythrocyte phenotypes / / 19862010 rs9385717 chr6 135458423 A G 4.56E-33 Red blood cell traits / / 23222517 rs9389272 chr6 135459837 G A 1.11E-25 Other erythrocyte phenotypes / / 19862010 rs9389272 chr6 135459837 G A 2.43E-08 Red blood cell traits / / 23222517 rs7740945 chr6 135461866 C A 1.46E-16 Other erythrocyte phenotypes / / 19862010 rs7740945 chr6 135461866 C A 5.83E-25 Red blood cell traits / / 23222517 rs1883355 chr6 135461937 A G 1.57E-16 Other erythrocyte phenotypes / / 19862010 rs1883355 chr6 135461937 A G 3.58E-34 Red blood cell traits / / 23222517 rs6909822 chr6 135463333 G A 1.60E-16 Other erythrocyte phenotypes / / 19862010 rs6909822 chr6 135463333 G A 5.67E-25 Red blood cell traits / / 23222517 rs2050019 chr6 135463947 C T 1.79E-16 Other erythrocyte phenotypes / / 19862010 rs2050019 chr6 135463947 C T 4.00E-11 Red blood cell count / / 22560525 rs2050019 chr6 135463947 C T 4.00E-12 Mean corpuscular volume / / 22560525 rs2050019 chr6 135463947 C T 6.00E-13 Mean corpuscular hemoglobin / / 22560525 rs2050019 chr6 135463947 C T 1.79E-34 Red blood cell traits / / 23222517 rs17064262 chr6 135465474 T C 1.57E-21 Other erythrocyte phenotypes / / 19862010 rs17064262 chr6 135465474 T C 2.00E-15 Mean corpuscular volume / / 22560525 rs17064262 chr6 135465474 T C 3.00E-16 Red blood cell count / / 22560525 rs17064262 chr6 135465474 T C 5.00E-17 Mean corpuscular hemoglobin / / 22560525 rs17064262 chr6 135465474 T C 2.76E-08 Red blood cell traits / / 23222517 rs2026310 chr6 135465551 A C 2.51E-16 Other erythrocyte phenotypes / / 19862010 rs2026310 chr6 135465551 A C 3.48E-34 Red blood cell traits / / 23222517 rs6924687 chr6 135467521 T A 1.63E-21 Other erythrocyte phenotypes / / 19862010 rs6924687 chr6 135467521 T A 3.01E-08 Red blood cell traits / / 23222517 rs9494154 chr6 135468005 A T 1.86E-21 Other erythrocyte phenotypes / / 19862010 rs9494154 chr6 135468005 A T 4.03E-43 Red blood cell traits / / 23222517 rs7756303 chr6 135469984 G C 3.14E-10 Red blood cell traits / / 23222517 rs7746481 chr6 135483811 T C 8.85E-11 Other erythrocyte phenotypes / / 19862010 rs7746481 chr6 135483811 T C 3.54E-17 Red blood cell traits / / 23222517 rs17706858 chr6 135485094 C T 7.07E-20 Other erythrocyte phenotypes / / 19862010 rs17706858 chr6 135485094 C T 1.44E-41 Red blood cell traits / / 23222517 rs9402691 chr6 135487502 G C 3.52E-11 Other erythrocyte phenotypes / / 19862010 rs9402691 chr6 135487502 G C 8.62E-18 Red blood cell traits / / 23222517 rs7757054 chr6 135487614 A G 3.42E-09 Other erythrocyte phenotypes / / 19862010 rs7757054 chr6 135487614 A G 0.000000007 Red blood cell count / / 22560525 rs7757054 chr6 135487614 A G 0.00000002 Mean corpuscular volume / / 22560525 rs7757054 chr6 135487614 A G 1.64E-13 Red blood cell traits / / 23222517 rs1041479 chr6 135488496 T C 4.66E-11 Other erythrocyte phenotypes / / 19862010 rs1041479 chr6 135488496 T C 5.88E-17 Red blood cell traits / / 23222517 rs9494167 chr6 135489069 T C 6.66E-11 Other erythrocyte phenotypes / / 19862010 rs9494167 chr6 135489069 T C 2.43E-17 Red blood cell traits / / 23222517 rs9483798 chr6 135490898 C T 8.06E-11 Other erythrocyte phenotypes / / 19862010 rs9483798 chr6 135490898 C T 1.16E-22 Red blood cell traits / / 23222517 rs7775140 chr6 135491487 G A 9.42E-11 Other erythrocyte phenotypes / / 19862010 rs7775140 chr6 135491487 G A 1.22E-17 Red blood cell traits / / 23222517 rs10872428 chr6 135491872 G T 1.27E-10 Other erythrocyte phenotypes / / 19862010 rs10872428 chr6 135491872 G T 5.08E-23 Red blood cell traits / / 23222517 rs10872428 chr6 135491872 G T 4.40E-04 Pulmonary function / / 23932459 rs6903449 chr6 135492408 C A 9.51E-11 Other erythrocyte phenotypes / / 19862010 rs6903449 chr6 135492408 C A 2.71E-18 Red blood cell traits / / 23222517 rs9321490 chr6 135494875 T C 3.63E-08 Other erythrocyte phenotypes / / 19862010 rs9321490 chr6 135494875 T C 2.00E-06 Multiple sclerosis / / 21833088 rs9321490 chr6 135494875 T C 1.27E-15 Red blood cell traits / / 23222517 rs2327586 chr6 135495226 C T 1.43E-07 Red blood cell traits / / 23222517 rs9399141 chr6 135495574 T C 3.66E-08 Other erythrocyte phenotypes / / 19862010 rs9399141 chr6 135495574 T C 1.08E-15 Red blood cell traits / / 23222517 rs11965277 chr6 135497832 G A 5.38E-09 Other erythrocyte phenotypes / / 19862010 rs11965277 chr6 135497832 G A 4.10E-15 Red blood cell traits / / 23222517 rs1320961 chr6 135498252 A T 3.22E-08 Other erythrocyte phenotypes / / 19862010 rs1320961 chr6 135498252 A T 1.78E-19 Red blood cell traits / / 23222517 rs210962 chr6 135503785 C T 3.38E-08 Other erythrocyte phenotypes MYB intron 19862010 rs210962 chr6 135503785 C T 4.70E-04 Blood cell counts and traits,in red and white blood cells MYB intron 21153663 rs210962 chr6 135503785 C T 1.72E-18 Red blood cell traits MYB intron 23222517 rs210796 chr6 135511108 A T 3.84E-16 Red blood cell traits MYB intron 23222517 rs1022506 chr6 135511587 G A 7.21E-09 Other erythrocyte phenotypes MYB intron 19862010 rs1022506 chr6 135511587 G A 3.08E-15 Red blood cell traits MYB intron 23222517 rs11154794 chr6 135515448 T C 7.31E-09 Other erythrocyte phenotypes MYB intron 19862010 rs11154794 chr6 135515448 T C 4.01E-15 Red blood cell traits MYB intron 23222517 rs12663543 chr6 135517614 A G 3.38E-08 Other erythrocyte phenotypes MYB intron 19862010 rs12663543 chr6 135517614 A G 3.12E-13 Red blood cell traits MYB intron 23222517 rs12660713 chr6 135517996 G A 4.08E-09 Other erythrocyte phenotypes MYB intron 19862010 rs12660713 chr6 135517996 G A 9.28E-15 Red blood cell traits MYB intron 23222517 rs6920829 chr6 135519500 T C 4.31E-09 Other erythrocyte phenotypes MYB intron 19862010 rs6920829 chr6 135519500 T C 2.12E-14 Red blood cell traits MYB intron 23222517 rs3752383 chr6 135522755 A G 3.53E-09 Other erythrocyte phenotypes MYB intron 19862010 rs3752383 chr6 135522755 A G 4.36E-15 Red blood cell traits MYB intron 23222517 rs743589 chr6 135522939 T C 2.89E-15 Red blood cell traits MYB intron 23222517 rs17639758 chr6 135523250 G A 2.04E-08 Other erythrocyte phenotypes MYB intron 19862010 rs17639758 chr6 135523250 G A 2.86E-09 Red blood cell traits MYB intron 23222517 rs9385719 chr6 135524516 A G 3.78E-15 Red blood cell traits MYB intron 23222517 rs3819409 chr6 135525396 G T 5.45E-15 Red blood cell traits MYB intron 23222517 rs9389278 chr6 135525927 T C 6.61E-15 Red blood cell traits MYB intron 23222517 rs9321493 chr6 135526768 C T 1.02E-13 Red blood cell traits MYB intron 23222517 rs723388 chr6 135528722 A G 3.48E-12 Red blood cell traits MYB intron 23222517 rs210950 chr6 135531451 C G 6.57E-15 Red blood cell traits MYB intron 23222517 rs210949 chr6 135531639 G T 1.67E-10 Red blood cell traits MYB intron 23222517 rs210943 chr6 135535240 C T 9.60E-11 Red blood cell traits MYB intron 23222517 rs210942 chr6 135535447 T C 8.65E-10 Red blood cell traits MYB intron 23222517 rs6936293 chr6 135536021 C T 1.01E-09 Other erythrocyte phenotypes MYB intron 19862010 rs6936293 chr6 135536021 C T 5.50E-04 Blood cell counts and traits,in red and white blood cells MYB intron 21153663 rs6936293 chr6 135536021 C T 3.51E-14 Red blood cell traits MYB intron 23222517 rs7738267 chr6 135537193 A G 1.32E-09 Other erythrocyte phenotypes MYB intron 19862010 rs7738267 chr6 135537193 A G 4.48E-14 Red blood cell traits MYB intron 23222517 rs210939 chr6 135537890 C G 2.44E-08 Red blood cell traits MYB intron 23222517 rs1013891 chr6 135538639 A G 1.50E-10 Red blood cell traits MYB intron 23222517 rs210937 chr6 135540380 G A 8.00E-06 Obesity-related traits MYB nearGene-3 23251661 rs11968112 chr6 135592211 G A 0.000009 Asthma / / 23040885 rs11964349 chr6 135596873 C T 0.0000015 Asthma / / 23040885 rs2223802 chr6 135623584 C T 1.20E-05 Urinary metabolites AHI1 intron 21572414 rs4896144 chr6 135646692 T C 1.70E-05 Urinary metabolites AHI1 intron 21572414 rs2614264 chr6 135710694 G A 7.10E-05 Immunoglobulin A AHI1 intron 20694011 rs2614264 chr6 135710694 G A 1.54E-04 Arthritis (juvenile idiopathic) AHI1 intron 22354554 rs13208164 chr6 135721285 G A 4.91E-05 Hodgkin's lymphoma AHI1 intron 24149102 rs11154801 chr6 135739355 C A 6.23E-06 Schizophrenia AHI1 intron 21795503 rs11154801 chr6 135739355 C A 1.00E-13 Multiple sclerosis AHI1 intron 21833088 rs2614280 chr6 135744127 C T 1.60E-05 Urinary metabolites AHI1 intron 21572414 rs7759971 chr6 135746884 C T 6.23E-06 Schizophrenia AHI1 intron 21795503 rs1535435 chr6 135757022 A G 1.00E-06 Type 2 diabetes AHI1 intron 17668382 rs1977239 chr6 135783742 A T 3.04E-04 Type 2 diabetes AHI1 intron 17463246 rs7769298 chr6 135809811 T C 7.10E-06 Urinary metabolites AHI1 intron 21572414 rs7750586 chr6 135827673 A G 4.68E-06 Lymphocyte counts LINC00271 intron 22286170 rs4896151 chr6 135829796 T C 8.17E-04 Type 2 diabetes LINC00271 intron 17463246 rs9494266 chr6 135851573 G A 3.96E-04 Type 2 diabetes LINC00271 intron 17463246 rs9494266 chr6 135851573 G A 2.28E-07 Type 2 diabetes LINC00271 intron 17668382 rs9402717 chr6 135870778 T C 8.90E-04 Parkinson's disease LINC00271 intron 17052657 rs9373141 chr6 135956534 G C 0.00005421 Sarcoidosis LINC00271 intron 22952805 rs9389316 chr6 136001003 C A 7.00E-13 Immune reponse to smallpox (secreted IL-2) LINC00271 intron 22610502 rs6905874 chr6 136011324 C T 6.50E-04 Type 2 diabetes / / 17463246 rs2038549 chr6 136052948 G A 3.27E-06 Schizophrenia / / 21795503 rs1475069 chr6 136056234 A C 6.97E-06 Schizophrenia / / 21795503 rs9399159 chr6 136064193 G A 5.04E-06 Multiple complex diseases / / 17554300 rs9402749 chr6 136064503 C G 5.73E-05 Multiple complex diseases / / 17554300 rs9402750 chr6 136064543 T G 8.62E-07 Multiple complex diseases / / 17554300 rs1885271 chr6 136132370 G A 8.72E-04 Multiple complex diseases / / 17554300 rs947583 chr6 136133659 T C 3.00E-12 Phosphorus levels / / 20558539 rs947583 chr6 136133659 T C 8.88E-04 Stroke / / pha002887 rs9376153 chr6 136141151 G C 1.37E-04 Multiple complex diseases / / 17554300 rs7745577 chr6 136145197 T G 8.91E-04 Multiple complex diseases / / 17554300 rs7745577 chr6 136145197 T G 7.40E-04 Smoking quantity / / 24665060 rs9385740 chr6 136164403 G A 2.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs9385741 chr6 136164707 G A 7.63E-05 Multiple complex diseases / / 17554300 rs9494397 chr6 136167568 A G 7.37E-04 Multiple complex diseases / / 17554300 rs9494397 chr6 136167568 A G 2.66E-05 Alzheimer's disease / / 17998437 rs6906788 chr6 136176728 C T 9.18E-04 Alzheimer's disease PDE7B intron 17998437 rs7743012 chr6 136179737 T C 4.35E-04 Alzheimer's disease PDE7B intron 17998437 rs7743012 chr6 136179737 T C 5.81E-04 Suicide attempts in bipolar disorder PDE7B intron 21423239 rs9376158 chr6 136184091 A G 7.56E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) PDE7B intron 22566498 rs9402765 chr6 136185184 A G 8.48E-04 Suicide attempts in bipolar disorder PDE7B intron 21423239 rs9402766 chr6 136185497 A G 7.40E-04 Suicide attempts in bipolar disorder PDE7B intron 21423239 rs6570048 chr6 136198594 C T 3.51E-04 Hemoglobin concentration PDE7B intron 20534544 rs10872447 chr6 136204505 A G 3.16E-04 Multiple complex diseases PDE7B intron 17554300 rs7772608 chr6 136209716 G C 1.22E-04 Multiple complex diseases PDE7B intron 17554300 rs6570053 chr6 136217299 C A 2.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE7B intron 20877124 rs6570053 chr6 136217299 C A 0.0000304 HIV-1 infection (natural long-term nonprogression) PDE7B intron 22238471 rs2327672 chr6 136228219 G A 1.80E-05 Bone mineral density (BMD),in women PDE7B intron 20164292 rs1418340 chr6 136259596 C G 1.27E-04 Major depressive disorder PDE7B intron 22472876 rs883799 chr6 136262043 C T 1.92E-04 Major depressive disorder PDE7B intron 22472876 rs9376168 chr6 136265021 G A 2.29E-04 Major depressive disorder PDE7B intron 22472876 rs7774640 chr6 136265165 G A 1.95E-04 Major depressive disorder PDE7B intron 22472876 rs2327665 chr6 136266316 C G 9.42E-05 Major depressive disorder PDE7B intron 22472876 rs2018448 chr6 136271527 A G 9.55E-05 Major depressive disorder PDE7B intron 22472876 rs10872455 chr6 136276087 A G 6.50E-05 Major depressive disorder PDE7B intron 22472876 rs4896187 chr6 136281844 G C 7.15E-05 Major depressive disorder PDE7B intron 22472876 rs12190806 chr6 136284331 T C 7.50E-05 Major depressive disorder PDE7B intron 22472876 rs11154835 chr6 136284476 G A 9.00E-05 Major depressive disorder PDE7B intron 22472876 rs4896189 chr6 136288944 A G 1.29E-04 Major depressive disorder PDE7B intron 22472876 rs4073748 chr6 136295252 C T 8.28E-04 Multiple complex diseases PDE7B intron 17554300 rs4254999 chr6 136311863 A C 9.87E-05 Major depressive disorder PDE7B intron 22472876 rs4896192 chr6 136317656 G A 2.10E-04 Major depressive disorder PDE7B intron 22472876 rs9376172 chr6 136332358 T C 6.79E-05 Major depressive disorder PDE7B intron 22472876 rs9402782 chr6 136333229 G A 7.61E-05 Major depressive disorder PDE7B intron 22472876 rs6931583 chr6 136333948 A C 7.21E-04 Smoking cessation PDE7B intron 24665060 rs9399177 chr6 136336210 C T 8.76E-04 Major depressive disorder PDE7B intron 22472876 rs9376173 chr6 136359446 A C 5.78E-04 Alzheimer's disease PDE7B intron 22005930 rs11154851 chr6 136368005 C T 1.00E-08 Alzheimer's disease (cognitive decline) PDE7B intron 23535033 rs6921041 chr6 136370658 T G 3.62E-04 Alcohol dependence PDE7B intron 24277619 rs7765567 chr6 136396874 A G 4.49E-04 Alcohol dependence PDE7B intron 24277619 rs9389370 chr6 136431265 C G 2.88E-04 Schizophrenia(treatment response to risperidone) PDE7B intron 19850283 rs9389370 chr6 136431265 C G 5.40E-04 Pulmonary function PDE7B intron 23932459 rs3757154 chr6 136435194 C G 4.07E-04 Suicide attempts in bipolar disorder PDE7B intron 21041247 rs2046092 chr6 136459238 A G 1.71E-04 Suicide attempts in bipolar disorder PDE7B intron 21041247 rs2046091 chr6 136459249 A G 1.70E-04 Suicide attempts in bipolar disorder PDE7B intron 21041247 rs7748159 chr6 136464535 T G 8.42E-05 Suicide attempts in bipolar disorder PDE7B intron 21041247 rs7770469 chr6 136464760 G A 2.06E-04 Suicide attempts in bipolar disorder PDE7B intron 21041247 rs4896198 chr6 136465433 T C 8.28E-05 Suicide attempts in bipolar disorder PDE7B intron 21041247 rs4896199 chr6 136465572 A C 8.28E-05 Suicide attempts in bipolar disorder PDE7B intron 21041247 rs1600620 chr6 136466041 A T 8.17E-05 Suicide attempts in bipolar disorder PDE7B intron 21041247 rs1600619 chr6 136466175 T A 7.99E-05 Suicide attempts in bipolar disorder PDE7B intron 21041247 rs12662330 chr6 136466619 A C 7.98E-05 Suicide attempts in bipolar disorder PDE7B intron 21041247 rs2170231 chr6 136467134 C T 7.40E-05 Suicide attempts in bipolar disorder PDE7B intron 21041247 rs1471545 chr6 136471707 T C 6.27E-05 Suicide attempts in bipolar disorder PDE7B intron 21041247 rs1471545 chr6 136471707 T C 4.68E-04 Amyotrophic lateral sclerosis (sporadic) PDE7B intron 24529757 rs1471545 chr6 136471707 T C 1.76E-04 Smoking initiation PDE7B intron 24665060 rs1471546 chr6 136471800 T C 6.28E-05 Suicide attempts in bipolar disorder PDE7B intron 21041247 rs4896201 chr6 136472439 G A 1.29E-04 Suicide attempts in bipolar disorder PDE7B intron 21041247 rs4896202 chr6 136472496 T G 6.18E-05 Suicide attempts in bipolar disorder PDE7B intron 21041247 rs9494457 chr6 136474794 T A 7.09E-05 Suicide attempts in bipolar disorder PDE7B intron 21041247 rs1038214 chr6 136479194 A G 8.60E-05 Suicide attempts in bipolar disorder PDE7B intron 21041247 rs3823159 chr6 136482727 A G 1.95E-11 Narcolepsy PDE7B intron 19629137 rs560713 chr6 136505036 A C 2.00E-06 Intraocular pressure PDE7B intron 24002674 rs113508841 chr6 136545273 C T 6.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs10484485 chr6 136560948 G A 2.28E-04 Multiple complex diseases FAM54A cds-synon 17554300 rs10484487 chr6 136561169 T C 5.17E-05 Multiple complex diseases FAM54A intron 17554300 rs564521054 chr6 136587019 G GT 8.72E-04 Type 2 diabetes BCLAF1 intron 17463246 rs797556 chr6 136587019 G C 8.72E-04 Type 2 diabetes BCLAF1 intron 17463246 rs3757156 chr6 136612111 C T 7.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7746031 chr6 136622032 T C 7.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3778297 chr6 136695212 G A 6.76E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs3778297 chr6 136695212 G A 8.58E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs7747460 chr6 136727603 T C 1.12E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs7747460 chr6 136727603 T C 9.51E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs2076193 chr6 136743135 G A 1.35E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs2076193 chr6 136743135 G A 5.60E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs3778303 chr6 136749066 T C 2.12E-04 Hemoglobin concentration MAP7 intron 20534544 rs724875 chr6 136759935 G A 5.23E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs724875 chr6 136759935 G A 8.86E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs7763427 chr6 136760658 T C 9.20E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs7763427 chr6 136760658 T C 9.89E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs1028332 chr6 136764016 C T 5.06E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs1028332 chr6 136764016 C T 5.31E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs3778307 chr6 136765459 C T 5.06E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs3778307 chr6 136765459 C T 5.31E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs720565 chr6 136792964 C G 9.80E-05 Longevity and age-related phenotypes MAP7 intron 17903295 rs12527012 chr6 136797211 G A 1.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs2181096 chr6 136812315 T C 7.74E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs2181096 chr6 136812315 T C 9.94E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs3778312 chr6 136815525 T C 1.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs3778312 chr6 136815525 T C 1.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs7748200 chr6 136832120 G A 7.13E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs7748200 chr6 136832120 G A 9.79E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs3799454 chr6 136839216 T C 7.18E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs3799454 chr6 136839216 T C 8.34E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs13191834 chr6 136860731 T C 5.66E-06 Triglycerides MAP7 intron 19074352 rs13191834 chr6 136860731 T C 5.66E-06 Polyunsaturated fatty acid levels,in plasma MAP7 intron 19148276 rs746973 chr6 136861575 C A 8.37E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs746973 chr6 136861575 C A 9.26E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs3799472 chr6 136868929 G A 6.29E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs3799472 chr6 136868929 G A 7.56E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP7 intron 20877124 rs2327742 chr6 136884168 A G 1.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP3K5 intron 20877124 rs2327742 chr6 136884168 A G 6.76E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP3K5 intron 20877124 rs13203080 chr6 136884811 G A 5.33E-05 Migraine MAP3K5 intron 23793025 rs2327743 chr6 136909242 T C 4.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP3K5 intron 20877124 rs2327743 chr6 136909242 T C 6.01E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP3K5 intron 20877124 rs760862 chr6 136909664 T C 2.56E-04 Multiple complex diseases MAP3K5 intron 17554300 rs760862 chr6 136909664 T C 7.13E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP3K5 intron 20877124 rs2076262 chr6 136913217 T C 3.43E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP3K5 intron 20877124 rs2076262 chr6 136913217 T C 6.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP3K5 intron 20877124 rs6926904 chr6 136915761 C G 5.18E-05 Multiple complex diseases MAP3K5 intron 17554300 rs9321564 chr6 136939818 A G 1.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP3K5 intron 20877124 rs9321564 chr6 136939818 A G 1.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP3K5 intron 20877124 rs3765258 chr6 136944063 A G 2.03E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP3K5 cds-synon 20877124 rs3765258 chr6 136944063 A G 5.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP3K5 cds-synon 20877124 rs3765258 chr6 136944063 A G 7.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP3K5 cds-synon 20877124 rs3765258 chr6 136944063 A G 7.38E-05 Nephrolithiasis MAP3K5 cds-synon 22396660 rs9389418 chr6 136947278 C A 2.00E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP3K5 intron 20877124 rs9389418 chr6 136947278 C A 7.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP3K5 intron 20877124 rs17723608 chr6 136947540 A G 1.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP3K5 intron 20877124 rs9494548 chr6 136963562 C T 0.00048 Coronary artery calcification MAP3K5 intron 23727086 rs9376219 chr6 136963890 C T 5.88E-05 Heart Rate MAP3K5 intron pha003053 rs9376221 chr6 136992379 T C 3.90E-07 Atopy MAP3K5 intron 19961619 rs911185 chr6 137033706 T C 1.15E-04 Diabetic nephropathy MAP3K5 intron pha002866 rs7769773 chr6 137050651 T G 1.10E-13 Cholesterol,total MAP3K5 intron 23063622 rs6570091 chr6 137050896 T C 7.31E-06 Lymphocyte counts MAP3K5 intron 22286170 rs7747030 chr6 137059166 T C 1.26E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers MAP3K5 intron 21775533 rs17654215 chr6 137061013 T C 6.43E-04 Suicide attempts in bipolar disorder MAP3K5 intron 21423239 rs9321570 chr6 137095679 G C 8.90E-05 Diabetic nephropathy MAP3K5 intron pha002866 rs9494569 chr6 137104793 C G 5.60E-05 Diabetic nephropathy MAP3K5 intron pha002866 rs9483947 chr6 137105400 C T 5.60E-05 Diabetic nephropathy MAP3K5 intron pha002866 rs3734552 chr6 137112633 A G 1.62E-04 Attention deficit hyperactivity disorder MAP3K5 intron pha002875 rs6919857 chr6 137140454 C T 4.79E-05 Attention deficit hyperactivity disorder / / 18980221 rs6919857 chr6 137140454 C T 9.21E-05 Attention deficit hyperactivity disorder / / pha002875 rs3757167 chr6 137140993 T C 7.00E-05 Diabetic nephropathy / / pha002866 rs9402850 chr6 137164622 G T 0.00029 Coronary artery calcification PEX7 intron 23727086 rs9373174 chr6 137185164 G A 1.22E-04 Diabetic nephropathy PEX7 intron pha002866 rs1474987 chr6 137185293 A G 9.20E-05 Diabetic nephropathy PEX7 intron pha002866 rs2327766 chr6 137209591 A G 8.22E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PEX7 intron 20877124 rs6937795 chr6 137291281 A C 7.00E-06 Type 2 diabetes / / 24509480 rs9376241 chr6 137292032 A G 1.02E-04 Type 2 diabetes / / 17463246 rs6906007 chr6 137296300 A C 2.30E-04 Type 2 diabetes / / 17463246 rs10872466 chr6 137297967 T C 5.07E-04 Type 2 diabetes / / 17463246 rs4896224 chr6 137298126 T C 1.92E-04 Type 2 diabetes / / 17463246 rs4407733 chr6 137299152 A G 6.60E-06 Type 2 diabetes / / 24509480 rs1891487 chr6 137301581 G A 2.86E-04 Type 2 diabetes / / 17463246 rs947733 chr6 137304427 T C 2.12E-04 Type 2 diabetes NHEG1 intron 17463246 rs1744062 chr6 137309186 G A 4.16E-06 Attention deficit hyperactivity disorder NHEG1 intron 22420046 rs10484795 chr6 137316830 C T 7.80E-06 Memory performance / / 22105620 rs1622583 chr6 137316887 G T 6.50E-04 Multiple complex diseases / / 17554300 rs1475119 chr6 137321910 T G 1.78E-05 Attention deficit hyperactivity disorder IL20RA UTR-3 22420046 rs1744061 chr6 137324655 C T 5.14E-04 Alcohol dependence IL20RA intron 24277619 rs1744065 chr6 137326635 G A 9.87E-04 Response to TNF antagonist treatment IL20RA intron 21061259 rs2010614 chr6 137333718 G A 4.77E-04 Multiple complex diseases IL20RA intron 17554300 rs9402865 chr6 137333851 G A 3.94E-04 Response to TNF antagonist treatment IL20RA intron 21061259 rs911827 chr6 137333909 T C 1.38E-04 Multiple complex diseases IL20RA intron 17554300 rs1167848 chr6 137347788 T C 3.62E-04 Multiple complex diseases IL20RA intron 17554300 rs276504 chr6 137352519 T C 5.93E-05 ldl cholesterol IL20RA intron pha003077 rs17066024 chr6 137358504 A G 4.01E-04 Multiple complex diseases IL20RA intron 17554300 rs276521 chr6 137367655 A G 7.83E-05 ldl cholesterol / / pha003077 rs9494644 chr6 137403294 C G 5.35E-04 Type 2 diabetes / / 17463246 rs276568 chr6 137422752 T C 3.37E-05 Bilirubin levels,in serum / / 19389676 rs276576 chr6 137437392 C T 2.63E-04 Type 2 diabetes / / 17463246 rs4895477 chr6 137444054 G A 1.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9321588 chr6 137445359 C T 9.76E-06 Bilirubin levels,in serum / / 19389676 rs17066096 chr6 137452908 A G 3.33E-05 Multiple sclerosis / / 19525953 rs17066096 chr6 137452908 A G 6.00E-13 Multiple sclerosis / / 21833088 rs17066096 chr6 137452908 A G 9.60E-04 Multiple sclerosis / / 24234648 rs72761 chr6 137454459 G A 7.02E-05 Prion diseases / / 22210626 rs10484798 chr6 137470756 T C 8.00E-06 Inflammatory demyelinating disease IL22RA2 intron 19850125 rs11154914 chr6 137480411 A G 5.89E-07 Body Mass Index IL22RA2 intron pha003009 rs11154914 chr6 137480411 A G 6.68E-05 Weight IL22RA2 intron pha003027 rs1040622 chr6 137483258 T C 3.72E-06 Body Mass Index IL22RA2 intron pha003009 rs6907770 chr6 137496802 G A 5.71E-04 Type 2 diabetes / / 17463246 rs7740905 chr6 137503528 G A,C 5.71E-04 Type 2 diabetes / / 17463246 rs6570140 chr6 137503597 G A 5.71E-04 Type 2 diabetes / / 17463246 rs4896243 chr6 137514790 C T 2.67E-05 Behcet's disease / / pha002888 rs7759040 chr6 137517491 A T 4.62E-05 Glycosylated haemoglobin levels / / 17255346 rs3799488 chr6 137519780 T C 7.27E-05 Glycosylated haemoglobin levels IFNGR1 intron 17255346 rs9376267 chr6 137531031 C T 4.22E-05 Glycosylated haemoglobin levels IFNGR1 intron 17255346 rs9376267 chr6 137531031 C T 4.72E-04 Multiple complex diseases IFNGR1 intron 17554300 rs9376268 chr6 137532751 G A 2.43E-05 Glycosylated haemoglobin levels IFNGR1 intron 17255346 rs9376268 chr6 137532751 G A 4.00E-06 Meningococcal disease IFNGR1 intron 20694013 rs1327474 chr6 137541075 C T 5.40E-05 Aging (time to event) IFNGR1 nearGene-5 21782286 rs17066180 chr6 137552527 G A 6.17E-06 Brain structure / / 22504417 rs9321590 chr6 137605627 T C 1.16E-04 Tourette syndrome / / 22889924 rs6928289 chr6 137673302 G A 9.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1022400 chr6 137674040 T C 6.52E-05 Asthma / / pha003128 rs4142802 chr6 137674345 T G 9.74E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1521173 chr6 137676458 T A 9.91E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs4613838 chr6 137686845 A C 7.20E-06 Urinary metabolites / / 21572414 rs932220 chr6 137687230 C A 2.60E-05 Urinary metabolites / / 21572414 rs9402890 chr6 137703331 A G 2.67E-04 Type 2 diabetes / / 17463246 rs7740396 chr6 137709191 A C 9.48E-04 Type 2 diabetes / / 17463246 rs12526230 chr6 137710766 G A 4.82E-04 Coronary heart disease / / 21606135 rs9389496 chr6 137712235 A G 4.34E-04 Hemoglobin concentration / / 20534544 rs1572101 chr6 137714458 C T 5.88E-04 Type 2 diabetes / / 17463246 rs9321599 chr6 137718533 G A 7.15E-04 Bipolar disorder / / 19259986 rs9321599 chr6 137718533 G A 4.34E-04 Hemoglobin concentration / / 20534544 rs6935663 chr6 137719667 C T 6.51E-04 Type 2 diabetes / / 17463246 rs9494756 chr6 137736998 A G 4.95E-05 Serum metabolites / / 19043545 rs7756251 chr6 137741990 A T 6.06E-04 Multiple complex diseases / / 17554300 rs7756962 chr6 137742188 G C 1.85E-04 Multiple complex diseases / / 17554300 rs9494759 chr6 137745086 G A 5.49E-04 Multiple complex diseases / / 17554300 rs9321611 chr6 137787843 A G 5.23E-05 Lactate dehydrogenase levels / / 20981236 rs12198924 chr6 137801589 T G 6.10E-04 Multiple complex diseases / / 17554300 rs1412926 chr6 137818611 T C 9.83E-04 Multiple complex diseases / / 17554300 rs1000738 chr6 137828235 A G 4.96E-05 Serum metabolites / / 19043545 rs12661016 chr6 137863516 G A 7.03E-04 Response to TNF antagonist treatment / / 21061259 rs12661016 chr6 137863516 G A 7.80E-07 Urinary metabolites / / 21572414 rs203691 chr6 137867448 A G 9.29E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12196933 chr6 137869831 C T 4.33E-06 Body Mass Index / / pha003019 rs12196933 chr6 137869831 C T 4.02E-07 Body Mass Index / / pha003022 rs408901 chr6 137871592 G A 5.05E-04 Hemoglobin concentration / / 20534544 rs17066538 chr6 137872918 G C 7.03E-04 Response to TNF antagonist treatment / / 21061259 rs17066538 chr6 137872918 G C 8.00E-06 Urinary metabolites / / 21572414 rs1412925 chr6 137873321 T G 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9321619 chr6 137874408 A G 1.71E-05 Multiple sclerosis / / 19525953 rs2876370 chr6 137917237 A T 1.36E-08 Multiple complex diseases / / 17554300 rs4895494 chr6 137937380 G A 7.44E-04 Type 2 diabetes / / 17463246 rs495610 chr6 137940936 G A 7.60E-04 Type 2 diabetes / / 23209189 rs6570180 chr6 137945924 G A 2.00E-04 Type 2 diabetes / / 23209189 rs9688558 chr6 137956333 G A 1.54E-05 Bone mineral density / / 19181680 rs6933404 chr6 137959235 T C 1.78E-20 Celiac disease and Rheumatoid arthritis / / 21383967 rs631204 chr6 137959455 C A 6.84E-05 HDL cholesterol / / pha003075 rs616885 chr6 137960354 T G 5.44E-04 Smoking initiation / / 24665060 rs563511 chr6 137960630 C T 4.12E-06 White blood cell count / / 21738479 rs634040 chr6 137960787 T C 2.06E-04 Smoking initiation / / 24665060 rs17066662 chr6 137961013 C T 9.45E-04 Multiple complex diseases / / 17554300 rs13207033 chr6 137965418 G A 6.95E-04 Multiple complex diseases / / 17554300 rs13192841 chr6 137967214 G A 8.54E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs13192841 chr6 137967214 G A 1.00E-08 Multiple sclerosis / / 21833088 rs12527282 chr6 137967252 C T 5.81E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs2327832 chr6 137973068 A G 2.93E-06 Multiple complex diseases / / 17554300 rs2327832 chr6 137973068 A G 4.52E-05 Rheumatoid arthritis / / 17804836 rs2327832 chr6 137973068 A G 2.36E-05 Type 1 diabetes / / 18978792 rs2327832 chr6 137973068 A G 3.82E-07 Rheumatoid arthritis / / 19503088 rs2327832 chr6 137973068 A G 4.00E-19 Celiac disease / / 20190752 rs2327832 chr6 137973068 A G 4.00E-19 Asthma / / 21150878 rs2327832 chr6 137973068 A G 4.46E-19 Celiac disease and Rheumatoid arthritis / / 21383967 rs2327832 chr6 137973068 A G 4.46E-19 Multiple sclerosis / / 22190364 rs17066681 chr6 137973349 G A 2.20E-04 Intelligence (childhood) / / 23358156 rs1878658 chr6 137978386 A G 1.86E-04 Type 1 diabetes / / 21980299 rs686851 chr6 137979971 C T 5.35E-04 Multiple complex diseases / / 17554300 rs686851 chr6 137979971 C T 2.60E-05 Urinary metabolites / / 21572414 rs2069311 chr6 137981227 C A 0.0005297 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2069311 chr6 137981227 C A 5.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs493179 chr6 137983293 T A 9.96E-04 Multiple complex diseases / / 17554300 rs12209575 chr6 137997995 A C 2.92E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs77027760 chr6 138002061 G A 2.10E-07 Celiac disease / / 22057235 rs77027760 chr6 138002061 G A 0.00000021 Celiac disease / / 23143596 rs10499194 chr6 138002637 C T 1.00E-09 Rheumatoid arthritis / / 17982456 rs10499194 chr6 138002637 C T 1.00E-09 Multiple sclerosis / / 22190364 rs10499194 chr6 138002637 C T 0.000212 Rheumatoid arthritis / / 23143596 rs606539 chr6 138005300 C T 8.22E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17264332 chr6 138005515 A G 5.00E-30 Celiac disease / / 22057235 rs17264332 chr6 138005515 A G 5.00E-30 Celiac disease / / 23143596 rs17264332 chr6 138005515 A G 3.90E-20 Rheumatoid arthritis / / 24390342 rs17264332 chr6 138005515 A G 4.10E-20 Rheumatoid arthritis / / 24390342 rs6920220 chr6 138006504 G A 7.40E-07 Multiple complex diseases / / 17554300 rs6920220 chr6 138006504 G A 1.30E-04 Rheumatoid arthritis / / 17804836 rs6920220 chr6 138006504 G A 1.00E-07 Rheumatoid arthritis / / 17982456 rs6920220 chr6 138006504 G A 2.00E-09 Rheumatoid arthritis / / 18794853 rs6920220 chr6 138006504 G A 9.60E-05 Type 1 diabetes / / 18978792 rs6920220 chr6 138006504 G A 9.00E-13 Rheumatoid arthritis / / 20453842 rs6920220 chr6 138006504 G A 8.00E-17 Ulcerative colitis / / 21297633 rs6920220 chr6 138006504 G A 8.90E-13 Celiac disease and Rheumatoid arthritis / / 21383967 rs6920220 chr6 138006504 G A 8.90E-13 Multiple sclerosis / / 22190364 rs6920220 chr6 138006504 G A 0.00000117 Primary biliary cirrhosis / / 22936693 rs6920220 chr6 138006504 G A 0.00000994 Primary biliary cirrhosis (anti-mitochondrial antibody positive) / / 22936693 rs6920220 chr6 138006504 G A 0.0000471 Primary biliary cirrhosis in females / / 22936693 rs6920220 chr6 138006504 G A 1.00E-21 Inflammatory bowel disease / / 23128233 rs6920220 chr6 138006504 G A 3.55E-18 Rheumatoid arthritis (CCP positive) / / 23143596 rs6920220 chr6 138006504 G A 4.24E-15 Rheumatoid arthritis / / 23143596 rs6920220 chr6 138006504 G A 3.00E-08 Rheumatoid arthritis / / 24449572 rs636393 chr6 138007530 G T 1.59E-07 Celiac disease and Rheumatoid arthritis / / 21383967 rs636393 chr6 138007530 G T 6.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs602414 chr6 138011665 G T 2.73E-04 Tourette syndrome / / 22889924 rs602414 chr6 138011665 G T 9.71E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs508214 chr6 138013665 A G 1.63E-04 Multiple complex diseases / / 17554300 rs508214 chr6 138013665 A G 7.01E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs667520 chr6 138016125 A G 8.70E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs6917441 chr6 138018439 A G 9.00E-05 Lung cancer / / 18978790 rs6917441 chr6 138018439 A G 1.35E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs647108 chr6 138022540 T G 8.62E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1518047 chr6 138037366 G A 9.90E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs7766288 chr6 138045051 G C 7.44E-04 Multiple complex diseases / / 17554300 rs1890370 chr6 138070058 T C 3.26E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11961697 chr6 138075443 C T 5.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6927210 chr6 138076153 T C 7.11E-06 Multiple complex diseases / / 17554300 rs6927210 chr6 138076153 T C 6.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs946227 chr6 138082762 G A 1.18E-05 Multiple complex diseases / / 17554300 rs7753394 chr6 138085248 C T 3.91E-06 Multiple complex diseases / / 17554300 rs7773904 chr6 138085365 T G 5.04E-06 Multiple complex diseases / / 17554300 rs12055552 chr6 138090140 C T 2.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs654039 chr6 138115266 T C 6.42E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs631609 chr6 138118915 T C 4.90E-06 Urinary metabolites / / 21572414 rs683122 chr6 138122262 A T 5.76E-04 Type 2 diabetes / / 17463246 rs683122 chr6 138122262 A T 1.50E-05 Urinary metabolites / / 21572414 rs774628 chr6 138126278 T C 4.20E-05 Systemic lupus erythematosus / / 23273568 rs619796 chr6 138130479 A G 9.40E-06 Systemic lupus erythematosus / / 23273568 rs10499197 chr6 138132516 T G 1.43E-06 Multiple complex diseases / / 17554300 rs10499197 chr6 138132516 T G 2.00E-09 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs892999 chr6 138138705 G A 3.12E-06 Multiple sclerosis / / 19525953 rs670369 chr6 138147048 C T 1.60E-06 Systemic lupus erythematosus LOC100507429 intron 23273568 rs6918329 chr6 138161013 A G 0.000115504 Primary sclerosing cholangitis / / 23603763 rs11970411 chr6 138179161 G C 1.10E-07 Multiple complex diseases / / 17554300 rs3757173 chr6 138190154 A G 7.20E-09 Systemic lupus erythematosus TNFAIP3 intron 23273568 rs5029937 chr6 138195151 G T 5.30E-13 Multiple sclerosis TNFAIP3 intron 22190364 rs5029937 chr6 138195151 G T 1.40E-07 Rheumatoid arthritis TNFAIP3 intron 22446963 rs5029939 chr6 138195723 C G 1.21E-08 Multiple complex diseases TNFAIP3 intron 17554300 rs5029939 chr6 138195723 C G 3.00E-12 Systemic lupus erythematosus TNFAIP3 intron 19165918 rs5029939 chr6 138195723 C G 8.00E-09 Sjogren's syndrome TNFAIP3 intron 24097066 rs2230926 chr6 138196066 T G 1.00E-17 Systemic lupus erythematosus TNFAIP3 missense 19838193 rs2230926 chr6 138196066 T G 2.00E-06 Rheumatoid arthritis TNFAIP3 missense 20453841 rs2230926 chr6 138196066 T G 1.00E-13 Systemic lupus erythematosus TNFAIP3 missense 23273568 rs5029949 chr6 138197506 A G 3.51E-08 Rheumatoid arthritis TNFAIP3 intron 23143596 rs582757 chr6 138197824 C T 8.31E-04 Multiple complex diseases TNFAIP3 intron 17554300 rs582757 chr6 138197824 C T 2.20E-25 Psoriasis TNFAIP3 intron 23143594 rs610604 chr6 138199417 G T 9.00E-12 Psoriasis TNFAIP3 intron 19169254 rs610604 chr6 138199417 G T 6.00E-12 Psoriasis TNFAIP3 intron 20953187 rs610604 chr6 138199417 G T 7.00E-07 Psoriasis TNFAIP3 intron 20953190 rs610604 chr6 138199417 G T 9.00E-12 Multiple sclerosis TNFAIP3 intron 22190364 rs7752903 chr6 138227364 T G 3.15E-08 Rheumatoid arthritis / / 23143596 rs7752903 chr6 138227364 T G 2.00E-20 Rheumatoid arthritis / / 24390342 rs7752903 chr6 138227364 T G 2.00E-29 Rheumatoid arthritis / / 24390342 rs7752903 chr6 138227364 T G 7.00E-11 Rheumatoid arthritis / / 24390342 rs7749323 chr6 138230389 G A 4.96E-08 Multiple complex diseases / / 17554300 rs7749323 chr6 138230389 G A 2.87E-08 Rheumatoid arthritis / / 23143596 rs6932056 chr6 138242437 T C 0.00000393 Rheumatoid arthritis / / 23143596 rs61117627 chr6 138243700 G A 1.25E-08 Rheumatoid arthritis / / 23143596 rs58721818 chr6 138243739 C T 4.07E-09 Rheumatoid arthritis / / 23143596 rs58721818 chr6 138243739 C T 5.94E-12 Rheumatoid arthritis (CCP positive) / / 23143596 rs1545092 chr6 138244943 C T 6.90E-05 Lung cancer / / 18978787 rs1545092 chr6 138244943 C T 5.00E-05 Lung cancer / / 18978790 rs17781283 chr6 138262773 G A 2.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs9321637 chr6 138266685 T C 8.00E-06 Cardiac Troponin-T levels / / 23247143 rs4388301 chr6 138282375 C T 9.60E-04 Suicidal ideation / / 22030708 rs9402935 chr6 138326693 G T 6.35E-05 Orofacial clefts / / 20023658 rs9389549 chr6 138343019 G A 6.15E-05 HIV-1 viral setpoint / / 22174851 rs12189591 chr6 138344875 C T 8.36E-05 Mammographic density / / 22532574 rs6570206 chr6 138347001 A G 6.17E-04 Type 2 diabetes / / 17463246 rs4895506 chr6 138347501 G A 1.50E-05 Urinary metabolites / / 21572414 rs12212617 chr6 138365571 A G 3.51E-05 Mammographic density / / 22532574 rs6420764 chr6 138374999 C T 2.21E-04 Blood pressure / / 17255346 rs666769 chr6 138415087 C T 1.09E-04 Premature ovarian failure PERP intron 19508998 rs2506843 chr6 138417080 C G 4.55E-04 Multiple complex diseases PERP intron 17554300 rs2506843 chr6 138417080 C G 3.06E-04 Alcohol dependence PERP intron 21314694 rs2484066 chr6 138417118 T G 1.50E-05 Alcohol dependence PERP intron 24277619 rs1556640 chr6 138426032 C T 2.00E-06 Bulimia nervosa PERP intron 23568457 rs9389565 chr6 138465225 A G 5.96E-05 Lung function (forced vital capacity) / / pha003104 rs1474664 chr6 138481591 C T 4.02E-05 Response to hepatitis C treatment / / 19684573 rs72986828 chr6 138484125 T G 0.0000056 post-traumatic stress disorder KIAA1244 intron 22869035 rs72986828 chr6 138484125 T G 5.61E-06 Schizophrenia KIAA1244 intron 22883433 rs6907714 chr6 138484764 A G 0.0000203 post-traumatic stress disorder KIAA1244 intron 22869035 rs6907714 chr6 138484764 A G 2.03E-05 Schizophrenia KIAA1244 intron 22883433 rs4896325 chr6 138484929 C A 1.22E-04 Type 2 diabetes KIAA1244 intron 17463246 rs3813339 chr6 138511585 T G 1.51E-04 Coronary Artery Disease KIAA1244 intron 17634449 rs2143164 chr6 138512023 T A 9.91E-05 Coronary Artery Disease KIAA1244 intron 17634449 rs9385828 chr6 138517241 T A 1.02E-04 Coronary Artery Disease KIAA1244 intron 17634449 rs1509683 chr6 138519929 A G 9.44E-04 Type 2 diabetes KIAA1244 intron 17463246 rs6903101 chr6 138525847 T C 0.0000439 Uterine leiomyomata KIAA1244 intron 23040493 rs4896331 chr6 138525916 T C 7.50E-06 Coronary Artery Disease KIAA1244 intron 17634449 rs4895514 chr6 138531504 C T 6.23E-05 Coronary Artery Disease KIAA1244 intron 17634449 rs9484130 chr6 138547964 A G 1.29E-04 Type 2 diabetes KIAA1244 intron 17463246 rs6907613 chr6 138548271 C T 4.75E-04 Type 2 diabetes KIAA1244 intron 17463246 rs1145972 chr6 138551654 G A 4.60E-06 Urinary metabolites KIAA1244 intron 21572414 rs41460351 chr6 138573338 A G 3.24E-04 Multiple complex diseases KIAA1244 intron 17554300 rs203136 chr6 138606252 T G 4.65E-05 Serum metabolites KIAA1244 intron 19043545 rs203136 chr6 138606252 T G 1.74E-07 Major depression (suicidal thoughts and behavior) KIAA1244 intron 21750702 rs203145 chr6 138615148 G A 1.41E-04 Bipolar disorder KIAA1244 cds-synon 18317468 rs9389575 chr6 138617243 C T 5.37E-04 Smoking initiation KIAA1244 intron 24665060 rs6570219 chr6 138622131 C T 5.39E-04 Smoking initiation KIAA1244 intron 24665060 rs9376340 chr6 138630513 G A 3.92E-04 Smoking initiation KIAA1244 intron 24665060 rs203139 chr6 138696398 A G 1.31E-04 Multiple complex diseases / / 17554300 rs9495079 chr6 138732756 G C 4.53E-04 Suicide attempts in bipolar disorder HEBP2 intron 21423239 rs2327891 chr6 138754323 A G 9.77E-04 Multiple complex diseases NHSL1 cds-synon 17554300 rs17067596 chr6 138767012 A G 5.57E-04 Alzheimer's disease NHSL1 intron 17998437 rs17067596 chr6 138767012 A G 1.44E-04 Alzheimer's disease NHSL1 intron pha002879 rs4895529 chr6 138770275 C G 9.24E-05 Alzheimer's disease NHSL1 intron pha002879 rs17782909 chr6 138772677 T C 6.40E-04 Multiple complex diseases NHSL1 intron 17554300 rs6902919 chr6 138777786 G A 1.78E-04 Amyotrophic lateral sclerosis NHSL1 intron 20801718 rs2183147 chr6 138784917 C T 5.69E-04 Smoking cessation NHSL1 intron 24665060 rs17067671 chr6 138811501 C G 8.88E-04 Multiple complex diseases NHSL1 intron 17554300 rs7775174 chr6 138812530 A G 8.98E-04 Multiple complex diseases NHSL1 intron 17554300 rs12193890 chr6 138823991 G A 3.78E-04 Amyotrophic Lateral Sclerosis NHSL1 intron 17362836 rs6922771 chr6 138830566 T C 1.40E-06 Urinary metabolites NHSL1 intron 21572414 rs4895532 chr6 138865324 C T 1.70E-05 Urinary metabolites NHSL1 intron 21572414 rs9495126 chr6 138876411 T C 7.16E-04 Multiple complex diseases NHSL1 intron 17554300 rs9495126 chr6 138876411 T C 7.49E-05 Response to TNF antagonist treatment NHSL1 intron 21061259 rs7764287 chr6 138894852 C T 6.15E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9484176 chr6 138899924 C A 2.95E-05 Response to TNF antagonist treatment / / 21061259 rs9495141 chr6 138899973 A G 3.20E-05 Response to TNF antagonist treatment / / 21061259 rs4348334 chr6 138900479 A C 2.95E-05 Response to TNF antagonist treatment / / 21061259 rs7758889 chr6 138922044 G A 6.95E-07 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7758889 chr6 138922044 G A 8.75E-07 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7767451 chr6 138928836 C T 6.29E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9495187 chr6 138980694 T C 2.90E-04 Multiple complex diseases / / 17554300 rs9495200 chr6 138995462 T C 9.60E-04 Obesity (extreme) / / 21935397 rs9321669 chr6 139013015 G A 9.99E-05 Premature ovarian failure / / 19508998 rs9321669 chr6 139013015 G A 9.99E-05 Other erythrocyte phenotypes / / 19862010 rs4896391 chr6 139042338 G A 5.11E-05 Premature ovarian failure / / 19508998 rs4896391 chr6 139042338 G A 5.11E-05 Other erythrocyte phenotypes / / 19862010 rs10457675 chr6 139050948 T C 2.13E-05 Bladder cancer LOC100507462 intron 19648920 rs4434486 chr6 139051062 T C 4.00E-05 Multiple complex diseases LOC100507462 intron 17554300 rs9495232 chr6 139069249 A T 7.80E-05 Height LOC100507462 intron 21998595 rs4321841 chr6 139076770 T C 7.44E-05 Coronary heart disease LOC100507462 intron pha003031 rs11759005 chr6 139084461 T C 1.10E-04 Hearing function LOC100507462 intron 17255346 rs2273509 chr6 139094355 T C 1.84E-04 Peripartum cardiomyopathy LOC100507462 intron 21665988 rs6927344 chr6 139102366 T C 8.72E-05 Nonalcoholic fatty liver disease CCDC28A intron 21423719 rs9389619 chr6 139135077 C T 1.20E-05 Urinary metabolites ECT2L intron 21572414 rs11155010 chr6 139142400 T C 7.04E-04 Type 2 diabetes ECT2L intron 17463246 rs10872493 chr6 139147421 A T 4.89E-04 Type 2 diabetes ECT2L intron 17463246 rs11155013 chr6 139151838 C T 5.04E-05 HDL cholesterol ECT2L intron pha003074 rs9399258 chr6 139167579 T C 4.60E-05 Immunoglobulin A ECT2L intron 20694011 rs10872500 chr6 139193673 T C 9.64E-04 Type 2 diabetes ECT2L intron 17463246 rs1188857 chr6 139200330 G A 7.36E-05 Waist Circumference ECT2L intron pha003024 rs10499204 chr6 139216426 T C 5.93E-04 Alcohol dependence ECT2L intron 21314694 rs1188846 chr6 139219390 C T 8.30E-04 Schizophrenia ECT2L intron 21674006 rs1188873 chr6 139221850 G T 7.10E-06 Urinary metabolites ECT2L intron 21572414 rs1212985 chr6 139227530 T G 7.42E-05 Asthma REPS1 intron 23181788 rs17068040 chr6 139227806 T C 1.95E-08 HDL cholesterol particle diameter REPS1 intron 23263444 rs1188868 chr6 139229743 C T 3.32E-04 Parkinson's disease REPS1 intron 16252231 rs2272432 chr6 139238599 G T 2.72E-04 Alcohol dependence REPS1 intron 21314694 rs2272432 chr6 139238599 G T 7.89E-05 Blood pressure (response to calcium channel blocker) REPS1 intron 24192120 rs3763188 chr6 139247076 T C 5.10E-04 Lipid traits REPS1 intron 17903299 rs4895549 chr6 139261293 T C 2.25E-08 HDL cholesterol particle diameter REPS1 intron 23263444 rs1188896 chr6 139268008 C T 3.75E-05 Lipoprotein-associated phospholipase A2 activity and mass REPS1 intron 20442857 rs2178333 chr6 139286096 C T 4.28E-05 Alzheimer's disease REPS1 intron 17998437 rs2498635 chr6 139328660 C T 9.66E-05 Multiple complex diseases / / 17554300 rs12664486 chr6 139328765 T C 4.32E-04 Smoking initiation / / 24665060 rs4243459 chr6 139345749 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6931523 chr6 139360529 A G 1.00E-04 Cognitive impairment induced by topiramate ABRACL intron 22091778 rs6906235 chr6 139363102 C T 1.30E-04 Coronary heart disease ABRACL intron 21971053 rs9495324 chr6 139365230 A C 7.96E-05 Serum metabolites / / 19043545 rs9484232 chr6 139365330 T C 6.85E-05 Serum metabolites / / 19043545 rs2473509 chr6 139413936 A G 7.69E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs17304375 chr6 139435878 A C 1.56E-04 Common variable immunodeficiency / / 21497890 rs6570310 chr6 139458954 G A 1.42E-04 Smoking quantity HECA intron 24665060 rs17068451 chr6 139576736 C T 7.31E-04 Aortic root size TXLNB missense 21223598 rs3861395 chr6 139622545 T C 4.92E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4279452 chr6 139629433 A G 5.76E-04 Body mass index / / 21701565 rs7775616 chr6 139637874 C T 4.96E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11155053 chr6 139660012 C T 9.00E-06 Obesity-related traits / / 23251661 rs6925308 chr6 139660091 G A 6.19E-04 Alzheimer's disease / / 24755620 rs10457687 chr6 139716715 A G 1.32E-04 Smoking cessation / / 24665060 rs11155061 chr6 139721842 G A 9.82E-05 Information processing speed / / 21130836 rs12215895 chr6 139729678 A G 6.67E-07 Red blood cell traits / / 23222517 rs11155066 chr6 139731589 A G 9.36E-04 Multiple complex diseases / / 17554300 rs9484272 chr6 139750933 T A 1.25E-08 Metabolite levels / / 23281178 rs3010301 chr6 139774853 A G 2.65E-05 Pulmonary function in asthmatics / / 23541324 rs4895561 chr6 139808000 G A 3.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs4895562 chr6 139808031 A G 2.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs2908509 chr6 139816862 T G 1.81E-07 Red blood cell traits / / 23222517 rs685279 chr6 139824415 C G 0.000444 Salmonella-induced pyroptosis / / 22837397 rs633382 chr6 139827741 T C 6.38E-09 Other erythrocyte phenotypes / / 19862010 rs633382 chr6 139827741 T C 4.19E-13 Red blood cell traits / / 23222517 rs3861397 chr6 139828916 A G 6.55E-12 Red blood cell traits / / 23222517 rs605066 chr6 139829666 C T 4.11E-12 Other erythrocyte phenotypes / / 19862010 rs605066 chr6 139829666 C T 3.00E-08 HDL cholesterol / / 20686565 rs605066 chr6 139829666 C T 2.69E-18 Red blood cell traits / / 23222517 rs605066 chr6 139829666 C T 3.00E-08 HDL cholesterol / / 24097068 rs17513809 chr6 139829917 G A 0.000116 Salmonella-induced pyroptosis / / 22837397 rs17513809 chr6 139829917 G A 2.04E-08 Red blood cell traits / / 23222517 rs679582 chr6 139831180 G A 1.28E-11 Other erythrocyte phenotypes / / 19862010 rs679582 chr6 139831180 G A 1.94E-20 Red blood cell traits / / 23222517 rs679582 chr6 139831180 G A 3.00E-06 Blood trace element (Se levels) / / 23720494 rs634869 chr6 139831757 T C 3.33E-12 Other erythrocyte phenotypes / / 19862010 rs634869 chr6 139831757 T C 2.56E-05 Prostate cancer mortality / / 20978177 rs634869 chr6 139831757 T C 7.52E-22 Red blood cell traits / / 23222517 rs632057 chr6 139834012 T G 8.71E-12 Other erythrocyte phenotypes / / 19862010 rs632057 chr6 139834012 T G 1.00E-09 Blood cell counts and other traits / / 20139978 rs632057 chr6 139834012 T G 1.08E-09 Blood cell counts and other traits / / 20139978 rs632057 chr6 139834012 T G 1.42E-09 Blood cell counts and other traits / / 20139978 rs632057 chr6 139834012 T G 1.69E-04 Prostate cancer mortality / / 20978177 rs632057 chr6 139834012 T G 8.54E-04 Myopia (pathological) / / 21095009 rs632057 chr6 139834012 T G 0.00000004 Mean corpuscular volume / / 22560525 rs632057 chr6 139834012 T G 7.58E-21 Red blood cell traits / / 23222517 rs668459 chr6 139835689 C T 5.58E-09 Other erythrocyte phenotypes / / 19862010 rs668459 chr6 139835689 C T 8.54E-04 Myopia (pathological) / / 21095009 rs668459 chr6 139835689 C T 3.00E-06 Adiponectin levels / / 22479202 rs668459 chr6 139835689 C T 0.000000005 Mean corpuscular volume / / 22560525 rs668459 chr6 139835689 C T 3.06E-17 Red blood cell traits / / 23222517 rs668459 chr6 139835689 C T 4.00E-08 Mean corpuscular volume / / 23263863 rs668459 chr6 139835689 C T 9.00E-09 Mean corpuscular hemoglobin / / 23263863 rs628751 chr6 139838419 C A 1.00E-17 Mean corpuscular hemoglobin / / 19862010 rs628751 chr6 139838419 C A 6.16E-09 Blood cell counts and other traits / / 20139978 rs628751 chr6 139838419 C A 2.77E-26 Red blood cell traits / / 23222517 rs643381 chr6 139839423 C A 5.00E-25 Mean corpuscular volume / / 19862010 rs643381 chr6 139839423 C A 1.24E-22 Red blood cell traits / / 23222517 rs592423 chr6 139840693 A C 1.84E-14 Other erythrocyte phenotypes / / 19862010 rs592423 chr6 139840693 A C 9.01E-05 Prostate cancer mortality / / 20978177 rs592423 chr6 139840693 A C 4.00E-07 Adiponectin levels / / 22479202 rs592423 chr6 139840693 A C 8.89E-26 Red blood cell traits / / 23222517 rs653468 chr6 139842563 G A 6.27E-10 Other erythrocyte phenotypes / / 19862010 rs653468 chr6 139842563 G A 4.15E-12 Red blood cell traits / / 23222517 rs653513 chr6 139842599 G T 3.47E-09 Other erythrocyte phenotypes / / 19862010 rs653513 chr6 139842599 G T 1.43E-12 Red blood cell traits / / 23222517 rs636202 chr6 139843583 T C 2.77E-18 Other erythrocyte phenotypes / / 19862010 rs636202 chr6 139843583 T C 1.47E-25 Red blood cell traits / / 23222517 rs4896469 chr6 139843787 A G 8.03E-04 Myopia (pathological) / / 21095009 rs4896469 chr6 139843787 A G 1.20E-11 Red blood cell traits / / 23222517 rs590856 chr6 139844429 G A 2.01E-14 Other erythrocyte phenotypes / / 19862010 rs590856 chr6 139844429 G A 5.00E-36 Red blood cell traits / / 23222517 rs9321726 chr6 139866922 A C 1.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7750201 chr6 139892016 T C 3.61E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs12664553 chr6 139904892 A C 1.10E-05 Urinary metabolites / / 21572414 rs17069158 chr6 139972188 G A 1.20E-05 Urinary metabolites / / 21572414 rs17069161 chr6 139972521 C T 1.70E-05 Urinary metabolites / / 21572414 rs2327977 chr6 139977660 G A 6.34E-05 Multiple complex diseases / / 17554300 rs9373243 chr6 139990860 T C 1.80E-05 Urinary metabolites / / 21572414 rs6570371 chr6 140010513 A G 6.60E-06 Urinary metabolites / / 21572414 rs7761526 chr6 140013919 A C 7.50E-06 Urinary metabolites / / 21572414 rs9376452 chr6 140016409 C T 2.67E-04 Depression (quantitative trait) / / 20800221 rs12055436 chr6 140023968 T C 3.04E-04 Depression (quantitative trait) / / 20800221 rs17069225 chr6 140024345 T C 3.05E-04 Depression (quantitative trait) / / 20800221 rs12055472 chr6 140025377 T G 3.09E-04 Depression (quantitative trait) / / 20800221 rs2185923 chr6 140033527 C A 9.88E-04 Depression (quantitative trait) / / 20800221 rs12663299 chr6 140040671 T C 3.08E-04 Depression (quantitative trait) / / 20800221 rs7752001 chr6 140042495 G A 9.78E-04 Depression (quantitative trait) / / 20800221 rs9376457 chr6 140046410 G A 9.80E-04 Depression (quantitative trait) / / 20800221 rs9389715 chr6 140046629 A G 9.78E-04 Depression (quantitative trait) / / 20800221 rs10452652 chr6 140049600 C A 9.96E-04 Depression (quantitative trait) / / 20800221 rs4421208 chr6 140079639 C T 1.60E-05 Urinary metabolites / / 21572414 rs3015437 chr6 140125075 A G 1.19E-04 Nicotine dependence LOC100132735 intron 17158188 rs9399294 chr6 140135009 A G 2.62E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LOC100132735 intron 24023788 rs9399294 chr6 140135009 A G 3.62E-04 Lung function (forced expiratory volume in 1 second) LOC100132735 intron 24023788 rs12664111 chr6 140139815 A G 6.00E-06 IgG glycosylation LOC100132735 intron 23382691 rs9484318 chr6 140158506 T C 2.80E-05 Urinary metabolites LOC100132735 intron 21572414 rs7738507 chr6 140161118 T C 9.00E-06 Urinary metabolites LOC100132735 intron 21572414 rs12111348 chr6 140183693 C T 1.53E-06 Common variable immunodeficiency / / 21497890 rs9373254 chr6 140194763 C A 2.40E-05 Urinary metabolites / / 21572414 rs4895576 chr6 140206760 C T 7.83E-11 Schizophrenia / / 21795503 rs6913694 chr6 140217584 G C 8.01E-04 Type 2 diabetes / / 17463246 rs621498 chr6 140230070 T C 9.62E-05 Tourette syndrome / / 22889924 rs592755 chr6 140237606 A G 2.07E-05 Post-operative nausea and vomiting / / 21694509 rs12524396 chr6 140238780 C T 7.67E-04 Depression (quantitative trait) / / 20800221 rs632430 chr6 140248121 G A 9.56E-04 Multiple complex diseases / / 17554300 rs9484329 chr6 140260472 A G 5.67E-04 Depression (quantitative trait) / / 20800221 rs603310 chr6 140262994 C T 1.40E-06 Urinary metabolites / / 21572414 rs1028471 chr6 140263141 C T 4.04E-04 Depression (quantitative trait) / / 20800221 rs1028469 chr6 140263343 C T 2.99E-04 Multiple complex diseases / / 17554300 rs592440 chr6 140263361 T A 2.10E-06 Urinary metabolites / / 21572414 rs1572674 chr6 140264234 C A 4.03E-04 Depression (quantitative trait) / / 20800221 rs642858 chr6 140273647 G A 2.00E-06 Type 2 diabetes / / 21490949 rs642858 chr6 140273647 G A 4.72E-06 Post-operative nausea and vomiting / / 21694509 rs10499215 chr6 140312592 C T 8.04E-04 Depression (quantitative trait) / / 20800221 rs1572671 chr6 140332096 G A 1.13E-05 Post-operative nausea and vomiting / / 21694509 rs2050717 chr6 140369781 C T 6.30E-06 Post-operative nausea and vomiting / / 21694509 rs644333 chr6 140417609 G A 1.29E-05 Post-operative nausea and vomiting / / 21694509 rs169291 chr6 140461008 G C 5.93E-05 Asthma / / 11022011 rs9321764 chr6 140490464 C T 2.89E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs1519592 chr6 140543636 T C 1.89E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs1856756 chr6 140730784 T C 1.47E-04 Age-related macular degeneration / / 22125219 rs1856757 chr6 140733855 C T 5.74E-05 Post-operative nausea and vomiting / / 21694509 rs1856757 chr6 140733855 C T 2.14E-04 Age-related macular degeneration / / 22125219 rs9376523 chr6 140849702 T G 4.47E-04 Multiple complex diseases / / 17554300 rs9321772 chr6 140863146 G A 9.62E-04 Multiple complex diseases / / 17554300 rs1414831 chr6 140864558 T C 1.46E-05 Post-operative nausea and vomiting / / 21694509 rs9385916 chr6 140866636 C T 6.96E-04 Multiple complex diseases / / 17554300 rs1414839 chr6 140893202 G C 1.99E-04 Weight loss (gastric bypass surgery) / / 23633212 rs967790 chr6 140893638 T C 8.72E-05 Weight loss (gastric bypass surgery) / / 23633212 rs2506854 chr6 141058627 C T 4.66E-04 Coronary Artery Disease / / 17634449 rs10499221 chr6 141080914 G T 5.92E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs647706 chr6 141096809 A T 6.90E-05 Malaria / / 19465909 rs1402509 chr6 141115064 C T 1.88E-04 Attention deficit hyperactivity disorder / / pha002875 rs11155133 chr6 141169825 A G 3.00E-07 Acute lymphoblastic leukemia (childhood) / / 19684603 rs11155133 chr6 141169825 A G 3.00E-07 Nasopharyngeal carcinoma / / 20512145 rs605671 chr6 141179655 T A 7.68E-04 Coronary Artery Disease / / 17634449 rs672033 chr6 141182209 G T 1.80E-04 Intelligence (childhood) / / 23358156 rs2066036 chr6 141197113 C G 4.60E-06 Schizophrenia / / 21795503 rs6570426 chr6 141197346 A T 2.74E-05 Attention deficit hyperactivity disorder / / 18980221 rs6570426 chr6 141197346 A T 8.73E-05 Attention deficit hyperactivity disorder / / pha002875 rs9484448 chr6 141219060 C T 7.52E-04 Type 2 diabetes / / 17463246 rs9484448 chr6 141219060 C T 2.94E-05 Attention deficit hyperactivity disorder / / 18980221 rs9484448 chr6 141219060 C T 6.19E-05 Attention deficit hyperactivity disorder / / pha002875 rs9389832 chr6 141244330 G A 5.33E-05 Coronary heart disease / / pha003056 rs9389835 chr6 141270660 T C 1.58E-05 Attention deficit hyperactivity disorder / / 18980221 rs9389835 chr6 141270660 T C 1.86E-05 Attention deficit hyperactivity disorder / / pha002875 rs1856363 chr6 141301076 A G 4.03E-04 Age-related macular degeneration / / 22125219 rs6907667 chr6 141303040 C T 9.19E-04 Multiple complex diseases / / 17554300 rs1832460 chr6 141328865 T C 4.86E-04 Age-related macular degeneration / / 22125219 rs11155161 chr6 141387139 T C 2.00E-05 Urinary metabolites / / 21572414 rs1819632 chr6 141399812 T C 1.47E-04 Age-related macular degeneration / / 22125219 rs9389870 chr6 141428255 T C 7.81E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs7738388 chr6 141453145 T C 2.00E-04 Schizophrenia / / 19197363 rs1037441 chr6 141457722 T C 7.24E-04 Body mass index / / 21701565 rs6916409 chr6 141491413 T C 3.81E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9321801 chr6 141491425 T C 5.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11754251 chr6 141494388 C T 6.60E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9385939 chr6 141506544 G A 6.31E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6925531 chr6 141508537 T C 6.31E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9373298 chr6 141519830 A C 6.58E-08 Narcolepsy / / 19629137 rs9373298 chr6 141519830 A C 3.55E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6922539 chr6 141529357 A G 9.33E-04 Myopia (pathological) / / 21095009 rs1377322 chr6 141533923 G A 9.33E-04 Myopia (pathological) / / 21095009 rs4280976 chr6 141557573 A C 2.72E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9495937 chr6 141582182 T C 8.35E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9376605 chr6 141634266 G A 7.13E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1335308 chr6 141645736 A G 7.55E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1932189 chr6 141709422 T G 9.94E-04 Type 2 diabetes / / 17463246 rs1932189 chr6 141709422 T G 3.05E-04 Multiple complex diseases / / 17554300 rs17070789 chr6 141713469 T G 8.65E-04 Multiple complex diseases / / 17554300 rs2184529 chr6 141728211 G A 4.34E-05 Height / / pha003010 rs2184529 chr6 141728211 G A 9.27E-06 Height / / pha003011 rs2184529 chr6 141728211 G A 6.52E-05 Sodium levels / / pha003093 rs17070882 chr6 141739208 G A 4.66E-05 Height / / pha003010 rs17070882 chr6 141739208 G A 9.97E-06 Height / / pha003011 rs17070882 chr6 141739208 G A 7.39E-05 Sodium levels / / pha003093 rs6930139 chr6 141760937 C T 3.05E-06 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs9376624 chr6 141809473 G T 8.46E-05 Monocyte counts / / pha003089 rs11155188 chr6 141823874 C T 6.85E-05 Sarcoidosis / / 19165924 rs9403314 chr6 141831351 C T 2.55E-04 Bipolar disorder / / 22925353 rs6570465 chr6 141856594 C T 4.00E-07 Methotrexate phramacokinetics (acute lymphoblastic leukemia) / / 19901119 rs7742587 chr6 141857134 C T 3.00E-07 Methotrexate phramacokinetics (acute lymphoblastic leukemia) / / 19901119 rs34596385 chr6 141926004 C T 6.00E-06 Telomere length / / 24478790 rs9376641 chr6 141974715 T A 6.33E-05 Bipolar disorder / / 22925353 rs1415913 chr6 141987584 A G 1.40E-05 Bipolar disorder / / 22925353 rs9321832 chr6 142021799 G T 1.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9403346 chr6 142026143 G T 2.00E-05 Bipolar disorder / / 22925353 rs17071124 chr6 142033726 A G 3.00E-06 Sleep quality / / 23728906 rs12208998 chr6 142035693 T C 4.14E-05 Waist Circumference / / pha003023 rs13212082 chr6 142050556 T C 5.00E-04 Rheumatoid arthritis / / 21452313 rs13212082 chr6 142050556 T C 8.84E-05 Monocyte counts / / pha003089 rs9496139 chr6 142093922 A G 7.02E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs10457728 chr6 142200163 T C 2.88E-05 Cognitive performance / / 19734545 rs12664387 chr6 142236578 T C 8.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1414743 chr6 142277769 G A 8.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7774877 chr6 142301142 T C 1.50E-05 Urinary metabolites / / 21572414 rs17054023 chr6 142306066 C T 1.32E-33 Narcolepsy / / 19629137 rs7741528 chr6 142311052 C T 1.10E-05 Urinary metabolites / / 21572414 rs9376667 chr6 142330999 A G 1.10E-05 Urinary metabolites / / 21572414 rs6570491 chr6 142359188 T C 2.90E-05 Urinary metabolites / / 21572414 rs6910529 chr6 142359683 C T 4.40E-06 Schizophrenia / / 22037555 rs7776318 chr6 142365171 G A 9.72E-05 Cognitive test performance / / 20125193 rs7776318 chr6 142365171 G A 8.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4455685 chr6 142429903 G A 9.62E-06 Bipolar disorder and schizophrenia / / 20889312 rs2842756 chr6 142430828 C T 6.59E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs9373338 chr6 142431047 T C 4.29E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2842757 chr6 142432970 T A 6.61E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs2842758 chr6 142435731 A G 6.65E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs2745471 chr6 142436861 G A 9.04E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2745470 chr6 142441540 T C 6.86E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs225606 chr6 142453907 A G 7.23E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs225622 chr6 142467387 G A 7.25E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs628311 chr6 142468266 C A 5.13E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs639658 chr6 142468271 G T 7.16E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs225630 chr6 142474031 C G 6.78E-06 Thiazide-induced adverse metabolic effects in hypertensive patients VTA1 intron 23400010 rs225634 chr6 142476619 A T 1.90E-04 Lipid traits VTA1 intron 17903299 rs225635 chr6 142476738 A G 6.15E-06 Thiazide-induced adverse metabolic effects in hypertensive patients VTA1 intron 23400010 rs4896580 chr6 142476836 A T 5.60E-05 Sleep and circadian phenotypes VTA1 intron 17903308 rs225641 chr6 142481003 T C 5.43E-06 Thiazide-induced adverse metabolic effects in hypertensive patients VTA1 intron 23400010 rs225642 chr6 142481723 C T 5.15E-06 Thiazide-induced adverse metabolic effects in hypertensive patients VTA1 intron 23400010 rs225643 chr6 142481846 A G 3.07E-06 Thiazide-induced adverse metabolic effects in hypertensive patients VTA1 intron 23400010 rs225652 chr6 142484485 C A 3.32E-07 Thiazide-induced adverse metabolic effects in hypertensive patients VTA1 intron 23400010 rs225653 chr6 142485419 G T 3.23E-07 Thiazide-induced adverse metabolic effects in hypertensive patients VTA1 intron 23400010 rs225654 chr6 142486485 A G 3.19E-07 Thiazide-induced adverse metabolic effects in hypertensive patients VTA1 intron 23400010 rs225657 chr6 142487725 C A 8.19E-04 Smoking cessation VTA1 intron 24665060 rs225659 chr6 142488115 G A 2.95E-07 Thiazide-induced adverse metabolic effects in hypertensive patients VTA1 intron 23400010 rs225662 chr6 142491122 G T 2.88E-07 Thiazide-induced adverse metabolic effects in hypertensive patients VTA1 intron 23400010 rs225665 chr6 142493790 C A 8.22E-07 Thiazide-induced adverse metabolic effects in hypertensive patients VTA1 intron 23400010 rs225666 chr6 142497476 C G 1.18E-07 Thiazide-induced adverse metabolic effects in hypertensive patients VTA1 intron 23400010 rs225671 chr6 142500925 G A 5.73E-06 Thiazide-induced adverse metabolic effects in hypertensive patients VTA1 intron 23400010 rs225673 chr6 142506290 T C 9.80E-06 Thiazide-induced adverse metabolic effects in hypertensive patients VTA1 intron 23400010 rs225674 chr6 142510167 T A 5.74E-06 Thiazide-induced adverse metabolic effects in hypertensive patients VTA1 intron 23400010 rs225675 chr6 142512136 A G 1.00E-07 Thiazide-induced adverse metabolic effects in hypertensive patients VTA1 intron 23400010 rs225676 chr6 142514226 C T 5.79E-06 Thiazide-induced adverse metabolic effects in hypertensive patients VTA1 intron 23400010 rs225678 chr6 142517609 G A 1.01E-05 Thiazide-induced adverse metabolic effects in hypertensive patients VTA1 intron 23400010 rs225694 chr6 142527142 A G 1.00E-07 Height VTA1 intron 20881960 rs225717 chr6 142548099 C T 1.00E-16 Retinal vascular caliber / / 21060863 rs2782527 chr6 142568305 C T 3.18E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs9321861 chr6 142587324 A C 3.28E-04 Smoking cessation / / 24665060 rs1931990 chr6 142597120 A G 8.05E-04 Aortic root size / / 21223598 rs12189801 chr6 142641606 T C 7.25E-06 Pulmonary function GPR126 intron 20010835 rs1418201 chr6 142648056 A T 5.72E-09 Pulmonary function GPR126 intron 20010835 rs1891308 chr6 142648235 G A 1.11E-08 Pulmonary function GPR126 intron 20010835 rs6925979 chr6 142651052 G A 2.83E-08 Pulmonary function GPR126 intron 20010835 rs9389985 chr6 142653898 A G 2.63E-09 Pulmonary function GPR126 intron 20010835 rs2039986 chr6 142655238 G A 5.79E-09 Pulmonary function GPR126 intron 20010835 rs2039987 chr6 142655490 A C 2.49E-09 Pulmonary function GPR126 intron 20010835 rs7741741 chr6 142655801 T A 2.45E-09 Pulmonary function GPR126 intron 20010835 rs7741741 chr6 142655801 T A 1.00E-20 Height GPR126 intron 23563607 rs2050157 chr6 142658162 G A 7.97E-09 Pulmonary function GPR126 intron 20010835 rs9389986 chr6 142661114 T A 8.74E-09 Pulmonary function GPR126 intron 20010835 rs9403381 chr6 142661156 G T 9.07E-09 Pulmonary function GPR126 intron 20010835 rs1342060 chr6 142663177 T C 7.79E-09 Pulmonary function GPR126 intron 20010835 rs972982 chr6 142666861 T C 8.62E-09 Pulmonary function GPR126 intron 20010835 rs9399401 chr6 142668901 T C 8.60E-09 Pulmonary function GPR126 intron 20010835 rs9496346 chr6 142669338 A G 6.42E-09 Pulmonary function GPR126 intron 20010835 rs9496346 chr6 142669338 A G 1.00E-08 adolescent idiopathic scoliosis GPR126 intron 24023777 rs7774095 chr6 142670862 C A 9.64E-09 Pulmonary function GPR126 intron 20010835 rs7756305 chr6 142670955 T C 8.89E-09 Pulmonary function GPR126 intron 20010835 rs6570507 chr6 142679572 G A 4.00E-11 Height GPR126 intron 19343178 rs6570507 chr6 142679572 G A 1.06E-08 Pulmonary function GPR126 intron 20010835 rs6570507 chr6 142679572 G A 2.00E-07 Height GPR126 intron 20397748 rs6570507 chr6 142679572 G A 1.00E-14 Scoliosis GPR126 intron 23666238 rs6570507 chr6 142679572 G A 4.00E-12 Scoliosis GPR126 intron 23666238 rs6570507 chr6 142679572 G A 3.78E-08 adolescent idiopathic scoliosis GPR126 intron 24023777 rs12190271 chr6 142681409 G A 1.52E-08 Pulmonary function GPR126 intron 20010835 rs7765770 chr6 142687305 C T 1.38E-08 Pulmonary function GPR126 intron 20010835 rs11155242 chr6 142691549 A C 9.13E-09 Pulmonary function GPR126 missense 20010835 rs9403383 chr6 142694049 G A 6.87E-09 Pulmonary function GPR126 intron 20010835 rs6903424 chr6 142699948 A C 7.40E-09 Pulmonary function GPR126 intron 20010835 rs6909857 chr6 142701158 A G 2.92E-09 Pulmonary function GPR126 intron 20010835 rs12213892 chr6 142702234 A G 7.21E-09 Pulmonary function GPR126 intron 20010835 rs7757571 chr6 142702589 A C 7.17E-09 Pulmonary function GPR126 intron 20010835 rs6922607 chr6 142703483 A G 8.91E-09 Pulmonary function GPR126 intron 20010835 rs1040525 chr6 142703669 C T 5.44E-09 Pulmonary function GPR126 intron 20010835 rs4896582 chr6 142703877 G A 2.00E-18 Height GPR126 intron 18391950 rs4896582 chr6 142703877 G A 3.56E-06 Height GPR126 intron 19570815 rs4896582 chr6 142703877 G A 2.06E-08 Pulmonary function GPR126 intron 20010835 rs12197866 chr6 142706063 C T 1.36E-08 Pulmonary function GPR126 intron 20010835 rs6937121 chr6 142707133 T G 2.46E-09 Pulmonary function GPR126 intron 20010835 rs10484733 chr6 142710988 C G 9.04E-09 Pulmonary function GPR126 intron 20010835 rs6570508 chr6 142713842 G A 1.46E-08 Pulmonary function GPR126 intron 20010835 rs17071756 chr6 142715195 T C 5.54E-09 Pulmonary function GPR126 intron 20010835 rs6570509 chr6 142716286 G T 3.31E-09 Pulmonary function GPR126 intron 20010835 rs6900233 chr6 142717283 C G 5.32E-09 Pulmonary function GPR126 intron 20010835 rs6900087 chr6 142717303 A T 8.19E-09 Pulmonary function GPR126 intron 20010835 rs11759653 chr6 142720354 G A 6.72E-09 Pulmonary function GPR126 intron 20010835 rs962554 chr6 142734204 T C 2.23E-09 Pulmonary function GPR126 intron 20010835 rs1040526 chr6 142735816 A G 2.08E-09 Pulmonary function GPR126 intron 20010835 rs2294764 chr6 142737504 G A 9.30E-05 Pulmonary function GPR126 intron 19300500 rs2294764 chr6 142737504 G A 2.14E-09 Pulmonary function GPR126 intron 20010835 rs6929442 chr6 142742659 T C 8.61E-05 Pulmonary function GPR126 intron 19300500 rs6929442 chr6 142742659 T C 1.78E-09 Pulmonary function GPR126 intron 20010835 rs113096699 chr6 142745883 T TG 9.50E-05 Pulmonary function GPR126 intron 19300500 rs113096699 chr6 142745883 T TG 1.27E-08 Pulmonary function GPR126 intron 20010835 rs7753012 chr6 142745883 T G 9.50E-05 Pulmonary function GPR126 intron 19300500 rs7753012 chr6 142745883 T G 1.27E-08 Pulmonary function GPR126 intron 20010835 rs9373346 chr6 142746992 G A 7.67E-05 Pulmonary function GPR126 intron 19300500 rs9373346 chr6 142746992 G A 1.99E-09 Pulmonary function GPR126 intron 20010835 rs7755109 chr6 142750392 A G 8.50E-05 Pulmonary function GPR126 intron 19300500 rs7755109 chr6 142750392 A G 1.76E-09 Pulmonary function GPR126 intron 20010835 rs3817928 chr6 142750516 A G 1.00E-09 Pulmonary function GPR126 intron 20010835 rs3817928 chr6 142750516 A G 3.00E-12 Pulmonary function (interaction) GPR126 intron 23284291 rs1360194 chr6 142752595 G A 5.57E-05 Pulmonary function GPR126 intron 19300500 rs1360194 chr6 142752595 G A 1.31E-09 Pulmonary function GPR126 intron 20010835 rs1329705 chr6 142753338 G A 2.37E-09 Pulmonary function GPR126 intron 20010835 rs1329705 chr6 142753338 G A 3.00E-06 Airflow obstruction GPR126 intron 22837378 rs6570510 chr6 142755024 C T 5.85E-05 Pulmonary function GPR126 intron 19300500 rs6570510 chr6 142755024 C T 2.21E-09 Pulmonary function GPR126 intron 20010835 rs6570511 chr6 142757368 G A 3.19E-10 Pulmonary function GPR126 intron 20010835 rs2294775 chr6 142766347 C G 7.52E-10 Pulmonary function GPR126 UTR-3 20010835 rs3748069 chr6 142767633 A G 5.00E-14 Height GPR126 nearGene-3 18391951 rs3748069 chr6 142767633 A G 6.92E-05 Pulmonary function GPR126 nearGene-3 19300500 rs3748069 chr6 142767633 A G 5.01E-06 Height GPR126 nearGene-3 19570815 rs3748069 chr6 142767633 A G 1.59E-09 Pulmonary function GPR126 nearGene-3 20010835 rs6906468 chr6 142769386 T C 8.75E-10 Pulmonary function / / 20010835 rs7776356 chr6 142777029 A G 8.56E-10 Pulmonary function / / 20010835 rs7776375 chr6 142777064 A G 3.21E-05 Pulmonary function / / 19300500 rs7776375 chr6 142777064 A G 1.33E-09 Pulmonary function / / 20010835 rs1928528 chr6 142779109 T G 9.32E-10 Pulmonary function / / 20010835 rs9373347 chr6 142779885 C T 9.58E-10 Pulmonary function / / 20010835 rs12664563 chr6 142785201 A G 9.90E-10 Pulmonary function / / 20010835 rs7763064 chr6 142797289 G A 1.28E-08 Pulmonary function / / 20010835 rs7763064 chr6 142797289 G A 1.00E-33 Height / / 20881960 rs9321870 chr6 142800758 T A 3.51E-08 Pulmonary function / / 20010835 rs262115 chr6 142817407 T C 7.71E-08 Pulmonary function / / 20010835 rs262114 chr6 142818218 C T 6.82E-05 Pulmonary function / / 19300500 rs262114 chr6 142818218 C T 8.55E-09 Pulmonary function / / 20010835 rs9496398 chr6 142822217 T C 4.00E-06 Neutrophil count / / 21507922 rs262121 chr6 142839498 T C 6.61E-05 Pulmonary function / / 19300500 rs262121 chr6 142839498 T C 6.02E-09 Pulmonary function / / 20010835 rs262120 chr6 142842360 C A 1.18E-08 Pulmonary function / / 20010835 rs262119 chr6 142842793 T C 8.68E-05 Pulmonary function / / 19300500 rs262119 chr6 142842793 T C 8.22E-09 Pulmonary function / / 20010835 rs643975 chr6 142844251 C G 1.44E-08 Pulmonary function / / 20010835 rs155259 chr6 142846565 G A 1.50E-08 Pulmonary function / / 20010835 rs171891 chr6 142850612 G A 2.09E-08 Pulmonary function LOC153910 intron 20010835 rs262130 chr6 142853486 C T 2.68E-07 Pulmonary function LOC153910 intron 20010835 rs263179 chr6 142863888 T C 2.30E-08 Pulmonary function LOC153910 intron 20010835 rs263178 chr6 142865106 C T 2.91E-08 Pulmonary function LOC153910 intron 20010835 rs611802 chr6 142866387 A C 4.94E-08 Pulmonary function LOC153910 intron 20010835 rs171915 chr6 142866845 G A 7.94E-07 Pulmonary function LOC153910 intron 20010835 rs146250 chr6 142888515 G A 1.53E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LOC153910 intron 20031582 rs7740146 chr6 142972752 G A 2.30E-20 Metabolite levels / / 22286219 rs7740440 chr6 142972917 G A 1.80E-05 Urinary metabolites / / 21572414 rs12195495 chr6 143005942 A G 7.53E-04 Multiple complex diseases / / 17554300 rs17071952 chr6 143006957 T G 7.88E-04 Multiple complex diseases / / 17554300 rs3850224 chr6 143035902 T A 6.70E-05 Parkinson's disease (age of onset) / / 19772629 rs534230 chr6 143039141 A G 2.42E-06 Elbow pain / / pha003008 rs574975 chr6 143044071 G T 5.80E-06 Urinary metabolites / / 21572414 rs513334 chr6 143051387 T C 2.40E-04 Type 2 diabetes / / 17463246 rs513334 chr6 143051387 T C 2.87E-05 Elbow pain / / pha003008 rs12192768 chr6 143053893 A G 3.30E-05 Parkinson's disease (age of onset) / / 19772629 rs7762241 chr6 143057591 G C 9.54E-04 Depression (quantitative trait) / / 20800221 rs538289 chr6 143058408 A G 5.44E-06 Elbow pain / / pha003008 rs197484 chr6 143068378 C T 5.80E-06 Urinary metabolites / / 21572414 rs197482 chr6 143069315 T C 2.70E-05 Urinary metabolites / / 21572414 rs578343 chr6 143069864 C T 1.52E-07 Elbow pain / / pha003008 rs578343 chr6 143069864 C T 1.57E-05 Weight / / pha003026 rs197480 chr6 143070505 C T 4.43E-06 Smooth-surface caries / / 24556642 rs117019703 chr6 143074549 G A 0.00086 Prostate cancer HIVEP2 missense 23555315 rs12524093 chr6 143076543 G A 4.05E-04 Response to alcohol consumption (flushing response) HIVEP2 intron 24277619 rs197470 chr6 143077232 G A 4.24E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) HIVEP2 intron 24023788 rs638880 chr6 143083063 G T 6.39E-04 Depression (quantitative trait) HIVEP2 intron 20800221 rs197457 chr6 143087003 G T 1.78E-04 Type 2 diabetes HIVEP2 intron 17463246 rs197508 chr6 143097493 G A 3.61E-04 Alzheimer's disease HIVEP2 intron 17998437 rs491414 chr6 143115636 G A 9.65E-05 Schizophrenia HIVEP2 intron 19571809 rs491414 chr6 143115636 G A 8.44E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy HIVEP2 intron 24578207 rs491414 chr6 143115636 G A 8.44E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy HIVEP2 intron 24578207 rs533173 chr6 143115760 T C 6.49E-05 Schizophrenia HIVEP2 intron 19571809 rs533173 chr6 143115760 T C 4.48E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy HIVEP2 intron 24578207 rs533173 chr6 143115760 T C 4.48E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy HIVEP2 intron 24578207 rs552928 chr6 143117774 A G 8.65E-05 Schizophrenia HIVEP2 intron 19571809 rs550149 chr6 143119086 T A 7.64E-05 Schizophrenia HIVEP2 intron 19571809 rs12211360 chr6 143119832 A G 6.00E-06 Adiponectin levels HIVEP2 intron 24105470 rs525928 chr6 143121577 T C 8.27E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy HIVEP2 intron 24578207 rs525928 chr6 143121577 T C 8.27E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy HIVEP2 intron 24578207 rs10484587 chr6 143141577 A T 5.20E-05 Kidney function and endocine traits HIVEP2 intron 17903292 rs7768492 chr6 143145232 T G 7.84E-04 Alcohol dependence HIVEP2 intron 20201924 rs493985 chr6 143149300 C A 3.02E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) HIVEP2 intron 24023788 rs9373363 chr6 143150043 A G 6.80E-05 Cognitive test performance HIVEP2 intron 20125193 rs13195550 chr6 143159284 C T 4.41E-04 Lung function (forced expiratory volume in 1 second) HIVEP2 intron 24023788 rs9403408 chr6 143166001 A G 5.95E-04 Suicide attempts in bipolar disorder HIVEP2 intron 21423239 rs6910072 chr6 143167856 A G 9.07E-04 Multiple complex diseases HIVEP2 intron 17554300 rs728035 chr6 143178021 G A 7.60E-04 Suicide attempts in bipolar disorder HIVEP2 intron 21423239 rs13209704 chr6 143180050 G A 5.21E-04 Suicide attempts in bipolar disorder HIVEP2 intron 21423239 rs9496470 chr6 143184472 G A 6.91E-04 Suicide attempts in bipolar disorder HIVEP2 intron 21423239 rs9496471 chr6 143184677 G A 6.67E-04 Suicide attempts in bipolar disorder HIVEP2 intron 21423239 rs6925325 chr6 143188247 G A 8.26E-04 Suicide attempts in bipolar disorder HIVEP2 intron 21423239 rs9376714 chr6 143219140 G A 1.83E-04 Multiple complex diseases HIVEP2 intron 17554300 rs1855561 chr6 143263141 G A 8.97E-05 Erythrocyte counts HIVEP2 intron pha003101 rs2095369 chr6 143270216 A G 3.90E-04 Alcohol dependence / / 20201924 rs2095369 chr6 143270216 A G 5.30E-04 Alcohol dependence / / 20201924 rs13201958 chr6 143290588 G T 5.69E-05 Suicide attempts in bipolar disorder LOC100507489 intron 21423239 rs6939141 chr6 143297507 T G 5.88E-06 Parkinson's disease LOC100507489 intron 17052657 rs6920570 chr6 143297660 C T 1.83E-04 Smoking cessation LOC100507489 intron 24665060 rs12201873 chr6 143297745 C A 4.69E-05 Cholesterol LOC100507489 intron pha003083 rs199254 chr6 143326705 C T 1.84E-05 Serum metabolites LOC100507489 intron 19043545 rs9321886 chr6 143340590 T C 4.14E-04 Suicide attempts in bipolar disorder LOC100507489 intron 21423239 rs17072149 chr6 143341271 G A 2.77E-04 Suicide attempts in bipolar disorder LOC100507489 intron 21423239 rs1022504 chr6 143341876 T C 3.51E-04 Suicide attempts in bipolar disorder LOC100507489 intron 21423239 rs12525141 chr6 143344136 C A 7.52E-04 Suicide attempts in bipolar disorder LOC100507489 intron 21423239 rs75796365 chr6 143362753 T C 3.00E-06 Age-related nuclear cataracts / / 24951543 rs3789783 chr6 143429476 A G 2.00E-05 Prostate cancer AIG1 intron 21743057 rs17072255 chr6 143447328 A G 4.85E-04 Multiple complex diseases AIG1 intron 17554300 rs3761997 chr6 143484787 C T 2.48E-06 Retinopathy in non-diabetics AIG1 intron 23393555 rs2154404 chr6 143487277 T G 2.31E-06 Retinopathy in non-diabetics AIG1 intron 23393555 rs4896622 chr6 143488835 A G 2.29E-06 Retinopathy in non-diabetics AIG1 intron 23393555 rs12210837 chr6 143520801 A C 4.30E-06 Urinary metabolites AIG1 intron 21572414 rs6931927 chr6 143555551 A G 8.48E-04 Myocardial Infarction AIG1 intron pha002883 rs4895606 chr6 143595887 T C 3.90E-06 Urinary metabolites AIG1 intron 21572414 rs7742280 chr6 143596160 G T 1.82E-04 Aortic root size AIG1 intron 21223598 rs9390075 chr6 143598107 A G 2.70E-06 Urinary metabolites AIG1 intron 21572414 rs9321897 chr6 143603782 C G 4.01E-04 Aortic root size AIG1 intron 21223598 rs9403480 chr6 143605472 G T 5.67E-05 Serum metabolites AIG1 intron 19043545 rs9496556 chr6 143606232 C T 1.80E-04 Aortic root size AIG1 intron 21223598 rs11754096 chr6 143612606 T G 7.50E-06 Urinary metabolites AIG1 intron 21572414 rs4896632 chr6 143614151 C T 2.10E-05 Urinary metabolites AIG1 intron 21572414 rs11752523 chr6 143614500 C T 7.00E-06 Urinary metabolites AIG1 intron 21572414 rs4896637 chr6 143615785 T C 2.10E-05 Urinary metabolites AIG1 intron 21572414 rs6901152 chr6 143659012 T C 4.19E-04 Acute lymphoblastic leukemia (childhood) AIG1 intron 22076464 rs6937122 chr6 143694843 T C 9.77E-04 Multiple complex diseases / / 17554300 rs1424935 chr6 143699146 A G 1.39E-05 Multiple complex diseases / / 17554300 rs223590 chr6 143724518 T A 1.80E-05 Urinary metabolites / / 21572414 rs223591 chr6 143725397 A C 3.00E-04 Lung function (forced vital capacity) / / 24023788 rs223591 chr6 143725397 A C 3.88E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2496585 chr6 143729447 C A 1.21E-04 Breast cancer / / pha002853 rs2496590 chr6 143735762 T C 6.41E-04 Alcohol dependence / / 21314694 rs9403494 chr6 143798448 G C 2.50E-05 Urinary metabolites PEX3 intron 21572414 rs6930325 chr6 143801286 A T 4.90E-07 Urinary metabolites PEX3 intron 21572414 rs6935346 chr6 143801674 A G 1.60E-05 Urinary metabolites PEX3 intron 21572414 rs2294506 chr6 143805339 A G 1.20E-05 Urinary metabolites PEX3 intron 21572414 rs9403496 chr6 143813668 T A 2.50E-05 Urinary metabolites / / 21572414 rs7743944 chr6 143834550 A T 3.50E-04 Multiple complex diseases FUCA2 nearGene-5 17554300 rs6915645 chr6 143841040 G A 6.00E-10 Brain microstructure and intellectual performance / / 22723713 rs17072766 chr6 143871690 G A 7.11E-05 Sarcoidosis / / 19165924 rs12199775 chr6 143898894 A G 2.00E-08 Inflammatory bowel disease / / 23128233 rs9321927 chr6 143913295 C T 2.41E-04 Bipolar disorder,schizoaffective / / 19567891 rs9386039 chr6 143916992 A T 4.66E-04 Bipolar disorder,schizoaffective / / 19567891 rs10484804 chr6 143930768 T C 5.59E-04 Bipolar disorder,schizoaffective PHACTR2 intron 19567891 rs9496703 chr6 143933408 A G 3.75E-04 Multiple complex diseases PHACTR2 intron 17554300 rs9496703 chr6 143933408 A G 2.00E-04 Cognitive impairment induced by topiramate PHACTR2 intron 22091778 rs9496704 chr6 143933486 G T 3.54E-04 Multiple complex diseases PHACTR2 intron 17554300 rs954349 chr6 143935807 G A 3.48E-04 Bipolar disorder,schizoaffective PHACTR2 intron 19567891 rs9496707 chr6 143936016 A T 3.51E-04 Bipolar disorder,schizoaffective PHACTR2 intron 19567891 rs6570569 chr6 143939639 G A 2.13E-05 Sarcoidosis PHACTR2 intron 19165924 rs6570569 chr6 143939639 G A 8.38E-05 Bipolar disorder,schizoaffective PHACTR2 intron 19567891 rs17072830 chr6 143940767 G A 1.78E-04 Sarcoidosis PHACTR2 intron 19165924 rs6912373 chr6 143941123 G A 1.53E-04 Sarcoidosis PHACTR2 intron 19165924 rs6912373 chr6 143941123 G A 1.70E-04 Bipolar disorder,schizoaffective PHACTR2 intron 19567891 rs9390123 chr6 143943314 T C 7.00E-06 Lung Cancer (DNA repair capacity) PHACTR2 intron 23108145 rs7741506 chr6 143951867 A C 1.21E-05 Fibrinogen PHACTR2 intron pha003068 rs1890403 chr6 143959214 G A 4.76E-04 Stroke PHACTR2 intron pha002886 rs11155313 chr6 143961577 A G 1.54E-05 Parkinson's disease PHACTR2 intron 16252231 rs3924969 chr6 143979399 C G 7.71E-04 Taste perception PHACTR2 intron 22132133 rs7741628 chr6 143981926 C T 7.18E-05 Glucose levels PHACTR2 intron pha002899 rs9403521 chr6 143994199 T C 8.00E-06 Obesity-related traits PHACTR2 intron 23251661 rs9484792 chr6 144005949 C T 9.22E-05 Hematocrit PHACTR2 intron pha003097 rs13214196 chr6 144017105 G A 5.90E-05 Eosinophil counts PHACTR2 intron pha003088 rs1884172 chr6 144017778 C T 5.26E-05 Serum metabolites PHACTR2 intron 19043545 rs1884172 chr6 144017778 C T 5.95E-05 Eosinophil counts PHACTR2 intron pha003088 rs9484795 chr6 144022040 T C 6.83E-05 Eosinophil counts PHACTR2 intron pha003088 rs2488099 chr6 144030493 A G 3.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PHACTR2 intron 20877124 rs10457752 chr6 144031408 G A 8.20E-04 Suicide attempts in bipolar disorder PHACTR2 intron 21423239 rs761627 chr6 144036937 G A 6.21E-04 Coronary heart disease PHACTR2 intron 21971053 rs9376783 chr6 144041290 C G 6.48E-05 Multiple sclerosis PHACTR2 intron 17660530 rs9403525 chr6 144041537 C T 3.46E-05 Multiple sclerosis PHACTR2 intron 17660530 rs6915752 chr6 144041704 G T 2.31E-05 Multiple sclerosis PHACTR2 intron 17660530 rs6915752 chr6 144041704 G T 4.22E-04 Coronary heart disease PHACTR2 intron 21971053 rs6915752 chr6 144041704 G T 8.56E-05 Orofacial clefts PHACTR2 intron 22419666 rs6570578 chr6 144042122 T C 1.19E-05 Multiple sclerosis PHACTR2 intron 17660530 rs9403527 chr6 144047833 C T 5.97E-05 Cognitive performance PHACTR2 intron 19734545 rs960710 chr6 144060958 G A 1.31E-04 IgE levels PHACTR2 intron 17255346 rs960710 chr6 144060958 G A 1.96E-04 Alcohol consumption PHACTR2 intron 23743675 rs9390132 chr6 144061689 G A 2.29E-04 Alcohol consumption PHACTR2 intron 23743675 rs9321941 chr6 144064904 G A 1.35E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) PHACTR2 intron 24023788 rs6931825 chr6 144079788 A C 3.31E-04 Alcohol dependence PHACTR2 intron 24277619 rs6931865 chr6 144079854 A G 4.00E-06 Erectile dysfunction PHACTR2 intron 22704111 rs722754 chr6 144083453 A C 2.71E-05 Fibrinogen PHACTR2 intron pha003068 rs2295202 chr6 144094948 T C 1.69E-05 Fibrinogen PHACTR2 intron pha003068 rs9390143 chr6 144139385 A G 6.84E-04 Myocardial Infarction PHACTR2 intron pha002883 rs9390143 chr6 144139385 A G 7.57E-04 Stroke PHACTR2 intron pha002886 rs9496773 chr6 144141545 A G 7.00E-05 Type 2 diabetes PHACTR2 intron 21874001 rs2047 chr6 144153278 A C 5.94E-05 Lymphocyte counts / / 22286170 rs2328508 chr6 144188805 A G 6.23E-05 Bilirubin levels,in serum ZC2HC1B intron 19389676 rs7764938 chr6 144220404 C T 5.65E-04 Stroke ZC2HC1B intron pha002886 rs147054773 chr6 144263042 T G 0.00031 Breast cancer PLAGL1 missense 23555315 rs2328534 chr6 144266093 G C 2.67E-04 Lipid traits PLAGL1 intron 22028671 rs17073273 chr6 144288550 A C 3.80E-04 Suicide attempts in bipolar disorder PLAGL1 intron 21423239 rs9403542 chr6 144305568 T C 5.11E-04 Blood pressure PLAGL1 intron 24001895 rs9484838 chr6 144344172 T C 3.34E-05 Serum alpha1-antitrypsin levels PLAGL1 intron 23990791 rs763773 chr6 144392386 G T 8.76E-05 Waist-Hip Ratio / / pha003013 rs4895631 chr6 144428387 G A 7.29E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7760281 chr6 144446518 T C 7.98E-04 Testicular germ cell tumor / / 23666239 rs17073406 chr6 144447391 T G 3.72E-04 Multiple complex diseases / / 17554300 rs7762250 chr6 144475064 C G 3.00E-04 Acute lymphoblastic leukemia (childhood) STX11 intron 20189245 rs4286803 chr6 144530533 T C 5.00E-05 Lung cancer / / 18978790 rs2473127 chr6 144587238 G T 4.37E-04 Alzheimer's disease / / 17998437 rs2473129 chr6 144596093 G A 5.86E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs849668 chr6 144623282 A G 6.88E-05 Serum albumin level UTRN intron pha003084 rs12664298 chr6 144683621 G A 4.52E-04 Alcohol dependence UTRN intron 20201924 rs6901521 chr6 144689543 G A 0.00000235 Tuberculosis with late age of onset UTRN intron 22551897 rs11965388 chr6 144714689 G A 0.00000235 Tuberculosis with late age of onset UTRN intron 22551897 rs1534443 chr6 144869785 A G 1.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) UTRN missense 21239504 rs1005974 chr6 144872051 C A 4.96E-04 Smoking initiation UTRN intron 24665060 rs2056744 chr6 144952934 T G 8.43E-04 Multiple complex diseases UTRN intron 17554300 rs12663692 chr6 144988922 A G 8.46E-05 Hypertension UTRN intron pha003041 rs1406045 chr6 145004411 C T 2.60E-05 Urinary metabolites UTRN intron 21572414 rs9403580 chr6 145006780 T C 8.47E-05 Pulmonary function UTRN intron 19300500 rs9390194 chr6 145011143 G A 8.38E-05 Pulmonary function UTRN intron 19300500 rs9376841 chr6 145012869 A G 7.84E-05 Pulmonary function UTRN intron 19300500 rs9390197 chr6 145017982 C G 9.79E-04 Multiple complex diseases UTRN intron 17554300 rs9390197 chr6 145017982 C G 1.80E-06 Urinary metabolites UTRN intron 21572414 rs9376844 chr6 145025611 T C 4.16E-05 Pulmonary function UTRN intron 19300500 rs9373424 chr6 145031860 A G 3.93E-05 Pulmonary function UTRN intron 19300500 rs7762384 chr6 145040295 C A 0.0000203 Alcohol craving with or without dependence UTRN intron 22481050 rs13198393 chr6 145074798 T C 3.60E-06 Urinary metabolites UTRN intron 21572414 rs17074175 chr6 145102847 A G 8.89E-04 Suicide attempts in bipolar disorder UTRN intron 21423239 rs7748226 chr6 145120256 G A 8.67E-04 Suicide attempts in bipolar disorder UTRN intron 21423239 rs2297846 chr6 145148111 A G 9.49E-04 HIV-1 viral setpoint UTRN intron 17641165 rs1111808 chr6 145162225 A G 1.88E-05 Leukocyte Counts UTRN intron pha003091 rs1111807 chr6 145162512 T G 1.98E-05 Leukocyte Counts UTRN intron pha003091 rs4143179 chr6 145164253 T C 3.10E-07 Statin-induced myopathy UTRN intron 21826682 rs6903007 chr6 145169607 T C 8.65E-06 Leukocyte Counts UTRN intron pha003091 rs4321838 chr6 145184504 A C 7.15E-06 Leukocyte Counts / / pha003091 rs1933752 chr6 145185269 T C 5.00E-06 Retinopathy in non-diabetics / / 23393555 rs6931199 chr6 145199302 C T 4.80E-06 Urinary metabolites / / 21572414 rs4143178 chr6 145200305 G A 4.70E-06 Urinary metabolites / / 21572414 rs11968590 chr6 145201896 A G 1.50E-04 Response to antidepressants / / 19736353 rs7742893 chr6 145207134 G A 4.55E-04 Multiple complex diseases / / 17554300 rs7742893 chr6 145207134 G A 2.10E-06 Urinary metabolites / / 21572414 rs17217446 chr6 145207744 A G 3.40E-06 Urinary metabolites / / 21572414 rs13210889 chr6 145208081 C T 4.79E-04 Multiple complex diseases / / 17554300 rs13210889 chr6 145208081 C T 9.90E-06 Urinary metabolites / / 21572414 rs9321999 chr6 145209853 T C 3.92E-04 Multiple complex diseases / / 17554300 rs9321999 chr6 145209853 T C 1.60E-05 Urinary metabolites / / 21572414 rs9376871 chr6 145210230 G A 3.40E-04 Multiple complex diseases / / 17554300 rs9376871 chr6 145210230 G A 1.60E-05 Urinary metabolites / / 21572414 rs9399516 chr6 145210654 C T 3.07E-04 Multiple complex diseases / / 17554300 rs9399516 chr6 145210654 C T 1.60E-05 Urinary metabolites / / 21572414 rs4637659 chr6 145213294 C A 2.46E-04 Multiple complex diseases / / 17554300 rs4637659 chr6 145213294 C A 1.60E-05 Urinary metabolites / / 21572414 rs1338697 chr6 145215653 A G 1.60E-05 Urinary metabolites / / 21572414 rs9403630 chr6 145224544 A G 3.73E-04 Multiple complex diseases / / 17554300 rs9283117 chr6 145241671 G C 9.06E-04 Multiple complex diseases / / 17554300 rs2153110 chr6 145243339 T C 5.05E-04 Multiple complex diseases / / 17554300 rs2153110 chr6 145243339 T C 1.10E-05 Urinary metabolites / / 21572414 rs1111810 chr6 145261448 T C 6.62E-05 Cognitive test performance / / 20125193 rs7753021 chr6 145268902 G T 3.57E-05 Cognitive test performance / / 20125193 rs9373437 chr6 145276644 C T 6.94E-04 Multiple complex diseases / / 17554300 rs6917204 chr6 145284716 T C 1.40E-04 Multiple complex diseases / / 17554300 rs1953793 chr6 145287366 A G 0.000000263 CD8+ T cell IFN-gamma response to smallpox vaccine / / 22661280 rs7760387 chr6 145288265 A C 6.23E-05 Multiple complex diseases / / 17554300 rs4895662 chr6 145288904 G A 2.14E-04 Multiple complex diseases / / 17554300 rs4896765 chr6 145289328 A G 9.18E-05 Multiple complex diseases / / 17554300 rs4896767 chr6 145311090 T C 2.27E-04 Multiple complex diseases / / 17554300 rs12526618 chr6 145322256 A T 9.90E-09 Schizophrenia / / 21926974 rs946317 chr6 145322373 A G 6.74E-04 Multiple complex diseases / / 17554300 rs12527070 chr6 145323128 A T 6.77E-05 Parkinson's disease (motor and cognition) / / 22658654 rs12527070 chr6 145323128 A T 6.77E-05 Immune response to anthrax vaccine / / 22658931 rs6929370 chr6 145353578 C T 9.48E-04 Type 2 diabetes / / 17846124 rs6570670 chr6 145367318 T G 4.74E-08 CD8+ T cell IFN-gamma response to smallpox vaccine / / 22661280 rs953804 chr6 145369032 A G 1.86E-04 Alzheimer's disease / / 22005930 rs953803 chr6 145369121 G A 1.90E-04 Alzheimer's disease / / 22005930 rs2153143 chr6 145370722 T C 3.58E-04 Alzheimer's disease / / 22005930 rs689103 chr6 145376485 T C 2.83E-05 Serum metabolites / / 19043545 rs501830 chr6 145380755 T C 8.94E-05 Serum metabolites / / 19043545 rs577157 chr6 145385798 G T 3.34E-05 Serum metabolites / / 19043545 rs646892 chr6 145386016 T C 7.13E-05 Serum metabolites / / 19043545 rs551923 chr6 145543523 G A 9.97E-04 Celiac disease / / 23936387 rs551096 chr6 145607108 C G 2.46E-05 Serum metabolites / / 19043545 rs9386110 chr6 145626208 T C 4.10E-05 Response to antidepressants / / 19736353 rs11752086 chr6 145630852 C G 9.00E-06 Urinary metabolites / / 21572414 rs17074985 chr6 145632202 G A 2.00E-04 Information processing speed / / 21130836 rs17315133 chr6 145635385 G A 8.68E-04 Acute lung injury / / 22295056 rs10223879 chr6 145688962 C T 3.03E-04 Type 2 diabetes / / 22158537 rs6922610 chr6 145689046 G C 4.26E-04 Type 2 diabetes / / 22158537 rs1970320 chr6 145698845 G A 2.81E-04 Type 2 diabetes / / 22158537 rs7452286 chr6 145698985 C T 4.82E-04 Multiple complex diseases / / 17554300 rs4370382 chr6 145700203 C T 1.38E-04 Type 2 diabetes / / 22158537 rs9373455 chr6 145704225 G A 2.99E-04 Type 2 diabetes / / 22158537 rs9376923 chr6 145708978 G A 1.97E-04 Type 2 diabetes / / 22158537 rs12664698 chr6 145709371 A G 2.81E-04 Type 2 diabetes / / 22158537 rs4896799 chr6 145712540 C G 1.12E-04 Type 2 diabetes / / 22158537 rs9376924 chr6 145715513 A C 2.64E-04 Type 2 diabetes / / 22158537 rs2039698 chr6 145716967 T C 1.59E-04 Type 2 diabetes / / 22158537 rs1856266 chr6 145717303 C G 1.37E-04 Type 2 diabetes / / 22158537 rs1856264 chr6 145718120 G A 1.19E-04 Type 2 diabetes / / 22158537 rs9376925 chr6 145722006 A C 9.97E-05 Type 2 diabetes / / 22158537 rs9403698 chr6 145723710 A G 9.41E-05 Type 2 diabetes / / 22158537 rs9390318 chr6 145723851 C T 9.19E-05 Type 2 diabetes / / 22158537 rs4896800 chr6 145725549 A G 1.54E-04 Type 2 diabetes / / 22158537 rs9399545 chr6 145726494 T A 1.49E-04 Type 2 diabetes / / 22158537 rs1396644 chr6 145728314 G A 2.20E-26 Narcolepsy / / 19629137 rs1355145 chr6 145728582 G T 7.39E-04 Type 2 diabetes / / 22158537 rs11155417 chr6 145728954 T C 7.27E-05 Type 2 diabetes / / 22158537 rs9376933 chr6 145738465 G A 8.32E-04 Type 2 diabetes / / 22158537 rs9497306 chr6 145765771 T C 8.37E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs11155422 chr6 145792046 A G 9.13E-04 Insulin resistance / / 21901158 rs6570687 chr6 145802158 A C 9.70E-04 Insulin resistance / / 21901158 rs449377 chr6 145852437 G C 2.13E-05 Tuberculosis / / 24057671 rs11155431 chr6 145885018 A G 7.43E-04 Iron levels / / pha002876 rs12200607 chr6 146122137 T G 2.00E-04 Information processing speed FBXO30 intron 21130836 rs17075407 chr6 146184407 C A 6.63E-04 Multiple complex diseases LOC100507557 intron 17554300 rs6936647 chr6 146209762 C T 4.34E-05 Multiple complex diseases SHPRH intron 17554300 rs17225973 chr6 146241241 A G 4.89E-04 Multiple complex diseases SHPRH intron 17554300 rs2814875 chr6 146305810 G A 8.68E-05 Cognitive test performance / / 20125193 rs1331635 chr6 146341755 T C 1.88E-04 Multiple complex diseases / / 17554300 rs863820 chr6 146347402 A G 5.00E-04 Primary nonsyndromic vesicoureteric reflex GRM1 nearGene-5 19959718 rs9390374 chr6 146368175 A T 9.19E-04 Multiple complex diseases GRM1 intron 17554300 rs1331644 chr6 146398660 T C 9.52E-05 Cognitive test performance GRM1 intron 20125193 rs6913400 chr6 146479408 G C 2.71E-05 Bipolar disorder and schizophrenia GRM1 intron 20889312 rs12194562 chr6 146520360 T C 2.11E-04 Iron levels GRM1 intron pha002876 rs7750018 chr6 146527731 T C 2.98E-04 Multiple complex diseases GRM1 intron 17554300 rs2056994 chr6 146543192 C T 1.95E-05 Cholesterol GRM1 intron pha003073 rs2056994 chr6 146543192 C T 8.84E-05 ldl cholesterol GRM1 intron pha003076 rs2056994 chr6 146543192 C T 4.62E-05 Cholesterol GRM1 intron pha003078 rs12210114 chr6 146547828 C T 2.70E-05 Urinary metabolites GRM1 intron 21572414 rs6900247 chr6 146571933 G A 1.95E-05 Cholesterol GRM1 intron pha003073 rs6900247 chr6 146571933 G A 8.84E-05 ldl cholesterol GRM1 intron pha003076 rs6900247 chr6 146571933 G A 4.62E-05 Cholesterol GRM1 intron pha003078 rs6570747 chr6 146577335 T C 3.73E-04 Multiple complex diseases GRM1 intron 17554300 rs7741271 chr6 146638981 T A 6.52E-04 Multiple complex diseases GRM1 intron 17554300 rs362977 chr6 146652278 G A 2.70E-05 Urinary metabolites GRM1 intron 21572414 rs362949 chr6 146652354 T C 2.13E-04 Multiple complex diseases GRM1 intron 17554300 rs362857 chr6 146659644 T G 7.64E-04 Suicide attempts in bipolar disorder GRM1 intron 21423239 rs362894 chr6 146678952 A G 6.35E-04 Type 2 diabetes GRM1 intron 17463246 rs362839 chr6 146679735 T C 3.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRM1 intron 20877124 rs362842 chr6 146680449 A G 9.27E-04 Type 2 diabetes GRM1 intron 17463246 rs362848 chr6 146682485 A G 2.23E-05 Alzheimer's disease (late onset) GRM1 intron 21379329 rs362851 chr6 146710584 G C 1.43E-04 Type 2 diabetes GRM1 intron 17463246 rs362852 chr6 146712761 T C 2.72E-04 Type 2 diabetes GRM1 intron 17463246 rs362853 chr6 146713098 C A 1.41E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) GRM1 intron 24023788 rs362853 chr6 146713098 C A 5.96E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) GRM1 intron 24023788 rs362856 chr6 146719883 C A 1.13E-04 Alzheimer's disease (late onset) GRM1 intron 21379329 rs2235875 chr6 146720966 C A 1.64E-04 Alzheimer's disease (late onset) GRM1 intron 21379329 rs6909716 chr6 146767345 G A 3.75E-05 Erythrocyte counts / / pha003090 rs12206335 chr6 146823851 A G 2.10E-05 Urinary metabolites / / 21572414 rs4543390 chr6 146824085 C G 1.10E-06 Ulcerative colitis / / 19915572 rs4896870 chr6 146827281 G A 4.35E-05 Type 2 diabetes / / 17463246 rs4896870 chr6 146827281 G A 1.50E-05 Urinary metabolites / / 21572414 rs11155474 chr6 146855097 A C 7.30E-05 Psoriasis / / 20953190 rs11155474 chr6 146855097 A C 8.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9386156 chr6 146855856 T C 2.50E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9377003 chr6 146861189 C A 5.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11155475 chr6 146872685 A G 3.27E-04 Response to taxane treatment (placlitaxel) RAB32 intron 23006423 rs9497572 chr6 146908634 C G 4.76E-07 Multiple complex diseases / / 17554300 rs2275606 chr6 146918950 G A 4.00E-14 Leprosy / / 22019778 rs9377010 chr6 146922544 A G 1.76E-04 Multiple complex diseases ADGB intron 17554300 rs9403792 chr6 146922849 C T 2.94E-04 Multiple complex diseases ADGB intron 17554300 rs17076148 chr6 146952100 T C 4.25E-04 Multiple complex diseases ADGB intron 17554300 rs17076148 chr6 146952100 T C 2.09E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ADGB intron 20031582 rs1885678 chr6 146967199 G A 1.00E-06 Ovarian response to FSH stimulation in IVF ADGB intron 21316307 rs9403799 chr6 146972141 T G 2.00E-06 Ovarian response to FSH stimulation in IVF ADGB intron 21316307 rs1340996 chr6 146988978 T C 2.10E-05 Urinary metabolites ADGB intron 21572414 rs2226067 chr6 146991045 A G 4.40E-04 Asperger disorder ADGB intron 21182207 rs4576267 chr6 146998463 C A 3.25E-04 Type 2 diabetes ADGB intron 17463246 rs1340994 chr6 147019376 T A 5.55E-05 Relative hand skill ADGB intron 24068947 rs10457805 chr6 147028097 A G 4.83E-04 Alzheimer's disease ADGB intron 24755620 rs913308 chr6 147041059 C A 8.08E-05 Cognitive test performance ADGB intron 20125193 rs913308 chr6 147041059 C A 0.000687 Salmonella-induced pyroptosis ADGB intron 22837397 rs13196492 chr6 147042284 G A 2.07E-06 Glycemic traits (pregnancy) ADGB intron 23903356 rs1327668 chr6 147050289 T C 8.40E-05 Cognitive test performance ADGB intron 20125193 rs6570777 chr6 147065550 A C 8.06E-05 Serum metabolites ADGB intron 19043545 rs9322073 chr6 147066010 G A 5.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADGB intron 20877124 rs7740560 chr6 147067355 C T 6.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADGB intron 20877124 rs1327676 chr6 147087739 C T 1.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADGB intron 20877124 rs17535206 chr6 147091074 T G 2.00E-05 Asthma (bronchodilator response) ADGB intron 22792082 rs259417 chr6 147094975 A G 1.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADGB intron 20877124 rs259411 chr6 147098414 C T 6.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADGB intron 20877124 rs1325701 chr6 147103358 A G 8.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADGB intron 20877124 rs259401 chr6 147115291 G A 1.60E-04 Lung function (forced expiratory volume in 1 second) ADGB intron 24023788 rs259401 chr6 147115291 G A 9.58E-05 Lung function (forced vital capacity) ADGB intron 24023788 rs9390422 chr6 147126874 T C 4.39E-04 Iron levels ADGB intron pha002876 rs12194244 chr6 147219298 C A 8.61E-04 Response to cytidine analogues (gemcitabine) LOC729178 intron 24483146 rs9403828 chr6 147222516 C A 2.47E-04 Insulin resistance LOC729178 intron 21901158 rs1924692 chr6 147225989 A G 1.20E-05 Urinary metabolites LOC729178 intron 21572414 rs12174849 chr6 147288705 C T 7.41E-05 Serum albumin level LOC729178 intron pha003084 rs1406537 chr6 147326634 C T 8.83E-04 Multiple complex diseases LOC729178 intron 17554300 rs1406537 chr6 147326634 C T 7.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) LOC729178 intron 23648065 rs9390449 chr6 147350566 A G 4.64E-04 Multiple complex diseases LOC729178 intron 17554300 rs1529017 chr6 147351302 C T 4.99E-04 Multiple complex diseases LOC729178 intron 17554300 rs6570785 chr6 147354068 T C 7.17E-04 Multiple complex diseases LOC729178 intron 17554300 rs11969474 chr6 147366538 T C 8.24E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LOC729178 intron 23648065 rs6907758 chr6 147368934 C T 8.24E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LOC729178 intron 23648065 rs12664682 chr6 147409180 G A 3.88E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LOC729178 intron 23648065 rs12661753 chr6 147409235 A G 3.88E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LOC729178 intron 23648065 rs7771711 chr6 147414032 G A 3.88E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LOC729178 intron 23648065 rs6920901 chr6 147429298 C T 2.83E-04 Type 2 diabetes LOC729178 intron 17463246 rs566028 chr6 147520965 T C 1.11E-05 Response to platinum-based chemotherapy in small-cell lung cancer LOC729178 intron 20463552 rs2786189 chr6 147531081 G T 5.00E-06 Bronchopulmonary dysplasia STXBP5 intron 23897914 rs1221638 chr6 147535305 G A 7.80E-06 Bronchopulmonary dysplasia STXBP5 intron 23897914 rs556493 chr6 147549297 A G 1.00E-06 Bronchopulmonary dysplasia STXBP5 intron 23897914 rs6921496 chr6 147568513 T C 3.61E-04 Response to alcohol consumption (flushing response) STXBP5 intron 24277619 rs620715 chr6 147570239 G T 5.16E-04 Heart Failure STXBP5 intron pha002885 rs619175 chr6 147590491 C G 2.49E-05 Response to platinum-based chemotherapy in small-cell lung cancer STXBP5 intron 20463552 rs597631 chr6 147591022 G A 8.06E-04 Heart Failure STXBP5 intron pha002885 rs614476 chr6 147606007 T A 6.45E-05 Response to platinum-based chemotherapy in small-cell lung cancer STXBP5 intron 20463552 rs1039084 chr6 147635413 A G 3.86E-04 Heart Failure STXBP5 missense pha002885 rs1039085 chr6 147635547 C T 1.26E-06 Response to platinum-based chemotherapy in small-cell lung cancer STXBP5 intron 20463552 rs1039085 chr6 147635547 C T 5.39E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) STXBP5 intron 23648065 rs9373522 chr6 147639534 C T 7.40E-06 Bronchopulmonary dysplasia STXBP5 intron 23897914 rs1496031 chr6 147662541 G T 1.49E-05 Response to platinum-based chemotherapy in small-cell lung cancer STXBP5 intron 20463552 rs12191720 chr6 147670086 T C 1.08E-05 Response to platinum-based chemotherapy in small-cell lung cancer STXBP5 intron 20463552 rs12191720 chr6 147670086 T C 4.10E-06 Bronchopulmonary dysplasia STXBP5 intron 23897914 rs1496033 chr6 147671833 C T 5.38E-05 Response to platinum-based chemotherapy in small-cell lung cancer STXBP5 intron 20463552 rs4896905 chr6 147671994 G A 4.17E-05 Response to platinum-based chemotherapy in small-cell lung cancer STXBP5 intron 20463552 rs4896905 chr6 147671994 G A 3.22E-05 Tuberculosis STXBP5 intron 20694014 rs9390459 chr6 147680359 A G 1.00E-22 Coagulation factor levels STXBP5 cds-synon 20231535 rs9390459 chr6 147680359 A G 2.10E-04 Heart Failure STXBP5 cds-synon pha002885 rs9497759 chr6 147686274 G A 1.05E-05 Response to platinum-based chemotherapy in small-cell lung cancer STXBP5 intron 20463552 rs9373523 chr6 147701133 T G 1.00E-06 Tuberculosis STXBP5 intron 20694014 rs9399599 chr6 147703299 A T 3.00E-14 Plasma plasminogen activator levels STXBP5 intron 24578379 rs7765526 chr6 147713764 A G 2.11E-06 Bronchopulmonary dysplasia / / 23897914 rs9403856 chr6 147759534 C T 2.00E-06 IgG glycosylation / / 23382691 rs9403856 chr6 147759534 C T 4.00E-07 IgG glycosylation / / 23382691 rs9403856 chr6 147759534 C T 7.00E-07 IgG glycosylation / / 23382691 rs325105 chr6 147764267 C T 2.20E-06 Urinary metabolites / / 21572414 rs325105 chr6 147764267 C T 1.95E-04 Breast cancer / / pha002853 rs325127 chr6 147806719 A T 4.13E-04 Nicotine dependence / / 17158188 rs325129 chr6 147807143 G A 6.03E-04 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs420209 chr6 147811712 G C 1.42E-04 Type 2 diabetes / / 17463246 rs389674 chr6 147813016 C T 7.85E-04 Nicotine dependence / / 17158188 rs419376 chr6 147815274 C T 7.53E-05 Type 2 diabetes / / 17463246 rs325120 chr6 147818468 T A 6.20E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1222119 chr6 147826913 C A 2.54E-05 Type 2 diabetes / / 17463246 rs12189702 chr6 147831166 A C 9.56E-04 Amyotrophic Lateral Sclerosis SAMD5 intron 17362836 rs1333712 chr6 147832444 C T 6.56E-05 Blood Pressure SAMD5 intron pha003045 rs536996 chr6 147839691 G A 2.36E-05 Type 2 diabetes SAMD5 intron 17463246 rs537817 chr6 147839749 C T 3.07E-05 Type 2 diabetes SAMD5 intron 17463246 rs655698 chr6 147839774 G A 1.32E-05 Type 2 diabetes SAMD5 intron 17463246 rs648995 chr6 147846247 A G 1.13E-04 Type 2 diabetes SAMD5 intron 17463246 rs650375 chr6 147846575 A G 7.58E-05 Type 2 diabetes SAMD5 intron 17463246 rs9497801 chr6 147856512 A T 7.88E-05 Bipolar disorder and schizophrenia SAMD5 intron 20889312 rs702346 chr6 147887218 A G 2.36E-04 Type 2 diabetes SAMD5 UTR-3 17463246 rs702347 chr6 147887569 C T 3.70E-04 Multiple complex diseases SAMD5 UTR-3 17554300 rs9322102 chr6 147898333 G A 4.51E-05 Serum metabolites / / 19043545 rs844626 chr6 147898558 A G 1.53E-04 Multiple complex diseases / / 17554300 rs844625 chr6 147899217 T C 3.61E-04 Nicotine dependence / / 17158188 rs844557 chr6 147906281 T C 8.18E-04 Nicotine dependence / / 17158188 rs702353 chr6 147906754 G A 7.04E-04 Nicotine dependence / / 17158188 rs844562 chr6 147908995 T C 7.14E-04 Nicotine dependence / / 17158188 rs844563 chr6 147909168 T C 4.30E-04 Nicotine dependence / / 17158188 rs9377060 chr6 147909846 G A 4.81E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs844568 chr6 147912431 G T 1.23E-04 Nicotine dependence / / 17158188 rs844574 chr6 147912715 A C 1.61E-04 Nicotine dependence / / 17158188 rs13218203 chr6 147913541 G T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs844577 chr6 147914060 A T 1.67E-04 Nicotine dependence / / 17158188 rs1944645 chr6 147915466 A C 1.48E-04 Nicotine dependence / / 17158188 rs844613 chr6 147918582 G C 1.52E-04 Nicotine dependence / / 17158188 rs702354 chr6 147922555 T C 1.73E-04 Nicotine dependence / / 17158188 rs844604 chr6 147924455 T G 1.12E-04 Nicotine dependence / / 17158188 rs9377063 chr6 147934947 G A 8.00E-06 Obesity-related traits / / 23251661 rs9377064 chr6 147934995 G A 9.31E-05 Blood Pressure / / pha003045 rs12197416 chr6 147940786 C T 4.02E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6933618 chr6 147955887 C T 7.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4896932 chr6 147956348 C T 7.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs844584 chr6 147964120 C T 1.08E-05 QT interval / / 22726844 rs17077142 chr6 147966534 G A 8.28E-04 Multiple complex diseases / / 17554300 rs1589738 chr6 147967761 A G 2.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1302019 chr6 147971574 C T 2.00E-23 Myopia (pathological) / / 23049088 rs2015102 chr6 147974090 G A 9.22E-04 Multiple complex diseases / / 17554300 rs1523965 chr6 147987530 C T 1.10E-05 Urinary metabolites LOC100507613 intron 21572414 rs9390491 chr6 147993054 A G 1.21E-04 Glycemic traits (pregnancy) LOC100507613 intron 23903356 rs1608530 chr6 148002142 C T 4.60E-04 White matter integrity LOC100507613 intron 22425255 rs17259684 chr6 148013048 A G 4.85E-04 White matter integrity LOC100507613 intron 22425255 rs17077242 chr6 148015300 G A 3.57E-05 Cholesterol LOC100507613 intron pha003083 rs35111633 chr6 148017729 A AG 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC100507613 intron 22628534 rs9399617 chr6 148017729 A G 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC100507613 intron 22628534 rs9322108 chr6 148045181 A G 6.10E-05 Alcoholism (heaviness of drinking) LOC100507613 intron 21529783 rs12662237 chr6 148108890 T C 2.20E-05 Urinary metabolites / / 21572414 rs12662237 chr6 148108890 T C 7.41E-04 Insulin resistance / / 21901158 rs9497871 chr6 148111074 T C 1.20E-05 Urinary metabolites / / 21572414 rs7764342 chr6 148115505 G C 6.23E-04 Multiple complex diseases / / 17554300 rs7764342 chr6 148115505 G C 3.76E-04 Insulin resistance / / 21901158 rs949073 chr6 148126416 G A 9.79E-04 Depression (quantitative trait) / / 20800221 rs6941498 chr6 148127584 A G 8.44E-04 Multiple complex diseases / / 17554300 rs6941498 chr6 148127584 A G 9.41E-04 Depression (quantitative trait) / / 20800221 rs6941498 chr6 148127584 A G 2.60E-05 Urinary metabolites / / 21572414 rs11963553 chr6 148132503 T G 6.30E-04 Insulin resistance / / 21901158 rs3850229 chr6 148178358 G A 1.06E-05 F-cell distribution / / 21326311 rs112667 chr6 148181592 C A 2.80E-04 Type 2 diabetes / / 17463246 rs3861426 chr6 148184099 A G 7.45E-04 Obesity (extreme) / / 21935397 rs11155528 chr6 148190213 A G 7.19E-06 Gaucher disease severity / / 22388998 rs678691 chr6 148192919 C T 2.28E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs13198106 chr6 148193929 C T 1.74E-06 Gaucher disease severity / / 22388998 rs3861430 chr6 148200177 C G 2.30E-05 Urinary metabolites / / 21572414 rs11759320 chr6 148200924 C A 2.60E-06 Gaucher disease severity / / 22388998 rs614002 chr6 148202273 G A 2.91E-05 Gaucher disease severity / / 22388998 rs540737 chr6 148206547 C T 6.31E-04 Iron levels / / pha002876 rs636023 chr6 148217181 A G 7.60E-07 Statin-induced myopathy / / 21826682 rs17077549 chr6 148220417 T A 8.70E-04 Obesity (extreme) / / 21935397 rs600222 chr6 148221015 G T 3.34E-05 Gaucher disease severity / / 22388998 rs12110586 chr6 148235498 C T 1.40E-05 Urinary metabolites / / 21572414 rs529563 chr6 148252713 G A 2.74E-06 Gaucher disease severity / / 22388998 rs510933 chr6 148255794 T C 9.47E-07 Gaucher disease severity / / 22388998 rs646839 chr6 148258033 G A 4.00E-07 Smoking behavior / / 20418888 rs10484679 chr6 148266449 G A 3.71E-05 Cognitive test performance / / 20125193 rs9403895 chr6 148271373 T C 8.64E-06 Gaucher disease severity / / 22388998 rs9399627 chr6 148288648 C T 7.81E-04 Multiple complex diseases / / 17554300 rs9322114 chr6 148292041 T C 6.11E-05 Alzheimer's disease / / 24755620 rs17649322 chr6 148293108 A G 2.54E-04 Alzheimer's disease / / 17998437 rs17649322 chr6 148293108 A G 2.70E-05 Urinary metabolites / / 21572414 rs12193181 chr6 148306502 T G 2.90E-05 Post-operative nausea and vomiting / / 21694509 rs6570808 chr6 148307918 A G 5.47E-05 Multiple complex diseases / / 17554300 rs9403906 chr6 148315090 C T 4.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9322115 chr6 148324907 A T 4.66E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs17077870 chr6 148327628 C G 3.84E-04 Coronary heart disease / / 21606135 rs6938902 chr6 148328176 C T 3.30E-04 Coronary heart disease / / 21606135 rs1404485 chr6 148328330 G T 1.93E-04 Coronary heart disease / / 21606135 rs1404484 chr6 148328367 C T 2.77E-04 Coronary heart disease / / 21606135 rs1358689 chr6 148333960 C T 1.74E-05 Word reading / / 23738518 rs1358689 chr6 148333960 C T 2.19E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs9386204 chr6 148334316 G A 1.74E-05 Word reading / / 23738518 rs9386204 chr6 148334316 G A 2.10E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs9399630 chr6 148337661 G C 2.13E-04 Coronary heart disease / / 21606135 rs7765323 chr6 148338905 C G 3.67E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs7765812 chr6 148339040 G A 6.22E-04 Coronary heart disease / / 21606135 rs7765812 chr6 148339040 G A 7.18E-05 Bipolar disorder / / 22925353 rs1406710 chr6 148340111 A T 4.05E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs1406709 chr6 148340146 T A 3.94E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs4896955 chr6 148340422 C T 8.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4896955 chr6 148340422 C T 6.04E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs9403913 chr6 148340812 G T 4.28E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs9403915 chr6 148340955 C T 4.21E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs9377097 chr6 148341115 G A 1.74E-05 Word reading / / 23738518 rs9377097 chr6 148341115 G A 3.03E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs1881827 chr6 148341674 G A 1.74E-05 Word reading / / 23738518 rs1881827 chr6 148341674 G A 3.11E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs1881826 chr6 148341758 A G 3.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1881826 chr6 148341758 A G 5.77E-04 White matter integrity / / 22425255 rs1881826 chr6 148341758 A G 1.74E-05 Word reading / / 23738518 rs9403916 chr6 148343053 C T 3.96E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs4896956 chr6 148344667 T G 8.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4896956 chr6 148344667 T G 3.57E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs4896957 chr6 148344769 C T 3.96E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs4896958 chr6 148344804 C T 3.90E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs9322117 chr6 148346318 C A 3.01E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs9322118 chr6 148346323 C T 3.02E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs1534773 chr6 148346615 C T 1.69E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs6570813 chr6 148348811 T A 3.84E-04 Response to TNF antagonist treatment / / 21061259 rs2328840 chr6 148350314 C A 2.58E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs9390526 chr6 148351816 C T 1.34E-05 Word reading / / 23738518 rs9390526 chr6 148351816 C T 2.83E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs1534774 chr6 148355552 G C 1.21E-05 Word reading / / 23738518 rs1534774 chr6 148355552 G C 1.67E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs1534775 chr6 148357042 G A 2.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1534775 chr6 148357042 G A 9.86E-04 White matter integrity / / 22425255 rs1534775 chr6 148357042 G A 1.21E-05 Word reading / / 23738518 rs1997380 chr6 148358891 T C 3.30E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs1404488 chr6 148360063 A G 1.21E-05 Word reading / / 23738518 rs1404488 chr6 148360063 A G 3.53E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs6934331 chr6 148365909 T A 2.00E-05 Word reading / / 23738518 rs2328843 chr6 148368217 C T 1.80E-05 Word reading / / 23738518 rs9322120 chr6 148368521 G A 1.80E-05 Word reading / / 23738518 rs2876678 chr6 148369104 A G 7.15E-05 Response to rate control therapy in atrial fibrillation / / 25015694 rs7766503 chr6 148369484 G A 3.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1973858 chr6 148370544 T C 1.47E-05 Word reading / / 23738518 rs7746768 chr6 148377749 C G 1.46E-05 Word reading / / 23738518 rs1007475 chr6 148403405 T G 4.00E-05 Lung cancer / / 18385738 rs7764264 chr6 148409331 A G 4.54E-04 Multiple complex diseases / / 17554300 rs9390537 chr6 148423371 C T 2.47E-04 Alzheimer's disease / / 17998437 rs9390537 chr6 148423371 C T 8.00E-06 Alzheimer's Disease / / 20061627 rs17078001 chr6 148425858 G A 1.64E-04 Multiple complex diseases / / 17554300 rs11760055 chr6 148462599 C T 6.48E-05 Serum metabolites / / 19043545 rs13195044 chr6 148464521 C G 5.72E-05 Serum metabolites / / 19043545 rs6936603 chr6 148465173 G T 7.98E-05 Serum metabolites / / 19043545 rs9377112 chr6 148467702 T C 1.51E-05 Acne (severe teenage) / / 24114350 rs1934811 chr6 148471561 T C 6.06E-07 Multiple complex diseases / / 17554300 rs1934811 chr6 148471561 T C 2.50E-05 Urinary metabolites / / 21572414 rs9377114 chr6 148473026 C A 1.10E-05 Urinary metabolites / / 21572414 rs9390544 chr6 148473059 A T 9.80E-06 Urinary metabolites / / 21572414 rs17594786 chr6 148473897 A G 1.66E-04 Alzheimer's disease (late onset) / / 21379329 rs6570819 chr6 148491574 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9497965 chr6 148521292 C T 2.00E-08 Thyroid hormone levels / / 23408906 rs9497965 chr6 148521292 C T 3.00E-08 Thyroid hormone levels / / 23408906 rs11752096 chr6 148528098 A G 4.20E-04 Alzheimer's disease (late onset) / / 21379329 rs9497975 chr6 148547802 G A 7.00E-08 HIV-1 control / / 20041166 rs2185509 chr6 148558124 T C 8.91E-06 White blood cell count / / 21738479 rs4896981 chr6 148581008 A G 2.00E-05 Asthma and hay fever / / 24388013 rs2493928 chr6 148615810 C T 1.45E-04 Multiple complex diseases / / 17554300 rs6570836 chr6 148621018 C A 7.42E-05 Intracranial aneurysm / / 20613766 rs6907655 chr6 148630944 A G 2.80E-05 Urinary metabolites / / 21572414 rs4896990 chr6 148639539 T C 7.43E-04 Smoking initiation / / 24665060 rs6940190 chr6 148644731 T A 4.60E-05 Methamphetamine dependence / / 23594818 rs6930576 chr6 148704954 G A 7.00E-07 Type 2 diabetes nephropathy SASH1 intron 21150874 rs6930576 chr6 148704954 G A 1.87E-05 Type 2 diabetes SASH1 intron 22238593 rs9373560 chr6 148726746 T C 2.10E-05 Urinary metabolites SASH1 intron 21572414 rs9498038 chr6 148761603 C A 2.70E-05 Urinary metabolites SASH1 intron 21572414 rs7751271 chr6 148770966 T C 3.70E-05 Serum metabolites SASH1 intron 19043545 rs9322150 chr6 148778680 A G 5.54E-05 Brain derived neurotrophic factor levels,in serum SASH1 intron 22047184 rs9399650 chr6 148781825 T C 3.00E-04 Iris characteristics SASH1 intron 21835309 rs6930337 chr6 148788006 C T 1.00E-06 Protein quantitative trait loci SASH1 intron 18464913 rs1883625 chr6 148792617 A G 1.55E-04 Multiple complex diseases SASH1 cds-synon 17554300 rs2294777 chr6 148795472 T C 9.91E-05 Response to mTOR inhibitor (rapamycin) SASH1 intron 24009623 rs1618036 chr6 148825030 C T 5.67E-04 Premature ovarian failure SASH1 intron 19508998 rs1147865 chr6 148827807 T G 9.26E-04 Depression (quantitative trait) SASH1 intron 20800221 rs1147862 chr6 148831252 T C 2.03E-05 Alzheimer's disease (late onset) SASH1 intron 21379329 rs7739956 chr6 148835642 A G 1.08E-04 Multiple complex diseases SASH1 intron 17554300 rs1147857 chr6 148841752 T C 2.00E-06 Smoking quantity SASH1 intron 24665060 rs1147855 chr6 148844451 G A 2.22E-04 Alzheimer's disease (late onset) SASH1 intron 21379329 rs2159965 chr6 148848996 A G 8.30E-05 Non-alcoholic fatty liver disease histology (other) SASH1 intron 20708005 rs9498061 chr6 148859288 A G 2.11E-05 Follicular lymphoma SASH1 intron 21533074 rs2294788 chr6 148862143 G C 6.15E-05 Insulin resistance SASH1 intron 21901158 rs9485296 chr6 148871389 A G 2.58E-04 Oral cancers (chewing tobacco related) SASH1 UTR-3 22503698 rs741116 chr6 148885566 T C 9.78E-05 Serum metabolites / / 19043545 rs208707 chr6 148891724 G A 3.66E-05 Magnesium levels / / pha003092 rs6928856 chr6 148895566 C T 7.11E-05 Magnesium levels / / pha003092 rs208704 chr6 148897510 A G 6.13E-04 Schizophrenia / / 19197363 rs13196614 chr6 148923789 G T 5.00E-06 Migraine / / 23793025 rs911979 chr6 148934993 T C 3.07E-05 stroke (ischemic) / / 17434096 rs9403969 chr6 148943174 T G 7.48E-05 Hearing impairment / / 19047183 rs6420783 chr6 148953088 C A 3.10E-04 Alcohol dependence / / 20201924 rs9498099 chr6 148981906 T C 5.23E-04 Myocardial Infarction / / pha002873 rs7739408 chr6 148991356 C T 4.97E-05 Serum metabolites / / 19043545 rs6570879 chr6 148994128 C T 7.99E-05 Serum metabolites / / 19043545 rs11754224 chr6 148996235 A G 5.62E-04 Smoking initiation / / 24665060 rs7453519 chr6 149016692 A G 7.90E-05 Myocardial Infarction / / pha002873 rs11155589 chr6 149027366 G A 5.88E-05 Serum metabolites / / 19043545 rs10457834 chr6 149042800 T C 6.00E-06 Kawasaki disease / / 22446962 rs4897043 chr6 149044264 C A 4.20E-06 Kawasaki disease / / 22446962 rs9498147 chr6 149074229 A G 9.53E-05 Prostate cancer UST intron 22923026 rs7760963 chr6 149083115 C T 7.62E-06 Height UST intron pha003011 rs17718177 chr6 149088754 T C 3.39E-05 Bipolar disorder UST intron 18317468 rs6904988 chr6 149092458 A G 2.84E-06 Height UST intron pha003011 rs6570896 chr6 149092757 C T 4.45E-06 Height UST intron pha003011 rs6570897 chr6 149099378 C A 5.17E-05 Height UST intron pha003010 rs6570897 chr6 149099378 C A 2.51E-06 Height UST intron pha003011 rs9386234 chr6 149105738 C A 6.70E-05 Coronary heart disease UST intron pha003030 rs9377158 chr6 149107853 G A 9.18E-06 Odorant perception UST intron 23910658 rs10499260 chr6 149112117 A G 2.58E-04 Multiple complex diseases UST intron 17554300 rs10499260 chr6 149112117 A G 2.33E-04 Suicide attempts in bipolar disorder UST intron 21423239 rs13211840 chr6 149112190 T C 2.19E-04 Multiple complex diseases UST intron 17554300 rs13211840 chr6 149112190 T C 2.52E-04 Suicide attempts in bipolar disorder UST intron 21423239 rs7753810 chr6 149112756 T G 2.55E-04 Nicotine dependence UST intron 17158188 rs17084964 chr6 149113078 T C 1.33E-04 Suicide attempts in bipolar disorder UST intron 21423239 rs9390613 chr6 149125116 C T 3.09E-04 Parkinson's disease UST intron 17052657 rs34969510 chr6 149162723 G GT 9.27E-12 Metabolite levels UST intron 22286219 rs9285515 chr6 149162723 G T 9.27E-12 Metabolite levels UST intron 22286219 rs4361637 chr6 149172368 T C 6.79E-05 Brain derived neurotrophic factor levels,in serum UST intron 22047184 rs11965507 chr6 149195423 G A 4.04E-05 Alcohol consumption UST intron 23743675 rs9322158 chr6 149242095 G A 0.0008931 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) UST intron 23233654 rs9322158 chr6 149242095 G A 8.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) UST intron 23233662 rs10499258 chr6 149242165 G A 0.0008236 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) UST intron 23233654 rs10499258 chr6 149242165 G A 8.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) UST intron 23233662 rs10499257 chr6 149242720 T C 0.0007741 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) UST intron 23233654 rs10499257 chr6 149242720 T C 7.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) UST intron 23233662 rs9498180 chr6 149242978 C G 0.0006283 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) UST intron 23233654 rs9498180 chr6 149242978 C G 6.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) UST intron 23233662 rs17080323 chr6 149265149 T C 9.31E-04 Multiple complex diseases UST intron 17554300 rs10872625 chr6 149269964 T A 9.37E-04 Alzheimer's disease UST intron 24755620 rs13219957 chr6 149270829 G A 7.00E-07 Job-related exhaustion UST intron 23620144 rs17729143 chr6 149283811 G A 9.67E-04 Response to taxane treatment (placlitaxel) UST intron 23006423 rs12197795 chr6 149293508 G T 7.53E-04 Response to taxane treatment (placlitaxel) UST intron 23006423 rs729503 chr6 149294576 G A 1.92E-05 Gallstones UST intron 17632509 rs7741054 chr6 149307684 A G 7.92E-04 Response to taxane treatment (placlitaxel) UST intron 23006423 rs2486404 chr6 149311607 A C 1.73E-08 Response to antidepressants UST intron 20360315 rs2500525 chr6 149312334 T C 1.74E-08 Response to antidepressants UST intron 20360315 rs2486403 chr6 149313157 A G 1.88E-08 Response to antidepressants UST intron 20360315 rs2486402 chr6 149314291 A G 3.70E-08 Response to antidepressants UST intron 20360315 rs2486398 chr6 149318799 T C 7.91E-08 Response to antidepressants UST intron 20360315 rs2500530 chr6 149320283 A T 7.95E-08 Response to antidepressants UST intron 20360315 rs2486397 chr6 149320682 C G 7.97E-08 Response to antidepressants UST intron 20360315 rs2486396 chr6 149321746 C T 7.99E-08 Response to antidepressants UST intron 20360315 rs2486396 chr6 149321746 C T 4.94E-04 Alcohol dependence UST intron 21314694 rs9390650 chr6 149322058 C T 2.78E-05 Serum alpha1-antitrypsin levels UST intron 23990791 rs2486390 chr6 149324196 T C 8.05E-08 Response to antidepressants UST intron 20360315 rs2500535 chr6 149329267 A G 4.00E-08 Response to antidepressants UST intron 20360315 rs2500535 chr6 149329267 A G 9.00E-06 Response to antidepressants UST intron 20360315 rs2500535 chr6 149329267 A G 0.0006 Change in depression severity with Norepinephrine reuptake inhibitors (NRI) UST intron 23091423 rs7770997 chr6 149331339 A G 3.16E-05 Serum alpha1-antitrypsin levels UST intron 23990791 rs2486416 chr6 149336009 C T 5.59E-08 Response to antidepressants UST intron 20360315 rs2486416 chr6 149336009 C T 6.91E-04 Alcohol dependence UST intron 21314694 rs2486415 chr6 149336177 G A 6.25E-07 Response to antidepressants UST intron 20360315 rs6930963 chr6 149354801 C G 4.55E-05 Serum alpha1-antitrypsin levels UST intron 23990791 rs10457074 chr6 149359829 G A 1.40E-05 Body mass index (non-asthmatics) UST intron 23517042 rs2153252 chr6 149366064 G T 3.45E-04 Response to taxane treatment (placlitaxel) UST intron 23006423 rs6914925 chr6 149369985 A C 4.75E-05 Response to taxane treatment (placlitaxel) UST intron 23006423 rs9322164 chr6 149374484 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) UST intron 20708005 rs1934221 chr6 149374605 C A 7.99E-04 Response to taxane treatment (placlitaxel) UST intron 23006423 rs2486411 chr6 149387231 G A 3.52E-04 Self-reported allergy UST intron 23817569 rs2486409 chr6 149401466 G A 4.80E-04 Self-reported allergy / / 23817569 rs2486409 chr6 149401466 G A 5.32E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7772697 chr6 149435111 T C 3.00E-06 Diabetic retinopathy / / 21441570 rs12205636 chr6 149443451 G T 8.89E-05 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs6570952 chr6 149518083 A G 6.83E-05 Paget's disease / / 20436471 rs636864 chr6 149525606 C T 6.00E-06 Hemostatic factors and hematological phenotypes / / 17903294 rs636864 chr6 149525606 C T 1.55E-06 Blood Pressure and Arterial Stiffness / / 17903302 rs9377195 chr6 149527462 C T 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs9377195 chr6 149527462 C T 4.06E-04 Smoking initiation / / 24665060 rs652720 chr6 149540264 A G 3.35E-05 Paget's disease / / 20436471 rs652720 chr6 149540264 A G 4.21E-05 Tunica Media / / pha003038 rs4897094 chr6 149558624 T C 0.000523 Breast cancer / / 22228098 rs1474637 chr6 149558895 T C 0.000272 Breast cancer / / 22228098 rs6570956 chr6 149562839 C T 0.000078 Breast cancer / / 22228098 rs6923382 chr6 149562876 T C 0.00022 Breast cancer / / 22228098 rs7747474 chr6 149565986 T C 0.00003 Breast cancer / / 22228098 rs6935566 chr6 149566825 A G 0.000198 Breast cancer / / 22228098 rs9498267 chr6 149568194 T G 0.000197 Breast cancer / / 22228098 rs7758080 chr6 149577079 A G 4.39E-06 Crohn's disease / / 18587394 rs4897103 chr6 149590439 A G 8.12E-04 Multiple complex diseases / / 17554300 rs727979 chr6 149593920 C T 8.00E-06 Hemostatic factors and hematological phenotypes / / 17903294 rs9498283 chr6 149605182 A G 5.30E-06 Breast cancer / / 22452962 rs9485372 chr6 149608874 G A 4.00E-12 Breast cancer / / 22383897 rs531486 chr6 149618404 T C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs491576 chr6 149623261 A G 8.77E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9498309 chr6 149625540 G A 5.82E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs661838 chr6 149628277 A G 5.78E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs1446556 chr6 149637106 C A 7.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs11155639 chr6 149637690 T C 6.79E-04 Suicide attempts in bipolar disorder TAB2 nearGene-5 21423239 rs1900300 chr6 149641627 T C 4.12E-04 Suicide attempts in bipolar disorder TAB2 intron 21423239 rs9498321 chr6 149643709 T C 1.27E-04 Follicular lymphoma TAB2 intron 21533074 rs4895787 chr6 149646500 G A 3.20E-04 Suicide attempts in bipolar disorder TAB2 intron 21423239 rs11155642 chr6 149654120 G A 3.16E-05 Gallstones TAB2 intron 17632509 rs11964335 chr6 149658101 A T 2.02E-04 Suicide attempts in bipolar disorder TAB2 intron 21423239 rs504985 chr6 149658978 T G 2.17E-05 Follicular lymphoma TAB2 intron 21533074 rs504985 chr6 149658978 T G 5.65E-04 Myocardial Infarction TAB2 intron pha002883 rs6942381 chr6 149662991 G C 6.20E-05 Suicide attempts in bipolar disorder TAB2 intron 21423239 rs12665694 chr6 149672323 A G 7.39E-04 Response to cytidine analogues (gemcitabine) TAB2 intron 24483146 rs6922130 chr6 149672375 C G 7.08E-05 Suicide attempts in bipolar disorder TAB2 intron 21423239 rs13219868 chr6 149686518 T G 4.25E-04 Suicide attempts in bipolar disorder TAB2 intron 21423239 rs6570963 chr6 149691355 T G 1.97E-04 Suicide attempts in bipolar disorder TAB2 intron 21423239 rs6570964 chr6 149691859 G A 2.43E-04 Suicide attempts in bipolar disorder TAB2 intron 21423239 rs9498335 chr6 149693784 C A 1.23E-04 Follicular lymphoma TAB2 intron 21533074 rs237035 chr6 149710848 C T 3.06E-04 Suicide attempts in bipolar disorder TAB2 intron 21423239 rs9404034 chr6 149711983 G C 8.17E-04 Multiple complex diseases TAB2 intron 17554300 rs237028 chr6 149718650 C T 4.12E-04 Suicide attempts in bipolar disorder TAB2 intron 21423239 rs237026 chr6 149720681 G A 3.49E-04 Suicide attempts in bipolar disorder TAB2 intron 21423239 rs237025 chr6 149721690 G A 9.56E-05 Serum metabolites SUMO4 missense 19043545 rs237025 chr6 149721690 G A 3.63E-04 Suicide attempts in bipolar disorder SUMO4 missense 21423239 rs805026 chr6 149728254 G C 3.72E-04 Suicide attempts in bipolar disorder TAB2 intron 21423239 rs237012 chr6 149729198 T C 3.72E-04 Suicide attempts in bipolar disorder TAB2 intron 21423239 rs366905 chr6 149735097 T A 1.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs681919 chr6 149735600 A G 1.13E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs237018 chr6 149743930 T C 1.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs237010 chr6 149758750 G T 8.13E-05 Suicide attempts in bipolar disorder / / 21423239 rs2179367 chr6 149762537 A G 7.10E-05 Follicular lymphoma / / 21533074 rs2179367 chr6 149762537 A G 3.00E-07 Dupuytren's disease / / 21732829 rs237008 chr6 149766961 G A 7.92E-04 Type 2 diabetes / / 17463246 rs452586 chr6 149779185 G A 4.96E-06 Gallstones ZC3H12D intron 17632509 rs420430 chr6 149785539 T G 2.18E-04 Suicide attempts in bipolar disorder ZC3H12D intron 21423239 rs448420 chr6 149785802 T C 2.07E-04 Suicide attempts in bipolar disorder ZC3H12D intron 21423239 rs512685 chr6 149793025 G A 3.94E-09 Atopic dermatitis ZC3H12D intron 21666691 rs438852 chr6 149794533 A G 9.13E-05 Suicide attempts in bipolar disorder ZC3H12D intron 21423239 rs384334 chr6 149796172 C A,G 1.02E-04 Suicide attempts in bipolar disorder ZC3H12D intron 21423239 rs394563 chr6 149797014 T G 1.04E-04 Suicide attempts in bipolar disorder ZC3H12D intron 21423239 rs444784 chr6 149798366 C G 1.22E-04 Suicide attempts in bipolar disorder ZC3H12D intron 21423239 rs369643 chr6 149799798 T C 1.50E-04 Suicide attempts in bipolar disorder ZC3H12D intron 21423239 rs2341768 chr6 149810195 G A 0.000183 Breast cancer / / 22228098 rs6911016 chr6 149810650 A C 0.000721 Breast cancer / / 22228098 rs60404985 chr6 149811693 A G 0.000711 Breast cancer / / 22228098 rs4897128 chr6 149813362 C A 0.00021 Breast cancer / / 22228098 rs4897129 chr6 149813527 A G 0.000224 Breast cancer / / 22228098 rs4897130 chr6 149813528 C T 0.000238 Breast cancer / / 22228098 rs6929614 chr6 149813737 C T 0.000863 Breast cancer / / 22228098 rs1474640 chr6 149813940 C G 0.000202 Breast cancer / / 22228098 rs2880075 chr6 149814658 T C 5.13E-04 Multiple complex diseases / / 17554300 rs2880075 chr6 149814658 T C 0.000825 Breast cancer / / 22228098 rs2341551 chr6 149814762 A G 0.000828 Breast cancer / / 22228098 rs2105200 chr6 149815393 C G 0.000828 Breast cancer / / 22228098 rs2341550 chr6 149815427 T A 0.000218 Breast cancer / / 22228098 rs62442787 chr6 149815469 T C 0.000828 Breast cancer / / 22228098 rs62442788 chr6 149815563 G A 0.000218 Breast cancer / / 22228098 rs17732745 chr6 149815782 G A 0.000218 Breast cancer / / 22228098 rs4897131 chr6 149816622 A G 0.000825 Breast cancer / / 22228098 rs4897132 chr6 149816815 G C 0.000825 Breast cancer / / 22228098 rs4897133 chr6 149816989 G A 0.000231 Breast cancer / / 22228098 rs7753560 chr6 149817319 A T 0.000818 Breast cancer / / 22228098 rs7774559 chr6 149820799 C T 0.000707 Breast cancer / / 22228098 rs6570968 chr6 149820973 A G 0.000717 Breast cancer / / 22228098 rs12524946 chr6 149821322 A G 0.000235 Breast cancer / / 22228098 rs9377220 chr6 149821744 A T 0.000241 Breast cancer / / 22228098 rs9377221 chr6 149821755 A T 0.00025 Breast cancer / / 22228098 rs9377222 chr6 149822006 A G 0.00024 Breast cancer / / 22228098 rs9390684 chr6 149822009 G A 0.000239 Breast cancer / / 22228098 rs62442789 chr6 149823896 C A 0.000678 Breast cancer / / 22228098 rs62442790 chr6 149823899 C A 0.000224 Breast cancer / / 22228098 rs12665533 chr6 149829761 C T 0.000356 Breast cancer PPIL4 intron 22228098 rs62442792 chr6 149831810 G A 0.000359 Breast cancer PPIL4 intron 22228098 rs62442793 chr6 149831874 G A 0.000359 Breast cancer PPIL4 intron 22228098 rs9377223 chr6 149832751 C T 0.000761 Breast cancer PPIL4 intron 22228098 rs9373594 chr6 149834574 T C 0.000426 Breast cancer PPIL4 intron 22228098 rs9373594 chr6 149834574 T C 3.00E-09 Rheumatoid arthritis PPIL4 intron 24390342 rs9373594 chr6 149834574 T C 5.00E-08 Rheumatoid arthritis PPIL4 intron 24390342 rs78296717 chr6 149836320 G A 0.00033 Breast cancer PPIL4 intron 22228098 rs4897137 chr6 149840177 G A 0.000329 Breast cancer PPIL4 intron 22228098 rs4897138 chr6 149840543 G A 0.000329 Breast cancer PPIL4 intron 22228098 rs1125107 chr6 149842694 T C 0.000332 Breast cancer PPIL4 intron 22228098 rs12663698 chr6 149844785 C T 0.000226 Breast cancer PPIL4 intron 22228098 rs10485097 chr6 149845650 G A 0.00033 Breast cancer PPIL4 intron 22228098 rs62442795 chr6 149846962 C T 0.000329 Breast cancer PPIL4 intron 22228098 rs9800648 chr6 149849132 C T 0.00033 Breast cancer PPIL4 intron 22228098 rs9390687 chr6 149850806 G A 0.000334 Breast cancer PPIL4 intron 22228098 rs9689569 chr6 149852038 G A 0.000338 Breast cancer PPIL4 intron 22228098 rs9377224 chr6 149853707 C G 0.000265 Breast cancer PPIL4 intron 22228098 rs761617 chr6 149855742 C T 0.000187 Breast cancer PPIL4 intron 22228098 rs9406344 chr6 149861604 A G 0.000184 Breast cancer PPIL4 intron 22228098 rs62442798 chr6 149865296 C T 0.000273 Breast cancer PPIL4 intron 22228098 rs3813675 chr6 149866780 C A 0.000271 Breast cancer PPIL4 intron 22228098 rs4869797 chr6 149868764 A G 0.000273 Breast cancer / / 22228098 rs9404044 chr6 149873067 G A 0.000273 Breast cancer / / 22228098 rs9373595 chr6 149873490 A G 0.000236 Breast cancer / / 22228098 rs9399690 chr6 149874177 G A 0.000274 Breast cancer / / 22228098 rs9390689 chr6 149874941 G A 0.000278 Breast cancer / / 22228098 rs4869701 chr6 149878005 T C 0.000285 Breast cancer / / 22228098 rs62439776 chr6 149878587 C A 0.000286 Breast cancer / / 22228098 rs28580659 chr6 149881414 T A 0.000234 Breast cancer / / 22228098 rs62439778 chr6 149886122 G A 0.000185 Breast cancer / / 22228098 rs7752089 chr6 150160434 A G 3.30E-05 Rheumatoid arthritis LRP11 intron 22446963 rs11968879 chr6 150161242 G A 1.54E-05 Type 2 diabetes LRP11 intron 23300278 rs9478945 chr6 150164190 G A 3.64E-06 Multiple complex diseases LRP11 missense 17554300 rs17079029 chr6 150239330 C T 7.43E-04 Alcohol dependence LOC100652739 intron 21314694 rs17079048 chr6 150246386 T C 9.49E-05 Blood Pressure / / pha003048 rs12524576 chr6 150271944 G A 6.17E-04 Stroke / / pha002886 rs6557200 chr6 150272532 T C 5.77E-04 Stroke / / pha002886 rs4242282 chr6 150273346 G C 3.87E-04 Type 2 diabetes / / 17463246 rs4242283 chr6 150273406 G C 6.24E-04 Type 2 diabetes / / 17463246 rs9397087 chr6 150277146 G A 3.96E-04 Multiple complex diseases / / 17554300 rs12194150 chr6 150277218 C T 2.81E-04 Type 2 diabetes / / 17463246 rs1853665 chr6 150298842 C T 7.00E-06 Radiation response / / 20923822 rs11155693 chr6 150313686 C T 1.90E-05 Urinary metabolites / / 21572414 rs9384030 chr6 150324908 T C 1.20E-05 Urinary metabolites RAET1K intron 21572414 rs9479482 chr6 150358012 T C 4.00E-19 Alopecia areata / / 20596022 rs12207804 chr6 150365343 G C 3.45E-05 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs11155700 chr6 150368264 A G 9.50E-06 Type 2 diabetes / / 17460697 rs12213837 chr6 150368963 C T 9.70E-06 Type 2 diabetes / / 17460697 rs17054300 chr6 150370552 G A 1.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs78546022 chr6 150380884 A G 4.00E-06 Metabolite levels (HVA/5-HIAA ratio) / / 23319000 rs4242288 chr6 150430400 C T 7.34E-04 Multiple complex diseases / / 17554300 rs9478466 chr6 150436223 A G 1.12E-04 Insulin resistance / / 21901158 rs7758196 chr6 150445836 C G 7.83E-04 Obesity (extreme) / / 21935397 rs9384189 chr6 150476319 G A 8.64E-04 Alzheimer's disease PPP1R14C intron 17998437 rs9384189 chr6 150476319 G A 6.10E-06 Urinary metabolites PPP1R14C intron 21572414 rs12530370 chr6 150482531 A C 5.53E-05 Height PPP1R14C intron pha003011 rs2057557 chr6 150494873 G A 8.21E-04 Type 2 diabetes PPP1R14C intron 17463246 rs11759558 chr6 150525791 T C 5.46E-04 Amyotrophic Lateral Sclerosis PPP1R14C intron 17362836 rs9885696 chr6 150538665 G T 8.65E-04 Alzheimer's disease PPP1R14C intron 22005930 rs6557376 chr6 150544304 T C 2.92E-05 Alzheimer's disease PPP1R14C intron 22005930 rs9384259 chr6 150550969 A C 6.25E-05 Alzheimer's disease PPP1R14C intron 22005930 rs4870384 chr6 150554040 C G 6.38E-06 Serum metabolites PPP1R14C intron 19043545 rs9478602 chr6 150554073 G A 2.38E-05 Multiple complex diseases PPP1R14C intron 17554300 rs6936990 chr6 150557220 T C 1.41E-04 Alzheimer's disease PPP1R14C intron 22005930 rs6936990 chr6 150557220 T C 8.64E-04 Response to taxane treatment (placlitaxel) PPP1R14C intron 23006423 rs200728075 chr6 150557779 G GCA 1.30E-04 Alzheimer's disease PPP1R14C intron 22005930 rs7749005 chr6 150557779 G A 1.30E-04 Alzheimer's disease PPP1R14C intron 22005930 rs9480032 chr6 150561269 A G 3.25E-04 Smoking initiation PPP1R14C intron 24665060 rs1086206 chr6 150564916 C T 3.92E-04 Smoking initiation PPP1R14C intron 24665060 rs3734729 chr6 150570867 A G 4.00E-06 Pulmonary function PPP1R14C UTR-3 21946350 rs3734729 chr6 150570867 A G 4.00E-07 Pulmonary function (interaction) PPP1R14C UTR-3 23284291 rs3734729 chr6 150570867 A G 7.00E-07 Pulmonary function (interaction) PPP1R14C UTR-3 23284291 rs1151 chr6 150571265 A C 3.83E-04 Alzheimer's disease PPP1R14C UTR-3 22005930 rs6910142 chr6 150572330 T C 2.40E-06 Stroke (ischemic) / / 22384361 rs789495 chr6 150575305 C T 9.01E-05 Alzheimer's disease / / 22005930 rs10484499 chr6 150577872 A G 2.80E-04 Schizophrenia / / 19197363 rs789498 chr6 150579911 T C 2.20E-04 Alzheimer's disease / / 22005930 rs11760085 chr6 150591429 T C 5.88E-04 Smoking initiation / / 24665060 rs6934008 chr6 150606182 T G 8.70E-05 White matter hyperintensity burden / / 21681796 rs1556879 chr6 150615876 T C 7.64E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11751092 chr6 150618750 A G 8.10E-05 Cognitive test performance / / 20125193 rs11751092 chr6 150618750 A G 8.29E-05 Prion diseases / / 22210626 rs11751092 chr6 150618750 A G 5.98E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9480192 chr6 150626291 C A,G,T 2.53E-07 Lung adenocarcinoma / / 19836008 rs4870465 chr6 150637115 G A 7.15E-04 Multiple complex diseases / / 17554300 rs1591830 chr6 150651900 G A 1.00E-07 Metabolite levels / / 19043545 rs688015 chr6 150675830 C T 5.14E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs670914 chr6 150682343 G A 3.64E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9397292 chr6 150687358 C T 7.41E-05 Cognitive impairment induced by topiramate / / 22091778 rs660382 chr6 150695460 A G 3.93E-04 Response to statin treatment (atorvastatin),change in cholesterol levels IYD intron 20031582 rs12211677 chr6 150698562 C A 7.31E-04 Response to statin treatment (atorvastatin),change in cholesterol levels IYD intron 20031582 rs12211979 chr6 150698920 G A 4.95E-04 Response to statin treatment (atorvastatin),change in cholesterol levels IYD intron 20031582 rs670292 chr6 150702847 C G 2.00E-06 Anger IYD intron 24489884 rs672605 chr6 150720439 C T 2.41E-04 Response to cytidine analogues (gemcitabine) IYD UTR-3 24483146 rs601223 chr6 150720571 T G 4.83E-04 IgE levels IYD UTR-3 17255346 rs601223 chr6 150720571 T G 2.32E-04 Multiple complex diseases IYD UTR-3 17554300 rs601223 chr6 150720571 T G 5.98E-04 Response to cytidine analogues (gemcitabine) IYD UTR-3 24483146 rs13197942 chr6 150726097 G T 1.34E-06 Alcohol consumption IYD nearGene-3 23953852 rs2008273 chr6 150726746 A G 9.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs2211105 chr6 150727240 G T 4.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs2211105 chr6 150727240 G T 3.74E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1416483 chr6 150728562 G C 9.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs1416483 chr6 150728562 G C 2.62E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs665670 chr6 150734256 T G 0.0008855 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs665670 chr6 150734256 T G 8.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs587968 chr6 150735846 T C 9.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs681442 chr6 150736760 C G 9.83E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4452652 chr6 150763053 A G 9.75E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4452652 chr6 150763053 A G 2.79E-04 Stroke / / pha002886 rs9384533 chr6 150775678 C T 0.00007 Amyotrophic lateral sclerosis / / 23587638 rs9398002 chr6 150785555 T C 0.000035 Amyotrophic lateral sclerosis / / 23587638 rs13208542 chr6 150856770 G C 5.88E-04 Nicotine dependence / / 17158188 rs9372072 chr6 150868815 C G 8.14E-05 Depression (quantitative trait) / / 20800221 rs9372078 chr6 150913961 T A 5.00E-07 Panic disorder / / 19165232 rs1352976 chr6 150950215 G A 5.03E-04 Multiple complex diseases PLEKHG1 intron 17554300 rs9383834 chr6 150957217 T C 8.81E-05 Aging (time to event) PLEKHG1 intron 21782286 rs9478775 chr6 150984290 G A 1.70E-05 Urinary metabolites PLEKHG1 intron 21572414 rs9480526 chr6 151000532 G A 3.25E-04 Schizophrenia PLEKHG1 intron 19197363 rs12663498 chr6 151003840 C T 0.0000128 Coronary artery disease PLEKHG1 intron 23202125 rs17080102 chr6 151004770 G C 2.00E-11 Blood pressure PLEKHG1 intron 23972371 rs17080102 chr6 151004770 G C 5.00E-08 Blood pressure PLEKHG1 intron 23972371 rs4869931 chr6 151009889 A G 8.00E-06 Systolic blood pressure in sickle cell anemia PLEKHG1 intron 24058526 rs654698 chr6 151016738 A G 4.68E-04 Schizophrenia PLEKHG1 intron 19197363 rs10872665 chr6 151018375 A G 3.08E-04 Alzheimer's disease PLEKHG1 intron 17998437 rs6921304 chr6 151018420 C T 1.40E-05 Urinary metabolites PLEKHG1 intron 21572414 rs7776166 chr6 151027008 A G 7.14E-05 Cardiovascular disease PLEKHG1 intron pha003064 rs7772795 chr6 151030107 C T 4.13E-05 Coronary heart disease PLEKHG1 intron pha003031 rs7772795 chr6 151030107 C T 8.71E-05 Triglycerides PLEKHG1 intron pha003080 rs6557088 chr6 151041385 C T 3.49E-04 Smoking initiation PLEKHG1 intron 24665060 rs17080212 chr6 151048123 T C 3.53E-04 Smoking cessation PLEKHG1 intron 24665060 rs7757414 chr6 151072955 A C 1.45E-04 Spine bone size PLEKHG1 intron 23207799 rs9397348 chr6 151077958 G A 9.25E-04 Spine bone size PLEKHG1 intron 23207799 rs7772605 chr6 151084927 G A 6.03E-04 Coronary Artery Disease PLEKHG1 intron 17634449 rs742636 chr6 151096419 C T 8.19E-05 Spine bone size PLEKHG1 intron 23207799 rs75253868 chr6 151102830 T A 2.00E-06 Alzheimer's disease (cognitive decline) PLEKHG1 intron 23535033 rs10046456 chr6 151125251 G T 2.00E-06 Obesity-related traits PLEKHG1 intron 23251661 rs10046456 chr6 151125251 G T 3.00E-06 Obesity-related traits PLEKHG1 intron 23251661 rs10046456 chr6 151125251 G T 3.00E-06 Obesity-related traits PLEKHG1 intron 23251661 rs803413 chr6 151149077 A G 6.87E-04 Multiple complex diseases PLEKHG1 intron 17554300 rs803412 chr6 151151170 C T 4.09E-04 Multiple complex diseases PLEKHG1 intron 17554300 rs17427019 chr6 151156167 G A 1.08E-05 Biliary atresia PLEKHG1 intron 20460270 rs17427389 chr6 151163115 G A 6.45E-06 Alcohol dependence PLEKHG1 UTR-3 20202923 rs17427389 chr6 151163115 G A 7.20E-06 Alcohol dependence PLEKHG1 UTR-3 21956439 rs17427389 chr6 151163115 G A 1.00E-06 Alcohol and nictotine co-dependence PLEKHG1 UTR-3 22488850 rs11757561 chr6 151193451 A G 2.00E-04 Cognitive impairment induced by topiramate MTHFD1L intron 22091778 rs2073066 chr6 151197731 A G 0.00022 Coronary artery calcification MTHFD1L intron 23727086 rs11754661 chr6 151207078 G A 2.00E-10 Alzheimer's disease (late onset) MTHFD1L intron 20885792 rs11754661 chr6 151207078 G A 2.00E-05 Alzheimer's disease (late onset) MTHFD1L intron 21460841 rs17349743 chr6 151213211 T C 8.76E-04 Amyotrophic Lateral Sclerosis MTHFD1L intron 17362836 rs803422 chr6 151215594 A G 1.65E-05 Coronary heart disease MTHFD1L intron pha003031 rs803422 chr6 151215594 A G 6.15E-06 Tunica Media MTHFD1L intron pha003034 rs712210 chr6 151225768 A G 1.98E-04 Multiple complex diseases MTHFD1L intron 17554300 rs712209 chr6 151228071 T C 3.83E-04 Multiple complex diseases MTHFD1L intron 17554300 rs712209 chr6 151228071 T C 1.10E-05 Malaria MTHFD1L intron 19465909 rs9371203 chr6 151241076 A G 3.42E-08 Coronary Artery Disease MTHFD1L intron 17634449 rs2295084 chr6 151243234 C T 2.59E-04 Type 2 diabetes MTHFD1L intron 17463246 rs175854 chr6 151243840 T C 0.000132 Breast cancer MTHFD1L intron 22228098 rs803455 chr6 151247439 A G 3.30E-04 Stroke MTHFD1L intron pha002887 rs803454 chr6 151247694 T C 9.97E-04 Response to cytidine analogues (gemcitabine) MTHFD1L intron 24483146 rs12201472 chr6 151247867 C T 1.13E-05 Multiple complex diseases MTHFD1L intron 17554300 rs4869954 chr6 151250567 T C 8.63E-04 Multiple complex diseases MTHFD1L intron 17554300 rs4869954 chr6 151250567 T C 2.45E-04 Coronary Artery Disease MTHFD1L intron 17634449 rs6922269 chr6 151252985 G A 6.33E-06 Multiple complex diseases MTHFD1L intron 17554300 rs6922269 chr6 151252985 G A 3.00E-08 Coronary heart disease MTHFD1L intron 17634449 rs6922269 chr6 151252985 G A 5.90E-04 Type 2 diabetes and 6 quantitative traits MTHFD1L intron 17848626 rs6922269 chr6 151252985 G A 3.00E-08 Coronary heart disease MTHFD1L intron 21347282 rs6907487 chr6 151252999 T A 5.57E-06 Multiple complex diseases MTHFD1L intron 17554300 rs6907487 chr6 151252999 T A 9.03E-08 Coronary Artery Disease MTHFD1L intron 17634449 rs1474787 chr6 151253382 C T 2.58E-04 Multiple complex diseases MTHFD1L intron 17554300 rs11155760 chr6 151254714 A T 3.45E-04 Multiple complex diseases MTHFD1L intron 17554300 rs6933598 chr6 151259770 C G 0.0000746 Alcohol consumption (Heavy) MTHFD1L intron 23422394 rs12214461 chr6 151260063 G A 8.49E-04 Suicide attempts in bipolar disorder MTHFD1L intron 21423239 rs803447 chr6 151264778 A G 6.52E-04 Multiple complex diseases MTHFD1L intron 17554300 rs803446 chr6 151265214 G A 1.50E-05 Urinary metabolites MTHFD1L intron 21572414 rs1555179 chr6 151271356 G A 0.000013 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 MTHFD1L intron 21873659 rs11155762 chr6 151272796 C T 0.00003 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 MTHFD1L intron 21873659 rs1771798 chr6 151281567 T C 5.83E-07 Corneal structure MTHFD1L intron 22003120 rs501215 chr6 151291193 G T 0.00036 Coronary artery calcification MTHFD1L intron 23727086 rs7752450 chr6 151301951 T C 1.50E-05 Personality dimensions MTHFD1L intron 18957941 rs9371205 chr6 151306916 A G 3.23E-04 Blood pressure MTHFD1L intron 17255346 rs9371205 chr6 151306916 A G 3.30E-05 Personality dimensions MTHFD1L intron 18957941 rs491552 chr6 151311055 C A,G 3.86E-05 Pulmonary function MTHFD1L intron 17903307 rs561060 chr6 151319827 C T 8.86E-05 Angioedema in response to angiotensin-converting enzyme inhibitor MTHFD1L intron 23838604 rs487637 chr6 151339442 C A,G,T 7.02E-04 Type 2 diabetes MTHFD1L intron 17463246 rs17080705 chr6 151340454 C T 1.02E-04 Insulin resistance MTHFD1L intron 21901158 rs9478918 chr6 151358299 T C 4.28E-04 Type 2 diabetes MTHFD1L intron 17463246 rs6914261 chr6 151372383 T C 9.30E-06 Urinary metabolites MTHFD1L intron 21572414 rs9371491 chr6 151373655 A T 2.90E-05 Urinary metabolites MTHFD1L intron 21572414 rs11751336 chr6 151392033 G C 9.03E-04 Suicide attempts in bipolar disorder MTHFD1L intron 21423239 rs6923669 chr6 151392273 A G 1.20E-05 Urinary metabolites MTHFD1L intron 21572414 rs9397032 chr6 151396691 T G 4.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MTHFD1L intron 20877124 rs7769455 chr6 151399471 A G 9.09E-04 Suicide attempts in bipolar disorder MTHFD1L intron 21423239 rs11753585 chr6 151400154 G A 9.50E-04 Suicide attempts in bipolar disorder MTHFD1L intron 21423239 rs9371494 chr6 151403148 G A 9.43E-05 Non-alcoholic fatty liver disease histology (other) MTHFD1L intron 20708005 rs41391451 chr6 151416371 T G 7.14E-04 Type 2 diabetes MTHFD1L intron 17463246 rs2295733 chr6 151422700 T C 1.66E-08 LDL cholesterol MTHFD1L UTR-3 23063622 rs6923696 chr6 151435955 C T 3.96E-04 Amyotrophic Lateral Sclerosis LOC100507662 intron 17362836 rs7771304 chr6 151452358 A C 1.61E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) LOC100507662 intron 24023788 rs9383557 chr6 151462646 T G 4.56E-04 Type 2 diabetes LOC100507662 intron 22158537 rs4869993 chr6 151473330 A G 5.47E-04 Type 2 diabetes LOC100507662 intron 17463246 rs752543 chr6 151501035 G A 1.11E-05 Cognitive performance / / 19734545 rs9478984 chr6 151513858 A G 3.87E-04 Alzheimer's disease (late onset) / / 21379329 rs10457871 chr6 151564453 T C 7.70E-05 Age-related macular degeneration AKAP12 intron 20861866 rs10499266 chr6 151572523 G A 3.03E-05 Eye color AKAP12 intron 23118974 rs7742224 chr6 151577270 A G 4.07E-05 Serum metabolites AKAP12 intron 19043545 rs11966225 chr6 151597937 A G 1.02E-04 Myopia (pathological) AKAP12 intron 21095009 rs6907228 chr6 151606034 C T 3.92E-05 Serum metabolites AKAP12 intron 19043545 rs11757358 chr6 151617185 C T 2.55E-05 Waist-Hip Ratio AKAP12 intron pha003029 rs9322313 chr6 151617320 C T 2.00E-04 Cognitive impairment induced by topiramate AKAP12 intron 22091778 rs926559 chr6 151621492 T C 3.28E-05 Cognitive impairment induced by topiramate AKAP12 intron 22091778 rs12205375 chr6 151641001 G A 2.32E-04 Glycosylated haemoglobin levels AKAP12 intron 17255346 rs2297778 chr6 151645078 A G 9.70E-06 Periodontal disease-related phenotypes AKAP12 intron 24347629 rs113035196 chr6 151649651 G C 0.000684 Breast cancer AKAP12 intron 22228098 rs2626356 chr6 151654269 T C 0.000422 Breast cancer AKAP12 intron 22228098 rs2786746 chr6 151654653 A T 0.000351 Breast cancer AKAP12 intron 22228098 rs2101240 chr6 151655394 A G 0.000457 Breast cancer AKAP12 intron 22228098 rs77354896 chr6 151655623 A G 0.000188 Breast cancer AKAP12 intron 22228098 rs55702615 chr6 151660544 G A 0.000109 Breast cancer AKAP12 intron 22228098 rs2128947 chr6 151661117 A G 0.00018 Breast cancer AKAP12 intron 22228098 rs2128948 chr6 151661141 G A 0.000175 Breast cancer AKAP12 intron 22228098 rs55643577 chr6 151663521 G A 0.000115 Breast cancer AKAP12 intron 22228098 rs900653 chr6 151663560 A G 2.73E-04 Alzheimer's disease (late onset) AKAP12 intron 21379329 rs7776145 chr6 151668244 G A 0.000152 Breast cancer AKAP12 intron 22228098 rs3734799 chr6 151670172 A C 2.42E-04 Amyotrophic Lateral Sclerosis AKAP12 missense 17362836 rs41289369 chr6 151671182 C T 0.000217 Breast cancer AKAP12 cds-synon 22228098 rs13212161 chr6 151672285 A G 9.37E-06 Asthma AKAP12 missense 21790008 rs3734797 chr6 151672812 G A 0.000376 Breast cancer AKAP12 missense 22228098 rs200925112 chr6 151672914 A G 0.00017 Prostate cancer (non-advanced prostate cancer) AKAP12 missense 23555315 rs200925112 chr6 151672914 A G 0.00036 Prostate cancer AKAP12 missense 23555315 rs3734795 chr6 151674593 G T 0.000359 Breast cancer AKAP12 missense 22228098 rs59387598 chr6 151676725 C T 0.000418 Breast cancer AKAP12 intron 22228098 rs3734794 chr6 151677358 C T 0.00042 Breast cancer AKAP12 UTR-3 22228098 rs41289379 chr6 151678063 C T 0.000421 Breast cancer AKAP12 UTR-3 22228098 rs4870013 chr6 151682362 C T 0.000515 Breast cancer / / 22228098 rs6557134 chr6 151716522 T C 6.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9371518 chr6 151740967 T C 5.09E-04 Multiple complex diseases RMND1 intron 17554300 rs3800277 chr6 151765356 G T 5.30E-04 Multiple complex diseases RMND1 intron 17554300 rs3800278 chr6 151765511 G T 8.40E-04 Multiple complex diseases RMND1 intron 17554300 rs17081262 chr6 151776164 G T 1.90E-05 Urinary metabolites C6orf211 intron 21572414 rs6937816 chr6 151794704 T C 7.87E-04 Stroke / / pha002887 rs9371522 chr6 151808248 A G 0.000605 Breast cancer / / 22228098 rs1971255 chr6 151816094 G A 4.52E-04 Multiple complex diseases C6orf97 intron 17554300 rs4869732 chr6 151822015 C T 0.000216 Breast cancer C6orf97 intron 22228098 rs1482061 chr6 151823813 C T 0.000248 Breast cancer C6orf97 intron 22228098 rs12173791 chr6 151824449 G A 2.12E-05 Suicide attempts in depression or bipolar disorder C6orf97 intron 24964207 rs4870024 chr6 151830769 T C 7.31E-05 Menarche (age at onset) C6orf97 intron 21102462 rs143390228 chr6 151835532 A G 0.00021 Breast cancer C6orf97 intron 22228098 rs57521493 chr6 151838856 C T 0.000401 Breast cancer C6orf97 intron 22228098 rs75318086 chr6 151839433 T A 0.000279 Breast cancer C6orf97 intron 22228098 rs79699315 chr6 151840638 G C 0.000251 Breast cancer C6orf97 intron 22228098 rs9397422 chr6 151840684 G A 1.45E-05 Menarche (age at onset) C6orf97 intron 21102462 rs954238 chr6 151844443 T A 1.43E-04 Menarche (age at onset) C6orf97 intron 21102462 rs77942641 chr6 151845594 A T 0.000231 Breast cancer C6orf97 intron 22228098 rs9383917 chr6 151846821 C T 0.000782 Breast cancer C6orf97 intron 22228098 rs9371531 chr6 151847849 A T 0.000814 Breast cancer C6orf97 intron 22228098 rs9479055 chr6 151847967 C A 1.40E-07 Bone mineral density (spine) C6orf97 intron 19079262 rs9479055 chr6 151847967 C A 6.85E-05 Menarche (age at onset) C6orf97 intron 21102462 rs35324372 chr6 151848066 G A 0.000811 Breast cancer C6orf97 intron 22228098 rs6919923 chr6 151849670 T C 5.26E-05 Menarche (age at onset) C6orf97 intron 21102462 rs4870032 chr6 151849927 C T 0.000717 Breast cancer C6orf97 intron 22228098 rs6900089 chr6 151851124 C A 7.70E-06 Urinary metabolites C6orf97 intron 21572414 rs11155795 chr6 151851339 G A 3.71E-05 Menarche (age at onset) C6orf97 intron 21102462 rs11753987 chr6 151851428 T C 4.87E-05 Menarche (age at onset) C6orf97 intron 21102462 rs17054385 chr6 151854094 C T 0.000717 Breast cancer C6orf97 intron 22228098 rs10872673 chr6 151855593 G T 4.30E-05 Menarche (age at onset) C6orf97 intron 21102462 rs1532401 chr6 151857370 T C 3.88E-06 Menarche (age at onset) C6orf97 intron 21102462 rs6931664 chr6 151857594 A G 3.40E-08 Bone mineral density (spine) C6orf97 intron 19801982 rs6931664 chr6 151857594 A G 1.12E-04 Menarche (age at onset) C6orf97 intron 21102462 rs9371220 chr6 151858598 C T 0.000695 Breast cancer C6orf97 intron 22228098 rs17824408 chr6 151859855 C G 1.62E-04 Menarche (age at onset) C6orf97 intron 21102462 rs1856859 chr6 151860110 T G 0.000646 Breast cancer C6orf97 intron 22228098 rs4463269 chr6 151862228 T C 2.23E-06 Menarche (age at onset) C6orf97 intron 21102462 rs3757317 chr6 151865531 C T 1.36E-04 Menarche (age at onset) C6orf97 intron 21102462 rs1023939 chr6 151868129 G A 1.17E-05 Menarche (age at onset) C6orf97 intron 21102462 rs9371534 chr6 151868736 G A 3.80E-05 Menarche (age at onset) C6orf97 intron 21102462 rs9371535 chr6 151868741 G A 3.21E-06 Menarche (age at onset) C6orf97 intron 21102462 rs9383922 chr6 151868790 C T 2.20E-06 Menarche (age at onset) C6orf97 intron 21102462 rs9371536 chr6 151868835 G A 3.47E-06 Menarche (age at onset) C6orf97 intron 21102462 rs3734803 chr6 151869645 G A 8.38E-05 Menarche (age at onset) C6orf97 intron 21102462 rs6557147 chr6 151870109 T C 1.72E-05 Menarche (age at onset) C6orf97 intron 21102462 rs1496108 chr6 151871019 G A 2.84E-06 Menarche (age at onset) C6orf97 intron 21102462 rs4870039 chr6 151871528 G C 2.97E-06 Menarche (age at onset) C6orf97 intron 21102462 rs4870040 chr6 151872090 T C 0.000627 Breast cancer C6orf97 intron 22228098 rs4870041 chr6 151872324 G A 0.000627 Breast cancer C6orf97 intron 22228098 rs9479068 chr6 151872448 G T 1.45E-04 Menarche (age at onset) C6orf97 intron 21102462 rs9479068 chr6 151872448 G T 1.10E-08 Bone mineral density (spine) C6orf97 intron 19801982 rs9371537 chr6 151872500 T C 0.000627 Breast cancer C6orf97 intron 22228098 rs7761420 chr6 151872567 C T 1.20E-08 Bone mineral density (spine) C6orf97 intron 19801982 rs7761420 chr6 151872567 C T 1.45E-04 Menarche (age at onset) C6orf97 intron 21102462 rs9397424 chr6 151872791 C T 0.000627 Breast cancer C6orf97 intron 22228098 rs9371538 chr6 151872963 A T 0.000634 Breast cancer C6orf97 intron 22228098 rs9397425 chr6 151873024 G T 0.000588 Breast cancer C6orf97 intron 22228098 rs9383581 chr6 151873358 C T 0.000679 Breast cancer C6orf97 intron 22228098 rs13213582 chr6 151873896 C T 0.00068 Breast cancer C6orf97 intron 22228098 rs9397427 chr6 151875034 A G 0.000336 Breast cancer C6orf97 intron 22228098 rs9383924 chr6 151875067 G A 0.000335 Breast cancer C6orf97 intron 22228098 rs9397428 chr6 151875080 T G 0.000285 Breast cancer C6orf97 intron 22228098 rs11759804 chr6 151875122 C T 0.000302 Breast cancer C6orf97 intron 22228098 rs35183457 chr6 151876044 C T 0.000336 Breast cancer C6orf97 intron 22228098 rs66775662 chr6 151876216 A C 0.000345 Breast cancer C6orf97 intron 22228098 rs71549128 chr6 151876256 G A 0.000248 Breast cancer C6orf97 intron 22228098 rs71549129 chr6 151876260 A G 0.000265 Breast cancer C6orf97 intron 22228098 rs28517362 chr6 151876387 G A 0.000339 Breast cancer C6orf97 intron 22228098 rs35106185 chr6 151876486 G A 0.000338 Breast cancer C6orf97 intron 22228098 rs35564624 chr6 151876494 T G 0.000338 Breast cancer C6orf97 intron 22228098 rs35025342 chr6 151876661 A G 0.000338 Breast cancer C6orf97 intron 22228098 rs67445790 chr6 151876730 T C 0.000338 Breast cancer C6orf97 intron 22228098 rs7753676 chr6 151876815 G A 9.40E-07 Bone mineral density (spine) C6orf97 intron 19079262 rs7753676 chr6 151876815 G A 1.50E-08 Bone mineral density (spine) C6orf97 intron 19801982 rs7753676 chr6 151876815 G A 1.61E-04 Menarche (age at onset) C6orf97 intron 21102462 rs975459 chr6 151876909 T C 0.000337 Breast cancer C6orf97 intron 22228098 rs9397429 chr6 151877569 G A 0.000315 Breast cancer C6orf97 intron 22228098 rs6904133 chr6 151881805 G T 0.00045 Breast cancer C6orf97 intron 22228098 rs9397431 chr6 151883930 C T 0.000322 Breast cancer C6orf97 intron 22228098 rs9371221 chr6 151885986 C A 0.000307 Breast cancer C6orf97 intron 22228098 rs958283 chr6 151887150 G A 0.000309 Breast cancer C6orf97 intron 22228098 rs4870042 chr6 151888053 G C 0.000342 Breast cancer C6orf97 intron 22228098 rs1340873 chr6 151890603 A T 0.000224 Breast cancer C6orf97 intron 22228098 rs9479072 chr6 151890789 C T 4.20E-08 Bone mineral density (spine) C6orf97 intron 19801982 rs9479072 chr6 151890789 C T 2.97E-04 Menarche (age at onset) C6orf97 intron 21102462 rs4869737 chr6 151892135 C T 1.91E-05 Menarche (age at onset) C6orf97 intron 21102462 rs4391273 chr6 151893073 T G 0.000772 Breast cancer C6orf97 intron 22228098 rs7741872 chr6 151893946 C G 0.000068 Breast cancer C6orf97 intron 22228098 rs6909279 chr6 151895456 G C 1.80E-08 Bone mineral density (spine) C6orf97 intron 19801982 rs6909279 chr6 151895456 G C 2.01E-04 Menarche (age at onset) C6orf97 intron 21102462 rs6909279 chr6 151895456 G C 1.00E-09 Bone mineral density C6orf97 intron 23437003 rs12197879 chr6 151895777 C T 1.90E-08 Bone mineral density (spine) C6orf97 intron 19801982 rs12197879 chr6 151895777 C T 2.50E-04 Menarche (age at onset) C6orf97 intron 21102462 rs9479075 chr6 151896235 G A 7.20E-09 Bone mineral density (spine) C6orf97 intron 19801982 rs9383928 chr6 151896937 A G 0.000029 Breast cancer C6orf97 intron 22228098 rs6916452 chr6 151897046 T C 9.10E-04 Type 2 diabetes and 6 quantitative traits C6orf97 intron 17848626 rs1871859 chr6 151898506 C T 0.00024 Breast cancer C6orf97 intron 22228098 rs1871859 chr6 151898506 C T 1.27E-10 Bone mineral density C6orf97 intron 24249740 rs1871859 chr6 151898506 C T 2.15E-04 Bone mineral density C6orf97 intron 24249740 rs1871859 chr6 151898506 C T 9.00E-13 Bone mineral density C6orf97 intron 24249740 rs7749563 chr6 151900657 G C 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) C6orf97 intron 17982456 rs7749563 chr6 151900657 G C 0.000034 Breast cancer C6orf97 intron 22228098 rs11155797 chr6 151901337 C T 1.50E-09 Bone mineral density (spine) C6orf97 intron 19801982 rs11155797 chr6 151901337 C T 1.34E-04 Menarche (age at onset) C6orf97 intron 21102462 rs4870044 chr6 151901409 C T 2.00E-07 Bone mineral density (hip) C6orf97 intron 18445777 rs4870044 chr6 151901409 C T 2.00E-11 Bone mineral density (spine) C6orf97 intron 18445777 rs4870044 chr6 151901409 C T 6.60E-13 Bone mineral density (spine) C6orf97 intron 19079262 rs4870044 chr6 151901409 C T 7.00E-09 Bone mineral density (spine) C6orf97 intron 19801982 rs4870044 chr6 151901409 C T 4.00E-06 Bone mineral density C6orf97 intron 21927923 rs4870044 chr6 151901409 C T 0.0000102 Femoral neck bone mineral density (premenopausal) C6orf97 intron 23074152 rs4870044 chr6 151901409 C T 1.40E-10 Lumbar spine bone mineral density (premenopausal) C6orf97 intron 23074152 rs4869739 chr6 151901802 A T 7.40E-09 Bone mineral density (spine) C6orf97 intron 19801982 rs4869739 chr6 151901802 A T 1.93E-09 Bone properties (heel) C6orf97 intron 24430505 rs4869739 chr6 151901802 A T 3.00E-18 Bone properties (heel) C6orf97 intron 24430505 rs4869741 chr6 151906293 T C 1.30E-08 Bone mineral density (spine) C6orf97 intron 19801982 rs4869742 chr6 151907748 C T 1.50E-08 Bone mineral density (spine) C6orf97 intron 19801982 rs4869742 chr6 151907748 C T 2.00E-06 Chronic myeloid leukemia C6orf97 intron 21540461 rs4869742 chr6 151907748 C T 4.00E-35 Bone mineral density C6orf97 intron 22504420 rs4869742 chr6 151907748 C T 0.000381 Femoral neck bone mineral density (premenopausal) C6orf97 intron 23074152 rs4869742 chr6 151907748 C T 1.37E-08 Lumbar spine bone mineral density (premenopausal) C6orf97 intron 23074152 rs4869742 chr6 151907748 C T 3.71E-04 Bone mineral density C6orf97 intron 24249740 rs4869742 chr6 151907748 C T 4.05E-07 Bone mineral density C6orf97 intron 24249740 rs4869742 chr6 151907748 C T 7.31E-07 Bone mineral density C6orf97 intron 24249740 rs9383929 chr6 151911872 T A 1.40E-09 Bone mineral density (spine) C6orf97 intron 19801982 rs3757318 chr6 151914113 G A 2.04E-04 Multiple complex diseases C6orf97 intron 17554300 rs3757318 chr6 151914113 G A 3.00E-06 Breast cancer C6orf97 intron 20453838 rs3757318 chr6 151914113 G A 2.00E-21 Breast cancer C6orf97 intron 23535729 rs3757318 chr6 151914113 G A 2.50E-11 Breast cancer C6orf97 intron 23535733 rs3757318 chr6 151914113 G A 9.00E-06 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) C6orf97 intron 24325915 rs9397064 chr6 151914951 T C 0.000019 Breast cancer C6orf97 intron 22228098 rs9397432 chr6 151916855 G C 0.0000037 Breast cancer C6orf97 intron 22228098 rs4524618 chr6 151918023 G A 0.0000037 Breast cancer C6orf97 intron 22228098 rs9397433 chr6 151919432 C A 0.000129 Breast cancer C6orf97 intron 22228098 rs9383934 chr6 151921337 A T 9.81E-04 Coronary heart disease C6orf97 intron 21606135 rs12055593 chr6 151922654 G A 0.0000047 Breast cancer C6orf97 intron 22228098 rs144381984 chr6 151922654 G GGT 0.0000047 Breast cancer C6orf97 intron 22228098 rs4304175 chr6 151923982 T C 0.000026 Breast cancer C6orf97 intron 22228098 rs11155799 chr6 151927268 T C 0.000072 Breast cancer C6orf97 intron 22228098 rs6557158 chr6 151929942 A G 0.000026 Breast cancer C6orf97 intron 22228098 rs1023940 chr6 151932778 A G 5.80E-10 Bone mineral density (spine) C6orf97 intron 19801982 rs1038304 chr6 151933175 A G 4.00E-11 Bone mineral density (spine) C6orf97 intron 18445777 rs1038304 chr6 151933175 A G 5.00E-09 Bone mineral density (hip) C6orf97 intron 18445777 rs1038304 chr6 151933175 A G 4.00E-10 Bone mineral density (hip) C6orf97 intron 19079262 rs1038304 chr6 151933175 A G 1.90E-09 Bone mineral density (spine) C6orf97 intron 19801982 rs1038304 chr6 151933175 A G 1.03E-04 Breast cancer C6orf97 intron 20852631 rs6929137 chr6 151936677 G A 2.00E-10 Bone mineral density (spine) C6orf97 missense 19079262 rs6929137 chr6 151936677 G A 1.30E-08 Bone mineral density (spine) C6orf97 missense 19801982 rs79692348 chr6 151937679 C T 0.0000021 Breast cancer C6orf97 intron 22228098 rs3734804 chr6 151939181 G A 5.30E-10 Bone mineral density (spine) C6orf97 missense 19801982 rs3734805 chr6 151939350 A C 1.00E-07 Breast cancer C6orf97 UTR-3 21263130 rs6932260 chr6 151939560 T C 4.80E-10 Bone mineral density (spine) C6orf97 UTR-3 19801982 rs6932603 chr6 151939770 T C 2.50E-10 Bone mineral density (spine) C6orf97 UTR-3 19801982 rs9383935 chr6 151939848 C T 3.40E-04 Coronary heart disease C6orf97 UTR-3 21606135 rs3734806 chr6 151941461 G A 1.70E-08 Bone mineral density (spine) C6orf97 UTR-3 19801982 rs3757322 chr6 151942194 T G 1.40E-08 Bone mineral density (spine) C6orf97 UTR-3 19801982 rs72501739 chr6 151943302 C G 0.0000023 Breast cancer / / 22228098 rs4591859 chr6 151943639 T C 4.90E-10 Bone mineral density (spine) / / 19801982 rs4591859 chr6 151943639 T C 8.60E-09 Breast cancer / / 22383897 rs10872676 chr6 151943977 C T 4.40E-10 Bone mineral density (spine) / / 19801982 rs7776340 chr6 151945666 C T 3.50E-10 Bone mineral density (spine) / / 19801982 rs7776340 chr6 151945666 C T 1.40E-08 Breast cancer / / 22383897 rs12665607 chr6 151946629 T A 2.05E-04 Coronary heart disease / / 21606135 rs7751941 chr6 151946658 G A 1.30E-07 Bone mineral density (spine) / / 19079262 rs7751941 chr6 151946658 G A 3.00E-09 Bone mineral density / / 23437003 rs7752591 chr6 151947068 G A 5.50E-07 Bone mineral density (spine) / / 19079262 rs7752591 chr6 151947068 G A 2.70E-10 Bone mineral density (spine) / / 19801982 rs7752591 chr6 151947068 G A 2.00E-06 Bone mineral density / / 21927923 rs7740686 chr6 151948173 A T 1.10E-08 Bone mineral density (spine) / / 19801982 rs2046210 chr6 151948366 G A 2.00E-15 Breast cancer / / 19219042 rs2046210 chr6 151948366 G A 3.80E-08 Bone mineral density (spine) / / 19801982 rs2046210 chr6 151948366 G A 2.00E-15 Nasopharyngeal carcinoma / / 20512145 rs2046210 chr6 151948366 G A 2.00E-19 Breast cancer / / 23535729 rs2046210 chr6 151948366 G A 5.00E-16 Breast cancer / / 23535733 rs2046210 chr6 151948366 G A 5.00E-09 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs2046210 chr6 151948366 G A 5.26E-05 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) / / 24325915 rs7763637 chr6 151949312 G A 1.00E-08 Bone mineral density (spine) / / 19801982 rs6557160 chr6 151949582 A C 1.00E-08 Bone mineral density (spine) / / 19801982 rs6913578 chr6 151949806 A C 2.00E-08 Bone mineral density (spine) / / 19801982 rs9397436 chr6 151952002 A G 3.46E-04 Coronary heart disease / / 21606135 rs6908732 chr6 151952890 G A 3.41E-04 Schizophrenia / / 20832056 rs6900157 chr6 151954127 T C 2.20E-09 Bone mineral density (spine) / / 19079262 rs4242278 chr6 151957612 A G 9.29E-04 Stroke (pediatric) / / 22990015 rs12173570 chr6 151957714 C T 6.00E-11 Breast size / / 22747683 rs6930633 chr6 151958091 A G 1.70E-08 Bone mineral density (spine) / / 19801982 rs6930633 chr6 151958091 A G 8.90E-11 Lumbar spine bone mineral density (premenopausal) / / 23074152 rs12197785 chr6 151960605 C G 4.10E-08 Bone mineral density (spine) / / 19801982 rs851974 chr6 151971687 G A 0.0000937 Oxaliplatin induced nausea/vomiting in response to colorectal cancer treatment / / 22310351 rs10484919 chr6 151974422 C T 5.70E-06 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) / / 24325915 rs78841457 chr6 151974492 G A 0.0000081 Breast cancer / / 22228098 rs78177662 chr6 151975565 C T 0.000006 Breast cancer / / 22228098 rs74728399 chr6 151977268 A G 0.0000067 Breast cancer / / 22228098 rs712219 chr6 151978439 T C 2.20E-07 Bone mineral density (spine) / / 19079262 rs59623026 chr6 151978964 A G 0.0000067 Breast cancer / / 22228098 rs17081551 chr6 151980730 T C 0.0000075 Breast cancer / / 22228098 rs60220348 chr6 151981844 T C 0.0000074 Breast cancer / / 22228098 rs58374672 chr6 151982681 T A 0.0000097 Breast cancer / / 22228098 rs77315705 chr6 151982879 C T 0.0000096 Breast cancer / / 22228098 rs77758681 chr6 151983383 C A 0.0000096 Breast cancer / / 22228098 rs9383938 chr6 151987357 G T 2.00E-10 Breast cancer / / 22976474 rs61176871 chr6 151990488 G A 0.000026 Breast cancer / / 22228098 rs75770678 chr6 151991750 G C 0.000027 Breast cancer / / 22228098 rs9479093 chr6 151992984 A G 0.000018 Breast cancer / / 22228098 rs77668774 chr6 151993715 A G 0.000016 Breast cancer / / 22228098 rs74431386 chr6 151993723 C T 0.000015 Breast cancer / / 22228098 rs146376469 chr6 151999415 C T 0.000018 Breast cancer / / 22228098 rs851993 chr6 152006011 G A 4.10E-05 Bone mineral density (spine) / / 19079262 rs3020331 chr6 152008780 C T 3.50E-09 Bone mineral density (spine) / / 19079262 rs3020331 chr6 152008780 C T 2.80E-09 Bone mineral density (spine) / / 19801982 rs3020331 chr6 152008780 C T 8.00E-06 Bone mineral density / / 21927923 rs3020331 chr6 152008780 C T 0.000557 Breast cancer / / 22228098 rs3020331 chr6 152008780 C T 2.91E-09 Bone properties (heel) / / 24430505 rs3020331 chr6 152008780 C T 3.00E-09 Bone properties (heel) / / 24430505 rs3020331 chr6 152008780 C T 6.64E-15 Bone properties (heel) / / 24430505 rs3020331 chr6 152008780 C T 7.00E-15 Bone properties (heel) / / 24430505 rs3020332 chr6 152008924 C T 2.80E-09 Bone mineral density (spine) / / 19801982 rs2941741 chr6 152008982 G A 2.10E-09 Bone mineral density (spine) / / 19801982 rs2941741 chr6 152008982 G A 0.000681 Breast cancer / / 22228098 rs2941740 chr6 152009638 A G 2.00E-10 Bone mineral density (hip) ESR1 nearGene-5 19801982 rs2941740 chr6 152009638 A G 0.000481 Breast cancer ESR1 nearGene-5 22228098 rs2941740 chr6 152009638 A G 0.00085 Breast cancer ESR1 nearGene-5 23555315 rs3020333 chr6 152010254 A G 2.90E-09 Bone mineral density (spine) ESR1 nearGene-5 19801982 rs2982573 chr6 152010534 T C 2.30E-09 Bone mineral density (spine) ESR1 nearGene-5 19801982 rs2982573 chr6 152010534 T C 0.000479 Breast cancer ESR1 nearGene-5 22228098 rs2982572 chr6 152010561 C T 0.000476 Breast cancer ESR1 nearGene-5 22228098 rs2982571 chr6 152012739 A T 3.90E-09 Bone mineral density (spine) ESR1 intron 19801982 rs2982571 chr6 152012739 A T 0.000808 Breast cancer ESR1 intron 22228098 rs3020334 chr6 152012956 A G 3.50E-09 Bone mineral density (spine) ESR1 intron 19801982 rs3020334 chr6 152012956 A G 0.000808 Breast cancer ESR1 intron 22228098 rs2941742 chr6 152012988 A G 0.000812 Breast cancer ESR1 intron 22228098 rs3020335 chr6 152013223 G T 3.30E-09 Bone mineral density (spine) ESR1 intron 19801982 rs3020335 chr6 152013223 G T 0.000806 Breast cancer ESR1 intron 22228098 rs2982570 chr6 152013748 C T 3.10E-09 Bone mineral density (spine) ESR1 intron 19801982 rs2982570 chr6 152013748 C T 0.000869 Breast cancer ESR1 intron 22228098 rs3020336 chr6 152013760 G T 0.000832 Breast cancer ESR1 intron 22228098 rs1293936 chr6 152017691 T G 3.60E-08 Bone mineral density (spine) ESR1 intron 19801982 rs1293935 chr6 152017958 C G 0.000562 Breast cancer ESR1 intron 22228098 rs851985 chr6 152020390 A C,G,T 0.000054 Breast cancer ESR1 intron 22228098 rs851984 chr6 152023191 G A 0.000072 Breast cancer ESR1 intron 22228098 rs851983 chr6 152024415 A G 0.000046 Breast cancer ESR1 intron 22228098 rs851982 chr6 152024985 T C 1.30E-08 Bone mineral density (spine) ESR1 intron 19079262 rs851982 chr6 152024985 T C 0.000089 Breast cancer ESR1 intron 22228098 rs9383591 chr6 152027012 G C 0.000011 Breast cancer ESR1 intron 22228098 rs851980 chr6 152027955 T C 2.93E-04 Coronary Artery Disease ESR1 intron 17634449 rs8180576 chr6 152035710 C A 0.000015 Breast cancer ESR1 intron 22228098 rs12525163 chr6 152040291 T C 9.80E-06 Endometriosis ESR1 intron 21151130 rs12525163 chr6 152040291 T C 0.00087 Breast cancer ESR1 intron 23555315 rs1159327 chr6 152048022 C T 2.00E-05 Endometriosis ESR1 intron 21151130 rs2982565 chr6 152051854 G A 1.80E-04 Coronary Artery Disease ESR1 intron 17634449 rs6899458 chr6 152052043 G A 8.62E-04 Type 2 diabetes ESR1 intron 17463246 rs6899458 chr6 152052043 G A 1.60E-04 Coronary Artery Disease ESR1 intron 17634449 rs2982562 chr6 152052601 C T 5.80E-09 Bone mineral density (spine) ESR1 intron 19801982 rs2982561 chr6 152052652 C T 8.90E-09 Bone mineral density (spine) ESR1 intron 19801982 rs3020343 chr6 152054363 C T 4.80E-09 Bone mineral density (spine) ESR1 intron 19801982 rs3020343 chr6 152054363 C T 9.60E-05 Endometriosis ESR1 intron 21151130 rs2982560 chr6 152055606 A T 4.30E-09 Bone mineral density (spine) ESR1 intron 19801982 rs2982558 chr6 152056146 A G 7.00E-09 Bone mineral density (spine) ESR1 intron 19801982 rs201941147 chr6 152056369 G GA 3.10E-09 Bone mineral density (spine) ESR1 intron 19801982 rs2982557 chr6 152056369 G A 3.10E-09 Bone mineral density (spine) ESR1 intron 19801982 rs2982556 chr6 152056842 G A 5.00E-09 Bone mineral density (spine) ESR1 intron 19801982 rs3020348 chr6 152057914 C A 2.00E-08 Bone mineral density (spine) ESR1 intron 19801982 rs3020348 chr6 152057914 C A 7.50E-05 Endometriosis ESR1 intron 21151130 rs2982554 chr6 152058010 A C 4.80E-09 Bone mineral density (spine) ESR1 intron 19801982 rs3020349 chr6 152058268 C A 5.50E-09 Bone mineral density (spine) ESR1 intron 19801982 rs3020300 chr6 152058844 T A 8.00E-09 Bone mineral density (spine) ESR1 intron 19801982 rs2982552 chr6 152059563 G A 1.50E-09 Bone mineral density (spine) ESR1 intron 19801982 rs2982552 chr6 152059563 G A 1.21E-04 Bone properties (heel) ESR1 intron 24430505 rs2982552 chr6 152059563 G A 2.00E-10 Bone properties (heel) ESR1 intron 24430505 rs2982552 chr6 152059563 G A 7.32E-16 Bone properties (heel) ESR1 intron 24430505 rs2982551 chr6 152061210 G T 2.10E-09 Bone mineral density (spine) ESR1 intron 19801982 rs2982551 chr6 152061210 G T 0.000565 Breast cancer ESR1 intron 22228098 rs2982550 chr6 152061474 G T 0.000623 Breast cancer ESR1 intron 22228098 rs3020301 chr6 152061579 T C 2.00E-09 Bone mineral density (spine) ESR1 intron 19801982 rs3020301 chr6 152061579 T C 0.000569 Breast cancer ESR1 intron 22228098 rs1415194 chr6 152063998 A G 5.00E-10 Bone mineral density (spine) ESR1 intron 19801982 rs1999807 chr6 152064199 C G 5.20E-10 Bone mineral density (spine) ESR1 intron 19801982 rs3020304 chr6 152064464 C T 1.70E-09 Bone mineral density (spine) ESR1 intron 19801982 rs3020306 chr6 152065886 C T 4.80E-10 Bone mineral density (spine) ESR1 intron 19801982 rs3020307 chr6 152067244 A C 5.40E-10 Bone mineral density (spine) ESR1 intron 19801982 rs9397445 chr6 152067500 T C 0.000124 Breast cancer ESR1 intron 22228098 rs1856057 chr6 152067869 A G 3.30E-10 Bone mineral density (spine) ESR1 intron 19801982 rs1999805 chr6 152068364 G A 2.00E-08 Bone mineral density (spine) ESR1 intron 18445777 rs1999805 chr6 152068364 G A 3.90E-09 Bone mineral density (spine) ESR1 intron 19079262 rs1999805 chr6 152068364 G A 3.40E-10 Bone mineral density (spine) ESR1 intron 19801982 rs1999805 chr6 152068364 G A 0.00041 Breast cancer ESR1 intron 23555315 rs3020308 chr6 152068685 A G 3.70E-10 Bone mineral density (spine) ESR1 intron 19801982 rs2982575 chr6 152069791 A G 8.00E-10 Bone mineral density (spine) ESR1 intron 19801982 rs2982575 chr6 152069791 A G 0.000000046 Lumbar spine bone mineral density (premenopausal) ESR1 intron 23074152 rs2982575 chr6 152069791 A G 0.00036 Femoral neck bone mineral density (premenopausal) ESR1 intron 23074152 rs2152750 chr6 152070145 T C 3.20E-10 Bone mineral density (spine) ESR1 intron 19801982 rs9322330 chr6 152073318 G A 0.000239 Breast cancer ESR1 intron 22228098 rs2982567 chr6 152075487 G A 2.90E-10 Bone mineral density (spine) ESR1 intron 19801982 rs11155811 chr6 152077846 C T 7.40E-10 Bone mineral density (spine) ESR1 intron 19801982 rs11155812 chr6 152077895 C T 0.000709 Breast cancer ESR1 intron 22228098 rs4644077 chr6 152080665 A T 0.000849 Breast cancer ESR1 intron 22228098 rs1124674 chr6 152080735 T G 1.00E-10 Bone mineral density (spine) ESR1 intron 19801982 rs60945108 chr6 152080832 C T 3.00E-06 Obesity-related traits ESR1 intron 23251661 rs1336981 chr6 152082369 C T 1.00E-08 Bone mineral density (spine) ESR1 intron 19801982 rs9371551 chr6 152082646 G A 0.000655 Breast cancer ESR1 intron 22228098 rs9371551 chr6 152082646 G A 6.45E-04 Smoking cessation ESR1 intron 24665060 rs73780860 chr6 152082681 T C 3.09E-06 Obesity-related traits ESR1 intron 23251661 rs9479107 chr6 152082973 T A 0.000787 Breast cancer ESR1 intron 22228098 rs2504071 chr6 152084862 T C 1.50E-10 Bone mineral density (spine) ESR1 intron 19801982 rs1890010 chr6 152085275 C T 1.10E-08 Bone mineral density (spine) ESR1 intron 19801982 rs2504069 chr6 152085517 C T 1.10E-08 Bone mineral density (spine) ESR1 intron 19801982 rs118028050 chr6 152087345 G A 0.000075 Breast cancer ESR1 intron 22228098 rs2504063 chr6 152090707 A G 1.50E-08 Bone mineral density (spine) ESR1 intron 19079262 rs2504063 chr6 152090707 A G 6.00E-11 Bone mineral density (spine) ESR1 intron 19801982 rs2504063 chr6 152090707 A G 5.60E-08 Bone mineral density ESR1 intron 21927923 rs1415193 chr6 152092638 T A 3.50E-09 Bone mineral density (spine) ESR1 intron 19801982 rs2504065 chr6 152095167 G A 3.10E-07 Bone mineral density (spine) ESR1 intron 19079262 rs543650 chr6 152110943 T G 1.00E-17 Height ESR1 intron 20881960 rs79994281 chr6 152123593 C A 0.000244 Breast cancer ESR1 intron 22228098 rs488133 chr6 152125444 T C 1.20E-10 Height ESR1 intron 21194676 rs488133 chr6 152125444 T C 1.50E-04 Height ESR1 intron 21194676 rs488133 chr6 152125444 T C 3.40E-06 Height ESR1 intron 21194676 rs867239 chr6 152128631 C G 0.000568 Breast cancer ESR1 UTR-5 22228098 rs6914438 chr6 152129588 C T 0.000213 Breast cancer ESR1 intron 22228098 rs532010 chr6 152130918 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) ESR1 intron 20708005 rs12660738 chr6 152131121 A G 0.000356 Breast cancer ESR1 intron 22228098 rs6920483 chr6 152131321 G A 0.000625 Breast cancer ESR1 intron 22228098 rs3778609 chr6 152133187 C T 0.000158 Breast cancer ESR1 intron 22228098 rs3778610 chr6 152133351 A G 0.000514 Breast cancer ESR1 intron 22228098 rs13362642 chr6 152137404 A G 0.000664 Breast cancer ESR1 intron 22228098 rs9479121 chr6 152140867 C T 0.000739 Breast cancer ESR1 intron 22228098 rs9479122 chr6 152140940 G A 0.000704 Breast cancer ESR1 intron 22228098 rs12523770 chr6 152141622 C T 0.000266 Breast cancer ESR1 intron 22228098 rs12523805 chr6 152141657 G T 0.000702 Breast cancer ESR1 intron 22228098 rs7771894 chr6 152145916 C T 0.000142 Breast cancer ESR1 intron 22228098 rs9479126 chr6 152146580 T C 0.000473 Breast cancer ESR1 intron 22228098 rs7753153 chr6 152148098 G A 3.53E-05 Intelligence ESR1 intron 21826061 rs17081740 chr6 152149667 T C 2.27E-04 Multiple complex diseases ESR1 intron 17554300 rs12527007 chr6 152151196 A G 0.000453 Breast cancer ESR1 intron 22228098 rs6909023 chr6 152153697 G A 2.45E-05 vWF levels,in plasma ESR1 intron 21534939 rs6937568 chr6 152153964 T C 2.20E-05 vWF levels,in plasma ESR1 intron 21534939 rs28457010 chr6 152155126 C T 0.000456 Breast cancer ESR1 intron 22228098 rs6902771 chr6 152157881 C T 8.00E-06 Alcohol dependence ESR1 intron 19581569 rs3853251 chr6 152160756 A G 2.29E-04 Self-reported allergy ESR1 intron 23817569 rs9322331 chr6 152162317 C T 2.01E-04 Self-reported allergy ESR1 intron 23817569 rs2234693 chr6 152163335 T C 1.92E-04 Smoking initiation ESR1 intron 24665060 rs9340799 chr6 152163381 A G 1 Drug response to Tamoxifen ESR1 intron 17713466 rs9340799 chr6 152163381 A G 2.77E-04 Self-reported allergy ESR1 intron 23817569 rs3936674 chr6 152167311 G A 2.07E-04 Self-reported allergy ESR1 intron 23817569 rs9322336 chr6 152200430 C T 2.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ESR1 intron 20877124 rs11155820 chr6 152204210 A G 7.13E-04 Multiple complex diseases ESR1 intron 17554300 rs2347867 chr6 152229850 G A 3.14E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) ESR1 intron 23648065 rs9397453 chr6 152236879 G A 1.53E-14 Multiple complex diseases ESR1 intron 17554300 rs9340907 chr6 152271978 G T 1.34E-08 LDL cholesterol ESR1 intron 23063622 rs9340907 chr6 152271978 G T 7.56E-08 Cholesterol,total ESR1 intron 23063622 rs2982694 chr6 152285687 G T 7.00E-10 Sudden cardiac arrest ESR1 intron 21658281 rs9340922 chr6 152292606 A C 5.87E-09 Triglycerides ESR1 intron 23063622 rs9383951 chr6 152295613 G C 2.00E-06 Breast cancer ESR1 intron 22383897 rs7768330 chr6 152302212 A G 5.34E-08 Triglycerides ESR1 intron 23063622 rs726281 chr6 152302578 G A 1.19E-04 Lung function (forced vital capacity) ESR1 intron 24023788 rs726281 chr6 152302578 G A 8.30E-05 Body Mass Index ESR1 intron pha003009 rs9340941 chr6 152313146 C T 6.90E-04 Asthma ESR1 intron 19910030 rs9340953 chr6 152319865 G A 0.000000687 Cholesterol,total ESR1 intron 23063622 rs2207232 chr6 152340288 T C 8.86E-04 Response to taxane treatment (placlitaxel) ESR1 intron 23006423 rs9340996 chr6 152342788 G T 2.90E-11 Triglycerides ESR1 intron 23063622 rs2982712 chr6 152358179 T C 4.00E-10 Height ESR1 intron 23563607 rs9341023 chr6 152383713 C T 3.50E-33 LDL cholesterol ESR1 intron 23063622 rs9341023 chr6 152383713 C T 4.22E-72 HDL cholesterol ESR1 intron 23063622 rs9341023 chr6 152383713 C T 8.20E-82 Cholesterol,total ESR1 intron 23063622 rs9341023 chr6 152383713 C T 9.51E-18 Triglycerides ESR1 intron 23063622 rs9341059 chr6 152418236 C T 5.51E-13 LDL cholesterol ESR1 intron 23063622 rs9341059 chr6 152418236 C T 6.06E-20 HDL cholesterol ESR1 intron 23063622 rs3798577 chr6 152421130 T C 2.31E-05 Height ESR1 UTR-3 pha003011 rs3798577 chr6 152421130 T C 3.58E-05 Lung function (forced vital capacity) ESR1 UTR-3 pha003104 rs9341074 chr6 152422455 T A 0.000000423 Triglycerides ESR1 UTR-3 23063622 rs3798757 chr6 152424243 T C 0.00000141 HDL cholesterol ESR1 UTR-3 23063622 rs2813544 chr6 152425582 A G 7.81E-05 Height / / pha003010 rs2813544 chr6 152425582 A G 5.51E-05 Height / / pha003011 rs2813554 chr6 152442338 G A 5.14E-05 Height SYNE1 nearGene-3 pha003011 rs2295193 chr6 152453094 G A 8.35E-08 Height SYNE1 intron pha003010 rs2295193 chr6 152453094 G A 3.78E-08 Height SYNE1 intron pha003011 rs2295193 chr6 152453094 G A 3.32E-06 Lung function (forced vital capacity) SYNE1 intron pha003104 rs3818109 chr6 152456475 A G 6.39E-05 Lung function (forced vital capacity) SYNE1 intron pha003104 rs17082180 chr6 152458093 G A 4.81E-05 Erythrocyte counts SYNE1 intron pha003099 rs10484863 chr6 152463488 C T 7.88E-04 Multiple complex diseases SYNE1 intron 17554300 rs9397084 chr6 152474790 T C 1.04E-04 Longevity SYNE1 intron 22279548 rs9397085 chr6 152478820 G T 1.34E-04 Lung function (forced vital capacity) SYNE1 intron 24023788 rs2813539 chr6 152521714 A G 4.80E-05 Type 2 diabetes SYNE1 intron 17463248 rs1408460 chr6 152522118 G C 8.30E-05 Type 2 diabetes SYNE1 intron 17463248 rs719764 chr6 152522373 G C,T 5.40E-05 Type 2 diabetes SYNE1 intron 17463248 rs2673776 chr6 152522812 T G 8.00E-05 Type 2 diabetes SYNE1 intron 17463248 rs2635441 chr6 152523143 G A 9.40E-05 Type 2 diabetes SYNE1 intron 17463248 rs2763025 chr6 152526179 C T 1.92E-05 Multiple complex diseases SYNE1 intron 17554300 rs139466191 chr6 152534783 A C 0.00025 Breast cancer SYNE1 missense 23555315 rs9383976 chr6 152542548 A G 8.49E-05 Height SYNE1 intron pha003010 rs9383976 chr6 152542548 A G 2.33E-05 Height SYNE1 intron pha003011 rs1359323 chr6 152547151 T C 1.37E-05 Height SYNE1 intron pha003010 rs1359323 chr6 152547151 T C 6.73E-05 Height SYNE1 intron pha003011 rs12110479 chr6 152554396 C T 1.20E-05 Endometriosis SYNE1 intron 21151130 rs9371245 chr6 152561348 C A 6.30E-07 Urinary metabolites SYNE1 intron 21572414 rs6901631 chr6 152567047 T C 2.65E-08 Metabolite levels SYNE1 intron 23281178 rs12664753 chr6 152615200 G A 9.18E-05 Cognitive test performance SYNE1 cds-synon 20125193 rs9371581 chr6 152629586 G A 2.86E-04 Alzheimer's disease SYNE1 intron 22005930 rs1890100 chr6 152638209 A G 1.60E-05 Endometriosis SYNE1 intron 21151130 rs1890100 chr6 152638209 A G 8.10E-06 Endometriosis SYNE1 intron 23104006 rs7775119 chr6 152671343 C G 1.76E-06 Multiple complex diseases SYNE1 missense 17554300 rs13220008 chr6 152700965 A G 3.97E-04 Major depressive disorder SYNE1 intron 22472876 rs214959 chr6 152702821 G A,C,T 1.19E-06 Fibrinogen SYNE1 intron pha003068 rs214950 chr6 152708310 G A 2.73E-04 Lung function (forced vital capacity) SYNE1 missense 24023788 rs9479307 chr6 152711045 G T 3.30E-06 Bipolar disorder and major depressive disorder (combined) SYNE1 intron 20351715 rs214944 chr6 152712752 C T 3.26E-06 Major depressive disorder SYNE1 intron 22472876 rs20585 chr6 152714446 C A 2.81E-06 Major depressive disorder SYNE1 intron 22472876 rs1203233 chr6 152714606 G T 6.81E-05 Bipolar disorder SYNE1 intron 19488044 rs1203233 chr6 152714606 G T 2.16E-06 Major depressive disorder SYNE1 intron 22472876 rs522437 chr6 152719218 C G 7.36E-05 Bipolar disorder SYNE1 intron 19488044 rs522437 chr6 152719218 C G 3.36E-06 Major depressive disorder SYNE1 intron 22472876 rs177330 chr6 152722228 A G 4.73E-06 Major depressive disorder SYNE1 intron 22472876 rs214952 chr6 152722715 A C 1.02E-05 Major depressive disorder SYNE1 intron 22472876 rs127196 chr6 152727331 C A 2.29E-05 Major depressive disorder SYNE1 intron 22472876 rs544863 chr6 152728814 C A 1.57E-05 Major depressive disorder SYNE1 intron 22472876 rs214978 chr6 152731398 A C 7.74E-06 Major depressive disorder SYNE1 intron 22472876 rs1489586 chr6 152732257 A T 4.30E-06 Bipolar disorder and major depressive disorder (combined) SYNE1 intron 20351715 rs214987 chr6 152733593 G A 1.19E-05 Major depressive disorder SYNE1 intron 22472876 rs742784 chr6 152736737 A C 4.50E-06 Bipolar disorder and major depressive disorder (combined) SYNE1 intron 20351715 rs761408 chr6 152736812 C T 4.40E-06 Bipolar disorder and major depressive disorder (combined) SYNE1 intron 20351715 rs2092602 chr6 152737092 T C 3.80E-06 Bipolar disorder and major depressive disorder (combined) SYNE1 intron 20351715 rs7738528 chr6 152738335 A C 3.80E-06 Bipolar disorder and major depressive disorder (combined) SYNE1 intron 20351715 rs214989 chr6 152738345 A G 2.46E-04 Substance dependence SYNE1 intron 21818250 rs17082664 chr6 152738754 A G 4.00E-06 Bipolar disorder SYNE1 intron 18711365 rs17082664 chr6 152738754 A G 1.00E-06 Bipolar disorder and major depressive disorder (combined) SYNE1 intron 20351715 rs6557219 chr6 152743448 G A 4.20E-06 Bipolar disorder and major depressive disorder (combined) SYNE1 intron 20351715 rs6913500 chr6 152744007 C T 4.20E-06 Bipolar disorder and major depressive disorder (combined) SYNE1 intron 20351715 rs9479313 chr6 152744750 T C 8.80E-06 Bipolar disorder and major depressive disorder (combined) SYNE1 intron 20351715 rs6909684 chr6 152746133 T C 4.10E-06 Bipolar disorder and major depressive disorder (combined) SYNE1 intron 20351715 rs9479314 chr6 152747321 G T 3.90E-06 Bipolar disorder and major depressive disorder (combined) SYNE1 intron 20351715 rs553642 chr6 152751558 C T 9.67E-06 Major depressive disorder SYNE1 intron 22472876 rs12661143 chr6 152752260 T C 4.30E-06 Bipolar disorder and major depressive disorder (combined) SYNE1 intron 20351715 rs525210 chr6 152752324 T C 6.64E-06 Major depressive disorder SYNE1 intron 22472876 rs215001 chr6 152760906 G A 4.72E-06 Major depressive disorder SYNE1 intron 22472876 rs214997 chr6 152762589 A G 9.63E-06 Major depressive disorder SYNE1 intron 22472876 rs214993 chr6 152766186 G A 7.25E-07 Major depressive disorder SYNE1 intron 22472876 rs527021 chr6 152768194 C T 6.21E-07 Major depressive disorder SYNE1 intron 22472876 rs502268 chr6 152768796 T G 6.17E-07 Major depressive disorder SYNE1 intron 22472876 rs214976 chr6 152772264 A G 2.52E-07 Major depressive disorder SYNE1 missense 22472876 rs70018 chr6 152774033 G A 3.04E-07 Major depressive disorder SYNE1 intron 22472876 rs169974 chr6 152775232 T C 2.59E-07 Major depressive disorder SYNE1 intron 22472876 rs214969 chr6 152776331 G C 2.08E-07 Major depressive disorder SYNE1 intron 22472876 rs214969 chr6 152776331 G C 1.82E-05 Odorant perception SYNE1 intron 23910658 rs214961 chr6 152781739 A G 9.00E-06 Bipolar disorder and major depressive disorder (combined) SYNE1 intron 20351715 rs579464 chr6 152782933 G A 2.08E-07 Major depressive disorder SYNE1 intron 22472876 rs7756410 chr6 152789197 A G 1.88E-07 Major depressive disorder SYNE1 intron 22472876 rs9371601 chr6 152790573 G T 8.79E-04 Multiple complex diseases SYNE1 intron 17554300 rs9371601 chr6 152790573 G T 7.00E-07 Bipolar disorder SYNE1 intron 21926972 rs9371601 chr6 152790573 G T 2.95E-07 Major depressive disorder SYNE1 intron 22472876 rs9371601 chr6 152790573 G T 0.000000138 Bipolar disorder SYNE1 intron 23070075 rs9371601 chr6 152790573 G T 4.00E-09 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) SYNE1 intron 23453885 rs9371601 chr6 152790573 G T 0.0000011 Bipolar disorder SYNE1 intron 23637625 rs7747960 chr6 152791474 C A 9.00E-06 Bipolar disorder SYNE1 intron 21738484 rs4318888 chr6 152792213 T C 1.99E-07 Major depressive disorder SYNE1 intron 22472876 rs9397510 chr6 152797065 G A 9.26E-05 Major depressive disorder SYNE1 intron 22472876 rs7751588 chr6 152797353 C T 7.85E-05 Major depressive disorder SYNE1 intron 22472876 rs7740022 chr6 152802209 C T 2.34E-05 Major depressive disorder SYNE1 intron 22472876 rs7763880 chr6 152802297 T C 6.36E-08 Major depressive disorder SYNE1 intron 22472876 rs9397512 chr6 152805889 C T 7.16E-08 Major depressive disorder SYNE1 intron 22472876 rs9397518 chr6 152810721 C T 8.15E-08 Major depressive disorder SYNE1 intron 22472876 rs2623963 chr6 152820395 G C 7.61E-10 Lipoprotein a [lp(a)] levels in plasma SYNE1 intron pha002870 rs9371604 chr6 152826222 T A 3.60E-05 Major depressive disorder SYNE1 intron 22472876 rs2449116 chr6 152838121 A T 2.78E-04 Major depressive disorder SYNE1 intron 22472876 rs2623981 chr6 152842018 C T 2.61E-05 Major depressive disorder SYNE1 intron 22472876 rs2623932 chr6 152848898 A G 9.73E-05 Major depressive disorder SYNE1 intron 22472876 rs7745725 chr6 152852284 A G 1.87E-11 Lipoprotein a [lp(a)] levels in plasma SYNE1 intron pha002870 rs1405695 chr6 152859643 G T 4.60E-04 Type 2 diabetes and 6 quantitative traits SYNE1 intron 17848626 rs1527369 chr6 152865466 A T 5.22E-04 Alzheimer's disease SYNE1 intron 17998437 rs1358317 chr6 152865556 A G 1.61E-08 Lipoprotein a [lp(a)] levels in plasma SYNE1 intron pha002870 rs7739404 chr6 152880866 A G 6.48E-04 Suicide attempts in bipolar disorder SYNE1 intron 21423239 rs2758791 chr6 152886326 T C 7.34E-04 Multiple complex diseases SYNE1 intron 17554300 rs818447 chr6 152889155 A G 3.45E-04 Suicide attempts in bipolar disorder SYNE1 intron 21423239 rs818441 chr6 152893252 G A 8.73E-04 Suicide attempts in bipolar disorder SYNE1 intron 21423239 rs1322509 chr6 152896755 A T 7.56E-04 Suicide attempts in bipolar disorder SYNE1 intron 21423239 rs17779152 chr6 152902786 G A 8.19E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SYNE1 intron 24023788 rs17701297 chr6 152910939 G A 1.33E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SYNE1 intron 24023788 rs2038615 chr6 152927267 A G 5.44E-04 Type 2 diabetes SYNE1 intron 17463246 rs1405691 chr6 152936650 A G 5.68E-04 Type 2 diabetes SYNE1 intron 17463246 rs1744385 chr6 152940466 A G 6.66E-04 Type 2 diabetes SYNE1 intron 17463246 rs1727046 chr6 152942044 A T 7.14E-04 Suicide attempts in bipolar disorder SYNE1 intron 21423239 rs1322512 chr6 152947953 C A 8.00E-06 Tonometry SYNE1 intron 17903302 rs732496 chr6 152953451 A C 2.00E-05 Urinary metabolites SYNE1 intron 21572414 rs1110227 chr6 152962280 C T 1.50E-05 Urinary metabolites / / 21572414 rs9397539 chr6 152973287 G A 2.50E-05 Urinary metabolites / / 21572414 rs2258974 chr6 152974550 A G 3.34E-04 Orofacial clefts / / 22863734 rs2800629 chr6 153007917 A C 4.37E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs9322389 chr6 153014355 T C 2.12E-04 Lung function (forced vital capacity) / / 24023788 rs4348331 chr6 153044949 T C 6.05E-04 Smoking quantity MYCT1 UTR-3 24665060 rs1282451 chr6 153045913 A G 5.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs17782898 chr6 153047588 A T 2.83E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1282450 chr6 153058758 T A 6.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs1282444 chr6 153065324 T A 2.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs633596 chr6 153065487 A G 5.06E-08 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs13211784 chr6 153066369 T G 4.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs17083011 chr6 153069342 A C 6.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs3757070 chr6 153069721 A G 9.09E-05 Cognitive test performance / / 20125193 rs12212849 chr6 153070203 C G 7.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs12213214 chr6 153070786 C A 7.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs3799142 chr6 153072696 T C 7.98E-04 Suicide attempts in bipolar disorder VIP intron 21423239 rs7764067 chr6 153074199 A T 7.67E-04 Suicide attempts in bipolar disorder VIP intron 21423239 rs3823082 chr6 153074322 C T 9.44E-05 Body Mass Index VIP intron pha003019 rs12201173 chr6 153075076 T C 6.91E-04 Suicide attempts in bipolar disorder VIP intron 21423239 rs1410489 chr6 153096503 G T 8.82E-05 Major depressive disorder (broad) / / 20038947 rs612400 chr6 153101244 G T 9.15E-04 Alzheimer's disease / / 17998437 rs554950 chr6 153105629 T C 5.89E-05 Bipolar disorder / / 22925353 rs546599 chr6 153118810 C A 2.19E-07 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs7767039 chr6 153119212 G A 9.93E-04 Alzheimer's disease / / 17998437 rs13205491 chr6 153151179 C T 6.87E-05 Body Mass Index / / pha003019 rs13208658 chr6 153164323 G A 1.61E-05 Major depressive disorder (broad) / / 20038947 rs13219094 chr6 153168437 T C 2.17E-05 Major depressive disorder (broad) / / 20038947 rs13199515 chr6 153175131 G C 4.61E-05 Major depressive disorder (broad) / / 20038947 rs13194909 chr6 153187682 T G 5.45E-05 Major depressive disorder (broad) / / 20038947 rs13203493 chr6 153198982 A T 5.38E-05 Major depressive disorder (broad) / / 20038947 rs13196491 chr6 153213122 T C 8.33E-05 Major depressive disorder (broad) / / 20038947 rs13196491 chr6 153213122 T C 6.06E-05 Stroke / / pha002887 rs570343 chr6 153215035 C A 1.49E-04 Schizophrenia(age at onset) / / 21688384 rs9479433 chr6 153226394 G A 4.88E-04 Multiple complex diseases / / 17554300 rs9285535 chr6 153261732 A G 3.43E-04 Alzheimer's disease / / 22005930 rs9322400 chr6 153261925 T A,C,G 3.81E-04 Common variable immunodeficiency / / 21497890 rs11969689 chr6 153262157 T C 1.39E-05 Blood Pressure / / pha003044 rs9479446 chr6 153262381 A G 3.29E-04 Alzheimer's disease / / 22005930 rs12208589 chr6 153263422 G A,C 3.28E-04 Alzheimer's disease / / 22005930 rs9479447 chr6 153264147 T C 3.27E-04 Alzheimer's disease / / 22005930 rs13218732 chr6 153265210 A C 2.24E-04 Migraine - clinic-based / / 23793025 rs13218732 chr6 153265210 A C 3.00E-06 Migraine / / 23793025 rs9478367 chr6 153266273 C G 3.43E-04 Alzheimer's disease / / 22005930 rs9478368 chr6 153266490 A C 3.33E-04 Alzheimer's disease / / 22005930 rs7766191 chr6 153267983 A G 3.46E-04 Alzheimer's disease / / 22005930 rs4870153 chr6 153269272 G C 3.08E-05 Schizophrenia(age at onset) / / 21688384 rs12211591 chr6 153270207 C T 2.66E-04 Alzheimer's disease / / 22005930 rs12212131 chr6 153270904 G A 3.57E-04 Alzheimer's disease / / 22005930 rs10484865 chr6 153271852 C T 8.59E-04 White matter integrity / / 22425255 rs6933316 chr6 153272167 C G 2.94E-04 Alzheimer's disease / / 22005930 rs9285536 chr6 153274321 A G 6.01E-05 Blood Pressure / / pha003044 rs9479453 chr6 153276423 C T 3.56E-04 Alzheimer's disease / / 22005930 rs6931585 chr6 153277155 C T 7.16E-04 Alzheimer's disease / / 22005930 rs4869774 chr6 153280912 A G 9.92E-04 Alzheimer's disease / / 22005930 rs9478375 chr6 153282302 A G 9.66E-04 Alzheimer's disease / / 22005930 rs12527968 chr6 153285437 A G 9.85E-04 Alzheimer's disease / / 22005930 rs12210184 chr6 153291031 T G 8.62E-04 Alzheimer's disease / / 22005930 rs1997960 chr6 153292712 T G 9.75E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FBXO5 intron 20877124 rs9479470 chr6 153293793 G C 2.11E-04 Alzheimer's disease FBXO5 intron 22005930 rs6906510 chr6 153295125 T C 9.83E-04 Alzheimer's disease FBXO5 intron 22005930 rs6921626 chr6 153295317 G T 9.79E-04 Alzheimer's disease FBXO5 intron 22005930 rs7745185 chr6 153295681 A G 2.64E-04 Alzheimer's disease FBXO5 intron 22005930 rs7763565 chr6 153296370 G A 9.57E-04 White matter integrity FBXO5 missense 22425255 rs6929544 chr6 153297150 T C 9.96E-04 Alzheimer's disease FBXO5 intron 22005930 rs2236012 chr6 153297524 T C 9.61E-04 Alzheimer's disease FBXO5 intron 22005930 rs5018162 chr6 153298072 C T 9.55E-04 Alzheimer's disease FBXO5 intron 22005930 rs7356981 chr6 153301010 G C 6.38E-04 Alzheimer's disease FBXO5 intron 22005930 rs9479476 chr6 153301542 T C 7.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FBXO5 intron 20877124 rs9479476 chr6 153301542 T C 1.80E-04 Alzheimer's disease FBXO5 intron 22005930 rs9384060 chr6 153307483 C A 9.14E-05 Blood Pressure / / pha003044 rs3799133 chr6 153315921 G A 1.14E-05 Major depressive disorder (broad) MTRF1L intron 20038947 rs650018 chr6 153333328 A G 1.03E-05 Major depressive disorder RGS17 intron 22472876 rs503366 chr6 153333550 T C 1.15E-05 Major depressive disorder RGS17 intron 22472876 rs637384 chr6 153340412 C A 5.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RGS17 intron 20877124 rs1292834 chr6 153357964 T G 0.0000871 Nonsyndromic striae distensae (stretch marks) RGS17 intron 23633020 rs7755574 chr6 153364643 G T 6.55E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs2295230 chr6 153365100 A C,T 6.79E-04 Suicide attempts in bipolar disorder RGS17 cds-synon 21423239 rs2295231 chr6 153365348 G A 4.17E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs2295232 chr6 153365384 T G 4.05E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs1338070 chr6 153365841 G T 4.01E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs7763717 chr6 153367347 T G 4.17E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs2349199 chr6 153367594 A T 4.07E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs4599660 chr6 153367910 C T 6.07E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs9397579 chr6 153368062 G T 6.75E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs9397124 chr6 153368153 A C 8.68E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs9371658 chr6 153368353 C T 9.01E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs9397125 chr6 153368447 T C 9.18E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs9397126 chr6 153368561 G C 9.81E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs9371276 chr6 153369161 T C 9.34E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs9384067 chr6 153369336 A G 9.27E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs7761503 chr6 153371328 C T 8.14E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs7747583 chr6 153371768 A C 8.98E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs6910440 chr6 153372108 A C 5.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RGS17 intron 20877124 rs6910440 chr6 153372108 A C 8.83E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs7775866 chr6 153379080 C T 0.0000756 Nonsyndromic striae distensae (stretch marks) RGS17 intron 23633020 rs4385321 chr6 153394728 G A 2.26E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs9371670 chr6 153395594 C G 9.60E-05 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs9397585 chr6 153396875 T C 7.83E-04 Suicide attempts in bipolar disorder RGS17 intron 21041247 rs9397585 chr6 153396875 T C 4.57E-05 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs6899427 chr6 153397064 G A 0.0000442 Nonsyndromic striae distensae (stretch marks) RGS17 intron 23633020 rs6927659 chr6 153397299 T G 3.96E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs7743048 chr6 153397729 G A 0.0000467 Nonsyndromic striae distensae (stretch marks) RGS17 intron 23633020 rs6920313 chr6 153402841 T C 5.30E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs3910736 chr6 153412476 C T 9.65E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs67494471 chr6 153412476 CA CCA,CTG 9.65E-04 Suicide attempts in bipolar disorder RGS17 intron 21423239 rs487972 chr6 153423252 A G 1.96E-07 Lipoprotein a [lp(a)] levels in plasma RGS17 intron pha002870 rs12055786 chr6 153431125 C T 5.51E-08 Fasting blood glucose RGS17 intron 22885924 rs12055786 chr6 153431125 C T 0.000089 Prostate cancer RGS17 intron 23555315 rs1933488 chr6 153441079 A G 4.00E-18 Prostate cancer RGS17 intron 23535732 rs1281967 chr6 153446191 A T 7.81E-06 Glycemic traits (pregnancy) RGS17 intron 23903356 rs12191018 chr6 153479726 G T 6.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12192214 chr6 153492871 A G 2.07E-04 Fibrinogen / / 17255346 rs9478395 chr6 153503386 C T 6.99E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11753918 chr6 153504188 T C 5.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs471508 chr6 153530447 C T 6.57E-04 Aortic root size / / 21223598 rs1871400 chr6 153539218 C T 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs315410 chr6 153540901 A C 5.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs10457087 chr6 153560575 G A 3.26E-05 Aortic root size / / 21223598 rs7762618 chr6 153572513 G A 3.73E-04 Aortic root size / / 21223598 rs7761260 chr6 153592043 T C 4.77E-04 Heart Failure / / pha002885 rs1382815 chr6 153651777 G A 1.10E-06 Urinary metabolites / / 21572414 rs2171249 chr6 153694029 T C 8.45E-06 Asthma / / 23181788 rs10485214 chr6 153698915 A T 4.95E-04 Alzheimer's disease / / 17998437 rs17083966 chr6 153698951 C T 8.58E-04 Multiple complex diseases / / 17554300 rs2790090 chr6 153701111 A G 4.47E-04 Myopia (pathological) / / 21095009 rs11760047 chr6 153705710 T C 5.49E-05 Lung function (forced vital capacity) / / 24023788 rs9479600 chr6 153746604 C A 7.84E-05 Bipolar disorder and schizophrenia / / 20889312 rs270301 chr6 153753285 T C 2.43E-05 Erythrocyte counts / / pha003099 rs13208348 chr6 153802064 A G 9.37E-05 Multiple sclerosis / / 17660530 rs17250161 chr6 153808077 G C 8.65E-05 Multiple sclerosis / / 17660530 rs11756951 chr6 153829610 C T 8.65E-05 Multiple sclerosis / / 17660530 rs9371705 chr6 153855165 T G 1.29E-04 Parkinson's disease / / 17052657 rs559901 chr6 153857936 A G 6.24E-05 Osteoarthritis (knee and hip) / / 21177295 rs476003 chr6 153875899 T C 9.80E-05 Elbow pain / / pha003008 rs492982 chr6 153879154 T G 1.90E-05 Urinary metabolites / / 21572414 rs3935973 chr6 153924581 A G 5.17E-04 Multiple complex diseases / / 17554300 rs4598087 chr6 153924868 A G 1.11E-10 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs7754521 chr6 153926453 C T 9.74E-11 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs4296898 chr6 153994951 C T 7.67E-04 Tourette syndrome / / 22889924 rs2186141 chr6 154004971 T C 4.00E-06 Migraine - clinic-based / / 23793025 rs2186140 chr6 154005613 C T 5.36E-07 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs9397637 chr6 154022718 C A 2.87E-04 Tourette syndrome / / 22889924 rs4869804 chr6 154062658 C T 3.63E-06 Coronary artery calcification / / 23870195 rs1937580 chr6 154076643 G A 6.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1937580 chr6 154076643 G A 8.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1937579 chr6 154077193 C T 3.00E-06 Coronary artery calcification / / 23870195 rs9397654 chr6 154107383 G A 5.77E-04 Type 2 diabetes / / 17463246 rs12527197 chr6 154107836 T C 9.30E-05 HIV-1 control / / 20041166 rs1937627 chr6 154109270 C T 4.88E-04 Type 2 diabetes / / 17463246 rs10485258 chr6 154113409 C T 8.74E-05 Response to metformin / / 21186350 rs17084501 chr6 154126738 T C 2.54E-09 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10485262 chr6 154140199 G A 2.62E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs6900489 chr6 154234867 G C 5.00E-06 Metabolite levels (X-11787) / / 23934736 rs1885629 chr6 154262894 T C 0.0000421 Panic disorder / / 23149450 rs1885629 chr6 154262894 T C 4.21E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs1885628 chr6 154262938 G A 0.0000434 Panic disorder / / 23149450 rs1885628 chr6 154262938 G A 4.34E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs17084721 chr6 154266022 A G 0.0000392 Panic disorder / / 23149450 rs17084721 chr6 154266022 A G 3.92E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs9397672 chr6 154266598 C A 0.0000363 Panic disorder / / 23149450 rs9397672 chr6 154266598 C A 3.63E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs9397673 chr6 154266709 A G 0.0000339 Panic disorder / / 23149450 rs9397673 chr6 154266709 A G 3.39E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs9397674 chr6 154267000 C T 0.0000323 Panic disorder / / 23149450 rs9397674 chr6 154267000 C T 3.23E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs2169411 chr6 154267147 A G 0.0000319 Panic disorder / / 23149450 rs2169411 chr6 154267147 A G 3.19E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs1033816 chr6 154268544 C T 0.0000352 Panic disorder / / 23149450 rs1033816 chr6 154268544 C T 3.52E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs7758009 chr6 154269510 T C 0.0000364 Panic disorder / / 23149450 rs7758009 chr6 154269510 T C 3.64E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs598832 chr6 154272618 G A 9.61E-04 Parkinson's disease / / 17052657 rs9384167 chr6 154275074 C T 0.000036 Panic disorder / / 23149450 rs9384167 chr6 154275074 C T 3.60E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs12174208 chr6 154278384 G T 0.0000347 Panic disorder / / 23149450 rs12174208 chr6 154278384 G T 3.47E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs9384168 chr6 154281391 C A 0.0000338 Panic disorder / / 23149450 rs9384168 chr6 154281391 C A 3.38E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs11966947 chr6 154288583 G A 0.0000216 Panic disorder / / 23149450 rs11966947 chr6 154288583 G A 2.16E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs712241 chr6 154293180 G T 8.24E-04 Nicotine dependence / / 17158188 rs7760028 chr6 154295073 A G 0.000028 Panic disorder / / 23149450 rs7760028 chr6 154295073 A G 2.80E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs790919 chr6 154298875 A T 6.79E-04 Nicotine dependence / / 17158188 rs1675903 chr6 154309594 A G 2.20E-05 Urinary metabolites / / 21572414 rs10499276 chr6 154309808 C T 0.000069 Coronary artery calcification / / 23727086 rs10499276 chr6 154309808 C T 8.08E-05 Triglycerides / / pha002904 rs1319339 chr6 154331184 T C 0.000000491 Total IFN-gamma response to smallpox vaccine OPRM1 nearGene-5 22661280 rs1799971 chr6 154360797 A G 1 Drug response to Naloxone OPRM1 missense 11751037 rs1799971 chr6 154360797 A G 1 Drug response to Naloxone OPRM1 missense 12627468 rs1799971 chr6 154360797 A G 1 Drug response to Heroin Addiction OPRM1 missense 15037869 rs1799971 chr6 154360797 A G 1 Drug response to Ethanol OPRM1 missense 15525999 rs1799971 chr6 154360797 A G 1 Drug response to Naltrexone OPRM1 missense 15525999 rs1799971 chr6 154360797 A G 1 Drug response to Ethanol OPRM1 missense 15608594 rs1799971 chr6 154360797 A G 1 Drug response to Naltrexone OPRM1 missense 15608594 rs1799971 chr6 154360797 A G 1 Drug response to Heroin Addiction OPRM1 missense 16476706 rs1799971 chr6 154360797 A G 1 Drug response to Morphine OPRM1 missense 17156920 rs1799971 chr6 154360797 A G 1 Drug response to Ethanol OPRM1 missense 17339526 rs1799971 chr6 154360797 A G 1 Drug response to Naltrexone OPRM1 missense 17339526 rs1799971 chr6 154360797 A G 1 Drug response to Naloxone OPRM1 missense 18004207 rs1799971 chr6 154360797 A G 1 Drug response to Ethanol OPRM1 missense 18250251 rs1799971 chr6 154360797 A G 1 Drug response to Naltrexone OPRM1 missense 18250251 rs1799971 chr6 154360797 A G 1 Drug response to Alfentanil OPRM1 missense 19605407 rs1799971 chr6 154360797 A G 1 Drug response to Ethanol OPRM1 missense 8072460 rs1799971 chr6 154360797 A G 1 Drug response to Naltrexone OPRM1 missense 8072460 rs3778145 chr6 154367080 A C 3.93E-04 Type 2 diabetes OPRM1 intron 17463246 rs41378646 chr6 154375838 C T 4.79E-04 Multiple complex diseases OPRM1 intron 17554300 rs3778146 chr6 154377925 T C 6.62E-04 Type 2 diabetes OPRM1 intron 17463246 rs3778149 chr6 154382139 C G 4.97E-04 Type 2 diabetes OPRM1 intron 17463246 rs7773995 chr6 154382367 C T 2.82E-04 Type 2 diabetes OPRM1 intron 17463246 rs17209711 chr6 154396455 T A 2.37E-04 Type 2 diabetes OPRM1 intron 17463246 rs17275521 chr6 154396472 G A 2.67E-04 Type 2 diabetes OPRM1 intron 17463246 rs17275521 chr6 154396472 G A 7.90E-04 Coronary Artery Disease OPRM1 intron 17634449 rs563649 chr6 154407967 C T 3.75E-04 Parkinson's disease OPRM1 UTR-5 17052657 rs563649 chr6 154407967 C T 3.10E-04 Amyotrophic Lateral Sclerosis OPRM1 UTR-5 17362836 rs563649 chr6 154407967 C T 1.00E-04 Cognitive impairment induced by topiramate OPRM1 UTR-5 22091778 rs9322446 chr6 154408702 G A 1.00E-05 Urinary metabolites OPRM1 UTR-5 21572414 rs17174822 chr6 154412236 C T 0.000001 Breast cancer(er negative) OPRM1 missense 23555315 rs675026 chr6 154414563 A G 5.00E-06 Coronary heart disease OPRM1 cds-synon 21347282 rs671531 chr6 154440742 A G 9.01E-05 Waist Circumference OPRM1 intron pha003024 rs2010884 chr6 154458207 G A 2.64E-04 Type 2 diabetes OPRM1 intron 17463246 rs2010884 chr6 154458207 G A 7.82E-04 Multiple complex diseases OPRM1 intron 17554300 rs655059 chr6 154458856 T C 7.31E-05 Height OPRM1 intron pha003010 rs9397178 chr6 154470217 A G 0.0000011 Endometrial cancer OPRM1 intron 22426144 rs2236256 chr6 154478440 C A 2.00E-10 Chronic lymphocytic leukemia IPCEF1 UTR-3 24292274 rs9479768 chr6 154480775 G A 1.77E-04 Multiple complex diseases IPCEF1 UTR-3 17554300 rs12208947 chr6 154491137 G A 0.0000046 Endometrial cancer OPRM1 intron 22426144 rs2281620 chr6 154515662 C A 5.18E-06 Glycemic traits (pregnancy) OPRM1 intron 23903356 rs1040822 chr6 154518638 T G 8.17E-05 Waist Circumference OPRM1 intron pha003023 rs1528045 chr6 154524225 A G 9.78E-04 Multiple complex diseases OPRM1 intron 17554300 rs17292684 chr6 154554607 A C 7.90E-04 Major depressive disorder OPRM1 intron 22472876 rs11155954 chr6 154566742 G T 9.92E-04 Parkinson's disease OPRM1 intron 17052657 rs11966376 chr6 154583206 C A 6.30E-05 Diabetes Mellitus IPCEF1 intron pha003059 rs17085260 chr6 154597660 C A 7.54E-04 Atopy IPCEF1 intron 21625490 rs13204400 chr6 154603498 G A 1.20E-04 Prion diseases IPCEF1 intron 22210626 rs1534446 chr6 154625192 T G 5.90E-08 Platelet aggregation(pre- and post-aspirin) IPCEF1 intron 20529293 rs7739184 chr6 154628854 C G 1.57E-05 Asthma IPCEF1 intron 23181788 rs11961438 chr6 154646581 G A 9.70E-06 Waist circumference IPCEF1 intron 23966867 rs9397709 chr6 154691025 C T 5.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs9384205 chr6 154692429 T C 5.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs9397710 chr6 154692520 C A 5.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs9371793 chr6 154692577 C A,T 5.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs9383704 chr6 154693575 A G 5.60E-04 Suicide attempts in bipolar disorder / / 21041247 rs9371795 chr6 154694160 C T 5.69E-04 Suicide attempts in bipolar disorder / / 21041247 rs9384206 chr6 154694179 C T 5.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs7744573 chr6 154697912 T C 6.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs6557347 chr6 154698761 T C 6.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs7746647 chr6 154699356 A T 8.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs12526737 chr6 154708633 T C 5.81E-04 Alcohol dependence / / 20201924 rs3812243 chr6 154719380 G A 3.19E-04 Hearing function / / 17255346 rs2275336 chr6 154726988 G A 9.00E-07 Parkinson's disease CNKSR3 UTR-3 22451204 rs9397716 chr6 154727408 T C 8.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CNKSR3 UTR-3 20877124 rs9322464 chr6 154748630 C T 3.09E-05 Left ventricular hypertrophy CNKSR3 intron pha003052 rs9397717 chr6 154749087 G A 1.86E-06 Left ventricular hypertrophy CNKSR3 intron pha003052 rs10872707 chr6 154757313 C T 2.20E-05 Urinary metabolites CNKSR3 intron 21572414 rs6911312 chr6 154761284 C A 6.56E-05 Left ventricular hypertrophy CNKSR3 intron pha003052 rs11155976 chr6 154801450 C T 3.84E-06 Blood Pressure CNKSR3 intron pha003046 rs9397724 chr6 154803684 G A 9.90E-06 Urinary metabolites CNKSR3 intron 21572414 rs4352688 chr6 154804650 A G 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CNKSR3 intron 22628534 rs1572662 chr6 154811597 A G 2.50E-05 Parkinson's disease (age of onset) CNKSR3 intron 19772629 rs6557362 chr6 154821186 T A 0.00033 Erectile dysfunction after radiotherapy for prostate cancer CNKSR3 intron 23021708 rs7768635 chr6 154827861 C T 0.0000701 Asthma CNKSR3 intron 22694930 rs12205238 chr6 154872954 C T 1.43E-04 Alzheimer's disease / / 24755620 rs9397738 chr6 154986664 G A 5.00E-06 Renal function-related traits (eGRFcrea) / / 22797727 rs6420139 chr6 155001410 C T 7.74E-04 Schizophrenia / / 19197363 rs7742281 chr6 155002720 C G 6.22E-04 Multiple complex diseases / / 17554300 rs7754964 chr6 155022713 C T 7.28E-05 Multiple complex diseases / / 17554300 rs9371823 chr6 155028910 C T 1.43E-04 Multiple complex diseases / / 17554300 rs4870308 chr6 155033024 G A 5.61E-04 Multiple complex diseases / / 17554300 rs6911728 chr6 155057907 T G 1.50E-04 Multiple complex diseases SCAF8 intron 17554300 rs10872710 chr6 155096462 T C 2.38E-04 Multiple complex diseases SCAF8 intron 17554300 rs9478583 chr6 155106052 A G 3.88E-04 Multiple complex diseases SCAF8 intron 17554300 rs9397747 chr6 155106151 C A 9.15E-05 Multiple complex diseases SCAF8 intron 17554300 rs3757291 chr6 155124583 T G 6.56E-06 Multiple complex diseases SCAF8 intron 17554300 rs9371352 chr6 155133680 C G 7.16E-05 Multiple complex diseases SCAF8 intron 17554300 rs3087697 chr6 155133742 C G 4.94E-05 Multiple complex diseases SCAF8 intron 17554300 rs9384245 chr6 155160128 T C 3.00E-05 Attention deficit hyperactivity disorder / / 22420046 rs12201149 chr6 155162163 T C 9.00E-04 Multiple complex diseases / / 17554300 rs1106753 chr6 155164271 G A 7.55E-05 Partial epilepsies / / 20522523 rs2351843 chr6 155165469 C A 6.07E-04 Taste perception / / 22132133 rs9384246 chr6 155167434 T C 1.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs9384246 chr6 155167434 T C 3.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs9384247 chr6 155175477 A G 2.11E-04 Taste perception / / 22132133 rs10485355 chr6 155194443 G A,C 4.78E-04 Multiple complex diseases LOC100505519 intron 17554300 rs6557383 chr6 155221600 C T 4.14E-05 Attention deficit hyperactivity disorder LOC100505519 intron 22420046 rs4870322 chr6 155273364 G A 1.83E-04 Blood pressure / / 21909110 rs9479998 chr6 155317769 A G 7.56E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2475861 chr6 155319478 T C 5.42E-04 Alzheimer's disease / / 17998437 rs9480006 chr6 155330107 G T 7.68E-05 Alzheimer's disease (late onset) / / 21379329 rs7746011 chr6 155345181 C A 6.78E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs9397769 chr6 155370384 G A 7.41E-04 Alzheimer's disease / / 17998437 rs9322495 chr6 155371513 T C 9.90E-05 Asthma / / pha003127 rs12528887 chr6 155387178 G A 1.10E-05 Bipolar disorder / / 19488044 rs12528887 chr6 155387178 G A 1.25E-05 Bipolar Disorder / / pha002858 rs12523857 chr6 155387239 T A 1.10E-05 Bipolar disorder / / 19488044 rs12523857 chr6 155387239 T A 1.25E-05 Bipolar Disorder / / pha002858 rs4869843 chr6 155407983 C T 7.23E-04 Bipolar disorder / / 19259986 rs10499305 chr6 155408417 T C 7.28E-05 Tunica Media / / pha003037 rs4870354 chr6 155439077 T C 8.64E-04 Response to statin treatment (atorvastatin),change in cholesterol levels TIAM2 intron 20031582 rs998318 chr6 155491391 T G 1.22E-05 Bone mineral traits,in men TIAM2 intron 21427758 rs998318 chr6 155491391 T G 1.30E-05 Bone mineral traits,in men TIAM2 intron 21427758 rs998318 chr6 155491391 T G 2.94E-05 Bone mineral traits,in men TIAM2 intron 21427758 rs17739072 chr6 155496740 G A 3.10E-06 Urinary metabolites TIAM2 intron 21572414 rs7741028 chr6 155528057 T C 9.05E-05 Bipolar disorder TIAM2 intron 19488044 rs7741028 chr6 155528057 T C 7.77E-05 Bipolar Disorder TIAM2 intron pha002858 rs9384296 chr6 155530844 G A 1.71E-09 Lipoprotein a [lp(a)] levels in plasma TIAM2 intron pha002870 rs3935935 chr6 155560480 C T 5.27E-05 Brain derived neurotrophic factor levels,in serum TIAM2 intron 22047184 rs3822964 chr6 155579400 A G 8.88E-05 Brain derived neurotrophic factor levels,in serum TFB1M intron 22047184 rs1408756 chr6 155581024 G T 9.04E-05 Brain derived neurotrophic factor levels,in serum TFB1M intron 22047184 rs2281838 chr6 155582350 G A 3.18E-04 Major depressive disorder TFB1M intron 22472876 rs6557416 chr6 155605487 A C,G,T 0.0002 Migraine TFB1M intron 22678113 rs324361 chr6 155614117 C T 1.60E-05 Parkinson's disease (age of onset) TFB1M intron 19772629 rs950994 chr6 155621019 G A 7.01E-04 Type 2 diabetes TFB1M intron 17463246 rs721101 chr6 155632844 T C 5.06E-05 Scoliosis TFB1M intron 21216876 rs324368 chr6 155642564 A G 2.66E-04 Major depressive disorder / / 22472876 rs4585573 chr6 155643247 G T 3.01E-06 Scoliosis / / 21216876 rs162977 chr6 155649655 A G 8.43E-05 Insulin Resistance / / pha003062 rs9397818 chr6 155700624 G A 2.00E-05 Urinary metabolites / / 21572414 rs9322522 chr6 155727016 G A 1.42E-07 Lipoprotein a [lp(a)] levels in plasma NOX3 intron pha002870 rs231948 chr6 155742113 G A 6.95E-05 Schizophrenia NOX3 intron 19197363 rs2281253 chr6 155748212 A C 2.08E-05 Schizophrenia NOX3 intron 19197363 rs231956 chr6 155751814 T C 5.34E-05 Schizophrenia NOX3 intron 19197363 rs9322524 chr6 155759778 T C 5.84E-06 Substance dependence phenotypes NOX3 intron 24832863 rs3749930 chr6 155761246 G T 8.93E-04 Multiple complex diseases NOX3 missense 17554300 rs2235673 chr6 155770432 T C 1.66E-04 Alzheimer's disease NOX3 intron 24755620 rs2235674 chr6 155771008 C T 9.00E-05 Rheumatoid arthritis NOX3 intron 17804836 rs7754577 chr6 155771250 G C 2.73E-07 Lipoprotein a [lp(a)] levels in plasma NOX3 intron pha002870 rs2181069 chr6 155804649 T C 4.59E-04 Type 2 diabetes / / 22158537 rs7756131 chr6 155809690 A G 3.19E-05 Type 2 diabetes / / 22158537 rs11156027 chr6 155810346 A G 2.25E-04 Type 2 diabetes / / 22158537 rs4869856 chr6 155813894 A G 1.45E-05 Type 2 diabetes / / 22158537 rs12665595 chr6 155817966 T A 3.55E-05 Type 2 diabetes / / 22158537 rs6930525 chr6 155820637 G A 8.50E-04 Insulin resistance / / 21901158 rs7764434 chr6 155827021 A G 3.66E-04 Multiple complex diseases / / 17554300 rs2181068 chr6 155843046 A G 2.50E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2181068 chr6 155843046 A G 3.16E-04 Lung function (forced vital capacity) / / 24023788 rs9478657 chr6 155858957 A G 7.47E-04 Type 2 diabetes / / 22158537 rs35229355 chr6 155929801 C T 5.00E-06 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs9322528 chr6 155953526 C T 8.64E-05 Creatinine levels / / pha003069 rs12211057 chr6 155966676 A C 3.86E-05 Creatinine levels / / pha003069 rs10499302 chr6 155968035 C T 8.44E-04 Multiple complex diseases / / 17554300 rs9371907 chr6 155969648 G A 6.87E-05 Creatinine levels / / pha003069 rs9480179 chr6 155978097 C T 9.71E-06 Sickle cell anemia (severity) / / 20029952 rs4870382 chr6 155988566 G A 3.74E-04 Insulin resistance / / 21901158 rs4256444 chr6 156050029 C T 1.82E-05 Creatinine levels / / pha003069 rs10499301 chr6 156058004 G A 7.99E-04 Insulin resistance / / 21901158 rs9371389 chr6 156066601 G A 6.73E-04 Alzheimer's disease / / 24755620 rs2353783 chr6 156075920 G A 8.53E-04 Alzheimer's disease / / 24755620 rs12207602 chr6 156084508 A G 7.52E-04 Parkinson's disease / / 17052657 rs6906823 chr6 156088458 G A 1.23E-04 Type 2 diabetes / / 17463246 rs6557446 chr6 156088762 A G 1.66E-05 Type 2 diabetes / / 17463246 rs9322536 chr6 156130723 A G 3.54E-05 Hypertension / / pha003042 rs9384366 chr6 156145699 A T 2.94E-04 Multiple complex diseases / / 17554300 rs9322538 chr6 156146284 A G 4.98E-04 Multiple complex diseases / / 17554300 rs9383781 chr6 156148946 G A 2.71E-04 Multiple complex diseases / / 17554300 rs4429959 chr6 156149387 G A 1.91E-04 Multiple complex diseases / / 17554300 rs4634473 chr6 156153087 A C 1.49E-04 Multiple complex diseases / / 17554300 rs4475337 chr6 156153163 T G 6.39E-05 Multiple complex diseases / / 17554300 rs9397270 chr6 156163798 T C 7.93E-04 Alcohol dependence / / 20201924 rs9371399 chr6 156177293 C G 4.47E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs9371399 chr6 156177293 C G 4.47E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs4269383 chr6 156197502 A G 7.00E-07 Pancreatic cancer / / 22158540 rs17054575 chr6 156209733 T C 6.82E-04 Multiple complex diseases / / 17554300 rs4292534 chr6 156240120 C G 1.40E-05 Urinary metabolites / / 21572414 rs11969718 chr6 156286386 G A 8.53E-04 Multiple complex diseases / / 17554300 rs6919345 chr6 156294343 A G 4.83E-04 Multiple complex diseases / / 17554300 rs4869875 chr6 156298643 T C 7.20E-05 Parkinson's disease (familial) / / 18985386 rs4870409 chr6 156300315 A C 2.12E-05 Brain structure / / 22504417 rs4242296 chr6 156304793 G A 1.30E-05 Parkinson's disease (familial) / / 18985386 rs9384403 chr6 156305681 C T 1.20E-05 Parkinson's disease (familial) / / 18985386 rs4870412 chr6 156308324 C T 7.20E-05 Parkinson's disease (familial) / / 18985386 rs9371951 chr6 156314920 T C 4.30E-05 Alcohol consumption (maxi-drinks) / / 24277619 rs11156073 chr6 156319889 T G 3.25E-05 Brain structure / / 22504417 rs17086940 chr6 156320116 C A 2.58E-04 Multiple complex diseases / / 17554300 rs4869880 chr6 156320573 C T 0.0000933 post-traumatic stress disorder / / 22869035 rs4869880 chr6 156320573 C T 9.33E-05 Schizophrenia / / 22883433 rs1449679 chr6 156335489 G A 4.10E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs1449675 chr6 156342622 T C 1.94E-04 Alcohol dependence / / 20201924 rs1449675 chr6 156342622 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1349239 chr6 156351816 C T 4.66E-04 Smoking initiation / / 24665060 rs9480261 chr6 156427957 T C 4.90E-07 Urinary metabolites / / 21572414 rs9478688 chr6 156428091 G T 1.00E-04 Prostate cancer / / 21743057 rs11156081 chr6 156451494 C G 9.16E-04 Alzheimer's disease / / 24755620 rs6914206 chr6 156463321 T C 5.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6928850 chr6 156468407 C G 6.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12201446 chr6 156475282 C T 2.12E-04 Alzheimer's disease / / 24755620 rs9689110 chr6 156488698 A G 4.95E-05 Orofacial clefts / / 22419666 rs9397906 chr6 156492674 G A 9.68E-04 Alcohol dependence / / 24277619 rs9384428 chr6 156499531 C T 8.51E-06 Type 2 diabetes and other traits / / 19734900 rs9384428 chr6 156499531 C T 8.51E-06 Alzheimer's disease (late onset) / / 21460841 rs4499945 chr6 156511222 T A 9.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs4486031 chr6 156517374 A G 6.68E-04 Smoking quantity / / 24665060 rs4573097 chr6 156520533 C T 5.28E-04 Alzheimer's disease / / 24755620 rs2820406 chr6 156540417 G A 9.53E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs2818055 chr6 156549168 C T 1.60E-05 Urinary metabolites / / 21572414 rs9384443 chr6 156560746 A C 3.54E-04 Smoking quantity / / 24665060 rs2820405 chr6 156564015 C T 2.85E-04 Smoking quantity / / 24665060 rs9384447 chr6 156575128 G A 4.59E-04 Smoking quantity / / 24665060 rs2818064 chr6 156575411 T C 3.27E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12661043 chr6 156582195 T C 5.09E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs17087267 chr6 156585893 T C 1.19E-08 Corneal structure / / 22003120 rs9478696 chr6 156586753 A G 1.50E-05 Urinary metabolites / / 21572414 rs6925021 chr6 156588729 A G 2.85E-04 Multiple complex diseases / / 17554300 rs6925021 chr6 156588729 A G 5.19E-05 Serum metabolites / / 19043545 rs6918956 chr6 156617792 A G 9.40E-05 Weight / / pha003027 rs9480303 chr6 156620306 T C 1.47E-08 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs9397922 chr6 156628874 T C 5.74E-10 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs12213468 chr6 156657842 G A 7.00E-06 IgG glycosylation / / 23382691 rs12213468 chr6 156657842 G A 1.02E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9397928 chr6 156673243 T C 7.13E-04 Celiac disease / / 23936387 rs7750205 chr6 156681729 A G 7.38E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9322573 chr6 156695781 A G 4.30E-05 Coffee consumption / / 21357676 rs4429960 chr6 156714899 A G 9.86E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs9384465 chr6 156731222 C A 2.80E-05 Triglycerides / / 19074352 rs2819088 chr6 156735886 C T 0.0006798 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2819088 chr6 156735886 C T 6.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs980814 chr6 156761338 T G 7.18E-04 Type 2 diabetes / / 17463246 rs9397300 chr6 156776194 G A 2.83E-05 Type 2 diabetes / / 17463246 rs6935694 chr6 156778527 T A 2.50E-05 Type 2 diabetes / / 17463246 rs11752570 chr6 156855335 C T 7.45E-04 Type 2 diabetes / / 17463246 rs9480347 chr6 156868655 C A 8.13E-05 Corneal structure / / 22003120 rs502281 chr6 156868948 G A 6.63E-07 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs2819071 chr6 156869564 A C 5.44E-06 Type 2 diabetes / / 17463246 rs474533 chr6 156869616 G A 2.83E-05 Type 2 diabetes / / 17463246 rs6927999 chr6 156871821 T C 0.000233374 Hypertension (early onset hypertension) / / 22479346 rs184086 chr6 156873263 A G 1.56E-05 Type 2 diabetes / / 17463246 rs188285 chr6 156873502 T A 1.32E-05 Type 2 diabetes / / 17463246 rs288967 chr6 156874623 G T 4.81E-05 Type 2 diabetes / / 17463246 rs288969 chr6 156875674 T A 1.48E-05 Type 2 diabetes / / 17463246 rs2767576 chr6 156879773 T C 6.30E-05 Type 2 diabetes and other traits / / 19734900 rs288944 chr6 156886655 C T 3.52E-04 Type 2 diabetes / / 17463246 rs288944 chr6 156886655 C T 3.28E-08 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs288945 chr6 156886834 G A 1.93E-04 Type 2 diabetes / / 17463246 rs288945 chr6 156886834 G A 5.18E-08 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs1998930 chr6 156904256 A G 9.94E-06 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs2817463 chr6 156907233 T C 3.90E-04 Type 2 diabetes / / 17463246 rs2817463 chr6 156907233 T C 6.50E-04 Alzheimer's disease / / 22005930 rs2817461 chr6 156913012 G A 4.00E-08 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs9384478 chr6 156916766 G A 1.20E-10 Metabolite levels / / 23281178 rs2767584 chr6 156922747 G A 9.80E-05 Amyotrophic Lateral Sclerosis / / 17362836 rs11156119 chr6 156949912 C T 5.02E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2817460 chr6 156955041 T A 1.40E-07 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs1246182 chr6 156969316 G A 7.68E-04 Type 2 diabetes / / 17463246 rs1246182 chr6 156969316 G A 1.54E-07 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs9384488 chr6 157009381 G A 3.00E-06 Alzheimer's disease biomarkers / / 23419831 rs9384488 chr6 157009381 G A 7.67E-04 Smoking cessation / / 24665060 rs6913743 chr6 157035647 A G 3.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs9397961 chr6 157039766 T C 7.09E-05 Diabetes Mellitus / / pha003060 rs9397313 chr6 157042018 A C 1.65E-05 Blood Pressure / / pha003039 rs9397313 chr6 157042018 A C 2.56E-05 Blood Pressure / / pha003045 rs4870482 chr6 157079675 C G 4.43E-04 Acute lung injury / / 22295056 rs6927409 chr6 157108163 T C 5.62E-04 Depression (quantitative trait) ARID1B intron 20800221 rs6927409 chr6 157108163 T C 8.97E-04 Acute lung injury ARID1B intron 22295056 rs11967485 chr6 157128257 G A 9.00E-07 Calcium levels ARID1B intron 24068962 rs9397970 chr6 157130042 T G 8.36E-05 Lipoproteins ARID1B intron pha003079 rs17054612 chr6 157159522 C T 5.00E-04 Multiple complex diseases ARID1B intron 17554300 rs287902 chr6 157164808 G A 7.11E-04 Aortic root size ARID1B intron 21223598 rs6905191 chr6 157196760 G A 6.09E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) ARID1B intron 17982456 rs12204046 chr6 157212870 T C 3.19E-11 Metabolite levels ARID1B intron 22286219 rs375927292 chr6 157212870 TC T 3.19E-11 Metabolite levels ARID1B intron 22286219 rs287943 chr6 157224212 T G 5.33E-05 Post-operative nausea and vomiting ARID1B intron 21694509 rs11961360 chr6 157236031 T C 3.33E-05 Post-operative nausea and vomiting ARID1B intron 21694509 rs284427 chr6 157249226 C T 5.69E-04 Obesity (extreme) ARID1B intron 21935397 rs284418 chr6 157255918 A G 9.55E-04 Depression (quantitative trait) ARID1B intron 20800221 rs9478740 chr6 157265449 T C 5.21E-05 Soluble levels of adhesion molecules ARID1B intron pha003072 rs10485203 chr6 157265752 T C 7.94E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ARID1B intron 23648065 rs10485203 chr6 157265752 T C 2.40E-05 Soluble levels of adhesion molecules ARID1B intron pha003072 rs6420142 chr6 157290122 T C 9.52E-04 Depression (quantitative trait) ARID1B intron 20800221 rs6917637 chr6 157342087 T C 3.21E-05 Cardiovascular disease ARID1B intron pha003064 rs13216156 chr6 157390781 G T 3.35E-04 Tourette syndrome ARID1B intron 22889924 rs6941753 chr6 157398853 T C 4.32E-04 Smoking cessation ARID1B intron 24665060 rs6912493 chr6 157402041 A G 7.84E-04 Type 2 diabetes ARID1B intron 17463246 rs17279589 chr6 157411143 A G 1.53E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ARID1B intron 24023788 rs9383820 chr6 157419508 C T 9.86E-04 Acute lung injury ARID1B intron 22295056 rs9384526 chr6 157422731 G A 9.97E-06 Cognitive impairment induced by topiramate ARID1B intron 22091778 rs4870508 chr6 157437193 A T 1.48E-05 Aging (time to event) ARID1B intron 21782286 rs9480441 chr6 157439261 A G 2.02E-06 Uric acid levels ARID1B intron 21294900 rs9478751 chr6 157441050 A G 3.00E-06 Uric acid levels ARID1B intron 21294900 rs17088149 chr6 157442069 G A 2.73E-05 Magnesium levels ARID1B intron pha003092 rs6917698 chr6 157443353 A G 2.61E-09 Lipoprotein a [lp(a)] levels in plasma ARID1B intron pha002870 rs9355674 chr6 157853575 G T 2.40E-05 Urinary metabolites ZDHHC14 intron 21572414 rs17165333 chr6 157862266 T C 7.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZDHHC14 intron 20877124 rs41372249 chr6 157903731 C T 2.75E-04 Coronary Artery Disease ZDHHC14 intron 17634449 rs4709298 chr6 157915006 G C 1.17E-05 Progressive supranuclear palsy ZDHHC14 intron 21685912 rs17165397 chr6 157956347 T C 4.55E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) ZDHHC14 intron 24192120 rs9457724 chr6 157960736 A C 2.80E-05 Urinary metabolites ZDHHC14 intron 21572414 rs17544218 chr6 158006804 T C 5.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZDHHC14 intron 20877124 rs16900289 chr6 158006856 T G 6.89E-04 Premature ovarian failure ZDHHC14 intron 19508998 rs9456539 chr6 158026780 C T 6.94E-04 Suicide attempts in bipolar disorder ZDHHC14 intron 21423239 rs2163287 chr6 158041283 G A 3.00E-06 Response to antidepressant treatment ZDHHC14 intron 22041458 rs9355850 chr6 158070192 C T 4.35E-04 Multiple complex diseases ZDHHC14 intron 17554300 rs681502 chr6 158071301 T G 2.80E-05 Urinary metabolites ZDHHC14 intron 21572414 rs621936 chr6 158073926 G A 2.20E-05 Urinary metabolites ZDHHC14 intron 21572414 rs16900301 chr6 158075135 G A 0.000613 Salmonella-induced pyroptosis ZDHHC14 intron 22837397 rs9355853 chr6 158077053 C T 2.60E-05 Urinary metabolites ZDHHC14 intron 21572414 rs9458064 chr6 158078064 C T 2.00E-05 Urinary metabolites ZDHHC14 intron 21572414 rs618368 chr6 158078716 G A 2.60E-05 Urinary metabolites ZDHHC14 intron 21572414 rs628389 chr6 158080876 A G 2.10E-05 Urinary metabolites ZDHHC14 intron 21572414 rs9365242 chr6 158085284 T C 7.10E-04 Multiple complex diseases ZDHHC14 intron 17554300 rs9365242 chr6 158085284 T C 6.70E-07 Lipoprotein a [lp(a)] levels in plasma ZDHHC14 intron pha002870 rs9365243 chr6 158085403 A C 9.21E-04 Multiple complex diseases ZDHHC14 intron 17554300 rs9365243 chr6 158085403 A C 4.53E-07 Lipoprotein a [lp(a)] levels in plasma ZDHHC14 intron pha002870 rs625880 chr6 158086912 G A 4.50E-06 Urinary metabolites ZDHHC14 intron 21572414 rs6913653 chr6 158088781 C T 6.37E-04 Tourette syndrome ZDHHC14 intron 22889924 rs9295140 chr6 158090743 A G 1.01E-04 Multiple complex diseases ZDHHC14 intron 17554300 rs9295140 chr6 158090743 A G 1.00E-05 Urinary metabolites ZDHHC14 intron 21572414 rs6903041 chr6 158111700 C G 1.19E-08 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs4354179 chr6 158122377 T C 9.79E-05 Epilepsy (remission after treatment) / / 23962720 rs4365956 chr6 158124826 G A 6.44E-05 Epilepsy (remission after treatment) / / 23962720 rs56233916 chr6 158125151 C T 7.46E-05 Epilepsy (remission after treatment) / / 23962720 rs56106045 chr6 158125188 C T 6.99E-05 Epilepsy (remission after treatment) / / 23962720 rs585067 chr6 158125633 G C 9.23E-05 Epilepsy (remission after treatment) / / 23962720 rs1743591 chr6 158126292 C T 8.24E-05 Epilepsy (remission after treatment) / / 23962720 rs630009 chr6 158126305 G A 7.84E-05 Epilepsy (remission after treatment) / / 23962720 rs631365 chr6 158126655 T C 8.28E-05 Epilepsy (remission after treatment) / / 23962720 rs7751767 chr6 158127196 T C 2.73E-05 Epilepsy (remission after treatment) / / 23962720 rs7762558 chr6 158127240 G A 8.03E-05 Epilepsy (remission after treatment) / / 23962720 rs7747180 chr6 158127305 A G 7.78E-05 Epilepsy (remission after treatment) / / 23962720 rs7747206 chr6 158127357 A G 7.78E-05 Epilepsy (remission after treatment) / / 23962720 rs4709528 chr6 158127600 C T 7.78E-05 Epilepsy (remission after treatment) / / 23962720 rs664159 chr6 158128185 G A 7.81E-05 Epilepsy (remission after treatment) / / 23962720 rs1630361 chr6 158128254 A G 7.81E-05 Epilepsy (remission after treatment) / / 23962720 rs4385339 chr6 158128316 G C 7.81E-05 Epilepsy (remission after treatment) / / 23962720 rs4530888 chr6 158128321 T G 7.81E-05 Epilepsy (remission after treatment) / / 23962720 rs662859 chr6 158128467 T C 7.85E-05 Epilepsy (remission after treatment) / / 23962720 rs660368 chr6 158128498 C T 7.80E-05 Epilepsy (remission after treatment) / / 23962720 rs12333210 chr6 158128603 T C 7.84E-05 Epilepsy (remission after treatment) / / 23962720 rs660868 chr6 158128655 G T 7.82E-05 Epilepsy (remission after treatment) / / 23962720 rs661974 chr6 158128664 G A 7.82E-05 Epilepsy (remission after treatment) / / 23962720 rs661545 chr6 158128747 T G 7.84E-05 Epilepsy (remission after treatment) / / 23962720 rs661158 chr6 158128812 T G 7.81E-05 Epilepsy (remission after treatment) / / 23962720 rs676017 chr6 158129715 G A 7.37E-05 Epilepsy (remission after treatment) / / 23962720 rs629465 chr6 158129952 C T 7.41E-05 Epilepsy (remission after treatment) / / 23962720 rs629427 chr6 158129974 C T 8.31E-05 Epilepsy (remission after treatment) / / 23962720 rs2364962 chr6 158130032 C T 7.41E-05 Epilepsy (remission after treatment) / / 23962720 rs66913145 chr6 158130032 CA CCA,CTG 7.41E-05 Epilepsy (remission after treatment) / / 23962720 rs2364961 chr6 158130033 A G 7.41E-05 Epilepsy (remission after treatment) / / 23962720 rs2364960 chr6 158130169 C T 7.37E-05 Epilepsy (remission after treatment) / / 23962720 rs2364959 chr6 158130251 C T 7.32E-05 Epilepsy (remission after treatment) / / 23962720 rs2364958 chr6 158130253 T C 7.32E-05 Epilepsy (remission after treatment) / / 23962720 rs7756028 chr6 158130397 C T 7.28E-05 Epilepsy (remission after treatment) / / 23962720 rs4618554 chr6 158130647 C T 7.38E-05 Epilepsy (remission after treatment) / / 23962720 rs4385340 chr6 158130792 G A 7.38E-05 Epilepsy (remission after treatment) / / 23962720 rs603862 chr6 158130808 A G 7.38E-05 Epilepsy (remission after treatment) / / 23962720 rs594216 chr6 158130888 C T 7.38E-05 Epilepsy (remission after treatment) / / 23962720 rs605192 chr6 158131090 C T 7.34E-05 Epilepsy (remission after treatment) / / 23962720 rs595618 chr6 158131240 C T 7.34E-05 Epilepsy (remission after treatment) / / 23962720 rs7773413 chr6 158131253 T C 7.34E-05 Epilepsy (remission after treatment) / / 23962720 rs597071 chr6 158131539 A C 7.34E-05 Epilepsy (remission after treatment) / / 23962720 rs597448 chr6 158131582 C T 7.38E-05 Epilepsy (remission after treatment) / / 23962720 rs598385 chr6 158131806 G A 7.38E-05 Epilepsy (remission after treatment) / / 23962720 rs598437 chr6 158131845 G A 7.38E-05 Epilepsy (remission after treatment) / / 23962720 rs9458285 chr6 158131946 G A 2.54E-05 Erythrocyte counts / / pha003090 rs7766023 chr6 158132992 G A 6.40E-05 Epilepsy (remission after treatment) / / 23962720 rs16900375 chr6 158144402 G A 7.90E-05 Endometriosis / / 21151130 rs16900375 chr6 158144402 G A 4.40E-06 Endometriosis / / 23104006 rs11754106 chr6 158152331 G A 3.94E-05 Erythrocyte counts / / pha003090 rs11757522 chr6 158152646 T C 3.94E-05 Erythrocyte counts / / pha003090 rs9346896 chr6 158188548 T C 1.30E-05 Menarche (age at onset) / / 19448622 rs2803363 chr6 158216859 A C 8.10E-04 Multiple complex diseases / / 17554300 rs2803353 chr6 158274398 A C 0.0000428 Tuberculosis with early age of onset SNX9 intron 22551897 rs9456882 chr6 158357861 A T 6.25E-05 Aging (time to event) SNX9 intron 21782286 rs577 chr6 158365035 C T 2.59E-04 Myopia (pathological) SNX9 UTR-3 21095009 rs9347800 chr6 158371084 T C 3.38E-04 Myopia (pathological) / / 21095009 rs576494360 chr6 158389741 C CT 7.00E-06 Cannabis use (initiation) / / 22823124 rs9458975 chr6 158389741 C T 7.00E-06 Cannabis use (initiation) / / 22823124 rs9365674 chr6 158411156 C T 9.27E-05 Alcohol dependence SYNJ2 intron 21703634 rs9459093 chr6 158424693 T C 5.83E-04 Amyotrophic Lateral Sclerosis SYNJ2 intron 17362836 rs9365723 chr6 158435572 A G 4.00E-06 Colorectal cancer SYNJ2 intron 23300701 rs12665500 chr6 158472331 G C 8.25E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SYNJ2 intron 20031582 rs1750034 chr6 158480144 A C 2.70E-04 Alcohol dependence SYNJ2 intron 24277619 rs17489570 chr6 158487953 G A 7.19E-05 Tunica Media SYNJ2 intron pha003034 rs1750047 chr6 158489240 C T 2.77E-04 Multiple complex diseases SYNJ2 intron 17554300 rs7755331 chr6 158494702 A G 7.63E-05 Serum metabolites SYNJ2 intron 19043545 rs6455990 chr6 158494775 A G 4.40E-05 Serum metabolites SYNJ2 intron 19043545 rs2256014 chr6 158502137 G T 7.70E-04 Smoking initiation SYNJ2 intron 24665060 rs1744169 chr6 158508225 A G 2.49E-04 Heart Failure SYNJ2 intron pha002884 rs2502601 chr6 158517308 A G 1.17E-04 Heart Failure SYNJ2 missense pha002884 rs2475556 chr6 158523142 A G 1.31E-04 Heart Failure / / pha002884 rs12197370 chr6 158557887 G A 2.70E-05 Magnesium levels SERAC1 intron pha003092 rs844140 chr6 158559634 T G 1.81E-04 Smoking quantity SERAC1 intron 24665060 rs6929274 chr6 158571501 G A 7.04E-04 Heart Failure SERAC1 cds-synon pha002884 rs9942466 chr6 158584409 T G 1.60E-24 Narcolepsy SERAC1 intron 19629137 rs4560672 chr6 158607473 C A 8.00E-06 Smoking quantity GTF2H5 intron 24665060 rs9459642 chr6 158611969 G A 7.27E-04 Smoking quantity GTF2H5 intron 24665060 rs6929952 chr6 158651395 C T 1.90E-05 Tunica Media / / pha003034 rs667778 chr6 158672384 T C 6.77E-04 Multiple complex diseases / / 17554300 rs9364885 chr6 158674176 A G 6.66E-04 Lymphocyte counts / / 22286170 rs262825 chr6 158678631 A G 1.81E-05 Tunica Media / / pha003034 rs9355613 chr6 158689753 T C 9.89E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs9348250 chr6 158708822 A G 3.10E-05 Cognitive impairment induced by topiramate / / 22091778 rs4709189 chr6 158737693 A C 6.73E-04 Multiple complex diseases TULP4 intron 17554300 rs7767157 chr6 158750405 A G 9.85E-04 Multiple complex diseases TULP4 intron 17554300 rs1547816 chr6 158753731 T G 7.77E-04 Multiple complex diseases TULP4 intron 17554300 rs6455579 chr6 158756739 C T 3.04E-04 Multiple complex diseases TULP4 intron 17554300 rs7755420 chr6 158757347 G C 4.96E-05 Type 1 diabetes TULP4 intron 18978792 rs6926291 chr6 158758501 C G 6.99E-04 Multiple complex diseases TULP4 intron 17554300 rs6926291 chr6 158758501 C G 6.31E-05 Type 1 diabetes TULP4 intron 18978792 rs1754405 chr6 158768466 A C 6.78E-04 Multiple complex diseases TULP4 intron 17554300 rs1754405 chr6 158768466 A C 6.30E-05 Type 1 diabetes TULP4 intron 18978792 rs828005 chr6 158776787 T C 3.43E-04 Multiple complex diseases TULP4 intron 17554300 rs705936 chr6 158812361 A G 4.15E-07 Lipoprotein a [lp(a)] levels in plasma TULP4 intron pha002870 rs697505 chr6 158816875 T G 7.63E-04 Amyotrophic Lateral Sclerosis TULP4 intron 17827064 rs341134 chr6 158868618 C T 3.75E-04 IgE levels TULP4 intron 17255346 rs341134 chr6 158868618 C T 4.94E-04 Multiple complex diseases TULP4 intron 17554300 rs6920842 chr6 158870547 G C 3.36E-07 Lipoprotein a [lp(a)] levels in plasma TULP4 intron pha002870 rs1754416 chr6 158877932 G A 4.22E-04 IgE levels TULP4 intron 17255346 rs602698 chr6 158881764 C G 3.27E-04 IgE levels TULP4 intron 17255346 rs635995 chr6 158886858 C T 2.32E-04 Amyotrophic Lateral Sclerosis TULP4 intron 17827064 rs660213 chr6 158890892 G A 2.32E-04 Amyotrophic Lateral Sclerosis TULP4 intron 17827064 rs675053 chr6 158891953 T G 3.56E-04 IgE levels TULP4 intron 17255346 rs1041566 chr6 158916972 G A 1.67E-04 Multiple complex diseases TULP4 intron 17554300 rs1041566 chr6 158916972 G A 4.71E-05 Type 1 diabetes TULP4 intron 18978792 rs9456307 chr6 158929442 T A 2.00E-09 Height TULP4 UTR-3 20881960 rs17583127 chr6 158931875 T G 9.73E-04 Suicide attempts in bipolar disorder TULP4 UTR-3 21423239 rs2033970 chr6 158966332 C T 4.30E-04 Multiple complex diseases TMEM181 intron 17554300 rs10447366 chr6 158969177 A G 3.13E-05 Serum metabolites TMEM181 intron 19043545 rs10447366 chr6 158969177 A G 1.54E-06 Cognitive test performance TMEM181 intron 20125193 rs10447366 chr6 158969177 A G 9.13E-05 Adipocyte fatty acid-binding protein concentration,in serum TMEM181 intron 21863005 rs9364973 chr6 158975716 C T 4.66E-06 Cognitive test performance TMEM181 intron 20125193 rs9457403 chr6 158980351 A G 4.76E-06 Stroke (ischemic) TMEM181 intron 22941190 rs10223384 chr6 158998571 G A 8.77E-04 White matter integrity TMEM181 intron 22425255 rs9457409 chr6 159012832 G A 9.35E-04 White matter integrity TMEM181 intron 22425255 rs9456330 chr6 159032234 A G 7.44E-06 Lung function (forced expiratory volume in 1 second) TMEM181 intron pha003102 rs9456330 chr6 159032234 A G 2.70E-05 Lung function (forced vital capacity) TMEM181 intron pha003104 rs9457417 chr6 159050540 G A 7.32E-05 Blood Pressure TMEM181 intron pha003046 rs7746447 chr6 159056576 C T 7.32E-05 Blood Pressure / / pha003046 rs317789 chr6 159101293 A G 3.56E-04 Amyotrophic Lateral Sclerosis SYTL3 intron 17827064 rs9364496 chr6 159122084 G A 1.79E-11 Lipoprotein a [lp(a)] levels in plasma SYTL3 intron pha002870 rs6455600 chr6 159146871 C T 1.05E-04 Smoking cessation SYTL3 intron 18519826 rs6455600 chr6 159146871 C T 1.19E-07 Lipoprotein a [lp(a)] levels in plasma SYTL3 intron pha002870 rs2129209 chr6 159155998 A C 2.62E-08 Lipoprotein a [lp(a)] levels in plasma SYTL3 intron pha002870 rs6455601 chr6 159166883 A G 1.32E-06 Smoking cessation SYTL3 intron 18519826 rs9456350 chr6 159167285 A G 2.32E-10 Lipoprotein a [lp(a)] levels in plasma SYTL3 intron pha002870 rs2171209 chr6 159183562 T C 0.000000602 Ankle-brachial index SYTL3 intron 22361517 rs3102970 chr6 159199519 G C 9.86E-05 Serum metabolites EZR intron 19043545 rs744893 chr6 159202240 G C 2.53E-07 Lipoprotein a [lp(a)] levels in plasma EZR intron pha002870 rs6455604 chr6 159215408 C T 4.49E-04 Type 2 diabetes EZR intron 17463246 rs3127194 chr6 159225284 A C 9.74E-05 Serum metabolites EZR intron 19043545 rs923198 chr6 159246717 C T 3.24E-04 Type 2 diabetes / / 17463246 rs4569991 chr6 159279294 T C 8.14E-04 Type 2 diabetes / / 17463246 rs4569991 chr6 159279294 T C 3.69E-04 Lymphocyte counts / / 22286170 rs12194837 chr6 159279451 A G 1.14E-05 Cytomegalovirus antibody response / / 21993531 rs9355684 chr6 159324086 A G 2.97E-04 Lung function (forced expiratory volume in 1 second) C6orf99 intron 24023788 rs9347272 chr6 159324551 T C 3.42E-04 Body mass index C6orf99 intron 17255346 rs9457516 chr6 159335251 C T 8.02E-05 Type 2 diabetes / / 17463246 rs9365006 chr6 159339600 C T 0.000128714 Primary sclerosing cholangitis / / 23603763 rs9365009 chr6 159340672 A C 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs9365009 chr6 159340672 A C 1.98E-05 Lung Function (Forced Expiratory Volume in 1 second) / / 25044411 rs9365009 chr6 159340672 A C 4.19E-07 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs3923899 chr6 159343363 C T 7.14E-04 Type 2 diabetes / / 17463246 rs12216499 chr6 159368524 G T 1.00E-06 Bladder cancer (smoking interaction) / / 24662972 rs10945582 chr6 159381088 G C 2.08E-05 Lymphocyte counts / / 22286170 rs3117162 chr6 159425007 C A 1.00E-04 Information processing speed / / 21130836 rs2016588 chr6 159425707 C T 1.29E-07 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs1033522 chr6 159435769 G A 5.96E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs2057061 chr6 159436594 G T 3.47E-08 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs926657 chr6 159463452 C T 3.98E-07 Celiac disease and Rheumatoid arthritis TAGAP intron 21383967 rs9295089 chr6 159463964 T C 1.71E-07 Celiac disease and Rheumatoid arthritis TAGAP intron 21383967 rs1738074 chr6 159465977 T C 7.00E-08 Celiac disease TAGAP UTR-5 18311140 rs1738074 chr6 159465977 T C 3.00E-15 Celiac disease TAGAP UTR-5 20190752 rs1738074 chr6 159465977 T C 3.00E-15 Asthma TAGAP UTR-5 21150878 rs1738074 chr6 159465977 T C 1.53E-04 Crohn's disease and Celiac disease TAGAP UTR-5 21298027 rs1738074 chr6 159465977 T C 2.94E-15 Celiac disease and Rheumatoid arthritis TAGAP UTR-5 21383967 rs1738074 chr6 159465977 T C 7.00E-15 Multiple sclerosis TAGAP UTR-5 21833088 rs1738074 chr6 159465977 T C 4.00E-07 Multiple sclerosis TAGAP UTR-5 22190364 rs1738074 chr6 159465977 T C 7.50E-04 Multiple sclerosis TAGAP UTR-5 24234648 rs1738074 chr6 159465977 T C 3.40E-08 Celiac disease TAGAP UTR-5 24999842 rs182429 chr6 159469574 A G 8.50E-16 Celiac disease / / 22057235 rs182429 chr6 159469574 A G 8.50E-16 Celiac disease / / 23143596 rs212402 chr6 159472295 G A 5.39E-06 Rheumatoid arthritis / / 19503088 rs212402 chr6 159472295 G A 9.32E-12 Celiac disease and Rheumatoid arthritis / / 21383967 rs212402 chr6 159472295 G A 2.11E-05 Type 1 diabetes / / 21980299 rs212402 chr6 159472295 G A 8.00E-09 Celiac disease / / 24999842 rs9457545 chr6 159478308 C T 4.01E-05 Information processing speed / / 21130836 rs394581 chr6 159482521 C T 8.48E-04 Multiple complex diseases / / 17554300 rs394581 chr6 159482521 C T 7.70E-04 Rheumatoid arthritis / / 22446963 rs394581 chr6 159482521 C T 0.0000162 Rheumatoid arthritis / / 23143596 rs169858 chr6 159484776 T C 6.89E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs169858 chr6 159484776 T C 1.27E-07 Celiac disease / / 24999842 rs212389 chr6 159489791 G A 2.70E-09 Celiac disease and Rheumatoid arthritis / / 21383967 rs212389 chr6 159489791 G A 2.70E-09 Multiple sclerosis / / 22190364 rs212389 chr6 159489791 G A 0.0000299 Rheumatoid arthritis / / 23143596 rs212389 chr6 159489791 G A 9.11E-09 Rheumatoid arthritis (CCP positive) / / 23143596 rs212388 chr6 159490436 C T 2.00E-11 Crohn's disease / / 21102463 rs212388 chr6 159490436 C T 2.00E-10 Crohn's disease and celiac disease / / 21298027 rs212388 chr6 159490436 C T 5.43E-12 Celiac disease and Rheumatoid arthritis / / 21383967 rs212388 chr6 159490436 C T 3.00E-14 Crohn's disease / / 23128233 rs212388 chr6 159490436 C T 1.82E-08 Celiac disease / / 24999842 rs629326 chr6 159496713 G T 0.0000011 Rheumatoid arthritis / / 23143596 rs629326 chr6 159496713 G T 0.00000259 Rheumatoid arthritis (CCP positive) / / 23143596 rs1107943 chr6 159498267 T C 2.80E-06 Celiac disease / / 22057235 rs1107943 chr6 159498267 T C 0.0000028 Celiac disease / / 23143596 rs3103418 chr6 159501256 G A 2.69E-05 Type 2 diabetes / / 17463246 rs2451258 chr6 159506600 C T 0.000000034 Psoriasis / / 23143594 rs2451258 chr6 159506600 C T 2.00E-10 Rheumatoid arthritis / / 24390342 rs2451258 chr6 159506600 C T 3.00E-11 Rheumatoid arthritis / / 24390342 rs654690 chr6 159514778 T C 3.76E-10 Celiac disease and Rheumatoid arthritis / / 21383967 rs654690 chr6 159514778 T C 3.05E-08 Celiac disease / / 24999842 rs2249937 chr6 159515309 T G 1.87E-09 Celiac disease and Rheumatoid arthritis / / 21383967 rs2249937 chr6 159515309 T G 2.74E-07 Celiac disease / / 24999842 rs7773991 chr6 159538417 C T 1.28E-05 Odorant perception / / 23910658 rs12208790 chr6 159546742 C T 2.60E-06 White blood cell count / / 21738479 rs7765276 chr6 159549389 G A 5.25E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs295327 chr6 159599952 A G 1.90E-05 Urinary metabolites FNDC1 intron 21572414 rs294917 chr6 159627077 C T 7.56E-04 Coronary heart disease FNDC1 intron 21606135 rs626959 chr6 159631397 C A 4.53E-04 Insulin resistance FNDC1 intron 21901158 rs400477 chr6 159635943 T G 2.90E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) FNDC1 intron 17982456 rs418851 chr6 159636476 G A 5.04E-04 Sarcoidosis FNDC1 intron 19165924 rs391128 chr6 159639572 G C 6.55E-04 Coronary Artery Disease FNDC1 intron 17634449 rs484504 chr6 159641400 C T 5.80E-04 Insulin resistance FNDC1 intron 21901158 rs444245 chr6 159642963 C T 4.40E-04 Coronary heart disease FNDC1 intron 21606135 rs2782552 chr6 159643696 C A 2.25E-04 Coronary heart disease FNDC1 intron 21606135 rs365302 chr6 159646333 T C 8.00E-07 Coronary heart disease FNDC1 intron 21606135 rs294890 chr6 159677498 C T 5.61E-04 Coronary Artery Disease FNDC1 intron 17634449 rs294888 chr6 159677992 A G 5.82E-04 Coronary Artery Disease FNDC1 intron 17634449 rs554978 chr6 159683857 C T 9.63E-04 Coronary Artery Disease FNDC1 intron 17634449 rs553068 chr6 159684082 C T 7.72E-04 Coronary Artery Disease FNDC1 intron 17634449 rs406914 chr6 159691622 A G 5.90E-04 Coronary Artery Disease FNDC1 intron 17634449 rs372415 chr6 159698312 T C 1.16E-04 Multiple complex diseases / / 17554300 rs10806706 chr6 159721945 A C 6.83E-08 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs4708818 chr6 159723503 C G 6.79E-07 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs1504257 chr6 159727806 G A 4.46E-04 Coronary Artery Disease / / 17634449 rs905685 chr6 159733448 G A 2.77E-04 Coronary Artery Disease / / 17634449 rs2036522 chr6 159748244 A C 7.20E-04 Coronary Artery Disease / / 17634449 rs9365056 chr6 159807939 G A 5.19E-05 Coronary heart disease / / pha003055 rs2880072 chr6 159825449 G A 2.98E-07 Chronic kidney disease / / 21931561 rs2880072 chr6 159825449 G A 4.90E-05 Chronic kidney disease / / 21931561 rs4709322 chr6 159857915 A G 0.0000127 Tuberculosis with late age of onset / / 22551897 rs1890579 chr6 159859517 T C 7.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs4709325 chr6 159863732 A C 4.82E-04 Multiple complex diseases / / 17554300 rs4708828 chr6 159869119 T C 9.28E-04 Alzheimer's disease / / 24755620 rs9295101 chr6 159873868 C T 4.14E-04 Alzheimer's disease / / 24755620 rs9364522 chr6 159881077 T C 4.53E-04 Alzheimer's disease / / 24755620 rs7742825 chr6 159891058 T C 1.53E-05 Intracerebral hemorrhage / / 24656865 rs7742825 chr6 159891058 T C 4.72E-05 Intracerebral hemorrhage / / 24656865 rs75966668 chr6 159892086 G C 1.66E-05 Intracerebral hemorrhage / / 24656865 rs75966668 chr6 159892086 G C 4.06E-05 Intracerebral hemorrhage / / 24656865 rs6919753 chr6 159896460 C A 5.63E-04 Smoking initiation / / 24665060 rs17186366 chr6 159898261 T C 1.72E-05 Intracerebral hemorrhage / / 24656865 rs17186366 chr6 159898261 T C 4.43E-05 Intracerebral hemorrhage / / 24656865 rs11962266 chr6 159898390 A G 6.19E-04 Smoking initiation / / 24665060 rs4709336 chr6 159898784 C T 1.60E-05 Intracerebral hemorrhage / / 24656865 rs4709336 chr6 159898784 C T 4.96E-05 Intracerebral hemorrhage / / 24656865 rs75445591 chr6 159900715 C T 1.72E-05 Intracerebral hemorrhage / / 24656865 rs75445591 chr6 159900715 C T 4.44E-05 Intracerebral hemorrhage / / 24656865 rs56366023 chr6 159900835 G A 1.38E-05 Intracerebral hemorrhage / / 24656865 rs56366023 chr6 159900835 G A 3.22E-05 Intracerebral hemorrhage / / 24656865 rs6929061 chr6 159903581 G A 1.10E-04 Alzheimer's disease / / 24755620 rs77811151 chr6 159905776 T C 1.54E-05 Intracerebral hemorrhage / / 24656865 rs77811151 chr6 159905776 T C 4.12E-05 Intracerebral hemorrhage / / 24656865 rs59722191 chr6 159906395 A G 1.41E-05 Intracerebral hemorrhage / / 24656865 rs59722191 chr6 159906395 A G 4.44E-05 Intracerebral hemorrhage / / 24656865 rs73585056 chr6 159907069 C T 1.42E-05 Intracerebral hemorrhage / / 24656865 rs73585056 chr6 159907069 C T 4.46E-05 Intracerebral hemorrhage / / 24656865 rs2100338 chr6 159911058 A T 2.25E-05 Intracerebral hemorrhage / / 24656865 rs2100338 chr6 159911058 A T 4.86E-05 Intracerebral hemorrhage / / 24656865 rs76959746 chr6 159911213 T C 1.65E-05 Intracerebral hemorrhage / / 24656865 rs76959746 chr6 159911213 T C 4.31E-05 Intracerebral hemorrhage / / 24656865 rs16890441 chr6 159912117 C T 1.52E-05 Intracerebral hemorrhage / / 24656865 rs16890441 chr6 159912117 C T 4.67E-05 Intracerebral hemorrhage / / 24656865 rs9295102 chr6 159912294 G A 3.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs192138 chr6 159912337 G A 3.41E-04 Alzheimer's disease (late onset) / / 21379329 rs192138 chr6 159912337 G A 8.36E-05 Body Fat Distribution / / pha003017 rs4709340 chr6 159912782 T C 1.40E-05 Intracerebral hemorrhage / / 24656865 rs4709340 chr6 159912782 T C 4.29E-05 Intracerebral hemorrhage / / 24656865 rs240865 chr6 159912854 A G 1.56E-04 Alzheimer's disease / / 24755620 rs77854375 chr6 159913356 T C 1.63E-05 Intracerebral hemorrhage / / 24656865 rs77854375 chr6 159913356 T C 4.32E-05 Intracerebral hemorrhage / / 24656865 rs73585061 chr6 159914043 G A 1.40E-05 Intracerebral hemorrhage / / 24656865 rs73585061 chr6 159914043 G A 4.28E-05 Intracerebral hemorrhage / / 24656865 rs365557 chr6 159914714 T C 1.77E-04 Alzheimer's disease / / 24755620 rs434558 chr6 159914754 G C 4.39E-04 Multiple complex diseases / / 17554300 rs240863 chr6 159915825 A G 2.50E-05 Alzheimer's disease / / 24755620 rs73585064 chr6 159917210 C A 1.47E-05 Intracerebral hemorrhage / / 24656865 rs73585064 chr6 159917210 C A 4.48E-05 Intracerebral hemorrhage / / 24656865 rs73586917 chr6 159917621 C T 1.47E-05 Intracerebral hemorrhage / / 24656865 rs73586917 chr6 159917621 C T 4.50E-05 Intracerebral hemorrhage / / 24656865 rs73586920 chr6 159919436 T C 1.50E-05 Intracerebral hemorrhage / / 24656865 rs73586920 chr6 159919436 T C 4.56E-05 Intracerebral hemorrhage / / 24656865 rs73586921 chr6 159920510 C T 1.41E-05 Intracerebral hemorrhage / / 24656865 rs73586921 chr6 159920510 C T 4.33E-05 Intracerebral hemorrhage / / 24656865 rs73586924 chr6 159920582 G A 1.80E-05 Intracerebral hemorrhage / / 24656865 rs73586925 chr6 159920607 C T 1.80E-05 Intracerebral hemorrhage / / 24656865 rs73586928 chr6 159920952 A C 1.71E-05 Intracerebral hemorrhage / / 24656865 rs73586930 chr6 159921535 G C 1.52E-05 Intracerebral hemorrhage / / 24656865 rs73586930 chr6 159921535 G C 4.64E-05 Intracerebral hemorrhage / / 24656865 rs73586931 chr6 159921935 C G 1.65E-05 Intracerebral hemorrhage / / 24656865 rs76681056 chr6 159922039 A G 1.88E-05 Intracerebral hemorrhage / / 24656865 rs240831 chr6 159922571 C T 2.00E-04 Alzheimer's disease (late onset) / / 21379329 rs73586936 chr6 159922820 C G 1.66E-05 Intracerebral hemorrhage / / 24656865 rs55875257 chr6 159923470 C A 1.47E-05 Intracerebral hemorrhage / / 24656865 rs80276229 chr6 159924294 T G 1.16E-05 Intracerebral hemorrhage / / 24656865 rs80276229 chr6 159924294 T G 3.56E-05 Intracerebral hemorrhage / / 24656865 rs7760303 chr6 159924923 G C 2.50E-05 Intracerebral hemorrhage / / 24656865 rs7743711 chr6 159925359 A G 2.16E-05 Intracerebral hemorrhage / / 24656865 rs6455651 chr6 159926784 G A 4.98E-05 Intracerebral hemorrhage / / 24656865 rs2341786 chr6 159928324 G A 5.81E-08 Metabolite levels / / 23281178 rs12197995 chr6 159942955 G A 1.53E-14 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs555627 chr6 159959673 G A 1.12E-08 Hepatitis B / / 24162738 rs10484949 chr6 159993273 A C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6941483 chr6 159993523 G A 7.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs6927511 chr6 159997892 G A 3.65E-04 Multiple complex diseases / / 17554300 rs6927511 chr6 159997892 G A 5.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs6455660 chr6 159998835 G T 7.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs10945621 chr6 159999186 G T 8.05E-05 Cognitive impairment induced by topiramate / / 22091778 rs6455662 chr6 160003421 C T 7.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs12664487 chr6 160022279 T A 3.24E-04 Multiple complex diseases / / 17554300 rs1551218 chr6 160024048 G C 2.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs1551219 chr6 160024181 A C 3.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs1551220 chr6 160024243 G T 2.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs7754295 chr6 160061229 C T 3.97E-04 Multiple complex diseases / / 17554300 rs2758317 chr6 160067287 C A 7.17E-04 Multiple complex diseases / / 17554300 rs2842992 chr6 160071159 G A 3.00E-07 Age-related macular degeneration (GA) / / 22705344 rs2842991 chr6 160071844 A C 3.66E-04 Multiple complex diseases / / 17554300 rs732498 chr6 160091560 G A 3.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs8031 chr6 160100640 A T 3.53E-04 Multiple complex diseases SOD2 intron 17554300 rs5746136 chr6 160103084 C T 4.71E-04 Suicide attempts in bipolar disorder SOD2 UTR-3 21423239 rs2758331 chr6 160105070 C A 2.93E-05 Longevity SOD2 intron 22279548 rs2842960 chr6 160113321 C T 6.42E-05 Glaucoma (primary open-angle) SOD2 intron 22605921 rs4880 chr6 160113872 A G 1 Drug response to Cyclophosphamide SOD2 missense 19509150 rs9355747 chr6 160135577 T G 9.91E-04 Multiple complex diseases / / 17554300 rs4516970 chr6 160137687 G A 1.00E-06 Iron status biomarkers / / 19084217 rs2842966 chr6 160141592 C T 8.20E-04 Multiple complex diseases / / 17554300 rs2842972 chr6 160157904 C T 1.96E-06 Serum metabolites WTAP intron 19043545 rs2842974 chr6 160159034 C T 8.49E-04 Multiple complex diseases WTAP intron 17554300 rs927450 chr6 160182096 A G 3.04E-06 Serum metabolites / / 19043545 rs4709368 chr6 160204127 T C 3.27E-04 Multiple complex diseases TCP1 intron 17554300 rs7765490 chr6 160204326 C T 3.79E-04 Multiple complex diseases TCP1 intron 17554300 rs3818299 chr6 160206631 T C 6.84E-06 Serum metabolites TCP1 intron 19043545 rs2273828 chr6 160207049 T C 6.84E-06 Serum metabolites TCP1 intron 19043545 rs927451 chr6 160213436 C A 2.60E-05 Serum metabolites MRPL18 intron 19043545 rs9365098 chr6 160230911 A G 7.90E-05 Waist-Hip Ratio PNLDC1 intron pha003029 rs6902339 chr6 160247249 G T 2.30E-06 Urinary metabolites / / 21572414 rs6904744 chr6 160264661 C T 6.50E-04 Type 2 diabetes / / 17463246 rs6924573 chr6 160286188 G T 8.52E-05 Waist-Hip Ratio / / pha003029 rs111910490 chr6 160293659 G A 6.62E-11 Metabolite levels / / 22286219 rs6925813 chr6 160301358 T C 7.94E-05 Brain lesion load / / 19010793 rs220721 chr6 160328620 C T 3.24E-04 Lymphocyte counts MAS1 cds-synon 22286170 rs12207188 chr6 160331654 C T 1.09E-07 Lipoproteins / / pha003079 rs9346799 chr6 160347111 A T 2.10E-05 Urinary metabolites / / 21572414 rs6920701 chr6 160358781 A G 4.86E-04 Type 2 diabetes / / 17463246 rs12202350 chr6 160379096 T C 1.95E-05 Brain lesion load / / 19010793 rs6934383 chr6 160384403 A G 7.89E-05 Major depressive disorder / / 19107115 rs6934383 chr6 160384403 A G 1.50E-05 Sickle cell anemia (severity) / / 20029952 rs6917747 chr6 160402705 G A 7.00E-06 Brain lesion load IGF2R intron 19010793 rs2277070 chr6 160445793 A G 2.80E-05 Urinary metabolites IGF2R intron 21572414 rs1867348 chr6 160456163 C T 0.000063 Pancreatic cancer and survival IGF2R intron 22665904 rs78797168 chr6 160459191 A G 2.00E-06 Periodontitis (CDC/AAP) IGF2R intron 24024966 rs13218689 chr6 160459205 G T 2.30E-05 Urinary metabolites IGF2R intron 21572414 rs435612 chr6 160463936 G A 2.53E-04 Suicide attempts in bipolar disorder IGF2R intron 21423239 rs8191818 chr6 160471191 T G 3.11E-07 Lipoprotein a [lp(a)] levels in plasma IGF2R intron pha002870 rs8191824 chr6 160477885 G A 1.35E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) IGF2R intron 22566498 rs8191829 chr6 160479478 G A 6.60E-04 Coronary Artery Disease IGF2R intron 17634449 rs8191829 chr6 160479478 G A 3.39E-14 Lipoprotein a [lp(a)] levels in plasma IGF2R intron pha002870 rs8191855 chr6 160485060 G A 3.65E-05 Multiple complex diseases IGF2R intron 17554300 rs3777401 chr6 160512748 G A 4.45E-05 Cognitive impairment induced by topiramate IGF2R intron 22091778 rs600324 chr6 160519276 T C 5.72E-04 Premature ovarian failure IGF2R intron 19508998 rs600324 chr6 160519276 T C 4.40E-05 Lipoproteins IGF2R intron pha003079 rs2297371 chr6 160525187 G A 8.09E-05 Taste perception IGF2R intron 22132133 rs7753051 chr6 160528057 T C 1.14E-12 Lipoprotein a [lp(a)] levels in plasma IGF2R nearGene-3 pha002870 rs10080371 chr6 160532075 G A 1.89E-05 Cognitive impairment induced by topiramate / / 22091778 rs1867351 chr6 160543123 T C 5.75E-04 Taste perception SLC22A1 cds-synon 22132133 rs12208357 chr6 160543148 C T 1 Drug response to Metformin SLC22A1 missense 17609683 rs12208357 chr6 160543148 C T 1 Drug response to Metformin SLC22A1 missense 19940846 rs4646272 chr6 160551093 T G 3.86E-05 Cognitive impairment induced by topiramate SLC22A1 intron 22091778 rs3798174 chr6 160552803 C T 6.83E-04 Response to cytadine analogues (cytosine arabinoside) SLC22A1 intron 24483146 rs34104736 chr6 160553314 C T 1 Drug response to Metformin SLC22A1 missense 19940846 rs36103319 chr6 160553407 G A,C,T 1 Drug response to Metformin SLC22A1 missense 19940846 rs34130495 chr6 160560824 G A 1 Drug response to Metformin SLC22A1 missense 19940846 rs142448543 chr6 160560881 A G 1 Drug response to Metformin SLC22A1 STOP-GAIN 19940846 rs34305973 chr6 160560881 AT A 1 Drug response to Metformin SLC22A1 STOP-GAIN 19940846 rs35191146 chr6 160560882 TG T 1 Drug response to Metformin SLC22A1 frameshift 19940846 rs662138 chr6 160564476 C G 7.00E-25 Metabolic traits SLC22A1 intron 21886157 rs662138 chr6 160564476 C G 1.00E-22 Blood metabolite levels SLC22A1 intron 24816252 rs662138 chr6 160564476 C G 3.00E-14 Blood metabolite levels SLC22A1 intron 24816252 rs662138 chr6 160564476 C G 5.00E-49 Blood metabolite levels SLC22A1 intron 24816252 rs662138 chr6 160564476 C G 9.00E-25 Blood metabolite levels SLC22A1 intron 24816252 rs622342 chr6 160572866 C A 1 Drug response to Metformin SLC22A1 intron 19381165 rs622342 chr6 160572866 C A 1 Drug response to Metformin SLC22A1 intron 19898263 rs622342 chr6 160572866 C A 3.00E-04 B cell non-Hodgkin lymphoma SLC22A1 intron 23749188 rs1443844 chr6 160574802 A G 7.06E-05 Lipoproteins SLC22A1 intron pha003079 rs34059508 chr6 160575837 G A,C,T 1 Drug response to Metformin SLC22A1 missense 17609683 rs34059508 chr6 160575837 G A,C,T 1 Drug response to Metformin SLC22A1 missense 19940846 rs2297374 chr6 160575985 C T 2.16E-05 HIV-1 viral setpoint SLC22A1 intron 21490045 rs9295125 chr6 160578271 G T 3.19E-07 Coronary heart disease SLC22A1 intron 22319020 rs1564348 chr6 160578860 T C 1.00E-16 Cholesterol,total SLC22A1 intron 20686565 rs1564348 chr6 160578860 T C 2.00E-17 LDL cholesterol SLC22A1 intron 20686565 rs1564348 chr6 160578860 T C 3.00E-21 LDL cholesterol SLC22A1 intron 24097068 rs1564348 chr6 160578860 T C 3.00E-23 Cholesterol,total SLC22A1 intron 24097068 rs651164 chr6 160581374 A G 2.00E-09 Prostate cancer / / 19767753 rs651164 chr6 160581374 A G 2.00E-09 Nasopharyngeal carcinoma / / 20512145 rs651164 chr6 160581374 A G 2.00E-10 Prostate cancer / / 21743057 rs4646283 chr6 160581502 T C 5.94E-04 Type 2 diabetes / / 17463246 rs4646283 chr6 160581502 T C 1.09E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6455682 chr6 160581911 G A 4.55E-09 Lipoproteins / / pha003079 rs3101826 chr6 160584853 C T 1.30E-06 Lipoproteins / / pha003079 rs791195 chr6 160598486 A G 1.07E-05 Rheumatoid arthritis / / 21452313 rs791190 chr6 160613707 T C 1.51E-05 Rheumatoid arthritis / / 21452313 rs476235 chr6 160622637 G A 7.92E-07 Lipoproteins / / pha003079 rs2619268 chr6 160625978 T G 2.08E-04 Multiple complex diseases / / 17554300 rs3103353 chr6 160638076 C T 1.35E-11 Lipoproteins SLC22A2 UTR-3 pha003079 rs3103352 chr6 160638725 G A 1.35E-11 Lipoproteins SLC22A2 intron pha003079 rs316000 chr6 160642528 G A 4.10E-04 Lung function (forced expiratory volume in 1 second) SLC22A2 intron 17255346 rs3798158 chr6 160646222 T G 1.20E-04 HDL particle features SLC22A2 intron 21283740 rs3798158 chr6 160646222 T G 9.00E-04 HDL particle features SLC22A2 intron 21283740 rs10945657 chr6 160652929 T G 4.33E-10 Lipoproteins SLC22A2 intron pha003079 rs315988 chr6 160660694 T C 7.80E-05 Lung function (forced expiratory volume in 1 second) SLC22A2 intron 17255346 rs8177517 chr6 160663420 T G 0.0000013 Cholesterol,total SLC22A2 missense 23063622 rs315995 chr6 160665461 G A 7.54E-04 Amyotrophic lateral sclerosis (sporadic) SLC22A2 intron 24529757 rs2279463 chr6 160668389 A G 6.00E-12 Chronic kidney disease SLC22A2 intron 20383146 rs2279463 chr6 160668389 A G 1.10E-11 Chronic kidney disease SLC22A2 intron 22479191 rs316020 chr6 160669081 A G 3.00E-286 Blood metabolite ratios SLC22A2 intron 24816252 rs316019 chr6 160670282 A C 1 Drug response to Cisplatin SLC22A2 missense 19625999 rs316019 chr6 160670282 A C 1 Drug response to Metformin SLC22A2 missense 19940846 rs316019 chr6 160670282 A C 7.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC22A2 missense 20877124 rs316019 chr6 160670282 A C 2.00E-259 Blood metabolite levels SLC22A2 missense 24816252 rs316016 chr6 160671500 T C 2.08E-05 Lung function (forced expiratory volume in 1 second) SLC22A2 intron 17255346 rs316015 chr6 160672264 C T 2.30E-05 Lung function (forced expiratory volume in 1 second) SLC22A2 intron 17255346 rs316013 chr6 160672625 G A 2.08E-05 Lung function (forced expiratory volume in 1 second) SLC22A2 intron 17255346 rs3798156 chr6 160676216 C T 1.20E-06 Chronic kidney disease SLC22A2 intron 21931561 rs3798156 chr6 160676216 C T 2.30E-04 Chronic kidney disease SLC22A2 intron 21931561 rs3798156 chr6 160676216 C T 2.30E-04 Chronic kidney disease SLC22A2 intron 21931561 rs316007 chr6 160676408 C T 2.09E-05 Lung function (forced expiratory volume in 1 second) SLC22A2 intron 17255346 rs3127573 chr6 160681393 A G 7.00E-10 Creatinine levels / / 20383145 rs3127573 chr6 160681393 A G 0.0000538 Triglycerides / / 23063622 rs3127572 chr6 160682218 A G 5.48E-05 Smoking initiation / / 24665060 rs3127572 chr6 160682218 A G 6.82E-12 Lipoproteins / / pha003079 rs7757997 chr6 160682897 A G 0.0000162 LDL cholesterol / / 23063622 rs576075 chr6 160685536 C T 1.70E-05 Serum metabolites / / 19043545 rs316029 chr6 160686668 T C 2.60E-07 Chronic kidney disease / / 21931561 rs7756836 chr6 160689257 T C 1.91E-05 Smoking initiation / / 24665060 rs3119311 chr6 160693107 T C 5.54E-06 Ankle-brachial index / / 22199011 rs3119311 chr6 160693107 T C 1.01E-11 Lipoproteins / / pha003079 rs3119312 chr6 160700301 T C 1.17E-06 Lipoproteins / / pha003079 rs3127586 chr6 160704912 T C 1.17E-08 Lp (a) levels / / 21900290 rs12206585 chr6 160713524 G A 1.06E-08 Lp (a) levels / / 21900290 rs12203303 chr6 160713696 T C 1.23E-08 Lp (a) levels / / 21900290 rs2183470 chr6 160715093 C T 8.92E-09 Lp (a) levels / / 21900290 rs3120151 chr6 160717472 C T 6.36E-09 Lp (a) levels / / 21900290 rs3103350 chr6 160723005 T C 4.41E-09 Lp (a) levels / / 21900290 rs3127583 chr6 160727131 G A 3.80E-09 Lp (a) levels / / 21900290 rs3127583 chr6 160727131 G A 3.20E-05 Body Mass Index / / pha003021 rs3127583 chr6 160727131 G A 4.15E-05 Coronary heart disease / / pha003030 rs3127583 chr6 160727131 G A 2.91E-17 Lipoproteins / / pha003079 rs3106172 chr6 160727975 A G 3.80E-09 Lp (a) levels / / 21900290 rs3106170 chr6 160729924 G A 3.80E-09 Lp (a) levels / / 21900290 rs3125057 chr6 160731672 T A 3.45E-08 Lp (a) levels / / 21900290 rs3125056 chr6 160735281 T C 5.93E-09 Lp (a) levels / / 21900290 rs3125056 chr6 160735281 T C 1.88E-15 Lipoproteins / / pha003079 rs410569 chr6 160735746 T G 2.45E-08 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs3125055 chr6 160736787 T A 8.88E-10 Lp (a) levels / / 21900290 rs3106167 chr6 160737390 T G 3.67E-09 Lp (a) levels / / 21900290 rs446809 chr6 160737581 C A 6.51E-07 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs3127591 chr6 160737802 G T 1.94E-09 Lp (a) levels / / 21900290 rs366920 chr6 160737950 T C 7.16E-05 Coronary heart disease / / pha003030 rs366920 chr6 160737950 T C 5.05E-08 Lipoproteins / / pha003079 rs3125052 chr6 160738373 T C 3.72E-09 Lp (a) levels / / 21900290 rs3120140 chr6 160738831 G A 8.53E-10 Lp (a) levels / / 21900290 rs667538 chr6 160738920 T G 3.09E-08 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs415897 chr6 160739505 C T 2.91E-08 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs16891392 chr6 160740671 A C 9.30E-04 Multiple complex diseases / / 17554300 rs3103349 chr6 160740721 C T 3.67E-09 Lp (a) levels / / 21900290 rs3125050 chr6 160740836 A C 8.80E-09 Lp (a) levels / / 21900290 rs3125050 chr6 160740836 A C 2.93E-05 Body Mass Index / / pha003021 rs3125050 chr6 160740836 A C 6.40E-05 Coronary heart disease / / pha003030 rs3125050 chr6 160740836 A C 6.39E-17 Lipoproteins / / pha003079 rs446291 chr6 160741106 C T 2.65E-05 Serum metabolites / / 19043545 rs3120139 chr6 160741622 G A 4.00E-09 Lp (a) levels / / 21900290 rs3120139 chr6 160741622 G A 0.000000524 Cholesterol,total / / 23202125 rs3120139 chr6 160741622 G A 0.0000403 LDL cholesterol / / 23202125 rs3120139 chr6 160741622 G A 0.000429 Triglycerides / / 23202125 rs384156 chr6 160745751 A C 9.10E-09 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs316169 chr6 160755657 T G 5.08E-08 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs2457561 chr6 160755810 G A 2.25E-04 Multiple complex diseases / / 17554300 rs316170 chr6 160756037 C T 2.21E-07 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs569919 chr6 160767183 C T 4.91E-04 Schizophrenia / / 19197363 rs569919 chr6 160767183 C T 1.30E-05 Schizophrenia / / 19571808 rs539298 chr6 160770360 A G 1.75E-07 Lipoproteins SLC22A3 intron pha003079 rs3120137 chr6 160771192 G A,C,T 4.37E-09 Lp (a) levels SLC22A3 intron 21900290 rs394487 chr6 160778639 C T 4.79E-04 Suicide attempts in bipolar disorder SLC22A3 intron 21423239 rs394468 chr6 160780912 G T 8.19E-04 Suicide attempts in bipolar disorder SLC22A3 intron 21423239 rs9346816 chr6 160782662 A G,T 3.48E-09 Lipoproteins SLC22A3 intron pha003079 rs402219 chr6 160789296 A G 6.00E-07 Monocyte early outgrowth colony forming units SLC22A3 intron 21493818 rs1018234 chr6 160796058 C T 2.30E-05 Schizophrenia SLC22A3 intron 19571808 rs1018234 chr6 160796058 C T 2.00E-04 Colorectal cancer SLC22A3 intron 21242260 rs1510228 chr6 160807403 G A 6.02E-05 Lipoproteins SLC22A3 intron pha003079 rs884742 chr6 160807432 C A 8.91E-04 Parkinson's disease SLC22A3 intron 17052657 rs884742 chr6 160807432 C A 8.71E-05 Colorectal cancer SLC22A3 intron 21242260 rs884742 chr6 160807432 C A 4.25E-08 Lipoproteins SLC22A3 intron pha003079 rs420038 chr6 160808148 C T 8.94E-05 Lipoprotein-associated phospholipase A2 activity and mass SLC22A3 intron 20442857 rs1567441 chr6 160812262 T C 2.68E-09 Metabolite levels SLC22A3 intron 23281178 rs2504916 chr6 160824028 T A 2.00E-06 Response to hepatitis C treatment SLC22A3 intron 22095909 rs9457918 chr6 160827835 T G 7.63E-04 Parkinson's disease SLC22A3 intron 17052657 rs9457918 chr6 160827835 T G 4.25E-08 Lipoproteins SLC22A3 intron pha003079 rs9364554 chr6 160833664 C T 6.00E-10 Prostate cancer SLC22A3 intron 18264097 rs9364554 chr6 160833664 C T 6.00E-10 Nasopharyngeal carcinoma SLC22A3 intron 20512145 rs9364554 chr6 160833664 C T 2.17E-05 Colorectal cancer SLC22A3 intron 21242260 rs9364554 chr6 160833664 C T 1.90E-04 Prostate cancer (early onset) SLC22A3 intron 24740154 rs9364554 chr6 160833664 C T 5.82E-06 Lipoproteins SLC22A3 intron pha003079 rs12194182 chr6 160834515 T C 8.86E-07 Autism SLC22A3 intron 22843504 rs2457571 chr6 160834828 T C 1.91E-05 Colorectal cancer SLC22A3 intron 21242260 rs2457572 chr6 160836406 T C 6.74E-05 Lipoproteins SLC22A3 intron pha003079 rs7758229 chr6 160840252 G T 8.00E-09 Colorectal cancer SLC22A3 intron 21242260 rs3123636 chr6 160842537 T C 2.09E-06 Colorectal cancer SLC22A3 intron 21242260 rs2504930 chr6 160845219 T C 4.05E-05 Lipoproteins SLC22A3 intron pha003079 rs2665357 chr6 160848167 A C 1.14E-04 Colorectal cancer SLC22A3 intron 21242260 rs2665357 chr6 160848167 A C 5.68E-08 Lipoproteins SLC22A3 intron pha003079 rs3106164 chr6 160850273 C T 6.82E-05 Colorectal cancer SLC22A3 intron 21242260 rs376563 chr6 160851766 T C 2.44E-08 Metabolite levels SLC22A3 intron 23281178 rs2292334 chr6 160858188 G A 3.77E-08 Lp (a) levels SLC22A3 cds-synon 21900290 rs2063345 chr6 160860154 A G 6.02E-05 Intelligence SLC22A3 intron 21826061 rs2048327 chr6 160863532 T C 3.87E-04 Multiple complex diseases SLC22A3 intron 17554300 rs2048327 chr6 160863532 T C 1.00E-09 Coronary artery disease SLC22A3 intron 19198611 rs2048327 chr6 160863532 T C 3.71E-08 Lp (a) levels SLC22A3 intron 21900290 rs2048327 chr6 160863532 T C 0.000000151 Coronary artery disease (CAD) age <=50 SLC22A3 intron 23202125 rs2048327 chr6 160863532 T C 0.000000955 Coronary artery disease (CAD) (males) SLC22A3 intron 23202125 rs2048327 chr6 160863532 T C 0.00000259 Coronary artery disease with myocardial infarction SLC22A3 intron 23202125 rs2048327 chr6 160863532 T C 0.0000375 Coronary artery disease (CAD) (females) SLC22A3 intron 23202125 rs2048327 chr6 160863532 T C 0.000595 Cholesterol,total SLC22A3 intron 23202125 rs2048327 chr6 160863532 T C 4.14E-11 Coronary artery disease SLC22A3 intron 23202125 rs2048327 chr6 160863532 T C 8.31E-08 Coronary artery disease (CAD) age >50 SLC22A3 intron 23202125 rs2048327 chr6 160863532 T C 1.00E-06 Coronary artery disease SLC22A3 intron 24262325 rs2048327 chr6 160863532 T C 8.37E-09 Lipoproteins SLC22A3 intron pha003079 rs7769879 chr6 160865645 G C 1.44E-08 Lp (a) levels SLC22A3 intron 21900290 rs3918285 chr6 160868654 C T 1.45E-08 Lp (a) levels SLC22A3 intron 21900290 rs3918286 chr6 160868668 A G 1.45E-08 Lp (a) levels SLC22A3 intron 21900290 rs1810126 chr6 160872151 C T 1.62E-08 Lp (a) levels SLC22A3 UTR-3 21900290 rs3088442 chr6 160872652 G A 1.53E-08 Lp (a) levels SLC22A3 UTR-3 21900290 rs1112073 chr6 160890842 A T 2.24E-08 Lp (a) levels LPAL2 intron 21900290 rs3127602 chr6 160892241 C T 3.22E-08 Lp (a) levels LPAL2 intron 21900290 rs3127602 chr6 160892241 C T 2.41E-10 Lipoproteins LPAL2 intron pha003079 rs2504921 chr6 160894006 T G 2.49E-08 Lipoproteins LPAL2 intron pha003079 rs1159259 chr6 160897320 G A 6.64E-04 Insulin resistance LPAL2 intron 21901158 rs3123629 chr6 160906086 G A 0.000000044 Triglycerides LPAL2 intron 23063622 rs3123629 chr6 160906086 G A 0.0000376 Triglycerides LPAL2 intron 23063622 rs3123629 chr6 160906086 G A 8.19E-11 Lipoproteins LPAL2 intron pha003079 rs3127599 chr6 160907134 C T 1.00E-09 Coronary artery disease LPAL2 intron 19198611 rs12214416 chr6 160910517 T A 5.00E-08 Lp (a) levels LPAL2 intron 21900290 rs12214416 chr6 160910517 T A 3.90E-04 Smoking initiation LPAL2 intron 24665060 rs10945673 chr6 160910899 C T 4.85E-04 Stroke LPAL2 intron pha002887 rs9364558 chr6 160929944 C G 8.59E-04 Parkinson's disease LPAL2 intron 17052657 rs7453836 chr6 160942891 T A 5.20E-08 Metabolite levels / / 23281178 rs3127596 chr6 160953035 A G 1.50E-14 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA intron 20032323 rs3124785 chr6 160954505 G A 9.24E-10 Lp (a) levels LPA intron 21900290 rs7449650 chr6 160957114 T G 9.10E-05 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA intron 20032323 rs6919346 chr6 160960359 T C 4.00E-11 Lp (a) levels LPA intron 19124843 rs6919346 chr6 160960359 T C 1.60E-16 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA intron 20032323 rs6919346 chr6 160960359 T C 9.78E-12 Lp (a) levels LPA intron 21900290 rs6919346 chr6 160960359 T C 9.57E-08 Metabolite levels LPA intron 23281178 rs6919346 chr6 160960359 T C 4.74E-12 Lipoprotein a [lp(a)] levels in plasma LPA intron pha002870 rs6919346 chr6 160960359 T C 6.65E-10 Lipoproteins LPA intron pha003079 rs3798220 chr6 160961137 T C 5.90E-51 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA missense 20032323 rs3798220 chr6 160961137 T C 9.00E-07 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA missense 20032323 rs3798220 chr6 160961137 T C 3.00E-11 Coronary heart disease LPA missense 21378990 rs3798220 chr6 160961137 T C 1.00E-15 Coronary heart disease LPA missense 21966275 rs3798220 chr6 160961137 T C 3.00E-11 Pericardial fat LPA missense 22589742 rs3798220 chr6 160961137 T C 0.00000196 Cholesterol,total LPA missense 23063622 rs3798220 chr6 160961137 T C 1.25E-08 LDL cholesterol LPA missense 23063622 rs3798220 chr6 160961137 T C 0.000019 LDL cholesterol LPA missense 23100282 rs3798220 chr6 160961137 T C 0.000025 Apolipoprotein B levels response after 40mg daily simvastatin treatment LPA missense 23100282 rs3798220 chr6 160961137 T C 0.000071 LDL cholesterol response after 40mg daily simvastatin treatment LPA missense 23100282 rs3798220 chr6 160961137 T C 2.60E-09 Apolipoprotein B levels LPA missense 23100282 rs3798220 chr6 160961137 T C 1.90E-05 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) LPA missense 23103227 rs3798220 chr6 160961137 T C 2.09E-31 Coronary artery disease with myocardial infarction LPA missense 23202125 rs3798220 chr6 160961137 T C 2.13E-31 Coronary artery disease (CAD) age >50 LPA missense 23202125 rs3798220 chr6 160961137 T C 2.14E-31 Coronary artery disease (CAD) (females) LPA missense 23202125 rs3798220 chr6 160961137 T C 3.62E-31 Coronary artery disease (CAD) (males) LPA missense 23202125 rs7767084 chr6 160962503 T C 1.00E-09 Coronary artery disease LPA intron 19198611 rs11751605 chr6 160963230 T C 5.90E-28 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA intron 20032323 rs11751605 chr6 160963230 T C 2.17E-12 Lp (a) levels LPA intron 21900290 rs11751605 chr6 160963230 T C 7.43E-16 Lipoproteins LPA intron pha003079 rs4708871 chr6 160969096 C T 1.00E-06 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA intron 20032323 rs4708871 chr6 160969096 C T 6.85E-06 Waist-hip ratio LPA intron 20935629 rs10755578 chr6 160969738 C G 1.00E-09 Coronary artery disease LPA intron 19198611 rs10755578 chr6 160969738 C G 3.40E-13 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA intron 20032323 rs7761293 chr6 160970963 G A 2.30E-06 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA intron 20032323 rs7761293 chr6 160970963 G A 8.42E-07 Lipoproteins LPA intron pha003079 rs6415084 chr6 160980330 T C 2.70E-09 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA intron 20032323 rs9365171 chr6 160981736 C A 4.00E-11 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA intron 20032323 rs9365171 chr6 160981736 C A 4.55E-06 Lipoproteins LPA intron pha003079 rs6455688 chr6 160996327 A G 1.16E-06 Lipoproteins LPA intron pha003079 rs6923877 chr6 160996797 A G 2.40E-11 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA intron 20032323 rs6923877 chr6 160996797 A G 4.92E-07 Lipoproteins LPA intron pha003079 rs3798221 chr6 160998148 G T 2.00E-09 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA intron 20032323 rs3798221 chr6 160998148 G T 4.32E-06 Lipoproteins LPA intron pha003079 rs55730499 chr6 161005610 C T 2.34E-26 Lipoprotein A (Lp(a)) LPA intron 23696881 rs7765781 chr6 161007496 G C 2.10E-11 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA missense 20032323 rs7765803 chr6 161007538 G C 2.40E-11 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA missense 20032323 rs10455872 chr6 161010118 A G 3.00E-15 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA intron 20032323 rs10455872 chr6 161010118 A G 3.60E-166 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA intron 20032323 rs10455872 chr6 161010118 A G 1.95E-04 Lipoprotein A [Lp(a)] levels in plasma LPA intron 21592478 rs10455872 chr6 161010118 A G 2.26E-04 Lipoprotein A [Lp(a)] levels in plasma LPA intron 21592478 rs10455872 chr6 161010118 A G 2.94E-306 Lipoprotein A [Lp(a)] levels in plasma LPA intron 21592478 rs10455872 chr6 161010118 A G 5.00E-39 Lp (a) levels LPA intron 21900290 rs10455872 chr6 161010118 A G 1.20E-20 Coronary heart disease LPA intron 21966275 rs10455872 chr6 161010118 A G 5.00E-15 Response to statin therapy (LDL-C) LPA intron 22331829 rs10455872 chr6 161010118 A G 1.00E-09 Response to statin therapy LPA intron 22368281 rs10455872 chr6 161010118 A G 0.0000761 LDL cholesterol (male) LPA intron 22629316 rs10455872 chr6 161010118 A G 1.95E-09 LDL cholesterol (female) LPA intron 22629316 rs10455872 chr6 161010118 A G 2.81E-12 LDL cholesterol LPA intron 22629316 rs10455872 chr6 161010118 A G 2.23E-24 LDL cholesterol LPA intron 23063622 rs10455872 chr6 161010118 A G 3.81E-20 Cholesterol,total LPA intron 23063622 rs10455872 chr6 161010118 A G 0.00022 LDL cholesterol LPA intron 23100282 rs10455872 chr6 161010118 A G 1.50E-11 Apolipoprotein B levels LPA intron 23100282 rs10455872 chr6 161010118 A G 6.50E-31 Apolipoprotein B levels response after 40mg daily simvastatin treatment LPA intron 23100282 rs10455872 chr6 161010118 A G 8.10E-28 LDL cholesterol response after 40mg daily simvastatin treatment LPA intron 23100282 rs10455872 chr6 161010118 A G 8.10E-28 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) LPA intron 23103227 rs10455872 chr6 161010118 A G 2.00E-16 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy LPA intron 23118302 rs10455872 chr6 161010118 A G 3.00E-11 Aortic-valve calcification LPA intron 23388002 rs10455872 chr6 161010118 A G 5.06E-25 Lipoprotein A (Lp(a)) LPA intron 23696881 rs10455872 chr6 161010118 A G 2.00E-12 Coronary artery disease or ischemic stroke LPA intron 24262325 rs10455872 chr6 161010118 A G 9.00E-14 Coronary artery disease or large artery stroke LPA intron 24262325 rs7755463 chr6 161012270 C T 0.000000679 Triglycerides LPA intron 23063622 rs6921516 chr6 161015762 G A 5.41E-07 Lipoproteins LPA intron pha003079 rs9355296 chr6 161017993 G A 0.000000351 HDL cholesterol LPA intron 23063622 rs7770628 chr6 161018174 C T 4.00E-10 Protein quantitative trait loci LPA intron 18464913 rs7770628 chr6 161018174 C T 7.30E-04 Suicide attempts in bipolar disorder LPA intron 21423239 rs7770628 chr6 161018174 C T 8.42E-10 Lipoproteins LPA intron pha003079 rs6926458 chr6 161019866 A G 0.00000882 Coronary artery disease LPA intron 23202125 rs6926458 chr6 161019866 A G 1.15E-07 Lipoproteins LPA intron pha003079 rs9365179 chr6 161024848 C T 1.54E-10 Lipoproteins LPA intron pha003079 rs13202636 chr6 161029728 T C 2.00E-14 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA intron 20032323 rs13202636 chr6 161029728 T C 1.15E-07 Lipoproteins LPA intron pha003079 rs9355813 chr6 161031172 T C 2.80E-17 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA intron 20032323 rs10945682 chr6 161069941 G A 1.80E-17 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA intron 20032323 rs10945682 chr6 161069941 G A 2.25E-10 Lipoproteins LPA intron pha003079 rs1740428 chr6 161081331 A G 2.46E-10 Lipoproteins LPA intron pha003079 rs1321196 chr6 161081842 C T 2.25E-10 Lipoproteins LPA intron pha003079 rs1652507 chr6 161082461 T C 6.00E-04 Insulin resistance LPA intron 21901158 rs1367211 chr6 161082695 T C 8.92E-06 Lipoproteins LPA intron pha003079 rs9365200 chr6 161083272 T C 1.00E-04 Prostate cancer LPA intron 21743057 rs9365201 chr6 161083481 T C 1.00E-04 Prostate cancer LPA intron 21743057 rs9347438 chr6 161083633 T C 4.00E-05 Prostate cancer LPA intron 21743057 rs1321195 chr6 161084156 A G 4.00E-07 Lipoprotein A [Lp(a)] levels and coronary artery disease LPA intron 20032323 rs9346833 chr6 161084642 C T 6.00E-05 Prostate cancer LPA intron 21743057 rs9346833 chr6 161084642 C T 8.51E-06 Lipoproteins LPA intron pha003079 rs783149 chr6 161088918 C A 0.000000281 HDL cholesterol LPA nearGene-5 23063622 rs783149 chr6 161088918 C A 0.0000102 HDL cholesterol (female) LPA nearGene-5 23063622 rs1084651 chr6 161089817 G A 3.00E-08 HDL cholesterol / / 20686565 rs1084651 chr6 161089817 G A 0.000000361 HDL cholesterol / / 23063622 rs1406888 chr6 161091593 C T 2.10E-05 Lipoprotein A [Lp(a)] levels and coronary artery disease / / 20032323 rs5014650 chr6 161099503 G A 1.11E-08 Lp (a) levels / / 21900290 rs2115868 chr6 161099959 T A 1.20E-08 Lp (a) levels / / 21900290 rs9457997 chr6 161107018 G A 7.34E-09 Lp (a) levels / / 21900290 rs2315065 chr6 161108144 C A 1.15E-23 Lp (a) levels / / 21900290 rs6935921 chr6 161108536 C T 2.70E-14 Lp (a) levels / / 21900290 rs6935921 chr6 161108536 C T 1.69E-06 Lipoproteins / / pha003079 rs6455698 chr6 161108803 G T 5.88E-14 Lp (a) levels / / 21900290 rs783144 chr6 161119239 C T 1.20E-15 Lp (a) levels / / 21900290 rs9458009 chr6 161120563 G A 2.75E-09 Lp (a) levels / / 21900290 rs2314852 chr6 161122787 G A 1.74E-12 Lp (a) levels PLG nearGene-5 21900290 rs4252072 chr6 161128264 A T 2.29E-11 Lp (a) levels PLG intron 21900290 rs1652508 chr6 161128947 G A 4.64E-04 Multiple complex diseases PLG intron 17554300 rs4252078 chr6 161131818 C T 2.91E-11 Lp (a) levels PLG intron 21900290 rs1830519 chr6 161132830 G A 1.79E-07 Multiple complex diseases PLG UTR-3 17554300 rs1853017 chr6 161133046 C T 2.36E-10 Lp (a) levels PLG intron 21900290 rs1853017 chr6 161133046 C T 9.03E-04 Alzheimer's disease PLG intron 24755620 rs4252087 chr6 161133244 G A 7.32E-12 Lp (a) levels PLG intron 21900290 rs4252093 chr6 161133685 A G 1.02E-12 Lp (a) levels PLG intron 21900290 rs4252096 chr6 161134273 C G 2.69E-13 Lp (a) levels PLG intron 21900290 rs9295131 chr6 161136294 G A 8.78E-04 Common variable immunodeficiency PLG intron 21497890 rs9295131 chr6 161136294 G A 2.15E-09 Lipoproteins PLG intron pha003079 rs4252107 chr6 161137518 T C 3.10E-13 Lp (a) levels PLG intron 21900290 rs4252109 chr6 161137663 T G 3.27E-14 Lp (a) levels PLG intron 21900290 rs4252109 chr6 161137663 T G 9.30E-04 Alzheimer's disease PLG intron 24755620 rs4252109 chr6 161137663 T G 3.07E-11 Lipoprotein a [lp(a)] levels in plasma PLG intron pha002870 rs14224 chr6 161137779 T C 1.90E-09 Lp (a) levels PLG cds-synon 21900290 rs14224 chr6 161137779 T C 3.04E-19 Lipoprotein a [lp(a)] levels in plasma PLG cds-synon pha002870 rs783147 chr6 161137990 G A 3.00E-17 Lp (a) levels PLG intron 21900290 rs783147 chr6 161137990 G A 1.69E-06 Lipoproteins PLG intron pha003079 rs783146 chr6 161138848 C G 7.32E-05 Hypertension (essential hypertension) PLG intron 22184326 rs3823055 chr6 161138917 A G 2.36E-07 Lipoproteins PLG intron pha003079 rs1130656 chr6 161139480 C T 8.77E-09 Lp (a) levels PLG cds-synon 21900290 rs2295368 chr6 161139502 G A 8.32E-09 Lp (a) levels PLG intron 21900290 rs13231 chr6 161139857 A G 2.10E-13 Lp (a) levels PLG cds-synon 21900290 rs13231 chr6 161139857 A G 1.70E-09 Lipoproteins PLG cds-synon pha003079 rs4709458 chr6 161141158 T C 5.71E-09 Lp (a) levels PLG intron 21900290 rs4252117 chr6 161143376 A G 6.68E-14 Lp (a) levels PLG intron 21900290 rs4252117 chr6 161143376 A G 3.07E-11 Lipoprotein a [lp(a)] levels in plasma PLG intron pha002870 rs4252120 chr6 161143608 T C 2.95E-14 Lp (a) levels PLG intron 21900290 rs4252120 chr6 161143608 T C 0.00000793 Coronary artery disease (CAD) (males) PLG intron 23202125 rs4252120 chr6 161143608 T C 0.0000148 Coronary artery disease (CAD) (females) PLG intron 23202125 rs4252120 chr6 161143608 T C 0.0000156 Coronary artery disease with myocardial infarction PLG intron 23202125 rs4252120 chr6 161143608 T C 0.0000354 Coronary artery disease (CAD) age >50 PLG intron 23202125 rs4252120 chr6 161143608 T C 0.0000744 Coronary artery disease (CAD) age <=50 PLG intron 23202125 rs4252120 chr6 161143608 T C 4.88E-10 Coronary artery disease PLG intron 23202125 rs4252120 chr6 161143608 T C 5.00E-24 Lipoprotein A (Lp(a)) PLG intron 23202125 rs4252120 chr6 161143608 T C 2.73E-05 Coronary artery disease PLG intron 24262325 rs4252120 chr6 161143608 T C 4.79E-10 Lipoprotein a [lp(a)] levels in plasma PLG intron pha002870 rs1897108 chr6 161146704 A G 2.98E-11 Lp (a) levels PLG intron 21900290 rs1897108 chr6 161146704 A G 7.95E-04 Alzheimer's disease PLG intron 24755620 rs9456578 chr6 161147368 A T 6.44E-14 Lp (a) levels PLG intron 21900290 rs9458017 chr6 161150251 G T 6.41E-14 Lp (a) levels PLG intron 21900290 rs4252125 chr6 161152240 G A 6.18E-14 Lp (a) levels PLG missense 21900290 rs4252125 chr6 161152240 G A 1.55E-11 Lipoprotein a [lp(a)] levels in plasma PLG missense pha002870 rs4252125 chr6 161152240 G A 1.07E-08 Lipoproteins PLG missense pha003079 rs4252126 chr6 161152294 A G 4.14E-14 Lp (a) levels PLG intron 21900290 rs4252126 chr6 161152294 A G 1.06E-10 Lipoprotein a [lp(a)] levels in plasma PLG intron pha002870 rs783145 chr6 161152449 G A 8.53E-07 Hypertension (essential hypertension) PLG intron 22184326 rs4252130 chr6 161153080 A C 1.06E-13 Lp (a) levels PLG intron 21900290 rs4252130 chr6 161153080 A C 3.57E-11 Lipoprotein a [lp(a)] levels in plasma PLG intron pha002870 rs4252134 chr6 161153527 T C 6.05E-14 Lp (a) levels PLG intron 21900290 rs813641 chr6 161153990 G A 5.05E-05 Hypertension (essential hypertension) PLG intron 22184326 rs4252135 chr6 161154232 G T 5.13E-14 Lp (a) levels PLG intron 21900290 rs4252135 chr6 161154232 G T 1.09E-09 Lipoprotein a [lp(a)] levels in plasma PLG intron pha002870 rs4252147 chr6 161158999 T A 9.13E-14 Lp (a) levels PLG intron 21900290 rs4252165 chr6 161161559 C A 1.79E-13 Lp (a) levels PLG intron 21900290 rs783182 chr6 161168548 G A 2.95E-06 Hypertension (essential hypertension) PLG intron 22184326 rs11902 chr6 161174871 C G 1.12E-05 Hypertension (essential hypertension) PLG UTR-3 22184326 rs783166 chr6 161177237 A G 1.04E-11 Lipoproteins / / pha003079 rs783165 chr6 161177842 A C 9.73E-06 Hypertension (essential hypertension) / / 22184326 rs1084656 chr6 161181292 A C,G,T 6.67E-06 Hypertension (essential hypertension) / / 22184326 rs1406891 chr6 161187080 T C 3.99E-06 Hypertension (essential hypertension) / / 22184326 rs1247555 chr6 161189018 A C 1.91E-13 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs1247557 chr6 161189670 A G 1.63E-14 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs1247558 chr6 161190199 A G 8.30E-06 Hypertension (essential hypertension) / / 22184326 rs1652500 chr6 161192189 C T 8.14E-09 Lipoproteins / / pha003079 rs1782629 chr6 161195866 C A 1.42E-09 Lp (a) levels / / 21900290 rs1782627 chr6 161196800 A G 1.24E-09 Lp (a) levels / / 21900290 rs1621801 chr6 161196966 A C 1.10E-05 Hypertension (essential hypertension) / / 22184326 rs1620921 chr6 161197087 A G 2.67E-14 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs1740442 chr6 161197558 T C 1.63E-14 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs2115869 chr6 161207892 G A 5.38E-08 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs1247571 chr6 161218651 A G 2.30E-05 Urinary metabolites / / 21572414 rs1247571 chr6 161218651 A G 1.79E-07 Lipoproteins / / pha003079 rs783153 chr6 161229578 T G 2.04E-15 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs3846778 chr6 161230801 T C 1.05E-05 Lipoproteins / / pha003079 rs783156 chr6 161231177 T C 2.37E-05 Hypertension (essential hypertension) / / 22184326 rs2565721 chr6 161235098 A G 1.71E-05 Hypertension (essential hypertension) / / 22184326 rs2565721 chr6 161235098 A G 2.85E-05 Height / / pha003010 rs2565721 chr6 161235098 A G 6.69E-06 Height / / pha003011 rs1782632 chr6 161249412 A G 2.68E-05 Height / / pha003010 rs1782632 chr6 161249412 A G 8.38E-06 Height / / pha003011 rs1652471 chr6 161254403 T C 8.38E-05 Hypertension (essential hypertension) / / 22184326 rs1937479 chr6 161255544 C T 3.04E-14 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs9355841 chr6 161267335 A G 8.73E-05 Hypertension (essential hypertension) / / 22184326 rs9355841 chr6 161267335 A G 8.41E-06 Height / / pha003010 rs9355841 chr6 161267335 A G 1.06E-06 Height / / pha003011 rs2465868 chr6 161287333 C T 1.54E-09 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs2489956 chr6 161315347 C T 5.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs1247318 chr6 161333937 G C 3.00E-06 Aging / / 22773346 rs1247311 chr6 161336460 T C 8.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs1247359 chr6 161340682 C G 6.20E-05 Bipolar disorder / / 19488044 rs1247299 chr6 161347496 C T 9.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs935181 chr6 161348069 T C 1.09E-05 Parkinson's disease / / 17052657 rs1247343 chr6 161371621 T C 2.28E-08 Lipoproteins / / pha003079 rs1247340 chr6 161374998 A C 1.70E-05 Urinary metabolites / / 21572414 rs7760467 chr6 161385757 A G 9.89E-04 Myopia (pathological) / / 21095009 rs7760467 chr6 161385757 A G 1.20E-08 Lipoproteins / / pha003079 rs2099938 chr6 161386772 G A 8.72E-04 Myopia (pathological) / / 21095009 rs9355860 chr6 161390787 G A 1.10E-08 Lipoproteins / / pha003079 rs7766870 chr6 161396138 C T 3.28E-05 Lipoproteins / / pha003079 rs9347476 chr6 161396687 A C 1.88E-05 Lipoproteins / / pha003079 rs9458073 chr6 161406871 A G 2.48E-06 Lipoproteins / / pha003079 rs6925502 chr6 161444152 A G 2.91E-04 Cholesterol MAP3K4 intron 17255346 rs6925502 chr6 161444152 A G 6.50E-04 Type 2 diabetes MAP3K4 intron 17463246 rs13200744 chr6 161449576 A G 9.99E-04 Response to cytidine analogues (gemcitabine) MAP3K4 intron 24483146 rs9295134 chr6 161450528 C T 7.00E-06 Alcohol dependence MAP3K4 intron 21956439 rs9295134 chr6 161450528 C T 4.51E-07 Response to tocilizumab in rheumatoid arthritis MAP3K4 intron 22491018 rs6455701 chr6 161459665 A G 1.12E-04 Cholesterol MAP3K4 intron 17255346 rs6455701 chr6 161459665 A G 9.37E-04 Type 2 diabetes MAP3K4 intron 17463246 rs1562026 chr6 161460937 T C 1.00E-04 Cognitive impairment induced by topiramate MAP3K4 intron 22091778 rs12110787 chr6 161474966 A C 5.00E-06 Alcohol dependence MAP3K4 intron 21956439 rs12110787 chr6 161474966 A C 3.03E-08 Response to tocilizumab in rheumatoid arthritis MAP3K4 intron 22491018 rs9355870 chr6 161495658 A G 7.00E-06 Alcohol dependence MAP3K4 intron 21956439 rs9355870 chr6 161495658 A G 4.28E-06 Response to tocilizumab in rheumatoid arthritis MAP3K4 intron 22491018 rs6933810 chr6 161496785 G A 2.54E-04 Cholesterol MAP3K4 intron 17255346 rs6902760 chr6 161503924 C T 7.72E-04 Smoking cessation MAP3K4 intron 24665060 rs9355332 chr6 161509003 T A 3.00E-04 Cholesterol MAP3K4 intron 17255346 rs3798917 chr6 161516831 T G 4.43E-06 Lipoproteins MAP3K4 intron pha003079 rs6905942 chr6 161518514 A G 8.39E-05 Alzheimer's disease (age of onset) MAP3K4 intron 22005931 rs2872613 chr6 161520226 A G 9.21E-05 Alzheimer's disease (age of onset) MAP3K4 intron 22005931 rs4709491 chr6 161522365 G A 6.94E-04 Smoking cessation MAP3K4 intron 24665060 rs9458121 chr6 161522478 A G 2.70E-05 Alcoholism (heaviness of drinking) MAP3K4 intron 21529783 rs9458121 chr6 161522478 A G 1.00E-06 Alcohol dependence MAP3K4 intron 21956439 rs9355872 chr6 161534333 T C 8.79E-05 Type 2 diabetes MAP3K4 intron 17463246 rs1488 chr6 161538250 G A 9.17E-05 HIV-1 viral setpoint MAP3K4 UTR-3 22174851 rs1488 chr6 161538250 G A 6.26E-05 Lipoproteins MAP3K4 UTR-3 pha003079 rs4709495 chr6 161550206 G A 2.25E-04 Cholesterol / / 17255346 rs3734462 chr6 161557662 G A 4.15E-05 Lipoproteins AGPAT4 cds-synon pha003079 rs7768457 chr6 161558036 A G 8.62E-06 Lipoproteins AGPAT4 intron pha003079 rs12195072 chr6 161559434 G C 0.00009708 Sarcoidosis AGPAT4 intron 22952805 rs12191615 chr6 161565158 T C 8.64E-04 Alcohol dependence AGPAT4 intron 20201924 rs11965825 chr6 161571151 T C 0.0000041 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes AGPAT4 intron 22628534 rs6934457 chr6 161582535 T C 5.46E-04 Iron levels AGPAT4 intron pha002876 rs729986 chr6 161586840 C T 2.00E-04 Cognitive impairment induced by topiramate AGPAT4 intron 22091778 rs729986 chr6 161586840 C T 8.41E-05 Cognitive impairment induced by topiramate AGPAT4 intron 22091778 rs729986 chr6 161586840 C T 2.27E-07 Lipoprotein a [lp(a)] levels in plasma AGPAT4 intron pha002870 rs12203149 chr6 161603980 G A 3.75E-04 Multiple complex diseases AGPAT4 intron 17554300 rs3778224 chr6 161608089 T C 0.00003311 Sarcoidosis AGPAT4 intron 22952805 rs3798929 chr6 161609279 T G 0.00001792 Sarcoidosis AGPAT4 intron 22952805 rs11961712 chr6 161615353 C T 9.86E-05 Lipoproteins AGPAT4 intron pha003079 rs3798943 chr6 161675491 T C 8.00E-06 Anxiety in major depressive disorder AGPAT4 intron 24047446 rs9458172 chr6 161676979 A G 1.00E-04 Cognitive impairment induced by topiramate AGPAT4 intron 22091778 rs12662114 chr6 161679188 C T 4.60E-06 Urinary metabolites AGPAT4 intron 21572414 rs3798953 chr6 161689816 A G 6.19E-04 Aortic root size AGPAT4 intron 21223598 rs1972203 chr6 161706942 A G 2.80E-04 Multiple complex diseases / / 17554300 rs1972203 chr6 161706942 A G 4.86E-05 Response to citalopram treatment / / 19846067 rs9365261 chr6 161707287 T C 6.55E-04 Multiple complex diseases / / 17554300 rs9355878 chr6 161709131 G A 1.24E-04 Multiple complex diseases / / 17554300 rs12205864 chr6 161716028 C A 0.000174706 Hypertension (early onset hypertension) / / 22479346 rs7760006 chr6 161722057 A G 1.75E-04 Multiple complex diseases / / 17554300 rs7760006 chr6 161722057 A G 5.25E-05 Response to citalopram treatment / / 19846067 rs11758285 chr6 161723705 C T 6.25E-04 White matter integrity / / 22425255 rs9347493 chr6 161731010 A G 9.82E-04 Heart Failure / / pha002884 rs4454114 chr6 161841791 C T 2.98E-05 Coronary heart disease PARK2 intron pha003031 rs9458254 chr6 161863510 C T 9.65E-04 Obesity (extreme) PARK2 intron 21935397 rs9458255 chr6 161863770 G A 9.49E-09 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs6903203 chr6 161888411 G A 1.74E-05 Paget's disease PARK2 intron 20436471 rs16892573 chr6 161896519 G A 6.16E-04 Nicotine smoking PARK2 intron 19268276 rs9456676 chr6 161899244 C T 4.26E-04 Iron levels PARK2 intron pha002876 rs4709531 chr6 161900199 T C 2.61E-04 Alzheimer's disease (late onset) PARK2 intron 21379329 rs9346859 chr6 161900525 C T 1.12E-04 Hearing function PARK2 intron 17255346 rs9346859 chr6 161900525 C T 1.97E-04 Alzheimer's disease (late onset) PARK2 intron 21379329 rs2315314 chr6 161902154 T C 4.80E-04 Alzheimer's disease (late onset) PARK2 intron 21379329 rs9364599 chr6 161906107 A G 4.95E-04 Alzheimer's disease (late onset) PARK2 intron 21379329 rs555637 chr6 161914659 C T 9.27E-04 Amyotrophic Lateral Sclerosis PARK2 intron 17362836 rs555637 chr6 161914659 C T 3.00E-06 Insulin Resistance PARK2 intron pha003062 rs555637 chr6 161914659 C T 9.16E-06 Insulin-related traits PARK2 intron pha003063 rs992421 chr6 161915982 C T 1.56E-08 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs10755582 chr6 161916248 C T 2.69E-08 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs9458289 chr6 161916480 C T 3.25E-04 Amyotrophic Lateral Sclerosis PARK2 intron 17362836 rs6937817 chr6 161917337 T C 1.71E-08 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs12191995 chr6 161919214 T C 7.53E-08 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs577876 chr6 161923155 A G 1.61E-05 Insulin Resistance PARK2 intron pha003062 rs577876 chr6 161923155 A G 1.58E-05 Insulin-related traits PARK2 intron pha003063 rs508605 chr6 161928356 T C 4.34E-06 Rheumatoid arthritis PARK2 intron 19503088 rs568893 chr6 161928772 A C 1.00E-04 Cognitive impairment induced by topiramate PARK2 intron 22091778 rs201328424 chr6 161929638 T TG 2.28E-06 Rheumatoid arthritis PARK2 intron 19503088 rs541480 chr6 161929638 T G 2.28E-06 Rheumatoid arthritis PARK2 intron 19503088 rs16892673 chr6 161933935 G A 5.00E-06 Aging PARK2 intron 22773346 rs475158 chr6 161936277 G C 1.30E-05 Urinary metabolites PARK2 intron 21572414 rs507499 chr6 161944035 T C 1.50E-05 Urinary metabolites PARK2 intron 21572414 rs6928997 chr6 161958165 T G 6.12E-05 Insulin Resistance PARK2 intron pha003062 rs17651062 chr6 161960834 T A,C 1.03E-07 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs527960 chr6 161963415 G A 4.17E-05 Lung function (forced vital capacity) PARK2 intron 24023788 rs527960 chr6 161963415 G A 9.91E-05 Lung function (forced expiratory volume in 1 second) PARK2 intron 24023788 rs2064419 chr6 161974304 G T 2.23E-05 Serum metabolites PARK2 intron 19043545 rs2315321 chr6 161974706 A T 1.96E-05 Serum metabolites PARK2 intron 19043545 rs9364602 chr6 161974956 G A 7.41E-05 Serum metabolites PARK2 intron 19043545 rs9355908 chr6 161976974 A G 2.89E-05 Job-related exhaustion PARK2 intron 23620144 rs17573347 chr6 161981289 T G 9.43E-06 Hearing function PARK2 intron 17255346 rs9456684 chr6 161988513 G A 3.79E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) PARK2 intron 23648065 rs9355351 chr6 161988767 A G 5.53E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) PARK2 intron 23648065 rs885782 chr6 161989903 A C 1.07E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) PARK2 intron 23648065 rs17651866 chr6 161989970 A G 9.43E-06 Hearing function PARK2 intron 17255346 rs737715 chr6 161990063 T C 2.00E-05 Urinary metabolites PARK2 intron 21572414 rs3765474 chr6 161990483 C T 5.23E-05 Serum metabolites PARK2 intron 19043545 rs3765475 chr6 161990516 G C 8.92E-05 Serum metabolites PARK2 intron 19043545 rs7755681 chr6 161996370 C T 2.90E-04 Obesity (extreme) PARK2 intron 21935397 rs7755681 chr6 161996370 C T 3.23E-04 Amyotrophic lateral sclerosis (sporadic) PARK2 intron 24529757 rs2143742 chr6 161998406 T A 4.32E-04 Obesity (extreme) PARK2 intron 21935397 rs1883875 chr6 161999398 C G 2.70E-04 Obesity (extreme) PARK2 intron 21935397 rs992037 chr6 162001436 T C 1.00E-07 Metabolite levels PARK2 intron 19043545 rs992037 chr6 162001436 T C 3.91E-04 Obesity (extreme) PARK2 intron 21935397 rs994465 chr6 162004731 G A 4.24E-04 Obesity (extreme) PARK2 intron 21935397 rs910177 chr6 162006529 T A 2.29E-04 Obesity (extreme) PARK2 intron 21935397 rs9364605 chr6 162006836 C T 2.16E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) PARK2 intron 23648065 rs9295157 chr6 162007822 A C 2.35E-04 Obesity (extreme) PARK2 intron 21935397 rs6927285 chr6 162010329 G A 7.29E-05 Serum metabolites PARK2 intron 19043545 rs6927285 chr6 162010329 G A 2.48E-04 Obesity (extreme) PARK2 intron 21935397 rs6940957 chr6 162012307 C T 4.62E-04 Obesity (extreme) PARK2 intron 21935397 rs9355914 chr6 162013511 T C 5.70E-04 Obesity (extreme) PARK2 intron 21935397 rs6455736 chr6 162014434 G C 5.05E-05 Serum metabolites PARK2 intron 19043545 rs6455736 chr6 162014434 G C 5.76E-04 Obesity (extreme) PARK2 intron 21935397 rs742769 chr6 162017174 T C 4.81E-04 Obesity (extreme) PARK2 intron 21935397 rs2003713 chr6 162018136 T C 5.97E-05 Serum metabolites PARK2 intron 19043545 rs2003713 chr6 162018136 T C 6.07E-04 Obesity (extreme) PARK2 intron 21935397 rs12055483 chr6 162021640 T C 2.36E-04 Obesity (extreme) PARK2 intron 21935397 rs9458314 chr6 162022492 C T 6.28E-04 Obesity (extreme) PARK2 intron 21935397 rs6924602 chr6 162032087 C T 2.30E-04 Obesity (extreme) PARK2 intron 21935397 rs10945759 chr6 162032127 G T 2.56E-04 Obesity (extreme) PARK2 intron 21935397 rs9456688 chr6 162038722 T C 4.74E-04 Multiple complex diseases PARK2 intron 17554300 rs6455737 chr6 162039061 C T 2.77E-04 Obesity (extreme) PARK2 intron 21935397 rs9295158 chr6 162039898 C T 4.76E-04 Obesity (extreme) PARK2 intron 21935397 rs6455738 chr6 162040405 A G 4.88E-04 Obesity (extreme) PARK2 intron 21935397 rs6455739 chr6 162040460 A G 5.09E-04 Obesity (extreme) PARK2 intron 21935397 rs9355356 chr6 162041758 A G 2.64E-04 Obesity (extreme) PARK2 intron 21935397 rs9365308 chr6 162042839 T C 9.12E-04 Multiple complex diseases PARK2 intron 17554300 rs6455740 chr6 162058997 T C 1.50E-06 Urinary metabolites PARK2 intron 21572414 rs6455741 chr6 162059082 C A 2.90E-06 Urinary metabolites PARK2 intron 21572414 rs9456695 chr6 162064528 G C 0.000893 Salmonella-induced pyroptosis PARK2 intron 22837397 rs7742460 chr6 162064609 G A 2.84E-04 Alzheimer's disease PARK2 intron 17998437 rs6455748 chr6 162065385 T C 1.75E-04 Alzheimer's disease PARK2 intron 17998437 rs7771544 chr6 162087050 C T 7.17E-05 Response to mTOR inhibitor (everolimus) PARK2 intron 24009623 rs9355357 chr6 162093021 T C 2.08E-04 Vaspin levels PARK2 intron 22907691 rs9355357 chr6 162093021 T C 0.000208 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks PARK2 intron 22907730 rs10484813 chr6 162093140 A G 8.10E-04 Type 2 diabetes and 6 quantitative traits PARK2 intron 17848626 rs7739751 chr6 162096566 T A 2.95E-05 Smoking initiation PARK2 intron 24665060 rs969760 chr6 162115812 A G 3.58E-05 Platelet counts PARK2 intron pha003100 rs17596816 chr6 162127514 G T 4.62E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PARK2 intron 20877124 rs6455764 chr6 162139357 A G 9.44E-04 Suicide attempts in bipolar disorder PARK2 intron 21423239 rs16892971 chr6 162157158 C T 5.88E-04 Insulin resistance PARK2 intron 21901158 rs2982903 chr6 162158268 G A 3.35E-05 Socioeconomic Factors PARK2 intron pha003067 rs926849 chr6 162161619 C T 3.00E-08 Disc degeneration (lumbar) PARK2 intron 22993228 rs1884158 chr6 162161666 C T 2.68E-04 Cholesterol PARK2 intron 17255346 rs11753802 chr6 162164600 A G 7.08E-05 Kawasaki disease PARK2 intron 22446961 rs3019447 chr6 162166163 C A 5.46E-05 Kawasaki disease PARK2 intron 22446961 rs763753 chr6 162168506 G A 8.57E-04 Type 2 diabetes PARK2 intron 17463246 rs16893004 chr6 162169823 T C 3.00E-04 Polycystic ovary syndrome PARK2 intron 22178785 rs3019442 chr6 162170524 G C 7.57E-11 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs3016563 chr6 162192856 C A 5.39E-11 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs3016562 chr6 162192874 G A 5.39E-11 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs9458363 chr6 162192994 G T 1.30E-05 Urinary metabolites PARK2 intron 21572414 rs9458363 chr6 162192994 G T 1.15E-11 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs9458366 chr6 162196730 C T 6.20E-06 Urinary metabolites PARK2 intron 21572414 rs12208429 chr6 162199140 T C 2.70E-05 Urinary metabolites PARK2 intron 21572414 rs12208431 chr6 162199157 T G 2.70E-05 Urinary metabolites PARK2 intron 21572414 rs3019433 chr6 162209898 A G 6.37E-08 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs3016557 chr6 162210934 T C 2.75E-08 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs3016551 chr6 162221720 A G 5.68E-08 Metabolite levels PARK2 intron 23281178 rs3016539 chr6 162236075 C T 7.00E-06 Pancreatic cancer PARK2 intron 20686608 rs2022991 chr6 162248169 C T 1.31E-22 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs9458393 chr6 162255535 G T 6.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PARK2 intron 20877124 rs12528179 chr6 162274381 T C 8.44E-04 Type 2 diabetes PARK2 intron 17463246 rs12665316 chr6 162275397 G A 5.47E-06 Cognitive impairment induced by topiramate PARK2 intron 22091778 rs4279411 chr6 162279198 A G 9.23E-04 Type 2 diabetes PARK2 intron 17463246 rs11752805 chr6 162279573 G A 8.93E-04 Type 2 diabetes PARK2 intron 17463246 rs2022989 chr6 162284206 A T 2.58E-05 Multiple complex diseases PARK2 intron 17554300 rs2022988 chr6 162288538 C T 8.11E-04 Multiple complex diseases PARK2 intron 17554300 rs9365334 chr6 162302398 C G 3.20E-06 Urinary metabolites PARK2 intron 21572414 rs12207186 chr6 162314921 A T 5.00E-06 IgG glycosylation PARK2 intron 23382691 rs9365344 chr6 162319145 A G 2.90E-05 Urinary metabolites PARK2 intron 21572414 rs9365344 chr6 162319145 A G 1.11E-09 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs6455783 chr6 162323997 T C 0.000188081 Hypertension (early onset hypertension) PARK2 intron 22479346 rs9347562 chr6 162328273 T C 1.39E-04 Parkinson's disease PARK2 intron 21248740 rs9365352 chr6 162340950 C T 0.000432233 Hypertension (early onset hypertension) PARK2 intron 22479346 rs9458419 chr6 162344712 C T 1.40E-05 Malaria PARK2 intron 19465909 rs9458420 chr6 162345938 G C 4.82E-05 Multiple complex diseases PARK2 intron 17554300 rs9458424 chr6 162368885 T C 8.11E-05 Age-related macular degeneration PARK2 intron 22125219 rs9458424 chr6 162368885 T C 1.18E-04 Response to taxane treatment (placlitaxel) PARK2 intron 23006423 rs6902304 chr6 162371705 G T 1.19E-04 Age-related macular degeneration PARK2 intron 22125219 rs6902304 chr6 162371705 G T 4.67E-05 Response to taxane treatment (placlitaxel) PARK2 intron 23006423 rs11964796 chr6 162392902 G A 1.35E-04 Age-related macular degeneration PARK2 intron 22125219 rs1623209 chr6 162406335 C T 6.32E-05 Blood Pressure PARK2 intron pha003046 rs9458428 chr6 162424579 C T 9.08E-04 Type 2 diabetes PARK2 intron 17463246 rs2849567 chr6 162450471 A C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes PARK2 intron 22628534 rs1105056 chr6 162453739 C T 3.72E-08 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs9458439 chr6 162465203 C T 7.63E-05 Lung function (forced expiratory volume in 1 second) PARK2 intron pha003102 rs9456734 chr6 162474893 A G 7.45E-11 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs4709566 chr6 162489533 A G 8.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PARK2 intron 20877124 rs9347586 chr6 162511254 G A 7.92E-05 Body Mass Index PARK2 intron pha003014 rs6901071 chr6 162520133 T G 6.04E-05 Cognitive impairment induced by topiramate PARK2 intron 22091778 rs9355384 chr6 162529567 C G 8.85E-04 Alzheimer's disease PARK2 intron 17998437 rs9456744 chr6 162537866 A G 4.69E-05 Job-related exhaustion PARK2 intron 23620144 rs9456745 chr6 162539650 A G 8.66E-05 Magnesium levels PARK2 intron pha003092 rs876145 chr6 162541706 G T 7.36E-04 Age-related macular degeneration PARK2 intron 22125219 rs11963472 chr6 162564054 T C 4.81E-05 Job-related exhaustion PARK2 intron 23620144 rs6904579 chr6 162569201 A G 5.28E-05 Serum metabolites PARK2 intron 19043545 rs869298 chr6 162575299 C T 5.27E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) PARK2 intron 23648065 rs2849609 chr6 162577258 C T 1.92E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) PARK2 intron 23648065 rs2849609 chr6 162577258 C T 3.08E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) PARK2 intron 23648065 rs12194653 chr6 162592495 C T 2.55E-04 Menopause (age at onset) PARK2 intron 22267201 rs9355987 chr6 162605266 T C 0.000122822 Hypertension (early onset hypertension) PARK2 intron 22479346 rs9295184 chr6 162609719 G C 3.26E-07 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs957374 chr6 162643427 C T 2.20E-05 Urinary metabolites PARK2 intron 21572414 rs2096982 chr6 162660989 A C 1.30E-05 Urinary metabolites PARK2 intron 21572414 rs9365393 chr6 162673561 A G 2.50E-05 Urinary metabolites PARK2 intron 21572414 rs9365397 chr6 162702534 T C 3.42E-05 Paclitaxel-induced neuropathy PARK2 intron 23776197 rs7746112 chr6 162715091 T C 0.00004646 Sarcoidosis PARK2 intron 22952805 rs4709595 chr6 162729381 G T 4.01E-04 Nicotine smoking PARK2 intron 19268276 rs7760647 chr6 162736476 A G 8.30E-05 Non-alcoholic fatty liver disease histology (other) PARK2 intron 20708005 rs2000753 chr6 162752050 A G 0.0000279 Skin naphthyl-keratin adduct (NKA) levels in workers exposed to naphthalene PARK2 intron 22391508 rs2179047 chr6 162778346 G T 0.000588635 Hypertension (early onset hypertension) PARK2 intron 22479346 rs6455813 chr6 162790478 C T 7.97E-04 Multiple complex diseases PARK2 intron 17554300 rs4709606 chr6 162828192 C T 7.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PARK2 intron 20877124 rs10806758 chr6 162841979 C T 3.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PARK2 intron 20877124 rs4708959 chr6 162869197 G A 3.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PARK2 intron 20877124 rs10945835 chr6 162871195 C T 2.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PARK2 intron 20877124 rs7755727 chr6 162887290 G A 4.95E-04 Multiple complex diseases PARK2 intron 17554300 rs7454474 chr6 162889975 C A 9.22E-04 Acute lung injury PARK2 intron 22295056 rs4493732 chr6 162904165 T C 1.81E-05 Triglycerides PARK2 intron 19074352 rs4493732 chr6 162904165 T C 1.81E-05 Polyunsaturated fatty acid levels,in plasma PARK2 intron 19148276 rs2846508 chr6 162946697 T C 8.48E-05 Hypertension PARK2 intron pha003041 rs2846494 chr6 162951587 G C 1.18E-09 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs2846470 chr6 162957575 C T 2.60E-05 Urinary metabolites PARK2 intron 21572414 rs2846488 chr6 162964682 C T 3.07E-10 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs4636000 chr6 162979147 C T 3.41E-08 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs2155510 chr6 162994639 T C 6.56E-09 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs1012424 chr6 162994752 G A 1.22E-08 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs9458611 chr6 162996263 C T 9.97E-04 Multiple complex diseases PARK2 intron 17554300 rs9458611 chr6 162996263 C T 5.98E-07 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs2803059 chr6 163012611 G T 9.79E-13 Lipoprotein a [lp(a)] levels in plasma PARK2 intron pha002870 rs2846530 chr6 163039045 C T 1.37E-04 Multiple complex diseases PARK2 intron 17554300 rs2846515 chr6 163053738 T C 2.80E-05 Urinary metabolites PARK2 intron 21572414 rs2803101 chr6 163070021 T C 3.52E-04 Multiple complex diseases PARK2 intron 17554300 rs949902 chr6 163250778 C A 4.29E-06 Gaucher disease severity PACRG intron 22388998 rs9458664 chr6 163308666 A G 2.81E-05 Hemoglobin PACRG intron pha003096 rs9458664 chr6 163308666 A G 7.21E-06 Hematocrit PACRG intron pha003097 rs7752376 chr6 163333298 C T 4.06E-05 Waist Circumference PACRG intron pha003024 rs7752376 chr6 163333298 C T 3.94E-05 Waist-Hip Ratio PACRG intron pha003029 rs1324965 chr6 163429010 C A 7.06E-04 Smoking initiation PACRG intron 24665060 rs500366 chr6 163439123 A G 9.73E-04 Type 2 diabetes PACRG intron 17463246 rs571644 chr6 163477104 A G 4.89E-05 Response to taxane treatment (placlitaxel) PACRG intron 23006423 rs491862 chr6 163483731 A G 9.74E-05 Response to taxane treatment (placlitaxel) PACRG intron 23006423 rs568041 chr6 163487685 G A 1.97E-04 Response to taxane treatment (placlitaxel) PACRG intron 23006423 rs569879 chr6 163487872 C A 2.31E-04 Response to taxane treatment (placlitaxel) PACRG intron 23006423 rs511715 chr6 163488937 A G 2.92E-04 Response to taxane treatment (placlitaxel) PACRG intron 23006423 rs17381249 chr6 163524816 A G 7.80E-04 Multiple complex diseases PACRG intron 17554300 rs476653 chr6 163539289 T G 1.50E-05 Urinary metabolites PACRG intron 21572414 rs10945872 chr6 163545674 T C 5.60E-05 Response to statin therapy PACRG intron 20339536 rs2874514 chr6 163547203 T G 7.60E-05 Response to statin therapy PACRG intron 20339536 rs554427 chr6 163549871 A G 9.93E-04 Response to cytidine analogues (gemcitabine) PACRG intron 24483146 rs6924869 chr6 163551422 A G 1.00E-04 Cognitive impairment induced by topiramate PACRG intron 22091778 rs16894545 chr6 163553748 C T 5.29E-04 Type 2 diabetes PACRG intron 17463246 rs483222 chr6 163555157 A G 5.42E-04 Smoking initiation PACRG intron 24665060 rs6455867 chr6 163572148 A G 5.67E-04 Smoking initiation PACRG intron 24665060 rs2747688 chr6 163576293 C T 4.65E-04 Smoking initiation PACRG intron 24665060 rs2982908 chr6 163583673 A T 3.90E-05 Femoral neck bone geometry PACRG intron 22087292 rs2235993 chr6 163590256 C T 9.81E-04 Amyotrophic Lateral Sclerosis PACRG intron 17827064 rs6907701 chr6 163633015 G A 7.73E-05 Orofacial clefts PACRG intron 20023658 rs7776125 chr6 163634122 T C 6.03E-04 Depression (quantitative trait) PACRG intron 20800221 rs2206256 chr6 163636248 T A 1.04E-07 Lipoprotein a [lp(a)] levels in plasma PACRG intron pha002870 rs11966842 chr6 163639850 C T 2.88E-07 Lipoprotein a [lp(a)] levels in plasma PACRG intron pha002870 rs11966948 chr6 163640262 C A 1.12E-08 Lipoprotein a [lp(a)] levels in plasma PACRG intron pha002870 rs6904305 chr6 163664812 T G 2.32E-08 Lipoprotein a [lp(a)] levels in plasma PACRG intron pha002870 rs2294458 chr6 163666336 T G 4.00E-05 Diabetic retinopathy PACRG intron 21441570 rs9346954 chr6 163686500 T C 5.75E-04 Type 2 diabetes PACRG intron 17463246 rs9458769 chr6 163695753 G A 4.41E-06 White blood cell count PACRG intron 21738479 rs12525605 chr6 163708338 G A 4.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PACRG intron 20877124 rs10945886 chr6 163709810 C A 6.65E-04 Response to cytadine analogues (cytosine arabinoside) PACRG intron 24483146 rs12055671 chr6 163718869 T C 7.31E-05 Major depressive disorder (broad) PACRG intron 20038947 rs6927758 chr6 163719115 C T 9.48E-05 Major depressive disorder (broad) PACRG intron 20038947 rs6455889 chr6 163719877 T C 5.51E-05 Body Mass Index PACRG intron pha003009 rs11757855 chr6 163730334 C A 3.79E-05 Triglycerides PACRG intron pha003080 rs9356107 chr6 163751551 G A 4.18E-04 Smoking initiation / / 24665060 rs3734284 chr6 163762236 A G 9.01E-04 Myopia (pathological) / / 21095009 rs10945893 chr6 163764804 T C 2.49E-04 Myopia (pathological) DKFZp451B082 intron 21095009 rs735752 chr6 163777215 G A 6.11E-04 Smoking initiation / / 24665060 rs1148 chr6 163789521 A C 6.53E-05 Cognitive test performance / / 20125193 rs9689060 chr6 163820968 C T 0.000000014 Mean arterial pressure / / 22510845 rs783137 chr6 163847852 T C 7.74E-05 Bipolar disorder QKI intron 17486107 rs783139 chr6 163875461 C T 8.91E-04 Type 2 diabetes QKI intron 17463246 rs1737600 chr6 163902509 C A,G,T 9.39E-04 Multiple complex diseases QKI intron 17554300 rs16895059 chr6 163913274 C T 0.0000025 Mean arterial pressure QKI intron 22510845 rs2179524 chr6 163934616 T A 1.71E-04 Multiple complex diseases QKI intron 17554300 rs16895106 chr6 163969931 T A 2.30E-06 White blood cell count QKI intron 21738479 rs9688970 chr6 163976873 A T 3.81E-06 White blood cell count QKI intron 21738479 rs9688570 chr6 163977125 C T 1.89E-06 White blood cell count QKI intron 21738479 rs16895109 chr6 163978326 G A 2.58E-06 White blood cell count QKI intron 21738479 rs16895112 chr6 163978972 C T 2.58E-06 White blood cell count QKI intron 21738479 rs16895119 chr6 163997266 C T 2.20E-10 Mean arterial pressure QKI UTR-3 22510845 rs12208278 chr6 164008112 G A 2.70E-04 Major depressive disorder / / 21042317 rs9346964 chr6 164020325 G A 1.80E-05 Crohn's disease (time to surgery) / / 23665963 rs4574608 chr6 164021403 C A 1.00E-05 Urinary metabolites / / 21572414 rs9364695 chr6 164026905 A G 7.40E-07 Urinary metabolites / / 21572414 rs17592412 chr6 164027663 T C 4.53E-04 Body mass index / / 17255346 rs7756185 chr6 164031621 G T 6.58E-05 Myocardial Infarction / / pha002873 rs12191684 chr6 164071406 C T 2.42E-04 Coronary Artery Disease / / 17634449 rs1407662 chr6 164091657 A G 2.70E-04 Alcohol dependence / / 20201924 rs4709745 chr6 164105984 T C 1.30E-05 Urinary metabolites / / 21572414 rs9365597 chr6 164106739 G A 1.85E-05 Vascular dementia / / 22116812 rs9346971 chr6 164119248 C G 1.40E-05 Urinary metabolites / / 21572414 rs9458896 chr6 164164233 T C 8.58E-05 Parkinson's disease / / 21738487 rs10945919 chr6 164186677 A G 3.00E-07 Response to TNF antagonist treatment / / 18615156 rs10945919 chr6 164186677 A G 2.50E-05 Urinary metabolites / / 21572414 rs9356147 chr6 164193413 A G 3.45E-08 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs9365619 chr6 164251746 A C 0.0000006 Myopia (Age of onset) / / 23468642 rs17441835 chr6 164264584 G A 8.00E-05 Parkinson's disease / / 21738487 rs10945926 chr6 164268604 G A 8.02E-05 Parkinson's disease / / 21738487 rs78921181 chr6 164322241 G A 8.39E-05 Epilepsy (remission after treatment) / / 23962720 rs2180042 chr6 164347674 C T 4.10E-06 Urinary metabolites / / 21572414 rs1555227 chr6 164347973 C T 4.70E-06 Urinary metabolites / / 21572414 rs16895604 chr6 164349026 G A 4.35E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs6928944 chr6 164351521 C T 4.80E-07 Urinary metabolites / / 21572414 rs6928944 chr6 164351521 C T 2.46E-04 Blood pressure (response to calcium channel blocker) / / 24192120 rs7775051 chr6 164353925 T C 7.51E-04 Multiple complex diseases / / 17554300 rs7775051 chr6 164353925 T C 4.60E-12 Mean arterial pressure / / 22510845 rs10428875 chr6 164393244 G T 3.84E-05 Type 2 diabetes / / 17463246 rs10428875 chr6 164393244 G T 8.47E-08 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs16895846 chr6 164406658 C T 3.30E-04 Type 2 diabetes / / 17463246 rs1756 chr6 164407062 A G 2.20E-04 Type 2 diabetes / / 17463246 rs12191111 chr6 164407297 C T 2.68E-04 Type 2 diabetes / / 17463246 rs205983 chr6 164422743 C G 1.24E-04 Type 2 diabetes / / 17463246 rs206002 chr6 164426451 A C,G 2.14E-04 Type 2 diabetes / / 17463246 rs206002 chr6 164426451 A C,G 5.14E-04 Alzheimer's disease / / 17998437 rs185871 chr6 164428889 C T 5.82E-04 Multiple complex diseases / / 17554300 rs105481 chr6 164429526 T A 1.80E-04 Type 2 diabetes / / 17463246 rs206011 chr6 164430998 G A 4.90E-04 Parkinson's disease / / 17052657 rs206011 chr6 164430998 G A 3.06E-04 Type 2 diabetes / / 17463246 rs206012 chr6 164431048 C T 3.81E-04 Type 2 diabetes / / 17463246 rs375691 chr6 164434573 G A 1.23E-04 Type 2 diabetes / / 17463246 rs388305 chr6 164434628 A C 9.65E-05 Type 2 diabetes / / 17463246 rs4709814 chr6 164440635 A G 2.33E-04 Type 2 diabetes / / 17463246 rs205986 chr6 164440916 G A 2.14E-04 Type 2 diabetes / / 17463246 rs11751409 chr6 164441841 C T 8.78E-05 Sudden cardiac arrest / / 21658281 rs205989 chr6 164447167 A G 4.45E-04 Type 2 diabetes / / 17463246 rs4709032 chr6 164455975 G A 3.21E-08 Red blood cell traits / / 23222517 rs2064793 chr6 164456716 A G 7.51E-08 Red blood cell traits / / 23222517 rs2064793 chr6 164456716 A G 4.14E-05 Eosinophil counts / / pha003088 rs724281 chr6 164457788 C G 2.02E-08 Red blood cell traits / / 23222517 rs2070286 chr6 164458287 T C 1.23E-08 Red blood cell traits / / 23222517 rs2070287 chr6 164458336 A G 4.57E-07 Red blood cell traits / / 23222517 rs4709034 chr6 164459225 G A 2.47E-09 Red blood cell traits / / 23222517 rs4709818 chr6 164459375 C T 1.38E-08 Red blood cell traits / / 23222517 rs7743991 chr6 164460115 C T 1.28E-08 Red blood cell traits / / 23222517 rs421640 chr6 164461749 T C 9.35E-09 Red blood cell traits / / 23222517 rs9458973 chr6 164462185 T C 8.95E-09 Red blood cell traits / / 23222517 rs446073 chr6 164462225 A G 4.40E-07 Red blood cell traits / / 23222517 rs438716 chr6 164462424 G C 7.08E-09 Red blood cell traits / / 23222517 rs4709819 chr6 164463355 G A 8.55E-10 Red blood cell traits / / 23222517 rs4709820 chr6 164463572 T C 1.29E-10 Red blood cell traits / / 23222517 rs2064792 chr6 164466497 T C 2.26E-09 Red blood cell traits / / 23222517 rs6901582 chr6 164471666 G T 2.10E-08 Red blood cell traits / / 23222517 rs454187 chr6 164471824 G A 9.19E-08 Red blood cell traits / / 23222517 rs2874705 chr6 164472121 G A 2.69E-10 Red blood cell traits / / 23222517 rs672706 chr6 164473619 C A 1.35E-07 Red blood cell traits / / 23222517 rs672706 chr6 164473619 C A 4.83E-05 Eosinophil counts / / pha003088 rs415182 chr6 164473821 C T 2.09E-08 Red blood cell traits / / 23222517 rs9356181 chr6 164477026 C A 6.02E-11 Red blood cell traits / / 23222517 rs381500 chr6 164478388 C A 1.64E-07 Red blood cell traits / / 23222517 rs395843 chr6 164478916 T C 6.90E-05 Alcoholism (heaviness of drinking) / / 21529783 rs9295254 chr6 164480838 C T 1.00E-08 Red blood cell traits / / 23222517 rs6905119 chr6 164480969 A G 2.80E-11 Red blood cell traits / / 23222517 rs9356182 chr6 164482601 A G 2.44E-09 Red blood cell traits / / 23222517 rs736661 chr6 164482836 A G 1.56E-11 Red blood cell traits / / 23222517 rs7765982 chr6 164487190 C T 9.44E-09 Red blood cell traits / / 23222517 rs1007176 chr6 164491837 A G 8.30E-09 Red blood cell traits / / 23222517 rs206696 chr6 164491926 T A 1.40E-08 Red blood cell traits / / 23222517 rs1010549 chr6 164492383 A C 4.23E-11 Red blood cell traits / / 23222517 rs16896061 chr6 164498432 C T 1.76E-07 Red blood cell traits / / 23222517 rs11963736 chr6 164501012 T G 8.37E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs206729 chr6 164501735 G A 2.51E-10 Red blood cell traits / / 23222517 rs10484511 chr6 164515765 G A 6.77E-04 Aortic root size / / 21223598 rs10085202 chr6 164515936 A G 3.70E-05 Type 2 diabetes / / 17460697 rs16896122 chr6 164527207 G T 9.09E-05 Multiple complex diseases / / 17554300 rs9456928 chr6 164528407 G A 7.18E-05 Cardiovascular disease / / pha003064 rs9458996 chr6 164541324 C T 4.67E-04 Body mass index / / 21701565 rs6926937 chr6 164556919 G C 9.18E-04 Type 2 diabetes / / 17463246 rs1359484 chr6 164569414 G A 3.75E-06 Alzheimer's disease (late onset) / / 21379329 rs4145454 chr6 164572036 C T 1.03E-06 Alzheimer's disease (late onset) / / 21379329 rs807915 chr6 164584860 C T 1.80E-05 Urinary metabolites / / 21572414 rs807914 chr6 164584877 G T 2.20E-05 Urinary metabolites / / 21572414 rs811581 chr6 164609334 C T 7.01E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs1106975 chr6 164616969 A G 4.04E-05 Brain structure / / 22504417 rs10945968 chr6 164683633 C T 3.93E-04 Multiple complex diseases / / 17554300 rs794108 chr6 164683715 C T 1.10E-05 Urinary metabolites / / 21572414 rs1417062 chr6 164699184 C T 7.78E-04 Type 2 diabetes / / 17463246 rs1361429 chr6 164704293 C T 5.94E-06 Fibrinogen / / 17255346 rs12525909 chr6 164711772 C T 6.97E-06 Fibrinogen / / 17255346 rs9365677 chr6 164717378 T C 2.78E-04 Fibrinogen / / 17255346 rs2322433 chr6 164718599 G A 4.71E-05 Fibrinogen / / 17255346 rs7450454 chr6 164719124 C A 3.85E-04 Type 2 diabetes / / 17463246 rs9295262 chr6 164719452 C T 3.66E-04 Multiple complex diseases / / 17554300 rs794114 chr6 164724047 A G 8.52E-05 stroke (ischemic) / / 17434096 rs794114 chr6 164724047 A G 4.97E-04 Multiple complex diseases / / 17554300 rs794114 chr6 164724047 A G 8.92E-04 Bipolar disorder,schizoaffective / / 19567891 rs9356198 chr6 164741842 A C 5.33E-04 Multiple complex diseases / / 17554300 rs9365685 chr6 164742202 G A 1.09E-04 Multiple complex diseases / / 17554300 rs9365685 chr6 164742202 G A 4.64E-04 Bipolar disorder,schizoaffective / / 19567891 rs2322438 chr6 164815194 G A 8.89E-04 Schizophrenia / / 21674006 rs9295275 chr6 164851904 G A 1.22E-06 Multiple complex diseases / / 17554300 rs1417056 chr6 164852232 A G 8.98E-04 Nicotine dependence / / 17158188 rs4709845 chr6 164900598 G A 9.00E-06 Major depressive disorder / / 20516156 rs1497737 chr6 164957966 A C 4.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9347871 chr6 164969901 C T 4.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12662298 chr6 164973625 A G 1.99E-04 Type 2 diabetes / / 17463246 rs2201806 chr6 164982150 C T 1.23E-07 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs1021614 chr6 164992157 G A 1.82E-04 Rheumatoid arthritis (ACPA-negative) / / 24532677 rs9364752 chr6 165079678 T C 1.40E-05 Urinary metabolites / / 21572414 rs11753244 chr6 165093088 G A 4.90E-05 Body Fat Distribution / / pha003017 rs9347899 chr6 165095352 A G 5.09E-04 Alzheimer's disease / / 24755620 rs9347902 chr6 165103679 G A 5.70E-04 Alzheimer's disease / / 24755620 rs9365755 chr6 165120884 C T 1.75E-05 Height / / 22021425 rs10946016 chr6 165130872 C A 4.02E-04 Alzheimer's disease / / 24755620 rs1012175 chr6 165170398 A G 5.65E-05 Body Fat Distribution / / pha003017 rs9356265 chr6 165173588 C T 4.56E-06 Height / / 22021425 rs4579331 chr6 165186467 C T 7.80E-05 Bipolar disorder / / 18317468 rs11752397 chr6 165189841 A G 3.29E-04 Alzheimer's disease / / 24755620 rs10806806 chr6 165222329 C T 6.00E-04 Alzheimer's disease / / 24755620 rs2063427 chr6 165246761 T C 6.04E-05 Bipolar disorder / / 18317468 rs9355513 chr6 165272413 T A 6.89E-05 Bipolar disorder / / 18317468 rs6455970 chr6 165316048 A G 2.15E-07 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs12189587 chr6 165332257 C T 3.51E-04 Alzheimer's disease / / 22005930 rs7772470 chr6 165332880 A C 0.000676 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs7752478 chr6 165333381 G A 0.000247 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs9365814 chr6 165339845 T C 2.16E-04 Alzheimer's disease / / 22005930 rs6455972 chr6 165341169 T G 2.13E-04 Alzheimer's disease / / 22005930 rs752486 chr6 165342423 C G 7.40E-04 Alzheimer's disease / / 22005930 rs752487 chr6 165342777 G A 2.69E-04 Alzheimer's disease / / 22005930 rs9365816 chr6 165343087 G A 7.30E-04 Alzheimer's disease / / 22005930 rs9364775 chr6 165343240 G A 8.17E-04 Alzheimer's disease / / 22005930 rs9356302 chr6 165343288 C T 5.46E-04 Alzheimer's disease / / 22005930 rs4709907 chr6 165343544 C G 7.74E-04 Alzheimer's disease / / 22005930 rs9347043 chr6 165345962 T C 7.40E-04 Alzheimer's disease / / 22005930 rs6920410 chr6 165346371 C T 5.74E-04 Alzheimer's disease / / 22005930 rs6920410 chr6 165346371 C T 2.70E-05 Coronary heart disease / / pha003035 rs9365820 chr6 165348305 T C 7.41E-04 Alzheimer's disease / / 22005930 rs10946043 chr6 165349015 C A 7.41E-04 Alzheimer's disease / / 22005930 rs716143 chr6 165350172 T C 7.44E-04 Alzheimer's disease / / 22005930 rs6929301 chr6 165350991 A G 7.43E-04 Alzheimer's disease / / 22005930 rs6906353 chr6 165351216 G A 7.44E-04 Alzheimer's disease / / 22005930 rs9347945 chr6 165352195 G T 7.43E-04 Alzheimer's disease / / 22005930 rs9356307 chr6 165353405 A G 7.43E-04 Alzheimer's disease / / 22005930 rs9347948 chr6 165354800 C G 7.44E-04 Alzheimer's disease / / 22005930 rs9347949 chr6 165354940 T C 7.45E-04 Alzheimer's disease / / 22005930 rs9356309 chr6 165355783 G A 5.79E-04 Alzheimer's disease / / 22005930 rs6911471 chr6 165357002 C T 6.44E-04 Alzheimer's disease / / 22005930 rs6938706 chr6 165357222 T C 8.00E-04 Alzheimer's disease / / 22005930 rs6917857 chr6 165358162 C T 6.03E-04 Alzheimer's disease / / 22005930 rs6917857 chr6 165358162 C T 2.70E-05 Coronary heart disease / / pha003035 rs9356312 chr6 165358271 G T 7.67E-04 Alzheimer's disease / / 22005930 rs6455975 chr6 165359087 G A 5.99E-04 Alzheimer's disease / / 22005930 rs6455976 chr6 165359103 C G 6.03E-04 Alzheimer's disease / / 22005930 rs2322648 chr6 165359483 A C 7.76E-04 Alzheimer's disease / / 22005930 rs6914484 chr6 165360760 A G 7.81E-04 Alzheimer's disease / / 22005930 rs6919069 chr6 165360775 T C 7.84E-04 Alzheimer's disease / / 22005930 rs12190489 chr6 165364626 A G 7.87E-04 Alzheimer's disease / / 22005930 rs9347957 chr6 165364652 G A 5.18E-04 Alzheimer's disease / / 22005930 rs9347957 chr6 165364652 G A 2.70E-05 Coronary heart disease / / pha003035 rs9295290 chr6 165365324 C G 7.99E-04 Alzheimer's disease / / 22005930 rs9295291 chr6 165365663 G T 8.10E-04 Alzheimer's disease / / 22005930 rs9355518 chr6 165367973 G T 6.41E-04 Alzheimer's disease / / 22005930 rs9365832 chr6 165369127 T C 6.99E-04 Alzheimer's disease / / 22005930 rs9355521 chr6 165377738 C T 6.16E-04 Alzheimer's disease / / 22005930 rs12203926 chr6 165380648 C G 4.67E-04 Alzheimer's disease / / 22005930 rs10946051 chr6 165381482 C T 4.68E-04 Alzheimer's disease / / 22005930 rs10946052 chr6 165385518 A G 4.65E-04 Alzheimer's disease / / 22005930 rs9347052 chr6 165387747 C A 4.32E-04 Alzheimer's disease / / 22005930 rs9356322 chr6 165387848 T A 3.79E-04 Alzheimer's disease / / 22005930 rs10946053 chr6 165388796 T G 4.13E-04 Alzheimer's disease / / 22005930 rs9356325 chr6 165394024 C G 2.53E-04 Alzheimer's disease / / 22005930 rs10946054 chr6 165394580 G A 3.53E-04 Alzheimer's disease / / 22005930 rs10946054 chr6 165394580 G A 8.55E-05 Coronary heart disease / / pha003035 rs4709067 chr6 165396982 T C 3.15E-04 Alzheimer's disease / / 22005930 rs10806816 chr6 165400961 G C 3.43E-04 Alzheimer's disease / / 22005930 rs911727 chr6 165405678 G A 5.67E-04 Alzheimer's disease / / 22005930 rs911727 chr6 165405678 G A 8.55E-05 Coronary heart disease / / pha003035 rs9364781 chr6 165406961 T C 2.40E-05 Urinary metabolites / / 21572414 rs6924339 chr6 165407104 G T 5.84E-04 Alzheimer's disease / / 22005930 rs1570279 chr6 165407690 G T 7.81E-04 Alzheimer's disease / / 22005930 rs7453732 chr6 165408604 C T 3.42E-04 Alzheimer's disease / / 22005930 rs9347060 chr6 165409810 A T 4.12E-04 Alzheimer's disease / / 22005930 rs9457028 chr6 165410382 G A 6.36E-04 Multiple complex diseases / / 17554300 rs11969313 chr6 165418519 G A 2.03E-04 Alzheimer's disease / / 22005930 rs1322203 chr6 165425145 C T 9.50E-06 Urinary metabolites / / 21572414 rs1322200 chr6 165425309 A G 5.60E-06 Urinary metabolites / / 21572414 rs2146031 chr6 165425338 C T 1.40E-05 Sudden cardiac arrest / / 21658281 rs2146031 chr6 165425338 C T 2.08E-04 Alzheimer's disease / / 22005930 rs1322199 chr6 165425517 G A 8.90E-06 Chronic kidney disease / / 22479191 rs1322198 chr6 165434579 C T 5.59E-04 Alzheimer's disease / / 22005930 rs9365856 chr6 165439028 T A 9.40E-06 Urinary metabolites / / 21572414 rs9347063 chr6 165441034 G A 1.60E-05 Urinary metabolites / / 21572414 rs1322197 chr6 165441064 C T 9.43E-04 Alzheimer's disease / / 22005930 rs1322197 chr6 165441064 C T 8.79E-05 Coronary heart disease / / pha003035 rs3967133 chr6 165451468 T G 7.47E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10455803 chr6 165455420 T G 5.68E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs227458 chr6 165466351 T C 5.49E-06 IgE levels / / 17255346 rs227458 chr6 165466351 T C 3.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs9295300 chr6 165467714 A G 1.97E-05 Anxiety in major depressive disorder / / 24047446 rs11752320 chr6 165475051 C T 4.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs227455 chr6 165478051 T C 1.60E-07 Diabetic retinopathy / / 21441570 rs227454 chr6 165478716 T C 3.59E-05 IgE levels / / 17255346 rs227453 chr6 165478798 A T 3.20E-07 Diabetic retinopathy / / 21441570 rs227452 chr6 165479017 A G 6.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs10452574 chr6 165484164 C T 5.96E-05 Hematocrit / / pha003097 rs10452574 chr6 165484164 C T 2.42E-06 Erythrocyte counts / / pha003101 rs1322192 chr6 165485578 G A 0.0000731 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1322193 chr6 165487131 C A 0.0000733 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1923380 chr6 165491551 G A 6.11E-04 Multiple complex diseases / / 17554300 rs566349 chr6 165503601 C G 6.29E-04 Multiple complex diseases / / 17554300 rs2675742 chr6 165505128 G A 8.26E-04 Multiple complex diseases / / 17554300 rs2675743 chr6 165505146 G A 8.43E-04 Multiple complex diseases / / 17554300 rs2758931 chr6 165505378 A G 5.99E-04 Multiple complex diseases / / 17554300 rs2675724 chr6 165565895 A C 2.00E-07 Asthma (sex interaction) / / 24824216 rs9459317 chr6 165590421 G T 6.76E-14 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs1764053 chr6 165612858 T C 8.09E-04 Multiple complex diseases / / 17554300 rs1764053 chr6 165612858 T C 5.00E-16 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs1923608 chr6 165621452 G A 7.61E-11 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs2197100 chr6 165631791 G A 6.17E-05 Orofacial clefts / / 20023658 rs7740603 chr6 165638896 G A 5.74E-05 Orofacial clefts / / 20023658 rs16897566 chr6 165640017 C T 4.53E-05 Cognitive test performance / / 20125193 rs16897566 chr6 165640017 C T 2.75E-09 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs1441891 chr6 165656232 T G 2.71E-04 Multiple complex diseases / / 17554300 rs559156 chr6 165663792 C A 7.91E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6912851 chr6 165666733 A G 4.60E-04 Alzheimer's disease / / 22005930 rs1547709 chr6 165705488 T C 9.11E-04 Suicide attempts in bipolar disorder C6orf118 intron 21423239 rs145070973 chr6 165711487 G A 0.00013 Prostate cancer (advanced) C6orf118 missense 23555315 rs551444 chr6 165742365 T C 4.77E-06 HDL cholesterol PDE10A UTR-3 pha003075 rs16897664 chr6 165742757 T C 7.59E-04 Multiple complex diseases PDE10A UTR-3 17554300 rs3778248 chr6 165754461 G A 4.34E-04 Lung function (forced expiratory volume in 1 second) PDE10A intron 24023788 rs3778248 chr6 165754461 G A 2.04E-05 HDL cholesterol PDE10A intron pha003075 rs484842 chr6 165759915 T C 7.57E-05 HDL cholesterol PDE10A intron pha003074 rs484842 chr6 165759915 T C 2.27E-06 HDL cholesterol PDE10A intron pha003075 rs484842 chr6 165759915 T C 3.93E-05 Lipid levels PDE10A intron pha003082 rs546311 chr6 165791239 A C 6.18E-06 HDL cholesterol PDE10A intron pha003074 rs546311 chr6 165791239 A C 2.08E-06 HDL cholesterol PDE10A intron pha003075 rs546311 chr6 165791239 A C 1.17E-05 Triglycerides PDE10A intron pha003080 rs546311 chr6 165791239 A C 3.46E-05 Triglycerides PDE10A intron pha003081 rs546311 chr6 165791239 A C 1.33E-06 Lipid levels PDE10A intron pha003082 rs16897780 chr6 165798443 G A 6.24E-05 Coronary heart disease PDE10A intron pha003055 rs3799162 chr6 165799614 G A 2.51E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) PDE10A intron 24023788 rs12528988 chr6 165814173 T C 5.46E-05 Receptive language ability PDE10A intron 24687471 rs538464 chr6 165819417 C T 4.51E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PDE10A intron 20031582 rs220768 chr6 165822068 C T 4.10E-04 Type 2 diabetes PDE10A intron 17463246 rs220752 chr6 165825566 C T 5.67E-04 Type 2 diabetes PDE10A intron 17463246 rs220749 chr6 165827194 A G 2.10E-04 Type 2 diabetes PDE10A intron 17463246 rs220740 chr6 165832227 C T 3.01E-04 Lung function (forced expiratory volume in 1 second) PDE10A cds-synon 24023788 rs9459417 chr6 165837992 T C 9.37E-05 Lung function (forced expiratory volume in 1 second) PDE10A intron pha003103 rs220821 chr6 165849238 A C 9.37E-04 Alcohol dependence PDE10A intron 24277619 rs6930290 chr6 165861834 C T 4.38E-04 Multiple complex diseases PDE10A intron 17554300 rs9459418 chr6 165867791 C A 3.86E-04 Alcohol dependence PDE10A intron 21314694 rs537694 chr6 165926997 T C 8.29E-04 Parkinson's disease PDE10A intron 17052657 rs635547 chr6 165932266 G A 2.00E-04 Cognitive impairment induced by topiramate PDE10A intron 22091778 rs519595 chr6 165935421 A G 2.00E-06 Response to fenofibrate PDE10A intron 22890011 rs519595 chr6 165935421 A G 5.00E-06 Response to fenofibrate PDE10A intron 22890011 rs6906719 chr6 165945970 C A 2.10E-05 Urinary metabolites PDE10A intron 21572414 rs484720 chr6 165948503 G A 2.49E-04 Type 2 diabetes PDE10A intron 17463246 rs484720 chr6 165948503 G A 2.50E-05 Urinary metabolites PDE10A intron 21572414 rs484594 chr6 165948551 G A 1.04E-05 Smoking behavior PDE10A intron 19188921 rs481701 chr6 165948886 G C 2.77E-05 Suicide attempts in bipolar disorder PDE10A intron 21423239 rs545099 chr6 165953127 C T 9.00E-06 Age-related nuclear cataracts PDE10A intron 24951543 rs1022180 chr6 165969396 G A 6.42E-04 Multiple complex diseases PDE10A intron 17554300 rs1022180 chr6 165969396 G A 8.72E-04 Alzheimer's disease PDE10A intron 17998437 rs9355540 chr6 165975003 C A 8.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE10A intron 20877124 rs1328379 chr6 166003641 G C 2.06E-04 Glycosylated haemoglobin levels PDE10A intron 17255346 rs2987297 chr6 166007270 T A 2.43E-04 Glycosylated haemoglobin levels PDE10A intron 17255346 rs6917844 chr6 166008387 G A 1.48E-04 Glycosylated haemoglobin levels PDE10A intron 17255346 rs720701 chr6 166011637 A G 4.13E-05 Orofacial clefts PDE10A intron 22419666 rs3008011 chr6 166013760 T C 2.43E-06 Scoliosis PDE10A intron 21216876 rs2983528 chr6 166013962 T C 3.68E-06 Scoliosis PDE10A intron 21216876 rs7762160 chr6 166015431 T C 1.00E-06 Conduct disorder (symptom count) PDE10A intron 20585324 rs7762160 chr6 166015431 T C 2.75E-05 Height PDE10A intron pha003011 rs9348022 chr6 166028274 T C 1.26E-05 Height PDE10A intron pha003011 rs753760 chr6 166046483 C G 1.00E-24 Thyroid hormone levels PDE10A intron 23408906 rs753760 chr6 166046483 C G 5.00E-09 Thyroid hormone levels PDE10A intron 23408906 rs753760 chr6 166046483 C G 6.00E-20 Thyroid hormone levels PDE10A intron 23408906 rs2983514 chr6 166050119 A G 9.20E-05 Hypothyroidism PDE10A intron 22493691 rs9365900 chr6 166064152 G A 6.05E-05 Depression (quantitative trait) PDE10A intron 23290196 rs10485103 chr6 166065660 T G 8.84E-05 Iron status biomarkers PDE10A intron 19084217 rs4709963 chr6 166096253 T A 1.50E-05 Urinary metabolites / / 21572414 rs9295312 chr6 166100058 C T 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs9365907 chr6 166100118 T C 0.0000315 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4352664 chr6 166105786 T C 2.11E-04 Type 2 diabetes / / 17463246 rs7753384 chr6 166126615 T C 3.52E-04 Type 2 diabetes / / 17463246 rs7753384 chr6 166126615 T C 3.11E-04 Multiple complex diseases / / 17554300 rs7753380 chr6 166126806 A G 9.63E-04 Type 2 diabetes / / 17463246 rs7753380 chr6 166126806 A G 5.34E-04 Multiple complex diseases / / 17554300 rs9364813 chr6 166128638 G A 8.00E-06 Economic and political preferences (immigration/crime) / / 22566634 rs6922233 chr6 166137201 G A 2.34E-04 Type 2 diabetes / / 17463246 rs6922233 chr6 166137201 G A 7.85E-04 Multiple complex diseases / / 17554300 rs6922436 chr6 166137319 G A 2.01E-04 Type 2 diabetes / / 17463246 rs6922436 chr6 166137319 G A 4.74E-04 Multiple complex diseases / / 17554300 rs6913046 chr6 166138045 T C 1.22E-04 Type 2 diabetes / / 17463246 rs6913046 chr6 166138045 T C 6.98E-04 Multiple complex diseases / / 17554300 rs12211996 chr6 166150463 C T 4.90E-06 Urinary metabolites / / 21572414 rs1039002 chr6 166155457 G A 2.00E-08 Bipolar disorder / / 22205951 rs12202881 chr6 166157760 G C 5.80E-06 Urinary metabolites / / 21572414 rs1389923 chr6 166160771 G T 7.18E-05 Attention deficit hyperactivity disorder / / pha002875 rs2088086 chr6 166163521 C T 8.58E-04 Coronary heart disease / / 21971053 rs2323029 chr6 166181220 T C 2.00E-07 Urinary metabolites / / 21572414 rs4709090 chr6 166184203 C T 9.18E-05 Blood Pressure / / pha002898 rs7748044 chr6 166186011 A G 8.60E-06 Urinary metabolites / / 21572414 rs9364815 chr6 166197239 A G 1.20E-05 Urinary metabolites / / 21572414 rs9348049 chr6 166263379 A G 5.55E-04 Aortic root size / / 21223598 rs2934848 chr6 166275046 T C 1.40E-04 Type 2 diabetes / / 17463246 rs2172784 chr6 166290093 T C 1.45E-04 Multiple complex diseases / / 17554300 rs13212052 chr6 166294190 T C 8.20E-05 Type 2 diabetes / / 17463248 rs2461718 chr6 166296306 T C 1.00E-04 Telomere length / / 21573004 rs2461719 chr6 166296357 A G 3.89E-05 Myocardial Infarction / / pha002883 rs11756707 chr6 166303168 T G 9.01E-05 Cognitive impairment induced by topiramate / / 22091778 rs6456029 chr6 166307718 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9459522 chr6 166309167 G A 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7747429 chr6 166310842 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6937183 chr6 166315607 C A 7.13E-04 Type 2 diabetes / / 17463246 rs9459531 chr6 166333799 A G 4.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2016694 chr6 166345564 C A 7.40E-06 Urinary metabolites LINC00473 intron 21572414 rs660244 chr6 166346764 G A 1.80E-05 Urinary metabolites LINC00473 intron 21572414 rs1397686 chr6 166348640 G A 4.56E-04 Multiple complex diseases LINC00473 intron 17554300 rs213997 chr6 166367429 G A 1.75E-04 Suicide attempts in bipolar disorder LINC00473 intron 21423239 rs4083115 chr6 166373897 C T 8.98E-05 Lung adenocarcinoma LINC00473 intron 19836008 rs705798 chr6 166381161 T C 4.00E-06 Urinary metabolites LINC00473 intron 21572414 rs9364827 chr6 166393047 C T 2.98E-05 Cognitive test performance LINC00473 intron 20125193 rs300122 chr6 166404335 A G 8.48E-04 Multiple complex diseases / / 17554300 rs300122 chr6 166404335 A G 2.80E-05 Urinary metabolites / / 21572414 rs9348064 chr6 166436895 C A 6.72E-04 White matter integrity / / 22425255 rs7739162 chr6 166442769 A T 7.90E-06 Urinary metabolites / / 21572414 rs12195036 chr6 166451697 T C 5.00E-07 Blood pressure / / 24954895 rs705819 chr6 166458910 T C 8.29E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs705825 chr6 166469700 A G 7.50E-05 Response to statin therapy / / 20339536 rs4710003 chr6 166470464 A C 7.60E-05 Response to statin therapy / / 20339536 rs9459565 chr6 166505526 A G 4.76E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs9459565 chr6 166505526 A G 8.00E-05 Lung function (forced vital capacity) / / pha003104 rs3127390 chr6 166510789 G A 8.91E-05 Multiple sclerosis (age of onset) / / 19010793 rs1445277 chr6 166512601 A C 9.54E-04 Type 2 diabetes / / 17463246 rs3924582 chr6 166519887 C A 9.84E-05 Post-operative nausea and vomiting / / 21694509 rs3127398 chr6 166522520 C T 0.00064858 Hypertension (early onset hypertension) / / 22479346 rs3099291 chr6 166528913 C T 4.33E-04 Multiple complex diseases / / 17554300 rs6910508 chr6 166531345 G A 6.10E-06 Urinary metabolites / / 21572414 rs6940243 chr6 166534658 G C 2.16E-04 Multiple complex diseases / / 17554300 rs6456042 chr6 166534742 A C 4.40E-04 Multiple complex diseases / / 17554300 rs6456042 chr6 166534742 A C 6.00E-06 Asthma / / 22538805 rs3127412 chr6 166535561 C T 2.59E-04 Multiple complex diseases / / 17554300 rs9348076 chr6 166541376 T G 2.70E-05 Urinary metabolites / / 21572414 rs12154075 chr6 166566271 G T 8.21E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9459593 chr6 166568971 G A 8.30E-06 Urinary metabolites / / 21572414 rs6927011 chr6 166569505 G C 1.10E-05 Urinary metabolites / / 21572414 rs6917533 chr6 166570156 T A 4.90E-06 Urinary metabolites / / 21572414 rs1056053 chr6 166571443 C T 4.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio T UTR-3 22589738 rs3127331 chr6 166572744 C T 7.51E-04 Multiple complex diseases T intron 17554300 rs2028792 chr6 166572941 C T 4.19E-04 Amyotrophic Lateral Sclerosis T intron 17362836 rs2028791 chr6 166573544 A G 4.04E-04 Amyotrophic Lateral Sclerosis T intron 17362836 rs1867594 chr6 166583501 A G 2.18E-04 Hearing function T nearGene-5 17255346 rs12215543 chr6 166584761 A C 1.34E-04 Hearing function / / 17255346 rs9356434 chr6 166585828 T C 7.58E-04 Schizophrenia / / 19197363 rs7738514 chr6 166589568 C T 6.66E-04 Lymphocyte counts / / 22286170 rs7750964 chr6 166609388 C T 1.40E-05 Urinary metabolites / / 21572414 rs9457141 chr6 166615748 C T 1.50E-05 Urinary metabolites / / 21572414 rs9348101 chr6 166654951 A G 9.36E-04 Type 2 diabetes / / 17463246 rs9348102 chr6 166654968 C T 6.50E-04 Type 2 diabetes / / 17463246 rs9348102 chr6 166654968 C T 2.08E-04 Lymphocyte counts / / 22286170 rs9356453 chr6 166660733 A C 3.01E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9356457 chr6 166661518 C T 1.47E-04 Alzheimer's disease (late onset) / / 21379329 rs1610314 chr6 166662004 A G 4.49E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9459625 chr6 166671337 G C 9.19E-05 Pulmonary function / / 19300500 rs12211694 chr6 166671763 T A 3.40E-04 Smoking initiation / / 24665060 rs10946146 chr6 166686875 C G 5.16E-04 Major depressive disorder / / 22472876 rs9355568 chr6 166691885 C G 6.42E-04 Insulin resistance / / 21901158 rs7759603 chr6 166704632 G A 3.23E-04 Type 2 diabetes / / 17463246 rs7763448 chr6 166704723 G A 5.97E-04 Type 2 diabetes / / 17463246 rs10946151 chr6 166704744 C T 8.80E-06 Urinary metabolites / / 21572414 rs6915183 chr6 166706169 A G 1.00E-06 Longevity / / 20834067 rs7748966 chr6 166709232 C T 1.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7753337 chr6 166715913 T A 2.14E-04 Multiple complex diseases / / 17554300 rs4075452 chr6 166722417 T C 9.65E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10946155 chr6 166724312 T C 1.09E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10946155 chr6 166724312 T C 1.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7767887 chr6 166731067 T C 9.64E-06 Response to amphetamines / / 22952603 rs10806847 chr6 166739684 G A 1.45E-04 Multiple complex diseases SFT2D1 intron 17554300 rs4144887 chr6 166747512 G A 3.19E-06 Mathematical ability SFT2D1 intron 24801482 rs9356478 chr6 166751416 C T 2.00E-04 Multiple complex diseases SFT2D1 intron 17554300 rs4709111 chr6 166751690 T G 2.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SFT2D1 intron 20877124 rs9457165 chr6 166761245 T C 9.16E-05 Vaspin levels LOC100289495 intron 22907691 rs9457165 chr6 166761245 T C 0.0000916 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks LOC100289495 intron 22907730 rs6902813 chr6 166766142 G A 2.52E-04 Type 2 diabetes / / 17463246 rs6902813 chr6 166766142 G A 5.37E-04 Multiple complex diseases / / 17554300 rs6918091 chr6 166771092 T A 3.84E-04 Multiple complex diseases / / 17554300 rs9348123 chr6 166771814 C T 8.83E-04 Multiple complex diseases / / 17554300 rs7449629 chr6 166798522 T A 4.68E-04 Multiple complex diseases / / 17554300 rs9364847 chr6 166813627 C T 5.74E-04 Multiple complex diseases / / 17554300 rs9355578 chr6 166819774 T C 6.85E-04 Schizophrenia / / 19197363 rs2984 chr6 166826021 C T 2.90E-05 Alzheimer's disease (late onset) RPS6KA2 UTR-3 21460841 rs6925364 chr6 166830696 A C 3.37E-04 Schizophrenia RPS6KA2 intron 19197363 rs9459678 chr6 166883981 T C 8.02E-05 Type 2 diabetes RPS6KA2 intron 17463246 rs9459678 chr6 166883981 T C 9.60E-05 Non-alcoholic fatty liver disease histology (other) RPS6KA2 intron 20708005 rs2235283 chr6 166884848 T G 1.30E-04 Tourette syndrome RPS6KA2 intron 22889924 rs909635 chr6 166886340 T C 6.99E-04 Tourette syndrome RPS6KA2 intron 22889924 rs9347129 chr6 166895934 A C 2.28E-05 Diabetes Mellitus RPS6KA2 intron pha003060 rs6935542 chr6 166897732 A G 8.69E-04 Multiple complex diseases RPS6KA2 intron 17554300 rs6935542 chr6 166897732 A G 2.10E-05 Diabetes Mellitus RPS6KA2 intron pha003060 rs9295350 chr6 166898856 G C 1.68E-04 Multiple complex diseases RPS6KA2 intron 17554300 rs9457173 chr6 166913485 T G 4.00E-05 Prostate cancer RPS6KA2 intron 21743057 rs10946174 chr6 166915130 G A 1.00E-04 Prostate cancer RPS6KA2 intron 21743057 rs3778430 chr6 166916557 T C 7.00E-05 Prostate cancer RPS6KA2 intron 21743057 rs763187 chr6 166955738 A G 2.60E-05 Platelet counts RPS6KA2 intron pha003100 rs3799631 chr6 166960154 T C 0.000581 Salmonella-induced pyroptosis RPS6KA2 intron 22837397 rs3799627 chr6 166967389 C T 3.81E-04 Oral cancers (chewing tobacco related) RPS6KA2 intron 22503698 rs3799627 chr6 166967389 C T 5.05E-04 Tourette syndrome RPS6KA2 intron 22889924 rs971152 chr6 166969936 C A,G,T 3.98E-04 Taste perception RPS6KA2 intron 22132133 rs9355584 chr6 166971926 A C 6.91E-04 Taste perception RPS6KA2 intron 22132133 rs12661820 chr6 166984656 A C 5.08E-05 HIV-1 viral setpoint RPS6KA2 intron 22174851 rs3823198 chr6 166997459 G T 0.0000416 Bipolar disorder RPS6KA2 intron 23637625 rs3799584 chr6 167019126 T C 5.23E-04 HIV-1 viral setpoint RPS6KA2 intron 17641165 rs3799570 chr6 167030620 G A 4.10E-04 Insulin resistance RPS6KA2 intron 21901158 rs3799570 chr6 167030620 G A 0.0000323 Skin naphthyl-keratin adduct (NKA) levels in workers exposed to naphthalene RPS6KA2 intron 22391508 rs4145432 chr6 167043542 G A 1.89E-04 Amyotrophic lateral sclerosis (sporadic) RPS6KA2 intron 24529757 rs12215660 chr6 167065904 G T 2.74E-04 Multiple complex diseases RPS6KA2 intron 17554300 rs6935679 chr6 167080717 A G 5.55E-04 Nicotine smoking RPS6KA2 intron 19268276 rs6921577 chr6 167083690 A G 1.09E-04 Osteoarthritis RPS6KA2 intron 19508968 rs12198299 chr6 167084275 T C 9.77E-05 Longevity RPS6KA2 intron 20304771 rs2281144 chr6 167091844 A G 9.10E-04 Type 2 diabetes RPS6KA2 intron 17463246 rs7766723 chr6 167107073 G A 9.10E-06 Urinary metabolites RPS6KA2 intron 21572414 rs909768 chr6 167108595 A G 1.36E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) RPS6KA2 intron 24023788 rs16899309 chr6 167114930 C T 5.35E-04 Heart Failure RPS6KA2 intron pha002885 rs7768395 chr6 167129817 G A 0.000603 Salmonella-induced pyroptosis RPS6KA2 intron 22837397 rs7750397 chr6 167142647 A T 3.85E-04 Multiple complex diseases RPS6KA2 intron 17554300 rs7740311 chr6 167151804 T C 4.27E-04 Multiple complex diseases RPS6KA2 intron 17554300 rs1883361 chr6 167161571 A G 1.00E-04 Cognitive impairment induced by topiramate RPS6KA2 intron 22091778 rs635808 chr6 167177422 G A 1.00E-07 Dental caries RPS6KA2 intron 23259602 rs481830 chr6 167182277 G A 9.29E-06 HIV-1 viral setpoint RPS6KA2 intron 17641165 rs17590608 chr6 167186024 T C 4.30E-05 Asthma (bronchodilator response) RPS6KA2 intron 22792082 rs9457212 chr6 167200671 T C 6.98E-04 Body mass index RPS6KA2 intron 21701565 rs1927432 chr6 167201033 G A 3.34E-04 Response to taxane treatment (placlitaxel) RPS6KA2 intron 23006423 rs7754623 chr6 167215384 C A 8.80E-05 Asthma (bronchodilator response) RPS6KA2 intron 22792082 rs2178806 chr6 167218762 C T 1.00E-05 Asthma (bronchodilator response) RPS6KA2 intron 22792082 rs845670 chr6 167223099 T G 7.79E-04 Response to taxane treatment (placlitaxel) RPS6KA2 intron 23006423 rs1099650 chr6 167229078 A G 9.03E-04 Multiple complex diseases RPS6KA2 intron 17554300 rs1099650 chr6 167229078 A G 1.93E-05 Serum metabolites RPS6KA2 intron 19043545 rs4710113 chr6 167229617 A C 7.82E-04 Smoking initiation RPS6KA2 intron 24665060 rs9348182 chr6 167232298 A G 5.37E-04 Smoking initiation RPS6KA2 intron 24665060 rs6902718 chr6 167232907 T C 4.79E-04 Smoking initiation RPS6KA2 intron 24665060 rs9355597 chr6 167234577 T A 5.30E-04 Smoking initiation RPS6KA2 intron 24665060 rs1103031 chr6 167237848 T C 8.95E-04 Multiple complex diseases RPS6KA2 intron 17554300 rs9459771 chr6 167251417 G A 3.86E-04 Multiple complex diseases RPS6KA2 intron 17554300 rs1854239 chr6 167261708 C G 4.05E-04 Insulin resistance RPS6KA2 intron 21901158 rs4709138 chr6 167286178 C A 3.81E-04 Multiple complex diseases / / 17554300 rs7755545 chr6 167327948 C T 7.36E-10 Adiponectin levels / / 20887962 rs9459805 chr6 167336151 A G 1.11E-05 Endometrial cancer / / 24096698 rs9459805 chr6 167336151 A G 2.10E-05 Endometrial cancer / / 24096698 rs9459805 chr6 167336151 A G 8.00E-06 Endometrial cancer / / 24096698 rs6940854 chr6 167337295 G C 5.84E-04 Multiple complex diseases / / 17554300 rs11159 chr6 167343141 G A 0.00067 Prostate cancer R/SET2 missense 23555315 rs35716361 chr6 167343185 G T 0.0000011 Prostate cancer (advanced) R/SET2 missense 23555315 rs2757045 chr6 167350963 A G 8.75E-04 Multiple complex diseases R/SET2 intron 17554300 rs2757048 chr6 167351120 C T 6.58E-05 Multiple complex diseases R/SET2 intron 17554300 rs3777722 chr6 167352104 C A 3.40E-05 Multiple complex diseases R/SET2 intron 17554300 rs3777722 chr6 167352104 C A 3.60E-06 Rheumatoid arthritis R/SET2 intron 20453841 rs3777722 chr6 167352104 C A 1.02E-06 Graves' disease R/SET2 intron 21841780 rs3777723 chr6 167353701 G A 3.30E-05 Rheumatoid arthritis R/SET2 intron 20453841 rs3777723 chr6 167353701 G A 7.00E-05 Graves' disease R/SET2 intron 21841780 rs3734247 chr6 167358121 T C 9.50E-04 Response to alcohol consumption (flushing response) R/SET2 intron 24277619 rs9459809 chr6 167359643 C A,G 9.80E-04 Multiple complex diseases R/SET2 intron 17554300 rs2236312 chr6 167360104 G A 1.30E-05 Rheumatoid arthritis R/SET2 intron 20453841 rs2236312 chr6 167360104 G A 2.36E-05 Graves' disease R/SET2 intron 21841780 rs2236312 chr6 167360104 G A 1.15E-04 Self-reported allergy R/SET2 intron 23817569 rs2236313 chr6 167360389 T C 5.77E-05 Bipolar disorder R/SET2 intron 19488044 rs2236313 chr6 167360389 T C 7.70E-06 Rheumatoid arthritis R/SET2 intron 20453841 rs2236313 chr6 167360389 T C 1.00E-16 Vitiligo R/SET2 intron 20526339 rs2236313 chr6 167360389 T C 3.02E-05 Graves' disease R/SET2 intron 21841780 rs1079145 chr6 167360724 G A 9.20E-06 Rheumatoid arthritis R/SET2 intron 20453841 rs1079145 chr6 167360724 G A 2.60E-05 Graves' disease R/SET2 intron 21841780 rs2093415 chr6 167361285 G A 3.44E-04 Multiple complex diseases R/SET2 intron 17554300 rs2093415 chr6 167361285 G A 1.12E-07 Lymphocyte counts R/SET2 intron 22286170 rs3798305 chr6 167363473 C T 7.00E-06 Smooth-surface caries R/SET2 intron 24556642 rs3798307 chr6 167363948 G A 1.52E-04 Self-reported allergy R/SET2 intron 23817569 rs2149085 chr6 167371110 T C 8.00E-12 Crohn's disease R/SET2 nearGene-5 23850713 rs1819333 chr6 167373547 T G 8.56E-06 Serum metabolites / / 19043545 rs1819333 chr6 167373547 T G 7.00E-21 Inflammatory bowel disease / / 23128233 rs9366076 chr6 167373708 C T 5.10E-07 Rheumatoid arthritis / / 20453841 rs9366076 chr6 167373708 C T 3.99E-09 Graves' disease / / 21841780 rs9355610 chr6 167383075 G A 3.60E-06 Rheumatoid arthritis / / 20453841 rs9355610 chr6 167383075 G A 7.78E-04 Rheumatoid arthritis / / 21452313 rs9355610 chr6 167383075 G A 7.00E-10 Graves' disease / / 21841780 rs429083 chr6 167383972 T C 2.60E-05 Lung adenocarcinoma / / 19836008 rs429083 chr6 167383972 T C 1.60E-05 Rheumatoid arthritis / / 20453841 rs429083 chr6 167383972 T C 3.64E-05 Graves' disease / / 21841780 rs429083 chr6 167383972 T C 1.40E-05 Hypothyroidism / / 22493691 rs429083 chr6 167383972 T C 1.11E-04 Crohn's disease / / 23266558 rs386548 chr6 167385533 T A 1.04E-05 Serum metabolites / / 19043545 rs386548 chr6 167385533 T A 4.81E-05 Lymphocyte counts / / 22286170 rs394522 chr6 167398071 A C 5.81E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs394522 chr6 167398071 A C 8.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs394522 chr6 167398071 A C 9.83E-11 Crohn's disease / / 23850713 rs408918 chr6 167399282 G T 1.13E-05 Serum metabolites / / 19043545 rs9366078 chr6 167399512 A G 4.10E-06 Rheumatoid arthritis / / 20453841 rs9366078 chr6 167399512 A G 1.31E-07 Graves' disease / / 21841780 rs933243 chr6 167403873 C A 4.00E-06 Rheumatoid arthritis / / 20453841 rs933243 chr6 167403873 C A 2.87E-04 Rheumatoid arthritis / / 21452313 rs933243 chr6 167403873 C A 1.50E-07 Graves' disease / / 21841780 rs422562 chr6 167406318 A G 1.00E-05 Serum metabolites / / 19043545 rs415890 chr6 167406633 G C 4.57E-04 Multiple complex diseases / / 17554300 rs415890 chr6 167406633 G C 3.00E-12 Crohn's disease / / 21102463 rs400837 chr6 167411008 T C 4.80E-05 Rheumatoid arthritis / / 20453841 rs400837 chr6 167411008 T C 2.26E-05 Graves' disease / / 21841780 rs400837 chr6 167411008 T C 1.40E-05 Hypothyroidism / / 22493691 rs400837 chr6 167411008 T C 1.83E-04 Crohn's disease / / 23266558 rs368397331 chr6 167418111 A C 0.000000164 Graves' disease and Hashimoto's thyroiditis FGFR1OP intron 22922229 rs368397331 chr6 167418111 A C 0.00000033 Graves' disease FGFR1OP intron 22922229 rs12526548 chr6 167431147 C T 1.70E-05 Rheumatoid arthritis FGFR1OP intron 20453841 rs12526548 chr6 167431147 C T 5.98E-07 Graves' disease FGFR1OP intron 21841780 rs7749278 chr6 167435325 T C 9.18E-04 Multiple complex diseases FGFR1OP intron 17554300 rs7749278 chr6 167435325 T C 5.80E-10 Crohn's disease FGFR1OP intron 18587394 rs2301436 chr6 167437988 C T 1.00E-12 Crohn's disease FGFR1OP intron 18587394 rs2301436 chr6 167437988 C T 3.60E-06 Rheumatoid arthritis FGFR1OP intron 20453841 rs2301436 chr6 167437988 C T 6.00E-08 Crohn's disease FGFR1OP intron 20570966 rs2301436 chr6 167437988 C T 1.00E-12 Asthma FGFR1OP intron 21150878 rs2301436 chr6 167437988 C T 1.37E-07 Graves' disease FGFR1OP intron 21841780 rs2301436 chr6 167437988 C T 1.04E-12 Multiple sclerosis FGFR1OP intron 22190364 rs2301436 chr6 167437988 C T 5.30E-04 Hypothyroidism FGFR1OP intron 22493691 rs2282859 chr6 167445139 T C 1.17E-11 Multiple complex diseases FGFR1OP intron 17554300 rs162295 chr6 167454097 A C 2.60E-06 Rheumatoid arthritis / / 20453841 rs162295 chr6 167454097 A C 1.13E-06 Graves' disease / / 21841780 rs162297 chr6 167455139 A G 3.75E-05 Graves' disease / / 21841780 rs12529876 chr6 167461501 G A 1.90E-06 Rheumatoid arthritis / / 20453841 rs12529876 chr6 167461501 G A 1.04E-06 Graves' disease / / 21841780 rs10484530 chr6 167461562 C T 4.30E-06 Rheumatoid arthritis / / 20453841 rs10484530 chr6 167461562 C T 1.26E-04 Graves' disease / / 21841780 rs10484530 chr6 167461562 C T 8.35E-04 Crohn's disease / / 23266558 rs9457262 chr6 167473685 A C,G,T 4.40E-06 Rheumatoid arthritis / / 20453841 rs6921588 chr6 167494397 C A 6.50E-06 Rheumatoid arthritis / / 20453841 rs6921588 chr6 167494397 C A 3.58E-04 Rheumatoid arthritis / / 21452313 rs6921588 chr6 167494397 C A 1.38E-06 Graves' disease / / 21841780 rs204295 chr6 167500562 C T 6.80E-06 Rheumatoid arthritis / / 20453841 rs204295 chr6 167500562 C T 3.54E-04 Rheumatoid arthritis / / 21452313 rs204295 chr6 167500562 C T 7.79E-07 Graves' disease / / 21841780 rs1331301 chr6 167502638 A C 4.61E-06 Graves' disease / / 21841780 rs6902119 chr6 167505791 T C 1.40E-06 Rheumatoid arthritis / / 20453841 rs6902119 chr6 167505791 T C 9.09E-08 Vitiligo / / 20526339 rs6902119 chr6 167505791 T C 5.72E-05 Vitiligo / / 21326295 rs6902119 chr6 167505791 T C 1.33E-05 Graves' disease / / 21841780 rs6902119 chr6 167505791 T C 3.81E-08 Vitiligo / / 22561518 rs150113 chr6 167509833 C T 3.75E-04 Multiple complex diseases / / 17554300 rs150110 chr6 167511766 G A 3.70E-07 Rheumatoid arthritis / / 20453841 rs150110 chr6 167511766 G A 8.28E-05 Graves' disease / / 21841780 rs4710181 chr6 167513998 T C 2.30E-07 Rheumatoid arthritis / / 20453841 rs10946213 chr6 167516095 C T 6.60E-10 Rheumatoid arthritis / / 20453841 rs10946213 chr6 167516095 C T 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10946213 chr6 167516095 C T 3.90E-05 Rheumatoid arthritis / / 21673997 rs9457273 chr6 167520749 A T 7.92E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs9457273 chr6 167520749 A T 7.92E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs9457274 chr6 167520865 G T 3.21E-04 Multiple complex diseases / / 17554300 rs6456156 chr6 167522300 T C 7.40E-09 Rheumatoid arthritis / / 20453841 rs4710185 chr6 167522386 G A 6.30E-07 Rheumatoid arthritis / / 20453841 rs1556413 chr6 167524743 G A 6.90E-08 Rheumatoid arthritis / / 20453841 rs2023305 chr6 167524898 C T 3.40E-08 Rheumatoid arthritis / / 20453841 rs1015077 chr6 167526506 A G 9.19E-04 Type 2 diabetes CCR6 intron 17463246 rs3093024 chr6 167532793 A G 8.00E-19 Rheumatoid arthritis CCR6 intron 20453841 rs3093024 chr6 167532793 A G 9.43E-05 Non-alcoholic fatty liver disease histology (other) CCR6 intron 20708005 rs3093024 chr6 167532793 A G 8.60E-07 Rheumatoid arthritis CCR6 intron 24782177 rs1854853 chr6 167533062 A G 2.00E-10 Rheumatoid arthritis CCR6 intron 24782177 rs1854853 chr6 167533062 A G 7.00E-15 Rheumatoid arthritis CCR6 intron 24782177 rs3093023 chr6 167534290 G A 2.00E-11 Rheumatoid arthritis CCR6 intron 20453842 rs3093023 chr6 167534290 G A 1.50E-11 Celiac disease and Rheumatoid arthritis CCR6 intron 21383967 rs3093023 chr6 167534290 G A 1.50E-11 Multiple sclerosis CCR6 intron 22190364 rs3093023 chr6 167534290 G A 5.70E-07 Rheumatoid arthritis CCR6 intron 22446963 rs3093023 chr6 167534290 G A 4.00E-09 Rheumatoid arthritis CCR6 intron 24782177 rs1855025 chr6 167537594 A G 3.40E-08 Rheumatoid arthritis CCR6 intron 20453841 rs59466457 chr6 167537754 A G 2.70E-10 Rheumatoid arthritis CCR6 intron 23143596 rs59466457 chr6 167537754 A G 2.74E-10 Rheumatoid arthritis (CCP positive) CCR6 intron 23143596 rs1571878 chr6 167540842 C T 1.23E-12 Rheumatoid arthritis (CCP positive) CCR6 intron 23143596 rs1571878 chr6 167540842 C T 2.29E-08 Rheumatoid arthritis CCR6 intron 23143596 rs1571878 chr6 167540842 C T 1.00E-22 Rheumatoid arthritis CCR6 intron 24390342 rs1571878 chr6 167540842 C T 2.00E-18 Rheumatoid arthritis CCR6 intron 24390342 rs1571878 chr6 167540842 C T 5.00E-35 Rheumatoid arthritis CCR6 intron 24390342 rs62436827 chr6 167548547 A G 6.88E-06 Triglycerides CCR6 intron 24886709 rs3093002 chr6 167554060 A G 7.15E-05 Hemoglobin / / pha003096 rs4710188 chr6 167555155 G A 5.74E-05 Hemoglobin / / pha003096 rs4710188 chr6 167555155 G A 9.09E-05 Hematocrit / / pha003097 rs6935031 chr6 167556667 T C 6.31E-05 Hemoglobin / / pha003096 rs6935031 chr6 167556667 T C 6.79E-05 Hematocrit / / pha003097 rs11575088 chr6 167557034 C A 3.00E-06 Social autistic-like traits / / 24133439 rs11575089 chr6 167557199 G A 3.41E-06 Social autistic-like traits / / 24133439 rs9355616 chr6 167557522 C T 4.35E-05 Hemoglobin / / pha003096 rs9355616 chr6 167557522 C T 4.00E-05 Hematocrit / / pha003097 rs9348236 chr6 167625119 T C 8.51E-05 Hypertension / / pha003041 rs9348236 chr6 167625119 T C 7.81E-05 Triglycerides / / pha003081 rs914331 chr6 167634544 A G 8.71E-05 Prion diseases / / 22210626 rs6927070 chr6 167647872 C T 7.07E-05 Hematocrit / / pha003097 rs6927070 chr6 167647872 C T 9.19E-05 Erythrocyte counts / / pha003101 rs2092090 chr6 167685635 C G 1.00E-05 Urinary metabolites / / 21572414 rs2092091 chr6 167685688 A G 1.00E-05 Urinary metabolites / / 21572414 rs13191136 chr6 167686340 G A 7.80E-06 Urinary metabolites / / 21572414 rs206975 chr6 167690356 A G 1.23E-04 Multiple complex diseases / / 17554300 rs2981956 chr6 167699704 C T 1.20E-05 Urinary metabolites / / 21572414 rs2072765 chr6 167717659 C T 2.03E-04 Response to cytadine analogues (cytosine arabinoside) UNC93A intron 24483146 rs34740867 chr6 167754401 A G 0.0000044 Prostate cancer (advanced) TTLL2 missense 23555315 rs909545 chr6 167754661 A G 7.80E-04 Acute lung injury TTLL2 missense 22295056 rs12528714 chr6 167754975 G T 8.00E-06 IgG glycosylation TTLL2 missense 23382691 rs2981988 chr6 167770736 T C 5.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2981988 chr6 167770736 T C 1.38E-05 Height / / pha003011 rs12213619 chr6 167778498 T G 7.88E-05 Osteoarthritis / / 19508968 rs11759295 chr6 167811750 G A 1.30E-06 Urinary metabolites / / 21572414 rs11753236 chr6 167812895 C T 6.00E-06 Urinary metabolites / / 21572414 rs4709177 chr6 167813062 T G 5.46E-04 Tourette syndrome / / 22889924 rs4601099 chr6 167813955 T C 1.43E-05 HIV-1 viral setpoint / / 21490045 rs4708777 chr6 167814784 A G 2.57E-05 Coronary heart disease / / pha003031 rs9457333 chr6 167818639 G T 1.80E-05 Urinary metabolites / / 21572414 rs4709182 chr6 167818861 G A 1.80E-05 Urinary metabolites / / 21572414 rs4075645 chr6 167825871 C T 6.37E-04 Type 2 diabetes / / 17463246 rs4075645 chr6 167825871 C T 0.0000405 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12197382 chr6 167826180 A C 6.27E-04 Type 2 diabetes / / 17463246 rs10945538 chr6 167830327 C T 3.10E-06 Urinary metabolites / / 21572414 rs4129277 chr6 167832036 A C 7.71E-05 Cholesterol / / pha003083 rs13216342 chr6 167833557 G A 9.16E-05 Cholesterol / / pha003083 rs4546466 chr6 167838993 T C 3.63E-05 Biliary atresia / / 20460270 rs6919615 chr6 168061056 C T 1.53E-04 Type 2 diabetes / / 17463246 rs6919615 chr6 168061056 C T 4.57E-04 Multiple complex diseases / / 17554300 rs6919615 chr6 168061056 C T 9.65E-04 Coronary Artery Disease / / 17634449 rs963522 chr6 168270238 G A 1.31E-04 Multiple complex diseases MLLT4 intron 17554300 rs2285240 chr6 168293920 G A 4.54E-04 Multiple complex diseases MLLT4 intron 17554300 rs10945454 chr6 168304320 C T 4.18E-04 Multiple complex diseases MLLT4 intron 17554300 rs7770588 chr6 168305276 A G 1.10E-04 Response to taxane treatment (placlitaxel) MLLT4 intron 23006423 rs6906754 chr6 168317816 A C 2.06E-07 Fibrinogen MLLT4 cds-synon pha003068 rs3778661 chr6 168328663 T C 2.14E-04 Hearing function MLLT4 intron 17255346 rs3823455 chr6 168329404 A G 1.06E-05 Fibrinogen MLLT4 intron pha003068 rs9346631 chr6 168330834 G T 1.21E-04 Multiple complex diseases MLLT4 intron 17554300 rs7772997 chr6 168337882 G C 3.54E-04 Response to taxane treatment (placlitaxel) MLLT4 intron 23006423 rs2076663 chr6 168375191 C T 8.88E-04 Alcohol dependence / / 21314694 rs6918659 chr6 168382157 G A 1.66E-05 Diabetes Mellitus / / pha003060 rs2843012 chr6 168388928 G A 6.00E-06 Metabolite levels (5-HIAA) / / 23319000 rs7764535 chr6 168389125 G A 9.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs7741791 chr6 168389324 C A 5.97E-05 Diabetes Mellitus / / pha003059 rs13197181 chr6 168389723 G A 9.27E-05 Diabetes Mellitus / / pha003060 rs13218329 chr6 168389848 A G 2.60E-05 Urinary metabolites / / 21572414 rs9364386 chr6 168432093 T G 6.76E-04 Type 2 diabetes KIF25 intron 17463246 rs225762 chr6 168450159 A G 7.06E-05 Body Fat Distribution / / pha003017 rs3734901 chr6 168463153 G A 8.57E-05 Orofacial clefts FRMD1 intron 22419666 rs4708431 chr6 168484085 A G 7.00E-06 Attention deficit hyperactivity disorder (combined symptoms) / / 23527680 rs4708431 chr6 168484085 A G 3.73E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9364220 chr6 168490568 G A 6.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs9364220 chr6 168490568 G A 7.00E-06 Attention deficit hyperactivity disorder (combined symptoms) / / 23527680 rs6913441 chr6 168491271 C T 3.14E-05 HDL particle features / / pha002900 rs9455954 chr6 168509485 G A 2.45E-04 Cholesterol / / 17255346 rs1473500 chr6 168511016 C T 3.00E-07 Immune reponse to smallpox (secreted IL-2) / / 22610502 rs4708650 chr6 168514084 T G 7.10E-06 Urinary metabolites / / 21572414 rs2171981 chr6 168526240 T C 3.32E-06 HDL particle features / / pha002900 rs13197982 chr6 168532450 G T 0.00064971 Hypertension (early onset hypertension) / / 22479346 rs4708443 chr6 168565614 G C 7.88E-04 Parkinson's disease / / 16252231 rs4708445 chr6 168580694 A C 8.43E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9455973 chr6 168583006 G A 4.50E-05 Alzheimer's disease (late onset) / / 20885792 rs9455973 chr6 168583006 G A 4.50E-05 Alzheimer's disease (late onset) / / 21460841 rs9455595 chr6 168597347 C T 6.80E-05 Bipolar disorder / / 20451256 rs9295055 chr6 168628680 G A 2.03E-05 Telomere length / / 23001564 rs9346682 chr6 168685533 A G 4.14E-04 Major depressive disorder / / 22472876 rs12204529 chr6 168698932 C G 3.41E-04 Depression (quantitative trait) / / 20800221 rs3800537 chr6 168700040 A G 1.92E-04 Depression (quantitative trait) / / 20800221 rs12202943 chr6 168700846 G A 3.57E-04 Depression (quantitative trait) / / 20800221 rs11757729 chr6 168704707 G C 5.15E-04 Depression (quantitative trait) / / 20800221 rs4708455 chr6 168714950 G A 2.16E-04 Insulin resistance DACT2 intron 21901158 rs6915443 chr6 168757111 C T 3.00E-06 Sexual dimorphism in anthropometric traits / / 23754948 rs12664175 chr6 168766708 C T 2.21E-05 Pulmonary function / / 20010835 rs1886399 chr6 168774529 T C 5.06E-04 Depression (quantitative trait) / / 20800221 rs4708462 chr6 168784850 T G 4.67E-04 Type 2 diabetes / / 17463246 rs4708462 chr6 168784850 T G 6.69E-04 Depression (quantitative trait) / / 20800221 rs4285297 chr6 168786135 T C 5.06E-04 Depression (quantitative trait) / / 20800221 rs3887828 chr6 168788974 C T 4.80E-06 Urinary metabolites / / 21572414 rs4524581 chr6 168791432 T G 7.70E-06 Urinary metabolites / / 21572414 rs7762561 chr6 168796995 G A 9.40E-06 Urinary metabolites / / 21572414 rs4708734 chr6 168797108 C T 7.70E-06 Urinary metabolites / / 21572414 rs6455518 chr6 168797557 G A 9.40E-06 Urinary metabolites / / 21572414 rs6455519 chr6 168797649 G A 8.80E-06 Urinary metabolites / / 21572414 rs4235919 chr6 168799824 A G 7.70E-06 Urinary metabolites / / 21572414 rs4626402 chr6 168800003 C T 7.90E-06 Urinary metabolites / / 21572414 rs4708737 chr6 168800537 G A 1.20E-05 Urinary metabolites / / 21572414 rs2609299 chr6 168808760 G A 0.0000163 HDL cholesterol particle diameter / / 23263444 rs9364458 chr6 168879958 T C 2.10E-05 Urinary metabolites SMOC2 intron 21572414 rs2609326 chr6 168898415 T C 2.92E-05 Monocyte counts SMOC2 intron pha003089 rs12525412 chr6 168898646 G A 3.91E-08 Multiple complex diseases SMOC2 intron 17554300 rs747994 chr6 168930758 C A 5.49E-04 Type 2 diabetes SMOC2 intron 17463246 rs13208776 chr6 168941624 G A 9.00E-08 Vitiligo SMOC2 intron 19890347 rs2180346 chr6 168944598 T C 5.65E-05 Coronary heart disease SMOC2 intron pha003032 rs4708757 chr6 168997347 C A 7.60E-04 Suicide attempts in bipolar disorder SMOC2 intron 21423239 rs16887198 chr6 169009635 T C 7.73E-04 Depression (quantitative trait) SMOC2 intron 20800221 rs13206739 chr6 169009688 C G 5.68E-04 Depression (quantitative trait) SMOC2 intron 20800221 rs6455538 chr6 169009874 A G 7.06E-04 Depression (quantitative trait) SMOC2 intron 20800221 rs16886236 chr6 169023879 G A 3.92E-04 Smoking cessation SMOC2 intron 24665060 rs4708483 chr6 169047901 T C 2.99E-04 Myocardial Infarction SMOC2 intron pha002873 rs1885633 chr6 169049871 G A 2.96E-06 Cognitive test performance SMOC2 intron 20125193 rs911942 chr6 169050237 T G 5.61E-06 Cognitive test performance SMOC2 intron 20125193 rs11751354 chr6 169052936 C T 7.16E-05 Major depressive disorder SMOC2 intron 21621269 rs2298292 chr6 169056267 G T 2.04E-05 Coronary restenosis SMOC2 intron 21878436 rs196455 chr6 169074455 C A 1.12E-05 Multiple complex diseases / / 17554300 rs12525551 chr6 169074585 G A 2.79E-05 Multiple complex diseases / / 17554300 rs12525551 chr6 169074585 G A 2.04E-05 Coronary restenosis / / 21878436 rs646277 chr6 169082211 T C 3.97E-26 Narcolepsy / / 19629137 rs677107 chr6 169084422 T G 5.37E-06 Coronary restenosis / / 21878436 rs607339 chr6 169085271 T A 1.12E-05 Multiple complex diseases / / 17554300 rs598132 chr6 169086223 C T 1.21E-05 Multiple complex diseases / / 17554300 rs9346563 chr6 169086561 G A 1.14E-05 Cognitive test performance / / 20125193 rs611525 chr6 169086978 A G 4.20E-05 Multiple complex diseases / / 17554300 rs613728 chr6 169087459 A G 6.58E-04 Multiple complex diseases / / 17554300 rs654940 chr6 169089741 C T 8.50E-06 Multiple complex diseases / / 17554300 rs627732 chr6 169106505 T C 3.06E-05 Multiple complex diseases / / 17554300 rs627782 chr6 169106548 A G 5.25E-05 Multiple complex diseases / / 17554300 rs641512 chr6 169107315 C T 5.22E-04 Multiple complex diseases / / 17554300 rs632737 chr6 169108233 A T 5.41E-05 Multiple complex diseases / / 17554300 rs661438 chr6 169110089 C T 1.56E-05 Multiple complex diseases / / 17554300 rs582637 chr6 169110582 G A 1.29E-04 Multiple complex diseases / / 17554300 rs196458 chr6 169117380 T G 1.44E-16 Narcolepsy / / 19629137 rs196469 chr6 169123297 T C 5.51E-05 Multiple complex diseases / / 17554300 rs196479 chr6 169127361 A G 1.51E-04 Multiple complex diseases / / 17554300 rs196501 chr6 169139351 A G 5.88E-05 Multiple complex diseases / / 17554300 rs196512 chr6 169145000 T C 5.15E-05 Multiple complex diseases / / 17554300 rs196515 chr6 169146541 C T 1.94E-04 Multiple complex diseases / / 17554300 rs9355010 chr6 169190139 C T 7.93E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9364299 chr6 169202852 G A 9.96E-05 Pulmonary function in asthmatics / / 23541324 rs12202782 chr6 169216296 A G 9.71E-05 Epilepsy (remission after treatment) / / 23962720 rs59840015 chr6 169219273 T A 9.99E-05 Epilepsy (remission after treatment) / / 23962720 rs56828463 chr6 169219279 A G 9.99E-05 Epilepsy (remission after treatment) / / 23962720 rs59454871 chr6 169219338 T C 9.97E-05 Epilepsy (remission after treatment) / / 23962720 rs4594925 chr6 169220177 T C 9.71E-05 Epilepsy (remission after treatment) / / 23962720 rs4295454 chr6 169220672 G A 9.69E-05 Epilepsy (remission after treatment) / / 23962720 rs4331960 chr6 169222679 C T 8.54E-05 Epilepsy (remission after treatment) / / 23962720 rs4360107 chr6 169222987 A C 5.98E-05 Epilepsy (remission after treatment) / / 23962720 rs4492172 chr6 169223898 C T 9.30E-05 Epilepsy (remission after treatment) / / 23962720 rs6933570 chr6 169224036 A G 9.30E-05 Epilepsy (remission after treatment) / / 23962720 rs6933599 chr6 169224091 A G 9.30E-05 Epilepsy (remission after treatment) / / 23962720 rs6911802 chr6 169224238 C T 9.31E-05 Epilepsy (remission after treatment) / / 23962720 rs6938879 chr6 169224378 T G 9.32E-05 Epilepsy (remission after treatment) / / 23962720 rs6934356 chr6 169224437 A G 9.32E-05 Epilepsy (remission after treatment) / / 23962720 rs6934393 chr6 169224496 A G 9.32E-05 Epilepsy (remission after treatment) / / 23962720 rs11751864 chr6 169244426 C G 9.49E-04 Type 2 diabetes / / 17463246 rs9455487 chr6 169248186 G A 7.63E-04 Type 2 diabetes / / 17463246 rs4296872 chr6 169249819 A G 1.50E-05 Insulin resistance / / 21901158 rs9455734 chr6 169252480 G A 7.67E-04 Multiple complex diseases / / 17554300 rs9364312 chr6 169254572 C T 8.54E-04 Type 2 diabetes / / 17463246 rs13191839 chr6 169270879 C T 4.62E-05 Orofacial clefts / / 22419666 rs6928867 chr6 169290332 C G 2.30E-07 Urinary metabolites / / 21572414 rs6455443 chr6 169290484 A G 6.78E-04 Type 2 diabetes / / 17463246 rs6927888 chr6 169290551 G A 8.39E-04 Type 2 diabetes / / 17463246 rs9455501 chr6 169299914 C T 1.90E-05 Urinary metabolites / / 21572414 rs10945320 chr6 169301357 T C 1.40E-06 Urinary metabolites / / 21572414 rs10945327 chr6 169303520 A G 7.80E-06 Urinary metabolites / / 21572414 rs4708537 chr6 169304359 G A 1.20E-05 Urinary metabolites / / 21572414 rs4235908 chr6 169316292 C A 1.50E-05 Urinary metabolites / / 21572414 rs6933614 chr6 169328643 G A 1.40E-05 Urinary metabolites / / 21572414 rs9364336 chr6 169372888 T C 7.66E-04 Smoking quantity / / 24665060 rs9346497 chr6 169388444 G A 8.55E-04 Alzheimer's disease / / 17998437 rs7770399 chr6 169409603 C T 9.94E-04 Multiple complex diseases / / 17554300 rs369417 chr6 169434121 C T 4.50E-05 Fibrinogen / / pha003068 rs416598 chr6 169436715 A C 7.90E-06 Urinary metabolites / / 21572414 rs7765333 chr6 169440856 T C 7.10E-05 Parkinson's disease / / 21248740 rs7741751 chr6 169440940 C T 2.25E-05 Asthma / / 11022011 rs17182988 chr6 169444202 G A 3.64E-04 Smoking quantity / / 24665060 rs432401 chr6 169448440 A C 4.37E-06 Eosinophil counts / / pha003088 rs17787659 chr6 169449213 C T 5.35E-05 Cervical cancer / / 24700089 rs10945364 chr6 169451803 C T 2.56E-04 Lung function (forced vital capacity) / / 24023788 rs9294948 chr6 169459130 A G 4.30E-07 Urinary metabolites / / 21572414 rs9689200 chr6 169463101 A G 9.98E-04 Disc degeneration (lumbar) / / 24216480 rs2057405 chr6 169463977 A G 1.80E-05 Urinary metabolites / / 21572414 rs2057405 chr6 169463977 A G 4.63E-04 Alzheimer's disease / / 22005930 rs9294949 chr6 169467285 G A 4.45E-04 Alzheimer's disease / / 22005930 rs9346610 chr6 169467561 G A 1.50E-04 Alzheimer's disease / / 22005930 rs41514848 chr6 169473251 A G 7.07E-05 Multiple complex diseases / / 17554300 rs633668 chr6 169473816 A G 1.54E-05 Hypertension / / 21082022 rs10485332 chr6 169474687 C T 2.38E-05 Heart Rate / / pha003051 rs10485332 chr6 169474687 C T 6.64E-06 Heart Rate / / pha003054 rs17788472 chr6 169482877 C T 2.10E-05 Urinary metabolites / / 21572414 rs12175557 chr6 169492699 G A 9.94E-06 Birth weight / / 17255346 rs12183440 chr6 169497693 T C 2.20E-05 Urinary metabolites / / 21572414 rs9767705 chr6 169503712 T G 3.70E-06 Urinary metabolites / / 21572414 rs6915990 chr6 169508876 T C 5.50E-07 Urinary metabolites / / 21572414 rs2224645 chr6 169509800 G A 4.30E-06 Urinary metabolites / / 21572414 rs2343365 chr6 169513187 T G 2.95E-05 Serum metabolites / / 19043545 rs17789278 chr6 169542663 G A 1.30E-06 Urinary metabolites / / 21572414 rs9505911 chr6 169543677 A G 1.00E-06 Urinary metabolites / / 21572414 rs9294963 chr6 169554727 T C 9.00E-06 Urinary metabolites / / 21572414 rs9294965 chr6 169559506 G A 2.20E-04 Celiac disease / / 23936387 rs9455882 chr6 169560597 T C 0.0000025 Circulating PCSK9 levels / / 22460556 rs1123753 chr6 169560839 A C 1.09E-04 Progressive supranuclear palsy / / 21685912 rs6910183 chr6 169565035 C A 1.87E-04 HIV-1 viral setpoint / / 17641165 rs6937001 chr6 169565086 T C 6.00E-04 Volumetric brain MRI / / 17903297 rs1555523 chr6 169589925 G A 2.74E-04 HIV-1 viral setpoint / / 17641165 rs9393162 chr6 169594553 T C 0.0000274 Circulating PCSK9 levels / / 22460556 rs12181211 chr6 169598871 A G 1.82E-05 Erythrocyte counts / / pha003101 rs9505932 chr6 169606389 C A 4.43E-05 Circulating vasoactive peptide levels / / 23381795 rs9505933 chr6 169606443 T C 6.25E-04 HIV-1 viral setpoint / / 17641165 rs10806665 chr6 169607093 C A 2.66E-06 Multiple complex diseases / / 17554300 rs12665286 chr6 169609256 A G 1.88E-05 HIV-1 viral setpoint / / 17641165 rs9379336 chr6 169639901 C T 1.20E-05 Urinary metabolites THBS2 intron 21572414 rs9505896 chr6 169646920 A G 3.26E-05 Serum albumin level THBS2 intron pha003084 rs11756439 chr6 169648030 T C 8.79E-05 Parent of origin effect on language impairment (maternal) THBS2 intron 24571439 rs6605523 chr6 169656248 A G 7.00E-04 Primary nonsyndromic vesicoureteric reflex / / 19959718 rs7452888 chr6 169696264 A G 4.00E-06 Lung cancer / / 18978790 rs7452888 chr6 169696264 A G 4.17E-05 Stroke (ischemic) / / 22941190 rs9505900 chr6 169706687 C T 2.00E-05 Lung cancer / / 18978790 rs9505900 chr6 169706687 C T 2.36E-05 Stroke (ischemic) / / 22941190 rs9505900 chr6 169706687 C T 4.93E-05 Blood Pressure / / pha003040 rs9406333 chr6 169718094 T G 6.13E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12190007 chr6 169727601 G A 5.00E-06 Obesity-related traits / / 23251661 rs9393169 chr6 169739798 C T 1.20E-05 Urinary metabolites / / 21572414 rs11970621 chr6 169744597 C T 6.39E-05 Cognitive impairment induced by topiramate / / 22091778 rs7749332 chr6 169746168 A C 6.39E-05 Cognitive impairment induced by topiramate / / 22091778 rs16887939 chr6 169765845 G T 4.82E-04 Response to alcohol consumption (flushing response) / / 24277619 rs9283855 chr6 169778429 C T 1.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs368028 chr6 169811294 C T 9.11E-04 Alcohol dependence / / 21314694 rs438465 chr6 169820381 T C 7.00E-06 Corneal astigmatism / / 23761726 rs16888021 chr6 169830754 C G 7.91E-04 Multiple complex diseases / / 17554300 rs4716360 chr6 169898317 A G 3.53E-04 Response to alcohol consumption (flushing response) WDR27 intron 24277619 rs2997887 chr6 169912559 A G 3.80E-06 Crohn's disease WDR27 intron 20570966 rs16888111 chr6 169935826 G A 5.75E-06 Asthma (childhood onset) WDR27 intron 23829686 rs2206325 chr6 169936955 G A 3.53E-04 Response to alcohol consumption (flushing response) WDR27 intron 24277619 rs3734905 chr6 169958982 G A 2.00E-06 HIV-1 control WDR27 intron 20041166 rs7740799 chr6 169988672 T G 1.86E-05 Asthma WDR27 intron 23181788 rs9295020 chr6 170043646 A G 2.61E-04 Cognitive decline WDR27 intron 23732972 rs4145868 chr6 170049421 T G 9.09E-05 Multiple complex diseases WDR27 intron 17554300 rs9396992 chr6 170061501 A G 5.10E-06 Urinary metabolites WDR27 intron 21572414 rs4236176 chr6 170070723 A G 7.99E-04 Multiple complex diseases WDR27 missense 17554300 rs9371122 chr6 170087042 T G 5.34E-04 Suicide attempts in bipolar disorder WDR27 intron 21423239 rs7750758 chr6 170091709 A G 5.32E-04 Suicide attempts in bipolar disorder WDR27 intron 21423239 rs3088034 chr6 170108417 C G 2.89E-04 Suicide attempts in bipolar disorder PHF10 intron 21423239 rs3211062 chr6 170108799 C T 9.91E-05 Multiple complex diseases PHF10 intron 17554300 rs7740499 chr6 170111601 G A 4.76E-04 Suicide attempts in bipolar disorder PHF10 intron 21423239 rs4626430 chr6 170111985 G C 7.02E-04 Multiple complex diseases PHF10 intron 17554300 rs7762018 chr6 170113244 C A 8.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients PHF10 intron 23400010 rs9478098 chr6 170122703 G C 3.87E-04 Suicide attempts in bipolar disorder PHF10 intron 21423239 rs9478098 chr6 170122703 G C 7.40E-06 Urinary metabolites PHF10 intron 21572414 rs6923339 chr6 170128033 T A 7.71E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs9478099 chr6 170130247 G C 4.54E-04 Multiple complex diseases / / 17554300 rs9478099 chr6 170130247 G C 8.08E-04 Alcohol dependence / / 21314694 rs6941766 chr6 170131653 A G 8.25E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs6904601 chr6 170131905 T G 8.27E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs9295023 chr6 170137054 C T 7.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs4716342 chr6 170137959 A G 8.32E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs7752261 chr6 170138994 T A 4.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs9383520 chr6 170140184 T C 4.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs6907286 chr6 170152991 G A 4.95E-04 Response to cytadine analogues (cytosine arabinoside) C6orf70 intron 24483146 rs914968 chr6 170163191 G A 4.04E-04 Response to cytadine analogues (cytosine arabinoside) C6orf70 intron 24483146 rs6459664 chr6 170180607 G A 2.00E-05 Urinary metabolites C6orf70 intron 21572414 rs6906751 chr6 170185467 A G 3.56E-04 Multiple complex diseases / / 17554300 rs11969604 chr6 170187851 A G 7.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11969604 chr6 170187851 A G 8.90E-05 Diabetic retinopathy / / 21441570 rs3823466 chr6 170189926 G A 7.90E-04 Multiple complex diseases / / 17554300 rs3807066 chr6 170190020 A T 8.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs1078211 chr6 170201300 T C 7.23E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3749889 chr6 170202171 G A 9.30E-05 Diabetic retinopathy / / 21441570 rs9371131 chr6 170232883 C G 2.82E-04 Type 2 diabetes / / 17463246 rs9383481 chr6 170241972 C G 6.40E-04 Type 2 diabetes / / 17463246 rs9396958 chr6 170242949 T C 5.93E-04 Type 2 diabetes / / 17463246 rs742813 chr6 170246395 A G 2.79E-04 Type 2 diabetes / / 17463246 rs4716412 chr6 170255046 C T 6.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16888481 chr6 170257845 T A 4.92E-07 Multiple complex diseases / / 17554300 rs2172905 chr6 170334502 C T 4.57E-07 Pancreatic cancer / / 22158540 rs1466749 chr6 170347127 G A 7.57E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs6917521 chr6 170350612 T C 8.58E-05 Alzheimer's disease / / 17998437 rs10946255 chr6 170356783 A G,T 4.14E-05 Serum metabolites / / 19043545 rs10946255 chr6 170356783 A G,T 7.30E-05 HIV-1 control / / 20041166 rs11753156 chr6 170365244 C T 1.93E-04 Depression (quantitative trait) / / 20800221 rs9460193 chr6 170374026 C T 2.64E-04 Depression (quantitative trait) / / 20800221 rs924043 chr6 170379025 T C 8.00E-09 Type 1 diabetes / / 21980299 rs9348346 chr6 170385304 A T 2.97E-04 Depression (quantitative trait) / / 20800221 rs10946292 chr6 170425521 A G 3.00E-06 Obesity-related traits / / 23251661 rs4710758 chr6 170455060 C T 9.77E-06 Information processing speed / / 21130836 rs13193455 chr6 170512479 G A 0.0000295 Antithrombin / / 23705025 rs9348260 chr6 170516123 G A 7.11E-04 Alcohol dependence / / 20201924 rs9366181 chr6 170526065 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2144667 chr6 170560679 T C 9.81E-05 Tourette syndrome / / 22889924 rs3012437 chr6 170572741 T C 8.82E-04 HIV-1 viral setpoint / / 17641165 rs7756780 chr6 170580521 T C 8.37E-04 Taste perception / / 22132133 rs1884190 chr6 170596699 C T 4.78E-05 Response to cytadine analogues (cytosine arabinoside) DLL1 intron 24483146 rs714869 chr6 170619840 A G 1.54E-05 Multiple complex diseases FAM120B intron 17554300 rs9348268 chr6 170636552 C T 2.22E-05 Multiple complex diseases FAM120B intron 17554300 rs9460121 chr6 170656242 T C 2.27E-04 Alzheimer's disease (late onset) FAM120B intron 21379329 rs9295396 chr6 170657593 C G 2.04E-05 Multiple complex diseases FAM120B intron 17554300 rs9348271 chr6 170669440 A G 3.83E-04 Multiple complex diseases FAM120B intron 17554300 rs2881062 chr6 170671587 A G 2.34E-04 Alzheimer's disease (late onset) FAM120B intron 21379329 rs9366215 chr6 170674366 T C 3.32E-04 Multiple complex diseases FAM120B intron 17554300 rs2103816 chr6 170676013 T A 1.10E-05 Urinary metabolites FAM120B intron 21572414 rs9366216 chr6 170676326 C A 1.49E-05 Multiple complex diseases FAM120B intron 17554300 rs6456202 chr6 170678494 G C 1.10E-05 Urinary metabolites FAM120B intron 21572414 rs760500 chr6 170725387 T C 9.26E-05 Multiple complex diseases / / 17554300 rs2294184 chr6 170735267 C G 5.76E-04 Multiple complex diseases / / 17554300 rs6456213 chr6 170735372 A C 9.90E-05 Lymphocyte counts / / 22286170 rs6456218 chr6 170756443 T C 2.30E-06 Lipid levels / / 18193043 rs12193425 chr6 170772252 G A 4.33E-04 Coronary heart disease / / 21606135 rs9460199 chr6 170787693 C G 1.30E-29 Health and aging,CVD and cancer age of onset / / 22174011 rs9460199 chr6 170787693 C G 2.70E-15 Health and aging,CVD and cancer age of onset / / 22174011 rs9460199 chr6 170787693 C G 5.10E-47 Health and aging,CVD and cancer age of onset / / 22174011 rs2345144 chr6 170814691 C T 2.59E-04 Lymphocyte counts / / 22286170 rs9356660 chr6 170822057 A G 9.40E-05 Multiple complex diseases / / 17554300 rs13207114 chr6 170877444 A G 7.03E-04 Multiple complex diseases TBP intron 17554300 rs7384563 chr7 45653 C T 7.90E-06 Cognitive test performance / / 20125193 rs6964622 chr7 63494 A G 9.11E-04 Multiple complex diseases / / 17554300 rs12718078 chr7 95673 C T 6.05E-05 Cognitive test performance / / 20125193 rs12718096 chr7 109624 A G 6.26E-04 Multiple complex diseases / / 17554300 rs12718098 chr7 113319 A G 5.54E-05 Cognitive test performance / / 20125193 rs12672125 chr7 116054 T C 8.31E-04 Cocaine dependence / / 23958962 rs12672125 chr7 116054 T C 9.85E-06 Cocaine dependence / / 23958962 rs3923903 chr7 123956 T C 2.90E-05 Electrocardiographic conduction measures / / 19389651 rs6972063 chr7 189720 C T 2.92E-04 Multiple complex diseases / / 17554300 rs7799786 chr7 198440 G A 8.11E-04 Multiple complex diseases FAM20C intron 17554300 rs9719226 chr7 670161 T G 7.10E-05 HIV-1 control PRKAR1B intron 20041166 rs10272685 chr7 677650 G T 1.20E-05 HIV-1 control PRKAR1B intron 20041166 rs7795258 chr7 795227 A G 3.34E-04 Fibrinogen HEATR2 intron 17255346 rs4357190 chr7 837407 C T 2.79E-04 Multiple complex diseases / / 17554300 rs6973278 chr7 866469 G C 6.05E-04 Type 2 diabetes SUN1 intron 17463246 rs6973278 chr7 866469 G C 6.90E-04 Multiple complex diseases SUN1 intron 17554300 rs4719500 chr7 871456 T G 4.96E-04 Type 2 diabetes SUN1 intron 17463246 rs4719500 chr7 871456 T G 9.15E-04 Multiple complex diseases SUN1 intron 17554300 rs1127460 chr7 878767 T C 4.96E-04 Type 2 diabetes SUN1 intron 17463246 rs1127460 chr7 878767 T C 8.37E-04 Multiple complex diseases SUN1 intron 17554300 rs1127460 chr7 878767 T C 5.86E-05 Lymphocyte counts SUN1 intron 22286170 rs6461378 chr7 881668 C T 1.00E-04 Cognitive impairment induced by topiramate SUN1 missense 22091778 rs4416731 chr7 893637 G A 4.35E-04 Type 2 diabetes SUN1 intron 17463246 rs4416731 chr7 893637 G A 5.06E-04 Multiple complex diseases SUN1 intron 17554300 rs7785776 chr7 894830 T C 4.67E-05 Multiple complex diseases SUN1 intron 17554300 rs7778360 chr7 902450 C G 4.82E-04 Type 2 diabetes SUN1 intron 17463246 rs10950832 chr7 906628 A G 3.45E-04 Type 2 diabetes SUN1 intron 17463246 rs1779 chr7 906739 A G 9.00E-04 Amyotrophic Lateral Sclerosis SUN1 intron 17362836 rs4722034 chr7 912755 C T 5.07E-04 Type 2 diabetes SUN1 intron 17463246 rs13242526 chr7 997334 C G 1.40E-08 Metabolite levels / / 23281178 rs10272099 chr7 1016948 T C 8.76E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs12701220 chr7 1022728 T C 3.00E-06 Bronchopulmonary dysplasia CYP2W1 nearGene-5 23897914 rs3817576 chr7 1023191 A G 4.61E-04 Alcohol consumption (maxi-drinks) CYP2W1 intron 24277619 rs10256972 chr7 1039003 A C 1.00E-06 Longevity C7orf50 intron 20834067 rs2030958 chr7 1076010 G T 4.90E-04 Iris characteristics C7orf50 intron 21835309 rs1997243 chr7 1083777 A G 3.00E-10 Cholesterol,total C7orf50 intron 24097068 rs79230706 chr7 1120390 G A 0.00004835 Sarcoidosis C7orf50 intron 22952805 rs76227513 chr7 1120426 G A 0.00004835 Sarcoidosis C7orf50 intron 22952805 rs75515957 chr7 1124986 C T 0.00003179 Sarcoidosis C7orf50 intron 22952805 rs77095258 chr7 1125746 G A 0.00004177 Sarcoidosis C7orf50 intron 22952805 rs78774273 chr7 1128572 G A 0.00004186 Sarcoidosis GPER intron 22952805 rs1133041 chr7 1132691 C T 0.00004192 Sarcoidosis GPER UTR-3 22952805 rs10235056 chr7 1132748 G A 3.00E-09 Health and aging,CVD and cancer age of onset GPER UTR-3 22174011 rs34811797 chr7 1135158 G A 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs78353663 chr7 1135530 G T 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs75137850 chr7 1136537 A G 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs75435391 chr7 1137442 G A 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs79250942 chr7 1137741 G A 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs118149751 chr7 1138347 G A 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs117322927 chr7 1140163 C T 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs80007722 chr7 1140309 C T 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs75683586 chr7 1140446 C T 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs79763120 chr7 1140572 G A 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs78224195 chr7 1141596 A T 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs75902321 chr7 1144501 G A 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs74803934 chr7 1145584 G A 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs79419793 chr7 1145815 C A,T 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs78442641 chr7 1146460 G A 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs75017329 chr7 1149993 C T 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs75183588 chr7 1150264 G A 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs77890691 chr7 1151572 G A 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs12112166 chr7 1153141 T C 9.40E-04 Iris characteristics C7orf50 intron 21835309 rs78227106 chr7 1153273 G A 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs78774472 chr7 1164026 G A 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs150684475 chr7 1165983 G A 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs74924401 chr7 1173104 C T 0.00004192 Sarcoidosis C7orf50 intron 22952805 rs76687420 chr7 1174232 C T 0.00006965 Sarcoidosis C7orf50 intron 22952805 rs76990427 chr7 1177009 T A 0.00006965 Sarcoidosis C7orf50 intron 22952805 rs77188166 chr7 1178364 C T 0.00007307 Sarcoidosis / / 22952805 rs78389908 chr7 1188300 C T 0.00005713 Sarcoidosis / / 22952805 rs79701362 chr7 1189965 A G 0.00005713 Sarcoidosis / / 22952805 rs6959783 chr7 1192018 T C 3.39E-04 Alzheimer's disease (late onset) / / 21379329 rs79891205 chr7 1193948 C G 0.00005713 Sarcoidosis ZFAND2A intron 22952805 rs76926989 chr7 1194333 C A 0.00005713 Sarcoidosis ZFAND2A intron 22952805 rs7781581 chr7 1195264 T C 1.36E-04 Type 2 diabetes ZFAND2A intron 17463246 rs7781581 chr7 1195264 T C 9.27E-06 Personality dimensions ZFAND2A intron 22628180 rs75674288 chr7 1195322 A C 0.00005713 Sarcoidosis ZFAND2A intron 22952805 rs79673567 chr7 1195334 G A 0.0000736 Sarcoidosis ZFAND2A intron 22952805 rs79661915 chr7 1197448 T C 0.00005775 Sarcoidosis ZFAND2A intron 22952805 rs80088127 chr7 1198316 C T 0.00005804 Sarcoidosis ZFAND2A intron 22952805 rs78067177 chr7 1198948 A G 0.00005804 Sarcoidosis ZFAND2A intron 22952805 rs76479268 chr7 1198964 G A 0.00005804 Sarcoidosis ZFAND2A intron 22952805 rs79344921 chr7 1199072 C T 0.00005804 Sarcoidosis ZFAND2A intron 22952805 rs78551298 chr7 1199547 C T 0.00005804 Sarcoidosis ZFAND2A intron 22952805 rs76116355 chr7 1200280 A T 0.00005804 Sarcoidosis / / 22952805 rs74368064 chr7 1200401 T G 0.00005804 Sarcoidosis / / 22952805 rs75448565 chr7 1201802 C G 0.00005804 Sarcoidosis / / 22952805 rs77904558 chr7 1202636 C T 0.00005774 Sarcoidosis / / 22952805 rs77861001 chr7 1202954 T C 0.00005774 Sarcoidosis / / 22952805 rs75810623 chr7 1203264 C T 0.00005774 Sarcoidosis / / 22952805 rs78062500 chr7 1204109 C G 0.00005774 Sarcoidosis / / 22952805 rs77978253 chr7 1204843 G A 0.00005774 Sarcoidosis / / 22952805 rs76243969 chr7 1204942 G A 0.00005774 Sarcoidosis / / 22952805 rs76168200 chr7 1206192 C T 0.00005774 Sarcoidosis / / 22952805 rs149548045 chr7 1207374 G C 0.00005742 Sarcoidosis / / 22952805 rs77953956 chr7 1207644 C T 0.00005742 Sarcoidosis / / 22952805 rs114660783 chr7 1207998 T C 0.00005742 Sarcoidosis / / 22952805 rs79255362 chr7 1208314 C T 0.00005742 Sarcoidosis / / 22952805 rs77550036 chr7 1208417 T G 0.00005742 Sarcoidosis / / 22952805 rs140950470 chr7 1208607 C T 0.00005742 Sarcoidosis / / 22952805 rs76970757 chr7 1209320 C G 0.00005643 Sarcoidosis / / 22952805 rs79937807 chr7 1209908 T C 0.00005373 Sarcoidosis / / 22952805 rs75624851 chr7 1210870 C T 0.00005415 Sarcoidosis / / 22952805 rs79465589 chr7 1211507 G A 0.00005579 Sarcoidosis / / 22952805 rs75032347 chr7 1211663 A C 0.00005415 Sarcoidosis / / 22952805 rs77764295 chr7 1211756 T C 0.00005579 Sarcoidosis / / 22952805 rs78710489 chr7 1211833 C T 0.00005579 Sarcoidosis / / 22952805 rs74564102 chr7 1216881 G A 0.000044 Sarcoidosis / / 22952805 rs17234336 chr7 1220005 C T 3.24E-05 Waist-Hip Ratio / / pha003013 rs17234336 chr7 1220005 C T 7.08E-06 Waist-Hip Ratio / / pha003028 rs17234336 chr7 1220005 C T 4.00E-05 HDL cholesterol / / pha003074 rs9640008 chr7 1231678 A G 9.00E-04 Body mass index / / 24827717 rs7456553 chr7 1243525 T C 2.10E-06 Prostate-specific antigen levels / / 23359319 rs10275044 chr7 1273845 A T 4.00E-09 Renal function-related traits (BUN) UNCX intron 22797727 rs10277115 chr7 1285195 A T 1.00E-10 Renal function-related traits (eGRFcrea) / / 22797727 rs10277115 chr7 1285195 A T 5.00E-11 Renal function-related traits (sCR) / / 22797727 rs13241427 chr7 1288639 G T 4.81E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13241427 chr7 1288639 G T 3.50E-07 Subcutaneous adipose tissue volume in HIV-infected men / / 21897333 rs13242133 chr7 1289279 G A 1.80E-06 Subcutaneous adipose tissue volume in HIV-infected men / / 21897333 rs13221166 chr7 1363454 A G 5.22E-04 Acute lung injury / / 22295056 rs7809940 chr7 1389397 A G 4.66E-06 Personality dimensions / / 23658558 rs4725071 chr7 1451014 T A 7.12E-04 Parkinson's disease / / 16252231 rs61747084 chr7 1484418 T C 0.00011 Prostate cancer MICALL2 missense 23555315 rs75056037 chr7 1486451 G A 0.00028 Breast cancer MICALL2 missense 23555315 rs6942930 chr7 1552420 G A 1.60E-05 Alzheimer's disease (late onset) / / 21460841 rs3814477 chr7 1569418 C T 7.08E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6463939 chr7 1614662 A G 1.15E-08 Multiple complex diseases KIAA1908 intron 17554300 rs10429166 chr7 1655601 C T 2.04E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12703010 chr7 1680165 C T 1.53E-04 Osteoarthritis (knee and hip) / / 21177295 rs12703010 chr7 1680165 C T 4.66E-05 Osteoarthritis (knee and hip) / / 21177295 rs6950626 chr7 1724090 A G 0.000446 Salmonella-induced pyroptosis / / 22837397 rs4720922 chr7 1733102 G T 9.35E-05 Type 2 diabetes and other traits / / 19734900 rs12699171 chr7 1746349 A G 8.49E-04 Multiple complex diseases / / 17554300 rs4720940 chr7 1750797 C T 3.38E-05 Height ELFN1 intron 17255346 rs6942534 chr7 1757236 T C 0.000898 Salmonella-induced pyroptosis ELFN1 intron 22837397 rs10227806 chr7 1819139 T G 5.62E-05 Information processing speed / / 21130836 rs10950377 chr7 1835894 C G 4.37E-04 Multiple complex diseases / / 17554300 rs6948971 chr7 1854263 A G 5.50E-04 Coronary heart disease / / 21966275 rs13225346 chr7 1866916 T C 5.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAD1L1 intron 20877124 rs13225346 chr7 1866916 T C 3.96E-06 Interstitial lung disease MAD1L1 intron 23583980 rs4721090 chr7 1873084 T C 4.95E-06 Bipolar disorder and schizophrenia MAD1L1 intron 20889312 rs11767177 chr7 1882914 G T 3.82E-06 Iron levels MAD1L1 intron 19880490 rs11767177 chr7 1882914 G T 3.82E-06 Iron levels MAD1L1 intron pha002876 rs10234557 chr7 1886333 A G 3.93E-04 Multiple complex diseases MAD1L1 intron 17554300 rs6952808 chr7 1886535 G C 2.00E-06 Bipolar disorder and schizophrenia MAD1L1 intron 20889312 rs6977733 chr7 1886725 T A 4.29E-06 Bipolar disorder and schizophrenia MAD1L1 intron 20889312 rs11764337 chr7 1892309 C T 1.90E-04 Multiple complex diseases MAD1L1 intron 17554300 rs11764337 chr7 1892309 C T 8.71E-05 Bipolar disorder and schizophrenia MAD1L1 intron 20889312 rs11764337 chr7 1892309 C T 3.86E-05 Schizophrenia MAD1L1 intron pha002857 rs4721121 chr7 1892565 T C 4.97E-06 Bipolar disorder and schizophrenia MAD1L1 intron 20889312 rs4721135 chr7 1912222 A G 1.00E-06 Longevity MAD1L1 intron 20834067 rs10275045 chr7 1920826 C T 6.57E-05 Bipolar disorder and schizophrenia MAD1L1 intron 20889312 rs10275045 chr7 1920826 C T 3.78E-10 Testicular germ cell tumor MAD1L1 intron 23666239 rs10275045 chr7 1920826 C T 2.16E-08 Schizophrenia,schizoaffective disorder or bipolar disorder MAD1L1 intron 24166486 rs10275045 chr7 1920826 C T 2.00E-06 Bipolar disorder and schizophrenia MAD1L1 intron 24280982 rs10275045 chr7 1920826 C T 2.00E-09 Bipolar disorder and schizophrenia MAD1L1 intron 24280982 rs10275045 chr7 1920826 C T 2.08E-04 Bipolar disorder and schizophrenia MAD1L1 intron 24280982 rs10244946 chr7 1921068 G A 8.71E-05 Bipolar disorder and schizophrenia MAD1L1 intron 20889312 rs10278591 chr7 1921362 C T 9.00E-04 Multiple complex diseases MAD1L1 intron 17554300 rs10278591 chr7 1921362 C T 7.21E-04 Alzheimer's disease MAD1L1 intron 17998437 rs7783715 chr7 1923385 T C 8.71E-06 Interstitial lung disease MAD1L1 intron 23583980 rs6951956 chr7 1934131 G A 6.63E-04 Multiple complex diseases MAD1L1 intron 17554300 rs12537914 chr7 1948359 C T 2.03E-08 Schizophrenia,schizoaffective disorder or bipolar disorder MAD1L1 intron 24166486 rs4721184 chr7 1950784 T C 2.74E-08 Schizophrenia,schizoaffective disorder or bipolar disorder MAD1L1 intron 24166486 rs4332037 chr7 1950809 C T 4.63E-04 Alcohol dependence MAD1L1 intron 20201924 rs4332037 chr7 1950809 C T 7.00E-06 Bipolar disorder MAD1L1 intron 21926972 rs4332037 chr7 1950809 C T 0.0000429 Bipolar disorder MAD1L1 intron 23070075 rs4332037 chr7 1950809 C T 0.0000397 Bipolar disorder MAD1L1 intron 23637625 rs2056480 chr7 1954301 G A 6.16E-05 Bipolar disorder and schizophrenia MAD1L1 intron 20889312 rs2056480 chr7 1954301 G A 1.54E-08 Schizophrenia,schizoaffective disorder or bipolar disorder MAD1L1 intron 24166486 rs4721190 chr7 1954732 G A 3.83E-08 Schizophrenia,schizoaffective disorder or bipolar disorder MAD1L1 intron 24166486 rs12699477 chr7 1968953 T C 6.00E-09 Testicular germ cell tumor MAD1L1 intron 23666239 rs12699477 chr7 1968953 T C 8.78E-09 Schizophrenia,schizoaffective disorder or bipolar disorder MAD1L1 intron 24166486 rs1801368 chr7 1976457 C A,G,T 0.00055 Prostate cancer MAD1L1 missense 23555315 rs2280550 chr7 1976556 G A 3.80E-08 Schizophrenia,schizoaffective disorder or bipolar disorder MAD1L1 intron 24166486 rs7804190 chr7 1993899 A C 7.12E-05 Receptive language ability MAD1L1 intron 24687471 rs12666575 chr7 2004421 C T 2.00E-09 Schizophrenia MAD1L1 intron 22688191 rs12666575 chr7 2004421 C T 8.27E-10 Schizophrenia,schizoaffective disorder or bipolar disorder MAD1L1 intron 24166486 rs6461049 chr7 2017445 C T 6.00E-13 Schizophrenia MAD1L1 intron 23974872 rs11764590 chr7 2032803 C T 5.84E-05 Neutrophil count MAD1L1 intron pha003095 rs4721295 chr7 2036669 T G 3.74E-05 Schizophrenia MAD1L1 intron 19571809 rs4721295 chr7 2036669 T G 3.42E-06 Bipolar disorder and schizophrenia MAD1L1 intron 20889312 rs4721295 chr7 2036669 T G 6.00E-10 Schizophrenia,schizoaffective disorder or bipolar disorder MAD1L1 intron 24166486 rs4721295 chr7 2036669 T G 2.21E-06 Schizophrenia MAD1L1 intron pha002857 rs10950503 chr7 2039594 A C 3.24E-05 Smoking initiation MAD1L1 intron 24665060 rs1107592 chr7 2041432 A G 3.84E-06 Schizophrenia MAD1L1 intron 19571809 rs1107592 chr7 2041432 A G 2.00E-06 Bipolar disorder and schizophrenia MAD1L1 intron 20889312 rs1107592 chr7 2041432 A G 5.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) MAD1L1 intron 23453885 rs1107592 chr7 2041432 A G 5.64E-09 Schizophrenia,schizoaffective disorder or bipolar disorder MAD1L1 intron 24166486 rs1107592 chr7 2041432 A G 3.85E-06 Schizophrenia MAD1L1 intron pha002857 rs7802187 chr7 2072978 G T 6.08E-04 Multiple complex diseases MAD1L1 intron 17554300 rs10276536 chr7 2086960 C T 7.69E-04 Alzheimer's disease MAD1L1 intron 17998437 rs10950536 chr7 2111636 G A 4.10E-05 Kawasaki disease MAD1L1 intron 22446962 rs1860827 chr7 2113327 T C 9.00E-05 Prostate cancer MAD1L1 intron 21743057 rs3778938 chr7 2114785 A G 9.00E-05 Prostate cancer MAD1L1 intron 21743057 rs2895202 chr7 2131829 T C 6.29E-04 Acute lung injury MAD1L1 intron 22295056 rs3778969 chr7 2139990 G A 3.66E-05 Bipolar disorder and schizophrenia MAD1L1 intron 20889312 rs3778969 chr7 2139990 G A 6.82E-04 Acute lung injury MAD1L1 intron 22295056 rs3778969 chr7 2139990 G A 6.43E-09 Schizophrenia,schizoaffective disorder or bipolar disorder MAD1L1 intron 24166486 rs3800902 chr7 2144378 C T 6.82E-04 Acute lung injury MAD1L1 intron 22295056 rs10224497 chr7 2149967 A G 8.68E-05 Bipolar disorder and schizophrenia MAD1L1 intron 20889312 rs10224497 chr7 2149967 A G 1.09E-08 Schizophrenia,schizoaffective disorder or bipolar disorder MAD1L1 intron 24166486 rs10224497 chr7 2149967 A G 4.88E-05 Schizophrenia MAD1L1 intron pha002857 rs10239050 chr7 2158390 A G 1.11E-08 Schizophrenia,schizoaffective disorder or bipolar disorder MAD1L1 intron 24166486 rs3800913 chr7 2163237 A G 4.03E-08 Schizophrenia,schizoaffective disorder or bipolar disorder MAD1L1 intron 24166486 rs3800917 chr7 2167939 G A 3.31E-05 Bipolar disorder and schizophrenia MAD1L1 intron 20889312 rs3800917 chr7 2167939 G A 2.29E-09 Schizophrenia,schizoaffective disorder or bipolar disorder MAD1L1 intron 24166486 rs3800917 chr7 2167939 G A 8.04E-04 Smoking initiation MAD1L1 intron 24665060 rs3800917 chr7 2167939 G A 2.47E-05 Schizophrenia MAD1L1 intron pha002857 rs3778987 chr7 2168495 C T 9.57E-04 Acute lung injury MAD1L1 intron 22295056 rs4721429 chr7 2171704 T C 5.20E-04 Acute lung injury MAD1L1 intron 22295056 rs3778991 chr7 2172455 G A 5.11E-04 Acute lung injury MAD1L1 intron 22295056 rs3778991 chr7 2172455 G A 6.73E-10 Testicular germ cell tumor MAD1L1 intron 23666239 rs3778991 chr7 2172455 G A 2.21E-09 Schizophrenia,schizoaffective disorder or bipolar disorder MAD1L1 intron 24166486 rs3778991 chr7 2172455 G A 2.73E-04 Smoking initiation MAD1L1 intron 24665060 rs3778994 chr7 2175855 C A 1.12E-04 Lung function (forced vital capacity) MAD1L1 intron 24023788 rs3778994 chr7 2175855 C A 2.53E-09 Schizophrenia,schizoaffective disorder or bipolar disorder MAD1L1 intron 24166486 rs3778995 chr7 2175871 T C 2.89E-04 HIV-1 viral setpoint MAD1L1 intron 17641165 rs3778996 chr7 2177190 G A 6.63E-04 Acute lung injury MAD1L1 intron 22295056 rs17132242 chr7 2179462 G A 0.000028 Alcohol craving with or without dependence MAD1L1 intron 22481050 rs3778998 chr7 2180753 C A 5.81E-04 Acute lung injury MAD1L1 intron 22295056 rs17132255 chr7 2182994 A G 7.27E-04 Multiple complex diseases MAD1L1 intron 17554300 rs3779002 chr7 2183219 C T 5.81E-04 Acute lung injury MAD1L1 intron 22295056 rs4721441 chr7 2184060 T C 9.06E-05 Bipolar disorder and schizophrenia MAD1L1 intron 20889312 rs4721441 chr7 2184060 T C 6.61E-04 Acute lung injury MAD1L1 intron 22295056 rs4721441 chr7 2184060 T C 9.41E-10 Schizophrenia,schizoaffective disorder or bipolar disorder MAD1L1 intron 24166486 rs4721441 chr7 2184060 T C 4.31E-04 Smoking initiation MAD1L1 intron 24665060 rs3779003 chr7 2184902 C T 4.64E-05 Bipolar disorder and schizophrenia MAD1L1 intron 20889312 rs3779003 chr7 2184902 C T 6.64E-04 Acute lung injury MAD1L1 intron 22295056 rs3779003 chr7 2184902 C T 2.33E-09 Schizophrenia,schizoaffective disorder or bipolar disorder MAD1L1 intron 24166486 rs3800924 chr7 2188249 C T 4.05E-04 Acute lung injury MAD1L1 intron 22295056 rs3800924 chr7 2188249 C T 9.29E-05 Smoking initiation MAD1L1 intron 24665060 rs3800924 chr7 2188249 C T 9.59E-04 Myocardial Infarction MAD1L1 intron pha002873 rs13230911 chr7 2203369 C T 3.46E-04 Multiple complex diseases MAD1L1 intron 17554300 rs13244625 chr7 2206690 A G 3.63E-04 Multiple complex diseases MAD1L1 intron 17554300 rs17790410 chr7 2220092 A G 2.28E-04 Multiple complex diseases MAD1L1 intron 17554300 rs17790410 chr7 2220092 A G 6.28E-05 Type 1 diabetes MAD1L1 intron 18978792 rs1637758 chr7 2220876 G A 9.69E-04 Multiple complex diseases MAD1L1 intron 17554300 rs10226475 chr7 2226162 A G 2.18E-05 Schizophrenia MAD1L1 intron 19571811 rs10226475 chr7 2226162 A G 5.06E-08 Schizophrenia MAD1L1 intron 21926974 rs11976342 chr7 2240094 C T 6.15E-04 Acute lung injury MAD1L1 intron 22295056 rs1612548 chr7 2248472 G A 3.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAD1L1 intron 20877124 rs1612548 chr7 2248472 G A 3.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAD1L1 intron 20877124 rs1639911 chr7 2249894 G A 1.50E-05 Urinary metabolites MAD1L1 intron 21572414 rs733611 chr7 2256779 G A 3.00E-04 Alzheimer's disease MAD1L1 intron 22005930 rs1639915 chr7 2258084 C G 8.65E-05 Bipolar disorder and schizophrenia MAD1L1 intron 20889312 rs1639915 chr7 2258084 C G 1.20E-05 Urinary metabolites MAD1L1 intron 21572414 rs6461233 chr7 2261468 G A 3.35E-04 Alzheimer's disease MAD1L1 intron 22005930 rs6461233 chr7 2261468 G A 0.000519 Bipolar disorder MAD1L1 intron 23637625 rs3757440 chr7 2272936 A G 5.58E-04 Alzheimer's disease MAD1L1 nearGene-5 22005930 rs3757440 chr7 2272936 A G 1.98E-08 Schizophrenia,schizoaffective disorder or bipolar disorder MAD1L1 nearGene-5 24166486 rs7787274 chr7 2275993 G A 4.57E-04 Alzheimer's disease FTSJ2 intron 22005930 rs7787274 chr7 2275993 G A 0.000327 Schizophrenia FTSJ2 intron 23637625 rs7787274 chr7 2275993 G A 1.08E-08 Schizophrenia,schizoaffective disorder or bipolar disorder FTSJ2 intron 24166486 rs7799006 chr7 2278226 C T 4.69E-04 Alzheimer's disease FTSJ2 intron 22005930 rs7799006 chr7 2278226 C T 5.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) FTSJ2 intron 23453885 rs7799006 chr7 2278226 C T 1.24E-08 Schizophrenia,schizoaffective disorder or bipolar disorder FTSJ2 intron 24166486 rs4721505 chr7 2287560 A G 3.26E-04 White matter integrity NUDT1 intron 22425255 rs2398668 chr7 2298227 C T 7.00E-06 Bipolar disorder and schizophrenia SNX8 intron 20889312 rs7792045 chr7 2316852 C T 8.58E-05 Bipolar disorder and schizophrenia SNX8 intron 20889312 rs4721548 chr7 2330496 A G 7.56E-04 Suicide attempts in bipolar disorder SNX8 intron 21423239 rs4721548 chr7 2330496 A G 9.64E-04 Alzheimer's disease SNX8 intron 22005930 rs12699820 chr7 2332968 G T 2.51E-04 Alzheimer's disease SNX8 intron 22005930 rs7781284 chr7 2339405 G T 7.81E-04 Alzheimer's disease SNX8 intron 22005930 rs13245097 chr7 2341055 C T 3.81E-05 Bipolar disorder SNX8 intron 21926972 rs13245097 chr7 2341055 C T 4.29E-04 Alzheimer's disease SNX8 intron 22005930 rs10249052 chr7 2346115 C T 1.94E-04 Taste perception SNX8 intron 22132133 rs6952809 chr7 2448493 T C 4.00E-06 Multiple sclerosis CHST12 intron 21833088 rs4719530 chr7 2452624 C T 5.90E-06 Urinary metabolites CHST12 intron 21572414 rs4719530 chr7 2452624 C T 9.55E-06 Schizophrenia CHST12 intron 21926974 rs12534223 chr7 2457682 G A 7.50E-06 Urinary metabolites CHST12 intron 21572414 rs10240036 chr7 2486368 G C 9.83E-04 Lymphocyte counts / / 22286170 rs2969070 chr7 2512545 G A 5.61E-07 Blood pressure / / 21909110 rs2969070 chr7 2512545 G A 1.31E-06 Systolic blood pressure / / 21909115 rs286551 chr7 2545487 C G 1.71E-04 Birth weight / / 17255346 rs6972204 chr7 2582452 T C 5.00E-06 Obesity-related traits BRAT1 intron 23251661 rs11773376 chr7 2594338 C T 2.30E-04 Multiple complex diseases BRAT1 intron 17554300 rs1550202 chr7 2605333 G A 4.88E-04 Amyotrophic Lateral Sclerosis IQCE intron 17362836 rs2917756 chr7 2607339 G A 5.51E-04 Obesity (extreme) IQCE intron 21935397 rs2293404 chr7 2644519 C T 2.52E-04 Alzheimer's disease (late onset) IQCE missense 21379329 rs1639046 chr7 2713683 T A 8.49E-04 Multiple complex diseases / / 17554300 rs2041342 chr7 2729765 G A 8.07E-04 Multiple complex diseases AMZ1 intron 17554300 rs2041342 chr7 2729765 G A 1.30E-05 Type 1 diabetes AMZ1 intron 18978792 rs1724888 chr7 2741019 C G 1.15E-08 Height AMZ1 intron 23563607 rs798554 chr7 2759795 C T 4.00E-23 Height / / 23563607 rs798544 chr7 2763102 C T 7.00E-15 Height / / 18391951 rs2266920 chr7 2775178 C T 5.76E-05 Parkinson's disease G/12 intron 21812969 rs33932857 chr7 2775718 G A 4.63E-04 Alzheimer's disease (late onset) G/12 intron 21379329 rs798502 chr7 2789880 A C 3.00E-15 Ulcerative colitis G/12 intron 21297633 rs798502 chr7 2789880 A C 6.00E-17 Ulcerative colitis G/12 intron 23128233 rs798497 chr7 2795957 A G 7.00E-07 Height G/12 intron 20189936 rs798489 chr7 2801803 C T 2.00E-33 Height G/12 intron 20881960 rs10487577 chr7 2810478 T C 2.00E-07 Breast cancer and prostate cancer G/12 intron 17903305 rs2258960 chr7 2827276 T C 5.44E-04 Multiple complex diseases G/12 intron 17554300 rs3846992 chr7 2830243 T G 9.56E-04 Multiple complex diseases G/12 intron 17554300 rs2644306 chr7 2831602 A G 7.82E-06 Scoliosis G/12 intron 21216876 rs757791 chr7 2867296 A G 2.89E-04 Scoliosis G/12 intron 21216876 rs1182188 chr7 2869985 T C 3.00E-09 Height G/12 intron 19343178 rs1182171 chr7 2878510 A G 3.57E-06 Lymphocyte counts G/12 intron 22286170 rs1636255 chr7 2892804 C A 4.10E-13 Height / / 21194676 rs1636255 chr7 2892804 C A 4.50E-07 Height / / 21194676 rs1636255 chr7 2892804 C A 7.00E-19 Height / / 21194676 rs1182144 chr7 2911972 A G 2.00E-04 Scoliosis / / 21216876 rs6977940 chr7 2915378 G T 5.00E-06 White matter integrity / / 23218918 rs7787896 chr7 2943134 C T 4.28E-04 Type 2 diabetes / / 17463246 rs7810813 chr7 2943818 A G 2.50E-05 HIV-1 control / / 20041166 rs3735118 chr7 2944317 C T 5.68E-06 HIV-1 control / / 20041166 rs2679258 chr7 2951346 A G 5.40E-05 Hematology traits CARD11 intron 23303382 rs7795713 chr7 3007393 C T 1.76E-04 Celiac disease CARD11 intron 23936387 rs17737044 chr7 3034038 G T 2.56E-04 Multiple complex diseases CARD11 intron 17554300 rs10236776 chr7 3049009 A G 4.30E-04 Major depressive disorder CARD11 intron 21042317 rs11768102 chr7 3093297 C T 5.90E-04 Alcohol dependence / / 20201924 rs6461814 chr7 3096211 G A 6.07E-04 Type 2 diabetes / / 17463246 rs12113392 chr7 3096687 A G 7.20E-04 Prostate cancer mortality / / 20978177 rs2396967 chr7 3100838 A G 3.89E-04 Type 2 diabetes / / 17463246 rs7805247 chr7 3110059 C T 5.68E-05 Nicotine smoking / / 19268276 rs1843938 chr7 3113034 G A 1.10E-05 Multiple sclerosis / / 21833088 rs7801254 chr7 3117801 A G 2.08E-08 Metabolite levels / / 23281178 rs17132944 chr7 3118298 C T 8.94E-05 Fibrinogen / / pha003068 rs6952343 chr7 3121829 A C 6.71E-05 Post-operative nausea and vomiting / / 21694509 rs7776783 chr7 3123454 C T 1.61E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7782384 chr7 3125512 T C 9.30E-04 Alzheimer's disease / / 22005930 rs3736222 chr7 3125768 C A 3.66E-04 Alzheimer's disease / / 22005930 rs4722404 chr7 3128789 T C 8.00E-09 Atopic dermatitis / / 23042114 rs10499320 chr7 3133383 G C 8.80E-04 Lipid traits / / 17903299 rs1011189 chr7 3134524 G C 6.85E-04 Bipolar disorder,schizoaffective / / 19567891 rs4236317 chr7 3134593 G A 5.86E-05 Post-operative nausea and vomiting / / 21694509 rs7809283 chr7 3140464 C T 9.73E-04 Obesity (extreme) / / 21935397 rs11773338 chr7 3144508 T C 5.19E-04 Alzheimer's disease / / 22005930 rs1872881 chr7 3148092 T C 3.34E-04 Alzheimer's disease / / 22005930 rs1872880 chr7 3148389 G C 3.62E-04 Alzheimer's disease / / 22005930 rs4722426 chr7 3150697 G A 2.63E-04 Alzheimer's disease / / 22005930 rs9986825 chr7 3151177 T C 4.73E-04 Alzheimer's disease / / 22005930 rs4722435 chr7 3152962 C T 2.35E-04 Alzheimer's disease / / 22005930 rs4722438 chr7 3155813 A G 3.72E-04 Alzheimer's disease / / 22005930 rs4722440 chr7 3155901 C T 4.59E-04 Alzheimer's disease / / 22005930 rs12700594 chr7 3156701 G A,T 4.59E-04 Alzheimer's disease / / 22005930 rs6955702 chr7 3157702 A G 5.68E-04 Alzheimer's disease / / 22005930 rs6975452 chr7 3160511 T A 8.11E-04 Alzheimer's disease / / 22005930 rs6942973 chr7 3167751 A G 1.64E-05 Blood Pressure / / pha002898 rs12532214 chr7 3169890 G C 2.90E-06 Urinary metabolites / / 21572414 rs7779245 chr7 3179991 T C 0.0000978 post-traumatic stress disorder / / 22869035 rs7779245 chr7 3179991 T C 9.78E-05 Schizophrenia / / 22883433 rs6964682 chr7 3180657 C T 0.0000802 post-traumatic stress disorder / / 22869035 rs6964682 chr7 3180657 C T 8.02E-05 Schizophrenia / / 22883433 rs4634530 chr7 3197867 T C 4.23E-04 Obesity (extreme) / / 21935397 rs10951095 chr7 3208071 A G 4.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1525550 chr7 3214048 A G 6.51E-04 Response to alcohol consumption (flushing response) / / 24277619 rs6961724 chr7 3216850 A G 6.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6961724 chr7 3216850 A G 0.000605292 Hypertension (early onset hypertension) / / 22479346 rs870226 chr7 3222960 G A 2.32E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs17810513 chr7 3227255 C T 1.90E-05 Urinary metabolites / / 21572414 rs10272892 chr7 3232378 T C 3.50E-05 Crohn's disease (need for surgery) / / 23665963 rs6972823 chr7 3235896 T A 1.69E-05 Pulmonary function / / 17903307 rs7807378 chr7 3246271 C A,G,T 3.36E-04 Bipolar disorder / / 18317468 rs12700717 chr7 3261827 T C 8.45E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs10951131 chr7 3272526 G A 1.40E-05 Personality dimensions / / 18957941 rs10951131 chr7 3272526 G A 6.81E-05 Body mass index / / 24827717 rs16870824 chr7 3284552 A G 0.000696 Salmonella-induced pyroptosis / / 22837397 rs11977745 chr7 3285433 G A 0.0000724 Salmonella-induced pyroptosis / / 22837397 rs2334063 chr7 3292151 G A 5.88E-04 Smoking quantity / / 24665060 rs2049477 chr7 3312870 A C 8.48E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11773532 chr7 3320172 C T 9.96E-04 Type 2 diabetes / / 17463246 rs17133257 chr7 3338448 T G 3.65E-04 Smoking initiation / / 24665060 rs1525554 chr7 3344017 G T 1.62E-04 Type 2 diabetes SDK1 intron 17463246 rs1525554 chr7 3344017 G T 9.08E-04 Multiple complex diseases SDK1 intron 17554300 rs10807839 chr7 3344629 G A 3.82E-04 Smoking initiation SDK1 intron 24665060 rs1404872 chr7 3344986 G A 3.25E-05 Tunica Media SDK1 intron pha003037 rs1880610 chr7 3349625 T C 5.61E-04 Smoking initiation SDK1 intron 24665060 rs10250444 chr7 3350027 G A 9.30E-05 Temperament (bipolar disorder) SDK1 intron 22365631 rs4722663 chr7 3350567 T C 9.30E-05 Temperament (bipolar disorder) SDK1 intron 22365631 rs6461994 chr7 3356483 G C 3.90E-05 Temperament (bipolar disorder) SDK1 intron 22365631 rs4316064 chr7 3358580 G A 6.40E-05 Temperament (bipolar disorder) SDK1 intron 22365631 rs6966619 chr7 3359491 T A 6.90E-05 Temperament (bipolar disorder) SDK1 intron 22365631 rs10951155 chr7 3359684 A G 1.80E-05 Temperament (bipolar disorder) SDK1 intron 22365631 rs4343997 chr7 3362918 G A 5.91E-05 Type 2 diabetes SDK1 intron 17463246 rs4343997 chr7 3362918 G A 4.08E-04 Multiple complex diseases SDK1 intron 17554300 rs4521670 chr7 3383603 T C 3.20E-05 Temperament (bipolar disorder) SDK1 intron 22365631 rs11766702 chr7 3388761 A G 5.32E-04 Smoking initiation SDK1 intron 24665060 rs11770681 chr7 3393170 A G 3.60E-04 Smoking initiation SDK1 intron 24665060 rs4286835 chr7 3400463 A C 2.11E-04 Smoking initiation SDK1 intron 24665060 rs12700827 chr7 3401796 A G 3.67E-04 Smoking initiation SDK1 intron 24665060 rs10262464 chr7 3406961 A C 7.18E-05 Bipolar disorder SDK1 intron 17486107 rs1915983 chr7 3408989 C T 4.57E-04 Smoking initiation SDK1 intron 24665060 rs10235815 chr7 3413867 T G 5.50E-04 Smoking initiation SDK1 intron 24665060 rs1554502 chr7 3418411 C T 2.20E-04 Smoking initiation SDK1 intron 24665060 rs10235080 chr7 3419502 A G 4.90E-04 Nicotine smoking SDK1 intron 19268276 rs939912 chr7 3420856 A G 2.43E-04 Smoking initiation SDK1 intron 24665060 rs4418248 chr7 3420940 G A 1.80E-04 Breast cancer and prostate cancer SDK1 intron 17903305 rs6967281 chr7 3431050 A C 2.24E-04 Smoking initiation SDK1 intron 24665060 rs11971511 chr7 3434275 G A 7.65E-05 HIV-1 control SDK1 intron 20041166 rs6952184 chr7 3445311 T C 7.64E-04 Bipolar disorder SDK1 intron 19259986 rs6952184 chr7 3445311 T C 1.68E-05 Bone mineral traits,in men SDK1 intron 21427758 rs6952184 chr7 3445311 T C 4.09E-05 Bone mineral traits,in men SDK1 intron 21427758 rs6952184 chr7 3445311 T C 5.97E-05 Bone mineral traits,in men SDK1 intron 21427758 rs6952184 chr7 3445311 T C 9.88E-05 Tunica Media SDK1 intron pha003037 rs17133300 chr7 3455694 G A 9.06E-04 Multiple complex diseases SDK1 intron 17554300 rs17133300 chr7 3455694 G A 3.34E-05 Tuberculosis SDK1 intron 24057671 rs6462071 chr7 3468287 A G 4.49E-04 Smoking initiation SDK1 intron 24665060 rs17133334 chr7 3469551 T A 5.13E-04 Smoking initiation SDK1 intron 24665060 rs7788172 chr7 3471241 A T 2.61E-04 Type 2 diabetes SDK1 intron 17463246 rs6969711 chr7 3473582 A G 9.83E-04 Type 2 diabetes SDK1 intron 17463246 rs1357309 chr7 3486358 T C 5.86E-05 Smoking initiation SDK1 intron 24665060 rs4719944 chr7 3496032 T C 5.10E-05 Temperament (bipolar disorder) SDK1 intron 22365631 rs6949513 chr7 3496731 G A 1.60E-05 Temperament (bipolar disorder) SDK1 intron 22365631 rs1464534 chr7 3505092 C G 1.21E-04 Smoking initiation SDK1 intron 24665060 rs1548210 chr7 3526685 C T 6.30E-06 Central corneal thickness SDK1 intron 20485516 rs17133467 chr7 3539819 T G 2.06E-04 Multiple complex diseases SDK1 intron 17554300 rs1882426 chr7 3544743 C T 3.99E-04 Smoking initiation SDK1 intron 24665060 rs2705613 chr7 3546710 T C 4.86E-04 Smoking initiation SDK1 intron 24665060 rs1108879 chr7 3556132 G A 1.87E-05 Cognitive test performance SDK1 intron 20125193 rs12672248 chr7 3559904 G C 1.29E-05 Smoking cessation SDK1 intron 18519826 rs13221445 chr7 3593565 G A 4.67E-04 Myocardial Infarction SDK1 intron pha002883 rs17133566 chr7 3612421 G A 3.21E-04 Birth weight SDK1 intron 17255346 rs10238338 chr7 3618143 G A 2.08E-04 Birth weight SDK1 intron 17255346 rs17824994 chr7 3626760 C G 1.42E-04 Birth weight SDK1 intron 17255346 rs10085602 chr7 3633017 C T 3.27E-07 Smoking cessation SDK1 intron 18519826 rs12531560 chr7 3682486 C T 8.40E-05 Amyotrophic lateral sclerosis (sporadic) SDK1 intron 24529757 rs10245071 chr7 3685015 G A 0.000097 Sarcoidosis SDK1 intron 22952805 rs968775 chr7 3686414 G A 0.00009898 Sarcoidosis SDK1 intron 22952805 rs2880087 chr7 3686490 T A 0.00009898 Sarcoidosis SDK1 intron 22952805 rs12701014 chr7 3687926 G A 0.00004827 Sarcoidosis SDK1 intron 22952805 rs6974872 chr7 3689661 G A 0.00009349 Sarcoidosis SDK1 intron 22952805 rs7805946 chr7 3692663 A G 5.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SDK1 intron 20877124 rs2341447 chr7 3703188 G C 2.36E-04 Smoking cessation SDK1 intron 18519826 rs13223746 chr7 3713194 T G 6.17E-05 Response to citalopram treatment SDK1 intron 19846067 rs6951842 chr7 3716892 A T 5.04E-04 Response to cytidine analogues (gemcitabine) SDK1 intron 24483146 rs7790719 chr7 3718051 A G 8.00E-05 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) SDK1 intron 24325915 rs7778346 chr7 3727896 A C 1.90E-05 Urinary metabolites SDK1 intron 21572414 rs17133677 chr7 3733670 G A 1.30E-05 Urinary metabolites SDK1 intron 21572414 rs1529661 chr7 3735435 T G 6.07E-04 Heart Failure SDK1 intron pha002884 rs10256504 chr7 3743555 A G 7.80E-04 Heart Failure SDK1 intron pha002884 rs6973944 chr7 3842790 G A 9.98E-06 Malignant mesothelioma SDK1 intron 23827383 rs6975313 chr7 3842905 C T 9.98E-06 Malignant mesothelioma SDK1 intron 23827383 rs6966030 chr7 3858681 C T 3.94E-06 Malignant mesothelioma SDK1 intron 23827383 rs2341959 chr7 3860836 G A 5.49E-06 Malignant mesothelioma SDK1 intron 23827383 rs6953604 chr7 3868788 C A 5.03E-06 Malignant mesothelioma SDK1 intron 23827383 rs1548612 chr7 3870493 T A 5.06E-06 Malignant mesothelioma SDK1 intron 23827383 rs12532040 chr7 3872020 C T 5.17E-06 Malignant mesothelioma SDK1 intron 23827383 rs12537696 chr7 3872917 G A 3.85E-06 Malignant mesothelioma SDK1 intron 23827383 rs6978964 chr7 3873619 G T 3.15E-06 Malignant mesothelioma SDK1 intron 23827383 rs6979937 chr7 3874194 G A 3.05E-06 Malignant mesothelioma SDK1 intron 23827383 rs6980085 chr7 3874237 G A 2.75E-06 Malignant mesothelioma SDK1 intron 23827383 rs13236719 chr7 3875010 T C 2.65E-06 Malignant mesothelioma SDK1 intron 23827383 rs7794504 chr7 3875748 G A 2.49E-06 Malignant mesothelioma SDK1 intron 23827383 rs6462361 chr7 3876162 A G 1.90E-06 Malignant mesothelioma SDK1 intron 23827383 rs7778705 chr7 3879686 G A 2.14E-06 Malignant mesothelioma SDK1 intron 23827383 rs12538997 chr7 3879912 G A 8.56E-06 Malignant mesothelioma SDK1 intron 23827383 rs11976915 chr7 3886609 C G 1.93E-06 Malignant mesothelioma SDK1 intron 23827383 rs11977993 chr7 3888188 C G 1.91E-06 Malignant mesothelioma SDK1 intron 23827383 rs12540101 chr7 3889905 A G 1.69E-06 Malignant mesothelioma SDK1 intron 23827383 rs12532903 chr7 3891226 G A 6.83E-06 Malignant mesothelioma SDK1 intron 23827383 rs12532912 chr7 3891289 G T 5.86E-06 Malignant mesothelioma SDK1 intron 23827383 rs13236653 chr7 3891887 G A 6.70E-06 Malignant mesothelioma SDK1 intron 23827383 rs7807003 chr7 3894015 A G 7.75E-06 Malignant mesothelioma SDK1 intron 23827383 rs12701229 chr7 3896634 G A 8.88E-06 Malignant mesothelioma SDK1 intron 23827383 rs6948552 chr7 3898212 C T 7.67E-06 Malignant mesothelioma SDK1 intron 23827383 rs6957166 chr7 3899445 G T 4.37E-06 Malignant mesothelioma SDK1 intron 23827383 rs10252169 chr7 3899866 G A 8.13E-06 Malignant mesothelioma SDK1 intron 23827383 rs10085568 chr7 3900810 T C 9.13E-06 Malignant mesothelioma SDK1 intron 23827383 rs10085400 chr7 3901191 C A 6.88E-06 Malignant mesothelioma SDK1 intron 23827383 rs6462411 chr7 3915564 T C 1.00E-06 Quantitative traits SDK1 intron 19197348 rs12701296 chr7 3970800 C T 1.70E-05 Urinary metabolites SDK1 intron 21572414 rs12536527 chr7 3983402 C T 5.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SDK1 intron 20877124 rs11978979 chr7 4026009 A T 1.22E-04 Alcohol dependence SDK1 intron 21314694 rs750291 chr7 4030435 C T 6.10E-05 Major depressive disorder SDK1 intron 21042317 rs17134117 chr7 4031064 C T 4.16E-08 Autism SDK1 intron 22935194 rs1025914 chr7 4033680 G A 7.60E-05 Major depressive disorder SDK1 intron 21042317 rs6950410 chr7 4038917 C T 1.12E-05 Multiple complex diseases SDK1 intron 17554300 rs6950410 chr7 4038917 C T 1.30E-05 Major depressive disorder SDK1 intron 21042317 rs17134146 chr7 4040129 C G 1.30E-04 Waist-hip ratio SDK1 intron 23966867 rs6462522 chr7 4042436 C T 1.70E-05 Major depressive disorder SDK1 intron 21042317 rs730771 chr7 4067574 G A 2.61E-04 Alzheimer's disease SDK1 intron 17998437 rs2880371 chr7 4070424 C T 0.0000588 Placental abruption SDK1 intron 23205182 rs2342494 chr7 4072223 G A 4.72E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs2342494 chr7 4072223 G A 0.000000472 Facial morphology SDK1 intron 23028347 rs10237319 chr7 4073601 C T 1.12E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs10237319 chr7 4073601 C T 0.000000112 Facial morphology SDK1 intron 23028347 rs10265937 chr7 4073649 G A 4.08E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs10265937 chr7 4073649 G A 0.000000408 Facial morphology SDK1 intron 23028347 rs10266101 chr7 4073819 G T 4.08E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs10266101 chr7 4073819 G T 0.000000408 Facial morphology SDK1 intron 23028347 rs10237838 chr7 4073998 C T 4.08E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs10237838 chr7 4073998 C T 0.000000408 Facial morphology SDK1 intron 23028347 rs10237488 chr7 4074342 T G 4.08E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs10237488 chr7 4074342 T G 0.000000408 Facial morphology SDK1 intron 23028347 rs10278187 chr7 4074373 C T 4.08E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs10278187 chr7 4074373 C T 0.000000408 Facial morphology SDK1 intron 23028347 rs10234405 chr7 4074459 A G 4.08E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs10234405 chr7 4074459 A G 0.000000408 Facial morphology SDK1 intron 23028347 rs6950754 chr7 4077123 T C 4.54E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs6950754 chr7 4077123 T C 0.000000454 Facial morphology SDK1 intron 23028347 rs6462544 chr7 4077620 G A 1.74E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs6462544 chr7 4077620 G A 0.000000174 Facial morphology SDK1 intron 23028347 rs7803030 chr7 4078190 C A 4.85E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs7803030 chr7 4078190 C A 0.000000485 Facial morphology SDK1 intron 23028347 rs12155314 chr7 4081194 G T 6.36E-04 Body mass index SDK1 intron 21701565 rs12155314 chr7 4081194 G T 4.37E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs12155314 chr7 4081194 G T 0.000000437 Facial morphology SDK1 intron 23028347 rs9692219 chr7 4083333 T C 2.56E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs9692219 chr7 4083333 T C 0.000000255 Facial morphology SDK1 intron 23028347 rs1562006 chr7 4083504 C T 4.29E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs1562006 chr7 4083504 C T 0.000000429 Facial morphology SDK1 intron 23028347 rs1562005 chr7 4083823 A G 4.01E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs1562005 chr7 4083823 A G 0.000000401 Facial morphology SDK1 intron 23028347 rs7810949 chr7 4084716 C T 6.20E-05 Schizophrenia SDK1 intron 19571811 rs7779616 chr7 4086040 G A 2.13E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs7779616 chr7 4086040 G A 0.000000213 Facial morphology SDK1 intron 23028347 rs7799331 chr7 4086123 A G 4.64E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs7799331 chr7 4086123 A G 0.000000464 Facial morphology SDK1 intron 23028347 rs7781059 chr7 4086319 C T 1.30E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs7781059 chr7 4086319 C T 0.00000013 Facial morphology SDK1 intron 23028347 rs7807181 chr7 4086444 T C 1.95E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs7807181 chr7 4086444 T C 0.000000195 Facial morphology SDK1 intron 23028347 rs6462562 chr7 4088555 A G 3.84E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs6462562 chr7 4088555 A G 0.000000384 Facial morphology SDK1 intron 23028347 rs10485860 chr7 4090283 T C 4.07E-07 Primary biliary cirrhosis SDK1 intron 23000144 rs10485860 chr7 4090283 T C 0.000000407 Facial morphology SDK1 intron 23028347 rs6462571 chr7 4097856 G T 3.55E-04 Multiple complex diseases SDK1 intron 17554300 rs6971090 chr7 4106198 C T 2.00E-05 Urinary metabolites SDK1 intron 21572414 rs10226621 chr7 4107640 A C 1.03E-28 Narcolepsy SDK1 intron 19629137 rs11976431 chr7 4121845 C G 2.17E-04 Type 2 diabetes SDK1 intron 17463246 rs11976431 chr7 4121845 C G 2.49E-04 Multiple complex diseases SDK1 intron 17554300 rs882362 chr7 4139785 A G 6.07E-05 Neuroblastoma SDK1 intron pha002895 rs1405476 chr7 4160114 A G 4.89E-04 Amyotrophic Lateral Sclerosis SDK1 intron 17362836 rs11766511 chr7 4173613 A G 6.65E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) SDK1 intron 24192120 rs619672 chr7 4195988 G A 4.59E-05 Alcohol and nictotine co-dependence SDK1 intron 20158304 rs669028 chr7 4199901 C T 8.44E-04 White matter integrity SDK1 intron 22425255 rs665163 chr7 4216771 T C 9.07E-05 Non-alcoholic fatty liver disease histology (other) SDK1 intron 20708005 rs7797803 chr7 4221064 A G 1.46E-04 Nicotine smoking SDK1 intron 19268276 rs17134460 chr7 4224833 A G 7.51E-04 Myopia (pathological) SDK1 intron 21095009 rs935568 chr7 4228612 G A 1.50E-04 Lung function (forced vital capacity) SDK1 intron 24023788 rs935568 chr7 4228612 G A 4.97E-04 Lung function (forced expiratory volume in 1 second) SDK1 intron 24023788 rs17134481 chr7 4229133 C G 5.54E-04 Multiple complex diseases SDK1 intron 17554300 rs7810341 chr7 4237801 G A 5.01E-04 Schizophrenia (cytomegalovirus infection interaction) SDK1 intron 23358160 rs113416442 chr7 4240923 C G 0.0003472 Sarcoidosis SDK1 intron 22952805 rs17134615 chr7 4248681 T C 8.37E-04 Nicotine smoking SDK1 intron 19268276 rs666121 chr7 4250040 C T 8.43E-06 Post-operative nausea and vomiting SDK1 intron 21694509 rs10260900 chr7 4251135 T C 6.31E-04 Myopia (pathological) SDK1 intron 21095009 rs149005994 chr7 4259879 A G 0.000052 Breast cancer (ER positive) SDK1 missense 23555315 rs149005994 chr7 4259879 A G 0.00014 Breast cancer SDK1 missense 23555315 rs4723505 chr7 4263659 C T 1.53E-04 Myopia (pathological) SDK1 intron 21095009 rs11761645 chr7 4265655 G A 5.95E-05 Blood Pressure SDK1 intron pha003044 rs10479843 chr7 4283769 A G 5.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SDK1 intron 20877124 rs10272180 chr7 4308985 C G 1.80E-05 Urinary metabolites / / 21572414 rs12701532 chr7 4325870 T C 0.0005781 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12701532 chr7 4325870 T C 5.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs765938 chr7 4328149 G C 0.0005323 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs765938 chr7 4328149 G C 5.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12701534 chr7 4328870 A G 0.0005302 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12701534 chr7 4328870 A G 5.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4723604 chr7 4332438 C T 2.97E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs2189973 chr7 4333275 A G 3.98E-05 Fibrinogen / / 17255346 rs10488357 chr7 4333610 T C 1.88E-05 Fibrinogen / / 17255346 rs6462756 chr7 4371785 A C 6.98E-04 Rheumatoid arthritis / / 21452313 rs17134702 chr7 4381743 A G 6.66E-04 Aortic root size / / 21223598 rs7792601 chr7 4384024 C T 3.90E-04 Coronary heart disease / / 21606135 rs10235433 chr7 4384859 C T 6.54E-04 Aortic root size / / 21223598 rs12668791 chr7 4386342 C T 4.60E-04 Coronary heart disease / / 21606135 rs10488360 chr7 4411209 G A 7.00E-06 Factor VII / / 17903294 rs314624 chr7 4418719 A G 4.28E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs73034881 chr7 4422800 G A 1.12E-04 Malignant pleural mesothelioma / / 23626673 rs73034881 chr7 4422800 G A 2.16E-05 Malignant pleural mesothelioma / / 23626673 rs6954458 chr7 4448778 T C 7.25E-04 Multiple complex diseases / / 17554300 rs13238627 chr7 4465198 T C 1.92E-05 Erythrocyte counts / / pha003090 rs2158628 chr7 4469845 G A 1.22E-04 Birth weight / / 17255346 rs314591 chr7 4473994 G C 5.01E-04 Bipolar disorder / / 19259986 rs314590 chr7 4474132 G A 4.00E-06 Obesity-related traits / / 23251661 rs314582 chr7 4477024 C A 5.00E-05 Bipolar disorder / / 19259986 rs2034313 chr7 4477587 G C 2.90E-05 Personality dimensions / / 18957941 rs403000 chr7 4479389 A T 9.87E-05 Kawasaki disease / / 22446961 rs11767910 chr7 4495373 C T 7.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs895710 chr7 4497688 C T 4.70E-05 Common variable immunodeficiency / / 21497890 rs17134833 chr7 4503701 C T 6.63E-05 Bipolar disorder and schizophrenia / / 20889312 rs12538175 chr7 4504475 A G 1.58E-05 Odorant perception / / 23910658 rs1466066 chr7 4508102 A G 9.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs1466067 chr7 4509658 T G 9.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs4720301 chr7 4513806 C T 3.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs11971741 chr7 4530940 G A 2.46E-04 Birth weight / / 17255346 rs7799050 chr7 4539599 A C 4.04E-04 Eye color / / 23118974 rs1447398 chr7 4552959 G A 2.69E-04 Osteoarthritis / / 19508968 rs1447399 chr7 4553216 A G 6.70E-05 Lung adenocarcinoma / / 22797724 rs10265380 chr7 4553521 A G 1.17E-04 Myopia (pathological) / / 21095009 rs12701792 chr7 4647262 T C 6.30E-05 Lung adenocarcinoma / / 22797724 rs9791644 chr7 4723534 G A 3.00E-06 Lung function (forced vital capacity) FOXK1 intron 24023788 rs4540325 chr7 4751840 C T 2.04E-06 Response to metformin FOXK1 intron 21186350 rs4523152 chr7 4759542 G A 7.58E-05 Coronary heart disease FOXK1 intron 21971053 rs6973046 chr7 4765018 A G 4.07E-04 Coronary heart disease FOXK1 intron 21971053 rs7788807 chr7 4768038 T C 2.80E-05 Bone mineral density (BMD),in women FOXK1 intron 20164292 rs7793919 chr7 4769030 T C 7.55E-05 Coronary heart disease FOXK1 intron 21971053 rs9690101 chr7 4787612 A G 3.20E-05 Blood pressure FOXK1 intron 17255346 rs748973 chr7 4792762 C T 1.91E-04 Multiple complex diseases FOXK1 intron 17554300 rs6463034 chr7 4799694 T C 9.98E-05 Bipolar disorder and schizophrenia FOXK1 intron 20889312 rs17135086 chr7 4805376 C T 2.40E-05 HIV-1 control FOXK1 UTR-3 20041166 rs17135096 chr7 4809660 G T 1.54E-04 Body mass index FOXK1 UTR-3 17255346 rs2306921 chr7 4839265 G A 6.00E-06 Obesity-related traits RADIL cds-synon 23251661 rs3763381 chr7 4877012 C T 3.24E-04 Smoking initiation RADIL intron 24665060 rs1565317 chr7 4877539 A G 4.02E-04 Smoking initiation RADIL intron 24665060 rs13243520 chr7 4880954 A G 2.58E-05 Smoking initiation RADIL intron 24665060 rs6976105 chr7 4882288 G A 8.78E-05 Smoking initiation RADIL intron 24665060 rs10275805 chr7 4904809 C G 8.75E-08 Metabolite levels RADIL intron 23281178 rs10266401 chr7 4909983 G A 1.85E-05 Bipolar disorder RADIL intron 17486107 rs4720435 chr7 4912398 G T 2.80E-05 Crohn's disease RADIL intron 20570966 rs404449 chr7 4926950 T C 7.77E-05 Serum metabolites / / 19043545 rs10951714 chr7 4946877 T C 4.44E-04 Smoking initiation MMD2 UTR-3 24665060 rs12540466 chr7 4951133 T A,C 5.65E-04 Type 2 diabetes MMD2 intron 17463246 rs12540466 chr7 4951133 T A,C 8.83E-04 Multiple complex diseases MMD2 intron 17554300 rs4380823 chr7 5052523 A G 2.76E-05 Serum metabolites / / 19043545 rs6960279 chr7 5052830 A G 7.70E-05 Serum metabolites / / 19043545 rs9886313 chr7 5054320 C T 2.16E-05 Serum metabolites / / 19043545 rs7795386 chr7 5122645 T C 1.73E-05 Body Mass Index / / pha003006 rs7795386 chr7 5122645 T C 5.13E-05 Body Mass Index / / pha003007 rs7795386 chr7 5122645 T C 1.26E-06 Body Mass Index / / pha003014 rs7795386 chr7 5122645 T C 9.46E-05 Body Fat Distribution / / pha003018 rs6463266 chr7 5153283 G T 2.00E-04 Breast cancer / / 17529967 rs6463266 chr7 5153283 G T 1.22E-05 Blood Pressure / / pha003046 rs4077856 chr7 5157617 G A 4.13E-04 Coronary Artery Disease / / 17634449 rs4427074 chr7 5237500 G A 1.37E-04 Multiple complex diseases WIPI2 intron 17554300 rs4427074 chr7 5237500 G A 1.90E-05 Urinary metabolites WIPI2 intron 21572414 rs6972587 chr7 5248495 A C 7.23E-04 Response to statin treatment (atorvastatin),change in cholesterol levels WIPI2 intron 20031582 rs4433032 chr7 5255320 G C 1.50E-06 Urinary metabolites WIPI2 intron 21572414 rs4724461 chr7 5261560 C A 4.58E-05 Bipolar disorder WIPI2 intron 22925353 rs4538779 chr7 5264171 G C 1.40E-05 Urinary metabolites WIPI2 intron 21572414 rs4720539 chr7 5267524 C T 3.12E-04 Schizophrenia WIPI2 intron 19197363 rs4720539 chr7 5267524 C T 4.96E-04 Myopia (pathological) WIPI2 intron 21095009 rs4720539 chr7 5267524 C T 4.67E-05 Alzheimer's disease (late onset) WIPI2 intron 21379329 rs7904 chr7 5273121 C T 5.90E-04 Myopia (pathological) WIPI2 UTR-3 21095009 rs148445986 chr7 5278176 G A,T 1.37E-05 Acne (severe) / / 24927181 rs10226233 chr7 5292732 C T 6.13E-04 Schizophrenia / / 19197363 rs11764517 chr7 5302259 C T 1.50E-04 Multiple complex diseases / / 17554300 rs6959643 chr7 5329216 A T 4.56E-04 Suicide attempts in bipolar disorder SLC29A4 intron 21041247 rs6943227 chr7 5359680 G T 8.38E-04 Schizophrenia TNRC18 intron 19197363 rs10278799 chr7 5366935 C T 4.57E-04 Alzheimer's disease TNRC18 intron 24755620 rs4724587 chr7 5393054 G C 6.29E-04 Type 2 diabetes TNRC18 intron 17463246 rs7805732 chr7 5396955 A G 5.93E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) TNRC18 intron 23648065 rs6945065 chr7 5409059 A G 3.73E-05 Serum albumin level TNRC18 intron pha003084 rs4527789 chr7 5512271 A G 7.50E-04 Myocardial Infarction / / pha002873 rs7808325 chr7 5516940 C T 3.37E-05 Left ventricular hypertrophy FBXL18 UTR-3 pha003052 rs10281893 chr7 5520663 G A 3.91E-06 Left ventricular hypertrophy FBXL18 UTR-3 pha003052 rs7806101 chr7 5523494 G C 6.96E-05 Relative hand skill in reading disability FBXL18 intron 24068947 rs10216189 chr7 5524805 G A 4.00E-06 Relative hand skill in reading disability FBXL18 intron 24068947 rs4724699 chr7 5526712 G A 7.74E-06 Relative hand skill in reading disability FBXL18 intron 24068947 rs7799970 chr7 5527714 G C 7.84E-06 Relative hand skill in reading disability FBXL18 intron 24068947 rs10807949 chr7 5528375 C T 2.75E-04 Alzheimer's disease (late onset) FBXL18 intron 21379329 rs10807949 chr7 5528375 C T 6.93E-05 Relative hand skill in reading disability FBXL18 intron 24068947 rs10807949 chr7 5528375 C T 5.05E-05 Left ventricular hypertrophy FBXL18 intron pha003052 rs4724701 chr7 5528883 G A 2.00E-06 Suicidal ideation FBXL18 intron 22030708 rs4724701 chr7 5528883 G A 4.83E-06 Relative hand skill in reading disability FBXL18 intron 24068947 rs4077245 chr7 5529922 A C 6.44E-06 Relative hand skill in reading disability FBXL18 intron 24068947 rs4560713 chr7 5532657 G A 2.27E-04 Alzheimer's disease (late onset) FBXL18 intron 21379329 rs4560713 chr7 5532657 G A 9.23E-06 Relative hand skill in reading disability FBXL18 intron 24068947 rs7799622 chr7 5539958 C T 9.71E-05 Relative hand skill in reading disability FBXL18 intron 24068947 rs852423 chr7 5568366 A G 4.93E-04 Alzheimer's disease (late onset) ACTB intron 21379329 rs852392 chr7 5572132 G A 9.91E-04 Amyotrophic Lateral Sclerosis LOC100505829 intron 17827064 rs2693946 chr7 5618237 C T 9.12E-05 Epilepsy / / 22116939 rs2693946 chr7 5618237 C T 7.07E-05 Monocyte chemoattractant protein-1 / / pha003071 rs1640235 chr7 5642631 G A 4.19E-05 Hypertension (essential hypertension) FSCN1 intron 22184326 rs852441 chr7 5660686 A G 4.86E-04 Multiple complex diseases RNF216 UTR-3 17554300 rs852375 chr7 5675700 A G 2.66E-04 Multiple complex diseases RNF216 intron 17554300 rs852519 chr7 5696125 C A,G,T 5.21E-04 Alcohol dependence RNF216 intron 21314694 rs852517 chr7 5697579 G T 5.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RNF216 intron 20877124 rs852394 chr7 5721448 G A 5.74E-05 Cognitive test performance RNF216 intron 20125193 rs1990836 chr7 5761152 T C 5.04E-04 Multiple complex diseases RNF216 intron 17554300 rs17135757 chr7 5817636 G A 1.53E-04 Multiple complex diseases RNF216 intron 17554300 rs13241373 chr7 5823221 T C 6.58E-05 Hypertension (essential hypertension) RNF216 nearGene-5 22184326 rs2017620 chr7 5835718 A G 2.76E-05 Neuroblastoma / / pha002895 rs7785084 chr7 5871225 T C 6.34E-04 Suicide attempts in bipolar disorder ZNF815 intron 21423239 rs117906625 chr7 5875996 G A 9.45E-05 Epilepsy (remission after treatment) ZNF815 intron 23962720 rs117344497 chr7 5876022 G T 9.46E-05 Epilepsy (remission after treatment) ZNF815 intron 23962720 rs77684921 chr7 5876393 C T 9.52E-05 Epilepsy (remission after treatment) ZNF815 intron 23962720 rs117807036 chr7 5878247 A C 9.32E-05 Epilepsy (remission after treatment) ZNF815 intron 23962720 rs74877311 chr7 5878371 T G 9.34E-05 Epilepsy (remission after treatment) ZNF815 intron 23962720 rs7794016 chr7 5878500 A C 2.60E-05 Urinary metabolites ZNF815 intron 21572414 rs78064266 chr7 5878958 C T 9.47E-05 Epilepsy (remission after treatment) ZNF815 intron 23962720 rs308097 chr7 5880377 G A,C,T 2.00E-06 IgG glycosylation / / 23382691 rs75286636 chr7 5880854 A G 9.52E-05 Epilepsy (remission after treatment) ZNF815 intron 23962720 rs116964157 chr7 5881298 T C 9.60E-05 Epilepsy (remission after treatment) ZNF815 intron 23962720 rs17135835 chr7 5882223 G C 9.60E-05 Epilepsy (remission after treatment) ZNF815 intron 23962720 rs28694105 chr7 5883935 C T 9.67E-05 Epilepsy (remission after treatment) ZNF815 intron 23962720 rs28412201 chr7 5883987 A G 9.68E-05 Epilepsy (remission after treatment) ZNF815 intron 23962720 rs2881189 chr7 5925156 A G 6.10E-04 Waist circumference OCM intron 23966867 rs10235277 chr7 6036245 C T 8.71E-04 Response to taxane treatment (placlitaxel) PMS2 intron 23006423 rs7803611 chr7 6055706 T C 9.92E-05 Response to taxane treatment (placlitaxel) AIMP2 intron 23006423 rs3779110 chr7 6056530 G A 7.20E-04 Multiple complex diseases AIMP2 intron 17554300 rs3801032 chr7 6062528 T G 3.25E-04 Response to taxane treatment (placlitaxel) EIF2AK1 UTR-3 23006423 rs4560 chr7 6063283 C T 5.09E-04 Type 2 diabetes AIMP2 cds-synon 17463246 rs10263017 chr7 6065804 G C 1.30E-13 Progranulin levels EIF2AK1 intron 21087763 rs10263017 chr7 6065804 G C 1.30E-13 Myocardial infarction EIF2AK1 intron 21211798 rs2302334 chr7 6075823 A T 3.75E-07 Lymphocyte counts EIF2AK1 intron 22286170 rs2302331 chr7 6078376 A C 1.70E-05 HIV-1 control EIF2AK1 intron 20041166 rs9655492 chr7 6082211 G A 1.70E-05 HIV-1 control EIF2AK1 intron 20041166 rs475323 chr7 6090600 A G 7.87E-04 Response to taxane treatment (placlitaxel) EIF2AK1 intron 23006423 rs627222 chr7 6128455 A G 1.84E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12667392 chr7 6151682 A C 9.77E-06 Alcohol and nictotine co-dependence USP42 intron 20158304 rs6973832 chr7 6178931 G A 1.18E-04 Multiple complex diseases USP42 intron 17554300 rs7803143 chr7 6244486 A G 0.0000157 Aging CYTH3 intron 22445811 rs6962026 chr7 6246523 C T 0.0000207 Aging CYTH3 intron 22445811 rs10085518 chr7 6285515 G A 0.0000459 Aging CYTH3 intron 22445811 rs4724793 chr7 6314766 T C 6.00E-05 Alcoholism (heaviness of drinking) / / 21529783 rs12531066 chr7 6326147 A G 2.13E-05 Alcohol dependence / / 21314694 rs11764399 chr7 6334747 A G 2.55E-05 Cognitive test performance / / 20125193 rs17136143 chr7 6352520 A G 2.53E-04 Multiple complex diseases / / 17554300 rs2113628 chr7 6362978 C A 3.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13244632 chr7 6396719 A G 3.94E-05 Elbow pain / / pha003008 rs2689420 chr7 6410321 A G 4.24E-04 Hemoglobin concentration / / 20534544 rs2689420 chr7 6410321 A G 3.76E-05 Self-reported allergy / / 23817569 rs4724800 chr7 6410528 A G 2.47E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4724800 chr7 6410528 A G 2.24E-05 Myopia (severe) / / 23933737 rs2347338 chr7 6418278 C T 2.42E-04 Suicide attempts in bipolar disorder RAC1 intron 21041247 rs10234438 chr7 6422800 A G 2.45E-04 Suicide attempts in bipolar disorder RAC1 intron 21041247 rs10238136 chr7 6423346 A T 2.44E-04 Suicide attempts in bipolar disorder RAC1 intron 21041247 rs702483 chr7 6426941 C T 2.94E-05 Self-reported allergy RAC1 intron 23817569 rs836483 chr7 6427741 A G 3.85E-05 Self-reported allergy RAC1 intron 23817569 rs836480 chr7 6431404 G T 4.48E-05 Self-reported allergy RAC1 intron 23817569 rs702484 chr7 6431933 C G 4.52E-05 Lung function (forced expiratory volume in 1 second) RAC1 intron 17255346 rs836474 chr7 6434087 G T 5.86E-07 Autism RAC1 intron 22843504 rs836472 chr7 6434904 G A 1.28E-04 Rheumatoid arthritis RAC1 intron 21452313 rs836549 chr7 6439945 A G 9.39E-05 Self-reported allergy RAC1 intron 23817569 rs836551 chr7 6441799 G C 9.89E-05 Self-reported allergy RAC1 intron 23817569 rs836554 chr7 6445235 C T 7.61E-04 Type 2 diabetes / / 17463246 rs836556 chr7 6447041 A G 2.51E-04 Hemoglobin concentration / / 20534544 rs836558 chr7 6447991 C A 2.36E-04 Self-reported allergy / / 23817569 rs836559 chr7 6448763 G C 2.13E-04 Self-reported allergy DAGLB UTR-3 23817569 rs702485 chr7 6449272 A G 5.95E-05 Self-reported allergy DAGLB UTR-3 23817569 rs702485 chr7 6449272 A G 6.00E-12 HDL cholesterol DAGLB UTR-3 24097068 rs2303361 chr7 6449496 T C 1.18E-04 Lung function (forced expiratory volume in 1 second) DAGLB missense 17255346 rs836516 chr7 6462203 A T 1.74E-04 Lung function (forced expiratory volume in 1 second) DAGLB intron 17255346 rs836525 chr7 6465909 C T 4.29E-04 Type 2 diabetes DAGLB intron 17463246 rs836534 chr7 6474073 C T 1.08E-04 Self-reported allergy DAGLB intron 23817569 rs117103601 chr7 6476104 G A 0.000055 Prostate cancer DAGLB missense 23555315 rs13238780 chr7 6481624 G A 2.51E-04 Hemoglobin concentration DAGLB intron 20534544 rs13238780 chr7 6481624 G A 5.09E-05 Self-reported allergy DAGLB intron 23817569 rs1105664 chr7 6567114 A G 4.31E-05 Cognitive performance GRID2IP intron 19734545 rs12538002 chr7 6611333 A G 5.40E-06 Urinary metabolites / / 21572414 rs2254249 chr7 6680674 G C 4.39E-04 IgE levels / / 17255346 rs2243544 chr7 6690270 T C 3.20E-04 IgE levels / / 17255346 rs2243544 chr7 6690270 T C 2.92E-04 Type 2 diabetes / / 17463246 rs2255471 chr7 6716546 C A 7.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs60192221 chr7 6716546 CA C 7.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs10250100 chr7 6720341 A G 1.36E-04 Lymphocyte counts / / 22286170 rs3801033 chr7 6734103 C T 3.20E-04 Suicidal ideation ZNF12 intron 22030708 rs10281898 chr7 6735409 G A 9.96E-04 Iron levels ZNF12 intron pha002876 rs6974325 chr7 6738483 G A 7.64E-04 Type 2 diabetes ZNF12 intron 17463246 rs17789828 chr7 6738637 C A,G,T 3.80E-05 Cognitive function ZNF12 intron 24684796 rs60111824 chr7 6774135 A G 9.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs4602795 chr7 6960802 T C 1.60E-06 Urinary metabolites / / 21572414 rs4074751 chr7 7040176 G T 3.20E-04 Atopy / / 21625490 rs7808194 chr7 7087350 G A 4.09E-05 Cholesterol / / 17255346 rs7793374 chr7 7088289 A T 8.35E-04 Multiple complex diseases / / 17554300 rs4720715 chr7 7111955 T G 8.52E-04 Response to alcohol consumption (flushing response) / / 24277619 rs2205543 chr7 7117650 T G 9.01E-04 Type 2 diabetes / / 17463246 rs2205541 chr7 7117866 C T 1.13E-04 Schizophrenia / / 21747397 rs4720720 chr7 7120438 G T 2.81E-05 Post-operative nausea and vomiting / / 21694509 rs1897414 chr7 7129074 G A 4.80E-05 IgE levels / / 22075330 rs6956689 chr7 7140066 A C 2.83E-04 Aortic root size / / 21223598 rs11971007 chr7 7154887 C T 4.79E-05 Odorant perception / / 23910658 rs6970410 chr7 7156472 C T 1.74E-04 Alcohol dependence / / 24277619 rs1025444 chr7 7178545 G A 5.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs12540582 chr7 7178992 C T 3.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs12535245 chr7 7179208 G T 4.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs12531403 chr7 7185752 C T 4.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs12537214 chr7 7187175 G A 4.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs4724950 chr7 7187491 C A 7.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs4724951 chr7 7187522 A G 3.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs12539444 chr7 7190173 G A 3.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs4724954 chr7 7190734 A G 4.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs16876789 chr7 7192273 C T 4.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs17164001 chr7 7192868 C G 5.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs891809 chr7 7206913 G A 4.36E-04 Alzheimer's disease / / 22005930 rs7790219 chr7 7252114 T G 2.90E-04 Multiple complex diseases C1GALT1 intron 17554300 rs12702595 chr7 7259270 C A 1.00E-06 Serum dimethylarginine levels (symmetric) C1GALT1 intron 24159190 rs12702595 chr7 7259270 C A 6.00E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) C1GALT1 intron 24159190 rs13244913 chr7 7264089 T C 2.01E-06 Serum dimethylarginine levels (symmetric) C1GALT1 intron 24159190 rs13244913 chr7 7264089 T C 4.33E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) C1GALT1 intron 24159190 rs2108783 chr7 7266867 G T 1.15E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) C1GALT1 intron 24159190 rs2108783 chr7 7266867 G T 2.35E-06 Serum dimethylarginine levels (symmetric) C1GALT1 intron 24159190 rs6960832 chr7 7267787 G T 1.40E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) C1GALT1 intron 24159190 rs6960832 chr7 7267787 G T 2.21E-06 Serum dimethylarginine levels (symmetric) C1GALT1 intron 24159190 rs10259085 chr7 7268431 C T 4.00E-06 Multiple sclerosis (severity) C1GALT1 intron 19010793 rs10259085 chr7 7268431 C T 2.17E-05 Suicidal ideation C1GALT1 intron 20877300 rs10259085 chr7 7268431 C T 2.24E-06 Serum dimethylarginine levels (symmetric) C1GALT1 intron 24159190 rs10259085 chr7 7268431 C T 6.87E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) C1GALT1 intron 24159190 rs7787942 chr7 7270012 A T 1.43E-06 Serum dimethylarginine levels (symmetric) C1GALT1 intron 24159190 rs7787942 chr7 7270012 A T 2.55E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) C1GALT1 intron 24159190 rs7791957 chr7 7270034 T C 1.43E-06 Serum dimethylarginine levels (symmetric) C1GALT1 intron 24159190 rs7791957 chr7 7270034 T C 2.55E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) C1GALT1 intron 24159190 rs7778301 chr7 7292458 A G 8.66E-04 White matter integrity / / 22425255 rs10279324 chr7 7296520 G C 8.00E-04 Multiple complex diseases / / 17554300 rs1299548 chr7 7302293 G A 4.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs10280773 chr7 7304142 C T 2.06E-04 White matter integrity / / 22425255 rs41356247 chr7 7307271 T G 9.08E-05 Multiple complex diseases / / 17554300 rs10487592 chr7 7307465 A G 6.00E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs6970785 chr7 7309566 C A 5.49E-05 Cardiovascular disease / / pha003064 rs1294658 chr7 7310023 G A 3.13E-04 Rheumatoid arthritis / / 21452313 rs1294656 chr7 7311593 T C 5.21E-05 Cardiovascular disease / / pha003065 rs1294654 chr7 7312086 C A 4.74E-04 Rheumatoid arthritis / / 21452313 rs1796120 chr7 7313044 G T 1.88E-04 Rheumatoid arthritis / / 21452313 rs6973768 chr7 7313294 T G 7.43E-06 Smooth-surface caries / / 24556642 rs6953213 chr7 7313485 G A 6.00E-06 Smooth-surface caries / / 24556642 rs1796118 chr7 7315733 C T 2.18E-04 Multiple complex diseases / / 17554300 rs1638210 chr7 7317960 T C 7.39E-04 Premature ovarian failure / / 19508998 rs2141911 chr7 7328775 G A 5.82E-04 Premature ovarian failure / / 19508998 rs1317198 chr7 7333294 C T 9.56E-05 Lipid levels / / pha003082 rs17166197 chr7 7335868 G A 0.00005 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17166197 chr7 7335868 G A 5.00E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6950430 chr7 7336294 C T 5.97E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs4724969 chr7 7342609 A G 9.29E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10486156 chr7 7348633 C T 2.15E-06 Behcet's disease / / 23291587 rs10486156 chr7 7348633 C T 3.69E-06 Behcet's disease / / pha002888 rs719423 chr7 7355115 G C 5.22E-04 Multiple complex diseases / / 17554300 rs2881814 chr7 7364390 A G 4.12E-05 Bipolar disorder and schizophrenia / / 20889312 rs2881814 chr7 7364390 A G 4.90E-05 Bipolar Disorder / / pha002858 rs1294610 chr7 7365657 T C 8.05E-05 Bipolar disorder and schizophrenia / / 20889312 rs6955140 chr7 7374823 T C 1.30E-05 Bipolar disorder and schizophrenia / / 20889312 rs6955140 chr7 7374823 T C 4.99E-05 Bipolar Disorder / / pha002858 rs1294622 chr7 7392714 T C 8.02E-05 Bipolar disorder and schizophrenia / / 20889312 rs1294623 chr7 7392861 A G 3.62E-05 Bipolar disorder and schizophrenia / / 20889312 rs977432 chr7 7397843 C T 3.34E-05 Bipolar disorder and schizophrenia / / 20889312 rs2159710 chr7 7399096 T G 6.82E-06 Bipolar disorder and schizophrenia COL28A1 intron 20889312 rs2159710 chr7 7399096 T G 5.50E-05 Bipolar Disorder COL28A1 intron pha002858 rs10486158 chr7 7399404 C T 8.51E-05 Bipolar disorder COL28A1 intron 19488044 rs10486158 chr7 7399404 C T 6.00E-06 Bipolar disorder and schizophrenia COL28A1 intron 20889312 rs10486158 chr7 7399404 C T 3.39E-05 Bipolar Disorder COL28A1 intron pha002858 rs7800159 chr7 7401954 T G 5.82E-05 Bipolar disorder COL28A1 intron 19488044 rs7800159 chr7 7401954 T G 9.53E-06 Bipolar disorder and schizophrenia COL28A1 intron 20889312 rs7800159 chr7 7401954 T G 2.22E-05 Acne (severe teenage) COL28A1 intron 24114350 rs7800159 chr7 7401954 T G 2.42E-05 Bipolar Disorder COL28A1 intron pha002858 rs10952053 chr7 7402150 A T 2.21E-05 Acne (severe teenage) COL28A1 intron 24114350 rs4724977 chr7 7403015 T C 3.78E-05 Bipolar disorder COL28A1 intron 19488044 rs4724977 chr7 7403015 T C 1.81E-05 Bipolar disorder and schizophrenia COL28A1 intron 20889312 rs4724977 chr7 7403015 T C 1.60E-05 Urinary metabolites COL28A1 intron 21572414 rs4724977 chr7 7403015 T C 1.78E-05 Bipolar Disorder COL28A1 intron pha002858 rs6974119 chr7 7403978 A G 4.93E-05 Bipolar disorder and schizophrenia COL28A1 intron 20889312 rs6960947 chr7 7410988 T C 4.63E-05 Bipolar disorder and schizophrenia COL28A1 intron 20889312 rs182575990 chr7 7412808 C T 0.00069 Prostate cancer COL28A1 missense 23555315 rs1294651 chr7 7415217 C T 4.90E-06 Urinary metabolites COL28A1 intron 21572414 rs1294625 chr7 7420613 T C 2.78E-05 Sodium levels COL28A1 intron pha003093 rs1294626 chr7 7421019 C A 5.28E-05 Bipolar disorder and schizophrenia COL28A1 intron 20889312 rs1294632 chr7 7424599 T C 3.79E-05 Bipolar disorder and schizophrenia COL28A1 intron 20889312 rs6962404 chr7 7442169 A C 2.37E-05 Rheumatoid arthritis COL28A1 intron 21452313 rs17151541 chr7 7461319 C T 5.16E-04 Parkinson's disease COL28A1 intron 16252231 rs17167625 chr7 7468774 C T 9.12E-04 Parkinson's disease COL28A1 intron 16252231 rs10486164 chr7 7492175 A G 6.91E-04 Amyotrophic Lateral Sclerosis COL28A1 intron 17362836 rs10486179 chr7 7560833 G A 3.00E-06 Statin-induced myopathy COL28A1 intron 21826682 rs17168526 chr7 7571420 T C 6.00E-08 Immune reponse to smallpox (secreted IL-1beta) COL28A1 cds-synon 22610502 rs13438746 chr7 7575662 T C 0.000797 Salmonella-induced pyroptosis / / 22837397 rs17168704 chr7 7604076 C G 6.40E-04 Addiction / / 17099884 rs6463703 chr7 7628579 A G 9.30E-05 Response to statin therapy MIOS intron 20339536 rs1476647 chr7 7659745 T G 1.63E-05 Statin-induced myopathy / / 21826682 rs13229270 chr7 7670718 C A 6.52E-05 Cholesterol / / 17255346 rs11773681 chr7 7671662 A G 2.06E-04 Aortic root size / / 21223598 rs17169194 chr7 7680697 A C 1.40E-04 Renal function-related traits (urea) LOC729852 intron 22797727 rs10230651 chr7 7688023 C T 7.57E-05 Cognitive test performance RPA3 intron 20125193 rs7781054 chr7 7703374 G T 5.06E-04 Multiple complex diseases RPA3 intron 17554300 rs7800719 chr7 7703401 A G 7.22E-04 Multiple complex diseases RPA3 intron 17554300 rs1012997 chr7 7703579 A C 1.11E-05 Myocardial Infarction RPA3 intron pha002873 rs1557997 chr7 7703960 G A 4.60E-05 Alcohol consumption (maxi-drinks) RPA3 intron 24277619 rs1557997 chr7 7703960 G A 6.02E-05 Cholesterol RPA3 intron pha003073 rs1557997 chr7 7703960 G A 1.69E-05 ldl cholesterol RPA3 intron pha003076 rs1557997 chr7 7703960 G A 4.22E-05 Cholesterol RPA3 intron pha003078 rs13231388 chr7 7711883 C T 5.36E-04 Multiple complex diseases RPA3 intron 17554300 rs10264890 chr7 7719987 T G 3.47E-04 Alcohol consumption (maxi-drinks) RPA3 intron 24277619 rs4720751 chr7 7769363 G A 1.20E-04 Alcohol consumption (maxi-drinks) LOC729852 intron 24277619 rs4720752 chr7 7769440 C T 0.0000193 Aging LOC729852 intron 22445811 rs11971584 chr7 7770203 C T 9.42E-05 Elbow pain LOC729852 intron pha003008 rs13237260 chr7 7779091 G T 3.00E-05 Alcohol consumption (maxi-drinks) LOC729852 intron 24277619 rs10486187 chr7 7779324 T C 1.10E-05 Alcohol consumption (maxi-drinks) LOC729852 intron 24277619 rs10486187 chr7 7779324 T C 1.66E-04 Amyotrophic lateral sclerosis (sporadic) LOC729852 intron 24529757 rs10486187 chr7 7779324 T C 4.99E-06 Smooth-surface caries LOC729852 intron 24556642 rs10486187 chr7 7779324 T C 5.00E-06 Smooth-surface caries LOC729852 intron 24556642 rs2024372 chr7 7782919 G A 2.00E-05 Alcohol consumption (maxi-drinks) LOC729852 intron 24277619 rs11984316 chr7 7787006 G A 4.59E-06 Cholesterol LOC729852 intron pha003073 rs11984316 chr7 7787006 G A 3.64E-05 ldl cholesterol LOC729852 intron pha003076 rs11984316 chr7 7787006 G A 1.82E-05 Cholesterol LOC729852 intron pha003078 rs1541549 chr7 7788142 T C 6.37E-05 Glucose levels LOC729852 intron pha003057 rs17137257 chr7 7792702 A G 9.10E-04 Response to alcohol consumption (flushing response) LOC729852 intron 24277619 rs11982195 chr7 7796886 C T 5.00E-05 Prostate cancer LOC729852 intron 21743057 rs7357092 chr7 7810122 A G 4.60E-05 Blood pressure LOC729852 intron 21228793 rs7357092 chr7 7810122 A G 7.90E-04 Blood pressure LOC729852 intron 21228793 rs10278342 chr7 7834469 A G 1.39E-04 Alzheimer's disease (late onset) LOC729852 intron 21379329 rs12671658 chr7 7842281 G T 6.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC729852 intron 20877124 rs7801961 chr7 7846920 G A 5.92E-04 Premature ovarian failure LOC729852 intron 19508998 rs10259199 chr7 7848912 T C 2.00E-06 Obesity-related traits LOC729852 intron 23251661 rs4725033 chr7 7854008 C T 4.69E-05 Cleft lip LOC729852 intron 20436469 rs4725033 chr7 7854008 C T 1.40E-05 Orofacial clefts LOC729852 intron 22863734 rs12702661 chr7 7864751 A G 1.32E-04 Rheumatoid arthritis LOC729852 intron 21452313 rs12702661 chr7 7864751 A G 2.00E-06 Obesity-related traits LOC729852 intron 23251661 rs1473213 chr7 7868752 C G 9.65E-04 Multiple complex diseases LOC729852 intron 17554300 rs10277940 chr7 7881021 G C 7.54E-07 Multiple complex diseases LOC729852 intron 17554300 rs7780564 chr7 7883323 A C 4.00E-07 Insulin-like growth factors LOC729852 intron 21216879 rs13241138 chr7 7888710 A C 7.05E-05 Lung adenocarcinoma LOC729852 intron 19836008 rs7803807 chr7 7892857 A C 8.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC729852 intron 20877124 rs2348763 chr7 7897715 A C 9.00E-05 Prostate cancer LOC729852 intron 21743057 rs7790025 chr7 7901510 T G 6.24E-05 Hemoglobin LOC729852 intron pha003096 rs6463730 chr7 7902171 A G 7.83E-05 Lung adenocarcinoma LOC729852 intron 19836008 rs7808919 chr7 7902687 C A 8.70E-04 Alzheimer's disease LOC729852 intron 17998437 rs2109971 chr7 7906204 T C 9.53E-05 Hemoglobin LOC729852 intron pha003096 rs11971467 chr7 7930535 T G 5.32E-04 Alzheimer's disease / / 24755620 rs17139306 chr7 7934974 A G 2.27E-04 Alzheimer's disease / / 17998437 rs7785709 chr7 7938344 G A 9.64E-05 Hearing function / / 17255346 rs10486201 chr7 7938596 C T 6.00E-06 Obesity-related traits / / 23251661 rs13239267 chr7 7941084 A G 2.10E-06 Urinary metabolites / / 21572414 rs12702677 chr7 7949890 G A 9.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs12702677 chr7 7949890 G A 1.00E-05 Urinary metabolites / / 21572414 rs732052 chr7 7952842 A G 2.56E-04 Alzheimer's disease (late onset) / / 21379329 rs6950643 chr7 7954298 A G 9.15E-04 Alzheimer's disease / / 24755620 rs6463749 chr7 7957841 C A 9.77E-04 Type 2 diabetes / / 17463246 rs6463749 chr7 7957841 C A 2.30E-05 Urinary metabolites / / 21572414 rs6975902 chr7 7964238 A G 3.53E-04 Alzheimer's disease (late onset) / / 21379329 rs7796084 chr7 7970560 G A 2.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7779286 chr7 7976243 A G 7.80E-04 Alcohol dependence / / 20201924 rs7779286 chr7 7976243 A G 4.97E-04 Alzheimer's disease (late onset) / / 21379329 rs16872207 chr7 7990477 C T 6.48E-04 Coronary Artery Disease LOC100505921 intron 17634449 rs37972 chr7 8007509 T C 7.00E-04 Response to glucocorticoid therapy in asthma GLCCI1 nearGene-5 21991891 rs37973 chr7 8007876 G A 7.00E-04 Response to glucocorticoid therapy in asthma GLCCI1 nearGene-5 21991891 rs37984 chr7 8021726 A G 8.01E-04 Type 2 diabetes GLCCI1 intron 17846125 rs37997 chr7 8032205 G C 7.52E-04 Body mass index GLCCI1 intron 21701565 rs37997 chr7 8032205 G C 8.52E-04 Body mass index GLCCI1 intron 21701565 rs17141865 chr7 8054779 C G 5.89E-06 White blood cell count GLCCI1 intron 21738479 rs10278726 chr7 8064509 T C 8.56E-04 Body mass index GLCCI1 intron 21701565 rs13223776 chr7 8071024 C A 6.49E-05 Cognitive impairment induced by topiramate GLCCI1 intron 22091778 rs9648623 chr7 8098140 G A 4.15E-05 Neuroblastoma GLCCI1 intron pha002895 rs1990368 chr7 8123650 G T 9.40E-04 Multiple complex diseases GLCCI1 intron 17554300 rs7795506 chr7 8128944 G T 9.96E-05 Bipolar disorder GLCCI1 nearGene-3 20451256 rs17401720 chr7 8131828 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17143021 chr7 8133429 C T 4.99E-04 Type 2 diabetes / / 17463246 rs7791362 chr7 8142927 T C 4.00E-06 Cognitive function / / 24684796 rs13227590 chr7 8150990 A G 8.25E-08 Intraocular pressure / / 23836780 rs59072263 chr7 8152067 G T 1.00E-08 Intraocular pressure / / 23836780 rs6463768 chr7 8157887 C G 1.00E-06 Metabolite levels (Pyroglutamine) ICA1 intron 23934736 rs4725072 chr7 8174587 A C 1.55E-05 Systemic lupus erythematosus and Systemic sclerosis ICA1 intron 23740937 rs2192346 chr7 8176301 G A 4.67E-06 Vitiligo ICA1 intron 22561518 rs17143586 chr7 8177397 C A 1.00E-06 Obesity-related traits ICA1 intron 23251661 rs2110333 chr7 8185089 C T 9.63E-05 Vitiligo ICA1 intron 22561518 rs10156091 chr7 8187094 T C 1.90E-07 Systemic lupus erythematosus ICA1 intron 18204446 rs2110334 chr7 8198622 G A 3.92E-04 Multiple complex diseases ICA1 intron 17554300 rs7802863 chr7 8233942 A G 5.60E-04 Multiple complex diseases ICA1 intron 17554300 rs1861032 chr7 8268155 T C 1.52E-05 Type 2 diabetes ICA1 intron 17463246 rs7805508 chr7 8269234 T C 8.80E-06 Type 2 diabetes ICA1 intron 17463246 rs6977682 chr7 8269678 T C 8.43E-04 Type 2 diabetes ICA1 intron 17463246 rs17145897 chr7 8269856 A C 9.85E-04 Multiple complex diseases ICA1 intron 17554300 rs17330771 chr7 8272692 A G 9.79E-04 Type 2 diabetes ICA1 intron 17463246 rs6972567 chr7 8309993 A C 6.81E-06 Response to tocilizumab in rheumatoid arthritis LOC100505938 intron 22491018 rs9640065 chr7 8312186 C A 5.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100505938 intron 20877124 rs7801871 chr7 8327061 A G 7.30E-05 Coronary heart disease LOC100505938 intron pha003033 rs7797010 chr7 8329762 G T 9.17E-04 Alcohol dependence LOC100505938 intron 24277619 rs10239677 chr7 8362456 G A 5.63E-05 Chronic Hepatitis C infection LOC100505938 intron 21725309 rs11768767 chr7 8365765 C T 8.90E-05 Bipolar disorder LOC100505938 intron 20451256 rs17147491 chr7 8370732 C T 4.70E-04 Response to taxane treatment (placlitaxel) LOC100505938 intron 23006423 rs4720777 chr7 8424851 C G 7.37E-05 Bipolar disorder / / 20451256 rs10268602 chr7 8425796 G C 3.11E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10259079 chr7 8426538 A G 2.26E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2349188 chr7 8444463 T C 8.60E-05 Schizophrenia / / 20185149 rs6463805 chr7 8447955 C T 4.16E-05 Schizophrenia / / 20185149 rs6463806 chr7 8457353 T C 8.70E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10252468 chr7 8458768 C A 8.70E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6978943 chr7 8485926 G C 9.90E-06 Urinary metabolites NXPH1 intron 21572414 rs10270530 chr7 8488691 T C 8.70E-06 Urinary metabolites NXPH1 intron 21572414 rs7795595 chr7 8489378 C A 1.10E-05 Urinary metabolites NXPH1 intron 21572414 rs4725092 chr7 8492840 G A 9.50E-06 Urinary metabolites NXPH1 intron 21572414 rs17404198 chr7 8509884 A C 2.10E-07 Urinary metabolites NXPH1 intron 21572414 rs6463813 chr7 8510243 G A 2.50E-05 Urinary metabolites NXPH1 intron 21572414 rs17149337 chr7 8510412 G T 4.90E-07 Urinary metabolites NXPH1 intron 21572414 rs17404218 chr7 8510644 T G 2.00E-07 Urinary metabolites NXPH1 intron 21572414 rs12667662 chr7 8510964 A C 4.92E-04 Response to taxane treatment (placlitaxel) NXPH1 intron 23006423 rs11976158 chr7 8512414 T C 3.90E-07 Urinary metabolites NXPH1 intron 21572414 rs41335449 chr7 8517766 T C 1.90E-05 Urinary metabolites NXPH1 intron 21572414 rs7803097 chr7 8521576 T C 3.20E-06 Urinary metabolites NXPH1 intron 21572414 rs10244428 chr7 8521943 C T 2.27E-05 Migraine NXPH1 intron 23793025 rs10273122 chr7 8522066 G A 2.40E-05 Urinary metabolites NXPH1 intron 21572414 rs10244689 chr7 8522190 C A 9.83E-04 Multiple complex diseases NXPH1 intron 17554300 rs10244689 chr7 8522190 C A 1.20E-06 Urinary metabolites NXPH1 intron 21572414 rs10265438 chr7 8527868 T C 6.40E-07 Urinary metabolites NXPH1 intron 21572414 rs6978212 chr7 8532844 C T 6.87E-05 Type 2 diabetes NXPH1 intron 17463246 rs757705 chr7 8540295 A G 2.79E-05 Type 2 diabetes NXPH1 intron 17846124 rs757705 chr7 8540295 A G 2.80E-05 Type 2 diabetes NXPH1 intron 21647700 rs757705 chr7 8540295 A G 8.16E-05 Tunica Media NXPH1 intron pha003034 rs2349485 chr7 8550956 G T 1.13E-04 Breast Cancer in BRCA1 mutation carriers NXPH1 intron 23544013 rs2349485 chr7 8550956 G T 7.38E-04 Breast Cancer in BRCA1 mutation carriers NXPH1 intron 23544013 rs2349485 chr7 8550956 G T 9.74E-06 Breast Cancer in BRCA1 mutation carriers NXPH1 intron 23544013 rs929337 chr7 8551854 T C 9.00E-06 Urinary metabolites NXPH1 intron 21572414 rs765855 chr7 8552614 A G 8.80E-06 Urinary metabolites NXPH1 intron 21572414 rs765855 chr7 8552614 A G 2.39E-05 Breast Cancer in BRCA1 mutation carriers NXPH1 intron 23544013 rs765855 chr7 8552614 A G 3.47E-04 Breast Cancer in BRCA1 mutation carriers NXPH1 intron 23544013 rs765855 chr7 8552614 A G 4.00E-06 Breast Cancer in BRCA1 mutation carriers NXPH1 intron 23544013 rs765855 chr7 8552614 A G 4.25E-06 Breast Cancer in BRCA1 mutation carriers NXPH1 intron 23544013 rs4401754 chr7 8557562 A T 8.34E-04 Type 2 diabetes NXPH1 intron 17463246 rs2040765 chr7 8561945 T C 3.79E-09 Narcolepsy NXPH1 intron 19629137 rs17150761 chr7 8575468 T G 7.80E-04 Type 2 diabetes NXPH1 intron 17463246 rs12667696 chr7 8580081 C T 1.00E-04 Prostate cancer NXPH1 intron 21743057 rs7812117 chr7 8588980 T G 2.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NXPH1 intron 20877124 rs7812117 chr7 8588980 T G 5.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NXPH1 intron 20877124 rs6956624 chr7 8604037 T G 8.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NXPH1 intron 20877124 rs2107280 chr7 8623714 A G 2.75E-06 Vitiligo NXPH1 intron 22561518 rs17151821 chr7 8628491 C G 1.05E-05 Attention deficit hyperactivity disorder NXPH1 intron 20732627 rs10249831 chr7 8628692 C T 6.45E-06 Vitiligo NXPH1 intron 22561518 rs12531005 chr7 8633332 A G 3.33E-05 Suicidal ideation NXPH1 intron 20877300 rs2107281 chr7 8636552 C T 1.19E-05 Attention deficit hyperactivity disorder NXPH1 intron 20732627 rs10251121 chr7 8641365 G A 8.36E-06 Obesity-related traits NXPH1 intron 23251661 rs10245124 chr7 8642354 T C 8.00E-06 Obesity-related traits NXPH1 intron 23251661 rs10226061 chr7 8692971 T C 4.00E-06 Amyotrophic Lateral Sclerosis NXPH1 intron 17362836 rs6955715 chr7 8704698 C T 4.00E-06 Amyotrophic Lateral Sclerosis NXPH1 intron 17362836 rs4725116 chr7 8712304 G A 8.20E-06 Amyotrophic Lateral Sclerosis NXPH1 intron 17362836 rs2349775 chr7 8718080 G A 7.00E-06 Neuroticism NXPH1 intron 18762592 rs1013812 chr7 8722688 G A 3.32E-05 Neuroblastoma NXPH1 intron pha002895 rs11536481 chr7 8739365 T C 3.33E-04 Response to taxane treatment (placlitaxel) NXPH1 intron 23006423 rs7782816 chr7 8740362 C T 2.75E-04 Lung function (forced expiratory volume in 1 second) NXPH1 intron 24023788 rs7782816 chr7 8740362 C T 2.05E-04 Alcohol consumption (maxi-drinks) NXPH1 intron 24277619 rs10253965 chr7 8742481 C T 5.41E-05 Pancreatic cancer NXPH1 intron pha002889 rs1017002 chr7 8751432 C T 3.53E-05 Body mass (lean) NXPH1 intron 19268274 rs4141002 chr7 8757367 C T 4.18E-06 Odorant perception NXPH1 intron 23910658 rs13228947 chr7 8758381 A G 9.41E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NXPH1 intron 20877124 rs12234501 chr7 8772150 C T 1.19E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NXPH1 intron 20877124 rs886505 chr7 8786057 A G 7.40E-06 Response to antidepressants NXPH1 intron 19736353 rs9791867 chr7 8793212 G C 0.000056 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9791870 chr7 8793237 G C 0.0000597 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs994247 chr7 8800568 C T 5.68E-06 Alcohol and nictotine co-dependence / / 20158304 rs9655529 chr7 8828827 C A,T 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs10255712 chr7 8833684 T C 5.00E-05 Diabetes Mellitus / / pha003059 rs10255712 chr7 8833684 T C 1.53E-05 Diabetes Mellitus / / pha003060 rs10245651 chr7 8859094 G A 2.00E-05 Asthma / / pha003127 rs10486260 chr7 8859616 C T 1.97E-04 IgE levels / / 17255346 rs17156505 chr7 8890921 A G 7.70E-04 Multiple complex diseases / / 17554300 rs17156520 chr7 8894102 A G 3.68E-04 Multiple complex diseases / / 17554300 rs1859416 chr7 8899901 A G 5.11E-05 Platelet counts / / pha003100 rs1859417 chr7 8900124 T C 2.49E-05 Platelet counts / / pha003100 rs17156538 chr7 8900417 G T 5.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs6951882 chr7 8925788 A G 3.30E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs11769910 chr7 8941632 T C 7.47E-04 Multiple complex diseases / / 17554300 rs12702792 chr7 8947176 G C 8.09E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10266202 chr7 8957041 C T 3.89E-05 Periodontitis (Chronic) / / 25008200 rs17157252 chr7 8962033 T C 6.71E-04 Alzheimer's disease / / 17998437 rs17157288 chr7 8967562 T G 2.87E-05 Type 2 diabetes / / 17463246 rs12702806 chr7 8985897 T C 0.00008789 Sarcoidosis / / 22952805 rs17157663 chr7 8998976 G A 9.00E-06 Quantitative traits / / 19197348 rs17157706 chr7 9002588 A G 8.00E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6959898 chr7 9010322 A G 5.36E-05 Alcohol dependence / / 19581569 rs17157938 chr7 9017053 G C 4.60E-04 Depression (quantitative trait) / / 20800221 rs4720814 chr7 9019746 T G 8.58E-05 Schizophrenia / / 24253340 rs4720815 chr7 9019826 A G 8.11E-05 Schizophrenia / / 24253340 rs10255740 chr7 9032295 G A 2.14E-05 Sleep duration / / 22105623 rs7792941 chr7 9064295 T C 0.000000579 HDL cholesterol particle diameter / / 23263444 rs7792941 chr7 9064295 T C 0.00000311 LDL cholesterol particle diameter / / 23263444 rs10952132 chr7 9066820 C T 1.00E-06 Response to fenofibrate / / 22890011 rs10952132 chr7 9066820 C T 7.00E-06 Response to fenofibrate / / 22890011 rs10952132 chr7 9066820 C T 2.49E-08 LDL cholesterol particle diameter / / 23263444 rs10952132 chr7 9066820 C T 3.95E-08 HDL cholesterol particle diameter / / 23263444 rs10952133 chr7 9066992 A G 9.83E-08 LDL cholesterol particle diameter / / 23263444 rs13233490 chr7 9070269 G C 7.29E-05 Bipolar disorder / / 19488044 rs13233490 chr7 9070269 G C 4.27E-05 Bipolar Disorder / / pha002858 rs543113560 chr7 9070269 GT G 7.29E-05 Bipolar disorder / / 19488044 rs543113560 chr7 9070269 GT G 4.27E-05 Bipolar Disorder / / pha002858 rs1030008 chr7 9072385 T C 2.80E-06 Amyotrophic Lateral Sclerosis / / 17362836 rs6959833 chr7 9073940 G T 4.00E-06 Amyotrophic Lateral Sclerosis / / 17362836 rs12537711 chr7 9074621 G A 0.000000154 HDL cholesterol particle diameter / / 23263444 rs12537711 chr7 9074621 G A 0.000000721 LDL cholesterol particle diameter / / 23263444 rs17158578 chr7 9076120 G C 7.74E-05 Bipolar Disorder / / pha002858 rs245661 chr7 9078789 G C 0.0000135 HDL cholesterol particle diameter / / 23263444 rs11983119 chr7 9081052 A G 0.00000023 HDL cholesterol particle diameter / / 23263444 rs11983119 chr7 9081052 A G 0.00000169 LDL cholesterol particle diameter / / 23263444 rs6463871 chr7 9087523 T C 0.000000167 HDL cholesterol particle diameter / / 23263444 rs6463871 chr7 9087523 T C 0.0000011 LDL cholesterol particle diameter / / 23263444 rs10247883 chr7 9108917 A G 9.86E-04 Alzheimer's disease / / 22005930 rs10247883 chr7 9108917 A G 5.66E-07 Delayed encephalopathy in acute carbon monoxide poisoning / / 24265751 rs10247883 chr7 9108917 A G 7.16E-07 Delayed encephalopathy in acute carbon monoxide poisoning / / 24265751 rs11514814 chr7 9138376 T C 2.25E-06 Uric acid levels / / 21294900 rs2079324 chr7 9140237 A G 2.25E-06 Uric acid levels / / 21294900 rs10269163 chr7 9140684 G A 2.65E-06 Uric acid levels / / 21294900 rs737714 chr7 9187294 G A 8.12E-06 Obesity-related traits / / 23251661 rs1371737 chr7 9189541 A C 7.00E-06 Obesity-related traits / / 23251661 rs10243151 chr7 9197737 A G 9.49E-06 Obesity-related traits / / 23251661 rs414660 chr7 9212201 T C 6.78E-05 Coronary Artery Disease / / 17634449 rs387523 chr7 9214103 G A 1.34E-04 Coronary Artery Disease / / 17634449 rs2057847 chr7 9215329 G A 4.99E-04 Schizophrenia / / 19197363 rs1285441 chr7 9219283 A C 0.0000052 Alpha-2-adrenoceptor-mediated vasoconstriction / / 23337848 rs1149540 chr7 9222776 A T 2.10E-05 Urinary metabolites / / 21572414 rs17203026 chr7 9234364 C T 1.14E-04 Substance dependence / / 21818250 rs10241701 chr7 9237526 A G 6.72E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs10499349 chr7 9245563 T A 8.25E-04 Body mass index / / 21701565 rs4720829 chr7 9247266 T C 2.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs1285407 chr7 9266388 T C 1.00E-06 Protein quantitative trait loci / / 18464913 rs1529233 chr7 9274493 A C 6.80E-05 Serum metabolites / / 19043545 rs1285434 chr7 9277269 G A 5.16E-04 Body mass index / / 21701565 rs7777070 chr7 9283620 G A 7.26E-04 Schizophrenia / / 19197363 rs12702875 chr7 9301716 G A 2.00E-04 Information processing speed / / 21130836 rs1919796 chr7 9323220 G A 6.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs6963754 chr7 9325970 C T 1.00E-04 Information processing speed / / 21130836 rs10253855 chr7 9341294 A G 1.04E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11773271 chr7 9387898 A C 6.41E-06 Neuroblastoma / / pha002895 rs12702896 chr7 9391363 A G 2.20E-05 Urinary metabolites / / 21572414 rs10952163 chr7 9404231 A G 8.59E-05 Waist-Hip Ratio / / pha003013 rs7801195 chr7 9435781 A G 6.10E-04 Type 2 diabetes / / 17463246 rs4509227 chr7 9447340 T C 2.70E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2350850 chr7 9534124 T C 5.82E-04 Taste perception / / 22132133 rs9918582 chr7 9537201 G A 4.72E-05 Hippocampal atrophy / / 19668339 rs9918508 chr7 9539279 C T 8.00E-06 Hippocampal atrophy / / 19668339 rs6968065 chr7 9539416 C G 5.65E-04 Multiple complex diseases / / 17554300 rs17161703 chr7 9540039 C A 6.88E-04 Multiple complex diseases / / 17554300 rs2713339 chr7 9548713 C A 8.85E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2709057 chr7 9548858 A G 1.00E-05 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs12702919 chr7 9550572 A C 5.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs10237257 chr7 9553854 G A 9.48E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs10499358 chr7 9554682 C T 5.42E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10499358 chr7 9554682 C T 4.40E-05 Basophils / / pha003087 rs2350862 chr7 9556555 A C 7.90E-05 Cognitive impairment induced by topiramate / / 22091778 rs4548084 chr7 9559594 G C 5.48E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs10452828 chr7 9559709 T G 5.47E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs1505310 chr7 9567524 G A 2.20E-06 Urinary metabolites / / 21572414 rs10245938 chr7 9569435 A G 6.78E-05 Serum metabolites / / 19043545 rs12113085 chr7 9569847 G C 3.88E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6463923 chr7 9571002 A G 1.00E-06 Smoking behavior / / 20418888 rs6463923 chr7 9571002 A G 1.23E-04 Rheumatoid arthritis (ACPA-negative) / / 24532677 rs10499360 chr7 9587425 G C 5.42E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2089220 chr7 9594985 A G 7.20E-05 Serum metabolites / / 19043545 rs4639407 chr7 9620759 G A 9.78E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10085496 chr7 9662807 A G 9.30E-05 Coronary heart disease / / pha003031 rs10236139 chr7 9667148 T C 3.13E-04 Multiple complex diseases / / 17554300 rs2882606 chr7 9667987 C T 6.25E-04 Response to TNF antagonist treatment / / 21061259 rs11978724 chr7 9669570 G A 7.42E-05 Cognitive impairment induced by topiramate / / 22091778 rs1505337 chr7 9687056 C T 1.07E-10 Metabolite levels / / 23281178 rs1394777 chr7 9687367 C T 1.07E-10 Metabolite levels / / 23281178 rs1394778 chr7 9687570 C T 4.91E-11 Metabolite levels / / 23281178 rs1394779 chr7 9687788 G A 1.07E-10 Metabolite levels / / 23281178 rs7796062 chr7 9694577 T G 2.99E-08 Metabolite levels / / 23281178 rs7784720 chr7 9697132 C G 1.51E-09 Metabolite levels / / 23281178 rs1033271 chr7 9709404 A C 1.98E-09 Metabolite levels / / 23281178 rs6973468 chr7 9711631 G T 6.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs1394773 chr7 9711981 G C,T 3.90E-06 Urinary metabolites / / 21572414 rs11764744 chr7 9713606 G A 4.91E-08 Metabolite levels / / 23281178 rs7800902 chr7 9715962 C G 3.58E-04 Type 2 diabetes / / 17463246 rs12056222 chr7 9739637 A C 4.39E-08 Metabolite levels / / 23281178 rs2138068 chr7 9740594 G A 4.39E-08 Metabolite levels / / 23281178 rs667922 chr7 9744833 T C 1.09E-05 Type 2 diabetes / / 17463246 rs318998 chr7 9855968 G C 8.24E-04 Multiple complex diseases / / 17554300 rs1639722 chr7 9886949 G T 1.30E-05 Urinary metabolites / / 21572414 rs1514882 chr7 9891469 C G 4.29E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs728260 chr7 9903357 G A 2.00E-05 Alcoholism (heaviness of drinking) / / 21529783 rs2915125 chr7 9906710 T C 2.50E-05 Alcoholism (heaviness of drinking) / / 21529783 rs17201398 chr7 9924758 A G 3.94E-05 Heart Rate / / pha003051 rs2915131 chr7 9926030 T C 2.00E-05 Alcoholism (heaviness of drinking) / / 21529783 rs1557978 chr7 9965912 T C 1.73E-04 Bone mass and geometry / / 17903296 rs1557978 chr7 9965912 T C 7.10E-05 Alcoholism (heaviness of drinking) / / 21529783 rs1016019 chr7 9978539 G T 1.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1016019 chr7 9978539 G T 4.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17162294 chr7 10003616 C T 1.39E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2906399 chr7 10069073 G A 4.02E-04 Alzheimer's disease / / 22005930 rs12333521 chr7 10081250 T C 5.97E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs41426 chr7 10096276 G A 4.13E-04 Schizophrenia / / 19197363 rs6463967 chr7 10122140 C G 1.89E-04 Arthritis (juvenile idiopathic) / / 22354554 rs7798735 chr7 10146577 C T 5.40E-04 Atrial fibrillation / / 21846873 rs7778619 chr7 10149976 C G 3.00E-06 Select biomarker traits / / 17903293 rs17162693 chr7 10172649 A G 9.58E-04 Alzheimer's disease / / 24755620 rs13240249 chr7 10185972 C T 2.38E-04 Alzheimer's disease (late onset) / / 21379329 rs13240249 chr7 10185972 C T 6.65E-04 Smoking quantity / / 24665060 rs12534108 chr7 10186070 G C 2.48E-05 Major depressive disorder / / 21621269 rs222324 chr7 10235811 G C 5.60E-04 Type 2 diabetes / / 17846124 rs2107809 chr7 10246371 A G 5.70E-05 Acute lung injury / / 22295056 rs6959382 chr7 10260962 T C 9.21E-05 Acute lung injury / / 22295056 rs17162797 chr7 10263846 C G 4.89E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7809395 chr7 10266858 C A 8.19E-05 Acute lung injury / / 22295056 rs2107813 chr7 10271915 C T 7.67E-04 Acute lung injury / / 22295056 rs10263113 chr7 10273150 C G 6.88E-04 Acute lung injury / / 22295056 rs7791960 chr7 10275598 C T 6.79E-04 Acute lung injury / / 22295056 rs2189956 chr7 10275796 G A 6.79E-04 Acute lung injury / / 22295056 rs3922335 chr7 10275979 C T 5.06E-04 Acute lung injury / / 22295056 rs3922335 chr7 10275979 C T 0.000348226 Hypertension (early onset hypertension) / / 22479346 rs2017532 chr7 10276673 A G 5.06E-04 Acute lung injury / / 22295056 rs2017532 chr7 10276673 A G 0.000348226 Hypertension (early onset hypertension) / / 22479346 rs10227676 chr7 10277258 G A 3.06E-04 Acute lung injury / / 22295056 rs10225194 chr7 10278806 T G 4.89E-04 Type 2 diabetes / / 17463246 rs10225194 chr7 10278806 T G 2.97E-04 Alcohol dependence / / 20201924 rs10807966 chr7 10280460 G C 4.52E-04 Acute lung injury / / 22295056 rs7808481 chr7 10297082 G A 8.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2189945 chr7 10298164 T C 0.000894447 Hypertension (early onset hypertension) / / 22479346 rs10271466 chr7 10316762 A G 1.05E-04 Alzheimer's disease / / 21059989 rs10271466 chr7 10316762 A G 5.98E-06 Alzheimer's disease / / 21059989 rs10488122 chr7 10317686 C G 9.49E-04 Multiple complex diseases / / 17554300 rs2217604 chr7 10347282 T C 8.46E-04 Acute lung injury / / 22295056 rs17162902 chr7 10347788 C G 7.53E-04 Acute lung injury / / 22295056 rs13226907 chr7 10348128 G A 7.53E-04 Acute lung injury / / 22295056 rs13244651 chr7 10348223 T A,C,G 7.53E-04 Acute lung injury / / 22295056 rs13244651 chr7 10348223 T A,C,G 5.03E-05 Tourette syndrome / / 22889924 rs10238173 chr7 10349708 G A 7.45E-04 Acute lung injury / / 22295056 rs12703001 chr7 10351144 G A 7.45E-04 Acute lung injury / / 22295056 rs17531553 chr7 10351330 A G 6.97E-04 Acute lung injury / / 22295056 rs17531553 chr7 10351330 A G 9.40E-05 Tourette syndrome / / 22889924 rs10488128 chr7 10352241 C T 5.30E-05 Tourette syndrome / / 22889924 rs10239989 chr7 10352339 T C 7.41E-04 Acute lung injury / / 22295056 rs960496 chr7 10352554 T C 7.41E-04 Acute lung injury / / 22295056 rs967744 chr7 10353214 G C 7.22E-04 Acute lung injury / / 22295056 rs7778453 chr7 10354120 A T 8.17E-04 Acute lung injury / / 22295056 rs7808057 chr7 10354549 G A 8.25E-04 Acute lung injury / / 22295056 rs2116616 chr7 10355943 G A 9.01E-04 Acute lung injury / / 22295056 rs2116615 chr7 10356078 C T 6.40E-05 Tourette syndrome / / 22889924 rs2163683 chr7 10356213 T C 9.14E-04 Acute lung injury / / 22295056 rs2882834 chr7 10364723 C G 1.00E-06 Capecitabine sensitivity / / 22864933 rs891854 chr7 10372184 T C 1.60E-06 Crohn's disease / / 20570966 rs11972492 chr7 10385961 T G 2.29E-05 Smoking quantity / / 24665060 rs12670345 chr7 10423884 G A 4.84E-04 Premature ovarian failure / / 19508998 rs1111644 chr7 10452576 T G 2.80E-05 Alcoholism (heaviness of drinking) / / 21529783 rs765805 chr7 10469534 C T 6.40E-05 Alcoholism (heaviness of drinking) / / 21529783 rs2352127 chr7 10525322 C T 4.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11766785 chr7 10536856 T C,G 3.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17568678 chr7 10556727 T C 5.52E-04 Multiple complex diseases / / 17554300 rs1990103 chr7 10558779 C A 4.16E-04 Type 2 diabetes / / 17463246 rs7791845 chr7 10577029 G A 3.64E-04 Type 2 diabetes / / 17463246 rs7795770 chr7 10577373 G A 3.45E-04 Type 2 diabetes / / 17463246 rs17569167 chr7 10579606 C T 6.79E-04 Multiple complex diseases / / 17554300 rs2158719 chr7 10593050 G T 5.02E-05 Serum metabolites / / 19043545 rs6947198 chr7 10609528 G A 1.10E-05 Urinary metabolites / / 21572414 rs6970987 chr7 10614934 T C 8.95E-05 Coronary heart disease / / pha003031 rs1024539 chr7 10634473 A C 6.70E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs200139269 chr7 10634473 A AC 6.70E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7804426 chr7 10645892 A G 1.95E-05 Coronary heart disease / / pha003031 rs757819 chr7 10660424 T G 1.96E-05 Coronary heart disease / / pha003031 rs10263926 chr7 10679384 C T 2.51E-05 Body Mass Index / / pha003021 rs2097903 chr7 10682409 A T 2.69E-04 Coronary heart disease / / 21606135 rs2079389 chr7 10682633 C T 2.68E-04 Coronary heart disease / / 21606135 rs17526402 chr7 10682925 C A 3.07E-04 Coronary heart disease / / 21606135 rs763397 chr7 10720330 T C 3.78E-05 Coronary heart disease / / pha003031 rs2214543 chr7 10796892 C T 1.60E-04 Multiple sclerosis / / 21833088 rs4720903 chr7 10804070 C T 3.95E-05 Glucose levels / / pha003058 rs1544411 chr7 10819547 A G 1 Drug response to Etidronic Acid / / 10692979 rs1544411 chr7 10819547 A G 1 Drug response to Alendronate / / 15739035 rs1544411 chr7 10819547 A G 1 Drug response to Calcium / / 15739035 rs1544411 chr7 10819547 A G 1 Drug response to Raloxifene / / 15739035 rs1544411 chr7 10819547 A G 1 Drug response to Clodronate / / 19020788 rs10230296 chr7 10821385 A C,G 9.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs10270250 chr7 10834488 G C 8.05E-04 Type 2 diabetes / / 17463246 rs12673360 chr7 10836089 C T 7.26E-04 Type 2 diabetes / / 17463246 rs12673360 chr7 10836089 C T 7.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs979059 chr7 10836447 T A 7.91E-04 Type 2 diabetes / / 17463246 rs979058 chr7 10836487 G A 7.05E-04 Type 2 diabetes / / 17463246 rs739891 chr7 10839023 C T 3.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs739889 chr7 10839255 T G 5.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs6947809 chr7 10841622 A C 3.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs17598491 chr7 10843707 A T 4.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs6460751 chr7 10845103 T C 2.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs10264013 chr7 10852392 G A 6.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs10264013 chr7 10852392 G A 1.74E-04 Smoking initiation / / 24665060 rs4720910 chr7 10855494 C T 7.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs12699153 chr7 10858235 C T 3.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs6944362 chr7 10858392 G T 4.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs10241575 chr7 10859440 A G 3.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs10271419 chr7 10859652 C T 4.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs10274493 chr7 10865582 G A 5.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs4720913 chr7 10875894 A G 1.77E-04 Hearing function / / 17255346 rs6460761 chr7 10877757 A G 0.0000131 Height (Pygmy height) / / 22570615 rs6973809 chr7 10881827 G A 9.18E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12537447 chr7 10887749 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12537447 chr7 10887749 G A 2.83E-04 Smoking initiation / / 24665060 rs968794 chr7 10889485 G A 8.40E-05 Psychosis / / 23871474 rs10269406 chr7 10904755 G A 3.29E-04 Premature ovarian failure / / 19508998 rs7357330 chr7 10928142 G A 4.82E-05 Cognitive performance / / 19734545 rs12699162 chr7 10944986 A C 5.30E-05 Cognitive performance / / 19734545 rs17163764 chr7 10957672 T C 4.51E-05 Cognitive impairment induced by topiramate / / 22091778 rs6953777 chr7 10960733 A C 4.21E-04 Multiple complex diseases / / 17554300 rs6953777 chr7 10960733 A C 4.24E-04 Blood pressure (response to calcium channel blocker) / / 24192120 rs1681300 chr7 10990312 G A 7.37E-04 Alcohol dependence / / 21314694 rs12112329 chr7 11008465 T C 9.03E-04 Alcohol dependence / / 21314694 rs218966 chr7 11022230 A G 5.50E-10 Stroke PHF14 missense 23422753 rs7790568 chr7 11140383 T C 7.03E-05 Cognitive performance PHF14 intron 19734545 rs10258526 chr7 11228243 C G 0.0000047 Lumbar spine bone mineral density (premenopausal) / / 23074152 rs10258526 chr7 11228243 C G 0.0000324 Femoral neck bone mineral density (premenopausal) / / 23074152 rs10226582 chr7 11239345 C T 3.98E-04 Alzheimer's disease (late onset) / / 21379329 rs200363799 chr7 11239345 C CTCT 3.98E-04 Alzheimer's disease (late onset) / / 21379329 rs2001817 chr7 11240247 A G 6.35E-04 Type 2 diabetes / / 17463246 rs11983466 chr7 11253503 T C 6.05E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10232432 chr7 11258798 A G 8.54E-04 Tourette syndrome / / 22889924 rs10486111 chr7 11266763 G A 5.69E-04 Tourette syndrome / / 22889924 rs10440955 chr7 11282369 T C 3.54E-04 Cognitive decline / / 23732972 rs4620184 chr7 11282387 C G 7.93E-05 Cognitive decline / / 23732972 rs13230115 chr7 11284015 A G 4.86E-04 Depression (quantitative trait) / / 20800221 rs10950343 chr7 11285339 T G 2.34E-04 Cognitive decline / / 23732972 rs2353803 chr7 11287042 C A 1.50E-05 Biomarkers / / 17903293 rs17539729 chr7 11290187 G A 7.88E-04 Substance dependence / / 21818250 rs4720952 chr7 11291400 G A 1.02E-04 Body mass index / / 20818722 rs4720952 chr7 11291400 G A 3.00E-07 IgG glycosylation / / 23382691 rs4720952 chr7 11291400 G A 4.00E-07 IgG glycosylation / / 23382691 rs4720952 chr7 11291400 G A 7.00E-07 IgG glycosylation / / 23382691 rs6945505 chr7 11305679 C T 2.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10253872 chr7 11321893 C T 7.65E-04 Alcohol dependence / / 24277619 rs9771478 chr7 11326981 A C 5.77E-04 Intracranial aneurysm / / 22286173 rs13231142 chr7 11356286 T G 9.28E-04 Multiple complex diseases / / 17554300 rs10232201 chr7 11383755 A G 9.89E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6953611 chr7 11385184 G C 4.62E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7797146 chr7 11387230 G A 2.40E-05 Urinary metabolites / / 21572414 rs17164512 chr7 11416541 A G 3.15E-04 Multiple complex diseases THSD7A intron 17554300 rs2189352 chr7 11418670 C A 4.91E-04 Multiple complex diseases THSD7A intron 17554300 rs2285757 chr7 11419104 G T 3.38E-04 Multiple complex diseases THSD7A intron 17554300 rs61996269 chr7 11446658 A G 0.00083 Prostate cancer THSD7A missense 23555315 rs7794215 chr7 11477364 T C 4.79E-04 Multiple complex diseases THSD7A intron 17554300 rs10262052 chr7 11485527 T C 3.86E-05 Brain structure THSD7A intron 22504417 rs39182 chr7 11494566 T C 5.29E-04 Type 2 diabetes THSD7A intron 17463246 rs7793532 chr7 11517770 T C 0.00000668 LDL cholesterol particle diameter THSD7A intron 23263444 rs4141318 chr7 11520106 T G 2.80E-06 Urinary metabolites THSD7A intron 21572414 rs10486133 chr7 11522525 A G 2.20E-06 Urinary metabolites THSD7A intron 21572414 rs10486135 chr7 11528500 C A 1.67E-04 Bone mass and geometry THSD7A intron 17903296 rs6943841 chr7 11544610 T C 2.63E-05 Type 2 diabetes THSD7A intron 17463246 rs6944001 chr7 11544687 T C 3.21E-05 Type 2 diabetes THSD7A intron 17463246 rs9638671 chr7 11553163 G A 4.45E-04 Response to cytidine analogues (gemcitabine) THSD7A intron 24483146 rs6972615 chr7 11554096 A G 2.80E-05 Urinary metabolites THSD7A intron 21572414 rs10277665 chr7 11559580 T C 0.0000542 Bipolar disorder THSD7A intron 23637625 rs17634127 chr7 11562863 T C 4.94E-04 Response to cytidine analogues (gemcitabine) THSD7A intron 24483146 rs10230612 chr7 11568098 T G 2.93E-04 Multiple complex diseases THSD7A intron 17554300 rs2354951 chr7 11568669 G C 8.35E-04 Type 2 diabetes THSD7A intron 17463246 rs2354951 chr7 11568669 G C 3.70E-06 Urinary metabolites THSD7A intron 21572414 rs2354951 chr7 11568669 G C 6.59E-04 Response to cytidine analogues (gemcitabine) THSD7A intron 24483146 rs6963353 chr7 11569734 A G 3.60E-06 Urinary metabolites THSD7A intron 21572414 rs12674351 chr7 11569853 C T 3.33E-05 Potassium levels THSD7A intron pha003086 rs53 chr7 11577625 C T 6.69E-04 Iron levels THSD7A intron pha002876 rs6979125 chr7 11578234 G A 4.31E-05 Potassium levels THSD7A intron pha003086 rs2074603 chr7 11581134 T C 3.36E-04 Iron levels THSD7A cds-synon pha002876 rs12699211 chr7 11586291 C T 9.50E-04 Suicide attempts in bipolar disorder THSD7A intron 21423239 rs6975510 chr7 11595247 G A 5.80E-04 Suicide attempts in bipolar disorder THSD7A intron 21423239 rs16 chr7 11602899 T C 2.97E-05 Potassium levels THSD7A intron pha003086 rs83 chr7 11605015 C G 7.20E-04 Response to cytidine analogues (gemcitabine) THSD7A intron 24483146 rs1989990 chr7 11605298 A C 1.64E-04 Multiple complex diseases THSD7A intron 17554300 rs10280061 chr7 11606046 T C 6.51E-04 Iron levels THSD7A intron pha002876 rs78 chr7 11611400 G A 1.56E-04 Alzheimer's disease THSD7A intron 17998437 rs74 chr7 11613755 G A 2.88E-04 Alzheimer's disease THSD7A intron 17998437 rs764195 chr7 11616845 G A 7.83E-04 Type 2 diabetes THSD7A intron 17846124 rs2189638 chr7 11622892 A G 4.32E-05 Hepatocellular carcinoma THSD7A intron 22807686 rs2189634 chr7 11626988 C G 7.20E-06 Urinary metabolites THSD7A intron 21572414 rs2526108 chr7 11640094 T C 7.46E-05 Body Mass Index THSD7A intron pha003019 rs2526108 chr7 11640094 T C 1.42E-05 Body Mass Index THSD7A intron pha003020 rs2681055 chr7 11645980 C T 2.51E-05 Type 2 diabetes THSD7A intron 17463246 rs2681052 chr7 11648939 A C 5.39E-04 Amyotrophic lateral sclerosis THSD7A intron 23624525 rs2681052 chr7 11648939 A C 9.22E-05 Body Mass Index THSD7A intron pha003019 rs2681052 chr7 11648939 A C 9.27E-06 Body Mass Index THSD7A intron pha003020 rs2681051 chr7 11649165 C T 2.84E-05 Body Mass Index THSD7A intron pha003020 rs2681050 chr7 11649473 C T 6.98E-05 Body Mass Index THSD7A intron pha003020 rs987904 chr7 11653904 C T 1.52E-05 Body Mass Index THSD7A intron pha003019 rs987904 chr7 11653904 C T 2.64E-06 Body Mass Index THSD7A intron pha003020 rs12673553 chr7 11659823 T C 6.10E-04 Response to statin treatment (atorvastatin),change in cholesterol levels THSD7A intron 20031582 rs17576226 chr7 11670855 C T 1.41E-06 Body Mass Index THSD7A intron pha003019 rs17576226 chr7 11670855 C T 4.18E-06 Body Mass Index THSD7A intron pha003020 rs17576226 chr7 11670855 C T 3.94E-05 Body Mass Index THSD7A intron pha003022 rs2074598 chr7 11676377 G A 0.0004019 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) THSD7A cds-synon 23233654 rs2074598 chr7 11676377 G A 4.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) THSD7A cds-synon 23233662 rs2074597 chr7 11676694 C A 3.49E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) THSD7A intron 24023788 rs12154996 chr7 11677126 A G 4.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) THSD7A intron 23648065 rs2526100 chr7 11677778 T C 5.69E-04 Multiple complex diseases THSD7A intron 17554300 rs2526100 chr7 11677778 T C 4.07E-04 Alcohol dependence THSD7A intron 21314694 rs12699252 chr7 11684576 A G 8.11E-04 Multiple complex diseases THSD7A intron 17554300 rs4721001 chr7 11704484 T C 3.52E-05 Multiple complex diseases THSD7A intron 17554300 rs1405318 chr7 11710892 C G 4.54E-06 Multiple complex diseases THSD7A intron 17554300 rs12537100 chr7 11712490 G C 4.77E-05 Multiple complex diseases THSD7A intron 17554300 rs1568974 chr7 11730333 T C 0.000683607 Hypertension (early onset hypertension) THSD7A intron 22479346 rs941034 chr7 11733818 T C 1.96E-04 Multiple complex diseases THSD7A intron 17554300 rs10499415 chr7 11735401 G C 1.85E-04 Multiple complex diseases THSD7A intron 17554300 rs9647954 chr7 11735998 A G 7.80E-06 Amyotrophic Lateral Sclerosis THSD7A intron 17362836 rs1405325 chr7 11748199 T G 2.20E-04 Multiple complex diseases THSD7A intron 17554300 rs2355066 chr7 11749879 T G 8.26E-04 Multiple complex diseases THSD7A intron 17554300 rs12699254 chr7 11759464 C T 6.79E-04 Amyotrophic Lateral Sclerosis THSD7A intron 17362836 rs1526538 chr7 11774241 G A 8.73E-05 Serum metabolites THSD7A intron 19043545 rs6968056 chr7 11834687 C G 1.90E-04 Primary sclerosing cholangitis THSD7A intron 19944697 rs2355100 chr7 11853670 C G 4.13E-05 Recombination rate THSD7A intron 21698098 rs2355106 chr7 11874058 T A 4.75E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2355111 chr7 11882922 G A 1.10E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6958721 chr7 11887677 C T 5.98E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10244081 chr7 11893588 C A 6.31E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6460851 chr7 11901812 G A 9.99E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7810903 chr7 11904138 C A 8.46E-06 Height / / pha003010 rs10250072 chr7 11916293 G T 6.15E-05 Sarcoidosis / / 19165924 rs10244189 chr7 11921402 A G 8.46E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11764106 chr7 11951026 A G 4.39E-04 Alzheimer's disease (late onset) / / 21379329 rs4291160 chr7 11974451 T G 3.98E-05 Serum metabolites / / 19043545 rs10234937 chr7 11991856 G C 6.23E-04 Type 2 diabetes / / 17463246 rs2908742 chr7 12016050 C T 2.90E-05 Urinary metabolites / / 21572414 rs17165486 chr7 12043231 A G 7.34E-04 Tourette syndrome / / 22889924 rs2966622 chr7 12048555 G C 1.40E-05 Urinary metabolites / / 21572414 rs17165506 chr7 12053370 A G 0.00000341 Colorectal cancer (females) / / 22532847 rs769111 chr7 12059806 T G 6.00E-06 Tourette syndrome / / 22889924 rs2058644 chr7 12061045 A G 2.28E-04 Tourette syndrome / / 22889924 rs2058643 chr7 12061061 T C 6.76E-04 Tourette syndrome / / 22889924 rs2966608 chr7 12066984 C T 2.10E-04 Tourette syndrome / / 22889924 rs6943558 chr7 12068095 G A 9.75E-05 Tourette syndrome / / 22889924 rs2908734 chr7 12070537 T C 7.62E-05 Multiple sclerosis / / 20598377 rs1035147 chr7 12094966 A C 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs10251790 chr7 12097701 T C 2.29E-05 Height / / pha003010 rs6959050 chr7 12128392 G A 1.02E-05 Height / / pha003010 rs6959050 chr7 12128392 G A 7.91E-05 Height / / pha003011 rs12535674 chr7 12129757 A C 3.78E-04 Type 2 diabetes / / 17463246 rs10226395 chr7 12135334 C T 7.80E-05 Height / / pha003010 rs13233832 chr7 12150915 A T 1.11E-04 Type 2 diabetes / / 17463246 rs10950383 chr7 12154013 A G 9.06E-04 Type 2 diabetes / / 17463246 rs1003433 chr7 12164100 G T 5.28E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs1003433 chr7 12164100 G T 5.51E-04 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs1369496 chr7 12173173 C G 1.70E-04 Alzheimer's disease / / 17998437 rs4719297 chr7 12174092 T C 3.23E-04 Birth weight / / 17255346 rs4719297 chr7 12174092 T C 5.67E-04 Multiple complex diseases / / 17554300 rs11977937 chr7 12177660 G A 3.24E-04 Birth weight / / 17255346 rs114945094 chr7 12193432 G A 4.00E-06 Anorexia nervosa / / 23568457 rs6963608 chr7 12195083 G A 3.75E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6952272 chr7 12200060 C T 2.62E-04 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs6952272 chr7 12200060 C T 4.75E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs1435536 chr7 12213484 A C 2.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12671332 chr7 12215562 T C 1.32E-04 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs12671332 chr7 12215562 T C 3.03E-07 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs12671332 chr7 12215562 T C 9.79E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs7786495 chr7 12219148 T C 6.63E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17594709 chr7 12219535 A G 5.00E-06 IgG glycosylation / / 23382691 rs1468915 chr7 12227892 A G 1.42E-04 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs1468915 chr7 12227892 A G 1.45E-04 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs1468915 chr7 12227892 A G 4.68E-07 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs17165701 chr7 12239274 T C 9.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs2160269 chr7 12247707 C T 2.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1435528 chr7 12249893 C T 2.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3807865 chr7 12250402 G A 4.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1019307 chr7 12251790 G C 8.05E-05 Response to taxane treatment (placlitaxel) TMEM106B intron 23006423 rs6460895 chr7 12252540 C G 2.90E-05 Response to taxane treatment (placlitaxel) TMEM106B intron 23006423 rs6460900 chr7 12253088 A G 3.13E-05 Response to taxane treatment (placlitaxel) TMEM106B intron 23006423 rs17149894 chr7 12254939 C T 7.66E-05 Serum metabolites TMEM106B intron 19043545 rs1020004 chr7 12255778 T C 1.10E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain TMEM106B intron 20154673 rs1020004 chr7 12255778 T C 1.93E-07 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain TMEM106B intron 20154673 rs1020004 chr7 12255778 T C 2.90E-11 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain TMEM106B intron 20154673 rs1020004 chr7 12255778 T C 4.15E-07 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain TMEM106B intron 20154673 rs6460903 chr7 12257728 T C 1.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM106B intron 20877124 rs6460903 chr7 12257728 T C 2.78E-05 HDL cholesterol TMEM106B intron pha003075 rs3823612 chr7 12258755 G C 1.24E-04 Response to taxane treatment (placlitaxel) TMEM106B intron 23006423 rs3800845 chr7 12264151 G C 9.62E-04 Response to taxane treatment (placlitaxel) TMEM106B intron 23006423 rs6966915 chr7 12265988 C T 3.92E-09 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain TMEM106B intron 20154673 rs6966915 chr7 12265988 C T 6.49E-07 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain TMEM106B intron 20154673 rs6966915 chr7 12265988 C T 6.87E-12 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain TMEM106B intron 20154673 rs6966915 chr7 12265988 C T 4.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM106B intron 20877124 rs6966915 chr7 12265988 C T 4.29E-04 Response to taxane treatment (placlitaxel) TMEM106B intron 23006423 rs4721059 chr7 12267495 G C 4.94E-04 Response to taxane treatment (placlitaxel) TMEM106B intron 23006423 rs14978 chr7 12273152 A G 7.00E-06 Response to amphetamines TMEM106B UTR-3 22952603 rs1468804 chr7 12275508 T C 1.42E-04 Response to taxane treatment (placlitaxel) TMEM106B UTR-3 23006423 rs1060700 chr7 12275818 A G 3.38E-04 Response to taxane treatment (placlitaxel) TMEM106B UTR-3 23006423 rs10488192 chr7 12277081 G A 1.46E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs1990622 chr7 12283787 A G 1.34E-09 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs1990622 chr7 12283787 A G 4.31E-12 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs1990622 chr7 12283787 A G 6.90E-07 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs1990622 chr7 12283787 A G 6.90E-08 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs1990622 chr7 12283787 A G 2.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1990622 chr7 12283787 A G 1.08E-11 Prion diseases / / 22210626 rs1990622 chr7 12283787 A G 5.73E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6945902 chr7 12286409 C A 7.17E-04 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs10234185 chr7 12298311 C A 9.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2098366 chr7 12304555 G A 1.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6460910 chr7 12310445 C T 2.45E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2192839 chr7 12326930 C T 7.65E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10232196 chr7 12337549 C G 2.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6947878 chr7 12339495 A G 1.45E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2356167 chr7 12360805 T C 5.82E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10269851 chr7 12369616 A G 7.47E-04 Alzheimer's disease / / 17998437 rs6460929 chr7 12373082 C T 6.60E-04 Response to taxane treatment (placlitaxel) VWDE intron 23006423 rs2192828 chr7 12376811 A C 6.00E-04 Response to taxane treatment (placlitaxel) VWDE missense 23006423 rs1440030 chr7 12382637 C T 6.33E-04 Response to taxane treatment (placlitaxel) VWDE intron 23006423 rs2110803 chr7 12385521 C T 8.59E-04 Response to taxane treatment (placlitaxel) VWDE intron 23006423 rs10280443 chr7 12390186 C T 3.55E-04 Response to taxane treatment (placlitaxel) VWDE intron 23006423 rs6967385 chr7 12391319 G T 6.00E-06 Response to taxane treatment (placlitaxel) VWDE missense 23006423 rs6460933 chr7 12391454 G A 6.32E-04 Type 2 diabetes VWDE intron 17463246 rs7804218 chr7 12391862 C T 4.97E-06 Waist-Hip Ratio VWDE intron pha003029 rs10249315 chr7 12392897 T C 2.33E-06 Prostate cancer VWDE intron pha002877 rs10249315 chr7 12392897 T C 2.26E-05 Prostate cancer VWDE intron pha002878 rs10249315 chr7 12392897 T C 1.05E-05 Waist-Hip Ratio VWDE intron pha003029 rs7809990 chr7 12393310 C T 2.61E-06 Prostate cancer VWDE intron pha002877 rs7809990 chr7 12393310 C T 2.62E-05 Prostate cancer VWDE intron pha002878 rs7809990 chr7 12393310 C T 3.60E-06 Waist-Hip Ratio VWDE intron pha003029 rs2053382 chr7 12400587 A G 2.00E-04 Response to taxane treatment (placlitaxel) VWDE intron 23006423 rs2053381 chr7 12400710 C A 2.71E-04 Response to taxane treatment (placlitaxel) VWDE intron 23006423 rs2033871 chr7 12405098 C A 1.73E-04 Response to taxane treatment (placlitaxel) VWDE intron 23006423 rs1371608 chr7 12406826 G A 4.81E-04 Endometrial cancer VWDE intron 24096698 rs1371608 chr7 12406826 G A 6.56E-04 Endometrial cancer VWDE intron 24096698 rs3823844 chr7 12409522 A G 4.73E-07 Prostate cancer VWDE missense pha002877 rs3823844 chr7 12409522 A G 2.24E-06 Prostate cancer VWDE missense pha002878 rs17165936 chr7 12414725 G A 1.13E-07 Prostate cancer VWDE STOP-GAIN pha002877 rs17165936 chr7 12414725 G A 6.77E-07 Prostate cancer VWDE STOP-GAIN pha002878 rs10270931 chr7 12418964 T C 9.65E-05 Birth weight VWDE intron 17255346 rs6460942 chr7 12420989 T C 3.43E-04 Response to taxane treatment (placlitaxel) VWDE intron 23006423 rs848016 chr7 12428803 G A 3.15E-04 Schizophrenia (cytomegalovirus infection interaction) VWDE missense 23358160 rs17166013 chr7 12443042 G A 3.71E-04 Multiple complex diseases VWDE intron 17554300 rs10254572 chr7 12448482 C T 2.00E-06 Prostate cancer / / pha002877 rs10254572 chr7 12448482 C T 1.73E-05 Prostate cancer / / pha002878 rs12539627 chr7 12476418 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12539627 chr7 12476418 A G 2.70E-05 Cognitive impairment induced by topiramate / / 22091778 rs17444621 chr7 12478819 A G 2.40E-05 Urinary metabolites / / 21572414 rs17445017 chr7 12481054 G A 1.30E-05 Urinary metabolites / / 21572414 rs9648158 chr7 12481612 G T 6.31E-04 Multiple complex diseases / / 17554300 rs4721099 chr7 12488535 C T 1.41E-05 Prostate cancer / / pha002878 rs12669338 chr7 12498138 T G 1.90E-06 Urinary metabolites / / 21572414 rs12669338 chr7 12498138 T G 9.42E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12667501 chr7 12498511 C T 2.72E-04 Multiple complex diseases / / 17554300 rs12699374 chr7 12498634 T C 4.84E-04 Multiple complex diseases / / 17554300 rs12699376 chr7 12498835 C G 1.10E-06 Urinary metabolites / / 21572414 rs12699376 chr7 12498835 C G 8.38E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10488158 chr7 12508894 C T 5.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7777618 chr7 12521982 C T 5.53E-04 Alzheimer's disease / / 17998437 rs11760555 chr7 12596535 C T 4.84E-05 HIV-1 viral setpoint / / 21490045 rs11764174 chr7 12596616 T C 6.05E-05 Major depressive disorder (broad) / / 20038947 rs10276226 chr7 12602211 A G 4.95E-04 Depression (quantitative trait) / / 20800221 rs6954578 chr7 12604609 C G 5.67E-04 Depression (quantitative trait) / / 20800221 rs1859989 chr7 12606847 C G 5.66E-04 Depression (quantitative trait) / / 20800221 rs1859990 chr7 12606852 A G 5.65E-04 Depression (quantitative trait) / / 20800221 rs2240571 chr7 12609988 G C 5.18E-05 Multiple sclerosis / / 21346779 rs1034856 chr7 12613252 C T 5.58E-04 Multiple complex diseases SCIN intron 17554300 rs116532633 chr7 12620790 C G 0.00019 Breast cancer (ER positive) SCIN missense 23555315 rs3173628 chr7 12627245 A G 4.80E-04 Heart Failure SCIN intron pha002884 rs6967031 chr7 12631920 C T 8.81E-05 Heart Failure SCIN intron pha002884 rs11764374 chr7 12632085 T C 6.92E-04 Heart Failure SCIN intron pha002884 rs10241553 chr7 12641202 C T 2.83E-04 Multiple complex diseases SCIN intron 17554300 rs849758 chr7 12666907 A G 2.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SCIN intron 20877124 rs2529784 chr7 12667208 G C 0.0000155 HDL cholesterol particle diameter SCIN intron 23263444 rs17357392 chr7 12671533 A G 9.89E-06 Response to cytadine analogues (cytosine arabinoside) SCIN intron 24483146 rs2529786 chr7 12671602 C T 0.0000054 HDL cholesterol particle diameter SCIN intron 23263444 rs740415 chr7 12672870 A C 0.00000772 HDL cholesterol particle diameter SCIN intron 23263444 rs2691816 chr7 12676187 C T 0.00000797 HDL cholesterol particle diameter SCIN intron 23263444 rs2529780 chr7 12676928 G A 0.00000806 HDL cholesterol particle diameter SCIN intron 23263444 rs849764 chr7 12677631 C G 7.98E-04 Suicide attempts in bipolar disorder SCIN intron 21041247 rs2529781 chr7 12677845 G A 0.00000824 HDL cholesterol particle diameter SCIN intron 23263444 rs849766 chr7 12679634 T G 7.92E-04 Suicide attempts in bipolar disorder SCIN intron 21041247 rs2074866 chr7 12680454 A G 0.00000839 HDL cholesterol particle diameter SCIN intron 23263444 rs2691810 chr7 12684340 C T 3.40E-04 Suicide attempts in bipolar disorder SCIN intron 21041247 rs6945041 chr7 12687771 C A,G 3.44E-04 Response to cytadine analogues (cytosine arabinoside) SCIN intron 24483146 rs10246960 chr7 12705413 C T 9.60E-06 Bipolar disorder / / 19416921 rs13226473 chr7 12708504 A G 3.36E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs10488226 chr7 12713070 G T 3.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs17615676 chr7 12718149 T C 4.73E-05 Parkinson's disease / / 21738487 rs11981294 chr7 12758624 A T 1.70E-05 Urinary metabolites / / 21572414 rs17616845 chr7 12781543 T C 8.49E-08 Alcohol dependence / / 23089632 rs849734 chr7 12791487 C A 3.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs849735 chr7 12793629 C G 4.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs849737 chr7 12795321 T C 1.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs702481 chr7 12805233 T G 3.24E-05 Bladder cancer / / 19648920 rs849745 chr7 12805598 A G 1.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs849746 chr7 12806268 A G 1.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs12666603 chr7 12808491 A G 3.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs12671025 chr7 12808672 G C 2.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs10215135 chr7 12814628 A C 3.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs10215136 chr7 12814645 A G 3.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs16877549 chr7 12819168 A G 3.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs7792487 chr7 12840090 T C 7.04E-04 Iron levels / / pha002876 rs2108476 chr7 12857338 C T 4.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2108476 chr7 12857338 C T 5.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs77842473 chr7 12876767 A G 0.0000758 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs111851535 chr7 12888186 A G 0.0000907 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10224102 chr7 12908159 A G 5.18E-04 Taste perception / / 22132133 rs17683020 chr7 12929111 C G 5.09E-06 Bipolar disorder and schizophrenia / / 20889312 rs1019171 chr7 12930400 C T 1.07E-04 Iron levels / / pha002876 rs732577 chr7 12932049 G T 4.00E-06 Sudden cardiac arrest / / 21658281 rs2191262 chr7 12932204 C A 6.40E-04 Multiple complex diseases / / 17554300 rs10950426 chr7 12933049 G A 9.01E-05 Iron levels / / 19880490 rs10950426 chr7 12933049 G A 9.01E-05 Iron levels / / pha002876 rs17166492 chr7 12934202 A G 9.25E-05 Multiple complex diseases / / 17554300 rs17166499 chr7 12937255 C G 5.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs28611315 chr7 12943414 G C 9.85E-06 Bipolar disorder and schizophrenia / / 20889312 rs10488242 chr7 12950947 G C 5.70E-04 Multiple complex diseases / / 17554300 rs10267804 chr7 13008198 T G 6.30E-06 Urinary metabolites / / 21572414 rs10267804 chr7 13008198 T G 5.61E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10238713 chr7 13094628 C T 4.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs10488244 chr7 13100035 C T 8.96E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2058613 chr7 13104434 C T 1.80E-05 Hodgkin's lymphoma / / 24920014 rs2108929 chr7 13146222 C T 6.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs2041235 chr7 13204843 C T 5.38E-05 Coronary heart disease / / pha003032 rs194027 chr7 13235083 T C 7.45E-05 Coronary heart disease / / pha003032 rs16877717 chr7 13238496 G A 1.85E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs6973933 chr7 13253069 G A 9.00E-06 Asthma / / 21790008 rs9647960 chr7 13256498 A G 2.74E-04 Obesity (extreme) / / 21935397 rs13221823 chr7 13263853 A T 5.49E-04 Obesity (extreme) / / 21935397 rs7780368 chr7 13268915 T C 5.51E-04 Obesity (extreme) / / 21935397 rs7787319 chr7 13287995 T C 1.91E-04 Type 2 diabetes / / 17463246 rs17136683 chr7 13307885 T A 8.38E-08 Metabolite levels / / 23281178 rs17655028 chr7 13320170 C T 4.91E-04 Type 2 diabetes / / 17463246 rs17655151 chr7 13321887 A G 6.33E-04 Type 2 diabetes / / 17463246 rs10488260 chr7 13325060 C A 8.73E-04 Type 2 diabetes / / 17463246 rs10248526 chr7 13362403 G A 3.72E-04 Insulin resistance / / 21901158 rs4298398 chr7 13388668 G A 8.01E-04 Obesity (extreme) / / 21935397 rs6954033 chr7 13392018 G C 7.85E-04 Obesity (extreme) / / 21935397 rs2116624 chr7 13404664 A G 8.67E-04 Multiple complex diseases / / 17554300 rs2568600 chr7 13424671 C T 5.31E-04 Multiple complex diseases / / 17554300 rs1368214 chr7 13425704 A G 8.61E-04 Multiple complex diseases / / 17554300 rs2723392 chr7 13428692 G A 6.14E-04 Multiple complex diseases / / 17554300 rs1347077 chr7 13429704 T C 7.84E-04 Multiple complex diseases / / 17554300 rs2568608 chr7 13438549 A C 6.42E-04 Iron levels / / pha002876 rs10255329 chr7 13440222 G C 7.00E-06 Metabolite levels (X-11787) / / 23934736 rs10262962 chr7 13441694 G A 1.79E-04 Smoking initiation / / 24665060 rs2723417 chr7 13442276 G C 9.80E-06 Urinary metabolites / / 21572414 rs11520742 chr7 13444059 G A 2.09E-04 Smoking initiation / / 24665060 rs1991763 chr7 13469277 G A 3.35E-04 IgE levels / / 17255346 rs13307587 chr7 13543729 A G 5.00E-06 Reading and spelling / / 23738518 rs12699504 chr7 13548809 G C 5.84E-06 Reading and spelling / / 23738518 rs13223493 chr7 13552754 G A 6.40E-06 Reading and spelling / / 23738518 rs13223493 chr7 13552754 G A 6.80E-06 Word reading / / 23738518 rs13227425 chr7 13554008 C T 6.40E-06 Reading and spelling / / 23738518 rs13227425 chr7 13554008 C T 7.00E-06 Word reading / / 23738518 rs1357978 chr7 13560221 C A 5.46E-06 Reading and spelling / / 23738518 rs1357978 chr7 13560221 C A 6.00E-06 Word reading / / 23738518 rs12699509 chr7 13561595 G A 2.53E-05 Word reading / / 23738518 rs12699509 chr7 13561595 G A 2.72E-05 Reading and spelling / / 23738518 rs2692472 chr7 13567908 G T 1.35E-05 Orofacial clefts / / 22419666 rs11972574 chr7 13571351 A T 9.56E-04 Type 2 diabetes / / 17463246 rs12699516 chr7 13578829 G C 4.72E-04 Multiple complex diseases / / 17554300 rs12699517 chr7 13578950 C T 3.36E-04 Multiple complex diseases / / 17554300 rs9638695 chr7 13579328 T C 2.11E-04 Multiple complex diseases / / 17554300 rs1880631 chr7 13591197 C T 1.18E-04 Telomere length / / 21573004 rs11773320 chr7 13621635 G A 6.59E-04 Multiple complex diseases / / 17554300 rs13232330 chr7 13630352 G A 2.19E-05 Suicidal ideation / / 20877300 rs17280766 chr7 13637369 A G 1.63E-05 Multiple sclerosis / / 19525953 rs1568885 chr7 13637531 T A 0.0000748 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1568885 chr7 13637531 T A 5.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6977948 chr7 13638892 T C 0.0005914 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6977948 chr7 13638892 T C 5.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1404947 chr7 13643552 A G 4.55E-04 Smoking initiation / / 24665060 rs34926451 chr7 13653824 C CT 3.98E-04 Smoking initiation / / 24665060 rs6971641 chr7 13653824 C A,T 3.98E-04 Smoking initiation / / 24665060 rs7788072 chr7 13656136 C T 3.70E-04 Smoking initiation / / 24665060 rs10950474 chr7 13663912 G A 4.42E-04 Multiple complex diseases / / 17554300 rs10269275 chr7 13674179 G A 9.86E-05 Hepatocellular carcinoma / / 22807686 rs6955325 chr7 13680696 A G 2.15E-04 Birth weight / / 17255346 rs1525683 chr7 13683080 A G 1.31E-04 Birth weight / / 17255346 rs7459053 chr7 13734272 T C 7.29E-05 Birth weight / / 17255346 rs2848839 chr7 13734285 A G 2.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6974412 chr7 13777723 G A 1.20E-05 Urinary metabolites / / 21572414 rs17167479 chr7 13779479 G C 1.20E-05 Urinary metabolites / / 21572414 rs10244073 chr7 13780786 G A 4.92E-05 Self-reported allergy / / 23817569 rs10486074 chr7 13780833 G A 1.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2190321 chr7 13783811 G A 6.05E-05 Self-reported allergy / / 23817569 rs917228 chr7 13784993 G A 5.17E-05 Self-reported allergy / / 23817569 rs917227 chr7 13785043 C T 5.32E-05 Self-reported allergy / / 23817569 rs4721261 chr7 13787154 T C 5.60E-05 Self-reported allergy / / 23817569 rs6949606 chr7 13792423 A G 4.94E-05 Self-reported allergy / / 23817569 rs7803649 chr7 13860150 A C 6.17E-04 Type 2 diabetes / / 17463246 rs7787720 chr7 13886654 C T 4.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17167587 chr7 13892190 G C 4.49E-04 Multiple complex diseases / / 17554300 rs1019029 chr7 13894276 A G 2.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7795991 chr7 13900731 A G 7.00E-07 Type 2 diabetes / / 24509480 rs17150029 chr7 13902115 C A 2.50E-05 Urinary metabolites / / 21572414 rs10225805 chr7 13911420 G A 8.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs251991 chr7 13914412 G C 5.37E-05 Serum metabolites / / 19043545 rs3801094 chr7 13959406 G A 8.20E-04 HIV-1 viral setpoint ETV1 intron 17641165 rs3801094 chr7 13959406 G A 2.52E-05 Malignant pleural mesothelioma ETV1 intron 23626673 rs3801094 chr7 13959406 G A 2.78E-05 Malignant pleural mesothelioma ETV1 intron 23626673 rs17136421 chr7 13971740 G A,T 2.96E-07 Pure-tone audiometry ETV1 intron pha001968 rs2237291 chr7 13972307 C T 6.59E-04 Iron levels ETV1 intron pha002876 rs10486064 chr7 13987644 C T 5.44E-04 Response to cytadine analogues (cytosine arabinoside) ETV1 intron 24483146 rs1476622 chr7 14013219 A G 5.29E-04 Type 2 diabetes ETV1 intron 17463246 rs7808321 chr7 14013452 G A 3.34E-04 Age-related macular degeneration ETV1 intron 22125219 rs2074670 chr7 14016939 T C 4.60E-04 Multiple complex diseases ETV1 intron 17554300 rs4721288 chr7 14019448 T C 5.09E-04 Multiple complex diseases ETV1 intron 17554300 rs4721291 chr7 14021121 C G 6.69E-04 Multiple complex diseases ETV1 intron 17554300 rs3823706 chr7 14026802 A C 2.59E-04 Smoking initiation ETV1 intron 24665060 rs12532319 chr7 14091524 A G 1.35E-04 Common variable immunodeficiency / / 21497890 rs11978961 chr7 14096261 G C 3.70E-06 Urinary metabolites / / 21572414 rs10486061 chr7 14098626 G A 8.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17167820 chr7 14102043 C T 5.10E-06 Urinary metabolites / / 21572414 rs17167824 chr7 14104517 T G 2.90E-06 Urinary metabolites / / 21572414 rs2190059 chr7 14123238 C T 2.70E-05 Urinary metabolites / / 21572414 rs1029544 chr7 14124065 T G 1.50E-05 Urinary metabolites / / 21572414 rs10266772 chr7 14132727 G A 8.78E-04 Body mass index / / 21701565 rs6461068 chr7 14133846 A G 3.55E-04 Body mass index / / 21701565 rs12533882 chr7 14144663 A G 7.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12533882 chr7 14144663 A G 8.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7800452 chr7 14147902 C T 8.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6964584 chr7 14172132 G A 7.09E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs80210789 chr7 14186821 T G 0.0000331 Placental abruption DGKB UTR-3 23205182 rs3735345 chr7 14187523 T C 0.0000331 Placental abruption DGKB UTR-3 23205182 rs17167929 chr7 14187669 T C 0.00000835 Placental abruption DGKB UTR-3 23205182 rs17167930 chr7 14187931 T C 0.0000722 Placental abruption DGKB UTR-3 23205182 rs75597508 chr7 14192330 G A 3.42E-05 Intracerebral hemorrhage DGKB intron 24656865 rs13438266 chr7 14195661 C A 1.45E-05 Intracerebral hemorrhage DGKB intron 24656865 rs76681193 chr7 14196909 G A 4.23E-05 Intracerebral hemorrhage DGKB intron 24656865 rs7799696 chr7 14209220 T G 6.46E-05 Bipolar disorder and schizophrenia DGKB intron 20889312 rs17167942 chr7 14213412 T A 3.20E-04 Smoking cessation DGKB intron 24665060 rs6949550 chr7 14214626 C A 3.23E-04 Smoking cessation DGKB intron 24665060 rs2068399 chr7 14228703 G A 9.00E-06 PR interval in Tripanosoma cruzi seropositivity DGKB intron 24324551 rs6461070 chr7 14233250 C T 4.42E-04 Smoking cessation DGKB intron 24665060 rs6969205 chr7 14244367 T C 5.12E-08 Metabolite levels DGKB intron 23281178 rs10486048 chr7 14244402 C T 7.59E-06 White blood cell count DGKB intron 21738479 rs6970198 chr7 14245002 T C 7.44E-08 Metabolite levels DGKB intron 23281178 rs10275474 chr7 14245765 C T 4.78E-08 Metabolite levels DGKB intron 23281178 rs6461071 chr7 14246698 T C 4.59E-08 Metabolite levels DGKB intron 23281178 rs6461072 chr7 14247066 G A 4.43E-08 Metabolite levels DGKB intron 23281178 rs6461073 chr7 14247103 G A 3.81E-08 Metabolite levels DGKB intron 23281178 rs6461074 chr7 14247170 T C 5.04E-08 Metabolite levels DGKB intron 23281178 rs10240257 chr7 14247635 T G 3.81E-08 Metabolite levels DGKB intron 23281178 rs6461075 chr7 14247910 G A 1.66E-08 Metabolite levels DGKB intron 23281178 rs17708126 chr7 14254864 A G 3.61E-04 Lung function (forced vital capacity) DGKB intron 24023788 rs4584047 chr7 14259246 G T 2.50E-05 Urinary metabolites DGKB intron 21572414 rs6943375 chr7 14280548 A G 2.50E-05 Serum metabolites DGKB intron 19043545 rs38280 chr7 14302631 T C 3.84E-04 Multiple complex diseases DGKB intron 17554300 rs10950516 chr7 14313907 A C 1.80E-04 Glycosylated haemoglobin levels DGKB intron 17255346 rs10950518 chr7 14326124 C T 9.12E-05 Glycosylated haemoglobin levels DGKB intron 17255346 rs7785249 chr7 14327966 A G 1.71E-04 Glycosylated haemoglobin levels DGKB intron 17255346 rs4721319 chr7 14334844 A G 9.60E-05 Glycosylated haemoglobin levels DGKB intron 17255346 rs6960014 chr7 14341345 G A 2.19E-04 Glycosylated haemoglobin levels DGKB intron 17255346 rs2215035 chr7 14350817 C G 6.55E-05 Glycosylated haemoglobin levels DGKB intron 17255346 rs2215035 chr7 14350817 C G 9.56E-04 Response to taxane treatment (placlitaxel) DGKB intron 23006423 rs13242229 chr7 14379559 T C 5.01E-04 Taste perception DGKB intron 22132133 rs6977358 chr7 14398086 G A 4.56E-05 Bipolar disorder DGKB intron 21771265 rs12699609 chr7 14415780 C T 6.01E-04 Response to statin treatment (atorvastatin),change in cholesterol levels DGKB intron 20031582 rs10245285 chr7 14424939 T G 2.61E-04 Response to statin treatment (atorvastatin),change in cholesterol levels DGKB intron 20031582 rs1036140 chr7 14435527 T A 6.59E-05 Type 2 diabetes DGKB intron 17463246 rs1036140 chr7 14435527 T A 6.76E-04 Suicide attempts in bipolar disorder DGKB intron 21423239 rs2357958 chr7 14436817 A G 8.71E-05 Hemoglobin DGKB intron pha003098 rs2357958 chr7 14436817 A G 7.41E-05 Erythrocyte counts DGKB intron pha003099 rs6461092 chr7 14438575 G A 8.62E-05 Hemoglobin DGKB intron pha003098 rs10243451 chr7 14443963 T C 9.94E-04 Suicide attempts in bipolar disorder DGKB intron 21423239 rs10243451 chr7 14443963 T C 5.32E-04 Tourette syndrome DGKB intron 22889924 rs7780569 chr7 14445041 C T 9.91E-04 Suicide attempts in bipolar disorder DGKB intron 21423239 rs6971925 chr7 14445917 T C 3.00E-06 Response to treatment for acute lymphoblastic leukemia DGKB intron 19176441 rs6971925 chr7 14445917 T C 7.50E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) DGKB intron 24023788 rs1560575 chr7 14446074 A T 1.87E-05 Type 2 diabetes DGKB intron 17463246 rs1560575 chr7 14446074 A T 9.82E-04 Suicide attempts in bipolar disorder DGKB intron 21423239 rs1560574 chr7 14446092 T C 9.54E-04 Suicide attempts in bipolar disorder DGKB intron 21423239 rs12535183 chr7 14450753 T C 6.91E-04 Suicide attempts in bipolar disorder DGKB intron 21423239 rs12532527 chr7 14450837 G A 8.47E-04 Suicide attempts in bipolar disorder DGKB intron 21423239 rs9639191 chr7 14452944 T A 7.37E-04 Suicide attempts in bipolar disorder DGKB intron 21423239 rs891808 chr7 14453061 G A 5.48E-06 Type 2 diabetes DGKB intron 17463246 rs891808 chr7 14453061 G A 6.21E-04 Suicide attempts in bipolar disorder DGKB intron 21423239 rs12536559 chr7 14461392 G C 9.05E-05 Type 2 diabetes DGKB intron 17463246 rs12536670 chr7 14462008 C T 1.54E-04 Type 2 diabetes DGKB intron 17463246 rs12532234 chr7 14462937 A C 0.00000418 Inter-adventitial common carotid artery diameter DGKB intron 23246012 rs196756 chr7 14463577 A G 0.00000591 Inter-adventitial common carotid artery diameter DGKB intron 23246012 rs17777395 chr7 14464605 C A 9.35E-04 Suicide attempts in bipolar disorder DGKB intron 21423239 rs10486031 chr7 14485463 C T 1.70E-05 Breast cancer and prostate cancer DGKB intron 17903305 rs10499440 chr7 14504325 G A 5.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) DGKB intron 17982456 rs12667053 chr7 14585555 C T 2.29E-04 Multiple complex diseases DGKB intron 17554300 rs17168255 chr7 14586028 G A 9.51E-04 Multiple complex diseases DGKB intron 17554300 rs10499450 chr7 14587889 C A 4.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DGKB intron 20877124 rs16878220 chr7 14590746 T G 8.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DGKB intron 20877124 rs2116312 chr7 14596054 C T 4.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DGKB intron 20877124 rs2033408 chr7 14612655 G A 7.79E-04 HIV-1 viral setpoint DGKB intron 17641165 rs13438451 chr7 14614930 C T 3.50E-06 Soluble leptin receptor levels DGKB intron 20167575 rs879693 chr7 14641925 G C 5.61E-04 Type 2 diabetes DGKB intron 17846124 rs9638713 chr7 14645949 A G 4.72E-04 Multiple complex diseases DGKB intron 17554300 rs17602660 chr7 14646285 A T 3.26E-04 Alcohol dependence DGKB intron 21314694 rs10254418 chr7 14666659 C T 9.48E-04 Alzheimer's disease DGKB intron 22005930 rs1525086 chr7 14704445 A G 6.25E-04 Multiple complex diseases DGKB intron 17554300 rs12333979 chr7 14809355 A G 3.72E-05 Lung function (forced expiratory volume in 1 second) DGKB intron pha003103 rs2358068 chr7 14818166 C T 1.97E-04 Body mass index DGKB intron 21701565 rs1120408 chr7 14835168 A G 1.20E-05 Urinary metabolites DGKB intron 21572414 rs1981680 chr7 14850053 A T 2.60E-05 Urinary metabolites DGKB intron 21572414 rs10277367 chr7 14851617 T C 2.50E-05 Urinary metabolites DGKB intron 21572414 rs10260109 chr7 14856355 C T 9.61E-04 Response to taxane treatment (placlitaxel) DGKB intron 23006423 rs2041407 chr7 14861101 T C 9.52E-04 Myocardial Infarction DGKB intron pha002873 rs4721380 chr7 14884246 C T 6.07E-04 Alzheimer's disease / / 17998437 rs1117750 chr7 14888418 C T 8.02E-06 Alzheimer's disease / / 21059989 rs17168486 chr7 14898282 C T 1.20E-13 Type 2 diabetes / / 22885922 rs17168486 chr7 14898282 C T 3.20E-28 Fasting blood glucose / / 22885922 rs17168486 chr7 14898282 C T 6.50E-13 Type 2 diabetes (males) / / 22885922 rs17168486 chr7 14898282 C T 3.17E-28 Fasting blood glucose / / 22885924 rs17168486 chr7 14898282 C T 3.00E-07 Type 2 diabetes / / 24509480 rs217560 chr7 14911602 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs217565 chr7 14914136 A T 6.46E-04 Type 2 diabetes / / 17463246 rs2109396 chr7 14933955 C A 7.44E-06 Myocardial Infarction / / pha002873 rs217598 chr7 14939924 C T 9.50E-05 Myocardial Infarction / / pha002873 rs118135044 chr7 14976138 C A 0.0000373 Menopause (age at onset) / / 23424626 rs36893 chr7 14991989 C T 0.0005054 Sarcoidosis / / 22952805 rs36909 chr7 15000298 A T 9.52E-04 Depression (quantitative trait) / / 20800221 rs36910 chr7 15000305 G A 5.24E-04 Depression (quantitative trait) / / 20800221 rs36914 chr7 15001308 G A 8.79E-04 Depression (quantitative trait) / / 20800221 rs217607 chr7 15008959 A G 3.67E-04 Depression (quantitative trait) / / 20800221 rs7800343 chr7 15021223 A G 4.25E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs1005256 chr7 15039605 C A 8.87E-05 Glucose levels / / pha002899 rs74984879 chr7 15040711 G C 0.000064 Menopause (age at onset) / / 23424626 rs10255000 chr7 15041529 T C 8.60E-04 Crohn's disease / / 17684544 rs17316151 chr7 15044801 T C 0.00007545 Sarcoidosis / / 22952805 rs6976086 chr7 15048611 T G 3.31E-06 Type 2 diabetes / / 22158537 rs6976086 chr7 15048611 T G 6.47E-06 Glucose levels / / pha002899 rs12699673 chr7 15049604 T C 1.21E-06 Type 2 diabetes / / 22158537 rs6960043 chr7 15052860 T C 0.00000034 Type 2 diabetes / / 22885922 rs6960043 chr7 15052860 T C 0.00000079 Type 2 diabetes (males) / / 22885922 rs17168600 chr7 15053050 T C 4.92E-04 Multiple complex diseases / / 17554300 rs17168600 chr7 15053050 T C 8.54E-04 Insulin resistance / / 21901158 rs10267273 chr7 15053589 C T 2.83E-06 Type 2 diabetes / / 22158537 rs10238161 chr7 15053827 A T 3.12E-06 Type 2 diabetes / / 22158537 rs2191346 chr7 15053878 G C 3.34E-06 Type 2 diabetes / / 22158537 rs2358158 chr7 15054063 T C 4.92E-06 Type 2 diabetes / / 22158537 rs10807778 chr7 15054190 C G 2.51E-04 Type 2 diabetes / / 22158537 rs10238625 chr7 15054232 A G 5.02E-06 Type 2 diabetes / / 22158537 rs11514706 chr7 15059272 A C 4.64E-04 Type 2 diabetes / / 20818381 rs6461153 chr7 15059796 G C 8.90E-05 Type 2 diabetes / / 22158537 rs4721400 chr7 15059906 G A 5.75E-05 Type 2 diabetes / / 22158537 rs2215383 chr7 15062983 T C 9.93E-07 Type 2 diabetes / / 22158537 rs10487796 chr7 15063430 T A 2.20E-07 Type 2 diabetes / / 22158537 rs10244051 chr7 15063833 T G 1.50E-05 Fasting plasma glucose / / 19060907 rs10244051 chr7 15063833 T G 1.00E-07 Metabolic traits / / 19060910 rs10244051 chr7 15063833 T G 2.90E-07 Type 2 diabetes / / 22158537 rs10244051 chr7 15063833 T G 1.45E-07 Glucose levels / / pha002899 rs10228456 chr7 15063926 C T 1.90E-18 Fasting blood glucose / / 22885924 rs10258074 chr7 15064216 A T 3.85E-09 Type 2 diabetes / / 22158537 rs2191348 chr7 15064255 G T 6.75E-09 Type 2 diabetes / / 22158537 rs2191348 chr7 15064255 G T 1.99E-07 Glucose levels / / pha002899 rs2191349 chr7 15064309 G T 3.00E-17 Fasting glucose-related traits / / 20081858 rs2191349 chr7 15064309 G T 3.00E-44 Fasting insulin-related traits / / 20081858 rs2191349 chr7 15064309 G T 3.88E-09 Type 2 diabetes / / 22158537 rs2191349 chr7 15064309 G T 3.00E-21 Fasting glucose-related traits (interaction with BMI) / / 22581228 rs2191349 chr7 15064309 G T 1.30E-42 Type 2 diabetes / / 22885922 rs2191349 chr7 15064309 G T 6.91E-28 Fasting blood glucose / / 22885924 rs6947830 chr7 15064984 G A 9.35E-08 Type 2 diabetes / / 22158537 rs6947830 chr7 15064984 G A 1.00E-13 Metabolic syndrome / / 22399527 rs4719433 chr7 15065003 T C 4.80E-09 Type 2 diabetes / / 22158537 rs1974620 chr7 15065467 C T 4.67E-08 Type 2 diabetes / / 22158537 rs1558317 chr7 15065564 T A 7.99E-09 Type 2 diabetes / / 22158537 rs1558318 chr7 15065612 A T 7.76E-09 Type 2 diabetes / / 22158537 rs758715 chr7 15071860 C T 5.90E-04 Coronary Artery Disease / / 17634449 rs758716 chr7 15071934 A G 2.48E-04 Coronary Artery Disease / / 17634449 rs11768011 chr7 15086375 G A 3.49E-04 Multiple complex diseases / / 17554300 rs218085 chr7 15087599 C T 0.000620869 Hypertension (early onset hypertension) / / 22479346 rs11526191 chr7 15110771 C A 7.83E-04 Multiple complex diseases / / 17554300 rs6971261 chr7 15114926 C A 7.30E-05 Lung adenocarcinoma / / 22797724 rs4598156 chr7 15121951 T C 1.12E-05 Smoking initiation / / 24665060 rs12699683 chr7 15133127 G T 7.00E-06 Paclitaxel-induced neuropathy / / 23776197 rs6963945 chr7 15163010 G C 3.89E-04 Height / / 17255346 rs764702 chr7 15172463 G A 2.75E-04 Myocardial Infarction / / pha002873 rs2961256 chr7 15181337 T G 4.20E-05 Diabetes Mellitus / / pha003060 rs2961257 chr7 15181728 G A 4.20E-05 Diabetes Mellitus / / pha003060 rs2908337 chr7 15207942 A G 1.14E-04 Smoking quantity / / 24665060 rs2908338 chr7 15209679 G A 4.00E-07 Smoking behavior / / 20418888 rs6962150 chr7 15225539 G T 6.18E-05 Cholesterol / / 17255346 rs6977610 chr7 15258456 C T 1.72E-04 Breast cancer AGMO intron pha002853 rs4563782 chr7 15262665 C G 5.43E-04 Alzheimer's disease AGMO intron 17998437 rs6461160 chr7 15265037 C A 2.33E-04 Cholesterol AGMO intron 17255346 rs4721420 chr7 15274261 A T 1.66E-04 Alzheimer's disease AGMO intron 17998437 rs7796519 chr7 15308585 C A 1.08E-04 Cholesterol AGMO intron 17255346 rs12333630 chr7 15318794 C T 2.18E-04 Cholesterol AGMO intron 17255346 rs12531027 chr7 15335936 T C 3.00E-07 Obesity-related traits AGMO intron 23251661 rs10245989 chr7 15354729 G C 2.40E-05 Urinary metabolites AGMO intron 21572414 rs4295557 chr7 15371932 G C 4.27E-04 Type 2 diabetes AGMO intron 17463246 rs4295557 chr7 15371932 G C 1.10E-05 Urinary metabolites AGMO intron 21572414 rs10227084 chr7 15399672 C A 2.10E-05 Urinary metabolites AGMO intron 21572414 rs7805596 chr7 15424706 T G 4.44E-04 Multiple complex diseases AGMO intron 17554300 rs7781293 chr7 15490983 C A 2.78E-05 Intracranial aneurysm AGMO intron 20613766 rs4628172 chr7 15495150 T G 1.32E-05 Intracranial aneurysm AGMO intron 20613766 rs2389409 chr7 15506789 A G 9.56E-05 Intracranial aneurysm AGMO intron 20613766 rs1529893 chr7 15507516 C T 9.00E-05 Height AGMO intron pha003010 rs10950561 chr7 15512407 C A 8.21E-05 Height AGMO intron pha003011 rs10950564 chr7 15537453 T C 6.88E-04 Response to cytadine analogues (cytosine arabinoside) AGMO intron 24483146 rs80017990 chr7 15549146 T G 0.0000233 Nonsyndromic striae distensae (stretch marks) AGMO intron 23633020 rs17389549 chr7 15603853 G A 5.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7782511 chr7 15607046 G A 1.56E-05 Post-operative nausea and vomiting / / 21694509 rs11763320 chr7 15630754 A G 3.81E-05 Orofacial clefts / / 22419666 rs11763353 chr7 15630871 A G 7.00E-07 Blood trace element (Zn levels) / / 23720494 rs6946852 chr7 15643347 C T 6.59E-04 Longevity / / 22279548 rs17168892 chr7 15646634 T C 4.02E-05 Type 2 diabetes / / 17463246 rs11526192 chr7 15646715 C T 2.21E-04 Type 2 diabetes / / 17463246 rs6946099 chr7 15648861 C A 6.26E-05 Serum metabolites / / 19043545 rs6969519 chr7 15654614 T C 1.40E-06 Bladder cancer MEOX2 intron 19648920 rs17168920 chr7 15667079 G C 8.55E-04 Type 2 diabetes MEOX2 intron 17463246 rs3801416 chr7 15667268 G C 8.66E-05 Serum metabolites MEOX2 intron 19043545 rs7786661 chr7 15667695 G T 6.50E-05 Serum metabolites MEOX2 intron 19043545 rs4436006 chr7 15668092 G C 7.25E-05 Serum metabolites MEOX2 intron 19043545 rs10278557 chr7 15699036 G A 5.00E-06 Lung adenocarcinoma MEOX2 intron 21242121 rs3801430 chr7 15722836 G A 9.94E-05 Coronary heart disease MEOX2 intron pha003031 rs3801430 chr7 15722836 G A 2.47E-05 Soluble levels of adhesion molecules MEOX2 intron pha003072 rs1156212 chr7 15729606 T C 2.80E-05 Urinary metabolites / / 21572414 rs10486776 chr7 15742786 G A 6.00E-06 Stroke / / 17434096 rs10486776 chr7 15742786 G A 9.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs6959204 chr7 15751645 G T 1.30E-05 Urinary metabolites / / 21572414 rs2159222 chr7 15758000 A T 8.00E-06 Migraine with aura / / 23793025 rs10264045 chr7 15760654 A C 6.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs531653 chr7 15760677 C T 3.09E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10268121 chr7 15761537 A G 8.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs10239570 chr7 15762169 C G 5.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs10239819 chr7 15762221 G A 6.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs10269078 chr7 15762255 A G 8.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs17169023 chr7 15764473 G A 6.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs17169046 chr7 15782789 A G 5.82E-04 Multiple complex diseases / / 17554300 rs9942711 chr7 15786677 G A 3.51E-04 Multiple complex diseases / / 17554300 rs17169056 chr7 15790826 A G 1.45E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs12533562 chr7 15837740 G A 4.28E-04 Blood pressure / / 17255346 rs11978788 chr7 15842315 G C 2.80E-05 Urinary metabolites / / 21572414 rs10950582 chr7 15852195 T G 8.05E-04 Smoking initiation / / 24665060 rs1942655 chr7 15858350 C T 3.04E-04 Alzheimer's disease / / 24755620 rs2023019 chr7 15862144 A G 2.40E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7782571 chr7 15868120 C T 4.96E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7782571 chr7 15868120 C T 8.20E-04 Alzheimer's disease / / 24755620 rs11768573 chr7 15868471 T G 9.75E-05 Alzheimer's disease / / 24755620 rs4346897 chr7 15877548 A G 7.87E-04 Type 2 diabetes / / 17463246 rs1942637 chr7 15881632 C T 9.16E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17169105 chr7 15883805 G A 1.80E-05 Schizophrenia / / 20832056 rs17169111 chr7 15891270 T C 3.20E-04 Schizophrenia / / 20832056 rs38169 chr7 15893300 C A 8.92E-04 Taste perception / / 22132133 rs38171 chr7 15893530 T C 6.96E-04 White matter integrity / / 22425255 rs38190 chr7 15903720 C T 1.85E-05 Serum metabolites / / 19043545 rs38193 chr7 15904759 C G 1.28E-05 Serum metabolites / / 19043545 rs38195 chr7 15905188 T G 9.81E-06 Serum metabolites / / 19043545 rs38203 chr7 15913115 T C 1.17E-05 Serum metabolites / / 19043545 rs38205 chr7 15913588 A C 5.97E-05 Serum metabolites / / 19043545 rs38218 chr7 15920821 T C 2.96E-05 Serum metabolites / / 19043545 rs38246 chr7 15941283 T C 1.11E-04 Type 2 diabetes / / 17463246 rs12699758 chr7 15964238 A C 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs808986 chr7 15969781 C T 6.02E-05 Serum metabolites / / 19043545 rs800714 chr7 15973072 T C 2.00E-05 Urinary metabolites / / 21572414 rs13239842 chr7 15993723 A G 6.75E-05 Waist Circumference / / pha003024 rs13239842 chr7 15993723 A G 7.32E-05 Waist Circumference / / pha003025 rs17169172 chr7 15993845 G A 3.29E-04 Taste perception / / 22132133 rs1950009 chr7 16003214 C T 2.58E-04 Taste perception / / 22132133 rs10486788 chr7 16015341 G C 4.70E-04 Lipid traits / / 17903299 rs2052028 chr7 16015863 G C 1.10E-06 Biomarkers / / 17903293 rs4719458 chr7 16020949 C G 9.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17169183 chr7 16022371 A G 9.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13234986 chr7 16025340 A G 7.28E-05 Waist Circumference / / pha003024 rs6953206 chr7 16027025 G T 7.56E-04 Taste perception / / 22132133 rs800711 chr7 16048144 C G 7.88E-04 Multiple complex diseases / / 17554300 rs2389575 chr7 16051401 C A 7.14E-04 Multiple complex diseases / / 17554300 rs11761043 chr7 16060201 C T 5.14E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7781422 chr7 16080411 C G 6.20E-04 Multiple complex diseases / / 17554300 rs7778992 chr7 16125447 G C 7.69E-04 Acute lung injury / / 22295056 rs7801576 chr7 16147768 G T 7.23E-04 Type 2 diabetes ISPD intron 17463246 rs1527199 chr7 16213150 G A 9.62E-04 Type 2 diabetes ISPD intron 17463246 rs17169316 chr7 16220314 C T 9.58E-04 Response to cytadine analogues (cytosine arabinoside) ISPD intron 24483146 rs2389591 chr7 16229442 A G 5.27E-05 Multiple complex diseases ISPD intron 17554300 rs10486791 chr7 16284326 C T 1.03E-05 Cognitive impairment induced by topiramate ISPD intron 22091778 rs1295148 chr7 16301526 A G 9.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) ISPD intron 23233662 rs10280613 chr7 16311996 A G 9.68E-05 Bipolar disorder ISPD intron 17486107 rs17150167 chr7 16317068 T C 5.74E-04 Multiple complex diseases ISPD intron 17554300 rs1295127 chr7 16317627 T C 7.83E-05 Acute lung injury ISPD intron 22295056 rs12111732 chr7 16321532 T C 9.80E-04 Acute lung injury ISPD intron 22295056 rs35681285 chr7 16326646 T C 4.00E-07 Serum tamsulosin hydrochloride concentration ISPD intron 23151678 rs2012268 chr7 16338822 T C 9.80E-04 Acute lung injury ISPD intron 22295056 rs13437646 chr7 16348091 A C 1.10E-05 Response to statin therapy ISPD intron 20339536 rs17169417 chr7 16348830 T C 4.30E-05 Response to statin therapy ISPD intron 20339536 rs1990016 chr7 16349164 G C 8.92E-04 Acute lung injury ISPD intron 22295056 rs6976273 chr7 16349755 G A 8.15E-04 Acute lung injury ISPD intron 22295056 rs2023935 chr7 16350130 C A 4.15E-05 Cognitive test performance ISPD intron 20125193 rs12666346 chr7 16351558 T C 4.60E-05 Response to statin therapy ISPD intron 20339536 rs13438718 chr7 16354230 C A 1.40E-05 Response to statin therapy ISPD intron 20339536 rs7785481 chr7 16357439 C A 1.70E-05 Response to statin therapy ISPD intron 20339536 rs6968164 chr7 16360570 A G 8.54E-05 Multiple complex diseases ISPD intron 17554300 rs16878716 chr7 16363446 T C 7.24E-04 Acute lung injury ISPD intron 22295056 rs757523 chr7 16363541 C T 7.13E-04 Acute lung injury ISPD intron 22295056 rs10225332 chr7 16365360 C T 8.50E-05 Multiple complex diseases ISPD intron 17554300 rs17169424 chr7 16367876 C G 5.77E-04 Acute lung injury ISPD intron 22295056 rs17169425 chr7 16367927 A G 5.84E-04 Acute lung injury ISPD intron 22295056 rs17169426 chr7 16368668 A G 4.20E-05 Response to statin therapy ISPD intron 20339536 rs17169428 chr7 16369115 A T 8.90E-06 Response to statin therapy ISPD intron 20339536 rs10950610 chr7 16370043 C G 3.00E-05 Response to statin therapy ISPD intron 20339536 rs9648214 chr7 16380806 C T 1.10E-05 Response to statin therapy ISPD intron 20339536 rs2704677 chr7 16381339 T C 3.20E-06 Response to statin therapy ISPD intron 20339536 rs2526604 chr7 16381366 A G 2.40E-06 Response to statin therapy ISPD intron 20339536 rs4537216 chr7 16383860 G T 2.87E-04 Hemoglobin concentration ISPD intron 20534544 rs12531973 chr7 16385256 A G 1.10E-05 Response to statin therapy ISPD intron 20339536 rs12666868 chr7 16388295 T C 9.70E-06 Response to statin therapy ISPD intron 20339536 rs4615457 chr7 16388624 A G 9.60E-06 Response to statin therapy ISPD intron 20339536 rs4001474 chr7 16389089 T G 1.10E-05 Response to statin therapy ISPD intron 20339536 rs6956331 chr7 16391887 T C 4.88E-04 Acute lung injury ISPD intron 22295056 rs6979033 chr7 16392642 A C 4.88E-04 Acute lung injury ISPD intron 22295056 rs4721492 chr7 16393115 T C 4.88E-04 Acute lung injury ISPD intron 22295056 rs11508469 chr7 16395072 G A 1.50E-05 Response to statin therapy ISPD intron 20339536 rs10950613 chr7 16395343 G A 1.50E-05 Response to statin therapy ISPD intron 20339536 rs6948482 chr7 16395434 T C 4.88E-04 Acute lung injury ISPD intron 22295056 rs10950614 chr7 16395531 C G 1.40E-05 Response to statin therapy ISPD intron 20339536 rs1921839 chr7 16398598 T A 1.30E-05 Response to statin therapy ISPD intron 20339536 rs10950616 chr7 16399822 T C 1.00E-05 Response to statin therapy ISPD intron 20339536 rs12671166 chr7 16404038 G A 7.89E-04 Acute lung injury ISPD intron 22295056 rs4721494 chr7 16404615 T C 4.88E-04 Acute lung injury ISPD intron 22295056 rs10272029 chr7 16457584 G A 5.36E-04 Multiple complex diseases ISPD intron 17554300 rs1921835 chr7 16484541 T C 2.90E-05 Response to statin therapy / / 20339536 rs4721500 chr7 16484903 A G 1.60E-05 Response to statin therapy / / 20339536 rs10238442 chr7 16486969 A G 1.20E-05 Response to statin therapy / / 20339536 rs10238442 chr7 16486969 A G 4.00E-06 Urinary metabolites / / 21572414 rs1921831 chr7 16487259 G A 1.30E-05 Response to statin therapy / / 20339536 rs4721503 chr7 16494407 T C 1.20E-05 Response to statin therapy / / 20339536 rs4721503 chr7 16494407 T C 2.50E-05 Urinary metabolites / / 21572414 rs10270805 chr7 16500142 A G 9.00E-06 Response to statin therapy / / 20339536 rs9791629 chr7 16500409 C T 9.30E-06 Response to statin therapy / / 20339536 rs6971172 chr7 16504273 G C 4.70E-05 Response to statin therapy SOSTDC1 intron 20339536 rs6945425 chr7 16505341 T C 7.80E-05 Response to statin therapy SOSTDC1 UTR-5 20339536 rs2528478 chr7 16506602 G C 5.30E-05 Response to statin therapy / / 20339536 rs1990130 chr7 16532088 G A 5.38E-05 Lipoproteins / / pha003079 rs7803242 chr7 16554669 C A 6.32E-05 Serum metabolites / / 19043545 rs57025232 chr7 16556076 T C 0.0000587 post-traumatic stress disorder / / 22869035 rs57025232 chr7 16556076 T C 5.87E-05 Schizophrenia / / 22883433 rs10214948 chr7 16560898 C T 2.34E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2190310 chr7 16561687 G T 1.71E-06 Serum metabolites / / 19043545 rs10228487 chr7 16591829 C G 2.01E-05 Serum metabolites LRRC72 intron 19043545 rs6968649 chr7 16596685 C G 2.88E-05 Serum metabolites LRRC72 intron 19043545 rs718796 chr7 16618982 T C 1.00E-04 Schizophrenia LRRC72 intron 19197363 rs11540037 chr7 16655387 C A,G,T 3.66E-04 Amyotrophic lateral sclerosis (sporadic) ANKMY2 cds-synon 24529757 rs7797003 chr7 16661137 C T 4.53E-05 Prion diseases ANKMY2 intron 22210626 rs2286223 chr7 16663446 G T 4.86E-05 Prion diseases ANKMY2 intron 22210626 rs10486793 chr7 16668034 C T 2.31E-05 Prion diseases ANKMY2 intron 22210626 rs13244390 chr7 16668402 T C 2.33E-05 Prion diseases ANKMY2 intron 22210626 rs3807504 chr7 16684099 G A 9.61E-04 Multiple complex diseases ANKMY2 intron 17554300 rs58370486 chr7 16707861 A G 6.00E-11 Alzheimer's disease (cognitive decline) BZW2 intron 23535033 rs10264017 chr7 16721781 A G 4.19E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) BZW2 intron 24192120 rs818503 chr7 16722353 A C 4.19E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) BZW2 intron 24192120 rs17627827 chr7 16764996 A G 1.71E-06 Osteoarthritis / / 22763110 rs706048 chr7 16772379 T A 0.0000107 LDL cholesterol particle diameter / / 23263444 rs2037705 chr7 16778383 T C 9.70E-06 Urinary metabolites / / 21572414 rs7800565 chr7 16780009 A G 7.95E-07 Autism / / 22843504 rs864211 chr7 16780932 A G 4.00E-05 HIV-1 control / / 20041166 rs1168056 chr7 16799266 C G 0.0000153 HDL cholesterol particle diameter TSPAN13 intron 23263444 rs1168055 chr7 16800461 G A 0.000013 HDL cholesterol particle diameter TSPAN13 intron 23263444 rs706059 chr7 16807890 T C 0.00000963 LDL cholesterol particle diameter TSPAN13 intron 23263444 rs706065 chr7 16811167 T C 0.0000121 LDL cholesterol particle diameter TSPAN13 intron 23263444 rs1380381 chr7 16813488 T C 9.06E-05 Cognitive test performance TSPAN13 intron 20125193 rs3807496 chr7 16821355 G A 8.27E-04 Type 2 diabetes TSPAN13 intron 17463246 rs2389700 chr7 16821637 T C 1.08E-05 Cholesterol TSPAN13 intron 17255346 rs1037791 chr7 16824662 G A 3.94E-06 Personality dimensions / / 18957941 rs1037791 chr7 16824662 G A 3.90E-06 Personality dimensions / / 21173776 rs1037791 chr7 16824662 G A 1.14E-04 Alzheimer's disease (late onset) / / 21379329 rs2272247 chr7 16834361 T C 9.99E-05 Erythrocyte counts AGR2 intron pha003090 rs2272246 chr7 16834444 C T 7.01E-04 Type 2 diabetes AGR2 intron 17463246 rs2272246 chr7 16834444 C T 8.35E-05 Personality dimensions AGR2 intron 18957941 rs4719480 chr7 16834551 C A 5.07E-04 Type 2 diabetes AGR2 intron 17463246 rs4719480 chr7 16834551 C A 8.10E-04 Lymphocyte counts AGR2 intron 22286170 rs6842 chr7 16834597 A G 3.70E-05 Personality dimensions AGR2 missense 18957941 rs2280655 chr7 16837454 C T 4.00E-06 IgG glycosylation AGR2 intron 23382691 rs3817512 chr7 16839100 A G 1.84E-06 Erythrocyte counts AGR2 intron pha003090 rs706080 chr7 16847778 A G 7.38E-05 Coronary heart disease / / pha003030 rs10224320 chr7 16855007 G T 1.80E-05 Urinary metabolites / / 21572414 rs10253216 chr7 16861849 G A 2.00E-07 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs7797977 chr7 16862235 G T 1.34E-04 IgE levels / / 17255346 rs7797977 chr7 16862235 G T 2.17E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs11768848 chr7 16863727 C A 2.03E-04 IgE levels / / 17255346 rs11768848 chr7 16863727 C A 2.16E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs10232481 chr7 16878113 T G 3.47E-07 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs1404966 chr7 16882053 A G 5.58E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs17136737 chr7 16884241 T G 4.90E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs17136737 chr7 16884241 T G 8.73E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs1917742 chr7 16885379 G T 2.23E-04 Type 2 diabetes / / 17463246 rs1525739 chr7 16889812 C G,T 6.00E-06 Type 2 diabetes (dietary heme iron intake interaction) / / 23386860 rs6951775 chr7 16894898 A G 5.89E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10249546 chr7 16919172 A C 5.57E-04 Tourette syndrome AGR3 intron 22889924 rs10950639 chr7 16925518 A G 6.52E-04 Body mass index / / 21701565 rs10950639 chr7 16925518 A G 7.92E-04 Body mass index / / 21701565 rs10271951 chr7 16942259 C G 7.36E-05 Cognitive decline / / 22054870 rs17268110 chr7 16957026 C T 1.02E-05 Cognitive decline / / 22054870 rs4532498 chr7 16957229 T A 6.41E-05 Cognitive decline / / 22054870 rs12113054 chr7 16960049 T G 4.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs847396 chr7 16968509 G A 4.16E-04 Type 2 diabetes / / 17463246 rs1990114 chr7 16977505 A G 5.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6461292 chr7 17004387 T C 9.94E-04 Multiple complex diseases / / 17554300 rs1721013 chr7 17009601 C T 8.98E-05 Alcohol dependence / / 21314694 rs1523635 chr7 17015695 G T 3.50E-06 HIV-1 progression to AIDS and death / / 21811574 rs1523635 chr7 17015695 G T 6.91E-05 HIV-1 progression to AIDS and death / / 21811574 rs847440 chr7 17018432 T C 6.48E-04 Multiple complex diseases / / 17554300 rs4529355 chr7 17028698 C T 9.29E-05 Neutrophil count / / pha003095 rs4529355 chr7 17028698 C T 3.16E-05 Platelet counts / / pha003100 rs9638738 chr7 17033088 T C 5.42E-05 Platelet counts / / pha003100 rs7782228 chr7 17034817 C G 2.71E-04 Multiple complex diseases / / 17554300 rs7808216 chr7 17040226 C A 7.95E-05 Cognitive performance / / 19734545 rs7808216 chr7 17040226 C A 1.03E-04 White matter integrity / / 22425255 rs1403795 chr7 17062071 T A 7.95E-04 Multiple complex diseases / / 17554300 rs7804595 chr7 17064307 C G 2.60E-05 Urinary metabolites / / 21572414 rs7804595 chr7 17064307 C G 1.56E-05 Substance dependence / / 21818250 rs10252687 chr7 17067366 T C 6.61E-04 Type 2 diabetes / / 17463246 rs4721562 chr7 17082894 A G 4.70E-06 Urinary metabolites / / 21572414 rs6961860 chr7 17085321 C T 5.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs581037 chr7 17089943 C T 4.66E-07 Esophageal cancer (squamous cell) / / 22960999 rs4721564 chr7 17089962 C T 7.68E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs819368 chr7 17109926 C T 9.60E-04 Type 2 diabetes / / 17463246 rs1997091 chr7 17170680 A G 9.85E-05 Myocardial Infarction / / pha002873 rs1997091 chr7 17170680 A G 9.24E-04 Heart Failure / / pha002884 rs17137304 chr7 17196857 A G 6.51E-04 Multiple complex diseases / / 17554300 rs1464906 chr7 17221063 G A 8.60E-05 Caffeine consumption / / 21490707 rs10454311 chr7 17237990 C T 4.09E-05 Lung adenocarcinoma / / 19836008 rs4364538 chr7 17246088 T C 7.69E-05 Serum albumin level / / pha003084 rs1476079 chr7 17277084 C A 7.43E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs4410790 chr7 17284577 T C 2.00E-19 Caffeine consumption / / 21490707 rs6968554 chr7 17287106 A G 9.00E-14 Blood metabolite levels / / 24816252 rs6968865 chr7 17287269 A T 2.00E-11 Coffee consumption / / 21357676 rs17137472 chr7 17296072 C T 4.22E-13 Caffeine consumption / / 21490707 rs12670403 chr7 17309279 C A 5.00E-15 Metabolic traits / / 21886157 rs13236243 chr7 17318312 G A 4.00E-06 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs4719495 chr7 17322683 T C 1.15E-05 Caffeine consumption / / 21490707 rs10247158 chr7 17325168 A T 7.50E-04 Sleep quality / / 23728906 rs3757824 chr7 17336035 T C 7.42E-04 Insomnia / / 23728906 rs1476080 chr7 17357873 T G 4.19E-06 Caffeine consumption AHR intron 21490707 rs2040623 chr7 17380662 A C 3.67E-05 Caffeine consumption AHR intron 21490707 rs7791070 chr7 17401027 T C 4.06E-05 Caffeine consumption / / 21490707 rs7780687 chr7 17405718 A G 2.70E-05 Crohn's disease (need for surgery) / / 23665963 rs9638742 chr7 17437474 A G 0.00004839 Sarcoidosis / / 22952805 rs1077773 chr7 17442679 G A 2.94E-05 Rheumatoid arthritis / / 21452313 rs10259316 chr7 17445706 G T 4.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs2034684 chr7 17475607 T C 4.20E-04 White matter integrity / / 22425255 rs2034684 chr7 17475607 T C 3.66E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs10499498 chr7 17480994 C A,G,T 7.73E-06 Rheumatoid arthritis / / 19503088 rs10499498 chr7 17480994 C A,G,T 1.88E-05 Myocardial Infarction / / pha002883 rs17703824 chr7 17491252 A T 6.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs1868361 chr7 17495669 C T 5.18E-04 Alcohol dependence / / 20201924 rs1868361 chr7 17495669 C T 6.92E-06 Caffeine consumption / / 21490707 rs1375240 chr7 17496069 C T 0.0000396 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs17652855 chr7 17502331 C T 1.67E-04 Type 2 diabetes / / 17463246 rs574007 chr7 17504193 G A 1.01E-08 Coronary heart disease (incident CHD) / / 21829389 rs611935 chr7 17514653 T C 9.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs17704831 chr7 17515826 T G 5.03E-04 Multiple complex diseases / / 17554300 rs13231337 chr7 17559830 A G 0.0000012 Perception of the odorant androstenone / / 22362865 rs10499504 chr7 17561583 A G 4.00E-07 Response to antipsychotic treatment / / 20195266 rs4721626 chr7 17566157 T G 1.80E-04 Taste perception / / 22132133 rs1375238 chr7 17566398 G A 6.43E-04 Taste perception / / 22132133 rs1031275 chr7 17566664 T C 1.98E-04 Taste perception / / 22132133 rs1031277 chr7 17566826 G A 3.57E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1448649 chr7 17571140 A C 5.57E-06 Schizophrenia / / 21795503 rs1979097 chr7 17582940 C G 2.40E-05 Urinary metabolites / / 21572414 rs17714316 chr7 17629654 G T 5.97E-05 Type 2 diabetes / / 17463246 rs10230521 chr7 17650204 T G 4.37E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2192073 chr7 17667816 T C 3.20E-05 HDL cholesterol / / pha003074 rs10488471 chr7 17702135 T C 9.08E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4721643 chr7 17711135 C T 9.93E-05 Alzheimer's disease / / 24755620 rs6977788 chr7 17712531 A G 3.63E-04 Alzheimer's disease / / 24755620 rs10253857 chr7 17713450 T C 5.00E-04 Alzheimer's disease / / 24755620 rs2723558 chr7 17728001 G C 2.67E-04 Type 2 diabetes / / 17463246 rs2723584 chr7 17763163 T C 4.36E-04 Multiple complex diseases / / 17554300 rs1468690 chr7 17764500 C T 1.50E-05 Urinary metabolites / / 21572414 rs2389851 chr7 17796043 T G 4.06E-05 Brain structure / / 22504417 rs1404418 chr7 17814085 A T 4.12E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2691556 chr7 17816060 T A 1.51E-04 Type 2 diabetes / / 17463246 rs1524776 chr7 17872093 C A 0.000031 Follicular lymphoma SNX13 intron 23025665 rs2691601 chr7 17875431 C T 0.0000182 Follicular lymphoma SNX13 intron 23025665 rs4142995 chr7 17919258 G T 9.00E-12 HDL cholesterol SNX13 intron 24097068 rs17138455 chr7 17965838 G A 2.99E-05 Information processing speed SNX13 intron 21130836 rs6973480 chr7 17978129 C T 2.21E-04 Type 2 diabetes SNX13 intron 17463246 rs10226084 chr7 17997612 T C 5.00E-10 Fibrinogen / / 23969696 rs12699927 chr7 18011752 A T 8.06E-04 Type 2 diabetes / / 17463246 rs6957876 chr7 18040264 C T 7.71E-04 Alzheimer's disease / / 17998437 rs4618585 chr7 18071200 G C 3.74E-04 Multiple complex diseases / / 17554300 rs6977061 chr7 18079091 A G 7.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs4642530 chr7 18107755 T C 2.72E-05 Non-small cell lung cancer / / 21866343 rs4642530 chr7 18107755 T C 6.91E-04 Heart Failure / / pha002885 rs7808162 chr7 18110113 T C 2.47E-04 Cholesterol / / 17255346 rs1919314 chr7 18140361 A T 0.00000105 Colorectal adenoma HDAC9 intron 23677573 rs1919314 chr7 18140361 A T 0.00000105 Colorectal adenoma (including hyperplasic) HDAC9 intron 23677573 rs1919314 chr7 18140361 A T 0.00000137 Colorectal adenoma (excluding hyperplasic) HDAC9 intron 23677573 rs2731564 chr7 18150431 G A 4.43E-05 Waist Circumference HDAC9 intron pha003023 rs4490725 chr7 18172374 A G 5.11E-04 Alzheimer's disease HDAC9 intron 17998437 rs12536864 chr7 18218581 A G 7.91E-06 Retinopathy in non-diabetics HDAC9 intron 23393555 rs11489326 chr7 18244502 C T 2.24E-04 Multiple complex diseases HDAC9 intron 17554300 rs2529749 chr7 18253060 A C 8.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HDAC9 intron 20877124 rs302132 chr7 18278088 C G 5.40E-05 Response to lithium treatment in bipolar disorder HDAC9 intron 19448189 rs302147 chr7 18285373 C T 1.60E-14 Narcolepsy HDAC9 intron 19629137 rs917325 chr7 18288593 A G 7.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HDAC9 intron 20877124 rs215122 chr7 18295790 C T 3.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HDAC9 intron 20877124 rs625733 chr7 18328568 G T 2.58E-05 Multiple complex diseases HDAC9 intron 17554300 rs2791300 chr7 18329077 C G 7.70E-05 Type 2 diabetes HDAC9 intron 17463248 rs590099 chr7 18336338 G A 0.000026 Primary sclerosing cholangitis HDAC9 intron 22521342 rs4721708 chr7 18370302 T C 3.80E-06 Type 2 diabetes HDAC9 intron 17463248 rs12666612 chr7 18375245 T C 8.00E-06 Obesity-related traits HDAC9 intron 23251661 rs596844 chr7 18383364 C T 2.63E-04 Alzheimer's disease HDAC9 intron 17998437 rs615545 chr7 18391871 C T 5.90E-06 Type 2 diabetes HDAC9 intron 17463248 rs1365893 chr7 18404917 C A 1.40E-05 Response to alcohol consumption (flushing response) HDAC9 intron 24277619 rs10486301 chr7 18409781 T C 1.94E-04 Bone mass and geometry HDAC9 intron 17903296 rs10486301 chr7 18409781 T C 2.70E-05 Obesity-related traits HDAC9 intron 17903300 rs10236525 chr7 18411672 T C 5.50E-04 Obesity-related traits HDAC9 intron 17903300 rs12155400 chr7 18428921 A G 8.00E-06 Retinopathy in non-diabetics HDAC9 intron 23393555 rs2012064 chr7 18447324 G C 4.50E-04 Obesity-related traits HDAC9 intron 17903300 rs2162563 chr7 18450104 G A 8.81E-04 Type 2 diabetes HDAC9 intron 17463246 rs11977093 chr7 18485913 T C 5.28E-04 Response to taxane treatment (placlitaxel) HDAC9 intron 23006423 rs213273 chr7 18504508 G A 2.00E-08 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) HDAC9 intron 24554482 rs17432356 chr7 18524133 C T 7.15E-04 Multiple complex diseases HDAC9 intron 17554300 rs2188495 chr7 18540461 A C 6.71E-04 Tourette syndrome HDAC9 intron 22889924 rs17432448 chr7 18548419 A G 1.60E-04 Blood pressure HDAC9 intron 21909110 rs13231835 chr7 18565058 T C 2.00E-05 Diastolic blood pressure HDAC9 intron 19430483 rs140585698 chr7 18631217 C G 0.000098 Prostate cancer (advanced) HDAC9 missense 23555315 rs3814991 chr7 18634903 T C 0.000146 Gains in maximal O2 uptake response HDAC9 intron 21183627 rs3814991 chr7 18634903 T C 3.89E-04 Stroke HDAC9 intron pha002886 rs1554772 chr7 18638811 C G 9.50E-06 Urinary metabolites HDAC9 intron 21572414 rs2254993 chr7 18647887 A G 7.95E-04 Amyotrophic lateral sclerosis (sporadic) HDAC9 intron 24529757 rs6963748 chr7 18666217 C T 1.20E-05 Cognitive impairment induced by topiramate HDAC9 intron 22091778 rs6963748 chr7 18666217 C T 3.63E-04 Response to cytadine analogues (cytosine arabinoside) HDAC9 intron 24483146 rs17432977 chr7 18666597 C T 8.43E-04 Response to cytadine analogues (cytosine arabinoside) HDAC9 intron 24483146 rs2285437 chr7 18681992 C G 2.20E-05 Urinary metabolites HDAC9 intron 21572414 rs3801983 chr7 18683672 T C 2.07E-04 Blood pressure HDAC9 intron 17255346 rs2239927 chr7 18689883 G T 2.12E-04 Type 2 diabetes HDAC9 intron 17463246 rs6979890 chr7 18693393 A G 6.17E-04 Type 2 diabetes HDAC9 intron 17463246 rs6979890 chr7 18693393 A G 4.35E-04 Gallstones HDAC9 intron 17632509 rs6979890 chr7 18693393 A G 9.12E-04 Type 2 diabetes HDAC9 intron 22238593 rs6973063 chr7 18697589 A G 4.62E-04 Type 2 diabetes HDAC9 intron 17463246 rs2269752 chr7 18699285 C A 4.75E-05 Stroke HDAC9 intron pha002886 rs2269753 chr7 18699466 A T 4.62E-04 Type 2 diabetes HDAC9 intron 17463246 rs2269754 chr7 18699475 A G 4.62E-04 Type 2 diabetes HDAC9 intron 17463246 rs2285443 chr7 18704889 G A 1.44E-04 Type 2 diabetes HDAC9 intron 17463246 rs801524 chr7 18706918 G A 1.46E-04 Blood pressure HDAC9 UTR-3 17255346 rs801524 chr7 18706918 G A 1.26E-04 Type 2 diabetes HDAC9 UTR-3 17463246 rs706087 chr7 18713515 A G 4.62E-04 Type 2 diabetes HDAC9 intron 17463246 rs17139571 chr7 18714254 T G 6.15E-05 Brain derived neurotrophic factor levels,in serum HDAC9 intron 22047184 rs756790 chr7 18714381 G A 4.62E-04 Type 2 diabetes HDAC9 intron 17463246 rs61584435 chr7 18717509 T G 4.15E-06 PR interval in Tripanosoma cruzi seropositivity HDAC9 intron 24324551 rs4484585 chr7 18718573 C A 6.74E-06 Brain derived neurotrophic factor levels,in serum HDAC9 intron 22047184 rs4484585 chr7 18718573 C A 6.14E-04 Stroke HDAC9 intron pha002886 rs73313346 chr7 18723232 T C 4.00E-06 PR interval in Tripanosoma cruzi seropositivity HDAC9 intron 24324551 rs2106362 chr7 18725261 C G 4.46E-04 Type 2 diabetes HDAC9 intron 17463246 rs6950376 chr7 18728485 A G 3.15E-04 Height HDAC9 intron 17255346 rs17139658 chr7 18730268 T C 8.60E-05 Brain derived neurotrophic factor levels,in serum HDAC9 intron 22047184 rs12669789 chr7 18734065 T C 9.53E-04 Stroke HDAC9 intron pha002886 rs212667 chr7 18739315 G A 7.24E-04 Smoking initiation HDAC9 intron 24665060 rs1178118 chr7 18751998 T C 6.28E-04 Stroke HDAC9 intron pha002887 rs6952102 chr7 18753386 G A 2.52E-04 Blood pressure HDAC9 intron 17255346 rs4721722 chr7 18755646 T C 3.27E-04 Blood pressure HDAC9 intron 17255346 rs17139817 chr7 18795250 T G 5.88E-05 Alzheimer's disease HDAC9 intron 24755620 rs11764116 chr7 18800413 G T 2.00E-06 Ulcerative colitis HDAC9 intron 20848476 rs17139857 chr7 18802346 T C 8.93E-04 Multiple complex diseases HDAC9 intron 17554300 rs17139867 chr7 18802944 A G 8.77E-04 Multiple complex diseases HDAC9 intron 17554300 rs6958865 chr7 18805948 A G 1.53E-04 Alzheimer's disease (late onset) HDAC9 intron 21379329 rs6958865 chr7 18805948 A G 5.96E-06 Alzheimer's disease HDAC9 intron 24755620 rs2519739 chr7 18812445 C A 4.38E-07 Cognitive test performance HDAC9 intron 20125193 rs10261308 chr7 18839183 A C 2.54E-04 Alzheimer's disease HDAC9 intron 24755620 rs17140017 chr7 18855192 A C 4.95E-04 Multiple complex diseases HDAC9 intron 17554300 rs3852256 chr7 18866844 A G 2.16E-08 Male-pattern baldness HDAC9 intron 22693459 rs17349860 chr7 18868031 C T 8.66E-09 Male-pattern baldness HDAC9 intron 22693459 rs3852257 chr7 18871692 C T 6.75E-11 Male-pattern baldness HDAC9 intron 22693459 rs2016515 chr7 18874385 T G 9.75E-10 Male-pattern baldness HDAC9 intron 22693459 rs13238389 chr7 18876899 C A 1.46E-11 Male-pattern baldness HDAC9 intron 22693459 rs957960 chr7 18877408 C A 2.32E-09 Male-pattern baldness HDAC9 intron 22693459 rs957958 chr7 18877616 A G 1.45E-12 Male-pattern baldness HDAC9 intron 22693459 rs2073963 chr7 18877874 T G 1.00E-12 Male-pattern baldness HDAC9 intron 22693459 rs2073964 chr7 18878150 G A 3.06E-12 Male-pattern baldness HDAC9 intron 22693459 rs12536836 chr7 18881075 C T 4.06E-11 Male-pattern baldness HDAC9 intron 22693459 rs6461386 chr7 18883690 G A 2.19E-09 Male-pattern baldness HDAC9 intron 22693459 rs756853 chr7 18890000 G A 3.26E-04 Coronary Artery Disease HDAC9 intron 17634449 rs756853 chr7 18890000 G A 1.40E-11 Male-pattern baldness HDAC9 intron 22693459 rs13245206 chr7 18891259 G A 7.39E-04 Depression (quantitative trait) HDAC9 intron 20800221 rs13245206 chr7 18891259 G A 1.33E-11 Male-pattern baldness HDAC9 intron 22693459 rs10230371 chr7 18894897 T C 1.39E-11 Male-pattern baldness HDAC9 intron 22693459 rs12699994 chr7 18895297 C T 1.25E-04 Coronary Artery Disease HDAC9 intron 17634449 rs2249817 chr7 18896011 A G 1.56E-11 Male-pattern baldness HDAC9 intron 22693459 rs6461387 chr7 18898305 G A 7.59E-04 Depression (quantitative trait) HDAC9 intron 20800221 rs6461387 chr7 18898305 G A 3.24E-11 Male-pattern baldness HDAC9 intron 22693459 rs756854 chr7 18903015 C T 8.40E-04 Depression (quantitative trait) HDAC9 intron 20800221 rs756854 chr7 18903015 C T 1.39E-10 Male-pattern baldness HDAC9 intron 22693459 rs6461389 chr7 18907030 C T 2.96E-04 Coronary Artery Disease HDAC9 intron 17634449 rs6461389 chr7 18907030 C T 3.13E-04 Depression (quantitative trait) HDAC9 intron 20800221 rs6973029 chr7 18908850 C T 2.94E-04 Depression (quantitative trait) HDAC9 intron 20800221 rs6461390 chr7 18910232 A G 2.31E-04 Depression (quantitative trait) HDAC9 intron 20800221 rs6461390 chr7 18910232 A G 2.44E-08 Male-pattern baldness HDAC9 intron 22693459 rs6951144 chr7 18911789 C G 5.30E-04 Depression (quantitative trait) HDAC9 intron 20800221 rs6951144 chr7 18911789 C G 1.95E-08 Male-pattern baldness HDAC9 intron 22693459 rs6951745 chr7 18911957 G A 3.96E-04 Depression (quantitative trait) HDAC9 intron 20800221 rs6951745 chr7 18911957 G A 1.32E-08 Male-pattern baldness HDAC9 intron 22693459 rs6461392 chr7 18912802 G A 4.01E-04 Depression (quantitative trait) HDAC9 intron 20800221 rs6461392 chr7 18912802 G A 1.24E-08 Male-pattern baldness HDAC9 intron 22693459 rs6461393 chr7 18912815 T G 3.06E-04 Depression (quantitative trait) HDAC9 intron 20800221 rs6461393 chr7 18912815 T G 2.89E-08 Male-pattern baldness HDAC9 intron 22693459 rs6461394 chr7 18912890 C G 4.40E-04 Depression (quantitative trait) HDAC9 intron 20800221 rs6461394 chr7 18912890 C G 9.54E-09 Male-pattern baldness HDAC9 intron 22693459 rs7794241 chr7 18913380 C A 2.74E-04 Depression (quantitative trait) HDAC9 intron 20800221 rs7794241 chr7 18913380 C A 2.67E-08 Male-pattern baldness HDAC9 intron 22693459 rs2286213 chr7 18914251 C G 3.04E-04 Depression (quantitative trait) HDAC9 intron 20800221 rs2286213 chr7 18914251 C G 2.60E-08 Male-pattern baldness HDAC9 intron 22693459 rs6959501 chr7 18915133 T C 9.23E-04 Type 2 diabetes HDAC9 intron 17463246 rs10237149 chr7 18915426 G A 2.10E-04 Depression (quantitative trait) HDAC9 intron 20800221 rs10237149 chr7 18915426 G A 3.73E-08 Male-pattern baldness HDAC9 intron 22693459 rs10237366 chr7 18915559 G C 2.68E-04 Depression (quantitative trait) HDAC9 intron 20800221 rs10237366 chr7 18915559 G C 4.56E-08 Male-pattern baldness HDAC9 intron 22693459 rs10237280 chr7 18915666 C T 2.69E-04 Depression (quantitative trait) HDAC9 intron 20800221 rs10237280 chr7 18915666 C T 3.49E-08 Male-pattern baldness HDAC9 intron 22693459 rs13233322 chr7 18915701 C A 1.41E-04 Depression (quantitative trait) HDAC9 intron 20800221 rs13233322 chr7 18915701 C A 3.81E-08 Male-pattern baldness HDAC9 intron 22693459 rs10486314 chr7 18915874 A G 1.57E-04 Depression (quantitative trait) HDAC9 intron 20800221 rs10486314 chr7 18915874 A G 4.96E-08 Male-pattern baldness HDAC9 intron 22693459 rs7811991 chr7 18918559 T C 1.24E-05 Multiple sclerosis (brain glutamate levels) HDAC9 intron 20802204 rs10486317 chr7 18935733 G A 7.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HDAC9 intron 20877124 rs201664762 chr7 18938958 T TC 7.10E-05 Coronary heart disease HDAC9 intron pha003030 rs2301949 chr7 18938958 T C 7.10E-05 Coronary heart disease HDAC9 intron pha003030 rs17350515 chr7 18941624 G A 1.90E-04 Response to taxane treatment (placlitaxel) HDAC9 intron 23006423 rs2853552 chr7 18980267 A G 7.00E-06 Obesity-related traits HDAC9 intron 23251661 rs2717344 chr7 19030853 G A 2.58E-05 Cytomegalovirus antibody response HDAC9 intron 21993531 rs11984041 chr7 19031935 C T 2.00E-11 Stroke HDAC9 intron 22306652 rs7788972 chr7 19034280 T A 3.73E-05 Aging (time to event) HDAC9 intron 21782286 rs7788972 chr7 19034280 T A 4.70E-05 Blood pressure HDAC9 intron 21909110 rs2023938 chr7 19036775 T C 0.000023 Coronary artery disease (CAD) (males) HDAC9 UTR-3 23202125 rs2023938 chr7 19036775 T C 0.000171 Coronary artery disease (CAD) age >50 HDAC9 UTR-3 23202125 rs2023938 chr7 19036775 T C 3.59E-10 Coronary artery disease HDAC9 UTR-3 23202125 rs2023938 chr7 19036775 T C 1.65E-06 Stroke (ischemic) HDAC9 UTR-3 24262325 rs2023938 chr7 19036775 T C 2.33E-09 Large artery stroke HDAC9 UTR-3 24262325 rs7776735 chr7 19036909 T C 5.98E-04 Depression (quantitative trait) HDAC9 UTR-3 20800221 rs432 chr7 19038332 A G 4.90E-04 Depression (quantitative trait) / / 20800221 rs10241753 chr7 19042101 C T 2.88E-04 Depression (quantitative trait) / / 20800221 rs112954726 chr7 19047369 T TC 7.15E-04 Depression (quantitative trait) / / 20800221 rs2717369 chr7 19047369 T C 7.15E-04 Depression (quantitative trait) / / 20800221 rs2107595 chr7 19049388 G A 7.68E-06 Stroke (ischemic) / / 21957438 rs2107595 chr7 19049388 G A 2.00E-16 Stroke (ischemic) / / 23041239 rs2107595 chr7 19049388 G A 4.00E-06 Stroke (ischemic) / / 23041239 rs2107595 chr7 19049388 G A 3.00E-12 Large artery stroke / / 24262325 rs2107595 chr7 19049388 G A 3.00E-12 Coronary artery disease or large artery stroke / / 24262325 rs2107595 chr7 19049388 G A 4.40E-06 Stroke (ischemic) / / 24262325 rs57301765 chr7 19052733 G A 7.55E-06 Stroke (ischemic) / / 21957438 rs9986679 chr7 19059315 T A 4.97E-04 Depression (quantitative trait) / / 20800221 rs1548576 chr7 19070165 A G 9.99E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs429 chr7 19106505 G C 4.96E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs430 chr7 19106539 G A 4.00E-07 Obesity-related traits / / 23251661 rs17435999 chr7 19131207 T C 3.57E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10225279 chr7 19133072 G T 8.50E-08 Primary tooth development (time to first tooth eruption) / / 23704328 rs985246 chr7 19148847 T G 7.86E-04 Schizophrenia / / 19197363 rs2189000 chr7 19161218 A G 8.28E-06 Personality dimensions / / 23658558 rs12055909 chr7 19163657 G C 4.00E-04 Body mass index / / 24827717 rs12669145 chr7 19190897 A C 4.62E-04 Depression (quantitative trait) / / 20800221 rs10257541 chr7 19193626 A C 8.32E-04 Depression (quantitative trait) / / 20800221 rs1544371 chr7 19197077 C T 8.08E-04 Depression (quantitative trait) / / 20800221 rs10486333 chr7 19200132 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11766540 chr7 19200815 T C 0.0000193 alzheimer's disease (late onset) / / 22785395 rs11973510 chr7 19211253 C A 8.66E-04 Alcohol dependence / / 21314694 rs17140875 chr7 19248278 G T 5.00E-06 Obesity-related traits / / 23251661 rs3922356 chr7 19250811 A G 1.26E-04 Heart Failure / / pha002885 rs6461405 chr7 19255957 G T 3.89E-04 Body mass index / / 17255346 rs4499987 chr7 19293207 C A 4.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10486343 chr7 19327430 A G 2.50E-05 Urinary metabolites / / 21572414 rs10486343 chr7 19327430 A G 7.04E-04 Heart Failure / / pha002884 rs1860799 chr7 19336160 T G 5.76E-04 Smoking initiation / / 24665060 rs6980408 chr7 19346506 G A 5.61E-04 Acute lung injury / / 22295056 rs17141121 chr7 19350615 T C 7.60E-04 Acute lung injury / / 22295056 rs11768982 chr7 19353107 G A 4.73E-05 Cervical cancer / / 24700089 rs13243246 chr7 19355187 G T 3.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13243246 chr7 19355187 G T 8.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9654950 chr7 19371245 A G 2.42E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs6963269 chr7 19380375 C G 2.00E-07 Urinary metabolites / / 21572414 rs6967799 chr7 19386915 C T 4.10E-06 Urinary metabolites / / 21572414 rs6967671 chr7 19386932 A T 3.10E-06 Urinary metabolites / / 21572414 rs6968088 chr7 19387069 C T 2.10E-06 Urinary metabolites / / 21572414 rs6461422 chr7 19387826 G C 2.30E-06 Urinary metabolites / / 21572414 rs7784569 chr7 19390577 G A 5.20E-06 Urinary metabolites / / 21572414 rs6461425 chr7 19392086 G C 3.49E-05 Cervical cancer / / 24700089 rs9639329 chr7 19399831 A G 4.43E-04 Type 2 diabetes / / 17463246 rs9639329 chr7 19399831 A G 3.20E-06 Cholesterol / / pha003073 rs9639329 chr7 19399831 A G 8.93E-06 ldl cholesterol / / pha003076 rs9639329 chr7 19399831 A G 1.80E-06 Cholesterol / / pha003078 rs12154698 chr7 19403816 C T 4.74E-05 Cholesterol / / pha003073 rs12154698 chr7 19403816 C T 2.66E-05 ldl cholesterol / / pha003076 rs12154698 chr7 19403816 C T 3.19E-05 Cholesterol / / pha003078 rs17437739 chr7 19437424 T G 6.60E-06 Urinary metabolites / / 21572414 rs10243311 chr7 19448729 G A 4.77E-07 Cholesterol / / pha003073 rs10243311 chr7 19448729 G A 1.09E-07 ldl cholesterol / / pha003076 rs10243311 chr7 19448729 G A 1.81E-07 Cholesterol / / pha003078 rs1024768 chr7 19454846 C T 2.90E-06 Urinary metabolites / / 21572414 rs1024768 chr7 19454846 C T 2.70E-05 Cholesterol / / pha003073 rs1024768 chr7 19454846 C T 2.30E-06 ldl cholesterol / / pha003076 rs1024768 chr7 19454846 C T 5.82E-06 Cholesterol / / pha003078 rs6977022 chr7 19458922 C T 3.86E-07 Cholesterol / / pha003073 rs6977022 chr7 19458922 C T 1.22E-07 ldl cholesterol / / pha003076 rs6977022 chr7 19458922 C T 1.30E-07 Cholesterol / / pha003078 rs10486347 chr7 19461203 C A 1.50E-07 Urinary metabolites / / 21572414 rs10486347 chr7 19461203 C A 2.39E-05 Cholesterol / / pha003073 rs10486347 chr7 19461203 C A 8.40E-07 ldl cholesterol / / pha003076 rs10486347 chr7 19461203 C A 6.98E-06 Cholesterol / / pha003078 rs2892930 chr7 19462953 T C,G 1.70E-06 Urinary metabolites / / 21572414 rs4286843 chr7 19463247 T C 2.20E-06 Urinary metabolites / / 21572414 rs17141298 chr7 19463507 T C 1.20E-05 Urinary metabolites / / 21572414 rs7811056 chr7 19476939 G A 5.69E-05 Cognitive test performance / / 20125193 rs10807792 chr7 19487492 A T 5.61E-04 Type 2 diabetes / / 17463246 rs11980263 chr7 19501541 A G 9.69E-04 Type 2 diabetes / / 17463246 rs2019077 chr7 19513563 T C 7.13E-04 Type 2 diabetes / / 17463246 rs12112466 chr7 19514347 G A 6.73E-04 Type 2 diabetes / / 17463246 rs2192491 chr7 19516492 G A 7.93E-04 Myocardial Infarction / / pha002873 rs17428326 chr7 19521578 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9648258 chr7 19524863 G A,C 6.57E-05 Blood Pressure / / pha003047 rs4719561 chr7 19527095 G A 3.82E-04 Type 2 diabetes / / 17463246 rs17141444 chr7 19531380 T C 3.86E-06 Body Mass Index / / pha003006 rs17141444 chr7 19531380 T C 1.49E-05 Body Mass Index / / pha003014 rs17141444 chr7 19531380 T C 2.51E-05 Weight / / pha003026 rs17141444 chr7 19531380 T C 3.68E-05 Blood Pressure / / pha003047 rs10216141 chr7 19532215 G A 0.000701 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10216141 chr7 19532215 G A 7.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7810842 chr7 19541920 C T 1.75E-05 Disc degeneration (lumbar) / / 24216480 rs7810842 chr7 19541920 C T 4.83E-06 Body Mass Index / / pha003006 rs7810842 chr7 19541920 C T 2.37E-05 Body Mass Index / / pha003014 rs7810842 chr7 19541920 C T 2.15E-05 Weight / / pha003026 rs7810842 chr7 19541920 C T 7.97E-05 Blood Pressure / / pha003047 rs11981985 chr7 19543561 A G 3.86E-06 Body Mass Index / / pha003006 rs11981985 chr7 19543561 A G 1.49E-05 Body Mass Index / / pha003014 rs11981985 chr7 19543561 A G 2.51E-05 Weight / / pha003026 rs11981985 chr7 19543561 A G 3.68E-05 Blood Pressure / / pha003047 rs3922288 chr7 19606855 C T 4.05E-04 Multiple complex diseases / / 17554300 rs10257637 chr7 19615992 A G 7.62E-05 Post-operative nausea and vomiting / / 21694509 rs4470914 chr7 19616522 C T 9.00E-10 Height / / 20881960 rs1121732 chr7 19621903 G C 9.76E-04 Type 2 diabetes / / 17463246 rs1476882 chr7 19687779 C T 8.85E-05 Weight / / pha003026 rs6947737 chr7 19706972 G A 7.13E-05 Bipolar disorder / / 22925353 rs4719581 chr7 19798123 C A 2.24E-05 Amyotrophic lateral sclerosis (sporadic) TMEM196 intron 24529757 rs10486365 chr7 19801364 A G 1.90E-04 Kidney function and endocine traits TMEM196 intron 17903292 rs6977660 chr7 19805480 C T 4.00E-06 Thyroid stimulating hormone TMEM196 intron 17903292 rs6953957 chr7 19820560 A G 3.67E-05 Colorectal cancer / / 24448986 rs17142054 chr7 19862221 A G 2.45E-04 HIV-1 viral setpoint / / 17641165 rs12670524 chr7 19900888 G A 3.71E-05 Cognitive impairment induced by topiramate / / 22091778 rs13240921 chr7 19959995 T C 1.30E-05 Urinary metabolites / / 21572414 rs2390203 chr7 19970430 T C 6.57E-05 Cholesterol / / pha003073 rs6461470 chr7 19978609 C A 6.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1558043 chr7 19979773 G C 1.18E-04 Multiple complex diseases / / 17554300 rs12531520 chr7 19986340 T C 1.03E-04 Multiple complex diseases / / 17554300 rs10486379 chr7 19994501 T C 8.63E-05 Multiple complex diseases / / 17554300 rs11971925 chr7 19994754 G C 1.44E-04 Multiple complex diseases / / 17554300 rs11984165 chr7 20010489 A G 9.25E-05 Post-operative nausea and vomiting / / 21694509 rs17142283 chr7 20030908 G T 6.06E-04 Multiple complex diseases / / 17554300 rs4530935 chr7 20036179 G T 0.0005863 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4530935 chr7 20036179 G T 5.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2158860 chr7 20044438 A G 4.47E-04 Longevity / / 22279548 rs38152 chr7 20047575 A C 7.00E-08 HIV-1 control / / 20041166 rs2390248 chr7 20048677 A C 2.96E-06 Multiple complex diseases / / 17554300 rs77629081 chr7 20072789 G T 0.0000712 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7795980 chr7 20084445 T C 2.91E-06 Non-word repetition / / 23738518 rs7777159 chr7 20084601 A G 5.81E-06 Non-word repetition / / 23738518 rs1019249 chr7 20085640 T G 1.40E-05 Non-word repetition / / 23738518 rs1019248 chr7 20085995 T G 2.21E-06 Non-word repetition / / 23738518 rs2041664 chr7 20086385 G A 2.21E-06 Non-word repetition / / 23738518 rs2041663 chr7 20086675 A G 2.21E-06 Non-word repetition / / 23738518 rs6954796 chr7 20086982 C G 2.00E-06 Non-word repetition / / 23738518 rs10240011 chr7 20088988 T C 2.90E-05 Non-word repetition / / 23738518 rs4721864 chr7 20093641 G A 2.45E-05 Non-word repetition / / 23738518 rs4721865 chr7 20093737 T C 3.30E-06 Non-word repetition / / 23738518 rs10269473 chr7 20098212 A G 2.78E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs10269473 chr7 20098212 A G 3.31E-05 Non-word repetition / / 23738518 rs6461475 chr7 20103335 G A 8.85E-06 Non-word repetition / / 23738518 rs9639354 chr7 20103456 T A 8.85E-06 Non-word repetition / / 23738518 rs4721870 chr7 20104412 C T 1.04E-05 Non-word repetition / / 23738518 rs11971426 chr7 20104908 G T 6.28E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11971426 chr7 20104908 G T 9.60E-06 HIV-1 control / / 20041166 rs1005499 chr7 20105490 T G 3.30E-06 Non-word repetition / / 23738518 rs10246471 chr7 20106196 T C 3.30E-06 Non-word repetition / / 23738518 rs6978921 chr7 20107086 C T 1.10E-05 Non-word repetition / / 23738518 rs2041660 chr7 20107623 T C 3.30E-06 Non-word repetition / / 23738518 rs7779287 chr7 20107743 A G,T 1.10E-05 Non-word repetition / / 23738518 rs6954985 chr7 20114589 G A 3.78E-04 Multiple complex diseases / / 17554300 rs12673150 chr7 20117491 T A 2.10E-06 Urinary metabolites / / 21572414 rs6461477 chr7 20120064 G A 6.78E-04 Type 2 diabetes / / 23300278 rs10235691 chr7 20154816 A G 2.85E-05 B cell non-Hodgkin lymphoma / / 23749188 rs11975851 chr7 20174508 G A 7.10E-04 Response to cytidine analogues (gemcitabine) MACC1 UTR-3 24483146 rs2390256 chr7 20177882 C T 1.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MACC1 UTR-3 20877124 rs2241056 chr7 20178865 C T 7.20E-05 Parkinson's disease (age of onset) MACC1 UTR-3 19772629 rs10479996 chr7 20188761 A G 2.95E-04 Type 2 diabetes MACC1 intron 17463246 rs3095008 chr7 20255705 G A 9.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) MACC1 intron 23648065 rs6966545 chr7 20289490 C A 9.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs6954393 chr7 20290620 T C 9.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs10486388 chr7 20291878 G A 8.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs17142623 chr7 20294461 T C 1.72E-05 Coronary heart disease / / pha003030 rs4141115 chr7 20302652 T A 6.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs2057991 chr7 20303015 C T 7.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs6461483 chr7 20303264 T C 7.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs6976594 chr7 20304287 C T 6.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs9691231 chr7 20305298 A G 6.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs6974950 chr7 20306752 C T 5.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs6975579 chr7 20307015 G T 5.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs6975721 chr7 20307061 G A 7.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs6961865 chr7 20307364 T C 7.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs2892978 chr7 20309378 C T 9.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs2529004 chr7 20319981 G A 2.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs2529031 chr7 20321176 G T 8.51E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2529027 chr7 20321757 T A 3.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs17142673 chr7 20326797 G A 2.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2529009 chr7 20328783 C T 3.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs3095209 chr7 20330345 G C 3.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs3114424 chr7 20331766 C T 3.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs2109366 chr7 20335554 G T 2.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs3095203 chr7 20337516 G A 1.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs3095201 chr7 20337722 C T 1.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs2302344 chr7 20338100 T C 2.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs6960555 chr7 20349870 T A 8.14E-04 Body mass index / / 21701565 rs10486391 chr7 20376018 A G 5.72E-04 Self-reported allergy ITGB8 intron 23817569 rs3807931 chr7 20381674 G A 3.54E-05 Serum metabolites ITGB8 intron 19043545 rs17364875 chr7 20392230 A G 2.39E-05 Serum metabolites ITGB8 intron 19043545 rs10950804 chr7 20396275 C G 6.14E-05 Serum metabolites ITGB8 intron 19043545 rs10265149 chr7 20397974 A G 2.87E-05 Serum metabolites ITGB8 intron 19043545 rs17455862 chr7 20402258 T C 7.79E-05 Serum metabolites ITGB8 intron 19043545 rs3779505 chr7 20405265 G A 6.76E-05 Monocyte chemoattractant protein-1 ITGB8 intron pha003071 rs12700186 chr7 20416711 T C 6.68E-04 Self-reported allergy ITGB8 intron 23817569 rs3823974 chr7 20442796 T C 0.0000676 Tuberculosis with late age of onset ITGB8 intron 22551897 rs17142799 chr7 20443960 G A,C,T 9.37E-04 Multiple complex diseases ITGB8 intron 17554300 rs10270074 chr7 20487120 G A,C,T 1.00E-04 Information processing speed / / 21130836 rs7796492 chr7 20489873 A G 7.11E-05 Information processing speed / / 21130836 rs11971231 chr7 20506347 C T 8.61E-05 Tourette syndrome / / 22889924 rs7807424 chr7 20520093 A G 5.64E-04 Tourette syndrome / / 22889924 rs4141371 chr7 20521616 C T 9.29E-04 Multiple complex diseases / / 17554300 rs2188873 chr7 20526266 G A 2.58E-04 Alcohol consumption / / 23743675 rs10226404 chr7 20530767 G T 3.84E-04 Alzheimer's disease / / 17998437 rs2023791 chr7 20534004 G A 2.70E-05 Urinary metabolites / / 21572414 rs12670982 chr7 20543838 G A 0.00000653 Inter-adventitial common carotid artery diameter / / 23246012 rs10273717 chr7 20552821 C T 2.80E-05 Urinary metabolites / / 21572414 rs4721914 chr7 20568162 A G 7.81E-04 Tourette syndrome / / 22889924 rs6461504 chr7 20572445 G A 3.00E-04 Body mass index / / 17255346 rs10244416 chr7 20575751 C T 1.64E-04 Self-reported allergy / / 23817569 rs999600 chr7 20596348 G T 0.000007 Mean arterial pressure / / 22510845 rs17143056 chr7 20596929 A G 4.20E-04 Body mass index / / 21701565 rs2188865 chr7 20604398 G A 6.04E-04 Multiple complex diseases / / 17554300 rs2188866 chr7 20604449 C T 2.85E-05 Sarcoidosis / / 19165924 rs2188866 chr7 20604449 C T 9.69E-04 Eye color / / 23118974 rs1858940 chr7 20636239 C T 5.93E-06 Left ventricular mass / / 21212386 rs17143143 chr7 20636465 A G 8.45E-04 Myopia (pathological) / / 21095009 rs1858943 chr7 20640509 T C 2.13E-05 Coronary heart disease / / pha003030 rs17143180 chr7 20646786 C G 1.50E-05 Response to statin therapy / / 20339536 rs10950821 chr7 20647015 C G 7.00E-06 Response to statin therapy / / 20339536 rs7809674 chr7 20656054 G A 2.70E-05 Urinary metabolites ABCB5 intron 21572414 rs12667658 chr7 20659545 T A 7.90E-05 Response to statin therapy ABCB5 intron 20339536 rs7777864 chr7 20663684 G C 1.10E-05 Response to statin therapy ABCB5 intron 20339536 rs59623110 chr7 20678749 T C 2.66E-07 PR interval in Tripanosoma cruzi seropositivity ABCB5 intron 24324551 rs73276602 chr7 20681850 A C 1.00E-07 PR interval in Tripanosoma cruzi seropositivity ABCB5 intron 24324551 rs12669250 chr7 20683447 A G 2.60E-05 Urinary metabolites ABCB5 intron 21572414 rs1858948 chr7 20686111 A C 2.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ABCB5 intron 20877124 rs17143272 chr7 20736577 T C 3.20E-06 Urinary metabolites ABCB5 intron 21572414 rs7793093 chr7 20736785 A G 2.10E-05 Urinary metabolites ABCB5 intron 21572414 rs2024045 chr7 20737300 C T 8.30E-06 Urinary metabolites ABCB5 intron 21572414 rs17218211 chr7 20740648 A G 8.88E-05 Orofacial clefts ABCB5 intron 22863734 rs17143304 chr7 20767954 G A 6.57E-04 Multiple complex diseases ABCB5 missense 17554300 rs6959944 chr7 20774091 A C 2.78E-04 Prostate cancer mortality ABCB5 intron 20978177 rs9638774 chr7 20777250 T G 0.00089 Salmonella-induced pyroptosis ABCB5 intron 22837397 rs10244045 chr7 20777911 A G 2.20E-05 Urinary metabolites ABCB5 intron 21572414 rs6461517 chr7 20787273 C T 6.87E-04 Multiple complex diseases ABCB5 intron 17554300 rs10266329 chr7 20791801 T C 6.72E-04 Multiple complex diseases ABCB5 intron 17554300 rs2108258 chr7 20791998 A G 2.00E-06 Dental caries ABCB5 intron 23259602 rs2709748 chr7 20819770 G A 1.38E-05 Behcet's disease / / pha002888 rs16872619 chr7 20831800 A G 2.50E-05 Urinary metabolites / / 21572414 rs10488575 chr7 20835440 T C 2.30E-06 Parkinson's disease (familial) / / 18985386 rs2058076 chr7 20840256 A G 2.10E-05 Urinary metabolites / / 21572414 rs2529754 chr7 20844897 C G 5.00E-04 Body mass index / / 24827717 rs2709736 chr7 20862302 C T 5.00E-07 Bipolar disorder / / 20386566 rs13245023 chr7 20885095 C G 9.00E-06 IgG glycosylation / / 23382691 rs17143423 chr7 20896062 A G 3.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs204595 chr7 20911427 C G 2.00E-05 Urinary metabolites / / 21572414 rs2160093 chr7 20950496 T C 2.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2160093 chr7 20950496 T C 8.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs1008132 chr7 20960966 A G 6.08E-06 Cognitive decline / / 23207651 rs12155172 chr7 20994491 A G 9.00E-06 Prostate cancer / / 19767753 rs12155172 chr7 20994491 A G 9.00E-06 Nasopharyngeal carcinoma / / 20512145 rs12155172 chr7 20994491 A G 5.00E-13 Prostate cancer / / 23535732 rs12155172 chr7 20994491 A G 8.46E-05 Height / / pha003010 rs12155172 chr7 20994491 A G 4.21E-05 Height / / pha003011 rs10229329 chr7 20999419 A G 5.63E-04 Type 2 diabetes / / 17463246 rs17732288 chr7 21000512 C T 6.71E-04 Response to TNF antagonist treatment / / 21061259 rs7798796 chr7 21002212 T A 2.72E-04 Type 2 diabetes / / 17463246 rs4721960 chr7 21014294 C T 5.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs17676175 chr7 21026663 C T 8.59E-05 Response to TNF antagonist treatment / / 21061259 rs10245794 chr7 21027606 T C 4.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17676368 chr7 21030508 A G 8.19E-05 Cognitive test performance / / 20125193 rs2192055 chr7 21062826 A G 7.40E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13243044 chr7 21085264 G A 1.55E-05 Prostate cancer / / pha002877 rs1019233 chr7 21088583 C T 8.86E-04 Nicotine dependence / / 17158188 rs2159851 chr7 21103691 T C 0.000761411 Hypertension (early onset hypertension) / / 22479346 rs10215875 chr7 21129084 A C 2.27E-05 Odorant perception / / 23910658 rs17678809 chr7 21136170 G T 9.73E-05 Coronary heart disease / / pha003033 rs971993 chr7 21140280 T A 2.81E-05 Bipolar disorder,schizoaffective / / 19567891 rs971992 chr7 21140343 A G 1.30E-05 Bipolar disorder,schizoaffective / / 19567891 rs971990 chr7 21140386 A G 2.88E-05 Bipolar disorder,schizoaffective / / 19567891 rs6962818 chr7 21142122 T C 8.35E-04 Bipolar disorder,schizoaffective / / 19567891 rs2893030 chr7 21142846 A T 2.55E-04 Aortic root size / / 21223598 rs12673221 chr7 21144053 C G 2.66E-04 Bipolar disorder,schizoaffective / / 19567891 rs10230986 chr7 21146266 A G 8.79E-04 Acute lung injury / / 22295056 rs11974269 chr7 21147678 A C 5.00E-06 Obesity-related traits / / 23251661 rs11974269 chr7 21147678 A C 8.00E-08 Obesity-related traits / / 23251661 rs2390472 chr7 21156006 T G 9.18E-04 Alzheimer's disease / / 22005930 rs9918539 chr7 21159018 G A 2.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs7778476 chr7 21160163 C T 8.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs10274515 chr7 21161384 A G 6.55E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17679859 chr7 21161819 G A 6.55E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10950840 chr7 21163355 C T 7.00E-06 Obesity-related traits / / 23251661 rs17143888 chr7 21163915 T C 8.15E-04 Alzheimer's disease / / 22005930 rs4721981 chr7 21164766 C A 8.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs17143897 chr7 21165694 A G 1.63E-04 Arthritis (juvenile idiopathic) / / 22354554 rs17143902 chr7 21166006 C A 1.99E-05 Multiple complex diseases / / 17554300 rs2192059 chr7 21170406 T C 6.18E-05 Cognitive impairment induced by topiramate / / 22091778 rs10488365 chr7 21171130 G T 5.81E-04 Acute lung injury / / 22295056 rs6967293 chr7 21172745 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6951646 chr7 21178927 G A 4.00E-04 HIV(mother-to-child transmission) / / 20487506 rs10229873 chr7 21182508 G A 8.31E-04 Acute lung injury / / 22295056 rs17143933 chr7 21183179 A C 8.31E-04 Acute lung injury / / 22295056 rs875929 chr7 21183711 G T 4.69E-04 Acute lung injury / / 22295056 rs887719 chr7 21184273 A G 9.50E-04 Multiple complex diseases / / 17554300 rs887717 chr7 21184366 T A 4.21E-04 Acute lung injury / / 22295056 rs887721 chr7 21184662 C G 5.46E-05 Acute lung injury / / 22295056 rs10275894 chr7 21185091 G T 3.85E-04 Acute lung injury / / 22295056 rs10246207 chr7 21185178 A C 3.85E-04 Acute lung injury / / 22295056 rs10441051 chr7 21188469 C G 5.43E-04 Acute lung injury / / 22295056 rs12112656 chr7 21189077 T C 4.91E-05 Acute lung injury / / 22295056 rs6461538 chr7 21192588 A T 3.26E-05 Acute lung injury / / 22295056 rs2215675 chr7 21193209 A G 8.57E-04 Acute lung injury / / 22295056 rs12700260 chr7 21195371 C T 0.000091 Panic disorder / / 23149450 rs12700260 chr7 21195371 C T 9.10E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs6461540 chr7 21196917 C T 6.63E-05 Cognitive performance / / 19734545 rs4721986 chr7 21197888 T C 3.49E-05 Acute lung injury / / 22295056 rs4236298 chr7 21199891 G A 4.26E-04 Acute lung injury / / 22295056 rs10269330 chr7 21202731 G A 3.25E-04 Acute lung injury / / 22295056 rs4236300 chr7 21206547 C T 4.40E-04 Acute lung injury / / 22295056 rs4236301 chr7 21206672 G C 4.41E-04 Acute lung injury / / 22295056 rs6971109 chr7 21222790 C T 7.00E-06 Capecitabine sensitivity / / 22864933 rs10228903 chr7 21245736 A G 1.56E-04 Multiple complex diseases / / 17554300 rs4236303 chr7 21277792 T C 3.82E-05 Birth weight / / 17255346 rs17144109 chr7 21279909 T C 7.23E-04 Type 2 diabetes / / 17463246 rs1637308 chr7 21350308 A G 4.68E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2700294 chr7 21357936 G C 0.000000802 Left ventricular internal diameter / / 23275298 rs2700294 chr7 21357936 G C 0.000000802 LV diastolic diameter / / 23275298 rs2041025 chr7 21362310 A G 4.51E-04 Alzheimer's disease / / 22005930 rs2041026 chr7 21362447 A G 4.12E-04 Alzheimer's disease / / 22005930 rs6461554 chr7 21378687 C T 7.83E-05 Alzheimer's disease (late onset) / / 21379329 rs7793253 chr7 21398774 A G 4.74E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4722019 chr7 21422747 G A 2.36E-04 Taste perception / / 22132133 rs4722020 chr7 21424543 C T 2.40E-05 HIV-1 progression to AIDS and death / / 21811574 rs7792922 chr7 21439191 G A 5.21E-04 Alzheimer's disease / / 22005930 rs6947410 chr7 21443716 A G 2.74E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12700284 chr7 21446889 G T 8.44E-05 Alcohol and nictotine co-dependence / / 20158304 rs39298 chr7 21460818 C T 6.83E-04 Schizophrenia / / 19197363 rs10261327 chr7 21462828 T C 9.01E-05 Waist Circumference / / pha003023 rs7795411 chr7 21474580 G A 2.01E-06 Major depressive disorder (broad) SP4 intron 20038947 rs2282887 chr7 21474664 C A 8.32E-06 Major depressive disorder (broad) SP4 intron 20038947 rs757429 chr7 21486346 A G 2.18E-04 Fibrinogen SP4 intron 17255346 rs2107449 chr7 21488929 A G 5.55E-07 Acute lymphoblastic leukemia (B-cell precursor) SP4 intron 23996088 rs10233357 chr7 21490045 C A 6.35E-06 Major depressive disorder (broad) SP4 intron 20038947 rs2282890 chr7 21490317 C G 3.31E-04 Body mass index SP4 intron 17255346 rs10950853 chr7 21492171 T A 8.19E-05 Major depressive disorder (broad) SP4 intron 20038947 rs7793276 chr7 21493866 A C 8.04E-05 Major depressive disorder (broad) SP4 intron 20038947 rs12672607 chr7 21496830 A T 1.50E-05 Major depressive disorder (broad) SP4 intron 20038947 rs3807644 chr7 21497574 C T 3.39E-05 Major depressive disorder (broad) SP4 intron 20038947 rs17144465 chr7 21504427 A G 8.00E-07 Major depressive disorder (broad) SP4 intron 20038947 rs17144465 chr7 21504427 A G 6.00E-06 Major depressive disorder SP4 intron 20125088 rs10235984 chr7 21506256 G T 3.60E-06 Major depressive disorder (broad) SP4 intron 20038947 rs2282896 chr7 21512722 G A 4.76E-05 Major depressive disorder (broad) SP4 intron 20038947 rs3807641 chr7 21530104 A G 9.56E-06 Major depressive disorder (broad) SP4 intron 20038947 rs7811417 chr7 21534152 T C 6.02E-05 Hypertension SP4 intron pha003042 rs12674215 chr7 21539783 A G 2.13E-05 Major depressive disorder (broad) SP4 intron 20038947 rs2390538 chr7 21542891 T C 1.31E-06 Acute lymphoblastic leukemia (B-cell precursor) SP4 intron 23996088 rs2390538 chr7 21542891 T C 5.05E-04 Response to cytadine analogues (cytosine arabinoside) SP4 intron 24483146 rs3823777 chr7 21549853 G A 6.75E-05 Major depressive disorder (broad) SP4 intron 20038947 rs10249014 chr7 21556942 A G 1.05E-06 Acute lymphoblastic leukemia (B-cell precursor) / / 23996088 rs6970985 chr7 21583597 G T 3.93E-04 Parkinson's disease D/H11 intron 17052657 rs10258022 chr7 21583667 A G 5.83E-04 Parkinson's disease D/H11 intron 17052657 rs2285947 chr7 21584088 G A 1.00E-06 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) D/H11 intron 23103227 rs2285947 chr7 21584088 G A 1.00E-16 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) D/H11 intron 23103227 rs2285947 chr7 21584088 G A 2.00E-08 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) D/H11 intron 23103227 rs2285947 chr7 21584088 G A 3.00E-06 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) D/H11 intron 23103227 rs4722037 chr7 21586595 C T 9.73E-04 Obesity (extreme) D/H11 intron 21935397 rs6977909 chr7 21606129 A G 0.000465 Cholesterol,total D/H11 intron 23063622 rs12670798 chr7 21607352 T C 6.00E-09 LDL cholesterol D/H11 intron 19060911 rs12670798 chr7 21607352 T C 9.00E-07 Cholesterol,total D/H11 intron 19060911 rs12670798 chr7 21607352 T C 7.00E-10 LDL cholesterol D/H11 intron 20686565 rs12670798 chr7 21607352 T C 6.00E-09 Coronary heart disease D/H11 intron 21347282 rs12670798 chr7 21607352 T C 0.00085 LDL cholesterol D/H11 intron 23100282 rs12670798 chr7 21607352 T C 1.00E-16 Cholesterol,total D/H11 intron 24097068 rs12670798 chr7 21607352 T C 5.00E-14 LDL cholesterol D/H11 intron 24097068 rs6947026 chr7 21632107 G T 8.73E-04 Amyotrophic lateral sclerosis (sporadic) D/H11 intron 24529757 rs17745898 chr7 21640618 C G 6.20E-05 Response to platinum-based chemotherapy in small-cell lung cancer D/H11 intron 20463552 rs17746573 chr7 21655667 T C 2.62E-04 Multiple complex diseases D/H11 intron 17554300 rs200581574 chr7 21659659 C T 0.000021 Prostate cancer (advanced) D/H11 missense 23555315 rs10950865 chr7 21680566 T C 9.91E-04 Obesity (extreme) D/H11 intron 21935397 rs10274168 chr7 21680849 C T 6.87E-05 Response to taxane treatment (placlitaxel) D/H11 intron 23006423 rs12700288 chr7 21683103 A G 8.47E-04 Obesity (extreme) D/H11 intron 21935397 rs9639385 chr7 21693607 C A 8.53E-05 Serum metabolites D/H11 intron 19043545 rs6975512 chr7 21706255 G A 1.00E-04 Cognitive impairment induced by topiramate D/H11 intron 22091778 rs11773573 chr7 21710425 C T 9.84E-05 Multiple complex diseases D/H11 intron 17554300 rs940433 chr7 21715868 T A 2.97E-05 Conotruncal heart defects D/H11 intron 24800985 rs2965392 chr7 21719802 T C 2.95E-04 Multiple complex diseases D/H11 intron 17554300 rs2033884 chr7 21728627 T G 4.29E-05 Parkinson's disease D/H11 intron 21044948 rs368331 chr7 21742974 A G 2.00E-06 Total ventricular volume D/H11 intron 21116278 rs368331 chr7 21742974 A G 4.00E-06 MRI atrophy measures D/H11 intron 21116278 rs763290 chr7 21750942 A G 3.99E-05 Post-operative nausea and vomiting D/H11 intron 21694509 rs12536928 chr7 21765452 C T 0.00039 Prostate cancer D/H11 cds-synon 23555315 rs9639391 chr7 21771290 T G 1.47E-05 Tuberculosis D/H11 intron 24057671 rs7800783 chr7 21771465 G A 1.45E-07 Body mass index D/H11 intron 19584900 rs7800783 chr7 21771465 G A 9.80E-08 Body mass index D/H11 intron 19584900 rs933353 chr7 21779104 C T 0.0000162 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity D/H11 intron 22945461 rs9639395 chr7 21779665 G A 1.97E-04 Alcohol consumption (maxi-drinks) D/H11 intron 24277619 rs6461597 chr7 21783145 C T 2.01E-04 Alzheimer's disease (late onset) D/H11 intron 21379329 rs6461597 chr7 21783145 C T 0.0000334 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity D/H11 intron 22945461 rs1029599 chr7 21783458 A G 3.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) D/H11 intron 20877124 rs41479046 chr7 21791371 C T 6.54E-04 Type 2 diabetes D/H11 intron 17463246 rs7780974 chr7 21798233 A G 3.22E-04 Alzheimer's disease (late onset) D/H11 intron 21379329 rs17277521 chr7 21799157 C T 0.0000267 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity D/H11 intron 22945461 rs6461599 chr7 21800459 A G 7.40E-04 Crohn's disease D/H11 intron 17684544 rs6978810 chr7 21807211 C A 6.35E-05 Orofacial clefts D/H11 intron 22419666 rs10268039 chr7 21807773 G A 3.70E-06 Urinary metabolites D/H11 intron 21572414 rs3926905 chr7 21814769 A G 1.85E-04 Alzheimer's disease (late onset) D/H11 intron 21379329 rs12164106 chr7 21830508 C T 5.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) D/H11 intron 20877124 rs2390593 chr7 21861112 C T 4.00E-06 Cognitive decline (age-related) D/H11 intron 24468470 rs4722063 chr7 21893504 T C 4.70E-05 Diabetic nephropathy D/H11 intron pha002866 rs11982264 chr7 21894133 C A 7.84E-04 Multiple complex diseases D/H11 intron 17554300 rs11980938 chr7 21897871 C T 1.76E-04 Multiple complex diseases D/H11 intron 17554300 rs10485986 chr7 21906677 C T 5.50E-09 Multiple myeloma D/H11 intron 22120009 rs886313 chr7 21909081 A C 3.78E-08 Multiple myeloma D/H11 intron 22120009 rs11766053 chr7 21910572 A G 3.25E-09 Multiple myeloma D/H11 intron 22120009 rs11761264 chr7 21912476 G A 9.61E-10 Multiple myeloma D/H11 intron 22120009 rs17361667 chr7 21914990 C A 1.90E-11 Multiple myeloma D/H11 intron 22120009 rs17361723 chr7 21915442 T C 2.55E-06 Multiple myeloma D/H11 intron 22120009 rs2390595 chr7 21915464 G A 2.02E-07 Multiple myeloma D/H11 intron 22120009 rs2390595 chr7 21915464 G A 5.00E-10 Multiple myeloma D/H11 intron 23955597 rs35107743 chr7 21915693 G A 2.16E-06 Multiple myeloma D/H11 intron 22120009 rs6964220 chr7 21917216 A G 2.84E-05 Multiple myeloma D/H11 intron 22120009 rs13308113 chr7 21917360 G A 2.66E-07 Multiple myeloma D/H11 intron 22120009 rs6979604 chr7 21919727 A G 1.14E-06 Multiple myeloma D/H11 intron 22120009 rs11763022 chr7 21920046 G A 1.16E-11 Multiple myeloma D/H11 intron 22120009 rs11763025 chr7 21920165 C T 2.87E-11 Multiple myeloma D/H11 intron 22120009 rs62445884 chr7 21920556 G A 1.07E-06 Multiple myeloma D/H11 intron 22120009 rs7350056 chr7 21922555 T C 1.11E-05 Multiple myeloma D/H11 intron 22120009 rs7350056 chr7 21922555 T C 2.00E-07 Multiple myeloma D/H11 intron 23955597 rs7349999 chr7 21922566 G A 7.23E-06 Multiple myeloma D/H11 intron 22120009 rs7349999 chr7 21922566 G A 1.00E-07 Multiple myeloma D/H11 intron 23955597 rs57437438 chr7 21923372 C G 3.44E-07 Multiple myeloma D/H11 intron 22120009 rs4439007 chr7 21923867 C G 3.27E-07 Multiple myeloma D/H11 intron 22120009 rs6963989 chr7 21924239 C G 1.36E-06 Multiple myeloma D/H11 intron 22120009 rs11769521 chr7 21925105 A T 7.70E-12 Multiple myeloma D/H11 intron 22120009 rs11770434 chr7 21925856 A T 5.74E-07 Multiple myeloma D/H11 intron 22120009 rs11763709 chr7 21925978 G C 2.92E-11 Multiple myeloma D/H11 intron 22120009 rs11763665 chr7 21925986 C A 2.92E-11 Multiple myeloma D/H11 intron 22120009 rs12154628 chr7 21926650 C T 1.79E-06 Multiple myeloma D/H11 intron 22120009 rs7785157 chr7 21927082 G C 2.25E-12 Multiple myeloma D/H11 intron 22120009 rs57104699 chr7 21928079 C A 2.29E-12 Multiple myeloma D/H11 intron 22120009 rs6461614 chr7 21928527 T C 6.83E-08 Multiple myeloma D/H11 intron 22120009 rs6461614 chr7 21928527 T C 2.00E-08 Multiple myeloma D/H11 intron 23955597 rs34894075 chr7 21928572 A G 1.04E-06 Multiple myeloma D/H11 intron 22120009 rs6948632 chr7 21929452 T G 2.29E-12 Multiple myeloma D/H11 intron 22120009 rs4392794 chr7 21929575 A C 7.40E-08 Smoking cessation D/H11 intron 18519826 rs6949101 chr7 21929756 T C 7.74E-07 Multiple myeloma D/H11 intron 22120009 rs6949101 chr7 21929756 T C 2.00E-08 Multiple myeloma D/H11 intron 23955597 rs35907340 chr7 21931262 T C 9.69E-07 Multiple myeloma D/H11 intron 22120009 rs12700323 chr7 21931586 C G 9.63E-07 Multiple myeloma D/H11 intron 22120009 rs12537531 chr7 21932044 C T 2.60E-09 Multiple myeloma D/H11 missense 22120009 rs12537531 chr7 21932044 C T 7.00E-10 Multiple myeloma D/H11 missense 23955597 rs12533111 chr7 21932973 A T 2.25E-10 Multiple myeloma D/H11 intron 22120009 rs4624929 chr7 21933924 C T 1.82E-10 Multiple myeloma D/H11 intron 22120009 rs75341503 chr7 21936698 A C 9.94E-14 Multiple myeloma D/H11 intron 22120009 rs7808371 chr7 21936857 A T 9.76E-04 Multiple complex diseases D/H11 intron 17554300 rs12700324 chr7 21937156 C T 1.12E-06 Multiple myeloma D/H11 intron 22120009 rs4636103 chr7 21937988 C T 3.30E-12 Multiple myeloma D/H11 intron 22120009 rs4636103 chr7 21937988 C T 1.00E-13 Multiple myeloma D/H11 intron 23955597 rs4487645 chr7 21938240 C A,T 3.00E-14 Multiple myeloma D/H11 intron 22120009 rs4487645 chr7 21938240 C A,T 1.00E-09 Multiple myeloma (hyperdiploidy) D/H11 intron 23502783 rs4487645 chr7 21938240 C A,T 2.00E-15 Multiple myeloma D/H11 intron 23955597 rs56333627 chr7 21939032 C A 2.66E-11 Multiple myeloma D/H11 cds-synon 22120009 rs55714084 chr7 21939089 C A 5.01E-14 Multiple myeloma D/H11 intron 22120009 rs35469450 chr7 21939382 A G 4.69E-08 Multiple myeloma D/H11 intron 22120009 rs35469450 chr7 21939382 A G 2.00E-08 Multiple myeloma D/H11 intron 23955597 rs34245961 chr7 21939485 C T 8.15E-07 Multiple myeloma D/H11 intron 22120009 rs56268505 chr7 21940480 C T 5.83E-07 Multiple myeloma D/H11 intron 22120009 rs7971 chr7 21940960 A G 4.04E-13 Multiple myeloma D/H11 UTR-3 22120009 rs7971 chr7 21940960 A G 8.00E-15 Multiple myeloma D/H11 UTR-3 23955597 rs12700325 chr7 21941439 A G 6.72E-04 Alzheimer's disease D/H11 UTR-3 22005930 rs12700325 chr7 21941439 A G 5.49E-07 Multiple myeloma D/H11 UTR-3 22120009 rs1128226 chr7 21941669 A C 9.32E-12 Multiple myeloma CDCA7L UTR-3 22120009 rs1128226 chr7 21941669 A C 3.00E-14 Multiple myeloma CDCA7L UTR-3 23955597 rs4534048 chr7 21944185 A G 8.20E-07 Multiple myeloma CDCA7L intron 22120009 rs6976370 chr7 21944239 A G 5.53E-07 Multiple myeloma CDCA7L intron 22120009 rs56249828 chr7 21944607 T C 1.10E-10 Multiple myeloma CDCA7L intron 22120009 rs6953368 chr7 21945086 C A 7.98E-06 Multiple myeloma CDCA7L intron 22120009 rs12540021 chr7 21945563 G A 9.07E-07 Multiple myeloma CDCA7L intron 22120009 rs6461617 chr7 21945687 A G 8.09E-05 Multiple myeloma CDCA7L intron 22120009 rs6461617 chr7 21945687 A G 0.0000471 Colorectal adenoma (excluding hyperplasic) CDCA7L intron 23677573 rs6461617 chr7 21945687 A G 0.0000471 Colorectal adenoma (including hyperplasic) CDCA7L intron 23677573 rs4445125 chr7 21945840 C T 1.30E-05 Multiple myeloma CDCA7L intron 22120009 rs4445125 chr7 21945840 C T 1.00E-07 Multiple myeloma CDCA7L intron 23955597 rs10238537 chr7 21946772 T C 7.09E-04 Multiple myeloma CDCA7L intron 22120009 rs12234262 chr7 21949303 C T 1.79E-10 Multiple myeloma CDCA7L intron 22120009 rs12234262 chr7 21949303 C T 2.00E-12 Multiple myeloma CDCA7L intron 23955597 rs7811690 chr7 21949865 C G 5.01E-04 Multiple myeloma CDCA7L intron 22120009 rs12700327 chr7 21955785 T C 2.04E-04 Smoking cessation CDCA7L intron 18519826 rs10447610 chr7 21957378 T A 9.49E-04 Multiple myeloma CDCA7L intron 22120009 rs4442026 chr7 21958303 T A 6.55E-04 Multiple myeloma CDCA7L intron 22120009 rs4566940 chr7 21962694 T C 1.13E-04 Multiple myeloma CDCA7L intron 22120009 rs6946675 chr7 21980773 A C 5.81E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) CDCA7L intron 23648065 rs1320800 chr7 21991532 C T 6.68E-04 Multiple complex diseases / / 17554300 rs1320800 chr7 21991532 C T 2.41E-04 Smoking quantity / / 24665060 rs6461625 chr7 22000425 G A 2.70E-06 Sickle cell anemia (severity) / / 20029952 rs3956550 chr7 22008406 A C 4.00E-04 Alzheimer's disease (late onset) / / 21379329 rs1175000 chr7 22024040 T C 5.00E-06 Height / / 20189936 rs1174999 chr7 22024392 C G 1.74E-04 Multiple complex diseases / / 17554300 rs1174962 chr7 22044442 A T 2.63E-05 Smoking cessation / / 18519826 rs1534765 chr7 22073635 C T 8.78E-04 Coronary Artery Disease / / 17634449 rs1637078 chr7 22097476 A G 4.33E-05 Personality dimensions / / 22628180 rs7812259 chr7 22098105 G C 3.28E-05 Serum metabolites / / 19043545 rs1419772 chr7 22098226 C T 4.52E-05 Serum metabolites / / 19043545 rs1833111 chr7 22098259 G A 4.45E-05 Serum metabolites / / 19043545 rs1730900 chr7 22100234 C A 2.22E-04 Multiple complex diseases / / 17554300 rs7805729 chr7 22103427 G T 5.93E-04 Smoking initiation / / 24665060 rs7784234 chr7 22109436 G A 4.35E-05 Cognitive performance / / 19734545 rs10499559 chr7 22109459 G A 8.00E-06 Thyroid stimulating hormone / / 17903292 rs6949977 chr7 22113206 T C 5.51E-04 Body mass index / / 21701565 rs12154589 chr7 22121378 G T 9.37E-04 Alzheimer's disease / / 17998437 rs10250173 chr7 22124074 G T 7.59E-04 Alzheimer's disease / / 17998437 rs4722094 chr7 22131881 T C 1.93E-05 Longevity / / 22279548 rs10264093 chr7 22138141 C T 8.65E-05 Post-operative nausea and vomiting / / 21694509 rs1859800 chr7 22140620 C T 3.37E-04 Body mass index / / 21701565 rs4421272 chr7 22141292 A G 3.02E-04 Multiple complex diseases / / 17554300 rs3915972 chr7 22141711 A G 2.91E-04 Body mass index / / 21701565 rs1054766 chr7 22145115 A G 3.14E-05 IgE levels / / 22075330 rs7793103 chr7 22146840 A G 1.28E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs7793103 chr7 22146840 A G 1.20E-04 Vaspin levels / / 22907691 rs7793103 chr7 22146840 A G 0.0001197 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs13227860 chr7 22154454 G A 3.14E-07 Parkinson's disease / / 17052657 rs17707505 chr7 22158064 C T 3.10E-04 Alcohol dependence RAPGEF5 UTR-3 20201924 rs6461638 chr7 22171582 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes RAPGEF5 intron 22628534 rs1981601 chr7 22202485 T C 5.80E-06 Crohn's disease RAPGEF5 intron 20570966 rs17766562 chr7 22224775 G A 6.03E-04 Type 2 diabetes RAPGEF5 intron 17463246 rs3813383 chr7 22233813 C A 0.0000618 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes RAPGEF5 intron 22628534 rs17146385 chr7 22237835 G A 3.18E-04 Type 2 diabetes RAPGEF5 intron 17463246 rs7776500 chr7 22250955 G T 9.61E-04 Type 2 diabetes RAPGEF5 intron 17463246 rs2214935 chr7 22295360 A G 2.93E-06 Multiple sclerosis RAPGEF5 intron 19525953 rs17774699 chr7 22311040 A T 5.74E-04 Multiple complex diseases RAPGEF5 intron 17554300 rs17774699 chr7 22311040 A T 2.80E-05 Urinary metabolites RAPGEF5 intron 21572414 rs17146521 chr7 22317659 A C 8.06E-04 Iron levels RAPGEF5 intron pha002876 rs1345253 chr7 22319020 T A,C,G 3.76E-04 Amyotrophic Lateral Sclerosis RAPGEF5 intron 17827064 rs1798806 chr7 22324993 T C 9.05E-04 Depression (quantitative trait) RAPGEF5 intron 20800221 rs1419767 chr7 22344911 C T 6.44E-04 Smoking initiation RAPGEF5 intron 24665060 rs13225921 chr7 22353246 T A 2.10E-05 Urinary metabolites RAPGEF5 intron 21572414 rs12333614 chr7 22358234 C T 0.0000068 Asthma (exacerbation) RAPGEF5 intron 23706709 rs12333614 chr7 22358234 C T 6.78E-04 Smoking cessation RAPGEF5 intron 24665060 rs12534999 chr7 22389452 C T 1.90E-05 Urinary metabolites RAPGEF5 intron 21572414 rs7779378 chr7 22409383 G A 8.52E-04 Alzheimer's disease / / 22005930 rs10485989 chr7 22478446 G A 5.05E-04 Type 2 diabetes STEAP1B intron 17463246 rs41472845 chr7 22487377 C A 5.35E-10 Multiple complex diseases STEAP1B intron 17554300 rs3114717 chr7 22492390 C T 7.35E-04 Alcohol consumption (maxi-drinks) STEAP1B intron 24277619 rs3114727 chr7 22496723 G A 2.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) STEAP1B intron 20877124 rs3114727 chr7 22496723 G A 2.00E-04 Dietary macronutrient intake STEAP1B intron 23636237 rs3114731 chr7 22501599 G A 4.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) STEAP1B intron 20877124 rs3114731 chr7 22501599 G A 2.22E-04 Dietary macronutrient intake STEAP1B intron 23636237 rs2893079 chr7 22506694 G A 5.93E-04 Stroke STEAP1B intron pha002887 rs17364464 chr7 22514053 A G 4.00E-06 Dialysis-related mortality STEAP1B intron 21546767 rs6964291 chr7 22580927 G A 4.03E-04 Multiple complex diseases / / 17554300 rs10255691 chr7 22585081 T A,G 3.66E-04 Multiple complex diseases / / 17554300 rs17146997 chr7 22594509 A G 6.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17366199 chr7 22603615 G A 5.42E-04 Multiple complex diseases LOC100506178 intron 17554300 rs17147027 chr7 22603972 C A 8.46E-05 Serum metabolites LOC100506178 intron 19043545 rs6964885 chr7 22608971 G A 9.72E-04 Type 2 diabetes LOC100506178 intron 17463246 rs2023718 chr7 22612164 C T 5.89E-04 Multiple complex diseases / / 17554300 rs2905346 chr7 22618248 G A 9.47E-06 Suicidal ideation / / 20877300 rs12535797 chr7 22684739 T G 4.79E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1989838 chr7 22701167 A C 3.37E-04 Multiple complex diseases / / 17554300 rs2961296 chr7 22702344 C G 7.28E-04 Multiple complex diseases / / 17554300 rs2961296 chr7 22702344 C G 1.80E-05 Urinary metabolites / / 21572414 rs2157958 chr7 22706707 C T 7.50E-06 Urinary metabolites / / 21572414 rs2961300 chr7 22708784 C G 9.20E-06 Urinary metabolites / / 21572414 rs2905324 chr7 22709003 C A 7.47E-04 Multiple complex diseases / / 17554300 rs2961310 chr7 22724407 T A 5.70E-06 Urinary metabolites / / 21572414 rs1548418 chr7 22725414 C A 3.87E-07 Esophageal cancer (squamous cell) / / 22960999 rs2097677 chr7 22732839 G A 4.00E-11 C-reactive protein / / 21196492 rs10155981 chr7 22756463 C T 2.00E-07 Bilirubin levels / / 22085899 rs7458109 chr7 22757915 G C 4.26E-04 Sleep duration / / 23728906 rs7801617 chr7 22758082 G A 5.11E-06 Bilirubin levels / / 22085899 rs12700386 chr7 22763009 C G 6.20E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs2069837 chr7 22768027 A G 6.60E-05 Waist Circumference IL6 intron pha003024 rs2069837 chr7 22768027 A G 1.62E-05 Waist-Hip Ratio IL6 intron pha003029 rs2066992 chr7 22768249 G T 6.30E-05 Multiple sclerosis IL6 intron 21833088 rs2066992 chr7 22768249 G T 0.000416468 Primary sclerosing cholangitis IL6 intron 23603763 rs13306436 chr7 22771296 G A 4.17E-08 HDL cholesterol IL6 UTR-3 23063622 rs13306436 chr7 22771296 G A 9.90E-11 Cholesterol,total IL6 UTR-3 23063622 rs7808122 chr7 22798080 T C 0.000000058 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs7808122 chr7 22798080 T C 0.0000189 Oligoarticular juvenile idiopathic arthritis / / 23603761 rs7808122 chr7 22798080 T C 0.000142 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis / / 23603761 rs17147265 chr7 22804939 A C 5.93E-06 Esophageal cancer (squamous cell) / / 22960999 rs6946509 chr7 22809490 T C 3.36E-08 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs13243243 chr7 22821019 C T 6.17E-05 Schizophrenia(age at onset) / / 21688384 rs7781074 chr7 22826360 C T 7.53E-04 Type 2 diabetes / / 17463246 rs2240727 chr7 22852512 C T 2.79E-06 Type 2 diabetes TOMM7 UTR-3 21647700 rs2286503 chr7 22856606 C T 7.00E-09 Fibrinogen TOMM7 intron 23969696 rs2286499 chr7 22857477 T C 6.23E-04 Type 2 diabetes TOMM7 intron 17463246 rs2286498 chr7 22857504 T C 5.34E-04 Type 2 diabetes TOMM7 intron 17463246 rs10224419 chr7 22870016 G A 5.81E-04 Multiple complex diseases / / 17554300 rs41487946 chr7 22872145 C G 7.26E-04 Type 2 diabetes / / 17463246 rs17147355 chr7 22883835 C G 2.31E-04 Multiple complex diseases / / 17554300 rs7811699 chr7 22899109 T C 1.48E-04 Type 2 diabetes / / 17463246 rs2270101 chr7 22936004 A G 1.26E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2270101 chr7 22936004 A G 4.10E-04 Suicidal ideation / / 22030708 rs7804486 chr7 22946782 C T 2.13E-04 Multiple complex diseases / / 17554300 rs4719720 chr7 22951843 G A 2.88E-04 Multiple complex diseases / / 17554300 rs4719720 chr7 22951843 G A 5.29E-05 Prion diseases / / 22210626 rs11768107 chr7 22959129 C G 7.30E-05 Diabetic retinopathy / / 21441570 rs727125 chr7 22974912 T G 1.07E-05 Word reading / / 23738518 rs7788668 chr7 22980638 C A 4.50E-04 Suicidal ideation FAM126A nearGene-3 22030708 rs4607514 chr7 22983702 A T 1.92E-05 Word reading FAM126A UTR-3 23738518 rs2286494 chr7 22984824 T C 1.92E-05 Word reading FAM126A UTR-3 23738518 rs2286492 chr7 22985010 A C 2.04E-05 Multiple complex diseases FAM126A UTR-3 17554300 rs2286492 chr7 22985010 A C 8.00E-06 Bipolar disorder FAM126A UTR-3 21254220 rs2286492 chr7 22985010 A C 4.03E-05 Intelligence FAM126A UTR-3 21826061 rs2286491 chr7 22985868 T C 5.56E-04 Amyotrophic Lateral Sclerosis FAM126A intron 17362836 rs4719722 chr7 22988820 A G 1.43E-05 Word reading FAM126A intron 23738518 rs1595127 chr7 22989204 A T 1.43E-05 Word reading FAM126A intron 23738518 rs73082373 chr7 22994186 T G 6.00E-06 Periodontitis (Mean PAL) FAM126A intron 24024966 rs6461679 chr7 23010063 T C 2.67E-06 Osteoarthritis FAM126A intron 22763110 rs2286707 chr7 23028610 G T 3.49E-05 Intelligence FAM126A intron 21826061 rs10225133 chr7 23040468 C T 4.16E-04 Multiple complex diseases FAM126A intron 17554300 rs4236312 chr7 23049832 T C 3.85E-04 Amyotrophic Lateral Sclerosis FAM126A intron 17362836 rs4719726 chr7 23054378 G A 6.92E-04 Amyotrophic Lateral Sclerosis FAM126A nearGene-5 17362836 rs2041357 chr7 23098548 A G 4.88E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6967419 chr7 23136310 C T 2.02E-05 Parkinson's disease / / 21738487 rs12700412 chr7 23140624 C T 1.30E-05 Urinary metabolites / / 21572414 rs13438188 chr7 23144197 T C 1.95E-05 Parkinson's disease KLHL7-AS1 intron 21738487 rs2072369 chr7 23146189 A G 1.51E-05 Parkinson's disease KLHL7 UTR-5 21738487 rs987257 chr7 23147840 G A 2.69E-05 Parkinson's disease KLHL7 intron 21738487 rs1034963 chr7 23148473 T C 2.82E-05 Parkinson's disease KLHL7 intron 21738487 rs10239760 chr7 23149950 C T 5.73E-05 Parkinson's disease KLHL7 intron 21738487 rs11984129 chr7 23152677 A G 2.79E-05 Parkinson's disease KLHL7 intron 21738487 rs764533 chr7 23153875 C T 3.20E-05 Parkinson's disease KLHL7 intron 21738487 rs764534 chr7 23153935 C T 5.49E-05 Parkinson's disease KLHL7 intron 21738487 rs1558313 chr7 23156079 G A 3.37E-05 Parkinson's disease KLHL7 intron 21738487 rs15775 chr7 23164701 C T 2.74E-05 Parkinson's disease KLHL7 cds-synon 21738487 rs955187 chr7 23194605 A G 7.10E-05 Parkinson's disease KLHL7 intron 21738487 rs955187 chr7 23194605 A G 1.82E-04 Prion diseases KLHL7 intron 22210626 rs10254544 chr7 23220235 T C 3.00E-04 HIV(mother-to-child transmission) / / 20487506 rs4719731 chr7 23271086 T A 7.29E-05 Lymphocyte counts / / 22286170 rs3757450 chr7 23285431 T C 0.00018 Salmonella-induced pyroptosis / / 22837397 rs201982196 chr7 23299676 C T 0.00000158 Ratio of free to total prostate-specific antigen GPNMB missense 23555315 rs156429 chr7 23306020 T C 2.15E-05 Parkinson's disease GPNMB intron 22451204 rs11971433 chr7 23333370 T C 0.000742 Salmonella-induced pyroptosis / / 22837397 rs460031 chr7 23335308 T G 6.20E-06 Urinary metabolites / / 21572414 rs7779544 chr7 23338022 A C 0.000668 Salmonella-induced pyroptosis / / 22837397 rs156418 chr7 23354413 G A 1.23E-04 Amyotrophic lateral sclerosis (sporadic) IGF2BP3 intron 24529757 rs17740440 chr7 23355241 C T 5.69E-05 Graves' disease IGF2BP3 intron 21841780 rs375092 chr7 23420767 A C 5.00E-06 Personality dimensions IGF2BP3 intron 23903073 rs12700428 chr7 23436427 G A 2.00E-04 Cognitive impairment induced by topiramate IGF2BP3 intron 22091778 rs6965776 chr7 23441968 G A 9.19E-05 Cognitive impairment induced by topiramate IGF2BP3 intron 22091778 rs12700439 chr7 23472061 T C 6.50E-05 Hemoglobin concentration IGF2BP3 intron 20534544 rs11763760 chr7 23480467 C T 2.00E-06 IgG glycosylation IGF2BP3 intron 23382691 rs6957923 chr7 23482685 G A 5.00E-10 Height IGF2BP3 intron 23563607 rs12534093 chr7 23502974 T A 2.00E-14 Height IGF2BP3 intron 20881960 rs6967145 chr7 23517468 G C 5.80E-07 Primary tooth development (number of teeth) / / 23704328 rs4719732 chr7 23547690 G C 7.12E-07 Lymphocyte counts TRA2A intron 22286170 rs1542608 chr7 23554613 A G 8.00E-04 Dietary macronutrient intake TRA2A intron 23636237 rs11767307 chr7 23584496 C G 9.78E-04 Type 2 diabetes / / 17463246 rs6949019 chr7 23594050 C T 5.53E-04 Multiple complex diseases / / 17554300 rs227942 chr7 23602915 G A 6.29E-05 Kawasaki disease / / 22081228 rs13230456 chr7 23607537 C T 0.000706 Salmonella-induced pyroptosis / / 22837397 rs798646 chr7 23619734 C T 5.89E-04 Iron levels / / pha002876 rs12673983 chr7 23654126 A G 1.87E-05 Aging (time to event) CCDC126 intron 21782286 rs6968174 chr7 23739795 T G 5.54E-05 Lymphocyte counts C7orf46 intron 22286170 rs6974500 chr7 23744549 C A 5.68E-04 Iron levels / / pha002876 rs1559012 chr7 23754915 G A 2.41E-05 Post-operative nausea and vomiting STK31 intron 21694509 rs10264952 chr7 23775454 G A 7.16E-04 Tourette syndrome STK31 missense 22889924 rs10278268 chr7 23802003 A G 1.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) STK31 intron 20877124 rs10278268 chr7 23802003 A G 8.30E-04 Obesity,menopause STK31 intron 21424828 rs12666547 chr7 23832103 C A 5.38E-04 Alcohol dependence STK31 intron 21314694 rs10276693 chr7 23901883 A G 3.17E-04 Tourette syndrome / / 22889924 rs10232590 chr7 23921205 A G 2.19E-04 Tourette syndrome / / 22889924 rs12700497 chr7 23928092 A G 5.66E-04 Tourette syndrome / / 22889924 rs6950415 chr7 23941098 A G 6.21E-04 Taste perception / / 22132133 rs10250841 chr7 23943265 C G 3.80E-05 Cognitive function / / 24684796 rs4722292 chr7 23946488 A G 2.56E-04 Coronary heart disease / / 21971053 rs2059448 chr7 23955245 C T 6.62E-04 Coronary heart disease / / 21606135 rs17148510 chr7 23955873 T A 5.48E-04 Multiple complex diseases / / 17554300 rs10225381 chr7 23957764 T C 9.03E-04 Type 2 diabetes / / 17463246 rs7780155 chr7 23957868 A G 1.59E-04 Multiple complex diseases / / 17554300 rs7781067 chr7 23958380 C G 2.72E-04 Multiple complex diseases / / 17554300 rs10252043 chr7 23961100 A G 1.12E-04 Coronary heart disease / / 21606135 rs11975049 chr7 23970771 G T 3.77E-04 Myocardial Infarction / / pha002873 rs1160371 chr7 23996767 G A 4.49E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7802177 chr7 24007472 A G 4.36E-04 Type 2 diabetes / / 17463246 rs13232567 chr7 24009757 C T 9.45E-04 Multiple complex diseases / / 17554300 rs2390854 chr7 24018377 C T 1.10E-06 Primary tooth development (number of teeth) / / 23704328 rs2216974 chr7 24055011 G A 1.83E-04 Alzheimer's disease (late onset) / / 21379329 rs2216974 chr7 24055011 G A 5.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs7809789 chr7 24056888 G C 5.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs10233834 chr7 24056995 A C 7.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs2194808 chr7 24058930 A G 7.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs6965878 chr7 24061417 G A 8.16E-04 Taste perception / / 22132133 rs2194484 chr7 24062392 A G 9.95E-05 Suicide attempts in bipolar disorder / / 21423239 rs11764999 chr7 24068343 T C 4.95E-04 Alzheimer's disease (late onset) / / 21379329 rs1494186 chr7 24087668 A T 6.87E-04 Insulin resistance / / 21901158 rs1996616 chr7 24091230 C A 4.34E-04 Alzheimer's disease (late onset) / / 21379329 rs1003634 chr7 24096501 C G 8.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10216322 chr7 24107326 G A 8.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy) / / 24554482 rs2813838 chr7 24149292 C G 2.10E-05 Personality dimensions / / 18957941 rs2813838 chr7 24149292 C G 2.10E-05 Personality dimensions / / 21173776 rs272709 chr7 24151097 T A 2.15E-05 Personality dimensions / / 18957941 rs1908268 chr7 24158948 G A 5.33E-05 Cognitive impairment induced by topiramate / / 22091778 rs17148836 chr7 24164718 A G 9.65E-04 Multiple complex diseases / / 17554300 rs6461782 chr7 24181478 T G 8.36E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17368843 chr7 24200818 C T 2.29E-04 Glycemic traits (pregnancy) / / 23903356 rs12538454 chr7 24201119 A T 2.36E-04 Glycemic traits (pregnancy) / / 23903356 rs17368919 chr7 24201526 T G 2.28E-04 Glycemic traits (pregnancy) / / 23903356 rs12534269 chr7 24208535 T C 2.43E-04 Glycemic traits (pregnancy) / / 23903356 rs156293 chr7 24236755 C T 9.88E-04 Coronary Artery Disease / / 17634449 rs17660880 chr7 24239207 T C 2.31E-04 Glycemic traits (pregnancy) / / 23903356 rs886448 chr7 24240165 G A 7.00E-08 Asthma (childhood onset) / / 23829686 rs2107310 chr7 24246688 T C 2.97E-04 Glycemic traits (pregnancy) / / 23903356 rs1908269 chr7 24247057 C G 8.89E-04 Multiple complex diseases / / 17554300 rs16213 chr7 24264513 T G 6.49E-05 Insulin-related traits / / pha002901 rs198284 chr7 24265343 C T 2.26E-07 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs16198 chr7 24273230 A G 0.000488 Salmonella-induced pyroptosis / / 22837397 rs16192 chr7 24280426 A C 9.48E-05 Receptive language ability / / 24687471 rs16192 chr7 24280426 A C 6.21E-05 Monocyte counts / / pha003089 rs2006643 chr7 24284325 C T 1.67E-04 Parkinson's disease / / 17052657 rs16130 chr7 24330162 C T 9.50E-05 Lipoprotein A [Lp(a)] levels in plasma NPY intron 21592478 rs16091 chr7 24347726 G C 2.29E-04 Multiple complex diseases / / 17554300 rs10487606 chr7 24377991 T C 7.17E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs2521634 chr7 24378040 G A 4.00E-07 Periodontitis / / 23459936 rs739609 chr7 24383739 T C 0.000046 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs873155 chr7 24383768 G A 0.0000141 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs739610 chr7 24383775 T C 0.0000128 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs739611 chr7 24383782 T C 0.0000129 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9942563 chr7 24394066 G C 6.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs1122806 chr7 24396473 C T 4.40E-06 Urinary metabolites / / 21572414 rs10244791 chr7 24402624 G C 1.20E-05 Urinary metabolites / / 21572414 rs10274084 chr7 24402773 A G 2.10E-05 Urinary metabolites / / 21572414 rs17325286 chr7 24411359 T A 1.65E-05 Alzheimer's disease / / 17998437 rs2722388 chr7 24421339 G T 4.68E-05 Multiple complex diseases / / 17554300 rs17149396 chr7 24423445 G C 6.37E-04 Type 2 diabetes / / 17463246 rs2722384 chr7 24426621 A G 2.10E-05 Urinary metabolites / / 21572414 rs2521642 chr7 24426796 G C 1.40E-05 Urinary metabolites / / 21572414 rs2722396 chr7 24428217 T C 9.14E-06 Glycemic traits (pregnancy) / / 23903356 rs17379222 chr7 24442901 G A 2.22E-05 Alzheimer's disease / / 17998437 rs17326733 chr7 24450054 C G 4.03E-06 Alzheimer's disease / / 17998437 rs12533743 chr7 24468539 T C 3.64E-05 Epilepsy / / 22116939 rs17386390 chr7 24480623 C G 8.50E-04 Multiple complex diseases / / 17554300 rs17327167 chr7 24480784 A G 9.00E-04 Multiple complex diseases / / 17554300 rs7791434 chr7 24495205 T G 4.63E-04 Stroke / / pha002887 rs6961237 chr7 24514729 A G 3.54E-05 Body Mass Index / / pha003015 rs11767990 chr7 24521566 C T 3.33E-04 Smoking initiation / / 24665060 rs11771214 chr7 24548327 A G 7.25E-06 C-Reactive Protein / / pha003070 rs11768140 chr7 24551993 G A 7.51E-04 Type 2 diabetes / / 17463246 rs11768140 chr7 24551993 G A 3.10E-06 Primary tooth development (number of teeth) / / 23704328 rs2255365 chr7 24561661 A C 9.51E-04 HIV-1 viral setpoint / / 17641165 rs2711103 chr7 24563064 G T 9.51E-04 HIV-1 viral setpoint / / 17641165 rs12155331 chr7 24578832 A T 4.96E-05 Odorant perception / / 23910658 rs3922327 chr7 24581129 G A 4.03E-05 C-Reactive Protein / / pha003070 rs2529059 chr7 24582774 T C 5.56E-05 Schizophrenia / / 19571809 rs2529059 chr7 24582774 T C 3.32E-05 Schizophrenia / / pha002859 rs2711116 chr7 24595020 T C 1.85E-04 Multiple complex diseases / / 17554300 rs2158889 chr7 24596097 T C 3.01E-04 Multiple complex diseases / / 17554300 rs2711093 chr7 24617290 C T 6.77E-04 Multiple complex diseases MPP6 intron 17554300 rs2529038 chr7 24620682 A T 3.92E-04 Multiple complex diseases MPP6 intron 17554300 rs4722378 chr7 24631245 T C 7.67E-05 Atopy MPP6 intron 21625490 rs12700538 chr7 24637056 G A 6.00E-05 Atopy MPP6 intron 21625490 rs2721800 chr7 24692552 G C,T 6.00E-07 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) MPP6 intron 23453885 rs2721816 chr7 24699329 A G 7.58E-04 Multiple complex diseases MPP6 intron 17554300 rs2721816 chr7 24699329 A G 8.56E-04 Bipolar disorder,schizoaffective MPP6 intron 19567891 rs1053962 chr7 24703298 G A 3.24E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17149842 chr7 24714129 T G 1.40E-04 Alzheimer's disease (late onset) MPP6 intron 21379329 rs17208431 chr7 24730111 T C 7.36E-06 IgE levels / / 22075330 rs2721777 chr7 24735746 A G 4.65E-04 Multiple complex diseases / / 17554300 rs2721777 chr7 24735746 A G 5.81E-05 Sarcoidosis / / 19165924 rs2721819 chr7 24742128 G A 8.47E-05 Parkinson's disease DF/5 intron 21738487 rs2237306 chr7 24757202 C A 6.70E-05 Oral cancers (chewing tobacco related) DF/5 intron 22503698 rs754554 chr7 24758818 G T 0.00000018 Stroke DF/5 missense 23422753 rs2237310 chr7 24759648 A C 1.11E-04 Atopy DF/5 intron 21625490 rs2237315 chr7 24761850 G T 9.09E-05 Atopy DF/5 intron 21625490 rs2521760 chr7 24767483 C T 1.01E-04 Multiple complex diseases DF/5 intron 17554300 rs2237318 chr7 24769278 C T 2.94E-05 Multiple complex diseases DF/5 intron 17554300 rs2237318 chr7 24769278 C T 6.62E-05 Serum metabolites DF/5 intron 19043545 rs12154597 chr7 24785882 C G 1.80E-05 Multiple complex diseases DF/5 intron 17554300 rs10276782 chr7 24805240 C T 1.00E-06 Carotid intima media thickness / / 21909108 rs11762966 chr7 24824774 C T 7.63E-05 Basophils / / pha003087 rs2285652 chr7 24843870 A G 6.47E-04 Multiple complex diseases OSBPL3 intron 17554300 rs1012775 chr7 24848829 A G 5.64E-06 Lymphocyte counts OSBPL3 intron 22286170 rs2106943 chr7 24857983 A C 1.97E-04 Vaspin levels OSBPL3 intron 22907691 rs2106943 chr7 24857983 A C 0.0001974 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit OSBPL3 intron 22907730 rs916860 chr7 24867482 C T 2.37E-05 Multiple complex diseases OSBPL3 intron 17554300 rs6952921 chr7 24870576 T C 1.44E-15 Varicose Veins OSBPL3 intron pha001416 rs1541363 chr7 24878612 C T 8.45E-04 Suicide attempts in bipolar disorder OSBPL3 intron 21041247 rs10238784 chr7 24890808 G A 0.0000176 LDL cholesterol particle diameter OSBPL3 intron 23263444 rs10486437 chr7 24896058 C T 4.59E-17 Varicose Veins OSBPL3 intron pha001416 rs2285690 chr7 24902762 C T 2.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OSBPL3 intron 20877124 rs2285690 chr7 24902762 C T 4.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OSBPL3 intron 20877124 rs17150421 chr7 24923761 C T 2.03E-04 Response to taxane treatment (placlitaxel) OSBPL3 intron 23006423 rs17150421 chr7 24923761 C T 5.41E-05 Glucose levels OSBPL3 intron pha003061 rs17150460 chr7 24931315 T G 2.00E-04 Gamma gluatamyl transferase levels (interaction with age) OSBPL3 intron 22010049 rs136 chr7 24936098 C T 7.12E-04 Response to taxane treatment (placlitaxel) OSBPL3 intron 23006423 rs134 chr7 24951382 G A 2.00E-07 Crohn's disease OSBPL3 intron 17804789 rs11974649 chr7 24974000 A T 2.72E-04 Body mass index OSBPL3 intron 17255346 rs6461831 chr7 24974375 G C 2.72E-04 Body mass index OSBPL3 intron 17255346 rs10242782 chr7 24979715 A C 6.20E-06 Urinary metabolites OSBPL3 intron 21572414 rs11771668 chr7 24980171 G A 8.33E-05 Orofacial clefts OSBPL3 intron 22419666 rs6972736 chr7 24983836 C T 7.78E-06 Lipid levels OSBPL3 intron 19016617 rs17150652 chr7 25012055 C T 8.42E-04 Multiple complex diseases OSBPL3 intron 17554300 rs2711028 chr7 25013893 T G 1.00E-04 Body mass index OSBPL3 intron 24827717 rs4719787 chr7 25023700 C T 3.89E-04 Alzheimer's disease (late onset) / / 21379329 rs180 chr7 25033755 G A 7.01E-04 Type 2 diabetes / / 17463246 rs175 chr7 25033791 A C 7.01E-04 Type 2 diabetes / / 17463246 rs174 chr7 25033874 A C 5.11E-04 Type 2 diabetes / / 17463246 rs169 chr7 25046341 A G 2.92E-04 Alzheimer's disease / / 17998437 rs4722416 chr7 25061014 A C 4.80E-05 Body Mass Index / / pha003009 rs4722416 chr7 25061014 A C 4.64E-06 Insulin Resistance / / pha003062 rs4722416 chr7 25061014 A C 7.42E-05 Insulin-related traits / / pha003063 rs10282247 chr7 25078543 T C 3.43E-06 IgE levels / / 22075330 rs2526401 chr7 25088336 A C 1.06E-05 Psoriasis / / 20953190 rs39420 chr7 25103256 A T 6.95E-04 Multiple complex diseases / / 17554300 rs7789951 chr7 25105848 G T 2.76E-04 Alzheimer's disease / / 17998437 rs7790129 chr7 25105932 G A 6.88E-05 Alzheimer's disease / / 17998437 rs17150871 chr7 25114648 G A 1.78E-04 Multiple complex diseases / / 17554300 rs9639504 chr7 25131521 G A 7.52E-05 Smoking initiation / / 24665060 rs39453 chr7 25133849 T C 2.00E-06 Colorectal cancer / / 23300701 rs1861525 chr7 25161602 A G 2.00E-07 Alzheimer's disease (cognitive decline) CYCS UTR-3 23535033 rs2717862 chr7 25207066 G A 8.25E-06 ldl cholesterol C7orf31 intron pha003077 rs2717862 chr7 25207066 G A 1.62E-06 Cholesterol C7orf31 intron pha003083 rs2717858 chr7 25207974 T C 9.79E-06 ldl cholesterol C7orf31 missense pha003077 rs2717858 chr7 25207974 T C 2.19E-06 Cholesterol C7orf31 missense pha003083 rs6461851 chr7 25244419 T C 1.20E-04 Intelligence (childhood) / / 23358156 rs1014769 chr7 25245068 C G 1.60E-05 Urinary metabolites / / 21572414 rs10263792 chr7 25255736 A C 1.20E-05 Urinary metabolites / / 21572414 rs2717891 chr7 25260498 A T 7.58E-04 Acute lung injury / / 22295056 rs997892 chr7 25260856 A C 1.30E-05 Urinary metabolites / / 21572414 rs2717889 chr7 25261910 G A 5.85E-04 Acute lung injury / / 22295056 rs739750 chr7 25262364 G A 4.90E-06 Height / / 20400458 rs739750 chr7 25262364 G A 4.90E-06 Obesity,menopause / / 21424828 rs877834 chr7 25267934 T C 8.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NPVF missense 20877124 rs3807887 chr7 25269753 T G 9.00E-05 Prostate cancer / / 21743057 rs111399899 chr7 25277300 A G 8.22E-06 Tuberculosis / / 22306650 rs17151212 chr7 25281241 A G 1.90E-05 Age-related macular degeneration / / 20861866 rs2107124 chr7 25299989 C T 4.98E-04 Schizophrenia / / 19197363 rs2717907 chr7 25303466 C T 2.05E-05 Schizophrenia / / 19197363 rs6961642 chr7 25306852 T C 6.58E-05 Glucose levels / / pha003057 rs6951835 chr7 25315821 C T 9.84E-05 Insulin-related traits / / 19902172 rs7808695 chr7 25325550 C T 8.57E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11762772 chr7 25344021 A G 3.50E-06 Height / / pha003010 rs11762772 chr7 25344021 A G 7.79E-06 Height / / pha003011 rs4722456 chr7 25371700 C T 2.50E-05 Urinary metabolites / / 21572414 rs2188995 chr7 25374807 A G 1.70E-05 Urinary metabolites / / 21572414 rs9655257 chr7 25377346 T C 2.50E-05 Urinary metabolites / / 21572414 rs9655259 chr7 25378585 T C 1.40E-05 Urinary metabolites / / 21572414 rs2214310 chr7 25378863 G A 5.70E-06 Urinary metabolites / / 21572414 rs2893205 chr7 25407621 A G 3.29E-05 Body Mass Index / / pha003015 rs2893205 chr7 25407621 A G 8.75E-05 Insulin Resistance / / pha003062 rs17310121 chr7 25467288 G A 9.12E-05 Glucose levels / / pha002899 rs6461867 chr7 25470191 G A 1.79E-05 Hypertension / / pha003041 rs2893208 chr7 25480930 G C 0.0000354 Major depressive disorder / / 23149448 rs10486456 chr7 25503103 A G 1.20E-05 Urinary metabolites / / 21572414 rs17151705 chr7 25511228 A C 9.44E-04 Multiple complex diseases / / 17554300 rs7791702 chr7 25523266 G A 2.13E-05 Pancreatic cancer / / pha002874 rs7791702 chr7 25523266 G A 2.89E-05 Pancreatic cancer / / pha002889 rs12668343 chr7 25545837 A C 2.56E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs12667972 chr7 25553702 T C 4.65E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs9638826 chr7 25554856 G A 8.73E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs11975146 chr7 25563961 G A 0.00044 Prostate cancer / / 23555315 rs289999 chr7 25564438 C T 4.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1502945 chr7 25578946 G A 4.33E-05 Serum metabolites / / 19043545 rs2960818 chr7 25598135 A G 5.35E-04 Myopia (pathological) / / 21095009 rs17151904 chr7 25608409 G A 1.00E-06 Carotid atherosclerosis in HIV infection / / 20009918 rs975369 chr7 25612661 G A 8.00E-06 Preeclampsia / / 23551011 rs12670768 chr7 25613246 G C 7.97E-04 Type 2 diabetes / / 17463246 rs16873895 chr7 25613513 A G 8.00E-04 Type 2 diabetes / / 17463246 rs1354264 chr7 25615221 C T 4.86E-05 Cognitive test performance / / 20125193 rs2653940 chr7 25615898 T C 8.78E-04 Coronary Artery Disease / / 17634449 rs16873909 chr7 25617723 T A 8.00E-04 Type 2 diabetes / / 17463246 rs1008263 chr7 25618459 T C 8.04E-06 Cognitive impairment induced by topiramate / / 22091778 rs208549 chr7 25621579 G T 5.84E-05 Glucose levels / / pha002899 rs208553 chr7 25622517 C T 4.22E-06 Cognitive impairment induced by topiramate / / 22091778 rs169642 chr7 25624089 G A 6.45E-05 Glucose levels / / pha002899 rs1393677 chr7 25634832 G A 1.38E-06 Cognitive impairment induced by topiramate / / 22091778 rs6979292 chr7 25665854 T C 2.83E-05 Cognitive impairment induced by topiramate / / 22091778 rs12538562 chr7 25676349 G A 2.51E-04 IgE levels / / 17255346 rs4719818 chr7 25704365 T G 5.28E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1859849 chr7 25718804 T C 5.80E-04 Alzheimer's disease (late onset) / / 21460841 rs2214976 chr7 25722313 C T 0.0000087 Asthma / / 23040885 rs17465340 chr7 25728623 T G 8.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs11489283 chr7 25751792 A G 0.0000036 Asthma / / 23040885 rs4719827 chr7 25814641 T A 4.56E-04 Multiple complex diseases / / 17554300 rs1014201 chr7 25815737 G A 3.44E-04 Multiple complex diseases / / 17554300 rs7798431 chr7 25860812 G A 1.90E-05 Endometriosis / / 21151130 rs7798431 chr7 25860812 G A 2.10E-06 Endometriosis / / 23104006 rs10225976 chr7 25869693 T C 7.29E-06 White blood cell count / / 21738479 rs1055144 chr7 25871109 C T 1.00E-24 Waist-hip ratio / / 20935629 rs1055144 chr7 25871109 C T 5.60E-07 Endometriosis / / 23104006 rs10282436 chr7 25873110 G T 7.40E-07 Endometriosis / / 23104006 rs6944682 chr7 25881427 C T 8.77E-04 Multiple complex diseases / / 17554300 rs12700667 chr7 25901639 G A 1.00E-09 Endometriosis / / 21151130 rs12700667 chr7 25901639 G A 4.00E-09 Endometriosis / / 23104006 rs10272701 chr7 25911033 C T 9.22E-05 Systemic sclerosis / / 21750679 rs4719833 chr7 25926872 G A 2.20E-05 Urinary metabolites / / 21572414 rs10261878 chr7 25950545 A C 1.00E-10 Body mass index / / 23583978 rs878655 chr7 25955056 G A 9.93E-05 Alzheimer's disease (late onset) / / 21460841 rs4722551 chr7 25991826 T C 4.00E-14 LDL cholesterol / / 24097068 rs4722551 chr7 25991826 T C 7.00E-09 Cholesterol,total / / 24097068 rs4722551 chr7 25991826 T C 9.00E-11 Triglycerides / / 24097068 rs4719842 chr7 25999018 C G 4.43E-04 Multiple complex diseases / / 17554300 rs745580 chr7 26008052 G A 3.00E-07 Obesity-related traits / / 23251661 rs745580 chr7 26008052 G A 8.97E-04 Alzheimer's disease / / 24755620 rs11980825 chr7 26010003 C T 7.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs11970922 chr7 26013689 C T 5.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs2067617 chr7 26013959 G A 5.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs6958870 chr7 26015963 T C 4.68E-04 Alzheimer's disease (late onset) / / 21379329 rs6958870 chr7 26015963 T C 2.75E-06 Obesity-related traits / / 23251661 rs10239682 chr7 26019353 T G 9.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs4722557 chr7 26019556 G A 8.30E-04 Multiple complex diseases / / 17554300 rs2391214 chr7 26020075 C T 2.60E-04 Multiple complex diseases / / 17554300 rs6947773 chr7 26023090 A G 4.37E-04 Multiple complex diseases / / 17554300 rs6947773 chr7 26023090 A G 1.67E-06 Obesity-related traits / / 23251661 rs6964512 chr7 26026149 G T 2.85E-04 Multiple complex diseases / / 17554300 rs766838 chr7 26030166 T C 6.21E-04 Multiple complex diseases / / 17554300 rs766838 chr7 26030166 T C 0.00042 Erectile dysfunction after radiotherapy for prostate cancer / / 23021708 rs17321514 chr7 26050920 C T 6.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs11982959 chr7 26059739 A C 3.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs6948960 chr7 26070505 G A 3.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs7788064 chr7 26071903 A G 4.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs17153090 chr7 26072299 G C 5.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs6960163 chr7 26072731 G C 4.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs6461909 chr7 26073266 T C 5.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs6461910 chr7 26073411 A G 6.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs10486490 chr7 26073549 C T 1.30E-05 Breast cancer and prostate cancer / / 17903305 rs17322566 chr7 26108984 A G 2.49E-05 Tunica Media / / pha003036 rs17322608 chr7 26109437 C A 2.22E-04 Body mass index / / 17255346 rs10272549 chr7 26116505 G A 3.54E-04 White matter integrity / / 22425255 rs916964 chr7 26146063 C G 4.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs3814095 chr7 26147219 C T 7.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs3814095 chr7 26147219 C T 7.10E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11973455 chr7 26152122 G A 8.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs11973430 chr7 26152232 C T 7.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs2158361 chr7 26154414 G A 7.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs2057763 chr7 26155399 G A 4.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs2107348 chr7 26155514 A G 6.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs12700705 chr7 26160458 A G 3.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs7799042 chr7 26162074 G A 6.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs4722585 chr7 26183366 G A 5.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy) / / 24554482 rs4722585 chr7 26183366 G A 5.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy) / / 24554482 rs2073536 chr7 26191698 T C 9.86E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs10951129 chr7 26282656 C A 4.36E-04 Smoking cessation / / 24665060 rs972158 chr7 26335007 G T 0.00000991 Coronary artery disease SNX10 intron 23202125 rs10499574 chr7 26348978 C T 5.78E-04 Stroke SNX10 intron pha002886 rs4563785 chr7 26349213 G T 3.85E-05 Parkinson's disease SNX10 intron 17052657 rs10951130 chr7 26385826 T G 8.44E-04 Type 2 diabetes SNX10 intron 17463246 rs10951130 chr7 26385826 T G 7.06E-04 Suicide attempts in bipolar disorder SNX10 intron 21423239 rs3801890 chr7 26386154 T C 7.32E-05 Glucose levels SNX10 intron pha002899 rs6967109 chr7 26392726 A G 2.95E-04 Alzheimer's disease (late onset) SNX10 intron 21379329 rs6967109 chr7 26392726 A G 9.70E-04 Alzheimer's disease SNX10 intron 24755620 rs7782538 chr7 26401513 C T 4.01E-04 Alzheimer's disease (late onset) SNX10 intron 21379329 rs7782538 chr7 26401513 C T 9.75E-04 Alzheimer's disease SNX10 intron 24755620 rs1406593 chr7 26427889 G A 6.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1406593 chr7 26427889 G A 7.64E-05 Pulmonary function in asthmatics / / 23541324 rs41443545 chr7 26434762 C T 2.61E-04 Type 2 diabetes / / 17463246 rs41443545 chr7 26434762 C T 8.15E-04 Multiple complex diseases / / 17554300 rs1229658 chr7 26435397 G A 4.38E-04 Multiple complex diseases / / 17554300 rs1229678 chr7 26460409 C T 6.22E-05 Lipoproteins / / pha003079 rs1229684 chr7 26465820 C T 9.22E-05 Lipoproteins / / pha003079 rs10238880 chr7 26474874 T C 8.82E-05 Prostate-specific antigen levels / / 23359319 rs10951138 chr7 26481804 G A 3.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs1016167 chr7 26491618 A C 2.88E-05 Relative hand skill / / 24068947 rs2391279 chr7 26494839 C A,G 3.12E-05 Relative hand skill / / 24068947 rs4722598 chr7 26501182 T C 6.61E-05 Relative hand skill / / 24068947 rs4722598 chr7 26501182 T C 2.80E-06 Hemoglobin / / pha003096 rs4722598 chr7 26501182 T C 3.75E-05 Hematocrit / / pha003097 rs757393 chr7 26532145 C T 6.26E-05 Asthma LOC441204 intron 20159242 rs757393 chr7 26532145 C T 6.17E-04 Suicide attempts in bipolar disorder LOC441204 intron 21041247 rs3180361 chr7 26536913 A G 5.83E-05 Asthma / / 20159242 rs7811868 chr7 26541336 G A 8.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs1859600 chr7 26543316 G A 5.38E-05 Asthma / / 20159242 rs6976807 chr7 26543624 T G 4.07E-04 Multiple complex diseases / / 17554300 rs886716 chr7 26557618 A G 8.00E-06 Smoking behavior / / 19247474 rs6943220 chr7 26566266 G A 7.76E-06 White blood cell count / / 21738479 rs6943003 chr7 26566387 A G 0.0004 Coronary artery calcification / / 23727086 rs1076284 chr7 26575513 C A 9.48E-06 Multiple complex diseases / / 17554300 rs4604331 chr7 26581035 G A 1.10E-05 Urinary metabolites / / 21572414 rs7457859 chr7 26581303 A G 1.10E-05 Urinary metabolites / / 21572414 rs2190188 chr7 26585869 C T 1.60E-05 Cognitive function / / 24684796 rs17153906 chr7 26586556 C T 1.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs17153917 chr7 26586609 A T 4.77E-04 Multiple complex diseases / / 17554300 rs757808 chr7 26586734 G A 2.30E-05 Cognitive function / / 24684796 rs1029558 chr7 26588391 T C 5.60E-06 Cognitive function / / 24684796 rs12672384 chr7 26592490 T C 2.37E-04 Suicide attempts in bipolar disorder LOC100506289 intron 21041247 rs12670740 chr7 26593732 C T 3.38E-04 Suicide attempts in bipolar disorder LOC100506289 intron 21041247 rs740183 chr7 26594315 T C 3.60E-05 Coronary restenosis LOC100506289 intron 21878436 rs740184 chr7 26594823 G T 3.07E-05 Coronary restenosis / / 21878436 rs740184 chr7 26594823 G T 8.29E-04 Taste perception / / 22132133 rs2286180 chr7 26596370 G C 4.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs6957717 chr7 26597211 A G 4.91E-05 Crohn's disease (time to surgery) / / 23665963 rs12671326 chr7 26600300 C T 5.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs11762404 chr7 26603973 T C 1.30E-05 Cognitive function / / 24684796 rs7800418 chr7 26606005 C T 7.00E-07 Cognitive function / / 24684796 rs4722613 chr7 26612333 C T 6.61E-05 Coronary heart disease / / pha003030 rs4722613 chr7 26612333 C T 8.64E-05 Coronary heart disease / / pha003031 rs10951141 chr7 26613558 T C 8.38E-06 Coronary heart disease / / pha003030 rs13311768 chr7 26615293 C T 7.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs11983370 chr7 26619480 C T 3.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs11983370 chr7 26619480 C T 2.15E-05 Coronary heart disease / / pha003030 rs11983370 chr7 26619480 C T 3.48E-05 Coronary heart disease / / pha003031 rs11980563 chr7 26624128 A G 3.85E-04 Type 2 diabetes / / 17463246 rs2286182 chr7 26624392 A C 8.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs2286182 chr7 26624392 A C 3.36E-05 Tuberculosis / / 24057671 rs2286183 chr7 26624865 A G 1.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs2190190 chr7 26625527 T C 8.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs2190190 chr7 26625527 T C 2.06E-04 Myocardial Infarction / / pha002873 rs10244951 chr7 26626018 C G 2.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs17286397 chr7 26626213 C T 6.76E-05 Suicide attempts in bipolar disorder / / 21423239 rs17286397 chr7 26626213 C T 9.64E-05 Coronary heart disease / / pha003031 rs11767539 chr7 26626411 A T 2.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs12531941 chr7 26652580 C G 8.45E-04 Parkinson's disease / / 16252231 rs4722626 chr7 26657962 G T 1.80E-06 Urinary metabolites / / 21572414 rs1012803 chr7 26688808 C T 0.00027 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs10248160 chr7 26692287 G A 4.70E-06 Urinary metabolites / / 21572414 rs212853 chr7 26726320 A G 1.20E-05 Urinary metabolites SKAP2 intron 21572414 rs17291131 chr7 26729740 G A 9.53E-04 Type 2 diabetes SKAP2 intron 17463246 rs10227898 chr7 26764618 C T 1.70E-05 Urinary metabolites SKAP2 intron 21572414 rs4722631 chr7 26774325 G A 1.60E-05 Urinary metabolites SKAP2 intron 21572414 rs11770043 chr7 26789814 G A 1.40E-05 Urinary metabolites SKAP2 intron 21572414 rs11773029 chr7 26793064 C T 1.00E-05 Urinary metabolites SKAP2 intron 21572414 rs12700761 chr7 26793515 G A 1.30E-05 Urinary metabolites SKAP2 intron 21572414 rs17372780 chr7 26804018 G C 1.60E-05 Urinary metabolites SKAP2 intron 21572414 rs7807640 chr7 26814394 T C 1.20E-05 Urinary metabolites SKAP2 intron 21572414 rs1123158 chr7 26816648 A G 1.20E-05 Urinary metabolites SKAP2 intron 21572414 rs3823934 chr7 26853934 T C 4.76E-04 Lung function (forced vital capacity) SKAP2 intron 24023788 rs7804356 chr7 26891665 T C 5.00E-09 Type 1 diabetes SKAP2 intron 19430480 rs7804356 chr7 26891665 T C 5.30E-09 Multiple sclerosis SKAP2 intron 22190364 rs10486483 chr7 26892440 G A 3.00E-08 Crohn's disease SKAP2 intron 23128233 rs11762308 chr7 26932929 T C 7.53E-05 Kawasaki disease / / 22081228 rs4722650 chr7 26942530 C T 1.18E-04 Multiple complex diseases / / 17554300 rs6461981 chr7 26945166 G C 3.94E-04 Multiple complex diseases / / 17554300 rs2462910 chr7 26969253 C A 8.56E-05 Alzheimer's disease / / 17998437 rs774257 chr7 26977192 G A 8.25E-05 Response to citalopram treatment / / 19846067 rs774257 chr7 26977192 G A 5.66E-05 Coronary heart disease / / 21606135 rs774246 chr7 26990816 A G 8.14E-05 Response to citalopram treatment / / 19846067 rs2465271 chr7 27002952 T C 5.81E-05 Alzheimer's disease / / 17998437 rs2264802 chr7 27013728 G T 3.06E-04 Alzheimer's disease / / 17998437 rs10081212 chr7 27089764 A G 9.51E-05 Bladder cancer / / 19648920 rs1725074 chr7 27144921 C T 3.04E-05 Suicide attempts in bipolar disorder / / 21423239 rs2465275 chr7 27145100 G A 2.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs11564055 chr7 27145350 A G 2.55E-04 Suicide attempts in bipolar disorder HOXA3 nearGene-3 21423239 rs2428433 chr7 27145517 T C 2.56E-04 Suicide attempts in bipolar disorder HOXA3 nearGene-3 21423239 rs2465276 chr7 27145717 G A 2.55E-04 Suicide attempts in bipolar disorder HOXA3 nearGene-3 21423239 rs2428434 chr7 27145735 T A 2.80E-04 Suicide attempts in bipolar disorder HOXA3 nearGene-3 21423239 rs6948297 chr7 27149404 A G 1.76E-04 Multiple complex diseases HOXA3 intron 17554300 rs6948297 chr7 27149404 A G 6.45E-04 Suicide attempts in bipolar disorder HOXA3 intron 21423239 rs6948297 chr7 27149404 A G 1.30E-05 Urinary metabolites HOXA3 intron 21572414 rs6461985 chr7 27150634 T C 6.45E-04 Suicide attempts in bipolar disorder HOXA3 intron 21423239 rs7801565 chr7 27158777 C A 4.88E-04 Suicide attempts in bipolar disorder HOXA3 intron 21423239 rs6969780 chr7 27159136 G C 5.16E-04 Suicide attempts in bipolar disorder HOXA3 UTR-5 21423239 rs6969780 chr7 27159136 G C 0.00079 Prostate cancer HOXA3 UTR-5 23555315 rs739734 chr7 27159405 C T 5.16E-04 Suicide attempts in bipolar disorder HOXA3 intron 21423239 rs929249 chr7 27167537 T C 6.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs1801085 chr7 27168590 A G 6.60E-04 Suicide attempts in bipolar disorder HOXA4 UTR-3 21423239 rs6957209 chr7 27169388 A C 6.64E-04 Suicide attempts in bipolar disorder HOXA4 intron 21423239 rs6973182 chr7 27172321 C T 4.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs1548497 chr7 27174316 G A 4.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs1548497 chr7 27174316 G A 1.10E-05 Urinary metabolites / / 21572414 rs12533947 chr7 27175295 G A 7.08E-04 Type 1 diabetes / / 21980299 rs6976129 chr7 27177746 C T 6.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs17471520 chr7 27178790 T C 7.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs983184 chr7 27188379 C T 5.41E-04 Weight loss (gastric bypass surgery) HOXA-AS3 intron 23643386 rs11762730 chr7 27190398 A C 2.02E-04 Smoking initiation HOXA-AS3 intron 24665060 rs6968828 chr7 27223563 G T 8.06E-04 Alzheimer's disease HOXA11 intron 22005930 rs7801581 chr7 27223771 C T 4.63E-04 Alzheimer's disease HOXA11 intron 22005930 rs2285724 chr7 27227359 G A 8.54E-04 Alzheimer's disease HOXA11-AS intron 22005930 rs4722670 chr7 27229549 C T 6.93E-05 Hypertension (essential hypertension) / / 22184326 rs17437544 chr7 27231189 T C 7.24E-05 Aging (time to event) / / 21782286 rs4722672 chr7 27231762 C T 2.00E-08 Ulcerative colitis / / 23128233 rs2023843 chr7 27243221 C T 2.01E-05 Hypertension (essential hypertension) HOTTIP intron 22184326 rs2023844 chr7 27243238 G A 1.10E-05 Response to statin therapy HOTTIP intron 20339536 rs4722675 chr7 27243962 A G 3.20E-05 Hypertension (essential hypertension) HOTTIP intron 22184326 rs111348777 chr7 27245101 G GT 2.13E-05 Hypertension (essential hypertension) / / 22184326 rs929250 chr7 27245101 G T 2.13E-05 Hypertension (essential hypertension) / / 22184326 rs3735533 chr7 27245893 T C 3.49E-05 Hypertension (essential hypertension) / / 22184326 rs3735533 chr7 27245893 T C 4.65E-04 Smoking initiation / / 24665060 rs10264581 chr7 27255417 G A 4.85E-05 Hypertension (essential hypertension) / / 22184326 rs10264581 chr7 27255417 G A 6.18E-04 Smoking initiation / / 24665060 rs10262140 chr7 27256464 T C 8.63E-05 Hypertension (essential hypertension) / / 22184326 rs6964896 chr7 27267341 T G 4.81E-04 Smoking initiation / / 24665060 rs6461998 chr7 27281157 T C 5.90E-04 Smoking initiation / / 24665060 rs2074399 chr7 27282483 G A 7.29E-04 Smoking initiation EVX1 UTR-5 24665060 rs11977099 chr7 27287536 C T 3.89E-04 Tourette syndrome / / 22889924 rs7794193 chr7 27294701 A G 6.71E-05 Hypertension (essential hypertension) / / 22184326 rs7794193 chr7 27294701 A G 9.47E-05 Smoking initiation / / 24665060 rs7783517 chr7 27298137 G A 1.84E-04 Tourette syndrome / / 22889924 rs6960464 chr7 27300262 A G 7.70E-04 Smoking initiation / / 24665060 rs11564044 chr7 27301441 C T 6.09E-04 Tourette syndrome / / 22889924 rs7808467 chr7 27303050 C T 9.98E-05 Lung adenocarcinoma / / 19836008 rs7808467 chr7 27303050 C T 8.63E-05 Hypertension (essential hypertension) / / 22184326 rs7808467 chr7 27303050 C T 2.12E-04 Smoking initiation / / 24665060 rs6943291 chr7 27303632 G A 4.14E-04 Smoking initiation / / 24665060 rs11764018 chr7 27314815 G A 6.54E-04 Smoking initiation / / 24665060 rs13225783 chr7 27330056 C T 7.00E-06 Heart failure / / 20445134 rs11564024 chr7 27335561 T G 3.00E-08 Immune reponse to smallpox (secreted IL-1beta) / / 22610502 rs17428471 chr7 27337867 G T 2.00E-09 Blood pressure / / 23972371 rs17428471 chr7 27337867 G T 2.00E-12 Blood pressure / / 23972371 rs13234537 chr7 27370708 T G 5.93E-04 Obesity (extreme) / / 21935397 rs66566739 chr7 27370708 T TG,TGT 5.93E-04 Obesity (extreme) / / 21935397 rs17429065 chr7 27388903 A G 3.11E-05 Major depressive disorder / / 21621269 rs10254677 chr7 27389198 G A 3.67E-04 Multiple complex diseases / / 17554300 rs10254677 chr7 27389198 G A 6.58E-04 Heart Failure / / pha002885 rs10257733 chr7 27389402 G C 7.23E-04 Multiple complex diseases / / 17554300 rs4722692 chr7 27391584 C A 8.95E-04 Parkinson's disease / / 17052657 rs4719890 chr7 27391639 T C 4.38E-04 Myopia (pathological) / / 21095009 rs2189037 chr7 27412812 T C 5.05E-04 Obesity (extreme) / / 21935397 rs6462011 chr7 27413655 A G 5.14E-04 Obesity (extreme) / / 21935397 rs10265742 chr7 27423024 T C 8.09E-04 Myopia (pathological) / / 21095009 rs6958873 chr7 27427936 A T 1.83E-04 Multiple complex diseases / / 17554300 rs10240666 chr7 27433363 A G 3.65E-05 Intelligence / / 21826061 rs10276966 chr7 27440020 C T 3.30E-04 Multiple complex diseases / / 17554300 rs6957243 chr7 27440061 C T 3.74E-04 Multiple complex diseases / / 17554300 rs4722699 chr7 27456500 C T 7.70E-04 Body mass index / / 21701565 rs11763775 chr7 27468350 A C 2.92E-04 Multiple complex diseases / / 17554300 rs17155270 chr7 27504332 A G 7.81E-04 Multiple complex diseases / / 17554300 rs11763233 chr7 27520326 G A 2.47E-04 Multiple complex diseases / / 17554300 rs6958922 chr7 27553155 A G 7.77E-21 Multiple complex diseases / / 17554300 rs940525 chr7 27560822 C T 6.03E-04 White matter integrity / / 22425255 rs1009253 chr7 27624471 T C 2.50E-04 Primary sclerosing cholangitis HIBADH intron 19944697 rs2110524 chr7 27680644 G T 1.51E-04 Heart Failure HIBADH intron pha002885 rs2893292 chr7 27681522 T C 7.74E-04 Schizophrenia HIBADH intron 19197363 rs13237776 chr7 27709673 C T 0.00000132 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs13237776 chr7 27709673 C T 0.00000177 Change in depression severity with Norepinephrine reuptake inhibitors (NRI) / / 23091423 rs12534474 chr7 27710555 G A 0.00000132 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs12534474 chr7 27710555 G A 0.00000177 Change in depression severity with Norepinephrine reuptake inhibitors (NRI) / / 23091423 rs17611272 chr7 27747063 C T 9.07E-04 Insulin resistance / / 21901158 rs11520772 chr7 27780476 A T 2.86E-04 Bone properties (heel) TAX1BP1 intron 24430505 rs4722740 chr7 27787009 T C 0.00023 Coronary artery calcification TAX1BP1 intron 23727086 rs17155787 chr7 27796710 G A 1.88E-04 Multiple complex diseases TAX1BP1 intron 17554300 rs1544414 chr7 27833693 T G 2.15E-08 Lymphocyte counts TAX1BP1 intron 22286170 rs17150567 chr7 27882935 G A 8.79E-04 Multiple complex diseases JAZF1 intron 17554300 rs17155928 chr7 27883018 A G 3.05E-05 Odorant perception JAZF1 intron 23910658 rs739898 chr7 27913060 C T 9.25E-05 Lung function (forced vital capacity) JAZF1 intron pha003104 rs720659 chr7 27916218 A C 1.10E-04 Response to taxane treatment (placlitaxel) JAZF1 intron 23006423 rs7789880 chr7 27917094 C T 7.93E-05 Response to taxane treatment (placlitaxel) JAZF1 intron 23006423 rs193 chr7 27943809 C T 3.15E-05 Blood Pressure JAZF1 intron pha003046 rs202 chr7 27948956 T C 1.78E-05 Blood Pressure JAZF1 intron pha003046 rs209 chr7 27952629 G A 3.67E-05 Blood Pressure JAZF1 intron pha003046 rs17621988 chr7 27958750 A G 8.70E-05 Blood Pressure JAZF1 intron pha003046 rs2040666 chr7 27968193 A G 1.64E-05 Blood Pressure JAZF1 intron pha003046 rs10486567 chr7 27976563 G A 2.00E-06 Prostate cancer JAZF1 intron 18264096 rs10486567 chr7 27976563 G A 2.00E-06 Nasopharyngeal carcinoma JAZF1 intron 20512145 rs10486567 chr7 27976563 G A 0.0000077 Prostate cancer JAZF1 intron 23555315 rs10486567 chr7 27976563 G A 0.000015 Prostate cancer (non-advanced prostate cancer) JAZF1 intron 23555315 rs192457106 chr7 27979924 T G 0.0000635 Menopause (age at onset) JAZF1 intron 23424626 rs17622746 chr7 27990391 A G 1.08E-05 Blood Pressure JAZF1 intron pha003046 rs1557780 chr7 27994847 T C 4.69E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) JAZF1 intron 24023788 rs17156085 chr7 27996570 C T 1.03E-05 Duodenal ulcer JAZF1 intron 22387998 rs17695685 chr7 27999156 A G 2.05E-04 Blood pressure (response to calcium channel blocker) JAZF1 intron 24192120 rs17695685 chr7 27999156 A G 2.79E-04 Blood pressure (response to calcium channel blocker) JAZF1 intron 24192120 rs2057671 chr7 27999195 C T 8.82E-06 Thiazide-induced adverse metabolic effects in hypertensive patients JAZF1 intron 23400010 rs4722750 chr7 28004198 C T 9.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients JAZF1 intron 23400010 rs17156099 chr7 28006442 G C 8.64E-06 Thiazide-induced adverse metabolic effects in hypertensive patients JAZF1 intron 23400010 rs17156100 chr7 28008384 C G 8.81E-06 Thiazide-induced adverse metabolic effects in hypertensive patients JAZF1 intron 23400010 rs17156102 chr7 28008696 C G 8.82E-06 Thiazide-induced adverse metabolic effects in hypertensive patients JAZF1 intron 23400010 rs12671522 chr7 28020731 C G 3.68E-04 Blood pressure (response to calcium channel blocker) JAZF1 intron 24192120 rs10282320 chr7 28055449 C A 3.53E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers JAZF1 intron 21775533 rs17156205 chr7 28060205 G A 7.87E-04 Multiple complex diseases JAZF1 intron 17554300 rs17156222 chr7 28063524 C T 5.80E-07 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers JAZF1 intron 21775533 rs6956395 chr7 28072245 A G 1.31E-05 Multiple complex diseases JAZF1 intron 17554300 rs6943061 chr7 28072700 T A 8.19E-04 Type 2 diabetes JAZF1 intron 17463246 rs6943061 chr7 28072700 T A 2.82E-05 Multiple complex diseases JAZF1 intron 17554300 rs17156238 chr7 28075172 T C 4.27E-05 Multiple complex diseases JAZF1 intron 17554300 rs7785730 chr7 28096199 A G 6.00E-06 Free thyroxine concentration JAZF1 intron 24722205 rs6462064 chr7 28103030 G A 2.74E-05 Multiple complex diseases JAZF1 intron 17554300 rs6968494 chr7 28119713 A G 4.79E-04 Multiple complex diseases JAZF1 intron 17554300 rs6968494 chr7 28119713 A G 1.73E-04 Gallstones JAZF1 intron 17632509 rs6971086 chr7 28138193 A G 3.77E-04 Bipolar disorder JAZF1 intron 22925353 rs10274928 chr7 28142088 A G 4.53E-05 Bipolar disorder JAZF1 intron 22925353 rs10274928 chr7 28142088 A G 7.70E-07 Esophageal cancer (squamous cell) JAZF1 intron 22960999 rs10245867 chr7 28142186 G T 9.56E-05 Self-reported allergy JAZF1 intron 23817569 rs6977955 chr7 28156887 C T 3.47E-05 Self-reported allergy JAZF1 intron 23817569 rs10951192 chr7 28161033 C G 4.36E-04 Self-reported allergy JAZF1 intron 23817569 rs17156432 chr7 28162405 T C 1.90E-05 Esophageal cancer (squamous cell) JAZF1 intron 22960999 rs740122 chr7 28166442 G A 3.84E-04 Self-reported allergy JAZF1 intron 23817569 rs2893312 chr7 28170403 T C 6.30E-05 Self-reported allergy JAZF1 intron 23817569 rs2189965 chr7 28172014 C T 7.01E-05 Self-reported allergy JAZF1 intron 23817569 rs2189966 chr7 28172066 T C 3.04E-04 Self-reported allergy JAZF1 intron 23817569 rs4722760 chr7 28172183 A G 7.00E-05 Self-reported allergy JAZF1 intron 23817569 rs917115 chr7 28172586 T C 2.52E-04 Self-reported allergy JAZF1 intron 23817569 rs67250450 chr7 28174986 T C 3.00E-09 Rheumatoid arthritis JAZF1 intron 24390342 rs67250450 chr7 28174986 T C 4.00E-09 Rheumatoid arthritis JAZF1 intron 24390342 rs917117 chr7 28176305 G A 3.88E-04 Schizophrenia JAZF1 intron 19197363 rs917117 chr7 28176305 G A 3.35E-05 Self-reported allergy JAZF1 intron 23817569 rs11495981 chr7 28177301 C T 3.82E-05 Self-reported allergy JAZF1 intron 23817569 rs4722762 chr7 28178262 G T 7.94E-05 Self-reported allergy JAZF1 intron 23817569 rs849139 chr7 28179396 C T 1.30E-04 Bipolar disorder JAZF1 intron 22925353 rs864745 chr7 28180556 T C 1.80E-04 Type 2 diabetes JAZF1 intron 17463249 rs864745 chr7 28180556 T C 4.90E-05 Multiple complex diseases JAZF1 intron 17554300 rs864745 chr7 28180556 T C 5.00E-14 Type 2 diabetes JAZF1 intron 18372903 rs864745 chr7 28180556 T C 1.50E-04 Height JAZF1 intron 21194676 rs864745 chr7 28180556 T C 1.70E-09 Height JAZF1 intron 21194676 rs864745 chr7 28180556 T C 3.10E-05 Height JAZF1 intron 21194676 rs864745 chr7 28180556 T C 5.00E-14 Coronary heart disease JAZF1 intron 21347282 rs864745 chr7 28180556 T C 5.00E-14 Type 2 diabetes JAZF1 intron 21647700 rs864745 chr7 28180556 T C 1.42E-11 Type 2 diabetes JAZF1 intron 22325160 rs864745 chr7 28180556 T C 2.10E-05 Bipolar disorder JAZF1 intron 22925353 rs864745 chr7 28180556 T C 4.00E-09 Crohn's disease JAZF1 intron 23128233 rs864745 chr7 28180556 T C 5.00E-14 Type 2 diabetes JAZF1 intron 23300278 rs864745 chr7 28180556 T C 7.66E-05 Type 2 diabetes JAZF1 intron 24390345 rs10280937 chr7 28182306 T C 0.00000066 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) JAZF1 intron 23603761 rs10280937 chr7 28182306 T C 0.0000356 Oligoarticular juvenile idiopathic arthritis JAZF1 intron 23603761 rs849140 chr7 28183702 T C 2.24E-05 Osteoarthritis (knee and hip) JAZF1 intron 21177295 rs849140 chr7 28183702 T C 2.91E-05 Osteoarthritis (knee and hip) JAZF1 intron 21177295 rs849140 chr7 28183702 T C 5.46E-04 Osteoarthritis (knee and hip) JAZF1 intron 21177295 rs849141 chr7 28185091 A G 3.00E-11 Height JAZF1 intron 19343178 rs849141 chr7 28185091 A G 8.97E-05 Height JAZF1 intron 19570815 rs849141 chr7 28185091 A G 3.30E-05 Bipolar disorder JAZF1 intron 22925353 rs849142 chr7 28185891 T C 1.50E-09 Multiple sclerosis JAZF1 intron 22190364 rs73300638 chr7 28187344 A C 0.000000112 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) JAZF1 intron 23603761 rs1029534 chr7 28189083 T G 8.00E-14 Height JAZF1 intron 23563607 rs1635852 chr7 28189411 T C 9.00E-10 Height JAZF1 intron 18952825 rs1635852 chr7 28189411 T C 2.00E-08 Systemic lupus erythematosus and Systemic sclerosis JAZF1 intron 23740937 rs1635853 chr7 28189549 T G 1.06E-04 Bipolar disorder JAZF1 intron 22925353 rs1708299 chr7 28189946 A G 6.00E-25 Height JAZF1 intron 20881960 rs849134 chr7 28196222 A G 3.00E-09 Type 2 diabetes JAZF1 intron 20581827 rs849134 chr7 28196222 A G 3.20E-10 Type 2 diabetes JAZF1 intron 22885922 rs849135 chr7 28196413 G A 0.00000002 Type 2 diabetes (females) JAZF1 intron 22885922 rs849135 chr7 28196413 G A 3.10E-17 Type 2 diabetes JAZF1 intron 22885922 rs849135 chr7 28196413 G A 3.20E-13 Type 2 diabetes (males) JAZF1 intron 22885922 rs849135 chr7 28196413 G A 2.00E-09 Type 2 diabetes JAZF1 intron 24509480 rs530649 chr7 28202430 G A 1.71E-04 Bipolar disorder JAZF1 intron 22925353 rs537124 chr7 28203142 C T 2.70E-05 Bipolar disorder JAZF1 intron 22925353 rs552707 chr7 28205303 T C 2.70E-05 Bipolar disorder JAZF1 intron 22925353 rs849320 chr7 28208836 T G 2.34E-04 Bipolar disorder JAZF1 intron 22925353 rs740259 chr7 28221672 G T 0.0000597 Menopause (age at onset) JAZF1-AS1 intron 23424626 rs849335 chr7 28223990 T C 9.38E-05 Self-reported allergy JAZF1-AS1 intron 23817569 rs849336 chr7 28224053 A G 9.19E-05 Self-reported allergy JAZF1-AS1 intron 23817569 rs78912482 chr7 28225811 C T 0.0000304 Menopause (age at onset) JAZF1-AS1 intron 23424626 rs550448 chr7 28229042 G A 5.00E-07 Type 1 diabetes JAZF1-AS1 intron 21980299 rs550448 chr7 28229042 G A 7.20E-05 Bipolar disorder JAZF1-AS1 intron 22925353 rs849327 chr7 28232457 A G 8.96E-05 Self-reported allergy JAZF1-AS1 intron 23817569 rs849315 chr7 28238860 A G 1.62E-04 Height JAZF1-AS1 intron 22216288 rs7801967 chr7 28245295 C T 1.79E-06 Esophageal cancer (squamous cell) JAZF1-AS1 intron 22960999 rs498475 chr7 28256240 G A 6.35E-04 Bipolar disorder JAZF1-AS1 intron 22925353 rs498475 chr7 28256240 G A 3.11E-05 Self-reported allergy JAZF1-AS1 intron 23817569 rs849326 chr7 28273072 G C 0.0000935 Menopause (age at onset) JAZF1-AS1 intron 23424626 rs4719932 chr7 28340850 C A 2.10E-05 Urinary metabolites CREB5 intron 21572414 rs6955393 chr7 28348386 A G 2.08E-05 Cognitive performance CREB5 intron 19734545 rs11765845 chr7 28391142 A G 7.00E-06 Diabetic retinopathy CREB5 intron 21441570 rs11765845 chr7 28391142 A G 7.26E-04 Body mass index CREB5 intron 21701565 rs7779602 chr7 28392168 T A 3.92E-04 Body mass index CREB5 intron 21701565 rs7796544 chr7 28392183 C A 2.64E-04 Body mass index CREB5 intron 21701565 rs7796544 chr7 28392183 C A 5.88E-04 Body mass index CREB5 intron 21701565 rs10239606 chr7 28396067 C T 1.70E-05 Multiple complex diseases CREB5 intron 17554300 rs721978 chr7 28397822 C T 9.40E-06 Diabetic retinopathy CREB5 intron 21441570 rs721978 chr7 28397822 C T 1.04E-04 Body mass index CREB5 intron 21701565 rs721978 chr7 28397822 C T 7.90E-04 Body mass index CREB5 intron 21701565 rs7799974 chr7 28397882 G A 2.23E-05 Serum metabolites CREB5 intron 19043545 rs714218 chr7 28397908 A G 9.40E-06 Diabetic retinopathy CREB5 intron 21441570 rs1860759 chr7 28398460 G A 5.09E-05 Cardiovascular disease risk factors CREB5 intron 21239051 rs12112050 chr7 28400173 C T 1.48E-05 Multiple complex diseases CREB5 intron 17554300 rs2191827 chr7 28401337 A G 1.21E-04 Hearing function CREB5 intron 17255346 rs4498447 chr7 28403772 T C 2.10E-04 Hearing function CREB5 intron 17255346 rs4498447 chr7 28403772 T C 3.05E-05 Cardiovascular disease risk factors CREB5 intron 21239051 rs4498447 chr7 28403772 T C 1.62E-04 Body mass index CREB5 intron 21701565 rs4498447 chr7 28403772 T C 3.96E-04 Body mass index CREB5 intron 21701565 rs6462077 chr7 28413008 A C 9.45E-06 Multiple complex diseases CREB5 intron 17554300 rs2058397 chr7 28420703 C T 7.27E-05 Asthma CREB5 intron pha003128 rs1811248 chr7 28421036 G T 1.41E-04 Amyotrophic Lateral Sclerosis CREB5 intron 17362836 rs887622 chr7 28422083 T C 5.94E-04 Multiple complex diseases CREB5 intron 17554300 rs887623 chr7 28422134 T C 6.43E-04 Type 2 diabetes CREB5 intron 17463246 rs42695 chr7 28430860 T C 3.05E-05 Cognitive test performance CREB5 intron 20125193 rs42695 chr7 28430860 T C 7.70E-05 Body Mass Index CREB5 intron pha003014 rs7799265 chr7 28432476 C G 2.00E-06 Airflow obstruction CREB5 intron 22837378 rs42698 chr7 28436730 G C 6.00E-06 Fasting plasma glucose CREB5 intron 19060907 rs174024 chr7 28465762 T C 8.00E-04 Multiple complex diseases CREB5 intron 17554300 rs17156694 chr7 28484955 A G 9.48E-05 Body Mass Index CREB5 intron pha003006 rs6978323 chr7 28506516 T C 9.74E-04 Multiple complex diseases CREB5 intron 17554300 rs6462090 chr7 28512241 G T 2.40E-05 Urinary metabolites CREB5 intron 21572414 rs217509 chr7 28517216 G T 8.67E-04 Multiple complex diseases CREB5 intron 17554300 rs217518 chr7 28522312 T A 8.52E-05 Multiple complex diseases CREB5 intron 17554300 rs217519 chr7 28523442 G A 5.68E-05 Multiple complex diseases CREB5 intron 17554300 rs217519 chr7 28523442 G A 2.00E-05 Urinary metabolites CREB5 intron 21572414 rs217496 chr7 28537579 A C 6.10E-04 Multiple complex diseases CREB5 intron 17554300 rs217498 chr7 28538169 T C 4.20E-04 Multiple complex diseases CREB5 intron 17554300 rs217513 chr7 28544875 C T 4.18E-05 Multiple complex diseases CREB5 intron 17554300 rs713345 chr7 28546652 C G 2.03E-04 Multiple complex diseases CREB5 intron 17554300 rs2391670 chr7 28552347 C T 8.40E-04 Type 2 diabetes CREB5 intron 17463246 rs2391671 chr7 28552377 A G 8.49E-04 Type 2 diabetes CREB5 intron 17463246 rs3857730 chr7 28562342 G A 5.28E-06 Multiple complex diseases CREB5 intron 17554300 rs216723 chr7 28576766 C T 5.28E-04 Response to taxane treatment (placlitaxel) CREB5 intron 23006423 rs10951200 chr7 28592608 G A 9.67E-04 Multiple complex diseases CREB5 intron 17554300 rs216743 chr7 28601707 A G 6.16E-05 HIV(mother-to-child transmission) CREB5 intron 20487506 rs216744 chr7 28601764 G A 6.16E-05 HIV(mother-to-child transmission) CREB5 intron 20487506 rs767834 chr7 28626376 C G 6.82E-05 Femoral neck bone geometry CREB5 intron 22087292 rs160375 chr7 28654701 A G 2.49E-04 Taste perception CREB5 intron 22132133 rs917275 chr7 28658522 A G 6.92E-05 Blood pressure CREB5 intron 21909110 rs10435018 chr7 28661040 G A 1.27E-04 Multiple complex diseases CREB5 intron 17554300 rs6974458 chr7 28664899 C T 1.00E-05 Urinary metabolites CREB5 intron 21572414 rs41298 chr7 28668780 G A 2.00E-05 Urinary metabolites CREB5 intron 21572414 rs41298 chr7 28668780 G A 0.00000511 HDL cholesterol particle diameter CREB5 intron 23263444 rs41305 chr7 28673541 G A 4.20E-06 Urinary metabolites CREB5 intron 21572414 rs3888613 chr7 28683976 G A 9.51E-05 Hypertension CREB5 intron pha003041 rs12540689 chr7 28689282 T C 9.01E-04 Suicide attempts in bipolar disorder CREB5 intron 21423239 rs7780656 chr7 28689433 G T 4.37E-06 White blood cell count CREB5 intron 21738479 rs41328 chr7 28690735 G A 9.15E-04 Suicide attempts in bipolar disorder CREB5 intron 21423239 rs16874653 chr7 28715056 A G 5.35E-04 Alcohol dependence CREB5 intron 20201924 rs41348 chr7 28716848 A G 9.55E-06 White blood cell count CREB5 intron 21738479 rs9691873 chr7 28730009 A C 9.61E-05 Osteosarcoma CREB5 intron 23727862 rs10951201 chr7 28745342 C A 9.92E-05 Lipoprotein-associated phospholipase A2 activity and mass CREB5 intron 20442857 rs12540480 chr7 28746913 T C 3.75E-04 Lung function (forced vital capacity) CREB5 intron 24023788 rs9648352 chr7 28757047 A G 1.00E-05 Urinary metabolites CREB5 intron 21572414 rs879592 chr7 28758648 A G 9.20E-04 Urinary albumin excretion rate in type 1 diabetes CREB5 intron 24595857 rs879591 chr7 28759014 C A 6.90E-04 Multiple complex diseases CREB5 intron 17554300 rs2237349 chr7 28762963 C T 5.00E-06 Attention deficit hyperactivity disorder CREB5 intron 18839057 rs10486589 chr7 28766560 A G 3.74E-05 Self-reported allergy CREB5 intron 23817569 rs73077843 chr7 28779698 T A 0.000049 Nonsyndromic striae distensae (stretch marks) CREB5 intron 23633020 rs73077845 chr7 28780350 G A 0.0000209 Nonsyndromic striae distensae (stretch marks) CREB5 intron 23633020 rs73077847 chr7 28780786 G A 0.0000225 Nonsyndromic striae distensae (stretch marks) CREB5 intron 23633020 rs112599908 chr7 28782664 G A 0.0000181 Nonsyndromic striae distensae (stretch marks) CREB5 intron 23633020 rs111354229 chr7 28784243 G C 0.0000305 Nonsyndromic striae distensae (stretch marks) CREB5 intron 23633020 rs10227088 chr7 28799411 A G 7.50E-05 Aortic root size CREB5 intron 21223598 rs10238623 chr7 28812493 A G 5.00E-06 Anxiety in major depressive disorder CREB5 intron 24047446 rs4719953 chr7 28813782 T A 7.45E-04 Alcohol dependence CREB5 intron 21314694 rs28464882 chr7 28817895 T A 3.53E-04 Aortic root size CREB5 intron 21223598 rs2237364 chr7 28842067 A G 7.74E-06 Cortisol secretion,in saliva CREB5 intron 21316860 rs1544469 chr7 28846044 C G 4.32E-04 Aortic root size CREB5 intron 21223598 rs12531253 chr7 28857606 G A 2.11E-04 Osteosarcoma CREB5 intron 23727862 rs10486595 chr7 28868819 T C 3.28E-04 Multiple complex diseases / / 17554300 rs10486595 chr7 28868819 T C 5.36E-04 Aortic root size / / 21223598 rs4719955 chr7 28884912 T C 5.50E-05 Endometriosis / / 21151130 rs13235271 chr7 28903158 G A 0.000782976 Hypertension (early onset hypertension) / / 22479346 rs4719959 chr7 28934503 A G 7.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2391703 chr7 28945721 C T 2.51E-04 Type 2 diabetes / / 17463246 rs2391704 chr7 28945827 C T 5.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs221111 chr7 28949299 A G 2.34E-07 White blood cell count / / 21738479 rs1695508 chr7 28966556 G A 8.50E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs2018683 chr7 29014195 G T 8.00E-07 non-small cell lung cancer / / 23478653 rs504453 chr7 29018593 G A 4.00E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs17157341 chr7 29029195 A G 1.18E-04 Type 2 diabetes LOC100506497 intron 17463246 rs1012090 chr7 29034840 C T 9.80E-04 Response to taxane treatment (placlitaxel) LOC100506497 intron 23006423 rs2252521 chr7 29041190 T C 5.00E-06 Cognitive performance CPVL intron 19734545 rs521384 chr7 29046972 T C 2.50E-05 Urinary metabolites CPVL intron 21572414 rs317750 chr7 29072629 A G 2.20E-05 Urinary metabolites CPVL intron 21572414 rs320088 chr7 29083262 C T 2.00E-04 Cognitive impairment induced by topiramate CPVL intron 22091778 rs505532 chr7 29084392 T C 4.75E-06 Alopecia areata CPVL intron 22027810 rs317711 chr7 29102308 C G 5.88E-04 Multiple complex diseases CPVL intron 17554300 rs317711 chr7 29102308 C G 1.00E-04 Behcet's disease CPVL intron 19442274 rs317711 chr7 29102308 C G 3.00E-04 Behcet's disease CPVL intron 19442274 rs317711 chr7 29102308 C G 4.00E-04 Behcet's disease CPVL intron 19442274 rs317711 chr7 29102308 C G 6.00E-04 Behcet's disease CPVL intron 19442274 rs2391720 chr7 29105096 T C 3.67E-05 Multiple sclerosis CPVL intron 17660530 rs550396 chr7 29105465 G A 5.94E-05 Multiple sclerosis CPVL intron 17660530 rs17675986 chr7 29110857 A T 7.01E-05 Multiple sclerosis CPVL intron 17660530 rs160862 chr7 29113023 C T 9.44E-05 Magnesium levels CPVL intron pha003092 rs17748997 chr7 29120445 C T 8.04E-05 Multiple sclerosis CPVL intron 17660530 rs2075127 chr7 29130712 T C 7.72E-06 Magnesium levels CPVL intron pha003092 rs7776819 chr7 29130762 A G 1.60E-04 Alcohol dependence CPVL intron 20201924 rs7776819 chr7 29130762 A G 2.60E-04 Alcohol dependence CPVL intron 20201924 rs2286992 chr7 29135569 C T 7.39E-05 IgE levels in asthmatics (D.f. specific) CPVL intron 23967269 rs323201 chr7 29139576 C T 9.64E-05 Magnesium levels CPVL intron pha003092 rs12670165 chr7 29140213 C T 9.83E-04 Multiple complex diseases CPVL intron 17554300 rs12670165 chr7 29140213 C T 8.94E-05 IgE levels in asthmatics (D.f. specific) CPVL intron 23967269 rs1522919 chr7 29145706 A G 2.94E-04 Osteoarthritis CPVL intron 19508968 rs11760588 chr7 29152778 G A 8.56E-05 Cognitive test performance CPVL intron 20125193 rs7804340 chr7 29174942 T C 8.99E-04 Acute lung injury CPVL intron 22295056 rs245866 chr7 29178492 C T 7.18E-04 Insulin resistance CPVL intron 21901158 rs12700934 chr7 29179168 A C 8.00E-05 Cognitive impairment induced by topiramate CPVL intron 22091778 rs13238274 chr7 29180335 C T 9.04E-05 Alcohol dependence CPVL intron 21314694 rs10486607 chr7 29184489 C T 8.00E-06 Diabetes related insulin traits CPVL intron 17903298 rs4562212 chr7 29210697 A G 7.42E-04 Multiple complex diseases / / 17554300 rs17157602 chr7 29211267 C T 2.90E-05 Urinary metabolites / / 21572414 rs17157602 chr7 29211267 C T 3.69E-05 Body Mass Index / / pha003006 rs17157602 chr7 29211267 C T 9.29E-06 Waist Circumference / / pha003024 rs245914 chr7 29218159 G T 3.00E-06 Obesity-related traits / / 23251661 rs245914 chr7 29218159 G T 6.00E-06 Obesity-related traits / / 23251661 rs245914 chr7 29218159 G T 2.00E-07 Psychosis (atypical) / / 24132900 rs3812389 chr7 29244759 C T 2.00E-04 Alzheimer's disease (late onset) CHN2 intron 21379329 rs3812389 chr7 29244759 C T 3.35E-05 Waist Circumference CHN2 intron pha003024 rs3812389 chr7 29244759 C T 5.56E-05 Weight CHN2 intron pha003026 rs17678863 chr7 29254534 C T 7.58E-05 Body mass (lean) CHN2 intron 19268274 rs39059 chr7 29255470 A G 5.00E-06 Diabetic nephropathy CHN2 intron 19252134 rs39059 chr7 29255470 A G 1.60E-05 Urinary metabolites CHN2 intron 21572414 rs39059 chr7 29255470 A G 5.91E-06 Diabetic nephropathy CHN2 intron pha002864 rs10486610 chr7 29256429 C T 9.40E-04 Type 2 diabetes and 6 quantitative traits CHN2 intron 17848626 rs10486610 chr7 29256429 C T 6.91E-06 Body mass (lean) CHN2 intron 19268274 rs245954 chr7 29276143 G T 3.43E-04 Multiple complex diseases CHN2 intron 17554300 rs39075 chr7 29276692 G A 1.70E-04 Diabetic nephropathy CHN2 intron 19252134 rs39075 chr7 29276692 G A 6.50E-07 Diabetic nephropathy CHN2 intron 19252134 rs39075 chr7 29276692 G A 0.00000065 Diabetic nephropathy in Type 1 diabetes CHN2 intron 22721967 rs39101 chr7 29294462 A G 3.81E-05 Blood Pressure CHN2 intron pha003049 rs39101 chr7 29294462 A G 7.07E-05 Blood Pressure CHN2 intron pha003050 rs6968010 chr7 29295784 G A 1.92E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CHN2 intron 21844884 rs6968010 chr7 29295784 G A 2.95E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CHN2 intron 21844884 rs245998 chr7 29310423 A G 1.81E-05 Prion diseases CHN2 intron 22210626 rs39108 chr7 29318397 T C 3.16E-04 Fibrinogen CHN2 intron 17255346 rs3812354 chr7 29319074 T C 8.55E-05 Prion diseases CHN2 intron 22210626 rs39109 chr7 29319266 C T 8.13E-04 Nicotine smoking CHN2 intron 19268276 rs3812350 chr7 29322583 G C 4.48E-04 Nicotine smoking CHN2 intron 19268276 rs39112 chr7 29324232 G A 8.61E-04 Bipolar disorder,schizoaffective CHN2 intron 19567891 rs2214570 chr7 29331602 A G 8.61E-05 Multiple complex diseases CHN2 intron 17554300 rs4722897 chr7 29332233 T C 5.10E-05 Response to ximelagatran treatment CHN2 intron 17505501 rs3812338 chr7 29343177 G A 4.58E-04 Rheumatoid arthritis CHN2 intron 21452313 rs3812338 chr7 29343177 G A 5.46E-05 Left ventricular hypertrophy CHN2 intron pha003052 rs7779958 chr7 29349416 C T 2.84E-04 Multiple complex diseases CHN2 intron 17554300 rs7780186 chr7 29349688 A G 2.07E-04 Multiple complex diseases CHN2 intron 17554300 rs190392 chr7 29350007 T C 3.74E-05 Obesity (early onset extreme) CHN2 intron 23563609 rs3793297 chr7 29351988 T C 2.34E-04 Multiple complex diseases CHN2 intron 17554300 rs3793295 chr7 29353445 C T 4.30E-04 Multiple complex diseases CHN2 intron 17554300 rs3793295 chr7 29353445 C T 5.48E-04 Rheumatoid arthritis CHN2 intron 21452313 rs3793295 chr7 29353445 C T 7.76E-05 Body Mass Index CHN2 intron pha003019 rs39118 chr7 29354032 C A 3.40E-04 Mathematical ability CHN2 intron 20039944 rs1016726 chr7 29356403 G A 1.51E-07 Prion diseases CHN2 intron 22210626 rs39131 chr7 29371948 A G 5.80E-04 Addiction CHN2 intron 17099884 rs3793283 chr7 29382710 G A 4.82E-05 Blood Pressure CHN2 intron pha003039 rs10225341 chr7 29388761 C T 3.83E-04 Type 2 diabetes CHN2 intron 17463246 rs10241383 chr7 29389182 T A 4.72E-04 Type 2 diabetes CHN2 intron 17463246 rs10253183 chr7 29391611 T C 1.40E-04 Type 2 diabetes CHN2 intron 17463246 rs12538858 chr7 29392533 A T 3.36E-04 Type 2 diabetes CHN2 intron 17463246 rs10215545 chr7 29394435 C G 3.33E-04 Type 2 diabetes CHN2 intron 17463246 rs10215935 chr7 29394539 T A 7.16E-04 Type 2 diabetes CHN2 intron 17463246 rs3793276 chr7 29409596 A G 2.20E-05 Body mass index CHN2 intron 20818722 rs3793276 chr7 29409596 A G 7.07E-05 Blood Pressure CHN2 intron pha003039 rs17157833 chr7 29416396 C T 4.77E-05 Body Mass Index CHN2 intron pha003020 rs2057737 chr7 29419095 C A 4.82E-04 Multiple complex diseases CHN2 intron 17554300 rs2057738 chr7 29420712 T C 1.66E-04 Hearing function CHN2 intron 17255346 rs7797836 chr7 29428760 C T 5.52E-05 Meningococcal disease CHN2 intron 20694013 rs2391756 chr7 29431458 C G 8.86E-04 Suicide attempts in bipolar disorder CHN2 intron 21423239 rs2391757 chr7 29431552 A G 4.41E-05 Meningococcal disease CHN2 intron 20694013 rs1034716 chr7 29434444 A G 3.15E-05 Osteoarthritis CHN2 intron 19508968 rs2189439 chr7 29447142 A G 6.56E-04 Response to cytadine analogues (cytosine arabinoside) CHN2 intron 24483146 rs17157908 chr7 29447357 T C 6.03E-04 Type 2 diabetes CHN2 intron 17463246 rs17157908 chr7 29447357 T C 5.44E-04 Multiple complex diseases CHN2 intron 17554300 rs17157914 chr7 29448420 G A 4.72E-04 Type 2 diabetes CHN2 intron 17463246 rs3793269 chr7 29453797 A C,G,T 1.23E-04 Multiple complex diseases CHN2 intron 17554300 rs3793269 chr7 29453797 A C,G,T 2.30E-05 Urinary metabolites CHN2 intron 21572414 rs2057739 chr7 29456005 G A 5.10E-05 Cognitive impairment induced by topiramate CHN2 intron 22091778 rs11763168 chr7 29461706 G A 8.00E-04 Acute lung injury CHN2 intron 22295056 rs7777877 chr7 29462185 G A 4.53E-04 Acute lung injury CHN2 intron 22295056 rs10486614 chr7 29463193 C T 4.66E-04 Multiple complex diseases CHN2 intron 17554300 rs10229219 chr7 29475564 T C 7.51E-04 Multiple complex diseases CHN2 intron 17554300 rs3909208 chr7 29487391 A G 6.05E-04 Body mass index CHN2 intron 21701565 rs3909209 chr7 29497630 A C 2.76E-04 Response to taxane treatment (placlitaxel) CHN2 intron 23006423 rs3793260 chr7 29498356 A G 9.65E-04 Response to taxane treatment (placlitaxel) CHN2 intron 23006423 rs849936 chr7 29500902 C A,T 2.45E-05 Diabetes Mellitus CHN2 intron pha003060 rs1362362 chr7 29511652 A G 4.80E-04 Lung function (forced expiratory volume in 1 second) CHN2 intron 17255346 rs12155094 chr7 29514210 C G 0.00028 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CHN2 intron 23233654 rs12155094 chr7 29514210 C G 2.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) CHN2 intron 23233662 rs3793252 chr7 29518458 C A 3.95E-04 Multiple complex diseases CHN2 intron 17554300 rs3793252 chr7 29518458 C A 0.0008766 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CHN2 intron 23233654 rs3793252 chr7 29518458 C A 8.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) CHN2 intron 23233662 rs17752156 chr7 29518841 G A 0.0006339 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CHN2 intron 23233654 rs17752156 chr7 29518841 G A 6.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) CHN2 intron 23233662 rs1990593 chr7 29535325 C T 7.93E-05 Post-operative nausea and vomiting CHN2 intron 21694509 rs1990593 chr7 29535325 C T 8.35E-04 Stroke CHN2 intron pha002886 rs17752574 chr7 29536231 T C 1.77E-05 Sodium levels CHN2 intron pha003093 rs3793251 chr7 29538924 C T 8.73E-05 Fibrinogen CHN2 intron pha003068 rs1990594 chr7 29539278 C T 5.16E-05 Intelligence CHN2 intron 21826061 rs1420143 chr7 29548324 T C 3.60E-06 Parkinson's disease (age of onset) CHN2 intron 19772629 rs1420145 chr7 29552463 C G 5.49E-04 Multiple complex diseases / / 17554300 rs6978690 chr7 29591429 C A 4.60E-05 Fibrinogen / / pha003068 rs10951234 chr7 29594370 C T 4.93E-05 Fibrinogen / / pha003068 rs17810895 chr7 29614491 G C 2.50E-06 Dietary macronutrient intake / / 23372041 rs715301 chr7 29615341 C T 2.75E-04 Schizophrenia / / 21674006 rs7784324 chr7 29626526 G A 4.51E-04 White matter integrity / / 22425255 rs10499585 chr7 29631927 C T 3.14E-05 Schizophrenia / / 21674006 rs17158276 chr7 29648077 T C 2.40E-06 Dietary macronutrient intake / / 23372041 rs10231275 chr7 29655828 G A 1.97E-05 Hypertension / / 19609347 rs1728539 chr7 29691213 C T 7.05E-04 Myocardial Infarction LOC646762 intron pha002883 rs12674026 chr7 29716685 G A 3.18E-06 Esophageal cancer (squamous cell) LOC646762 intron 22960999 rs850066 chr7 29748237 C T 6.65E-04 Multiple complex diseases DPY19L2P3 intron 17554300 rs850084 chr7 29771597 A C 3.47E-08 Parkinson's disease / / 17052657 rs12700978 chr7 29816649 C T 4.12E-05 HIV-1 control / / 20041166 rs17606308 chr7 29818707 T C 2.30E-05 Urinary metabolites / / 21572414 rs6971564 chr7 29835020 T C 1.73E-04 Multiple complex diseases / / 17554300 rs12700987 chr7 29843850 C T 3.99E-04 Multiple complex diseases / / 17554300 rs174909 chr7 29844320 T G 9.89E-04 Multiple complex diseases / / 17554300 rs7795668 chr7 29890343 A T 6.17E-04 Type 2 diabetes WIPF3 intron 17463246 rs174957 chr7 29910227 G A 0.000115 Salmonella-induced pyroptosis WIPF3 intron 22837397 rs1108402 chr7 29916618 C A,G,T 6.40E-05 Prion diseases WIPF3 intron 22210626 rs1108402 chr7 29916618 C A,G,T 1.20E-05 Alcohol and nictotine co-dependence WIPF3 intron 22488850 rs2893359 chr7 29921412 T C 7.85E-04 Alzheimer's disease WIPF3 intron 17998437 rs740145 chr7 29921524 G C 5.00E-06 Corneal curvature WIPF3 intron 22969067 rs174963 chr7 29922319 A G 7.10E-04 Response to cytidine analogues (gemcitabine) WIPF3 intron 24483146 rs17158483 chr7 29962524 C T 3.07E-04 Type 2 diabetes SCRN1 UTR-3 17463246 rs17158483 chr7 29962524 C T 9.00E-06 Obesity-related traits SCRN1 UTR-3 23251661 rs17158520 chr7 29973649 G A 8.25E-04 Multiple complex diseases SCRN1 intron 17554300 rs11763228 chr7 29993712 A C 5.71E-04 Amyotrophic lateral sclerosis (sporadic) SCRN1 intron 24529757 rs10234140 chr7 30015432 C A 4.20E-04 Testosterone levels SCRN1 intron 22675492 rs17158566 chr7 30031684 C G 9.56E-05 Pulmonary function / / 19300500 rs10274617 chr7 30036319 C G 3.80E-04 Testosterone levels / / 22675492 rs10282327 chr7 30060803 A G 2.30E-04 Testosterone levels FKBP14 intron 22675492 rs2302626 chr7 30062202 A G 6.81E-05 Lung function (forced vital capacity) FKBP14 intron pha003104 rs10231351 chr7 30062557 A G 2.00E-04 Testosterone levels FKBP14 intron 22675492 rs17150688 chr7 30065905 A G 7.22E-05 Pulmonary function FKBP14 intron 19300500 rs17150692 chr7 30065960 G A 6.89E-05 Pulmonary function FKBP14 cds-synon 19300500 rs10275475 chr7 30067626 T C 3.33E-05 Lung function (forced expiratory volume in 1 second) FKBP14 nearGene-5 pha003102 rs10275475 chr7 30067626 T C 5.67E-05 Lung function (forced vital capacity) FKBP14 nearGene-5 pha003104 rs10488084 chr7 30083021 A C 2.00E-06 Estradiol levels PLEKHA8 intron 22675492 rs10256675 chr7 30091671 C T 1.70E-04 Testosterone levels PLEKHA8 intron 22675492 rs10254969 chr7 30106795 G A 1.70E-04 Testosterone levels PLEKHA8 intron 22675492 rs10263852 chr7 30109353 G A 1.90E-04 Testosterone levels PLEKHA8 intron 22675492 rs2893363 chr7 30179054 A G 9.60E-06 Volumetric brain MRI C7orf41 intron 17903297 rs1558579 chr7 30198259 G A 7.12E-04 Myocardial Infarction C7orf41 UTR-3 pha002873 rs3750089 chr7 30200599 C T 3.81E-04 Acute lung injury C7orf41 UTR-3 22295056 rs12701008 chr7 30220830 G A 4.45E-05 Schizophrenia / / 24253340 rs4722971 chr7 30221628 A G 8.22E-04 Multiple complex diseases / / 17554300 rs4722971 chr7 30221628 A G 2.47E-04 Acute lung injury / / 22295056 rs11768178 chr7 30223434 T C 2.22E-04 Acute lung injury / / 22295056 rs2041682 chr7 30224152 A G 7.70E-04 Multiple complex diseases / / 17554300 rs2041682 chr7 30224152 A G 1.68E-04 Acute lung injury / / 22295056 rs6462192 chr7 30225119 G T 1.88E-04 Acute lung injury / / 22295056 rs2010216 chr7 30228256 A C 1.88E-04 Acute lung injury / / 22295056 rs2192398 chr7 30229904 T C 8.12E-04 Multiple complex diseases / / 17554300 rs2192398 chr7 30229904 T C 1.88E-04 Acute lung injury / / 22295056 rs2192399 chr7 30233732 T C 2.02E-04 Acute lung injury / / 22295056 rs7797599 chr7 30236760 G T 1.61E-04 Acute lung injury / / 22295056 rs6969684 chr7 30237609 C T 6.50E-05 Information processing speed / / 21130836 rs12535035 chr7 30243357 A G 9.80E-05 Schizophrenia / / 24253340 rs17158705 chr7 30244287 G A 2.82E-04 Multiple complex diseases / / 17554300 rs6462197 chr7 30299645 G A 2.33E-04 Multiple complex diseases / / 17554300 rs6946944 chr7 30419853 T G 5.36E-05 Body Composition / / pha003012 rs6956553 chr7 30443235 G A 2.23E-09 Multiple complex diseases / / 17554300 rs2975634 chr7 30491693 C T 0.00000011 HDL cholesterol NOD1 missense 23063622 rs2975634 chr7 30491693 C T 6.75E-08 Cholesterol,total NOD1 missense 23063622 rs2906766 chr7 30499575 T C 1.09E-05 C-Reactive Protein NOD1 UTR-5 pha003070 rs1558068 chr7 30503363 A T 7.41E-05 Diabetic retinopathy NOD1 intron 20871662 rs2037955 chr7 30511949 C A 8.75E-04 Alcohol dependence NOD1 intron 21314694 rs932272 chr7 30513159 G A 3.02E-05 C-Reactive Protein NOD1 intron pha003070 rs38402 chr7 30527363 C T 0.000082 Pancreatic cancer and survival / / 22665904 rs38471 chr7 30592856 C T 8.12E-05 Cognitive impairment induced by topiramate LOC401320 intron 22091778 rs4722999 chr7 30693775 C T 7.07E-05 HIV(mother-to-child transmission) CRHR2 intron 20487506 rs12701020 chr7 30694961 C T 0.0000187 HDL cholesterol particle diameter CRHR2 intron 23263444 rs34625936 chr7 30702347 C G 0.00007457 Sarcoidosis CRHR2 missense 22952805 rs2284216 chr7 30711961 G T 0.00000591 Type 2 diabetes CRHR2 intron 22325160 rs2284218 chr7 30714333 C T 7.70E-06 Type 2 diabetes CRHR2 intron 24509480 rs2284219 chr7 30714436 A G 8.00E-06 Type 2 diabetes CRHR2 intron 24509480 rs2267715 chr7 30716087 G A 1 Drug response to Salbutamol CRHR2 intron 18408560 rs2284220 chr7 30718103 G A 1 Drug response to Salbutamol CRHR2 intron 18408560 rs7793837 chr7 30726777 A T 1 Drug response to Salbutamol CRHR2 intron 18408560 rs255100 chr7 30728908 A T 1 Drug response to Salbutamol CRHR2 intron 18408560 rs11979875 chr7 30759776 G T 1.79E-04 Glycosylated haemoglobin levels / / 17255346 rs10227423 chr7 30800679 C A 5.63E-05 Waist Circumference INMT-FAM188B intron pha003025 rs7780659 chr7 30806949 C A 5.68E-04 Smoking initiation INMT-FAM188B intron 24665060 rs11765514 chr7 30820930 G T 7.51E-04 Alcohol dependence FAM188B intron 21314694 rs765508 chr7 30835269 G A 7.88E-04 Multiple complex diseases FAM188B intron 17554300 rs739981 chr7 30835879 A G 3.77E-05 Myocardial Infarction FAM188B intron pha002883 rs6969230 chr7 30865534 G C 8.30E-04 Suicide attempts in bipolar disorder FAM188B intron 21423239 rs10243139 chr7 30865765 T C 0.0000146 Amyotrophic lateral sclerosis FAM188B intron 23587638 rs10229281 chr7 30876642 G A 2.85E-05 Alcohol and nictotine co-dependence FAM188B intron 20158304 rs12672329 chr7 30879317 A G 8.47E-06 Nephrolithiasis FAM188B intron 22396660 rs7791980 chr7 30886500 G A 2.95E-06 Nephrolithiasis FAM188B intron 22396660 rs7792019 chr7 30886563 G C 2.95E-06 Nephrolithiasis FAM188B intron 22396660 rs12673857 chr7 30887150 A G 1.47E-06 Nephrolithiasis FAM188B intron 22396660 rs6959949 chr7 30887230 G A 3.93E-06 Nephrolithiasis FAM188B intron 22396660 rs1468313 chr7 30887782 T G 4.19E-06 Nephrolithiasis FAM188B intron 22396660 rs12671536 chr7 30890329 C T 3.16E-06 Nephrolithiasis FAM188B intron 22396660 rs12670734 chr7 30895840 A G 3.08E-06 Nephrolithiasis FAM188B intron 22396660 rs12674155 chr7 30899543 C T 2.47E-06 Nephrolithiasis FAM188B intron 22396660 rs10247175 chr7 30905875 C A 4.08E-04 Hemoglobin concentration FAM188B intron 20534544 rs3801324 chr7 30912007 C A 3.08E-04 Hemoglobin concentration FAM188B intron 20534544 rs7782896 chr7 30914408 A G 1.38E-05 Height FAM188B intron pha003010 rs12669187 chr7 30915478 G A 1.04E-06 Nephrolithiasis FAM188B intron 22396660 rs2107550 chr7 30918363 G A 4.25E-06 Stroke FAM188B intron 22306652 rs7805350 chr7 30929474 C T 3.69E-04 Hemoglobin concentration FAM188B intron 20534544 rs1203181 chr7 30931307 C T 3.08E-04 Hemoglobin concentration FAM188B intron 20534544 rs4723021 chr7 30934659 C T 1.61E-05 Nephrolithiasis / / 22396660 rs4723021 chr7 30934659 C T 4.66E-05 Formal thought disorder in schizophrenia / / 22648509 rs1465216 chr7 30935748 T C 3.02E-06 White blood cell count / / 21738479 rs1000597 chr7 30937178 T C 2.00E-14 Nephrolithiasis / / 22396660 rs10225302 chr7 31001075 C T 1.10E-05 Personality dimensions / / 18957941 rs4988496 chr7 31008686 G A 1.31E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy GHRHR missense 24578207 rs4988496 chr7 31008686 G A 1.31E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy GHRHR missense 24578207 rs11761979 chr7 31018138 C A 0.000077 Coronary artery calcification GHRHR intron 23727086 rs6962369 chr7 31019305 T C 5.28E-04 Body mass index GHRHR nearGene-3 21701565 rs12537375 chr7 31021462 T C 6.90E-04 Body mass index / / 21701565 rs1203188 chr7 31056355 G A 4.97E-04 White matter integrity / / 22425255 rs1894847 chr7 31066593 C A 9.63E-04 Multiple complex diseases / / 17554300 rs17159861 chr7 31085162 T C 1.76E-05 Sudden cardiac arrest / / 21658281 rs12668955 chr7 31116168 G A 7.88E-04 Alcohol dependence ADCYAP1R1 intron 20201924 rs2267727 chr7 31116266 A G 3.79E-05 Attention deficit hyperactivity disorder ADCYAP1R1 intron pha002875 rs2267733 chr7 31134809 T C 1.20E-05 Urinary metabolites ADCYAP1R1 intron 21572414 rs2267738 chr7 31136824 A G 3.80E-04 Amyotrophic Lateral Sclerosis ADCYAP1R1 intron 17362836 rs2267742 chr7 31140546 G A 6.96E-05 Age-related macular degeneration ADCYAP1R1 intron 21197116 rs2267742 chr7 31140546 G A 4.79E-06 Age-related macular degeneration ADCYAP1R1 intron pha000001 rs1558477 chr7 31155347 T C 1.78E-04 Body mass index / / 17255346 rs1558477 chr7 31155347 T C 1.00E-06 Major depressive disorder / / 19065144 rs1558477 chr7 31155347 T C 3.00E-07 Major depressive disorder / / 21621269 rs1558477 chr7 31155347 T C 2.58E-06 Major depressive disorder / / pha002850 rs7791986 chr7 31157479 C G 2.60E-05 Major depressive disorder / / 19065144 rs7791986 chr7 31157479 C G 1.04E-05 Major depressive disorder / / 21621269 rs7791986 chr7 31157479 C G 8.41E-05 Major depressive disorder / / pha002850 rs7808175 chr7 31161253 A G 4.42E-04 Multiple complex diseases / / 17554300 rs6462251 chr7 31209019 G A 3.37E-05 Triglycerides / / pha003080 rs7792372 chr7 31213561 T C 7.03E-05 Triglycerides / / pha003080 rs17159991 chr7 31242470 A G 7.67E-06 Uric acid levels / / 21294900 rs7805619 chr7 31331381 G A 1.49E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs6949499 chr7 31393552 C T 6.30E-06 Urinary metabolites / / 21572414 rs7801471 chr7 31412771 G A 2.10E-05 Urinary metabolites / / 21572414 rs10951291 chr7 31424899 C T 7.56E-04 Body mass index / / 21701565 rs7780365 chr7 31438610 A G 6.89E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7780365 chr7 31438610 A G 3.43E-04 Body mass index / / 21701565 rs17160130 chr7 31445815 C T 1.44E-05 Brain structure / / 22504417 rs11771371 chr7 31451928 A G 2.64E-04 Obesity (extreme) / / 21935397 rs12674467 chr7 31459659 A G 3.75E-04 Obesity (extreme) / / 21935397 rs17160143 chr7 31462045 A G 6.13E-04 Obesity (extreme) / / 21935397 rs13232983 chr7 31520800 C T 8.68E-08 Narcolepsy / / 19629137 rs4720038 chr7 31522092 C A 1.88E-07 Osteoarthritis (knee and hip) / / 21177295 rs4720038 chr7 31522092 C A 3.50E-05 Osteoarthritis (knee and hip) / / 21177295 rs4720038 chr7 31522092 C A 5.68E-04 Osteoarthritis (knee and hip) / / 21177295 rs6973071 chr7 31528056 T C 2.77E-04 Taste perception / / 22132133 rs6462280 chr7 31528385 T A 1.28E-04 Multiple complex diseases / / 17554300 rs6462280 chr7 31528385 T A 6.33E-04 Alzheimer's disease / / 17998437 rs882460 chr7 31533784 T C 5.70E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs882460 chr7 31533784 T C 5.79E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs4723083 chr7 31548371 G A 0.000081 Tuberculosis with early age of onset / / 22551897 rs719435 chr7 31551556 C T 1.10E-05 Volumetric brain MRI / / 17903297 rs217164 chr7 31562114 T G 2.20E-05 Urinary metabolites CCDC129 intron 21572414 rs61522085 chr7 31563818 A G 8.46E-05 Epilepsy (remission after treatment) CCDC129 intron 23962720 rs217168 chr7 31564179 C G 1.96E-05 Alzheimer's disease CCDC129 intron 17998437 rs2191342 chr7 31570401 C T 6.83E-04 Alzheimer's disease CCDC129 intron 17998437 rs10246900 chr7 31571181 A G 2.54E-05 Alzheimer's disease CCDC129 intron 17998437 rs10276779 chr7 31571192 G A 4.05E-04 Alzheimer's disease CCDC129 intron 17998437 rs10276589 chr7 31571212 C G 2.66E-05 Alzheimer's disease CCDC129 intron 17998437 rs10276592 chr7 31571231 C G 2.57E-05 Alzheimer's disease CCDC129 intron 17998437 rs10245230 chr7 31582964 C T 5.15E-05 Multiple complex diseases CCDC129 intron 17554300 rs10243603 chr7 31587618 C T 3.15E-04 Intracranial aneurysm CCDC129 intron 20613766 rs17160267 chr7 31607134 G A 9.45E-05 Epilepsy (remission after treatment) CCDC129 intron 23962720 rs1014137 chr7 31623746 T C 8.00E-06 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CCDC129 intron 24578207 rs1014137 chr7 31623746 T C 8.44E-06 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CCDC129 intron 24578207 rs1014137 chr7 31623746 T C 8.44E-06 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CCDC129 intron 24578207 rs10259423 chr7 31631736 G A 2.30E-05 Urinary metabolites CCDC129 intron 21572414 rs2109395 chr7 31646038 A G 4.85E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CCDC129 intron 24578207 rs2109395 chr7 31646038 A G 4.85E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CCDC129 intron 24578207 rs38332 chr7 31652328 A G 8.99E-04 Type 2 diabetes CCDC129 intron 17463246 rs38332 chr7 31652328 A G 5.77E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CCDC129 intron 24578207 rs38332 chr7 31652328 A G 5.77E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CCDC129 intron 24578207 rs38333 chr7 31652758 C T 4.34E-04 Multiple complex diseases CCDC129 intron 17554300 rs2058280 chr7 31657634 A G 2.33E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CCDC129 intron 24578207 rs2058280 chr7 31657634 A G 2.33E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CCDC129 intron 24578207 rs887463 chr7 31658728 T C 8.27E-05 Body Fat Distribution CCDC129 intron pha003017 rs1003405 chr7 31665800 T C 4.59E-04 Taste perception CCDC129 intron 22132133 rs1003405 chr7 31665800 T C 1.62E-05 Body Fat Distribution CCDC129 intron pha003017 rs1003405 chr7 31665800 T C 4.92E-05 Body Fat Distribution CCDC129 intron pha003018 rs6462290 chr7 31670531 A G 5.02E-05 Taste perception CCDC129 intron 22132133 rs38379 chr7 31672870 C T 2.36E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CCDC129 intron 24578207 rs38379 chr7 31672870 C T 2.36E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CCDC129 intron 24578207 rs38379 chr7 31672870 C T 1.38E-05 Body Fat Distribution CCDC129 intron pha003017 rs38379 chr7 31672870 C T 4.50E-05 Body Fat Distribution CCDC129 intron pha003018 rs34158 chr7 31726465 T C 1.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PPP1R17 nearGene-5 20877124 rs34198 chr7 31755670 T C 8.70E-04 Premature ovarian failure / / 19508998 rs10254520 chr7 31779145 C T 5.50E-06 Urinary metabolites / / 21572414 rs7795363 chr7 31786849 T C 6.60E-04 Crohn's disease / / 17684544 rs4723098 chr7 31787989 T C 6.52E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs758938 chr7 31799307 G A 0.0000012 Stressful life events PDE1C intron 23237013 rs11980485 chr7 31812836 T G 0.0000014 Stressful life events PDE1C intron 23237013 rs13232442 chr7 31843013 T A 3.53E-04 Acute lung injury PDE1C intron 22295056 rs372230970 chr7 31843013 T TA,TC,TTA,TTTA,TTTATTA 3.53E-04 Acute lung injury PDE1C intron 22295056 rs70989605 chr7 31843013 T TTTA 3.53E-04 Acute lung injury PDE1C intron 22295056 rs4723103 chr7 31868613 T C 0.000486 Salmonella-induced pyroptosis PDE1C intron 22837397 rs17160618 chr7 31895388 T C 8.26E-04 Obesity (extreme) PDE1C intron 21935397 rs2270221 chr7 31904027 C T 1.00E-06 Endometriosis PDE1C intron 23472165 rs2191866 chr7 31905615 G A 6.08E-04 Obesity (extreme) PDE1C intron 21935397 rs17160659 chr7 31937162 A T 1.59E-06 Type 2 diabetes PDE1C intron 17463246 rs13223209 chr7 31949763 G A 6.56E-05 Pulmonary function PDE1C intron 19300500 rs13223209 chr7 31949763 G A 8.59E-04 Alcohol dependence PDE1C intron 21314694 rs1160758 chr7 31951613 G C 6.45E-05 Pulmonary function PDE1C intron 19300500 rs10487739 chr7 31962380 G C 1.12E-05 Type 2 diabetes PDE1C intron 17463246 rs11770536 chr7 31973974 T C 5.45E-05 Alcohol and nictotine co-dependence PDE1C intron 20158304 rs2008835 chr7 31992173 T G 3.52E-05 Type 2 diabetes PDE1C intron 17463246 rs17160736 chr7 32014929 T C 1.20E-05 Urinary metabolites PDE1C intron 21572414 rs2392015 chr7 32030880 C T 3.90E-05 Pulmonary function PDE1C intron 19300500 rs4720051 chr7 32033492 G A 7.39E-05 Glucose levels PDE1C intron pha003061 rs6462322 chr7 32034404 A G 2.83E-04 Multiple complex diseases PDE1C intron 17554300 rs6968484 chr7 32038104 C T 9.05E-04 Response to cytadine analogues (cytosine arabinoside) PDE1C intron 24483146 rs7783203 chr7 32053691 G T 1.10E-05 Urinary metabolites PDE1C intron 21572414 rs17336609 chr7 32062898 T C 2.20E-05 Urinary metabolites PDE1C intron 21572414 rs30561 chr7 32064492 C T 5.17E-05 Orofacial clefts PDE1C intron 22419666 rs2214783 chr7 32083175 C A 5.08E-04 Nicotine smoking PDE1C intron 19268276 rs2214784 chr7 32083552 G C 9.56E-04 Suicide attempts in bipolar disorder PDE1C intron 21423239 rs11984354 chr7 32091715 G A 6.40E-06 Urinary metabolites PDE1C intron 21572414 rs30586 chr7 32093651 A G 2.13E-04 Type 2 diabetes PDE1C intron 17463246 rs6462324 chr7 32120897 A C 5.63E-05 Serum metabolites PDE1C intron 19043545 rs4551232 chr7 32127725 A G 2.67E-05 Serum metabolites PDE1C intron 19043545 rs10225488 chr7 32128882 T A 1.96E-05 Serum metabolites PDE1C intron 19043545 rs2392016 chr7 32129777 T G 1.96E-05 Serum metabolites PDE1C intron 19043545 rs1029549 chr7 32186706 A G 7.57E-05 Tunica Media PDE1C intron pha003036 rs11975235 chr7 32189540 A C 3.00E-06 Presence of antiphospholipid antibodies PDE1C intron 23509613 rs1557975 chr7 32191808 G A 9.99E-04 Response to TNF antagonist treatment PDE1C intron 21061259 rs6415258 chr7 32192596 A G 9.40E-04 Suicide attempts in bipolar disorder PDE1C intron 21423239 rs12154834 chr7 32204295 C T 1.70E-05 Urinary metabolites PDE1C intron 21572414 rs17160942 chr7 32204757 C T 6.13E-04 Multiple complex diseases PDE1C intron 17554300 rs10274609 chr7 32206323 T C 1.30E-05 Coronary heart disease PDE1C intron 21971053 rs10274609 chr7 32206323 T C 1.00E-04 Cognitive impairment induced by topiramate PDE1C intron 22091778 rs758318 chr7 32209359 A G 7.87E-06 Coronary heart disease PDE1C intron 21971053 rs17160951 chr7 32220641 T C 4.80E-05 Coronary heart disease PDE1C intron 21971053 rs4723127 chr7 32225283 T G 9.54E-06 Information processing speed PDE1C intron 21130836 rs4723127 chr7 32225283 T G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes PDE1C intron 22628534 rs10279087 chr7 32228040 T C 1.81E-04 Coronary heart disease PDE1C intron 21971053 rs6462341 chr7 32240959 C G 1.09E-04 Multiple complex diseases PDE1C intron 17554300 rs1860220 chr7 32241867 T G 6.19E-04 Suicide attempts in bipolar disorder PDE1C intron 21423239 rs11765220 chr7 32243360 C T 3.83E-04 Nicotine smoking PDE1C intron 19268276 rs13224521 chr7 32245912 C T 3.10E-04 Coronary heart disease PDE1C intron 21971053 rs4723132 chr7 32246865 A G 3.16E-05 Cognitive test performance PDE1C intron 20125193 rs4723133 chr7 32247043 T C 6.27E-05 HIV-1 control PDE1C intron 20041166 rs4723134 chr7 32255322 C T 9.09E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) PDE1C intron 23648065 rs6945244 chr7 32259273 C T 2.40E-05 Smoking behavior PDE1C intron 20418888 rs12669911 chr7 32262377 A C 2.70E-06 Smoking behavior PDE1C intron 20418888 rs12669911 chr7 32262377 A C 2.30E-05 Urinary metabolites PDE1C intron 21572414 rs10233045 chr7 32264492 G A 1.60E-06 Smoking behavior PDE1C intron 20418888 rs10237329 chr7 32265725 C T 1.30E-06 Smoking behavior PDE1C intron 20418888 rs1014242 chr7 32272305 C T 2.40E-07 Smoking behavior PDE1C intron 20418888 rs7786576 chr7 32272714 C A 4.20E-07 Smoking behavior PDE1C intron 20418888 rs7806224 chr7 32273107 T C 2.30E-07 Smoking behavior PDE1C intron 20418888 rs10259431 chr7 32281397 C T 1.50E-07 Smoking behavior PDE1C intron 20418888 rs9638875 chr7 32282914 T A 7.80E-07 Smoking behavior PDE1C intron 20418888 rs17161076 chr7 32290565 A G 6.40E-06 Urinary metabolites PDE1C intron 21572414 rs10236197 chr7 32291761 T C 3.40E-07 Smoking behavior PDE1C intron 20418888 rs11773343 chr7 32292316 C T 3.50E-05 Smoking behavior PDE1C intron 20418888 rs7798739 chr7 32292961 A T 4.10E-07 Smoking behavior PDE1C intron 20418888 rs13221985 chr7 32292985 C A 3.20E-05 Smoking behavior PDE1C intron 20418888 rs929456 chr7 32293644 G T 7.40E-07 Smoking behavior PDE1C intron 20418888 rs13224417 chr7 32298593 G A 2.60E-05 Smoking behavior PDE1C intron 20418888 rs11762194 chr7 32300169 G A 2.20E-05 Smoking behavior PDE1C intron 20418888 rs6948856 chr7 32302347 G A 2.40E-05 Smoking behavior PDE1C intron 20418888 rs975122 chr7 32302794 A T 1.50E-05 Smoking behavior PDE1C intron 20418888 rs7806397 chr7 32303339 T C 2.60E-07 Smoking behavior PDE1C intron 20418888 rs7796692 chr7 32304865 A G 2.10E-05 Smoking behavior PDE1C intron 20418888 rs7780515 chr7 32305274 T C 3.60E-07 Smoking behavior PDE1C intron 20418888 rs4368879 chr7 32307925 C T 1.70E-07 Smoking behavior PDE1C intron 20418888 rs4370439 chr7 32308101 C T 2.10E-05 Smoking behavior PDE1C intron 20418888 rs1450869 chr7 32311672 G T 1.70E-07 Smoking behavior PDE1C intron 20418888 rs1450869 chr7 32311672 G T 2.60E-05 Urinary metabolites PDE1C intron 21572414 rs1450870 chr7 32311726 T C 2.93E-04 Multiple complex diseases PDE1C intron 17554300 rs1450870 chr7 32311726 T C 7.10E-07 Smoking behavior PDE1C intron 20418888 rs1450870 chr7 32311726 T C 2.50E-05 Urinary metabolites PDE1C intron 21572414 rs7778162 chr7 32314484 T C 1.40E-05 Smoking behavior PDE1C intron 20418888 rs7778443 chr7 32314690 T C 3.07E-04 Multiple complex diseases PDE1C intron 17554300 rs7778443 chr7 32314690 T C 3.90E-07 Smoking behavior PDE1C intron 20418888 rs7778443 chr7 32314690 T C 2.40E-05 Urinary metabolites PDE1C intron 21572414 rs10226228 chr7 32315613 A G 2.40E-07 Smoking behavior PDE1C intron 20418888 rs10226228 chr7 32315613 A G 1.80E-05 Urinary metabolites PDE1C intron 21572414 rs1476765 chr7 32320458 G T 1.30E-07 Smoking behavior PDE1C intron 20418888 rs9771228 chr7 32322496 T C 3.50E-08 Smoking behavior PDE1C intron 20418888 rs12540232 chr7 32322961 T C 2.20E-07 Smoking behavior PDE1C intron 20418888 rs215596 chr7 32326373 A G 7.36E-04 Multiple complex diseases PDE1C intron 17554300 rs215596 chr7 32326373 A G 7.90E-08 Smoking behavior PDE1C intron 20418888 rs215596 chr7 32326373 A G 3.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE1C intron 20877124 rs11768207 chr7 32327307 G C 5.00E-05 Smoking behavior PDE1C intron 20418888 rs215599 chr7 32330129 C T 2.20E-07 Smoking behavior PDE1C intron 20418888 rs10271037 chr7 32330336 G T 1.50E-05 Smoking behavior PDE1C intron 20418888 rs215600 chr7 32333642 G A 7.00E-08 Smoking behavior PDE1C intron 20418888 rs215601 chr7 32333921 A C 3.10E-07 Smoking behavior PDE1C intron 20418888 rs215605 chr7 32336965 G T 5.40E-09 Smoking behavior PDE1C intron 20418888 rs215607 chr7 32338337 G A 5.60E-07 Smoking behavior PDE1C missense 20418888 rs215610 chr7 32339594 G A 1.10E-07 Smoking behavior / / 20418888 rs12531858 chr7 32340099 C A 1.20E-07 Smoking behavior / / 20418888 rs12531858 chr7 32340099 C A 2.35E-04 Cognitive decline / / 23732972 rs215611 chr7 32341438 C G 1.90E-05 Smoking behavior / / 20418888 rs7780009 chr7 32341543 G A 6.30E-08 Smoking behavior / / 20418888 rs6952609 chr7 32343335 A G 2.90E-07 Smoking behavior / / 20418888 rs7779181 chr7 32345283 T C 9.50E-08 Smoking behavior / / 20418888 rs7779130 chr7 32346958 G T 9.10E-08 Smoking behavior / / 20418888 rs7778788 chr7 32346974 A C 1.30E-07 Smoking behavior / / 20418888 rs7779180 chr7 32347202 A G 4.60E-08 Smoking behavior / / 20418888 rs215614 chr7 32347335 G A 2.00E-07 Smoking behavior / / 20418888 rs10951331 chr7 32354374 A G 1.40E-07 Smoking behavior / / 20418888 rs215622 chr7 32357659 C T 1.20E-07 Smoking behavior / / 20418888 rs215625 chr7 32358313 G A 1.00E-07 Smoking behavior / / 20418888 rs215629 chr7 32360464 G C 2.40E-08 Smoking behavior / / 20418888 rs1653876 chr7 32360619 T C 3.00E-05 Smoking behavior / / 20418888 rs6462354 chr7 32366483 A G 5.80E-06 Smoking behavior / / 20418888 rs1115318 chr7 32367650 G A 6.60E-06 Smoking behavior / / 20418888 rs215632 chr7 32368524 A G 1.90E-08 Smoking behavior / / 20418888 rs215634 chr7 32369148 A G 4.60E-08 Smoking behavior / / 20418888 rs6955346 chr7 32369553 T C 1.40E-07 Smoking behavior / / 20418888 rs6955346 chr7 32369553 T C 8.92E-04 Insulin resistance / / 21901158 rs215635 chr7 32370220 C T 2.00E-08 Smoking behavior / / 20418888 rs10264177 chr7 32370862 A G 2.40E-08 Smoking behavior / / 20418888 rs215636 chr7 32371919 C G 4.30E-05 Smoking behavior / / 20418888 rs215639 chr7 32373639 C T 2.60E-07 Smoking behavior / / 20418888 rs6977196 chr7 32373878 T C 2.00E-05 Smoking behavior / / 20418888 rs10237735 chr7 32376748 C T 1.00E-06 Palmitic acid (16:0) plasma levels / / 23362303 rs10238006 chr7 32376953 C A 3.10E-05 Smoking behavior / / 20418888 rs10447642 chr7 32377565 C T 3.70E-05 Smoking behavior / / 20418888 rs215669 chr7 32378979 G A 6.50E-07 Smoking behavior / / 20418888 rs215670 chr7 32379218 G A 3.70E-07 Smoking behavior / / 20418888 rs186229 chr7 32381557 C A 2.20E-06 Smoking behavior / / 20418888 rs1562830 chr7 32393467 C T 1.50E-05 Coronary heart disease / / pha003035 rs215692 chr7 32394858 T C 6.50E-06 Smoking behavior / / 20418888 rs12532023 chr7 32394878 G C 1.82E-04 Cognitive decline / / 23732972 rs412876 chr7 32395660 G T 3.00E-06 Smoking behavior / / 20418888 rs215694 chr7 32397026 T G 8.20E-06 Smoking behavior / / 20418888 rs7791060 chr7 32397269 A G 5.46E-04 Type 2 diabetes / / 17463246 rs7791060 chr7 32397269 A G 1.82E-04 Cognitive decline / / 23732972 rs215695 chr7 32397908 C T 4.03E-04 Multiple complex diseases / / 17554300 rs215698 chr7 32398094 C T 3.00E-05 Prostate cancer / / 21743057 rs4723147 chr7 32398156 G A 6.90E-05 Smoking behavior / / 20418888 rs215702 chr7 32399658 G A 6.40E-07 Smoking behavior / / 20418888 rs10486507 chr7 32399833 G T 8.60E-05 Smoking behavior / / 20418888 rs441261 chr7 32422077 G C 0.00000106 Colorectal cancer (females) / / 22532847 rs215738 chr7 32444435 G A 7.81E-06 Smooth-surface caries / / 24556642 rs215738 chr7 32444435 G A 8.00E-06 Smooth-surface caries / / 24556642 rs170016 chr7 32446317 G A 6.40E-06 Smoking behavior / / 20418888 rs430356 chr7 32447226 G A 8.75E-04 Depression (quantitative trait) / / 20800221 rs6975351 chr7 32452634 G C 9.28E-04 Multiple complex diseases / / 17554300 rs10226019 chr7 32460233 T C 8.80E-06 Urinary metabolites / / 21572414 rs10239812 chr7 32460348 A G 8.67E-06 Metabolite levels (MHPG) / / 23319000 rs10229071 chr7 32460436 T G 6.80E-06 Urinary metabolites / / 21572414 rs62458065 chr7 32460724 G T 1.00E-06 Metabolite levels (HVA/MHPG ratio) / / 23319000 rs10273165 chr7 32460840 G A 8.67E-06 Metabolite levels (MHPG) / / 23319000 rs7785659 chr7 32461015 C T 1.37E-08 Osteoarthritis / / 22763110 rs7785659 chr7 32461015 C T 8.67E-06 Metabolite levels (MHPG) / / 23319000 rs7804998 chr7 32461197 T C 8.67E-06 Metabolite levels (MHPG) / / 23319000 rs7785999 chr7 32461262 C A 9.22E-05 Glaucoma (primary open-angle) / / 22605921 rs7785999 chr7 32461262 C A 8.67E-06 Metabolite levels (MHPG) / / 23319000 rs1450868 chr7 32463666 G A 1.04E-06 Metabolite levels (MHPG) / / 23319000 rs979355 chr7 32463933 G A 6.42E-07 Metabolite levels (MHPG) / / 23319000 rs62458066 chr7 32464484 C T 8.67E-06 Metabolite levels (MHPG) / / 23319000 rs6462363 chr7 32464759 T G 1.04E-06 Metabolite levels (MHPG) / / 23319000 rs6462364 chr7 32464776 C T 1.04E-06 Metabolite levels (MHPG) / / 23319000 rs10246687 chr7 32465183 T A 1.04E-06 Metabolite levels (MHPG) / / 23319000 rs10231294 chr7 32465357 C T 1.04E-06 Metabolite levels (MHPG) / / 23319000 rs10250808 chr7 32466153 T C 1.04E-06 Metabolite levels (MHPG) / / 23319000 rs10275978 chr7 32466719 G T 1.04E-06 Metabolite levels (MHPG) / / 23319000 rs79538247 chr7 32467792 A G 1.04E-06 Metabolite levels (MHPG) / / 23319000 rs28693551 chr7 32469387 G A 8.67E-06 Metabolite levels (MHPG) / / 23319000 rs28677012 chr7 32469811 C A 8.67E-06 Metabolite levels (MHPG) / / 23319000 rs7808992 chr7 32470677 C T 8.67E-06 Metabolite levels (MHPG) / / 23319000 rs62458098 chr7 32471129 G A 8.67E-06 Metabolite levels (MHPG) / / 23319000 rs73096034 chr7 32472048 A G 8.67E-06 Metabolite levels (MHPG) / / 23319000 rs62458099 chr7 32472395 C T 8.67E-06 Metabolite levels (MHPG) / / 23319000 rs62458100 chr7 32473142 C G 8.67E-06 Metabolite levels (MHPG) / / 23319000 rs62458101 chr7 32474897 C T 7.56E-06 Metabolite levels (MHPG) / / 23319000 rs17458671 chr7 32490527 C T 8.73E-05 Menopause (age at onset) / / 19448619 rs17362231 chr7 32514580 T C 8.85E-05 Hemoglobin / / pha003098 rs17461475 chr7 32573063 G A 7.22E-04 Type 2 diabetes AVL9 intron 17463246 rs7805536 chr7 32573570 T C 1.30E-04 Systemic lupus erythematosus AVL9 intron 22291604 rs7805536 chr7 32573570 T C 4.38E-08 Osteoarthritis AVL9 intron 22763110 rs17364223 chr7 32575962 A G 8.48E-05 Hemoglobin AVL9 intron pha003098 rs17364223 chr7 32575962 A G 9.35E-05 Erythrocyte counts AVL9 intron pha003099 rs17161418 chr7 32604222 A G 1.10E-05 Urinary metabolites AVL9 intron 21572414 rs3173734 chr7 32625526 T G 9.71E-05 Arthritis (juvenile idiopathic) DPY19L1P1 intron 22354554 rs10951343 chr7 32634796 T C 3.98E-06 White blood cell count DPY19L1P1 intron 21738479 rs12701232 chr7 32643969 C T 7.41E-06 White blood cell count DPY19L1P1 intron 21738479 rs6945238 chr7 32646096 T C 7.57E-05 Telomere length DPY19L1P1 intron 21573004 rs17161473 chr7 32648315 C T 8.30E-06 Urinary metabolites DPY19L1P1 intron 21572414 rs11767444 chr7 32652236 C A 4.17E-06 White blood cell count DPY19L1P1 intron 21738479 rs2060708 chr7 32657110 T C 3.89E-06 White blood cell count DPY19L1P1 intron 21738479 rs2302067 chr7 32661085 T C 7.59E-06 White blood cell count DPY19L1P1 intron 21738479 rs11764583 chr7 32678958 G A 6.46E-06 White blood cell count / / 21738479 rs1839581 chr7 32700562 G A 6.27E-05 Asthma DPY19L1P1 intron pha003128 rs13226474 chr7 32704310 T C 2.95E-06 White blood cell count DPY19L1P1 intron 21738479 rs10242306 chr7 32791567 G A 4.90E-06 Urinary metabolites / / 21572414 rs13242520 chr7 32811970 T C 4.17E-06 White blood cell count / / 21738479 rs10243492 chr7 32820437 A G 1.97E-07 Hepatitis B / / 24162738 rs10951356 chr7 32824632 C T 9.22E-05 Telomere length / / 21573004 rs4723212 chr7 32829130 T G 2.60E-04 IgE levels / / 17255346 rs17382957 chr7 32858959 T G 2.18E-04 Alzheimer's disease / / 22005930 rs17170519 chr7 32861230 C G 2.02E-04 Alzheimer's disease / / 22005930 rs2392147 chr7 32866723 T G 4.78E-04 Suicide,with and without major depression / / 22059935 rs2392147 chr7 32866723 T G 2.24E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2392151 chr7 32890682 T C 1.35E-06 White blood cell count / / 21738479 rs2392151 chr7 32890682 T C 1.82E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4720083 chr7 32900246 C G 1.98E-04 Type 2 diabetes / / 17463246 rs1045477 chr7 32908704 T C 1.11E-04 Telomere length KBTBD2 UTR-3 21573004 rs752730 chr7 32909182 G A 2.56E-04 Type 2 diabetes KBTBD2 cds-synon 17463246 rs17468378 chr7 32912750 C G 6.06E-04 Type 2 diabetes KBTBD2 intron 17463246 rs6462430 chr7 32921831 G A 3.17E-04 Suicide,with and without major depression KBTBD2 intron 22059935 rs6462430 chr7 32921831 G A 4.30E-04 Suicide,with and without major depression KBTBD2 intron 22059935 rs4723222 chr7 32957661 A G 7.07E-05 Alzheimer's disease RP9P intron 22005930 rs12701264 chr7 32965040 A G 8.11E-05 Alzheimer's disease RP9P intron 22005930 rs6462446 chr7 33053281 G A 6.68E-04 Multiple complex diseases NT5C3 nearGene-3 17554300 rs7776847 chr7 33086391 G A 1.77E-05 Relative hand skill in reading disability NT5C3 intron 24068947 rs6462455 chr7 33109186 G A 0.00007945 Sarcoidosis / / 22952805 rs2893461 chr7 33109370 G A 8.73E-04 Multiple complex diseases / / 17554300 rs2022230 chr7 33119907 G A 9.16E-05 Platelet counts / / pha003100 rs17472556 chr7 33139147 G A 0.00086 Prostate cancer RP9 intron 23555315 rs3847009 chr7 33151181 A G 1.91E-05 Colorectal cancer / / 21242260 rs17169807 chr7 33181238 T C 4.00E-06 Smooth-surface caries BBS9 intron 24556642 rs4723264 chr7 33197515 A G 0.0000394 Carotid intima media thickness BBS9 intron 23152477 rs10486523 chr7 33241996 C T 1.18E-06 Blood Pressure BBS9 intron pha002903 rs9791555 chr7 33245128 A G 1.30E-06 Blood Pressure BBS9 intron pha002903 rs10262453 chr7 33256039 A C 6.00E-20 Sagittal craniosynostosis BBS9 intron 23160099 rs7799346 chr7 33312020 G A 1.11E-06 Blood Pressure BBS9 intron pha002903 rs6955645 chr7 33391139 T A 5.70E-07 Urinary metabolites BBS9 intron 21572414 rs2109525 chr7 33411267 T G 4.39E-08 Metabolite levels BBS9 intron 23281178 rs2109525 chr7 33411267 T G 7.52E-04 Smoking initiation BBS9 intron 24665060 rs17786463 chr7 33432951 A T 4.39E-08 Metabolite levels BBS9 intron 23281178 rs12668971 chr7 33469567 C A 4.15E-04 Multiple complex diseases BBS9 intron 17554300 rs4509212 chr7 33506645 T C 5.80E-04 Multiple complex diseases BBS9 intron 17554300 rs6462481 chr7 33510616 C T 3.14E-04 Amyotrophic Lateral Sclerosis BBS9 intron 17827064 rs740888 chr7 33541486 G A 1.60E-04 Multiple complex diseases BBS9 intron 17554300 rs12674093 chr7 33554162 G T 1 Drug response to Etoposide BBS9 intron 17537913 rs2392246 chr7 33571828 T C 5.78E-04 Amyotrophic Lateral Sclerosis BBS9 intron 17827064 rs10275888 chr7 33583128 G A 0.0000935 Nonsyndromic striae distensae (stretch marks) BBS9 intron 23633020 rs60221534 chr7 33584427 C T 0.0000939 Nonsyndromic striae distensae (stretch marks) BBS9 intron 23633020 rs1020516 chr7 33604021 C T 8.07E-05 Glaucoma (primary open-angle) BBS9 intron 22605921 rs4590341 chr7 33613560 C A 1.17E-04 IgA nephropathy BBS9 intron 22197929 rs10277926 chr7 33629413 C A 1.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BBS9 intron 20877124 rs10277926 chr7 33629413 C A 2.42E-04 Aortic root size BBS9 intron 21223598 rs10215226 chr7 33633443 C G 1.86E-04 Aortic root size BBS9 intron 21223598 rs2700689 chr7 33664944 C A 1.73E-05 Cytomegalovirus antibody response / / 21993531 rs12534049 chr7 33665379 C A 3.14E-05 Cytomegalovirus antibody response / / 21993531 rs10486541 chr7 33667314 G A 1.54E-05 Bone mass and geometry / / 17903296 rs12535011 chr7 33667945 T C 2.30E-05 Cytomegalovirus antibody response / / 21993531 rs12538989 chr7 33670275 A G 2.33E-05 Cytomegalovirus antibody response / / 21993531 rs17170315 chr7 33673151 A G 1.99E-05 Cytomegalovirus antibody response / / 21993531 rs17170316 chr7 33673265 G T 8.00E-07 Cytomegalovirus antibody response / / 21993531 rs1451019 chr7 33690186 T G 6.07E-04 Body mass index / / 21701565 rs1451010 chr7 33705491 C T 8.87E-05 Autism spectrum disorders (language delay) / / 21519539 rs4723308 chr7 33710954 G C 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10238579 chr7 33722022 G C 3.30E-04 Type 2 diabetes / / 17463246 rs4720133 chr7 33722689 A G 1.97E-04 Type 2 diabetes / / 17463246 rs4720135 chr7 33730681 T C 5.49E-04 Type 2 diabetes / / 17463246 rs1006358 chr7 33733087 A G 8.18E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4723317 chr7 33736100 T C 5.25E-06 White blood cell count / / 21738479 rs17170361 chr7 33753785 G A 9.63E-04 Multiple complex diseases / / 17554300 rs13240118 chr7 33758537 A G 8.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs3779238 chr7 33763789 C T 8.17E-05 Type 2 diabetes / / 17463246 rs6946492 chr7 33769464 G A 6.44E-05 Type 2 diabetes / / 17463246 rs17170396 chr7 33781221 C G 9.38E-04 Obesity (extreme) / / 21935397 rs11974259 chr7 33782235 C G 9.55E-04 Obesity (extreme) / / 21935397 rs16879230 chr7 33799055 T G 2.37E-04 Multiple complex diseases / / 17554300 rs12672495 chr7 33799576 G C 2.99E-04 Multiple complex diseases / / 17554300 rs17170410 chr7 33811489 C T 2.86E-04 Type 2 diabetes / / 17463246 rs4723331 chr7 33811929 A G 1.42E-04 Type 2 diabetes / / 17463246 rs6972902 chr7 33815290 C T 3.94E-04 Type 2 diabetes / / 17463246 rs1362927 chr7 33816709 G A 2.87E-05 Systemic lupus erythematosus / / pha002867 rs13240558 chr7 33837596 T A 3.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs6948754 chr7 33843821 T C 6.86E-07 White blood cell count / / 21738479 rs4723335 chr7 33847892 C T 2.75E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs10244781 chr7 33850385 T C 6.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs10244781 chr7 33850385 T C 1.24E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs11974796 chr7 33852599 G T 4.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs11974796 chr7 33852599 G T 7.20E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1421344 chr7 33883752 G A 1.19E-26 Narcolepsy / / 19629137 rs995544 chr7 33893190 T C 8.35E-04 Multiple complex diseases / / 17554300 rs17814369 chr7 33904258 C G 3.20E-06 Urinary metabolites / / 21572414 rs17741533 chr7 33904911 C T 5.96E-04 Alzheimer's disease / / 17998437 rs4723340 chr7 33908073 A G 5.83E-04 Multiple complex diseases / / 17554300 rs6975236 chr7 33975568 C T 2.72E-04 Type 2 diabetes BMPER intron 17463246 rs41448344 chr7 33977600 T C 5.12E-04 Type 2 diabetes BMPER intron 17463246 rs13233238 chr7 33991109 T C 5.03E-05 Femoral neck bone geometry BMPER intron 22087292 rs10265207 chr7 34009946 C T 5.41E-05 Cognitive test performance BMPER cds-synon 20125193 rs13243958 chr7 34013178 G T 2.60E-05 Urinary metabolites BMPER intron 21572414 rs13243958 chr7 34013178 G T 3.25E-04 Coronary heart disease BMPER intron 21606135 rs13243958 chr7 34013178 G T 5.08E-05 Kawasaki disease BMPER intron 22446961 rs10281667 chr7 34013493 G A 1.80E-05 Urinary metabolites BMPER intron 21572414 rs16879310 chr7 34013581 T C 9.15E-06 Odorant perception BMPER intron 23910658 rs10272728 chr7 34016965 G A 2.87E-04 Hearing function BMPER intron 17255346 rs75733828 chr7 34057913 T C 7.14E-07 Alzheimer's disease BMPER intron 24770881 rs74651988 chr7 34065142 T A 6.31E-07 Alzheimer's disease BMPER intron 24770881 rs79312206 chr7 34068665 G A 7.14E-07 Alzheimer's disease BMPER intron 24770881 rs74495807 chr7 34088535 C T 7.94E-07 Alzheimer's disease BMPER intron 24770881 rs7806522 chr7 34089823 T C 1.60E-05 Urinary metabolites BMPER intron 21572414 rs17169634 chr7 34093997 A G 1.00E-07 Alzheimer's disease BMPER intron 24770881 rs75353220 chr7 34094036 A G 1.82E-07 Alzheimer's disease BMPER intron 24770881 rs1362456 chr7 34104225 G A 6.36E-05 Alcohol dependence BMPER intron 19581569 rs1946146 chr7 34138717 G T 4.74E-04 Heart Failure BMPER intron pha002885 rs12539180 chr7 34142338 G A 5.21E-05 Blood Pressure BMPER intron pha003043 rs1420339 chr7 34143378 A G 8.09E-04 Multiple complex diseases BMPER intron 17554300 rs1420340 chr7 34158661 G A,C 4.52E-05 Parkinson's disease (motor and cognition) BMPER intron 22658654 rs1420340 chr7 34158661 G A,C 4.52E-05 Immune response to anthrax vaccine BMPER intron 22658931 rs1345347 chr7 34159138 T C 2.59E-05 Parkinson's disease (motor and cognition) BMPER intron 22658654 rs1345347 chr7 34159138 T C 2.59E-05 Immune response to anthrax vaccine BMPER intron 22658931 rs10951406 chr7 34173852 G A 4.36E-05 Parkinson's disease (motor and cognition) BMPER intron 22658654 rs10951406 chr7 34173852 G A 4.36E-05 Immune response to anthrax vaccine BMPER intron 22658931 rs12673452 chr7 34178283 G A 1.61E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) BMPER intron 23648065 rs10486632 chr7 34178645 C A 4.98E-05 Parkinson's disease (motor and cognition) BMPER intron 22658654 rs10486632 chr7 34178645 C A 4.98E-05 Immune response to anthrax vaccine BMPER intron 22658931 rs10226493 chr7 34192512 A T 7.50E-04 Aortic root size BMPER intron 21223598 rs6966433 chr7 34204683 C T 2.68E-05 Type 2 diabetes / / 17463246 rs6972636 chr7 34206156 G C 6.55E-05 Type 2 diabetes / / 17463246 rs6968694 chr7 34217401 T G 2.70E-05 Urinary metabolites / / 21572414 rs318653 chr7 34230676 T C 4.34E-04 Acute lung injury / / 22295056 rs318650 chr7 34232820 A C 7.27E-04 Acute lung injury / / 22295056 rs318571 chr7 34276627 A G 2.47E-04 Multiple complex diseases / / 17554300 rs318572 chr7 34276765 C T 4.40E-04 Multiple complex diseases / / 17554300 rs318576 chr7 34285221 A G 4.33E-05 Orofacial clefts / / 19270707 rs970437 chr7 34301107 G A 5.30E-05 Parkinson's disease (age of onset) / / 19772629 rs995415 chr7 34326342 G A 1.16E-04 Telomere length / / 21573004 rs1419842 chr7 34355100 C T 7.00E-05 Lupus / / 17911428 rs6957818 chr7 34373760 A G 0.000583964 Hypertension (early onset hypertension) / / 22479346 rs10486639 chr7 34374063 A G 2.44E-05 Hypertension (early onset hypertension) / / 22479346 rs1362182 chr7 34375553 G A 8.93E-04 Alcohol dependence / / 20201924 rs1419804 chr7 34382289 T G 6.48E-05 Hypertension (early onset hypertension) / / 22479346 rs1419805 chr7 34386440 A G 5.00E-05 Hypertension (early onset hypertension) / / 22479346 rs1419810 chr7 34399494 G T 0.00056164 Hypertension (early onset hypertension) AAA1 intron 22479346 rs7805161 chr7 34402963 T A 9.98E-04 Alzheimer's disease AAA1 intron 22005930 rs1001661 chr7 34403969 A G 6.65E-04 Alzheimer's disease AAA1 intron 22005930 rs17169771 chr7 34405042 A G 4.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) AAA1 intron 23648065 rs10251404 chr7 34407737 C T 0.000479739 Hypertension (early onset hypertension) AAA1 intron 22479346 rs10280909 chr7 34407843 A G 4.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) AAA1 intron 23648065 rs10251786 chr7 34407857 G A 0.000239333 Hypertension (early onset hypertension) AAA1 intron 22479346 rs4723357 chr7 34412689 C T 0.000310646 Hypertension (early onset hypertension) AAA1 intron 22479346 rs2392268 chr7 34414427 A G 0.000149769 Hypertension (early onset hypertension) AAA1 intron 22479346 rs7807919 chr7 34428181 G A 0.000184061 Hypertension (early onset hypertension) AAA1 intron 22479346 rs12537903 chr7 34429228 A C 2.87E-04 Response to taxane treatment (placlitaxel) AAA1 intron 23006423 rs17169791 chr7 34438755 C A 1.00E-05 Urinary metabolites AAA1 intron 21572414 rs1362195 chr7 34439570 A C,G 8.73E-05 Hypertension (early onset hypertension) AAA1 intron 22479346 rs2041176 chr7 34463595 C T 5.87E-05 IgE levels AAA1 intron 17255346 rs1019089 chr7 34464334 C G 3.99E-04 IgE levels AAA1 intron 17255346 rs10227970 chr7 34478120 T C 0.000304852 Hypertension (early onset hypertension) AAA1 intron 22479346 rs6970707 chr7 34481860 C G 4.50E-06 Urinary metabolites AAA1 intron 21572414 rs1946121 chr7 34525660 G A 4.42E-04 Type 2 diabetes AAA1 intron 17463246 rs17169815 chr7 34530573 T C 5.20E-06 Urinary metabolites AAA1 intron 21572414 rs16878934 chr7 34530855 T G 6.58E-04 Response to taxane treatment (placlitaxel) AAA1 intron 23006423 rs12673387 chr7 34543672 G C 3.36E-04 Type 2 diabetes AAA1 intron 17463246 rs17169830 chr7 34551891 T G 8.89E-04 Amyotrophic lateral sclerosis (sporadic) AAA1 intron 24529757 rs10258145 chr7 34599721 G A 3.58E-05 Attention deficit hyperactivity disorder AAA1 intron 20732627 rs12690808 chr7 34606336 G T 3.72E-05 Attention deficit hyperactivity disorder AAA1 intron 20732627 rs740514 chr7 34624796 G A 2.98E-04 Body mass index AAA1 intron 17255346 rs740515 chr7 34625387 G A 2.98E-04 Body mass index AAA1 intron 17255346 rs2392273 chr7 34627904 C T 2.98E-04 Body mass index AAA1 intron 17255346 rs2893482 chr7 34629104 A G 3.01E-05 Attention deficit hyperactivity disorder AAA1 intron 20732627 rs6462569 chr7 34638014 C T 3.40E-05 Attention deficit hyperactivity disorder AAA1 intron 20732627 rs10486650 chr7 34640485 C T 5.01E-04 Multiple complex diseases AAA1 intron 17554300 rs1362166 chr7 34652345 A G 4.86E-05 HIV-1 viral setpoint AAA1 intron 22174851 rs1023556 chr7 34696545 C T 2.61E-05 Attention deficit hyperactivity disorder AAA1 intron 20732627 rs2530544 chr7 34697060 G T 8.00E-07 IgG glycosylation AAA1 intron 23382691 rs2530545 chr7 34697140 C T 7.00E-06 IgG glycosylation AAA1 intron 23382691 rs10486653 chr7 34711663 C T 2.70E-04 Kidney function and endocine traits NPSR1 intron 17903292 rs10239860 chr7 34755473 A T 6.37E-05 Serum metabolites NPSR1 intron 19043545 rs2022143 chr7 34756290 T A 4.10E-05 Diabetic retinopathy NPSR1 intron 21441570 rs1419790 chr7 34775544 G T 7.40E-04 Crohn's disease NPSR1 intron 17684544 rs324389 chr7 34777714 C T 1.45E-04 Atopy NPSR1 intron 21625490 rs10270663 chr7 34786398 G T 9.96E-05 Atopy NPSR1 intron 21625490 rs10267134 chr7 34803103 A G 1.03E-04 Atopy NPSR1 intron 21625490 rs10278663 chr7 34808471 G A 4.36E-04 Atopy NPSR1 intron 21625490 rs324978 chr7 34814332 A G 9.70E-05 Type 2 diabetes NPSR1 intron 17463246 rs324981 chr7 34818113 A T 1.80E-05 Sleep and circadian phenotypes NPSR1 missense 17903308 rs325452 chr7 34832301 G T 6.93E-05 Atopic dermatitis NPSR1 intron 23042114 rs325465 chr7 34851424 A G 0.00000207 LDL cholesterol NPSR1 missense 23063622 rs325465 chr7 34851424 A G 5.78E-12 Cholesterol,total NPSR1 missense 23063622 rs17199853 chr7 34863866 C T 7.57E-04 Alzheimer's disease NPSR1 intron 24755620 rs1419868 chr7 34867557 T C 5.71E-06 Post-operative nausea and vomiting NPSR1 intron 21694509 rs11768189 chr7 34888517 C G 4.90E-04 Alzheimer's disease NPSR1 intron 24755620 rs10252228 chr7 34940039 A G 8.13E-05 Graves' disease / / 21841780 rs12701394 chr7 34944908 T C 5.70E-04 Acute lung injury / / 22295056 rs13234119 chr7 34986082 G A 7.19E-04 Acute lung injury DPY19L1 intron 22295056 rs17792411 chr7 34991080 C A 3.39E-04 Acute lung injury DPY19L1 intron 22295056 rs328928 chr7 35039201 C T 6.58E-05 Serum metabolites DPY19L1 intron 19043545 rs17204148 chr7 35040774 G A 8.72E-04 Acute lung injury DPY19L1 intron 22295056 rs329281 chr7 35083293 T G 2.66E-04 Acute lung injury / / 22295056 rs13222639 chr7 35101119 G T 3.65E-04 Acute lung injury / / 22295056 rs329554 chr7 35104460 T C 5.39E-04 Acute lung injury / / 22295056 rs329548 chr7 35110028 G A 5.81E-04 Acute lung injury / / 22295056 rs13232635 chr7 35113694 C T 5.81E-04 Acute lung injury / / 22295056 rs17205892 chr7 35142669 T C 9.99E-04 Depression (quantitative trait) DPY19L2P1 intron 20800221 rs66493729 chr7 35145941 TG TCA,TTG 9.45E-04 Depression (quantitative trait) DPY19L2P1 intron 20800221 rs6974100 chr7 35145941 T C 9.45E-04 Depression (quantitative trait) DPY19L2P1 intron 20800221 rs6978136 chr7 35152038 T C 8.99E-04 Depression (quantitative trait) DPY19L2P1 intron 20800221 rs11976145 chr7 35281684 G C 4.63E-05 Serum metabolites TBX20 intron 19043545 rs336286 chr7 35299812 T A 2.17E-04 Alzheimer's disease / / 17998437 rs1362212 chr7 35305306 G A 1.00E-13 Ventricular conduction / / 21076409 rs10486661 chr7 35310856 T A 9.34E-06 Bone mass and geometry / / 17903296 rs12538450 chr7 35329471 T G 4.00E-04 Multiple complex diseases / / 17554300 rs10807875 chr7 35366621 G A 4.00E-04 Suicide attempts in bipolar disorder LOC401324 intron 21423239 rs235397 chr7 35372749 C T 7.21E-04 Iron levels LOC401324 intron pha002876 rs340370 chr7 35388122 G A 3.50E-07 Rheumatoid arthritis LOC401324 intron 19503088 rs7800747 chr7 35389499 C T 4.57E-04 Sarcoidosis LOC401324 intron 19165924 rs7805453 chr7 35394424 T C 2.66E-05 Information processing speed LOC401324 intron 21130836 rs2392362 chr7 35401447 T C 2.00E-06 Information processing speed LOC401324 intron 21130836 rs21525 chr7 35402378 G A 6.48E-05 Information processing speed LOC401324 intron 21130836 rs340397 chr7 35412363 T G 3.18E-14 Narcolepsy LOC401324 intron 19629137 rs340406 chr7 35418632 A G 4.35E-06 Lipid traits / / 21777205 rs10236415 chr7 35444548 C A 8.04E-04 Multiple complex diseases / / 17554300 rs13234350 chr7 35446584 T C 1.84E-04 Alcohol consumption / / 23743675 rs13235830 chr7 35450900 G T 8.81E-05 Alcohol consumption / / 23743675 rs10228514 chr7 35463795 T G 0.000441 Height (Pygmy height) / / 22570615 rs1004584 chr7 35470228 C T 1.54E-04 Alcohol consumption / / 23743675 rs6969008 chr7 35533806 T C 6.76E-04 Type 2 diabetes / / 17463246 rs11767474 chr7 35545888 T C 9.96E-08 Metabolite levels / / 23281178 rs10486666 chr7 35547956 T C 6.30E-06 Urinary metabolites / / 21572414 rs4723430 chr7 35548202 G A 8.75E-04 Stroke / / pha002887 rs343064 chr7 35554788 C T 3.00E-08 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs867177 chr7 35561870 T C 8.76E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs343074 chr7 35564651 C T 6.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs343078 chr7 35566542 G T 5.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs343079 chr7 35567865 G A 3.68E-05 Cognitive test performance / / 20125193 rs343079 chr7 35567865 G A 8.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs343079 chr7 35567865 G A 9.78E-05 Coronary heart disease / / pha003031 rs343083 chr7 35571888 T G 5.85E-04 Multiple complex diseases / / 17554300 rs6462611 chr7 35576505 T C 6.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs6954895 chr7 35586206 T C 2.00E-07 Anger / / 24489884 rs889938 chr7 35591136 T C 3.41E-05 Waist Circumference / / pha003023 rs10951449 chr7 35596304 T C 7.90E-05 Lung adenocarcinoma / / 22797724 rs6979400 chr7 35605007 C T 2.46E-05 Waist Circumference / / pha003023 rs6979400 chr7 35605007 C T 9.04E-05 Waist Circumference / / pha003024 rs6979267 chr7 35605025 A G 2.46E-05 Waist Circumference / / pha003023 rs6979267 chr7 35605025 A G 9.04E-05 Waist Circumference / / pha003024 rs6973609 chr7 35607233 G A 9.00E-06 Obesity-related traits / / 23251661 rs1003247 chr7 35610162 T C 6.00E-06 Cognitive function / / 24684796 rs343719 chr7 35627351 A C 4.58E-04 Gallbladder cancer / / 22318345 rs2161868 chr7 35632938 G A 8.82E-04 Type 2 diabetes / / 17463246 rs766761 chr7 35638098 T C 8.76E-04 Multiple complex diseases / / 17554300 rs4640967 chr7 35646526 A C 4.63E-04 Gallbladder cancer / / 22318345 rs10279330 chr7 35646980 C T 4.63E-04 Gallbladder cancer / / 22318345 rs17171589 chr7 35650185 A G 4.95E-04 Multiple complex diseases / / 17554300 rs2242031 chr7 35669693 G A 3.11E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4142249 chr7 35684511 T C 2.75E-05 Brain derived neurotrophic factor levels,in serum HERPUD2 intron 22047184 rs17766832 chr7 35687137 G A 2.79E-05 Brain derived neurotrophic factor levels,in serum HERPUD2 intron 22047184 rs2392376 chr7 35690812 C T 3.30E-05 Insulin-related traits HERPUD2 intron pha003063 rs6945707 chr7 35699350 A T 1.90E-05 Brain derived neurotrophic factor levels,in serum HERPUD2 intron 22047184 rs9718654 chr7 35704901 G A 3.39E-05 Brain derived neurotrophic factor levels,in serum HERPUD2 intron 22047184 rs17766868 chr7 35707528 G A 3.52E-05 Brain derived neurotrophic factor levels,in serum HERPUD2 intron 22047184 rs17699327 chr7 35729576 G A 5.53E-05 Brain derived neurotrophic factor levels,in serum HERPUD2 intron 22047184 rs17699339 chr7 35729818 T C 6.83E-05 Brain derived neurotrophic factor levels,in serum HERPUD2 intron 22047184 rs17679280 chr7 35754758 G C 9.01E-04 Multiple complex diseases / / 17554300 rs17767211 chr7 35803310 C T 1.38E-04 Multiple complex diseases / / 17554300 rs7792246 chr7 35830920 A C 1.21E-04 Asthma / / 23181788 rs2727852 chr7 35886603 A G 3.10E-04 Multiple complex diseases SEPT7 intron 17554300 rs2715596 chr7 35908797 T C 3.06E-04 Multiple complex diseases SEPT7 intron 17554300 rs2727855 chr7 35930815 T G 3.09E-04 Multiple complex diseases SEPT7 intron 17554300 rs17172526 chr7 35984028 G A 4.60E-06 Migraine / / 21666692 rs10252097 chr7 36049833 G T 4.02E-05 Cognitive impairment induced by topiramate / / 22091778 rs6462639 chr7 36053412 G A 9.30E-05 Cognitive test performance / / 20125193 rs1882054 chr7 36073873 T C 5.38E-04 Depression (quantitative trait) / / 20800221 rs2700928 chr7 36075385 C T 3.86E-04 Depression (quantitative trait) / / 20800221 rs10215376 chr7 36077815 C T 2.53E-05 Alcohol and nictotine co-dependence / / 20158304 rs2718020 chr7 36081175 A C 1.42E-04 Depression (quantitative trait) / / 20800221 rs2718019 chr7 36081436 A T 1.19E-04 Depression (quantitative trait) / / 20800221 rs2710803 chr7 36083679 C T 1.15E-04 Depression (quantitative trait) / / 20800221 rs2718016 chr7 36084923 G A 1.07E-04 Depression (quantitative trait) / / 20800221 rs2700942 chr7 36090317 C A 3.15E-04 Depression (quantitative trait) / / 20800221 rs2710807 chr7 36094146 C T 4.42E-04 Depression (quantitative trait) / / 20800221 rs9638917 chr7 36094620 G T 8.51E-05 Brain lesion load / / 19010793 rs1882055 chr7 36095950 A G 4.46E-04 Depression (quantitative trait) / / 20800221 rs1806468 chr7 36103289 C T 7.41E-05 Brain lesion load / / 19010793 rs1882051 chr7 36104266 T A,C 3.55E-10 Alcohol consumption / / pha001402 rs1882053 chr7 36104598 G A 3.74E-04 Multiple complex diseases / / 17554300 rs4292595 chr7 36105035 C T 5.12E-04 Depression (quantitative trait) / / 20800221 rs17263412 chr7 36109747 C T 5.25E-04 Depression (quantitative trait) / / 20800221 rs3735405 chr7 36112365 G A 5.37E-04 Depression (quantitative trait) / / 20800221 rs6962918 chr7 36114716 G A 5.42E-04 Depression (quantitative trait) / / 20800221 rs6968302 chr7 36116073 A G 2.80E-05 Urinary metabolites / / 21572414 rs2254363 chr7 36122030 G A 9.51E-05 Body Mass Index PP13004 intron pha003009 rs2700962 chr7 36134758 T C 4.70E-06 Urinary metabolites / / 21572414 rs12534731 chr7 36134843 T G 7.16E-05 Serum metabolites / / 19043545 rs7783753 chr7 36147815 C T 1.40E-05 Urinary metabolites / / 21572414 rs9655367 chr7 36148979 G A 1.70E-06 Urinary metabolites / / 21572414 rs2893525 chr7 36149973 G A 2.32E-04 Multiple complex diseases / / 17554300 rs2726051 chr7 36155071 C A 8.57E-05 Bipolar disorder / / 18317468 rs2726075 chr7 36157804 C T 3.40E-07 Urinary metabolites / / 21572414 rs9638919 chr7 36159611 C T 8.64E-05 Serum metabolites / / 19043545 rs10951458 chr7 36170199 A G 2.18E-05 Brain structure / / 22504417 rs2700894 chr7 36172787 G A 1.00E-06 Urinary metabolites / / 21572414 rs17264966 chr7 36173508 G T 3.12E-04 Myocardial Infarction / / pha002883 rs2726072 chr7 36174104 C G 4.40E-07 Urinary metabolites / / 21572414 rs2700897 chr7 36177089 T G 5.70E-07 Urinary metabolites / / 21572414 rs2700899 chr7 36178740 G A 5.70E-07 Urinary metabolites / / 21572414 rs2700904 chr7 36186050 T C 9.18E-04 Brain structure / / 22504417 rs11982539 chr7 36191040 G A 3.31E-04 Multiple complex diseases / / 17554300 rs4302748 chr7 36191699 G A 5.00E-06 Platelet counts / / 21507922 rs1882057 chr7 36195991 C G 2.52E-04 Suicide attempts in bipolar disorder EEPD1 intron 21423239 rs12155215 chr7 36196921 A G 7.67E-05 Suicide attempts in bipolar disorder EEPD1 intron 21423239 rs12154572 chr7 36196956 C A 9.89E-05 Suicide attempts in bipolar disorder EEPD1 intron 21423239 rs12154575 chr7 36196971 G T 9.99E-05 Suicide attempts in bipolar disorder EEPD1 intron 21423239 rs6973372 chr7 36199921 A G 8.45E-05 Suicide attempts in bipolar disorder EEPD1 intron 21423239 rs11974488 chr7 36202112 G T 5.27E-04 Suicide attempts in bipolar disorder EEPD1 intron 21423239 rs2700910 chr7 36203997 A T 5.67E-04 Multiple complex diseases EEPD1 intron 17554300 rs4723486 chr7 36206875 C G 7.79E-05 Suicide attempts in bipolar disorder EEPD1 intron 21423239 rs4723487 chr7 36207287 G T 1.08E-04 Response to statin treatment (atorvastatin),change in cholesterol levels EEPD1 intron 20031582 rs4723487 chr7 36207287 G T 1.50E-04 Suicide attempts in bipolar disorder EEPD1 intron 21423239 rs6973373 chr7 36210485 G A 3.32E-05 Chronic obstructive pulmonary disease EEPD1 intron 19300482 rs6973373 chr7 36210485 G A 3.32E-05 Response to statin treatment (atorvastatin),change in cholesterol levels EEPD1 intron 20031582 rs6973373 chr7 36210485 G A 7.40E-04 Suicide attempts in bipolar disorder EEPD1 intron 21423239 rs9648428 chr7 36211749 C T 3.00E-06 Obesity-related traits EEPD1 intron 23251661 rs2726110 chr7 36215273 A C 4.86E-04 Response to cytadine analogues (cytosine arabinoside) EEPD1 intron 24483146 rs13225662 chr7 36216668 A G 8.30E-06 Urinary metabolites EEPD1 intron 21572414 rs16880939 chr7 36219846 C T 2.91E-05 Response to taxane treatment (placlitaxel) EEPD1 intron 23006423 rs4723504 chr7 36287719 T C 7.47E-05 Tardive dyskinesia EEPD1 intron 20939080 rs10262791 chr7 36335759 A G 2.03E-04 White matter integrity EEPD1 intron 22425255 rs11763116 chr7 36341759 C A 4.61E-05 Basophils / / pha003087 rs196639 chr7 36349821 T C 4.53E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs197318 chr7 36382183 T C 4.31E-05 Waist-Hip Ratio KIAA0895 intron pha003029 rs17277310 chr7 36391247 C T 6.11E-06 Hearing function KIAA0895 intron 21493956 rs197328 chr7 36396358 G A 4.83E-05 Blood Pressure KIAA0895 intron pha002903 rs6976779 chr7 36427461 T C 3.48E-05 Blood Pressure KIAA0895 intron pha002903 rs197365 chr7 36440522 A G 9.79E-07 Waist-Hip Ratio ANLN intron pha003029 rs1362269 chr7 36445335 A G 9.03E-05 Eosinophil counts ANLN intron pha003088 rs17213431 chr7 36459076 G A 4.44E-05 Body Mass Index ANLN cds-synon pha003019 rs17213431 chr7 36459076 G A 3.47E-05 Body Mass Index ANLN cds-synon pha003020 rs141247770 chr7 36492159 A G 0.00083 Prostate cancer ANLN missense 23555315 rs11765557 chr7 36514910 G T 5.16E-04 Alzheimer's disease / / 22005930 rs2098273 chr7 36518011 C T 2.93E-04 Alzheimer's disease / / 22005930 rs6954205 chr7 36519651 C T 3.97E-04 Alzheimer's disease / / 22005930 rs7788960 chr7 36544779 C G 5.27E-05 Multiple complex diseases / / 17554300 rs7788960 chr7 36544779 C G 3.40E-06 Urinary metabolites / / 21572414 rs7777593 chr7 36546069 T G 1.00E-06 Obesity-related traits / / 23251661 rs3779222 chr7 36567782 A G 8.69E-04 Type 2 diabetes AOAH intron 17463246 rs6948404 chr7 36610493 T C 3.00E-06 HIV-1 viral setpoint AOAH intron 20205591 rs4723546 chr7 36620678 G C 3.32E-05 Schizophrenia AOAH intron 19571809 rs2001600 chr7 36654081 G C 1.10E-05 Urinary metabolites AOAH intron 21572414 rs2001599 chr7 36654238 T C 1.42E-04 Body mass index AOAH intron 17255346 rs2001599 chr7 36654238 T C 2.40E-05 Urinary metabolites AOAH intron 21572414 rs12537490 chr7 36659892 C T 1.85E-04 Body mass index AOAH intron 17255346 rs200327644 chr7 36662843 A C 0.00000087 Breast cancer(er negative) AOAH missense 23555315 rs4504543 chr7 36682895 T C 2.66E-04 Type 2 diabetes AOAH intron 19184112 rs7804801 chr7 36688836 G T 4.34E-04 Alzheimer's disease (late onset) AOAH intron 21379329 rs11980004 chr7 36689836 G A 8.70E-04 Myocardial infarction AOAH intron 21107343 rs6959295 chr7 36698684 C T 2.98E-05 Cocaine dependence AOAH intron 23958962 rs7808629 chr7 36702492 A G 3.20E-04 Alzheimer's disease (late onset) AOAH intron 21379329 rs7808629 chr7 36702492 A G 8.56E-05 Age-related macular degeneration AOAH intron 22125219 rs7781084 chr7 36722581 T C 5.74E-04 Multiple complex diseases AOAH intron 17554300 rs12534128 chr7 36723665 T C 1.85E-04 Suicide attempts in bipolar disorder AOAH intron 21423239 rs7800651 chr7 36741011 G T 1.91E-04 Lung function (forced vital capacity) AOAH intron 24023788 rs7782947 chr7 36749782 C T 9.80E-05 Response to lithium treatment in bipolar disorder AOAH intron 19448189 rs7782947 chr7 36749782 C T 1.45E-05 Lung function (forced vital capacity) AOAH intron 24023788 rs7782947 chr7 36749782 C T 3.06E-05 Lung function (forced expiratory volume in 1 second) AOAH intron 24023788 rs9784916 chr7 36749919 T G 1.80E-05 Urinary metabolites AOAH intron 21572414 rs4723563 chr7 36757463 C T 3.28E-04 Lung function (forced vital capacity) AOAH intron 24023788 rs17170682 chr7 36762883 T C 4.72E-05 Alzheimer's disease (late onset) AOAH intron 21379329 rs3807609 chr7 36765758 G A 5.22E-05 Hypertension / / pha003042 rs3807609 chr7 36765758 G A 6.76E-05 Blood Pressure / / pha003045 rs3807609 chr7 36765758 G A 6.63E-06 Blood Pressure / / pha003047 rs11764769 chr7 36775458 A G 1.94E-05 Hypertension / / pha003042 rs11764769 chr7 36775458 A G 3.49E-05 Blood Pressure / / pha003045 rs11764769 chr7 36775458 A G 3.76E-06 Blood Pressure / / pha003047 rs17326657 chr7 36775923 A G 1.90E-05 Urinary metabolites / / 21572414 rs6961524 chr7 36776806 C T 3.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs1420323 chr7 36782282 C A 1.70E-05 Urinary metabolites / / 21572414 rs4720217 chr7 36786482 A G 3.47E-05 Glycosylated haemoglobin levels / / 17255346 rs7796377 chr7 36787744 A G 2.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs11972770 chr7 36790264 G A 4.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs2016547 chr7 36790307 C T 8.25E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7811855 chr7 36790907 C T 3.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs972098 chr7 36791393 T C 3.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs4133673 chr7 36791411 C T 6.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs11977641 chr7 36795424 G A,C 1.57E-05 Longevity (90 years and older) / / 24688116 rs565712872 chr7 36795424 G GC 1.57E-05 Longevity (90 years and older) / / 24688116 rs741303 chr7 36802159 C T 4.80E-06 Urinary metabolites / / 21572414 rs7806624 chr7 36824655 C T 9.35E-04 Multiple complex diseases / / 17554300 rs17329669 chr7 36851929 A G 2.30E-05 Parkinson's disease / / 16252231 rs2006882 chr7 36871201 C T 3.45E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4723582 chr7 36876924 C T 4.48E-05 Cytomegalovirus antibody response / / 21993531 rs3807163 chr7 36908759 T C 5.00E-04 Diabetic nephropathy ELMO1 intron 15793258 rs3734948 chr7 36915083 T G 3.95E-05 Multiple complex diseases ELMO1 intron 17554300 rs1558688 chr7 36915185 T C 6.00E-05 Diabetic nephropathy ELMO1 intron 15793258 rs741301 chr7 36917995 C T 8.00E-06 Diabetic nephropathy ELMO1 intron 15793258 rs741301 chr7 36917995 C T 8.00E-06 Type 2 diabetes nephropathy ELMO1 intron 17653210 rs741302 chr7 36918482 G A 6.52E-05 Cytomegalovirus antibody response ELMO1 intron 21993531 rs1861361 chr7 36922433 C T 4.29E-05 Cytomegalovirus antibody response ELMO1 intron 21993531 rs10281169 chr7 36922825 G A 4.30E-05 Cytomegalovirus antibody response ELMO1 intron 21993531 rs10281918 chr7 36923455 G A 4.35E-05 Cytomegalovirus antibody response ELMO1 intron 21993531 rs7799004 chr7 36928964 C T 2.00E-05 Diabetic nephropathy ELMO1 intron 15793258 rs4723593 chr7 36947292 G A 8.00E-04 Diabetic nephropathy ELMO1 intron 15793258 rs11983698 chr7 36948547 T C 2.00E-04 Diabetic nephropathy ELMO1 intron 15793258 rs10488023 chr7 36952021 A G 8.00E-06 Breast size ELMO1 intron 22747683 rs6942726 chr7 36957908 T C 8.37E-07 Height ELMO1 intron 20400458 rs13230047 chr7 36961320 C T 8.00E-06 Anticoagulant levels ELMO1 intron 22216198 rs1986619 chr7 36966916 T C 2.26E-04 Multiple complex diseases ELMO1 intron 17554300 rs17170799 chr7 36979876 T C 4.68E-04 Multiple complex diseases ELMO1 intron 17554300 rs1986858 chr7 36981343 G A 1.20E-05 Urinary metabolites ELMO1 intron 21572414 rs7782153 chr7 36996483 T C 7.92E-04 Bipolar disorder ELMO1 intron 19259986 rs17170826 chr7 37040366 C T 7.04E-04 Multiple complex diseases ELMO1 intron 17554300 rs10488029 chr7 37067395 A G 4.00E-06 IgG glycosylation ELMO1 intron 23382691 rs10488031 chr7 37076854 G A 2.00E-06 QT interval ELMO1 intron 20031603 rs17170851 chr7 37087232 A T 3.87E-31 Narcolepsy ELMO1 intron 19629137 rs7785575 chr7 37097476 T C 8.14E-04 Multiple complex diseases ELMO1 intron 17554300 rs1420422 chr7 37219753 G A 7.66E-04 Multiple complex diseases ELMO1 intron 17554300 rs4723619 chr7 37266352 T C 3.00E-06 Response to treatment for acute lymphoblastic leukemia ELMO1 intron 19176441 rs2080410 chr7 37286864 C T 8.76E-05 Cognitive impairment induced by topiramate ELMO1 intron 22091778 rs6462746 chr7 37293535 A G 1.13E-04 Multiple complex diseases ELMO1 intron 17554300 rs2541082 chr7 37298174 G A 7.89E-04 Multiple complex diseases ELMO1 intron 17554300 rs4723631 chr7 37305527 C T 2.15E-04 Type 2 diabetes ELMO1 intron 17463246 rs4723631 chr7 37305527 C T 4.49E-04 Multiple complex diseases ELMO1 intron 17554300 rs2541089 chr7 37307663 A G 5.58E-04 Type 2 diabetes ELMO1 intron 17463246 rs2717975 chr7 37315192 G A,T 1.77E-04 Type 2 diabetes ELMO1 intron 17463246 rs10238916 chr7 37315850 A G 2.87E-04 Type 2 diabetes ELMO1 intron 17463246 rs10238916 chr7 37315850 A G 1.70E-04 Multiple complex diseases ELMO1 intron 17554300 rs2723952 chr7 37316487 G T 1.52E-04 Type 2 diabetes ELMO1 intron 17463246 rs145751430 chr7 37331467 C G 0.00009242 Sarcoidosis ELMO1 intron 22952805 rs2724006 chr7 37333736 C T 4.77E-04 Type 2 diabetes ELMO1 intron 17463246 rs2724006 chr7 37333736 C T 4.71E-04 Multiple complex diseases ELMO1 intron 17554300 rs2717983 chr7 37333820 A T 5.22E-04 Multiple complex diseases ELMO1 intron 17554300 rs17198538 chr7 37337853 G A 0.00008857 Sarcoidosis ELMO1 intron 22952805 rs145865896 chr7 37338041 A G 0.00008205 Sarcoidosis ELMO1 intron 22952805 rs2723996 chr7 37344369 T C 5.80E-04 Multiple complex diseases ELMO1 intron 17554300 rs2723996 chr7 37344369 T C 7.51E-04 Myocardial Infarction ELMO1 intron pha002883 rs10282266 chr7 37359548 C T 3.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ELMO1 intron 20877124 rs2392492 chr7 37365196 G A 1.00E-06 Alzheimer's disease (cognitive decline) ELMO1 intron 23535033 rs10245068 chr7 37365234 C A 3.92E-05 Melanoma ELMO1 intron 21926416 rs2723980 chr7 37365422 G A 2.07E-04 Multiple complex diseases ELMO1 intron 17554300 rs12667592 chr7 37368161 C A 6.27E-04 Tourette syndrome ELMO1 intron 22889924 rs73112661 chr7 37373179 T C 0.000000169 Primary biliary cirrhosis ELMO1 intron 22961000 rs6974491 chr7 37374510 G A 2.00E-07 Celiac disease ELMO1 intron 20190752 rs6974491 chr7 37374510 G A 3.48E-05 Psoriasis ELMO1 intron 20953190 rs6974491 chr7 37374510 G A 4.00E-08 Primary biliary cirrhosis ELMO1 intron 21399635 rs2717947 chr7 37375317 G A 4.65E-04 Tourette syndrome ELMO1 intron 22889924 rs1962401 chr7 37377172 G C 1.62E-06 Primary biliary cirrhosis ELMO1 intron 21399635 rs2723990 chr7 37378236 T C 3.20E-06 Hematology traits ELMO1 intron 23303382 rs2700992 chr7 37378818 A G 3.70E-06 Hematology traits ELMO1 intron 23303382 rs2723992 chr7 37379575 C T 3.80E-04 Tourette syndrome ELMO1 intron 22889924 rs17259252 chr7 37382520 G A 4.76E-05 Psoriasis ELMO1 intron 20953190 rs17259252 chr7 37382520 G A 2.28E-04 Tourette syndrome ELMO1 intron 22889924 rs2700987 chr7 37386237 C A 4.30E-09 Psoriasis ELMO1 intron 23143594 rs2724014 chr7 37389778 G C 5.21E-04 Multiple complex diseases ELMO1 intron 17554300 rs2700981 chr7 37395768 G C 0.0000717 Primary biliary cirrhosis ELMO1 intron 22936693 rs17259795 chr7 37398273 C T 0.0000119 Primary biliary cirrhosis ELMO1 intron 22936693 rs17259795 chr7 37398273 C T 0.0000155 Primary biliary cirrhosis (anti-mitochondrial antibody positive) ELMO1 intron 22936693 rs17259795 chr7 37398273 C T 0.0000229 Primary biliary cirrhosis in females ELMO1 intron 22936693 rs1882070 chr7 37406352 A G 9.57E-05 AIDS ELMO1 intron 19754311 rs4723645 chr7 37412056 T C 9.76E-04 Alzheimer's disease ELMO1 intron 24755620 rs4723646 chr7 37412146 T C 9.96E-05 AIDS ELMO1 intron 19754311 rs79758729 chr7 37418454 A G 2.10E-08 Celiac disease ELMO1 intron 22057235 rs79758729 chr7 37418454 A G 0.000000021 Celiac disease ELMO1 intron 23143596 rs75351767 chr7 37427351 T C 0.000000294 Rheumatoid arthritis ELMO1 intron 23143596 rs75351767 chr7 37427351 T C 0.0000385 Rheumatoid arthritis (CCP positive) ELMO1 intron 23143596 rs75351767 chr7 37427351 T C 0.0000595 Rheumatoid arthritis (CCP negative) ELMO1 intron 23143596 rs1882075 chr7 37435506 A G 7.87E-06 Lipid levels ELMO1 intron 19016617 rs11984075 chr7 37436854 A G 5.00E-08 Celiac disease and Rheumatoid arthritis ELMO1 intron 21383967 rs11984075 chr7 37436854 A G 1.10E-05 Multiple sclerosis ELMO1 intron 21833088 rs1882077 chr7 37436929 T C 1.18E-04 Tourette syndrome ELMO1 intron 22889924 rs1882078 chr7 37436975 C T 1.92E-05 Tourette syndrome ELMO1 intron 22889924 rs13226064 chr7 37443902 G A 3.00E-05 Prostate cancer ELMO1 intron 21743057 rs1731986 chr7 37451325 T C 1.58E-04 Body mass index ELMO1 intron 17255346 rs1618858 chr7 37454120 T C 2.51E-04 Body mass index ELMO1 intron 17255346 rs17171047 chr7 37480923 G A 9.24E-04 Multiple complex diseases ELMO1 intron 17554300 rs11980720 chr7 37509747 A G 3.60E-07 Urinary metabolites / / 21572414 rs6953628 chr7 37510893 C A 1.88E-05 Multiple complex diseases / / 17554300 rs6462765 chr7 37515609 T A 1.60E-06 Urinary metabolites / / 21572414 rs4142165 chr7 37516065 A T 8.00E-05 Cognitive function / / 24684796 rs3928422 chr7 37528497 A G 5.30E-07 Urinary metabolites / / 21572414 rs6955499 chr7 37529037 A G 7.30E-07 Urinary metabolites / / 21572414 rs11770769 chr7 37552669 G T 9.40E-06 Urinary metabolites / / 21572414 rs10951521 chr7 37552703 A G 8.90E-06 Urinary metabolites / / 21572414 rs10951522 chr7 37552799 G A 8.34E-04 Multiple complex diseases / / 17554300 rs10951522 chr7 37552799 G A 8.28E-04 Alzheimer's disease / / 17998437 rs10951522 chr7 37552799 G A 2.10E-05 Urinary metabolites / / 21572414 rs7791331 chr7 37554798 A G 4.92E-04 Coronary heart disease / / 21606135 rs1967325 chr7 37556637 C T 2.98E-04 Multiple complex diseases / / 17554300 rs1425130 chr7 37558730 C A 3.32E-04 Multiple complex diseases / / 17554300 rs1425131 chr7 37558838 T C,G 1.75E-05 Multiple complex diseases / / 17554300 rs1425132 chr7 37562368 A G 3.70E-04 Multiple complex diseases / / 17554300 rs1425132 chr7 37562368 A G 5.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs724489 chr7 37562888 A G 5.96E-05 Multiple complex diseases / / 17554300 rs1863238 chr7 37590373 G A 2.00E-05 Urinary metabolites / / 21572414 rs11984007 chr7 37590707 G A 4.78E-06 Uric acid levels / / 21294900 rs918975 chr7 37590953 C T 7.49E-06 Uric acid levels / / 21294900 rs1364729 chr7 37618173 T C 1.63E-05 Bipolar disorder and schizophrenia / / 20889312 rs17265593 chr7 37619922 T C 9.60E-06 Urinary metabolites / / 21572414 rs2597279 chr7 37665849 G A 4.30E-06 Urinary metabolites / / 21572414 rs2597279 chr7 37665849 G A 8.90E-05 Diabetic nephropathy / / pha002866 rs2718071 chr7 37687705 A G 4.90E-06 Urinary metabolites / / 21572414 rs7805339 chr7 37704902 G T 3.03E-05 Bipolar disorder and schizophrenia / / 20889312 rs1982389 chr7 37726951 A G 2.30E-04 Alcohol dependence / / 20201924 rs9942609 chr7 37729896 C T 2.19E-04 Blood pressure / / 17255346 rs4723696 chr7 37740070 G A 2.43E-04 Blood pressure / / 17255346 rs4723696 chr7 37740070 G A 5.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2249089 chr7 37741892 T G 0.0000765 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17171141 chr7 37756233 A G 1.33E-04 Obesity (extreme) / / 21935397 rs6951258 chr7 37757556 T C 4.00E-06 Obesity-related traits / / 23251661 rs2718038 chr7 37779244 A T 6.53E-04 Multiple complex diseases / / 17554300 rs2709114 chr7 37790895 A G 9.24E-04 Multiple complex diseases / / 17554300 rs10250481 chr7 37790924 C G 8.81E-06 Serum metabolites / / 19043545 rs4142516 chr7 37811025 G A 1.00E-05 Urinary metabolites / / 21572414 rs2722289 chr7 37820351 A G 1.09E-04 Multiple complex diseases / / 17554300 rs2722292 chr7 37824581 A G 5.10E-05 Diabetic nephropathy / / pha002866 rs2718058 chr7 37841534 A G 5.00E-09 Alzheimer's disease (late onset) / / 24162737 rs4346913 chr7 37858969 T C 3.85E-05 Cognitive test performance / / 20125193 rs3807171 chr7 37908779 T C 4.28E-04 Myopia (pathological) TXNDC3 intron 21095009 rs3807171 chr7 37908779 T C 6.52E-05 Lipoproteins TXNDC3 intron pha003079 rs2722309 chr7 37912535 G T 3.80E-04 Response to alcohol consumption (flushing response) TXNDC3 intron 24277619 rs2598025 chr7 37914736 A C 6.78E-06 Personality dimensions TXNDC3 intron 23658558 rs1975640 chr7 37929568 T G 7.19E-04 Smoking cessation TXNDC3 intron 24665060 rs10226308 chr7 37938422 A G 6.00E-13 Bone mineral density TXNDC3 intron 22504420 rs2722325 chr7 37948289 G A 8.18E-04 Multiple complex diseases SFRP4 intron 17554300 rs2598107 chr7 37973014 C T 5.35E-04 Parkinson's disease EPDR1 intron 17052657 rs2598098 chr7 37980452 T A 8.16E-05 Coronary heart disease EPDR1 intron 21606135 rs16879765 chr7 37989095 C T 6.00E-39 Dupuytren's disease EPDR1 intron 21732829 rs2722278 chr7 37990917 A G 6.42E-04 Multiple complex diseases EPDR1 UTR-3 17554300 rs2722280 chr7 37991802 C T 4.27E-04 Type 2 diabetes / / 17463246 rs1717740 chr7 38003850 C T 4.40E-06 Urinary metabolites / / 21572414 rs1668357 chr7 38004406 G C,T 4.00E-08 Myopia (pathological) / / 23049088 rs1717742 chr7 38005001 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2722298 chr7 38008643 G A,C,T 1.00E-04 Information processing speed / / 21130836 rs952368 chr7 38046212 C T 1.08E-05 Nephrolithiasis / / 22396660 rs10227912 chr7 38051586 C T 5.70E-05 Triglycerides / / 19074352 rs1464717 chr7 38052205 G T 9.18E-05 Post-operative nausea and vomiting / / 21694509 rs7784959 chr7 38060543 A C 3.70E-06 Triglycerides / / 19074352 rs6462802 chr7 38064636 C T 2.70E-05 Post-operative nausea and vomiting / / 21694509 rs1524072 chr7 38067723 G A 6.70E-04 Myocardial Infarction / / pha002873 rs1357655 chr7 38075944 G C 7.03E-04 Multiple complex diseases / / 17554300 rs2392528 chr7 38094585 G A 6.41E-04 Acute lung injury / / 22295056 rs1357651 chr7 38097862 T G 8.00E-09 Bone mineral density (spine) / / 19801982 rs1721383 chr7 38103339 T G 5.25E-04 Multiple complex diseases / / 17554300 rs1464713 chr7 38108997 T G 4.53E-04 Multiple complex diseases / / 17554300 rs1403988 chr7 38109936 A G 9.80E-09 Bone mineral density (spine) / / 19801982 rs6974574 chr7 38110073 A T 3.89E-05 Bone properties (heel) / / 24430505 rs6974574 chr7 38110073 A T 8.25E-05 Bone properties (heel) / / 24430505 rs940347 chr7 38110425 A G 9.60E-09 Bone mineral density (spine) / / 19801982 rs1524068 chr7 38110626 T C 8.00E-09 Bone mineral density (spine) / / 19801982 rs1403987 chr7 38111941 A G 8.00E-09 Bone mineral density (spine) / / 19801982 rs10235021 chr7 38123667 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1464712 chr7 38125584 A G 7.20E-09 Bone mineral density (spine) / / 19801982 rs6959212 chr7 38128326 T C 1.60E-09 Bone mineral density (spine) / / 19801982 rs6959212 chr7 38128326 T C 2.00E-09 Height / / 20881960 rs6959212 chr7 38128326 T C 4.00E-38 Bone mineral density / / 22504420 rs6959212 chr7 38128326 T C 0.00011 Lumbar spine bone mineral density (premenopausal) / / 23074152 rs1524058 chr7 38136277 T C 1.00E-09 Bone mineral density (spine) / / 19801982 rs1524064 chr7 38141380 T A 1.30E-08 Bone mineral density (spine) / / 19801982 rs6963134 chr7 38144898 A G 1.80E-08 Bone mineral density (spine) / / 19801982 rs11972702 chr7 38147661 C T 2.80E-08 Bone mineral density (spine) / / 19801982 rs4576333 chr7 38153390 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2893552 chr7 38155563 A G 8.56E-04 Multiple complex diseases / / 17554300 rs17171299 chr7 38162780 T C 2.48E-06 Multiple complex diseases / / 17554300 rs9918503 chr7 38167124 T A 1.55E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6969314 chr7 38176373 G A 9.53E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs6462812 chr7 38178207 C T 2.21E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1019179 chr7 38218976 A G 0.0000564 HDL cholesterol STARD3NL intron 23063622 rs4723738 chr7 38240908 A G 6.00E-06 Treatment response for severe sepsis STARD3NL intron 22310353 rs3778893 chr7 38254140 C T 7.50E-06 Plasminogen activator inhibitor-1 (PAI1) levels,in plasma STARD3NL intron 20558613 rs756392 chr7 38262723 C T 3.80E-04 Atrial fibrillation STARD3NL intron 21846873 rs6978770 chr7 38271544 A G 1.30E-05 Personality dimensions / / 18957941 rs10262830 chr7 38311098 G A 6.20E-07 Urinary metabolites TARP intron 21572414 rs7782269 chr7 38318590 A G 7.25E-22 Neuroblastoma / / 19536264 rs2240826 chr7 38319339 A G 7.25E-22 Neuroblastoma / / 19536264 rs2240827 chr7 38319436 G A 7.25E-22 Neuroblastoma / / 19536264 rs1546833 chr7 38323690 C T 7.25E-22 Neuroblastoma / / 19536264 rs10155916 chr7 38325778 G A 8.61E-23 Neuroblastoma / / 19536264 rs10155916 chr7 38325778 G A 6.80E-07 Urinary metabolites / / 21572414 rs1860516 chr7 38325977 G A 8.61E-23 Neuroblastoma / / 19536264 rs2240832 chr7 38329013 T C 3.00E-23 Neuroblastoma / / 19536264 rs12154478 chr7 38329818 G A 9.76E-23 Neuroblastoma / / 19536264 rs1860517 chr7 38330810 A G 7.29E-23 Neuroblastoma / / 19536264 rs1860520 chr7 38331271 C A 7.29E-23 Neuroblastoma / / 19536264 rs1860521 chr7 38331504 C T 7.29E-23 Neuroblastoma / / 19536264 rs6462829 chr7 38332217 C T 2.22E-23 Neuroblastoma / / 19536264 rs10441090 chr7 38334818 C T 4.04E-23 Neuroblastoma / / 19536264 rs2191311 chr7 38335520 T G 2.19E-04 Multiple complex diseases / / 17554300 rs2191311 chr7 38335520 T G 1.29E-22 Neuroblastoma / / 19536264 rs2248839 chr7 38341226 C T 7.13E-22 Neuroblastoma / / 19536264 rs2248839 chr7 38341226 C T 9.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs2736973 chr7 38341615 A C 3.66E-22 Neuroblastoma / / 19536264 rs2736973 chr7 38341615 A C 9.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs2240839 chr7 38341925 A G 7.90E-19 Neuroblastoma / / 19536264 rs2392545 chr7 38342997 G A 1.28E-18 Neuroblastoma / / 19536264 rs2392546 chr7 38343085 G A 9.81E-17 Neuroblastoma / / 19536264 rs2056867 chr7 38343396 G C 6.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs2736970 chr7 38343670 T C 5.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs2736969 chr7 38343956 A C 3.13E-21 Neuroblastoma / / 19536264 rs2736964 chr7 38344769 T C 2.27E-21 Neuroblastoma / / 19536264 rs12533564 chr7 38348812 A G 1.56E-04 Alzheimer's disease / / 17998437 rs6953248 chr7 38356415 A C 6.76E-23 Neuroblastoma / / 19536264 rs17171329 chr7 38356545 C T 3.95E-23 Neuroblastoma / / 19536264 rs11769443 chr7 38357075 T C 2.96E-22 Neuroblastoma / / 19536264 rs11980080 chr7 38357194 T C 2.96E-22 Neuroblastoma / / 19536264 rs11765884 chr7 38357323 C T 7.43E-23 Neuroblastoma / / 19536264 rs2534565 chr7 38358227 C T 6.84E-36 Neuroblastoma / / 19536264 rs2240845 chr7 38358412 T C 3.45E-36 Neuroblastoma / / 19536264 rs3815397 chr7 38358728 C G 2.33E-04 Alzheimer's disease / / 17998437 rs2534567 chr7 38358956 C A 5.31E-35 Neuroblastoma / / 19536264 rs2534568 chr7 38359640 G A 1.05E-34 Neuroblastoma / / 19536264 rs2240848 chr7 38361467 A G 1.27E-34 Neuroblastoma / / 19536264 rs11975431 chr7 38361625 C T 8.43E-36 Neuroblastoma / / 19536264 rs718880 chr7 38361999 G A 2.20E-37 Neuroblastoma / / 19536264 rs2240849 chr7 38362072 A G 1.09E-36 Neuroblastoma / / 19536264 rs887458 chr7 38362461 C G 2.90E-05 Parkinson's disease (age of onset) / / 19772629 rs17171331 chr7 38362957 T C 1.25E-34 Neuroblastoma / / 19536264 rs11984094 chr7 38363566 A G 5.62E-32 Neuroblastoma / / 19536264 rs2240850 chr7 38363748 C A 6.73E-29 Neuroblastoma / / 19536264 rs2240851 chr7 38363929 A G 2.50E-28 Neuroblastoma / / 19536264 rs17496969 chr7 38364289 T C 2.34E-28 Neuroblastoma / / 19536264 rs2735179 chr7 38364605 T C 6.01E-30 Neuroblastoma / / 19536264 rs10487742 chr7 38366512 G A 7.01E-32 Neuroblastoma / / 19536264 rs2191312 chr7 38367259 C T 1.30E-29 Neuroblastoma / / 19536264 rs6966279 chr7 38369548 A C 6.11E-30 Neuroblastoma / / 19536264 rs2534575 chr7 38371474 T C 3.49E-27 Neuroblastoma / / 19536264 rs2534578 chr7 38373531 T C 2.28E-22 Neuroblastoma / / 19536264 rs2240853 chr7 38374697 G A 2.12E-20 Neuroblastoma / / 19536264 rs733905 chr7 38380446 T C 1.90E-17 Neuroblastoma / / 19536264 rs4373430 chr7 38412988 T C 8.92E-05 Non-alcoholic fatty liver disease histology (other) LOC100506776 intron 20708005 rs2072505 chr7 38424039 A G 3.39E-05 Alzheimer's disease (late onset) AMPH UTR-3 21379329 rs13231472 chr7 38424772 C T 7.90E-06 Urinary metabolites AMPH intron 21572414 rs1058655 chr7 38431481 C A 1.98E-04 Alzheimer's disease (late onset) AMPH cds-synon 21379329 rs12701628 chr7 38458789 A G 1.76E-04 Type 2 diabetes AMPH intron 17463246 rs13240983 chr7 38462153 C T 2.48E-04 Type 2 diabetes AMPH intron 17463246 rs973527 chr7 38474750 T C 1.90E-05 Urinary metabolites AMPH intron 21572414 rs973527 chr7 38474750 T C 2.14E-04 Disc degeneration (lumbar) AMPH intron 24216480 rs1019290 chr7 38506889 C G 3.26E-04 Hearing function AMPH intron 17255346 rs17415592 chr7 38507180 G A 7.82E-04 Coronary heart disease AMPH intron 21971053 rs11767573 chr7 38517331 A C 1.70E-05 Urinary metabolites AMPH intron 21572414 rs17171385 chr7 38532286 G C 5.20E-07 Urinary metabolites AMPH intron 21572414 rs7788738 chr7 38550138 G T 6.67E-04 Alzheimer's disease AMPH intron 22005930 rs3807404 chr7 38552626 A G 1.40E-05 Urinary metabolites AMPH intron 21572414 rs12536311 chr7 38565181 C T 6.31E-04 Response to cytidine analogues (gemcitabine) AMPH intron 24483146 rs3807398 chr7 38569711 C T 9.19E-04 Aortic root size AMPH intron 21223598 rs3807390 chr7 38573431 T C 7.82E-07 Esophageal cancer (squamous cell) AMPH intron 22960999 rs893412 chr7 38586223 C A 6.44E-05 Blood Pressure AMPH intron pha002903 rs10499602 chr7 38586972 G A,C,T 1.30E-05 Urinary metabolites AMPH intron 21572414 rs2392583 chr7 38598017 C G 8.86E-05 Bipolar disorder AMPH intron 19488044 rs6967370 chr7 38600176 A G 2.33E-05 Bipolar disorder AMPH intron 19488044 rs6967370 chr7 38600176 A G 5.10E-05 Bipolar Disorder AMPH intron pha002863 rs6965295 chr7 38622699 C T 3.09E-04 Type 2 diabetes AMPH intron 17463246 rs1030654 chr7 38623588 C T 2.71E-05 Job-related exhaustion AMPH intron 23620144 rs10499608 chr7 38629455 C A 2.71E-05 Job-related exhaustion AMPH intron 23620144 rs12536957 chr7 38636528 C G 9.11E-04 Response to taxane treatment (placlitaxel) AMPH intron 23006423 rs17499304 chr7 38638343 G C 3.10E-04 Follicle stimulating hormone AMPH intron 24049095 rs13225949 chr7 38641095 G A 1.00E-04 AIDS progression AMPH intron 19115949 rs10278233 chr7 38641903 T C 3.06E-04 Multiple complex diseases AMPH intron 17554300 rs10271846 chr7 38644504 G A 7.42E-05 Obesity (early onset extreme) AMPH intron 23563609 rs17500182 chr7 38655758 C A 9.01E-04 Multiple complex diseases AMPH intron 17554300 rs7806370 chr7 38687824 T C 4.69E-05 Basophils / / pha003087 rs11768984 chr7 38698314 T C 1.91E-06 White blood cell count / / 21738479 rs10279772 chr7 38706384 G A 3.97E-05 Fibrinogen / / 17255346 rs12701650 chr7 38709101 A C 6.36E-05 Monocyte chemoattractant protein-1 / / pha003071 rs6976166 chr7 38721192 T C 4.42E-05 Cognitive impairment induced by topiramate / / 22091778 rs2116666 chr7 38721690 G A 8.29E-05 Cognitive impairment induced by topiramate / / 22091778 rs13242754 chr7 38721867 G A 9.97E-05 Body Mass Index / / pha003019 rs10227687 chr7 38741626 G A 3.45E-04 Coronary Artery Disease / / 17634449 rs1059508 chr7 38765883 C T 5.38E-04 Insulin resistance VPS41 missense 21901158 rs2286080 chr7 38818131 G C 3.39E-04 Type 2 diabetes VPS41 intron 17463246 rs10486680 chr7 38823574 A G 7.28E-06 Cognitive performance VPS41 intron 19734545 rs11984145 chr7 38835035 C T 6.00E-06 Cognitive performance VPS41 intron 19734545 rs6462868 chr7 38853944 G A 2.56E-04 Type 2 diabetes VPS41 intron 17463246 rs2215032 chr7 38865194 C T 1.80E-05 Urinary metabolites VPS41 intron 21572414 rs10085487 chr7 38870380 T C 2.20E-05 Urinary metabolites VPS41 intron 21572414 rs10085898 chr7 38870444 C T 3.51E-04 Type 2 diabetes VPS41 intron 17463246 rs7803397 chr7 38905686 T C 2.02E-05 Formal thought disorder in schizophrenia VPS41 intron 22648509 rs10279181 chr7 38910230 C T 6.31E-06 White blood cell count VPS41 intron 21738479 rs3801119 chr7 38913831 A G 6.03E-06 White blood cell count VPS41 intron 21738479 rs7782140 chr7 38937978 A G 2.60E-05 Urinary metabolites VPS41 intron 21572414 rs7782277 chr7 38938054 A G 2.50E-05 Urinary metabolites VPS41 intron 21572414 rs3801113 chr7 38943116 G C 3.09E-06 White blood cell count VPS41 intron 21738479 rs4723807 chr7 38954251 A G 6.40E-04 Intelligence (childhood) / / 23358156 rs6973977 chr7 38955367 A G 6.04E-05 Socioeconomic Factors / / pha003066 rs6974798 chr7 38955773 C T 3.47E-06 White blood cell count / / 21738479 rs10255854 chr7 38959842 C T 6.67E-04 Common variable immunodeficiency / / 21497890 rs6978093 chr7 38961388 C T 6.88E-05 Socioeconomic Factors / / pha003066 rs4723810 chr7 38962722 C G 8.86E-04 Depression (quantitative trait) / / 20800221 rs17240051 chr7 38965611 G A 1.38E-05 Socioeconomic Factors / / pha003066 rs859522 chr7 38970166 C T 3.41E-05 Parkinson's disease / / pha002868 rs859522 chr7 38970166 C T 2.91E-05 Tunica Media / / pha003038 rs17171484 chr7 38970305 C T 6.83E-04 Type 2 diabetes / / 17463246 rs1229052 chr7 39000551 C T 6.40E-04 Alzheimer's disease / / 22005930 rs17255994 chr7 39060267 T C 5.82E-05 Triglycerides POU6F2 intron pha003080 rs1405987 chr7 39081494 A G 7.51E-05 Socioeconomic Factors POU6F2 intron pha003067 rs11765705 chr7 39106942 G T 5.70E-05 HIV-1 control POU6F2 intron 20041166 rs11769233 chr7 39117624 T A 0.0000503 Panic disorder POU6F2 intron 23149450 rs11769233 chr7 39117624 T A 5.03E-05 Serum tamsulosin hydrochloride concentration POU6F2 intron 23151678 rs10464366 chr7 39121500 A T 3.00E-06 IgG glycosylation POU6F2 intron 23382691 rs17171533 chr7 39129656 A C 7.21E-04 Multiple complex diseases POU6F2 intron 17554300 rs1525791 chr7 39156558 C T 1.25E-11 Multiple complex diseases POU6F2 intron 17554300 rs10234489 chr7 39165537 T C 1.10E-04 Type 2 diabetes and 6 quantitative traits POU6F2 intron 17848626 rs10273694 chr7 39194416 G A 6.04E-04 Multiple complex diseases POU6F2 intron 17554300 rs28459466 chr7 39195671 T C 8.87E-04 Type 2 diabetes POU6F2 intron 17463246 rs10242528 chr7 39197354 T G 7.94E-04 Multiple complex diseases POU6F2 intron 17554300 rs41437948 chr7 39198864 T G 9.77E-04 Alcohol dependence POU6F2 intron 21314694 rs17511572 chr7 39205663 A G 6.35E-04 Multiple complex diseases POU6F2 intron 17554300 rs10252129 chr7 39220732 T C 8.13E-04 Multiple complex diseases POU6F2 intron 17554300 rs9986786 chr7 39237586 T C 5.50E-05 Socioeconomic Factors POU6F2 intron pha003067 rs7802746 chr7 39239783 T C 9.29E-04 Type 2 diabetes POU6F2 intron 17463246 rs7787466 chr7 39239975 A G 9.29E-04 Type 2 diabetes POU6F2 intron 17463246 rs3924710 chr7 39241348 C T 7.86E-04 Type 2 diabetes POU6F2 intron 17463246 rs6954406 chr7 39277116 G C 4.67E-04 Insulin resistance POU6F2 intron 21901158 rs9655034 chr7 39292111 G T 8.80E-05 Parkinson's disease POU6F2 intron pha002865 rs9655034 chr7 39292111 G T 5.30E-05 Blood Pressure POU6F2 intron pha003039 rs10242061 chr7 39294042 A G 5.44E-05 Blood Pressure POU6F2 intron pha003039 rs6967316 chr7 39297668 C A 7.99E-05 Blood Pressure POU6F2 intron pha003045 rs4302750 chr7 39304125 A G 9.89E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) POU6F2 intron 23648065 rs13246263 chr7 39324470 C A 2.50E-04 Sudden cardiac arrest POU6F2 intron 21658281 rs13246263 chr7 39324470 C A 8.60E-05 Amyotrophic lateral sclerosis (sporadic) POU6F2 intron 24529757 rs6968121 chr7 39348637 C T 3.77E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) POU6F2 intron 24023788 rs6946515 chr7 39402851 T C 1.89E-04 Attention deficit hyperactivity disorder POU6F2 intron 22420046 rs10227915 chr7 39431588 A G 7.93E-04 Smoking quantity POU6F2 intron 24665060 rs7789243 chr7 39440893 A G 9.34E-04 Obesity (extreme) POU6F2 intron 21935397 rs3819426 chr7 39462495 G A 2.58E-04 Coronary Artery Disease POU6F2 intron 17634449 rs4723865 chr7 39503405 T C 8.62E-05 Information processing speed POU6F2 intron 21130836 rs2052017 chr7 39505737 G A 1.00E-04 Information processing speed / / 21130836 rs17769981 chr7 39511103 C G 1.56E-04 Multiple complex diseases / / 17554300 rs17769987 chr7 39513391 C G 4.42E-05 Multiple complex diseases / / 17554300 rs17620176 chr7 39531988 T C 1.17E-04 Attention deficit hyperactivity disorder / / 22420046 rs6971762 chr7 39544838 A G 1.20E-05 Urinary metabolites / / 21572414 rs6946031 chr7 39548121 T C 6.04E-04 Acute lung injury / / 22295056 rs6963017 chr7 39560862 A G 2.00E-04 Personality dimensions / / 23903073 rs7777434 chr7 39606074 G T 1.75E-05 Response to methylphenidate treatment YAE1D1 cds-synon 21130132 rs6947660 chr7 39610177 A G 9.20E-04 Multiple complex diseases YAE1D1 missense 17554300 rs2971 chr7 39610241 C G 2.70E-04 Multiple complex diseases YAE1D1 intron 17554300 rs2876859 chr7 39637227 A T 1.11E-04 Multiple complex diseases / / 17554300 rs10486799 chr7 39653226 T A,C,G 3.28E-04 Stroke / / pha002887 rs13311977 chr7 39713821 G T 1.83E-05 Calcium levels RALA intron pha003085 rs1034771 chr7 39720743 T C 4.59E-05 Body Mass Index RALA intron pha003014 rs10486802 chr7 39723768 G A 2.80E-05 Urinary metabolites RALA intron 21572414 rs10486804 chr7 39747905 G A 1.37E-15 Gallbladder disease / / pha001404 rs7796021 chr7 39761315 G C 2.44E-04 Multiple complex diseases / / 17554300 rs6462951 chr7 39852729 C T 4.33E-04 Fibrinogen / / 17255346 rs4720342 chr7 39854141 G A 9.08E-05 Information processing speed / / 21130836 rs12701773 chr7 39930518 G A 4.68E-04 Type 2 diabetes / / 17463246 rs12701775 chr7 39930699 A G 5.23E-04 Type 2 diabetes / / 17463246 rs10240222 chr7 39962864 T C 8.81E-04 Acute lung injury / / 22295056 rs10240222 chr7 39962864 T C 1.47E-05 Magnesium levels / / pha003092 rs1002749 chr7 39963888 G A 1.25E-04 Multiple complex diseases / / 17554300 rs6947071 chr7 39971649 A G 7.79E-05 Taste perception / / 22132133 rs9655407 chr7 39991673 G A 4.79E-05 Taste perception CDK13 intron 22132133 rs10225492 chr7 40058992 T C 4.79E-05 Taste perception CDK13 intron 22132133 rs17526699 chr7 40060180 T C 4.79E-05 Taste perception CDK13 intron 22132133 rs6971502 chr7 40067021 T C 5.29E-04 Amyotrophic Lateral Sclerosis CDK13 intron 17827064 rs699513 chr7 40077032 A G 1.11E-04 Response to cytadine analogues (cytosine arabinoside) CDK13 intron 24483146 rs798854 chr7 40090368 A G 4.79E-04 Response to cytadine analogues (cytosine arabinoside) CDK13 intron 24483146 rs1146042 chr7 40124137 G A 7.16E-04 Response to cytadine analogues (cytosine arabinoside) CDK13 intron 24483146 rs17171658 chr7 40158527 G T 9.66E-04 Multiple complex diseases / / 17554300 rs7790068 chr7 40161679 G A 1.93E-04 Multiple complex diseases / / 17554300 rs11760739 chr7 40193535 G A 7.91E-05 Taste perception C7orf10 intron 22132133 rs10269349 chr7 40242537 A G 6.53E-04 Taste perception C7orf10 intron 22132133 rs11768838 chr7 40247794 C T 7.22E-05 Taste perception C7orf10 intron 22132133 rs6951375 chr7 40248683 A G 7.91E-05 Taste perception C7orf10 intron 22132133 rs10262201 chr7 40288384 C T 1.20E-05 Urinary metabolites C7orf10 intron 21572414 rs10234315 chr7 40311382 C T 8.93E-05 Post-operative nausea and vomiting C7orf10 intron 21694509 rs10246797 chr7 40344361 C A 8.70E-08 Fasting plasma glucose C7orf10 intron 19060907 rs11761602 chr7 40391181 T C 3.85E-05 Amyotrophic Lateral Sclerosis C7orf10 intron 17827064 rs6462976 chr7 40396300 T C 9.78E-04 Insulin resistance C7orf10 intron 21901158 rs17171696 chr7 40399193 A G 6.28E-05 Coronary heart disease C7orf10 intron pha003031 rs17171705 chr7 40427000 G A 8.95E-05 Coronary heart disease C7orf10 intron pha003031 rs4379368 chr7 40466200 C T 1.00E-09 Migraine C7orf10 intron 23793025 rs4379368 chr7 40466200 C T 6.00E-08 Migraine without aura C7orf10 intron 23793025 rs4379368 chr7 40466200 C T 7.00E-07 Migraine - clinic-based C7orf10 intron 23793025 rs7809620 chr7 40489083 C T 2.90E-06 Urinary metabolites C7orf10 intron 21572414 rs17171713 chr7 40497278 G A 4.32E-04 Multiple complex diseases C7orf10 intron 17554300 rs17171713 chr7 40497278 G A 1.80E-07 Urinary metabolites C7orf10 intron 21572414 rs4320458 chr7 40525965 A G 4.70E-04 Coronary heart disease C7orf10 intron 21966275 rs2051919 chr7 40549589 A G 7.89E-04 Acute lung injury C7orf10 intron 22295056 rs7776976 chr7 40572879 G C 1.42E-04 Acute lung injury C7orf10 intron 22295056 rs17171730 chr7 40591747 G C 1.22E-04 Acute lung injury C7orf10 intron 22295056 rs6948900 chr7 40618995 A G 1.23E-04 Acute lung injury C7orf10 intron 22295056 rs11973006 chr7 40638365 T G 5.64E-05 Acute lung injury C7orf10 intron 22295056 rs6956277 chr7 40645261 A G 6.36E-05 Acute lung injury C7orf10 intron 22295056 rs17171747 chr7 40648210 T A 6.36E-05 Acute lung injury C7orf10 intron 22295056 rs10486811 chr7 40650855 G A 6.51E-05 Acute lung injury C7orf10 intron 22295056 rs6948724 chr7 40656275 A G 6.38E-05 Acute lung injury C7orf10 intron 22295056 rs6964059 chr7 40664412 G A 8.23E-05 Acute lung injury C7orf10 intron 22295056 rs11977013 chr7 40672689 T C 4.66E-05 Acute lung injury C7orf10 intron 22295056 rs17527624 chr7 40685202 C T 1.33E-04 Pancreatic cancer C7orf10 intron pha002874 rs6965055 chr7 40727223 T G 2.66E-05 Chronic Hepatitis C infection C7orf10 intron 21725309 rs10486813 chr7 40728610 G T 3.22E-05 Chronic Hepatitis C infection C7orf10 intron 21725309 rs6462987 chr7 40733756 C T 2.73E-05 Chronic Hepatitis C infection C7orf10 intron 21725309 rs1203733 chr7 40758141 T G 8.01E-04 Aortic root size C7orf10 intron 21223598 rs1203734 chr7 40758200 T G 2.60E-04 Aortic root size C7orf10 intron 21223598 rs6970230 chr7 40790382 A G 2.50E-04 Type 2 diabetes C7orf10 intron 23209189 rs1115715 chr7 40827962 A C 5.70E-06 Urinary metabolites C7orf10 intron 21572414 rs10243080 chr7 40839647 C T 2.30E-05 Urinary metabolites C7orf10 intron 21572414 rs10268219 chr7 40845802 C T 1.24E-05 Serum metabolites C7orf10 intron 19043545 rs886831 chr7 40848403 G C 8.76E-05 Serum metabolites C7orf10 intron 19043545 rs886831 chr7 40848403 G C 1.80E-05 Urinary metabolites C7orf10 intron 21572414 rs10252053 chr7 40857121 T C 1.70E-05 Urinary metabolites C7orf10 intron 21572414 rs1203571 chr7 40862445 A G 3.34E-08 Triglycerides C7orf10 intron 23063622 rs17688601 chr7 40866663 C A 3.62E-05 Pancreatic cancer C7orf10 intron pha002889 rs7801303 chr7 40918070 A G 4.00E-07 Parent of origin effect on language impairment (paternal) / / 24571439 rs10241209 chr7 40939081 G T 1.52E-04 Smoking cessation / / 24665060 rs6957585 chr7 40949872 T G 3.48E-04 Multiple complex diseases / / 17554300 rs29880 chr7 40954481 A G 7.00E-06 Iron status biomarkers / / 19084217 rs29881 chr7 40955755 A G 0.0000873 Salmonella-induced pyroptosis / / 22837397 rs7789197 chr7 40965127 G A 3.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs2190347 chr7 40987875 T C 5.10E-04 Multiple complex diseases / / 17554300 rs9648071 chr7 41004609 G A 0.000789 Salmonella-induced pyroptosis / / 22837397 rs6947654 chr7 41005940 A G 7.98E-04 Alzheimer's disease / / 22005930 rs6974676 chr7 41007730 T C 0.000825 Salmonella-induced pyroptosis / / 22837397 rs6954727 chr7 41007872 A C 2.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6947406 chr7 41046625 A G 2.34E-05 Menarche (age at onset) / / 23599027 rs10486704 chr7 41055230 G A 5.39E-04 Multiple complex diseases / / 17554300 rs17622696 chr7 41076615 C T 1.40E-05 Urinary metabolites / / 21572414 rs4724019 chr7 41083785 A G 1.78E-04 Cholesterol / / 17255346 rs6463000 chr7 41086556 C T 1.78E-04 Cholesterol / / 17255346 rs6947651 chr7 41099761 A C 6.48E-04 Multiple complex diseases / / 17554300 rs17171809 chr7 41100235 G A 9.16E-04 Multiple complex diseases / / 17554300 rs12701862 chr7 41123452 G A 8.76E-07 Autism / / 22843504 rs28880 chr7 41185851 A G 8.24E-05 Rheumatoid arthritis / / 17804836 rs2158560 chr7 41252194 T C 2.10E-05 Heart Failure / / pha002884 rs12019358 chr7 41275504 C T 5.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs11765463 chr7 41295903 G A 1.30E-05 Anorexia nervosa / / 21079607 rs11505535 chr7 41300832 G A 6.37E-05 Pancreatic cancer / / pha002874 rs10486710 chr7 41315586 A T 6.04E-04 Schizophrenia / / 21674006 rs7809878 chr7 41416071 A G 6.55E-04 HIV-1 viral setpoint / / 17641165 rs7810308 chr7 41416234 C T 6.55E-04 HIV-1 viral setpoint / / 17641165 rs273185 chr7 41430806 A G 6.33E-04 Cognition,early reading ability / / 17684495 rs1871938 chr7 41445478 C T 5.23E-04 Type 2 diabetes / / 17463246 rs4141153 chr7 41467946 A G 6.05E-04 Longevity / / 22279548 rs273207 chr7 41468649 A G 3.27E-05 Body Fat Distribution / / pha003016 rs273207 chr7 41468649 A G 2.98E-05 Body Fat Distribution / / pha003018 rs1079866 chr7 41470093 C G 6.00E-14 Menarche (age at onset) / / 21102462 rs273108 chr7 41476360 G A 4.40E-05 Body Fat Distribution / / pha003016 rs273108 chr7 41476360 G A 8.71E-05 Body Fat Distribution / / pha003018 rs10486715 chr7 41478608 G A 3.00E-06 Quantitative traits / / 19197348 rs273120 chr7 41481970 T C 5.25E-06 White blood cell count / / 21738479 rs1482556 chr7 41516733 C T 2.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs501002 chr7 41524616 G T 1.32E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs531088 chr7 41525592 A G 1.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs510486 chr7 41529681 A G 5.75E-04 Alzheimer's disease / / 17998437 rs1384383 chr7 41564993 C T 9.00E-05 Personality dimensions / / 18957941 rs566619 chr7 41608298 G A 3.08E-04 Multiple complex diseases / / 17554300 rs4724055 chr7 41622530 G T 6.70E-05 Illicit drug use / / 23942779 rs4724055 chr7 41622530 G T 8.00E-06 Non-substance related behavioral disinhibition / / 23942779 rs6951157 chr7 41675159 T C 4.68E-05 Alzheimer's disease (late onset) / / 21379329 rs2877098 chr7 41743294 T C 2.00E-06 Migraine without aura LOC285954 intron 23793025 rs1003291 chr7 41750087 G A 5.73E-05 Alzheimer's disease (late onset) LOC285954 intron 21379329 rs17776182 chr7 41757878 G A 7.60E-04 Acute lung injury LOC285954 intron 22295056 rs10251907 chr7 41762106 G T 5.73E-05 Alzheimer's disease (late onset) LOC285954 intron 21379329 rs720816 chr7 41775748 G A 6.13E-04 Smoking initiation LOC285954 intron 24665060 rs4720404 chr7 41776699 G A 6.87E-04 Smoking initiation LOC285954 intron 24665060 rs10951655 chr7 41776877 G T 6.72E-04 Smoking initiation LOC285954 intron 24665060 rs12537065 chr7 41781911 A G 4.98E-04 Smoking initiation LOC285954 intron 24665060 rs4724070 chr7 41783359 T C 1.44E-04 Alzheimer's disease (late onset) LOC285954 intron 21379329 rs13238259 chr7 41802753 G C 7.61E-04 Smoking initiation LOC285954 intron 24665060 rs6975680 chr7 41803450 T C 3.16E-04 Smoking initiation LOC285954 intron 24665060 rs10951660 chr7 41810335 A G 6.94E-04 Smoking initiation LOC285954 intron 24665060 rs10486722 chr7 41811908 C T 7.00E-06 Pit-and-Fissure caries LOC285954 intron 23470693 rs10486722 chr7 41811908 C T 2.56E-04 Smoking initiation LOC285954 intron 24665060 rs12701937 chr7 41821917 C T 3.50E-05 Colorectal cancer / / 20610541 rs10441105 chr7 41821956 C G 2.20E-05 Colorectal cancer / / 20610541 rs10234444 chr7 41828527 G A 5.64E-04 Smoking initiation / / 24665060 rs29684 chr7 41854652 G A 8.74E-05 Nicotine smoking / / 19268276 rs10486725 chr7 41872709 C T 6.80E-04 Crohn's disease / / 17684544 rs6943613 chr7 41892653 T C 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs6972429 chr7 41894842 C T 8.32E-05 Nicotine smoking / / 19268276 rs10486727 chr7 41899075 T C 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs11773613 chr7 41915184 C T 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs17171966 chr7 41926152 A G 3.10E-06 Urinary metabolites / / 21572414 rs17171967 chr7 41939090 A G 9.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12112972 chr7 41939690 C T 8.01E-05 Heart Failure / / pha002885 rs6976118 chr7 41958456 C T 5.50E-07 White blood cell count / / 21738479 rs10248913 chr7 41958865 T C 9.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2108178 chr7 41985476 A G 7.35E-04 Iron levels / / pha002876 rs17171989 chr7 41987124 G A 8.34E-04 Iron levels / / pha002876 rs3735361 chr7 42000924 C T 7.62E-04 Iron levels GLI3 UTR-3 pha002876 rs7802385 chr7 42018699 T C 6.40E-04 Asthma GLI3 intron 20698975 rs9648517 chr7 42031107 G A 7.52E-04 Multiple complex diseases GLI3 intron 17554300 rs846271 chr7 42036837 C T 2.00E-06 IgG glycosylation GLI3 intron 23382691 rs846335 chr7 42071698 T C 3.48E-04 Heart Failure GLI3 intron pha002885 rs846334 chr7 42072483 G A 8.13E-05 Serum metabolites GLI3 intron 19043545 rs2282920 chr7 42095836 G A 7.52E-04 Type 2 diabetes GLI3 intron 17463246 rs2237421 chr7 42101363 T C 7.95E-04 Type 2 diabetes GLI3 intron 17463246 rs6959829 chr7 42108145 C T 4.46E-04 Suicide attempts in bipolar disorder GLI3 intron 21423239 rs17640580 chr7 42108567 G C 7.00E-05 Iron levels GLI3 intron 21208937 rs10951666 chr7 42115888 C T 5.69E-05 Serum metabolites GLI3 intron 19043545 rs2108166 chr7 42125871 T C 4.51E-07 Primary biliary cirrhosis GLI3 intron 23000144 rs2108166 chr7 42125871 T C 0.000000451 Facial morphology GLI3 intron 23028347 rs3801177 chr7 42141947 G A 8.97E-04 Multiple complex diseases GLI3 intron 17554300 rs3801187 chr7 42156363 G A 3.76E-04 Multiple complex diseases GLI3 intron 17554300 rs3801187 chr7 42156363 G A 6.52E-04 Nicotine smoking GLI3 intron 19268276 rs10488187 chr7 42157545 T C 9.04E-04 Multiple complex diseases GLI3 intron 17554300 rs846397 chr7 42160728 A G 4.73E-05 Socioeconomic Factors GLI3 intron pha003067 rs1405755 chr7 42170486 A C 5.02E-04 Multiple complex diseases GLI3 intron 17554300 rs6974655 chr7 42174596 T G 1.85E-04 Coronary heart disease GLI3 intron 21606135 rs2049622 chr7 42176282 G A 9.00E-06 Age-related macular degeneration GLI3 intron 23326517 rs17753324 chr7 42179545 G T 3.77E-04 Type 2 diabetes GLI3 intron 17463246 rs17753324 chr7 42179545 G T 6.00E-04 Multiple complex diseases GLI3 intron 17554300 rs3801212 chr7 42207032 A G 2.04E-04 Multiple complex diseases GLI3 intron 17554300 rs6963356 chr7 42209050 C T 2.22E-04 Multiple complex diseases GLI3 intron 17554300 rs2190513 chr7 42209334 C T 7.00E-04 Polycystic ovary syndrome GLI3 intron 22178785 rs9886211 chr7 42217027 A G 9.98E-04 Multiple complex diseases GLI3 intron 17554300 rs10951671 chr7 42229946 C T 6.75E-04 Schizophrenia GLI3 intron 19197363 rs6955604 chr7 42256884 G C 1.73E-04 Nicotine smoking GLI3 intron 19268276 rs4724100 chr7 42264679 T C 2.00E-06 Allergic rhinitis GLI3 intron 22036096 rs10277168 chr7 42305237 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2190521 chr7 42324551 A G 7.72E-05 Cognitive impairment induced by topiramate / / 22091778 rs12532960 chr7 42325625 G T 3.00E-07 Inflammatory biomarkers / / 22228203 rs6968846 chr7 42328186 A C 2.86E-04 Multiple complex diseases / / 17554300 rs7792073 chr7 42333628 G A 2.93E-04 Multiple complex diseases / / 17554300 rs2190516 chr7 42378019 A C 8.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs17172042 chr7 42378358 G C 6.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs16880576 chr7 42378648 A G 3.67E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12532964 chr7 42378833 A G 7.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs7791745 chr7 42384620 T C 7.00E-07 Mean arterial pressure (alcohol consumption interaction) / / 24376456 rs10237371 chr7 42385870 C T 8.97E-05 Suicide attempts in bipolar disorder / / 21423239 rs1012325 chr7 42388197 G A 1.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs7794214 chr7 42389933 T G 2.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs1029618 chr7 42390706 G A 1.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs12540833 chr7 42394739 A G 1.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs12536150 chr7 42395101 C T 9.80E-05 Suicide attempts in bipolar disorder / / 21423239 rs10951684 chr7 42411818 G T 2.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs34268866 chr7 42411818 GA G 2.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs12537302 chr7 42412112 G A 2.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs12540103 chr7 42412337 T C 1.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs12537324 chr7 42412465 C T 2.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs12538188 chr7 42413870 G A 2.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs12538774 chr7 42413893 G A 2.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs12538751 chr7 42413989 C T 2.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs12531138 chr7 42414100 T C 2.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs12539588 chr7 42415341 G A 2.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs12531942 chr7 42415376 T C 2.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs4442015 chr7 42418849 T G 2.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs4442016 chr7 42418857 A G 3.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs12538671 chr7 42419653 C G 3.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs12531083 chr7 42419792 T G 3.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs6954249 chr7 42420811 G T 0.000613 Salmonella-induced pyroptosis / / 22837397 rs12540072 chr7 42421178 G A 2.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs10488182 chr7 42421781 G A 2.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs10488181 chr7 42422710 T C 1.55E-04 Multiple complex diseases / / 17554300 rs10488181 chr7 42422710 T C 2.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs12531129 chr7 42423051 G C 2.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs6969107 chr7 42423481 A G 2.01E-04 Multiple complex diseases / / 17554300 rs6969107 chr7 42423481 A G 2.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs12536071 chr7 42428460 A C 1.64E-04 Multiple complex diseases / / 17554300 rs12536071 chr7 42428460 A C 3.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs12530985 chr7 42428520 C G 4.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs12531052 chr7 42428629 G A 2.15E-04 Multiple complex diseases / / 17554300 rs12531052 chr7 42428629 G A 3.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs12536109 chr7 42428670 A G 3.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs12531069 chr7 42428714 G A 3.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs7805982 chr7 42429859 C T 3.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs12539139 chr7 42432703 A T 3.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs12534709 chr7 42433736 G A 3.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs12535237 chr7 42433955 C A 3.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs725876 chr7 42434148 G C 3.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs725875 chr7 42434407 C T 3.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs9942547 chr7 42447043 C T 0.000441 Salmonella-induced pyroptosis / / 22837397 rs12535724 chr7 42447314 A T 7.34E-05 Body mass (lean) / / 19268274 rs1560617 chr7 42447726 G T 5.25E-04 Multiple complex diseases / / 17554300 rs1560617 chr7 42447726 G T 3.11E-05 Body mass (lean) / / 19268274 rs12333485 chr7 42451224 T C 7.10E-04 Multiple complex diseases / / 17554300 rs12333485 chr7 42451224 T C 2.24E-05 Body mass (lean) / / 19268274 rs10241947 chr7 42458609 T A 1.22E-05 Body mass (lean) / / 19268274 rs6463106 chr7 42459467 G A 8.11E-06 Body mass (lean) / / 19268274 rs6463108 chr7 42459662 C G 8.88E-05 Serum metabolites / / 19043545 rs12701974 chr7 42499072 T C 8.47E-05 Glycosylated haemoglobin levels / / 17255346 rs4724107 chr7 42499307 C A 2.07E-04 Glycosylated haemoglobin levels / / 17255346 rs10085826 chr7 42504691 C T 2.71E-05 Glycosylated haemoglobin levels / / 17255346 rs10085847 chr7 42505017 C T 3.79E-05 Glycosylated haemoglobin levels / / 17255346 rs10499628 chr7 42525435 A C 3.47E-05 Iron status biomarkers / / 19084217 rs6962367 chr7 42552387 G T 6.02E-04 Heart Failure / / pha002885 rs10245508 chr7 42563307 C A,T 6.28E-04 Multiple complex diseases / / 17554300 rs7779765 chr7 42570385 T G 0.00001456 Sarcoidosis / / 22952805 rs7796984 chr7 42570476 G A 0.00001456 Sarcoidosis / / 22952805 rs7779934 chr7 42570552 T C 0.00001456 Sarcoidosis / / 22952805 rs11978344 chr7 42570929 G A 0.0000135 Sarcoidosis / / 22952805 rs11978347 chr7 42570947 G A 0.0000135 Sarcoidosis / / 22952805 rs61011113 chr7 42571141 A T 0.0000135 Sarcoidosis / / 22952805 rs56219237 chr7 42571229 G A 0.000005002 Sarcoidosis / / 22952805 rs56764893 chr7 42571236 A G 0.000006364 Sarcoidosis / / 22952805 rs60666201 chr7 42571290 C A 0.0000135 Sarcoidosis / / 22952805 rs59668339 chr7 42571411 G A 0.0000135 Sarcoidosis / / 22952805 rs61146595 chr7 42571507 G T 0.0000135 Sarcoidosis / / 22952805 rs2877168 chr7 42572541 G A 0.00001321 Sarcoidosis / / 22952805 rs4376419 chr7 42572664 G A 0.00001173 Sarcoidosis / / 22952805 rs55734259 chr7 42572745 A T 0.00001173 Sarcoidosis / / 22952805 rs10265323 chr7 42573443 G T 0.00001064 Sarcoidosis / / 22952805 rs10235768 chr7 42573520 A C 0.00001064 Sarcoidosis / / 22952805 rs73323094 chr7 42573785 T A 0.00001064 Sarcoidosis / / 22952805 rs113159876 chr7 42573839 A T 0.00001064 Sarcoidosis / / 22952805 rs74785251 chr7 42573939 C T 0.00001064 Sarcoidosis / / 22952805 rs73325003 chr7 42574177 A T 0.00001064 Sarcoidosis / / 22952805 rs67224828 chr7 42574509 T C 0.000006546 Sarcoidosis / / 22952805 rs73325012 chr7 42574602 G A 0.000006546 Sarcoidosis / / 22952805 rs10229847 chr7 42575126 T C 0.000005657 Sarcoidosis / / 22952805 rs10273296 chr7 42575208 C T 0.000006546 Sarcoidosis / / 22952805 rs2204351 chr7 42575875 T A 0.000007949 Sarcoidosis / / 22952805 rs10233679 chr7 42575908 T C 0.000009786 Sarcoidosis / / 22952805 rs2204352 chr7 42575911 A C 0.000007941 Sarcoidosis / / 22952805 rs2222551 chr7 42575971 C T 0.000009786 Sarcoidosis / / 22952805 rs2222552 chr7 42575997 A C 0.000009786 Sarcoidosis / / 22952805 rs574569081 chr7 42575997 AT A 0.000009786 Sarcoidosis / / 22952805 rs10247680 chr7 42576063 A G 0.000009786 Sarcoidosis / / 22952805 rs10277371 chr7 42576142 C T 0.000009786 Sarcoidosis / / 22952805 rs10233959 chr7 42576151 T G 0.000009786 Sarcoidosis / / 22952805 rs112831017 chr7 42576343 G C 0.000009786 Sarcoidosis / / 22952805 rs112899865 chr7 42576464 C T 0.000009786 Sarcoidosis / / 22952805 rs67009192 chr7 42576660 C A 0.000007941 Sarcoidosis / / 22952805 rs67057711 chr7 42576677 C A 0.000009786 Sarcoidosis / / 22952805 rs66482104 chr7 42576868 T C 0.000009786 Sarcoidosis / / 22952805 rs10238293 chr7 42577275 T C 0.000009786 Sarcoidosis / / 22952805 rs10281960 chr7 42577331 G A 0.000009786 Sarcoidosis / / 22952805 rs10281883 chr7 42577450 C T 0.000009786 Sarcoidosis / / 22952805 rs10238634 chr7 42577525 T C 0.000009786 Sarcoidosis / / 22952805 rs10282241 chr7 42577580 G T 0.000009786 Sarcoidosis / / 22952805 rs10282251 chr7 42577687 C G 0.000009786 Sarcoidosis / / 22952805 rs10282580 chr7 42577804 G C 0.000009786 Sarcoidosis / / 22952805 rs73325062 chr7 42578099 T C 0.000009786 Sarcoidosis / / 22952805 rs57835856 chr7 42578728 C A 0.000009786 Sarcoidosis / / 22952805 rs56228318 chr7 42578804 T C 0.000007941 Sarcoidosis / / 22952805 rs1404306 chr7 42579012 G T 0.000009786 Sarcoidosis / / 22952805 rs1404307 chr7 42579052 G T 0.000009786 Sarcoidosis / / 22952805 rs1404308 chr7 42579304 G T 0.000009786 Sarcoidosis / / 22952805 rs10268211 chr7 42579527 C T 0.000009786 Sarcoidosis / / 22952805 rs10268552 chr7 42579657 G A 0.000009786 Sarcoidosis / / 22952805 rs10225192 chr7 42579670 T C 0.000009786 Sarcoidosis / / 22952805 rs28535306 chr7 42580094 C G 0.000009786 Sarcoidosis / / 22952805 rs28544190 chr7 42580497 A C 0.000009786 Sarcoidosis / / 22952805 rs6951636 chr7 42580527 G A 0.000009786 Sarcoidosis / / 22952805 rs6951657 chr7 42580567 G A 0.000009786 Sarcoidosis / / 22952805 rs6951858 chr7 42580820 C T 0.000009786 Sarcoidosis / / 22952805 rs6956264 chr7 42581012 G C 0.000009786 Sarcoidosis / / 22952805 rs114184865 chr7 42581123 C T 0.000009786 Sarcoidosis / / 22952805 rs10246841 chr7 42581358 A G 0.000009786 Sarcoidosis / / 22952805 rs10247066 chr7 42581495 A G 0.000005333 Sarcoidosis / / 22952805 rs10233218 chr7 42581572 T C 0.00002097 Sarcoidosis / / 22952805 rs10233320 chr7 42581586 T C 0.000008845 Sarcoidosis / / 22952805 rs13438669 chr7 42581761 G A 0.000009786 Sarcoidosis / / 22952805 rs28825801 chr7 42582010 C A 0.000009786 Sarcoidosis / / 22952805 rs28787607 chr7 42582044 A G 0.00001334 Sarcoidosis / / 22952805 rs28795678 chr7 42582158 T G 0.000009786 Sarcoidosis / / 22952805 rs79729438 chr7 42582246 G A 0.000009786 Sarcoidosis / / 22952805 rs76065351 chr7 42582267 G A 0.000009786 Sarcoidosis / / 22952805 rs56260730 chr7 42582472 G A 0.000009786 Sarcoidosis / / 22952805 rs60457772 chr7 42582615 G A 0.000009786 Sarcoidosis / / 22952805 rs56098060 chr7 42582728 T A 0.000009786 Sarcoidosis / / 22952805 rs59140346 chr7 42582832 A G 0.000009786 Sarcoidosis / / 22952805 rs7795512 chr7 42582881 C G 0.000009786 Sarcoidosis / / 22952805 rs7799173 chr7 42582897 C A 0.000009786 Sarcoidosis / / 22952805 rs7782237 chr7 42582936 T C 0.000007941 Sarcoidosis / / 22952805 rs7782565 chr7 42583110 T C 0.000009786 Sarcoidosis / / 22952805 rs7782591 chr7 42583177 T G 0.000009786 Sarcoidosis / / 22952805 rs7799681 chr7 42583237 C T 0.000009786 Sarcoidosis / / 22952805 rs11971307 chr7 42583533 C T 0.000009786 Sarcoidosis / / 22952805 rs10255664 chr7 42583824 A C 0.000009786 Sarcoidosis / / 22952805 rs10229632 chr7 42583954 G A 0.000009786 Sarcoidosis / / 22952805 rs10258813 chr7 42584011 A C 0.000009786 Sarcoidosis / / 22952805 rs11979113 chr7 42584658 A G 0.000009786 Sarcoidosis / / 22952805 rs10259687 chr7 42584699 A T 0.000009786 Sarcoidosis / / 22952805 rs28794921 chr7 42585200 T A 0.000009786 Sarcoidosis / / 22952805 rs28832699 chr7 42585352 G A 0.000009786 Sarcoidosis / / 22952805 rs10237896 chr7 42586070 C T 0.00003665 Sarcoidosis / / 22952805 rs10253735 chr7 42586254 T C 0.000009786 Sarcoidosis / / 22952805 rs60854065 chr7 42586935 A G 0.000009786 Sarcoidosis / / 22952805 rs7802982 chr7 42587214 T A 0.00001 Sarcoidosis / / 22952805 rs10243287 chr7 42587813 G A 0.00001 Sarcoidosis / / 22952805 rs67193150 chr7 42587910 A G 0.00001 Sarcoidosis / / 22952805 rs1524592 chr7 42588491 A G 0.00001 Sarcoidosis / / 22952805 rs11971095 chr7 42588790 C T 0.00001 Sarcoidosis / / 22952805 rs10257453 chr7 42588943 A G 0.00001 Sarcoidosis / / 22952805 rs10228357 chr7 42589074 C T 0.00001 Sarcoidosis / / 22952805 rs10244077 chr7 42589111 T G 0.00001 Sarcoidosis / / 22952805 rs10257808 chr7 42589201 A G 0.00001 Sarcoidosis / / 22952805 rs10228774 chr7 42589260 G A 0.00001 Sarcoidosis / / 22952805 rs7803858 chr7 42589543 G C 0.00001 Sarcoidosis / / 22952805 rs7803796 chr7 42589751 A G 0.00001079 Sarcoidosis / / 22952805 rs7804297 chr7 42589784 G C 0.00001079 Sarcoidosis / / 22952805 rs7791184 chr7 42590071 T G 0.00001167 Sarcoidosis / / 22952805 rs55720301 chr7 42590261 T G 0.00001079 Sarcoidosis / / 22952805 rs59886204 chr7 42590556 G A 0.00001079 Sarcoidosis / / 22952805 rs28368781 chr7 42590783 T C 0.00001079 Sarcoidosis / / 22952805 rs28626586 chr7 42591010 G A 0.00001079 Sarcoidosis / / 22952805 rs28667695 chr7 42591263 T C 0.000009883 Sarcoidosis / / 22952805 rs28407823 chr7 42591264 G A 0.00001079 Sarcoidosis / / 22952805 rs28707452 chr7 42591790 G T 0.00001079 Sarcoidosis / / 22952805 rs28530661 chr7 42591979 A T 0.00001079 Sarcoidosis / / 22952805 rs17172082 chr7 42592174 T C 0.00001079 Sarcoidosis / / 22952805 rs28404616 chr7 42592183 A G 0.00001079 Sarcoidosis / / 22952805 rs28537316 chr7 42592503 T G 0.00003231 Sarcoidosis / / 22952805 rs28641959 chr7 42592507 G C 0.00001079 Sarcoidosis / / 22952805 rs6949743 chr7 42592679 G A 0.00001079 Sarcoidosis / / 22952805 rs6949554 chr7 42592689 C T 0.00001079 Sarcoidosis / / 22952805 rs6953705 chr7 42592901 A G 0.00001079 Sarcoidosis / / 22952805 rs6953862 chr7 42592911 C T 0.00001079 Sarcoidosis / / 22952805 rs6974001 chr7 42593048 T C 0.00001079 Sarcoidosis / / 22952805 rs6954632 chr7 42593209 G T 0.00001079 Sarcoidosis / / 22952805 rs17172084 chr7 42593356 T A 0.00001079 Sarcoidosis / / 22952805 rs28635392 chr7 42593422 T G 0.00001079 Sarcoidosis / / 22952805 rs28592063 chr7 42593429 C T 0.00001079 Sarcoidosis / / 22952805 rs4560711 chr7 42593722 C T 0.00001066 Sarcoidosis / / 22952805 rs4626496 chr7 42593812 A T 0.00001066 Sarcoidosis / / 22952805 rs4296955 chr7 42593852 A T 0.000007802 Sarcoidosis / / 22952805 rs4582457 chr7 42593865 C T 0.00001066 Sarcoidosis / / 22952805 rs4551243 chr7 42594030 T G 0.00001066 Sarcoidosis / / 22952805 rs4551244 chr7 42594033 T C 0.00001087 Sarcoidosis / / 22952805 rs7457032 chr7 42594106 C G 0.00001066 Sarcoidosis / / 22952805 rs28453207 chr7 42594182 T A 0.00001066 Sarcoidosis / / 22952805 rs28585429 chr7 42594372 A G 0.00001924 Sarcoidosis / / 22952805 rs7793215 chr7 42594614 A G 0.00001212 Sarcoidosis / / 22952805 rs7793771 chr7 42594773 G T 0.000009225 Sarcoidosis / / 22952805 rs7793542 chr7 42594836 A G 0.000009225 Sarcoidosis / / 22952805 rs7797233 chr7 42594916 C A 0.000009225 Sarcoidosis / / 22952805 rs7797254 chr7 42594960 C A 0.000009225 Sarcoidosis / / 22952805 rs6463126 chr7 42595049 T C 0.000009225 Sarcoidosis / / 22952805 rs4412280 chr7 42595060 G A 0.000006086 Sarcoidosis / / 22952805 rs4544979 chr7 42595187 A G 0.000009225 Sarcoidosis / / 22952805 rs4383879 chr7 42595484 G C 0.00001212 Sarcoidosis / / 22952805 rs10224713 chr7 42595739 A G 0.00001212 Sarcoidosis / / 22952805 rs10257755 chr7 42596367 C A 0.00001212 Sarcoidosis / / 22952805 rs28499432 chr7 42596446 A G 0.00001212 Sarcoidosis / / 22952805 rs28397988 chr7 42596480 A G 0.00001212 Sarcoidosis / / 22952805 rs6971309 chr7 42596741 G A 0.00001212 Sarcoidosis / / 22952805 rs6971447 chr7 42596799 G A 0.00001212 Sarcoidosis / / 22952805 rs6971475 chr7 42596868 G A 0.00001212 Sarcoidosis / / 22952805 rs6975727 chr7 42597205 C G 0.00001212 Sarcoidosis / / 22952805 rs6957960 chr7 42597226 T C 0.00001212 Sarcoidosis / / 22952805 rs6976054 chr7 42597439 C G 0.00001212 Sarcoidosis / / 22952805 rs6958749 chr7 42597723 T A 0.00001178 Sarcoidosis / / 22952805 rs66611014 chr7 42597774 C T 0.0000086 Sarcoidosis / / 22952805 rs73094540 chr7 42597976 A C 0.00001178 Sarcoidosis / / 22952805 rs112705176 chr7 42598341 T C 0.00001389 Sarcoidosis / / 22952805 rs34689906 chr7 42598459 G A 0.00001026 Sarcoidosis / / 22952805 rs10244660 chr7 42598708 C T 0.00002847 Sarcoidosis / / 22952805 rs7791386 chr7 42599161 G A 0.00000343 Sarcoidosis / / 22952805 rs7810181 chr7 42599185 T A 0.000003249 Sarcoidosis / / 22952805 rs6463127 chr7 42599290 A G 0.000002368 Sarcoidosis / / 22952805 rs11976585 chr7 42599379 G A 0.000002827 Sarcoidosis / / 22952805 rs6959025 chr7 42599622 G C 0.000003887 Sarcoidosis / / 22952805 rs6945007 chr7 42599973 T C 0.000004051 Sarcoidosis / / 22952805 rs6963127 chr7 42600102 A C 0.000004051 Sarcoidosis / / 22952805 rs6463128 chr7 42600270 G A 0.000003959 Sarcoidosis / / 22952805 rs6463129 chr7 42600275 T C 0.000003959 Sarcoidosis / / 22952805 rs6463130 chr7 42600410 C T 0.000003959 Sarcoidosis / / 22952805 rs6463131 chr7 42600422 T C 0.000003959 Sarcoidosis / / 22952805 rs6463132 chr7 42600595 T G 0.00000364 Sarcoidosis / / 22952805 rs6463133 chr7 42600665 A C 0.000003907 Sarcoidosis / / 22952805 rs7783966 chr7 42600968 T C 0.000005274 Sarcoidosis / / 22952805 rs7801071 chr7 42601026 C A 0.000005274 Sarcoidosis / / 22952805 rs7801350 chr7 42601073 G A 0.000005274 Sarcoidosis / / 22952805 rs7801851 chr7 42601552 C G 0.000005274 Sarcoidosis / / 22952805 rs7801867 chr7 42601643 A G 0.000005274 Sarcoidosis / / 22952805 rs7802146 chr7 42601772 C A,G 0.000005274 Sarcoidosis / / 22952805 rs55662501 chr7 42602065 G A 0.000005274 Sarcoidosis / / 22952805 rs6974108 chr7 42602316 A G 0.000005274 Sarcoidosis / / 22952805 rs73311852 chr7 42603523 A G 0.000005274 Sarcoidosis / / 22952805 rs113316670 chr7 42603623 C A 0.000003482 Sarcoidosis / / 22952805 rs1880407 chr7 42604008 C T 0.000005623 Sarcoidosis / / 22952805 rs7785587 chr7 42604984 G A 0.000005142 Sarcoidosis / / 22952805 rs7785714 chr7 42605354 A G 0.000003837 Sarcoidosis / / 22952805 rs7804992 chr7 42605405 T C 0.000005274 Sarcoidosis / / 22952805 rs7805320 chr7 42605677 T C 0.000004963 Sarcoidosis / / 22952805 rs55765316 chr7 42606355 T A 0.000006012 Sarcoidosis / / 22952805 rs55968999 chr7 42606464 G A 0.000006012 Sarcoidosis / / 22952805 rs60402639 chr7 42607146 T A 0.000007547 Sarcoidosis / / 22952805 rs1880408 chr7 42607637 A G 0.000008966 Sarcoidosis / / 22952805 rs1880408 chr7 42607637 A G 7.10E-06 Prostate cancer (early onset) / / 24740154 rs73688594 chr7 42608512 T A 0.000004994 Sarcoidosis / / 22952805 rs1404311 chr7 42609372 G A 0.000008867 Sarcoidosis / / 22952805 rs1829970 chr7 42609480 G A 0.000008867 Sarcoidosis / / 22952805 rs7794669 chr7 42610019 A T 0.000007946 Sarcoidosis / / 22952805 rs35150187 chr7 42611361 T C 0.000009565 Sarcoidosis / / 22952805 rs6972446 chr7 42612098 A T 0.000008207 Sarcoidosis / / 22952805 rs73311878 chr7 42612264 T C 0.00001605 Sarcoidosis / / 22952805 rs17172088 chr7 42612354 T C 0.000008207 Sarcoidosis / / 22952805 rs73311881 chr7 42612404 A C 0.000008207 Sarcoidosis / / 22952805 rs73311882 chr7 42612415 A G 0.000008207 Sarcoidosis / / 22952805 rs73311883 chr7 42612443 G T 0.000008207 Sarcoidosis / / 22952805 rs73311886 chr7 42612491 C T 0.000008207 Sarcoidosis / / 22952805 rs73311887 chr7 42612753 A G 0.000008207 Sarcoidosis / / 22952805 rs16880639 chr7 42612955 A G 0.00003615 Sarcoidosis / / 22952805 rs7811252 chr7 42613720 G A 0.000000166 Sarcoidosis / / 22952805 rs1524594 chr7 42614219 C T 2.86E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2583874 chr7 42690603 G A 6.81E-05 Femoral neck bone geometry / / 22087292 rs2330630 chr7 42706802 C T 4.98E-05 Femoral neck bone geometry / / 22087292 rs17543692 chr7 42745436 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs17172110 chr7 42756695 C A 1.64E-04 Glycosylated haemoglobin levels / / 17255346 rs6463139 chr7 42759430 A G 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2656510 chr7 42810378 C A 2.40E-05 Urinary metabolites / / 21572414 rs7800624 chr7 42842214 C G 3.93E-05 Type 2 diabetes / / 17463246 rs687029 chr7 42856862 G C 1.88E-05 Multiple complex diseases / / 17554300 rs17172125 chr7 42885952 C G 2.01E-05 Brain structure / / 22504417 rs591875 chr7 42960618 C A 1.63E-04 Lymphocyte counts PSMA2 intron 22286170 rs1427658 chr7 43009193 C T 1.95E-04 Multiple sclerosis / / 17660530 rs10951706 chr7 43029457 T A 7.70E-04 Type 2 diabetes / / 17463246 rs12670416 chr7 43029904 C A 2.57E-04 Type 2 diabetes / / 17463246 rs12670455 chr7 43029967 G T 3.20E-04 Type 2 diabetes / / 17463246 rs10267586 chr7 43054504 T C 5.61E-05 Tuberculosis / / 20694014 rs17708673 chr7 43069384 C T 6.73E-05 Type 2 diabetes / / 17463246 rs1019102 chr7 43142434 A C 8.27E-05 HDL cholesterol / / pha003074 rs1019102 chr7 43142434 A C 1.77E-05 HDL cholesterol / / pha003075 rs7798775 chr7 43147965 A G 1.00E-04 Body mass index / / 24827717 rs7787143 chr7 43158219 A C 1.79E-04 Body mass index HECW1 intron 17255346 rs2024125 chr7 43158477 G A 5.50E-06 Urinary metabolites HECW1 intron 21572414 rs2024125 chr7 43158477 G A 6.00E-06 Obesity-related traits HECW1 intron 23251661 rs1006106 chr7 43163055 C A 2.80E-05 Urinary metabolites HECW1 intron 21572414 rs17641812 chr7 43178373 G A 1.21E-04 Body mass index HECW1 intron 17255346 rs6960763 chr7 43184216 C T 2.76E-04 Birth weight HECW1 intron 17255346 rs6977397 chr7 43187398 G A 3.79E-04 Birth weight HECW1 intron 17255346 rs2057745 chr7 43189923 T A 1.32E-04 Birth weight HECW1 intron 17255346 rs10269585 chr7 43194078 C A 1.60E-04 Birth weight HECW1 intron 17255346 rs6463169 chr7 43207653 C T 4.40E-04 Multiple complex diseases HECW1 intron 17554300 rs12674179 chr7 43212606 G T 5.68E-05 Cognitive test performance HECW1 intron 20125193 rs4437556 chr7 43229414 C T 2.14E-04 Alzheimer's disease (late onset) HECW1 intron 21379329 rs17172171 chr7 43230504 T C 1.03E-04 Body mass index HECW1 intron 17255346 rs10229386 chr7 43244022 G T 3.39E-05 Cognitive test performance HECW1 intron 20125193 rs6975782 chr7 43250159 G T 9.24E-05 Alzheimer's disease (age of onset) HECW1 intron 22005931 rs6943440 chr7 43251304 G A 9.26E-05 Alzheimer's disease (age of onset) HECW1 intron 22005931 rs17172174 chr7 43255516 G A 9.89E-05 Bipolar disorder,affective HECW1 intron 20528957 rs2330785 chr7 43276428 T C 6.83E-04 Multiple complex diseases HECW1 intron 17554300 rs17172185 chr7 43286839 T C 4.09E-04 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) HECW1 intron 24121790 rs17172185 chr7 43286839 T C 5.00E-06 Esophageal adenocarcinoma HECW1 intron 24121790 rs17172185 chr7 43286839 T C 8.52E-05 Alcoholism HECW1 intron pha002893 rs17723330 chr7 43286893 G A 6.10E-05 Alcohol dependence HECW1 intron 20201924 rs17723330 chr7 43286893 G A 6.14E-05 Alcoholism HECW1 intron pha002893 rs17796324 chr7 43286908 A G 3.16E-05 Alzheimer's disease HECW1 intron 22832961 rs2240269 chr7 43289874 A G 2.38E-05 Alzheimer's disease HECW1 intron 22832961 rs463 chr7 43302784 T C 5.36E-05 Smoking cessation HECW1 intron 18519826 rs886550 chr7 43336243 G T 1.17E-05 Systemic lupus erythematosus HECW1 intron pha002867 rs2057809 chr7 43365819 A G 0.000735989 Hypertension (early onset hypertension) HECW1 intron 22479346 rs17172199 chr7 43377276 A C 1.00E-06 Alzheimer's disease (cognitive decline) HECW1 intron 23535033 rs10951725 chr7 43377532 G A 3.50E-05 Cognitive function HECW1 intron 24684796 rs6957847 chr7 43384376 G A 5.47E-04 Amyotrophic Lateral Sclerosis HECW1 intron 17362836 rs2330791 chr7 43393603 A C 4.30E-05 Schizophrenia HECW1 intron 24043878 rs17172204 chr7 43403369 G A 5.41E-04 Acute lung injury HECW1 intron 22295056 rs6980464 chr7 43405968 G T 5.83E-04 Acute lung injury HECW1 intron 22295056 rs7811003 chr7 43416129 A G 8.23E-05 Serum metabolites HECW1 intron 19043545 rs10246620 chr7 43424112 G A 2.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HECW1 intron 20877124 rs765865 chr7 43426306 A G 1.50E-05 Urinary metabolites HECW1 intron 21572414 rs7801372 chr7 43428040 T C 4.29E-04 Acute lung injury HECW1 intron 22295056 rs10257003 chr7 43428499 T C 1.06E-05 Serum metabolites HECW1 intron 19043545 rs10951730 chr7 43433870 G A 4.00E-04 Acute lung injury HECW1 intron 22295056 rs10951730 chr7 43433870 G A 9.58E-05 Pulmonary function in asthmatics HECW1 intron 23541324 rs10247622 chr7 43442058 A G 8.03E-05 Alzheimer's disease HECW1 intron 17998437 rs10238217 chr7 43443210 T C 4.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HECW1 intron 20877124 rs2330868 chr7 43460716 G T 8.02E-04 Alzheimer's disease HECW1 intron 22005930 rs7808277 chr7 43463644 A C 5.16E-04 Multiple complex diseases HECW1 intron 17554300 rs17801421 chr7 43474087 A G 2.95E-04 Multiple complex diseases HECW1 intron 17554300 rs2304331 chr7 43496138 T C 1.10E-04 Multiple complex diseases HECW1 intron 17554300 rs2304328 chr7 43506158 T C 8.17E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) HECW1 cds-synon 23648065 rs2304327 chr7 43519337 T C 1.81E-05 Lipid traits HECW1 cds-synon 22028671 rs1025540 chr7 43559539 G T 1.12E-04 Alzheimer's disease (late onset) HECW1 intron 21379329 rs17172223 chr7 43566266 G A 9.64E-04 Type 2 diabetes HECW1 intron 17463246 rs13226386 chr7 43568104 G A 4.22E-04 Alcohol dependence HECW1 intron 21314694 rs7802995 chr7 43645433 A G 4.79E-04 Response to taxane treatment (placlitaxel) STK17A intron 23006423 rs10081211 chr7 43699111 A T 5.90E-04 Type 2 diabetes and 6 quantitative traits C7orf44 intron 17848626 rs1181601 chr7 43794217 T C 3.54E-04 Multiple complex diseases / / 17554300 rs609979 chr7 43873390 C A 1.69E-05 Serum metabolites / / 19043545 rs10232743 chr7 43910882 C T 7.00E-06 Obesity-related traits URGCP-MRPS24 intron 23251661 rs2730616 chr7 43919266 C T 6.16E-04 Schizophrenia URGCP intron 19197363 rs2730617 chr7 43927792 C T 6.50E-04 Schizophrenia URGCP intron 19197363 rs2956425 chr7 43932910 T G 4.35E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) URGCP intron 24192120 rs10232919 chr7 43934974 G T 4.60E-04 Smoking quantity URGCP intron 24665060 rs2730623 chr7 43943569 G C 4.35E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) URGCP intron 24192120 rs2024010 chr7 43946470 T C 7.82E-04 Suicide attempts in bipolar disorder URGCP intron 21423239 rs6977217 chr7 43958509 A G 9.15E-04 Suicide attempts in bipolar disorder URGCP intron 21423239 rs2528374 chr7 43976548 C G 6.79E-04 Smoking quantity UBE2D4 intron 24665060 rs2595647 chr7 43976634 C T 7.81E-04 Multiple complex diseases UBE2D4 intron 17554300 rs2595647 chr7 43976634 C T 1.25E-04 Smoking quantity UBE2D4 intron 24665060 rs2595650 chr7 43983740 A G 2.00E-04 Information processing speed UBE2D4 intron 21130836 rs2527813 chr7 43984254 A G 2.00E-04 Information processing speed UBE2D4 intron 21130836 rs1894752 chr7 43997075 C T 6.39E-04 Schizophrenia POLR2J4 intron 19197363 rs4724276 chr7 44085535 T C 1.45E-06 Post-operative nausea and vomiting DBNL intron 21694509 rs17136005 chr7 44087234 A G 7.03E-05 Serum metabolites DBNL intron 19043545 rs7793194 chr7 44087271 C T 3.11E-05 Serum metabolites DBNL intron 19043545 rs10271244 chr7 44143341 A G 2.00E-05 Hypothyroidism / / 22493691 rs1558469 chr7 44145910 C T 1.44E-05 Post-operative nausea and vomiting AEBP1 intron 21694509 rs3217950 chr7 44160926 C T 9.73E-04 Multiple complex diseases POLD2 intron 17554300 rs2979422 chr7 44162355 T C 1.78E-11 Fasting blood glucose POLD2 intron 22885924 rs882020 chr7 44178743 C T 4.23E-04 Alcohol dependence MYL7 intron 21314694 rs2268575 chr7 44189274 T C 4.09E-27 Fasting blood glucose GCK intron 22885924 rs3808321 chr7 44191705 G A 0.00000216 HDL cholesterol GCK intron 23063622 rs2908297 chr7 44193404 C T 1.89E-05 Triglycerides GCK intron pha002904 rs2971676 chr7 44194482 G A 2.21E-06 Elbow pain GCK intron pha003008 rs2070971 chr7 44197583 G T 0.000000225 Triglycerides GCK intron 23063622 rs2070971 chr7 44197583 G T 0.00000223 Triglycerides GCK intron 23063622 rs758989 chr7 44203006 C T 7.57E-04 Lymphocyte counts GCK intron 22286170 rs2971672 chr7 44205906 A C 7.08E-08 Metabolite levels GCK intron 23281178 rs2971671 chr7 44211337 T C 7.07E-50 Fasting blood glucose GCK intron 22885924 rs2971671 chr7 44211337 T C 4.86E-06 Glucose levels GCK intron pha002899 rs2908290 chr7 44216137 G A 1.03E-05 Glucose levels GCK intron pha002899 rs2300586 chr7 44218856 G A 2.20E-05 Urinary metabolites GCK intron 21572414 rs2300584 chr7 44219338 A G 2.40E-08 Fasting glucose-related traits GCK intron 20152958 rs1990458 chr7 44222802 C T 0.00000167 Type 2 diabetes GCK intron 22325160 rs1990458 chr7 44222802 C T 5.24E-05 IgE levels in asthmatics GCK intron 23967269 rs730497 chr7 44223721 G A 6.00E-12 Glycated Hemoglobin levels GCK intron 19096518 rs730497 chr7 44223721 G A 8.28E-04 Suicide attempts in bipolar disorder GCK intron 21041247 rs730497 chr7 44223721 G A 2.75E-11 2-hour glucose tolerance test GCK intron 22885924 rs730497 chr7 44223721 G A 3.83E-19 Glycated hemoglobin levels GCK intron 22885924 rs730497 chr7 44223721 G A 8.14E-08 Glycated hemoglobin levels GCK intron 24244560 rs2908289 chr7 44223942 G A 2.60E-12 Fasting glucose-related traits GCK intron 20152958 rs2908289 chr7 44223942 G A 8.33E-04 Suicide attempts in bipolar disorder GCK intron 21041247 rs2908289 chr7 44223942 G A 3.30E-88 Type 2 diabetes GCK intron 22885922 rs2908289 chr7 44223942 G A 2.24E-19 Glycated hemoglobin levels GCK intron 22885924 rs2908289 chr7 44223942 G A 2.40E-11 2-hour glucose tolerance test GCK intron 22885924 rs2908289 chr7 44223942 G A 3.32E-88 Fasting blood glucose GCK intron 22885924 rs79396556 chr7 44226865 C T 9.76E-06 Obesity-related traits GCK intron 23251661 rs2268569 chr7 44227020 G T 0.0000698 Triglycerides GCK intron 23063622 rs75076102 chr7 44228079 C T 9.76E-06 Obesity-related traits GCK intron 23251661 rs1799884 chr7 44229068 C T 4.20E-06 Fasting plasma glucose GCK nearGene-5 19060907 rs1799884 chr7 44229068 C T 3.40E-11 Fasting glucose-related traits GCK nearGene-5 20152958 rs1799884 chr7 44229068 C T 1.00E-20 Glycated Hemoglobin levels GCK nearGene-5 20858683 rs1799884 chr7 44229068 C T 8.93E-04 Suicide attempts in bipolar disorder GCK nearGene-5 21041247 rs1799884 chr7 44229068 C T 2.00E-19 Metabolite levels GCK nearGene-5 21909109 rs1799884 chr7 44229068 C T 4.96E-11 Glycated hemoglobin levels GCK nearGene-5 22290723 rs1799884 chr7 44229068 C T 7.20E-38 Fasting blood glucose GCK nearGene-5 22885924 rs1799884 chr7 44229068 C T 3.00E-09 Glycemic traits GCK nearGene-5 23575436 rs1799884 chr7 44229068 C T 3.00E-10 Glycemic traits GCK nearGene-5 23575436 rs1799884 chr7 44229068 C T 5.00E-18 Glycemic traits GCK nearGene-5 23575436 rs1799884 chr7 44229068 C T 6.00E-08 Glycated hemoglobin levels GCK nearGene-5 24244560 rs1799884 chr7 44229068 C T 2.00E-22 Glycated hemoglobin levels GCK nearGene-5 24647736 rs3757840 chr7 44231216 T G 4.00E-13 Metabolic syndrome / / 22399527 rs3757840 chr7 44231216 T G 7.05E-05 IgE levels in asthmatics / / 23967269 rs6975024 chr7 44231886 T C 0.0000066 Type 2 diabetes / / 22885922 rs6975024 chr7 44231886 T C 2.88E-99 Fasting blood glucose / / 22885924 rs6975024 chr7 44231886 T C 4.93E-12 2-hour glucose tolerance test / / 22885924 rs4607517 chr7 44235668 G A 1.00E-25 Fasting plasma glucose / / 19060907 rs4607517 chr7 44235668 G A 2.00E-16 Fasting glucose-related traits / / 20081858 rs4607517 chr7 44235668 G A 7.00E-92 Fasting insulin-related traits / / 20081858 rs4607517 chr7 44235668 G A 1.00E-07 Fasting plasma glucose / / 22508271 rs4607517 chr7 44235668 G A 8.00E-56 Fasting glucose-related traits (interaction with BMI) / / 22581228 rs4607517 chr7 44235668 G A 0.0000046 Type 2 diabetes / / 22885922 rs4607517 chr7 44235668 G A 0.00052 Type 2 diabetes (females) / / 22885922 rs4607517 chr7 44235668 G A 2.80E-27 Fasting blood glucose / / 22885924 rs10278336 chr7 44245363 A G 0.0000064 Type 2 diabetes YKT6 intron 22885922 rs10278336 chr7 44245363 A G 0.00021 HOMA-B YKT6 intron 22885922 rs10278336 chr7 44245363 A G 1.90E-26 Fasting blood glucose YKT6 intron 22885922 rs2908282 chr7 44248828 G A 9.40E-11 Fasting glucose-related traits YKT6 intron 20152958 rs2908282 chr7 44248828 G A 2.40E-08 Glycated hemoglobin levels YKT6 intron 22290723 rs1127065 chr7 44259871 C G,T 9.00E-11 Metabolic syndrome CAMK2B cds-synon 22399527 rs3757837 chr7 44276651 T C 8.00E-10 Osteoarthritis (hip) CAMK2B intron 23989986 rs4524693 chr7 44354257 A G 6.02E-06 Osteoarthritis CAMK2B intron 21871595 rs4298415 chr7 44354265 C T 6.02E-06 Osteoarthritis CAMK2B intron 21871595 rs12535537 chr7 44376785 G A 3.64E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11765303 chr7 44420754 C T 1.80E-05 Urinary metabolites / / 21572414 rs2240100 chr7 44466729 T G 3.35E-04 Body mass index NUDCD3 intron 21701565 rs2240100 chr7 44466729 T G 4.27E-04 Body mass index NUDCD3 intron 21701565 rs307016 chr7 44515316 A G 1.07E-04 Body mass index NUDCD3 intron 21701565 rs307016 chr7 44515316 A G 1.79E-04 Body mass index NUDCD3 intron 21701565 rs217429 chr7 44555199 A C 6.18E-05 Lymphocyte counts NPC1L1 intron 22286170 rs217426 chr7 44558859 A C 7.20E-05 Schizophrenia NPC1L1 intron 19571811 rs2072183 chr7 44579180 G C 3.00E-11 Cholesterol,total NPC1L1 cds-synon 20686565 rs2072183 chr7 44579180 G C 4.00E-11 LDL cholesterol NPC1L1 cds-synon 20686565 rs2072183 chr7 44579180 G C 0.000125 LDL cholesterol NPC1L1 cds-synon 23063622 rs2072183 chr7 44579180 G C 0.000166 Cholesterol,total NPC1L1 cds-synon 23063622 rs2072183 chr7 44579180 G C 4.00E-15 Cholesterol,total NPC1L1 cds-synon 24097068 rs2072183 chr7 44579180 G C 7.00E-16 LDL cholesterol NPC1L1 cds-synon 24097068 rs17725246 chr7 44581986 T C 0.000000556 LDL cholesterol NPC1L1 nearGene-5 22629316 rs17725246 chr7 44581986 T C 0.00000822 LDL cholesterol (male) NPC1L1 nearGene-5 22629316 rs17725246 chr7 44581986 T C 0.000000489 Cholesterol,total NPC1L1 nearGene-5 23063622 rs10260606 chr7 44584551 G C 0.000000875 LDL cholesterol / / 23063622 rs217388 chr7 44599468 A G 9.85E-05 Multiple complex diseases / / 17554300 rs217378 chr7 44608103 A G 4.25E-04 Multiple complex diseases DDX56 intron 17554300 rs217377 chr7 44609852 C T 4.01E-05 Multiple complex diseases DDX56 intron 17554300 rs217376 chr7 44610490 C T 8.25E-05 Multiple complex diseases DDX56 intron 17554300 rs217375 chr7 44611077 T C 1.20E-05 Coronary heart disease DDX56 intron pha003031 rs217373 chr7 44612454 C A 2.77E-04 Multiple complex diseases DDX56 intron 17554300 rs217369 chr7 44615186 T C 1.20E-05 Coronary heart disease / / pha003031 rs217367 chr7 44615988 A T 4.88E-05 Multiple complex diseases / / 17554300 rs217361 chr7 44619302 T C 4.10E-05 Multiple complex diseases TMED4 intron 17554300 rs8580 chr7 44620836 C A 1.15E-11 Metabolite levels / / 22286219 rs217358 chr7 44622286 G A 1.65E-04 Multiple complex diseases / / 17554300 rs217355 chr7 44626377 T C 2.86E-04 Multiple complex diseases / / 17554300 rs6463240 chr7 44662873 C G 3.62E-05 Multiple complex diseases OGDH intron 17554300 rs740094 chr7 44669698 G A 1.94E-04 Multiple complex diseases OGDH intron 17554300 rs886651 chr7 44670154 T C 9.27E-06 Multiple complex diseases OGDH intron 17554300 rs10951768 chr7 44693897 G T 7.59E-06 White blood cell count OGDH intron 21738479 rs11979153 chr7 44702011 A T 6.31E-06 White blood cell count OGDH intron 21738479 rs12155014 chr7 44705721 T C 8.04E-04 Longevity OGDH intron 22279548 rs1050331 chr7 44808091 T G 8.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZMIZ2 UTR-3 20877124 rs1065646 chr7 44809273 A G 2.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZMIZ2 UTR-3 20877124 rs1065646 chr7 44809273 A G 5.94E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZMIZ2 UTR-3 20877124 rs10252662 chr7 44811223 C T 2.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10252662 chr7 44811223 C T 6.58E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13231886 chr7 44814172 G A 8.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13231886 chr7 44814172 G A 9.93E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4724321 chr7 44822385 T C 1.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2331175 chr7 44959923 A G 8.40E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10951777 chr7 44964910 G A 7.52E-07 C-Reactive Protein / / pha003070 rs7797034 chr7 44966771 C T 7.52E-07 C-Reactive Protein / / pha003070 rs7803214 chr7 44978151 C T 3.50E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs7800695 chr7 45090506 G T 7.72E-05 Bone mineral density CCM2 intron 19181680 rs1042984 chr7 45140914 C T 6.09E-04 Prostate cancer mortality TBRG4 cds-synon 20978177 rs6973982 chr7 45143892 A G 8.99E-04 Response to taxane treatment (placlitaxel) TBRG4 intron 23006423 rs3757572 chr7 45146656 C A 2.19E-04 Multiple complex diseases TBRG4 intron 17554300 rs2119050 chr7 45167943 G C 8.91E-05 Polycystic ovary syndrome / / 22178785 rs1866572 chr7 45184555 C T 2.04E-05 Non-word repetition / / 23738518 rs10230614 chr7 45186727 C T 9.66E-04 Multiple complex diseases / / 17554300 rs1294945 chr7 45215088 T C 3.43E-04 Parkinson's disease RAMP3 intron 17052657 rs1294945 chr7 45215088 T C 5.57E-04 Amyotrophic Lateral Sclerosis RAMP3 intron 17362836 rs1294939 chr7 45217854 T G 3.47E-05 Non-word repetition RAMP3 intron 23738518 rs1294906 chr7 45235862 T C 6.48E-05 Alzheimer's disease (late onset) / / 21379329 rs1294905 chr7 45235891 T C 9.69E-05 Alzheimer's disease (late onset) / / 21379329 rs1294892 chr7 45241408 C T 3.04E-04 Alzheimer's disease (late onset) / / 21379329 rs1294878 chr7 45250348 T C 8.20E-05 Malaria / / 19465909 rs756513 chr7 45250584 A C 9.94E-06 Type 2 diabetes / / 17463246 rs6463269 chr7 45261199 C G 6.06E-04 Multiple complex diseases / / 17554300 rs17230937 chr7 45263634 T G 5.49E-04 Multiple complex diseases / / 17554300 rs917088 chr7 45267645 G A 8.70E-05 Epilepsy (remission after treatment) / / 23962720 rs1294847 chr7 45269903 A G 0.0000348 Primary sclerosing cholangitis / / 23603763 rs13309815 chr7 45292046 G T 1.54E-04 Insulin resistance / / 21901158 rs13246285 chr7 45293329 T C 1.57E-04 Insulin resistance / / 21901158 rs17172528 chr7 45311709 T C 6.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs2079316 chr7 45313975 C T 2.82E-04 Insulin resistance / / 21901158 rs6978685 chr7 45324117 T C 3.86E-04 Insulin resistance / / 21901158 rs2331228 chr7 45335689 G A 3.79E-05 Heart Rate / / pha003053 rs11971136 chr7 45343699 A C 2.00E-05 Heart Rate / / pha003053 rs13246922 chr7 45367811 G A 5.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs12702136 chr7 45370510 A G 2.83E-04 Alzheimer's disease / / 24755620 rs1969510 chr7 45390815 G A 8.95E-06 Alzheimer's disease / / 24755620 rs17172560 chr7 45391169 A G 2.47E-05 Suicide attempts in bipolar disorder / / 21423239 rs6969682 chr7 45400336 T C 3.84E-04 Multiple complex diseases / / 17554300 rs1852612 chr7 45400895 C T 8.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs2103185 chr7 45435579 T C 0.0000564 Circulating PCSK9 levels / / 22460556 rs1880629 chr7 45437497 G T 0.0000585 Circulating PCSK9 levels / / 22460556 rs13233674 chr7 45455352 T C 2.26E-04 Alzheimer's disease / / 24755620 rs1917716 chr7 45464222 C A 8.40E-05 Left ventricular hypertrophy / / pha003052 rs12702146 chr7 45521048 C T 5.20E-04 Type 2 diabetes / / 17463249 rs12702146 chr7 45521048 C T 5.21E-04 Multiple complex diseases / / 17554300 rs7793106 chr7 45554986 A G 5.27E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs2139896 chr7 45631348 G A 2.45E-04 Multiple complex diseases ADCY1 intron 17554300 rs10241950 chr7 45723950 C T 7.39E-05 Cognitive performance ADCY1 intron 19734545 rs6956740 chr7 45903807 C T 5.00E-07 Rheumatoid arthritis / / 21156761 rs12667301 chr7 45906903 G A 2.39E-04 Alcohol dependence / / 21314694 rs1553009 chr7 45908994 G A 1.54E-04 Alcohol dependence / / 21314694 rs12673689 chr7 45918943 G A 9.74E-04 Obesity (extreme) / / 21935397 rs10231774 chr7 45922477 G C 8.93E-04 Obesity (extreme) / / 21935397 rs1874479 chr7 45932226 A G 5.40E-04 Obesity (extreme) IGFBP1 intron 21935397 rs4619 chr7 45932669 A G 2.30E-06 Height IGFBP1 missense 20400458 rs9658239 chr7 45934159 A G 5.28E-04 Obesity (extreme) / / 21935397 rs12671457 chr7 45946926 A C 3.71E-04 Obesity (extreme) / / 21935397 rs12671484 chr7 45947155 A G 3.79E-04 Obesity (extreme) / / 21935397 rs2462686 chr7 45982460 T C 9.00E-06 Major depressive disorder / / 23377640 rs2960439 chr7 46003633 A G 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs788718 chr7 46006544 G A 2.29E-05 Amyotrophic lateral sclerosis / / 20801717 rs11977526 chr7 46008110 G A 3.00E-101 Insulin-like growth factors / / 21216879 rs10260816 chr7 46010100 C G 2.07E-14 Insulin-like growth factor bp-3 / / 23696881 rs788748 chr7 46026181 A G 1.00E-04 Information processing speed / / 21130836 rs17578494 chr7 46073516 G C 8.11E-04 Multiple complex diseases / / 17554300 rs10499637 chr7 46095468 C T 4.82E-05 Coronary Artery Disease / / 17634449 rs12668291 chr7 46102732 A G 6.05E-05 Coronary Artery Disease / / 17634449 rs6968126 chr7 46116722 G A 1.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10230238 chr7 46117328 G C 0.0000606 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1722108 chr7 46124791 T C 2.33E-04 Smoking cessation / / 24665060 rs788782 chr7 46152051 A T 1.68E-05 Word reading / / 23738518 rs788725 chr7 46154496 C T 6.66E-05 Vaspin levels / / 22907691 rs10499638 chr7 46166931 A C 4.65E-04 Fibrinogen / / 17255346 rs10499638 chr7 46166931 A C 7.03E-05 Vaspin levels / / 22907691 rs10499639 chr7 46166991 T A 5.45E-04 Coronary Artery Disease / / 17634449 rs6944635 chr7 46171884 A G 4.05E-04 Fibrinogen / / 17255346 rs6950179 chr7 46172904 C T 7.04E-06 Type 2 diabetes / / 17463246 rs7794166 chr7 46175077 C T 6.19E-06 Type 2 diabetes / / 17463246 rs1586360 chr7 46176155 C T 3.21E-04 Multiple complex diseases / / 17554300 rs2171177 chr7 46196746 C T 9.12E-05 Bipolar disorder / / 19488044 rs1552365 chr7 46202756 G A 2.07E-04 Multiple complex diseases / / 17554300 rs17172643 chr7 46210984 T C 2.41E-04 Type 2 diabetes / / 17463246 rs1486147 chr7 46236053 T C 0.00057 Erectile dysfunction after radiotherapy for prostate cancer / / 23021708 rs6971381 chr7 46240548 C G 6.21E-04 Multiple complex diseases / / 17554300 rs6964415 chr7 46242583 T G 5.49E-05 Multiple complex diseases / / 17554300 rs6964415 chr7 46242583 T G 5.00E-07 Sudden cardiac arrest / / 21658281 rs9691259 chr7 46246580 A G 2.08E-05 Prostate cancer / / 23023329 rs2008562 chr7 46263170 T C 7.46E-04 Alzheimer's disease / / 17998437 rs4720535 chr7 46264235 G A 5.21E-04 Alzheimer's disease / / 17998437 rs4720535 chr7 46264235 G A 2.65E-04 Taste perception / / 22132133 rs1601539 chr7 46273496 G A 9.76E-04 Alzheimer's disease / / 17998437 rs1486140 chr7 46275637 T C 2.20E-06 Biomarkers / / 17903293 rs1486139 chr7 46275728 A G 2.00E-06 Select biomarker traits / / 17903293 rs10270664 chr7 46294240 T C 2.14E-04 Taste perception / / 22132133 rs11767887 chr7 46310371 C T 7.42E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6977956 chr7 46384262 C T 2.32E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17513961 chr7 46392567 T G 1.00E-07 Treatment response for severe sepsis / / 22310353 rs11771667 chr7 46444697 G A 7.27E-04 Multiple complex diseases / / 17554300 rs1157868 chr7 46447293 G A 9.99E-04 Multiple complex diseases / / 17554300 rs3890267 chr7 46511393 A G 8.97E-04 Type 2 diabetes / / 17463246 rs7783846 chr7 46514528 G A 7.46E-04 Type 2 diabetes / / 17463246 rs7806883 chr7 46515008 T A 7.15E-04 Type 2 diabetes / / 17463246 rs7784776 chr7 46620145 A G 1.00E-09 QRS duration / / 21076409 rs993183 chr7 46670743 A G 2.30E-05 Endometriosis / / 21151130 rs993183 chr7 46670743 A G 1.10E-04 Pancreatic cancer / / pha002874 rs767395 chr7 46678255 G A 3.50E-05 Endometriosis / / 21151130 rs17172738 chr7 46680058 C G 5.73E-05 Vaspin levels / / 22907691 rs856567 chr7 46721448 G C 3.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs856565 chr7 46721854 C A 4.35E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs856564 chr7 46722795 T A 5.11E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs856563 chr7 46723510 T C 1.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs856560 chr7 46726963 T C 1.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs856589 chr7 46734307 G A 7.67E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7804745 chr7 46742436 G A 2.98E-04 Smoking initiation / / 24665060 rs856575 chr7 46744660 A T 7.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs700750 chr7 46753491 C A 5.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs700750 chr7 46753491 C A 3.00E-06 Obesity-related traits / / 23251661 rs700752 chr7 46753553 C G 4.00E-21 Insulin-like growth factors / / 21216879 rs700752 chr7 46753553 C G 5.00E-09 Insulin-like growth factors / / 21216879 rs856541 chr7 46756141 C T 1.44E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs856541 chr7 46756141 C T 6.07E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs856554 chr7 46760129 T C 1.44E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs856554 chr7 46760129 T C 6.07E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs856548 chr7 46764468 A G 3.29E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs856548 chr7 46764468 A G 7.62E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1917611 chr7 46773055 A C 7.02E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1917611 chr7 46773055 A C 7.11E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6463347 chr7 46780614 C A 2.86E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17172760 chr7 46784825 A G 6.22E-04 Multiple complex diseases / / 17554300 rs1525238 chr7 46785947 A G 2.56E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11767621 chr7 46796544 A G 7.14E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1464841 chr7 46801428 T C 8.78E-04 Myocardial Infarction / / pha002873 rs1525240 chr7 46804913 A G 4.48E-04 Hemoglobin concentration / / 20534544 rs6976037 chr7 46873709 A T 6.48E-04 Sarcoidosis / / 19165924 rs12702255 chr7 46878747 G A 6.18E-04 Smoking initiation / / 24665060 rs4371897 chr7 46880341 T C 2.31E-04 Smoking initiation / / 24665060 rs4496874 chr7 46880728 C T 1.86E-04 Smoking initiation / / 24665060 rs4308634 chr7 46887213 C G 5.08E-05 Serum metabolites / / 19043545 rs4236382 chr7 46889411 G A 7.51E-04 Tourette syndrome / / 22889924 rs4640974 chr7 46899696 C A 4.87E-04 Smoking initiation / / 24665060 rs7803167 chr7 46902789 C T 2.41E-06 Schizophrenia / / 22037555 rs10259488 chr7 46916530 T C 2.76E-04 Smoking initiation / / 24665060 rs4724515 chr7 46918848 G A 2.10E-08 Narcolepsy / / 19629137 rs7797697 chr7 46920023 T C 9.39E-04 Multiple complex diseases / / 17554300 rs13247397 chr7 46971733 C T 8.99E-04 Body mass index / / 21701565 rs73694499 chr7 46987740 G T 1.26E-05 Tuberculosis / / 22306650 rs6955374 chr7 47022767 G A 2.51E-04 Height / / 17255346 rs6964317 chr7 47023974 A T 8.85E-05 Height / / 17255346 rs12672541 chr7 47033404 C A 7.09E-04 Smoking initiation / / 24665060 rs13238599 chr7 47039741 C T 9.86E-04 Obesity (extreme) / / 21935397 rs1544440 chr7 47065781 C G 9.36E-04 Obesity (extreme) / / 21935397 rs12537881 chr7 47079999 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6954269 chr7 47082218 G A 7.01E-05 Calcium levels / / pha003085 rs13231378 chr7 47083278 T C 4.48E-04 Coronary heart disease / / 21606135 rs13228000 chr7 47126710 A G 9.42E-04 Alzheimer's disease / / 17998437 rs12155471 chr7 47129422 A G 7.02E-04 Alzheimer's disease / / 17998437 rs1866361 chr7 47133202 G A 3.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2346863 chr7 47137071 G T 4.83E-04 Multiple complex diseases / / 17554300 rs10951891 chr7 47152328 C T 7.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6958332 chr7 47153390 G A 7.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11767755 chr7 47155356 G A 3.84E-04 Alzheimer's disease / / 17998437 rs6967504 chr7 47160484 G C 7.72E-04 Type 2 diabetes / / 17463246 rs1370916 chr7 47238707 C T 2.00E-06 Colorectal cancer (diet interaction) / / 24743840 rs12702316 chr7 47242308 C T 1.14E-04 Smoking cessation / / 24665060 rs2248842 chr7 47261563 A G 4.16E-05 Glucose levels / / pha003057 rs17172832 chr7 47270301 T A 3.44E-04 Multiple complex diseases / / 17554300 rs6463401 chr7 47282889 G A 3.67E-05 Alcohol and nictotine co-dependence / / 20158304 rs11766408 chr7 47305323 T C 0.0000988 Breast cancer early age of onset / / 18463975 rs17172840 chr7 47307108 A C 1.60E-05 Urinary metabolites / / 21572414 rs9876 chr7 47315291 G A 0.000146 Breast cancer early age of onset TNS3 UTR-3 18463975 rs6971754 chr7 47319852 C T 5.40E-06 Urinary metabolites TNS3 intron 21572414 rs4512293 chr7 47333101 G A 2.40E-05 Urinary metabolites TNS3 intron 21572414 rs4724564 chr7 47366909 T C 8.95E-04 Coronary Artery Disease TNS3 intron 17634449 rs10225497 chr7 47373153 C G 9.26E-04 Coronary Artery Disease TNS3 intron 17634449 rs2470996 chr7 47432669 A C 2.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) TNS3 intron 23648065 rs12673398 chr7 47441292 G T 8.50E-06 Response to citalopram in major depressive disorder TNS3 intron 20619826 rs12702337 chr7 47444053 C T 2.41E-05 Gaucher disease severity TNS3 intron 22388998 rs7798679 chr7 47503866 C T 1.21E-04 Type 2 diabetes TNS3 intron 17463246 rs6963440 chr7 47513110 A T 8.41E-04 Response to taxane treatment (placlitaxel) TNS3 intron 23006423 rs868107 chr7 47515257 A C 8.67E-04 Multiple complex diseases TNS3 intron 17554300 rs1543035 chr7 47520850 T C 5.17E-04 Multiple complex diseases TNS3 intron 17554300 rs2941538 chr7 47529258 G C 4.56E-04 Multiple complex diseases TNS3 intron 17554300 rs884972 chr7 47537679 T C 5.55E-05 Blood Pressure TNS3 intron pha003050 rs334517 chr7 47561348 T G 4.22E-05 Serum metabolites TNS3 intron 19043545 rs334527 chr7 47567227 T C 3.54E-04 Type 2 diabetes TNS3 intron 23300278 rs334504 chr7 47579031 C G 4.13E-05 Major depressive disorder TNS3 intron 21621269 rs12155302 chr7 47601082 C T 1.43E-04 Progressive supranuclear palsy TNS3 intron 21685912 rs11765593 chr7 47672464 A T 2.40E-05 Urinary metabolites / / 21572414 rs10233927 chr7 47706121 G A 1.70E-05 Urinary metabolites / / 21572414 rs4724613 chr7 47732411 A C 2.99E-04 Myocardial Infarction / / pha002873 rs10281623 chr7 47756822 C T 9.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs7783847 chr7 47759340 G C 9.59E-04 Multiple complex diseases / / 17554300 rs7783847 chr7 47759340 G C 1.20E-04 Bipolar disorder,schizoaffective / / 19567891 rs4724616 chr7 47761637 T C 5.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs6945610 chr7 47773965 T C 6.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs17659292 chr7 47778720 T C 6.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs7800244 chr7 47779969 G T 3.00E-06 Hepatitis C induced liver fibrosis / / 22841784 rs12671318 chr7 47781713 C T 2.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs6463435 chr7 47781978 C A 2.28E-04 Bipolar disorder,schizoaffective / / 19567891 rs6463435 chr7 47781978 C A 7.29E-05 Body mass index / / 24827717 rs4720613 chr7 47784580 A G 3.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs6965341 chr7 47791977 C T 1.93E-04 Parkinson's disease / / 17052657 rs4724626 chr7 47795664 C A 1.85E-05 Socioeconomic Factors / / pha003066 rs4720615 chr7 47804970 A G 2.96E-04 Suicide attempts in bipolar disorder LINC00525 intron 21423239 rs12670472 chr7 47811130 T A 5.75E-04 Alzheimer's disease / / 17998437 rs12670472 chr7 47811130 T A 2.77E-04 Alzheimer's disease / / pha002879 rs1551278 chr7 47811850 G A 4.96E-04 Multiple complex diseases / / 17554300 rs1551278 chr7 47811850 G A 7.11E-04 Aortic root size / / 21223598 rs3734931 chr7 47847751 G A 9.29E-04 Multiple complex diseases C7orf69 intron 17554300 rs17545682 chr7 47872483 C T 8.33E-04 Type 2 diabetes PKD1L1 intron 17463246 rs17710886 chr7 47877895 G A 3.75E-04 Multiple complex diseases PKD1L1 intron 17554300 rs1551275 chr7 47891139 G A 5.77E-04 Multiple complex diseases PKD1L1 intron 17554300 rs1554495 chr7 47904737 G A 8.96E-06 Sodium levels PKD1L1 intron pha003093 rs2686821 chr7 47975082 G A 1.12E-05 Amyotrophic lateral sclerosis PKD1L1 intron 19193627 rs2686831 chr7 47992986 T C 1.17E-05 Amyotrophic lateral sclerosis / / 19193627 rs2686838 chr7 48006649 C T 7.85E-05 Cervical cancer HUS1 intron 24700089 rs3176581 chr7 48008738 A G 1.01E-04 Parkinson's disease HUS1 intron 17052657 rs2307252 chr7 48016442 G A 4.50E-04 Parkinson's disease HUS1 intron 17052657 rs2708909 chr7 48051679 G T 6.98E-07 Amyotrophic lateral sclerosis SUN3 intron 19193627 rs2708909 chr7 48051679 G T 3.44E-05 Parkinson's disease SUN3 intron pha002868 rs2708851 chr7 48085802 G A 1.16E-06 Amyotrophic lateral sclerosis C7orf57 intron 19193627 rs2708912 chr7 48086077 C T 8.34E-04 Parkinson's disease C7orf57 missense 17052657 rs2708890 chr7 48089571 C A 8.34E-04 Parkinson's disease C7orf57 missense 17052657 rs12702428 chr7 48106209 A G 0.00007408 Hypertension (early onset hypertension) / / 22479346 rs6463462 chr7 48142194 G T 7.96E-05 Nicotine smoking UPP1 intron 19268276 rs6583476 chr7 48244414 A G 1.78E-04 Response to taxane treatment (placlitaxel) ABCA13 intron 23006423 rs4917139 chr7 48262153 A G 1.12E-04 Response to taxane treatment (placlitaxel) ABCA13 intron 23006423 rs17712049 chr7 48266195 T C 7.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ABCA13 intron 20877124 rs1880740 chr7 48274215 C T 4.95E-04 Lung function (forced expiratory volume in 1 second) ABCA13 intron 24023788 rs6943725 chr7 48339730 A G 7.81E-04 Type 2 diabetes ABCA13 intron 17463246 rs6943725 chr7 48339730 A G 5.59E-04 Suicide attempts in bipolar disorder ABCA13 intron 21041247 rs6969141 chr7 48349265 T C 3.79E-04 Lung function (forced expiratory volume in 1 second) ABCA13 intron 24023788 rs6949736 chr7 48360337 C A 2.84E-04 Osteoarthritis ABCA13 intron 19508968 rs6974064 chr7 48380678 A T 2.29E-04 Glycosylated haemoglobin levels ABCA13 intron 17255346 rs11983883 chr7 48392771 T G 3.97E-05 Non-word repetition ABCA13 intron 23738518 rs10223929 chr7 48403773 G A 7.20E-05 Bone mineral density (BMD),in women ABCA13 intron 20164292 rs6583405 chr7 48412335 T C 8.10E-08 Metabolite levels ABCA13 intron 23281178 rs1368653 chr7 48414939 T C 7.88E-08 Metabolite levels ABCA13 intron 23281178 rs2117090 chr7 48415368 C A 3.61E-05 Non-word repetition ABCA13 intron 23738518 rs7795985 chr7 48415821 A T 7.88E-08 Metabolite levels ABCA13 intron 23281178 rs1880739 chr7 48417856 T C 7.88E-08 Metabolite levels ABCA13 intron 23281178 rs17661898 chr7 48418038 T A 3.61E-05 Non-word repetition ABCA13 intron 23738518 rs17132278 chr7 48418190 A G 7.88E-08 Metabolite levels ABCA13 intron 23281178 rs6966454 chr7 48418944 G C 7.88E-08 Metabolite levels ABCA13 intron 23281178 rs17661929 chr7 48420261 A C 2.70E-05 Non-word repetition ABCA13 intron 23738518 rs7803797 chr7 48426930 G A 7.99E-04 Parkinson's disease ABCA13 intron 17052657 rs7803797 chr7 48426930 G A 9.15E-08 Metabolite levels ABCA13 intron 23281178 rs6946995 chr7 48432072 C T 9.15E-08 Metabolite levels ABCA13 intron 23281178 rs6955132 chr7 48432322 A G 7.67E-08 Metabolite levels ABCA13 intron 23281178 rs6957855 chr7 48434008 C T 5.60E-05 Height ABCA13 intron pha003011 rs10236551 chr7 48443116 A G 4.51E-04 Type 2 diabetes ABCA13 intron 17463246 rs7778020 chr7 48456511 G A 2.02E-05 Parkinson's disease ABCA13 intron 21738487 rs7803999 chr7 48456726 T C 1.37E-05 Parkinson's disease ABCA13 intron 21738487 rs1433515 chr7 48459516 C T 4.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ABCA13 intron 20877124 rs1433515 chr7 48459516 C T 4.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ABCA13 intron 20877124 rs1433515 chr7 48459516 C T 4.62E-05 Erythrocyte counts ABCA13 intron pha003101 rs875812 chr7 48462563 A C 1.89E-04 Schizophrenia(treatment response to risperidone) ABCA13 intron 19850283 rs1025520 chr7 48491825 C T 2.50E-05 Body Mass Index ABCA13 intron pha003020 rs1975193 chr7 48498051 A G 6.10E-05 Type 2 diabetes ABCA13 intron 17463246 rs4083233 chr7 48499310 T G 5.40E-05 Body Mass Index ABCA13 intron pha003020 rs10236459 chr7 48503292 A G 4.78E-04 Amyotrophic Lateral Sclerosis ABCA13 intron 17362836 rs1030708 chr7 48508819 C A 7.87E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) ABCA13 intron 17982456 rs4917157 chr7 48514511 A G 9.80E-04 Parkinson's disease ABCA13 intron 17052657 rs17132432 chr7 48557141 A C 1.10E-06 Urinary metabolites ABCA13 intron 21572414 rs41523451 chr7 48578492 C T 3.00E-07 Urinary metabolites ABCA13 intron 21572414 rs17132457 chr7 48605608 A C 6.00E-07 Urinary metabolites ABCA13 intron 21572414 rs41356045 chr7 48621915 T A 1.50E-06 Urinary metabolites ABCA13 intron 21572414 rs6974375 chr7 48623327 T C 9.21E-04 Amyotrophic Lateral Sclerosis ABCA13 intron 17362836 rs6951282 chr7 48625579 T C 2.80E-07 Urinary metabolites ABCA13 intron 21572414 rs4606009 chr7 48682093 T C 2.40E-06 Urinary metabolites ABCA13 intron 21572414 rs4419764 chr7 48700667 G A 5.82E-04 Multiple complex diseases / / 17554300 rs13438050 chr7 48718056 C G 6.88E-06 Stroke (ischemic) / / 21957438 rs10258912 chr7 48718406 T C 6.88E-06 Stroke (ischemic) / / 21957438 rs7811066 chr7 48739411 T C 5.72E-04 Multiple complex diseases / / 17554300 rs17388239 chr7 48781878 G A 5.52E-04 Multiple complex diseases / / 17554300 rs7801597 chr7 48794910 C T 9.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10487570 chr7 48809623 A T 4.00E-06 Urinary metabolites / / 21572414 rs11767191 chr7 48817965 T C 8.21E-04 Obesity (extreme) / / 21935397 rs11767191 chr7 48817965 T C 1.00E-06 Response to amphetamines / / 22952603 rs13308932 chr7 48832785 G A 3.28E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6979016 chr7 48840395 T C 8.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4557646 chr7 48850787 C T 5.64E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2363131 chr7 48850987 G A 6.58E-05 Cardiovascular disease / / pha003065 rs17331064 chr7 48855672 G T 1.90E-05 Urinary metabolites / / 21572414 rs17331092 chr7 48855741 T C 1.40E-05 Urinary metabolites / / 21572414 rs17331155 chr7 48855974 T C 1.60E-05 Urinary metabolites / / 21572414 rs917129 chr7 48868723 C T 1.00E-05 Urinary metabolites / / 21572414 rs17132676 chr7 48869945 T G 1.40E-05 Urinary metabolites / / 21572414 rs6945430 chr7 48870919 T C 4.56E-06 Multiple complex diseases / / 17554300 rs17132679 chr7 48872127 A G 4.40E-06 Urinary metabolites / / 21572414 rs10487566 chr7 48881802 G A 6.34E-04 Multiple complex diseases / / 17554300 rs2190012 chr7 48895330 T C 1.17E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs12668449 chr7 48914927 G A 1.81E-05 Waist Circumference / / pha003025 rs9918728 chr7 48925614 A G 2.55E-04 Diabetic retinopathy / / 20871662 rs885685 chr7 48928297 G A 1.09E-04 Alcohol dependence / / 20201924 rs10487563 chr7 48935167 G A 1.40E-04 Type 2 diabetes / / 17846126 rs10487563 chr7 48935167 G A 5.43E-05 Femoral neck bone geometry / / 22087292 rs38774 chr7 48939388 C T 6.87E-05 Body mass (lean) / / 19268274 rs10266289 chr7 48941456 G A 7.86E-05 Body mass (lean) / / 19268274 rs28657937 chr7 48963750 T C 6.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6968293 chr7 48964255 A C 4.78E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13247910 chr7 48972943 C T 4.60E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13247910 chr7 48972943 C T 2.67E-04 Lung function (forced vital capacity) / / 24023788 rs4917187 chr7 48973352 G A 4.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2215362 chr7 48973560 A G 3.38E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2215362 chr7 48973560 A G 2.09E-04 Lung function (forced vital capacity) / / 24023788 rs7806147 chr7 48981628 T G 1.06E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs993872 chr7 48993694 T G 1.25E-04 Diabetic retinopathy / / 20871662 rs993871 chr7 48993937 A G 1.24E-04 Diabetic retinopathy / / 20871662 rs993870 chr7 48994025 T C 9.36E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7357214 chr7 48997648 A G 9.48E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2191299 chr7 48997892 T C 9.48E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1473148 chr7 48999902 G A 9.46E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7780870 chr7 49014630 A G 7.83E-04 Multiple complex diseases / / 17554300 rs7780870 chr7 49014630 A G 4.92E-05 Serum metabolites / / 19043545 rs2058267 chr7 49015951 A G 7.09E-04 Multiple complex diseases / / 17554300 rs2364007 chr7 49016537 G A 1.23E-04 Multiple complex diseases / / 17554300 rs12673347 chr7 49025613 C G 7.88E-04 Multiple complex diseases / / 17554300 rs10258925 chr7 49060792 A G 5.53E-04 Suicide attempts in bipolar disorder / / 21041247 rs4132420 chr7 49066371 C T 7.13E-04 Multiple complex diseases / / 17554300 rs9969372 chr7 49067276 C A 9.07E-04 Multiple complex diseases / / 17554300 rs12718319 chr7 49068746 T C 7.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs4129516 chr7 49080824 T C 3.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs11762613 chr7 49105630 C A 4.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs7796330 chr7 49127859 T C 5.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs4576380 chr7 49138833 C T 6.98E-05 Serum metabolites / / 19043545 rs10267806 chr7 49200350 C T 1.16E-06 Multiple complex diseases / / 17554300 rs4244239 chr7 49205140 G A 7.77E-08 Multiple complex diseases / / 17554300 rs7787894 chr7 49205762 C T 8.80E-06 Urinary metabolites / / 21572414 rs7788232 chr7 49205988 C T 8.80E-06 Urinary metabolites / / 21572414 rs4606010 chr7 49213642 T C 7.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6956707 chr7 49317007 A G 4.06E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs7801534 chr7 49329680 A G 7.00E-07 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1529590 chr7 49362161 C T 2.20E-04 Epilepsy / / 22116939 rs12718184 chr7 49418292 T C 2.90E-05 Urinary metabolites / / 21572414 rs10250376 chr7 49422750 C A 9.44E-05 Glucose levels / / pha003061 rs7777085 chr7 49429157 C G 0.000541 Salmonella-induced pyroptosis / / 22837397 rs2217458 chr7 49431544 T C 0.000364 Salmonella-induced pyroptosis / / 22837397 rs1319235 chr7 49435561 G A 2.90E-05 Urinary metabolites / / 21572414 rs4917054 chr7 49438089 C T 0.000252 Salmonella-induced pyroptosis / / 22837397 rs41517645 chr7 49456824 C T 0.00039 Salmonella-induced pyroptosis / / 22837397 rs10236064 chr7 49480294 T C 1.99E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1409968 chr7 49509385 A G 3.65E-04 Type 2 diabetes / / 17463246 rs11766607 chr7 49519619 A G 2.06E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs6949916 chr7 49534244 A G 8.53E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs4487704 chr7 49556570 T G 4.07E-04 Type 2 diabetes / / 17463246 rs4289753 chr7 49556594 A G 4.07E-04 Type 2 diabetes / / 17463246 rs4289753 chr7 49556594 A G 7.19E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs1014222 chr7 49559855 G A 1.18E-04 Multiple complex diseases / / 17554300 rs7783539 chr7 49578602 T C 1.44E-04 Multiple complex diseases / / 17554300 rs6583376 chr7 49593138 T C 4.63E-04 Type 2 diabetes / / 17463246 rs2189829 chr7 49609863 G C 1.90E-05 Sleep and circadian phenotypes / / 17903308 rs6964509 chr7 49616003 C T 2.10E-05 Post-operative nausea and vomiting / / 21694509 rs4492324 chr7 49633802 A G 8.00E-06 Obesity-related traits / / 23251661 rs13244520 chr7 49639378 G A 2.70E-05 Major depressive disorder / / 21042317 rs10239768 chr7 49655966 C T 4.90E-05 Major depressive disorder / / 21042317 rs7796855 chr7 49657446 A C 1.20E-05 Parkinson's disease / / 17052657 rs4917070 chr7 49662736 G A 4.90E-05 Major depressive disorder / / 21042317 rs6968986 chr7 49688124 T C 7.63E-04 Heart Failure / / pha002885 rs4917075 chr7 49700411 A C 4.06E-04 Premature ovarian failure / / 19508998 rs4917075 chr7 49700411 A C 9.48E-05 Calcium levels / / pha003085 rs7784864 chr7 49713611 C T 2.24E-05 Calcium levels / / pha003085 rs11762002 chr7 49714210 C A 2.00E-05 Calcium levels / / pha003085 rs6962671 chr7 49737206 A G 5.09E-04 Schizophrenia / / 20832056 rs10248542 chr7 49738893 C T 4.83E-04 Schizophrenia / / 20832056 rs17550530 chr7 49761504 T A 6.02E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs13240380 chr7 49762598 C T 6.00E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12532230 chr7 49775431 A G 1.16E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4917088 chr7 49801060 A C 6.77E-04 Insulin resistance / / 21901158 rs4916992 chr7 49832872 T G 8.98E-04 Nicotine dependence VWC2 intron 17158188 rs13245988 chr7 49854861 T A 9.45E-04 Suicide attempts in bipolar disorder VWC2 intron 21423239 rs691895 chr7 49879539 G A 9.74E-05 Bipolar disorder VWC2 intron 22925353 rs959678 chr7 50060610 T C 2.20E-04 Type 2 diabetes and 6 quantitative traits ZPBP intron 17848626 rs6583418 chr7 50078299 C A 4.30E-05 Cognitive function ZPBP intron 24684796 rs1355037 chr7 50093078 C G 2.50E-04 Type 2 diabetes and 6 quantitative traits ZPBP intron 17848626 rs1355037 chr7 50093078 C G 4.39E-04 Sarcoidosis ZPBP intron 19165924 rs6972867 chr7 50147259 C T 5.19E-08 Colorectal cancer vs adenoma controls (males) C7orf72 intron 22532847 rs12718244 chr7 50175654 G A 4.09E-04 Smoking quantity C7orf72 intron 24665060 rs7805656 chr7 50178216 T C 7.48E-04 Schizophrenia C7orf72 intron 19197363 rs12531206 chr7 50207532 G A 5.47E-06 Alcohol dependence / / 23089632 rs10273199 chr7 50207547 A C 1.78E-04 Alcohol dependence / / 21314694 rs7782801 chr7 50207994 C T 5.78E-05 Response to methylphenidate treatment / / 21130132 rs17092894 chr7 50210078 T C 7.80E-05 Personality dimensions / / 18957941 rs1037674 chr7 50217850 G T 3.59E-04 Type 2 diabetes / / 17463246 rs7805803 chr7 50225391 G A 9.00E-06 Total ventricular volume / / 21116278 rs10263128 chr7 50233535 C T 6.58E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10235226 chr7 50241186 A G 2.42E-05 Acute lymphoblastic leukemia (childhood) / / 23512250 rs921909 chr7 50241695 T A 9.56E-05 Acute lymphoblastic leukemia (childhood) / / 23512250 rs921910 chr7 50241713 A T 1.19E-04 Acute lymphoblastic leukemia (childhood) / / 23512250 rs1037676 chr7 50243488 A C 6.10E-04 Insulin resistance / / 21901158 rs1037676 chr7 50243488 A C 5.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs11761913 chr7 50249013 C T 1.40E-05 Systemic lupus erythematosus / / 23273568 rs11761913 chr7 50249013 C T 1.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs11761913 chr7 50249013 C T 5.57E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs17133733 chr7 50250354 T C 5.90E-06 Self-reported allergy / / 23817569 rs17634132 chr7 50253721 G A 2.72E-04 Type 2 diabetes / / 17463246 rs17664743 chr7 50253897 G A 5.00E-06 Self-reported allergy / / 23817569 rs13223971 chr7 50263560 A G 1.67E-04 Alzheimer's disease / / 24755620 rs1598704 chr7 50263883 C T 4.84E-04 Multiple complex diseases / / 17554300 rs1598704 chr7 50263883 C T 0.000463 Salmonella-induced pyroptosis / / 22837397 rs1456893 chr7 50269672 G A 5.75E-05 Multiple complex diseases / / 17554300 rs1456893 chr7 50269672 G A 5.00E-09 Crohn's disease / / 18587394 rs1456893 chr7 50269672 G A 1.13E-05 Hippocampal atrophy / / 19668339 rs1456893 chr7 50269672 G A 5.00E-09 Asthma / / 21150878 rs1456893 chr7 50269672 G A 4.60E-09 Multiple sclerosis / / 22190364 rs1456893 chr7 50269672 G A 1.10E-04 Systemic lupus erythematosus / / 23273568 rs2124799 chr7 50270014 C T 8.87E-06 Hippocampal atrophy / / 19668339 rs2168589 chr7 50270105 T A 3.37E-04 Multiple complex diseases / / 17554300 rs12669163 chr7 50278585 A C 1.00E-04 Systemic lupus erythematosus / / 23273568 rs6963387 chr7 50289657 A C 1.87E-04 Alzheimer's disease / / 24755620 rs13241213 chr7 50294856 C T 4.15E-07 Alzheimer's disease (late onset) / / 21379329 rs10244399 chr7 50300254 G A 5.58E-04 Multiple complex diseases / / 17554300 rs10248090 chr7 50300869 G A 4.90E-04 Multiple complex diseases / / 17554300 rs1456896 chr7 50304461 C T 1.39E-09 Crohn's disease / / 18587394 rs1456896 chr7 50304461 C T 7.11E-05 Hippocampal atrophy / / 19668339 rs1456896 chr7 50304461 C T 1.00E-08 Crohn's disease / / 21102463 rs1456896 chr7 50304461 C T 7.00E-15 Inflammatory bowel disease / / 23128233 rs4917014 chr7 50305863 T G 3.00E-23 Systemic lupus erythematosus / / 19838193 rs4917014 chr7 50305863 T G 6.70E-06 Systemic lupus erythematosus / / 23273568 rs4917014 chr7 50305863 T G 1.00E-08 HDL cholesterol / / 24097068 rs10276619 chr7 50313352 G A 3.00E-06 Hippocampal atrophy / / 19668339 rs10276619 chr7 50313352 G A 1.19E-16 Systemic lupus erythematosus / / 19838193 rs10276619 chr7 50313352 G A 6.00E-06 Systemic lupus erythematosus / / 23273568 rs1026421 chr7 50320726 T C 4.40E-04 Myasthenia gravis / / 23055271 rs17634369 chr7 50321474 G A 4.95E-04 Multiple complex diseases / / 17554300 rs4917017 chr7 50335232 G A 1.00E-08 IgG glycosylation / / 23382691 rs4917017 chr7 50335232 G A 2.00E-07 IgG glycosylation / / 23382691 rs4917017 chr7 50335232 G A 1.11E-06 Acute lymphoblastic leukemia (B-cell precursor) / / 23996088 rs9886239 chr7 50336551 A C 6.25E-05 Acute lymphoblastic leukemia (childhood) / / 23512250 rs7781977 chr7 50346134 C T 5.00E-07 IgG glycosylation / / 23382691 rs7781977 chr7 50346134 C T 9.41E-07 Acute lymphoblastic leukemia (B-cell precursor) / / 23996088 rs7781977 chr7 50346134 C T 2.96E-04 Smoking quantity / / 24665060 rs6583437 chr7 50350267 G A 1.00E-08 IgG glycosylation / / 23382691 rs6583437 chr7 50350267 G A 1.00E-09 IgG glycosylation / / 23382691 rs6583437 chr7 50350267 G A 2.00E-09 IgG glycosylation / / 23382691 rs6583437 chr7 50350267 G A 3.00E-08 IgG glycosylation / / 23382691 rs6583437 chr7 50350267 G A 4.00E-08 IgG glycosylation / / 23382691 rs6583437 chr7 50350267 G A 5.00E-09 IgG glycosylation / / 23382691 rs6583437 chr7 50350267 G A 7.00E-06 IgG glycosylation / / 23382691 rs6583437 chr7 50350267 G A 7.00E-10 IgG glycosylation / / 23382691 rs6583437 chr7 50350267 G A 3.24E-04 Smoking quantity / / 24665060 rs7789913 chr7 50352695 C T 7.76E-04 Smoking quantity / / 24665060 rs6421315 chr7 50355207 G C 1.00E-08 IgG glycosylation / / 23382691 rs6421315 chr7 50355207 G C 2.00E-07 IgG glycosylation / / 23382691 rs6421315 chr7 50355207 G C 2.00E-13 IgG glycosylation / / 23382691 rs6421315 chr7 50355207 G C 5.00E-07 IgG glycosylation / / 23382691 rs6421315 chr7 50355207 G C 7.00E-06 IgG glycosylation / / 23382691 rs6421315 chr7 50355207 G C 7.00E-11 IgG glycosylation / / 23382691 rs6421315 chr7 50355207 G C 8.00E-09 IgG glycosylation / / 23382691 rs6421315 chr7 50355207 G C 8.00E-12 IgG glycosylation / / 23382691 rs11765988 chr7 50417522 A G 0.0008609 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11765988 chr7 50417522 A G 8.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11765988 chr7 50417522 A G 6.96E-05 Acute lymphoblastic leukemia (childhood) / / 23512250 rs7800411 chr7 50418625 T C 1.10E-04 Acute lymphoblastic leukemia (childhood) / / 23512250 rs12719039 chr7 50418949 T C 1.33E-09 Acute lymphoblastic leukemia (childhood) / / 23512250 rs7806674 chr7 50423963 C G 1.25E-09 Acute lymphoblastic leukemia (childhood) / / 23512250 rs7790846 chr7 50424061 A G 1.90E-07 Red blood cell traits / / 23222517 rs7790846 chr7 50424061 A G 1.99E-04 Acute lymphoblastic leukemia (childhood) / / 23512250 rs6963357 chr7 50425291 A G 7.86E-07 Red blood cell traits / / 23222517 rs12534526 chr7 50426097 G A 9.89E-12 Other erythrocyte phenotypes / / 19862010 rs12534526 chr7 50426097 G A 5.61E-11 Red blood cell traits / / 23222517 rs12718597 chr7 50428428 C A 5.00E-13 Mean corpuscular volume / / 19862010 rs12718597 chr7 50428428 C A 2.23E-11 Red blood cell traits / / 23222517 rs12718597 chr7 50428428 C A 5.31E-04 Red blood cell traits / / 23935956 rs12718598 chr7 50428445 T C 3.36E-08 Other erythrocyte phenotypes / / 19862010 rs12718598 chr7 50428445 T C 7.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12718598 chr7 50428445 T C 2.00E-13 Red blood cell traits / / 23222517 rs11765490 chr7 50430493 T A 6.07E-06 Telomere length / / 23900074 rs7385935 chr7 50430871 G A 8.73E-12 Other erythrocyte phenotypes / / 19862010 rs7385935 chr7 50430871 G A 2.81E-11 Red blood cell traits / / 23222517 rs12669559 chr7 50435777 T G 1.55E-09 Other erythrocyte phenotypes / / 19862010 rs12669559 chr7 50435777 T G 4.02E-10 Red blood cell traits / / 23222517 rs12669559 chr7 50435777 T G 4.62E-09 Acute lymphoblastic leukemia (childhood) / / 23512250 rs7809377 chr7 50442726 G A 3.36E-10 Acute lymphoblastic leukemia (B-cell precursor) / / 23996088 rs10230385 chr7 50452552 G A 2.08E-07 Red blood cell traits / / 23222517 rs10254237 chr7 50457637 G T 1.77E-07 Red blood cell traits IKZF1 intron 23222517 rs6954833 chr7 50458446 G A 7.91E-07 Red blood cell traits IKZF1 intron 23222517 rs6964823 chr7 50460096 G A 3.83E-07 Red blood cell traits IKZF1 intron 23222517 rs6964823 chr7 50460096 G A 2.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) IKZF1 intron 23648065 rs7797772 chr7 50460208 G A 1.08E-07 Acute lymphoblastic leukemia (B-cell precursor) IKZF1 intron 23996088 rs10248903 chr7 50461684 G A 1.14E-07 Red blood cell traits IKZF1 intron 23222517 rs10248903 chr7 50461684 G A 1.41E-06 Neuroblastoma IKZF1 intron pha002895 rs6952409 chr7 50462935 G A 1.39E-22 Acute lymphoblastic leukemia (B-cell precursor) IKZF1 intron 23996088 rs12533940 chr7 50462958 A G 6.58E-07 Red blood cell traits IKZF1 intron 23222517 rs12670555 chr7 50465654 A G 4.02E-08 Red blood cell traits IKZF1 intron 23222517 rs11978267 chr7 50466304 A G 8.00E-11 Acute lymphoblastic leukemia (childhood) IKZF1 intron 19684603 rs11978267 chr7 50466304 A G 8.00E-11 Nasopharyngeal carcinoma IKZF1 intron 20512145 rs11978267 chr7 50466304 A G 5.29E-24 Acute lymphoblastic leukemia (childhood) IKZF1 intron 23512250 rs11980379 chr7 50469981 T C 3.00E-33 Acute lymphoblastic leukemia (B-cell precursor) IKZF1 UTR-3 23996088 rs4132601 chr7 50470604 T G 1.00E-19 Acute lymphoblastic leukemia (childhood) IKZF1 UTR-3 19684604 rs4132601 chr7 50470604 T G 1.00E-19 Nasopharyngeal carcinoma IKZF1 UTR-3 20512145 rs4132601 chr7 50470604 T G 3.74E-33 Acute lymphoblastic leukemia (B-cell precursor) IKZF1 UTR-3 23996088 rs6964969 chr7 50473251 A G 1.59E-29 Acute lymphoblastic leukemia (childhood) / / 23512250 rs6964969 chr7 50473251 A G 2.00E-29 Acute lymphoblastic leukemia (childhood) / / 23512250 rs7789635 chr7 50473610 T C 8.64E-09 Red blood cell traits / / 23222517 rs6944602 chr7 50473751 G A 1.28E-19 Acute lymphoblastic leukemia (childhood) / / 23512250 rs11770117 chr7 50473763 A T 8.86E-05 Lymphocyte counts / / 22286170 rs11770117 chr7 50473763 A T 2.77E-07 Red blood cell traits / / 23222517 rs11770117 chr7 50473763 A T 3.98E-23 Acute lymphoblastic leukemia (childhood) / / 23512250 rs12719019 chr7 50476139 C T 2.09E-09 Red blood cell traits / / 23222517 rs12719019 chr7 50476139 C T 8.50E-23 Acute lymphoblastic leukemia (childhood) / / 23512250 rs12719019 chr7 50476139 C T 5.19E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs10261922 chr7 50482012 C T 5.05E-10 Acute lymphoblastic leukemia (childhood) / / 23512250 rs7792486 chr7 50486309 T C 1.30E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs4947641 chr7 50489038 C T 1.18E-09 Red blood cell traits / / 23222517 rs7779747 chr7 50491358 C T 3.21E-17 Lymphocyte counts / / 22286170 rs10499691 chr7 50493729 C T 3.55E-11 Acute lymphoblastic leukemia (B-cell precursor) / / 23996088 rs11976368 chr7 50494207 A G 4.84E-11 Acute lymphoblastic leukemia (B-cell precursor) / / 23996088 rs6945253 chr7 50501440 T G 2.39E-07 Red blood cell traits / / 23222517 rs963739 chr7 50507678 C T 6.76E-04 Substance dependence / / 21818250 rs11575575 chr7 50524208 C A 2.16E-10 Acute lymphoblastic leukemia (childhood) / / 23512250 rs11575557 chr7 50525900 G A 7.34E-04 Multiple complex diseases DDC nearGene-3 17554300 rs11575553 chr7 50526219 G A 1.45E-04 Acute lymphoblastic leukemia (childhood) DDC UTR-3 23512250 rs11575553 chr7 50526219 G A 5.00E-11 Acute lymphoblastic leukemia (B-cell precursor) DDC UTR-3 23996088 rs2242041 chr7 50529449 C G 3.50E-07 Acute lymphoblastic leukemia (childhood) DDC intron 19684603 rs11575549 chr7 50530177 C T 3.49E-05 Alcohol consumption DDC intron 23953852 rs11575548 chr7 50530309 G T 1.07E-06 Acute lymphoblastic leukemia (B-cell precursor) DDC intron 23996088 rs11575543 chr7 50530869 G A 3.57E-05 Alcohol consumption DDC intron 23953852 rs11575542 chr7 50530987 C T 4.17E-05 Alcohol consumption DDC missense 23953852 rs4947535 chr7 50531681 T A 1.74E-07 Red blood cell traits DDC intron 23222517 rs11575537 chr7 50531885 C T 3.44E-05 Alcohol consumption DDC intron 23953852 rs11575522 chr7 50535395 C T 4.45E-05 Alcohol consumption DDC intron 23953852 rs730092 chr7 50535754 C G 1.53E-08 Red blood cell traits DDC intron 23222517 rs11575501 chr7 50537187 A G 8.05E-04 Multiple complex diseases DDC intron 17554300 rs7803247 chr7 50540743 T C 5.80E-07 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs4490786 chr7 50544314 C T 1.85E-13 Acute lymphoblastic leukemia (B-cell precursor) DDC intron 23996088 rs2329365 chr7 50544945 C T 2.35E-08 Red blood cell traits DDC intron 23222517 rs3887825 chr7 50545093 T C 1.55E-07 Red blood cell traits DDC intron 23222517 rs3887825 chr7 50545093 T C 2.62E-09 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs4992502 chr7 50545191 C A 2.09E-07 Red blood cell traits DDC intron 23222517 rs12718527 chr7 50545549 A G 2.12E-06 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs12718528 chr7 50545571 A G 9.23E-07 Red blood cell traits DDC intron 23222517 rs12718528 chr7 50545571 A G 4.40E-06 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs12718529 chr7 50545593 A G 2.08E-08 Red blood cell traits DDC intron 23222517 rs11238138 chr7 50545992 C T 2.60E-08 Red blood cell traits DDC intron 23222517 rs4329234 chr7 50546006 C T 2.45E-08 Red blood cell traits DDC intron 23222517 rs4433100 chr7 50546037 G A 2.59E-07 Red blood cell traits DDC intron 23222517 rs4580999 chr7 50546261 C T 2.42E-08 Red blood cell traits DDC intron 23222517 rs4580999 chr7 50546261 C T 1.86E-06 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs1349492 chr7 50546459 G A 5.47E-07 Red blood cell traits DDC intron 23222517 rs10899734 chr7 50546764 C T 9.99E-07 Red blood cell traits DDC intron 23222517 rs10899734 chr7 50546764 C T 2.02E-06 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs10899735 chr7 50546891 C T 3.86E-08 Red blood cell traits DDC intron 23222517 rs10899735 chr7 50546891 C T 2.40E-06 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs10899736 chr7 50546925 G A 3.49E-12 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs11575457 chr7 50547584 A C 3.13E-08 Red blood cell traits DDC intron 23222517 rs11575457 chr7 50547584 A C 3.70E-06 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs4947577 chr7 50548609 G C 5.31E-07 Red blood cell traits DDC intron 23222517 rs4948196 chr7 50548651 C T 4.15E-08 Red blood cell traits DDC intron 23222517 rs4948196 chr7 50548651 C T 6.12E-05 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs13311361 chr7 50549008 T G 5.73E-07 Red blood cell traits DDC intron 23222517 rs17152020 chr7 50549859 T A 1.95E-09 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs17152020 chr7 50549859 T A 2.00E-09 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs11980368 chr7 50549939 A G 6.40E-08 Red blood cell traits DDC intron 23222517 rs2122822 chr7 50552152 G C 5.65E-07 Red blood cell traits DDC intron 23222517 rs1451371 chr7 50553051 T C 1 Drug response to Nicotine DDC intron 15879433 rs1451372 chr7 50553871 C G 8.39E-08 Red blood cell traits DDC intron 23222517 rs7785224 chr7 50562361 T C 7.44E-07 Red blood cell traits DDC intron 23222517 rs1037351 chr7 50565404 T C 1.85E-13 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs2167364 chr7 50565827 T C 5.55E-06 Acute lymphoblastic leukemia (childhood) DDC intron 19684603 rs2167364 chr7 50565827 T C 2.56E-14 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs4947582 chr7 50566090 G A 1.54E-10 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs11575387 chr7 50567435 T G 9.26E-09 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs6951648 chr7 50567493 G A 5.26E-11 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs1376523 chr7 50569341 C T 6.52E-04 Multiple complex diseases DDC intron 17554300 rs17133853 chr7 50569415 A G 3.53E-07 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs7791875 chr7 50570888 C T 5.80E-08 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs3823674 chr7 50571996 C T 5.40E-13 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs4947584 chr7 50572709 A T 1.83E-14 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs6592961 chr7 50572890 G A 9.89E-11 Acute lymphoblastic leukemia (B-cell precursor) DDC intron 23996088 rs6944090 chr7 50573140 T C 6.84E-05 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs12718572 chr7 50573325 C T 7.88E-08 Acute lymphoblastic leukemia (B-cell precursor) DDC intron 23996088 rs7809758 chr7 50573333 A G 2.31E-15 Acute lymphoblastic leukemia (B-cell precursor) DDC intron 23996088 rs7808025 chr7 50576903 G A 1.60E-06 Fasting plasma glucose DDC intron 19060907 rs7808025 chr7 50576903 G A 8.58E-12 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs6592963 chr7 50581845 T C 3.03E-05 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs12535064 chr7 50591070 G C 3.06E-06 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs12538830 chr7 50591132 T A 5.61E-05 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs9918702 chr7 50592082 T C 9.85E-06 Acute lymphoblastic leukemia (childhood) DDC intron 23512250 rs11575340 chr7 50596471 G T 4.64E-05 Alcohol consumption DDC intron 23953852 rs3735273 chr7 50596864 C T 1 Drug response to Nicotine DDC intron 15879433 rs4947631 chr7 50603379 C T 5.65E-04 Multiple complex diseases DDC intron 17554300 rs4245549 chr7 50603534 A C 4.27E-04 Multiple complex diseases DDC intron 17554300 rs11575302 chr7 50607694 G A 2.87E-05 Alcohol consumption DDC cds-synon 23953852 rs7809234 chr7 50610379 A T 6.00E-14 Blood metabolite ratios DDC intron 24816252 rs11575288 chr7 50611888 G C 3.30E-04 Multiple complex diseases DDC intron 17554300 rs10499695 chr7 50618604 T C 3.59E-04 Multiple complex diseases DDC intron 17554300 rs4947644 chr7 50618876 T C 1.95E-04 Multiple complex diseases DDC intron 17554300 rs930707 chr7 50619678 A G 5.27E-05 Alcohol consumption DDC intron 23953852 rs1451375 chr7 50622712 C A 6.00E-06 Malaria DDC intron 19465909 rs921451 chr7 50623285 T C 1 Drug response to Nicotine DDC intron 15879433 rs10249420 chr7 50623451 C G 6.80E-05 Malaria DDC intron 19465909 rs7803788 chr7 50625898 C T 7.90E-05 Malaria DDC intron 19465909 rs9791817 chr7 50661187 C G 3.36E-08 Acute lymphoblastic leukemia (childhood) GRB10 intron 23512250 rs4245555 chr7 50661409 T C 1.96E-08 Fasting blood glucose GRB10 intron 22885924 rs4245555 chr7 50661409 T C 6.12E-09 Acute lymphoblastic leukemia (childhood) GRB10 intron 23512250 rs4245556 chr7 50661661 C T 3.58E-09 Acute lymphoblastic leukemia (childhood) GRB10 intron 23512250 rs12540874 chr7 50664922 A G 1.00E-06 Systemic sclerosis GRB10 intron 21779181 rs12540874 chr7 50664922 A G 6.81E-09 Acute lymphoblastic leukemia (childhood) GRB10 intron 23512250 rs4947709 chr7 50672907 T C 6.69E-08 Acute lymphoblastic leukemia (childhood) GRB10 intron 23512250 rs2190498 chr7 50689514 A G 5.41E-05 Alcohol consumption GRB10 intron 23953852 rs2074778 chr7 50694429 G A 4.22E-06 Acute lymphoblastic leukemia (childhood) GRB10 intron 23512250 rs963161 chr7 50695317 G A 3.21E-04 Obesity (extreme) GRB10 intron 21935397 rs4947737 chr7 50700822 C T 6.51E-04 Multiple complex diseases GRB10 intron 17554300 rs4947737 chr7 50700822 C T 6.93E-05 Acute lymphoblastic leukemia (childhood) GRB10 intron 23512250 rs2237450 chr7 50716017 T C 3.50E-05 Acute lymphoblastic leukemia (childhood) GRB10 intron 23512250 rs2282927 chr7 50720271 A C 9.31E-05 Serum metabolites GRB10 intron 19043545 rs2237454 chr7 50723933 G A,C,T 7.12E-04 Multiple complex diseases GRB10 intron 17554300 rs2237457 chr7 50726144 C T 1.07E-05 Type 2 diabetes GRB10 intron 17846126 rs2237469 chr7 50735005 C T 2.40E-06 Urinary metabolites GRB10 intron 21572414 rs2244372 chr7 50739151 G A 1.17E-04 Acute lymphoblastic leukemia (childhood) GRB10 intron 23512250 rs2244353 chr7 50739455 T C 1.10E-04 Acute lymphoblastic leukemia (childhood) GRB10 intron 23512250 rs2190503 chr7 50742617 A G 4.60E-06 Urinary metabolites GRB10 intron 21572414 rs2237481 chr7 50748338 T C 9.70E-06 Urinary metabolites GRB10 intron 21572414 rs2715133 chr7 50749425 A G 2.99E-04 Multiple complex diseases GRB10 intron 17554300 rs2715133 chr7 50749425 A G 0.00022 Endometrial cancer GRB10 intron 22426144 rs10248619 chr7 50751090 T C 8.00E-08 Fasting glucose-related traits (interaction with BMI) GRB10 intron 22581228 rs2282930 chr7 50754679 G A 3.00E-06 Bone mineral density GRB10 intron 22504420 rs2237488 chr7 50755995 G A 1.20E-05 Urinary metabolites GRB10 intron 21572414 rs2715124 chr7 50756320 C T 8.34E-05 Multiple complex diseases GRB10 intron 17554300 rs6976501 chr7 50760220 G A 1.50E-04 Multiple complex diseases GRB10 intron 17554300 rs2190501 chr7 50767072 T C 1.10E-05 Urinary metabolites GRB10 intron 21572414 rs2715100 chr7 50769534 C T 7.74E-04 Multiple complex diseases GRB10 intron 17554300 rs4947432 chr7 50785133 T C 9.50E-06 Urinary metabolites GRB10 intron 21572414 rs1978208 chr7 50785448 C T 6.93E-04 Parkinson's disease GRB10 intron 17052657 rs6943153 chr7 50791579 T C 0.0000227 Fasting insulin-related traits GRB10 intron 22885924 rs6943153 chr7 50791579 T C 1.60E-12 Fasting blood glucose GRB10 intron 22885924 rs6593140 chr7 50798133 C T 6.20E-06 Urinary metabolites GRB10 intron 21572414 rs6593142 chr7 50798691 A G 5.80E-06 Urinary metabolites GRB10 intron 21572414 rs2074777 chr7 50799889 C T 3.44E-04 Multiple complex diseases GRB10 intron 17554300 rs962508 chr7 50801330 C G 1.10E-05 Urinary metabolites GRB10 intron 21572414 rs2329494 chr7 50804582 C T 5.46E-04 Type 2 diabetes GRB10 intron 17463246 rs12536500 chr7 50808033 T C 2.40E-04 Type 2 diabetes GRB10 intron 17463246 rs12536500 chr7 50808033 T C 6.52E-04 Multiple complex diseases GRB10 intron 17554300 rs4947444 chr7 50817465 T C 1.60E-05 Urinary metabolites GRB10 intron 21572414 rs4947446 chr7 50818546 G A 2.10E-05 Urinary metabolites GRB10 intron 21572414 rs6593171 chr7 50830471 A G 1.60E-05 Urinary metabolites GRB10 intron 21572414 rs2876846 chr7 50840056 C G 0.00028 Endometrial cancer GRB10 intron 22426144 rs6593182 chr7 50855847 G A 6.21E-04 Multiple complex diseases GRB10 intron 17554300 rs4947464 chr7 50878411 G A 2.06E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs7781440 chr7 50887174 T C 3.17E-05 Cognitive impairment induced by topiramate / / 22091778 rs4947475 chr7 50897276 G A 7.94E-05 Bipolar disorder and schizophrenia / / 20889312 rs10250209 chr7 50982884 A G 2.00E-05 Urinary metabolites / / 21572414 rs4948033 chr7 50989366 C G 2.10E-05 Urinary metabolites / / 21572414 rs2214654 chr7 50999204 G T 2.30E-05 Urinary metabolites / / 21572414 rs2189819 chr7 51005062 G A 2.30E-05 Urinary metabolites / / 21572414 rs4947522 chr7 51005519 C T 2.30E-05 Urinary metabolites / / 21572414 rs4948088 chr7 51027194 A C 4.00E-08 Type 1 diabetes / / 19430480 rs4948088 chr7 51027194 A C 4.40E-08 Multiple sclerosis / / 22190364 rs6942987 chr7 51029101 C T 3.52E-05 Cognitive test performance / / 20125193 rs17712532 chr7 51043908 A T 6.14E-05 Type 2 diabetes / / 17463246 rs10231420 chr7 51052815 G A 2.76E-06 Type 1 diabetes / / 21980299 rs17798871 chr7 51062256 A G 4.76E-04 Type 2 diabetes / / 17463246 rs2107259 chr7 51075228 C T 4.92E-05 Type 2 diabetes / / 17463246 rs10273 chr7 51084304 C A 5.03E-04 Type 2 diabetes COBL UTR-3 17463246 rs1046964 chr7 51084321 T C 1.94E-04 Type 2 diabetes COBL UTR-3 17463246 rs17134126 chr7 51084556 C T 7.03E-05 HIV-1 viral setpoint COBL UTR-3 22174851 rs2240089 chr7 51096036 G C 6.60E-04 Type 2 diabetes COBL missense 17463246 rs61737866 chr7 51096992 G A 0.00037 Prostate cancer COBL missense 23555315 rs61737866 chr7 51096992 G A 0.00057 Prostate cancer (non-advanced prostate cancer) COBL missense 23555315 rs17554286 chr7 51145573 T C 5.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COBL intron 20877124 rs17152220 chr7 51150108 G A 9.93E-05 Intelligence COBL intron 21826061 rs6593325 chr7 51156296 A G 4.12E-05 Soluble levels of adhesion molecules COBL intron pha003072 rs10156067 chr7 51158612 C T 9.57E-05 Glucose levels COBL intron pha003057 rs801145 chr7 51293047 G A 7.60E-06 Urinary metabolites COBL intron 21572414 rs12536110 chr7 51335049 G A 4.72E-04 Coronary Artery Disease COBL intron 17634449 rs315100 chr7 51366170 C T 5.26E-04 White matter integrity COBL intron 22425255 rs10258601 chr7 51371109 G A 4.38E-04 Multiple complex diseases COBL intron 17554300 rs7808985 chr7 51393548 A G 2.49E-04 White matter integrity / / 22425255 rs961088 chr7 51396890 G A 5.99E-04 White matter integrity / / 22425255 rs6969097 chr7 51423526 T C 8.68E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10499698 chr7 51435267 C T 1.50E-06 Urinary metabolites / / 21572414 rs1949829 chr7 51537887 C T 4.00E-07 Wegener's granulomatosis / / 23740775 rs17734557 chr7 51544056 C T 1.50E-06 Urinary metabolites / / 21572414 rs10261991 chr7 51546015 G A 9.69E-05 Parkinson's disease (motor and cognition) / / 22658654 rs10261991 chr7 51546015 G A 9.69E-05 Immune response to anthrax vaccine / / 22658931 rs6592926 chr7 51547147 G A 4.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6592927 chr7 51547212 A G 6.20E-05 Parkinson's disease (age of onset) / / 19772629 rs17555162 chr7 51550923 A G 3.22E-04 Multiple complex diseases / / 17554300 rs35205176 chr7 51615152 T A 2.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs4557653 chr7 51615505 G A 4.84E-04 Obesity (extreme) / / 21935397 rs4557653 chr7 51615505 G A 4.38E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs4460330 chr7 51615800 C G 8.10E-05 Cognitive function / / 24684796 rs11769683 chr7 51616830 G A 6.14E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs12533589 chr7 51618352 C T 4.82E-04 Obesity (extreme) / / 21935397 rs13239514 chr7 51624353 C T 3.71E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs12538073 chr7 51625595 T C 4.15E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs4439078 chr7 51626326 T C 4.42E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs4947372 chr7 51628005 C T 4.01E-04 Obesity (extreme) / / 21935397 rs13230827 chr7 51629529 G A 4.19E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs17134312 chr7 51632753 G C 6.21E-04 Multiple complex diseases / / 17554300 rs17636421 chr7 51633059 T C 4.34E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs12671195 chr7 51633574 C G 4.77E-04 Obesity (extreme) / / 21935397 rs1159835 chr7 51637583 G A 3.22E-04 Obesity (extreme) / / 21935397 rs12718513 chr7 51651047 C T 3.15E-04 Obesity (extreme) / / 21935397 rs9791671 chr7 51672999 G A 6.01E-04 Type 2 diabetes / / 17463246 rs4947623 chr7 51673344 C T 2.09E-04 Parkinson's disease / / 17052657 rs7788054 chr7 51673607 C A 5.10E-04 Type 2 diabetes / / 17463246 rs6979000 chr7 51674137 A C 5.81E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2876969 chr7 51676796 A C,G,T 1.27E-04 Multiple complex diseases / / 17554300 rs17578222 chr7 51679299 C A 3.30E-05 Neuroblastoma / / pha002895 rs4947627 chr7 51682401 G A 7.36E-04 Multiple complex diseases / / 17554300 rs6978695 chr7 51682815 C A 8.89E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs10281287 chr7 51694007 T C 1.20E-07 Urinary metabolites / / 21572414 rs17134353 chr7 51694472 G T 4.61E-04 Smoking quantity / / 24665060 rs7789538 chr7 51706830 A G 2.80E-05 Urinary metabolites / / 21572414 rs10240369 chr7 51708116 C T 1.76E-04 Coronary heart disease / / 21606135 rs10234700 chr7 51716684 C A 6.96E-05 Coronary heart disease / / 21606135 rs17579106 chr7 51718092 G T 6.03E-04 Multiple complex diseases / / 17554300 rs10267195 chr7 51730710 T C 9.06E-04 Heart Failure / / pha002884 rs12537160 chr7 51733827 C T 9.75E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11238140 chr7 51770760 C T 3.96E-04 Multiple complex diseases / / 17554300 rs1860867 chr7 51795300 G A 0.0000141 Antithrombin / / 23705025 rs10270760 chr7 51832226 T C 7.18E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs627093 chr7 51832566 A C 7.43E-05 Personality dimensions / / 18957941 rs7778886 chr7 51863287 A G 6.72E-05 Multiple complex diseases / / 17554300 rs2021874 chr7 51887749 G A 1.90E-05 Urinary metabolites / / 21572414 rs17134558 chr7 51893365 T A 8.98E-05 Multiple complex diseases / / 17554300 rs17134562 chr7 51894134 G A 1.02E-04 Smoking initiation / / 24665060 rs759003 chr7 51896824 C A 2.30E-05 Urinary metabolites / / 21572414 rs7778706 chr7 51909303 C G 2.10E-05 Urinary metabolites / / 21572414 rs7800313 chr7 51922013 G A 3.30E-06 Urinary metabolites / / 21572414 rs605705 chr7 51932604 C T 6.14E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17134622 chr7 51953424 T C 5.58E-04 Multiple complex diseases / / 17554300 rs7783471 chr7 51991339 G A 5.30E-05 Bone mineral density (BMD),in women / / 20164292 rs17152373 chr7 51999574 T C 9.50E-05 Personality dimensions / / 18957941 rs406001 chr7 52006415 T C 2.00E-08 Post-traumatic stress disorder (asjusted for relatedness) / / 23726511 rs406001 chr7 52006415 T C 2.77E-04 Post-traumatic stress disorder / / 23726511 rs406001 chr7 52006415 T C 3.00E-08 Post-traumatic stress disorder (asjusted for relatedness) / / 23726511 rs450378 chr7 52008734 C T 2.03E-04 Post-traumatic stress disorder / / 23726511 rs450378 chr7 52008734 C T 5.59E-04 Post-traumatic stress disorder / / 23726511 rs1382942 chr7 52013793 C G 4.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs6963466 chr7 52016050 C T 6.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs13223618 chr7 52016618 G T 6.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs11521104 chr7 52017424 A G 9.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs10488563 chr7 52020304 G C 8.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs1479690 chr7 52021647 A G 9.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs2081350 chr7 52029322 C A,G,T 8.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs17273415 chr7 52071790 G T 5.70E-07 Urinary metabolites / / 21572414 rs17273555 chr7 52073758 C A 6.20E-07 Urinary metabolites / / 21572414 rs4529415 chr7 52074322 A G 4.60E-07 Urinary metabolites / / 21572414 rs7804864 chr7 52078003 G C 6.80E-07 Urinary metabolites / / 21572414 rs10256394 chr7 52118989 T C 4.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs10256394 chr7 52118989 T C 4.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs10237629 chr7 52139899 A T 2.86E-04 Cognitive decline / / 23732972 rs11979834 chr7 52148307 G A 2.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs11979834 chr7 52148307 G A 5.48E-04 Suicide attempts in bipolar disorder / / 21041247 rs11979834 chr7 52148307 G A 9.99E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1986783 chr7 52158542 G A 1.45E-04 Cognitive decline / / 23732972 rs10277343 chr7 52162516 G T 1.79E-05 Longevity / / 21612516 rs4498494 chr7 52162885 A G 3.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs4473990 chr7 52163080 G A 3.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs2953422 chr7 52164120 G A 2.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs9690478 chr7 52166301 G C 2.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs9690478 chr7 52166301 G C 5.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs6965611 chr7 52167385 T G 2.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs7808716 chr7 52202071 G A 1.10E-05 Rheumatoid arthritis / / 22446963 rs10256183 chr7 52222322 G A 2.14E-05 Postoperative ventricular dysfunction / / 21980348 rs7793296 chr7 52246309 C A 7.30E-06 Urinary metabolites / / 21572414 rs7799235 chr7 52249779 T C 4.60E-06 Urinary metabolites / / 21572414 rs7802354 chr7 52261483 T G 5.67E-05 Psoriasis / / 18364390 rs11238186 chr7 52269884 A C 5.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs10250470 chr7 52270536 G A 5.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs6592988 chr7 52281433 T C 2.46E-05 Multiple complex diseases / / 17554300 rs6964146 chr7 52282461 C T 6.28E-05 Potassium levels / / pha003086 rs12718617 chr7 52287732 G A 3.70E-04 Type 2 diabetes / / 17463246 rs12718618 chr7 52292676 C G 3.29E-04 Type 2 diabetes / / 17463246 rs1115711 chr7 52312395 A G 2.55E-04 Type 2 diabetes / / 17463246 rs1115710 chr7 52312470 T C 3.83E-04 Type 2 diabetes / / 17463246 rs2464940 chr7 52318147 C T 4.99E-04 Type 2 diabetes / / 17463246 rs1120165 chr7 52319045 G A 6.17E-04 Type 2 diabetes / / 17463246 rs1125660 chr7 52319064 G C 4.31E-04 Type 2 diabetes / / 17463246 rs11973288 chr7 52339274 T C 2.50E-06 Urinary metabolites / / 21572414 rs996609 chr7 52460459 G C 7.63E-04 Multiple complex diseases / / 17554300 rs1012036 chr7 52472450 C T 5.00E-06 Emphysema-related traits / / 20709820 rs10266118 chr7 52520577 C T 2.57E-04 Alzheimer's disease / / 17998437 rs10266118 chr7 52520577 C T 2.46E-04 Alzheimer's disease / / pha002879 rs10254799 chr7 52530085 G A 5.60E-05 Alzheimer's disease / / 17998437 rs987490 chr7 52530263 T C 4.80E-04 Alzheimer's disease / / 17998437 rs7794935 chr7 52530601 G A 8.43E-04 Alzheimer's disease / / 17998437 rs12536967 chr7 52541831 G C 4.44E-04 Alzheimer's disease / / 17998437 rs1156298 chr7 52543602 G T 8.47E-04 Alzheimer's disease / / 17998437 rs17829881 chr7 52607774 A C 1.40E-05 Urinary metabolites / / 21572414 rs810833 chr7 52610334 C G 6.22E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs804747 chr7 52610470 G A 2.97E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs712013 chr7 52612271 G A 4.39E-05 Alcohol dependence / / 21703634 rs804753 chr7 52620633 T C 4.89E-05 Alcohol dependence / / 21703634 rs10259024 chr7 52624269 C G 6.69E-04 Type 2 diabetes / / 17463246 rs10259024 chr7 52624269 C G 5.65E-04 Alzheimer's disease / / 17998437 rs4947726 chr7 52664290 C A 5.05E-04 Multiple complex diseases / / 17554300 rs6957368 chr7 52664788 G A 6.50E-06 Urinary metabolites / / 21572414 rs10245005 chr7 52671177 T A 3.71E-04 Multiple complex diseases / / 17554300 rs1661638 chr7 52719712 T A 2.09E-07 Multiple complex diseases / / 17554300 rs6973042 chr7 52752010 A C 9.60E-05 HIV-1 control / / 20041166 rs1625358 chr7 52768518 T A 0.000706 Salmonella-induced pyroptosis / / 22837397 rs1528997 chr7 52790428 C T 4.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12532211 chr7 52794073 A G 3.14E-04 Multiple complex diseases / / 17554300 rs1230541 chr7 52794199 T A 9.69E-05 Type 2 diabetes / / 17463246 rs6977717 chr7 52804569 C T 2.00E-05 Urinary metabolites / / 21572414 rs10261201 chr7 52806232 A C 6.22E-04 Multiple complex diseases / / 17554300 rs10261201 chr7 52806232 A C 9.90E-06 Urinary metabolites / / 21572414 rs17135300 chr7 52831551 G A 8.43E-04 Multiple complex diseases / / 17554300 rs1528992 chr7 52842407 G A 1.10E-05 Urinary metabolites / / 21572414 rs2965505 chr7 52844295 G C 7.10E-06 Urinary metabolites / / 21572414 rs1528989 chr7 52859106 G A 8.60E-06 Urinary metabolites / / 21572414 rs2965532 chr7 52871539 A G 6.78E-04 Type 2 diabetes / / 17463246 rs2912911 chr7 52874174 G A 8.28E-04 Multiple complex diseases / / 17554300 rs11773612 chr7 52877992 G A 4.08E-05 Glucose levels / / pha003058 rs11773612 chr7 52877992 G A 2.49E-05 Glucose levels / / pha003061 rs2965545 chr7 52880570 C T 8.05E-04 Multiple complex diseases / / 17554300 rs2912953 chr7 52892494 A G 5.41E-05 Glucose levels / / pha003058 rs2912953 chr7 52892494 A G 2.84E-05 Glucose levels / / pha003061 rs2965590 chr7 52894247 T C 5.14E-05 Glucose levels / / pha003058 rs2965590 chr7 52894247 T C 2.77E-05 Glucose levels / / pha003061 rs2965606 chr7 52898154 T A 4.78E-06 Testicular cancer / / 19483682 rs1863786 chr7 52899187 T C 8.50E-04 Bladder cancer / / 21824976 rs4476958 chr7 52954110 G A 8.48E-05 Orofacial clefts / / 20023658 rs7800684 chr7 52957973 T C 5.98E-04 Alzheimer's disease / / 22005930 rs12540738 chr7 52971184 C T 2.30E-05 Urinary metabolites / / 21572414 rs12533066 chr7 52971408 A G 1.18E-05 Hypertension / / pha003041 rs11773742 chr7 52971553 C T 3.36E-05 Cognitive test performance / / 20125193 rs12718716 chr7 52972427 T C 2.20E-05 Urinary metabolites / / 21572414 rs10239546 chr7 52992974 G A 2.63E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4257963 chr7 52997182 C T 2.60E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs11769082 chr7 53006538 T C 5.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs11771058 chr7 53008596 T C 4.74E-04 Alzheimer's disease / / 24755620 rs1389272 chr7 53009002 A G 1.95E-04 Birth weight / / 17255346 rs1389272 chr7 53009002 A G 6.01E-04 Smoking initiation / / 24665060 rs1689299 chr7 53009877 T A 4.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs1919945 chr7 53011250 T C 1.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs1689304 chr7 53011628 A C 7.35E-05 Suicide attempts in bipolar disorder / / 21041247 rs1689306 chr7 53012272 A G 7.39E-05 Suicide attempts in bipolar disorder / / 21041247 rs7795100 chr7 53012513 C T 7.25E-04 Alzheimer's disease / / 24755620 rs1032428 chr7 53013671 C T 4.32E-05 AIDS progression / / 19115949 rs1032428 chr7 53013671 C T 3.68E-04 Alzheimer's disease / / 24755620 rs1358700 chr7 53040424 C T 5.05E-04 Acute lung injury / / 22295056 rs10236783 chr7 53041327 A C 5.05E-04 Acute lung injury / / 22295056 rs10236993 chr7 53041433 A T 5.93E-04 Acute lung injury / / 22295056 rs6943479 chr7 53045942 G C 6.05E-04 Acute lung injury / / 22295056 rs2330233 chr7 53048455 A G 6.05E-04 Acute lung injury / / 22295056 rs10273403 chr7 53055576 A G 5.44E-04 Acute lung injury / / 22295056 rs1689330 chr7 53102039 G C 8.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs4947776 chr7 53102259 A G 3.00E-06 Urinary metabolites / / 21572414 rs4947777 chr7 53102360 T G 8.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs13232128 chr7 53108190 A G 6.26E-05 Bipolar disorder / / 18317468 rs1174864 chr7 53127559 G A 5.00E-06 IgG glycosylation / / 23382691 rs1174863 chr7 53128263 T G 6.53E-05 Femoral neck bone geometry / / 22087292 rs1153883 chr7 53148897 T C 2.61E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1116031 chr7 53149133 A G 8.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10499716 chr7 53157460 C T 5.73E-05 Telomere length / / 21573004 rs10249125 chr7 53171595 G A 4.47E-04 Alzheimer's disease (late onset) / / 21379329 rs1830057 chr7 53190094 A T 4.45E-04 Multiple complex diseases / / 17554300 rs1980341 chr7 53259656 G A 8.97E-05 Smoking quantity / / 24665060 rs4257965 chr7 53295756 T A 6.41E-04 Smoking quantity / / 24665060 rs6971101 chr7 53311527 A G 3.00E-05 Personality dimensions / / 18957941 rs4947425 chr7 53321683 C G 6.57E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6946803 chr7 53326165 A G 9.93E-04 Parkinson's disease / / 17052657 rs7795810 chr7 53390930 C T 7.27E-04 Schizophrenia / / 19197363 rs3750141 chr7 53448643 T C 3.81E-04 White matter integrity / / 22425255 rs2877132 chr7 53455603 G A 3.52E-05 Cognitive decline / / 22054870 rs9642511 chr7 53456941 T G 2.89E-04 White matter integrity / / 22425255 rs10488321 chr7 53460686 C T 6.09E-04 Schizophrenia / / 19197363 rs12718791 chr7 53493705 G A 0.0004208 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12718791 chr7 53493705 G A 4.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17177762 chr7 53496499 A G 8.00E-05 Major depressive disorder (broad) / / 20038947 rs17692753 chr7 53537843 G A 4.97E-05 Major depressive disorder (broad) / / 20038947 rs2330522 chr7 53541479 G A 6.30E-05 Cognitive function / / 24684796 rs17620884 chr7 53552890 G A 7.33E-05 Major depressive disorder (broad) / / 20038947 rs7788902 chr7 53613284 C T 9.75E-04 Acute lung injury / / 22295056 rs12718797 chr7 53613811 G T 7.29E-05 Major depressive disorder (broad) / / 20038947 rs17695021 chr7 53615400 C A 5.13E-05 Cognitive decline / / 22054870 rs13231961 chr7 53620326 A G 8.34E-04 Acute lung injury / / 22295056 rs1030306 chr7 53639105 C T 8.46E-04 Schizophrenia / / 19197363 rs6962443 chr7 53686948 G A 0.0008645 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6962443 chr7 53686948 G A 8.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1155032 chr7 53712400 G C 3.84E-04 Multiple complex diseases / / 17554300 rs7785632 chr7 53712973 G T 6.29E-04 Alzheimer's disease / / 24755620 rs2193606 chr7 53713444 A C 6.10E-04 Alzheimer's disease / / 24755620 rs10236478 chr7 53725244 T C 4.88E-04 Alzheimer's disease FLJ45974 intron 24755620 rs10253516 chr7 53729573 T C 9.28E-04 Suicide attempts in bipolar disorder FLJ45974 intron 21423239 rs13229596 chr7 53772035 T C 8.08E-04 Suicide attempts in bipolar disorder FLJ45974 intron 21423239 rs13230883 chr7 53782155 C G,T 9.94E-04 Suicide attempts in bipolar disorder FLJ45974 intron 21423239 rs13235506 chr7 53785701 T G 5.92E-05 Longevity FLJ45974 intron 20304771 rs13235506 chr7 53785701 T G 2.21E-04 Suicide attempts in bipolar disorder FLJ45974 intron 21423239 rs12718817 chr7 53813283 C T 6.23E-05 Hemoglobin FLJ45974 intron pha003096 rs1264112 chr7 53834850 C T 8.61E-05 Hematocrit FLJ45974 intron pha003097 rs6966615 chr7 53836381 T C 7.76E-05 Hemoglobin FLJ45974 intron pha003096 rs6963388 chr7 53920963 G A 5.35E-06 Smooth-surface caries / / 24556642 rs1569247 chr7 53950851 T C 6.52E-06 Smooth-surface caries / / 24556642 rs12539883 chr7 53960934 C T 5.46E-06 Smooth-surface caries / / 24556642 rs17736906 chr7 53982626 A G 2.46E-06 Smooth-surface caries / / 24556642 rs4615525 chr7 53993722 T G 7.65E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1526780 chr7 53996432 C A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12668378 chr7 54009270 G A 3.39E-04 Aortic root size / / 21223598 rs6956800 chr7 54034670 T C 5.99E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs6956800 chr7 54034670 T C 8.24E-06 Smooth-surface caries / / 24556642 rs6971084 chr7 54034751 C T 8.43E-06 Smooth-surface caries / / 24556642 rs9918659 chr7 54039000 A G 3.82E-06 Asthma (childhood onset) / / 23829686 rs7785867 chr7 54044068 G A 2.88E-06 Smooth-surface caries / / 24556642 rs7789754 chr7 54048025 A G 9.86E-06 Smooth-surface caries / / 24556642 rs10227589 chr7 54163803 C T 1.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs10278778 chr7 54177399 T C 3.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs6593122 chr7 54181932 C T 4.00E-06 Vaccine-related adverse events / / 21396408 rs10225470 chr7 54188503 C T 1.61E-04 Alzheimer's disease (late onset) / / 20885792 rs1812433 chr7 54194609 A G 9.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs10224185 chr7 54208630 T C 4.43E-05 Duodenal ulcer / / 22387998 rs11238298 chr7 54219207 C T 1.91E-04 Multiple complex diseases / / 17554300 rs940464 chr7 54221539 T C 8.66E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1524405 chr7 54227617 G A 1.19E-08 Narcolepsy / / 19629137 rs7787286 chr7 54244766 G T 9.62E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6959808 chr7 54246057 G T 5.40E-04 Multiple complex diseases / / 17554300 rs17172318 chr7 54246537 A G 4.39E-05 Cognitive impairment induced by topiramate / / 22091778 rs7799840 chr7 54247600 C T 9.62E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4947877 chr7 54248330 C T 9.62E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1996991 chr7 54250014 C T 3.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2049407 chr7 54250626 G A 1.60E-04 Amyotrophic lateral sclerosis / / 23624525 rs4606013 chr7 54254629 G A 7.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4606013 chr7 54254629 G A 1.49E-04 Amyotrophic lateral sclerosis / / 23624525 rs4425715 chr7 54265587 G A 1.70E-05 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) / / 24325915 rs13437953 chr7 54313171 C A 9.69E-06 Obsessive-compulsive disorder / / 24821223 rs4245562 chr7 54403985 T C 9.00E-04 Chronic fatigue syndrome / / 21912186 rs10499740 chr7 54530581 T C 9.00E-04 Chronic fatigue syndrome / / 21912186 rs7776468 chr7 54534311 T C 6.65E-05 Cognitive test performance / / 20125193 rs5019857 chr7 54536350 T C 5.82E-05 Bipolar disorder / / 21771265 rs472724 chr7 54551310 T C 3.94E-05 Major depressive disorder / / 22472876 rs500456 chr7 54598782 A G 1.00E-06 Chronic kidney disease / / 22479191 rs2576507 chr7 54618943 A G 4.68E-05 Tuberculosis VSTM2A intron 24057671 rs6969762 chr7 54619599 C G 6.59E-04 Smoking cessation VSTM2A intron 24665060 rs964823 chr7 54621134 C A 2.61E-04 Smoking cessation VSTM2A intron 24665060 rs12533009 chr7 54646788 A G 2.60E-05 Information processing speed / / 21130836 rs679830 chr7 54674873 T C 6.00E-06 Obesity-related traits / / 23251661 rs1454517 chr7 54688844 T A 0.0001 Dyslexia / / 23190410 rs7806988 chr7 54703359 C T 5.23E-04 Parkinson's disease / / 17052657 rs41370345 chr7 54706286 C T 1.18E-04 Multiple complex diseases / / 17554300 rs17563093 chr7 54708056 A G 4.75E-04 Alcohol dependence / / 20201924 rs475048 chr7 54709473 T A 8.91E-04 Alcohol dependence / / 21314694 rs672644 chr7 54713309 T C 0.0000105 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs662865 chr7 54716920 A G 5.44E-05 Magnesium levels / / pha003092 rs568201 chr7 54717529 A G 4.15E-04 Acute lung injury / / 22295056 rs617308 chr7 54720184 A T 3.33E-04 Acute lung injury / / 22295056 rs616883 chr7 54720259 C A 3.33E-04 Acute lung injury / / 22295056 rs588571 chr7 54722020 A G 3.33E-04 Acute lung injury / / 22295056 rs504229 chr7 54727309 G T 1.82E-05 Cognitive performance / / 19734545 rs504229 chr7 54727309 G T 7.29E-05 Magnesium levels / / pha003092 rs17563596 chr7 54742309 A T 2.81E-04 Alzheimer's disease / / 17998437 rs10233228 chr7 54746604 A G 5.21E-04 Acute lung injury / / 22295056 rs1569256 chr7 54767639 C T 4.00E-06 Systemic lupus erythematosus / / 24871463 rs17649242 chr7 54779980 T C 2.60E-06 Urinary metabolites / / 21572414 rs6946131 chr7 54783373 T C 4.88E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs6946131 chr7 54783373 T C 2.00E-06 Systemic lupus erythematosus / / 24871463 rs2124018 chr7 54809935 T C 1.00E-05 Urinary metabolites / / 21572414 rs2709297 chr7 54834374 G A 4.60E-06 Urinary metabolites / / 21572414 rs2699239 chr7 54842549 C G 1.50E-05 Urinary metabolites / / 21572414 rs2709305 chr7 54845682 C T 1.20E-05 Urinary metabolites / / 21572414 rs4947941 chr7 54871175 T C 2.93E-04 Multiple complex diseases / / 17554300 rs12538089 chr7 54889414 T C 4.03E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9691864 chr7 54892071 G A 3.99E-05 Iron levels / / 19880490 rs9691864 chr7 54892071 G A 3.99E-05 Iron levels / / pha002876 rs4493865 chr7 54898402 A T 2.60E-04 Type 2 diabetes / / 17463249 rs4493865 chr7 54898402 A T 1.51E-04 Multiple complex diseases / / 17554300 rs10277377 chr7 54976715 C T 2.38E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs2252586 chr7 54978924 C T 8.00E-08 Glioma / / 21531791 rs11238340 chr7 55020736 T C 5.49E-04 Aortic root size / / 21223598 rs887809 chr7 55022654 G A 4.54E-04 Lung function (forced vital capacity) / / 24023788 rs11238344 chr7 55065119 A G 5.15E-04 Schizophrenia / / 19197363 rs712829 chr7 55086755 G T 1 Drug response to Gefitinib EGFR UTR-5 17375033 rs712829 chr7 55086755 G T 1 Drug response to Erlotinib EGFR UTR-5 18006781 rs712829 chr7 55086755 G T 1 Drug response to Erlotinib EGFR UTR-5 18652519 rs712829 chr7 55086755 G T 1 Drug response to Geldanamycin EGFR UTR-5 18652519 rs12538489 chr7 55099836 C T 4.60E-04 Smoking initiation EGFR intron 24665060 rs6956366 chr7 55101501 G C,T 2.80E-04 HDL particle features EGFR intron 21283740 rs1015793 chr7 55114316 A G 2.24E-04 Smoking initiation EGFR intron 24665060 rs17172430 chr7 55122650 G A 3.66E-04 Alzheimer's disease (late onset) EGFR intron 21379329 rs17172430 chr7 55122650 G A 1.94E-04 Smoking initiation EGFR intron 24665060 rs729969 chr7 55128207 A G 8.36E-08 Bipolar disorder EGFR intron 18317468 rs1344307 chr7 55137888 G A 3.00E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) EGFR intron 24023788 rs10488140 chr7 55138388 C T 1.02E-07 Bipolar disorder EGFR intron 18317468 rs17586365 chr7 55140786 G A 3.25E-04 Smoking initiation EGFR intron 24665060 rs17172438 chr7 55151537 T C 9.28E-07 Bipolar disorder EGFR intron 18317468 rs17172438 chr7 55151537 T C 7.35E-04 Smoking initiation EGFR intron 24665060 rs7785013 chr7 55152667 G A 4.08E-04 Smoking initiation EGFR intron 24665060 rs11979158 chr7 55159349 A G 7.00E-08 Glioma EGFR intron 21531791 rs4947491 chr7 55169291 A G 9.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) EGFR intron 23648065 rs2877260 chr7 55171629 A G 4.70E-05 Alcoholism (heaviness of drinking) EGFR intron 21529783 rs7803660 chr7 55174071 C G 0.00000197 Triglycerides EGFR intron 23063622 rs980653 chr7 55185890 C T 8.86E-04 Multiple complex diseases EGFR intron 17554300 rs9649847 chr7 55187138 G A 9.83E-05 HDL cholesterol EGFR intron pha003074 rs2072454 chr7 55214348 C T 8.80E-05 Diabetic retinopathy EGFR cds-synon 21441570 rs2072454 chr7 55214348 C T 2.00E-05 Prostate cancer EGFR cds-synon 21743057 rs2270247 chr7 55214647 G T 9.80E-05 Diabetic retinopathy EGFR intron 21441570 rs2270247 chr7 55214647 G T 2.00E-05 Prostate cancer EGFR intron 21743057 rs730437 chr7 55215018 A C 6.60E-05 Diabetic retinopathy EGFR intron 21441570 rs730437 chr7 55215018 A C 2.00E-05 Prostate cancer EGFR intron 21743057 rs2075109 chr7 55218903 T C 9.88E-05 Serum metabolites EGFR intron 19043545 rs2075110 chr7 55219159 C T 9.98E-05 Serum metabolites EGFR intron 19043545 rs138847501 chr7 55221725 G A 0.00023 Breast cancer EGFR missense 23555315 rs1558544 chr7 55228053 A T 4.11E-04 Alzheimer's disease EGFR intron 22005930 rs2227983 chr7 55229255 G A,C,T 1 Drug response to Erlotinib EGFR missense 18006781 rs7781264 chr7 55230840 A G 4.73E-04 Alzheimer's disease EGFR intron 22005930 rs10081281 chr7 55236796 C T 7.12E-04 Telomere length EGFR intron 23900074 rs845559 chr7 55247960 C T 6.76E-04 Cervical cancer EGFR intron 21716314 rs6593210 chr7 55254186 G A 2.06E-05 Height EGFR intron pha003011 rs6970262 chr7 55259763 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) EGFR intron 20708005 rs6593211 chr7 55277964 G A 6.06E-04 Type 2 diabetes / / 17846125 rs11761161 chr7 55281096 T C 2.83E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs883117 chr7 55307545 G A 7.35E-04 Multiple complex diseases / / 17554300 rs12718948 chr7 55307580 G A 9.77E-05 Brain lesion load / / 19010793 rs6593217 chr7 55340022 A G 9.00E-06 Serum metabolites / / 19043545 rs4948003 chr7 55354501 A T 7.47E-05 Serum metabolites / / 19043545 rs4948004 chr7 55354770 T C 8.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs4948004 chr7 55354770 T C 3.40E-06 Urinary metabolites / / 21572414 rs940812 chr7 55355448 T C 8.10E-05 Cognitive test performance / / 20125193 rs940883 chr7 55425140 C T 7.24E-04 Type 2 diabetes / / 17463246 rs10281500 chr7 55542890 C G 3.20E-21 Progranulin levels VOPP1 intron 21087763 rs10281500 chr7 55542890 C G 3.20E-21 Myocardial infarction VOPP1 intron 21211798 rs815953 chr7 55562631 G A 7.80E-04 Parkinson's disease VOPP1 intron 17052657 rs17565995 chr7 55604399 A C 1.31E-04 Multiple complex diseases VOPP1 intron 17554300 rs6948102 chr7 55654430 G A 1.73E-05 Cognitive test performance / / 20125193 rs4948041 chr7 55664717 A G 4.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10245396 chr7 55705566 A C 9.83E-04 Parkinson's disease / / 17052657 rs10245396 chr7 55705566 A C 2.90E-06 Urinary metabolites / / 21572414 rs10261624 chr7 55716356 G A 4.70E-06 Urinary metabolites / / 21572414 rs10251629 chr7 55716496 T C 1.20E-06 Urinary metabolites / / 21572414 rs9656709 chr7 55724445 A C 5.00E-06 Behavioural disinhibition (generation interaction) / / 23942779 rs10260354 chr7 55883818 T C 1.71E-08 Metabolite levels SEPT14 intron 23281178 rs11238381 chr7 55891901 C G 6.40E-06 Urinary metabolites SEPT14 intron 21572414 rs6978852 chr7 55899001 A G 1.96E-08 Metabolite levels SEPT14 intron 23281178 rs7779394 chr7 55901853 G A 1.79E-08 Metabolite levels SEPT14 intron 23281178 rs10230845 chr7 55905896 C T 3.37E-08 Metabolite levels SEPT14 intron 23281178 rs4294144 chr7 55912185 C T 4.47E-08 Metabolite levels SEPT14 intron 23281178 rs7790255 chr7 55969265 G A 2.38E-07 Lipid traits / / 21777205 rs15892 chr7 56022981 T C 9.42E-07 Lipid traits MRPS17 UTR-3 21777205 rs15892 chr7 56022981 T C 3.83E-18 Lymphocyte counts MRPS17 UTR-3 22286170 rs11238386 chr7 56033141 A C 5.96E-04 Response to alcohol consumption (flushing response) GBAS intron 24277619 rs4947534 chr7 56079094 T C 2.00E-14 Blood metabolite levels PSPH UTR-3 24816252 rs4948102 chr7 56097265 C G 1.00E-16 Plasma homocysteine levels (post-methionine load test) PSPH intron 24651765 rs7791221 chr7 56104688 G A 4.69E-05 Non-word repetition PSPH intron 23738518 rs6593296 chr7 56118293 C T 7.76E-06 Lipid traits PSPH intron 21777205 rs7806994 chr7 56139505 A T 6.00E-06 PR interval in Tripanosoma cruzi seropositivity SUMF2 intron 24324551 rs10248609 chr7 56262054 C T 4.60E-04 Alcohol dependence / / 20201924 rs698638 chr7 56265414 G A 7.60E-04 Lymphocyte counts / / 22286170 rs1357741 chr7 56291170 G A 3.40E-04 Alcohol dependence / / 20201924 rs1357741 chr7 56291170 G A 3.78E-04 Age-related macular degeneration / / 22125219 rs2877303 chr7 56319779 A G 1.72E-04 Type 2 diabetes / / 17463246 rs10267521 chr7 56580547 C T 8.19E-05 Cognitive test performance / / 20125193 rs17136508 chr7 56668499 T C 5.26E-05 Cognitive test performance / / 20125193 rs7799874 chr7 56711810 G A 2.21E-05 Cognitive test performance / / 20125193 rs13226574 chr7 56769818 A G 4.84E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12538805 chr7 56807732 A G 3.50E-06 Urinary metabolites / / 21572414 rs4481544 chr7 56823372 A G 6.70E-06 Urinary metabolites / / 21572414 rs10229556 chr7 56833052 A G 3.30E-06 Urinary metabolites / / 21572414 rs13240443 chr7 57208666 G A 2.68E-04 Coronary heart disease / / 21971053 rs10240751 chr7 57216012 A G 9.93E-04 Coronary heart disease / / 21971053 rs7777907 chr7 57256128 C T 3.38E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3887627 chr7 57279002 A C 2.73E-05 Alzheimer's disease / / 21098978 rs10281156 chr7 57338057 C A 6.98E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10281156 chr7 57338057 C A 3.93E-04 Taste perception / / 22132133 rs13240208 chr7 57354138 C T 1.00E-04 Prostate cancer / / 21743057 rs13228111 chr7 57366135 G A 1.00E-04 Prostate cancer / / 21743057 rs1916783 chr7 57366459 C A 1.00E-04 Prostate cancer / / 21743057 rs9649699 chr7 57377065 T C 2.51E-04 Bipolar disorder / / 18317468 rs7808342 chr7 57383753 A T 8.68E-06 Multiple complex diseases / / 17554300 rs17136173 chr7 57488801 G A 1.98E-05 Multiple complex diseases / / 17554300 rs10257462 chr7 57520410 T G 8.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZNF716 intron 20877124 rs11978684 chr7 57521365 A G 6.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZNF716 intron 20877124 rs11135654 chr7 57528311 G A 2.19E-05 Bipolar disorder and schizophrenia ZNF716 intron 20889312 rs4363145 chr7 57536959 C T 8.64E-05 Serum metabolites / / 19043545 rs10081282 chr7 57564932 G A 9.86E-04 Multiple complex diseases / / 17554300 rs10081282 chr7 57564932 G A 8.87E-05 Serum metabolites / / 19043545 rs4266595 chr7 57565524 C T 2.21E-05 Bipolar disorder and schizophrenia / / 20889312 rs4595080 chr7 57571771 A G 9.39E-05 Serum metabolites / / 19043545 rs11766519 chr7 57583856 T C 1.00E-07 Pulse pressure (alcohol consumption interaction) / / 24376456 rs4870622 chr7 57584913 A G 2.98E-05 Dental caries / / 21940522 rs13241368 chr7 57619922 C T 1.96E-05 Bipolar disorder and schizophrenia / / 20889312 rs10281732 chr7 57642390 T G 6.15E-06 Bipolar disorder and schizophrenia / / 20889312 rs4870675 chr7 57659267 T C 1.50E-05 Bipolar disorder and schizophrenia / / 20889312 rs4870684 chr7 57699151 C G,T 5.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs6955954 chr7 57830400 C A 2.22E-04 Multiple complex diseases / / 17554300 rs12666663 chr7 57839005 T C 8.76E-04 Multiple complex diseases / / 17554300 rs113837114 chr7 62005033 T G 3.89E-06 Blood pressure / / 21909110 rs117222503 chr7 62191737 A T 3.57E-05 Intracerebral hemorrhage / / 24656865 rs7293623 chr7 62386045 A G 2.88E-04 Alzheimer's disease / / 17998437 rs4379348 chr7 62453696 T C 9.53E-04 Alzheimer's disease / / 17998437 rs10237797 chr7 62467017 G T 9.71E-04 Alzheimer's disease / / 17998437 rs17137924 chr7 62483263 C A 7.97E-04 Alzheimer's disease / / 17998437 rs2969372 chr7 62496232 T A 4.91E-04 Alzheimer's disease / / 17998437 rs77865018 chr7 62497888 G A 4.18E-05 Intracerebral hemorrhage / / 24656865 rs77865018 chr7 62497888 G A 7.29E-06 Intracerebral hemorrhage / / 24656865 rs13247356 chr7 62535226 T C 2.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4628161 chr7 62535681 G A 9.32E-06 Intracerebral hemorrhage / / 24656865 rs17138457 chr7 62540790 A T 2.02E-05 Intracerebral hemorrhage / / 24656865 rs4718731 chr7 62546652 G T 0.0005028 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4718731 chr7 62546652 G T 5.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs75046180 chr7 62548420 T C 2.36E-05 Intracerebral hemorrhage / / 24656865 rs75046180 chr7 62548420 T C 6.97E-06 Intracerebral hemorrhage / / 24656865 rs113853629 chr7 62550364 G T 2.91E-05 Intracerebral hemorrhage / / 24656865 rs113853629 chr7 62550364 G T 4.88E-06 Intracerebral hemorrhage / / 24656865 rs112645808 chr7 62555084 C T 1.18E-05 Intracerebral hemorrhage / / 24656865 rs112645808 chr7 62555084 C T 4.92E-05 Intracerebral hemorrhage / / 24656865 rs17749368 chr7 62561484 T C 1.50E-05 LDL lipoproteins / / pha002902 rs1829737 chr7 62576000 G A 2.23E-04 Alzheimer's disease (late onset) / / 21379329 rs1829737 chr7 62576000 G A 9.01E-06 Obesity-related traits / / 23251661 rs6956675 chr7 62577770 A G 6.00E-06 Obesity-related traits / / 23251661 rs10231112 chr7 62601257 A G 9.05E-06 Obesity-related traits / / 23251661 rs1806453 chr7 62641533 C T 9.31E-05 Alzheimer's disease (late onset) / / 21379329 rs1806453 chr7 62641533 C T 8.45E-04 Alzheimer's disease / / 24755620 rs1879840 chr7 62653307 T C 7.76E-04 Alzheimer's disease / / 24755620 rs7783817 chr7 62671276 A G 2.60E-05 Urinary metabolites / / 21572414 rs11978034 chr7 62689447 C T 1.50E-05 Urinary metabolites / / 21572414 rs11978034 chr7 62689447 C T 7.28E-05 Body Fat Distribution / / pha003016 rs1990459 chr7 62698954 A C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1680923 chr7 63166234 G T 1.40E-05 Urinary metabolites / / 21572414 rs1313471 chr7 63266652 A G 7.60E-06 Urinary metabolites / / 21572414 rs1258685 chr7 63274846 A C 1.40E-05 Urinary metabolites / / 21572414 rs1680947 chr7 63277172 C A 1.70E-06 Urinary metabolites / / 21572414 rs1825257 chr7 63323866 A T 2.20E-05 Urinary metabolites / / 21572414 rs13437751 chr7 63346886 C T 9.00E-06 QT interval (interaction) / / 23459443 rs7808552 chr7 63428733 A G 9.28E-26 Gender / / 22362730 rs6974169 chr7 63537173 C T 8.97E-04 Myopia (pathological) ZNF727 intron 21095009 rs2164108 chr7 63565953 A C 3.71E-04 Myopia (pathological) / / 21095009 rs11770537 chr7 63573594 A G 3.71E-04 Myopia (pathological) / / 21095009 rs4717992 chr7 63581769 A G 3.71E-04 Myopia (pathological) / / 21095009 rs1897815 chr7 63662156 G A 6.31E-04 Coronary Artery Disease / / 17634449 rs11763256 chr7 63695082 C T 4.10E-04 Lung function (forced expiratory volume in 1 second) ZNF679 intron 17255346 rs10262403 chr7 63726230 T C 1.04E-04 Multiple complex diseases ZNF679 intron 17554300 rs1960321 chr7 63731284 T C 8.50E-06 Response to statin therapy / / 20339536 rs6972236 chr7 63732175 C T 8.30E-06 Response to statin therapy / / 20339536 rs10266483 chr7 63733331 A G 8.00E-06 Response to statin therapy / / 20339536 rs13221291 chr7 63739492 G A 3.00E-05 Response to statin therapy / / 20339536 rs683689 chr7 63742543 G C 7.00E-04 Type 2 diabetes / / 17463246 rs683689 chr7 63742543 G C 1.40E-05 Response to statin therapy / / 20339536 rs651934 chr7 63744350 C T 4.19E-04 Type 2 diabetes / / 17463246 rs651934 chr7 63744350 C T 1.30E-05 Response to statin therapy / / 20339536 rs687547 chr7 63744929 T C 1.30E-05 Response to statin therapy / / 20339536 rs624257 chr7 63745226 G A 1.30E-05 Response to statin therapy / / 20339536 rs683510 chr7 63749361 A C 1.70E-05 Response to statin therapy / / 20339536 rs679883 chr7 63750368 T C 2.28E-04 Type 2 diabetes / / 17463246 rs679883 chr7 63750368 T C 1.90E-05 Response to statin therapy / / 20339536 rs6960379 chr7 63750517 T C 6.58E-05 Nicotine smoking / / 19268276 rs667644 chr7 63750558 C A 2.00E-05 Response to statin therapy / / 20339536 rs1531556 chr7 63758739 G C 6.86E-04 Coronary Artery Disease / / 17634449 rs619102 chr7 63796171 C T 5.39E-04 Multiple complex diseases ZNF736 intron 17554300 rs11768537 chr7 63824042 G A 2.68E-04 Coronary Artery Disease / / 17634449 rs2199662 chr7 63836658 T G 6.24E-04 Coronary Artery Disease / / 17634449 rs2863321 chr7 63840770 T C 7.95E-04 Coronary Artery Disease / / 17634449 rs11768782 chr7 63966166 C T 3.81E-04 Premature ovarian failure / / 19508998 rs985668 chr7 64075993 C T 3.30E-05 Alzheimer's disease / / 17998437 rs1581570 chr7 64225274 T C 5.72E-04 Smoking quantity / / 24665060 rs7800678 chr7 64234032 G A 5.82E-04 Smoking quantity / / 24665060 rs4718112 chr7 64256482 C T 1.21E-05 Cognitive performance ZNF138 intron 19734545 rs6944297 chr7 64299645 G T 2.46E-25 Gender / / 22362730 rs10499782 chr7 64325909 A G 3.47E-04 Multiple complex diseases / / 17554300 rs10259713 chr7 64345822 T C 3.98E-04 Multiple complex diseases / / 17554300 rs10256006 chr7 64347622 G A 2.01E-04 Multiple complex diseases / / 17554300 rs13229816 chr7 64417052 T C 4.23E-04 Multiple complex diseases / / 17554300 rs4718173 chr7 64430406 G T 0.000407 Salmonella-induced pyroptosis / / 22837397 rs1060379 chr7 64435489 A T 2.08E-07 Lymphocyte counts ZNF117 UTR-3 22286170 rs1852015 chr7 64436980 A C 6.02E-05 Cognitive performance ZNF117 UTR-3 19734545 rs1608716 chr7 64443401 A G 0.000342 Salmonella-induced pyroptosis ZNF117 intron 22837397 rs10807685 chr7 64450556 T C 0.000556 Salmonella-induced pyroptosis ZNF117 UTR-5 22837397 rs2091224 chr7 64454022 G A 9.01E-05 Type 2 diabetes ERV3-1 intron 17463246 rs2091224 chr7 64454022 G A 5.47E-04 Multiple complex diseases ERV3-1 intron 17554300 rs1709470 chr7 64557394 G A 3.35E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs3857674 chr7 64729953 G A 3.87E-05 Serum metabolites / / 19043545 rs17139597 chr7 64731746 T G 9.61E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs6963801 chr7 64782426 T C 9.39E-05 Serum metabolites / / 19043545 rs12535182 chr7 64785827 A G 8.33E-04 Type 2 diabetes / / 17463246 rs6974876 chr7 64790768 A G 3.90E-04 Type 2 diabetes / / 17463246 rs17139526 chr7 64856957 G A 8.59E-04 Response to cytidine analogues (gemcitabine) ZNF92 intron 24483146 rs6979107 chr7 64870781 C T 7.39E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12668784 chr7 64876079 G A 5.93E-04 Type 2 diabetes / / 17463246 rs12668784 chr7 64876079 G A 4.16E-04 Multiple complex diseases / / 17554300 rs11771918 chr7 64901412 T C 5.61E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17783784 chr7 64901852 C T 5.61E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12154354 chr7 64903036 G A 3.61E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17146452 chr7 64904905 C A 1.26E-05 Psoriasis / / 20953187 rs2014614 chr7 64912835 C G 5.75E-04 Multiple complex diseases / / 17554300 rs10247230 chr7 64929281 C T 8.14E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11971971 chr7 65068631 T G 4.70E-04 Multiple complex diseases / / 17554300 rs4718278 chr7 65243596 C T 3.77E-05 Aortic root size / / 21223598 rs4717275 chr7 65265180 C T 1.82E-05 Aortic root size / / 21223598 rs17711722 chr7 65271197 C T 8.00E-09 Calcium levels / / 24068962 rs11763147 chr7 65326821 A G 3.80E-04 Aortic root size / / 21223598 rs11763147 chr7 65326821 A G 4.00E-09 Corneal structure / / 23291589 rs7791814 chr7 65365489 C T 8.18E-05 Aortic root size VKORC1L1 intron 21223598 rs4072879 chr7 65373851 A G 4.71E-04 Multiple complex diseases VKORC1L1 intron 17554300 rs3110902 chr7 65375102 A G 1.49E-04 Multiple complex diseases VKORC1L1 intron 17554300 rs6949812 chr7 65387101 G A 2.35E-05 Glucose levels VKORC1L1 intron pha003058 rs6949812 chr7 65387101 G A 6.91E-05 Glucose levels VKORC1L1 intron pha003061 rs7795242 chr7 65390094 T C 2.49E-05 Glucose levels VKORC1L1 intron pha003058 rs7795242 chr7 65390094 T C 7.17E-05 Glucose levels VKORC1L1 intron pha003061 rs4535605 chr7 65415425 C G 6.94E-04 Insulin resistance VKORC1L1 intron 21901158 rs1917563 chr7 65415647 A G 2.25E-04 Aortic root size VKORC1L1 intron 21223598 rs17138062 chr7 65427137 G C 3.27E-04 Aortic root size GUSB intron 21223598 rs1701760 chr7 65473688 A G 4.62E-05 Aortic root size / / 21223598 rs1701760 chr7 65473688 A G 1.60E-07 Corneal structure / / 23291589 rs420880 chr7 65509258 T C 8.38E-05 Aortic root size / / 21223598 rs6460270 chr7 65522783 C G 1.32E-04 Multiple complex diseases / / 17554300 rs160652 chr7 65538431 A G 5.40E-05 Glucose levels / / pha003058 rs1183245 chr7 65541185 C T 8.81E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ASL intron 20031582 rs313829 chr7 65552497 A G 5.44E-05 Psoriasis ASL intron 20953187 rs6946143 chr7 65579722 G T 1.97E-05 Aortic root size / / 21223598 rs383402 chr7 65586653 G T 1.12E-05 Lymphocyte counts CRCP intron 22286170 rs316328 chr7 65608838 T C 4.30E-05 Aortic root size CRCP intron 21223598 rs875971 chr7 65617595 T C 4.00E-06 Aortic root size CRCP UTR-3 21223598 rs1129531 chr7 65619104 G A 7.11E-05 Aortic root size CRCP UTR-3 21223598 rs10950029 chr7 65634321 T G 8.70E-04 Multiple complex diseases / / 17554300 rs10950029 chr7 65634321 T G 1.99E-05 Aortic root size / / 21223598 rs10256544 chr7 65675128 G A 6.19E-05 Aortic root size TPST1 intron 21223598 rs6944374 chr7 65686929 G C 1.08E-04 Aortic root size TPST1 intron 21223598 rs17138149 chr7 65693180 T C 4.85E-05 Aortic root size TPST1 intron 21223598 rs12537823 chr7 65720884 A G 1.10E-04 Aortic root size TPST1 intron 21223598 rs1909508 chr7 65766353 G T 8.48E-06 Aortic root size TPST1 intron 21223598 rs7794930 chr7 65778546 T G 3.50E-04 Aortic root size TPST1 intron 21223598 rs7783779 chr7 65796626 A G 2.14E-04 Aortic root size TPST1 intron 21223598 rs3757417 chr7 65825257 T G 6.23E-04 Amyotrophic lateral sclerosis (sporadic) TPST1 UTR-3 24529757 rs709597 chr7 65825983 C T 2.54E-04 Aortic root size / / 21223598 rs778720 chr7 65846275 C A 1.24E-04 Aortic root size LINC00174 intron 21223598 rs6947339 chr7 65888470 T C,G 5.47E-05 Aortic root size / / 21223598 rs3857685 chr7 65942882 T C 1.72E-04 Aortic root size / / 21223598 rs6460302 chr7 65960257 G C 7.12E-04 Aortic root size / / 21223598 rs3757419 chr7 66029429 C T 1.50E-05 Urinary metabolites / / 21572414 rs801193 chr7 66030612 T G 4.00E-06 Aortic root size / / 21223598 rs10249404 chr7 66046724 G A 4.87E-06 Aortic root size / / 21223598 rs6460307 chr7 66060871 G A 5.13E-05 Aortic root size / / 21223598 rs10258739 chr7 66062935 A T 2.50E-06 Aortic root size / / 21223598 rs1796226 chr7 66087710 T C 6.72E-04 Aortic root size / / 21223598 rs1638735 chr7 66095738 A G 2.63E-05 Aortic root size KCTD7 intron 21223598 rs10263935 chr7 66096028 G A 4.00E-07 Aortic root size KCTD7 intron 21223598 rs3764903 chr7 66098482 G A 3.90E-06 Corneal structure KCTD7 intron 23291589 rs2191268 chr7 66110224 A G 2.13E-05 Aortic root size / / 21223598 rs10244498 chr7 66116056 G A 7.61E-05 Aortic root size / / 21223598 rs10234018 chr7 66146284 A T 6.28E-05 Aortic root size / / 21223598 rs1882654 chr7 66146705 C A 6.89E-04 Aortic root size / / 21223598 rs2659915 chr7 66153101 A G 4.27E-06 Aortic root size / / 21223598 rs2659897 chr7 66187715 G A 6.58E-05 Aortic root size / / 21223598 rs2707856 chr7 66211010 T A 6.17E-06 Aortic root size RABGEF1 intron 21223598 rs10252765 chr7 66228732 G C 5.27E-06 Aortic root size RABGEF1 intron 21223598 rs17138012 chr7 66234585 A G 4.00E-04 Aortic root size RABGEF1 intron 21223598 rs10950050 chr7 66239588 T G 3.21E-04 Aortic root size RABGEF1 intron 21223598 rs1962050 chr7 66240008 A G 1.08E-04 Aortic root size RABGEF1 intron 21223598 rs10215516 chr7 66258080 G A 2.34E-05 Aortic root size RABGEF1 intron 21223598 rs2016325 chr7 66323500 T C 8.70E-07 Corneal structure / / 23291589 rs4718424 chr7 66376095 G A 1.50E-05 Corneal structure / / 23291589 rs12532805 chr7 66377234 C T 4.36E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12532805 chr7 66377234 C T 5.81E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10235423 chr7 66384315 G A 6.13E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12534188 chr7 66400120 T C 5.76E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines C7orf42 intron 21844884 rs3778916 chr7 66412246 C G 9.05E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines C7orf42 intron 21844884 rs4617036 chr7 66415609 C A 4.50E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines C7orf42 intron 21844884 rs3778914 chr7 66417683 C A 6.32E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines C7orf42 intron 21844884 rs4718428 chr7 66421446 T G 3.00E-10 Corneal structure C7orf42 UTR-3 23291589 rs17144722 chr7 66582164 T C 4.48E-04 Multiple complex diseases TYW1 intron 17554300 rs6974485 chr7 66614306 A T 2.94E-08 Lymphocyte counts TYW1 intron 22286170 rs7791642 chr7 66706398 A G 7.92E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs12698576 chr7 66823022 G A 1.33E-04 Lymphocyte counts / / 22286170 rs6948216 chr7 66904395 T C 2.75E-05 Body Fat Distribution / / pha003017 rs6460346 chr7 66907238 C T 2.75E-05 Body Fat Distribution / / pha003017 rs4618582 chr7 66908992 G A 2.75E-05 Body Fat Distribution / / pha003017 rs7810927 chr7 66945510 T C 3.56E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4718581 chr7 66952860 A G 3.53E-04 Type 2 diabetes / / 17463246 rs4718582 chr7 66954061 C T 2.25E-77 Multiple complex diseases / / 17554300 rs4718584 chr7 66954848 G A 6.34E-05 Serum metabolites / / 19043545 rs12666509 chr7 66956421 C A 4.35E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1015680 chr7 67031905 G A 1.00E-04 Information processing speed / / 21130836 rs758245 chr7 67035262 C T 1.90E-06 Urinary metabolites / / 21572414 rs4236215 chr7 67037628 G A 6.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10263639 chr7 67059267 T C 3.00E-06 Breast cancer / / 17903305 rs10263639 chr7 67059267 T C 3.00E-06 Nasopharyngeal carcinoma / / 20512145 rs10263639 chr7 67059267 T C 3.04E-05 Body Mass Index / / pha002896 rs1109786 chr7 67059296 G T 7.76E-05 Information processing speed / / 21130836 rs4717401 chr7 67077894 G T 9.45E-06 Body Mass Index / / pha002896 rs11772426 chr7 67088079 C T 1.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11979025 chr7 67098923 T C 4.61E-04 Multiple complex diseases / / 17554300 rs11974840 chr7 67098945 C A 6.49E-04 Multiple complex diseases / / 17554300 rs6946516 chr7 67099220 A T 4.11E-04 Multiple complex diseases / / 17554300 rs2864451 chr7 67117633 T C 2.40E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs887012 chr7 67125388 G C 4.33E-04 Aortic root size / / 21223598 rs970761 chr7 67125612 T C 1.04E-04 Aortic root size / / 21223598 rs12333519 chr7 67127889 C A 2.45E-04 Multiple complex diseases / / 17554300 rs2714610 chr7 67141247 G A 2.43E-04 Aortic root size / / 21223598 rs1024591 chr7 67146459 C T 4.19E-05 Schizophrenia / / 19571809 rs12698616 chr7 67165026 T C 2.98E-05 Schizophrenia / / 19571809 rs7807441 chr7 67188788 C T 3.00E-06 Menarche (age at onset) / / 23599027 rs10273223 chr7 67194578 G C 5.67E-05 Serum metabolites / / 19043545 rs12698621 chr7 67205472 C A 1.90E-05 Information processing speed / / 21130836 rs6947952 chr7 67242149 A G 9.26E-04 Type 2 diabetes / / 17463246 rs6947952 chr7 67242149 A G 0.0003513 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6947952 chr7 67242149 A G 3.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9638522 chr7 67247129 T C 0.0003538 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9638522 chr7 67247129 T C 3.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9638523 chr7 67247192 T C 0.0004779 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9638523 chr7 67247192 T C 4.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10807711 chr7 67247690 T C 9.70E-04 Type 2 diabetes / / 17463246 rs17652617 chr7 67249848 T C 9.26E-04 Type 2 diabetes / / 17463246 rs17652617 chr7 67249848 T C 0.0003555 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17652617 chr7 67249848 T C 3.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7795165 chr7 67253476 G C 9.36E-04 Type 2 diabetes / / 17463246 rs7795165 chr7 67253476 G C 0.0003992 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7795165 chr7 67253476 G C 3.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10499790 chr7 67255758 A C 0.0004007 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10499790 chr7 67255758 A C 4.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10279927 chr7 67261526 G A 4.97E-04 Type 2 diabetes / / 17463246 rs1564596 chr7 67262760 T C 0.0004087 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1564596 chr7 67262760 T C 4.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2865110 chr7 67269521 C T 9.26E-04 Type 2 diabetes / / 17463246 rs2865110 chr7 67269521 C T 0.0004308 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2865110 chr7 67269521 C T 4.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3943243 chr7 67288890 G A 2.85E-04 Multiple complex diseases / / 17554300 rs1032001 chr7 67311876 T A 0.0008382 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1032001 chr7 67311876 T A 8.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2865108 chr7 67326739 C A 7.09E-11 Gallstones / / 17632509 rs1600879 chr7 67352771 T C 2.00E-04 Information processing speed / / 21130836 rs12698626 chr7 67354119 C T 4.20E-05 Serum alpha1-antitrypsin levels / / 23990791 rs6971526 chr7 67361027 C T 2.74E-05 Serum alpha1-antitrypsin levels / / 23990791 rs12698637 chr7 67420743 A G 1.96E-04 Multiple complex diseases / / 17554300 rs6961611 chr7 67426323 T C 7.00E-06 Information processing speed / / 21130836 rs12673611 chr7 67434847 A G 1.10E-05 Urinary metabolites / / 21572414 rs17145009 chr7 67470740 C T 2.02E-04 Multiple complex diseases / / 17554300 rs6946096 chr7 67473550 C T 1.20E-05 Urinary metabolites / / 21572414 rs4431484 chr7 67496317 G A 3.96E-04 Alzheimer's disease / / 17998437 rs17145032 chr7 67498152 T G 9.77E-05 Multiple complex diseases / / 17554300 rs9638529 chr7 67584785 T C 2.20E-05 Urinary metabolites / / 21572414 rs2642123 chr7 67590433 A G 5.62E-05 Magnesium levels / / pha003092 rs77689838 chr7 67591039 C T 6.00E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs727845 chr7 67607209 A G 6.70E-04 Diabetic retinopathy / / 20871662 rs17642302 chr7 67612078 G A 2.62E-04 Taste perception / / 22132133 rs17715059 chr7 67612719 C T 1.33E-05 Taste perception / / 22132133 rs17145208 chr7 67668651 A C 3.92E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3108049 chr7 67742720 T C 1.57E-04 Breast cancer / / 21060860 rs3108069 chr7 67757263 A G 6.24E-05 Multiple complex diseases / / 17554300 rs1548218 chr7 67781270 C T 7.61E-04 Type 2 diabetes / / 17463246 rs1548218 chr7 67781270 C T 5.92E-04 Smoking initiation / / 24665060 rs3108090 chr7 67783656 T C 5.63E-04 Multiple complex diseases / / 17554300 rs1524865 chr7 67796007 G A 7.13E-04 Multiple complex diseases / / 17554300 rs3113073 chr7 67797680 C T 4.81E-04 Multiple complex diseases / / 17554300 rs3113079 chr7 67800393 C T 2.69E-04 Multiple complex diseases / / 17554300 rs1874243 chr7 67828081 G A 7.60E-04 Alcohol dependence / / 20201924 rs965540 chr7 67855610 G A 4.92E-04 Type 2 diabetes / / 17463246 rs11761035 chr7 67857423 C T 3.90E-05 Memory performance / / 22105620 rs73146440 chr7 67865802 A G 7.53E-06 Prostate cancer / / 24185611 rs17137443 chr7 67920764 A G 1.67E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7796950 chr7 67934228 A G 8.62E-04 Type 2 diabetes / / 17463246 rs11770239 chr7 68013164 G A 1.07E-04 Alzheimer's disease / / 24755620 rs7786924 chr7 68015015 A C 8.35E-04 Type 2 diabetes / / 17463246 rs7790867 chr7 68015028 T C 9.35E-05 ldl cholesterol / / pha003076 rs10226069 chr7 68025176 T A 9.69E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs10266640 chr7 68025239 C T 9.96E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs10282048 chr7 68025407 A G 7.88E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs10240115 chr7 68025960 G A 7.81E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs13236930 chr7 68026083 C G 7.00E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs11763670 chr7 68030927 G A 3.69E-04 Type 2 diabetes / / 17463246 rs11761388 chr7 68031033 T C 5.89E-05 Serum metabolites / / 19043545 rs4718785 chr7 68036455 T C 5.89E-05 Serum metabolites / / 19043545 rs4718786 chr7 68036715 A G 5.46E-05 Serum metabolites / / 19043545 rs10266534 chr7 68042746 G A 6.27E-04 Type 2 diabetes / / 17463246 rs10266534 chr7 68042746 G A 5.70E-05 Serum metabolites / / 19043545 rs1522499 chr7 68050119 A G 1.86E-04 Parkinson's disease / / 17052657 rs1403155 chr7 68050413 G A 3.78E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs1403155 chr7 68050413 G A 2.00E-08 Immune reponse to smallpox (secreted IL-2) / / 22610502 rs4535613 chr7 68083568 A G 3.41E-04 Insulin resistance / / 21901158 rs9791823 chr7 68084961 A G 5.53E-05 Suicide attempts in bipolar disorder / / 21423239 rs9791646 chr7 68085331 C T 4.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs4718795 chr7 68101280 C A 3.97E-04 Coronary heart disease / / 21606135 rs10280848 chr7 68104188 C T 3.99E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs12698712 chr7 68106789 A G 3.45E-04 Type 2 diabetes / / 17463246 rs12698712 chr7 68106789 A G 2.96E-04 Multiple complex diseases / / 17554300 rs12698712 chr7 68106789 A G 4.44E-04 Insulin resistance / / 21901158 rs7789613 chr7 68124949 G A 2.35E-04 Type 2 diabetes / / 17463246 rs11768279 chr7 68136274 G A 2.10E-05 Urinary metabolites / / 21572414 rs12531526 chr7 68156632 T G 1.59E-05 Socioeconomic Factors / / pha003067 rs6460466 chr7 68181976 G A 8.59E-04 Multiple complex diseases / / 17554300 rs6972020 chr7 68182022 A T 8.57E-04 Multiple complex diseases / / 17554300 rs6976492 chr7 68182148 T G 7.36E-04 Multiple complex diseases / / 17554300 rs6976520 chr7 68182205 T C 7.81E-04 Multiple complex diseases / / 17554300 rs6972513 chr7 68182289 A G 9.92E-04 Multiple complex diseases / / 17554300 rs10240244 chr7 68184132 C G 2.73E-04 Multiple complex diseases / / 17554300 rs4316055 chr7 68184434 A T 9.52E-04 Multiple complex diseases / / 17554300 rs4320430 chr7 68184758 G C 7.64E-04 Multiple complex diseases / / 17554300 rs4361657 chr7 68184833 C T 6.59E-04 Multiple complex diseases / / 17554300 rs11982155 chr7 68185001 G A 0.0001049 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11982155 chr7 68185001 G A 1.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6955848 chr7 68188319 G A 9.47E-04 Multiple complex diseases / / 17554300 rs1002606 chr7 68191264 T C 7.10E-04 Multiple complex diseases / / 17554300 rs6977542 chr7 68191806 C T 7.92E-04 Multiple complex diseases / / 17554300 rs12534964 chr7 68204103 G A 7.57E-05 Major depressive disorder / / 22472876 rs2711516 chr7 68243122 A G 9.28E-04 Multiple complex diseases / / 17554300 rs1859578 chr7 68254550 C T 2.15E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs2527635 chr7 68262726 C A 3.64E-04 Multiple complex diseases / / 17554300 rs9654886 chr7 68270995 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6460468 chr7 68287168 G A 8.59E-05 Serum metabolites / / 19043545 rs11977511 chr7 68349220 A T 2.88E-04 Multiple complex diseases / / 17554300 rs10499806 chr7 68431641 G A 4.94E-04 Depression (quantitative trait) / / 20800221 rs974468 chr7 68435475 T A 2.65E-04 Depression (quantitative trait) / / 20800221 rs2008127 chr7 68438751 T G 2.39E-04 Depression (quantitative trait) / / 20800221 rs1010779 chr7 68438954 T G 0.00000102 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2098183 chr7 68442130 T A 8.03E-04 Depression (quantitative trait) / / 20800221 rs4718837 chr7 68446151 A G 4.57E-04 Depression (quantitative trait) / / 20800221 rs1485695 chr7 68446862 C A 2.78E-04 Depression (quantitative trait) / / 20800221 rs2904243 chr7 68449516 A G 5.23E-04 Depression (quantitative trait) / / 20800221 rs12537001 chr7 68454743 C T 5.97E-04 Depression (quantitative trait) / / 20800221 rs10950161 chr7 68454882 A G 5.26E-04 Multiple complex diseases / / 17554300 rs1485694 chr7 68455493 C A 5.61E-04 Depression (quantitative trait) / / 20800221 rs1872492 chr7 68455892 C T 4.78E-05 Attention deficit hyperactivity disorder / / 22420046 rs10499807 chr7 68459734 C T 1.06E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10499807 chr7 68459734 C T 7.86E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs16868315 chr7 68462060 C T 1.94E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6973814 chr7 68470479 T C 2.74E-04 Prostate cancer mortality / / 20978177 rs2869738 chr7 68486634 A G 2.35E-05 Bipolar disorder,schizoaffective / / 19567891 rs1485709 chr7 68495804 T A 9.16E-04 Prostate cancer mortality / / 20978177 rs1385704 chr7 68497399 C T 9.16E-04 Prostate cancer mortality / / 20978177 rs767638 chr7 68514117 A G 1.77E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs767638 chr7 68514117 A G 1.01E-05 Socioeconomic Factors / / pha003066 rs1385706 chr7 68521944 C T 4.12E-05 Odorant perception / / 23910658 rs3113288 chr7 68532146 A G 1.15E-04 Bipolar disorder,schizoaffective / / 19567891 rs17683343 chr7 68535404 A G 4.28E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12534697 chr7 68539832 G C 2.37E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3113315 chr7 68561220 A G 4.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs3113316 chr7 68561321 A G 4.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs10215141 chr7 68564589 A G 6.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs12672651 chr7 68594277 A G 1.80E-06 Urinary metabolites / / 21572414 rs6947344 chr7 68607776 T C 2.14E-09 Male-pattern baldness / / 22693459 rs4718865 chr7 68610381 A G 1.81E-09 Male-pattern baldness / / 22693459 rs11526169 chr7 68610582 A G 1.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6945541 chr7 68611960 C T 2.00E-09 Male-pattern baldness / / 22693459 rs6965168 chr7 68611984 A G 2.41E-09 Male-pattern baldness / / 22693459 rs1916029 chr7 68612547 G T 2.46E-09 Male-pattern baldness / / 22693459 rs1195228 chr7 68615861 G A 9.92E-09 Male-pattern baldness / / 22693459 rs1718618 chr7 68632251 A G 2.53E-05 Lung adenocarcinoma / / 19836008 rs17683445 chr7 68664313 G T 4.99E-04 Type 2 diabetes / / 17463246 rs10499809 chr7 68666830 C T 5.90E-04 Type 2 diabetes / / 17463246 rs10499809 chr7 68666830 C T 4.00E-06 Urinary metabolites / / 21572414 rs17750977 chr7 68667162 C T 4.14E-04 Type 2 diabetes / / 17463246 rs17750977 chr7 68667162 C T 4.00E-06 Urinary metabolites / / 21572414 rs10265857 chr7 68667866 T C 7.65E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1195234 chr7 68684145 C T 1.50E-05 Urinary metabolites / / 21572414 rs7797307 chr7 68686127 G C 8.94E-08 Metabolite levels / / 23281178 rs12667374 chr7 68701972 G A 1.00E-05 F-cell distribution / / 17767159 rs12667374 chr7 68701972 G A 7.95E-06 Lung adenocarcinoma / / 19836008 rs12667374 chr7 68701972 G A 2.40E-05 Vitamin D concentrations / / 20600896 rs12667374 chr7 68701972 G A 2.40E-05 Vitamin D concentrations / / 20600896 rs10250140 chr7 68718752 T C 4.17E-06 Serum metabolites / / 19043545 rs10231898 chr7 68718888 C T 3.36E-05 Serum metabolites / / 19043545 rs1504274 chr7 68734969 G A 4.06E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs1879873 chr7 68738072 T C 1.33E-04 Multiple complex diseases / / 17554300 rs2938513 chr7 68826176 A G 5.42E-04 Insulin resistance / / 21901158 rs4718891 chr7 68907261 G C 7.13E-04 Type 2 diabetes / / 17463246 rs9791782 chr7 68916066 T C 1.60E-05 Urinary metabolites / / 21572414 rs10256311 chr7 69010087 A G 5.55E-04 Type 2 diabetes / / 22158537 rs17140663 chr7 69020039 C A 6.95E-04 Type 2 diabetes / / 22158537 rs10215282 chr7 69022383 G T 6.55E-04 Type 2 diabetes / / 22158537 rs11764821 chr7 69023499 G A 7.82E-04 Type 2 diabetes / / 22158537 rs6974900 chr7 69032990 A T 5.14E-04 Multiple complex diseases / / 17554300 rs10238487 chr7 69034409 C T 8.29E-04 Type 2 diabetes / / 22158537 rs7797529 chr7 69034883 G T 8.29E-04 Type 2 diabetes / / 22158537 rs11773581 chr7 69048337 G A 3.43E-04 Type 2 diabetes / / 22158537 rs10268221 chr7 69048690 A G 3.22E-04 Type 2 diabetes / / 22158537 rs10255613 chr7 69056369 G C 1.65E-04 Type 2 diabetes / / 22158537 rs17140693 chr7 69057208 G A 2.55E-04 Type 2 diabetes / / 22158537 rs10280018 chr7 69059915 C T 3.95E-04 Type 2 diabetes / / 22158537 rs3735260 chr7 69064637 A G 3.63E-04 Type 2 diabetes AUTS2 UTR-5 22158537 rs2851510 chr7 69080200 A G 1.50E-04 Multiple complex diseases AUTS2 intron 17554300 rs10256943 chr7 69084409 C G 1.64E-04 Type 2 diabetes AUTS2 intron 22158537 rs6977472 chr7 69088613 G C 9.68E-04 Type 2 diabetes AUTS2 intron 22158537 rs2851504 chr7 69113006 G T 6.29E-05 Multiple complex diseases AUTS2 intron 17554300 rs2851483 chr7 69128847 A G 1.57E-04 Multiple complex diseases AUTS2 intron 17554300 rs17140783 chr7 69135930 G A 8.60E-05 Body Mass Index AUTS2 intron pha003022 rs2851517 chr7 69141402 C T 8.63E-05 Multiple complex diseases AUTS2 intron 17554300 rs4305786 chr7 69142140 G A 9.07E-04 Type 2 diabetes AUTS2 intron 22158537 rs2851488 chr7 69146789 A T 1.51E-04 Multiple complex diseases AUTS2 intron 17554300 rs611052 chr7 69157267 C T 1.05E-04 Multiple complex diseases AUTS2 intron 17554300 rs576193 chr7 69157413 G A 1.41E-04 Multiple complex diseases AUTS2 intron 17554300 rs513150 chr7 69175653 G A 1.19E-04 Multiple complex diseases AUTS2 intron 17554300 rs10230750 chr7 69178418 C A 6.54E-05 Body Mass Index AUTS2 intron pha003022 rs595681 chr7 69190837 C T 1.20E-04 Multiple complex diseases AUTS2 intron 17554300 rs10241485 chr7 69207318 A G 8.62E-04 Nicotine smoking AUTS2 intron 19268276 rs7793984 chr7 69210523 G A 2.18E-04 Multiple complex diseases AUTS2 intron 17554300 rs210603 chr7 69236235 T C 6.65E-05 Multiple complex diseases AUTS2 intron 17554300 rs11765886 chr7 69238158 T C 4.00E-06 IgG glycosylation AUTS2 intron 23382691 rs11765886 chr7 69238158 T C 5.00E-06 IgG glycosylation AUTS2 intron 23382691 rs210599 chr7 69238399 C G 8.83E-05 Multiple complex diseases AUTS2 intron 17554300 rs10254086 chr7 69240484 A T 9.97E-04 Type 2 diabetes AUTS2 intron 22158537 rs10274099 chr7 69244795 A G 9.66E-04 Type 2 diabetes AUTS2 intron 22158537 rs11769738 chr7 69248220 A C 9.98E-04 Type 2 diabetes AUTS2 intron 22158537 rs10268729 chr7 69248860 A T 9.09E-04 Type 2 diabetes AUTS2 intron 22158537 rs763759 chr7 69291567 G A 1.46E-04 Multiple complex diseases AUTS2 intron 17554300 rs17140933 chr7 69291722 C T 2.50E-04 Multiple complex diseases AUTS2 intron 17554300 rs17458097 chr7 69292900 C T 4.86E-04 Multiple complex diseases AUTS2 intron 17554300 rs2865804 chr7 69300308 C T 8.34E-04 Type 2 diabetes AUTS2 intron 22158537 rs740946 chr7 69301613 G C 5.45E-04 Type 2 diabetes AUTS2 intron 22158537 rs1000874 chr7 69307703 A G 8.68E-04 Type 2 diabetes AUTS2 intron 22158537 rs2159679 chr7 69314965 T C 2.54E-04 Multiple complex diseases AUTS2 intron 17554300 rs10266126 chr7 69375390 G T 2.76E-05 Bipolar disorder AUTS2 intron 17486107 rs6979355 chr7 69384562 G A 6.51E-04 Multiple complex diseases AUTS2 intron 17554300 rs17141032 chr7 69403890 T C 7.05E-05 Body Mass Index AUTS2 intron pha003022 rs7785360 chr7 69409378 G A 8.75E-04 Multiple complex diseases AUTS2 intron 17554300 rs7785360 chr7 69409378 G A 9.73E-05 Hirschsprung's disease AUTS2 intron 19196962 rs12698820 chr7 69415279 A G 2.46E-04 Multiple complex diseases AUTS2 intron 17554300 rs12698828 chr7 69446594 C G 2.38E-04 Multiple complex diseases AUTS2 intron 17554300 rs12698832 chr7 69464184 G A 9.97E-05 Coronary heart disease AUTS2 intron pha003056 rs12667561 chr7 69510532 C G 5.11E-04 Multiple complex diseases AUTS2 intron 17554300 rs10487941 chr7 69522521 T C 8.09E-04 Bipolar disorder AUTS2 intron 19259986 rs917717 chr7 69523434 C T 2.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) AUTS2 intron 20877124 rs17365011 chr7 69528580 G A 4.05E-04 Multiple complex diseases AUTS2 intron 17554300 rs4557583 chr7 69601819 C G 7.30E-04 Prostate cancer mortality AUTS2 intron 20978177 rs10499812 chr7 69653990 A G 9.07E-04 Bipolar disorder AUTS2 intron 19259986 rs2866275 chr7 69713132 C T 2.80E-04 Acute lung injury AUTS2 intron 22295056 rs6975814 chr7 69732592 G A 8.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) AUTS2 intron 20877124 rs2866277 chr7 69759833 G A 6.38E-04 Bipolar disorder AUTS2 intron 19259986 rs12698891 chr7 69765505 A G 1.89E-04 Nicotine smoking AUTS2 intron 19268276 rs6460542 chr7 69775270 C T 5.54E-04 Bipolar disorder AUTS2 intron 19259986 rs10085696 chr7 69783020 A G 4.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) AUTS2 intron 20877124 rs6943555 chr7 69806023 T A 4.00E-08 Alcohol consumption AUTS2 intron 21471458 rs10486875 chr7 69819103 T A 8.91E-04 Bipolar disorder AUTS2 intron 19259986 rs12698902 chr7 69837319 A G 4.54E-05 Brain structure AUTS2 intron 22504417 rs12698903 chr7 69837848 G A 5.34E-04 Obesity (extreme) AUTS2 intron 21935397 rs10950200 chr7 69865264 T C 2.73E-04 Multiple complex diseases AUTS2 intron 17554300 rs11766624 chr7 69887085 A G 4.00E-07 Obesity-related traits AUTS2 intron 23251661 rs17141666 chr7 69928491 T A 4.90E-04 Type 2 diabetes AUTS2 intron 17463246 rs17141669 chr7 69928976 G T 4.86E-04 Type 2 diabetes AUTS2 intron 17463246 rs12670172 chr7 69935870 T C 0.0008448 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) AUTS2 intron 23233654 rs12670172 chr7 69935870 T C 8.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) AUTS2 intron 23233662 rs3094901 chr7 69937950 C T 5.17E-04 Type 2 diabetes AUTS2 intron 17463246 rs3094901 chr7 69937950 C T 8.30E-07 Urinary metabolites AUTS2 intron 21572414 rs10486873 chr7 69946964 G A 0.0008472 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) AUTS2 intron 23233654 rs10486873 chr7 69946964 G A 8.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) AUTS2 intron 23233662 rs11767893 chr7 69952187 C T 2.62E-04 Taste perception AUTS2 intron 22132133 rs17568303 chr7 69953910 C G 6.42E-04 Nicotine smoking AUTS2 intron 19268276 rs11760622 chr7 69954583 T C 3.00E-04 Response to antidepressants AUTS2 intron 19736353 rs3113282 chr7 69955610 C G 1.58E-04 Suicide attempts in bipolar disorder AUTS2 intron 21423239 rs3094895 chr7 69962688 G A 9.44E-04 Suicide attempts in bipolar disorder AUTS2 intron 21423239 rs10486872 chr7 69966192 G A 8.72E-05 Suicide attempts in bipolar disorder AUTS2 intron 21423239 rs3094893 chr7 69971020 T G 7.24E-05 Asthma AUTS2 intron 23181788 rs6978484 chr7 69979340 G A 7.57E-05 Type 2 diabetes AUTS2 intron 17463246 rs3094906 chr7 69980024 A G 4.04E-04 Suicide attempts in bipolar disorder AUTS2 intron 21423239 rs3094904 chr7 69990591 T C 1.84E-04 Suicide attempts in bipolar disorder AUTS2 intron 21423239 rs11977788 chr7 69992098 G A 1.00E-05 Urinary metabolites AUTS2 intron 21572414 rs4718958 chr7 70013591 G A 8.41E-05 Cognitive test performance AUTS2 intron 20125193 rs6967298 chr7 70014509 G A 4.57E-04 Alzheimer's disease (late onset) AUTS2 intron 21379329 rs10237317 chr7 70045941 A G 5.00E-06 Bipolar disorder AUTS2 intron 22925353 rs38324 chr7 70050621 C T 2.40E-04 Type 2 diabetes AUTS2 intron 17463246 rs10263367 chr7 70082089 C G 2.94E-04 Type 2 diabetes AUTS2 intron 17463246 rs11772435 chr7 70085409 C G 3.39E-04 Type 2 diabetes AUTS2 intron 17463246 rs7459368 chr7 70088696 A G 3.81E-04 Type 2 diabetes AUTS2 intron 17463246 rs17578487 chr7 70088909 A C 7.00E-04 Type 2 diabetes AUTS2 intron 17463246 rs17141908 chr7 70095460 A T 6.24E-04 Type 2 diabetes AUTS2 intron 17463246 rs7809475 chr7 70100347 A G 4.16E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) AUTS2 intron 17982456 rs2107942 chr7 70131823 T C 6.17E-04 Alcohol dependence AUTS2 intron 21314694 rs6966098 chr7 70135361 A T 8.84E-04 Type 2 diabetes AUTS2 intron 17463246 rs10257489 chr7 70137117 A G 5.62E-04 Nicotine smoking AUTS2 intron 19268276 rs7793102 chr7 70148676 C T 1.95E-05 Smoking cessation AUTS2 intron 18519826 rs6946693 chr7 70153068 G T 8.56E-04 Suicide attempts in bipolar disorder AUTS2 intron 21041247 rs6946693 chr7 70153068 G T 8.84E-04 Suicide attempts in bipolar disorder AUTS2 intron 21041247 rs11768039 chr7 70161221 T G 2.70E-04 Major depressive disorder AUTS2 intron 21042317 rs4075496 chr7 70169449 G A 8.00E-06 Urinary metabolites AUTS2 intron 21572414 rs10279132 chr7 70186936 T G 2.19E-06 Depression (quantitative trait) AUTS2 intron 23290196 rs10265371 chr7 70188375 C T 2.07E-04 Smoking cessation AUTS2 intron 18519826 rs10270627 chr7 70201815 G T 8.55E-04 Suicide attempts in bipolar disorder AUTS2 intron 21041247 rs7777347 chr7 70205048 G A 6.99E-04 Suicide attempts in bipolar disorder AUTS2 intron 21041247 rs10950213 chr7 70205453 C G 6.05E-04 Alzheimer's disease AUTS2 intron 24755620 rs4718991 chr7 70206133 G C 1.09E-04 Smoking cessation AUTS2 intron 18519826 rs4718991 chr7 70206133 G C 6.26E-04 Suicide attempts in bipolar disorder AUTS2 intron 21041247 rs7806434 chr7 70208933 G A 6.10E-04 Suicide attempts in bipolar disorder AUTS2 intron 21041247 rs6942467 chr7 70209816 C T 1.20E-05 Urinary metabolites AUTS2 intron 21572414 rs6460553 chr7 70215224 G T 6.70E-06 Urinary metabolites AUTS2 intron 21572414 rs6957385 chr7 70216429 A G 2.75E-07 Smoking cessation AUTS2 intron 18519826 rs1569079 chr7 70224743 C G 9.16E-04 Multiple complex diseases AUTS2 intron 17554300 rs9886351 chr7 70248469 A G 1.00E-04 Cognitive impairment induced by topiramate AUTS2 intron 22091778 rs9886351 chr7 70248469 A G 3.08E-04 Lung function (forced vital capacity) AUTS2 intron 24023788 rs2293501 chr7 70251923 G A 0.0000429 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity AUTS2 intron 22945461 rs941346 chr7 70254674 G T 0.00004994 Sarcoidosis AUTS2 intron 22952805 rs10257067 chr7 70281461 C T 8.25E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs13243605 chr7 70316564 C T 1.12E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2866834 chr7 70329434 G A 1.43E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10248926 chr7 70357329 G A 9.43E-05 Heart Rate / / pha003053 rs10277450 chr7 70363783 G T 7.54E-05 Heart Rate / / pha003053 rs7808758 chr7 70370469 T C 6.15E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4717562 chr7 70381922 C T 3.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1568866 chr7 70416214 A G 1.90E-05 Urinary metabolites / / 21572414 rs6460606 chr7 70434599 C G 1.33E-24 Narcolepsy / / 19629137 rs10269258 chr7 70440091 T C 1.60E-05 Urinary metabolites / / 21572414 rs1525288 chr7 70446316 T A 4.96E-04 Multiple complex diseases / / 17554300 rs1949857 chr7 70471892 C T 2.69E-04 Multiple complex diseases / / 17554300 rs1949857 chr7 70471892 C T 1.62E-05 F-cell distribution / / 21326311 rs1525293 chr7 70473005 C T 2.00E-06 Major depressive disorder / / 23377640 rs13227328 chr7 70500643 C T 2.90E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7776533 chr7 70511332 G T 3.77E-04 Multiple complex diseases / / 17554300 rs12538806 chr7 70562841 G A 0.000147 Gains in maximal O2 uptake response / / 21183627 rs13235325 chr7 70565007 T C 0.000147 Gains in maximal O2 uptake response / / 21183627 rs757839 chr7 70575268 C A 7.56E-06 Orofacial clefts / / 20023658 rs11762323 chr7 70601166 C T 1.50E-05 Personality dimensions WBSCR17 intron 18957941 rs10261209 chr7 70631020 G A 9.08E-04 Multiple complex diseases WBSCR17 intron 17554300 rs11772787 chr7 70719222 A G 6.40E-05 Alzheimer's disease WBSCR17 intron 17998437 rs11772787 chr7 70719222 A G 1.56E-05 Alzheimer's disease WBSCR17 intron pha002879 rs12673515 chr7 70740678 G A 4.31E-04 Lung function (forced expiratory volume in 1 second) WBSCR17 intron 17255346 rs1202640 chr7 70743033 G T 2.61E-04 Multiple complex diseases WBSCR17 intron 17554300 rs12699007 chr7 70751225 A G 5.72E-04 Insulin resistance WBSCR17 intron 21901158 rs1922526 chr7 70766943 A G 5.00E-04 Acute lymphoblastic leukemia (childhood) WBSCR17 intron 20189245 rs16869429 chr7 70811708 G A 3.20E-05 Multiple sclerosis (brain glutamate levels) WBSCR17 intron 20802204 rs2960883 chr7 70867166 A G 4.08E-04 Depression (quantitative trait) WBSCR17 intron 20800221 rs4585627 chr7 70904561 T C 3.42E-05 Systemic sclerosis WBSCR17 intron 21750679 rs12155355 chr7 70913398 T C 5.84E-04 Alzheimer's disease WBSCR17 intron 22005930 rs7794574 chr7 70915822 G A 4.97E-04 Alzheimer's disease WBSCR17 intron 22005930 rs11971260 chr7 70916208 A G 2.92E-04 Depression (quantitative trait) WBSCR17 intron 20800221 rs11974441 chr7 70916290 G A 7.43E-04 Depression (quantitative trait) WBSCR17 intron 20800221 rs4392778 chr7 70957750 C T 1.34E-04 Multiple complex diseases WBSCR17 intron 17554300 rs11977703 chr7 70960437 G A 5.98E-04 Depression (quantitative trait) WBSCR17 intron 20800221 rs4129606 chr7 70960893 A G 1.37E-08 Pure-tone audiometry WBSCR17 intron pha001966 rs6970463 chr7 70965242 C T 5.62E-04 Depression (quantitative trait) WBSCR17 intron 20800221 rs12699040 chr7 70967648 A G 9.81E-05 Serum metabolites WBSCR17 intron 19043545 rs4717599 chr7 70970026 G A 6.60E-05 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) WBSCR17 intron 24325915 rs4719136 chr7 70993604 C T 1.00E-04 Cognitive impairment induced by topiramate WBSCR17 intron 22091778 rs10259994 chr7 71001944 C T 2.17E-04 Suicide attempts in bipolar disorder WBSCR17 intron 21423239 rs4719141 chr7 71003462 A G 5.98E-04 Alzheimer's disease WBSCR17 intron 17998437 rs4719143 chr7 71005936 A G 2.52E-04 Suicide attempts in bipolar disorder WBSCR17 intron 21423239 rs6460666 chr7 71006669 C T 2.31E-04 Suicide attempts in bipolar disorder WBSCR17 intron 21423239 rs6969457 chr7 71007228 A G 5.99E-04 Suicide attempts in bipolar disorder WBSCR17 intron 21423239 rs4128374 chr7 71010135 C T 3.83E-04 Suicide attempts in bipolar disorder WBSCR17 intron 21423239 rs6460669 chr7 71011470 G A 5.30E-04 Suicide attempts in bipolar disorder WBSCR17 intron 21423239 rs4719147 chr7 71016159 T G 2.00E-06 Response to angiotensin II receptor blocker therapy WBSCR17 intron 22566498 rs6460672 chr7 71021037 G A 7.88E-04 Suicide attempts in bipolar disorder WBSCR17 intron 21423239 rs7806531 chr7 71023877 C T 6.69E-04 Amyotrophic Lateral Sclerosis WBSCR17 intron 17362836 rs7806531 chr7 71023877 C T 2.64E-04 Alzheimer's disease WBSCR17 intron 17998437 rs10950267 chr7 71043615 C T 5.15E-06 Post-operative nausea and vomiting WBSCR17 intron 21694509 rs12536756 chr7 71052523 T C 2.22E-05 Post-operative nausea and vomiting WBSCR17 intron 21694509 rs9638627 chr7 71055111 G A 5.56E-04 Response to taxane treatment (placlitaxel) WBSCR17 intron 23006423 rs6970080 chr7 71076106 G A 7.20E-04 Multiple complex diseases WBSCR17 intron 17554300 rs10807735 chr7 71080398 A G 8.07E-04 Response to taxane treatment (placlitaxel) WBSCR17 intron 23006423 rs3857700 chr7 71088735 G A 4.55E-04 Response to taxane treatment (placlitaxel) WBSCR17 intron 23006423 rs12699060 chr7 71093257 A G 8.26E-04 Response to taxane treatment (placlitaxel) WBSCR17 intron 23006423 rs4719155 chr7 71107224 A G 8.93E-04 Acute lung injury WBSCR17 intron 22295056 rs10281339 chr7 71109213 A C 7.30E-04 Acute lung injury WBSCR17 intron 22295056 rs6949744 chr7 71110031 T C 7.30E-04 Acute lung injury WBSCR17 intron 22295056 rs10243782 chr7 71110900 G T 4.02E-05 Heart Rate WBSCR17 intron pha003054 rs3973922 chr7 71112510 A C 7.22E-04 Acute lung injury WBSCR17 intron 22295056 rs2056647 chr7 71114444 T C 6.76E-06 Post-operative nausea and vomiting WBSCR17 intron 21694509 rs4719162 chr7 71126690 C A 9.84E-05 Post-operative nausea and vomiting WBSCR17 intron 21694509 rs641979 chr7 71141133 A G 7.48E-04 Multiple complex diseases WBSCR17 intron 17554300 rs10275110 chr7 71165833 C T 0.0003348 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WBSCR17 intron 23233654 rs10275110 chr7 71165833 C T 3.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) WBSCR17 intron 23233662 rs10950275 chr7 71167363 G A 4.36E-04 Type 2 diabetes WBSCR17 intron 17463246 rs2079969 chr7 71175631 G A 0.000628 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WBSCR17 intron 23233654 rs2079969 chr7 71175631 G A 6.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) WBSCR17 intron 23233662 rs11763519 chr7 71183404 A G 1.00E-04 Information processing speed / / 21130836 rs620269 chr7 71185237 G A 1.28E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs17143904 chr7 71187779 G A 0.0001323 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17143904 chr7 71187779 G A 1.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs678798 chr7 71189112 A G 5.75E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1203457 chr7 71199130 C T 9.22E-04 Multiple complex diseases / / 17554300 rs11773665 chr7 71230939 G A 9.09E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17423790 chr7 71273602 C T 3.24E-04 Response to cytadine analogues (cytosine arabinoside) CALN1 intron 24483146 rs7777622 chr7 71297516 T C 0.0001666 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CALN1 intron 23233654 rs7777622 chr7 71297516 T C 1.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) CALN1 intron 23233662 rs9638636 chr7 71299787 T A 0.0001631 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CALN1 intron 23233654 rs9638636 chr7 71299787 T A 1.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) CALN1 intron 23233662 rs2867517 chr7 71301495 T C 0.0001632 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CALN1 intron 23233654 rs2867517 chr7 71301495 T C 1.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) CALN1 intron 23233662 rs10226380 chr7 71302421 G A 0.0001643 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CALN1 intron 23233654 rs10226380 chr7 71302421 G A 1.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) CALN1 intron 23233662 rs12673420 chr7 71303007 A G 0.0001637 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CALN1 intron 23233654 rs12673420 chr7 71303007 A G 1.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) CALN1 intron 23233662 rs7794787 chr7 71304749 C T 0.0001695 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CALN1 intron 23233654 rs7794787 chr7 71304749 C T 1.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) CALN1 intron 23233662 rs11763757 chr7 71327836 C T 6.04E-04 HIV-1 viral setpoint CALN1 intron 17641165 rs7349979 chr7 71336068 A G 3.31E-04 HIV-1 viral setpoint CALN1 intron 17641165 rs17340639 chr7 71338530 G A 9.82E-04 HIV-1 viral setpoint CALN1 intron 17641165 rs11766496 chr7 71388850 G C 2.00E-06 Airflow obstruction CALN1 intron 22837378 rs7808924 chr7 71408814 T C 7.27E-04 Type 2 diabetes CALN1 intron 17463246 rs974134 chr7 71411789 C T 9.39E-04 Type 2 diabetes CALN1 intron 17463246 rs974134 chr7 71411789 C T 0.000404827 Hypertension (early onset hypertension) CALN1 intron 22479346 rs10215280 chr7 71414116 A C 9.07E-04 Type 2 diabetes CALN1 intron 17463246 rs1099451 chr7 71470001 C A 1.86E-04 Sarcoidosis CALN1 intron 19165924 rs844731 chr7 71474962 T C 7.41E-04 Amyotrophic Lateral Sclerosis CALN1 intron 17362836 rs844669 chr7 71504260 C A 1.99E-04 Amyotrophic Lateral Sclerosis CALN1 intron 17362836 rs844771 chr7 71512988 A G 3.49E-04 Amyotrophic Lateral Sclerosis CALN1 intron 17362836 rs12699121 chr7 71546947 A G 1.45E-04 Amyotrophic Lateral Sclerosis CALN1 intron 17362836 rs7798356 chr7 71578708 A G 3.95E-04 Amyotrophic Lateral Sclerosis CALN1 intron 17362836 rs2158562 chr7 71585126 C G 6.81E-05 Serum metabolites CALN1 intron 19043545 rs17673882 chr7 71654175 A C 1.33E-04 Response to taxane treatment (placlitaxel) CALN1 intron 23006423 rs4719220 chr7 71680703 G A 2.00E-04 Information processing speed CALN1 intron 21130836 rs4719220 chr7 71680703 G A 4.00E-06 Amyotrophic lateral sclerosis (sporadic) CALN1 intron 24529757 rs10236173 chr7 71693628 C T 6.81E-05 Serum metabolites CALN1 intron 19043545 rs11768892 chr7 71700452 T C 7.72E-05 Serum metabolites CALN1 intron 19043545 rs558800 chr7 71706790 A G 1.16E-04 Multiple complex diseases CALN1 intron 17554300 rs17503630 chr7 71711605 C T 5.23E-05 Multiple complex diseases CALN1 intron 17554300 rs6460708 chr7 71712135 C T 6.02E-04 Coronary Artery Disease CALN1 intron 17634449 rs12699130 chr7 71723211 A G 8.67E-04 Coronary Artery Disease CALN1 intron 17634449 rs17582005 chr7 71723377 A T 8.73E-04 Coronary Artery Disease CALN1 intron 17634449 rs10486883 chr7 71726874 C T 7.35E-04 Coronary Artery Disease CALN1 intron 17634449 rs4719222 chr7 71751116 G A 7.15E-05 Serum metabolites CALN1 intron 19043545 rs12699131 chr7 71751316 A G 2.00E-06 Schizophrenia CALN1 intron 21926974 rs2944825 chr7 71793386 T C 3.87E-04 Coronary Artery Disease CALN1 intron 17634449 rs10274751 chr7 71808745 T C 1.90E-05 Urinary metabolites CALN1 intron 21572414 rs10274751 chr7 71808745 T C 3.88E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CALN1 intron 24023788 rs11764286 chr7 71815170 T G 2.20E-05 Hypothyroidism CALN1 intron 22493691 rs10241386 chr7 71815307 T A 1.51E-05 Serum metabolites CALN1 intron 19043545 rs9638655 chr7 71837301 A G 7.00E-06 Uric acid levels CALN1 intron 21294900 rs2968538 chr7 71838207 G A 4.58E-05 Parkinson's disease CALN1 intron 21738487 rs1574549 chr7 71847345 T C 8.07E-04 Amyotrophic Lateral Sclerosis CALN1 intron 17362836 rs7778289 chr7 71851601 G A 7.65E-05 Serum metabolites CALN1 intron 19043545 rs4415209 chr7 71858547 G A 5.59E-04 Multiple complex diseases CALN1 intron 17554300 rs7784524 chr7 71860739 A G 3.87E-04 Multiple complex diseases CALN1 intron 17554300 rs7784524 chr7 71860739 A G 1.50E-05 Urinary metabolites CALN1 intron 21572414 rs6460722 chr7 71870676 G A 5.41E-04 Multiple complex diseases CALN1 intron 17554300 rs4615448 chr7 71871272 A G 6.09E-05 Serum metabolites CALN1 intron 19043545 rs993932 chr7 71888561 T C 6.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7809631 chr7 71908651 G T 8.50E-04 Nicotine smoking / / 19268276 rs2909967 chr7 71982441 C G 1.65E-04 Type 2 diabetes / / 17463246 rs2909969 chr7 71982924 G A 1.60E-10 Breast cancer (Postmenopausal women) / / 23423446 rs13234390 chr7 72096690 T C 9.63E-05 Stroke TYW1B intron pha002886 rs13238203 chr7 72129667 C T 1.00E-09 Triglycerides TYW1B intron 20686565 rs13238203 chr7 72129667 C T 3.00E-06 Triglycerides TYW1B intron 24097068 rs6460030 chr7 72207443 A G 7.15E-05 Serum metabolites TYW1B intron 19043545 rs4392770 chr7 72213451 C T 3.07E-05 Serum metabolites TYW1B intron 19043545 rs13224992 chr7 72217130 T C 9.66E-04 Multiple complex diseases TYW1B intron 17554300 rs13224992 chr7 72217130 T C 8.80E-06 Serum metabolites TYW1B intron 19043545 rs6460033 chr7 72263918 C A 2.04E-07 Parkinson's disease TYW1B intron 17052657 rs6957619 chr7 72268294 C T 1.35E-05 Serum metabolites TYW1B intron 19043545 rs2058059 chr7 72311817 T C 7.00E-06 Subcutaneous adipose tissue / / 22589738 rs6943090 chr7 72746648 C T 3.00E-07 Immune reponse to smallpox (secreted IL-12p40) FKBP6 intron 22610502 rs12539763 chr7 72762429 C T 7.13E-04 Type 2 diabetes FKBP6 intron 17463246 rs12534600 chr7 72762721 A G 4.57E-04 Type 2 diabetes FKBP6 intron 17463246 rs4717756 chr7 72765458 C G 3.62E-04 Type 2 diabetes FKBP6 intron 17463246 rs117382431 chr7 72801053 C T 0.0000217 Menopause (age at onset) / / 23424626 rs4717763 chr7 72825125 A G 0.00044 Breast cancer / / 23555315 rs1178947 chr7 72850178 T C 1.18E-11 Metabolite levels FZD9 UTR-3 22286219 rs2240466 chr7 72856269 G A 1.00E-12 Triglycerides BAZ1B intron 19060911 rs2240466 chr7 72856269 G A 3.29E-08 Lipid levels BAZ1B intron 19936222 rs2240466 chr7 72856269 G A 1.00E-06 Caffeine consumption BAZ1B intron 21490707 rs2240466 chr7 72856269 G A 9.96E-12 Metabolite levels BAZ1B intron 22286219 rs2240466 chr7 72856269 G A 2.98E-09 Urate levels BAZ1B intron 23263486 rs1178979 chr7 72856430 T C 6.90E-05 Response to statin therapy BAZ1B intron 20339536 rs1178979 chr7 72856430 T C 2.84E-08 Protein C levels BAZ1B intron 20802025 rs1178979 chr7 72856430 T C 2.00E-12 Triglycerides BAZ1B intron 20864672 rs1178979 chr7 72856430 T C 4.26E-13 Metabolite levels BAZ1B intron 22286219 rs1178979 chr7 72856430 T C 9.80E-12 Urate levels BAZ1B intron 23263486 rs1178977 chr7 72857049 A G 6.90E-05 Response to statin therapy BAZ1B intron 20339536 rs1178977 chr7 72857049 A G 2.83E-08 Protein C levels BAZ1B intron 20802025 rs1178977 chr7 72857049 A G 8.96E-11 Metabolite levels BAZ1B intron 22286219 rs1178977 chr7 72857049 A G 1.00E-12 Urate levels BAZ1B intron 23263486 rs13231516 chr7 72863249 T G 9.73E-12 Metabolite levels BAZ1B intron 22286219 rs714052 chr7 72864869 A G 3.00E-15 Triglycerides BAZ1B intron 19060906 rs714052 chr7 72864869 A G 1.61E-12 Triglycerides BAZ1B intron 19060911 rs714052 chr7 72864869 A G 4.38E-07 Lipid levels BAZ1B intron 19913121 rs714052 chr7 72864869 A G 1.58E-10 Lipid levels BAZ1B intron 19936222 rs714052 chr7 72864869 A G 2.98E-08 Lipid levels BAZ1B intron 19936222 rs714052 chr7 72864869 A G 3.00E-07 Blood cell counts and other traits BAZ1B intron 20139978 rs714052 chr7 72864869 A G 3.30E-07 Blood cell counts and other traits BAZ1B intron 20139978 rs714052 chr7 72864869 A G 3.00E-06 Hypertriglyceridemia BAZ1B intron 20657596 rs714052 chr7 72864869 A G 1.24E-06 Caffeine consumption BAZ1B intron 21490707 rs714052 chr7 72864869 A G 1.12E-11 Metabolite levels BAZ1B intron 22286219 rs714052 chr7 72864869 A G 1.34E-36 Triglycerides BAZ1B intron 23063622 rs714052 chr7 72864869 A G 3.68E-09 Urate levels BAZ1B intron 23263486 rs34763247 chr7 72866616 A T 9.90E-12 Metabolite levels BAZ1B intron 22286219 rs1306476 chr7 72868522 A G 9.20E-11 Metabolite levels BAZ1B intron 22286219 rs35330527 chr7 72870207 A G 5.56E-11 Metabolite levels BAZ1B intron 22286219 rs2074755 chr7 72877166 T C 3.51E-06 Cardiovascular disease BAZ1B intron 18179892 rs2074755 chr7 72877166 T C 2.94E-07 Lipid levels BAZ1B intron 19913121 rs2074755 chr7 72877166 T C 5.10E-04 Atrial fibrillation BAZ1B intron 21846873 rs2074755 chr7 72877166 T C 1.06E-11 Metabolite levels BAZ1B intron 22286219 rs2074755 chr7 72877166 T C 3.62E-35 Triglycerides BAZ1B intron 23063622 rs2074755 chr7 72877166 T C 1.61E-09 Urate levels BAZ1B intron 23263486 rs35797675 chr7 72878044 T G 8.12E-13 Metabolite levels BAZ1B intron 22286219 rs12056034 chr7 72878645 A G 5.00E-07 Triglycerides BAZ1B intron 18193046 rs12056034 chr7 72878645 A G 1.14E-11 Metabolite levels BAZ1B intron 22286219 rs12056034 chr7 72878645 A G 2.32E-09 Urate levels BAZ1B intron 23263486 rs62465144 chr7 72883106 T C 6.09E-13 Metabolite levels BAZ1B intron 22286219 rs6976930 chr7 72885810 G A 8.00E-05 Response to statin therapy BAZ1B intron 20339536 rs6976930 chr7 72885810 G A 2.83E-08 Protein C levels BAZ1B intron 20802025 rs6976930 chr7 72885810 G A 7.61E-13 Metabolite levels BAZ1B intron 22286219 rs6976930 chr7 72885810 G A 3.14E-11 Urate levels BAZ1B intron 23263486 rs35695283 chr7 72893403 A G 1.32E-11 Metabolite levels BAZ1B intron 22286219 rs7797566 chr7 72896395 A C 1.32E-11 Metabolite levels BAZ1B intron 22286219 rs10239940 chr7 72901390 A T 0.000000309 HDL cholesterol BAZ1B intron 23063622 rs10239940 chr7 72901390 A T 0.00000136 Triglycerides BAZ1B intron 23063622 rs17145713 chr7 72904810 C T 5.29E-10 Lipid levels BAZ1B intron 19913121 rs17145713 chr7 72904810 C T 8.00E-05 Response to statin therapy BAZ1B intron 20339536 rs17145713 chr7 72904810 C T 3.00E-08 Protein C levels BAZ1B intron 20802025 rs17145713 chr7 72904810 C T 5.09E-13 Metabolite levels BAZ1B intron 22286219 rs17145713 chr7 72904810 C T 1.35E-35 Triglycerides BAZ1B intron 23063622 rs17145713 chr7 72904810 C T 2.16E-11 Urate levels BAZ1B intron 23263486 rs13244268 chr7 72911843 T C 1.29E-11 Metabolite levels BAZ1B intron 22286219 rs13244268 chr7 72911843 T C 2.27E-09 Urate levels BAZ1B intron 23263486 rs13221253 chr7 72922233 A G 7.57E-12 Metabolite levels BAZ1B intron 22286219 rs7811265 chr7 72934510 A G 5.90E-05 Response to statin therapy BAZ1B intron 20339536 rs7811265 chr7 72934510 A G 3.92E-08 Protein C levels BAZ1B intron 20802025 rs7811265 chr7 72934510 A G 1.57E-12 Metabolite levels BAZ1B intron 22286219 rs7811265 chr7 72934510 A G 2.17E-10 Urate levels BAZ1B intron 23263486 rs62466264 chr7 72938718 T C 5.14E-13 Metabolite levels / / 22286219 rs11983997 chr7 72939244 G C 5.90E-05 Response to statin therapy / / 20339536 rs11983997 chr7 72939244 G C 4.21E-08 Protein C levels / / 20802025 rs11983997 chr7 72939244 G C 6.56E-13 Metabolite levels / / 22286219 rs11983997 chr7 72939244 G C 1.76E-11 Urate levels / / 23263486 rs17145732 chr7 72970268 T G 2.10E-06 Triglycerides BCL7B intron 18193046 rs17145732 chr7 72970268 T G 4.12E-11 Metabolite levels BCL7B intron 22286219 rs17145732 chr7 72970268 T G 1.25E-08 Urate levels BCL7B intron 23263486 rs13233571 chr7 72971231 C T 4.00E-09 C-reactive protein BCL7B intron 21300955 rs13233571 chr7 72971231 C T 3.71E-12 Metabolite levels BCL7B intron 22286219 rs13233571 chr7 72971231 C T 1.03E-09 Urate levels BCL7B intron 23263486 rs7793710 chr7 72971531 C G 3.31E-11 Metabolite levels BCL7B intron 22286219 rs13234157 chr7 72971728 C A 1.23E-11 Metabolite levels BCL7B intron 22286219 rs34594435 chr7 72977249 C T 2.53E-12 Metabolite levels / / 22286219 rs6946689 chr7 72977637 T A 2.90E-11 Metabolite levels / / 22286219 rs12539316 chr7 72977898 A G 9.39E-06 Lipid levels / / 19913121 rs12539316 chr7 72977898 A G 6.00E-10 Gamma glutamyl transpeptidase / / 21909109 rs12539316 chr7 72977898 A G 2.99E-11 Metabolite levels / / 22286219 rs12539316 chr7 72977898 A G 9.15E-25 Triglycerides / / 23063622 rs12539316 chr7 72977898 A G 5.95E-09 Urate levels / / 23263486 rs12539351 chr7 72978112 A G 2.76E-11 Metabolite levels / / 22286219 rs17145738 chr7 72982874 C T 6.73E-04 Multiple complex diseases TBL2 nearGene-3 17554300 rs17145738 chr7 72982874 C T 2.00E-12 Triglycerides TBL2 nearGene-3 18193043 rs17145738 chr7 72982874 C T 7.00E-22 Triglycerides TBL2 nearGene-3 18193044 rs17145738 chr7 72982874 C T 1.04E-05 Lipid levels TBL2 nearGene-3 19913121 rs17145738 chr7 72982874 C T 1.00E-09 HDL cholesterol TBL2 nearGene-3 20686565 rs17145738 chr7 72982874 C T 9.00E-59 Triglycerides TBL2 nearGene-3 20686565 rs17145738 chr7 72982874 C T 1.77E-12 Metabolite levels TBL2 nearGene-3 22286219 rs17145738 chr7 72982874 C T 0.000000984 HDL cholesterol TBL2 nearGene-3 23063622 rs17145738 chr7 72982874 C T 5.13E-39 Triglycerides TBL2 nearGene-3 23063622 rs17145738 chr7 72982874 C T 8.41E-39 Triglycerides TBL2 nearGene-3 23063622 rs17145738 chr7 72982874 C T 2.59E-09 Urate levels TBL2 nearGene-3 23263486 rs17145738 chr7 72982874 C T 5.00E-13 HDL cholesterol TBL2 nearGene-3 24097068 rs17145738 chr7 72982874 C T 9.00E-99 Triglycerides TBL2 nearGene-3 24097068 rs13232120 chr7 72983310 A T 9.70E-07 Lipid levels TBL2 UTR-3 18193043 rs13232120 chr7 72983310 A T 4.31E-12 Metabolite levels TBL2 UTR-3 22286219 rs13232120 chr7 72983310 A T 0.000000598 HDL cholesterol TBL2 UTR-3 23063622 rs13232120 chr7 72983310 A T 1.28E-34 Triglycerides TBL2 UTR-3 23063622 rs13232120 chr7 72983310 A T 2.38E-09 Urate levels TBL2 UTR-3 23263486 rs17341242 chr7 72984300 A G 2.40E-04 Blood pressure TBL2 UTR-3 17255346 rs14415 chr7 72984780 T C 2.39E-11 Metabolite levels TBL2 UTR-3 22286219 rs14415 chr7 72984780 T C 5.40E-09 Urate levels TBL2 UTR-3 23263486 rs2286276 chr7 72987354 C T 3.03E-09 Triglycerides TBL2 intron 19060911 rs2286276 chr7 72987354 C T 9.48E-06 Lipid levels TBL2 intron 19913121 rs2286276 chr7 72987354 C T 1.00E-15 Triglycerides TBL2 intron 21909109 rs2286276 chr7 72987354 C T 2.73E-11 Metabolite levels TBL2 intron 22286219 rs2286276 chr7 72987354 C T 8.01E-07 Esophageal cancer (squamous cell) TBL2 intron 22960999 rs2286276 chr7 72987354 C T 6.58E-26 Triglycerides TBL2 intron 23063622 rs2286276 chr7 72987354 C T 7.24E-09 Urate levels TBL2 intron 23263486 rs2286276 chr7 72987354 C T 2.00E-06 Hypertriglyceridemia TBL2 intron 23505323 rs2286276 chr7 72987354 C T 6.55E-06 Triglycerides TBL2 intron pha002904 rs35659126 chr7 72988069 C T 5.79E-13 Metabolite levels TBL2 intron 22286219 rs11974409 chr7 72989390 A G 2.13E-10 Triglycerides TBL2 intron 19060911 rs11974409 chr7 72989390 A G 5.10E-06 Lipid levels TBL2 intron 19802338 rs11974409 chr7 72989390 A G 5.66E-09 Lipid levels TBL2 intron 19913121 rs11974409 chr7 72989390 A G 1.49E-18 Lipid levels TBL2 intron 19936222 rs11974409 chr7 72989390 A G 2.10E-15 Lipid levels TBL2 intron 19936222 rs11974409 chr7 72989390 A G 2.60E-10 Lipid levels TBL2 intron 19936222 rs11974409 chr7 72989390 A G 3.20E-13 Lipid levels TBL2 intron 19936222 rs11974409 chr7 72989390 A G 3.80E-11 Lipid levels TBL2 intron 19936222 rs11974409 chr7 72989390 A G 5.70E-09 Lipid levels TBL2 intron 19936222 rs11974409 chr7 72989390 A G 6.29E-09 Lipid levels TBL2 intron 19936222 rs11974409 chr7 72989390 A G 8.40E-11 Lipid levels TBL2 intron 19936222 rs11974409 chr7 72989390 A G 5.20E-05 Response to statin therapy TBL2 intron 20339536 rs11974409 chr7 72989390 A G 6.44E-13 Metabolite levels TBL2 intron 22286219 rs11974409 chr7 72989390 A G 4.75E-08 HDL cholesterol TBL2 intron 23063622 rs11974409 chr7 72989390 A G 5.53E-39 Triglycerides TBL2 intron 23063622 rs11974409 chr7 72989390 A G 4.22E-11 Urate levels TBL2 intron 23263486 rs11974409 chr7 72989390 A G 4.38E-05 Triglycerides TBL2 intron pha002904 rs35624969 chr7 72991592 T C 2.88E-12 Metabolite levels TBL2 intron 22286219 rs35348663 chr7 72991593 G C 4.40E-13 Metabolite levels TBL2 intron 22286219 rs12540011 chr7 72991704 G A 6.45E-11 Metabolite levels TBL2 intron 22286219 rs13246490 chr7 72992350 C T 1.57E-12 Metabolite levels TBL2 intron 22286219 rs12666883 chr7 72994476 C A 6.00E-06 Obesity-related traits TBL2 nearGene-5 23251661 rs9638180 chr7 72998952 A G 5.49E-13 Metabolite levels / / 22286219 rs9638182 chr7 72999105 T G 5.48E-13 Metabolite levels / / 22286219 rs35173225 chr7 73001021 C T 3.43E-12 Metabolite levels / / 22286219 rs1051921 chr7 73007943 G A 1.25E-08 Lipid levels MLXIPL UTR-3 19913121 rs1051921 chr7 73007943 G A 4.40E-05 Response to statin therapy MLXIPL UTR-3 20339536 rs1051921 chr7 73007943 G A 5.00E-04 Gamma gluatamyl transferase levels (interaction with age) MLXIPL UTR-3 22010049 rs1051921 chr7 73007943 G A 5.14E-13 Metabolite levels MLXIPL UTR-3 22286219 rs1051921 chr7 73007943 G A 0.000000153 HDL cholesterol MLXIPL UTR-3 23063622 rs1051921 chr7 73007943 G A 1.13E-37 Triglycerides MLXIPL UTR-3 23063622 rs1051921 chr7 73007943 G A 1.15E-42 Triglycerides MLXIPL UTR-3 23063622 rs1051921 chr7 73007943 G A 5.06E-11 Urate levels MLXIPL UTR-3 23263486 rs13247874 chr7 73010442 C T 8.00E-14 Lipid metabolism phenotypes MLXIPL intron 22286219 rs35332062 chr7 73012042 G A 1.18E-12 Metabolite levels MLXIPL missense 22286219 rs13235543 chr7 73013901 C T 5.04E-12 Metabolite levels MLXIPL cds-synon 22286219 rs13240065 chr7 73015369 G A 7.74E-12 Metabolite levels MLXIPL intron 22286219 rs34346326 chr7 73016181 T C 1.83E-11 Metabolite levels MLXIPL intron 22286219 rs56383788 chr7 73016400 A G 1.15E-12 Metabolite levels MLXIPL intron 22286219 rs13226650 chr7 73017005 A G 8.76E-13 Metabolite levels MLXIPL intron 22286219 rs13226650 chr7 73017005 A G 2.00E-11 Metabolic syndrome MLXIPL intron 22399527 rs35368205 chr7 73017657 C T 1.53E-12 Metabolite levels MLXIPL intron 22286219 rs799157 chr7 73020301 T C 0.000672 Salmonella-induced pyroptosis MLXIPL cds-synon 22837397 rs3812316 chr7 73020337 C G 1.00E-10 Triglycerides MLXIPL missense 18193046 rs3812316 chr7 73020337 C G 1.09E-12 Metabolite levels MLXIPL missense 22286219 rs6968170 chr7 73020676 G A 7.62E-11 Metabolite levels MLXIPL intron 22286219 rs12531645 chr7 73023881 G A 3.28E-11 Metabolite levels MLXIPL intron 22286219 rs13234378 chr7 73026151 A T 2.57E-13 Metabolite levels MLXIPL intron 22286219 rs17145750 chr7 73026378 C T 1.48E-06 Lipid levels MLXIPL intron 19913121 rs17145750 chr7 73026378 C T 1.30E-05 Response to statin therapy MLXIPL intron 20339536 rs17145750 chr7 73026378 C T 3.00E-09 Liver enzyme levels (gamma-glutamyl transferase) MLXIPL intron 22001757 rs17145750 chr7 73026378 C T 1.01E-11 Metabolite levels MLXIPL intron 22286219 rs17145750 chr7 73026378 C T 1.12E-15 Triglycerides (males) MLXIPL intron 22629316 rs17145750 chr7 73026378 C T 4.22E-25 Triglycerides MLXIPL intron 22629316 rs17145750 chr7 73026378 C T 5.66E-13 Triglycerides (females) MLXIPL intron 22629316 rs17145750 chr7 73026378 C T 2.71E-36 Triglycerides MLXIPL intron 23063622 rs17145750 chr7 73026378 C T 6.05E-08 HDL cholesterol MLXIPL intron 23063622 rs17145750 chr7 73026378 C T 1.37E-09 Urate levels MLXIPL intron 23263486 rs7808877 chr7 73027450 C G 2.11E-11 Metabolite levels MLXIPL intron 22286219 rs33951980 chr7 73029437 C T 9.84E-13 Metabolite levels MLXIPL intron 22286219 rs7798357 chr7 73032265 G C 5.54E-11 Metabolite levels MLXIPL intron 22286219 rs7798357 chr7 73032265 G C 1.27E-08 Urate levels MLXIPL intron 23263486 rs7785479 chr7 73032835 T C 4.93E-11 Metabolite levels MLXIPL intron 22286219 rs7785479 chr7 73032835 T C 4.94E-08 Urate levels MLXIPL intron 23263486 rs7800944 chr7 73035857 T C 8.59E-06 Lipid levels MLXIPL intron 19913121 rs7800944 chr7 73035857 T C 3.83E-11 Metabolite levels MLXIPL intron 22286219 rs7800944 chr7 73035857 T C 2.46E-27 Triglycerides MLXIPL intron 23063622 rs7800944 chr7 73035857 T C 1.31E-08 Urate levels MLXIPL intron 23263486 rs55747707 chr7 73037366 G A 7.18E-13 Metabolite levels MLXIPL intron 22286219 rs34060476 chr7 73037956 A G 4.09E-12 Metabolite levels MLXIPL intron 22286219 rs35493868 chr7 73039406 C G 6.99E-13 Metabolite levels MLXIPL nearGene-5 22286219 rs34121855 chr7 73040814 T G 6.86E-13 Metabolite levels MLXIPL nearGene-5 22286219 rs62466318 chr7 73042085 C T 6.63E-13 Metabolite levels / / 22286219 rs7786376 chr7 73042614 A G 1.09E-11 Metabolite levels / / 22286219 rs34958196 chr7 73043101 G A 7.17E-11 Metabolite levels / / 22286219 rs17145817 chr7 73046779 A G 9.10E-05 Response to statin therapy / / 20339536 rs13230514 chr7 73048095 A G 8.60E-05 Response to statin therapy / / 20339536 rs13234805 chr7 73049182 G A 3.87E-11 Metabolite levels / / 22286219 rs799168 chr7 73050864 G A 1.09E-20 Triglycerides / / 23063622 rs799166 chr7 73051932 C G 3.97E-11 Metabolite levels / / 22286219 rs799166 chr7 73051932 C G 0.00000101 HDL cholesterol / / 23063622 rs799166 chr7 73051932 C G 2.85E-35 Triglycerides / / 23063622 rs799166 chr7 73051932 C G 4.02E-08 Urate levels / / 23263486 rs799165 chr7 73052057 T A 3.99E-11 Metabolite levels / / 22286219 rs799165 chr7 73052057 T A 0.0000011 HDL cholesterol / / 23063622 rs799165 chr7 73052057 T A 8.86E-36 Triglycerides / / 23063622 rs7777102 chr7 73058017 A G 3.50E-11 Lipid levels / / 19936222 rs7777102 chr7 73058017 A G 7.30E-05 Response to statin therapy / / 20339536 rs7777102 chr7 73058017 A G 4.84E-08 Protein C levels / / 20802025 rs7777102 chr7 73058017 A G 4.27E-06 Caffeine consumption / / 21490707 rs7777102 chr7 73058017 A G 1.24E-06 FVII levels / / 21676895 rs7777102 chr7 73058017 A G 7.70E-06 FVII levels / / 21676895 rs7777102 chr7 73058017 A G 3.50E-11 Metabolite levels / / 22286219 rs799160 chr7 73060006 C T 5.70E-05 Triglycerides / / 18193046 rs941297 chr7 73087046 A G 4.93E-05 HIV-1 viral setpoint / / 22174851 rs11769825 chr7 73101137 A G 3.21E-05 HIV-1 viral setpoint WBSCR22 intron 22174851 rs73702566 chr7 73104245 T G 0.0000635 Menopause (age at onset) WBSCR22 intron 23424626 rs1001220 chr7 73110603 C T 7.70E-05 Schizophrenia(treatment response to risperidone) WBSCR22 intron 19850283 rs11544049 chr7 73112341 C T 7.15E-05 HIV-1 viral setpoint WBSCR22 UTR-3 22174851 rs112580831 chr7 73151644 A ATG 4.44E-04 Type 2 diabetes ABHD11 cds-synon 17463246 rs112580831 chr7 73151644 A ATG 2.30E-05 Urinary metabolites ABHD11 cds-synon 21572414 rs6460052 chr7 73151644 A G 4.44E-04 Type 2 diabetes ABHD11 cds-synon 17463246 rs6460052 chr7 73151644 A G 2.30E-05 Urinary metabolites ABHD11 cds-synon 21572414 rs6979031 chr7 73198616 A G 2.80E-05 Urinary metabolites / / 21572414 rs4355658 chr7 73225692 A G 9.06E-04 Multiple complex diseases / / 17554300 rs4355658 chr7 73225692 A G 3.18E-18 Lymphocyte counts / / 22286170 rs8629 chr7 73245519 T C 5.26E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CLDN4 UTR-5 20031582 rs4262227 chr7 73258638 G C 8.00E-04 Response to statin treatment (atorvastatin),change in cholesterol levels WBSCR27 nearGene-5 20031582 rs201563407 chr7 73279484 G A 0.000013 Prostate cancer (advanced) WBSCR28 STOP-GAIN 23555315 rs13244770 chr7 73280691 G T 5.53E-05 Age-related macular degeneration / / 22125219 rs6460065 chr7 73376167 C T 0.00000143 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6460066 chr7 73387168 C T 0.00000445 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs117858990 chr7 73389546 G C 0.00000153 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs57756641 chr7 73390258 G C 0.00000676 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs74815547 chr7 73391884 C T 0.00000446 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7787362 chr7 73392603 T C 0.00007 Striae gravidarum (stretch marks during pregnancy) / / 23633020 rs7787362 chr7 73392603 T C 1.80E-23 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs28578577 chr7 73393980 G A 0.0000107 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4078435 chr7 73399246 C T 2.94E-23 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6964149 chr7 73403193 G A 1.52E-16 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6946106 chr7 73403267 T A 1.19E-22 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs56034028 chr7 73404165 A G 0.0000496 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6975355 chr7 73405455 G A 4.98E-19 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6975518 chr7 73405560 G A 8.12E-16 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13231684 chr7 73405677 T G 1.18E-15 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13244607 chr7 73405747 G T 4.88E-14 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13247385 chr7 73405854 C A 3.45E-13 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13247415 chr7 73405979 A G 1.51E-13 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13247503 chr7 73405983 C T 4.70E-13 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13231286 chr7 73414589 A C 0.0000903 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6971698 chr7 73422525 G A 0.00000157 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6948963 chr7 73425238 A C 0.00006 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12374753 chr7 73426009 G T 0.00000123 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34068091 chr7 73426561 G A 0.0000017 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs56072713 chr7 73427710 G A 0.0000396 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7811515 chr7 73428934 A G 0.0000345 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11762153 chr7 73431283 G A 0.00000127 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7792074 chr7 73432630 A G 0.0000187 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs73144900 chr7 73440265 G C 6.57E-11 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs3757583 chr7 73440659 G A 0.0000166 Nonsyndromic striae distensae (stretch marks) ELN nearGene-5 23633020 rs56020114 chr7 73441468 C T 1.64E-10 Nonsyndromic striae distensae (stretch marks) ELN nearGene-5 23633020 rs55855101 chr7 73443015 G A 7.66E-08 Nonsyndromic striae distensae (stretch marks) ELN intron 23633020 rs868005 chr7 73445114 T C 7.43E-08 Nonsyndromic striae distensae (stretch marks) ELN intron 23633020 rs884843 chr7 73445789 A G 0.0000259 Nonsyndromic striae distensae (stretch marks) ELN intron 23633020 rs2239691 chr7 73469169 C T 0.000000033 Nonsyndromic striae distensae (stretch marks) ELN intron 23633020 rs2071307 chr7 73470714 G A 2.63E-08 Nonsyndromic striae distensae (stretch marks) ELN missense 23633020 rs2856728 chr7 73470782 C T 0.0000069 Nonsyndromic striae distensae (stretch marks) ELN intron 23633020 rs28763986 chr7 73472050 C T 0.0000168 Nonsyndromic striae distensae (stretch marks) ELN intron 23633020 rs2528795 chr7 73473494 T C 0.0000344 Nonsyndromic striae distensae (stretch marks) ELN intron 23633020 rs12535378 chr7 73475775 G A 0.00000836 Nonsyndromic striae distensae (stretch marks) ELN intron 23633020 rs810556 chr7 73476236 T C 0.0000253 Nonsyndromic striae distensae (stretch marks) ELN intron 23633020 rs810555 chr7 73476249 C T 7.67E-08 Nonsyndromic striae distensae (stretch marks) ELN intron 23633020 rs34852121 chr7 73477983 G A 0.000000545 Cholesterol,total ELN missense 23063622 rs34852121 chr7 73477983 G A 0.000000853 Triglycerides ELN missense 23063622 rs113395463 chr7 73478524 A G 0.0000367 Nonsyndromic striae distensae (stretch marks) ELN intron 23633020 rs223011 chr7 73581402 C T 4.82E-04 Alcohol dependence / / 20201924 rs223002 chr7 73583703 G T 1.59E-04 Alcohol dependence / / 20201924 rs17146094 chr7 73609315 A G 1.31E-15 Multiple complex diseases EIF4H intron 17554300 rs3135698 chr7 73649825 T C 1.28E-04 Glycosylated haemoglobin levels RFC2 intron 17255346 rs6460075 chr7 73674477 T C 1.48E-05 Height / / pha003010 rs6460075 chr7 73674477 T C 5.14E-06 Height / / pha003011 rs229877 chr7 73724962 C T 8.18E-05 Leukocyte Counts CLIP2 intron pha003091 rs523434 chr7 73760704 G A 1.42E-05 Leukocyte Counts CLIP2 intron pha003091 rs61372645 chr7 73944758 C T 2.38E-34 Metabolite levels GTF2IRD1 intron 22286219 rs149209759 chr7 73971995 A G 0.00037 Prostate cancer GTF2IRD1 missense 23555315 rs13244286 chr7 74000679 G A 0.0005172 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) GTF2IRD1 intron 23233654 rs13244286 chr7 74000679 G A 5.17E-04 Methotrexate clearance (acute lymphoblastic leukemia) GTF2IRD1 intron 23233662 rs13244286 chr7 74000679 G A 3.61E-05 Alcohol consumption GTF2IRD1 intron 23743675 rs13246861 chr7 74000854 A G 0.0005195 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) GTF2IRD1 intron 23233654 rs13246861 chr7 74000854 A G 5.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) GTF2IRD1 intron 23233662 rs13246861 chr7 74000854 A G 4.92E-05 Alcohol consumption GTF2IRD1 intron 23743675 rs34158545 chr7 74000895 C G 4.87E-05 Alcohol consumption GTF2IRD1 intron 23743675 rs4412258 chr7 74068451 C G 3.53E-04 Multiple complex diseases / / 17554300 rs117026326 chr7 74126034 C A,G,T 1.00E-53 Sjogren's syndrome GTF2I intron 24097066 rs707395 chr7 74212048 C T 0.000111 Height (Pygmy height) GTF2IRD2 cds-synon 22570615 rs236670 chr7 75059331 T G 3.00E-06 Obesity-related traits POM121C intron 23251661 rs6974138 chr7 75063487 G C 2.40E-04 Sleep and circadian phenotypes POM121C intron 17903308 rs6963105 chr7 75097488 A G 2.47E-04 Obesity (extreme) POM121C intron 21935397 rs17207196 chr7 75101065 C T 2.72E-04 Obesity (extreme) POM121C intron 21935397 rs711302 chr7 75155747 G T 3.27E-06 Obesity-related traits PMS2P3 intron 23251661 rs1167827 chr7 75163169 A G 4.57E-04 Obesity (extreme) HIP1 UTR-3 21935397 rs1167827 chr7 75163169 A G 0.00000963 Body mass index HIP1 UTR-3 22885924 rs10499824 chr7 75171091 C A,G,T 1.43E-08 Pure-tone audiometry HIP1 intron pha001966 rs1167796 chr7 75173180 A G 2.00E-08 Systemic lupus erythematosus HIP1 intron 19838193 rs1167796 chr7 75173180 A G 8.80E-05 Systemic lupus erythematosus HIP1 intron 23273568 rs1167797 chr7 75175909 T C 1.77E-07 Systemic lupus erythematosus HIP1 intron 19838193 rs1167798 chr7 75175924 T C 9.70E-07 Urinary metabolites HIP1 intron 21572414 rs1167800 chr7 75176196 G A 0.000000529 Body mass index HIP1 intron 22885924 rs1167800 chr7 75176196 G A 2.60E-09 Fasting insulin-related traits HIP1 intron 22885924 rs1167800 chr7 75176196 G A 0.0000297 Coronary artery disease HIP1 intron 23202125 rs1167801 chr7 75176300 T C 8.40E-07 Urinary metabolites HIP1 cds-synon 21572414 rs17149023 chr7 75197518 A T 5.81E-04 Multiple complex diseases HIP1 missense 17554300 rs237240 chr7 75210659 C T 2.90E-05 Alcoholism (heaviness of drinking) HIP1 intron 21529783 rs237240 chr7 75210659 C T 7.71E-05 Tunica Media HIP1 intron pha003037 rs237238 chr7 75211414 A G 1.97E-05 Multiple complex diseases HIP1 cds-synon 17554300 rs237238 chr7 75211414 A G 7.00E-06 Alcoholism (12-month weekly alcohol consumption) HIP1 cds-synon 21529783 rs237238 chr7 75211414 A G 4.08E-06 Tunica Media HIP1 cds-synon pha003037 rs17149227 chr7 75235549 T G 3.56E-06 Aging (time to event) HIP1 intron 21782286 rs7794510 chr7 75240915 C T 6.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HIP1 intron 20877124 rs1179624 chr7 75255215 C T 5.00E-06 Age-related nuclear cataracts HIP1 intron 24951543 rs2240135 chr7 75329671 T G 8.61E-05 Prion diseases HIP1 intron 22210626 rs7777461 chr7 75348044 T C 6.44E-04 Smoking initiation HIP1 intron 24665060 rs11770686 chr7 75348306 T A 7.80E-04 Primary sclerosing cholangitis HIP1 intron 19944697 rs11767756 chr7 75380105 T G 3.85E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs17361077 chr7 75438763 C G 1.84E-04 Multiple complex diseases / / 17554300 rs13340490 chr7 75439671 G A 2.51E-05 Body Composition / / pha003012 rs13340490 chr7 75439671 G A 8.79E-06 Body Mass Index / / pha003021 rs62477635 chr7 75445194 C T 0.00008236 Sarcoidosis / / 22952805 rs757589 chr7 75495524 T C 2.91E-04 Multiple complex diseases / / 17554300 rs10255642 chr7 75511134 A G 2.06E-04 Cholesterol RHBDD2 intron 17255346 rs2868177 chr7 75589903 A G 8.84E-04 Type 2 diabetes POR intron 17463246 rs6978677 chr7 75636240 T C 1.06E-07 Lymphocyte counts STYXL1 intron 22286170 rs11770635 chr7 75794560 T C 3.91E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs11770635 chr7 75794560 T C 3.91E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs10245531 chr7 75822876 C G 6.03E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs10245531 chr7 75822876 C G 6.03E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs2961040 chr7 75946763 A C 5.14E-05 Information processing speed / / 21130836 rs2908192 chr7 75949617 C T 6.00E-05 Prostate cancer / / 21743057 rs7789940 chr7 75951230 A G 6.00E-06 Multiple sclerosis / / 21654844 rs758944 chr7 75953297 C A 8.00E-06 Multiple sclerosis / / 21654844 rs1046304 chr7 75957644 C A 1.08E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) YWHAG UTR-3 24023788 rs17149148 chr7 75974061 T C 9.52E-05 Multiple complex diseases YWHAG intron 17554300 rs7779014 chr7 75975586 C T 8.00E-06 Multiple sclerosis YWHAG intron 21654844 rs17149161 chr7 75978229 C A 6.00E-06 Multiple sclerosis YWHAG intron 21654844 rs999096 chr7 76019015 C T 5.75E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SRCRB4D UTR-3 24023788 rs1019096 chr7 76046324 A G 1.30E-05 Urinary metabolites ZP3 intron 21572414 rs3789833 chr7 76059561 C T 4.41E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ZP3 intron 24023788 rs17468652 chr7 76136389 G A 2.57E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs17645907 chr7 76289033 T C 1.11E-04 Multiple complex diseases / / 17554300 rs10488497 chr7 76342579 C G 4.00E-05 Lymphocyte counts / / 22286170 rs38664 chr7 76390970 T C 1.00E-07 Bone properties (heel) / / 24430505 rs38664 chr7 76390970 T C 3.25E-04 Bone properties (heel) / / 24430505 rs17663983 chr7 76405241 C T 8.10E-06 Parkinson's disease (age of onset) / / 19772629 rs2192268 chr7 76444648 T G 2.54E-04 Celiac disease / / 23936387 rs38598 chr7 76446322 T C 1.18E-04 Multiple complex diseases / / 17554300 rs28830 chr7 76449481 G A 9.36E-04 Multiple complex diseases / / 17554300 rs17842722 chr7 76493050 G C 5.14E-04 Alzheimer's disease / / 17998437 rs7798157 chr7 76499312 T C 3.00E-05 Lupus / / 17911428 rs3905501 chr7 76542080 T C 2.80E-05 Urinary metabolites / / 21572414 rs3912067 chr7 76557212 C T 8.27E-04 HIV-1 viral setpoint / / 17641165 rs10278476 chr7 76637441 G A 2.49E-04 Schizophrenia DTX2P1-UPK3BP1-PMS2P11 intron 19197363 rs6955651 chr7 76639871 T C 2.00E-06 Body mass index DTX2P1-UPK3BP1-PMS2P11 intron 20935630 rs3864639 chr7 76738591 C T 2.00E-07 Obesity-related traits / / 23251661 rs3095465 chr7 76813111 C T 4.47E-05 Serum metabolites CCDC146 intron 19043545 rs10252204 chr7 76820800 C A 1.97E-05 Bone mineral traits,in men CCDC146 intron 21427758 rs10252204 chr7 76820800 C A 6.29E-05 Bone mineral traits,in men CCDC146 intron 21427758 rs3114366 chr7 76838004 C T 4.88E-04 Type 2 diabetes CCDC146 intron 17463246 rs3114366 chr7 76838004 C T 7.34E-04 Multiple complex diseases CCDC146 intron 17554300 rs3108406 chr7 76853725 T C 5.55E-04 Type 2 diabetes CCDC146 intron 17463246 rs3108450 chr7 76860287 C T 0.000799942 Hypertension (early onset hypertension) CCDC146 intron 22479346 rs3108405 chr7 76865028 T C 3.24E-04 Type 2 diabetes CCDC146 intron 17463246 rs3108409 chr7 76871552 A G 4.16E-04 Type 2 diabetes CCDC146 intron 17463246 rs3108409 chr7 76871552 A G 9.20E-04 Multiple complex diseases CCDC146 intron 17554300 rs3108440 chr7 76896701 T C 6.63E-04 Type 2 diabetes CCDC146 intron 17463246 rs3108442 chr7 76901907 A T 1.08E-04 Type 2 diabetes CCDC146 intron 17463246 rs6958942 chr7 76917194 T G 1.76E-04 Height CCDC146 intron 17255346 rs17151246 chr7 76923550 C T 8.30E-04 Tourette syndrome CCDC146 intron 22889924 rs10273411 chr7 76928011 A C 1.20E-05 Urinary metabolites / / 21572414 rs10262175 chr7 76958980 C A 6.66E-05 Erythrocyte counts PION intron pha003101 rs3750045 chr7 76959784 T C 6.27E-05 Erythrocyte counts PION intron pha003101 rs17806432 chr7 76960884 C T 0.000012 Primary sclerosing cholangitis PION intron 22521342 rs11983527 chr7 76962868 C G 2.91E-04 Musician's dystonia PION intron 24375517 rs11505827 chr7 76968595 G A 3.48E-04 Musician's dystonia PION intron 24375517 rs17806725 chr7 76980832 G A 3.04E-05 Self-reported allergy PION intron 23817569 rs6979188 chr7 76983515 C T 0.000021 Primary sclerosing cholangitis PION intron 22521342 rs1181900 chr7 76991149 T C 4.59E-05 Self-reported allergy PION intron 23817569 rs1181899 chr7 76993184 T C 5.93E-05 Self-reported allergy PION intron 23817569 rs1181896 chr7 77005627 T C 5.11E-05 Self-reported allergy PION intron 23817569 rs1181895 chr7 77005697 A G 5.11E-05 Self-reported allergy PION intron 23817569 rs1181902 chr7 77009260 C T 5.16E-05 Self-reported allergy PION intron 23817569 rs4296977 chr7 77018542 C T 1.16E-04 Self-reported allergy PION intron 23817569 rs2051898 chr7 77025162 A T 1.27E-04 Self-reported allergy PION intron 23817569 rs1859572 chr7 77032997 C T 1.74E-06 Osteoarthritis PION intron 22763110 rs6949654 chr7 77035392 T C 7.59E-05 Self-reported allergy PION missense 23817569 rs2190097 chr7 77038945 C T 5.01E-05 Lung function (forced expiratory volume in 1 second) PION intron 17255346 rs2190097 chr7 77038945 C T 3.28E-05 Self-reported allergy PION intron 23817569 rs9641218 chr7 77044448 A G 2.00E-04 Cognitive impairment induced by topiramate PION intron 22091778 rs9641218 chr7 77044448 A G 7.52E-05 Cognitive impairment induced by topiramate PION intron 22091778 rs6971637 chr7 77054720 C T 1.60E-07 Primary sclerosing cholangitis / / 21151127 rs740158 chr7 77055836 T C 7.00E-05 Lung cancer / / 18978790 rs7791854 chr7 77057222 C T 1.00E-07 Primary sclerosing cholangitis / / 21151127 rs7780883 chr7 77062712 G A 2.00E-06 Cervical cancer / / 24700089 rs6465686 chr7 77099024 G C 4.56E-05 Aortic root size / / 21223598 rs17154100 chr7 77111497 C T 4.13E-04 Type 2 diabetes / / 17463246 rs17154100 chr7 77111497 C T 2.87E-05 Lymphocyte counts / / 22286170 rs6955503 chr7 77227241 C T 8.60E-05 Insulin-related traits PTPN12 intron pha002901 rs4729555 chr7 77238144 C T 5.60E-04 Type 2 diabetes PTPN12 intron 17463246 rs17156256 chr7 77297928 A G 6.17E-04 Type 2 diabetes / / 17463246 rs11514912 chr7 77302059 T C 5.95E-04 Type 2 diabetes / / 17463246 rs35216166 chr7 77327333 G A 1.02E-04 Alcohol dependence RSBN1L intron 24277619 rs7783032 chr7 77351705 G T 8.97E-04 Response to taxane treatment (placlitaxel) RSBN1L intron 23006423 rs4729710 chr7 77393739 T C 8.21E-06 Obesity-related traits RSBN1L intron 23251661 rs6465825 chr7 77416439 T C 2.00E-09 Chronic kidney disease / / 20383146 rs6465825 chr7 77416439 T C 2.05E-08 Chronic kidney disease / / 22479191 rs11761324 chr7 77432914 A G 1.53E-05 Insulin-related traits PHTF2 intron pha002901 rs11761324 chr7 77432914 A G 9.71E-05 Hemoglobin PHTF2 intron pha003096 rs11761324 chr7 77432914 A G 3.59E-05 Hematocrit PHTF2 intron pha003097 rs10953356 chr7 77449598 A G 1.55E-05 Insulin-related traits PHTF2 intron pha002901 rs6966446 chr7 77450358 T C 8.68E-06 Obesity-related traits PHTF2 intron 23251661 rs17158641 chr7 77468437 C T 8.68E-06 Obesity-related traits PHTF2 intron 23251661 rs10215731 chr7 77489783 T C 4.96E-05 Insulin-related traits PHTF2 intron pha002901 rs10215731 chr7 77489783 T C 3.82E-05 Hemoglobin PHTF2 intron pha003096 rs10215731 chr7 77489783 T C 3.08E-05 Hematocrit PHTF2 intron pha003097 rs12234571 chr7 77549906 T G 6.00E-06 Obesity-related traits PHTF2 intron 23251661 rs17159512 chr7 77557014 T G 6.82E-04 Multiple complex diseases PHTF2 intron 17554300 rs17159512 chr7 77557014 T G 6.26E-06 Obesity-related traits PHTF2 intron 23251661 rs848452 chr7 77596812 T C 2.00E-06 Dental caries / / 23064961 rs9986939 chr7 77628137 A G 1.70E-05 Urinary metabolites / / 21572414 rs10275914 chr7 77630243 T A 1.20E-05 Urinary metabolites / / 21572414 rs6973213 chr7 77636954 C A 2.75E-04 Chronic kidney disease / / 21931561 rs4729938 chr7 77637379 G C 6.20E-06 Urinary metabolites / / 21572414 rs6953446 chr7 77642996 T G 2.70E-05 Body Mass Index / / pha003014 rs12534352 chr7 77643059 A G 1.58E-05 Parkinson's disease (motor and cognition) / / 22658654 rs2428920 chr7 77653409 T C 4.88E-04 Type 2 diabetes MAGI2 intron 17463246 rs12668947 chr7 77667308 C T 8.01E-04 Multiple complex diseases MAGI2 intron 17554300 rs3807775 chr7 77673732 G A 5.36E-05 Cervical cancer MAGI2 intron 21716314 rs3807769 chr7 77679478 G A 9.22E-04 Response to taxane treatment (placlitaxel) MAGI2 intron 23006423 rs3807760 chr7 77692177 C A 9.93E-06 Odorant perception MAGI2 intron 23910658 rs1859459 chr7 77703080 T A 2.00E-04 Cervical cancer MAGI2 intron 21716314 rs3779312 chr7 77711756 C T 8.38E-06 Attention deficit hyperactivity disorder MAGI2 intron 22420046 rs7791394 chr7 77714611 T C 8.30E-04 Stroke (ischemic) MAGI2 intron 24262325 rs7791394 chr7 77714611 T C 9.91E-06 Large artery stroke MAGI2 intron 24262325 rs3807746 chr7 77716621 T A 2.10E-06 Primary sclerosing cholangitis MAGI2 intron 21151127 rs3807736 chr7 77733273 A C 1.15E-04 Vaspin levels MAGI2 intron 22907691 rs3807736 chr7 77733273 A C 0.0000446 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit MAGI2 intron 22907730 rs3807736 chr7 77733273 A C 0.0001146 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks MAGI2 intron 22907730 rs3807735 chr7 77740606 G A 1.32E-04 Vaspin levels MAGI2 intron 22907691 rs3807735 chr7 77740606 G A 0.0001318 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit MAGI2 intron 22907730 rs3807734 chr7 77740625 G A 1.32E-04 Vaspin levels MAGI2 intron 22907691 rs3807734 chr7 77740625 G A 0.0001318 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit MAGI2 intron 22907730 rs4296979 chr7 77745281 C T 2.29E-04 Type 2 diabetes MAGI2 intron 17463246 rs6466036 chr7 77750489 C T 1.38E-04 Type 2 diabetes MAGI2 intron 17463246 rs7812015 chr7 77756724 C T 1.62E-04 Type 2 diabetes MAGI2 cds-synon 17463246 rs2074645 chr7 77757104 G C 1.62E-04 Type 2 diabetes MAGI2 intron 17463246 rs7808611 chr7 77758935 A C 1.62E-04 Type 2 diabetes MAGI2 intron 17463246 rs11975124 chr7 77764079 G A 6.63E-04 Aortic root size MAGI2 intron 21223598 rs3807708 chr7 77769253 T A 4.65E-04 Type 2 diabetes MAGI2 intron 17463246 rs3823787 chr7 77773132 T C 6.31E-04 Nicotine smoking MAGI2 intron 19268276 rs17524120 chr7 77776110 A G 5.58E-04 Response to alcohol consumption (flushing response) MAGI2 intron 24277619 rs3807676 chr7 77802070 A C 3.18E-04 Suicide attempts in bipolar disorder MAGI2 intron 21423239 rs113527903 chr7 77838510 C G 3.00E-06 PR interval in Tripanosoma cruzi seropositivity MAGI2 intron 24324551 rs6976643 chr7 77841529 T C 4.67E-04 Major depressive disorder MAGI2 intron 22472876 rs699332 chr7 77875410 T G 9.70E-04 Obesity (extreme) MAGI2 intron 21935397 rs798334 chr7 77911947 A G 1.00E-04 Coronary heart disease MAGI2 intron 21606135 rs12668317 chr7 77934602 C A 2.55E-04 IgE levels MAGI2 intron 17255346 rs11971642 chr7 77952630 A C 1.82E-05 Height MAGI2 intron pha003010 rs11971642 chr7 77952630 A C 1.13E-05 Height MAGI2 intron pha003011 rs16885926 chr7 77953223 G A 5.99E-06 Type 2 diabetes MAGI2 intron 21799836 rs16885926 chr7 77953223 G A 1.11E-05 Height MAGI2 intron pha003010 rs16885926 chr7 77953223 G A 4.94E-05 Height MAGI2 intron pha003011 rs17150527 chr7 77956975 A T 3.09E-05 Type 2 diabetes MAGI2 intron 17463246 rs17150527 chr7 77956975 A T 4.70E-04 Multiple complex diseases MAGI2 intron 17554300 rs2691540 chr7 77964426 A C 3.13E-04 Type 2 diabetes MAGI2 intron 17463246 rs2691543 chr7 77964788 C T 5.00E-06 Height MAGI2 intron 20966902 rs2691546 chr7 77966572 G A 1.38E-06 Asthma MAGI2 intron 21790008 rs2691546 chr7 77966572 G A 8.69E-06 Asthma MAGI2 intron 21790008 rs2075013 chr7 77973456 C T 6.94E-06 Asthma MAGI2 intron 21790008 rs2075014 chr7 77973787 T C 6.74E-06 Asthma MAGI2 intron 21790008 rs2191323 chr7 77982085 C T 2.05E-04 Type 2 diabetes MAGI2 intron 17463246 rs2191323 chr7 77982085 C T 2.49E-04 Multiple complex diseases MAGI2 intron 17554300 rs728470 chr7 77982114 C G 8.40E-04 Multiple complex diseases MAGI2 intron 17554300 rs714437 chr7 77982497 C A 9.86E-04 Coronary heart disease MAGI2 intron 21971053 rs17413355 chr7 77985583 C T 8.50E-05 Response to acetaminophen (hepatotoxicity) MAGI2 intron 21177773 rs4730234 chr7 77985864 T C 0.0000725 post-traumatic stress disorder MAGI2 intron 22869035 rs4730234 chr7 77985864 T C 7.25E-05 Schizophrenia MAGI2 intron 22883433 rs41357146 chr7 77986639 C T 4.94E-04 Multiple complex diseases MAGI2 intron 17554300 rs12670218 chr7 77988279 C T 0.0000877 post-traumatic stress disorder MAGI2 intron 22869035 rs12670218 chr7 77988279 C T 8.77E-05 Schizophrenia MAGI2 intron 22883433 rs12539285 chr7 77993077 C T 4.91E-04 Smoking cessation MAGI2 intron 24665060 rs12539788 chr7 77999020 C T 2.43E-04 Multiple complex diseases MAGI2 intron 17554300 rs10245751 chr7 78002503 A G 6.96E-04 Multiple complex diseases MAGI2 intron 17554300 rs17150624 chr7 78013932 T G 7.12E-04 Multiple complex diseases MAGI2 intron 17554300 rs2012593 chr7 78014174 C T 3.10E-04 Multiple complex diseases MAGI2 intron 17554300 rs1468596 chr7 78019476 C T 7.77E-05 Cytomegalovirus antibody response MAGI2 intron 21993531 rs16886004 chr7 78021500 A G 7.84E-05 Coronary heart disease MAGI2 intron pha003032 rs7790008 chr7 78021636 A T 6.50E-05 Cytomegalovirus antibody response MAGI2 intron 21993531 rs10251797 chr7 78025427 G T 7.90E-05 Coronary heart disease MAGI2 intron pha003032 rs12667208 chr7 78029186 A G 3.62E-05 Cytomegalovirus antibody response MAGI2 intron 21993531 rs7804000 chr7 78038652 C T 9.43E-05 B cell non-Hodgkin lymphoma MAGI2 intron 23749188 rs10269990 chr7 78040277 G A 2.50E-05 Urinary metabolites MAGI2 intron 21572414 rs6967955 chr7 78040763 A G 3.09E-04 Multiple complex diseases MAGI2 intron 17554300 rs17150687 chr7 78043291 A G 3.00E-06 Response to antidepressant treatment MAGI2 intron 22041458 rs17150722 chr7 78058765 A T 6.41E-04 Nicotine smoking MAGI2 intron 19268276 rs11974883 chr7 78068524 G A,C,T 7.17E-04 Coronary heart disease MAGI2 intron 21606135 rs6466241 chr7 78104476 T C 8.70E-04 Alcohol dependence MAGI2 intron 20201924 rs10251915 chr7 78106093 G C 2.82E-04 Multiple complex diseases MAGI2 intron 17554300 rs10238963 chr7 78106556 A T 3.01E-04 Multiple complex diseases MAGI2 intron 17554300 rs13227908 chr7 78115241 C T 8.90E-04 Tourette syndrome MAGI2 intron 22889924 rs7784056 chr7 78117387 G T 1.60E-04 Lipid traits MAGI2 intron 17903299 rs10485902 chr7 78121406 G T 2.50E-05 Multiple complex diseases MAGI2 intron 17554300 rs2885560 chr7 78124424 C T 3.54E-05 Multiple complex diseases MAGI2 intron 17554300 rs62468577 chr7 78152672 C T 5.80E-06 Bronchopulmonary dysplasia MAGI2 intron 23897914 rs62468577 chr7 78152672 C T 6.00E-06 Bronchopulmonary dysplasia MAGI2 intron 23897914 rs12666870 chr7 78158472 T C 3.00E-06 Obesity-related traits MAGI2 intron 23251661 rs6466265 chr7 78160248 A G 3.72E-06 Osteoarthritis MAGI2 intron 22763110 rs17150980 chr7 78173734 T C 0.0000239 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes MAGI2 intron 22628534 rs11525066 chr7 78175977 G A 3.00E-06 Hippocampal atrophy MAGI2 intron 19668339 rs12670237 chr7 78179257 T C 0.0005618 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MAGI2 intron 23233654 rs12670237 chr7 78179257 T C 5.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI2 intron 23233662 rs2005876 chr7 78181304 T C 0.0003647 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MAGI2 intron 23233654 rs2005876 chr7 78181304 T C 3.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI2 intron 23233662 rs13245734 chr7 78183552 G T 1.95E-04 Alcohol consumption MAGI2 intron 23743675 rs12705579 chr7 78184222 G A 1.76E-04 Alcohol consumption MAGI2 intron 23743675 rs2215938 chr7 78184564 T C 0.000586 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MAGI2 intron 23233654 rs2215938 chr7 78184564 T C 5.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI2 intron 23233662 rs17372719 chr7 78190185 T G 0.0004336 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MAGI2 intron 23233654 rs17372719 chr7 78190185 T G 4.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI2 intron 23233662 rs13242509 chr7 78190213 T C 2.04E-04 Alcohol consumption MAGI2 intron 23743675 rs12705589 chr7 78190606 A G 9.88E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI2 intron 23233662 rs12705591 chr7 78191370 T C 1.80E-04 Alcohol consumption MAGI2 intron 23743675 rs17438461 chr7 78192343 A G 0.0005684 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MAGI2 intron 23233654 rs17438461 chr7 78192343 A G 5.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI2 intron 23233662 rs11979133 chr7 78215346 C T 0.0000612 Migraine MAGI2 intron 22678113 rs11979133 chr7 78215346 C T 6.12E-05 Migraine MAGI2 intron 22683712 rs319872 chr7 78230243 A G 0.000023 Salmonella-induced pyroptosis MAGI2 intron 22837397 rs38095 chr7 78234264 T C 1.49E-04 Suicide attempts in bipolar disorder MAGI2 intron 21423239 rs11770702 chr7 78249167 A G 5.08E-05 Asthma MAGI2 intron 23181788 rs38116 chr7 78256342 C T 4.90E-05 Major depressive disorder MAGI2 intron 19107115 rs1496770 chr7 78259010 C T 9.71E-04 Tourette syndrome MAGI2 intron 22889924 rs38121 chr7 78259702 T C 4.86E-04 Amyotrophic lateral sclerosis (sporadic) MAGI2 intron 24529757 rs4730427 chr7 78285960 C T 9.23E-05 Major depressive disorder MAGI2 intron 22472876 rs2047344 chr7 78309541 A T 4.26E-04 Multiple complex diseases MAGI2 intron 17554300 rs321967 chr7 78314549 G C 6.00E-05 Subclinical atherosclerosis MAGI2 intron 17903303 rs321967 chr7 78314549 G C 2.60E-05 Electrocardiographic traits and heart rate variability MAGI2 intron 17903306 rs12530747 chr7 78322498 T C 2.67E-05 Major depressive disorder MAGI2 intron 22472876 rs117545506 chr7 78323493 T C 0.00003717 Sarcoidosis MAGI2 intron 22952805 rs12536959 chr7 78326526 C T 2.51E-05 Major depressive disorder MAGI2 intron 22472876 rs1496766 chr7 78331465 T C 5.00E-06 Acute lymphoblastic leukemia (childhood) MAGI2 intron 23007406 rs142120214 chr7 78333636 C T 0.00001001 Sarcoidosis MAGI2 intron 22952805 rs1496768 chr7 78336775 A G 8.88E-04 Aortic root size MAGI2 intron 21223598 rs1390824 chr7 78343179 G C 3.96E-04 Multiple complex diseases MAGI2 intron 17554300 rs10485912 chr7 78344269 C T 6.96E-08 Metabolite levels MAGI2 intron 23281178 rs10229438 chr7 78353677 T C 5.62E-05 Major depressive disorder MAGI2 intron 22472876 rs10229458 chr7 78353733 T C 5.57E-05 Major depressive disorder MAGI2 intron 22472876 rs10230190 chr7 78354472 A T 5.62E-05 Major depressive disorder MAGI2 intron 22472876 rs6953739 chr7 78356377 T C 5.38E-05 Major depressive disorder MAGI2 intron 22472876 rs139385746 chr7 78392558 T A 0.00009718 Sarcoidosis MAGI2 intron 22952805 rs16886321 chr7 78396047 T C 8.48E-04 Cervical cancer MAGI2 intron 21716314 rs10244070 chr7 78403070 A G 6.58E-04 Response to taxane treatment (placlitaxel) MAGI2 intron 23006423 rs12705771 chr7 78403188 C T 7.59E-04 Response to taxane treatment (placlitaxel) MAGI2 intron 23006423 rs13308578 chr7 78408559 C T 4.03E-04 Alcohol dependence MAGI2 intron 20201924 rs37872 chr7 78428741 G A 5.97E-04 Response to taxane treatment (placlitaxel) MAGI2 intron 23006423 rs39731 chr7 78430226 G A 3.73E-04 Response to taxane treatment (placlitaxel) MAGI2 intron 23006423 rs1209400 chr7 78446898 T C 0.0000727 Panic disorder MAGI2 intron 23149450 rs1209400 chr7 78446898 T C 7.27E-05 Serum tamsulosin hydrochloride concentration MAGI2 intron 23151678 rs489403 chr7 78455169 A G 0.0000801 Panic disorder MAGI2 intron 23149450 rs489403 chr7 78455169 A G 8.01E-05 Serum tamsulosin hydrochloride concentration MAGI2 intron 23151678 rs519514 chr7 78456148 C T 0.0000817 Panic disorder MAGI2 intron 23149450 rs519514 chr7 78456148 C T 8.17E-05 Serum tamsulosin hydrochloride concentration MAGI2 intron 23151678 rs508733 chr7 78456168 G A 0.0000118 Panic disorder MAGI2 intron 23149450 rs508733 chr7 78456168 G A 1.18E-05 Serum tamsulosin hydrochloride concentration MAGI2 intron 23151678 rs2065198 chr7 78467217 A C 7.12E-04 Type 2 diabetes MAGI2 intron 17463246 rs1330495 chr7 78474408 C T 6.57E-04 Smoking quantity MAGI2 intron 24665060 rs10244943 chr7 78478168 T C 0.00041 Salmonella-induced pyroptosis MAGI2 intron 22837397 rs10259015 chr7 78491559 C T 0.000403 Salmonella-induced pyroptosis MAGI2 intron 22837397 rs4730552 chr7 78497786 T C 2.06E-04 Smoking quantity MAGI2 intron 24665060 rs1928913 chr7 78504420 G T 0.000261 Salmonella-induced pyroptosis MAGI2 intron 22837397 rs514463 chr7 78504731 G A 6.52E-04 Nicotine smoking MAGI2 intron 19268276 rs1799025 chr7 78507181 G A 0.00000098 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes MAGI2 intron 22628534 rs7788393 chr7 78513820 G A 4.04E-04 Smoking quantity MAGI2 intron 24665060 rs1642897 chr7 78516581 C T 8.81E-04 Schizophrenia MAGI2 intron 19197363 rs17469166 chr7 78528822 T G 8.93E-05 Bipolar disorder and schizophrenia MAGI2 intron 20889312 rs7791106 chr7 78537682 C T 1.25E-05 Bipolar disorder and schizophrenia MAGI2 intron 20889312 rs1799022 chr7 78544172 C T 8.29E-04 Tourette syndrome MAGI2 intron 22889924 rs12705836 chr7 78547202 G A 8.79E-05 Blood Pressure MAGI2 intron pha003043 rs17505 chr7 78561792 T C 8.93E-05 Serum metabolites MAGI2 intron 19043545 rs2191724 chr7 78601619 T G 5.39E-04 Obesity (extreme) MAGI2 intron 21935397 rs2215546 chr7 78609930 T C 5.48E-04 Obesity (extreme) MAGI2 intron 21935397 rs2215547 chr7 78610368 A G 5.58E-04 Obesity (extreme) MAGI2 intron 21935397 rs10259881 chr7 78612075 T G 5.58E-04 Obesity (extreme) MAGI2 intron 21935397 rs12534480 chr7 78613510 C T 5.61E-04 Obesity (extreme) MAGI2 intron 21935397 rs7793390 chr7 78615062 C A 5.63E-04 Obesity (extreme) MAGI2 intron 21935397 rs10269689 chr7 78615420 A C 5.72E-04 Obesity (extreme) MAGI2 intron 21935397 rs12537793 chr7 78616461 G A 9.28E-04 Obesity (extreme) MAGI2 intron 21935397 rs7799789 chr7 78617604 T C 2.72E-04 Multiple complex diseases MAGI2 intron 17554300 rs7809089 chr7 78619147 T C 5.76E-04 Obesity (extreme) MAGI2 intron 21935397 rs6466468 chr7 78633309 T A 9.80E-04 Obesity (extreme) MAGI2 intron 21935397 rs984312 chr7 78640790 C T 3.37E-05 Serum metabolites MAGI2 intron 19043545 rs1476106 chr7 78644077 C T 9.65E-04 Obesity (extreme) MAGI2 intron 21935397 rs2159687 chr7 78653594 A G 1.96E-05 Serum metabolites MAGI2 intron 19043545 rs4727796 chr7 78655374 T A 1.96E-05 Serum metabolites MAGI2 intron 19043545 rs10226001 chr7 78656541 G T 1.96E-05 Serum metabolites MAGI2 intron 19043545 rs12539532 chr7 78656919 A T 1.07E-05 Serum metabolites MAGI2 intron 19043545 rs10224972 chr7 78659447 A G 3.99E-04 Obesity (extreme) MAGI2 intron 21935397 rs13438061 chr7 78661550 G C 4.24E-04 Obesity (extreme) MAGI2 intron 21935397 rs13229394 chr7 78668408 G T 1.01E-04 Obesity (extreme) MAGI2 intron 21935397 rs10231279 chr7 78676614 A T 3.23E-04 Obesity (extreme) MAGI2 intron 21935397 rs4437570 chr7 78678354 C T 9.83E-04 Obesity (extreme) MAGI2 intron 21935397 rs1013571 chr7 78705521 C T 5.17E-05 Magnesium levels MAGI2 intron pha003092 rs1013572 chr7 78705576 T C 3.51E-05 Magnesium levels MAGI2 intron pha003092 rs7789445 chr7 78710811 A G 2.77E-06 Magnesium levels MAGI2 intron pha003092 rs10253328 chr7 78715532 C T 7.04E-05 Magnesium levels MAGI2 intron pha003092 rs2886053 chr7 78742376 T C 1.31E-05 Magnesium levels MAGI2 intron pha003092 rs2302442 chr7 78769110 C A 7.12E-06 Psoriasis MAGI2 intron 18364390 rs7780969 chr7 78801388 C T 2.61E-04 Birth weight MAGI2 intron 17255346 rs2159709 chr7 78856704 C A 8.40E-06 Urinary metabolites MAGI2 intron 21572414 rs2058393 chr7 78857007 A G 5.30E-06 Urinary metabolites MAGI2 intron 21572414 rs7782585 chr7 78884275 C T 3.27E-04 Response to platinum-based chemotherapy in small-cell lung cancer MAGI2 intron 20463552 rs12532467 chr7 78884853 A G 1.05E-04 Response to platinum-based chemotherapy in small-cell lung cancer MAGI2 intron 20463552 rs12532467 chr7 78884853 A G 7.29E-04 Coronary heart disease MAGI2 intron 21606135 rs6953771 chr7 78885581 G T 5.87E-04 Multiple complex diseases MAGI2 intron 17554300 rs10225262 chr7 78887925 A C 6.22E-04 Coronary Artery Disease MAGI2 intron 17634449 rs10225262 chr7 78887925 A C 6.77E-05 Response to platinum-based chemotherapy in small-cell lung cancer MAGI2 intron 20463552 rs10225262 chr7 78887925 A C 7.08E-04 Coronary heart disease MAGI2 intron 21606135 rs6952164 chr7 78890598 G A 6.53E-04 Coronary heart disease MAGI2 intron 21606135 rs6953483 chr7 78890691 C A 4.98E-04 Multiple complex diseases MAGI2 intron 17554300 rs6953483 chr7 78890691 C A 1.90E-05 Urinary metabolites MAGI2 intron 21572414 rs4730746 chr7 78900016 C T 5.52E-04 Multiple complex diseases MAGI2 intron 17554300 rs4730747 chr7 78900175 A C 9.47E-04 Multiple complex diseases MAGI2 intron 17554300 rs4730747 chr7 78900175 A C 2.50E-05 Urinary metabolites MAGI2 intron 21572414 rs1918939 chr7 78902684 G A 6.73E-04 Multiple complex diseases MAGI2 intron 17554300 rs1918939 chr7 78902684 G A 1.90E-05 Urinary metabolites MAGI2 intron 21572414 rs1406157 chr7 78910974 G A 9.10E-04 Multiple complex diseases MAGI2 intron 17554300 rs1528269 chr7 78911632 A G 9.44E-04 Multiple complex diseases MAGI2 intron 17554300 rs1528269 chr7 78911632 A G 2.60E-05 Urinary metabolites MAGI2 intron 21572414 rs1528269 chr7 78911632 A G 3.86E-04 Coronary heart disease MAGI2 intron 21606135 rs10270764 chr7 78913525 C T 2.00E-05 Urinary metabolites MAGI2 intron 21572414 rs1609276 chr7 78929161 G C 9.30E-04 Alcohol dependence MAGI2 intron 21314694 rs4129689 chr7 78935481 A T 4.44E-04 Multiple complex diseases MAGI2 intron 17554300 rs4129689 chr7 78935481 A T 2.80E-05 Urinary metabolites MAGI2 intron 21572414 rs10953835 chr7 78952979 A G 2.30E-05 Urinary metabolites MAGI2 intron 21572414 rs10270040 chr7 78964358 A G 9.70E-06 Urinary metabolites MAGI2 intron 21572414 rs17152290 chr7 78971742 T C 9.23E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI2 intron 23233662 rs17152303 chr7 78974253 T G 8.00E-06 Urinary metabolites MAGI2 intron 21572414 rs17152314 chr7 78976009 G T 0.0008789 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MAGI2 intron 23233654 rs17152314 chr7 78976009 G T 8.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI2 intron 23233662 rs7804381 chr7 78977963 A T 4.20E-06 Urinary metabolites MAGI2 intron 21572414 rs9641579 chr7 78981662 C T 0.0008912 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MAGI2 intron 23233654 rs9641579 chr7 78981662 C T 8.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI2 intron 23233662 rs2069132 chr7 78981719 C T 9.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI2 intron 23233662 rs6956190 chr7 78982307 A G 9.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI2 intron 23233662 rs9640776 chr7 78982970 C T 9.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI2 intron 23233662 rs7797165 chr7 78988777 A G 1.60E-05 Urinary metabolites MAGI2 intron 21572414 rs7808561 chr7 79025213 G A 9.17E-04 Type 2 diabetes MAGI2 intron 17463246 rs7808561 chr7 79025213 G A 9.25E-04 Alzheimer's disease MAGI2 intron 17998437 rs6953105 chr7 79025974 G A 9.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI2 intron 23233662 rs10953851 chr7 79027958 G T 8.21E-04 Type 2 diabetes MAGI2 intron 17463246 rs10953851 chr7 79027958 G T 9.78E-04 Alzheimer's disease MAGI2 intron 17998437 rs4730806 chr7 79030922 A C 7.49E-04 Suicide attempts in bipolar disorder MAGI2 intron 21041247 rs10238315 chr7 79043013 G T 4.11E-04 Suicide attempts in bipolar disorder MAGI2 intron 21041247 rs10238315 chr7 79043013 G T 0.0008738 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MAGI2 intron 23233654 rs10238315 chr7 79043013 G T 8.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI2 intron 23233662 rs2190179 chr7 79045496 C A,T 4.33E-04 Suicide attempts in bipolar disorder MAGI2 intron 21041247 rs2190179 chr7 79045496 C A,T 0.0008448 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MAGI2 intron 23233654 rs2190179 chr7 79045496 C A,T 8.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI2 intron 23233662 rs17152496 chr7 79062974 T C 0.0007901 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MAGI2 intron 23233654 rs17152496 chr7 79062974 T C 7.90E-04 Methotrexate clearance (acute lymphoblastic leukemia) MAGI2 intron 23233662 rs4730838 chr7 79070452 C T 8.60E-06 Urinary metabolites MAGI2 intron 21572414 rs1990099 chr7 79076436 T A 2.78E-05 Response to anti-TNF treatment in rheumatoid arthritis MAGI2 intron 23555300 rs1990099 chr7 79076436 T A 9.14E-05 Response to anti-TNF treatment in rheumatoid arthritis MAGI2 intron 23555300 rs10265155 chr7 79078161 T C 2.56E-05 Response to anti-TNF treatment in rheumatoid arthritis MAGI2 intron 23555300 rs10265155 chr7 79078161 T C 8.69E-05 Response to anti-TNF treatment in rheumatoid arthritis MAGI2 intron 23555300 rs991858 chr7 79079496 C T 5.87E-04 Response to cytidine analogues (gemcitabine) MAGI2 intron 24483146 rs4730857 chr7 79085543 C T 1.20E-08 Urinary metabolites MAGI2-AS3 intron 21572414 rs7812062 chr7 79109322 T C 1.70E-08 Urinary metabolites / / 21572414 rs6957113 chr7 79147585 T C 1.96E-04 Multiple complex diseases / / 17554300 rs7783895 chr7 79159240 A G 4.30E-06 Urinary metabolites / / 21572414 rs12534777 chr7 79221707 G T 2.09E-04 Coronary heart disease / / 21971053 rs2961531 chr7 79260820 T C 4.59E-04 Multiple complex diseases / / 17554300 rs2462131 chr7 79291506 T C 8.41E-05 Waist-Hip Ratio / / pha003013 rs2462131 chr7 79291506 T C 7.12E-05 Waist Circumference / / pha003025 rs2462131 chr7 79291506 T C 8.00E-05 Tunica Media / / pha003034 rs2714675 chr7 79293811 C A 8.41E-05 Waist-Hip Ratio / / pha003013 rs2714675 chr7 79293811 C A 7.12E-05 Waist Circumference / / pha003025 rs2714675 chr7 79293811 C A 8.00E-05 Tunica Media / / pha003034 rs2365695 chr7 79320736 G T 3.10E-05 Post-operative nausea and vomiting / / 21694509 rs11975512 chr7 79323090 T C 3.50E-05 Bilirubin levels / / 19414484 rs2462129 chr7 79324680 A G 3.17E-04 Alzheimer's disease (late onset) / / 21379329 rs12539478 chr7 79333681 G A 3.70E-05 Bilirubin levels / / 19414484 rs4419754 chr7 79337748 T C 3.40E-05 Bilirubin levels / / 19414484 rs2689791 chr7 79339923 G A 4.63E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2714703 chr7 79341676 G A 2.81E-04 Alzheimer's disease (late onset) / / 21379329 rs2714707 chr7 79347341 T C 5.09E-04 Taste perception / / 22132133 rs2689811 chr7 79363056 A C 1.10E-05 Urinary metabolites / / 21572414 rs2689812 chr7 79426756 A G 5.40E-07 Urinary metabolites / / 21572414 rs2707886 chr7 79445207 T C 2.50E-05 Urinary metabolites / / 21572414 rs1922725 chr7 79455233 A G 9.79E-05 Body Mass Index / / pha003014 rs2525815 chr7 79483480 C T 7.81E-05 Kawasaki disease / / 22081228 rs2707906 chr7 79519229 T G 8.77E-05 Kawasaki disease / / 22081228 rs2525835 chr7 79527088 G A 7.43E-05 Kawasaki disease / / 22081228 rs12531118 chr7 79565773 A G 9.65E-05 Kawasaki disease / / 22081228 rs6967965 chr7 79566078 T C 7.28E-05 Kawasaki disease / / 22081228 rs10229206 chr7 79585451 T C 6.80E-05 Kawasaki disease / / 22081228 rs981490 chr7 79595829 A C 2.49E-04 Graves' disease / / 21841780 rs981490 chr7 79595829 A C 6.06E-05 Kawasaki disease / / 22081228 rs17153296 chr7 79663989 C T 2.85E-04 Schizophrenia / / 20832056 rs10486922 chr7 79699054 A G 2.40E-05 Urinary metabolites / / 21572414 rs17804238 chr7 79707387 G C 9.00E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6466941 chr7 79710052 C G 6.56E-04 Obesity (extreme) / / 21935397 rs6966238 chr7 79713073 G A 6.42E-04 Alzheimer's disease / / 24755620 rs6960044 chr7 79715264 A G 7.22E-04 Obesity (extreme) / / 21935397 rs6946197 chr7 79717169 T C 2.22E-07 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs4731198 chr7 79718617 T A 8.37E-04 Obesity (extreme) / / 21935397 rs4731202 chr7 79721630 T G 1.62E-04 Alzheimer's disease / / 24755620 rs886364 chr7 79726578 C T 4.28E-04 Alzheimer's disease / / 24755620 rs2886607 chr7 79730561 C T 4.11E-04 Iron levels / / pha002876 rs10248649 chr7 79736039 T G 3.89E-04 Iron levels / / pha002876 rs12673522 chr7 79740668 G A 6.48E-04 Alzheimer's disease / / 24755620 rs1018933 chr7 79746561 C T 1.24E-04 Iron levels / / pha002876 rs2428469 chr7 79765622 C A 2.66E-04 Suicide attempts in bipolar disorder G/I1 intron 21423239 rs2714458 chr7 79766351 G A 8.75E-04 Suicide attempts in bipolar disorder G/I1 intron 21423239 rs2523194 chr7 79796815 A G 0.000000148 Total IFN-gamma response to smallpox vaccine G/I1 intron 22661280 rs10256687 chr7 79843487 G A 7.19E-05 Response to mTOR inhibitor (rapamycin) G/I1 intron 24009623 rs3890739 chr7 79844110 C A 9.10E-05 Response to mTOR inhibitor (rapamycin) G/I1 intron 24009623 rs7800163 chr7 79849484 G A 2.20E-05 Urinary metabolites / / 21572414 rs2886609 chr7 79856411 T C 1.56E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2886613 chr7 79870394 T G 4.75E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1858339 chr7 79874467 T C 2.66E-04 Heart Failure / / pha002885 rs1949131 chr7 79879451 G C 2.16E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs306705 chr7 79892337 G A 8.04E-04 White matter integrity / / 22425255 rs4728044 chr7 79903870 G A 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer / / 21245432 rs1995971 chr7 79930551 A C 1.03E-04 Endometrial cancer / / 24096698 rs1995971 chr7 79930551 A C 1.64E-04 Endometrial cancer / / 24096698 rs1995971 chr7 79930551 A C 2.50E-05 Endometrial cancer / / 24096698 rs37919 chr7 79943831 C T 1.59E-05 Epilepsy (remission after treatment) / / 23962720 rs43222 chr7 79945821 A C 2.13E-05 Epilepsy (remission after treatment) / / 23962720 rs37921 chr7 79947528 A G 1.60E-05 Epilepsy (remission after treatment) / / 23962720 rs304732 chr7 79952755 G A 6.83E-05 Epilepsy (remission after treatment) / / 23962720 rs37926 chr7 79955516 C A 7.26E-05 Epilepsy (remission after treatment) / / 23962720 rs306728 chr7 79955521 A G 8.60E-05 Epilepsy (remission after treatment) / / 23962720 rs37929 chr7 79957443 G A 6.64E-05 Epilepsy (remission after treatment) / / 23962720 rs37930 chr7 79957542 T G 9.43E-05 Epilepsy (remission after treatment) / / 23962720 rs6967989 chr7 79961806 G A 9.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs37933 chr7 79962755 A T 2.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs304739 chr7 79968083 T C 8.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs37935 chr7 79968519 T C 1.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs37936 chr7 79969058 A G 2.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs304752 chr7 79982060 T C 9.39E-05 Suicide attempts in bipolar disorder / / 21423239 rs304754 chr7 79982759 C G 9.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs304755 chr7 79984147 A G 5.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs304756 chr7 79987193 A G 4.27E-05 Suicide attempts in bipolar disorder / / 21423239 rs304757 chr7 79987206 A G 4.64E-05 Suicide attempts in bipolar disorder / / 21423239 rs10486931 chr7 79988723 A G 8.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs304763 chr7 79991144 G A 3.16E-05 Suicide attempts in bipolar disorder / / 21423239 rs6978235 chr7 79994650 T C 5.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs304774 chr7 80002614 T C 3.54E-04 Alzheimer's disease (late onset) / / 21379329 rs17153841 chr7 80039695 A G 8.43E-04 Multiple complex diseases / / 17554300 rs7784820 chr7 80050033 A G 5.30E-07 Chronic kidney disease / / 21931561 rs799940 chr7 80059557 G A 7.94E-04 Type 2 diabetes / / 17463246 rs1356254 chr7 80062550 T C 2.81E-04 Multiple complex diseases / / 17554300 rs11978272 chr7 80119690 G T 1.99E-04 Type 2 diabetes G/T3 intron 17463246 rs10954212 chr7 80140217 A G 2.97E-05 Blood pressure (response to angiotensin II receptor blocker) G/T3 intron 24192120 rs17260734 chr7 80143355 T A 5.75E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs17260769 chr7 80143428 T G 3.20E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs1524599 chr7 80145051 A G 4.19E-04 Schizophrenia / / 19197363 rs1404313 chr7 80154463 G A 2.96E-04 Schizophrenia / / 19197363 rs12706865 chr7 80166021 C A 5.46E-05 HIV-1 viral setpoint / / 21490045 rs1464794 chr7 80181115 C T 3.17E-04 Multiple complex diseases / / 17554300 rs7778094 chr7 80198588 C T 3.62E-04 Multiple complex diseases / / 17554300 rs2030711 chr7 80219942 A G 5.07E-04 Multiple complex diseases / / 17554300 rs2065668 chr7 80220608 C T 3.18E-04 Multiple complex diseases / / 17554300 rs2065668 chr7 80220608 C T 7.65E-04 Platelet CD36 surface expression / / 21478428 rs7789369 chr7 80226147 T G 3.34E-04 Multiple complex diseases / / 17554300 rs7789369 chr7 80226147 T G 7.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7807607 chr7 80226885 C T 2.11E-06 Platelet CD36 surface expression / / 21478428 rs11771839 chr7 80229221 G T 5.12E-04 Platelet CD36 surface expression / / 21478428 rs17154155 chr7 80234243 G T 1.63E-06 Platelet CD36 surface expression CD36 intron 21478428 rs10499858 chr7 80235846 A G 4.78E-04 Platelet CD36 surface expression CD36 intron 21478428 rs13236689 chr7 80236014 T G 3.00E-09 Mean platelet volume CD36 intron 22423221 rs1761662 chr7 80238463 C T 1.76E-06 Platelet CD36 surface expression CD36 intron 21478428 rs1722507 chr7 80238710 A G 2.92E-04 Multiple complex diseases CD36 intron 17554300 rs6973242 chr7 80238793 C T 1.47E-04 Multiple complex diseases CD36 intron 17554300 rs1761667 chr7 80244939 G A 4.17E-06 Platelet CD36 surface expression CD36 intron 21478428 rs11971740 chr7 80245921 A G 1.08E-05 Platelet CD36 surface expression CD36 intron 21478428 rs4731642 chr7 80248001 A G 2.24E-06 Platelet CD36 surface expression CD36 intron 21478428 rs4731643 chr7 80248029 G A 7.56E-04 Type 2 diabetes CD36 intron 17463246 rs6960369 chr7 80249319 G A 5.77E-06 Platelet CD36 surface expression CD36 intron 21478428 rs10480808 chr7 80250122 A T 8.07E-06 Platelet CD36 surface expression CD36 intron 21478428 rs12706912 chr7 80252295 A C 5.15E-06 Platelet CD36 surface expression CD36 intron 21478428 rs12706912 chr7 80252295 A C 8.05E-05 Platelet counts CD36 intron 23263863 rs4545029 chr7 80252518 T G 6.59E-06 Platelet CD36 surface expression CD36 intron 21478428 rs1537593 chr7 80253911 T C 1.46E-04 Platelet CD36 surface expression CD36 intron 21478428 rs6969989 chr7 80254410 A G 1.55E-04 Multiple complex diseases CD36 intron 17554300 rs10499859 chr7 80258810 A G 3.00E-06 Left ventricular mass CD36 intron 19454037 rs10499859 chr7 80258810 A G 9.21E-06 Platelet CD36 surface expression CD36 intron 21478428 rs9784998 chr7 80263001 C T 9.51E-06 Platelet CD36 surface expression CD36 intron 21478428 rs9784998 chr7 80263001 C T 2.20E-05 Urinary metabolites CD36 intron 21572414 rs1953298 chr7 80265451 T C 7.90E-04 Type 2 diabetes CD36 intron 17463246 rs9918586 chr7 80266736 T C 4.29E-05 Platelet CD36 surface expression CD36 intron 21478428 rs1534314 chr7 80271108 G A 2.31E-05 Platelet CD36 surface expression CD36 intron 21478428 rs1527479 chr7 80272568 T C 5.37E-04 Type 2 diabetes CD36 intron 17463246 rs1049654 chr7 80275455 A C 5.60E-06 Platelet CD36 surface expression CD36 UTR-5 21478428 rs3211817 chr7 80278107 T G 9.51E-06 Platelet CD36 surface expression CD36 intron 21478428 rs3211820 chr7 80278465 A C 9.60E-04 Type 2 diabetes and 6 quantitative traits CD36 intron 17848626 rs3211821 chr7 80278563 A G 5.84E-06 Platelet CD36 surface expression CD36 intron 21478428 rs3211830 chr7 80279718 C T 3.30E-04 Crohn's disease CD36 intron 17684544 rs3211830 chr7 80279718 C T 9.51E-06 Platelet CD36 surface expression CD36 intron 21478428 rs3211834 chr7 80280117 A C 0.000297 Antisocial behavior CD36 intron 23077488 rs3211841 chr7 80281476 C T 3.92E-08 Triglycerides CD36 intron 23063622 rs3211842 chr7 80282636 G A 2.18E-06 Platelet CD36 surface expression CD36 intron 21478428 rs3211849 chr7 80283323 A G 1.72E-06 Platelet CD36 surface expression CD36 intron 21478428 rs3211852 chr7 80283621 A G 1.65E-10 LDL cholesterol CD36 intron 23063622 rs11574703 chr7 80286908 T C 8.00E-08 Response to fenofibrate CD36 intron 22890011 rs3211867 chr7 80286940 C A 9.51E-06 Platelet CD36 surface expression CD36 intron 21478428 rs3211869 chr7 80287152 T A 1.13E-04 Platelet CD36 surface expression CD36 intron 21478428 rs3211870 chr7 80287209 C T 1.27E-06 Platelet CD36 surface expression CD36 intron 21478428 rs1358337 chr7 80288385 G A 3.44E-06 Platelet CD36 surface expression CD36 intron 21478428 rs3211883 chr7 80289043 A T 2.98E-04 Platelet CD36 surface expression CD36 intron 21478428 rs3212005 chr7 80289289 A G 6.12E-09 Cholesterol,total CD36 intron 23063622 rs3211886 chr7 80289439 G A 3.03E-04 Multiple complex diseases CD36 intron 17554300 rs1924 chr7 80291398 G A 9.51E-06 Platelet CD36 surface expression CD36 intron 21478428 rs3212011 chr7 80293910 A G 0.000000881 Triglycerides CD36 intron 23063622 rs3211916 chr7 80294810 T C 3.08E-04 Platelet CD36 surface expression CD36 intron 21478428 rs3211935 chr7 80299610 C G 1.03E-15 Triglycerides CD36 intron 23063622 rs3211935 chr7 80299610 C G 4.81E-12 Cholesterol,total CD36 intron 23063622 rs3211938 chr7 80300449 T G 4.80E-10 Metabolic syndrome phenotype CD36 STOP-GAIN 22022282 rs3211938 chr7 80300449 T G 9.00E-04 Metabolic syndrome phenotype CD36 STOP-GAIN 22022282 rs3211938 chr7 80300449 T G 9.40E-10 Metabolic syndrome phenotype CD36 STOP-GAIN 22022282 rs3211938 chr7 80300449 T G 1.40E-26 Health and aging,CVD and cancer age of onset CD36 STOP-GAIN 22174011 rs3211938 chr7 80300449 T G 1.70E-23 Health and aging,CVD and cancer age of onset CD36 STOP-GAIN 22174011 rs3211938 chr7 80300449 T G 3.80E-08 Health and aging,CVD and cancer age of onset CD36 STOP-GAIN 22174011 rs3211938 chr7 80300449 T G 0.00014 HDL cholesterol (male) CD36 STOP-GAIN 22629316 rs3211938 chr7 80300449 T G 1.37E-09 HDL cholesterol (female) CD36 STOP-GAIN 22629316 rs3211938 chr7 80300449 T G 2.60E-12 HDL cholesterol CD36 STOP-GAIN 22629316 rs3211938 chr7 80300449 T G 3.49E-12 HDL cholesterol CD36 STOP-GAIN 23236364 rs3211958 chr7 80304072 A G 3.30E-04 Taste perception CD36 intron 22132133 rs11574728 chr7 80305341 G A 1.08E-18 Triglycerides CD36 intron 23063622 rs11574728 chr7 80305341 G A 1.20E-10 LDL cholesterol CD36 intron 23063622 rs12706949 chr7 80307224 G T 6.05E-04 Taste perception CD36 UTR-3 22132133 rs6963015 chr7 80339976 T C 2.22E-04 Multiple complex diseases / / 17554300 rs2366858 chr7 80340622 C A 6.00E-10 HDL cholesterol / / 23726366 rs1880957 chr7 80354229 G A 4.68E-04 Myopia (pathological) / / 21095009 rs2886792 chr7 80376261 T C 2.03E-20 Varicose Veins SEMA3C intron pha001412 rs7456089 chr7 80385541 T G 0.0000391 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SEMA3C intron 23233654 rs7456089 chr7 80385541 T G 3.91E-05 Methotrexate clearance (acute lymphoblastic leukemia) SEMA3C intron 23233662 rs6978637 chr7 80385987 G A 0.0000563 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SEMA3C intron 23233654 rs6978637 chr7 80385987 G A 5.63E-05 Methotrexate clearance (acute lymphoblastic leukemia) SEMA3C intron 23233662 rs17147989 chr7 80386600 T C 0.0005238 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SEMA3C intron 23233654 rs17147989 chr7 80386600 T C 5.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) SEMA3C intron 23233662 rs10085651 chr7 80392371 T C 7.67E-04 Response to taxane treatment (placlitaxel) SEMA3C intron 23006423 rs1880959 chr7 80427495 C A 2.06E-04 Multiple complex diseases SEMA3C cds-synon 17554300 rs6979288 chr7 80453106 C T 2.09E-04 Multiple complex diseases SEMA3C intron 17554300 rs886660 chr7 80462839 T C 5.62E-04 Multiple complex diseases SEMA3C intron 17554300 rs17228184 chr7 80468801 A G 5.70E-05 Blood Pressure SEMA3C intron pha003045 rs17228184 chr7 80468801 A G 7.14E-05 Blood Pressure SEMA3C intron pha003047 rs1016840 chr7 80474046 T C 7.89E-05 Blood Pressure SEMA3C intron pha003046 rs17154557 chr7 80485976 C A 8.65E-05 Multiple complex diseases SEMA3C intron 17554300 rs17154557 chr7 80485976 C A 2.31E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) SEMA3C intron 24192120 rs17154557 chr7 80485976 C A 4.66E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) SEMA3C intron 24192120 rs7795137 chr7 80490446 C G 5.66E-05 Multiple complex diseases SEMA3C intron 17554300 rs7795137 chr7 80490446 C G 2.19E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) SEMA3C intron 24192120 rs7795137 chr7 80490446 C G 4.87E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) SEMA3C intron 24192120 rs2366970 chr7 80508149 A T 1.22E-04 Multiple complex diseases SEMA3C intron 17554300 rs11979430 chr7 80509256 C T 3.71E-04 Multiple complex diseases SEMA3C intron 17554300 rs11979430 chr7 80509256 C T 2.24E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) SEMA3C intron 24192120 rs11979430 chr7 80509256 C T 3.68E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) SEMA3C intron 24192120 rs7779029 chr7 80532112 T C 3.41E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) SEMA3C intron 24192120 rs7779029 chr7 80532112 T C 7.81E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) SEMA3C intron 24192120 rs7793465 chr7 80532595 C T 2.31E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) SEMA3C intron 24192120 rs7793465 chr7 80532595 C T 4.66E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) SEMA3C intron 24192120 rs10262428 chr7 80570142 T G 8.97E-06 Colorectal cancer / / 21242260 rs17296493 chr7 80584388 C A 4.39E-04 Tourette syndrome / / 22889924 rs4236644 chr7 80599357 A G 3.93E-05 Blood pressure / / 17255346 rs4236644 chr7 80599357 A G 2.00E-06 Bilirubin levels / / 19414484 rs853035 chr7 80604282 C T 2.50E-06 Bilirubin levels / / 19414484 rs853031 chr7 80605068 T A 3.10E-06 Bilirubin levels / / 19414484 rs853029 chr7 80605465 G A 1.33E-04 Blood pressure / / 17255346 rs853029 chr7 80605465 G A 6.70E-06 Bilirubin levels / / 19414484 rs853028 chr7 80605516 A C 6.70E-06 Bilirubin levels / / 19414484 rs853025 chr7 80608488 T C 6.70E-06 Bilirubin levels / / 19414484 rs853050 chr7 80619607 C T 6.62E-04 Alcohol dependence / / 21314694 rs9969152 chr7 80627183 C G 4.03E-04 Type 2 diabetes / / 17463246 rs6968624 chr7 80699831 T C 6.60E-04 Sarcoidosis / / 19165924 rs3914075 chr7 80768262 G A 3.93E-04 Multiple complex diseases / / 17554300 rs179172 chr7 80775656 A G 1.80E-05 Urinary metabolites / / 21572414 rs561061 chr7 80791180 T C 2.20E-05 Urinary metabolites / / 21572414 rs560921 chr7 80791231 T C 2.20E-05 Urinary metabolites / / 21572414 rs571662 chr7 80793782 C A 2.20E-05 Urinary metabolites / / 21572414 rs17532397 chr7 80796081 G A 3.45E-04 Multiple complex diseases / / 17554300 rs500454 chr7 80799834 T G 4.00E-06 Political ideology / / 24569950 rs471729 chr7 80801162 A G 2.20E-05 Urinary metabolites / / 21572414 rs1912367 chr7 80856984 C T 9.88E-04 Myocardial Infarction / / pha002873 rs2158376 chr7 80866153 T G 2.20E-05 Serum metabolites / / 19043545 rs976328 chr7 80873598 T G 7.86E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1509913 chr7 80874222 C T 2.55E-04 Multiple complex diseases / / 17554300 rs1509913 chr7 80874222 C T 8.03E-05 Multiple sclerosis / / 17660530 rs1509913 chr7 80874222 C T 8.43E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs325982 chr7 80886479 C T 4.24E-04 Multiple complex diseases / / 17554300 rs161837 chr7 80889221 A G 1.79E-04 Multiple complex diseases / / 17554300 rs161848 chr7 80898095 C T 3.25E-04 Multiple complex diseases / / 17554300 rs10486820 chr7 80947517 A G 7.70E-05 Vascular dementia / / 22116812 rs2189915 chr7 81001744 G A 1.61E-05 HIV-1 progression to AIDS and death / / 21811574 rs2189915 chr7 81001744 G A 8.65E-04 HIV-1 progression to AIDS and death / / 21811574 rs1557952 chr7 81031482 T C 0.0001498 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12154265 chr7 81036629 A G 0.0001505 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12154265 chr7 81036629 A G 1.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2967931 chr7 81044686 T A 0.0002397 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2967931 chr7 81044686 T A 2.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2967925 chr7 81046460 T C 0.0001491 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2967925 chr7 81046460 T C 1.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2967924 chr7 81046710 G A 0.0001484 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2967924 chr7 81046710 G A 1.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10271531 chr7 81113941 G A 3.60E-05 Anger / / 24489884 rs2098560 chr7 81225029 C T 8.14E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs10241976 chr7 81261897 G T 3.44E-04 Multiple complex diseases / / 17554300 rs7799610 chr7 81290522 A G 2.31E-06 Corneal structure / / 22003120 rs4339559 chr7 81313746 C T 2.01E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4339559 chr7 81313746 C T 3.49E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs5745711 chr7 81348021 C T 5.65E-05 Multiple complex diseases HGF intron 17554300 rs5745696 chr7 81358060 C T 5.12E-04 Suicide attempts in bipolar disorder HGF intron 21423239 rs5745696 chr7 81358060 C T 7.04E-06 Hemoglobin HGF intron pha003098 rs5745696 chr7 81358060 C T 5.48E-06 Erythrocyte counts HGF intron pha003099 rs4732404 chr7 81363897 T G 8.88E-05 Insulin resistance HGF intron 21901158 rs17427817 chr7 81364435 C G 1.14E-04 Insulin resistance HGF intron 21901158 rs5745676 chr7 81372156 A G 1.98E-04 Insulin resistance HGF UTR-3 21901158 rs5745642 chr7 81385592 G C 4.42E-10 HDL cholesterol HGF intron 23063622 rs7806326 chr7 81404628 A G 5.01E-04 Type 2 diabetes / / 17463246 rs1014091 chr7 81408549 G A 4.99E-05 Corneal structure / / 22003120 rs12666352 chr7 81411265 C T 1.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs7788432 chr7 81413055 A G 1.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs1019617 chr7 81428307 C T 3.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs4728480 chr7 81428946 A G 4.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs2194752 chr7 81433118 T G 4.74E-04 Taste perception / / 22132133 rs2367739 chr7 81458352 A G 3.70E-06 Urinary metabolites / / 21572414 rs11760903 chr7 81462447 A T 1.60E-06 Urinary metabolites / / 21572414 rs10485968 chr7 81463386 G C 1.60E-05 Blood Phenotypes / / 17903294 rs958766 chr7 81483607 A G 9.46E-05 Potassium levels / / pha003086 rs12155338 chr7 81499273 T A 3.68E-04 Major depressive disorder / / 22472876 rs1319121 chr7 81517707 C T 5.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1733623 chr7 81521295 C T 4.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1229459 chr7 81538309 G A 5.81E-04 Type 2 diabetes / / 17463246 rs1229487 chr7 81561257 T G 7.00E-05 Creatinine levels / / 20222955 rs4732418 chr7 81571561 T C 0.000218 Salmonella-induced pyroptosis / / 22837397 rs7797314 chr7 81656066 A G 9.88E-05 Follicle stimulating hormone CAC/2D1 intron 24049095 rs80063198 chr7 81714211 T C 0.00032 Breast cancer CAC/2D1 missense 23555315 rs6977982 chr7 81715040 G C 1.28E-06 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs10265730 chr7 81723112 A G 1.55E-05 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs10225295 chr7 81724717 G A 2.05E-04 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs258658 chr7 81725129 G A 1.40E-04 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs258665 chr7 81727702 G A 2.30E-05 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs10808296 chr7 81727778 T C 5.76E-04 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs258668 chr7 81728516 T C 1.77E-05 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs258671 chr7 81731446 C T 1.00E-06 Response to taxane treatment (docetaxel) CAC/2D1 intron 23006423 rs1963788 chr7 81732714 A G 5.12E-04 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs258679 chr7 81733751 A C 1.73E-05 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs258681 chr7 81734211 A G 3.40E-05 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs258683 chr7 81734933 G T 1.52E-04 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs258684 chr7 81735015 A G 2.15E-04 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs7786694 chr7 81735532 G A 3.80E-05 Diabetic retinopathy CAC/2D1 intron 21441570 rs4732421 chr7 81736267 G C 5.88E-04 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs6960102 chr7 81737327 T C 2.63E-04 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs2887115 chr7 81744432 G A 8.97E-04 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs10954663 chr7 81746620 C A 7.70E-05 Triglycerides CAC/2D1 intron 19074352 rs258688 chr7 81751207 G A 2.16E-04 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs7341478 chr7 81754449 G A 4.53E-04 Suicide attempts in bipolar disorder CAC/2D1 intron 21423239 rs2097915 chr7 81755456 C G 3.80E-05 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs929381 chr7 81756313 C A 4.36E-04 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs10486942 chr7 81758382 A G 9.50E-05 Triglycerides CAC/2D1 intron 19074352 rs258694 chr7 81758397 A G 7.95E-04 Type 2 diabetes CAC/2D1 intron 17463246 rs3801749 chr7 81759000 G C,T 3.29E-04 Suicide attempts in bipolar disorder CAC/2D1 intron 21423239 rs3801748 chr7 81759508 A G 3.99E-04 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs10234372 chr7 81764719 T C 3.94E-04 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs117566091 chr7 81765159 A G 6.24E-06 Serum dimethylarginine levels (asymmetric) CAC/2D1 intron 24159190 rs117576300 chr7 81768172 G A 6.00E-06 Serum dimethylarginine levels (asymmetric) CAC/2D1 intron 24159190 rs258723 chr7 81772396 A G 1.60E-05 Urinary metabolites CAC/2D1 intron 21572414 rs118177224 chr7 81773160 A G 6.99E-06 Serum dimethylarginine levels (asymmetric) CAC/2D1 intron 24159190 rs6942458 chr7 81782514 A G 6.13E-04 Nicotine smoking CAC/2D1 intron 19268276 rs6942458 chr7 81782514 A G 4.41E-04 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs6942458 chr7 81782514 A G 6.00E-07 Obesity-related traits CAC/2D1 intron 23251661 rs2367910 chr7 81786043 A C 3.40E-05 Asthma (bronchodilator response) CAC/2D1 intron 22792082 rs2367911 chr7 81786220 C T 5.00E-06 Bipolar disorder and schizophrenia CAC/2D1 intron 20889312 rs2367911 chr7 81786220 C T 5.90E-06 Bipolar disorder CAC/2D1 intron 21738484 rs38537 chr7 81792390 T G 7.81E-05 Cognitive impairment induced by topiramate CAC/2D1 intron 22091778 rs38545 chr7 81804220 A G 2.98E-04 Alzheimer's disease CAC/2D1 intron 17998437 rs1156450 chr7 81805657 C T 9.95E-04 Myopia (pathological) CAC/2D1 intron 21095009 rs3819437 chr7 81825697 C T 7.26E-05 Relative hand skill CAC/2D1 intron 24068947 rs4732434 chr7 81827009 A G 6.56E-04 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs3801712 chr7 81830463 G A 6.77E-04 Type 2 diabetes CAC/2D1 intron 17463246 rs11978472 chr7 81839553 A C 6.00E-06 Crohn's disease (need for surgery) CAC/2D1 intron 23665963 rs9692165 chr7 81843391 A G 3.60E-04 Age-related macular degeneration CAC/2D1 intron 22125219 rs9692165 chr7 81843391 A G 6.56E-04 Response to taxane treatment (placlitaxel) CAC/2D1 intron 23006423 rs10954668 chr7 81847651 G A 7.00E-06 Non-alcoholic fatty liver disease histology (lobular) CAC/2D1 intron 20708005 rs11514983 chr7 81853237 G A 2.41E-05 Serum metabolites CAC/2D1 intron 19043545 rs11514983 chr7 81853237 G A 8.03E-05 Blood pressure (response to calcium channel blocker) CAC/2D1 intron 24192120 rs929351 chr7 81857893 T G 9.47E-05 Non-alcoholic fatty liver disease histology (other) CAC/2D1 intron 20708005 rs929351 chr7 81857893 T G 8.00E-06 Ulcerative colitis CAC/2D1 intron 20848476 rs2299169 chr7 81923441 T C 6.18E-05 Cognitive performance CAC/2D1 intron 19734545 rs12673548 chr7 81944479 A G 9.81E-05 Cognitive performance CAC/2D1 intron 19734545 rs13221746 chr7 81951532 A G 7.02E-05 Cognitive performance CAC/2D1 intron 19734545 rs42050 chr7 81956740 A G 6.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D1 intron 20877124 rs42054 chr7 81958387 G A 6.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D1 intron 20877124 rs2368020 chr7 81981195 A G 7.26E-04 Schizophrenia CAC/2D1 intron 19197363 rs7804449 chr7 81990597 C T 3.97E-04 Schizophrenia CAC/2D1 intron 19197363 rs2299178 chr7 81997766 T C 5.53E-05 Cognitive performance CAC/2D1 intron 19734545 rs1544461 chr7 82005470 G A 3.64E-05 Systemic sclerosis CAC/2D1 intron 21750679 rs6975142 chr7 82017449 A T 4.67E-04 Alcohol dependence CAC/2D1 intron 21314694 rs3779449 chr7 82040753 A T 5.60E-04 Multiple complex diseases CAC/2D1 intron 17554300 rs12673314 chr7 82052912 C T 2.70E-04 Multiple complex diseases CAC/2D1 intron 17554300 rs10486960 chr7 82088388 C T 2.32E-05 Blood Pressure / / pha003049 rs10262537 chr7 82115240 C T 7.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) / / 23934736 rs6943870 chr7 82140732 G A 7.47E-05 Cognitive performance / / 19734545 rs2214733 chr7 82199173 G A 3.59E-04 Iron levels / / pha002876 rs11765558 chr7 82207636 T C 4.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1981576 chr7 82219425 C T 4.05E-04 Iron levels / / pha002876 rs12669461 chr7 82232623 T C 3.85E-05 Parkinson's disease (motor and cognition) / / 22658654 rs11768819 chr7 82245831 T C 1.35E-05 Coronary heart disease / / pha003055 rs916853 chr7 82295429 C T 2.04E-05 Height / / pha003010 rs11977086 chr7 82303501 T C 2.41E-06 Nasopharyngeal carcinoma / / 23209447 rs8180764 chr7 82334324 A G 1.39E-04 Coronary heart disease / / 21606135 rs2371208 chr7 82337859 G T 3.00E-06 Aging traits / / 17903295 rs17156589 chr7 82338298 C A 3.64E-04 Coronary heart disease / / 21606135 rs10238984 chr7 82340261 C T 6.32E-04 Coronary heart disease / / 21606135 rs10250565 chr7 82370821 G A 1.49E-05 Bipolar disorder,affective / / 20528957 rs10250565 chr7 82370821 G A 5.12E-04 Coronary heart disease / / 21606135 rs6979348 chr7 82375372 C T 2.84E-07 Schizophrenia / / 20185149 rs6979348 chr7 82375372 C T 1.97E-06 Bipolar disorder / / 20451256 rs34608268 chr7 82395241 G T 5.74E-04 Multiple complex diseases PCLO intron 17554300 rs17282875 chr7 82396925 A G 4.30E-05 Major depressive disorder PCLO intron 19065144 rs17282875 chr7 82396925 A G 7.50E-06 Major depressive disorder PCLO intron 19065144 rs17282875 chr7 82396925 A G 7.20E-05 Major depressive disorder PCLO intron 21621269 rs10954689 chr7 82402373 C T 9.90E-04 Multiple complex diseases PCLO intron 17554300 rs10954689 chr7 82402373 C T 4.90E-05 Major depressive disorder PCLO intron 19065144 rs10954689 chr7 82402373 C T 9.10E-05 Major depressive disorder PCLO intron 19065144 rs7785316 chr7 82415321 T C 1.23E-04 Multiple complex diseases PCLO intron 17554300 rs7785316 chr7 82415321 T C 9.61E-04 Bipolar disorder PCLO intron 19259986 rs6948464 chr7 82417332 C T 5.50E-04 Major depressive disorder PCLO intron 19065144 rs17156675 chr7 82422405 C T 1.00E-04 Major depressive disorder PCLO intron 19065144 rs17156675 chr7 82422405 C T 1.10E-04 Major depressive disorder PCLO intron 19065144 rs17156675 chr7 82422405 C T 6.80E-05 Major depressive disorder (broad) PCLO intron 20038947 rs6979066 chr7 82422937 G A 2.70E-04 Major depressive disorder PCLO intron 19065144 rs6979066 chr7 82422937 G A 8.10E-05 Major depressive disorder PCLO intron 19065144 rs6979066 chr7 82422937 G A 7.98E-05 Major depressive disorder PCLO intron 21621269 rs6954078 chr7 82435878 G T 6.50E-07 Major depressive disorder PCLO intron 19065144 rs6954078 chr7 82435878 G T 8.80E-06 Major depressive disorder PCLO intron 19065144 rs2522831 chr7 82448100 T C 3.44E-05 Major depressive disorder (broad) PCLO intron 20038947 rs2715147 chr7 82448405 C T 8.97E-05 Major depressive disorder (broad) PCLO intron 20038947 rs2715147 chr7 82448405 C T 9.80E-05 Bipolar disorder and major depressive disorder (combined) PCLO intron 20351715 rs2715147 chr7 82448405 C T 4.28E-04 Smoking initiation PCLO intron 24665060 rs2715148 chr7 82450035 A C 4.40E-07 Major depressive disorder PCLO UTR-3 19065144 rs2715148 chr7 82450035 A C 8.40E-08 Major depressive disorder PCLO UTR-3 19065144 rs2715148 chr7 82450035 A C 9.37E-05 Major depressive disorder (broad) PCLO UTR-3 20038947 rs2715148 chr7 82450035 A C 1.00E-06 Major depressive disorder PCLO UTR-3 21621269 rs2715148 chr7 82450035 A C 1.46E-05 Major depressive disorder PCLO UTR-3 pha002850 rs2522832 chr7 82450364 A G 3.15E-05 Major depressive disorder (broad) PCLO UTR-3 20038947 rs1044639 chr7 82451558 T G 6.37E-05 Major depressive disorder (broad) PCLO UTR-3 20038947 rs1044639 chr7 82451558 T G 5.90E-05 Bipolar disorder and major depressive disorder (combined) PCLO UTR-3 20351715 rs2522833 chr7 82453708 A C 6.40E-08 Major depressive disorder PCLO missense 19065144 rs2522833 chr7 82453708 A C 7.40E-07 Major depressive disorder PCLO missense 19065144 rs2522833 chr7 82453708 A C 6.44E-05 Major depressive disorder (broad) PCLO missense 20038947 rs2522833 chr7 82453708 A C 5.90E-05 Bipolar disorder and major depressive disorder (combined) PCLO missense 20351715 rs2522833 chr7 82453708 A C 2.46E-06 Major depressive disorder PCLO missense 21621269 rs2522833 chr7 82453708 A C 1.20E-06 Depression (quantitative trait) PCLO missense 23290196 rs2522833 chr7 82453708 A C 1.54E-05 Major depressive disorder PCLO missense pha002850 rs2247523 chr7 82454404 C G 3.00E-05 Major depressive disorder (broad) PCLO intron 20038947 rs2371214 chr7 82454672 T C 2.70E-05 Major depressive disorder (broad) PCLO intron 20038947 rs2715150 chr7 82455895 A G 7.05E-05 Major depressive disorder (broad) PCLO intron 20038947 rs2715150 chr7 82455895 A G 5.60E-05 Bipolar disorder and major depressive disorder (combined) PCLO intron 20351715 rs2715152 chr7 82457666 G A 8.78E-05 Major depressive disorder (broad) PCLO intron 20038947 rs2715152 chr7 82457666 G A 6.00E-05 Bipolar disorder and major depressive disorder (combined) PCLO intron 20351715 rs2715152 chr7 82457666 G A 1.70E-05 Urinary metabolites PCLO intron 21572414 rs2715154 chr7 82460866 G T 9.70E-06 Urinary metabolites PCLO intron 21572414 rs2715155 chr7 82462054 A G 7.59E-05 Major depressive disorder (broad) PCLO intron 20038947 rs2715155 chr7 82462054 A G 6.80E-05 Bipolar disorder and major depressive disorder (combined) PCLO intron 20351715 rs2715156 chr7 82462834 G A 7.64E-05 Major depressive disorder (broad) PCLO intron 20038947 rs2715156 chr7 82462834 G A 6.90E-05 Bipolar disorder and major depressive disorder (combined) PCLO intron 20351715 rs2257207 chr7 82468184 A T 7.82E-05 Major depressive disorder (broad) PCLO intron 20038947 rs2257207 chr7 82468184 A T 7.10E-05 Bipolar disorder and major depressive disorder (combined) PCLO intron 20351715 rs2715157 chr7 82468374 A C,G,T 8.81E-05 Major depressive disorder (broad) PCLO intron 20038947 rs2715158 chr7 82469606 G C 7.88E-05 Major depressive disorder (broad) PCLO intron 20038947 rs2715158 chr7 82469606 G C 7.20E-05 Bipolar disorder and major depressive disorder (combined) PCLO intron 20351715 rs2522838 chr7 82475557 T A 7.91E-05 Major depressive disorder (broad) PCLO intron 20038947 rs2522838 chr7 82475557 T A 7.20E-05 Bipolar disorder and major depressive disorder (combined) PCLO intron 20351715 rs2522839 chr7 82477648 A G 7.85E-05 Major depressive disorder (broad) PCLO intron 20038947 rs2522839 chr7 82477648 A G 7.30E-05 Bipolar disorder and major depressive disorder (combined) PCLO intron 20351715 rs2522840 chr7 82478415 T G 1.60E-06 Major depressive disorder PCLO intron 19065144 rs2522840 chr7 82478415 T G 9.90E-07 Major depressive disorder PCLO intron 19065144 rs2522840 chr7 82478415 T G 9.60E-05 Major depressive disorder (broad) PCLO intron 20038947 rs2522840 chr7 82478415 T G 7.30E-05 Bipolar disorder and major depressive disorder (combined) PCLO intron 20351715 rs2522840 chr7 82478415 T G 4.38E-06 Major depressive disorder PCLO intron 21621269 rs2522840 chr7 82478415 T G 2.85E-05 Major depressive disorder PCLO intron pha002850 rs2522841 chr7 82479194 G T 7.85E-05 Major depressive disorder (broad) PCLO intron 20038947 rs2522841 chr7 82479194 G T 7.30E-05 Bipolar disorder and major depressive disorder (combined) PCLO intron 20351715 rs2522843 chr7 82479722 C A 7.40E-05 Bipolar disorder and major depressive disorder (combined) PCLO intron 20351715 rs2522843 chr7 82479722 C A 8.30E-06 Urinary metabolites PCLO intron 21572414 rs2522844 chr7 82480092 C T 7.72E-05 Major depressive disorder (broad) PCLO intron 20038947 rs2522844 chr7 82480092 C T 7.30E-05 Bipolar disorder and major depressive disorder (combined) PCLO intron 20351715 rs2371362 chr7 82496254 C T 6.40E-05 Bipolar disorder and major depressive disorder (combined) PCLO intron 20351715 rs2888018 chr7 82501290 T G 1.50E-04 Major depressive disorder PCLO intron 19065144 rs2888018 chr7 82501290 T G 4.50E-05 Major depressive disorder PCLO intron 19065144 rs2888019 chr7 82503409 C T 5.50E-05 Bipolar disorder and major depressive disorder (combined) PCLO intron 20351715 rs1986742 chr7 82503442 T C 1.80E-05 Urinary metabolites PCLO intron 21572414 rs2371368 chr7 82532371 G A 9.70E-04 Tourette syndrome PCLO intron 22889924 rs12539066 chr7 82553949 C T 5.85E-04 Tourette syndrome PCLO intron 22889924 rs2107828 chr7 82555669 A T 2.80E-06 Major depressive disorder PCLO intron 19065144 rs2107828 chr7 82555669 A T 4.20E-06 Major depressive disorder PCLO intron 19065144 rs2107828 chr7 82555669 A T 1.48E-05 Major depressive disorder PCLO intron 21621269 rs2107828 chr7 82555669 A T 5.11E-05 Major depressive disorder PCLO intron pha002850 rs9690648 chr7 82561324 T C 9.10E-05 Multiple complex diseases PCLO intron 17554300 rs9690648 chr7 82561324 T C 6.50E-06 Urinary metabolites PCLO intron 21572414 rs7799260 chr7 82563516 C G 1.70E-05 Major depressive disorder PCLO intron 19065144 rs7799260 chr7 82563516 C G 2.80E-05 Major depressive disorder PCLO intron 19065144 rs7799260 chr7 82563516 C G 9.70E-05 Major depressive disorder PCLO intron 21621269 rs12669254 chr7 82573098 T C 2.05E-04 Depression (quantitative trait) PCLO intron 20800221 rs10487652 chr7 82610116 T C 4.41E-05 Multiple complex diseases PCLO intron 17554300 rs41593 chr7 82642109 C T 9.99E-04 Multiple complex diseases PCLO intron 17554300 rs28156 chr7 82646210 T C 0.000044 post-traumatic stress disorder PCLO intron 22869035 rs28156 chr7 82646210 T C 4.40E-05 Schizophrenia PCLO intron 22883433 rs11562068 chr7 82708581 T G 9.72E-04 Multiple complex diseases PCLO intron 17554300 rs12667413 chr7 82710559 C T 4.92E-04 Multiple complex diseases PCLO intron 17554300 rs2057899 chr7 82720226 C T 2.77E-05 Major depressive disorder (broad) PCLO intron 20038947 rs11562069 chr7 82721742 A G 2.86E-05 Major depressive disorder (broad) PCLO intron 20038947 rs6955217 chr7 82721814 T C 3.11E-05 Major depressive disorder (broad) PCLO intron 20038947 rs12531615 chr7 82724539 T C 5.27E-05 Multiple complex diseases PCLO intron 17554300 rs12531615 chr7 82724539 T C 5.92E-05 Major depressive disorder (broad) PCLO intron 20038947 rs975727 chr7 82725319 G A 4.68E-05 Major depressive disorder (broad) PCLO intron 20038947 rs6947662 chr7 82725618 G C 4.24E-05 Major depressive disorder (broad) PCLO intron 20038947 rs2023984 chr7 82727063 C T 4.46E-05 Major depressive disorder (broad) PCLO intron 20038947 rs6467929 chr7 82728378 A G 4.46E-05 Major depressive disorder (broad) PCLO intron 20038947 rs17157155 chr7 82729409 C T 2.87E-05 Major depressive disorder (broad) PCLO intron 20038947 rs12666717 chr7 82730446 A G 3.04E-05 Major depressive disorder (broad) PCLO intron 20038947 rs10954706 chr7 82730622 A G 4.48E-05 Major depressive disorder (broad) PCLO intron 20038947 rs10954707 chr7 82730637 C T 4.50E-05 Major depressive disorder (broad) PCLO intron 20038947 rs7781169 chr7 82730731 C T 4.50E-05 Major depressive disorder (broad) PCLO intron 20038947 rs17819684 chr7 82732583 G T 3.05E-05 Major depressive disorder (broad) PCLO intron 20038947 rs2190044 chr7 82734006 A G 4.52E-05 Major depressive disorder (broad) PCLO intron 20038947 rs7791742 chr7 82734845 T C 4.55E-05 Major depressive disorder (broad) PCLO intron 20038947 rs17157173 chr7 82735376 G A 4.75E-05 Major depressive disorder (broad) PCLO intron 20038947 rs17157177 chr7 82735618 C T 2.67E-05 Major depressive disorder (broad) PCLO intron 20038947 rs16887406 chr7 82735658 A G 3.57E-05 Major depressive disorder (broad) PCLO intron 20038947 rs6950924 chr7 82736474 C T 7.24E-05 Major depressive disorder (broad) PCLO intron 20038947 rs6467931 chr7 82736869 G A 8.70E-05 Major depressive disorder (broad) PCLO intron 20038947 rs2877 chr7 82764425 C G 3.71E-04 IgE levels PCLO missense 17255346 rs7783211 chr7 82771395 C T 5.90E-05 HIV-1 control PCLO intron 20041166 rs4644166 chr7 82779790 A G 5.87E-04 Major depressive disorder PCLO intron 22472876 rs61738783 chr7 82785304 G A 0.00024 Prostate cancer PCLO missense 23555315 rs7806474 chr7 82819038 T C 8.68E-04 Multiple complex diseases / / 17554300 rs10486909 chr7 82832058 T C 7.29E-04 White matter integrity / / 22425255 rs1557787 chr7 82833874 C T 8.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs1159635 chr7 82835999 A G 9.30E-04 Acute lung injury / / 22295056 rs1018922 chr7 82836847 G C 9.30E-04 Acute lung injury / / 22295056 rs6979858 chr7 82859871 G A 6.78E-04 Acute lung injury / / 22295056 rs2709950 chr7 82876269 C T 4.64E-04 Acute lung injury / / 22295056 rs10264381 chr7 82881692 C A 3.42E-04 Acute lung injury / / 22295056 rs17148193 chr7 82889177 A T 2.22E-06 Nasopharyngeal carcinoma / / 23209447 rs1011944 chr7 82891787 A G 5.13E-04 White matter integrity / / 22425255 rs17289395 chr7 82897336 G A 7.03E-05 Multiple complex diseases / / 17554300 rs929245 chr7 82919809 T C 6.37E-04 Acute lung injury / / 22295056 rs3109175 chr7 82922347 A T 4.99E-04 Multiple complex diseases / / 17554300 rs1974510 chr7 82927290 T C 2.92E-04 Acute lung injury / / 22295056 rs2522336 chr7 82930278 C T 5.05E-04 Acute lung injury / / 22295056 rs2522333 chr7 82932149 C T 5.28E-04 Acute lung injury / / 22295056 rs2522330 chr7 82933189 T C 5.33E-04 Multiple complex diseases / / 17554300 rs10085746 chr7 82941408 C T 4.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs10085746 chr7 82941408 C T 7.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs2522364 chr7 82947422 T C 4.44E-04 Aortic root size / / 21223598 rs9690922 chr7 82968522 A G 4.50E-04 Alcohol dependence / / 20201924 rs9690922 chr7 82968522 A G 8.10E-04 Alcohol dependence / / 20201924 rs12670243 chr7 82969350 T C 2.94E-72 Multiple complex diseases / / 17554300 rs17157566 chr7 83014104 G A 1.18E-04 Multiple complex diseases SEMA3E intron 17554300 rs9691085 chr7 83023366 T C 4.51E-04 Serum selenium levels SEMA3E intron 23698163 rs2722983 chr7 83036894 C T 4.53E-04 Lung function (forced vital capacity) SEMA3E intron 24023788 rs2247219 chr7 83067470 T G 6.23E-06 Alcohol and nictotine co-dependence SEMA3E intron 20158304 rs12536989 chr7 83071871 A C 4.16E-04 Serum selenium levels SEMA3E intron 23698163 rs7811465 chr7 83096699 T C 9.60E-04 Multiple complex diseases SEMA3E intron 17554300 rs2713189 chr7 83114212 C T 1.39E-04 Eating disorders (purging via substances) SEMA3E intron 23568457 rs2535375 chr7 83129383 T C 2.30E-05 Urinary metabolites SEMA3E intron 21572414 rs7791887 chr7 83130615 A T 1.63E-04 Obesity (extreme) SEMA3E intron 21935397 rs2041426 chr7 83147034 C G 7.81E-04 Obesity (extreme) SEMA3E intron 21935397 rs2535370 chr7 83147705 A G 3.95E-04 Obesity (extreme) SEMA3E intron 21935397 rs1860610 chr7 83149564 G T 7.67E-04 Obesity (extreme) SEMA3E intron 21935397 rs2535369 chr7 83151008 G A 7.67E-04 Obesity (extreme) SEMA3E intron 21935397 rs2109543 chr7 83152022 G A 7.67E-04 Obesity (extreme) SEMA3E intron 21935397 rs2535368 chr7 83157207 C T 5.90E-05 Staphylococcus aureus infection SEMA3E intron 24847357 rs2535364 chr7 83159490 T C 7.80E-04 Obesity (extreme) SEMA3E intron 21935397 rs2713140 chr7 83162571 C T 8.01E-04 Obesity (extreme) SEMA3E intron 21935397 rs978582 chr7 83165515 C A 8.46E-04 Obesity (extreme) SEMA3E intron 21935397 rs1639309 chr7 83174363 A G 1.00E-04 Prostate cancer SEMA3E intron 21743057 rs215274 chr7 83191870 T G 4.50E-04 Multiple complex diseases SEMA3E intron 17554300 rs215274 chr7 83191870 T G 4.51E-06 Serum metabolites SEMA3E intron 19043545 rs169992 chr7 83209312 G C 7.98E-04 Multiple complex diseases SEMA3E intron 17554300 rs169992 chr7 83209312 G C 7.55E-05 Serum metabolites SEMA3E intron 19043545 rs215302 chr7 83213264 G A 5.06E-04 Multiple complex diseases SEMA3E intron 17554300 rs215302 chr7 83213264 G A 1.38E-06 Serum metabolites SEMA3E intron 19043545 rs3801562 chr7 83223216 C G 3.36E-04 Multiple complex diseases SEMA3E intron 17554300 rs3801562 chr7 83223216 C G 1.38E-06 Serum metabolites SEMA3E intron 19043545 rs2371868 chr7 83234722 G A 8.70E-04 Type 2 diabetes SEMA3E intron 17463246 rs302121 chr7 83273775 T A 2.92E-04 Type 2 diabetes SEMA3E intron 17463246 rs302099 chr7 83314133 T C 7.32E-07 Schizophrenia / / 21926974 rs6949364 chr7 83403157 C T 1.63E-04 Lung function (forced vital capacity) / / 24023788 rs797649 chr7 83475222 G A 1.50E-05 Urinary metabolites / / 21572414 rs6467970 chr7 83502255 A G 1.97E-10 Multiple sclerosis / / 17660530 rs10954737 chr7 83533047 T C 1.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7796199 chr7 83577402 T C 8.40E-04 Type 2 diabetes / / 17463246 rs17158388 chr7 83581709 G A 8.38E-04 Acute lung injury / / 22295056 rs6963635 chr7 83593805 C T 1.23E-04 Diabetic nephropathy SEMA3A intron 21150874 rs6963635 chr7 83593805 C T 8.90E-04 Type 2 diabetes SEMA3A intron 22238593 rs797810 chr7 83596683 C T 8.90E-04 Alzheimer's disease SEMA3A intron 24755620 rs701320 chr7 83606518 G A 4.67E-04 Multiple complex diseases SEMA3A intron 17554300 rs797820 chr7 83609039 G A 8.00E-06 Attention deficit hyperactivity disorder SEMA3A intron 21784300 rs2535786 chr7 83613883 T C 1.69E-04 Multiple complex diseases SEMA3A intron 17554300 rs10499878 chr7 83639687 A G 4.54E-05 Post-operative nausea and vomiting SEMA3A intron 21694509 rs11974894 chr7 83652875 T C 7.43E-04 Smoking cessation SEMA3A intron 24665060 rs10235789 chr7 83656800 T C 3.00E-06 Iris characteristics SEMA3A intron 21835309 rs10235789 chr7 83656800 T C 7.00E-11 Iris characteristics SEMA3A intron 21835309 rs1357814 chr7 83658669 T C 6.29E-04 Smoking cessation SEMA3A intron 24665060 rs17158532 chr7 83661218 T C 2.00E-05 Urinary metabolites SEMA3A intron 21572414 rs2372020 chr7 83668574 T A,C 7.60E-06 Urinary metabolites SEMA3A intron 21572414 rs2372022 chr7 83671947 G A 2.62E-04 Smoking cessation SEMA3A intron 24665060 rs41323648 chr7 83673516 C T 2.64E-04 Coronary Artery Disease SEMA3A intron 17634449 rs41323648 chr7 83673516 C T 1.90E-05 Urinary metabolites SEMA3A intron 21572414 rs2527033 chr7 83705871 G C 9.10E-04 Type 2 diabetes SEMA3A intron 17463246 rs2527033 chr7 83705871 G C 5.52E-04 Multiple complex diseases SEMA3A intron 17554300 rs2527033 chr7 83705871 G C 8.43E-04 Coronary Artery Disease SEMA3A intron 17634449 rs41441447 chr7 83719152 A G 4.89E-04 Multiple complex diseases SEMA3A intron 17554300 rs41441447 chr7 83719152 A G 4.27E-04 Coronary Artery Disease SEMA3A intron 17634449 rs3801616 chr7 83721051 G A 9.92E-04 Multiple complex diseases SEMA3A intron 17554300 rs6965990 chr7 83721292 A T 5.64E-04 Multiple complex diseases SEMA3A intron 17554300 rs11976072 chr7 83721922 G T 5.47E-04 Multiple complex diseases SEMA3A intron 17554300 rs11976072 chr7 83721922 G T 5.81E-04 Coronary Artery Disease SEMA3A intron 17634449 rs7808864 chr7 83723347 A G 4.93E-04 Nicotine smoking SEMA3A intron 19268276 rs2057845 chr7 83723672 G T 6.14E-04 Multiple complex diseases SEMA3A intron 17554300 rs13228082 chr7 83726968 A G 6.86E-04 Multiple complex diseases SEMA3A intron 17554300 rs13228082 chr7 83726968 A G 4.89E-04 Coronary Artery Disease SEMA3A intron 17634449 rs7806871 chr7 83727983 A G 5.74E-04 Multiple complex diseases SEMA3A intron 17554300 rs7806871 chr7 83727983 A G 6.38E-04 Coronary Artery Disease SEMA3A intron 17634449 rs17298417 chr7 83730162 T C 5.64E-04 Multiple complex diseases SEMA3A intron 17554300 rs17298417 chr7 83730162 T C 1.72E-04 Coronary Artery Disease SEMA3A intron 17634449 rs10488268 chr7 83733446 C T 2.60E-05 Urinary metabolites SEMA3A intron 21572414 rs3801629 chr7 83734593 A G 6.70E-04 Coronary Artery Disease SEMA3A intron 17634449 rs3801631 chr7 83734989 G A 2.60E-05 Urinary metabolites SEMA3A intron 21572414 rs727650 chr7 83735838 A G 2.60E-05 Urinary metabolites SEMA3A intron 21572414 rs995866 chr7 83745039 A C 4.40E-05 Schizophrenia SEMA3A intron 19571809 rs10808306 chr7 83767093 G A 8.34E-04 Acute lung injury SEMA3A intron 22295056 rs447 chr7 83772415 T C 7.93E-04 Acute lung injury SEMA3A intron 22295056 rs447 chr7 83772415 T C 4.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) SEMA3A intron 23453885 rs10263314 chr7 83776972 C T 9.16E-04 Acute lung injury SEMA3A intron 22295056 rs73177474 chr7 83777151 T C 5.38E-05 Atopic dermatitis SEMA3A intron 23042114 rs6978184 chr7 83778360 C T 9.58E-04 Acute lung injury SEMA3A intron 22295056 rs73177481 chr7 83778559 A T 5.32E-05 Atopic dermatitis SEMA3A intron 23042114 rs7781152 chr7 83782435 T C 2.80E-05 Urinary metabolites SEMA3A intron 21572414 rs17158675 chr7 83782839 G A 9.00E-06 Obesity-related traits SEMA3A intron 23251661 rs10261069 chr7 83801652 C T 3.86E-04 Nicotine smoking SEMA3A intron 19268276 rs12707628 chr7 83817895 C T 6.70E-04 Adiposity SEMA3A intron 19461586 rs12707628 chr7 83817895 C T 1.28E-04 Alzheimer's disease (late onset) SEMA3A intron 21379329 rs12673519 chr7 83828000 G A 8.68E-06 Fibrinogen / / pha003068 rs7799452 chr7 83851234 T G 3.22E-04 Multiple complex diseases / / 17554300 rs1989964 chr7 83859120 G A 8.84E-04 Type 2 diabetes / / 17463246 rs526445 chr7 83883994 C T 7.11E-04 Acute lung injury / / 22295056 rs473880 chr7 83909080 G A 4.10E-04 Acute lung injury / / 22295056 rs488333 chr7 83911271 G A 3.00E-06 Prion diseases / / 22210626 rs594533 chr7 83936564 T C 5.41E-04 Type 2 diabetes / / 17463246 rs10488591 chr7 83944506 G T 7.61E-05 Fibrinogen / / pha003068 rs520536 chr7 83964438 G C 3.70E-04 Multiple complex diseases / / 17554300 rs1228861 chr7 83999393 C A,G 8.24E-04 Depression (quantitative trait) / / 20800221 rs1228877 chr7 84017279 C G 4.64E-04 Depression (quantitative trait) / / 20800221 rs622514 chr7 84022766 A C 4.62E-04 Depression (quantitative trait) / / 20800221 rs1228870 chr7 84028918 G T 7.62E-05 Systemic sclerosis / / 21750679 rs2158168 chr7 84031430 T C 4.50E-04 Depression (quantitative trait) / / 20800221 rs1634611 chr7 84041080 T A 4.45E-04 Depression (quantitative trait) / / 20800221 rs1228957 chr7 84046286 G A 4.33E-04 Depression (quantitative trait) / / 20800221 rs1228893 chr7 84056502 A C 4.33E-04 Depression (quantitative trait) / / 20800221 rs1228946 chr7 84065937 G A 9.59E-04 Depression (quantitative trait) / / 20800221 rs1228948 chr7 84068755 T G 2.51E-04 Multiple complex diseases / / 17554300 rs2706910 chr7 84071654 G C 5.23E-04 Depression (quantitative trait) / / 20800221 rs2527530 chr7 84076213 T C 9.69E-04 Depression (quantitative trait) / / 20800221 rs1228964 chr7 84082878 A T 4.35E-04 Depression (quantitative trait) / / 20800221 rs1228966 chr7 84086502 G A 8.77E-05 Systemic sclerosis / / 21750679 rs1228967 chr7 84086868 G A 4.37E-04 Depression (quantitative trait) / / 20800221 rs2715038 chr7 84095097 C A 8.63E-05 Multiple complex diseases / / 17554300 rs1228907 chr7 84101085 G A 4.78E-04 Depression (quantitative trait) / / 20800221 rs1228908 chr7 84102251 C G 4.81E-04 Depression (quantitative trait) / / 20800221 rs1228969 chr7 84103544 T G 4.77E-04 Depression (quantitative trait) / / 20800221 rs1228974 chr7 84105914 G A 4.06E-04 Depression (quantitative trait) / / 20800221 rs1228911 chr7 84110281 T A 4.69E-04 Depression (quantitative trait) / / 20800221 rs1228932 chr7 84115236 T C 3.99E-04 Depression (quantitative trait) / / 20800221 rs1235296 chr7 84126147 G A 4.29E-04 Depression (quantitative trait) / / 20800221 rs1029538 chr7 84127398 T C 3.79E-04 Depression (quantitative trait) / / 20800221 rs1228914 chr7 84130829 G T 5.16E-04 Depression (quantitative trait) / / 20800221 rs1228921 chr7 84133847 A T 5.15E-04 Depression (quantitative trait) / / 20800221 rs1228924 chr7 84136126 C T 5.02E-04 Depression (quantitative trait) / / 20800221 rs1228925 chr7 84136556 A G 4.99E-04 Depression (quantitative trait) / / 20800221 rs1228926 chr7 84136907 C T 4.95E-04 Depression (quantitative trait) / / 20800221 rs757747 chr7 84137622 C T 5.57E-05 Systemic sclerosis / / 21750679 rs1029541 chr7 84139004 C T 2.37E-05 Systemic sclerosis / / 21750679 rs1228928 chr7 84140810 C A 3.61E-04 Depression (quantitative trait) / / 20800221 rs1228968 chr7 84142487 A G 3.48E-04 Depression (quantitative trait) / / 20800221 rs1228897 chr7 84145460 G A 3.38E-04 Depression (quantitative trait) / / 20800221 rs722453 chr7 84199561 A G 6.43E-06 Ankle-brachial index / / 22199011 rs17159178 chr7 84205803 G A 4.92E-04 Multiple complex diseases / / 17554300 rs7780912 chr7 84272193 A G 6.57E-06 Ankle-brachial index / / 22199011 rs4422706 chr7 84273418 A G 7.38E-05 Magnesium levels / / pha003092 rs4278108 chr7 84317206 G A 3.63E-04 Depression (quantitative trait) / / 20800221 rs4732577 chr7 84318483 G A 3.61E-04 Depression (quantitative trait) / / 20800221 rs4481536 chr7 84325487 C T 3.67E-04 Depression (quantitative trait) / / 20800221 rs4329228 chr7 84328077 A C 3.58E-04 Depression (quantitative trait) / / 20800221 rs4329228 chr7 84328077 A C 7.46E-04 Rheumatoid arthritis / / 21452313 rs4329228 chr7 84328077 A C 1.08E-05 Systemic sclerosis / / 21750679 rs3924501 chr7 84331306 C G 3.44E-04 Depression (quantitative trait) / / 20800221 rs12707672 chr7 84335526 T C 7.75E-04 HIV-1 viral setpoint / / 17641165 rs12154270 chr7 84344258 C T 4.67E-05 Pancreatic cancer / / pha002889 rs12707680 chr7 84431297 A C 8.32E-05 Pancreatic cancer / / pha002889 rs10277279 chr7 84525520 G A 1.07E-04 Pancreatic cancer / / pha002874 rs10277279 chr7 84525520 G A 6.93E-05 Pancreatic cancer / / pha002889 rs782895 chr7 84530326 A G 1.15E-04 Pancreatic cancer / / pha002874 rs7796898 chr7 84593194 T C 8.81E-05 Magnesium levels / / pha003092 rs1528619 chr7 84593707 T G 7.17E-11 Multiple complex diseases / / 17554300 rs17148271 chr7 84641663 T G 2.17E-04 Multiple complex diseases SEMA3D intron 17554300 rs16887803 chr7 84668144 T C 4.29E-04 Multiple complex diseases SEMA3D intron 17554300 rs16887818 chr7 84691443 C G 4.44E-04 Suicide attempts in bipolar disorder SEMA3D intron 21041247 rs4461846 chr7 84692409 C T 4.40E-04 Suicide attempts in bipolar disorder SEMA3D intron 21041247 rs2240394 chr7 84692941 T C 4.36E-04 Suicide attempts in bipolar disorder SEMA3D intron 21041247 rs2240394 chr7 84692941 T C 1.52E-04 Major depression (suicidal thoughts and behavior) SEMA3D intron 21750702 rs7800255 chr7 84694134 T A 7.14E-04 Suicide attempts in bipolar disorder SEMA3D intron 21041247 rs16887821 chr7 84696314 G C 1.87E-04 Suicide attempts in bipolar disorder SEMA3D intron 21041247 rs6966472 chr7 84699387 T C 1.85E-04 Suicide attempts in bipolar disorder SEMA3D intron 21041247 rs6966472 chr7 84699387 T C 4.75E-05 Major depression (suicidal thoughts and behavior) SEMA3D intron 21750702 rs6957484 chr7 84702152 G T 1.84E-04 Suicide attempts in bipolar disorder SEMA3D intron 21041247 rs2286192 chr7 84704709 T C 1.79E-04 Suicide attempts in bipolar disorder SEMA3D intron 21041247 rs7809347 chr7 84707597 A G 1.93E-04 Suicide attempts in bipolar disorder SEMA3D intron 21041247 rs13222785 chr7 84708562 G A 1.93E-04 Suicide attempts in bipolar disorder SEMA3D intron 21041247 rs10486848 chr7 84737683 G A 8.43E-05 stroke (ischemic) SEMA3D intron 17434096 rs10486848 chr7 84737683 G A 2.01E-04 Suicide attempts in bipolar disorder SEMA3D intron 21041247 rs1029563 chr7 84738495 T G 5.36E-04 Suicide attempts in bipolar disorder SEMA3D intron 21041247 rs17561679 chr7 84739093 T C 5.51E-04 Suicide attempts in bipolar disorder SEMA3D intron 21041247 rs1029564 chr7 84739855 T G 5.55E-04 Suicide attempts in bipolar disorder SEMA3D intron 21041247 rs17561700 chr7 84742757 T G 2.31E-04 Suicide attempts in bipolar disorder SEMA3D intron 21041247 rs17647248 chr7 84744822 A T 2.76E-04 Coronary heart disease SEMA3D intron 21606135 rs2159575 chr7 84760424 C T 5.53E-04 Suicide attempts in bipolar disorder / / 21041247 rs764077 chr7 84764394 G A 1.23E-04 Coronary heart disease / / 21606135 rs2215439 chr7 84795710 G A 5.33E-05 Colorectal cancer / / 19723657 rs1013264 chr7 84820483 C T 5.90E-04 Type 2 diabetes / / 17463246 rs2732744 chr7 84842884 T C 7.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs2159579 chr7 84845546 G T 4.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs2159579 chr7 84845546 G T 9.97E-06 Kawasaki disease / / 21221998 rs2732743 chr7 84845930 T C 7.57E-04 Suicide attempts in bipolar disorder / / 21041247 rs2732742 chr7 84846819 A G 7.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs2732741 chr7 84847985 T A 6.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs2534851 chr7 84848151 G T 7.48E-04 Suicide attempts in bipolar disorder / / 21041247 rs2732738 chr7 84848689 A G 7.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs2732737 chr7 84848948 A G 7.43E-04 Suicide attempts in bipolar disorder / / 21041247 rs2534846 chr7 84875267 A G 8.09E-04 Multiple complex diseases / / 17554300 rs2696171 chr7 84956506 T G 9.86E-04 Depression (quantitative trait) / / 20800221 rs6944054 chr7 85002595 A G 7.00E-04 Response to interferon beta in multiple sclerosis / / 18195134 rs2435272 chr7 85007066 G T 0.00000725 LDL cholesterol particle diameter / / 23263444 rs2463468 chr7 85009349 C T 0.00000734 LDL cholesterol particle diameter / / 23263444 rs2463470 chr7 85011197 C A 2.46E-04 Type 2 diabetes / / 17463246 rs2463475 chr7 85016000 C T 0.00000699 LDL cholesterol particle diameter / / 23263444 rs1960550 chr7 85024643 C T 0.00000645 LDL cholesterol particle diameter / / 23263444 rs1916666 chr7 85026319 C T 1.32E-04 Type 2 diabetes / / 17463246 rs2463478 chr7 85030592 T G 0.00000605 LDL cholesterol particle diameter / / 23263444 rs1583081 chr7 85034227 G T 0.00000551 LDL cholesterol particle diameter / / 23263444 rs2463480 chr7 85036389 C T 0.00000535 LDL cholesterol particle diameter / / 23263444 rs2435264 chr7 85036405 A T 0.00000533 LDL cholesterol particle diameter / / 23263444 rs7794512 chr7 85045881 G A 0.00000603 LDL cholesterol particle diameter / / 23263444 rs11768400 chr7 85055535 A G 7.00E-07 Alzheimer's disease / / 19734903 rs11768400 chr7 85055535 A G 3.10E-05 Alzheimer's disease (late onset) / / 21460841 rs1074312 chr7 85056750 C G 4.78E-05 Brain structure / / 22504417 rs6465004 chr7 85056906 T C 7.10E-07 Alzheimer's disease / / 19734903 rs6465004 chr7 85056906 T C 3.10E-05 Alzheimer's disease (late onset) / / 21460841 rs17159934 chr7 85070736 A C 7.66E-05 Schizophrenia / / 20185149 rs1560315 chr7 85075150 G C 8.94E-05 Schizophrenia / / 20185149 rs11762648 chr7 85077205 C T 1.70E-06 Alzheimer's disease / / 19734903 rs11762648 chr7 85077205 C T 5.30E-05 Alzheimer's disease (late onset) / / 21460841 rs12704129 chr7 85079348 T A 7.91E-07 Alzheimer's disease / / 19734903 rs12704129 chr7 85079348 T A 2.70E-05 Alzheimer's disease (late onset) / / 21460841 rs2498553 chr7 85080339 C A 3.39E-05 Gallstones / / 17632509 rs11769386 chr7 85083869 G C 8.20E-07 Alzheimer's disease / / 19734903 rs11769386 chr7 85083869 G C 2.90E-05 Alzheimer's disease (late onset) / / 21460841 rs1852697 chr7 85097007 T C 2.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1852697 chr7 85097007 T C 4.96E-04 Tourette syndrome / / 22889924 rs2462051 chr7 85099770 G T 1.20E-05 Alzheimer's disease / / 19734903 rs2462051 chr7 85099770 G T 6.90E-04 Alzheimer's disease (late onset) / / 21460841 rs2462049 chr7 85099898 G T 1.10E-05 Alzheimer's disease / / 19734903 rs2462049 chr7 85099898 G T 5.00E-04 Alzheimer's disease (late onset) / / 21460841 rs2463670 chr7 85104293 C A 1.80E-07 Alzheimer's disease / / 19734903 rs2463670 chr7 85104293 C A 3.30E-06 Alzheimer's disease (late onset) / / 21460841 rs13231722 chr7 85115886 T C 2.40E-05 Alzheimer's disease LOC100505913 intron 19734903 rs10499889 chr7 85121064 T C 5.20E-05 Alzheimer's disease (late onset) / / 21460841 rs4142954 chr7 85123392 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17328908 chr7 85147760 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6951823 chr7 85160755 T G 1.10E-05 Alzheimer's disease / / 19734903 rs6951823 chr7 85160755 T G 3.10E-04 Alzheimer's disease (late onset) / / 21460841 rs10252600 chr7 85177938 T C 1.30E-05 Alzheimer's disease / / 19734903 rs10252600 chr7 85177938 T C 8.92E-05 Longevity / / 20304771 rs10252600 chr7 85177938 T C 3.70E-04 Alzheimer's disease (late onset) / / 21460841 rs12334143 chr7 85183016 T C 8.00E-07 Alzheimer's disease / / 19734903 rs12334143 chr7 85183016 T C 8.00E-06 Alzheimer's disease (late onset) / / 21460841 rs12333397 chr7 85183062 A G 1.80E-06 Alzheimer's disease / / 19734903 rs12333397 chr7 85183062 A G 1.40E-05 Alzheimer's disease (late onset) / / 21460841 rs4146052 chr7 85239145 T C 4.95E-04 Type 2 diabetes / / 17463246 rs4529380 chr7 85289738 G A 2.19E-05 Multiple sclerosis / / 17660530 rs4529380 chr7 85289738 G A 2.34E-04 Alzheimer's disease / / 17998437 rs4496887 chr7 85290558 T C 7.26E-04 Alzheimer's disease / / 17998437 rs10268142 chr7 85291081 G A 2.61E-04 Alzheimer's disease / / 17998437 rs10225574 chr7 85291746 T C 1.44E-04 Alzheimer's disease / / 17998437 rs4262259 chr7 85297072 C T 2.56E-04 Alzheimer's disease / / 17998437 rs4451233 chr7 85297266 C T 3.27E-04 Alzheimer's disease / / 17998437 rs4543471 chr7 85297352 A G 3.48E-04 Alzheimer's disease / / 17998437 rs9918655 chr7 85315048 C T 1.38E-05 Multiple complex diseases / / 17554300 rs4486107 chr7 85339248 T G 6.42E-04 Alzheimer's disease / / 17998437 rs16887998 chr7 85520378 C G 2.58E-04 Multiple complex diseases / / 17554300 rs1003308 chr7 85564573 C T 9.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs112716625 chr7 85564807 ATGGAC A 9.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs374210074 chr7 85564807 ATGGAC A 9.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs9640977 chr7 85564807 A G 9.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs7783505 chr7 85575393 C G 0.00006506 Sarcoidosis / / 22952805 rs10275700 chr7 85590238 T G 7.00E-05 Age-related macular degeneration / / 21197116 rs11972901 chr7 85595921 A G 9.23E-07 Esophageal cancer (squamous cell) / / 22960999 rs11974976 chr7 85598186 A G 3.12E-04 Multiple complex diseases / / 17554300 rs10274362 chr7 85611625 A G 9.73E-05 Age-related macular degeneration / / 21197116 rs988426 chr7 85616869 T C 7.43E-05 Age-related macular degeneration / / 21197116 rs17160554 chr7 85640225 C T 4.67E-04 Multiple complex diseases / / 17554300 rs17160554 chr7 85640225 C T 7.18E-05 Attention deficit hyperactivity disorder / / 23728934 rs9648874 chr7 85644442 G C 2.22E-04 Schizophrenia / / 20832056 rs2107940 chr7 85686982 T G 1.80E-04 Smoking cessation / / 24665060 rs7811160 chr7 85709526 C T 1.70E-05 HIV-1 control / / 20041166 rs13234452 chr7 85730832 T G 2.89E-04 Scoliosis / / 21216876 rs6971139 chr7 85750240 C G 9.15E-05 Attention deficit hyperactivity disorder / / 23728934 rs12704232 chr7 85802230 A G 4.07E-04 Lung function (forced vital capacity) / / 24023788 rs722970 chr7 85803265 G A 1.14E-04 Multiple complex diseases / / 17554300 rs722970 chr7 85803265 G A 1.14E-04 Attention deficit hyperactivity disorder / / 23728934 rs2191859 chr7 85829494 C T 2.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17324099 chr7 85856289 T C 1.34E-04 Multiple complex diseases / / 17554300 rs2708542 chr7 85904474 G A 8.31E-04 Response to alcohol consumption (flushing response) / / 24277619 rs12540580 chr7 85975566 T A 3.38E-04 Multiple complex diseases / / 17554300 rs2373207 chr7 85976321 G A 4.21E-04 Multiple complex diseases / / 17554300 rs7804971 chr7 85979209 G A 3.87E-05 Multiple complex diseases / / 17554300 rs9969120 chr7 85990367 G A 9.20E-06 Triglycerides / / 19074352 rs9969120 chr7 85990367 G A 9.20E-06 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs2373217 chr7 86002254 C G 3.13E-04 Multiple complex diseases / / 17554300 rs7801186 chr7 86024218 T C 3.36E-04 Multiple complex diseases / / 17554300 rs10215459 chr7 86036290 G A 2.55E-04 Multiple complex diseases / / 17554300 rs1320781 chr7 86036437 C T 1.71E-04 Multiple complex diseases / / 17554300 rs1861070 chr7 86040815 T C 3.87E-04 Multiple complex diseases / / 17554300 rs1881817 chr7 86072337 A G 1.10E-05 Parkinson's disease (age of onset) / / 19772629 rs2110391 chr7 86074295 A G 2.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs1406684 chr7 86090906 A G 4.11E-04 Body mass index / / 21701565 rs7779590 chr7 86099681 A G 6.40E-04 Coronary heart disease / / 21606135 rs12537221 chr7 86101009 T C 2.14E-04 Coronary heart disease / / 21606135 rs10952882 chr7 86104736 G A 5.33E-04 Coronary heart disease / / 21606135 rs4727126 chr7 86112596 A C 7.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs6965526 chr7 86115537 G A 1.60E-05 Obesity-related traits / / 17658951 rs1881819 chr7 86115922 G T 3.01E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3897749 chr7 86134197 C A 0.0000034 Confectionary intake / / 23408455 rs3847032 chr7 86149914 C A 8.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs3953457 chr7 86151345 A G 6.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs4728640 chr7 86153225 A G 8.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs2660969 chr7 86161514 T C 4.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs809088 chr7 86185407 G C 9.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs781028 chr7 86186533 T C 6.57E-04 Alcohol dependence / / 21314694 rs6972995 chr7 86213615 T C 9.07E-05 Age-related macular degeneration / / pha002890 rs13226602 chr7 86222547 C T 6.69E-04 Type 2 diabetes / / 17463246 rs13226513 chr7 86222572 A C 7.72E-04 Type 2 diabetes / / 17463246 rs1395887 chr7 86241642 T C 8.69E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs802457 chr7 86250071 G A 9.42E-05 Intelligence / / 21826061 rs1405881 chr7 86252782 T C 7.05E-04 Multiple complex diseases / / 17554300 rs1405880 chr7 86253081 G C 9.89E-04 Multiple complex diseases / / 17554300 rs701332 chr7 86277634 T C 5.71E-05 Intelligence GRM3 intron 21826061 rs802425 chr7 86294952 C T 5.70E-05 Response to statin treatment (atorvastatin),change in cholesterol levels GRM3 intron 20031582 rs724226 chr7 86325374 A G 1 Drug response to Risperidone GRM3 intron 19451915 rs2189816 chr7 86341446 T C 1.29E-05 Alcohol and nictotine co-dependence GRM3 intron 20158304 rs2189816 chr7 86341446 T C 5.48E-07 Alcohol and nictotine co-dependence GRM3 intron 20158304 rs2214653 chr7 86345495 G A 1.71E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GRM3 intron 20031582 rs2237547 chr7 86348037 A G 5.52E-04 Alcohol dependence GRM3 intron 21314694 rs2189812 chr7 86348999 C G 6.00E-06 IgG glycosylation GRM3 intron 23382691 rs10239714 chr7 86351217 T C 5.24E-04 Multiple complex diseases GRM3 intron 17554300 rs6465083 chr7 86361336 C T 0.000000397 Nicotine dependence (smoking) GRM3 intron 23542338 rs2237553 chr7 86374533 G A 9.57E-04 Multiple complex diseases GRM3 intron 17554300 rs2237554 chr7 86378896 A C 2.20E-04 Bipolar disorder GRM3 intron 18317468 rs723631 chr7 86401592 C G 7.28E-05 Multiple complex diseases GRM3 intron 17554300 rs2282965 chr7 86401804 T C 3.18E-04 Multiple complex diseases GRM3 intron 17554300 rs2158786 chr7 86406018 C T 4.39E-05 Multiple complex diseases GRM3 intron 17554300 rs2299221 chr7 86418414 A T 2.78E-04 Alzheimer's disease GRM3 intron 24755620 rs7804907 chr7 86428208 C T 2.01E-05 Multiple complex diseases GRM3 intron 17554300 rs2299222 chr7 86442404 T C 4.08E-04 Amyotrophic Lateral Sclerosis GRM3 intron 17362836 rs2299222 chr7 86442404 T C 4.46E-04 Alzheimer's disease GRM3 intron 24755620 rs7806785 chr7 86446316 C G 4.65E-05 Multiple complex diseases GRM3 intron 17554300 rs2299224 chr7 86447403 T C 4.66E-04 Alzheimer's disease GRM3 intron 24755620 rs17697609 chr7 86452383 T C 5.34E-04 Alzheimer's disease GRM3 intron 24755620 rs2237565 chr7 86455536 C T 8.50E-05 Response to statin therapy GRM3 intron 20339536 rs6465088 chr7 86470554 T G 1.30E-05 Response to statin therapy GRM3 intron 20339536 rs17126 chr7 86471913 G A 1.40E-05 Response to statin therapy GRM3 intron 20339536 rs7788115 chr7 86472331 A T 2.50E-04 Multiple complex diseases GRM3 intron 17554300 rs7788115 chr7 86472331 A T 6.80E-04 Obesity,menopause GRM3 intron 21424828 rs7789655 chr7 86481013 T G 1.40E-05 Response to statin therapy GRM3 intron 20339536 rs7788695 chr7 86502733 C T 5.57E-05 Intelligence / / 21826061 rs10258008 chr7 86535446 C A 9.00E-04 Type 2 diabetes KIAA1324L intron 17463246 rs7781178 chr7 86536344 A G 9.66E-04 Multiple complex diseases KIAA1324L intron 17554300 rs7781178 chr7 86536344 A G 5.93E-05 Intelligence KIAA1324L intron 21826061 rs11974622 chr7 86536377 C T 8.36E-04 Type 2 diabetes KIAA1324L intron 17463246 rs10271867 chr7 86539946 T C 4.62E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) KIAA1324L intron 24023788 rs7810135 chr7 86545305 T C 1.89E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) KIAA1324L intron 24023788 rs1557665 chr7 86577346 A T 8.97E-04 Type 2 diabetes KIAA1324L intron 17463246 rs11979332 chr7 86581745 G A 4.88E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) KIAA1324L intron 24023788 rs17697894 chr7 86582891 T C 9.07E-04 Type 2 diabetes KIAA1324L intron 17463246 rs1767721 chr7 86607231 A C 3.94E-05 Intelligence KIAA1324L intron 21826061 rs1024378 chr7 86609696 T A 4.11E-04 Multiple complex diseases KIAA1324L intron 17554300 rs1635034 chr7 86620077 G A 3.87E-04 Multiple complex diseases KIAA1324L intron 17554300 rs1635037 chr7 86621010 C T 3.34E-04 Multiple complex diseases KIAA1324L intron 17554300 rs1634997 chr7 86625642 G A 4.48E-04 Multiple complex diseases KIAA1324L intron 17554300 rs1767742 chr7 86625854 T G 3.81E-04 Multiple complex diseases KIAA1324L intron 17554300 rs1767741 chr7 86625909 G C 3.58E-04 Multiple complex diseases KIAA1324L intron 17554300 rs1767735 chr7 86627187 G A 4.78E-04 Multiple complex diseases KIAA1324L intron 17554300 rs767437 chr7 86627630 A G 4.69E-04 Multiple complex diseases KIAA1324L intron 17554300 rs767436 chr7 86627679 T G 3.70E-04 Multiple complex diseases KIAA1324L intron 17554300 rs767435 chr7 86627726 G A 4.66E-04 Multiple complex diseases KIAA1324L intron 17554300 rs767434 chr7 86627798 T C 5.44E-04 Multiple complex diseases KIAA1324L intron 17554300 rs1635003 chr7 86628006 C T 4.44E-04 Multiple complex diseases KIAA1324L intron 17554300 rs1012835 chr7 86628370 T C 8.28E-04 Multiple complex diseases KIAA1324L intron 17554300 rs1767725 chr7 86628526 T C 3.97E-04 Multiple complex diseases KIAA1324L intron 17554300 rs1635009 chr7 86629651 C T 4.15E-04 Multiple complex diseases KIAA1324L intron 17554300 rs1635010 chr7 86629756 T G 3.75E-04 Multiple complex diseases KIAA1324L intron 17554300 rs739875 chr7 86630550 G A 3.15E-04 Multiple complex diseases KIAA1324L intron 17554300 rs1635021 chr7 86633713 G A 3.39E-04 Multiple complex diseases KIAA1324L intron 17554300 rs2373338 chr7 86636477 C T 2.79E-04 Multiple complex diseases KIAA1324L intron 17554300 rs10282295 chr7 86657447 C G 1.62E-04 Multiple complex diseases KIAA1324L intron 17554300 rs10251861 chr7 86660733 T C 2.17E-04 Multiple complex diseases KIAA1324L intron 17554300 rs4728666 chr7 86678206 A G 1.30E-05 Urinary metabolites KIAA1324L intron 21572414 rs4728675 chr7 86679347 C T 4.20E-07 Urinary metabolites KIAA1324L intron 21572414 rs11768112 chr7 86681028 C T 2.50E-07 Urinary metabolites KIAA1324L intron 21572414 rs13243613 chr7 86691254 C T 8.93E-06 Brachial circumference / / 22479309 rs1476587 chr7 86696714 A G 7.00E-06 Brachial circumference / / 22479309 rs12690906 chr7 86716454 T G 2.40E-07 Urinary metabolites / / 21572414 rs1859122 chr7 86733473 C T 8.30E-07 Urinary metabolites / / 21572414 rs9886113 chr7 86737075 C A 5.90E-07 Urinary metabolites / / 21572414 rs720775 chr7 86743108 C T 6.80E-07 Urinary metabolites / / 21572414 rs886318 chr7 86746500 G C 7.40E-04 Multiple complex diseases / / 17554300 rs17161329 chr7 86770106 C T 3.50E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs3789251 chr7 86793303 A G 1.00E-04 Cognitive impairment induced by topiramate DMTF1 intron 22091778 rs11981403 chr7 86802025 C T 3.77E-05 Multiple complex diseases DMTF1 intron 17554300 rs11773103 chr7 86821980 A G 1.00E-06 Bipolar disorder and major depressive disorder (combined) DMTF1 intron 20351715 rs11971131 chr7 86823619 A C 1.30E-06 Bipolar disorder and major depressive disorder (combined) DMTF1 intron 20351715 rs11771569 chr7 86838068 G A 1.30E-06 Bipolar disorder and major depressive disorder (combined) C7orf23 intron 20351715 rs802031 chr7 86961362 T C 8.58E-04 Multiple complex diseases TP53TG1 intron 17554300 rs996745 chr7 86965599 C T 4.12E-05 Neutrophil count TP53TG1 intron pha003095 rs802041 chr7 86982937 G T 6.19E-04 Multiple complex diseases CROT intron 17554300 rs7808249 chr7 86983715 A G 3.68E-05 Hypertension (essential hypertension) CROT intron 22184326 rs7808249 chr7 86983715 A G 7.08E-05 Neutrophil count CROT intron pha003095 rs144004176 chr7 86990819 A C 0.000014 Breast cancer(er negative) CROT missense 23555315 rs2051950 chr7 86995922 T C 3.30E-06 Multiple complex diseases CROT intron 17554300 rs10487804 chr7 87036105 G A 5.21E-06 Major depressive disorder ABCB4 intron 22472876 rs17149539 chr7 87038074 A G 5.46E-06 Major depressive disorder ABCB4 intron 22472876 rs11761050 chr7 87041856 C A 6.79E-06 Major depressive disorder ABCB4 intron 22472876 rs17149547 chr7 87043230 A G 6.79E-06 Major depressive disorder ABCB4 intron 22472876 rs4148829 chr7 87046470 A G 6.17E-06 Major depressive disorder ABCB4 intron 22472876 rs7788404 chr7 87047813 T C 7.42E-06 Major depressive disorder ABCB4 intron 22472876 rs31674 chr7 87068464 T C 3.92E-05 Major depressive disorder ABCB4 intron 22472876 rs31676 chr7 87069880 T C 4.36E-05 Major depressive disorder ABCB4 intron 22472876 rs28364274 chr7 87133651 C T 1 Drug response to Paclitaxel ABCB1 missense 19940846 rs1045642 chr7 87138645 A G,T 1 Drug response to Fexofenadine ABCB1 cds-synon 11503014 rs1045642 chr7 87138645 A G,T 1 Drug response to Nortriptyline ABCB1 cds-synon 12082591 rs1045642 chr7 87138645 A G,T 1 Drug response to Cyclosporine ABCB1 cds-synon 12781336 rs1045642 chr7 87138645 A G,T 1 Drug response to Digoxin ABCB1 cds-synon 12781336 rs1045642 chr7 87138645 A G,T 1 Drug response to Verapamil ABCB1 cds-synon 12781336 rs1045642 chr7 87138645 A G,T 1 Drug response to Vinblastine ABCB1 cds-synon 12781336 rs1045642 chr7 87138645 A G,T 1 Drug response to Rifampin ABCB1 cds-synon 12914549 rs1045642 chr7 87138645 A G,T 1 Drug response to Verapamil ABCB1 cds-synon 12914549 rs1045642 chr7 87138645 A G,T 1 Drug response to Ritonavir ABCB1 cds-synon 14600574 rs1045642 chr7 87138645 A G,T 1 Drug response to Tipifarnib ABCB1 cds-synon 15122075 rs1045642 chr7 87138645 A G,T 1 Drug response to Tacrolimus ABCB1 cds-synon 15521904 rs1045642 chr7 87138645 A G,T 1 Drug response to Cytarabine ABCB1 cds-synon 16331627 rs1045642 chr7 87138645 A G,T 1 Drug response to Idarubicin ABCB1 cds-synon 16331627 rs1045642 chr7 87138645 A G,T 1 Drug response to Efavirenz ABCB1 cds-synon 16912956 rs1045642 chr7 87138645 A G,T 1 Drug response to Nevirapine ABCB1 cds-synon 16912956 rs1045642 chr7 87138645 A G,T 1 Drug response to Efavirenz ABCB1 cds-synon 16912957 rs1045642 chr7 87138645 A G,T 1 Drug response to Paclitaxel ABCB1 cds-synon 16950614 rs1045642 chr7 87138645 A G,T 1 Drug response to Olanzapine ABCB1 cds-synon 17038883 rs1045642 chr7 87138645 A G,T 1 Drug response to Clopidogrel ABCB1 cds-synon 17112805 rs1045642 chr7 87138645 A G,T 1 Drug response to Cyclosporine ABCB1 cds-synon 17185560 rs1045642 chr7 87138645 A G,T 1 Drug response to Verapamil ABCB1 cds-synon 17185560 rs1045642 chr7 87138645 A G,T 1 Drug response to Lansoprazole ABCB1 cds-synon 17190370 rs1045642 chr7 87138645 A G,T 1 Drug response to Tacrolimus ABCB1 cds-synon 17190370 rs1045642 chr7 87138645 A G,T 1 Drug response to Cyclosporine ABCB1 cds-synon 17206635 rs1045642 chr7 87138645 A G,T 1 Drug response to Paclitaxel ABCB1 cds-synon 18836089 rs1045642 chr7 87138645 A G,T 1 Drug response to Atorvastatin ABCB1 cds-synon 18851956 rs1045642 chr7 87138645 A G,T 1 Drug response to Methotrexate ABCB1 cds-synon 19093297 rs1045642 chr7 87138645 A G,T 1 Drug response to Doxorubicin ABCB1 cds-synon 19752884 rs1045642 chr7 87138645 A G,T 1 Drug response to Epirubicin ABCB1 cds-synon 19752884 rs1045642 chr7 87138645 A G,T 1 Drug response to Nevirapine ABCB1 cds-synon 20017669 rs2229107 chr7 87138659 A T 1 Drug response to Daunorubicin ABCB1 missense 19940846 rs2229107 chr7 87138659 A T 1 Drug response to Doxorubicin ABCB1 missense 19940846 rs35730308 chr7 87138758 A G 1 Drug response to Daunorubicin ABCB1 missense 19940846 rs35730308 chr7 87138758 A G 1 Drug response to Doxorubicin ABCB1 missense 19940846 rs4437575 chr7 87139316 A G 1.65E-04 Hemoglobin concentration ABCB1 intron 20534544 rs4148750 chr7 87143275 T C 6.42E-04 Suicide attempts in bipolar disorder ABCB1 intron 21423239 rs1922243 chr7 87143504 C T 5.66E-04 Suicide attempts in bipolar disorder ABCB1 intron 21423239 rs72552784 chr7 87145914 C T 1 Drug response to Bisantrene ABCB1 missense 12065748 rs72552784 chr7 87145914 C T 1 Drug response to Forskolin ABCB1 missense 12065748 rs72552784 chr7 87145914 C T 1 Drug response to Prazosin ABCB1 missense 12065748 rs72552784 chr7 87145914 C T 1 Drug response to Verapamil ABCB1 missense 12065748 rs72552784 chr7 87145914 C T 1 Drug response to Vinblastine ABCB1 missense 12065748 rs4148740 chr7 87152103 A G 1 Drug response to Amitriptyline ABCB1 intron 18215618 rs4148740 chr7 87152103 A G 1 Drug response to Citalopram ABCB1 intron 18215618 rs4148740 chr7 87152103 A G 1 Drug response to Paroxetine ABCB1 intron 18215618 rs4148740 chr7 87152103 A G 1 Drug response to Venlafaxine ABCB1 intron 18215618 rs10280101 chr7 87153585 A C 1 Drug response to Amitriptyline ABCB1 intron 18215618 rs10280101 chr7 87153585 A C 1 Drug response to Citalopram ABCB1 intron 18215618 rs10280101 chr7 87153585 A C 1 Drug response to Paroxetine ABCB1 intron 18215618 rs10280101 chr7 87153585 A C 1 Drug response to Venlafaxine ABCB1 intron 18215618 rs7787082 chr7 87157051 G A 1 Drug response to Amitriptyline ABCB1 intron 18215618 rs7787082 chr7 87157051 G A 1 Drug response to Citalopram ABCB1 intron 18215618 rs7787082 chr7 87157051 G A 1 Drug response to Paroxetine ABCB1 intron 18215618 rs7787082 chr7 87157051 G A 1 Drug response to Venlafaxine ABCB1 intron 18215618 rs2032583 chr7 87160561 A G 1 Drug response to Amitriptyline ABCB1 intron 18215618 rs2032583 chr7 87160561 A G 1 Drug response to Antidepressant Response ABCB1 intron 18215618 rs2032583 chr7 87160561 A G 1 Drug response to Citalopram ABCB1 intron 18215618 rs2032583 chr7 87160561 A G 1 Drug response to Paroxetine ABCB1 intron 18215618 rs2032583 chr7 87160561 A G 1 Drug response to Venlafaxine ABCB1 intron 18215618 rs2032582 chr7 87160618 A C,T 1 Drug response to Digoxin ABCB1 missense 11503014 rs2032582 chr7 87160618 A C,T 1 Drug response to Fexofenadine ABCB1 missense 11503014 rs2032582 chr7 87160618 A C,T 1 Drug response to Bisantrene ABCB1 missense 12065748 rs2032582 chr7 87160618 A C,T 1 Drug response to Forskolin ABCB1 missense 12065748 rs2032582 chr7 87160618 A C,T 1 Drug response to Prazosin ABCB1 missense 12065748 rs2032582 chr7 87160618 A C,T 1 Drug response to Verapamil ABCB1 missense 12065748 rs2032582 chr7 87160618 A C,T 1 Drug response to Vinblastine ABCB1 missense 12065748 rs2032582 chr7 87160618 A C,T 1 Drug response to Tacrolimus ABCB1 missense 12352921 rs2032582 chr7 87160618 A C,T 1 Drug response to Cyclosporine ABCB1 missense 12781336 rs2032582 chr7 87160618 A C,T 1 Drug response to Digoxin ABCB1 missense 12781336 rs2032582 chr7 87160618 A C,T 1 Drug response to Verapamil ABCB1 missense 12781336 rs2032582 chr7 87160618 A C,T 1 Drug response to Vinblastine ABCB1 missense 12781336 rs2032582 chr7 87160618 A C,T 1 Drug response to Rifampin ABCB1 missense 12914549 rs2032582 chr7 87160618 A C,T 1 Drug response to Verapamil ABCB1 missense 12914549 rs2032582 chr7 87160618 A C,T 1 Drug response to Ritonavir ABCB1 missense 14600574 rs2032582 chr7 87160618 A C,T 1 Drug response to Tipifarnib ABCB1 missense 15122075 rs2032582 chr7 87160618 A C,T 1 Drug response to Tacrolimus ABCB1 missense 15521904 rs2032582 chr7 87160618 A C,T 1 Drug response to Cytarabine ABCB1 missense 16331627 rs2032582 chr7 87160618 A C,T 1 Drug response to Idarubicin ABCB1 missense 16331627 rs2032582 chr7 87160618 A C,T 1 Drug response to Paclitaxel ABCB1 missense 16467099 rs2032582 chr7 87160618 A C,T 1 Drug response to Paclitaxel ABCB1 missense 16950614 rs2032582 chr7 87160618 A C,T 1 Drug response to Cyclosporine ABCB1 missense 17206635 rs2032582 chr7 87160618 A C,T 1 Drug response to Paroxetine ABCB1 missense 17913323 rs2032582 chr7 87160618 A C,T 1 Drug response to Dexamethasone ABCB1 missense 18408561 rs2032582 chr7 87160618 A C,T 1 Drug response to Doxorubicin ABCB1 missense 18408561 rs2032582 chr7 87160618 A C,T 1 Drug response to Vincristine ABCB1 missense 18408561 rs2032582 chr7 87160618 A C,T 1 Drug response to Cyclosporine ABCB1 missense 18717915 rs2032582 chr7 87160618 A C,T 1 Drug response to Atorvastatin ABCB1 missense 18851956 rs2032582 chr7 87160618 A C,T 1 Drug response to Paclitaxel ABCB1 missense 19143748 rs2032582 chr7 87160618 A C,T 1 Drug response to Carboplatin ABCB1 missense 19203783 rs2032582 chr7 87160618 A C,T 1 Drug response to Cisplatin ABCB1 missense 19203783 rs2032582 chr7 87160618 A C,T 1 Drug response to Docetaxel ABCB1 missense 19203783 rs2032582 chr7 87160618 A C,T 1 Drug response to Paclitaxel ABCB1 missense 19203783 rs2032582 chr7 87160618 A C,T 1 Drug response to Carbamazepine ABCB1 missense 19450124 rs2032582 chr7 87160618 A C,T 1 Drug response to Clobazam ABCB1 missense 19450124 rs2032582 chr7 87160618 A C,T 1 Drug response to Clonazepam ABCB1 missense 19450124 rs2032582 chr7 87160618 A C,T 1 Drug response to Gabapentin ABCB1 missense 19450124 rs2032582 chr7 87160618 A C,T 1 Drug response to Lamotrigine ABCB1 missense 19450124 rs2032582 chr7 87160618 A C,T 1 Drug response to Levetiracetam ABCB1 missense 19450124 rs2032582 chr7 87160618 A C,T 1 Drug response to Phenobarbital ABCB1 missense 19450124 rs2032582 chr7 87160618 A C,T 1 Drug response to Phenytoin ABCB1 missense 19450124 rs2032582 chr7 87160618 A C,T 1 Drug response to Topiramate ABCB1 missense 19450124 rs2032582 chr7 87160618 A C,T 1 Drug response to Valproic Acid ABCB1 missense 19450124 rs2032582 chr7 87160618 A C,T 1 Drug response to Vigabatrin ABCB1 missense 19450124 rs2032582 chr7 87160618 A C,T 1 Drug response to Paclitaxel ABCB1 missense 19940846 rs4148739 chr7 87161049 T C 1 Drug response to Amitriptyline ABCB1 intron 18215618 rs4148739 chr7 87161049 T C 1 Drug response to Citalopram ABCB1 intron 18215618 rs4148739 chr7 87161049 T C 1 Drug response to Paroxetine ABCB1 intron 18215618 rs4148739 chr7 87161049 T C 1 Drug response to Venlafaxine ABCB1 intron 18215618 rs11983225 chr7 87161520 T C 1 Drug response to Amitriptyline ABCB1 intron 18215618 rs11983225 chr7 87161520 T C 1 Drug response to Citalopram ABCB1 intron 18215618 rs11983225 chr7 87161520 T C 1 Drug response to Paroxetine ABCB1 intron 18215618 rs11983225 chr7 87161520 T C 1 Drug response to Venlafaxine ABCB1 intron 18215618 rs10248420 chr7 87164986 A G 1 Drug response to Amitriptyline ABCB1 intron 18215618 rs10248420 chr7 87164986 A G 1 Drug response to Citalopram ABCB1 intron 18215618 rs10248420 chr7 87164986 A G 1 Drug response to Paroxetine ABCB1 intron 18215618 rs10248420 chr7 87164986 A G 1 Drug response to Venlafaxine ABCB1 intron 18215618 rs2235040 chr7 87165750 C T 1 Drug response to Amitriptyline ABCB1 intron 18215618 rs2235040 chr7 87165750 C T 1 Drug response to Citalopram ABCB1 intron 18215618 rs2235040 chr7 87165750 C T 1 Drug response to Paroxetine ABCB1 intron 18215618 rs2235040 chr7 87165750 C T 1 Drug response to Venlafaxine ABCB1 intron 18215618 rs4728699 chr7 87168749 C T 7.90E-04 Alcohol dependence ABCB1 intron 20201924 rs12720067 chr7 87169356 C T 1 Drug response to Amitriptyline ABCB1 intron 18215618 rs12720067 chr7 87169356 C T 1 Drug response to Citalopram ABCB1 intron 18215618 rs12720067 chr7 87169356 C T 1 Drug response to Paroxetine ABCB1 intron 18215618 rs12720067 chr7 87169356 C T 1 Drug response to Venlafaxine ABCB1 intron 18215618 rs4728701 chr7 87172053 A G 7.90E-04 Alcohol dependence ABCB1 intron 20201924 rs35023033 chr7 87174198 G A 1 Drug response to Daunorubicin ABCB1 missense 19940846 rs35023033 chr7 87174198 G A 1 Drug response to Doxorubicin ABCB1 missense 19940846 rs1128503 chr7 87179601 A G 1 Drug response to Cyclosporine ABCB1 cds-synon 12781336 rs1128503 chr7 87179601 A G 1 Drug response to Digoxin ABCB1 cds-synon 12781336 rs1128503 chr7 87179601 A G 1 Drug response to Verapamil ABCB1 cds-synon 12781336 rs1128503 chr7 87179601 A G 1 Drug response to Vinblastine ABCB1 cds-synon 12781336 rs1128503 chr7 87179601 A G 1 Drug response to Tipifarnib ABCB1 cds-synon 15122075 rs1128503 chr7 87179601 A G 1 Drug response to Cyclosporine ABCB1 cds-synon 18717915 rs1128503 chr7 87179601 A G 1 Drug response to Risperidone ABCB1 cds-synon 19997080 rs2229109 chr7 87179809 C A,G,T 1 Drug response to Bisantrene ABCB1 missense 12065748 rs2229109 chr7 87179809 C A,G,T 1 Drug response to Forskolin ABCB1 missense 12065748 rs2229109 chr7 87179809 C A,G,T 1 Drug response to Prazosin ABCB1 missense 12065748 rs2229109 chr7 87179809 C A,G,T 1 Drug response to Verapamil ABCB1 missense 12065748 rs2229109 chr7 87179809 C A,G,T 1 Drug response to Vinblastine ABCB1 missense 12065748 rs10276036 chr7 87180198 C T 1 Drug response to Irinotecan ABCB1 intron 19940846 rs10276036 chr7 87180198 C T 1 Drug response to SN-38 ABCB1 intron 19940846 rs2235015 chr7 87199564 C A 1 Drug response to Amitriptyline ABCB1 intron 18215618 rs2235015 chr7 87199564 C A 1 Drug response to Citalopram ABCB1 intron 18215618 rs2235015 chr7 87199564 C A 1 Drug response to Paroxetine ABCB1 intron 18215618 rs2235015 chr7 87199564 C A 1 Drug response to Venlafaxine ABCB1 intron 18215618 rs35810889 chr7 87214848 A G 1 Drug response to Daunorubicin ABCB1 missense 19940846 rs35810889 chr7 87214848 A G 1 Drug response to Doxorubicin ABCB1 missense 19940846 rs3789243 chr7 87220886 A G 1 Drug response to Carbamazepine ABCB1 intron 19450124 rs3789243 chr7 87220886 A G 1 Drug response to Clobazam ABCB1 intron 19450124 rs3789243 chr7 87220886 A G 1 Drug response to Clonazepam ABCB1 intron 19450124 rs3789243 chr7 87220886 A G 1 Drug response to Gabapentin ABCB1 intron 19450124 rs3789243 chr7 87220886 A G 1 Drug response to Lamotrigine ABCB1 intron 19450124 rs3789243 chr7 87220886 A G 1 Drug response to Levetiracetam ABCB1 intron 19450124 rs3789243 chr7 87220886 A G 1 Drug response to Phenobarbital ABCB1 intron 19450124 rs3789243 chr7 87220886 A G 1 Drug response to Phenytoin ABCB1 intron 19450124 rs3789243 chr7 87220886 A G 1 Drug response to Topiramate ABCB1 intron 19450124 rs3789243 chr7 87220886 A G 1 Drug response to Valproic Acid ABCB1 intron 19450124 rs3789243 chr7 87220886 A G 1 Drug response to Vigabatrin ABCB1 intron 19450124 rs9282564 chr7 87229440 T C 1 Drug response to Bisantrene ABCB1 missense 12065748 rs9282564 chr7 87229440 T C 1 Drug response to Forskolin ABCB1 missense 12065748 rs9282564 chr7 87229440 T C 1 Drug response to Prazosin ABCB1 missense 12065748 rs9282564 chr7 87229440 T C 1 Drug response to Verapamil ABCB1 missense 12065748 rs9282564 chr7 87229440 T C 1 Drug response to Vinblastine ABCB1 missense 12065748 rs4148731 chr7 87239329 G A 7.50E-04 Smoking initiation ABCB1 intron 24665060 rs1015415 chr7 87330101 A T 7.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) ABCB1 intron 17982456 rs114137957 chr7 87374869 T G 1.00E-06 PR interval in Tripanosoma cruzi seropositivity RUNDC3B intron 24324551 rs10216040 chr7 87492141 A T 9.90E-04 Iris characteristics SLC25A40 intron 21835309 rs10225955 chr7 87513567 C T 9.10E-04 Iris characteristics DBF4 intron 21835309 rs2041049 chr7 87537177 A G 5.37E-04 Body mass index DBF4 missense 17255346 rs6966264 chr7 87543037 C G 4.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs10952902 chr7 87573611 A G 2.92E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ADAM22 intron 24023788 rs10952902 chr7 87573611 A G 8.67E-05 Weight ADAM22 intron pha003026 rs1637500 chr7 87594188 T G 2.12E-04 Prion diseases ADAM22 intron 22210626 rs2282956 chr7 87724607 C A 1.20E-05 Urinary metabolites ADAM22 intron 21572414 rs17150369 chr7 87839690 T C 5.03E-05 Body Composition SRI intron pha003012 rs17150369 chr7 87839690 T C 2.30E-05 Body Mass Index SRI intron pha003021 rs173850 chr7 87843127 A G 8.90E-04 Coronary heart disease SRI intron 21966275 rs43111 chr7 87856515 A G 7.26E-04 Suicide attempts in bipolar disorder SRI nearGene-5 21423239 rs8122 chr7 87906171 T C 8.05E-04 Suicide attempts in bipolar disorder STEAP4 UTR-3 21423239 rs8122 chr7 87906171 T C 9.97E-05 Height STEAP4 UTR-3 pha003010 rs201304806 chr7 87911975 C T 0.00068 Prostate cancer STEAP4 missense 23555315 rs43132 chr7 87915863 C T 6.82E-04 Suicide attempts in bipolar disorder STEAP4 intron 21423239 rs10263111 chr7 87927392 G C 3.71E-04 Suicide attempts in bipolar disorder STEAP4 intron 21423239 rs240000 chr7 87952094 T C 3.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs240005 chr7 87955716 C G 2.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs6954990 chr7 87960273 C T 4.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs2215428 chr7 87976945 C G 8.38E-04 Multiple complex diseases / / 17554300 rs733004 chr7 87997384 T C 1.84E-04 Multiple complex diseases / / 17554300 rs13244673 chr7 88049044 A G 7.68E-04 Obesity (extreme) / / 21935397 rs7799167 chr7 88050398 G A 7.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs10952918 chr7 88052236 G C 8.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs41654 chr7 88054557 G T 8.44E-04 Obesity (extreme) / / 21935397 rs7795474 chr7 88058263 T C 8.58E-04 Obesity (extreme) / / 21935397 rs7795579 chr7 88058285 T A 8.56E-04 Obesity (extreme) / / 21935397 rs41656 chr7 88058531 A T 7.49E-04 Obesity (extreme) / / 21935397 rs181125 chr7 88066707 A G 1.32E-04 Multiple complex diseases / / 17554300 rs181107 chr7 88079654 G A 2.23E-04 Multiple complex diseases / / 17554300 rs181100 chr7 88084127 C A 1.68E-04 Multiple complex diseases / / 17554300 rs181083 chr7 88093775 T C 1.19E-04 Multiple complex diseases / / 17554300 rs181075 chr7 88099065 G A 4.28E-04 Multiple complex diseases / / 17554300 rs181060 chr7 88109856 C G 4.27E-04 Multiple complex diseases / / 17554300 rs17167034 chr7 88118126 A G 2.30E-22 Narcolepsy / / 19629137 rs2106292 chr7 88122038 G T 8.24E-04 Alzheimer's disease / / 24755620 rs181046 chr7 88125207 C T 4.81E-05 Orofacial clefts / / 22419666 rs13225805 chr7 88130171 T G 7.66E-04 Alzheimer's disease / / 24755620 rs13244720 chr7 88136931 A G 7.89E-04 Alzheimer's disease / / 24755620 rs2213992 chr7 88141179 G A 7.98E-04 Alzheimer's disease / / 24755620 rs4728755 chr7 88144473 C T 8.11E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs181027 chr7 88148465 G A 5.09E-05 Orofacial clefts / / 22419666 rs2213991 chr7 88168700 G A 4.11E-04 Alzheimer's disease / / 24755620 rs2519526 chr7 88178616 C A 2.55E-04 Alzheimer's disease / / 24755620 rs2519525 chr7 88179419 C T 2.65E-04 Alzheimer's disease / / 24755620 rs717655 chr7 88201442 T C 2.49E-05 Kawasaki disease / / 22081228 rs12532887 chr7 88202717 T A 7.16E-08 Facial morphology / / 22341974 rs2188251 chr7 88204307 G C 8.15E-05 Pulmonary function / / 20010835 rs2718327 chr7 88207951 C T 4.02E-05 Pulmonary function / / 20010835 rs2718359 chr7 88233444 A G 8.11E-05 Post-operative nausea and vomiting / / 21694509 rs12531232 chr7 88295001 T C 4.30E-05 Crohn's disease (time to surgery) / / 23665963 rs6950169 chr7 88413385 A T 2.20E-05 Urinary metabolites ZNF804B intron 21572414 rs7779337 chr7 88433768 T C 1.96E-04 Type 2 diabetes ZNF804B intron 17463246 rs10237276 chr7 88441936 C T 7.98E-04 Multiple complex diseases ZNF804B intron 17554300 rs17164532 chr7 88447161 A G 3.18E-04 Type 2 diabetes ZNF804B intron 17463246 rs3915191 chr7 88447187 G A 9.35E-04 Multiple complex diseases ZNF804B intron 17554300 rs7796603 chr7 88450872 C T 6.51E-04 Multiple complex diseases ZNF804B intron 17554300 rs13221086 chr7 88451505 C T 1.67E-04 Multiple complex diseases ZNF804B intron 17554300 rs6974679 chr7 88453043 A G 5.84E-04 Multiple complex diseases ZNF804B intron 17554300 rs7800785 chr7 88464530 A G 5.34E-04 Multiple complex diseases ZNF804B intron 17554300 rs10248351 chr7 88481442 T C 7.00E-06 Hypothyroidism ZNF804B intron 22493691 rs6962263 chr7 88490822 A G 3.31E-05 Stroke ZNF804B intron pha002886 rs2373741 chr7 88554375 T G 2.99E-04 Multiple complex diseases ZNF804B intron 17554300 rs1406503 chr7 88560878 G C 9.00E-06 Body mass index ZNF804B intron 20966902 rs12535041 chr7 88573471 A C 4.25E-04 Amyotrophic lateral sclerosis (sporadic) ZNF804B intron 24529757 rs17165697 chr7 88580316 G A 8.06E-04 Alcohol dependence ZNF804B intron 20201924 rs6959888 chr7 88596385 A G 2.00E-06 Anorexia nervosa ZNF804B intron 21079607 rs3899697 chr7 88599785 T A 9.00E-06 Cervical cancer ZNF804B intron 24700089 rs17393952 chr7 88601192 C A 6.53E-04 Suicide attempts in bipolar disorder ZNF804B intron 21423239 rs11981551 chr7 88601281 C A 5.23E-04 Suicide attempts in bipolar disorder ZNF804B intron 21423239 rs10224451 chr7 88604651 C T 4.83E-04 Suicide attempts in bipolar disorder ZNF804B intron 21423239 rs10228160 chr7 88605170 G A 5.56E-04 Suicide attempts in bipolar disorder ZNF804B intron 21423239 rs10225850 chr7 88606218 T G 6.35E-04 Suicide attempts in bipolar disorder ZNF804B intron 21423239 rs11982334 chr7 88607573 C A 5.43E-04 Suicide attempts in bipolar disorder ZNF804B intron 21423239 rs6977385 chr7 88607980 T C 6.39E-04 Suicide attempts in bipolar disorder ZNF804B intron 21423239 rs6957843 chr7 88608302 A G 6.06E-04 Suicide attempts in bipolar disorder ZNF804B intron 21423239 rs6974749 chr7 88611622 G A 6.04E-04 Suicide attempts in bipolar disorder ZNF804B intron 21423239 rs6971362 chr7 88615862 A G 7.42E-04 Suicide attempts in bipolar disorder ZNF804B intron 21423239 rs10230089 chr7 88616369 G T 5.88E-04 Suicide attempts in bipolar disorder ZNF804B intron 21423239 rs10274856 chr7 88623459 T C 1.70E-04 Suicide attempts in bipolar disorder ZNF804B intron 21423239 rs10229706 chr7 88623520 A G 4.53E-04 Amyotrophic Lateral Sclerosis ZNF804B intron 17362836 rs10229706 chr7 88623520 A G 1.47E-04 Suicide attempts in bipolar disorder ZNF804B intron 21423239 rs6944177 chr7 88647858 C T 4.99E-05 Multiple complex diseases ZNF804B intron 17554300 rs10952942 chr7 88648135 C T 6.92E-05 Multiple complex diseases ZNF804B intron 17554300 rs2040524 chr7 88657022 A G 5.07E-06 Glycemic traits (pregnancy) ZNF804B intron 23903356 rs2040524 chr7 88657022 A G 8.93E-06 Glycemic traits (pregnancy) ZNF804B intron 23903356 rs10253454 chr7 88657093 G A 6.48E-04 Suicide attempts in bipolar disorder ZNF804B intron 21423239 rs2040525 chr7 88658120 G C 4.71E-06 Glycemic traits (pregnancy) ZNF804B intron 23903356 rs2040525 chr7 88658120 G C 8.31E-06 Glycemic traits (pregnancy) ZNF804B intron 23903356 rs10228159 chr7 88658348 A G 7.84E-06 Glycemic traits (pregnancy) ZNF804B intron 23903356 rs2040529 chr7 88665867 T A 7.62E-04 Suicide attempts in bipolar disorder ZNF804B intron 21423239 rs10236237 chr7 88695070 A T 5.00E-06 IgG glycosylation ZNF804B intron 23382691 rs10236237 chr7 88695070 A T 6.00E-06 IgG glycosylation ZNF804B intron 23382691 rs10236237 chr7 88695070 A T 7.00E-06 IgG glycosylation ZNF804B intron 23382691 rs2158142 chr7 88700818 A G 7.64E-04 Suicide attempts in bipolar disorder ZNF804B intron 21423239 rs7810045 chr7 88742607 C T 4.84E-05 Acute lymphoblastic leukemia (childhood) ZNF804B intron 19684603 rs2189064 chr7 88748737 G A 9.21E-04 Parkinson's disease ZNF804B intron 17052657 rs10260551 chr7 88759421 C T 2.27E-04 Hemoglobin concentration ZNF804B intron 20534544 rs2040677 chr7 88764418 G A 2.27E-04 Hemoglobin concentration ZNF804B intron 20534544 rs10486899 chr7 88774573 A T 2.30E-04 Type 2 diabetes and 6 quantitative traits ZNF804B intron 17848626 rs10486903 chr7 88783252 C T 5.99E-04 Parkinson's disease ZNF804B intron 17052657 rs2189052 chr7 88794199 T C 2.81E-04 Height ZNF804B intron 17255346 rs2214339 chr7 88813289 G A 7.93E-04 Multiple complex diseases ZNF804B intron 17554300 rs10277089 chr7 88821660 G A 1.00E-04 Cognitive impairment induced by topiramate ZNF804B intron 22091778 rs35422524 chr7 88890591 CT C 5.47E-05 Response to taxane treatment (placlitaxel) ZNF804B intron 23006423 rs529217692 chr7 88890591 CTT C 5.47E-05 Response to taxane treatment (placlitaxel) ZNF804B intron 23006423 rs7783629 chr7 88890591 C T 5.47E-05 Response to taxane treatment (placlitaxel) ZNF804B intron 23006423 rs38948 chr7 88945484 G A 6.79E-06 Asthma ZNF804B intron 21790008 rs16869415 chr7 88987180 T C 7.40E-04 Smoking quantity / / 24665060 rs801873 chr7 88995297 G A 7.49E-04 Smoking quantity / / 24665060 rs10272660 chr7 89003584 A G 9.99E-05 Alcohol withdrawal symptoms / / 22072270 rs2888697 chr7 89025801 C A 7.68E-05 Alcohol withdrawal symptoms / / 22072270 rs6973392 chr7 89060733 C T 7.00E-06 Dental caries / / 23259602 rs17617686 chr7 89104802 G A 9.20E-05 Heart Rate / / pha003054 rs6973834 chr7 89112808 A G 5.72E-04 Alzheimer's disease / / 17998437 rs4727203 chr7 89118409 T C 7.21E-04 Multiple complex diseases / / 17554300 rs1072107 chr7 89195515 G A 1.99E-04 Celiac disease / / 23936387 rs2521319 chr7 89333043 C T 0.000679 Salmonella-induced pyroptosis / / 22837397 rs2724463 chr7 89334668 T G 0.000499 Salmonella-induced pyroptosis / / 22837397 rs2724463 chr7 89334668 T G 2.17E-04 Breast cancer / / pha002853 rs1014736 chr7 89340308 T C 6.64E-04 Stroke / / pha002886 rs6944565 chr7 89345537 G A 6.04E-04 Spine bone size / / 23207799 rs12111709 chr7 89351479 T C 0.00061 Personality disorders (PD) - Cluster C / / 22981920 rs10264047 chr7 89362531 A C 1.30E-05 Urinary metabolites / / 21572414 rs12704479 chr7 89363018 C T 1.30E-05 Urinary metabolites / / 21572414 rs2023743 chr7 89483844 A C 5.87E-04 Myocardial Infarction / / pha002873 rs2191496 chr7 89507430 T G 5.08E-04 Taste perception / / 22132133 rs7787805 chr7 89519639 T C 4.22E-04 Multiple complex diseases / / 17554300 rs1981681 chr7 89538107 A G 1.81E-04 Myocardial Infarction / / pha002873 rs10259230 chr7 89635741 T C 8.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs740291 chr7 89647400 G A 3.70E-04 Smoking quantity / / 24665060 rs11978340 chr7 89719487 C T 1.26E-04 Alzheimer's disease / / 24755620 rs39201 chr7 89734104 G A 1.55E-05 Bipolar disorder / / 20451256 rs10266254 chr7 89763864 A G 6.00E-06 Coronary artery calcification / / 23870195 rs39263 chr7 89770344 T A 3.16E-05 Aging (time to event) / / 21782286 rs10256141 chr7 89802053 C T 6.76E-06 Coronary artery calcification / / 23870195 rs6465247 chr7 89824477 G A 9.80E-06 Urinary metabolites / / 21572414 rs194520 chr7 89854446 T G 0.00000172 Fasting blood glucose STEAP2 missense 22885924 rs2016903 chr7 89856644 C T 6.80E-06 Urinary metabolites STEAP2 cds-synon 21572414 rs11563921 chr7 89884167 G A 2.31E-06 Narcolepsy C7orf63 intron 20711174 rs10266179 chr7 89909982 G A 9.70E-05 Bipolar disorder C7orf63 intron 20451256 rs17867618 chr7 89948816 G A 1.15E-04 Smoking initiation / / 24665060 rs3948749 chr7 89963629 C G 1.53E-36 Metabolite levels / / 22286219 rs42639 chr7 89970723 G A 1.90E-06 Intraocular pressure / / 22570627 rs11563905 chr7 89976051 C T 1.06E-04 Alzheimer's disease GTPBP10 UTR-5 24755620 rs42648 chr7 89977760 A G 2.00E-08 Homocysteine levels GTPBP10 intron 23824729 rs7786462 chr7 89982559 A G 8.10E-04 Response to cytidine analogues (gemcitabine) GTPBP10 intron 24483146 rs11563279 chr7 90002416 C G 5.97E-04 Response to cytadine analogues (cytosine arabinoside) GTPBP10 intron 24483146 rs11563547 chr7 90003694 A C 1.48E-04 Smoking initiation GTPBP10 intron 24665060 rs13222379 chr7 90019837 G A 9.69E-05 Relative hand skill GTPBP10 UTR-3 24068947 rs6945128 chr7 90023079 G A 5.18E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17862175 chr7 90042176 C T 2.17E-05 Cognitive performance CLDN12 cds-synon 19734545 rs6945696 chr7 90053664 C T 5.60E-05 Pericardial fat / / 22589742 rs11563419 chr7 90151034 A G 8.05E-04 Heart Failure / / pha002885 rs6949622 chr7 90182290 G A 1.71E-04 Lung function (forced vital capacity) / / 24023788 rs6949622 chr7 90182290 G A 3.42E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10254430 chr7 90208374 G A 2.00E-04 Multiple complex diseases / / 17554300 rs1989827 chr7 90223051 G T 9.30E-06 Lipid levels LOC100507508 intron 18193043 rs1859023 chr7 90240585 A G 2.95E-09 Coronary heart disease (incident CHD) / / 21829389 rs1859023 chr7 90240585 A G 3.39E-04 Coronary heart disease (incident CHD) / / 21829389 rs2106730 chr7 90247308 T C 5.74E-05 Major depressive disorder / / 22472876 rs10242197 chr7 90259912 C T 0.0000423 Otitis media (children 3 years old or younger) / / 23133572 rs6963448 chr7 90315158 C T 6.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs17163076 chr7 90320415 G T 8.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs10281060 chr7 90385330 G C 2.19E-06 Testicular cancer CDK14 intron 21551455 rs6951213 chr7 90413101 G A 2.75E-06 Testicular cancer CDK14 intron 21551455 rs17394921 chr7 90425217 G A 1.34E-04 Multiple complex diseases CDK14 intron 17554300 rs13235734 chr7 90430199 A G 8.84E-05 Caffeine consumption CDK14 intron 21490707 rs7809531 chr7 90481699 A G 4.39E-04 White matter integrity CDK14 intron 22425255 rs6957439 chr7 90523546 T C 5.19E-05 Information processing speed CDK14 intron 21130836 rs3808256 chr7 90587851 T C 3.76E-04 Response to cytidine analogues (gemcitabine) CDK14 intron 24483146 rs3808263 chr7 90590656 T A 7.19E-04 Response to TNF antagonist treatment CDK14 intron 21061259 rs3808267 chr7 90595848 G A 5.04E-04 White matter integrity CDK14 intron 22425255 rs3808270 chr7 90597274 C T 4.09E-04 White matter integrity CDK14 intron 22425255 rs12704584 chr7 90600097 G A 7.86E-04 Type 2 diabetes CDK14 intron 17463246 rs975004 chr7 90600629 A G 1.69E-08 Common variable immunodeficiency CDK14 intron 21497890 rs4728949 chr7 90602176 C T 9.22E-04 White matter integrity CDK14 intron 22425255 rs10953028 chr7 90608006 C A 4.62E-04 Response to TNF antagonist treatment CDK14 intron 21061259 rs705343 chr7 90610023 G A 5.04E-04 White matter integrity CDK14 intron 22425255 rs802416 chr7 90624416 A G 9.32E-04 Type 2 diabetes CDK14 intron 17463246 rs10488001 chr7 90656040 G T 0.0000453 Otitis media (children 3 years old or younger) CDK14 intron 23133572 rs7782262 chr7 90671675 A C 7.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDK14 intron 20877124 rs705349 chr7 90673308 A T 3.13E-04 Response to cytidine analogues (gemcitabine) CDK14 intron 24483146 rs705349 chr7 90673308 A T 7.65E-04 Response to cytadine analogues (cytosine arabinoside) CDK14 intron 24483146 rs17163534 chr7 90679137 A G 6.51E-04 Multiple complex diseases CDK14 intron 17554300 rs705352 chr7 90698364 C T 2.95E-04 Lung function (forced vital capacity) CDK14 intron 24023788 rs705352 chr7 90698364 C T 4.08E-04 Response to cytidine analogues (gemcitabine) CDK14 intron 24483146 rs17163563 chr7 90708561 G A 3.90E-04 Type 2 diabetes CDK14 intron 24509480 rs3779585 chr7 90719298 T G 5.97E-05 Multiple complex diseases CDK14 intron 17554300 rs803166 chr7 90745624 G A 7.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDK14 intron 20877124 rs3735649 chr7 90747371 T C 4.33E-04 Alzheimer's disease (late onset) CDK14 intron 21379329 rs10488004 chr7 90758236 A G 1.30E-06 Urinary metabolites CDK14 intron 21572414 rs43005 chr7 90763178 C G 3.54E-05 Serum metabolites CDK14 intron 19043545 rs43005 chr7 90763178 C G 7.20E-06 Urinary metabolites CDK14 intron 21572414 rs705362 chr7 90782534 A G 5.34E-04 Alcohol dependence CDK14 intron 21314694 rs2724356 chr7 90787193 C A 1.79E-04 Type 2 diabetes CDK14 intron 17463246 rs803174 chr7 90794795 G A 9.41E-04 Multiple complex diseases CDK14 intron 17554300 rs803174 chr7 90794795 G A 3.26E-04 Alcohol dependence CDK14 intron 21314694 rs2518782 chr7 90800787 G T 5.88E-04 Depression (quantitative trait) CDK14 intron 20800221 rs7800926 chr7 90823113 G A 2.33E-04 Longevity CDK14 intron 22279548 rs11970859 chr7 90840353 G A 1.70E-05 Leukocyte Counts / / pha003091 rs11976442 chr7 90851322 G A 3.12E-05 Amyotrophic lateral sclerosis / / 19193627 rs6963218 chr7 90852632 A C 3.93E-05 Amyotrophic lateral sclerosis / / 19193627 rs10499903 chr7 90859617 A C,G,T 4.10E-06 Subclinical atherosclerosis / / 17903303 rs7809443 chr7 90860351 C T 6.30E-05 Amyotrophic lateral sclerosis / / 19193627 rs17351398 chr7 90871515 G A 6.28E-04 Multiple complex diseases / / 17554300 rs6977978 chr7 90888413 A C 0.00046 Coronary artery calcification / / 23727086 rs17163759 chr7 90907043 T C 2.46E-05 Odorant perception / / 23910658 rs2888830 chr7 90915354 G A 5.00E-05 HIV-1 control / / 20041166 rs2888830 chr7 90915354 G A 4.00E-06 Dental caries / / 23259602 rs2888830 chr7 90915354 G A 7.00E-06 Dental caries / / 23259602 rs1346666 chr7 90926212 G C 3.54E-04 Smoking initiation / / 24665060 rs7798734 chr7 90928757 G T 3.62E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs7802175 chr7 90928923 A G 4.16E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs55646004 chr7 90940897 C T 2.30E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs747236 chr7 90943564 C T 2.27E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs1429524 chr7 90944268 C G 2.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs1429524 chr7 90944268 C G 4.65E-04 Smoking initiation / / 24665060 rs6971954 chr7 90947268 C G 2.63E-05 Aortic root size / / 21223598 rs7807514 chr7 91017896 C T 3.12E-05 HDL particle features / / pha002900 rs13246435 chr7 91027815 C T 2.49E-05 HDL particle features / / pha002900 rs6951656 chr7 91033074 A C 6.77E-05 HDL particle features / / pha002900 rs4504558 chr7 91074248 A G 2.10E-05 HDL particle features / / pha002900 rs4626524 chr7 91113955 A G 2.60E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs17691129 chr7 91167602 A G 1.87E-05 HDL particle features / / pha002900 rs7787692 chr7 91174263 C A 2.15E-04 Taste perception / / 22132133 rs7787692 chr7 91174263 C A 1.60E-04 IgE levels in asthmatics / / 23967269 rs2710942 chr7 91181705 C T 2.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2710943 chr7 91182927 A C 1.38E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs2465153 chr7 91183628 G A 1.03E-05 Serum albumin level / / pha003084 rs1076464 chr7 91186474 A G 3.35E-04 Sudden cardiac arrest / / 21658281 rs2430448 chr7 91192292 A G 1.10E-05 Urinary metabolites / / 21572414 rs2110770 chr7 91194707 G C 7.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2430437 chr7 91228686 T C 4.63E-05 Schizophrenia / / 20185149 rs2540552 chr7 91240297 C T 8.00E-06 IgG glycosylation / / 23382691 rs4728985 chr7 91263039 T C 1.34E-06 Personality dimensions / / 23658558 rs10248566 chr7 91268163 G C 7.59E-09 Non-obstructive azoospermia / / 22197933 rs1476442 chr7 91272344 A C 3.00E-06 Obesity-related traits / / 23251661 rs1476443 chr7 91272544 C T 7.70E-05 Personality dimensions / / 18957941 rs77228931 chr7 91279905 G A 0.0007778 Sarcoidosis / / 22952805 rs60933298 chr7 91283834 C A 2.89E-06 Personality dimensions / / 23658558 rs728486 chr7 91296669 G A 6.71E-04 Coronary Artery Disease / / 17634449 rs80338320 chr7 91348346 G A 0.00007574 Sarcoidosis / / 22952805 rs75378995 chr7 91350736 C T 0.00009719 Sarcoidosis / / 22952805 rs803264 chr7 91362922 T C 0.00001108 Sarcoidosis / / 22952805 rs2905381 chr7 91365764 C G 0.00001449 Sarcoidosis / / 22952805 rs1089874 chr7 91367658 C T 0.00001224 Sarcoidosis / / 22952805 rs1089876 chr7 91368208 G A 0.000009312 Sarcoidosis / / 22952805 rs803265 chr7 91368746 T C 0.00001759 Sarcoidosis / / 22952805 rs2521455 chr7 91379996 T C 0.0000144 Sarcoidosis / / 22952805 rs803284 chr7 91382184 G T 0.00003438 Sarcoidosis / / 22952805 rs17164117 chr7 91407769 G C 1.10E-04 Breast cancer / / 22452962 rs1208998 chr7 91414124 T C 5.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs59516267 chr7 91415892 C T 0.00007225 Sarcoidosis / / 22952805 rs28595251 chr7 91416103 C T 0.00002582 Sarcoidosis / / 22952805 rs17164125 chr7 91417796 T C 0.0000404 Sarcoidosis / / 22952805 rs6950538 chr7 91417816 T C 0.000008978 Sarcoidosis / / 22952805 rs13231833 chr7 91420443 A G 0.00000649 Sarcoidosis / / 22952805 rs183888992 chr7 91421134 T A 0.00002988 Sarcoidosis / / 22952805 rs140690457 chr7 91423711 T C 0.00001105 Sarcoidosis / / 22952805 rs74440447 chr7 91431153 C T 0.00005658 Sarcoidosis / / 22952805 rs6949881 chr7 91433827 C T 0.00003266 Sarcoidosis / / 22952805 rs10275573 chr7 91434791 C T 0.00006021 Sarcoidosis / / 22952805 rs6952459 chr7 91435820 T A 0.000008272 Sarcoidosis / / 22952805 rs140402949 chr7 91437170 T C 0.00007531 Sarcoidosis / / 22952805 rs2020360 chr7 91439506 G C 0.000008233 Sarcoidosis / / 22952805 rs17731846 chr7 91440342 T C 0.00005025 Sarcoidosis / / 22952805 rs1209001 chr7 91440359 G A 4.46E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs80018233 chr7 91441009 T A 0.00005628 Sarcoidosis / / 22952805 rs13229273 chr7 91444472 G A 0.00001138 Sarcoidosis / / 22952805 rs13229505 chr7 91444679 G T 0.00000613 Sarcoidosis / / 22952805 rs9640598 chr7 91446142 C T 0.00001693 Sarcoidosis / / 22952805 rs10808086 chr7 91447515 T C 0.00002236 Sarcoidosis / / 22952805 rs10239125 chr7 91447692 T G 0.00002565 Sarcoidosis / / 22952805 rs974508 chr7 91448017 C T 0.00002111 Sarcoidosis / / 22952805 rs12666939 chr7 91448958 C G 0.00008546 Sarcoidosis / / 22952805 rs2213956 chr7 91449934 C T 0.00002871 Sarcoidosis / / 22952805 rs62466159 chr7 91450507 A G 0.00001253 Sarcoidosis / / 22952805 rs7780137 chr7 91450891 A G 0.00002871 Sarcoidosis / / 22952805 rs4729007 chr7 91452050 T C 0.00005908 Sarcoidosis / / 22952805 rs2188142 chr7 91452309 G A 0.00002038 Sarcoidosis / / 22952805 rs2188143 chr7 91452496 G A 0.00002922 Sarcoidosis / / 22952805 rs58604123 chr7 91453005 T C 0.00008558 Sarcoidosis / / 22952805 rs13246743 chr7 91453945 G T 0.000007241 Sarcoidosis / / 22952805 rs55998159 chr7 91457643 TTG T 0.00005799 Sarcoidosis / / 22952805 rs57440655 chr7 91457643 T TTGTG,TTGTGTG 0.00005799 Sarcoidosis / / 22952805 rs59303482 chr7 91457643 T TG 0.00005799 Sarcoidosis / / 22952805 rs66689400 chr7 91457643 TTG T 0.00005799 Sarcoidosis / / 22952805 rs77856026 chr7 91457643 T A 0.00005799 Sarcoidosis / / 22952805 rs61016462 chr7 91457858 G A 0.00008193 Sarcoidosis / / 22952805 rs2049314 chr7 91464134 C T 0.000007597 Sarcoidosis / / 22952805 rs4729009 chr7 91467582 T C 0.00007098 Sarcoidosis / / 22952805 rs148672561 chr7 91469031 C T 0.00001422 Sarcoidosis / / 22952805 rs62466809 chr7 91472801 A G 0.00003941 Sarcoidosis / / 22952805 rs17164154 chr7 91474788 T C 0.00009747 Sarcoidosis / / 22952805 rs9656002 chr7 91475007 A G 0.00005125 Sarcoidosis / / 22952805 rs6979024 chr7 91481512 T C 0.00009825 Sarcoidosis / / 22952805 rs55811257 chr7 91484799 T A 0.000021 Sarcoidosis / / 22952805 rs11769726 chr7 91485231 A G 0.00007006 Sarcoidosis / / 22952805 rs10236107 chr7 91485461 G A 0.00007006 Sarcoidosis / / 22952805 rs10242792 chr7 91492103 G T 0.00007547 Sarcoidosis / / 22952805 rs9632716 chr7 91516727 A G 0.00004921 Sarcoidosis / / 22952805 rs13307679 chr7 91518075 G A 0.00009361 Sarcoidosis / / 22952805 rs116343027 chr7 91527089 C T 0.00005961 Sarcoidosis / / 22952805 rs11761885 chr7 91544134 C A 0.00005016 Sarcoidosis / / 22952805 rs405 chr7 91546327 G C 2.00E-07 Hepatocellular carcinoma / / 22807686 rs10243083 chr7 91552530 G A 8.47E-06 Brachial circumference / / 22479309 rs12669943 chr7 91554238 G C 0.00005373 Sarcoidosis / / 22952805 rs12533497 chr7 91657672 G A 4.26E-06 Schizophrenia (treatment refractory) AKAP9 intron 22479419 rs6961928 chr7 91669808 G A 1.83E-06 Testicular cancer AKAP9 intron 19483682 rs10275125 chr7 91680974 G A 9.15E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) AKAP9 intron 23648065 rs12536529 chr7 91684086 A G 1.54E-04 Alcohol dependence AKAP9 intron 21314694 rs2961024 chr7 91691070 G T 9.15E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) AKAP9 intron 23648065 rs74969983 chr7 91694118 T G 0.00009155 Sarcoidosis AKAP9 intron 22952805 rs2006299 chr7 91707604 G A 0.00009155 Sarcoidosis AKAP9 intron 22952805 rs4080400 chr7 91707958 T A 0.00009155 Sarcoidosis AKAP9 intron 22952805 rs77863459 chr7 91709923 A G 0.00008009 Sarcoidosis AKAP9 intron 22952805 rs74298192 chr7 91721529 T C 0.00007618 Sarcoidosis AKAP9 intron 22952805 rs78291049 chr7 91721673 G C 0.00007618 Sarcoidosis AKAP9 intron 22952805 rs3750111 chr7 91728923 C T 0.00009687 Sarcoidosis AKAP9 intron 22952805 rs12538678 chr7 91736464 T G 4.78E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) AKAP9 intron 23648065 rs6465353 chr7 91779971 T G 1.70E-04 Alcohol dependence LRRD1 missense 21314694 rs10249873 chr7 91825168 A C 6.39E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs35350895 chr7 91864947 G A 2.41E-14 Triglycerides KRIT1 missense 23063622 rs12704637 chr7 91874686 C T 2.08E-04 Alcohol dependence KRIT1 intron 21314694 rs17164470 chr7 91892459 A G 3.91E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) ANKIB1 intron 23648065 rs10953069 chr7 91922541 T C 1.80E-05 Lymphocyte counts ANKIB1 intron 22286170 rs12740 chr7 92029302 G A 2.41E-04 Alcohol dependence ANKIB1 UTR-3 21314694 rs38795 chr7 92031948 G A 4.55E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs39744 chr7 92043016 G A 9.53E-04 Multiple complex diseases / / 17554300 rs4729043 chr7 92077716 G A 5.10E-04 Alcohol dependence GATAD1 intron 20201924 rs2287179 chr7 92080395 A G 3.80E-04 Alcohol dependence GATAD1 intron 20201924 rs10265704 chr7 92088823 T C 0.00001253 Sarcoidosis / / 22952805 rs6962245 chr7 92089626 G C 0.00005602 Sarcoidosis / / 22952805 rs75357900 chr7 92091330 A G 0.00003905 Sarcoidosis / / 22952805 rs28702411 chr7 92095351 T C 0.00006066 Sarcoidosis / / 22952805 rs1053204 chr7 92096342 G A 0.00005336 Sarcoidosis / / 22952805 rs7803469 chr7 92096679 C T 0.00003907 Sarcoidosis / / 22952805 rs10265541 chr7 92097870 C T 0.00003907 Sarcoidosis ERVW-1 UTR-3 22952805 rs10266695 chr7 92098776 C T 0.00005404 Sarcoidosis ERVW-1 missense 22952805 rs111405543 chr7 92104681 G A 0.00003548 Sarcoidosis ERVW-1 intron 22952805 rs6944759 chr7 92116101 C T 6.50E-04 Alcohol dependence PEX1 nearGene-3 20201924 rs10269874 chr7 92128835 G T 0.00006021 Sarcoidosis PEX1 intron 22952805 rs10953071 chr7 92129397 T A 0.00008168 Sarcoidosis PEX1 intron 22952805 rs3213609 chr7 92131029 A G 5.00E-04 Alcohol dependence PEX1 intron 20201924 rs7809455 chr7 92136073 T C 5.10E-04 Alcohol dependence PEX1 intron 20201924 rs7791858 chr7 92136754 G A 9.04E-04 Endometrial cancer PEX1 intron 24096698 rs6964848 chr7 92162535 C T 0.00009765 Sarcoidosis RBM48 intron 22952805 rs929412 chr7 92165862 C T 6.90E-04 Alcohol dependence RBM48 intron 20201924 rs113124124 chr7 92172893 A G 0.00008327 Sarcoidosis / / 22952805 rs76581721 chr7 92173304 T C 0.00008393 Sarcoidosis / / 22952805 rs4727279 chr7 92175469 G A 0.00005187 Sarcoidosis / / 22952805 rs2041044 chr7 92179229 G T 0.00002133 Sarcoidosis / / 22952805 rs758002 chr7 92180416 C T 0.00009228 Sarcoidosis / / 22952805 rs758003 chr7 92180705 A G 0.00009228 Sarcoidosis / / 22952805 rs58164473 chr7 92196258 C T 0.00002105 Sarcoidosis FAM133B intron 22952805 rs6465363 chr7 92207270 C T 9.00E-04 Alcohol dependence FAM133B intron 20201924 rs9656005 chr7 92208346 T C 0.00002299 Sarcoidosis FAM133B intron 22952805 rs10488517 chr7 92210340 A T 0.00001555 Sarcoidosis FAM133B intron 22952805 rs6956251 chr7 92213647 A C 0.00001605 Sarcoidosis FAM133B intron 22952805 rs4272 chr7 92236829 A G 1.80E-36 Height CDK6 UTR-3 21194676 rs4272 chr7 92236829 A G 3.10E-18 Height CDK6 UTR-3 21194676 rs4272 chr7 92236829 A G 7.20E-19 Height CDK6 UTR-3 21194676 rs4272 chr7 92236829 A G 1.00E-08 Rheumatoid arthritis CDK6 UTR-3 24390342 rs4272 chr7 92236829 A G 5.00E-09 Rheumatoid arthritis CDK6 UTR-3 24390342 rs42041 chr7 92246744 C G 4.00E-06 Rheumatoid arthritis CDK6 intron 18794853 rs42235 chr7 92248076 C T 8.00E-47 Height CDK6 intron 20881960 rs42235 chr7 92248076 C T 1.00E-28 Height CDK6 intron 23563607 rs10269774 chr7 92253972 G A 7.46E-05 IgE levels CDK6 intron 22075330 rs2040494 chr7 92256905 C T 4.00E-07 Height CDK6 intron 18391950 rs2040494 chr7 92256905 C T 1.81E-07 Height CDK6 intron 19570815 rs2282978 chr7 92264410 T C 1.00E-08 Height CDK6 intron 18391951 rs2282978 chr7 92264410 T C 8.00E-23 Height CDK6 intron 18391952 rs2282978 chr7 92264410 T C 1.00E-08 Height CDK6 intron 19343178 rs2282978 chr7 92264410 T C 2.66E-05 Height CDK6 intron 19570815 rs2282978 chr7 92264410 T C 5.01E-05 IgE levels CDK6 intron 22075330 rs3731343 chr7 92273536 A C 3.53E-05 AIDS progression CDK6 intron 19115949 rs2282983 chr7 92279363 T C 7.02E-04 Multiple complex diseases CDK6 intron 17554300 rs2282983 chr7 92279363 T C 7.46E-05 IgE levels CDK6 intron 22075330 rs2282984 chr7 92279693 T C 0.000014 Mean arterial pressure CDK6 intron 22510845 rs7804722 chr7 92288106 T C 1.51E-04 Multiple complex diseases CDK6 intron 17554300 rs9640606 chr7 92301040 C T 0.0001 Migraine CDK6 intron 22678113 rs12670783 chr7 92308798 A G 1.80E-04 White blood cell types CDK6 intron 21738478 rs2237573 chr7 92313733 A G 0.0001 Migraine CDK6 intron 22678113 rs10254840 chr7 92333408 A G 0.0001 Migraine CDK6 intron 22678113 rs445 chr7 92408370 C T 2.00E-08 Blood cell counts and other traits CDK6 intron 20139978 rs445 chr7 92408370 C T 2.44E-08 Blood cell counts and other traits CDK6 intron 20139978 rs445 chr7 92408370 C T 2.00E-08 Blood cell counts and traits,in red and white blood cells CDK6 intron 21153663 rs445 chr7 92408370 C T 4.10E-04 Blood cell counts and traits,in red and white blood cells CDK6 intron 21153663 rs445 chr7 92408370 C T 7.00E-10 White blood cell types CDK6 intron 21738478 rs445 chr7 92408370 C T 4.00E-07 White blood cell count CDK6 intron 21738479 rs11974095 chr7 92437786 T C 1.60E-04 Iris characteristics CDK6 intron 21835309 rs10269570 chr7 92470345 G A 7.07E-06 Odorant perception / / 23910658 rs10241695 chr7 92542849 C T 5.61E-04 Alcohol dependence / / 21314694 rs10230949 chr7 92615875 C T 7.51E-04 Type 2 diabetes / / 17463246 rs723668 chr7 92648340 C T 4.97E-04 Smoking initiation / / 24665060 rs11979483 chr7 92653680 G A 2.76E-05 Alzheimer's disease (late onset) / / 21460841 rs1123915 chr7 92665884 A T 1.86E-05 Sudden cardiac arrest / / 21658281 rs739385 chr7 92682609 G A 3.59E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10953089 chr7 92728427 C T 1.91E-05 Post-operative nausea and vomiting SAMD9 nearGene-3 21694509 rs4268 chr7 92760502 G A 5.75E-05 Post-operative nausea and vomiting SAMD9L UTR-3 21694509 rs1133906 chr7 92764982 C T 2.00E-07 Systemic lupus erythematosus and Systemic sclerosis SAMD9L cds-synon 23740937 rs11538791 chr7 92764982 C CC,CT 2.00E-07 Systemic lupus erythematosus and Systemic sclerosis SAMD9L cds-synon 23740937 rs4727286 chr7 92807377 C T 4.71E-05 stroke (ischemic) / / 17434096 rs42511 chr7 92824879 C T 3.23E-04 Multiple complex diseases HEPACAM2 intron 17554300 rs793 chr7 92836316 C A 4.71E-05 stroke (ischemic) HEPACAM2 intron 17434096 rs4729076 chr7 92857805 C A,G,T 4.71E-05 stroke (ischemic) / / 17434096 rs10488536 chr7 92881662 T G 7.96E-05 stroke (ischemic) CCDC132 intron 17434096 rs3802061 chr7 92913805 A T 5.36E-04 Multiple complex diseases CCDC132 intron 17554300 rs3802059 chr7 92915394 G A 5.82E-04 Multiple complex diseases CCDC132 intron 17554300 rs9918592 chr7 92961612 T C 1.91E-04 Multiple complex diseases CCDC132 intron 17554300 rs9641113 chr7 92967663 A G 2.74E-04 Multiple complex diseases CCDC132 intron 17554300 rs2285505 chr7 92987445 T C 7.45E-04 Multiple complex diseases CCDC132 intron 17554300 rs2285505 chr7 92987445 T C 3.07E-04 Cognitive decline CCDC132 intron 23732972 rs17165292 chr7 92987999 T C 6.06E-04 Multiple complex diseases CCDC132 UTR-3 17554300 rs3735650 chr7 92988398 T G 6.10E-04 Multiple complex diseases CCDC132 UTR-3 17554300 rs3735650 chr7 92988398 T G 4.93E-05 Cognitive decline CCDC132 UTR-3 23732972 rs13241604 chr7 92991370 G C 5.94E-05 Suicide attempts in bipolar disorder / / 21423239 rs11764153 chr7 93023568 T C 6.32E-05 Serum metabolites / / 19043545 rs41496647 chr7 93087152 T C 5.39E-05 Response to methylphenidate treatment CALCR intron 21130132 rs2074120 chr7 93107093 A C 5.36E-04 Type 2 diabetes CALCR intron 22158537 rs2299253 chr7 93110055 T C 5.49E-04 Type 2 diabetes CALCR intron 22158537 rs10488542 chr7 93114364 T G 5.05E-04 Type 2 diabetes CALCR intron 22158537 rs9690762 chr7 93115750 A G 5.23E-04 Type 2 diabetes CALCR intron 22158537 rs2301680 chr7 93116299 A G 5.84E-04 Type 2 diabetes CALCR missense 22158537 rs2188799 chr7 93143761 A G 0.000892 Salmonella-induced pyroptosis CALCR intron 22837397 rs2188799 chr7 93143761 A G 8.11E-04 Smoking quantity CALCR intron 24665060 rs6973591 chr7 93160671 A G 3.00E-05 Prostate cancer CALCR intron 21743057 rs6973591 chr7 93160671 A G 4.46E-04 Myocardial Infarction CALCR intron pha002873 rs2158044 chr7 93168399 A G 5.00E-06 Smoking behavior CALCR intron 20418888 rs2158044 chr7 93168399 A G 3.65E-04 Myocardial Infarction CALCR intron pha002873 rs6962312 chr7 93168766 G C 3.00E-05 Prostate cancer CALCR intron 21743057 rs12704677 chr7 93169389 T C 3.00E-05 Prostate cancer CALCR intron 21743057 rs13229065 chr7 93174631 T G 5.00E-06 Prostate cancer CALCR intron 21743057 rs12670169 chr7 93177533 T A 5.00E-06 Prostate cancer CALCR intron 21743057 rs12704683 chr7 93179970 A G 5.00E-06 Prostate cancer CALCR intron 21743057 rs5014937 chr7 93179990 A C 5.00E-06 Prostate cancer CALCR intron 21743057 rs1000912 chr7 93182557 C T 2.45E-05 Left ventricular hypertrophy CALCR intron pha003052 rs1548456 chr7 93192036 T C 3.77E-05 Left ventricular hypertrophy CALCR intron pha003052 rs1548457 chr7 93192710 T C 4.60E-04 Type 2 diabetes and 6 quantitative traits CALCR intron 17848626 rs9641123 chr7 93197732 G C 9.00E-05 Prostate cancer CALCR intron 21743057 rs10488555 chr7 93197760 T C 2.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) CALCR intron 17982456 rs10237272 chr7 93201902 C T 4.26E-04 Suicide attempts in bipolar disorder CALCR intron 21423239 rs2528521 chr7 93204544 C T 8.27E-04 Suicide attempts in bipolar disorder CALCR nearGene-5 21423239 rs2528528 chr7 93205096 T C 4.88E-04 Suicide attempts in bipolar disorder CALCR nearGene-5 21423239 rs6943527 chr7 93205706 T C 1.30E-04 Suicide attempts in bipolar disorder CALCR nearGene-5 21423239 rs16868443 chr7 93206264 G C 3.99E-05 Suicide attempts in bipolar disorder / / 21423239 rs6975603 chr7 93206375 A C 1.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs982692 chr7 93206613 T C 3.81E-05 Suicide attempts in bipolar disorder / / 21423239 rs2251307 chr7 93207036 A G 1.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs2528541 chr7 93208716 A G 1.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs201011308 chr7 93209930 A ATC 2.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs2190335 chr7 93209930 A C 2.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs2528555 chr7 93211388 T C 3.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs2528522 chr7 93222805 G A 3.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs1541433 chr7 93225118 G A 4.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs2677093 chr7 93226894 T C 3.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs7341502 chr7 93229453 G A 6.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs7799704 chr7 93229540 G A 2.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs7799704 chr7 93229540 G A 3.56E-05 Height / / 22021425 rs6954346 chr7 93230497 T C 3.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs2677072 chr7 93230742 T C 3.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs2677069 chr7 93231491 T A 3.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs13247665 chr7 93232057 T C 1.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs2528531 chr7 93236510 A C 1.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs2256354 chr7 93237836 G A 2.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs2528532 chr7 93239315 T C 3.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs2528532 chr7 93239315 T C 1.79E-05 Height / / 22021425 rs2528533 chr7 93239734 G A 3.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs2528533 chr7 93239734 G A 6.87E-06 Height / / 22021425 rs7780752 chr7 93241640 T C 5.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs7780752 chr7 93241640 T C 2.00E-07 Birth weight / / 23202124 rs2051931 chr7 93243060 C T 2.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs2528536 chr7 93245923 G A 9.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs13247154 chr7 93246551 G A 2.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs2528537 chr7 93247388 A T 5.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs2677095 chr7 93251234 C T 5.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs2677085 chr7 93255334 T C 4.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs2677080 chr7 93256222 G T 5.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs2677079 chr7 93256401 G C 7.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs2677078 chr7 93257986 C T 3.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs2677077 chr7 93259217 T C 5.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs2677090 chr7 93260140 C G 1.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs2677091 chr7 93261414 G A 1.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs2528542 chr7 93266368 T C 6.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs2528543 chr7 93267226 C T 1.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs6958537 chr7 93274953 A G 1.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs1029588 chr7 93277454 C T 7.94E-05 Suicide attempts in bipolar disorder / / 21423239 rs2528551 chr7 93278868 G C 9.82E-05 Suicide attempts in bipolar disorder / / 21423239 rs2051932 chr7 93280036 G A 1.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs2528553 chr7 93281088 A G 5.99E-05 Suicide attempts in bipolar disorder / / 21423239 rs2519570 chr7 93294162 G A 1.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs2677040 chr7 93297061 A G 1.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs2677039 chr7 93297506 T G 1.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs2519567 chr7 93301934 T C 1.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs10226698 chr7 93326060 T C 8.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2519613 chr7 93349851 T C 2.20E-05 Urinary metabolites / / 21572414 rs2677056 chr7 93360031 A C 1.38E-04 Multiple complex diseases / / 17554300 rs2519602 chr7 93363399 G T 8.43E-05 Multiple complex diseases / / 17554300 rs2724071 chr7 93368978 T G 8.99E-04 Type 2 diabetes / / 17463246 rs2188273 chr7 93369643 T C 8.09E-04 Type 2 diabetes / / 17463246 rs17165714 chr7 93379740 A G 5.96E-04 Multiple complex diseases / / 17554300 rs2519573 chr7 93399947 T A 2.94E-04 Type 2 diabetes / / 17463246 rs10464585 chr7 93435967 A G 6.41E-05 Alcohol consumption / / 23953852 rs2724122 chr7 93446357 T C 2.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2724122 chr7 93446357 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2724122 chr7 93446357 T C 9.03E-05 Cognitive impairment induced by topiramate / / 22091778 rs2519662 chr7 93468542 T C 2.33E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7807992 chr7 93484445 C T 3.30E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12667359 chr7 93502311 C T 9.58E-05 Cognitive impairment induced by topiramate / / 22091778 rs180273 chr7 93538295 A G 7.00E-06 Pulmonary function decline GNGT1 intron 22424883 rs180242 chr7 93549596 T A 7.00E-12 Heart rate / / 23583979 rs4261 chr7 93557117 A T 2.74E-05 Type 2 diabetes / / 17463246 rs12704703 chr7 93569305 C T 5.67E-04 Type 2 diabetes / / 17463246 rs12704705 chr7 93578679 A G 3.30E-05 Orofacial clefts / / 22419666 rs4729105 chr7 93606881 C T 1.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4729105 chr7 93606881 C T 6.95E-05 Waist-Hip Ratio / / pha003029 rs726820 chr7 93611910 G A 2.50E-05 Urinary metabolites / / 21572414 rs7794610 chr7 93654752 C A 7.60E-04 Endometriosis / / 23104006 rs41524 chr7 93683616 G A 2.88E-05 Glucose levels / / pha003058 rs9918668 chr7 93691744 G A 6.00E-07 Aging / / 22773346 rs11975386 chr7 93705033 C A 6.66E-06 Obesity-related traits / / 23251661 rs6949013 chr7 93706220 T C 5.17E-04 Tourette syndrome / / 22889924 rs10487245 chr7 93713521 G A 2.00E-06 Obesity-related traits / / 23251661 rs41542 chr7 93722036 T C 9.55E-04 Obesity (extreme) / / 21935397 rs929221 chr7 93757714 C T 2.33E-04 Multiple complex diseases / / 17554300 rs11973087 chr7 93766448 G A 3.11E-04 Alzheimer's disease / / 22005930 rs11973087 chr7 93766448 G A 5.09E-06 Obesity-related traits / / 23251661 rs7357193 chr7 93787413 C A 3.76E-04 Hemoglobin concentration / / 20534544 rs7357193 chr7 93787413 C A 3.01E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs7357193 chr7 93787413 C A 8.26E-04 Iron levels / / pha002876 rs1990543 chr7 93812586 A C 4.17E-06 Obesity-related traits / / 23251661 rs2192505 chr7 93865775 T C 4.43E-04 Multiple complex diseases / / 17554300 rs2110483 chr7 93880093 T C 7.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs1861113 chr7 93883367 G A 2.10E-05 White blood cell types / / 21738478 rs1861114 chr7 93883599 T G 7.26E-06 Parkinson's disease (motor and cognition) / / 22658654 rs7782469 chr7 93923144 A G 0.000407286 Hypertension (early onset hypertension) / / 22479346 rs735392 chr7 93928050 G A 2.45E-04 Age-related macular degeneration / / 22125219 rs12704714 chr7 93930713 C T 2.44E-04 Coronary Artery Disease / / 17634449 rs12704714 chr7 93930713 C T 7.88E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs2157811 chr7 93963296 T C 3.24E-04 Taste perception / / 22132133 rs4729116 chr7 93979599 T C 5.30E-05 Recombination rate / / 21698098 rs4729118 chr7 93982877 T C 3.89E-04 Alzheimer's disease / / 22005930 rs4729125 chr7 93997093 C G 3.80E-04 Alzheimer's disease / / 22005930 rs10262915 chr7 94000473 T C 9.00E-08 Intelligence / / 22449649 rs6465411 chr7 94003260 T C 1.78E-04 Osteoarthritis (knee and hip) / / 21177295 rs6465411 chr7 94003260 T C 6.49E-04 Osteoarthritis (knee and hip) / / 21177295 rs6465411 chr7 94003260 T C 7.37E-05 Osteoarthritis (knee and hip) / / 21177295 rs17166205 chr7 94003841 T A 3.93E-04 Alzheimer's disease / / 22005930 rs17166206 chr7 94004197 C T 3.87E-04 Alzheimer's disease / / 22005930 rs13221576 chr7 94006994 C T 4.26E-04 Iron levels / / pha002876 rs7799378 chr7 94007546 G C 3.84E-04 Alzheimer's disease / / 22005930 rs7799664 chr7 94007689 G A 1.11E-05 Cytomegalovirus antibody response / / 21993531 rs7792596 chr7 94009634 T C 6.00E-07 Intelligence / / 22449649 rs12665908 chr7 94010770 T C 5.13E-04 Alzheimer's disease / / 22005930 rs8180727 chr7 94011085 C T 5.13E-04 Alzheimer's disease / / 22005930 rs7793690 chr7 94013594 A T 5.19E-04 Alzheimer's disease / / 22005930 rs17166229 chr7 94017673 A G 4.59E-04 Alzheimer's disease / / 22005930 rs3763467 chr7 94022118 T C 3.32E-04 Alzheimer's disease COL1A2 nearGene-5 22005930 rs10255021 chr7 94031805 G A 1.71E-08 Type 1 diabetes COL1A2 intron 17632545 rs2299418 chr7 94032325 G A 9.94E-05 Coronary heart disease COL1A2 intron pha003032 rs2521206 chr7 94039187 A G 8.20E-05 Cognitive function COL1A2 intron 24684796 rs2621208 chr7 94039410 C G 1.06E-04 Arthritis (juvenile idiopathic) COL1A2 intron 22354554 rs389328 chr7 94040133 T A 7.70E-05 Carotid intima media thickness COL1A2 intron 19679847 rs2521205 chr7 94046541 G T 4.54E-04 Schizophrenia(treatment response to risperidone) COL1A2 intron 19850283 rs3736638 chr7 94047266 C A 3.00E-07 Immune reponse to smallpox (secreted IL-12p40) COL1A2 intron 22610502 rs10487255 chr7 94048545 G A 9.04E-04 Type 2 diabetes COL1A2 intron 17463246 rs10487255 chr7 94048545 G A 2.10E-05 Urinary metabolites COL1A2 intron 21572414 rs441051 chr7 94054000 T C 2.00E-06 Mean forced vital capacity from 2 exams COL1A2 intron 17903307 rs35820023 chr7 94056353 G A 7.52E-25 Triglycerides COL1A2 missense 23063622 rs115744676 chr7 94061404 G T 7.00E-09 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs116187617 chr7 94061601 C A 1.23E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs10487261 chr7 94081181 C A 5.13E-04 Type 2 diabetes / / 17463246 rs10273041 chr7 94087489 C T 5.75E-04 Myopia (pathological) / / 21095009 rs2301646 chr7 94146975 T G 9.83E-04 Myopia (pathological) CASD1 intron 21095009 rs6958243 chr7 94176627 G C 4.39E-06 Coronary heart disease CASD1 intron 22319020 rs2374736 chr7 94187422 A G 2.17E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17400379 chr7 94209932 T G 6.30E-05 Major depressive disorder / / 21042317 rs10232398 chr7 94227509 G A 7.80E-04 Myopia (pathological) SGCE intron 21095009 rs6465422 chr7 94311300 G A 8.70E-05 Lymphocyte counts / / pha003094 rs17166459 chr7 94339854 C T 6.05E-04 Parkinson's disease / / 16252231 rs10231524 chr7 94527827 C T 4.40E-06 Thyroid function / / 20826269 rs1527680 chr7 94534886 A G 1.90E-06 Thyroid function / / 20826269 rs12539414 chr7 94580041 T A 3.63E-04 Schizophrenia(age at onset) PPP1R9A intron 21688384 rs12666786 chr7 94580776 A G 1.20E-05 Urinary metabolites PPP1R9A intron 21572414 rs10499912 chr7 94589181 A G 1.20E-05 Urinary metabolites PPP1R9A intron 21572414 rs10499912 chr7 94589181 A G 3.63E-04 Schizophrenia(age at onset) PPP1R9A intron 21688384 rs41401247 chr7 94681698 G A 3.92E-04 Aortic root size PPP1R9A intron 21223598 rs11766387 chr7 94724450 T C 5.86E-04 Multiple complex diseases PPP1R9A intron 17554300 rs17305795 chr7 94742832 A G 2.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PPP1R9A intron 20877124 rs17305991 chr7 94751895 T C 7.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PPP1R9A intron 20877124 rs9649194 chr7 94754985 G T 3.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PPP1R9A intron 20877124 rs2374983 chr7 94871724 A G 6.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PPP1R9A intron 20877124 rs2240027 chr7 94903652 A G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes PPP1R9A intron 22628534 rs10156050 chr7 94905790 G A 4.05E-05 Soluble levels of adhesion molecules PPP1R9A intron pha003072 rs854536 chr7 94909899 G A 6.42E-05 Soluble levels of adhesion molecules PPP1R9A intron pha003072 rs2285694 chr7 94912404 G A 7.97E-04 Multiple complex diseases PPP1R9A intron 17554300 rs854541 chr7 94920480 T C 1.38E-06 Soluble levels of adhesion molecules PPP1R9A UTR-3 pha003072 rs3735590 chr7 94927495 G A 7.45E-05 Soluble levels of adhesion molecules PON1 nearGene-3 pha003072 rs854555 chr7 94930391 A C 2.00E-06 Response to TNF antagonist treatment PON1 intron 18615156 rs662 chr7 94937446 T C 0.000043 Stroke PON1 missense 23422753 rs2057681 chr7 94938257 A G 1.00E-303 Paraoxonase activity PON1 intron 22982463 rs2057681 chr7 94938257 A G 7.00E-15 Metabolite levels PON1 intron 23281178 rs2299257 chr7 94942765 A C 1.10E-05 Response to ximelagatran treatment PON1 intron 17505501 rs3917510 chr7 94943120 T G 3.34E-08 Cholesterol,total PON1 intron 23063622 rs3917502 chr7 94945744 C T 6.44E-09 Triglycerides PON1 intron 23063622 rs2299261 chr7 94949663 A G 5.72E-04 Smoking initiation PON1 intron 24665060 rs2299262 chr7 94949928 C T 0.0000396 Paraoxonase activity PON1 intron 23160181 rs2237583 chr7 94950177 C T 3.88E-08 Paraoxonase activity PON1 intron 23160181 rs3917478 chr7 94951569 T C 0.00000114 Paraoxonase activity PON1 intron 23160181 rs3917478 chr7 94951569 T C 4.08E-05 Elbow pain PON1 intron pha003008 rs3917478 chr7 94951569 T C 1.72E-05 Height PON1 intron pha003011 rs3917473 chr7 94952569 A G 5.94E-04 Multiple complex diseases PON1 intron 17554300 rs854572 chr7 94954696 C G 5.00E-116 Paraoxonase activity PON1 nearGene-5 22982463 rs3917463 chr7 94954899 A G 2.40E-05 Multiple complex diseases PON1 nearGene-5 17554300 rs9641162 chr7 94992468 A G 2.48E-05 Tunica Media PON3 intron pha003036 rs17885861 chr7 95022892 G A 0.00000199 Cholesterol,total PON3 intron 23063622 rs10259688 chr7 95056939 T C 6.04E-05 Cleft lip PON2 intron 20436469 rs10259688 chr7 95056939 T C 2.38E-04 Intracranial aneurysm PON2 intron 22286173 rs2299267 chr7 95061921 A G 6.19E-04 Multiple complex diseases PON2 intron 17554300 rs6978425 chr7 95068684 T G 9.79E-06 Schizophrenia / / 22037552 rs43041 chr7 95070838 C A 8.52E-04 Iron levels / / pha002876 rs10225097 chr7 95081990 G C 1.00E-05 Iris characteristics / / 21835309 rs11770226 chr7 95085431 A C 4.69E-05 Asthma / / 20159242 rs43061 chr7 95102534 C T 4.90E-06 Stroke (ischemic) / / 21957438 rs10487135 chr7 95157935 G A 6.04E-04 Acute lung injury ASB4 UTR-3 22295056 rs17774768 chr7 95158710 G A 7.39E-04 Acute lung injury ASB4 intron 22295056 rs2240003 chr7 95165274 C T 4.90E-05 Adiposity ASB4 intron 19461586 rs12704800 chr7 95173570 T C 6.60E-05 Major depressive disorder / / 21042317 rs12704800 chr7 95173570 T C 2.26E-04 Obesity (extreme) / / 21935397 rs12704801 chr7 95175185 T C 4.32E-04 Obesity (extreme) / / 21935397 rs12111976 chr7 95177577 A G 2.24E-04 Obesity (extreme) / / 21935397 rs7801196 chr7 95179261 T C 2.63E-04 Obesity (extreme) / / 21935397 rs12234734 chr7 95179513 C T 5.50E-05 Pericardial fat / / 22589742 rs6465469 chr7 95179593 G A 2.67E-04 Obesity (extreme) / / 21935397 rs6465470 chr7 95179757 G A 2.55E-04 Obesity (extreme) / / 21935397 rs6953838 chr7 95180018 G A 8.80E-05 Major depressive disorder / / 21042317 rs6953838 chr7 95180018 G A 2.78E-04 Obesity (extreme) / / 21935397 rs4727315 chr7 95180458 C A 2.98E-04 Obesity (extreme) / / 21935397 rs4727316 chr7 95180489 T C 2.40E-04 Obesity (extreme) / / 21935397 rs4727317 chr7 95180793 T C 2.61E-04 Type 2 diabetes / / 17463246 rs4729196 chr7 95180846 G A 5.62E-04 Obesity (extreme) / / 21935397 rs4727318 chr7 95180888 C T 6.04E-04 Obesity (extreme) / / 21935397 rs4727319 chr7 95181184 C G 7.97E-04 Obesity (extreme) / / 21935397 rs12704802 chr7 95181480 C T 5.73E-04 Obesity (extreme) / / 21935397 rs7785595 chr7 95183318 T C 5.90E-04 Obesity (extreme) / / 21935397 rs7802572 chr7 95183456 A G 6.27E-04 Obesity (extreme) / / 21935397 rs2375021 chr7 95184663 G C 7.28E-04 Obesity (extreme) / / 21935397 rs12704805 chr7 95185108 A C 7.30E-04 Obesity (extreme) / / 21935397 rs12704806 chr7 95185125 G A 7.33E-04 Obesity (extreme) / / 21935397 rs2106510 chr7 95186227 G A 7.41E-04 Obesity (extreme) / / 21935397 rs199959180 chr7 95186387 G GA 7.43E-04 Obesity (extreme) / / 21935397 rs2375006 chr7 95186387 G A 7.43E-04 Obesity (extreme) / / 21935397 rs35886975 chr7 95186387 G GA 7.43E-04 Obesity (extreme) / / 21935397 rs7810538 chr7 95186726 T G 8.60E-05 Major depressive disorder / / 21042317 rs7810538 chr7 95186726 T G 7.43E-04 Obesity (extreme) / / 21935397 rs7778478 chr7 95186950 T C 7.43E-04 Obesity (extreme) / / 21935397 rs10281863 chr7 95187578 C G 7.43E-04 Obesity (extreme) / / 21935397 rs10226503 chr7 95188015 C T 7.43E-04 Obesity (extreme) / / 21935397 rs916711 chr7 95190248 G T 7.40E-04 Obesity (extreme) / / 21935397 rs916712 chr7 95190521 G A 8.36E-04 Obesity (extreme) / / 21935397 rs916714 chr7 95190659 C T 7.14E-04 Obesity (extreme) / / 21935397 rs4269466 chr7 95190753 C T 2.70E-05 Pericardial fat / / 22589742 rs11772378 chr7 95198625 A G 2.10E-05 Pericardial fat / / 22589742 rs6465471 chr7 95210386 G A 3.90E-05 Major depressive disorder / / 21042317 rs6465472 chr7 95210421 A T 4.20E-05 Major depressive disorder / / 21042317 rs7811683 chr7 95211643 T A 7.20E-05 Major depressive disorder / / 21042317 rs7793172 chr7 95211716 G A 3.70E-05 Major depressive disorder / / 21042317 rs11531570 chr7 95213702 G A 3.40E-05 Major depressive disorder PDK4 UTR-3 21042317 rs10236474 chr7 95215377 G T 3.60E-05 Pericardial fat PDK4 intron 22589742 rs12668651 chr7 95218438 T C 4.50E-05 Pericardial fat PDK4 intron 22589742 rs2073983 chr7 95218737 G A 4.20E-05 Pericardial fat PDK4 intron 22589742 rs6965510 chr7 95229848 C T 2.40E-04 Body mass index / / 21701565 rs6965510 chr7 95229848 C T 3.57E-06 Body mass index / / 21701565 rs6965510 chr7 95229848 C T 4.01E-04 Body mass index / / 21701565 rs10259067 chr7 95231456 G A 4.85E-05 Alzheimer's disease (late onset) / / 20885792 rs1682724 chr7 95285490 T A 9.79E-04 Multiple complex diseases / / 17554300 rs1682729 chr7 95287106 T C 8.33E-04 Multiple complex diseases / / 17554300 rs854061 chr7 95305368 G A 7.22E-05 Alcohol dependence / / 21703634 rs854104 chr7 95325734 A G 6.25E-05 Alcohol dependence / / 21703634 rs2127187 chr7 95362855 C T 3.90E-06 Parkinson's disease (familial) / / 18985386 rs3912439 chr7 95395681 C T 7.30E-06 Parkinson's disease (familial) / / 18985386 rs4729206 chr7 95420677 C G 8.14E-04 Type 2 diabetes DYNC1I1 intron 17463246 rs12668564 chr7 95440273 A G 1.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DYNC1I1 intron 20877124 rs1922332 chr7 95441350 T C 6.60E-05 Tunica Media DYNC1I1 intron pha003036 rs6957233 chr7 95494080 C T 2.79E-05 Erythrocyte counts DYNC1I1 intron pha003101 rs17167225 chr7 95517176 G A 2.04E-04 Multiple complex diseases DYNC1I1 intron 17554300 rs4727329 chr7 95522927 A G 9.77E-05 HIV-1 viral setpoint DYNC1I1 intron 22174851 rs10246503 chr7 95529329 C T 4.07E-04 Insulin resistance DYNC1I1 intron 21901158 rs7808673 chr7 95532968 A T 2.75E-04 Multiple complex diseases DYNC1I1 intron 17554300 rs7808673 chr7 95532968 A T 4.07E-04 Insulin resistance DYNC1I1 intron 21901158 rs319329 chr7 95548031 C G 7.59E-05 Serum metabolites DYNC1I1 intron 19043545 rs13231718 chr7 95600368 T G 5.00E-09 Immune reponse to smallpox (secreted IL-10) DYNC1I1 intron 22610502 rs1488517 chr7 95608753 T C 3.56E-06 Osteoarthritis DYNC1I1 intron 22763110 rs319322 chr7 95609957 G A 6.68E-05 Lung function (forced vital capacity) DYNC1I1 intron pha003104 rs319321 chr7 95613748 A C 5.19E-04 Multiple complex diseases DYNC1I1 intron 17554300 rs2299268 chr7 95619073 T C 8.85E-05 Lung function (forced vital capacity) DYNC1I1 intron pha003104 rs81018 chr7 95629826 G A 2.00E-04 Cognitive impairment induced by topiramate DYNC1I1 intron 22091778 rs4727332 chr7 95630601 G T 1.36E-04 Alzheimer's disease (late onset) DYNC1I1 intron 21379329 rs1488515 chr7 95631196 T G 1.00E-06 Obesity-related traits DYNC1I1 intron 23251661 rs1488515 chr7 95631196 T G 2.00E-06 Obesity-related traits DYNC1I1 intron 23251661 rs2214096 chr7 95683119 C G 6.28E-05 Response to metformin DYNC1I1 intron 21186350 rs77909595 chr7 95700008 C T 2.00E-06 QRS duration in Tripanosoma cruzi seropositivity DYNC1I1 intron 24324551 rs6465486 chr7 95757895 G A 9.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) SLC25A13 intron 23233662 rs17167402 chr7 95815385 C A 5.67E-05 Multiple complex diseases SLC25A13 intron 17554300 rs4509239 chr7 95894214 C T 7.98E-04 Nicotine smoking SLC25A13 intron 19268276 rs55741569 chr7 95985489 G A 0.00000521 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs764454 chr7 95985961 G A 5.28E-04 Multiple complex diseases / / 17554300 rs10953171 chr7 95988621 C G 0.0007078 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10953171 chr7 95988621 C G 7.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12534880 chr7 95989040 G A 0.0000861 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7801095 chr7 95996613 C T 0.00000798 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62469976 chr7 96000164 T G 0.00000805 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7789537 chr7 96000818 G A 0.0008838 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7789537 chr7 96000818 G A 8.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10486028 chr7 96019473 G A 1.65E-04 Smoking initiation / / 24665060 rs6964209 chr7 96020434 C T 7.90E-04 Multiple complex diseases / / 17554300 rs6964209 chr7 96020434 C T 1.02E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11760823 chr7 96026380 A G 2.23E-05 Smoking initiation / / 24665060 rs10953173 chr7 96026753 C T 4.11E-05 Smoking initiation / / 24665060 rs6965746 chr7 96029161 T C 1.61E-04 Smoking initiation / / 24665060 rs2724031 chr7 96034268 C T 5.94E-04 Smoking initiation / / 24665060 rs722471 chr7 96036979 A C 6.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs2524976 chr7 96057340 T C 5.38E-04 Alzheimer's disease / / 17998437 rs4729260 chr7 96117918 G C 2.00E-10 Bone mineral density (spine) FLJ42280 intron 19801982 rs10429035 chr7 96119481 G A 1.43E-04 Bone mineral density FLJ42280 intron 24249740 rs10429035 chr7 96119481 G A 4.00E-12 Bone mineral density FLJ42280 intron 24249740 rs10429035 chr7 96119481 G A 8.93E-08 Bone mineral density FLJ42280 intron 24249740 rs11773399 chr7 96120292 A C,G 6.60E-05 Multiple complex diseases FLJ42280 intron 17554300 rs4727338 chr7 96120675 G C 8.60E-10 Bone mineral density (spine) FLJ42280 intron 19801982 rs4727338 chr7 96120675 G C 8.00E-48 Bone mineral density FLJ42280 intron 22504420 rs4727338 chr7 96120675 G C 1.44E-06 Bone mineral density FLJ42280 intron 24249740 rs4727338 chr7 96120675 G C 2.99E-07 Bone mineral density FLJ42280 intron 24249740 rs4727338 chr7 96120675 G C 1.53E-05 Bone mineral density (paediatric,total body less head) FLJ42280 intron 24945404 rs4727338 chr7 96120675 G C 4.93E-05 Bone mineral density (paediatric,lower limb) FLJ42280 intron 24945404 rs6465508 chr7 96127355 G A 1.70E-09 Bone mineral density (spine) FLJ42280 intron 19801982 rs10808100 chr7 96130553 C T 1.30E-09 Bone mineral density (spine) FLJ42280 intron 19801982 rs7781370 chr7 96133531 T C 5.00E-12 Bone mineral density (hip) / / 19801982 rs6465511 chr7 96134115 C G 1.20E-09 Bone mineral density (spine) / / 19801982 rs4370463 chr7 96134401 G A 1.50E-09 Bone mineral density (spine) / / 19801982 rs4342521 chr7 96136005 T G 2.80E-09 Bone mineral density (spine) / / 19801982 rs10085588 chr7 96137674 A G 1.70E-08 Bone mineral density (spine) / / 19801982 rs4427101 chr7 96141701 T C 3.00E-09 Bone mineral density (spine) / / 19801982 rs6971293 chr7 96148577 T C 3.60E-09 Bone mineral density (spine) / / 19801982 rs4448201 chr7 96154912 G C 3.60E-09 Bone mineral density (spine) / / 19801982 rs1404508 chr7 96228434 T C 2.46E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs10464592 chr7 96230686 G A 3.20E-09 Bone mineral density (spine) / / 19801982 rs3801293 chr7 96324499 G A 8.00E-04 Chronic fatigue syndrome SHFM1 intron 21912186 rs4729279 chr7 96354970 C A 9.81E-05 Cognitive performance / / 19734545 rs1464807 chr7 96362344 G T 1.10E-06 Attention deficit hyperactivity disorder / / 20732625 rs17167761 chr7 96369613 C A 1.51E-05 Attention deficit hyperactivity disorder / / 20732625 rs11981462 chr7 96376372 C T 0.00004717 Sarcoidosis / / 22952805 rs11971518 chr7 96376507 T C 0.00004619 Sarcoidosis / / 22952805 rs10953192 chr7 96376579 G A 0.00004619 Sarcoidosis / / 22952805 rs11971591 chr7 96376735 T C 0.00004619 Sarcoidosis / / 22952805 rs10953193 chr7 96376877 C T 0.00004619 Sarcoidosis / / 22952805 rs10953194 chr7 96377021 C T 0.00004619 Sarcoidosis / / 22952805 rs77494275 chr7 96377103 C A 0.00004619 Sarcoidosis / / 22952805 rs16869100 chr7 96377220 G A 0.00004619 Sarcoidosis / / 22952805 rs11972413 chr7 96377303 T C 0.00004619 Sarcoidosis / / 22952805 rs11982457 chr7 96377441 C T 0.00004619 Sarcoidosis / / 22952805 rs12673272 chr7 96377562 C T 9.40E-05 Personality dimensions / / 18957941 rs12673272 chr7 96377562 C T 8.14E-06 Attention deficit hyperactivity disorder / / 20732625 rs4729282 chr7 96377600 C A 0.00004619 Sarcoidosis / / 22952805 rs4729283 chr7 96377608 A G 0.00004619 Sarcoidosis / / 22952805 rs12673393 chr7 96378040 G A 3.09E-06 Attention deficit hyperactivity disorder / / 20732625 rs11983434 chr7 96378415 C A 0.00004754 Sarcoidosis / / 22952805 rs11983467 chr7 96378574 C T 0.00004754 Sarcoidosis / / 22952805 rs11983570 chr7 96378720 G A 0.00004754 Sarcoidosis / / 22952805 rs112537363 chr7 96379033 C T 0.00004754 Sarcoidosis / / 22952805 rs111229333 chr7 96379111 C T 0.00004754 Sarcoidosis / / 22952805 rs111929096 chr7 96379176 A G 0.00004754 Sarcoidosis / / 22952805 rs73394873 chr7 96379278 G T 0.00004754 Sarcoidosis / / 22952805 rs73394877 chr7 96379332 T G 0.00004754 Sarcoidosis / / 22952805 rs34990070 chr7 96379405 A C 0.00004754 Sarcoidosis / / 22952805 rs35192807 chr7 96379420 G A 0.00004754 Sarcoidosis / / 22952805 rs34850305 chr7 96379440 G T 0.0000422 Sarcoidosis / / 22952805 rs36042518 chr7 96379523 T C 0.00004754 Sarcoidosis / / 22952805 rs73394880 chr7 96379743 T C 0.00004754 Sarcoidosis / / 22952805 rs73394882 chr7 96379749 A G 0.00004754 Sarcoidosis / / 22952805 rs2091239 chr7 96380136 G T 0.00004754 Sarcoidosis / / 22952805 rs6465536 chr7 96380454 A G 0.00004754 Sarcoidosis / / 22952805 rs4729285 chr7 96381664 C G 0.00004754 Sarcoidosis / / 22952805 rs2037667 chr7 96381827 G A 0.00004754 Sarcoidosis / / 22952805 rs11980532 chr7 96382804 A C 0.00004754 Sarcoidosis / / 22952805 rs11980604 chr7 96382996 A T 0.00004754 Sarcoidosis / / 22952805 rs4729286 chr7 96383801 T C 0.00004754 Sarcoidosis / / 22952805 rs4729287 chr7 96384033 C T 0.00004754 Sarcoidosis / / 22952805 rs4729288 chr7 96384125 A C 0.00004754 Sarcoidosis / / 22952805 rs11975704 chr7 96384520 G A 0.00005794 Sarcoidosis / / 22952805 rs4729289 chr7 96385092 A G 0.00005794 Sarcoidosis / / 22952805 rs4729290 chr7 96386367 G A 0.00005794 Sarcoidosis / / 22952805 rs4729291 chr7 96386456 G A 0.00005794 Sarcoidosis / / 22952805 rs4729292 chr7 96386477 T C 0.00005794 Sarcoidosis / / 22952805 rs4729293 chr7 96386487 T C 0.00005794 Sarcoidosis / / 22952805 rs4727344 chr7 96386868 C T 0.00005794 Sarcoidosis / / 22952805 rs10260779 chr7 96387041 A G 0.00005794 Sarcoidosis / / 22952805 rs10234667 chr7 96387131 G A 0.00009045 Sarcoidosis / / 22952805 rs76491154 chr7 96387268 G C 0.00005794 Sarcoidosis / / 22952805 rs10264407 chr7 96387681 A G 0.00005794 Sarcoidosis / / 22952805 rs55767950 chr7 96388015 G A 0.00005794 Sarcoidosis / / 22952805 rs60832120 chr7 96388117 A T 0.00005794 Sarcoidosis / / 22952805 rs59333675 chr7 96388246 G A 0.00005794 Sarcoidosis / / 22952805 rs55767803 chr7 96388262 T C 0.00005794 Sarcoidosis / / 22952805 rs73396808 chr7 96388397 T G 0.00009045 Sarcoidosis / / 22952805 rs4727346 chr7 96388499 T C 0.00005519 Sarcoidosis / / 22952805 rs1852051 chr7 96388658 T G 0.00005794 Sarcoidosis / / 22952805 rs1852050 chr7 96388667 G T 0.00005794 Sarcoidosis / / 22952805 rs1852049 chr7 96388897 A C 0.00005794 Sarcoidosis / / 22952805 rs1852048 chr7 96388937 G A 0.00005794 Sarcoidosis / / 22952805 rs2922954 chr7 96389268 T G 0.00005794 Sarcoidosis / / 22952805 rs2922953 chr7 96389406 T C 0.00005794 Sarcoidosis / / 22952805 rs1839363 chr7 96389548 T C 0.00005794 Sarcoidosis / / 22952805 rs1839362 chr7 96389790 G T 0.00005794 Sarcoidosis / / 22952805 rs2922952 chr7 96389816 T C 0.00005794 Sarcoidosis / / 22952805 rs2922951 chr7 96389841 C A 0.00005794 Sarcoidosis / / 22952805 rs2969410 chr7 96389876 G T 0.00005794 Sarcoidosis / / 22952805 rs2969411 chr7 96389940 T C 0.00005794 Sarcoidosis / / 22952805 rs2969412 chr7 96390015 C T 0.00005794 Sarcoidosis / / 22952805 rs2969414 chr7 96390182 C A 0.00005794 Sarcoidosis / / 22952805 rs2922949 chr7 96390674 T C 0.00005794 Sarcoidosis / / 22952805 rs2922947 chr7 96390753 C G 0.00005794 Sarcoidosis / / 22952805 rs2922946 chr7 96390896 A G 0.00005794 Sarcoidosis / / 22952805 rs2922945 chr7 96391012 G A 0.00005794 Sarcoidosis / / 22952805 rs2922944 chr7 96391098 C T 0.00005794 Sarcoidosis / / 22952805 rs2922943 chr7 96391220 A T 0.00005794 Sarcoidosis / / 22952805 rs2922942 chr7 96391285 A G 0.00005794 Sarcoidosis / / 22952805 rs2969416 chr7 96391424 A G 0.00005209 Sarcoidosis / / 22952805 rs2922941 chr7 96391536 G C 0.00005794 Sarcoidosis / / 22952805 rs2922940 chr7 96391639 T C 0.00005794 Sarcoidosis / / 22952805 rs2922939 chr7 96391892 G T 0.00005794 Sarcoidosis / / 22952805 rs1900956 chr7 96392068 G A 0.00005794 Sarcoidosis / / 22952805 rs2969423 chr7 96392488 C A 5.94E-04 Multiple complex diseases / / 17554300 rs2969423 chr7 96392488 C A 0.00005794 Sarcoidosis / / 22952805 rs2922938 chr7 96392713 T C 0.00005794 Sarcoidosis / / 22952805 rs2969425 chr7 96393027 T G 0.00005794 Sarcoidosis / / 22952805 rs2969426 chr7 96393038 T C 0.00005794 Sarcoidosis / / 22952805 rs2922937 chr7 96393139 G T 0.00005794 Sarcoidosis / / 22952805 rs1375678 chr7 96393536 T A 0.00005794 Sarcoidosis / / 22952805 rs1375677 chr7 96393693 C T 0.00005794 Sarcoidosis / / 22952805 rs1375676 chr7 96393746 C T 0.00005794 Sarcoidosis / / 22952805 rs1375675 chr7 96393793 A G 0.00005794 Sarcoidosis / / 22952805 rs2394499 chr7 96394051 G A 0.00005794 Sarcoidosis / / 22952805 rs2922934 chr7 96394372 C T 0.00005794 Sarcoidosis / / 22952805 rs2969432 chr7 96394535 T C 0.00005794 Sarcoidosis / / 22952805 rs2922931 chr7 96394831 G A 0.00005794 Sarcoidosis / / 22952805 rs2969433 chr7 96394890 G A 0.00005794 Sarcoidosis / / 22952805 rs2922930 chr7 96395064 G A 0.00005794 Sarcoidosis / / 22952805 rs1449595 chr7 96395761 G T 0.00005794 Sarcoidosis / / 22952805 rs2922923 chr7 96397141 T C 0.00005794 Sarcoidosis / / 22952805 rs2922922 chr7 96397444 C G 0.00005096 Sarcoidosis / / 22952805 rs1449591 chr7 96397749 T C 2.39E-05 Attention deficit hyperactivity disorder / / 20732625 rs12375086 chr7 96401045 C T 2.56E-06 Attention deficit hyperactivity disorder / / 20732625 rs17499178 chr7 96405380 G T 1.41E-05 Attention deficit hyperactivity disorder / / 20732625 rs2922926 chr7 96412309 G A 0.000005708 Sarcoidosis / / 22952805 rs12669076 chr7 96415055 C T 2.00E-06 Immunoglobulin A / / 20694011 rs6465544 chr7 96421860 C T 3.36E-04 Multiple complex diseases / / 17554300 rs1004561 chr7 96424327 T A 2.26E-05 Attention deficit hyperactivity disorder / / 20732625 rs2922915 chr7 96435891 T C 1.85E-04 Alzheimer's disease (late onset) / / 21379329 rs2948268 chr7 96438318 C T 4.83E-04 Alzheimer's disease (late onset) / / 21379329 rs1947228 chr7 96461649 T C 5.61E-04 Sarcoidosis / / 19165924 rs41345049 chr7 96465856 A T 3.91E-04 Gallstones / / 17632509 rs7785299 chr7 96484741 A C 7.47E-04 White matter integrity / / 22425255 rs17168021 chr7 96542982 T C 1.35E-04 Alcohol dependence / / 24277619 rs1207688 chr7 96562031 C T 3.10E-05 Alcohol dependence / / 24277619 rs11976595 chr7 96567080 C T 6.98E-05 Information processing speed / / 21130836 rs1207692 chr7 96578640 C T 5.47E-04 Type 2 diabetes / / 17463246 rs17598306 chr7 96581811 C T 9.00E-06 Radiation response / / 20923822 rs11766960 chr7 96583332 T G 1.55E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2189772 chr7 96598368 G A 3.87E-04 Type 2 diabetes / / 17463246 rs6956369 chr7 96616012 G A 2.16E-05 Bipolar disorder and schizophrenia DLX6-AS1 intron 20889312 rs2240295 chr7 96631235 A T 5.96E-06 Multiple complex diseases DLX6-AS1 intron 17554300 rs2240295 chr7 96631235 A T 1.56E-04 Body mass index DLX6-AS1 intron 21701565 rs2240295 chr7 96631235 A T 2.60E-04 Body mass index DLX6-AS1 intron 21701565 rs6960249 chr7 96660132 T G 5.85E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1199292 chr7 96787597 G A 9.00E-04 Gamma gluatamyl transferase levels (interaction with age) ACN9 intron 22010049 rs10252691 chr7 96798820 A C 4.00E-05 Prostate cancer ACN9 intron 21743057 rs12671685 chr7 96806129 A G 5.37E-05 Bipolar disorder ACN9 intron 21771265 rs13235065 chr7 96832332 A C 4.08E-06 Coronary heart disease / / pha003031 rs10240426 chr7 96850237 A C 6.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs705384 chr7 96878550 C T 2.60E-05 Coronary heart disease / / pha003031 rs799584 chr7 96915005 C T 4.98E-04 Multiple complex diseases / / 17554300 rs2394620 chr7 96928091 A G 7.39E-05 Lipoproteins / / pha003079 rs41342645 chr7 96935261 G A 5.67E-06 Type 2 diabetes / / 17463246 rs2394626 chr7 96968536 G C 8.97E-04 Aortic root size / / 21223598 rs12704913 chr7 96968676 G A 8.06E-04 Aortic root size / / 21223598 rs7800407 chr7 96985788 T A 8.96E-04 Multiple complex diseases / / 17554300 rs1981727 chr7 96990891 C A 8.98E-04 Multiple complex diseases / / 17554300 rs10264553 chr7 97014330 C A 1.00E-04 Prostate cancer / / 21743057 rs6948852 chr7 97017222 T G 1.00E-04 Prostate cancer / / 21743057 rs10255878 chr7 97017795 G A 4.00E-06 Adverse response to radiation therapy / / 23719583 rs1861301 chr7 97021576 A G 7.99E-05 Elbow pain / / pha003008 rs2110784 chr7 97041696 A C 1.55E-04 Smoking initiation / / 24665060 rs992435 chr7 97050803 G C 3.37E-04 Multiple complex diseases / / 17554300 rs12669771 chr7 97065958 G A 2.11E-05 Coronary heart disease / / pha003030 rs2216074 chr7 97069550 T C 4.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10240105 chr7 97103593 G A 4.00E-05 Prostate cancer / / 21743057 rs7800682 chr7 97103911 T G 4.00E-05 Prostate cancer / / 21743057 rs7786172 chr7 97104598 C T 4.00E-05 Prostate cancer / / 21743057 rs10234240 chr7 97107457 C T 4.00E-05 Prostate cancer / / 21743057 rs10250050 chr7 97107498 T C 4.00E-05 Prostate cancer / / 21743057 rs11981782 chr7 97122053 C T 4.92E-04 Multiple complex diseases / / 17554300 rs7802958 chr7 97125486 C T 0.0000912 Breast cancer early age of onset / / 18463975 rs4727369 chr7 97146387 C A 0.000216 Breast cancer early age of onset / / 18463975 rs11983319 chr7 97184441 T G 3.53E-04 Type 2 diabetes / / 17463246 rs2394715 chr7 97196411 A G 2.31E-05 Blood Pressure / / pha003040 rs4729365 chr7 97198136 C T 6.77E-05 Heart Rate / / pha003051 rs6465598 chr7 97225761 C T 8.52E-05 Heart Rate / / pha003051 rs10486003 chr7 97229778 C T 5.00E-07 Response to platinum-based agents / / 22020760 rs4729366 chr7 97231644 G A 7.37E-04 Schizophrenia / / 19197363 rs10486004 chr7 97242254 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10486004 chr7 97242254 C T 7.45E-05 Cognitive impairment induced by topiramate / / 22091778 rs731289 chr7 97284383 A G 7.18E-04 Type 2 diabetes / / 17463246 rs4729368 chr7 97285625 C T 5.79E-04 Type 2 diabetes / / 17463246 rs2160774 chr7 97287858 T G 1.00E-04 Type 1 diabetes / / 21980299 rs2058894 chr7 97296791 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2058894 chr7 97296791 C T 6.58E-05 Cognitive impairment induced by topiramate / / 22091778 rs2072100 chr7 97361784 C T 4.23E-04 Alzheimer's disease (late onset) TAC1 intron 21379329 rs7795107 chr7 97366145 T G 3.22E-04 Alzheimer's disease (late onset) TAC1 intron 21379329 rs10085387 chr7 97389030 A G 4.15E-05 Chronic Hepatitis C infection / / 21725309 rs2058106 chr7 97421583 T A 2.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs2058105 chr7 97421596 A T 2.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs11764340 chr7 97422634 A C 2.37E-04 Suicide attempts in bipolar disorder / / 21041247 rs1229542 chr7 97422926 G T 2.00E-06 Myopia (pathological) / / 23049088 rs35368085 chr7 97422926 G GT 2.00E-06 Myopia (pathological) / / 23049088 rs1229540 chr7 97423394 G A 5.35E-05 Asthma / / pha003128 rs993059 chr7 97424424 T C 2.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs13245026 chr7 97424920 A G 2.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs1229568 chr7 97425721 C T 9.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs1229564 chr7 97428673 C T 8.55E-05 Heart Failure / / pha002885 rs459 chr7 97431347 C T 2.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs12669324 chr7 97432366 T C 2.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs1229553 chr7 97432533 T C 9.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs7786920 chr7 97436068 C G 1.95E-04 Suicide attempts in bipolar disorder / / 21041247 rs1912445 chr7 97447728 G T 4.90E-04 Parkinson's disease / / 17052657 rs12704945 chr7 97448754 T A 1.95E-04 Suicide attempts in bipolar disorder / / 21041247 rs7808642 chr7 97450461 G T 1.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs17131832 chr7 97455356 C T 4.37E-04 Type 2 diabetes / / 17463246 rs2078467 chr7 97459302 T C 1.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs10269471 chr7 97464809 A G 8.24E-04 Type 2 diabetes / / 17463246 rs12668997 chr7 97465888 C T 2.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs17344459 chr7 97466634 C T 2.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs6465629 chr7 97470490 C T 2.35E-04 Suicide attempts in bipolar disorder / / 21041247 rs13223125 chr7 97471627 A T 2.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs17131831 chr7 97475270 A G 2.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs6966699 chr7 97476841 C T 2.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs10486009 chr7 97478111 C G 2.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs10486010 chr7 97478318 T C 2.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs13224424 chr7 97480392 T C 2.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs10486011 chr7 97481812 C T 2.45E-04 Suicide attempts in bipolar disorder ASNS intron 21041247 rs2237289 chr7 97487346 A G 2.48E-05 Serum metabolites ASNS intron 19043545 rs1049674 chr7 97488569 A T 9.35E-04 Type 2 diabetes ASNS missense 17463246 rs17345759 chr7 97499410 A C 3.74E-04 Smoking initiation ASNS intron 24665060 rs7790127 chr7 97499700 G A 2.21E-04 Parkinson's disease ASNS intron 17052657 rs10081358 chr7 97545241 T C 7.52E-04 Alzheimer's disease / / 17998437 rs7809785 chr7 97595328 T G 1.10E-04 Multiple complex diseases / / 17554300 rs13438327 chr7 97620691 G A 2.00E-06 Sudden cardiac arrest / / 21658281 rs7799577 chr7 97623394 T G 2.57E-04 Parkinson's disease / / 17052657 rs705308 chr7 97695363 C A 4.70E-08 Prostate cancer / / 18264097 rs10270280 chr7 97781645 G A 5.26E-05 Body Fat Distribution LMTK2 intron pha003017 rs6465654 chr7 97786282 G A 7.50E-08 Prostate cancer LMTK2 intron 18264097 rs6465657 chr7 97816327 C T 1.00E-09 Prostate cancer LMTK2 intron 18264097 rs6465657 chr7 97816327 C T 2.00E-08 Prostate cancer LMTK2 intron 19767753 rs6465657 chr7 97816327 C T 1.00E-09 Nasopharyngeal carcinoma LMTK2 intron 20512145 rs2291745 chr7 97854393 G A 2.16E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) TECPR1 cds-synon 23648065 rs2270604 chr7 97857675 T C 4.17E-04 Epilepsy TECPR1 intron 22116939 rs115819213 chr7 97860299 G A 0.00000074 Prostate cancer (advanced) TECPR1 cds-synon 23555315 rs2291750 chr7 97863145 G A 2.16E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) TECPR1 cds-synon 23648065 rs79382137 chr7 97875349 C T 0.00078 Prostate cancer TECPR1 missense 23555315 rs954050 chr7 97880226 T C 1.18E-04 Epilepsy TECPR1 intron 22116939 rs6947340 chr7 97912241 C T 0.00053 Endometrial cancer BRI3 intron 22426144 rs77443149 chr7 97924554 G A 8.00E-06 Obesity-related traits BAIAP2L1 intron 23251661 rs3801263 chr7 97965016 A G 3.02E-04 Epilepsy BAIAP2L1 intron 22116939 rs6945554 chr7 97972946 T C 3.02E-04 Epilepsy BAIAP2L1 intron 22116939 rs6961129 chr7 97975542 T G 2.91E-04 Epilepsy BAIAP2L1 intron 22116939 rs3779195 chr7 97993362 T A 3.00E-08 Sex hormone-binding globulin levels BAIAP2L1 intron 22829776 rs9649213 chr7 98021211 A G 1.00E-06 Prostate cancer (gene x gene interaction) BAIAP2L1 intron 22219177 rs1472272 chr7 98112974 T C 1.44E-05 Male fertility / / 22633400 rs4729451 chr7 98125134 C T 7.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4729451 chr7 98125134 C T 3.56E-05 Arthritis (juvenile idiopathic) / / 22354554 rs1528549 chr7 98126830 A G 2.37E-04 Hearing function / / 17255346 rs817774 chr7 98141197 G C 6.50E-14 Mean arterial pressure / / 22510845 rs817759 chr7 98163939 T C 1.46E-04 Celiac disease / / 23936387 rs705312 chr7 98182505 G T 6.13E-04 Alzheimer's disease / / 24755620 rs705326 chr7 98192191 T C 8.12E-04 Alcohol dependence / / 21314694 rs7809098 chr7 98193506 A G 4.18E-04 Alzheimer's disease / / 24755620 rs17161415 chr7 98197531 G A 3.63E-04 Alzheimer's disease / / 24755620 rs817754 chr7 98201024 C T 5.19E-04 Alzheimer's disease / / 24755620 rs817750 chr7 98204112 A G 2.76E-04 Alzheimer's disease / / 24755620 rs6465691 chr7 98210558 A C 4.64E-04 Alzheimer's disease / / 24755620 rs1009344 chr7 98217568 T C 3.98E-04 Alzheimer's disease / / 24755620 rs705342 chr7 98217745 G A 3.47E-04 Alzheimer's disease / / 24755620 rs817771 chr7 98225036 A G 1.70E-04 Iris characteristics / / 21835309 rs7802882 chr7 98292814 A G 2.80E-05 Urinary metabolites / / 21572414 rs12704998 chr7 98299157 C T 3.31E-05 Parkinson's disease / / 21248740 rs13223648 chr7 98304764 C T 0.0000021 Asthma (exacerbation) / / 23706709 rs1038585 chr7 98321862 C T 4.37E-05 Intelligence / / 21826061 rs12540064 chr7 98381738 T C 6.58E-04 Coronary Artery Disease / / 17634449 rs10232758 chr7 98411980 A C 9.22E-04 HIV-1 viral setpoint / / 17641165 rs4526300 chr7 98439544 A C 6.52E-04 Type 2 diabetes / / 17463246 rs6465726 chr7 98478680 A G 1.00E-04 Gamma gluatamyl transferase levels (interaction with age) TRRAP intron 22010049 rs12155122 chr7 98483072 C T 1.90E-04 Cognitive decline TRRAP intron 23732972 rs17638888 chr7 98497625 G A 1.85E-04 Type 2 diabetes TRRAP intron 17463246 rs2237598 chr7 98540123 T C 7.02E-06 Parasitemia in Tripanosoma cruzi seropositivity TRRAP intron 24324551 rs6967970 chr7 98544342 T G 9.69E-06 Parasitemia in Tripanosoma cruzi seropositivity TRRAP intron 24324551 rs4727424 chr7 98545103 G A 9.62E-06 Parasitemia in Tripanosoma cruzi seropositivity TRRAP intron 24324551 rs7779292 chr7 98548842 C G 6.29E-06 Parasitemia in Tripanosoma cruzi seropositivity TRRAP intron 24324551 rs3815232 chr7 98551152 C T 8.75E-06 Parasitemia in Tripanosoma cruzi seropositivity TRRAP intron 24324551 rs41646 chr7 98571011 G C 8.45E-06 Parasitemia in Tripanosoma cruzi seropositivity TRRAP intron 24324551 rs219822 chr7 98590051 A G 9.56E-05 Bone mineral density TRRAP intron 19181680 rs736624 chr7 98608202 A G 4.39E-04 Multiple complex diseases TRRAP intron 17554300 rs170185 chr7 98611561 C G 3.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs7791007 chr7 98674362 G A 2.00E-04 Gamma gluatamyl transferase levels (interaction with age) SMURF1 intron 22010049 rs6952161 chr7 98733337 G A 5.52E-04 Multiple complex diseases SMURF1 intron 17554300 rs9297145 chr7 98759117 C A 8.46E-05 Multiple complex diseases / / 17554300 rs9297145 chr7 98759117 C A 8.00E-12 Inflammatory bowel disease / / 23128233 rs7809799 chr7 98760504 G A 9.00E-11 Ulcerative colitis / / 20228798 rs7809799 chr7 98760504 G A 9.00E-11 Multiple sclerosis / / 22190364 rs13244262 chr7 98767927 A G 2.70E-04 Psoriasis / / 20953189 rs17161604 chr7 98782350 G T 2.57E-04 Coronary heart disease KP/7 intron 21606135 rs9886136 chr7 98817797 T A 6.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs7799650 chr7 98845369 T C 4.12E-04 Alzheimer's disease / / 24755620 rs4255064 chr7 98846684 C T 8.44E-05 Parkinson's disease / / 21738487 rs6465748 chr7 98861307 T C 1.85E-04 Osteoarthritis / / 19508968 rs11972017 chr7 98879348 T C 4.13E-05 Major depressive disorder MYH16 intron 21621269 rs6960805 chr7 98880642 C T 1.61E-04 Vaspin levels MYH16 intron 22907691 rs6960805 chr7 98880642 C T 0.0001606 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks MYH16 intron 22907730 rs10953286 chr7 98887802 C T 4.40E-06 Crohn's disease MYH16 intron 20570966 rs17161687 chr7 98941909 C T 9.01E-05 Sarcoidosis ARPC1A intron 19165924 rs740160 chr7 98957880 C T 2.00E-16 Dehydroepiandrosterone sulphate levels ARPC1A intron 21533175 rs6960810 chr7 99005695 G A 7.67E-04 Smoking quantity PDAP1 intron 24665060 rs17161726 chr7 99008395 C G 3.57E-07 Coronary arterial lesions in patients with Kawasaki disease BUD31 intron 23677057 rs2003499 chr7 99014984 T C 2.38E-06 Coronary arterial lesions in patients with Kawasaki disease PTCD1 UTR-3 23677057 rs2003499 chr7 99014984 T C 2.16E-05 Blood Pressure PTCD1 UTR-3 pha003045 rs2003499 chr7 99014984 T C 4.12E-05 Blood Pressure PTCD1 UTR-3 pha003047 rs917154 chr7 99020806 A G 1.80E-17 Dehydroepiandrosterone sulphate levels PTCD1 intron 21533175 rs10271049 chr7 99026493 A G 1.74E-17 Dehydroepiandrosterone sulphate levels PTCD1 intron 21533175 rs2240384 chr7 99027044 T C 1.88E-17 Dehydroepiandrosterone sulphate levels PTCD1 intron 21533175 rs7794705 chr7 99029384 A G 1.66E-17 Dehydroepiandrosterone sulphate levels PTCD1 intron 21533175 rs10215854 chr7 99036920 G A 3.30E-28 Dehydroepiandrosterone sulphate levels CPSF4 intron 21533175 rs10215854 chr7 99036920 G A 5.52E-04 Smoking quantity CPSF4 intron 24665060 rs883403 chr7 99047978 T C 1.15E-17 Dehydroepiandrosterone sulphate levels CPSF4 cds-synon 21533175 rs2280600 chr7 99048432 T C 1.09E-17 Dehydroepiandrosterone sulphate levels CPSF4 intron 21533175 rs13243267 chr7 99053314 G C 1.24E-29 Dehydroepiandrosterone sulphate levels CPSF4 intron 21533175 rs13243267 chr7 99053314 G C 4.05E-04 Smoking quantity CPSF4 intron 24665060 rs12535424 chr7 99053816 G A 3.83E-04 Smoking quantity CPSF4 intron 24665060 rs2293256 chr7 99057701 G A 3.57E-07 Coronary arterial lesions in patients with Kawasaki disease ATP5J2 intron 23677057 rs1980307 chr7 99060603 A G 9.70E-18 Dehydroepiandrosterone sulphate levels ATP5J2 intron 21533175 rs13240600 chr7 99064466 A G 1.44E-20 Dehydroepiandrosterone sulphate levels / / 21533175 rs10808111 chr7 99070884 T A 3.20E-30 Dehydroepiandrosterone sulphate levels ZNF789 intron 21533175 rs10808112 chr7 99070988 C T 5.98E-29 Dehydroepiandrosterone sulphate levels ZNF789 intron 21533175 rs10808112 chr7 99070988 C T 7.82E-04 Smoking quantity ZNF789 intron 24665060 rs10235235 chr7 99075831 T C 1.00E-05 Bone mineral density (spine) ZNF789 intron 19079262 rs10235235 chr7 99075831 T C 1.75E-30 Dehydroepiandrosterone sulphate levels ZNF789 intron 21533175 rs10235235 chr7 99075831 T C 6.29E-04 Smoking quantity ZNF789 intron 24665060 rs6962772 chr7 99081730 A G 5.07E-18 Dehydroepiandrosterone sulphate levels ZNF789 missense 21533175 rs2037595 chr7 99085879 A G 1.30E-05 Osteoarthritis / / 19508968 rs2272168 chr7 99102777 G C 4.50E-18 Dehydroepiandrosterone sulphate levels ZKSCAN5 UTR-5 21533175 rs11973801 chr7 99102911 A G 4.77E-30 Dehydroepiandrosterone sulphate levels ZKSCAN5 intron 21533175 rs11973801 chr7 99102911 A G 5.17E-04 Smoking quantity ZKSCAN5 intron 24665060 rs9632722 chr7 99115568 A G 8.36E-29 Dehydroepiandrosterone sulphate levels ZKSCAN5 intron 21533175 rs9632722 chr7 99115568 A G 5.17E-04 Smoking quantity ZKSCAN5 intron 24665060 rs12533251 chr7 99115677 G A 8.34E-29 Dehydroepiandrosterone sulphate levels ZKSCAN5 intron 21533175 rs12533251 chr7 99115677 G A 5.17E-04 Smoking quantity ZKSCAN5 intron 24665060 rs12533251 chr7 99115677 G A 2.00E-11 Blood metabolite levels ZKSCAN5 intron 24816252 rs10226310 chr7 99118320 G A 3.26E-30 Dehydroepiandrosterone sulphate levels ZKSCAN5 intron 21533175 rs11761528 chr7 99118801 C T 3.00E-36 Dehydroepiandrosterone sulphate levels ZKSCAN5 intron 21533175 rs11761528 chr7 99118801 C T 0.000000967 Dehydroepiandrosterone ZKSCAN5 intron 23696881 rs11976018 chr7 99122437 G A 9.15E-18 Dehydroepiandrosterone sulphate levels ZKSCAN5 intron 21533175 rs3843540 chr7 99126640 T C 3.91E-18 Dehydroepiandrosterone sulphate levels ZKSCAN5 intron 21533175 rs34670419 chr7 99130834 G T 2.07E-09 Dehydroepiandrosterone ZKSCAN5 UTR-3 23696881 rs34670419 chr7 99130834 G T 2.35E-08 Cortisol:DHEAS ratio ZKSCAN5 UTR-3 23696881 rs3137 chr7 99130875 G A 6.36E-18 Dehydroepiandrosterone sulphate levels ZKSCAN5 UTR-3 21533175 rs10278040 chr7 99141373 G A 2.93E-34 Dehydroepiandrosterone sulphate levels / / 21533175 rs10278040 chr7 99141373 G A 0.0000117 Cortisol:DHEAS ratio / / 23696881 rs10278040 chr7 99141373 G A 1.00E-29 Blood metabolite levels / / 24816252 rs10278040 chr7 99141373 G A 9.00E-113 Blood metabolite levels / / 24816252 rs10238965 chr7 99145845 C T 6.24E-18 Dehydroepiandrosterone sulphate levels FAM200A cds-synon 21533175 rs34257469 chr7 99150185 T C 3.63E-04 Smoking quantity / / 24665060 rs6947941 chr7 99156446 G T 5.49E-04 Smoking quantity ZNF655 intron 24665060 rs6947974 chr7 99156506 G A 5.29E-30 Dehydroepiandrosterone sulphate levels ZNF655 UTR-5 21533175 rs6947826 chr7 99156520 C T 5.20E-30 Dehydroepiandrosterone sulphate levels ZNF655 UTR-5 21533175 rs6947826 chr7 99156520 C T 5.50E-04 Smoking quantity ZNF655 UTR-5 24665060 rs17161761 chr7 99156934 C T 5.15E-30 Dehydroepiandrosterone sulphate levels ZNF655 intron 21533175 rs17161761 chr7 99156934 C T 7.51E-04 Smoking quantity ZNF655 intron 24665060 rs11981478 chr7 99163950 C T 5.24E-30 Dehydroepiandrosterone sulphate levels ZNF655 intron 21533175 rs371912317 chr7 99163950 CA CCA,CG,CTG 5.24E-30 Dehydroepiandrosterone sulphate levels ZNF655 intron 21533175 rs67699618 chr7 99163950 CA CCA,CTG 5.24E-30 Dehydroepiandrosterone sulphate levels ZNF655 intron 21533175 rs11974702 chr7 99163951 A G 5.18E-30 Dehydroepiandrosterone sulphate levels ZNF655 intron 21533175 rs11974702 chr7 99163951 A G 5.87E-04 Smoking quantity ZNF655 intron 24665060 rs11974702 chr7 99163951 A G 3.00E-75 Blood metabolite levels ZNF655 intron 24816252 rs952319 chr7 99171449 C T 1.01E-20 Dehydroepiandrosterone sulphate levels ZNF655 UTR-3 21533175 rs952319 chr7 99171449 C T 2.38E-06 Coronary arterial lesions in patients with Kawasaki disease ZNF655 UTR-3 23677057 rs6961634 chr7 99181839 G A 3.28E-18 Dehydroepiandrosterone sulphate levels / / 21533175 rs28862110 chr7 99183531 T C 7.66E-04 Smoking quantity / / 24665060 rs7809615 chr7 99184778 G T 5.36E-30 Dehydroepiandrosterone sulphate levels / / 21533175 rs7809615 chr7 99184778 G T 8.00E-139 Blood metabolite ratios / / 24816252 rs1589739 chr7 99185747 A G 1.17E-17 Dehydroepiandrosterone sulphate levels / / 21533175 rs1581492 chr7 99186826 G A 5.29E-30 Dehydroepiandrosterone sulphate levels / / 21533175 rs1581492 chr7 99186826 G A 1.04E-04 Lymphocyte counts / / 22286170 rs10273424 chr7 99196073 T A 2.61E-28 Dehydroepiandrosterone sulphate levels LOC100289187 intron 21533175 rs10254729 chr7 99196428 T G 2.03E-17 Dehydroepiandrosterone sulphate levels LOC100289187 intron 21533175 rs1011024 chr7 99197401 A G 2.15E-17 Dehydroepiandrosterone sulphate levels LOC100289187 intron 21533175 rs7792939 chr7 99207876 T C 4.00E-06 Anthropometric traits LOC100289187 intron 19260139 rs7792939 chr7 99207876 T C 5.00E-06 Anthropometric traits LOC100289187 intron 19260139 rs7792939 chr7 99207876 T C 6.00E-06 Anthropometric traits LOC100289187 intron 19260139 rs10256395 chr7 99221956 T C 7.52E-04 Multiple complex diseases ZNF498 intron 17554300 rs11734 chr7 99229768 G C 3.57E-07 Coronary arterial lesions in patients with Kawasaki disease ZNF498 UTR-3 23677057 rs10242455 chr7 99240179 A G 3.60E-04 Multiple complex diseases / / 17554300 rs10242455 chr7 99240179 A G 2.00E-109 Blood metabolite levels / / 24816252 rs4646450 chr7 99266318 G A 8.80E-17 Dehydroepiandrosterone sulphate levels CYP3A5 intron 21533175 rs4646450 chr7 99266318 G A 0.00017 Coronary artery calcification CYP3A5 intron 23727086 rs776746 chr7 99270539 C T 1 Drug response to Tacrolimus CYP3A5 splice-5 12966368 rs776746 chr7 99270539 C T 1 Drug response to Tipifarnib CYP3A5 splice-5 15122075 rs776746 chr7 99270539 C T 1 Drug response to Cilostazol CYP3A5 splice-5 19516253 rs776746 chr7 99270539 C T 1 Drug response to Tacrolimus CYP3A5 splice-5 19865079 rs776746 chr7 99270539 C T 1 Drug response to Nevirapine CYP3A5 splice-5 20017669 rs28371764 chr7 99277593 G A 6.89E-04 Smoking quantity CYP3A5 UTR-5 24665060 rs1357319 chr7 99310181 A C 3.69E-04 Body mass index CYP3A7 intron 17255346 rs2741872 chr7 99339776 T A 3.15E-04 Multiple complex diseases / / 17554300 rs4986910 chr7 99358524 A G 1 Drug response to Tacrolimus CYP3A4 missense 12966368 rs2246709 chr7 99365719 A G 1 Drug response to Amlodipine CYP3A4 intron 19907160 rs2246709 chr7 99365719 A G 7.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CYP3A4 intron 20877124 rs2246709 chr7 99365719 A G 9.15E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CYP3A4 intron 20877124 rs12721627 chr7 99366093 G C 1 Drug response to Carbamazepine CYP3A4 missense 19255940 rs12721627 chr7 99366093 G C 1 Drug response to Midazolam CYP3A4 missense 19255940 rs2740574 chr7 99382096 C T 1 Drug response to Cyclosporine / / 12966368 rs2740574 chr7 99382096 C T 1 Drug response to Tacrolimus / / 12966368 rs2740574 chr7 99382096 C T 1 Drug response to Tipifarnib / / 15122075 rs2740574 chr7 99382096 C T 1 Drug response to Docetaxel / / 18509327 rs2740574 chr7 99382096 C T 1 Drug response to Cyclophosphamide / / 19376514 rs2740574 chr7 99382096 C T 1 Drug response to Indinavir / / 19440701 rs7811025 chr7 99385701 C T 1.01E-10 Triglycerides / / 23063622 rs7811025 chr7 99385701 C T 1.60E-27 HDL cholesterol / / 23063622 rs7811025 chr7 99385701 C T 4.56E-08 Cholesterol,total / / 23063622 rs651430 chr7 99429843 A G 6.47E-05 Response to cytadine analogues (cytosine arabinoside) CYP3A43 intron 24483146 rs496000 chr7 99435896 G A 9.79E-05 Brain derived neurotrophic factor levels,in serum CYP3A43 intron 22047184 rs800672 chr7 99436198 G A 8.04E-05 Response to cytadine analogues (cytosine arabinoside) CYP3A43 intron 24483146 rs533486 chr7 99440694 T C 7.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CYP3A43 intron 20877124 rs533486 chr7 99440694 T C 9.68E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CYP3A43 intron 20877124 rs533486 chr7 99440694 T C 5.51E-05 Response to cytadine analogues (cytosine arabinoside) CYP3A43 intron 24483146 rs580123 chr7 99460458 A G 8.03E-05 Bipolar disorder and schizophrenia CYP3A43 intron 20889312 rs11981167 chr7 99460611 T A 3.74E-05 Bipolar disorder and schizophrenia CYP3A43 intron 20889312 rs2527927 chr7 99477426 G A 2.33E-04 Multiple complex diseases / / 17554300 rs2572011 chr7 99487071 C T 3.04E-04 Multiple complex diseases / / 17554300 rs17277546 chr7 99489571 G A 2.00E-11 Dehydroepiandrosterone sulphate levels TRIM4 UTR-3 21533175 rs17277546 chr7 99489571 G A 9.00E-40 Metabolic traits TRIM4 UTR-3 21886157 rs2572000 chr7 99509324 C T 4.10E-04 Multiple complex diseases TRIM4 intron 17554300 rs1121592 chr7 99523631 T C 3.25E-04 Multiple complex diseases GJC3 intron 17554300 rs2527894 chr7 99538841 A G 5.36E-05 Lymphocyte counts / / 22286170 rs2107349 chr7 99558440 C T 2.14E-06 White blood cell count / / 21738479 rs2283017 chr7 99574758 A G 5.87E-07 Interstitial lung disease / / 23583980 rs2525556 chr7 99577744 T C 3.91E-08 Interstitial lung disease / / 23583980 rs4729562 chr7 99583650 G A 4.17E-05 Multiple complex diseases / / 17554300 rs6974373 chr7 99590893 C G 5.26E-10 Interstitial lung disease / / 23583980 rs6465760 chr7 99591418 G A 5.30E-05 Multiple complex diseases / / 17554300 rs4727443 chr7 99593346 C A 1.00E-08 Interstitial lung disease / / 23583980 rs4727443 chr7 99593346 C A 4.99E-10 Interstitial lung disease / / 23583980 rs4727443 chr7 99593346 C A 6.72E-09 Interstitial lung disease / / 23583980 rs4729565 chr7 99608557 C T 1.50E-15 Health and aging,CVD and cancer age of onset / / 22174011 rs4729565 chr7 99608557 C T 5.90E-17 Health and aging,CVD and cancer age of onset / / 22174011 rs4729566 chr7 99614313 G A 6.83E-06 Colorectal cancer ZKSCAN1 intron 21242260 rs6963345 chr7 99618606 G A 4.90E-13 Interstitial lung disease ZKSCAN1 intron 23583980 rs6955348 chr7 99633385 T G 3.28E-05 Cognitive test performance ZKSCAN1 UTR-3 20125193 rs4729568 chr7 99639445 T C 0.00061 Endometrial cancer / / 22426144 rs4424195 chr7 99642745 A G 1.56E-05 Multiple complex diseases / / 17554300 rs7778571 chr7 99664817 A G 8.63E-04 Multiple complex diseases ZNF3 intron 17554300 rs941290 chr7 99678622 A C 1.20E-04 Lymphocyte counts ZNF3 intron 22286170 rs2261360 chr7 99692993 G T 1.02E-06 Interstitial lung disease MCM7 intron 23583980 rs13242458 chr7 99695131 G A 9.98E-12 Dehydroepiandrosterone sulphate levels MCM7 intron 21533175 rs139603502 chr7 99695787 T C 0.0000074 Prostate cancer (advanced) MCM7 missense 23555315 rs1880949 chr7 99722266 G T 1.86E-05 Multiple complex diseases CNPY4 intron 17554300 rs1880949 chr7 99722266 G T 5.22E-08 Lymphocyte counts CNPY4 intron 22286170 rs1138417 chr7 99807146 C G 3.64E-05 Multiple complex diseases STAG3 intron 17554300 rs1727138 chr7 99815247 T C 3.10E-05 Multiple complex diseases GATS intron 17554300 rs17250196 chr7 99817196 G T 1.57E-20 Dehydroepiandrosterone sulphate levels PVRIG intron 21533175 rs13228694 chr7 99940307 C T 9.61E-10 Dehydroepiandrosterone sulphate levels PILRB intron 21533175 rs13228694 chr7 99940307 C T 6.00E-06 Obesity-related traits PILRB intron 23251661 rs2405442 chr7 99971313 T C 1.10E-04 Alzheimer's disease (late onset) PILRA cds-synon 21460841 rs1476679 chr7 100004446 C T 2.95E-05 Alzheimer's disease (late onset) ZCWPW1 intron 21460841 rs1476679 chr7 100004446 C T 6.00E-10 Alzheimer's disease (late onset) ZCWPW1 intron 24162737 rs5015755 chr7 100013402 G T 6.18E-05 Cognitive test performance ZCWPW1 intron 20125193 rs6465770 chr7 100014711 T C 0.00046 Prostate cancer ZCWPW1 missense 23555315 rs13222543 chr7 100015457 C T 8.83E-21 Dehydroepiandrosterone sulphate levels ZCWPW1 intron 21533175 rs13222543 chr7 100015457 C T 1.00E-20 Blood metabolite levels ZCWPW1 intron 24816252 rs13222543 chr7 100015457 C T 3.00E-47 Blood metabolite levels ZCWPW1 intron 24816252 rs13222543 chr7 100015457 C T 4.00E-104 Blood metabolite ratios ZCWPW1 intron 24816252 rs13222543 chr7 100015457 C T 7.00E-74 Blood metabolite levels ZCWPW1 intron 24816252 rs4074838 chr7 100032665 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs200078456 chr7 100033389 C T 0.00011 Prostate cancer (advanced) PPP1R35 cds-synon 23555315 rs6955362 chr7 100056166 C T 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes C7orf61 intron 22628534 rs7806537 chr7 100064719 A G 0.00000433 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6971558 chr7 100079857 A T 3.75E-05 Alzheimer's disease (late onset) / / 21460841 rs11763511 chr7 100081944 G A 7.34E-04 Amyotrophic lateral sclerosis (sporadic) NYAP1 intron 24529757 rs12539172 chr7 100091795 T C 2.51E-05 Alzheimer's disease (late onset) / / 21460841 rs11768465 chr7 100198386 C T 5.00E-07 Red blood cell traits FBXO24 missense 23222517 rs7812235 chr7 100211486 G C 3.37E-07 Red blood cell traits MOSPD3 intron 23222517 rs12532878 chr7 100212254 G A 5.44E-08 Red blood cell traits MOSPD3 intron 23222517 rs11764045 chr7 100212754 C T 2.81E-08 Red blood cell traits MOSPD3 intron 23222517 rs7786877 chr7 100214015 A G 3.00E-11 Mean corpuscular volume / / 19862010 rs7786877 chr7 100214015 A G 4.30E-07 Blood cell counts and traits,in red and white blood cells / / 21153663 rs7786877 chr7 100214015 A G 3.36E-09 Red blood cell traits / / 23222517 rs10487157 chr7 100214487 C G 4.44E-07 Red blood cell traits / / 23222517 rs10247962 chr7 100219929 G A 5.54E-09 Red blood cell traits TFR2 intron 23222517 rs4729598 chr7 100221867 T C 4.03E-08 Red blood cell traits TFR2 intron 23222517 rs2075674 chr7 100225031 G A 1.60E-05 Blood cell counts and traits,in red and white blood cells TFR2 cds-synon 21153663 rs2075674 chr7 100225031 G A 5.24E-08 Red blood cell traits TFR2 cds-synon 23222517 rs7457868 chr7 100227188 A C 2.96E-08 Red blood cell traits TFR2 intron 23222517 rs7385804 chr7 100235970 C A 5.00E-10 Hematological parameters TFR2 intron 19820697 rs7385804 chr7 100235970 C A 4.00E-10 Hematocrit TFR2 intron 19862010 rs7385804 chr7 100235970 C A 1.60E-07 Blood cell counts and traits,in red and white blood cells TFR2 intron 21153663 rs7385804 chr7 100235970 C A 7.00E-08 Iron levels TFR2 intron 21208937 rs7385804 chr7 100235970 C A 3.12E-16 Red blood cell traits TFR2 intron 23222517 rs4727457 chr7 100236593 T C 4.66E-09 Red blood cell traits TFR2 intron 23222517 rs4729600 chr7 100237357 T C 4.67E-09 Red blood cell traits TFR2 intron 23222517 rs4434553 chr7 100240191 A G 0.000000002 Mean corpuscular volume TFR2 nearGene-5 22560525 rs4434553 chr7 100240191 A G 0.00000002 Mean corpuscular hemoglobin TFR2 nearGene-5 22560525 rs4434553 chr7 100240191 A G 1.20E-14 Red blood cell traits TFR2 nearGene-5 23222517 rs4434553 chr7 100240191 A G 4.97E-05 Inflammation TFR2 nearGene-5 pha002897 rs2075672 chr7 100240296 A G 2.00E-20 Red blood cell traits / / 23222517 rs1052897 chr7 100240771 A T 6.68E-09 Red blood cell traits ACTL6B UTR-3 23222517 rs6952341 chr7 100256228 G T 9.40E-09 Red blood cell traits / / 23222517 rs4729602 chr7 100260591 T C 1.75E-05 Cognitive impairment induced by topiramate / / 22091778 rs4729602 chr7 100260591 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4729602 chr7 100260591 T C 7.76E-05 Cognitive impairment induced by topiramate / / 22091778 rs221786 chr7 100266081 T C 7.42E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs221786 chr7 100266081 T C 6.15E-07 Red blood cell traits / / 23222517 rs221790 chr7 100278282 G C 1.47E-13 Red blood cell traits GIGYF1 UTR-3 23222517 rs221794 chr7 100281768 T C 8.76E-09 Red blood cell traits GIGYF1 cds-synon 23222517 rs221794 chr7 100281768 T C 3.23E-06 Heart rate GIGYF1 cds-synon 23583979 rs221795 chr7 100283261 C T 1.75E-11 Red blood cell traits GIGYF1 intron 23222517 rs221795 chr7 100283261 C T 5.50E-05 Bulimia nervosa GIGYF1 intron 23568457 rs2272572 chr7 100285888 C T 6.42E-05 Response to hepatitis C treatment GIGYF1 UTR-5 19684573 rs2272572 chr7 100285888 C T 1.00E-04 Cognitive impairment induced by topiramate GIGYF1 UTR-5 22091778 rs2272572 chr7 100285888 C T 2.00E-04 Cognitive impairment induced by topiramate GIGYF1 UTR-5 22091778 rs221797 chr7 100285974 A C 5.92E-05 Brain derived neurotrophic factor levels,in serum GIGYF1 UTR-5 22047184 rs221797 chr7 100285974 A C 0.0000021 Fasting blood glucose GIGYF1 UTR-5 22885924 rs221797 chr7 100285974 A C 4.04E-07 Red blood cell traits GIGYF1 UTR-5 23222517 rs221801 chr7 100290031 C A 2.50E-15 Red blood cell traits / / 23222517 rs221780 chr7 100297035 G C 3.45E-08 Red blood cell traits / / 23222517 rs221770 chr7 100302094 A T 3.37E-05 Lymphocyte counts / / 22286170 rs221770 chr7 100302094 A T 1.98E-07 Red blood cell traits / / 23222517 rs10277087 chr7 100307538 G C 6.82E-16 Red blood cell traits / / 23222517 rs1734910 chr7 100309544 A G 1.16E-15 Red blood cell traits / / 23222517 rs506597 chr7 100313420 A G 6.00E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs506597 chr7 100313420 A G 0.00000135 Fasting blood glucose / / 22885924 rs506597 chr7 100313420 A G 2.68E-07 Red blood cell traits / / 23222517 rs1734907 chr7 100315517 A G 2.00E-13 Inflammatory bowel disease / / 23128233 rs1734907 chr7 100315517 A G 1.34E-10 Red blood cell traits / / 23222517 rs1617640 chr7 100317298 C A 0.000000002 Diabetic nephropathy in Type 1 diabetes EPO nearGene-5 22721967 rs1617640 chr7 100317298 C A 2.85E-15 Red blood cell traits EPO nearGene-5 23222517 rs564449 chr7 100321138 T G 1.23E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs551238 chr7 100321528 G T 1.30E-06 Blood cell counts and traits,in red and white blood cells EPO nearGene-3 21153663 rs551238 chr7 100321528 G T 4.49E-14 Red blood cell traits EPO nearGene-3 23222517 rs2293769 chr7 100344359 T C 1.45E-08 Red blood cell traits ZAN intron 23222517 rs2075671 chr7 100345106 G A 1.00E-09 Other erythrocyte phenotypes ZAN intron 19862010 rs2075671 chr7 100345106 G A 1.08E-04 Blood cell counts and other traits ZAN intron 20139978 rs2075671 chr7 100345106 G A 1.91E-07 Red blood cell traits ZAN intron 23222517 rs2075669 chr7 100348940 T C 1.58E-07 Red blood cell traits ZAN intron 23222517 rs6971700 chr7 100353125 A G 2.09E-07 Red blood cell traits ZAN intron 23222517 rs2293767 chr7 100361675 G A 1.00E-04 Cognitive impairment induced by topiramate ZAN missense 22091778 rs2293767 chr7 100361675 G A 1.71E-07 Red blood cell traits ZAN missense 23222517 rs2293767 chr7 100361675 G A 8.51E-05 Self-reported allergy ZAN missense 23817569 rs201491474 chr7 100363155 A C 0.00025 Prostate cancer (non-advanced prostate cancer) ZAN missense 23555315 rs10953302 chr7 100365567 C T 4.83E-08 Other erythrocyte phenotypes ZAN cds-synon 19862010 rs10953303 chr7 100365613 G T 5.05E-05 Cognitive impairment induced by topiramate ZAN missense 22091778 rs10232130 chr7 100366203 C G 1.29E-08 Red blood cell traits ZAN intron 23222517 rs10247980 chr7 100366284 T C 1.13E-07 Red blood cell traits ZAN missense 23222517 rs531503 chr7 100377082 T C 4.50E-04 Self-reported allergy ZAN missense 23817569 rs2437101 chr7 100401449 G A 9.85E-07 Red blood cell traits EPHB4 intron 23222517 rs314313 chr7 100423365 T C 3.73E-04 Multiple complex diseases EPHB4 intron 17554300 rs17162500 chr7 100451140 G A 0.00081 Salmonella-induced pyroptosis SLC12A9 intron 22837397 rs314370 chr7 100453208 T C 6.00E-10 Resting heart rate SLC12A9 intron 20639392 rs314376 chr7 100457356 A G 2.40E-09 Plasminogen activator inhibitor type 1 levels (PAI-1) SLC12A9 intron 22990020 rs314376 chr7 100457356 A G 2.50E-05 Body mass index (asthmatics) SLC12A9 intron 23517042 rs7801190 chr7 100458093 C G 3.00E-08 Coronary heart disease SLC12A9 intron 21347282 rs17162518 chr7 100462294 G A 1.71E-05 Prion diseases SLC12A9 intron 22210626 rs2075756 chr7 100466441 G A 2.70E-09 Plasminogen activator inhibitor type 1 levels (PAI-1) TRIP6 missense 22990020 rs17162522 chr7 100479167 C A 0.000802 Salmonella-induced pyroptosis SRRT intron 22837397 rs12672665 chr7 100483731 A G 6.10E-08 Plasminogen activator inhibitor type 1 levels (PAI-1) SRRT intron 22990020 rs12666989 chr7 100486754 G C 2.00E-08 Resting heart rate UFSP1 missense 20639392 rs7636 chr7 100490077 G A 5.00E-06 Type 2 diabetes ACHE cds-synon 21490949 rs17885778 chr7 100491451 G C 5.17E-08 HDL cholesterol ACHE missense 23063622 rs13245899 chr7 100497131 A G 8.00E-27 Heart rate / / 23583979 rs3847067 chr7 100500615 C A 4.10E-10 Plasminogen activator inhibitor type 1 levels (PAI-1) / / 22990020 rs7803865 chr7 100505792 A G 4.20E-05 Body mass index (asthmatics) / / 23517042 rs6976053 chr7 100512119 C T 6.00E-13 Plasminogen activator inhibitor type 1 levels (PAI-1) / / 22990020 rs13232524 chr7 100512824 C T 5.30E-05 Body mass index (asthmatics) / / 23517042 rs12530867 chr7 100627938 T C 2.35E-05 Odorant perception MUC12 intron 23910658 rs143984295 chr7 100634145 G A 0.000000015 Prostate cancer (advanced) MUC12 missense 23555315 rs4729644 chr7 100669857 C T 5.15E-04 Multiple complex diseases MUC17 intron 17554300 rs145279256 chr7 100675940 A G 0.0000046 Breast cancer(er negative) MUC17 missense 23555315 rs73712043 chr7 100680521 G A 0.000069 Prostate cancer MUC17 missense 23555315 rs73712044 chr7 100681751 A G 0.00011 Prostate cancer MUC17 missense 23555315 rs144198145 chr7 100691288 A T 0.00029 Breast cancer (ER positive) MUC17 missense 23555315 rs4729655 chr7 100701451 T C 5.13E-04 Multiple complex diseases MUC17 UTR-3 17554300 rs4729656 chr7 100701610 T A 9.01E-05 Multiple complex diseases MUC17 UTR-3 17554300 rs6942824 chr7 100739682 C T 2.92E-04 Multiple complex diseases / / 17554300 rs6942824 chr7 100739682 C T 0.000154 Salmonella-induced pyroptosis / / 22837397 rs12912 chr7 100740785 G A 0.000017 Salmonella-induced pyroptosis / / 22837397 rs10953322 chr7 100746658 G A 9.12E-04 Alzheimer's disease / / 24755620 rs6950982 chr7 100766603 A G 1.22E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs2227631 chr7 100769538 A G 1 Drug response to Citalopram SERPINE1 nearGene-5 18794724 rs2227631 chr7 100769538 A G 1 Drug response to Fluoxetine SERPINE1 nearGene-5 18794724 rs2227631 chr7 100769538 A G 3.00E-24 Plasminogen activator inhibitor type 1 levels (PAI-1) SERPINE1 nearGene-5 22990020 rs2227667 chr7 100774749 A G 3.00E-06 Plasma plasminogen activator levels SERPINE1 intron 24578379 rs2227672 chr7 100775686 G T 3.64E-04 Alzheimer's disease SERPINE1 intron 24755620 rs2227700 chr7 100782081 T C 3.07E-08 Triglycerides SERPINE1 UTR-3 23063622 rs1050955 chr7 100782460 G A 6.05E-04 Alzheimer's disease SERPINE1 UTR-3 24755620 rs6954408 chr7 100802316 C T 4.29E-04 Alzheimer's disease AP1S1 intron 24755620 rs10953326 chr7 100814722 G A 6.32E-04 Alzheimer's disease /T16 UTR-3 24755620 rs6970950 chr7 100820995 C T 5.41E-04 Alzheimer's disease /T16 intron 24755620 rs35587552 chr7 100821542 A G 5.41E-04 Alzheimer's disease /T16 intron 24755620 rs917112 chr7 100856991 T C 1.36E-15 Esophageal cancer PLOD3 intron 21642993 rs3757458 chr7 100881403 G A 2.00E-06 QT interval CLDN15 UTR-5 23166209 rs4574779 chr7 100917308 A G 2.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs13231009 chr7 100928302 A C 0.0000147 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13231313 chr7 100928303 G C 0.0000145 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4729680 chr7 100928541 A T 0.0000042 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11765751 chr7 100931471 C T 0.00000648 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11766480 chr7 100931663 G A 0.0000084 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6961898 chr7 100931873 C T 0.00000638 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10953331 chr7 100932330 G A 6.72E-04 Multiple complex diseases / / 17554300 rs10255019 chr7 100932693 C T 0.0000135 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2410814 chr7 100953446 G A 0.0000788 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4729685 chr7 100960495 C G 0.0000849 Nonsyndromic striae distensae (stretch marks) RABL5 intron 23633020 rs4729687 chr7 100962692 T C 0.0000874 Nonsyndromic striae distensae (stretch marks) RABL5 intron 23633020 rs3807513 chr7 100965601 G A 2.21E-04 Alzheimer's disease / / 17998437 rs2410819 chr7 100966578 T A 0.0000853 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7799285 chr7 100968363 G A 8.50E-06 Urinary metabolites / / 21572414 rs6958889 chr7 100979310 C T 4.59E-04 Multiple complex diseases / / 17554300 rs9692596 chr7 100980201 G A 0.0000666 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10081241 chr7 100980971 T C 0.0000652 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10247206 chr7 100982106 T C 0.0000618 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9690686 chr7 100984370 C T 0.0000676 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9692131 chr7 100984713 A G 0.0000858 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6465799 chr7 101007557 C A 1.41E-04 Glycosylated haemoglobin levels EMID2 intron 17255346 rs6465799 chr7 101007557 C A 3.90E-07 Urinary metabolites EMID2 intron 21572414 rs4729693 chr7 101007777 C T 1.38E-04 Glycosylated haemoglobin levels EMID2 intron 17255346 rs4729693 chr7 101007777 C T 4.90E-07 Urinary metabolites EMID2 intron 21572414 rs6963365 chr7 101009715 G A 1.70E-07 Urinary metabolites EMID2 intron 21572414 rs2898575 chr7 101017370 A G 4.70E-07 Urinary metabolites EMID2 intron 21572414 rs10435333 chr7 101025813 G A 5.30E-08 Urinary metabolites EMID2 intron 21572414 rs11772003 chr7 101043597 C G 6.26E-06 Height EMID2 intron 20400458 rs7782656 chr7 101080715 T C 1.80E-05 Urinary metabolites EMID2 intron 21572414 rs7782656 chr7 101080715 T C 9.03E-05 Cognitive decline EMID2 intron 22054870 rs10276579 chr7 101109073 C T 4.85E-04 Alzheimer's disease (late onset) EMID2 intron 21379329 rs17135437 chr7 101115994 C T 3.00E-06 Response to citalopram treatment EMID2 intron 22760553 rs17135437 chr7 101115994 C T 3.00E-08 Response to citalopram treatment EMID2 intron 22760553 rs73409616 chr7 101117102 C T 6.64E-06 PR interval in Tripanosoma cruzi seropositivity EMID2 intron 24324551 rs6967098 chr7 101121549 G A 9.11E-06 PR interval in Tripanosoma cruzi seropositivity EMID2 intron 24324551 rs10241622 chr7 101125074 C T 8.77E-06 PR interval in Tripanosoma cruzi seropositivity EMID2 intron 24324551 rs13232646 chr7 101127455 T C 4.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EMID2 intron 20877124 rs73712171 chr7 101129765 G T 7.00E-06 PR interval in Tripanosoma cruzi seropositivity EMID2 intron 24324551 rs113727105 chr7 101134055 G A 9.27E-06 PR interval in Tripanosoma cruzi seropositivity EMID2 intron 24324551 rs17469756 chr7 101137314 A G 3.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EMID2 intron 20877124 rs17469756 chr7 101137314 A G 2.57E-06 IgE levels EMID2 intron 22075330 rs9969331 chr7 101141971 G A 7.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EMID2 intron 20877124 rs12531666 chr7 101146836 G A 3.20E-06 Urinary metabolites EMID2 intron 21572414 rs1558015 chr7 101146995 T C 9.96E-05 IgE levels EMID2 intron 22075330 rs6954768 chr7 101155965 C A,T 6.17E-06 Myocardial Infarction EMID2 intron pha002883 rs1543885 chr7 101161537 G A 8.97E-04 Type 2 diabetes EMID2 intron 17463246 rs1859634 chr7 101165373 A G 1.21E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses EMID2 intron 17903301 rs6967280 chr7 101176040 C T 3.10E-05 IgE levels EMID2 intron 22075330 rs190166648 chr7 101183198 C T 0.00000015 Breast cancer(er negative) EMID2 missense 23555315 rs757824 chr7 101204556 A G 5.24E-05 Cognitive performance / / 19734545 rs4729735 chr7 101225780 A G 2.59E-04 Alzheimer's disease / / 22005930 rs7786803 chr7 101226230 C T 1.02E-04 Alzheimer's disease / / 22005930 rs7786803 chr7 101226230 C T 1.98E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs6465820 chr7 101226496 A G 1.33E-04 Alzheimer's disease / / 22005930 rs6979781 chr7 101229420 G T 1.14E-04 Alzheimer's disease / / 22005930 rs10242865 chr7 101230768 C A 2.63E-04 Type 2 diabetes / / 17463246 rs4729738 chr7 101232882 G A 1.39E-04 Alzheimer's disease / / 22005930 rs10275446 chr7 101234966 T A 8.99E-05 Alzheimer's disease / / 22005930 rs10275576 chr7 101235044 T G 8.88E-05 Alzheimer's disease / / 22005930 rs6965503 chr7 101236740 T C 1.23E-04 Alzheimer's disease / / 22005930 rs6945374 chr7 101236834 A C 1.40E-04 Alzheimer's disease / / 22005930 rs7794011 chr7 101237992 G T 9.35E-05 Alzheimer's disease / / 22005930 rs4727499 chr7 101238449 C T 9.21E-04 Alzheimer's disease / / 22005930 rs4727499 chr7 101238449 C T 5.75E-06 Coronary heart disease / / pha003032 rs2410855 chr7 101239368 G T 1.30E-04 Alzheimer's disease / / 22005930 rs7803577 chr7 101239724 G T 1.35E-04 Alzheimer's disease / / 22005930 rs17135656 chr7 101240262 G A 2.48E-04 Alzheimer's disease / / 22005930 rs1981582 chr7 101242973 C T 6.25E-04 Alzheimer's disease / / 22005930 rs17135662 chr7 101244974 C A 0.00000869 Central corneal thickness / / 22661486 rs17135662 chr7 101244974 C A 8.69E-06 Testosterone levels / / 22675492 rs17135662 chr7 101244974 C A 6.84E-06 Coronary heart disease / / pha003032 rs7799319 chr7 101269515 A G 1.22E-06 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) MYL10 intron 24528284 rs4727504 chr7 101269939 A G 1.28E-06 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) MYL10 intron 24528284 rs4727506 chr7 101270780 A G 1.22E-06 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) MYL10 intron 24528284 rs848645 chr7 101272926 T C 1.24E-06 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs848648 chr7 101274653 A G 1.15E-06 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs1619382 chr7 101284857 C T 1.07E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs1722229 chr7 101286177 G T 1.00E-06 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs11761486 chr7 101365388 A G 9.46E-05 Suicide attempts in bipolar disorder / / 21423239 rs11767486 chr7 101446907 A G 9.29E-04 Multiple complex diseases / / 17554300 rs10273526 chr7 101491772 A G 2.61E-05 Multiple complex diseases CUX1 intron 17554300 rs4073362 chr7 101523865 G T 3.10E-04 Myocardial Infarction CUX1 intron pha002873 rs10242019 chr7 101527827 T C 7.44E-04 Response to cytidine analogues (gemcitabine) CUX1 intron 24483146 rs4729759 chr7 101536886 G A 9.67E-04 Response to cytidine analogues (gemcitabine) CUX1 intron 24483146 rs10264866 chr7 101537526 G A 9.67E-04 Response to cytidine analogues (gemcitabine) CUX1 intron 24483146 rs4729760 chr7 101543497 C T 4.56E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CUX1 intron 24023788 rs13236072 chr7 101548786 C T 5.46E-04 Response to cytidine analogues (gemcitabine) CUX1 intron 24483146 rs2906649 chr7 101577038 T C 3.43E-04 Myocardial Infarction CUX1 intron pha002873 rs10488043 chr7 101649622 A G 4.19E-04 Alzheimer's disease CUX1 intron 22005930 rs10488042 chr7 101652458 G A 8.21E-04 Alzheimer's disease CUX1 intron 22005930 rs6465845 chr7 101671721 C T 4.32E-06 Schizophrenia CUX1 intron 21747397 rs370760 chr7 101715222 G A 2.65E-05 Schizophrenia CUX1 intron 21747397 rs404523 chr7 101724053 G A 3.84E-05 Schizophrenia CUX1 intron 21747397 rs201460 chr7 101741571 A G 4.18E-04 Response to taxane treatment (placlitaxel) CUX1 intron 23006423 rs10277680 chr7 101746353 G A 6.84E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CUX1 intron 20031582 rs1902 chr7 101768791 C T 2.38E-04 Suicide attempts in bipolar disorder CUX1 intron 21423239 rs201514 chr7 101768910 T C 2.19E-04 Suicide attempts in bipolar disorder CUX1 intron 21423239 rs201523 chr7 101771851 C T 1.73E-04 Suicide attempts in bipolar disorder CUX1 intron 21423239 rs365836 chr7 101809851 A G 2.00E-06 Response to antidepressants CUX1 intron 22584459 rs1725600 chr7 101909005 C T 2.00E-04 Information processing speed CUX1 intron 21130836 rs1725604 chr7 101914135 C T 5.23E-04 Type 2 diabetes CUX1 intron 17463246 rs1725604 chr7 101914135 C T 4.52E-05 Bipolar disorder and schizophrenia CUX1 intron 20889312 rs2230103 chr7 101921289 A G 0.00000201 HDL cholesterol particle diameter / / 23263444 rs2230103 chr7 101921289 A G 0.00000538 LDL cholesterol particle diameter / / 23263444 rs726890 chr7 101939759 A G 3.00E-05 Information processing speed SH2B2 intron 21130836 rs803105 chr7 101968921 G A 5.35E-05 AIDS progression / / 19115949 rs803105 chr7 101968921 G A 4.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs2694166 chr7 101971916 G A 2.44E-05 Telomere length / / 20139977 rs803118 chr7 101977945 C T 5.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs10953363 chr7 102024248 T A 3.19E-04 Suicide attempts in bipolar disorder LOC100630923 intron 21423239 rs10953363 chr7 102024248 T A 2.02E-04 Lymphocyte counts LOC100630923 intron 22286170 rs7385225 chr7 102041679 A G 4.68E-04 Response to taxane treatment (placlitaxel) PRKRIP1 intron 23006423 rs7797435 chr7 102053414 C A 4.58E-04 Suicide attempts in bipolar disorder PRKRIP1 intron 21423239 rs880924 chr7 102061261 C A 3.43E-04 Suicide attempts in bipolar disorder PRKRIP1 intron 21423239 rs12669274 chr7 102076562 G A 4.21E-04 Suicide attempts in bipolar disorder ORAI2 intron 21423239 rs1133471 chr7 102076677 G T 4.19E-04 Suicide attempts in bipolar disorder ORAI2 UTR-5 21423239 rs4342524 chr7 102082286 A G 1.23E-04 Self-reported allergy ORAI2 intron 23817569 rs2215673 chr7 102419316 T C 6.40E-04 Type 2 diabetes and 6 quantitative traits FAM185A intron 17848626 rs10487283 chr7 102471213 T C 8.60E-05 Crohn's disease FBXL13 intron 17684544 rs4357217 chr7 102472176 T C 1.60E-05 Urinary metabolites FBXL13 intron 21572414 rs11978799 chr7 102504041 A G 7.70E-04 Primary sclerosing cholangitis FBXL13 intron 19944697 rs17135875 chr7 102519031 T C 1.00E-06 Blood pressure measurement (cold pressor test) FBXL13 intron 24165912 rs17135875 chr7 102519031 T C 3.00E-06 Blood pressure measurement (cold pressor test) FBXL13 intron 24165912 rs17135875 chr7 102519031 T C 4.00E-09 Blood pressure measurement (cold pressor test) FBXL13 intron 24165912 rs7779854 chr7 102551582 G A 3.20E-05 Blood pressure measurement (cold pressor test) FBXL13 intron 24165912 rs7779854 chr7 102551582 G A 5.06E-08 Blood pressure measurement (cold pressor test) FBXL13 intron 24165912 rs7779854 chr7 102551582 G A 5.88E-06 Blood pressure measurement (cold pressor test) FBXL13 intron 24165912 rs17397797 chr7 102557718 C T 5.00E-06 Iron levels LRRC17 intron 21208937 rs4255065 chr7 102567397 G T 5.10E-06 Multiple complex diseases LRRC17 intron 17554300 rs1968199 chr7 102753771 G A 1.46E-05 Age-related macular degeneration /PEPLD intron pha000001 rs11760826 chr7 102791811 A G 1.49E-11 Cholesterol,total / / 23063622 rs7455141 chr7 102825732 T C 6.78E-04 Response to taxane treatment (placlitaxel) DPY19L2P2 intron 23006423 rs4266582 chr7 102828337 G A 5.64E-04 Response to taxane treatment (placlitaxel) DPY19L2P2 intron 23006423 rs4727563 chr7 102828569 A G 4.10E-04 Response to taxane treatment (placlitaxel) DPY19L2P2 intron 23006423 rs4729887 chr7 102828670 C T 6.53E-04 Response to taxane treatment (placlitaxel) DPY19L2P2 intron 23006423 rs4593456 chr7 102831775 A C 8.12E-04 Response to taxane treatment (placlitaxel) DPY19L2P2 intron 23006423 rs17136078 chr7 102850726 T A 6.53E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3757507 chr7 102936409 A G 7.03E-05 Cognitive performance / / 19734545 rs17136740 chr7 102990226 C A,G,T 1.19E-04 Multiple complex diseases PSMC2 intron 17554300 rs4363136 chr7 103035255 G A 1.10E-05 Urinary metabolites SLC26A5 intron 21572414 rs12539777 chr7 103060699 G A 1.40E-07 Urinary metabolites SLC26A5 intron 21572414 rs1075737 chr7 103071193 G A 2.48E-05 Bone mineral density SLC26A5 intron 19181680 rs7808106 chr7 103125585 T C 9.66E-05 Major depressive disorder RELN intron 22472876 rs736707 chr7 103130403 A G 3.46E-05 Major depressive disorder RELN intron 22472876 rs13232021 chr7 103141147 A G 8.07E-05 Major depressive disorder RELN intron 22472876 rs13235135 chr7 103141437 A G 9.15E-05 Major depressive disorder RELN intron 22472876 rs17152161 chr7 103141703 T C 7.71E-05 Major depressive disorder RELN intron 22472876 rs1008126 chr7 103175444 C T 8.00E-06 Metabolite levels (Pyroglutamine) RELN intron 23934736 rs362769 chr7 103188731 T C 8.24E-04 Alzheimer's disease RELN intron 17998437 rs362777 chr7 103190197 T C 6.49E-04 Tourette syndrome RELN intron 22889924 rs362721 chr7 103191428 C T 5.89E-04 Alzheimer's disease RELN intron 24755620 rs362794 chr7 103201263 T C 3.03E-05 Kawasaki disease RELN intron 21326860 rs362725 chr7 103205617 A G 3.10E-04 Schizophrenia (treatment refractory) RELN intron 22479419 rs362806 chr7 103208865 T C 7.16E-04 Multiple complex diseases RELN intron 17554300 rs4341089 chr7 103227979 C T 7.30E-06 Urinary metabolites RELN intron 21572414 rs2245617 chr7 103229035 T C 8.90E-06 Urinary metabolites RELN intron 21572414 rs2109697 chr7 103233209 G A 1.70E-06 Urinary metabolites RELN intron 21572414 rs362698 chr7 103277292 T C 2.29E-05 Cognitive test performance RELN intron 20125193 rs12705150 chr7 103356275 T C 6.78E-04 Type 2 diabetes RELN intron 17463246 rs10487166 chr7 103375266 C T 0.0000784 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes RELN intron 22628534 rs579030 chr7 103396604 T C 6.13E-05 Neutrophil count RELN intron pha003095 rs4446675 chr7 103397333 C G 2.80E-11 Gout RELN intron pha001406 rs2283029 chr7 103398219 T C 7.43E-04 Nicotine dependence RELN intron 17158188 rs7341475 chr7 103404815 G A 9.00E-07 Schizophrenia RELN intron 18282107 rs7341475 chr7 103404815 G A 2.90E-05 Schizophrenia (treatment refractory) RELN intron 22479419 rs39327 chr7 103444671 G A 0.0000619 Tuberculosis with early age of onset RELN intron 22551897 rs262366 chr7 103456952 T C 4.14E-04 Alzheimer's disease (late onset) RELN intron 21379329 rs262365 chr7 103457817 G A 4.24E-04 Alzheimer's disease (late onset) RELN intron 21379329 rs39343 chr7 103463998 T C 4.93E-04 Alzheimer's disease (late onset) RELN intron 21379329 rs39348 chr7 103466825 A T 5.71E-05 IgE levels RELN intron 22075330 rs39350 chr7 103467267 C T 1.10E-06 Urinary metabolites RELN intron 21572414 rs39359 chr7 103470499 G A 9.81E-04 Myopia (pathological) RELN intron 21095009 rs39383 chr7 103480243 G A 7.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RELN intron 20877124 rs39399 chr7 103489992 G A 1.66E-05 Otosclerosis RELN intron 19230858 rs39399 chr7 103489992 G A 7.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RELN intron 20877124 rs13232645 chr7 103496696 A G 7.96E-04 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) RELN intron 23103227 rs9986961 chr7 103507670 A C 7.94E-04 Myopia (pathological) RELN intron 21095009 rs17321820 chr7 103511405 T G 7.20E-04 Multiple complex diseases RELN intron 17554300 rs2299394 chr7 103511943 G A 6.93E-04 Type 2 diabetes RELN intron 17463246 rs3914132 chr7 103527369 C T 2.00E-08 Otosclerosis RELN intron 19230858 rs802787 chr7 103549724 T G 9.91E-04 Suicide attempts in bipolar disorder RELN intron 21423239 rs3808018 chr7 103575321 T A 6.41E-04 Suicide attempts in bipolar disorder RELN intron 21423239 rs10230291 chr7 103591822 T C 7.24E-04 Response to taxane treatment (placlitaxel) RELN intron 23006423 rs722278 chr7 103595363 A C 1.00E-04 Prostate cancer RELN intron 21743057 rs722277 chr7 103595652 C T 7.07E-05 Cognitive test performance RELN intron 20125193 rs722277 chr7 103595652 C T 5.89E-05 Angioedema in response to angiotensin-converting enzyme inhibitor RELN intron 23838604 rs6943822 chr7 103598671 T C 6.54E-05 Angioedema in response to angiotensin-converting enzyme inhibitor RELN intron 23838604 rs10246267 chr7 103601185 T C 8.91E-04 Suicide attempts in bipolar disorder RELN intron 21041247 rs10487180 chr7 103619298 C A 2.51E-05 Multiple sclerosis (age of onset) RELN intron 19010793 rs10244615 chr7 103619783 C T 2.88E-05 Multiple sclerosis (age of onset) RELN intron 19010793 rs11772975 chr7 103621267 A G 9.88E-04 Response to taxane treatment (placlitaxel) RELN intron 23006423 rs4298437 chr7 103625877 T C 2.00E-06 Alzheimer's disease RELN intron 20452100 rs17157903 chr7 103628036 C T 8.80E-06 Breast cancer RELN intron 17529973 rs17157903 chr7 103628036 C T 3.00E-06 Multiple sclerosis (age of onset) RELN intron 19010793 rs17157903 chr7 103628036 C T 1.03E-05 Breast cancer RELN intron pha002853 rs6955789 chr7 103637906 G A 3.18E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs10254364 chr7 103646910 G A 6.89E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2891652 chr7 103703322 T G 2.57E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2891652 chr7 103703322 T G 2.33E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs4727586 chr7 103706936 T C 5.39E-04 Myopia (pathological) / / 21095009 rs6465960 chr7 103709766 G A 7.85E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6465960 chr7 103709766 G A 8.97E-04 Myopia (pathological) / / 21095009 rs4729956 chr7 103720836 A G 8.06E-04 Myopia (pathological) / / 21095009 rs7808273 chr7 103759385 C A 5.16E-05 Blood Pressure / / pha003040 rs194844 chr7 103771201 A C 3.98E-05 Angioedema in response to angiotensin-converting enzyme inhibitor ORC5 intron 23838604 rs6946744 chr7 103809217 G C 2.26E-05 Multiple complex diseases ORC5 intron 17554300 rs2385134 chr7 103810129 G A 7.91E-04 Alcohol dependence ORC5 intron 20201924 rs3808008 chr7 103811841 G A 6.43E-04 Amyotrophic Lateral Sclerosis ORC5 intron 17362836 rs10260238 chr7 103836980 C T 6.94E-04 Alcohol dependence ORC5 intron 20201924 rs6949887 chr7 103837341 G A 5.83E-04 Alcohol dependence ORC5 intron 20201924 rs2385142 chr7 103869191 A G 6.42E-04 Alzheimer's disease / / 17998437 rs10259086 chr7 103893012 T G 5.16E-06 Aging (time to event) / / 21782286 rs12056137 chr7 103907680 G T 3.75E-04 Multiple complex diseases / / 17554300 rs17136356 chr7 103908438 A T 2.04E-04 Multiple complex diseases / / 17554300 rs12056177 chr7 103909059 G A 1.57E-04 Multiple complex diseases / / 17554300 rs41515 chr7 103928963 A C 4.85E-06 Alopecia areata / / 22027810 rs11770570 chr7 103970510 T C 3.50E-04 Response to cytadine analogues (cytosine arabinoside) LHFPL3 intron 24483146 rs1468143 chr7 104023190 A G 9.64E-04 Multiple complex diseases LHFPL3 intron 17554300 rs1468144 chr7 104023332 G T 5.03E-04 Multiple complex diseases LHFPL3 intron 17554300 rs2385168 chr7 104078657 C A 6.60E-08 Coronary heart disease LHFPL3 intron 21971053 rs12333888 chr7 104117988 C A 0.0002 Migraine LHFPL3 intron 22678113 rs13232636 chr7 104126670 G C 1.60E-05 Urinary metabolites LHFPL3 intron 21572414 rs41026 chr7 104140521 T G 8.36E-05 Aging (time to event) LHFPL3 intron 21782286 rs993262 chr7 104156150 C T 4.24E-04 Tourette syndrome LHFPL3 intron 22889924 rs10254402 chr7 104192398 T C 6.67E-04 Nicotine smoking LHFPL3 intron 19268276 rs4400323 chr7 104215832 C T 4.27E-05 Hypertension LHFPL3 intron pha003041 rs4400323 chr7 104215832 C T 7.57E-05 Left ventricular hypertrophy LHFPL3 intron pha003052 rs10245966 chr7 104240125 G A 1.89E-04 Alzheimer's disease LHFPL3 intron 17998437 rs10275240 chr7 104240186 A G 1.83E-04 Alzheimer's disease LHFPL3 intron 17998437 rs9641335 chr7 104240200 C A 2.30E-05 Urinary metabolites LHFPL3 intron 21572414 rs1990704 chr7 104247146 T C 8.76E-04 Alzheimer's disease LHFPL3 intron 17998437 rs3919550 chr7 104252401 C T 3.09E-04 Alzheimer's disease LHFPL3 intron 17998437 rs2385245 chr7 104262292 C T 1.18E-04 Multiple complex diseases LHFPL3 intron 17554300 rs6969085 chr7 104268965 T G 2.04E-05 Multiple complex diseases LHFPL3 intron 17554300 rs6944590 chr7 104283520 T G 5.09E-04 Smoking initiation LHFPL3 intron 24665060 rs1468864 chr7 104291453 T A 6.77E-05 Response to citalopram treatment LHFPL3 intron 19846067 rs10487222 chr7 104295232 A G 1.90E-05 Urinary metabolites LHFPL3 intron 21572414 rs7801387 chr7 104307987 A G 2.40E-05 Urinary metabolites LHFPL3 intron 21572414 rs11761950 chr7 104316145 G A 5.78E-04 Nicotine smoking LHFPL3 intron 19268276 rs17490586 chr7 104317105 T C 6.52E-04 Alzheimer's disease LHFPL3 intron 17998437 rs10953450 chr7 104403270 T A 7.87E-04 Substance dependence LHFPL3 intron 21818250 rs12705275 chr7 104413055 T C 5.08E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LHFPL3 intron 20031582 rs4530975 chr7 104415415 C T 6.62E-04 Multiple complex diseases LHFPL3 intron 17554300 rs4460308 chr7 104420060 T C 6.00E-06 Social communication problems LHFPL3 intron 24564958 rs4730049 chr7 104430056 A G 7.68E-04 Stroke LHFPL3 intron pha002887 rs4073894 chr7 104466964 G A 6.00E-06 Educational attainment LHFPL3 intron 23722424 rs17777379 chr7 104491000 G A 9.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) LHFPL3 intron 23233662 rs10259925 chr7 104491405 A T 9.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) LHFPL3 intron 23233662 rs1468813 chr7 104494163 A G 9.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) LHFPL3 intron 23233662 rs10247246 chr7 104501165 G A 9.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) LHFPL3 intron 23233662 rs10250365 chr7 104501334 G T 9.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) LHFPL3 intron 23233662 rs12535201 chr7 104501521 C T 9.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) LHFPL3 intron 23233662 rs17777439 chr7 104502149 G C 9.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) LHFPL3 intron 23233662 rs10953454 chr7 104503813 G A 7.00E-07 Obesity LHFPL3 intron 21552555 rs10953454 chr7 104503813 G A 9.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) LHFPL3 intron 23233662 rs10953455 chr7 104503978 T C 9.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) LHFPL3 intron 23233662 rs2385466 chr7 104510915 T C 1.42E-05 Non-obstructive azoospermia LHFPL3 intron 22541561 rs7781864 chr7 104511576 C A 9.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) LHFPL3 intron 23233662 rs10216243 chr7 104513624 C A 9.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) LHFPL3 intron 23233662 rs2891786 chr7 104558939 C T 8.93E-04 Alcohol dependence LOC723809 intron 20201924 rs6961188 chr7 104596755 C T 5.60E-05 Hypothyroidism / / 22493691 rs10249746 chr7 104636900 C T 1.12E-05 Body Mass Index / / pha003009 rs2240453 chr7 104696188 T C 2.50E-05 Urinary metabolites MLL5 intron 21572414 rs2240453 chr7 104696188 T C 2.20E-05 Body Mass Index MLL5 intron pha003009 rs10808139 chr7 104709946 G A 1.54E-05 Body Mass Index MLL5 intron pha003009 rs2299297 chr7 104745295 T C 7.50E-05 Lung adenocarcinoma MLL5 intron 21242121 rs6968355 chr7 104758250 T C 2.00E-07 Myopia (pathological) SRPK2 UTR-3 23049088 rs2299300 chr7 104763580 G C 7.03E-04 Multiple complex diseases SRPK2 intron 17554300 rs2237606 chr7 104793841 G T 2.08E-05 Body Mass Index SRPK2 intron pha003009 rs111622941 chr7 104805504 C CT 2.18E-05 Body Mass Index SRPK2 intron pha003009 rs111622941 chr7 104805504 C CT 7.96E-05 Waist Circumference SRPK2 intron pha003025 rs111622941 chr7 104805504 C CT 8.18E-05 Insulin Resistance SRPK2 intron pha003062 rs1859786 chr7 104805504 C T 2.18E-05 Body Mass Index SRPK2 intron pha003009 rs1859786 chr7 104805504 C T 7.96E-05 Waist Circumference SRPK2 intron pha003025 rs1859786 chr7 104805504 C T 8.18E-05 Insulin Resistance SRPK2 intron pha003062 rs2385542 chr7 104838765 A G 3.65E-06 Body Mass Index SRPK2 intron pha003009 rs2385542 chr7 104838765 A G 2.70E-05 Waist Circumference SRPK2 intron pha003025 rs3801279 chr7 104904868 C T 4.85E-06 Insulin-related traits SRPK2 intron 19902172 rs7808226 chr7 104916166 T C 4.63E-06 Insulin-related traits SRPK2 intron 19902172 rs201109165 chr7 104938874 AG A 8.80E-05 Insulin-related traits SRPK2 intron 19902172 rs201109165 chr7 104938874 AG A 6.44E-05 Body Mass Index SRPK2 intron pha003009 rs9641345 chr7 104938874 A C 8.80E-05 Insulin-related traits SRPK2 intron 19902172 rs9641345 chr7 104938874 A C 6.44E-05 Body Mass Index SRPK2 intron pha003009 rs17721991 chr7 104947553 A G 8.95E-04 Lymphocyte counts SRPK2 intron 22286170 rs10241415 chr7 104948076 A G 3.18E-05 Monocyte chemoattractant protein-1 SRPK2 intron pha003071 rs1204077 chr7 104984019 T C 4.43E-05 Monocyte chemoattractant protein-1 SRPK2 intron pha003071 rs10261782 chr7 105012975 A C 8.80E-05 Insulin-related traits SRPK2 intron 19902172 rs10261782 chr7 105012975 A C 6.44E-05 Body Mass Index SRPK2 intron pha003009 rs3801999 chr7 105027646 G A 9.60E-05 Monocyte chemoattractant protein-1 SRPK2 intron pha003071 rs4266584 chr7 105059606 A C 3.45E-05 Monocyte chemoattractant protein-1 / / pha003071 rs13437626 chr7 105096661 T C 1.70E-04 Alzheimer's disease (late onset) / / 21379329 rs818477 chr7 105112489 C A 3.61E-06 Insulin resistance PUS7 intron 21901158 rs3735369 chr7 105138947 C T 6.20E-04 Blood pressure PUS7 intron 21228793 rs3735369 chr7 105138947 C T 6.40E-04 Blood pressure PUS7 intron 21228793 rs6963495 chr7 105166853 T C 5.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs10271614 chr7 105208492 C T 8.30E-05 Personality dimensions EFCAB10 intron 18957941 rs1706923 chr7 105221097 A G 5.16E-04 Alcohol dependence EFCAB10 intron 21314694 rs116979167 chr7 105222451 C A 5.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs12154239 chr7 105246821 C T 9.80E-04 Amyotrophic Lateral Sclerosis ATXN7L1 UTR-3 17362836 rs2272171 chr7 105264302 T C 4.79E-05 Body Mass Index ATXN7L1 intron pha003019 rs10242311 chr7 105273720 A C 6.00E-07 Dental caries ATXN7L1 intron 23064961 rs11983798 chr7 105281188 G A 1.00E-06 Alzheimer's disease (late onset) ATXN7L1 intron 22881374 rs590966 chr7 105299515 T C 2.00E-05 Urinary metabolites ATXN7L1 intron 21572414 rs511220 chr7 105314015 T A 4.07E-05 Pulmonary function ATXN7L1 intron 20010835 rs17151220 chr7 105336616 A T 2.74E-04 Smoking initiation ATXN7L1 intron 24665060 rs11760426 chr7 105339909 A G 5.37E-04 Smoking quantity ATXN7L1 intron 24665060 rs17151401 chr7 105345947 A G 2.50E-04 Smoking initiation ATXN7L1 intron 24665060 rs17151401 chr7 105345947 A G 4.79E-04 Smoking quantity ATXN7L1 intron 24665060 rs562850 chr7 105346117 G A 1.20E-05 Cognitive test performance ATXN7L1 intron 20125193 rs669641 chr7 105346238 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ATXN7L1 intron 22628534 rs17151463 chr7 105348894 G A 2.72E-04 Smoking initiation ATXN7L1 intron 24665060 rs4727625 chr7 105359695 C G 0.0000171 VLDL cholesterol particle diameter ATXN7L1 intron 23263444 rs538249 chr7 105360021 C A 0.00000434 VLDL cholesterol particle diameter ATXN7L1 intron 23263444 rs497105 chr7 105367513 C A 0.00067874 Hypertension (early onset hypertension) ATXN7L1 intron 22479346 rs567184 chr7 105373405 T C 2.87E-05 Cognitive test performance ATXN7L1 intron 20125193 rs567184 chr7 105373405 T C 0.000639802 Hypertension (early onset hypertension) ATXN7L1 intron 22479346 rs2078623 chr7 105375615 A T 5.62E-04 Suicide attempts in bipolar disorder ATXN7L1 intron 21423239 rs17151834 chr7 105379625 G A 4.91E-04 Suicide attempts in bipolar disorder ATXN7L1 intron 21423239 rs570801 chr7 105383239 A G 0.000000759 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ATXN7L1 intron 22628534 rs577004 chr7 105383875 T C 9.78E-04 Suicide attempts in bipolar disorder ATXN7L1 intron 21423239 rs12532552 chr7 105384560 C A 6.72E-04 Suicide attempts in bipolar disorder ATXN7L1 intron 21423239 rs516802 chr7 105384666 T C 8.87E-05 Hypertension (early onset hypertension) ATXN7L1 intron 22479346 rs516802 chr7 105384666 T C 2.77E-04 Iron levels ATXN7L1 intron pha002876 rs12667632 chr7 105384906 C T 5.99E-04 Suicide attempts in bipolar disorder ATXN7L1 intron 21423239 rs12536717 chr7 105386465 T G 6.13E-04 Suicide attempts in bipolar disorder ATXN7L1 intron 21423239 rs3601 chr7 105390559 A G 8.52E-04 Acute lung injury ATXN7L1 intron 22295056 rs498280 chr7 105401015 T C 3.84E-05 HIV-1 progression ATXN7L1 UTR-3 20064070 rs514122 chr7 105406916 T C 4.52E-04 Suicide attempts in bipolar disorder ATXN7L1 intron 21423239 rs1544476 chr7 105411928 C T 2.23E-04 Suicide attempts in bipolar disorder ATXN7L1 intron 21423239 rs1204371 chr7 105420269 T C 4.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ATXN7L1 intron 20877124 rs589647 chr7 105422210 C T 4.71E-04 Suicide attempts in bipolar disorder ATXN7L1 intron 21423239 rs6953952 chr7 105459112 T C 2.65E-04 Nonalcoholic fatty liver disease ATXN7L1 intron 21423719 rs10245474 chr7 105462708 C A 1.70E-05 Parkinson's disease (age of onset) ATXN7L1 intron 19772629 rs997438 chr7 105472752 G A 3.18E-04 Amyotrophic Lateral Sclerosis ATXN7L1 intron 17362836 rs12672355 chr7 105485886 A C 1.83E-04 Amyotrophic Lateral Sclerosis ATXN7L1 intron 17362836 rs13438712 chr7 105542580 T C 2.00E-06 Obesity-related traits / / 23251661 rs13438712 chr7 105542580 T C 8.00E-06 Obesity-related traits / / 23251661 rs757842 chr7 105546511 G C 9.71E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17152264 chr7 105548398 A G 9.16E-04 Nicotine dependence / / 17158188 rs1017045 chr7 105560018 A G 5.14E-04 Smoking cessation / / 24665060 rs10248057 chr7 105563314 G A 6.74E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7805904 chr7 105566395 A G 3.70E-06 Urinary metabolites / / 21572414 rs4730122 chr7 105568282 A G 8.15E-04 Myopia (pathological) / / 21095009 rs17152320 chr7 105570700 C G 9.03E-05 Kawasaki disease / / 22446961 rs10755868 chr7 105572183 G A 7.36E-04 Multiple complex diseases / / 17554300 rs10953485 chr7 105572736 C T 1.26E-04 Myopia (pathological) / / 21095009 rs12533809 chr7 105574754 A G 2.08E-05 Information processing speed / / 21130836 rs193847 chr7 105580889 A C 1.76E-04 White matter integrity / / 22425255 rs2727744 chr7 105586946 C T 1.23E-04 Multiple complex diseases / / 17554300 rs17152375 chr7 105588639 C T 5.85E-04 Type 2 diabetes / / 17463246 rs193837 chr7 105593583 G C 5.79E-04 Multiple complex diseases / / 17554300 rs2727758 chr7 105612806 A G 2.32E-05 Monocyte chemoattractant protein-1 CDHR3 intron pha003071 rs193795 chr7 105621512 G T 3.81E-05 Sudden cardiac arrest CDHR3 cds-synon 21658281 rs7793669 chr7 105639848 C T 6.15E-04 Endometrial cancer CDHR3 intron 24096698 rs7793669 chr7 105639848 C T 6.34E-04 Endometrial cancer CDHR3 intron 24096698 rs7793669 chr7 105639848 C T 6.03E-05 Tunica Media CDHR3 intron pha003038 rs11770729 chr7 105649492 C T 1.05E-05 Tunica Media CDHR3 intron pha003038 rs6967330 chr7 105658451 G A 3.20E-06 Asthma CDHR3 missense 21907864 rs6967330 chr7 105658451 G A 3.00E-14 Asthma (childhood,severe) CDHR3 missense 24241537 rs6967330 chr7 105658451 G A 8.43E-05 Behcet's disease CDHR3 missense pha002888 rs105347 chr7 105670992 T C 8.80E-05 Response to antidepressants CDHR3 intron 19736353 rs10270308 chr7 105671267 T C 6.00E-06 Warfarin maintenance dose CDHR3 cds-synon 20833655 rs4599742 chr7 105691096 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12533103 chr7 105691437 G A 4.46E-05 Bipolar disorder / / 19488044 rs10487831 chr7 105700868 C T 1.90E-05 Urinary metabolites / / 21572414 rs16872046 chr7 105710737 C T 7.38E-04 Multiple complex diseases / / 17554300 rs6960290 chr7 105718337 T C 2.57E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs3757491 chr7 105753608 C G 2.24E-05 Body mass (lean) / / 19268274 rs6466086 chr7 105763426 A G 0.0000126 Alcohol craving with or without dependence / / 22481050 rs10249088 chr7 105769949 G C 7.17E-04 Smoking initiation / / 24665060 rs717462 chr7 105773626 A G 6.94E-04 Smoking initiation / / 24665060 rs7781623 chr7 105775151 A G 7.47E-04 Smoking initiation / / 24665060 rs10258864 chr7 105784313 A G 3.95E-04 Gallstones / / 17632509 rs10953493 chr7 105790965 C T 8.25E-04 Type 2 diabetes / / 17463246 rs176517 chr7 105791617 A G 3.55E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs10487823 chr7 105807990 A G 4.80E-05 Blood pressure / / 19114657 rs176573 chr7 105818985 C T 9.18E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs176573 chr7 105818985 C T 1.06E-05 Waist-Hip Ratio / / pha003013 rs176573 chr7 105818985 C T 8.75E-05 Waist Circumference / / pha003025 rs176573 chr7 105818985 C T 3.83E-06 Waist-Hip Ratio / / pha003028 rs176588 chr7 105827361 T C 1.03E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs10808149 chr7 105837700 C G 6.38E-05 Serum metabolites / / 19043545 rs16872148 chr7 105845867 T C 1.32E-05 Aortic root size / / 21223598 rs9719404 chr7 105855618 C A,T 9.31E-05 Epilepsy (remission after treatment) / / 23962720 rs7791378 chr7 105865194 G A 6.75E-04 Aortic root size / / 21223598 rs17372176 chr7 105865217 T G 2.06E-04 Self-reported allergy / / 23817569 rs4451226 chr7 105872420 T C 4.79E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs13236748 chr7 105880915 G A 4.90E-04 Amyotrophic Lateral Sclerosis LOC100509105 intron 17827064 rs10271556 chr7 105898874 C T 1.58E-14 HDL cholesterol /MPT intron 23063622 rs10271556 chr7 105898874 C T 4.43E-08 LDL cholesterol /MPT intron 23063622 rs711438 chr7 105907311 G A 7.20E-05 Amyotrophic Lateral Sclerosis /MPT intron 17827064 rs6963243 chr7 105923947 C G 3.30E-06 Urinary metabolites /MPT intron 21572414 rs7789066 chr7 105927752 A G 1.10E-05 Socioeconomic Factors / / pha003066 rs17314507 chr7 105936054 T C 5.68E-04 Multiple complex diseases / / 17554300 rs17314507 chr7 105936054 T C 1.88E-05 Self-reported allergy / / 23817569 rs2704966 chr7 105954740 T C 2.09E-05 Body Mass Index / / pha003019 rs2704966 chr7 105954740 T C 6.56E-05 Body Mass Index / / pha003020 rs17315097 chr7 105956055 G A 7.00E-05 Response to statin therapy / / 20339536 rs2106303 chr7 105970988 C A 1.23E-04 Cholesterol / / 17255346 rs2704956 chr7 105972007 G T 6.64E-05 Cholesterol / / 17255346 rs2704955 chr7 105972102 G T 7.54E-05 Cholesterol / / 17255346 rs2704955 chr7 105972102 G T 3.57E-06 Schizophrenia(age at onset) / / 21688384 rs2704952 chr7 105973489 A T 4.44E-06 Schizophrenia(age at onset) / / 21688384 rs2519681 chr7 105984496 C T 8.48E-05 Cholesterol / / 17255346 rs2078806 chr7 105990439 A G 7.94E-05 Cholesterol / / 17255346 rs2078805 chr7 105990752 C T 8.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs2040542 chr7 105995670 C A 9.13E-05 Cholesterol / / 17255346 rs2705001 chr7 106005837 A G 9.60E-05 Response to statin therapy / / 20339536 rs2705001 chr7 106005837 A G 7.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs179861 chr7 106006952 G A 1.48E-04 Cholesterol / / 17255346 rs179862 chr7 106007074 C T 1.69E-06 Schizophrenia(age at onset) / / 21688384 rs179863 chr7 106009721 C T 2.87E-04 Cholesterol / / 17255346 rs179863 chr7 106009721 C T 4.57E-06 Schizophrenia(age at onset) / / 21688384 rs7800250 chr7 106018205 A G 2.91E-04 Cholesterol / / 17255346 rs179877 chr7 106018959 T A 6.97E-05 Cholesterol / / 17255346 rs2893638 chr7 106055504 A G 9.46E-05 Chronic Hepatitis C infection / / 21725309 rs17153102 chr7 106069466 G A 1.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs17153112 chr7 106070167 A G 3.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs6956300 chr7 106074017 T C 6.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs6978745 chr7 106074447 G A 9.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs6978366 chr7 106074468 A C 8.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs17288506 chr7 106147658 A C 5.66E-05 Serum metabolites / / 19043545 rs17153258 chr7 106149219 C A 1.93E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs9886235 chr7 106156253 G C 3.82E-05 Serum metabolites / / 19043545 rs6951915 chr7 106157477 C T 4.79E-05 Serum metabolites / / 19043545 rs3889245 chr7 106193955 G A 4.80E-04 Insulin resistance / / 21901158 rs6951495 chr7 106194530 C G 9.89E-04 Insulin resistance / / 21901158 rs11765476 chr7 106200906 A C 4.40E-05 Iron levels / / 21208937 rs78230823 chr7 106206611 T C 2.28E-06 Personality dimensions / / 23658558 rs7802274 chr7 106215850 A G 1.20E-04 Body mass index / / 17255346 rs7802274 chr7 106215850 A G 1.40E-06 Urinary metabolites / / 21572414 rs2108237 chr7 106216583 A G 2.30E-06 Urinary metabolites / / 21572414 rs10248481 chr7 106224098 C T 1.70E-06 Urinary metabolites / / 21572414 rs6974751 chr7 106227109 G T 2.99E-04 Fibrinogen / / 17255346 rs1476676 chr7 106227947 A G 2.20E-06 Urinary metabolites / / 21572414 rs41803 chr7 106232438 G A 2.30E-06 Urinary metabolites / / 21572414 rs41805 chr7 106234010 T G 2.30E-07 Urinary metabolites / / 21572414 rs41807 chr7 106234973 A G 3.05E-04 Body mass index / / 17255346 rs41807 chr7 106234973 A G 3.50E-07 Urinary metabolites / / 21572414 rs41809 chr7 106238062 A G 2.20E-06 Urinary metabolites / / 21572414 rs1003802 chr7 106279551 C A 6.64E-04 Type 2 diabetes / / 17463246 rs342240 chr7 106337250 G A 5.00E-22 Mean platelet volume / / 24026423 rs4727659 chr7 106357487 T G 2.84E-06 Mean platelet volume / / 22423221 rs342275 chr7 106359216 C T 6.00E-25 Platelet counts / / 22139419 rs342275 chr7 106359216 C T 2.00E-05 Platelet counts / / 24026423 rs342293 chr7 106372219 C G 1.00E-24 Mean platelet volume / / 19221038 rs342293 chr7 106372219 C G 2.00E-33 Mean platelet volume / / 19820697 rs342293 chr7 106372219 C G 7.00E-57 Mean platelet volume / / 22139419 rs342293 chr7 106372219 C G 2.00E-08 Mean platelet volume / / 22423221 rs342293 chr7 106372219 C G 5.00E-22 Mean platelet volume / / 24026423 rs342294 chr7 106372622 T C 7.37E-07 Mean platelet volume / / 22423221 rs342295 chr7 106372760 C T 3.68E-11 Mean platelet volume / / 22423221 rs342296 chr7 106372903 G A 1.00E-11 Mean platelet volume / / 22423221 rs342298 chr7 106373646 C T 3.61E-11 Mean platelet volume / / 22423221 rs11760619 chr7 106378634 C T 8.48E-04 Insulin resistance / / 21901158 rs342307 chr7 106382318 A T 2.02E-04 Sudden cardiac arrest / / 21658281 rs10953517 chr7 106398153 G A 7.73E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs10953518 chr7 106399882 G A 5.40E-04 Type 2 diabetes / / 17463246 rs6947609 chr7 106400106 G C 8.46E-04 Type 2 diabetes / / 17463246 rs17398575 chr7 106409452 G A 2.00E-12 Carotid intima media thickness / / 21909108 rs17398575 chr7 106409452 G A 3.00E-06 Carotid intima media thickness / / 21909108 rs7804859 chr7 106410069 C T 7.88E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs17477177 chr7 106411858 T C 2.00E-13 Blood pressure / / 21909110 rs12535670 chr7 106431237 G A 2.70E-05 Urinary metabolites / / 21572414 rs6958012 chr7 106459561 G C 4.10E-06 Urinary metabolites / / 21572414 rs42162 chr7 106475927 C T 1.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs42162 chr7 106475927 C T 0.00000055 Common carotid artery thickness (average of near and far wall measures) / / 23487405 rs42162 chr7 106475927 C T 0.00000474 Common carotid artery thickness (far walls) / / 23487405 rs42169 chr7 106482087 T C 3.50E-06 Urinary metabolites / / 21572414 rs10487287 chr7 106489003 G T 6.19E-05 Major depressive disorder (broad) / / 20038947 rs193740 chr7 106491633 G A 1.30E-05 Urinary metabolites / / 21572414 rs193740 chr7 106491633 G A 0.00005 Common carotid artery thickness (average of near and far wall measures) / / 23487405 rs1636808 chr7 106492776 C A 2.12E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs17153527 chr7 106495809 T C 4.00E-07 Menopause (age at onset) / / 19448619 rs1526083 chr7 106510076 A G 2.42E-04 Type 2 diabetes PIK3CG intron 17463246 rs1526083 chr7 106510076 A G 0.00006 Common carotid artery thickness (average of near and far wall measures) PIK3CG intron 23487405 rs1526083 chr7 106510076 A G 3.05E-05 Smoking cessation PIK3CG intron 24665060 rs12667819 chr7 106546657 G A 3.66E-05 Smoking cessation / / 24665060 rs11976223 chr7 106550661 T C 1.38E-04 Smoking cessation / / 24665060 rs6966290 chr7 106558171 T C 4.21E-04 Smoking cessation / / 24665060 rs6466139 chr7 106580081 C A 8.22E-05 Serum metabolites / / 19043545 rs6959577 chr7 106593595 T C 4.21E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7779057 chr7 106594885 C T 0.0000111 Asthma / / 22694930 rs7779057 chr7 106594885 C T 2.00E-07 Serum tamsulosin hydrochloride concentration / / 23151678 rs6957941 chr7 106607515 G C 8.25E-04 Insulin resistance / / 21901158 rs12530679 chr7 106632113 A G 5.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7786720 chr7 106642123 C T 3.38E-04 Parkinson's disease / / 17052657 rs7786720 chr7 106642123 C T 7.77E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs849308 chr7 106661128 C A 7.43E-05 Glycemic traits (pregnancy) / / 23903356 rs849309 chr7 106661150 T C 6.16E-04 Glycemic traits (pregnancy) / / 23903356 rs849310 chr7 106661176 C A 7.42E-05 Glycemic traits (pregnancy) / / 23903356 rs7798500 chr7 106662083 A G 6.00E-06 Adverse response to lamotrigine and phenytoin / / 22379998 rs849298 chr7 106664847 T A 3.82E-04 Glycemic traits (pregnancy) / / 23903356 rs2395833 chr7 106686448 G T 5.60E-04 Lipid traits PRKAR2B intron 17903299 rs2395833 chr7 106686448 G T 5.62E-05 Anorexia nervosa PRKAR2B intron 24514567 rs1544582 chr7 106687838 G A 6.71E-04 Parkinson's disease PRKAR2B intron 16252231 rs2251838 chr7 106720167 G A 2.25E-05 Statin-induced myopathy PRKAR2B intron 21826682 rs12154324 chr7 106720932 G A 4.65E-04 Multiple complex diseases PRKAR2B intron 17554300 rs7786692 chr7 106730033 A C 7.66E-04 Multiple complex diseases PRKAR2B intron 17554300 rs17153823 chr7 106730211 A G 4.24E-04 Multiple complex diseases PRKAR2B intron 17554300 rs10272371 chr7 106762847 T A 5.66E-04 Multiple complex diseases PRKAR2B intron 17554300 rs13224682 chr7 106763218 G A 6.54E-04 Type 2 diabetes PRKAR2B intron 17463246 rs13224682 chr7 106763218 G A 6.00E-08 Response to antipsychotic treatment PRKAR2B intron 20195266 rs13224682 chr7 106763218 G A 4.38E-04 Insulin resistance PRKAR2B intron 21901158 rs17425839 chr7 106763278 C A 6.39E-04 Multiple complex diseases PRKAR2B intron 17554300 rs9656135 chr7 106768356 C T 6.51E-04 Alzheimer's disease PRKAR2B intron 17998437 rs6960708 chr7 106777203 T C 4.18E-04 Multiple complex diseases PRKAR2B intron 17554300 rs3752645 chr7 106782683 G A 6.00E-06 Bladder cancer (smoking interaction) PRKAR2B intron 24662972 rs7794915 chr7 106849393 C T 8.36E-05 Calcium levels COG5 UTR-3 pha003085 rs3815148 chr7 106938420 A C 8.00E-08 Osteoarthritis COG5 intron 20112360 rs3815148 chr7 106938420 A C 7.00E-05 Osteoarthritis (knee and hip) COG5 intron 21177295 rs3815148 chr7 106938420 A C 7.00E-05 Osteoarthritis (knee and hip) COG5 intron 21177295 rs3815148 chr7 106938420 A C 8.00E-08 Osteoarthritis (knee and hip) COG5 intron 21177295 rs2395858 chr7 106964433 T G 0.0000306 Coronary artery disease COG5 intron 23202125 rs2520241 chr7 107135443 T C 7.51E-04 Lymphocyte counts COG5 intron 22286170 rs4730250 chr7 107207695 A G 6.00E-08 Osteoarthritis DUS4L intron 21068099 rs10953541 chr7 107244545 C T 3.20E-05 Endometriosis BCAP29 intron 21151130 rs10953541 chr7 107244545 C T 3.00E-08 Coronary heart disease BCAP29 intron 21378988 rs10953541 chr7 107244545 C T 9.98E-05 LDL lipoproteins BCAP29 intron pha002902 rs2248465 chr7 107303628 C T 3.66E-05 Inflammation SLC26A4 intron pha002897 rs2712210 chr7 107327852 C T 4.75E-05 Alcohol consumption SLC26A4 intron 23743675 rs1858930 chr7 107328537 A C 1.10E-05 Alcohol consumption SLC26A4 intron 23743675 rs2237679 chr7 107334026 C T 7.77E-05 Alcohol consumption SLC26A4 intron 23743675 rs2188561 chr7 107336058 C A 9.00E-06 Alcohol consumption SLC26A4 intron 23743675 rs982915 chr7 107339911 G A 1.27E-05 Alcohol consumption SLC26A4 intron 23743675 rs2712208 chr7 107343762 C G 1.32E-05 Alcohol consumption SLC26A4 intron 23743675 rs2712207 chr7 107352117 G A 1.93E-05 Alcohol consumption SLC26A4 intron 23743675 rs2712218 chr7 107356759 G A 2.35E-05 Alcohol consumption SLC26A4 UTR-3 23743675 rs10265205 chr7 107360123 G A 3.73E-05 Alcohol consumption / / 23743675 rs4730252 chr7 107361297 C T 3.97E-05 Alcohol consumption / / 23743675 rs4730253 chr7 107361436 A G 3.97E-05 Alcohol consumption / / 23743675 rs2157949 chr7 107369536 G A 6.12E-05 Alcohol consumption / / 23743675 rs4727685 chr7 107372058 G A 6.54E-05 Alcohol consumption / / 23743675 rs10953545 chr7 107372335 T C 6.55E-05 Alcohol consumption / / 23743675 rs2188563 chr7 107373871 G A 6.04E-05 Alcohol consumption / / 23743675 rs7782475 chr7 107386251 C T 9.38E-05 Alcohol consumption CBLL1 intron 23743675 rs10808154 chr7 107386396 G A 8.33E-05 Alcohol consumption CBLL1 intron 23743675 rs6956243 chr7 107388911 T C 7.24E-05 Alcohol consumption CBLL1 intron 23743675 rs13231387 chr7 107389979 C T 7.27E-05 Alcohol consumption CBLL1 intron 23743675 rs2023712 chr7 107390287 C T 4.77E-05 Alcohol consumption CBLL1 intron 23743675 rs2188565 chr7 107391069 G A 4.99E-05 Alcohol consumption CBLL1 intron 23743675 rs10280767 chr7 107393420 C A 4.60E-05 Alcohol consumption CBLL1 intron 23743675 rs13226711 chr7 107395342 G A 6.59E-05 Alcohol consumption CBLL1 intron 23743675 rs4730258 chr7 107396232 A G 7.57E-05 Alcohol consumption CBLL1 intron 23743675 rs12705421 chr7 107401429 A G 7.57E-05 Alcohol consumption CBLL1 UTR-3 23743675 rs7787927 chr7 107404360 C A 6.22E-05 Alcohol consumption / / 23743675 rs10247487 chr7 107420354 C T 6.60E-04 Alzheimer's disease SLC26A3 intron 24755620 rs4730264 chr7 107438561 C T 2.02E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SLC26A3 intron 21844884 rs4730268 chr7 107443386 C T 5.00E-06 IgG glycosylation SLC26A3 intron 23382691 rs2108225 chr7 107453103 G A 1.00E-07 Ulcerative colitis / / 19915573 rs4730273 chr7 107479519 C A 5.00E-06 Ulcerative colitis / / 19122664 rs4380874 chr7 107480315 T C 2.00E-26 Ulcerative colitis / / 23128233 rs4730276 chr7 107484437 G A 9.00E-06 Ulcerative colitis / / 19122664 rs4510766 chr7 107492789 A G 2.00E-16 Ulcerative colitis / / 21297633 rs2395932 chr7 107495145 C T 1.30E-05 Urinary metabolites / / 21572414 rs2395932 chr7 107495145 C T 8.33E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6949033 chr7 107495217 T C 1.30E-05 Urinary metabolites / / 21572414 rs6949033 chr7 107495217 T C 4.53E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1468433 chr7 107495331 G A 1.30E-05 Urinary metabolites / / 21572414 rs886774 chr7 107495434 G A 3.00E-08 Ulcerative colitis / / 19915572 rs886774 chr7 107495434 G A 1.00E-05 Urinary metabolites / / 21572414 rs10215427 chr7 107498242 A G 2.40E-06 Urinary metabolites / / 21572414 rs6964905 chr7 107499761 G A 8.60E-06 Urinary metabolites / / 21572414 rs6964905 chr7 107499761 G A 2.42E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6947045 chr7 107499947 T C 4.74E-05 Personality dimensions / / 18957941 rs6947045 chr7 107499947 T C 8.90E-06 Urinary metabolites / / 21572414 rs6964972 chr7 107499996 A G 5.00E-05 Personality dimensions / / 18957941 rs6964972 chr7 107499996 A G 8.60E-06 Urinary metabolites / / 21572414 rs4598195 chr7 107503441 A C 1.00E-06 Ulcerative colitis / / 19122664 rs4598195 chr7 107503441 A C 8.00E-08 Ulcerative colitis / / 20228799 rs12669950 chr7 107508000 T C 4.00E-04 Type 2 diabetes / / 22158537 rs4348408 chr7 107509273 G A 8.72E-05 Personality dimensions / / 18957941 rs4348408 chr7 107509273 G A 7.50E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10267797 chr7 107515300 C T 4.36E-05 Personality dimensions / / 18957941 rs10267797 chr7 107515300 C T 2.00E-05 Urinary metabolites / / 21572414 rs2108230 chr7 107515524 C T 1.70E-05 Urinary metabolites / / 21572414 rs6956931 chr7 107521188 C T 7.91E-04 Type 2 diabetes / / 22158537 rs7778092 chr7 107522092 T C 5.43E-04 Type 2 diabetes / / 22158537 rs756382 chr7 107522867 T C 7.65E-04 Type 2 diabetes / / 22158537 rs881176 chr7 107573254 T G 8.24E-04 Response to taxane treatment (placlitaxel) LAMB1 intron 23006423 rs2158836 chr7 107580839 A G 7.00E-06 Ulcerative colitis LAMB1 intron 19122664 rs2158836 chr7 107580839 A G 6.17E-04 Response to taxane treatment (placlitaxel) LAMB1 intron 23006423 rs10953555 chr7 107581346 T C 1.20E-05 Personality dimensions LAMB1 intron 18957941 rs10953555 chr7 107581346 T C 1.20E-05 Personality dimensions LAMB1 intron 21173776 rs10953555 chr7 107581346 T C 6.86E-04 Response to taxane treatment (placlitaxel) LAMB1 intron 23006423 rs4730281 chr7 107581936 A G 8.05E-05 Personality dimensions LAMB1 intron 18957941 rs757931 chr7 107586518 A C 7.50E-05 Heart Rate LAMB1 intron pha003054 rs2072209 chr7 107592198 A G 1.00E-08 IgG glycosylation LAMB1 intron 23382691 rs2072209 chr7 107592198 A G 2.00E-06 IgG glycosylation LAMB1 intron 23382691 rs2072209 chr7 107592198 A G 2.00E-07 IgG glycosylation LAMB1 intron 23382691 rs2072209 chr7 107592198 A G 8.00E-06 IgG glycosylation LAMB1 intron 23382691 rs11766345 chr7 107611650 G T 5.97E-05 Cardiovascular disease LAMB1 intron pha003064 rs4727695 chr7 107614003 A G 8.50E-05 Type 2 diabetes LAMB1 intron 19184112 rs2237701 chr7 107622150 A G 8.21E-04 Suicide attempts in bipolar disorder LAMB1 intron 21041247 rs2237702 chr7 107622288 G A 8.21E-04 Suicide attempts in bipolar disorder LAMB1 intron 21041247 rs2701039 chr7 107623542 A G 2.20E-05 Homocysteine levels,in plasma LAMB1 intron 19525478 rs10229305 chr7 107638236 T C 3.10E-05 Height LAMB1 intron pha003011 rs17154865 chr7 107696289 C T 6.86E-04 Response to taxane treatment (placlitaxel) LAMB4 cds-synon 23006423 rs9690688 chr7 107720162 C A 2.16E-07 Common variable immunodeficiency LAMB4 missense 21497890 rs390547 chr7 107721121 G A 3.05E-05 Arthritis (juvenile idiopathic) LAMB4 intron 22354554 rs418255 chr7 107730034 T C 7.70E-06 Urinary metabolites LAMB4 intron 21572414 rs446566 chr7 107730650 G A 1.20E-05 Urinary metabolites LAMB4 intron 21572414 rs448559 chr7 107739485 A G 1.04E-04 Multiple complex diseases LAMB4 intron 17554300 rs378962 chr7 107739538 A C 5.45E-05 Multiple complex diseases LAMB4 intron 17554300 rs401487 chr7 107743409 A G 2.55E-04 Multiple complex diseases LAMB4 intron 17554300 rs403731 chr7 107744217 A G 1.23E-04 Multiple complex diseases LAMB4 intron 17554300 rs409815 chr7 107745443 G A 3.00E-04 Multiple complex diseases LAMB4 intron 17554300 rs7794978 chr7 107765230 C A 1.67E-04 Alcohol dependence LAMB4 intron 21314694 rs2395958 chr7 107767517 G T 1.65E-04 Multiple complex diseases LAMB4 intron 17554300 rs382140 chr7 107782200 A G 4.00E-09 Coffee consumption / / 21876539 rs7795932 chr7 107782812 A G 4.30E-04 Type 2 diabetes / / 17463246 rs409797 chr7 107797860 G A 7.58E-05 Schizophrenia NRCAM intron 19571809 rs409797 chr7 107797860 G A 8.78E-05 Schizophrenia NRCAM intron pha002859 rs428459 chr7 107818851 T C 4.88E-05 Height NRCAM intron 22021425 rs41338849 chr7 107878671 A G 9.28E-04 Multiple complex diseases NRCAM intron 17554300 rs1269688 chr7 107925339 A C 3.46E-04 Alzheimer's disease NRCAM intron 22005930 rs2267881 chr7 107935905 C T 1.39E-05 IgE levels NRCAM intron 17255346 rs2193241 chr7 107946905 C T 2.08E-04 Systolic blood pressure NRCAM intron 21909115 rs10274696 chr7 107952211 G A 3.10E-04 Type 2 diabetes and 6 quantitative traits NRCAM intron 17848626 rs2111202 chr7 107966075 C T 5.24E-05 Cardiovascular disease NRCAM intron 22029572 rs10953562 chr7 107967042 T C 2.46E-05 Serum metabolites NRCAM intron 19043545 rs2267887 chr7 107968803 G A 9.09E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) NRCAM intron 23648065 rs6975557 chr7 107973297 A G 1.56E-04 Femoral neck bone geometry and menarche (age at onset) NRCAM intron 23593202 rs6975557 chr7 107973297 A G 5.00E-08 Femoral neck bone geometry and menarche (age at onset) NRCAM intron 23593202 rs17419000 chr7 107974078 C T 2.22E-05 Serum metabolites NRCAM intron 19043545 rs10487849 chr7 107987085 T C 3.85E-05 Serum metabolites NRCAM intron 19043545 rs13230316 chr7 107991567 C G 1.22E-07 Femoral neck bone geometry and menarche (age at onset) NRCAM intron 23593202 rs13230316 chr7 107991567 C G 3.67E-04 Femoral neck bone geometry and menarche (age at onset) NRCAM intron 23593202 rs13227836 chr7 108064399 T C 9.94E-04 Type 2 diabetes NRCAM intron 17463246 rs4730310 chr7 108066166 C G 3.95E-05 Multiple complex diseases NRCAM intron 17554300 rs4730310 chr7 108066166 C G 2.60E-05 Urinary metabolites NRCAM intron 21572414 rs2300048 chr7 108066989 C T 2.28E-04 Smoking cessation NRCAM intron 24665060 rs17338021 chr7 108069353 T C 3.84E-04 Smoking initiation NRCAM intron 24665060 rs13238841 chr7 108081965 G A 3.87E-04 Smoking cessation NRCAM intron 24665060 rs2041001 chr7 108083099 C T 1.10E-05 Urinary metabolites NRCAM intron 21572414 rs41347845 chr7 108105883 A G 1.30E-05 Urinary metabolites / / 21572414 rs2240449 chr7 108201328 C A 1.15E-04 Asthma / / 23181788 rs40947 chr7 108206653 G A 5.57E-04 Type 2 diabetes THAP5 intron 17463246 rs10706757 chr7 108335735 T A 6.23E-07 Multiple complex diseases / / 17554300 rs4727715 chr7 108340749 C T 9.00E-04 Spine bone size / / 21947420 rs4730328 chr7 108351652 C A 5.76E-04 Multiple complex diseases / / 17554300 rs10252772 chr7 108490660 A G 6.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6959243 chr7 108497232 A G 1.96E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9690914 chr7 108497479 T C 7.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1525183 chr7 108503008 A C 9.81E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1525181 chr7 108505208 T C 9.81E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6979581 chr7 108506274 G A 0.000276 Salmonella-induced pyroptosis / / 22837397 rs2280645 chr7 108524003 T G 8.72E-05 Cognitive test performance / / 20125193 rs2280645 chr7 108524003 T G 9.70E-06 Glycemic traits (pregnancy) / / 23903356 rs1404697 chr7 108544461 G C 5.00E-06 Smoking behavior / / 22006218 rs1404697 chr7 108544461 G C 8.00E-06 Smoking behavior / / 22006218 rs1404696 chr7 108544482 A G 6.65E-04 Multiple complex diseases / / 17554300 rs11770605 chr7 108548634 T G 1.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11770605 chr7 108548634 T G 2.60E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs848353 chr7 108548660 A G 2.00E-06 Smoking behavior / / 22006218 rs848353 chr7 108548660 A G 3.00E-07 Smoking behavior / / 22006218 rs848353 chr7 108548660 A G 9.00E-07 Smoking behavior / / 22006218 rs848331 chr7 108575242 G C 4.82E-04 Sarcoidosis / / 19165924 rs848324 chr7 108585436 T C 1.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs848324 chr7 108585436 T C 5.08E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs848321 chr7 108586855 T C 1.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs848321 chr7 108586855 T C 5.08E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1513921 chr7 108606430 C T 7.84E-04 Multiple complex diseases / / 17554300 rs7790207 chr7 108718165 G T 1.60E-06 Urinary metabolites / / 21572414 rs1399004 chr7 108718486 A G 9.66E-04 Myocardial Infarction / / pha002883 rs7806077 chr7 108729486 T C 2.40E-06 Urinary metabolites / / 21572414 rs2090051 chr7 108732222 A T 8.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs12531470 chr7 108733279 G A 9.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs9768602 chr7 108757561 A G 0.0003924 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9768602 chr7 108757561 A G 3.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4143238 chr7 108757705 G A 9.00E-05 Blood Pressure / / pha003046 rs1581541 chr7 108765223 G C 4.69E-05 Body mass (lean) / / 19268274 rs11489625 chr7 108809771 C A 7.66E-04 Multiple complex diseases / / 17554300 rs11979965 chr7 108812127 C T 2.01E-04 Alzheimer's disease / / 17998437 rs10953597 chr7 108829829 A G 8.85E-05 Information processing speed / / 21130836 rs1858897 chr7 108908382 A G 3.76E-04 Longevity / / 22279548 rs2106444 chr7 108927013 T C 7.40E-05 Blood pressure / / 19114657 rs10277209 chr7 109003574 C T 4.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs10233050 chr7 109008914 T C 3.04E-05 Multiple complex diseases / / 17554300 rs10953607 chr7 109052359 G A 5.43E-04 Gallbladder cancer / / 22318345 rs11975565 chr7 109081747 T C 4.51E-04 Gallbladder cancer / / 22318345 rs13222164 chr7 109098364 A G 3.25E-05 Cytomegalovirus antibody response / / 21993531 rs11561993 chr7 109102855 C T 8.51E-04 Taste perception / / 22132133 rs12705596 chr7 109106383 G A 6.04E-05 Cytomegalovirus antibody response / / 21993531 rs10499973 chr7 109111118 G A 6.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1358545 chr7 109118261 C A 8.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10231280 chr7 109152563 C T 8.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10231280 chr7 109152563 C T 3.20E-05 Gaucher disease severity / / 22388998 rs10953615 chr7 109152711 A G 9.00E-06 Gallbladder cancer / / 22318345 rs10499977 chr7 109160687 C T 9.08E-06 Gallbladder cancer / / 22318345 rs12705610 chr7 109161891 T C 9.08E-06 Gallbladder cancer / / 22318345 rs11770336 chr7 109166664 C T 5.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1524271 chr7 109217355 C T 2.43E-04 Major depressive disorder / / 22472876 rs1568778 chr7 109250932 T C 2.90E-04 Gallstones / / 17632509 rs10255690 chr7 109252043 A G 4.76E-05 Post-operative nausea and vomiting / / 21694509 rs711453 chr7 109260732 A C 8.78E-04 Bipolar disorder,schizoaffective / / 19567891 rs10261639 chr7 109262114 T G 9.26E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs820940 chr7 109302398 T C 7.09E-04 Parkinson's disease / / 17052657 rs820935 chr7 109304670 T C 2.21E-04 Multiple complex diseases / / 17554300 rs820935 chr7 109304670 T C 4.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs711481 chr7 109314773 A C 7.05E-04 Parkinson's disease / / 17052657 rs711483 chr7 109315509 T C 8.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs3857827 chr7 109320013 T G 9.32E-04 Type 2 diabetes / / 17463246 rs2692877 chr7 109341952 G A 5.00E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs10276075 chr7 109344381 C T 6.39E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs990943 chr7 109345821 C T 0.000872053 Hypertension (early onset hypertension) / / 22479346 rs10275927 chr7 109350011 G A 4.77E-04 Multiple complex diseases / / 17554300 rs1850393 chr7 109357639 T G 2.17E-04 Type 2 diabetes / / 17463246 rs711517 chr7 109375034 G T 6.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12667013 chr7 109474492 T A 5.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs12673333 chr7 109474530 C G 6.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs3114738 chr7 109506438 G T 3.69E-04 Multiple complex diseases / / 17554300 rs3114834 chr7 109598161 C T 1.21E-05 Multiple complex diseases / / 17554300 rs2523214 chr7 109619777 G A 8.34E-06 Body Mass Index / / pha003009 rs2257148 chr7 109629539 A G 5.75E-05 Body Mass Index / / pha003009 rs2523239 chr7 109639751 G A 1.13E-04 Glycosylated haemoglobin levels / / 17255346 rs2711344 chr7 109640021 T A 4.93E-04 Type 2 diabetes / / 17846124 rs2189358 chr7 109644867 T C 3.81E-05 Body Mass Index / / pha003009 rs6971210 chr7 109697521 T C 8.27E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7805074 chr7 109729286 A G 2.40E-05 Urinary metabolites / / 21572414 rs2244263 chr7 109751674 C T 2.79E-04 Alzheimer's disease (late onset) / / 21379329 rs1722052 chr7 109782499 T G 4.10E-05 Crohn's disease (need for surgery) / / 23665963 rs1962007 chr7 109787765 A C 1.36E-04 Alzheimer's disease (late onset) / / 21379329 rs2692419 chr7 109851356 C A 9.60E-05 Insulin resistance / / 21901158 rs2396220 chr7 109856125 T C 8.20E-06 Urinary metabolites / / 21572414 rs17507839 chr7 109867444 G A 9.29E-04 Alzheimer's disease / / 22005930 rs10258980 chr7 109875729 T C 9.93E-05 Insulin resistance / / 21901158 rs11977979 chr7 109883755 G A 6.83E-04 Insulin resistance / / 21901158 rs10274223 chr7 109893606 C T 6.88E-04 Multiple complex diseases / / 17554300 rs2188810 chr7 109973244 C T 4.93E-04 Multiple complex diseases / / 17554300 rs12536111 chr7 110010335 T C 9.40E-06 Urinary metabolites / / 21572414 rs12155146 chr7 110017222 C T 1.68E-04 Multiple complex diseases / / 17554300 rs12155146 chr7 110017222 C T 4.59E-04 Substance dependence / / 21818250 rs17157642 chr7 110023361 A G 9.02E-04 Multiple complex diseases / / 17554300 rs10487324 chr7 110036601 G A 3.62E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7783665 chr7 110039196 G A 4.10E-05 Tuberculosis / / 24057671 rs6974080 chr7 110046716 T C 4.78E-06 Bone mineral density / / 21124946 rs6954034 chr7 110046765 A G 3.83E-06 Bone mineral density / / 21124946 rs6968385 chr7 110047471 C T 2.00E-06 Attention deficit hyperactivity disorder (time to onset) / / 18937294 rs4730430 chr7 110047964 C T 3.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs211814 chr7 110056478 G A 1.59E-04 Multiple complex diseases / / 17554300 rs211793 chr7 110071514 T G 3.58E-06 Bone mineral density / / 21124946 rs211793 chr7 110071514 T G 6.10E-07 Urinary metabolites / / 21572414 rs211790 chr7 110072910 T C 3.31E-06 Bone mineral density / / 21124946 rs211797 chr7 110078237 C G 2.60E-06 Thyroid function / / 20826269 rs211797 chr7 110078237 C G 7.91E-07 Bone mineral density / / 21124946 rs169833 chr7 110078549 G A 2.60E-06 Thyroid function / / 20826269 rs169833 chr7 110078549 G A 7.81E-07 Bone mineral density / / 21124946 rs211812 chr7 110083052 C G 2.80E-06 Thyroid function / / 20826269 rs211812 chr7 110083052 C G 7.56E-07 Bone mineral density / / 21124946 rs211811 chr7 110083672 A G 3.30E-07 Thyroid function / / 20826269 rs211811 chr7 110083672 A G 1.09E-06 Bone mineral density / / 21124946 rs211811 chr7 110083672 A G 2.80E-06 Urinary metabolites / / 21572414 rs211810 chr7 110088524 T A,C,G 2.90E-06 Thyroid function / / 20826269 rs211810 chr7 110088524 T A,C,G 6.87E-07 Bone mineral density / / 21124946 rs211809 chr7 110088623 G A 6.84E-07 Bone mineral density / / 21124946 rs211808 chr7 110089321 A C 2.40E-06 Thyroid function / / 20826269 rs211808 chr7 110089321 A C 6.85E-07 Bone mineral density / / 21124946 rs211804 chr7 110091460 A C 2.70E-06 Thyroid function / / 20826269 rs211804 chr7 110091460 A C 4.25E-07 Bone mineral density / / 21124946 rs211803 chr7 110091748 T G 2.70E-06 Thyroid function / / 20826269 rs211803 chr7 110091748 T G 7.21E-07 Bone mineral density / / 21124946 rs402946 chr7 110095056 T G 2.30E-06 Thyroid function / / 20826269 rs402946 chr7 110095056 T G 7.31E-07 Bone mineral density / / 21124946 rs416050 chr7 110095211 G A 2.30E-06 Thyroid function / / 20826269 rs416050 chr7 110095211 G A 8.16E-07 Bone mineral density / / 21124946 rs7795082 chr7 110096274 G A 2.23E-06 Bone mineral density / / 21124946 rs396911 chr7 110096685 A G 4.50E-06 Thyroid function / / 20826269 rs396911 chr7 110096685 A G 2.23E-06 Bone mineral density / / 21124946 rs396911 chr7 110096685 A G 3.50E-06 Urinary metabolites / / 21572414 rs367898 chr7 110097040 C G 4.50E-06 Thyroid function / / 20826269 rs367898 chr7 110097040 C G 2.23E-06 Bone mineral density / / 21124946 rs367898 chr7 110097040 C G 7.50E-06 Urinary metabolites / / 21572414 rs442451 chr7 110101546 A G 3.80E-06 Thyroid function / / 20826269 rs442451 chr7 110101546 A G 2.25E-06 Bone mineral density / / 21124946 rs398554 chr7 110101603 G A 3.80E-06 Thyroid function / / 20826269 rs398554 chr7 110101603 G A 2.26E-06 Bone mineral density / / 21124946 rs409006 chr7 110104450 A G 4.10E-06 Thyroid function / / 20826269 rs409006 chr7 110104450 A G 2.30E-06 Bone mineral density / / 21124946 rs388129 chr7 110106507 G C 3.90E-06 Thyroid function / / 20826269 rs388129 chr7 110106507 G C 2.33E-06 Bone mineral density / / 21124946 rs388129 chr7 110106507 G C 8.50E-06 Urinary metabolites / / 21572414 rs440568 chr7 110106593 C T 5.58E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs10226721 chr7 110107348 G A 4.10E-06 Thyroid function / / 20826269 rs10226721 chr7 110107348 G A 2.34E-06 Bone mineral density / / 21124946 rs10226721 chr7 110107348 G A 6.60E-06 Urinary metabolites / / 21572414 rs10270301 chr7 110133558 C T 8.60E-05 Response to hepatitis C treatment / / 19684573 rs10270301 chr7 110133558 C T 3.94E-05 Osteoarthritis (knee and hip) / / 21177295 rs10270301 chr7 110133558 C T 2.61E-05 Height / / pha003010 rs10270301 chr7 110133558 C T 7.30E-06 Height / / pha003011 rs7811230 chr7 110144415 G A 2.72E-05 Response to hepatitis C treatment / / 19684573 rs2966417 chr7 110157546 A G 6.57E-07 Osteoarthritis / / 22763110 rs10238549 chr7 110181022 C T 6.34E-06 Elbow pain / / pha003008 rs10238549 chr7 110181022 C T 6.66E-06 Height / / pha003010 rs10238549 chr7 110181022 C T 2.07E-06 Height / / pha003011 rs10499991 chr7 110322162 C T 3.30E-04 Type 2 diabetes and 6 quantitative traits IMMP2L intron 17848626 rs10266246 chr7 110338460 C T 4.36E-04 Multiple complex diseases IMMP2L intron 17554300 rs17157913 chr7 110340974 T C 2.00E-06 PR interval in Tripanosoma cruzi seropositivity IMMP2L intron 24324551 rs7807935 chr7 110374713 A G 4.76E-05 Cognitive performance IMMP2L intron 19734545 rs868824 chr7 110391921 T C 9.55E-06 Multiple sclerosis (age of onset) IMMP2L intron 19010793 rs17157942 chr7 110400223 C T 7.08E-05 Multiple sclerosis (age of onset) IMMP2L intron 19010793 rs1528036 chr7 110410652 G A 7.28E-05 Lipoproteins IMMP2L intron pha003079 rs6980230 chr7 110411171 A T 7.71E-04 Lymphocyte counts IMMP2L intron 22286170 rs12530971 chr7 110418829 C T 6.10E-05 Cognitive performance IMMP2L intron 19734545 rs1528041 chr7 110419154 C T 6.46E-05 Multiple sclerosis (age of onset) IMMP2L intron 19010793 rs6978082 chr7 110420611 A G 7.98E-05 Amyotrophic lateral sclerosis (sporadic) IMMP2L intron 24529757 rs1881164 chr7 110429536 C T 2.82E-05 Multiple sclerosis (age of onset) IMMP2L intron 19010793 rs1881164 chr7 110429536 C T 2.10E-05 Urinary metabolites IMMP2L intron 21572414 rs12537293 chr7 110432527 G A 8.58E-05 Panic disorder IMMP2L intron 19165232 rs1950004 chr7 110435602 T C 4.47E-05 Multiple sclerosis (age of onset) IMMP2L intron 19010793 rs1528039 chr7 110442772 A G 9.10E-04 Crohn's disease IMMP2L intron 17684544 rs1528039 chr7 110442772 A G 5.54E-05 Cognitive performance IMMP2L intron 19734545 rs7778910 chr7 110451383 C A 2.04E-05 Multiple sclerosis (age of onset) IMMP2L intron 19010793 rs10279573 chr7 110467221 C T 3.00E-06 Cognitive performance IMMP2L intron 19734545 rs1528035 chr7 110470629 T C 9.90E-05 Lipoproteins IMMP2L intron pha003079 rs12531640 chr7 110479535 G T 6.00E-06 Cognitive performance IMMP2L intron 19734545 rs10500003 chr7 110482753 C T 3.63E-04 Heart Failure IMMP2L intron pha002884 rs799618 chr7 110485378 G A 2.11E-05 Intracerebral hemorrhage IMMP2L intron 24656865 rs6944312 chr7 110494098 G A 6.61E-06 Intracerebral hemorrhage IMMP2L intron 24656865 rs6948090 chr7 110494399 A G 2.87E-06 Atopy IMMP2L intron 21625490 rs6973561 chr7 110495290 T G 6.56E-06 Intracerebral hemorrhage IMMP2L intron 24656865 rs740341 chr7 110497173 A G 7.57E-06 Intracerebral hemorrhage IMMP2L intron 24656865 rs799642 chr7 110499232 A G 3.96E-06 Intracerebral hemorrhage IMMP2L intron 24656865 rs764864 chr7 110499965 C T 4.89E-06 Intracerebral hemorrhage IMMP2L intron 24656865 rs799643 chr7 110501952 A T 5.92E-06 Intracerebral hemorrhage IMMP2L intron 24656865 rs2190527 chr7 110503515 T C 2.10E-05 Intracerebral hemorrhage IMMP2L intron 24656865 rs2190528 chr7 110503518 A T 2.08E-05 Intracerebral hemorrhage IMMP2L intron 24656865 rs1406049 chr7 110505179 C T 7.19E-06 Intracerebral hemorrhage IMMP2L intron 24656865 rs799623 chr7 110509136 C T 6.71E-05 Atopy IMMP2L intron 21625490 rs799623 chr7 110509136 C T 1.88E-05 Intracerebral hemorrhage IMMP2L intron 24656865 rs799624 chr7 110511038 C T 1.54E-05 Intracerebral hemorrhage IMMP2L intron 24656865 rs799626 chr7 110513423 T G 4.14E-06 Intracerebral hemorrhage IMMP2L intron 24656865 rs799628 chr7 110513735 A C 1.42E-05 Intracerebral hemorrhage IMMP2L intron 24656865 rs12705741 chr7 110513744 C A 2.00E-06 Intracerebral hemorrhage IMMP2L intron 24656865 rs12705741 chr7 110513744 C A 4.21E-05 Intracerebral hemorrhage IMMP2L intron 24656865 rs2190529 chr7 110516563 G A 3.65E-06 Intracerebral hemorrhage IMMP2L intron 24656865 rs799616 chr7 110520903 T C 1.59E-05 Intracerebral hemorrhage IMMP2L intron 24656865 rs258975 chr7 110527201 T C 1.93E-05 Intracerebral hemorrhage IMMP2L intron 24656865 rs258978 chr7 110530288 C T 1.75E-05 Intracerebral hemorrhage IMMP2L intron 24656865 rs258979 chr7 110530334 T C 1.68E-05 Intracerebral hemorrhage IMMP2L intron 24656865 rs258982 chr7 110530745 C T 1.89E-05 Intracerebral hemorrhage IMMP2L intron 24656865 rs258983 chr7 110532851 C T 1.97E-05 Intracerebral hemorrhage IMMP2L intron 24656865 rs258984 chr7 110534002 G A 2.63E-05 Intracerebral hemorrhage IMMP2L intron 24656865 rs185441 chr7 110534429 T C 1.76E-05 Intracerebral hemorrhage IMMP2L intron 24656865 rs725272 chr7 110586127 G C 5.81E-04 Cognition,early reading ability IMMP2L intron 17684495 rs4730472 chr7 110610696 C G 9.92E-05 Serum metabolites IMMP2L intron 19043545 rs4727753 chr7 110635497 A G 8.64E-05 Atopy IMMP2L intron 21625490 rs7801774 chr7 110670551 T G 1.09E-04 Atopy IMMP2L intron 21625490 rs6958325 chr7 110677656 A G 2.33E-05 Asthma IMMP2L intron 20159242 rs17158277 chr7 110678370 T C 7.63E-04 Smoking quantity IMMP2L intron 24665060 rs10257931 chr7 110820901 G T 6.97E-05 Height IMMP2L intron pha003011 rs10487306 chr7 110825467 T C 7.18E-04 Smoking cessation IMMP2L intron 24665060 rs10214984 chr7 110838098 C T 3.91E-05 Height IMMP2L intron pha003011 rs10262486 chr7 110869432 A G 7.05E-05 Height IMMP2L intron pha003010 rs10262486 chr7 110869432 A G 7.32E-06 Height IMMP2L intron pha003011 rs37712 chr7 110875153 C T 7.94E-05 Height IMMP2L intron pha003010 rs37712 chr7 110875153 C T 1.16E-05 Height IMMP2L intron pha003011 rs37713 chr7 110876320 C A 2.51E-05 Height IMMP2L intron pha003010 rs37713 chr7 110876320 C A 1.40E-06 Height IMMP2L intron pha003011 rs7810543 chr7 110894778 A G 7.19E-04 Multiple complex diseases IMMP2L intron 17554300 rs2109298 chr7 110899634 C T 3.86E-05 Multiple complex diseases IMMP2L intron 17554300 rs37747 chr7 110920180 C G 5.00E-04 Response to antidepressant treatment (citalopram) IMMP2L intron 23726668 rs37748 chr7 110920216 G A 6.71E-05 Height IMMP2L intron pha003011 rs37749 chr7 110920302 G A,C 1.12E-05 Height IMMP2L intron pha003011 rs11534045 chr7 110935979 G A 5.90E-05 Alcoholism (heaviness of drinking) IMMP2L intron 21529783 rs12672270 chr7 110949522 T A 5.46E-04 Suicide attempts in bipolar disorder IMMP2L intron 21423239 rs6962665 chr7 110949566 C A 6.50E-05 Alcoholism (heaviness of drinking) IMMP2L intron 21529783 rs1981713 chr7 110957294 A C 9.69E-06 Height IMMP2L intron pha003011 rs37644 chr7 110982360 C T 1.20E-05 Urinary metabolites IMMP2L intron 21572414 rs37683 chr7 111044971 G A 1.60E-05 Height IMMP2L intron pha003010 rs37683 chr7 111044971 G A 1.03E-06 Height IMMP2L intron pha003011 rs12673775 chr7 111058213 T C 4.99E-04 Suicide attempts in bipolar disorder IMMP2L intron 21423239 rs38752 chr7 111078912 T G 4.60E-05 Schizophrenia IMMP2L intron 21791550 rs38752 chr7 111078912 T G 0.000046 Psychosis IMMP2L intron 23164818 rs10232025 chr7 111085618 T C 7.32E-06 Height IMMP2L intron pha003010 rs10232025 chr7 111085618 T C 1.56E-07 Height IMMP2L intron pha003011 rs11767630 chr7 111098773 A G 1.10E-05 Height IMMP2L intron pha003010 rs11767630 chr7 111098773 A G 8.10E-07 Height IMMP2L intron pha003011 rs2529489 chr7 111159896 C T 3.32E-04 Multiple complex diseases IMMP2L intron 17554300 rs11975331 chr7 111160356 A G 3.69E-06 Height IMMP2L intron pha003010 rs11975331 chr7 111160356 A G 2.42E-07 Height IMMP2L intron pha003011 rs2613588 chr7 111183610 T C 4.84E-05 Height IMMP2L intron pha003010 rs2613588 chr7 111183610 T C 6.69E-06 Height IMMP2L intron pha003011 rs2613585 chr7 111186693 G A 2.98E-05 Height IMMP2L intron pha003010 rs2613585 chr7 111186693 G A 2.07E-06 Height IMMP2L intron pha003011 rs2396393 chr7 111191200 T C 6.12E-05 Height IMMP2L intron pha003010 rs2396393 chr7 111191200 T C 5.17E-06 Height IMMP2L intron pha003011 rs2894612 chr7 111193237 T G 2.98E-05 Height IMMP2L intron pha003010 rs2894612 chr7 111193237 T G 2.07E-06 Height IMMP2L intron pha003011 rs12705779 chr7 111199771 G A 1.82E-05 Height IMMP2L intron pha003011 rs17158652 chr7 111228173 G A 5.18E-04 White matter integrity / / 22425255 rs17158652 chr7 111228173 G A 3.77E-05 Height / / pha003010 rs17158652 chr7 111228173 G A 1.23E-06 Height / / pha003011 rs11979526 chr7 111240313 A G 8.18E-04 White matter integrity / / 22425255 rs11979526 chr7 111240313 A G 7.56E-06 Height / / pha003010 rs11979526 chr7 111240313 A G 1.62E-07 Height / / pha003011 rs2613610 chr7 111245156 A G 8.97E-04 White matter integrity / / 22425255 rs2613611 chr7 111246951 A C 5.19E-06 Psoriasis / / 18364390 rs2613611 chr7 111246951 A C 2.19E-05 Height / / pha003010 rs2613611 chr7 111246951 A C 2.63E-06 Height / / pha003011 rs870668 chr7 111311611 A G 6.58E-05 Creatinine levels / / pha003069 rs12538300 chr7 111314282 C T 5.54E-05 Creatinine levels / / pha003069 rs10262821 chr7 111329082 G A 4.12E-05 Height / / pha003010 rs10262821 chr7 111329082 G A 6.24E-05 Height / / pha003011 rs17158733 chr7 111332403 A G 5.01E-04 Type 2 diabetes / / 17463246 rs17158733 chr7 111332403 A G 7.44E-05 Multiple complex diseases / / 17554300 rs1582274 chr7 111339228 C T 2.38E-05 Blood Pressure / / pha003040 rs1859746 chr7 111365935 C G 1.62E-04 Multiple complex diseases DOCK4 nearGene-3 17554300 rs2301678 chr7 111376840 T C 4.33E-06 Adiponectin levels DOCK4 intron 20887962 rs2074115 chr7 111379582 A G 9.32E-05 Multiple complex diseases DOCK4 intron 17554300 rs3757647 chr7 111382498 T C 9.59E-05 Multiple complex diseases DOCK4 intron 17554300 rs1859025 chr7 111387739 A G 1.03E-04 Multiple complex diseases DOCK4 intron 17554300 rs2074119 chr7 111399977 G A 3.26E-06 Multiple complex diseases DOCK4 intron 17554300 rs3801777 chr7 111421342 G C 2.89E-05 Personality dimensions DOCK4 intron 22628180 rs2074114 chr7 111451659 T C 3.00E-06 PR interval in Tripanosoma cruzi seropositivity DOCK4 intron 24324551 rs10275038 chr7 111487026 G A 0.00018 Cognitive impairment (no dementia) DOCK4 intron 23042215 rs739617 chr7 111510866 C T 7.76E-05 Schizophrenia (treatment refractory) DOCK4 intron 22479419 rs17158926 chr7 111510963 A T 1.61E-04 Schizophrenia (treatment refractory) DOCK4 intron 22479419 rs17158930 chr7 111511138 A G 1.34E-04 Schizophrenia (treatment refractory) DOCK4 intron 22479419 rs757036 chr7 111518413 G A 5.80E-06 Stroke (ischemic) DOCK4 intron 22384361 rs10255299 chr7 111527560 G A 7.00E-11 C-reactive protein and white blood cell count DOCK4 intron 22788528 rs10228638 chr7 111531648 T C 5.40E-06 Stroke (ischemic) DOCK4 intron 22384361 rs2074132 chr7 111535863 T C 5.40E-06 Stroke (ischemic) DOCK4 intron 22384361 rs6954980 chr7 111558797 T C 7.28E-05 Vitiligo DOCK4 intron 22951725 rs61159171 chr7 111642646 C T 6.00E-06 Breast size DOCK4 intron 22747683 rs2522217 chr7 111661836 T G 1.70E-04 Type 2 diabetes DOCK4 intron 17463246 rs254869 chr7 111664992 A G 8.64E-04 Type 2 diabetes DOCK4 intron 17463246 rs6466396 chr7 111666943 C T 7.11E-05 Cognitive impairment induced by topiramate DOCK4 intron 22091778 rs10428959 chr7 111677906 C T 1.00E-07 Response to fenofibrate DOCK4 intron 22890011 rs489356 chr7 111717793 T G 4.56E-05 Heart Rate DOCK4 intron pha003051 rs17565212 chr7 111730179 A G 4.60E-05 Cognitive function DOCK4 intron 24684796 rs2729538 chr7 111730967 A C 1.42E-05 Heart Rate DOCK4 intron pha003051 rs10273453 chr7 111732480 G A 7.09E-04 Type 2 diabetes DOCK4 intron 17463246 rs10273453 chr7 111732480 G A 1.10E-04 Cognitive function DOCK4 intron 24684796 rs2560656 chr7 111752847 C G 2.43E-04 Multiple complex diseases DOCK4 intron 17554300 rs2434357 chr7 111766512 A G 7.93E-05 Cleft lip DOCK4 intron 20436469 rs13247109 chr7 111778425 T C 1.75E-05 Behcet's disease DOCK4 intron 23291587 rs13232973 chr7 111778586 C T 2.26E-05 Behcet's disease DOCK4 intron 23291587 rs6466401 chr7 111782891 T C 2.30E-05 Urinary metabolites DOCK4 intron 21572414 rs11536571 chr7 111809072 T C 5.21E-04 Obesity (extreme) DOCK4 intron 21935397 rs10953703 chr7 111809140 A G 1.30E-05 Urinary metabolites DOCK4 intron 21572414 rs1154953 chr7 111810763 C T 8.41E-04 Suicide attempts in bipolar disorder DOCK4 intron 21423239 rs10232440 chr7 111814812 A G 6.29E-04 Suicide attempts in bipolar disorder DOCK4 intron 21423239 rs17159389 chr7 111896878 G C 1.60E-05 Urinary metabolites ZNF277 intron 21572414 rs2301725 chr7 111972769 G A 9.59E-05 Intelligence ZNF277 intron 21826061 rs2708600 chr7 112005565 C A 8.29E-04 Depression (quantitative trait) / / 20800221 rs10435366 chr7 112016581 T C 4.30E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs2708593 chr7 112036947 C T 9.73E-05 Depression (quantitative trait) / / 20800221 rs991632 chr7 112038730 G A 6.06E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs2523036 chr7 112040361 G C 8.28E-05 Depression (quantitative trait) / / 20800221 rs2520480 chr7 112044527 C T 8.31E-05 Depression (quantitative trait) / / 20800221 rs2520479 chr7 112047345 T C 7.57E-05 Depression (quantitative trait) / / 20800221 rs1557698 chr7 112050437 A G 7.60E-05 Depression (quantitative trait) / / 20800221 rs2520484 chr7 112062186 T C 4.67E-04 Depression (quantitative trait) IFRD1 nearGene-5 20800221 rs2520483 chr7 112062274 G C 5.23E-04 Depression (quantitative trait) IFRD1 nearGene-5 20800221 rs2708599 chr7 112063748 A G 4.72E-04 Depression (quantitative trait) IFRD1 intron 20800221 rs2520481 chr7 112064238 T C 5.72E-04 Depression (quantitative trait) IFRD1 intron 20800221 rs9640740 chr7 112064376 G A 3.34E-06 Brain derived neurotrophic factor levels,in serum IFRD1 intron 22047184 rs728273 chr7 112068101 G C 9.19E-04 Depression (quantitative trait) IFRD1 intron 20800221 rs11771128 chr7 112075293 G A 7.10E-05 Parkinson's disease (age of onset) IFRD1 intron 19772629 rs17159640 chr7 112086333 A T 9.00E-06 Heart failure IFRD1 intron 20400778 rs6966318 chr7 112092857 T C 5.46E-04 Cystic fibrosis(lung disease) IFRD1 intron 19242412 rs6956741 chr7 112094743 A G 2.00E-06 Amyotrophic lateral sclerosis (age of onset) IFRD1 intron 22959728 rs2529587 chr7 112102734 A G 7.88E-05 Cognitive impairment induced by topiramate IFRD1 intron 22091778 rs2529588 chr7 112103055 A G 4.00E-06 Cystic fibrosis(lung disease) IFRD1 intron 19242412 rs2708607 chr7 112109331 A G 7.88E-05 Cognitive impairment induced by topiramate IFRD1 intron 22091778 rs3128376 chr7 112129333 G A 7.86E-04 Bipolar disorder,schizoaffective C7orf53 intron 19567891 rs11767398 chr7 112130009 A C 5.95E-06 Post-traumatic stress disorder C7orf53 UTR-3 24080187 rs11772829 chr7 112140430 A G 2.50E-05 Urinary metabolites / / 21572414 rs2966473 chr7 112155176 C T 1.04E-04 IgE levels / / 17255346 rs5009270 chr7 112159178 G A 3.00E-06 Osteoarthritis (hip) / / 23989986 rs1981610 chr7 112166964 A G 2.26E-04 Cystic fibrosis(lung disease) / / 19242412 rs3111453 chr7 112169173 G A 4.38E-04 Taste perception / / 22132133 rs3111449 chr7 112194733 T C 2.99E-04 Cystic fibrosis(lung disease) / / 19242412 rs3128408 chr7 112205263 C A,G 1.90E-05 Urinary metabolites / / 21572414 rs11768435 chr7 112219017 C T 1.40E-05 Urinary metabolites / / 21572414 rs11769472 chr7 112220214 C A 4.90E-06 Urinary metabolites / / 21572414 rs1922901 chr7 112236153 A G 1.92E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs6977807 chr7 112249863 G A 3.20E-06 Urinary metabolites / / 21572414 rs1796502 chr7 112259849 T G 0.00077 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines / / 23204130 rs2966478 chr7 112261226 T C 9.78E-05 Prostate cancer / / 22923026 rs1234382 chr7 112262811 C T 4.39E-04 Multiple complex diseases / / 17554300 rs1796507 chr7 112278964 T G 6.48E-04 Insulin resistance / / 21901158 rs2966479 chr7 112290310 T C 9.00E-05 Prostate cancer / / 21743057 rs10244551 chr7 112352542 A T 4.66E-05 Insulin resistance / / 21901158 rs7806781 chr7 112420072 C T 6.60E-05 Alcoholism (heaviness of drinking) TMEM168 intron 21529783 rs2396570 chr7 112443541 G T 8.60E-05 Insulin resistance / / 21901158 rs7798366 chr7 112582173 T C 8.68E-04 Multiple complex diseases / / 17554300 rs10500013 chr7 112595762 C T 4.58E-05 Hemoglobin / / pha003098 rs10229603 chr7 112628373 T C 5.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs1017600 chr7 112632068 T C 8.13E-05 Cognitive impairment induced by topiramate / / 22091778 rs13221289 chr7 112646801 T C 6.58E-05 Monocyte counts / / pha003089 rs6969802 chr7 112649414 A G 3.00E-06 IgG glycosylation / / 23382691 rs6969802 chr7 112649414 A G 5.00E-06 IgG glycosylation / / 23382691 rs11983499 chr7 112654549 G T 7.31E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4730573 chr7 112675885 T C 2.43E-05 Monocyte counts / / pha003089 rs13221267 chr7 112716152 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2255323 chr7 112718186 C T 8.86E-09 Crohn's disease and psoriasis / / 22482804 rs1590154 chr7 112729182 A C 7.61E-04 Multiple complex diseases / / 17554300 rs1525804 chr7 112823086 G A 5.79E-05 Serum metabolites / / 19043545 rs10953726 chr7 112848629 T C 1.56E-04 Multiple complex diseases / / 17554300 rs10953726 chr7 112848629 T C 4.37E-06 Serum metabolites / / 19043545 rs7797620 chr7 112862269 G A 5.73E-04 Multiple complex diseases / / 17554300 rs7797620 chr7 112862269 G A 9.82E-05 Serum metabolites / / 19043545 rs10500023 chr7 112864760 G A 7.22E-04 Multiple complex diseases / / 17554300 rs10500023 chr7 112864760 G A 7.19E-05 Serum metabolites / / 19043545 rs6466440 chr7 112908788 T C 1.25E-04 Vaspin levels / / 22907691 rs6466440 chr7 112908788 T C 0.0001247 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs6466440 chr7 112908788 T C 0.0001898 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs10953730 chr7 112911410 A G 2.00E-07 Metabolite levels / / 19043545 rs6962650 chr7 112922865 T C 9.88E-05 Vaspin levels / / 22907691 rs6962650 chr7 112922865 T C 0.0000988 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs6962650 chr7 112922865 T C 0.0001873 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs6947946 chr7 112924068 A G 1.26E-05 Serum metabolites / / 19043545 rs13240515 chr7 112948157 G A 7.30E-05 Serum metabolites / / 19043545 rs1701821 chr7 112950671 G A 3.66E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs1722332 chr7 112989772 T C 6.67E-04 Tourette syndrome / / 22889924 rs2692198 chr7 112994204 A G 6.61E-05 Bipolar disorder and schizophrenia / / 20889312 rs17498088 chr7 113008273 G A 0.0000597 Panic disorder / / 23149450 rs17498088 chr7 113008273 G A 5.97E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs1701843 chr7 113008823 G A 6.40E-04 Multiple complex diseases / / 17554300 rs17136288 chr7 113027011 T A 5.72E-05 Bipolar disorder and schizophrenia / / 20889312 rs1404228 chr7 113050788 A G 1.91E-04 Alzheimer's disease / / 24755620 rs17136351 chr7 113123047 C T 4.20E-07 HIV-1 viral setpoint / / 17641165 rs2940341 chr7 113209562 G A 4.01E-05 Post-operative nausea and vomiting / / 21694509 rs2462671 chr7 113236510 T A 8.10E-06 Urinary metabolites / / 21572414 rs10487510 chr7 113302262 A G 7.98E-05 Post-operative nausea and vomiting / / 21694509 rs2188422 chr7 113339175 C A 0.000359483 Hypertension (early onset hypertension) / / 22479346 rs10240330 chr7 113436542 C T 2.77E-04 Aortic root size / / 21223598 rs2023692 chr7 113438644 G A 0.0000038 Major depressive disorder / / 22915352 rs4574781 chr7 113461464 G A 5.78E-04 Multiple complex diseases / / 17554300 rs10500037 chr7 113707787 T C 9.10E-04 Crohn's disease / / 17684544 rs6466479 chr7 113741105 T G 2.00E-06 IgG glycosylation FOXP2 intron 23382691 rs6466479 chr7 113741105 T G 2.00E-06 IgG glycosylation FOXP2 intron 23382691 rs6466479 chr7 113741105 T G 3.00E-06 IgG glycosylation FOXP2 intron 23382691 rs6466479 chr7 113741105 T G 4.00E-06 IgG glycosylation FOXP2 intron 23382691 rs6466479 chr7 113741105 T G 5.00E-07 IgG glycosylation FOXP2 intron 23382691 rs6466479 chr7 113741105 T G 6.00E-06 IgG glycosylation FOXP2 intron 23382691 rs6466479 chr7 113741105 T G 7.00E-06 IgG glycosylation FOXP2 intron 23382691 rs10243972 chr7 113826438 G A 8.82E-05 Waist-Hip Ratio FOXP2 intron pha003013 rs10243972 chr7 113826438 G A 7.21E-05 Waist Circumference FOXP2 intron pha003025 rs12112572 chr7 113924219 T C 1.72E-05 Platelet counts FOXP2 intron 21507922 rs2690833 chr7 113997624 C T 5.45E-04 Smoking initiation FOXP2 intron 24665060 rs12705959 chr7 113998246 C T 2.43E-05 Cardiovascular disease FOXP2 intron pha003065 rs10249531 chr7 114014574 T C 7.90E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs2396724 chr7 114033544 G A 4.52E-04 Smoking initiation FOXP2 intron 24665060 rs2396751 chr7 114115049 A G 2.90E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs2189011 chr7 114115268 T C 2.90E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs17372022 chr7 114119935 T G 9.90E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs2106900 chr7 114122506 C T 3.20E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs2189008 chr7 114123308 C T 3.30E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs17372211 chr7 114128992 G A 8.50E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs12113612 chr7 114139684 G A 3.20E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs9649368 chr7 114143651 T A 3.00E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs10279936 chr7 114147217 C A 3.20E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs17372842 chr7 114159242 G A 4.12E-04 Response to cytadine analogues (cytosine arabinoside) FOXP2 intron 24483146 rs6957330 chr7 114164165 A G 8.50E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs10486023 chr7 114178653 A G 5.32E-04 Suicide attempts in bipolar disorder FOXP2 intron 21423239 rs6953359 chr7 114188174 A G 6.59E-04 Response to cytadine analogues (cytosine arabinoside) FOXP2 intron 24483146 rs17374201 chr7 114214120 A T 1.00E-25 Narcolepsy FOXP2 intron 19629137 rs936146 chr7 114294405 G C 6.40E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs10250103 chr7 114294942 C T 6.40E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs6966051 chr7 114296104 C T 7.53E-04 Smoking cessation FOXP2 intron 24665060 rs12154391 chr7 114300717 T C 6.60E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs1005958 chr7 114302855 A G 6.60E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs1563408 chr7 114303189 G A 8.20E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs4730637 chr7 114303833 G A 8.40E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs1378771 chr7 114304563 C T 7.90E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs1378772 chr7 114304630 A T 7.80E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs2396765 chr7 114304969 T C 7.70E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs12705970 chr7 114307150 C G 6.40E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs12705971 chr7 114310053 G T 6.70E-05 White matter hyperintensity burden FOXP2 intron 21681796 rs12705978 chr7 114334482 G A 6.00E-05 White matter hyperintensity burden / / 21681796 rs12705979 chr7 114334571 C T 5.90E-05 White matter hyperintensity burden / / 21681796 rs12705980 chr7 114334843 G A 6.00E-05 White matter hyperintensity burden / / 21681796 rs12705981 chr7 114334957 A C 6.30E-05 White matter hyperintensity burden / / 21681796 rs12705982 chr7 114336114 C T 5.30E-05 White matter hyperintensity burden / / 21681796 rs12705984 chr7 114337615 G A 6.70E-05 White matter hyperintensity burden / / 21681796 rs12705985 chr7 114337975 G A 9.00E-05 White matter hyperintensity burden / / 21681796 rs7795485 chr7 114338815 T C 3.49E-04 Alzheimer's disease (late onset) / / 21379329 rs662217 chr7 114345500 T C 3.97E-04 Type 2 diabetes / / 17463246 rs647318 chr7 114346537 T G 9.48E-04 Type 2 diabetes / / 17463246 rs647318 chr7 114346537 T G 3.65E-04 Multiple complex diseases / / 17554300 rs13246064 chr7 114347493 G A 9.80E-05 White matter hyperintensity burden / / 21681796 rs13222712 chr7 114348562 C A 9.80E-05 White matter hyperintensity burden / / 21681796 rs12705988 chr7 114355002 A G 6.45E-04 Alcohol dependence / / 21314694 rs1378769 chr7 114355097 A G 4.17E-04 Type 2 diabetes / / 17463246 rs1869839 chr7 114357543 A G 7.00E-06 Crohn's disease / / 22936669 rs627579 chr7 114360951 C A 4.45E-04 Type 2 diabetes / / 17463246 rs647055 chr7 114372026 T C 3.80E-04 Type 2 diabetes / / 17846126 rs589252 chr7 114382389 A G 9.33E-04 Type 2 diabetes / / 17463246 rs17137211 chr7 114392509 A T 2.04E-04 Type 2 diabetes / / 17463246 rs6942664 chr7 114399271 A T 4.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs6945846 chr7 114402916 T C 7.90E-06 White matter hyperintensity burden / / 21681796 rs6945846 chr7 114402916 T C 0.000103 white matter hyperintensity burden / / 23674528 rs1530680 chr7 114407396 T G 1.70E-04 Reading disability and language impairment / / 24024963 rs12667130 chr7 114425799 G A 6.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9649371 chr7 114428313 C T 3.00E-04 Type 2 diabetes / / 17463246 rs1448351 chr7 114447648 A G 3.37E-04 Type 2 diabetes / / 17463246 rs289194 chr7 114454794 T C 8.32E-04 Type 2 diabetes / / 17463246 rs2007801 chr7 114473540 G A 9.57E-04 Type 2 diabetes / / 17463246 rs2007801 chr7 114473540 G A 4.63E-04 Multiple complex diseases / / 17554300 rs2157825 chr7 114476011 G A 6.72E-04 Type 2 diabetes / / 17463246 rs4730650 chr7 114506265 C T 5.13E-04 Taste perception / / 22132133 rs12705999 chr7 114516019 C T 6.19E-04 Type 2 diabetes / / 17463246 rs4727809 chr7 114592049 G A 3.71E-04 HIV-1 viral setpoint MDFIC intron 17641165 rs12538651 chr7 114613275 A G 2.77E-05 Tunica Media MDFIC intron pha003034 rs7786588 chr7 114625346 T A 6.29E-04 Aortic root size MDFIC intron 21223598 rs7784447 chr7 114629285 G A 4.00E-06 Obesity MDFIC intron 23818313 rs7792017 chr7 114642928 A G 3.51E-04 Aortic root size MDFIC intron 21223598 rs13237006 chr7 114658486 A G 4.36E-04 Alcohol dependence MDFIC UTR-3 21314694 rs17585678 chr7 114663162 G C 9.32E-04 Depression (quantitative trait) / / 20800221 rs998903 chr7 114663499 G A 7.70E-05 Lung adenocarcinoma / / 22797724 rs7791565 chr7 114672720 A G 9.79E-04 Depression (quantitative trait) / / 20800221 rs1978097 chr7 114682603 G T 2.27E-04 Depression (quantitative trait) / / 20800221 rs425956 chr7 114719858 T C 5.40E-05 Cognitive test performance / / 20125193 rs2460485 chr7 114736232 T C 7.58E-04 Depression (quantitative trait) / / 20800221 rs7795179 chr7 114736595 A G 3.60E-05 Lung adenocarcinoma / / 22797724 rs1476479 chr7 114739166 C T 2.80E-05 Urinary metabolites / / 21572414 rs12706009 chr7 114750436 C T 9.40E-04 Depression (quantitative trait) / / 20800221 rs13229627 chr7 114772802 T C 5.80E-05 Lung adenocarcinoma / / 22797724 rs6466518 chr7 114863612 C G 9.25E-04 Type 2 diabetes / / 17463246 rs79274420 chr7 114914128 A G 4.79E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs10274759 chr7 114914608 A G 3.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2188540 chr7 114964446 T C 4.73E-04 Type 2 diabetes / / 17463246 rs12706029 chr7 114988956 G A 8.23E-04 Coronary heart disease / / 21606135 rs9641538 chr7 115031575 G A 9.62E-05 Insulin resistance / / 21901158 rs17228457 chr7 115031894 C T 6.75E-04 Coronary heart disease / / 21606135 rs1527741 chr7 115050715 T C 8.93E-04 Coronary heart disease / / 21606135 rs9641540 chr7 115082872 A C 1.33E-05 Sickle cell anemia (severity) / / 20029952 rs1534378 chr7 115087024 T C 5.51E-05 Cognitive decline / / 22054870 rs4645504 chr7 115087633 C T 3.76E-04 Coronary heart disease / / 21606135 rs11521023 chr7 115100690 A G 2.59E-05 Hypertension / / 19609347 rs4730682 chr7 115104563 T C 6.98E-04 Alzheimer's disease / / 17998437 rs1544011 chr7 115134092 C T 8.18E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4727818 chr7 115135220 A G 5.86E-04 Smoking initiation / / 24665060 rs1918526 chr7 115138008 G A 7.00E-06 Smoking cessation / / 24665060 rs7788749 chr7 115146784 T C 1.20E-05 Smoking cessation / / 24665060 rs1918528 chr7 115153775 G T 5.92E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6955743 chr7 115155837 G T 7.87E-06 Intelligence / / 21826061 rs1534376 chr7 115156835 A C 6.98E-06 Intelligence / / 21826061 rs11773711 chr7 115169343 G A 4.93E-04 Acute lung injury / / 22295056 rs7790613 chr7 115174007 C A 2.93E-04 Multiple complex diseases / / 17554300 rs7790613 chr7 115174007 C A 4.93E-04 Acute lung injury / / 22295056 rs6977572 chr7 115181271 T A 1.51E-04 Smoking cessation / / 24665060 rs1986847 chr7 115257756 C T 4.29E-05 Blood pressure / / 17255346 rs10251693 chr7 115283613 T C 1.10E-05 Cocaine dependence / / 23958962 rs10251693 chr7 115283613 T C 7.12E-05 Cocaine dependence / / 23958962 rs10267413 chr7 115327840 T C 4.40E-04 Myasthenia gravis / / 23055271 rs6466555 chr7 115362547 A G 4.20E-04 Myasthenia gravis / / 23055271 rs10245192 chr7 115374142 A G 4.50E-04 Myasthenia gravis / / 23055271 rs6946417 chr7 115375732 T C 4.40E-04 Myasthenia gravis / / 23055271 rs12706046 chr7 115412350 A G 1.90E-05 Telomere length / / 23001564 rs11979121 chr7 115447435 A G 0.000045 Menopause (age at onset) / / 23424626 rs11979121 chr7 115447435 A G 5.84E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs10500052 chr7 115456973 A G 3.23E-05 HIV-1 viral setpoint / / 17641165 rs10273354 chr7 115473965 G A 2.38E-04 Hemoglobin concentration / / 20534544 rs6950702 chr7 115480352 A G 1.29E-05 Telomere length / / 23001564 rs7783740 chr7 115485745 G T 2.38E-04 Hemoglobin concentration / / 20534544 rs6948855 chr7 115525876 G A 8.41E-04 Type 2 diabetes / / 17463246 rs2402002 chr7 115563547 C T 9.81E-04 Tourette syndrome / / 22889924 rs10253192 chr7 115609848 T C 5.76E-04 Type 2 diabetes TFEC intron 17463246 rs11764575 chr7 115611309 G A 6.00E-05 Prostate cancer TFEC intron 21743057 rs11767053 chr7 115619298 C T 6.00E-05 Prostate cancer TFEC intron 21743057 rs6466562 chr7 115647212 G A 1.00E-04 Cognitive impairment induced by topiramate TFEC intron 22091778 rs1003252 chr7 115656320 A G 8.47E-04 Type 2 diabetes TFEC intron 17463246 rs17301900 chr7 115668022 C T 1.70E-05 Urinary metabolites TFEC intron 21572414 rs17302005 chr7 115669432 A G 1.80E-05 Urinary metabolites TFEC intron 21572414 rs17302122 chr7 115677373 C T 2.10E-05 Urinary metabolites / / 21572414 rs1464776 chr7 115708565 T G 1.55E-06 Systemic lupus erythematosus / / pha002867 rs10269713 chr7 115744180 G A 2.19E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs12374699 chr7 115747757 C T 5.25E-05 Orofacial clefts / / 22419666 rs2402053 chr7 115836797 T C 3.67E-05 Serum metabolites / / 19043545 rs17248419 chr7 115924557 C T 8.86E-05 Blood Pressure / / pha003046 rs6952197 chr7 115945391 A C 4.71E-05 Blood Pressure / / pha003046 rs10263833 chr7 115946754 T C 6.21E-05 Blood Pressure / / pha003046 rs6466573 chr7 115949014 G A 8.47E-05 Blood Pressure / / pha003046 rs10276740 chr7 115949929 T C 7.71E-05 Blood Pressure / / pha003046 rs17138596 chr7 115955097 T C 4.98E-04 Insulin resistance / / 21901158 rs1918910 chr7 115959205 T C 8.56E-05 Schizophrenia / / 19571811 rs2697061 chr7 116001042 C T 4.79E-04 Multiple complex diseases / / 17554300 rs2157799 chr7 116003990 A T 4.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs1180290 chr7 116006052 C G 9.71E-04 Multiple complex diseases / / 17554300 rs11772856 chr7 116034844 C T 1.60E-04 Osteoarthritis / / 19508968 rs10252986 chr7 116043100 G A 4.66E-04 Depression (quantitative trait) / / 20800221 rs1918923 chr7 116044566 A G 3.45E-05 Personality dimensions / / 18957941 rs1918923 chr7 116044566 A G 4.65E-04 Depression (quantitative trait) / / 20800221 rs1918924 chr7 116044688 G T 2.99E-05 Personality dimensions / / 18957941 rs1918924 chr7 116044688 G T 4.68E-04 Depression (quantitative trait) / / 20800221 rs10247635 chr7 116047011 G C,T 3.73E-04 Depression (quantitative trait) / / 20800221 rs10247800 chr7 116047190 G A 5.05E-04 Depression (quantitative trait) / / 20800221 rs17138675 chr7 116055528 C T 3.04E-04 Coronary heart disease / / 21606135 rs10237417 chr7 116057028 A G 4.95E-04 Depression (quantitative trait) / / 20800221 rs6952334 chr7 116063402 A G 4.43E-04 Depression (quantitative trait) / / 20800221 rs10228039 chr7 116067175 G A 3.45E-05 Personality dimensions / / 18957941 rs10228039 chr7 116067175 G A 4.39E-04 Depression (quantitative trait) / / 20800221 rs10227962 chr7 116067291 C A,G 4.41E-04 Depression (quantitative trait) / / 20800221 rs6963408 chr7 116072835 A G 4.38E-04 Depression (quantitative trait) / / 20800221 rs10282315 chr7 116073292 A G 4.34E-04 Depression (quantitative trait) / / 20800221 rs10464649 chr7 116073567 C T 6.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs17138685 chr7 116074348 T C 1.56E-04 Multiple complex diseases / / 17554300 rs6466577 chr7 116079236 G A 4.11E-04 Depression (quantitative trait) / / 20800221 rs111886141 chr7 116080283 T G 2.29E-11 Metabolite levels / / 22286219 rs12706089 chr7 116084367 T C 6.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs9656238 chr7 116095006 A G 4.54E-04 Depression (quantitative trait) / / 20800221 rs717957 chr7 116113107 G C 9.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs926197 chr7 116118330 C A 1.90E-04 Taste perception / / 22132133 rs6975771 chr7 116122845 A G 3.17E-05 Brain structure / / 22504417 rs6976316 chr7 116122943 G A 7.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs10228178 chr7 116132211 G A 8.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs17138749 chr7 116133098 A C 3.02E-04 Taste perception / / 22132133 rs4730742 chr7 116137892 T G 5.80E-05 Glaucoma (primary open-angle) CAV2 nearGene-5 20835238 rs2270188 chr7 116140524 G T 8.02E-04 Suicide attempts in bipolar disorder CAV2 intron 21423239 rs10271007 chr7 116145849 A G 5.25E-04 Suicide attempts in bipolar disorder CAV2 intron 21423239 rs10271007 chr7 116145849 A G 3.14E-05 Glycemic traits (pregnancy) CAV2 intron 23903356 rs10271007 chr7 116145849 A G 6.10E-05 Glycemic traits (pregnancy) CAV2 intron 23903356 rs4730743 chr7 116145957 A T 5.32E-04 Suicide attempts in bipolar disorder CAV2 intron 21423239 rs4730743 chr7 116145957 A T 3.94E-05 Glycemic traits (pregnancy) CAV2 intron 23903356 rs4727833 chr7 116147908 C G 4.61E-04 Suicide attempts in bipolar disorder CAV2 UTR-3 21423239 rs4727833 chr7 116147908 C G 1.84E-04 Taste perception CAV2 UTR-3 22132133 rs4727833 chr7 116147908 C G 6.68E-05 Glycemic traits (pregnancy) CAV2 UTR-3 23903356 rs1052990 chr7 116148370 T G 1.10E-09 Glaucoma (primary open-angle) CAV2 UTR-3 20835238 rs1052990 chr7 116148370 T G 6.00E-06 Taste perception CAV2 UTR-3 22132133 rs6466579 chr7 116151155 T C 5.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs6466579 chr7 116151155 T C 3.97E-04 Taste perception / / 22132133 rs3919515 chr7 116151784 G C 8.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs3919515 chr7 116151784 G C 7.02E-05 Glycemic traits (pregnancy) / / 23903356 rs4236601 chr7 116162729 G A 2.00E-11 Glaucoma (primary open-angle) / / 20835238 rs3807986 chr7 116177825 G A 6.03E-04 Suicide attempts in bipolar disorder CAV1 intron 21423239 rs3807989 chr7 116186241 A G 4.00E-28 PR interval CAV1 intron 20062060 rs3807989 chr7 116186241 A G 7.00E-13 Electrocardiographic traits CAV1 intron 20062063 rs3807989 chr7 116186241 A G 4.00E-12 Atrial fibrillation CAV1 intron 22544366 rs3807989 chr7 116186241 A G 5.00E-12 PR segment CAV1 intron 24850809 rs3815412 chr7 116190693 T C 7.96E-04 Suicide attempts in bipolar disorder CAV1 intron 21041247 rs11773845 chr7 116191301 C A 4.00E-12 PR interval CAV1 intron 23139255 rs11773845 chr7 116191301 C A 4.33E-11 PR segment CAV1 intron 24850809 rs1997572 chr7 116198828 A G 1.51E-11 PR segment CAV1 intron 24850809 rs1049337 chr7 116200587 C T 8.30E-11 PR segment CAV1 UTR-3 24850809 rs147347909 chr7 116202067 T C 8.57E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs6959106 chr7 116204058 T C 1.94E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs11974088 chr7 116205306 C T 6.77E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs7802124 chr7 116205914 T C 2.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2052106 chr7 116206665 A G 4.23E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2052106 chr7 116206665 A G 8.08E-10 PR segment / / 24850809 rs11979486 chr7 116206894 T G 3.02E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs6976011 chr7 116210739 C T 4.22E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs7795356 chr7 116217029 T C 3.68E-06 Adiponectin levels / / 20887962 rs2402091 chr7 116218675 A G 5.34E-05 Systemic sclerosis / / 21750679 rs2402091 chr7 116218675 A G 2.08E-05 Orofacial clefts / / 22419666 rs7800573 chr7 116224638 G T 3.86E-06 Adiponectin levels / / 20887962 rs7800573 chr7 116224638 G T 1.50E-05 Urinary metabolites / / 21572414 rs1002399 chr7 116285715 T C 5.00E-04 Polycystic ovary syndrome / / 22178785 rs42476 chr7 116296778 G A 4.23E-05 Polycystic ovary syndrome / / 22178785 rs38833 chr7 116303551 A G 7.00E-04 Polycystic ovary syndrome / / 22178785 rs38841 chr7 116319926 A G 9.59E-04 Type 2 diabetes MET intron 17463246 rs10487353 chr7 116323936 G T 9.15E-05 Cognitive impairment induced by topiramate MET intron 22091778 rs10243024 chr7 116346603 G A 6.00E-06 Multiple sclerosis (severity) MET intron 19010793 rs38852 chr7 116354525 T A 8.15E-05 Serum metabolites MET intron 19043545 rs38855 chr7 116358044 A G 2.00E-08 Triglycerides MET intron 24097068 rs2402118 chr7 116428573 A C 2.00E-04 Cognitive impairment induced by topiramate MET intron 22091778 rs41751 chr7 116449050 T C 5.87E-04 Multiple complex diseases / / 17554300 rs41775 chr7 116478649 G A 2.85E-04 Multiple complex diseases / / 17554300 rs7782376 chr7 116577124 G A 8.00E-06 Cognitive performance / / 20125193 rs7776604 chr7 116613167 C T 3.54E-05 Multiple complex diseases ST7 intron 17554300 rs2429032 chr7 116685621 G T 1.60E-05 Urinary metabolites ST7 intron 21572414 rs2429010 chr7 116736682 G A 7.56E-04 Type 2 diabetes ST7 intron 17463246 rs13226446 chr7 116888161 A G 5.48E-05 Cholesterol / / 17255346 rs13226446 chr7 116888161 A G 1.64E-06 Waist-hip ratio / / 20935629 rs13226446 chr7 116888161 A G 1.00E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs13226446 chr7 116888161 A G 6.62E-06 Lung function (forced vital capacity) / / pha003104 rs38902 chr7 116889718 G A 3.92E-04 Multiple complex diseases / / 17554300 rs38904 chr7 116892846 T C 1.00E-08 Inflammatory bowel disease / / 23128233 rs6958283 chr7 116901160 T C 7.92E-04 Multiple complex diseases / / 17554300 rs10256129 chr7 116904528 G A 2.09E-04 Multiple complex diseases / / 17554300 rs10280067 chr7 116906682 T C 3.07E-04 Multiple complex diseases / / 17554300 rs10235236 chr7 116906912 A T 2.31E-04 Multiple complex diseases / / 17554300 rs6951125 chr7 116914043 G A 4.03E-04 Multiple complex diseases / / 17554300 rs4730775 chr7 116917118 C T 3.00E-08 Dupuytren's disease WNT2 UTR-3 21732829 rs39312 chr7 116954785 A C 4.37E-05 Cardiovascular disease WNT2 intron 17903304 rs39317 chr7 116966304 G A 6.72E-05 Cardiovascular disease / / 17903304 rs6977665 chr7 116976830 A G 9.42E-05 Bipolar disorder / / 19488044 rs2023708 chr7 116981071 G A 8.58E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11761305 chr7 116987910 C T 3.73E-05 Alzheimer's disease (late onset) / / 21379329 rs9886209 chr7 117005224 C A 6.95E-05 Cardiovascular disease ASZ1 intron 17903304 rs4730778 chr7 117016924 G C 9.55E-04 Suicide attempts in bipolar disorder ASZ1 intron 21423239 rs4730779 chr7 117023535 G A 4.00E-06 Waist circumference ASZ1 intron 23966867 rs1029396 chr7 117024820 T G 7.84E-04 Suicide attempts in bipolar disorder ASZ1 missense 21423239 rs7805063 chr7 117041069 C T 8.77E-05 Non-alcoholic fatty liver disease histology (other) ASZ1 intron 20708005 rs4730781 chr7 117044221 G T 3.56E-04 Multiple complex diseases ASZ1 intron 17554300 rs10953842 chr7 117044682 T G 2.69E-04 Multiple complex diseases ASZ1 intron 17554300 rs10487364 chr7 117058220 A G 5.25E-06 Bilirubin levels,in serum ASZ1 intron 19389676 rs7808424 chr7 117067822 T G 1.00E-06 Coronary heart disease / / 21378990 rs7808424 chr7 117067822 T G 7.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs4730786 chr7 117104891 G A 4.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs4148682 chr7 117119183 T G 7.44E-04 Suicide attempts in bipolar disorder CFTR nearGene-5 21423239 rs2283054 chr7 117126401 G A 6.68E-04 Suicide attempts in bipolar disorder CFTR intron 21423239 rs2237721 chr7 117133720 T C 6.05E-04 Suicide attempts in bipolar disorder CFTR intron 21423239 rs4148686 chr7 117134517 C G 1.13E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses CFTR intron 17903301 rs4148688 chr7 117135025 G C 1.90E-04 Statin-induced myopathy CFTR intron 21826682 rs4148698 chr7 117173114 T C 5.65E-04 Suicide attempts in bipolar disorder CFTR intron 21423239 rs2237725 chr7 117181152 A G 4.40E-04 Suicide attempts in bipolar disorder CFTR intron 21423239 rs4148703 chr7 117181509 G A 8.12E-04 Suicide attempts in bipolar disorder CFTR intron 21423239 rs213950 chr7 117199533 G A 9.67E-05 Non-alcoholic fatty liver disease histology (other) CFTR missense 20708005 rs1896887 chr7 117200481 G C 8.91E-06 Statin-induced myopathy CFTR intron 21826682 rs1896886 chr7 117200510 G T 5.42E-04 Suicide attempts in bipolar disorder CFTR intron 21423239 rs3808185 chr7 117214089 T C 6.94E-04 Suicide attempts in bipolar disorder CFTR intron 21423239 rs1469486 chr7 117219835 C T 8.14E-04 Suicide attempts in bipolar disorder CFTR intron 21423239 rs4148709 chr7 117220684 G A 1.32E-04 Suicide attempts in bipolar disorder CFTR intron 21423239 rs3808183 chr7 117230780 T C 1.78E-04 Suicide attempts in bipolar disorder CFTR intron 21423239 rs11978434 chr7 117231852 T C 6.72E-05 IgE levels CFTR intron 17255346 rs1042077 chr7 117235055 T A,G 2.00E-04 IgE levels CFTR cds-synon 17255346 rs2299445 chr7 117246315 A C 1.15E-04 Suicide attempts in bipolar disorder CFTR intron 21423239 rs2237726 chr7 117256374 C T 1.19E-04 Suicide attempts in bipolar disorder CFTR intron 21423239 rs17451754 chr7 117256712 G A 5.34E-04 Suicide attempts in bipolar disorder CFTR intron 21423239 rs7797932 chr7 117257687 C T 2.21E-04 Suicide attempts in bipolar disorder CFTR intron 21423239 rs213988 chr7 117262304 G A 2.03E-06 Paclitaxel sensitivity in NCI60 cancer cell lines CFTR intron 21314952 rs2254742 chr7 117264126 T C 3.85E-04 Suicide attempts in bipolar disorder CFTR intron 21423239 rs12534186 chr7 117292336 C T 4.67E-04 Suicide attempts in bipolar disorder CFTR intron 21423239 rs17140297 chr7 117300259 C G 2.10E-04 IgE levels CFTR intron 17255346 rs2283058 chr7 117302910 A C 8.05E-04 Suicide attempts in bipolar disorder CFTR intron 21423239 rs6980032 chr7 117303145 C A 2.10E-04 IgE levels CFTR intron 17255346 rs17549557 chr7 117303243 G T 2.10E-04 IgE levels CFTR intron 17255346 rs4148724 chr7 117305151 C T 3.97E-04 Suicide attempts in bipolar disorder CFTR intron 21423239 rs4727855 chr7 117305374 G A 2.88E-04 IgE levels CFTR intron 17255346 rs13237279 chr7 117314915 G A 8.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs12672572 chr7 117324640 C T 6.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs4730795 chr7 117337912 C A 3.06E-04 IgE levels / / 17255346 rs369002355 chr7 117337948 CT C 7.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs4373465 chr7 117337948 C G 7.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs7784537 chr7 117367930 A G 3.42E-04 Suicide attempts in bipolar disorder CTTNBP2 intron 21423239 rs757278 chr7 117377645 G T 5.00E-07 Response to methotrexate in juvenile idiopathic arthritis CTTNBP2 intron 24709693 rs10487375 chr7 117423860 C T 4.24E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CTTNBP2 intron 20031582 rs7800668 chr7 117459043 G C 6.00E-06 Response to methotrexate in juvenile idiopathic arthritis CTTNBP2 intron 24709693 rs10273158 chr7 117480396 G A 4.60E-04 Type 2 diabetes CTTNBP2 intron 17463246 rs6466626 chr7 117482870 A C 2.21E-05 Brain structure CTTNBP2 intron 22504417 rs7807677 chr7 117502574 C T 1.54E-04 Iron levels CTTNBP2 intron pha002876 rs10259910 chr7 117503982 T G 7.98E-04 Multiple complex diseases CTTNBP2 intron 17554300 rs6965740 chr7 117514840 T G 1.40E-05 Urinary metabolites / / 21572414 rs6965740 chr7 117514840 T G 2.28E-04 Iron levels / / pha002876 rs115255079 chr7 117528054 T C 7.28E-05 Response to methotrexate in juvenile idiopathic arthritis / / 24709693 rs12667152 chr7 117536046 G T 2.88E-05 Depression (quantitative trait) / / 23290196 rs11977246 chr7 117536700 T C 3.10E-05 Depression (quantitative trait) / / 23290196 rs17488749 chr7 117544391 G A 8.16E-06 Depression (quantitative trait) / / 23290196 rs17488784 chr7 117544428 T A 8.28E-06 Depression (quantitative trait) / / 23290196 rs2158050 chr7 117578862 C G 9.85E-04 Multiple complex diseases / / 17554300 rs16870152 chr7 117579363 T C 2.46E-05 Depression (quantitative trait) / / 23290196 rs2188833 chr7 117580488 G T 4.45E-04 Multiple complex diseases / / 17554300 rs916784 chr7 117599514 A G 7.59E-04 Iron levels / / pha002876 rs7801876 chr7 117602126 A G 6.69E-04 Iron levels / / pha002876 rs10280709 chr7 117613109 C T 6.37E-04 Iron levels / / pha002876 rs12706164 chr7 117613287 G A,T 5.23E-05 Pancreatic cancer / / pha002874 rs7793280 chr7 117617919 C T 7.07E-04 Iron levels / / pha002876 rs7777391 chr7 117621877 A G 4.78E-04 Type 2 diabetes / / 17463246 rs7777391 chr7 117621877 A G 1.00E-04 Primary sclerosing cholangitis / / 19944697 rs7777391 chr7 117621877 A G 2.70E-06 Alcohol dependence / / 20202923 rs7777391 chr7 117621877 A G 3.00E-07 Alcohol dependence / / 22096494 rs7777391 chr7 117621877 A G 2.50E-06 Alcohol and nictotine co-dependence / / 22488850 rs1859032 chr7 117631978 G A 9.44E-04 Myopia (pathological) / / 21095009 rs7456706 chr7 117669962 C A 8.33E-05 Pancreatic cancer / / pha002874 rs1319470 chr7 117670654 C T 7.50E-04 Myopia (pathological) / / 21095009 rs12537079 chr7 117704706 T G 6.95E-07 Prostate cancer / / 24185611 rs38828 chr7 117716385 T C 7.24E-05 Orofacial clefts / / 22419666 rs38828 chr7 117716385 T C 8.06E-05 Coronary heart disease / / pha003031 rs38831 chr7 117719876 C T 5.19E-05 Coronary heart disease / / pha003030 rs6466643 chr7 117739400 C T 7.27E-05 Serum metabolites / / 19043545 rs11771456 chr7 117777412 T C 7.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs17140937 chr7 117788484 T C 9.94E-07 Common variable immunodeficiency / / 21497890 rs1054032 chr7 117835656 A T 7.41E-05 Serum metabolites /A38 UTR-3 19043545 rs41905 chr7 117893776 G C 6.42E-05 Serum metabolites / / 19043545 rs41943 chr7 117960973 T C 1.61E-04 Pancreatic cancer / / pha002874 rs20598 chr7 117965959 C T 2.26E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs41962 chr7 117976279 A C 9.60E-05 Parkinson's disease / / 17052657 rs41988 chr7 117989281 T C 3.08E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs41997 chr7 117991895 A G 4.00E-07 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs17584024 chr7 117998472 C T 3.70E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs4727865 chr7 118005595 G A 3.51E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs17584359 chr7 118006306 C T 4.66E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs1014268 chr7 118035388 A C 5.52E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs6959273 chr7 118041733 C T 7.84E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs7808154 chr7 118068040 C T 8.34E-05 Coronary heart disease / / pha003030 rs881802 chr7 118099945 T G 4.94E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs13230485 chr7 118116178 G A 4.52E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs2106595 chr7 118159549 G A 3.59E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs2106595 chr7 118159549 G A 5.00E-06 Smoking behavior / / 23049750 rs10953870 chr7 118205866 C A 2.15E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs1510498 chr7 118216736 G T 7.71E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1355313 chr7 118222312 G A 2.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13244206 chr7 118268560 T C 5.55E-04 Obesity (extreme) / / 21935397 rs13226251 chr7 118325614 A T 8.98E-04 Obesity (extreme) / / 21935397 rs778858 chr7 118329337 C T 2.57E-04 Type 2 diabetes / / 17463246 rs2136768 chr7 118332808 G C 3.00E-04 Spine bone size / / 21947420 rs11767120 chr7 118336837 C T 4.00E-04 Spine bone size / / 21947420 rs1721221 chr7 118346511 T G 4.23E-05 Bipolar disorder,affective / / 20528957 rs1912492 chr7 118346890 T C 4.70E-05 Hypertension / / 19609347 rs2689751 chr7 118387417 C T 2.24E-05 Cognitive performance / / 19734545 rs13226384 chr7 118423031 G T 9.41E-05 Cognitive impairment induced by topiramate / / 22091778 rs2204779 chr7 118438184 T C 8.44E-05 Cognitive performance / / 19734545 rs2590585 chr7 118452826 A T 1.90E-05 Urinary metabolites / / 21572414 rs10500069 chr7 118515456 A G 8.30E-04 Crohn's disease / / 17684544 rs10249276 chr7 118578684 A G 0.000000799 Alcohol consumption / / 22613542 rs10281955 chr7 118584691 G A 0.000000872 Alcohol consumption / / 22613542 rs4268066 chr7 118601105 C T 0.000000344 Alcohol consumption / / 22613542 rs10953881 chr7 118608125 C T 0.000000821 Alcohol consumption / / 22613542 rs10953885 chr7 118608403 T C 0.000000663 Alcohol consumption / / 22613542 rs4518581 chr7 118610655 G A 0.000000407 Alcohol consumption / / 22613542 rs7812233 chr7 118618162 G A 0.000000859 Alcohol consumption / / 22613542 rs6466686 chr7 118636817 C T 5.86E-08 Alcohol consumption / / 22613542 rs4295599 chr7 118637655 A C 0.0000579 Alcohol consumption / / 22613542 rs4730908 chr7 118658010 C G 0.000000112 Alcohol consumption / / 22613542 rs10238286 chr7 118709754 T G 5.21E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs2402460 chr7 118775101 A C 6.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2402455 chr7 118792218 T G 6.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6976018 chr7 118817770 C T 6.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2402465 chr7 118825110 G A 6.26E-05 Serum metabolites / / 19043545 rs6962597 chr7 118876711 T G 4.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11978545 chr7 118923413 T C 5.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1489123 chr7 118941365 C T 7.10E-04 Multiple complex diseases / / 17554300 rs170099 chr7 119000212 C T 0.000000716 Alcohol consumption / / 22613542 rs949687 chr7 119085238 C T 1.42E-04 Multiple complex diseases / / 17554300 rs4130671 chr7 119277137 A C 4.29E-05 Serum metabolites / / 19043545 rs10464520 chr7 119283017 G A 3.76E-05 Serum metabolites / / 19043545 rs11532787 chr7 119301786 C T 3.49E-05 Body Mass Index / / pha003006 rs11532787 chr7 119301786 C T 4.22E-05 Body Mass Index / / pha003007 rs11532787 chr7 119301786 C T 7.74E-05 Body Fat Distribution / / pha003016 rs11532787 chr7 119301786 C T 3.65E-05 Waist Circumference / / pha003025 rs4727899 chr7 119349199 G A 4.37E-05 Longevity / / 21612516 rs1524204 chr7 119438294 A G 6.88E-05 Multiple complex diseases / / 17554300 rs846427 chr7 119493570 T C 3.82E-05 Longevity / / 21612516 rs10231641 chr7 119572391 C T 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs13234712 chr7 119579473 A G 1.25E-05 Left ventricular hypertrophy / / pha003052 rs10233545 chr7 119583406 G A 4.23E-05 Left ventricular hypertrophy / / pha003052 rs17142462 chr7 119606632 C T 3.00E-09 Immune reponse to smallpox (secreted IL-12p40) / / 22610502 rs6965513 chr7 119658991 G A 4.16E-05 Multiple complex diseases / / 17554300 rs6963590 chr7 119701068 G A 1.99E-05 Multiple complex diseases / / 17554300 rs7792606 chr7 119766504 T C 3.53E-04 Multiple complex diseases / / 17554300 rs7778213 chr7 120003915 C T 9.08E-04 Amyotrophic lateral sclerosis (sporadic) KCND2 intron 24529757 rs917901 chr7 120096711 C T 6.70E-04 Heroin addiction KCND2 intron 20520587 rs7785571 chr7 120112487 C T 4.53E-04 Alzheimer's disease (late onset) KCND2 intron 21379329 rs12531042 chr7 120114294 A C 4.44E-04 Alzheimer's disease (late onset) KCND2 intron 21379329 rs12531042 chr7 120114294 A C 6.52E-05 Cytomegalovirus antibody response KCND2 intron 21993531 rs17142782 chr7 120138084 A G 3.35E-04 Multiple complex diseases KCND2 intron 17554300 rs10268591 chr7 120144923 A G 5.24E-05 Bipolar disorder KCND2 intron 17486107 rs702416 chr7 120155270 C T 2.61E-04 Epilepsy KCND2 intron 22116939 rs802333 chr7 120156307 T C 5.12E-04 Epilepsy KCND2 intron 22116939 rs10488301 chr7 120167316 C T 2.00E-04 Information processing speed KCND2 intron 21130836 rs10488301 chr7 120167316 C T 1.64E-05 Schizophrenia KCND2 intron 24253340 rs802372 chr7 120169316 A G 4.16E-04 Epilepsy KCND2 intron 22116939 rs10488302 chr7 120180671 C A 5.96E-05 Bipolar disorder and schizophrenia KCND2 intron 20889312 rs17142823 chr7 120195608 T C 8.32E-04 Multiple complex diseases KCND2 intron 17554300 rs728115 chr7 120305149 G A 4.00E-06 Alcohol and nictotine co-dependence KCND2 intron 22488850 rs41474345 chr7 120321318 C T 2.36E-04 Multiple complex diseases KCND2 intron 17554300 rs10239799 chr7 120405335 C T 4.89E-10 Autism / / 22935194 rs12154976 chr7 120410201 C T 3.35E-04 Multiple complex diseases / / 17554300 rs17617539 chr7 120588565 T C 6.60E-06 Urinary metabolites / / 21572414 rs17617539 chr7 120588565 T C 8.60E-04 Sleep quality / / 23728906 rs6964344 chr7 120591936 A G 4.22E-05 Monocyte chemoattractant protein-1 ING3 intron pha003071 rs6964344 chr7 120591936 A G 3.50E-05 Sodium levels ING3 intron pha003093 rs2525724 chr7 120609943 A G 1.90E-05 Sleep and circadian phenotypes ING3 intron 17903308 rs41688 chr7 120633006 A G 6.80E-05 Response to lithium treatment in bipolar disorder C7orf58 intron 19448189 rs6949989 chr7 120641731 C T 6.30E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs7782552 chr7 120646897 G A 6.30E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1118142 chr7 120648485 C T 9.80E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6958635 chr7 120654148 G C 5.20E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10277935 chr7 120654290 A G 2.20E-05 Urinary metabolites C7orf58 intron 21572414 rs10277935 chr7 120654290 A G 4.60E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10953923 chr7 120661851 G A 1.50E-05 Urinary metabolites C7orf58 intron 21572414 rs10953923 chr7 120661851 G A 5.50E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1981711 chr7 120664459 A G 1.70E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs12706305 chr7 120666663 C A 1.70E-11 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs12706306 chr7 120666769 G T 1.70E-11 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6944789 chr7 120671034 A G 6.20E-06 Urinary metabolites C7orf58 intron 21572414 rs6944789 chr7 120671034 A G 1.40E-11 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs2896299 chr7 120674048 T A 9.50E-04 Type 2 diabetes and 6 quantitative traits C7orf58 intron 17848626 rs2058501 chr7 120680236 C T 1.40E-11 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10257314 chr7 120680841 C T 1.00E-11 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs2721375 chr7 120704289 C T 7.00E-13 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs2538491 chr7 120705176 A G 1.70E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs2538492 chr7 120705246 A C 1.90E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6466766 chr7 120705300 T C 2.85E-12 Bone mineral density C7orf58 intron 22792070 rs6466766 chr7 120705300 T C 1.80E-15 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6466766 chr7 120705300 T C 3.00E-13 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs2192289 chr7 120706892 G A 1.40E-11 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs2402554 chr7 120709059 A C 1.10E-11 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs9641653 chr7 120709280 C T 5.90E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10268570 chr7 120709789 T G 5.90E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs2721349 chr7 120710473 C G 5.70E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs9690143 chr7 120710973 A G 3.00E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10261386 chr7 120711855 C T 4.14E-09 Bone mineral density C7orf58 intron 22792070 rs2192291 chr7 120712972 A T 1.90E-08 Bone mineral density C7orf58 intron 22792070 rs13246689 chr7 120712996 T C 7.02E-13 Bone mineral density C7orf58 intron 22792070 rs13246689 chr7 120712996 T C 1.60E-15 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs13246689 chr7 120712996 T C 6.90E-14 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs2402555 chr7 120713364 A T 2.21E-08 Bone mineral density C7orf58 intron 22792070 rs11977285 chr7 120714457 G A 2.21E-08 Bone mineral density C7orf58 intron 22792070 rs6962509 chr7 120714475 G A 1.28E-08 Bone mineral density C7orf58 intron 22792070 rs6962260 chr7 120714512 A G 8.10E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs11766764 chr7 120714924 G T 8.43E-13 Bone mineral density C7orf58 intron 22792070 rs11766764 chr7 120714924 G T 1.30E-15 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs11766764 chr7 120714924 G T 8.70E-14 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs10953924 chr7 120715129 T C 7.60E-13 Bone mineral density C7orf58 intron 22792070 rs10953924 chr7 120715129 T C 1.10E-13 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs10953924 chr7 120715129 T C 1.30E-15 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10953925 chr7 120715154 A G 6.07E-13 Bone mineral density C7orf58 intron 22792070 rs10953925 chr7 120715154 A G 3.40E-15 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10953925 chr7 120715154 A G 6.90E-14 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs12672958 chr7 120716129 T C 2.13E-08 Bone mineral density C7orf58 intron 22792070 rs12666340 chr7 120716152 A C 1.95E-08 Bone mineral density C7orf58 intron 22792070 rs12666345 chr7 120716188 A G 2.13E-08 Bone mineral density C7orf58 intron 22792070 rs10275526 chr7 120716537 T C 1.78E-08 Bone mineral density C7orf58 intron 22792070 rs2110280 chr7 120718419 T C 1.96E-12 Bone mineral density C7orf58 intron 22792070 rs2110280 chr7 120718419 T C 1.80E-13 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs2110280 chr7 120718419 T C 5.40E-15 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs17143147 chr7 120719961 C T 1.01E-08 Bone mineral density C7orf58 intron 22792070 rs17143147 chr7 120719961 C T 3.61E-05 Endometrial cancer C7orf58 intron 24096698 rs17143147 chr7 120719961 C T 4.28E-05 Endometrial cancer C7orf58 intron 24096698 rs17143147 chr7 120719961 C T 2.60E-09 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs17143147 chr7 120719961 C T 3.20E-08 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6976513 chr7 120720438 T C 8.70E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6956851 chr7 120720657 C A 2.90E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs7790569 chr7 120720819 G A 7.80E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs17536644 chr7 120721025 A G 1.87E-10 Bone mineral density C7orf58 intron 22792070 rs17536644 chr7 120721025 A G 1.10E-09 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs17536644 chr7 120721025 A G 1.10E-10 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs759157 chr7 120722308 G A 4.90E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs4140913 chr7 120722943 A G 4.30E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1024743 chr7 120725427 A C 3.20E-14 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs2110281 chr7 120725809 G A 3.15E-21 Bone mineral density C7orf58 intron 22792070 rs2110281 chr7 120725809 G A 2.10E-25 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs2110281 chr7 120725809 G A 2.10E-33 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs2110281 chr7 120725809 G A 4.70E-08 Bone mineral density (paediatric,total body less head) C7orf58 intron 24945404 rs2160013 chr7 120725996 C T 2.30E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs2968349 chr7 120726926 A C 2.23E-08 Bone mineral density C7orf58 intron 22792070 rs2968349 chr7 120726926 A C 2.90E-18 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs2968349 chr7 120726926 A C 3.40E-26 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs2968345 chr7 120728872 A G 1.57E-21 Bone mineral density C7orf58 intron 22792070 rs2968345 chr7 120728872 A G 1.50E-25 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs2968345 chr7 120728872 A G 9.40E-34 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6466767 chr7 120731577 C G 9.25E-22 Bone mineral density C7orf58 intron 22792070 rs6466767 chr7 120731577 C G 1.50E-25 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6466767 chr7 120731577 C G 4.80E-33 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1917114 chr7 120732120 A G 4.09E-16 Bone mineral density C7orf58 intron 22792070 rs1917114 chr7 120732120 A G 2.60E-13 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1917114 chr7 120732120 A G 8.30E-18 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1917113 chr7 120735062 G A 3.43E-22 Bone mineral density C7orf58 intron 22792070 rs1917113 chr7 120735062 G A 1.40E-32 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1917113 chr7 120735062 G A 3.30E-26 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs12673968 chr7 120737058 G A 6.41E-22 Bone mineral density C7orf58 intron 22792070 rs12673968 chr7 120737058 G A 2.10E-25 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs12673968 chr7 120737058 G A 9.70E-33 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1005400 chr7 120738269 A G 3.41E-16 Bone mineral density C7orf58 intron 22792070 rs1005400 chr7 120738269 A G 1.70E-17 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1005400 chr7 120738269 A G 2.60E-13 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs798937 chr7 120740103 G T 2.30E-11 Bone mineral density (paediatric,upper limb) C7orf58 cds-synon 24945404 rs1917112 chr7 120740225 C G 2.51E-11 Bone mineral density C7orf58 intron 22792070 rs1917112 chr7 120740225 C G 2.00E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1917112 chr7 120740225 C G 2.60E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs798938 chr7 120741223 T C 2.20E-11 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6466769 chr7 120742103 A G 1.53E-22 Bone mineral density C7orf58 intron 22792070 rs6466769 chr7 120742103 A G 1.90E-32 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6466769 chr7 120742103 A G 3.10E-26 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6954757 chr7 120743182 G A 8.52E-23 Bone mineral density C7orf58 intron 22792070 rs6954757 chr7 120743182 G A 1.90E-32 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6954757 chr7 120743182 G A 2.10E-26 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs17143161 chr7 120746209 A G 3.00E-11 Bone mineral density C7orf58 intron 22792070 rs17143161 chr7 120746209 A G 4.80E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs17143161 chr7 120746209 A G 5.40E-11 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs798939 chr7 120747228 A G 2.40E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs13223036 chr7 120747308 T G 1.05E-24 Bone mineral density C7orf58 intron 22792070 rs13223036 chr7 120747308 T G 2.59E-08 Cortical thickness C7orf58 intron 22792071 rs13223036 chr7 120747308 T G 1.20E-34 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs13223036 chr7 120747308 T G 2.00E-28 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs13223036 chr7 120747308 T G 3.00E-22 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs13226812 chr7 120748257 T G 1.30E-09 Bone mineral density C7orf58 intron 22792070 rs13226812 chr7 120748257 T G 1.00E-08 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs13226812 chr7 120748257 T G 1.70E-13 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs798940 chr7 120748775 C T 1.50E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10230185 chr7 120751399 A C 3.09E-08 Cortical thickness C7orf58 intron 22792071 rs10251139 chr7 120755002 G C 8.22E-12 Bone mineral density C7orf58 intron 22792070 rs10251139 chr7 120755002 G C 1.40E-10 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs10251139 chr7 120755002 G C 4.00E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs798943 chr7 120758899 G A 2.59E-10 Bone mineral density C7orf58 intron 22792070 rs798943 chr7 120758899 G A 1.03E-08 Cortical thickness C7orf58 intron 22792071 rs798943 chr7 120758899 G A 1.00E-37 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs798943 chr7 120758899 G A 1.30E-08 Bone mineral density (paediatric,total body less head) C7orf58 intron 24945404 rs798943 chr7 120758899 G A 3.00E-32 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs798943 chr7 120758899 G A 9.40E-28 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs798946 chr7 120762842 T C 1.02E-08 Cortical thickness C7orf58 intron 22792071 rs10225539 chr7 120762908 G A 2.93E-08 Cortical thickness C7orf58 intron 22792071 rs798947 chr7 120763212 G A 1.50E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1524498 chr7 120764477 G C 8.94E-12 Bone mineral density C7orf58 cds-synon 22792070 rs1524498 chr7 120764477 G C 1.70E-10 Bone mineral density (paediatric,skull) C7orf58 cds-synon 24945404 rs1524498 chr7 120764477 G C 3.30E-10 Bone mineral density (paediatric,upper limb) C7orf58 cds-synon 24945404 rs1558541 chr7 120764775 G C 8.94E-12 Bone mineral density C7orf58 intron 22792070 rs1558541 chr7 120764775 G C 1.70E-10 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1558541 chr7 120764775 G C 3.30E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs798949 chr7 120765954 T C 6.61E-04 Alcohol dependence C7orf58 intron 21314694 rs798949 chr7 120765954 T C 1.65E-12 Bone mineral density C7orf58 intron 22792070 rs798949 chr7 120765954 T C 4.00E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs798949 chr7 120765954 T C 4.30E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs13221538 chr7 120768246 C T 1.18E-08 Cortical thickness C7orf58 intron 22792071 rs13221538 chr7 120768246 C T 5.40E-17 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs12706314 chr7 120772486 G A 1.48E-12 Bone mineral density C7orf58 intron 22792070 rs12706314 chr7 120772486 G A 1.90E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs12706314 chr7 120772486 G A 7.10E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs17283542 chr7 120772964 A G 1.80E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs7801723 chr7 120774160 C T 2.72E-10 Bone mineral density C7orf58 intron 22792070 rs7801723 chr7 120774160 C T 9.75E-09 Cortical thickness C7orf58 intron 22792071 rs7801723 chr7 120774160 C T 1.10E-08 Bone mineral density (paediatric,total body less head) C7orf58 intron 24945404 rs7801723 chr7 120774160 C T 2.60E-28 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs7801723 chr7 120774160 C T 4.50E-37 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs12706318 chr7 120774941 A G 2.72E-10 Bone mineral density C7orf58 intron 22792070 rs12706318 chr7 120774941 A G 9.69E-09 Cortical thickness C7orf58 intron 22792071 rs12706318 chr7 120774941 A G 2.10E-08 Bone mineral density (paediatric,total body less head) C7orf58 intron 24945404 rs12706318 chr7 120774941 A G 6.40E-37 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs12706318 chr7 120774941 A G 9.40E-28 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs13232048 chr7 120776281 G T 2.72E-10 Bone mineral density C7orf58 intron 22792070 rs13232048 chr7 120776281 G T 9.64E-09 Cortical thickness C7orf58 intron 22792071 rs13232048 chr7 120776281 G T 2.10E-08 Bone mineral density (paediatric,total body less head) C7orf58 intron 24945404 rs13232048 chr7 120776281 G T 6.40E-37 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs13232048 chr7 120776281 G T 9.40E-28 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs13235373 chr7 120776757 G A 1.80E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6947453 chr7 120777183 G T 1.42E-08 Bone mineral density C7orf58 intron 22792070 rs6947453 chr7 120777183 G T 1.10E-24 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6947453 chr7 120777183 G T 9.10E-31 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6952113 chr7 120777619 G A 3.32E-10 Bone mineral density C7orf58 intron 22792070 rs6952113 chr7 120777619 G A 9.49E-09 Cortical thickness C7orf58 intron 22792071 rs6952113 chr7 120777619 G A 1.00E-36 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6952113 chr7 120777619 G A 1.90E-27 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6952113 chr7 120777619 G A 2.10E-08 Bone mineral density (paediatric,total body less head) C7orf58 intron 24945404 rs10259383 chr7 120778011 T C 1.27E-11 Bone mineral density C7orf58 intron 22792070 rs10259383 chr7 120778011 T C 3.10E-10 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs10259383 chr7 120778011 T C 4.80E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10248011 chr7 120778814 G A 1.11E-11 Bone mineral density C7orf58 intron 22792070 rs10248011 chr7 120778814 G A 2.10E-10 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs10248011 chr7 120778814 G A 3.30E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10248019 chr7 120778831 G A 1.04E-08 Cortical thickness C7orf58 intron 22792071 rs10248019 chr7 120778831 G A 6.90E-17 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs872007 chr7 120779949 C T 3.23E-10 Bone mineral density C7orf58 intron 22792070 rs872007 chr7 120779949 C T 9.47E-09 Cortical thickness C7orf58 intron 22792071 rs872007 chr7 120779949 C T 1.00E-36 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs872007 chr7 120779949 C T 1.90E-27 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs872007 chr7 120779949 C T 2.60E-08 Bone mineral density (paediatric,total body less head) C7orf58 intron 24945404 rs2177578 chr7 120781350 G A 1.00E-11 Bone mineral density C7orf58 intron 22792070 rs2177578 chr7 120781350 G A 2.10E-10 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs2177578 chr7 120781350 G A 3.30E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10275439 chr7 120783425 A G 4.57E-10 Bone mineral density C7orf58 intron 22792070 rs10275439 chr7 120783425 A G 3.59E-08 Cortical thickness C7orf58 intron 22792071 rs10275439 chr7 120783425 A G 1.50E-36 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10275439 chr7 120783425 A G 2.90E-27 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs10275439 chr7 120783425 A G 3.20E-08 Bone mineral density (paediatric,total body less head) C7orf58 intron 24945404 rs10261671 chr7 120783551 T C 4.19E-10 Bone mineral density C7orf58 intron 22792070 rs10261671 chr7 120783551 T C 2.10E-36 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10261671 chr7 120783551 T C 2.90E-08 Bone mineral density (paediatric,total body less head) C7orf58 intron 24945404 rs10261671 chr7 120783551 T C 3.90E-27 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs13245690 chr7 120785064 A G 2.00E-11 Bone mineral density C7orf58 intron 22504420 rs13245690 chr7 120785064 A G 3.37E-10 Bone mineral density C7orf58 intron 22792070 rs13245690 chr7 120785064 A G 1.88E-08 Cortical thickness C7orf58 intron 22792071 rs13245690 chr7 120785064 A G 1.00E-08 Bone mineral density (paediatric,total body less head) C7orf58 intron 24945404 rs13245690 chr7 120785064 A G 1.00E-36 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs13245690 chr7 120785064 A G 1.01E-08 Bone mineral density (paediatric,total body less head) C7orf58 intron 24945404 rs13245690 chr7 120785064 A G 1.03E-36 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs13245690 chr7 120785064 A G 2.88E-28 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs13245690 chr7 120785064 A G 2.90E-28 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1112208 chr7 120788288 A G 9.67E-12 Bone mineral density C7orf58 intron 22792070 rs1112208 chr7 120788288 A G 1.70E-10 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1112208 chr7 120788288 A G 3.30E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6950680 chr7 120790287 A G 3.10E-10 Bone mineral density C7orf58 intron 22792070 rs6950680 chr7 120790287 A G 6.48E-09 Cortical thickness C7orf58 intron 22792071 rs6950680 chr7 120790287 A G 1.30E-08 Bone mineral density (paediatric,total body less head) C7orf58 intron 24945404 rs6950680 chr7 120790287 A G 4.30E-28 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6950680 chr7 120790287 A G 7.20E-37 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10246521 chr7 120791130 A T 9.67E-12 Bone mineral density C7orf58 intron 22792070 rs10246521 chr7 120791130 A T 1.40E-10 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs10246521 chr7 120791130 A T 7.10E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs2402560 chr7 120792617 C T 5.60E-12 Bone mineral density C7orf58 intron 22792070 rs2402560 chr7 120792617 C T 6.70E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs2402560 chr7 120792617 C T 7.10E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs10235934 chr7 120793328 A G 8.91E-12 Bone mineral density C7orf58 intron 22792070 rs10235934 chr7 120793328 A G 6.70E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10235934 chr7 120793328 A G 7.10E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs2402561 chr7 120795567 T C 1.10E-11 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1125447 chr7 120797134 C A 5.24E-12 Bone mineral density C7orf58 intron 22792070 rs1125447 chr7 120797134 C A 6.70E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1125447 chr7 120797134 C A 7.10E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs10228519 chr7 120799084 G C 1.20E-19 Bone mineral density C7orf58 intron 22792070 rs10228519 chr7 120799084 G C 1.20E-16 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10228519 chr7 120799084 G C 6.60E-19 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs10215148 chr7 120799682 G A 5.24E-12 Bone mineral density C7orf58 intron 22792070 rs10215148 chr7 120799682 G A 6.70E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10215148 chr7 120799682 G A 7.10E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs10215475 chr7 120799792 T C 5.24E-12 Bone mineral density C7orf58 intron 22792070 rs10215475 chr7 120799792 T C 6.70E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10215475 chr7 120799792 T C 7.10E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs10232353 chr7 120799877 G C 3.83E-08 Cortical thickness C7orf58 intron 22792071 rs11531545 chr7 120799973 A G 5.89E-12 Bone mineral density C7orf58 intron 22792070 rs11531545 chr7 120799973 A G 4.30E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs11531545 chr7 120799973 A G 8.70E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1357755 chr7 120800837 T C 5.24E-12 Bone mineral density C7orf58 intron 22792070 rs1357755 chr7 120800837 T C 6.30E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1357755 chr7 120800837 T C 7.10E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6951173 chr7 120807362 C A 3.60E-08 Cortical thickness C7orf58 intron 22792071 rs10244109 chr7 120808200 G A 3.60E-08 Cortical thickness C7orf58 intron 22792071 rs10277559 chr7 120809246 A C 3.57E-08 Cortical thickness C7orf58 intron 22792071 rs4144090 chr7 120811339 T C 5.40E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10260002 chr7 120811681 G A 5.16E-09 Cortical thickness C7orf58 intron 22792071 rs10260631 chr7 120812143 G C 4.85E-09 Cortical thickness C7orf58 intron 22792071 rs11981613 chr7 120816063 T C 1.90E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10216123 chr7 120816389 T G 1.17E-11 Bone mineral density C7orf58 intron 22792070 rs10216123 chr7 120816389 T G 8.10E-10 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6971407 chr7 120816628 C T 7.50E-19 Bone mineral density C7orf58 intron 22792070 rs6971407 chr7 120816628 C T 3.30E-17 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6971407 chr7 120816628 C T 6.10E-13 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6972481 chr7 120817119 G C 7.82E-19 Bone mineral density C7orf58 intron 22792070 rs6972481 chr7 120817119 G C 4.20E-17 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6972481 chr7 120817119 G C 6.10E-13 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs13233295 chr7 120818489 C T 2.80E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs4730998 chr7 120819121 T C 1.36E-05 Endometrial cancer C7orf58 intron 24096698 rs4730998 chr7 120819121 T C 1.79E-04 Endometrial cancer C7orf58 intron 24096698 rs1404267 chr7 120820484 A G 2.20E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs7798060 chr7 120822386 C T 5.91E-09 Bone mineral density C7orf58 intron 22792070 rs7798060 chr7 120822386 C T 8.71E-10 Cortical thickness C7orf58 intron 22792071 rs7798060 chr7 120822386 C T 1.50E-29 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs7798060 chr7 120822386 C T 7.20E-24 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6965592 chr7 120822559 C A 2.82E-09 Cortical thickness C7orf58 intron 22792071 rs6965592 chr7 120822559 C A 9.21E-04 Response to cytadine analogues (cytosine arabinoside) C7orf58 intron 24483146 rs12706321 chr7 120825166 A G 5.93E-10 Bone mineral density C7orf58 intron 22792070 rs12706321 chr7 120825166 A G 2.90E-13 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs12706321 chr7 120825166 A G 9.70E-09 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs17143194 chr7 120825942 G A 1.90E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1554634 chr7 120826238 C T 5.71E-09 Bone mineral density C7orf58 intron 22792070 rs1554634 chr7 120826238 C T 7.38E-10 Cortical thickness C7orf58 intron 22792071 rs1554634 chr7 120826238 C T 1.20E-22 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1554634 chr7 120826238 C T 4.80E-29 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10085590 chr7 120832023 G A 5.44E-09 Bone mineral density C7orf58 intron 22792070 rs10085590 chr7 120832023 G A 7.17E-10 Cortical thickness C7orf58 intron 22792071 rs10085590 chr7 120832023 G A 4.10E-22 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs10085590 chr7 120832023 G A 6.70E-29 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs7808138 chr7 120836416 T A 2.82E-09 Cortical thickness C7orf58 intron 22792071 rs12706322 chr7 120839167 A G 1.70E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs13238393 chr7 120843117 A G 1.70E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs7797976 chr7 120843516 C T 9.75E-09 Bone mineral density C7orf58 intron 22792070 rs7797976 chr7 120843516 C T 7.11E-10 Cortical thickness C7orf58 intron 22792071 rs7797976 chr7 120843516 C T 2.30E-28 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs7797976 chr7 120843516 C T 2.70E-23 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6947494 chr7 120843708 T C 7.04E-09 Bone mineral density C7orf58 intron 22792070 rs6947494 chr7 120843708 T C 6.82E-10 Cortical thickness C7orf58 intron 22792071 rs6947494 chr7 120843708 T C 2.30E-22 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6947494 chr7 120843708 T C 6.70E-29 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1917118 chr7 120844324 C T 1.09E-08 Bone mineral density C7orf58 intron 22792070 rs1917118 chr7 120844324 C T 7.08E-10 Cortical thickness C7orf58 intron 22792071 rs1917118 chr7 120844324 C T 2.70E-22 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1917118 chr7 120844324 C T 6.00E-28 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10274486 chr7 120845243 T C 1.39E-10 Bone mineral density C7orf58 intron 22792070 rs10274486 chr7 120845243 T C 1.00E-08 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs13229354 chr7 120845747 G A 1.70E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6954210 chr7 120848385 G A 7.33E-04 Alzheimer's disease C7orf58 intron 17998437 rs6954210 chr7 120848385 G A 1.19E-08 Bone mineral density C7orf58 intron 22792070 rs6954210 chr7 120848385 G A 7.33E-10 Cortical thickness C7orf58 intron 22792071 rs6954210 chr7 120848385 G A 2.70E-22 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6954210 chr7 120848385 G A 6.00E-28 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6970762 chr7 120852034 A T 1.54E-08 Bone mineral density C7orf58 intron 22792070 rs6970762 chr7 120852034 A T 8.59E-10 Cortical thickness C7orf58 intron 22792071 rs6970762 chr7 120852034 A T 2.30E-28 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6970762 chr7 120852034 A T 2.70E-23 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1357756 chr7 120852193 T C 1.73E-08 Bone mineral density C7orf58 intron 22792070 rs1357756 chr7 120852193 T C 8.55E-10 Cortical thickness C7orf58 intron 22792071 rs1357756 chr7 120852193 T C 1.70E-22 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1357756 chr7 120852193 T C 6.70E-29 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1534015 chr7 120853065 A G 1.94E-08 Bone mineral density C7orf58 intron 22792070 rs1534015 chr7 120853065 A G 8.86E-10 Cortical thickness C7orf58 intron 22792071 rs1534015 chr7 120853065 A G 1.70E-22 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1534015 chr7 120853065 A G 6.70E-29 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs7786203 chr7 120853607 G A 6.36E-05 Alzheimer's disease C7orf58 intron 17998437 rs7786203 chr7 120853607 G A 2.51E-08 Bone mineral density C7orf58 intron 22792070 rs7786203 chr7 120853607 G A 8.47E-10 Cortical thickness C7orf58 intron 22792071 rs7786203 chr7 120853607 G A 3.60E-27 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs7786203 chr7 120853607 G A 4.90E-23 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs10251901 chr7 120855328 A G 2.30E-10 Bone mineral density C7orf58 intron 22792070 rs10251901 chr7 120855328 A G 1.00E-08 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs12706326 chr7 120855779 C A 2.75E-11 Bone mineral density C7orf58 intron 22792070 rs12706326 chr7 120855779 C A 3.20E-14 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs12706326 chr7 120855779 C A 3.60E-10 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1404268 chr7 120857747 A G 1.50E-08 Bone mineral density C7orf58 intron 22792070 rs1404268 chr7 120857747 A G 1.73E-09 Cortical thickness C7orf58 intron 22792071 rs1404268 chr7 120857747 A G 1.50E-24 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1404268 chr7 120857747 A G 1.50E-26 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1524503 chr7 120868003 A C 1.30E-04 Alzheimer's disease C7orf58 intron 17998437 rs1524503 chr7 120868003 A C 5.24E-09 Bone mineral density C7orf58 intron 22792070 rs1524503 chr7 120868003 A C 2.38E-09 Cortical thickness C7orf58 intron 22792071 rs1524503 chr7 120868003 A C 1.30E-28 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1524503 chr7 120868003 A C 2.70E-26 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1949803 chr7 120869625 G T 7.97E-09 Bone mineral density C7orf58 intron 22792070 rs1949803 chr7 120869625 G T 1.70E-11 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1949803 chr7 120869625 G T 8.80E-12 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs17284918 chr7 120870160 G A 3.94E-09 Bone mineral density C7orf58 intron 22792070 rs17284918 chr7 120870160 G A 5.80E-11 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs17284918 chr7 120870160 G A 7.80E-12 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6978080 chr7 120870955 C A 2.99E-09 Bone mineral density C7orf58 intron 22792070 rs6978080 chr7 120870955 C A 1.40E-11 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6978080 chr7 120870955 C A 2.50E-13 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs17357115 chr7 120872121 C A 3.30E-09 Bone mineral density C7orf58 intron 22792070 rs17357115 chr7 120872121 C A 4.80E-11 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs17357115 chr7 120872121 C A 9.60E-12 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs12672898 chr7 120872569 G A 2.99E-09 Bone mineral density C7orf58 intron 22792070 rs12672898 chr7 120872569 G A 1.40E-11 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs12672898 chr7 120872569 G A 3.10E-13 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs10953932 chr7 120872660 C G 3.09E-09 Bone mineral density C7orf58 intron 22792070 rs10953932 chr7 120872660 C G 1.40E-11 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10953932 chr7 120872660 C G 3.10E-13 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1534016 chr7 120873078 T C 6.03E-09 Bone mineral density C7orf58 intron 22792070 rs1534016 chr7 120873078 T C 1.80E-21 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1534016 chr7 120873078 T C 6.20E-24 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6965195 chr7 120873438 G A 6.03E-09 Bone mineral density C7orf58 intron 22792070 rs6965195 chr7 120873438 G A 1.80E-21 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6965195 chr7 120873438 G A 6.20E-24 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1534017 chr7 120874542 T C 2.99E-09 Bone mineral density C7orf58 intron 22792070 rs1534017 chr7 120874542 T C 1.40E-11 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1534017 chr7 120874542 T C 3.10E-13 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1524506 chr7 120877001 A T 5.97E-09 Bone mineral density C7orf58 intron 22792070 rs1524506 chr7 120877001 A T 1.60E-13 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1524506 chr7 120877001 A T 2.60E-11 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs11771945 chr7 120878361 C G 8.00E-10 Bone mineral density C7orf58 intron 22792070 rs11771945 chr7 120878361 C G 3.50E-23 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs11771945 chr7 120878361 C G 7.30E-21 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs11765163 chr7 120878702 A T 7.73E-10 Bone mineral density C7orf58 intron 22792070 rs11765163 chr7 120878702 A T 3.50E-23 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs11765163 chr7 120878702 A T 7.30E-21 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1534019 chr7 120879318 C T 1.98E-09 Bone mineral density C7orf58 intron 22792070 rs1534019 chr7 120879318 C T 1.20E-12 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1534019 chr7 120879318 C T 6.80E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10480747 chr7 120880573 A C 5.89E-10 Bone mineral density C7orf58 intron 22792070 rs10480747 chr7 120880573 A C 2.60E-23 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs10480747 chr7 120880573 A C 5.60E-21 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs7808120 chr7 120882722 G A 2.07E-09 Bone mineral density C7orf58 intron 22792070 rs7808120 chr7 120882722 G A 2.00E-12 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs7808120 chr7 120882722 G A 6.80E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1534014 chr7 120883281 A C 2.26E-09 Bone mineral density C7orf58 intron 22792070 rs1534014 chr7 120883281 A C 2.00E-12 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs1534014 chr7 120883281 A C 6.80E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10500083 chr7 120883602 T C 4.87E-10 Bone mineral density C7orf58 intron 22792070 rs10500083 chr7 120883602 T C 2.00E-23 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs10500083 chr7 120883602 T C 2.60E-20 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10230310 chr7 120883889 T C 4.90E-06 Urinary metabolites C7orf58 intron 21572414 rs7805374 chr7 120883911 T G 1.84E-09 Bone mineral density C7orf58 intron 22792070 rs7805374 chr7 120883911 T G 2.00E-12 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs7805374 chr7 120883911 T G 6.80E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs2272196 chr7 120884453 G A 5.17E-10 Bone mineral density C7orf58 intron 22792070 rs2272196 chr7 120884453 G A 1.80E-20 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs2272196 chr7 120884453 G A 2.00E-23 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs7792071 chr7 120885264 C G,T 8.53E-10 Bone mineral density C7orf58 intron 22792070 rs7792071 chr7 120885264 C G,T 4.40E-12 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs7792071 chr7 120885264 C G,T 4.70E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs7795660 chr7 120885323 C T 6.26E-10 Bone mineral density C7orf58 intron 22792070 rs7795660 chr7 120885323 C T 4.60E-23 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs7795660 chr7 120885323 C T 5.10E-21 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs7795692 chr7 120885423 A G 5.32E-10 Bone mineral density C7orf58 intron 22792070 rs7795692 chr7 120885423 A G 1.80E-20 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs7795692 chr7 120885423 A G 2.00E-23 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs7778938 chr7 120885505 T C 7.07E-10 Bone mineral density C7orf58 intron 22792070 rs7778938 chr7 120885505 T C 4.60E-23 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs7778938 chr7 120885505 T C 6.60E-21 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6466774 chr7 120886915 T C 2.13E-09 Bone mineral density C7orf58 intron 22792070 rs6466774 chr7 120886915 T C 2.00E-12 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6466774 chr7 120886915 T C 6.80E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs7806875 chr7 120888143 A T 2.34E-09 Bone mineral density C7orf58 intron 22792070 rs7806875 chr7 120888143 A T 2.00E-12 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs7806875 chr7 120888143 A T 8.20E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6979948 chr7 120888956 C T 1.76E-09 Bone mineral density C7orf58 intron 22792070 rs6979948 chr7 120888956 C T 5.70E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6979948 chr7 120888956 C T 6.90E-13 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6942652 chr7 120889272 G C 2.15E-09 Bone mineral density C7orf58 intron 22792070 rs6942652 chr7 120889272 G C 1.70E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6942652 chr7 120889272 G C 2.80E-09 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs11509199 chr7 120894677 C T 1.78E-09 Bone mineral density C7orf58 intron 22792070 rs11509199 chr7 120894677 C T 1.40E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs11509199 chr7 120894677 C T 2.40E-09 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10953933 chr7 120895261 C T 1.78E-09 Bone mineral density C7orf58 intron 22792070 rs10953933 chr7 120895261 C T 1.40E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs10953933 chr7 120895261 C T 2.40E-09 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs11770502 chr7 120895302 A G 1.19E-08 Bone mineral density C7orf58 intron 22792070 rs11770502 chr7 120895302 A G 1.10E-08 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs11770502 chr7 120895302 A G 8.60E-12 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs12706333 chr7 120897650 C T 2.15E-09 Bone mineral density C7orf58 intron 22792070 rs12706333 chr7 120897650 C T 1.70E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs12706333 chr7 120897650 C T 2.80E-09 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10266975 chr7 120898292 T C 2.15E-09 Bone mineral density C7orf58 intron 22792070 rs10266975 chr7 120898292 T C 1.20E-09 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10266975 chr7 120898292 T C 1.70E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs10225276 chr7 120898560 A G 2.15E-09 Bone mineral density C7orf58 intron 22792070 rs10225276 chr7 120898560 A G 1.20E-09 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10225276 chr7 120898560 A G 2.10E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6948725 chr7 120898661 T C 9.00E-10 Bone mineral density C7orf58 intron 22792070 rs6948725 chr7 120898661 T C 5.60E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6948725 chr7 120898661 T C 7.40E-10 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6967129 chr7 120899070 A G 2.14E-10 Bone mineral density C7orf58 intron 22792070 rs6967129 chr7 120899070 A G 3.50E-24 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6967129 chr7 120899070 A G 7.70E-20 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10274324 chr7 120899341 T G 3.82E-08 Cortical thickness C7orf58 intron 22792071 rs10229198 chr7 120899467 A G 4.51E-08 Cortical thickness C7orf58 intron 22792071 rs12539571 chr7 120900004 T C 2.33E-09 Bone mineral density C7orf58 intron 22792070 rs12539571 chr7 120900004 T C 1.50E-09 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs12539571 chr7 120900004 T C 2.60E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs12706334 chr7 120900014 A G 2.21E-10 Bone mineral density C7orf58 intron 22792070 rs12706334 chr7 120900014 A G 4.60E-24 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs12706334 chr7 120900014 A G 7.70E-20 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs10259598 chr7 120900162 C T 4.64E-08 Cortical thickness C7orf58 intron 22792071 rs4731006 chr7 120902676 G T 1.99E-10 Bone mineral density C7orf58 intron 22792070 rs4731006 chr7 120902676 G T 1.10E-19 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs4731006 chr7 120902676 G T 7.50E-24 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6970383 chr7 120902740 T C 2.22E-09 Bone mineral density C7orf58 intron 22792070 rs6970383 chr7 120902740 T C 1.90E-09 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6970383 chr7 120902740 T C 4.30E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs4609139 chr7 120903815 A T 1.00E-10 Bone mineral density C7orf58 intron 22792070 rs4609139 chr7 120903815 A T 1.10E-19 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs4609139 chr7 120903815 A T 1.10E-24 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs6947934 chr7 120904135 T C 2.43E-09 Bone mineral density C7orf58 intron 22792070 rs6947934 chr7 120904135 T C 2.30E-09 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs6947934 chr7 120904135 T C 5.20E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs4731007 chr7 120904659 A G 2.21E-09 Bone mineral density C7orf58 intron 22792070 rs4731007 chr7 120904659 A G 2.30E-09 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs4731007 chr7 120904659 A G 5.20E-11 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs798924 chr7 120905433 A G 5.63E-04 Multiple complex diseases C7orf58 intron 17554300 rs2536150 chr7 120908082 T C 2.59E-25 Bone mineral density C7orf58 intron 22792070 rs2536150 chr7 120908082 T C 1.30E-18 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs2536150 chr7 120908082 T C 7.00E-21 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs798913 chr7 120908198 G A 4.81E-08 Bone mineral density C7orf58 intron 22792070 rs798913 chr7 120908198 G A 2.10E-08 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs17508510 chr7 120908459 A T 3.70E-09 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs2536149 chr7 120908822 G A 3.30E-15 Bone mineral density C7orf58 intron 22792070 rs2536149 chr7 120908822 G A 7.40E-13 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs2536149 chr7 120908822 G A 7.50E-13 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs2691034 chr7 120908956 A G 5.38E-08 Bone mineral density C7orf58 intron 22792070 rs2691034 chr7 120908956 A G 1.70E-08 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs2536148 chr7 120915987 C T 1.27E-14 Bone mineral density C7orf58 intron 22792070 rs2536148 chr7 120915987 C T 1.30E-12 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs2536148 chr7 120915987 C T 8.40E-13 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs798905 chr7 120918780 T C 3.51E-08 Bone mineral density C7orf58 intron 22792070 rs798903 chr7 120919495 C T 1.64E-13 Bone mineral density C7orf58 intron 22792070 rs798903 chr7 120919495 C T 6.70E-14 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs2952559 chr7 120920169 G C 6.22E-23 Bone mineral density C7orf58 intron 22792070 rs2952559 chr7 120920169 G C 7.50E-20 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs2952559 chr7 120920169 G C 8.30E-15 Bone mineral density (paediatric,skull) C7orf58 intron 24945404 rs798902 chr7 120920258 G A 4.20E-09 Bone mineral density (paediatric,upper limb) C7orf58 intron 24945404 rs1547960 chr7 120945217 A G 1.70E-05 Bone mineral density (spine) / / 19079262 rs13247600 chr7 120950910 G C 1.02E-12 Bone mineral density / / 22792070 rs13247600 chr7 120950910 G C 2.50E-13 Bone mineral density (paediatric,upper limb) / / 24945404 rs2908007 chr7 120962164 A G 1.80E-08 Cortical thickness / / 22792071 rs2908007 chr7 120962164 A G 1.00E-09 Bone properties (heel) / / 24430505 rs2908007 chr7 120962164 A G 2.00E-59 Bone properties (heel) / / 24430505 rs2908007 chr7 120962164 A G 4.00E-35 Bone properties (heel) / / 24430505 rs3757552 chr7 120963965 A G 4.06E-13 Bone mineral density WNT16 nearGene-5 22792070 rs3757552 chr7 120963965 A G 1.60E-09 Bone mineral density (paediatric,upper limb) WNT16 nearGene-5 24945404 rs3779381 chr7 120966790 A G 8.84E-13 Bone mineral density WNT16 intron 22792070 rs3779381 chr7 120966790 A G 1.59E-11 Cortical thickness WNT16 intron 22792071 rs3779381 chr7 120966790 A G 1.10E-21 Bone mineral density (paediatric,upper limb) WNT16 intron 24945404 rs3779381 chr7 120966790 A G 4.60E-16 Bone mineral density (paediatric,total body less head) WNT16 intron 24945404 rs2908004 chr7 120969769 G A 9.11E-16 Bone mineral density WNT16 missense 22792070 rs2908004 chr7 120969769 G A 1.00E-15 Bone mineral density WNT16 missense 22792071 rs2908004 chr7 120969769 G A 1.00E-09 Bone mineral density (paediatric,lower limb) WNT16 missense 24945404 rs2908004 chr7 120969769 G A 1.40E-32 Bone mineral density (paediatric,upper limb) WNT16 missense 24945404 rs2908004 chr7 120969769 G A 2.90E-18 Bone mineral density (paediatric,total body less head) WNT16 missense 24945404 rs2908004 chr7 120969769 G A 3.00E-11 Bone mineral density (paediatric,lower limb) WNT16 missense 24945404 rs2908004 chr7 120969769 G A 3.60E-09 Bone mineral density (paediatric,skull) WNT16 missense 24945404 rs116350731 chr7 120971816 T C 0.000022 Prostate cancer (advanced) WNT16 missense 23555315 rs2536189 chr7 120973621 C G 1.07E-15 Bone mineral density WNT16 intron 22792070 rs2536189 chr7 120973621 C G 8.45E-16 Cortical thickness WNT16 intron 22792071 rs2536189 chr7 120973621 C G 2.00E-32 Bone mineral density (paediatric,upper limb) WNT16 intron 24945404 rs2536189 chr7 120973621 C G 3.50E-09 Bone mineral density (paediatric,skull) WNT16 intron 24945404 rs2536189 chr7 120973621 C G 3.70E-11 Bone mineral density (paediatric,lower limb) WNT16 intron 24945404 rs2536189 chr7 120973621 C G 3.80E-18 Bone mineral density (paediatric,total body less head) WNT16 intron 24945404 rs3801387 chr7 120974765 A G 3.00E-51 Bone mineral density WNT16 intron 22504420 rs3801387 chr7 120974765 A G 4.68E-15 Bone mineral density WNT16 intron 22792070 rs3801387 chr7 120974765 A G 3.56E-13 Cortical thickness WNT16 intron 22792071 rs3801387 chr7 120974765 A G 0.000000403 Femoral neck bone mineral density (premenopausal) WNT16 intron 23074152 rs3801387 chr7 120974765 A G 1.30E-11 Lumbar spine bone mineral density (premenopausal) WNT16 intron 23074152 rs3801387 chr7 120974765 A G 2.31E-05 Bone mineral density WNT16 intron 24249740 rs3801387 chr7 120974765 A G 8.53E-07 Bone mineral density WNT16 intron 24249740 rs3801387 chr7 120974765 A G 9.80E-08 Bone mineral density WNT16 intron 24249740 rs3801387 chr7 120974765 A G 4.70E-08 Bone mineral density (paediatric,skull) WNT16 intron 24945404 rs3801387 chr7 120974765 A G 4.71E-08 Bone mineral density (paediatric,skull) WNT16 intron 24945404 rs3801387 chr7 120974765 A G 4.97E-27 Bone mineral density (paediatric,upper limb) WNT16 intron 24945404 rs3801387 chr7 120974765 A G 5.00E-27 Bone mineral density (paediatric,upper limb) WNT16 intron 24945404 rs3801387 chr7 120974765 A G 5.40E-19 Bone mineral density (paediatric,total body less head) WNT16 intron 24945404 rs3801387 chr7 120974765 A G 5.44E-19 Bone mineral density (paediatric,total body less head) WNT16 intron 24945404 rs3801387 chr7 120974765 A G 8.80E-09 Bone mineral density (paediatric,lower limb) WNT16 intron 24945404 rs3801387 chr7 120974765 A G 8.82E-09 Bone mineral density (paediatric,lower limb) WNT16 intron 24945404 rs111841453 chr7 120976886 A AG 3.95E-04 Lymphocyte counts WNT16 intron 22286170 rs2707469 chr7 120976886 A G 3.95E-04 Lymphocyte counts WNT16 intron 22286170 rs3801385 chr7 120977543 T C 3.86E-10 Bone mineral density WNT16 intron 22792070 rs2707466 chr7 120979089 C T 9.98E-13 Bone mineral density WNT16 missense 22792070 rs2707466 chr7 120979089 C T 2.00E-10 Cortical thickness WNT16 missense 22792071 rs2707466 chr7 120979089 C T 1.90E-10 Bone mineral density (paediatric,lower limb) WNT16 missense 24945404 rs2707466 chr7 120979089 C T 1.90E-16 Bone mineral density (paediatric,total body less head) WNT16 missense 24945404 rs2707466 chr7 120979089 C T 4.10E-29 Bone mineral density (paediatric,upper limb) WNT16 missense 24945404 rs10242100 chr7 120983343 A G 2.00E-10 Bone mineral density / / 24249740 rs2536182 chr7 120990837 C G 2.07E-14 Bone mineral density FAM3C intron 22792070 rs2536182 chr7 120990837 C G 1.68E-14 Cortical thickness FAM3C intron 22792071 rs2536182 chr7 120990837 C G 1.40E-16 Bone mineral density (paediatric,total body less head) FAM3C intron 24945404 rs2536182 chr7 120990837 C G 1.50E-09 Bone mineral density (paediatric,lower limb) FAM3C intron 24945404 rs2536182 chr7 120990837 C G 4.30E-08 Bone mineral density (paediatric,skull) FAM3C intron 24945404 rs2536182 chr7 120990837 C G 6.00E-31 Bone mineral density (paediatric,upper limb) FAM3C intron 24945404 rs2536180 chr7 120994673 T C 6.63E-14 Bone mineral density FAM3C intron 22792070 rs2536180 chr7 120994673 T C 2.15E-14 Cortical thickness FAM3C intron 22792071 rs2536180 chr7 120994673 T C 1.10E-31 Bone mineral density (paediatric,upper limb) FAM3C intron 24945404 rs2536180 chr7 120994673 T C 3.00E-08 Bone mineral density (paediatric,skull) FAM3C intron 24945404 rs2536180 chr7 120994673 T C 4.60E-10 Bone mineral density (paediatric,lower limb) FAM3C intron 24945404 rs2536180 chr7 120994673 T C 9.30E-17 Bone mineral density (paediatric,total body less head) FAM3C intron 24945404 rs3801382 chr7 120998277 T G 8.14E-16 Bone mineral density FAM3C intron 22792070 rs3801382 chr7 120998277 T G 9.88E-14 Cortical thickness FAM3C intron 22792071 rs3801382 chr7 120998277 T G 1.20E-08 Bone mineral density (paediatric,skull) FAM3C intron 24945404 rs3801382 chr7 120998277 T G 1.20E-27 Bone mineral density (paediatric,upper limb) FAM3C intron 24945404 rs3801382 chr7 120998277 T G 3.40E-19 Bone mineral density (paediatric,total body less head) FAM3C intron 24945404 rs3801382 chr7 120998277 T G 7.50E-09 Bone mineral density (paediatric,lower limb) FAM3C intron 24945404 rs2254595 chr7 121007249 T C 9.16E-05 Bone mineral density FAM3C intron 19181680 rs2254595 chr7 121007249 T C 8.51E-14 Bone mineral density FAM3C intron 22792070 rs2254595 chr7 121007249 T C 1.41E-14 Cortical thickness FAM3C intron 22792071 rs2254595 chr7 121007249 T C 1.50E-16 Bone mineral density (paediatric,total body less head) FAM3C intron 24945404 rs2254595 chr7 121007249 T C 4.30E-31 Bone mineral density (paediatric,upper limb) FAM3C intron 24945404 rs2254595 chr7 121007249 T C 6.70E-10 Bone mineral density (paediatric,lower limb) FAM3C intron 24945404 rs917727 chr7 121018579 C T 1.00E-27 Bone mineral density FAM3C intron 22792070 rs917727 chr7 121018579 C T 1.25E-14 Cortical thickness FAM3C intron 22792071 rs917727 chr7 121018579 C T 2.40E-09 Bone mineral density (paediatric,skull) FAM3C intron 24945404 rs917727 chr7 121018579 C T 4.40E-19 Bone mineral density (paediatric,total body less head) FAM3C intron 24945404 rs917727 chr7 121018579 C T 9.10E-28 Bone mineral density (paediatric,upper limb) FAM3C intron 24945404 rs917727 chr7 121018579 C T 9.90E-09 Bone mineral density (paediatric,lower limb) FAM3C intron 24945404 rs917726 chr7 121018857 A T 3.90E-16 Bone mineral density FAM3C intron 22792070 rs917726 chr7 121018857 A T 1.34E-14 Cortical thickness FAM3C intron 22792071 rs917726 chr7 121018857 A T 2.00E-27 Bone mineral density (paediatric,upper limb) FAM3C intron 24945404 rs917726 chr7 121018857 A T 5.30E-19 Bone mineral density (paediatric,total body less head) FAM3C intron 24945404 rs917726 chr7 121018857 A T 8.20E-09 Bone mineral density (paediatric,skull) FAM3C intron 24945404 rs917726 chr7 121018857 A T 8.20E-09 Bone mineral density (paediatric,lower limb) FAM3C intron 24945404 rs718766 chr7 121025502 T C 8.78E-16 Bone mineral density FAM3C intron 22792070 rs718766 chr7 121025502 T C 9.83E-15 Cortical thickness FAM3C intron 22792071 rs718766 chr7 121025502 T C 1.50E-08 Bone mineral density (paediatric,skull) FAM3C intron 24945404 rs718766 chr7 121025502 T C 5.30E-19 Bone mineral density (paediatric,total body less head) FAM3C intron 24945404 rs718766 chr7 121025502 T C 8.00E-28 Bone mineral density (paediatric,upper limb) FAM3C intron 24945404 rs718766 chr7 121025502 T C 8.20E-09 Bone mineral density (paediatric,lower limb) FAM3C intron 24945404 rs371847000 chr7 121030907 CGGGGGGGGGGG C 1.22E-05 Bone mineral density FAM3C intron 24249740 rs371847000 chr7 121030907 CGGGGGGGGGGG C 3.39E-07 Bone mineral density FAM3C intron 24249740 rs4727923 chr7 121030907 C T 1.22E-05 Bone mineral density FAM3C intron 24249740 rs4727923 chr7 121030907 C T 3.39E-07 Bone mineral density FAM3C intron 24249740 rs529951808 chr7 121030907 CGGGGGG C 1.22E-05 Bone mineral density FAM3C intron 24249740 rs529951808 chr7 121030907 CGGGGGG C 3.39E-07 Bone mineral density FAM3C intron 24249740 rs58750532 chr7 121030907 CGGG C 1.22E-05 Bone mineral density FAM3C intron 24249740 rs58750532 chr7 121030907 CGGG C 3.39E-07 Bone mineral density FAM3C intron 24249740 rs4727924 chr7 121031879 C T 1.93E-14 Bone mineral density FAM3C intron 22792070 rs4727924 chr7 121031879 C T 2.24E-15 Cortical thickness FAM3C intron 22792071 rs4727924 chr7 121031879 C T 1.00E-18 Bone mineral density (paediatric,total body less head) FAM3C intron 24945404 rs4727924 chr7 121031879 C T 1.50E-34 Bone mineral density (paediatric,upper limb) FAM3C intron 24945404 rs4727924 chr7 121031879 C T 4.80E-09 Bone mineral density (paediatric,skull) FAM3C intron 24945404 rs4727924 chr7 121031879 C T 7.90E-11 Bone mineral density (paediatric,lower limb) FAM3C intron 24945404 rs7776725 chr7 121033121 T C 1.00E-11 Biomedical quantitative traits FAM3C intron 19396169 rs7776725 chr7 121033121 T C 2.00E-06 Biomedical quantitative traits FAM3C intron 19396169 rs7776725 chr7 121033121 T C 4.74E-16 Bone mineral density FAM3C intron 22792070 rs7776725 chr7 121033121 T C 8.54E-15 Cortical thickness FAM3C intron 22792071 rs7776725 chr7 121033121 T C 1.10E-08 Bone mineral density (paediatric,skull) FAM3C intron 24945404 rs7776725 chr7 121033121 T C 1.70E-28 Bone mineral density (paediatric,upper limb) FAM3C intron 24945404 rs7776725 chr7 121033121 T C 2.00E-15 Bone mineral density (paediatric,total body less head) FAM3C intron 24945404 rs7776725 chr7 121033121 T C 3.10E-09 Bone mineral density (paediatric,lower limb) FAM3C intron 24945404 rs7776725 chr7 121033121 T C 6.00E-20 Bone mineral density (paediatric,total body less head) FAM3C intron 24945404 rs6466790 chr7 121108696 G A 4.98E-04 Multiple complex diseases / / 17554300 rs1528356 chr7 121121455 G A 1.99E-98 Multiple complex diseases / / 17554300 rs4731018 chr7 121123423 A G 7.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2049702 chr7 121154854 C T 7.08E-05 Multiple complex diseases / / 17554300 rs1528351 chr7 121167875 T C 4.47E-04 Multiple complex diseases / / 17554300 rs4731028 chr7 121172202 T A 2.64E-04 Multiple complex diseases / / 17554300 rs12530956 chr7 121183736 T C 0.0005918 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12530956 chr7 121183736 T C 5.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11762591 chr7 121185603 T C 0.0005896 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11762591 chr7 121185603 T C 5.90E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12531667 chr7 121193781 C G 0.000586 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12531667 chr7 121193781 C G 5.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6466798 chr7 121221761 G A 5.96E-05 Multiple complex diseases / / 17554300 rs2214706 chr7 121223857 C T 7.99E-05 Hematocrit / / pha003097 rs10488051 chr7 121247936 A G 8.76E-04 Rheumatoid arthritis / / 21452313 rs10488051 chr7 121247936 A G 2.90E-05 Urinary metabolites / / 21572414 rs2402581 chr7 121250594 A C 4.52E-04 Multiple complex diseases / / 17554300 rs41407748 chr7 121266861 G C 3.18E-04 Multiple complex diseases / / 17554300 rs10258169 chr7 121270857 C T 9.40E-07 Diabetes Mellitus / / pha003059 rs10253361 chr7 121275229 C T 6.00E-06 Alcoholism (alcohol dependence factor score) / / 21529783 rs10227063 chr7 121275477 A G 5.20E-05 Alcoholism (heaviness of drinking) / / 21529783 rs4731030 chr7 121283078 G A 4.37E-05 Aging (time to event) / / 21782286 rs10238961 chr7 121284051 A C 7.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs10233161 chr7 121285809 T G 7.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs10277185 chr7 121286274 C G 9.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs10225864 chr7 121287494 G C 8.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs6951011 chr7 121291868 C T 9.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs2402585 chr7 121299300 A C 9.54E-04 Type 2 diabetes / / 17463246 rs10228122 chr7 121300485 A G 8.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs2192296 chr7 121383828 T C 4.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs2192299 chr7 121389822 C T 4.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs13233007 chr7 121390643 C A 5.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs12706372 chr7 121390837 G C 4.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs17438627 chr7 121391810 G A 4.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs13240498 chr7 121392636 A T 2.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs17438787 chr7 121393479 G A 2.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs11983105 chr7 121439019 A G 2.78E-04 Myopia (pathological) / / 21095009 rs10262109 chr7 121444199 T C 3.37E-77 Multiple complex diseases / / 17554300 rs7798109 chr7 121482703 C T 3.63E-04 Alzheimer's disease (late onset) / / 21379329 rs7797305 chr7 121488137 C T 1.48E-04 Myopia (pathological) / / 21095009 rs10256242 chr7 121488393 A C 1.48E-04 Myopia (pathological) / / 21095009 rs10488056 chr7 121505920 C A 7.19E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs1916886 chr7 121530556 C T 1.26E-04 Myopia (pathological) PTPRZ1 intron 21095009 rs1916885 chr7 121536180 A G 7.30E-05 White matter hyperintensity burden PTPRZ1 intron 21681796 rs9641678 chr7 121538004 A G 7.40E-05 White matter hyperintensity burden PTPRZ1 intron 21681796 rs11978007 chr7 121541149 G A 1.04E-04 Myopia (pathological) PTPRZ1 intron 21095009 rs6971645 chr7 121542081 C G 7.60E-05 White matter hyperintensity burden PTPRZ1 intron 21681796 rs12669706 chr7 121545143 G A 7.70E-05 White matter hyperintensity burden PTPRZ1 intron 21681796 rs6946211 chr7 121554791 C T 9.00E-05 White matter hyperintensity burden PTPRZ1 intron 21681796 rs1206501 chr7 121563947 T C 9.59E-04 Myopia (pathological) PTPRZ1 intron 21095009 rs1196493 chr7 121599940 A G 3.24E-04 Common variable immunodeficiency PTPRZ1 intron 21497890 rs6964319 chr7 121633671 A G 5.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTPRZ1 intron 20877124 rs6964319 chr7 121633671 A G 7.85E-04 Myopia (pathological) PTPRZ1 intron 21095009 rs1206384 chr7 121657708 C T 4.97E-05 Cytomegalovirus antibody response PTPRZ1 intron 21993531 rs1147501 chr7 121666642 A G 8.72E-04 Acute lung injury PTPRZ1 intron 22295056 rs758692 chr7 121707222 G T 6.32E-05 Orofacial clefts / / 22419666 rs12217 chr7 121714653 C T 6.15E-05 Orofacial clefts AASS UTR-3 22419666 rs10233433 chr7 121721201 C A 1.08E-05 Personality dimensions AASS intron 22628180 rs4140745 chr7 121754695 C T 5.90E-06 Lipid levels AASS intron 18193043 rs4140745 chr7 121754695 C T 9.73E-06 Personality dimensions AASS intron 22628180 rs12374930 chr7 121841563 A G 3.51E-06 Intelligence / / 21826061 rs284371 chr7 121925267 T C 2.66E-04 Body mass index / / 17255346 rs1604329 chr7 121926111 C G 2.50E-04 Body mass index / / 17255346 rs6968240 chr7 121942674 C A 4.78E-05 Schizophrenia FEZF1 intron 21926974 rs1443753 chr7 121949318 T C 7.17E-04 Schizophrenia LOC154860 intron 19197363 rs1443753 chr7 121949318 T C 9.27E-05 Creatinine levels LOC154860 intron pha003069 rs1899689 chr7 121964349 C T 6.84E-04 Stroke CADPS2 intron pha002887 rs920802 chr7 121970118 G A 6.69E-04 Suicide attempts in bipolar disorder CADPS2 intron 21041247 rs2289705 chr7 121983843 A G 1.19E-04 Attention deficit hyperactivity disorder CADPS2 intron 22420046 rs10258797 chr7 122008804 A G 3.60E-05 Anger CADPS2 intron 24489884 rs6466819 chr7 122097058 G A 7.25E-04 Smoking initiation CADPS2 intron 24665060 rs2429582 chr7 122202593 C T 6.00E-07 Brain structure CADPS2 intron 20171287 rs2471201 chr7 122280035 C T 1.99E-05 Multiple complex diseases CADPS2 intron 17554300 rs7777183 chr7 122316632 C A 9.39E-04 Acute lung injury CADPS2 intron 22295056 rs7777183 chr7 122316632 C A 1.60E-06 Ejection fraction in Tripanosoma cruzi seropositivity CADPS2 intron 24324551 rs2080045 chr7 122331491 A G 9.54E-04 Acute lung injury CADPS2 intron 22295056 rs2080045 chr7 122331491 A G 1.37E-06 Ejection fraction in Tripanosoma cruzi seropositivity CADPS2 intron 24324551 rs1860859 chr7 122333168 T C 9.54E-04 Acute lung injury CADPS2 intron 22295056 rs1860859 chr7 122333168 T C 1.66E-06 Ejection fraction in Tripanosoma cruzi seropositivity CADPS2 intron 24324551 rs6466831 chr7 122337678 G A 1.78E-06 Ejection fraction in Tripanosoma cruzi seropositivity CADPS2 intron 24324551 rs6466832 chr7 122341149 T C 1.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity CADPS2 intron 24324551 rs2109965 chr7 122362142 C T 6.22E-06 Ejection fraction in Tripanosoma cruzi seropositivity CADPS2 intron 24324551 rs9770057 chr7 122363026 G C 5.64E-06 Ejection fraction in Tripanosoma cruzi seropositivity CADPS2 intron 24324551 rs6466839 chr7 122364384 C T 6.12E-06 Ejection fraction in Tripanosoma cruzi seropositivity CADPS2 intron 24324551 rs2402620 chr7 122364801 T C 4.91E-06 Ejection fraction in Tripanosoma cruzi seropositivity CADPS2 intron 24324551 rs7794272 chr7 122365469 A G 2.48E-06 Ejection fraction in Tripanosoma cruzi seropositivity CADPS2 intron 24324551 rs6948815 chr7 122366496 T G 5.28E-06 Ejection fraction in Tripanosoma cruzi seropositivity CADPS2 intron 24324551 rs9969220 chr7 122371707 A G 8.33E-05 Triglycerides CADPS2 intron pha003080 rs929569 chr7 122376318 T C 1.70E-05 Parkinson's disease (age of onset) CADPS2 intron 19772629 rs37903 chr7 122411623 A G 2.80E-05 Parkinson's disease (age of onset) CADPS2 intron 19772629 rs2501439 chr7 122527198 A G 9.29E-05 Systemic sclerosis CADPS2 nearGene-5 21750679 rs17145097 chr7 122536794 A G 5.85E-05 Gallstones / / 17632509 rs2501443 chr7 122542437 A G 7.01E-10 Non-obstructive azoospermia / / 22197933 rs2428769 chr7 122542645 C A 9.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2428769 chr7 122542645 C A 1.10E-05 Urinary metabolites / / 21572414 rs2428769 chr7 122542645 C A 6.87E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs981696 chr7 122552741 A G 1.20E-05 Personality dimensions / / 18957941 rs1544436 chr7 122558052 T C 1.00E-05 Personality dimensions / / 18957941 rs846683 chr7 122610494 G A 1.70E-05 Urinary metabolites / / 21572414 rs719605 chr7 122613859 T C 8.91E-05 Schizophrenia(age at onset) / / 21688384 rs10248362 chr7 122616642 T A 7.86E-04 Alzheimer's disease / / 17998437 rs9769253 chr7 122626742 T A,G 3.00E-04 Alzheimer's disease / / 17998437 rs1308712 chr7 122627896 T A 2.40E-05 Urinary metabolites / / 21572414 rs1308710 chr7 122628013 A T 2.40E-05 Urinary metabolites / / 21572414 rs1525489 chr7 122633473 A G 6.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs846664 chr7 122635173 A C 1 Drug response to Ethanol TAS2R16 missense 16385453 rs9770283 chr7 122640101 G A 1.55E-05 Serum metabolites / / 19043545 rs12706460 chr7 122648062 A G 2.20E-05 Urinary metabolites / / 21572414 rs4319013 chr7 122648394 A G 5.75E-04 Type 2 diabetes / / 17463246 rs10258404 chr7 122664695 T C 4.61E-05 Type 2 diabetes / / 22238593 rs2037689 chr7 122670809 G A 0.0000791 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13221935 chr7 122679919 G A 9.30E-05 Cognitive impairment induced by topiramate / / 22091778 rs1404838 chr7 122696223 T C 7.69E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs1404837 chr7 122696659 A T 3.82E-04 Type 2 diabetes / / 17463246 rs4288316 chr7 122708851 C T 4.68E-04 Multiple complex diseases / / 17554300 rs1404835 chr7 122726458 C G 9.26E-04 Multiple complex diseases / / 17554300 rs2177755 chr7 122727551 T C 4.80E-25 Narcolepsy / / 19629137 rs4727963 chr7 122759980 C T 1.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SLC13A1 intron 23648065 rs10255262 chr7 122762539 G A 8.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC13A1 intron 20877124 rs10487980 chr7 122766270 A G 5.30E-04 Type 2 diabetes and 6 quantitative traits SLC13A1 intron 17848626 rs2204292 chr7 122766907 C T 1.04E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SLC13A1 intron 23648065 rs12706494 chr7 122773032 A G 1.56E-04 Autism spectrum disorders (language delay) SLC13A1 intron 21519539 rs2470983 chr7 122774603 C A 6.64E-06 Type 2 diabetes SLC13A1 intron 23300278 rs2470984 chr7 122774729 C A 9.00E-05 Type 2 diabetes SLC13A1 intron 17463248 rs6466855 chr7 122777190 G A 7.00E-05 Type 2 diabetes SLC13A1 intron 17463248 rs6964272 chr7 122780027 C T 1.70E-05 Type 2 diabetes SLC13A1 intron 17463248 rs10251971 chr7 122783281 T G 1.80E-05 Type 2 diabetes SLC13A1 intron 17463248 rs10251971 chr7 122783281 T G 2.21E-05 Blood Pressure SLC13A1 intron pha003043 rs2470975 chr7 122785428 A G 5.29E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SLC13A1 intron 23648065 rs2222510 chr7 122785671 A G 4.17E-04 Type 2 diabetes SLC13A1 intron 17463246 rs2462150 chr7 122790213 C G 3.27E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SLC13A1 intron 23648065 rs6963735 chr7 122800683 T C 1.80E-05 Type 2 diabetes SLC13A1 intron 17463248 rs10280430 chr7 122805355 T C 1.90E-05 Type 2 diabetes SLC13A1 intron 17463248 rs1343905 chr7 122807680 T C 6.25E-05 Autism spectrum disorders (language delay) SLC13A1 intron 21519539 rs6953295 chr7 122807917 C T 4.98E-05 Alzheimer's disease SLC13A1 intron 17998437 rs2204290 chr7 122808044 C G 6.25E-05 Autism spectrum disorders (language delay) SLC13A1 intron 21519539 rs1880178 chr7 122809111 T C 1.90E-05 Type 2 diabetes SLC13A1 intron 17463248 rs2140516 chr7 122809234 T C 4.52E-04 Myocardial Infarction SLC13A1 missense pha002883 rs2402635 chr7 122819879 G A 4.73E-05 Response to taxane treatment (placlitaxel) SLC13A1 intron 23006423 rs10253693 chr7 122825956 C T 3.29E-04 Response to taxane treatment (placlitaxel) SLC13A1 intron 23006423 rs10265711 chr7 122828502 G T 5.88E-04 Response to taxane treatment (placlitaxel) SLC13A1 intron 23006423 rs7780966 chr7 122835155 A G 1.30E-04 Type 2 diabetes and 6 quantitative traits SLC13A1 intron 17848626 rs2204294 chr7 122835742 C A 1.32E-04 Response to taxane treatment (placlitaxel) SLC13A1 intron 23006423 rs10487976 chr7 122836025 G C 7.00E-05 Type 2 diabetes SLC13A1 intron 17903298 rs2204295 chr7 122838090 G C 7.00E-05 Type 2 diabetes SLC13A1 intron 17903298 rs1880180 chr7 122838862 T C 1.97E-04 Response to taxane treatment (placlitaxel) SLC13A1 intron 23006423 rs3824026 chr7 122841575 G A 9.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10487975 chr7 122845289 A G 1.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7810239 chr7 122846211 C A 3.08E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2222514 chr7 122846527 A G 1.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10487974 chr7 122848616 C T 1.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7776703 chr7 122858776 A G 1.43E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs4731086 chr7 122864924 C A 1.93E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2402637 chr7 122872334 C G 8.77E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10487973 chr7 122873665 C T 6.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12670549 chr7 122874252 A C 3.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7807163 chr7 122878459 T G 2.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6942730 chr7 122888627 G A 5.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10269555 chr7 122889404 G A 8.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4318999 chr7 122935021 C A 8.71E-04 Multiple complex diseases / / 17554300 rs12706511 chr7 122958129 G A 4.02E-04 Multiple complex diseases / / 17554300 rs17145801 chr7 122961470 G A 4.49E-04 Multiple complex diseases / / 17554300 rs2215579 chr7 122970804 C T 4.86E-04 Type 2 diabetes / / 17463246 rs7797180 chr7 122980848 A G 3.19E-04 Multiple complex diseases / / 17554300 rs4731102 chr7 122986940 T C 7.43E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs805803 chr7 123055555 G A 7.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs1525627 chr7 123097194 A G 2.50E-05 Urinary metabolites IQUB intron 21572414 rs1525629 chr7 123112856 G A 2.70E-05 Urinary metabolites IQUB intron 21572414 rs4276609 chr7 123150236 C T 5.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IQUB intron 20877124 rs2037697 chr7 123162177 T C 2.70E-05 Urinary metabolites IQUB intron 21572414 rs1525636 chr7 123208829 A G 2.10E-05 Urinary metabolites / / 21572414 rs805787 chr7 123220948 G A 8.92E-04 Alzheimer's disease / / 22005930 rs6962756 chr7 123256427 C T 3.87E-07 Rheumatoid arthritis ASB15 missense 19503088 rs4731112 chr7 123269118 G C 6.97E-05 Serum metabolites ASB15 missense 19043545 rs7776792 chr7 123335350 A G 2.39E-04 Lymphocyte counts WASL intron 22286170 rs9649465 chr7 123376560 G A 1.00E-06 Migraine WASL intron 23793025 rs2267875 chr7 123384781 T C 7.03E-05 Information processing speed WASL intron 21130836 rs4731120 chr7 123411223 A C 3.00E-12 Platelet counts / / 22139419 rs1506639 chr7 123467419 T C 3.80E-04 Type 2 diabetes / / 17463246 rs17703063 chr7 123504320 G A 6.34E-04 Response to taxane treatment (placlitaxel) HYAL4 intron 23006423 rs6949082 chr7 123514896 G T 7.92E-04 Response to taxane treatment (placlitaxel) HYAL4 missense 23006423 rs10246008 chr7 123574229 A T 5.76E-05 Multiple complex diseases SPAM1 intron 17554300 rs989926 chr7 123581229 T C 5.86E-04 Multiple complex diseases SPAM1 intron 17554300 rs10269135 chr7 123584796 A G 7.56E-04 Response to taxane treatment (placlitaxel) SPAM1 intron 23006423 rs12706565 chr7 123610077 A G 8.62E-04 Response to taxane treatment (placlitaxel) SPAM1 intron 23006423 rs11975640 chr7 123610348 C T 9.00E-06 Amyotrophic Lateral Sclerosis SPAM1 UTR-3 17362836 rs17146546 chr7 123623403 T C 6.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs17146591 chr7 123664221 A G 1.80E-05 Urinary metabolites / / 21572414 rs12334155 chr7 123665085 T C 2.70E-05 Urinary metabolites / / 21572414 rs6466890 chr7 123759980 A G 9.25E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6466890 chr7 123759980 A G 5.41E-08 Metabolite levels / / 23281178 rs10266035 chr7 123761405 G A 5.41E-08 Metabolite levels / / 23281178 rs12538016 chr7 123761909 C G 9.99E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs12538016 chr7 123761909 C G 5.41E-08 Metabolite levels / / 23281178 rs7780197 chr7 123764045 T A 5.41E-08 Metabolite levels / / 23281178 rs1990393 chr7 123854695 G A 3.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11760702 chr7 123859390 C T 1.74E-04 Multiple complex diseases / / 17554300 rs10487814 chr7 123869567 A G 7.56E-04 Obesity (extreme) / / 21935397 rs10487815 chr7 123869912 C A 9.93E-04 Bipolar disorder / / 19259986 rs17556632 chr7 123875104 G A 9.31E-04 Obesity (extreme) / / 21935397 rs1019196 chr7 123887029 C G 9.55E-04 Obesity (extreme) / / 21935397 rs17556666 chr7 123891923 C T 9.59E-04 Obesity (extreme) / / 21935397 rs17556861 chr7 123892711 G A 9.62E-04 Obesity (extreme) / / 21935397 rs4427107 chr7 123893838 C T 9.63E-04 Obesity (extreme) / / 21935397 rs12706574 chr7 123895019 G A 9.65E-04 Obesity (extreme) / / 21935397 rs12706575 chr7 123895151 C A 9.48E-04 Obesity (extreme) / / 21935397 rs17637743 chr7 123897234 T A 9.14E-04 Obesity (extreme) / / 21935397 rs12706576 chr7 123897688 T C 9.07E-04 Obesity (extreme) / / 21935397 rs13224724 chr7 123899016 T A 8.71E-04 Obesity (extreme) / / 21935397 rs12706577 chr7 123903144 G A 8.71E-04 Obesity (extreme) / / 21935397 rs12706578 chr7 123903176 T C 8.71E-04 Obesity (extreme) / / 21935397 rs12706579 chr7 123903268 C T 8.72E-04 Obesity (extreme) / / 21935397 rs13231290 chr7 123906080 T G 8.71E-04 Obesity (extreme) / / 21935397 rs12706581 chr7 123907124 C T 8.70E-04 Obesity (extreme) / / 21935397 rs13228061 chr7 123908575 G C 8.70E-04 Obesity (extreme) / / 21935397 rs12706584 chr7 123913133 A G 8.69E-04 Obesity (extreme) / / 21935397 rs13231197 chr7 123914987 G A 8.98E-04 Obesity (extreme) / / 21935397 rs13234240 chr7 123926120 C T 8.91E-04 Obesity (extreme) / / 21935397 rs6976230 chr7 123967269 G T 2.25E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1978185 chr7 123991814 G T 5.32E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17147033 chr7 124006740 C T 8.89E-04 Type 2 diabetes / / 17463246 rs6466910 chr7 124007114 G A 8.00E-04 Type 2 diabetes / / 17463246 rs10487263 chr7 124010036 T C 7.00E-05 Obesity-related traits / / 17903300 rs2402711 chr7 124018435 A G 2.20E-05 Urinary metabolites / / 21572414 rs2190930 chr7 124059626 G A 4.11E-05 Menopause (age at onset) / / 19448619 rs1860144 chr7 124063498 C T 4.09E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2215159 chr7 124065696 C T 9.31E-04 Type 2 diabetes / / 17463246 rs2215159 chr7 124065696 C T 2.60E-05 Urinary metabolites / / 21572414 rs720547 chr7 124075494 G A 6.39E-05 Interstitial lung disease / / 23583980 rs13239910 chr7 124078609 T G 7.54E-05 Alcohol dependence / / 21703634 rs993079 chr7 124079038 C T 4.81E-05 Waist Circumference / / pha003023 rs993079 chr7 124079038 C T 8.83E-05 Tunica Media / / pha003037 rs993080 chr7 124079220 A G 7.71E-04 Type 2 diabetes / / 17463246 rs12537567 chr7 124155319 C A 5.90E-05 Parkinson's disease (familial) / / 18985386 rs2159181 chr7 124164859 C T 5.45E-13 Metabolite levels / / 22286219 rs1524771 chr7 124233296 A C 1.80E-05 Urinary metabolites / / 21572414 rs1917364 chr7 124284209 A C 6.44E-04 Smoking quantity / / 24665060 rs1917365 chr7 124284298 G A 1.50E-05 Urinary metabolites / / 21572414 rs1917366 chr7 124284486 C T 1.50E-05 Urinary metabolites / / 21572414 rs11975826 chr7 124301144 G T 1.30E-05 Urinary metabolites / / 21572414 rs6972148 chr7 124314939 G A 1.00E-05 Urinary metabolites / / 21572414 rs10954043 chr7 124322409 A G 6.69E-05 HIV-1 control / / 20041166 rs2091218 chr7 124328175 C T 1.10E-05 Urinary metabolites / / 21572414 rs7802263 chr7 124384327 G T 8.00E-06 Reading and spelling / / 23738518 rs9655844 chr7 124385252 C A 8.19E-06 Reading and spelling / / 23738518 rs4731205 chr7 124385442 A C 8.19E-06 Reading and spelling / / 23738518 rs724356 chr7 124387374 A G 8.19E-06 Reading and spelling / / 23738518 rs2402750 chr7 124396488 A G 3.10E-06 Urinary metabolites GPR37 intron 21572414 rs3807544 chr7 124400705 G A 7.41E-06 Post-operative nausea and vomiting GPR37 intron 21694509 rs2402752 chr7 124439599 T C 4.06E-04 Multiple complex diseases / / 17554300 rs17246404 chr7 124462661 C T 3.00E-08 Chronic lymphocytic leukemia POT1 UTR-3 24292274 rs12540261 chr7 124586837 T C 2.61E-04 Smoking cessation / / 18519826 rs12535807 chr7 124591433 A T 2.07E-04 Smoking cessation / / 18519826 rs7806530 chr7 124659884 T C 1.04E-04 Smoking cessation / / 18519826 rs10269342 chr7 124693845 G C 7.53E-05 Smoking cessation / / 18519826 rs13246702 chr7 124784605 A C 1.90E-05 Height / / 21998595 rs648619 chr7 124803868 A G 1.60E-06 Urinary metabolites / / 21572414 rs648619 chr7 124803868 A G 3.19E-05 Bipolar disorder / / 22925353 rs2968865 chr7 124810399 A G 1.50E-06 Urinary metabolites / / 21572414 rs2968865 chr7 124810399 A G 3.51E-05 Bipolar disorder / / 22925353 rs7776954 chr7 124890022 A G 6.82E-04 Suicide attempts in bipolar disorder / / 21041247 rs62477096 chr7 124936442 A G 6.63E-07 Prostate cancer / / 24185611 rs6965492 chr7 124944982 G T 6.92E-07 Prostate cancer / / 24185611 rs1559971 chr7 124962085 T C 1.00E-05 Homocysteine levels,in plasma / / 19525478 rs7795867 chr7 124977736 T C 5.40E-05 Homocysteine levels,in plasma / / 19525478 rs17148196 chr7 124979488 T C 5.09E-04 Aortic root size / / 21223598 rs12533496 chr7 125036538 C T 5.76E-06 Asthma / / 23181788 rs1593758 chr7 125044642 G A 3.18E-04 Multiple complex diseases / / 17554300 rs1834821 chr7 125062904 G A 2.78E-04 Multiple complex diseases / / 17554300 rs1526411 chr7 125064358 T G 9.89E-05 Multiple complex diseases / / 17554300 rs1526410 chr7 125064386 C T 2.41E-04 Multiple complex diseases / / 17554300 rs17148343 chr7 125068636 A T 3.20E-04 Multiple complex diseases / / 17554300 rs10500113 chr7 125068993 C T 9.66E-04 Multiple complex diseases / / 17554300 rs6956995 chr7 125073353 A G 5.40E-04 Multiple complex diseases / / 17554300 rs1526413 chr7 125088151 A G 1.20E-04 Asthma LOC100506664 intron 23181788 rs12113012 chr7 125088391 A G 2.70E-04 Multiple complex diseases LOC100506664 intron 17554300 rs1852090 chr7 125088892 T G 3.97E-04 Multiple complex diseases LOC100506664 intron 17554300 rs10267468 chr7 125104792 T C 1.40E-04 Response to alcohol consumption (flushing response) / / 24277619 rs2693985 chr7 125188186 A T 5.82E-04 Multiple complex diseases / / 17554300 rs9649011 chr7 125202672 G A 4.70E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs2694006 chr7 125203203 C T 1.70E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs792416 chr7 125203939 T G 4.50E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs792160 chr7 125214809 A T 1.70E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs792162 chr7 125216928 T C 5.50E-07 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs6965493 chr7 125218204 G A 4.40E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs1123461 chr7 125219202 A T 4.40E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs813781 chr7 125219237 A G 1.70E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs1833082 chr7 125219904 G A 1.70E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs1833083 chr7 125219953 C T 1.70E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs3857841 chr7 125224602 T C 4.40E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs792191 chr7 125225892 C G 1.70E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs792196 chr7 125228133 G T 1.70E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs792197 chr7 125228294 T C 2.30E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs10954077 chr7 125230442 T C 2.30E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs2524888 chr7 125234107 G A 1.70E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs986278 chr7 125235065 G C 1.70E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs9649481 chr7 125237574 T C 1.70E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs3847096 chr7 125239058 G A 8.40E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs4731254 chr7 125240393 C T 3.30E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs792177 chr7 125241131 C T 3.30E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs792180 chr7 125241529 T A 3.40E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs10259370 chr7 125241872 G A 7.92E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7793003 chr7 125244668 G A 6.80E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs2040752 chr7 125245184 C T 6.80E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs1419702 chr7 125245398 C T 6.80E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs1419703 chr7 125245418 T G 6.80E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs1859261 chr7 125246971 G C 7.40E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs996867 chr7 125247321 G A 7.40E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs983849 chr7 125248586 T C 7.20E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs1419698 chr7 125249438 G A 7.40E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs1579222 chr7 125251771 A T 7.50E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs1419699 chr7 125261928 G T 5.50E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs1160839 chr7 125264301 G A 3.50E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs10954078 chr7 125265983 G A 5.50E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs10234626 chr7 125266178 G A 5.50E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs2189416 chr7 125267628 T C 7.10E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs2189417 chr7 125267702 G A 7.10E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs1158631 chr7 125270615 G C 8.10E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs12530516 chr7 125275758 G A 7.30E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs10278107 chr7 125278195 T C 9.50E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs2107113 chr7 125281369 A T 8.80E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs7781719 chr7 125364162 T C 6.20E-04 Primary sclerosing cholangitis / / 19944697 rs1419607 chr7 125391645 A G 7.00E-06 Obesity-related traits / / 23251661 rs6974130 chr7 125407937 C T 7.24E-06 Obesity-related traits / / 23251661 rs4731264 chr7 125414227 A G 8.47E-04 Depression (quantitative trait) / / 20800221 rs739739 chr7 125414439 A G 8.48E-04 Depression (quantitative trait) / / 20800221 rs11761281 chr7 125489826 C T 7.39E-05 Cognitive test performance / / 20125193 rs2158214 chr7 125532656 G T 5.84E-06 Colorectal cancer / / 21242260 rs2107062 chr7 125532747 T G 9.29E-09 Multiple complex diseases / / 17554300 rs6947579 chr7 125533006 G C 4.80E-04 Crohn's disease / / 17684544 rs10238157 chr7 125537419 G A 7.22E-06 Colorectal cancer / / 21242260 rs10487428 chr7 125570097 A T 5.40E-04 Crohn's disease / / 17684544 rs11772544 chr7 125657970 G A 7.30E-05 Diabetic retinopathy / / 21441570 rs719320 chr7 125712783 T C 6.17E-05 Bilirubin levels,in serum / / 19389676 rs17149269 chr7 125725221 T G 1.50E-05 Urinary metabolites / / 21572414 rs9641783 chr7 125744831 G A 1.80E-05 Urinary metabolites / / 21572414 rs594391 chr7 125767907 C T 2.00E-04 Information processing speed / / 21130836 rs626762 chr7 125776626 C A 7.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs639211 chr7 125777139 A C 7.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs642710 chr7 125777907 C T 6.75E-04 Suicide attempts in bipolar disorder / / 21041247 rs651763 chr7 125777959 C A 6.57E-04 Suicide attempts in bipolar disorder / / 21041247 rs653569 chr7 125777978 G A 6.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs4431537 chr7 125778020 G A 9.84E-07 Multiple complex diseases / / 17554300 rs492757 chr7 125780357 A T 6.43E-04 Suicide attempts in bipolar disorder / / 21041247 rs618766 chr7 125781804 T G 6.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs473816 chr7 125783434 G A 6.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs648172 chr7 125783798 T A 6.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs654111 chr7 125784723 T C 6.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs674616 chr7 125785097 T C 6.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs585146 chr7 125786836 C T 6.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs498875 chr7 125790458 T C 7.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs635680 chr7 125790888 G C 7.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs650045 chr7 125791790 G A 7.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs553952 chr7 125791900 C T 7.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs556478 chr7 125792145 T C 7.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs475294 chr7 125793029 C T 7.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs501483 chr7 125793616 A G 7.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs505793 chr7 125794026 T C 7.71E-04 Suicide attempts in bipolar disorder / / 21041247 rs507803 chr7 125794295 C T 7.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs613484 chr7 125794581 A G 7.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs489655 chr7 125796030 A G 8.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs515267 chr7 125796527 T G 8.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs518066 chr7 125796847 C T 8.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs683493 chr7 125805301 G A 6.90E-04 Atrial fibrillation / / 21846873 rs660143 chr7 125841251 G A 6.26E-06 Hearing function / / 21493956 rs637306 chr7 125842651 A C 6.07E-06 Hearing function / / 21493956 rs471173 chr7 125848263 A G 6.02E-06 Hearing function / / 21493956 rs2521027 chr7 125856418 A G 9.51E-06 Hearing function / / 21493956 rs1073341 chr7 125863804 C A 6.52E-06 Hearing function / / 21493956 rs2687479 chr7 125868015 A G 4.87E-07 Hearing function / / 21493956 rs2687481 chr7 125869122 G T 3.22E-07 Hearing function / / 21493956 rs2521030 chr7 125869316 G C 4.56E-07 Hearing function / / 21493956 rs1673373 chr7 125873458 A G 1.87E-06 Hearing function / / 21493956 rs1673373 chr7 125873458 A G 3.39E-06 Hearing function / / 21493956 rs1673371 chr7 125874070 A G 2.61E-06 Hearing function / / 21493956 rs1719101 chr7 125876526 C T 2.57E-06 Hearing function / / 21493956 rs2687473 chr7 125878744 T C 2.58E-06 Hearing function / / 21493956 rs1719094 chr7 125882099 A G 2.60E-06 Hearing function / / 21493956 rs1719093 chr7 125883890 T G 1.60E-06 Hearing function / / 21493956 rs1719093 chr7 125883890 T G 2.94E-06 Hearing function / / 21493956 rs1719091 chr7 125884341 G A 1.58E-06 Hearing function / / 21493956 rs1719091 chr7 125884341 G A 2.93E-06 Hearing function / / 21493956 rs1719090 chr7 125884871 C T 1.57E-06 Hearing function / / 21493956 rs1719090 chr7 125884871 C T 2.92E-06 Hearing function / / 21493956 rs1719089 chr7 125887997 C T 1.50E-06 Hearing function / / 21493956 rs1719089 chr7 125887997 C T 2.82E-06 Hearing function / / 21493956 rs1673365 chr7 125890607 C T 1.45E-06 Hearing function / / 21493956 rs1673365 chr7 125890607 C T 2.73E-06 Hearing function / / 21493956 rs1673366 chr7 125892242 G A 2.85E-06 Hearing function / / 21493956 rs117982730 chr7 125896748 G A 4.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs1673369 chr7 125897582 T C 1.46E-06 Hearing function / / 21493956 rs1673369 chr7 125897582 T C 2.91E-06 Hearing function / / 21493956 rs1719105 chr7 125900703 C T 3.29E-06 Hearing function / / 21493956 rs1673374 chr7 125910503 G A 2.75E-06 Hearing function / / 21493956 rs1719108 chr7 125926314 G C 2.79E-06 Hearing function / / 21493956 rs1719107 chr7 125926628 A G 2.78E-06 Hearing function / / 21493956 rs1419500 chr7 125932208 C T 7.81E-06 Hearing function / / 21493956 rs10254771 chr7 125960953 G A 8.30E-06 Myocardial Infarction / / pha002873 rs10487440 chr7 125976560 C A,G,T 2.00E-04 Type 2 diabetes / / 17846126 rs10487442 chr7 126063256 G A 3.00E-04 Type 2 diabetes / / 17846126 rs10256068 chr7 126066742 G C 4.62E-04 Type 2 diabetes / / 17463246 rs13240504 chr7 126089319 C T 8.74E-05 Myocardial Infarction GRM8 intron pha002873 rs1858789 chr7 126124217 C T 7.01E-04 Multiple complex diseases GRM8 intron 17554300 rs2283064 chr7 126125053 T C 3.00E-05 Electrocardiographic traits and heart rate variability GRM8 intron 17903306 rs17680718 chr7 126130872 T C 6.65E-04 Response to TNF antagonist treatment GRM8 intron 21061259 rs17149848 chr7 126133668 T A 9.04E-04 Multiple complex diseases GRM8 intron 17554300 rs17691394 chr7 126324591 A G 9.00E-07 Carotid atherosclerosis in HIV infection GRM8 intron 20009918 rs6969693 chr7 126325356 C G 3.91E-04 Alzheimer's disease GRM8 intron 22005930 rs1008907 chr7 126327399 A C 3.99E-04 Alzheimer's disease GRM8 intron 22005930 rs7780253 chr7 126333583 A T 2.92E-04 Alzheimer's disease GRM8 intron 22005930 rs6963108 chr7 126336762 C G 4.42E-04 Alzheimer's disease GRM8 intron 22005930 rs886176 chr7 126346893 T C 6.78E-04 Alzheimer's disease GRM8 intron 22005930 rs7784073 chr7 126346951 A G 6.78E-04 Alzheimer's disease GRM8 intron 22005930 rs2299498 chr7 126357927 A G 6.00E-04 Type 2 diabetes and 6 quantitative traits GRM8 intron 17848626 rs552763491 chr7 126357927 AGGAGT A 6.00E-04 Type 2 diabetes and 6 quantitative traits GRM8 intron 17848626 rs10256873 chr7 126368292 G A 9.14E-04 Alcohol dependence GRM8 intron 21314694 rs6974018 chr7 126368826 G A 5.63E-04 Alzheimer's disease GRM8 intron 22005930 rs7804521 chr7 126371957 T C 5.93E-04 Alzheimer's disease GRM8 intron 22005930 rs1345211 chr7 126372269 G A 2.00E-05 Urinary metabolites GRM8 intron 21572414 rs2299500 chr7 126372389 G A 6.04E-04 Alzheimer's disease GRM8 intron 22005930 rs11978951 chr7 126373578 G A 6.37E-04 Alzheimer's disease GRM8 intron 22005930 rs10279350 chr7 126405246 T C 8.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRM8 intron 20877124 rs2299514 chr7 126409064 A G 7.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRM8 intron 20877124 rs2023735 chr7 126421750 T C 7.90E-05 Parkinson's disease (familial) GRM8 intron 18985386 rs1989850 chr7 126425473 T C 8.90E-05 Parkinson's disease (familial) GRM8 intron 18985386 rs6951643 chr7 126429517 A G 7.30E-05 Parkinson's disease (familial) GRM8 intron 18985386 rs10243157 chr7 126435170 G A 9.77E-05 Multiple complex diseases GRM8 intron 17554300 rs11971186 chr7 126437897 A G 9.00E-06 Chemerin levels GRM8 intron 20237162 rs974441 chr7 126439383 C T 6.01E-04 Multiple complex diseases GRM8 intron 17554300 rs1419492 chr7 126484050 C T 4.64E-05 Brain derived neurotrophic factor levels,in serum GRM8 intron 22047184 rs1361988 chr7 126484315 G A 6.34E-05 Brain derived neurotrophic factor levels,in serum GRM8 intron 22047184 rs13242233 chr7 126490357 C T 8.17E-05 Brain derived neurotrophic factor levels,in serum GRM8 intron 22047184 rs2283079 chr7 126496513 A G 7.15E-05 Brain derived neurotrophic factor levels,in serum GRM8 intron 22047184 rs1204515 chr7 126503027 T C 1.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRM8 intron 20877124 rs1204522 chr7 126507693 C G 4.50E-04 Alzheimer's disease GRM8 intron 22005930 rs1204524 chr7 126508489 A G 4.54E-04 Alzheimer's disease GRM8 intron 22005930 rs17150350 chr7 126566897 C T 2.33E-04 Multiple complex diseases GRM8 intron 17554300 rs1419471 chr7 126582814 G A 9.60E-05 Body Mass Index GRM8 intron pha003019 rs10232276 chr7 126583521 T C 6.96E-07 Body Mass Index GRM8 intron pha003019 rs10232276 chr7 126583521 T C 8.19E-06 Body Mass Index GRM8 intron pha003020 rs10232276 chr7 126583521 T C 6.53E-06 Body Mass Index GRM8 intron pha003022 rs13224108 chr7 126595060 T G 9.03E-05 Body Mass Index GRM8 intron pha003019 rs1003037 chr7 126599012 A G 9.08E-04 Bipolar disorder GRM8 intron 19259986 rs1211384 chr7 126612058 C T 6.02E-04 Alzheimer's disease GRM8 intron 17998437 rs1155597 chr7 126613163 G T 7.66E-04 Alzheimer's disease GRM8 intron 17998437 rs17867725 chr7 126631568 T C 4.18E-04 Depression (quantitative trait) GRM8 intron 20800221 rs12164089 chr7 126633169 G C 1 Drug response to Etoposide GRM8 intron 17537913 rs17864092 chr7 126639604 T C 6.00E-06 Depression (quantitative trait) GRM8 intron 20800221 rs17864092 chr7 126639604 T C 5.50E-06 Depression (quantitative trait) GRM8 intron 23290196 rs2237781 chr7 126675050 G A 4.02E-05 Nicotine smoking GRM8 intron 19268276 rs10487465 chr7 126696781 T C 2.04E-27 Narcolepsy GRM8 intron 19629137 rs6467108 chr7 126697650 T C 3.00E-04 Heroin addiction GRM8 intron 20520587 rs3808122 chr7 126714702 T C 4.66E-05 Hirschsprung's disease GRM8 intron 19196962 rs12375090 chr7 126742112 C T 6.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRM8 intron 20877124 rs6950264 chr7 126772602 G A 2.25E-04 Multiple complex diseases GRM8 intron 17554300 rs1419425 chr7 126794731 G A 5.97E-05 Schizophrenia GRM8 intron 19571809 rs7791345 chr7 126837621 A G 1.59E-05 Schizophrenia GRM8 intron 19571809 rs3808118 chr7 126840170 G A 4.47E-04 Lung function (forced vital capacity) GRM8 intron 24023788 rs886003 chr7 126847016 C T 8.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRM8 intron 20877124 rs886004 chr7 126847044 G A 7.48E-04 Amyotrophic Lateral Sclerosis GRM8 intron 17362836 rs2283100 chr7 126856057 T C 6.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRM8 intron 20877124 rs13232763 chr7 126856229 T C 1.53E-04 Suicide attempts in bipolar disorder GRM8 intron 21423239 rs13232763 chr7 126856229 T C 5.15E-05 Post-operative nausea and vomiting GRM8 intron 21694509 rs2299556 chr7 126859062 C G 7.20E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GRM8 intron 20031582 rs7806403 chr7 126870612 C A 9.76E-05 Cognitive test performance GRM8 intron 20125193 rs11563676 chr7 126871034 G A 6.30E-05 Cognitive test performance GRM8 intron 20125193 rs6961944 chr7 126873668 A G 9.76E-05 Cognitive test performance GRM8 intron 20125193 rs17866154 chr7 126881702 G C 1.58E-04 Suicide attempts in bipolar disorder GRM8 intron 21423239 rs1120908 chr7 126889294 G C,T 2.66E-04 Suicide attempts in bipolar disorder GRM8 intron 21423239 rs10236720 chr7 126919656 A C 8.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs17869724 chr7 126924704 C T 2.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs17866046 chr7 126926738 A G 7.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs17866467 chr7 126929793 G A 4.48E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs28947798 chr7 126931895 G A 4.34E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs28947799 chr7 126932352 G T 4.33E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs10248665 chr7 126932944 A G 9.41E-04 Type 2 diabetes / / 17463246 rs28947801 chr7 126933347 G A 4.30E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs10259338 chr7 126940621 A G 4.51E-04 Type 2 diabetes / / 17463246 rs10246291 chr7 126941074 T G 8.48E-04 Parkinson's disease / / 17052657 rs74789234 chr7 126941086 A C 3.89E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs6943547 chr7 126944260 T C 3.37E-04 Obesity (extreme) / / 21935397 rs17867823 chr7 126952294 A G 8.69E-04 Obesity (extreme) / / 21935397 rs6467120 chr7 126961533 G A 6.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11563651 chr7 126962968 G C 6.46E-04 Type 2 diabetes / / 17463246 rs3944151 chr7 126970005 A G 3.11E-05 Insulin-related traits / / pha003063 rs6961281 chr7 126974042 G A 3.73E-05 Insulin-related traits / / pha003063 rs17862359 chr7 126988290 C T 9.24E-04 Obesity (extreme) / / 21935397 rs17867832 chr7 126996837 T G 0.00047 Type 2 diabetes (females) / / 22885922 rs200123813 chr7 126996837 T TG 0.00047 Type 2 diabetes (females) / / 22885922 rs4731350 chr7 126997587 T C 2.93E-05 Insulin-related traits / / pha003063 rs10253460 chr7 127002341 T C 8.86E-04 Obesity (extreme) / / 21935397 rs11563620 chr7 127059236 C T 6.14E-04 Myopia (pathological) / / 21095009 rs12112128 chr7 127068880 T C 1.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs10487483 chr7 127074138 C T 2.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs10263237 chr7 127089357 C T 2.44E-04 Multiple complex diseases / / 17554300 rs17133015 chr7 127108868 T C 9.61E-04 Type 2 diabetes / / 17463246 rs10487487 chr7 127148153 A T 1.03E-05 Type 2 diabetes / / 22158537 rs11768389 chr7 127150250 T C 8.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs1592365 chr7 127151323 C A 1.53E-06 Type 2 diabetes / / 22158537 rs10487490 chr7 127155539 C T 4.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10258162 chr7 127158623 C T 7.95E-07 Type 2 diabetes / / 22158537 rs1419433 chr7 127158935 A T 2.19E-05 Type 2 diabetes / / 22158537 rs6467136 chr7 127164958 A G 7.26E-05 Type 2 diabetes and other traits / / 19734900 rs6467136 chr7 127164958 A G 5.00E-11 Type 2 diabetes / / 22158537 rs6467136 chr7 127164958 A G 4.96E-11 Type 2 diabetes / / 23300278 rs10269701 chr7 127166578 G A 1.34E-06 Type 2 diabetes / / 22158537 rs17150996 chr7 127174679 G A 1.53E-05 Type 2 diabetes / / 22158537 rs4551267 chr7 127175236 C T 1.97E-06 Type 2 diabetes / / 22158537 rs4731367 chr7 127178162 C T 9.08E-04 Multiple complex diseases / / 17554300 rs6962882 chr7 127182308 C T 6.82E-05 Meningococcal disease / / 20694013 rs6962882 chr7 127182308 C T 7.27E-06 Type 2 diabetes / / 22158537 rs6970053 chr7 127194176 A C 8.59E-06 Type 2 diabetes / / 22158537 rs11761988 chr7 127194573 A G 9.05E-06 Type 2 diabetes / / 22158537 rs1419430 chr7 127195294 C T 1.40E-05 Type 2 diabetes / / 22158537 rs17715255 chr7 127195850 C T 6.54E-06 Type 2 diabetes / / 22158537 rs17715285 chr7 127195932 C T 5.69E-06 Type 2 diabetes / / 22158537 rs6976685 chr7 127203576 T C 7.21E-06 Type 2 diabetes / / 22158537 rs10281056 chr7 127204844 C T 7.46E-06 Type 2 diabetes / / 22158537 rs1557643 chr7 127206134 C T 6.10E-06 Type 2 diabetes / / 22158537 rs4728075 chr7 127209982 A G 6.08E-06 Type 2 diabetes / / 22158537 rs4731370 chr7 127210207 G A 6.16E-06 Type 2 diabetes / / 22158537 rs10954161 chr7 127211475 G A 7.41E-06 Type 2 diabetes / / 22158537 rs989099 chr7 127220827 A G 3.24E-07 Type 2 diabetes GCC1 UTR-3 22158537 rs10229583 chr7 127246903 G A 2.00E-10 Type 2 diabetes / / 23532257 rs327512 chr7 127257251 G A 7.83E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) PAX4 nearGene-5 22566498 rs327510 chr7 127257894 G A 7.69E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs806179 chr7 127284044 T C 8.60E-06 Urinary metabolites / / 21572414 rs2141259 chr7 127286897 A G 3.59E-05 Duodenal ulcer / / 22387998 rs3808115 chr7 127293963 T C 8.87E-04 Prostate cancer mortality SND1 intron 20978177 rs7778413 chr7 127357716 T C 9.86E-06 Oral cancers (chewing tobacco related) SND1 intron 22503698 rs2043981 chr7 127400473 G T 2.10E-05 Urinary metabolites SND1 intron 21572414 rs6467148 chr7 127428382 A G 2.90E-05 Urinary metabolites SND1 intron 21572414 rs7783102 chr7 127515670 A G 1.10E-05 Urinary metabolites SND1 intron 21572414 rs7786786 chr7 127526479 C T 2.40E-05 Urinary metabolites SND1 intron 21572414 rs3757769 chr7 127541062 A G 1.02E-04 Oral cancers (chewing tobacco related) SND1 intron 22503698 rs3808084 chr7 127553025 A G 2.55E-05 Duodenal ulcer SND1 intron 22387998 rs1075206 chr7 127556713 T C 1.84E-05 Duodenal ulcer SND1 intron 22387998 rs3808081 chr7 127567900 T C 1.80E-05 Urinary metabolites SND1 intron 21572414 rs3808081 chr7 127567900 T C 1.01E-05 Oral cancers (chewing tobacco related) SND1 intron 22503698 rs3757764 chr7 127587849 C T 2.60E-05 Urinary metabolites SND1 intron 21572414 rs10447854 chr7 127795804 T C 1.44E-05 Meningococcal disease / / 20694013 rs73226626 chr7 127796040 C T 5.85E-05 Acne (severe) / / 24927181 rs17735958 chr7 127796952 C T 2.00E-04 Multiple complex diseases / / 17554300 rs12155383 chr7 127806005 C T 6.57E-04 Alzheimer's disease / / 22005930 rs1017607 chr7 127814357 A G 7.35E-04 Parkinson's disease / / 21044948 rs6976221 chr7 127833995 T G 1.88E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs12538332 chr7 127839654 A C 6.14E-05 Orofacial clefts / / 22419666 rs6467165 chr7 127842526 A G 8.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2167289 chr7 127857891 G T 2.08E-05 Smoking behavior / / 19188921 rs11764840 chr7 127858048 A T 0.0004148 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11764840 chr7 127858048 A T 4.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs791595 chr7 127862802 A G 3.00E-13 Type 2 diabetes / / 23945395 rs10954172 chr7 127864005 G A 0.0004193 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10954172 chr7 127864005 G A 4.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7799039 chr7 127878783 G A 1 Drug response to Risperidone / / 19873684 rs4731426 chr7 127882070 G C 1 Drug response to Olanzapine LEP intron 18681781 rs17151914 chr7 127894407 C T 8.41E-04 Multiple complex diseases LEP intron 17554300 rs10954175 chr7 127905557 G A 9.20E-05 Parkinson's disease (familial) / / 18985386 rs4731437 chr7 127912566 T C 1.00E-04 Myasthenia gravis / / 23055271 rs1466146 chr7 127915376 G A 2.10E-05 Myasthenia gravis / / 23055271 rs6979784 chr7 127916208 G A 2.10E-04 Myasthenia gravis / / 23055271 rs7811892 chr7 127923778 C T 6.44E-05 Blood Pressure / / pha003040 rs7811892 chr7 127923778 C T 5.20E-05 Erythrocyte counts / / pha003099 rs1545444 chr7 127927674 T C 9.70E-05 Serum metabolites / / 19043545 rs4731441 chr7 127956258 T A 3.94E-04 Alzheimer's disease RBM28 intron 17998437 rs1651939 chr7 128014136 C A 6.62E-04 Alcohol dependence / / 21314694 rs17537088 chr7 128027749 T C 4.44E-04 Lymphocyte counts / / 22286170 rs2278294 chr7 128040699 C T 1 Drug response to Mycophenolate Mofetil IMPDH1 intron 17851563 rs2278293 chr7 128040752 C T 1 Drug response to Mycophenolate Mofetil IMPDH1 intron 17851563 rs12540762 chr7 128073326 A G 7.46E-04 Intracranial aneurysm / / 20613766 rs10230965 chr7 128222966 G T 5.30E-04 Alcohol dependence / / 20201924 rs6977126 chr7 128327283 G A 4.43E-04 Type 2 diabetes / / 17463246 rs6976879 chr7 128327374 A C 8.79E-04 Type 2 diabetes / / 17463246 rs2060719 chr7 128331092 T C 2.74E-04 Aortic root size / / 21223598 rs7804472 chr7 128333758 G A 4.76E-04 Type 2 diabetes / / 17463246 rs6946321 chr7 128353840 A G 9.20E-04 Parkinson's disease / / 17052657 rs339078 chr7 128360997 A G 8.00E-05 Prostate cancer FAM71F1 intron 21743057 rs339077 chr7 128361129 G A 9.90E-04 Suicide attempts in bipolar disorder FAM71F1 intron 21423239 rs339075 chr7 128362426 A G 7.16E-04 Suicide attempts in bipolar disorder FAM71F1 intron 21423239 rs339075 chr7 128362426 A G 5.96E-05 Response to cholinesterase inhibitors in Alzheimer's disease FAM71F1 intron 23374588 rs6971091 chr7 128363287 G A 7.13E-04 Stroke FAM71F1 missense pha002886 rs11653 chr7 128409580 T A 1 Drug response to Warfarin CALU UTR-3 19794411 rs1799922 chr7 128415195 T G 4.00E-09 Primary tooth development (number of teeth) OPN1SW cds-synon 23704328 rs1799922 chr7 128415195 T G 9.00E-07 Primary tooth development (time to first tooth eruption) OPN1SW cds-synon 23704328 rs339039 chr7 128416561 G A 2.20E-07 Primary tooth development (time to first tooth eruption) OPN1SW nearGene-5 23704328 rs339038 chr7 128416587 T C 6.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OPN1SW nearGene-5 20877124 rs3736279 chr7 128434900 T C 2.02E-04 Alzheimer's disease (late onset) CCDC136 intron 21379329 rs1565630 chr7 128445266 T C 6.67E-04 Obesity (extreme) CCDC136 intron 21935397 rs2270590 chr7 128455916 G A 6.21E-04 Obesity (extreme) CCDC136 cds-synon 21935397 rs1994765 chr7 128472981 A G 1.77E-04 Obesity (extreme) FLNC intron 21935397 rs2132256 chr7 128476726 G C 1.10E-07 Health and aging,CVD and cancer age of onset FLNC intron 22174011 rs2132256 chr7 128476726 G C 5.10E-11 Health and aging,CVD and cancer age of onset FLNC intron 22174011 rs2291560 chr7 128477472 T C 3.21E-05 Attention deficit hyperactivity disorder FLNC cds-synon 20732627 rs2291567 chr7 128483227 T C 1.97E-06 Attention deficit hyperactivity disorder FLNC intron 20732627 rs2291567 chr7 128483227 T C 1.34E-05 Obesity (extreme) FLNC intron 21935397 rs3734973 chr7 128484816 A G 2.97E-06 Attention deficit hyperactivity disorder FLNC cds-synon 20732627 rs13227216 chr7 128490553 T C 2.90E-05 Attention deficit hyperactivity disorder FLNC intron 20732627 rs902842 chr7 128500139 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs13238831 chr7 128516470 T C 5.57E-06 Attention deficit hyperactivity disorder / / 20732627 rs729302 chr7 128568960 A C 2.00E-10 Systemic lupus erythematosus / / 18204446 rs729302 chr7 128568960 A C 4.62E-05 Alcohol dependence / / 19581569 rs729302 chr7 128568960 A C 1.45E-04 Systemic lupus erythematosus / / 19838193 rs729302 chr7 128568960 A C 7.90E-07 Systemic lupus erythematosus / / 21408207 rs729302 chr7 128568960 A C 4.00E-08 Systemic lupus erythematosus / / 23053960 rs729302 chr7 128568960 A C 2.30E-05 Myasthenia gravis / / 23055271 rs729302 chr7 128568960 A C 1.00E-09 Systemic lupus erythematosus / / 23273568 rs4728142 chr7 128573967 G A 8.00E-19 Systemic lupus erythematosus / / 19838193 rs4728142 chr7 128573967 G A 2.00E-08 Ulcerative colitis / / 21297633 rs4728142 chr7 128573967 G A 9.90E-12 Systemic lupus erythematosus / / 21408207 rs4728142 chr7 128573967 G A 0.0000113 Primary biliary cirrhosis / / 22936693 rs4728142 chr7 128573967 G A 1.31E-15 Primary biliary cirrhosis / / 22961000 rs4728142 chr7 128573967 G A 3.60E-04 Myasthenia gravis / / 23055271 rs4728142 chr7 128573967 G A 4.00E-14 Ulcerative colitis / / 23128233 rs4728142 chr7 128573967 G A 3.00E-09 Systemic lupus erythematosus / / 23273568 rs4728142 chr7 128573967 G A 3.35E-04 Ulcerative colitis / / 23511034 rs4728142 chr7 128573967 G A 7.00E-10 Systemic lupus erythematosus / / 24871463 rs4728142 chr7 128573967 G A 7.30E-07 Systemic lupus erythematosus / / pha002867 rs3778754 chr7 128575552 C G 2.81E-19 Primary biliary cirrhosis / / 22961000 rs3757387 chr7 128576086 T C 3.69E-19 Primary biliary cirrhosis IRF5 nearGene-5 22961000 rs3807307 chr7 128579202 T C 1.73E-19 Primary biliary cirrhosis IRF5 intron 22961000 rs3823536 chr7 128579666 G A 5.66E-19 Primary biliary cirrhosis IRF5 intron 22961000 rs3778753 chr7 128580042 A G 4.23E-19 Primary biliary cirrhosis IRF5 intron 22961000 rs3778753 chr7 128580042 A G 4.23E-19 Primary biliary cirrhosis IRF5 intron 22961000 rs3807306 chr7 128580680 G T 3.03E-05 Multiple complex diseases IRF5 intron 17554300 rs3807306 chr7 128580680 G T 2.00E-14 Progranulin levels IRF5 intron 21087763 rs3807306 chr7 128580680 G T 3.00E-07 Rheumatoid arthritis IRF5 intron 21156761 rs3807306 chr7 128580680 G T 2.00E-14 Myocardial infarction IRF5 intron 21211798 rs3807306 chr7 128580680 G T 0.00000493 Primary biliary cirrhosis IRF5 intron 22936693 rs3807306 chr7 128580680 G T 2.65E-17 Primary biliary cirrhosis IRF5 intron 22961000 rs3807306 chr7 128580680 G T 4.75E-10 Rheumatoid arthritis (CCP positive) IRF5 intron 23143596 rs3807306 chr7 128580680 G T 7.12E-10 Rheumatoid arthritis IRF5 intron 23143596 rs3807306 chr7 128580680 G T 7.74E-05 Smoking initiation IRF5 intron 24665060 rs7808907 chr7 128584084 T C 5.40E-09 Systemic lupus erythematosus IRF5 intron 21408207 rs7808907 chr7 128584084 T C 1.40E-08 Systemic lupus erythematosus IRF5 intron 24871463 rs7808907 chr7 128584084 T C 6.08E-06 Systemic lupus erythematosus IRF5 intron pha002867 rs10488631 chr7 128594183 T C 2.00E-11 Systemic lupus erythematosus TNPO3 nearGene-3 18204098 rs10488631 chr7 128594183 T C 2.00E-07 Primary biliary cirrhosis TNPO3 nearGene-3 19458352 rs10488631 chr7 128594183 T C 2.00E-13 Systemic sclerosis TNPO3 nearGene-3 20383147 rs10488631 chr7 128594183 T C 4.00E-11 Rheumatoid arthritis TNPO3 nearGene-3 20453842 rs10488631 chr7 128594183 T C 3.00E-10 Primary biliary cirrhosis TNPO3 nearGene-3 20639880 rs10488631 chr7 128594183 T C 4.20E-11 Celiac disease and Rheumatoid arthritis TNPO3 nearGene-3 21383967 rs10488631 chr7 128594183 T C 7.00E-18 Systemic lupus erythematosus TNPO3 nearGene-3 21408207 rs10488631 chr7 128594183 T C 4.00E-07 Systemic sclerosis TNPO3 nearGene-3 21750679 rs10488631 chr7 128594183 T C 1.00E-09 Systemic sclerosis TNPO3 nearGene-3 21779181 rs10488631 chr7 128594183 T C 2.00E-07 Systemic sclerosis TNPO3 nearGene-3 21779181 rs10488631 chr7 128594183 T C 2.00E-10 Systemic sclerosis TNPO3 nearGene-3 21779181 rs10488631 chr7 128594183 T C 8.00E-07 Systemic sclerosis TNPO3 nearGene-3 21779181 rs10488631 chr7 128594183 T C 4.20E-11 Multiple sclerosis TNPO3 nearGene-3 22190364 rs10488631 chr7 128594183 T C 2.52E-12 Primary biliary cirrhosis TNPO3 nearGene-3 22936693 rs10488631 chr7 128594183 T C 7.28E-11 Primary biliary cirrhosis in females TNPO3 nearGene-3 22936693 rs10488631 chr7 128594183 T C 9.32E-12 Primary biliary cirrhosis (anti-mitochondrial antibody positive) TNPO3 nearGene-3 22936693 rs10488631 chr7 128594183 T C 3.55E-21 Primary biliary cirrhosis TNPO3 nearGene-3 22961000 rs10488631 chr7 128594183 T C 4.00E-05 Myasthenia gravis TNPO3 nearGene-3 23055271 rs10488631 chr7 128594183 T C 4.20E-11 Rheumatoid arthritis TNPO3 nearGene-3 23143596 rs10488631 chr7 128594183 T C 2.00E-13 Systemic lupus erythematosus TNPO3 nearGene-3 24871463 rs10488631 chr7 128594183 T C 2.48E-06 Systemic lupus erythematosus TNPO3 nearGene-3 pha002867 rs2172876 chr7 128603292 G C 8.63E-06 Lymphocyte counts TNPO3 intron 22286170 rs1874332 chr7 128614613 C T 1.50E-04 Amyotrophic Lateral Sclerosis TNPO3 intron 17362836 rs12531711 chr7 128617466 A C,G 9.00E-17 Primary biliary cirrhosis TNPO3 intron 21399635 rs12531711 chr7 128617466 A C,G 6.00E-09 Systemic lupus erythematosus TNPO3 intron 21408207 rs12531711 chr7 128617466 A C,G 6.00E-13 Systemic lupus erythematosus TNPO3 intron 23053960 rs7789423 chr7 128621204 A G 9.20E-07 Systemic lupus erythematosus TNPO3 intron 24871463 rs2305324 chr7 128641226 G C 9.06E-05 Parkinson's disease TNPO3 cds-synon 17052657 rs13238352 chr7 128647942 C T 4.75E-11 Primary biliary cirrhosis TNPO3 intron 22936693 rs35234849 chr7 128648953 T C 2.31E-21 Primary biliary cirrhosis TNPO3 intron 22961000 rs2305325 chr7 128654840 T A 9.90E-05 Parkinson's disease TNPO3 intron 17052657 rs6965542 chr7 128655918 C T 2.10E-06 Systemic lupus erythematosus TNPO3 intron 21408207 rs12539476 chr7 128657483 T C 1.47E-16 Primary biliary cirrhosis TNPO3 intron 21399635 rs12155080 chr7 128658739 G C 4.15E-04 Alzheimer's disease TNPO3 intron 17998437 rs12155080 chr7 128658739 G C 2.50E-32 Lymphocyte counts TNPO3 intron 22286170 rs13236009 chr7 128663173 T G 2.31E-21 Primary biliary cirrhosis TNPO3 intron 22961000 rs10239340 chr7 128668510 T G 6.98E-16 Systemic lupus erythematosus TNPO3 intron 18204446 rs10239340 chr7 128668510 T G 9.30E-07 Systemic lupus erythematosus TNPO3 intron 21408207 rs10239340 chr7 128668510 T G 1.10E-07 Systemic lupus erythematosus TNPO3 intron 24871463 rs35188261 chr7 128683539 G A 6.52E-22 Primary biliary cirrhosis TNPO3 intron 22961000 rs10279821 chr7 128683547 T C 6.50E-09 Systemic lupus erythematosus TNPO3 intron 18204446 rs10279821 chr7 128683547 T C 3.80E-06 Systemic lupus erythematosus TNPO3 intron 24871463 rs2167273 chr7 128689413 C T 1.39E-04 Parkinson's disease TNPO3 intron 17052657 rs2167273 chr7 128689413 C T 1.60E-04 Amyotrophic Lateral Sclerosis TNPO3 intron 17362836 rs13239597 chr7 128695983 C A 1.00E-29 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs17167079 chr7 128709171 C T 2.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs1901198 chr7 128709789 A G 4.02E-04 Parkinson's disease / / 17052657 rs1901198 chr7 128709789 A G 4.50E-05 Amyotrophic Lateral Sclerosis / / 17362836 rs7795214 chr7 128710460 A G 2.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs13232316 chr7 128715299 T A 3.78E-04 Type 2 diabetes / / 17463246 rs12537284 chr7 128717906 G A 4.00E-19 Systemic lupus erythematosus / / 18204446 rs12537284 chr7 128717906 G A 2.80E-11 Systemic lupus erythematosus / / 21408207 rs12537284 chr7 128717906 G A 1.20E-11 Systemic lupus erythematosus / / 24871463 rs12537284 chr7 128717906 G A 2.37E-05 Systemic lupus erythematosus / / pha002867 rs2084654 chr7 128729128 A G 3.60E-06 Systemic lupus erythematosus / / 21408207 rs2084654 chr7 128729128 A G 4.10E-08 Systemic lupus erythematosus / / 24871463 rs11975493 chr7 128773770 G A 4.00E-05 Prostate cancer / / 21743057 rs2648 chr7 128808488 C T 8.00E-04 Lung adenocarcinoma TSPAN33 UTR-3 21242121 rs721691 chr7 128891659 C T 3.00E-05 Electrocardiographic traits and heart rate variability AHCYL2 intron 17903306 rs2056694 chr7 128923817 C T 1.10E-04 Kidney function and endocine traits AHCYL2 intron 17903292 rs1526897 chr7 128957954 G A 6.04E-04 Multiple complex diseases AHCYL2 intron 17554300 rs13227656 chr7 128972202 G A 5.70E-05 HIV-1 control AHCYL2 intron 20041166 rs11979476 chr7 128993756 T G 2.00E-06 Inflammatory biomarkers AHCYL2 intron 22228203 rs11766298 chr7 129004847 C T 4.00E-09 Response to fenofibrate AHCYL2 intron 22890011 rs2303303 chr7 129019736 G A 2.80E-04 Fibrinogen AHCYL2 intron 17255346 rs7787531 chr7 129023597 C T 9.00E-06 Tuberculosis AHCYL2 intron 20694014 rs1665105 chr7 129068978 G A 1.61E-04 Fibrinogen AHCYL2 UTR-3 17255346 rs1665105 chr7 129068978 G A 4.90E-05 Self-reported allergy AHCYL2 UTR-3 23817569 rs1665105 chr7 129068978 G A 7.36E-04 Heart Failure AHCYL2 UTR-3 pha002884 rs1272593 chr7 129103228 A G 6.80E-04 Type 2 diabetes FAM40B intron 17463246 rs17553578 chr7 129124748 C T 7.97E-04 Multiple complex diseases FAM40B intron 17554300 rs676947 chr7 129125825 T C 9.22E-04 Type 2 diabetes FAM40B UTR-3 17463246 rs613068 chr7 129128722 A G 3.70E-04 Type 2 diabetes / / 17463246 rs13223151 chr7 129129740 A G 9.83E-04 Multiple complex diseases / / 17554300 rs11771549 chr7 129147485 T G 5.29E-04 Tourette syndrome LOC100287482 intron 22889924 rs2598179 chr7 129187430 A C 0.000332967 Hypertension (early onset hypertension) / / 22479346 rs659495 chr7 129194092 C T 9.53E-05 Cognitive performance / / 19734545 rs10245560 chr7 129199328 G A 6.03E-05 Cognitive performance / / 19734545 rs754386 chr7 129214174 G A 7.78E-04 Type 2 diabetes / / 17463246 rs6961403 chr7 129218091 G A 3.80E-04 Major depressive disorder / / 21042317 rs6942490 chr7 129244793 C T 5.90E-04 Major depressive disorder LOC100127891 intron 21042317 rs753947 chr7 129252853 G A 4.10E-04 Major depressive disorder NRF1 intron 21042317 rs12706898 chr7 129254997 G T 8.30E-05 Serum metabolites NRF1 intron 19043545 rs7797729 chr7 129310092 T C 2.90E-04 Major depressive disorder NRF1 intron 21042317 rs17556430 chr7 129346290 C T 0.0000442 Amyotrophic lateral sclerosis NRF1 intron 23587638 rs17556430 chr7 129346290 C T 0.000048 Amyotrophic lateral sclerosis NRF1 intron 23587638 rs3736626 chr7 129350170 A C 5.97E-05 Amyotrophic lateral sclerosis NRF1 intron 20801717 rs3736626 chr7 129350170 A C 0.0000373 Amyotrophic lateral sclerosis NRF1 intron 23587638 rs3736626 chr7 129350170 A C 0.0000399 Amyotrophic lateral sclerosis NRF1 intron 23587638 rs9641855 chr7 129356206 G A 2.00E-06 Obesity-related traits NRF1 intron 23251661 rs2293629 chr7 129357298 T C 0.0000311 Amyotrophic lateral sclerosis NRF1 intron 23587638 rs2293629 chr7 129357298 T C 0.0000335 Amyotrophic lateral sclerosis NRF1 intron 23587638 rs7796553 chr7 129380243 T C 2.30E-04 Major depressive disorder NRF1 intron 21042317 rs7777812 chr7 129380421 C T 7.37E-04 Multiple complex diseases NRF1 intron 17554300 rs7777812 chr7 129380421 C T 2.60E-04 Major depressive disorder NRF1 intron 21042317 rs2631611 chr7 129454817 T C 2.04E-04 Alzheimer's disease (late onset) / / 21379329 rs2727464 chr7 129502461 G A 1.49E-04 Alzheimer's disease (late onset) UBE2H intron 21379329 rs3817530 chr7 129587224 T G 4.78E-04 Longevity UBE2H intron 22279548 rs2177773 chr7 129617357 T C 5.50E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11768743 chr7 129632081 A T 2.67E-05 Serum metabolites / / 19043545 rs940790 chr7 129645798 G A 5.71E-05 Type 2 diabetes / / 17463246 rs2402987 chr7 129646734 A G 3.58E-04 Type 2 diabetes / / 17463246 rs2402987 chr7 129646734 A G 4.49E-04 Multiple complex diseases / / 17554300 rs10265116 chr7 129655876 G A 1.82E-04 Multiple complex diseases / / 17554300 rs2242487 chr7 129657882 A G 2.15E-04 Schizophrenia / / 19197363 rs11556924 chr7 129663496 C T 2.35E-05 Multiple complex diseases ZC3HC1 missense 17554300 rs11556924 chr7 129663496 C T 9.00E-18 Coronary heart disease ZC3HC1 missense 21378990 rs11556924 chr7 129663496 C T 3.10E-07 Coronary heart disease ZC3HC1 missense 21966275 rs11556924 chr7 129663496 C T 2.81E-08 Coronary heart disease ZC3HC1 missense 22319020 rs11556924 chr7 129663496 C T 9.18E-18 Pericardial fat ZC3HC1 missense 22589742 rs11556924 chr7 129663496 C T 0.000000468 Coronary artery disease (CAD) age >50 ZC3HC1 missense 23202125 rs11556924 chr7 129663496 C T 0.0000179 Diastolic blood pressure ZC3HC1 missense 23202125 rs11556924 chr7 129663496 C T 0.000047 Coronary artery disease (CAD) (females) ZC3HC1 missense 23202125 rs11556924 chr7 129663496 C T 0.000127 Systolic blood pressure ZC3HC1 missense 23202125 rs11556924 chr7 129663496 C T 3.18E-12 Coronary artery disease with myocardial infarction ZC3HC1 missense 23202125 rs11556924 chr7 129663496 C T 4.83E-12 Coronary artery disease (CAD) (males) ZC3HC1 missense 23202125 rs11556924 chr7 129663496 C T 5.73E-10 Coronary artery disease (CAD) age <=50 ZC3HC1 missense 23202125 rs11556924 chr7 129663496 C T 0.00012 Coronary artery calcification ZC3HC1 missense 23727086 rs11556924 chr7 129663496 C T 3.00E-10 Coronary artery disease ZC3HC1 missense 24262325 rs11556924 chr7 129663496 C T 8.00E-10 Coronary artery disease or large artery stroke ZC3HC1 missense 24262325 rs11556924 chr7 129663496 C T 9.00E-10 Coronary artery disease or ischemic stroke ZC3HC1 missense 24262325 rs1464890 chr7 129664312 T C 2.62E-04 Schizophrenia ZC3HC1 missense 19197363 rs4507692 chr7 129670412 T C 2.30E-04 Schizophrenia ZC3HC1 intron 19197363 rs4507692 chr7 129670412 T C 2.10E-04 Renal cell carcinoma ZC3HC1 intron 22010048 rs6973585 chr7 129721932 A G 3.10E-04 Multiple complex diseases KLHDC10 intron 17554300 rs10251765 chr7 129723707 T G 1.60E-04 Asperger disorder KLHDC10 intron 21182207 rs17133163 chr7 129738451 T C 3.00E-05 Asperger disorder KLHDC10 intron 21182207 rs4236628 chr7 129751085 C T 9.98E-05 Coronary heart disease KLHDC10 intron pha003035 rs6821 chr7 129774714 C T 0.000451 Salmonella-induced pyroptosis KLHDC10 UTR-3 22837397 rs17647134 chr7 129776182 C G 7.69E-04 Multiple complex diseases / / 17554300 rs10241132 chr7 129799845 G A 4.84E-05 Cortisol secretion,in saliva / / 21316860 rs6467287 chr7 129822797 A G 3.22E-04 Alzheimer's disease TMEM209 intron 17998437 rs17164729 chr7 129842229 T C 1.82E-05 Cortisol secretion,in saliva TMEM209 intron 21316860 rs13229221 chr7 129886699 G A 7.16E-04 Heart Failure / / pha002885 rs4731688 chr7 129997061 A G 1.52E-04 Attention deficit hyperactivity disorder CPA5 intron pha002875 rs17164838 chr7 130000679 G C 5.98E-05 Multiple complex diseases CPA5 intron 17554300 rs4731689 chr7 130009839 C T 1.91E-06 Serum metabolites / / 19043545 rs12706927 chr7 130023539 C T 1.42E-04 Attention deficit hyperactivity disorder CPA1 cds-synon pha002875 rs10263705 chr7 130027633 A G 5.45E-05 Serum metabolites CPA1 intron 19043545 rs17164981 chr7 130101373 G T 4.98E-05 HIV-1 control / / 20041166 rs1990788 chr7 130125849 G A 7.35E-05 Bipolar disorder and schizophrenia MEST nearGene-5 20889312 rs12706940 chr7 130128793 C T 7.92E-04 Body mass index MEST intron 21701565 rs10863 chr7 130145589 A G 6.97E-06 Left ventricular mass MEST UTR-3 21212386 rs10128 chr7 130151694 T G 9.35E-04 Parkinson's disease / / 17052657 rs933752 chr7 130326837 G A 1.29E-04 Body mass index / / 21701565 rs933752 chr7 130326837 G A 2.15E-04 Body mass index / / 21701565 rs933752 chr7 130326837 G A 7.05E-04 Lymphocyte counts / / 22286170 rs11972315 chr7 130335560 A T 6.42E-05 Body mass index / / 21701565 rs11972315 chr7 130335560 A T 6.96E-05 Body mass index / / 21701565 rs6467312 chr7 130348044 C T 8.12E-04 Body mass index / / 21701565 rs6964185 chr7 130386523 A G 5.53E-05 Depression (quantitative trait) / / 23290196 rs11761863 chr7 130393780 C T 3.80E-04 Body mass index / / 21701565 rs4067228 chr7 130404776 G A 7.71E-04 Iron levels / / pha002876 rs11972183 chr7 130406015 A G 7.13E-04 Body mass index / / 21701565 rs290795 chr7 130415686 A T 3.83E-04 Body mass index / / 21701565 rs4731702 chr7 130433384 C T 1.00E-10 Lipid levels / / 19936222 rs4731702 chr7 130433384 C T 1.50E-09 Lipid levels / / 19936222 rs4731702 chr7 130433384 C T 2.20E-09 Lipid levels / / 19936222 rs4731702 chr7 130433384 C T 2.70E-11 Lipid levels / / 19936222 rs4731702 chr7 130433384 C T 3.90E-09 Lipid levels / / 19936222 rs4731702 chr7 130433384 C T 4.90E-07 Lipid levels / / 19936222 rs4731702 chr7 130433384 C T 5.40E-11 Lipid levels / / 19936222 rs4731702 chr7 130433384 C T 1.00E-15 HDL cholesterol / / 20686565 rs4731702 chr7 130433384 C T 5.00E-17 HDL cholesterol / / 24097068 rs11976955 chr7 130433594 C G 1.70E-04 Smoking behavior / / 20418888 rs11979110 chr7 130436459 C T 6.91E-04 Multiple complex diseases / / 17554300 rs13230111 chr7 130437124 A G 3.74E-04 Multiple complex diseases / / 17554300 rs13233731 chr7 130437689 G A 3.60E-04 Multiple complex diseases / / 17554300 rs13233731 chr7 130437689 G A 0.00000017 Type 2 diabetes / / 22885922 rs13233731 chr7 130437689 G A 7.00E-04 Type 2 diabetes / / 24509480 rs6467314 chr7 130442141 C G 0.0000022 Type 2 diabetes (females) / / 22885922 rs12667251 chr7 130449458 G A 0.0000542 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs149522 chr7 130449842 C T 0.000081 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs185963 chr7 130450151 C T 0.0000432 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs288484 chr7 130450197 A G 0.0000461 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs172306 chr7 130450387 G A 0.000045 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10954284 chr7 130463758 T A 4.09E-04 Multiple complex diseases / / 17554300 rs972283 chr7 130466854 A G 2.00E-10 Type 2 diabetes / / 20581827 rs972283 chr7 130466854 A G 2.00E-10 Type 2 diabetes / / 21647700 rs972283 chr7 130466854 A G 2.70E-04 Type 2 diabetes / / 21874001 rs972283 chr7 130466854 A G 0.00000058 Type 2 diabetes / / 22885922 rs972283 chr7 130466854 A G 2.00E-10 Type 2 diabetes / / 23300278 rs12234349 chr7 130490614 C T 5.74E-04 Smoking initiation / / 24665060 rs11981709 chr7 130509390 G A 3.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs11974908 chr7 130509410 A C 4.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs11972393 chr7 130509546 T C 4.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs11974458 chr7 130513816 A G 4.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs11982418 chr7 130515429 G T 3.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs17165157 chr7 130515505 T C 3.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs17165161 chr7 130515565 A G 2.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs2290027 chr7 130515801 T G 4.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs6963481 chr7 130517137 C T 8.32E-06 Scoliosis / / 21216876 rs6963481 chr7 130517137 C T 1.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs4425699 chr7 130518565 A G 1.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs11973626 chr7 130520459 C T 8.32E-06 Scoliosis / / 21216876 rs11973626 chr7 130520459 C T 1.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs6948655 chr7 130522773 T A 8.32E-06 Scoliosis / / 21216876 rs6948655 chr7 130522773 T A 2.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs207204 chr7 130523468 G T 1.50E-05 Urinary metabolites / / 21572414 rs7805466 chr7 130524369 G A 8.32E-06 Scoliosis / / 21216876 rs7805466 chr7 130524369 G A 1.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs4728200 chr7 130536491 C T 6.54E-04 Multiple complex diseases / / 17554300 rs7788240 chr7 130540408 G T 8.13E-04 Suicide attempts in bipolar disorder LOC100506860 intron 21423239 rs17165207 chr7 130565697 G C 4.90E-06 Urinary metabolites LOC100506860 intron 21572414 rs731730 chr7 130566755 T C 5.11E-04 Suicide attempts in bipolar disorder LOC100506860 intron 21423239 rs731729 chr7 130566795 T C 4.25E-04 Suicide attempts in bipolar disorder LOC100506860 intron 21423239 rs7783273 chr7 130567374 C T 4.09E-04 Suicide attempts in bipolar disorder LOC100506860 intron 21423239 rs157914 chr7 130568456 T C 4.90E-06 Urinary metabolites LOC646329 intron 21572414 rs157916 chr7 130569393 G A 9.96E-04 Suicide attempts in bipolar disorder LOC646329 intron 21423239 rs16873842 chr7 130570490 G A 6.66E-05 Suicide attempts in bipolar disorder LOC646329 intron 21423239 rs157917 chr7 130572600 T C 3.06E-04 Suicide attempts in bipolar disorder LOC646329 intron 21423239 rs207222 chr7 130575897 T G 1.76E-04 Suicide attempts in bipolar disorder LOC646329 intron 21423239 rs157921 chr7 130576263 G A 9.10E-04 Suicide attempts in bipolar disorder LOC646329 intron 21423239 rs157935 chr7 130585553 T G 9.00E-11 Basal cell carcinoma LOC646329 intron 24403052 rs205712 chr7 130612808 G C 4.10E-05 Heart rate / / 23583979 rs2048672 chr7 130653851 C A 6.00E-06 Breast cancer FLJ43663 intron 21908515 rs4141794 chr7 130667258 G A 6.86E-05 Pancreatic cancer FLJ43663 intron pha002889 rs10237038 chr7 130691182 C T 2.66E-05 Pancreatic cancer FLJ43663 intron pha002889 rs1588769 chr7 130696720 C T 8.07E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) FLJ43663 intron 23648065 rs11980527 chr7 130713621 C T 2.29E-04 Coronary heart disease FLJ43663 intron 21606135 rs350655 chr7 130713701 C A 0.000246 Common carotid artery thickness (average of near and far wall measures) FLJ43663 intron 23487405 rs350655 chr7 130713701 C A 0.000747 Internal carotid artery thickness (average of near and far walls) FLJ43663 intron 23487405 rs6951855 chr7 130724496 T A 1.17E-04 Coronary heart disease FLJ43663 intron 21606135 rs6973492 chr7 130724614 C G 1.99E-04 Coronary heart disease FLJ43663 intron 21606135 rs6944165 chr7 130744352 G A 1 Drug response to Etoposide FLJ43663 intron 17537913 rs10263975 chr7 130796393 A C 1.19E-04 Multiple complex diseases MKLN1 intron 17554300 rs4445168 chr7 130810971 G A 9.85E-04 Multiple complex diseases MKLN1 intron 17554300 rs4445168 chr7 130810971 G A 1.91E-05 Kawasaki disease MKLN1 intron 22446961 rs12532412 chr7 130826099 C T 1.88E-04 Multiple complex diseases MKLN1 intron 17554300 rs4731757 chr7 130839278 A C 6.66E-04 Multiple complex diseases MKLN1 intron 17554300 rs326234 chr7 130875552 G A 5.12E-05 Asthma MKLN1 intron 20159242 rs6978508 chr7 130884163 A C 9.83E-05 Major depressive disorder (broad) MKLN1 intron 20038947 rs17165483 chr7 130888388 A G 6.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MKLN1 intron 20877124 rs17165484 chr7 130888500 A G 9.82E-05 Major depressive disorder (broad) MKLN1 intron 20038947 rs1565051 chr7 130897144 G C 3.19E-06 Major depressive disorder (broad) MKLN1 intron 20038947 rs10265216 chr7 130900121 T A 3.00E-06 Major depressive disorder (broad) MKLN1 intron 20038947 rs7811386 chr7 130901642 C G 8.80E-06 Major depressive disorder (broad) MKLN1 intron 20038947 rs1979567 chr7 130903178 T C 1.62E-05 Major depressive disorder (broad) MKLN1 intron 20038947 rs6960667 chr7 130923445 A G 3.89E-04 Multiple complex diseases MKLN1 intron 17554300 rs6979264 chr7 130938585 G C 5.46E-04 Type 2 diabetes MKLN1 intron 17463246 rs6978995 chr7 130938612 C T 4.82E-04 Type 2 diabetes MKLN1 intron 17463246 rs6978995 chr7 130938612 C T 1.50E-05 Cholesterol MKLN1 intron pha003073 rs6978995 chr7 130938612 C T 8.33E-05 Cholesterol MKLN1 intron pha003078 rs10226063 chr7 130940227 T C 1.66E-05 Cholesterol MKLN1 intron pha003073 rs10226063 chr7 130940227 T C 9.32E-05 Cholesterol MKLN1 intron pha003078 rs4731776 chr7 130949410 G T 9.67E-05 Non-alcoholic fatty liver disease histology (other) MKLN1 intron 20708005 rs10236300 chr7 130953394 T C 0.0002685 Sarcoidosis MKLN1 intron 22952805 rs6943595 chr7 130957256 A G 9.82E-04 Alzheimer's disease MKLN1 intron 22005930 rs4728215 chr7 130960827 A G 5.01E-04 Smoking initiation MKLN1 intron 24665060 rs2171356 chr7 130963871 C A 4.43E-04 Type 2 diabetes MKLN1 intron 17463246 rs10268466 chr7 130967875 G C 4.31E-04 Alzheimer's disease (late onset) MKLN1 intron 21379329 rs10954312 chr7 130969771 C T 5.49E-06 Body Fat Distribution MKLN1 intron pha003017 rs10954312 chr7 130969771 C T 3.15E-05 Body Fat Distribution MKLN1 intron pha003018 rs4731781 chr7 130975108 A C 6.04E-04 Type 2 diabetes MKLN1 intron 17463246 rs17165557 chr7 130987321 T C 4.32E-06 Height MKLN1 intron 22021425 rs3823483 chr7 131010943 T C 6.60E-04 Amyotrophic Lateral Sclerosis MKLN1 intron 17362836 rs7807274 chr7 131021099 G A 4.00E-06 Asthma (childhood onset) MKLN1 intron 23829686 rs6963574 chr7 131041582 C T 7.70E-05 Schizophrenia MKLN1 intron 19571809 rs6963574 chr7 131041582 C T 3.99E-05 Schizophrenia MKLN1 intron pha002859 rs4099560 chr7 131050758 G A 9.42E-05 Blood Pressure MKLN1 intron pha003049 rs7799613 chr7 131190554 C G 7.73E-05 Cognitive impairment induced by topiramate PODXL intron 22091778 rs2433294 chr7 131199903 C G 1.87E-04 Breast cancer PODXL intron 21060860 rs1625957 chr7 131212431 C A 3.03E-05 Monocyte chemoattractant protein-1 PODXL intron pha003071 rs9649034 chr7 131212459 G A 2.15E-04 Smoking initiation PODXL intron 24665060 rs6953894 chr7 131223177 A G 7.16E-04 Alcohol dependence PODXL intron 21314694 rs7807320 chr7 131226911 G T 1.02E-04 Alcohol dependence PODXL intron 21314694 rs1465387 chr7 131231032 G A 2.68E-05 Serum metabolites PODXL intron 19043545 rs1465387 chr7 131231032 G A 5.77E-05 Hepatocellular carcinoma PODXL intron 22807686 rs1582412 chr7 131244686 T C 1.00E-05 Urinary metabolites / / 21572414 rs4731800 chr7 131287491 G A 4.58E-05 Triglycerides / / pha003081 rs4731800 chr7 131287491 G A 7.71E-05 Lipid levels / / pha003082 rs12534221 chr7 131287990 C A 9.00E-07 AB1-42 levels / / 20932310 rs11765908 chr7 131288662 G A 3.09E-04 Obesity (extreme) / / 21935397 rs4728225 chr7 131327412 A G 5.04E-04 Smoking quantity / / 24665060 rs918339 chr7 131327818 T C 5.50E-04 Smoking quantity / / 24665060 rs2909678 chr7 131334001 T C 1.73E-05 Aging (time to event) / / 21782286 rs199973478 chr7 131334612 T TC 5.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs2909679 chr7 131334612 T C 5.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs3885619 chr7 131347009 T C 9.74E-04 Multiple complex diseases / / 17554300 rs11764710 chr7 131363452 G A 3.81E-05 Major depressive disorder / / 21621269 rs11761231 chr7 131370039 T C 4.00E-07 Rheumatoid arthritis / / 17554300 rs11761231 chr7 131370039 T C 0.000335 Rate of forced expiratory volume in 1 second (FEV1) decline (young adult women) / / 23527081 rs11769128 chr7 131373213 G A 8.12E-05 Lipoproteins / / pha003079 rs6467383 chr7 131375360 C T 4.78E-05 Post-operative nausea and vomiting / / 21694509 rs6467383 chr7 131375360 C T 8.39E-05 Lipoproteins / / pha003079 rs4076505 chr7 131380008 T C 3.65E-06 Glaucoma (primary open-angle) / / 22605921 rs10282190 chr7 131383556 C T 6.43E-05 Cognitive impairment induced by topiramate / / 22091778 rs10231383 chr7 131385220 G A 7.01E-05 Major depressive disorder / / 19107115 rs10231383 chr7 131385220 G A 6.43E-06 Amyotrophic lateral sclerosis / / 19193627 rs10231383 chr7 131385220 G A 9.36E-05 Information processing speed / / 21130836 rs10231383 chr7 131385220 G A 3.19E-05 Cognitive impairment induced by topiramate / / 22091778 rs11764453 chr7 131452984 C T 1.60E-05 Urinary metabolites / / 21572414 rs1106683 chr7 131453525 G A 1.80E-04 Multiple complex diseases / / 17554300 rs1106683 chr7 131453525 G A 1.00E-07 Body mass index / / 17903300 rs1106684 chr7 131453665 C G 1.67E-04 Multiple complex diseases / / 17554300 rs1106684 chr7 131453665 C G 2.00E-06 Body mass index / / 17903300 rs1106684 chr7 131453665 C G 2.80E-05 Urinary metabolites / / 21572414 rs12534413 chr7 131453964 C T 2.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4535659 chr7 131454056 G A 1.12E-04 Multiple complex diseases / / 17554300 rs4535659 chr7 131454056 G A 2.80E-05 Urinary metabolites / / 21572414 rs1477226 chr7 131455364 T C 7.01E-05 Multiple complex diseases / / 17554300 rs1477228 chr7 131455563 C T 3.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12535855 chr7 131455993 C T 9.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs10954327 chr7 131458006 A G 1.34E-04 Multiple complex diseases / / 17554300 rs10954328 chr7 131458025 C T 1.46E-04 Multiple complex diseases / / 17554300 rs10954328 chr7 131458025 C T 1.60E-05 Urinary metabolites / / 21572414 rs11767669 chr7 131462696 T G 6.81E-05 Multiple complex diseases / / 17554300 rs11767669 chr7 131462696 T G 5.10E-06 Urinary metabolites / / 21572414 rs11770938 chr7 131462790 A G 1.16E-04 Multiple complex diseases / / 17554300 rs11770938 chr7 131462790 A G 1.80E-05 Urinary metabolites / / 21572414 rs17792713 chr7 131463279 C T 5.91E-05 Multiple complex diseases / / 17554300 rs17792713 chr7 131463279 C T 2.80E-05 Urinary metabolites / / 21572414 rs2058965 chr7 131472013 A G 8.14E-04 Parkinson's disease / / 17052657 rs6467390 chr7 131480515 T G 5.27E-04 Parkinson's disease / / 17052657 rs1122732 chr7 131505116 T G 2.10E-04 Vaspin levels / / 22907691 rs1122732 chr7 131505116 T G 0.0002104 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs10954340 chr7 131522786 G A 5.25E-05 Blood Pressure / / pha003046 rs11771563 chr7 131526745 T C 7.27E-05 Weight / / pha003027 rs3885260 chr7 131532931 A G 8.87E-05 Cognitive test performance / / 20125193 rs9641911 chr7 131572510 G T 8.06E-05 Cognitive test performance / / 20125193 rs10271989 chr7 131606162 G A 5.60E-06 Brain size / / 22156575 rs2113889 chr7 131643432 A G 4.98E-05 Serum metabolites / / 19043545 rs1514055 chr7 131679290 A C 3.39E-04 Coronary heart disease / / 21606135 rs7811818 chr7 131708281 T C 7.37E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17166082 chr7 131713360 G A 9.00E-06 Self-employment / / 23593239 rs1567857 chr7 131727515 A G 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10954355 chr7 131750195 C T 1.56E-05 Major depressive disorder (broad) / / 20038947 rs10248132 chr7 131750471 C T 2.18E-05 Major depressive disorder (broad) / / 20038947 rs4731841 chr7 131761018 G T 3.25E-05 Major depressive disorder (broad) / / 20038947 rs4731843 chr7 131762179 A G 9.95E-05 Major depressive disorder (broad) / / 20038947 rs4731844 chr7 131763974 C T 3.05E-05 Major depressive disorder (broad) / / 20038947 rs4731845 chr7 131766198 C T 2.81E-05 Major depressive disorder (broad) / / 20038947 rs9649571 chr7 131767043 T C 2.95E-05 Major depressive disorder (broad) / / 20038947 rs12707024 chr7 131768074 G A 2.91E-05 Major depressive disorder (broad) / / 20038947 rs1514051 chr7 131768282 C T 2.91E-05 Major depressive disorder (broad) / / 20038947 rs6976275 chr7 131769118 G A 1.90E-05 Urinary metabolites / / 21572414 rs6963716 chr7 131770215 T C 0.00000204 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1355883 chr7 131775747 A G 4.32E-05 Body Fat Distribution / / pha003017 rs1355883 chr7 131775747 A G 8.05E-05 Body Fat Distribution / / pha003018 rs12113818 chr7 131783493 G A 4.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs281916 chr7 131802832 G A 7.21E-08 Cognitive impairment induced by topiramate / / 22091778 rs33938893 chr7 131807918 C T 8.10E-06 Urinary metabolites / / 21572414 rs10954361 chr7 131815343 G A 7.00E-06 Cognitive function PLX/4 intron 24684796 rs6977223 chr7 131816872 C T 9.26E-05 Cognitive test performance PLX/4 intron 20125193 rs281877 chr7 131821468 T A 6.16E-06 Bilirubin levels,in serum PLX/4 intron 19389676 rs4728251 chr7 131828336 C T 2.14E-05 Serum metabolites PLX/4 intron 19043545 rs10273901 chr7 131828567 T C 2.03E-04 Multiple complex diseases PLX/4 intron 17554300 rs1399090 chr7 131829128 C T 7.00E-06 Economic and political preferences PLX/4 intron 22566634 rs1450883 chr7 131834268 C T 4.49E-04 Smoking initiation PLX/4 intron 24665060 rs10251791 chr7 131852610 T C 3.84E-06 Homeostasis model assessment of beta-cell function (interaction) PLX/4 intron 24204828 rs12386622 chr7 131853601 G A 3.00E-06 Homeostasis model assessment of beta-cell function (interaction) PLX/4 intron 24204828 rs10277421 chr7 131859077 T C 8.45E-05 Alcohol consumption PLX/4 intron 23743675 rs7808586 chr7 131859496 G A 9.35E-05 Alcohol consumption PLX/4 intron 23743675 rs3734992 chr7 131862530 G T 8.43E-04 Type 2 diabetes PLX/4 intron 17463246 rs3734992 chr7 131862530 G T 6.31E-04 Coronary Artery Disease PLX/4 intron 17634449 rs3734991 chr7 131862710 G A 1.62E-05 Systemic lupus erythematosus PLX/4 intron pha002867 rs3734989 chr7 131864591 T C 2.01E-05 Alcohol consumption PLX/4 cds-synon 23743675 rs896170 chr7 131865092 T C 3.09E-04 Alcohol dependence PLX/4 intron 20201924 rs7809724 chr7 131865683 T C 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer PLX/4 intron 21245432 rs6968634 chr7 131867842 G A 4.50E-05 Alcohol consumption PLX/4 intron 23743675 rs6946056 chr7 131870597 A C 1.47E-04 Alcohol consumption PLX/4 intron 23743675 rs1868778 chr7 131889536 T C 4.49E-04 Longevity PLX/4 intron 22279548 rs9692157 chr7 131895155 A G 1.42E-05 Calcium intake levels and metabolic syndrome PLX/4 intron 22170361 rs13227818 chr7 131899254 C T 7.40E-04 Myocardial infarction PLX/4 intron 21107343 rs2880160 chr7 131900703 G C 6.52E-05 Calcium intake levels and metabolic syndrome PLX/4 intron 22170361 rs1991118 chr7 131921239 T C 6.00E-04 Multiple complex diseases PLX/4 intron 17554300 rs10488380 chr7 131922415 G A 2.02E-06 Alzheimer's disease PLX/4 intron 17998437 rs6944400 chr7 131932485 T C 8.20E-05 Subclinical atherosclerosis PLX/4 intron 17903303 rs7799929 chr7 131933308 A G 3.19E-04 Alzheimer's disease PLX/4 intron 25043464 rs6973565 chr7 131942644 T A 1.40E-06 Primary sclerosing cholangitis PLX/4 intron 21151127 rs4731857 chr7 131947532 G A 0.000410084 Hypertension (early onset hypertension) PLX/4 intron 22479346 rs717007 chr7 131950297 C A 1.25E-04 Glycosylated haemoglobin levels PLX/4 intron 17255346 rs11763817 chr7 131982301 G A 2.66E-04 Alzheimer's disease PLX/4 intron 25043464 rs13231950 chr7 131996949 T C 4.30E-06 Primary sclerosing cholangitis PLX/4 intron 21151127 rs2042513 chr7 132007379 T C 1.16E-04 Height PLX/4 intron 17255346 rs2042513 chr7 132007379 T C 4.60E-04 Primary sclerosing cholangitis PLX/4 intron 19944697 rs965801 chr7 132007770 G C 1.58E-04 Height PLX/4 intron 17255346 rs10244929 chr7 132008454 G C 1.94E-04 Alzheimer's disease PLX/4 intron 25043464 rs1364505 chr7 132030011 G A 2.00E-09 Venous thromboembolism (gene x gene interaction) PLX/4 intron 23509962 rs6959579 chr7 132032495 G A 5.20E-04 Alzheimer's disease PLX/4 intron 25043464 rs11761937 chr7 132034826 C A 5.91E-05 Alzheimer's disease PLX/4 intron 25043464 rs12539196 chr7 132037683 A C 2.82E-05 Alzheimer's disease PLX/4 intron 25043464 rs10954373 chr7 132063153 T G 4.79E-04 Myopia (pathological) PLX/4 intron 21095009 rs6467438 chr7 132063248 T G 4.79E-04 Myopia (pathological) PLX/4 intron 21095009 rs7807933 chr7 132063522 A G 1.20E-05 Urinary metabolites PLX/4 intron 21572414 rs10269601 chr7 132064886 C A 1.10E-05 Malaria PLX/4 intron 19465909 rs10269601 chr7 132064886 C A 1.20E-05 Urinary metabolites PLX/4 intron 21572414 rs4731867 chr7 132069727 T G 9.00E-05 Malaria PLX/4 UTR-3 19465909 rs17221229 chr7 132070086 C A 2.40E-05 Urinary metabolites PLX/4 intron 21572414 rs1529764 chr7 132079413 C T 4.99E-04 Myopia (pathological) PLX/4 intron 21095009 rs1560769 chr7 132085809 T C 5.70E-06 Urinary metabolites PLX/4 intron 21572414 rs2341825 chr7 132094453 C A 5.60E-04 Atrial fibrillation PLX/4 intron 21846873 rs1000058 chr7 132097016 C A 7.33E-04 Response to taxane treatment (placlitaxel) PLX/4 intron 23006423 rs277470 chr7 132110923 C G 4.05E-08 Alzheimer's disease PLX/4 intron 25043464 rs277472 chr7 132113187 G T 2.32E-06 Alzheimer's disease PLX/4 intron 25043464 rs277476 chr7 132114540 C T 9.88E-04 Alzheimer's disease PLX/4 intron 25043464 rs2288975 chr7 132114617 A G 9.14E-04 Type 2 diabetes PLX/4 intron 17463246 rs2241728 chr7 132115060 C T 2.19E-04 Response to cytidine analogues (gemcitabine) PLX/4 intron 24483146 rs277481 chr7 132115820 A G 4.19E-05 Odorant perception PLX/4 intron 23910658 rs277484 chr7 132119654 T C 4.96E-06 Alzheimer's disease PLX/4 intron 25043464 rs7784129 chr7 132137650 G A 9.84E-05 Type 2 diabetes PLX/4 intron 17463246 rs10808265 chr7 132189689 G A 2.00E-06 Pulmonary function decline PLX/4 intron 22424883 rs156962 chr7 132192949 T C 9.85E-04 Type 2 diabetes PLX/4 cds-synon 17463246 rs10273006 chr7 132321422 G A 6.73E-04 Multiple complex diseases PLX/4 intron 17554300 rs34411527 chr7 132323469 T C 8.86E-04 Multiple complex diseases PLX/4 intron 17554300 rs34411527 chr7 132323469 T C 9.36E-04 Suicide attempts in bipolar disorder PLX/4 intron 21423239 rs4731889 chr7 132325309 A G 7.36E-04 Suicide attempts in bipolar disorder PLX/4 intron 21423239 rs4731889 chr7 132325309 A G 5.00E-06 Oleic acid (18:1n-9) plasma levels PLX/4 intron 23362303 rs6948781 chr7 132325596 C T 5.59E-04 Multiple complex diseases PLX/4 intron 17554300 rs6948781 chr7 132325596 C T 6.73E-04 Suicide attempts in bipolar disorder PLX/4 intron 21423239 rs679868 chr7 132328170 A C 6.11E-06 Blood Pressure PLX/4 intron pha003043 rs13224271 chr7 132335088 A G 7.16E-04 Response to statin treatment (atorvastatin),change in cholesterol levels FLJ40288 intron 20031582 rs1544832 chr7 132351489 T C 1.00E-05 Endometriosis FLJ40288 intron 21151130 rs728469 chr7 132367230 C T 6.10E-05 Blood pressure FLJ40288 intron 19114657 rs665506 chr7 132372533 C T 3.18E-04 Multiple complex diseases FLJ40288 intron 17554300 rs7790859 chr7 132373204 C A 2.19E-04 Aortic root size FLJ40288 intron 21223598 rs523343 chr7 132386086 T G 9.30E-05 Major depressive disorder FLJ40288 intron 21042317 rs527159 chr7 132386513 A T 1.10E-04 Major depressive disorder FLJ40288 intron 21042317 rs541186 chr7 132389459 G C 8.30E-05 Major depressive disorder FLJ40288 intron 21042317 rs580068 chr7 132409194 C A 2.10E-04 Major depressive disorder FLJ40288 intron 21042317 rs10233448 chr7 132411901 G A 7.35E-04 White matter integrity FLJ40288 intron 22425255 rs10215173 chr7 132441715 G A 2.52E-05 Panic disorder / / 19165232 rs1318460 chr7 132469174 C A 1.83E-04 Obesity (extreme) / / 21935397 rs2241439 chr7 132480895 T G 7.75E-04 Response to taxane treatment (placlitaxel) CHCHD3 intron 23006423 rs10244815 chr7 132485072 C T 2.24E-04 Multiple complex diseases CHCHD3 intron 17554300 rs13246875 chr7 132490352 T A 4.87E-04 Type 2 diabetes CHCHD3 intron 17463246 rs889944 chr7 132491704 G A 6.91E-04 Obesity (extreme) CHCHD3 intron 21935397 rs10435414 chr7 132495299 T C 7.06E-04 Obesity (extreme) CHCHD3 intron 21935397 rs10435414 chr7 132495299 T C 4.92E-04 Response to taxane treatment (placlitaxel) CHCHD3 intron 23006423 rs4731901 chr7 132508581 T A 7.05E-04 Type 2 diabetes CHCHD3 intron 17463246 rs4731903 chr7 132521731 G C 8.33E-04 Obesity (extreme) CHCHD3 intron 21935397 rs3807325 chr7 132523462 A G 4.64E-04 Response to taxane treatment (placlitaxel) CHCHD3 intron 23006423 rs12667678 chr7 132533663 T C 3.74E-04 Response to taxane treatment (placlitaxel) CHCHD3 intron 23006423 rs7790698 chr7 132586161 C T 8.59E-05 Response to taxane treatment (placlitaxel) CHCHD3 intron 23006423 rs4731919 chr7 132599986 G A 4.35E-04 Multiple complex diseases CHCHD3 intron 17554300 rs4731919 chr7 132599986 G A 4.00E-04 Response to taxane treatment (placlitaxel) CHCHD3 intron 23006423 rs2058943 chr7 132603303 C T 5.56E-04 Response to taxane treatment (placlitaxel) CHCHD3 intron 23006423 rs4731920 chr7 132604899 G A 6.26E-04 Multiple complex diseases CHCHD3 intron 17554300 rs7790787 chr7 132607171 T C 8.93E-04 Multiple complex diseases CHCHD3 intron 17554300 rs7790787 chr7 132607171 T C 5.56E-04 Response to taxane treatment (placlitaxel) CHCHD3 intron 23006423 rs2042066 chr7 132611681 C T 9.37E-04 Response to taxane treatment (placlitaxel) CHCHD3 intron 23006423 rs6968495 chr7 132639435 T G 2.18E-04 Multiple complex diseases CHCHD3 intron 17554300 rs12533584 chr7 132639577 G A 5.08E-04 Multiple complex diseases CHCHD3 intron 17554300 rs7787607 chr7 132657680 A T 9.00E-06 Urinary metabolites CHCHD3 intron 21572414 rs2058945 chr7 132658084 C A 9.17E-04 Type 2 diabetes CHCHD3 intron 17463246 rs10247648 chr7 132681093 C G 6.26E-04 Multiple complex diseases CHCHD3 intron 17554300 rs6977953 chr7 132681426 T G 3.96E-04 Multiple complex diseases CHCHD3 intron 17554300 rs2111815 chr7 132699246 G A 1.14E-04 Amyotrophic Lateral Sclerosis CHCHD3 intron 17362836 rs2111815 chr7 132699246 G A 9.00E-04 Type 2 diabetes CHCHD3 intron 21874001 rs11982160 chr7 132702771 G C 2.10E-05 Urinary metabolites CHCHD3 intron 21572414 rs41519445 chr7 132835204 T G 7.48E-05 Schizophrenia / / 19571809 rs6942866 chr7 132869834 T C 1.78E-04 Multiple sclerosis / / 17660530 rs4389875 chr7 132873077 C T 1.79E-04 Multiple sclerosis / / 17660530 rs4275150 chr7 132880264 C T 2.15E-05 Triglycerides / / pha003080 rs13242614 chr7 132966299 T C 6.81E-05 Schizophrenia EXOC4 intron 19571809 rs10488165 chr7 133137644 T C 2.60E-06 Obesity-related traits EXOC4 intron 17903300 rs12707092 chr7 133188145 C G 6.26E-04 Multiple complex diseases EXOC4 intron 17554300 rs17167141 chr7 133235334 G A 2.05E-05 Smoking quantity EXOC4 intron 24665060 rs11526285 chr7 133280339 G T 2.79E-04 Smoking quantity EXOC4 intron 24665060 rs17167177 chr7 133310218 G C 4.26E-04 Smoking quantity EXOC4 intron 24665060 rs2042000 chr7 133322697 T C 3.04E-05 Information processing speed EXOC4 intron 21130836 rs17167187 chr7 133330853 C T 3.71E-04 Smoking quantity EXOC4 intron 24665060 rs10488172 chr7 133335176 T G 8.00E-06 Tonometry EXOC4 intron 17903302 rs7792396 chr7 133345526 T C 1.56E-05 Information processing speed EXOC4 intron 21130836 rs7803626 chr7 133351360 G T 3.59E-04 Smoking quantity EXOC4 intron 24665060 rs10954428 chr7 133388056 G A 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes EXOC4 intron 22628534 rs6976491 chr7 133401063 T G 3.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EXOC4 intron 20877124 rs10274328 chr7 133409403 T C 3.28E-04 Multiple complex diseases EXOC4 intron 17554300 rs10274328 chr7 133409403 T C 8.68E-05 Bone mineral density EXOC4 intron 19181680 rs6963221 chr7 133440786 T G 3.14E-04 Multiple complex diseases EXOC4 intron 17554300 rs6963221 chr7 133440786 T G 5.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EXOC4 intron 20877124 rs985101 chr7 133441165 A T 4.07E-04 Multiple complex diseases EXOC4 intron 17554300 rs7797067 chr7 133441408 T C 2.45E-04 Multiple complex diseases EXOC4 intron 17554300 rs13222377 chr7 133466346 G A 4.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EXOC4 intron 20877124 rs7809238 chr7 133468327 C A 1.20E-05 Urinary metabolites EXOC4 intron 21572414 rs1476118 chr7 133474772 C T 1.25E-04 Alcohol dependence EXOC4 intron 20201924 rs17167308 chr7 133551324 T C 1.90E-05 Urinary metabolites EXOC4 intron 21572414 rs2113340 chr7 133555580 G A 7.43E-04 Multiple complex diseases EXOC4 intron 17554300 rs958404 chr7 133597186 A C 1.00E-04 Information processing speed EXOC4 intron 21130836 rs1030268 chr7 133606631 A G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes EXOC4 intron 22628534 rs2971955 chr7 133665939 A G 9.75E-04 Type 2 diabetes EXOC4 intron 17463246 rs7785128 chr7 133684991 T C 3.08E-04 Response to cytidine analogues (gemcitabine) EXOC4 intron 24483146 rs7785128 chr7 133684991 T C 5.93E-04 Response to cytadine analogues (cytosine arabinoside) EXOC4 intron 24483146 rs2002866 chr7 133690378 A G 3.08E-04 Response to cytidine analogues (gemcitabine) EXOC4 intron 24483146 rs4731992 chr7 133702097 A G 3.40E-04 Body mass index EXOC4 intron 21701565 rs4731992 chr7 133702097 A G 7.53E-04 Response to cytidine analogues (gemcitabine) EXOC4 intron 24483146 rs2346443 chr7 133706383 G A 9.26E-04 Response to cytidine analogues (gemcitabine) EXOC4 intron 24483146 rs4728307 chr7 133730639 C T 9.44E-05 Cognitive impairment induced by topiramate EXOC4 intron 22091778 rs4731997 chr7 133746764 T G 7.96E-04 Tourette syndrome EXOC4 intron 22889924 rs11770757 chr7 133747946 G A,C,T 5.00E-07 Alzheimer's disease (cognitive decline) EXOC4 intron 23535033 rs7782175 chr7 133827457 T C 9.11E-04 Multiple complex diseases LRGUK intron 17554300 rs146922831 chr7 133886309 G T 3.01E-08 Body mass index LRGUK missense 23555315 rs2544165 chr7 133920443 G A 6.01E-04 Lymphocyte counts LRGUK intron 22286170 rs1450890 chr7 133934197 G A 7.03E-04 Amyotrophic Lateral Sclerosis LRGUK intron 17362836 rs1901214 chr7 133945108 T C 8.29E-05 Acute lymphoblastic leukemia (childhood) LRGUK intron 19684603 rs393459 chr7 133970444 T G 9.61E-04 Alcohol dependence / / 21314694 rs1619682 chr7 133996703 T G 1.00E-04 Obesity-related traits SLC35B4 intron 17903300 rs759856 chr7 134028580 T C 4.46E-04 Multiple complex diseases / / 17554300 rs6972323 chr7 134029281 G A 7.80E-04 Multiple complex diseases / / 17554300 rs1558993 chr7 134041588 C T 7.12E-04 Alzheimer's disease / / 17998437 rs6946578 chr7 134041878 G A 8.08E-04 Multiple complex diseases / / 17554300 rs6946578 chr7 134041878 G A 7.40E-04 Alzheimer's disease / / 17998437 rs6957963 chr7 134044182 G A 5.98E-04 Alzheimer's disease / / 17998437 rs1364427 chr7 134061955 G A 4.60E-05 HIV-1 control / / 20041166 rs1618398 chr7 134071269 T A 9.98E-04 Type 2 diabetes / / 17463246 rs7811948 chr7 134076208 G A 4.00E-04 Alzheimer's disease / / 17998437 rs17772766 chr7 134079073 G C 1.00E-04 Prostate cancer / / 21743057 rs10263438 chr7 134118483 A T 2.17E-04 Type 2 diabetes / / 17463246 rs1708416 chr7 134123831 A G 1.70E-05 Urinary metabolites / / 21572414 rs1791001 chr7 134125056 G C 1.40E-04 Type 2 diabetes / / 17463246 rs7788953 chr7 134171722 A G 3.86E-04 Parkinson's disease / / 17052657 rs782522 chr7 134193822 A G 4.38E-05 Serum metabolites / / 19043545 rs12667598 chr7 134201331 A T 6.95E-05 Serum metabolites / / 19043545 rs7789833 chr7 134202422 A G 9.19E-05 Serum metabolites / / 19043545 rs9656438 chr7 134208616 G A 8.04E-05 Serum metabolites / / 19043545 rs10232478 chr7 134209074 T C 9.19E-05 Serum metabolites / / 19043545 rs2347377 chr7 134216318 A G 7.53E-04 Insulin resistance AKR1B10 intron 21901158 rs2347377 chr7 134216318 A G 2.10E-10 HDL cholesterol AKR1B10 intron 23063622 rs4728329 chr7 134225827 A G 0.00003 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer AKR1B10 missense 21245432 rs4732038 chr7 134250322 A C 1.00E-06 Longevity AKR1B15 intron 20834067 rs13228697 chr7 134296733 T G 3.44E-04 Psoriasis / / 20953187 rs4142278 chr7 134305426 C T 2.44E-04 Psoriasis / / 20953187 rs2032943 chr7 134314404 G T 5.25E-04 Rheumatoid arthritis / / 21452313 rs12533064 chr7 134315856 T C 4.27E-04 Rheumatoid arthritis / / 21452313 rs3800695 chr7 134345543 T C 9.51E-04 Rheumatoid arthritis BPGM intron 21452313 rs10274047 chr7 134370479 T G 2.56E-05 Waist Circumference / / pha003024 rs10274047 chr7 134370479 T G 6.99E-07 Waist-Hip Ratio / / pha003029 rs7803568 chr7 134370518 A C 6.73E-04 Obesity (extreme) / / 21935397 rs12707169 chr7 134384117 T C 6.54E-04 Multiple complex diseases / / 17554300 rs6972896 chr7 134388518 A G 3.51E-04 Multiple complex diseases / / 17554300 rs6467552 chr7 134390473 C T 7.24E-04 Multiple complex diseases / / 17554300 rs10488449 chr7 134391874 A G 6.59E-05 Serum metabolites / / 19043545 rs12707170 chr7 134392953 T C 3.00E-07 Urinary metabolites / / 21572414 rs6978666 chr7 134410561 T C 4.50E-07 Urinary metabolites / / 21572414 rs10954465 chr7 134412209 A G 6.00E-07 Urinary metabolites / / 21572414 rs2347713 chr7 134414528 T G 9.55E-04 Acute lung injury / / 22295056 rs10808276 chr7 134425170 T C 7.66E-04 Acute lung injury / / 22295056 rs11763293 chr7 134425369 C G 8.23E-04 Acute lung injury / / 22295056 rs11766904 chr7 134425447 T C 1.10E-06 Urinary metabolites / / 21572414 rs10808277 chr7 134425852 T A 1.80E-06 Urinary metabolites / / 21572414 rs11771203 chr7 134426682 A T 3.10E-06 Urinary metabolites / / 21572414 rs11768639 chr7 134426763 T C 1.80E-06 Urinary metabolites / / 21572414 rs10954467 chr7 134426906 A G 1.80E-06 Urinary metabolites / / 21572414 rs17791917 chr7 134428889 T G 1.70E-06 Urinary metabolites / / 21572414 rs17202648 chr7 134428978 T A 1.80E-06 Urinary metabolites / / 21572414 rs12538586 chr7 134429410 T C 1.80E-06 Urinary metabolites / / 21572414 rs12670849 chr7 134430040 C G 6.90E-07 Urinary metabolites / / 21572414 rs12539126 chr7 134435437 T C 6.73E-05 Bipolar disorder / / 19488044 rs12539126 chr7 134435437 T C 8.96E-05 Bipolar Disorder / / pha002863 rs6956766 chr7 134436349 T C 1.70E-06 Urinary metabolites / / 21572414 rs716180 chr7 134436831 A C 3.30E-06 Urinary metabolites / / 21572414 rs10488456 chr7 134438524 A G 2.30E-05 Bipolar disorder / / 19488044 rs10488456 chr7 134438524 A G 6.08E-05 Bipolar Disorder / / pha002863 rs13229443 chr7 134445433 T C 1.30E-05 Urinary metabolites / / 21572414 rs2347896 chr7 134465394 C A 5.03E-04 Alcohol dependence CALD1 intron 21314694 rs6467557 chr7 134471211 T G 7.44E-05 Leukocyte Counts CALD1 intron pha003091 rs1470841 chr7 134476237 C T 3.55E-05 Coronary restenosis CALD1 intron 21878436 rs17169635 chr7 134490462 C T 6.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy) CALD1 intron 24554482 rs12707180 chr7 134493344 G A 3.19E-05 Mammographic density CALD1 intron 22532574 rs759987 chr7 134494323 C A 5.22E-05 Coronary restenosis CALD1 intron 21878436 rs1452912 chr7 134508087 G A 2.73E-04 Response to taxane treatment (placlitaxel) CALD1 intron 23006423 rs978269 chr7 134511947 T C 2.12E-05 Mammographic density CALD1 intron 22532574 rs3778850 chr7 134530915 G A 4.59E-04 Mammographic density CALD1 intron 22532574 rs17168102 chr7 134534725 G A 2.56E-05 Multiple complex diseases CALD1 intron 17554300 rs4732063 chr7 134552028 A T 3.36E-04 Multiple complex diseases CALD1 intron 17554300 rs2218988 chr7 134564363 T C 9.50E-05 Response to acetaminophen (hepatotoxicity) CALD1 intron 21177773 rs7809057 chr7 134607676 A G 2.30E-06 Endometriosis CALD1 intron 23104006 rs6973420 chr7 134618710 A G 4.70E-06 Endometriosis CALD1 missense 23104006 rs3800752 chr7 134630642 G A 1.15E-04 Alzheimer's disease CALD1 intron 24755620 rs17168134 chr7 134651624 A G 3.27E-04 Alzheimer's disease (late onset) CALD1 intron 21379329 rs17168135 chr7 134652029 G A 1.65E-05 Graves' disease CALD1 intron 21841780 rs2718151 chr7 134674190 C A 3.11E-28 Varicose Veins AGBL3 intron pha001414 rs4415249 chr7 134696880 C A 4.18E-06 Schizophrenia AGBL3 intron 21926974 rs6978050 chr7 134720269 A G 4.53E-04 Alzheimer's disease (late onset) AGBL3 intron 21379329 rs2348054 chr7 134730151 G C 7.46E-04 Multiple complex diseases AGBL3 intron 17554300 rs17231212 chr7 134785741 T C 2.00E-08 Immune reponse to smallpox (secreted IL-10) AGBL3 intron 22610502 rs12707217 chr7 134827792 C T 5.47E-04 Smoking quantity LOC653739 intron 24665060 rs3250 chr7 134845432 G A 4.00E-04 Asthma (childhood onset) TMEM140 intron 21359210 rs292501 chr7 134849280 T A 0.00021 Breast cancer / / 23555315 rs17168319 chr7 134914953 A G 1.51E-09 Multiple complex diseases / / 17554300 rs2033050 chr7 134933768 C A 6.76E-05 Serum metabolites STRA8 intron 19043545 rs292639 chr7 134946179 T C 2.64E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs292641 chr7 134946744 C G 2.64E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs292644 chr7 134947500 A G 5.09E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1019621 chr7 134947623 C T 7.25E-04 Alzheimer's disease / / 17998437 rs2161862 chr7 134953606 C T 4.36E-04 Multiple complex diseases / / 17554300 rs2113546 chr7 134953755 T A 3.51E-04 Multiple complex diseases / / 17554300 rs12537514 chr7 134963884 T C 1.96E-04 Multiple complex diseases / / 17554300 rs12537514 chr7 134963884 T C 4.76E-04 Alzheimer's disease / / 17998437 rs292670 chr7 134964072 T C 1.84E-04 Multiple complex diseases / / 17554300 rs292671 chr7 134964443 T G 1.79E-04 Multiple complex diseases / / 17554300 rs292671 chr7 134964443 T G 8.63E-04 Alzheimer's disease / / 17998437 rs10954491 chr7 134972126 C T 2.81E-05 Major depressive disorder (broad) / / 20038947 rs10954491 chr7 134972126 C T 7.57E-05 Major depressive disorder / / 21621269 rs17235985 chr7 134994297 G T 1.30E-04 Alcohol dependence / / 20201924 rs10954494 chr7 134998517 G A 8.75E-04 Multiple complex diseases / / 17554300 rs17236136 chr7 134998591 G A 8.08E-05 Multiple complex diseases / / 17554300 rs12707223 chr7 135006869 C T 9.12E-05 Glycosylated haemoglobin levels / / 17255346 rs12707223 chr7 135006869 C T 6.11E-05 Multiple complex diseases / / 17554300 rs12707224 chr7 135009485 A T 6.43E-05 Glycosylated haemoglobin levels / / 17255346 rs12707224 chr7 135009485 A T 6.70E-04 Multiple complex diseases / / 17554300 rs4732118 chr7 135011937 A C 6.43E-05 Glycosylated haemoglobin levels / / 17255346 rs4732118 chr7 135011937 A C 5.60E-04 Multiple complex diseases / / 17554300 rs4075518 chr7 135018862 G C 4.02E-05 Glycosylated haemoglobin levels / / 17255346 rs4075518 chr7 135018862 G C 6.93E-04 Multiple complex diseases / / 17554300 rs7803365 chr7 135021399 G A 4.40E-04 Obesity (extreme) / / 21935397 rs11767423 chr7 135021898 T C 5.55E-05 Obesity (extreme) / / 21935397 rs11772685 chr7 135023914 A G 2.16E-04 Obesity (extreme) / / 21935397 rs4732120 chr7 135028488 T C 4.80E-05 Multiple complex diseases / / 17554300 rs6467586 chr7 135028856 A G 8.47E-05 Multiple complex diseases / / 17554300 rs12673359 chr7 135032103 T C 6.34E-04 Obesity (extreme) / / 21935397 rs11765559 chr7 135036378 A G 1.52E-04 Obesity (extreme) / / 21935397 rs889933 chr7 135038388 A G 7.19E-05 Obesity (extreme) / / 21935397 rs3812265 chr7 135048804 C T 2.00E-05 Height CNOT4 missense 21194676 rs3812265 chr7 135048804 C T 3.40E-08 Height CNOT4 missense 21194676 rs3812265 chr7 135048804 C T 3.90E-04 Height CNOT4 missense 21194676 rs11772832 chr7 135073047 T C 1.92E-04 HIV-1 viral setpoint CNOT4 UTR-3 17641165 rs2551767 chr7 135139011 C T 2.07E-04 HIV-1 viral setpoint CNOT4 intron 17641165 rs2696888 chr7 135170448 A G 3.43E-04 HIV-1 viral setpoint CNOT4 intron 17641165 rs17168452 chr7 135223025 A T 1.24E-05 Multiple complex diseases / / 17554300 rs4294134 chr7 135293128 A G 8.00E-10 Paget's disease NUP205 intron 21623375 rs4294134 chr7 135293128 A G 2.07E-05 Hepatitis B NUP205 intron 21750111 rs7784162 chr7 135305886 C A 7.54E-04 Type 2 diabetes NUP205 intron 17463246 rs7784162 chr7 135305886 C A 1 Drug response to Etoposide NUP205 intron 17537913 rs12530845 chr7 135329978 T C 3.00E-08 Red blood cell traits NUP205 intron 23222517 rs4291211 chr7 135335373 C T 5.90E-04 Type 2 diabetes / / 17463246 rs6946136 chr7 135423424 A G 7.39E-04 Suicide attempts in bipolar disorder FAM180A intron 21423239 rs4430037 chr7 135428793 G T 8.72E-04 Suicide attempts in bipolar disorder FAM180A intron 21423239 rs12707249 chr7 135479573 C T 3.00E-06 Obesity-related traits / / 23251661 rs6946494 chr7 135488621 A G 8.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs7789670 chr7 135490024 C T 3.00E-06 Multiple complex diseases / / 17554300 rs17236461 chr7 135496205 G A 7.30E-04 Type 2 diabetes / / 17463246 rs2960898 chr7 135497401 T C 5.85E-04 Type 2 diabetes / / 17463246 rs2960903 chr7 135500754 G C 5.50E-04 Type 2 diabetes / / 17463246 rs13237474 chr7 135501469 C T 2.00E-07 Periodontitis (CDC/AAP) / / 24024966 rs17168478 chr7 135522389 G A 2.80E-05 Urinary metabolites / / 21572414 rs4732154 chr7 135524500 T C 7.60E-04 Intelligence (childhood) / / 23358156 rs6975150 chr7 135525219 T A 2.60E-05 Urinary metabolites / / 21572414 rs2348914 chr7 135531524 T C 2.50E-05 Urinary metabolites / / 21572414 rs4355718 chr7 135545415 A G 4.90E-06 Urinary metabolites / / 21572414 rs13228917 chr7 135549855 T G 1.31E-04 Multiple complex diseases / / 17554300 rs7778081 chr7 135560317 G A 1.90E-05 Urinary metabolites / / 21572414 rs7794499 chr7 135608912 A G 6.70E-04 Multiple complex diseases / / 17554300 rs1443762 chr7 135641580 T C 4.56E-05 Heart Rate MTPN intron pha003054 rs7781558 chr7 135680055 T C 1.68E-04 Type 2 diabetes / / 17463246 rs1994464 chr7 135682419 A G 1.14E-04 Type 2 diabetes / / 17463246 rs1078922 chr7 135684383 T C 1.00E-04 Type 2 diabetes / / 17463246 rs1290720 chr7 135717116 A G 2.24E-04 Multiple complex diseases / / 17554300 rs12537465 chr7 135729761 C G,T 5.25E-06 Gallstones / / 17632509 rs4728376 chr7 135761671 C A 1.50E-05 Urinary metabolites / / 21572414 rs6944889 chr7 135771582 C G 7.21E-05 Chronic obstructive pulmonary disease / / 19300482 rs6944889 chr7 135771582 C G 7.21E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1488004 chr7 135800955 A G 9.22E-05 Multiple complex diseases / / 17554300 rs1488004 chr7 135800955 A G 7.65E-05 Serum metabolites / / 19043545 rs17242111 chr7 135811879 A C 6.77E-04 Multiple complex diseases / / 17554300 rs2171491 chr7 135815329 G A 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12540907 chr7 135840322 C T 2.20E-05 Urinary metabolites / / 21572414 rs12531679 chr7 135846937 G A 2.72E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs12531679 chr7 135846937 G A 3.20E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs17242799 chr7 135847686 C G 7.75E-04 Multiple complex diseases / / 17554300 rs834771 chr7 135848396 T C 9.87E-05 Multiple complex diseases / / 17554300 rs834775 chr7 135850699 T G 1.29E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10954517 chr7 135871947 T C 2.76E-05 stroke (ischemic) / / 17434096 rs834809 chr7 135879016 A G 8.22E-04 Type 2 diabetes / / 17463246 rs6950690 chr7 135890568 G A 9.08E-05 stroke (ischemic) / / 17434096 rs11768716 chr7 135896478 T G 9.76E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10278072 chr7 135897003 A G 5.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1346208 chr7 135904371 A G 4.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs1863555 chr7 135906639 A T 7.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs1863556 chr7 135906726 C A 7.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs1426478 chr7 135906754 G C 7.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs1426479 chr7 135906817 G A 7.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs1426479 chr7 135906817 G A 1.29E-04 Iron levels / / pha002876 rs10225765 chr7 135907584 T A 7.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs1820463 chr7 135911233 G A 6.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs6945182 chr7 135912395 G C 1.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs1365361 chr7 135912932 A T 1.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs1426483 chr7 135920630 G A 4.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs1426483 chr7 135920630 G A 1.24E-04 Iron levels / / pha002876 rs4728385 chr7 135928071 A G 7.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs12707279 chr7 135928102 T C 1.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs1025195 chr7 135928415 C A 9.49E-05 Iron levels / / 19880490 rs1025195 chr7 135928415 C A 9.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs1025195 chr7 135928415 C A 9.49E-05 Iron levels / / pha002876 rs11982963 chr7 135929763 T G 1.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs741631 chr7 135940550 T G 6.57E-05 Multiple complex diseases / / 17554300 rs1365353 chr7 135943264 G A 9.23E-04 Alzheimer's disease / / 24755620 rs1365353 chr7 135943264 G A 5.16E-04 Iron levels / / pha002876 rs1834615 chr7 135947870 C A 8.28E-04 Alzheimer's disease / / 17998437 rs1820462 chr7 135948486 T C 8.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs10270360 chr7 135949778 A G 7.35E-04 Multiple complex diseases / / 17554300 rs2250603 chr7 135971307 G A 7.74E-04 Multiple complex diseases / / 17554300 rs2701016 chr7 135971714 A C 9.41E-05 Serum metabolites / / 19043545 rs2555050 chr7 135977444 G A 5.37E-04 Smoking initiation / / 24665060 rs6467644 chr7 136009382 T A 9.58E-04 Multiple complex diseases / / 17554300 rs10488407 chr7 136012354 G A 2.30E-05 Urinary metabolites / / 21572414 rs4520107 chr7 136024177 C T 5.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6467646 chr7 136025735 C T 4.20E-04 Multiple complex diseases / / 17554300 rs7783200 chr7 136025835 A C 6.29E-04 Multiple complex diseases / / 17554300 rs7788841 chr7 136026926 G A 6.43E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12707301 chr7 136078014 C T 5.31E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs10276384 chr7 136085428 A G 2.48E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10276384 chr7 136085428 A G 6.71E-04 Bipolar disorder / / 19259986 rs4732209 chr7 136134819 A C 9.17E-05 Cognitive performance / / 19734545 rs12707309 chr7 136135072 C T 8.12E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10250997 chr7 136146536 C A 8.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs10250997 chr7 136146536 C A 8.59E-04 Heart Failure / / pha002884 rs2350179 chr7 136323977 G A 4.72E-04 Parkinson's disease / / 16252231 rs10435421 chr7 136339058 C T 7.57E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs10259281 chr7 136389040 G A 7.74E-04 Heart Failure / / pha002884 rs10249472 chr7 136399178 A G 5.18E-04 Heart Failure / / pha002884 rs4404863 chr7 136410156 G T 3.21E-04 Heart Failure / / pha002884 rs7796493 chr7 136426223 T C 1.35E-04 Scoliosis / / 21216876 rs6467684 chr7 136427638 A G 7.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs10954544 chr7 136432937 A G 9.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs1364491 chr7 136440496 A T 9.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs6977141 chr7 136440854 T C 7.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs2098789 chr7 136441240 A G 8.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs10954545 chr7 136441648 T G 7.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs12707331 chr7 136442580 C T 5.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs4732232 chr7 136442834 C T 5.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs7809426 chr7 136442955 A G 5.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs1593217 chr7 136453253 C G 9.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs4732235 chr7 136458524 G C 7.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs1424567 chr7 136468261 A G 8.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs1424566 chr7 136468341 C T 8.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs1121168 chr7 136472832 C T 7.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs6957348 chr7 136474379 G A 7.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs6467688 chr7 136475070 A T 7.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs1115781 chr7 136477714 C T 7.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs3943917 chr7 136479042 A T 7.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs10755884 chr7 136480221 T A 8.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs10738130 chr7 136480413 G A 7.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs10738131 chr7 136480539 C A 6.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs7792231 chr7 136483470 T C 1.00E-04 Asthma (childhood onset) / / 21359210 rs1991086 chr7 136485371 C T 8.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs1364490 chr7 136489616 T C 8.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs11984255 chr7 136491089 T C 9.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs2350447 chr7 136493255 A G 6.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs7784657 chr7 136494145 T G 8.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs1593210 chr7 136496419 A G 5.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs12538537 chr7 136496981 G A 4.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs2216862 chr7 136503137 T C 3.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs2350449 chr7 136506932 A G 3.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs2350451 chr7 136507199 T C 3.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs7810141 chr7 136508139 G A 4.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs4342537 chr7 136511000 T C 4.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs4407820 chr7 136511089 C T 4.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs2113551 chr7 136511544 A G 4.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs6467690 chr7 136515086 C A 4.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs6970010 chr7 136515717 T C 4.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs6950239 chr7 136515742 G T 4.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs1981896 chr7 136522159 C G 4.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs1981895 chr7 136522257 G C 4.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs7811987 chr7 136526263 G A 1.10E-05 Melanoma / / 21983785 rs10257657 chr7 136542022 A T 6.79E-04 Prostate cancer mortality / / 20978177 rs10228878 chr7 136542373 C T 8.76E-04 Prostate cancer mortality / / 20978177 rs6467694 chr7 136546916 C T 7.25E-05 Epilepsy (remission after treatment) / / 23962720 rs3735028 chr7 136558158 T C 8.54E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CHRM2 intron 24023788 rs2113550 chr7 136566533 A G 6.46E-04 Suicide attempts in bipolar disorder CHRM2 intron 21423239 rs1424569 chr7 136569416 T C 7.06E-04 Parkinson's disease CHRM2 intron 17052657 rs1364402 chr7 136584363 T C 4.00E-06 Migraine with aura CHRM2 intron 23793025 rs2350782 chr7 136642634 T C 1.00E-12 Heart rate CHRM2 intron 23583979 rs17168865 chr7 136683212 T C 1.19E-14 Esophageal cancer CHRM2 intron 21642993 rs7800093 chr7 136689381 A G 2.80E-109 Multiple complex diseases CHRM2 intron 17554300 rs10488602 chr7 136690503 T C 0.00000994 Polycystic ovary syndrome CHRM2 intron 22951595 rs10488602 chr7 136690503 T C 9.94E-06 Intracranial aneurysm CHRM2 intron 22961961 rs1424548 chr7 136709760 C T 1.69E-04 Diabetic retinopathy LOC349160 intron 20871662 rs324658 chr7 136715167 A C 7.74E-04 Type 2 diabetes LOC349160 intron 17463246 rs324662 chr7 136723463 A G 4.96E-04 Tourette syndrome LOC349160 intron 22889924 rs324572 chr7 136765572 T C 3.95E-04 Tourette syndrome LOC349160 intron 22889924 rs1477523 chr7 136805138 C T 4.33E-241 Multiple complex diseases LOC349160 intron 17554300 rs4732243 chr7 136811496 A G 2.69E-04 Acute lung injury LOC349160 intron 22295056 rs1725021 chr7 136893320 T C 2.20E-05 Sleep and circadian phenotypes / / 17903308 rs1725022 chr7 136893417 T A 7.06E-04 Alzheimer's disease / / 17998437 rs17168987 chr7 136911966 G A 1.11E-04 Type 2 diabetes / / 17463246 rs12668115 chr7 136912038 T C 5.83E-05 Type 2 diabetes / / 17463246 rs11561959 chr7 136915362 T C 1.12E-04 Alzheimer's disease PTN intron 17998437 rs4142090 chr7 136925134 C G 2.80E-05 Urinary metabolites PTN intron 21572414 rs322302 chr7 136931552 C T 2.60E-05 Urinary metabolites PTN intron 21572414 rs322297 chr7 136935459 T G 2.70E-05 Triglycerides PTN intron pha003080 rs322314 chr7 136945107 T C 2.84E-05 Coronary heart disease PTN intron pha003030 rs322239 chr7 136956607 C A 4.80E-06 Neuroticism PTN intron 17667963 rs322239 chr7 136956607 C A 2.22E-05 Body Composition PTN intron pha003012 rs322239 chr7 136956607 C A 2.75E-05 Body Mass Index PTN intron pha003021 rs322239 chr7 136956607 C A 5.36E-05 Coronary heart disease PTN intron pha003030 rs1880791 chr7 136965864 G T 5.12E-04 Schizophrenia PTN intron 21674006 rs7786318 chr7 136969917 A G 5.45E-06 Lipid traits PTN intron 21777205 rs16874937 chr7 136984716 C T 6.44E-04 Depression (quantitative trait) PTN intron 20800221 rs2242045 chr7 137005808 G A 1.10E-05 Obesity,menopause PTN intron 21424828 rs10255150 chr7 137013466 G A 3.68E-04 Birth weight PTN intron 17255346 rs320686 chr7 137040948 A G 4.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs320692 chr7 137043484 A C 3.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs320703 chr7 137050827 C T 8.00E-06 Urinary metabolites / / 21572414 rs320704 chr7 137051175 C T 3.94E-05 Cognitive test performance / / 20125193 rs320704 chr7 137051175 C T 1.58E-04 Myopia (pathological) / / 21095009 rs161338 chr7 137053658 A G 7.10E-04 Multiple complex diseases / / 17554300 rs12534625 chr7 137067616 T G 4.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4613918 chr7 137071264 G A 1.40E-05 Urinary metabolites / / 21572414 rs1451526 chr7 137081223 A G 4.19E-04 Schizophrenia DGKI intron 19197363 rs1451526 chr7 137081223 A G 8.80E-05 Schizophrenia DGKI intron 19571808 rs7804771 chr7 137132593 C G 9.81E-05 Nicotine dependence DGKI intron 18227835 rs1161937 chr7 137138736 C G 7.08E-04 Alzheimer's disease DGKI intron 22005930 rs13247935 chr7 137150382 C T 1.89E-04 Multiple complex diseases DGKI intron 17554300 rs10254089 chr7 137199692 T C 4.40E-05 Response to statin therapy DGKI intron 20339536 rs6467710 chr7 137203819 G C 6.00E-07 AIDS progression DGKI intron 21502085 rs834063 chr7 137227544 A G 7.77E-05 Response to mTOR inhibitor (everolimus) DGKI intron 24009623 rs834436 chr7 137260639 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes DGKI intron 22628534 rs706562 chr7 137276670 G C 8.45E-05 Suicide attempts in bipolar disorder DGKI intron 21041247 rs706567 chr7 137283212 T C 8.22E-05 Suicide attempts in bipolar disorder DGKI intron 21041247 rs6949094 chr7 137284359 T C 2.38E-05 Suicide attempts in bipolar disorder DGKI intron 21041247 rs706568 chr7 137284480 T A 2.26E-05 Suicide attempts in bipolar disorder DGKI intron 21041247 rs706578 chr7 137298910 G A 6.14E-05 Response to cytidine analogues (gemcitabine) DGKI intron 24483146 rs1424367 chr7 137352991 C A 5.83E-04 Multiple complex diseases DGKI intron 17554300 rs1424368 chr7 137359182 C T 4.49E-05 Multiple complex diseases DGKI intron 17554300 rs3778799 chr7 137385075 G A 9.03E-04 Response to cytidine analogues (gemcitabine) DGKI intron 24483146 rs2113428 chr7 137392687 T C 5.51E-04 Response to cytidine analogues (gemcitabine) DGKI intron 24483146 rs12056089 chr7 137399820 T C 5.16E-04 Response to cytidine analogues (gemcitabine) DGKI intron 24483146 rs10234581 chr7 137404781 C T 3.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DGKI intron 20877124 rs10234581 chr7 137404781 C T 4.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DGKI intron 20877124 rs3800644 chr7 137421386 T C 6.08E-04 Smoking initiation DGKI intron 24665060 rs2059320 chr7 137424771 C T 9.58E-05 Neuroblastoma DGKI intron pha002895 rs6978230 chr7 137529578 G A 6.00E-06 Cognitive decline (age-related) DGKI intron 24468470 rs7788967 chr7 137565799 G A 3.96E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers CREB3L2 intron 21775533 rs1564225 chr7 137577454 A T 4.21E-05 Mammographic density CREB3L2 intron 22532574 rs273944 chr7 137583206 T C 2.32E-04 Lung function (forced vital capacity) CREB3L2 intron 24023788 rs1646540 chr7 137584688 C T 1.75E-04 Lung function (forced vital capacity) CREB3L2 intron 24023788 rs1677499 chr7 137584781 A G 1.90E-04 Lung function (forced vital capacity) CREB3L2 intron 24023788 rs273961 chr7 137596147 C T 3.97E-04 Insulin resistance CREB3L2 intron 21901158 rs273957 chr7 137600690 C A,G,T 1.55E-05 Osteoarthritis (knee and hip) CREB3L2 missense 21177295 rs273957 chr7 137600690 C A,G,T 2.08E-05 Osteoarthritis (knee and hip) CREB3L2 missense 21177295 rs273957 chr7 137600690 C A,G,T 6.69E-04 Atopy CREB3L2 missense 21625490 rs13245803 chr7 137621377 G A 2.75E-04 Multiple complex diseases CREB3L2 intron 17554300 rs274002 chr7 137635292 C T 1.26E-05 Stroke CREB3L2 intron pha002887 rs274009 chr7 137647262 T C 8.04E-05 Coronary restenosis CREB3L2 intron 21878436 rs6948572 chr7 137661589 C T 5.45E-04 Amyotrophic Lateral Sclerosis CREB3L2 intron 17827064 rs13232124 chr7 137691708 T C 9.00E-05 Prostate cancer / / 21743057 rs11972734 chr7 137692888 A G 6.00E-05 Prostate cancer / / 21743057 rs10954596 chr7 137694764 A G 9.00E-05 Prostate cancer / / 21743057 rs11971315 chr7 137703336 G A 5.50E-04 Alcohol dependence / / 20201924 rs6467733 chr7 137749862 G C 5.09E-04 Multiple complex diseases / / 17554300 rs17277937 chr7 137755143 C T 3.01E-04 Multiple complex diseases / / 17554300 rs6980334 chr7 137788492 G A 4.00E-20 Blood metabolite ratios AKR1D1 intron 24816252 rs2035647 chr7 137799569 A G 2.00E-17 Blood metabolite levels AKR1D1 intron 24816252 rs9656504 chr7 137816732 A C 2.78E-04 Multiple complex diseases / / 17554300 rs10238886 chr7 137848981 A G 0.000496 Breast cancer early age of onset / / 18463975 rs2465075 chr7 137854038 T C 1.48E-04 Alzheimer's disease (late onset) / / 21379329 rs10255295 chr7 137858766 A G 3.02E-06 Major depressive disorder / / 22472876 rs10255295 chr7 137858766 A G 5.00E-06 Bipolar disorder (mood-incongruent) / / 23092984 rs10255295 chr7 137858766 A G 5.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs1602105 chr7 137902633 C T 4.14E-04 Coronary Artery Disease / / 17634449 rs7791618 chr7 137909675 C G 2.61E-05 Alzheimer's disease (late onset) / / 21460841 rs2465904 chr7 137926501 G A 8.70E-04 Multiple complex diseases / / 17554300 rs7802723 chr7 137929307 T C 2.07E-07 Non-obstructive azoospermia / / 22541561 rs2253200 chr7 137942208 G A 4.72E-05 Lung function (forced vital capacity) / / pha003104 rs10246131 chr7 137972605 C T 7.90E-04 Insulin resistance / / 21901158 rs6467756 chr7 137973629 T C 0.0000127 HDL cholesterol particle diameter / / 23263444 rs357394 chr7 138049387 C G 9.00E-06 Pulmonary function / / 17903307 rs357361 chr7 138054445 A G 7.14E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs438660 chr7 138065330 G A 3.70E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs451408 chr7 138065670 T C 3.70E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs427508 chr7 138067176 G A 3.70E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs430435 chr7 138074130 C A 6.69E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs2047234 chr7 138076980 C T 1.30E-05 Glaucoma (primary open-angle) / / 20835238 rs11981141 chr7 138084513 C T 1.99E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs12668708 chr7 138092362 C T 6.97E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4728435 chr7 138095694 T G 7.69E-05 Psoriasis / / 20953187 rs4728435 chr7 138095694 T G 6.84E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4732315 chr7 138098677 C T 4.26E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4732316 chr7 138098748 C G 2.32E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs13229601 chr7 138132827 C T 4.80E-06 Urinary metabolites / / 21572414 rs2353349 chr7 138133502 C T 5.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7786347 chr7 138140578 C A 3.10E-06 Urinary metabolites / / 21572414 rs1874326 chr7 138157390 A G 9.00E-06 Quantitative traits TRIM24 intron 19197348 rs1874326 chr7 138157390 A G 5.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRIM24 intron 20877124 rs6467778 chr7 138178222 A G 5.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRIM24 intron 20877124 rs3847124 chr7 138191524 A G 1.53E-14 Gender TRIM24 intron 22362730 rs3807155 chr7 138222987 A G 5.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRIM24 intron 20877124 rs1544733 chr7 138230820 C T 6.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRIM24 intron 20877124 rs3778705 chr7 138262890 A G 4.54E-05 Smoking cessation TRIM24 intron 18519826 rs2353354 chr7 138266009 C A 6.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRIM24 intron 20877124 rs7799136 chr7 138276634 C T 2.43E-05 Alcohol and nictotine co-dependence / / 20158304 rs1673223 chr7 138297714 C A 4.45E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SVOPL intron 20877124 rs1659821 chr7 138299511 G A 5.84E-04 Aortic root size SVOPL intron 21223598 rs4728438 chr7 138313295 C T 1.57E-04 Blood pressure SVOPL intron 17255346 rs6956225 chr7 138335246 C T 1.09E-05 Smoking cessation SVOPL intron 18519826 rs6944016 chr7 138380477 G A 1.99E-05 Leukocyte Counts / / pha003091 rs400800 chr7 138382677 G A 1.07E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6971887 chr7 138396013 A G 4.89E-05 Response to platinum-based chemotherapy in small-cell lung cancer ATP6V0A4 intron 20463552 rs6977910 chr7 138397297 A G 6.07E-04 Insulin resistance ATP6V0A4 intron 21901158 rs999229 chr7 138400796 C T 9.04E-05 HIV-1 viral setpoint ATP6V0A4 intron 17641165 rs999229 chr7 138400796 C T 3.95E-05 Diabetes Mellitus ATP6V0A4 intron pha003060 rs999228 chr7 138400858 A C 4.17E-05 Aging (time to event) ATP6V0A4 intron 21782286 rs17441563 chr7 138409421 C T 5.04E-04 Alzheimer's disease ATP6V0A4 intron 17998437 rs3800569 chr7 138411425 C T 6.00E-06 F-cell distribution ATP6V0A4 intron 21326311 rs1344381 chr7 138418204 C T 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ATP6V0A4 intron 22628534 rs6467797 chr7 138429851 T C 6.69E-06 Fibrinogen ATP6V0A4 intron pha003068 rs366193 chr7 138434485 T C 8.90E-05 Age-related macular degeneration ATP6V0A4 intron pha002890 rs3931139 chr7 138442791 T C 8.28E-05 Alzheimer's disease ATP6V0A4 intron 21098978 rs13230648 chr7 138444432 C T 3.55E-04 HIV-1 viral setpoint ATP6V0A4 intron 17641165 rs7780678 chr7 138453352 G A 2.11E-05 Alzheimer's disease ATP6V0A4 intron 21098978 rs7780678 chr7 138453352 G A 4.34E-05 Suicide attempts in bipolar disorder ATP6V0A4 intron 21423239 rs6969815 chr7 138486536 T C 1.36E-04 Pancreatic cancer TMEM213 intron pha002874 rs2034507 chr7 138489883 G A 4.52E-04 Coronary Artery Disease TMEM213 UTR-3 17634449 rs10435432 chr7 138494176 A G 4.98E-04 Multiple complex diseases / / 17554300 rs10435432 chr7 138494176 A G 4.47E-04 Coronary Artery Disease / / 17634449 rs1037329 chr7 138494866 A G 5.88E-04 Type 2 diabetes / / 17463246 rs1037329 chr7 138494866 A G 5.62E-04 Coronary Artery Disease / / 17634449 rs10808294 chr7 138497225 C T 8.22E-04 Type 2 diabetes / / 17463246 rs12670097 chr7 138497794 T C 9.68E-06 Pancreatic cancer / / pha002874 rs12670097 chr7 138497794 T C 2.85E-06 Pancreatic cancer / / pha002889 rs6953540 chr7 138499661 C A 9.54E-04 Type 2 diabetes / / 17463246 rs6953540 chr7 138499661 C A 9.59E-04 Coronary Artery Disease / / 17634449 rs6952440 chr7 138504964 C T 1.32E-05 Coronary Artery Disease / / 17634449 rs878992 chr7 138518783 C T 6.17E-04 Alzheimer's disease KIAA1549 UTR-3 24755620 rs6974263 chr7 138567110 A C 6.00E-06 Personality dimensions KIAA1549 intron 18957941 rs10270572 chr7 138577911 T G 1.87E-04 Schizophrenia KIAA1549 intron 20832056 rs10954638 chr7 138590990 C A 4.21E-05 Blood Pressure KIAA1549 intron pha003046 rs16873582 chr7 138596001 G A 3.21E-04 Stroke KIAA1549 cds-synon pha002887 rs2774960 chr7 138602417 G A 7.58E-04 Multiple complex diseases KIAA1549 missense 17554300 rs7809049 chr7 138609531 G A 4.23E-04 White matter integrity KIAA1549 intron 22425255 rs6963169 chr7 138615831 T G 1.18E-05 White matter integrity KIAA1549 intron 22425255 rs17160621 chr7 138617682 C T 1.55E-04 Taste perception KIAA1549 intron 22132133 rs2718136 chr7 138622572 T C 1.70E-04 White matter integrity KIAA1549 intron 22425255 rs12707405 chr7 138627997 C T 5.05E-05 White matter integrity KIAA1549 intron 22425255 rs2774966 chr7 138632455 A G 6.70E-04 Multiple complex diseases KIAA1549 intron 17554300 rs661079 chr7 138638846 G A 4.00E-04 Myasthenia gravis KIAA1549 intron 23055271 rs512927 chr7 138648537 G A 8.13E-04 Multiple complex diseases KIAA1549 intron 17554300 rs6952395 chr7 138660337 A C 4.39E-04 Suicide attempts in bipolar disorder KIAA1549 intron 21423239 rs1888349 chr7 138664132 G T 3.06E-05 Amyotrophic lateral sclerosis (sporadic) KIAA1549 intron 24529757 rs7797152 chr7 138677481 C T 2.23E-06 Glaucoma (primary open-angle) / / 22605921 rs7783319 chr7 138735413 G A 9.91E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines ZC3HAV1 intron 21844884 rs17133444 chr7 138742775 C T 2.45E-05 Post-operative nausea and vomiting ZC3HAV1 intron 21694509 rs12666903 chr7 138742792 T C 1.37E-04 Suicide attempts in bipolar disorder ZC3HAV1 intron 21423239 rs17133451 chr7 138742981 A C 1.12E-04 Parkinson's disease ZC3HAV1 intron 21248740 rs1814170 chr7 138794149 A T 3.40E-05 Bulimia nervosa ZC3HAV1 UTR-5 23568457 rs2883569 chr7 138809447 C T 5.90E-04 Type 2 diabetes / / 17463246 rs10500130 chr7 138815913 C A 5.03E-05 Smoking initiation / / 24665060 rs7798474 chr7 138817240 T G 6.90E-05 Anorexia nervosa / / 23568457 rs17133455 chr7 138853500 A G 9.55E-05 Cognitive impairment induced by topiramate TTC26 intron 22091778 rs10954644 chr7 138977206 G A 1.44E-06 Response to tocilizumab in rheumatoid arthritis UBN2 intron 22491018 rs17160863 chr7 138993919 A G 8.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs4728464 chr7 139017670 T C 4.12E-04 Multiple complex diseases / / 17554300 rs10954646 chr7 139061069 C G 5.11E-04 Multiple complex diseases LUC7L2 intron 17554300 rs6960876 chr7 139112176 T C 7.02E-04 Multiple complex diseases / / 17554300 rs12113878 chr7 139143445 C G 1 Drug response to Etoposide KLRG2 intron 17537913 rs7798842 chr7 139180102 A G 2.71E-05 Elbow pain / / pha003008 rs2190933 chr7 139236512 A G 5.90E-24 Narcolepsy / / 19629137 rs1638196 chr7 139269931 G A 8.59E-04 Alzheimer's disease / / 17998437 rs4732392 chr7 139305028 T A 2.43E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs9969246 chr7 139343366 T G 2.00E-05 Urinary metabolites / / 21572414 rs10954654 chr7 139359087 C T 2.80E-05 Type 2 diabetes / / 17463248 rs10954654 chr7 139359087 C T 8.40E-05 Alcoholism (heaviness of drinking) / / 21529783 rs10277603 chr7 139359432 T C 1.50E-05 Type 2 diabetes / / 17463248 rs10277603 chr7 139359432 T C 4.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10261979 chr7 139359577 C G 1.30E-05 Type 2 diabetes / / 17463248 rs10262338 chr7 139359658 G A 1.50E-05 Type 2 diabetes / / 17463248 rs9692401 chr7 139359992 T C 1.10E-05 Type 2 diabetes / / 17463248 rs9692401 chr7 139359992 T C 4.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9691662 chr7 139360198 G A 1.60E-05 Type 2 diabetes / / 17463248 rs9691662 chr7 139360198 G A 4.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9690418 chr7 139360240 A G 1.60E-05 Type 2 diabetes / / 17463248 rs12707449 chr7 139360728 T A 1.60E-05 Type 2 diabetes / / 17463248 rs10271287 chr7 139362262 C T 1.60E-05 Type 2 diabetes / / 17463248 rs9692080 chr7 139374012 T C 1.27E-05 Bipolar disorder,schizoaffective / / 19567891 rs4074826 chr7 139415943 G A 3.85E-04 Multiple complex diseases / / 17554300 rs12703395 chr7 139427361 T C 7.73E-05 Multiple complex diseases / / 17554300 rs10236187 chr7 139447377 A C 1.00E-05 Multiple complex diseases / / 17554300 rs1015122 chr7 139454843 A G 1.19E-04 Multiple complex diseases / / 17554300 rs10244528 chr7 139486394 T C 1.76E-04 Multiple complex diseases TBXAS1 intron 17554300 rs10252208 chr7 139487942 T G 6.39E-04 Multiple complex diseases TBXAS1 intron 17554300 rs4726715 chr7 139488790 T G 1.24E-04 Bipolar disorder,schizoaffective TBXAS1 intron 19567891 rs2270163 chr7 139488835 C T 2.35E-04 Bipolar disorder,schizoaffective TBXAS1 intron 19567891 rs6958644 chr7 139496215 A G 6.30E-04 Alcohol dependence TBXAS1 intron 20201924 rs6954520 chr7 139499771 G T 2.08E-04 Multiple complex diseases TBXAS1 intron 17554300 rs10277664 chr7 139506580 C T 1.00E-07 Gray matter volume (schizophrenia interaction) TBXAS1 intron 24086445 rs10233386 chr7 139515216 T C 8.01E-07 Gray matter volume (schizophrenia interaction) TBXAS1 intron 24086445 rs1107952 chr7 139518205 C T 8.04E-07 Gray matter volume (schizophrenia interaction) TBXAS1 intron 24086445 rs6961627 chr7 139518783 G A 3.92E-04 Smoking initiation TBXAS1 intron 24665060 rs1019178 chr7 139525624 G T 1.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TBXAS1 intron 20877124 rs194151 chr7 139557947 C T 9.00E-06 Obesity-related traits TBXAS1 intron 23251661 rs17161201 chr7 139576284 G A 0.00000015 Total IFN-gamma response to smallpox vaccine TBXAS1 intron 22661280 rs2267684 chr7 139585718 G C 8.60E-06 Urinary metabolites TBXAS1 intron 21572414 rs7810727 chr7 139591860 C T 8.00E-06 Migraine without aura TBXAS1 intron 23793025 rs2284203 chr7 139612333 A G 1.80E-05 Urinary metabolites TBXAS1 intron 21572414 rs1557967 chr7 139652819 T C 7.91E-04 Longevity TBXAS1 intron 22279548 rs4725563 chr7 139654256 C T 2.80E-05 Nicotine smoking TBXAS1 intron 19268276 rs917148 chr7 139654531 G C 3.90E-10 Triglycerides TBXAS1 intron 23063622 rs41721 chr7 139666196 T C 5.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TBXAS1 intron 20877124 rs42334 chr7 139670494 G T 7.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TBXAS1 intron 20877124 rs10260531 chr7 139672617 G T 3.21E-05 Major depressive disorder TBXAS1 intron 22472876 rs3801150 chr7 139685695 C T 5.60E-05 Response to statin therapy TBXAS1 intron 20339536 rs3801150 chr7 139685695 C T 2.96E-05 Parent of origin effect on language impairment (child trend) TBXAS1 intron 24571439 rs8192851 chr7 139687304 T G 2.00E-06 Amyotrophic lateral sclerosis (sporadic) TBXAS1 intron 24529757 rs3801148 chr7 139694500 C T 1.99E-04 Taste perception TBXAS1 intron 22132133 rs3801148 chr7 139694500 C T 2.09E-04 Response to taxane treatment (placlitaxel) TBXAS1 intron 23006423 rs17837497 chr7 139702593 G A 2.00E-06 Acute lymphoblastic leukemia (childhood) TBXAS1 intron 23007406 rs17837497 chr7 139702593 G A 2.92E-09 Triglycerides TBXAS1 intron 23063622 rs4526 chr7 139715581 G A 0.000000179 Triglycerides TBXAS1 missense 23063622 rs4527 chr7 139715598 C T 0.000000893 Triglycerides TBXAS1 cds-synon 23063622 rs757835 chr7 139717178 T C 1.20E-04 Coronary heart disease TBXAS1 intron 21966275 rs2269997 chr7 139723400 G A 2.90E-06 Coronary heart disease / / 21966275 rs17161378 chr7 139744802 T G 3.42E-05 Heart Rate PARP12 intron pha003054 rs10241819 chr7 139753080 T C 9.20E-04 Multiple complex diseases PARP12 intron 17554300 rs10237377 chr7 139757136 G T 0.0000693 Coronary artery disease PARP12 intron 23202125 rs12538215 chr7 139772295 C T 7.30E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6954229 chr7 139773410 G T 4.65E-04 Acute lung injury / / 22295056 rs12539669 chr7 139774014 C T 7.24E-04 Acute lung injury / / 22295056 rs10234943 chr7 139776358 T G 4.65E-04 Acute lung injury / / 22295056 rs10279641 chr7 139778556 A G 4.93E-04 Acute lung injury / / 22295056 rs10279641 chr7 139778556 A G 2.99E-05 Telomere length / / 23001564 rs2362537 chr7 139781703 C G 4.93E-04 Acute lung injury / / 22295056 rs11972958 chr7 139786186 G A 3.00E-05 Iris characteristics JHDM1D UTR-3 21835309 rs4725626 chr7 139831169 T C 5.90E-04 Acute lung injury JHDM1D intron 22295056 rs6464552 chr7 139832548 A G 5.79E-04 Acute lung injury JHDM1D intron 22295056 rs2107741 chr7 139846826 T C 4.37E-04 Acute lung injury JHDM1D intron 22295056 rs6464578 chr7 139878802 T C 4.40E-04 Acute lung injury / / 22295056 rs4726695 chr7 139899574 C T 4.47E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4626515 chr7 139904130 T C 4.62E-07 Celiac disease and Rheumatoid arthritis / / 21383967 rs34908937 chr7 139904406 A T 4.60E-07 Urinary metabolites / / 21572414 rs6956540 chr7 139905735 T C 5.44E-05 Acute lung injury / / 22295056 rs2363101 chr7 139913599 A G 2.44E-04 Acute lung injury / / 22295056 rs17161425 chr7 139914286 C T 7.55E-04 Acute lung injury / / 22295056 rs7797205 chr7 139914961 C T 7.52E-05 Acute lung injury / / 22295056 rs7783361 chr7 139915140 G A 7.41E-04 Acute lung injury / / 22295056 rs7809423 chr7 139915392 T C 8.26E-04 Acute lung injury / / 22295056 rs4725655 chr7 139918895 G A 4.37E-04 Acute lung injury / / 22295056 rs880290 chr7 139921521 G A 5.29E-04 Acute lung injury / / 22295056 rs2079615 chr7 139923008 C A 6.15E-04 Acute lung injury / / 22295056 rs111976500 chr7 139934683 T C 4.21E-05 Epilepsy (remission after treatment) / / 23962720 rs2471281 chr7 139936877 T G 3.24E-06 Scoliosis / / 21216876 rs17161443 chr7 139939203 T C 6.10E-05 Bipolar disorder and schizophrenia / / 20889312 rs17161447 chr7 139944473 C A 3.23E-06 Coronary heart disease / / 21606135 rs6464620 chr7 139945539 G A 9.17E-05 Coronary heart disease / / 21606135 rs2471282 chr7 139975028 G A 4.62E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6948262 chr7 139976963 C T 9.10E-05 Vaspin levels / / 22907691 rs6948262 chr7 139976963 C T 0.000091 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs7795852 chr7 140000505 G A 6.93E-05 Erythrocyte counts / / pha003101 rs6970317 chr7 140014425 T G 2.89E-04 Gallstones / / 17632509 rs7777468 chr7 140071315 C T 6.50E-05 Alcohol dependence SLC37A3 intron 20201924 rs7777468 chr7 140071315 C T 6.51E-05 Alcoholism SLC37A3 intron pha002892 rs6955063 chr7 140077428 A C 6.64E-04 Multiple complex diseases SLC37A3 intron 17554300 rs6955063 chr7 140077428 A C 4.00E-05 Alcohol dependence SLC37A3 intron 20201924 rs6955063 chr7 140077428 A C 4.02E-05 Alcoholism SLC37A3 intron pha002892 rs6947516 chr7 140079848 G A 6.30E-05 Alcohol dependence SLC37A3 intron 20201924 rs6947516 chr7 140079848 G A 6.25E-05 Alcoholism SLC37A3 intron pha002892 rs374748684 chr7 140081814 A C 9.58E-12 Metabolite levels SLC37A3 intron 22286219 rs9640465 chr7 140096157 C T 2.80E-04 Alcohol dependence SLC37A3 intron 20201924 rs9640467 chr7 140096203 C T 4.90E-04 Alcohol dependence SLC37A3 intron 20201924 rs11971702 chr7 140120546 T C 1.81E-04 Multiple complex diseases RAB19 intron 17554300 rs11981557 chr7 140217244 G A 7.81E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6948786 chr7 140224024 A G 2.08E-05 Cognitive test performance DENND2A intron 20125193 rs2252397 chr7 140225750 G A 2.50E-05 Cognitive test performance DENND2A intron 20125193 rs10237118 chr7 140231130 C A 4.00E-06 optic disc size (cup) DENND2A intron 20395239 rs871272 chr7 140235310 G A 6.10E-04 Multiple complex diseases DENND2A intron 17554300 rs11767611 chr7 140335570 C A 6.98E-07 Cognitive impairment induced by topiramate / / 22091778 rs269247 chr7 140338653 T C 9.57E-04 Type 2 diabetes / / 17463246 rs2930329 chr7 140360644 C T 2.40E-05 Urinary metabolites / / 21572414 rs4727040 chr7 140393176 G A 1.07E-05 Height ADCK2 intron pha003011 rs7803697 chr7 140400670 C G 2.00E-05 Urinary metabolites NDUFB2 intron 21572414 rs6464036 chr7 140455238 C T 7.28E-04 Type 2 diabetes BRAF intron 17463246 rs1267638 chr7 140473446 T C 3.45E-05 Height BRAF intron pha003011 rs1267648 chr7 140505100 T C 8.03E-04 Multiple complex diseases BRAF intron 17554300 rs1267612 chr7 140511760 G A 5.01E-04 Multiple complex diseases BRAF intron 17554300 rs13241719 chr7 140538991 T C 3.18E-05 Response to Vitamin E supplementation BRAF intron 22437554 rs1267619 chr7 140561286 G A 2.29E-05 Height BRAF intron pha003011 rs7798324 chr7 140567452 G A 7.65E-04 Multiple complex diseases BRAF intron 17554300 rs10281173 chr7 140579876 C T 7.79E-04 Multiple complex diseases BRAF intron 17554300 rs10269699 chr7 140586927 T C 3.45E-05 Height BRAF intron pha003011 rs17623382 chr7 140592227 T G 4.00E-06 Response to Vitamin E supplementation BRAF intron 22437554 rs10244133 chr7 140603329 G T 7.39E-04 Multiple complex diseases BRAF intron 17554300 rs801088 chr7 140650632 C T 1.30E-06 Urinary metabolites / / 21572414 rs2533307 chr7 140658283 A G 1.30E-05 Urinary metabolites / / 21572414 rs3852286 chr7 140673434 G C 6.50E-06 Volumetric brain MRI / / 17903297 rs38723 chr7 140695812 A G 2.76E-05 Rheumatoid arthritis (ACPA-negative) / / 24532677 rs38732 chr7 140705162 A T 6.90E-05 Type 2 diabetes / / 17463248 rs9274 chr7 140706031 G A 7.50E-05 Type 2 diabetes MRPS33 UTR-3 17463248 rs6464239 chr7 140719702 C T 1.82E-04 Type 2 diabetes / / 17463246 rs544081 chr7 140756549 G A 6.70E-05 Type 2 diabetes / / 17463248 rs488795 chr7 140757886 T G 6.80E-05 Type 2 diabetes / / 17463248 rs512509 chr7 140758147 T C 6.70E-05 Type 2 diabetes / / 17463248 rs548245 chr7 140759767 T C 8.90E-05 Type 2 diabetes / / 17463248 rs471817 chr7 140761247 A C 6.80E-05 Type 2 diabetes / / 17463248 rs801155 chr7 140767950 A G 6.80E-05 Type 2 diabetes / / 17463248 rs528957 chr7 140769459 T C 7.80E-05 Type 2 diabetes / / 17463248 rs557962 chr7 140779740 T C 5.90E-05 Type 2 diabetes LOC100507421 intron 17463248 rs10277943 chr7 140800690 A C 2.12E-04 Type 2 diabetes LOC100507421 intron 17463246 rs1012435 chr7 140863646 G A 1.38E-05 Hepatitis B LOC100507421 intron 21750111 rs10282021 chr7 140868944 G A 9.22E-06 Multiple complex diseases LOC100507421 intron 17554300 rs16882396 chr7 140888321 C G 2.00E-06 Smooth-surface caries LOC100507421 intron 24556642 rs6980270 chr7 140906424 G A 3.96E-05 Serum metabolites LOC100507421 intron 19043545 rs17566000 chr7 140920388 C T 8.70E-07 Urinary metabolites LOC100507421 intron 21572414 rs17488258 chr7 140931391 C T 2.70E-06 Urinary metabolites LOC100507421 intron 21572414 rs2191934 chr7 140946633 C T 9.77E-05 Cognitive performance LOC100507421 intron 19734545 rs2191934 chr7 140946633 C T 8.32E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines LOC100507421 intron 21844884 rs4140983 chr7 140964275 A G 6.64E-04 Multiple complex diseases LOC100507421 intron 17554300 rs13245084 chr7 141015529 C A 0.0000507 Menopause (age at onset) LOC100507421 intron 23424626 rs10488012 chr7 141018508 G T 4.66E-04 Iron levels LOC100507421 intron pha002876 rs10215677 chr7 141085514 A G 3.73E-04 Type 2 diabetes LOC100507421 intron 17463246 rs1558211 chr7 141117744 A G 1.40E-05 Urinary metabolites LOC100507421 intron 21572414 rs11760722 chr7 141119143 A G 2.00E-04 Cognitive impairment induced by topiramate LOC100507421 intron 22091778 rs1181729 chr7 141124286 G A 2.76E-04 Multiple complex diseases LOC100507421 intron 17554300 rs1181733 chr7 141127558 A G 9.28E-04 Multiple complex diseases LOC100507421 intron 17554300 rs1181736 chr7 141130932 G A 8.03E-04 Multiple complex diseases LOC100507421 intron 17554300 rs1005335 chr7 141137004 A G 3.48E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181744 chr7 141138204 T C 4.80E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1727487 chr7 141139536 G T 4.53E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181747 chr7 141140130 C T 3.84E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181754 chr7 141142597 A G 3.36E-04 Aortic root size LOC100507421 intron 21223598 rs1181755 chr7 141145284 T C 1.21E-05 Aortic root size LOC100507421 intron 21223598 rs1181758 chr7 141146100 G A 6.10E-04 Type 2 diabetes LOC100507421 intron 17463246 rs1181758 chr7 141146100 G A 3.23E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181759 chr7 141146425 A G 6.10E-04 Type 2 diabetes LOC100507421 intron 17463246 rs1181759 chr7 141146425 A G 5.74E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181760 chr7 141146548 C G 5.14E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181761 chr7 141146937 C T 4.67E-04 Type 2 diabetes LOC100507421 intron 17463246 rs1181761 chr7 141146937 C T 5.16E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181762 chr7 141147070 T A 5.10E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181763 chr7 141147241 C T 3.13E-04 Aortic root size LOC100507421 intron 21223598 rs1181764 chr7 141147356 T C 4.60E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181765 chr7 141147736 G T 1.68E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181766 chr7 141148209 C G 1.68E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181767 chr7 141149278 A G 4.75E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181768 chr7 141149608 A G 4.73E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181769 chr7 141151271 T C 7.18E-05 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181770 chr7 141151394 A G 6.35E-05 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181771 chr7 141151668 G A 5.78E-05 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181772 chr7 141151683 C G 1.82E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181773 chr7 141152103 A G 9.86E-05 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181774 chr7 141152490 G A 1.04E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1638516 chr7 141152664 A T 2.23E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181775 chr7 141152680 A G 1.41E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181776 chr7 141152866 A T 2.77E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1181777 chr7 141153209 A C 1.74E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs2366240 chr7 141157148 C A 2.73E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs41507647 chr7 141158582 T A 5.00E-04 Type 2 diabetes LOC100507421 intron 17463246 rs12535734 chr7 141161163 A T 1.64E-04 Suicide attempts in bipolar disorder LOC100507421 intron 21423239 rs1569085 chr7 141241540 A G 1.30E-04 Taste perception / / 22132133 rs7786043 chr7 141242042 C A 7.96E-05 Type 2 diabetes / / 22238593 rs4725559 chr7 141287652 G A 5.38E-07 Taste perception AGK intron 22132133 rs11773340 chr7 141316834 C T 2.44E-06 Taste perception AGK intron 22132133 rs12703398 chr7 141329651 T C 1.94E-05 Taste perception AGK intron 22132133 rs17520514 chr7 141332730 G A 5.78E-04 Type 2 diabetes AGK intron 17463246 rs3800989 chr7 141360585 A G 1.10E-04 Taste perception KIAA1147 UTR-3 22132133 rs4726463 chr7 141366639 A G 6.10E-07 Taste perception KIAA1147 intron 22132133 rs7791469 chr7 141389640 A G 1.36E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer KIAA1147 intron 21483023 rs10261374 chr7 141398588 A T 3.21E-04 Multiple complex diseases KIAA1147 intron 17554300 rs10261374 chr7 141398588 A T 6.94E-06 Taste perception KIAA1147 intron 22132133 rs13231650 chr7 141398942 T C 8.27E-06 Taste perception KIAA1147 intron 22132133 rs4726468 chr7 141407424 T C 2.46E-05 Taste perception FLJ40852 intron 22132133 rs6963959 chr7 141407716 A C 1.94E-05 Taste perception FLJ40852 intron 22132133 rs6963959 chr7 141407716 A C 8.93E-05 Height FLJ40852 intron pha003011 rs768055 chr7 141413051 C A 8.94E-04 Taste perception FLJ40852 intron 22132133 rs11760572 chr7 141436390 C T 1.47E-05 Taste perception FLJ40852 intron 22132133 rs145241704 chr7 141505087 T G 2.00E-07 Anorexia nervosa / / 23568457 rs10464444 chr7 141532187 G A 1.03E-06 Taste perception / / 22132133 rs9640357 chr7 141543098 C T 2.95E-05 Taste perception / / 22132133 rs12703413 chr7 141546847 G A 5.87E-06 Taste perception / / 22132133 rs6959360 chr7 141569606 C A 1.16E-04 Taste perception / / 22132133 rs1285957 chr7 141589278 T C 1.00E-06 Anorexia nervosa / / 23568457 rs11767119 chr7 141612116 G A 2.55E-07 Taste perception / / 22132133 rs11767947 chr7 141612621 G A 1.53E-07 Taste perception / / 22132133 rs6976028 chr7 141612717 C T 3.37E-07 Taste perception / / 22132133 rs12539499 chr7 141630267 T C 1.90E-07 Taste perception CLEC5A intron 22132133 rs1285950 chr7 141636563 C A 1.29E-04 Taste perception CLEC5A intron 22132133 rs7794708 chr7 141653637 T C 1.34E-04 Taste perception / / 22132133 rs2570407 chr7 141654892 C A 5.04E-06 Taste perception / / 22132133 rs11762634 chr7 141656487 G A 8.11E-07 Taste perception / / 22132133 rs4726481 chr7 141668403 G T 3.04E-36 Taste perception / / 22132133 rs10246939 chr7 141672604 T C 1.49E-52 Taste perception TAS2R38 missense 22132133 rs10246939 chr7 141672604 T C 4.08E-04 Response to taxane treatment (placlitaxel) TAS2R38 missense 23006423 rs10246939 chr7 141672604 T C 2.00E-62 Bitter taste perception TAS2R38 missense 23966204 rs1726866 chr7 141672705 G A 3.95E-36 Taste perception / / 22132133 rs1726866 chr7 141672705 G A 8.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs713598 chr7 141673345 C G 2.00E-104 Bitter taste response TAS2R38 missense 20675712 rs713598 chr7 141673345 C G 1.21E-52 Taste perception TAS2R38 missense 22132133 rs17162635 chr7 141677963 T A 1.16E-07 Taste perception / / 22132133 rs1294351 chr7 141686659 C G 4.20E-04 Body mass index / / 17255346 rs10225228 chr7 141687327 T C 6.80E-05 Taste perception / / 22132133 rs12703414 chr7 141689666 C A,G,T 9.67E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs6947481 chr7 141692808 T G 1.88E-05 Alcohol and nictotine co-dependence / / 20158304 rs1285938 chr7 141701356 A G 0.000298103 Hypertension (early onset hypertension) MGAM intron 22479346 rs1298582 chr7 141707530 A T 6.14E-04 Response to taxane treatment (placlitaxel) MGAM intron 23006423 rs2204607 chr7 141709694 C T 6.92E-05 Alcohol consumption MGAM intron pha001399 rs2204607 chr7 141709694 C T 5.65E-05 Alcohol consumption MGAM intron pha001401 rs1527307 chr7 141710899 T C 9.00E-05 Amyotrophic lateral sclerosis MGAM intron 20801717 rs1527307 chr7 141710899 T C 3.70E-04 Taste perception MGAM intron 22132133 rs1880924 chr7 141717225 C T 4.23E-05 Bipolar disorder and schizophrenia MGAM intron 20889312 rs1880924 chr7 141717225 C T 0.000422324 Hypertension (early onset hypertension) MGAM intron 22479346 rs2272330 chr7 141727526 G T 6.44E-04 Response to statin treatment (atorvastatin),change in cholesterol levels MGAM missense 20031582 rs6946799 chr7 141729747 T C 6.94E-04 Suicide attempts in bipolar disorder MGAM intron 21423239 rs4276595 chr7 141765705 T C 1.58E-05 Alcohol and nictotine co-dependence MGAM intron 20158304 rs3800993 chr7 141801007 C T 2.00E-15 Blood metabolite levels MGAM intron 24816252 rs10216068 chr7 141847221 G A 1.59E-04 Self-reported allergy / / 23817569 rs10280771 chr7 141856674 T C 9.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs11761774 chr7 141861469 G A 2.60E-05 Common variable immunodeficiency / / 21497890 rs2960765 chr7 141972755 C T 3.10E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs928923 chr7 142005088 C T 2.08E-05 Bilirubin levels,in serum / / 19389676 rs17162969 chr7 142009774 C T 9.35E-04 Type 2 diabetes / / 17463246 rs7803986 chr7 142022327 A T 1.80E-05 Urinary metabolites / / 21572414 rs17162992 chr7 142023231 A T 6.20E-05 White matter hyperintensity burden / / 21681796 rs17162994 chr7 142023396 G T 2.90E-05 Urinary metabolites / / 21572414 rs7796556 chr7 142100911 C T 5.50E-05 Alcoholism (heaviness of drinking) / / 21529783 rs111223299 chr7 142104571 G A 9.00E-07 Capecitabine sensitivity / / 22864933 rs361433 chr7 142104571 G A 9.00E-07 Capecitabine sensitivity / / 22864933 rs2226967 chr7 142126627 G A 8.07E-05 Weight / / pha003026 rs2040369 chr7 142137119 T C 5.14E-05 Nephrolithiasis / / 22396660 rs2040369 chr7 142137119 T C 7.82E-05 Weight / / pha003026 rs10240026 chr7 142140446 T A 1.83E-26 Narcolepsy / / 19629137 rs11982969 chr7 142141746 G A 4.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs10276363 chr7 142191647 A G 6.52E-04 Multiple complex diseases / / 17554300 rs10271914 chr7 142192818 A G 6.58E-05 Serum metabolites / / 19043545 rs1114694 chr7 142196639 C T 1.50E-05 Urinary metabolites / / 21572414 rs4725583 chr7 142198814 C A 9.23E-05 Serum metabolites / / 19043545 rs4725583 chr7 142198814 C A 2.30E-05 Urinary metabolites / / 21572414 rs6977669 chr7 142211193 C T 7.00E-06 White blood cell count / / 21738479 rs6974551 chr7 142211508 G A 7.00E-06 White blood cell count / / 21738479 rs17231 chr7 142216436 G T 3.88E-06 White blood cell count / / 21738479 rs4439035 chr7 142218717 C A 3.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4439035 chr7 142218717 C A 0.0000329 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6961143 chr7 142222364 T G 4.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6961143 chr7 142222364 T G 0.0000329 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7798099 chr7 142228586 C T 1.75E-04 Schizophrenia / / 19197363 rs11770471 chr7 142236708 C A 2.41E-06 White blood cell count / / 21738479 rs17209 chr7 142239946 T C 0.000035 Coronary artery calcification / / 23727086 rs2855914 chr7 142244168 A G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs17304 chr7 142245627 A G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2734103 chr7 142247764 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs361440 chr7 142250680 G A 2.62E-04 Schizophrenia / / 19197363 rs2734072 chr7 142254269 A C 0.00043 Coronary artery calcification / / 23727086 rs361493 chr7 142259134 G A 0.00000111 Cholesterol,total / / 23063622 rs2734062 chr7 142261012 A G 8.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10487530 chr7 142261607 T C 3.00E-05 Suicide attempts in bipolar disorder / / 21423239 rs2097229 chr7 142263758 A T 8.46E-06 White blood cell count / / 21738479 rs2854536 chr7 142274854 G A 4.00E-08 Narcolepsy / / 24204295 rs10243991 chr7 142337300 A G 4.92E-04 Gallstones / / 17632509 rs6951033 chr7 142344202 A C 1.31E-08 Triglycerides / / 23063622 rs10156121 chr7 142380488 T C 0.000000475 LDL cholesterol / / 23063622 rs10156121 chr7 142380488 T C 1.76E-12 Triglycerides / / 23063622 rs10156121 chr7 142380488 T C 3.46E-08 Cholesterol,total / / 23063622 rs2213212 chr7 142406737 A C 1.05E-10 Neuroblastoma / / 19536264 rs2027801 chr7 142420689 A G 1.45E-10 Neuroblastoma / / 19536264 rs17251 chr7 142423289 C A 7.42E-11 Neuroblastoma / / 19536264 rs4726572 chr7 142424843 C A 7.42E-11 Neuroblastoma / / 19536264 rs6464528 chr7 142424885 G A 7.42E-11 Neuroblastoma / / 19536264 rs17163638 chr7 142426331 C T 7.94E-04 Insulin resistance / / 21901158 rs6959895 chr7 142434960 T C 3.02E-11 Neuroblastoma / / 19536264 rs1964986 chr7 142447631 C A 4.09E-10 Neuroblastoma / / 19536264 rs10273639 chr7 142456928 T C 2.00E-14 Pancreatitis / / 23143602 rs2734222 chr7 142487836 T C 3.66E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2734222 chr7 142487836 T C 2.14E-10 Neuroblastoma / / 19536264 rs2734224 chr7 142488688 A G 1.49E-09 Neuroblastoma / / 19536264 rs2367486 chr7 142492130 A G 8.85E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2367486 chr7 142492130 A G 1.03E-08 Neuroblastoma / / 19536264 rs3114479 chr7 142502287 T C 5.98E-05 Coronary heart disease / / pha003031 rs3134904 chr7 142503276 G T 5.73E-05 Coronary heart disease / / pha003031 rs17163738 chr7 142507502 A G 0.000000201 Triglycerides / / 23063622 rs7779406 chr7 142554278 G A 2.20E-04 Major depressive disorder EPHB6 intron 21042317 rs8177113 chr7 142554845 C A,G 2.00E-04 Major depressive disorder EPHB6 intron 21042317 rs6950043 chr7 142560701 G C 9.91E-04 Coronary heart disease EPHB6 intron 21606135 rs4987687 chr7 142568878 A G 2.30E-05 Urinary metabolites EPHB6 nearGene-3 21572414 rs4987622 chr7 142579929 T C 2.20E-05 Urinary metabolites TRPV6 intron 21572414 rs4987620 chr7 142580056 T C 2.20E-05 Urinary metabolites TRPV6 intron 21572414 rs4987613 chr7 142581288 G A 2.20E-05 Urinary metabolites TRPV6 intron 21572414 rs4987612 chr7 142581668 T C 9.37E-04 Coronary heart disease TRPV6 intron 21606135 rs4252402 chr7 142627138 G A 7.06E-05 Cognitive impairment induced by topiramate TRPV5 intron 22091778 rs4252400 chr7 142627580 G T 9.12E-04 Multiple complex diseases TRPV5 intron 17554300 rs6947073 chr7 142637062 G C 1.30E-05 Urinary metabolites C7orf34 intron 21572414 rs8176044 chr7 142639321 T C 2.40E-05 Personality dimensions KEL intron 22628180 rs7809414 chr7 142674366 A G 2.10E-25 Kell system antigen / / 22611595 rs6464536 chr7 142689472 C T 9.27E-05 Parkinson's disease / / 21738487 rs9885986 chr7 142724062 C T 9.80E-04 Response to cytidine analogues (gemcitabine) OR9A2 missense 24483146 rs1506403 chr7 142750951 C T 1.61E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1994497 chr7 142816927 A G 2.80E-04 Intelligence (childhood) / / 23358156 rs315293 chr7 142817552 C G 7.78E-04 Smoking quantity / / 24665060 rs12703516 chr7 142839168 A G 7.12E-04 Alcohol dependence / / 20201924 rs28404932 chr7 142981741 C T 9.28E-04 Response to cytadine analogues (cytosine arabinoside) TMEM139 nearGene-5 24483146 rs6954291 chr7 143027055 C T 7.59E-05 Elbow pain CLCN1 intron pha003008 rs7802536 chr7 143049973 A G 1.16E-05 Lung adenocarcinoma / / 19836008 rs13232480 chr7 143069310 T C 0.0003 Endometrial cancer / / 22426144 rs4726618 chr7 143101984 C T 3.78E-06 Alzheimer's disease (late onset) EPHA1 intron 21460841 rs4421280 chr7 143103217 G A 5.03E-04 Insulin resistance EPHA1 intron 21901158 rs12703526 chr7 143107588 G T 2.45E-05 Alzheimer's disease (late onset) LOC285965 intron 21460841 rs11767557 chr7 143109139 T C 6.00E-10 Alzheimer's disease (late onset) LOC285965 intron 21460841 rs11767557 chr7 143109139 T C 6.00E-10 Prion diseases LOC285965 intron 22210626 rs11767557 chr7 143109139 T C 6.19E-04 Tourette syndrome LOC285965 intron 22889924 rs11771145 chr7 143110762 G A 1.32E-08 Alzheimer's disease (late onset) LOC285965 intron 21460841 rs11771145 chr7 143110762 G A 1.00E-13 Alzheimer's disease (late onset) LOC285965 intron 24162737 rs77531530 chr7 143111805 C T 0.00006975 Sarcoidosis LOC285965 intron 22952805 rs79853540 chr7 143113840 G A 0.00006784 Sarcoidosis LOC285965 intron 22952805 rs4726620 chr7 143114740 C T 0.00004038 Sarcoidosis LOC285965 intron 22952805 rs12534861 chr7 143117083 C T 0.0000427 Sarcoidosis LOC285965 intron 22952805 rs12534810 chr7 143124769 G A 0.00004207 Sarcoidosis LOC285965 intron 22952805 rs10228407 chr7 143127771 T G 1.45E-04 Multiple complex diseases LOC285965 intron 17554300 rs10228407 chr7 143127771 T G 2.30E-05 Urinary metabolites LOC285965 intron 21572414 rs12534427 chr7 143141583 C G 4.85E-04 Smoking cessation LOC285965 intron 24665060 rs2949739 chr7 143186653 T G 9.28E-05 Bone mineral density LOC285965 intron 19181680 rs2949739 chr7 143186653 T G 4.52E-05 Myopia (severe) LOC285965 intron 23933737 rs2966701 chr7 143203582 A G 0.0000864 Panic disorder LOC285965 intron 23149450 rs2966701 chr7 143203582 A G 8.64E-05 Serum tamsulosin hydrochloride concentration LOC285965 intron 23151678 rs2949761 chr7 143211942 A G 3.80E-05 Triglycerides LOC285965 intron 19074352 rs2949763 chr7 143214801 C T 3.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC285965 intron 20877124 rs2949763 chr7 143214801 C T 6.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC285965 intron 20877124 rs13230093 chr7 143437434 A G 1.18E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs11768025 chr7 143575983 G A 3.11E-04 Multiple complex diseases FAM115A intron 17554300 rs7806823 chr7 143610550 G A 0.000447 Salmonella-induced pyroptosis / / 22837397 rs10226688 chr7 143682946 G T 1.84E-04 Vaspin levels / / 22907691 rs10226688 chr7 143682946 G T 0.0001838 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs6964734 chr7 143724757 A G 1.57E-04 Multiple complex diseases / / 17554300 rs6965390 chr7 143725181 A T 1.93E-04 Multiple complex diseases / / 17554300 rs6949653 chr7 143725270 C T 2.29E-04 Multiple complex diseases / / 17554300 rs6948665 chr7 143725358 G A 6.06E-04 Multiple complex diseases / / 17554300 rs13247635 chr7 143727265 G A 5.48E-04 Obesity (extreme) / / 21935397 rs7776489 chr7 143729774 G A 2.11E-04 Multiple complex diseases / / 17554300 rs7796641 chr7 143733713 G A 2.44E-04 Multiple complex diseases / / 17554300 rs7784532 chr7 143734001 T C 1.96E-04 Multiple complex diseases / / 17554300 rs7780844 chr7 143734056 A C 2.17E-04 Multiple complex diseases / / 17554300 rs7787537 chr7 143739539 T G 1.01E-04 Multiple complex diseases / / 17554300 rs7787537 chr7 143739539 T G 5.76E-06 Stroke (ischemic) / / 22941190 rs17164583 chr7 143739937 C T 0.0000488 Carotid intima media thickness / / 23152477 rs11976180 chr7 143741580 A C 7.00E-06 Obesity-related traits / / 23251661 rs6464573 chr7 143748098 G T 4.61E-04 Multiple complex diseases OR2A5 missense 17554300 rs2951308 chr7 143767149 C A 5.92E-04 Multiple complex diseases / / 17554300 rs2961134 chr7 143771062 A T 5.91E-04 Multiple complex diseases / / 17554300 rs720475 chr7 144074929 G A 7.03E-04 Taste perception ARHGEF5 intron 22132133 rs720475 chr7 144074929 G A 7.00E-11 Breast cancer ARHGEF5 intron 23535729 rs1635079 chr7 144075749 A G 3.00E-04 Multiple complex diseases ARHGEF5 intron 17554300 rs727714 chr7 144098992 G A 2.96E-04 Schizophrenia(treatment response to risperidone) NOBOX cds-synon 19850283 rs929289 chr7 144112357 G A 9.38E-05 Major depressive disorder / / 19107115 rs10952577 chr7 144113535 A G 9.96E-04 Multiple complex diseases / / 17554300 rs17280674 chr7 144128962 G A 8.12E-04 Multiple complex diseases / / 17554300 rs9648813 chr7 144134651 C T 2.84E-05 Major depressive disorder / / 19107115 rs2371549 chr7 144172841 C T 5.38E-09 Serum chloride TPK1 intron 23696881 rs6977069 chr7 144230643 G A 1.20E-05 Urinary metabolites TPK1 intron 21572414 rs17169947 chr7 144232075 C G 2.00E-05 Urinary metabolites TPK1 intron 21572414 rs7804157 chr7 144277770 T G 2.00E-05 Urinary metabolites TPK1 intron 21572414 rs10224675 chr7 144292762 A G 3.80E-05 Alcohol dependence TPK1 intron 21956439 rs17170233 chr7 144298550 G C 6.57E-04 Multiple complex diseases TPK1 intron 17554300 rs1476625 chr7 144300725 G T 3.00E-05 Prostate cancer TPK1 intron 21743057 rs10251353 chr7 144346919 G A 2.11E-04 Multiple complex diseases TPK1 intron 17554300 rs228587 chr7 144429379 C T 1.80E-05 Urinary metabolites TPK1 intron 21572414 rs1406720 chr7 144480670 A G 8.17E-04 Type 2 diabetes TPK1 intron 17846124 rs13245214 chr7 144559966 G A 1.53E-05 Erythrocyte counts / / pha003101 rs2692390 chr7 144603425 T C 1.13E-04 Lymphocyte counts / / 22286170 rs10500148 chr7 144675704 C G 2.54E-04 Body mass index / / 21701565 rs10258763 chr7 144679309 C T 1.14E-04 Body mass index / / 21701565 rs1525459 chr7 144684050 A G 6.00E-05 Cognitive test performance / / 20125193 rs10251934 chr7 144702577 C T 2.50E-05 Breast cancer / / 22452962 rs7788803 chr7 144710520 C A 2.91E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10226541 chr7 144711359 T C 2.16E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7781772 chr7 144721441 C T 6.01E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1973815 chr7 144730377 C T 7.60E-05 Blood Pressure / / pha003048 rs6464644 chr7 144747898 A G 1.30E-04 Primary sclerosing cholangitis / / 19944697 rs9640436 chr7 144783523 C T 0.0000392 Major depressive disorder / / 23149448 rs478437 chr7 144793834 C T 0.00006 Endoxifen sentivity (10 uM) / / 23508821 rs7789134 chr7 144798554 C T 4.96E-05 Blood Pressure / / pha003048 rs642782 chr7 144824230 G T 1.80E-05 Blood Pressure / / pha003048 rs17729038 chr7 144827132 T G 9.19E-05 Serum metabolites / / 19043545 rs725849 chr7 144840724 T C 3.57E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10487524 chr7 144841531 G A 9.00E-06 Attention deficit hyperactivity disorder / / 20732626 rs1525731 chr7 144849002 C T 2.41E-04 Multiple complex diseases / / 17554300 rs2040979 chr7 144855345 C T 4.34E-05 Body Mass Index / / pha003006 rs10239806 chr7 144970651 C A 2.20E-05 Urinary metabolites / / 21572414 rs1118226 chr7 144976210 T C 2.07E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1859566 chr7 144986806 A C 8.01E-05 Height / / pha003011 rs10487514 chr7 145003322 A G 3.65E-04 Multiple complex diseases / / 17554300 rs996343 chr7 145018517 A G 4.42E-04 Multiple complex diseases / / 17554300 rs996342 chr7 145018727 A G 4.88E-04 Multiple complex diseases / / 17554300 rs6972400 chr7 145028967 A G 3.17E-04 Multiple complex diseases / / 17554300 rs1468375 chr7 145034612 C A 1.13E-07 Parkinson's disease / / 17052657 rs12112509 chr7 145077179 C T 1.12E-04 Multiple complex diseases / / 17554300 rs1100694 chr7 145079941 C G 7.28E-04 Type 2 diabetes / / 17463246 rs850354 chr7 145082844 T G 6.58E-04 Multiple complex diseases / / 17554300 rs850390 chr7 145133150 G A 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs6947759 chr7 145175716 G T 0.000671237 Hypertension (early onset hypertension) / / 22479346 rs13222586 chr7 145185358 C T 1.00E-04 Information processing speed / / 21130836 rs13222586 chr7 145185358 C T 2.34E-04 Cognitive decline / / 23732972 rs7804968 chr7 145208265 G A 6.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7804968 chr7 145208265 G A 3.49E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10500154 chr7 145286533 G T 7.72E-04 Taste perception / / 22132133 rs11761986 chr7 145327959 G T 1.65E-04 Atopy / / 21625490 rs4342507 chr7 145576623 T C 7.03E-05 Smoking initiation / / 24665060 rs4370447 chr7 145583955 A G 8.53E-04 Suicide attempts in bipolar disorder / / 21041247 rs12666281 chr7 145627287 C T 3.25E-04 Aortic root size / / 21223598 rs11983463 chr7 145650488 C A 5.35E-04 Aortic root size / / 21223598 rs11972095 chr7 145654449 A C 4.48E-04 Aortic root size / / 21223598 rs4591940 chr7 145671873 G A 3.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17169908 chr7 145695083 C T 3.83E-04 Aortic root size / / 21223598 rs1554690 chr7 145746333 A C 9.34E-04 Stroke / / pha002887 rs7802176 chr7 145747458 T G 6.61E-04 Multiple complex diseases / / 17554300 rs6464720 chr7 145752465 G A 9.13E-04 Multiple complex diseases / / 17554300 rs1917651 chr7 145768267 A G 5.44E-04 Aortic root size / / 21223598 rs1880597 chr7 145788161 G A 9.29E-04 Stroke / / pha002886 rs6952493 chr7 145791905 T A 2.60E-05 Urinary metabolites / / 21572414 rs2140840 chr7 145792848 C T 6.30E-06 Urinary metabolites / / 21572414 rs940932 chr7 145877708 C T 8.69E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CNT/P2 intron 21844884 rs12703781 chr7 145882353 G A 9.12E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CNT/P2 intron 21844884 rs11765641 chr7 145933013 C T 6.38E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CNT/P2 intron 20877124 rs802524 chr7 145951642 T C 8.73E-04 Type 2 diabetes CNT/P2 intron 17463246 rs802524 chr7 145951642 T C 7.00E-07 Bipolar disorder and schizophrenia CNT/P2 intron 20889312 rs802568 chr7 145959243 T G 4.53E-04 Type 2 diabetes CNT/P2 intron 17463246 rs802568 chr7 145959243 T G 2.00E-07 Bipolar disorder and schizophrenia CNT/P2 intron 20889312 rs17503262 chr7 146043176 A G 1.60E-05 Urinary metabolites CNT/P2 intron 21572414 rs965003 chr7 146046444 C T 9.68E-05 Bipolar disorder and schizophrenia CNT/P2 intron 20889312 rs7799181 chr7 146048830 A G 3.82E-05 Coronary Artery Disease CNT/P2 intron 17634449 rs7799181 chr7 146048830 A G 2.00E-06 Bipolar disorder and schizophrenia CNT/P2 intron 20889312 rs10225674 chr7 146049748 A C,G 7.77E-05 Chronic Hepatitis C infection CNT/P2 intron 21725309 rs1724527 chr7 146098510 A G 4.97E-04 Multiple complex diseases CNT/P2 intron 17554300 rs1724526 chr7 146098555 T G 5.11E-04 Multiple complex diseases CNT/P2 intron 17554300 rs1718101 chr7 146122788 T C 7.78E-09 Autism CNT/P2 intron 22843504 rs1358075 chr7 146135938 T C 9.00E-06 Obesity-related traits CNT/P2 intron 23251661 rs17170106 chr7 146170918 C G 7.26E-04 Type 2 diabetes CNT/P2 intron 17463246 rs1917950 chr7 146225448 C A 1.17E-04 Stroke CNT/P2 intron pha002887 rs17513926 chr7 146243404 C T 1.62E-04 Hypertension (young onset) CNT/P2 intron 24892410 rs4726793 chr7 146276890 G A 1.17E-05 Odorant perception CNT/P2 intron 23910658 rs454612 chr7 146292088 C T 7.16E-05 Parent of origin effect on language impairment (paternal) CNT/P2 intron 24571439 rs347223 chr7 146317074 C T 0.00038626 Hypertension (early onset hypertension) CNT/P2 intron 22479346 rs347220 chr7 146323187 G A 0.000129153 Hypertension (early onset hypertension) CNT/P2 intron 22479346 rs35077106 chr7 146339248 T TG 2.20E-04 Urinary metabolites CNT/P2 intron 21572414 rs10952650 chr7 146360917 C T 1.24E-05 Diabetes Mellitus CNT/P2 intron pha003059 rs6951437 chr7 146406407 A G 4.62E-05 Reading disability and language impairment CNT/P2 intron 24024963 rs344470 chr7 146413497 T C 7.61E-05 Cognitive decline CNT/P2 intron 22054870 rs344465 chr7 146420571 A G 2.74E-05 Diabetes Mellitus CNT/P2 intron pha003059 rs10487920 chr7 146458079 C A 3.90E-04 Breast cancer and prostate cancer CNT/P2 intron 17903305 rs7794745 chr7 146489606 A T 8.25E-04 Multiple complex diseases CNT/P2 intron 17554300 rs7794745 chr7 146489606 A T 1.74E-05 Autism CNT/P2 intron 18179894 rs4367451 chr7 146559474 A G 8.82E-04 Suicide attempts in bipolar disorder CNT/P2 intron 21423239 rs4529377 chr7 146585987 G A 3.27E-05 Multiple complex diseases CNT/P2 intron 17554300 rs10081247 chr7 146600338 G C 2.00E-05 Major depressive disorder CNT/P2 intron 22472876 rs17170293 chr7 146642350 C T 8.28E-04 Suicide attempts in bipolar disorder CNT/P2 intron 21423239 rs12703863 chr7 146652162 T C 1.25E-05 Major depressive disorder CNT/P2 intron 22472876 rs940455 chr7 146663568 G T 1.76E-05 Major depressive disorder CNT/P2 intron 22472876 rs12703869 chr7 146668551 G T 2.34E-05 Major depressive disorder CNT/P2 intron 22472876 rs10238991 chr7 146672902 A G 2.48E-04 Bipolar disorder CNT/P2 intron 18317468 rs10241470 chr7 146678508 A G 1.93E-04 Bipolar disorder CNT/P2 intron 18317468 rs10808041 chr7 146681594 T A 8.57E-04 Suicide attempts in bipolar disorder CNT/P2 intron 21041247 rs10251794 chr7 146685549 T A 3.43E-05 Personality dimensions CNT/P2 intron 18957941 rs2372806 chr7 146690737 G A 1.34E-05 Fibrinogen CNT/P2 intron 17255346 rs7800935 chr7 146690926 T C 3.54E-06 Fibrinogen CNT/P2 intron 17255346 rs12669418 chr7 146701480 G T 8.32E-05 Graves' disease CNT/P2 intron 21841780 rs7804520 chr7 146719195 C T 6.03E-05 Bone mineral density CNT/P2 intron 19181680 rs1524346 chr7 146727346 T C 6.30E-05 Personality dimensions CNT/P2 intron 18957941 rs6980283 chr7 146750254 G T 1.20E-05 Inflammatory demyelinating disease CNT/P2 intron 19850125 rs10266239 chr7 146751635 G A 1.08E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) CNT/P2 intron 23648065 rs10266239 chr7 146751635 G A 6.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) CNT/P2 intron 23648065 rs11770843 chr7 146795379 T C 6.20E-05 Scoliosis CNT/P2 intron 21216876 rs7795067 chr7 146887300 C T 5.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CNT/P2 intron 20877124 rs10273775 chr7 146897403 A G 9.00E-06 Alzheimer's disease CNT/P2 intron 22159054 rs7806237 chr7 146920089 C A 1.02E-04 Alzheimer's disease (late onset) CNT/P2 intron 21379329 rs6943628 chr7 146934096 G A 4.88E-05 Alzheimer's disease (late onset) CNT/P2 intron 21379329 rs6943628 chr7 146934096 G A 9.38E-05 Anorexia nervosa CNT/P2 intron 24514567 rs1496545 chr7 146942272 G A 7.44E-05 Major depressive disorder (broad) CNT/P2 intron 20038947 rs9769600 chr7 146954397 G A 4.26E-05 Serum metabolites CNT/P2 intron 19043545 rs9769600 chr7 146954397 G A 3.22E-05 Blood Pressure CNT/P2 intron pha002903 rs7790788 chr7 146966876 T C 3.33E-04 IgE levels CNT/P2 intron 17255346 rs10279700 chr7 146968295 T C 4.08E-05 Alcohol dependence CNT/P2 intron 21314694 rs1472361 chr7 146969399 T C 6.74E-05 IgE levels CNT/P2 intron 17255346 rs2692179 chr7 147006044 A G 5.42E-05 Blood Pressure CNT/P2 intron pha002903 rs2692133 chr7 147023537 A G 1.39E-04 Telomere length CNT/P2 intron 21573004 rs2692131 chr7 147026076 G C 3.14E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CNT/P2 intron 20031582 rs700293 chr7 147027883 A C 6.63E-05 Insulin resistance CNT/P2 intron 21901158 rs6973542 chr7 147029028 A G 7.10E-05 IgE levels CNT/P2 intron 17255346 rs747139 chr7 147032714 G T 5.13E-05 IgE levels CNT/P2 intron 17255346 rs826802 chr7 147035067 G T 7.22E-05 Lung cancer CNT/P2 intron 18978787 rs826802 chr7 147035067 G T 7.72E-04 Suicide attempts in bipolar disorder CNT/P2 intron 21041247 rs826802 chr7 147035067 G T 2.75E-04 Oral cancers (chewing tobacco related) CNT/P2 intron 22503698 rs7791755 chr7 147036688 C T 1.51E-04 IgE levels CNT/P2 intron 17255346 rs12703906 chr7 147040778 C T 1.85E-04 IgE levels CNT/P2 intron 17255346 rs700296 chr7 147044852 G T 1.74E-04 Insulin resistance CNT/P2 intron 21901158 rs826822 chr7 147054250 G T 1.94E-04 IgE levels CNT/P2 intron 17255346 rs826824 chr7 147058991 G A 4.28E-04 IgE levels CNT/P2 intron 17255346 rs861160 chr7 147064346 A C 3.50E-05 White matter hyperintensity burden CNT/P2 intron 21681796 rs826809 chr7 147067719 C T 3.50E-05 White matter hyperintensity burden CNT/P2 intron 21681796 rs2022226 chr7 147157421 C T 2.74E-04 IgE levels CNT/P2 intron 17255346 rs2107856 chr7 147188685 G T 3.00E-04 Pseudoexfoliation syndrome CNT/P2 intron 20808326 rs2141388 chr7 147189740 C T 2.00E-04 Pseudoexfoliation syndrome CNT/P2 intron 20808326 rs1528512 chr7 147206369 G A 2.44E-04 Suicide attempts in bipolar disorder CNT/P2 intron 21423239 rs10234171 chr7 147207930 T C 1.67E-04 Suicide attempts in bipolar disorder CNT/P2 intron 21423239 rs10282028 chr7 147209008 C T 1.40E-05 Fasting plasma glucose CNT/P2 intron 19060907 rs10282028 chr7 147209008 C T 1.94E-04 Suicide attempts in bipolar disorder CNT/P2 intron 21423239 rs1919188 chr7 147209601 A G 1.13E-04 Suicide attempts in bipolar disorder CNT/P2 intron 21423239 rs851844 chr7 147210936 C T 3.47E-04 Suicide attempts in bipolar disorder CNT/P2 intron 21423239 rs851832 chr7 147213472 T C 3.25E-04 Suicide attempts in bipolar disorder CNT/P2 intron 21423239 rs851829 chr7 147214833 C A 6.92E-04 Suicide attempts in bipolar disorder CNT/P2 intron 21423239 rs6464816 chr7 147226891 G A 9.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio CNT/P2 intron 22589738 rs17170584 chr7 147236757 G A 5.89E-04 Multiple complex diseases CNT/P2 intron 17554300 rs4118165 chr7 147240784 C G 8.95E-04 Obesity (extreme) CNT/P2 intron 21935397 rs3915304 chr7 147246979 G C 8.46E-04 Multiple complex diseases CNT/P2 intron 17554300 rs3915304 chr7 147246979 G C 2.91E-04 Body mass index CNT/P2 intron 21701565 rs4425670 chr7 147259105 G A 3.22E-04 Lung function (forced expiratory volume in 1 second) CNT/P2 intron 24023788 rs6980002 chr7 147267528 G A 7.67E-04 Smoking initiation CNT/P2 intron 24665060 rs995891 chr7 147281247 T C 5.95E-04 Smoking initiation CNT/P2 intron 24665060 rs7794693 chr7 147296158 C A 1.41E-04 Lung function (forced expiratory volume in 1 second) CNT/P2 intron 24023788 rs10244236 chr7 147351071 A G 5.53E-05 Waist-Hip Ratio CNT/P2 intron pha003029 rs4314574 chr7 147354931 A G 1.99E-04 Lung function (forced expiratory volume in 1 second) CNT/P2 intron 24023788 rs17327575 chr7 147360817 T C 2.74E-04 Lung function (forced expiratory volume in 1 second) CNT/P2 intron 24023788 rs851729 chr7 147365490 A G 9.26E-06 Multiple complex diseases CNT/P2 intron 17554300 rs1543265 chr7 147408493 T C 6.04E-05 Type 2 diabetes CNT/P2 intron 22158537 rs10952705 chr7 147417555 G A 3.95E-06 Insulin-related traits CNT/P2 intron 22791750 rs4142924 chr7 147422076 A G 4.52E-04 Type 2 diabetes CNT/P2 intron 17463246 rs1525259 chr7 147424462 C T 6.93E-04 Type 2 diabetes CNT/P2 intron 17463246 rs1525260 chr7 147445495 G A 7.32E-04 Multiple complex diseases CNT/P2 intron 17554300 rs1525262 chr7 147445646 G A 7.30E-04 Multiple complex diseases CNT/P2 intron 17554300 rs17824874 chr7 147511618 A G 3.25E-05 Lipoprotein-associated phospholipase A2 activity and mass CNT/P2 intron 20442857 rs10246029 chr7 147524566 C T 8.00E-06 Prostate cancer CNT/P2 intron 21743057 rs851712 chr7 147528731 A G 2.61E-06 Alcohol and nictotine co-dependence CNT/P2 intron 20158304 rs10246598 chr7 147549110 C T 8.00E-06 Prostate cancer CNT/P2 intron 21743057 rs10263791 chr7 147554296 T C 8.00E-06 Prostate cancer CNT/P2 intron 21743057 rs13235812 chr7 147556653 A G 3.39E-04 Multiple complex diseases CNT/P2 intron 17554300 rs13235812 chr7 147556653 A G 3.35E-04 Cognitive decline CNT/P2 intron 23732972 rs6464842 chr7 147558292 A G 4.34E-05 Serum metabolites CNT/P2 intron 19043545 rs6975343 chr7 147559148 A C 2.03E-04 Multiple complex diseases CNT/P2 intron 17554300 rs2373269 chr7 147567018 G A 5.64E-04 Multiple complex diseases CNT/P2 intron 17554300 rs17170715 chr7 147568889 G T 1.00E-05 Prostate cancer CNT/P2 intron 21743057 rs10255352 chr7 147569131 G A 1.00E-05 Prostate cancer CNT/P2 intron 21743057 rs6947415 chr7 147569595 C T 1.00E-05 Prostate cancer CNT/P2 intron 21743057 rs2710102 chr7 147574390 A G 7.56E-05 Elbow pain CNT/P2 intron pha003008 rs2708240 chr7 147577537 G A 3.16E-04 Multiple complex diseases CNT/P2 intron 17554300 rs2708240 chr7 147577537 G A 4.00E-06 QT interval (interaction) CNT/P2 intron 23459443 rs2708240 chr7 147577537 G A 7.56E-05 Elbow pain CNT/P2 intron pha003008 rs10270982 chr7 147578229 G T 1.00E-05 Prostate cancer CNT/P2 intron 21743057 rs17170724 chr7 147579634 T C 1.00E-05 Prostate cancer CNT/P2 intron 21743057 rs2538990 chr7 147580041 C T 3.09E-04 Multiple complex diseases CNT/P2 intron 17554300 rs2538990 chr7 147580041 C T 5.12E-05 Elbow pain CNT/P2 intron pha003008 rs2538979 chr7 147582719 T C 2.98E-04 Multiple complex diseases CNT/P2 intron 17554300 rs10232583 chr7 147583054 G A 1.00E-05 Prostate cancer CNT/P2 intron 21743057 rs17170728 chr7 147583978 C T 1.00E-05 Prostate cancer CNT/P2 intron 21743057 rs10263426 chr7 147584109 T C 1.00E-05 Prostate cancer CNT/P2 intron 21743057 rs2538976 chr7 147585819 T C 6.61E-05 Elbow pain CNT/P2 intron pha003008 rs2710107 chr7 147593314 T G 2.67E-05 Multiple complex diseases CNT/P2 intron 17554300 rs7778252 chr7 147594096 C T 0.0000226 Major depressive disorder CNT/P2 intron 23149448 rs2710109 chr7 147595362 A G 4.60E-04 Alzheimer's disease CNT/P2 intron 17998437 rs7797634 chr7 147605413 T C 1.00E-04 Prostate cancer CNT/P2 intron 21743057 rs2710121 chr7 147608448 G A 5.15E-05 Multiple complex diseases CNT/P2 intron 17554300 rs2538959 chr7 147613758 T G 8.13E-04 Suicide attempts in bipolar disorder CNT/P2 intron 21041247 rs2710123 chr7 147613866 G A 0.00004538 Sarcoidosis CNT/P2 intron 22952805 rs2538958 chr7 147615640 C T 8.00E-06 IgG glycosylation CNT/P2 intron 23382691 rs2538957 chr7 147616124 T C 7.32E-04 Suicide attempts in bipolar disorder CNT/P2 intron 21041247 rs56283447 chr7 147616819 G A 0.00005955 Sarcoidosis CNT/P2 intron 22952805 rs56181151 chr7 147616879 G A 0.00005955 Sarcoidosis CNT/P2 intron 22952805 rs7805223 chr7 147617727 T C 7.35E-04 Suicide attempts in bipolar disorder CNT/P2 intron 21041247 rs7805492 chr7 147617841 T C 7.35E-04 Suicide attempts in bipolar disorder CNT/P2 intron 21041247 rs7805515 chr7 147617886 T C 7.38E-04 Suicide attempts in bipolar disorder CNT/P2 intron 21041247 rs7805990 chr7 147618210 T G 7.39E-04 Suicide attempts in bipolar disorder CNT/P2 intron 21041247 rs2708252 chr7 147654381 C T 6.70E-06 Stroke (ischemic) CNT/P2 intron 22384361 rs2710082 chr7 147660103 G A 1.40E-05 Urinary metabolites CNT/P2 intron 21572414 rs2707592 chr7 147660453 A G 1.11E-04 Alcohol and nictotine co-dependence CNT/P2 intron 20158304 rs2178771 chr7 147663492 T G 4.99E-05 Alcohol and nictotine co-dependence CNT/P2 intron 20158304 rs2204926 chr7 147663609 T C 1.20E-05 Urinary metabolites CNT/P2 intron 21572414 rs2373283 chr7 147674047 C G 0.0008358 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CNT/P2 intron 23233654 rs2373283 chr7 147674047 C G 8.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) CNT/P2 intron 23233662 rs13229141 chr7 147676287 C T 0.0008008 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CNT/P2 intron 23233654 rs13229141 chr7 147676287 C T 8.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) CNT/P2 intron 23233662 rs11771941 chr7 147679535 G A 4.87E-05 Alcohol and nictotine co-dependence CNT/P2 intron 20158304 rs11771941 chr7 147679535 G A 2.80E-05 Urinary metabolites CNT/P2 intron 21572414 rs2189883 chr7 147688887 G A 2.90E-05 Urinary metabolites CNT/P2 intron 21572414 rs2214681 chr7 147702692 A G 3.00E-06 Bone mineral density CNT/P2 intron 17903296 rs13233277 chr7 147722727 T C 3.57E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CNT/P2 intron 24023788 rs10485844 chr7 147759461 G A 8.21E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CNT/P2 intron 20031582 rs10485843 chr7 147781074 G A 9.23E-05 Bipolar Disorder CNT/P2 intron pha002863 rs41498044 chr7 147797462 C T 9.14E-04 Type 2 diabetes CNT/P2 intron 17463246 rs10238586 chr7 147798444 T A 6.14E-04 Type 2 diabetes CNT/P2 intron 17463246 rs10235838 chr7 147798729 A G 8.71E-04 Type 2 diabetes CNT/P2 intron 17463246 rs2972108 chr7 147864611 G A 2.33E-04 Body mass index CNT/P2 intron 21701565 rs2972108 chr7 147864611 G A 2.91E-04 Body mass index CNT/P2 intron 21701565 rs2074711 chr7 147869670 T C 7.87E-05 Post-operative nausea and vomiting CNT/P2 intron 21694509 rs10255956 chr7 147870469 G A 5.60E-08 Metabolite levels CNT/P2 intron 23281178 rs12534650 chr7 147871787 A T 5.76E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CNT/P2 intron 20031582 rs4549702 chr7 147901016 C G 1.00E-06 Body mass index (interaction) CNT/P2 intron 23192594 rs10952735 chr7 147908210 T G 4.50E-05 Parkinson's disease (age of onset) CNT/P2 intron 19772629 rs6952506 chr7 147931329 C T 3.81E-04 Multiple complex diseases CNT/P2 intron 17554300 rs4725770 chr7 147933546 T C 6.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CNT/P2 intron 20877124 rs1881726 chr7 147933618 C T 1.62E-06 Systemic lupus erythematosus and Systemic sclerosis CNT/P2 intron 23740937 rs6964680 chr7 147977039 T G 4.40E-05 Hypothyroidism CNT/P2 intron 22493691 rs17434745 chr7 147989522 T C 3.68E-05 Amyotrophic lateral sclerosis (sporadic) CNT/P2 intron 24529757 rs11514853 chr7 148013258 G A 4.41E-04 Multiple complex diseases CNT/P2 intron 17554300 rs11771834 chr7 148013853 A G 2.10E-06 Urinary metabolites CNT/P2 intron 21572414 rs10277969 chr7 148035192 A G 7.82E-04 Tourette syndrome CNT/P2 intron 22889924 rs17170960 chr7 148038227 G A 1.20E-04 Type 2 diabetes CNT/P2 intron 17463246 rs1177927 chr7 148038771 A G 4.40E-04 Type 2 diabetes CNT/P2 intron 17463246 rs1177926 chr7 148038823 C T 5.25E-04 Type 2 diabetes CNT/P2 intron 17463246 rs1177924 chr7 148040248 A G 4.62E-04 Type 2 diabetes CNT/P2 intron 17463246 rs6464877 chr7 148050508 A G 5.36E-04 Type 2 diabetes CNT/P2 intron 17463246 rs6464877 chr7 148050508 A G 4.33E-04 Multiple complex diseases CNT/P2 intron 17554300 rs6464877 chr7 148050508 A G 1.10E-05 Urinary metabolites CNT/P2 intron 21572414 rs12531117 chr7 148053799 G T 2.46E-06 Amyotrophic lateral sclerosis CNT/P2 intron 19193627 rs1177942 chr7 148059842 T C 8.97E-04 Type 2 diabetes CNT/P2 intron 17463246 rs987456 chr7 148112987 C A 6.92E-04 Response to cytadine analogues (cytosine arabinoside) CNT/P2 UTR-3 24483146 rs2717829 chr7 148117505 G C 1.94E-04 Type 2 diabetes CNT/P2 UTR-3 17463246 rs2530309 chr7 148118249 C T 4.95E-04 Type 2 diabetes CNT/P2 nearGene-3 17463246 rs7780899 chr7 148143442 C T 6.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7780899 chr7 148143442 C T 2.86E-05 Body Mass Index / / pha003015 rs2538483 chr7 148188150 G A 4.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2717795 chr7 148195053 T G 1.57E-04 Multiple complex diseases / / 17554300 rs2538466 chr7 148232245 G A 8.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2717770 chr7 148232643 C T 6.22E-04 Multiple complex diseases / / 17554300 rs6957883 chr7 148239179 C T 2.29E-06 Alzheimer's disease (late onset) / / 20885792 rs10280054 chr7 148245573 C T 1.22E-04 Multiple complex diseases / / 17554300 rs10280425 chr7 148245802 C T 1.18E-04 Progressive supranuclear palsy / / 21685912 rs887822 chr7 148256554 C A,G,T 9.48E-05 Multiple complex diseases / / 17554300 rs887822 chr7 148256554 C A,G,T 5.21E-05 Serum metabolites / / 19043545 rs887822 chr7 148256554 C A,G,T 5.43E-04 Sarcoidosis / / 19165924 rs7807268 chr7 148258048 G C 4.00E-06 Crohn's disease / / 17554300 rs7807268 chr7 148258048 G C 1.74E-05 Serum metabolites / / 19043545 rs12704036 chr7 148258161 C T 1.97E-05 Multiple complex diseases / / 17554300 rs12704036 chr7 148258161 C T 3.50E-05 Serum metabolites / / 19043545 rs17171051 chr7 148272945 T C 9.35E-04 Type 2 diabetes / / 17463246 rs17171051 chr7 148272945 T C 3.81E-05 Odorant perception / / 23910658 rs6948227 chr7 148274786 T C 9.11E-04 Type 2 diabetes / / 17463246 rs6959357 chr7 148309458 G A 9.63E-05 Non-alcoholic fatty liver disease histology (other) C7orf33 intron 20708005 rs6962292 chr7 148312520 T C 6.59E-04 Type 2 diabetes / / 17463246 rs9648855 chr7 148322585 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4577876 chr7 148372320 C T 9.65E-05 Multiple complex diseases / / 17554300 rs6955043 chr7 148373356 C T 8.40E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6971248 chr7 148376567 C T 2.83E-05 Multiple complex diseases / / 17554300 rs11773084 chr7 148458644 C T 7.93E-05 Serum metabolites CUL1 intron 19043545 rs2373414 chr7 148470319 C T 9.50E-05 Serum metabolites CUL1 intron 19043545 rs7783459 chr7 148573898 G A 9.04E-04 Alzheimer's disease EZH2 intron 22005930 rs7804456 chr7 148615643 T C 5.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs822552 chr7 148650634 C G 3.00E-08 Height / / 20881960 rs1676904 chr7 148656280 A G 9.56E-04 Coronary heart disease / / 21606135 rs10236884 chr7 148659616 A G 3.01E-04 Body mass index / / 17255346 rs6946304 chr7 148746224 G A 3.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6973937 chr7 148771346 C T 3.70E-04 Alcohol dependence ZNF786 intron 20201924 rs12113550 chr7 148778682 A G 3.70E-04 Alcohol dependence ZNF786 intron 20201924 rs7797617 chr7 148785721 A C 3.86E-04 Alcohol dependence ZNF786 intron 20201924 rs3801979 chr7 148851273 G C 0.0000396 Nonsyndromic striae distensae (stretch marks) ZNF398 missense 23633020 rs1724305 chr7 148855216 G C 5.92E-04 Type 2 diabetes ZNF398 intron 17463246 rs1202460 chr7 148870799 G A 3.22E-04 Multiple complex diseases ZNF398 intron 17554300 rs1202468 chr7 148887137 T C 5.08E-04 Type 2 diabetes / / 17463246 rs6464945 chr7 148903773 C T 4.35E-04 Multiple complex diseases ZNF282 intron 17554300 rs1123992 chr7 148907201 C G 9.64E-05 Serum metabolites ZNF282 intron 19043545 rs1202390 chr7 148914122 G A 9.84E-05 Major depressive disorder ZNF282 intron 21621269 rs114143440 chr7 148914320 T C 2.92E-05 Epilepsy (remission after treatment) ZNF282 intron 23962720 rs1202397 chr7 148916627 T C 2.57E-04 Multiple complex diseases ZNF282 intron 17554300 rs11976830 chr7 148922666 T C 9.43E-05 Non-alcoholic fatty liver disease histology (other) ZNF282 UTR-3 20708005 rs917121 chr7 148934699 A G 9.42E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10487889 chr7 148950023 G A 9.42E-05 Non-alcoholic fatty liver disease histology (other) ZNF212 intron 20708005 rs7788681 chr7 148976137 C T 1.05E-05 Coronary heart disease ZNF783 intron pha003030 rs4727044 chr7 149007531 C T 7.00E-04 Cardiovascular heart disease in diabetics / / 23982368 rs886714 chr7 149018975 T C 1.71E-05 Height / / pha003010 rs886714 chr7 149018975 T C 7.62E-05 Height / / pha003011 rs4725805 chr7 149019712 C T 1.97E-05 Height / / pha003010 rs4725805 chr7 149019712 C T 7.88E-05 Height / / pha003011 rs736548 chr7 149028791 C T 7.60E-05 Height / / pha003010 rs736548 chr7 149028791 C T 5.01E-05 Blood Pressure / / pha003039 rs736548 chr7 149028791 C T 3.54E-05 Blood Pressure / / pha003045 rs765951 chr7 149054004 T C 2.34E-05 Personality dimensions / / 22628180 rs2462608 chr7 149060494 C T 8.65E-05 Hypertension / / pha003042 rs1636375 chr7 149064937 T C 5.90E-05 Height / / pha003010 rs1636409 chr7 149094701 G A 2.86E-05 Blood Pressure / / pha003048 rs7808416 chr7 149169534 A G 6.22E-05 Multiple complex diseases / / 17554300 rs6464979 chr7 149201467 C A 2.81E-04 Fibrinogen / / 17255346 rs855913 chr7 149203662 A C 4.00E-08 Amyotrophic lateral sclerosis / / 19451621 rs10563058 chr7 149256438 CTG C 5.79E-04 Multiple complex diseases ZNF767 intron 17554300 rs1859583 chr7 149256438 C T 5.79E-04 Multiple complex diseases ZNF767 intron 17554300 rs553610754 chr7 149256438 CTG C 5.79E-04 Multiple complex diseases ZNF767 intron 17554300 rs4727088 chr7 149264153 C T 6.53E-04 Multiple complex diseases ZNF767 intron 17554300 rs4727089 chr7 149265242 C T 7.35E-04 Multiple complex diseases ZNF767 intron 17554300 rs354033 chr7 149289464 G A 5.00E-09 Multiple sclerosis ZNF767 intron 21833088 rs354033 chr7 149289464 G A 7.90E-04 Multiple sclerosis ZNF767 intron 24234648 rs886707 chr7 149299744 A G 3.47E-04 Multiple complex diseases ZNF767 intron 17554300 rs12536925 chr7 149301904 T C 8.39E-04 Lymphocyte counts ZNF767 intron 22286170 rs354064 chr7 149319439 T C 3.67E-04 Response to taxane treatment (placlitaxel) ZNF767 intron 23006423 rs354075 chr7 149329991 T C 3.84E-04 Multiple complex diseases / / 17554300 rs12234594 chr7 149344332 G A 7.65E-04 Taste perception / / 22132133 rs731489 chr7 149361282 G A 6.48E-04 Taste perception / / 22132133 rs12533800 chr7 149362009 T C 7.28E-04 Taste perception / / 22132133 rs13220986 chr7 149362552 G T 6.31E-04 Taste perception / / 22132133 rs12536519 chr7 149363857 G A 4.67E-04 Myopia (pathological) / / 21095009 rs855746 chr7 149398065 A G 6.81E-05 Myocardial Infarction / / pha002883 rs6974985 chr7 149403770 C T 1.45E-05 Glycosylated haemoglobin levels / / 17255346 rs12674335 chr7 149450663 A G 8.13E-05 Major depressive disorder / / 19107115 rs855675 chr7 149465674 C T 6.60E-05 Cognitive impairment induced by topiramate ZNF467 intron 22091778 rs200849829 chr7 149475056 G A 0.00031 Breast cancer SSPO missense 23555315 rs200849829 chr7 149475056 G A 0.00075 Prostate cancer SSPO missense 23555315 rs740111 chr7 149509817 G T 6.94E-05 Suicide attempts in bipolar disorder SSPO intron 21423239 rs2074688 chr7 149513780 A G 1.35E-04 Suicide attempts in bipolar disorder SSPO intron 21423239 rs34094057 chr7 149513780 A AG 1.35E-04 Suicide attempts in bipolar disorder SSPO intron 21423239 rs2072169 chr7 149513846 A G 1.42E-04 Suicide attempts in bipolar disorder SSPO intron 21423239 rs10265226 chr7 149513886 G C 1.37E-04 Suicide attempts in bipolar disorder SSPO intron 21423239 rs10261620 chr7 149514028 T G 1.64E-04 Suicide attempts in bipolar disorder SSPO intron 21423239 rs735499 chr7 149516165 T C 1.47E-04 Suicide attempts in bipolar disorder SSPO intron 21423239 rs2074697 chr7 149522366 T G 1.79E-04 Suicide attempts in bipolar disorder SSPO intron 21423239 rs1004200 chr7 149523277 A G 1.22E-04 Suicide attempts in bipolar disorder SSPO missense 21423239 rs2074701 chr7 149559465 C T 6.42E-04 Acute lung injury ZNF862 cds-synon 22295056 rs1859529 chr7 149562285 C G 5.36E-04 Acute lung injury ZNF862 UTR-3 22295056 rs12703055 chr7 149582906 A G 2.45E-04 Alzheimer's disease (late onset) / / 21379329 rs6954118 chr7 149585379 T C 5.99E-05 Blood Pressure / / pha003039 rs6954118 chr7 149585379 T C 3.44E-06 Blood Pressure / / pha003045 rs6954118 chr7 149585379 T C 9.44E-06 Blood Pressure / / pha003047 rs2373680 chr7 149844639 A G 9.28E-04 Aortic root size / / 21223598 rs2969637 chr7 149855335 G T 9.24E-05 Bipolar disorder / / 19488044 rs17835738 chr7 149992098 C G 0.000000079 Ovarian follicle number and menopause ACTR3C intron 22696150 rs10237116 chr7 150008330 G A,C,T 2.33E-05 Multiple complex diseases ACTR3C intron 17554300 rs2108854 chr7 150017408 T C 6.07E-04 Type 2 diabetes ACTR3C intron 17463246 rs11767726 chr7 150018096 G T 5.66E-04 Type 2 diabetes ACTR3C intron 17463246 rs1464753 chr7 150021350 G C 7.10E-06 Parkinson's disease LRRC61 intron 20711177 rs3735172 chr7 150028958 A G 8.35E-04 Type 2 diabetes C7orf29 UTR-3 17463246 rs17173608 chr7 150036664 T G 2.00E-07 Suicide attempts in depression or bipolar disorder RARRES2 intron 24964207 rs10229175 chr7 150041564 G T 6.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs10244748 chr7 150041610 T C 6.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs10244748 chr7 150041610 T C 2.87E-04 Response to alcohol consumption (flushing response) / / 24277619 rs9640161 chr7 150045910 C A 2.34E-04 Response to alcohol consumption (flushing response) / / 24277619 rs10263613 chr7 150060163 G A 8.94E-04 Alcohol dependence / / 20201924 rs4725336 chr7 150067445 C A 1.31E-04 Alzheimer's disease (late onset) REPIN1 intron 21460841 rs4725336 chr7 150067445 C A 8.24E-06 Personality dimensions REPIN1 intron 23658558 rs3757425 chr7 150067640 A C 6.79E-04 Multiple complex diseases REPIN1 intron 17554300 rs1880316 chr7 150092031 G T 6.75E-04 Response to taxane treatment (placlitaxel) ZNF775 intron 23006423 rs940453 chr7 150093701 A C 2.74E-04 Multiple complex diseases ZNF775 cds-synon 17554300 rs7393 chr7 150095271 T C 6.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZNF775 UTR-3 20877124 rs2888635 chr7 150119076 G T 1.80E-05 Immunoglobulin A / / 20694011 rs11769211 chr7 150160458 G A 1.51E-05 Prostate cancer GIMAP8 intron pha002878 rs6969414 chr7 150167583 A G 2.05E-05 Prostate cancer GIMAP8 intron pha002878 rs7776515 chr7 150176946 A G 2.24E-06 Parent of origin effect on language impairment (maternal) / / 24571439 rs4725905 chr7 150212634 C A 0.0005482 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) GIMAP7 intron 23233654 rs4725905 chr7 150212634 C A 5.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) GIMAP7 intron 23233662 rs4725906 chr7 150212654 T G 0.0005473 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) GIMAP7 intron 23233654 rs4725906 chr7 150212654 T G 5.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) GIMAP7 intron 23233662 rs12703077 chr7 150214426 G C 0.0005452 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) GIMAP7 intron 23233654 rs12703077 chr7 150214426 G C 5.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) GIMAP7 intron 23233662 rs7800829 chr7 150217089 G A 4.51E-05 Body Mass Index GIMAP7 cds-synon pha003009 rs7800829 chr7 150217089 G A 6.13E-05 Weight GIMAP7 cds-synon pha003026 rs3735080 chr7 150217309 C T 0.0000461 Behcet's disease GIMAP7 missense 23041938 rs3735079 chr7 150217335 G T 0.0003813 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) GIMAP7 cds-synon 23233654 rs3735079 chr7 150217335 G T 3.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) GIMAP7 cds-synon 23233662 rs11772952 chr7 150220886 T C 7.90E-04 Multiple complex diseases / / 17554300 rs11772952 chr7 150220886 T C 0.0000559 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11772952 chr7 150220886 T C 5.59E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10277380 chr7 150230692 T C 0.000000398 Behcet's disease / / 23041938 rs11769828 chr7 150231309 C T 0.0000016 Behcet's disease / / 23041938 rs1916012 chr7 150233827 A G 0.000000262 Behcet's disease / / 23041938 rs4725908 chr7 150235077 C T 8.43E-04 Multiple complex diseases / / 17554300 rs4725908 chr7 150235077 C T 0.0000257 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4725908 chr7 150235077 C T 2.57E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1522596 chr7 150235783 A G 0.000000347 Behcet's disease / / 23041938 rs1568627 chr7 150239676 T C 0.0001293 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1568627 chr7 150239676 T C 1.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10236188 chr7 150245256 T C 0.000000398 Behcet's disease / / 23041938 rs12703080 chr7 150245988 A G 0.0001596 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12703080 chr7 150245988 A G 1.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1608157 chr7 150247024 C G 6.01E-08 Behcet's disease / / 23041938 rs11768988 chr7 150251708 T C 0.0001566 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11768988 chr7 150251708 T C 1.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1403222 chr7 150253913 A G 4.00E-05 Prostate cancer / / 21743057 rs1916001 chr7 150254030 A C 1.63E-04 Multiple complex diseases / / 17554300 rs6949018 chr7 150255583 G A 4.00E-05 Prostate cancer / / 21743057 rs11770957 chr7 150255761 A T 0.0003267 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11770957 chr7 150255761 A T 3.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9986903 chr7 150256384 T C 6.00E-05 Prostate cancer / / 21743057 rs939958 chr7 150257768 C A 8.03E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs1110093 chr7 150258381 G A 0.0003268 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1110093 chr7 150258381 G A 3.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12703083 chr7 150259959 T C 0.0003272 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12703083 chr7 150259959 T C 3.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6464080 chr7 150260388 T C 4.29E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs13231883 chr7 150261328 C T 0.0003052 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13231883 chr7 150261328 C T 3.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13232597 chr7 150261901 C T 0.0002925 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13232597 chr7 150261901 C T 2.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2177189 chr7 150263323 G A 0.0005975 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2177189 chr7 150263323 G A 5.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2177188 chr7 150263761 G A 0.0000354 Behcet's disease / / 23041938 rs2177188 chr7 150263761 G A 0.0004942 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2177188 chr7 150263761 G A 4.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3807382 chr7 150263795 A G 0.000153308 Primary sclerosing cholangitis / / 23603763 rs13222905 chr7 150263989 G A 0.0002713 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13222905 chr7 150263989 G A 2.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2373815 chr7 150265475 T C 0.0002712 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) GIMAP4 intron 23233654 rs2373815 chr7 150265475 T C 2.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) GIMAP4 intron 23233662 rs2293174 chr7 150267230 T G 0.0002716 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) GIMAP4 intron 23233654 rs2293174 chr7 150267230 T G 2.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) GIMAP4 intron 23233662 rs9640279 chr7 150268098 G T 1.54E-04 Alcohol consumption (maxi-drinks) GIMAP4 intron 24277619 rs1317277 chr7 150268236 A G 7.98E-04 Insulin resistance GIMAP4 intron 21901158 rs11771561 chr7 150268562 C T 0.0002673 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) GIMAP4 intron 23233654 rs11771561 chr7 150268562 C T 2.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) GIMAP4 intron 23233662 rs13242186 chr7 150269087 G C 0.0002678 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) GIMAP4 intron 23233654 rs13242186 chr7 150269087 G C 2.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) GIMAP4 intron 23233662 rs2293172 chr7 150269542 G T 0.0002689 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) GIMAP4 missense 23233654 rs2293172 chr7 150269542 G T 2.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) GIMAP4 missense 23233662 rs3807378 chr7 150271429 G A 0.0002693 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs3807378 chr7 150271429 G A 2.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6969250 chr7 150292545 C T 0.0000562 Behcet's disease / / 23041938 rs6964548 chr7 150312916 T A 5.48E-04 Insulin resistance / / 21901158 rs2373802 chr7 150313689 G C 0.0001901 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2373802 chr7 150313689 G C 1.90E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11771962 chr7 150316914 A G 0.0001919 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11771962 chr7 150316914 A G 1.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11762727 chr7 150324157 G A 0.0002343 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) GIMAP6 UTR-3 23233654 rs11762727 chr7 150324157 G A 2.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) GIMAP6 UTR-3 23233662 rs13226190 chr7 150326562 T G 0.000059 Behcet's disease GIMAP6 intron 23041938 rs10266069 chr7 150349937 A G 0.00000223 Behcet's disease / / 23041938 rs10256482 chr7 150350975 T C 0.0000001 Behcet's disease / / 23041938 rs1403220 chr7 150363700 T A 6.35E-04 Multiple complex diseases / / 17554300 rs10244273 chr7 150381356 C T 5.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1860871 chr7 150389593 T C 0.000228 Behcet's disease GIMAP2 cds-synon 23041938 rs2075078 chr7 150389856 A G 4.33E-04 Multiple complex diseases GIMAP2 missense 17554300 rs4725927 chr7 150392005 C A 0.000231 Behcet's disease / / 23041938 rs2286900 chr7 150418045 G A 0.00000922 Behcet's disease GIMAP1 UTR-3 23041938 rs6945478 chr7 150425351 G T 8.06E-04 Multiple complex diseases GIMAP1-GIMAP5 intron 17554300 rs2159843 chr7 150427628 A G 2.55E-04 Multiple complex diseases GIMAP1-GIMAP5 intron 17554300 rs11772925 chr7 150428109 C T 8.01E-05 Multiple sclerosis GIMAP1-GIMAP5 intron 19525953 rs6972271 chr7 150444233 T C 3.84E-04 Gallstones / / 17632509 rs741061 chr7 150501245 C T 3.23E-04 Type 2 diabetes TMEM176A intron 17463246 rs9088 chr7 150501516 A G 6.92E-04 Rheumatoid arthritis TMEM176A missense 21452313 rs11772167 chr7 150503079 T C 7.68E-04 Type 2 diabetes / / 17463246 rs10231759 chr7 150512172 T C 4.00E-09 Height / / 23563607 rs2110001 chr7 150517022 C G 3.00E-13 Height / / 20881960 rs7787744 chr7 150521096 A G 9.96E-04 Multiple complex diseases / / 17554300 rs10952289 chr7 150524681 T C 2.23E-05 Squamous cell carcinoma / / 23341777 rs4725367 chr7 150525879 T C 6.50E-05 Myasthenia gravis / / 23055271 rs17173637 chr7 150529449 T C 2.00E-08 HDL cholesterol / / 24097068 rs6956432 chr7 150539151 A G 2.00E-04 Myasthenia gravis / / 23055271 rs1005390 chr7 150543721 T G 3.00E-14 Blood metabolite levels / / 24816252 rs1005390 chr7 150543721 T G 3.00E-16 Blood metabolite ratios / / 24816252 rs4725970 chr7 150558611 C T 6.50E-05 Waist-Hip Ratio / / pha003013 rs4725970 chr7 150558611 C T 4.03E-05 Waist-Hip Ratio / / pha003029 rs10250704 chr7 150564418 A C 6.52E-05 Waist-Hip Ratio / / pha003013 rs10250704 chr7 150564418 A C 9.46E-05 Waist-Hip Ratio / / pha003028 rs10250704 chr7 150564418 A C 1.85E-05 Waist-Hip Ratio / / pha003029 rs10264084 chr7 150592362 A T 2.63E-05 Sudden cardiac arrest / / 21658281 rs12533255 chr7 150593418 C T 6.65E-06 Waist-Hip Ratio / / pha003029 rs740954 chr7 150598492 T C 1.78E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs17173656 chr7 150598659 T C 1.53E-05 Sudden cardiac arrest / / 21658281 rs10216051 chr7 150599205 A G 7.59E-04 Tourette syndrome / / 22889924 rs11762978 chr7 150610100 A G 7.92E-04 Tourette syndrome / / 22889924 rs17173658 chr7 150611161 G T 1.21E-04 Sudden cardiac arrest / / 21658281 rs2968864 chr7 150622162 T C 8.00E-16 QT interval / / 19305408 rs2968864 chr7 150622162 T C 6.18E-09 QT interval / / 19305409 rs2968863 chr7 150623137 C T 2.00E-15 QT interval / / 19305409 rs758887 chr7 150634448 C T 9.38E-06 QT interval / / 23166209 rs13228494 chr7 150637094 A G 8.04E-06 QT interval / / 23166209 rs4725982 chr7 150637863 C T 5.00E-16 QT interval / / 19305408 rs4725982 chr7 150637863 C T 3.00E-06 Electrocardiographic traits / / 20062061 rs4725982 chr7 150637863 C T 8.51E-06 QT interval / / 23166209 rs36210421 chr7 150644428 C A 1 Drug response to Dofetilide KCNH2 missense 15522280 rs12720441 chr7 150647304 G A,C,T 1 Drug response to Amiodarone KCNH2 missense 11997281 rs3807375 chr7 150667210 C T 5.00E-11 Electrocardiographic traits KCNH2 intron 20062063 rs3807375 chr7 150667210 C T 3.05E-04 Tourette syndrome KCNH2 intron 22889924 rs4725984 chr7 150668514 T C 0.000000172 LDL cholesterol KCNH2 intron 23063622 rs3778873 chr7 150669867 C G 7.90E-05 QT interval KCNH2 intron 19305409 rs3778873 chr7 150669867 C G 3.24E-06 QT interval KCNH2 intron 23166209 rs3778872 chr7 150669976 C G 3.00E-06 QT interval KCNH2 intron 23166209 rs3807370 chr7 150673314 A G 0.00000338 LDL cholesterol KCNH2 intron 23063622 rs1800783 chr7 150689397 A T 1.20E-06 Height NOS3 intron 21194676 rs1800783 chr7 150689397 A T 1.70E-04 Height NOS3 intron 21194676 rs2070744 chr7 150690079 C T 6.42E-04 Hypertension (essential hypertension) NOS3 intron 22184326 rs3918226 chr7 150690176 C T 1.40E-04 Coronary heart disease NOS3 intron 21966275 rs3918226 chr7 150690176 C T 1.12E-06 Blood pressure NOS3 intron 22100073 rs3918226 chr7 150690176 C T 1.34E-08 Blood pressure NOS3 intron 22100073 rs3918226 chr7 150690176 C T 2.19E-09 Blood pressure NOS3 intron 22100073 rs3918226 chr7 150690176 C T 3.95E-08 Blood pressure NOS3 intron 22100073 rs3918226 chr7 150690176 C T 6.20E-16 Hypertension (essential hypertension) NOS3 intron 22184326 rs1549758 chr7 150695726 T C 3.32E-04 Hypertension (essential hypertension) NOS3 cds-synon 22184326 rs2853792 chr7 150699877 G A 7.76E-05 Hypertension (essential hypertension) NOS3 intron 22184326 rs3918186 chr7 150702432 A T 7.29E-04 Multiple complex diseases NOS3 intron 17554300 rs3918198 chr7 150706377 C A 4.01E-16 Triglycerides NOS3 intron 23063622 rs2288645 chr7 150747746 A G 3.53E-04 Acute lung injury ASIC3 intron 22295056 rs891507 chr7 150752066 T C 3.95E-04 Insulin resistance CDK5 intron 21901158 rs2303929 chr7 150761314 G A 6.30E-04 Coronary heart disease SLC4A2 missense 21971053 rs2303942 chr7 150775306 G A 5.67E-04 Smoking cessation FASTK intron 24665060 rs13239507 chr7 150784407 T C 5.07E-04 Smoking cessation AGAP3 intron 24665060 rs6464126 chr7 150785321 C T 2.89E-05 Body Mass Index AGAP3 intron pha003022 rs1978655 chr7 150797581 G A,T 8.76E-05 Smoking cessation AGAP3 intron 24665060 rs1978655 chr7 150797581 G A,T 1.17E-05 Body Mass Index AGAP3 intron pha003022 rs7783954 chr7 150799379 T C 9.58E-05 Smoking cessation AGAP3 intron 24665060 rs729712 chr7 150822192 C T 6.88E-05 Body Mass Index AGAP3 intron pha003019 rs729712 chr7 150822192 C T 7.24E-06 Body Mass Index AGAP3 intron pha003022 rs6968877 chr7 150830015 A G 2.17E-05 Body Mass Index AGAP3 intron pha003019 rs6968877 chr7 150830015 A G 2.53E-05 Body Mass Index AGAP3 intron pha003022 rs4725999 chr7 150844687 C T 2.51E-05 Smoking cessation / / 24665060 rs6464132 chr7 150849164 A G 8.70E-05 Smoking cessation GBX1 intron 24665060 rs4725394 chr7 150851566 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes GBX1 intron 22628534 rs4725394 chr7 150851566 T C 8.64E-06 Body Mass Index GBX1 intron pha003019 rs4725394 chr7 150851566 T C 7.32E-06 Body Mass Index GBX1 intron pha003022 rs768403 chr7 150860246 G A 3.42E-04 Smoking cessation GBX1 intron 24665060 rs2487150 chr7 150882626 G A 6.26E-05 Smoking cessation ASB10 intron 24665060 rs2608291 chr7 150905444 C T 8.49E-04 Lymphocyte counts ABCF2 intron 22286170 rs1122979 chr7 150915071 G A 1.00E-09 IgG glycosylation ABCF2 intron 23382691 rs1122979 chr7 150915071 G A 2.00E-09 IgG glycosylation ABCF2 intron 23382691 rs1122979 chr7 150915071 G A 2.00E-10 IgG glycosylation ABCF2 intron 23382691 rs1122979 chr7 150915071 G A 6.00E-10 IgG glycosylation ABCF2 intron 23382691 rs1122979 chr7 150915071 G A 7.00E-06 IgG glycosylation ABCF2 intron 23382691 rs7812088 chr7 150919829 G A 7.00E-09 Bone mineral density ABCF2 intron 22504420 rs7812088 chr7 150919829 G A 2.80E-04 Bone mineral density ABCF2 intron 24249740 rs7812088 chr7 150919829 G A 4.36E-04 Bone mineral density ABCF2 intron 24249740 rs7812088 chr7 150919829 G A 4.60E-04 Bone mineral density (paediatric,upper limb) ABCF2 intron 24945404 rs219236 chr7 150956627 A G 2.83E-04 Alzheimer's disease (late onset) SMARCD3 intron 21379329 rs1860116 chr7 150997313 A G 7.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs432519 chr7 151013263 G T 9.34E-05 Cognitive performance / / 19734545 rs17173096 chr7 151043221 T C 2.17E-04 Hearing function NUB1 intron 17255346 rs405281 chr7 151062348 G A 6.88E-04 Amyotrophic Lateral Sclerosis NUB1 intron 17362836 rs6963048 chr7 151069296 A G 2.45E-04 IgE levels NUB1 intron 17255346 rs6963048 chr7 151069296 A G 6.55E-06 Corneal structure NUB1 intron 22003120 rs199876601 chr7 151071225 C T 0.000031 Breast cancer(er negative) NUB1 missense 23555315 rs202096934 chr7 151073747 G A 0.000039 Breast cancer (ER positive) NUB1 missense 23555315 rs11764733 chr7 151076661 G C 1.75E-06 Recombination rate / / 21698098 rs1558164 chr7 151086797 C T 2.11E-05 Heart Rate WDR86 intron pha003054 rs11761588 chr7 151094048 T C 3.10E-04 White blood cell types WDR86 intron 21738478 rs11761588 chr7 151094048 T C 1.09E-04 Vaspin levels WDR86 intron 22907691 rs11761588 chr7 151094048 T C 0.0001089 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit WDR86 intron 22907730 rs13232179 chr7 151120948 T A 1.00E-06 Coronary heart disease / / 21347282 rs7792547 chr7 151123529 A G 5.57E-04 Smoking initiation / / 24665060 rs1109089 chr7 151170019 C T 1.10E-04 Suicidal ideation RHEB intron 22030708 rs2074997 chr7 151174286 C A 3.00E-04 Suicidal ideation RHEB intron 22030708 rs965118 chr7 151178423 T A 1.00E-04 Suicidal ideation RHEB intron 22030708 rs3753151 chr7 151184985 C T 5.10E-04 Suicidal ideation RHEB intron 22030708 rs2299965 chr7 151192662 C T 8.50E-04 Suicidal ideation RHEB intron 22030708 rs2299967 chr7 151205211 T C 8.50E-04 Suicidal ideation RHEB intron 22030708 rs6948196 chr7 151213212 T C 2.90E-04 Suicidal ideation RHEB intron 22030708 rs7811407 chr7 151220444 C T 4.29E-04 Type 2 diabetes / / 17463246 rs7811407 chr7 151220444 C T 1.97E-04 Multiple complex diseases / / 17554300 rs1029952 chr7 151245254 T G 1.70E-05 Urinary metabolites / / 21572414 rs2302533 chr7 151261490 A T 4.95E-04 Fibrinogen PRKAG2 intron 17255346 rs2302530 chr7 151267397 G A 7.23E-04 Nicotine smoking PRKAG2 intron 19268276 rs17173197 chr7 151268920 C T 1.39E-07 Atopic dermatitis PRKAG2 intron 21666691 rs1029947 chr7 151275752 T C 9.20E-07 ECG dimensions,brachial artery endothelial function,treadmill exercise responses PRKAG2 intron 17903301 rs1029946 chr7 151275806 A G 3.89E-06 ECG dimensions,brachial artery endothelial function,treadmill exercise responses PRKAG2 intron 17903301 rs6946498 chr7 151283034 T C 0.00015 Coronary artery calcification PRKAG2 intron 23727086 rs3789809 chr7 151289823 T C 4.64E-07 Multiple complex diseases PRKAG2 intron 17554300 rs12111653 chr7 151297837 G A 0.00029 Coronary artery calcification PRKAG2 intron 23727086 rs12113155 chr7 151304973 A C 4.94E-18 LDL cholesterol PRKAG2 intron 23063622 rs12113155 chr7 151304973 A C 5.07E-17 Cholesterol,total PRKAG2 intron 23063622 rs1860736 chr7 151325193 A G 5.05E-04 Multiple complex diseases PRKAG2 intron 17554300 rs12535806 chr7 151325259 C T 3.26E-04 Multiple complex diseases PRKAG2 intron 17554300 rs4726075 chr7 151335260 A G 1 Drug response to Etoposide PRKAG2 intron 17537913 rs112730042 chr7 151345995 T TCTTTT,TTTTTC 2.79E-05 Breast cancer(er negative) PRKAG2 intron 21062454 rs4726078 chr7 151345995 T C 2.79E-05 Breast cancer(er negative) PRKAG2 intron 21062454 rs57131053 chr7 151345995 T TTTTTC 2.79E-05 Breast cancer(er negative) PRKAG2 intron 21062454 rs4726081 chr7 151350262 A G 1.09E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PRKAG2 intron 20877124 rs6964824 chr7 151351232 T C 1.08E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PRKAG2 intron 20877124 rs2536090 chr7 151381200 A G 4.64E-04 Alzheimer's disease (late onset) PRKAG2 intron 21379329 rs2536090 chr7 151381200 A G 2.27E-05 Blood Pressure PRKAG2 intron pha003039 rs6952398 chr7 151396253 T C 1.04E-06 Monocyte chemoattractant protein-1 PRKAG2 intron pha003071 rs11983465 chr7 151396971 C G 1.34E-08 Red blood cell traits PRKAG2 intron 23222517 rs6947064 chr7 151397343 A G 4.48E-07 Red blood cell traits PRKAG2 intron 23222517 rs6967507 chr7 151397487 T C 5.41E-09 Red blood cell traits PRKAG2 intron 23222517 rs6947912 chr7 151397645 G C 1.10E-09 Red blood cell traits PRKAG2 intron 23222517 rs6967838 chr7 151397688 T C 1.29E-09 Red blood cell traits PRKAG2 intron 23222517 rs6947707 chr7 151397773 A T 8.42E-09 Red blood cell traits PRKAG2 intron 23222517 rs6948449 chr7 151398133 C T 1.89E-08 Red blood cell traits PRKAG2 intron 23222517 rs2374270 chr7 151402790 C A 7.12E-10 Red blood cell traits PRKAG2 intron 23222517 rs10480299 chr7 151405818 T C 5.12E-14 Red blood cell traits PRKAG2 intron 23222517 rs10480300 chr7 151406005 C T 2.64E-08 Other erythrocyte phenotypes PRKAG2 intron 19862010 rs10480300 chr7 151406005 C T 8.00E-15 Red blood cell traits PRKAG2 intron 23222517 rs10480300 chr7 151406005 C T 4.00E-09 Urate levels PRKAG2 intron 23263486 rs7805747 chr7 151407801 G A 4.00E-12 Chronic kidney disease PRKAG2 intron 20383146 rs7805747 chr7 151407801 G A 2.72E-13 Chronic kidney disease PRKAG2 intron 22479191 rs7805747 chr7 151407801 G A 1.80E-09 Red blood cell traits PRKAG2 intron 23222517 rs7805747 chr7 151407801 G A 3.10E-04 Glomerular filtration rate PRKAG2 intron 23535967 rs7805747 chr7 151407801 G A 7.00E-04 Glomerular filtration rate PRKAG2 intron 23535967 rs7805747 chr7 151407801 G A 7.30E-04 Glomerular filtration rate PRKAG2 intron 23535967 rs7805747 chr7 151407801 G A 0.00043 Breast cancer PRKAG2 intron 23555315 rs10224210 chr7 151413194 T C 2.10E-08 Other erythrocyte phenotypes PRKAG2 intron 19862010 rs10224210 chr7 151413194 T C 4.10E-14 Red blood cell traits PRKAG2 intron 23222517 rs10224002 chr7 151415041 A G 3.00E-15 Hemoglobin PRKAG2 intron 19862010 rs10224002 chr7 151415041 A G 6.00E-15 Hematocrit PRKAG2 intron 19862010 rs10224002 chr7 151415041 A G 1.60E-10 Blood cell counts and traits,in red and white blood cells PRKAG2 intron 21153663 rs10224002 chr7 151415041 A G 7.28E-04 Alcohol dependence PRKAG2 intron 21314694 rs10224002 chr7 151415041 A G 1.23E-13 Red blood cell traits PRKAG2 intron 23222517 rs2536076 chr7 151415181 T C 4.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PRKAG2 intron 20877124 rs885273 chr7 151436352 A G 5.31E-05 Tunica Media PRKAG2 intron pha003034 rs6970522 chr7 151449553 A G 0.0000324 LDL cholesterol PRKAG2 intron 23063622 rs7801616 chr7 151452628 T C 8.70E-04 Coronary heart disease PRKAG2 intron 21606135 rs4725431 chr7 151473179 T C 5.05E-04 Amyotrophic lateral sclerosis PRKAG2 intron 23624525 rs4725432 chr7 151473418 C A 6.43E-04 Nicotine smoking PRKAG2 intron 19268276 rs7809589 chr7 151473813 G T 1.38E-05 Attention deficit hyperactivity disorder PRKAG2 intron 20732625 rs4530949 chr7 151506985 T C 7.51E-04 Suicide attempts in bipolar disorder PRKAG2 intron 21423239 rs12539356 chr7 151508257 G T 9.57E-04 Suicide attempts in bipolar disorder PRKAG2 intron 21423239 rs1881638 chr7 151508844 A G 4.14E-04 Suicide attempts in bipolar disorder PRKAG2 intron 21423239 rs7805942 chr7 151520931 A C 5.51E-04 Alzheimer's disease PRKAG2 intron 22005930 rs6978617 chr7 151521578 C T 6.45E-04 Multiple complex diseases PRKAG2 intron 17554300 rs1108845 chr7 151522715 C T 2.77E-04 Type 2 diabetes PRKAG2 intron 17463246 rs1881626 chr7 151522808 T C 2.00E-12 HDL cholesterol PRKAG2 intron 23063622 rs7795096 chr7 151546589 T C 2.00E-06 Bipolar disorder (age of onset and psychomotor symptoms) PRKAG2 intron 21305692 rs9640302 chr7 151561573 A G 2.90E-05 Taste perception PRKAG2 intron 22132133 rs2374271 chr7 151596307 T C 4.41E-05 Heart Rate / / pha003053 rs13238381 chr7 151608112 C T 2.64E-05 Heart Rate / / pha003053 rs13238381 chr7 151608112 C T 2.69E-05 Monocyte counts / / pha003089 rs1919520 chr7 151611931 T C 5.93E-06 Heart Rate / / pha003053 rs12703182 chr7 151617908 C G 2.18E-04 Multiple complex diseases / / 17554300 rs2374297 chr7 151626599 A G 5.80E-06 Urinary metabolites / / 21572414 rs10952332 chr7 151634463 C T 6.24E-05 Body mass index / / 24827717 rs17491367 chr7 151642034 A G 5.41E-04 Coronary Artery Disease / / 17634449 rs7804751 chr7 151645370 A G 1.90E-06 Urinary metabolites / / 21572414 rs10233081 chr7 151646012 A G 2.50E-06 Urinary metabolites / / 21572414 rs7797169 chr7 151652711 T C 0.000322 Salmonella-induced pyroptosis / / 22837397 rs10952334 chr7 151653635 G C 7.81E-04 Alcohol dependence GALNTL5 UTR-5 21314694 rs11765654 chr7 151697032 G A 7.46E-05 Chronic Hepatitis C infection GALNTL5 intron 21725309 rs7810799 chr7 151734581 G A 3.00E-05 AIDS GALNT11 intron 19754311 rs10277069 chr7 151755007 G A 4.41E-05 AIDS GALNT11 intron 19754311 rs149373512 chr7 151874581 G C 0.00089 Prostate cancer MLL3 missense 23555315 rs7781309 chr7 152051190 T C 7.90E-06 Vitamin D concentrations MLL3 intron 20600896 rs7781309 chr7 152051190 T C 7.90E-06 Vitamin D concentrations MLL3 intron 20600896 rs12669177 chr7 152189795 T C 5.14E-05 Amyotrophic lateral sclerosis / / 19193627 rs1107394 chr7 152192121 A G 5.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4726177 chr7 152272282 T C 4.28E-04 Schizophrenia / / 19197363 rs4726178 chr7 152272347 C T 9.72E-06 Obesity-related traits / / 23251661 rs7792702 chr7 152290536 A G 7.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10239037 chr7 152297038 C T 4.20E-05 Lung adenocarcinoma / / 22797724 rs6464268 chr7 152381150 A G 4.36E-04 Myopia (pathological) / / 21095009 rs10234749 chr7 152387869 T G 4.00E-06 Palmitic acid (16:0) plasma levels / / 23362303 rs13232006 chr7 152391899 C G 3.75E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs13236792 chr7 152394108 T C 7.52E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10253827 chr7 152406533 C T 4.20E-04 Alzheimer's disease (late onset) / / 21379329 rs10253827 chr7 152406533 C T 4.48E-04 Alzheimer's disease / / 24755620 rs11769572 chr7 152421188 A T 1.38E-04 Cholesterol / / 17255346 rs4476919 chr7 152431851 T C 1.50E-05 Urinary metabolites / / 21572414 rs56216502 chr7 152499822 G A 4.67E-05 Bipolar Disorder ACTR3B intron pha002858 rs11773902 chr7 152501825 G A 3.05E-05 Parkinson's disease (motor and cognition) ACTR3B intron 22658654 rs1568734 chr7 152535908 T C 2.30E-05 Urinary metabolites ACTR3B intron 21572414 rs4236441 chr7 152589802 T C 2.30E-04 Multiple complex diseases / / 17554300 rs7795581 chr7 152595852 T C 8.26E-05 Celiac disease / / 23936387 rs4574762 chr7 152603378 A G 2.29E-06 Longevity / / 21612516 rs6464286 chr7 152605215 C A 3.57E-04 Type 2 diabetes / / 17463246 rs6954929 chr7 152608306 G A 2.60E-04 Type 2 diabetes / / 17463246 rs2535960 chr7 152616099 A T 7.28E-04 Type 2 diabetes / / 17463246 rs4338010 chr7 152624870 C T 3.00E-04 Type 2 diabetes / / 17463246 rs6952411 chr7 152633164 G A 1.40E-06 Urinary metabolites / / 21572414 rs1523638 chr7 152636629 G A 4.73E-04 Type 2 diabetes / / 17463246 rs11981919 chr7 152669840 G A 9.00E-06 Obesity-related traits / / 23251661 rs3937454 chr7 152676940 C T 4.91E-04 Multiple complex diseases / / 17554300 rs10238976 chr7 152716386 G A 9.17E-05 Epilepsy (remission after treatment) / / 23962720 rs10254412 chr7 152716394 T C 9.10E-05 Epilepsy (remission after treatment) / / 23962720 rs7798882 chr7 152735972 C T 9.77E-05 Lipoproteins / / pha003079 rs5029723 chr7 152751140 T C 9.21E-04 Multiple complex diseases / / 17554300 rs4448172 chr7 152753726 T C 5.88E-04 Multiple complex diseases / / 17554300 rs1015997 chr7 152758651 G A 3.01E-05 Cardiovascular disease / / pha003064 rs6959411 chr7 152767561 G A 2.44E-05 Blood pressure / / 17255346 rs7790094 chr7 152786529 G A 1.50E-05 Urinary metabolites / / 21572414 rs17520767 chr7 152801121 G A 7.20E-05 Cognitive function / / 24684796 rs2710234 chr7 152801831 C A 0.00000002 Brain microstructure and intellectual performance / / 22723713 rs760226 chr7 152802220 G A 1.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs760228 chr7 152802742 T C 2.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs672366 chr7 152803420 C G 2.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs496724 chr7 152804939 G A 2.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs498474 chr7 152805111 A G 2.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs521309 chr7 152805336 A G 4.06E-04 Suicide attempts in bipolar disorder / / 21041247 rs593793 chr7 152805344 A G 2.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs593874 chr7 152805404 G A 2.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs594243 chr7 152805455 T C 2.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs2018083 chr7 152806717 G A 3.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs760229 chr7 152809138 A G 3.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs607348 chr7 152812643 T C 4.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs607348 chr7 152812643 T C 0.000507 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs607348 chr7 152812643 T C 5.07E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4726247 chr7 152822009 G A 3.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs2311855 chr7 152823941 T G 3.35E-04 Suicide attempts in bipolar disorder / / 21041247 rs1107875 chr7 152824044 A G 5.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs1107874 chr7 152824289 T A 5.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs4726258 chr7 152844064 C T 1.80E-05 Urinary metabolites / / 21572414 rs7810943 chr7 152844101 A G 4.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs2312035 chr7 152846221 A G 2.70E-05 Urinary metabolites / / 21572414 rs3857768 chr7 152850059 C T 1.20E-05 Urinary metabolites / / 21572414 rs4725486 chr7 152852588 T G 9.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs960600 chr7 152853444 G A 1.40E-05 Urinary metabolites / / 21572414 rs7803687 chr7 152854895 A G 8.28E-04 Alzheimer's disease / / 24755620 rs7792156 chr7 152855875 T C 0.00000729 Tuberculosis with late age of onset / / 22551897 rs6971042 chr7 152858034 G A 0.0002813 Sarcoidosis / / 22952805 rs6971053 chr7 152858048 G C 0.0002732 Sarcoidosis / / 22952805 rs6971077 chr7 152858102 G A 0.0001988 Sarcoidosis / / 22952805 rs28862588 chr7 152858197 T C 0.0002859 Sarcoidosis / / 22952805 rs28786403 chr7 152858232 A G 0.0002859 Sarcoidosis / / 22952805 rs28795220 chr7 152858362 A G 0.0002867 Sarcoidosis / / 22952805 rs11768667 chr7 152858535 T C 0.0002184 Sarcoidosis / / 22952805 rs10278457 chr7 152859520 A G 0.0003402 Sarcoidosis / / 22952805 rs73481210 chr7 152860501 G C 0.0003652 Sarcoidosis / / 22952805 rs10259781 chr7 152867025 G A 6.95E-05 Alcohol consumption / / 23953852 rs7795531 chr7 152868506 C T 8.39E-05 Alcohol consumption / / 23953852 rs4285401 chr7 152878333 A G 2.00E-06 Nicotine use / / 23942779 rs7788751 chr7 152879625 C T 9.38E-04 Response to alcohol consumption (flushing response) / / 24277619 rs4999662 chr7 152885590 T G 9.79E-04 Response to alcohol consumption (flushing response) / / 24277619 rs2710201 chr7 152924893 A G 3.00E-09 Venous thromboembolism (gene x gene interaction) / / 23509962 rs2710201 chr7 152924893 A G 4.77E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2312400 chr7 152944748 G C 1.12E-11 Metabolite levels / / 22286219 rs6948646 chr7 152945284 A G 1.41E-05 Staphylococcus aureus infection / / 24847357 rs1404560 chr7 152946603 C T 6.91E-04 Body mass index / / 21701565 rs10256177 chr7 152954519 A G 8.81E-05 Aging (time to event) / / 21782286 rs12155011 chr7 152958702 T C 6.13E-04 Body mass index / / 21701565 rs12155011 chr7 152958702 T C 6.48E-04 Body mass index / / 21701565 rs1404556 chr7 152960298 T C 7.21E-04 Type 2 diabetes / / 17463246 rs588958 chr7 153001234 G A 2.40E-05 Type 1 diabetes / / 18978792 rs715457 chr7 153031342 T C 8.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4726278 chr7 153050837 A G 0.000109 Salmonella-induced pyroptosis / / 22837397 rs4726290 chr7 153066044 T C 9.19E-04 Insulin resistance / / 21901158 rs10952419 chr7 153151033 C A 8.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10952420 chr7 153154926 C T 4.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4726300 chr7 153155865 A G 4.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs930575 chr7 153155931 G A 4.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4629773 chr7 153176705 A G 6.16E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6958821 chr7 153253567 C T 3.66E-04 Multiple complex diseases / / 17554300 rs10281586 chr7 153254290 C G 4.95E-05 Suicide attempts in bipolar disorder / / 21423239 rs10282321 chr7 153254763 G A 8.25E-05 Suicide attempts in bipolar disorder / / 21423239 rs11771429 chr7 153271877 C T 7.00E-06 Barrett's esophagus / / 24121790 rs11771429 chr7 153271877 C T 8.00E-06 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs4725502 chr7 153282382 T G 2.58E-06 Cognitive test performance / / 20125193 rs4726308 chr7 153290520 G T 4.22E-04 Myopia (pathological) / / 21095009 rs10250553 chr7 153296249 G A 1.66E-04 Myocardial Infarction / / pha002873 rs10250553 chr7 153296249 G A 4.81E-04 Heart Failure / / pha002884 rs4726318 chr7 153338113 T C 5.14E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4726318 chr7 153338113 T C 3.24E-04 Taste perception / / 22132133 rs1558301 chr7 153399165 A G 5.80E-05 Malaria / / 19465909 rs2622247 chr7 153530273 T C 6.00E-05 Response to statin therapy / / 20339536 rs2538414 chr7 153532690 A G 2.60E-05 Response to statin therapy / / 20339536 rs10251606 chr7 153532830 A C 2.70E-05 Response to statin therapy / / 20339536 rs7788310 chr7 153532834 T C 3.00E-05 Response to statin therapy / / 20339536 rs2110267 chr7 153535689 C G 5.00E-07 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs2110267 chr7 153535689 C G 6.00E-06 Attention deficit hyperactivity disorder (combined symptoms) / / 23527680 rs2192271 chr7 153549296 C T 1.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs6947495 chr7 153553064 A T 1.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs4726340 chr7 153557107 A T 4.66E-05 Coronary Artery Disease / / 17634449 rs12671878 chr7 153558949 C A 1.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs38993 chr7 153576257 G A 3.01E-06 Coronary Artery Disease / / 17634449 rs38989 chr7 153578416 A G 7.00E-06 IgG glycosylation / / 23382691 rs10487688 chr7 153607630 T C 6.71E-05 Response to citalopram treatment / / 19846067 rs6464375 chr7 153625843 C T 4.00E-07 Pancreatic cancer / / 20686608 rs10255684 chr7 153642578 T C 9.51E-06 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs10255684 chr7 153642578 T C 9.51E-06 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs10255684 chr7 153642578 T C 9.51E-06 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs11974308 chr7 153647231 G A 5.97E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2159483 chr7 153696087 C G 5.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10280963 chr7 153886568 A C 1.60E-05 Urinary metabolites / / 21572414 rs6955717 chr7 153891841 T C 6.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7811481 chr7 153893160 G A 7.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4507682 chr7 153913004 A G 2.42E-04 Type 2 diabetes / / 17463246 rs4507682 chr7 153913004 A G 3.48E-04 Multiple complex diseases / / 17554300 rs4294116 chr7 153915895 G A 1.98E-04 Type 2 diabetes / / 17463246 rs4076277 chr7 153916456 C T 3.38E-04 Multiple complex diseases / / 17554300 rs10280940 chr7 153923591 G A 3.34E-04 Multiple complex diseases / / 17554300 rs10259108 chr7 153928811 C T 1.59E-04 Multiple complex diseases / / 17554300 rs9640345 chr7 153946551 C T 1.34E-04 Obesity (extreme) / / 21935397 rs13245274 chr7 153956654 A T 1.85E-04 Obesity (extreme) / / 21935397 rs12703333 chr7 153966592 T C 6.97E-04 Obesity (extreme) / / 21935397 rs10274025 chr7 153967280 G A 1.85E-05 Alcohol and nictotine co-dependence / / 20158304 rs10274025 chr7 153967280 G A 9.06E-06 HDL cholesterol / / pha003075 rs10274585 chr7 153967819 C G 7.62E-04 Obesity (extreme) / / 21935397 rs12703334 chr7 153969807 T A 7.79E-04 Obesity (extreme) / / 21935397 rs4556012 chr7 153972548 C T 1.01E-05 HDL cholesterol / / pha003075 rs9655634 chr7 153987075 G A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1861139 chr7 154011749 A T 2.15E-04 Type 2 diabetes / / 17463246 rs7780487 chr7 154011984 G A 1.13E-04 Type 2 diabetes / / 17463246 rs10275513 chr7 154015635 A T 1.40E-04 Type 2 diabetes / / 17463246 rs4726405 chr7 154016421 G A,C,T 2.69E-05 Type 2 diabetes / / 17463246 rs10257714 chr7 154018045 C T 1.66E-05 Odorant perception / / 23910658 rs6959816 chr7 154026438 C T 8.10E-04 Multiple complex diseases / / 17554300 rs887926 chr7 154034329 G A 3.77E-05 Heart Rate / / pha003053 rs12536378 chr7 154058474 C T 1.30E-04 IgE levels in asthmatics / / 23967269 rs12536378 chr7 154058474 C T 4.15E-05 Endometrial cancer / / 24096698 rs12703349 chr7 154070594 T C 9.38E-05 Prion diseases / / 22210626 rs6977820 chr7 154072020 T C 5.00E-06 Tardive dyskinesia / / 21826085 rs17174381 chr7 154078232 C A 2.66E-04 Multiple complex diseases / / 17554300 rs7804017 chr7 154079635 C T 9.38E-05 Prion diseases / / 22210626 rs6464419 chr7 154083325 A G 0.000000811 Nicotine dependence (smoking) / / 23542338 rs1292312 chr7 154090156 T G 9.38E-05 Prion diseases / / 22210626 rs286833 chr7 154098477 G C 7.62E-04 Insulin resistance / / 21901158 rs286855 chr7 154111855 T C 1.50E-05 Urinary metabolites / / 21572414 rs13225765 chr7 154125005 T C 8.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs10952478 chr7 154126156 A T 6.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs6965651 chr7 154136555 T G 9.49E-05 Cognitive test performance / / 20125193 rs2279534 chr7 154149286 A C 9.42E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs9640200 chr7 154167651 T G 1.03E-04 Nicotine smoking / / 19268276 rs10237228 chr7 154173108 G A 2.60E-07 Urinary metabolites / / 21572414 rs10278985 chr7 154174813 C T 1.90E-06 Urinary metabolites / / 21572414 rs10278985 chr7 154174813 C T 5.03E-05 Hemoglobin / / pha003096 rs10278985 chr7 154174813 C T 2.74E-05 Hematocrit / / pha003097 rs10235672 chr7 154174868 T G 1.50E-05 Urinary metabolites / / 21572414 rs12533390 chr7 154175885 T C 3.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs12535735 chr7 154175955 A C 3.60E-06 Urinary metabolites / / 21572414 rs6959127 chr7 154177426 G A 4.66E-05 HDL cholesterol / / pha003074 rs6960076 chr7 154178188 C T 9.73E-05 Bipolar disorder / / 20451256 rs6960076 chr7 154178188 C T 9.30E-06 Urinary metabolites / / 21572414 rs12671881 chr7 154181631 T C 6.58E-05 Type 2 diabetes and other traits / / 19734900 rs744684 chr7 154196001 T G 2.32E-05 Educational attainment / / 21694764 rs10952488 chr7 154199870 G A 0.000614 Salmonella-induced pyroptosis / / 22837397 rs12703357 chr7 154200130 T C 0.000839 Salmonella-induced pyroptosis / / 22837397 rs6955044 chr7 154201314 G A 1.52E-05 Serum metabolites / / 19043545 rs11766937 chr7 154205508 A G 0.000614 Salmonella-induced pyroptosis / / 22837397 rs10260404 chr7 154210798 T C 5.84E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10260404 chr7 154210798 T C 3.00E-06 Amyotrophic lateral sclerosis / / 18057069 rs10260404 chr7 154210798 T C 5.00E-08 Amyotrophic lateral sclerosis / / 18084291 rs10260404 chr7 154210798 T C 3.00E-06 Amyotrophic lateral sclerosis / / 18987618 rs6464429 chr7 154213814 G A 6.89E-06 Serum metabolites / / 19043545 rs13246178 chr7 154217178 G T 1.50E-05 Urinary metabolites / / 21572414 rs9690048 chr7 154221889 T G 8.40E-05 Response to statin therapy / / 20339536 rs2055017 chr7 154225365 C T 0.0003857 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2055017 chr7 154225365 C T 3.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7803828 chr7 154225655 T G 5.41E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7809068 chr7 154228632 C T 9.30E-05 Response to statin therapy / / 20339536 rs11975187 chr7 154232976 A G 1.02E-05 Male-pattern baldness / / 18849994 rs902743 chr7 154248268 G A 5.80E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs902739 chr7 154249412 T C 9.77E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs902739 chr7 154249412 T C 2.65E-04 Alzheimer's disease (late onset) / / 21379329 rs2337393 chr7 154254861 C T 2.92E-05 Body Mass Index / / pha003019 rs2337393 chr7 154254861 C T 5.73E-06 Body Mass Index / / pha003020 rs2878957 chr7 154257107 A G 2.82E-05 Body Mass Index / / pha003020 rs7458507 chr7 154374448 C T 7.49E-04 Esophageal adenocarcinoma / / 24121790 rs6970199 chr7 154382776 G T 4.18E-07 Multiple complex diseases / / 17554300 rs1488927 chr7 154402669 C G 6.10E-04 Crohn's disease / / 17684544 rs6975879 chr7 154404264 A G 3.50E-08 Narcolepsy / / 19629137 rs749120 chr7 154407807 G T 1.20E-04 Coronary heart disease / / 21606135 rs7800390 chr7 154428941 T C 4.91E-04 Alzheimer's disease (late onset) / / 21379329 rs7800390 chr7 154428941 T C 4.13E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1387180 chr7 154439597 A G 7.50E-04 Parkinson's disease / / 17052657 rs1387180 chr7 154439597 A G 0.0001 High platelet reactivity in patients with type 2 diabetes during acetylsalicylic acid (ASA) treatment (defined as CEPI-CT score of <193 s) / / 23054467 rs12719711 chr7 154443865 T C 1.04E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2009483 chr7 154468373 C T 4.64E-04 Multiple complex diseases / / 17554300 rs7792530 chr7 154476131 G A 0.0000753 Polycystic ovary syndrome / / 22951595 rs7792530 chr7 154476131 G A 7.53E-05 Intracranial aneurysm / / 22961961 rs3823518 chr7 154476409 T C 8.87E-06 Brain structure / / 22504417 rs3807230 chr7 154476554 C T 3.05E-05 Brain structure / / 22504417 rs3807235 chr7 154477378 A C 9.25E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs10259988 chr7 154508225 G A 5.87E-05 Celiac disease / / 23936387 rs4960602 chr7 154508288 G A 6.37E-05 Celiac disease / / 23936387 rs12666280 chr7 154509324 T C 2.00E-06 QT interval / / 23534349 rs10081323 chr7 154581951 C T 2.04E-05 Information processing speed / / 21130836 rs71534169 chr7 154592866 T G 4.00E-06 Post-traumatic stress disorder / / 24677629 rs2316533 chr7 154636349 G A 6.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6597432 chr7 154643569 C A 4.41E-04 Alzheimer's disease (late onset) / / 21379329 rs4960560 chr7 154646763 A C 1.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3823527 chr7 154648330 A G 4.29E-05 Type 2 diabetes / / 17463246 rs6968203 chr7 154652791 C G 2.15E-04 Multiple complex diseases / / 17554300 rs10242745 chr7 154653720 T C 3.28E-04 Substance dependence / / 21818250 rs877471 chr7 154654195 C T 1.82E-04 Multiple complex diseases / / 17554300 rs3778738 chr7 154656966 A G 8.42E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6597434 chr7 154665934 G A 3.26E-05 Serum metabolites / / 19043545 rs6597434 chr7 154665934 G A 2.10E-05 Urinary metabolites / / 21572414 rs3817518 chr7 154672809 G A 5.11E-04 Bipolar disorder,schizoaffective / / 19567891 rs12534701 chr7 154680910 G T 2.00E-06 Colorectal cancer (diet interaction) / / 24743840 rs882467 chr7 154701338 G A 5.25E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3800580 chr7 154760889 A C 2.97E-04 Lymphocyte counts PAXIP1 intron 22286170 rs6597442 chr7 154792046 C A 2.00E-04 Personality dimensions PAXIP1 intron 23903073 rs11243330 chr7 154803512 G T 7.86E-04 Smoking cessation / / 24665060 rs2698497 chr7 154846527 C T 2.70E-04 Multiple complex diseases / / 17554300 rs1440455 chr7 154855689 A T 6.99E-04 Type 2 diabetes / / 17463246 rs1561600 chr7 154855829 C A 1.84E-04 Type 2 diabetes / / 17463246 rs4960677 chr7 154856968 C T 1.92E-04 Type 2 diabetes / / 17463246 rs6320 chr7 154862621 T A 3.40E-06 Urinary metabolites HTR5A cds-synon 21572414 rs2581841 chr7 154863839 C T 2.27E-04 Type 2 diabetes HTR5A intron 17463246 rs1079515 chr7 154866259 T A 8.21E-05 Type 2 diabetes HTR5A intron 17463246 rs1657268 chr7 154874614 C T 5.68E-05 Type 2 diabetes HTR5A intron 17463246 rs1730213 chr7 154879939 T A,C,G 5.13E-05 Type 2 diabetes / / 17463246 rs1657273 chr7 154880169 G T 5.78E-05 Monocyte counts / / pha003089 rs1657276 chr7 154882800 C A 8.16E-05 Type 2 diabetes / / 17463246 rs1436818 chr7 154885237 A G 7.81E-05 Type 2 diabetes / / 17463246 rs1657283 chr7 154887403 C G 3.24E-04 Multiple complex diseases / / 17554300 rs1657294 chr7 154889545 T G 8.16E-05 Type 2 diabetes / / 17463246 rs893109 chr7 154892874 G A 1.68E-05 Monocyte counts / / pha003089 rs1730140 chr7 154894331 C T 1.81E-04 Type 2 diabetes / / 17463246 rs1730142 chr7 154895661 G A 5.18E-04 Type 2 diabetes / / 17463246 rs1618158 chr7 154897972 T C 5.63E-04 Type 2 diabetes / / 17463246 rs1619015 chr7 154898078 T C 1.20E-04 Type 2 diabetes / / 17463246 rs1620008 chr7 154898237 A C 1.33E-04 Multiple complex diseases / / 17554300 rs2951007 chr7 154899391 C T 2.15E-04 Type 2 diabetes / / 17463246 rs2969540 chr7 154900857 C T 4.85E-04 Alcohol dependence / / 20201924 rs2969540 chr7 154900857 C T 2.00E-06 Bladder cancer (smoking interaction) / / 24662972 rs1730146 chr7 154901217 T C 2.12E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4355727 chr7 154905319 G A 3.53E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs4960687 chr7 154934171 G C 1.42E-06 Non-small cell lung cancer / / 21866343 rs4146256 chr7 154934501 C A 6.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs4307294 chr7 154942609 C T 3.55E-07 Elbow pain / / pha003008 rs1730202 chr7 154946061 G T 7.27E-05 Formal thought disorder in schizophrenia / / 22648509 rs4960691 chr7 154946421 G A 3.27E-07 Elbow pain / / pha003008 rs7800026 chr7 154947071 A G 3.27E-07 Elbow pain / / pha003008 rs10254908 chr7 154963263 T C 4.01E-04 Multiple complex diseases / / 17554300 rs10246702 chr7 154966534 G A 2.48E-04 Multiple complex diseases / / 17554300 rs10246702 chr7 154966534 G A 1.60E-05 Parkinson's disease (familial) / / 18985386 rs10246702 chr7 154966534 G A 7.38E-04 Coronary heart disease / / 21606135 rs10246702 chr7 154966534 G A 9.05E-06 Formal thought disorder in schizophrenia / / 22648509 rs10267084 chr7 154966695 A G 8.77E-04 HIV-1 viral setpoint / / 17641165 rs10263087 chr7 154970469 G C 3.93E-04 Multiple complex diseases / / 17554300 rs10263087 chr7 154970469 G C 3.50E-05 Parkinson's disease (familial) / / 18985386 rs10263087 chr7 154970469 G C 5.96E-04 Coronary heart disease / / 21606135 rs10263087 chr7 154970469 G C 7.00E-06 Formal thought disorder in schizophrenia / / 22648509 rs6597472 chr7 154978874 G A 6.61E-04 Type 2 diabetes / / 17463246 rs1561176 chr7 155008713 T G 7.00E-06 Personality dimensions / / 23903073 rs12719705 chr7 155052274 A G 8.35E-05 Bipolar disorder and schizophrenia / / 20889312 rs4506162 chr7 155057997 A G 1.27E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs1128636 chr7 155088371 T C 7.70E-06 Urinary metabolites / / 21572414 rs9770059 chr7 155099637 T G 1.20E-05 Urinary metabolites INSIG1 intron 21572414 rs1421318 chr7 155169830 G T 9.59E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4398781 chr7 155187426 T C 8.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs4716915 chr7 155206518 A G 2.30E-05 Urinary metabolites / / 21572414 rs1861969 chr7 155213071 C T 9.64E-06 Cytomegalovirus antibody response / / 21993531 rs10949778 chr7 155213122 A G 8.37E-05 Personality dimensions / / 18957941 rs749539 chr7 155218440 G C 0.0000127 Sasang constitution (Soyang) / / 22394158 rs4716569 chr7 155220093 T C 2.03E-05 Cytomegalovirus antibody response / / 21993531 rs10281279 chr7 155220256 C T 8.25E-05 Cytomegalovirus antibody response / / 21993531 rs4716950 chr7 155220911 A G 2.35E-05 Cytomegalovirus antibody response / / 21993531 rs6459971 chr7 155220964 A C 3.23E-05 Cytomegalovirus antibody response / / 21993531 rs7779804 chr7 155221416 C T 3.65E-05 Cytomegalovirus antibody response / / 21993531 rs1477213 chr7 155222338 G A 3.62E-05 Cytomegalovirus antibody response / / 21993531 rs10271403 chr7 155240753 T G 4.39E-05 Cholesterol / / pha003073 rs10271403 chr7 155240753 T G 7.16E-05 Cholesterol / / pha003078 rs4717002 chr7 155241247 C T 6.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs12538214 chr7 155276541 G A 7.04E-04 Obesity (extreme) / / 21935397 rs10224330 chr7 155277339 C T 5.37E-04 Obesity (extreme) / / 21935397 rs7803510 chr7 155278216 G C 5.18E-04 Obesity (extreme) / / 21935397 rs1861960 chr7 155285135 T G 6.00E-06 Migraine / / 23793025 rs6971850 chr7 155304172 A C 1.15E-05 Alcohol and nictotine co-dependence CNPY1 intron 20158304 rs6459707 chr7 155305104 C T 8.49E-06 Alcohol and nictotine co-dependence CNPY1 intron 20158304 rs2098797 chr7 155326428 G C 6.47E-04 Aortic root size CNPY1 intron 21223598 rs10949646 chr7 155361928 C A,G,T 5.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10949646 chr7 155361928 C A,G,T 5.15E-05 Blood Pressure / / pha003050 rs6459883 chr7 155487071 C G 2.20E-05 Urinary metabolites RBM33 intron 21572414 rs2007922 chr7 155569983 G A 2.00E-04 Information processing speed RBM33 UTR-3 21130836 rs1233560 chr7 155593438 G A 4.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1233571 chr7 155594294 T C 9.64E-05 Soluble levels of adhesion molecules / / pha003072 rs872723 chr7 155605744 C T 2.00E-04 Cognitive impairment induced by topiramate SHH nearGene-5 22091778 rs172310 chr7 155615627 A C 4.13E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs172310 chr7 155615627 A C 2.98E-05 Pancreatic cancer / / pha002874 rs172310 chr7 155615627 A C 3.95E-06 Pancreatic cancer / / pha002889 rs167020 chr7 155619733 A G 7.52E-06 Pancreatic cancer / / pha002874 rs167020 chr7 155619733 A G 2.87E-06 Pancreatic cancer / / pha002889 rs1731836 chr7 155650247 T G 1.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1731839 chr7 155651102 C T 1.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1731847 chr7 155655522 C T 6.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1106697 chr7 155672944 G A 7.00E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs7786445 chr7 155677943 T C 4.00E-05 Asperger disorder / / 21182207 rs6950784 chr7 155695674 T G 2.40E-06 Urinary metabolites / / 21572414 rs6459959 chr7 155698151 C G 1.36E-06 Postoperative ventricular dysfunction / / 21980348 rs6459961 chr7 155698255 C A 2.49E-06 Postoperative ventricular dysfunction / / 21980348 rs4716929 chr7 155718114 A T 3.68E-04 Multiple complex diseases / / 17554300 rs2885941 chr7 155722851 A G 2.44E-04 Fibrinogen / / 17255346 rs4716932 chr7 155723534 G A 3.24E-04 Fibrinogen / / 17255346 rs4716943 chr7 155734614 A G 5.79E-04 Multiple complex diseases / / 17554300 rs11767234 chr7 155753928 T A 5.18E-04 Smoking cessation / / 24665060 rs2007015 chr7 155755826 A G 8.40E-06 Fibrinogen / / 17255346 rs112857065 chr7 155762157 G GTGCC 8.00E-08 Platelet aggregation / / 20526338 rs112857065 chr7 155762157 G GTGCC 9.61E-06 Hypertension / / pha003041 rs112857065 chr7 155762157 G GTGCC 1.16E-05 Heart Rate / / pha003051 rs6943029 chr7 155762157 G A 8.00E-08 Platelet aggregation / / 20526338 rs6943029 chr7 155762157 G A 9.61E-06 Hypertension / / pha003041 rs6943029 chr7 155762157 G A 1.16E-05 Heart Rate / / pha003051 rs12534938 chr7 155765548 C T 1.12E-05 Hypertension / / pha003041 rs12534938 chr7 155765548 C T 1.36E-05 Heart Rate / / pha003051 rs10267337 chr7 155768749 A C 8.00E-06 Obesity-related traits / / 23251661 rs10434949 chr7 155771394 C T 2.27E-05 Hypertension / / pha003041 rs10434949 chr7 155771394 C T 2.51E-05 Triglycerides / / pha003080 rs6962792 chr7 155811043 A G 2.32E-05 Glycosylated haemoglobin levels / / 17255346 rs999920 chr7 155834061 G A 5.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10226930 chr7 155837295 T C 8.00E-07 Corneal astigmatism / / 23322567 rs11531437 chr7 155866361 G T 3.30E-05 Type 2 diabetes / / 17463246 rs10251705 chr7 155866470 C T 3.64E-05 Type 2 diabetes / / 17463246 rs10243628 chr7 155866994 G A 3.97E-05 Type 2 diabetes / / 17463246 rs760199 chr7 155875167 G A 3.86E-05 Type 2 diabetes / / 17463246 rs4716985 chr7 155884468 A G 1.71E-04 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs4716985 chr7 155884468 A G 2.05E-05 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs4716985 chr7 155884468 A G 4.38E-05 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs10252939 chr7 155894687 T C 2.21E-04 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs10252939 chr7 155894687 T C 7.02E-05 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs10252939 chr7 155894687 T C 7.21E-05 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs10464142 chr7 155915525 G A 9.97E-04 Insulin resistance / / 21901158 rs11770182 chr7 155935568 C A 6.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11760649 chr7 155937917 A G 1.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6459997 chr7 155939883 T C 8.18E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1735004 chr7 155941878 C G 7.99E-04 Multiple complex diseases / / 17554300 rs7793353 chr7 155946592 A C 8.08E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1181917 chr7 155952846 G A 4.95E-05 HIV-1 viral setpoint / / 22174851 rs1181908 chr7 155973540 A C 3.67E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10243418 chr7 155989669 C T 4.19E-04 Smoking cessation / / 24665060 rs1005229 chr7 156002990 C T 6.79E-05 Lymphocyte counts / / pha003094 rs4717017 chr7 156010297 G A 1.04E-07 Facial morphology / / 22341974 rs4717018 chr7 156010499 C T 6.02E-08 Facial morphology / / 22341974 rs4717019 chr7 156011060 T G 5.96E-08 Facial morphology / / 22341974 rs4716593 chr7 156011415 G A 2.65E-07 Facial morphology / / 22341974 rs4717020 chr7 156011465 G A 2.68E-07 Facial morphology / / 22341974 rs4717021 chr7 156011879 C T 2.76E-07 Facial morphology / / 22341974 rs4717023 chr7 156014722 T A 4.06E-07 Facial morphology / / 22341974 rs1922086 chr7 156016226 T C 5.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9638164 chr7 156025003 A C 5.39E-05 Lymphocyte counts / / pha003094 rs9638164 chr7 156025003 A C 3.57E-05 Neutrophil count / / pha003095 rs1175446 chr7 156025396 T C 2.86E-04 Tourette syndrome / / 22889924 rs1175446 chr7 156025396 T C 3.06E-05 Lymphocyte counts / / pha003094 rs1175446 chr7 156025396 T C 2.64E-05 Neutrophil count / / pha003095 rs1175449 chr7 156029667 T C 2.79E-05 Coronary heart disease / / 21971053 rs4446619 chr7 156042243 G A 7.63E-04 Alcohol dependence / / 24277619 rs12698388 chr7 156046295 G A 3.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10949808 chr7 156048649 T G 1.92E-05 Bipolar disorder / / 19488044 rs10949808 chr7 156048649 T G 1.00E-07 Bipolar disorder and schizophrenia / / 20889312 rs10949808 chr7 156048649 T G 1.72E-05 Bipolar Disorder / / pha002858 rs12386611 chr7 156056343 G A 1.76E-05 Bipolar disorder and schizophrenia / / 20889312 rs9638080 chr7 156056480 A G 6.24E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6965845 chr7 156057072 G A 5.44E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10216266 chr7 156062719 G A 1.57E-05 Bipolar disorder and schizophrenia / / 20889312 rs10261536 chr7 156073244 A G 7.17E-04 Type 2 diabetes / / 17463246 rs4645464 chr7 156092540 T C 1.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4435995 chr7 156102061 C T 4.70E-04 Coronary Artery Disease / / 17634449 rs10949810 chr7 156104544 C T 3.85E-05 Amyotrophic lateral sclerosis / / 19193627 rs12698422 chr7 156151184 C T 6.71E-04 Multiple complex diseases / / 17554300 rs12698431 chr7 156152606 T C 1.89E-04 Multiple complex diseases / / 17554300 rs11769797 chr7 156187901 T C 5.80E-06 Urinary metabolites / / 21572414 rs6975141 chr7 156194064 G C 2.50E-05 Urinary metabolites / / 21572414 rs1880342 chr7 156208176 G A 8.00E-08 Urinary metabolites / / 21572414 rs6946401 chr7 156228841 T C 1.00E-04 Information processing speed / / 21130836 rs6961453 chr7 156231105 T C 2.37E-05 Coronary heart disease / / pha003030 rs2365281 chr7 156236883 G A 1.58E-04 Type 2 diabetes LOC285889 intron 17463246 rs2365281 chr7 156236883 G A 2.96E-04 Rheumatoid arthritis LOC285889 intron 21452313 rs7795670 chr7 156254799 T C 4.33E-04 Parkinson's disease / / 17052657 rs6459678 chr7 156255115 C T 5.92E-05 Bipolar disorder / / 20451256 rs6967289 chr7 156255343 T C 2.78E-04 Multiple complex diseases / / 17554300 rs6967289 chr7 156255343 T C 6.75E-05 Bipolar disorder / / 20451256 rs2140630 chr7 156265286 A G 6.86E-04 Multiple complex diseases / / 17554300 rs11975618 chr7 156277976 T C 8.14E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LOC100506380 intron 20031582 rs12536996 chr7 156347769 T G 2.78E-04 Hearing function LOC100506380 intron 17255346 rs17837682 chr7 156352856 C G 8.24E-06 Asthma (childhood onset) LOC100506380 intron 23829686 rs6960855 chr7 156374358 C T 8.84E-05 Serum metabolites LOC100506380 intron 19043545 rs878715 chr7 156383237 T C 4.13E-04 Body mass index LOC100506380 intron 17255346 rs878716 chr7 156383348 T A 4.62E-04 Body mass index LOC100506380 intron 17255346 rs1547584 chr7 156395030 A G 3.39E-04 Body mass index LOC100506380 intron 17255346 rs1881006 chr7 156399064 G A 3.86E-04 Myocardial Infarction / / pha002873 rs737982 chr7 156407224 A G 2.38E-04 HIV-1 viral setpoint / / 17641165 rs4716438 chr7 156442203 T C 4.02E-08 Lymphocyte counts RNF32 intron 22286170 rs2108794 chr7 156447708 G A 1.41E-04 Smoking quantity RNF32 intron 24665060 rs3823617 chr7 156468559 T C 3.62E-04 Acute lung injury RNF32 splice-5 22295056 rs1014236 chr7 156474169 T C 6.10E-04 Taste perception LMBR1 UTR-3 22132133 rs10242938 chr7 156479117 A G 1.72E-04 Acute lung injury LMBR1 intron 22295056 rs10243052 chr7 156479158 A G 2.32E-04 Acute lung injury LMBR1 intron 22295056 rs12671098 chr7 156497533 C T 2.80E-05 Urinary metabolites LMBR1 intron 21572414 rs2108796 chr7 156500801 A C 5.74E-04 Alzheimer's disease LMBR1 intron 22005930 rs4716655 chr7 156507281 T C 6.16E-04 Type 2 diabetes LMBR1 intron 17463246 rs7785147 chr7 156510208 G A 2.66E-04 Acute lung injury LMBR1 intron 22295056 rs11974194 chr7 156513716 A C 2.20E-05 Parkinson's disease (age of onset) LMBR1 intron 19772629 rs7779517 chr7 156514088 C A 4.06E-05 Acute lung injury LMBR1 intron 22295056 rs1861094 chr7 156518809 T C 1.97E-04 Alzheimer's disease LMBR1 intron 22005930 rs10265924 chr7 156521894 G A 5.40E-05 Acute lung injury LMBR1 intron 22295056 rs7807076 chr7 156524851 G T 4.06E-05 Acute lung injury LMBR1 intron 22295056 rs10488062 chr7 156537276 C T 8.79E-05 Acute lung injury LMBR1 intron 22295056 rs6956930 chr7 156537630 A G 1.71E-04 Acute lung injury LMBR1 intron 22295056 rs10239199 chr7 156538670 A T 8.16E-04 Acute lung injury LMBR1 intron 22295056 rs6972360 chr7 156541851 C T 1.45E-04 Obesity (extreme) LMBR1 intron 21935397 rs6954725 chr7 156542221 A G 7.78E-04 Response to taxane treatment (placlitaxel) LMBR1 intron 23006423 rs10488060 chr7 156548645 T C 9.88E-04 Response to taxane treatment (placlitaxel) LMBR1 intron 23006423 rs6957768 chr7 156554830 T C 1.86E-04 Obesity (extreme) LMBR1 missense 21935397 rs17837692 chr7 156557743 T C 2.52E-04 Obesity (extreme) LMBR1 intron 21935397 rs11765182 chr7 156564273 C T 2.01E-04 Acute lung injury LMBR1 intron 22295056 rs11972575 chr7 156568317 G T 1.55E-04 Acute lung injury LMBR1 intron 22295056 rs10274927 chr7 156571699 C T 9.39E-04 Acute lung injury LMBR1 intron 22295056 rs17837694 chr7 156572976 A G 1.99E-04 Obesity (extreme) LMBR1 intron 21935397 rs11981344 chr7 156575665 C T 1.58E-04 Acute lung injury LMBR1 intron 22295056 rs10243302 chr7 156576682 G T 1.86E-04 Obesity (extreme) LMBR1 intron 21935397 rs2270264 chr7 156577314 G A 3.84E-05 Cholesterol LMBR1 intron pha003083 rs10250838 chr7 156578131 G A 1.86E-04 Obesity (extreme) LMBR1 intron 21935397 rs10235980 chr7 156582910 A C 1.88E-04 Obesity (extreme) LMBR1 intron 21935397 rs6949624 chr7 156585184 C G 6.84E-04 Alzheimer's disease LMBR1 intron 22005930 rs6945929 chr7 156593270 A G 8.74E-05 Schizophrenia LMBR1 intron 24253340 rs10226504 chr7 156600414 A G 2.59E-04 Obesity (extreme) LMBR1 intron 21935397 rs10244145 chr7 156601463 G A 1.92E-04 Obesity (extreme) LMBR1 intron 21935397 rs9654686 chr7 156606632 G A 4.92E-04 Obesity (extreme) LMBR1 intron 21935397 rs9654687 chr7 156606712 T C 1.92E-04 Obesity (extreme) LMBR1 intron 21935397 rs2286993 chr7 156611180 T C 1.92E-04 Obesity (extreme) LMBR1 intron 21935397 rs10265935 chr7 156616952 G C 2.53E-04 Obesity (extreme) LMBR1 intron 21935397 rs10253387 chr7 156626404 C T 2.45E-04 Obesity (extreme) LMBR1 intron 21935397 rs6946878 chr7 156627482 G A 1.80E-04 Obesity (extreme) LMBR1 intron 21935397 rs2886451 chr7 156627906 T A 1.80E-04 Obesity (extreme) LMBR1 intron 21935397 rs9886041 chr7 156629235 G A 1.78E-04 Obesity (extreme) LMBR1 intron 21935397 rs10479647 chr7 156638106 A C 1.17E-04 Obesity (extreme) LMBR1 intron 21935397 rs10479648 chr7 156638317 T C 1.58E-04 Obesity (extreme) LMBR1 intron 21935397 rs11765003 chr7 156679832 T C 6.99E-05 Schizophrenia LMBR1 intron 24253340 rs11760288 chr7 156701918 G A 2.06E-04 Celiac disease / / 23936387 rs2969123 chr7 156708467 T C 4.90E-05 Myasthenia gravis / / 23055271 rs10275055 chr7 156712603 C T 5.12E-04 Obesity (extreme) / / 21935397 rs11980132 chr7 156722649 G A 9.32E-05 Schizophrenia / / 24253340 rs11980132 chr7 156722649 G A 7.88E-05 Elbow pain / / pha003008 rs7791257 chr7 156722842 C T 2.70E-05 Myasthenia gravis / / 23055271 rs10256184 chr7 156757513 C A 3.96E-04 Lymphocyte counts NOM1 intron 22286170 rs2024265 chr7 156757619 T C 7.00E-04 Type 2 diabetes and 6 quantitative traits NOM1 intron 17848626 rs2024265 chr7 156757619 T C 6.48E-05 Cognitive impairment induced by topiramate NOM1 intron 22091778 rs12919 chr7 156762248 G A 9.00E-04 Stroke NOM1 missense pha002887 rs7777527 chr7 156763847 A G 2.27E-04 Obesity (extreme) NOM1 UTR-3 21935397 rs12671438 chr7 156781605 G A 3.71E-04 Obesity (extreme) / / 21935397 rs10262191 chr7 156804510 C A 4.79E-04 Type 2 diabetes LOC645249 intron 17463246 rs4716447 chr7 156815971 A G 8.16E-05 Coronary heart disease / / pha003031 rs6966038 chr7 156880398 A G 4.00E-07 Response to citalopram treatment / / 19846067 rs6966038 chr7 156880398 A G 5.00E-07 Response to citalopram treatment / / 19846067 rs6966038 chr7 156880398 A G 5.24E-07 Biliary atresia / / 20460270 rs6966038 chr7 156880398 A G 4.65E-07 Vaspin levels / / 22907691 rs6459728 chr7 156915086 G A 2.43E-05 Panic disorder / / 19165232 rs7807856 chr7 156934498 T C 2.02E-04 Type 2 diabetes UBE3C intron 22158537 rs6967012 chr7 156937492 G T 2.16E-04 Multiple complex diseases UBE3C intron 17554300 rs6967012 chr7 156937492 G T 9.60E-06 Urinary metabolites UBE3C intron 21572414 rs10251112 chr7 156963524 A G 2.80E-04 Lung function (forced expiratory volume in 1 second) UBE3C intron 17255346 rs10251112 chr7 156963524 A G 5.79E-05 Type 2 diabetes UBE3C intron 22158537 rs3802120 chr7 156977794 C T 6.18E-05 Post-operative nausea and vomiting UBE3C intron 21694509 rs17718923 chr7 156983426 T C 8.04E-05 Sudden cardiac arrest UBE3C intron 21658281 rs7786095 chr7 156983847 A G 7.77E-04 Multiple complex diseases UBE3C intron 17554300 rs7786095 chr7 156983847 A G 9.90E-06 Urinary metabolites UBE3C intron 21572414 rs6969244 chr7 157004012 A G 2.18E-04 Type 2 diabetes UBE3C intron 22158537 rs10228145 chr7 157007337 A G 4.07E-05 Type 2 diabetes UBE3C intron 22158537 rs17837729 chr7 157007665 G A 2.26E-04 Multiple complex diseases UBE3C intron 17554300 rs2051877 chr7 157008813 A T 1.87E-04 Type 2 diabetes UBE3C intron 22158537 rs2051876 chr7 157009037 G A 3.72E-04 Lung function (forced expiratory volume in 1 second) UBE3C intron 17255346 rs2051876 chr7 157009037 G A 2.29E-04 Type 2 diabetes UBE3C intron 22158537 rs2023974 chr7 157012195 A G 8.98E-04 Multiple complex diseases UBE3C intron 17554300 rs1182363 chr7 157019151 A G 2.08E-04 Type 2 diabetes UBE3C intron 22158537 rs1182360 chr7 157020550 G C 3.72E-04 Lung function (forced expiratory volume in 1 second) UBE3C intron 17255346 rs1182360 chr7 157020550 G C 2.75E-05 Type 2 diabetes UBE3C intron 22158537 rs1636608 chr7 157020640 C A 2.26E-04 Lung function (forced expiratory volume in 1 second) UBE3C intron 17255346 rs6459743 chr7 157027108 G A 3.35E-04 Type 2 diabetes UBE3C intron 22158537 rs6946713 chr7 157028580 C G 5.60E-04 Multiple complex diseases UBE3C intron 17554300 rs6946713 chr7 157028580 C G 9.90E-06 Urinary metabolites UBE3C intron 21572414 rs6949802 chr7 157028880 G A 7.95E-04 Type 2 diabetes UBE3C intron 22158537 rs6960676 chr7 157030917 G A 9.45E-04 Type 2 diabetes UBE3C intron 22158537 rs7807 chr7 157061642 C A 6.00E-05 Post-operative nausea and vomiting UBE3C UTR-3 21694509 rs2527866 chr7 157090296 C A 3.00E-06 Quantitative traits / / 19197348 rs6459750 chr7 157112363 T C 3.97E-04 Multiple complex diseases / / 17554300 rs7798373 chr7 157258659 T C 1.26E-04 Coronary heart disease / / 21606135 rs4716745 chr7 157261275 C T 6.06E-04 Coronary heart disease / / 21606135 rs7785035 chr7 157263532 C T 5.62E-04 Coronary heart disease / / 21606135 rs741000 chr7 157277828 C T 4.21E-04 Multiple complex diseases / / 17554300 rs741000 chr7 157277828 C T 7.80E-04 Alcohol dependence / / 21314694 rs1076435 chr7 157278764 T C 6.06E-05 HIV-1 control / / 20041166 rs758927 chr7 157289982 T G 7.21E-05 Fibrinogen / / pha003068 rs10227331 chr7 157294938 T A 4.00E-06 Inattentive symptoms LOC100506534 intron 18821565 rs10237006 chr7 157298250 A G 8.75E-05 Monocyte chemoattractant protein-1 / / pha003071 rs10949653 chr7 157312607 T A,C,G 4.42E-05 Relative hand skill / / 24068947 rs10235058 chr7 157319423 G C 9.04E-05 Relative hand skill / / 24068947 rs6944484 chr7 157320143 A C 2.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs221238 chr7 157322882 C T 2.63E-04 Suicide attempts in bipolar disorder / / 21041247 rs221242 chr7 157324591 A C 2.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs221250 chr7 157330266 G A 2.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs221277 chr7 157346535 G A 6.99E-05 Response to radiotherapy in cancer (late toxicity) PTPRN2 intron 24785509 rs221281 chr7 157350699 A G 6.22E-04 Smoking initiation PTPRN2 intron 24665060 rs221293 chr7 157359289 A C 6.87E-04 Smoking initiation PTPRN2 intron 24665060 rs221298 chr7 157364630 T C 6.15E-04 Smoking initiation PTPRN2 intron 24665060 rs221300 chr7 157367523 T C 7.61E-04 Smoking initiation PTPRN2 intron 24665060 rs7791552 chr7 157368550 A G 5.96E-04 Smoking initiation PTPRN2 intron 24665060 rs221302 chr7 157369885 G A 4.25E-04 Smoking initiation PTPRN2 intron 24665060 rs11769121 chr7 157385078 A T 8.10E-05 Pericardial fat PTPRN2 intron 22589742 rs10274279 chr7 157387441 T C 4.00E-11 Myopia (pathological) PTPRN2 intron 23049088 rs1263572 chr7 157429866 C A 8.60E-04 Schizophrenia PTPRN2 intron 19197363 rs1638021 chr7 157438037 T C 1.10E-13 Progranulin levels PTPRN2 intron 21087763 rs1638021 chr7 157438037 T C 1.10E-13 Myocardial infarction PTPRN2 intron 21211798 rs12333884 chr7 157452854 C T 6.22E-05 Insulin resistance PTPRN2 intron 21901158 rs2366645 chr7 157458015 T A,C,G 4.00E-04 Insulin resistance PTPRN2 intron 21901158 rs11764539 chr7 157458872 T C 8.70E-04 Nicotine smoking PTPRN2 intron 19268276 rs17837793 chr7 157464422 G A 2.87E-04 Multiple complex diseases PTPRN2 intron 17554300 rs17837793 chr7 157464422 G A 5.27E-04 Suicide attempts in bipolar disorder PTPRN2 intron 21423239 rs1263550 chr7 157470412 C T 5.33E-05 Amyotrophic lateral sclerosis PTPRN2 intron 19193627 rs1263556 chr7 157476460 A G 3.70E-05 Amyotrophic lateral sclerosis PTPRN2 intron 19193627 rs6459804 chr7 157510195 C T 8.00E-06 Bipolar disorder and schizophrenia PTPRN2 intron 21057379 rs2907684 chr7 157539417 C T 4.84E-04 Type 2 diabetes PTPRN2 intron 22238593 rs1638755 chr7 157552812 C T 1.29E-04 Nicotine smoking PTPRN2 intron 19268276 rs2117522 chr7 157662955 T C 3.50E-04 Multiple complex diseases PTPRN2 intron 17554300 rs12540633 chr7 157694992 T C 1.93E-04 Hearing function PTPRN2 intron 17255346 rs6944306 chr7 157700614 C T 7.59E-04 Epilepsy PTPRN2 intron 22116939 rs10253045 chr7 157713090 T C 5.00E-04 Type 2 diabetes PTPRN2 intron 17463246 rs6955644 chr7 157713244 G A 7.74E-04 Type 2 diabetes PTPRN2 intron 17463246 rs1865457 chr7 157727292 A C 4.07E-04 Type 2 diabetes PTPRN2 intron 17463246 rs10231307 chr7 157727839 T C 1.34E-04 Multiple complex diseases PTPRN2 intron 17554300 rs920023 chr7 157734314 A G 7.91E-04 Amyotrophic Lateral Sclerosis PTPRN2 intron 17827064 rs920023 chr7 157734314 A G 8.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTPRN2 intron 20877124 rs920023 chr7 157734314 A G 4.02E-04 Epilepsy PTPRN2 intron 22116939 rs12670619 chr7 157735966 G T 5.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTPRN2 intron 20877124 rs12670619 chr7 157735966 G T 6.76E-05 Epilepsy PTPRN2 intron 22116939 rs10249811 chr7 157736936 T G 2.32E-04 Epilepsy PTPRN2 intron 22116939 rs2241749 chr7 157743465 G A 0.000067 Nicotine dependence (smoking) PTPRN2 intron 22377092 rs2164217 chr7 157743779 C T 3.56E-04 Epilepsy PTPRN2 intron 22116939 rs4019375 chr7 157745547 G C 2.21E-04 Smoking quantity PTPRN2 intron 24665060 rs4716828 chr7 157747326 G A 7.40E-04 Smoking quantity PTPRN2 intron 24665060 rs11773068 chr7 157750152 A G 4.95E-05 Bipolar disorder PTPRN2 intron 21771265 rs2164220 chr7 157755225 C T 0.0000504 Nicotine dependence (smoking) PTPRN2 intron 22377092 rs4716857 chr7 157765602 G A 0.0000723 Nonsyndromic striae distensae (stretch marks) PTPRN2 intron 23633020 rs11984274 chr7 157791029 A G 5.57E-05 Lipoproteins PTPRN2 intron pha003079 rs11772608 chr7 157819325 T C 7.23E-04 Alcohol dependence PTPRN2 intron 24277619 rs7783724 chr7 157837357 G A 1.59E-04 Smoking initiation PTPRN2 intron 24665060 rs10256092 chr7 157844387 T G 3.91E-04 Smoking initiation PTPRN2 intron 24665060 rs10232468 chr7 157868374 T C 3.63E-05 Bipolar disorder and schizophrenia PTPRN2 intron 20889312 rs7780849 chr7 157880135 A G 9.00E-06 Asthma PTPRN2 intron 21790008 rs12698138 chr7 157885603 G A 7.27E-05 Longevity PTPRN2 intron 20304771 rs2335847 chr7 157904447 A G 4.64E-04 Type 2 diabetes PTPRN2 intron 17463246 rs6943534 chr7 157927166 A T 2.20E-05 Urinary metabolites PTPRN2 intron 21572414 rs6960916 chr7 157927193 G A 2.10E-05 Urinary metabolites PTPRN2 intron 21572414 rs6966663 chr7 157928460 G C 1.90E-05 Urinary metabolites PTPRN2 intron 21572414 rs4475429 chr7 157928710 C T 1.20E-05 Urinary metabolites PTPRN2 intron 21572414 rs1130499 chr7 157931144 C T 0.0000091 Prostate cancer PTPRN2 missense 23555315 rs4243839 chr7 157958591 C T 1.85E-04 Body mass index PTPRN2 intron 17255346 rs1130495 chr7 157959911 A G 3.64E-04 Age-related macular degeneration PTPRN2 missense 22125219 rs4909112 chr7 157962887 T C 1.85E-04 Age-related macular degeneration PTPRN2 intron 22125219 rs1806612 chr7 157986458 T C 8.25E-05 Coronary heart disease PTPRN2 intron 21606135 rs10235911 chr7 158038989 C T 5.91E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) PTPRN2 intron 23648065 rs10949703 chr7 158043004 C T 5.19E-05 HDL cholesterol PTPRN2 intron pha003075 rs4909057 chr7 158044535 T C 5.19E-05 HDL cholesterol PTPRN2 intron pha003075 rs11973244 chr7 158075769 A G 2.10E-04 Multiple complex diseases PTPRN2 intron 17554300 rs11973244 chr7 158075769 A G 7.82E-05 Serum albumin level PTPRN2 intron pha003084 rs4909062 chr7 158103844 G A 0.00040306 Hypertension (early onset hypertension) PTPRN2 intron 22479346 rs10949714 chr7 158110434 T C 7.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTPRN2 intron 20877124 rs71547529 chr7 158135469 G T 3.69E-06 Response to amphetamines PTPRN2 intron 22952603 rs62493649 chr7 158135556 C G 2.81E-06 Response to amphetamines PTPRN2 intron 22952603 rs62493650 chr7 158135570 G T 2.74E-06 Response to amphetamines PTPRN2 intron 22952603 rs62493651 chr7 158135592 T C 8.46E-06 Response to amphetamines PTPRN2 intron 22952603 rs11766348 chr7 158135857 G A 6.61E-06 Response to amphetamines PTPRN2 intron 22952603 rs11764065 chr7 158135974 T C 4.62E-06 Response to amphetamines PTPRN2 intron 22952603 rs4909189 chr7 158136986 A T 3.00E-06 Response to amphetamines PTPRN2 intron 22952603 rs4521711 chr7 158139851 A C 5.27E-04 Type 2 diabetes PTPRN2 intron 17463246 rs6962413 chr7 158177006 A G 7.84E-04 Multiple complex diseases PTPRN2 intron 17554300 rs896763 chr7 158182388 G A 7.86E-04 Multiple complex diseases PTPRN2 intron 17554300 rs7786808 chr7 158223106 A G 8.00E-06 Obesity-related traits PTPRN2 intron 23251661 rs7788970 chr7 158227262 C T 1.60E-04 Multiple complex diseases PTPRN2 intron 17554300 rs7789415 chr7 158227617 C T 9.61E-77 Multiple complex diseases PTPRN2 intron 17554300 rs1670377 chr7 158245174 C T 6.87E-04 Smoking initiation PTPRN2 intron 24665060 rs1670365 chr7 158257969 T C 6.86E-04 Type 2 diabetes PTPRN2 intron 17463246 rs1733133 chr7 158265190 C T 8.18E-04 Type 2 diabetes PTPRN2 intron 17463246 rs1632730 chr7 158265455 A G 7.85E-04 Type 2 diabetes PTPRN2 intron 17463246 rs5016021 chr7 158279130 G A 8.31E-05 Bipolar disorder PTPRN2 intron 19488044 rs7801395 chr7 158290427 T C 5.58E-04 Nicotine smoking PTPRN2 intron 19268276 rs2091718 chr7 158304646 A G 0.000871 Salmonella-induced pyroptosis PTPRN2 intron 22837397 rs12532121 chr7 158385584 G A 1.55E-04 Glaucoma (primary open-angle) / / 22605921 rs1466210 chr7 158444975 T G 8.97E-05 Amyotrophic lateral sclerosis (sporadic) NCAPG2 intron 24529757 rs9801117 chr7 158505638 C T 1.10E-05 Urinary metabolites / / 21572414 rs2709855 chr7 158591851 C T 7.96E-04 Type 2 diabetes ESYT2 intron 17463246 rs2709855 chr7 158591851 C T 1.56E-04 Multiple complex diseases ESYT2 intron 17554300 rs2788500 chr7 158592431 A G 5.44E-04 Type 2 diabetes ESYT2 intron 17463246 rs10282118 chr7 158665987 C T 4.54E-05 Weight WDR60 intron pha003027 rs6459911 chr7 158692050 T C 2.85E-04 Type 2 diabetes WDR60 intron 17463246 rs6943562 chr7 158714238 C T 1.90E-05 Urinary metabolites WDR60 intron 21572414 rs10281870 chr7 158717184 A G 2.30E-05 Urinary metabolites WDR60 intron 21572414 rs2730245 chr7 158724789 G C 3.00E-07 Height WDR60 intron 18391950 rs2527202 chr7 158738849 T C 1.66E-04 Amyotrophic lateral sclerosis (sporadic) WDR60 UTR-3 24529757 rs262145 chr7 158747403 T G 6.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs10279232 chr7 158750346 C T 6.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs7809017 chr7 158759063 A G 9.25E-05 Weight / / pha003026 rs7809017 chr7 158759063 A G 8.56E-05 Weight / / pha003027 rs262152 chr7 158775172 A C 9.52E-05 Waist Circumference / / pha003025 rs2657404 chr7 158783155 G A 9.37E-05 Bipolar disorder,affective / / 20528957 rs1017033 chr7 158827401 A G 3.54E-04 Type 2 diabetes VIPR2 intron 17463246 rs16868144 chr7 158846831 C T 7.32E-05 Body Mass Index VIPR2 intron pha003015 rs2730260 chr7 158846929 G T 2.28E-05 Mammographic density VIPR2 intron 22532574 rs2730260 chr7 158846929 G T 9.00E-14 Myopia (pathological) VIPR2 intron 23406873 rs3793217 chr7 158848821 A G 6.18E-05 Mammographic density VIPR2 intron 22532574 rs2730267 chr7 158854873 C T 2.96E-05 Aging (time to event) VIPR2 intron 21782286 rs2864946 chr7 158876392 G C 3.04E-04 Multiple complex diseases VIPR2 intron 17554300 rs11979984 chr7 158877658 T C 4.90E-04 Multiple complex diseases VIPR2 intron 17554300 rs12674049 chr7 158883950 G A 2.28E-04 Alzheimer's disease (late onset) VIPR2 intron 21379329 rs3793227 chr7 158885928 A G 4.06E-04 Type 2 diabetes VIPR2 intron 22158537 rs2270314 chr7 158896624 C G 2.86E-04 Type 2 diabetes VIPR2 intron 22158537 rs3828962 chr7 158900606 T C 4.06E-04 Type 2 diabetes VIPR2 intron 22158537 rs17837875 chr7 158903083 T C 1.96E-04 Type 2 diabetes VIPR2 intron 22158537 rs3793235 chr7 158910655 C T 9.70E-06 Urinary metabolites VIPR2 intron 21572414 rs7780644 chr7 158910780 G A 2.20E-05 Urinary metabolites VIPR2 intron 21572414 rs6459928 chr7 158928569 C T 4.00E-05 Volumetric brain MRI VIPR2 intron 17903297 rs429102 chr7 159000871 T G 1.66E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17744505 chr8 179693 G T 1.65E-04 Response to cytidine analogues (gemcitabine) RPL23AP53 intron 24483146 rs17744517 chr8 182340 A G 4.80E-04 Response to cytidine analogues (gemcitabine) ZNF596 UTR-5 24483146 rs10488368 chr8 190568 A G 1.27E-04 Response to cytidine analogues (gemcitabine) ZNF596 intron 24483146 rs9314442 chr8 191226 A G 2.29E-04 Response to cytidine analogues (gemcitabine) ZNF596 intron 24483146 rs2072174 chr8 196274 T G 7.69E-05 Response to cytidine analogues (gemcitabine) ZNF596 missense 24483146 rs17206521 chr8 221671 G A 7.12E-04 Gallbladder cancer / / 22318345 rs17206521 chr8 221671 G A 1.32E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1989173 chr8 227598 G A 1.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs741554 chr8 238648 C T 8.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs55680580 chr8 240578 T A 8.00E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11136541 chr8 268482 T C 3.30E-06 Urinary metabolites / / 21572414 rs6984826 chr8 280468 T A 6.40E-06 Urinary metabolites / / 21572414 rs7018431 chr8 280645 A G 2.89E-05 Parkinson's disease / / 21738487 rs10112533 chr8 293820 T C 1.76E-04 Sudden cardiac arrest / / 21658281 rs12546771 chr8 297118 C T 7.21E-04 Coronary heart disease / / 21606135 rs1550950 chr8 334709 G A 1.73E-04 Arthritis (juvenile idiopathic) / / 22354554 rs6996216 chr8 335118 G C 6.06E-04 Multiple complex diseases / / 17554300 rs6996216 chr8 335118 G C 4.80E-06 Urinary metabolites / / 21572414 rs1550948 chr8 335646 C T 1.71E-04 Arthritis (juvenile idiopathic) / / 22354554 rs11136697 chr8 399124 C T 2.00E-05 Pulmonary function FBXO25 intron 20010835 rs17738225 chr8 418277 A T 6.28E-04 Suicide attempts in bipolar disorder FBXO25 intron 21423239 rs11774384 chr8 423694 A G 6.78E-06 Magnesium levels / / pha003092 rs4735847 chr8 437030 A C 5.24E-05 Waist Circumference / / pha003025 rs62484362 chr8 437397 C A 2.74E-04 Acne (severe) / / 24927181 rs6999653 chr8 444485 A G 6.81E-06 Erythrocyte counts C8orf42 intron pha003090 rs17665859 chr8 445601 T C 5.00E-07 Bilirubin levels C8orf42 intron 21646302 rs1075035 chr8 458148 G C 1.60E-04 Type 2 diabetes and 6 quantitative traits C8orf42 intron 17848626 rs7002094 chr8 460350 A G 7.09E-05 C-Reactive Protein C8orf42 intron pha003070 rs1597137 chr8 464083 C T 5.05E-05 Cognitive test performance C8orf42 intron 20125193 rs1703940 chr8 504401 G A 1.12E-07 Neuroblastoma / / pha002895 rs722782 chr8 516479 A C 8.20E-05 Age-related macular degeneration / / 21665990 rs722782 chr8 516479 A C 2.00E-06 Age-related macular degeneration (GA) / / 22705344 rs896523 chr8 520044 A G 2.08E-04 Cholesterol / / 17255346 rs17065149 chr8 522863 A G 8.97E-04 Obesity (extreme) / / 21935397 rs11136864 chr8 531083 A C 5.37E-05 Post-operative nausea and vomiting / / 21694509 rs11136864 chr8 531083 A C 2.07E-04 Alcohol dependence / / 24277619 rs876412 chr8 549870 T C 3.29E-04 Stroke / / pha002886 rs17666538 chr8 566207 T C 7.00E-06 IgG glycosylation / / 23382691 rs336425 chr8 571611 T G 5.30E-06 Urinary metabolites / / 21572414 rs336430 chr8 576209 C T 9.80E-06 Urinary metabolites / / 21572414 rs12542241 chr8 586951 C T 2.07E-05 Sleep duration / / 22105623 rs89975 chr8 587113 C T 7.00E-06 Urinary metabolites / / 21572414 rs1669715 chr8 593641 T C 4.61E-05 Sodium levels / / pha003093 rs1669681 chr8 606117 G A 2.00E-04 Type 2 diabetes / / 17463246 rs13252487 chr8 606356 C A 3.23E-05 Gaucher disease severity / / 22388998 rs1703937 chr8 606452 T A 4.92E-04 Type 2 diabetes / / 17463246 rs1669733 chr8 606696 T C 2.85E-04 Cholesterol / / 17255346 rs11137016 chr8 633684 A G 9.10E-05 Hypothyroidism ERICH1 intron 22493691 rs10104028 chr8 655056 G C 5.99E-04 Aortic root size ERICH1 intron 21223598 rs1669625 chr8 657581 T C 0.0000206 Colorectal adenoma (excluding hyperplasic) ERICH1 intron 23677573 rs1669625 chr8 657581 T C 0.0000206 Colorectal adenoma ERICH1 intron 23677573 rs1669625 chr8 657581 T C 0.0000206 Colorectal adenoma (including hyperplasic) ERICH1 intron 23677573 rs4735916 chr8 677305 G A 7.02E-05 Pulmonary function in asthmatics ERICH1 intron 23541324 rs7819958 chr8 710587 G T 7.10E-05 Cytomegalovirus antibody response / / 21993531 rs11776586 chr8 733406 C G 3.61E-04 Alzheimer's disease / / 17998437 rs7827510 chr8 754025 T G 9.90E-05 Heart Rate / / pha003054 rs13278087 chr8 758307 C T 2.14E-04 Smoking initiation / / 24665060 rs1393703 chr8 782845 A G 1.86E-10 Narcolepsy / / 19629137 rs1393701 chr8 783099 C A 9.58E-04 Type 2 diabetes / / 17463246 rs10106538 chr8 783664 C T 5.73E-04 Smoking initiation / / 24665060 rs7357355 chr8 811180 T C 7.61E-05 Cognitive impairment induced by topiramate / / 22091778 rs17065443 chr8 843432 A T 1.98E-04 Multiple complex diseases / / 17554300 rs7822510 chr8 877433 A C 2.51E-05 Multiple sclerosis (age of onset) / / 19010793 rs4601343 chr8 947445 G A 9.75E-04 Type 2 diabetes / / 17463246 rs13251306 chr8 953948 A G 1.23E-04 Telomere length / / 21573004 rs13251306 chr8 953948 A G 6.58E-04 Smoking initiation / / 24665060 rs4735971 chr8 996634 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2701909 chr8 1003057 A G 2.62E-04 HIV-1 viral setpoint / / 17641165 rs2701907 chr8 1003292 T C 2.25E-04 HIV-1 viral setpoint / / 17641165 rs10503156 chr8 1008232 G A 2.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7011999 chr8 1008446 A G 2.01E-07 Statin-induced myopathy / / 21826682 rs2123060 chr8 1009313 T C 9.49E-04 HIV-1 viral setpoint / / 17641165 rs17065653 chr8 1010965 C T 2.58E-12 Multiple complex diseases / / 17554300 rs17668154 chr8 1014566 C A 4.19E-05 Serum metabolites / / 19043545 rs2336695 chr8 1033625 A G 8.16E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs6982844 chr8 1034497 C T 5.79E-05 HDL cholesterol / / pha003075 rs7842241 chr8 1068910 G A 8.10E-05 Type 2 diabetes / / 17463248 rs6983835 chr8 1071853 A G 3.86E-04 Multiple complex diseases / / 17554300 rs1451882 chr8 1083364 G T 4.48E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1451882 chr8 1083364 G T 4.55E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11136359 chr8 1152506 A T 9.42E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs760179 chr8 1240600 A G 9.30E-06 Urinary metabolites / / 21572414 rs17669535 chr8 1244224 C G 6.00E-07 Menarche (age at onset) / / 23599027 rs10103190 chr8 1269326 C T 3.80E-06 Digit length ratio / / 20303062 rs6558446 chr8 1270993 T C 3.15E-04 Birth weight / / 17255346 rs6558446 chr8 1270993 T C 8.30E-05 Bipolar disorder / / 17486107 rs6994475 chr8 1273426 T G 6.30E-06 Digit length ratio / / 20303062 rs17063833 chr8 1275384 T C 8.83E-04 Bipolar disorder,schizoaffective / / 19567891 rs17063833 chr8 1275384 T C 5.50E-06 Digit length ratio / / 20303062 rs17748002 chr8 1284369 T C 3.80E-04 Multiple complex diseases / / 17554300 rs10110073 chr8 1294073 G A 3.11E-04 Multiple complex diseases / / 17554300 rs12682470 chr8 1332297 T C 5.42E-04 Smoking cessation / / 24665060 rs10109491 chr8 1362269 A T 6.88E-05 Kawasaki disease / / 22446961 rs28680850 chr8 1373720 G A 2.77E-06 Triglycerides / / 24886709 rs7813445 chr8 1378488 T C 5.81E-04 Multiple complex diseases / / 17554300 rs7002326 chr8 1380611 T C 2.89E-04 Multiple complex diseases / / 17554300 rs1990126 chr8 1484510 G A 1.59E-05 Type 2 diabetes DLGAP2 intron 17463246 rs7815979 chr8 1484887 T C 5.64E-05 Serum metabolites DLGAP2 intron 19043545 rs11136406 chr8 1489033 T G 0.000113903 Hypertension (early onset hypertension) DLGAP2 intron 22479346 rs10503166 chr8 1489918 A G 4.02E-05 Triglycerides DLGAP2 intron pha003080 rs2019513 chr8 1490055 C A 8.34E-04 Obesity (extreme) DLGAP2 intron 21935397 rs2214861 chr8 1490604 T C 9.52E-04 Type 2 diabetes DLGAP2 intron 17463246 rs2214861 chr8 1490604 T C 0.000134578 Hypertension (early onset hypertension) DLGAP2 intron 22479346 rs6994849 chr8 1492839 A C 6.11E-05 Hypertension (early onset hypertension) DLGAP2 intron 22479346 rs2956896 chr8 1505290 G A 4.28E-04 Obesity (extreme) DLGAP2 intron 21935397 rs2404631 chr8 1513121 T C 9.00E-04 Obesity (extreme) DLGAP2 intron 21935397 rs3815235 chr8 1513814 A G 4.70E-04 Multiple complex diseases DLGAP2 intron 17554300 rs2301963 chr8 1514009 C A 5.60E-04 Primary sclerosing cholangitis DLGAP2 missense 19944697 rs2956917 chr8 1514749 G A 8.62E-06 Type 2 diabetes DLGAP2 intron 17463246 rs2906589 chr8 1518001 T C 9.77E-04 Obesity (extreme) DLGAP2 intron 21935397 rs7819115 chr8 1561756 A C 1.18E-05 Menarche (age at onset) DLGAP2 intron 23599027 rs7819115 chr8 1561756 A C 7.86E-04 Menarche (age at onset) DLGAP2 intron 23599027 rs2957086 chr8 1566505 G A 0.000738022 Hypertension (early onset hypertension) DLGAP2 intron 22479346 rs17064167 chr8 1600167 G A 8.19E-04 Type 2 diabetes DLGAP2 intron 17463246 rs17064167 chr8 1600167 G A 6.90E-06 Urinary metabolites DLGAP2 intron 21572414 rs17064176 chr8 1601145 G T 2.01E-05 Alcohol and nictotine co-dependence DLGAP2 intron 20158304 rs17064198 chr8 1613600 T C 8.54E-04 Type 2 diabetes DLGAP2 intron 17463246 rs17064198 chr8 1613600 T C 6.60E-06 Urinary metabolites DLGAP2 intron 21572414 rs17064201 chr8 1614159 G A 1.00E-05 Urinary metabolites DLGAP2 intron 21572414 rs17064201 chr8 1614159 G A 9.43E-04 Insulin resistance DLGAP2 intron 21901158 rs4471073 chr8 1615694 G A 3.77E-04 Type 2 diabetes DLGAP2 intron 17463246 rs7834457 chr8 1621755 G C 9.43E-04 Obesity (extreme) DLGAP2 intron 21935397 rs2235114 chr8 1625104 T C 0.000447075 Hypertension (early onset hypertension) DLGAP2 intron 22479346 rs4507794 chr8 1632525 T C 2.19E-04 Response to cytidine analogues (gemcitabine) DLGAP2 intron 24483146 rs4507794 chr8 1632525 T C 8.28E-04 Response to cytadine analogues (cytosine arabinoside) DLGAP2 intron 24483146 rs7825359 chr8 1648035 A G 5.01E-04 Alcohol dependence DLGAP2 intron 24277619 rs7005715 chr8 1649960 G A 4.60E-05 Alcohol dependence DLGAP2 UTR-3 24277619 rs2957055 chr8 1658593 A C 4.17E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs12545625 chr8 1678257 G T 1.35E-04 Prion diseases / / 22210626 rs12545625 chr8 1678257 G T 8.10E-04 Iron levels / / pha002876 rs11990748 chr8 1680901 A C 6.25E-04 Depression (quantitative trait) / / 20800221 rs41526952 chr8 1689290 G A 7.85E-05 Alzheimer's disease / / 17998437 rs2957085 chr8 1692005 G C,T 9.09E-04 Obesity (extreme) / / 21935397 rs7842741 chr8 1693749 G C 9.42E-05 Cytomegalovirus antibody response / / 21993531 rs7845723 chr8 1697086 T G 9.19E-05 Gaucher disease severity / / 22388998 rs7005592 chr8 1700398 T C 6.79E-06 Gaucher disease severity / / 22388998 rs10105317 chr8 1701432 G A 6.00E-05 Gaucher disease severity / / 22388998 rs6558527 chr8 1702911 T G 9.18E-04 Obesity (extreme) / / 21935397 rs6558527 chr8 1702911 T G 2.25E-05 Glaucoma (primary open-angle) / / 22605921 rs4595147 chr8 1703569 G T 1.11E-05 Gaucher disease severity / / 22388998 rs6558533 chr8 1709918 A G 6.36E-04 Obesity (extreme) CLN8 nearGene-5 21935397 rs6558534 chr8 1709972 A G 6.32E-04 Obesity (extreme) CLN8 nearGene-5 21935397 rs2293977 chr8 1711121 C G 4.85E-04 Obesity (extreme) LOC100507448 intron 21935397 rs11136424 chr8 1717036 G A 1.59E-05 Gaucher disease severity CLN8 intron 22388998 rs4875958 chr8 1721090 G A 2.69E-05 Gaucher disease severity CLN8 intron 22388998 rs10089616 chr8 1731855 C T 7.72E-04 Response to taxane treatment (placlitaxel) CLN8 UTR-3 23006423 rs11986414 chr8 1746950 A G 1.00E-06 Gaucher disease severity / / 22388998 rs4875960 chr8 1748166 A G 1.75E-06 Gaucher disease severity / / 22388998 rs6558545 chr8 1756585 G A 6.26E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs9802017 chr8 1778697 T C 6.08E-04 Type 2 diabetes ARHGEF10 intron 22158537 rs11136431 chr8 1791433 C T 3.78E-04 Suicide attempts in bipolar disorder ARHGEF10 intron 21041247 rs11136431 chr8 1791433 C T 4.90E-05 Suicide attempts in bipolar disorder ARHGEF10 intron 21041247 rs11136435 chr8 1791685 A G 2.11E-05 Suicide attempts in bipolar disorder ARHGEF10 intron 21041247 rs10099567 chr8 1792842 G A 4.89E-04 Suicide attempts in bipolar disorder ARHGEF10 intron 21041247 rs10099567 chr8 1792842 G A 6.81E-05 Suicide attempts in bipolar disorder ARHGEF10 intron 21041247 rs749822 chr8 1808256 A G 4.49E-04 Nicotine smoking ARHGEF10 cds-synon 19268276 rs17829629 chr8 1817961 C A 6.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARHGEF10 intron 20877124 rs12545104 chr8 1821516 A G 1.86E-05 Osteosarcoma ARHGEF10 intron 23727862 rs11779246 chr8 1835366 C T 3.77E-04 Acute lung injury ARHGEF10 intron 22295056 rs3758004 chr8 1842729 C T 3.28E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) ARHGEF10 cds-synon 23648065 rs1006520 chr8 1849882 A G 2.50E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ARHGEF10 intron 24023788 rs4480162 chr8 1854815 G C 6.90E-07 Stroke(atherothrombotic) ARHGEF10 intron 20042462 rs4376531 chr8 1854818 C G 6.90E-07 Stroke(atherothrombotic) ARHGEF10 intron 20042462 rs2280887 chr8 1855764 C G 1.20E-06 Stroke(atherothrombotic) ARHGEF10 intron 20042462 rs12548089 chr8 1860200 T C 8.38E-05 Height ARHGEF10 intron pha003011 rs13250852 chr8 1866796 C A 1.63E-04 Aortic root size ARHGEF10 intron 21223598 rs11136442 chr8 1868842 G A 2.30E-05 Urinary metabolites ARHGEF10 intron 21572414 rs4242548 chr8 1880530 T C 5.59E-05 Response to mTOR inhibitor (everolimus) ARHGEF10 intron 24009623 rs13279485 chr8 1883352 T C 1.00E-06 Multiple sclerosis ARHGEF10 intron 23412934 rs7386016 chr8 1890533 T C 8.85E-04 Parkinson's disease ARHGEF10 intron 17052657 rs17064407 chr8 1897174 A G 7.30E-05 Hypothyroidism ARHGEF10 intron 22493691 rs2280823 chr8 1897657 A G 7.30E-07 Corneal curvature ARHGEF10 intron 24963161 rs4448323 chr8 1913747 A G 5.00E-06 Urinary metabolites / / 21572414 rs6558568 chr8 1918352 G T 3.90E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs10098493 chr8 1933161 C A 1.00E-06 Parkinson's disease (interaction with coffee consumption) KBTBD11 intron 21876681 rs13263558 chr8 1951300 G A 3.00E-06 Obesity-related traits KBTBD11 UTR-3 23251661 rs1043225 chr8 1953567 C A 8.39E-05 Parkinson's disease KBTBD11 UTR-3 17052657 rs1043226 chr8 1953759 A T 1.52E-04 Parkinson's disease KBTBD11 UTR-3 17052657 rs2280820 chr8 1968128 T C 2.34E-04 Lymphocyte counts / / 22286170 rs6558578 chr8 1969726 T G 7.00E-06 Cervical cancer / / 24700089 rs7814914 chr8 1983582 G A 6.20E-04 Multiple complex diseases / / 17554300 rs11136457 chr8 1997993 A G 7.60E-05 Cervical cancer MYOM2 intron 24700089 rs6558590 chr8 2004903 A G 1.63E-04 Hearing function MYOM2 intron 17255346 rs4876235 chr8 2004955 A G 2.19E-04 Hearing function MYOM2 intron 17255346 rs1542065 chr8 2005085 G C 2.93E-04 Multiple complex diseases MYOM2 intron 17554300 rs11136463 chr8 2020224 A G 8.06E-04 Suicide attempts in bipolar disorder MYOM2 intron 21423239 rs2235120 chr8 2027434 G C 5.53E-04 Suicide attempts in bipolar disorder MYOM2 intron 21423239 rs1440291 chr8 2027633 C G 1.10E-05 Urinary metabolites MYOM2 intron 21572414 rs6558599 chr8 2028573 G C 6.57E-05 Bipolar disorder and schizophrenia MYOM2 intron 20889312 rs6558599 chr8 2028573 G C 9.01E-04 Suicide attempts in bipolar disorder MYOM2 intron 21423239 rs1440294 chr8 2030094 T G 6.84E-04 Suicide attempts in bipolar disorder MYOM2 intron 21423239 rs7815609 chr8 2034776 A C 6.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MYOM2 intron 20877124 rs13269383 chr8 2036476 C T 5.67E-04 Nicotine smoking MYOM2 intron 19268276 rs2235121 chr8 2040104 C T 8.00E-06 Bipolar disorder and schizophrenia MYOM2 intron 20889312 rs2235121 chr8 2040104 C T 7.41E-05 Post-operative nausea and vomiting MYOM2 intron 21694509 rs17684416 chr8 2054066 A G 8.94E-04 Taste perception MYOM2 cds-synon 22132133 rs1542067 chr8 2055095 T G 1.79E-05 Odorant perception MYOM2 intron 23910658 rs4876225 chr8 2059994 A G 5.63E-04 Amyotrophic lateral sclerosis (sporadic) MYOM2 intron 24529757 rs17751773 chr8 2060960 G A,C,T 2.21E-04 Type 2 diabetes MYOM2 intron 17463246 rs17684547 chr8 2061006 G A 9.33E-04 Type 2 diabetes MYOM2 intron 17463246 rs12548396 chr8 2064121 C T 9.11E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) MYOM2 intron 23648065 rs10503170 chr8 2092484 C T 8.46E-04 Premature ovarian failure MYOM2 intron 19508998 rs2099746 chr8 2095441 G T 8.31E-04 Myopia (pathological) / / 21095009 rs9314453 chr8 2097007 A G 7.55E-05 Hematocrit / / pha003097 rs6986035 chr8 2097403 C G 9.38E-10 Lymphocyte counts / / 22286170 rs12676956 chr8 2101655 C A 7.87E-05 Lipoproteins / / pha003079 rs17685088 chr8 2103975 C G 5.52E-04 Obesity (extreme) / / 21935397 rs10112140 chr8 2105379 T C 2.34E-04 Body mass index / / 21701565 rs12543116 chr8 2105621 C A 7.08E-04 Body mass index / / 21701565 rs12547890 chr8 2105733 G T 9.68E-04 Obesity (extreme) / / 21935397 rs7829100 chr8 2110230 C T 1.50E-04 Insulin resistance / / 21901158 rs1440288 chr8 2112440 G C 3.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs11987758 chr8 2128786 G A 8.00E-07 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs317221 chr8 2146093 T C 2.13E-05 Cognitive impairment induced by topiramate / / 22091778 rs317221 chr8 2146093 T C 5.44E-05 Cognitive impairment induced by topiramate / / 22091778 rs10107918 chr8 2226763 T C 1.20E-05 Urinary metabolites / / 21572414 rs315237 chr8 2281592 C G 6.43E-04 Multiple complex diseases / / 17554300 rs2266378 chr8 2285156 C A 8.03E-04 Alzheimer's disease / / 24755620 rs6981064 chr8 2289893 G A 8.18E-04 Multiple complex diseases / / 17554300 rs897445 chr8 2295755 G A 6.03E-05 Multiple complex diseases / / 17554300 rs897445 chr8 2295755 G A 8.32E-05 Serum metabolites / / 19043545 rs10111830 chr8 2302926 C T 9.40E-04 Multiple complex diseases / / 17554300 rs10111830 chr8 2302926 C T 6.73E-05 Serum metabolites / / 19043545 rs4876153 chr8 2304334 A G 2.38E-05 Educational attainment / / 21694764 rs4876153 chr8 2304334 A G 7.46E-05 Stroke / / pha002887 rs6558653 chr8 2311153 A T 9.00E-06 Urinary metabolites / / 21572414 rs7827690 chr8 2313612 A G 5.63E-04 Alzheimer's disease / / 24755620 rs11777784 chr8 2314436 A T 8.86E-04 Multiple complex diseases / / 17554300 rs17063040 chr8 2321764 C T 3.66E-04 Type 2 diabetes / / 17463246 rs10866938 chr8 2322814 G T 3.65E-04 Multiple complex diseases / / 17554300 rs10866938 chr8 2322814 G T 6.55E-05 Serum metabolites / / 19043545 rs536909149 chr8 2322814 G T 3.65E-04 Multiple complex diseases / / 17554300 rs536909149 chr8 2322814 G T 6.55E-05 Serum metabolites / / 19043545 rs7386029 chr8 2347851 A C 2.28E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4875983 chr8 2349916 G T 3.23E-04 IgE levels / / 17255346 rs11990785 chr8 2350097 C T 3.02E-04 IgE levels / / 17255346 rs2198944 chr8 2355115 A G 4.69E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2100623 chr8 2365648 G T 3.49E-04 Stroke / / pha002887 rs35388444 chr8 2365648 G GA 3.49E-04 Stroke / / pha002887 rs2045423 chr8 2366333 A G 0.000316154 Hypertension (early onset hypertension) / / 22479346 rs4092400 chr8 2383703 T A 9.70E-04 Type 2 diabetes / / 17463246 rs4092400 chr8 2383703 T A 9.90E-04 Pulmonary function / / 23932459 rs10104810 chr8 2384141 G A 9.13E-04 Type 2 diabetes / / 17463246 rs897855 chr8 2385228 T C 0.000806753 Hypertension (early onset hypertension) / / 22479346 rs897855 chr8 2385228 T C 4.76E-04 Lung function (forced vital capacity) / / 24023788 rs6420206 chr8 2396588 C T 4.18E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6420206 chr8 2396588 C T 4.41E-05 Erythrocyte counts / / pha003099 rs7005818 chr8 2494954 C G 9.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs10097215 chr8 2506899 C T 3.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs10097215 chr8 2506899 C T 2.00E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4876024 chr8 2511536 C T 4.35E-06 Suicide attempts in bipolar disorder / / 21423239 rs9314462 chr8 2513884 T C 3.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs9314462 chr8 2513884 T C 9.09E-05 Schizophrenia (treatment refractory) / / 22479419 rs9314462 chr8 2513884 T C 5.30E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs4876025 chr8 2515736 G A 7.60E-06 Suicide attempts in bipolar disorder / / 21423239 rs10109021 chr8 2528745 A C 6.80E-05 White matter hyperintensity burden / / 21681796 rs13278616 chr8 2535086 A G 4.09E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6997305 chr8 2536024 G A 2.30E-05 Urinary metabolites / / 21572414 rs13268647 chr8 2549517 T C 2.97E-04 Type 2 diabetes / / 17463246 rs11777049 chr8 2552810 C T 1.71E-05 Alzheimer's disease / / 22832961 rs6558687 chr8 2604187 G T 9.10E-07 Dietary macronutrient intake / / 23372041 rs6988292 chr8 2609760 G C 7.50E-04 Type 2 diabetes / / 17463246 rs6988292 chr8 2609760 G C 2.11E-04 Multiple complex diseases / / 17554300 rs974120 chr8 2646618 T C 3.20E-04 Pulmonary function / / 23932459 rs7814325 chr8 2655994 C T 4.02E-04 Alzheimer's disease / / 17998437 rs7829596 chr8 2659364 C A 4.80E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1026378 chr8 2662135 G A 9.42E-04 Type 2 diabetes / / 17463246 rs12542624 chr8 2664858 G A 8.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs6989127 chr8 2665803 A G 8.10E-05 Parkinson's disease (familial) / / 18985386 rs17761209 chr8 2666481 C G 4.28E-04 Sudden cardiac arrest / / 21658281 rs2924881 chr8 2699507 C A 0.0000063 Mean arterial pressure / / 22510845 rs2978310 chr8 2713726 G A 1.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17761793 chr8 2727315 A G 1.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2978341 chr8 2728891 T G 5.71E-04 Type 2 diabetes / / 17463246 rs2942805 chr8 2729078 C G 9.10E-04 Type 2 diabetes / / 17463246 rs2924911 chr8 2730069 G A 8.94E-04 Multiple complex diseases / / 17554300 rs341672 chr8 2734202 T C 8.50E-06 Emphysema-related traits / / 20709820 rs341672 chr8 2734202 T C 3.52E-05 Common variable immunodeficiency / / 21497890 rs4875854 chr8 2734771 T C 6.02E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs641525 chr8 2740502 T G 5.00E-07 Emphysema-related traits / / 20709820 rs12676437 chr8 2744272 T C 2.00E-05 Alcohol consumption / / 23743675 rs12677935 chr8 2744515 G C 2.03E-05 Alcohol consumption / / 23743675 rs2721271 chr8 2750762 C T 1.13E-04 Type 2 diabetes / / 17463246 rs6989916 chr8 2778041 T C 9.56E-04 Self-reported allergy / / 23817569 rs2627282 chr8 2780956 G A 3.00E-07 Blood pressure measurement (high sodium intervention) / / 24165912 rs2627282 chr8 2780956 G A 3.79E-04 Blood pressure measurement (high sodium intervention) / / 24165912 rs2627282 chr8 2780956 G A 6.00E-07 Blood pressure measurement (high sodium intervention) / / 24165912 rs583087 chr8 2795835 T C 0.00028 Breast cancer CSMD1 UTR-3 23555315 rs897275 chr8 2796810 G A 5.09E-04 Type 2 diabetes CSMD1 intron 17463246 rs599016 chr8 2797119 C A 1.22E-04 IgE levels CSMD1 intron 17255346 rs599814 chr8 2797246 C T 1.44E-04 IgE levels CSMD1 intron 17255346 rs584541 chr8 2802745 T C 4.90E-05 Schizophrenia (cytomegalovirus infection interaction) CSMD1 intron 23358160 rs865303 chr8 2812271 C A 4.75E-05 HDL cholesterol CSMD1 intron pha003075 rs4875857 chr8 2819809 T C 5.00E-06 IgG glycosylation CSMD1 intron 23382691 rs666276 chr8 2832449 C T 1.46E-04 Insulin resistance CSMD1 intron 21901158 rs643229 chr8 2850401 G A 9.55E-08 Longevity,exceptional CSMD1 intron 20595579 rs596215 chr8 2860515 A G 5.94E-05 Alcohol consumption CSMD1 intron 23743675 rs596681 chr8 2860602 C A 9.87E-05 Alcohol consumption CSMD1 intron 23743675 rs11779410 chr8 2872533 A T 4.55E-04 Alzheimer's disease CSMD1 intron 17998437 rs13280616 chr8 2890809 A G 3.52E-04 Stroke CSMD1 intron pha002887 rs7013027 chr8 2923969 A G 1.85E-06 Parkinson's disease CSMD1 intron pha002868 rs6992732 chr8 2924238 G A 3.32E-05 Parkinson's disease CSMD1 intron pha002868 rs11779935 chr8 2927589 C A 3.92E-04 Alzheimer's disease CSMD1 intron 17998437 rs7844468 chr8 2929436 A G 2.74E-05 Parkinson's disease CSMD1 intron pha002868 rs6982967 chr8 2946963 G T 9.25E-04 Rheumatoid arthritis CSMD1 intron 21452313 rs7813351 chr8 2953412 A G 7.28E-05 Age-related macular degeneration CSMD1 intron pha002890 rs144394317 chr8 2957718 C T 0.00004423 Sarcoidosis CSMD1 intron 22952805 rs143228952 chr8 2957947 A G 0.00004423 Sarcoidosis CSMD1 intron 22952805 rs4875731 chr8 2959872 G A 2.80E-05 Urinary metabolites CSMD1 intron 21572414 rs10503192 chr8 2964003 T C 6.40E-04 Primary sclerosing cholangitis CSMD1 intron 19944697 rs201853182 chr8 2964003 T TC 6.40E-04 Primary sclerosing cholangitis CSMD1 intron 19944697 rs4875249 chr8 2970998 G C 2.10E-04 Type 2 diabetes and 6 quantitative traits CSMD1 intron 17848626 rs1460397 chr8 2972313 A G 2.31E-05 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs1460398 chr8 2972563 A G 7.78E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs17318682 chr8 2973047 T G 1.76E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs10092828 chr8 2973141 T C 7.84E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs10216636 chr8 2973634 T C 1.76E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs7016346 chr8 2974074 G C 3.65E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs7016528 chr8 2974198 G C 3.62E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs6999596 chr8 2974379 A G 3.39E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs7837930 chr8 2975126 T C 2.91E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs2045636 chr8 2975525 C G 1.58E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs7841865 chr8 2975578 T C 4.98E-05 Psoriasis CSMD1 intron 20953190 rs2045638 chr8 2975905 A G 3.14E-05 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs10105872 chr8 2977254 A G 2.23E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs2045640 chr8 2977909 A G 2.16E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs2045641 chr8 2978078 G A 1.70E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs2125953 chr8 2978749 T A 4.09E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs7832068 chr8 2979693 A T 2.50E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs9987129 chr8 2980134 A G 9.72E-05 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs9314474 chr8 2980491 C G 1.47E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs17390734 chr8 2980878 C G 2.84E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs7837404 chr8 2980976 A G 1.36E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs6991828 chr8 2981466 G C 2.66E-05 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs7842818 chr8 2982351 A G 1.57E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs17079488 chr8 2986574 G A 6.94E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs17390797 chr8 2986880 G C 3.81E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs7015423 chr8 3000033 A G 8.30E-04 Multiple complex diseases CSMD1 cds-synon 17554300 rs11136584 chr8 3005039 A C 5.45E-04 Rheumatoid arthritis CSMD1 intron 21452313 rs17079498 chr8 3018344 T C 1.46E-04 Multiple complex diseases CSMD1 intron 17554300 rs10503197 chr8 3025495 T C 3.31E-04 Type 2 diabetes CSMD1 intron 17846125 rs7823658 chr8 3026693 T G 6.59E-05 Calcium levels CSMD1 intron pha003085 rs7827348 chr8 3032815 T C 3.60E-04 Breast cancer and prostate cancer CSMD1 intron 17903305 rs983782 chr8 3051690 T A 1.80E-07 Urinary metabolites CSMD1 intron 21572414 rs1077153 chr8 3053592 G A,C,T 6.75E-04 Substance dependence CSMD1 intron 21818250 rs1442398 chr8 3061993 G A 4.80E-04 Intelligence (childhood) CSMD1 intron 23358156 rs10099364 chr8 3069893 T C 7.03E-04 Taste perception CSMD1 intron 22132133 rs28455997 chr8 3076959 T C 3.00E-06 Periodontitis (CDC/AAP) CSMD1 missense 24024966 rs55737375 chr8 3081727 C T 6.98E-06 Periodontitis (CDC/AAP) CSMD1 intron 24024966 rs10091165 chr8 3082687 C A 8.24E-06 Periodontitis (CDC/AAP) CSMD1 intron 24024966 rs13258433 chr8 3086506 C G 4.92E-04 Smoking quantity CSMD1 intron 24665060 rs73660619 chr8 3088173 T C 8.00E-07 Alzheimer's disease (cognitive decline) CSMD1 intron 23535033 rs1540507 chr8 3088763 C T 9.00E-06 Periodontitis (CDC/AAP) CSMD1 intron 24024966 rs1540508 chr8 3088862 C G 9.34E-06 Periodontitis (CDC/AAP) CSMD1 intron 24024966 rs1540509 chr8 3088938 C G 9.37E-06 Periodontitis (CDC/AAP) CSMD1 intron 24024966 rs2406453 chr8 3090794 G C 8.69E-04 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs1442407 chr8 3091584 G T 8.00E-06 Systolic blood pressure in sickle cell anemia CSMD1 intron 24058526 rs7814326 chr8 3093194 G T 2.47E-05 Body Mass Index CSMD1 intron pha002896 rs11781371 chr8 3098189 A G 1.80E-05 Urinary metabolites CSMD1 intron 21572414 rs10090255 chr8 3102385 C G 9.57E-05 Alzheimer's disease CSMD1 intron 24755620 rs17319596 chr8 3104594 T C 3.47E-04 Alzheimer's disease CSMD1 intron 24755620 rs73185595 chr8 3116686 T A 2.06E-05 Response to methotrexate in juvenile idiopathic arthritis CSMD1 intron 24709693 rs17319659 chr8 3116831 G C 8.15E-04 Alzheimer's disease CSMD1 intron 24755620 rs12542184 chr8 3127029 A G 8.85E-05 Rheumatoid arthritis CSMD1 intron 21452313 rs13272161 chr8 3128048 G C 9.76E-05 Multiple sclerosis CSMD1 intron 17660530 rs7822374 chr8 3136705 C G 3.39E-04 Obesity (extreme) CSMD1 intron 21935397 rs10108636 chr8 3139715 C T 5.20E-05 Personality dimensions CSMD1 intron 18957941 rs142816172 chr8 3156220 C T 6.00E-06 Eating disorders (purging via substances) CSMD1 intron 23568457 rs718121 chr8 3159561 T C 2.96E-05 Alopecia areata CSMD1 intron 22027810 rs6987564 chr8 3164143 C T 6.68E-04 Response to cytadine analogues (cytosine arabinoside) CSMD1 intron 24483146 rs11988807 chr8 3164485 T G 2.63E-04 Aortic root size CSMD1 intron 21223598 rs10503201 chr8 3170594 A G 2.48E-04 Schizophrenia CSMD1 intron 19197363 rs10217058 chr8 3170812 G A 9.76E-04 Response to cytadine analogues (cytosine arabinoside) CSMD1 intron 24483146 rs4875610 chr8 3177911 C A 4.10E-04 Neuroticism CSMD1 intron 17667963 rs2551043 chr8 3189896 A G 7.00E-06 Obesity-related traits CSMD1 intron 23251661 rs2589293 chr8 3197443 C G 8.30E-04 Nicotine dependence CSMD1 intron 17407593 rs11783305 chr8 3215267 T C 2.27E-04 Fibrinogen CSMD1 intron 17255346 rs1348267 chr8 3215497 G A 1.69E-04 Premature ovarian failure CSMD1 intron 19508998 rs11774749 chr8 3217858 G A 5.31E-05 Hemoglobin CSMD1 intron pha003098 rs11774749 chr8 3217858 G A 1.59E-05 Erythrocyte counts CSMD1 intron pha003099 rs4487803 chr8 3219355 G C 1.20E-06 Urinary metabolites CSMD1 intron 21572414 rs12541278 chr8 3219970 T C 1.70E-06 Urinary metabolites CSMD1 intron 21572414 rs17065939 chr8 3223524 C G 5.02E-04 Alzheimer's disease CSMD1 intron 17998437 rs11136613 chr8 3226205 T A 1.70E-07 Fetal hemoglobin levels CSMD1 intron 18245381 rs13257496 chr8 3230281 A G 8.67E-05 Erythrocyte counts CSMD1 intron pha003099 rs7015057 chr8 3230582 A G 3.14E-05 Hemoglobin CSMD1 intron pha003098 rs7015057 chr8 3230582 A G 8.65E-06 Erythrocyte counts CSMD1 intron pha003099 rs7011397 chr8 3233443 C T 6.51E-05 Hemoglobin CSMD1 intron pha003098 rs7011397 chr8 3233443 C T 4.91E-05 Erythrocyte counts CSMD1 intron pha003099 rs895696 chr8 3244615 A G 7.10E-05 Tuberculosis CSMD1 intron 24057671 rs895695 chr8 3244815 T C 4.00E-05 Tuberculosis CSMD1 intron 24057671 rs147739031 chr8 3247408 A G 9.96E-07 Prostate cancer CSMD1 intron 24185611 rs17066062 chr8 3272541 G C 4.09E-04 Response to taxane treatment (placlitaxel) CSMD1 intron 23006423 rs2922086 chr8 3272853 A G 8.07E-08 Metabolite levels CSMD1 intron 23281178 rs270091 chr8 3273911 C T 8.08E-08 Metabolite levels CSMD1 intron 23281178 rs270077 chr8 3280226 C T 6.20E-08 Metabolite levels CSMD1 intron 23281178 rs270076 chr8 3280568 G T 6.20E-08 Metabolite levels CSMD1 intron 23281178 rs166582 chr8 3280732 G T 6.20E-08 Metabolite levels CSMD1 intron 23281178 rs270073 chr8 3281827 A T 6.20E-08 Metabolite levels CSMD1 intron 23281178 rs270067 chr8 3283564 A C 6.20E-08 Metabolite levels CSMD1 intron 23281178 rs2938236 chr8 3287682 A C 2.40E-05 Urinary metabolites CSMD1 intron 21572414 rs2938236 chr8 3287682 A C 4.01E-08 Metabolite levels CSMD1 intron 23281178 rs17066135 chr8 3292868 G A 5.99E-08 Metabolite levels CSMD1 intron 23281178 rs200131128 chr8 3300163 CG C 0.00000629 Antisocial behavior CSMD1 intron 23077488 rs6558776 chr8 3300163 C T 0.00000629 Antisocial behavior CSMD1 intron 23077488 rs17394429 chr8 3316986 G A 7.00E-06 Obesity-related traits CSMD1 intron 23251661 rs17394506 chr8 3324801 A G 5.88E-04 Iron levels CSMD1 intron pha002876 rs10112704 chr8 3331716 T C 1.62E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs10094963 chr8 3332025 G C 2.20E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs6558779 chr8 3332750 C T 5.62E-05 Information processing speed CSMD1 intron 21130836 rs6558780 chr8 3332767 A C 5.35E-05 Information processing speed CSMD1 intron 21130836 rs6558780 chr8 3332767 A C 2.85E-05 Soluble levels of adhesion molecules CSMD1 intron pha003072 rs10106960 chr8 3333127 C T 1.26E-05 Information processing speed CSMD1 intron 21130836 rs10106960 chr8 3333127 C T 4.94E-05 Soluble levels of adhesion molecules CSMD1 intron pha003072 rs10100145 chr8 3334015 T C 1.28E-05 Information processing speed CSMD1 intron 21130836 rs10100145 chr8 3334015 T C 7.34E-05 Soluble levels of adhesion molecules CSMD1 intron pha003072 rs10087333 chr8 3343547 T C 8.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CSMD1 intron 20877124 rs17066250 chr8 3346096 A G 7.42E-04 Iron levels CSMD1 intron pha002876 rs2055340 chr8 3346335 A T 1.40E-05 Urinary metabolites CSMD1 intron 21572414 rs10103966 chr8 3351798 G C 5.32E-04 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs10103966 chr8 3351798 G C 8.92E-04 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs1499682 chr8 3354811 A T 7.76E-04 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs1499682 chr8 3354811 A T 8.94E-04 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs2100119 chr8 3356245 G A 7.18E-04 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs11783295 chr8 3372977 G C 2.58E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CSMD1 intron 20031582 rs17066342 chr8 3392200 T C 3.41E-05 Response to Vitamin E supplementation CSMD1 intron 22437554 rs17066348 chr8 3394133 G A 2.51E-05 Multiple complex diseases CSMD1 intron 17554300 rs10112072 chr8 3403501 A G 6.68E-05 Multiple complex diseases CSMD1 intron 17554300 rs11136641 chr8 3416852 T C 2.91E-04 Tourette syndrome CSMD1 intron 22889924 rs11991146 chr8 3417189 C G 1.10E-04 Asthma CSMD1 intron 23181788 rs11785740 chr8 3427849 C T 4.86E-04 Tourette syndrome CSMD1 intron 22889924 rs11985561 chr8 3452262 A C 2.30E-05 Urinary metabolites CSMD1 intron 21572414 rs5026429 chr8 3454813 T A 9.56E-04 Acute lung injury CSMD1 intron 22295056 rs17066529 chr8 3454992 C T 1.00E-04 Cognitive impairment induced by topiramate CSMD1 intron 22091778 rs931201 chr8 3456076 G T 9.96E-04 Acute lung injury CSMD1 intron 22295056 rs2469338 chr8 3466917 G T 3.22E-04 Alzheimer's disease (late onset) CSMD1 intron 21460841 rs1842728 chr8 3473855 C T 3.72E-05 Multiple complex diseases CSMD1 intron 17554300 rs1600857 chr8 3478336 C A 6.60E-06 Obesity-related traits CSMD1 intron 23251661 rs11786532 chr8 3479419 T C 8.11E-04 Tourette syndrome CSMD1 intron 22889924 rs1158563 chr8 3480244 C G 5.05E-04 Multiple complex diseases CSMD1 intron 17554300 rs2449215 chr8 3488338 A G 7.00E-07 Obesity-related traits CSMD1 intron 23251661 rs7837887 chr8 3492284 G A 4.05E-05 Serum metabolites CSMD1 intron 19043545 rs13269536 chr8 3502637 G C 9.40E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs13273027 chr8 3502719 A G 9.74E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs1586030 chr8 3508977 A G 7.07E-05 Schizophrenia CSMD1 intron 19197363 rs7813880 chr8 3511692 G T 4.68E-05 Magnesium levels CSMD1 intron pha003092 rs17063131 chr8 3515718 G T 1.40E-04 Lung function (forced expiratory volume in 1 second) CSMD1 intron 17255346 rs10503214 chr8 3516836 T C 4.24E-04 Schizophrenia CSMD1 intron 19197363 rs2624088 chr8 3520923 T G 6.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CSMD1 intron 20877124 rs12542057 chr8 3522251 T C 2.16E-04 Depression (quantitative trait) CSMD1 intron 20800221 rs2624095 chr8 3525667 A C 2.44E-04 Type 2 diabetes CSMD1 intron 17463246 rs2624095 chr8 3525667 A C 5.28E-04 Multiple complex diseases CSMD1 intron 17554300 rs41491246 chr8 3525815 G C 1.38E-04 Multiple complex diseases CSMD1 intron 17554300 rs7822379 chr8 3526097 G A 2.20E-04 Depression (quantitative trait) CSMD1 intron 20800221 rs6998429 chr8 3527234 C T 0.0000067 Asthma (exacerbation) CSMD1 intron 23706709 rs7815362 chr8 3529525 G A 2.58E-04 Depression (quantitative trait) CSMD1 intron 20800221 rs10088000 chr8 3530700 G C 8.94E-04 Multiple complex diseases CSMD1 intron 17554300 rs10088000 chr8 3530700 G C 4.43E-05 Male fertility CSMD1 intron 22633400 rs13261262 chr8 3533558 A C 2.59E-04 Multiple complex diseases CSMD1 intron 17554300 rs17326146 chr8 3547988 C T 2.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CSMD1 intron 20877124 rs2086532 chr8 3548027 A G 9.68E-05 Heart Rate CSMD1 intron pha003053 rs7837233 chr8 3549581 G A 9.19E-05 Heart Rate CSMD1 intron pha003053 rs2624070 chr8 3549936 T C 1.60E-05 Urinary metabolites CSMD1 intron 21572414 rs2624108 chr8 3556145 C T 6.45E-04 Multiple complex diseases CSMD1 intron 17554300 rs17326642 chr8 3563251 C A 8.40E-04 Type 2 diabetes CSMD1 intron 17463246 rs17067079 chr8 3564181 A T 9.79E-06 Substance dependence CSMD1 intron 21818250 rs6981596 chr8 3566615 T G 3.86E-05 Stroke CSMD1 intron pha002886 rs2623570 chr8 3572810 G T 1.29E-04 Stroke CSMD1 intron pha002886 rs2623746 chr8 3586061 G T 6.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CSMD1 intron 20877124 rs17067182 chr8 3586818 G A 3.95E-07 Schizophrenia CSMD1 intron 21926974 rs2623702 chr8 3594906 T C 9.00E-06 Pulmonary function decline CSMD1 intron 22424883 rs17067303 chr8 3600055 A G 8.58E-04 Multiple complex diseases CSMD1 intron 17554300 rs13264640 chr8 3612816 G C 4.74E-05 Atopic dermatitis CSMD1 intron 23042114 rs7825008 chr8 3616875 T C 6.75E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CSMD1 intron 21844884 rs1994056 chr8 3623014 C A 5.17E-05 Atopic dermatitis CSMD1 intron 23042114 rs12678875 chr8 3624046 C T 5.16E-05 Alcohol consumption CSMD1 intron 23953852 rs62479698 chr8 3625407 G A 3.36E-05 Atopic dermatitis CSMD1 intron 23042114 rs2623659 chr8 3636371 T C 3.97E-04 Schizophrenia CSMD1 intron 20832056 rs7836369 chr8 3636817 T C 2.11E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers CSMD1 intron 21775533 rs41460646 chr8 3641333 G C 4.70E-07 Urinary metabolites CSMD1 intron 21572414 rs7010872 chr8 3642919 T C 1.84E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers CSMD1 intron 21775533 rs1383951 chr8 3643255 C T 7.80E-04 Alcohol dependence CSMD1 intron 20201924 rs1383953 chr8 3643559 C T 5.66E-06 Carotenoid and tocopherol levels CSMD1 intron 19185284 rs11774223 chr8 3666582 C T 9.50E-04 Nicotine dependence CSMD1 intron 17407593 rs900090 chr8 3666844 G A 7.38E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs2720887 chr8 3668651 A G 1.07E-05 Prion diseases CSMD1 intron 22210626 rs2954201 chr8 3671549 A G 2.90E-05 Prion diseases CSMD1 intron 22210626 rs17063168 chr8 3677594 G A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CSMD1 intron 22628534 rs7007032 chr8 3679446 C T 3.78E-08 Psoriasis CSMD1 intron 20953187 rs7007032 chr8 3679446 C T 5.10E-08 Psoriasis CSMD1 intron 20953187 rs7830364 chr8 3682023 A G 1.10E-04 Alcohol dependence CSMD1 intron 21314694 rs10088247 chr8 3684199 C T 4.54E-09 Psoriasis CSMD1 intron 20953187 rs10088247 chr8 3684199 C T 8.60E-09 Psoriasis CSMD1 intron 20953187 rs9650512 chr8 3688710 G C 4.20E-04 Multiple complex diseases CSMD1 intron 17554300 rs10216665 chr8 3695148 A G 3.20E-05 Psoriasis CSMD1 intron 19169255 rs2954219 chr8 3706150 G T 8.19E-04 Multiple complex diseases CSMD1 intron 17554300 rs2930357 chr8 3709660 T C 2.08E-05 Nicotine smoking CSMD1 intron 19268276 rs2975357 chr8 3731867 G C 7.22E-04 Multiple complex diseases CSMD1 intron 17554300 rs2930345 chr8 3734727 G C 3.90E-06 Parasitemia in Tripanosoma cruzi seropositivity CSMD1 intron 24324551 rs17067840 chr8 3736282 G C 3.25E-06 Parasitemia in Tripanosoma cruzi seropositivity CSMD1 intron 24324551 rs10089350 chr8 3736934 C G 7.52E-04 Multiple complex diseases CSMD1 intron 17554300 rs10090300 chr8 3739619 T C 4.57E-06 Parasitemia in Tripanosoma cruzi seropositivity CSMD1 intron 24324551 rs10113221 chr8 3743704 T G 2.00E-06 Parasitemia in Tripanosoma cruzi seropositivity CSMD1 intron 24324551 rs10092638 chr8 3758472 T C 5.12E-04 Insulin resistance CSMD1 intron 21901158 rs2688402 chr8 3763463 C T 8.39E-06 Parasitemia in Tripanosoma cruzi seropositivity CSMD1 intron 24324551 rs17067986 chr8 3777923 C T 6.84E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CSMD1 intron 20031582 rs2912263 chr8 3778212 G T 3.59E-05 Chronic obstructive pulmonary disease CSMD1 intron 19300482 rs2912263 chr8 3778212 G T 3.59E-05 Response to statin treatment (atorvastatin),change in cholesterol levels CSMD1 intron 20031582 rs2627395 chr8 3778852 C T 2.88E-04 Body mass index CSMD1 intron 17255346 rs2954616 chr8 3779128 C A 6.90E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CSMD1 intron 20031582 rs2954613 chr8 3780119 C A 3.57E-04 Body mass index CSMD1 intron 17255346 rs1834570 chr8 3787730 A G 1.48E-06 Orofacial clefts CSMD1 intron 22419666 rs11779222 chr8 3806925 C A 4.42E-05 Kawasaki disease CSMD1 intron 22081228 rs2740866 chr8 3807826 G A 0.00029 Salmonella-induced pyroptosis CSMD1 intron 22837397 rs756095 chr8 3808039 G A 4.65E-04 Coronary heart disease CSMD1 intron 21971053 rs2740860 chr8 3809788 A C 0.000552 Salmonella-induced pyroptosis CSMD1 intron 22837397 rs2740859 chr8 3810546 G A 2.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CSMD1 intron 20877124 rs17068216 chr8 3816368 G C 4.20E-05 Multiple complex diseases CSMD1 intron 17554300 rs2554506 chr8 3819083 C T 8.99E-05 Monocyte counts CSMD1 intron pha003089 rs11136688 chr8 3819123 A G 3.16E-05 Multiple complex diseases CSMD1 intron 17554300 rs2140340 chr8 3819578 G A 3.89E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CSMD1 intron 24023788 rs2627468 chr8 3825199 G A 9.98E-05 Lipoproteins CSMD1 intron pha003079 rs1529316 chr8 3828138 C T 2.00E-06 Multiple sclerosis CSMD1 intron 19010793 rs2688352 chr8 3828758 C A 3.93E-05 Serum alpha1-antitrypsin levels CSMD1 intron 23990791 rs940155 chr8 3848750 A G 4.22E-05 Major depressive disorder CSMD1 intron 21621269 rs940155 chr8 3848750 A G 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CSMD1 intron 22628534 rs2261759 chr8 3861116 C A,G,T 3.51E-04 Type 2 diabetes CSMD1 intron 17463246 rs2740950 chr8 3869214 A T 4.51E-04 Type 2 diabetes CSMD1 intron 17463246 rs2740947 chr8 3869858 T G 6.73E-04 Type 2 diabetes CSMD1 intron 17463246 rs4099546 chr8 3881975 C G 1.10E-05 Urinary metabolites CSMD1 intron 21572414 rs4379463 chr8 3896625 G A 1.88E-05 Cognitive test performance CSMD1 intron 20125193 rs10503226 chr8 3897678 A T 8.88E-04 Bipolar disorder CSMD1 intron 19259986 rs10503226 chr8 3897678 A T 1.37E-07 Statin-induced myopathy CSMD1 intron 21826682 rs10503227 chr8 3897724 G C 5.51E-04 Bipolar disorder CSMD1 intron 19259986 rs2912272 chr8 3898329 T G 2.50E-04 Addiction CSMD1 intron 17099884 rs2912272 chr8 3898329 T G 9.45E-04 Multiple complex diseases CSMD1 intron 17554300 rs10503228 chr8 3898433 A G 4.94E-04 Bipolar disorder CSMD1 intron 19259986 rs12680399 chr8 3899607 G A 2.32E-05 Cognitive test performance CSMD1 intron 20125193 rs6991934 chr8 3920296 C T 2.00E-04 Cognitive impairment induced by topiramate CSMD1 intron 22091778 rs1820437 chr8 3922696 A G 4.28E-05 Body Mass Index CSMD1 intron pha003015 rs2113669 chr8 3926858 T A,G 4.67E-05 Cognitive test performance CSMD1 intron 20125193 rs2552122 chr8 3928521 C A 9.00E-04 Dietary macronutrient intake CSMD1 intron 23636237 rs2554635 chr8 3936904 C G 4.38E-05 Major depressive disorder CSMD1 intron 22472876 rs1971078 chr8 3937595 A G 4.54E-05 Major depressive disorder CSMD1 intron 22472876 rs11783062 chr8 3947325 T G 4.18E-06 Alcohol dependence CSMD1 intron 23089632 rs13340565 chr8 3952388 G A 2.65E-04 Response to taxane treatment (placlitaxel) CSMD1 intron 23006423 rs13340606 chr8 3952623 A C 8.11E-04 Response to taxane treatment (placlitaxel) CSMD1 intron 23006423 rs13340578 chr8 3952966 C A,G,T 2.37E-04 Response to taxane treatment (placlitaxel) CSMD1 intron 23006423 rs918917 chr8 3955025 A C 2.22E-04 Response to taxane treatment (placlitaxel) CSMD1 intron 23006423 rs17068975 chr8 3957182 G C 2.66E-04 Response to taxane treatment (placlitaxel) CSMD1 intron 23006423 rs17068984 chr8 3957949 A G 7.91E-04 Alzheimer's disease CSMD1 intron 22005930 rs17332560 chr8 3959728 T C 3.80E-04 Multiple complex diseases CSMD1 intron 17554300 rs17404489 chr8 3961279 T G 0.000675 Salmonella-induced pyroptosis CSMD1 intron 22837397 rs17404503 chr8 3961579 G C 2.22E-04 Alzheimer's disease CSMD1 intron 17998437 rs11780970 chr8 3961865 G A 3.30E-04 Multiple complex diseases CSMD1 intron 17554300 rs17069009 chr8 3961881 C G 1.40E-05 Urinary metabolites CSMD1 intron 21572414 rs4606080 chr8 3965999 T C 6.72E-04 Multiple complex diseases CSMD1 intron 17554300 rs7013621 chr8 3969595 G C 3.03E-04 Alzheimer's disease CSMD1 intron 22005930 rs17404627 chr8 3969602 A G 1.54E-04 Response to taxane treatment (placlitaxel) CSMD1 intron 23006423 rs4875284 chr8 3978130 A T 3.00E-06 Serum selenium levels CSMD1 intron 23698163 rs1991139 chr8 3978488 C A 4.98E-04 Response to taxane treatment (placlitaxel) CSMD1 intron 23006423 rs766045 chr8 3980978 T C 1.03E-04 Response to taxane treatment (placlitaxel) CSMD1 intron 23006423 rs2680611 chr8 3984909 A G 1.65E-04 Response to taxane treatment (placlitaxel) CSMD1 intron 23006423 rs17069064 chr8 3985885 T C 5.55E-04 Insulin resistance CSMD1 intron 21901158 rs3849825 chr8 4008816 T G 8.27E-04 Myopia (pathological) CSMD1 intron 21095009 rs3849825 chr8 4008816 T G 9.79E-05 Sodium levels CSMD1 intron pha003093 rs3843922 chr8 4013272 T A 3.90E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CSMD1 intron 21844884 rs17069157 chr8 4013928 A G 7.82E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CSMD1 intron 21844884 rs4395908 chr8 4025644 C G 1.00E-06 Response to methotrexate in juvenile idiopathic arthritis CSMD1 intron 24709693 rs10503238 chr8 4040057 A G 4.40E-05 Volumetric brain MRI CSMD1 intron 17903297 rs10503238 chr8 4040057 A G 5.90E-05 Hemoglobin CSMD1 intron pha003096 rs1625309 chr8 4040458 G A 3.75E-04 Response to taxane treatment (placlitaxel) CSMD1 intron 23006423 rs17405426 chr8 4040963 A C 1.80E-05 Urinary metabolites CSMD1 intron 21572414 rs4875302 chr8 4041477 A C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CSMD1 intron 22628534 rs4875303 chr8 4041575 A G 3.00E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs4875303 chr8 4041575 A G 8.00E-04 Alzheimer's disease CSMD1 intron 22005930 rs7018112 chr8 4042746 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CSMD1 intron 22628534 rs17069257 chr8 4043515 T C 3.60E-05 Smoking behavior CSMD1 intron 20418888 rs17069257 chr8 4043515 T C 3.00E-04 Cognitive impairment induced by topiramate CSMD1 intron 22091778 rs17069257 chr8 4043515 T C 2.91E-05 Hemoglobin CSMD1 intron pha003096 rs17069257 chr8 4043515 T C 7.11E-05 Hematocrit CSMD1 intron pha003097 rs7015381 chr8 4045300 T C 2.40E-05 Urinary metabolites CSMD1 intron 21572414 rs779130 chr8 4049374 A G 2.77E-04 Response to taxane treatment (placlitaxel) CSMD1 intron 23006423 rs17069312 chr8 4049955 T C 7.31E-04 Multiple complex diseases CSMD1 intron 17554300 rs968370 chr8 4053047 G C 5.75E-04 Type 2 diabetes CSMD1 intron 17463246 rs7013270 chr8 4055776 A G 3.10E-06 Urinary metabolites CSMD1 intron 21572414 rs11989184 chr8 4056083 A C 6.33E-04 Alzheimer's disease CSMD1 intron 22005930 rs17069371 chr8 4056592 G C 5.69E-04 Alzheimer's disease CSMD1 intron 22005930 rs17069379 chr8 4057395 A G,T 6.81E-04 Alzheimer's disease CSMD1 intron 22005930 rs17069382 chr8 4057686 G C 2.66E-04 Alzheimer's disease CSMD1 intron 22005930 rs4875308 chr8 4060604 G A 9.39E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) CSMD1 intron 23648065 rs1519167 chr8 4067803 T G 6.51E-04 Response to taxane treatment (placlitaxel) CSMD1 intron 23006423 rs3849840 chr8 4070495 C A,T 1.85E-04 Response to taxane treatment (placlitaxel) CSMD1 intron 23006423 rs3849840 chr8 4070495 C A,T 2.27E-04 Alcohol dependence CSMD1 intron 24277619 rs13249547 chr8 4071104 C T 1.68E-04 IgE levels CSMD1 intron 17255346 rs890000 chr8 4071438 C G 8.46E-04 Response to taxane treatment (placlitaxel) CSMD1 intron 23006423 rs2407312 chr8 4073225 T G 3.16E-05 Height CSMD1 intron pha003011 rs1401483 chr8 4074533 G T 8.56E-05 Body Fat Distribution CSMD1 intron pha003017 rs3849843 chr8 4076049 A G 4.87E-05 Diabetes Mellitus CSMD1 intron pha003060 rs12674947 chr8 4076758 A G 7.12E-04 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs3843924 chr8 4078053 T C 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) CSMD1 intron 17982456 rs2407314 chr8 4078353 G C 8.00E-06 Insulin resistance CSMD1 intron 21901158 rs1714821 chr8 4084879 T C 2.09E-05 Insulin resistance CSMD1 intron 21901158 rs1700055 chr8 4084970 G T 8.02E-04 Body mass index CSMD1 intron 21701565 rs1700055 chr8 4084970 G T 2.67E-06 Insulin resistance CSMD1 intron 21901158 rs1625889 chr8 4085763 T A 7.04E-04 Body mass index CSMD1 intron 21701565 rs1625889 chr8 4085763 T A 7.59E-04 Body mass index CSMD1 intron 21701565 rs17069640 chr8 4087686 T G 5.54E-04 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs1700049 chr8 4088818 T C 8.49E-04 Insulin resistance CSMD1 intron 21901158 rs11992222 chr8 4089116 A G 4.80E-04 Body mass index CSMD1 intron 21701565 rs11992222 chr8 4089116 A G 8.78E-04 Body mass index CSMD1 intron 21701565 rs11993028 chr8 4089238 T A 5.56E-04 Body mass index CSMD1 intron 21701565 rs17069667 chr8 4092133 T C 3.33E-06 Cognitive decline CSMD1 intron 23732972 rs7819694 chr8 4092879 T C 1.30E-04 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs1714685 chr8 4093419 T C 7.99E-04 Multiple complex diseases CSMD1 intron 17554300 rs17069674 chr8 4094027 T C 5.69E-05 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs17069679 chr8 4094253 G A 2.74E-05 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs13270159 chr8 4096223 C T 8.59E-05 Height CSMD1 intron pha003011 rs17069682 chr8 4096574 C A 1.48E-05 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs17069688 chr8 4096979 G C 1.39E-05 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs1504771 chr8 4100151 A T 1 Drug response to Etoposide CSMD1 intron 17537913 rs1504769 chr8 4101948 C T 3.28E-05 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs7838274 chr8 4102471 A T 2.98E-05 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs4875310 chr8 4103130 G A 3.20E-05 Bipolar disorder CSMD1 intron 18317468 rs1714746 chr8 4105147 G A 7.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) CSMD1 intron 23648065 rs6998882 chr8 4108050 A C 1.93E-05 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs971555 chr8 4108330 A G 1.93E-05 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs6984808 chr8 4109163 C T 7.45E-04 Amyotrophic Lateral Sclerosis CSMD1 intron 17362836 rs6984808 chr8 4109163 C T 5.76E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CSMD1 intron 20877124 rs6984808 chr8 4109163 C T 7.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CSMD1 intron 20877124 rs2407941 chr8 4109900 T C 2.92E-05 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs13259289 chr8 4110032 T C 2.20E-04 Alcohol consumption CSMD1 intron 23942779 rs13259289 chr8 4110032 T C 5.30E-04 Alcohol dependence CSMD1 intron 23942779 rs13259289 chr8 4110032 T C 6.00E-06 Illicit drug use CSMD1 intron 23942779 rs13259289 chr8 4110032 T C 6.40E-05 Non-substance related behavioral disinhibition CSMD1 intron 23942779 rs17069762 chr8 4113044 G C 7.26E-04 Smoking initiation CSMD1 intron 24665060 rs12675002 chr8 4114274 G A 5.40E-05 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs17069769 chr8 4117636 C G 0.0007138 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CSMD1 intron 23233654 rs17069769 chr8 4117636 C G 7.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) CSMD1 intron 23233662 rs779107 chr8 4119076 C A 9.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) CSMD1 intron 23233662 rs1504761 chr8 4119374 T C 6.59E-04 Smoking initiation CSMD1 intron 24665060 rs1394485 chr8 4120154 C T 2.70E-04 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs17069778 chr8 4121520 A T 3.11E-04 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs17069782 chr8 4121989 A G 1.34E-05 Bipolar disorder and schizophrenia CSMD1 intron 20889312 rs9693235 chr8 4122003 G A 2.09E-04 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs17069790 chr8 4125100 G A 3.97E-04 Suicide attempts in bipolar disorder CSMD1 intron 21041247 rs6999771 chr8 4125505 A G 0.0005619 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CSMD1 intron 23233654 rs6999771 chr8 4125505 A G 5.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) CSMD1 intron 23233662 rs10503246 chr8 4130363 A G 2.31E-04 Coronary Artery Disease CSMD1 intron 17634449 rs809649 chr8 4130968 T C 2.40E-09 Multiple complex diseases CSMD1 intron 17554300 rs2407940 chr8 4134874 C T 3.05E-05 Lipoproteins CSMD1 intron pha003079 rs10503248 chr8 4136571 C T 3.42E-04 Tourette syndrome CSMD1 intron 22889924 rs2656288 chr8 4138427 G A 8.30E-05 Coronary Artery Disease CSMD1 intron 17634449 rs2656288 chr8 4138427 G A 3.39E-05 Serum metabolites CSMD1 intron 19043545 rs4304342 chr8 4138886 T C 0.0008867 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CSMD1 intron 23233654 rs4304342 chr8 4138886 T C 8.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) CSMD1 intron 23233662 rs17413239 chr8 4143688 A G 1.67E-05 Lipoproteins CSMD1 intron pha003079 rs17413343 chr8 4155860 G A 7.53E-04 Type 2 diabetes CSMD1 intron 17463246 rs17413343 chr8 4155860 G A 2.87E-05 Lung function (forced vital capacity) CSMD1 intron 24023788 rs17413343 chr8 4155860 G A 7.70E-05 Lung function (forced expiratory volume in 1 second) CSMD1 intron 24023788 rs9314521 chr8 4157782 G A 9.10E-04 Alzheimer's disease CSMD1 intron 22005930 rs10866965 chr8 4158919 G T 7.41E-04 Amyotrophic Lateral Sclerosis CSMD1 intron 17362836 rs4875320 chr8 4164013 A T 6.00E-06 Coronary heart disease CSMD1 intron 21347282 rs13258014 chr8 4165460 C T 4.85E-05 Telomere length CSMD1 intron 20139977 rs6984591 chr8 4166781 C A 1.72E-04 Glycosylated haemoglobin levels CSMD1 intron 17255346 rs4875322 chr8 4167608 T G 2.15E-04 Glycosylated haemoglobin levels CSMD1 intron 17255346 rs10099850 chr8 4179486 T C 6.03E-07 Post-operative nausea and vomiting CSMD1 intron 21694509 rs10100098 chr8 4179859 A G 1.49E-04 Type 2 diabetes CSMD1 intron 17463246 rs10503253 chr8 4180844 C A 2.00E-08 Schizophrenia CSMD1 intron 21926974 rs10503253 chr8 4180844 C A 4.00E-08 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) CSMD1 intron 23453885 rs1504752 chr8 4181634 A G 1.47E-04 Type 2 diabetes CSMD1 intron 17463246 rs1394474 chr8 4183209 G T 1.83E-04 Type 2 diabetes CSMD1 intron 17463246 rs11776532 chr8 4188239 C A 4.02E-05 Cognitive test performance CSMD1 intron 20125193 rs10108270 chr8 4190793 C A 8.02E-05 Serum metabolites CSMD1 intron 19043545 rs13267437 chr8 4196066 A G 9.50E-06 Asthma CSMD1 intron 20698975 rs13267437 chr8 4196066 A G 1.00E-04 Information processing speed CSMD1 intron 21130836 rs6558867 chr8 4201343 A G 2.40E-05 Urinary metabolites CSMD1 intron 21572414 rs12681147 chr8 4202281 C T 7.86E-05 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs12676910 chr8 4202441 G C 7.45E-05 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs3990909 chr8 4213293 A G 6.69E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs10503256 chr8 4214179 A G 3.74E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs10503256 chr8 4214179 A G 1.97E-07 Schizophrenia CSMD1 intron 21926974 rs10503256 chr8 4214179 A G 9.00E-07 Schizophrenia CSMD1 intron 22688191 rs10092429 chr8 4215270 G A,C,T 0.000276513 Hypertension (early onset hypertension) CSMD1 intron 22479346 rs10100309 chr8 4217133 G T 0.0004324 Hypertension (early onset hypertension) CSMD1 intron 22479346 rs10101532 chr8 4217464 C A 2.79E-04 Alzheimer's disease CSMD1 intron 17998437 rs10101622 chr8 4217497 C G 1.10E-05 Urinary metabolites CSMD1 intron 21572414 rs7833644 chr8 4219533 A G 2.60E-05 Urinary metabolites CSMD1 intron 21572414 rs10216514 chr8 4221884 C T 0.000321892 Hypertension (early onset hypertension) CSMD1 intron 22479346 rs1583651 chr8 4226590 T C 9.05E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs11993860 chr8 4228083 G T 3.29E-04 Type 2 diabetes CSMD1 intron 17463246 rs11993860 chr8 4228083 G T 4.69E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs6558872 chr8 4238139 G A 5.00E-08 Schizophrenia,schizoaffective disorder or bipolar disorder CSMD1 intron 24166486 rs12542717 chr8 4245779 G C 8.26E-04 Acute lung injury CSMD1 intron 22295056 rs10089026 chr8 4265397 A G 3.49E-05 Cognitive test performance CSMD1 intron 20125193 rs13264886 chr8 4266162 A G 6.64E-04 Response to taxane treatment (placlitaxel) CSMD1 intron 23006423 rs1228293 chr8 4276452 A G 4.97E-05 Triglycerides CSMD1 intron pha003081 rs1217535 chr8 4277876 T A 4.62E-04 Multiple complex diseases CSMD1 intron 17554300 rs980238 chr8 4282618 C A 3.80E-04 Type 2 diabetes and 6 quantitative traits CSMD1 intron 17848626 rs980238 chr8 4282618 C A 9.00E-06 Disc degeneration (lumbar) CSMD1 intron 22993228 rs980238 chr8 4282618 C A 0.0007306 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CSMD1 intron 23233654 rs980238 chr8 4282618 C A 7.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) CSMD1 intron 23233662 rs980238 chr8 4282618 C A 7.31E-04 Response to antipsychotic treatment CSMD1 intron 23241943 rs4875102 chr8 4284692 G A 4.00E-07 Disc degeneration (lumbar) CSMD1 intron 22993228 rs1154053 chr8 4285390 G C 4.00E-06 Disc degeneration (lumbar) CSMD1 intron 22993228 rs7015706 chr8 4287134 A G 5.65E-04 Schizophrenia CSMD1 intron 19197363 rs7000593 chr8 4287576 C T 2.38E-04 Smoking initiation CSMD1 intron 24665060 rs17070309 chr8 4299883 G A 1.00E-04 Cognitive impairment induced by topiramate CSMD1 intron 22091778 rs17070309 chr8 4299883 G A 5.00E-07 Immune response to smallpox vaccine (IL-6) CSMD1 intron 22542470 rs17336607 chr8 4302217 G A 4.28E-05 Triglycerides CSMD1 intron pha003080 rs7813376 chr8 4309952 T C 9.06E-04 Acute lung injury CSMD1 intron 22295056 rs11136744 chr8 4310404 C G 7.16E-04 Acute lung injury CSMD1 intron 22295056 rs1526337 chr8 4336502 A T 0.0008196 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CSMD1 intron 23233654 rs1526337 chr8 4336502 A T 8.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) CSMD1 intron 23233662 rs1725122 chr8 4339207 G A 3.46E-05 Body Fat Distribution CSMD1 intron pha003016 rs1725122 chr8 4339207 G A 9.16E-05 Body Fat Distribution CSMD1 intron pha003017 rs10106998 chr8 4339509 T C 2.20E-05 Body Fat Distribution CSMD1 intron pha003016 rs10106998 chr8 4339509 T C 8.99E-05 Weight CSMD1 intron pha003026 rs1725111 chr8 4341641 G A 7.17E-05 Schizophrenia CSMD1 intron 19197363 rs1626142 chr8 4345284 G A 1.10E-05 Urinary metabolites CSMD1 intron 21572414 rs1725130 chr8 4352157 C T 2.62E-05 Cognitive test performance CSMD1 intron 20125193 rs4609213 chr8 4369334 A G 7.06E-04 Bipolar disorder,schizoaffective CSMD1 intron 19567891 rs4875356 chr8 4383871 C G 1.12E-05 Odorant perception CSMD1 intron 23910658 rs11994887 chr8 4391719 T C 7.24E-06 Odorant perception CSMD1 intron 23910658 rs17344058 chr8 4393969 G A 2.50E-05 Urinary metabolites CSMD1 intron 21572414 rs17070552 chr8 4398557 G A 9.43E-04 Suicide attempts in bipolar disorder CSMD1 intron 21423239 rs17416046 chr8 4399587 C T 4.12E-05 Heart Rate CSMD1 intron pha003054 rs11786902 chr8 4401124 A G 1.34E-04 Alzheimer's disease CSMD1 intron 21059989 rs11786902 chr8 4401124 A G 8.67E-06 Alzheimer's disease CSMD1 intron 21059989 rs17070576 chr8 4402031 T C 8.28E-05 Heart Rate CSMD1 intron pha003053 rs17344217 chr8 4404738 T G 1.44E-04 Disc degeneration (lumbar) CSMD1 intron 24216480 rs6558891 chr8 4410752 G C 5.80E-06 Urinary metabolites CSMD1 intron 21572414 rs6992457 chr8 4413282 A C 3.40E-04 Amyotrophic Lateral Sclerosis CSMD1 intron 17362836 rs2725059 chr8 4433716 T G 6.40E-05 Parkinson's disease (age of onset) CSMD1 intron 19772629 rs2724989 chr8 4445573 G T 3.91E-04 Response to cytidine analogues (gemcitabine) CSMD1 intron 24483146 rs2617078 chr8 4445944 T G 6.39E-05 Height CSMD1 intron pha003011 rs2617080 chr8 4446598 A G 4.40E-05 Iron levels CSMD1 intron 21208937 rs2617084 chr8 4447768 A C 5.30E-05 Height CSMD1 intron pha003010 rs2617084 chr8 4447768 A C 4.56E-05 Height CSMD1 intron pha003011 rs2724985 chr8 4448387 A G 8.20E-07 Urinary metabolites CSMD1 intron 21572414 rs2724982 chr8 4449647 C G 2.80E-05 Urinary metabolites CSMD1 intron 21572414 rs1382249 chr8 4458212 G A 8.90E-05 Lung adenocarcinoma CSMD1 intron 19836008 rs2725045 chr8 4467334 G T 4.45E-05 Schizophrenia CSMD1 intron 19571809 rs2725045 chr8 4467334 G T 2.00E-04 Major depressive disorder CSMD1 intron 21042317 rs2617104 chr8 4467788 G C 9.15E-05 Glaucoma (primary open-angle) CSMD1 intron 22605921 rs2725046 chr8 4467853 A G 3.88E-05 Schizophrenia CSMD1 intron 19571809 rs2725046 chr8 4467853 A G 9.30E-05 Major depressive disorder CSMD1 intron 21042317 rs1564179 chr8 4469330 G A 7.56E-05 Major depressive disorder (broad) CSMD1 intron 20038947 rs1564179 chr8 4469330 G A 7.70E-05 Major depressive disorder CSMD1 intron 21042317 rs2725041 chr8 4470821 A G 8.54E-04 Alzheimer's disease CSMD1 intron 22005930 rs2725039 chr8 4471292 G C 8.22E-04 Alzheimer's disease CSMD1 intron 22005930 rs17070808 chr8 4471581 T C 3.88E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CSMD1 intron 22566498 rs17417078 chr8 4473133 T C 0.0000529 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CSMD1 intron 23233654 rs17417078 chr8 4473133 T C 5.29E-05 Methotrexate clearance (acute lymphoblastic leukemia) CSMD1 intron 23233662 rs2616982 chr8 4480689 G A 1.60E-04 Prion diseases CSMD1 intron 22210626 rs17417225 chr8 4481743 C A 2.69E-05 Cognitive test performance CSMD1 intron 20125193 rs2616984 chr8 4483141 A G 4.00E-06 Cognitive performance CSMD1 intron 20125193 rs10104818 chr8 4484498 G A 1.97E-05 Cognitive test performance CSMD1 intron 20125193 rs10094093 chr8 4505914 C T 6.48E-04 Alzheimer's disease CSMD1 intron 17998437 rs10094093 chr8 4505914 C T 2.18E-04 Alzheimer's disease CSMD1 intron 22005930 rs10102231 chr8 4508159 C T 3.05E-04 Alzheimer's disease CSMD1 intron 22005930 rs7465218 chr8 4508910 C G 4.15E-04 Alzheimer's disease CSMD1 intron 22005930 rs12543670 chr8 4511452 A G 1.09E-04 Alzheimer's disease CSMD1 intron 22005930 rs2617014 chr8 4550458 A G 5.51E-06 Melanoma CSMD1 intron 21926416 rs2724961 chr8 4560227 T C 5.98E-04 Insulin resistance CSMD1 intron 21901158 rs2724961 chr8 4560227 T C 1.07E-05 Melanoma CSMD1 intron 21926416 rs2617055 chr8 4561224 A T 8.34E-04 Multiple complex diseases CSMD1 intron 17554300 rs2617055 chr8 4561224 A T 7.37E-04 Insulin resistance CSMD1 intron 21901158 rs10094500 chr8 4571273 C A 7.68E-06 Melanoma CSMD1 intron 21926416 rs1676976 chr8 4578479 G C 7.50E-06 Urinary metabolites CSMD1 intron 21572414 rs293881 chr8 4587592 A G 4.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CSMD1 intron 20877124 rs293881 chr8 4587592 A G 2.10E-05 Cognitive impairment induced by topiramate CSMD1 intron 22091778 rs293884 chr8 4589168 G A 2.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CSMD1 intron 20877124 rs293884 chr8 4589168 G A 6.40E-05 Cognitive impairment induced by topiramate CSMD1 intron 22091778 rs293888 chr8 4589698 C T 4.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CSMD1 intron 20877124 rs293888 chr8 4589698 C T 2.46E-05 Cognitive impairment induced by topiramate CSMD1 intron 22091778 rs1478263 chr8 4595668 A C 1.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CSMD1 intron 20877124 rs7826378 chr8 4595814 T G 1.42E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CSMD1 intron 20877124 rs7826378 chr8 4595814 T G 1.00E-04 Cognitive impairment induced by topiramate CSMD1 intron 22091778 rs10503274 chr8 4605810 C T 3.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CSMD1 intron 20877124 rs7827261 chr8 4606082 G A 3.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CSMD1 intron 20877124 rs1673257 chr8 4606609 C T 4.18E-04 Lung function (forced vital capacity) CSMD1 intron 24023788 rs7831951 chr8 4606955 G A 4.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CSMD1 intron 20877124 rs12541886 chr8 4609232 A G 4.31E-05 Hearing function CSMD1 intron 17255346 rs2407592 chr8 4610345 A G 2.38E-05 Hearing function CSMD1 intron 17255346 rs17418933 chr8 4611071 C A 8.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CSMD1 intron 20877124 rs12546236 chr8 4614665 C T 4.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CSMD1 intron 20877124 rs1379326 chr8 4617810 T C 1.30E-05 Urinary metabolites CSMD1 intron 21572414 rs1379326 chr8 4617810 T C 1.00E-07 Interstitial lung disease CSMD1 intron 23583980 rs1379326 chr8 4617810 T C 5.74E-09 Interstitial lung disease CSMD1 intron 23583980 rs17080168 chr8 4622661 C T 9.80E-06 Urinary metabolites CSMD1 intron 21572414 rs7830263 chr8 4624230 C G 4.15E-04 Sudden cardiac arrest CSMD1 intron 21658281 rs10091902 chr8 4631106 T C 7.32E-05 Tunica Media CSMD1 intron pha003038 rs6986423 chr8 4634415 G T 1.27E-05 Behcet's disease CSMD1 intron pha002888 rs6991415 chr8 4634442 C G 7.38E-04 Multiple complex diseases CSMD1 intron 17554300 rs6991428 chr8 4634475 C T 9.66E-05 Tunica Media CSMD1 intron pha003038 rs10503282 chr8 4638706 A G 3.10E-04 Crohn's disease CSMD1 intron 17684544 rs10081503 chr8 4639285 A G 8.01E-06 Tunica Media CSMD1 intron pha003038 rs1457184 chr8 4641590 G A 1.81E-04 Alzheimer's disease (late onset) CSMD1 intron 21379329 rs9644372 chr8 4658410 T G 5.96E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs9644374 chr8 4658686 A G 5.96E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs12677863 chr8 4659322 A C 5.96E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs12678251 chr8 4659380 T C 5.96E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs12680174 chr8 4659628 G A 5.96E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs17071407 chr8 4660114 T C 5.96E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs17071408 chr8 4660204 C T 2.22E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs17071413 chr8 4660963 G A 5.96E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs17071414 chr8 4661534 T C 5.96E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs17071420 chr8 4661660 A G 5.96E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs2118574 chr8 4663010 A C 5.96E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs2164907 chr8 4663201 C A 5.96E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs17071435 chr8 4664285 T G 1.12E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs17071459 chr8 4666654 C T 9.44E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs17071462 chr8 4666701 T C 9.44E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs7843673 chr8 4667365 C A 3.21E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs17071481 chr8 4668871 T G 1.12E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs1561357 chr8 4670279 C T 1.63E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs17071510 chr8 4671348 G A,T 4.69E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs17071555 chr8 4675997 A C 3.89E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs17071569 chr8 4676416 T G 1.40E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs17071569 chr8 4676416 T G 3.32E-05 F-cell distribution CSMD1 intron 21326311 rs10113508 chr8 4677622 A G 1.65E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs17071583 chr8 4677972 A C 2.54E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs12674959 chr8 4678344 T C 1.63E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs10156221 chr8 4681869 G T 6.47E-04 HIV-1 viral setpoint CSMD1 intron 17641165 rs11774281 chr8 4682750 T G 1.13E-05 Inflammation CSMD1 intron pha002897 rs1992205 chr8 4684203 A C 2.19E-04 Response to taxane treatment (placlitaxel) CSMD1 intron 23006423 rs9657403 chr8 4688296 C A 2.46E-04 Lung function (forced vital capacity) CSMD1 intron 24023788 rs12156083 chr8 4700898 C T 1.38E-05 HDL cholesterol CSMD1 intron pha003075 rs13271752 chr8 4701631 G C 2.00E-05 Urinary metabolites CSMD1 intron 21572414 rs7840299 chr8 4701881 G C 1.30E-06 Urinary metabolites CSMD1 intron 21572414 rs4875398 chr8 4705811 C T 8.40E-09 Urinary metabolites CSMD1 intron 21572414 rs2407668 chr8 4710428 G A 2.60E-05 Urinary metabolites CSMD1 intron 21572414 rs1031612 chr8 4728688 A G 2.78E-04 Hearing function CSMD1 intron 17255346 rs6990325 chr8 4742724 T C 9.92E-05 Triglycerides CSMD1 intron pha003081 rs6990325 chr8 4742724 T C 7.52E-05 Lipid levels CSMD1 intron pha003082 rs6986644 chr8 4742921 A C 0.000607998 Hypertension (early onset hypertension) CSMD1 intron 22479346 rs6986644 chr8 4742921 A C 9.14E-05 Vitiligo CSMD1 intron 22951725 rs13266795 chr8 4746885 G A 0.000649058 Hypertension (early onset hypertension) CSMD1 intron 22479346 rs4607643 chr8 4779452 G A 2.29E-04 Alzheimer's disease (late onset) CSMD1 intron 21379329 rs4620305 chr8 4797831 A T 8.61E-04 Alzheimer's disease CSMD1 intron 17998437 rs12056859 chr8 4800589 T C 9.11E-04 Multiple complex diseases CSMD1 intron 17554300 rs12675859 chr8 4809932 T C 0.00000562 Composite episodic memory score CSMD1 intron 22865056 rs11136809 chr8 4811915 T C 1.20E-05 Urinary metabolites CSMD1 intron 21572414 rs7815832 chr8 4812436 A C 2.40E-05 Urinary metabolites CSMD1 intron 21572414 rs10503295 chr8 4815873 A G 8.99E-05 Serum albumin level CSMD1 intron pha003084 rs10503296 chr8 4816030 A G 2.71E-06 Triglycerides CSMD1 intron 19074352 rs10503296 chr8 4816030 A G 2.71E-06 Polyunsaturated fatty acid levels,in plasma CSMD1 intron 19148276 rs6982358 chr8 4816363 C T 5.90E-05 Orofacial clefts CSMD1 intron 22419666 rs6982358 chr8 4816363 C T 8.72E-05 Serum albumin level CSMD1 intron pha003084 rs11996295 chr8 4816492 A C 1.21E-05 Orofacial clefts CSMD1 intron 22419666 rs11996295 chr8 4816492 A C 4.76E-04 Lung function (forced vital capacity) CSMD1 intron 24023788 rs12155630 chr8 4817188 G C 6.31E-04 Multiple complex diseases CSMD1 intron 17554300 rs12542818 chr8 4817813 G T 4.88E-05 Serum albumin level CSMD1 intron pha003084 rs17348805 chr8 4822770 C G 6.39E-04 Multiple complex diseases CSMD1 intron 17554300 rs17348805 chr8 4822770 C G 1.30E-05 Urinary metabolites CSMD1 intron 21572414 rs7823766 chr8 4826467 A G 8.31E-05 Serum albumin level CSMD1 intron pha003084 rs11988448 chr8 4827122 T A 1.80E-05 Urinary metabolites CSMD1 intron 21572414 rs4242497 chr8 4834787 G A 6.83E-04 Alzheimer's disease CSMD1 intron 17998437 rs3886808 chr8 4852925 T C 4.66E-04 Multiple complex diseases / / 17554300 rs13258018 chr8 4854637 A T 5.42E-04 Alzheimer's disease / / 17998437 rs7828112 chr8 4860637 A G 6.66E-04 Multiple complex diseases / / 17554300 rs17072025 chr8 4861787 T C 9.37E-04 Type 2 diabetes / / 17463246 rs10112481 chr8 4875172 G T 4.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) / / 24025145 rs11787515 chr8 4883613 A G 1.77E-04 Multiple complex diseases / / 17554300 rs17072101 chr8 4889651 A G 8.87E-05 Blood Pressure / / pha003043 rs10503289 chr8 4893071 C T 9.67E-05 Cognitive impairment induced by topiramate / / 22091778 rs17072141 chr8 4896351 G A 9.55E-04 Type 2 diabetes / / 17463246 rs41462944 chr8 4909122 T C 6.88E-04 Alzheimer's disease / / 17998437 rs7843140 chr8 4924197 A C 1.26E-06 Osteoarthritis (knee and hip) / / 21177295 rs7843140 chr8 4924197 A C 6.18E-05 Osteoarthritis (knee and hip) / / 21177295 rs17072203 chr8 4924940 G C 8.61E-04 Multiple complex diseases / / 17554300 rs1454292 chr8 4926465 C A,G,T 8.00E-06 Hair morphology / / 19896111 rs4875138 chr8 4930433 G A 5.60E-04 Multiple complex diseases / / 17554300 rs2407743 chr8 4936746 C T 8.87E-05 Orofacial clefts / / 22419666 rs11778281 chr8 4942910 C T 3.99E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11136823 chr8 4953341 G T 6.36E-04 Body mass index / / 21701565 rs11786333 chr8 4969414 G A,C 5.15E-05 Multiple sclerosis / / 20598377 rs6980727 chr8 4974195 C T 4.00E-04 Coronary heart disease / / 21606135 rs13279982 chr8 4975298 A G 2.95E-04 Multiple complex diseases / / 17554300 rs11778306 chr8 4988269 T G 9.56E-04 Multiple complex diseases / / 17554300 rs17435668 chr8 4990641 T C 2.97E-04 Type 2 diabetes / / 17463246 rs17351125 chr8 4992706 G C 6.16E-05 Type 2 diabetes / / 17463246 rs11774681 chr8 4993943 C T 9.88E-04 Type 2 diabetes / / 17463246 rs17351138 chr8 4994012 G C 5.29E-05 Type 2 diabetes / / 17463246 rs13252356 chr8 5000625 G A 4.68E-05 Type 2 diabetes / / 17463246 rs11786744 chr8 5002099 T G 7.50E-05 Coffee consumption / / 21357676 rs4495448 chr8 5013433 G A 2.45E-04 Type 2 diabetes / / 17463246 rs7818064 chr8 5013745 A G 2.49E-04 Type 2 diabetes / / 17463246 rs7014649 chr8 5015699 G C 5.94E-04 Type 2 diabetes / / 17463246 rs12056538 chr8 5071270 T C 2.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12056538 chr8 5071270 T C 5.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7816936 chr8 5071412 T C 6.00E-06 Endometriosis / / 23472165 rs4373539 chr8 5076309 C T 6.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4373539 chr8 5076309 C T 8.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4392924 chr8 5077252 T C 7.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11783485 chr8 5079254 G A 2.63E-04 Birth weight / / 17255346 rs12156380 chr8 5099914 C A 4.86E-06 Tuberculosis / / 22306650 rs10503298 chr8 5142325 T C 2.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1420838 chr8 5150113 C T 8.24E-05 Blood Pressure / / pha003048 rs13273557 chr8 5157922 G A 8.86E-04 Taste perception / / 22132133 rs17351786 chr8 5158004 G A 9.20E-05 Taste perception / / 22132133 rs4875501 chr8 5160591 G A 3.85E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7009701 chr8 5160626 C T 3.88E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6995656 chr8 5160847 T C 3.88E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7009066 chr8 5160984 G A 4.07E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs10780171 chr8 5161465 T C 4.08E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11136856 chr8 5161506 A G 4.09E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11136857 chr8 5161577 G A 4.09E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4875503 chr8 5161666 A G 4.11E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12678029 chr8 5163378 C A 9.85E-06 Multiple complex diseases / / 17554300 rs12678029 chr8 5163378 C A 4.60E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7013641 chr8 5165143 A C 6.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs17072969 chr8 5165199 C A 4.54E-04 Multiple complex diseases / / 17554300 rs17072969 chr8 5165199 C A 6.23E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6983919 chr8 5165467 T C 6.20E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs17073003 chr8 5179481 C T 9.41E-04 Acute lung injury / / 22295056 rs9657415 chr8 5180760 C G 9.41E-04 Acute lung injury / / 22295056 rs2160678 chr8 5183566 T C 7.48E-04 Acute lung injury / / 22295056 rs10282750 chr8 5194473 C G 1.29E-04 Acute lung injury / / 22295056 rs6559005 chr8 5209980 G A 7.95E-04 Obesity (extreme) / / 21935397 rs7819482 chr8 5211617 G A 7.00E-06 Urinary metabolites / / 21572414 rs2052335 chr8 5212268 T G 1.50E-05 Urinary metabolites / / 21572414 rs2052335 chr8 5212268 T G 8.07E-04 Acute lung injury / / 22295056 rs2052334 chr8 5212413 C G 8.10E-06 Urinary metabolites / / 21572414 rs1420825 chr8 5213080 C G 9.57E-05 Acute lung injury / / 22295056 rs10110892 chr8 5215640 C G 1.02E-04 Birth weight / / 17255346 rs10110892 chr8 5215640 C G 1.72E-04 Acute lung injury / / 22295056 rs17352626 chr8 5218250 C G 5.37E-04 Obesity (extreme) / / 21935397 rs17352626 chr8 5218250 C G 1.74E-04 Acute lung injury / / 22295056 rs17437164 chr8 5218878 G C 7.21E-05 Birth weight / / 17255346 rs17073184 chr8 5219508 A G 1.60E-05 Urinary metabolites / / 21572414 rs7817922 chr8 5220269 A C 5.47E-04 Obesity (extreme) / / 21935397 rs7817922 chr8 5220269 A C 1.03E-04 Acute lung injury / / 22295056 rs10089694 chr8 5221093 A C 7.09E-04 Obesity (extreme) / / 21935397 rs10089694 chr8 5221093 A C 7.12E-04 Acute lung injury / / 22295056 rs17352703 chr8 5222156 C A 5.62E-04 Obesity (extreme) / / 21935397 rs17352703 chr8 5222156 C A 9.09E-05 Acute lung injury / / 22295056 rs17352703 chr8 5222156 C A 3.14E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11136865 chr8 5224235 T C 5.22E-04 Obesity (extreme) / / 21935397 rs11136865 chr8 5224235 T C 1.98E-04 Acute lung injury / / 22295056 rs11780353 chr8 5224983 A G 5.15E-04 Obesity (extreme) / / 21935397 rs11780353 chr8 5224983 A G 2.00E-04 Acute lung injury / / 22295056 rs9644388 chr8 5225281 T C 5.13E-04 Obesity (extreme) / / 21935397 rs9644388 chr8 5225281 T C 3.01E-04 Acute lung injury / / 22295056 rs1420823 chr8 5225481 C T 7.09E-04 Obesity (extreme) / / 21935397 rs1420822 chr8 5225512 A G 5.05E-04 Obesity (extreme) / / 21935397 rs1420822 chr8 5225512 A G 3.14E-04 Acute lung injury / / 22295056 rs77265424 chr8 5227102 A G 4.00E-06 Metabolite levels (5-HIAA) / / 23319000 rs13272940 chr8 5227409 T C 1.70E-04 Acute lung injury / / 22295056 rs11785007 chr8 5228896 T C 2.19E-04 Acute lung injury / / 22295056 rs1405248 chr8 5229074 G A 9.33E-05 Multiple complex diseases / / 17554300 rs9314565 chr8 5230140 C T 3.64E-05 HIV(mother-to-child transmission) / / 20487506 rs9314565 chr8 5230140 C T 1.34E-04 Acute lung injury / / 22295056 rs1812623 chr8 5233675 G C 9.65E-04 Acute lung injury / / 22295056 rs4400407 chr8 5234173 G T 9.83E-04 Acute lung injury / / 22295056 rs1420818 chr8 5235666 A G 7.86E-04 Acute lung injury / / 22295056 rs13264497 chr8 5235928 C T 7.88E-04 Acute lung injury / / 22295056 rs12115167 chr8 5236659 T C 6.28E-04 Acute lung injury / / 22295056 rs12676390 chr8 5237620 G T 7.73E-04 Acute lung injury / / 22295056 rs7014774 chr8 5242938 A G 4.61E-04 Alzheimer's disease (late onset) / / 21379329 rs11778829 chr8 5244868 G A 4.84E-04 Acute lung injury / / 22295056 rs6992051 chr8 5245451 A C 2.71E-04 Alzheimer's disease (late onset) / / 21379329 rs12676661 chr8 5246298 T C 4.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs7842656 chr8 5249426 G A 5.28E-04 Taste perception / / 22132133 rs10102287 chr8 5251062 G A 8.87E-04 Taste perception / / 22132133 rs1358128 chr8 5268073 G C 9.87E-04 Alzheimer's disease / / 17998437 rs10503301 chr8 5275923 G A 1.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs7841853 chr8 5276592 T C 3.67E-06 Kawasaki disease / / 21221998 rs7841853 chr8 5276592 T C 2.55E-04 Taste perception / / 22132133 rs6559017 chr8 5277457 C T 4.78E-06 Kawasaki disease / / 21221998 rs1526355 chr8 5283604 G T 8.15E-04 Taste perception / / 22132133 rs1358129 chr8 5300742 C G 9.32E-04 Type 2 diabetes / / 17463246 rs12682256 chr8 5306139 C G 3.84E-04 Multiple complex diseases / / 17554300 rs4875174 chr8 5317452 G A 7.18E-04 Taste perception / / 22132133 rs6997581 chr8 5334160 T C 3.16E-10 Non-small cell lung cancer,hypertriglyceridemia with bexarotene treatment of / / 21737656 rs7010898 chr8 5334272 G T 8.82E-04 Taste perception / / 22132133 rs7819214 chr8 5336597 G A 3.44E-04 Type 2 diabetes / / 17463246 rs17073753 chr8 5340317 C G 3.27E-04 Multiple complex diseases / / 17554300 rs62494762 chr8 5373540 T C 2.00E-06 Metabolite levels (HVA/MHPG ratio) / / 23319000 rs17073854 chr8 5377735 C T 5.62E-05 Cholesterol / / pha003073 rs17073854 chr8 5377735 C T 2.92E-05 Cholesterol / / pha003078 rs7843051 chr8 5380180 C T 2.10E-05 Cholesterol / / pha003073 rs7843051 chr8 5380180 C T 9.28E-05 ldl cholesterol / / pha003076 rs7843051 chr8 5380180 C T 2.03E-05 Cholesterol / / pha003078 rs17073881 chr8 5380363 A G 5.14E-05 Cholesterol / / pha003073 rs17073881 chr8 5380363 A G 2.57E-05 Cholesterol / / pha003078 rs17354272 chr8 5384208 G C 2.00E-05 Urinary metabolites / / 21572414 rs17073968 chr8 5400313 A G 3.70E-04 Type 2 diabetes / / 17463246 rs17073975 chr8 5401811 T C 5.37E-04 Type 2 diabetes / / 17463246 rs12678575 chr8 5402268 G A 2.40E-04 Multiple complex diseases / / 17554300 rs17073982 chr8 5406191 C G 6.69E-06 Kawasaki disease / / 21221998 rs17073986 chr8 5408321 C T 0.000755551 Hypertension (early onset hypertension) / / 22479346 rs767239 chr8 5409371 G T 0.000862263 Hypertension (early onset hypertension) / / 22479346 rs1468391 chr8 5426256 T C 1.50E-05 Urinary metabolites / / 21572414 rs11777345 chr8 5426531 C G 3.00E-06 Waist-hip ratio / / 23966867 rs2733066 chr8 5427015 G A 4.30E-06 Urinary metabolites / / 21572414 rs4875186 chr8 5430301 A G 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11776337 chr8 5443069 G A 5.21E-05 Vascular dementia / / 22116812 rs4875598 chr8 5461753 G A 9.00E-06 Attention deficit hyperactivity disorder symptoms (interaction) / / 18846501 rs4875599 chr8 5461936 C T 7.77E-04 Depression (quantitative trait) / / 20800221 rs10503311 chr8 5461996 A C 2.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10503313 chr8 5464846 C T 2.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs6997449 chr8 5471806 C A 1.60E-05 Urinary metabolites / / 21572414 rs1076275 chr8 5474369 C G 1.60E-06 Phospholipid levels (plasma) / / 21829377 rs9644295 chr8 5476648 A T 4.61E-04 Multiple complex diseases / / 17554300 rs2733081 chr8 5491128 T C 3.60E-05 Blood Pressure / / pha002898 rs12680594 chr8 5494638 A G 6.68E-05 Major depressive disorder / / 21621269 rs4875607 chr8 5511450 A C 2.85E-04 Coronary Artery Disease / / 17634449 rs2732972 chr8 5513388 A G 3.54E-06 Heart Rate / / pha003051 rs2527171 chr8 5521576 T C 9.99E-04 Multiple complex diseases / / 17554300 rs2725644 chr8 5522149 G A 1.37E-05 Heart Rate / / pha003051 rs10100498 chr8 5522724 A C 5.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs17362595 chr8 5533942 A G 1.58E-04 Depression (quantitative trait) / / 20800221 rs2527161 chr8 5534849 G T 4.70E-06 Urinary metabolites / / 21572414 rs2725672 chr8 5536072 A G 5.30E-06 Urinary metabolites / / 21572414 rs6985780 chr8 5536623 C G 6.90E-04 Multiple complex diseases / / 17554300 rs2725673 chr8 5539122 G A 7.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs17362797 chr8 5541910 T C 1.35E-04 Depression (quantitative trait) / / 20800221 rs2107778 chr8 5542779 C T 1.00E-05 Urinary metabolites / / 21572414 rs2158588 chr8 5543121 A G 6.30E-06 Urinary metabolites / / 21572414 rs11774578 chr8 5543809 T C 7.42E-05 Depression (quantitative trait) / / 20800221 rs7015554 chr8 5544223 A G 7.90E-05 Depression (quantitative trait) / / 20800221 rs7817815 chr8 5544991 T C 4.96E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs7817815 chr8 5544991 T C 7.84E-05 Depression (quantitative trait) / / 20800221 rs7814262 chr8 5545069 A G 7.84E-05 Depression (quantitative trait) / / 20800221 rs7831044 chr8 5545090 C A 7.84E-05 Depression (quantitative trait) / / 20800221 rs17362923 chr8 5546824 C G 8.59E-05 Depression (quantitative trait) / / 20800221 rs10503333 chr8 5548229 A T 6.86E-05 Depression (quantitative trait) / / 20800221 rs17453815 chr8 5549619 A G 2.49E-04 Depression (quantitative trait) / / 20800221 rs17453815 chr8 5549619 A G 6.60E-06 Personality dimensions / / 21173776 rs4875612 chr8 5551013 A G 2.30E-04 Depression (quantitative trait) / / 20800221 rs7006473 chr8 5551530 T C 6.93E-04 Depression (quantitative trait) / / 20800221 rs6982207 chr8 5551845 G A 1.68E-04 Depression (quantitative trait) / / 20800221 rs6982207 chr8 5551845 G A 5.50E-06 Personality dimensions / / 21173776 rs17363043 chr8 5552197 T A 3.85E-04 Depression (quantitative trait) / / 20800221 rs17453899 chr8 5552794 G A 2.38E-04 Depression (quantitative trait) / / 20800221 rs17453906 chr8 5552825 G C 1.71E-04 Depression (quantitative trait) / / 20800221 rs17453906 chr8 5552825 G C 5.70E-06 Personality dimensions / / 21173776 rs17363064 chr8 5552851 G A 1.71E-04 Depression (quantitative trait) / / 20800221 rs17363064 chr8 5552851 G A 5.80E-06 Personality dimensions / / 21173776 rs7819155 chr8 5553067 G C 3.92E-04 Depression (quantitative trait) / / 20800221 rs10448113 chr8 5553276 G C 2.51E-04 Depression (quantitative trait) / / 20800221 rs10448113 chr8 5553276 G C 4.30E-06 Personality dimensions / / 21173776 rs10866995 chr8 5553797 T A 2.55E-04 Depression (quantitative trait) / / 20800221 rs10866995 chr8 5553797 T A 4.40E-06 Personality dimensions / / 21173776 rs11774958 chr8 5554098 C A 5.79E-04 Depression (quantitative trait) / / 20800221 rs11778521 chr8 5554323 A G 7.95E-04 Depression (quantitative trait) / / 20800221 rs2214688 chr8 5555854 G A 2.98E-04 Alzheimer's disease (late onset) / / 21379329 rs2214688 chr8 5555854 G A 3.56E-04 Blood pressure / / 24001895 rs2158587 chr8 5556029 A T 2.10E-05 Urinary metabolites / / 21572414 rs2733005 chr8 5556629 A C 1.10E-05 Urinary metabolites / / 21572414 rs1707428 chr8 5559875 C T 2.30E-05 Urinary metabolites / / 21572414 rs1635662 chr8 5561851 A G 8.30E-06 Urinary metabolites / / 21572414 rs1635657 chr8 5563282 T C 3.10E-04 Alzheimer's disease (late onset) / / 21379329 rs2408088 chr8 5566444 C T 2.13E-04 Alzheimer's disease / / 24755620 rs1615810 chr8 5567808 A G 3.33E-05 Alzheimer's disease (late onset) / / 21379329 rs34176953 chr8 5570917 G C 7.83E-04 Multiple complex diseases / / 17554300 rs116659 chr8 5574358 A G 6.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs263332 chr8 5576744 T C 7.94E-04 Depression (quantitative trait) / / 20800221 rs10104853 chr8 5578059 T C 5.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs263328 chr8 5579875 T G 2.10E-04 Alcohol dependence / / 20201924 rs1512791 chr8 5580761 A G 3.60E-04 Alcohol dependence / / 20201924 rs2725730 chr8 5581652 A C 2.60E-04 Alcohol dependence / / 20201924 rs2733020 chr8 5581690 A C 2.30E-04 Alcohol dependence / / 20201924 rs2733022 chr8 5582174 T C 2.60E-04 Alcohol dependence / / 20201924 rs2527128 chr8 5584374 C A 7.20E-04 Alcohol dependence / / 20201924 rs859815 chr8 5593343 G T 3.48E-05 Schizophrenia / / 24253340 rs2527120 chr8 5594132 G C 6.96E-04 Multiple complex diseases / / 17554300 rs1635627 chr8 5607156 A G 4.31E-05 Serum metabolites / / 19043545 rs1707418 chr8 5607214 C T 5.70E-06 Urinary metabolites / / 21572414 rs1707422 chr8 5608082 T C 4.90E-06 Urinary metabolites / / 21572414 rs17074838 chr8 5616990 C T 1.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17074840 chr8 5617042 G A 1.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7813894 chr8 5641443 C T 1.90E-04 Alcohol dependence / / 20201924 rs7813894 chr8 5641443 C T 8.50E-04 Alcohol dependence / / 20201924 rs1512817 chr8 5644933 G A 3.55E-05 Response to methotrexate in juvenile idiopathic arthritis / / 24709693 rs2137452 chr8 5652595 T C 5.99E-04 Taste perception / / 22132133 rs1398482 chr8 5662902 G C 4.23E-05 Telomere length / / 20139977 rs4875628 chr8 5666765 A G 3.24E-05 Brain lesion load / / 19010793 rs10095515 chr8 5668075 C A 6.53E-04 Type 2 diabetes / / 17463246 rs10092548 chr8 5676058 A G 3.24E-05 Anxiety in major depressive disorder / / 24047446 rs7013836 chr8 5679132 A G 8.20E-05 Obesity-related traits / / 17903300 rs17074954 chr8 5679269 A G 9.65E-04 Heart Failure / / pha002885 rs6988227 chr8 5707888 C G 6.37E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs17075013 chr8 5718908 C T 0.0008382 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17075013 chr8 5718908 C T 8.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6992867 chr8 5732000 G A 1.00E-04 Prostate cancer / / 21743057 rs12677512 chr8 5755548 A G 7.00E-05 Prostate cancer / / 21743057 rs11136938 chr8 5755611 A G 7.00E-05 Prostate cancer / / 21743057 rs2840445 chr8 5764942 G A 5.00E-06 Dietary macronutrient intake / / 23636237 rs2840461 chr8 5793752 C T 5.84E-04 Multiple complex diseases / / 17554300 rs2703301 chr8 5809543 T C 2.28E-05 Serum metabolites / / 19043545 rs2816428 chr8 5824341 T G 5.30E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1920473 chr8 5829711 C G 5.01E-04 Alzheimer's disease / / 17998437 rs2700791 chr8 5830891 T C 6.99E-04 Alzheimer's disease / / 17998437 rs2703326 chr8 5831547 G C 9.90E-04 Alzheimer's disease / / 17998437 rs2703332 chr8 5833790 C A 4.84E-04 Alzheimer's disease / / 17998437 rs2700768 chr8 5837974 C G 6.32E-04 Alzheimer's disease / / 17998437 rs7839113 chr8 5847587 G C 3.90E-06 Urinary metabolites / / 21572414 rs10503348 chr8 5848366 A T 3.86E-04 Bipolar disorder / / 19259986 rs13271355 chr8 5850799 C T 6.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2816465 chr8 5852081 G A 2.80E-06 Urinary metabolites / / 21572414 rs2816466 chr8 5852185 G A 2.80E-06 Urinary metabolites / / 21572414 rs2141642 chr8 5852695 G A 1.30E-05 Urinary metabolites / / 21572414 rs9802103 chr8 5872347 C A,T 7.92E-04 HIV-1 viral setpoint / / 17641165 rs4875668 chr8 5872394 A G 6.33E-04 HIV-1 viral setpoint / / 17641165 rs1424724 chr8 5875495 C T 4.72E-05 Alzheimer's disease / / 24755620 rs17075807 chr8 5883129 T C 1.83E-04 Alzheimer's disease / / 24755620 rs4875678 chr8 5888705 T C 6.95E-04 HIV-1 viral setpoint / / 17641165 rs4875217 chr8 5901098 T C 6.56E-04 HIV-1 viral setpoint / / 17641165 rs11783989 chr8 5912591 G A 8.75E-04 Myopia (pathological) / / 21095009 rs2897871 chr8 5923715 A G 7.43E-04 Myopia (pathological) / / 21095009 rs1364553 chr8 5925196 G A 7.91E-04 Myopia (pathological) / / 21095009 rs12547659 chr8 5926632 G A 2.00E-06 Urinary metabolites / / 21572414 rs4875223 chr8 5942699 A C 2.70E-05 Urinary metabolites / / 21572414 rs989538 chr8 5950845 G A 4.00E-07 Urinary metabolites / / 21572414 rs4875699 chr8 5955405 G T 2.50E-05 Urinary metabolites / / 21572414 rs12164204 chr8 5966081 A G 7.43E-04 Multiple complex diseases / / 17554300 rs12164204 chr8 5966081 A G 1.16E-05 Sudden cardiac arrest / / 21658281 rs11136971 chr8 5973842 A G 3.70E-05 Parkinson's disease (age of onset) / / 19772629 rs7812354 chr8 5995366 C G 8.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs6983976 chr8 5995912 G A 9.33E-05 Orofacial clefts / / 22419666 rs2700713 chr8 5997583 C G 2.70E-04 Insulin resistance / / 21901158 rs11136973 chr8 6000754 G C 1.70E-05 Urinary metabolites / / 21572414 rs2570683 chr8 6021203 C A 2.07E-05 Orofacial clefts / / 22419666 rs890032 chr8 6024175 A G 7.66E-05 Cognitive impairment induced by topiramate / / 22091778 rs2552238 chr8 6031645 G C 4.13E-05 Height / / 22021425 rs4317601 chr8 6060446 C T 3.90E-04 Multiple complex diseases / / 17554300 rs6997905 chr8 6062071 G C 5.89E-04 Type 2 diabetes / / 17463246 rs6990263 chr8 6063493 A G 7.24E-04 Multiple complex diseases / / 17554300 rs41363145 chr8 6064108 G C 8.84E-05 Multiple complex diseases / / 17554300 rs7015351 chr8 6065210 C A 9.21E-05 Heart Failure / / pha002885 rs13273875 chr8 6096432 A G 9.57E-05 Soluble levels of adhesion molecules / / pha003072 rs11136989 chr8 6098244 G T 7.02E-05 Soluble levels of adhesion molecules / / pha003072 rs10092383 chr8 6104318 C G 2.40E-06 Psoriasis / / 20953190 rs145225541 chr8 6104318 CAA C 2.40E-06 Psoriasis / / 20953190 rs13272289 chr8 6118630 G A 2.96E-07 Platelet aggregation(pre- and post-aspirin) / / 20529293 rs4466421 chr8 6129100 A G 3.52E-06 Serum metabolites / / 19043545 rs7827867 chr8 6136512 T G 2.20E-05 Serum metabolites / / 19043545 rs6994029 chr8 6146323 G A 1.00E-05 Urinary metabolites / / 21572414 rs6559140 chr8 6152919 T A 7.00E-06 Metabolite levels (5-HIAA) / / 23319000 rs7004340 chr8 6175712 G C 4.60E-04 Prostate cancer mortality / / 20978177 rs17533328 chr8 6209256 A T 3.40E-05 Coffee consumption / / 21357676 rs17076502 chr8 6215165 G T 2.02E-04 Multiple complex diseases / / 17554300 rs2916687 chr8 6221675 T C 2.12E-04 Myopia (pathological) / / 21095009 rs2916674 chr8 6229808 T C 7.54E-04 Myopia (pathological) / / 21095009 rs1057187 chr8 6263083 G T 1.30E-05 Urinary metabolites LOC100287015 intron 21572414 rs7018378 chr8 6278512 G A 3.95E-05 Nicotine smoking MCPH1 intron 19268276 rs2916733 chr8 6323278 G A 2.00E-09 Epirubicin-induced leukopenia MCPH1 intron 21799462 rs3020285 chr8 6334101 T C 1.48E-05 Cytomegalovirus antibody response MCPH1 intron 21993531 rs17540702 chr8 6337387 A G 1.13E-04 Suicide attempts in bipolar disorder MCPH1 intron 21423239 rs17077154 chr8 6351252 T C 8.00E-06 Cytomegalovirus antibody response MCPH1 intron 21993531 rs1031309 chr8 6352358 A C 4.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) MCPH1 intron 23648065 rs17077194 chr8 6363623 G C 0.00013 Coronary artery calcification ANGPT2 intron 23727086 rs2442468 chr8 6363950 C G 0.00023 Coronary artery calcification ANGPT2 intron 23727086 rs3020213 chr8 6369930 C T 8.47E-04 Nicotine smoking ANGPT2 intron 19268276 rs2442623 chr8 6376338 G A 6.11E-04 Nicotine smoking ANGPT2 intron 19268276 rs1868554 chr8 6386747 T A 3.34E-05 Acute lung injury ANGPT2 intron 21257790 rs2515477 chr8 6388640 C T 8.56E-06 Common variable immunodeficiency ANGPT2 intron 21497890 rs12550622 chr8 6394494 A G 8.03E-05 Hypertension (early onset hypertension) ANGPT2 intron 22479346 rs2442598 chr8 6394821 T C 2.52E-05 Acute lung injury ANGPT2 intron 21257790 rs2922876 chr8 6396696 C T 2.53E-04 Response to cytadine analogues (cytosine arabinoside) ANGPT2 intron 24483146 rs13269021 chr8 6396763 G T 1.00E-06 Response to cytidine analogues (gemcitabine) ANGPT2 intron 24483146 rs1375668 chr8 6396870 G A 2.39E-04 Response to cytidine analogues (gemcitabine) ANGPT2 intron 24483146 rs1375668 chr8 6396870 G A 3.72E-04 Response to cytadine analogues (cytosine arabinoside) ANGPT2 intron 24483146 rs2922874 chr8 6398170 A G 8.76E-04 Response to cytadine analogues (cytosine arabinoside) ANGPT2 intron 24483146 rs13255574 chr8 6398677 C T 5.15E-04 Response to cytidine analogues (gemcitabine) ANGPT2 intron 24483146 rs2922867 chr8 6409312 G A 8.35E-04 Multiple complex diseases ANGPT2 intron 17554300 rs3739391 chr8 6420534 A G 6.29E-04 Type 2 diabetes ANGPT2 UTR-5 17463246 rs3739391 chr8 6420534 A G 3.00E-05 Lipid levels ANGPT2 UTR-5 18193043 rs3739392 chr8 6420574 A G 9.25E-04 Type 2 diabetes ANGPT2 UTR-5 17463246 rs3739392 chr8 6420574 A G 5.47E-05 Schizophrenia ANGPT2 UTR-5 19571809 rs2167072 chr8 6423911 G T 5.18E-04 Type 2 diabetes MCPH1 intron 17463246 rs13255093 chr8 6447277 T A 3.33E-04 Multiple complex diseases MCPH1 intron 17554300 rs2442580 chr8 6447523 C T 7.10E-04 Alzheimer's disease MCPH1 intron 17998437 rs2980666 chr8 6469440 G A 5.62E-04 Myopia (pathological) MCPH1 intron 21095009 rs2515559 chr8 6479432 A G 4.44E-05 Heart Rate MCPH1 intron pha003051 rs2912057 chr8 6483482 C T 0.0000112 Panic disorder MCPH1 intron 23149450 rs2912057 chr8 6483482 C T 1.12E-05 Serum tamsulosin hydrochloride concentration MCPH1 intron 23151678 rs2912063 chr8 6486033 A G 5.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MCPH1 intron 20877124 rs3020263 chr8 6487449 G A 2.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MCPH1 intron 20877124 rs2911968 chr8 6488505 T C 0.00000505 Panic disorder MCPH1 intron 23149450 rs2911968 chr8 6488505 T C 5.05E-06 Serum tamsulosin hydrochloride concentration MCPH1 intron 23151678 rs3020265 chr8 6488921 G A 0.00000936 Panic disorder MCPH1 intron 23149450 rs3020265 chr8 6488921 G A 9.36E-06 Serum tamsulosin hydrochloride concentration MCPH1 intron 23151678 rs2912065 chr8 6490665 T G 0.0000408 Panic disorder MCPH1 intron 23149450 rs2912065 chr8 6490665 T G 4.08E-05 Serum tamsulosin hydrochloride concentration MCPH1 intron 23151678 rs1057091 chr8 6500544 C T 4.41E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MCPH1 missense 20877124 rs2912004 chr8 6507839 T C 3.36E-04 Alzheimer's disease / / 22005930 rs11784671 chr8 6507903 G T 2.50E-05 Coronary heart disease / / pha003033 rs17077763 chr8 6508498 A G 2.67E-08 Metabolite levels / / 23281178 rs2408473 chr8 6516340 G A 2.27E-08 Metabolite levels / / 23281178 rs2928584 chr8 6528057 T A,C,G 7.54E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6559175 chr8 6534000 G A 7.99E-05 Amyotrophic lateral sclerosis / / 20801718 rs6559175 chr8 6534000 G A 4.35E-04 Alzheimer's disease / / 22005930 rs7820038 chr8 6534176 G A 6.43E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11783611 chr8 6554615 T C 6.11E-04 Alzheimer's disease / / 17998437 rs11137056 chr8 6555558 G C 1.81E-04 Schizophrenia / / 20832056 rs2114060 chr8 6563253 A G 8.63E-04 Type 2 diabetes / / 17463246 rs2911981 chr8 6575518 T G 2.78E-04 Type 2 diabetes AGPAT5 intron 17463246 rs1559745 chr8 6576414 A G 2.95E-04 Type 2 diabetes AGPAT5 intron 17463246 rs3780081 chr8 6577560 G A 0.0000189 VLDL cholesterol particle diameter AGPAT5 intron 23263444 rs17078011 chr8 6590753 C G 2.72E-11 Multiple complex diseases AGPAT5 intron 17554300 rs2936512 chr8 6599005 T C 3.21E-04 Alcohol consumption (maxi-drinks) AGPAT5 intron 24277619 rs7012528 chr8 6604403 T C 8.75E-05 Heart Rate AGPAT5 intron pha003053 rs2980700 chr8 6612836 G A 7.30E-04 Alcohol dependence AGPAT5 intron 21314694 rs1046449 chr8 6615754 G A 1.14E-05 Alcohol and nictotine co-dependence AGPAT5 UTR-3 20158304 rs10106377 chr8 6622327 T G 8.62E-04 Type 2 diabetes / / 17463246 rs744441 chr8 6632610 G C 5.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs17637986 chr8 6633702 T G 5.20E-05 Alcohol dependence / / 20201924 rs17637986 chr8 6633702 T G 5.50E-05 Alcohol dependence / / 20201924 rs17637986 chr8 6633702 T G 5.45E-05 Alcoholism / / pha002892 rs17637986 chr8 6633702 T G 5.17E-05 Alcoholism / / pha002893 rs2912091 chr8 6634214 C T 1.40E-04 Alcohol dependence / / 20201924 rs2912091 chr8 6634214 C T 3.90E-05 Alcohol dependence / / 20201924 rs2912091 chr8 6634214 C T 3.87E-05 Alcoholism / / pha002893 rs2912089 chr8 6634774 G A 1.51E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs2912089 chr8 6634774 G A 1.60E-04 Alcohol dependence / / 20201924 rs2912089 chr8 6634774 G A 3.70E-05 Alcohol dependence / / 20201924 rs2912089 chr8 6634774 G A 1.83E-05 Cognitive impairment induced by topiramate / / 22091778 rs2912089 chr8 6634774 G A 3.72E-05 Alcoholism / / pha002893 rs2006658 chr8 6635267 C T 4.00E-07 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs9694007 chr8 6636018 C G 6.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs17078124 chr8 6637188 C T 6.31E-04 Alcohol dependence / / 20201924 rs9693942 chr8 6648542 C T 6.47E-04 Smoking cessation / / 24665060 rs10503364 chr8 6663323 T C 6.30E-04 Nicotine dependence / / 17407593 rs17078199 chr8 6665742 C T 9.89E-05 Cognitive impairment induced by topiramate / / 22091778 rs10104503 chr8 6679031 C T 3.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) XKR5 intron 20877124 rs2977798 chr8 6697450 C T 8.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100652791 intron 20877124 rs2980946 chr8 6715719 A C 0.0000757 post-traumatic stress disorder / / 22869035 rs2980946 chr8 6715719 A C 7.57E-05 Schizophrenia / / 22883433 rs2980945 chr8 6715751 A G 3.25E-04 Prostate cancer / / 23023329 rs2977790 chr8 6716312 T C 8.88E-04 Tourette syndrome / / 22889924 rs7834740 chr8 6722382 G A 2.68E-04 Birth weight / / 17255346 rs5743467 chr8 6731529 C G 7.93E-04 Type 2 diabetes DEFB1 intron 17463246 rs2978869 chr8 6731751 C A 7.28E-04 Alzheimer's disease DEFB1 intron 17998437 rs2741136 chr8 6737196 A G 1.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs5743401 chr8 6737582 A G 7.95E-04 Alzheimer's disease / / 17998437 rs5743401 chr8 6737582 A G 1.52E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2977826 chr8 6740074 C T 3.07E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2738173 chr8 6740938 A G 3.46E-05 Longevity / / 22279548 rs4841787 chr8 6749563 G A 2.40E-05 Urinary metabolites / / 21572414 rs7842755 chr8 6749770 A C 2.09E-04 Multiple complex diseases / / 17554300 rs2741711 chr8 6763661 C T 1.67E-04 Multiple complex diseases / / 17554300 rs2702888 chr8 6765032 G C 4.00E-07 Blood pressure / / 24954895 rs2738133 chr8 6774414 G A 1.95E-04 Atopy / / 21625490 rs2003880 chr8 6788102 G A 2.60E-04 Multiple complex diseases / / 17554300 rs6990786 chr8 6788172 A G 7.66E-05 Multiple complex diseases / / 17554300 rs2702863 chr8 6791559 C T 2.95E-04 Multiple complex diseases / / 17554300 rs2702867 chr8 6793322 T C 9.30E-04 Type 2 diabetes / / 17463246 rs736227 chr8 6793540 C T 9.23E-04 Type 2 diabetes DEFA4 UTR-3 17463246 rs2239668 chr8 6794019 G A 8.11E-04 Type 2 diabetes DEFA4 intron 17463246 rs2741675 chr8 6797532 C A 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs13263953 chr8 6801000 C T 5.99E-05 Insulin resistance / / 21901158 rs17078409 chr8 6815031 G A 9.10E-05 Multiple complex diseases / / 17554300 rs2738058 chr8 6821617 T C 6.00E-06 Periodontitis (PAL4Q3) / / 24024966 rs2738058 chr8 6821617 T C 7.00E-06 Periodontitis (PAL4Q3) / / 24024966 rs2738048 chr8 6822785 A G 3.00E-14 IgA nephropathy / / 22197929 rs2738045 chr8 6823568 T C 6.39E-05 Alzheimer's disease (late onset) / / 21460841 rs2702910 chr8 6823891 G A 1.30E-04 Alzheimer's disease (late onset) / / 21460841 rs4543566 chr8 6825536 C G 8.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs17078435 chr8 6826290 A G 0.00000106 HDL cholesterol DEFA10P intron 23063622 rs2738113 chr8 6829085 G T 3.00E-07 Endometriosis / / 21151130 rs2738113 chr8 6829085 G T 3.00E-04 Atrial fibrillation / / 21846873 rs11776120 chr8 6889635 G A 5.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11776120 chr8 6889635 G A 8.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4840666 chr8 6896083 G T 6.87E-04 Multiple complex diseases / / 17554300 rs6998687 chr8 6904195 A C 6.25E-04 Type 2 diabetes / / 17463246 rs13257750 chr8 6905455 T C 8.48E-04 Type 2 diabetes / / 17463246 rs2945230 chr8 8109936 A G 3.58E-05 Osteoarthritis (knee and hip) / / 21177295 rs2945230 chr8 8109936 A G 7.89E-05 Osteoarthritis (knee and hip) / / 21177295 rs2945230 chr8 8109936 A G 9.56E-05 Osteoarthritis (knee and hip) / / 21177295 rs13274039 chr8 8111659 A G 1.56E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs712255 chr8 8119716 A G 9.47E-05 Serum metabolites / / 19043545 rs712255 chr8 8119716 A G 1.00E-04 Information processing speed / / 21130836 rs872137 chr8 8119987 G C 5.37E-04 Multiple complex diseases / / 17554300 rs867657 chr8 8124510 T C 1.33E-04 Multiple complex diseases / / 17554300 rs10112645 chr8 8125496 G A 1.40E-05 Serum metabolites / / 19043545 rs7836459 chr8 8148289 T C 6.80E-05 Serum metabolites / / 19043545 rs17155252 chr8 8152283 A C 6.24E-04 Multiple complex diseases / / 17554300 rs2945891 chr8 8155475 G A 3.79E-04 Multiple complex diseases / / 17554300 rs2945891 chr8 8155475 G A 1.71E-04 Alcohol dependence / / 21314694 rs6601689 chr8 8172283 A G 4.41E-05 Serum metabolites / / 19043545 rs7011400 chr8 8174504 C T 7.20E-05 Hypothyroidism / / 22493691 rs2979208 chr8 8186167 T C 1.31E-04 Sarcoidosis SGK223 intron 19165924 rs7833103 chr8 8206753 A G 3.10E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SGK223 intron 22566498 rs2921010 chr8 8230361 G A 3.35E-06 Alcohol and nictotine co-dependence SGK223 intron 20158304 rs13280051 chr8 8231691 A G 7.18E-06 Mammographic density SGK223 intron 22532574 rs2921005 chr8 8234113 G A 9.14E-04 Multiple complex diseases SGK223 cds-synon 17554300 rs4840953 chr8 8234192 G C 8.36E-04 Birth weight SGK223 missense 17255346 rs2976956 chr8 8241772 T C 9.10E-05 Hypothyroidism / / 22493691 rs2979151 chr8 8258019 G A 2.66E-04 Multiple complex diseases / / 17554300 rs2979151 chr8 8258019 G A 5.99E-05 Serum metabolites / / 19043545 rs2976929 chr8 8258712 T C 6.30E-05 Hypothyroidism / / 22493691 rs11785930 chr8 8263629 T C 4.50E-05 Acne (severe) / / 24927181 rs2030280 chr8 8266309 A G 6.40E-05 Response to statin therapy / / 20339536 rs12680238 chr8 8271383 G A 4.87E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10092809 chr8 8271710 T C 8.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs1971412 chr8 8273043 T G 4.90E-05 Response to statin therapy / / 20339536 rs13256028 chr8 8275062 C A 6.96E-04 Alzheimer's disease / / 17998437 rs2945861 chr8 8283667 A G 5.82E-04 Multiple complex diseases / / 17554300 rs10110708 chr8 8287056 T C 4.68E-05 Odorant perception / / 23910658 rs7818421 chr8 8290881 T C 1.02E-06 Amyotrophic lateral sclerosis / / 17671248 rs7818421 chr8 8290881 T C 8.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs7007713 chr8 8292284 G A 2.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs7830429 chr8 8295058 C T 2.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs7830690 chr8 8295202 C G 2.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs2921080 chr8 8301412 A G 9.40E-04 Multiple complex diseases / / 17554300 rs6990282 chr8 8303845 T C 8.38E-05 Suicide attempts in bipolar disorder / / 21423239 rs2921060 chr8 8317817 A C 4.32E-04 Multiple complex diseases / / 17554300 rs2921031 chr8 8338670 A C 0.0000329 Transmission distortion / / 22377632 rs2979202 chr8 8344127 T C 5.93E-04 Premature ovarian failure / / 19508998 rs2921026 chr8 8347248 A T 6.10E-04 Pulmonary function / / 23932459 rs11783173 chr8 8362710 C T 3.28E-04 Multiple complex diseases / / 17554300 rs17153139 chr8 8374037 G A 5.67E-04 Multiple complex diseases / / 17554300 rs11777086 chr8 8384479 G T 8.90E-05 Alcoholism (heaviness of drinking) / / 21529783 rs10903346 chr8 8400723 A G 8.76E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs17153596 chr8 8405963 A G 5.76E-04 Multiple complex diseases / / 17554300 rs6986647 chr8 8415810 T C 7.00E-05 Hematology traits / / 23303382 rs12544932 chr8 8429600 C A 6.62E-06 Response to cytidine analogues (gemcitabine) / / 24483146 rs4840991 chr8 8429687 A G 1.23E-05 Orofacial clefts / / 22419666 rs4840991 chr8 8429687 A G 1.76E-05 Height / / pha003011 rs4272382 chr8 8433488 G A 2.00E-06 Response to cytidine analogues (gemcitabine) / / 24483146 rs11784527 chr8 8433584 A C 6.42E-05 Orofacial clefts / / 22419666 rs4595128 chr8 8433876 G A 3.13E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs7832468 chr8 8446774 G A 7.36E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs10216570 chr8 8472758 T C 1.86E-04 Coronary heart disease / / 21971053 rs11784888 chr8 8473160 G C 1.80E-05 Urinary metabolites / / 21572414 rs11782269 chr8 8490151 T G 8.38E-04 Coronary heart disease / / 21971053 rs7013418 chr8 8501322 T G 3.70E-06 Prostate cancer (early onset) / / 24740154 rs13268432 chr8 8506834 C A 6.30E-05 Endometriosis / / 21151130 rs13269639 chr8 8517524 T C 3.52E-04 Coronary heart disease / / 21971053 rs7824480 chr8 8520663 G C 1.80E-05 Urinary metabolites / / 21572414 rs9693402 chr8 8523158 C T 2.46E-05 Cognitive test performance / / 20125193 rs11249877 chr8 8534774 T C 3.82E-04 Schizophrenia / / 19197363 rs9644772 chr8 8557685 G A 7.67E-06 Obesity-related traits / / 23251661 rs9644773 chr8 8558080 T C 4.18E-06 Obesity-related traits / / 23251661 rs12153 chr8 8560909 G C 6.39E-06 Obesity-related traits CLDN23 UTR-3 23251661 rs1060106 chr8 8561452 A G 3.30E-06 Obesity-related traits CLDN23 UTR-3 23251661 rs11249884 chr8 8561552 T C 7.09E-04 Multiple complex diseases CLDN23 UTR-3 17554300 rs11249884 chr8 8561552 T C 4.60E-06 Obesity-related traits CLDN23 UTR-3 23251661 rs885000 chr8 8568875 G T 3.87E-06 Obesity-related traits / / 23251661 rs9329165 chr8 8576642 A G 3.00E-05 Neuroticism / / 17667963 rs4841017 chr8 8577093 T C 6.50E-06 Neuroticism / / 17667963 rs13256369 chr8 8577379 T C 3.00E-06 Obesity-related traits / / 23251661 rs13248096 chr8 8577476 C T 6.60E-04 Multiple complex diseases / / 17554300 rs12678414 chr8 8586016 G T 4.21E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs554241 chr8 8595612 C T 1.76E-04 Stroke / / pha002887 rs559534 chr8 8596181 C T 7.98E-04 Acute lung injury / / 22295056 rs4841020 chr8 8601350 A G 3.04E-06 Osteoarthritis / / 22763110 rs481061 chr8 8629795 A T 5.30E-04 Multiple complex diseases / / 17554300 rs500115 chr8 8635515 T C 5.78E-06 Schizophrenia / / 21926974 rs2409088 chr8 8645725 G C 1.34E-04 Acne (severe) MFHAS1 intron 24927181 rs950721 chr8 8676490 T C 3.76E-04 Lung function (forced expiratory volume in 1 second) MFHAS1 intron 24023788 rs1876836 chr8 8681756 T C 6.59E-07 Osteoarthritis MFHAS1 intron 22763110 rs7017739 chr8 8707639 C G 3.36E-04 Blood pressure MFHAS1 intron 17255346 rs4523255 chr8 8713038 C T 2.46E-04 Barrett's esophagus MFHAS1 intron 24121790 rs4523255 chr8 8713038 C T 4.15E-05 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) MFHAS1 intron 24121790 rs332034 chr8 8717007 T C 6.00E-06 Conduct disorder (interaction) MFHAS1 intron 18846501 rs332034 chr8 8717007 T C 6.74E-05 HDL cholesterol MFHAS1 intron pha003075 rs10108954 chr8 8722378 C T 7.00E-06 Prion diseases MFHAS1 intron 22210626 rs4841067 chr8 8747245 A G 5.40E-06 Osteoarthritis MFHAS1 intron 22763110 rs332013 chr8 8759261 T C 6.96E-05 Taste perception / / 22132133 rs400404 chr8 8770454 T G 6.80E-05 Common variable immunodeficiency / / 21497890 rs373204 chr8 8771402 T C 8.28E-04 Nicotine dependence / / 17158188 rs17700611 chr8 8793654 A G 6.20E-05 Multiple complex diseases / / 17554300 rs17701675 chr8 8850633 G A 2.43E-04 Breast cancer / / 21060860 rs6987558 chr8 8862521 G C 1.40E-04 Multiple complex diseases ERI1 intron 17554300 rs1016512 chr8 8881820 C T 2.86E-04 Response to taxane treatment (placlitaxel) ERI1 intron 23006423 rs1045528 chr8 8890079 T C 8.58E-04 Multiple complex diseases ERI1 UTR-3 17554300 rs1045529 chr8 8890098 C T 3.00E-06 Myopia (pathological) ERI1 UTR-3 23049088 rs895253 chr8 8898704 G A 1.55E-31 Narcolepsy / / 19629137 rs6601281 chr8 8911004 A G 6.91E-04 Multiple complex diseases / / 17554300 rs3989373 chr8 8911308 C A 6.64E-04 Multiple complex diseases / / 17554300 rs6601285 chr8 8937942 C T 7.82E-04 Multiple complex diseases / / 17554300 rs2077869 chr8 8967434 A T 9.68E-04 Multiple complex diseases / / 17554300 rs12334460 chr8 8979689 T C 4.52E-05 Bipolar disorder / / 19488044 rs12334460 chr8 8979689 T C 2.92E-05 Bipolar Disorder / / pha002863 rs189798 chr8 8990577 A G 6.00E-07 Myopia (pathological) / / 23049088 rs9949 chr8 8994512 A G 1.50E-04 Alzheimer's disease (late onset) PPP1R3B UTR-3 21379329 rs9949 chr8 8994512 A G 8.62E-07 Myopia (pathological) PPP1R3B UTR-3 23049088 rs330911 chr8 8996273 C T 2.70E-04 Alzheimer's disease (late onset) PPP1R3B UTR-3 21379329 rs3748140 chr8 8999019 C T 3.00E-07 Alzheimer's disease PPP1R3B missense 22832961 rs7011581 chr8 9000465 G A 4.02E-07 Alzheimer's disease PPP1R3B intron 22832961 rs6998837 chr8 9000681 T C 4.35E-07 Alzheimer's disease PPP1R3B intron 22832961 rs6999855 chr8 9001565 A T 4.46E-07 Alzheimer's disease PPP1R3B intron 22832961 rs19334 chr8 9009906 G A 8.66E-04 Multiple complex diseases PPP1R3B nearGene-5 17554300 rs19334 chr8 9009906 G A 1.40E-05 Urinary metabolites PPP1R3B nearGene-5 21572414 rs19334 chr8 9009906 G A 5.44E-05 Myopia (pathological) PPP1R3B nearGene-5 23049088 rs10107835 chr8 9025783 C G 3.08E-05 Reading and spelling / / 23738518 rs439989 chr8 9033744 C G 3.83E-06 Phospholipid levels (plasma) / / 21829377 rs367543 chr8 9034148 C T 1.29E-06 Phospholipid levels (plasma) / / 21829377 rs106380 chr8 9035078 G C 3.88E-06 Phospholipid levels (plasma) / / 21829377 rs12547955 chr8 9035829 G T 3.57E-06 Phospholipid levels (plasma) / / 21829377 rs1968853 chr8 9046312 A C 1.48E-04 Depression (quantitative trait) / / 20800221 rs17155367 chr8 9053914 T C 3.13E-04 Coronary Artery Disease / / 17634449 rs17149522 chr8 9065964 C G 1.05E-04 Depression (quantitative trait) / / 20800221 rs2929287 chr8 9073921 A T 5.38E-04 Depression (quantitative trait) / / 20800221 rs17149548 chr8 9075279 G A 6.22E-04 Multiple complex diseases / / 17554300 rs7841403 chr8 9085355 G A 2.16E-04 Depression (quantitative trait) / / 20800221 rs10108415 chr8 9086451 C A 4.77E-04 Depression (quantitative trait) / / 20800221 rs330053 chr8 9088280 G T 5.97E-04 Depression (quantitative trait) / / 20800221 rs6601296 chr8 9091739 G A 3.35E-04 Depression (quantitative trait) / / 20800221 rs17149618 chr8 9103134 A G 0.0000203 Panic disorder / / 23149450 rs17149618 chr8 9103134 A G 2.03E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs1383691 chr8 9140236 T A 7.95E-04 Obesity (extreme) / / 21935397 rs10503387 chr8 9150525 C T 8.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs719409 chr8 9151226 C T 7.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs747751 chr8 9152517 A G 4.30E-05 Cognitive function / / 24684796 rs330071 chr8 9159895 G A 9.00E-07 Acne (severe) / / 24927181 rs603441 chr8 9167797 T A 3.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs13439173 chr8 9167865 C T 3.32E-05 Orofacial clefts / / 22419666 rs17715588 chr8 9169549 C G 2.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs713286 chr8 9171735 T C 4.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs13279173 chr8 9175433 C T 3.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs330092 chr8 9176044 G A 1.75E-06 Glycemic traits (pregnancy) / / 23903356 rs330092 chr8 9176044 G A 6.51E-07 Glycemic traits (pregnancy) / / 23903356 rs983309 chr8 9177732 T G 3.70E-05 Lipid levels / / 19936222 rs983309 chr8 9177732 T G 3.80E-09 Lipid levels / / 19936222 rs983309 chr8 9177732 T G 5.70E-06 Lipid levels / / 19936222 rs983309 chr8 9177732 T G 6.38E-09 Lipid levels / / 19936222 rs983309 chr8 9177732 T G 4.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs983309 chr8 9177732 T G 0.0005912 2-hour glucose tolerance test / / 22885924 rs983309 chr8 9177732 T G 3.80E-14 Fasting insulin-related traits / / 22885924 rs983309 chr8 9177732 T G 6.29E-15 Fasting blood glucose / / 22885924 rs983309 chr8 9177732 T G 7.96E-06 Glycemic traits (pregnancy) / / 23903356 rs983309 chr8 9177732 T G 6.34E-05 Inflammation / / pha002897 rs6984305 chr8 9178268 A T 5.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs6984305 chr8 9178268 A T 2.00E-10 Liver enzyme levels (alkaline phosphatase) / / 22001757 rs6984305 chr8 9178268 A T 5.78E-06 Glycemic traits (pregnancy) / / 23903356 rs6984305 chr8 9178268 A T 9.03E-06 Glycemic traits (pregnancy) / / 23903356 rs10099512 chr8 9178821 C G 5.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs10098803 chr8 9178896 G T 6.67E-04 Multiple complex diseases / / 17554300 rs12543276 chr8 9178921 G A 0.000138 Schizophrenia / / 23637625 rs12543276 chr8 9178921 G A 6.54E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7464067 chr8 9179494 C G 7.02E-04 Type 2 diabetes / / 17463246 rs17716118 chr8 9180134 C T 8.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs9987289 chr8 9183358 A G 6.00E-25 HDL cholesterol LOC157273 intron 20686565 rs9987289 chr8 9183358 A G 7.00E-15 LDL cholesterol LOC157273 intron 20686565 rs9987289 chr8 9183358 A G 9.00E-24 Cholesterol,total LOC157273 intron 20686565 rs9987289 chr8 9183358 A G 3.00E-13 C-reactive protein LOC157273 intron 21300955 rs9987289 chr8 9183358 A G 1.00E-08 HDL Cholesterol - Triglycerides (HDLC-TG) LOC157273 intron 21386085 rs9987289 chr8 9183358 A G 4.00E-08 Metabolic syndrome (bivariate traits) LOC157273 intron 21386085 rs9987289 chr8 9183358 A G 1.06E-07 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs9987289 chr8 9183358 A G 1.55E-08 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs9987289 chr8 9183358 A G 8.25E-07 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs9987289 chr8 9183358 A G 8.61E-09 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs9987289 chr8 9183358 A G 2.00E-36 Cholesterol,total LOC157273 intron 24097068 rs9987289 chr8 9183358 A G 2.00E-41 HDL cholesterol LOC157273 intron 24097068 rs9987289 chr8 9183358 A G 9.00E-24 LDL cholesterol LOC157273 intron 24097068 rs4841132 chr8 9183596 A G 2.00E-10 Fasting insulin-related traits (interaction with BMI) / / 22581228 rs4841132 chr8 9183596 A G 8.00E-09 Fasting glucose-related traits (interaction with BMI) / / 22581228 rs4841132 chr8 9183596 A G 2.00E-09 Metabolite levels (atherosclerosis) / / 22916037 rs4841132 chr8 9183596 A G 1.29E-12 Glycemic traits (pregnancy) / / 23903356 rs4841132 chr8 9183596 A G 1.42E-10 Glycemic traits (pregnancy) / / 23903356 rs4841132 chr8 9183596 A G 3.00E-13 Glycemic traits (pregnancy) / / 23903356 rs4841132 chr8 9183596 A G 3.79E-13 Glycemic traits (pregnancy) / / 23903356 rs4841132 chr8 9183596 A G 4.79E-09 Glycemic traits (pregnancy) / / 23903356 rs4841132 chr8 9183596 A G 5.00E-15 Glycemic traits (pregnancy) / / 23903356 rs4841133 chr8 9183664 A G 1.05E-07 Glycemic traits (pregnancy) / / 23903356 rs4841133 chr8 9183664 A G 1.51E-08 Glycemic traits (pregnancy) / / 23903356 rs4841133 chr8 9183664 A G 8.37E-07 Glycemic traits (pregnancy) / / 23903356 rs4841133 chr8 9183664 A G 8.70E-09 Glycemic traits (pregnancy) / / 23903356 rs4240624 chr8 9184231 G A 3.68E-18 Nonalcoholic fatty liver disease LOC157273 intron 21423719 rs4240624 chr8 9184231 G A 1.12E-07 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs4240624 chr8 9184231 G A 1.55E-08 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs4240624 chr8 9184231 G A 8.00E-09 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs4240624 chr8 9184231 G A 8.53E-07 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs10106829 chr8 9184628 A G 5.39E-04 Response to taxane treatment (placlitaxel) LOC157273 intron 23006423 rs10106829 chr8 9184628 A G 1.27E-08 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs10106829 chr8 9184628 A G 2.21E-07 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs10106829 chr8 9184628 A G 6.90E-06 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs10106829 chr8 9184628 A G 7.55E-08 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs6601299 chr8 9184691 T C 1.00E-08 Coronary heart disease LOC157273 intron 21347282 rs6601299 chr8 9184691 T C 4.88E-08 Fatty liver disease LOC157273 intron 23477746 rs6601299 chr8 9184691 T C 1.36E-08 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs6601299 chr8 9184691 T C 1.52E-09 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs6601299 chr8 9184691 T C 6.10E-10 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs6601299 chr8 9184691 T C 6.91E-07 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs2126260 chr8 9185081 T C 1.42E-07 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs2126260 chr8 9185081 T C 1.58E-08 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs2126260 chr8 9185081 T C 2.51E-09 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs2126260 chr8 9185081 T C 5.66E-06 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs2126259 chr8 9185146 T C 7.00E-12 LDL cholesterol LOC157273 intron 20864672 rs2126259 chr8 9185146 T C 1.75E-07 2-hour glucose tolerance test LOC157273 intron 22885924 rs2126259 chr8 9185146 T C 3.30E-13 Fasting insulin-related traits LOC157273 intron 22885924 rs2126259 chr8 9185146 T C 5.42E-10 Fasting blood glucose LOC157273 intron 22885924 rs2126259 chr8 9185146 T C 3.28E-08 Fatty liver disease LOC157273 intron 23477746 rs2126259 chr8 9185146 T C 1.00E-06 HDL cholesterol LOC157273 intron 23505323 rs2126259 chr8 9185146 T C 1.02E-08 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs2126259 chr8 9185146 T C 1.11E-07 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs2126259 chr8 9185146 T C 1.50E-08 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs2126259 chr8 9185146 T C 1.89E-06 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs1461729 chr8 9187242 A G 4.81E-08 Fatty liver disease LOC157273 intron 23477746 rs1461729 chr8 9187242 A G 7.00E-09 HDL cholesterol LOC157273 intron 23726366 rs1461729 chr8 9187242 A G 1.54E-09 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs1461729 chr8 9187242 A G 3.34E-10 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs1461729 chr8 9187242 A G 5.48E-07 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs1461729 chr8 9187242 A G 6.50E-09 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs7004769 chr8 9187595 A G 4.80E-04 Response to taxane treatment (placlitaxel) LOC157273 intron 23006423 rs7004769 chr8 9187595 A G 1.38E-10 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs7004769 chr8 9187595 A G 6.85E-09 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs7004769 chr8 9187595 A G 8.03E-08 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs7004769 chr8 9187595 A G 8.43E-11 Glycemic traits (pregnancy) LOC157273 intron 23903356 rs11781511 chr8 9192423 A G 3.61E-07 Glycemic traits (pregnancy) / / 23903356 rs11781511 chr8 9192423 A G 3.76E-06 Glycemic traits (pregnancy) / / 23903356 rs11781511 chr8 9192423 A G 8.23E-07 Glycemic traits (pregnancy) / / 23903356 rs6999153 chr8 9193501 G A 5.57E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs732839 chr8 9194172 G A 7.78E-04 Type 2 diabetes / / 17463246 rs732839 chr8 9194172 G A 4.93E-05 Serum metabolites / / 19043545 rs732839 chr8 9194172 G A 4.40E-06 Urinary metabolites / / 21572414 rs13265179 chr8 9194694 C A 6.43E-05 Glycemic traits (pregnancy) / / 23903356 rs13265179 chr8 9194694 C A 6.53E-06 Glycemic traits (pregnancy) / / 23903356 rs717595 chr8 9197585 A C 2.20E-06 Urinary metabolites / / 21572414 rs958374 chr8 9197661 C T 1.20E-05 Urinary metabolites / / 21572414 rs17717355 chr8 9198695 G T 1.20E-05 Urinary metabolites / / 21572414 rs4332138 chr8 9200251 C T 6.54E-06 Glycemic traits (pregnancy) / / 23903356 rs1461727 chr8 9200350 C T 2.10E-05 Urinary metabolites / / 21572414 rs12545922 chr8 9200618 C T 1.50E-05 Urinary metabolites / / 21572414 rs2199402 chr8 9201003 C T 7.79E-06 Cognitive impairment induced by topiramate / / 22091778 rs11782386 chr8 9201787 C T 0.000000549 Fasting blood glucose / / 22885924 rs11782386 chr8 9201787 C T 0.000000686 Fasting insulin-related traits / / 22885924 rs11782386 chr8 9201787 C T 2.03E-09 2-hour glucose tolerance test / / 22885924 rs11782386 chr8 9201787 C T 6.62E-06 Glycemic traits (pregnancy) / / 23903356 rs7018002 chr8 9205584 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2169385 chr8 9206678 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2169385 chr8 9206678 G A 1.17E-07 Glycemic traits (pregnancy) / / 23903356 rs2169385 chr8 9206678 G A 6.27E-06 Glycemic traits (pregnancy) / / 23903356 rs10089120 chr8 9209061 T G 7.90E-06 Urinary metabolites / / 21572414 rs9329191 chr8 9216584 T G 3.26E-05 Bipolar disorder / / 19488044 rs9329191 chr8 9216584 T G 1.40E-05 Urinary metabolites / / 21572414 rs9329191 chr8 9216584 T G 6.16E-05 Bipolar Disorder / / pha002863 rs12550199 chr8 9216924 C G 5.50E-06 Urinary metabolites / / 21572414 rs4345557 chr8 9217123 T A 9.70E-06 Urinary metabolites / / 21572414 rs1381350 chr8 9217195 C T 3.61E-04 Multiple complex diseases / / 17554300 rs4361767 chr8 9217449 G A 7.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7834497 chr8 9224139 C T 8.35E-07 Glycemic traits (pregnancy) / / 23903356 rs7834497 chr8 9224139 C T 9.33E-06 Glycemic traits (pregnancy) / / 23903356 rs11784552 chr8 9224907 C T 7.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7011130 chr8 9225696 C T 7.12E-06 Glycemic traits (pregnancy) / / 23903356 rs10091799 chr8 9225872 A C 6.70E-06 Urinary metabolites / / 21572414 rs12234997 chr8 9237708 A G 3.06E-06 Schizophrenia / / 21926974 rs7841407 chr8 9243428 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17662123 chr8 9246837 G A 1.37E-04 Osteoarthritis (knee and hip) / / 21177295 rs17662123 chr8 9246837 G A 3.11E-04 Osteoarthritis (knee and hip) / / 21177295 rs17662123 chr8 9246837 G A 5.32E-04 Osteoarthritis (knee and hip) / / 21177295 rs17662123 chr8 9246837 G A 6.68E-06 Osteoarthritis (knee and hip) / / 21177295 rs10099338 chr8 9257739 A G 4.50E-04 Glomerular filtration rate / / 24351856 rs6601306 chr8 9264711 C T 4.00E-06 Response to inhaled corticosteroid treatment in asthma (percentage change of FEV1) / / 24792382 rs17730481 chr8 9276163 G A 2.50E-05 Urinary metabolites / / 21572414 rs11993746 chr8 9277795 C T 9.03E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13281098 chr8 9279553 C A 2.38E-04 Acne (severe) / / 24927181 rs1458944 chr8 9279811 G T 1.64E-04 Acne (severe) / / 24927181 rs4841147 chr8 9290599 A T 3.89E-04 Multiple complex diseases / / 17554300 rs7006727 chr8 9298347 A G 8.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12680337 chr8 9308933 C T 4.17E-04 Multiple complex diseases / / 17554300 rs17150066 chr8 9310511 G A 1.60E-05 Urinary metabolites / / 21572414 rs6995907 chr8 9313017 T C 6.88E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs10105543 chr8 9323515 C T 6.56E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs11249927 chr8 9361606 C T 7.17E-05 Height / / pha003010 rs11249928 chr8 9363260 T C 7.75E-05 Height / / pha003010 rs10090821 chr8 9372305 C G 7.42E-04 Depression (quantitative trait) / / 20800221 rs7839849 chr8 9373545 C T 7.03E-04 Depression (quantitative trait) / / 20800221 rs7839849 chr8 9373545 C T 6.83E-04 Body mass index / / 21701565 rs6601323 chr8 9376344 C T 2.10E-04 Glycemic traits (pregnancy) / / 23903356 rs6601324 chr8 9376657 A G 2.39E-04 Glycemic traits (pregnancy) / / 23903356 rs6985776 chr8 9378796 T C 1.73E-04 Glycemic traits (pregnancy) / / 23903356 rs6601327 chr8 9395532 G A 1.99E-07 Systemic lupus erythematosus / / 18204446 rs6601327 chr8 9395532 G A 1.13E-04 Osteoarthritis (knee and hip) / / 21177295 rs6601327 chr8 9395532 G A 7.56E-05 Osteoarthritis (knee and hip) / / 21177295 rs6601327 chr8 9395532 G A 8.00E-06 Multiple myeloma (hyperdiploidy) / / 23502783 rs4840426 chr8 9408978 T G 4.25E-04 Multiple complex diseases / / 17554300 rs9644677 chr8 9411808 G A 5.10E-05 Multiple sclerosis / / 19525955 rs6980831 chr8 9415390 G A 2.38E-04 Multiple complex diseases TNKS intron 17554300 rs6986386 chr8 9421789 C T 1.60E-05 Multiple sclerosis TNKS intron 21833088 rs12681719 chr8 9424503 G C 6.25E-04 Multiple complex diseases TNKS intron 17554300 rs7002917 chr8 9449132 C T 6.58E-04 Response to alcohol consumption (flushing response) TNKS intron 24277619 rs4841179 chr8 9460449 A G 1.40E-04 Multiple complex diseases TNKS intron 17554300 rs7832096 chr8 9462583 T C 1.19E-04 Multiple complex diseases TNKS intron 17554300 rs4240626 chr8 9471060 A G 8.61E-05 Multiple complex diseases TNKS intron 17554300 rs12674762 chr8 9484126 C T 1.49E-04 Multiple complex diseases TNKS intron 17554300 rs4128324 chr8 9508879 A G 9.85E-04 Alcohol dependence TNKS intron 24277619 rs6985140 chr8 9537427 A G 2.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TNKS intron 20877124 rs13273033 chr8 9540693 G A 1.28E-04 Multiple complex diseases TNKS intron 17554300 rs4841197 chr8 9555111 C T 1.42E-04 Multiple complex diseases TNKS intron 17554300 rs7010270 chr8 9556847 G A 1.35E-04 Multiple complex diseases TNKS intron 17554300 rs7010270 chr8 9556847 G A 2.50E-06 Glaucoma (primary open-angle) TNKS intron 22605921 rs9644708 chr8 9600917 T C 3.44E-05 Asthma TNKS intron 11022011 rs12545912 chr8 9601699 G T 3.77E-04 Multiple complex diseases TNKS intron 17554300 rs12545912 chr8 9601699 G T 7.00E-06 Multiple myeloma (hyperdiploidy) TNKS intron 23502783 rs4840437 chr8 9606264 G A 1.67E-05 Myopia (pathological) TNKS intron 23049088 rs6989782 chr8 9610538 C T 2.43E-05 Myopia (pathological) TNKS intron 23049088 rs6986755 chr8 9622559 G A 4.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TNKS intron 20877124 rs11785739 chr8 9640400 C A 3.28E-04 Multiple complex diseases / / 17554300 rs2898223 chr8 9647603 C T 3.62E-04 Multiple complex diseases / / 17554300 rs7820917 chr8 9647868 C T 3.90E-05 Anger / / 24489884 rs7829463 chr8 9649691 G C 6.74E-04 Multiple complex diseases / / 17554300 rs1567836 chr8 9679926 A G 5.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1567837 chr8 9680025 G C 6.19E-04 Multiple complex diseases / / 17554300 rs10110146 chr8 9685362 A C 3.51E-04 Smoking cessation / / 24665060 rs10094528 chr8 9740329 T C 8.00E-08 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs17150703 chr8 9745798 G A 2.00E-08 Obesity (early onset extreme) / / 20421936 rs13278851 chr8 9750872 G A 2.09E-08 Obesity (early onset extreme) / / 20421936 rs13252510 chr8 9765888 G A 9.08E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs516175 chr8 9769573 G A 9.88E-08 Obesity (early onset extreme) / / 20421936 rs10503396 chr8 9780861 G A 7.59E-04 Type 2 diabetes / / 17463246 rs17150816 chr8 9790737 C A 1.76E-04 Multiple complex diseases / / 17554300 rs17150816 chr8 9790737 C A 9.30E-05 Type 2 diabetes / / 24509480 rs2055729 chr8 9792662 G A 8.00E-07 Multiple myeloma (hyperdiploidy) / / 23502783 rs471480 chr8 9812462 C T 5.46E-04 Multiple complex diseases / / 17554300 rs656319 chr8 9814411 A G 3.00E-06 Myopia (pathological) / / 23049088 rs609792 chr8 9819890 T C 4.61E-06 Osteoarthritis / / 22763110 rs11774592 chr8 9821024 G T 7.97E-04 Multiple complex diseases / / 17554300 rs7820910 chr8 9826340 T C 6.69E-04 Sarcoidosis / / 19165924 rs545854 chr8 9860080 G C 3.57E-07 Asthma / / 11022011 rs545854 chr8 9860080 G C 9.00E-09 Adiposity / / 19557161 rs545854 chr8 9860080 G C 9.00E-09 Adiposity / / 19557161 rs6987670 chr8 9883177 C T 5.38E-05 Glucose levels / / pha003061 rs12216712 chr8 9895811 G T 1.46E-04 Smoking initiation / / 24665060 rs1980262 chr8 9906271 G T 5.29E-04 Smoking initiation / / 24665060 rs598523 chr8 9919486 G C 6.30E-05 Personality dimensions MSRA intron 18957941 rs583167 chr8 9920570 G A 8.60E-05 Personality dimensions MSRA intron 18957941 rs2628136 chr8 9920901 A G 6.12E-04 Smoking cessation MSRA intron 24665060 rs7836284 chr8 9932555 C T 0.000000252 LDL cholesterol MSRA intron 23063622 rs7836284 chr8 9932555 C T 0.00000198 Cholesterol,total MSRA intron 23063622 rs7012397 chr8 9949033 A G 0.000000128 LDL cholesterol MSRA intron 23063622 rs17151064 chr8 9952907 G C 1.49E-10 Multiple complex diseases MSRA intron 17554300 rs17151064 chr8 9952907 G C 0.0000016 Mean arterial pressure MSRA intron 22510845 rs10087178 chr8 9968794 T C 4.07E-08 LDL cholesterol MSRA intron 23063622 rs6983332 chr8 9977918 C T 3.90E-05 Myopia (pathological) MSRA intron 23049088 rs1484641 chr8 9986524 C A 1.29E-04 Multiple complex diseases MSRA intron 17554300 rs1484642 chr8 9986655 G C 3.00E-06 Bipolar disorder and schizophrenia MSRA intron 22688191 rs4841284 chr8 10001780 T C 8.61E-04 Multiple complex diseases MSRA intron 17554300 rs13249013 chr8 10005367 G A 4.40E-04 Coronary heart disease MSRA intron 21966275 rs10107815 chr8 10014155 G C 0.000000134 HDL cholesterol MSRA intron 23063622 rs10107815 chr8 10014155 G C 5.36E-08 LDL cholesterol MSRA intron 23063622 rs12678938 chr8 10016969 T C 5.99E-05 Myopia (pathological) MSRA intron 23049088 rs10104376 chr8 10020799 T G 2.70E-04 Multiple complex diseases MSRA intron 17554300 rs7017212 chr8 10022938 G T 6.06E-04 Myopia (pathological) MSRA intron 21095009 rs7017212 chr8 10022938 G T 4.00E-06 Schizophrenia MSRA intron 21679298 rs1484646 chr8 10028396 G T 5.53E-04 Myopia (pathological) MSRA intron 21095009 rs11783143 chr8 10035151 A G 5.91E-04 Myopia (pathological) MSRA intron 21095009 rs17748464 chr8 10050618 G A 2.06E-05 Multiple complex diseases MSRA intron 17554300 rs17151287 chr8 10052192 G C 6.21E-06 Nonalcoholic fatty liver disease MSRA intron 21423719 rs4448276 chr8 10054928 G T 1.01E-05 Multiple complex diseases MSRA intron 17554300 rs11774836 chr8 10062543 G A,C,T 4.96E-04 Myopia (pathological) MSRA intron 21095009 rs7844115 chr8 10064495 C G 4.90E-05 Nicotine smoking MSRA intron 19268276 rs7844115 chr8 10064495 C G 5.57E-05 Femoral neck bone geometry MSRA intron 22087292 rs6992349 chr8 10067407 G A 2.35E-05 Femoral neck bone geometry MSRA intron 22087292 rs17749155 chr8 10068073 G A 1.70E-04 Multiple complex diseases MSRA intron 17554300 rs11775334 chr8 10071620 A G 4.00E-06 Hypertension MSRA intron 19430479 rs11775334 chr8 10071620 A G 4.00E-06 Coronary heart disease MSRA intron 21347282 rs10503404 chr8 10085359 A G 6.46E-05 Asthma MSRA intron 23181788 rs6999631 chr8 10086411 G C 8.00E-06 Bulimia nervosa MSRA intron 23568457 rs6999631 chr8 10086411 G C 8.01E-06 Bulimia nervosa MSRA intron 23568457 rs17693451 chr8 10087393 G A 9.59E-04 Multiple complex diseases MSRA intron 17554300 rs2975735 chr8 10089454 G T 4.19E-07 Soluble levels of adhesion molecules MSRA intron pha003072 rs7842910 chr8 10095707 A G 4.75E-05 Creatinine levels MSRA intron pha003069 rs6992153 chr8 10100169 C T 9.14E-05 Neuroblastoma MSRA intron pha002895 rs2975693 chr8 10114474 T C 1.24E-05 Soluble levels of adhesion molecules MSRA intron pha003072 rs7001567 chr8 10114537 C G 0.000000877 HDL cholesterol MSRA intron 23063622 rs7001567 chr8 10114537 C G 9.03E-08 LDL cholesterol MSRA intron 23063622 rs2975687 chr8 10116819 A C 4.47E-07 Soluble levels of adhesion molecules MSRA intron pha003072 rs17151505 chr8 10117956 C T 9.22E-04 Multiple complex diseases MSRA intron 17554300 rs7001821 chr8 10129773 T C 2.96E-04 Type 2 diabetes MSRA intron 19184112 rs2975648 chr8 10135976 T C 0.0000374 Triglycerides MSRA intron 23063622 rs10102621 chr8 10140875 G A 9.67E-05 Non-alcoholic fatty liver disease histology (other) MSRA intron 20708005 rs4403412 chr8 10153281 T C 8.33E-08 Blood pressure MSRA intron 21909110 rs4240644 chr8 10164259 G A 1.32E-06 Brachial circumference MSRA intron 22479309 rs6601431 chr8 10170545 A G 2.56E-04 Myocardial Infarction MSRA intron pha002883 rs7835507 chr8 10175137 C A 3.37E-04 Schizophrenia MSRA intron 19197363 rs6997224 chr8 10176363 T C 6.06E-04 Schizophrenia MSRA intron 19197363 rs6601438 chr8 10179667 A C 1.30E-04 Myocardial Infarction MSRA intron pha002883 rs4509385 chr8 10180196 A G 8.01E-05 Nicotine smoking MSRA intron 19268276 rs17151759 chr8 10181406 G C 6.79E-04 Sarcoidosis MSRA intron 19165924 rs12680918 chr8 10183540 G T 8.78E-04 White matter integrity MSRA intron 22425255 rs7832708 chr8 10190040 C T 3.96E-05 Bleomycin sensitivity MSRA intron 21106707 rs11784828 chr8 10191298 T G 0.000000145 Triglycerides MSRA intron 23063622 rs6601443 chr8 10207943 G A 8.16E-05 Schizophrenia MSRA intron 19197363 rs6997710 chr8 10210451 A G 4.18E-04 Depression (quantitative trait) MSRA intron 20800221 rs6997710 chr8 10210451 A G 6.92E-06 Osteoarthritis MSRA intron 22763110 rs7842443 chr8 10230044 T A 3.41E-04 Multiple complex diseases MSRA intron 17554300 rs17151901 chr8 10253455 C T 0.0000653 Ankle-brachial index MSRA intron 22361517 rs17151901 chr8 10253455 C T 0.00026 Coronary artery calcification MSRA intron 23727086 rs17151903 chr8 10253537 A G 2.66E-05 Schizophrenia(age at onset) MSRA intron 21688384 rs13254942 chr8 10257678 T C 6.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MSRA intron 20877124 rs13254942 chr8 10257678 T C 7.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MSRA intron 20877124 rs1962392 chr8 10262373 C G 0.000058 Skin naphthyl-keratin adduct (NKA) levels in workers exposed to naphthalene MSRA intron 22391508 rs6999466 chr8 10265712 A G 6.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MSRA intron 20877124 rs1986972 chr8 10268805 G A 8.62E-04 Body mass index MSRA intron 21701565 rs10112584 chr8 10279503 G A 9.88E-04 Myopia (pathological) MSRA intron 21095009 rs10112584 chr8 10279503 G A 4.45E-05 HDL cholesterol MSRA intron pha003074 rs7009513 chr8 10284051 T C 2.38E-05 Hearing function MSRA intron 17255346 rs4841337 chr8 10288007 G T 4.52E-04 Body mass index / / 21701565 rs10089552 chr8 10288480 T C 2.80E-05 Hypothyroidism / / 22493691 rs10096610 chr8 10289663 T C 4.00E-05 Hypothyroidism / / 22493691 rs13266986 chr8 10289706 A G 1.20E-06 Digit length ratio / / 20303062 rs11250010 chr8 10292007 G C 5.20E-06 Digit length ratio / / 20303062 rs11250013 chr8 10292990 G C 5.20E-06 Digit length ratio / / 20303062 rs4471098 chr8 10294057 T G 2.00E-06 Digit length ratio / / 20303062 rs11783249 chr8 10295310 T A 4.60E-06 Digit length ratio / / 20303062 rs13257718 chr8 10298408 G T 1.70E-06 Digit length ratio / / 20303062 rs7837520 chr8 10300132 A G 4.30E-06 Digit length ratio / / 20303062 rs7005230 chr8 10303387 C A 5.70E-05 Hypothyroidism / / 22493691 rs10090800 chr8 10306432 T C 1.10E-06 Digit length ratio / / 20303062 rs6993523 chr8 10308074 C A 6.50E-04 Taste perception / / 22132133 rs6999196 chr8 10309262 C T 7.13E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1986357 chr8 10316236 G A 1.83E-04 Body mass index / / 21701565 rs1986357 chr8 10316236 G A 0.00015 Breast cancer / / 23555315 rs11250017 chr8 10320019 T C 7.90E-04 Suicidal ideation / / 22030708 rs6601465 chr8 10321881 A G 8.10E-06 Digit length ratio / / 20303062 rs9329223 chr8 10331754 A G 7.02E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs7833781 chr8 10333477 G A 8.40E-05 Information processing speed / / 21130836 rs11782819 chr8 10334781 T C 3.00E-06 Alzheimer's disease / / 20452100 rs11782819 chr8 10334781 T C 2.26E-05 Coronary heart disease / / pha003031 rs4380891 chr8 10338924 C T 2.90E-06 Digit length ratio / / 20303062 rs4523215 chr8 10339508 G A 3.00E-06 Digit length ratio / / 20303062 rs11780245 chr8 10343887 G T 1.20E-06 Digit length ratio / / 20303062 rs4392859 chr8 10345022 T C 7.21E-04 Body mass index / / 21701565 rs13282174 chr8 10345753 C T 1.20E-06 Digit length ratio / / 20303062 rs13282174 chr8 10345753 C T 6.84E-05 Body mass index / / 21701565 rs7821267 chr8 10346583 A C 6.60E-06 Digit length ratio / / 20303062 rs7821273 chr8 10346588 A G 1.20E-06 Digit length ratio / / 20303062 rs7821273 chr8 10346588 A G 7.46E-05 Heart Rate / / pha003051 rs11250019 chr8 10347231 A G 1.20E-06 Digit length ratio / / 20303062 rs7842925 chr8 10347654 C T 1.10E-06 Digit length ratio / / 20303062 rs11250020 chr8 10347924 C G 4.40E-06 Digit length ratio / / 20303062 rs12543028 chr8 10348096 T C 4.40E-06 Digit length ratio / / 20303062 rs4281086 chr8 10352308 C A 4.00E-06 Obesity-related traits / / 23251661 rs4295624 chr8 10352463 C G 5.10E-06 Digit length ratio / / 20303062 rs4532561 chr8 10352528 G T 5.10E-06 Digit length ratio / / 20303062 rs4532561 chr8 10352528 G T 8.85E-05 Heart Rate / / pha003051 rs11987962 chr8 10353111 C G 5.10E-06 Digit length ratio / / 20303062 rs10086950 chr8 10355378 C A 9.50E-07 Digit length ratio / / 20303062 rs10086950 chr8 10355378 C A 7.85E-05 Body mass index / / 21701565 rs10086950 chr8 10355378 C A 4.30E-04 Stroke / / pha002887 rs6989332 chr8 10355517 G A 7.34E-04 Body mass index / / 21701565 rs4361726 chr8 10356358 A G 3.20E-06 Digit length ratio / / 20303062 rs11775128 chr8 10356433 C A 3.10E-06 Digit length ratio / / 20303062 rs4392860 chr8 10356449 G A 3.10E-06 Digit length ratio / / 20303062 rs13279329 chr8 10357494 T G 7.30E-07 Digit length ratio / / 20303062 rs13279329 chr8 10357494 T G 2.26E-04 Body mass index / / 21701565 rs11995447 chr8 10362343 A T 8.40E-06 Digit length ratio / / 20303062 rs11995447 chr8 10362343 A T 1.62E-04 Body mass index / / 21701565 rs10102650 chr8 10367049 T C 9.50E-07 Digit length ratio / / 20303062 rs4841363 chr8 10376148 A T 7.70E-06 Digit length ratio / / 20303062 rs71203333 chr8 10376148 A AT 7.70E-06 Digit length ratio / / 20303062 rs11250024 chr8 10377484 C T 7.50E-06 Digit length ratio / / 20303062 rs11250024 chr8 10377484 C T 2.09E-04 Body mass index / / 21701565 rs6984615 chr8 10379024 G A 5.60E-06 Digit length ratio / / 20303062 rs4841365 chr8 10388498 G C 5.00E-06 Breast cancer PRSS55 intron 17529967 rs4841367 chr8 10388826 G A 3.98E-05 HIV-1 control PRSS55 cds-synon 20041166 rs7011457 chr8 10407928 T C 8.70E-04 Multiple complex diseases PRSS55 intron 17554300 rs6601491 chr8 10416017 A G 4.68E-05 Serum metabolites / / 19043545 rs7815294 chr8 10419303 G A 3.26E-04 Cognitive decline / / 23732972 rs12543042 chr8 10445702 G A 8.95E-04 Alzheimer's disease / / 17998437 rs12681639 chr8 10448142 C T 8.10E-04 Aortic root size / / 21223598 rs4841390 chr8 10453419 A C 0.000855 Salmonella-induced pyroptosis / / 22837397 rs4841398 chr8 10462806 C T 3.00E-06 Obesity-related traits / / 23251661 rs199965589 chr8 10466933 C T 0.00033 Prostate cancer (non-advanced prostate cancer) RP1L1 missense 23555315 rs199965589 chr8 10466933 C T 0.00081 Prostate cancer RP1L1 missense 23555315 rs6996950 chr8 10469817 G A 9.72E-06 Obesity-related traits RP1L1 cds-synon 23251661 rs7017819 chr8 10478745 C T 2.15E-04 Response to statin treatment (atorvastatin),change in cholesterol levels RP1L1 intron 20031582 rs9329228 chr8 10482372 C A 3.91E-04 Schizophrenia RP1L1 intron 19197363 rs4427133 chr8 10543091 A C 1.71E-05 Serum metabolites C8orf74 intron 19043545 rs6601505 chr8 10560878 C T 1.48E-04 Type 2 diabetes / / 17463246 rs6601505 chr8 10560878 C T 4.99E-04 Multiple complex diseases / / 17554300 rs6601506 chr8 10561155 T C 6.87E-05 Type 2 diabetes / / 17463246 rs6601506 chr8 10561155 T C 3.89E-04 Multiple complex diseases / / 17554300 rs4840510 chr8 10564067 A G 1.46E-04 Type 2 diabetes / / 17463246 rs11250060 chr8 10566217 A C 5.10E-05 Type 2 diabetes / / 17463246 rs11250060 chr8 10566217 A C 5.35E-04 Multiple complex diseases / / 17554300 rs4503064 chr8 10579392 A G 3.00E-06 Digit length ratio / / 20303062 rs11250064 chr8 10581882 A C 9.20E-07 Digit length ratio SOX7 UTR-3 20303062 rs1139843 chr8 10582097 C G 1.68E-04 Type 2 diabetes SOX7 UTR-3 17463246 rs6601513 chr8 10594843 T C 8.44E-04 Multiple complex diseases / / 17554300 rs6601513 chr8 10594843 T C 7.16E-04 Alzheimer's disease / / 17998437 rs10094497 chr8 10602829 T G 1.51E-04 Multiple complex diseases / / 17554300 rs17711248 chr8 10615949 G C 9.90E-05 Personality dimensions / / 18957941 rs17774023 chr8 10626333 T C 5.07E-05 Asthma PINX1 intron pha003128 rs7826189 chr8 10627860 G A 4.26E-04 Multiple complex diseases PINX1 intron 17554300 rs7012388 chr8 10644560 A T 1.22E-04 Multiple complex diseases PINX1 intron 17554300 rs12679010 chr8 10647783 A C 6.49E-04 Smoking initiation PINX1 intron 24665060 rs12681375 chr8 10657596 A G 3.98E-04 Smoking initiation PINX1 intron 24665060 rs12680846 chr8 10659832 C A 3.08E-04 Smoking initiation PINX1 intron 24665060 rs6601530 chr8 10671272 G A 2.00E-08 Carotid intima media thickness PINX1 intron 21909108 rs1544980 chr8 10677981 T C 3.71E-04 Suicide attempts in bipolar disorder PINX1 intron 21041247 rs7005531 chr8 10682217 G A 5.95E-04 Type 2 diabetes PINX1 intron 17463246 rs17152571 chr8 10682777 G A 7.80E-04 Type 2 diabetes PINX1 intron 17463246 rs17152571 chr8 10682777 G A 1.04E-04 Suicide attempts in bipolar disorder PINX1 intron 21041247 rs7840785 chr8 10683127 C T 8.93E-04 Suicide attempts in bipolar disorder PINX1 intron 21041247 rs2271356 chr8 10683776 T A 8.68E-04 Suicide attempts in bipolar disorder PINX1 intron 21041247 rs11776767 chr8 10683929 G C 1.00E-08 Triglycerides PINX1 intron 20686565 rs11776767 chr8 10683929 G C 3.00E-11 Triglycerides PINX1 intron 24097068 rs10109550 chr8 10685586 G T 8.48E-04 Suicide attempts in bipolar disorder PINX1 intron 21041247 rs17152584 chr8 10685851 G A 7.77E-04 Type 2 diabetes PINX1 intron 17463246 rs17152584 chr8 10685851 G A 1.03E-04 Suicide attempts in bipolar disorder PINX1 intron 21041247 rs6989846 chr8 10686085 C T 8.30E-04 Suicide attempts in bipolar disorder PINX1 intron 21041247 rs6601534 chr8 10691993 A G 8.72E-05 Body Mass Index PINX1 intron pha003019 rs6601534 chr8 10691993 A G 1.67E-05 Body Mass Index PINX1 intron pha003020 rs7010709 chr8 10701959 T C 1.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs6990589 chr8 10702534 G A 2.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs11250082 chr8 10703794 C T 2.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs11990167 chr8 10704398 C T 1.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs1469557 chr8 10706801 C T 1.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs17152619 chr8 10710199 G C 3.96E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs13260821 chr8 10712027 A G 4.77E-04 Smoking quantity / / 24665060 rs4841455 chr8 10720969 C T 9.88E-04 Type 2 diabetes / / 17463246 rs10095927 chr8 10729177 G T 6.22E-05 Lung function (forced vital capacity) / / pha003104 rs2409667 chr8 10729623 A G 1.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs10903331 chr8 10732547 C G 1.68E-05 Suicide attempts in bipolar disorder / / 21041247 rs2409665 chr8 10736233 G C 2.09E-04 Nicotine dependence / / 17158188 rs10090444 chr8 10745469 C G 4.92E-04 Multiple complex diseases / / 17554300 rs6985109 chr8 10761585 G A 2.51E-11 Systemic lupus erythematosus XKR6 intron 18204446 rs4240671 chr8 10767748 G A 8.51E-04 Multiple complex diseases XKR6 intron 17554300 rs4240671 chr8 10767748 G A 6.60E-09 Systemic lupus erythematosus XKR6 intron 18204446 rs7016385 chr8 10779472 C T 2.08E-04 Multiple complex diseases XKR6 intron 17554300 rs4240673 chr8 10787612 T C 3.81E-04 Longevity XKR6 intron 22279548 rs11783247 chr8 10788875 C T 8.00E-10 Systemic lupus erythematosus XKR6 intron 18204446 rs11783247 chr8 10788875 C T 9.44E-05 Longevity XKR6 intron 22279548 rs6984496 chr8 10796093 G T 2.00E-10 Systemic lupus erythematosus XKR6 intron 18204446 rs6984496 chr8 10796093 G T 4.86E-05 Longevity XKR6 intron 22279548 rs6982751 chr8 10813474 C G 4.00E-07 Asthma and hay fever XKR6 intron 24388013 rs7016760 chr8 10916523 A G 6.85E-05 Serum metabolites XKR6 intron 19043545 rs17152841 chr8 10942929 T C 8.35E-04 Multiple complex diseases XKR6 intron 17554300 rs9657544 chr8 10944616 C G 2.47E-04 Multiple complex diseases XKR6 intron 17554300 rs2409715 chr8 11010136 A T 9.90E-07 Lipid levels XKR6 intron 18193043 rs2409716 chr8 11010748 T C 5.00E-06 Lipid levels XKR6 intron 18193043 rs17152930 chr8 11010826 G A 3.10E-169 Non-small cell lung cancer XKR6 intron 21866343 rs7819412 chr8 11045161 G A 3.00E-08 Triglycerides XKR6 intron 19060906 rs2409748 chr8 11078862 T A 7.94E-04 Multiple complex diseases / / 17554300 rs4841511 chr8 11079259 T C 4.03E-06 Asthma / / 21790008 rs958648 chr8 11103895 A G 0.000408714 Hypertension (early onset hypertension) / / 22479346 rs7824557 chr8 11104111 G A 4.00E-07 Retinal vascular caliber / / 21060863 rs2572430 chr8 11105304 T G 3.70E-05 Anger / / 24489884 rs2736372 chr8 11106041 T C 0.000591219 Hypertension (early onset hypertension) / / 22479346 rs7012033 chr8 11107610 C T 9.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs17728678 chr8 11116661 A G 6.68E-05 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs10503418 chr8 11118983 C T 2.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs2251301 chr8 11119037 C T 1.00E-06 Response to antipsychotic therapy (extrapyramidal side effects) / / 19875103 rs11776159 chr8 11119886 G A 5.77E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11776159 chr8 11119886 G A 5.93E-04 Acute lung injury / / 22295056 rs6986275 chr8 11120910 G A 1.10E-04 Acute lung injury / / 22295056 rs6990463 chr8 11121260 G A 5.76E-04 Acute lung injury / / 22295056 rs17796315 chr8 11124758 G A 8.56E-04 Acute lung injury / / 22295056 rs17153082 chr8 11125086 G A 1.33E-04 Acute lung injury / / 22295056 rs2736379 chr8 11125262 C A 1.33E-04 Acute lung injury / / 22295056 rs17153088 chr8 11128712 A G 7.79E-04 Multiple complex diseases / / 17554300 rs2293855 chr8 11177410 G A 1.30E-07 Obesity (extreme) MTMR9 intron 17855449 rs2293855 chr8 11177410 G A 5.00E-04 Obesity (extreme) MTMR9 intron 17855449 rs2736280 chr8 11223022 C A 6.12E-04 Schizophrenia TDH intron 19197363 rs7836059 chr8 11272164 G A 4.00E-10 Systemic lupus erythematosus C8orf12 intron 18204446 rs2002030 chr8 11276542 T C 5.00E-06 Cognitive performance C8orf12 intron 20125193 rs11989613 chr8 11277314 A G 3.76E-04 Type 2 diabetes C8orf12 intron 17463246 rs2409764 chr8 11281273 A G 5.78E-07 Esophageal cancer (squamous cell) FAM167A UTR-3 22960999 rs11780980 chr8 11282893 C T 6.53E-05 Parkinson's disease FAM167A intron 21738487 rs12156009 chr8 11285219 A C 1.88E-04 Response to cytidine analogues (gemcitabine) FAM167A intron 24483146 rs10089185 chr8 11285609 A C 8.64E-04 Type 2 diabetes FAM167A intron 17463246 rs10503423 chr8 11287081 G C 8.70E-04 Multiple complex diseases FAM167A intron 17554300 rs6982606 chr8 11287122 G T 2.32E-04 Multiple complex diseases FAM167A intron 17554300 rs7007712 chr8 11290802 T C 8.44E-04 Rheumatoid arthritis FAM167A intron 21452313 rs7003814 chr8 11290955 A G 8.96E-04 Alzheimer's disease FAM167A intron 17998437 rs6984212 chr8 11290966 C T 7.85E-04 Rheumatoid arthritis FAM167A intron 21452313 rs4310165 chr8 11294575 C T 8.39E-04 Alcohol dependence FAM167A intron 21314694 rs2001462 chr8 11294810 C T 7.81E-04 Response to cytadine analogues (cytosine arabinoside) FAM167A intron 24483146 rs2898280 chr8 11321292 A G 1.69E-04 IgE levels FAM167A intron 17255346 rs2898280 chr8 11321292 A G 8.40E-04 Kawasaki disease FAM167A intron 22446962 rs2618431 chr8 11324464 A G 4.80E-04 Kawasaki disease / / 22446962 rs2244234 chr8 11336467 T G 5.50E-11 Kawasaki disease / / 22446962 rs2409780 chr8 11337587 T C 5.10E-11 Kawasaki disease / / 22446962 rs1564267 chr8 11337887 T C 3.30E-10 Kawasaki disease / / 22446962 rs1564267 chr8 11337887 T C 3.50E-13 Systemic lupus erythematosus / / 23273568 rs2618444 chr8 11338370 A C 6.20E-11 Kawasaki disease / / 22446962 rs62489069 chr8 11338383 A G 7.90E-12 Kawasaki disease / / 22446962 rs35393613 chr8 11338466 C T 3.60E-12 Kawasaki disease / / 22446962 rs1531577 chr8 11338561 C T 1.40E-11 Kawasaki disease / / 22446962 rs13256690 chr8 11338568 G C 3.10E-12 Kawasaki disease / / 22446962 rs2061831 chr8 11339882 T C 6.10E-11 Kawasaki disease / / 22446962 rs2736332 chr8 11339965 G C 4.20E-11 Kawasaki disease / / 22446962 rs7812879 chr8 11340181 T C 2.00E-24 Systemic lupus erythematosus / / 19838193 rs7812879 chr8 11340181 T C 5.50E-10 Kawasaki disease / / 22446962 rs7812879 chr8 11340181 T C 3.40E-13 Systemic lupus erythematosus / / 23273568 rs2254891 chr8 11341129 G C 1.60E-10 Kawasaki disease / / 22446962 rs2736335 chr8 11341487 A G 4.50E-12 Kawasaki disease / / 22446962 rs2736336 chr8 11341870 G C,T 3.10E-12 Kawasaki disease / / 22446962 rs2736337 chr8 11341880 T C 5.60E-12 Kawasaki disease / / 22446962 rs2736337 chr8 11341880 T C 2.00E-07 Rheumatoid arthritis / / 24390342 rs2736337 chr8 11341880 T C 3.00E-13 Rheumatoid arthritis / / 24390342 rs2736337 chr8 11341880 T C 8.00E-08 Rheumatoid arthritis / / 24390342 rs2736338 chr8 11341883 A C 5.60E-12 Kawasaki disease / / 22446962 rs2254546 chr8 11343680 A G 8.00E-21 Kawasaki disease / / 22446962 rs2254546 chr8 11343680 A G 2.00E-13 Systemic lupus erythematosus / / 23273568 rs2736340 chr8 11343973 C T 6.00E-09 Rheumatoid arthritis / / 19503088 rs2736340 chr8 11343973 C T 3.42E-06 Systemic lupus erythematosus / / 19838193 rs2736340 chr8 11343973 C T 6.00E-09 Celiac disease and Rheumatoid arthritis / / 21383967 rs2736340 chr8 11343973 C T 3.00E-07 Systemic lupus erythematosus / / 21408207 rs2736340 chr8 11343973 C T 3.40E-12 Multiple sclerosis / / 22190364 rs2736340 chr8 11343973 C T 9.00E-10 Kawasaki disease / / 22446961 rs2736340 chr8 11343973 C T 1.30E-09 Kawasaki disease / / 22446962 rs2736340 chr8 11343973 C T 3.30E-12 Systemic lupus erythematosus / / 23273568 rs2736340 chr8 11343973 C T 1.00E-08 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs2736340 chr8 11343973 C T 6.53E-05 Dermatomyositis / / 23983088 rs2618473 chr8 11344127 C T 3.30E-11 Kawasaki disease / / 22446962 rs4840565 chr8 11345545 G C 8.10E-12 Kawasaki disease / / 22446962 rs4840565 chr8 11345545 G C 0.0000039 Rheumatoid arthritis / / 23143596 rs1478900 chr8 11347660 C T 2.52E-05 Kawasaki disease / / 22446961 rs1478900 chr8 11347660 C T 6.50E-11 Kawasaki disease / / 22446962 rs1478901 chr8 11347833 G C 2.10E-11 Kawasaki disease / / 22446962 rs9693589 chr8 11348961 G A 9.40E-11 Kawasaki disease / / 22446962 rs13277113 chr8 11349186 G A 1.00E-10 Systemic lupus erythematosus / / 18204098 rs13277113 chr8 11349186 G A 3.07E-07 Systemic lupus erythematosus / / 19838193 rs13277113 chr8 11349186 G A 2.70E-08 Kawasaki disease / / 22446962 rs13277113 chr8 11349186 G A 2.00E-10 Systemic lupus erythematosus / / 23053960 rs13277113 chr8 11349186 G A 1.10E-12 Systemic lupus erythematosus / / 23273568 rs2736343 chr8 11349250 C T 1.80E-10 Kawasaki disease / / 22446962 rs2251056 chr8 11349576 C A 1.50E-10 Kawasaki disease BLK nearGene-5 22446962 rs2736344 chr8 11350678 T C 3.00E-10 Kawasaki disease BLK nearGene-5 22446962 rs9694294 chr8 11350721 C G 1.40E-10 Kawasaki disease BLK nearGene-5 22446962 rs4840568 chr8 11351019 G A 1.20E-10 Kawasaki disease BLK nearGene-5 22446962 rs1382568 chr8 11351220 A C,G 5.90E-10 Kawasaki disease BLK nearGene-5 22446962 rs922483 chr8 11351912 C T 5.10E-11 Kawasaki disease BLK UTR-5 22446962 rs2250788 chr8 11352056 A G 6.10E-10 Kawasaki disease BLK UTR-5 22446962 rs2736345 chr8 11352485 A G 5.20E-10 Kawasaki disease BLK intron 22446962 rs2618476 chr8 11352541 T C 2.00E-08 Systemic lupus erythematosus BLK intron 19165918 rs2618476 chr8 11352541 T C 2.23E-06 Kawasaki disease BLK intron 22446961 rs2618476 chr8 11352541 T C 3.80E-10 Kawasaki disease BLK intron 22446962 rs998683 chr8 11353000 G A 1.28E-05 Lymphocyte counts BLK intron 22286170 rs998683 chr8 11353000 G A 8.20E-06 Kawasaki disease BLK intron 22446961 rs998683 chr8 11353000 G A 1.20E-10 Kawasaki disease BLK intron 22446962 rs998682 chr8 11353052 A G 1.06E-05 Kawasaki disease BLK intron 22446961 rs998682 chr8 11353052 A G 6.60E-10 Kawasaki disease BLK intron 22446962 rs1478895 chr8 11353335 G C 1.09E-05 Kawasaki disease BLK intron 22446961 rs1478895 chr8 11353335 G C 7.50E-10 Kawasaki disease BLK intron 22446962 rs2618481 chr8 11354097 C T 1.70E-10 Kawasaki disease BLK intron 22446962 rs2250412 chr8 11354570 G A 1.70E-11 Kawasaki disease BLK intron 22446962 rs2618479 chr8 11355821 A G 1.01E-05 Kawasaki disease BLK intron 22446961 rs2618479 chr8 11355821 A G 3.60E-09 Kawasaki disease BLK intron 22446962 rs1478887 chr8 11355980 C T 3.60E-11 Kawasaki disease BLK intron 22446962 rs2618478 chr8 11356002 C A 2.30E-09 Kawasaki disease BLK intron 22446962 rs2618471 chr8 11359020 C G 1.30E-09 Kawasaki disease BLK intron 22446962 rs2736346 chr8 11359112 G A 5.20E-10 Kawasaki disease BLK intron 22446962 rs2736347 chr8 11359377 G A 4.00E-11 Kawasaki disease BLK intron 22446962 rs2618469 chr8 11359380 G A 9.40E-10 Kawasaki disease BLK intron 22446962 rs2409781 chr8 11359557 T C 8.10E-10 Kawasaki disease BLK intron 22446962 rs1600249 chr8 11359638 G T 5.00E-06 Rheumatoid arthritis BLK intron 21452313 rs1600249 chr8 11359638 G T 1.90E-07 Kawasaki disease BLK intron 22446962 rs1585729 chr8 11360045 G C 1.10E-11 Kawasaki disease BLK intron 22446962 rs2736350 chr8 11361552 T G 1.10E-09 Kawasaki disease BLK intron 22446962 rs2618467 chr8 11362243 T C 2.00E-08 Kawasaki disease BLK intron 22446962 rs10100215 chr8 11362272 G T 1.10E-08 Kawasaki disease BLK intron 22446962 rs2280805 chr8 11363784 A T 4.40E-06 Kawasaki disease BLK intron 22446962 rs2736353 chr8 11367038 C T 4.30E-07 Kawasaki disease BLK intron 22446962 rs2252729 chr8 11368219 A G 1.30E-07 Kawasaki disease BLK intron 22446962 rs2736354 chr8 11368731 T C 8.19E-05 Kawasaki disease BLK intron 22446961 rs2736354 chr8 11368731 T C 7.30E-07 Kawasaki disease BLK intron 22446962 rs2736354 chr8 11368731 T C 7.35E-05 Smoking cessation BLK intron 24665060 rs569648905 chr8 11368731 TC T 8.19E-05 Kawasaki disease BLK intron 22446961 rs569648905 chr8 11368731 TC T 7.30E-07 Kawasaki disease BLK intron 22446962 rs569648905 chr8 11368731 TC T 7.35E-05 Smoking cessation BLK intron 24665060 rs2618458 chr8 11369068 A G 6.90E-07 Kawasaki disease BLK intron 22446962 rs2618457 chr8 11369177 A G 8.70E-07 Kawasaki disease BLK intron 22446962 rs2736355 chr8 11369777 T C 1.10E-06 Kawasaki disease BLK intron 22446962 rs6993775 chr8 11369989 G T 3.86E-05 Kawasaki disease BLK intron 22446961 rs6993775 chr8 11369989 G T 8.00E-09 Kawasaki disease BLK intron 22446962 rs6993775 chr8 11369989 G T 3.16E-05 Smoking cessation BLK intron 24665060 rs2736356 chr8 11370451 C T 1.00E-05 Kawasaki disease BLK intron 22446962 rs2618456 chr8 11370733 G C 4.80E-05 Kawasaki disease BLK intron 22446962 rs2618455 chr8 11370878 A G 9.50E-08 Kawasaki disease BLK intron 22446962 rs2618455 chr8 11370878 A G 3.17E-05 Smoking cessation BLK intron 24665060 rs12674768 chr8 11371547 C T 4.40E-05 Kawasaki disease BLK intron 22446962 rs11990277 chr8 11372085 T C 4.80E-07 Kawasaki disease BLK intron 22446962 rs2736359 chr8 11372099 G A 1.90E-04 Kawasaki disease BLK intron 22446962 rs11250141 chr8 11372141 G A 3.30E-07 Kawasaki disease BLK intron 22446962 rs11250141 chr8 11372141 G A 9.86E-05 Smoking cessation BLK intron 24665060 rs11250142 chr8 11372533 G A 1.50E-04 Kawasaki disease BLK intron 22446962 rs12677903 chr8 11372637 T C 3.40E-04 Kawasaki disease BLK intron 22446962 rs17153385 chr8 11373264 C T 1.30E-04 Kawasaki disease BLK intron 22446962 rs17153385 chr8 11373264 C T 5.21E-05 Smoking cessation BLK intron 24665060 rs2736360 chr8 11373467 G A 4.50E-07 Kawasaki disease BLK intron 22446962 rs2736360 chr8 11373467 G A 4.98E-05 Smoking cessation BLK intron 24665060 rs4841546 chr8 11374107 C T 3.80E-04 Kawasaki disease BLK intron 22446962 rs11991127 chr8 11378740 A G 5.00E-04 Kawasaki disease BLK intron 22446962 rs2898282 chr8 11383200 T A 6.90E-04 Kawasaki disease BLK intron 22446962 rs2021819 chr8 11384199 G C 7.30E-04 Kawasaki disease BLK intron 22446962 rs1382566 chr8 11384841 G C 4.40E-05 Kawasaki disease BLK intron 22446961 rs1382566 chr8 11384841 G C 2.60E-04 Kawasaki disease BLK intron 22446962 rs1382566 chr8 11384841 G C 0.0000023 Ovarian follicle number and menopause BLK intron 22696150 rs7814834 chr8 11387861 C T 4.00E-05 Kawasaki disease BLK intron 22446962 rs7814834 chr8 11387861 C T 8.08E-05 Smoking cessation BLK intron 24665060 rs2249259 chr8 11388764 A G 1.80E-04 Kawasaki disease BLK intron 22446962 rs2249259 chr8 11388764 A G 6.68E-04 Smoking cessation BLK intron 24665060 rs58373594 chr8 11390627 A T 7.90E-04 Kawasaki disease BLK intron 22446962 rs2249040 chr8 11390779 A T 4.10E-04 Kawasaki disease BLK intron 22446962 rs2248932 chr8 11391650 A G 7.00E-10 Systemic lupus erythematosus BLK intron 18204446 rs2248932 chr8 11391650 A G 1.63E-14 Systemic lupus erythematosus BLK intron 19838193 rs2248932 chr8 11391650 A G 5.30E-04 Kawasaki disease BLK intron 22446962 rs2248700 chr8 11393745 G A 1.50E-04 Kawasaki disease BLK intron 22446962 rs17153419 chr8 11394233 A G 3.52E-05 Kawasaki disease BLK intron 22446961 rs1478897 chr8 11395232 T A 5.60E-05 Kawasaki disease BLK intron 22446961 rs1478897 chr8 11395232 T A 5.80E-04 Kawasaki disease BLK intron 22446962 rs7014565 chr8 11396818 C T 3.20E-05 Kawasaki disease BLK intron 22446962 rs7014565 chr8 11396818 C T 2.48E-05 Smoking cessation BLK intron 24665060 rs2169889 chr8 11396914 C T 2.81E-04 Smoking initiation BLK intron 24665060 rs7820492 chr8 11404514 G A 9.01E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) BLK intron 23648065 rs2255327 chr8 11409992 C T 3.00E-07 Immune response to smallpox vaccine (IL-6) BLK intron 22610502 rs936550 chr8 11410987 C A 6.74E-04 Amyotrophic Lateral Sclerosis BLK intron 17362836 rs13280813 chr8 11425105 G T 4.02E-04 Acne (severe) / / 24927181 rs1382563 chr8 11426790 G C 2.20E-05 Urinary metabolites / / 21572414 rs12547947 chr8 11427341 T G 6.10E-05 Serum metabolites / / 19043545 rs7831039 chr8 11427637 A T 2.10E-05 Urinary metabolites / / 21572414 rs732947 chr8 11429147 A G 2.30E-06 Urinary metabolites / / 21572414 rs732947 chr8 11429147 A G 4.23E-05 Myopia (pathological) / / 23049088 rs11776081 chr8 11431222 G A 9.20E-07 Urinary metabolites / / 21572414 rs12677326 chr8 11439225 G A 6.41E-05 Birth weight / / 17255346 rs12677326 chr8 11439225 G A 1.40E-06 Systemic lupus erythematosus / / 21408207 rs1478892 chr8 11448529 G T 4.42E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs10903340 chr8 11450587 T G 1.46E-07 Systemic lupus erythematosus / / 18204446 rs17807624 chr8 11463015 C T 5.56E-04 Multiple complex diseases / / 17554300 rs10106995 chr8 11469622 C T 3.76E-04 Multiple complex diseases / / 17554300 rs2243407 chr8 11480457 T C 6.00E-06 Periodontitis (CDC/AAP) / / 24024966 rs2243407 chr8 11480457 T C 9.00E-06 Periodontitis (CDC/AAP) / / 24024966 rs4841578 chr8 11516373 A G 2.30E-05 Hypothyroidism / / 22493691 rs4841579 chr8 11516592 T G 1.45E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs2409809 chr8 11547150 T C 7.90E-06 Brain size / / 22156575 rs13262332 chr8 11551982 G A 5.72E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs12550668 chr8 11579954 A G 5.60E-04 Lymphocyte counts GATA4 intron 22286170 rs10503426 chr8 11589383 G T 3.69E-05 Myopia (pathological) GATA4 intron 23049088 rs6983129 chr8 11591136 C A 0.0000023 Triglycerides GATA4 intron 23063622 rs6983129 chr8 11591136 C A 2.62E-08 Triglycerides GATA4 intron 23063622 rs2898295 chr8 11595969 G A 0.0000132 Triglycerides GATA4 intron 23063622 rs7006733 chr8 11607990 G A 3.10E-04 Volumetric brain MRI GATA4 intron 17903297 rs2740434 chr8 11608905 A G 1.35E-04 Suicide attempts in bipolar disorder GATA4 intron 21423239 rs804283 chr8 11611043 G A 2.81E-04 Longevity GATA4 intron 22279548 rs13273672 chr8 11612381 T C 0.00014 Coronary artery calcification GATA4 intron 23727086 rs804280 chr8 11612698 C A 4.00E-06 Myopia (pathological) GATA4 intron 23049088 rs11785481 chr8 11617142 C T 5.26E-04 Amyotrophic lateral sclerosis (sporadic) GATA4 UTR-3 24529757 rs6601606 chr8 11638244 A G 1.00E-06 Neutrophil count NEIL2 intron 21507922 rs804292 chr8 11643915 G A 1.50E-04 Non-substance related behavioral disinhibition NEIL2 UTR-3 23942779 rs804292 chr8 11643915 G A 2.00E-06 Alcohol dependence NEIL2 UTR-3 23942779 rs804292 chr8 11643915 G A 3.00E-06 Nicotine use NEIL2 UTR-3 23942779 rs804292 chr8 11643915 G A 6.80E-05 Illicit drug use NEIL2 UTR-3 23942779 rs7001819 chr8 11650475 T C 1.53E-07 Body mass index / / 18325910 rs2645444 chr8 11651553 C T 6.48E-05 IgE levels / / 17255346 rs2645444 chr8 11651553 C T 8.77E-05 Response to hepatitis C treatment / / 19684573 rs2645430 chr8 11659109 A G 4.00E-07 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs1497042 chr8 11660614 C T 4.53E-07 Ejection fraction in Tripanosoma cruzi seropositivity FDFT1 intron 24324551 rs2252567 chr8 11660916 C T 5.67E-07 Ejection fraction in Tripanosoma cruzi seropositivity FDFT1 intron 24324551 rs10098874 chr8 11662885 G A 6.36E-05 Non-alcoholic fatty liver disease histology (other) FDFT1 intron 20708005 rs1736057 chr8 11665217 G A 4.01E-06 Ejection fraction in Tripanosoma cruzi seropositivity FDFT1 intron 24324551 rs1534863 chr8 11668153 T C 4.78E-05 LDL lipoproteins FDFT1 intron pha002902 rs1736058 chr8 11671041 G A 1.76E-05 LDL lipoproteins FDFT1 intron pha002902 rs2645424 chr8 11684463 A C,G,T 3.00E-06 Non-alcoholic fatty liver disease histology (lobular) FDFT1 intron 20708005 rs2645424 chr8 11684463 A C,G,T 7.00E-07 Non-alcoholic fatty liver disease histology (other) FDFT1 intron 20708005 rs2409836 chr8 11689228 T G 0.0000451 Body mass index FDFT1 intron 22885924 rs1293314 chr8 11690106 T C 8.30E-04 Coronary heart disease FDFT1 intron 21966275 rs6601615 chr8 11692854 C T 0.000000997 HDL cholesterol FDFT1 intron 23063622 rs1296028 chr8 11698747 A G 1.00E-06 Parkinson's disease / / 22451204 rs1296028 chr8 11698747 A G 1.26E-04 Acne (severe) / / 24927181 rs4839 chr8 11701933 T C 5.08E-05 Acne (severe) CTSB UTR-3 24927181 rs1296023 chr8 11726817 A G 1.36E-05 Type 1 diabetes CTSB nearGene-5 18978792 rs2250903 chr8 11735184 G T 8.79E-05 Type 1 diabetes / / 18978792 rs1630828 chr8 11745820 G A 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2645408 chr8 11746358 A G 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs7818169 chr8 11747232 C T 8.94E-04 Multiple complex diseases / / 17554300 rs4841617 chr8 11769328 T C 2.32E-04 Insulin resistance / / 21901158 rs7817266 chr8 11773889 A G 1.38E-06 Personality dimensions / / 23658558 rs4840599 chr8 11805380 T C 1.00E-04 Spine bone size / / 21947420 rs11250182 chr8 11807576 T A 1.00E-04 Spine bone size / / 21947420 rs9657521 chr8 11830502 A C,G,T 9.41E-04 Alcohol dependence / / 24277619 rs7823808 chr8 11836622 C T 2.19E-04 Smoking cessation / / 24665060 rs12550733 chr8 11859851 C A 6.41E-04 Schizophrenia / / 19197363 rs7821214 chr8 11896831 T C 3.55E-05 Left ventricular hypertrophy / / pha003052 rs4841689 chr8 11897177 A G 9.94E-05 Smoking cessation / / 24665060 rs2905026 chr8 12481379 A G 4.87E-06 Aortic root size LOC729732 intron 21223598 rs1715410 chr8 12481979 A G 4.95E-04 Multiple complex diseases LOC729732 intron 17554300 rs11781870 chr8 12593429 C T 7.32E-05 Major depressive disorder LONRF1 intron 21621269 rs4560793 chr8 12620287 G A 3.96E-49 Metabolite levels / / 22286219 rs17830061 chr8 12623036 G C 6.56E-04 Type 2 diabetes / / 17463246 rs10503428 chr8 12667357 C T 3.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC340357 intron 20877124 rs6980603 chr8 12673698 A G 6.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7814546 chr8 12686004 A G 4.69E-05 Blood Pressure / / pha003046 rs17120471 chr8 12691871 T C 6.00E-06 IgG glycosylation / / 23382691 rs6985529 chr8 12698470 C T 5.65E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12548516 chr8 12701924 C T 1.36E-05 Relative hand skill in reading disability / / 24068947 rs4831837 chr8 12711863 G A 5.00E-07 Morbidity-free survival / / 17903295 rs10091521 chr8 12717076 A G 3.79E-04 Insulin resistance / / 21901158 rs12547628 chr8 12717564 T C 6.76E-05 Hypertension / / 19609347 rs13272401 chr8 12726062 T G 1.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs13272401 chr8 12726062 T G 2.79E-04 Suicide attempts in bipolar disorder / / 21041247 rs6989010 chr8 12772755 G T 2.00E-06 Colorectal cancer (diet interaction) / / 24743840 rs2947384 chr8 12786594 T C 9.38E-05 Serum metabolites / / 19043545 rs1401471 chr8 12807061 T C 7.40E-06 Urinary metabolites KIAA1456 intron 21572414 rs1401471 chr8 12807061 T C 1.96E-05 Coronary heart disease KIAA1456 intron pha003031 rs62488971 chr8 12808108 C T 8.37E-06 Post-traumatic stress disorder KIAA1456 intron 24677629 rs2946505 chr8 12811152 T G 9.00E-06 Migraine KIAA1456 intron 23793025 rs6999231 chr8 12817882 A C 8.50E-07 Urinary metabolites KIAA1456 intron 21572414 rs2203837 chr8 12819839 T C 9.60E-07 Urinary metabolites KIAA1456 intron 21572414 rs10108595 chr8 12824163 G T 1.00E-04 Prostate cancer KIAA1456 intron 21743057 rs2203834 chr8 12824893 A C 1.40E-06 Migraine KIAA1456 intron 21666692 rs2203834 chr8 12824893 A C 1.21E-04 Vaspin levels KIAA1456 intron 22907691 rs2203834 chr8 12824893 A C 0.0001157 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit KIAA1456 intron 22907730 rs2203834 chr8 12824893 A C 0.0001214 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks KIAA1456 intron 22907730 rs2460915 chr8 12826036 T A 2.87E-05 Schizophrenia KIAA1456 intron 19571809 rs2460905 chr8 12834600 G A 5.00E-06 Post-traumatic stress disorder KIAA1456 intron 24677629 rs10101284 chr8 12844441 C T 1.00E-04 Prostate cancer KIAA1456 intron 21743057 rs10109366 chr8 12846619 C T 1.00E-04 Prostate cancer KIAA1456 intron 21743057 rs1519150 chr8 12848860 A T 5.97E-04 Suicide attempts in bipolar disorder KIAA1456 intron 21041247 rs10108476 chr8 12854134 G A 1.00E-04 Prostate cancer KIAA1456 intron 21743057 rs10104432 chr8 12855077 T C 1.00E-04 Prostate cancer KIAA1456 intron 21743057 rs2466273 chr8 12866004 A C 7.10E-06 Post-traumatic stress disorder KIAA1456 intron 24677629 rs2954191 chr8 12867352 G A 2.00E-05 Urinary metabolites KIAA1456 intron 21572414 rs12156420 chr8 12870186 C G 4.29E-04 Multiple complex diseases KIAA1456 UTR-5 17554300 rs10091369 chr8 12870928 A G 4.04E-04 Blood pressure KIAA1456 intron 17255346 rs10091369 chr8 12870928 A G 7.11E-04 Multiple complex diseases KIAA1456 intron 17554300 rs11779957 chr8 12874915 T G 1.84E-04 Type 2 diabetes KIAA1456 intron 19184112 rs544302 chr8 12901247 A G 1.74E-04 Type 2 diabetes / / 17463246 rs606181 chr8 12917220 T C 5.07E-05 Type 2 diabetes / / 17463246 rs557128 chr8 12917312 C G 5.91E-05 Type 2 diabetes / / 17463246 rs634228 chr8 12918912 A G,T 4.95E-05 Type 2 diabetes / / 17463246 rs1044011 chr8 12941709 C A 5.24E-05 Cognitive decline DLC1 UTR-3 23732972 rs142253103 chr8 12943382 C T 0.00044 Prostate cancer (non-advanced prostate cancer) DLC1 missense 23555315 rs569510 chr8 12968657 A T 4.16E-04 Lung function (forced expiratory volume in 1 second) DLC1 intron 17255346 rs2410025 chr8 12973575 C A 3.16E-04 Lung function (forced expiratory volume in 1 second) DLC1 intron 17255346 rs12541254 chr8 12979400 G A 3.00E-09 Venous thromboembolism (gene x gene interaction) DLC1 intron 23509962 rs6987766 chr8 12995772 G C 1.70E-05 Urinary metabolites DLC1 intron 21572414 rs1431207 chr8 13031265 C G 1.45E-04 Multiple complex diseases DLC1 intron 17554300 rs35393495 chr8 13046807 A G 1.98E-04 Multiple complex diseases DLC1 intron 17554300 rs2016444 chr8 13058674 C G 1.00E-12 Fractional exhaled nitric oxide (childhood) DLC1 intron 24315451 rs2016444 chr8 13058674 C G 9.00E-07 Fractional exhaled nitric oxide (childhood) DLC1 intron 24315451 rs1653032 chr8 13086762 G A 1.10E-05 HIV-1 control DLC1 intron 20041166 rs17793145 chr8 13109645 C T 7.25E-07 Schizophrenia DLC1 intron 21926974 rs1618938 chr8 13143966 G T 1.31E-05 Post-operative nausea and vomiting DLC1 intron 21694509 rs13250216 chr8 13147465 A C 3.45E-04 Type 2 diabetes DLC1 intron 17463246 rs17128435 chr8 13147657 C T 2.92E-06 Left ventricular mass DLC1 intron 21212386 rs10503446 chr8 13147702 C T 3.86E-06 Left ventricular mass DLC1 intron 21212386 rs10888181 chr8 13150955 T C 5.25E-04 Type 2 diabetes DLC1 intron 17463246 rs13279835 chr8 13153938 C T 6.44E-05 Post-operative nausea and vomiting DLC1 intron 21694509 rs3988460 chr8 13164214 G A 7.52E-05 Post-operative nausea and vomiting DLC1 intron 21694509 rs1188130 chr8 13173084 T C 7.44E-04 Alzheimer's disease DLC1 intron 17998437 rs17801135 chr8 13173319 A G 0.000484 Breast cancer early age of onset DLC1 intron 18463975 rs3848999 chr8 13174945 C T 9.10E-08 Post-operative nausea and vomiting DLC1 intron 21694509 rs1653033 chr8 13176302 T C 6.50E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) DLC1 intron 22566498 rs1671400 chr8 13176407 A G 3.92E-05 Orofacial clefts DLC1 intron 19270707 rs1671400 chr8 13176407 A G 4.00E-06 Obesity-related traits DLC1 intron 23251661 rs12681573 chr8 13204116 T C 2.56E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) DLC1 intron 24023788 rs289566 chr8 13253219 G A 8.14E-05 Bipolar disorder DLC1 intron 20451256 rs289585 chr8 13260536 C T 5.00E-06 Bipolar disorder DLC1 intron 22688191 rs7816046 chr8 13260785 A G 3.34E-04 Alzheimer's disease (late onset) DLC1 intron 21379329 rs7822301 chr8 13273425 T G 1.43E-04 Tourette syndrome DLC1 intron 22889924 rs7834383 chr8 13273477 G T 5.94E-04 Tourette syndrome DLC1 intron 22889924 rs427561 chr8 13283641 T C 5.26E-06 Coronary heart disease DLC1 intron pha003030 rs7003283 chr8 13285702 G A 1.66E-05 Coronary heart disease DLC1 intron pha003030 rs289620 chr8 13294635 T C 2.53E-06 Coronary heart disease DLC1 intron pha003030 rs192627 chr8 13297265 G A 3.16E-04 Lung function (forced expiratory volume in 1 second) DLC1 intron 24023788 rs192627 chr8 13297265 G A 6.34E-05 Erythrocyte counts DLC1 intron pha003099 rs289542 chr8 13315533 T G 1.98E-05 Coronary heart disease DLC1 intron pha003030 rs7008646 chr8 13326917 C A 3.69E-05 Coronary heart disease DLC1 intron pha003030 rs11783108 chr8 13329776 G C 1.60E-05 Urinary metabolites DLC1 intron 21572414 rs4376497 chr8 13330640 G A 9.35E-06 Coronary heart disease DLC1 intron pha003030 rs4376498 chr8 13330729 G A 1.60E-05 Urinary metabolites DLC1 intron 21572414 rs1155204 chr8 13334842 C T 5.38E-05 Schizophrenia DLC1 intron 24253340 rs1481692 chr8 13339368 G A 8.32E-04 Iron levels DLC1 intron pha002876 rs3988457 chr8 13348853 C A 6.14E-04 Iron levels DLC1 intron pha002876 rs17094050 chr8 13348868 G T 2.73E-06 Schizophrenia DLC1 intron 24253340 rs4615570 chr8 13349014 A T 6.58E-04 Multiple complex diseases DLC1 intron 17554300 rs4348493 chr8 13349163 A T 5.92E-04 Multiple complex diseases DLC1 intron 17554300 rs10104278 chr8 13349274 G C 8.34E-04 Multiple complex diseases DLC1 intron 17554300 rs11775251 chr8 13349359 A G 1.48E-04 Multiple complex diseases DLC1 intron 17554300 rs12675813 chr8 13366751 G A 4.96E-04 Multiple complex diseases DLC1 intron 17554300 rs17094404 chr8 13370143 T C 4.97E-05 Multiple complex diseases DLC1 intron 17554300 rs13281337 chr8 13381591 C T 3.33E-05 Blood Pressure / / pha003039 rs13281337 chr8 13381591 C T 3.26E-05 Blood Pressure / / pha003040 rs17222409 chr8 13385822 G T 1.17E-04 Type 2 diabetes / / 17463246 rs979728 chr8 13390938 C T 8.60E-05 Type 2 diabetes / / 17463248 rs10089628 chr8 13395662 T C 6.87E-05 Meningococcal disease / / 20694013 rs10089628 chr8 13395662 T C 1.89E-05 Suicide attempts in depression or bipolar disorder / / 24964207 rs966212 chr8 13397766 T C 8.61E-04 Stroke / / pha002886 rs150638755 chr8 13434785 T C 0.00005982 Sarcoidosis / / 22952805 rs11785331 chr8 13434921 T C 2.92E-04 Alzheimer's disease / / 17998437 rs11785331 chr8 13434921 T C 2.85E-04 Alzheimer's disease / / pha002879 rs1481590 chr8 13454418 C T 8.59E-06 Type 2 diabetes / / 17463246 rs41363347 chr8 13455181 G T 7.13E-05 Gallstones / / 17632509 rs75810959 chr8 13455489 C T 0.00001799 Sarcoidosis / / 22952805 rs1982691 chr8 13456548 C G 5.30E-05 Type 2 diabetes / / 17463246 rs17227506 chr8 13458794 C T 1.44E-04 Type 2 diabetes / / 17463246 rs7838784 chr8 13470249 T C 9.70E-05 Response to antidepressants / / 19736353 rs6530658 chr8 13481885 T C 4.76E-04 Rheumatoid arthritis / / 21452313 rs7006666 chr8 13486906 C A 2.42E-05 Blood Pressure / / pha003049 rs4629867 chr8 13490323 T C 5.63E-04 Insulin resistance / / 21901158 rs17116959 chr8 13509864 A C 6.25E-05 Prion diseases / / 22210626 rs17237212 chr8 13529635 C A 1.04E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs17237212 chr8 13529635 C A 1.24E-04 Lung function (forced vital capacity) / / 24023788 rs6982631 chr8 13530101 T C 4.58E-04 Lung function (forced vital capacity) / / 24023788 rs6982631 chr8 13530101 T C 5.81E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs17237821 chr8 13535612 G T 1.60E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11785907 chr8 13536022 A T 1.90E-06 Urinary metabolites / / 21572414 rs11785907 chr8 13536022 A T 7.06E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12375315 chr8 13553686 A T 5.13E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2410094 chr8 13557493 C T 6.00E-05 Malaria / / 19465909 rs1384057 chr8 13560003 G A 2.40E-05 Malaria / / 19465909 rs12681268 chr8 13574646 C T 4.14E-05 Mammographic density / / 22532574 rs7835380 chr8 13574900 G T 4.31E-04 Mammographic density / / 22532574 rs17253084 chr8 13602156 G C 2.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs12678711 chr8 13610731 C T 5.05E-04 Smoking initiation / / 24665060 rs11984607 chr8 13610818 G A 5.13E-04 Rheumatoid arthritis / / 21452313 rs1871841 chr8 13630046 G C 2.10E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs17254431 chr8 13632016 A G 2.34E-05 Telomere length / / 23001564 rs2410098 chr8 13634384 A G 7.86E-05 Bipolar disorder / / 17486107 rs2410098 chr8 13634384 A G 8.55E-05 Potassium levels / / pha003086 rs28454879 chr8 13639227 A C 0.00008354 Sarcoidosis / / 22952805 rs11203531 chr8 13674039 C A 2.35E-04 Smoking initiation / / 24665060 rs9886538 chr8 13674318 C G 2.25E-04 Smoking initiation / / 24665060 rs9325677 chr8 13674554 A C 6.01E-04 Smoking initiation / / 24665060 rs10503477 chr8 13686816 A C 4.45E-04 Rheumatoid arthritis / / 21452313 rs10503477 chr8 13686816 A C 5.59E-04 Smoking initiation / / 24665060 rs6989085 chr8 13694367 G A 3.11E-09 Statin-induced myopathy / / 21826682 rs969895 chr8 13698050 G A 2.91E-04 Multiple complex diseases / / 17554300 rs7818612 chr8 13727064 A G 4.70E-05 Response to statin therapy / / 20339536 rs11779478 chr8 13729995 A G 6.80E-05 Response to statin therapy / / 20339536 rs35220997 chr8 13730430 T G 0.000163 Salmonella-induced pyroptosis / / 22837397 rs12547223 chr8 13742298 C T 1.01E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs12547223 chr8 13742298 C T 2.24E-04 Lung function (forced vital capacity) / / 24023788 rs9325678 chr8 13749974 T G 8.85E-04 Alzheimer's disease / / 24755620 rs10888075 chr8 13760419 T G 1.04E-05 Migraine / / 20802479 rs2682665 chr8 13798005 C T 7.62E-08 Common variable immunodeficiency / / 21497890 rs1601430 chr8 13810422 C T 7.10E-06 Urinary metabolites / / 21572414 rs4370533 chr8 13827184 A G 9.31E-05 Serum metabolites / / 19043545 rs11780201 chr8 13847960 G A 9.11E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10503470 chr8 13866128 T A 7.16E-04 Type 2 diabetes / / 17463246 rs11785994 chr8 13876049 C G 1.85E-05 Postoperative ventricular dysfunction / / 21980348 rs6986405 chr8 13884029 G A 4.06E-04 HIV-1 viral setpoint / / 17641165 rs12677452 chr8 13888364 C T 3.87E-04 HIV-1 viral setpoint / / 17641165 rs4401861 chr8 13891030 C T 2.32E-04 Type 2 diabetes / / 17463246 rs12549458 chr8 13891610 C T 2.32E-04 Type 2 diabetes / / 17463246 rs4831521 chr8 13893189 A G 1.92E-04 Type 2 diabetes / / 17463246 rs2410138 chr8 13893422 T C 2.16E-04 Type 2 diabetes / / 17463246 rs2898379 chr8 13893514 A T 1.91E-04 Type 2 diabetes / / 17463246 rs11784664 chr8 13905487 T G 1.35E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs4642648 chr8 13908572 G A 2.60E-05 Urinary metabolites / / 21572414 rs10111041 chr8 13908794 A T 1.60E-05 Urinary metabolites / / 21572414 rs973583 chr8 13908974 T C 1.60E-05 Urinary metabolites / / 21572414 rs973582 chr8 13909182 G A 1.90E-05 Urinary metabolites / / 21572414 rs973582 chr8 13909182 G A 1.50E-05 Mathematical ability / / 24801482 rs17118474 chr8 13910159 A T 1.70E-05 Urinary metabolites / / 21572414 rs17118482 chr8 13910942 T C 1.00E-05 Urinary metabolites / / 21572414 rs3915658 chr8 13917083 G A 6.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs3915662 chr8 13917514 C A 6.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs6530714 chr8 13920241 C T 9.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs6984874 chr8 13920404 A G 9.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs7007313 chr8 13921226 G A 9.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs7008553 chr8 13921326 C T 7.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs6990047 chr8 13921358 A G 7.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs7008741 chr8 13921482 C A 7.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs7007810 chr8 13921547 G T 8.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs7826184 chr8 13922433 A T 8.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs7842848 chr8 13922446 C T 8.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs11777177 chr8 13922681 T G 9.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs6980790 chr8 13923712 G C 8.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs6982182 chr8 13923883 C T 8.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs6981128 chr8 13923923 G A 8.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs17118571 chr8 13936956 A G 9.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs6997103 chr8 13956948 G A 6.18E-04 Alzheimer's disease SGCZ intron 22005930 rs7007117 chr8 13958463 G A 8.77E-04 Alzheimer's disease SGCZ intron 22005930 rs10503484 chr8 13961133 G T 2.10E-05 Platelet counts SGCZ intron pha003100 rs10503485 chr8 13966546 T C 6.28E-04 Type 2 diabetes SGCZ intron 17846124 rs10503487 chr8 13968625 A C 7.43E-04 Type 2 diabetes SGCZ intron 17846124 rs13259591 chr8 13971646 T C 6.82E-06 Platelet counts SGCZ intron pha003100 rs13253386 chr8 14002020 T G 4.40E-05 Platelet counts SGCZ intron pha003100 rs10105802 chr8 14009278 C A 4.31E-05 Platelet counts SGCZ intron pha003100 rs7841810 chr8 14017547 G A 9.87E-05 Calcium levels SGCZ intron pha003085 rs2014581 chr8 14017890 C T 4.63E-05 Calcium levels SGCZ intron pha003085 rs12547822 chr8 14019665 C T 5.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SGCZ intron 20877124 rs12547822 chr8 14019665 C T 5.42E-05 Calcium levels SGCZ intron pha003085 rs2059675 chr8 14060081 C A 3.53E-05 Serum metabolites SGCZ intron 19043545 rs2054422 chr8 14060841 T C 9.47E-05 Serum metabolites SGCZ intron 19043545 rs7815140 chr8 14084378 G C 2.48E-06 Serum metabolites SGCZ intron 19043545 rs7816456 chr8 14084582 C G 3.86E-05 Serum metabolites SGCZ intron 19043545 rs6989764 chr8 14085219 C G 1.13E-05 Serum metabolites SGCZ intron 19043545 rs10216716 chr8 14087736 G A 3.72E-05 Serum metabolites SGCZ intron 19043545 rs4637829 chr8 14088127 A G 8.45E-05 Diabetes Mellitus SGCZ intron pha003059 rs13255607 chr8 14088351 G A 1.82E-05 Serum metabolites SGCZ intron 19043545 rs4831559 chr8 14089730 G C 2.79E-06 Serum metabolites SGCZ intron 19043545 rs1365649 chr8 14105921 G T 7.62E-05 Serum metabolites SGCZ intron 19043545 rs1427000 chr8 14110654 C T 9.81E-05 Diabetes Mellitus SGCZ intron pha003059 rs7839860 chr8 14113760 A G 6.22E-05 Serum metabolites SGCZ intron 19043545 rs9886428 chr8 14113816 G A 1.00E-06 IgG glycosylation SGCZ intron 23382691 rs9886428 chr8 14113816 G A 2.00E-06 IgG glycosylation SGCZ intron 23382691 rs9886428 chr8 14113816 G A 2.00E-06 IgG glycosylation SGCZ intron 23382691 rs9886428 chr8 14113816 G A 3.00E-06 IgG glycosylation SGCZ intron 23382691 rs9886428 chr8 14113816 G A 5.00E-06 IgG glycosylation SGCZ intron 23382691 rs17118897 chr8 14129444 T C 4.45E-04 Alzheimer's disease (late onset) SGCZ intron 21379329 rs7818984 chr8 14130732 C T 1.45E-04 Smoking initiation SGCZ intron 24665060 rs7818984 chr8 14130732 C T 7.65E-04 Smoking quantity SGCZ intron 24665060 rs1365641 chr8 14133626 C G 1.63E-06 Multiple complex diseases SGCZ intron 17554300 rs10089704 chr8 14145436 T C 9.45E-05 Cognitive impairment induced by topiramate SGCZ intron 22091778 rs12114757 chr8 14149802 C T 5.70E-06 Cognitive impairment induced by topiramate SGCZ intron 22091778 rs10109318 chr8 14156422 A G 5.75E-05 Tunica Media SGCZ intron pha003036 rs10089267 chr8 14160078 C T 2.70E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) SGCZ intron 24192120 rs17119030 chr8 14161143 A C 4.09E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) SGCZ intron 24192120 rs12547474 chr8 14164104 T C 6.86E-05 Cognitive impairment induced by topiramate SGCZ intron 22091778 rs13254837 chr8 14172773 C T 5.14E-05 Socioeconomic Factors SGCZ intron pha003066 rs7000337 chr8 14203326 C T 7.82E-04 Type 2 diabetes SGCZ intron 17463246 rs7824519 chr8 14222796 T G 2.99E-05 Parkinson's disease SGCZ intron 17052657 rs7831260 chr8 14251611 G T 4.54E-04 Multiple complex diseases SGCZ intron 17554300 rs11203607 chr8 14276147 G A 2.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SGCZ intron 20877124 rs10503497 chr8 14282382 A C 1.40E-04 Blood Pressure and Arterial Stiffness SGCZ intron 17903302 rs6986126 chr8 14291317 T G 4.14E-06 Glycosylated haemoglobin levels SGCZ intron 17255346 rs11989070 chr8 14307817 T G 3.10E-05 Myasthenia gravis SGCZ intron 23055271 rs3848991 chr8 14339483 G A 9.38E-04 Response to cytidine analogues (gemcitabine) SGCZ intron 24483146 rs17303140 chr8 14346985 T G 3.97E-04 Response to cytidine analogues (gemcitabine) SGCZ intron 24483146 rs12679497 chr8 14352083 T A 3.55E-05 Serum metabolites SGCZ intron 19043545 rs10216809 chr8 14364923 C T 1.20E-08 Panic disorder SGCZ intron 19165232 rs1381410 chr8 14385320 G A 5.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SGCZ intron 20877124 rs10503499 chr8 14385337 G C 7.00E-06 Serum metabolites SGCZ intron 19043545 rs1461858 chr8 14386985 C A 6.09E-04 Smoking initiation SGCZ intron 24665060 rs1903595 chr8 14389481 A G 5.00E-06 Platelet aggregation SGCZ intron 20526338 rs1903595 chr8 14389481 A G 1.31E-04 Alzheimer's disease (late onset) SGCZ intron 21379329 rs1461854 chr8 14389640 G A 5.00E-04 Amyotrophic lateral sclerosis (sporadic) SGCZ intron 24529757 rs13279780 chr8 14391526 C A 7.20E-05 Smoking quantity SGCZ intron 24665060 rs11994326 chr8 14394225 A G 6.59E-04 Iron levels SGCZ intron pha002876 rs4831602 chr8 14400878 C T 3.07E-06 Cognitive test performance SGCZ intron 20125193 rs1381407 chr8 14405822 G A 1.19E-05 Cognitive test performance SGCZ intron 20125193 rs2410194 chr8 14416529 A G 4.92E-05 HIV-1 viral setpoint SGCZ intron 17641165 rs10503501 chr8 14429143 G A 8.36E-04 Myocardial Infarction SGCZ intron pha002883 rs1510424 chr8 14450366 A G 6.75E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) SGCZ intron 23648065 rs870615 chr8 14453851 T C 8.87E-05 Cognitive test performance SGCZ intron 20125193 rs4240170 chr8 14465018 T G 5.54E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers SGCZ intron 21775533 rs4289812 chr8 14465207 G T 3.25E-04 Type 2 diabetes SGCZ intron 17463246 rs12542406 chr8 14465315 T C 4.45E-05 Cognitive test performance SGCZ intron 20125193 rs4623425 chr8 14465478 A G 2.43E-04 Type 2 diabetes SGCZ intron 17463246 rs7837164 chr8 14465681 C T 8.34E-06 Brachial circumference SGCZ intron 22479309 rs11203638 chr8 14467351 G A 1.94E-04 Type 2 diabetes SGCZ intron 17463246 rs11203638 chr8 14467351 G A 6.52E-04 Multiple complex diseases SGCZ intron 17554300 rs4831619 chr8 14473500 G A 9.08E-05 Cognitive test performance SGCZ intron 20125193 rs1397294 chr8 14474165 G C 0.00037 Erectile dysfunction after radiotherapy for prostate cancer SGCZ intron 23021708 rs34862383 chr8 14502954 A C 4.97E-04 Multiple complex diseases SGCZ intron 17554300 rs7003341 chr8 14508176 A G 2.59E-05 Cognitive test performance SGCZ intron 20125193 rs9987304 chr8 14513780 T C 7.79E-05 Response to cytadine analogues (cytosine arabinoside) SGCZ intron 24483146 rs11203649 chr8 14517294 T C 5.00E-07 Obesity-related traits SGCZ intron 23251661 rs10097849 chr8 14529851 T G 5.52E-07 Obesity-related traits SGCZ intron 23251661 rs9657208 chr8 14530457 A C 1.50E-06 Obesity-related traits SGCZ intron 23251661 rs920616 chr8 14543582 A C 3.81E-06 Obesity-related traits SGCZ intron 23251661 rs6989198 chr8 14547284 T G 5.48E-06 Obesity-related traits SGCZ intron 23251661 rs11989868 chr8 14550156 A C 2.00E-06 Obesity-related traits SGCZ intron 23251661 rs13282394 chr8 14552065 G T 1.50E-05 Urinary metabolites SGCZ intron 21572414 rs13282394 chr8 14552065 G T 4.30E-06 Obesity-related traits SGCZ intron 23251661 rs11998116 chr8 14558663 A G 8.26E-05 Cholesterol SGCZ intron pha003078 rs7009889 chr8 14566410 G A 9.29E-05 Multiple complex diseases SGCZ intron 17554300 rs12680142 chr8 14576060 G A 4.04E-04 Multiple complex diseases SGCZ intron 17554300 rs2089750 chr8 14578406 T C 7.01E-04 Multiple complex diseases SGCZ intron 17554300 rs2102516 chr8 14578709 T A 8.31E-04 Multiple complex diseases SGCZ intron 17554300 rs2264044 chr8 14578805 G A 6.62E-04 Multiple complex diseases SGCZ intron 17554300 rs1441938 chr8 14581348 G A 6.04E-04 Multiple complex diseases SGCZ intron 17554300 rs1441939 chr8 14581674 A G 4.77E-04 Multiple complex diseases SGCZ intron 17554300 rs13263700 chr8 14587716 G A 1.36E-05 Cholesterol SGCZ intron pha003073 rs13263700 chr8 14587716 G A 6.30E-05 ldl cholesterol SGCZ intron pha003076 rs13263700 chr8 14587716 G A 1.66E-05 Cholesterol SGCZ intron pha003078 rs7011408 chr8 14587928 A G 0.00000121 Fetal hemoglobin levels SGCZ intron 22936743 rs2254310 chr8 14589872 T A 2.34E-04 Multiple complex diseases SGCZ intron 17554300 rs2255685 chr8 14625850 T C 2.63E-05 Monocyte chemoattractant protein-1 SGCZ intron pha003071 rs2256304 chr8 14630901 A G 1.92E-05 Monocyte chemoattractant protein-1 SGCZ intron pha003071 rs2256311 chr8 14630927 G A 3.12E-04 Multiple complex diseases SGCZ intron 17554300 rs2256560 chr8 14632825 T C 4.78E-05 Monocyte chemoattractant protein-1 SGCZ intron pha003071 rs1031053 chr8 14633573 A G 6.51E-04 Type 2 diabetes SGCZ intron 17463246 rs1031053 chr8 14633573 A G 4.78E-05 Monocyte chemoattractant protein-1 SGCZ intron pha003071 rs1992448 chr8 14634314 C T 1.98E-05 Monocyte chemoattractant protein-1 SGCZ intron pha003071 rs2253245 chr8 14640325 A G 8.71E-05 Monocyte chemoattractant protein-1 SGCZ intron pha003071 rs2247142 chr8 14660575 A G 6.83E-04 Response to cytidine analogues (gemcitabine) SGCZ intron 24483146 rs6995984 chr8 14667283 A G 3.02E-05 Monocyte chemoattractant protein-1 SGCZ intron pha003071 rs7002469 chr8 14668859 A G 0.00000167 Major depressive disorder age at onset>25 SGCZ intron 22915352 rs6530805 chr8 14673138 A G 3.26E-04 Aortic root size SGCZ intron 21223598 rs17120353 chr8 14687097 C T 4.88E-05 Aortic root size SGCZ intron 21223598 rs12681897 chr8 14687178 T C 4.84E-05 Chronic obstructive pulmonary disease SGCZ intron 19300482 rs12681897 chr8 14687178 T C 4.84E-05 Response to statin treatment (atorvastatin),change in cholesterol levels SGCZ intron 20031582 rs7013782 chr8 14687887 T A 1.78E-04 Aortic root size SGCZ intron 21223598 rs17120493 chr8 14756351 A G 5.22E-05 Lung adenocarcinoma SGCZ intron 19836008 rs17120493 chr8 14756351 A G 0.000168 Salmonella-induced pyroptosis SGCZ intron 22837397 rs1480691 chr8 14764364 T C 7.49E-04 Parkinson's disease SGCZ intron 17052657 rs1480691 chr8 14764364 T C 5.13E-04 Amyotrophic Lateral Sclerosis SGCZ intron 17362836 rs7841995 chr8 14775389 T G 9.54E-05 HIV-1 viral setpoint SGCZ intron 22174851 rs17470444 chr8 14808002 A G 8.50E-05 Cognitive function SGCZ intron 24684796 rs4607611 chr8 14808713 T G 5.64E-04 Response to taxane treatment (placlitaxel) SGCZ intron 23006423 rs931148 chr8 14808903 C T 6.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SGCZ intron 20877124 rs931147 chr8 14808933 C A 8.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SGCZ intron 20877124 rs17608413 chr8 14811169 C T 2.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SGCZ intron 20877124 rs13439657 chr8 14811233 C T 2.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SGCZ intron 20877124 rs7827121 chr8 14822757 G A 6.52E-05 Heart Rate SGCZ intron pha003053 rs13261120 chr8 14832272 T C 5.92E-04 Suicide attempts in bipolar disorder SGCZ intron 21041247 rs9650382 chr8 14834697 G A 6.20E-04 Suicide attempts in bipolar disorder SGCZ intron 21041247 rs10109779 chr8 14839946 A G 6.30E-04 Suicide attempts in bipolar disorder SGCZ intron 21041247 rs10097898 chr8 14840401 G A 4.86E-04 Suicide attempts in bipolar disorder SGCZ intron 21041247 rs2046099 chr8 14846014 T C 4.45E-05 Relative hand skill in reading disability SGCZ intron 24068947 rs13278000 chr8 14852684 A G 3.85E-04 Smoking initiation SGCZ intron 24665060 rs4427170 chr8 14853781 A T 4.00E-06 Methamphetamine dependence SGCZ intron 23594818 rs7836895 chr8 14854831 G T 6.96E-04 Smoking initiation SGCZ intron 24665060 rs7005262 chr8 14859480 G A 8.27E-04 Suicide attempts in bipolar disorder SGCZ intron 21041247 rs7814519 chr8 14862125 G C 7.15E-04 Multiple complex diseases SGCZ intron 17554300 rs10888094 chr8 14862366 G A 3.87E-04 Suicide attempts in bipolar disorder SGCZ intron 21041247 rs10888095 chr8 14862414 C A 7.60E-04 Multiple complex diseases SGCZ intron 17554300 rs10888095 chr8 14862414 C A 9.81E-07 Gallstones SGCZ intron 17632509 rs10888095 chr8 14862414 C A 3.22E-04 Suicide attempts in bipolar disorder SGCZ intron 21041247 rs2012994 chr8 14863257 G A 7.56E-04 Suicide attempts in bipolar disorder SGCZ intron 21041247 rs1125265 chr8 14863434 C T 3.29E-04 Suicide attempts in bipolar disorder SGCZ intron 21041247 rs2127774 chr8 14868162 G A 3.10E-05 Post-operative nausea and vomiting SGCZ intron 21694509 rs10111834 chr8 14868636 C T 5.15E-04 Multiple complex diseases SGCZ intron 17554300 rs10111834 chr8 14868636 C T 8.20E-05 Eosinophil counts SGCZ intron pha003088 rs7817295 chr8 14871426 A G,T 3.70E-05 Suicide attempts in bipolar disorder SGCZ intron 21041247 rs2170239 chr8 14874924 C T 4.66E-05 Non-word repetition SGCZ intron 23738518 rs7844246 chr8 14909339 T G 9.82E-06 Cognitive performance SGCZ intron 19734545 rs1454598 chr8 14912769 C T 4.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SGCZ intron 20877124 rs10108640 chr8 14913465 G C 5.64E-04 Alzheimer's disease SGCZ intron 24755620 rs13281953 chr8 14922477 T C 1.38E-04 Aortic root size SGCZ intron 21223598 rs1378038 chr8 14929422 A G 3.08E-05 Alzheimer's disease SGCZ intron 17998437 rs1454591 chr8 14935290 G C 8.88E-04 Alzheimer's disease SGCZ intron 24755620 rs2410229 chr8 14938404 G T 5.68E-04 Multiple complex diseases SGCZ intron 17554300 rs2410229 chr8 14938404 G T 9.48E-05 Tunica Media SGCZ intron pha003037 rs10503531 chr8 14944908 T C 5.02E-04 Multiple complex diseases SGCZ intron 17554300 rs7015642 chr8 14949079 G A 2.48E-04 Multiple complex diseases SGCZ intron 17554300 rs7015642 chr8 14949079 G A 1.99E-05 Tunica Media SGCZ intron pha003037 rs7821053 chr8 14951436 C T 2.65E-05 Tunica Media SGCZ intron pha003037 rs13265356 chr8 14969057 C A 4.20E-04 Lung function (forced vital capacity) SGCZ intron 24023788 rs268436 chr8 14983832 T G 6.70E-04 Type 2 diabetes and 6 quantitative traits SGCZ intron 17848626 rs17120994 chr8 14991459 T C 5.44E-05 Tunica Media SGCZ intron pha003037 rs10108992 chr8 15008108 C T 6.55E-04 Schizophrenia SGCZ intron 19197363 rs268379 chr8 15008979 T C 5.40E-06 Coronary heart disease SGCZ intron pha003030 rs10503536 chr8 15013234 A G 9.60E-04 Crohn's disease SGCZ intron 17684544 rs17575734 chr8 15045825 A G 8.00E-06 Urinary metabolites SGCZ intron 21572414 rs17472351 chr8 15051872 A G 8.50E-06 Urinary metabolites SGCZ intron 21572414 rs12680924 chr8 15054424 G A 1.00E-04 Schizophrenia SGCZ intron 19197363 rs10503541 chr8 15109207 A C 4.57E-05 Parkinson's disease / / 17052657 rs11987274 chr8 15113977 T G 6.08E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10101186 chr8 15145387 A C 1.12E-04 Body mass index / / 17255346 rs12548410 chr8 15157843 A G 6.99E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12114442 chr8 15168644 G T 1.00E-05 HIV-1 control / / 20041166 rs11785407 chr8 15169150 A T 3.78E-04 Obesity (extreme) / / 21935397 rs13255369 chr8 15172256 A T 7.83E-04 Obesity (extreme) / / 21935397 rs11784248 chr8 15187962 A C 6.20E-04 Obesity (extreme) / / 21935397 rs4421354 chr8 15188930 A C 5.80E-04 Obesity (extreme) / / 21935397 rs4383971 chr8 15191015 A G 2.92E-04 Multiple complex diseases / / 17554300 rs12676170 chr8 15197417 A G 8.00E-06 Corneal astigmatism / / 23322567 rs11991432 chr8 15203469 G C 6.26E-04 Multiple complex diseases / / 17554300 rs4487765 chr8 15230119 G C 8.74E-05 Response to methylphenidate treatment / / 21130132 rs4077191 chr8 15230180 A G 4.04E-04 Multiple complex diseases / / 17554300 rs4831710 chr8 15235806 C G 1.84E-04 Self-reported allergy / / 23817569 rs6530854 chr8 15236462 C T 1.57E-04 Self-reported allergy / / 23817569 rs9325755 chr8 15269585 G A 4.01E-05 Warfarin maintenance dose / / 19300499 rs6981134 chr8 15278285 T C 3.01E-05 Cognitive impairment induced by topiramate / / 22091778 rs1110854 chr8 15284720 C T 1.51E-05 Waist Circumference / / pha003024 rs1110854 chr8 15284720 C T 1.46E-05 Weight / / pha003026 rs7837736 chr8 15296703 G A 7.00E-11 Multiple complex diseases / / 17554300 rs1908465 chr8 15308433 T A 8.61E-05 Serum metabolites / / 19043545 rs1495081 chr8 15314955 C T 7.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs2172820 chr8 15325668 T G 2.00E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2172820 chr8 15325668 T G 2.25E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6985300 chr8 15355669 A C 4.00E-04 Alcohol dependence / / 20201924 rs6985300 chr8 15355669 A C 4.40E-05 Alcohol dependence / / 20201924 rs6985300 chr8 15355669 A C 4.38E-05 Alcoholism / / pha002893 rs6530877 chr8 15356034 C T 1.10E-04 Alcohol dependence / / 20201924 rs6530877 chr8 15356034 C T 7.30E-04 Alcohol dependence / / 20201924 rs1390052 chr8 15356384 A C 5.30E-04 Alcohol dependence / / 20201924 rs1390052 chr8 15356384 A C 8.00E-05 Alcohol dependence / / 20201924 rs1390052 chr8 15356384 A C 8.02E-05 Alcoholism / / pha002893 rs1390053 chr8 15356455 C T 4.40E-04 Alcohol dependence / / 20201924 rs1390053 chr8 15356455 C T 7.00E-05 Alcohol dependence / / 20201924 rs1390053 chr8 15356455 C T 7.02E-05 Alcoholism / / pha002893 rs1390054 chr8 15356535 C T 1.10E-04 Alcohol dependence / / 20201924 rs1390054 chr8 15356535 C T 6.10E-04 Alcohol dependence / / 20201924 rs7013543 chr8 15357053 C A 1.70E-04 Alcohol dependence / / 20201924 rs13271637 chr8 15357809 G A 1.40E-04 Alcohol dependence / / 20201924 rs13271637 chr8 15357809 G A 6.50E-04 Alcohol dependence / / 20201924 rs17577118 chr8 15357824 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17611665 chr8 15358801 A G 1.68E-05 Acute lymphoblastic leukemia (childhood) / / 22076464 rs17657626 chr8 15374863 C T 8.22E-04 Myopia (pathological) / / 21095009 rs6530885 chr8 15385716 T A 6.04E-04 Acute lung injury / / 22295056 rs4430095 chr8 15386048 A G 6.04E-04 Acute lung injury / / 22295056 rs7007573 chr8 15386471 G C 1.63E-04 Multiple complex diseases / / 17554300 rs2132138 chr8 15386569 C A 4.61E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2132138 chr8 15386569 C A 8.68E-04 Acute lung injury / / 22295056 rs10110189 chr8 15393380 T C 5.98E-04 Multiple complex diseases / / 17554300 rs10110189 chr8 15393380 T C 4.28E-04 Smoking initiation / / 24665060 rs1560216 chr8 15424898 A G 3.71E-04 Multiple complex diseases TUSC3 intron 17554300 rs1560216 chr8 15424898 A G 8.20E-04 Smoking initiation TUSC3 intron 24665060 rs1975057 chr8 15427448 G A 8.06E-04 Multiple complex diseases TUSC3 intron 17554300 rs7007500 chr8 15440586 A T 4.70E-04 Multiple complex diseases TUSC3 intron 17554300 rs7819262 chr8 15456039 A T 9.04E-04 Multiple complex diseases TUSC3 intron 17554300 rs7819262 chr8 15456039 A T 6.01E-04 Smoking initiation TUSC3 intron 24665060 rs12114398 chr8 15456901 G T 5.59E-04 Alzheimer's disease TUSC3 intron 24755620 rs7009035 chr8 15461996 G A 7.20E-04 Response to cytadine analogues (cytosine arabinoside) TUSC3 intron 24483146 rs6530890 chr8 15465489 A G 2.53E-04 Smoking initiation TUSC3 intron 24665060 rs17577614 chr8 15470729 A G 9.82E-04 Response to cytadine analogues (cytosine arabinoside) TUSC3 intron 24483146 rs17612219 chr8 15474579 A G 5.51E-04 Response to cytadine analogues (cytosine arabinoside) TUSC3 intron 24483146 rs4831757 chr8 15476868 G A 5.43E-04 Smoking initiation TUSC3 intron 24665060 rs10107831 chr8 15478125 A G 6.50E-05 Smoking initiation TUSC3 intron 24665060 rs10094375 chr8 15478924 C T 6.72E-05 QT interval TUSC3 intron 22726844 rs13271080 chr8 15484010 G C 2.78E-04 Smoking initiation TUSC3 intron 24665060 rs3788996 chr8 15486397 C T 7.06E-05 Lymphocyte counts TUSC3 intron pha003094 rs4258002 chr8 15493417 G T 6.56E-04 Multiple complex diseases TUSC3 intron 17554300 rs766472 chr8 15503648 T C 5.72E-05 Lymphocyte counts TUSC3 intron pha003094 rs766472 chr8 15503648 T C 8.14E-05 Neutrophil count TUSC3 intron pha003095 rs10094720 chr8 15520892 A C 6.71E-04 Smoking initiation TUSC3 intron 24665060 rs354521 chr8 15525267 A G 5.63E-05 Smoking initiation TUSC3 intron 24665060 rs4831760 chr8 15532585 T C 5.00E-08 Pulmonary function decline TUSC3 intron 22424883 rs2098507 chr8 15540363 A T 4.30E-04 Multiple complex diseases TUSC3 intron 17554300 rs4590441 chr8 15544928 A G 5.70E-04 Smoking initiation TUSC3 intron 24665060 rs7841137 chr8 15545152 C T 1.28E-04 Coronary heart disease TUSC3 intron 21606135 rs7841137 chr8 15545152 C T 6.15E-04 Smoking initiation TUSC3 intron 24665060 rs1362865 chr8 15547450 C T 2.99E-04 Coronary heart disease TUSC3 intron 21606135 rs1421260 chr8 15561260 A G 5.49E-05 Smoking initiation TUSC3 intron 24665060 rs12680995 chr8 15561631 C T 9.93E-06 Smoking initiation TUSC3 intron 24665060 rs1421259 chr8 15562672 A G 5.74E-06 Osteoarthritis TUSC3 intron 22763110 rs10104063 chr8 15565126 A G 1.27E-04 Alzheimer's disease (late onset) TUSC3 intron 21379329 rs1421255 chr8 15576123 T C 6.55E-04 Smoking initiation TUSC3 intron 24665060 rs352750 chr8 15590011 A G 6.49E-05 Parent of origin effect on language impairment (child trend) TUSC3 intron 24571439 rs17474411 chr8 15591606 A C 0.00000126 Common carotid artery thickness (average of near and far wall measures) TUSC3 intron 23487405 rs17474411 chr8 15591606 A C 0.00000146 Common carotid artery thickness (near walls) TUSC3 intron 23487405 rs918245 chr8 15596087 C T 1.96E-04 Alzheimer's disease (late onset) TUSC3 intron 21379329 rs7827167 chr8 15598698 A C 9.42E-06 Response to cytadine analogues (cytosine arabinoside) TUSC3 intron 24483146 rs7827167 chr8 15598698 A C 1.24E-05 Parent of origin effect on language impairment (child trend) TUSC3 intron 24571439 rs17121874 chr8 15599492 C T 2.47E-04 Response to cytadine analogues (cytosine arabinoside) TUSC3 intron 24483146 rs17121874 chr8 15599492 C T 7.09E-05 Lymphocyte counts TUSC3 intron pha003094 rs17121874 chr8 15599492 C T 9.89E-05 Neutrophil count TUSC3 intron pha003095 rs168474 chr8 15599587 A G 2.79E-05 Parent of origin effect on language impairment (child trend) TUSC3 intron 24571439 rs7826947 chr8 15600787 G A 1.62E-04 Response to cytadine analogues (cytosine arabinoside) TUSC3 intron 24483146 rs751687 chr8 15608896 A G 2.38E-04 Response to cytadine analogues (cytosine arabinoside) TUSC3 intron 24483146 rs352809 chr8 15622454 C T 6.41E-04 Multiple complex diseases TUSC3 UTR-3 17554300 rs2278947 chr8 15622658 T C 5.99E-04 Response to cytadine analogues (cytosine arabinoside) TUSC3 UTR-3 24483146 rs7842027 chr8 15628324 G A 5.29E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1598293 chr8 15631108 A G 6.66E-04 Multiple complex diseases / / 17554300 rs1598294 chr8 15631291 A G 6.48E-04 Multiple complex diseases / / 17554300 rs735861 chr8 15633397 G T 8.40E-04 Type 2 diabetes / / 17463246 rs12677979 chr8 15636187 T C 4.21E-05 Lymphocyte counts / / pha003094 rs12677979 chr8 15636187 T C 8.49E-05 Neutrophil count / / pha003095 rs1362867 chr8 15637392 A G 4.68E-04 Alzheimer's disease (late onset) / / 21379329 rs2604376 chr8 15642213 C T 1.92E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12678466 chr8 15643179 A G 6.56E-05 Lymphocyte counts / / pha003094 rs352768 chr8 15644927 G A 3.43E-04 Alzheimer's disease (late onset) / / 21379329 rs17121980 chr8 15646708 G A 6.22E-04 Body mass index / / 21701565 rs17121980 chr8 15646708 G A 4.15E-04 Smoking initiation / / 24665060 rs17121980 chr8 15646708 G A 1.62E-05 Lymphocyte counts / / pha003094 rs17121980 chr8 15646708 G A 3.67E-05 Neutrophil count / / pha003095 rs352774 chr8 15647677 A G 2.45E-04 Multiple complex diseases / / 17554300 rs373806 chr8 15648936 T C 0.00000168 Common carotid artery thickness (average of near and far wall measures) / / 23487405 rs11785210 chr8 15652878 T C 1.40E-13 Coronary heart disease / / 21971053 rs2205236 chr8 15655686 G A 1.50E-05 Urinary metabolites / / 21572414 rs2410284 chr8 15657119 T C 3.65E-05 Serum metabolites / / 19043545 rs240664 chr8 15660239 G A 7.79E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs240657 chr8 15665612 G A 2.00E-06 Intelligence / / 22449649 rs6989226 chr8 15666113 G C 1.81E-06 Major depressive disorder / / 20516156 rs6989226 chr8 15666113 G C 5.84E-04 Major depressive disorder / / 22472876 rs2049833 chr8 15666800 A G 3.42E-05 Major depressive disorder / / 20516156 rs17675226 chr8 15669601 T C 1.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs1455068 chr8 15675469 C T 5.53E-04 Multiple complex diseases / / 17554300 rs2604308 chr8 15677287 A C 4.18E-04 Multiple complex diseases / / 17554300 rs2720625 chr8 15682305 A G 6.33E-04 Smoking initiation / / 24665060 rs2720633 chr8 15700860 T C 5.20E-04 Multiple complex diseases / / 17554300 rs2736010 chr8 15702415 C T 5.83E-05 Multiple complex diseases / / 17554300 rs2736070 chr8 15709114 T G 3.68E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs2736070 chr8 15709114 T G 4.68E-04 Alzheimer's disease (late onset) / / 21379329 rs2720623 chr8 15733498 G C 6.30E-06 White matter hyperintensity burden / / 21681796 rs1563297 chr8 15738015 T C 2.92E-06 Common variable immunodeficiency / / 21497890 rs9325770 chr8 15742366 C A 3.90E-06 White matter hyperintensity burden / / 21681796 rs6992136 chr8 15742487 G A 3.20E-06 White matter hyperintensity burden / / 21681796 rs1968723 chr8 15743366 G T 6.80E-06 White matter hyperintensity burden / / 21681796 rs17122137 chr8 15743793 G T 6.50E-06 White matter hyperintensity burden / / 21681796 rs7826382 chr8 15746211 A G 6.50E-06 White matter hyperintensity burden / / 21681796 rs748596 chr8 15747321 G T 2.40E-04 Multiple complex diseases / / 17554300 rs9650356 chr8 15752261 G A,C 5.40E-06 White matter hyperintensity burden / / 21681796 rs9650357 chr8 15752275 T C 6.50E-06 White matter hyperintensity burden / / 21681796 rs6996022 chr8 15755815 G C 5.50E-06 White matter hyperintensity burden / / 21681796 rs2720602 chr8 15757611 C G 2.50E-05 White matter hyperintensity burden / / 21681796 rs17476016 chr8 15761128 A G 5.40E-04 Multiple complex diseases / / 17554300 rs4291272 chr8 15786340 A C 1.63E-04 Type 2 diabetes / / 22158537 rs4341162 chr8 15788269 C T 9.75E-05 Serum metabolites / / 19043545 rs4831358 chr8 15788925 C T 7.14E-04 Multiple complex diseases / / 17554300 rs9325774 chr8 15808896 A G 2.38E-05 Serum metabolites / / 19043545 rs13271046 chr8 15809365 C T 5.37E-05 Serum metabolites / / 19043545 rs13271046 chr8 15809365 C T 6.37E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs17614179 chr8 15809423 C G 2.60E-05 Urinary metabolites / / 21572414 rs1074844 chr8 15810092 T G 9.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs12548837 chr8 15817522 T C 9.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs9325777 chr8 15822369 T C 6.29E-05 Coronary heart disease / / pha003030 rs4831792 chr8 15850431 C G 5.72E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs8181023 chr8 15885126 T C 8.82E-05 Neuroblastoma / / pha002895 rs765262 chr8 15899688 A G 1.52E-04 Alzheimer's disease (late onset) / / 21379329 rs11203752 chr8 15901219 T C 4.16E-05 Alzheimer's disease (late onset) / / 21379329 rs13278411 chr8 15901774 A C 2.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13278411 chr8 15901774 A C 2.54E-04 Alzheimer's disease (late onset) / / 21379329 rs2628294 chr8 15902596 A G 1.72E-05 Alzheimer's disease (late onset) / / 21379329 rs12544662 chr8 15906277 T C 4.17E-05 Alzheimer's disease (late onset) / / 21379329 rs4831803 chr8 15934868 G A 1.78E-04 Alzheimer's disease (late onset) / / 21379329 rs10099900 chr8 15935790 A G 2.52E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17122455 chr8 15963080 T C 5.43E-06 Multiple complex diseases / / 17554300 rs351547 chr8 15972005 G A 4.20E-04 Multiple complex diseases MSR1 intron 17554300 rs351562 chr8 15999039 C T 8.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MSR1 intron 20877124 rs351557 chr8 16000750 G T 1.55E-04 Multiple complex diseases MSR1 intron 17554300 rs970440 chr8 16012193 C T 0.000217763 Hypertension (early onset hypertension) MSR1 intron 22479346 rs34722146 chr8 16023677 T C 0.000000761 HDL cholesterol MSR1 intron 23063622 rs34722146 chr8 16023677 T C 1.19E-08 Triglycerides MSR1 intron 23063622 rs35525373 chr8 16024173 C G 0.000000139 HDL cholesterol MSR1 intron 23063622 rs406652 chr8 16042507 G C 1.56E-09 90K Protein MSR1 intron 23696881 rs28491433 chr8 16050871 C G 4.29E-10 90K Protein MSR1 nearGene-5 23696881 rs899683 chr8 16069524 G A 0.000499651 Hypertension (early onset hypertension) / / 22479346 rs12676548 chr8 16071018 A G 0.000126519 Hypertension (early onset hypertension) / / 22479346 rs12676548 chr8 16071018 A G 6.99E-05 Cholesterol / / pha003073 rs9325782 chr8 16090473 C T 8.20E-04 Breast cancer and prostate cancer / / 17903305 rs17677992 chr8 16153800 T C 8.64E-04 Multiple complex diseases / / 17554300 rs7016675 chr8 16189726 C G 4.96E-04 Multiple complex diseases / / 17554300 rs1429670 chr8 16232429 G A 4.66E-04 Type 2 diabetes / / 17463246 rs62490068 chr8 16333537 G T 9.40E-04 Urinary metabolites / / 21572414 rs10101200 chr8 16339528 G A,C,T 4.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11998535 chr8 16342717 G A 3.10E-04 Multiple complex diseases / / 17554300 rs1474448 chr8 16353123 T C 9.58E-04 Multiple complex diseases / / 17554300 rs17122998 chr8 16353375 T C,G 2.17E-04 Multiple complex diseases / / 17554300 rs10091356 chr8 16369596 T A 8.38E-04 Multiple complex diseases / / 17554300 rs17123126 chr8 16383844 C T 9.15E-04 Multiple complex diseases / / 17554300 rs12681937 chr8 16406371 G T 8.67E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs10108146 chr8 16418240 C T 4.90E-05 Diabetic retinopathy / / 21441570 rs822249 chr8 16461726 T C 4.50E-06 Urinary metabolites / / 21572414 rs822304 chr8 16474041 A G 4.60E-06 Urinary metabolites / / 21572414 rs6586747 chr8 16482909 A T 3.27E-04 Multiple complex diseases / / 17554300 rs1368535 chr8 16503978 T A 6.80E-05 Diabetic retinopathy / / 21441570 rs11203796 chr8 16522929 A G 3.30E-04 Multiple complex diseases / / 17554300 rs10097146 chr8 16558730 G A 1.40E-04 Alcohol dependence / / 20201924 rs1580852 chr8 16575112 C T 4.71E-04 Alcohol dependence / / 20201924 rs1697648 chr8 16607394 A G 9.71E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7827906 chr8 16608872 T C 1.15E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6996349 chr8 16610997 C T 2.80E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13276809 chr8 16616050 C G 2.30E-05 Urinary metabolites / / 21572414 rs6586877 chr8 16625172 T C 8.47E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4922231 chr8 16625729 A T 1.20E-05 Cognitive function / / 24684796 rs971797 chr8 16634751 T G 0.0000657 Polycystic ovary syndrome / / 22951595 rs971797 chr8 16634751 T G 6.57E-05 Intracranial aneurysm / / 22961961 rs496037 chr8 16635052 T C 0.00000559 LDL cholesterol particle diameter / / 23263444 rs530909 chr8 16636574 A C 0.00000542 LDL cholesterol particle diameter / / 23263444 rs6586894 chr8 16646624 G A 7.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2461020 chr8 16648183 A T 6.58E-05 Multiple complex diseases / / 17554300 rs591323 chr8 16697091 G A 1.59E-05 Parkinson's disease / / 22451204 rs6990641 chr8 16704905 C T 1.36E-05 Personality dimensions / / 18957941 rs6990641 chr8 16704905 C T 3.46E-04 Myocardial Infarction / / pha002883 rs477516 chr8 16713991 C T 5.10E-04 Breast cancer and prostate cancer / / 17903305 rs11778346 chr8 16726107 T C 2.29E-05 Personality dimensions / / 18957941 rs13250792 chr8 16740339 A G 6.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs1565741 chr8 16755485 A G 7.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4406442 chr8 16796681 C T 2.91E-04 Type 2 diabetes / / 17463246 rs823600 chr8 16817433 G T 3.40E-05 Glaucoma (primary open-angle) / / 20835238 rs2898452 chr8 16818895 C G 7.92E-06 Glycemic traits (pregnancy) / / 23903356 rs7008346 chr8 16819485 C G 5.39E-05 Height / / 17255346 rs1523648 chr8 16820357 G A 8.55E-06 Glycemic traits (pregnancy) / / 23903356 rs963080 chr8 16823525 C T 9.91E-04 Bipolar disorder / / 19259986 rs1721078 chr8 16830934 A G 5.67E-04 Alcohol dependence / / 24277619 rs1908145 chr8 16831026 T C 8.56E-05 Height / / 17255346 rs823583 chr8 16837199 A G 9.97E-04 Alcohol dependence / / 24277619 rs1689879 chr8 16839594 C T 7.31E-06 Glycemic traits (pregnancy) / / 23903356 rs7001414 chr8 16841656 A G 7.84E-04 Multiple complex diseases / / 17554300 rs7822029 chr8 16864155 A G 4.30E-04 Alzheimer's disease (late onset) / / 21379329 rs709844 chr8 16870536 A C 9.30E-04 Urinary metabolites / / 21572414 rs2014301 chr8 16907317 T A 9.83E-04 Response to taxane treatment (placlitaxel) EFHA2 intron 23006423 rs17686698 chr8 16911418 A G 9.13E-05 Glucose levels EFHA2 intron pha003061 rs17624782 chr8 16915980 G T 9.58E-05 Glucose levels EFHA2 intron pha003061 rs4541971 chr8 16920644 T C 5.39E-04 Suicide attempts in bipolar disorder EFHA2 intron 21423239 rs2285261 chr8 16922013 C A 5.30E-04 Suicide attempts in bipolar disorder EFHA2 intron 21423239 rs10090288 chr8 16929635 A C 3.40E-04 Alcohol dependence EFHA2 intron 20201924 rs10090288 chr8 16929635 A C 8.00E-06 Depression and alcohol dependence EFHA2 intron 22064162 rs10090288 chr8 16929635 A C 3.67E-05 Glucose levels EFHA2 intron pha003061 rs6992842 chr8 16936160 C T 6.60E-04 Suicide attempts in bipolar disorder EFHA2 intron 21423239 rs12056715 chr8 16939284 G A 6.54E-04 Response to taxane treatment (placlitaxel) EFHA2 intron 23006423 rs3850761 chr8 16941351 G A 4.28E-04 Suicide attempts in bipolar disorder EFHA2 intron 21423239 rs2285265 chr8 16942849 C T 6.52E-04 Suicide attempts in bipolar disorder EFHA2 intron 21423239 rs10090466 chr8 16945798 C T 5.22E-04 Suicide attempts in bipolar disorder EFHA2 intron 21423239 rs17624958 chr8 16953674 T C 6.51E-04 Response to taxane treatment (placlitaxel) EFHA2 intron 23006423 rs2705215 chr8 17000463 A C 4.55E-05 Waist-Hip Ratio / / pha003013 rs2705215 chr8 17000463 A C 3.84E-05 Waist-Hip Ratio / / pha003028 rs7387589 chr8 17003994 G C 1.87E-05 Multiple complex diseases / / 17554300 rs2705195 chr8 17010169 G T 3.65E-05 Waist-Hip Ratio / / pha003013 rs2705195 chr8 17010169 G T 3.64E-05 Waist-Hip Ratio / / pha003028 rs2952131 chr8 17010298 A G 8.05E-04 Type 2 diabetes / / 17463246 rs13267854 chr8 17025769 C T 1.91E-04 Type 2 diabetes ZDHHC2 intron 17463246 rs730243 chr8 17028091 C A 5.56E-05 Glaucoma (primary open-angle) ZDHHC2 intron 22605921 rs2023628 chr8 17047134 T C 6.47E-05 Multiple complex diseases ZDHHC2 intron 17554300 rs2904670 chr8 17056529 T C 5.46E-04 Multiple complex diseases ZDHHC2 intron 17554300 rs2904671 chr8 17056651 G A 3.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) ZDHHC2 intron 23648065 rs17124270 chr8 17091344 T C 1.85E-05 Multiple complex diseases CNOT7 intron 17554300 rs2959604 chr8 17093932 C G 1.96E-05 Multiple complex diseases CNOT7 intron 17554300 rs3793427 chr8 17143830 G C 2.00E-06 Tonometry VPS37A intron 17903302 rs10090731 chr8 17176644 G A 3.30E-05 Body Mass Index MTMR7 intron pha003015 rs2239874 chr8 17194223 C T 8.42E-04 Acute lung injury MTMR7 intron 22295056 rs2239878 chr8 17195411 C T 4.08E-04 Acute lung injury MTMR7 intron 22295056 rs739337 chr8 17202871 A G 1.35E-04 Lung function (forced vital capacity) MTMR7 intron 24023788 rs4921542 chr8 17205577 T G 2.00E-08 Creutzfeldt-Jakob disease (variant) MTMR7 intron 22137330 rs2898465 chr8 17229152 C T 3.07E-04 Lung function (forced vital capacity) MTMR7 intron 24023788 rs2157640 chr8 17258906 G A 3.24E-04 Myopia (pathological) MTMR7 intron 21095009 rs11203854 chr8 17263238 T C 3.84E-04 Myopia (pathological) MTMR7 intron 21095009 rs6981038 chr8 17274709 T C 1.90E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs13271465 chr8 17282411 T C 1.10E-04 Endometriosis / / 21151130 rs13271465 chr8 17282411 T C 8.00E-06 Obesity-related traits / / 23251661 rs10503595 chr8 17283970 G T 6.00E-04 Premature ovarian failure / / 19508998 rs17587917 chr8 17284486 T C 2.40E-05 Urinary metabolites / / 21572414 rs10086318 chr8 17284564 A G 1.60E-04 Endometriosis / / 21151130 rs200106441 chr8 17300209 T TC 3.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs2410516 chr8 17300209 T C 3.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs1012641 chr8 17312773 C T 8.01E-04 Multiple complex diseases / / 17554300 rs4554505 chr8 17314613 C T 3.65E-04 Myocardial Infarction / / pha002883 rs2705044 chr8 17322180 G T 7.46E-05 Pulmonary function in asthmatics / / 23541324 rs17632191 chr8 17329075 T A 4.75E-04 IgE levels / / 17255346 rs2720508 chr8 17329827 C T 7.00E-06 Conduct disorder (symptom count) / / 20585324 rs11778372 chr8 17338423 G T 5.46E-05 Creatinine levels / / pha003069 rs11203868 chr8 17369376 A G 9.41E-07 Plasma omega-6 polyunsaturated fatty acid levels SLC7A2 intron 24823311 rs1962772 chr8 17370776 C T 9.00E-07 Plasma omega-6 polyunsaturated fatty acid levels SLC7A2 intron 24823311 rs17124738 chr8 17371287 T G 1.88E-04 Multiple complex diseases SLC7A2 intron 17554300 rs17124738 chr8 17371287 T G 2.07E-04 Type 2 diabetes SLC7A2 intron 22238593 rs6997118 chr8 17371403 G A 9.78E-07 Plasma omega-6 polyunsaturated fatty acid levels SLC7A2 intron 24823311 rs6997306 chr8 17371520 G C 9.97E-07 Plasma omega-6 polyunsaturated fatty acid levels SLC7A2 intron 24823311 rs2213906 chr8 17377057 C G 4.82E-06 Plasma omega-6 polyunsaturated fatty acid levels SLC7A2 intron 24823311 rs2188021 chr8 17377242 C A 4.82E-06 Plasma omega-6 polyunsaturated fatty acid levels SLC7A2 intron 24823311 rs2188022 chr8 17377393 G A 4.13E-06 Plasma omega-6 polyunsaturated fatty acid levels SLC7A2 intron 24823311 rs2720498 chr8 17391277 T G 1.77E-05 Body Mass Index SLC7A2 intron pha003020 rs2720498 chr8 17391277 T G 6.94E-05 Waist Circumference SLC7A2 intron pha003024 rs11993109 chr8 17396224 A G 1.19E-04 Type 2 diabetes SLC7A2 intron 17463246 rs2517252 chr8 17401878 G A 1.42E-04 Smoking initiation SLC7A2 intron 24665060 rs2285295 chr8 17427541 A G 1.63E-05 Acute lymphoblastic leukemia (childhood) SLC7A2 UTR-3 19684603 rs2588164 chr8 17435908 C T 7.81E-04 Type 2 diabetes PDGFRL intron 17463246 rs2720574 chr8 17436191 C G 5.72E-04 Type 2 diabetes PDGFRL intron 17463246 rs2517269 chr8 17438716 G A 2.21E-04 Suicide attempts in bipolar disorder PDGFRL intron 21423239 rs2517270 chr8 17438729 A G 2.00E-04 Suicide attempts in bipolar disorder PDGFRL intron 21423239 rs2517273 chr8 17439187 C T 2.16E-04 Suicide attempts in bipolar disorder PDGFRL intron 21423239 rs2517273 chr8 17439187 C T 5.76E-05 Cognitive impairment induced by topiramate PDGFRL intron 22091778 rs2720568 chr8 17439220 G C 2.35E-04 Suicide attempts in bipolar disorder PDGFRL intron 21423239 rs2588156 chr8 17446444 T G 5.27E-04 Tourette syndrome PDGFRL intron 22889924 rs2246488 chr8 17454300 A G 1.25E-05 Body Mass Index PDGFRL intron pha003019 rs2246488 chr8 17454300 A G 7.89E-05 Body Mass Index PDGFRL intron pha003020 rs2246488 chr8 17454300 A G 5.60E-05 Body Mass Index PDGFRL intron pha003022 rs2246376 chr8 17455169 A G 3.44E-05 Smoking initiation PDGFRL intron 24665060 rs2517168 chr8 17457420 A G 7.22E-06 Hemoglobin PDGFRL intron pha003098 rs2517175 chr8 17459430 A T 3.94E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity PDGFRL intron 24324551 rs2517177 chr8 17460245 A G 3.23E-05 Hemoglobin PDGFRL intron pha003098 rs2588131 chr8 17460753 C T 3.90E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity PDGFRL intron 24324551 rs2245667 chr8 17461328 C G 3.11E-07 Adiposity PDGFRL intron 19557161 rs13256095 chr8 17461421 G T 6.00E-06 Amyotrophic lateral sclerosis (sporadic) PDGFRL intron 24529757 rs7829987 chr8 17462222 T G 4.00E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity PDGFRL intron 24324551 rs2517202 chr8 17467855 G A 4.31E-08 Multiple complex diseases PDGFRL intron 17554300 rs2237825 chr8 17474391 A G 4.14E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PDGFRL intron 20031582 rs2588112 chr8 17476314 C G 5.47E-04 Nicotine smoking PDGFRL intron 19268276 rs13259157 chr8 17483028 A G 2.10E-06 Stroke (ischemic) PDGFRL intron 22384361 rs6981782 chr8 17498232 C T 3.56E-04 Suicide attempts in bipolar disorder PDGFRL intron 21041247 rs3817664 chr8 17501192 G T 8.09E-04 Suicide attempts in bipolar disorder MTUS1 nearGene-3 21041247 rs4921798 chr8 17501907 T C 4.42E-06 Orofacial clefts MTUS1 UTR-3 22419666 rs1043883 chr8 17503431 G C 6.59E-04 Suicide attempts in bipolar disorder MTUS1 UTR-3 21041247 rs4921799 chr8 17507964 A G 3.36E-04 Tourette syndrome MTUS1 intron 22889924 rs11203884 chr8 17516564 C T 6.58E-05 Tourette syndrome MTUS1 intron 22889924 rs7460737 chr8 17540390 G A 2.00E-04 Information processing speed MTUS1 intron 21130836 rs2410501 chr8 17541691 G A 5.41E-04 Myocardial Infarction MTUS1 intron pha002873 rs6421404 chr8 17542215 C T 1.00E-04 Information processing speed MTUS1 intron 21130836 rs4595159 chr8 17544864 C T 9.69E-05 Response to mTOR inhibitor (everolimus) MTUS1 intron 24009623 rs7845231 chr8 17545706 C T 1.00E-04 Information processing speed MTUS1 intron 21130836 rs4921804 chr8 17550623 G A 3.70E-06 Urinary metabolites MTUS1 intron 21572414 rs7846560 chr8 17550982 G C 3.50E-06 Urinary metabolites MTUS1 intron 21572414 rs2979790 chr8 17555422 A C 1.60E-05 Urinary metabolites MTUS1 intron 21572414 rs4921809 chr8 17565061 T C 1.22E-04 Birth weight MTUS1 intron 17255346 rs7830863 chr8 17566902 C T 5.43E-05 Birth weight MTUS1 intron 17255346 rs3862100 chr8 17575319 G T 2.48E-04 Birth weight MTUS1 intron 17255346 rs4921559 chr8 17577087 G A 1.53E-04 Birth weight MTUS1 intron 17255346 rs4921559 chr8 17577087 G A 8.55E-04 Multiple complex diseases MTUS1 intron 17554300 rs2937887 chr8 17578819 C G 2.40E-05 Urinary metabolites MTUS1 intron 21572414 rs6982255 chr8 17579135 C T 2.80E-04 Birth weight MTUS1 intron 17255346 rs6586637 chr8 17583151 A G 5.19E-04 Multiple complex diseases MTUS1 intron 17554300 rs6586639 chr8 17589960 C T 2.96E-05 Glycosylated haemoglobin levels MTUS1 intron 17255346 rs117979 chr8 17595300 C G 7.68E-04 Insulin resistance MTUS1 intron 21901158 rs17125231 chr8 17603857 C G 6.78E-04 Multiple complex diseases MTUS1 intron 17554300 rs17125240 chr8 17608896 C A 5.10E-04 Smoking initiation MTUS1 intron 24665060 rs6586642 chr8 17611074 C T 2.81E-04 Suicide attempts in bipolar disorder MTUS1 intron 21041247 rs381826 chr8 17619304 A G 5.80E-04 Urinary metabolites MTUS1 intron 21572414 rs6986402 chr8 17630589 T C 4.43E-05 Educational attainment MTUS1 intron 21694764 rs447516 chr8 17632737 A C 5.75E-05 Acute lung injury MTUS1 intron 22295056 rs1008705 chr8 17633455 T C 8.70E-04 Urinary metabolites MTUS1 intron 21572414 rs407352 chr8 17638323 C T 6.33E-04 Myopia (pathological) MTUS1 intron 21095009 rs10093997 chr8 17654427 G C 8.00E-08 Parkinson's disease (interaction with coffee consumption) MTUS1 intron 21876681 rs396462 chr8 17670196 G C 6.90E-04 Crohn's disease / / 17684544 rs429412 chr8 17674988 G A 3.28E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs414677 chr8 17681402 G A 3.25E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs687105 chr8 17698251 T C 4.12E-05 Suicidal ideation / / 20877300 rs6586666 chr8 17724768 A G 0.00000181 Triglycerides FGL1 intron 23063622 rs371092 chr8 17771870 G C 8.55E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs12718385 chr8 17781257 T C 4.08E-05 Duodenal ulcer PCM1 intron 22387998 rs3850746 chr8 17787536 A G 4.74E-04 Type 2 diabetes PCM1 intron 17463246 rs2299587 chr8 17800769 T G 9.00E-07 Economic and political preferences PCM1 intron 22566634 rs6586674 chr8 17810464 T C 3.60E-05 HIV-1 control PCM1 intron 20041166 rs17635381 chr8 17817553 G T 1.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) PCM1 missense 17982456 rs11203929 chr8 17819812 T C 6.13E-05 Serum metabolites PCM1 intron 19043545 rs2299598 chr8 17836399 G T 9.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) PCM1 intron 17982456 rs208029 chr8 17840987 T G 7.43E-04 Multiple complex diseases PCM1 intron 17554300 rs437707 chr8 17864832 A G 2.24E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PCM1 intron 20877124 rs10503607 chr8 17874480 G T 2.29E-05 Cognitive test performance PCM1 intron 20125193 rs382752 chr8 17898383 G A 6.36E-04 Multiple complex diseases / / 17554300 rs6981333 chr8 17910211 G A 7.12E-04 Multiple complex diseases / / 17554300 rs3753116 chr8 17930999 A G 5.49E-04 Multiple complex diseases ASAH1 intron 17554300 rs7833836 chr8 17935642 A C 9.05E-05 Serum metabolites ASAH1 intron 19043545 rs13282042 chr8 17936029 G A 9.05E-05 Serum metabolites ASAH1 intron 19043545 rs7824280 chr8 17937313 G A 7.29E-05 Serum metabolites ASAH1 intron 19043545 rs11986226 chr8 17937530 G A 4.81E-05 Serum metabolites ASAH1 intron 19043545 rs6586689 chr8 17948054 C G 6.04E-06 Uric acid levels / / 21294900 rs13263637 chr8 17948885 T G 3.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4628288 chr8 17950757 T C 1.32E-05 Uric acid levels / / 21294900 rs6586693 chr8 17951005 C G 2.36E-06 Uric acid levels / / 21294900 rs11774166 chr8 17953439 C T 1.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9325825 chr8 17953808 T G 7.30E-06 Uric acid levels / / 21294900 rs916552 chr8 17954504 A G 7.53E-04 Type 2 diabetes / / 17463246 rs7015927 chr8 17955139 A T 1.35E-05 Uric acid levels / / 21294900 rs2739684 chr8 17955256 C T 8.70E-05 Diabetic retinopathy / / 21441570 rs13280846 chr8 17956265 A T 1.66E-06 Uric acid levels / / 21294900 rs11778007 chr8 17957417 C T 8.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6421410 chr8 17958253 A C 4.19E-06 Uric acid levels / / 21294900 rs7844251 chr8 17964559 G A 0.0000011 Brain activation patterns in response to human facial expressions-for the positive faces task / / 22828495 rs7844251 chr8 17964559 G A 1.22E-09 Brain activation patterns in response to human facial expressions-for the negative faces task / / 22828495 rs7844251 chr8 17964559 G A 1.22E-09 Airflow obstruction / / 22837378 rs7011695 chr8 17971559 T G 8.43E-06 Uric acid levels / / 21294900 rs17126232 chr8 17977650 C T 2.00E-07 Obesity / / 21552555 rs17126232 chr8 17977650 C T 4.00E-07 Obesity / / 21552555 rs17126232 chr8 17977650 C T 8.00E-08 Obesity / / 21552555 rs6995047 chr8 17979181 A G 1.08E-05 Uric acid levels / / 21294900 rs17126237 chr8 17981089 C T 4.92E-05 Parkinson's disease / / 21738487 rs992617 chr8 17996495 A G 8.71E-05 Blood Pressure / / pha003049 rs4921865 chr8 17998436 G T 7.39E-04 Multiple complex diseases / / 17554300 rs4921865 chr8 17998436 G T 2.10E-05 Urinary metabolites / / 21572414 rs2739734 chr8 18004224 G A 3.03E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs11203940 chr8 18005973 G A 6.76E-05 Multiple complex diseases / / 17554300 rs2078711 chr8 18013316 C T 4.43E-06 Panic disorder / / 19165232 rs7016806 chr8 18013447 A C 5.20E-04 Multiple complex diseases / / 17554300 rs4557740 chr8 18015120 T C 2.59E-05 Psoriasis / / 20953190 rs6586704 chr8 18020696 G A 4.23E-04 Blood pressure (response to calcium channel blocker) / / 24192120 rs7818834 chr8 18044101 T C 5.87E-05 Major depressive disorder /T1 intron 21621269 rs10888150 chr8 18066126 T C 8.57E-04 Coronary heart disease /T1 intron 21971053 rs4921581 chr8 18071095 A G 3.69E-04 Coronary heart disease /T1 intron 21971053 rs6586730 chr8 18121307 A G 6.19E-04 Depression (quantitative trait) / / 20800221 rs6586730 chr8 18121307 A G 2.20E-05 Urinary metabolites / / 21572414 rs17594712 chr8 18123295 T C 2.41E-05 Fibrinogen / / pha003068 rs1353035 chr8 18140633 C T 8.51E-04 Type 2 diabetes / / 17463246 rs7832516 chr8 18150001 G T 7.07E-05 Insulin resistance / / 21901158 rs11787149 chr8 18153140 C T 1.28E-04 Insulin resistance / / 21901158 rs7818288 chr8 18154498 G A 1.42E-05 Insulin resistance / / 21901158 rs1159351 chr8 18169275 G A 2.78E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs1159351 chr8 18169275 G A 2.78E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs11782404 chr8 18169778 A T 9.80E-04 Depression (quantitative trait) / / 20800221 rs7815626 chr8 18171218 C T 8.50E-06 Urinary metabolites / / 21572414 rs17642444 chr8 18172011 G T 8.07E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs17642444 chr8 18172011 G T 8.07E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs4921893 chr8 18194218 A C 6.60E-06 Urinary metabolites / / 21572414 rs6586734 chr8 18194387 C T 9.43E-05 Femoral neck bone geometry / / 22087292 rs62494356 chr8 18194856 T C 5.00E-05 Urinary metabolites / / 21572414 rs1493036 chr8 18194861 A G 3.30E-05 Urinary metabolites / / 21572414 rs10216945 chr8 18195270 T G 3.70E-04 Urinary metabolites / / 21572414 rs7827099 chr8 18196020 C T 4.00E-04 Urinary metabolites / / 21572414 rs9987384 chr8 18196466 T C 4.10E-04 Urinary metabolites / / 21572414 rs56177898 chr8 18196743 T C 5.70E-05 Urinary metabolites / / 21572414 rs61532871 chr8 18198127 T C 3.50E-04 Urinary metabolites / / 21572414 rs9987160 chr8 18198956 T A 3.60E-04 Urinary metabolites / / 21572414 rs7812408 chr8 18200916 T C 4.60E-04 Urinary metabolites / / 21572414 rs1602782 chr8 18201818 A G 7.30E-05 Urinary metabolites / / 21572414 rs4921597 chr8 18202237 A G 7.70E-05 Urinary metabolites / / 21572414 rs11203955 chr8 18202594 G A 3.90E-05 Urinary metabolites / / 21572414 rs10094342 chr8 18204272 T C 2.00E-04 Urinary metabolites / / 21572414 rs12541911 chr8 18204475 A G 4.30E-05 Urinary metabolites / / 21572414 rs7844137 chr8 18205097 G C 3.60E-05 Urinary metabolites / / 21572414 rs7844137 chr8 18205097 G C 5.05E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11203956 chr8 18205455 C T 1.20E-04 Urinary metabolites / / 21572414 rs1493042 chr8 18205516 A C 1.80E-05 Urinary metabolites / / 21572414 rs10095674 chr8 18205573 A C 1.80E-04 Urinary metabolites / / 21572414 rs1587147 chr8 18207414 C T 2.00E-06 Urinary metabolites / / 21572414 rs201137499 chr8 18207414 C CT 2.00E-06 Urinary metabolites / / 21572414 rs35526974 chr8 18207414 C CT 2.00E-06 Urinary metabolites / / 21572414 rs1353403 chr8 18209379 C T 1.70E-05 Urinary metabolites / / 21572414 rs1353404 chr8 18209468 C G 1.80E-04 Urinary metabolites / / 21572414 rs10093448 chr8 18209487 T G 1.30E-04 Urinary metabolites / / 21572414 rs11785231 chr8 18209674 C G 1.30E-04 Urinary metabolites / / 21572414 rs11775054 chr8 18209776 A G 1.70E-04 Urinary metabolites / / 21572414 rs11785281 chr8 18209795 C A 1.20E-04 Urinary metabolites / / 21572414 rs10093868 chr8 18209874 T C 1.60E-04 Urinary metabolites / / 21572414 rs10094010 chr8 18209976 T C 1.70E-04 Urinary metabolites / / 21572414 rs10094103 chr8 18209982 T C 1.60E-04 Urinary metabolites / / 21572414 rs10091001 chr8 18209990 A G 1.20E-04 Urinary metabolites / / 21572414 rs1907955 chr8 18211158 T C 1.70E-05 Urinary metabolites / / 21572414 rs10098142 chr8 18211298 A T 1.00E-04 Urinary metabolites / / 21572414 rs1907953 chr8 18211370 G A 1.30E-06 Urinary metabolites / / 21572414 rs11777730 chr8 18211861 T C 1.10E-05 Urinary metabolites / / 21572414 rs4921598 chr8 18212172 A G 8.10E-05 Urinary metabolites / / 21572414 rs10086768 chr8 18212354 G A,C,T 7.40E-06 Urinary metabolites / / 21572414 rs10086768 chr8 18212354 G A,C,T 3.64E-04 Smoking initiation / / 24665060 rs2410552 chr8 18212381 G A 5.70E-05 Urinary metabolites / / 21572414 rs2898472 chr8 18212433 A T 6.80E-05 Urinary metabolites / / 21572414 rs2410553 chr8 18212511 G A 2.30E-06 Urinary metabolites / / 21572414 rs62492961 chr8 18212912 C T 1.70E-05 Urinary metabolites / / 21572414 rs62492962 chr8 18213114 C G 1.20E-05 Urinary metabolites / / 21572414 rs62492964 chr8 18213235 T G 1.40E-05 Urinary metabolites / / 21572414 rs62492965 chr8 18213254 T C 1.40E-05 Urinary metabolites / / 21572414 rs62492966 chr8 18213344 T C 6.50E-05 Urinary metabolites / / 21572414 rs10106233 chr8 18213457 A C 1.00E-05 Urinary metabolites / / 21572414 rs10109204 chr8 18213460 T C 1.20E-05 Urinary metabolites / / 21572414 rs2410554 chr8 18213586 T C 3.70E-05 Urinary metabolites / / 21572414 rs2172431 chr8 18214103 A G 5.80E-06 Urinary metabolites / / 21572414 rs2131425 chr8 18214323 G C 9.76E-04 Multiple complex diseases / / 17554300 rs12542798 chr8 18214811 C G 2.10E-05 Urinary metabolites / / 21572414 rs13282848 chr8 18215611 C G 5.31E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs13282848 chr8 18215611 C G 4.10E-08 Urinary metabolites / / 21572414 rs13256693 chr8 18215738 T C 9.00E-08 Urinary metabolites / / 21572414 rs971769 chr8 18217607 T C 2.70E-05 Urinary metabolites / / 21572414 rs13277039 chr8 18218402 C T 3.50E-07 Urinary metabolites / / 21572414 rs1390361 chr8 18219310 A T 5.60E-07 Urinary metabolites / / 21572414 rs2015440 chr8 18220434 T A 2.70E-09 Urinary metabolites / / 21572414 rs1603296 chr8 18220513 T C 4.00E-07 Urinary metabolites / / 21572414 rs982546 chr8 18220992 G A 3.50E-04 Urinary metabolites / / 21572414 rs7011551 chr8 18221791 G T 8.24E-04 Multiple complex diseases / / 17554300 rs1603298 chr8 18222388 C T 3.90E-04 Urinary metabolites / / 21572414 rs6982218 chr8 18226049 T C 3.70E-05 Urinary metabolites / / 21572414 rs13278827 chr8 18227113 A G 3.90E-05 Urinary metabolites / / 21572414 rs10088180 chr8 18228116 A G 8.50E-07 Urinary metabolites / / 21572414 rs12548816 chr8 18229188 T C 4.10E-05 Urinary metabolites / / 21572414 rs2220734 chr8 18231019 T C 5.00E-05 Urinary metabolites / / 21572414 rs34134499 chr8 18231120 G T 3.40E-04 Urinary metabolites / / 21572414 rs62492969 chr8 18231934 G A 3.10E-04 Urinary metabolites / / 21572414 rs1495749 chr8 18233386 T A 3.10E-05 Urinary metabolites / / 21572414 rs7006687 chr8 18233582 C T 2.00E-06 QT interval (interaction) / / 23459443 rs7006687 chr8 18233582 C T 6.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs35048938 chr8 18234224 G A 3.30E-04 Urinary metabolites / / 21572414 rs12549893 chr8 18235152 C G 6.50E-04 Urinary metabolites / / 21572414 rs2047252 chr8 18237987 T C 3.20E-05 Urinary metabolites / / 21572414 rs6991507 chr8 18239365 A T 3.00E-05 Urinary metabolites / / 21572414 rs13266992 chr8 18239697 T C 3.90E-08 Urinary metabolites / / 21572414 rs62492994 chr8 18240176 A T 1.80E-04 Urinary metabolites / / 21572414 rs28417619 chr8 18240765 G A 4.00E-05 Urinary metabolites / / 21572414 rs59416053 chr8 18240800 G C 3.30E-08 Urinary metabolites / / 21572414 rs28629910 chr8 18240991 G A 3.90E-05 Urinary metabolites / / 21572414 rs28369048 chr8 18241114 G A 2.30E-05 Urinary metabolites / / 21572414 rs28755857 chr8 18241151 C T 3.70E-05 Urinary metabolites / / 21572414 rs28546593 chr8 18241164 C T 3.70E-05 Urinary metabolites / / 21572414 rs28670948 chr8 18241172 A T 3.70E-05 Urinary metabolites / / 21572414 rs35354956 chr8 18241319 T C 1.30E-07 Urinary metabolites / / 21572414 rs28558914 chr8 18241351 T C 2.10E-05 Urinary metabolites / / 21572414 rs17516895 chr8 18241373 C G 2.00E-05 Urinary metabolites / / 21572414 rs13277738 chr8 18241507 C T 4.00E-10 Urinary metabolites / / 21572414 rs28521336 chr8 18241521 A T 1.90E-05 Urinary metabolites / / 21572414 rs17642674 chr8 18241755 T C 1.70E-04 Urinary metabolites / / 21572414 rs17642674 chr8 18241755 T C 2.76E-05 Rheumatoid arthritis (ACPA-negative) / / 24532677 rs34546534 chr8 18241771 C T 1.40E-05 Urinary metabolites / / 21572414 rs62492996 chr8 18241801 C T 1.70E-05 Urinary metabolites / / 21572414 rs4921905 chr8 18242244 G C 1.40E-05 Urinary metabolites / / 21572414 rs6586745 chr8 18243089 C T 9.30E-06 Urinary metabolites / / 21572414 rs13262341 chr8 18243097 A G 3.10E-08 Urinary metabolites / / 21572414 rs7016785 chr8 18243113 T C 2.60E-07 Urinary metabolites / / 21572414 rs6992093 chr8 18243193 G A 9.30E-06 Urinary metabolites / / 21572414 rs7013253 chr8 18243468 A G 2.50E-07 Urinary metabolites / / 21572414 rs11775300 chr8 18243551 C T 9.60E-06 Urinary metabolites / / 21572414 rs10109286 chr8 18243603 T C 1.30E-11 Urinary metabolites / / 21572414 rs10109286 chr8 18243603 T C 3.33E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs10095072 chr8 18244662 G T 2.60E-08 Urinary metabolites / / 21572414 rs10095159 chr8 18244684 G A 2.60E-07 Urinary metabolites / / 21572414 rs13282367 chr8 18244986 T G 2.60E-08 Urinary metabolites / / 21572414 rs10085931 chr8 18245449 A G 3.50E-08 Urinary metabolites / / 21572414 rs11780884 chr8 18246053 A G 8.00E-10 Urinary metabolites / / 21572414 rs11992530 chr8 18246133 A C 5.60E-04 Urinary metabolites / / 21572414 rs11992530 chr8 18246133 A C 0.0000306 Triglycerides / / 23063622 rs4646241 chr8 18246696 T C 2.80E-05 Urinary metabolites / / 21572414 rs4646242 chr8 18247449 A G 2.10E-05 Urinary metabolites /T2 nearGene-5 21572414 rs4646243 chr8 18247609 T C 4.50E-10 Urinary metabolites /T2 nearGene-5 21572414 rs4646244 chr8 18247718 T A 8.50E-04 Urinary metabolites /T2 nearGene-5 21572414 rs4646267 chr8 18247913 A G 8.00E-08 Urinary metabolites /T2 nearGene-5 21572414 rs4345600 chr8 18248208 A G 6.10E-05 Urinary metabolites /T2 nearGene-5 21572414 rs4271002 chr8 18248268 G C 8.20E-05 Urinary metabolites /T2 nearGene-5 21572414 rs4646246 chr8 18248661 A G 6.90E-08 Urinary metabolites /T2 nearGene-5 21572414 rs11780272 chr8 18249652 T C 1.80E-04 Urinary metabolites /T2 intron 21572414 rs55686478 chr8 18250375 G A 4.30E-10 Urinary metabolites /T2 intron 21572414 rs13277605 chr8 18250592 G T 2.00E-04 Urinary metabolites /T2 intron 21572414 rs9987109 chr8 18250922 T C 8.40E-05 Urinary metabolites /T2 intron 21572414 rs35149886 chr8 18251809 G A 7.40E-04 Urinary metabolites /T2 intron 21572414 rs7011792 chr8 18252069 G C 3.90E-07 Urinary metabolites /T2 intron 21572414 rs1390358 chr8 18252755 T C 8.10E-07 Urinary metabolites /T2 intron 21572414 rs923796 chr8 18253409 C G 7.30E-04 Urinary metabolites /T2 intron 21572414 rs4546703 chr8 18254367 G A 2.00E-04 Urinary metabolites /T2 intron 21572414 rs4634684 chr8 18254372 T C 1.10E-04 Urinary metabolites /T2 intron 21572414 rs35583283 chr8 18254509 G C 8.60E-11 Urinary metabolites /T2 intron 21572414 rs4621844 chr8 18254939 T C 4.50E-04 Urinary metabolites /T2 intron 21572414 rs1115784 chr8 18255410 A G 1.40E-13 Urinary metabolites /T2 intron 21572414 rs1961456 chr8 18255709 A G 1.80E-12 Urinary metabolites /T2 intron 21572414 rs1961456 chr8 18255709 A G 0.000000593 Triglycerides in males /T2 intron 23063622 rs1961456 chr8 18255709 A G 0.000102 Cholesterol,total /T2 intron 23063622 rs1961456 chr8 18255709 A G 1.23E-09 Triglycerides /T2 intron 23063622 rs1961456 chr8 18255709 A G 7.04E-10 Triglycerides /T2 intron 23063622 rs62492997 chr8 18255784 G A 1.10E-04 Urinary metabolites /T2 intron 21572414 rs28510118 chr8 18256441 T C 4.00E-04 Urinary metabolites /T2 intron 21572414 rs11782802 chr8 18256655 C T 2.90E-06 Urinary metabolites /T2 intron 21572414 rs1495744 chr8 18257023 A G 4.00E-04 Urinary metabolites /T2 intron 21572414 rs7832071 chr8 18257280 C T 1.60E-06 Urinary metabolites /T2 intron 21572414 rs45477599 chr8 18257583 T A 0.00024 Breast cancer (ER positive) /T2 missense 23555315 rs1041983 chr8 18257795 C T 1 Drug response to Clonazepam /T2 cds-synon 19356010 rs1041983 chr8 18257795 C T 9.70E-04 Urinary metabolites /T2 cds-synon 21572414 rs1801280 chr8 18257854 T C 1 Drug response to Clonazepam /T2 missense 19356010 rs1801280 chr8 18257854 T C 8.20E-05 Urinary metabolites /T2 missense 21572414 rs1799929 chr8 18257994 C T 1 Drug response to Clonazepam /T2 cds-synon 19356010 rs1799929 chr8 18257994 C T 8.90E-08 Urinary metabolites /T2 cds-synon 21572414 rs1799930 chr8 18258103 G A 1 Drug response to Clonazepam /T2 missense 19356010 rs1208 chr8 18258316 G A 1 Drug response to Clonazepam /T2 missense 19356010 rs1208 chr8 18258316 G A 1.00E-06 Urinary metabolites /T2 missense 21572414 rs1799931 chr8 18258370 G A 1 Drug response to Docetaxel /T2 missense 20038957 rs1799931 chr8 18258370 G A 1 Drug response to Thalidomide /T2 missense 20038957 rs4646247 chr8 18258908 G A 8.80E-04 Urinary metabolites /T2 nearGene-3 21572414 rs721398 chr8 18259305 A G 7.60E-04 Urinary metabolites / / 21572414 rs721399 chr8 18259366 C T 7.90E-14 Urinary metabolites / / 21572414 rs721399 chr8 18259366 C T 4.00E-58 Blood metabolite levels / / 24816252 rs11780610 chr8 18259876 C T 7.50E-14 Urinary metabolites / / 21572414 rs11784251 chr8 18260013 A G 1.80E-13 Urinary metabolites / / 21572414 rs11787313 chr8 18260026 G C 7.50E-14 Urinary metabolites / / 21572414 rs45605031 chr8 18260239 G T 9.00E-04 Urinary metabolites / / 21572414 rs4646248 chr8 18260355 C T 8.00E-14 Urinary metabolites / / 21572414 rs4646249 chr8 18260431 T G 7.70E-14 Urinary metabolites / / 21572414 rs4646250 chr8 18260598 G A 7.60E-14 Urinary metabolites / / 21572414 rs4646251 chr8 18261216 C G 4.30E-07 Urinary metabolites / / 21572414 rs1390360 chr8 18261493 G A 9.40E-14 Urinary metabolites / / 21572414 rs1908586 chr8 18261497 A G 3.10E-04 Urinary metabolites / / 21572414 rs1908587 chr8 18261679 A C 7.00E-07 Urinary metabolites / / 21572414 rs4646254 chr8 18262059 A G 2.60E-07 Urinary metabolites / / 21572414 rs4646255 chr8 18262374 C T 3.30E-04 Urinary metabolites / / 21572414 rs4244446 chr8 18262518 C A,G,T 6.70E-14 Urinary metabolites / / 21572414 rs4646257 chr8 18262546 T C 5.21E-04 Multiple complex diseases / / 17554300 rs4646257 chr8 18262546 T C 3.00E-11 Urinary metabolites / / 21572414 rs4646258 chr8 18262679 G C 3.90E-04 Urinary metabolites / / 21572414 rs1495745 chr8 18262723 T G 1.90E-13 Urinary metabolites / / 21572414 rs1495746 chr8 18262842 C T 5.30E-14 Urinary metabolites / / 21572414 rs4646259 chr8 18262845 T C 9.80E-04 Urinary metabolites / / 21572414 rs1495747 chr8 18262861 T C 6.90E-14 Urinary metabolites / / 21572414 rs1495748 chr8 18263112 A G 6.60E-14 Urinary metabolites / / 21572414 rs2410558 chr8 18263484 T C 1.70E-13 Urinary metabolites / / 21572414 rs4540438 chr8 18263603 A C 3.80E-04 Urinary metabolites / / 21572414 rs12674710 chr8 18263663 A C 2.00E-07 Urinary metabolites / / 21572414 rs13249400 chr8 18263814 G A 3.90E-04 Urinary metabolites / / 21572414 rs4282612 chr8 18264158 G T 4.00E-04 Urinary metabolites / / 21572414 rs4398966 chr8 18264226 G A 4.00E-04 Urinary metabolites / / 21572414 rs1495737 chr8 18264837 C T 4.60E-04 Urinary metabolites / / 21572414 rs1495738 chr8 18265123 G A 6.80E-04 Urinary metabolites / / 21572414 rs1495740 chr8 18265167 C T 4.10E-04 Urinary metabolites / / 21572414 rs11779202 chr8 18265226 G C 3.90E-04 Urinary metabolites / / 21572414 rs57134942 chr8 18265260 A C 9.50E-04 Urinary metabolites / / 21572414 rs11776893 chr8 18265410 T C 4.20E-04 Urinary metabolites / / 21572414 rs13270462 chr8 18265537 C T 4.40E-04 Urinary metabolites / / 21572414 rs34074180 chr8 18266001 C T 1.00E-04 Urinary metabolites / / 21572414 rs34953230 chr8 18266011 A G 1.00E-04 Urinary metabolites / / 21572414 rs56264179 chr8 18266064 C T 9.00E-04 Urinary metabolites / / 21572414 rs34940519 chr8 18266158 G A 1.10E-04 Urinary metabolites / / 21572414 rs35721866 chr8 18266362 G A 1.40E-04 Urinary metabolites / / 21572414 rs35566315 chr8 18266428 A G 1.10E-04 Urinary metabolites / / 21572414 rs12676857 chr8 18266572 T C 2.50E-09 Urinary metabolites / / 21572414 rs2410561 chr8 18266774 G A 2.00E-09 Urinary metabolites / / 21572414 rs7818999 chr8 18266919 G A 1.20E-04 Urinary metabolites / / 21572414 rs2898476 chr8 18266924 G A 2.50E-09 Urinary metabolites / / 21572414 rs7820005 chr8 18266953 C T 1.20E-04 Urinary metabolites / / 21572414 rs7460653 chr8 18266983 G C 2.50E-09 Urinary metabolites / / 21572414 rs10103029 chr8 18267338 A G 2.00E-09 Urinary metabolites / / 21572414 rs55959056 chr8 18267394 C T 2.60E-04 Urinary metabolites / / 21572414 rs10103148 chr8 18267429 A C 2.60E-09 Urinary metabolites / / 21572414 rs35963355 chr8 18267431 A G 1.20E-04 Urinary metabolites / / 21572414 rs10087857 chr8 18267461 G C 2.60E-09 Urinary metabolites / / 21572414 rs6988857 chr8 18267673 G T 3.30E-04 Urinary metabolites / / 21572414 rs10088333 chr8 18267878 G A 2.60E-09 Urinary metabolites / / 21572414 rs61290794 chr8 18268000 G A 8.70E-04 Urinary metabolites / / 21572414 rs1587145 chr8 18268416 A G 1.30E-04 Urinary metabolites / / 21572414 rs13265064 chr8 18268480 C A 1.30E-04 Urinary metabolites / / 21572414 rs10089958 chr8 18269343 A G 2.60E-09 Urinary metabolites / / 21572414 rs1603291 chr8 18269403 A C 1.30E-04 Urinary metabolites / / 21572414 rs1908583 chr8 18269510 G A 1.30E-04 Urinary metabolites / / 21572414 rs57180587 chr8 18269581 A T 2.70E-09 Urinary metabolites / / 21572414 rs7826755 chr8 18270067 A G 1.40E-04 Urinary metabolites / / 21572414 rs13270123 chr8 18271048 A C 1.40E-04 Urinary metabolites / / 21572414 rs12543640 chr8 18271120 T C 2.70E-07 Urinary metabolites / / 21572414 rs13276600 chr8 18271190 C T 1.60E-04 Urinary metabolites / / 21572414 rs13276600 chr8 18271190 C T 5.82E-06 Prostate cancer / / pha002878 rs2410563 chr8 18271251 C T 1.40E-04 Urinary metabolites / / 21572414 rs7813156 chr8 18271299 G C 1.40E-04 Urinary metabolites / / 21572414 rs12543166 chr8 18271508 A C 8.30E-05 Urinary metabolites / / 21572414 rs4921913 chr8 18272377 C T 6.80E-16 Urinary metabolites / / 21572414 rs4921913 chr8 18272377 C T 3.00E-47 Blood metabolite ratios / / 24816252 rs4921914 chr8 18272438 C T 1.00E-28 Urinary metabolites / / 21572414 rs4921914 chr8 18272438 C T 4.00E-32 Urinary metabolites (H-NMR features) / / 24586186 rs4921914 chr8 18272438 C T 1.00E-60 Blood metabolite levels / / 24816252 rs4921914 chr8 18272438 C T 8.20E-62 Skin fluorescence / / 24934506 rs4921915 chr8 18272466 G A 6.90E-16 Urinary metabolites / / 21572414 rs35246381 chr8 18272535 C T 6.90E-16 Urinary metabolites / / 21572414 rs35570672 chr8 18272635 T C 6.90E-16 Urinary metabolites / / 21572414 rs1495741 chr8 18272881 G A 2.00E-09 Cholesterol,total / / 20686565 rs1495741 chr8 18272881 G A 4.00E-14 Triglycerides / / 20686565 rs1495741 chr8 18272881 G A 4.00E-11 Bladder cancer / / 20972438 rs1495741 chr8 18272881 G A 6.90E-16 Urinary metabolites / / 21572414 rs1495741 chr8 18272881 G A 3.00E-08 Cholesterol,total / / 24097068 rs1495741 chr8 18272881 G A 3.00E-12 Triglycerides / / 24097068 rs1495741 chr8 18272881 G A 2.00E-10 Bladder cancer / / 24163127 rs1495741 chr8 18272881 G A 1.36E-05 Bladder cancer (smoking interaction) / / 24662972 rs1495741 chr8 18272881 G A 1.00E-27 Blood metabolite levels / / 24816252 rs1495741 chr8 18272881 G A 6.60E-05 Urinary bladder cancer / / 24861552 rs1495741 chr8 18272881 G A 3.00E-50 Skin fluorescence / / 24934506 rs1495742 chr8 18272901 C T 1.60E-04 Urinary metabolites / / 21572414 rs62493026 chr8 18272907 C T 4.50E-07 Urinary metabolites / / 21572414 rs13254811 chr8 18273018 A G 1.80E-08 Urinary metabolites / / 21572414 rs1495743 chr8 18273300 G A,C 6.50E-16 Urinary metabolites / / 21572414 rs1495743 chr8 18273300 G A,C 2.00E-40 Metabolic traits / / 21886157 rs1018070 chr8 18273627 T A 1.10E-07 Urinary metabolites / / 21572414 rs35942058 chr8 18274398 G A 2.30E-08 Urinary metabolites / / 21572414 rs34987019 chr8 18274443 T C 2.30E-08 Urinary metabolites / / 21572414 rs7816847 chr8 18275189 A C 2.40E-08 Urinary metabolites / / 21572414 rs62493050 chr8 18275378 C G 4.50E-07 Urinary metabolites / / 21572414 rs2410564 chr8 18275845 A G 4.50E-08 Urinary metabolites / / 21572414 rs2410565 chr8 18276090 G C 7.60E-08 Urinary metabolites / / 21572414 rs4560828 chr8 18276294 A T 9.30E-09 Urinary metabolites / / 21572414 rs34585362 chr8 18276742 G A 1.60E-04 Urinary metabolites / / 21572414 rs1466753 chr8 18277119 C T 3.20E-04 Urinary metabolites / / 21572414 rs1466753 chr8 18277119 C T 4.36E-05 Prostate cancer / / pha002878 rs7827087 chr8 18277483 A G 1.70E-04 Urinary metabolites / / 21572414 rs983776 chr8 18277958 T C 1.70E-04 Urinary metabolites / / 21572414 rs983777 chr8 18277979 A G 2.50E-04 Urinary metabolites / / 21572414 rs11780022 chr8 18278148 C T 5.90E-07 Urinary metabolites / / 21572414 rs7005648 chr8 18278208 T A 5.00E-08 Urinary metabolites / / 21572414 rs12545110 chr8 18279731 A G 1.80E-04 Urinary metabolites / / 21572414 rs11776943 chr8 18280550 C T 7.90E-07 Urinary metabolites / / 21572414 rs17126633 chr8 18281867 T C 2.70E-04 Urinary metabolites / / 21572414 rs1390357 chr8 18282880 C T 1.03E-05 Cognitive test performance / / 20125193 rs1390357 chr8 18282880 C T 1.70E-09 Urinary metabolites / / 21572414 rs13273265 chr8 18283352 C G 8.20E-09 Urinary metabolites / / 21572414 rs7829695 chr8 18284795 G C 3.90E-04 Urinary metabolites / / 21572414 rs6997340 chr8 18286997 T C 9.70E-04 Parkinson's disease / / 17052657 rs6997340 chr8 18286997 T C 4.50E-09 Urinary metabolites / / 21572414 rs7015972 chr8 18288003 G A 3.10E-08 Urinary metabolites / / 21572414 rs34370554 chr8 18288772 T G 9.50E-09 Urinary metabolites / / 21572414 rs35152003 chr8 18291401 T A 3.80E-08 Urinary metabolites / / 21572414 rs11784369 chr8 18291590 G C 2.90E-08 Urinary metabolites / / 21572414 rs2201554 chr8 18295044 A C,G,T 7.26E-04 Type 2 diabetes / / 17463246 rs7817770 chr8 18307161 C T 2.41E-04 Parkinson's disease / / 17052657 rs7817770 chr8 18307161 C T 2.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7000897 chr8 18315721 G A 8.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs62494886 chr8 18328704 G A 5.40E-04 Urinary metabolites / / 21572414 rs4921930 chr8 18355897 C T 1.15E-12 CD8+ T cell IFN-gamma response to smallpox vaccine / / 22661280 rs1110820 chr8 18360301 T C 1.15E-12 CD8+ T cell IFN-gamma response to smallpox vaccine / / 22661280 rs12546956 chr8 18361385 C T 6.57E-04 Substance dependence / / 21818250 rs12546956 chr8 18361385 C T 7.18E-06 Venous thromboembolism / / 22672568 rs766143 chr8 18379513 T C 4.80E-06 Urinary metabolites / / 21572414 rs4921604 chr8 18379863 A G 2.26E-05 Attention deficit hyperactivity disorder / / 23728934 rs10090117 chr8 18381235 T C 4.00E-06 Paclitaxel-induced neuropathy / / 23776197 rs10112277 chr8 18384691 G A 2.10E-05 Urinary metabolites / / 21572414 rs13275817 chr8 18387374 A G 8.50E-06 Urinary metabolites PSD3 UTR-3 21572414 rs901935 chr8 18391332 T C 1.80E-05 Urinary metabolites PSD3 UTR-3 21572414 rs1565229 chr8 18398884 A G 7.59E-04 Suicide attempts in bipolar disorder PSD3 intron 21423239 rs1908588 chr8 18403964 A G 9.17E-04 Suicide attempts in bipolar disorder PSD3 intron 21423239 rs17126808 chr8 18414060 C G 9.14E-04 Type 2 diabetes PSD3 intron 17463246 rs2717757 chr8 18429003 A G 2.49E-05 Cognitive test performance PSD3 intron 20125193 rs2634446 chr8 18442085 C A 2.71E-05 Cognitive test performance PSD3 intron 20125193 rs17126870 chr8 18443369 G C 5.82E-04 Multiple complex diseases PSD3 intron 17554300 rs2410573 chr8 18449741 G A 3.90E-04 Alzheimer's disease PSD3 intron 22005930 rs1487760 chr8 18469396 A C 9.61E-04 Depression (quantitative trait) PSD3 intron 20800221 rs17518437 chr8 18471243 G C 3.29E-04 Suicide attempts in bipolar disorder PSD3 intron 21423239 rs17518444 chr8 18471418 G C 3.86E-04 Suicide attempts in bipolar disorder PSD3 intron 21423239 rs17596758 chr8 18471772 G A 1.81E-04 Suicide attempts in bipolar disorder PSD3 intron 21423239 rs2129703 chr8 18482596 C T 9.80E-04 Multiple complex diseases PSD3 intron 17554300 rs11785801 chr8 18501321 T C 2.56E-05 Gallbladder cancer PSD3 intron 22318345 rs13256549 chr8 18508649 C T 4.81E-05 Lung adenocarcinoma PSD3 intron 19836008 rs13268366 chr8 18511097 A G 8.05E-05 Lung adenocarcinoma PSD3 intron 19836008 rs17518764 chr8 18513274 T G 4.95E-05 Suicide attempts in bipolar disorder PSD3 intron 21423239 rs10081421 chr8 18516802 T A 6.22E-06 White blood cell count PSD3 intron 21738479 rs11203979 chr8 18522287 G C 4.86E-04 Type 2 diabetes PSD3 intron 17463246 rs10087403 chr8 18534285 A C 0.00000694 HIV-1 infection (natural long-term nonprogression) PSD3 intron 22238471 rs17127037 chr8 18539063 T C 5.28E-04 Suicide attempts in bipolar disorder PSD3 intron 21423239 rs901733 chr8 18559665 G T 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes PSD3 intron 22628534 rs901729 chr8 18565805 A G 1.18E-04 Stroke PSD3 intron pha002887 rs1872890 chr8 18575581 A G 1.29E-04 Insulin resistance PSD3 intron 21901158 rs17127110 chr8 18588911 A G 2.03E-04 Tourette syndrome PSD3 intron 22889924 rs335231 chr8 18629355 C T 4.87E-04 Response to cytidine analogues (gemcitabine) PSD3 intron 24483146 rs6586764 chr8 18632093 C T 5.49E-04 Coronary heart disease PSD3 intron 21971053 rs2172289 chr8 18663483 A G 8.94E-05 Bipolar disorder and schizophrenia PSD3 intron 20889312 rs1386688 chr8 18664294 C G 6.59E-05 Schizophrenia PSD3 intron 19571809 rs11778064 chr8 18665597 G T 4.61E-04 Alzheimer's disease PSD3 intron 24755620 rs17127252 chr8 18673264 G A,C 0.0007272 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PSD3 intron 23233654 rs17127252 chr8 18673264 G A,C 7.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) PSD3 intron 23233662 rs2638663 chr8 18673731 T G 1.19E-05 Lung function (forced vital capacity) PSD3 intron 24023788 rs2638663 chr8 18673731 T G 8.00E-07 Lung function (forced expiratory volume in 1 second) PSD3 intron 24023788 rs2632839 chr8 18674701 C T 1.62E-04 Autism spectrum disorders (language delay) PSD3 intron 21519539 rs2632839 chr8 18674701 C T 0.0006194 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PSD3 intron 23233654 rs2632839 chr8 18674701 C T 6.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) PSD3 intron 23233662 rs2638609 chr8 18674800 G A 0.0006294 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PSD3 intron 23233654 rs2638609 chr8 18674800 G A 6.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) PSD3 intron 23233662 rs2638610 chr8 18674835 G A 1.62E-04 Autism spectrum disorders (language delay) PSD3 intron 21519539 rs2638610 chr8 18674835 G A 0.0006467 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PSD3 intron 23233654 rs2638610 chr8 18674835 G A 6.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) PSD3 intron 23233662 rs2638611 chr8 18674896 C T 0.0007305 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PSD3 intron 23233654 rs2638611 chr8 18674896 C T 7.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) PSD3 intron 23233662 rs2632837 chr8 18675150 A G 0.0007315 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PSD3 intron 23233654 rs2632837 chr8 18675150 A G 7.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) PSD3 intron 23233662 rs2632836 chr8 18675250 C T 0.0007311 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PSD3 intron 23233654 rs2632836 chr8 18675250 C T 7.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) PSD3 intron 23233662 rs2638636 chr8 18675864 C CC,CT 0.0007258 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PSD3 intron 23233654 rs2638636 chr8 18675864 C CC,CT 7.26E-04 Methotrexate clearance (acute lymphoblastic leukemia) PSD3 intron 23233662 rs871762 chr8 18676521 T C 0.000726 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PSD3 intron 23233654 rs871762 chr8 18676521 T C 7.26E-04 Methotrexate clearance (acute lymphoblastic leukemia) PSD3 intron 23233662 rs7844500 chr8 18703343 A G 9.86E-06 Obesity-related traits PSD3 intron 23251661 rs7833787 chr8 18707871 A G 5.00E-06 Obesity-related traits PSD3 intron 23251661 rs13273954 chr8 18729459 T C 2.00E-05 Urinary metabolites PSD3 cds-synon 21572414 rs4921617 chr8 18782047 C T 4.00E-06 Neutrophil count PSD3 intron 21507922 rs930023 chr8 18786787 G A 3.20E-05 Bilirubin levels PSD3 intron 19414484 rs932648 chr8 18789630 C T 3.50E-05 Bilirubin levels PSD3 intron 19414484 rs6999315 chr8 18795045 A G 8.30E-04 Alcohol dependence PSD3 intron 20201924 rs12543327 chr8 18807608 T A 1.04E-04 Type 2 diabetes PSD3 intron 17463246 rs17469038 chr8 18817263 C A 1.65E-04 Type 2 diabetes PSD3 intron 17463246 rs17469059 chr8 18817493 A G 1.60E-04 Type 2 diabetes PSD3 intron 17463246 rs2059645 chr8 18818257 A G 6.19E-06 Hemoglobin concentration PSD3 intron 20534544 rs17127550 chr8 18826960 G A 1.62E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) PSD3 intron 24023788 rs17127550 chr8 18826960 G A 2.33E-04 Lung function (forced expiratory volume in 1 second) PSD3 intron 24023788 rs6586789 chr8 18829714 C T 5.83E-04 Type 2 diabetes PSD3 intron 17463246 rs4921978 chr8 18836545 T C 2.40E-05 Hemoglobin concentration PSD3 intron 20534544 rs11987117 chr8 18837940 A G 1.52E-05 Hemoglobin concentration PSD3 intron 20534544 rs1426919 chr8 18839091 A C 9.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) PSD3 intron 23648065 rs10216388 chr8 18844382 C A 9.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) PSD3 intron 23648065 rs7010496 chr8 18866368 C T 5.39E-05 Hemoglobin concentration PSD3 intron 20534544 rs1025230 chr8 18882181 A G 5.38E-04 Alzheimer's disease / / 24755620 rs334198 chr8 18888809 A C 3.64E-06 Coronary heart disease / / pha003031 rs10104732 chr8 18898040 A G 2.01E-04 Multiple complex diseases / / 17554300 rs2063076 chr8 18898789 C A 3.54E-04 Multiple complex diseases / / 17554300 rs751217 chr8 18900079 G A 2.74E-04 Multiple complex diseases / / 17554300 rs919149 chr8 18904368 G A 6.61E-05 Multiple complex diseases / / 17554300 rs919149 chr8 18904368 G A 1.27E-05 Prostate cancer / / 22923026 rs890519 chr8 18905049 C A 2.51E-04 Hemoglobin concentration / / 20534544 rs890519 chr8 18905049 C A 7.70E-05 Prostate cancer / / 22923026 rs7833499 chr8 18905296 C T 1.56E-05 Prostate cancer / / 22923026 rs1814160 chr8 18908815 C G 1.60E-05 Multiple complex diseases / / 17554300 rs1506895 chr8 18909558 A G 3.06E-04 Hemoglobin concentration / / 20534544 rs334210 chr8 18910248 C T 2.01E-04 Multiple complex diseases / / 17554300 rs334213 chr8 18910834 C T 1.62E-05 Coronary heart disease / / pha003031 rs6985805 chr8 18914420 C A 2.83E-05 Coronary heart disease / / pha003031 rs1027803 chr8 18919720 T C 3.78E-06 Coronary heart disease / / pha003031 rs2410601 chr8 18922577 G C 4.00E-06 Urinary albumin excretion rate in type 1 diabetes / / 24595857 rs7843518 chr8 18925159 G A 3.15E-05 Multiple complex diseases / / 17554300 rs36110451 chr8 18926800 C T 7.23E-05 Multiple complex diseases / / 17554300 rs11204020 chr8 18947138 G A 3.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12677573 chr8 18950578 T C 8.92E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17469961 chr8 18961067 A G 0.0006589 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17469961 chr8 18961067 A G 6.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10102187 chr8 18962087 A C 2.93E-05 Cardiovascular disease / / pha003064 rs925037 chr8 18979716 C T 8.20E-04 Intelligence (childhood) / / 23358156 rs13268591 chr8 18981713 A C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs13271407 chr8 18985111 A G 9.75E-04 Alzheimer's disease / / 22005930 rs692512 chr8 18989735 A G 6.29E-04 Multiple complex diseases / / 17554300 rs13264451 chr8 18991089 A G 8.35E-04 Alzheimer's disease / / 22005930 rs662032 chr8 18993883 C T 8.07E-04 Multiple complex diseases / / 17554300 rs11204021 chr8 18994430 C T 8.75E-04 Alzheimer's disease / / 22005930 rs10094231 chr8 18994752 T C 1.13E-04 Multiple complex diseases / / 17554300 rs6999655 chr8 18994855 T C 3.71E-04 Acute lung injury / / 22295056 rs189147 chr8 18996437 A T 3.67E-04 Multiple complex diseases / / 17554300 rs7845276 chr8 19004704 A G 5.88E-04 Multiple complex diseases / / 17554300 rs333067 chr8 19008072 T C 7.75E-05 Acute lung injury / / 22295056 rs170773 chr8 19008265 T G 5.32E-04 Acute lung injury / / 22295056 rs2063081 chr8 19008962 T C 2.03E-04 Acute lung injury / / 22295056 rs2063080 chr8 19009002 G C 5.24E-05 Acute lung injury / / 22295056 rs691872 chr8 19017328 T C 4.45E-04 Acute lung injury / / 22295056 rs333063 chr8 19034022 T C 1.79E-04 Fibrinogen / / 17255346 rs333047 chr8 19049811 T C 3.70E-04 Schizophrenia LOC100128993 intron 19197363 rs6986748 chr8 19049824 C G,T 1.75E-04 Multiple complex diseases LOC100128993 intron 17554300 rs2898487 chr8 19064892 C T 4.68E-04 Schizophrenia LOC100128993 intron 19197363 rs11986238 chr8 19067320 A G 8.75E-05 Hypertension (early onset hypertension) LOC100128993 intron 22479346 rs1193327 chr8 19070373 A C 0.000697156 Hypertension (early onset hypertension) LOC100128993 intron 22479346 rs17127984 chr8 19072556 T C 4.30E-05 HIV-1 viral setpoint LOC100128993 intron 22174851 rs4922003 chr8 19072672 C T 0.000121335 Hypertension (early onset hypertension) LOC100128993 intron 22479346 rs2672245 chr8 19074872 G T 6.88E-04 Schizophrenia LOC100128993 intron 19197363 rs17127995 chr8 19076408 A G 3.83E-04 Suicide attempts in bipolar disorder LOC100128993 intron 21423239 rs2683291 chr8 19080556 C A,G,T 2.97E-04 Suicide attempts in bipolar disorder LOC100128993 intron 21423239 rs17128007 chr8 19083152 C T 7.00E-06 Smooth-surface caries LOC100128993 intron 24556642 rs991359 chr8 19085172 C T 0.000370718 Hypertension (early onset hypertension) LOC100128993 intron 22479346 rs1118972 chr8 19086353 C T 1.40E-05 Urinary metabolites LOC100128993 intron 21572414 rs76461710 chr8 19096706 G A 5.25E-06 Telomere length LOC100128993 intron 24478790 rs11787341 chr8 19102564 G A 9.00E-07 Telomere length LOC100128993 intron 24478790 rs17128056 chr8 19118147 C G 7.60E-06 Urinary metabolites / / 21572414 rs2683279 chr8 19128886 A G 9.63E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10091480 chr8 19129651 T A,C 3.10E-05 HIV-1 control / / 20041166 rs10503656 chr8 19150880 C T 4.91E-04 Multiple complex diseases / / 17554300 rs10503656 chr8 19150880 C T 3.80E-05 Serum metabolites / / 19043545 rs6997589 chr8 19177772 G A 6.25E-05 Longevity SH2D4A intron 22279548 rs5018145 chr8 19200063 A C 6.51E-05 Birth weight SH2D4A intron 17255346 rs17128272 chr8 19213714 G A 8.95E-05 Coronary heart disease SH2D4A intron pha003030 rs11778175 chr8 19267830 C T 2.80E-05 Urinary metabolites CSGAL/CT1 intron 21572414 rs17479085 chr8 19277109 G A 2.41E-04 Birth weight CSGAL/CT1 intron 17255346 rs10481426 chr8 19279199 G A 9.90E-06 Urinary metabolites CSGAL/CT1 intron 21572414 rs5009989 chr8 19284215 A G 6.62E-04 Suicide attempts in bipolar disorder CSGAL/CT1 intron 21423239 rs4922030 chr8 19322771 G A 9.14E-04 Response to cytidine analogues (gemcitabine) CSGAL/CT1 intron 24483146 rs4922031 chr8 19323062 T A 3.88E-04 Suicide attempts in bipolar disorder CSGAL/CT1 intron 21423239 rs6994352 chr8 19325753 T C 2.83E-04 Response to cytadine analogues (cytosine arabinoside) CSGAL/CT1 intron 24483146 rs4921651 chr8 19339085 A G 6.18E-04 Response to cytadine analogues (cytosine arabinoside) CSGAL/CT1 intron 24483146 rs4921651 chr8 19339085 A G 9.75E-04 Response to cytidine analogues (gemcitabine) CSGAL/CT1 intron 24483146 rs13265751 chr8 19340019 T C 5.49E-04 Response to cytadine analogues (cytosine arabinoside) CSGAL/CT1 intron 24483146 rs13265751 chr8 19340019 T C 7.19E-04 Response to cytidine analogues (gemcitabine) CSGAL/CT1 intron 24483146 rs7003470 chr8 19342285 G A 8.91E-06 Amyotrophic lateral sclerosis CSGAL/CT1 intron 20801717 rs7003470 chr8 19342285 G A 0.00000568 Amyotrophic lateral sclerosis CSGAL/CT1 intron 23587638 rs7003470 chr8 19342285 G A 0.000056 Amyotrophic lateral sclerosis CSGAL/CT1 intron 23587638 rs4921653 chr8 19359853 G A 1.78E-05 Serum metabolites CSGAL/CT1 intron 19043545 rs4921654 chr8 19359974 A C 4.28E-05 Serum metabolites CSGAL/CT1 intron 19043545 rs4922048 chr8 19360814 T C 4.28E-05 Serum metabolites CSGAL/CT1 intron 19043545 rs146273214 chr8 19362732 G A 0.00013 Breast cancer CSGAL/CT1 missense 23555315 rs9644631 chr8 19370830 C T 5.60E-05 Serum metabolites CSGAL/CT1 intron 19043545 rs4921657 chr8 19370867 C G 2.60E-05 Serum metabolites CSGAL/CT1 intron 19043545 rs2975468 chr8 19377781 T C 2.96E-05 Major depressive disorder CSGAL/CT1 intron 22472876 rs10107533 chr8 19379421 C A 2.35E-04 Response to taxane treatment (placlitaxel) CSGAL/CT1 intron 23006423 rs4922053 chr8 19379676 G A 1.63E-05 Major depressive disorder CSGAL/CT1 intron 22472876 rs6992386 chr8 19380311 C T 3.00E-05 Major depressive disorder CSGAL/CT1 intron 22472876 rs17480050 chr8 19381917 T G 5.37E-72 Multiple complex diseases CSGAL/CT1 intron 17554300 rs2975494 chr8 19382331 A G 1.53E-05 Major depressive disorder CSGAL/CT1 intron 22472876 rs17128573 chr8 19389740 T A 8.07E-04 Suicide attempts in bipolar disorder CSGAL/CT1 intron 21423239 rs10503652 chr8 19389899 G A 1.86E-05 Major depressive disorder CSGAL/CT1 intron 22472876 rs10101192 chr8 19391665 A G 3.27E-05 Blood Pressure CSGAL/CT1 intron pha003048 rs4472532 chr8 19394182 C T 3.52E-05 Blood Pressure CSGAL/CT1 intron pha003048 rs10089231 chr8 19395884 A G 2.78E-05 Blood Pressure CSGAL/CT1 intron pha003048 rs4921659 chr8 19400018 C T 3.55E-04 Response to taxane treatment (placlitaxel) CSGAL/CT1 intron 23006423 rs4922060 chr8 19408508 T A 5.19E-04 Response to taxane treatment (placlitaxel) CSGAL/CT1 intron 23006423 rs10503649 chr8 19415503 A T 5.95E-04 Schizophrenia CSGAL/CT1 intron 21674006 rs11995671 chr8 19416443 A C 3.98E-05 Blood Pressure CSGAL/CT1 intron pha003048 rs13263246 chr8 19417904 C A 3.98E-05 Blood Pressure CSGAL/CT1 intron pha003048 rs6996732 chr8 19418028 C T 5.86E-05 Serum metabolites CSGAL/CT1 intron 19043545 rs13281882 chr8 19427464 T C 5.40E-05 Recombination rate CSGAL/CT1 intron 21698098 rs6992213 chr8 19435147 G T 4.28E-05 Blood Pressure CSGAL/CT1 intron pha003048 rs17128691 chr8 19439635 T C 4.92E-04 Multiple complex diseases CSGAL/CT1 intron 17554300 rs13257337 chr8 19482098 C A 2.20E-04 Type 2 diabetes CSGAL/CT1 intron 17463246 rs4922070 chr8 19483259 A G 8.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CSGAL/CT1 intron 20877124 rs7846346 chr8 19485638 C T 8.52E-04 Multiple complex diseases CSGAL/CT1 intron 17554300 rs2975424 chr8 19493786 T C 1.20E-05 Urinary metabolites CSGAL/CT1 intron 21572414 rs867930 chr8 19498087 A T 5.23E-05 Serum metabolites CSGAL/CT1 intron 19043545 rs4535751 chr8 19508835 C T 1.43E-04 Insulin resistance CSGAL/CT1 intron 21901158 rs11779629 chr8 19511972 A T 3.55E-05 Alcohol dependence CSGAL/CT1 intron 21314694 rs12543757 chr8 19533672 T A 4.47E-04 Smoking initiation CSGAL/CT1 intron 24665060 rs7816924 chr8 19539638 C T 2.00E-07 Response to antidepressant treatment (citalopram) CSGAL/CT1 intron 23726668 rs11985450 chr8 19540122 C T 4.75E-05 F-cell distribution CSGAL/CT1 intron 21326311 rs11204064 chr8 19540262 A G 1.57E-05 Anorexia nervosa / / 24514567 rs17481249 chr8 19544426 C A 1.13E-04 Smoking initiation / / 24665060 rs10503659 chr8 19548644 A G 2.57E-04 Alzheimer's disease (late onset) / / 21379329 rs1492636 chr8 19555398 C T 2.15E-05 Cognitive performance / / 19734545 rs1967103 chr8 19559379 G C 5.60E-04 Multiple complex diseases / / 17554300 rs10503661 chr8 19577136 T C 7.48E-04 Rheumatoid arthritis / / 21452313 rs7825914 chr8 19590012 A G 6.78E-04 Multiple complex diseases / / 17554300 rs7825914 chr8 19590012 A G 7.71E-05 Serum metabolites / / 19043545 rs7825914 chr8 19590012 A G 9.87E-08 Metabolite levels / / 23281178 rs6981526 chr8 19591202 C G 6.55E-04 Multiple complex diseases / / 17554300 rs6983139 chr8 19600329 A G 2.60E-05 Alcohol dependence / / 20201924 rs6983139 chr8 19600329 A G 5.10E-05 Alcohol dependence / / 20201924 rs6983139 chr8 19600329 A G 2.65E-05 Alcoholism / / pha002892 rs6983139 chr8 19600329 A G 5.10E-05 Alcoholism / / pha002893 rs9644633 chr8 19606602 C T 3.22E-04 Multiple complex diseases / / 17554300 rs1472162 chr8 19607661 C G 3.80E-04 Multiple complex diseases / / 17554300 rs4921670 chr8 19608716 C T 4.30E-06 Lipid traits / / 24386095 rs11204070 chr8 19629768 A G 3.36E-05 Cholesterol / / 17255346 rs920590 chr8 19651161 T C 2.00E-06 Acute lymphoblastic leukemia (childhood) / / 22076464 rs920590 chr8 19651161 T C 0.00000142 Triglycerides / / 23063622 rs920590 chr8 19651161 T C 2.22E-10 HDL cholesterol / / 23063622 rs4244456 chr8 19710468 T C 0.0000101 Circulating PCSK9 levels / / 22460556 rs6586879 chr8 19762732 C T 2.45E-04 Alcohol dependence / / 21314694 rs3900537 chr8 19784574 T C 0.0001 Migraine / / 22678113 rs7816032 chr8 19786891 C T 2.00E-06 Hyperactive-impulsive symptoms / / 18821565 rs7009128 chr8 19787528 T C 2.65E-16 HDL cholesterol / / 23063622 rs7009128 chr8 19787528 T C 3.07E-12 Triglycerides / / 23063622 rs1470186 chr8 19795789 T C 2.59E-14 HDL cholesterol LPL nearGene-5 23063622 rs1470186 chr8 19795789 T C 5.13E-09 Triglycerides LPL nearGene-5 23063622 rs17091742 chr8 19796130 C T 1.07E-10 Triglycerides LPL nearGene-5 23063622 rs17091742 chr8 19796130 C T 1.29E-15 HDL cholesterol LPL nearGene-5 23063622 rs1800590 chr8 19796671 T G 2.16E-14 HDL cholesterol LPL UTR-5 23063622 rs1800590 chr8 19796671 T G 6.89E-11 Triglycerides LPL UTR-5 23063622 rs1031045 chr8 19801112 G A 2.80E-14 HDL cholesterol LPL intron 23063622 rs1031045 chr8 19801112 G A 8.49E-11 Triglycerides LPL intron 23063622 rs28615996 chr8 19802711 T C 6.55E-11 Triglycerides LPL intron 23063622 rs28615996 chr8 19802711 T C 9.87E-14 HDL cholesterol LPL intron 23063622 rs28645722 chr8 19802894 G A 2.16E-09 Triglycerides LPL intron 23063622 rs28645722 chr8 19802894 G A 3.25E-08 Triglycerides LPL intron 23063622 rs28645722 chr8 19802894 G A 6.75E-14 HDL cholesterol LPL intron 23063622 rs28575919 chr8 19802969 C G 1.19E-09 Triglycerides LPL intron 23063622 rs28575919 chr8 19802969 C G 1.19E-10 Triglycerides LPL intron 23063622 rs28575919 chr8 19802969 C G 1.94E-16 HDL cholesterol LPL intron 23063622 rs6999612 chr8 19803084 T C 1.57E-14 HDL cholesterol LPL intron 23063622 rs6999612 chr8 19803084 T C 2.97E-10 Triglycerides LPL intron 23063622 rs3779788 chr8 19803093 C T 1.16E-24 Triglycerides LPL intron 23063622 rs3779788 chr8 19803093 C T 4.51E-27 HDL cholesterol LPL intron 23063622 rs7000460 chr8 19803802 A C 2.55E-13 HDL cholesterol LPL intron 23063622 rs7000460 chr8 19803802 A C 6.39E-10 Triglycerides LPL intron 23063622 rs28445964 chr8 19804596 A G 1.85E-14 HDL cholesterol LPL intron 23063622 rs28445964 chr8 19804596 A G 4.87E-10 Triglycerides LPL intron 23063622 rs7016529 chr8 19806631 T C 5.85E-15 HDL cholesterol LPL intron 23063622 rs7016529 chr8 19806631 T C 6.24E-11 Triglycerides LPL intron 23063622 rs343 chr8 19810787 C A 3.60E-05 Response to statin therapy LPL intron 20339536 rs343 chr8 19810787 C A 2.28E-15 Triglycerides LPL intron 23063622 rs343 chr8 19810787 C A 3.11E-16 HDL cholesterol LPL intron 23063622 rs253 chr8 19811417 C T 6.48E-06 Lipid levels LPL intron 19913121 rs253 chr8 19811417 C T 1.39E-10 Triglycerides LPL intron 23063622 rs253 chr8 19811417 C T 8.22E-09 HDL cholesterol LPL intron 23063622 rs255 chr8 19811901 T C 2.46E-06 Lipid levels LPL intron 19913121 rs255 chr8 19811901 T C 8.76E-04 Lipid levels LPL intron 19913121 rs255 chr8 19811901 T C 3.50E-05 Response to statin therapy LPL intron 20339536 rs255 chr8 19811901 T C 2.34E-32 Triglycerides LPL intron 23063622 rs255 chr8 19811901 T C 8.48E-36 HDL cholesterol LPL intron 23063622 rs256 chr8 19811967 C T 2.07E-06 Lipid levels LPL intron 19913121 rs256 chr8 19811967 C T 4.76E-04 Lipid levels LPL intron 19913121 rs256 chr8 19811967 C T 5.70E-05 Response to statin therapy LPL intron 20339536 rs256 chr8 19811967 C T 2.02E-32 Triglycerides LPL intron 23063622 rs256 chr8 19811967 C T 3.88E-37 HDL cholesterol LPL intron 23063622 rs258 chr8 19812252 G C 8.69E-06 Lipid levels LPL intron 19913121 rs258 chr8 19812252 G C 2.92E-09 HDL cholesterol LPL intron 23063622 rs258 chr8 19812252 G C 5.51E-10 Triglycerides LPL intron 23063622 rs263 chr8 19812812 C T 5.27E-04 Type 2 diabetes LPL intron 17463246 rs263 chr8 19812812 C T 3.09E-06 Lipid levels LPL intron 19913121 rs263 chr8 19812812 C T 6.10E-05 Response to statin therapy LPL intron 20339536 rs263 chr8 19812812 C T 1.83E-31 Triglycerides LPL intron 23063622 rs263 chr8 19812812 C T 8.35E-35 HDL cholesterol LPL intron 23063622 rs263 chr8 19812812 C T 5.42E-06 Lipid traits LPL intron 24023261 rs264 chr8 19813180 G A 1.74E-10 Triglycerides LPL intron 19060911 rs264 chr8 19813180 G A 4.70E-08 Lipid levels LPL intron 19802338 rs264 chr8 19813180 G A 2.51E-06 Lipid levels LPL intron 19913121 rs264 chr8 19813180 G A 4.96E-04 Lipid levels LPL intron 19913121 rs264 chr8 19813180 G A 5.50E-05 Response to statin therapy LPL intron 20339536 rs264 chr8 19813180 G A 2.44E-37 HDL cholesterol LPL intron 23063622 rs264 chr8 19813180 G A 9.26E-32 Triglycerides LPL intron 23063622 rs264 chr8 19813180 G A 2.88E-09 Coronary artery disease LPL intron 23202125 rs264 chr8 19813180 G A 5.66E-46 Triglycerides LPL intron 23202125 rs264 chr8 19813180 G A 7.02E-48 HDL cholesterol LPL intron 23202125 rs264 chr8 19813180 G A 3.00E-07 Coronary artery disease LPL intron 24262325 rs268 chr8 19813529 A G 2.00E-12 Metabolic syndrome LPL missense 22399527 rs268 chr8 19813529 A G 4.55E-11 HDL cholesterol LPL missense 22629316 rs268 chr8 19813529 A G 9.49E-13 Triglycerides LPL missense 22629316 rs268 chr8 19813529 A G 1.86E-24 Triglycerides LPL missense 23063622 rs268 chr8 19813529 A G 5.13E-32 HDL cholesterol LPL missense 23063622 rs270 chr8 19813676 C A 8.01E-05 Iron levels LPL intron 19880490 rs270 chr8 19813676 C A 8.01E-05 Iron levels LPL intron pha002876 rs271 chr8 19813702 G A 5.77E-04 Type 2 diabetes LPL intron 17463246 rs271 chr8 19813702 G A 6.59E-07 Lipid levels LPL intron 19913121 rs271 chr8 19813702 G A 8.72E-05 Lipid levels LPL intron 19913121 rs271 chr8 19813702 G A 2.50E-05 Response to statin therapy LPL intron 20339536 rs271 chr8 19813702 G A 1.38E-30 HDL cholesterol LPL intron 23063622 rs271 chr8 19813702 G A 1.45E-25 Triglycerides LPL intron 23063622 rs271 chr8 19813702 G A 1.54E-06 Lipid traits LPL intron 24023261 rs283 chr8 19815098 C T 6.68E-04 Obesity (extreme) LPL intron 21935397 rs285 chr8 19815189 C T 1.61E-06 Lipid levels LPL intron 19913121 rs285 chr8 19815189 C T 2.65E-09 Lipid levels LPL intron 19913121 rs285 chr8 19815189 C T 8.32E-04 Lipid levels LPL intron 19913121 rs285 chr8 19815189 C T 1.22E-21 Triglycerides LPL intron 23063622 rs285 chr8 19815189 C T 3.92E-18 HDL cholesterol LPL intron 23063622 rs286 chr8 19815256 A T 6.47E-13 Metabolite levels LPL intron 22286219 rs291 chr8 19815852 T C 3.60E-06 Response to statin therapy LPL intron 20339536 rs295 chr8 19816238 A C 3.70E-06 Response to statin therapy LPL intron 20339536 rs295 chr8 19816238 A C 2.00E-09 Metabolic syndrome LPL intron 21386085 rs297 chr8 19816371 T C 9.60E-09 Lipid levels LPL intron 19802338 rs297 chr8 19816371 T C 4.80E-06 Response to statin therapy LPL intron 20339536 rs297 chr8 19816371 T C 1.52E-05 HDL cholesterol LPL intron 21589926 rs297 chr8 19816371 T C 6.16E-06 HDL cholesterol LPL intron 21589926 rs297 chr8 19816371 T C 0.0000649 Salmonella-induced pyroptosis LPL intron 22837397 rs297 chr8 19816371 T C 1.44E-05 HDL cholesterol LPL intron pha003075 rs301 chr8 19816934 T C 2.17E-11 Lipid levels LPL intron 19913121 rs301 chr8 19816934 T C 2.41E-06 Lipid levels LPL intron 19913121 rs301 chr8 19816934 T C 9.25E-11 Lipid levels LPL intron 19913121 rs301 chr8 19816934 T C 4.20E-06 Response to statin therapy LPL intron 20339536 rs301 chr8 19816934 T C 3.00E-11 Metabolic syndrome (bivariate traits) LPL intron 21386085 rs301 chr8 19816934 T C 6.31E-09 Cardiovascular disease risk factors LPL intron 21943158 rs301 chr8 19816934 T C 1.40E-08 Metabolic syndrome phenotype LPL intron 22022282 rs301 chr8 19816934 T C 7.40E-18 Metabolic syndrome phenotype LPL intron 22022282 rs301 chr8 19816934 T C 9.50E-20 Metabolic syndrome phenotype LPL intron 22022282 rs301 chr8 19816934 T C 0.000136 Salmonella-induced pyroptosis LPL intron 22837397 rs301 chr8 19816934 T C 1.28E-82 Triglycerides LPL intron 23063622 rs301 chr8 19816934 T C 7.95E-74 HDL cholesterol LPL intron 23063622 rs301 chr8 19816934 T C 0.000764 Triglycerides LPL intron 23236364 rs316 chr8 19818436 C A 3.92E-16 Triglycerides LPL cds-synon 23063622 rs316 chr8 19818436 C A 7.08E-13 HDL cholesterol LPL cds-synon 23063622 rs320 chr8 19819077 T G 1 Drug response to Fenofibrate LPL intron 19207029 rs320 chr8 19819077 T G 1.52E-04 Lipid levels LPL intron 19913121 rs320 chr8 19819077 T G 1.79E-10 Lipid levels LPL intron 19913121 rs320 chr8 19819077 T G 3.61E-09 Lipid levels LPL intron 19913121 rs320 chr8 19819077 T G 1.90E-05 Response to statin therapy LPL intron 20339536 rs320 chr8 19819077 T G 1.56E-74 Triglycerides LPL intron 23063622 rs320 chr8 19819077 T G 5.22E-67 HDL cholesterol LPL intron 23063622 rs325 chr8 19819328 T C 1.50E-11 Triglycerides LPL intron 18193046 rs325 chr8 19819328 T C 5.70E-08 Response to statin therapy LPL intron 20339536 rs325 chr8 19819328 T C 8.00E-26 HDL cholesterol LPL intron 20864672 rs325 chr8 19819328 T C 3.32E-13 Metabolite levels LPL intron 22286219 rs326 chr8 19819439 A G 5.00E-12 Triglycerides LPL intron 18193046 rs326 chr8 19819439 A G 1.16E-08 Triglycerides LPL intron 23063622 rs326 chr8 19819439 A G 1.37E-08 HDL cholesterol LPL intron 23063622 rs326 chr8 19819439 A G 1.00E-08 HDL cholesterol LPL intron 23726366 rs327 chr8 19819536 T G 2.40E-10 Lipid levels LPL intron 19913121 rs327 chr8 19819536 T G 2.53E-04 Lipid levels LPL intron 19913121 rs327 chr8 19819536 T G 6.71E-09 Lipid levels LPL intron 19913121 rs327 chr8 19819536 T G 4.80E-05 Response to statin therapy LPL intron 20339536 rs327 chr8 19819536 T G 8.72E-09 Cardiovascular disease risk factors LPL intron 21943158 rs327 chr8 19819536 T G 1.01E-21 Triglycerides (males) LPL intron 22629316 rs327 chr8 19819536 T G 2.72E-36 Triglycerides LPL intron 22629316 rs327 chr8 19819536 T G 7.34E-19 Triglycerides (females) LPL intron 22629316 rs327 chr8 19819536 T G 1.20E-65 HDL cholesterol LPL intron 23063622 rs327 chr8 19819536 T G 3.13E-72 Triglycerides LPL intron 23063622 rs328 chr8 19819724 C G 5.00E-07 Triglycerides LPL STOP-GAIN 17463246 rs328 chr8 19819724 C G 2.00E-28 Triglycerides LPL STOP-GAIN 18193044 rs328 chr8 19819724 C G 9.00E-23 HDL cholesterol LPL STOP-GAIN 18193044 rs328 chr8 19819724 C G 1.90E-11 Triglycerides LPL STOP-GAIN 18193046 rs328 chr8 19819724 C G 4.70E-11 Lipid levels LPL STOP-GAIN 19802338 rs328 chr8 19819724 C G 3.17E-08 Lipid levels LPL STOP-GAIN 19913121 rs328 chr8 19819724 C G 8.42E-10 Lipid levels LPL STOP-GAIN 19913121 rs328 chr8 19819724 C G 1.35E-25 Lipid levels LPL STOP-GAIN 19936222 rs328 chr8 19819724 C G 1.36E-12 Lipid levels LPL STOP-GAIN 19936222 rs328 chr8 19819724 C G 1.80E-18 Lipid levels LPL STOP-GAIN 19936222 rs328 chr8 19819724 C G 2.20E-27 Lipid levels LPL STOP-GAIN 19936222 rs328 chr8 19819724 C G 2.37E-26 Lipid levels LPL STOP-GAIN 19936222 rs328 chr8 19819724 C G 2.80E-15 Lipid levels LPL STOP-GAIN 19936222 rs328 chr8 19819724 C G 2.90E-30 Lipid levels LPL STOP-GAIN 19936222 rs328 chr8 19819724 C G 9.20E-09 Lipid levels LPL STOP-GAIN 19936222 rs328 chr8 19819724 C G 5.20E-08 Response to statin therapy LPL STOP-GAIN 20339536 rs328 chr8 19819724 C G 9.00E-23 Coronary heart disease LPL STOP-GAIN 21347282 rs328 chr8 19819724 C G 1.01E-11 Cardiovascular disease risk factors LPL STOP-GAIN 21943158 rs328 chr8 19819724 C G 3.70E-05 Coronary heart disease LPL STOP-GAIN 21966275 rs328 chr8 19819724 C G 1.00E-09 Triglycerides LPL STOP-GAIN 22171074 rs328 chr8 19819724 C G 3.32E-13 Metabolite levels LPL STOP-GAIN 22286219 rs328 chr8 19819724 C G 2.27E-68 HDL cholesterol LPL STOP-GAIN 23063622 rs328 chr8 19819724 C G 5.14E-74 Triglycerides LPL STOP-GAIN 23063622 rs328 chr8 19819724 C G 0.000000115 Triglycerides LPL STOP-GAIN 23236364 rs328 chr8 19819724 C G 2.00E-14 Lipid traits LPL STOP-GAIN 24386095 rs328 chr8 19819724 C G 3.00E-10 Lipid traits LPL STOP-GAIN 24386095 rs331 chr8 19820405 G A 1.70E-09 Lipid levels LPL intron 19802338 rs331 chr8 19820405 G A 4.00E-08 Lipid levels LPL intron 19802338 rs331 chr8 19820405 G A 9.10E-07 Lipid levels LPL intron 19802338 rs331 chr8 19820405 G A 1.73E-11 Lipid levels LPL intron 19913121 rs331 chr8 19820405 G A 2.83E-10 Lipid levels LPL intron 19913121 rs331 chr8 19820405 G A 4.65E-05 Lipid levels LPL intron 19913121 rs331 chr8 19820405 G A 1.00E-11 Lipid levels LPL intron 19936222 rs331 chr8 19820405 G A 1.10E-14 Lipid levels LPL intron 19936222 rs331 chr8 19820405 G A 1.20E-17 Lipid levels LPL intron 19936222 rs331 chr8 19820405 G A 1.50E-10 Lipid levels LPL intron 19936222 rs331 chr8 19820405 G A 1.50E-16 Lipid levels LPL intron 19936222 rs331 chr8 19820405 G A 1.82E-14 Lipid levels LPL intron 19936222 rs331 chr8 19820405 G A 2.10E-11 Lipid levels LPL intron 19936222 rs331 chr8 19820405 G A 2.46E-15 Lipid levels LPL intron 19936222 rs331 chr8 19820405 G A 2.50E-14 Lipid levels LPL intron 19936222 rs331 chr8 19820405 G A 3.06E-09 Lipid levels LPL intron 19936222 rs331 chr8 19820405 G A 3.55E-14 Lipid levels LPL intron 19936222 rs331 chr8 19820405 G A 1.80E-05 Response to statin therapy LPL intron 20339536 rs331 chr8 19820405 G A 1.18E-05 HDL cholesterol LPL intron 21589926 rs331 chr8 19820405 G A 1.82E-06 HDL cholesterol LPL intron 21589926 rs331 chr8 19820405 G A 4.10E-05 Coronary heart disease LPL intron 21966275 rs331 chr8 19820405 G A 1.73E-73 HDL cholesterol LPL intron 23063622 rs331 chr8 19820405 G A 9.70E-81 Triglycerides LPL intron 23063622 rs331 chr8 19820405 G A 1.96E-05 HDL cholesterol LPL intron pha003075 rs12679834 chr8 19820433 T C 1.06E-09 Lipid levels LPL intron 19913121 rs12679834 chr8 19820433 T C 5.39E-08 Lipid levels LPL intron 19913121 rs12679834 chr8 19820433 T C 5.40E-08 Response to statin therapy LPL intron 20339536 rs12679834 chr8 19820433 T C 1.04E-10 Cardiovascular disease risk factors LPL intron 21943158 rs12679834 chr8 19820433 T C 5.15E-13 Metabolite levels LPL intron 22286219 rs12679834 chr8 19820433 T C 1.29E-32 Triglycerides LPL intron 22629316 rs12679834 chr8 19820433 T C 1.38E-71 Triglycerides LPL intron 23063622 rs12679834 chr8 19820433 T C 2.84E-67 HDL cholesterol LPL intron 23063622 rs10099160 chr8 19821815 T G 7.66E-08 HDL cholesterol LPL intron 23063622 rs11570891 chr8 19822810 C T 3.80E-08 Response to statin therapy LPL intron 20339536 rs11570891 chr8 19822810 C T 4.52E-13 Metabolite levels LPL intron 22286219 rs4922115 chr8 19822830 G A 1.64E-12 HDL cholesterol LPL UTR-3 23063622 rs4922115 chr8 19822830 G A 4.66E-15 Triglycerides LPL UTR-3 23063622 rs3289 chr8 19823192 T C 3.16E-06 Lipid levels LPL UTR-3 19913121 rs3289 chr8 19823192 T C 6.06E-04 Lipid levels LPL UTR-3 19913121 rs3289 chr8 19823192 T C 7.00E-18 Metabolic syndrome phenotype LPL UTR-3 22022282 rs3289 chr8 19823192 T C 8.70E-18 Metabolic syndrome phenotype LPL UTR-3 22022282 rs3289 chr8 19823192 T C 1.49E-20 HDL cholesterol LPL UTR-3 23063622 rs3289 chr8 19823192 T C 1.87E-16 Triglycerides LPL UTR-3 23063622 rs3289 chr8 19823192 T C 0.00000282 Triglycerides LPL UTR-3 23236364 rs3289 chr8 19823192 T C 5.07E-08 HDL cholesterol LPL UTR-3 23236364 rs11570892 chr8 19823617 A G 2.43E-15 Triglycerides LPL UTR-3 23063622 rs11570892 chr8 19823617 A G 2.76E-13 HDL cholesterol LPL UTR-3 23063622 rs3208305 chr8 19823648 A T 1.48E-04 Lipid levels LPL UTR-3 19913121 rs3208305 chr8 19823648 A T 3.06E-11 Lipid levels LPL UTR-3 19913121 rs3208305 chr8 19823648 A T 5.35E-10 Lipid levels LPL UTR-3 19913121 rs3208305 chr8 19823648 A T 2.05E-67 HDL cholesterol LPL UTR-3 23063622 rs3208305 chr8 19823648 A T 2.54E-76 Triglycerides LPL UTR-3 23063622 rs1803924 chr8 19823674 C A,G,T 4.47E-13 Metabolite levels LPL UTR-3 22286219 rs1059507 chr8 19823963 C T 4.37E-13 HDL cholesterol LPL UTR-3 23063622 rs1059507 chr8 19823963 C T 7.33E-15 Triglycerides LPL UTR-3 23063622 rs3735964 chr8 19824045 C A 1.17E-07 Lipid levels LPL UTR-3 19913121 rs3735964 chr8 19824045 C A 9.09E-09 Lipid levels LPL UTR-3 19913121 rs3735964 chr8 19824045 C A 3.80E-08 Response to statin therapy LPL UTR-3 20339536 rs3735964 chr8 19824045 C A 8.19E-13 Metabolite levels LPL UTR-3 22286219 rs3735964 chr8 19824045 C A 1.38E-67 Triglycerides LPL UTR-3 23063622 rs3735964 chr8 19824045 C A 1.62E-65 HDL cholesterol LPL UTR-3 23063622 rs3735964 chr8 19824045 C A 4.29E-71 Triglycerides LPL UTR-3 23063622 rs3200218 chr8 19824071 A C,G,T 0.000000196 HDL cholesterol LPL UTR-3 23063622 rs3200218 chr8 19824071 A C,G,T 0.000000986 Triglycerides LPL UTR-3 23063622 rs13702 chr8 19824492 T C 1.86E-04 Lipid levels LPL UTR-3 19913121 rs13702 chr8 19824492 T C 2.85E-11 Lipid levels LPL UTR-3 19913121 rs13702 chr8 19824492 T C 7.49E-10 Lipid levels LPL UTR-3 19913121 rs13702 chr8 19824492 T C 3.60E-06 Response to statin therapy LPL UTR-3 20339536 rs13702 chr8 19824492 T C 1.00E-16 HDL Cholesterol - Triglycerides (HDLC-TG) LPL UTR-3 21386085 rs13702 chr8 19824492 T C 2.14E-28 HDL cholesterol LPL UTR-3 22629316 rs13702 chr8 19824492 T C 4.72E-16 HDL cholesterol (female) LPL UTR-3 22629316 rs13702 chr8 19824492 T C 5.61E-16 HDL cholesterol (male) LPL UTR-3 22629316 rs13702 chr8 19824492 T C 1.01E-29 Triglycerides in females LPL UTR-3 23063622 rs13702 chr8 19824492 T C 2.32E-75 HDL cholesterol LPL UTR-3 23063622 rs13702 chr8 19824492 T C 8.39E-81 Triglycerides LPL UTR-3 23063622 rs13702 chr8 19824492 T C 8.79E-44 Triglycerides in males LPL UTR-3 23063622 rs13702 chr8 19824492 T C 1.14E-09 HDL cholesterol LPL UTR-3 23236364 rs1059611 chr8 19824563 T C 9.30E-11 Lipid levels LPL UTR-3 19802338 rs1059611 chr8 19824563 T C 1.17E-12 Lipid levels LPL UTR-3 19936222 rs1059611 chr8 19824563 T C 1.48E-20 Lipid levels LPL UTR-3 19936222 rs1059611 chr8 19824563 T C 1.60E-17 Lipid levels LPL UTR-3 19936222 rs1059611 chr8 19824563 T C 4.00E-08 Response to statin therapy LPL UTR-3 20339536 rs1059611 chr8 19824563 T C 1.02E-12 Metabolite levels LPL UTR-3 22286219 rs15285 chr8 19824667 C T 4.80E-08 Response to statin therapy LPL UTR-3 20339536 rs15285 chr8 19824667 C T 1.00E-10 Triglycerides-Blood Pressure (TG-BP) LPL UTR-3 21386085 rs3916027 chr8 19824868 G A 1.04E-10 Lipid levels LPL nearGene-3 19913121 rs3916027 chr8 19824868 G A 5.39E-10 Lipid levels LPL nearGene-3 19913121 rs3916027 chr8 19824868 G A 5.83E-05 Lipid levels LPL nearGene-3 19913121 rs3916027 chr8 19824868 G A 1.10E-05 Response to statin therapy LPL nearGene-3 20339536 rs3916027 chr8 19824868 G A 1.01E-31 HDL cholesterol LPL nearGene-3 22629316 rs3916027 chr8 19824868 G A 1.20E-40 Triglycerides LPL nearGene-3 22629316 rs3916027 chr8 19824868 G A 1.43E-17 HDL cholesterol (male) LPL nearGene-3 22629316 rs3916027 chr8 19824868 G A 1.47E-23 Triglycerides (males) LPL nearGene-3 22629316 rs3916027 chr8 19824868 G A 4.37E-18 HDL cholesterol (female) LPL nearGene-3 22629316 rs3916027 chr8 19824868 G A 9.43E-22 Triglycerides (females) LPL nearGene-3 22629316 rs3916027 chr8 19824868 G A 2.80E-75 Triglycerides LPL nearGene-3 23063622 rs3916027 chr8 19824868 G A 4.60E-68 HDL cholesterol LPL nearGene-3 23063622 rs9644636 chr8 19824896 T G 3.92E-11 HDL cholesterol LPL nearGene-3 23063622 rs9644636 chr8 19824896 T G 8.88E-15 Triglycerides LPL nearGene-3 23063622 rs4921683 chr8 19825068 T A 2.08E-14 Triglycerides LPL nearGene-3 23063622 rs4921683 chr8 19825068 T A 8.57E-13 HDL cholesterol LPL nearGene-3 23063622 rs2197089 chr8 19826373 G A 1.10E-12 Lipid levels / / 18193043 rs2197089 chr8 19826373 G A 2.68E-06 Lipid levels / / 19913121 rs2197089 chr8 19826373 G A 5.03E-09 Lipid levels / / 19913121 rs2197089 chr8 19826373 G A 5.10E-05 Response to statin therapy / / 20339536 rs2197089 chr8 19826373 G A 2.00E-09 Metabolic syndrome (bivariate traits) / / 21386085 rs2197089 chr8 19826373 G A 2.04E-23 HDL cholesterol / / 23063622 rs2197089 chr8 19826373 G A 3.16E-30 Triglycerides / / 23063622 rs10105606 chr8 19827848 C A 2.30E-05 Response to statin therapy / / 20339536 rs10105606 chr8 19827848 C A 4.00E-26 Triglycerides / / 20864672 rs2410616 chr8 19828679 C T 5.83E-09 Multiple complex diseases / / 17554300 rs1569209 chr8 19830170 T G 5.10E-08 Response to statin therapy / / 20339536 rs1569209 chr8 19830170 T G 2.71E-13 Metabolite levels / / 22286219 rs1569209 chr8 19830170 T G 0.000000167 Coronary artery disease (CAD) age <=50 / / 23202125 rs1569209 chr8 19830170 T G 0.000000241 Coronary artery disease (CAD) age >50 / / 23202125 rs1569209 chr8 19830170 T G 0.00000083 Coronary artery disease (CAD) (males) / / 23202125 rs1569209 chr8 19830170 T G 0.00000119 Coronary artery disease with myocardial infarction / / 23202125 rs1011685 chr8 19830769 C T 2.10E-08 Response to statin therapy / / 20339536 rs1011685 chr8 19830769 C T 2.65E-13 Metabolite levels / / 22286219 rs10096633 chr8 19830921 C T 5.00E-08 Metabolic traits / / 19060910 rs10096633 chr8 19830921 C T 2.00E-18 Triglycerides / / 19060911 rs10096633 chr8 19830921 C T 1.40E-08 Lipid levels / / 19802338 rs10096633 chr8 19830921 C T 9.00E-14 Blood cell counts and other traits / / 20139978 rs10096633 chr8 19830921 C T 9.30E-14 Blood cell counts and other traits / / 20139978 rs10096633 chr8 19830921 C T 1.70E-07 Response to statin therapy / / 20339536 rs10096633 chr8 19830921 C T 3.16E-08 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs10096633 chr8 19830921 C T 1.68E-05 HDL cholesterol / / 21589926 rs10096633 chr8 19830921 C T 5.42E-06 HDL cholesterol / / 21589926 rs10096633 chr8 19830921 C T 2.92E-13 Cardiovascular disease risk factors / / 21943158 rs10096633 chr8 19830921 C T 1.10E-15 Metabolic syndrome phenotype / / 22022282 rs10096633 chr8 19830921 C T 1.80E-12 Metabolic syndrome phenotype / / 22022282 rs10096633 chr8 19830921 C T 2.50E-13 Metabolite levels / / 22286219 rs10096633 chr8 19830921 C T 1.09E-12 Triglycerides / / 23063622 rs10096633 chr8 19830921 C T 1.12E-15 HDL cholesterol / / 23063622 rs10096633 chr8 19830921 C T 4.18E-13 HDL cholesterol (female) / / 23063622 rs10096633 chr8 19830921 C T 2.25E-06 HDL particle features / / pha002900 rs10096633 chr8 19830921 C T 5.16E-08 Triglycerides / / pha002904 rs10096633 chr8 19830921 C T 5.89E-05 Coronary heart disease / / pha003030 rs10096633 chr8 19830921 C T 1.68E-05 HDL cholesterol / / pha003074 rs10096633 chr8 19830921 C T 9.46E-05 HDL cholesterol / / pha003075 rs10096633 chr8 19830921 C T 4.15E-05 Triglycerides / / pha003080 rs10096633 chr8 19830921 C T 4.34E-05 Triglycerides / / pha003081 rs10096633 chr8 19830921 C T 4.94E-06 Lipid levels / / pha003082 rs1372339 chr8 19831798 A G 0.0000219 Menopause (age at onset) / / 23424626 rs17482753 chr8 19832646 G T 4.85E-07 Type 2 diabetes / / 17463246 rs17482753 chr8 19832646 G T 5.23E-15 Cardiovascular disease / / 18179892 rs17482753 chr8 19832646 G T 5.90E-19 Lipid levels / / 18193043 rs17482753 chr8 19832646 G T 3.20E-09 Lipid levels / / 19913121 rs17482753 chr8 19832646 G T 5.31E-08 Lipid levels / / 19913121 rs17482753 chr8 19832646 G T 3.00E-11 HDL cholesterol / / 20031538 rs17482753 chr8 19832646 G T 4.30E-08 Response to statin therapy / / 20339536 rs17482753 chr8 19832646 G T 3.50E-09 Lipid levels / / 20370913 rs17482753 chr8 19832646 G T 1.31E-11 Cardiovascular disease risk factors / / 21943158 rs17482753 chr8 19832646 G T 9.79E-05 Calcium intake levels and metabolic syndrome / / 22170361 rs17482753 chr8 19832646 G T 3.17E-13 Metabolite levels / / 22286219 rs17482753 chr8 19832646 G T 4.04E-78 Triglycerides / / 23063622 rs17482753 chr8 19832646 G T 7.93E-69 HDL cholesterol / / 23063622 rs17482753 chr8 19832646 G T 6.00E-10 Lipid traits / / 24023261 rs4922116 chr8 19832778 G A 0.0000218 Menopause (age at onset) / / 23424626 rs58946909 chr8 19840341 G A 2.62E-13 Metabolite levels / / 22286219 rs7825274 chr8 19842188 G C 2.79E-05 Schizophrenia / / 19571809 rs7825274 chr8 19842188 G C 2.62E-05 Schizophrenia / / pha002859 rs17091891 chr8 19843171 T C 4.70E-07 Response to statin therapy / / 20339536 rs17091891 chr8 19843171 T C 4.51E-13 Metabolite levels / / 22286219 rs17410914 chr8 19843462 C A 8.10E-12 Triglycerides / / 18193046 rs17410914 chr8 19843462 C A 2.66E-13 Metabolite levels / / 22286219 rs17410914 chr8 19843462 C A 8.69E-12 Triglycerides / / 23063622 rs17410914 chr8 19843462 C A 9.84E-09 HDL cholesterol / / 23063622 rs59147390 chr8 19843879 T C 1.31E-10 Metabolite levels / / 22286219 rs12678919 chr8 19844222 A G 1.30E-11 Lipid levels / / 18193043 rs12678919 chr8 19844222 A G 2.00E-34 HDL cholesterol / / 19060906 rs12678919 chr8 19844222 A G 2.00E-41 Triglycerides / / 19060906 rs12678919 chr8 19844222 A G 2.42E-13 Blood cell counts and other traits / / 20139978 rs12678919 chr8 19844222 A G 9.00E-06 Blood cell counts and other traits / / 20139978 rs12678919 chr8 19844222 A G 9.41E-06 Blood cell counts and other traits / / 20139978 rs12678919 chr8 19844222 A G 4.40E-07 Response to statin therapy / / 20339536 rs12678919 chr8 19844222 A G 1.00E-97 HDL cholesterol / / 20686565 rs12678919 chr8 19844222 A G 2.00E-115 Triglycerides / / 20686565 rs12678919 chr8 19844222 A G 2.00E-34 Coronary heart disease / / 21347282 rs12678919 chr8 19844222 A G 1.58E-05 HDL cholesterol / / 21589926 rs12678919 chr8 19844222 A G 1.99E-07 HDL cholesterol / / 21589926 rs12678919 chr8 19844222 A G 1.30E-11 Cardiovascular disease risk factors / / 21943158 rs12678919 chr8 19844222 A G 4.90E-08 Triglycerides / / 22171074 rs12678919 chr8 19844222 A G 5.81E-13 Metabolite levels / / 22286219 rs12678919 chr8 19844222 A G 9.00E-13 Metabolite levels (atherosclerosis) / / 22916037 rs12678919 chr8 19844222 A G 0.000000013 HDL cholesterol / / 23063622 rs12678919 chr8 19844222 A G 1.23E-11 Triglycerides / / 23063622 rs12678919 chr8 19844222 A G 1.00E-149 HDL cholesterol / / 24097068 rs12678919 chr8 19844222 A G 2.00E-199 Triglycerides / / 24097068 rs12678919 chr8 19844222 A G 3.04E-07 Lipid traits / / 24386095 rs12678919 chr8 19844222 A G 5.86E-11 Lipid traits / / 24386095 rs12678919 chr8 19844222 A G 2.67E-05 HDL cholesterol / / pha003075 rs12678919 chr8 19844222 A G 2.80E-05 Lipid levels / / pha003082 rs7819706 chr8 19844415 A G 5.50E-07 Response to statin therapy / / 20339536 rs7819706 chr8 19844415 A G 2.38E-13 Metabolite levels / / 22286219 rs7841189 chr8 19845376 C T 5.50E-07 Response to statin therapy / / 20339536 rs7841189 chr8 19845376 C T 2.01E-13 Metabolite levels / / 22286219 rs7841189 chr8 19845376 C T 1.00E-14 Metabolic syndrome / / 22399527 rs12682115 chr8 19847060 G A 2.42E-13 Metabolite levels / / 22286219 rs10503669 chr8 19847690 C A 1.74E-06 Type 2 diabetes / / 17463246 rs10503669 chr8 19847690 C A 9.10E-04 Lipid traits / / 17903299 rs10503669 chr8 19847690 C A 4.00E-19 HDL cholesterol / / 18193043 rs10503669 chr8 19847690 C A 4.00E-22 Triglycerides / / 18193043 rs10503669 chr8 19847690 C A 1.05E-09 Lipid levels / / 19913121 rs10503669 chr8 19847690 C A 6.00E-08 Lipid levels / / 19913121 rs10503669 chr8 19847690 C A 1.20E-06 Response to statin therapy / / 20339536 rs10503669 chr8 19847690 C A 1.14E-08 Lipid levels / / 20370913 rs10503669 chr8 19847690 C A 4.00E-19 Coronary heart disease / / 21347282 rs10503669 chr8 19847690 C A 7.00E-39 Triglycerides / / 21909109 rs10503669 chr8 19847690 C A 8.00E-43 HDL cholesterol / / 21909109 rs10503669 chr8 19847690 C A 5.23E-11 Cardiovascular disease risk factors / / 21943158 rs10503669 chr8 19847690 C A 1.16E-04 Calcium intake levels and metabolic syndrome / / 22170361 rs10503669 chr8 19847690 C A 2.70E-13 Metabolite levels / / 22286219 rs10503669 chr8 19847690 C A 3.77E-28 HDL cholesterol / / 22629316 rs10503669 chr8 19847690 C A 3.71E-58 HDL cholesterol / / 23063622 rs10503669 chr8 19847690 C A 4.73E-70 Triglycerides / / 23063622 rs10503669 chr8 19847690 C A 4.00E-09 Lipid traits / / 24023261 rs17410962 chr8 19848080 G A 8.21E-06 Type 2 diabetes / / 17463246 rs17410962 chr8 19848080 G A 1.31E-07 Lipid levels / / 19913121 rs17410962 chr8 19848080 G A 4.64E-09 Lipid levels / / 19913121 rs17410962 chr8 19848080 G A 5.70E-07 Response to statin therapy / / 20339536 rs17410962 chr8 19848080 G A 4.27E-09 Lipid levels / / 20370913 rs17410962 chr8 19848080 G A 2.80E-13 Cardiovascular disease risk factors / / 21943158 rs17410962 chr8 19848080 G A 1.00E-04 Calcium intake levels and metabolic syndrome / / 22170361 rs17410962 chr8 19848080 G A 1.94E-13 Metabolite levels / / 22286219 rs17410962 chr8 19848080 G A 4.15E-63 Triglycerides / / 23063622 rs17410962 chr8 19848080 G A 7.93E-56 HDL cholesterol / / 23063622 rs17410962 chr8 19848080 G A 7.00E-09 Triglycerides / / 23726366 rs17410962 chr8 19848080 G A 3.29E-09 Lipid traits / / 24023261 rs17489185 chr8 19848499 G C 2.67E-13 Metabolite levels / / 22286219 rs17410983 chr8 19848693 C T 2.67E-13 Metabolite levels / / 22286219 rs17489226 chr8 19848878 A T 2.67E-13 Metabolite levels / / 22286219 rs17410996 chr8 19849272 T G 2.67E-13 Metabolite levels / / 22286219 rs17091905 chr8 19849757 G A 5.80E-07 Response to statin therapy / / 20339536 rs17091905 chr8 19849757 G A 5.00E-15 Cardiovascular disease risk factors / / 21943158 rs17091905 chr8 19849757 G A 6.00E-12 Cardiovascular disease risk factors / / 21943158 rs17091905 chr8 19849757 G A 2.29E-13 Metabolite levels / / 22286219 rs17489268 chr8 19852045 T A 8.18E-06 Type 2 diabetes / / 17463246 rs17489268 chr8 19852045 T A 1.19E-04 Lipid levels / / 19913121 rs17489268 chr8 19852045 T A 1.19E-09 Lipid levels / / 19913121 rs17489268 chr8 19852045 T A 1.78E-10 Lipid levels / / 19913121 rs17489268 chr8 19852045 T A 1.90E-05 Response to statin therapy / / 20339536 rs17489268 chr8 19852045 T A 5.97E-11 Lipid levels / / 20370913 rs17489268 chr8 19852045 T A 6.35E-09 Cardiovascular disease risk factors / / 21943158 rs17489268 chr8 19852045 T A 1.14E-61 Triglycerides / / 23063622 rs17489268 chr8 19852045 T A 3.18E-57 HDL cholesterol / / 23063622 rs17411024 chr8 19852134 G A,T 2.63E-06 Type 2 diabetes / / 17463246 rs17411024 chr8 19852134 G A,T 4.40E-07 Response to statin therapy / / 20339536 rs17411024 chr8 19852134 G A,T 3.68E-13 Metabolite levels / / 22286219 rs17411024 chr8 19852134 G A,T 1.09E-08 Lipid traits / / 24023261 rs17091909 chr8 19852156 G T 2.04E-13 Metabolite levels / / 22286219 rs17411031 chr8 19852310 C G 5.75E-06 Type 2 diabetes / / 17463246 rs17411031 chr8 19852310 C G 1.28E-10 Cardiovascular disease / / 18179892 rs17411031 chr8 19852310 C G 1.09E-09 Lipid levels / / 19913121 rs17411031 chr8 19852310 C G 2.90E-10 Lipid levels / / 19913121 rs17411031 chr8 19852310 C G 9.78E-05 Lipid levels / / 19913121 rs17411031 chr8 19852310 C G 2.10E-05 Response to statin therapy / / 20339536 rs17411031 chr8 19852310 C G 7.21E-11 Lipid levels / / 20370913 rs17411031 chr8 19852310 C G 6.35E-09 Cardiovascular disease risk factors / / 21943158 rs17411031 chr8 19852310 C G 2.29E-79 Triglycerides / / 23063622 rs17411031 chr8 19852310 C G 4.42E-69 HDL cholesterol / / 23063622 rs17411045 chr8 19852362 T C 2.40E-05 Response to statin therapy / / 20339536 rs17489282 chr8 19852518 C T 3.80E-06 Type 2 diabetes / / 17463246 rs17489282 chr8 19852518 C T 2.13E-10 Lipid levels / / 19913121 rs17489282 chr8 19852518 C T 7.54E-10 Lipid levels / / 19913121 rs17489282 chr8 19852518 C T 7.69E-05 Lipid levels / / 19913121 rs17489282 chr8 19852518 C T 2.40E-05 Response to statin therapy / / 20339536 rs17489282 chr8 19852518 C T 6.54E-10 Lipid levels / / 20370913 rs17489282 chr8 19852518 C T 6.35E-09 Cardiovascular disease risk factors / / 21943158 rs17489282 chr8 19852518 C T 1.06E-78 Triglycerides / / 23063622 rs17489282 chr8 19852518 C T 4.67E-68 HDL cholesterol / / 23063622 rs4922117 chr8 19852586 T C 2.50E-05 Response to statin therapy / / 20339536 rs4922117 chr8 19852586 T C 7.73E-10 Lipid levels / / 20370913 rs4922117 chr8 19852586 T C 6.35E-09 Cardiovascular disease risk factors / / 21943158 rs1372344 chr8 19852939 A T 1.80E-07 Response to statin therapy / / 20339536 rs2410618 chr8 19853500 G A 2.60E-05 Response to statin therapy / / 20339536 rs2410620 chr8 19854660 C T 2.30E-05 Response to statin therapy / / 20339536 rs2410621 chr8 19854682 T C 2.30E-05 Response to statin therapy / / 20339536 rs2410622 chr8 19854773 T C 2.30E-05 Response to statin therapy / / 20339536 rs2410623 chr8 19854889 A G 2.10E-05 Response to statin therapy / / 20339536 rs17411113 chr8 19855006 C G 2.68E-13 Metabolite levels / / 22286219 rs17411126 chr8 19855272 T C 7.29E-06 Type 2 diabetes / / 17463246 rs17411126 chr8 19855272 T C 1.74E-04 Lipid levels / / 19913121 rs17411126 chr8 19855272 T C 1.74E-10 Lipid levels / / 19913121 rs17411126 chr8 19855272 T C 7.77E-10 Lipid levels / / 19913121 rs17411126 chr8 19855272 T C 2.10E-05 Response to statin therapy / / 20339536 rs17411126 chr8 19855272 T C 1.23E-10 Lipid levels / / 20370913 rs17411126 chr8 19855272 T C 6.35E-09 Cardiovascular disease risk factors / / 21943158 rs17411126 chr8 19855272 T C 3.57E-72 HDL cholesterol / / 23063622 rs17411126 chr8 19855272 T C 4.39E-81 Triglycerides / / 23063622 rs4523270 chr8 19856539 T C 7.79E-09 Triglycerides / / 19060911 rs2103325 chr8 19858343 C T 2.80E-05 Response to statin therapy / / 20339536 rs1581675 chr8 19858499 T A 1.20E-05 Response to statin therapy / / 20339536 rs4490856 chr8 19859120 T C 4.10E-05 Response to statin therapy / / 20339536 rs2119690 chr8 19859539 G A 4.90E-06 Response to statin therapy / / 20339536 rs2119690 chr8 19859539 G A 1.23E-10 Metabolite levels / / 22286219 rs2165556 chr8 19859627 C T 2.10E-05 Response to statin therapy / / 20339536 rs79236614 chr8 19860460 C G 3.79E-08 Triglycerides / / 24886709 rs4083261 chr8 19861226 T C 5.40E-05 Response to statin therapy / / 20339536 rs1441766 chr8 19862788 A T 5.60E-05 Response to statin therapy / / 20339536 rs6586884 chr8 19863358 T C 2.64E-13 Metabolite levels / / 22286219 rs6999813 chr8 19863471 T A 1.90E-07 Response to statin therapy / / 20339536 rs6999813 chr8 19863471 T A 2.64E-13 Metabolite levels / / 22286219 rs2119689 chr8 19863507 C T 1.80E-05 Response to statin therapy / / 20339536 rs1441762 chr8 19864687 G A 1.90E-05 Response to statin therapy / / 20339536 rs1441762 chr8 19864687 G A 1.53E-06 HDL cholesterol / / 21589926 rs1441762 chr8 19864687 G A 2.34E-05 HDL cholesterol / / 21589926 rs2083637 chr8 19865175 A G 5.00E-06 Waist circumference and related phenotypes / / 18454146 rs2083637 chr8 19865175 A G 6.00E-18 HDL cholesterol / / 19060911 rs2083637 chr8 19865175 A G 3.00E-10 Lipid levels / / 19802338 rs2083637 chr8 19865175 A G 1.36E-15 Lipid levels / / 19936222 rs2083637 chr8 19865175 A G 2.82E-21 Lipid levels / / 19936222 rs2083637 chr8 19865175 A G 2.99E-12 Lipid levels / / 19936222 rs2083637 chr8 19865175 A G 4.98E-12 Lipid levels / / 19936222 rs2083637 chr8 19865175 A G 6.26E-12 Lipid levels / / 19936222 rs2083637 chr8 19865175 A G 9.37E-10 Lipid levels / / 19936222 rs2083637 chr8 19865175 A G 1.90E-05 Response to statin therapy / / 20339536 rs2083637 chr8 19865175 A G 2.00E-10 Metabolic syndrome / / 20694148 rs2083637 chr8 19865175 A G 6.00E-18 Coronary heart disease / / 21347282 rs2083637 chr8 19865175 A G 2.45E-05 HDL cholesterol / / 21589926 rs2083637 chr8 19865175 A G 2.99E-06 HDL cholesterol / / 21589926 rs2083637 chr8 19865175 A G 1.02E-08 Cardiovascular disease risk factors / / 21943158 rs2083637 chr8 19865175 A G 8.88E-08 HDL cholesterol / / 23063622 rs2083637 chr8 19865175 A G 9.99E-10 Triglycerides / / 23063622 rs2083637 chr8 19865175 A G 6.53E-05 HDL particle features / / pha002900 rs2083637 chr8 19865175 A G 1.16E-05 HDL cholesterol / / pha003075 rs2083636 chr8 19865263 T G 1.80E-05 Response to statin therapy / / 20339536 rs35495249 chr8 19865509 C A 1.22E-10 Metabolite levels / / 22286219 rs894211 chr8 19865747 C T 3.00E-05 Response to statin therapy / / 20339536 rs894210 chr8 19865843 G A 4.90E-06 Response to statin therapy / / 20339536 rs894210 chr8 19865843 G A 0.000608 Salmonella-induced pyroptosis / / 22837397 rs894210 chr8 19865843 G A 0.000000147 Coronary artery disease (CAD) age >50 / / 23202125 rs894210 chr8 19865843 G A 0.00000141 Coronary artery disease (CAD) (males) / / 23202125 rs894210 chr8 19865843 G A 0.00000299 Coronary artery disease with myocardial infarction / / 23202125 rs894210 chr8 19865843 G A 0.000617 Coronary artery disease (CAD) age <=50 / / 23202125 rs765547 chr8 19866274 G A 1.52E-05 Type 2 diabetes / / 17463246 rs765547 chr8 19866274 G A 1.30E-04 Lipid levels / / 19913121 rs765547 chr8 19866274 G A 2.02E-10 Lipid levels / / 19913121 rs765547 chr8 19866274 G A 5.55E-10 Lipid levels / / 19913121 rs765547 chr8 19866274 G A 3.07E-11 Lipid levels / / 20370913 rs765547 chr8 19866274 G A 2.61E-69 Triglycerides / / 23063622 rs765547 chr8 19866274 G A 4.19E-57 HDL cholesterol / / 23063622 rs765548 chr8 19866594 C T 1.20E-05 Response to statin therapy / / 20339536 rs9644637 chr8 19867220 T C 2.40E-05 Response to statin therapy / / 20339536 rs11986942 chr8 19867445 C G 4.42E-05 Type 2 diabetes / / 17463246 rs11986942 chr8 19867445 C G 4.01E-08 Lipid levels / / 19913121 rs11986942 chr8 19867445 C G 4.79E-08 Lipid levels / / 19913121 rs11986942 chr8 19867445 C G 2.00E-05 Response to statin therapy / / 20339536 rs11986942 chr8 19867445 C G 5.53E-08 Lipid levels / / 20370913 rs11986942 chr8 19867445 C G 6.35E-09 Cardiovascular disease risk factors / / 21943158 rs11986942 chr8 19867445 C G 5.49E-65 Triglycerides / / 23063622 rs11986942 chr8 19867445 C G 9.99E-58 HDL cholesterol / / 23063622 rs1837842 chr8 19868290 T C 7.87E-06 Type 2 diabetes / / 17463246 rs1837842 chr8 19868290 T C 1.40E-05 Response to statin therapy / / 20339536 rs1837842 chr8 19868290 T C 4.09E-11 Lipid levels / / 20370913 rs1441756 chr8 19868386 A C 2.20E-05 Response to statin therapy / / 20339536 rs1441756 chr8 19868386 A C 3.00E-08 Metabolic syndrome (bivariate traits) / / 21386085 rs4406409 chr8 19868971 T C 6.80E-07 Triglycerides / / 18193046 rs4406409 chr8 19868971 T C 5.70E-05 Response to statin therapy / / 20339536 rs1919484 chr8 19869676 G A 8.36E-06 Type 2 diabetes / / 17463246 rs1919484 chr8 19869676 G A 1.46E-10 Lipid levels / / 19913121 rs1919484 chr8 19869676 G A 2.13E-04 Lipid levels / / 19913121 rs1919484 chr8 19869676 G A 9.68E-10 Lipid levels / / 19913121 rs1919484 chr8 19869676 G A 1.00E-05 Response to statin therapy / / 20339536 rs1919484 chr8 19869676 G A 7.21E-11 Lipid levels / / 20370913 rs1919484 chr8 19869676 G A 1.02E-08 Cardiovascular disease risk factors / / 21943158 rs1919484 chr8 19869676 G A 2.68E-06 Coronary heart disease / / 22319020 rs1919484 chr8 19869676 G A 3.73E-81 Triglycerides / / 23063622 rs1919484 chr8 19869676 G A 4.54E-72 HDL cholesterol / / 23063622 rs7461115 chr8 19871540 C G 5.61E-34 Triglycerides / / 23063622 rs7461115 chr8 19871540 C G 5.88E-29 HDL cholesterol / / 23063622 rs17489539 chr8 19873582 T A 4.60E-05 Response to statin therapy / / 20339536 rs4922119 chr8 19874153 C T 4.70E-05 Response to statin therapy / / 20339536 rs4333617 chr8 19875004 A G 4.60E-05 Response to statin therapy / / 20339536 rs2410630 chr8 19875100 C T 8.98E-12 Triglycerides / / 19060911 rs2410630 chr8 19875100 C T 5.30E-09 Lipid levels / / 19802338 rs2410630 chr8 19875100 C T 3.50E-05 Response to statin therapy / / 20339536 rs6586886 chr8 19875408 G A 8.30E-05 Response to statin therapy / / 20339536 rs28675909 chr8 19876234 A T 2.35E-13 Metabolite levels / / 22286219 rs7016880 chr8 19876746 G C 6.60E-07 Response to statin therapy / / 20339536 rs7016880 chr8 19876746 G C 2.00E-07 Hypertriglyceridemia / / 20657596 rs7016880 chr8 19876746 G C 2.14E-13 Metabolite levels / / 22286219 rs7007609 chr8 19876797 T C 7.30E-07 Response to statin therapy / / 20339536 rs7007609 chr8 19876797 T C 2.12E-13 Metabolite levels / / 22286219 rs7007797 chr8 19876970 T G 5.00E-04 Lipid traits / / 17903299 rs7007797 chr8 19876970 T G 8.70E-07 Response to statin therapy / / 20339536 rs7007797 chr8 19876970 T G 2.12E-13 Metabolite levels / / 22286219 rs7004149 chr8 19877208 A G 7.70E-07 Response to statin therapy / / 20339536 rs7004149 chr8 19877208 A G 1.71E-13 Metabolite levels / / 22286219 rs7004158 chr8 19877233 A G 8.20E-07 Response to statin therapy / / 20339536 rs7004158 chr8 19877233 A G 2.11E-13 Metabolite levels / / 22286219 rs6983430 chr8 19877253 G C 8.00E-07 Response to statin therapy / / 20339536 rs6983430 chr8 19877253 G C 2.11E-13 Metabolite levels / / 22286219 rs12678603 chr8 19877732 C T 7.60E-07 Response to statin therapy / / 20339536 rs12678603 chr8 19877732 C T 2.09E-13 Metabolite levels / / 22286219 rs12678604 chr8 19877773 C G 7.40E-07 Response to statin therapy / / 20339536 rs12678604 chr8 19877773 C G 2.09E-13 Metabolite levels / / 22286219 rs7013777 chr8 19878356 T C 7.60E-05 Serum metabolites / / 19043545 rs7013777 chr8 19878356 T C 3.79E-29 HDL cholesterol / / 23063622 rs7013777 chr8 19878356 T C 5.32E-34 Triglycerides / / 23063622 rs11989309 chr8 19880330 C T 4.90E-07 Response to statin therapy / / 20339536 rs11989309 chr8 19880330 C T 1.93E-13 Metabolite levels / / 22286219 rs60223219 chr8 19881801 A G 1.84E-13 Metabolite levels / / 22286219 rs7816447 chr8 19882950 T C 4.80E-07 Response to statin therapy / / 20339536 rs7816447 chr8 19882950 T C 1.38E-13 Metabolite levels / / 22286219 rs10103634 chr8 19890612 G A 6.30E-05 Response to statin therapy / / 20339536 rs10103634 chr8 19890612 G A 6.51E-05 Triglycerides / / pha002904 rs4442164 chr8 19892181 A G 7.11E-05 Serum metabolites / / 19043545 rs4244457 chr8 19899046 C T 7.47E-04 Type 2 diabetes / / 17463246 rs4244457 chr8 19899046 C T 5.90E-07 Lipid levels / / 18193043 rs6993414 chr8 19902918 A G 1.40E-13 Lipid levels / / 18193043 rs6993414 chr8 19902918 A G 4.70E-07 Response to statin therapy / / 20339536 rs6993414 chr8 19902918 A G 7.53E-14 Metabolite levels / / 22286219 rs4449813 chr8 19903320 G A 7.64E-05 Serum metabolites / / 19043545 rs1590120 chr8 19903355 A G 7.78E-05 Serum metabolites / / 19043545 rs12544475 chr8 19906693 A G 3.55E-05 Serum metabolites / / 19043545 rs11991231 chr8 19907912 T C 5.30E-07 Response to statin therapy / / 20339536 rs11991231 chr8 19907912 T C 8.18E-14 Metabolite levels / / 22286219 rs115849089 chr8 19912370 G A 4.00E-15 Lipid metabolism phenotypes / / 22286219 rs6586891 chr8 19914598 C A 6.85E-04 Type 2 diabetes / / 17463246 rs6586891 chr8 19914598 C A 2.90E-09 Lipid levels / / 18193043 rs6586891 chr8 19914598 C A 4.17E-06 Lipid levels / / 19913121 rs6586891 chr8 19914598 C A 7.65E-05 Lipid levels / / 19913121 rs6586891 chr8 19914598 C A 1.33E-38 Triglycerides / / 23063622 rs6586891 chr8 19914598 C A 6.70E-30 HDL cholesterol / / 23063622 rs10086580 chr8 19919486 A G 2.00E-07 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs4128744 chr8 19919655 C T 1.40E-07 Response to statin therapy / / 20339536 rs4128744 chr8 19919655 C T 8.14E-05 Lipid levels / / pha003082 rs6999158 chr8 19928013 T A 3.20E-06 Response to statin therapy / / 20339536 rs10106652 chr8 19928160 G A 7.70E-06 Response to statin therapy / / 20339536 rs9644568 chr8 19928582 G A 4.50E-08 Response to statin therapy / / 20339536 rs9644568 chr8 19928582 G A 4.00E-11 Hypertriglyceridemia / / 23505323 rs12545731 chr8 19938044 T C 2.23E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7015766 chr8 19939049 C T 4.11E-13 Metabolite levels / / 22286219 rs13263508 chr8 19942181 G T 3.65E-04 Type 2 diabetes / / 17463246 rs13265868 chr8 19943027 G A 5.95E-06 Intelligence / / 21826061 rs12676079 chr8 19943364 C T 6.76E-06 Intelligence / / 21826061 rs17092016 chr8 19963512 A G 4.69E-04 Multiple complex diseases / / 17554300 rs1566122 chr8 19970337 C T 3.22E-05 Sodium levels / / pha003093 rs10107943 chr8 19976239 G A 9.79E-05 Sodium levels / / pha003093 rs17092048 chr8 19986669 A G 7.43E-04 Multiple complex diseases / / 17554300 rs10503672 chr8 19987703 C T 3.00E-06 Amyotrophic lateral sclerosis (age of onset) / / 22959728 rs4481613 chr8 19995192 T A 7.77E-04 Acute lung injury / / 22295056 rs4921691 chr8 19995717 G A 7.05E-04 Acute lung injury / / 22295056 rs6982939 chr8 19996141 A G 7.00E-04 Acute lung injury / / 22295056 rs73602388 chr8 19999312 C T 5.79E-05 Cocaine dependence / / 23958962 rs6586898 chr8 20037938 C A 5.98E-04 Multiple complex diseases SLC18A1 intron 17554300 rs1390939 chr8 20040712 T C 8.22E-06 Stroke (ischemic) SLC18A1 UTR-5 22941190 rs6586899 chr8 20058757 T G 2.47E-06 Major depressive disorder (broad) ATP6V1B2 intron 20038947 rs2410638 chr8 20063137 G T 2.03E-06 Major depressive disorder (broad) ATP6V1B2 intron 20038947 rs4335136 chr8 20064771 T C 3.20E-05 Major depressive disorder (broad) ATP6V1B2 intron 20038947 rs4335136 chr8 20064771 T C 8.92E-05 Hemoglobin ATP6V1B2 intron pha003096 rs1106634 chr8 20066049 G A 6.74E-05 Bipolar disorder ATP6V1B2 intron 19488044 rs1106634 chr8 20066049 G A 7.00E-07 Major depressive disorder (broad) ATP6V1B2 intron 20038947 rs1106634 chr8 20066049 G A 4.00E-06 Bipolar disorder and schizophrenia ATP6V1B2 intron 20889312 rs11778205 chr8 20066618 A G 3.35E-05 Major depressive disorder (broad) ATP6V1B2 intron 20038947 rs10156354 chr8 20069789 G C 9.38E-05 Major depressive disorder (broad) ATP6V1B2 intron 20038947 rs13253777 chr8 20071770 C G 5.74E-05 Major depressive disorder (broad) ATP6V1B2 intron 20038947 rs1390943 chr8 20081890 T G 3.69E-05 Major depressive disorder (broad) / / 20038947 rs1390943 chr8 20081890 T G 9.00E-07 Circulating myeloperoxidase levels (serum) / / 23620142 rs10095373 chr8 20088118 T G 2.22E-05 Major depressive disorder (broad) / / 20038947 rs974994 chr8 20088733 T C 2.10E-05 Major depressive disorder (broad) / / 20038947 rs11780242 chr8 20105996 G C 3.94E-04 Smoking initiation LZTS1 UTR-3 24665060 rs141630311 chr8 20107816 G A 0.00036 Breast cancer LZTS1 missense 23555315 rs56268521 chr8 20130102 G A 8.80E-05 Urinary metabolites / / 21572414 rs4922145 chr8 20130379 G T 3.10E-04 Urinary metabolites / / 21572414 rs4922146 chr8 20130816 G A 3.20E-04 Urinary metabolites / / 21572414 rs200260343 chr8 20131287 T TA 3.20E-04 Urinary metabolites / / 21572414 rs4922147 chr8 20131287 T A 3.20E-04 Urinary metabolites / / 21572414 rs59153219 chr8 20131501 A G 1.20E-04 Urinary metabolites / / 21572414 rs11995187 chr8 20132391 C T 4.98E-05 Insulin-related traits / / pha003063 rs11997874 chr8 20140144 C G 6.46E-04 Alzheimer's disease / / 17998437 rs11988036 chr8 20140207 T A 1.95E-05 Hypertension / / 19609347 rs6998516 chr8 20146804 A C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1484799 chr8 20174467 A T 0.0006492 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1484799 chr8 20174467 A T 6.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11775998 chr8 20189399 G T 1.30E-05 Urinary metabolites / / 21572414 rs10503677 chr8 20204044 T G 4.00E-05 Type 2 diabetes / / 17293876 rs10503677 chr8 20204044 T G 4.00E-05 Type 2 diabetes / / 19184112 rs17490805 chr8 20217928 G C 8.35E-04 Type 2 diabetes / / 17463246 rs10503679 chr8 20228008 G C 2.60E-06 Coronary spasm / / 18075462 rs17412740 chr8 20246758 G A 2.00E-06 Preeclampsia / / 23551011 rs1016646 chr8 20263408 G A 9.45E-06 Preeclampsia / / 23551011 rs6995343 chr8 20283918 G A 0.000802 Salmonella-induced pyroptosis / / 22837397 rs4922199 chr8 20301437 A C 8.00E-06 Dental caries / / 23259602 rs7011366 chr8 20322223 C T 8.57E-04 Type 2 diabetes / / 17463246 rs10101153 chr8 20328614 G A 2.97E-04 Alzheimer's disease (late onset) / / 21379329 rs10111661 chr8 20336573 G A 2.00E-06 Dental caries / / 23064961 rs1871662 chr8 20342314 A C 3.68E-04 Type 2 diabetes / / 17463246 rs6995224 chr8 20370606 A G 3.84E-04 Aortic root size / / 21223598 rs4922211 chr8 20371501 G A 8.93E-04 Aortic root size / / 21223598 rs10464996 chr8 20390921 C T 7.37E-05 Diabetes Mellitus / / pha003060 rs1979431 chr8 20423245 G A 9.07E-05 Diabetes Mellitus / / pha003060 rs1351381 chr8 20425772 C A 0.00084 Salmonella-induced pyroptosis / / 22837397 rs4244463 chr8 20434567 C T 1.66E-04 Self-reported allergy / / 23817569 rs7829571 chr8 20435818 A G 8.81E-05 Self-reported allergy / / 23817569 rs7820589 chr8 20437926 G A 1.10E-04 Self-reported allergy / / 23817569 rs4592052 chr8 20465952 T C 4.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11992855 chr8 20468363 C A 8.95E-05 Insulin Resistance / / pha003062 rs13277342 chr8 20484514 G A 2.32E-05 Coronary heart disease / / pha003030 rs13277342 chr8 20484514 G A 1.52E-06 Coronary heart disease / / pha003031 rs1868660 chr8 20486184 C T 2.96E-05 Triglycerides / / pha003080 rs4922226 chr8 20487794 A G 8.08E-05 Glucose levels / / pha003057 rs4922226 chr8 20487794 A G 2.54E-05 Triglycerides / / pha003080 rs10095297 chr8 20498043 G T 2.20E-05 Bipolar disorder / / 21771265 rs17493092 chr8 20532943 C A 6.29E-05 Cervical cancer / / 24700089 rs2597384 chr8 20550536 A C 5.98E-05 Abdominal aortic aneurysm / / 24046328 rs2218794 chr8 20564601 G T 2.20E-05 Urinary metabolites / / 21572414 rs6992419 chr8 20565015 A C 6.43E-06 Dental caries / / 21940522 rs2616170 chr8 20566145 A T 9.00E-06 Urinary metabolites / / 21572414 rs13258625 chr8 20576761 T C 1.91E-05 Dental caries / / 21940522 rs1530781 chr8 20580511 G A 3.35E-05 Dental caries / / 21940522 rs11985951 chr8 20592509 T C 6.00E-06 Cervical cancer / / 24700089 rs1376010 chr8 20592764 T G 3.15E-04 Multiple complex diseases / / 17554300 rs1450291 chr8 20593491 A G 1.47E-05 Cervical cancer / / 24700089 rs2597419 chr8 20594766 C T 5.03E-05 Cervical cancer / / 24700089 rs28581693 chr8 20596957 A G 8.48E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2122469 chr8 20626321 G A 7.00E-07 Serum tamsulosin hydrochloride concentration / / 23151678 rs1470687 chr8 20628793 C G 1.80E-05 Immunoglobulin A / / 20694011 rs10108962 chr8 20629465 C G 6.14E-06 Malignant mesothelioma / / 23827383 rs10109087 chr8 20629550 C G 6.11E-06 Malignant mesothelioma / / 23827383 rs17604209 chr8 20629958 G A 5.99E-06 Malignant mesothelioma / / 23827383 rs10101364 chr8 20634888 C T 6.72E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10101364 chr8 20634888 C T 1.09E-05 Triglycerides / / pha002904 rs10089021 chr8 20639494 T C 8.10E-05 Alcoholism (heaviness of drinking) / / 21529783 rs10089418 chr8 20639861 T C 4.64E-06 Malignant mesothelioma / / 23827383 rs7007919 chr8 20647375 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7007919 chr8 20647375 C T 1.71E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2583664 chr8 20672827 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1530288 chr8 20680983 A G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10103263 chr8 20685467 T G 4.45E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2616186 chr8 20724468 G A 4.21E-04 Type 2 diabetes / / 17463246 rs1441782 chr8 20753081 A C 1.71E-05 Iron status biomarkers / / 19084217 rs7015342 chr8 20754365 C G 7.78E-06 Multiple complex diseases / / 17554300 rs7822570 chr8 20757040 G C 8.20E-05 Parkinson's disease (age of onset) / / 19772629 rs1348196 chr8 20764282 G A 5.87E-05 Height / / 17255346 rs6988688 chr8 20764823 A G 6.63E-05 Type 2 diabetes / / 17463246 rs17093344 chr8 20770926 T C 5.73E-05 Height / / 17255346 rs12549758 chr8 20774711 T A 6.68E-04 Type 2 diabetes / / 17463246 rs1441784 chr8 20776419 G A 3.23E-05 Height / / 17255346 rs502740 chr8 20803341 T G 9.63E-04 Multiple complex diseases / / 17554300 rs3134185 chr8 20816918 A G 1.18E-04 Smoking initiation / / 24665060 rs7001189 chr8 20851968 G C 9.13E-04 Type 2 diabetes LOC286114 intron 17463246 rs7001189 chr8 20851968 G C 4.41E-04 Multiple complex diseases LOC286114 intron 17554300 rs7821595 chr8 20881539 A G 6.49E-04 Multiple complex diseases / / 17554300 rs7821595 chr8 20881539 A G 8.27E-05 Serum metabolites / / 19043545 rs17577994 chr8 20885995 G A 5.97E-05 Interstitial lung disease / / 23583980 rs6986709 chr8 20944386 C T 2.12E-05 Attention deficit hyperactivity disorder / / 20732627 rs1471295 chr8 20947906 A G 3.50E-05 Parkinson's disease (familial) / / 18985386 rs7839300 chr8 20950485 A C 9.20E-05 Primary sclerosing cholangitis / / 19944697 rs10111769 chr8 20958756 T C 4.95E-04 Type 2 diabetes / / 17463246 rs10111769 chr8 20958756 T C 5.40E-05 Primary sclerosing cholangitis / / 19944697 rs10111769 chr8 20958756 T C 1.49E-05 Migraine / / 20802479 rs7015657 chr8 20967551 C G 1.18E-04 Migraine - clinic-based / / 23793025 rs7015657 chr8 20967551 C G 8.00E-08 Migraine with aura / / 23793025 rs17423865 chr8 20976715 G C 6.90E-04 Type 2 diabetes / / 17463246 rs12549890 chr8 21000894 C T 2.32E-05 Multiple complex diseases / / 17554300 rs4739279 chr8 21000968 A C 3.90E-04 Multiple complex diseases / / 17554300 rs12676503 chr8 21005710 C T 9.57E-04 Obesity (extreme) / / 21935397 rs13257229 chr8 21028044 C T 2.58E-04 Obesity (extreme) / / 21935397 rs17496355 chr8 21043793 T C 3.80E-05 Multiple complex diseases / / 17554300 rs2631855 chr8 21046469 C T 6.13E-05 Insulin-related traits / / 19902172 rs2613675 chr8 21051235 A G 7.88E-05 Insulin-related traits / / 19902172 rs1381005 chr8 21060181 A G 2.70E-05 Urinary metabolites / / 21572414 rs7842037 chr8 21067151 C T 8.78E-04 Type 2 diabetes / / 17463246 rs7842037 chr8 21067151 C T 6.05E-05 Odorant perception / / 23910658 rs2631923 chr8 21075672 T C 4.71E-04 Multiple complex diseases / / 17554300 rs989329 chr8 21087783 A G 2.32E-04 Stroke / / pha002887 rs718068 chr8 21102896 T C 5.25E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs1380292 chr8 21104408 A G 7.64E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs1599096 chr8 21118224 C T 6.86E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs2446620 chr8 21124700 T G 2.10E-05 Urinary metabolites / / 21572414 rs2631878 chr8 21129059 G A 1.90E-04 Schizophrenia / / 19197363 rs2631879 chr8 21130702 C T 3.81E-05 Schizophrenia / / 19197363 rs898246 chr8 21144067 C G 7.00E-04 Multiple complex diseases / / 17554300 rs6981910 chr8 21156726 C T 7.96E-05 Weight / / pha003027 rs6981910 chr8 21156726 C T 3.73E-06 Soluble levels of adhesion molecules / / pha003072 rs10087005 chr8 21157773 G A 9.95E-05 Weight / / pha003027 rs10087005 chr8 21157773 G A 6.35E-05 Soluble levels of adhesion molecules / / pha003072 rs2631889 chr8 21164751 G A 8.27E-04 HIV-1 viral setpoint / / 17641165 rs898250 chr8 21173055 C G 2.96E-04 Prostate cancer mortality / / 20978177 rs2610984 chr8 21180713 G A 2.19E-04 Prostate cancer mortality / / 20978177 rs2066940 chr8 21190268 T C 9.86E-04 Coronary Artery Disease / / 17634449 rs2066940 chr8 21190268 T C 5.59E-07 Soluble levels of adhesion molecules / / pha003072 rs999207 chr8 21200881 T C 9.14E-04 Coronary Artery Disease / / 17634449 rs2926426 chr8 21214731 T G 3.03E-04 Orofacial clefts / / 22419666 rs2959389 chr8 21238755 G A 4.81E-05 Body Mass Index / / pha003007 rs2959389 chr8 21238755 G A 6.40E-05 Body Mass Index / / pha003015 rs2959389 chr8 21238755 G A 4.32E-05 Waist Circumference / / pha003025 rs6998330 chr8 21240546 C T 1.55E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1426186 chr8 21243101 G T 6.85E-05 Multiple complex diseases / / 17554300 rs1426186 chr8 21243101 G T 6.82E-04 Substance dependence / / 21818250 rs974306 chr8 21246529 C T 1.64E-04 Multiple complex diseases / / 17554300 rs1426187 chr8 21249296 C A 2.36E-05 Multiple complex diseases / / 17554300 rs12156057 chr8 21285108 A G 5.78E-05 Multiple complex diseases / / 17554300 rs13262320 chr8 21285395 A G 1.24E-04 Multiple complex diseases / / 17554300 rs7837682 chr8 21285710 T C 7.70E-05 Effectiveness of iloperidone treatment in schizophrenia / / 18521090 rs17607798 chr8 21296977 A C 1.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs7006259 chr8 21297645 T C 6.98E-04 Multiple complex diseases / / 17554300 rs734364 chr8 21298535 T C 1.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs7460673 chr8 21298588 C T 1.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs13280180 chr8 21299092 C T 3.46E-05 Multiple complex diseases / / 17554300 rs17580072 chr8 21299880 G A 5.15E-04 Multiple complex diseases / / 17554300 rs10089304 chr8 21300015 T C 4.86E-05 Multiple complex diseases / / 17554300 rs17607868 chr8 21306658 G A 9.28E-04 Multiple complex diseases / / 17554300 rs4739204 chr8 21330710 A T 3.83E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4739207 chr8 21368779 G A 6.19E-05 Prostate cancer / / 22923026 rs13272802 chr8 21383205 C T 7.22E-04 Tourette syndrome / / 22889924 rs6995069 chr8 21392919 G C 1.12E-05 Bipolar disorder and schizophrenia / / 20889312 rs6997836 chr8 21418702 G T 6.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4587321 chr8 21455291 G T 2.00E-05 Urinary metabolites / / 21572414 rs2010282 chr8 21470887 T C 3.27E-04 Obesity (extreme) / / 21935397 rs1383582 chr8 21492975 A G 2.46E-05 Aging (time to event) / / 21782286 rs6980554 chr8 21532970 G A 3.07E-04 Multiple complex diseases / / 17554300 rs7826525 chr8 21562155 A G 5.69E-05 Serum albumin level GFRA2 intron pha003084 rs7826525 chr8 21562155 A G 8.95E-05 Calcium levels GFRA2 intron pha003085 rs4078157 chr8 21573095 T C 1 Drug response to Etoposide GFRA2 intron 17537913 rs6587002 chr8 21581220 T C 7.19E-04 Multiple complex diseases GFRA2 intron 17554300 rs6587002 chr8 21581220 T C 4.36E-04 Alzheimer's disease GFRA2 intron 24755620 rs11786696 chr8 21615817 C T 8.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) GFRA2 intron 23648065 rs7008137 chr8 21639132 A G 2.42E-05 Cognitive impairment induced by topiramate GFRA2 intron 22091778 rs17581368 chr8 21662445 C A 7.00E-06 Entorhinal cortical thickness / / 21116278 rs7013204 chr8 21673695 C T 7.59E-04 Multiple complex diseases / / 17554300 rs7013204 chr8 21673695 C T 2.00E-06 Urinary metabolites / / 21572414 rs899430 chr8 21699477 A G 2.00E-04 Longevity / / 22279548 rs4872521 chr8 21707713 C G 5.40E-07 Neuropathic pain in type 2 diabetes / / 24974787 rs4872522 chr8 21707844 A C 6.47E-07 Neuropathic pain in type 2 diabetes / / 24974787 rs10098807 chr8 21708824 G A 7.00E-07 Neuropathic pain in type 2 diabetes / / 24974787 rs11774105 chr8 21710146 T C 4.03E-07 Neuropathic pain in type 2 diabetes / / 24974787 rs13260283 chr8 21711191 T G 6.20E-05 Intelligence (childhood) / / 23358156 rs17428041 chr8 21711431 T C 2.00E-07 Neuropathic pain in type 2 diabetes / / 24974787 rs17615364 chr8 21711580 G A 2.20E-07 Neuropathic pain in type 2 diabetes / / 24974787 rs11776842 chr8 21711651 A C 2.20E-07 Neuropathic pain in type 2 diabetes / / 24974787 rs12545534 chr8 21712401 G A 2.62E-07 Neuropathic pain in type 2 diabetes / / 24974787 rs11780601 chr8 21717841 G T 7.98E-07 Neuropathic pain in type 2 diabetes / / 24974787 rs4872104 chr8 21780744 A G 0.0000902 HDL cholesterol XPO7 intron 23063622 rs6996493 chr8 21793608 A G 7.16E-04 Alcohol dependence XPO7 intron 21314694 rs13278159 chr8 21799737 C A 0.0001501 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 intron 23233654 rs13278159 chr8 21799737 C A 1.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 intron 23233662 rs11135741 chr8 21801091 C T 0.0001526 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 intron 23233654 rs11135741 chr8 21801091 C T 1.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 intron 23233662 rs1564305 chr8 21803816 A C 0.0002101 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 intron 23233654 rs1564305 chr8 21803816 A C 2.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 intron 23233662 rs9314269 chr8 21804989 A G 0.0002106 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 intron 23233654 rs9314269 chr8 21804989 A G 2.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 intron 23233662 rs17615770 chr8 21812730 A G 0.0002229 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 intron 23233654 rs17615770 chr8 21812730 A G 2.23E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 intron 23233662 rs36110951 chr8 21812730 A AG 0.0002229 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 intron 23233654 rs36110951 chr8 21812730 A AG 2.23E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 intron 23233662 rs11135763 chr8 21813962 A G 0.0001854 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 intron 23233654 rs11135763 chr8 21813962 A G 1.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 intron 23233662 rs7843479 chr8 21820813 C A 3.00E-08 Blood cell counts and other traits XPO7 intron 20139978 rs7843479 chr8 21820813 C A 3.32E-08 Blood cell counts and other traits XPO7 intron 20139978 rs7843479 chr8 21820813 C A 0.0001864 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 intron 23233654 rs7843479 chr8 21820813 C A 1.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 intron 23233662 rs2291317 chr8 21827162 C T 0.0002297 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 intron 23233654 rs2291317 chr8 21827162 C T 2.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 intron 23233662 rs4871903 chr8 21827833 A G 0.00023 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 intron 23233654 rs4871903 chr8 21827833 A G 2.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 intron 23233662 rs1484162 chr8 21831385 A G 0.0001894 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 intron 23233654 rs1484162 chr8 21831385 A G 1.89E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 intron 23233662 rs2306641 chr8 21833965 C T 3.40E-04 Lymphocyte counts XPO7 cds-synon 22286170 rs2306641 chr8 21833965 C T 0.0002285 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 cds-synon 23233654 rs2306641 chr8 21833965 C T 2.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 cds-synon 23233662 rs733543 chr8 21835465 A G 0.0002309 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 intron 23233654 rs733543 chr8 21835465 A G 2.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 intron 23233662 rs1809498 chr8 21836384 C G 0.000736 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 intron 23233654 rs1809498 chr8 21836384 C G 7.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 intron 23233662 rs2054713 chr8 21840534 A G 0.0002188 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 intron 23233654 rs2054713 chr8 21840534 A G 2.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 intron 23233662 rs2054713 chr8 21840534 A G 8.17E-05 Serum albumin level XPO7 intron pha003084 rs13248727 chr8 21842063 T C 0.0002188 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 intron 23233654 rs13248727 chr8 21842063 T C 2.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 intron 23233662 rs17060709 chr8 21842728 G C 1.90E-04 Multiple complex diseases XPO7 intron 17554300 rs4871908 chr8 21844096 T C 0.0003242 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 intron 23233654 rs4871908 chr8 21844096 T C 3.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 intron 23233662 rs727694 chr8 21849962 T C 0.0002502 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 intron 23233654 rs727694 chr8 21849962 T C 2.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 intron 23233662 rs10503715 chr8 21850687 G A 0.0002046 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 intron 23233654 rs10503715 chr8 21850687 G A 2.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 intron 23233662 rs17616085 chr8 21857267 G A 0.0002082 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 intron 23233654 rs17616085 chr8 21857267 G A 2.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 intron 23233662 rs3816786 chr8 21860425 T A 0.0003082 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) XPO7 intron 23233654 rs3816786 chr8 21860425 T A 3.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) XPO7 intron 23233662 rs7813420 chr8 21866084 A C 1.67E-04 Hemoglobin concentration / / 20534544 rs7813420 chr8 21866084 A C 0.0000329 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7813420 chr8 21866084 A C 3.29E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10503716 chr8 21866662 T C 5.01E-07 Red blood cell traits / / 23222517 rs10503716 chr8 21866662 T C 2.82E-04 Myocardial Infarction / / pha002883 rs11776272 chr8 21884544 A G 8.38E-05 Hemoglobin concentration NPM2 intron 20534544 rs11776272 chr8 21884544 A G 5.00E-06 Obesity-related traits NPM2 intron 23251661 rs10089142 chr8 21891939 G A 7.90E-05 Hemoglobin concentration NPM2 intron 20534544 rs10089142 chr8 21891939 G A 1.05E-04 Response to cytadine analogues (cytosine arabinoside) NPM2 intron 24483146 rs3176292 chr8 21903316 G A 1.11E-04 Intracranial aneurysm FGF17 intron 20613766 rs3176295 chr8 21904126 G A 7.84E-05 Multiple complex diseases FGF17 cds-synon 17554300 rs7820576 chr8 21950426 A G 1.95E-04 Lymphocyte counts FAM160B2 intron 22286170 rs76547188 chr8 21978372 C T 5.00E-06 Obesity-related traits HR missense 23251661 rs7819541 chr8 22042151 G T 2.93E-04 Type 2 diabetes BMP1 intron 17463246 rs11775186 chr8 22058122 T G 3.38E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BMP1 intron 20877124 rs13257482 chr8 22059606 G A 1.24E-05 Cognitive impairment induced by topiramate BMP1 intron 22091778 rs11778448 chr8 22069018 C T 1.30E-05 Urinary metabolites BMP1 intron 21572414 rs4871976 chr8 22086491 G A 4.49E-05 Longevity PHYHIP intron 22279548 rs12541335 chr8 22088432 A G 7.00E-06 Hypertriglyceridemia PHYHIP intron 23505323 rs7816385 chr8 22256689 C G 2.40E-05 Urinary metabolites SLC39A14 intron 21572414 rs79856562 chr8 22267473 T A 0.000033 Prostate cancer (advanced) SLC39A14 missense 23555315 rs17060853 chr8 22272167 C T 5.84E-04 Multiple complex diseases SLC39A14 intron 17554300 rs10108011 chr8 22320806 G A 8.23E-04 Alzheimer's disease PPP3CC intron 24755620 rs2469757 chr8 22360938 C T 6.85E-04 Type 2 diabetes PPP3CC intron 17463246 rs17671456 chr8 22385077 C G 2.97E-04 Alzheimer's disease PPP3CC intron 24755620 rs117993834 chr8 22398155 A G 0.0000051 Breast cancer(er negative) PPP3CC missense 23555315 rs4872511 chr8 22400989 C T 9.00E-06 HIV-1 viral setpoint / / 20205591 rs2280890 chr8 22404840 C T 9.00E-06 HIV-1 viral setpoint / / 20205591 rs397797352 chr8 22404840 C CT 9.00E-06 HIV-1 viral setpoint / / 20205591 rs536407218 chr8 22404840 C CT 9.00E-06 HIV-1 viral setpoint / / 20205591 rs5890043 chr8 22404840 C CT 9.00E-06 HIV-1 viral setpoint / / 20205591 rs2449346 chr8 22415992 T A,C 7.68E-05 Lung adenocarcinoma SORBS3 intron 19836008 rs2449346 chr8 22415992 T A,C 5.61E-05 Blood Pressure SORBS3 intron pha003045 rs2449346 chr8 22415992 T A,C 1.39E-05 Blood Pressure SORBS3 intron pha003047 rs11781149 chr8 22473158 C T 5.19E-04 Smoking initiation KIAA1967 intron 24665060 rs1545837 chr8 22477807 T C 1.00E-05 Alcohol consumption (maxi-drinks) KIAA1967 UTR-3 24277619 rs4872524 chr8 22489537 T C 1.28E-04 Alzheimer's disease BIN3 intron 17998437 rs7831119 chr8 22489678 A G 1.78E-04 Alzheimer's disease BIN3 intron 17998437 rs6558172 chr8 22492052 G A 6.99E-04 Alzheimer's disease BIN3 intron 17998437 rs11985023 chr8 22531463 C T 4.44E-04 Heart Failure / / pha002884 rs17674754 chr8 22533388 G A 3.17E-04 Blood pressure / / 17255346 rs4520160 chr8 22561884 G A 6.73E-04 Smoking cessation / / 24665060 rs1877672 chr8 22563196 A G 7.99E-07 Kawasaki disease / / 21221998 rs1877672 chr8 22563196 A G 2.40E-05 Urinary metabolites / / 21572414 rs11777370 chr8 22567600 T C 5.71E-04 Rheumatoid arthritis / / 21452313 rs4872534 chr8 22568403 A T 7.99E-07 Kawasaki disease / / 21221998 rs17088602 chr8 22597858 T C 5.97E-06 Cardiovascular disease PEBP4 intron pha003064 rs2048651 chr8 22600953 T C 3.59E-04 Self-reported allergy PEBP4 intron 23817569 rs17676443 chr8 22601427 T G 5.15E-04 Self-reported allergy PEBP4 intron 23817569 rs11781835 chr8 22608029 A G 9.16E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) PEBP4 intron 23648065 rs11781835 chr8 22608029 A G 1.95E-04 Response to cytadine analogues (cytosine arabinoside) PEBP4 intron 24483146 rs12682145 chr8 22613172 A G 3.11E-05 Parent of origin effect on language impairment (paternal) PEBP4 intron 24571439 rs17676811 chr8 22617365 G A 3.63E-05 Hirschsprung's disease PEBP4 intron 19196962 rs10503719 chr8 22617903 C T 1.57E-04 Response to cytadine analogues (cytosine arabinoside) PEBP4 intron 24483146 rs11998649 chr8 22619551 A C 7.00E-06 Visceral fat PEBP4 intron 22589738 rs12155789 chr8 22643707 A G 1.00E-06 Serum dimethylarginine levels (asymmetric) PEBP4 intron 24159190 rs17088625 chr8 22647850 T C 7.20E-05 Male fertility PEBP4 intron 22633400 rs4871834 chr8 22650159 G C 6.33E-05 Arthritis (juvenile idiopathic) PEBP4 intron 22354554 rs4872018 chr8 22652170 G T 1.57E-07 Esophageal cancer (squamous cell) PEBP4 intron 22960999 rs10216846 chr8 22661286 T C 8.83E-05 Male fertility PEBP4 intron 22633400 rs12682049 chr8 22663527 A G 6.35E-04 Insulin resistance PEBP4 intron 21901158 rs12548355 chr8 22689751 T A 8.64E-05 Aging (time to event) PEBP4 intron 21782286 rs11135681 chr8 22703333 C T 8.53E-05 Intelligence PEBP4 intron 21826061 rs9644059 chr8 22719438 C T 7.80E-05 Coronary heart disease PEBP4 intron pha003030 rs2457432 chr8 22751224 G A 1.20E-05 Urinary metabolites PEBP4 intron 21572414 rs4872037 chr8 22760430 G A 6.92E-04 Suicide attempts in bipolar disorder PEBP4 intron 21423239 rs4872037 chr8 22760430 G A 1.03E-05 HDL cholesterol PEBP4 intron pha003075 rs6557600 chr8 22763248 A G 1.00E-06 Preschool internalizing problems PEBP4 intron 24839885 rs7829314 chr8 22774103 G A 7.42E-05 HDL cholesterol PEBP4 intron pha003075 rs2466225 chr8 22785386 T G 4.89E-04 Type 2 diabetes PEBP4 UTR-5 17463246 rs2457426 chr8 22786150 A C 2.11E-04 Type 2 diabetes / / 17463246 rs1123828 chr8 22802380 T C 4.06E-04 Type 2 diabetes / / 17463246 rs7840814 chr8 22817170 G C 9.00E-06 Urinary metabolites / / 21572414 rs7845953 chr8 22828463 C T 2.90E-05 Urinary metabolites / / 21572414 rs2466236 chr8 22836788 T C 2.05E-04 Multiple complex diseases / / 17554300 rs7826882 chr8 22849422 G T 1.58E-05 Hypertension RHOBTB2 intron pha003041 rs876435 chr8 22873533 G A 1.97E-05 Magnesium levels RHOBTB2 intron pha003092 rs17088895 chr8 22884231 T C 6.56E-04 Type 2 diabetes TNFRSF10B intron 17463246 rs17088895 chr8 22884231 T C 9.62E-05 Blood pressure (response to calcium channel blocker) TNFRSF10B intron 24192120 rs141856351 chr8 22885246 G A 0.00029 Breast cancer TNFRSF10B missense 23555315 rs883429 chr8 22886818 C T 4.15E-05 Magnesium levels TNFRSF10B intron pha003092 rs9644062 chr8 22920149 C T 7.64E-04 Suicide attempts in bipolar disorder TNFRSF10B intron 21423239 rs28873480 chr8 22928311 C T 1.63E-06 Parasitemia in Tripanosoma cruzi seropositivity LOC286059 intron 24324551 rs57302454 chr8 22938661 G C 6.00E-07 Parasitemia in Tripanosoma cruzi seropositivity LOC286059 intron 24324551 rs7830593 chr8 22944695 G A 9.14E-04 Suicide attempts in bipolar disorder LOC254896 intron 21423239 rs12681965 chr8 22963602 T G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes TNFRSF10C intron 22628534 rs7843320 chr8 22987837 C T 8.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs7843602 chr8 22987993 C T 8.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs4872058 chr8 22989954 G A 7.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs7957 chr8 22993367 T C 7.21E-04 Suicide attempts in bipolar disorder TNFRSF10D UTR-3 21423239 rs3924519 chr8 23004629 T C 8.68E-05 Heart Rate TNFRSF10D intron pha003054 rs10102276 chr8 23019249 G A 8.60E-05 Response to lithium treatment in bipolar disorder TNFRSF10D intron 19448189 rs4871856 chr8 23041334 G T 6.08E-04 Age-related macular degeneration / / 21909106 rs56793025 chr8 23042674 C T 6.22E-05 Age-related macular degeneration / / 21909106 rs59693001 chr8 23042694 C A 8.60E-05 Age-related macular degeneration / / 21909106 rs10099175 chr8 23045962 C A 8.51E-05 Age-related macular degeneration / / 21909106 rs67902577 chr8 23046738 A C 5.94E-05 Age-related macular degeneration / / 21909106 rs67820469 chr8 23051216 G C 5.98E-05 Age-related macular degeneration TNFRSF10A intron 21909106 rs2235126 chr8 23057181 C T 1.01E-06 Age-related macular degeneration TNFRSF10A intron 21909106 rs6557632 chr8 23058472 T C 6.93E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs4872078 chr8 23059280 G T 1.43E-04 Parkinson's disease TNFRSF10A intron 17052657 rs20575 chr8 23059324 C G 2.49E-04 Parkinson's disease TNFRSF10A missense 17052657 rs17620 chr8 23060256 T C 2.51E-04 Parkinson's disease TNFRSF10A missense 17052657 rs4242392 chr8 23061633 T C 7.23E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs4242392 chr8 23061633 T C 9.36E-04 Self-reported allergy TNFRSF10A intron 23817569 rs6982233 chr8 23061792 T C 4.24E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs4526369 chr8 23063874 A G 9.54E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs4385477 chr8 23067540 T C 8.53E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs4872082 chr8 23068151 C T 9.04E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs57254474 chr8 23071054 A G 6.20E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs13250183 chr8 23071433 C T 4.29E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs35561835 chr8 23071772 A G 6.09E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs34194030 chr8 23071987 C A 3.84E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs7821298 chr8 23073540 C T 3.09E-05 Age-related macular degeneration TNFRSF10A intron 21909106 rs11987637 chr8 23073568 T G 5.05E-05 Age-related macular degeneration TNFRSF10A intron 21909106 rs7820465 chr8 23073686 G A 1.77E-05 Age-related macular degeneration TNFRSF10A intron 21909106 rs4133054 chr8 23074718 T C 6.40E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs4496974 chr8 23075021 G A 2.67E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs4532600 chr8 23075040 C T 3.37E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs4288383 chr8 23075214 G C 2.99E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs4336619 chr8 23075215 G A 3.67E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs73222596 chr8 23075319 C T 5.11E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs4872085 chr8 23075488 G C 4.75E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs4872086 chr8 23075678 T A 3.64E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs4607622 chr8 23076159 T G 2.72E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs4872088 chr8 23076180 G A 4.23E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs4872089 chr8 23076334 T G 4.08E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs4623437 chr8 23076346 A G 2.64E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs73222598 chr8 23076631 A C 2.66E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs12056510 chr8 23076854 G A 2.45E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs12056385 chr8 23076876 T G 2.34E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs7812959 chr8 23076885 G A 3.10E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs12056387 chr8 23076891 T C 2.44E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs7831909 chr8 23076907 A G 2.33E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs7814117 chr8 23076914 C A 2.02E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs7835686 chr8 23076916 T C 2.77E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs7831919 chr8 23076934 A G 1.89E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs7813082 chr8 23076941 G T 2.24E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs7835716 chr8 23076976 T C 2.15E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs7832037 chr8 23076990 A G 2.36E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs7814465 chr8 23077163 C G 6.21E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs73222599 chr8 23077289 C A 1.73E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs73222600 chr8 23077290 A G 6.03E-05 Age-related macular degeneration TNFRSF10A intron 21909106 rs7842021 chr8 23079204 A G 4.16E-05 Parkinson's disease TNFRSF10A intron 17052657 rs73222601 chr8 23080049 A G 2.39E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs1000294 chr8 23080135 G A 3.67E-04 Age-related macular degeneration TNFRSF10A intron 21909106 rs13278062 chr8 23082971 G T 1.00E-12 Age-related macular degeneration / / 21909106 rs13278062 chr8 23082971 G T 3.00E-15 Age-related macular degeneration / / 23455636 rs13281363 chr8 23083015 A T 6.80E-06 Age-related macular degeneration / / 21909106 rs13255394 chr8 23083546 T C 4.07E-05 Age-related macular degeneration / / 21909106 rs13254617 chr8 23083836 C A 5.26E-05 Age-related macular degeneration LOC389641 intron 21909106 rs11777697 chr8 23088984 C G 1.09E-04 Age-related macular degeneration / / 21909106 rs13268919 chr8 23096594 G A 5.33E-06 Attention deficit hyperactivity disorder / / 20732625 rs7463256 chr8 23101620 T C 3.17E-06 Attention deficit hyperactivity disorder CHMP7 intron 20732625 rs2294123 chr8 23104195 G T 4.07E-06 Attention deficit hyperactivity disorder CHMP7 UTR-5 20732625 rs2280934 chr8 23106665 A G 1.33E-05 Attention deficit hyperactivity disorder CHMP7 intron 20732625 rs11135712 chr8 23110503 C T 4.77E-06 Attention deficit hyperactivity disorder CHMP7 intron 20732625 rs13255552 chr8 23122100 T A 8.71E-05 Body mass index / / 17255346 rs10091786 chr8 23139436 C T 3.49E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs10091786 chr8 23139436 C T 2.15E-05 Orofacial clefts / / 19270707 rs10091786 chr8 23139436 C T 7.02E-04 Alzheimer's disease / / 22005930 rs9918794 chr8 23142869 A C 3.29E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4348504 chr8 23154131 T C 5.60E-04 Lipid levels / / 18193043 rs4278162 chr8 23169455 G A 1.57E-04 Cognitive decline LOXL2 intron 23732972 rs7013955 chr8 23201103 G A 6.98E-05 Brain derived neurotrophic factor levels,in serum LOXL2 intron 22047184 rs17089136 chr8 23202347 G A 2.88E-05 Serum metabolites LOXL2 intron 19043545 rs7832355 chr8 23202401 A G 2.88E-05 Serum metabolites LOXL2 intron 19043545 rs7010362 chr8 23218101 G A 6.81E-04 Type 2 diabetes LOXL2 intron 17463246 rs17768448 chr8 23223713 T C 5.52E-05 HDL cholesterol LOXL2 intron pha003074 rs6557666 chr8 23239629 A G 3.51E-04 Type 2 diabetes LOXL2 intron 17463246 rs8180974 chr8 23240061 G A 6.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOXL2 intron 20877124 rs10095723 chr8 23243323 T C 3.98E-08 Metabolite levels LOXL2 intron 23281178 rs10096495 chr8 23245783 C T 3.98E-08 Metabolite levels LOXL2 intron 23281178 rs4639518 chr8 23256092 G T 2.19E-05 Cognitive decline LOXL2 intron 23732972 rs7823585 chr8 23275784 A G 5.27E-04 Multiple complex diseases / / 17554300 rs6557672 chr8 23286234 G A 5.00E-09 Lymphocyte counts / / 22286170 rs6557672 chr8 23286234 G A 3.02E-04 Cognitive decline / / 23732972 rs7843529 chr8 23289536 G A 3.21E-04 Cognitive decline ENTPD4 UTR-3 23732972 rs1061293 chr8 23289901 G A 4.11E-04 Response to cytadine analogues (cytosine arabinoside) ENTPD4 UTR-3 24483146 rs2272643 chr8 23294392 C T 4.11E-04 Response to cytadine analogues (cytosine arabinoside) ENTPD4 intron 24483146 rs2272642 chr8 23294412 A G 5.44E-05 Response to cytadine analogues (cytosine arabinoside) ENTPD4 intron 24483146 rs4571739 chr8 23295026 C T 4.11E-04 Response to cytadine analogues (cytosine arabinoside) ENTPD4 intron 24483146 rs7822769 chr8 23304456 C A 3.21E-04 Cognitive decline ENTPD4 intron 23732972 rs2293936 chr8 23307253 A C 4.92E-04 Response to cytadine analogues (cytosine arabinoside) ENTPD4 intron 24483146 rs562230222 chr8 23309914 G GA 3.53E-04 Cognitive decline ENTPD4 intron 23732972 rs6993786 chr8 23309914 G A 3.53E-04 Cognitive decline ENTPD4 intron 23732972 rs10216695 chr8 23344403 T C 1.45E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17698981 chr8 23396101 C A 7.98E-05 stroke (ischemic) SLC25A37 intron 17434096 rs10503725 chr8 23396537 G A 1.33E-04 Multiple complex diseases SLC25A37 intron 17554300 rs4872145 chr8 23397750 T C 7.09E-05 Glycosylated haemoglobin levels SLC25A37 intron 17255346 rs17089358 chr8 23411275 T C 6.88E-04 Alcohol dependence SLC25A37 intron 21314694 rs7816824 chr8 23411798 A C 5.44E-04 Multiple complex diseases SLC25A37 intron 17554300 rs13254494 chr8 23414743 C T 5.62E-07 Red blood cell traits SLC25A37 intron 23222517 rs2942202 chr8 23418444 A C 3.61E-07 Red blood cell traits SLC25A37 intron 23222517 rs41460846 chr8 23435916 A T 3.77E-04 Multiple complex diseases / / 17554300 rs11776817 chr8 23454052 C T 1.66E-04 Breast cancer / / pha002853 rs13264439 chr8 23465063 C A 6.79E-06 Personality dimensions / / 22628180 rs1858401 chr8 23466466 T C 7.48E-06 Personality dimensions / / 22628180 rs10866831 chr8 23468924 A T 2.36E-05 Height / / 22021425 rs11135759 chr8 23469088 C T 8.36E-06 Personality dimensions / / 22628180 rs7813472 chr8 23469614 A G 3.96E-05 Height / / 22021425 rs7817344 chr8 23469922 A T 2.10E-05 Height / / 22021425 rs7837631 chr8 23474426 A G 4.13E-05 Personality dimensions / / 22628180 rs11986046 chr8 23478809 A G 4.35E-05 Personality dimensions / / 22628180 rs7003364 chr8 23482464 C T 1.24E-04 White matter integrity / / 22425255 rs11135762 chr8 23491191 G A 1.32E-07 Prostate cancer / / 22923026 rs1398240 chr8 23501606 C A 9.64E-08 Prostate cancer / / 22923026 rs4872171 chr8 23514289 A G 2.46E-07 Prostate cancer / / 22923026 rs4872172 chr8 23514343 T A,C,G 1.22E-07 Prostate cancer / / 22923026 rs1512268 chr8 23526463 T C 3.00E-30 Prostate cancer / / 19767753 rs1512268 chr8 23526463 T C 3.00E-30 Nasopharyngeal carcinoma / / 20512145 rs1512268 chr8 23526463 T C 4.00E-11 Prostate cancer / / 20676098 rs1512268 chr8 23526463 T C 5.00E-06 Prostate cancer / / 22923026 rs1512268 chr8 23526463 T C 0.00000024 Prostate cancer / / 23555315 rs1512268 chr8 23526463 T C 0.00000076 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs1512268 chr8 23526463 T C 1.20E-04 Prostate cancer (early onset) / / 24740154 rs10503734 chr8 23528230 T C 4.36E-05 Job-related exhaustion / / 23620144 rs10503733 chr8 23534018 G T 1.79E-05 Bone mass and geometry / / 17903296 rs10503733 chr8 23534018 G T 8.00E-08 Prostate cancer / / 22923026 rs1866347 chr8 23547510 G A 9.82E-05 LDL lipoproteins / / pha002902 rs4469464 chr8 23551651 G A 4.37E-04 Type 2 diabetes / / 17463246 rs4872179 chr8 23551904 T C 1.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs9632856 chr8 23552102 A G 1.11E-04 Type 2 diabetes / / 17463246 rs13273510 chr8 23552997 T C 1.77E-04 Multiple complex diseases / / 17554300 rs7834389 chr8 23565878 T G 7.23E-05 Post-operative nausea and vomiting NKX2-6 nearGene-5 21694509 rs4430099 chr8 23574813 G C 5.35E-04 Parkinson's disease / / 16252231 rs13273073 chr8 23584226 G T 7.00E-06 Treatment response for severe sepsis / / 22310353 rs11992320 chr8 23590047 T C 1.63E-04 Type 2 diabetes / / 17463246 rs6998928 chr8 23593988 C T 5.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs443535 chr8 23603029 C T 1.34E-04 Multiple complex diseases / / 17554300 rs443535 chr8 23603029 C T 0.0000471 Colorectal adenoma (excluding hyperplasic) / / 23677573 rs443535 chr8 23603029 C T 0.0000471 Colorectal adenoma (including hyperplasic) / / 23677573 rs568890 chr8 23604431 C G 1.19E-04 Multiple complex diseases / / 17554300 rs412403 chr8 23604730 A G 2.59E-04 Multiple complex diseases / / 17554300 rs10866835 chr8 23607733 T C 3.75E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1561105 chr8 23610799 T G 2.20E-06 Psoriasis / / 19169255 rs1561105 chr8 23610799 T G 9.40E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs11985119 chr8 23612138 C T 8.02E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs310286 chr8 23612779 T G 5.04E-04 Acute lung injury / / 22295056 rs17089603 chr8 23612956 A G 4.64E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs192841 chr8 23625062 A G 1.68E-05 Body Mass Index / / pha003009 rs1972844 chr8 23629252 C T 4.86E-05 Post-operative nausea and vomiting / / 21694509 rs13272072 chr8 23633291 C T 9.87E-06 Response to mTOR inhibitor (everolimus) / / 24009623 rs218869 chr8 23636281 T A 4.00E-06 Response to mTOR inhibitor (everolimus) / / 24009623 rs310272 chr8 23643489 C G 6.00E-06 Preschool internalizing problems / / 24839885 rs167456 chr8 23649551 G A 1.01E-05 Coronary heart disease / / pha003033 rs310324 chr8 23685395 A G 5.68E-05 Coronary heart disease / / pha003033 rs310318 chr8 23689919 G T 1.38E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17784945 chr8 23691273 A G 5.50E-04 Alcohol dependence / / 20201924 rs10104396 chr8 23697412 C T 6.64E-04 Insulin resistance / / 21901158 rs11135775 chr8 23702603 C T 9.33E-04 Acute lung injury STC1 intron 22295056 rs7010237 chr8 23702685 G A 7.12E-05 Coronary heart disease STC1 intron pha003033 rs1369836 chr8 23714122 A G 6.02E-05 Cognitive performance STC1 nearGene-5 19734545 rs11785244 chr8 23732250 C T 5.67E-06 Multiple complex diseases / / 17554300 rs819194 chr8 23741712 C T 9.43E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs10109414 chr8 23751151 C T 1.00E-08 Chronic kidney disease / / 20383146 rs10109414 chr8 23751151 C T 2.08E-09 Chronic kidney disease / / 22479191 rs10109414 chr8 23751151 C T 2.40E-04 Glomerular filtration rate / / 23535967 rs10103918 chr8 23762005 C T 3.50E-06 Left ventricular mass / / 21212386 rs17786744 chr8 23777006 A G 1.00E-08 Urate levels / / 23263486 rs1631550 chr8 23786381 A G 8.87E-06 Multiple complex diseases / / 17554300 rs4872206 chr8 23787739 G A 3.44E-04 Type 2 diabetes / / 17463246 rs7833268 chr8 23818687 G C 6.00E-07 Subcutaneous adipose tissue / / 22589738 rs2141560 chr8 23866772 C T 9.09E-04 Acute lung injury / / 22295056 rs41318948 chr8 23972838 A G 3.39E-04 Multiple complex diseases / / 17554300 rs11777116 chr8 24044301 C T 5.36E-05 Migraine with aura / / 23793025 rs11777116 chr8 24044301 C T 6.00E-08 Migraine - clinic-based / / 23793025 rs2013265 chr8 24092500 C T 6.90E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2013265 chr8 24092500 C T 4.38E-05 Coronary heart disease / / pha003033 rs6993052 chr8 24094893 G A 9.91E-04 Alzheimer's disease / / 22005930 rs6989000 chr8 24101897 T C 6.47E-04 Alzheimer's disease / / 22005930 rs11995495 chr8 24104749 G C 9.50E-04 Alzheimer's disease / / 22005930 rs983977 chr8 24105267 T C 6.95E-04 White matter integrity / / 22425255 rs17051757 chr8 24108980 A G 2.70E-05 Urinary metabolites / / 21572414 rs11135784 chr8 24109907 A G 2.10E-05 Urinary metabolites / / 21572414 rs11135786 chr8 24110203 G C 7.89E-04 Alzheimer's disease / / 22005930 rs17088190 chr8 24111330 C T 2.57E-04 Alzheimer's disease / / 22005930 rs1013208 chr8 24116127 G C 2.53E-04 Alzheimer's disease / / 22005930 rs1013209 chr8 24116304 C T 2.00E-09 Height / / 20881960 rs1013209 chr8 24116304 C T 2.34E-04 Alzheimer's disease / / 22005930 rs1013210 chr8 24116722 G A 2.34E-04 Alzheimer's disease / / 22005930 rs1877217 chr8 24117358 G C 6.35E-04 Alzheimer's disease / / 22005930 rs4872218 chr8 24118642 C T 1.78E-04 Alzheimer's disease / / 22005930 rs7010251 chr8 24120750 C T 4.77E-04 Alzheimer's disease / / 22005930 rs6991946 chr8 24120814 A C 6.07E-04 Alzheimer's disease / / 22005930 rs12542304 chr8 24143011 C T 6.62E-04 Alzheimer's disease / / 22005930 rs6557727 chr8 24143829 C T 6.56E-04 Alzheimer's disease / / 22005930 rs12677577 chr8 24157147 C T 6.25E-06 Post-operative nausea and vomiting ADAM28 intron 21694509 rs17051863 chr8 24188263 A C 6.44E-05 Coronary heart disease ADAM28 intron pha003033 rs7018020 chr8 24198514 G A 3.58E-05 Post-operative nausea and vomiting ADAM28 intron 21694509 rs7012077 chr8 24282721 A G 6.01E-05 Attention deficit hyperactivity disorder / / 23728934 rs1492422 chr8 24297413 T C 3.27E-05 Lipid traits / / 24023261 rs11781622 chr8 24378741 G A 3.00E-06 White matter integrity / / 23218918 rs13253754 chr8 24390118 C T 3.99E-04 Type 2 diabetes / / 17463246 rs6557751 chr8 24403455 T C 5.73E-04 Multiple complex diseases / / 17554300 rs17052270 chr8 24477725 T G 1.55E-04 Multiple complex diseases / / 17554300 rs4344084 chr8 24532644 A C 2.60E-05 Urinary metabolites / / 21572414 rs10091460 chr8 24534278 T C 0.000000001 Brain microstructure and intellectual performance / / 22723713 rs10088359 chr8 24536448 G T 8.00E-10 Brain microstructure and intellectual performance / / 22723713 rs11135816 chr8 24548070 A G 8.00E-10 Brain microstructure and intellectual performance / / 22723713 rs4872253 chr8 24551492 G A 9.96E-05 Lung adenocarcinoma / / 19836008 rs11781277 chr8 24556926 A G 1.27E-04 Type 2 diabetes / / 17463246 rs4377969 chr8 24562232 T C 1.40E-06 Urinary metabolites / / 21572414 rs11135818 chr8 24564264 T C 3.00E-06 Urinary metabolites / / 21572414 rs11783712 chr8 24580756 G A 8.84E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17751246 chr8 24586812 C G 7.40E-05 Serum metabolites / / 19043545 rs11990537 chr8 24589078 C G 8.44E-04 Type 2 diabetes / / 17463246 rs7844580 chr8 24589592 T G 9.12E-04 Type 2 diabetes / / 17463246 rs4242415 chr8 24597176 G A 3.11E-04 Type 2 diabetes / / 17463246 rs13278742 chr8 24601467 T A 5.40E-06 Urinary metabolites / / 21572414 rs1824190 chr8 24604793 A C 2.49E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs12680982 chr8 24624709 C T 0.00000003 Brain microstructure and intellectual performance / / 22723713 rs4872262 chr8 24625718 G A 6.24E-06 Common variable immunodeficiency / / 21497890 rs4872262 chr8 24625718 G A 0.00000003 Brain microstructure and intellectual performance / / 22723713 rs958036 chr8 24663097 A G 3.58E-05 Odorant perception / / 23910658 rs1016446 chr8 24677490 A G 9.14E-05 Major depressive disorder (broad) / / 20038947 rs926105 chr8 24720502 G A 0.00033 Coronary artery calcification / / 23727086 rs442641 chr8 24720883 T G 5.62E-04 Smoking cessation / / 24665060 rs7844382 chr8 24729914 T C 2.43E-05 Psoriasis / / 18364390 rs2925773 chr8 24741725 G A 3.17E-04 Multiple complex diseases / / 17554300 rs2925774 chr8 24741839 G A 3.32E-04 Multiple complex diseases / / 17554300 rs1457266 chr8 24769852 A G 1 Drug response to Risperidone NEFM nearGene-5 16734940 rs1457266 chr8 24769852 A G 2.90E-05 Major depressive disorder NEFM nearGene-5 19065144 rs1457266 chr8 24769852 A G 4.27E-05 Major depressive disorder NEFM nearGene-5 pha002850 rs1379357 chr8 24781579 G C 1 Drug response to Risperidone / / 16734940 rs196854 chr8 24783980 C T 1.86E-07 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs196833 chr8 24792758 C A 1.40E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs196826 chr8 24794276 G A,C,T 1.40E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs196822 chr8 24794560 T C 1.80E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs6557786 chr8 24799742 G A 5.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy) / / 24554482 rs11779795 chr8 24838662 T G 5.49E-04 Stroke (pediatric) / / 22990015 rs2950347 chr8 24862709 T G 5.28E-05 Alcohol and nictotine co-dependence / / 20158304 rs2976456 chr8 24869436 C T 2.67E-04 Alzheimer's disease (late onset) / / 21379329 rs17052988 chr8 24876277 G A 4.67E-04 Multiple complex diseases / / 17554300 rs34394753 chr8 24970163 C G 5.82E-04 Type 2 diabetes / / 17463246 rs2979831 chr8 24993705 G A 9.72E-04 Alzheimer's disease / / 17998437 rs6557819 chr8 25002551 T C 8.02E-05 Panic disorder / / 19165232 rs2979846 chr8 25009642 T G 3.48E-04 Alzheimer's disease / / 17998437 rs1405534 chr8 25010126 G C 0.00000899 Lumbar spine bone mineral density / / 22692763 rs1405534 chr8 25010126 G C 0.0000117 Lumbar spine bone mineral density (females) / / 22692763 rs6983609 chr8 25010505 A C 9.29E-05 Monocyte counts / / pha003089 rs17053182 chr8 25053938 C T 1.50E-05 Urinary metabolites DOCK5 intron 21572414 rs1510761 chr8 25076964 C G 8.68E-04 Multiple complex diseases DOCK5 intron 17554300 rs1606035 chr8 25112955 A G 8.58E-05 Response to mTOR inhibitor (everolimus) DOCK5 intron 24009623 rs12549196 chr8 25115730 A G 2.53E-05 AIDS DOCK5 intron 19754311 rs17053273 chr8 25123492 G A 7.41E-05 Response to mTOR inhibitor (everolimus) DOCK5 intron 24009623 rs11782634 chr8 25124350 G T 2.40E-04 Myocardial Infarction DOCK5 intron pha002873 rs2666172 chr8 25182969 C T 2.91E-05 Type 2 diabetes DOCK5 cds-synon 21799836 rs12542851 chr8 25188065 G A 2.50E-05 Urinary metabolites DOCK5 intron 21572414 rs2468896 chr8 25190752 G T 8.70E-06 Type 2 diabetes DOCK5 intron 21799836 rs2468896 chr8 25190752 G T 1.18E-04 Smoking initiation DOCK5 intron 24665060 rs13267838 chr8 25196710 G A,C,T 8.16E-05 Hypertension DOCK5 intron 19609347 rs17053426 chr8 25205538 C T 8.43E-04 Multiple complex diseases DOCK5 intron 17554300 rs7012335 chr8 25209144 A G 1.24E-05 Type 2 diabetes DOCK5 intron 21799836 rs2271110 chr8 25224745 T G 4.49E-04 Suicide attempts in bipolar disorder DOCK5 intron 21423239 rs925033 chr8 25225288 A G 4.43E-04 Suicide attempts in bipolar disorder DOCK5 intron 21423239 rs7840392 chr8 25225352 G A 4.42E-04 Suicide attempts in bipolar disorder DOCK5 intron 21423239 rs10103395 chr8 25226595 A G 5.06E-04 Suicide attempts in bipolar disorder DOCK5 intron 21423239 rs10106554 chr8 25226619 T C 3.68E-04 Suicide attempts in bipolar disorder DOCK5 intron 21423239 rs11135862 chr8 25226812 A C 4.86E-04 Suicide attempts in bipolar disorder DOCK5 intron 21423239 rs2048081 chr8 25227336 C G 6.55E-04 Suicide attempts in bipolar disorder DOCK5 intron 21423239 rs199635925 chr8 25228022 T TG 9.31E-04 Suicide attempts in bipolar disorder DOCK5 intron 21423239 rs2960176 chr8 25228022 T C 9.31E-04 Suicide attempts in bipolar disorder DOCK5 intron 21423239 rs2271108 chr8 25230168 C T 8.41E-04 Suicide attempts in bipolar disorder DOCK5 cds-synon 21423239 rs13276812 chr8 25230959 T C 9.18E-04 Suicide attempts in bipolar disorder DOCK5 intron 21423239 rs6993060 chr8 25231756 G A 9.44E-04 Suicide attempts in bipolar disorder DOCK5 intron 21423239 rs7812830 chr8 25232484 T C 8.08E-04 Suicide attempts in bipolar disorder DOCK5 intron 21423239 rs7813096 chr8 25232630 T C 8.20E-04 Suicide attempts in bipolar disorder DOCK5 intron 21423239 rs10105328 chr8 25232899 T C 8.82E-04 Suicide attempts in bipolar disorder DOCK5 intron 21423239 rs2709623 chr8 25235842 G A 9.83E-04 Suicide attempts in bipolar disorder DOCK5 intron 21423239 rs17053529 chr8 25238462 G A 8.95E-05 Cognitive performance DOCK5 intron 19734545 rs925031 chr8 25242876 G A 5.51E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DOCK5 intron 20877124 rs7005823 chr8 25255584 A G 7.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DOCK5 intron 20877124 rs17053800 chr8 25363628 A G 6.00E-04 Type 2 diabetes CDCA2 intron 17463246 rs17053891 chr8 25390280 T C 3.90E-04 Type 2 diabetes / / 17463246 rs2979742 chr8 25395597 T C 1.75E-05 Alopecia areata / / 22027810 rs7845279 chr8 25398570 A C 5.05E-04 Prostate cancer mortality / / 20978177 rs17053914 chr8 25400988 A G 5.60E-04 Type 2 diabetes / / 17463246 rs7832226 chr8 25407292 T C 2.64E-04 Type 2 diabetes / / 17463246 rs7812975 chr8 25455282 G A 6.01E-04 Myocardial Infarction / / pha002883 rs11135875 chr8 25477344 G A 1.10E-05 HIV-1 control / / 20041166 rs11135876 chr8 25477382 C T 4.47E-05 Job-related exhaustion / / 23620144 rs17054045 chr8 25484685 A G 8.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs10081452 chr8 25488542 G T 2.19E-04 Smoking cessation / / 24665060 rs1425739 chr8 25493423 T A 2.81E-04 Smoking cessation / / 24665060 rs4872336 chr8 25495087 C A 1.04E-04 Smoking cessation / / 24665060 rs2467728 chr8 25496597 G A 5.85E-04 Smoking cessation / / 24665060 rs17054131 chr8 25523455 C T 4.48E-04 Multiple complex diseases / / 17554300 rs2433084 chr8 25529047 C A 8.13E-04 Smoking cessation / / 24665060 rs17054141 chr8 25532328 T G 2.97E-04 Blood pressure / / 17255346 rs1025157 chr8 25536852 T C 2.70E-05 Blood pressure / / 17255346 rs4872343 chr8 25547166 A G 6.30E-04 Type 2 diabetes / / 17463246 rs6986695 chr8 25567088 G A 6.90E-06 Diabetic nephropathy / / 20347642 rs12547975 chr8 25630398 G A 4.14E-05 Schizophrenia / / 19571809 rs1035722 chr8 25633531 C T 3.89E-04 Schizophrenia / / 19197363 rs2278144 chr8 25634077 G A 2.24E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2278144 chr8 25634077 G A 3.94E-05 Obsessive-compulsive disorder / / 24821223 rs4872354 chr8 25639033 A T 5.99E-05 Diabetic nephropathy / / pha002864 rs7823561 chr8 25641764 A C 2.59E-04 Parkinson's disease / / 17052657 rs10096045 chr8 25642182 G A 3.00E-06 Urinary metabolites / / 21572414 rs7815749 chr8 25644561 G A 6.34E-04 Type 2 diabetes / / 17463246 rs10106174 chr8 25646179 A G 1.50E-05 Urinary metabolites / / 21572414 rs1978544 chr8 25648792 C T 1.68E-06 Substance dependence phenotypes / / 24832863 rs1978544 chr8 25648792 C T 2.04E-05 Blood Pressure / / pha003043 rs12679210 chr8 25653123 G A 7.59E-04 Type 2 diabetes / / 17463246 rs7010578 chr8 25654527 C T 1.80E-05 Urinary metabolites / / 21572414 rs28380736 chr8 25655470 G A 9.70E-06 Urinary metabolites / / 21572414 rs4073167 chr8 25705079 T G 7.70E-04 Type 2 diabetes and 6 quantitative traits EBF2 intron 17848626 rs17054476 chr8 25707103 C A 1.98E-04 Multiple complex diseases EBF2 intron 17554300 rs10503776 chr8 25709869 C T 3.80E-05 Obesity-related traits EBF2 intron 17903300 rs4131261 chr8 25732695 T C 7.00E-04 Type 2 diabetes and 6 quantitative traits EBF2 intron 17848626 rs11989071 chr8 25797627 C A 2.55E-05 Kawasaki disease EBF2 intron 22081228 rs4242426 chr8 25799079 G T 9.88E-06 Kawasaki disease EBF2 intron 22081228 rs1026976 chr8 25809524 A G 3.98E-05 Coronary heart disease EBF2 intron pha003056 rs11984569 chr8 25834968 G T 1.91E-04 Alcohol dependence EBF2 intron 20201924 rs901173 chr8 25836119 A G 4.97E-04 Response to taxane treatment (placlitaxel) EBF2 intron 23006423 rs4419819 chr8 25845515 G A 5.70E-04 Type 2 diabetes and 6 quantitative traits EBF2 intron 17848626 rs7006324 chr8 25846741 C T 6.25E-04 Multiple complex diseases EBF2 intron 17554300 rs4276697 chr8 25847271 C T 8.02E-04 Multiple complex diseases EBF2 intron 17554300 rs17818622 chr8 25888552 A G 5.02E-04 Type 2 diabetes EBF2 intron 17463246 rs11135910 chr8 25892142 C T 8.00E-11 Prostate cancer EBF2 intron 23535732 rs4872391 chr8 25914693 G A 6.87E-04 Type 2 diabetes / / 17463246 rs2200439 chr8 25917074 A G 7.07E-04 Type 2 diabetes / / 17463246 rs4872393 chr8 25917711 G A 1.90E-05 Osteoarthritis (knee and hip) / / 21177295 rs4872393 chr8 25917711 G A 7.18E-05 Osteoarthritis (knee and hip) / / 21177295 rs4872393 chr8 25917711 G A 8.18E-04 Osteoarthritis (knee and hip) / / 21177295 rs1485740 chr8 25918153 T A 6.92E-04 Type 2 diabetes / / 17463246 rs13269936 chr8 25938238 T G 3.65E-04 Acute lung injury / / 22295056 rs11787090 chr8 25952339 C T 9.40E-04 Tourette syndrome / / 22889924 rs11777227 chr8 25973828 G T 2.90E-05 Urinary metabolites / / 21572414 rs12675615 chr8 25980961 A G 2.90E-05 Urinary metabolites / / 21572414 rs17243549 chr8 26022075 G A 4.90E-04 Smoking initiation / / 24665060 rs2952017 chr8 26023492 C T 1.34E-04 Progressive supranuclear palsy / / 21685912 rs7822763 chr8 26024267 C T 1.47E-04 Progressive supranuclear palsy / / 21685912 rs2951976 chr8 26037078 T C 1.40E-04 Multiple complex diseases / / 17554300 rs11782690 chr8 26038663 T C 4.51E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4527882 chr8 26059846 C T 4.45E-04 Multiple complex diseases / / 17554300 rs4376504 chr8 26078324 A G 7.04E-04 Multiple complex diseases / / 17554300 rs17055069 chr8 26123579 C T 8.98E-04 Acute lung injury / / 22295056 rs7829309 chr8 26129295 G A 9.11E-05 Scoliosis / / 21216876 rs7838409 chr8 26187537 A G 7.35E-05 Hypertension PPP2R2A intron pha003042 rs6557912 chr8 26200338 G A 3.00E-05 Cognitive function PPP2R2A intron 24684796 rs17055142 chr8 26201601 C T 4.57E-05 Bipolar disorder,affective PPP2R2A intron 20528957 rs1594829 chr8 26206077 C T 4.00E-08 Height PPP2R2A intron 23563607 rs3808565 chr8 26227640 A G 2.81E-04 Alcohol dependence PPP2R2A intron 20201924 rs4871977 chr8 26280472 A G 0.0000084 Asthma (exacerbation) / / 23706709 rs12164179 chr8 26291436 A G 4.36E-05 Body mass index / / 19584900 rs12164179 chr8 26291436 A G 8.45E-05 Body mass index / / 19584900 rs11781866 chr8 26298209 T C 1.11E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs11781866 chr8 26298209 T C 8.16E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs4872440 chr8 26326894 T C 1.82E-05 Hemoglobin / / pha003098 rs328082 chr8 26327887 C G 0.0006311 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs328082 chr8 26327887 C G 6.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2585462 chr8 26329516 C T 4.13E-05 Insulin resistance / / 21901158 rs2585463 chr8 26330245 G A 7.40E-04 Parkinson's disease / / 17052657 rs4872441 chr8 26332723 A G 8.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs4872441 chr8 26332723 A G 5.39E-05 Hemoglobin / / pha003098 rs1978949 chr8 26339656 G A 1.96E-04 Sarcoidosis / / 19165924 rs328096 chr8 26340833 C T 4.05E-04 Insulin resistance / / 21901158 rs13258081 chr8 26360366 A G 5.00E-06 Lymphocyte counts / / 22286170 rs2233701 chr8 26365716 C T 6.57E-06 Hemoglobin PNMA2 missense pha003098 rs2233701 chr8 26365716 C T 3.37E-05 Erythrocyte counts PNMA2 missense pha003099 rs9886448 chr8 26369707 T C 5.13E-05 Hemoglobin PNMA2 intron pha003098 rs7826601 chr8 26410379 A C 8.49E-04 Multiple complex diseases DPYSL2 intron 17554300 rs7826601 chr8 26410379 A C 3.26E-05 Serum metabolites DPYSL2 intron 19043545 rs431217 chr8 26426579 G A 7.29E-05 Hemoglobin DPYSL2 intron pha003098 rs431217 chr8 26426579 G A 3.02E-05 Erythrocyte counts DPYSL2 intron pha003099 rs327236 chr8 26444116 C T 5.00E-04 Adverse response to radiation therapy DPYSL2 intron 23719583 rs327234 chr8 26444669 T C 5.30E-05 Iron levels DPYSL2 intron 21208937 rs327229 chr8 26462161 T C 3.64E-05 Height DPYSL2 intron 22021425 rs327229 chr8 26462161 T C 8.59E-05 ldl cholesterol DPYSL2 intron pha003076 rs13249543 chr8 26463344 A G 9.58E-04 Suicide attempts in bipolar disorder DPYSL2 intron 21423239 rs13249543 chr8 26463344 A G 1.07E-05 Post-operative nausea and vomiting DPYSL2 intron 21694509 rs7832234 chr8 26469638 A C 3.11E-04 Multiple complex diseases DPYSL2 intron 17554300 rs17055515 chr8 26471104 A G 8.49E-04 Multiple complex diseases DPYSL2 intron 17554300 rs327224 chr8 26483022 A G 2.44E-04 Response to cytidine analogues (gemcitabine) DPYSL2 intron 24483146 rs327227 chr8 26483478 G A 2.84E-04 Response to cytidine analogues (gemcitabine) DPYSL2 intron 24483146 rs327215 chr8 26492962 C T 2.17E-05 Response to cytidine analogues (gemcitabine) DPYSL2 intron 24483146 rs13271910 chr8 26497506 A G 9.62E-04 Multiple complex diseases DPYSL2 intron 17554300 rs4733048 chr8 26499089 C T 8.29E-04 Suicide attempts in bipolar disorder DPYSL2 intron 21041247 rs4076071 chr8 26503991 T C 7.82E-04 Suicide attempts in bipolar disorder DPYSL2 intron 21041247 rs7828056 chr8 26516038 A C 4.81E-04 Type 2 diabetes DPYSL2 nearGene-3 17463246 rs7842128 chr8 26518780 A G 9.76E-05 Cognitive impairment induced by topiramate / / 22091778 rs17055673 chr8 26524421 C T 6.10E-06 Urinary metabolites / / 21572414 rs11783368 chr8 26541693 A G 4.15E-04 Alzheimer's disease (late onset) / / 21379329 rs10503794 chr8 26556765 C T 6.70E-04 Heroin addiction / / 20520587 rs2028554 chr8 26571605 T G 2.90E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6994883 chr8 26575680 A G 5.70E-05 Major depressive disorder / / 21621269 rs6994883 chr8 26575680 A G 2.31E-04 Smoking quantity / / 24665060 rs11779314 chr8 26576125 C T 4.67E-05 Schizophrenia / / 19571809 rs11779314 chr8 26576125 C T 3.25E-05 Major depressive disorder / / 21621269 rs11779314 chr8 26576125 C T 8.66E-05 Smoking quantity / / 24665060 rs13278281 chr8 26577021 C T 2.92E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1000987 chr8 26579782 G T 2.77E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6557945 chr8 26581229 T G 5.15E-04 Smoking quantity / / 24665060 rs6993922 chr8 26584614 G A 6.18E-06 Breast cancer(er negative) / / 21062454 rs4732831 chr8 26585177 C T 2.10E-05 Urinary metabolites / / 21572414 rs1908650 chr8 26585613 T C 2.10E-05 Urinary metabolites / / 21572414 rs9314327 chr8 26603955 T C 1.22E-04 Tourette syndrome / / 22889924 rs1442341 chr8 26610427 T C 4.45E-04 Hemoglobin concentration ADRA1A intron 20534544 rs13277287 chr8 26628765 T C 4.89E-04 Alzheimer's disease (late onset) ADRA1A intron 21379329 rs2036108 chr8 26663100 C A,G,T 6.20E-04 Alzheimer's disease ADRA1A intron 17998437 rs7816340 chr8 26665587 C T 1.20E-06 Iron levels ADRA1A intron 21208937 rs7816340 chr8 26665587 C T 4.34E-05 Weight ADRA1A intron pha003026 rs7816340 chr8 26665587 C T 1.48E-05 Weight ADRA1A intron pha003027 rs4732897 chr8 26670795 C T 2.19E-04 Alzheimer's disease (late onset) ADRA1A intron 21379329 rs6987037 chr8 26676517 C T 7.05E-08 HDL cholesterol ADRA1A intron 23063622 rs4732900 chr8 26677655 T C 7.71E-04 Cocaine dependence ADRA1A intron 23958962 rs11781115 chr8 26681450 T G 3.04E-04 Alzheimer's disease ADRA1A intron 22005930 rs3102087 chr8 26699937 A C 4.15E-05 ldl cholesterol ADRA1A intron pha003076 rs10093667 chr8 26704875 G T 9.37E-05 Bleomycin sensitivity ADRA1A intron 21106707 rs558455 chr8 26705581 A G 1.12E-05 Triglycerides ADRA1A intron 19074352 rs558455 chr8 26705581 A G 1.12E-05 Polyunsaturated fatty acid levels,in plasma ADRA1A intron 19148276 rs13278849 chr8 26714874 G A 7.66E-06 Response to amphetamines ADRA1A intron 22952603 rs13278849 chr8 26714874 G A 3.00E-11 Blood metabolite levels ADRA1A intron 24816252 rs563097 chr8 26717123 A G 3.30E-05 Inflammatory demyelinating disease ADRA1A intron 19850125 rs34303150 chr8 26718363 A G 8.80E-06 Response to amphetamines ADRA1A intron 22952603 rs4732957 chr8 26718880 A C 7.00E-06 Response to amphetamines ADRA1A intron 22952603 rs17056112 chr8 26720515 G A 0.00033 Coronary artery calcification ADRA1A intron 23727086 rs562843 chr8 26727818 T G 3.10E-05 Coffee consumption / / 21357676 rs12677733 chr8 26777509 G A 2.33E-06 Gallstones / / 17632509 rs7825001 chr8 26814879 C T 2.70E-05 Urinary metabolites / / 21572414 rs10102438 chr8 26818256 G C 2.10E-05 Urinary metabolites / / 21572414 rs12547343 chr8 26833198 C A 5.38E-05 Obsessive-compulsive disorder / / 24821223 rs12547343 chr8 26833198 C A 5.38E-05 Obsessive-compulsive disorder / / 24821223 rs13280864 chr8 26835967 A T 3.77E-04 Bipolar disorder,schizoaffective / / 19567891 rs17430706 chr8 26838170 T C 8.09E-04 Smoking cessation / / 24665060 rs11135970 chr8 26863596 T C 1.60E-05 Urinary metabolites / / 21572414 rs4733006 chr8 26879078 T A 6.70E-06 Urinary metabolites / / 21572414 rs7841833 chr8 26886807 C G 3.50E-06 Urinary metabolites / / 21572414 rs7461897 chr8 26894544 A C 1.10E-06 Urinary metabolites / / 21572414 rs17056689 chr8 26894569 A G 3.28E-04 Tourette syndrome / / 22889924 rs7834392 chr8 26895432 T C 6.94E-04 Coronary heart disease / / 21606135 rs7818211 chr8 26907073 G A 9.60E-06 Urinary metabolites / / 21572414 rs10503808 chr8 26907907 G C 3.39E-04 Multiple complex diseases / / 17554300 rs10503808 chr8 26907907 G C 1.30E-05 Urinary metabolites / / 21572414 rs17060993 chr8 26922112 T A 2.00E-06 Musician's dystonia / / 24375517 rs12549849 chr8 26930402 G A 1.20E-05 Urinary metabolites / / 21572414 rs17056753 chr8 26942360 A G 2.30E-05 Urinary metabolites / / 21572414 rs17056753 chr8 26942360 A G 6.53E-04 Insulin resistance / / 21901158 rs17056757 chr8 26942639 T C 2.65E-04 Multiple complex diseases / / 17554300 rs17056757 chr8 26942639 T C 1.20E-05 Urinary metabolites / / 21572414 rs17056788 chr8 26962579 T C 2.49E-06 Bipolar disorder,affective / / 20528957 rs2322509 chr8 26996374 T C 4.91E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs10109159 chr8 26998447 T A 6.50E-06 Urinary metabolites / / 21572414 rs10094592 chr8 27069416 C T 2.20E-06 Urinary metabolites / / 21572414 rs10094592 chr8 27069416 C T 7.54E-04 Alzheimer's disease / / 22005930 rs7841213 chr8 27069943 G C 1.00E-04 Prostate cancer / / 21743057 rs1446684 chr8 27073268 A C 0.0000821 post-traumatic stress disorder / / 22869035 rs1446684 chr8 27073268 A C 8.21E-05 Schizophrenia / / 22883433 rs1446684 chr8 27073268 A C 1.03E-04 Tourette syndrome / / 22889924 rs1446682 chr8 27076598 T A 6.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs1446682 chr8 27076598 T A 3.17E-04 Insulin resistance / / 21901158 rs4733037 chr8 27093495 C T 2.10E-05 Urinary metabolites / / 21572414 rs4733037 chr8 27093495 C T 2.83E-04 Alzheimer's disease / / 22005930 rs7846477 chr8 27106633 C A 3.16E-05 Bipolar disorder and schizophrenia STMN4 intron 20889312 rs4733045 chr8 27124966 T C 3.00E-05 Prostate cancer / / 21743057 rs7832778 chr8 27125887 C T 9.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs957008 chr8 27134100 A C 5.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs12681837 chr8 27135971 G T 1.90E-05 Urinary metabolites / / 21572414 rs12681837 chr8 27135971 G T 5.23E-04 Insulin resistance / / 21901158 rs6997728 chr8 27140083 T A 1.30E-05 Urinary metabolites / / 21572414 rs4733047 chr8 27142157 G A 8.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs10098291 chr8 27143174 T A 9.13E-04 Suicide attempts in bipolar disorder TRIM35 UTR-3 21423239 rs12386801 chr8 27147716 A C 6.10E-04 Suicide attempts in bipolar disorder TRIM35 intron 21423239 rs7833348 chr8 27171486 T C 7.55E-05 Major depressive disorder PTK2B intron pha002850 rs28834970 chr8 27195121 T C 7.00E-14 Alzheimer's disease (late onset) PTK2B intron 24162737 rs4534095 chr8 27204598 A G 5.40E-07 Urinary metabolites PTK2B intron 21572414 rs10097651 chr8 27217763 C T 7.30E-07 Urinary metabolites PTK2B intron 21572414 rs755951 chr8 27226790 A C 5.93E-04 Tourette syndrome PTK2B intron 22889924 rs12679874 chr8 27230819 A G 9.34E-05 Tourette syndrome PTK2B intron 22889924 rs10106782 chr8 27235818 G A 1.10E-05 Urinary metabolites PTK2B intron 21572414 rs4732720 chr8 27237708 G A 4.98E-04 Tourette syndrome PTK2B intron 22889924 rs10086852 chr8 27238115 G C 2.50E-05 Urinary metabolites PTK2B intron 21572414 rs11783759 chr8 27245790 C T 2.42E-05 Lipoproteins PTK2B intron pha003079 rs7000615 chr8 27263433 G T 3.80E-05 Major depressive disorder PTK2B intron 21621269 rs725789 chr8 27265680 G C 8.44E-04 Multiple complex diseases PTK2B intron 17554300 rs11782673 chr8 27265887 A G 3.38E-05 Smoking behavior PTK2B intron 20418889 rs11782789 chr8 27266287 A T 9.15E-05 Smoking behavior PTK2B intron 20418889 rs11998069 chr8 27297575 G A 1.18E-04 Multiple complex diseases PTK2B intron 17554300 rs17057205 chr8 27307717 C A 8.40E-04 Multiple complex diseases PTK2B intron 17554300 rs751019 chr8 27308585 A C 6.36E-04 Tourette syndrome PTK2B missense 22889924 rs11778371 chr8 27319905 C T 8.10E-07 Asthma CHR/2 intron 19426955 rs11778371 chr8 27319905 C T 7.92E-07 Asthma CHR/2 intron 20698975 rs2472553 chr8 27328511 G A 6.22E-04 Atopy CHR/2 missense 21625490 rs2565067 chr8 27331119 A G 3.40E-04 Tourette syndrome CHR/2 intron 22889924 rs2741339 chr8 27334969 A G 4.09E-04 Lung function (forced vital capacity) CHR/2 intron 24023788 rs7017417 chr8 27345305 A G 8.02E-05 Type 2 diabetes and other traits / / 19734900 rs7846038 chr8 27362142 T C 1.20E-04 Response to antidepressants EPHX2 intron 19736353 rs2741334 chr8 27364787 T C 9.22E-05 Tourette syndrome EPHX2 intron 22889924 rs17057288 chr8 27367839 G A 1.43E-04 Multiple complex diseases EPHX2 intron 17554300 rs4149246 chr8 27383901 G T 1.95E-04 Height EPHX2 intron 17255346 rs4149253 chr8 27396208 G A 1.95E-04 Height EPHX2 cds-synon 17255346 rs2565050 chr8 27404354 T C 5.05E-05 Tourette syndrome / / 22889924 rs2741354 chr8 27415476 C T 6.10E-06 Lung adenocarcinoma / / 19836008 rs17057381 chr8 27416801 G A 4.00E-07 Dental caries / / 23259602 rs11776293 chr8 27418429 C T 6.48E-05 Schizophrenia / / 19571809 rs1532275 chr8 27424988 G A 3.44E-05 Self-reported allergy / / 23817569 rs6558008 chr8 27438306 A C 6.28E-04 Type 2 diabetes / / 17463246 rs7828131 chr8 27441010 T C 6.84E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7012010 chr8 27448729 T C 5.03E-05 Orofacial clefts / / 20023658 rs17466684 chr8 27452847 G A 7.00E-07 Panic disorder / / 19165232 rs2279591 chr8 27453763 C T 1.64E-04 Nicotine smoking / / 19268276 rs3087554 chr8 27455442 T C 1.00E-04 Alzheimer's disease (late onset) CLU UTR-3 21460841 rs2279590 chr8 27456253 T C 6.00E-10 Alzheimer's disease CLU intron 19734903 rs2279590 chr8 27456253 T C 4.11E-05 Alzheimer's disease (late onset) CLU intron 21460841 rs11136000 chr8 27464519 T C 1.42E-09 Type 2 diabetes and other traits CLU intron 19734900 rs11136000 chr8 27464519 T C 9.00E-10 Alzheimer's disease CLU intron 19734902 rs11136000 chr8 27464519 T C 6.00E-10 Alzheimer's disease CLU intron 19734903 rs11136000 chr8 27464519 T C 1.42E-09 Alzheimer's disease (late onset) CLU intron 21460841 rs11136000 chr8 27464519 T C 1.40E-09 Prion diseases CLU intron 22210626 rs11136000 chr8 27464519 T C 8.65E-04 Alzheimer's disease CLU intron 24755620 rs11136000 chr8 27464519 T C 3.50E-04 Heart Failure CLU intron pha002885 rs1532278 chr8 27466315 T C 8.00E-08 Alzheimer's disease (late onset) CLU intron 21460841 rs9331896 chr8 27467686 C T 3.00E-25 Alzheimer's disease (late onset) CLU intron 24162737 rs9331888 chr8 27468862 C G 6.00E-10 Alzheimer's disease CLU intron 19734903 rs9331888 chr8 27468862 C G 1.20E-06 Alzheimer's disease (late onset) CLU intron 21460841 rs538181 chr8 27476815 G A 3.55E-05 Height / / 22021425 rs2582367 chr8 27480025 C T 2.11E-07 Type 2 diabetes and other traits / / 19734900 rs2582367 chr8 27480025 C T 2.11E-07 Alzheimer's disease (late onset) / / 21460841 rs569214 chr8 27487790 G T 1.31E-05 Type 2 diabetes and other traits / / 19734900 rs569214 chr8 27487790 G T 4.00E-08 Alzheimer's disease / / 21627779 rs12542107 chr8 27500427 G A 7.42E-04 Coronary heart disease SCARA3 intron 21971053 rs12677898 chr8 27512786 A G 7.99E-04 Alcohol dependence SCARA3 intron 21314694 rs2640732 chr8 27517821 T G 8.27E-05 Smoking behavior SCARA3 intron 20418889 rs35495833 chr8 27522576 C CG 8.66E-05 Smoking behavior SCARA3 intron 20418889 rs505295 chr8 27522576 C A 8.66E-05 Smoking behavior SCARA3 intron 20418889 rs1036710 chr8 27530475 C T 3.25E-05 Left ventricular hypertrophy SCARA3 UTR-3 pha003052 rs559251 chr8 27539370 T C 1.17E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs17384485 chr8 27560651 C T 8.32E-05 Cholesterol / / pha003073 rs17384485 chr8 27560651 C T 6.70E-05 Cholesterol / / pha003078 rs17469423 chr8 27564087 G A 1.36E-05 Cholesterol / / pha003073 rs17469423 chr8 27564087 G A 5.29E-06 Cholesterol / / pha003078 rs17469423 chr8 27564087 G A 6.45E-05 Triglycerides / / pha003080 rs4352802 chr8 27582825 T C 6.60E-05 Temperament (bipolar disorder) / / 22365631 rs17469886 chr8 27583328 C A 3.52E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs13282289 chr8 27586201 A G 6.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs898476 chr8 27590224 A G 7.00E-05 Temperament (bipolar disorder) / / 22365631 rs7833799 chr8 27590575 T G 4.70E-05 Temperament (bipolar disorder) / / 22365631 rs1048887 chr8 27593150 G A 7.60E-05 Temperament (bipolar disorder) CCDC25 UTR-3 22365631 rs7016934 chr8 27604755 T C 9.60E-05 Temperament (bipolar disorder) CCDC25 intron 22365631 rs2280884 chr8 27614138 A G 6.60E-05 Temperament (bipolar disorder) CCDC25 intron 22365631 rs13262948 chr8 27625201 G A 5.52E-05 Lymphocyte counts CCDC25 intron 22286170 rs1052873 chr8 27667793 C T 6.68E-04 Suicide attempts in bipolar disorder PBK UTR-3 21041247 rs11136015 chr8 27702453 T C 9.94E-05 Prostate cancer / / 22923026 rs4732776 chr8 27711673 T C 4.36E-05 Prostate cancer / / 22923026 rs7823922 chr8 27716308 C T 3.62E-05 Prostate cancer / / 22923026 rs7003622 chr8 27736630 T C 9.03E-08 Metabolite levels SCARA5 intron 23281178 rs6999359 chr8 27740066 G A 1.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) SCARA5 intron 23648065 rs11774576 chr8 27740417 C T 3.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) SCARA5 intron 23648065 rs11774576 chr8 27740417 C T 4.65E-05 Odorant perception SCARA5 intron 23910658 rs10103507 chr8 27740693 A G 4.45E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) SCARA5 intron 23648065 rs2726971 chr8 27754785 C T 3.21E-10 Metabolite levels SCARA5 intron 23281178 rs2726972 chr8 27754827 C T 3.81E-10 Metabolite levels SCARA5 intron 23281178 rs17058204 chr8 27767066 G A 7.15E-05 Premature ovarian failure SCARA5 intron 19508998 rs17058204 chr8 27767066 G A 7.15E-05 Other erythrocyte phenotypes SCARA5 intron 19862010 rs4732788 chr8 27779968 T C 2.90E-05 Temperament (bipolar disorder) SCARA5 intron 22365631 rs11136019 chr8 27781598 C T 2.60E-05 Temperament (bipolar disorder) SCARA5 intron 22365631 rs2685309 chr8 27796020 G C 6.98E-04 Alzheimer's disease SCARA5 intron 17998437 rs7816579 chr8 27805815 A G 8.47E-04 Response to cytidine analogues (gemcitabine) SCARA5 intron 24483146 rs2685419 chr8 27806407 G A 2.33E-04 Response to cytidine analogues (gemcitabine) SCARA5 intron 24483146 rs2726934 chr8 27826902 T C 2.94E-05 Serum metabolites SCARA5 intron 19043545 rs2727006 chr8 27832166 A G 5.12E-05 Serum metabolites SCARA5 intron 19043545 rs13268221 chr8 27877350 C T 8.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs1377337 chr8 27877588 G A 8.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs7459596 chr8 27879537 C T 1.91E-04 Taste perception C8orf80 UTR-3 22132133 rs10046724 chr8 27880155 G A 2.94E-04 Taste perception C8orf80 UTR-3 22132133 rs921597 chr8 27880826 C T 2.19E-04 Taste perception C8orf80 UTR-3 22132133 rs4433104 chr8 27884134 A G 4.51E-04 Suicide attempts in bipolar disorder C8orf80 intron 21423239 rs11993800 chr8 27885843 A G 3.51E-04 Suicide attempts in bipolar disorder C8orf80 intron 21423239 rs17485781 chr8 27887562 C A 0.0000371 Coronary artery disease C8orf80 intron 23202125 rs6983473 chr8 27905888 A T 4.00E-06 Cardiac Troponin-T levels C8orf80 intron 23247143 rs4732812 chr8 27923388 C T 3.00E-06 Suicidal ideation C8orf80 intron 20877300 rs17058568 chr8 27931238 G A 2.58E-04 Multiple complex diseases C8orf80 intron 17554300 rs17058573 chr8 27931751 C T 5.30E-04 Multiple complex diseases C8orf80 intron 17554300 rs1377338 chr8 27946373 T G 4.47E-05 Serum metabolites / / 19043545 rs4732828 chr8 27994241 T G 9.31E-05 Sensory disturbances after bilateral sagittal split ramus osteotomy ELP3 intron 23834954 rs2015443 chr8 28022926 C T 3.58E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ELP3 intron 20031582 rs4732838 chr8 28042187 A G 1.68E-05 Schizophrenia ELP3 intron 19571809 rs4732838 chr8 28042187 A G 4.66E-05 Schizophrenia ELP3 intron pha002859 rs13268953 chr8 28055236 G A 8.89E-05 Blood Pressure / / pha003049 rs7840565 chr8 28060783 G A 2.23E-04 Acute lung injury / / 22295056 rs7840565 chr8 28060783 G A 9.98E-05 Waist Circumference / / pha003023 rs10866872 chr8 28065022 C G 1.71E-04 Multiple complex diseases / / 17554300 rs12543257 chr8 28069928 A C 5.50E-05 Asthma / / pha003127 rs6985192 chr8 28076422 T C 7.19E-04 Schizophrenia / / 19197363 rs7813471 chr8 28124898 T C 2.21E-04 Multiple complex diseases / / 17554300 rs7016687 chr8 28125483 A C 2.35E-05 Multiple complex diseases / / 17554300 rs1993736 chr8 28125616 T C 2.91E-04 Multiple complex diseases / / 17554300 rs13263030 chr8 28151145 C T 7.67E-04 Multiple complex diseases / / 17554300 rs13263030 chr8 28151145 C T 6.86E-05 Cholesterol / / pha003073 rs13263030 chr8 28151145 C T 4.02E-05 Cholesterol / / pha003078 rs2926827 chr8 28154205 G T 3.54E-04 Age-related macular degeneration / / 22125219 rs11779594 chr8 28181755 C T 9.00E-06 IgG glycosylation PNOC intron 23382691 rs2614091 chr8 28183219 G C 6.41E-04 Multiple complex diseases PNOC intron 17554300 rs2614100 chr8 28186446 A G 8.13E-04 Multiple complex diseases PNOC intron 17554300 rs2645722 chr8 28186474 A C 7.42E-04 Multiple complex diseases PNOC intron 17554300 rs2645717 chr8 28193963 G A 7.74E-04 Multiple complex diseases PNOC intron 17554300 rs3735736 chr8 28194097 G A 3.06E-04 Lung function (forced expiratory volume in 1 second) PNOC intron 24023788 rs3735736 chr8 28194097 G A 5.23E-05 Lung function (forced vital capacity) PNOC intron 24023788 rs351787 chr8 28195525 C A 6.69E-04 Multiple complex diseases PNOC intron 17554300 rs351784 chr8 28197747 G C 4.10E-05 Hematology traits PNOC intron 23303382 rs17059018 chr8 28216592 T C 6.46E-05 Cognitive impairment induced by topiramate ZNF395 intron 22091778 rs17059020 chr8 28217976 C T 2.40E-05 Urinary metabolites ZNF395 intron 21572414 rs3735730 chr8 28227332 A G 1.00E-05 Urinary metabolites ZNF395 intron 21572414 rs12056907 chr8 28240092 C A 6.82E-05 Post-operative nausea and vomiting ZNF395 intron 21694509 rs12056907 chr8 28240092 C A 1.00E-04 Oral cancers (chewing tobacco related) ZNF395 intron 22503698 rs2007972 chr8 28282925 G C 1.60E-05 Urinary metabolites / / 21572414 rs17059084 chr8 28291883 T C 9.95E-06 Amyotrophic lateral sclerosis (sporadic) FBXO16 intron 24529757 rs6992329 chr8 28325411 G A 3.32E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FBXO16 intron 24023788 rs3922392 chr8 28343234 C T 7.54E-04 Multiple complex diseases FBXO16 intron 17554300 rs6997072 chr8 28359611 G A 1.60E-04 Brain structure FZD3 intron 22504417 rs7842884 chr8 28362459 C T 1.27E-04 Brain structure FZD3 intron 22504417 rs7833751 chr8 28362792 T G 5.50E-05 Serum metabolites FZD3 intron 19043545 rs7833751 chr8 28362792 T G 8.56E-05 Brain structure FZD3 intron 22504417 rs7833751 chr8 28362792 T G 7.50E-09 Paclitaxel-induced sensory peripheral neuropathy FZD3 intron 22843789 rs7001034 chr8 28363378 A G 9.80E-05 Brain structure FZD3 intron 22504417 rs7001034 chr8 28363378 A G 3.10E-09 Paclitaxel-induced sensory peripheral neuropathy FZD3 intron 22843789 rs6984655 chr8 28369097 C T 1.62E-04 Brain structure FZD3 intron 22504417 rs2874941 chr8 28373348 G T 1.47E-05 Serum metabolites FZD3 intron 19043545 rs2874941 chr8 28373348 G T 2.27E-04 Brain structure FZD3 intron 22504417 rs2241802 chr8 28384712 A G 2.34E-04 Brain structure FZD3 cds-synon 22504417 rs352203 chr8 28394701 C T 2.84E-05 Serum metabolites FZD3 intron 19043545 rs352203 chr8 28394701 C T 2.08E-04 Brain structure FZD3 intron 22504417 rs11783087 chr8 28404027 G A 1.57E-04 Brain structure FZD3 intron 22504417 rs10092491 chr8 28411072 T C 1.78E-04 Brain structure FZD3 intron 22504417 rs13260884 chr8 28415829 T C 2.72E-05 Serum metabolites FZD3 intron 19043545 rs13260884 chr8 28415829 T C 1.58E-04 Brain structure FZD3 intron 22504417 rs6980605 chr8 28416551 G A 1.19E-04 Brain structure FZD3 intron 22504417 rs352222 chr8 28421781 A C 8.44E-06 Serum metabolites FZD3 UTR-3 19043545 rs352222 chr8 28421781 A C 7.57E-05 Brain structure FZD3 UTR-3 22504417 rs352217 chr8 28426263 G A 1.25E-04 Brain structure FZD3 UTR-3 22504417 rs4415271 chr8 28426419 A G 1.13E-04 Brain structure FZD3 UTR-3 22504417 rs352214 chr8 28434641 C G 6.21E-05 Brain structure / / 22504417 rs352213 chr8 28435030 C T 7.00E-04 Type 2 diabetes / / 17463246 rs11779401 chr8 28435668 G A 3.14E-05 Serum metabolites / / 19043545 rs11779401 chr8 28435668 G A 1.30E-04 Brain structure / / 22504417 rs17059209 chr8 28439942 G A 6.93E-08 Type 2 diabetes / / 17463246 rs352199 chr8 28441331 G A 5.17E-06 Serum metabolites / / 19043545 rs352199 chr8 28441331 G A 1.83E-04 Brain structure / / 22504417 rs164658 chr8 28441566 G A 8.00E-06 Serum metabolites / / 19043545 rs164658 chr8 28441566 G A 1.07E-05 Brain structure / / 22504417 rs17440025 chr8 28442098 A G 1.02E-05 Brain structure / / 22504417 rs17440102 chr8 28444787 G A 3.42E-05 Brain structure / / 22504417 rs12056676 chr8 28451539 A C 7.19E-06 Brain structure / / 22504417 rs2028486 chr8 28459468 G A 3.63E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6985395 chr8 28487460 C A 3.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7009699 chr8 28488086 A C 4.02E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs189517 chr8 28520558 A G 8.61E-06 Coronary arterial lesions in patients with Kawasaki disease / / 23677057 rs240919 chr8 28531939 T C 2.25E-05 Autism / / 24189344 rs240920 chr8 28535241 T C 7.80E-04 Aortic root size / / 21223598 rs7015836 chr8 28593399 C T 2.91E-04 Body mass index EXTL3 intron 21701565 rs241175 chr8 28628420 A G 2.54E-15 Lymphocyte counts INTS9 intron 22286170 rs241202 chr8 28633685 C G 3.20E-05 Schizophrenia(treatment response to risperidone) INTS9 intron 19850283 rs241192 chr8 28641187 G A 7.81E-04 Premature ovarian failure INTS9 intron 19508998 rs17059413 chr8 28642222 G A 6.72E-04 Multiple complex diseases INTS9 intron 17554300 rs6558079 chr8 28642471 C T 5.15E-04 Multiple complex diseases INTS9 intron 17554300 rs171313 chr8 28643722 T C 1.60E-05 Urinary metabolites INTS9 intron 21572414 rs241187 chr8 28645271 C T 5.40E-06 Urinary metabolites INTS9 intron 21572414 rs17522554 chr8 28651801 G A 9.45E-05 Obesity (extreme) INTS9 intron 21935397 rs17059456 chr8 28655931 C T 3.35E-04 Multiple complex diseases INTS9 intron 17554300 rs17059487 chr8 28679096 C A 5.64E-05 Alzheimer's disease (late onset) INTS9 intron 21379329 rs10866874 chr8 28694244 T C 1.50E-05 Urinary metabolites INTS9 intron 21572414 rs907133 chr8 28694549 C T 8.51E-04 Response to taxane treatment (placlitaxel) INTS9 intron 23006423 rs10096475 chr8 28698588 C T 1.02E-04 Cholesterol INTS9 intron 17255346 rs7839852 chr8 28706065 T C 8.28E-05 Bipolar disorder INTS9 intron 19259986 rs17451343 chr8 28706275 C T 1.02E-04 Obesity (extreme) INTS9 intron 21935397 rs11786316 chr8 28718830 C A 7.15E-05 Obesity (extreme) INTS9 intron 21935397 rs10503833 chr8 28719284 T G 6.97E-05 Obesity (extreme) INTS9 intron 21935397 rs17523818 chr8 28727042 A G 7.01E-05 Obesity (extreme) INTS9 intron 21935397 rs12547794 chr8 28741584 T G 6.48E-04 Obesity (extreme) INTS9 intron 21935397 rs11782284 chr8 28746324 A G 5.07E-04 Multiple complex diseases INTS9 intron 17554300 rs7009478 chr8 28753368 T C 8.40E-04 Multiple complex diseases HMBOX1 intron 17554300 rs7009478 chr8 28753368 T C 3.50E-06 Urinary metabolites HMBOX1 intron 21572414 rs7009478 chr8 28753368 T C 4.49E-04 Lymphocyte counts HMBOX1 intron 22286170 rs13280242 chr8 28756738 G A 6.93E-06 Obesity-related traits HMBOX1 intron 23251661 rs1512851 chr8 28770472 G T 3.87E-04 Obesity (extreme) HMBOX1 intron 21935397 rs7843057 chr8 28776909 T C 1.28E-04 Multiple complex diseases HMBOX1 intron 17554300 rs7843057 chr8 28776909 T C 3.50E-06 Urinary metabolites HMBOX1 intron 21572414 rs17524494 chr8 28779203 A C 3.93E-04 Obesity (extreme) HMBOX1 intron 21935397 rs11784622 chr8 28782519 C T 3.94E-04 Obesity (extreme) HMBOX1 intron 21935397 rs2221894 chr8 28791159 G A 6.00E-06 Obesity-related traits HMBOX1 intron 23251661 rs4732893 chr8 28794678 C T 5.39E-05 Serum metabolites HMBOX1 intron 19043545 rs17524918 chr8 28805908 G A 3.89E-04 Obesity (extreme) HMBOX1 intron 21935397 rs11778263 chr8 28825422 C G 3.84E-04 Obesity (extreme) HMBOX1 intron 21935397 rs17525359 chr8 28829417 C A 3.67E-04 Obesity (extreme) HMBOX1 intron 21935397 rs1487969 chr8 28885661 T C 4.86E-05 Serum metabolites HMBOX1 intron 19043545 rs6558089 chr8 28894237 C T 5.98E-05 Serum metabolites HMBOX1 intron 19043545 rs936921 chr8 28912907 C A 6.14E-05 Cholesterol / / 17255346 rs11136057 chr8 28922727 A G 2.14E-05 Waist-Hip Ratio / / pha003013 rs11136057 chr8 28922727 A G 5.44E-05 Waist-Hip Ratio / / pha003028 rs936920 chr8 28923898 T C 5.88E-05 Cholesterol / / 17255346 rs2693 chr8 28924858 C T 2.97E-05 Serum metabolites KIF13B UTR-3 19043545 rs17454230 chr8 28926081 G T 3.53E-04 Obesity (extreme) KIF13B UTR-3 21935397 rs4732901 chr8 28931379 G A,T 6.59E-04 Amyotrophic Lateral Sclerosis KIF13B intron 17827064 rs17526904 chr8 28947843 C T 3.31E-04 Obesity (extreme) KIF13B intron 21935397 rs7844537 chr8 28954892 T G 6.00E-06 Metabolite levels (X-11787) KIF13B intron 23934736 rs3816826 chr8 28967877 T C 1.70E-05 Urinary metabolites KIF13B intron 21572414 rs936922 chr8 28975073 C T 1.38E-04 Lung function (forced vital capacity) KIF13B intron 24023788 rs3750263 chr8 28981063 T G 9.92E-04 Response to taxane treatment (placlitaxel) KIF13B intron 23006423 rs3763566 chr8 28984572 G A 8.91E-05 Post-operative nausea and vomiting KIF13B intron 21694509 rs11786712 chr8 28984960 C T 6.16E-05 Waist-Hip Ratio KIF13B intron pha003029 rs13251954 chr8 28995022 A G,T 2.00E-06 Metabolite levels (HVA-5-HIAA Factor score) KIF13B intron 23319000 rs11780819 chr8 29000059 A T 9.45E-04 Obesity (extreme) KIF13B intron 21935397 rs17455458 chr8 29019988 T G 1.14E-04 Obesity (extreme) KIF13B intron 21935397 rs17455598 chr8 29022007 G A 2.09E-04 Obesity (extreme) KIF13B intron 21935397 rs6991271 chr8 29063172 T G 5.52E-04 Longevity KIF13B intron 22279548 rs75609241 chr8 29082285 G A 5.00E-07 PR interval in Tripanosoma cruzi seropositivity KIF13B intron 24324551 rs17456888 chr8 29083927 G A 3.17E-04 Obesity (extreme) KIF13B intron 21935397 rs2954793 chr8 29106059 C T 3.00E-06 Metabolite levels (HVA) KIF13B intron 23319000 rs10503851 chr8 29108379 T C 7.00E-05 Prostate cancer KIF13B intron 21743057 rs12682460 chr8 29109127 G A 7.00E-05 Prostate cancer KIF13B intron 21743057 rs11775002 chr8 29119115 A T 2.37E-04 Obesity (extreme) KIF13B intron 21935397 rs746959 chr8 29231378 C T 1.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17060069 chr8 29239838 T C 3.16E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs601962 chr8 29250546 T C 4.03E-05 Schizophrenia / / 19571809 rs601962 chr8 29250546 T C 5.33E-05 Schizophrenia / / pha002859 rs10503840 chr8 29254901 A G 8.24E-07 Lipid levels / / 19016617 rs10503841 chr8 29255584 G A 6.58E-04 Type 2 diabetes / / 17463246 rs6558112 chr8 29291624 C T 9.24E-05 Coronary heart disease / / pha003032 rs10087980 chr8 29305755 T C 4.02E-04 Type 2 diabetes / / 17463246 rs11136070 chr8 29316237 G A 3.60E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7842304 chr8 29325661 C T 9.07E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11786009 chr8 29327431 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11996339 chr8 29330180 C T 3.40E-06 Urinary metabolites / / 21572414 rs12548021 chr8 29344462 A G 3.00E-06 Colorectal cancer / / 23350875 rs17552942 chr8 29353675 A C 3.98E-05 Type 2 diabetes / / 17463246 rs17552942 chr8 29353675 A C 1.78E-04 Multiple complex diseases / / 17554300 rs13274558 chr8 29357789 A T 3.60E-06 Response to statin therapy / / 20339536 rs10091038 chr8 29360305 A C 3.00E-08 Response to statin therapy / / 20339536 rs10503848 chr8 29361255 A G 4.62E-05 HDL cholesterol / / pha003075 rs10109103 chr8 29361659 C T 4.30E-06 Response to statin therapy / / 20339536 rs4445269 chr8 29363220 C T 3.40E-06 Response to statin therapy / / 20339536 rs4445269 chr8 29363220 C T 5.46E-04 Insulin resistance / / 21901158 rs4732962 chr8 29363265 T C 4.80E-06 Response to statin therapy / / 20339536 rs12679976 chr8 29365363 G A 3.60E-06 Response to statin therapy / / 20339536 rs4415360 chr8 29369491 C T 5.50E-06 Response to statin therapy / / 20339536 rs13439445 chr8 29369679 G A 7.96E-04 Insulin resistance / / 21901158 rs11991416 chr8 29370855 A G 1.40E-05 Response to statin therapy / / 20339536 rs17462248 chr8 29371007 T G 2.06E-04 Schizophrenia / / 20832056 rs10098962 chr8 29371024 C A 6.10E-06 Response to statin therapy / / 20339536 rs13281383 chr8 29371314 C A 3.90E-06 Response to statin therapy / / 20339536 rs10088728 chr8 29371374 T C 4.56E-04 Type 2 diabetes / / 17463246 rs10088728 chr8 29371374 T C 3.70E-06 Response to statin therapy / / 20339536 rs17060351 chr8 29413436 G A 8.39E-05 Serum metabolites / / 19043545 rs17060351 chr8 29413436 G A 7.70E-06 Urinary metabolites / / 21572414 rs10103840 chr8 29419713 C A 1.46E-05 Smoking behavior / / 19188921 rs10103840 chr8 29419713 C A 5.05E-04 Antisocial behavior / / 20345837 rs17555326 chr8 29441884 A C 5.57E-06 Elbow pain / / pha003008 rs11991132 chr8 29449771 C A 3.21E-05 Elbow pain / / pha003008 rs10503852 chr8 29470675 T C 3.96E-05 Elbow pain / / pha003008 rs6558132 chr8 29470947 T C 1.58E-05 Pulmonary function / / 17903307 rs9693444 chr8 29509616 A C 9.00E-14 Breast cancer / / 23535729 rs7010903 chr8 29513003 C T 2.74E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs7003746 chr8 29552383 G A 6.69E-04 Type 2 diabetes / / 17463246 rs10448083 chr8 29565755 C T 5.05E-04 Type 2 diabetes / / 17463246 rs6982080 chr8 29630942 G T 2.28E-05 Prostate cancer / / 18264096 rs6985017 chr8 29697382 T C 8.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7017060 chr8 29704789 G A 1.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1545405 chr8 29718019 G T 3.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6468360 chr8 29743994 G C 4.55E-04 Gallstones / / 17632509 rs16876177 chr8 29778575 C T 2.80E-05 Cognitive performance / / 19734545 rs7003522 chr8 29821160 G A,C,T 2.80E-05 Cognitive performance / / 19734545 rs16876298 chr8 29838800 G A 1.96E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs12681671 chr8 29846366 G C 8.57E-05 Serum metabolites / / 19043545 rs10954792 chr8 29846492 A G 8.57E-05 Serum metabolites / / 19043545 rs2595040 chr8 29852450 C G 5.18E-05 Serum metabolites / / 19043545 rs167450 chr8 29872140 A G 5.11E-04 Alzheimer's disease / / 24755620 rs309853 chr8 29873603 A G 3.76E-04 Alcohol dependence / / 24277619 rs4107736 chr8 29875964 G A 5.53E-05 Breast cancer / / pha002853 rs9297181 chr8 29876605 G A 3.70E-04 Alcohol dependence / / 24277619 rs12682293 chr8 29884077 A C 7.12E-05 Breast cancer / / pha002853 rs6981350 chr8 29913870 T C 1.49E-06 Multiple complex diseases / / 17554300 rs3189926 chr8 29921288 A C 8.67E-04 Multiple complex diseases TMEM66 UTR-3 17554300 rs16876445 chr8 29957664 G A 4.00E-05 White matter hyperintensity burden LEPROTL1 intron 21681796 rs11557703 chr8 29961951 C T 3.00E-05 White matter hyperintensity burden LEPROTL1 cds-synon 21681796 rs16876487 chr8 29969421 G A 3.10E-05 White matter hyperintensity burden LEPROTL1 intron 21681796 rs3735989 chr8 29970904 C G 6.50E-05 Serum metabolites LEPROTL1 intron 19043545 rs16876489 chr8 29971290 C T 2.80E-05 White matter hyperintensity burden LEPROTL1 intron 21681796 rs16876504 chr8 29975318 A G 5.30E-05 White matter hyperintensity burden LEPROTL1 intron 21681796 rs1511167 chr8 29980716 G A 3.50E-05 White matter hyperintensity burden LEPROTL1 intron 21681796 rs12681963 chr8 29982518 T C 2.00E-07 Migraine LEPROTL1 intron 23793025 rs7844678 chr8 30019582 A G 6.05E-04 Type 2 diabetes DCTN6 intron 17463246 rs7829853 chr8 30023540 A G 4.26E-04 Body mass index DCTN6 intron 21701565 rs16876600 chr8 30024144 G C 1.54E-04 Body mass index DCTN6 intron 21701565 rs10503863 chr8 30045554 A G 5.39E-04 Body mass index / / 21701565 rs2938234 chr8 30048320 T G 4.79E-04 Body mass index / / 21701565 rs10503866 chr8 30056453 G T 1.41E-04 Body mass index / / 21701565 rs2958750 chr8 30057949 C T 5.36E-04 Body mass index / / 21701565 rs7830778 chr8 30060304 C T 2.39E-05 Body mass index / / 21701565 rs1566741 chr8 30078429 A G 4.00E-05 White matter hyperintensity burden / / 21681796 rs2938231 chr8 30079112 A G 3.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs6987718 chr8 30080900 C T 4.30E-05 White matter hyperintensity burden / / 21681796 rs6468193 chr8 30081218 C T 5.99E-04 Multiple complex diseases / / 17554300 rs6468234 chr8 30112932 T G 1.50E-04 Multiple complex diseases / / 17554300 rs7014742 chr8 30116071 C T 1.34E-04 Body mass index / / 21701565 rs2938212 chr8 30123236 G A 8.71E-04 Multiple complex diseases / / 17554300 rs2938212 chr8 30123236 G A 2.32E-04 Body mass index / / 21701565 rs2938206 chr8 30127459 C G 9.40E-05 White matter hyperintensity burden / / 21681796 rs2958759 chr8 30127555 C A 8.50E-05 White matter hyperintensity burden / / 21681796 rs7830496 chr8 30135341 T C 9.02E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs12542640 chr8 30146429 T C 4.32E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs17535262 chr8 30175153 T A 2.39E-04 Multiple complex diseases / / 17554300 rs7829473 chr8 30177969 T C 9.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7822813 chr8 30178766 C G 0.0001805 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7822813 chr8 30178766 C G 1.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7015785 chr8 30179213 G A 0.0001893 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7015785 chr8 30179213 G A 1.89E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7017620 chr8 30179242 C G 0.0008197 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7017620 chr8 30179242 C G 8.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4733480 chr8 30182641 T C 9.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12541729 chr8 30185572 T C 5.38E-04 IgA nephropathy / / 22197929 rs12549436 chr8 30187279 G A 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs6980718 chr8 30198086 A G 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs7842024 chr8 30213292 T C 9.91E-18 Multiple complex diseases / / 17554300 rs10087801 chr8 30237882 G A 1.89E-04 Height / / 17255346 rs2979481 chr8 30262786 T C 4.00E-06 Heart rate variability traits RBPMS intron 22174390 rs2915616 chr8 30273058 C G 5.63E-05 Multiple complex diseases RBPMS intron 17554300 rs13248936 chr8 30316162 A G 7.44E-04 Type 2 diabetes RBPMS intron 17463246 rs13248936 chr8 30316162 A G 1.54E-04 Multiple complex diseases RBPMS intron 17554300 rs7824823 chr8 30322735 T G 1.76E-04 Multiple complex diseases RBPMS intron 17554300 rs16877081 chr8 30344591 G A 8.39E-04 Multiple complex diseases RBPMS intron 17554300 rs7812836 chr8 30352258 C T 2.19E-04 Multiple complex diseases RBPMS intron 17554300 rs10503868 chr8 30369438 G A 3.51E-05 Cognitive test performance RBPMS intron 20125193 rs7013873 chr8 30386291 C T 6.16E-04 Type 2 diabetes RBPMS intron 17463246 rs2979510 chr8 30390205 G A 2.43E-05 Cognitive test performance RBPMS intron 20125193 rs2979510 chr8 30390205 G A 7.73E-04 Smoking initiation RBPMS intron 24665060 rs2915595 chr8 30402817 G A 6.28E-04 Coronary Artery Disease RBPMS intron 17634449 rs3757915 chr8 30420597 T C 4.52E-05 Cognitive test performance RBPMS intron 20125193 rs10099372 chr8 30424915 A G 1.92E-05 Cognitive test performance RBPMS intron 20125193 rs2294085 chr8 30436779 C T 8.02E-04 Obesity (extreme) GTF2E2 intron 21935397 rs10503871 chr8 30436852 C T 7.92E-04 Obesity (extreme) GTF2E2 intron 21935397 rs10503871 chr8 30436852 C T 3.00E-06 Metabolite levels (X-11787) GTF2E2 intron 23934736 rs11783765 chr8 30437008 A C 1.84E-04 Body mass index GTF2E2 intron 21701565 rs11783765 chr8 30437008 A C 4.17E-04 Body mass index GTF2E2 intron 21701565 rs10503872 chr8 30437031 G C 7.72E-04 Obesity (extreme) GTF2E2 intron 21935397 rs2979520 chr8 30447818 C G 0.000688 Asthma GTF2E2 intron 22502797 rs7833529 chr8 30455200 T C 6.61E-04 Obesity (extreme) GTF2E2 intron 21935397 rs2978263 chr8 30498859 T C 8.00E-06 Cognitive performance GTF2E2 intron 20125193 rs7016919 chr8 30522958 C G 2.57E-04 Body mass index / / 21701565 rs7016919 chr8 30522958 C G 5.34E-04 Body mass index / / 21701565 rs8191030 chr8 30539281 A G 0.000000124 LDL cholesterol GSR intron 23063622 rs3779647 chr8 30560887 C T 3.47E-04 Lymphocyte counts GSR intron 22286170 rs3779647 chr8 30560887 C T 0.0001 High platelet reactivity in patients with type 2 diabetes during acetylsalicylic acid (ASA) treatment (defined as CEPI-CT score of <193 s) GSR intron 23054467 rs17557435 chr8 30575838 T C 3.09E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) GSR intron 24023788 rs8190893 chr8 30583904 C T 1.51E-06 Coronary heart disease GSR intron pha003031 rs16877322 chr8 30598424 A G 1.66E-04 Body mass index / / 21701565 rs16877322 chr8 30598424 A G 3.25E-04 Body mass index / / 21701565 rs16877322 chr8 30598424 A G 5.76E-04 Body mass index / / 21701565 rs2278092 chr8 30601805 C T 2.17E-04 Body mass index UBXN8 intron 21701565 rs2278092 chr8 30601805 C T 4.50E-04 Body mass index UBXN8 intron 21701565 rs2911691 chr8 30607588 C G 2.14E-04 Body mass index UBXN8 intron 21701565 rs2911691 chr8 30607588 C G 3.27E-04 Body mass index UBXN8 intron 21701565 rs2911691 chr8 30607588 C G 7.22E-04 Body mass index UBXN8 intron 21701565 rs12156104 chr8 30607671 C T 2.15E-04 Body mass index UBXN8 intron 21701565 rs12156104 chr8 30607671 C T 3.30E-04 Body mass index UBXN8 intron 21701565 rs12156104 chr8 30607671 C T 8.14E-04 Body mass index UBXN8 intron 21701565 rs1116003 chr8 30655363 G A 3.44E-04 Alzheimer's disease (late onset) PPP2CB intron 21379329 rs7829173 chr8 30799563 G A 8.59E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1421331 chr8 30820815 C T 4.17E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11783562 chr8 30838546 T G 8.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2543600 chr8 30849740 A G 4.20E-06 Longevity and age-related phenotypes / / 17903295 rs2725376 chr8 30867266 G C 8.95E-05 Major depressive disorder PURG intron 21621269 rs13278463 chr8 30896969 T A 3.19E-04 Obesity (extreme) WRN intron 21935397 rs2725344 chr8 30918098 A G 3.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WRN intron 20877124 rs2015230 chr8 30920785 C T 2.89E-04 Iron levels WRN intron pha002876 rs2725385 chr8 30928146 T C 8.22E-04 Iron levels WRN intron pha002876 rs11574214 chr8 30933274 T A 5.21E-04 Multiple complex diseases WRN intron 17554300 rs2553268 chr8 30936356 G T 6.00E-06 Exercise treadmill test traits WRN intron 17903301 rs2737327 chr8 30957765 A G 2.38E-05 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia WRN intron 24039173 rs2553258 chr8 30965159 G C 1.99E-05 Multiple complex diseases WRN intron 17554300 rs11574304 chr8 30973811 C T 2.11E-04 Obesity (extreme) WRN intron 21935397 rs1800392 chr8 30973957 G T 1.79E-04 Longevity WRN cds-synon 22279548 rs2737333 chr8 30993135 G T 5.60E-05 Serum metabolites WRN intron 19043545 rs2725361 chr8 30997326 A G 9.23E-04 Iron levels WRN intron pha002876 rs3024239 chr8 30999122 C T 3.24E-04 Longevity WRN intron 22279548 rs6982140 chr8 30999428 T C 7.30E-04 Type 2 diabetes WRN intron 17463246 rs7001440 chr8 31000860 G A 2.11E-06 Retinopathy in non-diabetics WRN intron 23393555 rs11574358 chr8 31004582 T G 1.00E-20 Health and aging,CVD and cancer age of onset WRN missense 22174011 rs11574358 chr8 31004582 T G 1.10E-11 Health and aging,CVD and cancer age of onset WRN missense 22174011 rs11574358 chr8 31004582 T G 1.60E-19 Health and aging,CVD and cancer age of onset WRN missense 22174011 rs11574358 chr8 31004582 T G 1.90E-11 Health and aging,CVD and cancer age of onset WRN missense 22174011 rs6988789 chr8 31010288 C T 1.56E-06 Retinopathy in non-diabetics WRN intron 23393555 rs2737342 chr8 31013960 G A 2.25E-04 Coronary heart disease WRN intron 21971053 rs6994361 chr8 31018685 C T 6.79E-04 Iron levels WRN intron pha002876 rs1882928 chr8 31023822 A G 3.25E-04 Menopause (age at onset) WRN intron 22267201 rs2553256 chr8 31027314 T C 3.16E-04 Iron levels WRN intron pha002876 rs11774682 chr8 31034275 C T 1.00E-06 IgG glycosylation / / 23382691 rs11774682 chr8 31034275 C T 3.00E-06 IgG glycosylation / / 23382691 rs2737351 chr8 31042668 A C 7.88E-05 Waist-Hip Ratio / / pha003013 rs2737351 chr8 31042668 A C 9.29E-05 Waist-Hip Ratio / / pha003028 rs1559681 chr8 31107532 C T 1.60E-04 Endometriosis / / 21151130 rs4373482 chr8 31126376 T C 3.92E-05 Serum metabolites / / 19043545 rs7016886 chr8 31149113 T G 2.70E-05 Urinary metabolites / / 21572414 rs2575029 chr8 31174830 T C 6.00E-06 Obesity-related traits / / 23251661 rs745957 chr8 31249870 A G 1.50E-04 Taste perception / / 22132133 rs2681600 chr8 31272592 G A 8.71E-04 Multiple complex diseases / / 17554300 rs16878064 chr8 31276365 C T 7.00E-05 Iron levels / / 19880490 rs16878064 chr8 31276365 C T 7.00E-05 Iron levels / / pha002876 rs2681599 chr8 31297286 A G 4.74E-05 Socioeconomic Factors / / pha003066 rs10107214 chr8 31297579 C T 7.89E-05 Socioeconomic Factors / / pha003066 rs1865756 chr8 31303415 T C 8.73E-05 Socioeconomic Factors / / pha003066 rs10101482 chr8 31352499 A G 2.90E-05 Urinary metabolites / / 21572414 rs2247267 chr8 31354758 A G 1.77E-05 Socioeconomic Factors / / pha003066 rs4478530 chr8 31398144 T C 8.60E-05 Amyotrophic Lateral Sclerosis / / 17362836 rs4478530 chr8 31398144 T C 7.89E-04 Taste perception / / 22132133 rs4478530 chr8 31398144 T C 3.97E-06 Socioeconomic Factors / / pha003066 rs10113124 chr8 31422640 G A 1.15E-05 Socioeconomic Factors / / pha003066 rs1476540 chr8 31433801 T C 3.10E-05 Socioeconomic Factors / / pha003066 rs1557800 chr8 31434385 C T 9.13E-05 Colorectal cancer / / 19723657 rs763552 chr8 31445407 T C 8.53E-04 Cognition,early reading ability / / 17684495 rs763552 chr8 31445407 T C 4.70E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs13258147 chr8 31448469 G A 0.0000878 post-traumatic stress disorder / / 22869035 rs13258147 chr8 31448469 G A 8.78E-05 Schizophrenia / / 22883433 rs4268090 chr8 31480888 C T 6.01E-05 Cognitive impairment induced by topiramate / / 22091778 rs4733267 chr8 31504639 C T 1.98E-05 Atrial fibrillation NRG1 intron 21846873 rs10113797 chr8 31510337 C T 9.82E-05 Non-alcoholic fatty liver disease histology (other) NRG1 intron 20708005 rs10098401 chr8 31531460 G C 0.00018 Coronary artery calcification NRG1 intron 23727086 rs12677942 chr8 31539942 G A 7.66E-04 Multiple complex diseases NRG1 intron 17554300 rs4733271 chr8 31567006 A T 4.56E-06 Cardiac Troponin-T levels NRG1 intron 23247143 rs4469409 chr8 31581496 T C 2.52E-04 Insulin resistance NRG1 intron 21901158 rs10954811 chr8 31586453 G A 8.25E-04 Multiple complex diseases NRG1 intron 17554300 rs11775125 chr8 31594919 G A 3.19E-04 Multiple complex diseases NRG1 intron 17554300 rs6468064 chr8 31603821 G A 1.62E-04 Insulin resistance NRG1 intron 21901158 rs10503887 chr8 31633447 G T 2.00E-07 Hip geometry NRG1 intron 17903296 rs10503888 chr8 31633553 T C 7.70E-04 Atrial fibrillation NRG1 intron 21846873 rs1875723 chr8 31635670 T A 1.90E-04 Insulin resistance NRG1 intron 21901158 rs16878272 chr8 31635834 G C 2.06E-05 Atrial fibrillation NRG1 intron 21846873 rs4733099 chr8 31640005 C T 1.38E-04 Insulin resistance NRG1 intron 21901158 rs10503889 chr8 31642796 G A 1.72E-06 Paclitaxel sensitivity in NCI60 cancer cell lines NRG1 intron 21314952 rs4733275 chr8 31649069 T C 1.42E-04 Multiple complex diseases NRG1 intron 17554300 rs7004465 chr8 31649224 A G 1.98E-04 Insulin resistance NRG1 intron 21901158 rs7820923 chr8 31650669 T G 8.14E-04 Multiple complex diseases NRG1 intron 17554300 rs16878301 chr8 31650694 G C 3.25E-04 Multiple complex diseases NRG1 intron 17554300 rs7001470 chr8 31653121 T G 4.83E-04 Multiple complex diseases NRG1 intron 17554300 rs2047848 chr8 31656862 T C 2.45E-04 Insulin resistance NRG1 intron 21901158 rs4733277 chr8 31682290 A G 2.33E-04 Insulin resistance NRG1 intron 21901158 rs1503487 chr8 31690588 G A 7.62E-04 Multiple complex diseases NRG1 intron 17554300 rs776404 chr8 31706695 T G 4.51E-05 Orofacial clefts NRG1 intron 22419666 rs1383893 chr8 31724648 T C 8.90E-04 Volumetric brain MRI NRG1 intron 17903297 rs17680540 chr8 31753921 G C 2.10E-04 Atrial fibrillation NRG1 intron 21846873 rs756266 chr8 31770158 T C 1.10E-04 Atrial fibrillation NRG1 intron 21846873 rs1462872 chr8 31794109 A G 9.00E-06 Coronary artery calcification NRG1 intron 23870195 rs1599676 chr8 31903405 T A 8.75E-04 Multiple complex diseases NRG1 intron 17554300 rs7821190 chr8 31908605 C T 4.91E-07 Multiple complex diseases NRG1 intron 17554300 rs16878694 chr8 31911305 A C 3.05E-05 Multiple complex diseases NRG1 intron 17554300 rs899008 chr8 31921797 T A,C 3.89E-04 Multiple complex diseases NRG1 intron 17554300 rs6992071 chr8 31940655 A G 6.87E-96 Multiple complex diseases NRG1 intron 17554300 rs10503899 chr8 31947234 A G 1.32E-14 Schizophrenia NRG1 intron 22440650 rs6993043 chr8 31965188 T C 8.40E-04 Atrial fibrillation NRG1 intron 21846873 rs16878847 chr8 31971619 C T 2.76E-09 Multiple complex diseases NRG1 intron 17554300 rs1481737 chr8 31977229 A G 1.61E-04 Stroke NRG1 intron pha002887 rs2170416 chr8 31992037 C T 6.06E-04 Multiple complex diseases NRG1 intron 17554300 rs1481763 chr8 31993810 G T 8.03E-05 Height NRG1 intron pha003010 rs4733298 chr8 32008766 G C 9.66E-04 Coronary Artery Disease NRG1 intron 17634449 rs16878890 chr8 32020891 T C 1.36E-04 Coronary Artery Disease NRG1 intron 17634449 rs1383965 chr8 32079101 C T 5.45E-04 Coronary Artery Disease NRG1 intron 17634449 rs1948097 chr8 32080255 G T 8.19E-04 Coronary Artery Disease NRG1 intron 17634449 rs988031 chr8 32083405 A T 5.03E-04 Coronary Artery Disease NRG1 intron 17634449 rs7839084 chr8 32084146 T C 3.44E-04 Coronary Artery Disease NRG1 intron 17634449 rs1383966 chr8 32084692 G T 5.05E-04 Coronary Artery Disease NRG1 intron 17634449 rs7812985 chr8 32091384 A G 8.31E-04 Coronary Artery Disease NRG1 intron 17634449 rs11784296 chr8 32106823 T A 4.56E-05 Coronary Artery Disease NRG1 intron 17634449 rs1872800 chr8 32108495 T A 2.32E-04 Coronary Artery Disease NRG1 intron 17634449 rs900102 chr8 32120188 A G 8.08E-04 Response to taxane treatment (placlitaxel) NRG1 intron 23006423 rs17624670 chr8 32126374 G A 0.00000562 Carotid intima media thickness NRG1 intron 23152477 rs11787395 chr8 32137271 G C 5.50E-06 Urinary metabolites NRG1 intron 21572414 rs1487141 chr8 32139652 G C 3.00E-06 Metabolite levels (X-11787) NRG1 intron 23934736 rs7818821 chr8 32153164 A G 7.74E-05 Waist Circumference NRG1 intron pha003023 rs41388144 chr8 32168607 A C 1.94E-04 Type 2 diabetes NRG1 intron 17463246 rs10503906 chr8 32171962 G A 2.33E-04 Type 2 diabetes NRG1 intron 17463246 rs10503906 chr8 32171962 G A 4.20E-04 Volumetric brain MRI NRG1 intron 17903297 rs6999977 chr8 32173061 A G 7.50E-04 Type 2 diabetes and 6 quantitative traits NRG1 intron 17848626 rs2632006 chr8 32197248 C A 3.01E-04 Multiple complex diseases NRG1 intron 17554300 rs1685103 chr8 32200072 C A 4.16E-05 vWF levels,in plasma NRG1 intron 21534939 rs16879268 chr8 32215790 G A 8.64E-05 vWF levels,in plasma NRG1 intron 21534939 rs2347510 chr8 32241799 G A 8.08E-08 Metabolite levels NRG1 intron 23281178 rs16879344 chr8 32262521 G A 8.59E-08 Metabolite levels NRG1 intron 23281178 rs10954843 chr8 32277111 G A 1.69E-11 HDL cholesterol NRG1 intron 23063622 rs9918832 chr8 32282597 T C 5.50E-05 Fasting plasma glucose NRG1 intron 19060907 rs41335651 chr8 32298258 C T 7.31E-05 Multiple complex diseases NRG1 intron 17554300 rs12550427 chr8 32307782 G A 2.20E-05 Urinary metabolites NRG1 intron 21572414 rs12542743 chr8 32318355 T C 4.00E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity NRG1 intron 24324551 rs10954846 chr8 32320220 G A 5.48E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity NRG1 intron 24324551 rs17717485 chr8 32341045 A G 2.40E-05 Urinary metabolites NRG1 intron 21572414 rs10503917 chr8 32345350 A T 1.10E-05 Urinary metabolites NRG1 intron 21572414 rs17645417 chr8 32351333 T C 5.49E-05 Cleft lip NRG1 intron 20436469 rs7007147 chr8 32378493 G A 4.26E-04 Multiple complex diseases NRG1 intron 17554300 rs10107065 chr8 32390558 A G 9.87E-04 Tourette syndrome NRG1 intron 22889924 rs10503919 chr8 32399742 C A 1.90E-04 Volumetric brain MRI NRG1 intron 17903297 rs16879552 chr8 32411216 C T 2.00E-08 Hirschsprung's disease NRG1 intron 19196962 rs7835688 chr8 32411499 G C 4.77E-05 Hirschsprung's disease NRG1 intron 19196962 rs2439312 chr8 32412359 A G 7.00E-06 Dialysis-related mortality NRG1 intron 21546767 rs6989777 chr8 32415682 G A 1.80E-05 Schizophrenia NRG1 intron 19571809 rs6989777 chr8 32415682 G A 2.96E-05 Schizophrenia NRG1 intron pha002859 rs16879557 chr8 32415818 C T 4.89E-05 Hirschsprung's disease NRG1 intron 19196962 rs7825175 chr8 32416274 G A 2.00E-08 Thyroid hormone levels NRG1 intron 23408906 rs7825175 chr8 32416274 G A 3.00E-09 Thyroid hormone levels NRG1 intron 23408906 rs4316112 chr8 32420347 C A 1.59E-05 Schizophrenia NRG1 intron 19571809 rs4316112 chr8 32420347 C A 2.73E-05 Schizophrenia NRG1 intron pha002859 rs4733132 chr8 32425743 C G 3.15E-05 Schizophrenia NRG1 intron 19571809 rs4733132 chr8 32425743 C G 4.82E-05 Schizophrenia NRG1 intron pha002859 rs2466096 chr8 32430732 A T 0.0004 Coronary artery calcification NRG1 intron 23727086 rs2439302 chr8 32432369 G C 2.00E-09 Thyroid cancer NRG1 intron 22267200 rs2466063 chr8 32441651 G A 6.52E-06 Left ventricular mass NRG1 intron 21212386 rs3924999 chr8 32453358 G A 3.16E-05 Multiple sclerosis NRG1 missense 20598377 rs17665441 chr8 32455027 G T 7.30E-04 Coronary heart disease NRG1 intron 21966275 rs10954863 chr8 32456511 G A 4.50E-05 Multiple sclerosis NRG1 intron 20598377 rs2466058 chr8 32507149 C T 1.78E-05 Amyotrophic lateral sclerosis (sporadic) NRG1 intron 24529757 rs2466058 chr8 32507149 C T 1.50E-05 Coronary heart disease NRG1 intron pha003032 rs2466046 chr8 32517162 G A 3.80E-04 Alcohol dependence NRG1 intron 20201924 rs2919390 chr8 32526955 A C 2.09E-04 Suicide attempts in bipolar disorder NRG1 intron 21041247 rs12541855 chr8 32527909 C T 3.96E-04 Suicide attempts in bipolar disorder NRG1 intron 21041247 rs6468122 chr8 32539327 C T 3.36E-05 Coronary heart disease NRG1 intron pha003032 rs6468122 chr8 32539327 C T 2.74E-05 Coronary heart disease NRG1 intron pha003035 rs10503926 chr8 32541216 A C 4.67E-04 Type 2 diabetes NRG1 intron 17846124 rs10503926 chr8 32541216 A C 8.70E-05 Volumetric brain MRI NRG1 intron 17903297 rs10503927 chr8 32543230 C T 5.29E-04 Type 2 diabetes NRG1 intron 17846124 rs10503927 chr8 32543230 C T 2.00E-04 Volumetric brain MRI NRG1 intron 17903297 rs12541309 chr8 32545001 G A 7.00E-04 Multiple complex diseases NRG1 intron 17554300 rs12541309 chr8 32545001 G A 7.46E-04 Suicide attempts in bipolar disorder NRG1 intron 21041247 rs41511347 chr8 32547055 C A 1.03E-04 Multiple complex diseases NRG1 intron 17554300 rs2919381 chr8 32563924 A G 7.56E-04 Osteoarthritis (knee and hip) NRG1 intron 21177295 rs2919381 chr8 32563924 A G 8.81E-05 Osteoarthritis (knee and hip) NRG1 intron 21177295 rs2919381 chr8 32563924 A G 7.40E-04 Smoking cessation NRG1 intron 24665060 rs16879809 chr8 32572873 C T 6.95E-04 Type 2 diabetes NRG1 intron 17463246 rs2919377 chr8 32573741 A G 6.03E-04 Multiple complex diseases NRG1 intron 17554300 rs2976526 chr8 32574651 G A 5.91E-04 Multiple complex diseases NRG1 intron 17554300 rs2975504 chr8 32578999 A G 5.99E-04 Multiple complex diseases NRG1 intron 17554300 rs2919389 chr8 32588901 C T 3.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NRG1 intron 20877124 rs4512342 chr8 32607874 T G 2.00E-09 Asthma (childhood onset) NRG1 intron 17611496 rs7005288 chr8 32620467 A G 3.13E-05 Bone mineral density NRG1 intron 19181680 rs10088561 chr8 32662782 C T 0.000337 fMRI brain tests in schizophrenia / / 22440650 rs12548772 chr8 32727726 A G 1.49E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7820795 chr8 32739460 C T 8.34E-04 Type 2 diabetes / / 17463246 rs10503936 chr8 32812230 G A 5.69E-06 Cognitive impairment induced by topiramate / / 22091778 rs4236722 chr8 32842853 G T 6.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs12544147 chr8 32843055 G A 9.95E-05 Alzheimer's disease (late onset) / / 21379329 rs16875688 chr8 32869279 G A 5.19E-04 Multiple complex diseases / / 17554300 rs6998559 chr8 32872083 G C 4.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs4733142 chr8 32875127 T A 3.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs7008340 chr8 32968530 G T 1.55E-04 Multiple complex diseases / / 17554300 rs16880392 chr8 32991147 G T 3.68E-04 Multiple complex diseases / / 17554300 rs4413730 chr8 33070458 C T 7.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs10091183 chr8 33073498 A G 3.02E-28 Narcolepsy / / 19629137 rs13271230 chr8 33097234 G C 7.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs11991723 chr8 33098541 C G 7.95E-05 Multiple sclerosis / / 17660530 rs4733419 chr8 33113316 G A 5.42E-04 Multiple complex diseases / / 17554300 rs7004191 chr8 33113921 G A 8.38E-04 Multiple complex diseases / / 17554300 rs7005486 chr8 33114022 C T 5.83E-04 Multiple complex diseases / / 17554300 rs4733420 chr8 33114628 T A 7.22E-04 Multiple complex diseases / / 17554300 rs4733422 chr8 33114837 C T 6.01E-04 Multiple complex diseases / / 17554300 rs7843085 chr8 33115544 G A 6.33E-04 Multiple complex diseases / / 17554300 rs7843085 chr8 33115544 G A 3.93E-07 Atopy / / 19961619 rs13273924 chr8 33126999 T G 7.50E-07 Atopy / / 19961619 rs4427132 chr8 33143930 A G 5.93E-05 Prostate cancer / / 22923026 rs10954899 chr8 33147612 A G 9.67E-05 Multiple complex diseases / / 17554300 rs4273816 chr8 33153501 T G 7.07E-05 Multiple complex diseases / / 17554300 rs4367490 chr8 33157431 A G 2.48E-07 Multiple complex diseases / / 17554300 rs3923524 chr8 33168975 G A 5.45E-05 Multiple complex diseases / / 17554300 rs10954904 chr8 33171588 A G 6.67E-05 Prostate cancer / / 22923026 rs11773958 chr8 33179652 G A 5.75E-05 Prostate cancer / / 22923026 rs4609155 chr8 33181409 T C 3.03E-05 Multiple complex diseases / / 17554300 rs4609155 chr8 33181409 T C 9.60E-05 Multiple sclerosis / / 17660530 rs12542920 chr8 33185211 T A 8.80E-04 Type 2 diabetes / / 17463246 rs871355 chr8 33215426 C T 4.30E-06 Cocaine dependence / / 23958962 rs871355 chr8 33215426 C T 7.70E-04 Cocaine dependence / / 23958962 rs1474035 chr8 33228162 A C 3.87E-04 Multiple complex diseases / / 17554300 rs7837460 chr8 33235671 A G 1.48E-05 Prostate cancer FUT10 intron 22923026 rs4430053 chr8 33238981 G C 6.67E-04 Multiple complex diseases FUT10 intron 17554300 rs11996351 chr8 33240084 T G 1.48E-05 Prostate cancer FUT10 intron 22923026 rs1568117 chr8 33242939 G A 4.28E-04 Multiple complex diseases FUT10 intron 17554300 rs17855838 chr8 33246591 G C 0.00054 Prostate cancer FUT10 missense 23555315 rs16880852 chr8 33246685 G A 6.87E-04 Multiple complex diseases FUT10 cds-synon 17554300 rs10113699 chr8 33269631 G C 2.45E-04 Multiple complex diseases FUT10 intron 17554300 rs7813318 chr8 33269745 C T 6.21E-04 Multiple complex diseases FUT10 intron 17554300 rs16880931 chr8 33270568 G A 2.03E-05 Multiple complex diseases FUT10 intron 17554300 rs10503946 chr8 33272421 G C 2.35E-04 Multiple complex diseases FUT10 intron 17554300 rs9656764 chr8 33274399 C G 7.17E-04 Multiple complex diseases FUT10 intron 17554300 rs9656765 chr8 33274426 T C 4.45E-05 Multiple complex diseases FUT10 intron 17554300 rs6468171 chr8 33356074 A G 1.99E-04 Gallstones MAK16 missense 17632509 rs7841518 chr8 33363620 G C 2.63E-07 Lymphocyte counts TTI2 intron 22286170 rs7812958 chr8 33407341 T G 9.48E-04 Amyotrophic Lateral Sclerosis RNF122 intron 17827064 rs7840674 chr8 33471273 T C 9.15E-05 Serum metabolites / / 19043545 rs3943670 chr8 33479496 T C 6.86E-04 Coronary heart disease / / 21606135 rs4733161 chr8 33497651 C T 8.91E-04 Coronary heart disease / / 21606135 rs10107668 chr8 33524179 T C 8.00E-04 Pulmonary function / / 23932459 rs1838041 chr8 33524782 C T 2.52E-04 Coronary heart disease / / 21606135 rs1530345 chr8 33532126 G C 6.43E-04 Multiple complex diseases / / 17554300 rs1530345 chr8 33532126 G C 6.07E-04 Coronary heart disease / / 21606135 rs4733163 chr8 33534284 C T 5.74E-04 Coronary heart disease / / 21606135 rs7833393 chr8 33536037 A G 1.26E-05 Serum metabolites / / 19043545 rs4469412 chr8 33565378 G A 9.00E-07 Immune response to smallpox vaccine (IL-6) / / 22542470 rs4469412 chr8 33565378 G A 1.37E-04 Smoking initiation / / 24665060 rs17770975 chr8 33589206 G A 9.15E-04 Multiple complex diseases / / 17554300 rs16881175 chr8 33594388 T C 3.40E-04 Smoking initiation / / 24665060 rs4733171 chr8 33615617 G C 1.74E-05 Multiple sclerosis / / 17660530 rs16881206 chr8 33628306 G A 3.49E-04 Smoking initiation / / 24665060 rs10503951 chr8 33665680 A G 5.41E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10503951 chr8 33665680 A G 3.00E-09 Immune response to smallpox vaccine (IL-6) / / 22542470 rs11786194 chr8 33673011 A G 1.22E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11786194 chr8 33673011 A G 9.00E-07 Immune response to smallpox vaccine (IL-6) / / 22542470 rs11787122 chr8 33696302 A G 3.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11787122 chr8 33696302 A G 8.54E-07 Immune response to smallpox vaccine (IL-6) / / 22542470 rs16881274 chr8 33713382 T C 1.51E-04 Multiple complex diseases / / 17554300 rs13274995 chr8 33740766 G T 3.35E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10503953 chr8 33797783 C T 1.32E-05 Bone mass and geometry / / 17903296 rs11780927 chr8 33806910 G A 3.66E-05 Neutrophil count / / pha003095 rs10100986 chr8 33850748 C A 5.50E-04 Multiple complex diseases / / 17554300 rs7465297 chr8 33853868 G A 8.21E-05 Lymphocyte counts / / pha003094 rs7465297 chr8 33853868 G A 3.70E-06 Neutrophil count / / pha003095 rs7459878 chr8 33854699 G A 5.13E-04 Multiple complex diseases / / 17554300 rs10088032 chr8 33854917 G A 3.30E-04 Multiple complex diseases / / 17554300 rs7823476 chr8 33862069 G A 5.05E-06 Height / / 20400458 rs10088296 chr8 33882742 G A 9.19E-04 Alzheimer's disease / / 17998437 rs16881395 chr8 33924633 G T 5.84E-05 Multiple complex diseases / / 17554300 rs6999743 chr8 33936209 T C 1.42E-04 Multiple complex diseases / / 17554300 rs10954951 chr8 33936891 A G 5.76E-05 Neutrophil count / / pha003095 rs17782229 chr8 33937316 T C 5.45E-04 Alzheimer's disease / / 17998437 rs7006050 chr8 33938017 A G 4.57E-04 Multiple complex diseases / / 17554300 rs17709548 chr8 33940365 A G 4.81E-04 Alzheimer's disease / / 17998437 rs7818248 chr8 33955849 G A 7.27E-06 Neutrophil count / / pha003095 rs12674520 chr8 33958171 A G 2.31E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7832148 chr8 33958412 G A 7.69E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2729990 chr8 33980998 T C 9.31E-04 Multiple complex diseases / / 17554300 rs16875745 chr8 33994378 A G 2.60E-05 Urinary metabolites / / 21572414 rs924008 chr8 33996986 T C 4.20E-05 Type 2 diabetes / / 17463246 rs2729993 chr8 33997051 C G 2.14E-05 Schizophrenia / / 19571809 rs2729993 chr8 33997051 C G 2.27E-05 Schizophrenia / / pha002859 rs7839708 chr8 34005746 G A 1.00E-04 Prostate cancer / / 21743057 rs6468235 chr8 34020667 C T 2.86E-05 Schizophrenia / / 19571809 rs6468235 chr8 34020667 C T 3.14E-05 Schizophrenia / / pha002859 rs16881601 chr8 34022494 G A 3.81E-04 Type 2 diabetes / / 17463246 rs2730003 chr8 34044529 G A 3.93E-05 stroke (ischemic) / / 17434096 rs9297216 chr8 34045261 C A,G,T 1.00E-06 Asthma (childhood onset) / / 23829686 rs16881792 chr8 34065815 T C 3.01E-04 Multiple complex diseases / / 17554300 rs10503957 chr8 34067018 A C 8.08E-05 stroke (ischemic) / / 17434096 rs2643261 chr8 34089670 A G 4.10E-05 Parkinson's disease (familial) / / 18985386 rs2643261 chr8 34089670 A G 5.67E-05 Sarcoidosis / / 19165924 rs1495233 chr8 34115911 C G 2.16E-05 Multiple complex diseases / / 17554300 rs1495233 chr8 34115911 C G 6.20E-05 Parkinson's disease (familial) / / 18985386 rs1495233 chr8 34115911 C G 3.20E-06 Urinary metabolites / / 21572414 rs2978846 chr8 34118121 A C 3.61E-06 Multiple complex diseases / / 17554300 rs2978846 chr8 34118121 A C 3.90E-06 Urinary metabolites / / 21572414 rs1495235 chr8 34119062 C A 3.90E-06 Urinary metabolites / / 21572414 rs1495236 chr8 34119750 C A 1.36E-05 Multiple complex diseases / / 17554300 rs1495236 chr8 34119750 C A 3.90E-06 Urinary metabolites / / 21572414 rs6990255 chr8 34126948 C T 6.00E-06 Bipolar disorder / / 19416921 rs6990255 chr8 34126948 C T 8.12E-07 Major depressive disorder / / 22472876 rs6990255 chr8 34126948 C T 2.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs16881910 chr8 34131986 C T 9.46E-05 Multiple complex diseases / / 17554300 rs2953932 chr8 34149465 A G 5.57E-04 Multiple complex diseases / / 17554300 rs16881965 chr8 34172860 T C 5.19E-04 Multiple complex diseases / / 17554300 rs2168963 chr8 34176474 G A 1.41E-06 Glucose levels / / pha003057 rs16881979 chr8 34185162 C T 2.40E-04 Multiple complex diseases / / 17554300 rs10503961 chr8 34210268 G A 9.65E-05 White matter integrity / / 22425255 rs2590467 chr8 34226744 A G 5.88E-04 Multiple complex diseases / / 17554300 rs978438 chr8 34228341 T C 8.18E-04 Multiple complex diseases / / 17554300 rs978439 chr8 34228681 C T 4.75E-04 Multiple complex diseases / / 17554300 rs2719277 chr8 34230254 C T 6.48E-04 Multiple complex diseases / / 17554300 rs2719276 chr8 34231198 C T 3.70E-04 Multiple complex diseases / / 17554300 rs2609653 chr8 34236992 C T 2.54E-06 Multiple complex diseases / / 17554300 rs2609653 chr8 34236992 C T 7.00E-06 Bipolar disorder / / 21254220 rs2609653 chr8 34236992 C T 8.92E-07 Major depressive disorder / / 22472876 rs2609653 chr8 34236992 C T 3.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs4327859 chr8 34239277 T C 8.31E-04 Multiple complex diseases / / 17554300 rs16875809 chr8 34259803 A G 1.77E-04 Type 2 diabetes / / 17463246 rs13253514 chr8 34308654 G A 9.55E-08 Metabolite levels / / 23281178 rs13260305 chr8 34319461 A G 2.41E-08 Metabolite levels / / 23281178 rs10099704 chr8 34339520 C T 5.00E-06 Glucose levels / / pha003057 rs7815445 chr8 34352349 A G 2.48E-06 Glucose levels / / pha003057 rs10112003 chr8 34360493 G A 3.05E-06 Glucose levels / / pha003057 rs4260892 chr8 34414823 G A 1.97E-04 Multiple complex diseases / / 17554300 rs16882599 chr8 34489289 T G 9.92E-04 Multiple complex diseases / / 17554300 rs16882612 chr8 34498386 C A 5.85E-04 Multiple complex diseases / / 17554300 rs7817181 chr8 34515169 C T 5.07E-06 Glucose levels / / pha003057 rs4739598 chr8 34516642 A G 7.86E-04 Multiple complex diseases / / 17554300 rs6987004 chr8 34524003 A G 7.00E-06 Pulmonary function decline / / 22424883 rs1916175 chr8 34611275 C T 6.50E-05 Cognitive function / / 24684796 rs7007425 chr8 34629901 C A 1.40E-05 Urinary metabolites / / 21572414 rs2685592 chr8 34654772 T G 1.07E-04 Cognitive function / / 24684796 rs1403375 chr8 34665107 T C 1.07E-04 Cognitive function / / 24684796 rs2687543 chr8 34680220 C T 1.07E-04 Cognitive function / / 24684796 rs7833796 chr8 34694420 G T 5.97E-04 Multiple complex diseases / / 17554300 rs16883114 chr8 34700530 A G 8.52E-106 Multiple complex diseases / / 17554300 rs16883168 chr8 34732452 A G 1.35E-04 Multiple complex diseases / / 17554300 rs16883169 chr8 34734034 A G 1.36E-04 Multiple complex diseases / / 17554300 rs6468299 chr8 34856134 A G 1.20E-05 Urinary metabolites / / 21572414 rs4613990 chr8 34892197 A G 6.53E-04 Smoking initiation / / 24665060 rs9297228 chr8 34899821 C T 6.00E-06 Personality dimensions / / 18957941 rs9297228 chr8 34899821 C T 8.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11786195 chr8 34901301 C T 6.96E-06 Cognitive decline / / 23207651 rs4314649 chr8 34933127 G A 9.46E-06 Cognitive decline / / 23207651 rs2923661 chr8 34941640 A G 6.71E-06 Cognitive decline / / 23207651 rs4739296 chr8 34953807 G A 3.30E-06 Cognitive decline / / 23207651 rs1026217 chr8 34970917 A G 9.96E-04 Coronary heart disease / / 21606135 rs1451355 chr8 35003886 A G 1.51E-04 Coronary heart disease / / 21606135 rs6997817 chr8 35067119 G A 9.96E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs9297235 chr8 35075019 T C 5.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs16883885 chr8 35223470 A T 1.76E-06 Multiple complex diseases UNC5D intron 17554300 rs16875831 chr8 35253634 A G 1.82E-25 Narcolepsy UNC5D intron 19629137 rs2921219 chr8 35323410 A G 1.80E-05 Urinary metabolites UNC5D intron 21572414 rs2579892 chr8 35380121 T G 5.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) UNC5D intron 20877124 rs2589338 chr8 35429073 G A 5.75E-06 Post-operative nausea and vomiting UNC5D intron 21694509 rs17353731 chr8 35479468 A G 3.74E-05 Post-operative nausea and vomiting UNC5D intron 21694509 rs12678392 chr8 35572788 T A 5.24E-04 Body mass index UNC5D intron 21701565 rs12678392 chr8 35572788 T A 8.59E-04 Body mass index UNC5D intron 21701565 rs1347609 chr8 35630102 T G 1.61E-04 Multiple complex diseases UNC5D intron 17554300 rs10106027 chr8 35721527 G A 1.61E-04 Multiple complex diseases / / 17554300 rs17359272 chr8 35798548 C T 3.72E-04 Hearing function / / 17255346 rs6987006 chr8 35803681 A G 0.000512 Salmonella-induced pyroptosis / / 22837397 rs2226323 chr8 35825293 G T 7.28E-04 Alzheimer's disease / / 17998437 rs2051169 chr8 35934191 C A 7.53E-04 Multiple complex diseases / / 17554300 rs2702469 chr8 36034017 C T 1.00E-04 Information processing speed / / 21130836 rs642174 chr8 36124334 A G 2.88E-04 Multiple complex diseases / / 17554300 rs670603 chr8 36158771 C T 2.57E-04 Type 2 diabetes / / 17463246 rs670603 chr8 36158771 C T 1.48E-04 Alcohol dependence / / 20201924 rs12544826 chr8 36161990 A G 8.71E-04 Suicide attempts in bipolar disorder / / 21041247 rs490767 chr8 36235570 G A 1.13E-04 Multiple complex diseases / / 17554300 rs490767 chr8 36235570 G A 8.79E-06 Gallstones / / 17632509 rs17372694 chr8 36282280 G T 2.63E-04 Alzheimer's disease / / 22005930 rs16885018 chr8 36294501 G A 1.39E-10 Multiple complex diseases / / 17554300 rs17301525 chr8 36331445 G T 2.98E-04 Alzheimer's disease / / 22005930 rs7004799 chr8 36341083 G T 5.63E-04 Multiple complex diseases / / 17554300 rs2703872 chr8 36377899 C A 3.53E-04 Alzheimer's disease / / 22005930 rs2843860 chr8 36378197 T C 2.22E-04 Alzheimer's disease / / 22005930 rs2843859 chr8 36380395 C T 3.51E-04 Alzheimer's disease / / 22005930 rs2703871 chr8 36380480 G A 3.41E-04 Alzheimer's disease / / 22005930 rs2703870 chr8 36382322 A G 3.09E-04 Alzheimer's disease / / 22005930 rs2843856 chr8 36383736 C T 1.52E-04 Alzheimer's disease / / 22005930 rs2843855 chr8 36384437 T A 3.46E-04 Alzheimer's disease / / 22005930 rs2507717 chr8 36384831 T C 3.46E-04 Alzheimer's disease / / 22005930 rs2464444 chr8 36384853 T C 3.45E-04 Alzheimer's disease / / 22005930 rs2703868 chr8 36384998 G A 3.44E-04 Alzheimer's disease / / 22005930 rs2703867 chr8 36385017 A G 3.42E-04 Alzheimer's disease / / 22005930 rs2843849 chr8 36386688 T A 3.42E-04 Alzheimer's disease / / 22005930 rs2703862 chr8 36395585 C A 8.65E-04 Alzheimer's disease / / 22005930 rs2406761 chr8 36405499 A G 8.73E-04 Alzheimer's disease / / 22005930 rs12682267 chr8 36407642 G A 4.54E-04 Alzheimer's disease / / 22005930 rs763878 chr8 36409988 T C 8.18E-04 Alzheimer's disease / / 22005930 rs10503990 chr8 36410648 G A 8.14E-04 Alzheimer's disease / / 22005930 rs11985207 chr8 36419741 G A 7.64E-04 Alzheimer's disease / / 22005930 rs10503991 chr8 36420002 A G 9.73E-05 Alzheimer's disease / / 22005930 rs10503991 chr8 36420002 A G 4.22E-06 Alopecia areata / / 22027810 rs7005989 chr8 36420164 A G 7.69E-04 Alzheimer's disease / / 22005930 rs7830903 chr8 36422827 G T 8.03E-04 Alzheimer's disease / / 22005930 rs16885223 chr8 36423707 T G 7.47E-04 Alzheimer's disease / / 22005930 rs6468370 chr8 36425166 C T 9.07E-04 Alzheimer's disease / / 22005930 rs7815569 chr8 36426620 G T 7.62E-04 Alzheimer's disease / / 22005930 rs7816204 chr8 36427107 G T 6.90E-04 Alzheimer's disease / / 22005930 rs7835510 chr8 36427319 A G 7.64E-04 Alzheimer's disease / / 22005930 rs11991128 chr8 36428948 A G 7.82E-04 Alzheimer's disease / / 22005930 rs7821548 chr8 36441582 T A 8.18E-04 Alzheimer's disease / / 22005930 rs16885235 chr8 36449677 A T 7.42E-04 Alzheimer's disease / / 22005930 rs7001165 chr8 36453052 G A 7.56E-04 Alzheimer's disease / / 22005930 rs7814403 chr8 36459454 T C 2.00E-06 Obesity-related traits / / 23251661 rs7814403 chr8 36459454 T C 3.00E-07 Obesity-related traits / / 23251661 rs2211743 chr8 36492258 T G 8.47E-05 Lymphocyte counts / / pha003094 rs2406835 chr8 36523577 T C 8.37E-04 Alzheimer's disease / / 22005930 rs13270289 chr8 36525139 C A 6.32E-04 Alzheimer's disease / / 22005930 rs7815357 chr8 36526816 C T 8.25E-04 Alzheimer's disease / / 22005930 rs13277766 chr8 36530975 A C 9.65E-04 Alzheimer's disease / / 22005930 rs13277766 chr8 36530975 A C 4.26E-05 Lymphocyte counts / / pha003094 rs2000446 chr8 36535542 T C 9.53E-04 Alzheimer's disease / / 22005930 rs6982811 chr8 36547313 T C 4.26E-05 Lymphocyte counts / / pha003094 rs3890448 chr8 36565705 C T 7.21E-05 ldl cholesterol / / pha003076 rs4739324 chr8 36568951 T C 2.87E-04 Alzheimer's disease / / 22005930 rs17305805 chr8 36628405 C A 6.29E-05 Cognitive test performance / / 20125193 rs10110896 chr8 36709011 G C 6.00E-08 Parkinson's disease (interaction with coffee consumption) KCNU1 intron 21876681 rs1005583 chr8 36787153 T C 1.81E-04 Heart Failure KCNU1 intron pha002885 rs16885577 chr8 36788479 A G 5.40E-06 Urinary metabolites KCNU1 missense 21572414 rs16885583 chr8 36789733 C T 5.40E-06 Urinary metabolites KCNU1 intron 21572414 rs7816345 chr8 36846109 C T 2.00E-14 Breast size / / 22747683 rs10110651 chr8 36847115 T C 2.14E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs4739466 chr8 36941542 G T 2.07E-05 Multiple complex diseases / / 17554300 rs4739466 chr8 36941542 G T 4.00E-06 Bipolar disorder / / 21254220 rs3015689 chr8 36948617 G A 3.89E-04 Insulin resistance / / 21901158 rs2407103 chr8 36951914 A G 2.00E-06 Insulin resistance / / 21901158 rs16885945 chr8 36992242 G A 5.08E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs9642764 chr8 36994086 C A 7.66E-05 Type 2 diabetes / / 17463246 rs576778 chr8 36994665 T A 1.21E-04 Asthma / / 23181788 rs543864 chr8 36995907 G A 9.77E-04 Type 2 diabetes / / 17463246 rs541139 chr8 36996228 G C 9.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs529423 chr8 37006062 A G 2.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs16886092 chr8 37015767 A C 5.14E-04 Multiple complex diseases / / 17554300 rs41523746 chr8 37038507 G A 3.02E-05 Multiple complex diseases / / 17554300 rs1157242 chr8 37039365 C T 7.00E-06 Type 2 diabetes and other traits / / 19734900 rs1157242 chr8 37039365 C T 7.00E-06 Alzheimer's disease (late onset) / / 21460841 rs1850650 chr8 37065784 G A 4.47E-05 Brain lesion load / / 19010793 rs1015003 chr8 37096059 G T 1.00E-06 Heart rate / / 23534349 rs1015003 chr8 37096059 G T 3.09E-05 Lipoproteins / / pha003079 rs6997125 chr8 37097563 T C 0.000692 Salmonella-induced pyroptosis / / 22837397 rs6985083 chr8 37100928 A G 2.76E-04 Multiple complex diseases / / 17554300 rs6468400 chr8 37118078 T G 9.85E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs6468401 chr8 37120864 A C 1.55E-06 Heart rate / / 23534349 rs10504003 chr8 37128540 G T 8.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs443831 chr8 37133141 C G 6.06E-04 Insulin resistance / / 21901158 rs11785575 chr8 37161801 G A 1.66E-06 Colorectal cancer / / 21242260 rs430801 chr8 37186241 T C 1.69E-05 Insulin resistance / / 21901158 rs11785595 chr8 37209300 C T 5.22E-05 Asthma / / 11022011 rs2843813 chr8 37209522 T A 1.30E-10 Narcolepsy / / 19629137 rs146670197 chr8 37218777 CT C 4.31E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs16886535 chr8 37218777 C G 4.31E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs10504004 chr8 37230090 T A 6.71E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs16886589 chr8 37233637 C G 6.68E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs16886686 chr8 37246921 T G 6.55E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs10108822 chr8 37253472 T C 6.55E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs16886714 chr8 37261465 A G 9.34E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6415415 chr8 37348106 T C 4.42E-04 Multiple complex diseases LOC100507439 intron 17554300 rs10955028 chr8 37405397 G T 0.0000022 Common carotid artery thickness (near walls) / / 23487405 rs6996881 chr8 37407920 G T 4.35E-04 Type 2 diabetes / / 17463246 rs6996881 chr8 37407920 G T 2.10E-05 Urinary metabolites / / 21572414 rs7017907 chr8 37408130 A C 1.72E-04 Type 2 diabetes / / 17463246 rs7017907 chr8 37408130 A C 1.20E-05 Urinary metabolites / / 21572414 rs7017907 chr8 37408130 A C 0.00000257 Common carotid artery thickness (near walls) / / 23487405 rs7017907 chr8 37408130 A C 0.00000447 Common carotid artery thickness (average of near and far wall measures) / / 23487405 rs7017907 chr8 37408130 A C 5.01E-04 Stroke / / pha002887 rs7003946 chr8 37409288 C T 4.73E-05 Nephrolithiasis / / 22396660 rs12682266 chr8 37428991 G A 6.69E-06 Liver cancer (hepatocellular carcinoma) in patients with chronic hepatitis B virus infection / / 22174901 rs12682266 chr8 37428991 G A 3.76E-05 Hepatocellular carcinoma (hepatitis B virus related) / / 23242368 rs7821974 chr8 37450001 T C 7.01E-06 Liver cancer (hepatocellular carcinoma) in patients with chronic hepatitis B virus infection / / 22174901 rs7821974 chr8 37450001 T C 2.32E-04 Hepatocellular carcinoma (hepatitis B virus related) / / 23242368 rs2275959 chr8 37455059 G A 6.35E-06 Liver cancer (hepatocellular carcinoma) in patients with chronic hepatitis B virus infection / / 22174901 rs2275959 chr8 37455059 G A 5.19E-04 Hepatocellular carcinoma (hepatitis B virus related) / / 23242368 rs4739526 chr8 37459524 G A 5.70E-06 Urinary metabolites / / 21572414 rs1573266 chr8 37462419 A G 7.44E-06 Liver cancer (hepatocellular carcinoma) in patients with chronic hepatitis B virus infection / / 22174901 rs1573266 chr8 37462419 A G 0.000262365 Hypertension (early onset hypertension) / / 22479346 rs1573266 chr8 37462419 A G 2.71E-05 Hepatocellular carcinoma (hepatitis B virus related) / / 23242368 rs7832424 chr8 37493505 A G 5.41E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10110753 chr8 37521658 C T 3.50E-06 White blood cell count / / 21738479 rs4976893 chr8 37660948 G A 6.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) GPR124 intron 23648065 rs12676965 chr8 37681426 T C 3.00E-06 Axial length GPR124 intron 24144296 rs6468442 chr8 37686749 A G 3.00E-07 Menopause (age at onset) GPR124 intron 19448619 rs35381288 chr8 37822624 C G 0.000000221 Triglycerides ADRB3 intron 23063622 rs35381288 chr8 37822624 C G 2.15E-23 Cholesterol,total ADRB3 intron 23063622 rs35381288 chr8 37822624 C G 9.36E-14 HDL cholesterol ADRB3 intron 23063622 rs35381288 chr8 37822624 C G 9.39E-12 LDL cholesterol ADRB3 intron 23063622 rs4994 chr8 37823798 A G 1 Drug response to Olanzapine ADRB3 missense 19193342 rs35361594 chr8 37824817 C T 5.00E-04 Atrial fibrillation ADRB3 nearGene-5 21846873 rs2517388 chr8 37977732 T G 9.00E-15 Menopause (age at onset) ASH2L intron 22267201 rs2517388 chr8 37977732 T G 1.00E-07 Menopause (age at onset) ASH2L intron 23307926 rs2517388 chr8 37977732 T G 4.89E-06 Triglycerides ASH2L intron pha003080 rs16887217 chr8 38004425 T C 4.00E-06 Orthostatic hypotension STAR intron 24124408 rs16887244 chr8 38031345 A G 1.00E-10 Schizophrenia LSM1 intron 22037555 rs7000184 chr8 38034194 C T 3.29E-09 LDL cholesterol BAG4 UTR-5 23063622 rs7000184 chr8 38034194 C T 4.76E-15 Cholesterol,total BAG4 UTR-5 23063622 rs7000184 chr8 38034194 C T 6.25E-13 HDL cholesterol BAG4 UTR-5 23063622 rs7825208 chr8 38327287 A G 2.83E-04 Longevity FGFR1 nearGene-5 22279548 rs7825208 chr8 38327287 A G 9.95E-05 Coronary heart disease FGFR1 nearGene-5 pha003031 rs7829058 chr8 38332095 G C 3.25E-04 Menarche (age at onset) / / 21102462 rs7829058 chr8 38332095 G C 3.25E-04 Menarche (age at onset) / / 21102462 rs881301 chr8 38332318 T C 3.31E-04 Type 2 diabetes / / 17463246 rs7830964 chr8 38350315 G T 8.56E-05 Body Fat Distribution / / pha003017 rs7830964 chr8 38350315 G T 5.42E-05 Body Fat Distribution / / pha003018 rs7845393 chr8 38359468 A C 1.04E-04 Obesity (extreme) / / 21935397 rs7813370 chr8 38399485 G A 7.90E-04 Parkinson's disease / / 17052657 rs11985941 chr8 38419633 T G 0.0001 Migraine / / 22678113 rs2461343 chr8 38441641 A G 7.95E-04 Type 2 diabetes / / 17463246 rs16887478 chr8 38442043 G A 3.64E-05 Parkinson's disease / / 16252231 rs16887478 chr8 38442043 G A 1.32E-04 IgE levels / / 17255346 rs1466050 chr8 38445999 A G 1.39E-04 IgE levels / / 17255346 rs1471009 chr8 38447349 C G 1.30E-04 IgE levels / / 17255346 rs1455189 chr8 38448914 A G 1.16E-04 IgE levels / / 17255346 rs6474427 chr8 38450131 T C 1.74E-04 Menarche (age at onset) / / 21102462 rs6474427 chr8 38450131 T C 1.74E-04 Menarche (age at onset) / / 21102462 rs2593094 chr8 38468681 G A 6.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs7832232 chr8 38469303 A G 5.00E-06 Pancreatic cancer / / 20686608 rs7835320 chr8 38471372 C T 7.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs13276269 chr8 38471616 G A 7.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs7845862 chr8 38471714 A G 4.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs1447057 chr8 38514745 C A 1.73E-04 Alzheimer's disease (late onset) / / 21379329 rs10958805 chr8 38540944 C T 0.0001 Migraine / / 22678113 rs10282916 chr8 38558577 G A 2.25E-06 Body Mass Index / / pha003009 rs10282916 chr8 38558577 G A 3.46E-05 Waist Circumference / / pha003024 rs10282916 chr8 38558577 G A 1.91E-05 Weight / / pha003026 rs4733891 chr8 38561031 C T 1.19E-04 Multiple complex diseases / / 17554300 rs13278546 chr8 38597727 C T 3.93E-04 Alzheimer's disease (late onset) TACC1 intron 21379329 rs13252226 chr8 38606606 G A 2.49E-05 Bipolar disorder TACC1 intron 21771265 rs6998357 chr8 38668319 T C 8.32E-04 Type 2 diabetes TACC1 intron 17463246 rs34235313 chr8 38677322 C T 6.61E-05 Epilepsy (remission after treatment) TACC1 missense 23962720 rs10808998 chr8 38691139 A G 8.32E-04 Type 2 diabetes TACC1 intron 17463246 rs1135990 chr8 38709553 C T 5.50E-06 Bipolar disorder TACC1 UTR-3 21771265 rs16887815 chr8 38715287 G A 6.02E-04 Type 2 diabetes / / 17463246 rs16887815 chr8 38715287 G A 3.31E-04 Multiple complex diseases / / 17554300 rs10092059 chr8 38718726 G A 2.50E-05 Urinary metabolites / / 21572414 rs4566997 chr8 38720556 A G 5.89E-04 Type 2 diabetes / / 17463246 rs2012230 chr8 38732792 C G 8.61E-05 Epilepsy (remission after treatment) / / 23962720 rs10958811 chr8 38772162 A C 8.38E-04 Coronary heart disease PLEKHA2 intron 21606135 rs6474512 chr8 38780606 A C 3.55E-04 Myopia (pathological) PLEKHA2 intron 21095009 rs11785248 chr8 38781696 T C 2.90E-05 Urinary metabolites PLEKHA2 intron 21572414 rs7007530 chr8 38813046 C T 3.21E-05 Glucose levels PLEKHA2 intron pha003057 rs6998440 chr8 38821665 G A 4.26E-04 Multiple complex diseases PLEKHA2 intron 17554300 rs12056655 chr8 38874444 C T 2.49E-05 Tunica Media ADAM9 intron pha003036 rs13268394 chr8 38875649 G A 4.78E-05 Tunica Media ADAM9 intron pha003036 rs6985673 chr8 38884176 T C 4.81E-05 Multiple complex diseases ADAM9 intron 17554300 rs12541231 chr8 38949532 C T 2.93E-05 Tunica Media ADAM9 intron pha003036 rs4733905 chr8 38959498 G A 3.54E-05 Tunica Media ADAM9 intron pha003036 rs9792291 chr8 38970749 C T 9.70E-06 Urinary metabolites ADAM32 intron 21572414 rs4733975 chr8 38973147 T C 4.10E-06 Urinary metabolites ADAM32 intron 21572414 rs6994035 chr8 38993605 C T 1.33E-04 Multiple complex diseases ADAM32 intron 17554300 rs4527834 chr8 39002753 T A 1.19E-04 Multiple complex diseases ADAM32 intron 17554300 rs4527834 chr8 39002753 T A 4.20E-06 Urinary metabolites ADAM32 intron 21572414 rs4636164 chr8 39014454 T C 2.17E-04 Multiple complex diseases ADAM32 intron 17554300 rs13439696 chr8 39019036 G C 2.20E-06 Urinary metabolites ADAM32 intron 21572414 rs13439859 chr8 39021035 G T 1.90E-06 Urinary metabolites ADAM32 intron 21572414 rs199865553 chr8 39027494 G A 0.0000056 Breast cancer(er negative) ADAM32 missense 23555315 rs4273822 chr8 39042042 T C 3.32E-04 Smoking initiation ADAM32 intron 24665060 rs10095244 chr8 39046387 C G 1.80E-06 Urinary metabolites ADAM32 intron 21572414 rs7830326 chr8 39068176 A G 2.70E-26 Meningococcal disease ADAM32 intron 20694013 rs7830326 chr8 39068176 A G 5.38E-04 Smoking initiation ADAM32 intron 24665060 rs7016661 chr8 39088049 T C 6.50E-07 Urinary metabolites ADAM32 intron 21572414 rs4422746 chr8 39123820 C T 7.22E-05 Cognitive performance ADAM32 intron 19734545 rs7830120 chr8 39131690 G A 9.31E-04 Alcohol dependence ADAM32 intron 21314694 rs6980625 chr8 39136231 T C 7.70E-07 Urinary metabolites ADAM32 intron 21572414 rs6415695 chr8 39304153 A G 2.58E-04 Multiple complex diseases / / 17554300 rs10095849 chr8 39408586 T G 7.80E-05 Parkinson's disease (age of onset) / / 19772629 rs3735880 chr8 39505826 C A 8.03E-06 HIV-1 viral setpoint ADAM18 intron 22174851 rs1349547 chr8 39548378 C T 2.00E-06 HIV-1 susceptibility ADAM18 intron 22174851 rs1901388 chr8 39553261 T C 4.63E-05 HIV-1 viral setpoint ADAM18 intron 22174851 rs201997 chr8 39584168 C G 2.70E-04 Neuroticism ADAM18 intron 17667963 rs6474182 chr8 39722457 C G 2.36E-04 Type 2 diabetes / / 17463246 rs3808606 chr8 39769375 A G 9.19E-05 Blood Pressure IDO1 nearGene-5 pha003050 rs6990252 chr8 39816468 A G 3.70E-07 Central corneal thickness IDO2 intron 20485516 rs2160860 chr8 39823145 A T 7.00E-11 Blood metabolite levels IDO2 intron 24816252 rs10109853 chr8 39862881 C T 3.60E-04 Myasthenia gravis IDO2 missense 23055271 rs35212142 chr8 39862893 T A 0.000096 Breast cancer IDO2 missense 23555315 rs10958579 chr8 39867827 G A 4.70E-04 Myasthenia gravis IDO2 intron 23055271 rs7008343 chr8 39872362 A G 4.30E-06 Urinary metabolites IDO2 intron 21572414 rs2981169 chr8 39881365 T G 4.60E-06 Urinary metabolites / / 21572414 rs2981170 chr8 39881648 T C 4.30E-06 Urinary metabolites / / 21572414 rs12544923 chr8 39887665 C T 6.68E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6983223 chr8 39901373 C T 9.89E-06 Multiple complex diseases / / 17554300 rs2955864 chr8 39901761 C T 9.51E-04 Response to TNF antagonist treatment / / 21061259 rs2929111 chr8 39904922 C A 4.20E-06 Parkinson's disease (familial) / / 18985386 rs2981189 chr8 39910665 A G 7.21E-06 Response to TNF antagonist treatment / / 21061259 rs7838116 chr8 39929155 G A 9.96E-04 Multiple complex diseases / / 17554300 rs7014749 chr8 39943820 A G 7.15E-06 Parkinson's disease (motor and cognition) / / 22658654 rs4367521 chr8 39978160 G A 6.34E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6989571 chr8 39986379 T G 3.08E-05 Coronary heart disease / / 21606135 rs7825010 chr8 39993166 A G 6.74E-05 Depression (quantitative trait) / / 23290196 rs10091355 chr8 40003790 T C 1.16E-05 Depression (quantitative trait) / / 23290196 rs10101533 chr8 40004060 G A 1.77E-05 Depression (quantitative trait) / / 23290196 rs10101647 chr8 40004160 G A 8.51E-05 Depression (quantitative trait) / / 23290196 rs7833452 chr8 40007469 A G 2.27E-05 Depression (quantitative trait) / / 23290196 rs7814906 chr8 40007597 G A 9.54E-06 Height / / 22021425 rs1383605 chr8 40010253 T A 1.88E-06 Depression (quantitative trait) / / 23290196 rs7004479 chr8 40010710 C T 1.87E-05 Depression (quantitative trait) / / 23290196 rs2242277 chr8 40010820 T C 2.28E-06 Depression (quantitative trait) / / 23290196 rs10958604 chr8 40013811 G T 6.88E-06 Depression (quantitative trait) / / 23290196 rs12679544 chr8 40014026 C T 2.80E-06 Depression (quantitative trait) / / 23290196 rs11784532 chr8 40016464 C T 8.58E-06 Depression (quantitative trait) / / 23290196 rs12541821 chr8 40019174 G A 7.51E-05 Depression (quantitative trait) / / 23290196 rs7822661 chr8 40020831 C T 9.75E-05 HIV-1 viral setpoint / / 22174851 rs7822661 chr8 40020831 C T 8.66E-05 Depression (quantitative trait) / / 23290196 rs7844209 chr8 40020906 T C 8.33E-04 Multiple complex diseases / / 17554300 rs10958605 chr8 40053605 C A 2.00E-06 Parkinson's disease (motor and cognition) / / 22658654 rs16888959 chr8 40060810 T C 9.51E-04 Coronary Artery Disease / / 17634449 rs3116102 chr8 40069791 G T 4.73E-04 Coronary Artery Disease / / 17634449 rs7002429 chr8 40073856 G C 5.28E-04 Coronary Artery Disease / / 17634449 rs2980848 chr8 40082330 C T 4.21E-04 Body mass index / / 21701565 rs1584996 chr8 40103055 T G 7.12E-04 Body mass index / / 21701565 rs2980835 chr8 40106771 A G 7.32E-04 Body mass index / / 21701565 rs2925015 chr8 40110259 T C 8.65E-04 Body mass index / / 21701565 rs16889079 chr8 40149921 A G 5.23E-05 Tuberculosis / / 24057671 rs16889118 chr8 40162609 A G 8.47E-05 Schizophrenia LOC100507481 intron 24253340 rs2168282 chr8 40164860 A G 2.00E-04 Myopia (pathological) LOC100507481 intron 21095009 rs16889133 chr8 40176490 A G 9.09E-05 Schizophrenia LOC100507481 intron 24253340 rs210660 chr8 40181632 G A 7.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100507481 intron 20877124 rs11779911 chr8 40181978 C A 7.00E-04 Pulmonary function LOC100507481 intron 23932459 rs210677 chr8 40196002 A G 3.19E-05 Personality dimensions LOC100507481 intron 22628180 rs11776037 chr8 40208140 C T 2.39E-05 Cognitive impairment induced by topiramate / / 22091778 rs11776037 chr8 40208140 C T 9.72E-05 Cognitive impairment induced by topiramate / / 22091778 rs210696 chr8 40217410 T A 2.00E-05 Personality dimensions / / 22628180 rs210697 chr8 40218405 C T 2.13E-05 Personality dimensions / / 22628180 rs210698 chr8 40219267 T C 1.81E-05 Personality dimensions / / 22628180 rs210700 chr8 40219804 C T 1.94E-05 Personality dimensions / / 22628180 rs210701 chr8 40220194 A G 2.29E-05 Personality dimensions / / 22628180 rs210704 chr8 40221484 G C 2.67E-05 Personality dimensions / / 22628180 rs210705 chr8 40221754 A C 2.67E-05 Personality dimensions / / 22628180 rs369891 chr8 40223247 A G 2.67E-05 Personality dimensions / / 22628180 rs451685 chr8 40225112 C A 2.12E-05 Personality dimensions / / 22628180 rs813406 chr8 40225630 G A 2.12E-05 Personality dimensions / / 22628180 rs7836057 chr8 40225832 A G 2.12E-05 Personality dimensions / / 22628180 rs9692857 chr8 40225876 C T 2.12E-05 Personality dimensions / / 22628180 rs7819163 chr8 40226460 C T 2.12E-05 Personality dimensions / / 22628180 rs6474247 chr8 40226685 A C 2.41E-05 Personality dimensions / / 22628180 rs3736647 chr8 40228421 A G 2.40E-05 Personality dimensions / / 22628180 rs184132 chr8 40237646 T C 2.00E-05 Urinary metabolites / / 21572414 rs11786458 chr8 40252701 G T 9.00E-06 Inattentive symptoms / / 18821565 rs11781238 chr8 40258904 C T 9.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs210884 chr8 40259573 C G 9.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs12679419 chr8 40259876 C T 8.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs12679452 chr8 40260048 C T 2.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs10107051 chr8 40260338 A G 3.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs182395 chr8 40260551 T C 3.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs10110212 chr8 40260813 A G 3.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs169788 chr8 40261358 G A 4.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs10092471 chr8 40267596 C T 3.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs2730204 chr8 40268296 T A 3.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs2730131 chr8 40269110 A G 7.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs2730133 chr8 40276217 A G 6.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs7845477 chr8 40277407 C A 3.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs2730145 chr8 40284780 A G 1.17E-04 Hemoglobin concentration / / 20534544 rs11785101 chr8 40314118 A C 8.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs2730200 chr8 40314852 C T 6.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs1560349 chr8 40315534 G A 6.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs2730201 chr8 40315684 C A 6.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs2565142 chr8 40315939 C T 1.24E-08 Metabolite levels / / 23281178 rs2565143 chr8 40316818 G A 7.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs2730202 chr8 40316900 G A 7.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs1560346 chr8 40318087 C G 6.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs4736865 chr8 40319197 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4736865 chr8 40319197 G A 1.02E-05 Cognitive impairment induced by topiramate / / 22091778 rs4736865 chr8 40319197 G A 8.32E-05 Cognitive impairment induced by topiramate / / 22091778 rs2565068 chr8 40319953 C T 9.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs2565071 chr8 40322353 C T 5.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs4737133 chr8 40324394 G T 5.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs12681030 chr8 40328020 C T 8.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs11785779 chr8 40329035 C T 8.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs7819777 chr8 40330071 A G 3.42E-04 Alzheimer's disease (late onset) / / 21379329 rs7819777 chr8 40330071 A G 7.24E-09 Metabolite levels / / 23281178 rs13278529 chr8 40333321 T G 5.05E-04 Hemoglobin concentration / / 20534544 rs11782411 chr8 40336076 A G 1.02E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11779687 chr8 40347975 T G 1.21E-08 Metabolite levels / / 23281178 rs12545330 chr8 40348491 T C 2.44E-08 Metabolite levels / / 23281178 rs16889497 chr8 40352640 G A 3.26E-04 Multiple complex diseases / / 17554300 rs16889498 chr8 40352899 C T 3.52E-04 Multiple complex diseases / / 17554300 rs11786932 chr8 40352948 G A 6.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs2195588 chr8 40356700 A G 3.98E-04 Type 2 diabetes / / 17463246 rs1367104 chr8 40359895 A C 2.18E-08 Metabolite levels / / 23281178 rs10091962 chr8 40362878 T C 2.47E-04 Hemoglobin concentration / / 20534544 rs2589916 chr8 40382481 T C 6.69E-04 Parkinson's disease / / 17052657 rs2251671 chr8 40382816 T C 4.90E-05 Subclinical atherosclerosis / / 17903303 rs2599675 chr8 40411787 T C 7.74E-04 Type 2 diabetes ZMAT4 intron 17463246 rs2722413 chr8 40423517 C T 0.0002653 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ZMAT4 intron 23233654 rs2722413 chr8 40423517 C T 2.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) ZMAT4 intron 23233662 rs2722410 chr8 40456407 T C 0.0003028 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ZMAT4 intron 23233654 rs2722410 chr8 40456407 T C 3.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) ZMAT4 intron 23233662 rs2599693 chr8 40478096 C A 0.000266 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ZMAT4 intron 23233654 rs2599693 chr8 40478096 C A 2.66E-04 Methotrexate clearance (acute lymphoblastic leukemia) ZMAT4 intron 23233662 rs6474262 chr8 40480966 G T 6.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZMAT4 intron 20877124 rs6474262 chr8 40480966 G T 7.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZMAT4 intron 20877124 rs2122950 chr8 40482821 G A 6.95E-04 Multiple complex diseases ZMAT4 intron 17554300 rs2122950 chr8 40482821 G A 1.34E-05 Bipolar disorder ZMAT4 intron 19488044 rs2122950 chr8 40482821 G A 2.02E-05 Bipolar Disorder ZMAT4 intron pha002863 rs2722425 chr8 40484239 T C 1.78E-08 Type 2 diabetes and 6 quantitative traits ZMAT4 intron 17848626 rs2722425 chr8 40484239 T C 2.00E-08 Fasting plasma glucose ZMAT4 intron 17903298 rs2722425 chr8 40484239 T C 9.00E-06 Fasting plasma glucose ZMAT4 intron 17903298 rs2589870 chr8 40492659 C T 0.0004351 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ZMAT4 intron 23233654 rs2589870 chr8 40492659 C T 4.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) ZMAT4 intron 23233662 rs1451683 chr8 40493711 G A 0.0008042 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ZMAT4 intron 23233654 rs1451683 chr8 40493711 G A 8.04E-04 Methotrexate clearance (acute lymphoblastic leukemia) ZMAT4 intron 23233662 rs12375383 chr8 40533909 G A 4.12E-05 Coronary heart disease ZMAT4 intron pha003032 rs7008373 chr8 40536636 C T 2.57E-05 Coronary heart disease ZMAT4 intron pha003032 rs6474266 chr8 40552727 G A 2.00E-04 Multiple complex diseases ZMAT4 intron 17554300 rs7842073 chr8 40565003 C T 3.20E-04 Lung function (forced vital capacity) ZMAT4 intron 24023788 rs7842073 chr8 40565003 C T 3.25E-04 Lung function (forced expiratory volume in 1 second) ZMAT4 intron 24023788 rs4326371 chr8 40593310 C T 5.55E-04 Multiple complex diseases ZMAT4 intron 17554300 rs7820759 chr8 40640413 C T 9.04E-05 Postoperative ventricular dysfunction ZMAT4 intron 21980348 rs10104640 chr8 40643406 A C 8.07E-05 Postoperative ventricular dysfunction ZMAT4 intron 21980348 rs7835606 chr8 40671114 C T 2.80E-05 Cognitive impairment induced by topiramate ZMAT4 intron 22091778 rs17647194 chr8 40674273 T C 3.16E-05 Height ZMAT4 intron 17255346 rs16889986 chr8 40676437 G A 8.87E-04 Response to taxane treatment (placlitaxel) ZMAT4 intron 23006423 rs16889988 chr8 40676775 C T 4.92E-05 Height ZMAT4 intron 17255346 rs1028014 chr8 40698232 T C 2.34E-04 Height ZMAT4 intron 17255346 rs868586 chr8 40704851 A G 1.55E-05 Myopia (severe) ZMAT4 intron 23933737 rs13254457 chr8 40707884 A C 3.07E-05 Myopia (severe) ZMAT4 intron 23933737 rs1553930 chr8 40713794 C T 2.59E-04 Multiple complex diseases ZMAT4 intron 17554300 rs869422 chr8 40723970 A G 2.22E-05 Myopia (severe) ZMAT4 intron 23933737 rs7829127 chr8 40726394 A G 3.71E-04 Multiple complex diseases ZMAT4 intron 17554300 rs7829127 chr8 40726394 A G 4.00E-10 Refractive error ZMAT4 intron 23396134 rs16890057 chr8 40726582 G A 3.86E-04 Multiple complex diseases ZMAT4 intron 17554300 rs6994354 chr8 40729498 G T 1.36E-04 Multiple complex diseases ZMAT4 intron 17554300 rs6994354 chr8 40729498 G T 7.75E-08 Metabolite levels ZMAT4 intron 23281178 rs2137277 chr8 40734662 A G 4.70E-16 Myopia (Age of onset) ZMAT4 intron 23468642 rs1533178 chr8 40739249 T C 8.82E-05 Myopia (severe) ZMAT4 intron 23933737 rs4736884 chr8 40739692 G A 2.90E-04 Multiple complex diseases ZMAT4 intron 17554300 rs4736893 chr8 40807189 A G 9.91E-05 Depression (quantitative trait) / / 23290196 rs4736788 chr8 40828429 C T 4.88E-05 Parkinson's disease / / pha002865 rs10094981 chr8 40831294 A C 4.82E-05 Parkinson's disease / / pha002865 rs7000419 chr8 40866962 A G 9.53E-05 Waist-Hip Ratio / / pha003013 rs12549460 chr8 40943837 T A 6.89E-04 Alzheimer's disease / / 17998437 rs11776952 chr8 40955447 A G 9.78E-05 Relative hand skill / / 24068947 rs77359933 chr8 40965396 C T 4.90E-05 Epilepsy (remission after treatment) / / 23962720 rs6474300 chr8 40965681 A G 4.38E-05 Alcohol dependence / / 21703634 rs12550040 chr8 40967164 G T 4.18E-05 Alcohol dependence / / 21703634 rs12547609 chr8 40972233 A C 3.02E-05 Alcohol dependence / / 21703634 rs12548368 chr8 40973567 A G 5.68E-05 Alcohol dependence / / 21703634 rs737505 chr8 40980390 C T 8.82E-04 Alcohol dependence / / 20201924 rs13266712 chr8 40984060 C A 7.37E-06 Carotenoid and tocopherol levels / / 19185284 rs13266712 chr8 40984060 C A 4.27E-05 Opioid sensitivity / / 23183491 rs7827040 chr8 40988523 C T 1.00E-04 Prostate cancer / / 21743057 rs11996523 chr8 40996160 G A 1.00E-05 Smoking behavior / / 20418888 rs13261501 chr8 41019095 G C 2.90E-06 Urinary metabolites / / 21572414 rs11985631 chr8 41022542 C T 2.20E-06 Urinary metabolites / / 21572414 rs4540396 chr8 41028701 T C 2.40E-06 Urinary metabolites / / 21572414 rs7018442 chr8 41030948 A G 4.57E-04 Response to TNF antagonist treatment / / 21061259 rs10089270 chr8 41034682 C T 3.10E-06 Urinary metabolites / / 21572414 rs10100775 chr8 41037284 C A 2.80E-06 Urinary metabolites / / 21572414 rs7005744 chr8 41049689 C T 1.40E-06 Urinary metabolites / / 21572414 rs13276051 chr8 41102763 C G 1.80E-05 Urinary metabolites / / 21572414 rs11774662 chr8 41137442 T C 1.54E-24 Narcolepsy SFRP1 intron 19629137 rs7834090 chr8 41142695 C T 6.96E-04 Multiple complex diseases SFRP1 intron 17554300 rs1447210 chr8 41180008 A G 2.29E-05 Lung cancer / / 18978787 rs7814391 chr8 41181421 G A 3.66E-05 Lung cancer / / 18978787 rs6474330 chr8 41201248 A G 8.39E-04 Multiple complex diseases / / 17554300 rs11779994 chr8 41203570 C T 8.08E-06 White blood cell count / / 21738479 rs12549180 chr8 41204995 A G 4.73E-04 Alzheimer's disease (late onset) / / 21379329 rs12549180 chr8 41204995 A G 9.69E-06 White blood cell count / / 21738479 rs4546646 chr8 41215593 T C 2.94E-06 White blood cell count / / 21738479 rs10958680 chr8 41228458 C T 1.75E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs10958680 chr8 41228458 C T 1.80E-06 White blood cell count / / 21738479 rs10958680 chr8 41228458 C T 0.0000981 post-traumatic stress disorder / / 22869035 rs10958680 chr8 41228458 C T 9.81E-05 Schizophrenia / / 22883433 rs4736805 chr8 41231323 A G 5.29E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs2883471 chr8 41231950 C T 0.0000236 post-traumatic stress disorder / / 22869035 rs2883471 chr8 41231950 C T 2.36E-05 Schizophrenia / / 22883433 rs973441 chr8 41260259 C T 1.54E-04 Alzheimer's disease / / 24755620 rs10097592 chr8 41261544 A G 7.63E-05 Amyotrophic lateral sclerosis / / 23624525 rs4029762 chr8 41313512 T C 8.55E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs16890592 chr8 41314843 G C 8.55E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs72633890 chr8 41346644 C T 7.53E-12 Metabolite levels / / 22286219 rs17657196 chr8 41365708 G A 3.28E-04 Type 2 diabetes GOLGA7 intron 17463246 rs919033 chr8 41377203 G A 2.79E-04 Cholesterol / / 17255346 rs7819949 chr8 41387921 C T 1.30E-04 Alcohol dependence GINS4 intron 20201924 rs7819949 chr8 41387921 C T 1.40E-04 Alcohol dependence GINS4 intron 20201924 rs11787055 chr8 41418135 A G 1.97E-04 Coronary Artery Disease / / 17634449 rs11987150 chr8 41418163 G A 1.42E-10 Non-obstructive azoospermia / / 22197933 rs17600159 chr8 41445509 A G 5.56E-06 White blood cell count AGPAT6 intron 21738479 rs12677439 chr8 41472845 C T 1.80E-05 Urinary metabolites AGPAT6 intron 21572414 rs13248554 chr8 41474290 T C 6.26E-05 Coronary Artery Disease AGPAT6 intron 17634449 rs890220 chr8 41478361 G A 8.82E-04 Response to taxane treatment (placlitaxel) AGPAT6 intron 23006423 rs7010532 chr8 41487885 T A 2.07E-04 Coronary Artery Disease / / 17634449 rs12549902 chr8 41509259 G A 7.57E-04 Type 2 diabetes / / 17463246 rs516946 chr8 41519248 T C 0.00053 HOMA-B ANK1 intron 22885922 rs516946 chr8 41519248 T C 5.20E-34 Type 2 diabetes ANK1 intron 22885922 rs516946 chr8 41519248 T C 7.80E-11 Type 2 diabetes (males) ANK1 intron 22885922 rs516946 chr8 41519248 T C 9.02E-04 Type 2 diabetes ANK1 intron 24390345 rs516946 chr8 41519248 T C 2.00E-07 Type 2 diabetes ANK1 intron 24509480 rs515071 chr8 41519462 A G 1.00E-08 Type 2 diabetes ANK1 intron 22456796 rs474059 chr8 41521469 C G 4.36E-05 Coronary Artery Disease ANK1 intron 17634449 rs563118 chr8 41521663 T C 3.12E-05 Coronary Artery Disease ANK1 intron 17634449 rs6989203 chr8 41523745 G A 1.90E-34 Type 2 diabetes ANK1 intron 22885922 rs475831 chr8 41524287 A G 8.35E-04 Coronary Artery Disease ANK1 intron 17634449 rs750625 chr8 41525914 C T 9.12E-04 Response to taxane treatment (placlitaxel) ANK1 cds-synon 23006423 rs13266210 chr8 41533514 A G 0.0000024 Type 2 diabetes ANK1 intron 22885922 rs11986485 chr8 41540387 C T 5.10E-06 Urinary metabolites ANK1 intron 21572414 rs4737004 chr8 41540884 G A 2.26E-05 Cognitive impairment induced by topiramate ANK1 intron 22091778 rs7831590 chr8 41547386 A G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ANK1 intron 22628534 rs6987404 chr8 41548312 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ANK1 intron 22628534 rs6474359 chr8 41549194 T C 1.00E-08 Glycated hemoglobin levels ANK1 intron 20858683 rs6474359 chr8 41549194 T C 1.18E-08 Glycated hemoglobin levels ANK1 intron 22885924 rs2241896 chr8 41555473 T C 9.99E-06 Ankle-brachial index ANK1 intron 22199011 rs10504043 chr8 41567871 C T 1.70E-04 Smoking initiation ANK1 intron 24665060 rs2099861 chr8 41581287 T C 3.64E-06 Ankle-brachial index ANK1 intron 22199011 rs1872877 chr8 41585571 C T 4.66E-06 Ankle-brachial index ANK1 intron 22199011 rs7003385 chr8 41586750 T C 5.24E-07 Ankle-brachial index ANK1 intron 22199011 rs2279437 chr8 41588186 A G 5.69E-06 Ankle-brachial index ANK1 intron 22199011 rs17661532 chr8 41591274 G A 2.00E-04 Myasthenia gravis ANK1 intron 23055271 rs516606 chr8 41595613 T C 4.85E-05 Insulin-related traits ANK1 intron pha002901 rs551580 chr8 41600648 G A 4.07E-04 Multiple complex diseases ANK1 intron 17554300 rs521184 chr8 41601685 C T 6.93E-06 Insulin-related traits ANK1 intron pha002901 rs488758 chr8 41607715 G A 6.72E-07 Red blood cell traits ANK1 intron 23222517 rs501154 chr8 41608164 C G 3.20E-04 Multiple complex diseases ANK1 intron 17554300 rs7831492 chr8 41614503 G A 5.02E-04 Multiple complex diseases ANK1 intron 17554300 rs7006290 chr8 41615138 G A 5.00E-06 Pulmonary function decline ANK1 intron 22424883 rs11780780 chr8 41623602 G A 3.67E-05 Meningococcal disease ANK1 intron 20694013 rs7461534 chr8 41628650 A G 1.54E-09 Red blood cell traits ANK1 intron 23222517 rs4737009 chr8 41630405 G A 6.00E-12 Glycated Hemoglobin levels ANK1 intron 20858683 rs4737009 chr8 41630405 G A 1.31E-08 Glycated hemoglobin levels ANK1 intron 22290723 rs4737009 chr8 41630405 G A 6.11E-12 Glycated hemoglobin levels ANK1 intron 22885924 rs4737009 chr8 41630405 G A 4.85E-11 Red blood cell traits ANK1 intron 23222517 rs4737009 chr8 41630405 G A 1.00E-15 Glycated hemoglobin levels ANK1 intron 24647736 rs1372725 chr8 41630702 G A 2.55E-05 Multiple complex diseases ANK1 intron 17554300 rs990174 chr8 41632230 C T 1.40E-10 Red blood cell traits ANK1 intron 23222517 rs2032736 chr8 41639266 C A 2.17E-08 Red blood cell traits ANK1 intron 23222517 rs2111805 chr8 41643457 G C 3.53E-10 Red blood cell traits ANK1 intron 23222517 rs2111804 chr8 41644266 A T 7.75E-04 Alzheimer's disease ANK1 intron 17998437 rs2111804 chr8 41644266 A T 2.76E-07 Red blood cell traits ANK1 intron 23222517 rs7823138 chr8 41644861 T C 3.88E-09 Red blood cell traits ANK1 intron 23222517 rs10099197 chr8 41654458 C T 4.03E-07 Red blood cell traits ANK1 intron 23222517 rs3758128 chr8 41657366 G A 5.11E-09 Red blood cell traits ANK1 intron 23222517 rs1579274 chr8 41658923 T G 9.99E-07 Red blood cell traits ANK1 intron 23222517 rs6999814 chr8 41660854 C A 1.24E-08 Red blood cell traits ANK1 intron 23222517 rs10090395 chr8 41666874 T C 9.03E-05 Prostate cancer ANK1 intron pha002877 rs2010743 chr8 41673929 T A 2.78E-07 Red blood cell traits ANK1 intron 23222517 rs4466386 chr8 41679853 T C 4.11E-04 Alzheimer's disease ANK1 intron 17998437 rs4466386 chr8 41679853 T C 1.64E-07 Red blood cell traits ANK1 intron 23222517 rs4466386 chr8 41679853 T C 6.52E-05 Alzheimer's disease ANK1 intron pha002879 rs2102360 chr8 41688828 A G 2.95E-07 Multiple complex diseases ANK1 intron 17554300 rs2102360 chr8 41688828 A G 9.12E-05 HIV-1 viral setpoint ANK1 intron 22174851 rs2883727 chr8 41698292 C T 2.27E-05 Height ANK1 intron pha003011 rs10111604 chr8 41727736 C T 2.20E-05 Urinary metabolites ANK1 intron 21572414 rs10092480 chr8 41874591 A T 0.0007109 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KAT6A intron 23233654 rs10092480 chr8 41874591 A T 7.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) KAT6A intron 23233662 rs7845738 chr8 41878427 T G 0.0006882 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KAT6A intron 23233654 rs7845738 chr8 41878427 T G 6.88E-04 Methotrexate clearance (acute lymphoblastic leukemia) KAT6A intron 23233662 rs12155532 chr8 41947770 T C 2.13E-04 Type 2 diabetes / / 17463246 rs12155532 chr8 41947770 T C 6.73E-04 Multiple complex diseases / / 17554300 rs7840827 chr8 41969770 G A 1.84E-06 Cardiovascular disease / / 18179892 rs7842131 chr8 41969930 C T 3.10E-04 Multiple complex diseases / / 17554300 rs8178811 chr8 42031992 A G 7.69E-13 Multiple complex diseases PLAT nearGene-3 17554300 rs2020921 chr8 42044965 G A 2.00E-08 Plasma plasminogen activator levels PLAT missense 24578379 rs9298621 chr8 42127453 T C 0.000035 Coronary artery calcification / / 23727086 rs5029748 chr8 42140549 G T 8.20E-04 Atrial fibrillation IKBKB intron 21846873 rs17875677 chr8 42147453 C T 0.000000289 Triglycerides IKBKB intron 23063622 rs4282553 chr8 42150362 C T 4.71E-05 Type 2 diabetes IKBKB intron 17463246 rs11992861 chr8 42184393 G T 0.0002 Coronary artery calcification IKBKB intron 23727086 rs16891227 chr8 42186026 C T 1.41E-12 LDL cholesterol IKBKB intron 23063622 rs3136739 chr8 42205080 A G 1.00E-09 Plasma plasminogen activator levels POLB intron 24578379 rs2272615 chr8 42219048 A G 4.01E-04 Type 2 diabetes POLB intron 23945395 rs3136788 chr8 42224155 A G 3.13E-04 Type 2 diabetes POLB intron 17463246 rs3136797 chr8 42226805 C G 7.64E-04 Height POLB missense 17255346 rs6841 chr8 42274264 G C 3.28E-05 Type 2 diabetes SLC20A2 UTR-3 17463246 rs3888124 chr8 42285336 G C 4.20E-05 Type 2 diabetes SLC20A2 intron 17463246 rs3888124 chr8 42285336 G C 2.97E-05 Schizophrenia SLC20A2 intron 19571809 rs4368963 chr8 42344238 G T 9.85E-05 Psoriasis SLC20A2 intron 20953190 rs6988165 chr8 42351176 C G 2.09E-09 Red blood cell traits SLC20A2 intron 23222517 rs2272685 chr8 42354102 C T 3.84E-08 Red blood cell traits SLC20A2 intron 23222517 rs7818789 chr8 42354257 C T 3.14E-08 Red blood cell traits SLC20A2 intron 23222517 rs4361746 chr8 42355041 C T 6.39E-09 Red blood cell traits SLC20A2 intron 23222517 rs4737048 chr8 42359035 G T 8.58E-09 Red blood cell traits SLC20A2 intron 23222517 rs12542076 chr8 42360593 C G 2.28E-09 Red blood cell traits SLC20A2 intron 23222517 rs13281070 chr8 42374546 A G 8.90E-05 Body Mass Index SLC20A2 intron pha003009 rs2923428 chr8 42388301 T C 1.99E-09 Red blood cell traits SLC20A2 intron 23222517 rs1901282 chr8 42392942 C G 2.98E-07 Red blood cell traits SLC20A2 intron 23222517 rs2974341 chr8 42398302 T A 1.57E-09 Red blood cell traits C8orf40 intron 23222517 rs2923446 chr8 42404177 G A 5.59E-07 Red blood cell traits C8orf40 intron 23222517 rs13250124 chr8 42404737 G A 2.18E-09 Red blood cell traits C8orf40 intron 23222517 rs2923448 chr8 42406008 G A 1.45E-09 Red blood cell traits C8orf40 intron 23222517 rs2974354 chr8 42413943 A G 8.54E-07 Red blood cell traits / / 23222517 rs12677427 chr8 42414226 T A 1.22E-09 Red blood cell traits / / 23222517 rs2974322 chr8 42424724 T C 2.65E-10 Red blood cell traits / / 23222517 rs1343875 chr8 42424749 C T 5.19E-07 Red blood cell traits / / 23222517 rs2923437 chr8 42425399 A C 1.04E-07 Red blood cell traits / / 23222517 rs10958722 chr8 42425487 T C 1.20E-09 Red blood cell traits / / 23222517 rs2974309 chr8 42426961 G A 1.32E-09 Red blood cell traits / / 23222517 rs4736834 chr8 42427350 C A 2.84E-05 Suicide attempts in bipolar disorder / / 21423239 rs2923441 chr8 42429937 T G 8.79E-05 Lymphocyte counts / / 22286170 rs2923441 chr8 42429937 T G 3.35E-10 Red blood cell traits / / 23222517 rs2923442 chr8 42435493 T C 9.49E-10 Red blood cell traits / / 23222517 rs2974342 chr8 42436651 T G 1.67E-10 Red blood cell traits / / 23222517 rs2923399 chr8 42439509 G A 4.17E-07 Red blood cell traits / / 23222517 rs2356610 chr8 42446238 T G 1.33E-10 Red blood cell traits / / 23222517 rs2923405 chr8 42448126 T G 1.68E-10 Red blood cell traits / / 23222517 rs2167338 chr8 42455079 A G 4.85E-08 Red blood cell traits / / 23222517 rs2923411 chr8 42455206 T C 1.62E-10 Red blood cell traits / / 23222517 rs10109400 chr8 42455353 T C 2.52E-08 Red blood cell traits / / 23222517 rs2923415 chr8 42455577 A G 5.09E-08 Red blood cell traits / / 23222517 rs6987853 chr8 42457450 T C 6.05E-11 Red blood cell traits / / 23222517 rs13251378 chr8 42468218 C T 7.03E-04 Acute lung injury / / 22295056 rs4737051 chr8 42468348 A G 4.07E-05 Suicide attempts in bipolar disorder / / 21423239 rs7341565 chr8 42469639 T C 2.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs11996441 chr8 42476205 C T 8.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs2974325 chr8 42481880 T G 1.12E-04 Multiple complex diseases / / 17554300 rs2974325 chr8 42481880 T G 4.01E-04 Body mass index / / 21701565 rs4737055 chr8 42483326 T C 8.16E-05 Hemoglobin / / pha003096 rs4737055 chr8 42483326 T C 7.31E-05 Hematocrit / / pha003097 rs1530850 chr8 42504953 G C 9.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs6989472 chr8 42505466 T C 3.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs1376442 chr8 42509597 G A 2.98E-04 Fibrinogen / / 17255346 rs10958725 chr8 42524584 T G 8.50E-08 Smoking behavior / / 20418888 rs10958725 chr8 42524584 T G 3.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs10958725 chr8 42524584 T G 1.41E-05 Blood Pressure / / pha003050 rs7837296 chr8 42526894 A C 3.80E-07 Smoking behavior / / 20418888 rs34325700 chr8 42528667 G GA 4.40E-07 Smoking behavior / / 20418888 rs5005909 chr8 42528667 G A 4.40E-07 Smoking behavior / / 20418888 rs1979140 chr8 42530836 T C 2.30E-08 Smoking behavior / / 20418888 rs1979140 chr8 42530836 T C 3.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs10958726 chr8 42535909 G T 1.70E-08 Smoking behavior / / 20418888 rs10958726 chr8 42535909 G T 3.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs7842601 chr8 42537055 C T 2.70E-08 Smoking behavior / / 20418888 rs7842601 chr8 42537055 C T 3.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs13273442 chr8 42544017 A G 4.30E-08 Smoking behavior / / 20418888 rs13273442 chr8 42544017 A G 2.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs13273442 chr8 42544017 A G 1.75E-05 Blood Pressure / / pha003050 rs1451239 chr8 42546542 G A 3.20E-08 Smoking behavior / / 20418888 rs1451239 chr8 42546542 G A 2.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs1451240 chr8 42546711 A G 3.20E-08 Smoking behavior / / 20418888 rs1451240 chr8 42546711 A G 2.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs1451240 chr8 42546711 A G 7.00E-16 Nicotine dependence / / 22524403 rs1451240 chr8 42546711 A G 1.49E-05 Blood Pressure / / pha003050 rs1955185 chr8 42549647 C T 1.84E-04 Nicotine dependence / / 17158188 rs1955185 chr8 42549647 C T 2.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs13277254 chr8 42549982 G A 6.54E-05 Nicotine dependence / / 17158188 rs13277524 chr8 42550057 G T 1.14E-04 Nicotine dependence / / 17158188 rs6474412 chr8 42550498 C T 2.00E-04 Nicotine dependence / / 17158188 rs6474412 chr8 42550498 C T 1.00E-08 Smoking behavior / / 20418888 rs6474412 chr8 42550498 C T 2.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs7004381 chr8 42551161 A G 3.00E-08 Smoking behavior / / 20418888 rs7004381 chr8 42551161 A G 2.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs4950 chr8 42552633 G A 1.77E-04 Suicide attempts in bipolar disorder CHRNB3 UTR-5 21423239 rs1530848 chr8 42552908 G T 4.80E-08 Smoking behavior CHRNB3 intron 20418888 rs1530848 chr8 42552908 G T 2.60E-04 Suicide attempts in bipolar disorder CHRNB3 intron 21423239 rs13280604 chr8 42559586 G A 1.30E-08 Smoking behavior CHRNB3 intron 20418888 rs13280604 chr8 42559586 G A 2.75E-04 Suicide attempts in bipolar disorder CHRNB3 intron 21423239 rs6997909 chr8 42560249 A G 2.30E-08 Smoking behavior CHRNB3 intron 20418888 rs6997909 chr8 42560249 A G 2.83E-04 Suicide attempts in bipolar disorder CHRNB3 intron 21423239 rs6474414 chr8 42560336 A C 3.90E-08 Smoking behavior CHRNB3 intron 20418888 rs6474414 chr8 42560336 A C 2.74E-04 Suicide attempts in bipolar disorder CHRNB3 intron 21423239 rs6474414 chr8 42560336 A C 2.23E-05 Blood Pressure CHRNB3 intron pha003050 rs6474415 chr8 42562938 G A 2.90E-08 Smoking behavior CHRNB3 intron 20418888 rs6474415 chr8 42562938 G A 2.75E-04 Suicide attempts in bipolar disorder CHRNB3 intron 21423239 rs11783289 chr8 42574596 C T 6.65E-04 Suicide attempts in bipolar disorder CHRNB3 intron 21423239 rs386724911 chr8 42578059 TAT TTC 9.62E-04 Suicide attempts in bipolar disorder CHRNB3 intron 21423239 rs4236926 chr8 42578059 T G 9.62E-04 Suicide attempts in bipolar disorder CHRNB3 intron 21423239 rs16891561 chr8 42579739 T C 1.10E-07 Smoking behavior CHRNB3 intron 20418888 rs56198260 chr8 42587552 G A 0.00074 Breast cancer CHRNB3 missense 23555315 rs7017612 chr8 42599245 A C 3.80E-07 Smoking behavior / / 20418888 rs892413 chr8 42614378 C A 5.79E-04 Heart Failure CHR/6 intron pha002885 rs2196128 chr8 42618286 T C 4.64E-04 Multiple complex diseases CHR/6 intron 17554300 rs6474421 chr8 42657098 G A 2.80E-05 Systemic sclerosis / / 21750679 rs7829867 chr8 42769951 C T 9.40E-05 Pericardial fat HOOK3 intron 22589742 rs13251524 chr8 42820508 A G 7.00E-05 Pericardial fat HOOK3 intron 22589742 rs1620525 chr8 42864916 G A 2.81E-04 Alzheimer's disease (late onset) HOOK3 intron 21379329 rs1052654 chr8 42885355 C A 7.20E-05 Pericardial fat HOOK3 UTR-3 22589742 rs10958736 chr8 42918890 A G 7.84E-04 Alzheimer's disease FNTA intron 24755620 rs4236927 chr8 42937608 C T 1.94E-04 Alzheimer's disease (late onset) FNTA intron 21379329 rs7001861 chr8 42951287 T C 2.47E-04 Alzheimer's disease (late onset) SGK196 intron 21379329 rs13271956 chr8 42979828 T C 5.80E-05 Pericardial fat / / 22589742 rs4272427 chr8 43024625 T G 4.07E-04 Alzheimer's disease (late onset) HGS/T intron 21379329 rs4559283 chr8 43027010 G A 9.83E-04 Type 2 diabetes HGS/T intron 17463246 rs4559283 chr8 43027010 G A 1.63E-04 Alzheimer's disease (late onset) HGS/T intron 21379329 rs13253966 chr8 43058385 C T 5.30E-05 Pericardial fat HGS/T nearGene-3 22589742 rs13271165 chr8 43066188 T C 5.40E-05 Pericardial fat / / 22589742 rs16891713 chr8 43078894 A G 4.95E-04 Multiple complex diseases / / 17554300 rs13266490 chr8 43084405 C T 4.20E-05 Pericardial fat / / 22589742 rs10958740 chr8 43086928 A G 2.73E-05 Alzheimer's disease (late onset) / / 21379329 rs13268355 chr8 43102563 G T 1.30E-05 Pericardial fat / / 22589742 rs2170206 chr8 43107096 C T 1.20E-05 Pericardial fat / / 22589742 rs1825011 chr8 43107776 A G 1.70E-04 Alzheimer's disease (late onset) / / 21379329 rs13274253 chr8 43108207 G T 2.30E-05 Pericardial fat / / 22589742 rs7013548 chr8 43123361 A G 1.00E-05 Pericardial fat / / 22589742 rs7816853 chr8 43124666 T C 2.88E-05 Alzheimer's disease (late onset) / / 21379329 rs7015816 chr8 43127585 C T 5.10E-06 Pericardial fat / / 22589742 rs6981146 chr8 43128013 G C 4.70E-06 Pericardial fat / / 22589742 rs7012007 chr8 43129447 T C 4.20E-06 Pericardial fat / / 22589742 rs7012014 chr8 43129466 T C 6.90E-06 Pericardial fat / / 22589742 rs7008122 chr8 43129576 A C 6.90E-06 Pericardial fat / / 22589742 rs6988652 chr8 43129677 C T 7.00E-06 Pericardial fat / / 22589742 rs6474435 chr8 43134673 T A 6.40E-06 Pericardial fat / / 22589742 rs7007170 chr8 43137728 C A 3.80E-06 Pericardial fat / / 22589742 rs7000815 chr8 43140557 A C 6.40E-06 Pericardial fat / / 22589742 rs13256973 chr8 43140709 T C 2.00E-06 Pericardial fat / / 22589742 rs13254336 chr8 43141070 G A,T 6.40E-06 Pericardial fat / / 22589742 rs16875576 chr8 43141572 T C 3.80E-06 Pericardial fat / / 22589742 rs16891786 chr8 43142080 G T 3.80E-06 Pericardial fat / / 22589742 rs13250275 chr8 43143803 C T 6.40E-06 Pericardial fat / / 22589742 rs7016102 chr8 43145298 G A 9.10E-06 Pericardial fat / / 22589742 rs6474439 chr8 43150282 A G 5.80E-06 Pericardial fat POTEA intron 22589742 rs1971957 chr8 43215240 A G 3.75E-05 Alzheimer's disease (late onset) POTEA intron 21379329 rs881907 chr8 43217541 T C 3.76E-05 Alzheimer's disease (late onset) POTEA intron 21379329 rs1921716 chr8 43257648 G A 1.55E-05 Alzheimer's disease (late onset) / / 21379329 rs35525166 chr8 43262177 C T 2.96E-11 Metabolite levels / / 22286219 rs2978832 chr8 43318100 G A 9.62E-06 Alzheimer's disease (late onset) / / 21379329 rs4737108 chr8 43389423 T C 3.65E-04 Alzheimer's disease / / 24755620 rs4736858 chr8 43409351 A G 8.60E-06 Urinary metabolites / / 21572414 rs4737118 chr8 43414015 A G 3.63E-26 Gender / / 22362730 rs11995771 chr8 43426690 C T 1.96E-05 Alzheimer's disease (late onset) / / 21379329 rs7463498 chr8 43447235 G A 9.59E-04 Alzheimer's disease / / 24755620 rs8175525 chr8 43473748 A G 3.65E-05 Alzheimer's disease (late onset) / / 21379329 rs10105921 chr8 43478468 G A 5.00E-08 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs6474486 chr8 43539041 C T 4.59E-04 Alzheimer's disease / / 24755620 rs7465445 chr8 43552252 T C 5.24E-05 Alzheimer's disease (late onset) / / 21379329 rs9802066 chr8 43612054 A G 3.49E-05 Alzheimer's disease (late onset) / / 21379329 rs13249243 chr8 43641044 T G 8.27E-05 Alzheimer's disease (late onset) / / 21379329 rs10808981 chr8 43646413 A G 3.17E-05 Alzheimer's disease (late onset) / / 21379329 rs8185857 chr8 43657438 G A 9.21E-04 Multiple complex diseases / / 17554300 rs8175501 chr8 43662756 G C 1.16E-04 Alzheimer's disease / / 24755620 rs4131198 chr8 43663675 A G 3.79E-05 Alzheimer's disease (late onset) / / 21379329 rs8185905 chr8 43674370 A G 4.83E-05 Alzheimer's disease (late onset) / / 21379329 rs4976932 chr8 43690577 T C 8.60E-05 Alzheimer's disease (late onset) / / 21379329 rs8185920 chr8 43692822 A G 4.90E-05 Alzheimer's disease (late onset) / / 21379329 rs58810682 chr8 43695234 G T 8.00E-06 Response to amphetamines / / 22952603 rs4976933 chr8 43696117 G A 1.40E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12677461 chr8 43712587 A G 3.43E-05 Vitiligo / / 22951725 rs8175350 chr8 43749726 A G 2.15E-05 Alzheimer's disease (late onset) / / 21379329 rs8185786 chr8 43762681 C T 3.89E-05 Alzheimer's disease / / 24755620 rs4976912 chr8 43773306 T C 5.15E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12676279 chr8 43784378 C T 5.02E-04 Alzheimer's disease / / 24755620 rs2353199 chr8 46924357 C T 6.39E-05 Alzheimer's disease / / 24755620 rs35526436 chr8 46929173 G A 2.16E-05 Alzheimer's disease / / 24755620 rs4872731 chr8 46936840 G A 6.45E-04 Alzheimer's disease / / 24755620 rs11136104 chr8 46945571 A G 3.98E-04 Alzheimer's disease / / 24755620 rs4242436 chr8 46953540 G A 7.02E-05 Alzheimer's disease / / 24755620 rs6558207 chr8 46994437 T C 1.20E-04 Alzheimer's disease / / 24755620 rs13267299 chr8 47001431 A G 7.35E-04 Alzheimer's disease / / 24755620 rs13261801 chr8 47023574 C T 7.73E-04 Alzheimer's disease / / 24755620 rs12679978 chr8 47033200 C T 7.75E-04 Alzheimer's disease / / 24755620 rs11136135 chr8 47075668 A G 5.77E-05 Alzheimer's disease (late onset) / / 21379329 rs11775579 chr8 47115069 C T 3.10E-04 Alzheimer's disease (late onset) / / 21379329 rs11136146 chr8 47136695 G C 4.22E-05 Multiple complex diseases / / 17554300 rs4872703 chr8 47141802 C T 7.96E-04 Alzheimer's disease / / 24755620 rs11136151 chr8 47151239 G A 4.83E-04 Alzheimer's disease / / 24755620 rs2353447 chr8 47286693 C T 1.40E-25 Narcolepsy / / 19629137 rs10094715 chr8 47384963 A G 3.65E-04 Multiple complex diseases / / 17554300 rs10094715 chr8 47384963 A G 3.33E-16 Gallstones / / 17632509 rs4313171 chr8 47415084 C T 3.51E-04 Alzheimer's disease / / 24755620 rs4631476 chr8 47434054 C A 8.65E-04 Alzheimer's disease / / 24755620 rs13279826 chr8 47628565 T A 4.31E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2049451 chr8 47633440 A G 9.82E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs13252450 chr8 47706157 G A 1.01E-05 Serum metabolites / / 19043545 rs11136098 chr8 47874769 A G 3.36E-04 Multiple complex diseases / / 17554300 rs10108436 chr8 47876101 C A 4.80E-04 Multiple complex diseases / / 17554300 rs2287654 chr8 47947701 T G 4.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs7016791 chr8 47994691 A G 6.80E-05 Pericardial fat / / 22589742 rs13273902 chr8 48003688 A T 6.80E-05 Pericardial fat / / 22589742 rs7004078 chr8 48014191 G A 6.60E-05 Pericardial fat / / 22589742 rs6991259 chr8 48014704 A T 6.50E-05 Pericardial fat / / 22589742 rs4477031 chr8 48016835 C T 6.50E-05 Pericardial fat / / 22589742 rs12543695 chr8 48017316 G A 6.50E-05 Pericardial fat / / 22589742 rs7012121 chr8 48033010 C G 7.40E-04 Multiple complex diseases / / 17554300 rs11776212 chr8 48055966 G A 9.14E-05 Monocyte counts / / pha003089 rs4495437 chr8 48086804 G T 8.50E-05 Pericardial fat / / 22589742 rs10086987 chr8 48089531 G C 8.20E-05 Pericardial fat / / 22589742 rs10086987 chr8 48089531 G C 8.27E-07 Red blood cell traits / / 23222517 rs10102598 chr8 48089751 A G 7.97E-04 Heart Failure / / pha002884 rs4388466 chr8 48115012 C T 9.07E-07 Red blood cell traits / / 23222517 rs118006186 chr8 48205314 A C 9.32E-05 Serum metabolites KIAA0146 intron 19043545 rs10105470 chr8 48218380 G C 5.57E-04 Multiple complex diseases KIAA0146 intron 17554300 rs111186683 chr8 48218380 G C 5.57E-04 Multiple complex diseases KIAA0146 intron 17554300 rs12682269 chr8 48343122 G A 8.71E-07 Red blood cell traits KIAA0146 intron 23222517 rs4594029 chr8 48458223 G A 9.45E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines KIAA0146 intron 21844884 rs2130413 chr8 48482098 T G 4.44E-04 Alzheimer's disease KIAA0146 intron 24755620 rs6473187 chr8 48483958 G A 2.17E-05 Paclitaxel-induced neuropathy KIAA0146 intron 23776197 rs4873395 chr8 48506628 G A 4.10E-04 Alzheimer's disease KIAA0146 intron 24755620 rs4608108 chr8 48515523 T G 6.41E-04 Alzheimer's disease KIAA0146 intron 24755620 rs4608108 chr8 48515523 T G 9.84E-05 Waist Circumference KIAA0146 intron pha003023 rs41528455 chr8 48560706 G A 4.95E-04 Multiple complex diseases KIAA0146 intron 17554300 rs11778548 chr8 48630207 G A 8.54E-04 Alzheimer's disease KIAA0146 intron 24755620 rs8178258 chr8 48689366 C T 2.47E-04 Multiple complex diseases PRKDC intron 17554300 rs41390145 chr8 48691906 C T 4.95E-04 Multiple complex diseases PRKDC intron 17554300 rs10504062 chr8 48737224 T C 2.65E-17 Triglycerides PRKDC intron 23063622 rs10504062 chr8 48737224 T C 4.90E-23 LDL cholesterol PRKDC intron 23063622 rs4521758 chr8 48741570 C T 0.000073 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 PRKDC intron 21873659 rs6473879 chr8 48797292 C A 6.95E-04 Multiple complex diseases PRKDC intron 17554300 rs2213178 chr8 48816716 G A 9.67E-05 Non-alcoholic fatty liver disease histology (other) PRKDC intron 20708005 rs2213178 chr8 48816716 G A 6.65E-05 Elbow pain PRKDC intron pha003008 rs2213178 chr8 48816716 G A 9.88E-05 Weight PRKDC intron pha003026 rs8178046 chr8 48841708 G A 1.48E-04 Response to radiotherapy in cancer (late toxicity) PRKDC missense 24785509 rs8178046 chr8 48841708 G A 8.00E-05 Response to radiotherapy in cancer (late toxicity) PRKDC missense 24785509 rs9657054 chr8 48882899 C T 4.14E-04 Multiple complex diseases MCM4 intron 17554300 rs10808897 chr8 48974616 G T 1.85E-04 Multiple complex diseases / / 17554300 rs4873777 chr8 48984250 A C 9.14E-04 Multiple complex diseases / / 17554300 rs11778329 chr8 49053165 C T 7.00E-06 Attention deficit hyperactivity disorder / / 21784300 rs10099462 chr8 49156890 T C 2.10E-05 Urinary metabolites / / 21572414 rs4552930 chr8 49170958 A G 0.000000142 Left ventricular mass / / 23275298 rs4552931 chr8 49171227 A G 0.000000143 Left ventricular mass / / 23275298 rs1022140 chr8 49213910 A G 3.92E-04 Multiple complex diseases / / 17554300 rs1022140 chr8 49213910 A G 0.0000952 Salmonella-induced pyroptosis / / 22837397 rs6987448 chr8 49323385 C T 6.70E-04 Alcohol dependence / / 20201924 rs1123189 chr8 49358439 C T 5.80E-05 White matter hyperintensity burden / / 21681796 rs13280598 chr8 49364880 C A 5.70E-04 Alcohol dependence / / 20201924 rs10091807 chr8 49409929 T C 8.55E-04 Stroke / / pha002886 rs10098707 chr8 49424260 T G 6.90E-05 White matter hyperintensity burden / / 21681796 rs16937605 chr8 49427509 C T 1.17E-04 Multiple complex diseases / / 17554300 rs2891639 chr8 49441535 G A 6.70E-05 White matter hyperintensity burden / / 21681796 rs970214 chr8 49447398 A G 6.40E-05 White matter hyperintensity burden / / 21681796 rs1393550 chr8 49452997 G T 6.20E-05 White matter hyperintensity burden / / 21681796 rs16937767 chr8 49457532 C T 7.40E-05 White matter hyperintensity burden / / 21681796 rs10094801 chr8 49460592 G A 7.40E-05 White matter hyperintensity burden / / 21681796 rs5001149 chr8 49462954 G T 7.50E-05 White matter hyperintensity burden / / 21681796 rs6981394 chr8 49465977 A G 7.60E-05 White matter hyperintensity burden / / 21681796 rs10087665 chr8 49487238 A C 6.50E-05 White matter hyperintensity burden / / 21681796 rs16937921 chr8 49491875 T C 4.60E-05 White matter hyperintensity burden / / 21681796 rs868444 chr8 49502481 C A 4.60E-05 White matter hyperintensity burden / / 21681796 rs2384925 chr8 49529028 T C 5.42E-04 Schizophrenia / / 19197363 rs2279302 chr8 49536604 C G 9.20E-04 Type 2 diabetes / / 17463246 rs745487 chr8 49548261 A G 6.15E-04 Type 2 diabetes / / 17463246 rs10957183 chr8 49551144 G C 8.50E-05 Personality dimensions / / 18957941 rs6999204 chr8 49567497 A C 1.39E-05 Amyotrophic lateral sclerosis / / 20801717 rs878995 chr8 49581767 G T 0.0000761 Salmonella-induced pyroptosis / / 22837397 rs1473441 chr8 49588463 A G 7.40E-05 Personality dimensions / / 18957941 rs10097910 chr8 49606500 T C 2.70E-05 Urinary metabolites / / 21572414 rs17712506 chr8 49691705 G A 9.42E-04 Type 2 diabetes / / 17463246 rs10108023 chr8 49717484 G A 8.60E-05 Personality dimensions / / 18957941 rs4075257 chr8 49773584 T G 9.23E-04 Multiple complex diseases / / 17554300 rs16938992 chr8 49779947 T G 4.59E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11781930 chr8 49803153 C A,T 6.06E-04 Taste perception / / 22132133 rs12155623 chr8 49812201 A T 3.00E-07 Sudden cardiac arrest / / 21658281 rs10087659 chr8 49820430 G A 4.74E-05 Sudden cardiac arrest / / 21658281 rs11774804 chr8 49880975 T C 9.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17641971 chr8 49884817 T C 3.00E-22 Blood metabolite levels / / 24816252 rs6982145 chr8 49941703 G A 8.12E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10504073 chr8 50024944 C T 3.00E-32 Blood metabolite ratios / / 24816252 rs11987140 chr8 50080612 G A 6.27E-05 Lung function (forced vital capacity) / / 24023788 rs1480390 chr8 50108120 T C 9.62E-06 Socioeconomic Factors / / pha003066 rs1480391 chr8 50108420 C T 7.53E-05 Lung function (forced vital capacity) / / 24023788 rs6988643 chr8 50109638 A T 0.00008096 Sarcoidosis / / 22952805 rs7844930 chr8 50115193 A C 0.0001951 Sarcoidosis / / 22952805 rs12681413 chr8 50133938 A G 6.24E-04 Multiple complex diseases / / 17554300 rs1383271 chr8 50170400 C T 0.000307 Salmonella-induced pyroptosis / / 22837397 rs17664823 chr8 50195185 C T 9.61E-05 Lung function (forced vital capacity) / / 24023788 rs9643586 chr8 50217597 T C 7.23E-04 Multiple complex diseases / / 17554300 rs6989237 chr8 50222788 A G 8.69E-04 Multiple complex diseases / / 17554300 rs1356755 chr8 50258845 T A 1.06E-04 Multiple complex diseases / / 17554300 rs2139454 chr8 50259111 T C 5.49E-05 Recombination rate / / 21698098 rs2139451 chr8 50306815 C T 5.44E-05 HDL cholesterol / / pha003075 rs769127 chr8 50359113 G A 8.31E-05 Blood Pressure / / pha003040 rs1458574 chr8 50379250 T C 5.86E-04 Multiple complex diseases / / 17554300 rs723497 chr8 50386621 C G 3.48E-05 Personality dimensions / / 18957941 rs1620518 chr8 50407950 A G 6.22E-04 Type 2 diabetes / / 17846124 rs1620518 chr8 50407950 A G 6.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7838995 chr8 50506522 G A 5.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13263794 chr8 50511244 A G 7.90E-05 Personality dimensions / / 18957941 rs11778828 chr8 50520030 C T 9.38E-05 Personality dimensions / / 18957941 rs10104518 chr8 50522915 A T 5.53E-04 Multiple complex diseases / / 17554300 rs1496306 chr8 50540708 T C 0.0000163 Otitis media (children 3 years old or younger) / / 23133572 rs1021576 chr8 50548726 T A 2.10E-05 Urinary metabolites / / 21572414 rs2385525 chr8 50605610 A G 5.52E-04 Type 2 diabetes / / 17846124 rs2385525 chr8 50605610 A G 7.93E-08 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs2132528 chr8 50605655 T C 3.77E-08 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs2132528 chr8 50605655 T C 0.0000241 Otitis media (children 3 years old or younger) / / 23133572 rs6472664 chr8 50648090 G T 2.10E-04 Obesity,menopause / / 21424828 rs7818806 chr8 50653706 A G 7.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4873367 chr8 50654181 C T 7.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2891809 chr8 50756640 A C,G,T 1.12E-04 Multiple complex diseases / / 17554300 rs10504092 chr8 50777948 G T 1.75E-06 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs1552317 chr8 50799622 G A 6.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs443682 chr8 50806102 T C 2.77E-04 Multiple complex diseases / / 17554300 rs451034 chr8 50808334 C T 7.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs318853 chr8 50818327 A G 7.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs318853 chr8 50818327 A G 8.60E-04 Myocardial Infarction / / pha002883 rs318885 chr8 50868176 T G 1.70E-09 Paclitaxel sensitivity in NCI60 cancer cell lines SNTG1 intron 21314952 rs7840320 chr8 50886370 T C 8.96E-04 Multiple complex diseases SNTG1 intron 17554300 rs16914128 chr8 50888985 G C 4.80E-04 Multiple complex diseases SNTG1 intron 17554300 rs9298278 chr8 51072013 G A 4.61E-05 Serum metabolites SNTG1 intron 19043545 rs7016161 chr8 51115028 C T 4.89E-05 Serum metabolites SNTG1 intron 19043545 rs4873135 chr8 51127196 G A 6.79E-05 Serum metabolites SNTG1 intron 19043545 rs16914526 chr8 51130853 C T 1.89E-13 Schizophrenia SNTG1 intron 22440650 rs16914726 chr8 51255308 A G 6.22E-04 Multiple complex diseases SNTG1 intron 17554300 rs4367564 chr8 51297020 A G 4.72E-04 Tourette syndrome SNTG1 intron 22889924 rs4524809 chr8 51300298 G C 3.03E-04 Multiple complex diseases SNTG1 intron 17554300 rs4242461 chr8 51312479 C A 5.25E-04 Multiple complex diseases SNTG1 intron 17554300 rs13257851 chr8 51316694 C T 1.60E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma SNTG1 intron 22205395 rs7839067 chr8 51337745 G T 9.52E-05 Meningococcal disease SNTG1 intron 20694013 rs145093612 chr8 51362258 G A 0.00024 Breast cancer SNTG1 missense 23555315 rs11785209 chr8 51375321 G A 6.40E-05 Diabetic retinopathy SNTG1 intron 21441570 rs13272236 chr8 51384987 A G 2.00E-06 IgG glycosylation SNTG1 intron 23382691 rs13272236 chr8 51384987 A G 6.00E-07 IgG glycosylation SNTG1 intron 23382691 rs2068238 chr8 51403548 T C 9.92E-05 Amyotrophic lateral sclerosis (sporadic) SNTG1 intron 24529757 rs310558 chr8 51412591 C T 5.00E-06 Pulmonary function SNTG1 intron 17903307 rs16915013 chr8 51461010 G C 3.64E-04 Sudden cardiac arrest SNTG1 intron 21658281 rs4873466 chr8 51481394 C A 7.99E-05 Cognitive impairment induced by topiramate SNTG1 intron 22091778 rs1580413 chr8 51488959 C T 3.13E-04 Type 2 diabetes SNTG1 intron 17463246 rs6473235 chr8 51494398 C T 1.30E-05 Cognitive impairment induced by topiramate SNTG1 intron 22091778 rs6473238 chr8 51500032 T C 2.57E-05 Cognitive impairment induced by topiramate SNTG1 intron 22091778 rs2046355 chr8 51506770 C A 3.39E-06 Age-related macular degeneration SNTG1 intron pha000001 rs16915079 chr8 51522706 A T 5.54E-05 Neuroticism SNTG1 intron 23229837 rs16915088 chr8 51528073 A C 5.21E-04 Tourette syndrome SNTG1 intron 22889924 rs16915088 chr8 51528073 A C 1.36E-04 Response to cholinesterase inhibitors in Alzheimer's disease SNTG1 intron 23374588 rs1483637 chr8 51533206 A G 1.00E-04 Cognitive impairment induced by topiramate SNTG1 intron 22091778 rs11991826 chr8 51538534 T C 7.78E-04 Multiple complex diseases SNTG1 intron 17554300 rs10216995 chr8 51549845 T A 1.30E-05 Urinary metabolites SNTG1 intron 21572414 rs13252069 chr8 51556084 G A 1.40E-05 Urinary metabolites SNTG1 intron 21572414 rs4401874 chr8 51557286 C G 1.10E-05 Urinary metabolites SNTG1 intron 21572414 rs1384831 chr8 51560905 G C 2.60E-05 Urinary metabolites SNTG1 intron 21572414 rs2271204 chr8 51569293 C A 1.20E-05 Urinary metabolites SNTG1 intron 21572414 rs6473291 chr8 51600102 G A 7.18E-04 Smoking initiation SNTG1 intron 24665060 rs713179 chr8 51613483 A G 5.06E-04 Alcohol dependence SNTG1 intron 21314694 rs1484127 chr8 51725654 G A 6.22E-04 Coronary Artery Disease / / 17634449 rs6473406 chr8 51737729 T C 8.43E-05 Schizophrenia / / 19571809 rs6473406 chr8 51737729 T C 3.88E-05 Schizophrenia / / pha002859 rs6473431 chr8 51764858 A G 9.09E-05 Schizophrenia / / pha002859 rs4520181 chr8 51769889 T C 6.23E-05 Serum metabolites / / 19043545 rs7013653 chr8 51770931 A G 3.21E-05 Schizophrenia / / pha002859 rs7016107 chr8 51789319 A T 6.32E-05 Schizophrenia / / pha002859 rs10102886 chr8 51805575 C T 8.71E-05 Schizophrenia / / 19571809 rs10102886 chr8 51805575 C T 8.33E-05 Schizophrenia / / pha002859 rs11785563 chr8 51842345 G T 3.00E-05 Prostate cancer / / 21743057 rs16915613 chr8 51843851 A T 3.00E-05 Prostate cancer / / 21743057 rs13281139 chr8 51844053 G T 6.15E-05 Serum metabolites / / 19043545 rs2893613 chr8 51844394 A G 3.00E-05 Prostate cancer / / 21743057 rs7820203 chr8 51845693 A C 3.00E-05 Prostate cancer / / 21743057 rs10958207 chr8 51848452 T A 1.00E-04 Prostate cancer / / 21743057 rs7004006 chr8 51853927 A G 3.00E-05 Prostate cancer / / 21743057 rs13268263 chr8 51855262 G A 1.00E-04 Prostate cancer / / 21743057 rs16915637 chr8 51858459 T G 1.00E-04 Prostate cancer / / 21743057 rs1159997 chr8 51859233 T C 2.00E-05 Prostate cancer / / 21743057 rs6473538 chr8 51860365 C T 1.00E-04 Prostate cancer / / 21743057 rs1471727 chr8 51860828 A T 1.00E-04 Prostate cancer / / 21743057 rs6473539 chr8 51862244 T C 2.00E-05 Prostate cancer / / 21743057 rs1484125 chr8 51862991 C T 2.00E-05 Prostate cancer / / 21743057 rs7837741 chr8 51865104 A G 1.00E-04 Prostate cancer / / 21743057 rs2170853 chr8 51871507 G A 2.00E-05 Prostate cancer / / 21743057 rs2129112 chr8 51871658 C T 2.00E-05 Prostate cancer / / 21743057 rs2170854 chr8 51871861 C T 1.00E-04 Prostate cancer / / 21743057 rs6989442 chr8 51873582 A T 2.00E-05 Prostate cancer / / 21743057 rs9969399 chr8 51874673 T C 1.00E-05 Prostate cancer / / 21743057 rs4873486 chr8 51882116 G A 1.00E-04 Prostate cancer / / 21743057 rs1484130 chr8 51883407 G C 2.00E-05 Prostate cancer / / 21743057 rs12114822 chr8 51883927 A G 2.00E-05 Prostate cancer / / 21743057 rs1601197 chr8 51898028 A G 1.00E-04 Prostate cancer / / 21743057 rs1531083 chr8 51908977 T G 1.00E-04 Prostate cancer / / 21743057 rs7828653 chr8 51910303 T G 1.00E-04 Prostate cancer / / 21743057 rs6473558 chr8 51914146 T G 1.00E-04 Prostate cancer / / 21743057 rs12681234 chr8 51924336 C T 2.00E-05 Prostate cancer / / 21743057 rs12681235 chr8 51924347 C T 2.00E-05 Prostate cancer / / 21743057 rs10958231 chr8 51925820 A G 8.00E-05 Prostate cancer / / 21743057 rs2198695 chr8 51936209 C T 7.00E-05 Prostate cancer / / 21743057 rs13262736 chr8 51936945 C T 7.00E-05 Prostate cancer / / 21743057 rs966216 chr8 51937911 T C 4.00E-05 Prostate cancer / / 21743057 rs17727577 chr8 51959112 C T 2.04E-05 Cholesterol / / pha003083 rs6993652 chr8 51991602 T C 7.31E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4294195 chr8 52022731 G A 3.75E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs10110228 chr8 52026122 C T 4.65E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11991676 chr8 52035023 T C 9.50E-04 Alzheimer's disease / / 24755620 rs11991676 chr8 52035023 T C 8.17E-05 Cholesterol / / pha003083 rs17735532 chr8 52050166 C T 5.19E-04 Alzheimer's disease / / 24755620 rs6473584 chr8 52072991 T C 6.12E-04 Alzheimer's disease / / 22005930 rs7827396 chr8 52075739 A G 6.00E-04 Alzheimer's disease / / 22005930 rs7843430 chr8 52075981 G A 6.49E-04 Alzheimer's disease / / 22005930 rs6473586 chr8 52076217 C T 6.10E-04 Alzheimer's disease / / 22005930 rs7462308 chr8 52092897 T C 7.32E-04 Alzheimer's disease / / 22005930 rs13267688 chr8 52094532 T C 6.93E-04 Alzheimer's disease / / 22005930 rs2028157 chr8 52097911 G A 9.66E-04 Alzheimer's disease / / 22005930 rs12543396 chr8 52099253 G C 7.18E-04 Alzheimer's disease / / 22005930 rs7815157 chr8 52100048 C A,G 8.88E-04 Alzheimer's disease / / 22005930 rs10958249 chr8 52102658 G A 2.47E-04 Alzheimer's disease / / 22005930 rs11990142 chr8 52109316 T C 9.24E-04 Alzheimer's disease / / 22005930 rs1529993 chr8 52110410 G T 9.47E-04 Alzheimer's disease / / 22005930 rs7841709 chr8 52110882 G A 9.62E-04 Alzheimer's disease / / 24755620 rs1119176 chr8 52120526 C T 2.91E-04 Alzheimer's disease / / 22005930 rs1437603 chr8 52146146 G A 8.07E-04 Alzheimer's disease / / 24755620 rs7836612 chr8 52147041 G A 9.71E-04 Alzheimer's disease / / 24755620 rs7824835 chr8 52147196 T G 8.08E-05 Serum metabolites / / 19043545 rs4873523 chr8 52148556 G A 5.37E-04 Alzheimer's disease / / 22005930 rs4873188 chr8 52157579 A G 3.10E-04 Coronary heart disease / / 21971053 rs16915914 chr8 52158439 T C 6.28E-04 Multiple complex diseases / / 17554300 rs10110815 chr8 52167705 T A 1.40E-05 Urinary metabolites / / 21572414 rs10112321 chr8 52169159 A T 4.10E-06 Urinary metabolites / / 21572414 rs4873534 chr8 52188213 A G 1.17E-05 Tuberculosis / / 20694014 rs16915954 chr8 52189472 G A 1.56E-05 Tuberculosis / / 20694014 rs10113485 chr8 52190571 G A 4.90E-04 Alzheimer's disease / / 17998437 rs7821565 chr8 52216762 T C 8.00E-06 Tuberculosis / / 20694014 rs6986651 chr8 52219117 G A 8.45E-06 Tuberculosis / / 20694014 rs7844531 chr8 52219631 T A 5.43E-04 Alzheimer's disease / / 17998437 rs7844531 chr8 52219631 T A 8.45E-06 Tuberculosis / / 20694014 rs1837087 chr8 52226463 G T 6.93E-04 Alzheimer's disease / / 17998437 rs1837087 chr8 52226463 G T 1.52E-05 Tuberculosis / / 20694014 rs10110193 chr8 52226750 C T 1.52E-05 Tuberculosis / / 20694014 rs1052704 chr8 52232487 G T 4.70E-04 Alzheimer's disease PXDNL missense 17998437 rs7827306 chr8 52233276 C A 3.76E-04 Alzheimer's disease PXDNL intron 17998437 rs9298444 chr8 52249319 G A 6.10E-06 Urinary metabolites PXDNL intron 21572414 rs1219680 chr8 52254067 C G 1.40E-05 Urinary metabolites PXDNL intron 21572414 rs972025 chr8 52254579 A C 1.20E-05 Urinary metabolites PXDNL intron 21572414 rs972026 chr8 52254657 T G 1.50E-05 Urinary metabolites PXDNL intron 21572414 rs2976998 chr8 52275140 C T 9.02E-04 Suicide attempts in bipolar disorder PXDNL intron 21423239 rs2976999 chr8 52275200 G T 7.00E-04 Suicide attempts in bipolar disorder PXDNL intron 21423239 rs2977000 chr8 52275393 G C 7.55E-04 Suicide attempts in bipolar disorder PXDNL intron 21423239 rs2977001 chr8 52276911 C T 8.49E-04 Suicide attempts in bipolar disorder PXDNL intron 21423239 rs2915492 chr8 52277121 G A 8.57E-04 Suicide attempts in bipolar disorder PXDNL intron 21423239 rs2915493 chr8 52278541 T A 8.48E-04 Suicide attempts in bipolar disorder PXDNL intron 21423239 rs2977002 chr8 52285963 T C 9.13E-04 Suicide attempts in bipolar disorder PXDNL intron 21423239 rs9298446 chr8 52296100 G A 5.99E-04 Coronary heart disease PXDNL intron 21971053 rs994127 chr8 52297865 C T 3.00E-05 Prostate cancer PXDNL intron 21743057 rs10958264 chr8 52300534 G A 6.14E-04 Coronary heart disease PXDNL intron 21971053 rs17263853 chr8 52309919 A G 1.08E-13 Multiple complex diseases PXDNL intron 17554300 rs2977010 chr8 52311233 C T 1.29E-04 Suicide attempts in bipolar disorder PXDNL intron 21423239 rs719162 chr8 52311584 A G 5.80E-06 Urinary metabolites PXDNL intron 21572414 rs11990397 chr8 52314484 G C 5.80E-06 Urinary metabolites PXDNL intron 21572414 rs2977013 chr8 52314595 G A 3.00E-05 Prostate cancer PXDNL intron 21743057 rs2977016 chr8 52315863 T C 3.00E-05 Prostate cancer PXDNL intron 21743057 rs200259163 chr8 52320669 T A 0.0000183 Ratio of free to total prostate-specific antigen PXDNL missense 23555315 rs2116349 chr8 52324466 T G 1.48E-04 Suicide attempts in bipolar disorder PXDNL intron 21423239 rs10093611 chr8 52331018 T C 5.01E-04 Coronary heart disease PXDNL intron 21971053 rs17264278 chr8 52331311 C T 2.70E-05 Urinary metabolites PXDNL intron 21572414 rs2392900 chr8 52338934 T C 9.18E-05 Cognitive performance PXDNL intron 19734545 rs6989713 chr8 52357128 G A 9.04E-06 Kawasaki disease PXDNL intron 21221998 rs6982550 chr8 52416201 T C 3.29E-04 Multiple complex diseases PXDNL intron 17554300 rs16916425 chr8 52419882 A G 9.21E-04 Alzheimer's disease PXDNL intron 22005930 rs17181677 chr8 52420536 T C 6.02E-04 Amyotrophic Lateral Sclerosis PXDNL intron 17362836 rs3097708 chr8 52433074 C A 8.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PXDNL intron 20877124 rs3097708 chr8 52433074 C A 8.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PXDNL intron 20877124 rs4873558 chr8 52437547 G T 0.000142407 Hypertension (early onset hypertension) PXDNL intron 22479346 rs10109203 chr8 52438302 G A 5.00E-08 Parkinson's disease (interaction with coffee consumption) PXDNL intron 21876681 rs4501569 chr8 52439270 A G 0.000123689 Hypertension (early onset hypertension) PXDNL intron 22479346 rs6994583 chr8 52442080 A G 1.76E-04 Multiple complex diseases PXDNL intron 17554300 rs16916544 chr8 52498385 T C 3.99E-05 Multiple complex diseases PXDNL intron 17554300 rs16916587 chr8 52518677 T C 6.54E-04 Multiple complex diseases PXDNL intron 17554300 rs6998137 chr8 52536828 T C 4.79E-04 Type 2 diabetes PXDNL intron 17463246 rs10097683 chr8 52537205 C A 5.81E-04 Type 2 diabetes PXDNL intron 17463246 rs7017902 chr8 52538501 T C 4.70E-05 Blood Pressure PXDNL intron pha003047 rs4873568 chr8 52557431 T C 4.10E-04 Alcohol dependence PXDNL intron 20201924 rs12548130 chr8 52558395 C A 5.09E-04 Type 2 diabetes PXDNL intron 17463246 rs7012655 chr8 52578414 T C 8.40E-05 Electrocardiographic traits and heart rate variability PXDNL intron 17903306 rs7818832 chr8 52693940 A T 9.70E-05 Neuroticism PXDNL intron 23229837 rs4873605 chr8 52705810 C A 2.34E-04 Type 2 diabetes PXDNL intron 17463246 rs763550 chr8 52715465 C T 7.44E-05 Height PXDNL intron 17255346 rs763550 chr8 52715465 C T 4.20E-04 Type 2 diabetes and 6 quantitative traits PXDNL intron 17848626 rs6990379 chr8 52716137 G A 8.39E-05 Glaucoma (primary open-angle) PXDNL intron 22605921 rs16916856 chr8 52739150 T C 5.62E-05 Height PCMTD1 intron 17255346 rs16916865 chr8 52745850 G A 7.44E-05 Height PCMTD1 intron 17255346 rs16916867 chr8 52746000 T C 1.69E-05 Multiple complex diseases PCMTD1 intron 17554300 rs10504130 chr8 52757093 G A 7.44E-05 Height PCMTD1 intron 17255346 rs10504130 chr8 52757093 G A 8.50E-04 Type 2 diabetes and 6 quantitative traits PCMTD1 intron 17848626 rs10504130 chr8 52757093 G A 4.00E-09 Venous thromboembolism (gene x gene interaction) PCMTD1 intron 23509962 rs10504130 chr8 52757093 G A 2.48E-04 Myocardial Infarction PCMTD1 intron pha002873 rs7013587 chr8 52792173 A C 9.53E-05 Neuroticism PCMTD1 intron 23229837 rs1013621 chr8 52801391 C T 4.00E-05 Electrocardiographic traits and heart rate variability PCMTD1 intron 17903306 rs10090573 chr8 52814768 A G 4.48E-04 Multiple complex diseases LOC100287313 intron 17554300 rs11775611 chr8 52820274 T C 4.07E-06 Crohn's disease LOC100287313 intron 17804789 rs16916961 chr8 52831178 C G 1.51E-04 Height LOC100287313 intron 17255346 rs12676835 chr8 52832330 C A 6.72E-04 Smoking quantity LOC100287313 intron 24665060 rs6473666 chr8 52838295 A G 2.09E-04 Amyotrophic lateral sclerosis (sporadic) LOC100287313 intron 24529757 rs1015213 chr8 52887541 C T 9.97E-04 Multiple complex diseases / / 17554300 rs1015213 chr8 52887541 C T 3.00E-09 Glaucoma (primary open-angle) / / 22922875 rs6990124 chr8 52888148 A G 3.89E-04 Multiple complex diseases / / 17554300 rs16917012 chr8 52891075 A G 8.65E-04 Multiple complex diseases / / 17554300 rs16917014 chr8 52891122 C T 2.67E-04 Multiple complex diseases / / 17554300 rs12541693 chr8 52894246 C T 4.30E-04 Type 2 diabetes / / 17463246 rs1399860 chr8 52913652 C T 8.89E-04 Type 2 diabetes / / 17463246 rs1399859 chr8 52913747 T A 9.47E-04 Type 2 diabetes / / 17463246 rs2280179 chr8 52920335 A G 8.97E-04 Tourette syndrome / / 22889924 rs2433235 chr8 52929877 C T 5.11E-05 Tourette syndrome / / 22889924 rs2249244 chr8 52948481 C T 3.89E-04 Multiple complex diseases / / 17554300 rs12541286 chr8 52949557 A G 8.96E-05 Body Mass Index / / pha003007 rs12541286 chr8 52949557 A G 3.12E-05 Body Mass Index / / pha003014 rs2252399 chr8 52951973 A C 9.79E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2252647 chr8 52953283 A G 2.82E-04 Multiple complex diseases / / 17554300 rs268928 chr8 52967818 A G 7.37E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2450153 chr8 52971672 A G 5.82E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs3909673 chr8 52975387 T C 4.99E-05 Body Mass Index / / pha003014 rs3849811 chr8 53010152 C T 6.70E-05 Hearing impairment / / 19047183 rs3892512 chr8 53010163 G C 9.86E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1346159 chr8 53031607 G A 1.61E-04 Epilepsy ST18 intron 22116939 rs1346159 chr8 53031607 G A 5.50E-05 Temperament (bipolar disorder) ST18 intron 22365631 rs2114226 chr8 53037349 T C 2.10E-04 Alcohol dependence ST18 intron 20201924 rs7821217 chr8 53039720 G A 4.20E-04 Alcohol dependence ST18 intron 20201924 rs9694119 chr8 53041190 T C 2.70E-04 Alcohol dependence ST18 intron 20201924 rs11990195 chr8 53046681 G A 1.70E-04 Alcohol dependence ST18 intron 20201924 rs11990195 chr8 53046681 G A 3.10E-04 Alcohol dependence ST18 intron 20201924 rs10107218 chr8 53047978 A G 8.10E-05 Temperament (bipolar disorder) ST18 intron 22365631 rs3815868 chr8 53049037 T C 3.40E-04 Alcohol dependence ST18 intron 20201924 rs16917282 chr8 53050299 A G 3.60E-05 Temperament (bipolar disorder) ST18 intron 22365631 rs7010548 chr8 53055483 C T 3.10E-04 Alcohol dependence ST18 intron 20201924 rs7010548 chr8 53055483 C T 8.40E-04 Alcohol dependence ST18 intron 20201924 rs7837915 chr8 53058501 G A 1.00E-04 Alcohol dependence ST18 intron 20201924 rs7837915 chr8 53058501 G A 2.60E-04 Alcohol dependence ST18 intron 20201924 rs3891723 chr8 53059486 G A 1.60E-04 Alcohol dependence ST18 intron 20201924 rs3891723 chr8 53059486 G A 2.60E-04 Alcohol dependence ST18 intron 20201924 rs17290977 chr8 53068920 C T 1.20E-04 Alcohol dependence ST18 intron 20201924 rs7829966 chr8 53081817 G A 1.88E-04 Nicotine dependence ST18 intron 17158188 rs6992634 chr8 53098200 C T 7.60E-04 Multiple complex diseases ST18 intron 17554300 rs7000382 chr8 53102751 A G 3.73E-04 Type 2 diabetes ST18 intron 17463246 rs78744452 chr8 53105573 C G 3.68E-04 Acne (severe) ST18 intron 24927181 rs7816288 chr8 53108864 C T 2.10E-07 Facial morphology ST18 intron 22341974 rs6983307 chr8 53112386 A G 3.20E-04 Body mass index ST18 intron 21701565 rs7820725 chr8 53117537 T A 4.56E-04 Multiple complex diseases ST18 intron 17554300 rs4074067 chr8 53137329 C T 4.10E-04 Pemphigus vulgaris ST18 intron 22437316 rs16917588 chr8 53175282 T C 1.73E-04 Alzheimer's disease ST18 intron 24755620 rs4639533 chr8 53193238 C T 2.21E-04 Pemphigus vulgaris ST18 intron 22437316 rs7009219 chr8 53214265 C T 5.00E-07 Alzheimer's disease (cognitive decline) ST18 intron 23535033 rs6996763 chr8 53276947 G A 6.48E-04 Multiple complex diseases ST18 intron 17554300 rs1317186 chr8 53318644 A C 1.00E-04 Personality dimensions ST18 intron 23903073 rs16917819 chr8 53324496 G A 1.72E-04 Multiple complex diseases / / 17554300 rs7840491 chr8 53328331 T C 3.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs10958318 chr8 53329511 G T 6.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs10089950 chr8 53330550 C T 8.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs10104582 chr8 53330582 A G 3.00E-04 Multiple complex diseases / / 17554300 rs3906806 chr8 53375759 A G 9.31E-04 Coronary heart disease / / 21606135 rs10958322 chr8 53377236 T C 3.01E-04 Coronary heart disease / / 21606135 rs2613258 chr8 53393301 C A 6.85E-05 Epilepsy / / 22116939 rs12334429 chr8 53409744 T G 5.64E-05 Multiple complex diseases / / 17554300 rs7832724 chr8 53416951 A G 2.01E-04 Parkinson's disease / / 21248740 rs7836283 chr8 53431744 C T 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs984309 chr8 53434613 G A 1.12E-04 Parkinson's disease / / 21248740 rs6473735 chr8 53436068 T G 0.0000467 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10504139 chr8 53444854 G T 2.65E-05 Parkinson's disease / / 21248740 rs12677394 chr8 53463412 C G 1.10E-05 Urinary metabolites FAM150A intron 21572414 rs2360279 chr8 53501285 G A 0.0000167 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4319121 chr8 53505755 C T 3.60E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs7825939 chr8 53538495 A G 7.91E-04 Parkinson's disease RB1CC1 intron 17052657 rs10097108 chr8 53550826 C A 2.64E-04 Parkinson's disease RB1CC1 intron 17052657 rs7002395 chr8 53605442 A G 2.54E-04 Parkinson's disease RB1CC1 intron 17052657 rs4873679 chr8 53677171 C A 9.20E-04 Parkinson's disease / / 17052657 rs7822058 chr8 53684861 T C 3.00E-07 Obesity-related traits / / 23251661 rs2360243 chr8 53734355 C T 9.14E-06 Hearing function / / 21493956 rs7341687 chr8 53734657 C T 6.70E-04 Multiple complex diseases / / 17554300 rs11775217 chr8 53738033 G A 6.27E-04 Multiple complex diseases / / 17554300 rs4342624 chr8 53748776 A G 2.80E-06 Urinary metabolites / / 21572414 rs12677436 chr8 53753748 C T 8.92E-04 Sarcoidosis / / 19165924 rs10112899 chr8 53758886 G A 7.97E-04 Alcohol dependence / / 21314694 rs10808877 chr8 53766392 G A 3.90E-06 Urinary metabolites / / 21572414 rs6473756 chr8 53769237 A G 3.40E-06 Urinary metabolites / / 21572414 rs6473757 chr8 53769367 A G 7.60E-06 Urinary metabolites / / 21572414 rs10095137 chr8 53808956 C T 1.30E-06 Urinary metabolites / / 21572414 rs3906476 chr8 53810264 A G 3.60E-06 Urinary metabolites / / 21572414 rs10958335 chr8 53827968 T C 7.78E-04 Acute lung injury / / 22295056 rs533402 chr8 53880054 T C 5.09E-04 Aortic root size / / 21223598 rs567971 chr8 53885194 T C 3.26E-04 Longevity / / 22279548 rs7013767 chr8 53895283 T C 6.12E-04 Acute lung injury / / 22295056 rs9643807 chr8 53895448 A G 8.70E-04 Acute lung injury / / 22295056 rs9643808 chr8 53895820 C T 6.22E-04 Acute lung injury / / 22295056 rs10102212 chr8 53896591 A G 6.22E-04 Acute lung injury / / 22295056 rs11995936 chr8 53897326 A T 6.22E-04 Acute lung injury / / 22295056 rs7002365 chr8 53899017 A C 6.35E-04 Acute lung injury / / 22295056 rs7002365 chr8 53899017 A C 8.12E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1822590 chr8 53900796 C A 2.87E-04 Longevity / / 22279548 rs360983 chr8 53917467 T C 2.00E-05 Urinary metabolites / / 21572414 rs1426562 chr8 53935694 A G 3.01E-05 Major depressive disorder / / 21621269 rs1426562 chr8 53935694 A G 3.34E-05 Major depressive disorder / / pha002850 rs6473783 chr8 53939511 C T 4.14E-05 Major depressive disorder / / 21621269 rs6473783 chr8 53939511 C T 5.28E-05 Major depressive disorder / / pha002850 rs10101465 chr8 53948692 T G 7.00E-08 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs1596504 chr8 53951054 A G 7.00E-04 Smoking initiation / / 24665060 rs1596502 chr8 53964383 A G 1.50E-05 Urinary metabolites / / 21572414 rs2120560 chr8 53981711 C A 9.62E-05 Diabetes Mellitus / / pha003059 rs2120560 chr8 53981711 C A 3.74E-05 Insulin Resistance / / pha003062 rs13253278 chr8 53984713 C T 2.60E-05 Urinary metabolites / / 21572414 rs2553915 chr8 54038721 A G 6.14E-05 Insulin Resistance / / pha003062 rs6986413 chr8 54045515 A C 7.28E-05 Acute lung injury / / 22295056 rs16918619 chr8 54057761 G A 5.82E-04 Multiple complex diseases / / 17554300 rs1116749 chr8 54065232 C G 8.36E-04 Alzheimer's disease / / 17998437 rs16918678 chr8 54083168 T C 7.56E-04 Multiple complex diseases / / 17554300 rs1425898 chr8 54115304 A G 1.76E-05 Lung adenocarcinoma / / 19836008 rs7822237 chr8 54117233 A G 4.67E-04 Alzheimer's disease / / 17998437 rs1425902 chr8 54119214 G A 1.00E-06 IgE levels in asthmatics (D.p. specific) / / 23967269 rs7827334 chr8 54127102 C G 3.21E-04 Multiple complex diseases / / 17554300 rs6473795 chr8 54130678 G T 3.50E-04 Multiple complex diseases / / 17554300 rs16918909 chr8 54150034 A G 6.73E-04 Suicide attempts in bipolar disorder OPRK1 intron 21041247 rs6989250 chr8 54166395 C G 3.20E-05 Cognitive function / / 24684796 rs16918960 chr8 54175050 T A 7.16E-05 Suicide attempts in bipolar disorder / / 21041247 rs2162181 chr8 54184230 C T 5.96E-05 Suicide attempts in bipolar disorder / / 21041247 rs9792157 chr8 54186391 C A 5.87E-05 Suicide attempts in bipolar disorder / / 21041247 rs9792266 chr8 54190320 T A 5.84E-05 Suicide attempts in bipolar disorder / / 21041247 rs9792384 chr8 54190369 G A 5.82E-05 Suicide attempts in bipolar disorder / / 21041247 rs9792306 chr8 54190761 T C 7.00E-05 Suicide attempts in bipolar disorder / / 21041247 rs16918988 chr8 54190997 C T 5.00E-05 Suicide attempts in bipolar disorder / / 21041247 rs2059547 chr8 54193095 T C 5.77E-05 Suicide attempts in bipolar disorder / / 21041247 rs2376422 chr8 54194232 A G 5.78E-05 Suicide attempts in bipolar disorder / / 21041247 rs2376420 chr8 54194412 T A 5.75E-05 Suicide attempts in bipolar disorder / / 21041247 rs2376419 chr8 54194489 G A 5.75E-05 Suicide attempts in bipolar disorder / / 21041247 rs2376418 chr8 54194530 A T 5.77E-05 Suicide attempts in bipolar disorder / / 21041247 rs4565474 chr8 54194644 A G 5.77E-05 Suicide attempts in bipolar disorder / / 21041247 rs11995818 chr8 54215475 A T 9.26E-05 Suicide attempts in bipolar disorder / / 21041247 rs7465082 chr8 54224082 G T 8.81E-05 Suicide attempts in bipolar disorder / / 21041247 rs7462232 chr8 54224120 A G 1.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs7819906 chr8 54249089 C T 7.75E-05 Suicide attempts in bipolar disorder / / 21041247 rs11995645 chr8 54264513 C T 8.15E-05 Suicide attempts in bipolar disorder / / 21041247 rs11985025 chr8 54264566 A T 8.22E-05 Suicide attempts in bipolar disorder / / 21041247 rs7001769 chr8 54274100 C T 7.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs7465458 chr8 54277247 G A 5.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs3887558 chr8 54308503 A G 8.39E-05 Bipolar disorder and schizophrenia / / 20889312 rs16919123 chr8 54312886 A G 2.22E-04 Multiple complex diseases / / 17554300 rs2126800 chr8 54317551 T G 7.74E-04 Multiple complex diseases / / 17554300 rs16919143 chr8 54330686 C A 2.59E-05 Alcohol and nictotine co-dependence / / 20158304 rs10429416 chr8 54366491 C A 3.17E-05 Alcohol and nictotine co-dependence / / 20158304 rs16919190 chr8 54393060 A G 2.07E-04 Multiple complex diseases / / 17554300 rs10958369 chr8 54410208 G A 2.00E-06 Response to antineoplastic agents / / 21659360 rs13279206 chr8 54429644 G A 3.89E-04 Type 2 diabetes / / 17463246 rs6473877 chr8 54547981 T C 6.91E-05 Left ventricular hypertrophy / / pha003052 rs11773966 chr8 54555200 A C 2.00E-06 Bipolar disorder (mood-incongruent) / / 23092984 rs6473883 chr8 54574505 G T 3.65E-05 Serum metabolites / / 19043545 rs6473884 chr8 54574527 C T 3.90E-05 Serum metabolites / / 19043545 rs10958390 chr8 54578044 A G 1.03E-04 Amyotrophic lateral sclerosis / / 23624525 rs13269498 chr8 54578332 C A 4.17E-04 Amyotrophic lateral sclerosis / / 23624525 rs11991573 chr8 54582515 A G 6.59E-05 Serum metabolites / / 19043545 rs12056719 chr8 54663985 C T 7.39E-04 Coronary Artery Disease ATP6V1H intron 17634449 rs1552148 chr8 54674723 T C 1.00E-05 Urinary metabolites ATP6V1H intron 21572414 rs16919588 chr8 54751691 C T 1.75E-04 Insulin resistance ATP6V1H intron 21901158 rs11783925 chr8 54770860 C T 0.0005798 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS20 intron 23233654 rs11783925 chr8 54770860 C T 5.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS20 intron 23233662 rs6997050 chr8 54780174 C T 6.60E-05 Cognitive function RGS20 intron 24684796 rs1466525 chr8 54780209 C T 6.27E-04 Type 2 diabetes RGS20 intron 17463246 rs12708158 chr8 54835697 T C 3.37E-04 Fibrinogen RGS20 intron 17255346 rs16919692 chr8 54852787 T C 2.89E-04 Lung function (forced expiratory volume in 1 second) RGS20 intron 24023788 rs16919692 chr8 54852787 T C 9.51E-05 Lung function (forced vital capacity) RGS20 intron 24023788 rs6473902 chr8 54918223 T C 4.29E-05 Amyotrophic Lateral Sclerosis TCEA1 intron 18057069 rs11984645 chr8 55069305 G A 5.17E-05 Multiple complex diseases / / 17554300 rs4737503 chr8 55071319 A G 8.94E-04 Amyotrophic lateral sclerosis / / 23624525 rs379532 chr8 55094784 T C 7.42E-05 Diabetes Mellitus / / pha003060 rs7825422 chr8 55114241 A T 6.30E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs312108 chr8 55155640 C T 5.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs379593 chr8 55161461 A G 5.10E-05 Blood Pressure / / pha003043 rs2656271 chr8 55263672 A C 4.99E-04 Type 2 diabetes / / 17463246 rs7827900 chr8 55269485 G T 5.20E-06 Erythrocyte counts / / pha003099 rs2956788 chr8 55280831 C T 2.15E-05 Erythrocyte counts / / pha003099 rs1504749 chr8 55310711 A C 5.00E-07 Intracranial aneurysm / / 20364137 rs1504749 chr8 55310711 A C 0.00051 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs10958409 chr8 55327091 G A 1.00E-10 Intracranial aneurysm / / 18997786 rs10958409 chr8 55327091 G A 9.00E-07 Intracranial aneurysm / / 20364137 rs10958409 chr8 55327091 G A 0.00000559 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs10958409 chr8 55327091 G A 4.12E-04 Myocardial Infarction / / pha002873 rs6987174 chr8 55327862 G T 0.000043 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs12543193 chr8 55338193 C T 0.000468 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs12543193 chr8 55338193 C T 3.96E-05 Erythrocyte counts / / pha003099 rs16920292 chr8 55343273 A G 1.30E-05 Multiple complex diseases / / 17554300 rs4523231 chr8 55365190 C T 0.000899 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs16920345 chr8 55365229 T C 1.22E-04 Alzheimer's disease (late onset) / / 21379329 rs12545082 chr8 55366048 T C 0.000855 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs12541742 chr8 55371154 C T 0.000586 Internal carotid artery thickness (average of near and far walls) SOX17 intron 23487405 rs4259400 chr8 55385972 C G 3.92E-05 Aortic root size / / 21223598 rs16920368 chr8 55392853 A G 5.10E-05 Cognitive performance / / 19734545 rs16920368 chr8 55392853 A G 1.22E-04 Alzheimer's disease (late onset) / / 21379329 rs17400569 chr8 55421420 T C 6.94E-04 Type 2 diabetes / / 17463246 rs10102164 chr8 55421614 G A 4.00E-11 LDL cholesterol / / 24097068 rs10102164 chr8 55421614 G A 5.00E-11 Cholesterol,total / / 24097068 rs10089685 chr8 55431353 G A 9.81E-05 Neuroblastoma / / pha002895 rs9298506 chr8 55437524 A G 4.13E-04 Multiple complex diseases / / 17554300 rs9298506 chr8 55437524 A G 2.00E-09 Intracranial aneurysm / / 18997786 rs9298506 chr8 55437524 A G 1.00E-12 Intracranial aneurysm / / 20364137 rs10104997 chr8 55440068 C T 9.00E-07 Dengue shock syndrome / / 22001756 rs17310011 chr8 55445568 C G 1.93E-04 Type 2 diabetes / / 17463246 rs9657161 chr8 55482647 G A 1.55E-05 Aging (time to event) / / 21782286 rs147990983 chr8 55538687 C T 0.000086 Breast cancer (ER positive) RP1 missense 23555315 rs147990983 chr8 55538687 C T 0.00018 Breast cancer RP1 missense 23555315 rs114797722 chr8 55540418 G C 0.00000002 Prostate cancer (advanced) RP1 missense 23555315 rs423841 chr8 55556069 G A 8.09E-05 Serum metabolites / / 19043545 rs6992427 chr8 55633440 A G 1.33E-04 Insulin resistance LOC100287651 intron 21901158 rs10958427 chr8 55676689 G A 7.03E-04 Multiple complex diseases LOC100287651 intron 17554300 rs17405784 chr8 55721066 G A 1.70E-05 Urinary metabolites LOC100287651 intron 21572414 rs17405784 chr8 55721066 G A 2.02E-04 Insulin resistance LOC100287651 intron 21901158 rs10095485 chr8 55745607 G A 3.16E-04 Lung function (forced expiratory volume in 1 second) LOC100287651 intron 17255346 rs9298511 chr8 55748402 G T 3.32E-04 Lung function (forced expiratory volume in 1 second) LOC100287651 intron 17255346 rs4737744 chr8 55771502 C A,T 2.20E-05 Erythrocyte counts LOC100287651 intron pha003099 rs1396895 chr8 55779565 T C 2.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) LOC100287651 intron 23648065 rs9643483 chr8 55797674 G T 5.50E-05 Effectiveness of iloperidone treatment in schizophrenia / / 18521090 rs9643483 chr8 55797674 G T 2.63E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6473956 chr8 55820605 G A 4.04E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs270796 chr8 55835446 G C 3.73E-04 Type 2 diabetes / / 17463246 rs270792 chr8 55849427 G A 5.27E-04 Type 2 diabetes / / 17463246 rs16920998 chr8 55907794 C T 6.29E-05 Waist-Hip Ratio / / pha003013 rs16920998 chr8 55907794 C T 8.82E-05 Waist-Hip Ratio / / pha003028 rs12678533 chr8 55913750 C A 2.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs3924878 chr8 55919502 C T 6.09E-05 Cognitive impairment induced by topiramate / / 22091778 rs3924878 chr8 55919502 C T 8.01E-05 Cognitive impairment induced by topiramate / / 22091778 rs899914 chr8 55973415 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6988356 chr8 56002516 T G 1.41E-05 Response to methylphenidate treatment / / 21130132 rs996825 chr8 56004352 C T 4.68E-04 Multiple complex diseases / / 17554300 rs7004582 chr8 56011715 A T 9.09E-04 Multiple complex diseases / / 17554300 rs6984280 chr8 56011982 G A 1.26E-04 Multiple complex diseases / / 17554300 rs10504186 chr8 56017972 G A 8.96E-05 Multiple complex diseases XKR4 intron 17554300 rs1031938 chr8 56018554 G C 6.33E-04 Multiple complex diseases XKR4 intron 17554300 rs9298526 chr8 56022292 C A 7.02E-04 Multiple complex diseases XKR4 intron 17554300 rs1480766 chr8 56023087 T C 3.31E-05 Multiple complex diseases XKR4 intron 17554300 rs7821849 chr8 56034433 A G 2.11E-04 Multiple complex diseases XKR4 intron 17554300 rs16921164 chr8 56036147 A G 9.25E-05 Schizophrenia XKR4 intron 19571809 rs16921167 chr8 56036859 C A 8.19E-04 Alzheimer's disease XKR4 intron 17998437 rs16921167 chr8 56036859 C A 1.92E-05 Schizophrenia XKR4 intron 19571809 rs16921196 chr8 56045247 A C 9.42E-06 Height XKR4 intron 17255346 rs1480764 chr8 56048107 C T 2.46E-04 Height XKR4 intron 17255346 rs997855 chr8 56059868 G A 9.51E-05 Cognitive impairment induced by topiramate XKR4 intron 22091778 rs7821964 chr8 56088521 G T 3.05E-04 Multiple complex diseases XKR4 intron 17554300 rs4737264 chr8 56111322 A C 3.11E-08 Paclitaxel-induced neuropathy XKR4 intron 23776197 rs11783005 chr8 56116482 C T 7.79E-05 Depression (quantitative trait) XKR4 intron 23290196 rs13250310 chr8 56119840 A T 4.99E-05 Depression (quantitative trait) XKR4 intron 23290196 rs13248919 chr8 56120404 G A 8.92E-05 Depression (quantitative trait) XKR4 intron 23290196 rs8180956 chr8 56120462 C T 5.59E-04 White matter integrity XKR4 intron 22425255 rs13253286 chr8 56137658 A G 0.00000229 Internal carotid artery thickness (far walls) XKR4 intron 23487405 rs12542677 chr8 56168059 C T 2.00E-07 Immune reponse to smallpox (secreted IL-1beta) XKR4 intron 22610502 rs11786627 chr8 56201783 G A 3.53E-04 Amyotrophic lateral sclerosis (sporadic) XKR4 intron 24529757 rs2939678 chr8 56247138 A G 7.11E-05 Attention deficit hyperactivity disorder XKR4 intron pha002875 rs1532899 chr8 56253581 T C 1.24E-04 Attention deficit hyperactivity disorder XKR4 intron pha002875 rs2979062 chr8 56314919 T C 7.08E-04 Nicotine smoking XKR4 intron 19268276 rs2622590 chr8 56358274 G A 2.00E-10 Thyroid stimulating hormone XKR4 intron 24852370 rs2975982 chr8 56365451 G A 9.90E-05 Serum metabolites XKR4 intron 19043545 rs955363 chr8 56368456 G A 8.15E-05 Serum metabolites XKR4 intron 19043545 rs2939654 chr8 56380810 G A 7.98E-05 Serum metabolites XKR4 intron 19043545 rs2658935 chr8 56413969 C T 7.57E-04 Type 2 diabetes XKR4 intron 17463246 rs7839596 chr8 56429003 G T 1.07E-05 Alzheimer's disease (age of onset) XKR4 intron 22005931 rs2929012 chr8 56434186 A T 2.47E-04 Lung function (forced expiratory volume in 1 second) XKR4 intron 17255346 rs2929012 chr8 56434186 A T 2.80E-05 Urinary metabolites XKR4 intron 21572414 rs16922037 chr8 56464725 G T 3.00E-05 Serum metabolites / / 19043545 rs9298535 chr8 56464791 T G 7.70E-04 Lipid levels / / 18193043 rs7013055 chr8 56472808 A G 3.99E-04 Myocardial Infarction / / pha002873 rs7833645 chr8 56482536 T C 2.56E-04 Myocardial Infarction / / pha002873 rs7833645 chr8 56482536 T C 9.78E-04 Heart Failure / / pha002884 rs4236995 chr8 56492754 T C 1.44E-04 Myocardial Infarction / / pha002873 rs4738287 chr8 56499526 G A 1.12E-04 Diabetic nephropathy / / pha002866 rs16922095 chr8 56511811 T C 9.31E-05 Cholesterol / / pha003083 rs10108350 chr8 56519673 C A 4.63E-05 Post-operative nausea and vomiting / / 21694509 rs6988277 chr8 56540035 T C 3.20E-05 Diabetic nephropathy / / pha002866 rs10107657 chr8 56540235 T C 3.60E-05 Diabetic nephropathy / / pha002866 rs4738382 chr8 56567649 C A 2.60E-05 Diabetic nephropathy / / pha002866 rs10086858 chr8 56592291 G A 4.78E-05 Taste perception / / 22132133 rs7463339 chr8 56593195 G T 1.63E-04 Taste perception / / 22132133 rs4737395 chr8 56599548 G A 5.00E-09 Myopia (pathological) / / 23049088 rs4738393 chr8 56599777 G A 2.03E-04 Migraine with aura / / 23793025 rs4738393 chr8 56599777 G A 6.00E-06 Migraine - clinic-based / / 23793025 rs7827790 chr8 56774541 G A 9.90E-06 Obesity-related traits / / 23251661 rs16922296 chr8 56779665 C T 3.77E-04 Type 2 diabetes / / 17463246 rs333616 chr8 56800997 C T 1.70E-05 Bone mineral density (BMD),in women LYN intron 20164292 rs7003770 chr8 56819335 T C 5.99E-05 Serum metabolites LYN intron 19043545 rs1546518 chr8 56824894 G C 2.20E-05 Parkinson's disease (familial) LYN intron 18985386 rs16922400 chr8 56827739 C T 3.15E-04 Multiple complex diseases LYN intron 17554300 rs16922412 chr8 56835832 C A 4.35E-09 HDL cholesterol LYN intron 23063622 rs10091244 chr8 56843930 T G 6.36E-05 Weight LYN intron pha003027 rs13249338 chr8 56847170 A G 0.000354 Common carotid artery thickness (average of near and far wall measures) LYN intron 23487405 rs13249338 chr8 56847170 A G 0.000882 Internal carotid artery thickness (average of near and far walls) LYN intron 23487405 rs7829816 chr8 56849386 A G 7.90E-04 HIV-1 viral setpoint LYN intron 17641165 rs7829816 chr8 56849386 A G 5.40E-09 Systemic lupus erythematosus LYN intron 18204446 rs16922434 chr8 56849422 G A 1.61E-04 HIV-1 viral setpoint LYN intron 17641165 rs16922434 chr8 56849422 G A 3.16E-05 Smoking quantity LYN intron 24665060 rs16922441 chr8 56851332 C G 7.77E-05 Smoking quantity LYN intron 24665060 rs16922459 chr8 56854172 C T 9.15E-05 Smoking quantity LYN intron 24665060 rs16922463 chr8 56861669 C A 7.36E-04 HIV-1 viral setpoint LYN intron 17641165 rs17811397 chr8 56861768 T G 1.43E-04 Smoking quantity LYN intron 24665060 rs7813271 chr8 56863151 A G 7.36E-04 HIV-1 viral setpoint LYN intron 17641165 rs2667978 chr8 56897951 A G 5.30E-04 HIV-1 viral setpoint LYN intron 17641165 rs2667978 chr8 56897951 A G 5.10E-08 Systemic lupus erythematosus LYN intron 18204446 rs2668011 chr8 56924058 C T 1.00E-04 Prostate cancer LYN UTR-3 21743057 rs12547683 chr8 56933602 A G 7.54E-04 HIV-1 viral setpoint / / 17641165 rs16920278 chr8 56963885 T C 1.58E-05 Type 2 diabetes / / 17463246 rs16920295 chr8 56984164 A C 6.47E-05 Multiple complex diseases RPS20 intron 17554300 rs10958476 chr8 57095808 T C 7.00E-08 Height PLAG1 intron 18391951 rs10958476 chr8 57095808 T C 1.00E-09 Height PLAG1 intron 20881960 rs7833986 chr8 57100149 G A 8.00E-10 Height PLAG1 intron 20189936 rs13273123 chr8 57100791 A G 1.00E-09 Height PLAG1 intron 19396169 rs13273123 chr8 57100791 A G 3.00E-06 Height PLAG1 intron 19893584 rs10534078 chr8 57109510 CGTGTGTGT C 9.87E-05 HIV-1 control PLAG1 intron 20041166 rs13272882 chr8 57109510 C T 9.87E-05 HIV-1 control PLAG1 intron 20041166 rs528064089 chr8 57109510 C CGTGT 9.87E-05 HIV-1 control PLAG1 intron 20041166 rs60025705 chr8 57109510 C CGTGT 9.87E-05 HIV-1 control PLAG1 intron 20041166 rs71256592 chr8 57109510 CGTGTGTGT C 9.87E-05 HIV-1 control PLAG1 intron 20041166 rs9650315 chr8 57155598 G T 4.00E-07 Height / / 18391950 rs9650315 chr8 57155598 G T 2.64E-05 Height / / 19570815 rs7815788 chr8 57179020 C T 5.00E-06 Height / / 19343178 rs7460090 chr8 57194163 T C 8.00E-27 Height / / 20881960 rs4075154 chr8 57209246 A G 3.00E-09 Height / / 23563607 rs7011325 chr8 57228317 A C 3.06E-04 Height SDR16C5 intron 17255346 rs6998873 chr8 57299697 G A 9.20E-06 Urinary metabolites SDR16C6P intron 21572414 rs10086766 chr8 57306703 G T 5.21E-12 Multiple complex diseases SDR16C6P intron 17554300 rs12545109 chr8 57313906 A C 9.00E-06 Obesity-related traits / / 23251661 rs1025669 chr8 57318034 G A 7.86E-06 Glycemic traits (pregnancy) / / 23903356 rs2196586 chr8 57347126 T C 0.00000792 Panic disorder / / 23149450 rs2196586 chr8 57347126 T C 7.92E-06 Serum tamsulosin hydrochloride concentration / / 23151678 rs6474063 chr8 57355545 C T 0.0000569 Panic disorder PENK intron 23149450 rs6474063 chr8 57355545 C T 5.69E-05 Serum tamsulosin hydrochloride concentration PENK intron 23151678 rs2016795 chr8 57390386 A G 7.82E-05 Panic disorder / / 19165232 rs2118261 chr8 57393286 G A 3.95E-05 Panic disorder / / 19165232 rs2118261 chr8 57393286 G A 0.0000758 Panic disorder / / 23149450 rs2118261 chr8 57393286 G A 7.58E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs2055984 chr8 57418332 T C 0.000047 Panic disorder / / 23149450 rs2055984 chr8 57418332 T C 4.70E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs2610034 chr8 57451312 T C 8.48E-04 Alzheimer's disease LOC100507632 intron 24755620 rs1812456 chr8 57488573 A G 5.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs756008 chr8 57500283 T C 6.49E-04 Multiple complex diseases / / 17554300 rs16920808 chr8 57511482 C A 7.94E-04 Type 2 diabetes / / 17463246 rs1371938 chr8 57524603 C A 6.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10504207 chr8 57557038 C T 1.00E-05 Urinary metabolites / / 21572414 rs12679072 chr8 57565864 C T 7.03E-06 Psoriasis / / 20953187 rs10111407 chr8 57599805 G A 7.79E-05 Multiple complex diseases / / 17554300 rs16920984 chr8 57644926 T C 4.39E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13254646 chr8 57648762 G A 2.20E-04 Body mass index / / 17255346 rs1834414 chr8 57659691 C T 6.00E-05 Body mass index / / 17255346 rs9298556 chr8 57683880 C T 9.40E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs353747 chr8 57706906 G C 3.39E-04 Insulin resistance / / 21901158 rs6474080 chr8 57710655 T C 1.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs10105950 chr8 57728592 G A 9.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs1424687 chr8 57747018 A G 7.33E-05 Calcium levels / / pha003085 rs1834197 chr8 57755644 T C 8.20E-05 Calcium levels / / pha003085 rs918911 chr8 57772008 C T 1.39E-04 Myocardial Infarction / / pha002883 rs918912 chr8 57772111 A G 5.45E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4304324 chr8 57792222 G A 1.39E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11987435 chr8 57811594 T A 5.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs12681817 chr8 57826568 T C 6.33E-05 Multiple complex diseases / / 17554300 rs10504214 chr8 57845199 G A 2.70E-05 Urinary metabolites / / 21572414 rs2089515 chr8 57926726 C T 9.91E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs2089515 chr8 57926726 C T 1.70E-06 Urinary metabolites / / 21572414 rs7836564 chr8 57961214 C T 1.30E-05 Urinary metabolites / / 21572414 rs4060655 chr8 57963649 G A 6.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1992461 chr8 57976625 G A 7.60E-04 Alzheimer's disease / / 17998437 rs4541915 chr8 57982790 C T 8.95E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs6474100 chr8 58031161 G A 3.78E-04 Age-related macular degeneration / / 22125219 rs12678187 chr8 58113766 G A 8.69E-07 White blood cell count / / 21738479 rs185048472 chr8 58133986 G T 0.0000031 Bisphosphonate-induced osteonecrosis of the jaw / / 22267851 rs10089625 chr8 58179299 G A 7.31E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16921974 chr8 58200173 T C 7.00E-06 Hypertension / / 22384028 rs16921991 chr8 58224012 T C 4.67E-04 Sudden cardiac arrest / / 21658281 rs6981613 chr8 58264011 C T 2.50E-05 Urinary metabolites / / 21572414 rs12679553 chr8 58265798 T C 1.20E-04 Myasthenia gravis / / 23055271 rs1317890 chr8 58290110 T A 2.28E-04 Sudden cardiac arrest / / 21658281 rs16922088 chr8 58298072 C T 6.40E-04 Multiple complex diseases / / 17554300 rs954295 chr8 58306018 T G 1.00E-05 Prostate cancer / / 21743057 rs2875734 chr8 58315646 A G 3.13E-05 Multiple complex diseases / / 17554300 rs10086935 chr8 58336604 T G 8.19E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7845730 chr8 58349767 T C 6.99E-05 Sudden cardiac arrest / / 21658281 rs6980937 chr8 58353996 A G 9.35E-05 Glucose levels / / pha003057 rs16922177 chr8 58354950 A G 6.47E-06 Hearing function / / 21493956 rs11996539 chr8 58355572 A T 6.76E-06 Hearing function / / 21493956 rs10957002 chr8 58379774 T C 5.37E-04 HIV-1 viral setpoint / / 17641165 rs1451151 chr8 58394712 T C 5.14E-04 HIV-1 viral setpoint / / 17641165 rs4737459 chr8 58405076 T C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1545453 chr8 58411643 G A 7.85E-04 Multiple complex diseases / / 17554300 rs1545454 chr8 58411723 G T 9.48E-04 Multiple complex diseases / / 17554300 rs10099982 chr8 58451160 T A 3.00E-07 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs16922281 chr8 58453913 C T 7.09E-04 Multiple complex diseases / / 17554300 rs10109157 chr8 58457374 C T 6.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10109157 chr8 58457374 C T 2.99E-06 Post-operative nausea and vomiting / / 21694509 rs1451143 chr8 58459736 C G 2.10E-05 Urinary metabolites / / 21572414 rs10094794 chr8 58469034 C G 6.80E-06 Urinary metabolites / / 21572414 rs6471626 chr8 58476028 T A 9.40E-08 Metabolite levels / / 23281178 rs6471628 chr8 58477896 G T 9.40E-08 Metabolite levels / / 23281178 rs10099945 chr8 58478850 T C 6.24E-04 Coronary heart disease / / 21971053 rs6984003 chr8 58479044 T C 9.40E-08 Metabolite levels / / 23281178 rs921419 chr8 58484111 C T 2.68E-04 Coronary heart disease / / 21971053 rs921419 chr8 58484111 C T 9.40E-08 Metabolite levels / / 23281178 rs7001688 chr8 58485950 G T 6.72E-04 Coronary heart disease / / 21971053 rs6471632 chr8 58486824 G A 9.40E-08 Metabolite levels / / 23281178 rs1451137 chr8 58492691 A T 4.40E-08 Metabolite levels / / 23281178 rs1542270 chr8 58492825 A C 4.40E-08 Metabolite levels / / 23281178 rs12677701 chr8 58497257 C T 3.36E-09 Metabolite levels / / 23281178 rs7838167 chr8 58498026 A G 5.84E-09 Metabolite levels / / 23281178 rs2167316 chr8 58507102 C T 5.27E-05 Coronary heart disease / / 21971053 rs2167316 chr8 58507102 C T 5.84E-09 Metabolite levels / / 23281178 rs2875744 chr8 58509605 C T 1.33E-04 Coronary heart disease / / 21971053 rs2875744 chr8 58509605 C T 5.84E-09 Metabolite levels / / 23281178 rs1993076 chr8 58513905 T G 5.84E-09 Metabolite levels / / 23281178 rs2325777 chr8 58514086 C T 9.66E-04 Type 2 diabetes / / 17463246 rs2325777 chr8 58514086 C T 1.70E-04 Alcohol dependence / / 20201924 rs4738606 chr8 58514933 A G 5.84E-09 Metabolite levels / / 23281178 rs1376403 chr8 58518393 A G 3.19E-09 Metabolite levels / / 23281178 rs1584638 chr8 58526263 C A 8.43E-08 Metabolite levels / / 23281178 rs7012400 chr8 58531932 T C 2.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7827899 chr8 58532919 C T 8.43E-08 Metabolite levels / / 23281178 rs10097830 chr8 58536773 A C 3.52E-04 IgE levels / / 17255346 rs7002096 chr8 58539133 G T 2.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10087587 chr8 58542880 T C 2.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1451145 chr8 58549252 T C 8.56E-08 Metabolite levels / / 23281178 rs1010278 chr8 58553786 A C 8.56E-08 Metabolite levels / / 23281178 rs13280052 chr8 58564501 T C 8.56E-08 Metabolite levels / / 23281178 rs7004631 chr8 58616620 G A 3.82E-04 Alcohol dependence / / 24277619 rs4404901 chr8 58619055 C T 9.12E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs7836900 chr8 58628032 G A 7.10E-06 Response to citalopram in major depressive disorder / / 20619826 rs9694511 chr8 58664288 T C 7.92E-04 Alcohol dependence / / 24277619 rs10096565 chr8 58670352 A C 4.10E-04 Alcohol dependence / / 24277619 rs13265778 chr8 58678194 C T 5.76E-06 Osteoarthritis / / 19508968 rs13249012 chr8 58679518 G A 5.63E-05 Heart Rate / / pha003051 rs1561081 chr8 58694111 G A 3.18E-05 Osteoarthritis / / 19508968 rs10103386 chr8 58731685 A T 8.28E-04 Multiple complex diseases / / 17554300 rs1436027 chr8 58740093 A G 2.10E-05 Urinary metabolites / / 21572414 rs1436003 chr8 58757734 G A 3.48E-04 Multiple complex diseases / / 17554300 rs6471656 chr8 58760048 G A 3.11E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs6471657 chr8 58760524 A G 4.11E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs6997028 chr8 58779172 C T 8.49E-05 Post-operative nausea and vomiting / / 21694509 rs10504249 chr8 58789081 A G 1.00E-07 Blood pressure measurement (low sodium intervention) / / 24165912 rs10504249 chr8 58789081 A G 4.00E-07 Blood pressure measurement (low sodium intervention) / / 24165912 rs10504248 chr8 58789168 T C 7.80E-05 Malaria / / 19465909 rs13273087 chr8 58795132 A G 0.000278 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs13253940 chr8 58801821 A C 0.000565 Common carotid artery thickness (average of near and far wall measures) / / 23487405 rs1369771 chr8 58801922 T C 9.58E-04 Multiple complex diseases / / 17554300 rs11784185 chr8 58809656 T G 3.41E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs11784185 chr8 58809656 T G 0.000381 Common carotid artery thickness (average of near and far wall measures) / / 23487405 rs1992044 chr8 58840908 G T 3.84E-07 Bipolar disorder and schizophrenia / / 20889312 rs1992045 chr8 58840924 C T 2.00E-07 Bipolar disorder and schizophrenia / / 20889312 rs1992045 chr8 58840924 C T 7.75E-05 Bipolar Disorder / / pha002858 rs1436022 chr8 58843630 A G 0.000231 Common carotid artery thickness (average of near and far wall measures) / / 23487405 rs1436023 chr8 58843783 A G 0.000141 Common carotid artery thickness (average of near and far wall measures) / / 23487405 rs7832353 chr8 58926419 T A 3.67E-04 Multiple complex diseases FAM110B intron 17554300 rs10504244 chr8 58984774 A G 8.30E-05 Kidney function and endocine traits FAM110B intron 17903292 rs13273891 chr8 58986459 G A 1.95E-06 Smooth-surface caries FAM110B intron 24556642 rs9792139 chr8 59028860 G A 7.29E-05 Cognitive performance FAM110B intron 19734545 rs7820808 chr8 59033392 C T 4.94E-05 Cognitive performance FAM110B intron 19734545 rs16923100 chr8 59045950 C T 2.00E-04 Personality dimensions FAM110B intron 23903073 rs4738648 chr8 59057413 T C 0.0001 Migraine FAM110B intron 22678113 rs2939975 chr8 59080312 T C 2.00E-05 Urinary metabolites / / 21572414 rs1395614 chr8 59081551 C T 7.89E-04 Multiple complex diseases / / 17554300 rs2939976 chr8 59081949 G A 9.70E-04 Multiple complex diseases / / 17554300 rs12547204 chr8 59082547 G C 8.47E-05 Insulin resistance / / 21901158 rs1354816 chr8 59082622 G T 6.07E-04 Multiple complex diseases / / 17554300 rs7839850 chr8 59087582 C A 3.40E-05 Response to statin therapy / / 20339536 rs723314 chr8 59122062 G A 4.91E-07 Bipolar disorder / / 22182935 rs3888939 chr8 59143461 A G 4.84E-07 Bipolar disorder / / 22182935 rs16923209 chr8 59144177 G T 7.03E-07 Bipolar disorder / / 22182935 rs4738654 chr8 59152769 A G 1.52E-05 Tuberculosis / / 24057671 rs6995423 chr8 59167584 G A 2.53E-05 Tuberculosis / / 24057671 rs6995423 chr8 59167584 G A 8.27E-05 Blood Pressure / / pha003045 rs6995423 chr8 59167584 G A 8.16E-05 Blood Pressure / / pha003047 rs4072993 chr8 59169071 A C 5.70E-04 Tourette syndrome / / 22889924 rs4237026 chr8 59171944 C A 7.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9643503 chr8 59174576 G A 7.48E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10504252 chr8 59217726 A C 7.40E-04 Crohn's disease / / 17684544 rs10111165 chr8 59241092 A C 2.20E-05 Urinary metabolites / / 21572414 rs17259642 chr8 59250140 C T 2.50E-05 Urinary metabolites / / 21572414 rs1457037 chr8 59250585 C T 2.60E-05 Urinary metabolites / / 21572414 rs7820691 chr8 59254904 T C 2.00E-05 Urinary metabolites / / 21572414 rs7820691 chr8 59254904 T C 1.93E-04 Epilepsy / / 22116939 rs2925663 chr8 59261869 T C 0.0000107 Carotid intima media thickness / / 23152477 rs7839217 chr8 59271041 A C 3.28E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6997474 chr8 59271832 T C 5.78E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6471711 chr8 59281825 G A 5.52E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10102916 chr8 59303550 G T 2.80E-05 Urinary metabolites / / 21572414 rs897735 chr8 59307275 G A 5.20E-06 Urinary metabolites / / 21572414 rs12546225 chr8 59307338 A G 6.89E-05 Waist-Hip Ratio / / pha003029 rs7835920 chr8 59308732 T G 5.54E-07 Atopy / / 21094521 rs7835920 chr8 59308732 T G 5.79E-04 Atopy / / 21094521 rs2859998 chr8 59324162 G A 1.00E-07 Narcolepsy with cataplexy UBXN2B intron 23496005 rs6471719 chr8 59380723 T C 8.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs6471720 chr8 59384675 G A 8.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs17202769 chr8 59386354 T C 1.39E-06 Atopy / / 21094521 rs2081687 chr8 59388565 T C 4.00E-09 LDL cholesterol / / 20686565 rs2081687 chr8 59388565 T C 9.00E-13 Cholesterol,total / / 20686565 rs2081687 chr8 59388565 T C 1.00E-07 LDL cholesterol / / 24097068 rs2081687 chr8 59388565 T C 9.00E-12 Cholesterol,total / / 24097068 rs16923500 chr8 59389093 G A 2.80E-05 Type 2 diabetes / / 21874001 rs16923506 chr8 59390497 G A 0.000643 Salmonella-induced pyroptosis / / 22837397 rs1457043 chr8 59410439 C T 1.50E-05 Inflammatory demyelinating disease CYP7A1 intron 19850125 rs8192870 chr8 59412066 T G 0.000000217 Cholesterol,total CYP7A1 intron 23063622 rs8192870 chr8 59412066 T G 0.0000101 LDL cholesterol CYP7A1 intron 23063622 rs3808607 chr8 59412924 G T 1.00E-04 Inflammatory demyelinating disease CYP7A1 nearGene-5 19850125 rs12542483 chr8 59460073 C T 1.99E-04 Acute lung injury / / 22295056 rs3808609 chr8 59465377 G C 2.00E-04 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs11994937 chr8 59508580 C T 5.00E-06 IgG glycosylation NSMAF intron 23382691 rs973807 chr8 59571287 C T 1.49E-04 Amyotrophic Lateral Sclerosis NSMAF intron 17827064 rs973807 chr8 59571287 C T 1.49E-05 Serum metabolites NSMAF intron 19043545 rs4738700 chr8 59599500 T C 7.98E-05 Depression (quantitative trait) / / 23290196 rs1565236 chr8 59675214 T C 1.10E-05 Urinary metabolites / / 21572414 rs2634518 chr8 59681732 G A 5.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2693451 chr8 59704437 A G 3.95E-04 Type 2 diabetes / / 17463246 rs17213095 chr8 59707985 A G 1.90E-05 Urinary metabolites / / 21572414 rs960089 chr8 59708309 C T 6.00E-06 Cognitive performance / / 19734545 rs960089 chr8 59708309 C T 0.00017 Breast cancer / / 23555315 rs2726596 chr8 59710386 T C 9.80E-04 Multiple complex diseases / / 17554300 rs2726600 chr8 59720604 G A 1.46E-04 Multiple complex diseases TOX intron 17554300 rs13251536 chr8 59759418 G A 6.14E-04 Multiple complex diseases TOX intron 17554300 rs7003713 chr8 59788913 G A 7.42E-04 Multiple complex diseases TOX intron 17554300 rs2726585 chr8 59793692 C T 6.00E-08 Urinary metabolites TOX intron 21572414 rs6471757 chr8 59805738 G A 3.47E-04 Schizophrenia TOX intron 19197363 rs4737527 chr8 59823491 A G 7.40E-04 Type 2 diabetes TOX intron 17463246 rs1463142 chr8 59837504 C T 5.07E-05 Neuroblastoma TOX intron pha002895 rs1375193 chr8 59846943 T C 9.84E-04 Parkinson's disease TOX intron 17052657 rs1375192 chr8 59856761 G A 6.53E-04 Type 2 diabetes TOX intron 17463246 rs7012303 chr8 59860799 A G 9.38E-04 Parkinson's disease TOX intron 17052657 rs7016545 chr8 59865138 T C 4.81E-04 Multiple complex diseases TOX intron 17554300 rs1448547 chr8 59867483 G A 9.84E-04 Parkinson's disease TOX intron 17052657 rs3780001 chr8 59872615 T G 7.89E-04 Type 2 diabetes TOX intron 17463246 rs2168409 chr8 59878233 C T 5.68E-04 Multiple complex diseases TOX intron 17554300 rs17241424 chr8 59899608 G A,C,T 6.60E-04 Coronary Artery Disease TOX intron 17634449 rs7813241 chr8 59900712 T C 1.00E-04 Cognitive impairment induced by topiramate TOX intron 22091778 rs7813241 chr8 59900712 T C 3.90E-04 Myasthenia gravis TOX intron 23055271 rs422729 chr8 59908029 A G 9.77E-04 Nicotine dependence TOX intron 17158188 rs10098381 chr8 59909747 G A 9.90E-04 Coronary Artery Disease TOX intron 17634449 rs10098381 chr8 59909747 G A 1.00E-04 Prostate cancer TOX intron 21743057 rs10504273 chr8 59913422 A C 1.00E-04 Prostate cancer TOX intron 21743057 rs402443 chr8 59918204 G A 1.01E-06 Waist-hip ratio TOX intron 20935629 rs367116 chr8 59929562 C T 1.52E-04 Multiple complex diseases TOX intron 17554300 rs172652 chr8 59958141 A G 9.77E-04 Multiple complex diseases TOX intron 17554300 rs2956799 chr8 59969305 G T 8.50E-06 Urinary metabolites TOX intron 21572414 rs16924541 chr8 59982514 C G 2.75E-04 Multiple complex diseases TOX intron 17554300 rs10957078 chr8 60034329 G A 3.91E-04 Multiple complex diseases / / 17554300 rs3110145 chr8 60042411 C T 2.50E-05 Anger / / 24489884 rs6996132 chr8 60043130 C T 1.30E-05 Urinary metabolites / / 21572414 rs3122694 chr8 60093954 G A 2.60E-05 Urinary metabolites / / 21572414 rs3110106 chr8 60110235 A T 1.80E-05 Urinary metabolites / / 21572414 rs3110116 chr8 60116168 C T 1.80E-05 Urinary metabolites / / 21572414 rs3122659 chr8 60126710 T C 1.80E-05 Urinary metabolites / / 21572414 rs3110127 chr8 60130296 C T 4.00E-06 RR interval (heart rate) / / 20031603 rs10504290 chr8 60153096 G A 2.20E-06 Urinary metabolites / / 21572414 rs12375413 chr8 60157579 A C 3.08E-04 Age-related macular degeneration / / 22125219 rs72621438 chr8 60178580 C G 3.50E-19 Myopia (Age of onset) / / 23468642 rs10089517 chr8 60178721 C A 2.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs7837791 chr8 60179086 G T 4.00E-12 Refractive error / / 23396134 rs10088994 chr8 60185632 A T 7.63E-04 Type 2 diabetes / / 17463246 rs10088994 chr8 60185632 A T 3.26E-05 Serum metabolites / / 19043545 rs6997052 chr8 60214029 G A 7.97E-04 Alcohol dependence / / 20201924 rs10957086 chr8 60220328 T C 5.43E-05 Alzheimer's disease (age of onset) / / 22005931 rs7835993 chr8 60221132 G A 7.97E-04 Alcohol dependence / / 20201924 rs4237032 chr8 60229452 A G 7.45E-06 Lipoproteins / / pha003079 rs6980657 chr8 60241157 A G 0.0004423 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6980657 chr8 60241157 A G 4.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4386970 chr8 60253104 T C 7.46E-05 Alzheimer's disease (age of onset) / / 22005931 rs6983294 chr8 60264416 C T 0.0006856 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6983294 chr8 60264416 C T 6.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7004358 chr8 60290816 G A 5.47E-05 Celiac disease / / 23936387 rs13282650 chr8 60302901 G A 4.09E-04 Type 2 diabetes / / 22158537 rs11775907 chr8 60305327 G T 2.69E-04 Type 2 diabetes / / 22158537 rs6471785 chr8 60308883 T G 2.99E-04 Type 2 diabetes / / 22158537 rs3942395 chr8 60309850 G A 3.09E-04 Type 2 diabetes / / 22158537 rs1554342 chr8 60318813 C T 1.15E-04 Type 2 diabetes / / 22158537 rs1949479 chr8 60319127 G A 2.37E-04 Type 2 diabetes / / 22158537 rs1401423 chr8 60320233 T C 2.79E-04 Type 2 diabetes / / 22158537 rs1519067 chr8 60320429 G T 7.51E-06 Lipoproteins / / pha003079 rs2222249 chr8 60375664 T G 4.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13439810 chr8 60389920 A G 4.93E-04 Multiple complex diseases / / 17554300 rs10103231 chr8 60413073 C T 3.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1607475 chr8 60416468 T C 9.35E-04 Type 2 diabetes / / 22158537 rs2056264 chr8 60430255 C A 6.27E-04 Type 2 diabetes / / 22158537 rs2460266 chr8 60437335 A G 7.38E-05 Type 2 diabetes / / 22158537 rs2139231 chr8 60445734 A G 4.26E-04 Type 2 diabetes / / 22158537 rs2467610 chr8 60458038 T C 5.24E-04 Type 2 diabetes / / 22158537 rs4607594 chr8 60470686 T C 1.56E-04 Smoking cessation / / 24665060 rs4737547 chr8 60545664 A G 3.00E-06 Multiple myeloma (IgH translocation) / / 23502783 rs16925150 chr8 60604193 T C 1.10E-07 Platelet aggregation(pre- and post-aspirin) / / 20529293 rs12541902 chr8 60623348 A C 9.00E-06 Obesity-related traits / / 23251661 rs4237035 chr8 60626099 T C 9.66E-06 Obesity-related traits / / 23251661 rs867743 chr8 60694647 G A 7.83E-05 Monocyte counts / / pha003089 rs6471814 chr8 60697874 T G 9.81E-05 Monocyte counts / / pha003089 rs10101487 chr8 60718495 A G 7.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs12541924 chr8 60806217 C T 0.000255 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs7012579 chr8 60824302 G C 2.37E-04 Multiple complex diseases / / 17554300 rs569688 chr8 60961821 G T 4.00E-07 Myopia (pathological) / / 23049088 rs6995588 chr8 61003897 C T 2.00E-06 Cardiac hypertrophy / / 21348951 rs2681561 chr8 61004320 C A 3.54E-05 Post-operative nausea and vomiting / / 21694509 rs16925769 chr8 61028037 A G 1.90E-05 Urinary metabolites / / 21572414 rs11998573 chr8 61035433 G A 1.80E-05 Urinary metabolites / / 21572414 rs2681543 chr8 61056493 T G 7.88E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2681543 chr8 61056493 T G 8.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2681543 chr8 61056493 T G 4.30E-05 HIV-1 viral setpoint / / 22174851 rs2681543 chr8 61056493 T G 6.92E-05 Neutrophil count / / pha003095 rs2611339 chr8 61057832 G T 7.88E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2611339 chr8 61057832 G T 8.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2611339 chr8 61057832 G T 3.10E-05 HIV-1 viral setpoint / / 22174851 rs2611339 chr8 61057832 G T 6.92E-05 Neutrophil count / / pha003095 rs2611348 chr8 61067170 T C 0.000467 Common carotid artery thickness (average of near and far wall measures) / / 23487405 rs720208 chr8 61096176 G A 6.54E-06 Obesity-related traits / / 23251661 rs2242154 chr8 61100494 C T 8.34E-05 Lung cancer / / 21725308 rs10098647 chr8 61105199 T C 5.00E-06 Obesity-related traits CA8 intron 23251661 rs10086973 chr8 61105603 C G 8.95E-04 Multiple complex diseases CA8 intron 17554300 rs56227154 chr8 61150883 C G 5.03E-06 Response to amphetamines CA8 intron 22952603 rs6994129 chr8 61155149 T C 6.62E-05 Body Mass Index CA8 intron pha003009 rs10216440 chr8 61185722 T C 8.72E-04 Multiple complex diseases CA8 intron 17554300 rs10957125 chr8 61194170 T G 4.00E-06 Response to amphetamines CA8 nearGene-5 22952603 rs11778498 chr8 61194476 T A 9.03E-06 Response to amphetamines CA8 nearGene-5 22952603 rs13281067 chr8 61196775 T C 7.81E-06 Response to amphetamines / / 22952603 rs13280153 chr8 61197179 C A 8.87E-06 Response to amphetamines / / 22952603 rs9657070 chr8 61203084 T C 8.32E-06 Response to amphetamines / / 22952603 rs9298035 chr8 61233350 C T 5.32E-05 Elbow pain / / pha003008 rs7011237 chr8 61243357 A G 2.77E-04 Type 2 diabetes / / 17463246 rs11998308 chr8 61276247 A G 3.00E-04 Type 2 diabetes / / 17463246 rs6471873 chr8 61293772 T C 9.70E-05 Parkinson's disease (age of onset) / / 19772629 rs13438846 chr8 61330269 G A 2.70E-04 Stroke / / 22306652 rs9650199 chr8 61346197 C T 6.00E-06 Response to amphetamines / / 22952603 rs11776511 chr8 61360266 A G 9.34E-05 Height / / pha003011 rs7829407 chr8 61369006 G A 2.19E-04 Body mass index / / 17255346 rs7413 chr8 61534428 A G 8.90E-06 Lymphocyte counts RAB2A UTR-3 22286170 rs626913 chr8 61548494 A C 1.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs657718 chr8 61566655 A G 7.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs623917 chr8 61568210 G A 1.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs597123 chr8 61572983 C T 7.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs601778 chr8 61576519 T C 1.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10113128 chr8 61585542 T C 8.35E-05 Multiple complex diseases / / 17554300 rs16926379 chr8 61595606 A G 2.02E-06 Pulmonary function CHD7 intron 19300500 rs7013969 chr8 61597447 G A 1.48E-06 Pulmonary function CHD7 intron 19300500 rs16926398 chr8 61606745 G A 1.41E-06 Pulmonary function CHD7 intron 19300500 rs13269361 chr8 61607451 A G 1.40E-06 Pulmonary function CHD7 intron 19300500 rs6471894 chr8 61613404 T C 7.36E-04 Type 2 diabetes CHD7 intron 17463246 rs6986750 chr8 61616515 C G 9.52E-05 Pulmonary function CHD7 intron 19300500 rs6471895 chr8 61624949 T C 1.34E-06 Pulmonary function CHD7 intron 19300500 rs6988200 chr8 61640052 G T 5.98E-05 Pulmonary function CHD7 intron 19300500 rs6988200 chr8 61640052 G T 1.71E-04 Insulin resistance CHD7 intron 21901158 rs10808713 chr8 61647048 A G 8.84E-04 Type 2 diabetes CHD7 intron 17463246 rs61995713 chr8 61654847 A G 0.000052 Breast cancer(er negative) CHD7 missense 23555315 rs9298040 chr8 61656805 T G 9.65E-04 Type 2 diabetes CHD7 intron 17463246 rs11993480 chr8 61657073 A G 4.66E-04 Nicotine dependence CHD7 intron 17158188 rs7000766 chr8 61657833 A G 5.43E-04 Type 2 diabetes CHD7 intron 17463246 rs6471898 chr8 61658362 G A 7.79E-04 Type 2 diabetes CHD7 intron 17463246 rs11986627 chr8 61678330 C T 3.52E-04 Insulin resistance CHD7 intron 21901158 rs6982898 chr8 61704083 G A 8.92E-04 Type 2 diabetes CHD7 intron 17463246 rs6994642 chr8 61723777 C T 1.75E-04 Insulin resistance CHD7 intron 21901158 rs10092214 chr8 61726879 G A 6.29E-05 Caffeine consumption CHD7 intron 21490707 rs6471903 chr8 61740277 A T 4.79E-04 Type 2 diabetes CHD7 intron 17463246 rs3763591 chr8 61764389 G T 2.67E-04 Alcohol dependence CHD7 intron 20201924 rs13280121 chr8 61783211 C T 3.35E-04 Birth weight / / 17255346 rs13280121 chr8 61783211 C T 7.10E-04 Myopia (pathological) / / 21095009 rs4237042 chr8 61785874 T C 2.96E-04 Alzheimer's disease / / 17998437 rs13279465 chr8 61791482 A G 1.07E-05 Self-reported allergy / / 23817569 rs7835942 chr8 61797791 T G 1.01E-05 Self-reported allergy / / 23817569 rs4237043 chr8 61802987 C G 6.49E-04 Substance dependence / / 21818250 rs13251621 chr8 61804729 C T 2.52E-04 Vaspin levels / / 22907691 rs13251621 chr8 61804729 C T 0.0002521 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs12546463 chr8 61805324 T C 1.43E-04 Alzheimer's disease / / 24755620 rs6984384 chr8 61809929 C T 3.96E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10504321 chr8 61812901 C A 4.52E-04 Schizophrenia / / 19197363 rs11784736 chr8 61819013 T C 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs12680914 chr8 61827676 G T 2.46E-04 Celiac disease / / 23936387 rs7840653 chr8 61828910 T A 1.50E-05 Urinary metabolites / / 21572414 rs7008176 chr8 61831999 G A 5.91E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1982638 chr8 61849890 G T 3.84E-04 Parkinson's disease / / 17052657 rs3748648 chr8 61851466 T C 5.58E-05 Parkinson's disease / / 17052657 rs3748648 chr8 61851466 T C 3.54E-04 Smoking initiation / / 24665060 rs10957174 chr8 61858213 T C 2.60E-06 Urinary metabolites / / 21572414 rs1812535 chr8 61859020 A C 9.57E-04 Diabetic retinopathy / / 20871662 rs11988660 chr8 61863392 A G 0.0000069 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) / / 23080225 rs7011500 chr8 61872781 C T 5.24E-04 Multiple complex diseases / / 17554300 rs10104895 chr8 61876044 G A 2.00E-06 Pulmonary function decline / / 22424883 rs12678105 chr8 61882751 C A 6.16E-04 Tourette syndrome / / 22889924 rs10957176 chr8 61906651 T C 6.60E-05 Alzheimer's disease / / 21098978 rs16926675 chr8 61909133 T C 1.04E-05 Podoconiosis / / 22455414 rs41378150 chr8 61941030 C T 3.53E-04 Multiple complex diseases / / 17554300 rs1962862 chr8 61947573 T C 5.90E-05 Multiple sclerosis / / 20598377 rs12550021 chr8 61958271 A T 6.10E-06 Urinary metabolites / / 21572414 rs7007162 chr8 61967297 G C 6.71E-04 Type 2 diabetes / / 17463246 rs4738861 chr8 61979873 G A 1.49E-04 Type 2 diabetes / / 17463246 rs12544001 chr8 61981403 C G 4.07E-04 Type 2 diabetes / / 17463246 rs11987923 chr8 61998100 A G 5.89E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs3864668 chr8 62039073 T C 3.14E-04 Scoliosis / / 21216876 rs1367975 chr8 62044066 G A 5.85E-04 Heart Failure / / pha002885 rs12681792 chr8 62054463 C A 1.66E-04 Migraine without aura / / 23793025 rs12681792 chr8 62054463 C A 9.00E-07 Migraine / / 23793025 rs7830371 chr8 62055667 G T 8.00E-07 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11785638 chr8 62099814 C A 6.79E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs2931327 chr8 62115211 G C 6.85E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1486649 chr8 62147995 A C 5.35E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs10435604 chr8 62152674 T C 4.39E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs3864670 chr8 62152901 G A 7.47E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs3864671 chr8 62153049 T C 4.79E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs3864675 chr8 62180142 C T 6.54E-04 Multiple complex diseases / / 17554300 rs2931288 chr8 62187703 C T 2.31E-04 Multiple complex diseases / / 17554300 rs2931291 chr8 62194006 G A 3.28E-04 Multiple complex diseases / / 17554300 rs2978522 chr8 62194900 C T 6.33E-04 Multiple complex diseases / / 17554300 rs2053409 chr8 62230513 C T 9.06E-04 Multiple complex diseases CLVS1 intron 17554300 rs16927174 chr8 62230844 T C 1.63E-04 Insulin resistance CLVS1 intron 21901158 rs1386220 chr8 62240033 C A 5.90E-04 Multiple complex diseases CLVS1 intron 17554300 rs16927192 chr8 62243083 A T 2.03E-04 Insulin resistance CLVS1 intron 21901158 rs4738886 chr8 62278767 A G 2.80E-04 Multiple complex diseases CLVS1 intron 17554300 rs2083437 chr8 62330024 G C 2.31E-05 Body mass index CLVS1 intron 19584900 rs2083437 chr8 62330024 G C 3.72E-06 Body mass index CLVS1 intron 19584900 rs7012122 chr8 62330609 T C 4.22E-05 Hemoglobin CLVS1 intron pha003098 rs7012122 chr8 62330609 T C 2.82E-05 Erythrocyte counts CLVS1 intron pha003099 rs2291607 chr8 62371260 C T 7.70E-05 Bone mineral density (BMD),in women CLVS1 intron 20164292 rs10107557 chr8 62380439 T C 6.16E-05 Erythrocyte counts CLVS1 intron pha003099 rs2610520 chr8 62399207 G A 4.73E-05 Hemoglobin CLVS1 intron pha003098 rs2610520 chr8 62399207 G A 7.62E-06 Erythrocyte counts CLVS1 intron pha003099 rs7826834 chr8 62401962 C T 3.00E-06 Plasma omega-6 polyunsaturated fatty acid levels CLVS1 intron 24823311 rs41384350 chr8 62404632 T C 9.28E-05 Multiple complex diseases CLVS1 intron 17554300 rs903027 chr8 62409428 G T 6.00E-06 MRI atrophy measures CLVS1 intron 21116278 rs7013189 chr8 62419120 T C 4.30E-04 Multiple complex diseases ASPH intron 17554300 rs10504329 chr8 62437042 A G 3.83E-04 Type 2 diabetes ASPH intron 17463246 rs16927460 chr8 62441024 A T 4.03E-04 Body mass index ASPH intron 17255346 rs16927460 chr8 62441024 A T 5.67E-04 Type 2 diabetes ASPH intron 17463246 rs17201182 chr8 62441608 C T 1.23E-04 Type 2 diabetes ASPH intron 17463246 rs4237044 chr8 62447998 G C 8.81E-04 Multiple complex diseases ASPH intron 17554300 rs4737588 chr8 62459660 G A 6.50E-05 Coffee consumption ASPH intron 21357676 rs11774171 chr8 62477247 T C 8.77E-04 Multiple complex diseases ASPH intron 17554300 rs1320082 chr8 62481666 A G 6.94E-04 Coronary heart disease ASPH intron 21971053 rs16927566 chr8 62484860 A T 2.06E-04 Type 2 diabetes ASPH intron 17463246 rs16927566 chr8 62484860 A T 4.85E-04 Response to taxane treatment (placlitaxel) ASPH intron 23006423 rs2350620 chr8 62497607 C T 5.66E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ASPH intron 20877124 rs7015848 chr8 62498627 A G 1.65E-04 Amyotrophic Lateral Sclerosis ASPH intron 17362836 rs2882460 chr8 62525896 C A 0.0000496 Otitis media (children 3 years old or younger) ASPH intron 23133572 rs6471969 chr8 62566832 G T 0.00000373 Otitis media (children 3 years old or younger) ASPH intron 23133572 rs11990408 chr8 62584995 A G 0.000011 Otitis media (children 3 years old or younger) ASPH intron 23133572 rs11787089 chr8 62620839 C T 0.00000454 Otitis media (children 3 years old or younger) ASPH intron 23133572 rs17801727 chr8 62683067 A T 4.60E-04 Type 2 diabetes / / 17463246 rs1390027 chr8 62728573 C T 6.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10957204 chr8 62729423 C A 7.82E-04 Tourette syndrome / / 22889924 rs7010373 chr8 62775573 A C 2.19E-04 Multiple complex diseases / / 17554300 rs16928019 chr8 62781264 T C 2.38E-04 White matter integrity / / 22425255 rs16928027 chr8 62782976 G C 1.82E-04 Multiple complex diseases / / 17554300 rs7842001 chr8 62794183 A G 7.12E-05 Longevity / / 21612516 rs6981356 chr8 62839354 T C 7.52E-04 Alcohol dependence / / 20201924 rs7836571 chr8 62843726 T A 1.77E-04 Nonalcoholic fatty liver disease / / 21423719 rs1431918 chr8 62885853 G A 7.00E-06 Upper aerodigestive tract cancers / / 21437268 rs2351434 chr8 63043079 C T 3.15E-04 Type 2 diabetes / / 17463246 rs7821022 chr8 63072917 G A 5.30E-04 Smoking quantity / / 24665060 rs2351644 chr8 63077129 C T 8.47E-04 Type 2 diabetes / / 17463246 rs1471678 chr8 63096322 C T 4.70E-07 Coronary heart disease / / 21971053 rs2351950 chr8 63249610 C T 1.79E-05 Cognitive test performance NKAIN3 intron 20125193 rs2351950 chr8 63249610 C T 5.14E-04 Stroke NKAIN3 intron pha002886 rs142014203 chr8 63258917 T G 9.00E-07 Bulimia nervosa NKAIN3 intron 23568457 rs6988778 chr8 63308955 C A 4.88E-05 Stroke NKAIN3 intron pha002886 rs16928927 chr8 63356625 C T 5.94E-04 Multiple complex diseases NKAIN3 intron 17554300 rs2053938 chr8 63386197 G T 1.74E-04 Tourette syndrome NKAIN3 intron 22889924 rs1451835 chr8 63388176 A T 1.90E-05 Urinary metabolites NKAIN3 intron 21572414 rs1993125 chr8 63393027 A G 2.90E-05 Urinary metabolites NKAIN3 intron 21572414 rs13281544 chr8 63393632 T A 5.39E-04 Type 2 diabetes NKAIN3 intron 17463246 rs16929095 chr8 63422929 A G 6.71E-29 Narcolepsy NKAIN3 intron 19629137 rs1079157 chr8 63436369 G A 9.97E-04 Multiple complex diseases NKAIN3 intron 17554300 rs1079158 chr8 63436476 G C 9.57E-04 Multiple complex diseases NKAIN3 intron 17554300 rs41362445 chr8 63459672 G A 2.25E-04 Multiple complex diseases NKAIN3 intron 17554300 rs1451856 chr8 63463330 T C 1.00E-04 Prostate cancer NKAIN3 intron 21743057 rs2928389 chr8 63463719 T G 7.83E-04 Response to taxane treatment (placlitaxel) NKAIN3 intron 23006423 rs827700 chr8 63475139 T A 3.43E-04 Alzheimer's disease NKAIN3 intron 17998437 rs7812978 chr8 63523673 T C 1.52E-39 Metabolite levels NKAIN3 intron 22286219 rs7007264 chr8 63561778 T C 6.95E-04 Type 2 diabetes NKAIN3 intron 17846124 rs16929397 chr8 63598350 G T 9.65E-06 Periodontitis (PAL4Q3) NKAIN3 intron 24024966 rs931131 chr8 63617113 A G 7.50E-06 Periodontitis (PAL4Q3) NKAIN3 intron 24024966 rs2882925 chr8 63621550 T G 7.46E-06 Periodontitis (PAL4Q3) NKAIN3 intron 24024966 rs2882926 chr8 63621569 A T 7.00E-06 Periodontitis (PAL4Q3) NKAIN3 intron 24024966 rs7008492 chr8 63625756 G C 7.48E-06 Periodontitis (PAL4Q3) NKAIN3 intron 24024966 rs11780445 chr8 63629549 G A 5.65E-04 Age-related macular degeneration NKAIN3 intron 22125219 rs4737611 chr8 63630969 C T 7.53E-06 Periodontitis (PAL4Q3) NKAIN3 intron 24024966 rs1600537 chr8 63649211 A C 9.57E-06 Periodontitis (PAL4Q3) NKAIN3 intron 24024966 rs6996317 chr8 63650049 T A 9.78E-06 Periodontitis (PAL4Q3) NKAIN3 intron 24024966 rs1021012 chr8 63664434 C T 9.81E-05 Age-related macular degeneration NKAIN3 intron 22125219 rs7015211 chr8 63678121 G A 9.81E-05 Age-related macular degeneration NKAIN3 intron 22125219 rs12708012 chr8 63695919 T C 9.99E-06 Periodontitis (PAL4Q3) NKAIN3 intron 24024966 rs16929587 chr8 63709449 A G 5.37E-04 Smoking initiation NKAIN3 intron 24665060 rs2086369 chr8 63723888 A G 1.39E-04 Age-related macular degeneration NKAIN3 intron 22125219 rs899676 chr8 63737308 T C 5.06E-05 Age-related macular degeneration NKAIN3 intron 22125219 rs10504354 chr8 63737799 A C 9.42E-04 Multiple complex diseases NKAIN3 intron 17554300 rs17265947 chr8 63738525 A G 2.73E-05 Cognitive test performance NKAIN3 intron 20125193 rs1480113 chr8 63738926 T G 2.41E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs1480113 chr8 63738926 T G 5.11E-04 Response to cytidine analogues (gemcitabine) NKAIN3 intron 24483146 rs899674 chr8 63740190 C G 1.39E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs4636200 chr8 63740593 G A 4.59E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs9785076 chr8 63743617 C T 7.30E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs13266003 chr8 63750069 A G 1.89E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs16929679 chr8 63750539 T G 7.18E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs17181223 chr8 63750578 C A 7.19E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs16929687 chr8 63751641 T C 7.18E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs9332437 chr8 63752741 C T 1.39E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs4358793 chr8 63755284 A T 1.34E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs4604421 chr8 63756837 G A 1.25E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs17273052 chr8 63756961 T C 7.30E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs7830715 chr8 63758070 C T 1.24E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs7830715 chr8 63758070 C T 8.06E-04 Response to cytidine analogues (gemcitabine) NKAIN3 intron 24483146 rs1904571 chr8 63767430 C T 8.58E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs10102831 chr8 63767741 G A 4.55E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs899680 chr8 63768731 G A 1.46E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs899680 chr8 63768731 G A 8.06E-04 Response to cytidine analogues (gemcitabine) NKAIN3 intron 24483146 rs1600534 chr8 63770259 T C 7.25E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs13249030 chr8 63770647 C G 1.31E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs10504356 chr8 63772977 C G 5.07E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs10504357 chr8 63773093 C G 6.11E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs1480119 chr8 63773701 C G 9.63E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs1480119 chr8 63773701 C G 8.33E-04 Insulin resistance NKAIN3 intron 21901158 rs10504358 chr8 63773787 A G 7.30E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs10504359 chr8 63774643 C G 7.04E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs4302833 chr8 63775608 T C 1.62E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs4302833 chr8 63775608 T C 8.06E-04 Response to cytidine analogues (gemcitabine) NKAIN3 intron 24483146 rs13274287 chr8 63776740 G A 3.31E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs7842329 chr8 63778353 A G 4.50E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs7842329 chr8 63778353 A G 2.41E-04 Response to cytidine analogues (gemcitabine) NKAIN3 intron 24483146 rs7018025 chr8 63778587 G T 5.06E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs7018025 chr8 63778587 G T 3.26E-04 Response to cytidine analogues (gemcitabine) NKAIN3 intron 24483146 rs7018340 chr8 63778768 G A 5.09E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs7826606 chr8 63781563 G A 4.88E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs7826606 chr8 63781563 G A 4.28E-04 Response to cytidine analogues (gemcitabine) NKAIN3 intron 24483146 rs4554461 chr8 63784444 T A 8.79E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs4439119 chr8 63790083 G T 1.98E-04 Vaspin levels NKAIN3 intron 22907691 rs4439119 chr8 63790083 G T 0.0001981 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks NKAIN3 intron 22907730 rs10095936 chr8 63790879 A C 6.73E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs10095936 chr8 63790879 A C 3.34E-04 Response to cytidine analogues (gemcitabine) NKAIN3 intron 24483146 rs7016805 chr8 63791208 C T 8.86E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs10957251 chr8 63792454 T G 8.62E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs10957252 chr8 63795245 A C 8.45E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs11995740 chr8 63795640 T G 8.54E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs11995740 chr8 63795640 T G 2.53E-04 Response to cytidine analogues (gemcitabine) NKAIN3 intron 24483146 rs10102270 chr8 63797489 C T 9.38E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs2124296 chr8 63798898 G A 6.73E-04 Response to taxane treatment (placlitaxel) NKAIN3 intron 23006423 rs10435607 chr8 63800000 G A 8.29E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs1563325 chr8 63802825 G A 7.88E-04 Response to statin treatment (atorvastatin),change in cholesterol levels NKAIN3 intron 20031582 rs1869733 chr8 63808400 C T 6.70E-05 Blood Phenotypes NKAIN3 intron 17903294 rs1869733 chr8 63808400 C T 2.19E-05 Vaspin levels NKAIN3 intron 22907691 rs1869733 chr8 63808400 C T 0.0000219 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks NKAIN3 intron 22907730 rs1869731 chr8 63809687 T C 4.70E-04 Obesity-related traits NKAIN3 intron 17903300 rs1455583 chr8 63812686 G T 4.06E-05 Vaspin levels NKAIN3 intron 22907691 rs1455583 chr8 63812686 G T 0.0000406 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks NKAIN3 intron 22907730 rs1455576 chr8 63822440 A G 1.86E-04 Vaspin levels NKAIN3 intron 22907691 rs1455576 chr8 63822440 A G 0.0001862 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks NKAIN3 intron 22907730 rs1455576 chr8 63822440 A G 4.71E-05 Neuroblastoma NKAIN3 intron pha002895 rs17274940 chr8 63827191 T A 7.76E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs4134468 chr8 63841096 T C 7.74E-05 Neuroblastoma NKAIN3 intron pha002895 rs10089287 chr8 63844153 C T 9.51E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs10089486 chr8 63844165 G A 9.48E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs7845898 chr8 63845950 C T 1.09E-05 Cleft lip NKAIN3 intron 20436469 rs12676096 chr8 63846002 G A 8.66E-04 Parkinson's disease NKAIN3 intron 16252231 rs10100440 chr8 63846472 C T 5.97E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs10100648 chr8 63846536 G A 7.59E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs4237066 chr8 63848298 G A 6.36E-06 Orofacial clefts NKAIN3 intron 20023658 rs1350059 chr8 63848556 A G 2.92E-05 Orofacial clefts NKAIN3 intron 20023658 rs10110565 chr8 63850889 T C 1.38E-04 Suicide attempts in bipolar disorder NKAIN3 intron 21423239 rs16929920 chr8 63862040 G T 4.68E-04 Multiple complex diseases NKAIN3 intron 17554300 rs7835051 chr8 63867493 T G 5.97E-05 Orofacial clefts NKAIN3 intron 20023658 rs9298070 chr8 63870658 G T 4.72E-06 Orofacial clefts NKAIN3 intron 20023658 rs9298070 chr8 63870658 G T 6.10E-04 Tourette syndrome NKAIN3 intron 22889924 rs7834588 chr8 63883593 C T 6.00E-07 Response to Vitamin E supplementation NKAIN3 intron 22437554 rs16930023 chr8 63892585 G A 3.90E-05 Response to Vitamin E supplementation NKAIN3 intron 22437554 rs4737623 chr8 63898146 A G 1.80E-04 Myasthenia gravis NKAIN3 intron 23055271 rs10957262 chr8 63905567 T C 2.50E-05 Urinary metabolites / / 21572414 rs1031553 chr8 63906828 G A 2.20E-04 Myasthenia gravis / / 23055271 rs16930073 chr8 63915482 G A 9.67E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs11545078 chr8 63938764 G A 1 Drug response to Methotrexate GGH missense 15284538 rs11545078 chr8 63938764 G A 1 Drug response to Methotrexate GGH missense 17286537 rs11545078 chr8 63938764 G A 0.0002 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 GGH missense 21873659 rs11786893 chr8 63948265 C T 1 Drug response to Methotrexate GGH cds-synon 15284538 rs3780126 chr8 63949912 G A 1 Drug response to Bevacizumab GGH intron 19841321 rs3780126 chr8 63949912 G A 1 Drug response to Pemetrexed GGH intron 19841321 rs11545077 chr8 63951237 C T 1 Drug response to Bevacizumab GGH missense 19841321 rs11545077 chr8 63951237 C T 1 Drug response to Pemetrexed GGH missense 19841321 rs11545077 chr8 63951237 C T 2.90E-05 Response to Vitamin E supplementation GGH missense 22437554 rs1800909 chr8 63951312 A G 1 Drug response to Methotrexate GGH missense 15284538 rs1800909 chr8 63951312 A G 1 Drug response to Methotrexate GGH missense 17286537 rs3758149 chr8 63951728 G A 1 Drug response to Methotrexate GGH nearGene-5 15564880 rs10464904 chr8 63955160 T C 4.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1031551 chr8 63963847 G T 2.90E-05 Response to Vitamin E supplementation / / 22437554 rs6472073 chr8 64001936 C A 2.10E-05 Response to Vitamin E supplementation / / 22437554 rs4737627 chr8 64006201 T C 8.19E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1030788 chr8 64035651 A G 3.91E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4739071 chr8 64171122 A C 9.75E-05 Lymphocyte counts / / 22286170 rs7459968 chr8 64205487 C T 4.82E-04 Stroke / / pha002886 rs6472088 chr8 64219345 G T 1.98E-04 Body mass index / / 17255346 rs6472088 chr8 64219345 G T 2.36E-05 Erythrocyte counts / / pha003090 rs7837234 chr8 64220654 G T 5.59E-05 Erythrocyte counts / / pha003090 rs10113836 chr8 64227210 C G 4.99E-05 Body mass index / / 17255346 rs7015856 chr8 64247381 G A 9.43E-05 Intracranial aneurysm / / 22286173 rs7015856 chr8 64247381 G A 3.31E-05 Magnesium levels / / pha003092 rs7461453 chr8 64248381 G A 7.63E-05 stroke (ischemic) / / 17434096 rs4737639 chr8 64263770 G A 7.63E-05 stroke (ischemic) / / 17434096 rs10112358 chr8 64296883 C T 5.32E-04 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs10112358 chr8 64296883 C T 6.70E-04 Barrett's esophagus / / 24121790 rs17282840 chr8 64307009 G A 3.43E-04 Multiple complex diseases / / 17554300 rs1431594 chr8 64334749 C T 5.57E-05 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs1431594 chr8 64334749 C T 9.76E-05 Barrett's esophagus / / 24121790 rs1431586 chr8 64390729 T C 5.18E-04 Multiple complex diseases / / 17554300 rs1431586 chr8 64390729 T C 6.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6472116 chr8 64498360 T C 9.59E-05 Alzheimer's disease / / 22005930 rs2084862 chr8 64507475 A G 1.99E-04 Alzheimer's disease / / 22005930 rs11777872 chr8 64525347 A G 2.49E-04 Alzheimer's disease / / 22005930 rs1217091 chr8 64527399 T C 2.43E-04 Alzheimer's disease / / 22005930 rs790570 chr8 64537557 C T 4.36E-04 Alzheimer's disease / / 22005930 rs1234627 chr8 64574537 T A 2.64E-04 Alzheimer's disease / / 22005930 rs812603 chr8 64602654 C T 3.33E-04 Alzheimer's disease / / 22005930 rs790564 chr8 64604218 A C 2.87E-04 Alzheimer's disease / / 22005930 rs978336 chr8 64604350 T C 8.23E-04 Alzheimer's disease / / 22005930 rs1149471 chr8 64609862 A G 8.27E-04 Alzheimer's disease / / 22005930 rs1149473 chr8 64612643 A G 8.35E-04 Alzheimer's disease / / 22005930 rs1149474 chr8 64613191 G A 8.33E-04 Alzheimer's disease / / 22005930 rs790561 chr8 64618026 A G 2.35E-04 Alzheimer's disease / / 22005930 rs806255 chr8 64619016 G A 8.92E-04 Alzheimer's disease / / 22005930 rs790566 chr8 64621373 T C 8.71E-04 Alzheimer's disease / / 22005930 rs790567 chr8 64621434 T C 3.50E-04 Alzheimer's disease / / 22005930 rs1217096 chr8 64623146 T G 3.40E-04 Alzheimer's disease / / 22005930 rs1217097 chr8 64623330 A G 2.28E-04 Alzheimer's disease / / 22005930 rs1217098 chr8 64623652 A C 8.87E-04 Alzheimer's disease / / 22005930 rs1217103 chr8 64625292 T C 8.21E-04 Multiple complex diseases / / 17554300 rs1217103 chr8 64625292 T C 3.64E-04 Alzheimer's disease / / 22005930 rs1217105 chr8 64626932 T G 2.28E-04 Alzheimer's disease / / 22005930 rs6992714 chr8 64628120 T C 7.17E-04 Alzheimer's disease / / 22005930 rs6988374 chr8 64630920 C T 8.71E-04 Alzheimer's disease / / 22005930 rs11997190 chr8 64632186 G A 8.69E-04 Alzheimer's disease / / 22005930 rs1406489 chr8 64633242 A T 8.70E-04 Alzheimer's disease / / 22005930 rs1406490 chr8 64633312 T C 5.21E-04 Multiple complex diseases / / 17554300 rs1406490 chr8 64633312 T C 8.65E-04 Alzheimer's disease / / 22005930 rs1406491 chr8 64633425 C A 1.18E-04 Alzheimer's disease / / 22005930 rs11994082 chr8 64636395 A G 8.73E-04 Alzheimer's disease / / 22005930 rs10113566 chr8 64636629 T C 3.13E-05 Alzheimer's disease / / 22005930 rs10099382 chr8 64637188 A G 8.93E-04 Alzheimer's disease / / 22005930 rs6472118 chr8 64638710 C T 9.05E-04 Alzheimer's disease / / 22005930 rs10957297 chr8 64677404 T G 7.27E-04 Alzheimer's disease / / 22005930 rs1520928 chr8 64686162 G A 3.53E-04 Alzheimer's disease LOC286184 intron 22005930 rs1915790 chr8 64686271 C T 6.66E-04 Alzheimer's disease LOC286184 intron 22005930 rs7834671 chr8 64691770 G A 6.66E-04 Alzheimer's disease / / 22005930 rs1996708 chr8 64691973 A C 7.25E-04 Alzheimer's disease / / 22005930 rs6472121 chr8 64692412 G T 1.21E-04 Alzheimer's disease / / 22005930 rs6472122 chr8 64692560 G A 4.99E-04 Type 2 diabetes / / 17463246 rs6472123 chr8 64692729 G A 3.51E-04 Alzheimer's disease / / 22005930 rs10091567 chr8 64693006 A C 7.26E-04 Alzheimer's disease / / 22005930 rs1402380 chr8 64694198 C G 6.42E-04 Alzheimer's disease LOC286184 intron 22005930 rs1520919 chr8 64696606 G A 6.37E-04 Alzheimer's disease LOC286184 intron 22005930 rs791402 chr8 64708524 A G 7.48E-04 Multiple complex diseases / / 17554300 rs17288962 chr8 64708707 C A 3.25E-04 Multiple complex diseases / / 17554300 rs755223 chr8 64718119 A C 9.60E-05 Electrocardiographic conduction measures / / 19389651 rs10095012 chr8 64723619 A G 2.91E-05 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia / / 24039173 rs16930672 chr8 64727598 C T 3.58E-04 Insulin resistance / / 21901158 rs705984 chr8 64735494 A G 0.000424271 Hypertension (early onset hypertension) / / 22479346 rs7829551 chr8 64750803 G A 8.09E-04 Type 2 diabetes / / 17463246 rs10504368 chr8 64784543 A G 2.70E-04 Obesity-related traits / / 17903300 rs28591602 chr8 64785625 G T 3.24E-04 Insulin resistance / / 21901158 rs2162119 chr8 64835981 T C 9.75E-06 Schizophrenia / / 21926974 rs10093096 chr8 64907701 T C 0.000536 Salmonella-induced pyroptosis / / 22837397 rs6988624 chr8 64931948 C T 9.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs6988624 chr8 64931948 C T 6.40E-07 Lung adenocarcinoma / / 22797724 rs874777 chr8 64984947 T C 2.98E-04 Body mass index / / 17255346 rs1444511 chr8 65008255 G A 8.13E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16930874 chr8 65049334 G A 2.71E-05 Cognitive performance / / 19734545 rs1485510 chr8 65059823 C T 3.63E-04 Body mass index / / 17255346 rs12545053 chr8 65073605 A G 9.18E-04 Multiple complex diseases / / 17554300 rs12545053 chr8 65073605 A G 1.28E-04 Coronary Artery Disease / / 17634449 rs7824886 chr8 65085905 C A 6.92E-06 Waist circumference / / 19557197 rs4517161 chr8 65087982 T C 1.31E-05 Type 2 diabetes / / 17463246 rs11778954 chr8 65090848 G A 1.76E-05 Type 2 diabetes / / 17463246 rs6998794 chr8 65092350 C T 7.37E-06 Waist circumference / / 19557197 rs16930931 chr8 65106360 C T 7.43E-06 Waist circumference / / 19557197 rs11778132 chr8 65114514 G T 7.98E-06 Waist circumference / / 19557197 rs11990688 chr8 65121729 G C 8.97E-06 Waist circumference / / 19557197 rs11780082 chr8 65122379 G A 9.23E-06 Waist circumference / / 19557197 rs4620321 chr8 65132948 T C 1.60E-04 Type 2 diabetes / / 17463246 rs16930988 chr8 65165645 T G 4.31E-04 Type 2 diabetes / / 17463246 rs16930988 chr8 65165645 T G 1.90E-04 Multiple complex diseases / / 17554300 rs16930988 chr8 65165645 T G 2.50E-05 Urinary metabolites / / 21572414 rs7000098 chr8 65192690 C T 5.63E-04 Type 2 diabetes / / 17463246 rs7000098 chr8 65192690 C T 4.34E-04 Multiple complex diseases / / 17554300 rs7000098 chr8 65192690 C T 6.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs6982872 chr8 65193137 T C 3.18E-04 Multiple complex diseases / / 17554300 rs190937 chr8 65216854 T C 5.39E-05 Type 2 diabetes / / 17463246 rs17223648 chr8 65244543 G A 3.02E-04 Multiple complex diseases / / 17554300 rs7836768 chr8 65387467 A G 4.52E-04 Type 2 diabetes / / 17463246 rs7836768 chr8 65387467 A G 1.51E-04 Arthritis (juvenile idiopathic) / / 22354554 rs1451866 chr8 65400793 A T 3.33E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10103787 chr8 65403455 A G 5.00E-08 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs6996198 chr8 65463442 C T 7.76E-08 HIV-1 acquisition / / 22362864 rs16931326 chr8 65495333 G A 8.64E-06 Lipid traits BHLHE22 UTR-3 21777205 rs9298086 chr8 65535398 C A,T 2.01E-05 Alzheimer's disease CYP7B1 intron 17998437 rs10808738 chr8 65544125 G A 1.40E-04 Alzheimer's disease CYP7B1 intron 17998437 rs10808738 chr8 65544125 G A 4.28E-06 Alzheimer's disease CYP7B1 intron pha002879 rs35073384 chr8 65563626 A T 4.80E-05 Urinary metabolites CYP7B1 intron 21572414 rs6999999 chr8 65585409 T C 5.73E-05 Alzheimer's disease CYP7B1 intron 17998437 rs11998077 chr8 65593996 C A 4.59E-05 Alzheimer's disease CYP7B1 intron 17998437 rs7827287 chr8 65605719 G T 4.97E-06 Retinopathy in non-diabetics CYP7B1 intron 23393555 rs10957321 chr8 65605878 G A 5.12E-06 Retinopathy in non-diabetics CYP7B1 intron 23393555 rs7002672 chr8 65606916 G A 3.85E-05 Schizophrenia CYP7B1 intron 19571809 rs7002672 chr8 65606916 G A 5.04E-05 Schizophrenia CYP7B1 intron pha002859 rs13277887 chr8 65608240 T C 2.80E-05 Urinary metabolites CYP7B1 intron 21572414 rs7830315 chr8 65608361 T C 5.32E-06 Retinopathy in non-diabetics CYP7B1 intron 23393555 rs10112206 chr8 65611761 A C 4.90E-06 Retinopathy in non-diabetics CYP7B1 intron 23393555 rs6472147 chr8 65612697 A T 5.32E-06 Retinopathy in non-diabetics CYP7B1 intron 23393555 rs10808739 chr8 65640260 G A 1.00E-06 HIV-1 susceptibility CYP7B1 intron 22174851 rs10957322 chr8 65670364 G A 3.90E-06 HIV-1 viral setpoint CYP7B1 intron 22174851 rs12548518 chr8 65674039 A G 9.54E-05 Serum albumin level CYP7B1 intron pha003084 rs6980478 chr8 65720734 A G 8.20E-04 Type 2 diabetes / / 17463246 rs6472155 chr8 65730207 G A 4.00E-06 Retinopathy in non-diabetics / / 23393555 rs4077788 chr8 65770668 C A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7820286 chr8 65796450 T G 5.95E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4546701 chr8 65850022 G T 3.77E-04 Multiple complex diseases / / 17554300 rs16931697 chr8 65964517 G T 1.80E-04 Insulin resistance / / 21901158 rs2980003 chr8 65999963 C T 5.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs2956307 chr8 66003840 G A 8.75E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs12544654 chr8 66102770 T C 7.66E-04 Coronary heart disease / / 21606135 rs4737206 chr8 66129990 C T 0.0000919 Migraine / / 22678113 rs4737206 chr8 66129990 C T 9.19E-05 Migraine / / 22683712 rs6981388 chr8 66159277 T C 2.00E-06 Urinary metabolites / / 21572414 rs13273164 chr8 66162156 T C 2.00E-05 Urinary metabolites / / 21572414 rs1514504 chr8 66170558 G A 5.70E-06 Urinary metabolites / / 21572414 rs873354 chr8 66211217 G A 2.90E-05 Response to hepatitis C treatment / / 19684573 rs9650215 chr8 66224991 T C 7.24E-05 Insulin resistance / / 21901158 rs964437 chr8 66228435 A G 2.55E-04 Insulin resistance / / 21901158 rs7830803 chr8 66235381 T G 1.09E-05 Multiple complex diseases / / 17554300 rs4737214 chr8 66288887 A T 9.20E-04 Insulin resistance / / 21901158 rs1973642 chr8 66291884 T A 1.70E-06 Urinary metabolites / / 21572414 rs9886640 chr8 66301579 A C 1.44E-05 Alzheimer's disease / / 17998437 rs10096019 chr8 66304887 C T 7.70E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs1399298 chr8 66313907 T C 4.95E-05 Cognitive performance / / 19734545 rs10429417 chr8 66366223 C T 3.36E-04 Multiple complex diseases / / 17554300 rs4551406 chr8 66372564 T C 4.52E-04 Multiple complex diseases / / 17554300 rs16932135 chr8 66387563 T A 8.25E-05 Femoral neck bone geometry / / 22087292 rs4413813 chr8 66396831 G A 9.62E-04 Alzheimer's disease / / 17998437 rs7831778 chr8 66437645 G A 3.50E-04 Multiple complex diseases / / 17554300 rs16932169 chr8 66438548 G A 2.93E-04 Insulin resistance / / 21901158 rs6981589 chr8 66449457 T G 8.61E-04 Parkinson's disease LOC286186 intron 17052657 rs6981589 chr8 66449457 T G 2.08E-05 Multiple complex diseases LOC286186 intron 17554300 rs6981992 chr8 66463478 G T 8.00E-06 Obesity-related traits LOC286186 intron 23251661 rs16932223 chr8 66470243 A G 9.27E-05 Schizophrenia LOC286186 intron 20185149 rs11992528 chr8 66473879 C T 7.46E-04 Body mass index LOC286186 intron 21701565 rs6472209 chr8 66474748 T A 4.52E-04 Body mass index LOC286186 intron 21701565 rs7463649 chr8 66485995 C T 5.49E-05 Pulmonary function / / 20010835 rs4236943 chr8 66497560 G A 2.40E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs4320587 chr8 66499226 G A 1.51E-04 Cholesterol / / 17255346 rs14213 chr8 66514954 T C 9.17E-05 Serum metabolites ARMC1 UTR-3 19043545 rs6997959 chr8 66540482 T C 6.98E-05 Pulmonary function ARMC1 intron 20010835 rs6997959 chr8 66540482 T C 4.42E-05 Personality dimensions ARMC1 intron 22628180 rs10504389 chr8 66556187 C T 5.53E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs7842162 chr8 66556292 T G 4.45E-05 Personality dimensions / / 22628180 rs13251307 chr8 66577146 T G 4.21E-05 Personality dimensions MTFR1 intron 22628180 rs13281090 chr8 66590479 C A 3.77E-05 Personality dimensions MTFR1 intron 22628180 rs17395275 chr8 66591238 G A 3.77E-05 Personality dimensions MTFR1 intron 22628180 rs7007987 chr8 66612989 T C 4.37E-05 Personality dimensions MTFR1 intron 22628180 rs13274205 chr8 66620359 G A 3.54E-05 Personality dimensions MTFR1 cds-synon 22628180 rs10504390 chr8 66624232 A G 1.00E-07 IgG glycosylation / / 23382691 rs10504390 chr8 66624232 A G 2.00E-07 IgG glycosylation / / 23382691 rs10504390 chr8 66624232 A G 8.00E-06 IgG glycosylation / / 23382691 rs7822627 chr8 66626374 C A 3.41E-05 Personality dimensions / / 22628180 rs7829434 chr8 66629144 T C 3.21E-05 Personality dimensions PDE7A UTR-3 22628180 rs869151 chr8 66638722 A G 3.14E-05 Personality dimensions PDE7A intron 22628180 rs10808746 chr8 66644713 G A 6.73E-05 Cognitive decline PDE7A intron 22054870 rs17396080 chr8 66654703 T C 3.61E-05 Personality dimensions PDE7A intron 22628180 rs13280521 chr8 66661074 G A 4.56E-05 Personality dimensions PDE7A intron 22628180 rs7818909 chr8 66661472 T C 4.31E-05 Personality dimensions PDE7A intron 22628180 rs7822707 chr8 66667850 T C 4.10E-05 Personality dimensions PDE7A intron 22628180 rs974149 chr8 66690822 A G 3.02E-05 Epilepsy PDE7A intron 22116939 rs6472225 chr8 66753261 C T 7.09E-06 Epilepsy PDE7A intron 22116939 rs6472235 chr8 66822030 T G 7.84E-04 Alzheimer's disease / / 17998437 rs6472235 chr8 66822030 T G 4.29E-05 HIV-1 viral setpoint / / 22174851 rs6472235 chr8 66822030 T G 1.00E-07 Myopia (pathological) / / 23049088 rs6472236 chr8 66832681 T C 4.29E-05 HIV-1 viral setpoint / / 22174851 rs6994725 chr8 66844743 G A 3.46E-05 HIV-1 viral setpoint / / 22174851 rs4601292 chr8 66851731 G A 6.00E-06 HIV-1 viral setpoint / / 22174851 rs6981354 chr8 66865183 C T 9.10E-06 Urinary metabolites / / 21572414 rs6472239 chr8 66900280 T C 1.77E-05 Non-word repetition / / 23738518 rs2357566 chr8 66911221 C T 8.32E-04 Smoking cessation / / 24665060 rs17397530 chr8 66913287 T C 2.93E-04 Alzheimer's disease / / 24755620 rs4317552 chr8 66914293 G T 2.38E-05 Smoking cessation / / 24665060 rs10504394 chr8 66918243 T C 4.06E-05 Non-word repetition / / 23738518 rs6992002 chr8 66927237 G A 2.93E-04 Smoking cessation / / 24665060 rs16932415 chr8 66928053 G A 5.03E-04 Multiple complex diseases / / 17554300 rs7006789 chr8 66935288 G A 7.53E-04 Smoking cessation D/JC5B intron 24665060 rs17307227 chr8 66941141 G A 2.20E-05 Urinary metabolites D/JC5B intron 21572414 rs2357668 chr8 66955651 A G 3.74E-04 Smoking cessation D/JC5B intron 24665060 rs13279522 chr8 66974252 T C 5.00E-07 Response to statin therapy D/JC5B intron 22666496 rs10100725 chr8 66979712 T C 3.54E-05 Erythrocyte counts D/JC5B intron pha003101 rs6998258 chr8 67039389 G A 5.94E-05 HIV-1 viral setpoint TRIM55 UTR-5 22174851 rs9643575 chr8 67052316 A C 8.27E-05 Tunica Media TRIM55 intron pha003036 rs7831234 chr8 67052395 A G 2.10E-05 Urinary metabolites TRIM55 intron 21572414 rs16932564 chr8 67059253 A G 5.40E-06 Urinary metabolites TRIM55 intron 21572414 rs6998761 chr8 67061637 A G 2.10E-05 Urinary metabolites TRIM55 intron 21572414 rs9694082 chr8 67066780 C G 2.10E-05 Urinary metabolites TRIM55 intron 21572414 rs7822243 chr8 67069388 T C 2.10E-05 Urinary metabolites TRIM55 intron 21572414 rs7842707 chr8 67069773 G A 1.40E-05 Urinary metabolites TRIM55 intron 21572414 rs7842761 chr8 67069978 C T 1.20E-05 Urinary metabolites TRIM55 intron 21572414 rs7843038 chr8 67070155 C T 8.10E-04 Atrial fibrillation TRIM55 intron 21846873 rs6999100 chr8 67082732 T C 7.10E-06 Urinary metabolites TRIM55 intron 21572414 rs6472257 chr8 67092180 C A,G,T 2.10E-05 Urinary metabolites CRH nearGene-5 21572414 rs1870392 chr8 67098511 C G 3.46E-05 Multiple complex diseases / / 17554300 rs16932632 chr8 67108896 G A 2.10E-05 Urinary metabolites LOC100505659 intron 21572414 rs2469298 chr8 67139649 A C 2.50E-04 Cholesterol / / 17255346 rs2469260 chr8 67169917 A C 1.41E-04 Cholesterol / / 17255346 rs936430 chr8 67171962 T C 4.30E-05 Cholesterol / / 17255346 rs2446448 chr8 67177062 C T 9.52E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs16932705 chr8 67186381 C T 1.33E-81 Metabolite levels / / 22286219 rs4737771 chr8 67192379 T C 2.92E-04 Birth weight / / 17255346 rs16932725 chr8 67192629 G A 1.00E-04 Cholesterol / / 17255346 rs12334877 chr8 67194171 G A 8.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs4737773 chr8 67194991 G T 7.98E-04 Schizophrenia / / 19197363 rs10504395 chr8 67221434 C T 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs7007961 chr8 67276508 A G 2.80E-04 Endometrial cancer / / 24096698 rs1030420 chr8 67360725 C T 1.00E-11 Blood metabolite levels ADHFE1 intron 24816252 rs10112574 chr8 67381268 G A 3.00E-14 Blood metabolite ratios / / 24816252 rs10099908 chr8 67398654 T C 8.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs4448262 chr8 67399516 C A 8.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs2433596 chr8 67400061 A G 1.80E-05 Urinary metabolites / / 21572414 rs2555586 chr8 67400347 G A 1.00E-05 Urinary metabolites / / 21572414 rs10100008 chr8 67407874 C T 3.08E-04 Multiple complex diseases C8orf46 intron 17554300 rs2555561 chr8 67432106 C T 9.49E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7012434 chr8 67465588 G T 4.00E-05 HIV-1 control / / 20041166 rs141575513 chr8 67505363 A T 0.00065 Prostate cancer MYBL1 missense 23555315 rs7840192 chr8 67579795 T C 7.80E-04 Type 2 diabetes C8orf44 UTR-5 17463246 rs11996861 chr8 67627906 A C 5.94E-04 Type 2 diabetes SGK3 intron 17463246 rs16933060 chr8 67723050 A T 8.04E-04 Type 2 diabetes SGK3 intron 17463246 rs16933080 chr8 67760268 C T 9.09E-04 Type 2 diabetes SGK3 intron 17463246 rs16933125 chr8 67896026 A G 1.00E-04 Prostate cancer / / 21743057 rs6997490 chr8 67970243 A G 3.60E-04 Atrial fibrillation COPS5 intron 21846873 rs6997490 chr8 67970243 A G 0.00035 Prostate cancer COPS5 intron 23555315 rs11985037 chr8 67983796 G A 1.00E-04 Prostate cancer CSPP1 intron 21743057 rs11989855 chr8 67993933 G A 1.00E-04 Prostate cancer CSPP1 intron 21743057 rs7004549 chr8 68019208 A G 1.00E-04 Prostate cancer CSPP1 intron 21743057 rs11992626 chr8 68032058 G T 1.00E-04 Prostate cancer CSPP1 intron 21743057 rs1466283 chr8 68091026 G A 1.00E-04 Prostate cancer CSPP1 intron 21743057 rs6991974 chr8 68124170 G A 1.00E-04 Prostate cancer ARFGEF1 intron 21743057 rs3780131 chr8 68132706 C T 1.00E-04 Prostate cancer ARFGEF1 intron 21743057 rs6993324 chr8 68189124 C T 1.00E-04 Prostate cancer ARFGEF1 intron 21743057 rs7823436 chr8 68195817 G A 7.69E-04 Type 2 diabetes ARFGEF1 intron 17463246 rs7823436 chr8 68195817 G A 1.00E-04 Prostate cancer ARFGEF1 intron 21743057 rs12678025 chr8 68196817 A G 1.00E-04 Prostate cancer ARFGEF1 intron 21743057 rs13267015 chr8 68205187 C T 5.00E-05 Prostate cancer ARFGEF1 intron 21743057 rs12682412 chr8 68207909 G A 7.00E-05 Prostate cancer ARFGEF1 intron 21743057 rs1821026 chr8 68218476 T A 3.00E-05 Prostate cancer ARFGEF1 intron 21743057 rs10957384 chr8 68219564 C A 1.00E-04 Prostate cancer ARFGEF1 intron 21743057 rs12675528 chr8 68225858 T C 3.00E-05 Prostate cancer ARFGEF1 intron 21743057 rs6987724 chr8 68239000 T C 3.00E-05 Prostate cancer ARFGEF1 intron 21743057 rs1544986 chr8 68244589 G A 6.99E-04 Type 2 diabetes ARFGEF1 intron 17463246 rs7830183 chr8 68245202 A C 9.55E-04 Type 2 diabetes ARFGEF1 intron 17463246 rs7830183 chr8 68245202 A C 2.00E-05 Prostate cancer ARFGEF1 intron 21743057 rs7813810 chr8 68254242 C T 7.20E-05 Body mass index ARFGEF1 intron 20818722 rs7837952 chr8 68346693 G C 7.91E-04 Type 2 diabetes CPA6 intron 17463246 rs7837952 chr8 68346693 G C 0.00016 Coronary artery calcification CPA6 intron 23727086 rs7002216 chr8 68351170 A C 0.000022 Coronary artery calcification CPA6 intron 23727086 rs12682102 chr8 68369098 T C 0.00006 Coronary artery calcification CPA6 intron 23727086 rs4386963 chr8 68404165 T C 5.34E-04 Type 2 diabetes CPA6 intron 17463246 rs2380414 chr8 68442747 C T 7.16E-04 Type 2 diabetes CPA6 intron 17463246 rs7824497 chr8 68456459 G T 5.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CPA6 intron 20877124 rs1545824 chr8 68490139 C A 4.19E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CPA6 intron 24023788 rs10808755 chr8 68516681 G T 3.56E-05 Cognitive impairment induced by topiramate CPA6 intron 22091778 rs990004 chr8 68517859 T C 5.10E-04 Multiple complex diseases CPA6 intron 17554300 rs990004 chr8 68517859 T C 1.00E-04 Cognitive impairment induced by topiramate CPA6 intron 22091778 rs900114 chr8 68527890 G T 9.85E-04 Response to taxane treatment (placlitaxel) CPA6 intron 23006423 rs900114 chr8 68527890 G T 6.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) CPA6 intron 23648065 rs10092095 chr8 68540972 A G 4.38E-05 Gallstones CPA6 intron 17632509 rs10112728 chr8 68574359 A G 6.00E-04 Atrial fibrillation CPA6 intron 21846873 rs6993502 chr8 68577966 A G 1.60E-05 Blood pressure CPA6 intron 21060006 rs6993502 chr8 68577966 A G 5.20E-05 Blood pressure CPA6 intron 21060006 rs6980851 chr8 68588027 A G 9.30E-05 HIV-1 control CPA6 intron 20041166 rs7011473 chr8 68598907 C T 9.30E-05 HIV-1 control CPA6 intron 20041166 rs6472330 chr8 68599959 C T 6.75E-04 Type 2 diabetes CPA6 intron 17463246 rs2098874 chr8 68607109 C T 4.30E-05 HIV-1 control CPA6 intron 20041166 rs2380427 chr8 68608292 C A 4.21E-04 Type 2 diabetes CPA6 intron 17463246 rs2217028 chr8 68617269 C T 7.42E-04 Type 2 diabetes CPA6 intron 17463246 rs7014010 chr8 68624443 G A,C,T 0.00000061 LDL cholesterol CPA6 intron 23063622 rs7014010 chr8 68624443 G A,C,T 0.00000159 Cholesterol,total CPA6 intron 23063622 rs16933569 chr8 68653516 G A 0.000000231 Triglycerides CPA6 intron 23063622 rs2623858 chr8 68677368 C T 3.15E-04 Multiple complex diseases / / 17554300 rs2623850 chr8 68679248 C T 8.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16933666 chr8 68679833 G A 5.60E-06 Urinary metabolites / / 21572414 rs2553687 chr8 68683874 T C 4.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4737247 chr8 68686779 A G 7.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2911959 chr8 68687506 C T 4.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2623825 chr8 68690040 T C 7.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2623825 chr8 68690040 T C 4.49E-04 Alzheimer's disease / / 24755620 rs16933674 chr8 68695641 G A 1.05E-04 Aortic root size / / 21223598 rs2623828 chr8 68695731 C T 4.26E-04 Aortic root size / / 21223598 rs2623813 chr8 68706223 G A 6.15E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2553648 chr8 68707363 C T 5.69E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1365027 chr8 68708402 A C 6.15E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4620272 chr8 68709691 T C 2.42E-04 Alzheimer's disease / / 24755620 rs1834446 chr8 68711093 C T 6.15E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1834447 chr8 68711214 A G 4.15E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10113600 chr8 68717091 C T 3.89E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4430075 chr8 68718260 G A 3.70E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13278432 chr8 68721847 A G 3.64E-04 Alzheimer's disease / / 17998437 rs4585742 chr8 68734769 G A 6.05E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs13249327 chr8 68739932 T C 7.34E-04 Multiple complex diseases / / 17554300 rs4394376 chr8 68745287 G A 9.40E-04 Multiple complex diseases / / 17554300 rs9969560 chr8 68752667 T C 3.92E-04 Multiple complex diseases / / 17554300 rs4131931 chr8 68758974 A C 1.94E-04 Multiple complex diseases / / 17554300 rs12545592 chr8 68762313 C T 9.71E-04 Multiple complex diseases / / 17554300 rs4535726 chr8 68775817 T C 6.06E-06 Serum metabolites / / 19043545 rs6472346 chr8 68777634 G A 7.32E-04 Multiple complex diseases / / 17554300 rs7010672 chr8 68778176 T C 7.67E-05 Type 2 diabetes / / 17846124 rs6472348 chr8 68782879 G A 6.40E-06 Urinary metabolites / / 21572414 rs10098688 chr8 68788493 A C 2.10E-05 Urinary metabolites / / 21572414 rs4496953 chr8 68796160 A G 9.82E-05 Cognitive test performance / / 20125193 rs4428657 chr8 68797071 C A 3.00E-06 Urinary metabolites / / 21572414 rs6990917 chr8 68799377 T C 2.00E-06 Adverse response to lamotrigine and phenytoin / / 22379998 rs7014964 chr8 68817841 A G 8.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs4338089 chr8 68818449 T A 8.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs7824245 chr8 68820877 G C 9.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs6472357 chr8 68821800 A G 8.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs13328427 chr8 68825259 T C 2.58E-06 Adverse response to lamotrigine and phenytoin / / 22379998 rs7815559 chr8 68827528 T A 5.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs4370518 chr8 68830223 T A 2.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs6995479 chr8 68837242 T C 4.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs12334331 chr8 68840630 C G 6.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs7845447 chr8 68842957 G T 5.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs7833293 chr8 68843496 T C 3.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs10283286 chr8 68846038 G A 4.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs7000218 chr8 68846925 C T 4.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs10113761 chr8 68848857 T C 7.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs10107290 chr8 68851094 C T 5.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs4437632 chr8 68851492 A C 6.52E-05 Lipid levels / / 19913121 rs4448260 chr8 68853258 A G 5.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs4628245 chr8 68853271 T C 3.95E-04 Type 2 diabetes / / 17463246 rs12676935 chr8 68884736 C G 5.00E-05 Systolic blood pressure PREX2 intron 19430483 rs10504412 chr8 68885634 G T 8.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PREX2 intron 20877124 rs13275330 chr8 68916920 A C 9.14E-06 Type 2 diabetes PREX2 intron 21573907 rs4512367 chr8 68927592 C T 2.92E-04 Oral cancers (chewing tobacco related) PREX2 intron 22503698 rs10096711 chr8 68958704 C A 7.36E-04 Multiple complex diseases PREX2 intron 17554300 rs41358945 chr8 68959482 T C 9.28E-04 Multiple complex diseases PREX2 intron 17554300 rs7002771 chr8 68980919 A C 6.79E-05 Information processing speed PREX2 intron 21130836 rs12546214 chr8 68998925 C T 0.00051 Endometrial cancer PREX2 intron 22426144 rs4382459 chr8 68999938 C T 1.24E-05 Pancreatic cancer PREX2 intron 23180869 rs1434757 chr8 69042585 G A 1.70E-06 Urinary metabolites PREX2 intron 21572414 rs1434756 chr8 69042668 T G 2.10E-04 Response to antidepressants PREX2 intron 19736353 rs13251311 chr8 69057145 T G 1.17E-04 Response to taxane treatment (placlitaxel) PREX2 intron 23006423 rs7839608 chr8 69057972 C A 6.22E-04 Response to taxane treatment (placlitaxel) PREX2 intron 23006423 rs7839608 chr8 69057972 C A 5.83E-05 Pancreatic cancer PREX2 intron pha002874 rs1369165 chr8 69065096 A C 5.48E-05 Pancreatic cancer PREX2 intron pha002874 rs6984885 chr8 69077685 G A 3.26E-04 Birth weight PREX2 intron 17255346 rs874805 chr8 69077751 C A 8.67E-05 Pancreatic cancer PREX2 intron pha002874 rs4737253 chr8 69080036 G C 4.32E-04 Multiple complex diseases PREX2 intron 17554300 rs41529947 chr8 69093864 A C,T 4.00E-06 Urinary metabolites PREX2 intron 21572414 rs1155491 chr8 69100070 G A 4.44E-04 Response to taxane treatment (placlitaxel) PREX2 intron 23006423 rs9792403 chr8 69119721 T C 4.34E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) PREX2 intron 23648065 rs9792403 chr8 69119721 T C 6.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) PREX2 intron 23648065 rs1525053 chr8 69133585 C T 5.61E-05 Alzheimer's disease PREX2 intron 21098978 rs12546271 chr8 69145346 T C 7.41E-04 Multiple complex diseases / / 17554300 rs12548558 chr8 69145385 A G 6.68E-04 Multiple complex diseases / / 17554300 rs13262547 chr8 69146354 T G 7.39E-04 Multiple complex diseases / / 17554300 rs10504423 chr8 69147931 A G 3.03E-05 Cognitive impairment induced by topiramate / / 22091778 rs10504423 chr8 69147931 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs13282050 chr8 69150183 C T 7.59E-04 Multiple complex diseases / / 17554300 rs1917544 chr8 69150440 C A 7.46E-04 Multiple complex diseases / / 17554300 rs13258486 chr8 69151029 T C 7.61E-04 Multiple complex diseases / / 17554300 rs1608757 chr8 69162031 C T 9.33E-05 Creatinine levels / / pha003069 rs7835997 chr8 69185487 T G 4.03E-04 Schizophrenia / / 21674006 rs7843469 chr8 69198036 T A 4.60E-05 Anger / / 24489884 rs4737256 chr8 69203721 T C 9.35E-05 Tunica Media / / pha003037 rs6982836 chr8 69208366 G T 0.0000564 Bipolar disorder / / 23637625 rs1914328 chr8 69288170 A T 3.21E-05 Multiple complex diseases C8orf34 intron 17554300 rs16934533 chr8 69299417 C T 4.00E-04 Multiple complex diseases C8orf34 intron 17554300 rs16934605 chr8 69348741 G A 2.96E-05 Type 2 diabetes C8orf34 intron 17463246 rs2591007 chr8 69354777 C T 3.45E-04 Rheumatoid arthritis C8orf34 intron 21452313 rs1517114 chr8 69389217 C G 9.00E-06 Response to irinotecan in non-small-cell lung cancer C8orf34 intron 22664479 rs4466385 chr8 69398810 T C 3.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C8orf34 intron 20877124 rs4588839 chr8 69408783 T C 1.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C8orf34 intron 20877124 rs1434939 chr8 69504262 T A 4.97E-05 Blood Pressure and Arterial Stiffness C8orf34 intron 17903302 rs1434939 chr8 69504262 T A 5.35E-05 Serum metabolites C8orf34 intron 19043545 rs7006075 chr8 69531207 G A 7.15E-04 Type 2 diabetes C8orf34 intron 17463246 rs4313142 chr8 69534542 A G 9.23E-06 Elbow pain C8orf34 intron pha003008 rs1369225 chr8 69535087 A G 8.79E-05 Elbow pain C8orf34 intron pha003008 rs1434928 chr8 69540612 G A 4.22E-06 Elbow pain C8orf34 intron pha003008 rs920016 chr8 69541218 A C 3.26E-07 Obesity-related traits C8orf34 intron 23251661 rs16934837 chr8 69562029 G A 2.60E-05 Urinary metabolites C8orf34 intron 21572414 rs7825271 chr8 69563695 G T 3.00E-07 Obesity-related traits C8orf34 intron 23251661 rs2890437 chr8 69566817 C T 1.40E-06 Urinary metabolites C8orf34 intron 21572414 rs16919105 chr8 69578869 G C 2.70E-05 Urinary metabolites C8orf34 intron 21572414 rs11989456 chr8 69580838 G A 5.70E-04 Iris characteristics C8orf34 intron 21835309 rs1434937 chr8 69581985 G A 8.20E-06 Post-operative nausea and vomiting C8orf34 intron 21694509 rs17478857 chr8 69582073 A G 1.46E-27 Narcolepsy C8orf34 intron 19629137 rs1434938 chr8 69583552 C A 2.70E-05 Urinary metabolites C8orf34 intron 21572414 rs16919108 chr8 69629087 T C 9.54E-04 Obesity (extreme) C8orf34 intron 21935397 rs16934962 chr8 69636599 C T 9.67E-05 Bone mineral density C8orf34 intron 19181680 rs12544474 chr8 69640783 G A 9.77E-05 Myocardial Infarction C8orf34 intron pha002873 rs7838605 chr8 69666889 G A 4.18E-04 Sudden cardiac arrest C8orf34 intron 21658281 rs2978243 chr8 69704366 C G,T 5.98E-05 Elbow pain C8orf34 intron pha003008 rs10086703 chr8 69718688 G A 4.18E-09 Multiple complex diseases C8orf34 intron 17554300 rs2978225 chr8 69719361 G A 7.05E-06 Elbow pain C8orf34 intron pha003008 rs16935110 chr8 69730719 A T 5.00E-06 Obesity-related traits C8orf34 UTR-3 23251661 rs16935125 chr8 69733918 T G 8.15E-05 Multiple complex diseases / / 17554300 rs12550697 chr8 69751572 T C 0.000616072 Hypertension (early onset hypertension) / / 22479346 rs4737921 chr8 69771489 C T 0.00007544 Hypertension (early onset hypertension) / / 22479346 rs16919120 chr8 69811773 A G 3.00E-05 Prostate cancer / / 21743057 rs17685111 chr8 69857932 C G 1.72E-04 Response to TNF antagonist treatment LOC100505718 intron 21061259 rs10504433 chr8 69858880 C T 5.54E-04 Response to TNF antagonist treatment LOC100505718 intron 21061259 rs4737930 chr8 69883505 C T 4.12E-05 Cognitive impairment induced by topiramate LOC100505718 intron 22091778 rs10504434 chr8 69883967 C T 9.32E-04 Alzheimer's disease LOC100505718 intron 24755620 rs16935327 chr8 69893091 G A 4.70E-06 Gamma gluatamyl transferase levels (interaction with age) LOC100505718 intron 22010049 rs7825569 chr8 69895021 C T 1.25E-04 Alzheimer's disease (late onset) LOC100505718 intron 21379329 rs7825569 chr8 69895021 C T 9.14E-05 Sensory disturbances after bilateral sagittal split ramus osteotomy LOC100505718 intron 23834954 rs2981068 chr8 69937973 A C 3.14E-04 Multiple complex diseases LOC100505718 intron 17554300 rs7010538 chr8 69941460 T C 0.0008095 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100505718 intron 23233654 rs7010538 chr8 69941460 T C 8.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100505718 intron 23233662 rs13264856 chr8 69950689 T C 6.00E-04 Type 2 diabetes LOC100505718 intron 17463246 rs11774326 chr8 69956803 C T 4.74E-04 Type 2 diabetes LOC100505718 intron 17463246 rs13254975 chr8 69977887 G A 6.94E-04 Type 2 diabetes LOC100505718 intron 17463246 rs2981042 chr8 69977928 G A 6.50E-04 Type 2 diabetes LOC100505718 intron 17463246 rs2912522 chr8 69992380 G A 2.00E-13 Dupuytren's disease LOC100505718 intron 21732829 rs542453 chr8 70057081 T C 6.91E-05 Type 2 diabetes / / 17463246 rs542453 chr8 70057081 T C 1.70E-05 Urinary metabolites / / 21572414 rs13273714 chr8 70058894 G A 7.02E-04 Multiple complex diseases / / 17554300 rs4348505 chr8 70064868 A G 7.01E-04 Multiple complex diseases / / 17554300 rs601115 chr8 70065006 G C 5.01E-05 Type 2 diabetes / / 17463246 rs601115 chr8 70065006 G C 2.60E-05 Urinary metabolites / / 21572414 rs485219 chr8 70065359 C T 1.66E-04 Type 2 diabetes / / 17463246 rs1863591 chr8 70065399 C T 6.64E-04 Multiple complex diseases / / 17554300 rs683567 chr8 70076233 A G 7.50E-04 Alzheimer's disease / / 17998437 rs6472447 chr8 70076264 G A 9.90E-04 Multiple complex diseases / / 17554300 rs10957469 chr8 70077344 C G 3.87E-04 Type 2 diabetes / / 17463246 rs7839374 chr8 70079037 G A 4.28E-04 Type 2 diabetes / / 17463246 rs10093842 chr8 70082788 T A 4.64E-05 Type 2 diabetes / / 17463246 rs16935708 chr8 70097053 T C 7.91E-04 White matter integrity / / 22425255 rs2380522 chr8 70100725 A G 5.80E-04 White matter integrity / / 22425255 rs9298146 chr8 70104164 T G 7.48E-04 White matter integrity / / 22425255 rs831741 chr8 70149257 A C 2.36E-04 Type 2 diabetes / / 17463246 rs831739 chr8 70150552 A G 8.09E-04 Type 2 diabetes / / 17463246 rs1809311 chr8 70151979 T C 5.93E-04 Type 2 diabetes / / 17463246 rs2655173 chr8 70155917 C T 7.11E-04 Type 2 diabetes / / 17463246 rs2615100 chr8 70174476 G A 5.18E-04 Type 2 diabetes / / 17463246 rs283324 chr8 70180251 G A 1.79E-04 Multiple complex diseases / / 17554300 rs831728 chr8 70184331 C T 2.35E-04 Multiple complex diseases / / 17554300 rs283333 chr8 70199014 T A 4.68E-04 Multiple complex diseases / / 17554300 rs283330 chr8 70200598 G A 3.54E-04 Multiple complex diseases / / 17554300 rs283319 chr8 70205185 A G 4.14E-04 Smoking initiation / / 24665060 rs283318 chr8 70205499 A G 7.78E-05 Smoking initiation / / 24665060 rs283316 chr8 70206603 A C 7.00E-04 Multiple complex diseases / / 17554300 rs6983293 chr8 70237924 T C 3.66E-04 Glaucoma (primary open-angle) / / 22419738 rs4737961 chr8 70253769 G A 4.84E-04 Multiple complex diseases / / 17554300 rs2199978 chr8 70286328 T C 9.96E-04 Multiple complex diseases / / 17554300 rs13270342 chr8 70314428 T C 6.33E-04 Multiple complex diseases / / 17554300 rs16935901 chr8 70373965 T C 8.23E-04 Rheumatoid arthritis / / 21452313 rs2099800 chr8 70381561 A G 3.41E-05 stroke (ischemic) SULF1 intron 17434096 rs6982250 chr8 70412450 C T 1.00E-06 Height SULF1 intron 21998595 rs7836170 chr8 70442828 T C 2.15E-05 Pulmonary function in asthmatics SULF1 intron 23541324 rs7836170 chr8 70442828 T C 9.77E-05 Pulmonary function in asthmatics SULF1 intron 23541324 rs16936012 chr8 70442873 G T 3.36E-04 Type 2 diabetes SULF1 intron 17463246 rs16936012 chr8 70442873 G T 7.30E-05 Alcohol dependence SULF1 intron 22096494 rs10957496 chr8 70449375 A C 7.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SULF1 intron 20877124 rs6472463 chr8 70450071 T G 2.66E-05 Mammographic density SULF1 intron 22532574 rs13281284 chr8 70451302 C T 7.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SULF1 intron 20877124 rs12678877 chr8 70451613 A G 6.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SULF1 intron 20877124 rs10504454 chr8 70470354 C G 3.07E-04 Diabetic retinopathy SULF1 intron 20871662 rs10504455 chr8 70470602 C G 2.78E-04 Diabetic retinopathy SULF1 intron 20871662 rs7838730 chr8 70475308 G A 8.66E-04 Diabetic retinopathy SULF1 intron 20871662 rs920529 chr8 70481334 T A 5.54E-04 Multiple complex diseases SULF1 intron 17554300 rs17646998 chr8 70484161 C T 3.61E-05 Pulmonary function in asthmatics SULF1 intron 23541324 rs13273088 chr8 70493974 G A 7.00E-07 Fasting insulin-related traits (interaction with BMI) SULF1 intron 22581228 rs17720343 chr8 70509789 G T 0.0000144 Circulating PCSK9 levels SULF1 intron 22460556 rs4737998 chr8 70516940 G T 4.41E-05 Obesity (extreme) SULF1 intron 21935397 rs4738000 chr8 70519026 A T 4.79E-05 Obesity (extreme) SULF1 intron 21935397 rs1866897 chr8 70526296 C A 9.84E-04 Alzheimer's disease SULF1 intron 22005930 rs16936184 chr8 70539296 C A 1.84E-05 Multiple complex diseases SULF1 intron 17554300 rs3802275 chr8 70540216 C T 3.79E-05 Odorant perception SULF1 intron 23910658 rs7814130 chr8 70554689 A G 2.91E-04 Response to taxane treatment (placlitaxel) SULF1 intron 23006423 rs17665471 chr8 70556602 T C 4.99E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SULF1 intron 20031582 rs4738017 chr8 70576130 G T 5.10E-05 Glaucoma (primary open-angle) / / 20835238 rs16936266 chr8 70580782 C T 7.74E-04 Multiple complex diseases / / 17554300 rs10504456 chr8 70597549 C T 6.97E-05 Post-operative nausea and vomiting SLCO5A1 intron 21694509 rs2933069 chr8 70602926 A C 7.04E-05 Lupus nephritis in systemic lupus erythematosus SLCO5A1 intron 24925725 rs2933068 chr8 70602944 A G 7.07E-05 Lupus nephritis in systemic lupus erythematosus SLCO5A1 intron 24925725 rs2380563 chr8 70605072 G T 7.43E-05 Lupus nephritis in systemic lupus erythematosus SLCO5A1 intron 24925725 rs2933061 chr8 70607090 G A 3.94E-04 Multiple complex diseases SLCO5A1 intron 17554300 rs2933061 chr8 70607090 G A 7.91E-05 Lupus nephritis in systemic lupus erythematosus SLCO5A1 intron 24925725 rs10504458 chr8 70607162 A G 1.00E-04 Cognitive impairment induced by topiramate SLCO5A1 intron 22091778 rs2933060 chr8 70608241 G A 4.40E-05 Lupus nephritis in systemic lupus erythematosus SLCO5A1 intron 24925725 rs7000631 chr8 70609438 A G 4.52E-05 Post-operative nausea and vomiting SLCO5A1 intron 21694509 rs2860282 chr8 70610089 T C 3.45E-05 Lupus nephritis in systemic lupus erythematosus SLCO5A1 intron 24925725 rs2959579 chr8 70616633 G A 3.45E-05 Lupus nephritis in systemic lupus erythematosus SLCO5A1 intron 24925725 rs2933054 chr8 70616800 A G 3.45E-05 Lupus nephritis in systemic lupus erythematosus SLCO5A1 intron 24925725 rs2380575 chr8 70633391 A G 1.50E-07 Non-obstructive azoospermia SLCO5A1 intron 22197933 rs13263918 chr8 70657236 A T 7.27E-04 Suicide attempts in bipolar disorder SLCO5A1 intron 21423239 rs10090896 chr8 70680983 G A 2.00E-06 Metabolite levels (X-11787) SLCO5A1 intron 23934736 rs16936455 chr8 70724754 A G 7.00E-06 HIV-1 control SLCO5A1 intron 20041166 rs3814489 chr8 70748924 T C 3.41E-05 Duodenal ulcer / / 22387998 rs4738034 chr8 70761910 C T 6.55E-05 HDL cholesterol / / pha003074 rs10957505 chr8 70788124 A C 2.27E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7834952 chr8 70792702 G A 5.56E-04 Myocardial Infarction / / pha002883 rs6472491 chr8 70796305 G C 3.28E-05 Schizophrenia / / 19571809 rs6472491 chr8 70796305 G C 3.15E-05 Schizophrenia / / pha002859 rs12680109 chr8 70809261 T C 6.73E-06 Attention deficit hyperactivity disorder / / 20732625 rs7016786 chr8 70818012 G A 4.93E-04 Tourette syndrome / / 22889924 rs11777264 chr8 70825984 C T 3.08E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs896381 chr8 70828273 A G 1.30E-04 Attention deficit hyperactivity disorder / / 22420046 rs7836791 chr8 70859624 T C 4.70E-05 Tooth agenesis (maxillary third molar) / / 24172245 rs17671921 chr8 70864617 C T 9.76E-05 Hemoglobin / / pha003098 rs17671921 chr8 70864617 C T 7.89E-06 Erythrocyte counts / / pha003099 rs389540 chr8 70871068 A G 0.0000095 Major depressive disorder / / 22915352 rs2044888 chr8 70887835 A G 0.0000941 Polycystic ovary syndrome / / 22951595 rs2044888 chr8 70887835 A G 9.41E-05 Intracranial aneurysm / / 22961961 rs1371322 chr8 70926678 C T 1.12E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9298155 chr8 70927758 A G 3.94E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2044885 chr8 70938271 T C 6.24E-04 Smoking initiation / / 24665060 rs7011482 chr8 70942408 C T 4.17E-04 Multiple complex diseases / / 17554300 rs6993479 chr8 70945599 A G 4.68E-05 Multiple sclerosis (age of onset) / / 19010793 rs10504463 chr8 70946593 C T 3.51E-04 Alzheimer's disease / / 22005930 rs10504464 chr8 70946629 A C 5.81E-04 Alzheimer's disease / / 22005930 rs17745692 chr8 70952199 C T 6.96E-04 Alzheimer's disease / / 22005930 rs10113363 chr8 70962698 G A 7.45E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16936661 chr8 70970618 T C 2.73E-04 Alcohol dependence PRDM14 intron 21314694 rs7010162 chr8 70976505 C T 5.00E-08 Testicular germ cell tumor PRDM14 intron 23666240 rs16936670 chr8 70976653 G C 2.26E-04 Suicide attempts in bipolar disorder PRDM14 intron 21423239 rs7819743 chr8 70978195 G A 4.58E-04 Suicide attempts in bipolar disorder PRDM14 intron 21423239 rs3750227 chr8 70978690 C T 3.45E-04 Suicide attempts in bipolar disorder PRDM14 cds-synon 21423239 rs6994178 chr8 70979433 G T 2.70E-04 Suicide attempts in bipolar disorder PRDM14 intron 21423239 rs3750228 chr8 70980738 T C 1.81E-05 Post-operative nausea and vomiting PRDM14 missense 21694509 rs3750229 chr8 70981311 C T 2.61E-04 Suicide attempts in bipolar disorder PRDM14 intron 21423239 rs16936692 chr8 70987280 A G 2.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs16936693 chr8 70987483 G C 9.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs10504465 chr8 70987809 T G 2.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs13274876 chr8 70995467 A C 4.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs13278052 chr8 71004987 A G 8.18E-04 Alzheimer's disease / / 22005930 rs3892266 chr8 71011957 T C 7.85E-04 Alzheimer's disease / / 22005930 rs6982451 chr8 71014079 G A 6.36E-04 Alzheimer's disease / / 22005930 rs12674927 chr8 71014691 T C 7.25E-04 Alzheimer's disease / / 22005930 rs16936754 chr8 71048959 C A 5.15E-04 Type 2 diabetes NCOA2 intron 17463246 rs2977983 chr8 71070788 T C 3.48E-05 Orofacial clefts NCOA2 intron 22419666 rs41391448 chr8 71073700 T C 9.82E-04 Multiple complex diseases NCOA2 intron 17554300 rs72663933 chr8 71075113 T C 6.80E-06 Metabolite levels (MHPG) NCOA2 intron 23319000 rs2958371 chr8 71077195 G A 4.48E-07 Multiple complex diseases NCOA2 intron 17554300 rs72663937 chr8 71086893 T C 6.80E-06 Metabolite levels (MHPG) NCOA2 intron 23319000 rs11993276 chr8 71095359 A G 1.23E-05 QT interval NCOA2 intron 22726844 rs3812429 chr8 71101719 T C 6.20E-05 White matter hyperintensity burden NCOA2 intron 21681796 rs10957517 chr8 71125435 C T 6.99E-05 Cognitive performance NCOA2 intron 19734545 rs72663955 chr8 71139330 T G 6.00E-06 Metabolite levels (HVA-5-HIAA Factor score) NCOA2 intron 23319000 rs75349541 chr8 71152803 C T 6.44E-06 Metabolite levels (MHPG) NCOA2 intron 23319000 rs2926702 chr8 71167994 C T 7.00E-06 Non-small cell lung cancer NCOA2 intron 23144319 rs7824655 chr8 71210021 G A 3.10E-04 Multiple complex diseases NCOA2 intron 17554300 rs72663980 chr8 71269991 G A 9.19E-06 Metabolite levels (MHPG) NCOA2 intron 23319000 rs61578937 chr8 71333858 A G 9.19E-06 Metabolite levels (MHPG) / / 23319000 rs59992508 chr8 71334127 C T 9.19E-06 Metabolite levels (MHPG) / / 23319000 rs10429374 chr8 71338720 G A 3.97E-04 Smoking initiation / / 24665060 rs72663998 chr8 71339057 A G 9.19E-06 Metabolite levels (MHPG) / / 23319000 rs16937001 chr8 71340989 C T 1.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16937001 chr8 71340989 C T 3.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10089804 chr8 71342777 G T 2.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10089804 chr8 71342777 G T 4.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs72665706 chr8 71344462 T A 9.19E-06 Metabolite levels (MHPG) / / 23319000 rs66636673 chr8 71345186 G T 9.19E-06 Metabolite levels (MHPG) / / 23319000 rs72665710 chr8 71345771 G A 9.19E-06 Metabolite levels (MHPG) / / 23319000 rs7817760 chr8 71346171 C T 8.71E-06 Metabolite levels (MHPG) / / 23319000 rs7836173 chr8 71346198 T A 8.71E-06 Metabolite levels (MHPG) / / 23319000 rs6991106 chr8 71346806 C G 9.48E-04 Alzheimer's disease / / 22005930 rs16937025 chr8 71352113 G A 3.75E-04 Alzheimer's disease (late onset) / / 21379329 rs10091864 chr8 71359103 C G 7.89E-08 Cardiac Troponin-T levels / / 23247143 rs10092365 chr8 71359358 G A 2.56E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6989313 chr8 71383357 T C 2.33E-08 Cardiac Troponin-T levels / / 23247143 rs10091374 chr8 71386904 T A 9.00E-09 Cardiac Troponin-T levels / / 23247143 rs10087358 chr8 71387645 G A 4.72E-05 Information processing speed / / 21130836 rs12678139 chr8 71393750 G A 8.17E-05 Serum metabolites / / 19043545 rs12678139 chr8 71393750 G A 9.15E-04 Tourette syndrome / / 22889924 rs10106461 chr8 71405288 C T 9.67E-05 Orofacial clefts / / 20023658 rs10106461 chr8 71405288 C T 0.000046 Primary sclerosing cholangitis / / 23603763 rs4077921 chr8 71433755 T C 4.08E-05 Orofacial clefts / / 20023658 rs10106858 chr8 71449445 T C 6.30E-06 Cardiac Troponin-T levels / / 23247143 rs10106858 chr8 71449445 T C 9.80E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs4556114 chr8 71454529 G A 9.80E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs2726312 chr8 71459506 A G 4.82E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs13272623 chr8 71544748 T G 2.00E-06 IgG glycosylation LOC286190 intron 23382691 rs13272623 chr8 71544748 T G 4.00E-06 IgG glycosylation LOC286190 intron 23382691 rs441890 chr8 71564667 T C 1.19E-04 Follicular lymphoma LACTB2 intron 21533074 rs7814274 chr8 71570411 T C 0.000363 Breast cancer early age of onset LACTB2 intron 18463975 rs17760069 chr8 71574842 C T 6.10E-06 Urinary metabolites LACTB2 intron 21572414 rs7017914 chr8 71591203 A G 2.00E-07 Bone mineral density XKR9 intron 22504420 rs12675271 chr8 71602009 A G 0.00031 Breast cancer early age of onset XKR9 intron 18463975 rs12675271 chr8 71602009 A G 0.000026 Follicular lymphoma XKR9 intron 23025665 rs7013657 chr8 71637559 G A 0.0000289 Follicular lymphoma XKR9 intron 23025665 rs6472542 chr8 71654087 A G 0.000439 Breast cancer early age of onset / / 18463975 rs41517045 chr8 71654499 G C 8.60E-06 Urinary metabolites / / 21572414 rs1348535 chr8 71662741 T G 0.000136 Breast cancer early age of onset / / 18463975 rs16937223 chr8 71685145 C T 1.16E-12 Lymphocyte counts / / 22286170 rs7828552 chr8 71700207 C T 9.34E-06 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs13257800 chr8 71714133 T C 0.000136 Breast cancer early age of onset / / 18463975 rs17688987 chr8 71738304 T C 6.40E-06 Urinary metabolites / / 21572414 rs903004 chr8 71775259 G A 6.40E-06 Urinary metabolites / / 21572414 rs6472551 chr8 71781849 G A 0.000136 Breast cancer early age of onset / / 18463975 rs17689525 chr8 71818623 G A 6.90E-06 Urinary metabolites / / 21572414 rs17689648 chr8 71821115 A G 6.40E-06 Urinary metabolites / / 21572414 rs17689776 chr8 71832012 G A 5.60E-06 Urinary metabolites / / 21572414 rs2732148 chr8 71861536 G A 6.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs3098859 chr8 71865032 G A 0.0000821 Follicular lymphoma / / 23025665 rs1493202 chr8 71905587 T G 0.000000781 Follicular lymphoma / / 23025665 rs17771244 chr8 71943753 G A 6.87E-05 Type 2 diabetes / / 17463246 rs17771710 chr8 71962628 A G 7.97E-05 Type 2 diabetes / / 17463246 rs17699155 chr8 71964904 T C 4.53E-05 Type 2 diabetes / / 17463246 rs17699552 chr8 71976018 A G 7.98E-04 Multiple complex diseases / / 17554300 rs10504493 chr8 71980630 T A 1.72E-05 Type 2 diabetes / / 17463246 rs10504494 chr8 71980727 C T 2.03E-05 Type 2 diabetes / / 17463246 rs6472566 chr8 72000484 G A 4.08E-05 Longevity / / 20304771 rs10957534 chr8 72008303 C G 4.55E-05 Longevity / / 20304771 rs13277069 chr8 72009531 T C 4.07E-05 Longevity / / 20304771 rs6990397 chr8 72011772 C T 3.96E-05 Longevity / / 20304771 rs1481795 chr8 72013005 C T 1.62E-04 Type 2 diabetes / / 17846124 rs12677424 chr8 72020610 T C 1.33E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs13277972 chr8 72025535 T C 4.28E-04 Type 2 diabetes / / 17463246 rs1481789 chr8 72040468 G A 9.42E-04 Type 2 diabetes / / 17463246 rs13253868 chr8 72041269 T C 1.53E-04 Type 2 diabetes / / 17463246 rs12675959 chr8 72043334 T C 2.29E-04 Type 2 diabetes / / 17463246 rs12675959 chr8 72043334 T C 3.69E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1481785 chr8 72043751 G A 5.34E-04 Multiple complex diseases / / 17554300 rs7819928 chr8 72081678 C A 1.13E-05 Smoking cessation / / 24665060 rs7819928 chr8 72081678 C A 5.42E-05 Prostate cancer / / pha002878 rs16937466 chr8 72083227 A C 1.60E-05 Personality dimensions / / 18957941 rs16937466 chr8 72083227 A C 2.78E-04 Smoking cessation / / 24665060 rs10504502 chr8 72093841 C T 3.58E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs7845690 chr8 72095503 T C 2.30E-05 Urinary metabolites / / 21572414 rs4738110 chr8 72105951 C A 1.79E-04 Alzheimer's disease (late onset) / / 21379329 rs4072400 chr8 72108660 A G 4.97E-04 Alzheimer's disease (late onset) / / 21379329 rs13260349 chr8 72136861 C T 9.17E-04 Response to taxane treatment (placlitaxel) EYA1 intron 23006423 rs6989867 chr8 72195318 A G 8.03E-04 Substance dependence EYA1 intron 21818250 rs13264845 chr8 72200466 G C 8.95E-04 Type 2 diabetes EYA1 intron 17463246 rs10092844 chr8 72213290 T G 7.22E-04 Sleep duration EYA1 intron 23728906 rs4738127 chr8 72215867 T C 1.95E-04 Amyotrophic lateral sclerosis EYA1 intron 20801718 rs1031180 chr8 72222349 G A 2.10E-04 Birth weight EYA1 intron 17255346 rs1031180 chr8 72222349 G A 1.30E-05 Urinary metabolites EYA1 intron 21572414 rs10104134 chr8 72238635 T C 8.27E-05 Information processing speed EYA1 intron 21130836 rs4738128 chr8 72245087 C T 3.13E-05 Schizophrenia (cytomegalovirus infection interaction) EYA1 intron 23358160 rs4738128 chr8 72245087 C T 9.65E-06 Height EYA1 intron pha003010 rs4738128 chr8 72245087 C T 1.62E-06 Height EYA1 intron pha003011 rs6472583 chr8 72245458 A G 2.10E-05 Alzheimer's disease (late onset) EYA1 intron 21379329 rs6472583 chr8 72245458 A G 4.54E-05 Height EYA1 intron pha003011 rs2218488 chr8 72263956 C T 3.00E-06 Sleepiness EYA1 intron 17903308 rs7006821 chr8 72270082 T C 5.00E-06 Chronic obstructive pulmonary disease-related biomarkers EYA1 intron 23144326 rs10957550 chr8 72294588 G A 1.00E-06 Longevity (85 years and older) / / 24688116 rs7827299 chr8 72301916 C T 4.48E-04 Type 2 diabetes / / 17463246 rs4440662 chr8 72326920 T A 2.04E-04 Type 2 diabetes / / 17463246 rs7825729 chr8 72343966 G T 5.64E-04 Type 2 diabetes / / 17463246 rs6995211 chr8 72344191 C T 4.76E-04 Type 2 diabetes / / 17463246 rs13274765 chr8 72349490 G A 5.37E-04 Type 2 diabetes / / 17463246 rs7846453 chr8 72349557 T C 8.50E-05 Type 2 diabetes / / 17463246 rs13280162 chr8 72381735 A G 4.10E-05 Cognitive test performance / / 20125193 rs7846030 chr8 72399360 A G 3.07E-05 Cognitive test performance / / 20125193 rs3763548 chr8 72439883 G A 4.44E-04 Alzheimer's disease / / 17998437 rs13263568 chr8 72447418 T G 2.00E-06 Migraine / / 23793025 rs13263568 chr8 72447418 T G 1.72E-04 Stroke / / pha002886 rs13249127 chr8 72464866 A C 2.07E-05 Cognitive test performance / / 20125193 rs11989086 chr8 72525927 A C 3.45E-07 Blood pressure (response to calcium channel blocker) / / 24192120 rs6472593 chr8 72535129 T A 3.24E-04 Multiple complex diseases / / 17554300 rs7834018 chr8 72561742 C T 8.00E-07 Autism / / 22843504 rs1469199 chr8 72562783 G A 3.89E-04 Bipolar disorder,affective / / 20528957 rs16937766 chr8 72563838 A G 5.51E-05 Bipolar disorder,affective / / 20528957 rs7818637 chr8 72565496 A G 4.86E-04 Bipolar disorder,affective / / 20528957 rs10504514 chr8 72583559 G A 5.69E-05 Bipolar disorder,affective / / 20528957 rs1424883 chr8 72597686 T C 7.40E-05 Body Mass Index / / pha003021 rs1424863 chr8 72602833 T C 8.13E-04 Alzheimer's disease / / 17998437 rs10283242 chr8 72619613 A C 6.76E-05 Body Mass Index / / pha003014 rs10283255 chr8 72619818 C T 8.82E-04 Multiple complex diseases / / 17554300 rs4737326 chr8 72636402 A G 1.00E-06 Urinary metabolites / / 21572414 rs4737327 chr8 72639231 G A 6.73E-05 Elbow pain / / pha003008 rs4737327 chr8 72639231 G A 8.23E-06 Weight / / pha003026 rs4737327 chr8 72639231 G A 2.23E-05 Weight / / pha003027 rs10112853 chr8 72639327 A G 2.20E-06 Urinary metabolites / / 21572414 rs4431633 chr8 72648612 A C 2.30E-05 Urinary metabolites / / 21572414 rs11989824 chr8 72649840 C T 1.07E-04 Osteoarthritis / / 19508968 rs4738159 chr8 72684401 C T 6.38E-04 Alcohol dependence / / 21314694 rs4590481 chr8 72715401 T C 7.17E-04 Type 2 diabetes / / 17463246 rs4590481 chr8 72715401 T C 1.09E-04 Alzheimer's disease / / pha002879 rs4133002 chr8 72718581 C T 6.17E-05 Multiple complex diseases / / 17554300 rs6992600 chr8 72720198 G A 9.37E-04 Type 2 diabetes / / 17463246 rs6985839 chr8 72748608 C T 4.81E-05 Type 1 diabetes / / 18978792 rs3779757 chr8 72753740 C A 7.30E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7812453 chr8 72755040 A C 3.35E-05 Response to taxane treatment (placlitaxel) MSC intron 23006423 rs979451 chr8 72757443 T C 9.43E-05 Non-alcoholic fatty liver disease histology (other) LOC100132891 intron 20708005 rs2035376 chr8 72761190 C T 9.18E-05 Orofacial clefts LOC100132891 intron 19270707 rs7816487 chr8 72766110 C G 2.10E-05 Personality dimensions LOC100132891 intron 18957941 rs13278460 chr8 72774349 G A 9.78E-05 Personality dimensions LOC100132891 intron 18957941 rs1481847 chr8 72781495 G A 2.38E-06 Lung cancer LOC100132891 intron 18978787 rs4738170 chr8 72805884 G A 1.77E-05 Personality dimensions LOC100132891 intron 18957941 rs1585995 chr8 72811321 A T 2.87E-05 Personality dimensions LOC100132891 intron 18957941 rs10504517 chr8 72817776 C T 5.62E-05 Orofacial clefts LOC100132891 intron 19270707 rs1481855 chr8 72828300 T C 1.51E-05 Lung cancer LOC100132891 intron 18978787 rs1481855 chr8 72828300 T C 9.43E-05 Non-alcoholic fatty liver disease histology (other) LOC100132891 intron 20708005 rs1020312 chr8 72830625 T C 7.48E-06 Lung cancer LOC100132891 intron 18978787 rs1020312 chr8 72830625 T C 9.43E-05 Non-alcoholic fatty liver disease histology (other) LOC100132891 intron 20708005 rs7009241 chr8 72835478 G C 2.05E-04 Telomere length LOC100132891 intron 23900074 rs9298190 chr8 72844334 T C 1.60E-05 End-stage renal disease LOC100132891 intron 19929986 rs7836062 chr8 72853184 A G 1.11E-04 Telomere length LOC100132891 intron 23900074 rs12543469 chr8 72888965 C T 7.18E-04 Multiple complex diseases LOC100132891 intron 17554300 rs17799174 chr8 72890003 A T 9.20E-05 Longevity LOC100132891 intron 20304771 rs17799174 chr8 72890003 A T 5.00E-05 Aging (time to event) LOC100132891 intron 21782286 rs13258140 chr8 72890067 G A 2.15E-05 Attention deficit hyperactivity disorder LOC100132891 intron pha002875 rs1481849 chr8 72916721 G C 8.38E-04 Type 2 diabetes LOC100132891 intron 17463246 rs7844273 chr8 72918023 A G 2.57E-05 Blood Pressure LOC100132891 intron pha003044 rs1531750 chr8 72919626 T C 2.79E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LOC100132891 intron 24023788 rs4738201 chr8 72930711 A G 2.88E-05 Blood Pressure LOC100132891 intron pha003044 rs9298197 chr8 72934391 G T 2.10E-05 Urinary metabolites TRPA1 UTR-3 21572414 rs17812163 chr8 72941497 G A 9.13E-05 Relative hand skill in reading disability TRPA1 intron 24068947 rs3824150 chr8 72941733 A T 9.10E-06 Urinary metabolites TRPA1 intron 21572414 rs1025926 chr8 72953158 C T 2.80E-05 Urinary metabolites TRPA1 intron 21572414 rs1373302 chr8 72957716 T A 2.00E-05 Urinary metabolites TRPA1 intron 21572414 rs3735942 chr8 72965973 G A 1.40E-05 Urinary metabolites TRPA1 intron 21572414 rs1443952 chr8 72980652 C T 1.60E-05 Urinary metabolites TRPA1 intron 21572414 rs2587559 chr8 72989828 G A 1.18E-06 Personality dimensions / / 23658558 rs2587561 chr8 72990199 A G 1.15E-06 Personality dimensions / / 23658558 rs2587562 chr8 72991038 G A 1.56E-05 Schizophrenia / / 19571809 rs2587562 chr8 72991038 G A 4.42E-05 Schizophrenia / / pha002859 rs17741463 chr8 73000881 G A 3.42E-04 Alzheimer's disease / / 17998437 rs17741463 chr8 73000881 G A 6.61E-05 Response to metformin / / 21186350 rs10504528 chr8 73001662 A G 8.17E-04 Type 2 diabetes / / 17463246 rs10087771 chr8 73001986 T C 2.50E-05 Urinary metabolites / / 21572414 rs2701453 chr8 73004807 G A 8.76E-04 Heart Failure / / pha002884 rs2587577 chr8 73007576 G A 6.53E-06 Personality dimensions / / 23658558 rs2701448 chr8 73008249 C T 1.80E-09 Personality dimensions / / 23658558 rs2701445 chr8 73009445 G T 5.45E-04 Multiple complex diseases / / 17554300 rs2701445 chr8 73009445 G T 3.19E-04 Suicide attempts in bipolar disorder / / 21041247 rs2701444 chr8 73009519 T C 3.19E-04 Suicide attempts in bipolar disorder / / 21041247 rs2587578 chr8 73009605 A G 5.54E-04 Multiple complex diseases / / 17554300 rs2587578 chr8 73009605 A G 3.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs2587579 chr8 73009819 C T 8.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs2587580 chr8 73010547 G C 9.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs2701441 chr8 73011718 G A 8.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs2701440 chr8 73012834 C T 9.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs2701439 chr8 73013050 G C 8.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs2701438 chr8 73013238 G T 3.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs28439133 chr8 73016162 C T 9.89E-05 Tuberculosis / / 22306650 rs2701437 chr8 73016526 G A 3.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs16938030 chr8 73023295 T C 5.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs9650241 chr8 73027424 G T 1.65E-09 Personality dimensions / / 23658558 rs4738207 chr8 73028752 A G 6.75E-04 Suicide attempts in bipolar disorder / / 21041247 rs4738208 chr8 73029138 T C 6.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs4738209 chr8 73029170 C A 7.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs4467976 chr8 73030495 G A 7.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs6472663 chr8 73030939 G A 6.01E-04 Alzheimer's disease / / 17998437 rs4614034 chr8 73035202 C T 7.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs11775093 chr8 73038310 T C 1.60E-04 Type 2 diabetes / / 17463246 rs10504532 chr8 73053079 G A 7.16E-05 Major depressive disorder / / 21621269 rs10504533 chr8 73058766 A C 2.72E-04 Multiple complex diseases / / 17554300 rs11994034 chr8 73070735 C T 7.00E-06 Attention deficit hyperactivity disorder (combined symptoms) / / 23527680 rs1963982 chr8 73106916 A G 3.00E-06 Blood pressure / / 17903302 rs9298203 chr8 73107722 C G 8.28E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs1842717 chr8 73116459 T C 1.55E-06 Phospholipid levels (plasma) / / 21829377 rs7837478 chr8 73161144 T C 2.65E-05 Bilirubin levels,in serum LOC392232 intron 19389676 rs6472675 chr8 73170304 C T 6.51E-04 Smoking initiation / / 24665060 rs7002837 chr8 73190234 T C 2.54E-05 Multiple complex diseases / / 17554300 rs7814567 chr8 73214479 C A 6.93E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7017184 chr8 73231464 A C 3.72E-04 Myocardial Infarction / / pha002883 rs7006742 chr8 73236810 C T 1.00E-07 Pulmonary function decline / / 22424883 rs17825727 chr8 73239547 G A 3.99E-04 Multiple complex diseases / / 17554300 rs16938165 chr8 73242471 G A 9.31E-05 Multiple complex diseases / / 17554300 rs346613 chr8 73242673 T C 2.13E-05 Type 2 diabetes / / 17463246 rs346613 chr8 73242673 T C 8.78E-04 Multiple complex diseases / / 17554300 rs346613 chr8 73242673 T C 5.46E-05 Serum metabolites / / 19043545 rs715452 chr8 73295935 G A 2.30E-05 Alzheimer's disease / / 17998437 rs830491 chr8 73296427 A G 1.23E-04 Bipolar disorder / / 18317468 rs1835480 chr8 73303661 A G 1.24E-04 Alzheimer's disease / / 17998437 rs1835482 chr8 73305674 G C 2.58E-04 Alzheimer's disease / / pha002879 rs830495 chr8 73308176 A G 1.30E-04 Bipolar disorder / / 18317468 rs830497 chr8 73309315 T G 1.09E-04 Bipolar disorder / / 18317468 rs16938215 chr8 73358588 C T 7.78E-04 Stroke / / pha002887 rs348164 chr8 73363183 C A 1.29E-05 Multiple sclerosis (age of onset) / / 19010793 rs2116078 chr8 73363989 T G 3.00E-06 Multiple sclerosis (age of onset) / / 19010793 rs2082282 chr8 73384933 T C 7.76E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs2060109 chr8 73406457 C T 2.70E-05 Urinary metabolites / / 21572414 rs16938230 chr8 73427888 A C 6.48E-04 Multiple complex diseases / / 17554300 rs349363 chr8 73431801 T C 6.35E-08 Bilirubin levels,in serum / / 20639394 rs349363 chr8 73431801 T C 3.11E-05 Post-operative nausea and vomiting / / 21694509 rs1431659 chr8 73439070 A G 3.87E-04 Alcohol dependence / / 21314694 rs349358 chr8 73451475 C T 8.21E-04 Type 2 diabetes KCNB2 intron 17463246 rs349358 chr8 73451475 C T 5.92E-07 Post-operative nausea and vomiting KCNB2 intron 21694509 rs16938233 chr8 73451973 G A 6.62E-04 Multiple complex diseases KCNB2 intron 17554300 rs349355 chr8 73455770 A G 7.53E-04 Type 2 diabetes KCNB2 intron 17463246 rs6989807 chr8 73487114 G A 2.15E-04 Obesity (extreme) KCNB2 intron 21935397 rs12547092 chr8 73505068 T C 5.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNB2 intron 20877124 rs12547092 chr8 73505068 T C 6.53E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNB2 intron 20877124 rs2264036 chr8 73560155 C T 9.23E-05 Cognitive test performance KCNB2 intron 20125193 rs2246456 chr8 73582738 C A 6.41E-04 Coronary Artery Disease KCNB2 intron 17634449 rs2245973 chr8 73586681 A G 4.02E-05 Cognitive test performance KCNB2 intron 20125193 rs2439332 chr8 73588474 T C 3.57E-05 Cognitive test performance KCNB2 intron 20125193 rs2247672 chr8 73632103 T C 2.77E-06 Cognitive test performance KCNB2 intron 20125193 rs2247572 chr8 73633028 C T 1.00E-06 Cognitive performance KCNB2 intron 20125193 rs2053421 chr8 73658605 T C 2.90E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) KCNB2 intron 24023788 rs2053421 chr8 73658605 T C 3.23E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) KCNB2 intron 24023788 rs1440350 chr8 73669098 A G 8.08E-04 Type 2 diabetes KCNB2 intron 17463246 rs2245261 chr8 73678362 C T 4.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNB2 intron 20877124 rs2255512 chr8 73685532 A G 8.49E-04 Coronary Artery Disease KCNB2 intron 17634449 rs1866739 chr8 73702832 G A 6.95E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) KCNB2 intron 23648065 rs1866739 chr8 73702832 G A 2.12E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) KCNB2 intron 24023788 rs1866739 chr8 73702832 G A 8.97E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) KCNB2 intron 24023788 rs1440336 chr8 73730866 T C 9.04E-04 Multiple complex diseases KCNB2 intron 17554300 rs2958416 chr8 73746579 G A 4.80E-06 Urinary metabolites KCNB2 intron 21572414 rs6472704 chr8 73746989 A G 2.00E-05 Left ventricular hypertrophy KCNB2 intron pha003052 rs4452828 chr8 73759484 C T 5.68E-04 Type 2 diabetes KCNB2 intron 17463246 rs13262194 chr8 73760226 A C 9.40E-04 Type 2 diabetes KCNB2 intron 17463246 rs13262971 chr8 73760359 C T 9.19E-04 Type 2 diabetes KCNB2 intron 17463246 rs13264816 chr8 73777863 C T 4.68E-05 Lupus nephritis in systemic lupus erythematosus KCNB2 intron 24925725 rs10504543 chr8 73778642 G A 5.00E-06 Echocardiographic traits KCNB2 intron 17903301 rs7816119 chr8 73780011 A G 4.69E-05 Lupus nephritis in systemic lupus erythematosus KCNB2 intron 24925725 rs13250976 chr8 73780152 G A 3.52E-05 Lupus nephritis in systemic lupus erythematosus KCNB2 intron 24925725 rs11782342 chr8 73784837 G A 2.08E-04 Multiple complex diseases KCNB2 intron 17554300 rs17189856 chr8 73798992 G A 1.20E-05 Urinary metabolites KCNB2 intron 21572414 rs2128158 chr8 73830100 G A 2.28E-07 Alcohol consumption KCNB2 intron 23953852 rs13251382 chr8 73834777 A G 9.31E-05 Alcohol consumption KCNB2 intron 23953852 rs7006287 chr8 73844315 A G 6.00E-04 Response to statin treatment (atorvastatin),change in cholesterol levels KCNB2 intron 20031582 rs16938508 chr8 73850812 A G 2.31E-08 Parkinson's disease / / 21812969 rs4738296 chr8 73857539 A C 4.23E-08 Alopecia areata LOC100288310 intron 22027810 rs2929562 chr8 73870170 C A 5.08E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2981108 chr8 73872063 G A 6.82E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2975830 chr8 73872452 G A 5.03E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16938550 chr8 73927124 G A 7.00E-04 Atrial fibrillation TERF1 intron 21846873 rs10095169 chr8 73929721 T C 5.04E-04 Multiple complex diseases TERF1 intron 17554300 rs12677663 chr8 74007347 G T 2.00E-08 Crohn's disease / / 22412388 rs12676049 chr8 74022305 A C 3.84E-05 Serum metabolites / / 19043545 rs6984102 chr8 74022804 A G 4.85E-05 Serum metabolites / / 19043545 rs6988466 chr8 74028940 G T 6.26E-04 Coronary heart disease / / 21971053 rs6472748 chr8 74034680 G A 6.93E-05 Lipid levels / / pha003082 rs4737367 chr8 74046334 G A 4.90E-05 Information processing speed / / 21130836 rs2383887 chr8 74047835 C T 2.10E-04 Parkinson's disease / / 17052657 rs4403397 chr8 74052203 A G 1.15E-04 Parkinson's disease / / 17052657 rs2383879 chr8 74058147 A G 2.01E-04 Parkinson's disease / / 17052657 rs4559234 chr8 74058617 A G 2.12E-04 Parkinson's disease / / 17052657 rs6472750 chr8 74063433 T C 4.58E-05 Information processing speed / / 21130836 rs2383876 chr8 74066179 A T 5.00E-06 Corneal curvature / / 22969067 rs12675110 chr8 74094212 T C 9.00E-04 Multiple complex diseases / / 17554300 rs10108126 chr8 74109307 T C 9.51E-04 Acute lung injury / / 22295056 rs2605877 chr8 74146766 A G 3.00E-06 Stroke (ischemic) / / 22384361 rs13248977 chr8 74156494 A G 7.88E-06 Coronary arterial lesions in patients with Kawasaki disease LOC100130301 intron 23677057 rs2070764 chr8 74204653 A T 9.66E-06 Serum metabolites RPL7 intron 19043545 rs2925455 chr8 74217659 A C 5.15E-04 Suicide attempts in bipolar disorder RDH10 intron 21423239 rs11776584 chr8 74222769 G A 6.78E-04 Lymphocyte counts RDH10 intron 22286170 rs6989495 chr8 74230223 G T 1.65E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) RDH10 intron 23648065 rs6989495 chr8 74230223 G T 6.08E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) RDH10 intron 23648065 rs79520422 chr8 74234628 A C 1.11E-04 Acne (severe) RDH10 intron 24927181 rs4738324 chr8 74257612 G C 9.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs12334531 chr8 74263630 C T 6.30E-05 Blood Pressure / / pha003040 rs10957657 chr8 74266265 A T 9.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6987005 chr8 74269489 G C 0.0008992 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6987005 chr8 74269489 G C 8.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12679254 chr8 74274191 C T 2.00E-06 Inattentive symptoms / / 18821565 rs10216697 chr8 74299041 C T 1.50E-04 Smoking initiation / / 24665060 rs7832342 chr8 74299242 T C 1.05E-04 Smoking initiation / / 24665060 rs4738350 chr8 74316068 G A 3.90E-04 Multiple sclerosis / / 17660530 rs7812709 chr8 74326486 T A 7.89E-04 Type 2 diabetes / / 17463246 rs13256021 chr8 74329796 T C 8.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs11786318 chr8 74343770 C T 7.89E-04 Multiple complex diseases STAU2 intron 17554300 rs2383893 chr8 74348353 T C 6.36E-05 Cognitive test performance STAU2 intron 20125193 rs2383894 chr8 74348656 T C 8.96E-04 Multiple complex diseases STAU2 intron 17554300 rs2383894 chr8 74348656 T C 4.10E-05 Cognitive test performance STAU2 intron 20125193 rs4389931 chr8 74355018 C T 7.70E-04 Type 2 diabetes STAU2 intron 23209189 rs4738367 chr8 74392900 G A 7.47E-04 Multiple complex diseases STAU2 intron 17554300 rs16938679 chr8 74393996 C T 4.31E-04 Multiple complex diseases STAU2 intron 17554300 rs4738372 chr8 74394066 G A 5.90E-05 Response to statin therapy STAU2 intron 20339536 rs4737383 chr8 74395088 G A 6.00E-05 Response to statin therapy STAU2 intron 20339536 rs4737384 chr8 74395840 A G 6.10E-05 Response to statin therapy STAU2 intron 20339536 rs4738374 chr8 74396039 C T 6.60E-05 Response to statin therapy STAU2 intron 20339536 rs13271172 chr8 74401855 C G 6.10E-05 Response to statin therapy STAU2 intron 20339536 rs11783372 chr8 74402277 T G 2.29E-05 Multiple complex diseases STAU2 intron 17554300 rs16938689 chr8 74423329 G C 3.73E-05 Multiple complex diseases STAU2 intron 17554300 rs7812995 chr8 74453600 G A 9.65E-05 Progressive supranuclear palsy STAU2 intron 21685912 rs4342585 chr8 74467504 C G 9.00E-06 Axial length STAU2 intron 24144296 rs13277065 chr8 74499435 T C 5.61E-04 Major depressive disorder STAU2 intron 22472876 rs16938705 chr8 74533942 C T 2.91E-06 Cognitive impairment induced by topiramate STAU2 intron 22091778 rs16938730 chr8 74705150 C T 3.98E-05 Multiple complex diseases UBE2W UTR-3 17554300 rs6982398 chr8 74746209 T C 9.00E-05 Prostate cancer UBE2W intron 21743057 rs6996756 chr8 74760815 C G 1.00E-04 Prostate cancer UBE2W intron 21743057 rs13258782 chr8 74810467 A G 2.40E-05 Urinary metabolites / / 21572414 rs10504553 chr8 74876403 C T 2.00E-04 Type 2 diabetes TCEB1 intron 17846126 rs16938747 chr8 74879087 C G 2.30E-05 Attention deficit hyperactivity disorder TCEB1 intron 20732625 rs7822407 chr8 74907813 G A 2.84E-05 Type 2 diabetes LY96 intron 17463246 rs6982935 chr8 74959000 C T 1.76E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6982935 chr8 74959000 C T 9.23E-05 Lung function (forced vital capacity) / / 24023788 rs16938774 chr8 74970249 T C 3.62E-04 Multiple complex diseases / / 17554300 rs6987422 chr8 75026885 C T 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs16938799 chr8 75033393 T G 5.62E-04 Coronary Artery Disease / / 17634449 rs13273697 chr8 75033848 T C 7.31E-04 Type 2 diabetes / / 17463246 rs12679744 chr8 75037406 G A 9.25E-05 Pancreatic cancer / / pha002889 rs10957696 chr8 75053297 A G 2.90E-05 Urinary metabolites / / 21572414 rs7008430 chr8 75053542 A G 1.60E-05 Urinary metabolites / / 21572414 rs10504562 chr8 75054462 T C 7.50E-06 Urinary metabolites / / 21572414 rs17249487 chr8 75061350 A G 4.91E-04 Stroke / / pha002886 rs1499646 chr8 75068112 C T 9.00E-04 Chronic fatigue syndrome / / 21912186 rs1875067 chr8 75087343 T C 7.40E-04 Intelligence (childhood) / / 23358156 rs4385459 chr8 75096991 A G 9.78E-04 Celiac disease / / 23936387 rs4385459 chr8 75096991 A G 4.10E-05 Glucose levels / / pha003058 rs4385459 chr8 75096991 A G 6.17E-05 Glucose levels / / pha003061 rs2956060 chr8 75109785 A G 2.84E-04 Celiac disease / / 23936387 rs10957702 chr8 75143753 C T 2.50E-05 Urinary metabolites / / 21572414 rs17337083 chr8 75154867 T C 5.27E-04 Alcohol dependence JPH1 intron 21314694 rs10090211 chr8 75160656 T G 4.76E-04 Multiple complex diseases JPH1 intron 17554300 rs10504567 chr8 75177088 G C 3.89E-12 Alcohol consumption JPH1 intron pha001400 rs16938848 chr8 75193062 C T 2.38E-04 Type 2 diabetes JPH1 intron 17463246 rs16938849 chr8 75193280 G A 3.03E-04 Type 2 diabetes JPH1 intron 17463246 rs4738443 chr8 75207653 G A 5.38E-05 Multiple complex diseases JPH1 intron 17554300 rs1003406 chr8 75218725 A G 8.97E-04 Multiple complex diseases JPH1 intron 17554300 rs6983232 chr8 75220022 C A,T 7.32E-33 Narcolepsy JPH1 intron 19629137 rs6988741 chr8 75221116 C T 2.00E-05 Multiple complex diseases JPH1 intron 17554300 rs10504572 chr8 75239978 C T 2.62E-06 Post-operative nausea and vomiting / / 21694509 rs6989476 chr8 75245770 A G 2.07E-05 Post-operative nausea and vomiting / / 21694509 rs10504576 chr8 75266679 A G 7.10E-07 Obesity-related traits GDAP1 intron 17903300 rs9298238 chr8 75267618 A G 8.38E-04 Nicotine dependence GDAP1 intron 17158188 rs7846006 chr8 75271974 A G 6.83E-04 Nicotine dependence GDAP1 intron 17158188 rs4310196 chr8 75272727 C A 8.64E-04 Nicotine dependence GDAP1 intron 17158188 rs6996971 chr8 75292492 C T 4.90E-07 Obesity-related traits / / 17903300 rs4471028 chr8 75294975 T G 2.00E-07 Waist circumference / / 17903300 rs4469448 chr8 75295110 G C 2.60E-07 Obesity-related traits / / 17903300 rs7813767 chr8 75297342 G A 8.19E-04 Nicotine dependence / / 17158188 rs7813767 chr8 75297342 G A 8.89E-04 Multiple complex diseases / / 17554300 rs7819969 chr8 75316243 C A 9.15E-04 Nicotine dependence / / 17158188 rs6472851 chr8 75338630 C G 3.16E-04 Nicotine dependence / / 17158188 rs9650250 chr8 75339236 A T 1.23E-05 Odorant perception / / 23910658 rs13266218 chr8 75346762 G C 1.70E-05 Urinary metabolites / / 21572414 rs58584032 chr8 75367299 C A 0.00002085 Sarcoidosis / / 22952805 rs16938910 chr8 75373948 C T 4.00E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs78009076 chr8 75378469 T C 0.00000752 Sarcoidosis / / 22952805 rs73331394 chr8 75387201 G A 0.00004514 Sarcoidosis / / 22952805 rs60501864 chr8 75387449 A T 0.00004514 Sarcoidosis / / 22952805 rs73331402 chr8 75391897 C T 0.00004497 Sarcoidosis / / 22952805 rs11998553 chr8 75394321 A G 0.00003353 Sarcoidosis / / 22952805 rs4483131 chr8 75462340 C G 2.05E-04 Obesity (extreme) / / 21935397 rs2042662 chr8 75469603 C A 7.24E-04 Myocardial Infarction / / pha002883 rs12542221 chr8 75483809 G T 7.12E-04 Multiple complex diseases / / 17554300 rs1425761 chr8 75487288 C T 9.72E-06 Asperger disorder / / 21182207 rs6472866 chr8 75513134 C T 8.00E-07 Protein quantitative trait loci FLJ39080 intron 18464913 rs10106137 chr8 75527633 C A 8.71E-07 Longevity,exceptional FLJ39080 intron 20595579 rs10504581 chr8 75540619 G T 6.94E-04 Obesity (extreme) FLJ39080 intron 21935397 rs10504582 chr8 75542325 T C 4.44E-04 Obesity (extreme) FLJ39080 intron 21935397 rs3793404 chr8 75544780 T C 4.42E-04 Obesity (extreme) FLJ39080 intron 21935397 rs4735660 chr8 75548891 A G 6.27E-04 Obesity (extreme) FLJ39080 intron 21935397 rs1365032 chr8 75553100 C T 1.40E-04 Lipid traits FLJ39080 intron 17903299 rs10504583 chr8 75555788 A G 2.54E-04 Obesity (extreme) FLJ39080 intron 21935397 rs4735663 chr8 75558459 A G 2.85E-04 Obesity (extreme) FLJ39080 intron 21935397 rs12544130 chr8 75562293 G A 9.29E-04 Obesity (extreme) FLJ39080 intron 21935397 rs4735664 chr8 75562486 C T 3.33E-04 Obesity (extreme) FLJ39080 intron 21935397 rs16938932 chr8 75563602 T A 4.35E-04 Obesity (extreme) FLJ39080 intron 21935397 rs10104416 chr8 75675410 A G 7.36E-05 Body Fat Distribution / / pha003016 rs11987589 chr8 75685474 G T 9.20E-06 Urinary metabolites / / 21572414 rs7842758 chr8 75707662 A G 6.25E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs1594758 chr8 75725647 A C 0.000598 fMRI brain tests in schizophrenia / / 22440650 rs7835278 chr8 75765947 G A 6.70E-06 Urinary metabolites PI15 UTR-3 21572414 rs2956606 chr8 75767414 C T 8.81E-04 Parkinson's disease / / 17052657 rs2570147 chr8 75798861 T C 1.80E-05 Alcohol consumption / / 23743675 rs2570148 chr8 75799449 A G 1.74E-05 Alcohol consumption / / 23743675 rs1560784 chr8 75803536 A C 1.31E-05 Alcohol consumption / / 23743675 rs2117085 chr8 75810487 G T 1.19E-04 Birth weight / / 17255346 rs1368635 chr8 75811090 G T 1.99E-04 Birth weight / / 17255346 rs7823460 chr8 75836154 C T 8.47E-04 Multiple complex diseases / / 17554300 rs10957743 chr8 75881442 T C 9.38E-05 Longevity / / 20304771 rs2956605 chr8 75883054 A C 6.80E-05 Longevity / / 20304771 rs11984778 chr8 75889078 G T 4.55E-05 Cognitive test performance / / 20125193 rs2383928 chr8 75910104 C T 0.0002 Migraine CRISPLD1 intron 22678113 rs11778674 chr8 75963988 C A 3.13E-05 Longevity / / 20304771 rs17369174 chr8 75966047 T G 2.30E-05 Longevity / / 20304771 rs17369209 chr8 75966258 A C 2.30E-05 Longevity / / 20304771 rs11785349 chr8 75967299 T G 2.30E-05 Longevity / / 20304771 rs17297422 chr8 75990812 A C 3.74E-05 Longevity / / 20304771 rs17369819 chr8 75997034 C T 0.0001 Migraine / / 22678113 rs11987494 chr8 76022121 G A 9.75E-05 Body Mass Index / / pha003006 rs11987494 chr8 76022121 G A 2.73E-05 Waist Circumference / / pha003024 rs11987494 chr8 76022121 G A 2.20E-05 Waist-Hip Ratio / / pha003029 rs1378615 chr8 76028740 C T 4.43E-05 Leukocyte Counts / / pha003091 rs1531590 chr8 76036444 T C 2.14E-04 Birth weight / / 17255346 rs1531590 chr8 76036444 T C 3.00E-06 IgG glycosylation / / 23382691 rs10504591 chr8 76037160 T C 1.95E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs1382669 chr8 76077838 T G 5.48E-05 Body Mass Index / / pha003009 rs11785697 chr8 76106596 C T 3.12E-04 Alzheimer's disease (late onset) / / 21379329 rs13258096 chr8 76138344 C G 0.000508 Salmonella-induced pyroptosis / / 22837397 rs1351224 chr8 76141132 A G 0.000576 Salmonella-induced pyroptosis / / 22837397 rs16939046 chr8 76147954 T C 4.00E-06 Information processing speed / / 21130836 rs9886508 chr8 76152991 C T 0.000875 Salmonella-induced pyroptosis / / 22837397 rs79749241 chr8 76202586 G A 1.17E-04 Cocaine dependence / / 23958962 rs6472903 chr8 76230301 G T 2.00E-17 Breast cancer / / 23535729 rs9650254 chr8 76263403 A G 0.000635 Salmonella-induced pyroptosis / / 22837397 rs10100727 chr8 76307676 T C 4.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2980222 chr8 76307872 T G 2.40E-05 Urinary metabolites / / 21572414 rs17303296 chr8 76338381 T C 3.69E-04 Alzheimer's disease (late onset) / / 21379329 rs16939073 chr8 76367712 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11774812 chr8 76373646 C A 6.93E-05 Cognitive impairment induced by topiramate / / 22091778 rs2037095 chr8 76389346 C T 0.000196775 Hypertension (early onset hypertension) / / 22479346 rs16939078 chr8 76391584 T A 4.03E-04 Coronary heart disease / / 21606135 rs7814178 chr8 76393702 C T 8.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs12115105 chr8 76396460 G C 7.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs11998082 chr8 76396971 C T 9.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs7842728 chr8 76397788 G T 9.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs7843073 chr8 76398186 C T 9.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs9298256 chr8 76399376 C T 9.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs7828282 chr8 76402118 G A 9.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs7846254 chr8 76402176 T C 9.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs7008442 chr8 76404081 C T 9.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs2943598 chr8 76404448 C T 9.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs2926578 chr8 76404475 T C 9.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs2943600 chr8 76406349 C T 9.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs2977914 chr8 76406392 C A 9.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs2926580 chr8 76407181 G A 9.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs2926587 chr8 76414794 C G 5.45E-04 Multiple complex diseases / / 17554300 rs1380693 chr8 76415354 A G 6.37E-04 Multiple complex diseases / / 17554300 rs2943559 chr8 76417937 A G 6.00E-15 Breast cancer / / 23535729 rs2943559 chr8 76417937 A G 2.50E-04 Breast cancer / / 23535733 rs2941454 chr8 76442347 G A 7.25E-14 Urate levels / / 23263486 rs1515016 chr8 76444129 G T 2.41E-13 Urate levels / / 23263486 rs1515017 chr8 76444404 C T 2.99E-12 Urate levels / / 23263486 rs1473951 chr8 76445102 G A 3.06E-12 Urate levels / / 23263486 rs938343 chr8 76446033 A G 4.16E-14 Urate levels / / 23263486 rs2006717 chr8 76446509 C T 9.93E-05 Serum metabolites / / 19043545 rs2006717 chr8 76446509 C T 5.60E-14 Urate levels / / 23263486 rs2941462 chr8 76447633 G A 4.30E-14 Urate levels / / 23263486 rs2977926 chr8 76448847 G T 5.36E-12 Urate levels / / 23263486 rs2943543 chr8 76448956 A G 3.89E-14 Urate levels / / 23263486 rs2943547 chr8 76451098 A G 5.51E-11 Urate levels / / 23263486 rs2977928 chr8 76451580 A T 3.48E-14 Urate levels / / 23263486 rs2943549 chr8 76452313 G A 3.65E-14 Urate levels HNF4G missense 23263486 rs2943551 chr8 76452421 G A 3.70E-14 Urate levels HNF4G intron 23263486 rs2943552 chr8 76452939 T G 3.72E-14 Urate levels HNF4G intron 23263486 rs2943553 chr8 76453492 T A 3.73E-14 Urate levels HNF4G intron 23263486 rs2977932 chr8 76456641 A T 8.58E-15 Urate levels HNF4G intron 23263486 rs2943554 chr8 76458962 A T 5.70E-15 Urate levels HNF4G intron 23263486 rs1800922 chr8 76459726 G A 5.25E-15 Urate levels HNF4G intron 23263486 rs2977937 chr8 76460589 A C 5.54E-15 Urate levels HNF4G intron 23263486 rs2977938 chr8 76461226 A G 4.72E-15 Urate levels HNF4G intron 23263486 rs2056090 chr8 76462397 G A 1.20E-13 Urate levels HNF4G intron 23263486 rs2272667 chr8 76463397 T C 4.71E-15 Urate levels HNF4G intron 23263486 rs2272668 chr8 76463571 T C 7.97E-06 Carotenoid and tocopherol levels HNF4G intron 19185284 rs2943592 chr8 76464840 G T 3.79E-13 Urate levels HNF4G intron 23263486 rs1800924 chr8 76465522 T G 4.62E-13 Urate levels HNF4G intron 23263486 rs2977942 chr8 76465823 T G 3.18E-05 Coronary heart disease HNF4G intron 21606135 rs2941465 chr8 76465909 C T 7.35E-13 Urate levels HNF4G intron 23263486 rs2943591 chr8 76465910 A G 5.27E-15 Urate levels HNF4G intron 23263486 rs2941468 chr8 76468139 C G 5.37E-15 Urate levels HNF4G intron 23263486 rs1805098 chr8 76468282 G A 5.15E-15 Urate levels HNF4G missense 23263486 rs2941469 chr8 76469031 T C 1.49E-15 Urate levels HNF4G intron 23263486 rs2941470 chr8 76470020 G A 1.56E-15 Urate levels HNF4G intron 23263486 rs2941471 chr8 76470404 G A 1.58E-15 Urate levels HNF4G intron 23263486 rs2941473 chr8 76472560 A G,T 5.12E-17 Urate levels HNF4G intron 23263486 rs2943611 chr8 76473939 T C 1.76E-08 Urate levels HNF4G intron 23263486 rs1464093 chr8 76474058 A G 0.00000505 Beta cryptoxanthin HNF4G intron 23696881 rs2941475 chr8 76474404 T C 1.45E-15 Urate levels HNF4G intron 23263486 rs2943612 chr8 76474559 A G 9.50E-16 Urate levels HNF4G intron 23263486 rs2977944 chr8 76474719 G A 6.79E-17 Urate levels HNF4G intron 23263486 rs2977945 chr8 76475125 G A 5.11E-17 Urate levels HNF4G intron 23263486 rs1805100 chr8 76476396 G A 6.22E-17 Urate levels HNF4G UTR-3 23263486 rs1805100 chr8 76476396 G A 7.60E-05 Pancreatic cancer HNF4G UTR-3 pha002889 rs2272669 chr8 76476457 G A 7.10E-17 Urate levels HNF4G UTR-3 23263486 rs2941477 chr8 76476670 G A 9.03E-17 Urate levels HNF4G UTR-3 23263486 rs2941479 chr8 76476959 C A 2.30E-15 Urate levels HNF4G UTR-3 23263486 rs2941480 chr8 76477122 T C 3.87E-12 Urate levels HNF4G UTR-3 23263486 rs2941481 chr8 76477368 G A 6.86E-17 Urate levels HNF4G UTR-3 23263486 rs1515020 chr8 76477590 C T 3.27E-14 Urate levels HNF4G UTR-3 23263486 rs2941484 chr8 76478768 C T 4.00E-17 Urate levels HNF4G UTR-3 23263486 rs2943539 chr8 76479839 C T 5.22E-17 Urate levels / / 23263486 rs2941489 chr8 76482263 C T 3.96E-13 Urate levels / / 23263486 rs1913640 chr8 76483008 G A 4.43E-14 Urate levels / / 23263486 rs1913641 chr8 76483239 T G 6.41E-15 Urate levels / / 23263486 rs1464092 chr8 76483560 C T 4.59E-11 Urate levels / / 23263486 rs1399564 chr8 76483856 C T 5.33E-05 Serum metabolites / / 19043545 rs1399564 chr8 76483856 C T 4.25E-13 Urate levels / / 23263486 rs12334682 chr8 76484015 C T 1.01E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1399567 chr8 76484097 T A 4.55E-13 Urate levels / / 23263486 rs2941492 chr8 76487628 A G 4.99E-12 Urate levels / / 23263486 rs10957767 chr8 76492185 A G 9.55E-10 Urate levels / / 23263486 rs1817003 chr8 76499260 A C 5.68E-09 Urate levels / / 23263486 rs2922778 chr8 76502347 C T 3.83E-04 Coronary heart disease / / 21606135 rs2122262 chr8 76503582 G A 5.81E-12 Urate levels / / 23263486 rs2922783 chr8 76506358 A G 3.11E-12 Urate levels / / 23263486 rs2943570 chr8 76506385 A G 4.43E-13 Multiple complex diseases / / 17554300 rs2943570 chr8 76506385 A G 5.45E-05 Serum metabolites / / 19043545 rs2943570 chr8 76506385 A G 5.45E-12 Urate levels / / 23263486 rs2943573 chr8 76507001 A G 2.31E-12 Urate levels / / 23263486 rs2012410 chr8 76509248 G A 3.03E-12 Urate levels / / 23263486 rs1375646 chr8 76517117 A T 1.88E-12 Urate levels / / 23263486 rs2922790 chr8 76518326 T G 1.41E-08 Urate levels / / 23263486 rs1449555 chr8 76518933 A C 2.64E-05 Serum metabolites / / 19043545 rs1449555 chr8 76518933 A C 3.35E-12 Urate levels / / 23263486 rs962711 chr8 76519323 A G 2.66E-05 Serum metabolites / / 19043545 rs962711 chr8 76519323 A G 1.85E-12 Urate levels / / 23263486 rs962712 chr8 76519490 G C 2.66E-05 Serum metabolites / / 19043545 rs962712 chr8 76519490 G C 1.61E-12 Urate levels / / 23263486 rs2941422 chr8 76519834 C T 9.84E-04 Alzheimer's disease / / 17998437 rs2941422 chr8 76519834 C T 2.66E-05 Serum metabolites / / 19043545 rs2941422 chr8 76519834 C T 2.30E-12 Urate levels / / 23263486 rs1449556 chr8 76519942 T C 5.81E-04 Type 2 diabetes / / 17463246 rs2941423 chr8 76519969 C T 8.18E-04 Alzheimer's disease / / 22005930 rs2941423 chr8 76519969 C T 1.87E-14 Urate levels / / 23263486 rs1913638 chr8 76523922 A G 2.77E-10 Urate levels / / 23263486 rs9298259 chr8 76524363 T C 1.26E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2943574 chr8 76524852 A G 4.44E-10 Urate levels / / 23263486 rs2941427 chr8 76524901 C A 4.66E-10 Urate levels / / 23263486 rs2922794 chr8 76525574 A G 5.24E-10 Urate levels / / 23263486 rs2941428 chr8 76525586 G A 2.84E-09 Urate levels / / 23263486 rs16939113 chr8 76528335 G A 9.59E-04 Type 2 diabetes / / 17463246 rs2941429 chr8 76529765 G C 2.90E-09 Urate levels / / 23263486 rs2922774 chr8 76531881 A C 7.00E-10 Urate levels / / 23263486 rs1839330 chr8 76532640 A T 3.17E-09 Urate levels / / 23263486 rs2922758 chr8 76542446 C T 2.15E-10 Urate levels / / 23263486 rs7818923 chr8 76542560 C T 4.22E-04 Coronary heart disease / / 21606135 rs12680925 chr8 76545757 T C 3.40E-05 Elbow pain / / pha003008 rs7822447 chr8 76555824 G A 5.56E-04 Schizophrenia / / 19197363 rs2941444 chr8 76559040 G A 2.96E-10 Urate levels / / 23263486 rs2167065 chr8 76560454 C T 8.77E-12 Urate levels / / 23263486 rs2060603 chr8 76564169 A G 3.67E-10 Urate levels / / 23263486 rs2060602 chr8 76564405 G A 3.21E-10 Urate levels / / 23263486 rs2922763 chr8 76573711 G T 6.00E-08 Body mass index / / 20935630 rs16939127 chr8 76573834 T C 5.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7833566 chr8 76579052 G A 4.67E-05 Intelligence / / 21826061 rs1449546 chr8 76584886 G A 5.81E-05 Tuberculosis / / 24057671 rs4735692 chr8 76615663 A G 8.00E-05 Prostate cancer / / 21743057 rs4735692 chr8 76615663 A G 2.00E-09 Obesity / / 23563607 rs4735692 chr8 76615663 A G 4.00E-10 Obesity / / 23563607 rs2596127 chr8 76636044 T G 1.00E-04 Prostate cancer / / 21743057 rs2596126 chr8 76640621 A G 1.00E-04 Prostate cancer / / 21743057 rs2060604 chr8 76650334 T C 6.90E-04 Parkinson's disease / / 17052657 rs9693229 chr8 76711112 A G 3.01E-04 Coronary Artery Disease / / 17634449 rs2920917 chr8 76713409 C A 3.83E-05 Glucose levels / / pha003057 rs2977343 chr8 76726747 C G 3.73E-04 Nicotine dependence / / 17158188 rs2035166 chr8 76749722 A G 6.59E-09 Urate levels / / 23263486 rs1531460 chr8 76752696 G A 2.72E-09 Urate levels / / 23263486 rs1531461 chr8 76752763 C T 2.31E-09 Urate levels / / 23263486 rs1531462 chr8 76752790 A G 7.20E-05 Pancreatic cancer / / pha002889 rs2927234 chr8 76754904 G A 2.49E-09 Urate levels / / 23263486 rs2977332 chr8 76754934 T C 2.29E-09 Urate levels / / 23263486 rs2927235 chr8 76755997 T A 2.08E-09 Urate levels / / 23263486 rs11785824 chr8 76756551 C T 2.63E-09 Urate levels / / 23263486 rs2927237 chr8 76757519 C G 1.79E-09 Urate levels / / 23263486 rs2927239 chr8 76758822 A T 2.12E-09 Urate levels / / 23263486 rs1599589 chr8 76761762 A G 9.41E-09 Urate levels / / 23263486 rs10087208 chr8 76762380 G A 1.58E-09 Urate levels / / 23263486 rs1381666 chr8 76767476 C G 3.80E-09 Urate levels / / 23263486 rs1381665 chr8 76767584 A G 4.13E-09 Urate levels / / 23263486 rs1462441 chr8 76768738 C T 1.11E-09 Urate levels / / 23263486 rs7827221 chr8 76773218 G A 1.04E-09 Urate levels / / 23263486 rs3911770 chr8 76811708 T G 6.60E-05 Alcoholism (heaviness of drinking) / / 21529783 rs10504605 chr8 76931893 A G 8.86E-05 Iron levels / / 19880490 rs10504605 chr8 76931893 A G 8.86E-05 Iron levels / / pha002876 rs830437 chr8 76937594 A G 2.40E-05 Urinary metabolites / / 21572414 rs10957789 chr8 77043635 A C 6.86E-04 Obesity (extreme) / / 21935397 rs1459174 chr8 77044582 A G 6.87E-04 Obesity (extreme) / / 21935397 rs7011070 chr8 77045275 T C 6.89E-04 Obesity (extreme) / / 21935397 rs10504609 chr8 77046073 A G 1.91E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs10504609 chr8 77046073 A G 6.39E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7844413 chr8 77047918 A G 6.98E-04 Obesity (extreme) / / 21935397 rs2054262 chr8 77051468 G A 6.94E-04 Obesity (extreme) / / 21935397 rs17331643 chr8 77054179 C T 1.86E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1903129 chr8 77056147 A T 9.57E-04 Obesity (extreme) / / 21935397 rs10102325 chr8 77059481 C A 6.87E-04 Obesity (extreme) / / 21935397 rs10102558 chr8 77059673 C T 9.44E-04 Obesity (extreme) / / 21935397 rs7846206 chr8 77061627 T C 6.65E-04 Obesity (extreme) / / 21935397 rs17331811 chr8 77061650 A G 8.15E-04 Multiple complex diseases / / 17554300 rs17331811 chr8 77061650 A G 1.50E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17331811 chr8 77061650 A G 8.53E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6985418 chr8 77062687 T C 6.37E-04 Obesity (extreme) / / 21935397 rs1380229 chr8 77065095 T C 6.22E-04 Obesity (extreme) / / 21935397 rs9298266 chr8 77068493 G A 8.47E-04 Obesity (extreme) / / 21935397 rs1380230 chr8 77069389 T C 8.37E-04 Obesity (extreme) / / 21935397 rs10957791 chr8 77071018 T C 8.32E-04 Obesity (extreme) / / 21935397 rs6472953 chr8 77071291 C T 8.28E-04 Obesity (extreme) / / 21935397 rs7006542 chr8 77072449 T C 2.43E-04 Bipolar disorder / / 19259986 rs7006542 chr8 77072449 T C 8.18E-04 Obesity (extreme) / / 21935397 rs13281526 chr8 77074858 G T 5.72E-04 Obesity (extreme) / / 21935397 rs1431017 chr8 77074921 G T 7.94E-04 Obesity (extreme) / / 21935397 rs1431018 chr8 77077752 A G 7.75E-04 Obesity (extreme) / / 21935397 rs6472954 chr8 77079399 C G 7.76E-04 Obesity (extreme) / / 21935397 rs6982578 chr8 77080132 T C 5.56E-04 Obesity (extreme) / / 21935397 rs1367564 chr8 77080922 A G 5.56E-04 Obesity (extreme) / / 21935397 rs10103327 chr8 77081322 T C 7.78E-04 Obesity (extreme) / / 21935397 rs1431019 chr8 77085557 A G 7.79E-04 Obesity (extreme) / / 21935397 rs6994771 chr8 77086286 A C 7.95E-04 Obesity (extreme) / / 21935397 rs7463018 chr8 77088811 T G 5.78E-04 Obesity (extreme) / / 21935397 rs9643701 chr8 77090476 T C 8.08E-04 Obesity (extreme) / / 21935397 rs10091125 chr8 77094272 G A 8.08E-04 Obesity (extreme) / / 21935397 rs7013630 chr8 77094594 A G 8.09E-04 Obesity (extreme) / / 21935397 rs10100261 chr8 77097912 T C 5.82E-04 Obesity (extreme) / / 21935397 rs6989292 chr8 77108063 A G 8.12E-04 Obesity (extreme) / / 21935397 rs7825295 chr8 77109050 A G 8.17E-04 Obesity (extreme) / / 21935397 rs7835161 chr8 77111109 A G 8.22E-04 Obesity (extreme) / / 21935397 rs9298268 chr8 77113611 C A 8.37E-04 Obesity (extreme) / / 21935397 rs9298269 chr8 77117490 C T 6.18E-04 Obesity (extreme) / / 21935397 rs6991713 chr8 77120480 A G 8.50E-04 Obesity (extreme) / / 21935397 rs13282738 chr8 77122534 A G 8.33E-04 Obesity (extreme) / / 21935397 rs13256169 chr8 77128946 C T 5.83E-04 Obesity (extreme) / / 21935397 rs1431015 chr8 77131580 T C 5.99E-04 Obesity (extreme) / / 21935397 rs1431014 chr8 77134718 T C 6.10E-04 Obesity (extreme) / / 21935397 rs17424935 chr8 77137533 C T 8.86E-04 Multiple complex diseases / / 17554300 rs4735717 chr8 77139250 A G 6.10E-04 Obesity (extreme) / / 21935397 rs9298270 chr8 77142993 C T 6.10E-04 Obesity (extreme) / / 21935397 rs919577 chr8 77145581 G A 6.10E-04 Obesity (extreme) / / 21935397 rs919577 chr8 77145581 G A 2.33E-04 Stroke / / pha002887 rs7845313 chr8 77187010 T C 4.27E-04 Obesity (extreme) / / 21935397 rs1405350 chr8 77191302 C T 4.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs17334720 chr8 77201822 T C 1.40E-05 Urinary metabolites / / 21572414 rs17334720 chr8 77201822 T C 1.53E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10112136 chr8 77213833 T C 2.10E-05 Urinary metabolites / / 21572414 rs7827536 chr8 77258716 T G 6.13E-06 Personality dimensions / / 21173776 rs75226183 chr8 77295977 A G 1.69E-09 Beta cryptoxanthin / / 23696881 rs4548159 chr8 77333714 A G 9.22E-06 Corneal structure / / 22003120 rs12548378 chr8 77344816 C G 6.17E-04 Multiple complex diseases / / 17554300 rs10283138 chr8 77361439 C T 9.50E-04 Multiple complex diseases / / 17554300 rs12543538 chr8 77372597 C T 2.90E-05 Urinary metabolites / / 21572414 rs11996335 chr8 77374126 A G 6.33E-05 Hypertension (essential hypertension) / / 22184326 rs16939280 chr8 77389676 G C 6.88E-04 Multiple complex diseases / / 17554300 rs10092692 chr8 77401080 C A 8.00E-08 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs6991339 chr8 77486652 G T 6.54E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7846606 chr8 77507613 A G 7.00E-06 Orofacial clefts / / 22863734 rs7846606 chr8 77507613 A G 8.83E-05 Smoking cessation / / 24665060 rs11991707 chr8 77512173 G A 2.81E-05 Bladder cancer / / 19648920 rs10504631 chr8 77538487 A G 7.76E-04 Nicotine dependence LOC100192378 intron 17158188 rs16939329 chr8 77564178 G C 6.51E-04 Nicotine dependence LOC100192378 intron 17158188 rs7011404 chr8 77604704 T C 4.82E-05 HIV-1 control ZFHX4 intron 20041166 rs1865294 chr8 77610042 A G 8.41E-06 Menarche (age at onset) ZFHX4 intron 23667675 rs6995390 chr8 77611012 A T 5.30E-06 Menarche (age at onset) ZFHX4 intron 23667675 rs4735738 chr8 77611625 A G 5.00E-06 Menarche (age at onset) ZFHX4 intron 23667675 rs7822501 chr8 77662796 A G 7.16E-06 Menarche (age at onset) ZFHX4 intron 23667675 rs7822914 chr8 77663038 C T 7.16E-06 Menarche (age at onset) ZFHX4 intron 23667675 rs6472982 chr8 77663402 C T 7.44E-06 Menarche (age at onset) ZFHX4 intron 23667675 rs6472983 chr8 77671877 G T 7.56E-06 Menarche (age at onset) ZFHX4 intron 23667675 rs16939362 chr8 77698990 A G 1.56E-04 Fibrinogen ZFHX4 intron 17255346 rs16939363 chr8 77699504 C G 4.61E-04 Fibrinogen ZFHX4 intron 17255346 rs10957818 chr8 77736646 T A 1.87E-05 Multiple complex diseases ZFHX4 intron 17554300 rs10957819 chr8 77737624 A G 5.72E-04 Response to radiotherapy in cancer (late toxicity) ZFHX4 intron 24785509 rs16939380 chr8 77768390 T G 5.81E-04 Fibrinogen ZFHX4 missense 17255346 rs13249915 chr8 77774263 T C 3.30E-04 Multiple complex diseases ZFHX4 intron 17554300 rs13249915 chr8 77774263 T C 0.0001242 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ZFHX4 intron 23233654 rs13255855 chr8 77774547 G A 0.0001616 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ZFHX4 intron 23233654 rs13255855 chr8 77774547 G A 1.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) ZFHX4 intron 23233662 rs11990691 chr8 77782003 G T 0.0001498 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11990691 chr8 77782003 G T 1.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs16939382 chr8 77785447 A G 6.28E-05 Intelligence / / 21826061 rs4568596 chr8 77844735 T C 3.52E-05 Height / / pha003010 rs9694705 chr8 77870248 A G 5.84E-05 Blood Pressure / / pha003040 rs4128631 chr8 77884972 C T 3.94E-04 Multiple complex diseases / / 17554300 rs10090601 chr8 77997405 C T 5.27E-06 Hearing function / / 21493956 rs16939415 chr8 77998069 C T 5.18E-06 Hearing function / / 21493956 rs10095813 chr8 78039062 C T 4.49E-04 Type 2 diabetes / / 17463246 rs1993196 chr8 78050714 A G 7.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1452806 chr8 78088522 C T 7.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10113207 chr8 78088940 G T 2.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7821178 chr8 78093837 C A,G,T 4.94E-04 Alcohol dependence / / 20201924 rs7821178 chr8 78093837 C A,G,T 3.00E-09 Menarche (age at onset) / / 21102462 rs7821178 chr8 78093837 C A,G,T 9.63E-05 Permanent tooth development / / 21931568 rs17379354 chr8 78108034 T C 4.30E-06 Urinary metabolites / / 21572414 rs2123403 chr8 78110825 G A 8.29E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10504649 chr8 78119533 A G 5.21E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17380635 chr8 78124431 C A 2.80E-05 Urinary metabolites / / 21572414 rs1452820 chr8 78133483 G T 4.96E-04 Multiple complex diseases / / 17554300 rs7846385 chr8 78160179 T C 5.00E-08 Height / / 18391951 rs7846385 chr8 78160179 T C 1.90E-09 Menarche (age at onset) / / 21102462 rs7846385 chr8 78160179 T C 7.20E-06 Urinary metabolites / / 21572414 rs6473015 chr8 78178485 A C 7.00E-13 Height / / 20881960 rs6473015 chr8 78178485 A C 6.07E-06 Permanent tooth development / / 21931568 rs4490807 chr8 78202838 G A 2.69E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4515522 chr8 78218666 G T 2.64E-04 Multiple complex diseases / / 17554300 rs12682053 chr8 78257162 A T 9.50E-06 Urinary metabolites / / 21572414 rs7015264 chr8 78305777 G T 9.83E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2338961 chr8 78311815 C T 5.74E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17375981 chr8 78322244 A G 1.06E-04 Multiple complex diseases / / 17554300 rs13258743 chr8 78325636 G A 3.44E-04 Alcohol dependence / / 20201924 rs13258743 chr8 78325636 G A 9.75E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs13259667 chr8 78325885 G A 5.60E-04 Behavioural disinhibition (generation interaction) / / 23942779 rs13259667 chr8 78325885 G A 6.20E-04 Behavioural disinhibition (generation interaction) / / 23942779 rs13259667 chr8 78325885 G A 8.00E-06 Behavioural disinhibition (generation interaction) / / 23942779 rs1515074 chr8 78365902 A G 8.80E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs374350 chr8 78462768 C A 6.20E-06 Urinary metabolites / / 21572414 rs443531 chr8 78468952 C A 6.82E-04 Multiple complex diseases / / 17554300 rs723510 chr8 78500065 T C 6.20E-04 Crohn's disease / / 17684544 rs16939538 chr8 78592664 A T 8.46E-04 Multiple complex diseases / / 17554300 rs7016717 chr8 78630367 G A 9.03E-04 Multiple complex diseases / / 17554300 rs3864663 chr8 78680349 T C 2.00E-06 Sudden cardiac arrest / / 21658281 rs10094496 chr8 78757703 C T 9.10E-05 Personality dimensions / / 18957941 rs10091852 chr8 78812089 C T 8.64E-05 Neuroblastoma / / pha002895 rs10957875 chr8 78822971 G A 9.58E-04 Stroke / / pha002887 rs10504663 chr8 78868679 A T 5.00E-05 Lactate dehydrogenase levels / / 20981236 rs6473077 chr8 78915948 T G 1.52E-04 Multiple complex diseases / / 17554300 rs2219968 chr8 78956658 G A 6.00E-07 Prostate cancer (gene x gene interaction) / / 22219177 rs11780588 chr8 79001991 T G 1.90E-06 Urinary metabolites / / 21572414 rs13272568 chr8 79034459 C A 6.00E-07 Bone mineral density / / 22504420 rs11996072 chr8 79174222 G A 7.93E-04 Multiple complex diseases / / 17554300 rs1030547 chr8 79186223 G A 3.00E-04 Alcohol dependence / / 20201924 rs1030547 chr8 79186223 G A 7.70E-04 Alcohol dependence / / 20201924 rs2009073 chr8 79206042 C T 4.98E-04 Taste perception / / 22132133 rs6473094 chr8 79206819 G T 5.12E-04 Taste perception / / 22132133 rs2195687 chr8 79276063 C T 2.90E-04 Taste perception / / 22132133 rs7016026 chr8 79284507 A C 3.93E-04 Smoking quantity / / 24665060 rs7016982 chr8 79372723 G C 9.63E-04 Type 2 diabetes / / 17463246 rs1520333 chr8 79401038 A G 2.00E-07 Multiple sclerosis / / 21833088 rs12681308 chr8 79404893 C T 4.86E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4294171 chr8 79413343 C T 3.47E-06 Waist-Hip Ratio / / pha003013 rs4294171 chr8 79413343 C T 5.68E-06 Waist-Hip Ratio / / pha003028 rs7837755 chr8 79447414 T C 9.74E-05 Partial epilepsies PKIA intron 20522523 rs10504676 chr8 79451370 G A 4.96E-04 Alzheimer's disease PKIA intron 17998437 rs2369293 chr8 79491345 C T 3.53E-05 Bipolar disorder PKIA intron 20451256 rs16905824 chr8 79501241 A G 2.03E-05 Multiple sclerosis PKIA intron 17660530 rs16905824 chr8 79501241 A G 2.60E-04 Alzheimer's disease PKIA intron 17998437 rs6473109 chr8 79526456 G A 3.05E-05 Cognitive test performance / / 20125193 rs2369294 chr8 79532730 C T 8.38E-05 Multiple sclerosis / / 17660530 rs2369294 chr8 79532730 C T 2.29E-04 Alzheimer's disease / / 17998437 rs2369294 chr8 79532730 C T 8.45E-05 Bipolar disorder / / 20451256 rs11782836 chr8 79564187 T G 3.24E-04 Myocardial Infarction / / pha002873 rs6993386 chr8 79654145 A G 6.87E-05 Multiple sclerosis IL7 intron 17660530 rs7816685 chr8 79658906 T C 8.00E-05 HIV-1 control IL7 intron 20041166 rs17506603 chr8 79750813 A G 0.000149 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17506603 chr8 79750813 A G 1.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2887502 chr8 79756591 C T 7.58E-05 Creatinine levels / / pha003069 rs11992182 chr8 79766499 C A 1.11E-04 Alzheimer's disease (late onset) / / 21379329 rs1858120 chr8 79790796 C T 2.76E-04 Alzheimer's disease (late onset) / / 21379329 rs1858120 chr8 79790796 C T 1.59E-04 Alzheimer's disease (late onset) / / 21460841 rs1858122 chr8 79790960 C T 1.59E-04 Alzheimer's disease (late onset) / / 21460841 rs10104891 chr8 79793824 G T 1.58E-04 Alzheimer's disease (late onset) / / 21460841 rs10808826 chr8 79794041 C T 2.45E-04 Alzheimer's disease (late onset) / / 21379329 rs10808826 chr8 79794041 C T 1.57E-04 Alzheimer's disease (late onset) / / 21460841 rs1443898 chr8 79804155 A G 8.60E-05 Alzheimer's disease (late onset) / / 21379329 rs2012054 chr8 79807241 C T 9.71E-05 Alzheimer's disease (late onset) / / 21379329 rs11985613 chr8 79815285 G A 1.23E-04 Alzheimer's disease (late onset) / / 21460841 rs10097478 chr8 79846530 G A 4.50E-06 Digit length ratio / / 20303062 rs1427257 chr8 79886961 G A 9.79E-04 Multiple complex diseases / / 17554300 rs17517571 chr8 79973576 G A 9.13E-05 Breast cancer / / 21060860 rs677681 chr8 79979285 T C 9.14E-05 Cholesterol / / pha003073 rs677681 chr8 79979285 T C 4.90E-05 Cholesterol / / pha003078 rs7017025 chr8 80048545 T C 9.26E-04 Stroke / / pha002886 rs10504696 chr8 80060941 G A 1.79E-04 Bipolar disorder / / 19259986 rs10504696 chr8 80060941 G A 4.79E-04 Stroke / / pha002886 rs1460172 chr8 80098526 A G 8.54E-05 Orofacial clefts / / 22419666 rs12680612 chr8 80099221 A G 1.00E-05 Urinary metabolites / / 21572414 rs11778216 chr8 80099821 G A 9.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs12677623 chr8 80121676 T C 9.55E-04 Multiple complex diseases / / 17554300 rs6473143 chr8 80123772 T C 1.04E-04 Multiple complex diseases / / 17554300 rs1227635 chr8 80157790 T C 8.88E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1227664 chr8 80162053 C A 9.29E-05 Bipolar disorder / / 17486107 rs1227661 chr8 80162687 C T 5.57E-05 Potassium levels / / pha003086 rs10504702 chr8 80211249 G A 8.29E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs1460163 chr8 80227448 G A 6.00E-08 Creutzfeldt-Jakob disease / / 19081515 rs16906775 chr8 80246590 C T 1.76E-04 HIV-1 viral setpoint / / 17641165 rs10504708 chr8 80246955 T C 7.29E-04 Type 2 diabetes / / 17846125 rs7462051 chr8 80266553 G A 1.69E-05 Obsessive-compulsive disorder / / 24821223 rs11985579 chr8 80279515 C A 4.69E-04 Smoking initiation / / 24665060 rs9886374 chr8 80308603 G A 9.70E-04 Multiple complex diseases / / 17554300 rs10086740 chr8 80308664 G A 7.50E-08 Urinary metabolites / / 21572414 rs7460206 chr8 80358313 C T 5.16E-05 Eosinophil counts / / pha003088 rs16906925 chr8 80491853 G T 2.39E-04 Schizophrenia / / 20832056 rs16906934 chr8 80497148 A G 2.25E-04 Schizophrenia / / 20832056 rs16906958 chr8 80520645 G A 5.38E-07 Estradiol plasma levels (breast cancer) / / 23518928 rs6473171 chr8 80541807 A T 4.11E-04 Sarcoidosis STMN2 intron 19165924 rs16907010 chr8 80544154 T G 6.93E-04 Response to statin treatment (atorvastatin),change in cholesterol levels STMN2 intron 20031582 rs4739642 chr8 80553207 C T 6.99E-05 Chronic obstructive pulmonary disease STMN2 intron 19300482 rs4739642 chr8 80553207 C T 6.99E-05 Response to statin treatment (atorvastatin),change in cholesterol levels STMN2 intron 20031582 rs2979715 chr8 80562259 C T 4.63E-07 Osteoarthritis STMN2 intron 22763110 rs2467753 chr8 80597253 G T 1.54E-06 Osteoarthritis / / 22763110 rs2920942 chr8 80612714 C T 6.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1813496 chr8 80617721 G C 9.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2920951 chr8 80654655 A G 1.80E-05 Blood Pressure / / pha003044 rs962695 chr8 80656206 T C 4.11E-04 Tourette syndrome / / 22889924 rs6992703 chr8 80669279 T A 4.80E-04 Insulin resistance / / 21901158 rs6986945 chr8 80675277 T G 9.66E-05 Multiple complex diseases / / 17554300 rs7838496 chr8 80705936 A G 1.00E-04 Cognitive impairment induced by topiramate LOC100507186 intron 22091778 rs2278667 chr8 80714935 A G 9.71E-05 Cognitive impairment induced by topiramate / / 22091778 rs13259642 chr8 80728453 C T 6.11E-04 Multiple complex diseases / / 17554300 rs2457401 chr8 80752449 A G 3.30E-05 Diabetic nephropathy / / pha002866 rs6473185 chr8 80782703 A G 7.40E-05 Cognitive test performance / / 20125193 rs16907253 chr8 80790220 T C 4.38E-04 Multiple complex diseases / / 17554300 rs2100346 chr8 80841972 T C 3.82E-05 Parent of origin effect on language impairment (paternal) MRPS28 intron 24571439 rs2084860 chr8 80842949 G C 0.0001849 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs2084860 chr8 80842949 G C 1.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs3953125 chr8 80850032 A T 0.0003714 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs3953125 chr8 80850032 A T 3.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs2123269 chr8 80856693 C T 0.000159 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs2123269 chr8 80856693 C T 1.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs6987013 chr8 80867359 C T 0.0005424 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs6987013 chr8 80867359 C T 5.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs2053962 chr8 80870910 G A 0.0005861 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs2053962 chr8 80870910 G A 5.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs10094992 chr8 80873478 T C 0.0005881 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs10094992 chr8 80873478 T C 5.88E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs1509624 chr8 80874211 A G 0.0006362 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs1509624 chr8 80874211 A G 6.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs16907353 chr8 80877238 T A 0.0006568 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs16907353 chr8 80877238 T A 6.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs6988730 chr8 80878082 C T 0.0001784 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs6988730 chr8 80878082 C T 1.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs7015849 chr8 80883283 A G 0.0001786 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs7015849 chr8 80883283 A G 1.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs12545981 chr8 80883914 T C 2.24E-04 Multiple complex diseases MRPS28 intron 17554300 rs12545981 chr8 80883914 T C 0.000685 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs12545981 chr8 80883914 T C 6.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs6992037 chr8 80890872 G A 0.0006904 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs6992037 chr8 80890872 G A 6.90E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs1562986 chr8 80903607 G A 8.89E-04 Multiple complex diseases MRPS28 intron 17554300 rs1562986 chr8 80903607 G A 0.0002772 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs1562986 chr8 80903607 G A 2.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs7014295 chr8 80909229 T C 9.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs4740097 chr8 80909949 G A 0.00026 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs4740097 chr8 80909949 G A 2.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs11989508 chr8 80911668 T C 0.000255 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs11989508 chr8 80911668 T C 2.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs13282493 chr8 80922910 C T 0.0001849 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs13282493 chr8 80922910 C T 1.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs10113767 chr8 80922988 C A 0.0002108 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs10113767 chr8 80922988 C A 2.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs1979184 chr8 80927600 C G 0.0006135 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs1979184 chr8 80927600 C G 6.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs10112519 chr8 80927909 C T 0.0001536 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs10112519 chr8 80927909 C T 1.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs2123268 chr8 80928940 T C 0.0005923 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs2123268 chr8 80928940 T C 5.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs6473196 chr8 80931107 C T 4.75E-04 Multiple complex diseases MRPS28 intron 17554300 rs6473196 chr8 80931107 C T 0.0002268 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPS28 intron 23233654 rs6473196 chr8 80931107 C T 2.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPS28 intron 23233662 rs181166265 chr8 80985035 T C 3.00E-06 Metabolite levels (HVA/MHPG ratio) TPD52 intron 23319000 rs10106183 chr8 80986180 A G 1.06E-05 Multiple complex diseases TPD52 intron 17554300 rs10957961 chr8 81031822 A G 2.00E-07 Metabolite levels (Pyroglutamine) TPD52 intron 23934736 rs6473202 chr8 81036045 T C 2.29E-04 Multiple complex diseases TPD52 intron 17554300 rs4440674 chr8 81054942 G C 9.34E-04 Multiple complex diseases TPD52 intron 17554300 rs10755964 chr8 81077969 G A 7.23E-04 Amyotrophic lateral sclerosis (sporadic) TPD52 intron 24529757 rs7814569 chr8 81089866 A G 1.62E-04 Alzheimer's disease (late onset) / / 21379329 rs7814569 chr8 81089866 A G 5.13E-05 Prostate cancer / / pha002878 rs998731 chr8 81095395 C T 2.00E-08 Rheumatoid arthritis LOC100133047 intron 24390342 rs998731 chr8 81095395 C T 7.00E-09 Rheumatoid arthritis LOC100133047 intron 24390342 rs7821167 chr8 81107011 T C 2.35E-05 Type 2 diabetes LOC100133047 intron 17463246 rs7830310 chr8 81110456 A G 2.77E-05 Type 2 diabetes LOC100133047 intron 17463246 rs6983074 chr8 81120044 C T 6.45E-04 Multiple complex diseases LOC100133047 intron 17554300 rs4415363 chr8 81120189 C T 0.0000321 Asthma LOC100133047 intron 22694930 rs7814057 chr8 81126925 A C 0.0000644 Asthma LOC100133047 intron 22694930 rs7832840 chr8 81136286 C T 7.56E-04 Type 2 diabetes LOC100133047 intron 17463246 rs7011326 chr8 81142630 G A 7.21E-04 Myopia (pathological) LOC100133047 intron 21095009 rs5019763 chr8 81214320 A G 8.63E-05 Self-reported allergy / / 23817569 rs13277346 chr8 81220185 G A 3.89E-06 Self-reported allergy / / 23817569 rs11987678 chr8 81228826 T C 4.00E-06 Sleep duration / / 23728906 rs6473219 chr8 81245003 T C 1.78E-04 Myopia (pathological) / / 21095009 rs6473219 chr8 81245003 T C 6.71E-05 Self-reported allergy / / 23817569 rs7822328 chr8 81246659 A G 9.70E-07 Self-reported allergy / / 23817569 rs7822342 chr8 81246699 A G 2.37E-05 Self-reported allergy / / 23817569 rs7006626 chr8 81247676 C A 9.73E-07 Self-reported allergy / / 23817569 rs12542017 chr8 81252135 T C 1.14E-06 Self-reported allergy / / 23817569 rs6996867 chr8 81253389 G A 1.71E-05 Self-reported allergy / / 23817569 rs13267071 chr8 81255947 T G 4.64E-06 Self-reported allergy / / 23817569 rs13265296 chr8 81256041 C G 4.81E-06 Self-reported allergy / / 23817569 rs13266315 chr8 81256181 G A 5.32E-06 Self-reported allergy / / 23817569 rs13275909 chr8 81256542 T C 5.51E-06 Self-reported allergy / / 23817569 rs13275219 chr8 81259826 T C 1.56E-07 Self-reported allergy / / 23817569 rs4739735 chr8 81259877 C T 4.19E-07 Self-reported allergy / / 23817569 rs11776367 chr8 81260051 A T 4.53E-07 Self-reported allergy / / 23817569 rs3913969 chr8 81261064 C T 3.33E-07 Self-reported allergy / / 23817569 rs7462675 chr8 81263962 C A 2.09E-07 Self-reported allergy / / 23817569 rs1911714 chr8 81265936 G C 2.81E-07 Self-reported allergy / / 23817569 rs1911713 chr8 81266044 G A 2.84E-07 Self-reported allergy / / 23817569 rs6992476 chr8 81267706 A G 1.41E-07 Self-reported allergy / / 23817569 rs6992476 chr8 81267706 A G 9.10E-05 Diabetic nephropathy / / pha002864 rs7012968 chr8 81267808 T C 2.42E-07 Self-reported allergy / / 23817569 rs6473222 chr8 81267937 A G 2.41E-07 Self-reported allergy / / 23817569 rs6473223 chr8 81268155 T C 8.00E-08 Self-reported allergy / / 23817569 rs6473224 chr8 81268217 T A 2.14E-07 Self-reported allergy / / 23817569 rs6987042 chr8 81273883 A G 2.32E-07 Self-reported allergy / / 23817569 rs2202749 chr8 81274338 A G 8.72E-08 Self-reported allergy / / 23817569 rs13275449 chr8 81276113 G A 8.81E-08 Self-reported allergy / / 23817569 rs12543811 chr8 81278885 G A 9.95E-08 Self-reported allergy / / 23817569 rs16907620 chr8 81279782 A G 1.57E-08 Multiple complex diseases / / 17554300 rs16907620 chr8 81279782 A G 8.43E-24 Narcolepsy / / 19629137 rs16907623 chr8 81280056 C T 2.12E-04 Alzheimer's disease (late onset) / / 21379329 rs13270496 chr8 81280666 A C 4.20E-07 Self-reported allergy / / 23817569 rs6473225 chr8 81281007 G A 4.70E-07 Self-reported allergy / / 23817569 rs7837153 chr8 81283376 A C 1.09E-07 Self-reported allergy / / 23817569 rs6473226 chr8 81285759 T C 5.60E-05 Orofacial clefts / / 22419666 rs6473226 chr8 81285759 T C 5.84E-07 Self-reported allergy / / 23817569 rs952559 chr8 81288634 A G 3.83E-07 Self-reported allergy / / 23817569 rs952558 chr8 81288734 A T 6.94E-07 Self-reported allergy / / 23817569 rs4739737 chr8 81289625 G T 3.16E-07 Self-reported allergy / / 23817569 rs10957979 chr8 81289787 A G 4.84E-07 Self-reported allergy / / 23817569 rs2370615 chr8 81290387 C T 1.30E-06 Self-reported allergy / / 23817569 rs7009110 chr8 81291879 T C 1.15E-06 Self-reported allergy / / 23817569 rs7009110 chr8 81291879 T C 4.00E-09 Asthma and hay fever / / 24388013 rs6989309 chr8 81292208 A T 1.15E-06 Self-reported allergy / / 23817569 rs2202750 chr8 81294504 T C 9.52E-07 Self-reported allergy / / 23817569 rs1543857 chr8 81295224 G A 1.23E-06 Self-reported allergy / / 23817569 rs2102418 chr8 81295744 G T 8.00E-07 Self-reported allergy / / 23817569 rs10504716 chr8 81299085 A T 2.41E-05 Self-reported allergy / / 23817569 rs7003011 chr8 81299603 A G 1.26E-06 Self-reported allergy / / 23817569 rs872218 chr8 81303433 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12550844 chr8 81306695 A G 4.99E-05 Self-reported allergy / / 23817569 rs7018262 chr8 81308078 A G 5.04E-04 Myopia (pathological) / / 21095009 rs7000782 chr8 81308150 T A 1.00E-06 Atopic dermatitis / / 22197932 rs11784307 chr8 81312277 T C 2.61E-05 Self-reported allergy / / 23817569 rs4739744 chr8 81312920 G A 5.61E-05 Self-reported allergy / / 23817569 rs484681 chr8 81330198 A G 5.60E-05 Glucose levels / / pha003058 rs16907708 chr8 81347419 G A 2.16E-04 Type 2 diabetes / / 17463246 rs400824 chr8 81357702 C T 2.10E-05 Hypothyroidism / / 22493691 rs400824 chr8 81357702 C T 9.00E-06 Migraine - clinic-based / / 23793025 rs7830160 chr8 81381871 C T 2.30E-05 Hypothyroidism / / 22493691 rs28644470 chr8 81404932 T A 0.00007283 Sarcoidosis ZBTB10 intron 22952805 rs4587368 chr8 81407333 A G 2.07E-04 Response to taxane treatment (placlitaxel) ZBTB10 intron 23006423 rs41462451 chr8 81411335 A G 2.20E-06 Urinary metabolites ZBTB10 intron 21572414 rs16907781 chr8 81435942 A G 2.07E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1051920 chr8 81438420 C T 4.00E-06 Hypothyroidism / / 22493691 rs1863593 chr8 81449141 T C 1.49E-05 Duodenal ulcer / / 22387998 rs381349 chr8 81451995 G A 2.87E-05 Arthritis (juvenile idiopathic) / / 22354554 rs440837 chr8 81461974 A G 3.00E-09 Sex hormone-binding globulin levels / / 22829776 rs440837 chr8 81461974 A G 7.00E-08 Sex hormone-binding globulin levels / / 22829776 rs474402 chr8 81467155 G C 9.50E-04 Iris characteristics / / 21835309 rs272594 chr8 81470120 A C 1.00E-06 Neutrophil count / / 21507922 rs272595 chr8 81470769 A G 2.44E-06 Platelet counts / / 21507922 rs1978564 chr8 81477367 C T 5.45E-05 Multiple complex diseases / / 17554300 rs272610 chr8 81482337 T C 2.93E-05 Type 2 diabetes and other traits / / 19734900 rs7005189 chr8 81500656 C T 2.80E-05 Major depressive disorder / / 19065144 rs7005189 chr8 81500656 C T 1.81E-05 Major depressive disorder / / 21621269 rs7005189 chr8 81500656 C T 9.35E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7005189 chr8 81500656 C T 4.15E-05 Major depressive disorder / / pha002850 rs11987529 chr8 81704158 G A 8.64E-04 Amyotrophic lateral sclerosis (sporadic) ZNF704 intron 24529757 rs4308687 chr8 81710837 G A 4.68E-07 Longevity,exceptional ZNF704 intron 20595579 rs3907424 chr8 81733727 C A 2.60E-04 Iris characteristics ZNF704 missense 21835309 rs1199028 chr8 81771461 A C 8.08E-05 Scoliosis ZNF704 intron 21216876 rs10957988 chr8 81820594 T C 2.05E-05 Serum metabolites / / 19043545 rs16908125 chr8 81827639 T A 1.17E-04 Multiple complex diseases / / 17554300 rs1445570 chr8 81839692 G A 9.50E-05 Major depressive disorder / / 22472876 rs1445570 chr8 81839692 G A 2.60E-06 Primary tooth development (number of teeth) / / 23704328 rs10504727 chr8 81846682 T C 5.27E-05 Hearing function / / 17255346 rs10504727 chr8 81846682 T C 2.49E-05 HDL cholesterol / / pha003074 rs12679573 chr8 81861220 G A 6.20E-05 Personality dimensions / / 18957941 rs895274 chr8 81862549 A G 3.90E-05 Personality dimensions / / 18957941 rs1866274 chr8 81878654 A G 6.58E-06 Post-operative nausea and vomiting / / 21694509 rs920983 chr8 81878670 G A 4.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6984342 chr8 81883905 T C 1.90E-05 Parkinson's disease (familial) PAG1 UTR-3 18985386 rs6473257 chr8 81891362 C A 0.000511494 Hypertension (early onset hypertension) PAG1 intron 22479346 rs6984368 chr8 81892909 G T 8.76E-06 HIV-1 progression PAG1 intron 20064070 rs7006101 chr8 81897200 C T 4.81E-05 HIV-1 progression PAG1 cds-synon 20064070 rs2016459 chr8 81905314 A C 5.00E-05 Cognitive function PAG1 intron 24684796 rs7830556 chr8 81918882 C T 6.15E-05 Lung function (forced expiratory volume in 1 second) PAG1 intron pha003102 rs2127937 chr8 81934664 G A 9.61E-05 Lung function (forced expiratory volume in 1 second) PAG1 intron pha003102 rs2127938 chr8 81959579 C T 6.56E-04 Suicide attempts in bipolar disorder PAG1 intron 21041247 rs11986666 chr8 81961455 A C 6.71E-04 Suicide attempts in bipolar disorder PAG1 intron 21041247 rs4585701 chr8 81962644 C T 6.49E-04 Suicide attempts in bipolar disorder PAG1 intron 21041247 rs11985427 chr8 81972883 G C 5.67E-05 Multiple complex diseases PAG1 intron 17554300 rs4574807 chr8 81973259 T G 9.52E-04 Response to taxane treatment (placlitaxel) PAG1 intron 23006423 rs11778741 chr8 81976972 G A 5.97E-05 Serum metabolites PAG1 intron 19043545 rs10957998 chr8 81978867 T C 5.58E-05 Serum metabolites PAG1 intron 19043545 rs5003154 chr8 81986953 T C 1.00E-06 Bladder cancer PAG1 intron 24163127 rs7828228 chr8 81995592 A G 1.17E-04 Multiple complex diseases PAG1 intron 17554300 rs7018273 chr8 82004857 A G 1.00E-04 Cognitive impairment induced by topiramate PAG1 intron 22091778 rs10504730 chr8 82017372 G A 4.74E-04 Smoking initiation PAG1 intron 24665060 rs4445178 chr8 82020528 G A 5.55E-05 Tourette syndrome PAG1 intron 22889924 rs10097731 chr8 82027672 G T 6.00E-08 Serum total protein level / / 23022100 rs10504731 chr8 82033527 T C 1.51E-05 Panic disorder / / 19165232 rs12542990 chr8 82034451 G C 1.16E-12 Esophageal cancer / / 21642993 rs17578381 chr8 82037051 C T 3.66E-04 Coronary Artery Disease / / 17634449 rs7824819 chr8 82042630 A G 8.59E-04 HIV-1 viral setpoint / / 17641165 rs10958000 chr8 82055665 T C 7.99E-04 Type 2 diabetes / / 17463246 rs10958000 chr8 82055665 T C 8.48E-04 Coronary Artery Disease / / 17634449 rs11988289 chr8 82069207 A C 0.0000286 post-traumatic stress disorder / / 22869035 rs11988289 chr8 82069207 A C 2.86E-05 Schizophrenia / / 22883433 rs10504736 chr8 82107026 G A 8.20E-04 HIV-1 viral setpoint / / 17641165 rs12216812 chr8 82151747 G A 3.00E-09 Myopia (pathological) / / 23049088 rs10090760 chr8 82158027 T C 6.81E-04 Smoking quantity / / 24665060 rs1909936 chr8 82245451 T C 1.12E-04 Multiple complex diseases / / 17554300 rs1346291 chr8 82251964 A G 3.70E-07 Esophageal cancer (squamous cell) / / 20729853 rs17582647 chr8 82284413 T C 2.76E-04 Nicotine dependence / / 17158188 rs7821877 chr8 82352251 T C 6.35E-05 Monocyte counts / / pha003089 rs2167255 chr8 82353078 T G 9.16E-04 Type 2 diabetes PMP2 UTR-3 17463246 rs16909187 chr8 82390717 G A 0.000069 Coronary artery calcification / / 23727086 rs16919639 chr8 82407985 T C 6.92E-04 Type 2 diabetes / / 17463246 rs11996913 chr8 82435447 T G 7.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs11986725 chr8 82435544 A T 7.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs17703680 chr8 82435985 G C 8.70E-04 Self-reported allergy / / 23817569 rs11994340 chr8 82437457 T C 7.99E-04 Suicide attempts in bipolar disorder FABP12 intron 21423239 rs11995519 chr8 82439111 T A 7.12E-04 Suicide attempts in bipolar disorder FABP12 intron 21423239 rs11992576 chr8 82439521 C G 4.22E-04 Suicide attempts in bipolar disorder FABP12 intron 21423239 rs16909318 chr8 82445224 C A 7.00E-07 Visceral fat / / 22589738 rs6985243 chr8 82455143 G T 2.90E-06 Lung cancer / / 18385738 rs10958027 chr8 82465610 G A 1.53E-04 Lymphocyte counts / / 22286170 rs2195099 chr8 82523326 A G 5.67E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4081825 chr8 82541752 A C 2.40E-04 Lipid levels / / 18193043 rs2912807 chr8 82556146 G A 8.32E-04 Multiple complex diseases / / 17554300 rs2912821 chr8 82598908 A G 3.87E-04 Lung function (forced vital capacity) IMPA1 nearGene-5 24023788 rs11782652 chr8 82653644 A G 6.00E-09 Ovarian cancer CHMP4C intron 23535730 rs11782652 chr8 82653644 A G 7.00E-10 Ovarian cancer CHMP4C intron 23535730 rs13276421 chr8 82657693 C T 3.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CHMP4C intron 20877124 rs2291490 chr8 82667211 A G 3.06E-05 HIV-1 viral setpoint CHMP4C intron 17641165 rs1565314 chr8 82668678 G A 6.64E-04 Taste perception CHMP4C intron 22132133 rs10112819 chr8 82691708 A G 5.02E-04 Smoking initiation / / 24665060 rs7815272 chr8 82691809 T G 1.00E-04 Schizophrenia / / 19197363 rs7834555 chr8 82697625 A G 3.43E-05 Alcohol consumption / / 23743675 rs7835342 chr8 82698092 A G 3.08E-05 Alcohol consumption / / 23743675 rs6415652 chr8 82702257 G A 3.66E-05 Alcohol consumption / / 23743675 rs6415653 chr8 82702536 A G 3.42E-05 Alcohol consumption / / 23743675 rs7834483 chr8 82704828 A G 5.65E-05 Alcohol consumption / / 23743675 rs10091077 chr8 82705464 A G 5.34E-05 Alcohol consumption / / 23743675 rs2400474 chr8 82706439 A G 2.16E-05 Alcohol consumption / / 23743675 rs6473308 chr8 82707708 G A 3.66E-05 Alcohol consumption / / 23743675 rs6473309 chr8 82707880 A G 3.54E-05 Alcohol consumption / / 23743675 rs6473310 chr8 82707981 A G 3.42E-05 Alcohol consumption / / 23743675 rs7004177 chr8 82710137 G C 3.60E-04 Smoking initiation / / 24665060 rs1054078 chr8 82712153 A G 3.02E-05 Alcohol consumption SNX16 UTR-3 23743675 rs7846521 chr8 82718107 A G 3.38E-05 Alcohol consumption SNX16 intron 23743675 rs2600604 chr8 82720700 G A 2.10E-04 Smoking initiation SNX16 intron 24665060 rs10958045 chr8 82722994 T C 3.20E-05 Alcohol consumption SNX16 intron 23743675 rs774469 chr8 82723869 C T 6.99E-04 Smoking initiation SNX16 intron 24665060 rs7825180 chr8 82723991 T A 3.17E-05 Alcohol consumption SNX16 intron 23743675 rs6473311 chr8 82726682 G A 3.20E-05 Alcohol consumption SNX16 intron 23743675 rs13255262 chr8 82728024 T G 3.31E-05 Alcohol consumption SNX16 intron 23743675 rs1869077 chr8 82729674 C A 6.56E-04 Multiple complex diseases SNX16 intron 17554300 rs12544174 chr8 82731477 G A 3.38E-05 Alcohol consumption SNX16 intron 23743675 rs4739627 chr8 82734657 A G 3.00E-05 Alcohol consumption SNX16 intron 23743675 rs1463259 chr8 82737745 T C 3.17E-05 Schizophrenia SNX16 intron 19197363 rs1451995 chr8 82746123 G C 3.44E-05 Alcohol consumption SNX16 intron 23743675 rs10504741 chr8 82755353 C A 5.61E-04 Smoking initiation / / 24665060 rs7839178 chr8 82763479 A G 3.51E-05 Alcohol consumption / / 23743675 rs2400540 chr8 82763948 A C 3.51E-05 Alcohol consumption / / 23743675 rs28390260 chr8 82769175 A T 3.51E-05 Alcohol consumption / / 23743675 rs12676336 chr8 82771008 C T 3.77E-05 Alcohol consumption / / 23743675 rs1451994 chr8 82777062 A G 6.11E-04 Smoking initiation / / 24665060 rs1817107 chr8 82789609 T C 7.29E-04 Type 2 diabetes / / 17846124 rs10113213 chr8 82888608 T C 3.00E-06 Response to methotrexate in juvenile idiopathic arthritis / / 24709693 rs7839040 chr8 82894306 G A 2.00E-06 Response to methotrexate in juvenile idiopathic arthritis / / 24709693 rs111629714 chr8 82899934 A C 2.74E-05 Response to methotrexate in juvenile idiopathic arthritis / / 24709693 rs7830040 chr8 82916953 C T 3.47E-05 Orofacial clefts / / 22863734 rs4529421 chr8 82921979 A G 1.25E-05 Orofacial clefts / / 22863734 rs7820074 chr8 82928598 T C 9.00E-06 Orofacial clefts / / 22863734 rs13269635 chr8 82973614 T C 9.22E-04 Multiple complex diseases / / 17554300 rs16919670 chr8 83035709 C T 6.02E-05 Multiple complex diseases / / 17554300 rs4739638 chr8 83036411 T C 9.00E-05 Multiple complex diseases / / 17554300 rs1395620 chr8 83061796 T C 2.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6987445 chr8 83072572 G C 1.05E-04 Multiple complex diseases / / 17554300 rs13264970 chr8 83073829 C T 4.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs1598260 chr8 83161615 T C 8.07E-04 Multiple complex diseases / / 17554300 rs1904275 chr8 83183692 C T 7.83E-04 Acute lung injury / / 22295056 rs10504752 chr8 83212040 T C 7.83E-04 Acute lung injury / / 22295056 rs4582559 chr8 83218162 G A 7.83E-04 Acute lung injury / / 22295056 rs751443 chr8 83228738 C T 5.47E-04 Acute lung injury / / 22295056 rs750571 chr8 83229436 A G 5.47E-04 Acute lung injury / / 22295056 rs7823718 chr8 83230515 T C 5.47E-04 Acute lung injury / / 22295056 rs17719800 chr8 83244737 A G 6.57E-04 Acute lung injury / / 22295056 rs17663476 chr8 83251024 C A 9.33E-05 Multiple complex diseases / / 17554300 rs16910284 chr8 83271395 T C 8.58E-05 Multiple complex diseases / / 17554300 rs1031877 chr8 83293872 G A 6.16E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16910334 chr8 83299109 G A 9.53E-05 Multiple complex diseases / / 17554300 rs1382617 chr8 83311669 C T 4.19E-05 Coronary heart disease / / pha003030 rs13261207 chr8 83313348 T C 8.60E-05 Coronary heart disease / / pha003030 rs6981943 chr8 83315422 G A 4.92E-05 Coronary heart disease / / pha003030 rs988664 chr8 83329097 T C 2.80E-05 Height / / pha003010 rs988664 chr8 83329097 T C 8.69E-06 Height / / pha003011 rs988664 chr8 83329097 T C 1.56E-05 Coronary heart disease / / pha003030 rs6473351 chr8 83333935 C T 2.69E-05 Height / / pha003010 rs6473351 chr8 83333935 C T 6.63E-06 Height / / pha003011 rs6473351 chr8 83333935 C T 2.34E-05 Coronary heart disease / / pha003030 rs7013518 chr8 83334905 T C 2.71E-05 Height / / pha003010 rs7013518 chr8 83334905 T C 6.70E-06 Height / / pha003011 rs7013518 chr8 83334905 T C 2.35E-05 Coronary heart disease / / pha003030 rs925673 chr8 83344525 C T 1.76E-05 Height / / pha003010 rs925673 chr8 83344525 C T 4.12E-06 Height / / pha003011 rs925673 chr8 83344525 C T 2.92E-05 Coronary heart disease / / pha003030 rs1011844 chr8 83383071 A C 2.10E-05 Urinary metabolites / / 21572414 rs979908 chr8 83384151 C T 6.49E-05 Height / / pha003010 rs979908 chr8 83384151 C T 2.17E-05 Height / / pha003011 rs7350073 chr8 83385804 A G 2.80E-05 Urinary metabolites / / 21572414 rs7838079 chr8 83401252 A G 1.20E-05 Urinary metabolites / / 21572414 rs7829847 chr8 83424411 A C 9.56E-05 Height / / pha003011 rs2137962 chr8 83427914 A G 4.25E-07 Height / / pha003010 rs2137962 chr8 83427914 A G 2.33E-07 Height / / pha003011 rs2137962 chr8 83427914 A G 9.53E-05 Coronary heart disease / / pha003030 rs7013595 chr8 83432030 A G 2.51E-05 Height / / pha003011 rs16910586 chr8 83451139 A G 2.02E-04 Insulin resistance / / 21901158 rs9298389 chr8 83516216 A G 3.09E-04 Multiple complex diseases / / 17554300 rs1356714 chr8 83516626 G A 4.27E-04 Multiple complex diseases / / 17554300 rs10958116 chr8 83541684 G A 4.14E-05 Multiple complex diseases / / 17554300 rs10958116 chr8 83541684 G A 2.62E-05 Serum metabolites / / 19043545 rs12543690 chr8 83621901 G A 1.85E-04 Multiple complex diseases / / 17554300 rs4270965 chr8 83629042 A G 4.71E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10504765 chr8 83642224 G A 8.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17733712 chr8 83666344 T C 0.0008935 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17733712 chr8 83666344 T C 8.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6473383 chr8 83669120 G A 3.00E-06 Heart failure / / 20445134 rs6473383 chr8 83669120 G A 2.29E-05 Heart Failure / / pha002884 rs9643449 chr8 83670807 A G 9.75E-05 Multiple complex diseases / / 17554300 rs11997468 chr8 83672742 T C 6.73E-06 Heart Failure / / pha002884 rs16910908 chr8 83682157 A T 7.08E-04 Multiple complex diseases / / 17554300 rs10099589 chr8 83691724 G A 4.84E-04 Multiple complex diseases / / 17554300 rs6994051 chr8 83693810 G A 1.14E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6999352 chr8 83694664 G T 1.14E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6999352 chr8 83694664 G T 2.76E-05 Waist-Hip Ratio / / pha003029 rs7828288 chr8 83700014 C A 2.05E-04 Multiple complex diseases / / 17554300 rs9643765 chr8 83701130 G A 0.0007689 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9643765 chr8 83701130 G A 7.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs16910980 chr8 83711123 T G 9.06E-05 HIV-1 viral setpoint / / 22174851 rs4739909 chr8 83717017 C T 7.38E-05 HIV-1 viral setpoint / / 22174851 rs10504768 chr8 83717972 C G 9.33E-04 Multiple complex diseases / / 17554300 rs17673952 chr8 83719374 A G 9.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12164158 chr8 83720569 G A 9.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12164159 chr8 83720674 G A 9.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1357917 chr8 83720912 A G 9.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1357919 chr8 83721091 A G 9.83E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13268825 chr8 83723890 T C 2.14E-04 Taste perception / / 22132133 rs7001967 chr8 83743358 C T 8.10E-04 Pulmonary function / / 23932459 rs7006993 chr8 83889759 C T 3.06E-06 Asthma (childhood onset) / / 23829686 rs7015622 chr8 83903814 A G 1.51E-04 Multiple complex diseases / / 17554300 rs7015622 chr8 83903814 A G 1.00E-06 Response to antidepressant treatment / / 22041458 rs1375788 chr8 83946036 T C 3.83E-04 Multiple complex diseases / / 17554300 rs7824274 chr8 83950492 T A 5.74E-04 Type 2 diabetes / / 17463246 rs7824274 chr8 83950492 T A 7.80E-06 Urinary metabolites / / 21572414 rs2122342 chr8 83955796 A C 9.53E-04 Type 2 diabetes / / 17463246 rs2122342 chr8 83955796 A C 7.10E-06 Urinary metabolites / / 21572414 rs2100221 chr8 83956561 C T 6.04E-04 Type 2 diabetes / / 17463246 rs2100221 chr8 83956561 C T 7.10E-06 Urinary metabolites / / 21572414 rs7820422 chr8 83957420 T C,G 6.02E-04 Type 2 diabetes / / 17463246 rs7820422 chr8 83957420 T C,G 4.50E-06 Urinary metabolites / / 21572414 rs7825517 chr8 83957991 C G 4.68E-04 Type 2 diabetes / / 17463246 rs10958138 chr8 83958106 A G 5.63E-04 Type 2 diabetes / / 17463246 rs10958138 chr8 83958106 A G 1.00E-05 Urinary metabolites / / 21572414 rs7825851 chr8 83958227 C G 5.30E-04 Type 2 diabetes / / 17463246 rs7000231 chr8 83958928 C A 5.51E-04 Type 2 diabetes / / 17463246 rs7000231 chr8 83958928 C A 6.90E-06 Urinary metabolites / / 21572414 rs4546659 chr8 83967140 G A 2.30E-05 Urinary metabolites / / 21572414 rs1823437 chr8 83968656 T C 2.70E-06 Urinary metabolites / / 21572414 rs10101004 chr8 83971478 T C 5.62E-04 Type 2 diabetes / / 17463246 rs10101004 chr8 83971478 T C 7.00E-06 Urinary metabolites / / 21572414 rs1584543 chr8 83974710 T C 5.04E-04 Type 2 diabetes / / 17463246 rs1584543 chr8 83974710 T C 7.10E-06 Urinary metabolites / / 21572414 rs1584544 chr8 83974721 T C 5.43E-04 Type 2 diabetes / / 17463246 rs1584544 chr8 83974721 T C 7.10E-06 Urinary metabolites / / 21572414 rs9298400 chr8 83975909 T C 3.31E-04 Type 2 diabetes / / 17463246 rs9298400 chr8 83975909 T C 5.00E-06 Urinary metabolites / / 21572414 rs1449811 chr8 83979627 A C 1.99E-05 Information processing speed / / 21130836 rs896009 chr8 83984625 C G 4.32E-04 Type 2 diabetes / / 17463246 rs896010 chr8 83984810 A G 4.58E-04 Type 2 diabetes / / 17463246 rs896010 chr8 83984810 A G 2.21E-05 Information processing speed / / 21130836 rs896010 chr8 83984810 A G 4.75E-05 Monocyte counts / / pha003089 rs4739919 chr8 83985296 C T 2.18E-04 Type 2 diabetes / / 17463246 rs4739919 chr8 83985296 C T 2.21E-05 Information processing speed / / 21130836 rs4739919 chr8 83985296 C T 7.14E-05 Monocyte counts / / pha003089 rs1375785 chr8 83991231 A C 8.00E-06 Information processing speed / / 21130836 rs1375785 chr8 83991231 A C 8.36E-05 Monocyte counts / / pha003089 rs6473411 chr8 83992779 G C 5.35E-04 Type 2 diabetes / / 17463246 rs6473411 chr8 83992779 G C 7.90E-06 Urinary metabolites / / 21572414 rs1449820 chr8 83993238 G A 1.80E-05 Urinary metabolites / / 21572414 rs6998971 chr8 84025585 C T 4.38E-04 Multiple complex diseases / / 17554300 rs6998971 chr8 84025585 C T 4.60E-04 Smoking cessation / / 24665060 rs2400882 chr8 84030397 A C 3.80E-04 Smoking cessation / / 24665060 rs13265895 chr8 84037048 T G 6.42E-04 Smoking cessation / / 24665060 rs4469455 chr8 84044940 C T 4.13E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4481591 chr8 84050892 T C 5.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11998040 chr8 84059022 G T 7.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1464467 chr8 84072321 G A 4.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2140016 chr8 84075113 A G 2.26E-04 Schizophrenia / / 20832056 rs2140016 chr8 84075113 A G 3.43E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10087985 chr8 84077832 C T 5.02E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1521825 chr8 84084432 G A 9.12E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1521826 chr8 84085561 C T 1.33E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12676236 chr8 84089379 T C 4.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1521829 chr8 84099766 C T 1.00E-04 Information processing speed / / 21130836 rs1568528 chr8 84114931 C T 1.00E-04 Information processing speed / / 21130836 rs7813189 chr8 84122752 C T 6.14E-05 Longevity / / 20304771 rs2140013 chr8 84133180 C T 6.06E-04 Smoking cessation / / 24665060 rs2140012 chr8 84149158 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs16919746 chr8 84171759 T G 3.89E-04 Smoking initiation / / 24665060 rs1915806 chr8 84211031 C T 3.76E-04 Schizophrenia / / 20832056 rs7005418 chr8 84211465 T C 2.65E-04 Schizophrenia / / 20832056 rs1552549 chr8 84471850 T C 1.93E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs10958163 chr8 84572978 T C 3.00E-04 Body mass index / / 24827717 rs6473464 chr8 84595596 G T 4.81E-04 Alzheimer's disease / / 17998437 rs6473464 chr8 84595596 G T 8.19E-05 Alzheimer's disease / / pha002879 rs10958167 chr8 84620608 C T 5.66E-04 Alzheimer's disease / / 17998437 rs11773921 chr8 84625017 T A 5.30E-04 Smoking behavior / / 20418888 rs4524788 chr8 84631221 G A 3.97E-04 Alzheimer's disease / / 17998437 rs4524788 chr8 84631221 G A 5.67E-05 Alzheimer's disease / / pha002879 rs10958172 chr8 84672003 C T 1.51E-04 Type 2 diabetes / / 22158537 rs12681958 chr8 84673149 C T 5.36E-04 Type 2 diabetes / / 22158537 rs12156341 chr8 84698627 T G 3.95E-04 Type 2 diabetes / / 22158537 rs7006609 chr8 84705236 A C 3.68E-05 Alzheimer's disease / / 17998437 rs7006609 chr8 84705236 A C 6.24E-05 Alzheimer's disease / / pha002879 rs10112734 chr8 84717841 T G 8.18E-05 Type 2 diabetes / / 22158537 rs4443665 chr8 84729923 C T 4.55E-04 Type 2 diabetes / / 22158537 rs6980733 chr8 84738607 T G 2.68E-04 Alzheimer's disease / / 17998437 rs6980733 chr8 84738607 T G 1.02E-04 Alzheimer's disease / / pha002879 rs7818592 chr8 84805338 T A 4.26E-04 Acute lung injury / / 22295056 rs7465130 chr8 84806620 G A 4.26E-04 Acute lung injury / / 22295056 rs7003447 chr8 84810178 C T 4.34E-04 Acute lung injury / / 22295056 rs728153 chr8 84822481 C T 3.61E-04 Acute lung injury / / 22295056 rs7820174 chr8 84823255 T C 4.26E-04 Acute lung injury / / 22295056 rs7836452 chr8 84823278 C G 4.26E-04 Acute lung injury / / 22295056 rs10808855 chr8 84824015 T C 7.10E-04 Acute lung injury / / 22295056 rs6994239 chr8 84824234 T C 4.34E-04 Acute lung injury / / 22295056 rs1115967 chr8 84826056 A G 4.26E-04 Acute lung injury / / 22295056 rs6473515 chr8 84828638 A G 4.26E-04 Acute lung injury / / 22295056 rs11777393 chr8 84855938 A G 4.44E-05 Multiple complex diseases / / 17554300 rs7009279 chr8 84856648 T C 8.41E-05 Multiple complex diseases / / 17554300 rs731956 chr8 84864301 A G 7.04E-04 Multiple complex diseases / / 17554300 rs2067807 chr8 84864845 T C 6.78E-04 Stroke / / pha002887 rs7830695 chr8 84886671 C T 7.41E-05 Multiple complex diseases / / 17554300 rs7836559 chr8 84911232 C T 1.30E-04 Multiple complex diseases / / 17554300 rs3847186 chr8 84911664 C T 1.71E-04 Multiple complex diseases / / 17554300 rs4478570 chr8 84973109 T C 9.60E-06 Calcium levels / / 20705733 rs13270104 chr8 84987503 T C 0.0001062 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13270104 chr8 84987503 T C 1.06E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1866085 chr8 85012273 A G 0.0003529 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1866085 chr8 85012273 A G 3.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10098485 chr8 85017171 T G 8.68E-04 Acute lung injury / / 22295056 rs7341568 chr8 85026929 G A 0.000298718 Hypertension (early onset hypertension) / / 22479346 rs12682316 chr8 85040119 C T 9.66E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10481281 chr8 85048690 C A 0.000655289 Hypertension (early onset hypertension) / / 22479346 rs7839847 chr8 85070052 A G 0.000238 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7839847 chr8 85070052 A G 2.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7845564 chr8 85118619 C T 8.16E-04 Alcohol dependence RALYL intron 21314694 rs16912577 chr8 85146868 C T 8.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RALYL intron 20877124 rs16912577 chr8 85146868 C T 4.15E-05 Heart Rate RALYL intron pha003054 rs7000150 chr8 85180841 C T 5.23E-04 Stroke RALYL intron pha002887 rs6982764 chr8 85276246 T C 9.88E-05 Platelet counts RALYL intron pha003100 rs4740011 chr8 85346588 G A 3.40E-06 Coffee consumption RALYL intron 21357676 rs16912908 chr8 85396742 G T 0.000274595 Hypertension (early onset hypertension) RALYL intron 22479346 rs783784 chr8 85404144 C T 5.50E-04 Acute lung injury RALYL intron 22295056 rs711029 chr8 85409778 C T 1.10E-08 Metabolite levels RALYL intron 23281178 rs711034 chr8 85413303 C T 1.10E-08 Metabolite levels RALYL intron 23281178 rs711037 chr8 85417425 G A 1.14E-08 Metabolite levels RALYL intron 23281178 rs711060 chr8 85457894 A G 8.89E-05 Cognitive impairment induced by topiramate RALYL intron 22091778 rs13279255 chr8 85636554 T C 8.60E-05 Blood Pressure RALYL intron pha003043 rs1488708 chr8 85658327 T C 2.89E-05 Coronary heart disease RALYL intron pha003055 rs1427050 chr8 85715494 C T 5.20E-06 Acute lymphoblastic leukemia (B-cell precursor) RALYL intron 23996088 rs17797872 chr8 85749529 T G 6.90E-05 HIV-1 viral setpoint RALYL intron 17641165 rs4740033 chr8 85762603 A C 1.35E-04 Prostate cancer mortality RALYL intron 20978177 rs1365671 chr8 85789366 C T 5.21E-04 Prostate cancer mortality RALYL intron 20978177 rs1427067 chr8 85791349 G A 6.43E-04 Prostate cancer mortality RALYL intron 20978177 rs9298430 chr8 85794689 T C 4.42E-04 Prostate cancer mortality RALYL intron 20978177 rs7818056 chr8 85796202 T G 4.42E-04 Prostate cancer mortality RALYL intron 20978177 rs7834730 chr8 85796332 G A 2.51E-04 Prostate cancer mortality RALYL intron 20978177 rs10097414 chr8 85803697 A G 4.42E-04 Prostate cancer mortality RALYL intron 20978177 rs10112387 chr8 85803833 T C 4.42E-04 Prostate cancer mortality RALYL intron 20978177 rs1025233 chr8 85809058 A G 4.42E-04 Prostate cancer mortality RALYL intron 20978177 rs10095682 chr8 85821389 A G 8.95E-04 Prostate cancer mortality RALYL intron 20978177 rs10046686 chr8 85825440 T A 5.57E-04 Prostate cancer mortality RALYL intron 20978177 rs1991352 chr8 85832512 T G 9.75E-04 Prostate cancer mortality RALYL intron 20978177 rs3937521 chr8 85832854 C A 7.55E-04 Prostate cancer mortality RALYL intron 20978177 rs12604 chr8 85833817 G A 7.55E-04 Prostate cancer mortality RALYL UTR-3 20978177 rs10958230 chr8 85838265 A T 5.57E-04 Prostate cancer mortality / / 20978177 rs1524646 chr8 85863234 G C 8.18E-04 Prostate cancer mortality / / 20978177 rs7829144 chr8 86028331 T C 6.38E-04 Prostate cancer mortality LRRCC1 intron 20978177 rs4150880 chr8 86101451 T A 1.70E-05 Anorexia nervosa E2F5 intron 23568457 rs4150893 chr8 86104754 T C 5.96E-04 Prostate cancer mortality E2F5 intron 20978177 rs4150894 chr8 86104868 G A 3.28E-05 Multiple sclerosis E2F5 intron 17660530 rs2403083 chr8 86108149 C A 3.00E-06 Plasma amyloid beta peptide concentrations (ABx-40) E2F5 intron 24535457 rs2132589 chr8 86135096 A G 1.42E-06 Brachial circumference LOC100507258 intron 22479309 rs10090196 chr8 86139996 T C 1.63E-06 Brachial circumference LOC100507258 intron 22479309 rs16913721 chr8 86182289 A G 2.15E-06 Brachial circumference CA13 intron 22479309 rs13257749 chr8 86217265 C A 9.70E-05 Breast cancer / / 21060860 rs1532423 chr8 86268313 A G 6.00E-12 Blood trace element (Zn levels) CA1 intron 23720494 rs1389247 chr8 86322583 G A 4.67E-04 Smoking quantity / / 24665060 rs650498 chr8 86473397 T C 1.51E-04 Alzheimer's disease / / 17998437 rs987390 chr8 86547351 G A 1.58E-06 Major depressive disorder / / 20516156 rs987390 chr8 86547351 G A 0.000000147 Major depressive disorder age at onset<35 / / 22915352 rs987390 chr8 86547351 G A 0.00000312 Major depressive disorder age at onset<30 / / 22915352 rs987390 chr8 86547351 G A 0.0000038 Major depressive disorder age at onset<25 / / 22915352 rs2930553 chr8 86849171 G T 2.48E-06 Major depressive disorder / / 20516156 rs185900 chr8 87009529 C T 0.00003618 Sarcoidosis / / 22952805 rs980086 chr8 87010204 G A 3.56E-04 Type 2 diabetes / / 17463246 rs811336 chr8 87022359 C T 0.00002079 Sarcoidosis / / 22952805 rs285406 chr8 87025013 T C 4.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs285406 chr8 87025013 T C 5.00E-06 Adverse response to lamotrigine and phenytoin / / 22379998 rs2046370 chr8 87083747 G A 9.61E-04 Alzheimer's disease / / 17998437 rs16880855 chr8 87087968 T C 3.73E-04 Multiple complex diseases / / 17554300 rs11775441 chr8 87092120 A G 9.00E-05 Pulmonary function / / 20010835 rs17660230 chr8 87097147 C T 7.17E-05 Pulmonary function / / 20010835 rs7846145 chr8 87106710 A C 8.11E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7836003 chr8 87111515 A C 1.50E-04 Amyotrophic Lateral Sclerosis ATP6V0D2 intron 17362836 rs1384878 chr8 87118690 G T 3.82E-04 Amyotrophic Lateral Sclerosis ATP6V0D2 intron 17362836 rs16886892 chr8 87132931 A G 7.04E-04 Coronary heart disease ATP6V0D2 intron 21606135 rs17603302 chr8 87136320 C T 2.73E-05 Myopia (pathological) ATP6V0D2 intron 23049088 rs16887456 chr8 87136710 C T 4.20E-05 Serum metabolites ATP6V0D2 intron 19043545 rs975818 chr8 87139845 C G 4.91E-04 Multiple complex diseases ATP6V0D2 intron 17554300 rs953147 chr8 87149355 A G 3.05E-04 Multiple complex diseases ATP6V0D2 intron 17554300 rs2128930 chr8 87159653 T C 6.67E-04 Multiple complex diseases ATP6V0D2 intron 17554300 rs2721244 chr8 87161437 A G 8.36E-04 Multiple complex diseases ATP6V0D2 intron 17554300 rs10094744 chr8 87162515 G A 0.00033 Prostate cancer ATP6V0D2 missense 23555315 rs6470428 chr8 87187050 G T 6.82E-04 Multiple complex diseases / / 17554300 rs13282492 chr8 87194764 A G 7.61E-04 Multiple complex diseases / / 17554300 rs17605526 chr8 87195980 C T 9.55E-04 Multiple complex diseases / / 17554300 rs6981984 chr8 87212693 A G 8.94E-04 Multiple complex diseases / / 17554300 rs6470733 chr8 87219072 A G 3.06E-04 Multiple complex diseases / / 17554300 rs13262822 chr8 87221488 G C 4.83E-04 Multiple complex diseases / / 17554300 rs13262822 chr8 87221488 G C 1.09E-07 Coronary Artery Disease / / 17634449 rs9693999 chr8 87226647 C T 0.00000053 Stroke SLC7A13 missense 23422753 rs2954348 chr8 87245044 C T 8.29E-05 Smoking quantity / / 24665060 rs1595207 chr8 87308070 G A 5.14E-05 Recombination rate / / 21698098 rs10090107 chr8 87417586 A G 1.00E-07 Parkinson's disease (interaction with coffee consumption) WWP1 intron 21876681 rs10102229 chr8 87557789 C T 5.00E-08 Parkinson's disease (interaction with coffee consumption) CPNE3 intron 21876681 rs10504825 chr8 87567848 A C 4.77E-04 Alzheimer's disease CPNE3 intron 22005930 rs10504825 chr8 87567848 A C 3.01E-04 Lung function (forced vital capacity) CPNE3 intron 24023788 rs1044730 chr8 87573120 C T 9.85E-04 Suicide attempts in bipolar disorder CPNE3 UTR-3 21423239 rs4961199 chr8 87580944 G A 1.26E-05 Prostate cancer / / 18264096 rs3735972 chr8 87588198 T C 6.59E-05 Orofacial clefts CNGB3 missense 22419666 rs3735972 chr8 87588198 T C 0.0008169 Hypertension (early onset hypertension) CNGB3 missense 22479346 rs958401 chr8 87591778 G T 0.0008169 Hypertension (early onset hypertension) CNGB3 intron 22479346 rs1992405 chr8 87605131 T A,C,G 8.47E-05 Alcohol and nictotine co-dependence CNGB3 intron 20158304 rs7012943 chr8 87606048 T G 1.11E-04 Aortic root size CNGB3 intron 21223598 rs9297935 chr8 87617188 T C 4.95E-05 Type 2 diabetes CNGB3 intron 17463246 rs9297935 chr8 87617188 T C 1.47E-05 Serum metabolites CNGB3 intron 19043545 rs16916102 chr8 87617600 G A 5.27E-06 Coronary Artery Disease CNGB3 intron 17634449 rs3779804 chr8 87623585 C T 6.87E-04 Aortic root size CNGB3 intron 21223598 rs2362267 chr8 87626463 G A,C,T 5.75E-05 Alcohol and nictotine co-dependence CNGB3 intron 20158304 rs6991672 chr8 87652115 C T 4.17E-04 Schizophrenia CNGB3 intron 19197363 rs4960986 chr8 87677217 G A 2.90E-05 Urinary metabolites CNGB3 intron 21572414 rs6471482 chr8 87679303 A C 3.57E-05 Heart Failure CNGB3 missense pha002885 rs1372173 chr8 87684674 A G 3.00E-05 Heart Failure CNGB3 intron pha002885 rs10504826 chr8 87690019 A G 0.0000749 Tuberculosis with early age of onset CNGB3 intron 22551897 rs7814749 chr8 87721349 A G 2.00E-05 Urinary metabolites CNGB3 intron 21572414 rs4961216 chr8 87761007 A C 2.80E-05 Alcoholism (heaviness of drinking) / / 21529783 rs6995498 chr8 87785997 T C 5.97E-04 Type 2 diabetes / / 17463246 rs28415886 chr8 87789846 C T 5.13E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17620495 chr8 87799007 A G 1.86E-05 Rheumatoid arthritis / / 21452313 rs16917773 chr8 87805634 G A 1.39E-04 Type 2 diabetes / / 17463246 rs7834685 chr8 87806604 A C 7.19E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7834685 chr8 87806604 A C 3.86E-06 Rheumatoid arthritis / / 21452313 rs17693567 chr8 87813527 A G 1.29E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs7018237 chr8 87813597 T C 2.18E-05 Rheumatoid arthritis / / 21452313 rs10808349 chr8 87833711 A G 1.08E-05 Rheumatoid arthritis / / 21452313 rs10808349 chr8 87833711 A G 0.000696207 Hypertension (early onset hypertension) / / 22479346 rs2199022 chr8 87842077 A C 9.80E-06 Rheumatoid arthritis / / 21452313 rs2199022 chr8 87842077 A C 0.000696207 Hypertension (early onset hypertension) / / 22479346 rs7846655 chr8 87844003 A G 3.73E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4320564 chr8 87853542 G A 1.04E-05 Rheumatoid arthritis / / 21452313 rs4320564 chr8 87853542 G A 0.000667527 Hypertension (early onset hypertension) / / 22479346 rs1841019 chr8 87854415 G T 1.00E-04 Gallstones / / 17632509 rs10955074 chr8 87856462 C T 9.48E-06 Rheumatoid arthritis / / 21452313 rs10955074 chr8 87856462 C T 0.000478076 Hypertension (early onset hypertension) / / 22479346 rs10955074 chr8 87856462 C T 9.60E-04 Pulmonary function / / 23932459 rs13438948 chr8 87858778 G A 0.0000119 Otitis media (children 3 years old or younger) / / 23133572 rs12675797 chr8 87861178 T G 5.61E-05 Rheumatoid arthritis / / 21452313 rs1471160 chr8 87863824 T C 5.83E-05 Rheumatoid arthritis / / 21452313 rs41486944 chr8 87864480 A G 7.49E-23 Narcolepsy / / 19629137 rs2045506 chr8 87867347 G A 1.58E-04 Rheumatoid arthritis / / 21452313 rs2453436 chr8 87881874 A G 0.000440075 Hypertension (early onset hypertension) CNBD1 intron 22479346 rs12543040 chr8 87892533 C A 6.80E-05 Serum metabolites CNBD1 intron 19043545 rs7827816 chr8 87914176 C A 5.81E-04 Response to TNF antagonist treatment CNBD1 intron 21061259 rs16894901 chr8 87917355 C A 4.20E-24 Health and aging,CVD and cancer age of onset CNBD1 missense 22174011 rs16894901 chr8 87917355 C A 4.30E-08 Health and aging,CVD and cancer age of onset CNBD1 missense 22174011 rs16894901 chr8 87917355 C A 9.20E-25 Health and aging,CVD and cancer age of onset CNBD1 missense 22174011 rs7825717 chr8 87925926 C A 1.30E-06 Multiple complex diseases CNBD1 intron 17554300 rs4526378 chr8 87934432 G T 4.66E-04 Alcohol dependence CNBD1 intron 21314694 rs7461192 chr8 87980088 C T 9.56E-04 Multiple complex diseases CNBD1 intron 17554300 rs1852027 chr8 88007114 A G 7.60E-05 Type 2 diabetes CNBD1 intron 17463248 rs6468613 chr8 88009165 G T 4.95E-05 Endometrial cancer CNBD1 intron 24096698 rs6468613 chr8 88009165 G T 6.19E-04 Endometrial cancer CNBD1 intron 24096698 rs1880473 chr8 88010106 C A 2.88E-04 Suicide attempts in bipolar disorder CNBD1 intron 21423239 rs4368998 chr8 88011025 G C 3.04E-04 Suicide attempts in bipolar disorder CNBD1 intron 21423239 rs2462517 chr8 88028750 T C 3.37E-04 Suicide attempts in bipolar disorder CNBD1 intron 21423239 rs7012451 chr8 88047579 C T 9.82E-04 Suicide attempts in bipolar disorder CNBD1 intron 21423239 rs2943177 chr8 88052397 T C 9.96E-04 Suicide attempts in bipolar disorder CNBD1 intron 21423239 rs2336871 chr8 88055826 T A 9.71E-04 Suicide attempts in bipolar disorder CNBD1 intron 21423239 rs719779 chr8 88125718 T C 7.92E-04 Alcohol dependence CNBD1 intron 20201924 rs13260751 chr8 88255320 C A 2.00E-04 Cognitive impairment induced by topiramate CNBD1 intron 22091778 rs2336981 chr8 88255964 G A 5.01E-05 Alcohol dependence CNBD1 intron 20201924 rs2336981 chr8 88255964 G A 5.01E-05 Alcoholism CNBD1 intron pha002891 rs7833568 chr8 88261791 T C 3.55E-05 Alcohol dependence CNBD1 intron 20201924 rs7833568 chr8 88261791 T C 3.55E-05 Alcoholism CNBD1 intron pha002891 rs10216557 chr8 88277833 G A 2.42E-05 Cognitive impairment induced by topiramate CNBD1 intron 22091778 rs10216557 chr8 88277833 G A 7.84E-05 Cognitive impairment induced by topiramate CNBD1 intron 22091778 rs11777136 chr8 88284636 T G 3.10E-06 Urinary metabolites CNBD1 intron 21572414 rs7844269 chr8 88285165 A G 3.70E-06 Urinary metabolites CNBD1 intron 21572414 rs7826953 chr8 88285385 C T 2.50E-06 Urinary metabolites CNBD1 intron 21572414 rs7845383 chr8 88289450 G T 8.93E-04 Suicide attempts in bipolar disorder CNBD1 intron 21423239 rs7835052 chr8 88290593 A G 9.43E-04 Suicide attempts in bipolar disorder CNBD1 intron 21423239 rs7816463 chr8 88290821 G A 4.20E-06 Urinary metabolites CNBD1 intron 21572414 rs7820165 chr8 88290994 G A 3.70E-06 Urinary metabolites CNBD1 intron 21572414 rs16898282 chr8 88292359 C A 4.70E-06 Urinary metabolites CNBD1 intron 21572414 rs4302859 chr8 88295982 A G 3.70E-06 Urinary metabolites CNBD1 intron 21572414 rs13439527 chr8 88296344 A G 1.60E-06 Urinary metabolites CNBD1 intron 21572414 rs13439583 chr8 88296639 T A 3.70E-06 Urinary metabolites CNBD1 intron 21572414 rs11783918 chr8 88297657 A G 4.30E-06 Urinary metabolites CNBD1 intron 21572414 rs6468774 chr8 88350109 T G 8.85E-04 Multiple complex diseases CNBD1 intron 17554300 rs10109797 chr8 88352744 T C 1.70E-05 Urinary metabolites CNBD1 intron 21572414 rs6468777 chr8 88353988 G A 3.20E-06 Urinary metabolites CNBD1 intron 21572414 rs10094122 chr8 88356270 A C 7.79E-04 Amyotrophic lateral sclerosis (sporadic) CNBD1 intron 24529757 rs10504830 chr8 88379205 A G 1.10E-04 Neuroticism CNBD1 intron 17667963 rs7017661 chr8 88379475 C G 2.30E-06 Urinary metabolites CNBD1 intron 21572414 rs4344102 chr8 88387183 G A 1.00E-04 Cognitive impairment induced by topiramate CNBD1 intron 22091778 rs4344102 chr8 88387183 G A 8.89E-05 Cognitive impairment induced by topiramate CNBD1 intron 22091778 rs10955278 chr8 88411745 G T 1.10E-05 Urinary metabolites / / 21572414 rs4961033 chr8 88414581 A G 6.45E-05 Body Composition / / pha003012 rs6985617 chr8 88416318 T G 6.45E-05 Body Composition / / pha003012 rs4130030 chr8 88420387 G C 2.00E-05 Urinary metabolites / / 21572414 rs10112865 chr8 88440271 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs13266973 chr8 88444701 G T 6.16E-05 Body Composition / / pha003012 rs13266973 chr8 88444701 G T 9.92E-05 Body Mass Index / / pha003021 rs405999 chr8 88447171 G A 2.00E-04 Height / / 17255346 rs7007973 chr8 88451088 A G 1.10E-05 Urinary metabolites / / 21572414 rs2977766 chr8 88469794 G A 1.49E-04 Type 2 diabetes / / 22158537 rs2977764 chr8 88472362 C T 9.92E-04 Type 2 diabetes / / 22158537 rs726366 chr8 88480013 T C 1.21E-04 Type 2 diabetes / / 22158537 rs428838 chr8 88480902 T C 2.70E-04 Alcohol dependence / / 20201924 rs428838 chr8 88480902 T C 6.60E-04 Alcohol dependence / / 20201924 rs2905414 chr8 88481828 A G 1.22E-04 Type 2 diabetes / / 22158537 rs1160280 chr8 88484882 C T 1.26E-04 Type 2 diabetes / / 22158537 rs1160279 chr8 88485142 A G 1.47E-04 Type 2 diabetes / / 22158537 rs2977031 chr8 88485560 T C 1.57E-04 Type 2 diabetes / / 22158537 rs2905413 chr8 88485683 A G 2.60E-04 Type 2 diabetes / / 22158537 rs2905412 chr8 88485705 A G 1.48E-04 Type 2 diabetes / / 22158537 rs2977761 chr8 88485717 T C 1.82E-04 Type 2 diabetes / / 22158537 rs2977760 chr8 88485910 C A 1.58E-04 Type 2 diabetes / / 22158537 rs1468174 chr8 88500831 T C 4.64E-05 Type 2 diabetes / / 22158537 rs4445240 chr8 88500881 G T 5.93E-06 Liver disease in chronic hepatitis B virus infection / / 24065354 rs375734 chr8 88501864 T C 6.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17634200 chr8 88515868 G C 5.03E-05 Type 2 diabetes / / 22158537 rs2188748 chr8 88519621 T C 4.41E-05 Type 2 diabetes / / 22158537 rs7832480 chr8 88538005 A G 4.43E-05 Type 2 diabetes / / 22158537 rs10087353 chr8 88541079 C T 1.96E-05 Type 2 diabetes / / 22158537 rs10086700 chr8 88541187 G A 1.59E-05 Type 2 diabetes / / 22158537 rs10504835 chr8 88547780 A G 3.01E-05 Type 2 diabetes / / 22158537 rs10282790 chr8 88549327 T G 8.49E-06 Type 2 diabetes / / 22158537 rs4339661 chr8 88550263 G A 2.47E-05 Type 2 diabetes / / 22158537 rs17635091 chr8 88558575 A G 5.35E-05 Type 2 diabetes / / 22158537 rs17635207 chr8 88559023 C A 1.33E-04 Type 2 diabetes / / 22158537 rs12375279 chr8 88561866 G A,C 2.22E-05 Type 2 diabetes / / 22158537 rs12156259 chr8 88564667 A T 2.43E-05 Type 2 diabetes / / 22158537 rs2056863 chr8 88573498 A C 1.49E-04 Type 2 diabetes / / 22158537 rs17635336 chr8 88576267 T G 3.11E-04 Type 2 diabetes / / 22158537 rs741868 chr8 88578142 T C 2.26E-05 Type 2 diabetes / / 22158537 rs17635428 chr8 88578255 G A 9.37E-06 Hearing function / / 21493956 rs17635695 chr8 88591883 C T 1.13E-04 Type 2 diabetes / / 22158537 rs10504836 chr8 88600593 A C 1.72E-05 Pulmonary function / / 17903307 rs1569332 chr8 88634705 G A 1.73E-04 Nicotine dependence / / 17158188 rs11774111 chr8 88707191 T C 1.70E-05 Urinary metabolites / / 21572414 rs7013934 chr8 88790626 C T 3.12E-05 Cleft lip / / 20436469 rs2240458 chr8 88801153 C T 9.22E-06 Duodenal ulcer / / 22387998 rs7819401 chr8 88831715 A G 7.28E-06 Cleft lip / / 20436469 rs7819401 chr8 88831715 A G 7.45E-06 Orofacial clefts / / 22863734 rs12543318 chr8 88868340 C A 5.17E-07 Cleft lip / / 20436469 rs12543318 chr8 88868340 C A 2.00E-08 Orofacial clefts / / 22863734 rs10429299 chr8 88881431 T C 2.10E-06 Urinary metabolites / / 21572414 rs1911665 chr8 88896480 G A 3.39E-04 Orofacial clefts / / 22863734 rs11786656 chr8 88904358 C T 1.13E-05 Orofacial clefts / / 22863734 rs1034832 chr8 88918331 T G 4.89E-05 Orofacial clefts / / 22863734 rs16875013 chr8 88925380 A C 5.81E-04 Multiple complex diseases / / 17554300 rs7839686 chr8 88925728 C T 5.52E-04 Orofacial clefts / / 22863734 rs10091380 chr8 88932269 T A 1.00E-04 Prostate cancer / / 21743057 rs10088179 chr8 88948825 G A 1.00E-04 Prostate cancer / / 21743057 rs6469114 chr8 88949742 T C 1.00E-04 Orofacial clefts / / 22863734 rs2337160 chr8 88962066 C T 1.39E-04 Orofacial clefts / / 22863734 rs16875583 chr8 88962865 T C 1.00E-04 Prostate cancer / / 21743057 rs4400429 chr8 88970682 A G 3.75E-04 Orofacial clefts / / 22863734 rs278897 chr8 88975898 A G 1.00E-04 Prostate cancer / / 21743057 rs13268358 chr8 88976786 G T 1.00E-05 Urinary metabolites / / 21572414 rs1477915 chr8 88981540 A G 7.15E-05 Orofacial clefts / / 22863734 rs6995841 chr8 88983236 T C 6.46E-04 Orofacial clefts / / 22863734 rs17718458 chr8 88994530 T A 1.95E-04 Insulin resistance / / 21901158 rs10106275 chr8 89046119 G A 6.76E-05 Insulin resistance / / 21901158 rs6469206 chr8 89084691 T G 0.000165258 Hypertension (early onset hypertension) MMP16 intron 22479346 rs17663841 chr8 89091272 T C 1.94E-04 Type 2 diabetes MMP16 intron 17463246 rs17720271 chr8 89091412 C A 3.91E-04 Type 2 diabetes MMP16 intron 17463246 rs2664352 chr8 89093298 T C 3.83E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MMP16 intron 22566498 rs13277637 chr8 89105496 C T 3.48E-05 Cognitive test performance MMP16 intron 20125193 rs16878625 chr8 89125990 T C 5.79E-05 Aging (time to event) MMP16 intron 21782286 rs12334533 chr8 89169780 C T 8.51E-06 Rheumatoid arthritis MMP16 intron 19503088 rs2139481 chr8 89207580 T A 0.0003728 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MMP16 intron 23233654 rs2139481 chr8 89207580 T A 3.73E-04 Methotrexate clearance (acute lymphoblastic leukemia) MMP16 intron 23233662 rs17666351 chr8 89224646 A G 9.45E-05 Orofacial clefts MMP16 intron 22419666 rs16880086 chr8 89245613 C G 0.0007545 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MMP16 intron 23233654 rs16880086 chr8 89245613 C G 7.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) MMP16 intron 23233662 rs6994019 chr8 89268543 T G 3.79E-04 Type 2 diabetes MMP16 intron 17846125 rs6994019 chr8 89268543 T G 2.71E-04 Breast cancer MMP16 intron 20852631 rs6994019 chr8 89268543 T G 1.70E-07 Schizophrenia MMP16 intron 21791550 rs6994019 chr8 89268543 T G 0.00001 Psychosis MMP16 intron 23164818 rs1879203 chr8 89298199 C T 6.05E-05 Cognitive performance MMP16 intron 19734545 rs7834743 chr8 89311785 A G 3.68E-04 Response to taxane treatment (placlitaxel) MMP16 intron 23006423 rs12114851 chr8 89332979 C T 0.00000193 HDL cholesterol MMP16 intron 23063622 rs16881203 chr8 89343458 G T 2.90E-04 Coronary heart disease / / 21966275 rs7004601 chr8 89371594 A C 8.14E-04 Type 2 diabetes / / 17463246 rs1463922 chr8 89391509 T C 3.90E-05 Response to statin therapy / / 20339536 rs10504842 chr8 89415202 A G 9.41E-04 Type 2 diabetes / / 17463246 rs9297469 chr8 89431787 G A,C,T 8.28E-04 Multiple complex diseases / / 17554300 rs16883010 chr8 89460453 T C 8.97E-04 Multiple complex diseases / / 17554300 rs7834603 chr8 89534091 T C 6.03E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10504861 chr8 89547932 C T 1.00E-08 Migraine without aura / / 23793025 rs12549036 chr8 89577074 G A 5.98E-04 Multiple complex diseases / / 17554300 rs7838490 chr8 89585048 G A 6.00E-08 Body mass index and cholesterol (psychopharmacological treatment) / / 22417934 rs11995572 chr8 89592083 G T 3.00E-08 Schizophrenia / / 23974872 rs13274015 chr8 89600751 T C 1.50E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4269585 chr8 89608690 T C 9.28E-04 Type 2 diabetes / / 17463246 rs7833665 chr8 89721771 C T 6.27E-04 Type 2 diabetes / / 17463246 rs7004633 chr8 89760311 A G 2.00E-07 Schizophrenia / / 21926974 rs7004633 chr8 89760311 A G 6.00E-08 Schizophrenia / / 22688191 rs7004633 chr8 89760311 A G 3.00E-08 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs7004633 chr8 89760311 A G 0.00000017 Schizophrenia / / 23637625 rs6990979 chr8 89779302 G A 8.29E-05 Body mass (lean) / / 19268274 rs1391627 chr8 89790979 G A 5.89E-05 Kawasaki disease / / 22446961 rs1498539 chr8 89843820 G A 2.21E-05 Kawasaki disease / / 22446961 rs2454333 chr8 89892646 C T 5.70E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10429371 chr8 89993488 C T 3.00E-06 Smooth-surface caries / / 23470693 rs1487792 chr8 89994834 G A 1.90E-05 Urinary metabolites / / 21572414 rs1240138 chr8 90018152 G A 7.71E-04 Type 2 diabetes / / 17463246 rs7014732 chr8 90020164 T C 5.29E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17678109 chr8 90028155 A C 1.94E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs13282617 chr8 90029977 C G 1.72E-04 Coronary heart disease / / 21606135 rs2007900 chr8 90030332 T C 7.00E-06 Urinary metabolites / / 21572414 rs1240117 chr8 90047427 C G 2.90E-05 Serum metabolites / / 19043545 rs16890421 chr8 90055044 C T 7.01E-05 Serum metabolites / / 19043545 rs1240034 chr8 90091570 T C 9.98E-05 Relative hand skill in reading disability / / 24068947 rs1681444 chr8 90094210 C T 5.80E-06 Urinary metabolites / / 21572414 rs1681444 chr8 90094210 C T 9.16E-05 Relative hand skill in reading disability / / 24068947 rs1681437 chr8 90095123 T C 5.80E-06 Urinary metabolites / / 21572414 rs1681437 chr8 90095123 T C 5.14E-05 Relative hand skill in reading disability / / 24068947 rs1240087 chr8 90113946 A G 5.90E-06 Urinary metabolites / / 21572414 rs1483359 chr8 90137645 A G 6.50E-06 Urinary metabolites / / 21572414 rs7014508 chr8 90137908 T C 6.90E-06 Urinary metabolites / / 21572414 rs11776005 chr8 90187417 G A 1.59E-12 Multiple complex diseases / / 17554300 rs318321 chr8 90202984 T A 0.000218 Salmonella-induced pyroptosis / / 22837397 rs11780756 chr8 90205333 T A 2.02E-07 Red blood cell traits / / 23222517 rs318249 chr8 90206309 G A 8.51E-04 Type 2 diabetes / / 17463246 rs2046315 chr8 90211100 A G 3.00E-06 Dental caries / / 23259602 rs2046315 chr8 90211100 A G 7.00E-07 Pit-and-Fissure caries / / 23470693 rs2046315 chr8 90211100 A G 8.00E-08 Smooth-surface caries / / 23470693 rs1483370 chr8 90220717 C T 3.16E-04 Type 2 diabetes / / 17463246 rs7833317 chr8 90275942 C T 7.80E-04 Multiple complex diseases / / 17554300 rs989108 chr8 90281984 C T 1.53E-39 Metabolite levels / / 22286219 rs4568650 chr8 90331084 A C 4.52E-06 Testicular cancer / / 21551455 rs4397449 chr8 90342186 A G 3.00E-06 Cognitive performance / / 20125193 rs9297680 chr8 90597465 A G 0.000696139 Hypertension (early onset hypertension) / / 22479346 rs11780016 chr8 90601100 A G 6.09E-05 Alcohol dependence / / 19581569 rs311637 chr8 90603625 T C 0.000503042 Hypertension (early onset hypertension) / / 22479346 rs311636 chr8 90605197 A G 3.18E-05 Brain structure / / 22504417 rs10808529 chr8 90605445 C G 5.33E-04 Multiple complex diseases / / 17554300 rs7835902 chr8 90608086 T G 1.70E-05 Urinary metabolites / / 21572414 rs160414 chr8 90637625 T C 3.42E-04 Premature ovarian failure / / 19508998 rs160410 chr8 90648728 A G 7.42E-04 Multiple complex diseases / / 17554300 rs160441 chr8 90656988 T C 8.00E-06 Tuberculosis / / 20694014 rs160447 chr8 90659660 A G 5.24E-04 Multiple complex diseases / / 17554300 rs10956191 chr8 90670102 G C 5.87E-04 Multiple complex diseases / / 17554300 rs6981616 chr8 90708428 C T 1.57E-04 Glycosylated haemoglobin levels / / 17255346 rs34827646 chr8 90731683 C CA 3.40E-05 Urinary metabolites / / 21572414 rs218904 chr8 90734506 C T 3.27E-04 Multiple complex diseases / / 17554300 rs13262484 chr8 90774723 A G 6.30E-06 Personality dimensions RIPK2 intron 21173776 rs42490 chr8 90778513 G A 1.00E-16 Leprosy RIPK2 intron 20018961 rs42490 chr8 90778513 G A 1.01E-07 Leprosy RIPK2 intron 22019778 rs10097279 chr8 90795768 G A 7.47E-05 Major depressive disorder RIPK2 intron 21621269 rs416324 chr8 90815235 G A 5.86E-04 Multiple complex diseases / / 17554300 rs39767 chr8 90819998 A G 2.50E-05 Multiple sclerosis / / 19525955 rs40457 chr8 90823687 A G 1.00E-12 Leprosy / / 20018961 rs432457 chr8 90865908 A G 1.84E-04 Type 2 diabetes / / 17463246 rs7015630 chr8 90875918 T C 1.00E-08 Crohn's disease / / 23128233 rs10504885 chr8 90951053 C A 8.35E-05 HIV-1 viral setpoint NBN intron 21490045 rs16893166 chr8 90952245 G A 8.49E-05 Birth weight NBN intron 17255346 rs10109454 chr8 90961512 T C 6.38E-04 Alzheimer's disease NBN intron 17998437 rs2073635 chr8 90995366 C T 5.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NBN intron 20877124 rs16902273 chr8 91018507 T A 8.47E-07 Schizophrenia DECR1 intron 21926974 rs1805884 chr8 91033746 A G 5.11E-05 Bipolar disorder and schizophrenia DECR1 intron 20889312 rs1805885 chr8 91041294 T A 3.43E-04 Birth weight DECR1 intron 17255346 rs1805888 chr8 91042703 T G 2.55E-04 Birth weight DECR1 intron 17255346 rs7844005 chr8 91044281 G A 1.54E-04 Birth weight DECR1 intron 17255346 rs1805901 chr8 91077016 C G 3.11E-04 Height CALB1 intron 17255346 rs6988013 chr8 91111193 G T 4.17E-04 Lymphocyte counts / / 22286170 rs10106310 chr8 91175874 C T 0.000057 Oxaliplatin induced haematologic in response to colorectal cancer treatment / / 22310351 rs16904018 chr8 91179126 A C 1.45E-04 Multiple complex diseases / / 17554300 rs988851 chr8 91182886 C A 2.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10956500 chr8 91186718 C T 5.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7010298 chr8 91208807 C T 6.40E-04 Type 2 diabetes / / 17463246 rs7831194 chr8 91209703 T A 3.23E-04 Type 2 diabetes / / 17463246 rs4577996 chr8 91235335 T C 6.85E-04 Type 2 diabetes / / 17463246 rs10111402 chr8 91235642 C A 7.26E-04 Type 2 diabetes / / 17463246 rs16904193 chr8 91258298 A C 8.44E-05 Type 2 diabetes / / 17463246 rs16904193 chr8 91258298 A C 9.40E-06 Urinary metabolites / / 21572414 rs9297813 chr8 91258647 C T 9.53E-04 Type 2 diabetes / / 17463246 rs16904195 chr8 91258967 A G 3.82E-05 Type 2 diabetes / / 17463246 rs16904195 chr8 91258967 A G 1.70E-05 Urinary metabolites / / 21572414 rs4735301 chr8 91288667 A G 2.28E-04 Alcohol dependence / / 24277619 rs10956586 chr8 91334498 G T 4.90E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10956588 chr8 91336731 T C 3.27E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10956590 chr8 91336887 G A 6.50E-05 Parkinson's disease (familial) / / 18985386 rs4560835 chr8 91357862 G A 3.82E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10956649 chr8 91431075 G A 9.82E-04 Type 2 diabetes / / 17463246 rs734546 chr8 91433947 C T 7.20E-04 Type 2 diabetes / / 17463246 rs2205156 chr8 91440226 T C 5.70E-06 Malaria / / 19465909 rs7002775 chr8 91476765 A G 1.00E-05 Urinary metabolites / / 21572414 rs7017295 chr8 91482356 A G 1.60E-05 Urinary metabolites / / 21572414 rs2205152 chr8 91483618 T C 1.20E-05 Urinary metabolites / / 21572414 rs2285232 chr8 91546162 C G 5.34E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs1858673 chr8 91551526 C A 5.56E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs756568 chr8 91557038 G C 6.20E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs10086462 chr8 91558089 A G 6.37E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs10091275 chr8 91559751 A G 9.42E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs7840846 chr8 91565501 T A 6.11E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs7819519 chr8 91565504 C T 2.55E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs4735224 chr8 91567046 C A 2.53E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs7833025 chr8 91568470 G C 5.95E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs4734246 chr8 91569028 A C 3.98E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs4735225 chr8 91569100 G C 6.51E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs4734247 chr8 91569144 A G 2.52E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs4735226 chr8 91569238 T A 4.42E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs10808615 chr8 91569704 A T 6.11E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs1018836 chr8 91570362 A G 2.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs4735230 chr8 91574184 G C 6.15E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs10956720 chr8 91576222 C T 5.55E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs7823461 chr8 91581075 T C 5.29E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs5005585 chr8 91581975 A G 2.50E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs2023625 chr8 91619162 A G 7.50E-05 Diabetic retinopathy / / 21441570 rs2740791 chr8 91938917 T G 1.46E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) NECAB1 intron 24192120 rs2740791 chr8 91938917 T G 8.17E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) NECAB1 intron 24192120 rs11989738 chr8 91954454 C A 8.57E-04 Type 2 diabetes NECAB1 intron 17463246 rs11989738 chr8 91954454 C A 2.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NECAB1 intron 20877124 rs10490979 chr8 91964558 G A 2.03E-04 Type 2 diabetes NECAB1 intron 17463246 rs73694351 chr8 92008044 C A 0.00053 Prostate cancer TMEM55A missense 23555315 rs7846412 chr8 92044528 A G 5.12E-08 Parkinson's disease TMEM55A intron 17052657 rs4549728 chr8 92046783 T C 3.00E-06 Urinary metabolites TMEM55A intron 21572414 rs4493873 chr8 92075643 A C 5.00E-06 Migraine - clinic-based / / 23793025 rs4373488 chr8 92078257 A C 5.90E-07 Urinary metabolites LOC100506365 intron 21572414 rs4501550 chr8 92088212 A G 2.80E-05 Urinary metabolites OTUD6B intron 21572414 rs9918929 chr8 92091710 C T 2.50E-07 Urinary metabolites OTUD6B intron 21572414 rs10956792 chr8 92109738 A T 1.10E-06 Urinary metabolites / / 21572414 rs3885969 chr8 92127463 C T 9.70E-07 Urinary metabolites LRRC69 intron 21572414 rs10956794 chr8 92128840 C T 2.10E-07 Urinary metabolites LRRC69 intron 21572414 rs4620242 chr8 92131089 A G 2.30E-07 Urinary metabolites LRRC69 intron 21572414 rs4577919 chr8 92140428 G A 1.70E-07 Urinary metabolites LRRC69 intron 21572414 rs12546650 chr8 92140589 G A 3.99E-04 Heart Failure LRRC69 intron pha002884 rs7009676 chr8 92149748 T G 2.61E-04 Response to cytidine analogues (gemcitabine) LRRC69 intron 24483146 rs4609161 chr8 92174115 G A 6.99E-04 Rheumatoid arthritis LRRC69 intron 21452313 rs4609161 chr8 92174115 G A 5.18E-06 Neuroblastoma LRRC69 intron pha002895 rs13254176 chr8 92175393 G A 2.40E-06 Gallstones LRRC69 intron 17632509 rs6471268 chr8 92179965 T C 3.10E-07 Urinary metabolites LRRC69 intron 21572414 rs7821050 chr8 92183567 C T 2.30E-05 Urinary metabolites LRRC69 intron 21572414 rs7821050 chr8 92183567 C T 8.48E-04 Lymphocyte counts LRRC69 intron 22286170 rs7823844 chr8 92183838 G A 1.80E-05 Urinary metabolites LRRC69 intron 21572414 rs4419777 chr8 92187013 C T 1.60E-07 Urinary metabolites LRRC69 intron 21572414 rs7010715 chr8 92187738 G A 1.40E-05 Urinary metabolites LRRC69 intron 21572414 rs10097502 chr8 92200002 G A 1.20E-05 Urinary metabolites LRRC69 intron 21572414 rs3923174 chr8 92203762 T C 9.38E-04 Heart Failure LRRC69 intron pha002884 rs7845508 chr8 92218776 C T 1.30E-05 Urinary metabolites LRRC69 intron 21572414 rs4515507 chr8 92226354 T G 8.00E-06 Urinary metabolites LRRC69 intron 21572414 rs11784415 chr8 92227075 A C 4.00E-06 Urinary metabolites LRRC69 intron 21572414 rs7832896 chr8 92227957 C T 9.50E-06 Urinary metabolites LRRC69 intron 21572414 rs4596614 chr8 92228517 G A 1.40E-07 Urinary metabolites LRRC69 intron 21572414 rs4501551 chr8 92240554 C G 6.70E-08 Urinary metabolites / / 21572414 rs4476968 chr8 92241460 G A 2.70E-06 Urinary metabolites / / 21572414 rs11779990 chr8 92247648 A T 4.10E-07 Urinary metabolites / / 21572414 rs7814787 chr8 92271863 C T 9.98E-04 Rheumatoid arthritis SLC26A7 intron 21452313 rs4734009 chr8 92301249 G A 4.32E-04 Multiple complex diseases SLC26A7 intron 17554300 rs921231 chr8 92360396 T C 2.20E-06 Subcutaneous adipose tissue volume in HIV-infected men SLC26A7 intron 21897333 rs921231 chr8 92360396 T C 9.80E-07 Subcutaneous adipose tissue volume in HIV-infected men SLC26A7 intron 21897333 rs10504904 chr8 92402207 A G 7.18E-05 Cognitive test performance SLC26A7 intron 20125193 rs16912805 chr8 92406021 C T 4.43E-05 Nephrolithiasis SLC26A7 intron 22396660 rs13267998 chr8 92417267 A G 7.80E-06 Subcutaneous adipose tissue volume in HIV-infected men / / 21897333 rs10504906 chr8 92418628 G A 7.50E-06 Subcutaneous adipose tissue volume in HIV-infected men / / 21897333 rs9643322 chr8 92464180 G A 4.26E-05 Serum metabolites / / 19043545 rs2657195 chr8 92559915 A G 8.00E-06 Disc degeneration (lumbar) / / 22993228 rs16914358 chr8 92580448 C A 1.53E-04 Multiple complex diseases / / 17554300 rs843092 chr8 92599661 T C 3.72E-04 White matter integrity / / 22425255 rs1014764 chr8 92619874 T C 3.31E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1014765 chr8 92620097 T C 4.49E-06 Multiple complex diseases / / 17554300 rs865214 chr8 92621938 G A 7.73E-04 White matter integrity / / 22425255 rs16914398 chr8 92622980 C A 7.50E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16914429 chr8 92629403 C T 7.00E-05 Cognitive function / / 24684796 rs16914442 chr8 92631969 T C 6.07E-04 Multiple complex diseases / / 17554300 rs4734739 chr8 92638248 A G 5.59E-04 Multiple complex diseases / / 17554300 rs4734739 chr8 92638248 A G 9.44E-05 Response to methylphenidate treatment / / 21130132 rs7819525 chr8 92669390 G T 3.62E-04 White matter integrity / / 22425255 rs7003371 chr8 92676942 C T 1.59E-04 Multiple complex diseases / / 17554300 rs12545507 chr8 92688278 T C 2.83E-04 White matter integrity / / 22425255 rs11991025 chr8 92688693 T C 2.03E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10104996 chr8 92696565 C A 8.60E-04 Multiple complex diseases / / 17554300 rs10104018 chr8 92725917 C T 5.33E-05 Multiple complex diseases / / 17554300 rs4310163 chr8 92733817 C A 9.29E-04 White matter integrity / / 22425255 rs17732285 chr8 92838980 C T 6.88E-05 Type 2 diabetes / / 17463246 rs1348403 chr8 92864072 T C 1.52E-04 Body mass index / / 21701565 rs1348403 chr8 92864072 T C 4.93E-04 Body mass index / / 21701565 rs6994274 chr8 92864224 G T 2.59E-04 Body mass index / / 21701565 rs6994274 chr8 92864224 G T 5.05E-04 Body mass index / / 21701565 rs1867307 chr8 92880676 T C 5.64E-04 Type 2 diabetes / / 17463246 rs1867307 chr8 92880676 T C 2.82E-04 Taste perception / / 22132133 rs10103191 chr8 92902432 G A 7.60E-06 Urinary metabolites / / 21572414 rs3936419 chr8 92909899 G A 2.14E-05 Psoriasis / / 20953190 rs1031115 chr8 92933613 A G 1.00E-05 Urinary metabolites / / 21572414 rs3863252 chr8 92941038 C T 7.12E-05 Cognitive test performance / / 20125193 rs2920468 chr8 92966495 C T 1.50E-06 Urinary metabolites / / 21572414 rs4500123 chr8 92970153 A G 1.39E-04 Epilepsy RUNX1T1 UTR-3 22116939 rs13252280 chr8 93088151 C T 3.30E-04 Response to cytidine analogues (gemcitabine) RUNX1T1 intron 24483146 rs7461004 chr8 93088828 T G 2.74E-04 Response to cytidine analogues (gemcitabine) RUNX1T1 intron 24483146 rs13273012 chr8 93092337 G A 4.86E-04 Response to cytidine analogues (gemcitabine) RUNX1T1 intron 24483146 rs1552314 chr8 93104805 G A 2.72E-04 Response to cytidine analogues (gemcitabine) RUNX1T1 intron 24483146 rs3857913 chr8 93183772 G A 5.57E-05 Coronary heart disease / / pha003056 rs3857915 chr8 93189631 G A 8.37E-05 Caffeine consumption / / 21490707 rs2120710 chr8 93210803 A G 3.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2046395 chr8 93213010 G A 3.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1373528 chr8 93214830 T C 5.33E-04 Multiple complex diseases / / 17554300 rs116951791 chr8 93219721 A G 7.00E-07 Bipolar disorder (body mass index interaction) / / 24322204 rs6471334 chr8 93226038 C T 8.04E-04 Parkinson's disease / / 16252231 rs4286925 chr8 93237876 A G 2.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1444492 chr8 93246084 A G 4.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6471335 chr8 93247362 G A 1.33E-04 Breast cancer / / pha002853 rs17748153 chr8 93284681 C T 3.19E-04 Schizophrenia / / 20832056 rs7014625 chr8 93293461 A G 1.86E-04 Alzheimer's disease / / 17998437 rs12544183 chr8 93298704 G T 8.50E-06 Osteoarthritis / / 22566624 rs10956832 chr8 93346831 T C 1.42E-04 Fibrinogen / / 17255346 rs10956832 chr8 93346831 T C 5.85E-04 Multiple complex diseases / / 17554300 rs1480895 chr8 93357620 A G 2.38E-05 Fibrinogen / / 17255346 rs1125730 chr8 93358204 C T 2.78E-04 Fibrinogen / / 17255346 rs1125729 chr8 93358410 T C 9.79E-05 Fibrinogen / / 17255346 rs1125729 chr8 93358410 T C 4.63E-04 Multiple complex diseases / / 17554300 rs10808648 chr8 93393331 A G 7.91E-05 Blood Pressure / / pha003043 rs12155836 chr8 93443393 A G 5.53E-05 Blood Pressure / / pha003043 rs2013056 chr8 93468175 T C 0.0000163 Carotid intima media thickness / / 23152477 rs551496 chr8 93486707 T C 4.05E-04 White matter integrity / / 22425255 rs532481 chr8 93512866 C T 4.40E-04 Multiple complex diseases / / 17554300 rs536161 chr8 93513027 A T 6.19E-04 Multiple complex diseases / / 17554300 rs10956850 chr8 93554257 C T 4.46E-04 IgE levels / / 17255346 rs2197890 chr8 93563752 T C 2.04E-04 Height / / 17255346 rs2256182 chr8 93568065 T C 6.00E-04 Alcohol dependence / / 20201924 rs12678829 chr8 93575293 T C 1.84E-04 IgE levels / / 17255346 rs1449247 chr8 93578304 T G 4.54E-04 IgE levels / / 17255346 rs1449246 chr8 93578333 T C 1.44E-04 Height / / 17255346 rs1839263 chr8 93582343 A G 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1449249 chr8 93597541 C T 8.91E-05 Major depressive disorder (broad) / / 20038947 rs1463186 chr8 93600470 T C 8.23E-05 Major depressive disorder (broad) / / 20038947 rs2256792 chr8 93656961 T G 1.91E-05 Hemoglobin / / pha003096 rs2256792 chr8 93656961 T G 4.86E-05 Hematocrit / / pha003097 rs2339658 chr8 93680269 G A 2.43E-05 Cognitive performance / / 19734545 rs397015 chr8 93965636 C G 0.0001767 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) C8orf83 intron 23233654 rs397015 chr8 93965636 C G 1.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) C8orf83 intron 23233662 rs279976 chr8 93973036 A T 0.0002716 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) C8orf83 intron 23233654 rs279976 chr8 93973036 A T 2.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) C8orf83 intron 23233662 rs16915399 chr8 93977436 T C 5.78E-04 Parkinson's disease C8orf83 intron 16252231 rs440973 chr8 93977796 A G 0.0003747 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) C8orf83 UTR-5 23233654 rs440973 chr8 93977796 A G 3.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) C8orf83 UTR-5 23233662 rs1875882 chr8 93996721 A G 1.54E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs279956 chr8 94022601 G C 0.0003882 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs279956 chr8 94022601 G C 3.88E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs279955 chr8 94023146 T C 0.0003577 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs279955 chr8 94023146 T C 3.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs279978 chr8 94032622 A G 0.0001716 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs279978 chr8 94032622 A G 1.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs279979 chr8 94032666 A G 0.0005163 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs279979 chr8 94032666 A G 5.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs279980 chr8 94033266 G C 0.0005903 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs279980 chr8 94033266 G C 5.90E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs378417 chr8 94034306 T G 0.0002833 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs378417 chr8 94034306 T G 2.83E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17689237 chr8 94036027 A G 1.52E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs279968 chr8 94060339 A C 1.18E-05 Interstitial lung disease / / 23583980 rs11990542 chr8 94079985 G A 2.63E-05 Alcohol consumption / / 23953852 rs1472747 chr8 94081031 A G 1.25E-05 Attention deficit hyperactivity disorder / / 20732625 rs16915515 chr8 94082827 A G 8.37E-06 Attention deficit hyperactivity disorder / / 20732625 rs1384769 chr8 94084336 G A 1.12E-05 Attention deficit hyperactivity disorder / / 20732625 rs1027730 chr8 94085539 G A 6.89E-06 Attention deficit hyperactivity disorder / / 20732625 rs1483453 chr8 94115528 A G 6.89E-05 Alcohol consumption / / 23953852 rs1483452 chr8 94121822 G A 6.28E-05 Elbow pain / / pha003008 rs11776167 chr8 94134191 C T 9.92E-06 Elbow pain / / pha003008 rs2036542 chr8 94135486 C T 1.07E-05 Elbow pain / / pha003008 rs1483460 chr8 94143207 C T 3.49E-05 Elbow pain / / pha003008 rs10504926 chr8 94152088 A G 3.49E-05 Elbow pain C8orf87 intron pha003008 rs11994496 chr8 94167808 T A 3.18E-05 Bipolar disorder and schizophrenia C8orf87 intron 20889312 rs278567 chr8 94169350 T C 8.00E-06 Bipolar disorder and schizophrenia C8orf87 intron 20889312 rs16915713 chr8 94190752 G A 2.09E-05 Bipolar disorder and schizophrenia / / 20889312 rs2197673 chr8 94192043 T A 4.21E-05 Bipolar disorder and schizophrenia / / 20889312 rs10504927 chr8 94193643 A T 4.93E-05 Bipolar disorder and schizophrenia / / 20889312 rs16915724 chr8 94194050 G A 2.14E-05 Bipolar disorder and schizophrenia / / 20889312 rs7845022 chr8 94218476 G A 5.63E-05 Body Mass Index / / pha003009 rs278541 chr8 94222945 C T 4.00E-08 IgG glycosylation / / 23382691 rs278559 chr8 94255270 C A 9.20E-04 Multiple complex diseases / / 17554300 rs203132 chr8 94257394 T G 2.12E-05 Coronary heart disease / / pha003030 rs278533 chr8 94258624 A G 1.58E-05 Waist Circumference / / pha003023 rs1550882 chr8 94305482 A G 7.34E-04 Multiple complex diseases / / 17554300 rs1447301 chr8 94323772 T G 6.07E-05 Waist Circumference / / pha003023 rs1447301 chr8 94323772 T G 9.73E-05 Glucose levels / / pha003058 rs368998 chr8 94327562 G T 3.00E-05 Waist Circumference / / pha003023 rs368998 chr8 94327562 G T 6.64E-05 Glucose levels / / pha003058 rs277781 chr8 94330970 C A 1.02E-05 Waist Circumference / / pha003023 rs277781 chr8 94330970 C A 4.05E-05 Glucose levels / / pha003058 rs372745 chr8 94350209 T C 9.02E-05 Waist Circumference / / pha003023 rs277778 chr8 94352802 A G 4.31E-05 Alcohol dependence / / 19581569 rs277777 chr8 94354185 C T 2.06E-04 Type 2 diabetes / / 17463246 rs7821394 chr8 94356019 G A 1.85E-04 Type 2 diabetes / / 17463246 rs7387468 chr8 94358098 G T 3.00E-06 Temperament / / 22832960 rs1431565 chr8 94367767 G A 5.08E-04 Type 2 diabetes LINC00535 intron 17463246 rs1367793 chr8 94370855 T C 3.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00535 intron 20877124 rs1367793 chr8 94370855 T C 9.02E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00535 intron 20877124 rs16915889 chr8 94375844 A G 7.53E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00535 intron 20877124 rs6996302 chr8 94377919 A G 9.33E-04 Type 2 diabetes LINC00535 intron 17463246 rs965549 chr8 94378703 G A 9.51E-04 Type 2 diabetes LINC00535 intron 17463246 rs4461874 chr8 94436541 C A 9.54E-04 Type 2 diabetes LINC00535 intron 17463246 rs7006045 chr8 94442727 T C 9.02E-04 Type 2 diabetes LINC00535 intron 17463246 rs6985330 chr8 94442973 G A 8.66E-04 Type 2 diabetes LINC00535 intron 17463246 rs1491946 chr8 94468311 T A 9.98E-04 Type 2 diabetes LINC00535 intron 17463246 rs1491947 chr8 94471469 T C 3.09E-04 Lung function (forced vital capacity) LINC00535 intron 24023788 rs1491947 chr8 94471469 T C 4.97E-05 Lung function (forced expiratory volume in 1 second) LINC00535 intron 24023788 rs1124697 chr8 94477479 T C 4.59E-07 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00535 intron 20877124 rs1124697 chr8 94477479 T C 9.12E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00535 intron 20877124 rs4735228 chr8 94513773 A T 5.90E-04 Type 2 diabetes LINC00535 intron 17463246 rs2914960 chr8 94690198 T G 1.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00535 intron 20877124 rs2914960 chr8 94690198 T G 8.34E-07 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00535 intron 20877124 rs2976347 chr8 94706439 A C 7.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00535 intron 20877124 rs2914944 chr8 94724043 A G 0.000747 Salmonella-induced pyroptosis FAM92A1 intron 22837397 rs2914941 chr8 94729211 C G 0.000606 Salmonella-induced pyroptosis FAM92A1 intron 22837397 rs2914940 chr8 94731826 T C 0.00046 Salmonella-induced pyroptosis FAM92A1 intron 22837397 rs36117362 chr8 94738629 G A 0.00012 Prostate cancer FAM92A1 missense 23555315 rs2914959 chr8 94739345 A G 0.0000606 Salmonella-induced pyroptosis FAM92A1 intron 22837397 rs11549490 chr8 94745050 T C 0.000647 Salmonella-induced pyroptosis RBM12B UTR-3 22837397 rs16916186 chr8 94745386 G T 0.000785 Salmonella-induced pyroptosis RBM12B UTR-3 22837397 rs16916191 chr8 94749565 C T 0.000615 Salmonella-induced pyroptosis RBM12B UTR-5 22837397 rs3813853 chr8 94752754 G A 0.000402 Salmonella-induced pyroptosis RBM12B intron 22837397 rs3134012 chr8 94755226 T C 2.18E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4282532 chr8 94892477 G T 5.66E-04 Type 2 diabetes / / 17463246 rs4735246 chr8 94895433 A G 3.86E-04 Type 2 diabetes / / 17463246 rs4735247 chr8 94895646 T G 4.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4735253 chr8 94903990 T A 1.90E-05 Heart rate / / 23583979 rs11995678 chr8 94904325 T C 3.39E-04 Type 2 diabetes / / 17463246 rs7813669 chr8 94905067 A G 5.23E-04 Type 2 diabetes / / 17463246 rs7813695 chr8 94905126 A C 5.58E-04 Type 2 diabetes / / 17463246 rs35820208 chr8 94916103 G A 3.00E-06 Response to amphetamines / / 22952603 rs3115904 chr8 94948595 A C 5.10E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3115913 chr8 94952580 G C 3.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs4735259 chr8 94953295 T C 4.89E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs755600 chr8 94974328 A G 7.21E-04 Type 2 diabetes / / 17463246 rs6989092 chr8 94989038 A C 2.63E-04 Multiple complex diseases / / 17554300 rs16916331 chr8 94992958 T G 4.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs62523048 chr8 95015990 C T 4.71E-05 Epilepsy (remission after treatment) / / 23962720 rs2978169 chr8 95023498 G A 5.17E-06 Multiple complex diseases / / 17554300 rs2978141 chr8 95047195 A G 3.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2978138 chr8 95050753 A G 4.53E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16916451 chr8 95086300 T C 0.000429 Salmonella-induced pyroptosis / / 22837397 rs2978133 chr8 95095163 T C 0.00032 Coronary artery calcification / / 23727086 rs2446834 chr8 95110924 T C 5.79E-05 Gallstones / / 17632509 rs4421324 chr8 95124056 A G 2.37E-06 Sickle cell anemia (severity) / / 20029952 rs745173 chr8 95125371 T G 2.20E-05 Urinary metabolites / / 21572414 rs10956902 chr8 95132887 C T 2.92E-04 Type 2 diabetes / / 17463246 rs6471432 chr8 95150036 A G 3.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDH17 intron 20877124 rs2514801 chr8 95159158 T C 4.95E-05 Type 2 diabetes CDH17 intron 17463246 rs4446705 chr8 95173672 T G 3.02E-06 Serum metabolites CDH17 intron 19043545 rs11776675 chr8 95176015 T C 2.70E-06 Asthma CDH17 intron 21907864 rs11776675 chr8 95176015 T C 1.82E-07 Esophageal cancer (squamous cell) CDH17 intron 22960999 rs11786144 chr8 95176118 C T 1.70E-05 Urinary metabolites CDH17 intron 21572414 rs10098593 chr8 95191507 G A 6.27E-04 Multiple complex diseases CDH17 intron 17554300 rs2613235 chr8 95193235 T A 0.0000655 Carotid intima media thickness CDH17 intron 23152477 rs2613221 chr8 95202353 A C 2.10E-05 Urinary metabolites CDH17 intron 21572414 rs978639 chr8 95226693 A T 2.80E-05 Urinary metabolites CDH17 intron 21572414 rs1531209 chr8 95237025 G C 1.40E-05 Urinary metabolites / / 21572414 rs2446852 chr8 95242693 G C 1.49E-05 Odorant perception / / 23910658 rs2607072 chr8 95255357 T C 3.54E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs930869 chr8 95259942 T C 3.62E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17036 chr8 95261955 T C 2.60E-05 Urinary metabolites GEM UTR-3 21572414 rs10111251 chr8 95488800 G T 1.90E-05 Urinary metabolites RAD54B nearGene-5 21572414 rs3102841 chr8 95519205 C A 1.00E-07 Smoking behavior KIAA1429 intron 20418888 rs12334990 chr8 95559186 T C 2.10E-05 Urinary metabolites KIAA1429 intron 21572414 rs12679345 chr8 95564533 A G 2.38E-05 Lymphocyte counts KIAA1429 intron 22286170 rs3133614 chr8 95621820 G C 6.18E-04 Lymphocyte counts / / 22286170 rs3133615 chr8 95621863 A T 3.58E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12543503 chr8 95811984 T C 6.50E-05 Lipid levels / / 18193043 rs12543525 chr8 95812058 T C 0.000215 Salmonella-induced pyroptosis / / 22837397 rs11786021 chr8 95820969 T C 6.01E-06 Personality dimensions / / 21173776 rs7845219 chr8 95937502 T C 0.0000046 Type 2 diabetes / / 22885922 rs7845219 chr8 95937502 T C 0.0000072 Type 2 diabetes (males) / / 22885922 rs7845219 chr8 95937502 T C 0.00018 Fasting blood glucose / / 22885922 rs7845219 chr8 95937502 T C 6.00E-08 Type 2 diabetes / / 24509480 rs1713669 chr8 95958637 C G 4.29E-05 Response to metformin TP53INP1 intron 21186350 rs896854 chr8 95960511 T C 4.33E-06 Cognitive test performance TP53INP1 intron 20125193 rs896854 chr8 95960511 T C 1.00E-09 Type 2 diabetes TP53INP1 intron 20581827 rs896854 chr8 95960511 T C 1.00E-09 Type 2 diabetes TP53INP1 intron 21647700 rs896854 chr8 95960511 T C 0.000014 Type 2 diabetes TP53INP1 intron 22885922 rs896854 chr8 95960511 T C 1.00E-09 Type 2 diabetes TP53INP1 intron 23300278 rs527234 chr8 95963798 C G 4.27E-05 Response to metformin / / 21186350 rs481887 chr8 95967838 A G 1.98E-05 Cognitive test performance / / 20125193 rs4735337 chr8 95973465 T C 1.35E-05 Cognitive test performance / / 20125193 rs16893776 chr8 95973604 C T 3.13E-04 Blood pressure / / 21909110 rs16917233 chr8 96044967 A C 1.57E-04 Systolic blood pressure C8orf38 intron 21909115 rs7818382 chr8 96054000 C T 8.00E-08 Alzheimer's disease (late onset) C8orf38 intron 24162737 rs9297952 chr8 96065878 G A 4.69E-04 Response to cytidine analogues (gemcitabine) C8orf38 intron 24483146 rs4641029 chr8 96085317 C T 8.76E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6471514 chr8 96100272 C T 9.45E-04 Multiple complex diseases / / 17554300 rs4590408 chr8 96106037 A G 6.00E-06 Metabolite levels (HVA-5-HIAA Factor score) / / 23319000 rs7833057 chr8 96115476 G A 6.20E-05 Waist-Hip Ratio / / pha003029 rs4392868 chr8 96120072 A G 8.00E-06 Radiation response / / 20923822 rs7000734 chr8 96127030 G A 4.00E-07 Radiation response / / 20923822 rs17668689 chr8 96185350 C T 9.85E-05 Attention deficit hyperactivity disorder / / pha002875 rs730820 chr8 96230428 G A 9.60E-05 Cholesterol / / 17255346 rs10096750 chr8 96247235 G C 8.64E-06 Body mass index / / 19557197 rs10956944 chr8 96282926 C T 9.08E-04 Multiple complex diseases LOC100616530 intron 17554300 rs13268795 chr8 96322185 G A 2.31E-04 Amyotrophic lateral sclerosis (sporadic) LOC100616530 intron 24529757 rs10956946 chr8 96331853 T C 6.27E-04 Smoking initiation LOC100616530 intron 24665060 rs17732201 chr8 96333993 A G 3.71E-04 Smoking initiation LOC100616530 intron 24665060 rs7842046 chr8 96356624 A C 8.50E-06 Urinary metabolites LOC100616530 intron 21572414 rs6996947 chr8 96357013 G T 1.40E-06 Urinary metabolites LOC100616530 intron 21572414 rs995939 chr8 96357975 G T 1.70E-06 Urinary metabolites LOC100616530 intron 21572414 rs200845336 chr8 96390839 T TG 1.55E-04 Heart Failure LOC100616530 intron pha002884 rs3103765 chr8 96390839 T G 1.55E-04 Heart Failure LOC100616530 intron pha002884 rs9297957 chr8 96393714 C G 4.55E-04 Body mass index LOC100616530 intron 17255346 rs16917517 chr8 96396070 T C 2.24E-04 Response to alcohol consumption (flushing response) LOC100616530 intron 24277619 rs6997004 chr8 96418497 A G 8.68E-04 Multiple complex diseases LOC100616530 intron 17554300 rs3133755 chr8 96444628 G A 4.23E-04 Body mass index LOC100616530 intron 21701565 rs10113800 chr8 96445002 G A 6.70E-04 Body mass index LOC100616530 intron 21701565 rs17746436 chr8 96453705 C T 8.17E-04 Response to taxane treatment (placlitaxel) LOC100616530 intron 23006423 rs7001207 chr8 96454743 A G 2.20E-04 Multiple complex diseases LOC100616530 intron 17554300 rs3104917 chr8 96468981 A G 2.52E-05 Schizophrenia LOC100616530 intron pha002857 rs1392795 chr8 96478763 C T 4.39E-04 Multiple complex diseases LOC100616530 intron 17554300 rs10504951 chr8 96483912 A G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) LOC100616530 intron 17982456 rs1500896 chr8 96486682 G A 4.60E-07 Chronic kidney disease LOC100616530 intron 22479191 rs77742018 chr8 96504472 A G 4.00E-06 Anorexia nervosa LOC100616530 intron 23568457 rs1909881 chr8 96515888 A G 7.00E-06 Obesity-related traits LOC100616530 intron 23251661 rs16917799 chr8 96518550 T C 9.12E-04 Multiple complex diseases LOC100616530 intron 17554300 rs3104891 chr8 96524316 T G 2.04E-05 Cognitive performance LOC100616530 intron 19734545 rs2221220 chr8 96533330 C A,G,T 8.12E-04 Aortic root size LOC100616530 intron 21223598 rs11776832 chr8 96536023 G A 5.63E-06 Substance dependence phenotypes LOC100616530 intron 24832863 rs11776832 chr8 96536023 G A 5.73E-04 Substance dependence phenotypes LOC100616530 intron 24832863 rs10808678 chr8 96551323 C T 2.32E-04 Taste perception LOC100616530 intron 22132133 rs4532570 chr8 96592937 A G 6.01E-04 Aortic root size LOC100616530 intron 21223598 rs3104964 chr8 96595736 G A 4.00E-06 Colorectal cancer LOC100616530 intron 23350875 rs3104961 chr8 96599566 C T 9.58E-06 Asthma LOC100616530 intron 21790008 rs7833855 chr8 96599781 G C 3.16E-04 Type 2 diabetes LOC100616530 intron 17463246 rs3134236 chr8 96609971 A G 9.58E-06 Asthma LOC100616530 intron 21790008 rs3134211 chr8 96625550 C T 9.58E-06 Asthma LOC100616530 intron 21790008 rs7011745 chr8 96632350 A G 2.12E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LOC100616530 intron 20031582 rs6471550 chr8 96645599 T C 9.33E-05 Serum metabolites LOC100616530 intron 19043545 rs1385237 chr8 96672404 G A 2.75E-04 Type 2 diabetes LOC100616530 intron 17463246 rs3134204 chr8 96694458 A G 4.83E-05 Longevity LOC100616530 intron 21612516 rs1484583 chr8 96698947 C A 3.74E-05 Longevity LOC100616530 intron 21612516 rs3102484 chr8 96705190 C T 9.20E-05 Longevity LOC100616530 intron 21612516 rs7836535 chr8 96705572 C T 2.63E-05 Cardiovascular disease LOC100616530 intron 17903304 rs4735382 chr8 96706331 T G 5.54E-04 Type 2 diabetes LOC100616530 intron 17463246 rs7012001 chr8 96723902 G A 8.36E-04 Heart Failure LOC100616530 intron pha002884 rs2016718 chr8 96744205 G A 2.20E-07 ECG dimensions,brachial artery endothelial function,treadmill exercise responses LOC100616530 intron 17903301 rs3102477 chr8 96746100 G T 8.28E-04 Multiple complex diseases LOC100616530 intron 17554300 rs6982567 chr8 96750281 C T 8.90E-05 Age-related macular degeneration LOC100616530 intron 20385819 rs6982567 chr8 96750281 C T 4.70E-04 Age-related macular degeneration LOC100616530 intron 21665990 rs6982567 chr8 96750281 C T 2.07E-05 Post-operative nausea and vomiting LOC100616530 intron 21694509 rs6982567 chr8 96750281 C T 2.33E-07 Age-related macular degeneration LOC100616530 intron pha002869 rs6982567 chr8 96750281 C T 2.80E-07 Age-related macular degeneration LOC100616530 intron pha002890 rs3134497 chr8 96751374 G T 5.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100616530 intron 20877124 rs3107060 chr8 96762545 T C 3.78E-05 Rheumatoid arthritis LOC100616530 intron 17804836 rs7817825 chr8 96764258 T G 8.13E-04 Iron levels LOC100616530 intron pha002876 rs12676394 chr8 96784526 C A 1.45E-04 Hemoglobin concentration LOC100616530 intron 20534544 rs12676394 chr8 96784526 C A 2.09E-04 Vaspin levels LOC100616530 intron 22907691 rs12676394 chr8 96784526 C A 0.000209 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks LOC100616530 intron 22907730 rs3102536 chr8 96784901 A G 3.80E-05 Primary sclerosing cholangitis LOC100616530 intron 19944697 rs10106907 chr8 96786148 C T 2.34E-05 Monocyte chemoattractant protein-1 LOC100616530 intron pha003071 rs3099105 chr8 96788760 T C 7.60E-05 Primary sclerosing cholangitis LOC100616530 intron 19944697 rs10086120 chr8 96791775 T C 4.02E-05 Monocyte chemoattractant protein-1 LOC100616530 intron pha003071 rs10109483 chr8 96792058 C T 1.00E-07 Parkinson's disease (interaction with coffee consumption) LOC100616530 intron 21876681 rs7009898 chr8 96819810 C G 5.43E-04 Alzheimer's disease LOC100616530 intron 24755620 rs568815 chr8 96835380 A C 1.90E-04 Major depressive disorder / / 21042317 rs492534 chr8 96849931 A G 0.000348 Sarcoidosis / / 22952805 rs6995659 chr8 96855764 T C 9.04E-06 Coronary heart disease / / 21971053 rs12681330 chr8 96863437 G A 1.92E-05 Monocyte chemoattractant protein-1 / / pha003071 rs980160 chr8 96893825 C T 7.65E-05 Birth weight / / 17255346 rs920200 chr8 96901876 T G 1.22E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs17767910 chr8 96907406 A G 5.11E-05 Serum metabolites / / 19043545 rs17767910 chr8 96907406 A G 5.74E-04 Bipolar disorder,schizoaffective / / 19567891 rs10504958 chr8 96959819 T C 2.08E-04 Multiple complex diseases / / 17554300 rs1155562 chr8 96972943 G C 8.02E-04 Multiple complex diseases / / 17554300 rs16894170 chr8 96996210 G A 9.37E-04 Multiple complex diseases / / 17554300 rs7001358 chr8 97018675 G A 0.000558 Salmonella-induced pyroptosis / / 22837397 rs514589 chr8 97067179 G A 2.16E-04 Multiple complex diseases / / 17554300 rs535343 chr8 97070673 G A 7.64E-05 Myocardial Infarction / / pha002873 rs580234 chr8 97081252 T C 7.55E-04 Multiple complex diseases / / 17554300 rs6994748 chr8 97095890 T A 3.67E-04 Coronary heart disease / / 21606135 rs16894295 chr8 97102896 G A 1.20E-04 Suicide attempts in bipolar disorder / / 21041247 rs542253 chr8 97108727 A G 1.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs546474 chr8 97112032 G A 1.13E-04 Suicide attempts in bipolar disorder / / 21041247 rs553892 chr8 97112826 A G 1.57E-04 Glycemic traits (pregnancy) / / 23903356 rs530696 chr8 97140193 T C 1.77E-05 Odorant perception / / 23910658 rs2514532 chr8 97175088 G T 4.30E-04 Smoking initiation / / 24665060 rs2245832 chr8 97181050 A G 8.37E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2245832 chr8 97181050 A G 7.61E-04 Smoking initiation / / 24665060 rs2466130 chr8 97182269 A G 3.23E-05 Progressive supranuclear palsy / / 21685912 rs10216734 chr8 97194671 T C 1.00E-04 Information processing speed / / 21130836 rs2440212 chr8 97201453 A G 6.47E-04 Type 2 diabetes / / 17463246 rs7827095 chr8 97239126 T C 1.57E-05 Lung function (forced vital capacity) UQCRB UTR-3 24023788 rs7827095 chr8 97239126 T C 1.68E-04 Lung function (forced expiratory volume in 1 second) UQCRB UTR-3 24023788 rs2643338 chr8 97247469 A G 1.34E-04 Lymphocyte counts UQCRB intron 22286170 rs7814319 chr8 97263418 C T 2.00E-06 Lung function (forced vital capacity) MTERFD1 intron 24023788 rs7814319 chr8 97263418 C T 5.80E-05 Lung function (forced expiratory volume in 1 second) MTERFD1 intron 24023788 rs3808386 chr8 97273543 G A 5.37E-05 Parkinson's disease MTERFD1 intron 21812969 rs17707746 chr8 97315645 A C 8.70E-05 Type 2 diabetes PTDSS1 intron 17463248 rs883655 chr8 97317181 T C 8.90E-05 Type 2 diabetes PTDSS1 intron 17463248 rs13439240 chr8 97318660 C T 8.90E-05 Type 2 diabetes PTDSS1 intron 17463248 rs7822351 chr8 97326087 T G 8.18E-04 Acute lung injury PTDSS1 intron 22295056 rs11786602 chr8 97327229 T C 8.18E-04 Acute lung injury PTDSS1 intron 22295056 rs13255914 chr8 97329366 C A 8.33E-04 Acute lung injury PTDSS1 intron 22295056 rs7824505 chr8 97330691 C A 9.07E-04 Acute lung injury PTDSS1 intron 22295056 rs7824518 chr8 97330751 A C 9.13E-04 Acute lung injury PTDSS1 intron 22295056 rs7821730 chr8 97334850 A T 7.07E-04 Acute lung injury PTDSS1 intron 22295056 rs17781044 chr8 97338931 A G 7.77E-04 Acute lung injury PTDSS1 intron 22295056 rs6985074 chr8 97340925 A T 8.48E-04 Acute lung injury PTDSS1 intron 22295056 rs7001397 chr8 97342582 C T 3.64E-04 Acute lung injury PTDSS1 intron 22295056 rs954626 chr8 97360685 T C 1.91E-04 Multiple complex diseases / / 17554300 rs16894512 chr8 97365736 G A 1.79E-04 Multiple complex diseases / / 17554300 rs17708958 chr8 97366044 C T 1.35E-04 Multiple complex diseases / / 17554300 rs6997395 chr8 97366701 A C 1.73E-04 Multiple complex diseases / / 17554300 rs2640806 chr8 97369634 C A 5.00E-06 Obesity-related traits / / 23251661 rs10504962 chr8 97384973 C T 2.70E-05 Urinary metabolites / / 21572414 rs1517933 chr8 97393072 C A 5.84E-04 Multiple complex diseases / / 17554300 rs784804 chr8 97394480 T C 6.20E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6991277 chr8 97400151 A G 5.39E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs784799 chr8 97401079 G T 2.81E-04 Multiple complex diseases / / 17554300 rs7839974 chr8 97408993 A G 5.39E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs746736 chr8 97432021 T C 4.75E-04 Alzheimer's disease (late onset) / / 21379329 rs1373543 chr8 97446035 C T 3.90E-04 Alzheimer's disease (late onset) / / 21379329 rs12550085 chr8 97454130 A G 6.81E-04 Multiple complex diseases / / 17554300 rs1020344 chr8 97457533 G A 6.41E-05 Corneal structure / / 22003120 rs7816225 chr8 97471539 G A 8.16E-04 Multiple complex diseases / / 17554300 rs12675232 chr8 97474401 C T 7.63E-04 Multiple complex diseases / / 17554300 rs17711201 chr8 97474533 A G 5.61E-04 Type 2 diabetes / / 17463246 rs17711201 chr8 97474533 A G 4.26E-04 Multiple complex diseases / / 17554300 rs7843589 chr8 97475303 A T 5.31E-04 Multiple complex diseases / / 17554300 rs7843589 chr8 97475303 A T 1.45E-05 Lipid traits / / 24023261 rs6468507 chr8 97476956 A C 4.50E-05 Height / / pha003011 rs11988485 chr8 97487001 C T 4.57E-04 Multiple complex diseases / / 17554300 rs2582814 chr8 97516984 T C 7.27E-04 Stroke SDC2 intron pha002887 rs2589183 chr8 97522509 G A 4.50E-05 Chronic obstructive pulmonary disease SDC2 intron 19300482 rs6985568 chr8 97522587 G A 2.51E-04 Multiple complex diseases SDC2 intron 17554300 rs6985568 chr8 97522587 G A 9.49E-05 Lipoproteins SDC2 intron pha003079 rs2439523 chr8 97535033 A G 5.80E-05 Response to lithium treatment in bipolar disorder SDC2 intron 19448189 rs874644 chr8 97542409 G A 1.60E-06 Urinary metabolites SDC2 intron 21572414 rs880078 chr8 97543019 C T 2.40E-06 Urinary metabolites SDC2 intron 21572414 rs880077 chr8 97543089 G A 1.90E-06 Urinary metabolites SDC2 intron 21572414 rs895034 chr8 97543390 T C 1.90E-06 Urinary metabolites SDC2 intron 21572414 rs2589204 chr8 97548162 C T 1.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SDC2 intron 20877124 rs2589203 chr8 97549700 A G 1.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SDC2 intron 20877124 rs2582839 chr8 97558267 G A 0.00016 Coronary artery calcification SDC2 intron 23727086 rs10100191 chr8 97559162 A G 7.50E-06 Urinary metabolites SDC2 intron 21572414 rs724235 chr8 97582987 G A 7.40E-04 Coronary heart disease SDC2 intron 21966275 rs2514781 chr8 97586152 T C 2.58E-05 Cognitive performance SDC2 intron 19734545 rs2319696 chr8 97594103 A C 2.12E-05 Bipolar disorder and schizophrenia SDC2 intron 20889312 rs1436606 chr8 97598940 T C 0.000066 Coronary artery calcification SDC2 intron 23727086 rs2704261 chr8 97602833 G A 1.35E-04 Coronary heart disease SDC2 intron 21606135 rs2028086 chr8 97604178 G C 1.70E-04 Coronary heart disease SDC2 intron 21606135 rs2704259 chr8 97606307 G A 2.46E-04 Coronary heart disease SDC2 intron 21606135 rs1042381 chr8 97614661 T A 0.000074 Coronary artery calcification SDC2 missense 23727086 rs2651460 chr8 97637672 G T 9.92E-04 Obesity (extreme) / / 21935397 rs7003624 chr8 97638714 G A 7.90E-06 Urinary metabolites / / 21572414 rs10090649 chr8 97639794 G A 1.60E-05 Urinary metabolites / / 21572414 rs750341 chr8 97643212 G A 9.72E-05 Prion diseases / / 22210626 rs750343 chr8 97643454 G A 9.72E-05 Prion diseases / / 22210626 rs1836911 chr8 97643737 T C 9.72E-05 Prion diseases / / 22210626 rs2018041 chr8 97643765 T C 9.72E-05 Prion diseases / / 22210626 rs2704255 chr8 97644783 C T 9.72E-05 Prion diseases / / 22210626 rs10101890 chr8 97656072 T A 8.50E-04 Diabetic nephropathy / / 20347642 rs6468514 chr8 97662363 G C 1.80E-04 Multiple complex diseases CPQ intron 17554300 rs4392869 chr8 97663264 T C 3.97E-05 Prion diseases CPQ intron 22210626 rs7813101 chr8 97664572 A G 3.35E-05 Prion diseases CPQ intron 22210626 rs4552870 chr8 97672160 G A 4.96E-04 Multiple complex diseases CPQ intron 17554300 rs2455051 chr8 97677082 G A 6.16E-04 Smoking quantity CPQ intron 24665060 rs12675345 chr8 97685591 C A 3.18E-04 Alcohol dependence CPQ intron 20201924 rs2874113 chr8 97747125 G T 4.77E-05 Sudden cardiac arrest CPQ intron 21658281 rs4145699 chr8 97776978 T A 7.72E-04 Multiple complex diseases CPQ intron 17554300 rs3763558 chr8 97796731 C A 1.00E-06 DNA methylation (variation) CPQ intron 23725790 rs7814447 chr8 97826743 T C 8.78E-05 Heart Rate CPQ intron pha003051 rs17796172 chr8 97856937 C G 1.32E-04 Multiple complex diseases CPQ intron 17554300 rs4734351 chr8 97861325 A G 2.30E-04 Type 2 diabetes CPQ intron 17463246 rs10282845 chr8 97870282 G A 2.86E-04 Type 2 diabetes CPQ intron 17463246 rs4734352 chr8 97870671 G A 5.58E-04 Type 2 diabetes CPQ intron 17463246 rs4628230 chr8 97874768 T C 4.73E-04 Type 2 diabetes CPQ intron 17463246 rs11993103 chr8 97946169 C T 3.59E-04 Type 2 diabetes CPQ intron 17463246 rs2513342 chr8 98076093 G A 2.36E-04 Multiple complex diseases CPQ intron 17554300 rs2513342 chr8 98076093 G A 2.30E-05 Urinary metabolites CPQ intron 21572414 rs2513399 chr8 98080225 A C 5.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) CPQ intron 23648065 rs7844514 chr8 98130180 C T 1.65E-04 Type 2 diabetes CPQ intron 17463246 rs17737465 chr8 98154441 A G 2.00E-06 Sleep duration CPQ intron 23728906 rs1835740 chr8 98166913 T C 2.00E-11 Migraine / / 20802479 rs1835740 chr8 98166913 T C 1.44E-04 Migraine - clinic-based / / 23793025 rs1835740 chr8 98166913 T C 1.49E-04 Migraine with aura / / 23793025 rs7845940 chr8 98177987 G A 4.04E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7812584 chr8 98178668 G A 7.28E-05 Multiple complex diseases / / 17554300 rs1431884 chr8 98178978 T G 1.07E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs6468535 chr8 98186414 C G 2.18E-04 Multiple complex diseases / / 17554300 rs7823062 chr8 98195883 A T 6.73E-04 Type 2 diabetes / / 17463246 rs4734357 chr8 98196280 T C 9.14E-05 Blood Pressure / / pha003047 rs10105830 chr8 98238719 A G 1.51E-04 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs6468538 chr8 98251638 A G 8.96E-05 Birth weight / / 17255346 rs17739295 chr8 98260909 G A 8.88E-05 Neutrophil count / / pha003095 rs2436042 chr8 98262162 A G 1.00E-04 Birth weight / / 17255346 rs2116422 chr8 98262244 G A 4.53E-05 Relative hand skill / / 24068947 rs1367917 chr8 98266645 T C 1.51E-05 Birth weight / / 17255346 rs1367917 chr8 98266645 T C 5.58E-05 Hypertension / / pha003042 rs2513380 chr8 98271030 G T 3.35E-04 Birth weight / / 17255346 rs2439702 chr8 98272647 C T 6.60E-09 Estradiol plasma levels (breast cancer) / / 23518928 rs2451113 chr8 98273448 G A 4.62E-09 Estradiol plasma levels (breast cancer) / / 23518928 rs2451114 chr8 98273762 G A 1.50E-09 Estradiol plasma levels (breast cancer) / / 23518928 rs1348184 chr8 98276912 C G 1.58E-08 Estradiol plasma levels (breast cancer) / / 23518928 rs2439700 chr8 98277168 G A 1.58E-08 Estradiol plasma levels (breast cancer) / / 23518928 rs2053481 chr8 98278923 C T 1.58E-08 Estradiol plasma levels (breast cancer) / / 23518928 rs2053481 chr8 98278923 C T 4.29E-05 Relative hand skill / / 24068947 rs2053480 chr8 98278951 T A 6.84E-09 Estradiol plasma levels (breast cancer) / / 23518928 rs2053480 chr8 98278951 T A 3.87E-05 Relative hand skill / / 24068947 rs2567773 chr8 98279182 G A 6.84E-09 Estradiol plasma levels (breast cancer) / / 23518928 rs2853312 chr8 98281319 T C 8.27E-09 Estradiol plasma levels (breast cancer) / / 23518928 rs2853312 chr8 98281319 T C 3.52E-05 Relative hand skill / / 24068947 rs2583506 chr8 98281847 G A 1.55E-08 Estradiol plasma levels (breast cancer) / / 23518928 rs2583506 chr8 98281847 G A 3.51E-05 Relative hand skill / / 24068947 rs1864729 chr8 98282189 G A 3.00E-08 Estradiol plasma levels (breast cancer) / / 23518928 rs1864729 chr8 98282189 G A 3.45E-05 Relative hand skill / / 24068947 rs1835743 chr8 98282643 T C 2.29E-08 Estradiol plasma levels (breast cancer) / / 23518928 rs1835743 chr8 98282643 T C 3.41E-05 Relative hand skill / / 24068947 rs1431891 chr8 98282716 A G 2.29E-08 Estradiol plasma levels (breast cancer) / / 23518928 rs1431891 chr8 98282716 A G 3.40E-05 Relative hand skill / / 24068947 rs2635161 chr8 98282907 G T 2.29E-08 Estradiol plasma levels (breast cancer) / / 23518928 rs2635161 chr8 98282907 G T 3.44E-05 Relative hand skill / / 24068947 rs2583504 chr8 98283404 G C 2.03E-08 Estradiol plasma levels (breast cancer) / / 23518928 rs2853318 chr8 98283509 A T 1.78E-08 Estradiol plasma levels (breast cancer) / / 23518928 rs2853320 chr8 98283523 C G 1.78E-08 Estradiol plasma levels (breast cancer) / / 23518928 rs2635162 chr8 98283629 G A 1.50E-08 Estradiol plasma levels (breast cancer) / / 23518928 rs2635162 chr8 98283629 G A 3.46E-05 Relative hand skill / / 24068947 rs2289496 chr8 98288164 A C 4.78E-06 Osteoarthritis TSPYL5 UTR-3 22763110 rs16895443 chr8 98293969 G A 4.13E-04 Type 2 diabetes / / 17463246 rs2567769 chr8 98297848 G A 6.49E-08 Estradiol plasma levels (breast cancer) / / 23518928 rs2567768 chr8 98303151 G A 2.61E-07 Estradiol plasma levels (breast cancer) / / 23518928 rs4400351 chr8 98325837 C T 3.06E-04 Birth weight / / 17255346 rs4400351 chr8 98325837 C T 6.30E-05 Blood Pressure / / pha003050 rs16895513 chr8 98326973 C T 2.46E-04 Birth weight / / 17255346 rs6468544 chr8 98329765 C G 1.71E-04 Birth weight / / 17255346 rs6468544 chr8 98329765 C G 8.00E-07 Antipsychotic-induced QTc interval prolongation / / 20921969 rs2635148 chr8 98330958 T C 1.43E-04 Multiple complex diseases / / 17554300 rs16895526 chr8 98331166 G A 7.37E-04 Multiple complex diseases / / 17554300 rs6468549 chr8 98350880 T G 2.08E-04 Birth weight / / 17255346 rs6468549 chr8 98350880 T G 4.19E-04 Alzheimer's disease (late onset) / / 21379329 rs7007792 chr8 98352162 G A 4.67E-04 Alzheimer's disease (late onset) / / 21379329 rs7840663 chr8 98356553 T C 1.34E-04 Birth weight / / 17255346 rs4520131 chr8 98357081 T C 6.61E-05 Birth weight / / 17255346 rs4520131 chr8 98357081 T C 3.58E-04 Alzheimer's disease (late onset) / / 21379329 rs11786542 chr8 98357382 G A 6.53E-04 Alzheimer's disease / / 24755620 rs7832008 chr8 98358246 G A 1.68E-04 Alzheimer's disease / / 24755620 rs2247105 chr8 98360795 G A 3.50E-04 Multiple complex diseases / / 17554300 rs2247105 chr8 98360795 G A 3.33E-04 Alzheimer's disease / / 24755620 rs1316792 chr8 98361046 C T 1.18E-04 Alzheimer's disease / / 24755620 rs2679768 chr8 98361688 G T 1.60E-04 Alzheimer's disease / / 24755620 rs17741775 chr8 98362363 G A 9.83E-05 Multiple complex diseases / / 17554300 rs2679765 chr8 98364203 A G 3.37E-05 Multiple complex diseases / / 17554300 rs6998052 chr8 98365938 T G 5.79E-05 Multiple complex diseases / / 17554300 rs7833199 chr8 98367001 T C 4.46E-05 Major depressive disorder (broad) / / 20038947 rs4735451 chr8 98367884 C T 7.22E-05 Major depressive disorder (broad) / / 20038947 rs4735454 chr8 98368210 C T 7.76E-05 Major depressive disorder (broad) / / 20038947 rs11780372 chr8 98370806 C T 9.50E-05 Major depressive disorder (broad) / / 20038947 rs10087523 chr8 98370906 G C 9.76E-05 Bipolar disorder / / 22925353 rs7834781 chr8 98371242 A T 9.63E-05 Major depressive disorder (broad) / / 20038947 rs16895640 chr8 98372762 A G 1.21E-04 Multiple complex diseases / / 17554300 rs4735457 chr8 98373598 A C 5.37E-05 Major depressive disorder (broad) / / 20038947 rs6468552 chr8 98374249 G T 6.16E-05 Major depressive disorder (broad) / / 20038947 rs4734360 chr8 98374866 C G 7.69E-05 Major depressive disorder (broad) / / 20038947 rs4735458 chr8 98375057 A T 7.78E-05 Major depressive disorder (broad) / / 20038947 rs10504971 chr8 98376560 T C 7.00E-05 Multiple complex diseases / / 17554300 rs6468553 chr8 98377549 A C 8.67E-05 Major depressive disorder (broad) / / 20038947 rs10808355 chr8 98385871 G T 8.96E-05 Major depressive disorder (broad) / / 20038947 rs9649913 chr8 98386508 A G 1.80E-05 Prostate cancer / / pha002878 rs2853286 chr8 98388568 G T 3.69E-05 Orofacial clefts / / 19270707 rs2853286 chr8 98388568 G T 6.86E-05 Orofacial clefts / / 20023658 rs2853288 chr8 98389164 G A 1.33E-05 Asthma / / 23181788 rs2679774 chr8 98390992 T C 4.42E-05 Odorant perception / / 23910658 rs2448166 chr8 98454136 G A 5.29E-05 Type 2 diabetes and other traits / / 19734900 rs1968838 chr8 98456284 C T 4.01E-04 Smoking initiation / / 24665060 rs17744327 chr8 98466377 A C 6.54E-04 Coronary Artery Disease / / 17634449 rs6995779 chr8 98474916 A G 4.07E-05 Vitiligo / / 19890347 rs9656841 chr8 98476935 T C 3.20E-05 Schizophrenia / / 19571809 rs10808356 chr8 98485861 T C 1.37E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs9297278 chr8 98503412 C A 1.29E-05 Multiple complex diseases / / 17554300 rs7015322 chr8 98581957 G A 3.77E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1871313 chr8 98582908 T C 2.36E-05 Height / / pha003010 rs1871313 chr8 98582908 T C 9.35E-05 Height / / pha003011 rs7013802 chr8 98585277 T C 8.93E-05 Cognitive test performance / / 20125193 rs1478955 chr8 98591093 T C 5.20E-06 Urinary metabolites / / 21572414 rs2512418 chr8 98608825 G A 2.90E-05 Urinary metabolites / / 21572414 rs2448148 chr8 98626459 T C 6.64E-04 Depression (quantitative trait) / / 20800221 rs2512429 chr8 98627865 T A 7.22E-04 Depression (quantitative trait) / / 20800221 rs2512431 chr8 98631311 A G 6.90E-04 Depression (quantitative trait) / / 20800221 rs2512433 chr8 98632764 A G 6.89E-04 Depression (quantitative trait) / / 20800221 rs2512434 chr8 98634070 T G 6.88E-04 Depression (quantitative trait) / / 20800221 rs2512435 chr8 98634789 T C 6.90E-04 Depression (quantitative trait) / / 20800221 rs2512436 chr8 98635877 C T 6.90E-04 Depression (quantitative trait) / / 20800221 rs2512437 chr8 98635943 A G 6.90E-04 Depression (quantitative trait) / / 20800221 rs2512438 chr8 98636391 A T 6.92E-04 Depression (quantitative trait) / / 20800221 rs2438228 chr8 98637212 G A 6.93E-04 Depression (quantitative trait) / / 20800221 rs2448145 chr8 98637731 C A 6.96E-04 Depression (quantitative trait) / / 20800221 rs1013412 chr8 98640579 C T 6.63E-04 Depression (quantitative trait) / / 20800221 rs2438226 chr8 98641733 T C 4.89E-04 Depression (quantitative trait) / / 20800221 rs10955127 chr8 98664225 A G 6.53E-06 Left ventricular mass MTDH intron 21212386 rs4448244 chr8 98664528 C T 4.46E-05 Duodenal ulcer MTDH intron 22387998 rs2513980 chr8 98762432 G A 5.60E-06 Urinary metabolites / / 21572414 rs2449517 chr8 98762621 T G 7.80E-06 Urinary metabolites / / 21572414 rs2917964 chr8 98766490 T G 1.50E-05 Urinary metabolites / / 21572414 rs6998101 chr8 98771048 C G 1.20E-06 Urinary metabolites / / 21572414 rs2449524 chr8 98819195 G C 9.17E-04 Suicide attempts in bipolar disorder LAPTM4B intron 21423239 rs2513956 chr8 98838201 C G 6.10E-04 Suicide attempts in bipolar disorder LAPTM4B intron 21423239 rs7004748 chr8 98848366 A C 7.61E-04 Type 2 diabetes LAPTM4B intron 17463246 rs10504981 chr8 98849017 T A 4.75E-04 Type 2 diabetes LAPTM4B intron 17463246 rs1136594 chr8 98863876 G A 2.61E-04 Sudden cardiac arrest LAPTM4B UTR-3 21658281 rs4360265 chr8 98889153 C T 9.86E-04 Tourette syndrome MATN2 intron 22889924 rs2513840 chr8 98947000 C T 7.33E-04 Multiple complex diseases MATN2 intron 17554300 rs2085144 chr8 98953076 G A 2.12E-04 Vaspin levels MATN2 intron 22907691 rs2085144 chr8 98953076 G A 0.0000609 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit MATN2 intron 22907730 rs2085144 chr8 98953076 G A 0.0002123 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks MATN2 intron 22907730 rs897189 chr8 98963817 C T 5.58E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) MATN2 intron 23648065 rs2512032 chr8 98969239 T G 4.78E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) MATN2 intron 23648065 rs2512032 chr8 98969239 T G 7.93E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) MATN2 intron 23648065 rs2512033 chr8 98970479 G A 1.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MATN2 intron 20877124 rs2444876 chr8 98970756 C T 1.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MATN2 intron 20877124 rs6987225 chr8 98975672 A C 9.17E-07 Lipid traits MATN2 intron 22028671 rs16896476 chr8 98987744 A G 9.61E-04 Multiple complex diseases MATN2 intron 17554300 rs977795 chr8 98996027 G A 5.28E-05 Potassium levels MATN2 intron pha003086 rs2061053 chr8 98999397 A G 9.87E-04 Multiple complex diseases MATN2 intron 17554300 rs2513852 chr8 99008727 C A 6.45E-04 Eye color MATN2 intron 23118974 rs2444895 chr8 99020949 C T 5.20E-05 Response to statin therapy MATN2 intron 20339536 rs2444896 chr8 99022009 C A 2.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) MATN2 intron 23648065 rs12549802 chr8 99022171 G A 6.80E-05 Response to statin therapy MATN2 intron 20339536 rs2290467 chr8 99040154 A C 5.83E-04 Type 2 diabetes MATN2 intron 17463246 rs2290468 chr8 99042226 G A 8.20E-05 Response to statin therapy MATN2 intron 20339536 rs6985709 chr8 99045454 G A 7.70E-05 Response to statin therapy MATN2 intron 20339536 rs2279120 chr8 99046040 C T 4.40E-05 Response to statin therapy MATN2 intron 20339536 rs2279120 chr8 99046040 C T 5.06E-05 Post-operative nausea and vomiting MATN2 intron 21694509 rs16896577 chr8 99046566 A G 7.40E-06 Multiple complex diseases MATN2 intron 17554300 rs11997426 chr8 99046985 G C 5.83E-04 Type 2 diabetes MATN2 intron 17463246 rs11997426 chr8 99046985 G C 5.80E-05 Response to statin therapy MATN2 intron 20339536 rs3088121 chr8 99048049 A G 7.40E-05 Response to statin therapy MATN2 UTR-3 20339536 rs7016999 chr8 99050878 G A 6.00E-05 Response to statin therapy / / 20339536 rs13278732 chr8 99088581 C T 6.00E-06 Eosinophilic esophagitis (pediatric) C8orf47 intron 20208534 rs2444861 chr8 99100932 A G 1.41E-04 Height C8orf47 intron 17255346 rs2444861 chr8 99100932 A G 0.00000899 Aging C8orf47 intron 22445811 rs2444861 chr8 99100932 A G 8.65E-05 Amyotrophic lateral sclerosis C8orf47 intron 23624525 rs10107366 chr8 99113687 T C 6.00E-07 Obesity-related traits / / 23251661 rs2071598 chr8 99129507 G T 9.00E-06 Prion diseases / / 22210626 rs2071597 chr8 99129649 A G 6.10E-04 Alcohol dependence POP1 intron 20201924 rs4734384 chr8 99133678 A C 2.15E-04 Alcohol dependence POP1 intron 20201924 rs10808358 chr8 99137153 G A 3.84E-04 Alcohol dependence POP1 intron 20201924 rs4735529 chr8 99139610 C T 1.31E-04 Alcohol dependence POP1 intron 20201924 rs3802195 chr8 99140208 T G 8.96E-05 Parent of origin effect on language impairment (paternal) POP1 intron 24571439 rs3802196 chr8 99140379 T G 5.57E-05 Parent of origin effect on language impairment (paternal) POP1 intron 24571439 rs16896735 chr8 99184897 G A 3.58E-04 Height / / 17255346 rs2447494 chr8 99191257 G A 6.37E-04 Psoriasis / / 20953187 rs896418 chr8 99192597 C G 2.50E-05 Urinary metabolites / / 21572414 rs16896762 chr8 99198772 C T 2.67E-05 Height / / pha003011 rs7016814 chr8 99200570 T C 3.91E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12547555 chr8 99214709 C T 1.61E-04 Response to cytadine analogues (cytosine arabinoside) NIPAL2 intron 24483146 rs2514323 chr8 99236899 A G 1.78E-04 Lung function (forced expiratory volume in 1 second) NIPAL2 intron 24023788 rs7016352 chr8 99262445 A G 2.99E-04 Response to cytadine analogues (cytosine arabinoside) NIPAL2 intron 24483146 rs17360790 chr8 99315540 A G 2.10E-05 Urinary metabolites / / 21572414 rs11785622 chr8 99317739 C T 4.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs17360909 chr8 99318057 A C 4.06E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs17288913 chr8 99318745 C T 4.79E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs4366057 chr8 99335932 C A 5.83E-04 Coronary heart disease / / 21971053 rs4644205 chr8 99336995 A G 8.41E-04 Coronary heart disease / / 21971053 rs4735554 chr8 99346537 C T 8.26E-04 Coronary heart disease / / 21971053 rs4131951 chr8 99351226 T G 9.54E-04 Coronary heart disease / / 21971053 rs4346964 chr8 99352637 A G 5.60E-04 Coronary heart disease / / 21971053 rs4734399 chr8 99355819 C A 4.28E-04 Coronary heart disease / / 21971053 rs7006634 chr8 99372936 C T 8.69E-04 Aortic root size / / 21223598 rs6989037 chr8 99373167 T G 6.48E-04 Schizophrenia / / 19197363 rs10955167 chr8 99374877 A G 7.99E-05 Blood Pressure / / pha003047 rs7831552 chr8 99379259 G A 8.84E-04 Coronary heart disease / / 21971053 rs6984462 chr8 99386594 C T 7.94E-05 Alcohol withdrawal symptoms / / 22072270 rs17310732 chr8 99415437 G A 6.26E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs4130405 chr8 99420775 A C 0.000017 Anxiety Composite (ARBQ) in children / / 23565138 rs17370425 chr8 99428499 C T 2.90E-04 Iris characteristics / / 21835309 rs7826857 chr8 99436341 A G 1.40E-05 Methamphetamine dependence / / 23594818 rs12546344 chr8 99450646 A C 1.93E-05 Smoking initiation / / 24665060 rs4236853 chr8 99463047 A G 3.20E-04 Smoking initiation / / 24665060 rs12542022 chr8 99492875 T C 2.30E-04 Smoking initiation STK3 intron 24665060 rs4370499 chr8 99497671 C T 2.67E-04 Smoking initiation STK3 intron 24665060 rs12056323 chr8 99520594 G A 2.32E-04 Smoking initiation STK3 intron 24665060 rs16897061 chr8 99532578 A G 8.74E-05 Smoking initiation STK3 intron 24665060 rs12547922 chr8 99542022 T C 3.87E-04 Smoking initiation STK3 intron 24665060 rs10955181 chr8 99543172 T C 3.59E-05 Smoking initiation STK3 intron 24665060 rs3802198 chr8 99548029 T C 5.61E-04 Smoking initiation STK3 intron 24665060 rs6991043 chr8 99553244 C T 9.07E-05 Smoking initiation STK3 intron 24665060 rs7011216 chr8 99553256 T C 6.00E-05 Height STK3 intron pha003010 rs7011216 chr8 99553256 T C 7.03E-05 Height STK3 intron pha003011 rs7011216 chr8 99553256 T C 6.39E-05 Creatinine levels STK3 intron pha003069 rs12542758 chr8 99563035 G C 1.19E-04 Smoking initiation STK3 intron 24665060 rs12542069 chr8 99569735 A G 1.29E-04 Smoking initiation STK3 intron 24665060 rs6651182 chr8 99585434 G A 1.81E-04 Smoking initiation STK3 intron 24665060 rs4735568 chr8 99625091 A C 1.18E-04 Smoking initiation STK3 intron 24665060 rs12550012 chr8 99640048 T C 6.31E-05 Smoking initiation STK3 intron 24665060 rs12550783 chr8 99643487 A G 5.79E-05 Smoking initiation STK3 intron 24665060 rs10755896 chr8 99647154 G T 2.82E-05 Smoking initiation STK3 intron 24665060 rs10755897 chr8 99647451 A G 1.02E-04 Smoking initiation STK3 intron 24665060 rs12549803 chr8 99681858 A G 3.37E-05 Smoking initiation STK3 intron 24665060 rs12675964 chr8 99686314 A G 3.33E-04 Smoking initiation STK3 intron 24665060 rs11774463 chr8 99721307 G A 2.62E-05 Smoking initiation STK3 intron 24665060 rs12547297 chr8 99731503 T C 3.08E-05 Smoking initiation STK3 intron 24665060 rs12680195 chr8 99734032 A G 5.31E-05 Smoking initiation STK3 intron 24665060 rs11780500 chr8 99758904 T C 2.55E-04 Hearing function STK3 intron 17255346 rs11778767 chr8 99766557 G A 2.05E-04 Hearing function STK3 intron 17255346 rs34366206 chr8 99767861 G A 6.37E-05 Smoking initiation STK3 intron 24665060 rs10447977 chr8 99770659 C T 8.28E-05 Smoking initiation STK3 intron 24665060 rs12679734 chr8 99786317 A C 7.83E-05 Smoking initiation STK3 intron 24665060 rs4255105 chr8 99794459 A G 5.14E-05 Smoking initiation STK3 intron 24665060 rs2515218 chr8 99821668 T C 3.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) STK3 intron 20877124 rs2922074 chr8 99851715 A G 5.57E-05 Smoking initiation STK3 intron 24665060 rs2922078 chr8 99865301 G A 2.21E-04 Hearing function STK3 intron 17255346 rs3019290 chr8 99874520 T C 7.09E-05 Smoking initiation STK3 intron 24665060 rs2922066 chr8 99901622 G A 3.40E-05 Smoking initiation STK3 intron 24665060 rs985794 chr8 99955574 A G 5.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12547301 chr8 99991838 A G 1.79E-04 Smoking initiation / / 24665060 rs4260868 chr8 99996980 A G 2.23E-04 Smoking initiation / / 24665060 rs10955193 chr8 100013562 C T 2.14E-04 Glycemic traits (pregnancy) / / 23903356 rs10955193 chr8 100013562 C T 5.30E-04 Glycemic traits (pregnancy) / / 23903356 rs12547849 chr8 100026275 T C 2.01E-04 Smoking initiation VPS13B intron 24665060 rs10955197 chr8 100046692 C A 1.16E-04 Smoking initiation VPS13B intron 24665060 rs4520132 chr8 100055558 T G 3.31E-04 Smoking initiation VPS13B intron 24665060 rs6989201 chr8 100107731 A G 1.99E-04 Smoking initiation VPS13B intron 24665060 rs6468663 chr8 100110510 T C 1.07E-04 Smoking initiation VPS13B intron 24665060 rs6468665 chr8 100111912 A G 1.69E-04 Smoking initiation VPS13B intron 24665060 rs7462457 chr8 100114643 G A 6.66E-05 Smoking initiation VPS13B intron 24665060 rs10098153 chr8 100118121 G A 2.67E-04 Smoking initiation VPS13B intron 24665060 rs6991283 chr8 100119963 A G 2.15E-04 Smoking initiation VPS13B intron 24665060 rs6468666 chr8 100121616 C T 2.05E-04 Smoking initiation VPS13B intron 24665060 rs10096925 chr8 100130520 A G 2.41E-04 Smoking initiation VPS13B intron 24665060 rs7460625 chr8 100133706 T G 3.97E-05 Psoriasis VPS13B STOP-GAIN 18364390 rs7842393 chr8 100138056 T C 1.72E-04 Smoking initiation VPS13B intron 24665060 rs7461275 chr8 100141089 T C 8.99E-05 Smoking initiation VPS13B intron 24665060 rs4317539 chr8 100152265 G A 8.61E-05 Smoking initiation VPS13B intron 24665060 rs6468671 chr8 100155676 T C 4.82E-04 Smoking initiation VPS13B intron 24665060 rs7011648 chr8 100159314 A G 3.23E-04 Smoking initiation VPS13B intron 24665060 rs7818051 chr8 100172398 A G 3.49E-04 Smoking initiation VPS13B intron 24665060 rs4735603 chr8 100178122 A G 1.03E-04 Smoking initiation VPS13B intron 24665060 rs7460376 chr8 100179172 C T 9.56E-05 Smoking initiation VPS13B intron 24665060 rs4442113 chr8 100180871 A G 2.70E-04 Atrial fibrillation VPS13B intron 21846873 rs4442113 chr8 100180871 A G 2.18E-04 Glycemic traits (pregnancy) VPS13B intron 23903356 rs12550128 chr8 100184653 G A 2.66E-04 Smoking initiation VPS13B intron 24665060 rs4735604 chr8 100189337 T C 1.53E-04 Smoking initiation VPS13B intron 24665060 rs10808361 chr8 100191783 C G 5.69E-04 Alzheimer's disease VPS13B intron 17998437 rs10808361 chr8 100191783 C G 8.57E-05 Smoking initiation VPS13B intron 24665060 rs10808362 chr8 100191814 T A 2.76E-04 Glycemic traits (pregnancy) VPS13B intron 23903356 rs7017261 chr8 100208966 T C 7.32E-05 Smoking initiation VPS13B intron 24665060 rs4735607 chr8 100222436 T C 9.31E-05 Smoking initiation VPS13B intron 24665060 rs369187183 chr8 100223397 AT AAT,AGA 5.25E-04 Smoking initiation VPS13B intron 24665060 rs7016044 chr8 100223397 A G 5.25E-04 Smoking initiation VPS13B intron 24665060 rs7016304 chr8 100223494 C T 5.08E-04 Smoking initiation VPS13B intron 24665060 rs7014877 chr8 100226715 T C 1.74E-04 Smoking initiation VPS13B intron 24665060 rs7815414 chr8 100231689 G A 6.29E-04 Smoking initiation VPS13B intron 24665060 rs12056311 chr8 100240140 G T 2.77E-04 Smoking initiation VPS13B intron 24665060 rs7826945 chr8 100244481 G A 2.14E-04 Smoking initiation VPS13B intron 24665060 rs10216478 chr8 100292744 G A 1.25E-04 Smoking initiation VPS13B intron 24665060 rs4446702 chr8 100293807 T C 1.98E-04 Smoking initiation VPS13B intron 24665060 rs7823291 chr8 100296142 G T 4.71E-04 Smoking initiation VPS13B intron 24665060 rs4493885 chr8 100299162 A C 6.84E-05 Smoking initiation VPS13B intron 24665060 rs7002148 chr8 100301621 T C 1.07E-04 Smoking initiation VPS13B intron 24665060 rs34671840 chr8 100310931 A AG 1.84E-04 Smoking initiation VPS13B intron 24665060 rs7006027 chr8 100310931 A G 1.84E-04 Smoking initiation VPS13B intron 24665060 rs10104264 chr8 100313571 C G 3.77E-04 Smoking initiation VPS13B intron 24665060 rs7839332 chr8 100317189 C T 1.58E-04 Smoking initiation VPS13B intron 24665060 rs6468681 chr8 100317365 A G 4.99E-04 Smoking initiation VPS13B intron 24665060 rs7828262 chr8 100318246 T G 5.01E-04 Smoking initiation VPS13B intron 24665060 rs3134305 chr8 100326769 A G 5.76E-05 Smoking initiation VPS13B intron 24665060 rs3103712 chr8 100327501 C T 2.49E-04 Smoking initiation VPS13B intron 24665060 rs3134306 chr8 100328798 A G 8.34E-05 Smoking initiation VPS13B intron 24665060 rs2029595 chr8 100330674 C T 4.00E-04 Smoking initiation VPS13B intron 24665060 rs3103711 chr8 100331779 A G 9.52E-05 Smoking initiation VPS13B intron 24665060 rs2291548 chr8 100336447 T C 4.82E-04 Smoking initiation VPS13B intron 24665060 rs3103709 chr8 100337529 T C 1.58E-04 Smoking initiation VPS13B intron 24665060 rs3110396 chr8 100338448 A G 6.21E-04 Smoking initiation VPS13B intron 24665060 rs3103732 chr8 100341253 G T 4.90E-04 Smoking initiation VPS13B intron 24665060 rs3103730 chr8 100344845 C T 6.17E-05 Smoking initiation VPS13B intron 24665060 rs13260338 chr8 100350744 T C 5.60E-07 Red blood cell traits VPS13B intron 23222517 rs1492077 chr8 100350841 A G,T 4.71E-04 Smoking initiation VPS13B intron 24665060 rs3103707 chr8 100352261 G A 1.16E-04 Smoking initiation VPS13B intron 24665060 rs3134178 chr8 100355681 C T 7.45E-04 Smoking initiation VPS13B intron 24665060 rs3134178 chr8 100355681 C T 9.53E-05 Smoking initiation VPS13B intron 24665060 rs3110400 chr8 100363242 T C 1.40E-04 Smoking initiation VPS13B intron 24665060 rs3110401 chr8 100364236 T C 1.90E-04 Smoking initiation VPS13B intron 24665060 rs3103718 chr8 100371208 T C 3.32E-04 Smoking initiation VPS13B intron 24665060 rs3134173 chr8 100388260 C T 7.57E-05 Smoking initiation VPS13B intron 24665060 rs3103698 chr8 100398670 A G 4.17E-04 Smoking initiation VPS13B intron 24665060 rs3105182 chr8 100415307 C T 3.81E-04 Smoking initiation VPS13B intron 24665060 rs3105186 chr8 100422599 A G 4.27E-05 Smoking initiation VPS13B intron 24665060 rs3103705 chr8 100432976 C T 1.34E-05 Osteoarthritis (knee and hip) VPS13B intron 21177295 rs3103705 chr8 100432976 C T 3.19E-05 Osteoarthritis (knee and hip) VPS13B intron 21177295 rs3103705 chr8 100432976 C T 8.80E-04 Atrial fibrillation VPS13B intron 21846873 rs3110393 chr8 100435240 A C 4.01E-05 Smoking initiation VPS13B intron 24665060 rs3105193 chr8 100448081 T C 5.91E-05 Smoking initiation VPS13B intron 24665060 rs766675 chr8 100450929 A G 6.52E-05 Smoking initiation VPS13B intron 24665060 rs3105195 chr8 100455110 G A 5.53E-05 Smoking initiation VPS13B intron 24665060 rs3105196 chr8 100456061 T C 5.40E-04 Smoking initiation VPS13B intron 24665060 rs3105198 chr8 100460268 G A 1.23E-04 Smoking initiation VPS13B intron 24665060 rs3103724 chr8 100476525 A G 6.62E-05 Smoking initiation VPS13B intron 24665060 rs1844947 chr8 100478611 G A 3.33E-04 Smoking initiation VPS13B intron 24665060 rs3134156 chr8 100479917 T C 2.34E-04 Smoking initiation VPS13B intron 24665060 rs3105205 chr8 100481030 C T 1.63E-04 Smoking initiation VPS13B intron 24665060 rs1117459 chr8 100485074 T C 4.33E-05 Smoking initiation VPS13B intron 24665060 rs16897394 chr8 100494336 G A 8.82E-04 Multiple complex diseases VPS13B intron 17554300 rs3105169 chr8 100495639 C A 8.00E-06 Smoking initiation VPS13B intron 24665060 rs3105170 chr8 100496094 A G 2.41E-05 Smoking initiation VPS13B intron 24665060 rs1825754 chr8 100505237 C T 1.70E-04 Smoking initiation VPS13B intron 24665060 rs3103100 chr8 100506322 A G 3.15E-05 Smoking initiation VPS13B intron 24665060 rs3105176 chr8 100511898 A G 3.38E-05 Smoking initiation VPS13B intron 24665060 rs3134171 chr8 100524572 G A 6.10E-04 Smoking initiation VPS13B intron 24665060 rs1487022 chr8 100529826 G T 1.64E-04 Smoking initiation VPS13B intron 24665060 rs6986467 chr8 100538070 A T 9.82E-05 Smoking initiation VPS13B intron 24665060 rs7827408 chr8 100539843 C T 0.000000242 LDL cholesterol VPS13B intron 23063622 rs7827408 chr8 100539843 C T 6.61E-08 Triglycerides VPS13B intron 23063622 rs16897430 chr8 100540270 T G 2.59E-04 Smoking initiation VPS13B intron 24665060 rs16897435 chr8 100541978 T G 1.09E-04 Smoking initiation VPS13B intron 24665060 rs16897440 chr8 100548975 C T 2.14E-05 Smoking initiation VPS13B intron 24665060 rs7004966 chr8 100559342 A G 3.09E-05 Smoking initiation VPS13B intron 24665060 rs7837577 chr8 100565126 A C 2.71E-04 Smoking initiation VPS13B intron 24665060 rs1487024 chr8 100568593 C T 4.80E-04 Smoking initiation VPS13B intron 24665060 rs1825755 chr8 100572576 C T 1.10E-04 Smoking initiation VPS13B intron 24665060 rs1386373 chr8 100572797 T C 3.90E-05 Smoking initiation VPS13B intron 24665060 rs10955216 chr8 100574388 A G 6.45E-05 Smoking initiation VPS13B intron 24665060 rs16897453 chr8 100576226 A G 2.22E-05 Smoking initiation VPS13B intron 24665060 rs7832109 chr8 100576641 G A 9.57E-05 Smoking initiation VPS13B intron 24665060 rs7835824 chr8 100576942 C T 1.19E-04 Smoking initiation VPS13B intron 24665060 rs7829651 chr8 100579184 T C 4.45E-04 Smoking initiation VPS13B intron 24665060 rs7816355 chr8 100580414 A G 4.34E-05 Smoking initiation VPS13B intron 24665060 rs12548482 chr8 100583364 G A 3.70E-05 Smoking initiation VPS13B intron 24665060 rs1949123 chr8 100588610 T G 3.11E-04 Smoking initiation VPS13B intron 24665060 rs4391399 chr8 100588945 A G 1.57E-04 Smoking initiation VPS13B intron 24665060 rs16897473 chr8 100591430 C A 2.18E-04 Smoking initiation VPS13B intron 24665060 rs34273034 chr8 100598721 G A 5.10E-05 Smoking initiation VPS13B intron 24665060 rs34273034 chr8 100598721 G A 2.40E-05 Cognitive function VPS13B intron 24684796 rs7816771 chr8 100608071 G T 1.69E-04 Smoking initiation VPS13B intron 24665060 rs16897489 chr8 100612018 G A 2.53E-04 Smoking initiation VPS13B intron 24665060 rs7009315 chr8 100630636 C A 4.02E-04 Smoking initiation VPS13B intron 24665060 rs7009315 chr8 100630636 C A 8.40E-05 Cognitive function VPS13B intron 24684796 rs7008019 chr8 100635818 C T 1.05E-04 Smoking initiation VPS13B intron 24665060 rs7008019 chr8 100635818 C T 4.90E-05 Cognitive function VPS13B intron 24684796 rs4735627 chr8 100635915 A G 3.51E-06 Alzheimer's disease VPS13B intron 17998437 rs4735627 chr8 100635915 A G 4.54E-04 Smoking initiation VPS13B intron 24665060 rs4735627 chr8 100635915 A G 2.26E-04 Alzheimer's disease VPS13B intron pha002879 rs2035618 chr8 100636386 A G 1.52E-04 Smoking initiation VPS13B intron 24665060 rs16897517 chr8 100645287 G T 1.29E-04 Smoking initiation VPS13B intron 24665060 rs12541910 chr8 100648118 C G 7.60E-05 Smoking initiation VPS13B intron 24665060 rs12541910 chr8 100648118 C G 4.90E-05 Cognitive function VPS13B intron 24684796 rs12542004 chr8 100648280 G A 3.39E-04 Smoking initiation VPS13B intron 24665060 rs12542004 chr8 100648280 G A 4.90E-05 Cognitive function VPS13B intron 24684796 rs16897530 chr8 100656483 A T 4.74E-05 Alzheimer's disease VPS13B intron 17998437 rs12550139 chr8 100657978 A G 4.63E-05 Smoking initiation VPS13B intron 24665060 rs16897533 chr8 100658319 A G 4.27E-05 Smoking initiation VPS13B intron 24665060 rs16897536 chr8 100660251 A C 1.01E-04 Smoking initiation VPS13B intron 24665060 rs16897536 chr8 100660251 A C 6.30E-05 Cognitive function VPS13B intron 24684796 rs1449792 chr8 100663992 C T 1.31E-04 Smoking initiation VPS13B intron 24665060 rs16897546 chr8 100664856 C A 2.54E-04 Smoking initiation VPS13B intron 24665060 rs12546643 chr8 100665814 G A 2.89E-04 Smoking initiation VPS13B intron 24665060 rs2167102 chr8 100668211 C T 3.10E-04 Smoking initiation VPS13B intron 24665060 rs1667644 chr8 100670473 A G 1.09E-04 Smoking initiation VPS13B intron 24665060 rs1667644 chr8 100670473 A G 3.80E-05 Cognitive function VPS13B intron 24684796 rs1788157 chr8 100671851 C A 4.64E-04 Smoking initiation VPS13B intron 24665060 rs1667642 chr8 100673094 A G 5.38E-05 Smoking initiation VPS13B intron 24665060 rs1788156 chr8 100673421 G A 6.98E-05 Smoking initiation VPS13B intron 24665060 rs1788154 chr8 100680047 C T 4.94E-05 Smoking initiation VPS13B intron 24665060 rs1788153 chr8 100680428 C T 2.99E-04 Smoking initiation VPS13B intron 24665060 rs1788151 chr8 100681208 A G 7.16E-05 Smoking initiation VPS13B intron 24665060 rs1788147 chr8 100690385 A G 2.90E-04 Smoking initiation VPS13B intron 24665060 rs1449785 chr8 100691629 C T 4.11E-04 Smoking initiation VPS13B intron 24665060 rs1449784 chr8 100692370 A G 5.12E-05 Smoking initiation VPS13B intron 24665060 rs2510202 chr8 100717925 T G 9.54E-05 Smoking initiation VPS13B intron 24665060 rs1788145 chr8 100724773 G T 1.19E-04 Smoking initiation VPS13B intron 24665060 rs1788146 chr8 100726548 G T 4.57E-04 Smoking initiation VPS13B intron 24665060 rs1667631 chr8 100727872 T C 9.61E-05 Smoking initiation VPS13B intron 24665060 rs1788148 chr8 100758980 T C 1.86E-04 Arthritis (juvenile idiopathic) VPS13B intron 22354554 rs1788148 chr8 100758980 T C 1.29E-04 Smoking initiation VPS13B intron 24665060 rs1449789 chr8 100763677 T A,G 4.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VPS13B intron 20877124 rs959695 chr8 100835182 T C 1.00E-06 Hippocampal atrophy VPS13B intron 22745009 rs6981691 chr8 100855843 C T 0.00000015 LDL cholesterol VPS13B intron 23063622 rs1130569 chr8 100899793 G A 5.50E-05 Memory performance COX6C cds-synon 22105620 rs12547260 chr8 100916000 T C 3.23E-04 Type 2 diabetes / / 17463246 rs7837596 chr8 100924271 G A 1.60E-05 Memory performance / / 22105620 rs7006527 chr8 101024505 A C 4.57E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) RGS22 intron 23648065 rs7006527 chr8 101024505 A C 9.00E-10 Basal cell carcinoma RGS22 intron 24403052 rs7006527 chr8 101024505 A C 9.00E-13 Basal cell carcinoma RGS22 intron 24403052 rs11779445 chr8 101043237 T C 6.11E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) RGS22 intron 23648065 rs2446930 chr8 101085056 C T 7.40E-04 Major depressive disorder RGS22 intron 22472876 rs113394050 chr8 101096089 T C 7.38E-04 Basal cell carcinoma RGS22 intron 24403052 rs2453626 chr8 101137897 T C 2.82E-07 Asthma / / 21804549 rs2919471 chr8 101232701 T C 9.87E-04 Suicide attempts in bipolar disorder SPAG1 intron 21423239 rs2919469 chr8 101233896 T C 8.52E-04 Suicide attempts in bipolar disorder SPAG1 intron 21423239 rs1660338 chr8 101242757 C G 9.64E-04 Suicide attempts in bipolar disorder SPAG1 intron 21423239 rs1660350 chr8 101268237 G A 1.82E-05 Leukocyte Counts / / pha003091 rs1371867 chr8 101330209 A C 9.00E-06 Atrioventricular conduction / / 21041692 rs16898280 chr8 101368080 C T 1.63E-04 Sarcoidosis / / 19165924 rs3019086 chr8 101393896 A G 0.000242 Salmonella-induced pyroptosis / / 22837397 rs17425970 chr8 101429696 C T 7.10E-05 Orofacial clefts / / 22419666 rs10107200 chr8 101452935 C T 6.55E-04 Myopia (pathological) / / 21095009 rs6999599 chr8 101461664 C T 8.20E-04 Myopia (pathological) / / 21095009 rs881491 chr8 101484612 G C 5.02E-05 Major depressive disorder (broad) / / 20038947 rs881492 chr8 101484638 C G 4.54E-05 Major depressive disorder (broad) / / 20038947 rs881485 chr8 101485007 A C 7.57E-05 Major depressive disorder (broad) / / 20038947 rs2154637 chr8 101486501 G A 9.00E-05 HDL cholesterol / / pha003075 rs2844044 chr8 101488120 G C 9.57E-05 Major depressive disorder (broad) / / 20038947 rs2844043 chr8 101488821 A C 1.96E-05 Major depressive disorder (broad) / / 20038947 rs2844043 chr8 101488821 A C 6.44E-05 HDL cholesterol / / pha003075 rs2154636 chr8 101492039 C T 7.47E-05 Major depressive disorder (broad) / / 20038947 rs4734457 chr8 101504357 C A 2.47E-05 Longevity / / 20304771 rs4734459 chr8 101505135 G A 2.38E-05 Height / / pha003011 rs16898460 chr8 101522503 T C 6.44E-04 Type 2 diabetes / / 17463246 rs17349757 chr8 101527505 T C 2.52E-04 Type 2 diabetes / / 17463246 rs17428901 chr8 101555261 A C 1.48E-04 Type 2 diabetes ANKRD46 intron 17463246 rs2507768 chr8 101556737 C T 1.31E-04 Type 2 diabetes ANKRD46 intron 17463246 rs2507768 chr8 101556737 C T 0.000618386 Hypertension (early onset hypertension) ANKRD46 intron 22479346 rs7835153 chr8 101573820 A G 3.47E-05 Atopy / / 21094521 rs7835153 chr8 101573820 A G 4.50E-07 Atopy / / 21094521 rs17429734 chr8 101579985 A G 5.96E-05 Coronary Artery Disease / / 17634449 rs10087412 chr8 101580604 A T 1.33E-04 Type 2 diabetes / / 17463246 rs2154639 chr8 101590470 T G 4.50E-05 HIV-1 control SNX31 intron 20041166 rs7841497 chr8 101657658 C T 5.80E-04 Alzheimer's disease SNX31 intron 22005930 rs7846275 chr8 101658636 C T 5.69E-04 Alzheimer's disease SNX31 intron 22005930 rs7815631 chr8 101658926 C T 5.42E-04 Alzheimer's disease SNX31 intron 22005930 rs7815950 chr8 101659168 A G 6.89E-08 Common variable immunodeficiency SNX31 intron 21497890 rs7815950 chr8 101659168 A G 5.08E-04 Alzheimer's disease SNX31 intron 22005930 rs1807959 chr8 101662721 G A 6.28E-04 Alzheimer's disease / / 22005930 rs7002825 chr8 101671221 T C 2.95E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs7002825 chr8 101671221 T C 7.44E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs1693549 chr8 101675374 C T 1.39E-04 Alzheimer's disease / / 22005930 rs7831729 chr8 101676572 T C 1.75E-04 Alzheimer's disease / / 22005930 rs1693566 chr8 101676969 A G 2.30E-04 Alzheimer's disease / / 22005930 rs1693569 chr8 101677774 C T 7.27E-05 Alzheimer's disease / / 22005930 rs3016884 chr8 101678178 T C 3.58E-05 Telomere length / / 23001564 rs1693560 chr8 101680292 A G 9.07E-04 Alzheimer's disease / / 22005930 rs2935548 chr8 101680355 A G 1.92E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs1786339 chr8 101682642 T C 1.24E-04 Alzheimer's disease / / 22005930 rs7831907 chr8 101683408 C T 1.40E-05 Urinary metabolites / / 21572414 rs1693572 chr8 101684412 A G 2.25E-04 Alzheimer's disease / / 22005930 rs1786330 chr8 101692130 C T 2.96E-05 Major depressive disorder (broad) / / 20038947 rs11785473 chr8 101702119 T A 2.08E-05 Major depressive disorder (broad) / / 20038947 rs1693543 chr8 101709538 C T 2.53E-05 Major depressive disorder (broad) / / 20038947 rs1786322 chr8 101712153 A C 2.53E-05 Major depressive disorder (broad) / / 20038947 rs13270692 chr8 101712174 A T 1.61E-04 Fibrinogen / / 17255346 rs1693547 chr8 101714394 C T 5.72E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1976322 chr8 101732447 T C 5.54E-04 Fibrinogen PABPC1 intron 17255346 rs11996206 chr8 101760660 G A 4.35E-04 Multiple complex diseases / / 17554300 rs61101261 chr8 101806055 C A 2.10E-05 Alcohol consumption / / 23743675 rs36061340 chr8 101807230 C T 7.00E-06 Alcohol consumption / / 23743675 rs35866478 chr8 101807365 G A 3.43E-05 Alcohol consumption / / 23743675 rs10464815 chr8 101808151 A C 3.43E-05 Alcohol consumption / / 23743675 rs58751921 chr8 101808965 A G 3.40E-05 Alcohol consumption / / 23743675 rs60243676 chr8 101809513 C G 3.43E-05 Alcohol consumption / / 23743675 rs59317432 chr8 101809662 G A 3.43E-05 Alcohol consumption / / 23743675 rs3847151 chr8 101809800 A G 3.49E-05 Alcohol consumption / / 23743675 rs10808365 chr8 101810491 T C 4.18E-05 Alcohol consumption / / 23743675 rs10808366 chr8 101810647 T G 4.14E-05 Alcohol consumption / / 23743675 rs10808367 chr8 101810651 C G 4.54E-05 Alcohol consumption / / 23743675 rs6993814 chr8 101810732 T G 4.01E-05 Alcohol consumption / / 23743675 rs10808368 chr8 101810846 T G 4.18E-05 Alcohol consumption / / 23743675 rs7016087 chr8 101810936 G A 4.18E-05 Alcohol consumption / / 23743675 rs7016436 chr8 101811224 G A 4.21E-05 Alcohol consumption / / 23743675 rs7016174 chr8 101811248 A C 1.00E-04 Alcohol consumption / / 23743675 rs7016480 chr8 101811390 C T 4.48E-05 Alcohol consumption / / 23743675 rs7012929 chr8 101811997 T G 4.52E-05 Alcohol consumption / / 23743675 rs7013576 chr8 101812400 T C 4.51E-05 Alcohol consumption / / 23743675 rs13274060 chr8 101812827 A T 4.41E-05 Alcohol consumption / / 23743675 rs13276772 chr8 101812937 T C 4.41E-05 Alcohol consumption / / 23743675 rs3843551 chr8 101813045 A G 4.39E-05 Alcohol consumption / / 23743675 rs3847152 chr8 101813074 C T 3.27E-05 Alcohol consumption / / 23743675 rs3847153 chr8 101813156 A G 9.00E-08 Premature ovarian failure / / 21989058 rs3847153 chr8 101813156 A G 5.46E-05 Alcohol consumption / / 23743675 rs3847153 chr8 101813156 A G 4.93E-05 Lipoproteins / / pha003079 rs3847154 chr8 101813178 C T 6.61E-05 Alcohol consumption / / 23743675 rs3843552 chr8 101813268 G T 6.61E-05 Alcohol consumption / / 23743675 rs3843552 chr8 101813268 G T 4.59E-05 Lipoproteins / / pha003079 rs10955242 chr8 101813630 G A 9.10E-05 Alcohol consumption / / 23743675 rs13279103 chr8 101813797 T C 9.02E-05 Alcohol consumption / / 23743675 rs13249189 chr8 101813902 C T 9.10E-05 Alcohol consumption / / 23743675 rs13250895 chr8 101814325 G C 9.10E-05 Alcohol consumption / / 23743675 rs3108919 chr8 101841546 T C 4.00E-06 AIDS / / 19754311 rs3105453 chr8 101849796 A G 4.89E-05 AIDS / / 19754311 rs2386492 chr8 101870990 G T 8.99E-04 Acne (severe) / / 24927181 rs2386492 chr8 101870990 G T 5.95E-05 Blood Pressure / / pha003040 rs17364251 chr8 101876999 T C 7.62E-04 Acne (severe) / / 24927181 rs884488 chr8 101898523 G C 9.45E-07 Telomere length / / 23001564 rs931812 chr8 101919321 C T 5.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs17365948 chr8 101956877 C T 1.59E-08 Blood pressure YWHAZ intron 21378095 rs17365948 chr8 101956877 C T 6.91E-09 Interleukin levels (IL10,IL1Ra,IL6),in plasma YWHAZ intron 22205395 rs2386922 chr8 101975479 T G 2.04E-06 Crohn's disease / / 17804789 rs6468747 chr8 102006405 G A 8.56E-05 Type 2 diabetes / / 17463246 rs6468748 chr8 102006633 A T 1.19E-04 Type 2 diabetes / / 17463246 rs1026228 chr8 102007701 T C 2.57E-06 Carotenoid and tocopherol levels / / 19185284 rs1026228 chr8 102007701 T C 3.20E-04 Adiposity / / 19461586 rs2053931 chr8 102013597 A G 3.02E-06 Carotenoid and tocopherol levels / / 19185284 rs737707 chr8 102083452 A G 6.23E-05 Schizophrenia FLJ42969 intron 19571809 rs4734517 chr8 102118012 C T 8.01E-04 Type 2 diabetes / / 17463246 rs7814514 chr8 102118645 A G 8.01E-04 Type 2 diabetes / / 17463246 rs6468759 chr8 102119855 A T 8.01E-04 Type 2 diabetes / / 17463246 rs11986462 chr8 102120409 T A 8.01E-04 Type 2 diabetes / / 17463246 rs3886153 chr8 102131154 T C 1.70E-05 Urinary metabolites / / 21572414 rs2053741 chr8 102140698 G A 4.25E-04 Breast cancer / / 21060860 rs2441708 chr8 102141998 C T 4.80E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2441696 chr8 102143941 C T 4.80E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2386931 chr8 102156862 C T 2.16E-05 Hemoglobin concentration / / 20534544 rs10092729 chr8 102164667 C T 9.31E-04 Tourette syndrome / / 22889924 rs11990866 chr8 102165283 T C 3.74E-05 Hemoglobin concentration / / 20534544 rs2441701 chr8 102170103 C T 5.99E-05 Blood Pressure / / pha002898 rs2441701 chr8 102170103 C T 5.31E-05 HDL particle features / / pha002900 rs7011529 chr8 102192178 A G 4.78E-05 Hemoglobin concentration / / 20534544 rs2441706 chr8 102203690 C T 6.63E-04 Myopia (pathological) / / 21095009 rs2232687 chr8 102212398 G C 1.07E-04 Multiple complex diseases ZNF706 intron 17554300 rs1264202 chr8 102227923 A C 2.00E-06 Response to antipsychotic treatment in schizophrenia (reasoning) / / 21107309 rs7004632 chr8 102233239 G A 3.06E-04 Multiple complex diseases / / 17554300 rs1447016 chr8 102236994 G A 9.58E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1947124 chr8 102252632 T C 1.52E-04 Hemoglobin concentration / / 20534544 rs1529605 chr8 102261691 C T 1.13E-04 Hemoglobin concentration / / 20534544 rs10097578 chr8 102278176 G A 3.72E-05 Multiple complex diseases / / 17554300 rs2099226 chr8 102297967 T C 5.81E-04 Heart Failure / / pha002885 rs9297302 chr8 102308173 T C 4.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10505007 chr8 102330393 A G 3.78E-04 Crohn's disease / / 17435756 rs1125111 chr8 102333475 G C 3.76E-05 Serum metabolites / / 19043545 rs1431012 chr8 102333707 C T 3.44E-05 Serum metabolites / / 19043545 rs477351 chr8 102346409 G A 4.74E-04 Acute lung injury / / 22295056 rs4734024 chr8 102355663 C T 2.02E-04 Substance dependence / / 21818250 rs16867579 chr8 102375267 A C 1.00E-06 Smooth-surface caries / / 24556642 rs4734025 chr8 102398892 A T 3.27E-04 Alzheimer's disease / / 17998437 rs16867625 chr8 102413837 G A 0.00005 Pancreatic cancer and survival / / 22665904 rs16867661 chr8 102419419 G C 9.64E-04 Self-reported allergy / / 23817569 rs12335148 chr8 102450006 C T 3.60E-04 Smoking cessation / / 24665060 rs497123 chr8 102450266 A C 2.03E-04 Multiple complex diseases / / 17554300 rs678347 chr8 102463602 G A 2.00E-08 Rheumatoid arthritis / / 24390342 rs678347 chr8 102463602 G A 7.00E-09 Rheumatoid arthritis / / 24390342 rs646514 chr8 102466061 C T 5.18E-07 Rheumatoid arthritis / / 19503088 rs539674 chr8 102484486 C T 5.87E-05 Progressive supranuclear palsy LOC100506689 intron 21685912 rs2447962 chr8 102490354 C G 8.98E-04 Multiple complex diseases LOC100506689 intron 17554300 rs2509765 chr8 102490380 C T 5.51E-05 Post-operative nausea and vomiting LOC100506689 intron 21694509 rs2509770 chr8 102490873 T A 3.00E-06 Urinary metabolites LOC100506689 intron 21572414 rs2509770 chr8 102490873 T A 1.84E-04 Smoking initiation LOC100506689 intron 24665060 rs509356 chr8 102500389 G A 6.21E-04 Iron levels LOC100506689 intron pha002876 rs476321 chr8 102509799 C T 2.15E-05 HIV(mother-to-child transmission) GRHL2 intron 20487506 rs608337 chr8 102511718 G A 4.71E-05 Multiple complex diseases GRHL2 intron 17554300 rs666026 chr8 102557218 C A 6.58E-04 Suicide attempts in bipolar disorder GRHL2 intron 21423239 rs11996495 chr8 102577783 T A 2.94E-05 Bipolar disorder,affective GRHL2 intron 20528957 rs16867848 chr8 102590841 G A 1.54E-04 Alzheimer's disease GRHL2 intron 17998437 rs11996871 chr8 102593462 T A 7.16E-05 Bipolar disorder,affective GRHL2 intron 20528957 rs6988306 chr8 102596210 C T 3.00E-06 Bronchopulmonary dysplasia GRHL2 intron 23897914 rs6980991 chr8 102607311 A G 7.78E-04 Multiple complex diseases GRHL2 intron 17554300 rs16867971 chr8 102609456 T C 9.97E-04 Alcohol dependence GRHL2 intron 21314694 rs16867973 chr8 102610279 A G 7.90E-04 Multiple complex diseases GRHL2 intron 17554300 rs13275653 chr8 102649681 C T 2.49E-04 Alzheimer's disease GRHL2 intron 17998437 rs2226399 chr8 102654182 T C 1.79E-04 Vaspin levels GRHL2 intron 22907691 rs2226399 chr8 102654182 T C 0.000179 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit GRHL2 intron 22907730 rs4734571 chr8 102672613 G A 2.82E-04 Lung function (forced vital capacity) GRHL2 intron 24023788 rs4734571 chr8 102672613 G A 5.11E-05 Lung function (forced expiratory volume in 1 second) GRHL2 intron 24023788 rs3824090 chr8 102679216 C T 9.00E-04 Diabetic nephropathy GRHL2 UTR-3 17671797 rs3824091 chr8 102679217 G A 9.00E-04 Diabetic nephropathy GRHL2 UTR-3 17671797 rs1131863 chr8 102700295 T C 4.00E-05 Diabetic nephropathy NCALD UTR-3 17671797 rs6468788 chr8 102712894 T C 7.29E-04 Suicide attempts in bipolar disorder NCALD intron 21423239 rs4734589 chr8 102728781 G A 2.17E-04 Fibrinogen NCALD intron 17255346 rs4734039 chr8 102740594 C T 9.02E-04 Myopia (pathological) NCALD intron 21095009 rs2226401 chr8 102743812 G C 7.27E-05 Serum metabolites NCALD intron 19043545 rs2387618 chr8 102762074 G A 6.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NCALD intron 20877124 rs16868426 chr8 102794121 A G 2.60E-04 Multiple complex diseases NCALD intron 17554300 rs11986905 chr8 102895645 G A 5.83E-04 Multiple complex diseases NCALD intron 17554300 rs16868715 chr8 102922409 A G 1.31E-04 Multiple complex diseases NCALD intron 17554300 rs517811 chr8 102944863 G A 5.00E-06 Cognitive performance NCALD intron 20125193 rs2387333 chr8 102965754 A G 9.82E-04 Amyotrophic lateral sclerosis (sporadic) NCALD intron 24529757 rs1269707 chr8 103044676 G A 8.28E-04 Type 2 diabetes NCALD intron 17463246 rs1269706 chr8 103044839 A T 3.30E-04 Type 2 diabetes NCALD intron 17463246 rs1269705 chr8 103044932 G A 8.79E-05 Heart Rate NCALD intron pha003051 rs6987078 chr8 103044961 G A 7.30E-04 Major depressive disorder NCALD intron 21042317 rs1269704 chr8 103045368 A T 7.29E-04 Type 2 diabetes NCALD intron 17463246 rs16868941 chr8 103052377 G A 8.00E-07 Coffee consumption NCALD intron 21876539 rs6991144 chr8 103058601 C T 5.78E-05 Type 1 diabetes NCALD intron 18978792 rs2155235 chr8 103067627 C T 2.10E-05 Alcohol and nictotine co-dependence NCALD intron 20158304 rs11784583 chr8 103085037 G T 3.83E-05 Blood Pressure and Arterial Stiffness NCALD intron 17903302 rs17507512 chr8 103111516 T G 9.99E-04 Multiple complex diseases NCALD intron 17554300 rs9642976 chr8 103115999 A G 7.10E-04 Coronary heart disease NCALD intron 21966275 rs10955280 chr8 103118797 C T 3.16E-04 Type 2 diabetes NCALD intron 17463246 rs7013304 chr8 103120655 C A 3.94E-04 Type 2 diabetes NCALD intron 17463246 rs503342 chr8 103130360 C A 8.55E-05 Type 2 diabetes NCALD intron 17463246 rs648119 chr8 103138045 A G 4.00E-05 Celiac disease / / 17558408 rs6980591 chr8 103144592 A C 6.97E-06 Hearing function / / 17255346 rs1111912 chr8 103165042 G A 2.20E-05 Urinary metabolites / / 21572414 rs1573311 chr8 103167015 C T 6.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10955282 chr8 103176946 G A 2.28E-05 Suicidal ideation / / 20877300 rs73281583 chr8 103185479 T C 0.000322 Sarcoidosis / / 22952805 rs59212627 chr8 103185554 T C 0.0003317 Sarcoidosis / / 22952805 rs2067029 chr8 103187804 G A 0.0004346 Sarcoidosis / / 22952805 rs11989838 chr8 103190340 T G 7.74E-04 Acute lung injury / / 22295056 rs16869317 chr8 103274478 C G 4.12E-04 Type 2 diabetes UBR5 intron 17463246 rs10481053 chr8 103356112 A C 3.87E-04 Major depressive disorder UBR5 intron 22472876 rs6983758 chr8 103512785 T C 3.26E-04 Multiple complex diseases / / 17554300 rs4734058 chr8 103524176 C T 2.04E-04 Celiac disease / / 23936387 rs6468833 chr8 103524461 A G 4.69E-04 Multiple complex diseases / / 17554300 rs7002944 chr8 103537659 C G 7.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs10096299 chr8 103545317 A G 2.45E-04 Multiple complex diseases / / 17554300 rs2511733 chr8 103560356 T C 1.00E-05 Urinary metabolites / / 21572414 rs2511734 chr8 103560526 A C 1.80E-05 Urinary metabolites / / 21572414 rs998201 chr8 103566428 G A 4.41E-05 Glucose levels ODF1 intron pha003061 rs2289032 chr8 103573448 G C 9.37E-04 Lymphocyte counts ODF1 nearGene-3 22286170 rs2436893 chr8 103574663 G A 5.10E-05 Malaria / / 19465909 rs2436893 chr8 103574663 G A 7.49E-05 Progressive supranuclear palsy / / 21685912 rs2436889 chr8 103576658 G A 4.74E-04 Type 2 diabetes / / 17463246 rs2511714 chr8 103578874 T G 0.0000755 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2511714 chr8 103578874 T G 5.00E-08 Chronic lymphocytic leukemia / / 23770605 rs17186961 chr8 103630028 G A 8.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6998277 chr8 103639941 T C 2.00E-06 Migraine / / 23793025 rs2436964 chr8 103649935 T C 2.62E-04 Schizophrenia / / 19197363 rs2513929 chr8 103714346 C T 7.07E-04 Alcohol dependence / / 21314694 rs2511694 chr8 103715226 A G 5.78E-04 Type 2 diabetes / / 17463246 rs1574480 chr8 103726919 T C 8.18E-04 Coronary heart disease / / 21971053 rs1529796 chr8 103782719 A G 8.20E-04 Type 2 diabetes / / 17463246 rs1529796 chr8 103782719 A G 7.70E-06 Urinary metabolites / / 21572414 rs16869786 chr8 103789455 T C 8.84E-07 Type 2 diabetes / / 17463246 rs2513922 chr8 103830188 C T 8.65E-04 Multiple complex diseases / / 17554300 rs2513922 chr8 103830188 C T 1.14E-04 Lymphocyte counts / / 22286170 rs12546520 chr8 103832256 G A 8.41E-04 Coronary Artery Disease / / 17634449 rs2304348 chr8 103845526 A C 9.65E-04 Alcohol consumption (maxi-drinks) AZIN1 intron 24277619 rs2679749 chr8 103858488 C T 6.60E-04 Multiple complex diseases AZIN1 intron 17554300 rs2679752 chr8 103864118 G A 8.15E-04 Multiple complex diseases AZIN1 intron 17554300 rs2679754 chr8 103868000 G A 9.46E-04 Multiple complex diseases AZIN1 intron 17554300 rs2570950 chr8 103883865 A C 9.08E-04 Multiple complex diseases / / 17554300 rs2570950 chr8 103883865 A C 9.98E-05 Serum metabolites / / 19043545 rs17776569 chr8 103890807 T G 4.97E-04 Multiple complex diseases / / 17554300 rs667927 chr8 103912414 A T 9.72E-04 Multiple complex diseases / / 17554300 rs678839 chr8 103912514 C T 1.64E-04 Arthritis (juvenile idiopathic) / / 22354554 rs6998032 chr8 103943414 C T 3.33E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs651816 chr8 103953990 G A 5.84E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs563201 chr8 103960710 A G 3.99E-05 Waist Circumference / / pha003023 rs2458284 chr8 103963319 C A 6.39E-05 Waist Circumference / / pha003023 rs4075572 chr8 103967694 G A 6.71E-05 Waist Circumference / / pha003023 rs6468852 chr8 103975989 A G 1.00E-06 Alzheimer's disease (late onset) / / 22881374 rs7827655 chr8 103980407 A G 2.30E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs543736 chr8 104012949 G A 7.00E-04 Chronic fatigue syndrome / / 21912186 rs2047378 chr8 104037681 T A 2.12E-04 Alzheimer's disease ATP6V1C1 intron 17998437 rs2453998 chr8 104089618 C A 3.77E-04 Parkinson's disease / / 17052657 rs2453998 chr8 104089618 C A 2.98E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2453998 chr8 104089618 C A 8.18E-04 Stroke / / pha002887 rs2453999 chr8 104090979 T C 2.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs2047375 chr8 104097396 G A 4.65E-04 Type 2 diabetes / / 17463246 rs1110115 chr8 104098620 C T 9.54E-06 Hearing function / / 21493956 rs2454015 chr8 104108882 T C 3.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2515210 chr8 104109811 A G 4.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs2454018 chr8 104113007 G A 2.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs2454020 chr8 104113302 C T 2.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs2454021 chr8 104113644 G A 4.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2454021 chr8 104113644 G A 3.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs2454023 chr8 104115580 C A 3.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs2515212 chr8 104115614 G T 4.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs2454025 chr8 104116112 C T 2.63E-04 Type 2 diabetes / / 17463246 rs2454025 chr8 104116112 C T 5.00E-05 Suicide attempts in bipolar disorder / / 21423239 rs16870093 chr8 104117091 A T 6.25E-05 Serum metabolites / / 19043545 rs979670 chr8 104117387 C T 5.20E-04 Type 2 diabetes / / 17463246 rs979670 chr8 104117387 C T 6.73E-05 Suicide attempts in bipolar disorder / / 21423239 rs979672 chr8 104117511 C G 7.05E-05 Suicide attempts in bipolar disorder / / 21423239 rs2454026 chr8 104118305 A G 6.14E-05 Suicide attempts in bipolar disorder / / 21423239 rs6983777 chr8 104118566 A G 8.00E-06 Attention deficit hyperactivity disorder (combined symptoms) / / 23527680 rs2515173 chr8 104121274 G T 5.70E-04 Iris characteristics / / 21835309 rs16870112 chr8 104122246 C A,G,T 5.85E-06 Osteoarthritis / / 22763110 rs2515181 chr8 104135859 G A 7.44E-04 Multiple complex diseases / / 17554300 rs2388493 chr8 104138586 C T 1.19E-04 Multiple complex diseases / / 17554300 rs11774996 chr8 104142090 T A 5.00E-05 Prostate cancer / / 21743057 rs6468861 chr8 104171886 C T 1.10E-04 Telomere length BAALC intron 21573004 rs7839419 chr8 104176386 A G 3.70E-05 Pulmonary function BAALC intron 19300500 rs10099640 chr8 104178381 C T 1.39E-05 Triglycerides BAALC intron 19074352 rs10099640 chr8 104178381 C T 1.39E-05 Polyunsaturated fatty acid levels,in plasma BAALC intron 19148276 rs7843029 chr8 104180465 T C 3.71E-05 Pulmonary function BAALC intron 19300500 rs7843452 chr8 104180743 T G 3.70E-05 Pulmonary function BAALC intron 19300500 rs4645535 chr8 104196509 C T 5.38E-04 Multiple complex diseases BAALC intron 17554300 rs16870243 chr8 104204654 C T 8.99E-04 Multiple complex diseases BAALC intron 17554300 rs16870245 chr8 104204858 C T 9.19E-04 Multiple complex diseases BAALC intron 17554300 rs7017690 chr8 104213889 T C 4.68E-05 Erythrocyte counts BAALC intron pha003101 rs2220825 chr8 104216746 C T 6.50E-04 Multiple complex diseases BAALC intron 17554300 rs2201369 chr8 104222025 T C 2.98E-06 Lymphocyte counts BAALC intron 22286170 rs7001084 chr8 104226946 A G 4.54E-05 Intracerebral hemorrhage BAALC intron 24656865 rs10112923 chr8 104257064 G A 8.12E-06 Coronary Artery Disease / / 17634449 rs1138873 chr8 104279038 G A 6.24E-05 Hemoglobin / / pha003098 rs1138873 chr8 104279038 G A 6.34E-06 Erythrocyte counts / / pha003099 rs6990501 chr8 104290148 A G 1.90E-04 Myasthenia gravis / / 23055271 rs3107648 chr8 104322803 C G 1.99E-04 Schizophrenia FZD6 intron 21674006 rs827536 chr8 104323026 C A 8.06E-04 Schizophrenia FZD6 intron 21674006 rs2131860 chr8 104328309 A G 4.55E-05 Multiple complex diseases FZD6 intron 17554300 rs827581 chr8 104357507 G A 9.17E-05 Cognitive test performance / / 20125193 rs827593 chr8 104365056 A G 4.02E-04 Alzheimer's disease / / 17998437 rs16870366 chr8 104365362 G A 8.70E-04 Multiple complex diseases / / 17554300 rs827599 chr8 104376913 A G 1.88E-04 Alzheimer's disease (late onset) / / 21379329 rs6995597 chr8 104384780 A G 8.74E-05 Socioeconomic Factors CTHRC1 missense pha003066 rs3098233 chr8 104394744 T C 8.40E-05 Elbow pain CTHRC1 cds-synon pha003008 rs3133813 chr8 104419442 T C 5.01E-05 Elbow pain SLC25A32 intron pha003008 rs3134292 chr8 104426045 C A 1.49E-04 Dental caries SLC25A32 intron 21940522 rs3133817 chr8 104426245 A G 1.42E-04 Dental caries SLC25A32 intron 21940522 rs3098224 chr8 104446696 C T 5.33E-05 Elbow pain DCAF13 intron pha003008 rs12676448 chr8 104479217 C T 1.42E-05 Type 2 diabetes / / 17463246 rs2437769 chr8 104487840 A G 1.80E-05 Urinary metabolites / / 21572414 rs17806104 chr8 104535511 C T 1.46E-05 Type 2 diabetes RIMS2 intron 17463246 rs2469978 chr8 104537715 C T 1.31E-05 Serum metabolites RIMS2 intron 19043545 rs2080610 chr8 104553408 A C 2.80E-04 Asperger disorder RIMS2 intron 21182207 rs10102124 chr8 104570862 T G 5.00E-08 Parkinson's disease (interaction with coffee consumption) RIMS2 intron 21876681 rs75686122 chr8 104573789 C A,G,T 1.30E-04 Cocaine dependence RIMS2 intron 23958962 rs75686122 chr8 104573789 C A,G,T 3.00E-06 Cocaine dependence RIMS2 intron 23958962 rs2433253 chr8 104581317 T C 9.82E-04 Multiple complex diseases RIMS2 intron 17554300 rs2433253 chr8 104581317 T C 2.88E-06 Serum metabolites RIMS2 intron 19043545 rs11783937 chr8 104658283 T G 2.60E-05 Iron levels RIMS2 intron 21208937 rs1834571 chr8 104659899 T C 2.21E-05 Serum metabolites RIMS2 intron 19043545 rs1426295 chr8 104688122 A C 2.40E-05 Serum metabolites RIMS2 intron 19043545 rs7845768 chr8 104749734 G A 8.99E-06 Type 2 diabetes RIMS2 intron 17463246 rs3110474 chr8 104760352 G T 3.71E-05 Serum metabolites RIMS2 intron 19043545 rs2935295 chr8 104861362 A G 8.39E-04 Multiple complex diseases RIMS2 intron 17554300 rs16870792 chr8 104884203 A T 3.85E-06 Kawasaki disease RIMS2 intron 21221998 rs7840870 chr8 104919476 A C 3.70E-06 Kawasaki disease RIMS2 intron 21221998 rs10110236 chr8 105043211 T C 4.88E-05 Glucose levels RIMS2 intron pha003061 rs11774939 chr8 105054446 A C 5.97E-05 Glucose levels RIMS2 intron pha003061 rs4366052 chr8 105080921 A G 7.54E-04 Type 2 diabetes RIMS2 intron 17463246 rs12155943 chr8 105114065 T A 2.90E-06 Urinary metabolites RIMS2 intron 21572414 rs13279907 chr8 105123036 C G 2.50E-06 Urinary metabolites RIMS2 intron 21572414 rs7001645 chr8 105123350 C G 4.63E-04 Fibrinogen RIMS2 intron 17255346 rs4512346 chr8 105128752 T C 2.30E-06 Urinary metabolites RIMS2 intron 21572414 rs7842508 chr8 105142985 G A 3.46E-04 Fibrinogen RIMS2 intron 17255346 rs2340768 chr8 105153786 A G 5.80E-06 Urinary metabolites RIMS2 intron 21572414 rs10505056 chr8 105162953 T C 6.40E-04 Type 2 diabetes and 6 quantitative traits RIMS2 intron 17848626 rs1545370 chr8 105174941 A G 3.30E-05 Lung function (forced expiratory volume in 1 second) RIMS2 intron pha003102 rs1545370 chr8 105174941 A G 7.77E-06 Lung function (forced vital capacity) RIMS2 intron pha003104 rs2441872 chr8 105175796 G T 3.60E-04 Fibrinogen RIMS2 intron 17255346 rs2441882 chr8 105183912 G C 3.16E-04 Fibrinogen RIMS2 intron 17255346 rs2441901 chr8 105207142 A T 7.27E-04 Response to statin treatment (atorvastatin),change in cholesterol levels RIMS2 intron 20031582 rs2511549 chr8 105216321 C A 8.48E-05 Lung function (forced expiratory volume in 1 second) RIMS2 intron pha003102 rs2511549 chr8 105216321 C A 2.51E-05 Lung function (forced vital capacity) RIMS2 intron pha003104 rs2511550 chr8 105220099 G A 9.65E-05 Lung function (forced expiratory volume in 1 second) RIMS2 intron pha003102 rs2511550 chr8 105220099 G A 3.69E-05 Lung function (forced vital capacity) RIMS2 intron pha003104 rs2511552 chr8 105221905 C T 3.81E-05 Lung function (forced vital capacity) RIMS2 intron pha003104 rs2511571 chr8 105232783 A G 7.00E-04 Heroin addiction RIMS2 intron 20520587 rs2511576 chr8 105234814 T C 7.00E-04 Heroin addiction RIMS2 intron 20520587 rs2441791 chr8 105238202 C T 3.10E-04 Response to statin treatment (atorvastatin),change in cholesterol levels RIMS2 intron 20031582 rs1156813 chr8 105247118 C T 3.00E-04 Heroin addiction RIMS2 intron 20520587 rs2511586 chr8 105253840 A G 7.14E-04 Suicide attempts in bipolar disorder RIMS2 intron 21041247 rs1868009 chr8 105268769 G T 0.0000255 Nicotine dependence (smoking) / / 22377092 rs1562399 chr8 105274827 G A 9.08E-06 Acute lymphoblastic leukemia (childhood) / / 19684603 rs2511602 chr8 105284865 A G 2.70E-05 Lung function (forced vital capacity) / / pha003104 rs1374520 chr8 105307981 C A 6.00E-05 Asperger disorder / / 21182207 rs2514631 chr8 105309103 C A 3.36E-05 Lung function (forced vital capacity) / / pha003104 rs1868011 chr8 105310154 G A 8.00E-05 Asperger disorder / / 21182207 rs2441851 chr8 105310905 A G 3.21E-04 Body mass index / / 21701565 rs2441851 chr8 105310905 A G 9.23E-05 Body mass index / / 21701565 rs2441851 chr8 105310905 A G 4.66E-05 Lung function (forced vital capacity) / / pha003104 rs2441859 chr8 105316734 A G 3.37E-05 Lung function (forced vital capacity) / / pha003104 rs1026054 chr8 105317279 G A 5.65E-05 Lung function (forced vital capacity) / / pha003104 rs2514653 chr8 105329096 T C 2.80E-05 Urinary metabolites / / 21572414 rs2458419 chr8 105337141 G C 5.76E-04 Fibrinogen / / 17255346 rs2458416 chr8 105351467 A G 9.64E-05 Cognitive test performance / / 20125193 rs2458415 chr8 105351998 A C 9.30E-05 Cognitive function / / 24684796 rs2458413 chr8 105359432 C T 4.14E-07 Paget's disease TM7SF4 intron 20436471 rs2458413 chr8 105359432 C T 7.00E-17 Paget's disease TM7SF4 intron 21623375 rs4734782 chr8 105374656 C A 1 Drug response to Etoposide / / 17537913 rs1317221 chr8 105387457 T G 9.29E-04 Myocardial Infarction / / pha002873 rs2253336 chr8 105393687 G A 7.27E-05 Soluble levels of adhesion molecules DPYS intron pha003072 rs6999483 chr8 105405921 G A 9.94E-04 Suicide attempts in bipolar disorder DPYS intron 21423239 rs2246650 chr8 105408828 T C 7.66E-04 Response to taxane treatment (placlitaxel) DPYS intron 23006423 rs1317472 chr8 105409476 G A 6.96E-04 Response to taxane treatment (placlitaxel) DPYS intron 23006423 rs2853160 chr8 105422209 A C 3.14E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) DPYS intron 24023788 rs6468928 chr8 105467509 C T 4.06E-04 Multiple complex diseases DPYS intron 17554300 rs2942570 chr8 105481705 T C 4.61E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7819498 chr8 105558914 G T 7.66E-04 Response to taxane treatment (placlitaxel) LRP12 intron 23006423 rs2880074 chr8 105641573 G A 9.75E-05 Meningococcal disease / / 20694013 rs4734805 chr8 105700583 T C 6.19E-06 Periodontitis (DPAL) / / 24024966 rs4734806 chr8 105700680 A G 6.00E-06 Periodontitis (DPAL) / / 24024966 rs725403 chr8 105709236 A T 7.45E-04 Multiple complex diseases / / 17554300 rs1866313 chr8 105713065 C A 2.84E-05 Waist-Hip Ratio / / pha003029 rs36072167 chr8 105713240 T C 9.85E-06 Periodontitis (DPAL) / / 24024966 rs1438342 chr8 105717183 G A 1.96E-04 Myocardial Infarction / / pha002873 rs10105004 chr8 105773886 T C 8.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs7006735 chr8 105777023 T C 8.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs35422619 chr8 105794290 T TG 1.60E-04 Urinary metabolites / / 21572414 rs17180310 chr8 105810705 C A 8.26E-05 Serum metabolites / / 19043545 rs1460239 chr8 105811365 C T 9.19E-05 Serum metabolites / / 19043545 rs1460239 chr8 105811365 C T 1.00E-06 Asthma / / 21790008 rs10098370 chr8 105811743 G A 3.70E-04 Mathematical ability / / 20039944 rs4734824 chr8 105873463 G A 7.55E-04 Type 2 diabetes / / 17463246 rs4734825 chr8 105878647 T G 8.83E-05 Hemoglobin concentration / / 20534544 rs10094493 chr8 105878832 T C 8.83E-05 Hemoglobin concentration / / 20534544 rs117523291 chr8 105907982 G C 2.20E-05 Corneal curvature / / 24963161 rs1545699 chr8 105915256 G A 1.28E-04 Schizophrenia / / 19197363 rs16872043 chr8 105940195 T A,C 1.34E-04 Multiple complex diseases / / 17554300 rs1851292 chr8 105956843 T C 6.92E-10 Glaucoma (primary open-angle) / / 22570617 rs284487 chr8 105957432 C T 6.92E-10 Glaucoma (primary open-angle) / / 22570617 rs284488 chr8 105957464 A G 6.92E-10 Glaucoma (primary open-angle) / / 22570617 rs16872085 chr8 105957540 A G 1.00E-06 Sudden cardiac arrest / / 21658281 rs284489 chr8 105958020 A G 9.00E-10 Glaucoma (primary open-angle) / / 22570617 rs284490 chr8 105958196 A C 6.92E-10 Glaucoma (primary open-angle) / / 22570617 rs284491 chr8 105958633 C T 9.71E-10 Glaucoma (primary open-angle) / / 22570617 rs284492 chr8 105959600 C T 1.42E-09 Glaucoma (primary open-angle) / / 22570617 rs284495 chr8 105965578 T C 1.42E-09 Glaucoma (primary open-angle) / / 22570617 rs284496 chr8 105965737 A C 1.67E-09 Glaucoma (primary open-angle) / / 22570617 rs1521771 chr8 105966757 A T 2.26E-09 Glaucoma (primary open-angle) / / 22570617 rs1521772 chr8 105966760 A G 1.42E-09 Glaucoma (primary open-angle) / / 22570617 rs1521774 chr8 105978990 G A 1.19E-09 Glaucoma (primary open-angle) / / 22570617 rs10106029 chr8 105982203 A G 6.03E-09 Glaucoma (primary open-angle) / / 22570617 rs977396 chr8 105992696 G A 3.00E-07 Response to antipsychotic treatment / / 20195266 rs4734838 chr8 105994885 A G 4.85E-05 Body Mass Index / / pha003006 rs4734838 chr8 105994885 A G 4.98E-07 Waist Circumference / / pha003024 rs4734838 chr8 105994885 A G 8.32E-05 Weight / / pha003026 rs4734838 chr8 105994885 A G 3.91E-05 Waist-Hip Ratio / / pha003029 rs9886642 chr8 106022458 T C 1.49E-06 Waist Circumference / / pha003024 rs9886642 chr8 106022458 T C 4.00E-05 Waist-Hip Ratio / / pha003029 rs16872224 chr8 106043079 C A 9.73E-04 Type 2 diabetes / / 17463246 rs285872 chr8 106058347 T C 7.80E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs3107547 chr8 106086536 G A 6.88E-05 Cognitive test performance / / 20125193 rs2125984 chr8 106107997 G T 3.87E-04 Tourette syndrome / / 22889924 rs627350 chr8 106109017 T C 4.35E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs17278154 chr8 106109678 C T 2.50E-05 Urinary metabolites / / 21572414 rs10505073 chr8 106112262 G C 8.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9297357 chr8 106142333 C T 4.00E-07 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs4734846 chr8 106182260 T C 9.06E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1460580 chr8 106207406 C G 4.68E-04 Multiple complex diseases / / 17554300 rs12675553 chr8 106228851 C T 5.99E-04 Alzheimer's disease / / 22005930 rs10955382 chr8 106253881 G A 7.29E-04 Alzheimer's disease / / 22005930 rs9642799 chr8 106257210 C T 7.32E-04 Alzheimer's disease / / 22005930 rs10955383 chr8 106259387 G T 2.68E-04 Multiple complex diseases / / 17554300 rs10955383 chr8 106259387 G T 8.00E-04 Alzheimer's disease / / 22005930 rs12680208 chr8 106260065 A C,G,T 6.77E-04 Alzheimer's disease / / 22005930 rs12678274 chr8 106260115 T C 6.26E-04 Alzheimer's disease / / 22005930 rs10097782 chr8 106260316 C T 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12543827 chr8 106261108 G A 9.26E-05 Multiple complex diseases / / 17554300 rs12543827 chr8 106261108 G A 6.37E-04 Alzheimer's disease / / 22005930 rs2342778 chr8 106261959 T G 5.02E-04 Alzheimer's disease / / 22005930 rs2342782 chr8 106269004 G T 5.90E-04 Alzheimer's disease / / 22005930 rs2880439 chr8 106269195 A G 9.12E-04 Alcohol dependence / / 21314694 rs2880439 chr8 106269195 A G 8.70E-06 Blood pressure / / 21572416 rs2957422 chr8 106276364 G A 8.24E-05 Amyotrophic lateral sclerosis / / 20801717 rs2880438 chr8 106276723 G A 3.31E-04 Hemoglobin concentration / / 20534544 rs2880438 chr8 106276723 G A 8.46E-04 Alzheimer's disease / / 22005930 rs2941627 chr8 106283030 G A 3.93E-04 Hemoglobin concentration / / 20534544 rs2941627 chr8 106283030 G A 0.0000035 Paclitaxel-induced sensory peripheral neuropathy / / 22843789 rs2941627 chr8 106283030 G A 0.0000353 Amyotrophic lateral sclerosis / / 23587638 rs13282933 chr8 106285042 A G 9.98E-04 Alzheimer's disease / / 22005930 rs1078330 chr8 106286732 G A 3.25E-04 Multiple complex diseases / / 17554300 rs7002014 chr8 106288608 T C 9.94E-04 Alzheimer's disease / / 22005930 rs6981965 chr8 106288739 A G 9.91E-04 Alzheimer's disease / / 22005930 rs12155641 chr8 106290578 T C 9.97E-04 Alzheimer's disease / / 22005930 rs16872634 chr8 106291213 T C 6.05E-05 Multiple complex diseases / / 17554300 rs16872634 chr8 106291213 T C 5.22E-04 Alzheimer's disease / / 22005930 rs12176634 chr8 106292504 C T 1.14E-04 Multiple complex diseases / / 17554300 rs12176634 chr8 106292504 C T 4.94E-04 Alzheimer's disease / / 22005930 rs6468994 chr8 106296720 C T 1.14E-04 Menarche (age at onset) / / 23599027 rs13280761 chr8 106297534 A C 5.33E-04 Alzheimer's disease / / 22005930 rs4078084 chr8 106297815 T C 4.78E-04 Alzheimer's disease / / 22005930 rs10808402 chr8 106299096 G A 4.06E-04 Alzheimer's disease / / 22005930 rs4507730 chr8 106299899 T A 5.39E-04 Alzheimer's disease / / 22005930 rs12676616 chr8 106301227 G A 1.10E-04 Multiple complex diseases / / 17554300 rs12676616 chr8 106301227 G A 4.88E-04 Alzheimer's disease / / 22005930 rs13251320 chr8 106303110 A G 6.49E-04 Alzheimer's disease / / 22005930 rs2001571 chr8 106310305 T G 2.30E-04 Type 2 diabetes / / 17463246 rs2001571 chr8 106310305 T G 1.70E-04 Multiple complex diseases / / 17554300 rs2957464 chr8 106312385 G A 8.97E-05 Cognitive impairment induced by topiramate / / 22091778 rs2941652 chr8 106364072 A G 1.35E-06 Cholesterol ZFPM2 intron 17255346 rs10464844 chr8 106419754 A G 3.12E-05 Heart Rate ZFPM2 intron pha003053 rs1383591 chr8 106419828 A G 9.38E-05 Schizophrenia ZFPM2 intron 19571809 rs11988529 chr8 106428022 T C 2.17E-05 Schizophrenia ZFPM2 intron 19571809 rs1383592 chr8 106430676 G A 6.12E-05 Heart Rate ZFPM2 intron pha003053 rs12677825 chr8 106435223 T C 8.20E-05 Personality dimensions ZFPM2 intron 18957941 rs16873003 chr8 106435981 T C 8.78E-05 Schizophrenia ZFPM2 intron 19571809 rs4734863 chr8 106437978 A G 5.82E-05 Schizophrenia ZFPM2 intron 19571809 rs7823133 chr8 106438580 C T 3.66E-05 Schizophrenia ZFPM2 intron 19571809 rs10101650 chr8 106498715 T C 1.81E-05 Personality dimensions ZFPM2 intron 22628180 rs2122444 chr8 106503845 A G 5.34E-04 Amyotrophic Lateral Sclerosis ZFPM2 intron 17362836 rs2622633 chr8 106509975 G A 6.00E-06 Coronary artery calcification ZFPM2 intron 23870195 rs302960 chr8 106517677 A G 1.03E-04 Nicotine smoking ZFPM2 intron 19268276 rs302964 chr8 106518412 C T 4.60E-04 Nicotine smoking ZFPM2 intron 19268276 rs16873291 chr8 106528030 C T 2.99E-16 Vascular endothelial growth factor levels ZFPM2 intron 21757650 rs1349319 chr8 106556634 A G 4.55E-11 Vascular endothelial growth factor levels ZFPM2 intron 21757650 rs16873365 chr8 106558235 C T 5.17E-15 Vascular endothelial growth factor levels ZFPM2 intron 21757650 rs1037306 chr8 106561277 T C 4.21E-04 Nicotine smoking ZFPM2 intron 19268276 rs6993696 chr8 106581284 G A 1.67E-15 Vascular endothelial growth factor levels ZFPM2 intron 21757650 rs6993770 chr8 106581528 A T 5.00E-23 Vascular endothelial growth factor levels ZFPM2 intron 21757650 rs6993770 chr8 106581528 A T 4.00E-17 Platelet counts ZFPM2 intron 22139419 rs13260447 chr8 106587719 C A 7.36E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ZFPM2 intron 21844884 rs16873402 chr8 106589247 C T 3.39E-20 Vascular endothelial growth factor levels ZFPM2 intron 21757650 rs7013321 chr8 106593558 G A 2.48E-13 Vascular endothelial growth factor levels ZFPM2 intron 21757650 rs7015353 chr8 106606008 A G 2.97E-05 Major depressive disorder (broad) ZFPM2 intron 20038947 rs17217757 chr8 106613321 G C 3.00E-06 Tuberculosis ZFPM2 intron 24057671 rs12679854 chr8 106618662 G A 1.39E-05 Major depressive disorder (broad) ZFPM2 intron 20038947 rs7015025 chr8 106618733 G A 1.39E-05 Major depressive disorder (broad) ZFPM2 intron 20038947 rs6981187 chr8 106619255 A G 1.39E-05 Major depressive disorder (broad) ZFPM2 intron 20038947 rs1450168 chr8 106621481 C G 7.72E-05 Major depressive disorder (broad) ZFPM2 intron 20038947 rs9785073 chr8 106621925 G A 1.33E-05 Major depressive disorder (broad) ZFPM2 intron 20038947 rs1037304 chr8 106627197 A G 1.27E-05 Major depressive disorder (broad) ZFPM2 intron 20038947 rs1817023 chr8 106628965 T G 7.47E-05 Tuberculosis ZFPM2 intron 24057671 rs1901064 chr8 106635651 G A 3.11E-05 Major depressive disorder (broad) ZFPM2 intron 20038947 rs9656868 chr8 106654909 C T 2.08E-04 Prion diseases ZFPM2 intron 22210626 rs2218279 chr8 106674812 T C 8.16E-05 Kawasaki disease ZFPM2 intron 22081228 rs6469010 chr8 106707739 T C 1.90E-05 Crohn's disease (time to surgery) ZFPM2 intron 23665963 rs7826613 chr8 106715359 A G 3.67E-04 Smoking quantity ZFPM2 intron 24665060 rs16873557 chr8 106724711 C T 6.37E-04 Multiple complex diseases ZFPM2 intron 17554300 rs16873564 chr8 106729039 G A 4.38E-04 Smoking quantity ZFPM2 intron 24665060 rs1025856 chr8 106733869 A G 4.24E-04 Smoking initiation ZFPM2 intron 24665060 rs1025856 chr8 106733869 A G 7.44E-04 Smoking quantity ZFPM2 intron 24665060 rs2165644 chr8 106734485 C T 5.79E-04 Smoking quantity ZFPM2 intron 24665060 rs2165644 chr8 106734485 C T 8.46E-05 Smoking initiation ZFPM2 intron 24665060 rs7816793 chr8 106741456 T G 5.50E-04 Smoking initiation ZFPM2 intron 24665060 rs12541049 chr8 106741666 A C,G,T 6.35E-04 Smoking quantity ZFPM2 intron 24665060 rs6469013 chr8 106746435 A G 1.72E-04 Smoking initiation ZFPM2 intron 24665060 rs10106386 chr8 106753057 T C 3.30E-04 Smoking initiation ZFPM2 intron 24665060 rs1442326 chr8 106755759 A G 7.29E-04 Smoking initiation ZFPM2 intron 24665060 rs16873621 chr8 106758967 A C 2.44E-04 Smoking quantity ZFPM2 intron 24665060 rs2958709 chr8 106769070 G A 6.61E-05 Socioeconomic Factors ZFPM2 intron pha003066 rs2958710 chr8 106772453 T G 3.49E-04 Smoking initiation ZFPM2 intron 24665060 rs10505082 chr8 106780628 G A 6.57E-04 Smoking initiation ZFPM2 intron 24665060 rs1442324 chr8 106792591 A G 3.27E-05 Smoking initiation ZFPM2 intron 24665060 rs10505088 chr8 106818453 G A 6.16E-05 Multiple complex diseases / / 17554300 rs11986537 chr8 106880649 C T 7.88E-05 Serum albumin level / / pha003084 rs11986537 chr8 106880649 C T 6.07E-05 Calcium levels / / pha003085 rs2088267 chr8 106903519 C T 8.21E-05 Graves' disease / / 21841780 rs7012171 chr8 106913294 C T 4.54E-05 Serum albumin level / / pha003084 rs7012171 chr8 106913294 C T 1.96E-05 Calcium levels / / pha003085 rs12542647 chr8 106926096 G A 3.79E-05 Calcium levels / / pha003085 rs10955406 chr8 106926778 G A 3.10E-04 Smoking initiation / / 24665060 rs1353449 chr8 106943245 G A 1.04E-04 Progressive supranuclear palsy / / 21685912 rs7013082 chr8 106943787 G A 1.41E-04 Progressive supranuclear palsy / / 21685912 rs11988877 chr8 106958185 G A 1.01E-04 Progressive supranuclear palsy / / 21685912 rs6997487 chr8 106965511 A C 1.15E-05 Smoking initiation / / 24665060 rs1006480 chr8 106975524 T A,C,G 4.26E-05 Smoking initiation / / 24665060 rs201476982 chr8 106975524 T TC 4.26E-05 Smoking initiation / / 24665060 rs6469023 chr8 106989558 T C 1.10E-04 Smoking initiation / / 24665060 rs7819043 chr8 106989783 T C 2.62E-04 Smoking initiation / / 24665060 rs6987512 chr8 106998770 C T 3.29E-05 Smoking initiation / / 24665060 rs10808408 chr8 107005034 C T 1.09E-05 Smoking initiation / / 24665060 rs7819501 chr8 107006962 T C 3.72E-05 Smoking initiation / / 24665060 rs12546875 chr8 107012915 C T 1.50E-04 Smoking initiation / / 24665060 rs6999580 chr8 107018254 G A 4.14E-05 Smoking initiation / / 24665060 rs10955409 chr8 107022586 A C 3.11E-04 Smoking initiation / / 24665060 rs1603363 chr8 107031319 A G 1.74E-04 Smoking initiation / / 24665060 rs34872724 chr8 107033071 A G 4.57E-04 Smoking initiation / / 24665060 rs1353450 chr8 107035120 G A 1.10E-04 Smoking initiation / / 24665060 rs6415444 chr8 107043797 G A 6.88E-05 Smoking initiation / / 24665060 rs7830351 chr8 107048825 G A 1.32E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs7003520 chr8 107061724 G A 9.37E-05 Smoking initiation / / 24665060 rs13277300 chr8 107062819 G A 4.26E-05 Smoking initiation / / 24665060 rs1864318 chr8 107064887 C T 4.00E-05 Prostate cancer / / 21743057 rs1864319 chr8 107064929 A G 7.00E-05 Prostate cancer / / 21743057 rs2059943 chr8 107071607 G T 1.40E-04 Volumetric brain MRI / / 17903297 rs2345070 chr8 107072027 G A 1.16E-05 Smoking initiation / / 24665060 rs727419 chr8 107076421 G A 2.73E-04 Smoking initiation / / 24665060 rs1366968 chr8 107083663 T C 4.00E-05 Prostate cancer / / 21743057 rs1366966 chr8 107084000 A T 4.00E-05 Prostate cancer / / 21743057 rs13256474 chr8 107086419 T C 2.85E-05 Smoking initiation / / 24665060 rs6415445 chr8 107088936 T C 8.80E-05 Smoking initiation / / 24665060 rs1864320 chr8 107088979 A G 1.39E-04 Smoking initiation / / 24665060 rs12541635 chr8 107090000 C T 1.00E-06 Smoking initiation / / 24665060 rs1896918 chr8 107090500 G A 5.73E-05 Smoking initiation / / 24665060 rs4734131 chr8 107096504 G A 1.90E-04 Smoking initiation / / 24665060 rs7016835 chr8 107096837 A G 7.41E-04 Smoking initiation / / 24665060 rs1835266 chr8 107099240 C T 5.02E-04 Smoking initiation / / 24665060 rs7000924 chr8 107101226 A G 6.64E-04 Smoking initiation / / 24665060 rs6989082 chr8 107104545 A G 3.93E-04 Smoking initiation / / 24665060 rs17227540 chr8 107141215 A G 0.0008746 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17227540 chr8 107141215 A G 8.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11783203 chr8 107162670 A G 3.55E-04 Smoking quantity / / 24665060 rs11776357 chr8 107162795 C T 9.71E-04 Type 2 diabetes / / 17463246 rs1366963 chr8 107163978 C A 9.60E-07 Response to antidepressants / / 19736353 rs2914860 chr8 107175621 C T 4.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16874205 chr8 107202148 T C 9.43E-10 Multiple complex diseases / / 17554300 rs41386646 chr8 107207156 T C 4.40E-06 Type 2 diabetes / / 17463246 rs11993758 chr8 107209378 C T 1.00E-04 Prostate cancer / / 21743057 rs16874228 chr8 107227569 C T 5.54E-05 Type 2 diabetes / / 17463246 rs13282023 chr8 107233554 T A 1.06E-04 Type 2 diabetes / / 17463246 rs1393978 chr8 107236280 G T 6.60E-05 Type 2 diabetes / / 17463246 rs6469053 chr8 107239780 T C 2.50E-04 Type 2 diabetes / / 17463246 rs1393977 chr8 107242314 A G 1.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs958630 chr8 107249559 T C 3.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17249646 chr8 107251414 A C 7.82E-06 Type 2 diabetes / / 17463246 rs2938305 chr8 107278277 C T 5.81E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2938302 chr8 107308858 T C 8.42E-04 Suicide attempts in bipolar disorder OXR1 intron 21423239 rs11991006 chr8 107312126 C T 7.99E-04 Multiple complex diseases OXR1 intron 17554300 rs7013315 chr8 107326900 A G 2.30E-05 Asthma (bronchodilator response) OXR1 intron 22792082 rs12682157 chr8 107331653 A G 1.70E-05 Asthma (bronchodilator response) OXR1 intron 22792082 rs9297380 chr8 107333828 C T 2.70E-06 Asthma (bronchodilator response) OXR1 intron 22792082 rs9283944 chr8 107334109 C T 2.80E-06 Asthma (bronchodilator response) OXR1 intron 22792082 rs9297381 chr8 107334331 G A 2.80E-06 Asthma (bronchodilator response) OXR1 intron 22792082 rs2345581 chr8 107334686 A G 2.80E-06 Asthma (bronchodilator response) OXR1 intron 22792082 rs10105383 chr8 107335570 A T 2.90E-06 Asthma (bronchodilator response) OXR1 intron 22792082 rs9774587 chr8 107336888 C A 3.80E-06 Asthma (bronchodilator response) OXR1 intron 22792082 rs16874388 chr8 107336940 T C 5.50E-06 Asthma (bronchodilator response) OXR1 intron 22792082 rs10092617 chr8 107339141 A G 7.30E-06 Asthma (bronchodilator response) OXR1 intron 22792082 rs61372898 chr8 107349327 G A 5.31E-34 Metabolite levels OXR1 intron 22286219 rs6992673 chr8 107353313 G A 7.00E-06 Asthma (bronchodilator response) OXR1 intron 22792082 rs10283328 chr8 107353858 G A 6.90E-06 Asthma (bronchodilator response) OXR1 intron 22792082 rs905557 chr8 107355371 C T 5.72E-04 Suicide attempts in bipolar disorder OXR1 intron 21423239 rs1954755 chr8 107395988 C A 4.90E-04 Multiple complex diseases OXR1 intron 17554300 rs16874483 chr8 107396660 G C 6.13E-04 Multiple complex diseases OXR1 intron 17554300 rs7827856 chr8 107411853 C A 6.96E-05 Body Mass Index OXR1 intron pha003007 rs7827856 chr8 107411853 C A 2.07E-05 Body Mass Index OXR1 intron pha003014 rs2167801 chr8 107494071 A T 1.17E-05 Telomere length OXR1 intron 20139977 rs16874737 chr8 107502431 C T 1.51E-05 Reading and spelling OXR1 intron 23738518 rs1453226 chr8 107503845 A G 7.67E-06 Lung function (forced expiratory volume in 1 second) OXR1 intron pha003103 rs1614808 chr8 107514061 G A 9.11E-06 Lung function (forced expiratory volume in 1 second) OXR1 intron pha003103 rs10108020 chr8 107524424 A G 2.93E-05 Reading and spelling OXR1 intron 23738518 rs12549912 chr8 107524789 G T 2.93E-05 Reading and spelling OXR1 intron 23738518 rs6996005 chr8 107532927 T G 7.03E-05 Alcohol consumption OXR1 intron 23743675 rs16874819 chr8 107533392 G A 7.44E-04 Multiple complex diseases OXR1 intron 17554300 rs16874819 chr8 107533392 G A 5.60E-34 Narcolepsy OXR1 intron 19629137 rs7813598 chr8 107534131 G A 1.90E-06 Urinary metabolites OXR1 intron 21572414 rs16874823 chr8 107538660 T C 5.60E-06 Urinary metabolites OXR1 intron 21572414 rs1453227 chr8 107544383 G A 1.67E-05 Reading and spelling OXR1 intron 23738518 rs1453227 chr8 107544383 G A 2.48E-05 Word reading OXR1 intron 23738518 rs1453227 chr8 107544383 G A 7.50E-05 Temporomandibular joint disorders OXR1 intron 23746317 rs6469074 chr8 107545590 C T 1.35E-05 Reading and spelling OXR1 intron 23738518 rs6469074 chr8 107545590 C T 1.76E-05 Word reading OXR1 intron 23738518 rs6469074 chr8 107545590 C T 8.90E-05 Temporomandibular joint disorders OXR1 intron 23746317 rs16874846 chr8 107557642 C T 1.67E-05 Reading and spelling OXR1 intron 23738518 rs16874846 chr8 107557642 C T 2.01E-05 Word reading OXR1 intron 23738518 rs3134125 chr8 107591712 A C 2.64E-04 Type 2 diabetes OXR1 intron 17463246 rs3110430 chr8 107606599 G A 2.12E-04 Type 2 diabetes OXR1 intron 17463246 rs3101548 chr8 107635851 G A 5.41E-04 Type 2 diabetes OXR1 intron 17463246 rs776966 chr8 107698729 A G 1.68E-04 Type 2 diabetes OXR1 intron 17463246 rs1580428 chr8 107710543 T C 9.02E-05 Type 2 diabetes OXR1 intron 17463246 rs1580429 chr8 107710800 A G 1.47E-05 Type 2 diabetes OXR1 intron 17463246 rs776942 chr8 107717026 C T 1.39E-04 Type 2 diabetes OXR1 intron 17463246 rs1784485 chr8 107789382 G C 1.39E-04 Type 2 diabetes / / 17463246 rs16875079 chr8 107791095 G T 9.55E-05 Type 2 diabetes and other traits / / 19734900 rs6999688 chr8 107817656 T C 3.28E-04 Lung function (forced vital capacity) / / 24023788 rs2449836 chr8 107817846 C A 5.00E-04 Schizophrenia / / 19197363 rs2449837 chr8 107823148 G A 3.70E-05 Cholesterol / / pha003073 rs2449837 chr8 107823148 G A 2.13E-05 ldl cholesterol / / pha003076 rs2449837 chr8 107823148 G A 4.23E-05 Cholesterol / / pha003078 rs17353424 chr8 107823281 G A 0.000128 Ovarian cancer / / 22794196 rs2981220 chr8 107833777 T C 8.17E-04 Coronary heart disease / / 21606135 rs2981218 chr8 107835544 T G 7.77E-04 Coronary heart disease / / 21606135 rs2981205 chr8 107844447 C T 5.00E-06 Intelligence (childhood) / / 23358156 rs959782 chr8 107852506 G C 1.35E-04 Multiple complex diseases / / 17554300 rs2981255 chr8 107870660 T A 0.00082 Salmonella-induced pyroptosis / / 22837397 rs7827343 chr8 107886992 T C 7.01E-04 Multiple complex diseases / / 17554300 rs2981256 chr8 107893477 A G 5.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13271148 chr8 107908203 T C 4.65E-04 Multiple complex diseases / / 17554300 rs4269515 chr8 107909009 A G 4.00E-06 Dental caries / / 23259602 rs4615542 chr8 107913396 C T 3.63E-05 Multiple sclerosis (age of onset) / / 19010793 rs11992975 chr8 107916446 A G 3.63E-05 Multiple sclerosis (age of onset) / / 19010793 rs16875279 chr8 107926808 G T 8.60E-04 Multiple complex diseases / / 17554300 rs10504089 chr8 107931278 G A 3.12E-04 Bipolar disorder / / 19259986 rs4236780 chr8 107936951 G C 6.00E-04 Chronic fatigue syndrome / / 21912186 rs4734938 chr8 107937739 T C 9.40E-05 Age-related macular degeneration / / 20861866 rs4734938 chr8 107937739 T C 8.67E-05 Age-related macular degeneration / / pha000002 rs16875331 chr8 107939696 G A 8.70E-04 Type 2 diabetes / / 17463249 rs16875331 chr8 107939696 G A 8.70E-04 Multiple complex diseases / / 17554300 rs2447243 chr8 107940668 A G 2.06E-04 Hemoglobin concentration / / 20534544 rs2927119 chr8 107958968 A G 7.63E-04 Multiple complex diseases / / 17554300 rs7829009 chr8 107974270 C T 6.03E-04 Multiple complex diseases / / 17554300 rs1461999 chr8 108003878 T C 7.31E-04 Multiple complex diseases / / 17554300 rs1462014 chr8 108008913 C T 4.49E-04 Hemoglobin concentration / / 20534544 rs11985867 chr8 108011442 G C 5.56E-04 Multiple complex diseases / / 17554300 rs7004587 chr8 108040352 G A 3.00E-06 Obesity-related traits / / 23251661 rs6469090 chr8 108047032 C A 7.86E-04 Multiple complex diseases / / 17554300 rs1461992 chr8 108086678 T G 0.0000336 alzheimer's disease (late onset) / / 22785395 rs2584388 chr8 108104411 A C 2.37E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11778352 chr8 108173197 A G 5.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs2844262 chr8 108174854 G A 1.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs2584370 chr8 108175983 G T 6.17E-05 Bladder cancer / / 19648920 rs2584370 chr8 108175983 G T 3.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs2000482 chr8 108181329 C G 3.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs2844277 chr8 108181407 T A 4.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs2584372 chr8 108182891 A T 4.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs2022954 chr8 108211253 T C 3.10E-06 Urinary metabolites / / 21572414 rs2584383 chr8 108213026 C T 2.00E-06 Urinary metabolites / / 21572414 rs16875856 chr8 108224687 A G 8.97E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4305876 chr8 108224765 G A 8.80E-04 Endometriosis / / 23104006 rs7017095 chr8 108227061 T C 9.97E-05 Progressive supranuclear palsy / / 21685912 rs7017095 chr8 108227061 T C 8.94E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2186397 chr8 108234717 T C 1.02E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10094991 chr8 108247892 G A 3.95E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs41466146 chr8 108266007 C T 1.20E-05 Urinary metabolites ANGPT1 intron 21572414 rs2514878 chr8 108273016 T C 9.27E-04 Response to cytidine analogues (gemcitabine) ANGPT1 intron 24483146 rs6993449 chr8 108281427 C G 3.00E-06 IgG glycosylation ANGPT1 intron 23382691 rs9297393 chr8 108287577 T G 6.40E-05 Electrocardiographic traits and heart rate variability ANGPT1 intron 17903306 rs4341141 chr8 108320785 T A 9.95E-05 Personality dimensions ANGPT1 intron 18957941 rs2163870 chr8 108377901 A G 3.00E-06 Fractional exhaled nitric oxide (childhood) ANGPT1 intron 24315451 rs2163870 chr8 108377901 A G 5.24E-05 Fractional exhaled nitric oxide (childhood) ANGPT1 intron 24315451 rs1672195 chr8 108383641 T C 6.53E-05 Neutrophil count ANGPT1 intron pha003095 rs1654712 chr8 108385748 G A 6.53E-05 Neutrophil count ANGPT1 intron pha003095 rs1672184 chr8 108387747 A G 1.37E-05 Neutrophil count ANGPT1 intron pha003095 rs1433175 chr8 108390053 T C 2.70E-05 Urinary metabolites ANGPT1 intron 21572414 rs1283663 chr8 108409931 C A 3.73E-04 Schizophrenia ANGPT1 intron 19197363 rs892248 chr8 108422946 G A 1.60E-04 Endometriosis ANGPT1 intron 21151130 rs1283673 chr8 108431161 T C 4.43E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ANGPT1 intron 20031582 rs13263947 chr8 108439362 G A 5.90E-05 Endometriosis ANGPT1 intron 21151130 rs1004460 chr8 108439898 C A 3.02E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ANGPT1 intron 20031582 rs13280030 chr8 108446403 A G 6.50E-05 Endometriosis ANGPT1 intron 21151130 rs13255500 chr8 108447543 A G 3.90E-05 Endometriosis ANGPT1 intron 21151130 rs1433186 chr8 108447610 C T 6.26E-04 Multiple complex diseases ANGPT1 intron 17554300 rs1433184 chr8 108452794 T C 5.69E-05 Lung function (forced vital capacity) ANGPT1 intron 24023788 rs13273578 chr8 108454681 G A 4.87E-04 Amyotrophic lateral sclerosis (sporadic) ANGPT1 intron 24529757 rs10098499 chr8 108458582 T C 5.10E-05 Endometriosis ANGPT1 intron 21151130 rs11991529 chr8 108463840 C T 1.20E-04 Endometriosis ANGPT1 intron 21151130 rs1283720 chr8 108472328 G A 5.20E-04 Pulmonary function ANGPT1 intron 23932459 rs1283726 chr8 108475856 C T 5.71E-05 Cognitive test performance ANGPT1 intron 20125193 rs1433168 chr8 108476951 T C 4.10E-05 Endometriosis ANGPT1 intron 21151130 rs951759 chr8 108489996 A C 8.85E-04 Schizophrenia ANGPT1 intron 19197363 rs951759 chr8 108489996 A C 1.10E-04 Endometriosis ANGPT1 intron 21151130 rs13257142 chr8 108499883 A G 2.45E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ANGPT1 intron 20031582 rs1368492 chr8 108520771 C T 0.0004609 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1368492 chr8 108520771 C T 4.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12678353 chr8 108525120 T C 0.0001654 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12678353 chr8 108525120 T C 1.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4427142 chr8 108526260 G T 0.0000794 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4427142 chr8 108526260 G T 7.94E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2347770 chr8 108526444 A G 0.0000784 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2347770 chr8 108526444 A G 7.84E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2881721 chr8 108526545 C T 0.0000743 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2881721 chr8 108526545 C T 7.43E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10105614 chr8 108532794 A G 0.0005415 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10105614 chr8 108532794 A G 5.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1368493 chr8 108533278 G A 4.35E-04 Stroke (pediatric) / / 22990015 rs1368493 chr8 108533278 G A 0.0000505 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1368493 chr8 108533278 G A 5.05E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1368493 chr8 108533278 G A 5.05E-05 Response to antipsychotic treatment / / 23241943 rs281710 chr8 108540140 T G 2.70E-05 Urinary metabolites / / 21572414 rs281712 chr8 108543427 T G 6.97E-04 Schizophrenia / / 19197363 rs281713 chr8 108545055 G T 7.39E-04 Age-related macular degeneration / / 21909106 rs7818981 chr8 108547805 T C 9.90E-05 Attention deficit hyperactivity disorder / / pha002875 rs16876501 chr8 108635058 G A 4.37E-04 Smoking initiation / / 24665060 rs903489 chr8 108649072 T C 6.57E-04 Parkinson's disease / / 17052657 rs903489 chr8 108649072 T C 3.90E-05 Type 2 diabetes / / 17463246 rs903489 chr8 108649072 T C 7.09E-05 Personality dimensions / / 18957941 rs903489 chr8 108649072 T C 1.24E-04 Diabetic retinopathy / / 20871662 rs1494971 chr8 108650188 T C 3.98E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4236787 chr8 108658437 C T 1.40E-05 Urinary metabolites / / 21572414 rs2036033 chr8 108669727 A G 1.20E-05 Urinary metabolites / / 21572414 rs13253953 chr8 108709307 C T 6.46E-04 Type 2 diabetes / / 17463246 rs7819970 chr8 108778342 T A 2.56E-04 Alzheimer's disease / / 22005930 rs11986940 chr8 108783667 C T 2.87E-04 Type 2 diabetes / / 17463246 rs11785730 chr8 108785847 A G 1.26E-04 Type 2 diabetes / / 17463246 rs893227 chr8 108787967 T C 3.96E-04 Alzheimer's disease / / 22005930 rs4538845 chr8 108788472 G T 2.03E-04 Type 2 diabetes / / 17463246 rs4534106 chr8 108789816 T C 1.00E-06 Brain structure / / 20171287 rs7843449 chr8 108790178 G A 9.70E-04 Alzheimer's disease / / 22005930 rs1437250 chr8 108790989 T A 7.01E-04 Alzheimer's disease / / 22005930 rs10109867 chr8 108792440 A C 4.75E-04 Alzheimer's disease / / 22005930 rs7843427 chr8 108813231 A C 7.54E-05 Platelet counts / / pha003100 rs2934939 chr8 108813477 G A 2.90E-04 Alzheimer's disease / / 22005930 rs16876800 chr8 108819971 A G 1.42E-04 Multiple complex diseases / / 17554300 rs1494913 chr8 108888650 T C 1.73E-05 Amyotrophic lateral sclerosis / / 20801717 rs1494913 chr8 108888650 T C 0.0000158 Amyotrophic lateral sclerosis / / 23587638 rs1494913 chr8 108888650 T C 0.0000361 Amyotrophic lateral sclerosis / / 23587638 rs1389976 chr8 108890004 T C,G 1.94E-05 Amyotrophic lateral sclerosis / / 20801717 rs1389976 chr8 108890004 T C,G 0.0000179 Amyotrophic lateral sclerosis / / 23587638 rs1389976 chr8 108890004 T C,G 0.0000407 Amyotrophic lateral sclerosis / / 23587638 rs618673 chr8 108916870 T G 5.88E-04 Obesity (extreme) RSPO2 intron 21935397 rs630662 chr8 108972298 A G 1.36E-04 Acute lymphoblastic leukemia (childhood) RSPO2 intron 22076464 rs2453423 chr8 108990217 T C 9.52E-05 Obesity (extreme) RSPO2 intron 21935397 rs16877056 chr8 108998935 T C 6.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RSPO2 intron 20877124 rs1434520 chr8 108999623 A G 1.33E-05 Serum metabolites RSPO2 intron 19043545 rs2060415 chr8 109008033 A G 3.85E-05 Serum metabolites RSPO2 intron 19043545 rs2514827 chr8 109013948 G T 9.16E-05 Femoral neck bone geometry RSPO2 intron 22087292 rs1036351 chr8 109013996 T A 7.30E-04 Suicide attempts in bipolar disorder RSPO2 intron 21423239 rs2514830 chr8 109015798 C A 4.48E-05 Femoral neck bone geometry RSPO2 intron 22087292 rs989291 chr8 109020400 C T 2.06E-05 Alzheimer's disease (late onset) RSPO2 intron 21379329 rs989291 chr8 109020400 C T 9.47E-05 Femoral neck bone geometry RSPO2 intron 22087292 rs2514831 chr8 109023496 T C 8.74E-04 Suicide attempts in bipolar disorder RSPO2 intron 21423239 rs2443786 chr8 109028325 A G 8.03E-06 Alzheimer's disease (late onset) RSPO2 intron 21379329 rs2443786 chr8 109028325 A G 3.71E-04 Lung function (forced vital capacity) RSPO2 intron 24023788 rs1452018 chr8 109039417 G A 8.46E-04 Suicide attempts in bipolar disorder RSPO2 intron 21423239 rs2514836 chr8 109041459 G C 8.44E-04 Suicide attempts in bipolar disorder RSPO2 intron 21423239 rs2443780 chr8 109044587 G T 3.12E-04 Response to taxane treatment (placlitaxel) RSPO2 intron 23006423 rs2443779 chr8 109046727 C T 9.80E-06 Alzheimer's disease (late onset) RSPO2 intron 21379329 rs16877095 chr8 109054668 C T 6.32E-06 Bone mineral density RSPO2 intron 21124946 rs16877097 chr8 109054928 T C 6.37E-06 Bone mineral density RSPO2 intron 21124946 rs1452019 chr8 109058494 A G 8.46E-04 Suicide attempts in bipolar disorder RSPO2 intron 21423239 rs988886 chr8 109060280 C T 7.71E-04 Suicide attempts in bipolar disorder RSPO2 intron 21423239 rs988886 chr8 109060280 C T 3.59E-05 Femoral neck bone geometry RSPO2 intron 22087292 rs2514839 chr8 109060469 G A 4.62E-04 Suicide attempts in bipolar disorder RSPO2 intron 21423239 rs13256880 chr8 109086419 G A 8.31E-05 Multiple sclerosis RSPO2 intron 17660530 rs374810 chr8 109096029 G A 1.58E-04 Alcohol dependence / / 20201924 rs374810 chr8 109096029 G A 1.00E-04 Prostate cancer / / 21743057 rs611744 chr8 109228008 A G 8.00E-15 Dupuytren's disease EIF3E intron 21732829 rs635941 chr8 109235457 G A 6.00E-05 Prostate cancer EIF3E intron 21743057 rs7826090 chr8 109288442 A G 0.000823244 Hypertension (early onset hypertension) / / 22479346 rs1975804 chr8 109291233 T C 3.32E-07 Alzheimer's disease (late onset) / / 21379329 rs1975804 chr8 109291233 T C 2.28E-06 Bipolar disorder / / 21771265 rs6994837 chr8 109348150 C A 6.00E-05 Prostate cancer / / 21743057 rs1448160 chr8 109373125 T C 8.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs1597145 chr8 109374894 G T 8.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs11780184 chr8 109378912 C T 8.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs2023100 chr8 109390257 G T 7.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs10108399 chr8 109396911 T C 8.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs7812466 chr8 109398145 A G 8.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs4363174 chr8 109402654 C T 8.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs13281088 chr8 109407785 C T 8.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs2156740 chr8 109408549 C G 8.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs1893887 chr8 109409955 C G 8.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs4735062 chr8 109422900 T G 8.71E-04 Suicide attempts in bipolar disorder / / 21041247 rs4735063 chr8 109423496 T A 8.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs6998163 chr8 109424801 C T 8.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs13249775 chr8 109425192 T C 8.81E-04 Suicide attempts in bipolar disorder / / 21041247 rs1955032 chr8 109426294 T G 8.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs10098022 chr8 109428521 A G 8.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs1893889 chr8 109437949 A G 3.64E-05 Brain structure / / 22504417 rs9969501 chr8 109440751 G A 0.000809559 Hypertension (early onset hypertension) / / 22479346 rs10089406 chr8 109446828 T C 8.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs13253202 chr8 109452201 G T 6.00E-04 Type 2 diabetes / / 17463246 rs3737501 chr8 109455802 G A 1.68E-04 Type 2 diabetes / / 17463246 rs9656879 chr8 109464302 G T 8.47E-04 Type 2 diabetes TTC35 intron 17463246 rs7816000 chr8 109464415 A G 6.39E-04 Type 2 diabetes TTC35 intron 17463246 rs7816458 chr8 109464435 G A 4.79E-04 Type 2 diabetes TTC35 intron 17463246 rs11774379 chr8 109467962 C T 7.14E-04 Type 2 diabetes TTC35 intron 17463246 rs11774379 chr8 109467962 C T 9.01E-05 Schizophrenia TTC35 intron pha002859 rs7832889 chr8 109483336 A G 4.60E-04 Type 2 diabetes TTC35 intron 17463246 rs11992814 chr8 109484743 A G 5.12E-04 Type 2 diabetes TTC35 intron 17463246 rs6986900 chr8 109487465 C T 2.00E-04 Gamma gluatamyl transferase levels (interaction with age) TTC35 intron 22010049 rs13271967 chr8 109494655 G A 5.78E-04 Type 2 diabetes TTC35 intron 17463246 rs3802246 chr8 109496174 G T 8.20E-04 Type 2 diabetes TTC35 intron 17463246 rs3802247 chr8 109496280 G T 9.70E-04 Type 2 diabetes TTC35 intron 17463246 rs747691 chr8 109500217 A G 5.08E-04 Type 2 diabetes / / 17463246 rs747690 chr8 109501031 A G 6.10E-04 Type 2 diabetes / / 17463246 rs7814794 chr8 109504167 G A 5.82E-04 Type 2 diabetes / / 17463246 rs7007095 chr8 109526717 C T 5.11E-04 Type 2 diabetes / / 17463246 rs1789964 chr8 109526728 G A 1.62E-06 Alzheimer's disease (late onset) / / 21379329 rs1789964 chr8 109526728 G A 6.33E-05 Alzheimer's disease / / 24755620 rs2127736 chr8 109526827 G A 5.78E-04 Type 2 diabetes / / 17463246 rs6983374 chr8 109534628 A G 6.39E-04 Type 2 diabetes / / 17463246 rs11984683 chr8 109538021 C A 1.17E-04 Type 2 diabetes / / 17463246 rs1679666 chr8 109539847 C A 1.14E-06 Alzheimer's disease (late onset) / / 21379329 rs1955030 chr8 109552168 G A 4.65E-04 Type 2 diabetes / / 17463246 rs6988786 chr8 109556576 T C 5.15E-04 Type 2 diabetes / / 17463246 rs7837696 chr8 109565358 T G 1.87E-04 Type 2 diabetes / / 17463246 rs10110856 chr8 109567140 A G 1.86E-04 Type 2 diabetes / / 17463246 rs1480559 chr8 109571076 C T 2.73E-04 Type 2 diabetes / / 17463246 rs7831079 chr8 109576387 T C 1.50E-05 Type 2 diabetes / / 17463246 rs7812742 chr8 109576431 A G 1.86E-04 Type 2 diabetes / / 17463246 rs1480562 chr8 109580059 A G 1.86E-04 Type 2 diabetes / / 17463246 rs10100996 chr8 109580680 T A 1.45E-04 Type 2 diabetes / / 17463246 rs13257259 chr8 109584147 T A 1.22E-05 Smoking cessation / / 24665060 rs7816073 chr8 109587144 A G 2.73E-04 Type 2 diabetes / / 17463246 rs1480561 chr8 109587774 A G 1.86E-04 Type 2 diabetes / / 17463246 rs10089785 chr8 109599969 T C 6.24E-05 Orofacial clefts / / 22419666 rs2935776 chr8 109629903 A G 6.00E-07 T-tau levels / / 20932310 rs2935766 chr8 109657849 T C 2.35E-04 Multiple complex diseases / / 17554300 rs1909023 chr8 109657916 C T 3.38E-04 Multiple complex diseases / / 17554300 rs1909024 chr8 109657992 A T 2.64E-04 Multiple complex diseases / / 17554300 rs2935762 chr8 109660089 A G 9.89E-05 Orofacial clefts / / 22419666 rs981736 chr8 109685655 G T 6.06E-05 Cognitive performance / / 19734545 rs3019343 chr8 109722443 C A 9.42E-04 Heart Failure / / pha002884 rs7820557 chr8 109735830 C T 9.04E-05 Magnesium levels / / pha003092 rs1391195 chr8 109746057 C T 8.19E-04 Coronary Artery Disease / / 17634449 rs1391195 chr8 109746057 C T 1.50E-05 Urinary metabolites / / 21572414 rs6993219 chr8 109749049 C T 9.43E-05 Magnesium levels / / pha003092 rs4735076 chr8 109779789 C T 2.17E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs4735076 chr8 109779789 C T 1.93E-04 Heart Failure / / pha002884 rs13253194 chr8 109857400 G A 8.77E-05 Height / / pha003011 rs12681052 chr8 109924310 C A 3.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs4336584 chr8 109940377 C T 2.78E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4620259 chr8 109991668 A C 8.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs10955500 chr8 109999992 T A 6.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs550123513 chr8 109999992 TA T 6.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs17520 chr8 110002080 A G 3.20E-04 Lung function (forced vital capacity) / / 24023788 rs12541959 chr8 110003907 C T 5.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs7838433 chr8 110007151 T G 1.40E-04 Lung function (forced vital capacity) / / 24023788 rs12546846 chr8 110007406 T C 6.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs12546383 chr8 110010721 C T 7.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs12544066 chr8 110012191 G A 7.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs12543291 chr8 110018582 A G 6.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs4735081 chr8 110020230 T C 1.80E-05 Periodontitis (Chronic) / / 25008200 rs12550242 chr8 110021320 C T 3.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs4374960 chr8 110023904 G A 3.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs4469429 chr8 110075358 T G 7.22E-05 Body mass (lean) / / 19268274 rs4236799 chr8 110076032 G A 2.82E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7817222 chr8 110081937 G A 2.35E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4466373 chr8 110085866 C T 7.41E-06 Body mass (lean) / / 19268274 rs7012225 chr8 110086855 A G 2.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs3110052 chr8 110090458 C T 2.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs3110052 chr8 110090458 C T 4.50E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs3134106 chr8 110101775 G T 2.21E-04 Suicide attempts in bipolar disorder TRHR intron 21423239 rs3134106 chr8 110101775 G T 9.84E-05 Brain derived neurotrophic factor levels,in serum TRHR intron 22047184 rs3134107 chr8 110103867 G A 3.56E-04 Suicide attempts in bipolar disorder TRHR intron 21423239 rs3134107 chr8 110103867 G A 4.49E-05 Brain derived neurotrophic factor levels,in serum TRHR intron 22047184 rs3110045 chr8 110106120 C T 3.59E-04 Suicide attempts in bipolar disorder TRHR intron 21423239 rs3110045 chr8 110106120 C T 5.37E-05 Brain derived neurotrophic factor levels,in serum TRHR intron 22047184 rs16892486 chr8 110109433 G C 5.63E-05 Serum metabolites TRHR intron 19043545 rs7829028 chr8 110109530 C T 7.35E-04 Multiple complex diseases TRHR intron 17554300 rs16892496 chr8 110109851 A C 9.21E-05 Serum metabolites TRHR intron 19043545 rs16892496 chr8 110109851 A C 7.55E-08 Body mass (lean) TRHR intron 19268274 rs7832552 chr8 110115676 C T 8.02E-05 Serum metabolites TRHR intron 19043545 rs7832552 chr8 110115676 C T 4.00E-10 Body mass (lean) TRHR intron 19268274 rs3925087 chr8 110122678 T C 4.34E-06 Body mass (lean) TRHR intron 19268274 rs4546626 chr8 110125762 T G 1.37E-05 Body mass (lean) TRHR intron 19268274 rs4446710 chr8 110126270 A G 1.00E-04 Cognitive impairment induced by topiramate TRHR intron 22091778 rs4735098 chr8 110155891 A G 2.57E-06 Body mass (lean) / / 19268274 rs4314624 chr8 110166016 C G 4.95E-05 Serum metabolites / / 19043545 rs4314624 chr8 110166016 C G 2.42E-05 Body mass (lean) / / 19268274 rs4607576 chr8 110166036 G A 6.47E-05 Serum metabolites / / 19043545 rs4607576 chr8 110166036 G A 2.65E-05 Body mass (lean) / / 19268274 rs4628236 chr8 110172145 G A 5.62E-05 Serum metabolites / / 19043545 rs4628236 chr8 110172145 G A 3.09E-05 Body mass (lean) / / 19268274 rs7845815 chr8 110177844 G A 4.30E-05 Serum metabolites / / 19043545 rs7845815 chr8 110177844 G A 2.04E-05 Body mass (lean) / / 19268274 rs4734197 chr8 110178505 T C 6.18E-05 Serum metabolites / / 19043545 rs4734197 chr8 110178505 T C 2.39E-05 Body mass (lean) / / 19268274 rs10111874 chr8 110185018 A G 5.62E-05 Serum metabolites / / 19043545 rs10111874 chr8 110185018 A G 2.35E-05 Body mass (lean) / / 19268274 rs10112296 chr8 110185293 C T 5.95E-05 Serum metabolites / / 19043545 rs10112296 chr8 110185293 C T 6.20E-05 Body mass (lean) / / 19268274 rs11785243 chr8 110190183 G A 4.95E-05 Serum metabolites / / 19043545 rs11785243 chr8 110190183 G A 3.12E-05 Body mass (lean) / / 19268274 rs10955513 chr8 110214265 C T 2.23E-05 Serum metabolites / / 19043545 rs10955513 chr8 110214265 C T 4.09E-05 Body mass (lean) / / 19268274 rs7823896 chr8 110217266 T C 3.00E-06 Myopia (pathological) / / 23049088 rs1380099 chr8 110219148 C G 3.35E-05 Serum metabolites / / 19043545 rs1380099 chr8 110219148 C G 8.97E-05 Body mass (lean) / / 19268274 rs6469245 chr8 110220807 C G 3.26E-05 Serum metabolites / / 19043545 rs6469245 chr8 110220807 C G 9.42E-05 Body mass (lean) / / 19268274 rs4735116 chr8 110221604 A C 5.19E-05 Serum metabolites / / 19043545 rs4735116 chr8 110221604 A C 8.51E-05 Body mass (lean) / / 19268274 rs79076257 chr8 110244623 T C 2.00E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs1380098 chr8 110248632 G A 5.34E-05 Serum metabolites / / 19043545 rs1380098 chr8 110248632 G A 6.28E-05 Body mass (lean) / / 19268274 rs2926220 chr8 110248891 G A 8.76E-05 Body mass (lean) / / 19268274 rs1548083 chr8 110253879 A T 5.15E-05 Serum metabolites NUDCD1 UTR-3 19043545 rs1548083 chr8 110253879 A T 6.39E-05 Body mass (lean) NUDCD1 UTR-3 19268274 rs16879265 chr8 110267999 A T 4.90E-04 Multiple complex diseases NUDCD1 intron 17554300 rs1458926 chr8 110270695 C G 5.15E-05 Serum metabolites NUDCD1 intron 19043545 rs1458926 chr8 110270695 C G 5.41E-05 Body mass (lean) NUDCD1 intron 19268274 rs1993593 chr8 110289581 C T 1.09E-04 Stroke NUDCD1 intron pha002887 rs2926273 chr8 110299760 T C 3.00E-05 Serum metabolites NUDCD1 intron 19043545 rs78908257 chr8 110330474 T C 3.79E-06 PR interval in Tripanosoma cruzi seropositivity NUDCD1 intron 24324551 rs2926247 chr8 110341005 A G 4.16E-05 Serum metabolites NUDCD1 intron 19043545 rs2926247 chr8 110341005 A G 1.41E-05 Body mass (lean) NUDCD1 intron 19268274 rs2980571 chr8 110348249 A T 2.00E-05 Urinary metabolites ENY2 intron 21572414 rs2349436 chr8 110391080 G A 5.97E-04 Coronary Artery Disease PKHD1L1 intron 17634449 rs964307 chr8 110413762 T C 3.27E-05 Hypertension PKHD1L1 missense 21082022 rs9297425 chr8 110421113 C T 3.21E-05 Hypertension PKHD1L1 intron 21082022 rs2349761 chr8 110427024 A C 2.06E-04 Coronary Artery Disease PKHD1L1 intron 17634449 rs7016609 chr8 110431217 G T 8.25E-04 Coronary Artery Disease PKHD1L1 intron 17634449 rs7015262 chr8 110436604 A G 7.30E-05 Hypertension PKHD1L1 intron 21082022 rs73313124 chr8 110478822 C A 3.00E-06 Obesity-related traits PKHD1L1 missense 23251661 rs1026437 chr8 110492949 G C 2.60E-04 Primary sclerosing cholangitis PKHD1L1 intron 19944697 rs1673411 chr8 110528149 A G 3.70E-04 Primary sclerosing cholangitis PKHD1L1 intron 19944697 rs1673411 chr8 110528149 A G 6.06E-08 Lymphocyte counts PKHD1L1 intron 22286170 rs1783168 chr8 110528870 A G 3.70E-04 Primary sclerosing cholangitis PKHD1L1 intron 19944697 rs7819565 chr8 110556519 G A 3.49E-04 Suicide attempts in bipolar disorder EBAG9 intron 21423239 rs2844234 chr8 110582366 A G 4.71E-04 Hemoglobin concentration / / 20534544 rs2703388 chr8 110582762 G C 2.40E-05 Urinary metabolites / / 21572414 rs7824177 chr8 110585288 A G 5.78E-04 Schizophrenia / / 19197363 rs6990312 chr8 110602317 G T 7.36E-04 Obesity (extreme) SYBU intron 21935397 rs6989019 chr8 110608843 C A 2.04E-04 Obesity (extreme) SYBU intron 21935397 rs6982592 chr8 110613000 G A 9.57E-04 Obesity (extreme) SYBU intron 21935397 rs7833753 chr8 110616963 G A 2.39E-04 Obesity (extreme) SYBU intron 21935397 rs1892759 chr8 110616994 G A 5.53E-04 Schizophrenia SYBU intron 19197363 rs1954714 chr8 110622831 T C 9.76E-05 ldl cholesterol SYBU intron pha003076 rs2844241 chr8 110624637 C T 9.76E-05 ldl cholesterol SYBU intron pha003076 rs2844244 chr8 110626130 G T 5.59E-04 Multiple complex diseases SYBU intron 17554300 rs4367512 chr8 110637344 C T 5.89E-04 Multiple complex diseases SYBU intron 17554300 rs6469270 chr8 110643295 A G 9.38E-05 ldl cholesterol SYBU intron pha003076 rs6469270 chr8 110643295 A G 6.69E-05 Cholesterol SYBU intron pha003078 rs16879844 chr8 110648272 T C 5.35E-04 Multiple complex diseases SYBU intron 17554300 rs3134325 chr8 110681716 T G 2.61E-04 Body mass index SYBU intron 17255346 rs3134326 chr8 110683804 C T 8.33E-05 ldl cholesterol SYBU intron pha003076 rs3134326 chr8 110683804 C T 6.85E-05 Cholesterol SYBU intron pha003078 rs3133926 chr8 110689378 A G 3.20E-07 Longevity,exceptional SYBU intron 20595579 rs10099504 chr8 110692206 T C 6.41E-05 Body mass index SYBU intron 17255346 rs7826348 chr8 110698582 C G 7.56E-05 Body mass index SYBU intron 17255346 rs3935694 chr8 110701498 A G 2.42E-04 Body mass index SYBU intron 17255346 rs10102228 chr8 110714321 G T 2.69E-04 Body mass index / / 17255346 rs3108844 chr8 110722139 G T 8.60E-06 Urinary metabolites / / 21572414 rs3133944 chr8 110724836 C T 3.30E-07 Urinary metabolites / / 21572414 rs3108871 chr8 110735843 A G 2.10E-06 Urinary metabolites / / 21572414 rs7822375 chr8 110745065 G A 5.70E-06 Urinary metabolites / / 21572414 rs3133916 chr8 110782414 A G 9.70E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3887088 chr8 110812412 A G 0.000826 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs3887088 chr8 110812412 A G 8.26E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7011741 chr8 110812770 G A 0.0008268 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7011741 chr8 110812770 G A 8.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1542624 chr8 110817650 T C 0.0005741 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1542624 chr8 110817650 T C 5.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7844635 chr8 110820713 A C 0.0006251 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7844635 chr8 110820713 A C 6.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12548341 chr8 110821596 A G 3.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4259393 chr8 110825738 C G 0.0005147 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4259393 chr8 110825738 C G 5.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs922971 chr8 110830109 G T 2.66E-08 Coronary heart disease / / 21971053 rs2129035 chr8 110843613 C A 1.57E-09 Coronary heart disease / / 21971053 rs7813186 chr8 110856481 A G 8.57E-09 Coronary heart disease / / 21971053 rs7813186 chr8 110856481 A G 5.79E-05 Smoking cessation / / 24665060 rs7834319 chr8 110878162 G A 7.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs7834319 chr8 110878162 G A 6.37E-09 Coronary heart disease / / 21971053 rs12679278 chr8 110879189 A T 9.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs1505652 chr8 110888220 T C 1.22E-06 Coronary heart disease / / 21971053 rs11995060 chr8 110909309 C A 8.86E-04 Obesity (extreme) / / 21935397 rs7832016 chr8 110914474 T G 8.79E-04 Obesity (extreme) / / 21935397 rs1017876 chr8 110915398 C T 8.65E-04 Obesity (extreme) / / 21935397 rs12675695 chr8 110920215 G A 8.61E-04 Obesity (extreme) / / 21935397 rs1605128 chr8 110975199 G A 7.06E-04 Obesity (extreme) / / 21935397 rs6980482 chr8 110981060 A G 4.77E-04 Coronary heart disease KCNV1 intron 21971053 rs10092842 chr8 110990156 A C 3.40E-05 Coronary heart disease / / 21971053 rs7011544 chr8 111113707 C T 5.75E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7836676 chr8 111137306 G C 9.68E-04 Type 2 diabetes / / 17463246 rs1450744 chr8 111140898 C A 2.59E-04 Type 2 diabetes / / 17463246 rs10505137 chr8 111141609 G A 1.30E-05 Breast cancer and prostate cancer / / 17903305 rs1868750 chr8 111144619 G T 9.77E-04 Type 2 diabetes / / 17463246 rs1947270 chr8 111172487 C T 4.62E-04 Type 2 diabetes / / 17463246 rs2350728 chr8 111184071 T C 2.90E-04 Type 2 diabetes / / 17463246 rs13265962 chr8 111187698 C T 1.14E-04 Type 2 diabetes / / 17463246 rs10100415 chr8 111263697 C G 4.38E-04 Coronary Artery Disease / / 17634449 rs10505143 chr8 111280576 T C 6.03E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7011447 chr8 111326504 G A 6.09E-05 Erythrocyte counts / / pha003090 rs7350095 chr8 111352939 G A 4.35E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17480167 chr8 111354022 C A 3.43E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs16880653 chr8 111377089 G T 3.78E-05 Erythrocyte counts / / pha003090 rs4735158 chr8 111547789 A G 9.43E-05 Height / / pha003010 rs6469312 chr8 111557027 T A 1.58E-04 Multiple complex diseases / / 17554300 rs7825323 chr8 111593882 G A 6.14E-05 Height / / pha003010 rs6469315 chr8 111600899 T C 6.63E-05 Height / / pha003010 rs16880916 chr8 111610809 A T 1.25E-04 Multiple complex diseases / / 17554300 rs7012481 chr8 111614965 A G 1.35E-04 Cognitive function / / 24684796 rs7012481 chr8 111614965 A G 5.21E-05 Height / / pha003010 rs11991106 chr8 111625175 A G 2.53E-04 Multiple complex diseases / / 17554300 rs16881002 chr8 111674630 T C 0.0003261 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16881002 chr8 111674630 T C 3.26E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11995209 chr8 111708039 T C 9.33E-04 HIV-1 viral setpoint / / 17641165 rs7838042 chr8 111726964 A G 3.17E-05 Lung adenocarcinoma / / 19836008 rs4493937 chr8 112021630 C A 1.80E-05 Urinary metabolites / / 21572414 rs1896238 chr8 112079211 A G 3.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs11781492 chr8 112098293 G A 4.20E-04 Alcohol dependence / / 20201924 rs11781492 chr8 112098293 G A 6.50E-04 Alcohol dependence / / 20201924 rs9297443 chr8 112112068 G A 6.43E-05 Multiple complex diseases / / 17554300 rs7827820 chr8 112114179 A G 5.20E-08 Iron levels / / 21208937 rs890564 chr8 112164318 T C 2.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs960209 chr8 112173085 C T 7.32E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2195066 chr8 112184059 C T 9.03E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16881763 chr8 112201392 A G 3.87E-04 Multiple complex diseases / / 17554300 rs4332164 chr8 112238390 A G 2.52E-05 Cognitive test performance / / 20125193 rs12682510 chr8 112340417 C A 8.17E-05 Cognitive test performance / / 20125193 rs10955576 chr8 112359706 A G 8.41E-05 Waist Circumference / / pha003023 rs6999561 chr8 112461244 T C 6.35E-04 Type 2 diabetes / / 17463246 rs2217375 chr8 112556687 C T 1.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs2217375 chr8 112556687 C T 6.80E-04 Stroke / / pha002886 rs1807420 chr8 112591382 T C 3.44E-04 Fibrinogen / / 17255346 rs13279316 chr8 112607588 T C 7.96E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13279316 chr8 112607588 T C 2.75E-05 stroke (ischemic) / / 17434096 rs13279316 chr8 112607588 T C 4.09E-05 Serum alpha1-antitrypsin levels / / 23990791 rs7818900 chr8 112626595 A T 6.45E-04 Type 2 diabetes / / 17463246 rs7813372 chr8 112741133 T G 8.86E-04 Body mass index / / 21701565 rs11995581 chr8 112801961 C T 6.94E-04 Body mass index / / 21701565 rs10955602 chr8 112825223 C A 6.43E-05 Body Mass Index / / pha003021 rs1397370 chr8 112846250 T C 8.93E-05 stroke (ischemic) / / 17434096 rs1397374 chr8 112848267 G A 8.93E-05 stroke (ischemic) / / 17434096 rs320558 chr8 112882444 C T 1.38E-05 stroke (ischemic) / / 17434096 rs440036 chr8 112887611 C T 6.62E-04 Type 2 diabetes / / 17463246 rs10505164 chr8 112899056 G C 7.66E-05 stroke (ischemic) / / 17434096 rs10505164 chr8 112899056 G C 6.76E-04 Type 2 diabetes / / 17463246 rs3106198 chr8 112902124 A G 5.83E-05 stroke (ischemic) / / 17434096 rs320503 chr8 112902645 G T 5.16E-05 stroke (ischemic) / / 17434096 rs10755907 chr8 112914996 T C 7.97E-04 Type 2 diabetes / / 17463246 rs320538 chr8 112927580 A G 1.46E-04 Type 2 diabetes / / 17463246 rs186489 chr8 112929032 C T 1.57E-05 stroke (ischemic) / / 17434096 rs320497 chr8 112947262 T A 1.97E-04 Type 2 diabetes / / 17463246 rs3101275 chr8 112957484 C A 1.34E-05 stroke (ischemic) / / 17434096 rs119671 chr8 112959051 G A 1.63E-04 Type 2 diabetes / / 17463246 rs9643068 chr8 112962370 C T 8.42E-06 Bilirubin levels / / 22085899 rs2352574 chr8 112964502 A T 8.42E-06 Bilirubin levels / / 22085899 rs12546646 chr8 112975369 T G 2.87E-06 Bilirubin levels / / 22085899 rs12549576 chr8 112976141 A G 1.00E-06 Bilirubin levels / / 22085899 rs1460592 chr8 112977188 A G 2.82E-05 stroke (ischemic) / / 17434096 rs12548439 chr8 112996827 G T 9.45E-06 Bilirubin levels / / 22085899 rs16882968 chr8 113006288 A T 9.45E-06 Bilirubin levels / / 22085899 rs12675200 chr8 113007075 C T 9.45E-06 Bilirubin levels / / 22085899 rs1551724 chr8 113010491 G C 3.76E-04 Body mass index / / 21701565 rs9693350 chr8 113011661 T A 9.45E-06 Bilirubin levels / / 22085899 rs16882992 chr8 113015316 G T 9.45E-06 Bilirubin levels / / 22085899 rs16883001 chr8 113022780 G A 9.45E-06 Bilirubin levels / / 22085899 rs10955609 chr8 113027210 T A 9.45E-06 Bilirubin levels / / 22085899 rs10955610 chr8 113027918 A T 9.45E-06 Bilirubin levels / / 22085899 rs1996720 chr8 113074096 C T 2.00E-06 Temperament / / 22832960 rs6469398 chr8 113078106 T C 1.80E-04 Type 2 diabetes / / 17463246 rs13279755 chr8 113081551 T C 9.75E-04 Acute lung injury / / 22295056 rs7839302 chr8 113155380 G A 9.50E-04 Type 2 diabetes / / 17463246 rs4876460 chr8 113246250 T C 9.73E-04 Alcohol dependence CSMD3 intron 21314694 rs6995441 chr8 113256222 T C 9.47E-05 Cocaine dependence CSMD3 intron 23958962 rs1420852 chr8 113264777 C G 8.00E-06 Cocaine dependence CSMD3 intron 23958962 rs2098455 chr8 113264960 C T 3.19E-05 stroke (ischemic) CSMD3 intron 17434096 rs10505182 chr8 113268098 G T 5.20E-04 Subclinical atherosclerosis CSMD3 intron 17903303 rs990616 chr8 113274853 A G 6.05E-05 stroke (ischemic) CSMD3 intron 17434096 rs16883350 chr8 113283214 T A 8.25E-05 Type 2 diabetes CSMD3 intron 17463246 rs2193430 chr8 113301744 C G 1.30E-15 Health and aging,CVD and cancer age of onset CSMD3 missense 22174011 rs2193430 chr8 113301744 C G 1.50E-10 Health and aging,CVD and cancer age of onset CSMD3 missense 22174011 rs2193430 chr8 113301744 C G 9.70E-16 Health and aging,CVD and cancer age of onset CSMD3 missense 22174011 rs2131298 chr8 113366165 G C 4.86E-04 Type 2 diabetes CSMD3 intron 17463246 rs1492678 chr8 113374404 T A 2.91E-04 Type 2 diabetes CSMD3 intron 17463246 rs3950676 chr8 113374673 T A 3.18E-04 Type 2 diabetes CSMD3 intron 17463246 rs41340951 chr8 113376378 T C 2.44E-04 Type 2 diabetes CSMD3 intron 17463246 rs41467949 chr8 113376502 A G 2.75E-04 Type 2 diabetes CSMD3 intron 17463246 rs4563913 chr8 113382793 G T 2.26E-04 Type 2 diabetes CSMD3 intron 17463246 rs1873746 chr8 113383063 G A 2.26E-04 Type 2 diabetes CSMD3 intron 17463246 rs7463918 chr8 113404601 T A 5.83E-05 Alzheimer's disease CSMD3 intron 21098978 rs16883889 chr8 113652365 C T 9.95E-04 Suicide attempts in bipolar disorder CSMD3 intron 21423239 rs7814711 chr8 113671290 G A 3.93E-05 Post-operative nausea and vomiting CSMD3 intron 21694509 rs13271162 chr8 113681944 G A 3.79E-04 Blood pressure CSMD3 intron 17255346 rs4345583 chr8 113690799 A C 1.83E-05 Post-operative nausea and vomiting CSMD3 intron 21694509 rs16883953 chr8 113702131 A G 3.90E-04 Coronary heart disease CSMD3 cds-synon 21966275 rs2432742 chr8 113825058 A G 5.22E-04 Response to diuretic therapy in hypertension CSMD3 intron 23753411 rs7013313 chr8 113828578 C A 4.47E-04 Longevity CSMD3 intron 22279548 rs2432743 chr8 113828980 C T 8.95E-05 HDL cholesterol CSMD3 intron pha003075 rs231307 chr8 113865970 C T 6.07E-05 Waist Circumference CSMD3 intron pha003025 rs231307 chr8 113865970 C T 3.75E-05 Erythrocyte counts CSMD3 intron pha003101 rs10955638 chr8 113883227 T G 4.03E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CSMD3 intron 24023788 rs11985714 chr8 113903152 C T 8.93E-05 Waist Circumference CSMD3 intron pha003024 rs11985714 chr8 113903152 C T 3.67E-05 Waist-Hip Ratio CSMD3 intron pha003029 rs10097475 chr8 113917259 A C 2.59E-06 Post-operative nausea and vomiting CSMD3 intron 21694509 rs13251514 chr8 113931884 T G 3.47E-04 Multiple complex diseases CSMD3 intron 17554300 rs13262072 chr8 113933101 T C 5.24E-04 Multiple complex diseases CSMD3 intron 17554300 rs2355754 chr8 113957532 C A 2.55E-05 Post-operative nausea and vomiting CSMD3 intron 21694509 rs1903097 chr8 113959268 A C 4.10E-07 Post-operative nausea and vomiting CSMD3 intron 21694509 rs10505197 chr8 113975571 C T 8.26E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CSMD3 intron 24023788 rs17659540 chr8 113989126 A G 2.70E-06 Urinary metabolites CSMD3 intron 21572414 rs6993468 chr8 113995218 G A 2.46E-04 Multiple complex diseases CSMD3 intron 17554300 rs1532799 chr8 114017477 C A 3.40E-06 Urinary metabolites CSMD3 intron 21572414 rs964764 chr8 114029421 A G 2.60E-06 Urinary metabolites CSMD3 intron 21572414 rs964763 chr8 114029454 A G 2.60E-06 Urinary metabolites CSMD3 intron 21572414 rs4876502 chr8 114030491 T C 2.10E-06 Urinary metabolites CSMD3 intron 21572414 rs9297482 chr8 114030993 C A 2.60E-06 Urinary metabolites CSMD3 intron 21572414 rs10094069 chr8 114034531 C T 2.06E-32 Narcolepsy CSMD3 intron 19629137 rs10094069 chr8 114034531 C T 3.60E-06 Urinary metabolites CSMD3 intron 21572414 rs12545742 chr8 114035418 T A 5.56E-04 Type 2 diabetes CSMD3 intron 17463246 rs12545742 chr8 114035418 T A 1.70E-05 Urinary metabolites CSMD3 intron 21572414 rs12541754 chr8 114049073 T C 1.71E-04 Type 2 diabetes CSMD3 intron 17463246 rs3967800 chr8 114118732 T C 3.11E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CSMD3 intron 24023788 rs2883875 chr8 114184419 G A 6.80E-04 Coronary heart disease CSMD3 intron 21966275 rs10505201 chr8 114226643 G A 6.60E-04 Alcohol dependence CSMD3 intron 20201924 rs6996697 chr8 114274275 A G 4.00E-04 Alcohol dependence CSMD3 intron 20201924 rs7813842 chr8 114324003 A G 3.47E-05 Diabetes Mellitus CSMD3 intron pha003059 rs10100569 chr8 114349314 G T 3.57E-05 Diabetes Mellitus CSMD3 intron pha003059 rs4311682 chr8 114399612 A G 3.12E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CSMD3 intron 24023788 rs4311682 chr8 114399612 A G 4.79E-04 Lung function (forced expiratory volume in 1 second) CSMD3 intron 24023788 rs16884651 chr8 114440178 G T 7.63E-05 Graves' disease CSMD3 intron 21841780 rs16884680 chr8 114445055 T G 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CSMD3 intron 22628534 rs12679004 chr8 114552521 G A 9.92E-05 Coronary heart disease / / pha003031 rs6469464 chr8 114643852 A G 7.54E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4876526 chr8 114753087 G A 2.86E-04 Multiple complex diseases / / 17554300 rs13273350 chr8 114795407 A G 1.81E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs13274174 chr8 114795629 A C 2.10E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2044999 chr8 114799224 G A 3.84E-04 Crohn's disease / / 17435756 rs6469481 chr8 114811374 A G 9.13E-04 Tourette syndrome / / 22889924 rs11998298 chr8 114822319 G T 5.01E-05 Neutrophil count / / pha003095 rs16885222 chr8 114858878 C T 5.00E-06 Urinary metabolites / / 21572414 rs16892681 chr8 114867123 T C 7.90E-05 Diabetic retinopathy / / 21441570 rs16892681 chr8 114867123 T C 1.20E-05 Urinary metabolites / / 21572414 rs1912816 chr8 114873380 A G 5.90E-06 Bronchopulmonary dysplasia / / 23897914 rs1912816 chr8 114873380 A G 6.00E-06 Bronchopulmonary dysplasia / / 23897914 rs1511712 chr8 114885107 C A 3.50E-06 Urinary metabolites / / 21572414 rs6469488 chr8 114885432 G A 7.00E-06 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction) / / 24280104 rs16885259 chr8 114889902 A G 4.00E-06 Urinary metabolites / / 21572414 rs10955687 chr8 114918088 A G 3.59E-04 Multiple complex diseases / / 17554300 rs10955688 chr8 114918137 C T 1.86E-04 Multiple complex diseases / / 17554300 rs2458064 chr8 114956591 C A 0.000180231 Hypertension (early onset hypertension) / / 22479346 rs12678528 chr8 114959873 G A 2.49E-04 Alzheimer's disease / / 22005930 rs16885350 chr8 114967644 G A 2.96E-04 Alzheimer's disease / / 22005930 rs16892683 chr8 114980627 C T 5.83E-04 Multiple complex diseases / / 17554300 rs1533146 chr8 114981023 G C 3.22E-04 Alzheimer's disease / / 22005930 rs16885381 chr8 114985008 C T 2.59E-04 Alzheimer's disease / / 22005930 rs4147331 chr8 114991022 G A 7.87E-06 Intelligence / / 21826061 rs4263797 chr8 115009392 C T 2.26E-04 Multiple complex diseases / / 17554300 rs4440660 chr8 115009813 C T 2.46E-04 Multiple complex diseases / / 17554300 rs13257991 chr8 115010308 C A 8.59E-05 Intelligence / / 21826061 rs10109903 chr8 115022709 A G 1.00E-04 Prostate cancer / / 21743057 rs13261349 chr8 115028312 C T 7.00E-05 Prostate cancer / / 21743057 rs4469489 chr8 115034577 G A 1.70E-05 Urinary metabolites / / 21572414 rs6983475 chr8 115039038 G A 7.34E-05 Cognitive decline / / 23732972 rs7834425 chr8 115097689 T C 2.70E-05 Urinary metabolites / / 21572414 rs6993893 chr8 115098900 A C 7.35E-04 Schizophrenia / / 19197363 rs7825123 chr8 115112879 T C 2.00E-05 Urinary metabolites / / 21572414 rs10086149 chr8 115118818 G A 5.51E-05 Multiple complex diseases / / 17554300 rs10089040 chr8 115119136 A G 6.18E-05 Multiple complex diseases / / 17554300 rs12675001 chr8 115119439 G T 9.05E-04 Age-related macular degeneration / / 21909106 rs9942773 chr8 115121027 A C 2.00E-06 Periodontal microbiota / / 22699663 rs7836915 chr8 115228215 T C 2.28E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16885593 chr8 115231680 A G 1.25E-04 Multiple complex diseases / / 17554300 rs10088282 chr8 115249567 C T 1.38E-04 Multiple complex diseases / / 17554300 rs2132786 chr8 115304991 A T 5.16E-04 Multiple complex diseases / / 17554300 rs7017226 chr8 115309734 A G 5.70E-04 Multiple complex diseases / / 17554300 rs7834624 chr8 115312812 A G 4.40E-04 Multiple complex diseases / / 17554300 rs12677904 chr8 115321191 T C 7.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10091463 chr8 115350817 G C 4.78E-04 Multiple complex diseases / / 17554300 rs931634 chr8 115356184 A C 7.95E-04 Multiple complex diseases / / 17554300 rs9643087 chr8 115382484 C T 2.00E-07 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs9643088 chr8 115382534 A C 6.13E-04 Multiple complex diseases / / 17554300 rs9886364 chr8 115412625 A G 6.90E-05 Multiple complex diseases / / 17554300 rs13439856 chr8 115424320 C T 6.23E-05 Multiple complex diseases / / 17554300 rs4242562 chr8 115475287 T G 9.60E-04 Myocardial infarction / / 21107343 rs6991398 chr8 115477600 A G 5.74E-04 White matter integrity / / 22425255 rs1390808 chr8 115532721 A G 6.60E-05 Lung adenocarcinoma / / 22797724 rs10109346 chr8 115536093 A G 3.62E-05 Cognitive test performance / / 20125193 rs2884202 chr8 115538801 A G 3.62E-05 Cognitive test performance / / 20125193 rs10505222 chr8 115543245 A G 3.62E-05 Cognitive test performance / / 20125193 rs10088429 chr8 115564240 T C 1.44E-04 White matter integrity / / 22425255 rs12676786 chr8 115571779 A G 7.65E-04 Multiple complex diseases / / 17554300 rs12676786 chr8 115571779 A G 8.01E-04 White matter integrity / / 22425255 rs12680446 chr8 115571990 T A 5.82E-04 Multiple complex diseases / / 17554300 rs7819013 chr8 115573110 T G 9.36E-04 Multiple complex diseases / / 17554300 rs7014900 chr8 115578307 T G 4.10E-04 White matter integrity / / 22425255 rs7014900 chr8 115578307 T G 1.31E-04 Post-traumatic stress disorder / / 23726511 rs7014900 chr8 115578307 T G 2.00E-06 Post-traumatic stress disorder (asjusted for relatedness) / / 23726511 rs7014900 chr8 115578307 T G 3.90E-04 Post-traumatic stress disorder / / 23726511 rs7014900 chr8 115578307 T G 4.00E-06 Post-traumatic stress disorder (asjusted for relatedness) / / 23726511 rs11987094 chr8 115623858 T G 4.40E-04 Multiple complex diseases / / 17554300 rs10087123 chr8 115643325 C T 6.68E-04 Alzheimer's disease / / 22005930 rs10505226 chr8 115698493 C T 7.82E-04 White matter integrity / / 22425255 rs13260311 chr8 115836040 G C 5.14E-04 Multiple complex diseases / / 17554300 rs16886466 chr8 115836494 C A 3.66E-04 Type 2 diabetes / / 17463246 rs9297534 chr8 115843061 T C 6.20E-05 Intelligence (childhood) / / 23358156 rs41348046 chr8 115843843 T C 3.66E-04 Type 2 diabetes / / 17463246 rs41497745 chr8 115844123 G T 4.01E-04 Type 2 diabetes / / 17463246 rs9642829 chr8 115854395 A G 2.09E-05 Cognitive performance / / 19734545 rs2357731 chr8 115868407 G A 6.93E-04 Type 2 diabetes / / 17463246 rs2357734 chr8 115871995 A C 9.21E-04 Type 2 diabetes / / 17463246 rs12114165 chr8 115886433 C G 5.73E-04 Type 2 diabetes / / 17463246 rs10097028 chr8 115892114 A G 8.01E-04 Type 2 diabetes / / 17463246 rs10097028 chr8 115892114 A G 5.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10283101 chr8 115892932 C A 1.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10505239 chr8 115907227 T C 1.30E-04 Longevity and age-related phenotypes / / 17903295 rs7834387 chr8 115908949 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs10046735 chr8 115911849 C A 5.75E-05 Orofacial clefts / / 22419666 rs11989244 chr8 115923992 C T 3.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2575933 chr8 115990717 T C 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs17733014 chr8 115996511 T C 5.40E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs604449 chr8 116005882 C A 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1684978 chr8 116009906 G A 1.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1684978 chr8 116009906 G A 7.40E-05 Body Mass Index / / pha003007 rs4433181 chr8 116020787 A G 0.000012 Major depressive disorder / / 23149448 rs756404 chr8 116037155 C T 3.34E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs756404 chr8 116037155 C T 3.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1436720 chr8 116037798 A C 4.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1436720 chr8 116037798 A C 4.63E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2036012 chr8 116066542 G T 9.29E-04 Multiple complex diseases / / 17554300 rs218361 chr8 116110725 G A 7.00E-06 Eating disorders / / 22911880 rs309610 chr8 116116608 A G 1.43E-05 Odorant perception / / 23910658 rs309609 chr8 116116736 T C 8.36E-04 Multiple complex diseases / / 17554300 rs777808 chr8 116203234 T C 5.63E-06 Rheumatoid arthritis / / 19503088 rs16887135 chr8 116208407 T C 1.67E-05 Cognitive impairment induced by topiramate / / 22091778 rs16887135 chr8 116208407 T C 2.51E-05 Cognitive impairment induced by topiramate / / 22091778 rs13439821 chr8 116213886 C T 1.66E-04 Multiple complex diseases / / 17554300 rs16887186 chr8 116231704 A G 6.98E-04 Multiple complex diseases / / 17554300 rs11987973 chr8 116236244 A G 8.89E-05 Cognitive test performance / / 20125193 rs12677395 chr8 116249908 G A 2.30E-05 Diabetic nephropathy / / pha002864 rs16887231 chr8 116253370 A G 3.88E-04 Acute lung injury / / 22295056 rs9297539 chr8 116298465 G C 1.98E-04 Acute lung injury / / 22295056 rs7010965 chr8 116299406 C T 4.64E-04 Acute lung injury / / 22295056 rs7003434 chr8 116302933 C G 4.64E-04 Acute lung injury / / 22295056 rs7003718 chr8 116302943 G T 1.67E-04 Acute lung injury / / 22295056 rs10094369 chr8 116304971 A T 4.64E-04 Acute lung injury / / 22295056 rs10094733 chr8 116305224 C T 4.65E-04 Acute lung injury / / 22295056 rs16887291 chr8 116305353 T G 4.35E-07 Multiple complex diseases / / 17554300 rs6469576 chr8 116320062 G A 7.07E-04 Alcohol dependence / / 24277619 rs6983039 chr8 116330855 G A 9.00E-06 IgG glycosylation / / 23382691 rs17658378 chr8 116394075 A G 9.00E-06 Attention deficit hyperactivity disorder (time to onset) / / 18937294 rs800897 chr8 116421936 A C 5.43E-04 Parkinson's disease TRPS1 UTR-3 17052657 rs800899 chr8 116425860 A G 2.24E-04 Parkinson's disease TRPS1 UTR-3 17052657 rs16887447 chr8 116428430 C T 5.79E-05 Multiple complex diseases TRPS1 intron 17554300 rs800907 chr8 116429663 T C 4.74E-04 Parkinson's disease TRPS1 intron 17052657 rs10955750 chr8 116449467 G C 7.35E-04 Multiple complex diseases TRPS1 intron 17554300 rs1180626 chr8 116476393 G A 5.69E-05 Post-operative nausea and vomiting TRPS1 intron 21694509 rs800911 chr8 116495909 T A 5.60E-06 Urinary metabolites TRPS1 intron 21572414 rs2293889 chr8 116599199 T G 6.00E-11 HDL cholesterol TRPS1 intron 20686565 rs2293889 chr8 116599199 T G 4.00E-17 HDL cholesterol TRPS1 intron 24097068 rs61745721 chr8 116631660 T C 0.00028 Breast cancer TRPS1 missense 23555315 rs2721937 chr8 116633699 C T 2.14E-06 Rheumatoid arthritis TRPS1 intron 19503088 rs2721937 chr8 116633699 C T 8.00E-06 Major depressive disorder TRPS1 intron 22472876 rs2737229 chr8 116648565 A C 2.00E-08 Cholesterol,total TRPS1 intron 20686565 rs2737244 chr8 116658231 A T 6.19E-04 Type 2 diabetes TRPS1 intron 17846126 rs2737245 chr8 116658583 G T 2.00E-04 Type 2 diabetes TRPS1 intron 17846126 rs179456 chr8 116695112 G A 9.30E-05 Proinsulin levels / / 21873549 rs1526463 chr8 116765231 G A 4.54E-04 Alzheimer's disease (late onset) / / 21379329 rs2694035 chr8 116794593 G C 2.80E-05 Urinary metabolites / / 21572414 rs2960157 chr8 116795541 T G 2.70E-05 Urinary metabolites / / 21572414 rs800586 chr8 116813905 G A 2.00E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs12544542 chr8 116816440 G A 5.60E-04 Celiac disease / / 23936387 rs16887798 chr8 116818578 C T 1.29E-04 Multiple complex diseases / / 17554300 rs2975509 chr8 116845863 C T 5.78E-06 Stroke (ischemic) / / 22941190 rs16887811 chr8 116847725 C T 2.53E-04 Smoking initiation / / 24665060 rs813890 chr8 116855975 T G 2.94E-06 Rheumatoid arthritis / / 19503088 rs2251858 chr8 116863571 A C 5.98E-06 Rheumatoid arthritis / / 19503088 rs800583 chr8 116864498 T C 7.05E-07 Rheumatoid arthritis / / 19503088 rs1569339 chr8 116888468 A C 6.29E-05 Hypertension / / pha003042 rs11993108 chr8 116980396 C T 2.40E-06 Urinary metabolites LINC00536 intron 21572414 rs10808479 chr8 117056361 C T 9.71E-04 Coronary Artery Disease LINC00536 intron 17634449 rs6997637 chr8 117068939 T C 9.25E-04 Type 2 diabetes LINC00536 intron 17463246 rs7004124 chr8 117107236 G C 9.20E-04 Coronary Artery Disease LINC00536 intron 17634449 rs6469633 chr8 117136227 T C 3.00E-07 Breast cancer LINC00536 intron 17529967 rs10955767 chr8 117179913 T C 6.14E-04 Alzheimer's disease LINC00536 intron 17998437 rs17662374 chr8 117190718 A G 3.66E-24 Narcolepsy LINC00536 intron 19629137 rs799887 chr8 117253721 T C 2.64E-05 Orofacial clefts LINC00536 intron 22419666 rs799885 chr8 117256951 C T 0.0000651 Height (Pygmy height) LINC00536 intron 22570615 rs799882 chr8 117260443 A G 3.40E-07 Iron levels LINC00536 intron 21208937 rs16888238 chr8 117271045 T G 9.19E-04 Multiple complex diseases LINC00536 intron 17554300 rs8181015 chr8 117293884 T C 9.67E-05 Non-alcoholic fatty liver disease histology (other) LINC00536 intron 20708005 rs11986435 chr8 117415285 C T 8.10E-06 Urinary metabolites / / 21572414 rs6996185 chr8 117418925 C T 5.76E-04 Type 2 diabetes / / 17463246 rs6996185 chr8 117418925 C T 7.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10955775 chr8 117418945 G A 2.37E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10955775 chr8 117418945 G A 7.07E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10955775 chr8 117418945 G A 7.10E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4515584 chr8 117429845 A G 7.92E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4515584 chr8 117429845 A G 8.56E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6989815 chr8 117430691 A C 7.92E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6989815 chr8 117430691 A C 8.56E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10429325 chr8 117440179 A G 7.92E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10429325 chr8 117440179 A G 8.56E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7007515 chr8 117444194 A G 7.92E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7007515 chr8 117444194 A G 8.56E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13263375 chr8 117462506 T C 1.81E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs13270180 chr8 117462992 G A 2.21E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs11774963 chr8 117468999 C T 3.76E-04 Taste perception / / 22132133 rs4129295 chr8 117475597 A C 3.92E-06 Alcohol withdrawal symptoms / / 22072270 rs6995653 chr8 117482191 G A 2.89E-04 Aortic root size / / 21223598 rs6469646 chr8 117484100 A C 1.23E-05 Suicidal ideation / / 20877300 rs7005255 chr8 117487677 T C 1.43E-05 Aortic root size / / 21223598 rs6997203 chr8 117507487 A G 3.55E-04 Type 2 diabetes / / 17463246 rs11775732 chr8 117510129 C T 5.48E-04 Type 2 diabetes / / 17463246 rs4876358 chr8 117521293 T C 2.11E-05 Aortic root size / / 21223598 rs4876662 chr8 117556270 A G 2.00E-06 Aortic root size / / 21223598 rs16888518 chr8 117564278 T C 2.69E-04 Multiple complex diseases / / 17554300 rs140355816 chr8 117574515 C G 2.00E-08 Colorectal cancer / / 24737748 rs6469650 chr8 117592429 G A 4.18E-05 Glucose levels / / pha002899 rs1317644 chr8 117616701 C T 4.79E-04 Stroke / / pha002887 rs7814028 chr8 117616931 G A 2.92E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16892766 chr8 117630683 A C 3.00E-18 Colorectal cancer / / 18372905 rs16892766 chr8 117630683 A C 1.10E-10 Colorectal cancer / / 19011631 rs16892766 chr8 117630683 A C 3.00E-18 Nasopharyngeal carcinoma / / 20512145 rs16892766 chr8 117630683 A C 4.00E-07 Colorectal cancer / / 21761138 rs16892766 chr8 117630683 A C 0.000000627 Colorectal cancer / / 22532847 rs16892766 chr8 117630683 A C 0.0000411 Colorectal cancer (females) / / 22532847 rs16892766 chr8 117630683 A C 4.59E-10 Colorectal cancer / / 23266556 rs11986063 chr8 117640315 C T 5.70E-10 Colorectal cancer / / 19011631 rs11987235 chr8 117641610 G A 7.00E-06 Corneal curvature / / 22969067 rs6469656 chr8 117647788 G A 5.00E-08 Colorectal cancer / / 24836286 rs1436767 chr8 117665191 G A 7.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EIF3H intron 20877124 rs7833054 chr8 117681031 A G 4.82E-04 Alcohol dependence EIF3H intron 21314694 rs4876679 chr8 117763873 A G 7.28E-05 Serum metabolites EIF3H intron 19043545 rs6983626 chr8 117802148 T C 4.40E-06 Colorectal cancer / / 19011631 rs2317587 chr8 117823709 T C 0.00006123 Sarcoidosis / / 22952805 rs7835543 chr8 117836722 T C 6.20E-04 Multiple complex diseases / / 17554300 rs10093705 chr8 117864753 G A 9.93E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines RAD21 intron 21844884 rs7821544 chr8 117895239 A G 8.09E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2921755 chr8 117915557 A G 1.57E-05 Lung function (forced vital capacity) / / 24023788 rs2921755 chr8 117915557 A G 4.07E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs720131 chr8 117916015 G A 6.20E-04 Cognition,early reading ability / / 17684495 rs720133 chr8 117916281 T C 3.20E-05 Alcohol dependence / / 20201924 rs720133 chr8 117916281 T C 3.20E-05 Alcoholism / / pha002891 rs12541437 chr8 117918897 T A 5.64E-05 Lymphocyte counts / / 22286170 rs3020164 chr8 117926775 T G 1.42E-05 Heart Failure / / pha002884 rs1584221 chr8 117927841 G A 3.54E-05 Multiple complex diseases / / 17554300 rs1584217 chr8 117928099 C A 2.04E-04 Heart Failure / / pha002884 rs3020167 chr8 117928825 C T 5.82E-05 Crohn's disease / / 23850713 rs3020168 chr8 117930817 C T 1.11E-05 Heart Failure / / pha002884 rs16889285 chr8 117951238 C A 1.97E-05 Multiple complex diseases C8orf85 intron 17554300 rs6998067 chr8 117951521 G T 3.84E-04 Response to taxane treatment (placlitaxel) C8orf85 intron 23006423 rs3020107 chr8 117960214 A G 4.54E-05 Alzheimer's disease / / 24755620 rs3020108 chr8 117960386 G A 7.34E-04 Alzheimer's disease / / 24755620 rs3020114 chr8 117972195 G A 3.82E-05 Alzheimer's disease SLC30A8 intron 24755620 rs3020116 chr8 117975153 G T 3.82E-05 Alzheimer's disease SLC30A8 intron 24755620 rs4269571 chr8 118001867 G T 5.41E-04 Alzheimer's disease SLC30A8 intron 24755620 rs2938864 chr8 118012265 G A 2.16E-05 Cognitive test performance SLC30A8 intron 20125193 rs3019880 chr8 118018874 C T 9.32E-05 Hemoglobin SLC30A8 intron pha003098 rs3019880 chr8 118018874 C T 4.55E-05 Erythrocyte counts SLC30A8 intron pha003099 rs3019885 chr8 118025645 T G 5.00E-13 Asthma SLC30A8 intron 21814517 rs3019885 chr8 118025645 T G 2.32E-10 Abdominal aortic aneurysm SLC30A8 intron 22055160 rs3019885 chr8 118025645 T G 4.53E-04 Alzheimer's disease SLC30A8 intron 24755620 rs11781136 chr8 118028297 A G 4.93E-04 Alzheimer's disease (late onset) SLC30A8 intron 21379329 rs1001646 chr8 118034120 G A 6.18E-04 Cognition,early reading ability SLC30A8 intron 17684495 rs11781519 chr8 118037316 T C 3.87E-04 Alzheimer's disease (late onset) SLC30A8 intron 21379329 rs2062947 chr8 118078696 G A 5.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC30A8 intron 20877124 rs7815720 chr8 118089513 G A 2.00E-06 Intraocular pressure SLC30A8 intron 24002674 rs11989843 chr8 118150993 A G 8.00E-06 Obesity-related traits SLC30A8 intron 23251661 rs2466297 chr8 118183892 T C 2.38E-04 Alzheimer's disease (late onset) SLC30A8 intron 21379329 rs2466296 chr8 118184127 A G 1.37E-04 Alzheimer's disease (late onset) SLC30A8 intron 21379329 rs13266634 chr8 118184783 C T 6.00E-08 Type 2 diabetes SLC30A8 missense 17293876 rs13266634 chr8 118184783 C T 3.00E-06 Type 2 diabetes SLC30A8 missense 17460697 rs13266634 chr8 118184783 C T 5.00E-08 Type 2 diabetes SLC30A8 missense 17463246 rs13266634 chr8 118184783 C T 5.00E-08 Type 2 diabetes SLC30A8 missense 17463248 rs13266634 chr8 118184783 C T 5.00E-08 Type 2 diabetes SLC30A8 missense 17463249 rs13266634 chr8 118184783 C T 7.00E-06 Type 2 diabetes SLC30A8 missense 19056611 rs13266634 chr8 118184783 C T 5.00E-08 Glycated hemoglobin levels SLC30A8 missense 19096518 rs13266634 chr8 118184783 C T 1.80E-05 Type 2 diabetes SLC30A8 missense 19184112 rs13266634 chr8 118184783 C T 2.00E-14 Type 2 diabetes SLC30A8 missense 19401414 rs13266634 chr8 118184783 C T 8.00E-08 Type 2 diabetes and other traits SLC30A8 missense 19734900 rs13266634 chr8 118184783 C T 4.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC30A8 missense 20877124 rs13266634 chr8 118184783 C T 8.00E-08 Coronary heart disease SLC30A8 missense 21347282 rs13266634 chr8 118184783 C T 2.00E-14 Type 2 diabetes SLC30A8 missense 21647700 rs13266634 chr8 118184783 C T 9.00E-13 Type 2 diabetes SLC30A8 missense 21874001 rs13266634 chr8 118184783 C T 4.04E-08 Type 2 diabetes SLC30A8 missense 22158537 rs13266634 chr8 118184783 C T 2.71E-10 Type 2 diabetes SLC30A8 missense 22325160 rs13266634 chr8 118184783 C T 3.66E-11 Positivity for ZnT8A in Type 1 diabetes SLC30A8 missense 22526605 rs13266634 chr8 118184783 C T 7.20E-17 Positivity for ZnT8RA in Type 1 diabetes SLC30A8 missense 22526605 rs13266634 chr8 118184783 C T 9.26E-27 Positivity for ZnT8WA in Type 1 diabetes SLC30A8 missense 22526605 rs13266634 chr8 118184783 C T 5.30E-08 Type 2 diabetes SLC30A8 missense 23300278 rs13266634 chr8 118184783 C T 5.00E-07 Type 2 diabetes SLC30A8 missense 23945395 rs13266634 chr8 118184783 C T 2.00E-07 Glycated hemoglobin levels SLC30A8 missense 24647736 rs3802177 chr8 118185025 G A 9.90E-04 Type 2 diabetes SLC30A8 UTR-3 17463248 rs3802177 chr8 118185025 G A 1.00E-08 Type 2 diabetes SLC30A8 UTR-3 20581827 rs3802177 chr8 118185025 G A 5.53E-05 Type 2 diabetes SLC30A8 UTR-3 22158537 rs3802177 chr8 118185025 G A 4.00E-08 Type 2 diabetes SLC30A8 UTR-3 22693455 rs3802177 chr8 118185025 G A 0.00002 HOMA-B SLC30A8 UTR-3 22885922 rs3802177 chr8 118185025 G A 1.30E-21 Type 2 diabetes SLC30A8 UTR-3 22885922 rs3802177 chr8 118185025 G A 1.40E-16 Type 2 diabetes (males) SLC30A8 UTR-3 22885922 rs3802177 chr8 118185025 G A 1.80E-32 Fasting blood glucose SLC30A8 UTR-3 22885922 rs3802177 chr8 118185025 G A 7.20E-11 Type 2 diabetes (females) SLC30A8 UTR-3 22885922 rs3802177 chr8 118185025 G A 2.00E-18 Type 2 diabetes SLC30A8 UTR-3 24509480 rs11558471 chr8 118185733 A G 3.00E-11 Fasting insulin-related traits SLC30A8 UTR-3 20081858 rs11558471 chr8 118185733 A G 3.00E-18 Proinsulin levels SLC30A8 UTR-3 21873549 rs11558471 chr8 118185733 A G 4.02E-05 Type 2 diabetes SLC30A8 UTR-3 22158537 rs11558471 chr8 118185733 A G 3.00E-20 Fasting glucose-related traits (interaction with BMI) SLC30A8 UTR-3 22581228 rs11558471 chr8 118185733 A G 7.80E-37 Type 2 diabetes SLC30A8 UTR-3 22885922 rs11558471 chr8 118185733 A G 0.0000583 Glycated hemoglobin levels SLC30A8 UTR-3 22885924 rs11558471 chr8 118185733 A G 7.80E-37 Fasting blood glucose SLC30A8 UTR-3 22885924 rs11558471 chr8 118185733 A G 1.30E-12 Insulin processing and secretion SLC30A8 UTR-3 23263489 rs2466291 chr8 118190393 A G 6.30E-04 Type 2 diabetes / / 17463248 rs35859536 chr8 118191475 C T 1.50E-14 Fasting blood glucose / / 22885924 rs2466316 chr8 118217597 G A 3.44E-06 Hemoglobin / / pha003098 rs2466316 chr8 118217597 G A 4.23E-06 Erythrocyte counts / / pha003099 rs2464577 chr8 118218521 A G 2.55E-06 Hemoglobin / / pha003098 rs2464577 chr8 118218521 A G 1.13E-05 Erythrocyte counts / / pha003099 rs2466315 chr8 118219383 G A 2.55E-06 Hemoglobin / / pha003098 rs2466315 chr8 118219383 G A 1.13E-05 Erythrocyte counts / / pha003099 rs10505308 chr8 118237145 A G 1.38E-05 Mammographic density / / 22532574 rs17813547 chr8 118237364 T C 7.16E-05 Mammographic density / / 22532574 rs1392044 chr8 118240824 C A 3.59E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs11989734 chr8 118244191 G C 7.23E-05 Cognitive decline / / 22054870 rs7011815 chr8 118293451 G T 8.50E-04 Type 2 diabetes / / 17463246 rs7000854 chr8 118319624 T C 8.01E-05 Bipolar disorder and schizophrenia / / 20889312 rs1793699 chr8 118320953 G A 4.89E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1499424 chr8 118322087 T G 8.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12155554 chr8 118322451 A G 2.57E-05 Obesity (extreme) / / 21935397 rs12156001 chr8 118322562 C T 2.68E-05 Obesity (extreme) / / 21935397 rs10505305 chr8 118329011 A C 3.53E-05 Obesity (extreme) / / 21935397 rs1948674 chr8 118392828 A C 5.40E-110 Multiple complex diseases / / 17554300 rs2023139 chr8 118400711 A T 1.22E-04 Diabetic retinopathy / / 20871662 rs1387434 chr8 118403267 C G 6.00E-05 Prostate cancer / / 21743057 rs1686354 chr8 118404959 G A 6.00E-05 Prostate cancer / / 21743057 rs1586601 chr8 118418008 G A 4.00E-05 Prostate cancer / / 21743057 rs1548124 chr8 118457084 A G 6.92E-04 Myocardial Infarction / / pha002873 rs4876377 chr8 118486989 C T 1.93E-05 Bone mass and geometry / / 17903296 rs2873645 chr8 118515249 G A 5.83E-05 Serum metabolites / / 19043545 rs6997585 chr8 118528789 G C 6.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs17667932 chr8 118549376 T C 5.00E-07 Kawasaki disease MED30 intron 22446961 rs17667990 chr8 118557129 T C 2.52E-05 Kawasaki disease / / 22446961 rs922587 chr8 118560491 C T 3.70E-05 Personality dimensions / / 18957941 rs1993980 chr8 118608208 T C 9.12E-05 Multiple complex diseases / / 17554300 rs3134390 chr8 118720058 T C 6.95E-04 Type 2 diabetes / / 17463246 rs3105764 chr8 118734726 T A 5.46E-05 Major depressive disorder / / pha002850 rs10113582 chr8 118808893 T C 4.30E-05 Alcoholism (heaviness of drinking) / / 21529783 rs17429936 chr8 118820371 T G 1.90E-04 Depression (quantitative trait) EXT1 intron 20800221 rs28357253 chr8 118820442 A T 2.40E-04 Depression (quantitative trait) EXT1 intron 20800221 rs4370563 chr8 118823626 C A 7.88E-05 Body Mass Index EXT1 intron pha003006 rs11783511 chr8 118826698 A G 6.21E-05 Body Mass Index EXT1 intron pha003006 rs11989122 chr8 118827839 G A 6.00E-06 Height EXT1 intron 19893584 rs10955837 chr8 118830820 T C 5.83E-06 Post-operative nausea and vomiting EXT1 intron 21694509 rs4876759 chr8 118839512 T C 1.44E-04 Lymphocyte counts EXT1 intron 22286170 rs9656922 chr8 118856069 T C 2.08E-04 Multiple complex diseases EXT1 intron 17554300 rs7836010 chr8 118861367 G C 6.47E-07 Left ventricular mass EXT1 intron 21212386 rs111709825 chr8 118868366 T C 1.75E-11 Metabolite levels EXT1 intron 22286219 rs17475190 chr8 118898839 A C 9.88E-04 Depression (quantitative trait) EXT1 intron 20800221 rs13252084 chr8 118901452 C T 9.05E-04 Depression (quantitative trait) EXT1 intron 20800221 rs4621831 chr8 118901524 T C 9.02E-04 Depression (quantitative trait) EXT1 intron 20800221 rs4480148 chr8 118901585 A G 8.99E-04 Depression (quantitative trait) EXT1 intron 20800221 rs7459527 chr8 118909260 A C 2.00E-06 Obesity-related traits EXT1 intron 23251661 rs7822297 chr8 118910911 G A 9.25E-04 Depression (quantitative trait) EXT1 intron 20800221 rs10106675 chr8 118911796 C T 8.66E-04 Depression (quantitative trait) EXT1 intron 20800221 rs28357275 chr8 118916104 G A 9.26E-04 Depression (quantitative trait) EXT1 intron 20800221 rs28357277 chr8 118916467 T G 9.03E-04 Depression (quantitative trait) EXT1 intron 20800221 rs17453043 chr8 118916779 C T 9.60E-04 Depression (quantitative trait) EXT1 intron 20800221 rs4391466 chr8 118917627 T C 8.82E-04 Depression (quantitative trait) EXT1 intron 20800221 rs5005135 chr8 118917677 A G 8.83E-04 Depression (quantitative trait) EXT1 intron 20800221 rs17430610 chr8 118918885 C G 6.73E-04 Depression (quantitative trait) EXT1 intron 20800221 rs7824395 chr8 118922172 A G 8.72E-04 Depression (quantitative trait) EXT1 intron 20800221 rs7842917 chr8 118922226 T C 7.38E-04 Depression (quantitative trait) EXT1 intron 20800221 rs7843515 chr8 118922698 T C 8.36E-04 Depression (quantitative trait) EXT1 intron 20800221 rs3923167 chr8 118923187 A G 9.01E-04 Multiple complex diseases EXT1 intron 17554300 rs6999867 chr8 118930741 C T 2.55E-06 Obesity-related traits EXT1 intron 23251661 rs2514722 chr8 118944585 G A 4.11E-04 Amyotrophic lateral sclerosis (sporadic) EXT1 intron 24529757 rs10955841 chr8 118946541 G A 0.0000752 Uterine leiomyomata EXT1 intron 23040493 rs13255959 chr8 119012781 T C 5.79E-04 Myocardial Infarction EXT1 intron pha002883 rs10505325 chr8 119058534 T G 4.72E-04 Rheumatoid arthritis EXT1 intron 21452313 rs2514756 chr8 119081943 G A 8.70E-04 Alzheimer's disease EXT1 intron 17998437 rs11562721 chr8 119081993 T C 9.19E-05 Neuroblastoma EXT1 intron pha002895 rs6983199 chr8 119093994 T C 4.90E-04 Rheumatoid arthritis EXT1 intron 21452313 rs2445904 chr8 119095507 C T 4.55E-06 Left ventricular hypertrophy EXT1 intron pha003052 rs2468133 chr8 119095747 C T 3.73E-06 Left ventricular hypertrophy EXT1 intron pha003052 rs2445906 chr8 119106346 C T 2.69E-06 Left ventricular hypertrophy EXT1 intron pha003052 rs10755915 chr8 119113236 A G 7.47E-04 Multiple complex diseases EXT1 intron 17554300 rs2468140 chr8 119113307 G A 5.70E-05 Multiple complex diseases EXT1 intron 17554300 rs4876400 chr8 119114110 A G 7.94E-04 Multiple complex diseases EXT1 intron 17554300 rs2445912 chr8 119138912 G A 2.27E-04 Multiple complex diseases / / 17554300 rs2451167 chr8 119152919 C A 2.07E-06 Asthma (childhood onset) / / 23829686 rs4147527 chr8 119165749 T C 3.00E-04 Body mass index / / 24827717 rs723268 chr8 119166694 T C 7.15E-05 Parkinson's disease / / 16252231 rs2514732 chr8 119180015 T C 7.44E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs2514733 chr8 119180149 A G 1.39E-04 Type 2 diabetes / / 17463246 rs2514733 chr8 119180149 A G 7.69E-04 Multiple complex diseases / / 17554300 rs12155549 chr8 119186397 T C 8.24E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs4467962 chr8 119209213 G A 4.93E-04 Multiple complex diseases SAMD12 UTR-3 17554300 rs17451949 chr8 119217328 G A 5.40E-04 Response to alcohol consumption (flushing response) SAMD12 intron 24277619 rs2451138 chr8 119238473 C T 2.92E-04 Multiple complex diseases SAMD12 intron 17554300 rs12680308 chr8 119240025 G A 3.79E-04 Multiple complex diseases SAMD12 intron 17554300 rs2514971 chr8 119250940 G C 9.86E-04 Multiple complex diseases SAMD12 intron 17554300 rs6989069 chr8 119280694 T C 9.09E-07 Bleomycin sensitivity SAMD12 intron 21106707 rs7825192 chr8 119281723 T C 2.10E-05 Urinary metabolites SAMD12 intron 21572414 rs9297582 chr8 119298134 T C 1.01E-06 Bleomycin sensitivity SAMD12 intron 21106707 rs3849851 chr8 119309329 C A 6.34E-05 Serum metabolites SAMD12 intron 19043545 rs7823536 chr8 119323304 G A 6.07E-06 Serum metabolites SAMD12 intron 19043545 rs7823689 chr8 119323381 G A 1.95E-05 Serum metabolites SAMD12 intron 19043545 rs7827637 chr8 119323839 C T 1.20E-05 Urinary metabolites SAMD12 intron 21572414 rs3802185 chr8 119326042 C T 1.07E-05 Serum metabolites SAMD12 intron 19043545 rs7832024 chr8 119337617 G A 6.35E-07 Bleomycin sensitivity SAMD12 intron 21106707 rs7000702 chr8 119342798 C T 1.83E-04 Response to TNF antagonist treatment SAMD12 intron 21061259 rs6994270 chr8 119348495 C G 1.85E-04 Response to TNF antagonist treatment SAMD12 intron 21061259 rs6994852 chr8 119348622 G C 8.38E-05 Serum metabolites SAMD12 intron 19043545 rs2450316 chr8 119351241 T C 7.97E-04 Stroke SAMD12 intron pha002887 rs2515029 chr8 119356466 T C 2.70E-05 Urinary metabolites SAMD12 intron 21572414 rs17749211 chr8 119391409 C T 8.00E-06 Multiple sclerosis SAMD12 UTR-3 23412934 rs7817780 chr8 119416966 A G 2.00E-04 Type 2 diabetes SAMD12 intron 17846126 rs7002648 chr8 119425710 G T 1.30E-04 Acute lung injury SAMD12 intron 22295056 rs4876414 chr8 119427594 C G 2.29E-04 Acute lung injury SAMD12 intron 22295056 rs10505334 chr8 119428764 T C 5.41E-04 Acute lung injury SAMD12 intron 22295056 rs2515065 chr8 119429115 G A 7.23E-04 Multiple complex diseases SAMD12 intron 17554300 rs2514990 chr8 119432245 T C 1.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SAMD12 intron 20877124 rs4130593 chr8 119432302 G C 9.96E-04 Type 2 diabetes SAMD12 intron 17463246 rs13269591 chr8 119436240 T A 7.54E-04 Acute lung injury SAMD12 intron 22295056 rs12679873 chr8 119436711 T C 6.29E-04 Acute lung injury SAMD12 intron 22295056 rs12678159 chr8 119436865 G C 6.29E-04 Acute lung injury SAMD12 intron 22295056 rs13263320 chr8 119448148 A G 5.45E-04 Acute lung injury SAMD12 intron 22295056 rs13265657 chr8 119448220 T G 7.16E-04 Acute lung injury SAMD12 intron 22295056 rs12681581 chr8 119448268 C T 7.16E-04 Acute lung injury SAMD12 intron 22295056 rs12681600 chr8 119448373 C G 8.03E-04 Acute lung injury SAMD12 intron 22295056 rs12675551 chr8 119448453 T C 7.89E-04 Acute lung injury SAMD12 intron 22295056 rs4242580 chr8 119448782 C T 7.88E-04 Acute lung injury SAMD12 intron 22295056 rs9297587 chr8 119449425 C T 8.68E-04 Acute lung injury SAMD12 intron 22295056 rs4128894 chr8 119451204 G A 9.16E-04 Acute lung injury SAMD12 intron 22295056 rs10955883 chr8 119452526 C T 9.21E-04 Acute lung injury SAMD12 intron 22295056 rs17682712 chr8 119453249 G A 2.26E-04 Multiple complex diseases SAMD12 intron 17554300 rs4876837 chr8 119455366 T C 9.56E-04 Acute lung injury SAMD12 intron 22295056 rs4876838 chr8 119455598 G A 9.56E-04 Acute lung injury SAMD12 intron 22295056 rs10955885 chr8 119459298 T C 7.93E-04 Acute lung injury SAMD12 intron 22295056 rs9656927 chr8 119460973 C A 9.73E-04 Acute lung injury SAMD12 intron 22295056 rs12679343 chr8 119462095 A G 9.45E-04 Acute lung injury SAMD12 intron 22295056 rs4876839 chr8 119462771 G A 9.15E-04 Acute lung injury SAMD12 intron 22295056 rs4876841 chr8 119463191 A G 9.02E-04 Acute lung injury SAMD12 intron 22295056 rs10096317 chr8 119463790 A G 9.02E-04 Acute lung injury SAMD12 intron 22295056 rs7830423 chr8 119467795 C T 9.65E-04 Acute lung injury SAMD12 intron 22295056 rs4075614 chr8 119475627 A G 9.71E-04 Acute lung injury SAMD12 intron 22295056 rs17750253 chr8 119495773 A G 2.09E-04 Multiple complex diseases SAMD12 intron 17554300 rs4514016 chr8 119507415 G C 3.70E-05 Blood Pressure and Arterial Stiffness SAMD12 intron 17903302 rs17829808 chr8 119510462 G A 4.60E-07 Multiple complex diseases SAMD12 intron 17554300 rs4129893 chr8 119518190 A G 1.14E-04 Aortic root size SAMD12 intron 21223598 rs10097320 chr8 119537273 T C 7.09E-06 Glycemic traits (pregnancy) SAMD12 intron 23903356 rs4876852 chr8 119542307 C A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SAMD12 intron 22628534 rs12548521 chr8 119552755 G A 9.05E-05 Body mass (lean) SAMD12 intron 19268274 rs7005188 chr8 119556362 A C 2.41E-04 Multiple complex diseases SAMD12 intron 17554300 rs1607924 chr8 119602607 C T 7.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SAMD12 intron 20877124 rs1402513 chr8 119660179 C T 6.90E-04 Bipolar disorder SAMD12-AS1 intron 19259986 rs16891338 chr8 119671197 A G 2.00E-85 Multiple complex diseases SAMD12-AS1 intron 17554300 rs2514576 chr8 119671763 T C 2.30E-04 Suicide attempts in bipolar disorder SAMD12-AS1 intron 21423239 rs2460982 chr8 119672112 C G 8.90E-04 Suicide attempts in bipolar disorder SAMD12-AS1 intron 21423239 rs2460983 chr8 119672134 G T 6.02E-04 Suicide attempts in bipolar disorder SAMD12-AS1 intron 21423239 rs952493 chr8 119701152 G A 4.24E-04 Response to radiotherapy in cancer (late toxicity) SAMD12-AS1 intron 24785509 rs952493 chr8 119701152 G A 8.35E-05 Response to radiotherapy in cancer (late toxicity) SAMD12-AS1 intron 24785509 rs1013456 chr8 119751929 G A 7.65E-05 Nonalcoholic fatty liver disease / / 21423719 rs10505338 chr8 119755490 G A 4.39E-05 Serum metabolites / / 19043545 rs11988997 chr8 119766194 C T 6.00E-06 Pancreatitis / / 23143602 rs10505337 chr8 119767165 G A 2.00E-05 Vitamin D concentrations / / 20600896 rs10505337 chr8 119767165 G A 2.00E-05 Vitamin D concentrations / / 20600896 rs1493937 chr8 119777586 G T 0.000214136 Primary sclerosing cholangitis / / 23603763 rs7823550 chr8 119779639 A G 4.97E-04 Acute lung injury / / 22295056 rs7845606 chr8 119779882 T C 5.04E-04 Acute lung injury / / 22295056 rs4384011 chr8 119780061 G T 5.06E-04 Acute lung injury / / 22295056 rs4373549 chr8 119780310 T C 4.83E-04 Acute lung injury / / 22295056 rs4576456 chr8 119780575 A T 4.94E-04 Acute lung injury / / 22295056 rs12543747 chr8 119781394 T G 5.28E-04 Acute lung injury / / 22295056 rs12546069 chr8 119781534 A C 5.28E-04 Acute lung injury / / 22295056 rs12541149 chr8 119781759 G T 7.19E-04 Acute lung injury / / 22295056 rs4876859 chr8 119783003 A C 8.00E-04 Acute lung injury / / 22295056 rs4443689 chr8 119783233 C A 8.00E-04 Acute lung injury / / 22295056 rs4389969 chr8 119783522 T A 7.61E-04 Acute lung injury / / 22295056 rs4406429 chr8 119783551 G A 7.61E-04 Acute lung injury / / 22295056 rs12545780 chr8 119784453 A G 7.61E-04 Acute lung injury / / 22295056 rs11781319 chr8 119785144 A G 7.59E-04 Acute lung injury / / 22295056 rs4541956 chr8 119786126 A G 7.48E-04 Type 2 diabetes / / 17463246 rs16891487 chr8 119788112 C G 9.83E-04 Insulin resistance / / 21901158 rs1874032 chr8 119792200 C T 6.28E-04 Acute lung injury / / 22295056 rs7832641 chr8 119793175 T A 7.92E-04 Acute lung injury / / 22295056 rs7814509 chr8 119793245 C T 8.02E-04 Acute lung injury / / 22295056 rs7833385 chr8 119793638 T C 6.30E-04 Acute lung injury / / 22295056 rs1552871 chr8 119794269 C T 6.39E-04 Acute lung injury / / 22295056 rs1010606 chr8 119794361 A C 1.55E-04 Acute lung injury / / 22295056 rs1493942 chr8 119795008 G A 7.29E-04 Acute lung injury / / 22295056 rs1493941 chr8 119795239 A G 7.29E-04 Acute lung injury / / 22295056 rs1493940 chr8 119795289 G A 7.32E-04 Acute lung injury / / 22295056 rs4876860 chr8 119796643 G T 7.32E-04 Acute lung injury / / 22295056 rs4876861 chr8 119797378 A T 7.32E-04 Acute lung injury / / 22295056 rs1845389 chr8 119800385 A G 5.67E-04 Acute lung injury / / 22295056 rs3133581 chr8 119826164 C A 1.36E-04 Alzheimer's disease / / 17998437 rs903614 chr8 119830680 A C 3.00E-06 Chronic obstructive pulmonary disease-related biomarkers / / 23144326 rs3133585 chr8 119837151 A G 3.80E-08 Bone mineral density (paediatric,skull) / / 24945404 rs1493935 chr8 119848956 G A 0.000507 Salmonella-induced pyroptosis / / 22837397 rs3103969 chr8 119859803 A G 4.90E-08 Bone mineral density (spine) / / 19801982 rs7815486 chr8 119861904 T A 1.03E-04 Multiple complex diseases / / 17554300 rs2035979 chr8 119872439 A G 2.00E-08 Bone mineral density (spine) / / 19801982 rs3103995 chr8 119872951 A C 4.90E-08 Bone mineral density (spine) / / 19801982 rs2035977 chr8 119882287 C G 2.70E-09 Bone mineral density (paediatric,skull) / / 24945404 rs16891617 chr8 119886889 T C 5.47E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2055101 chr8 119886923 C T 3.10E-10 Bone mineral density (spine) / / 19801982 rs2055101 chr8 119886923 C T 4.30E-11 Bone mineral density (paediatric,skull) / / 24945404 rs3890832 chr8 119892216 C G 1.05E-04 Type 2 diabetes / / 17463246 rs3890832 chr8 119892216 C G 8.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs11775992 chr8 119892489 G C 6.07E-05 Type 2 diabetes / / 17463246 rs4242591 chr8 119897611 C A 5.82E-05 Type 2 diabetes / / 17463246 rs10955908 chr8 119904557 C A 1.10E-11 Bone mineral density (spine) / / 19801982 rs10955908 chr8 119904557 C A 1.60E-09 Bone mineral density (paediatric,skull) / / 24945404 rs13250753 chr8 119906692 C G 1.10E-11 Bone mineral density (spine) / / 19801982 rs13250753 chr8 119906692 C G 1.60E-09 Bone mineral density (paediatric,skull) / / 24945404 rs4407910 chr8 119917117 A G 9.20E-13 Bone mineral density (spine) / / 19801982 rs4407910 chr8 119917117 A G 5.50E-10 Bone mineral density (paediatric,skull) / / 24945404 rs13439134 chr8 119918868 G C 8.20E-13 Bone mineral density (spine) / / 19801982 rs13439134 chr8 119918868 G C 4.50E-10 Bone mineral density (paediatric,skull) / / 24945404 rs13277230 chr8 119922993 C T 6.10E-13 Bone mineral density (spine) / / 19801982 rs13277230 chr8 119922993 C T 4.20E-10 Bone mineral density (paediatric,skull) / / 24945404 rs10101385 chr8 119923850 A G 6.00E-13 Bone mineral density (spine) / / 19801982 rs10101385 chr8 119923850 A G 5.10E-10 Bone mineral density (paediatric,skull) / / 24945404 rs4355801 chr8 119923873 A G,T 8.00E-10 Bone mineral density / / 18455228 rs4355801 chr8 119923873 A G,T 5.20E-10 Bone mineral density (spine) / / 19079262 rs4355801 chr8 119923873 A G,T 7.60E-13 Bone mineral density (spine) / / 19801982 rs4355801 chr8 119923873 A G,T 6.20E-10 Bone mineral density (paediatric,skull) / / 24945404 rs4319131 chr8 119947651 A G 9.80E-14 Bone mineral density (spine) TNFRSF11B intron 19801982 rs4319131 chr8 119947651 A G 3.70E-10 Bone mineral density (paediatric,skull) TNFRSF11B intron 24945404 rs11573885 chr8 119949165 T C 1.80E-09 Bone mineral density (spine) TNFRSF11B intron 19801982 rs3102725 chr8 119951005 A G 6.55E-04 Suicide attempts in bipolar disorder TNFRSF11B intron 21041247 rs1905786 chr8 119951692 T C 1.90E-09 Bone mineral density (spine) TNFRSF11B intron 19801982 rs6469788 chr8 119952750 A C 6.70E-12 Bone mineral density (spine) TNFRSF11B intron 19801982 rs6469788 chr8 119952750 A C 2.80E-09 Bone mineral density (paediatric,skull) TNFRSF11B intron 24945404 rs11573871 chr8 119952765 C T 1.10E-04 Primary sclerosing cholangitis TNFRSF11B intron 19944697 rs1485289 chr8 119954279 G A 1.60E-09 Bone mineral density (spine) TNFRSF11B intron 19801982 rs7464496 chr8 119954842 T C 1.70E-09 Bone mineral density (spine) TNFRSF11B intron 19801982 rs6415470 chr8 119955111 G A 6.00E-14 Bone mineral density (spine) TNFRSF11B intron 19801982 rs6415470 chr8 119955111 G A 3.10E-10 Bone mineral density (paediatric,skull) TNFRSF11B intron 24945404 rs3102726 chr8 119955350 A T 6.87E-04 Suicide attempts in bipolar disorder TNFRSF11B intron 21041247 rs3134059 chr8 119955852 T C 6.89E-04 Suicide attempts in bipolar disorder TNFRSF11B intron 21041247 rs3134060 chr8 119956043 A G 6.91E-04 Suicide attempts in bipolar disorder TNFRSF11B intron 21041247 rs3134061 chr8 119956319 T A 3.22E-04 Type 2 diabetes TNFRSF11B intron 17463246 rs3134061 chr8 119956319 T A 8.41E-04 Alzheimer's disease TNFRSF11B intron 17998437 rs3134061 chr8 119956319 T A 6.92E-04 Suicide attempts in bipolar disorder TNFRSF11B intron 21041247 rs3102729 chr8 119956505 G A 6.90E-04 Suicide attempts in bipolar disorder TNFRSF11B intron 21041247 rs7463176 chr8 119957625 A G 3.90E-14 Bone mineral density (spine) TNFRSF11B intron 19801982 rs7463176 chr8 119957625 A G 2.40E-10 Bone mineral density (paediatric,skull) TNFRSF11B intron 24945404 rs11573838 chr8 119957639 T C 7.65E-04 Type 2 diabetes TNFRSF11B intron 17463246 rs3134062 chr8 119959278 A G 6.86E-04 Suicide attempts in bipolar disorder TNFRSF11B intron 21041247 rs3102731 chr8 119959389 G A 6.85E-04 Suicide attempts in bipolar disorder TNFRSF11B intron 21041247 rs11573829 chr8 119959623 T C 3.40E-14 Bone mineral density (spine) TNFRSF11B intron 19801982 rs11573829 chr8 119959623 T C 2.40E-10 Bone mineral density (paediatric,skull) TNFRSF11B intron 24945404 rs3134063 chr8 119959657 C T 1.00E-11 Bone mineral density (spine) TNFRSF11B intron 19801982 rs3134063 chr8 119959657 C T 1.80E-08 Bone mineral density (paediatric,skull) TNFRSF11B intron 24945404 rs3134066 chr8 119960351 A T 6.81E-04 Suicide attempts in bipolar disorder TNFRSF11B intron 21041247 rs6469789 chr8 119960661 C G 3.30E-14 Bone mineral density (spine) TNFRSF11B intron 19801982 rs6469789 chr8 119960661 C G 2.40E-10 Bone mineral density (paediatric,skull) TNFRSF11B intron 24945404 rs3134067 chr8 119961438 C T 6.78E-04 Suicide attempts in bipolar disorder TNFRSF11B intron 21041247 rs3102733 chr8 119962120 T C 6.76E-04 Suicide attempts in bipolar disorder TNFRSF11B intron 21041247 rs3134068 chr8 119962659 T C 6.70E-04 Suicide attempts in bipolar disorder TNFRSF11B intron 21041247 rs3102734 chr8 119964016 G A 6.66E-04 Suicide attempts in bipolar disorder TNFRSF11B intron 21041247 rs2073618 chr8 119964052 G C 1.60E-09 Bone mineral density (spine) TNFRSF11B missense 19801982 rs2073618 chr8 119964052 G C 1.29E-05 Statin-induced myopathy TNFRSF11B missense 21826682 rs2073617 chr8 119964283 G A 1.10E-11 Bone mineral density (spine) TNFRSF11B UTR-5 19801982 rs2073617 chr8 119964283 G A 1.70E-08 Bone mineral density (paediatric,skull) TNFRSF11B UTR-5 24945404 rs3134069 chr8 119964988 A C 6.57E-04 Suicide attempts in bipolar disorder TNFRSF11B nearGene-5 21041247 rs3134070 chr8 119965024 C T 6.56E-04 Suicide attempts in bipolar disorder TNFRSF11B nearGene-5 21041247 rs3134072 chr8 119965537 C T 6.50E-04 Suicide attempts in bipolar disorder TNFRSF11B nearGene-5 21041247 rs1564861 chr8 119965909 A C 1.20E-05 Urinary metabolites TNFRSF11B nearGene-5 21572414 rs1385505 chr8 119966387 C T 1.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs3134073 chr8 119966721 A G 6.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs12386956 chr8 119968028 G A 6.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs4242592 chr8 119968975 T G 9.50E-15 Bone mineral density (spine) / / 19801982 rs4242592 chr8 119968975 T G 2.90E-10 Bone mineral density (paediatric,skull) / / 24945404 rs4876872 chr8 119969157 A G 6.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs4876873 chr8 119970020 C A 6.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs7006553 chr8 119970779 C T 9.40E-15 Bone mineral density (spine) / / 19801982 rs7006553 chr8 119970779 C T 2.90E-10 Bone mineral density (paediatric,skull) / / 24945404 rs12335174 chr8 119972671 G T 6.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs10505348 chr8 119972696 T C 9.30E-15 Bone mineral density (spine) / / 19801982 rs10505348 chr8 119972696 T C 2.90E-10 Bone mineral density (paediatric,skull) / / 24945404 rs17758011 chr8 119973564 T G 4.63E-04 Alzheimer's disease / / 17998437 rs17758011 chr8 119973564 T G 6.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs1385499 chr8 119974708 G A 2.10E-10 Bone mineral density (spine) / / 19801982 rs1564860 chr8 119975670 C T 7.90E-07 Bone mineral density (spine) / / 19079262 rs1564860 chr8 119975670 C T 6.10E-09 Bone mineral density (spine) / / 19801982 rs1485302 chr8 119976144 G A 1.80E-09 Bone mineral density (spine) / / 19801982 rs1485302 chr8 119976144 G A 2.50E-05 Urinary metabolites / / 21572414 rs1485303 chr8 119976256 G A 1.10E-09 Bone mineral density (spine) / / 19801982 rs7839059 chr8 119976542 C A 7.30E-11 Bone mineral density (spine) / / 19801982 rs7839059 chr8 119976542 C A 1.00E-10 Bone mineral density / / 23437003 rs7014574 chr8 119977077 C T 6.30E-15 Bone mineral density (spine) / / 19801982 rs7014574 chr8 119977077 C T 6.06E-05 C-reactive protein / / 24763700 rs7014574 chr8 119977077 C T 4.20E-10 Bone mineral density (paediatric,skull) / / 24945404 rs12679857 chr8 119977337 A G 4.00E-07 Type 1 diabetes / / 21980299 rs2062375 chr8 119977792 G C 2.20E-15 Bone mineral density (spine) / / 19801982 rs2062375 chr8 119977792 G C 3.00E-11 Osteoporosis / / 20548944 rs2062375 chr8 119977792 G C 3.77E-05 C-reactive protein / / 24763700 rs2062375 chr8 119977792 G C 1.10E-09 Bone mineral density (paediatric,skull) / / 24945404 rs6992497 chr8 119980069 A G 1.50E-15 Bone mineral density (spine) / / 19801982 rs6992497 chr8 119980069 A G 6.90E-10 Bone mineral density (paediatric,skull) / / 24945404 rs4876876 chr8 119986235 T C 6.40E-12 Bone mineral density (spine) / / 19801982 rs4563920 chr8 119993689 A G 6.20E-12 Bone mineral density (spine) / / 19801982 rs11985044 chr8 119998209 A G 4.77E-04 Insulin resistance / / 21901158 rs11992136 chr8 120003727 C G 6.80E-12 Bone mineral density (spine) / / 19801982 rs11992136 chr8 120003727 C G 4.35E-05 C-reactive protein / / 24763700 rs9969672 chr8 120006080 T A 6.80E-12 Bone mineral density (spine) / / 19801982 rs9969672 chr8 120006080 T A 4.17E-05 C-reactive protein / / 24763700 rs2062377 chr8 120007420 T A 4.00E-16 Bone mineral density (spine) / / 19801982 rs2062377 chr8 120007420 T A 3.00E-39 Bone mineral density / / 22504420 rs2062377 chr8 120007420 T A 1.00E-07 Bone mineral density / / 23437003 rs2062377 chr8 120007420 T A 1.68E-08 Bone mineral density / / 24249740 rs2062377 chr8 120007420 T A 2.55E-04 Bone mineral density / / 24249740 rs2062377 chr8 120007420 T A 9.39E-05 C-reactive protein / / 24763700 rs2062377 chr8 120007420 T A 4.67E-10 Bone mineral density (paediatric,skull) / / 24945404 rs2062377 chr8 120007420 T A 4.70E-10 Bone mineral density (paediatric,skull) / / 24945404 rs2220189 chr8 120007708 C G 3.30E-15 Bone mineral density (spine) / / 19801982 rs4567065 chr8 120008274 C A 2.30E-15 Bone mineral density (spine) / / 19801982 rs4567065 chr8 120008274 C A 2.30E-10 Bone mineral density (paediatric,skull) / / 24945404 rs6469792 chr8 120008371 T C 1.10E-15 Bone mineral density (spine) / / 19079262 rs6469792 chr8 120008371 T C 5.50E-15 Bone mineral density (spine) / / 19801982 rs6469792 chr8 120008371 T C 3.40E-08 Bone mineral density (paediatric,skull) / / 24945404 rs7842942 chr8 120008587 T C 1.70E-15 Bone mineral density (spine) / / 19801982 rs7842942 chr8 120008587 T C 1.90E-10 Bone mineral density (paediatric,skull) / / 24945404 rs4876434 chr8 120009573 T C 6.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs2062376 chr8 120010009 C G 6.60E-15 Bone mineral density (spine) / / 19801982 rs2062376 chr8 120010009 C G 3.40E-08 Bone mineral density (paediatric,skull) / / 24945404 rs1485306 chr8 120010261 C G 8.43E-04 Type 2 diabetes / / 17463246 rs1485305 chr8 120010520 A T 2.80E-09 Bone mineral density (spine) / / 19801982 rs1485305 chr8 120010520 A T 6.00E-06 Urinary metabolites / / 21572414 rs7010043 chr8 120011331 G T 3.00E-15 Bone mineral density (spine) / / 19801982 rs7010043 chr8 120011331 G T 1.80E-08 Bone mineral density (paediatric,skull) / / 24945404 rs11995824 chr8 120012700 C G 7.00E-09 Bone mineral density (hip) / / 19801982 rs11995824 chr8 120012700 C G 1.20E-09 Bone mineral density (paediatric,skull) / / 24945404 rs13264172 chr8 120012861 T A 1.00E-14 Bone mineral density (spine) / / 19801982 rs13264172 chr8 120012861 T A 4.60E-08 Bone mineral density (paediatric,skull) / / 24945404 rs13264791 chr8 120013090 T C 1.60E-14 Bone mineral density (spine) / / 19801982 rs13264791 chr8 120013090 T C 9.90E-11 Bone mineral density (paediatric,skull) / / 24945404 rs4424296 chr8 120013276 C T 2.20E-14 Bone mineral density (spine) / / 19801982 rs4424296 chr8 120013276 C T 5.94E-10 Bone mineral density / / 24249740 rs4424296 chr8 120013276 C T 9.00E-14 Bone mineral density / / 24249740 rs4424296 chr8 120013276 C T 7.20E-09 Bone mineral density (paediatric,skull) / / 24945404 rs4335155 chr8 120013469 A C 2.50E-14 Bone mineral density (spine) / / 19801982 rs4335155 chr8 120013469 A C 2.70E-08 Bone mineral density (paediatric,skull) / / 24945404 rs1905784 chr8 120014623 G A 1.30E-14 Bone mineral density (spine) / / 19801982 rs1905784 chr8 120014623 G A 6.30E-09 Bone mineral density (paediatric,skull) / / 24945404 rs1905783 chr8 120014836 C T 1.20E-14 Bone mineral density (spine) / / 19801982 rs1905783 chr8 120014836 C T 5.20E-09 Bone mineral density (paediatric,skull) / / 24945404 rs4354338 chr8 120016060 A C 2.20E-15 Bone mineral density (spine) / / 19801982 rs4354338 chr8 120016060 A C 3.40E-10 Bone mineral density (paediatric,skull) / / 24945404 rs6469794 chr8 120016099 C T 2.30E-15 Bone mineral density (spine) / / 19801982 rs6469795 chr8 120016469 G A 3.30E-14 Bone mineral density (spine) / / 19801982 rs6469795 chr8 120016469 G A 5.20E-09 Bone mineral density (paediatric,skull) / / 24945404 rs9650075 chr8 120017079 A G 4.20E-14 Bone mineral density (spine) / / 19801982 rs9650075 chr8 120017079 A G 5.20E-09 Bone mineral density (paediatric,skull) / / 24945404 rs7013203 chr8 120017159 A G 3.80E-15 Bone mineral density (spine) / / 19801982 rs6469796 chr8 120018042 G A 4.20E-15 Bone mineral density (spine) / / 19801982 rs6469797 chr8 120018159 C T 4.40E-14 Bone mineral density (spine) / / 19801982 rs6469797 chr8 120018159 C T 1.90E-08 Bone mineral density (paediatric,skull) / / 24945404 rs6469798 chr8 120018291 C T 4.30E-15 Bone mineral density (spine) / / 19801982 rs6469798 chr8 120018291 C T 3.40E-10 Bone mineral density (paediatric,skull) / / 24945404 rs4424291 chr8 120018735 A G 4.10E-14 Bone mineral density (spine) / / 19801982 rs4424291 chr8 120018735 A G 5.20E-09 Bone mineral density (paediatric,skull) / / 24945404 rs4495460 chr8 120019316 A T 5.00E-14 Bone mineral density (spine) / / 19801982 rs4495460 chr8 120019316 A T 6.30E-09 Bone mineral density (paediatric,skull) / / 24945404 rs7822098 chr8 120020129 A T 5.90E-15 Bone mineral density (spine) / / 19801982 rs7822098 chr8 120020129 A T 3.40E-10 Bone mineral density (paediatric,skull) / / 24945404 rs10955919 chr8 120020918 C G 5.50E-14 Bone mineral density (spine) / / 19801982 rs10955919 chr8 120020918 C G 4.10E-09 Bone mineral density (paediatric,skull) / / 24945404 rs1905777 chr8 120021840 A T 5.90E-15 Bone mineral density (spine) / / 19801982 rs1905777 chr8 120021840 A T 7.10E-10 Bone mineral density (paediatric,skull) / / 24945404 rs7017691 chr8 120023414 G C 5.70E-14 Bone mineral density (spine) / / 19801982 rs6469801 chr8 120025675 T C 6.20E-15 Bone mineral density (spine) / / 19801982 rs6469801 chr8 120025675 T C 2.60E-10 Bone mineral density (paediatric,skull) / / 24945404 rs1586274 chr8 120026562 A G 2.50E-13 Bone mineral density (spine) / / 19801982 rs1586274 chr8 120026562 A G 3.10E-10 Bone mineral density (paediatric,skull) / / 24945404 rs2326193 chr8 120029709 A C 2.40E-14 Bone mineral density (spine) / / 19801982 rs2326193 chr8 120029709 A C 1.90E-05 Methamphetamine dependence / / 23594818 rs2326193 chr8 120029709 A C 3.20E-10 Bone mineral density (paediatric,skull) / / 24945404 rs7016585 chr8 120030098 C A 1.10E-13 Bone mineral density (spine) / / 19801982 rs7016585 chr8 120030098 C A 4.20E-09 Bone mineral density (paediatric,skull) / / 24945404 rs7004052 chr8 120031029 T A 8.30E-14 Bone mineral density (spine) / / 19801982 rs7004052 chr8 120031029 T A 6.70E-09 Bone mineral density (paediatric,skull) / / 24945404 rs4403440 chr8 120031575 G A 1.80E-11 Bone mineral density (spine) / / 19801982 rs6999476 chr8 120032259 G C 1.80E-14 Bone mineral density (spine) / / 19801982 rs6999476 chr8 120032259 G C 8.90E-10 Bone mineral density (paediatric,skull) / / 24945404 rs12682278 chr8 120032328 A G 1.80E-14 Bone mineral density (spine) / / 19801982 rs12682278 chr8 120032328 A G 8.90E-10 Bone mineral density (paediatric,skull) / / 24945404 rs7813486 chr8 120032525 T C 8.40E-14 Bone mineral density (spine) / / 19801982 rs7813486 chr8 120032525 T C 6.70E-09 Bone mineral density (paediatric,skull) / / 24945404 rs13262276 chr8 120033918 T A 1.60E-14 Bone mineral density (spine) / / 19801982 rs13262276 chr8 120033918 T A 4.30E-10 Bone mineral density (paediatric,skull) / / 24945404 rs10505351 chr8 120033998 C T 8.40E-14 Bone mineral density (spine) / / 19801982 rs10505351 chr8 120033998 C T 5.60E-09 Bone mineral density (paediatric,skull) / / 24945404 rs10091277 chr8 120034387 A G 5.10E-11 Bone mineral density (spine) / / 19801982 rs6996754 chr8 120034870 T C 1.60E-14 Bone mineral density (spine) / / 19801982 rs6996754 chr8 120034870 T C 5.20E-10 Bone mineral density (paediatric,skull) / / 24945404 rs4615609 chr8 120035493 A G 8.60E-14 Bone mineral density (spine) / / 19801982 rs4615609 chr8 120035493 A G 5.60E-09 Bone mineral density (paediatric,skull) / / 24945404 rs4307369 chr8 120036953 A G 1.70E-14 Bone mineral density (spine) / / 19801982 rs4307369 chr8 120036953 A G 3.60E-10 Bone mineral density (paediatric,skull) / / 24945404 rs7013731 chr8 120038365 T C 8.90E-14 Bone mineral density (spine) / / 19801982 rs7013731 chr8 120038365 T C 4.70E-09 Bone mineral density (paediatric,skull) / / 24945404 rs1485295 chr8 120039462 A G 1.70E-14 Bone mineral density (spine) / / 19801982 rs1485295 chr8 120039462 A G 4.30E-10 Bone mineral density (paediatric,skull) / / 24945404 rs10098408 chr8 120039721 T C 9.00E-14 Bone mineral density (spine) / / 19801982 rs10098408 chr8 120039721 T C 6.20E-09 Bone mineral density (paediatric,skull) / / 24945404 rs10086835 chr8 120040181 C T 9.10E-14 Bone mineral density (spine) / / 19801982 rs10086835 chr8 120040181 C T 4.60E-09 Bone mineral density (paediatric,skull) / / 24945404 rs1905779 chr8 120041165 C T 9.00E-14 Bone mineral density (spine) / / 19801982 rs1905779 chr8 120041165 C T 6.20E-09 Bone mineral density (paediatric,skull) / / 24945404 rs1905780 chr8 120041650 A G 9.10E-14 Bone mineral density (spine) / / 19801982 rs1905780 chr8 120041650 A G 3.90E-09 Bone mineral density (paediatric,skull) / / 24945404 rs1485312 chr8 120043935 T C 9.00E-14 Bone mineral density (spine) / / 19801982 rs1485312 chr8 120043935 T C 5.20E-09 Bone mineral density (paediatric,skull) / / 24945404 rs4401893 chr8 120044383 C T 9.00E-14 Bone mineral density (spine) / / 19801982 rs4401893 chr8 120044383 C T 5.20E-09 Bone mineral density (paediatric,skull) / / 24945404 rs6469804 chr8 120044829 G A 7.00E-15 Bone mineral density (spine) / / 18445777 rs6469804 chr8 120044829 G A 1.40E-15 Bone mineral density (spine) / / 19079262 rs6469804 chr8 120044829 G A 1.40E-14 Bone mineral density (spine) / / 19801982 rs6469804 chr8 120044829 G A 6.20E-10 Bone mineral density (paediatric,skull) / / 24945404 rs6984675 chr8 120045227 T G 9.20E-14 Bone mineral density (spine) / / 19801982 rs7013722 chr8 120047621 A T 9.00E-14 Bone mineral density (spine) / / 19801982 rs7013722 chr8 120047621 A T 5.20E-09 Bone mineral density (paediatric,skull) / / 24945404 rs7018198 chr8 120048033 A G 9.20E-14 Bone mineral density (spine) / / 19801982 rs7018198 chr8 120048033 A G 6.20E-09 Bone mineral density (paediatric,skull) / / 24945404 rs6469805 chr8 120048149 C T 1.70E-14 Bone mineral density (spine) / / 19801982 rs6469805 chr8 120048149 C T 4.30E-10 Bone mineral density (paediatric,skull) / / 24945404 rs1485310 chr8 120051656 A T 5.60E-11 Bone mineral density (spine) / / 19801982 rs6993813 chr8 120052238 T C 3.00E-11 Bone mineral density (hip) / / 18445777 rs6993813 chr8 120052238 T C 2.10E-15 Bone mineral density (spine) / / 19079262 rs6993813 chr8 120052238 T C 1.70E-14 Bone mineral density (spine) / / 19801982 rs6993813 chr8 120052238 T C 5.30E-10 Bone mineral density (paediatric,skull) / / 24945404 rs10955924 chr8 120053343 C A 9.50E-14 Bone mineral density (spine) / / 19801982 rs10955924 chr8 120053343 C A 6.20E-09 Bone mineral density (paediatric,skull) / / 24945404 rs4305930 chr8 120058021 C T 1.60E-14 Bone mineral density (spine) / / 19801982 rs4305930 chr8 120058021 C T 6.20E-10 Bone mineral density (paediatric,skull) / / 24945404 rs2450083 chr8 120063542 T C 5.00E-13 Bone mineral density (spine) / / 19801982 rs2450083 chr8 120063542 T C 2.00E-11 Bone mineral density (paediatric,skull) / / 24945404 rs2450083 chr8 120063542 T C 3.00E-08 Bone mineral density (paediatric,skull) / / 24945404 rs2465403 chr8 120090827 G A 0.000328 5-fluorouracil induced mucositis in response to colorectal cancer treatment COLEC10 intron 22310351 rs11993915 chr8 120100059 C T 4.78E-04 Response to statin treatment (atorvastatin),change in cholesterol levels COLEC10 intron 20031582 rs16891984 chr8 120101140 G A 8.79E-04 Multiple complex diseases COLEC10 intron 17554300 rs2242313 chr8 120102529 C G 1.90E-05 Urinary metabolites COLEC10 intron 21572414 rs1351952 chr8 120117168 G A 1.30E-05 Urinary metabolites COLEC10 intron 21572414 rs2468168 chr8 120169638 T C 6.00E-05 Type 2 diabetes / / 17903298 rs1549415 chr8 120183109 T C 2.00E-05 Type 2 diabetes / / 17903298 rs1364709 chr8 120189392 T C 2.40E-05 Urinary metabolites / / 21572414 rs2432961 chr8 120197015 G C 5.00E-05 Type 2 diabetes / / 17903298 rs9297594 chr8 120218302 C T 1.30E-04 Volumetric brain MRI / / 17903297 rs9297594 chr8 120218302 C T 2.24E-04 Osteosarcoma / / 23727862 rs12677274 chr8 120222541 T C 9.00E-04 Acute lymphoblastic leukemia (childhood) MAL2 intron 20189245 rs1364705 chr8 120224806 A G 9.00E-06 Hippocampal atrophy MAL2 intron 19668339 rs1364705 chr8 120224806 A G 8.00E-04 Acute lymphoblastic leukemia (childhood) MAL2 intron 20189245 rs13262685 chr8 120226145 A G 1.79E-04 Birth weight MAL2 intron 17255346 rs4871600 chr8 120226576 C G 1.41E-04 Birth weight MAL2 intron 17255346 rs4871600 chr8 120226576 C G 8.00E-04 Acute lymphoblastic leukemia (childhood) MAL2 intron 20189245 rs12677951 chr8 120226900 G C 1.51E-04 Birth weight MAL2 intron 17255346 rs12677951 chr8 120226900 G C 8.00E-04 Acute lymphoblastic leukemia (childhood) MAL2 intron 20189245 rs1425068 chr8 120239647 G A 3.73E-04 Multiple complex diseases MAL2 intron 17554300 rs2432984 chr8 120242063 C G 2.51E-04 Multiple complex diseases MAL2 intron 17554300 rs10096000 chr8 120278815 G A 8.30E-05 Multiple complex diseases / / 17554300 rs12676931 chr8 120279927 G T 2.96E-04 Birth weight / / 17255346 rs2970402 chr8 120342423 A C 5.60E-06 Urinary metabolites / / 21572414 rs2469997 chr8 120353267 G C 3.00E-16 Hypertension / / 21626137 rs2447182 chr8 120353984 A G 3.00E-16 Hypertension / / 21626137 rs2071518 chr8 120435812 C T 4.00E-09 Blood pressure NOV UTR-3 21909110 rs6990760 chr8 120444628 A C 6.27E-04 Response to TNF antagonist treatment / / 21061259 rs7015188 chr8 120454085 A G 6.27E-04 Response to TNF antagonist treatment / / 21061259 rs7015188 chr8 120454085 A G 2.80E-05 Urinary metabolites / / 21572414 rs6997943 chr8 120463608 A C 9.38E-04 Response to TNF antagonist treatment / / 21061259 rs4871222 chr8 120467209 C G 6.82E-04 Smoking quantity / / 24665060 rs7008190 chr8 120500062 C T 2.95E-05 Lung function (forced vital capacity) / / pha003104 rs4871269 chr8 120505581 T C 1.30E-05 Smoking cessation / / 24665060 rs7000665 chr8 120507738 T C 1.12E-04 Pancreatic cancer / / pha002874 rs6469828 chr8 120508030 T A 8.86E-05 Smoking cessation / / 24665060 rs10505364 chr8 120509104 A G 2.87E-05 Smoking cessation / / 24665060 rs17794271 chr8 120517731 A T 6.70E-05 Smoking cessation / / 24665060 rs9643136 chr8 120540143 C T 1.15E-04 Pancreatic cancer / / pha002874 rs11987056 chr8 120542647 A G 1.25E-05 Smoking cessation / / 24665060 rs6993464 chr8 120544948 C T 1.78E-05 Smoking cessation / / 24665060 rs6993464 chr8 120544948 C T 6.39E-05 Pancreatic cancer / / pha002874 rs11782176 chr8 120548677 A G 1.83E-05 Smoking cessation / / 24665060 rs11782176 chr8 120548677 A G 5.55E-05 Pancreatic cancer / / pha002874 rs1446071 chr8 120550360 C T 1.83E-05 Smoking cessation / / 24665060 rs10102546 chr8 120556574 C T 7.00E-06 Smoking cessation / / 24665060 rs201633161 chr8 120556967 G GTT 9.48E-06 Smoking cessation / / 24665060 rs201633161 chr8 120556967 G GTT 5.01E-05 Pancreatic cancer / / pha002874 rs6991756 chr8 120556967 G T 9.48E-06 Smoking cessation / / 24665060 rs6991756 chr8 120556967 G T 5.01E-05 Pancreatic cancer / / pha002874 rs11782782 chr8 120581942 C G 4.98E-04 Acute lung injury ENPP2 intron 22295056 rs16892786 chr8 120582871 T C 8.31E-04 Response to TNF antagonist treatment ENPP2 intron 21061259 rs16892786 chr8 120582871 T C 7.55E-04 Acute lung injury ENPP2 intron 22295056 rs6987751 chr8 120584680 A G 6.15E-04 Acute lung injury ENPP2 intron 22295056 rs7012314 chr8 120584983 T G 6.15E-04 Acute lung injury ENPP2 intron 22295056 rs3793375 chr8 120586411 A G 6.15E-04 Acute lung injury ENPP2 intron 22295056 rs3793376 chr8 120586617 T C 6.19E-04 Multiple complex diseases ENPP2 intron 17554300 rs6986021 chr8 120590832 A G 7.68E-05 Multiple complex diseases ENPP2 intron 17554300 rs10505367 chr8 120591464 C T 2.25E-04 Multiple complex diseases ENPP2 intron 17554300 rs965670 chr8 120597546 C A 7.90E-06 Obesity-related traits ENPP2 intron 17658951 rs2305128 chr8 120599487 T C 1.80E-04 Multiple complex diseases ENPP2 intron 17554300 rs6987103 chr8 120614318 C T 6.78E-04 Alzheimer's disease ENPP2 intron 22005930 rs1374100 chr8 120615323 C T 6.87E-04 Alzheimer's disease ENPP2 intron 22005930 rs16892902 chr8 120644739 T C 4.81E-04 Multiple complex diseases ENPP2 intron 17554300 rs7007970 chr8 120647929 C G 6.00E-06 Height ENPP2 intron 21998595 rs1368845 chr8 120674453 G T 5.32E-05 Post-operative nausea and vomiting / / 21694509 rs1433948 chr8 120706244 C A 8.70E-04 Response to TNF antagonist treatment / / 21061259 rs4871528 chr8 120712611 A G 2.70E-05 Urinary metabolites / / 21572414 rs13253139 chr8 120730465 G T 1.50E-05 Urinary metabolites / / 21572414 rs2164021 chr8 120738163 A C 2.70E-04 Insulin resistance / / 21901158 rs4380974 chr8 120742400 A C 1.59E-04 Tourette syndrome / / 22889924 rs7818587 chr8 120762233 G A 9.26E-04 Tourette syndrome TAF2 intron 22889924 rs7843034 chr8 120782863 A G 8.90E-04 Multiple complex diseases TAF2 intron 17554300 rs12541733 chr8 120789086 A G 8.34E-04 Suicide attempts in bipolar disorder TAF2 intron 21423239 rs12541733 chr8 120789086 A G 6.25E-04 Amyotrophic lateral sclerosis (sporadic) TAF2 intron 24529757 rs6989791 chr8 120824357 T G 9.80E-05 Attention deficit hyperactivity disorder TAF2 intron 23728934 rs7012857 chr8 120825225 A C 6.28E-05 Attention deficit hyperactivity disorder TAF2 intron 23728934 rs1055130 chr8 120847188 T C 2.10E-04 Tourette syndrome DSCC1 missense 22889924 rs3812463 chr8 120852100 C T 9.17E-05 Attention deficit hyperactivity disorder DSCC1 intron 23728934 rs6469849 chr8 120857169 G A 9.17E-05 Attention deficit hyperactivity disorder DSCC1 intron 23728934 rs6469852 chr8 120860735 A G 1.15E-04 Attention deficit hyperactivity disorder DSCC1 intron 23728934 rs7815122 chr8 120869022 G T 0.0001 Migraine / / 22678113 rs1467044 chr8 120887041 G A 1.90E-05 Interstitial lung disease DEPTOR intron 23583980 rs11781657 chr8 120889242 G T 1.83E-05 Interstitial lung disease DEPTOR intron 23583980 rs9649948 chr8 120913535 T C 1.28E-04 Cocaine dependence DEPTOR intron 23958962 rs9649948 chr8 120913535 T C 3.38E-04 Cocaine dependence DEPTOR intron 23958962 rs6999724 chr8 120920831 T C 6.93E-04 Multiple complex diseases DEPTOR intron 17554300 rs16892877 chr8 120931351 T C 9.76E-04 Multiple complex diseases DEPTOR intron 17554300 rs869340 chr8 120932612 T C 4.41E-04 Common variable immunodeficiency DEPTOR intron 21497890 rs7818752 chr8 120933031 C G 6.47E-04 Multiple complex diseases DEPTOR intron 17554300 rs9987332 chr8 120933963 G A 2.50E-05 Interstitial lung disease DEPTOR intron 23583980 rs4871793 chr8 120941528 C T 1.10E-04 Malaria DEPTOR intron 19465909 rs7005380 chr8 120953873 G A,C 2.00E-07 Interstitial lung disease DEPTOR intron 23583980 rs7005380 chr8 120953873 G A,C 2.92E-06 Interstitial lung disease DEPTOR intron 23583980 rs9297608 chr8 120969685 C G 1.55E-05 Serum metabolites DEPTOR intron 19043545 rs6469888 chr8 121018175 A G 7.84E-04 Alzheimer's disease DEPTOR intron 17998437 rs7386139 chr8 121027419 G A 6.35E-04 HIV-1 viral setpoint DEPTOR intron 17641165 rs7386139 chr8 121027419 G A 7.18E-04 Alzheimer's disease DEPTOR intron 17998437 rs4871031 chr8 121031777 T C 8.23E-04 HIV-1 viral setpoint DEPTOR intron 17641165 rs7821842 chr8 121033982 C T 3.67E-04 HIV-1 viral setpoint DEPTOR intron 17641165 rs4871825 chr8 121034642 T C 4.83E-04 Multiple complex diseases DEPTOR intron 17554300 rs4871032 chr8 121042074 A G 4.86E-05 Alzheimer's disease DEPTOR intron 17998437 rs2326434 chr8 121047798 T G 1.16E-04 HIV-1 viral setpoint DEPTOR intron 17641165 rs2326434 chr8 121047798 T G 1.40E-04 Alzheimer's disease DEPTOR intron 17998437 rs960887 chr8 121048383 G A 6.56E-04 Suicide attempts in bipolar disorder DEPTOR intron 21423239 rs1051534 chr8 121062077 A G 8.30E-04 Atrial fibrillation DEPTOR UTR-3 21846873 rs17823756 chr8 121068644 A G 3.87E-04 Alzheimer's disease LOC100506966 intron 17998437 rs17226296 chr8 121096284 C A 7.25E-04 Multiple complex diseases / / 17554300 rs7016388 chr8 121101865 A G 9.13E-05 HIV-1 viral setpoint / / 17641165 rs10104973 chr8 121104385 G A 1.56E-04 HIV-1 viral setpoint / / 17641165 rs4633103 chr8 121116156 G A 4.17E-09 Narcolepsy / / 19629137 rs4588897 chr8 121139142 A G 1.90E-04 HIV-1 viral setpoint COL14A1 intron 17641165 rs10087151 chr8 121172261 G A 1.79E-04 HIV-1 viral setpoint COL14A1 intron 17641165 rs10110722 chr8 121178112 G A 2.40E-04 HIV-1 viral setpoint COL14A1 intron 17641165 rs13261812 chr8 121207893 T A 3.40E-06 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs2305598 chr8 121210069 T C 1.80E-06 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 cds-synon 24324551 rs7013781 chr8 121214291 G A 9.04E-07 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs7013555 chr8 121214396 A G 1.01E-06 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs7018328 chr8 121214922 C G 1.18E-06 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs6980799 chr8 121215102 G A 1.29E-06 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs2305600 chr8 121215991 T C 1.05E-06 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 cds-synon 24324551 rs2054148 chr8 121216510 C T 8.61E-07 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs10955961 chr8 121218601 T C 3.00E-07 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs541656652 chr8 121218601 T TTTGC 3.00E-07 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs10955962 chr8 121219597 A T 4.98E-07 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs957694 chr8 121219820 T C 1.44E-06 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs957695 chr8 121219826 A T 1.61E-06 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs957696 chr8 121219876 A G 1.60E-06 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs3765062 chr8 121220395 G A 1.13E-06 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs2875940 chr8 121221530 C T 4.67E-06 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs10505377 chr8 121221871 C G 2.49E-04 Smoking initiation COL14A1 intron 24665060 rs6994973 chr8 121222900 G T 2.80E-05 Urinary metabolites COL14A1 intron 21572414 rs2034841 chr8 121223998 T C 1.12E-06 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs2034842 chr8 121224037 T C 6.36E-07 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs2219246 chr8 121225335 A C 6.18E-06 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs12547117 chr8 121226479 C T 6.45E-06 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs12542144 chr8 121226554 A G 6.23E-06 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs10808508 chr8 121227068 C T 4.18E-07 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs4870723 chr8 121228679 A C 7.51E-06 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 missense 24324551 rs4870724 chr8 121229023 T G 1.36E-06 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs7387094 chr8 121230787 A G 4.89E-07 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs7387373 chr8 121230950 C T 8.38E-07 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs56159702 chr8 121231250 T C 3.79E-07 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs58829748 chr8 121231299 C T 7.19E-07 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs12543412 chr8 121231618 T C 9.08E-06 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs11773991 chr8 121233481 T C 1.83E-06 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs6989074 chr8 121234756 G A 5.03E-07 Parasitemia in Tripanosoma cruzi seropositivity COL14A1 intron 24324551 rs4279641 chr8 121283832 G A 6.81E-05 HIV-1 viral setpoint COL14A1 intron 22174851 rs1563389 chr8 121301474 C T 4.24E-06 Alzheimer's disease (late onset) COL14A1 intron 21379329 rs6994888 chr8 121318096 C T 4.42E-04 Response to TNF antagonist treatment COL14A1 intron 21061259 rs4871056 chr8 121326581 T G 6.47E-04 Response to TNF antagonist treatment COL14A1 intron 21061259 rs6469916 chr8 121332791 G A 2.96E-04 Suicide,with and without major depression COL14A1 intron 22059935 rs7821312 chr8 121377780 C T 3.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) COL14A1 intron 23648065 rs7821312 chr8 121377780 C T 4.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) COL14A1 intron 23648065 rs2429 chr8 121384163 G T 2.03E-04 Amyotrophic Lateral Sclerosis COL14A1 UTR-3 17362836 rs2429 chr8 121384163 G T 2.98E-07 Coronary heart disease COL14A1 UTR-3 pha003030 rs12545308 chr8 121385167 T C 2.03E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12545308 chr8 121385167 T C 5.50E-07 Coronary heart disease / / pha003030 rs4870728 chr8 121386925 C T 5.20E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs7818026 chr8 121429676 A C 2.65E-04 Taste perception MRPL13 intron 22132133 rs7812590 chr8 121458163 G A 2.43E-05 Coronary heart disease MTBP intron pha003030 rs3922897 chr8 121555764 G A 9.32E-05 Hypertension SNTB1 intron pha003042 rs7839488 chr8 121562418 G A 2.00E-11 Myopia (pathological) SNTB1 intron 23406873 rs7839488 chr8 121562418 G A 6.27E-05 Myopia (severe) SNTB1 intron 23933737 rs4395927 chr8 121568921 C T 1.11E-05 Myopia (severe) SNTB1 intron 23933737 rs4455882 chr8 121583283 A G 4.73E-06 Myopia (severe) SNTB1 intron 23933737 rs7823782 chr8 121597725 T C 8.91E-06 Myopia (severe) SNTB1 intron 23933737 rs4870734 chr8 121610299 C T 4.85E-05 Glucose levels SNTB1 intron pha003057 rs6469937 chr8 121610438 G A 2.00E-09 Myopia (severe) SNTB1 intron 23933737 rs6986444 chr8 121626094 T C 2.69E-05 Myopia (severe) SNTB1 intron 23933737 rs6988232 chr8 121630172 G A 2.79E-05 Myopia (severe) SNTB1 intron 23933737 rs6986718 chr8 121635396 C A 9.00E-06 Bipolar disorder and schizophrenia SNTB1 intron 20889312 rs11780390 chr8 121650125 G A 5.52E-04 Alcohol dependence SNTB1 intron 21314694 rs4870742 chr8 121676913 G A,T 1.40E-04 Multiple complex diseases SNTB1 intron 17554300 rs11989782 chr8 121694650 C A 7.00E-06 Eosinophilic esophagitis (pediatric) SNTB1 intron 20208534 rs12679182 chr8 121810147 C T 8.58E-04 Oral cancers (chewing tobacco related) SNTB1 intron 22503698 rs10090787 chr8 121810549 C T 2.60E-04 Oral cancers (chewing tobacco related) SNTB1 intron 22503698 rs7007426 chr8 121845280 G A 8.40E-04 Rheumatoid arthritis / / 21452313 rs7017161 chr8 121852680 G A 9.28E-04 Rheumatoid arthritis / / 21452313 rs4871134 chr8 121853405 A G 8.67E-04 Multiple complex diseases / / 17554300 rs4621851 chr8 121855512 C G 7.55E-05 Serum metabolites / / 19043545 rs4871135 chr8 121855774 G A 7.33E-05 Neuroticism / / 23229837 rs10110670 chr8 121926125 G A 8.19E-04 Alzheimer's disease / / 17998437 rs10110895 chr8 121926352 G A 8.26E-05 Serum metabolites / / 19043545 rs10505382 chr8 121928369 T G 9.10E-07 Alcohol and nictotine co-dependence / / 20158304 rs10105297 chr8 121937245 C T 8.67E-06 Diabetes Mellitus / / pha003060 rs10086706 chr8 121948408 T C 9.55E-06 Coronary artery calcification / / 23870195 rs4871140 chr8 121948558 A G 6.20E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7824584 chr8 121971039 T C 7.40E-04 Alcohol dependence / / 20201924 rs6988609 chr8 121972058 A C 6.40E-04 Alcohol dependence / / 20201924 rs939144 chr8 121979657 G A 1.60E-04 Alcohol dependence / / 20201924 rs939144 chr8 121979657 G A 7.20E-04 Alcohol dependence / / 20201924 rs17196271 chr8 121984358 C T 6.95E-04 Smoking quantity / / 24665060 rs1714645 chr8 122031221 G A 0.000434 Salmonella-induced pyroptosis / / 22837397 rs1714646 chr8 122035990 A G 0.00087 Salmonella-induced pyroptosis / / 22837397 rs13270327 chr8 122052796 T A 8.00E-06 Urinary metabolites / / 21572414 rs2043374 chr8 122055715 A G 0.000119 Salmonella-induced pyroptosis / / 22837397 rs2163920 chr8 122141692 T C 0.00007792 Sarcoidosis / / 22952805 rs2163920 chr8 122141692 T C 3.59E-05 Smoking cessation / / 24665060 rs10505391 chr8 122175826 C T 1.75E-04 Longevity / / 22279548 rs1604897 chr8 122182310 C T 8.00E-06 IgG glycosylation / / 23382691 rs4304334 chr8 122183825 A G 7.00E-06 Urinary metabolites / / 21572414 rs1394426 chr8 122200459 G A 2.60E-06 Urinary metabolites / / 21572414 rs11401596 chr8 122207956 A AT 7.00E-06 Periodontitis (CDC/AAP) / / 24024966 rs397711003 chr8 122207956 A AT 7.00E-06 Periodontitis (CDC/AAP) / / 24024966 rs397830377 chr8 122207956 A AT 7.00E-06 Periodontitis (CDC/AAP) / / 24024966 rs2386229 chr8 122208658 G A 3.80E-06 Periodontitis (CDC/AAP) / / 24024966 rs13271594 chr8 122209249 A G 4.54E-06 Periodontitis (CDC/AAP) / / 24024966 rs13271594 chr8 122209249 A G 8.28E-06 Periodontitis (CDC/AAP) / / 24024966 rs7819988 chr8 122210890 T C 3.00E-06 Periodontitis (CDC/AAP) / / 24024966 rs7815968 chr8 122212386 C G 8.45E-06 Periodontitis (CDC/AAP) / / 24024966 rs527469349 chr8 122212869 TA T 3.25E-06 Periodontitis (CDC/AAP) / / 24024966 rs7838368 chr8 122212869 T A 3.25E-06 Periodontitis (CDC/AAP) / / 24024966 rs7818568 chr8 122215915 T G 8.71E-06 Periodontitis (CDC/AAP) / / 24024966 rs7834765 chr8 122275906 G T 1.00E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs7834648 chr8 122275983 C T 1.07E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs7834813 chr8 122276148 A C 1.14E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs10505399 chr8 122314537 C A 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1013326 chr8 122320560 C T 9.83E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2046571 chr8 122355712 G A 1.90E-06 Parkinson's disease / / 20711177 rs1386443 chr8 122358307 A G 6.27E-04 Smoking quantity / / 24665060 rs901563 chr8 122360847 G A 3.24E-04 Smoking quantity / / 24665060 rs6415475 chr8 122375165 T C 1.31E-04 Smoking quantity / / 24665060 rs1487163 chr8 122385614 C A 1.08E-04 Smoking quantity / / 24665060 rs11776333 chr8 122393961 A C 1.00E-04 Smoking quantity / / 24665060 rs11786247 chr8 122397336 C A 6.25E-05 Smoking quantity / / 24665060 rs5018304 chr8 122420903 T C 7.87E-04 Multiple complex diseases / / 17554300 rs13275393 chr8 122440174 G A 6.87E-04 Smoking quantity / / 24665060 rs13252445 chr8 122458943 C T 6.90E-06 Urinary metabolites / / 21572414 rs6988127 chr8 122468690 C T 5.05E-06 Glycosylated haemoglobin levels / / 17255346 rs1384182 chr8 122506305 G C 9.16E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs4871199 chr8 122515820 C T 3.53E-04 Body mass index / / 17255346 rs7003256 chr8 122525611 T A 3.90E-06 Urinary metabolites / / 21572414 rs1482184 chr8 122535739 T C 2.31E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7016973 chr8 122549595 A C 5.50E-06 Urinary metabolites / / 21572414 rs16895672 chr8 122586618 T G 7.95E-04 Depression (quantitative trait) / / 20800221 rs7009299 chr8 122587966 C T 8.25E-04 Depression (quantitative trait) / / 20800221 rs16895680 chr8 122589015 C T 8.30E-04 Depression (quantitative trait) / / 20800221 rs16895701 chr8 122599626 T C 1.31E-05 Personality dimensions / / 18957941 rs11995252 chr8 122621909 T C 5.00E-06 Obesity-related traits / / 23251661 rs17232789 chr8 122622500 T C 6.00E-06 Dialysis-related mortality / / 21546767 rs10505408 chr8 122623421 C T 9.27E-05 Pure-tone audiometry / / pha001963 rs6998348 chr8 122636841 T G 6.63E-05 Alzheimer's disease HAS2 intron 17998437 rs7016481 chr8 122636868 G T 6.56E-05 Alzheimer's disease HAS2 intron 17998437 rs11784137 chr8 122641770 T G 1.30E-05 Urinary metabolites HAS2 intron 21572414 rs10089677 chr8 122660248 G A 7.80E-05 Colorectal cancer / / 19723657 rs10089677 chr8 122660248 G A 4.90E-08 Urinary metabolites / / 21572414 rs10108494 chr8 122663330 A G 8.84E-04 Alzheimer's disease / / 17998437 rs10108494 chr8 122663330 A G 2.10E-07 Urinary metabolites / / 21572414 rs10095460 chr8 122663354 T C 1.90E-07 Urinary metabolites / / 21572414 rs9297647 chr8 122683440 A G 9.38E-04 Alcohol dependence / / 21314694 rs10441515 chr8 122685940 A G 9.00E-06 Urinary metabolites / / 21572414 rs17299987 chr8 122691195 T C 8.02E-04 Insulin resistance / / 21901158 rs10113295 chr8 122692580 G A 3.60E-06 Urinary metabolites / / 21572414 rs2891979 chr8 122694752 C T 1.50E-05 Urinary metabolites / / 21572414 rs2891979 chr8 122694752 C T 6.24E-05 Myopia (pathological) / / 23049088 rs7816221 chr8 122696143 G A 9.20E-06 Periodontal disease-related phenotypes / / 24347629 rs3870371 chr8 122697132 C A 6.00E-06 Periodontal disease-related phenotypes / / 24347629 rs200345796 chr8 122700197 AT A 9.20E-06 Periodontal disease-related phenotypes / / 24347629 rs200345796 chr8 122700197 AT A 1.71E-04 Breast cancer / / pha002853 rs920455 chr8 122700197 A G 9.20E-06 Periodontal disease-related phenotypes / / 24347629 rs920455 chr8 122700197 A G 1.71E-04 Breast cancer / / pha002853 rs279612 chr8 122706291 A G 7.00E-06 Metabolite levels (5-HIAA) / / 23319000 rs17300641 chr8 122709299 C G 1.40E-05 Urinary metabolites / / 21572414 rs1036775 chr8 122725668 G C 2.70E-05 Urinary metabolites / / 21572414 rs17241794 chr8 122728424 G C 2.40E-05 Urinary metabolites / / 21572414 rs6999197 chr8 122734202 G A 1.80E-05 Urinary metabolites / / 21572414 rs10106208 chr8 122745330 G A 3.88E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs279620 chr8 122788225 A G 1.26E-04 Smoking cessation / / 24665060 rs12680003 chr8 122813393 C T 1.40E-05 Odorant perception / / 23910658 rs10101403 chr8 122869651 G C 5.04E-04 Multiple complex diseases / / 17554300 rs7844723 chr8 122908503 C T 2.00E-06 Hemostatic factors and hematological phenotypes / / 17903294 rs956225 chr8 122909687 A G 9.00E-06 Alzheimer's disease / / 22159054 rs7842229 chr8 122925802 G A 1.01E-04 Alzheimer's disease / / 17998437 rs7017404 chr8 122926095 C G 1.97E-05 Multiple complex diseases / / 17554300 rs12676697 chr8 122948438 T C 0.0000939 post-traumatic stress disorder / / 22869035 rs12676697 chr8 122948438 T C 9.39E-05 Schizophrenia / / 22883433 rs907121 chr8 122963215 C T 2.00E-06 Weight / / 20966902 rs10106572 chr8 122976341 G A 1.70E-05 Urinary metabolites / / 21572414 rs12542166 chr8 122982838 A C 5.69E-06 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs12542166 chr8 122982838 A C 5.69E-06 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs12542166 chr8 122982838 A C 6.00E-06 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs16896479 chr8 122989850 C T 9.21E-04 Type 2 diabetes / / 17463246 rs16896527 chr8 123006138 G A 7.68E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs16896563 chr8 123039950 A T 4.45E-04 Multiple complex diseases / / 17554300 rs17317732 chr8 123043443 G A 9.40E-06 Urinary metabolites / / 21572414 rs10109042 chr8 123047409 A G 7.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11987687 chr8 123062194 G A 9.02E-04 Rheumatoid arthritis / / 21452313 rs11986700 chr8 123147376 T A 2.30E-05 Urinary metabolites / / 21572414 rs1355256 chr8 123153680 A G 0.000431236 Hypertension (early onset hypertension) / / 22479346 rs12542596 chr8 123156649 G A 0.000578657 Hypertension (early onset hypertension) / / 22479346 rs4401867 chr8 123200925 A C 1.77E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4581057 chr8 123202492 G T 2.48E-04 Amyotrophic lateral sclerosis / / 23624525 rs4642655 chr8 123219109 A G 1.37E-04 Rheumatoid arthritis / / 21452313 rs12541018 chr8 123249217 C G 1.05E-05 Type 2 diabetes / / 17463246 rs7006639 chr8 123325803 G A 0.000310511 Hypertension (early onset hypertension) / / 22479346 rs12056619 chr8 123354335 A G 0.0000028 Asthma (exacerbation) / / 23706709 rs2023121 chr8 123363426 A G 1.25E-05 Cognitive performance / / 19734545 rs7826716 chr8 123369269 T C 1.94E-04 Smoking quantity / / 24665060 rs2023118 chr8 123374679 A G 1.26E-05 Cognitive performance / / 19734545 rs11781551 chr8 123408091 G A 2.00E-11 Carotid intima media thickness / / 21909108 rs7008596 chr8 123446887 T C 9.88E-06 Cognitive performance / / 19734545 rs7813226 chr8 123448950 T C 6.68E-05 Osteoarthritis / / 19508968 rs4412375 chr8 123450875 G A 1.70E-06 Urinary metabolites / / 21572414 rs4570163 chr8 123451096 T C 2.50E-06 Urinary metabolites / / 21572414 rs4282579 chr8 123452320 A G 1.90E-07 Urinary metabolites / / 21572414 rs6997590 chr8 123461171 A C 9.30E-08 Urinary metabolites / / 21572414 rs2981074 chr8 123461288 G T 1.30E-07 Urinary metabolites / / 21572414 rs7007579 chr8 123468522 C T 1.49E-04 Multiple complex diseases / / 17554300 rs3019878 chr8 123469978 G A 2.83E-04 Multiple complex diseases / / 17554300 rs3019878 chr8 123469978 G A 6.40E-07 Urinary metabolites / / 21572414 rs6980713 chr8 123470712 G A 6.61E-04 Alzheimer's disease / / 17998437 rs6990139 chr8 123496567 T C 3.73E-04 Rheumatoid arthritis / / 21452313 rs12542215 chr8 123502642 G C 7.41E-04 Coronary heart disease / / 21606135 rs4637834 chr8 123525406 C T 2.79E-05 Cholesterol / / pha003073 rs4637834 chr8 123525406 C T 7.39E-05 Cholesterol / / pha003078 rs4636213 chr8 123536380 G A 2.59E-05 Depression (quantitative trait) / / 23290196 rs4242337 chr8 123536456 G A 9.70E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs10505424 chr8 123539936 C A 3.24E-05 Depression (quantitative trait) / / 23290196 rs16893023 chr8 123545374 C A 3.80E-05 Depression (quantitative trait) / / 23290196 rs7818523 chr8 123547148 C A 2.30E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs869092 chr8 123587077 C T 1.02E-05 Multiple complex diseases / / 17554300 rs6990818 chr8 123648234 A G 0.00087 Salmonella-induced pyroptosis / / 22837397 rs2140330 chr8 123649642 A C 4.20E-04 Multiple complex diseases / / 17554300 rs2140330 chr8 123649642 A C 0.000435 Salmonella-induced pyroptosis / / 22837397 rs1608361 chr8 123663461 T C 4.13E-05 Neuroticism / / 23229837 rs16897288 chr8 123691458 C T 9.03E-04 Myocardial Infarction / / pha002873 rs4871297 chr8 123706155 G A 2.00E-06 Type 1 diabetes nephropathy / / 23028342 rs17356990 chr8 123744784 T C 9.62E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs2044351 chr8 123749956 T C 5.62E-04 Insulin resistance / / 21901158 rs17285645 chr8 123764552 A T 2.80E-06 Urinary metabolites / / 21572414 rs11779779 chr8 123767773 C T 8.32E-04 Type 2 diabetes / / 17463246 rs997795 chr8 123772834 T G 9.67E-04 Alcohol dependence / / 21314694 rs998358 chr8 123772952 A T 2.93E-06 Bilirubin levels,in serum / / 19389676 rs1562180 chr8 123783276 A G 9.88E-04 Rheumatoid arthritis / / 21452313 rs2384844 chr8 123806240 G A 6.50E-06 Triglycerides ZHX2 intron 19074352 rs11993964 chr8 123811377 A G 6.71E-04 Alzheimer's disease ZHX2 intron 22005930 rs11783697 chr8 123817194 A C 2.87E-04 Nonalcoholic fatty liver disease ZHX2 intron 21423719 rs10505427 chr8 123817944 G A 5.95E-05 Atopy ZHX2 intron 21625490 rs10505427 chr8 123817944 G A 9.78E-05 Hepatocellular carcinoma ZHX2 intron 22807686 rs4870815 chr8 123818170 C A 1.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZHX2 intron 20877124 rs10095188 chr8 123833865 G C 8.77E-04 Type 2 diabetes ZHX2 intron 17463246 rs10095188 chr8 123833865 G C 5.63E-05 Multiple complex diseases ZHX2 intron 17554300 rs4870819 chr8 123855237 G A 5.08E-04 Suicide attempts in bipolar disorder ZHX2 intron 21423239 rs7833075 chr8 123874681 C A 6.63E-04 Suicide attempts in bipolar disorder ZHX2 intron 21423239 rs6470120 chr8 123881218 G A 7.00E-07 Nicotine use ZHX2 intron 23942779 rs6470120 chr8 123881218 G A 8.50E-04 Alcohol consumption ZHX2 intron 23942779 rs4871323 chr8 123897867 A G 7.97E-05 Cognitive test performance ZHX2 intron 20125193 rs4871323 chr8 123897867 A G 2.83E-05 Height ZHX2 intron pha003010 rs4871323 chr8 123897867 A G 6.29E-05 Height ZHX2 intron pha003011 rs4871326 chr8 123943147 T C 4.89E-04 Nicotine smoking ZHX2 intron 19268276 rs7841763 chr8 123971081 C T 1.62E-05 Erythrocyte counts ZHX2 intron pha003099 rs10108684 chr8 123973068 G A 1.00E-08 Immune response to smallpox vaccine (IL-6) ZHX2 intron 22542470 rs11779459 chr8 123980551 C T 5.37E-04 Amyotrophic Lateral Sclerosis ZHX2 intron 17362836 rs3802266 chr8 123985708 A G 1.27E-04 Parkinson's disease ZHX2 UTR-3 17052657 rs2833 chr8 123986649 A G 2.02E-04 Parkinson's disease ZHX2 UTR-3 17052657 rs17312183 chr8 124020903 C T 0.0006675 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17312183 chr8 124020903 C T 6.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7159 chr8 124027628 T C 6.75E-05 AIDS progression DERL1 UTR-3 19115949 rs4871338 chr8 124032259 G A 8.50E-04 Insulin resistance DERL1 intron 21901158 rs16897903 chr8 124048170 A G 3.34E-05 Multiple complex diseases DERL1 intron 17554300 rs17313372 chr8 124070432 A G 7.41E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6992733 chr8 124076688 T G 1.04E-04 Prion diseases / / 22210626 rs10956114 chr8 124086827 A G 3.09E-06 Osteoarthritis WDR67 intron 22763110 rs13254600 chr8 124089526 C A 6.40E-04 Multiple complex diseases WDR67 intron 17554300 rs12547393 chr8 124117332 A G 6.43E-05 IgE levels WDR67 intron 17255346 rs2385165 chr8 124122514 A C 2.77E-05 IgE levels WDR67 intron 17255346 rs2385165 chr8 124122514 A C 3.80E-05 Eating disorders (purging via substances) WDR67 intron 23568457 rs952656 chr8 124127595 G A 1.90E-05 Type 2 diabetes WDR67 intron 17460697 rs7824293 chr8 124137984 G A 7.30E-05 Birth weight WDR67 intron 17255346 rs16898012 chr8 124138855 G A 1.85E-05 IgE levels WDR67 cds-synon 17255346 rs16898013 chr8 124138891 G A 4.75E-05 Birth weight WDR67 cds-synon 17255346 rs10505429 chr8 124145469 C T 6.97E-05 IgE levels WDR67 intron 17255346 rs10505429 chr8 124145469 C T 4.80E-04 Type 2 diabetes and 6 quantitative traits WDR67 intron 17848626 rs7828295 chr8 124151817 A G 3.75E-05 IgE levels WDR67 intron 17255346 rs7844632 chr8 124156453 T G 9.66E-05 IgE levels WDR67 intron 17255346 rs7008474 chr8 124167267 T C 2.64E-04 IgE levels / / 17255346 rs1713736 chr8 124170826 G A 4.08E-05 IgE levels / / 17255346 rs1670190 chr8 124171479 A G 3.17E-04 IgE levels / / 17255346 rs1670178 chr8 124177121 A G 7.71E-04 Premature ovarian failure / / 19508998 rs1670178 chr8 124177121 A G 2.20E-05 Eosinophil counts / / pha003088 rs3107194 chr8 124184067 G A 1.32E-05 Eosinophil counts / / pha003088 rs6988636 chr8 124185970 T C 9.00E-07 Urinary uromodulin levels / / 24578125 rs10505430 chr8 124191933 G A 8.54E-04 Multiple complex diseases / / 17554300 rs1670173 chr8 124192307 T C 2.90E-05 Urinary metabolites / / 21572414 rs1044714 chr8 124264927 T C 7.71E-05 Postoperative ventricular dysfunction ZHX1 intron 21980348 rs13248086 chr8 124379755 C T 6.54E-05 Postoperative ventricular dysfunction ATAD2 intron 21980348 rs3779983 chr8 124407846 C T 1.28E-04 Alzheimer's disease (late onset) ATAD2 intron 21379329 rs3739284 chr8 124514400 C T 9.31E-05 Systemic sclerosis FBXO32 UTR-3 21750679 rs2294088 chr8 124526607 G A 0.00014 Prostate cancer FBXO32 intron 23555315 rs4436105 chr8 124548436 G A 5.36E-04 Type 2 diabetes FBXO32 intron 17463246 rs4436105 chr8 124548436 G A 1.13E-04 Vaspin levels FBXO32 intron 22907691 rs4436105 chr8 124548436 G A 0.0001131 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks FBXO32 intron 22907730 rs4436105 chr8 124548436 G A 0.0001801 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit FBXO32 intron 22907730 rs7835298 chr8 124552303 G A 2.69E-04 Cholesterol FBXO32 intron 17255346 rs16898553 chr8 124556006 C T 2.13E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6996389 chr8 124566356 T C 2.25E-04 Vaspin levels / / 22907691 rs6996389 chr8 124566356 T C 0.000225 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs7816339 chr8 124580116 G T 1.76E-04 Vaspin levels / / 22907691 rs7816339 chr8 124580116 G T 0.0001764 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs4871388 chr8 124581200 C T 1.24E-05 Taste perception / / 22132133 rs7844912 chr8 124581970 G A 6.89E-04 Type 2 diabetes / / 17463246 rs13267913 chr8 124585155 A T 1.42E-04 Multiple complex diseases / / 17554300 rs2385296 chr8 124586305 A C 3.42E-05 Vaspin levels / / 22907691 rs2385296 chr8 124586305 A C 0.0000342 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs6470157 chr8 124589848 T C 4.44E-04 Multiple complex diseases / / 17554300 rs9650084 chr8 124604759 G A 6.90E-05 Lung cancer / / 18978787 rs6986850 chr8 124616867 T G 0.0000779 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6986850 chr8 124616867 T G 7.79E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2385295 chr8 124618652 C A 4.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6470162 chr8 124620851 G A 9.04E-04 Multiple complex diseases / / 17554300 rs4871395 chr8 124623095 G A 9.30E-04 Multiple complex diseases / / 17554300 rs4871396 chr8 124626983 T C 8.53E-04 Type 2 diabetes / / 17463246 rs4871396 chr8 124626983 T C 6.00E-04 Multiple complex diseases / / 17554300 rs11780783 chr8 124629036 C G 8.80E-04 Multiple complex diseases / / 17554300 rs10956139 chr8 124649459 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs16898671 chr8 124658210 C T 0.000076 Stroke KLHL38 cds-synon 23422753 rs4871402 chr8 124660447 A C 2.05E-04 Common variable immunodeficiency KLHL38 intron 21497890 rs7463896 chr8 124665575 A G 9.60E-05 Osteoarthritis (knee and hip) / / 21177295 rs4870864 chr8 124689847 A C 1.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4870864 chr8 124689847 A C 6.38E-04 Major depressive disorder / / 22472876 rs2294015 chr8 124696867 C T 9.00E-06 Event-related brain oscillations ANXA13 missense 21184583 rs2294015 chr8 124696867 C T 5.83E-04 Stroke ANXA13 missense pha002887 rs17256536 chr8 124699175 A G 9.59E-04 Alcohol dependence ANXA13 intron 21314694 rs13258681 chr8 124714722 T C 4.00E-06 Prostate cancer (gene x gene interaction) ANXA13 intron 22219177 rs16898757 chr8 124718333 T G 3.32E-04 Type 2 diabetes ANXA13 intron 17463246 rs12156087 chr8 124727761 T G 6.30E-04 Multiple complex diseases ANXA13 intron 17554300 rs4006384 chr8 124743796 A G 2.55E-04 Alzheimer's disease (late onset) ANXA13 intron 21379329 rs2116353 chr8 124750228 C T 3.96E-04 Alzheimer's disease (late onset) / / 21379329 rs41483948 chr8 124758273 A G 3.37E-10 Adiponectin levels / / 20887962 rs10088262 chr8 124765702 A G 4.00E-06 Pancreatic cancer / / 20686608 rs12550235 chr8 124776245 C T 7.10E-05 Psoriasis / / 20953190 rs13275308 chr8 124776537 C A 8.01E-05 Psoriasis / / 20953190 rs13253599 chr8 124787892 G T 3.02E-05 Psoriasis FAM91A1 intron 20953190 rs7015861 chr8 124795613 C T 6.87E-04 Type 2 diabetes FAM91A1 intron 17463246 rs7828192 chr8 124804669 C T 4.79E-05 Psoriasis FAM91A1 intron 20953190 rs6470186 chr8 124812933 T C 7.24E-05 Psoriasis FAM91A1 intron 20953190 rs11991217 chr8 124817145 G A 9.62E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) FAM91A1 intron 24023788 rs10481151 chr8 124831834 T C 4.00E-07 Cognitive performance / / 19734545 rs964059 chr8 124835357 A C 2.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7826622 chr8 124846750 G T 1.11E-05 Lung adenocarcinoma / / 19836008 rs6470189 chr8 124850733 A C 8.77E-05 Lung adenocarcinoma / / 19836008 rs1431671 chr8 124855776 C A 7.03E-05 Lung adenocarcinoma / / 19836008 rs6470190 chr8 124857300 C T 7.25E-05 Lung adenocarcinoma / / 19836008 rs6470192 chr8 124862503 C T 9.34E-05 LDL lipoproteins / / pha002902 rs1897318 chr8 124864404 G A 3.87E-05 LDL lipoproteins FER1L6 UTR-5 pha002902 rs6989166 chr8 124885640 G C 9.70E-05 Bipolar disorder FER1L6 intron 20451256 rs6998986 chr8 124887024 G A 2.78E-05 AIDS FER1L6 intron 19754311 rs12548510 chr8 124923123 T C 6.02E-05 Bipolar disorder FER1L6 intron 20451256 rs7826132 chr8 124934256 G A 3.20E-07 Urinary metabolites FER1L6 intron 21572414 rs4871429 chr8 124938412 G A 1.92E-04 Alzheimer's disease (late onset) FER1L6 intron 21379329 rs4871429 chr8 124938412 G A 2.00E-04 Cognitive impairment induced by topiramate FER1L6 intron 22091778 rs1007106 chr8 124943607 G A 1.62E-04 Alzheimer's disease (late onset) FER1L6 intron 21379329 rs1007106 chr8 124943607 G A 2.00E-04 Cognitive impairment induced by topiramate FER1L6 intron 22091778 rs7842762 chr8 124946585 T C 1.85E-04 Alzheimer's disease (late onset) FER1L6 intron 21379329 rs7018193 chr8 124946823 T C 3.82E-05 Cognitive impairment induced by topiramate FER1L6 intron 22091778 rs4870880 chr8 124951527 A G 3.25E-05 Asthma FER1L6 intron 22561531 rs11993947 chr8 124971455 T G 0.00000105 HIV-1 infection (natural long-term nonprogression) FER1L6 intron 22238471 rs10106438 chr8 124972613 T C 5.80E-05 Bipolar disorder FER1L6 intron 18317468 rs7008604 chr8 124982215 G A 0.000000687 HIV-1 infection (natural long-term nonprogression) FER1L6 intron 22238471 rs7844981 chr8 125022733 T G 5.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FER1L6-AS1 intron 20877124 rs7844981 chr8 125022733 T G 9.62E-04 Amyotrophic lateral sclerosis FER1L6-AS1 intron 23624525 rs7006395 chr8 125081858 G A 2.38E-04 Type 2 diabetes FER1L6 intron 17463246 rs4531036 chr8 125204721 G C 2.60E-06 Thyroid function / / 20826269 rs4242363 chr8 125206503 T C 3.20E-06 Thyroid function / / 20826269 rs4242363 chr8 125206503 T C 5.15E-05 Blood Pressure / / pha003048 rs10100499 chr8 125231083 T C 2.04E-04 Multiple complex diseases / / 17554300 rs4242365 chr8 125238368 A G 5.90E-05 Vaspin levels / / 22907691 rs4242365 chr8 125238368 A G 0.000059 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs7015300 chr8 125243975 G A 2.26E-04 Depression (quantitative trait) / / 20800221 rs7015300 chr8 125243975 G A 3.13E-05 Smoking quantity / / 24665060 rs6989030 chr8 125246795 C T 1.63E-04 Depression (quantitative trait) / / 20800221 rs6993070 chr8 125246937 C T 2.08E-04 Depression (quantitative trait) / / 20800221 rs6993070 chr8 125246937 C T 7.73E-05 Smoking quantity / / 24665060 rs7822802 chr8 125250405 T C 3.28E-04 Type 2 diabetes / / 17463246 rs17360690 chr8 125266807 G A 6.67E-06 Schizophrenia / / 19571811 rs11985656 chr8 125283389 G T 1.37E-04 Type 2 diabetes / / 17463246 rs4457311 chr8 125284359 G A 1.44E-04 Vaspin levels / / 22907691 rs4457311 chr8 125284359 G A 0.0001438 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs9886564 chr8 125343256 T C 1.69E-04 Lung function (forced vital capacity) TMEM65 intron 24023788 rs4506195 chr8 125407101 A C 9.91E-04 Type 2 diabetes / / 17463246 rs4620270 chr8 125437811 G T 7.86E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs4620270 chr8 125437811 G T 5.06E-04 Alzheimer's disease / / 17998437 rs13271420 chr8 125448760 C G 4.68E-05 Bipolar disorder / / 22925353 rs6981043 chr8 125462986 G C 2.44E-04 Alzheimer's disease / / 22005930 rs3812473 chr8 125463083 G T 2.48E-04 Alzheimer's disease TRMT12 UTR-5 22005930 rs9643197 chr8 125469158 C G 5.45E-04 Alzheimer's disease / / 22005930 rs4527852 chr8 125473424 G A 1.92E-04 Alzheimer's disease / / 22005930 rs4330675 chr8 125488907 C T 6.14E-04 Alzheimer's disease RNF139 intron 22005930 rs3812470 chr8 125507538 A G 4.78E-04 Alzheimer's disease TATDN1 intron 22005930 rs12548836 chr8 125529355 G A 8.89E-05 Blood Pressure TATDN1 intron pha002898 rs17298171 chr8 125531989 G A 4.66E-04 Alzheimer's disease TATDN1 intron 22005930 rs16899656 chr8 125532891 T G 4.51E-04 Alzheimer's disease TATDN1 intron 22005930 rs16899660 chr8 125534041 T C 4.53E-04 Alzheimer's disease TATDN1 intron 22005930 rs11989584 chr8 125553102 C T 9.59E-04 Multiple complex diseases NDUFB9 intron 17554300 rs3829038 chr8 125561755 G A 5.62E-05 Meningococcal disease NDUFB9 intron 20694013 rs3829033 chr8 125564642 A T 8.94E-04 Alzheimer's disease MTSS1 UTR-3 22005930 rs4870903 chr8 125570144 G A 2.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MTSS1 intron 20877124 rs6470248 chr8 125570554 A C 8.54E-05 Cholesterol MTSS1 intron pha003083 rs17298759 chr8 125571412 A C 3.89E-05 Cholesterol MTSS1 intron pha003083 rs6470250 chr8 125571747 T C 9.72E-05 Leukocyte Counts MTSS1 intron pha003091 rs17299208 chr8 125576681 G A 4.24E-05 Cholesterol MTSS1 intron pha003083 rs4871503 chr8 125582099 A C 3.96E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) MTSS1 intron 24023788 rs6470253 chr8 125596256 G A 1.30E-05 Schizophrenia MTSS1 intron 19571808 rs17372901 chr8 125600160 G A 1.50E-05 Urinary metabolites MTSS1 intron 21572414 rs3857946 chr8 125606254 C T 1.74E-04 Lung function (forced expiratory volume in 1 second) MTSS1 intron 17255346 rs2013845 chr8 125619203 T C 3.30E-05 Taste perception MTSS1 intron 22132133 rs919544 chr8 125639455 A T 5.19E-04 Multiple complex diseases MTSS1 intron 17554300 rs10094360 chr8 125645225 C T 7.36E-04 Taste perception MTSS1 intron 22132133 rs4871527 chr8 125650653 C T 2.61E-04 Lung function (forced expiratory volume in 1 second) MTSS1 intron 17255346 rs4007936 chr8 125654354 C T 2.25E-04 Lung function (forced expiratory volume in 1 second) MTSS1 intron 17255346 rs6470257 chr8 125660721 T C 7.61E-04 Taste perception MTSS1 intron 22132133 rs7813190 chr8 125667226 T C 2.50E-04 Osteosarcoma MTSS1 intron 23727862 rs7831518 chr8 125683083 C T 1.00E-04 Cognitive impairment induced by topiramate MTSS1 intron 22091778 rs3915792 chr8 125688407 A G 1.80E-04 Myasthenia gravis MTSS1 intron 23055271 rs2382991 chr8 125696872 C G 9.17E-04 Suicide attempts in bipolar disorder MTSS1 intron 21423239 rs2382992 chr8 125697259 A G 8.04E-04 Suicide attempts in bipolar disorder MTSS1 intron 21423239 rs2116081 chr8 125697673 T C 6.00E-06 Cognitive function MTSS1 intron 24684796 rs7816758 chr8 125717193 G T 4.12E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MTSS1 intron 20877124 rs11781525 chr8 125721366 G A 6.00E-06 IgG glycosylation MTSS1 intron 23382691 rs9969518 chr8 125725222 T G 1.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MTSS1 intron 20877124 rs1430848 chr8 125736453 G A 4.35E-05 Waist-Hip Ratio MTSS1 intron pha003029 rs891541 chr8 125742166 A G 9.30E-05 Type 2 diabetes / / 17463246 rs10956203 chr8 125749707 G T 4.37E-06 Waist-Hip Ratio / / pha003029 rs6988023 chr8 125750897 T C 4.57E-06 Waist-Hip Ratio / / pha003029 rs2017614 chr8 125751611 C T 4.49E-06 Waist-Hip Ratio / / pha003029 rs1367501 chr8 125753813 T C 9.26E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4871533 chr8 125761998 C T 6.27E-04 Taste perception / / 22132133 rs16900003 chr8 125763884 G A 8.30E-04 Alcohol dependence / / 21314694 rs16900006 chr8 125769955 C T 4.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13270557 chr8 125772282 A G 7.51E-04 Alzheimer's disease / / 22005930 rs10441517 chr8 125801595 T C 1.35E-04 Gallstones / / 17632509 rs10095165 chr8 125816438 C G 1.83E-04 Multiple complex diseases / / 17554300 rs12544599 chr8 125831705 G A 5.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs13257530 chr8 125835978 C G 7.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs13279419 chr8 125838746 A T 4.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs7015626 chr8 125876814 G A 2.22E-07 Pancreatic cancer / / 22158540 rs11993071 chr8 125927906 A C 1.34E-04 Insulin resistance / / 21901158 rs7814843 chr8 125929876 C G 1.83E-04 Insulin resistance / / 21901158 rs2555716 chr8 125937406 T C 5.59E-04 Tourette syndrome / / 22889924 rs2555718 chr8 125939953 G A 8.69E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs723231 chr8 125949053 A C 2.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2590662 chr8 125950209 C T 5.92E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs2590673 chr8 125968156 A G 5.85E-06 Reading disability and language impairment / / 24024963 rs7842994 chr8 125971035 G A 2.13E-26 Narcolepsy / / 19629137 rs16900178 chr8 126024398 C G 5.83E-06 Telomere length SQLE intron 23001564 rs16900344 chr8 126080268 C T 3.48E-04 Multiple complex diseases KIAA0196 intron 17554300 rs12546767 chr8 126082565 T C 1.32E-05 Reading disability and language impairment KIAA0196 intron 24024963 rs7831515 chr8 126132816 C T 3.44E-04 Body mass index NSMCE2 intron 21701565 rs7831515 chr8 126132816 C T 3.80E-04 Body mass index NSMCE2 intron 21701565 rs4871574 chr8 126224517 G A 4.88E-04 Body mass index NSMCE2 intron 21701565 rs4871574 chr8 126224517 G A 5.42E-04 Body mass index NSMCE2 intron 21701565 rs11995484 chr8 126224719 G A 6.20E-04 Body mass index NSMCE2 intron 21701565 rs11995484 chr8 126224719 G A 6.57E-04 Body mass index NSMCE2 intron 21701565 rs3955404 chr8 126254259 C T 5.35E-04 Body mass index NSMCE2 intron 21701565 rs3955404 chr8 126254259 C T 6.97E-04 Body mass index NSMCE2 intron 21701565 rs7008482 chr8 126267630 T G 6.80E-04 Alcohol dependence NSMCE2 intron 20201924 rs7011185 chr8 126283766 T C 2.44E-04 Bipolar disorder NSMCE2 intron 18317468 rs11779422 chr8 126284010 G C 0.00000188 Nonsyndromic striae distensae (stretch marks) NSMCE2 intron 23633020 rs10112737 chr8 126285326 C T 1.44E-04 Stroke NSMCE2 intron pha002886 rs7845165 chr8 126287888 G A 8.42E-04 Depression (quantitative trait) NSMCE2 intron 20800221 rs3812467 chr8 126302789 G A 2.81E-04 Body mass index NSMCE2 intron 21701565 rs3812467 chr8 126302789 G A 2.92E-04 Body mass index NSMCE2 intron 21701565 rs7003102 chr8 126303493 A G 3.46E-06 Myopia (pathological) NSMCE2 intron 21640322 rs7003102 chr8 126303493 A G 2.54E-04 Body mass index NSMCE2 intron 21701565 rs7003102 chr8 126303493 A G 4.02E-04 Body mass index NSMCE2 intron 21701565 rs7003102 chr8 126303493 A G 5.14E-05 Obsessive-compulsive disorder NSMCE2 intron 24821223 rs7003102 chr8 126303493 A G 5.14E-05 Obsessive-compulsive disorder NSMCE2 intron 24821223 rs7007866 chr8 126303847 G A 1.69E-04 Body mass index NSMCE2 intron 21701565 rs7007866 chr8 126303847 G A 3.15E-04 Body mass index NSMCE2 intron 21701565 rs6989594 chr8 126303867 T G 2.91E-04 Body mass index NSMCE2 intron 21701565 rs6989594 chr8 126303867 T G 3.56E-04 Body mass index NSMCE2 intron 21701565 rs7004739 chr8 126328383 G A 8.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NSMCE2 intron 20877124 rs7004739 chr8 126328383 G A 2.49E-05 Behcet's disease NSMCE2 intron 23291587 rs7004739 chr8 126328383 G A 2.14E-05 Behcet's disease NSMCE2 intron pha002888 rs10956241 chr8 126338887 A G 8.53E-04 Response to taxane treatment (placlitaxel) NSMCE2 intron 23006423 rs2385092 chr8 126346977 G A 0.00000499 Nonsyndromic striae distensae (stretch marks) NSMCE2 intron 23633020 rs4870938 chr8 126351822 G A 3.13E-05 Myopia (pathological) NSMCE2 intron 21640322 rs9297716 chr8 126355162 G A 2.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NSMCE2 intron 20877124 rs7822592 chr8 126368375 G A 9.64E-04 Response to taxane treatment (placlitaxel) NSMCE2 intron 23006423 rs4871589 chr8 126380443 T C 5.77E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs11780099 chr8 126384977 G A 0.00000556 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs16893118 chr8 126385095 A G 7.08E-04 Body mass index / / 21701565 rs34225920 chr8 126389121 G C 0.00000646 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2954165 chr8 126398091 G A 0.0000244 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34614341 chr8 126402564 C T 3.60E-04 Multiple complex diseases / / 17554300 rs4332153 chr8 126404148 C T 5.67E-05 LDL lipoproteins / / pha002902 rs10089064 chr8 126404584 C A 3.00E-07 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs2980872 chr8 126416920 G A 1.10E-04 Suicidal ideation / / 22030708 rs2980874 chr8 126444788 G A 0.0000804 Triglycerides TRIB1 intron 23063622 rs2385114 chr8 126447308 C T 8.96E-05 HDL cholesterol TRIB1 intron 21589926 rs2385114 chr8 126447308 C T 2.80E-18 Triglycerides TRIB1 intron 23063622 rs2235108 chr8 126448789 G A 0.000000708 Triglycerides TRIB1 UTR-3 23063622 rs17405319 chr8 126449406 C T 0.00000144 Triglycerides TRIB1 UTR-3 23063622 rs17320616 chr8 126456376 A C,G 0.0000022 Triglycerides / / 23063622 rs13273254 chr8 126457553 A G 0.00000108 Triglycerides / / 23063622 rs12547199 chr8 126459962 A G 0.00000152 Triglycerides / / 23063622 rs4871598 chr8 126459990 G A 3.00E-04 HDL particle features / / 21283740 rs4871598 chr8 126459990 G A 3.45E-08 Triglycerides / / 23063622 rs6470355 chr8 126460535 A G 1.14E-04 Coronary Artery Disease / / 17634449 rs12544984 chr8 126462070 A G 3.75E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs10109137 chr8 126462698 C T 2.78E-05 Intracerebral hemorrhage / / 24656865 rs74736238 chr8 126465108 A G 6.85E-06 Intracerebral hemorrhage / / 24656865 rs17730649 chr8 126465305 C A 2.37E-09 Triglycerides / / 23063622 rs4518686 chr8 126470817 A G 1.60E-09 Triglycerides / / 23063622 rs12678799 chr8 126470831 C T 0.000000467 Triglycerides / / 23063622 rs12679189 chr8 126473565 T C 0.000000534 Triglycerides / / 23063622 rs2980885 chr8 126474306 G A 7.29E-05 Major depressive disorder / / 19107115 rs2980885 chr8 126474306 G A 0.00000216 Cholesterol,total / / 23063622 rs2980885 chr8 126474306 G A 3.86E-14 Triglycerides / / 23063622 rs2980884 chr8 126474356 G A 6.24E-04 Body mass index / / 21701565 rs2980884 chr8 126474356 G A 1.56E-17 Triglycerides / / 23063622 rs2980883 chr8 126474405 T G 1.53E-10 Triglycerides / / 23063622 rs2980856 chr8 126476379 C G 2.60E-05 Response to statin therapy / / 20339536 rs11781960 chr8 126477116 G C 4.60E-06 Response to statin therapy / / 20339536 rs2954018 chr8 126477153 C T 2.00E-05 Response to statin therapy / / 20339536 rs2954018 chr8 126477153 C T 4.54E-05 Body mass index / / 21701565 rs2980855 chr8 126477476 T C 2.40E-05 Response to statin therapy / / 20339536 rs2980854 chr8 126477497 C T 2.40E-05 Response to statin therapy / / 20339536 rs2980854 chr8 126477497 C T 1.69E-11 Cholesterol,total / / 23063622 rs2980854 chr8 126477497 C T 2.54E-24 Triglycerides / / 23063622 rs2954019 chr8 126477759 G A 2.40E-05 Response to statin therapy / / 20339536 rs2001945 chr8 126477978 G C 1.47E-04 Multiple complex diseases / / 17554300 rs2001945 chr8 126477978 G C 1.20E-05 Response to statin therapy / / 20339536 rs2001945 chr8 126477978 G C 1.00E-20 Triglycerides / / 21909109 rs2001945 chr8 126477978 G C 1.03E-08 HDL cholesterol / / 23063622 rs2001945 chr8 126477978 G C 1.04E-11 LDL cholesterol / / 23063622 rs2001945 chr8 126477978 G C 2.76E-35 Triglycerides / / 23063622 rs2001945 chr8 126477978 G C 2.98E-24 Cholesterol,total / / 23063622 rs2980853 chr8 126478350 A C 2.40E-05 Response to statin therapy / / 20339536 rs2001845 chr8 126478644 A G 1.90E-05 Response to statin therapy / / 20339536 rs2001844 chr8 126478745 A G 6.16E-04 Lipid levels / / 19913121 rs2001844 chr8 126478745 A G 8.89E-06 Lipid levels / / 19913121 rs2001844 chr8 126478745 A G 2.30E-05 Response to statin therapy / / 20339536 rs2001844 chr8 126478745 A G 1.65E-08 HDL cholesterol / / 23063622 rs2001844 chr8 126478745 A G 1.91E-09 LDL cholesterol / / 23063622 rs2001844 chr8 126478745 A G 2.09E-20 Cholesterol,total / / 23063622 rs2001844 chr8 126478745 A G 3.01E-38 Triglycerides / / 23063622 rs6982636 chr8 126479315 G A 2.10E-08 Lipid levels / / 18193043 rs6982636 chr8 126479315 G A 1.18E-11 Lipid levels / / 19936222 rs6982636 chr8 126479315 G A 2.40E-12 Lipid levels / / 19936222 rs6982636 chr8 126479315 G A 4.20E-10 Lipid levels / / 19936222 rs6982636 chr8 126479315 G A 5.96E-10 Lipid levels / / 19936222 rs6982636 chr8 126479315 G A 7.45E-12 Lipid levels / / 19936222 rs6982636 chr8 126479315 G A 8.46E-10 Lipid levels / / 19936222 rs6982636 chr8 126479315 G A 9.35E-10 Lipid levels / / 19936222 rs6982636 chr8 126479315 G A 2.60E-05 Response to statin therapy / / 20339536 rs6982636 chr8 126479315 G A 3.38E-06 HDL cholesterol / / 21589926 rs6982636 chr8 126479315 G A 0.00000637 LDL cholesterol (female) / / 22629316 rs6982636 chr8 126479315 G A 0.0000832 LDL cholesterol (male) / / 22629316 rs6982636 chr8 126479315 G A 4.29E-09 LDL cholesterol / / 22629316 rs6982636 chr8 126479315 G A 1.43E-09 HDL cholesterol / / 23063622 rs6982636 chr8 126479315 G A 2.07E-08 LDL cholesterol / / 23063622 rs6982636 chr8 126479315 G A 2.56E-39 Triglycerides / / 23063622 rs6982636 chr8 126479315 G A 3.59E-19 Cholesterol,total / / 23063622 rs6982502 chr8 126479362 C T 1.10E-05 Response to statin therapy / / 20339536 rs6982502 chr8 126479362 C T 5.53E-06 HDL cholesterol / / 21589926 rs6982502 chr8 126479362 C T 7.85E-04 HDL cholesterol / / 21589926 rs6982502 chr8 126479362 C T 5.35E-07 Coronary heart disease / / 22319020 rs4871603 chr8 126480367 C T 2.61E-06 HDL cholesterol / / 21589926 rs4871603 chr8 126480367 C T 7.06E-04 HDL cholesterol / / 21589926 rs4871603 chr8 126480367 C T 0.000000124 HDL cholesterol / / 23063622 rs4871603 chr8 126480367 C T 3.97E-26 Triglycerides / / 23063622 rs4871603 chr8 126480367 C T 7.49E-10 Cholesterol,total / / 23063622 rs2980882 chr8 126480700 A G 2.40E-05 Response to statin therapy / / 20339536 rs2980880 chr8 126480972 G A 2.60E-05 Response to statin therapy / / 20339536 rs2980880 chr8 126480972 G A 0.000000585 HDL cholesterol / / 22629316 rs2980880 chr8 126480972 G A 0.000233 HDL cholesterol (male) / / 22629316 rs2980880 chr8 126480972 G A 0.000379 HDL cholesterol (female) / / 22629316 rs2980880 chr8 126480972 G A 0.000000106 LDL cholesterol / / 23063622 rs2980880 chr8 126480972 G A 1.29E-27 Triglycerides / / 23063622 rs2980880 chr8 126480972 G A 1.75E-10 HDL cholesterol / / 23063622 rs2980880 chr8 126480972 G A 6.34E-15 Cholesterol,total / / 23063622 rs2980879 chr8 126481475 A T 2.70E-05 Response to statin therapy / / 20339536 rs2980879 chr8 126481475 A T 1.00E-09 Adiponectin levels / / 22479202 rs2980879 chr8 126481475 A T 7.00E-09 Adiponectin levels / / 22479202 rs2980878 chr8 126481527 G A,C 2.50E-05 Response to statin therapy / / 20339536 rs2980876 chr8 126481694 C T 5.12E-05 Major depressive disorder / / 19107115 rs2980876 chr8 126481694 C T 1.85E-05 Cognitive test performance / / 20125193 rs2980876 chr8 126481694 C T 3.10E-05 Response to statin therapy / / 20339536 rs2980875 chr8 126481747 A G 6.87E-04 Type 2 diabetes / / 17463246 rs2980875 chr8 126481747 A G 7.07E-04 Multiple complex diseases / / 17554300 rs2980875 chr8 126481747 A G 2.20E-05 Response to statin therapy / / 20339536 rs2980875 chr8 126481747 A G 0.000000105 Triglycerides (females) / / 22629316 rs2980875 chr8 126481747 A G 1.15E-15 Triglycerides / / 22629316 rs2980875 chr8 126481747 A G 9.61E-11 Triglycerides (males) / / 22629316 rs2980875 chr8 126481747 A G 2.46E-20 Cholesterol,total / / 23063622 rs2980875 chr8 126481747 A G 3.26E-09 HDL cholesterol / / 23063622 rs2980875 chr8 126481747 A G 4.57E-09 LDL cholesterol / / 23063622 rs2980875 chr8 126481747 A G 6.80E-39 Triglycerides / / 23063622 rs2954020 chr8 126481952 A G 5.12E-05 Major depressive disorder / / 19107115 rs2954020 chr8 126481952 A G 1.85E-05 Cognitive test performance / / 20125193 rs2954020 chr8 126481952 A G 3.10E-05 Response to statin therapy / / 20339536 rs2954020 chr8 126481952 A G 1.34E-04 Body mass index / / 21701565 rs2954021 chr8 126482077 A G 7.30E-06 Response to statin therapy / / 20339536 rs2954021 chr8 126482077 A G 1.00E-07 LDL cholesterol / / 20864672 rs2954021 chr8 126482077 A G 2.00E-13 Liver enzyme levels (alkaline phosphatase) / / 22001757 rs2954021 chr8 126482077 A G 5.00E-09 Liver enzyme levels (alanine transaminase) / / 22001757 rs2954021 chr8 126482077 A G 1.20E-11 Metabolic syndrome phenotype / / 22022282 rs2954021 chr8 126482077 A G 1.30E-10 Metabolic syndrome phenotype / / 22022282 rs2954022 chr8 126482621 C A 2.20E-05 Response to statin therapy / / 20339536 rs2954025 chr8 126484463 C T 9.95E-04 Type 2 diabetes / / 17463246 rs2954025 chr8 126484463 C T 1.68E-04 Body mass index / / 21701565 rs2954026 chr8 126484526 T G 1.90E-05 Response to statin therapy / / 20339536 rs2954026 chr8 126484526 T G 8.00E-09 HDL Cholesterol - Triglycerides (HDLC-TG) / / 21386085 rs2980862 chr8 126484638 G C 2.00E-05 Response to statin therapy / / 20339536 rs2980862 chr8 126484638 G C 3.51E-05 Body mass index / / 21701565 rs7846466 chr8 126485531 T C 1.46E-05 Major depressive disorder / / 19107115 rs7846466 chr8 126485531 T C 1.90E-05 Response to statin therapy / / 20339536 rs17321515 chr8 126486409 A G 6.50E-04 Type 2 diabetes / / 17463246 rs17321515 chr8 126486409 A G 7.00E-13 Triglycerides / / 18193043 rs17321515 chr8 126486409 A G 4.00E-17 Triglycerides / / 18193044 rs17321515 chr8 126486409 A G 3.47E-06 Lipid levels / / 19913121 rs17321515 chr8 126486409 A G 6.97E-04 Lipid levels / / 19913121 rs17321515 chr8 126486409 A G 3.00E-05 Response to statin therapy / / 20339536 rs17321515 chr8 126486409 A G 6.50E-07 Coronary heart disease / / 21966275 rs17321515 chr8 126486409 A G 0.000000155 LDL cholesterol (female) / / 23063622 rs17321515 chr8 126486409 A G 1.07E-08 HDL cholesterol / / 23063622 rs17321515 chr8 126486409 A G 1.10E-37 Triglycerides / / 23063622 rs17321515 chr8 126486409 A G 4.22E-09 LDL cholesterol / / 23063622 rs17321515 chr8 126486409 A G 6.47E-19 Cholesterol,total / / 23063622 rs17321515 chr8 126486409 A G 8.00E-07 Lipid traits / / 24386095 rs2980867 chr8 126487691 T G 1.70E-05 Response to statin therapy / / 20339536 rs2980867 chr8 126487691 T G 6.19E-05 Body mass index / / 21701565 rs2980869 chr8 126488250 C T 5.18E-04 Lipid levels / / 19913121 rs2980869 chr8 126488250 C T 6.88E-06 Lipid levels / / 19913121 rs2980869 chr8 126488250 C T 2.90E-05 Response to statin therapy / / 20339536 rs2980869 chr8 126488250 C T 2.66E-06 HDL cholesterol / / 21589926 rs2980869 chr8 126488250 C T 0.000000012 HDL cholesterol / / 23063622 rs2980869 chr8 126488250 C T 1.58E-35 Triglycerides / / 23063622 rs2980869 chr8 126488250 C T 1.90E-20 Cholesterol,total / / 23063622 rs2980869 chr8 126488250 C T 3.01E-09 LDL cholesterol / / 23063622 rs2980871 chr8 126488930 A G 1.60E-05 Response to statin therapy / / 20339536 rs2954029 chr8 126490972 A T 2.80E-08 Lipid levels / / 18193043 rs2954029 chr8 126490972 A T 3.00E-19 Triglycerides / / 19060906 rs2954029 chr8 126490972 A T 1.54E-05 Lipid levels / / 19913121 rs2954029 chr8 126490972 A T 2.91E-07 Blood cell counts and other traits / / 20139978 rs2954029 chr8 126490972 A T 3.00E-07 Blood cell counts and other traits / / 20139978 rs2954029 chr8 126490972 A T 2.50E-05 Response to statin therapy / / 20339536 rs2954029 chr8 126490972 A T 3.00E-29 LDL cholesterol / / 20686565 rs2954029 chr8 126490972 A T 3.00E-55 Triglycerides / / 20686565 rs2954029 chr8 126490972 A T 5.00E-36 Cholesterol,total / / 20686565 rs2954029 chr8 126490972 A T 6.00E-19 HDL cholesterol / / 20686565 rs2954029 chr8 126490972 A T 2.00E-11 Triglycerides / / 20864672 rs2954029 chr8 126490972 A T 1.97E-21 Cholesterol,total / / 23063622 rs2954029 chr8 126490972 A T 2.33E-39 Triglycerides / / 23063622 rs2954029 chr8 126490972 A T 2.92E-10 LDL cholesterol / / 23063622 rs2954029 chr8 126490972 A T 3.18E-09 HDL cholesterol / / 23063622 rs2954029 chr8 126490972 A T 7.74E-39 Triglycerides / / 23063622 rs2954029 chr8 126490972 A T 0.000000549 Coronary artery disease (CAD) age <=50 / / 23202125 rs2954029 chr8 126490972 A T 0.00000422 Coronary artery disease (CAD) (males) / / 23202125 rs2954029 chr8 126490972 A T 0.0000103 Coronary artery disease with myocardial infarction / / 23202125 rs2954029 chr8 126490972 A T 0.0000626 Coronary artery disease (CAD) age >50 / / 23202125 rs2954029 chr8 126490972 A T 0.000245 Coronary artery disease (CAD) (females) / / 23202125 rs2954029 chr8 126490972 A T 1.17E-35 Cholesterol,total / / 23202125 rs2954029 chr8 126490972 A T 3.29E-55 Triglycerides / / 23202125 rs2954029 chr8 126490972 A T 4.75E-09 Coronary artery disease / / 23202125 rs2954029 chr8 126490972 A T 4.85E-18 HDL cholesterol / / 23202125 rs2954029 chr8 126490972 A T 5.36E-29 LDL cholesterol / / 23202125 rs2954029 chr8 126490972 A T 1.00E-107 Triglycerides / / 24097068 rs2954029 chr8 126490972 A T 2.00E-50 LDL cholesterol / / 24097068 rs2954029 chr8 126490972 A T 2.00E-65 Cholesterol,total / / 24097068 rs2954029 chr8 126490972 A T 3.00E-29 HDL cholesterol / / 24097068 rs2954029 chr8 126490972 A T 1.28E-05 Coronary artery disease / / 24262325 rs2954029 chr8 126490972 A T 1.52E-04 Lipid traits / / 24386095 rs2954030 chr8 126491304 T C 9.70E-05 Response to statin therapy / / 20339536 rs2954031 chr8 126491733 G T 1.60E-05 Response to statin therapy / / 20339536 rs2954031 chr8 126491733 G T 0.000000843 HDL cholesterol / / 23063622 rs2954031 chr8 126491733 G T 1.88E-29 Triglycerides / / 23063622 rs2954031 chr8 126491733 G T 6.36E-12 Cholesterol,total / / 23063622 rs2954032 chr8 126493392 A G 1.50E-05 Response to statin therapy / / 20339536 rs2954032 chr8 126493392 A G 5.82E-05 Body mass index / / 21701565 rs2954032 chr8 126493392 A G 2.79E-20 Triglycerides / / 23063622 rs2954032 chr8 126493392 A G 9.30E-12 Cholesterol,total / / 23063622 rs2954033 chr8 126493746 A G 1.10E-05 Response to statin therapy / / 20339536 rs2954033 chr8 126493746 A G 9.00E-09 Triglycerides-Blood Pressure (TG-BP) / / 21386085 rs2954033 chr8 126493746 A G 0.000000367 Triglycerides in females / / 23063622 rs2954033 chr8 126493746 A G 0.00000103 LDL cholesterol / / 23063622 rs2954033 chr8 126493746 A G 1.24E-28 Triglycerides / / 23063622 rs2954033 chr8 126493746 A G 2.45E-14 Cholesterol,total / / 23063622 rs2954033 chr8 126493746 A G 6.38E-08 HDL cholesterol / / 23063622 rs2954033 chr8 126493746 A G 8.75E-22 Triglycerides in males / / 23063622 rs4350001 chr8 126494562 C T 3.54E-04 Sarcoidosis / / 19165924 rs10808546 chr8 126495818 C T 1.70E-06 Lipid levels / / 19802338 rs10808546 chr8 126495818 C T 3.60E-06 Lipid levels / / 19802338 rs10808546 chr8 126495818 C T 3.80E-04 Lipid levels / / 19802338 rs10808546 chr8 126495818 C T 2.38E-12 Lipid levels / / 19936222 rs10808546 chr8 126495818 C T 5.20E-09 Lipid levels / / 19936222 rs10808546 chr8 126495818 C T 2.00E-05 Response to statin therapy / / 20339536 rs10808546 chr8 126495818 C T 5.23E-04 HDL cholesterol / / 21589926 rs10808546 chr8 126495818 C T 6.93E-06 HDL cholesterol / / 21589926 rs10808546 chr8 126495818 C T 1.49E-40 Triglycerides / / 23063622 rs10808546 chr8 126495818 C T 2.45E-37 Triglycerides / / 23063622 rs10808546 chr8 126495818 C T 3.38E-09 HDL cholesterol / / 23063622 rs10808546 chr8 126495818 C T 8.32E-16 Cholesterol,total / / 23063622 rs2980859 chr8 126499429 C G 1.20E-05 Response to statin therapy / / 20339536 rs4351435 chr8 126499878 G A 4.80E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs8180991 chr8 126500350 C G 0.000000248 Cholesterol,total / / 23063622 rs12677676 chr8 126502526 A G 0.000000313 Cholesterol,total / / 23063622 rs6987702 chr8 126504726 T C 3.00E-06 LDL cholesterol / / 19060911 rs6987702 chr8 126504726 T C 3.00E-09 Cholesterol,total / / 19060911 rs6987702 chr8 126504726 T C 3.00E-06 Coronary heart disease / / 21347282 rs13271368 chr8 126506140 C T 0.000000323 Cholesterol,total / / 23063622 rs28635570 chr8 126506632 C T 0.000000165 Cholesterol,total / / 23063622 rs374077976 chr8 126506632 CTT C 0.000000165 Cholesterol,total / / 23063622 rs398009785 chr8 126506632 C CT 0.000000165 Cholesterol,total / / 23063622 rs550475737 chr8 126506632 CTT C 0.000000165 Cholesterol,total / / 23063622 rs2980888 chr8 126507308 T C 7.10E-06 Response to statin therapy / / 20339536 rs2954038 chr8 126507389 C A 7.00E-06 Response to statin therapy / / 20339536 rs7012891 chr8 126514676 T C 8.45E-05 Pancreatic cancer / / pha002889 rs4512391 chr8 126516988 T C 1.13E-06 Osteoarthritis (knee and hip) / / 21177295 rs4512391 chr8 126516988 T C 1.80E-06 Osteoarthritis (knee and hip) / / 21177295 rs4360309 chr8 126523523 C T 1.60E-06 Triglycerides / / 24886709 rs2168131 chr8 126530530 C T 8.20E-05 Multiple complex diseases / / 17554300 rs921720 chr8 126534671 A G 8.88E-05 Multiple complex diseases / / 17554300 rs921720 chr8 126534671 A G 2.78E-09 Crohn's disease / / 18587394 rs921720 chr8 126534671 A G 5.32E-04 Response to TNF antagonist treatment / / 21061259 rs921720 chr8 126534671 A G 8.00E-20 Inflammatory bowel disease / / 23128233 rs921720 chr8 126534671 A G 3.00E-06 Obesity-related traits / / 23251661 rs4871611 chr8 126537570 G A 2.00E-12 Crohn's disease / / 21102463 rs1551398 chr8 126540051 G A 5.00E-09 Crohn's disease / / 18587394 rs1551398 chr8 126540051 G A 5.00E-09 Asthma / / 21150878 rs1551398 chr8 126540051 G A 4.50E-09 Multiple sclerosis / / 22190364 rs1551398 chr8 126540051 G A 2.68E-06 Obesity-related traits / / 23251661 rs4871612 chr8 126540587 T C 2.58E-05 Multiple complex diseases / / 17554300 rs921719 chr8 126546197 T G 2.67E-04 Body mass index / / 17255346 rs921719 chr8 126546197 T G 3.64E-04 Multiple complex diseases / / 17554300 rs4870943 chr8 126546389 G A 5.83E-06 Multiple complex diseases / / 17554300 rs7829236 chr8 126570279 G A 7.50E-04 Alcohol dependence / / 20201924 rs2124038 chr8 126602130 C G 3.68E-04 Obesity (extreme) / / 21935397 rs10110589 chr8 126603390 G T 4.72E-04 Obesity (extreme) / / 21935397 rs7002040 chr8 126610907 A G 5.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17330462 chr8 126611047 T C 2.64E-04 Gallstones / / 17632509 rs17330462 chr8 126611047 T C 8.59E-04 Alzheimer's disease / / 17998437 rs17330462 chr8 126611047 T C 4.37E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs7017801 chr8 126612515 A G 4.37E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs10956253 chr8 126614369 C T 4.37E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs1979221 chr8 126620703 G A 1.07E-05 Myopia (pathological) / / 21640322 rs4557721 chr8 126631628 A G 6.88E-05 Multiple complex diseases / / 17554300 rs16900764 chr8 126648806 T C 6.43E-05 Multiple complex diseases / / 17554300 rs16900766 chr8 126649041 A G 9.18E-05 Multiple complex diseases / / 17554300 rs16900767 chr8 126649392 T A 1.69E-04 Multiple complex diseases / / 17554300 rs16900768 chr8 126649511 T C 3.45E-05 Multiple complex diseases / / 17554300 rs16900769 chr8 126649545 G A 1.19E-04 Multiple complex diseases / / 17554300 rs2385226 chr8 126681996 C T 8.15E-05 Heart Rate / / pha003053 rs11987816 chr8 126689998 A G 3.54E-04 Smoking initiation / / 24665060 rs7821386 chr8 126700303 T G 3.85E-04 Smoking initiation / / 24665060 rs4871632 chr8 126705306 G T 2.44E-04 Smoking initiation / / 24665060 rs10216366 chr8 126717244 A G 0.000175 Transmission distortion / / 22377632 rs7014615 chr8 126731757 G A 5.97E-05 Blood Pressure / / pha003046 rs7014615 chr8 126731757 G A 7.21E-05 Blood Pressure / / pha003048 rs7014615 chr8 126731757 G A 8.53E-05 Blood Pressure / / pha003050 rs1444003 chr8 126774314 A G 3.39E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1036966 chr8 126789900 C T 4.35E-16 Metabolite levels / / 22286219 rs1036966 chr8 126789900 C T 5.93E-06 Asthma (childhood onset) / / 23829686 rs6470380 chr8 126795581 A G 0.0000414 Panic disorder / / 23149450 rs6470380 chr8 126795581 A G 4.14E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs10956263 chr8 126818719 G A 5.26E-04 Multiple complex diseases / / 17554300 rs4871643 chr8 126842732 A C,G 8.80E-04 Multiple complex diseases / / 17554300 rs4871644 chr8 126842917 A C 9.49E-04 Multiple complex diseases / / 17554300 rs7016183 chr8 126850883 G A 6.89E-04 Multiple complex diseases / / 17554300 rs6470389 chr8 126863470 C T 7.80E-04 Multiple complex diseases / / 17554300 rs3955454 chr8 126867367 G A 9.29E-05 Serum metabolites / / 19043545 rs4006531 chr8 126867505 G A 7.00E-07 Metabolite levels (Dihydroxy docosatrienoic acid) / / 23934736 rs6999325 chr8 126909415 T G 7.91E-04 Type 2 diabetes / / 17463246 rs2385503 chr8 126928009 T A 8.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs17344625 chr8 126928137 T C 2.05E-04 Type 2 diabetes / / 17463246 rs1388372 chr8 126936152 T C 4.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100130231 intron 20877124 rs1491476 chr8 126938044 A G 2.48E-04 Suicide attempts in bipolar disorder LOC100130231 intron 21041247 rs1491474 chr8 126942346 A C 4.39E-04 Type 2 diabetes LOC100130231 intron 17463246 rs1491474 chr8 126942346 A C 1.35E-04 Suicide attempts in bipolar disorder LOC100130231 intron 21041247 rs2087688 chr8 126944294 G A 4.39E-04 Type 2 diabetes LOC100130231 intron 17463246 rs2087688 chr8 126944294 G A 4.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100130231 intron 20877124 rs2087688 chr8 126944294 G A 1.63E-04 Suicide attempts in bipolar disorder LOC100130231 intron 21041247 rs7819223 chr8 126946246 C T 1.64E-04 Suicide attempts in bipolar disorder LOC100130231 intron 21041247 rs4568586 chr8 126949677 A T 3.06E-04 Type 2 diabetes LOC100130231 intron 17463246 rs4568586 chr8 126949677 A T 1.72E-04 Suicide attempts in bipolar disorder LOC100130231 intron 21041247 rs1491470 chr8 126950730 T C 3.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100130231 intron 20877124 rs10956273 chr8 126966158 A G 7.40E-14 Narcolepsy / / 19629137 rs2172166 chr8 126994412 A G 7.70E-04 Myocardial Infarction / / pha002883 rs12681165 chr8 127004354 A G 9.29E-06 Odorant perception / / 23910658 rs17346240 chr8 127026494 A G 0.0005377 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17346240 chr8 127026494 A G 5.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7016046 chr8 127032660 A C 0.000031 Pancreatic cancer and survival / / 22665904 rs17346512 chr8 127062266 A G 0.0002197 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17346512 chr8 127062266 A G 2.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs780322 chr8 127084591 A G 2.95E-04 Hearing function / / 17255346 rs780322 chr8 127084591 A G 2.14E-04 HIV-1 viral setpoint / / 17641165 rs6470404 chr8 127088907 C A 9.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs7008601 chr8 127092140 T A 8.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs1906493 chr8 127092882 G T 3.00E-06 Crohn's disease / / 22412388 rs13266318 chr8 127092900 G A 8.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs10505466 chr8 127099135 A T 1.50E-04 Type 2 diabetes / / 17463246 rs10505466 chr8 127099135 A T 9.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs7824248 chr8 127100245 C A 9.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs1488024 chr8 127103441 A G 8.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs13256210 chr8 127104512 T G 7.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs16901099 chr8 127106518 C G 8.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs1463649 chr8 127119609 G A 7.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs7006495 chr8 127150370 G A 4.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs1488028 chr8 127153156 C A 6.31E-04 Type 2 diabetes / / 17463246 rs16901163 chr8 127176405 A G 3.53E-04 Type 2 diabetes / / 17463246 rs7838729 chr8 127177084 T C 4.06E-04 Rheumatoid arthritis / / 21452313 rs2385523 chr8 127181094 A C 4.69E-04 Suicide attempts in bipolar disorder / / 21041247 rs16901179 chr8 127181744 A C 9.25E-05 Type 2 diabetes / / 17463246 rs16901182 chr8 127182030 G A 9.50E-05 Type 2 diabetes / / 17463246 rs41352547 chr8 127184558 G A 9.31E-05 Type 2 diabetes / / 17463246 rs1488027 chr8 127199752 G T 4.30E-06 Parkinson's disease (familial) / / 18985386 rs6470423 chr8 127253029 C G 3.20E-05 Multiple complex diseases / / 17554300 rs13282350 chr8 127254859 G A 5.23E-05 Multiple complex diseases / / 17554300 rs4422742 chr8 127292996 T C 8.23E-05 Cervical cancer / / 24700089 rs9650091 chr8 127325402 A G 4.17E-04 Blood pressure / / 17255346 rs11986011 chr8 127332657 C T 5.00E-06 Age-related macular degeneration / / 23326517 rs2253162 chr8 127335010 A G 9.50E-05 Alcohol dependence / / 24277619 rs2471935 chr8 127337494 A C 3.17E-05 Multiple complex diseases / / 17554300 rs10101575 chr8 127343692 T C 1.01E-04 Asthma / / 23181788 rs10090539 chr8 127344452 G A 3.35E-05 Blood Pressure / / pha003046 rs10090539 chr8 127344452 G A 4.68E-05 Eosinophil counts / / pha003088 rs16901313 chr8 127346311 G T 4.31E-05 Height / / pha003011 rs10095552 chr8 127363405 A G 2.70E-04 Obesity (extreme) / / 21935397 rs6470436 chr8 127388454 G C 3.06E-04 Response to TNF antagonist treatment / / 21061259 rs16901346 chr8 127391255 C T 6.20E-06 Urinary metabolites / / 21572414 rs16893145 chr8 127394126 C T 4.70E-06 Urinary metabolites / / 21572414 rs2721112 chr8 127398043 A G 1.47E-04 Type 2 diabetes / / 17463246 rs16901354 chr8 127399415 C T 2.08E-04 Multiple complex diseases / / 17554300 rs2736000 chr8 127399987 C A 1.88E-04 Parkinson's disease / / 17052657 rs2736000 chr8 127399987 C A 2.53E-04 Multiple complex diseases / / 17554300 rs2721095 chr8 127438638 A G 3.09E-04 Type 2 diabetes / / 17463246 rs4870976 chr8 127478325 G A 6.40E-05 Alcohol dependence / / 19581569 rs4870976 chr8 127478325 G A 9.61E-05 Body Mass Index / / pha003015 rs16901441 chr8 127507141 G A 8.69E-04 Multiple complex diseases / / 17554300 rs11986722 chr8 127528740 C G 6.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs11986722 chr8 127528740 C G 4.25E-04 Obesity (extreme) / / 21935397 rs2290839 chr8 127530775 G A 5.52E-05 Femoral neck bone geometry / / 22087292 rs6989132 chr8 127539599 T C 6.71E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6989132 chr8 127539599 T C 4.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs6989132 chr8 127539599 T C 5.12E-04 Obesity (extreme) / / 21935397 rs11990954 chr8 127543114 C A 5.06E-04 Suicide attempts in bipolar disorder / / 21041247 rs11990954 chr8 127543114 C A 6.74E-04 Obesity (extreme) / / 21935397 rs16901493 chr8 127545045 T G 5.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs16901493 chr8 127545045 T G 6.72E-04 Obesity (extreme) / / 21935397 rs10156297 chr8 127551826 C A 0.000068 Primary sclerosing cholangitis / / 22521342 rs12682088 chr8 127554930 G A 6.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs7818201 chr8 127560353 G A 2.38E-04 Obesity (extreme) / / 21935397 rs7818201 chr8 127560353 G A 8.67E-05 Femoral neck bone geometry / / 22087292 rs16901512 chr8 127575580 A G 4.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs12675790 chr8 127575939 A G 4.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs12679982 chr8 127576362 G C 9.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs7012323 chr8 127581827 T C 3.90E-05 Anger / / 24489884 rs6998716 chr8 127583567 C T 5.00E-04 Obesity (extreme) / / 21935397 rs7832762 chr8 127584005 A G 7.48E-05 Waist Circumference / / pha003025 rs10087205 chr8 127584635 G A 5.17E-05 Cognitive impairment induced by topiramate / / 22091778 rs10090632 chr8 127585326 C G 5.24E-04 Obesity (extreme) / / 21935397 rs4345522 chr8 127587374 C T 5.26E-04 Heart Failure / / pha002885 rs16901549 chr8 127596184 G T 6.42E-07 Esophageal cancer (squamous cell) / / 22960999 rs13248347 chr8 127613934 C T 2.60E-07 Urinary metabolites / / 21572414 rs16901571 chr8 127619912 T A 7.70E-05 Parkinson's disease (familial) / / 18985386 rs16901592 chr8 127644440 C T 7.46E-04 Multiple complex diseases / / 17554300 rs2385686 chr8 127659536 A G 6.21E-05 Myocardial Infarction / / pha002873 rs13260097 chr8 127661127 G A 0.0000255 Carotid intima media thickness / / 23152477 rs13260284 chr8 127661447 A G 1.31E-04 Body mass index / / 17255346 rs11991700 chr8 127674144 G A 1.52E-05 Body mass index / / 17255346 rs10090062 chr8 127675166 C T 1.83E-05 Body mass index / / 17255346 rs13259828 chr8 127675497 G A 1.08E-04 Body mass index / / 17255346 rs7845830 chr8 127687049 A C,G,T 5.93E-04 Type 2 diabetes / / 17463246 rs7828662 chr8 127692210 T C 8.50E-04 Type 2 diabetes / / 17463246 rs6470464 chr8 127727973 A G 1.90E-05 Urinary metabolites / / 21572414 rs1021330 chr8 127731717 G T 1.40E-05 Urinary metabolites / / 21572414 rs1387565 chr8 127737855 G A 7.90E-06 Urinary metabolites / / 21572414 rs7017667 chr8 127738121 T C 1.00E-05 Urinary metabolites / / 21572414 rs4870982 chr8 127740139 A G 1.60E-05 Urinary metabolites / / 21572414 rs4871734 chr8 127740153 C A 2.50E-05 Urinary metabolites / / 21572414 rs7826744 chr8 127780708 C G 7.78E-04 Type 2 diabetes / / 17463246 rs7822593 chr8 127795609 A G 4.41E-04 Multiple complex diseases / / 17554300 rs6983330 chr8 127836007 A G 9.97E-04 Depression (quantitative trait) / / 20800221 rs7003931 chr8 127836137 T C 9.89E-04 Depression (quantitative trait) / / 20800221 rs6994585 chr8 127838101 G A 9.94E-04 Depression (quantitative trait) / / 20800221 rs13270320 chr8 127838809 G A 9.70E-04 Depression (quantitative trait) / / 20800221 rs13270320 chr8 127838809 G A 9.90E-06 Personality dimensions / / 21173776 rs16901732 chr8 127839267 T C 9.47E-04 Depression (quantitative trait) / / 20800221 rs16901733 chr8 127839603 G C 9.63E-04 Depression (quantitative trait) / / 20800221 rs13279644 chr8 127839806 C T 9.70E-04 Depression (quantitative trait) / / 20800221 rs979965 chr8 127864941 A G 1.52E-05 Statin-induced myopathy / / 21826682 rs979963 chr8 127865119 T C 1.32E-04 Statin-induced myopathy / / 21826682 rs4871750 chr8 127902003 G A 4.90E-05 Cognitive test performance / / 20125193 rs4871750 chr8 127902003 G A 4.00E-07 Obesity-related traits / / 23251661 rs7817717 chr8 127903262 T G 6.88E-07 Obesity-related traits / / 23251661 rs10956341 chr8 127908177 G C 3.74E-04 Multiple complex diseases / / 17554300 rs2220321 chr8 127911596 G A 8.00E-06 Obesity-related traits / / 23251661 rs7012789 chr8 127917208 A G 6.11E-07 Obesity-related traits / / 23251661 rs4871752 chr8 127920586 G A 4.19E-07 Obesity-related traits / / 23251661 rs979201 chr8 127923372 C T 1.70E-05 Intelligence (childhood) / / 23358156 rs12543663 chr8 127924659 C A 9.10E-07 Prostate cancer / / 18264097 rs12543663 chr8 127924659 C A 9.10E-05 Prostate cancer (early onset) / / 24740154 rs13270753 chr8 127926753 G A 9.93E-04 Multiple complex diseases / / 17554300 rs7844523 chr8 127929829 G A 2.15E-04 Type 2 diabetes / / 17463246 rs9297749 chr8 127930096 G C 5.54E-04 Type 2 diabetes / / 17463246 rs9297749 chr8 127930096 G C 8.30E-06 Personality dimensions / / 21173776 rs4871753 chr8 127930885 C A 3.70E-04 Type 2 diabetes / / 17463246 rs4871753 chr8 127930885 C A 7.10E-06 Personality dimensions / / 21173776 rs4870993 chr8 127931003 A G 3.39E-04 Type 2 diabetes / / 17463246 rs4870993 chr8 127931003 A G 5.60E-06 Personality dimensions / / 21173776 rs6983692 chr8 127931310 A T 6.80E-06 Personality dimensions / / 21173776 rs4871755 chr8 127934830 C T 3.46E-04 Type 2 diabetes / / 17463246 rs4871755 chr8 127934830 C T 8.98E-04 Multiple complex diseases / / 17554300 rs1516952 chr8 127938759 C T 5.30E-06 Personality dimensions / / 21173776 rs1516950 chr8 127942683 C A 2.61E-04 Type 2 diabetes / / 17463246 rs4871759 chr8 127970915 G T 2.47E-04 Type 2 diabetes / / 17463246 rs4871761 chr8 127974199 T C 2.48E-04 Type 2 diabetes / / 17463246 rs980427 chr8 127980936 C T 2.26E-04 Type 2 diabetes / / 17463246 rs1027041 chr8 128001639 G C 6.93E-04 Type 2 diabetes / / 17463246 rs16901902 chr8 128024201 T A 9.23E-07 Multiple complex diseases / / 17554300 rs1026411 chr8 128026410 G A 3.92E-04 Breast cancer PCAT1 intron 21060860 rs16901904 chr8 128027502 T C 6.08E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PCAT1 intron 20031582 rs785005 chr8 128028973 C T 6.14E-04 Multiple complex diseases PCAT1 intron 17554300 rs1386470 chr8 128047588 T C 7.45E-05 Multiple complex diseases / / 17554300 rs1487237 chr8 128048974 A C 3.95E-05 Multiple complex diseases / / 17554300 rs12334903 chr8 128050513 T C 7.33E-05 Cognitive test performance / / 20125193 rs12056374 chr8 128052255 C T 6.33E-04 Multiple complex diseases / / 17554300 rs1456310 chr8 128052433 A G 6.73E-04 Multiple complex diseases / / 17554300 rs980171 chr8 128054522 A G 2.08E-05 Cognitive test performance / / 20125193 rs7827583 chr8 128062582 A G 0.0000703 Amyotrophic lateral sclerosis / / 23587638 rs4288339 chr8 128067300 C T 6.68E-04 Multiple complex diseases / / 17554300 rs16901935 chr8 128076545 A G 6.18E-06 Personality dimensions / / 18957941 rs2392729 chr8 128079666 C T 4.28E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs6470494 chr8 128087904 T C 1.27E-04 Colorectal cancer / / 17618284 rs1016343 chr8 128093297 C T 1.00E-07 Prostate cancer / / 18264097 rs1016343 chr8 128093297 C T 1.00E-07 Nasopharyngeal carcinoma / / 20512145 rs1016343 chr8 128093297 C T 4.00E-10 Prostate cancer / / 21743057 rs1016343 chr8 128093297 C T 6.70E-09 Prostate cancer / / 22923026 rs1016343 chr8 128093297 C T 1.10E-13 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs1016343 chr8 128093297 C T 1.50E-15 Prostate cancer / / 23555315 rs13252298 chr8 128095156 A G 4.00E-06 Prostate cancer / / 21743057 rs13252298 chr8 128095156 A G 0.000000043 Prostate cancer / / 23555315 rs13252298 chr8 128095156 A G 0.0000016 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs11993508 chr8 128100076 C T 4.50E-04 Multiple complex diseases / / 17554300 rs1456315 chr8 128103937 T C 2.00E-29 Prostate cancer / / 20676098 rs1456315 chr8 128103937 T C 2.30E-12 Prostate cancer / / 22923026 rs1456315 chr8 128103937 T C 1.00E-12 Prostate cancer / / 23023329 rs1456315 chr8 128103937 T C 7.40E-21 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs1456315 chr8 128103937 T C 8.60E-22 Prostate cancer / / 23555315 rs13254738 chr8 128104343 C A 4.00E-10 Prostate cancer / / 22923026 rs6983561 chr8 128106880 A C 4.00E-13 Prostate cancer / / 22923026 rs17832285 chr8 128108993 A G 4.39E-05 Celiac disease / / 23936387 rs16901966 chr8 128110252 A G 2.90E-08 Prostate cancer / / 18264097 rs16901966 chr8 128110252 A G 1.07E-14 Prostate cancer / / 22923026 rs7001069 chr8 128110646 A G 3.00E-05 Breast cancer and prostate cancer / / 17903305 rs16901970 chr8 128112715 T G 2.90E-08 Prostate cancer / / 18264097 rs16901970 chr8 128112715 T G 1.07E-14 Prostate cancer / / 22923026 rs1456306 chr8 128116500 G A 7.47E-08 Prostate cancer / / 22923026 rs1378897 chr8 128122659 C T 1.64E-07 Prostate cancer / / 22923026 rs16901979 chr8 128124916 C A 1.00E-12 Prostate cancer / / 17401366 rs16901979 chr8 128124916 C A 3.00E-14 Prostate cancer / / 19767754 rs16901979 chr8 128124916 C A 3.00E-14 Nasopharyngeal carcinoma / / 20512145 rs16901979 chr8 128124916 C A 0.0000012 Prostate cancer (advanced) / / 23555315 rs16901979 chr8 128124916 C A 1.10E-21 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs16901979 chr8 128124916 C A 6.20E-25 Prostate cancer / / 23555315 rs10505483 chr8 128125195 C T 4.00E-05 Breast cancer and prostate cancer / / 17903305 rs10505483 chr8 128125195 C T 4.20E-08 Prostate cancer / / 18264097 rs10505483 chr8 128125195 C T 7.00E-15 Prostate cancer / / 22923026 rs7817677 chr8 128125504 A G 6.20E-08 Prostate cancer / / 18264097 rs7817677 chr8 128125504 A G 3.38E-14 Prostate cancer / / 22923026 rs7816535 chr8 128137668 G A 8.41E-04 Type 2 diabetes / / 17463246 rs2466024 chr8 128188019 G A 3.00E-06 Chronic lymphocytic leukemia / / 24292274 rs2456449 chr8 128192981 A G 8.00E-10 Chronic lymphocytic leukemia / / 20062064 rs2456449 chr8 128192981 A G 8.00E-10 Nasopharyngeal carcinoma / / 20512145 rs2456449 chr8 128192981 A G 6.31E-04 Chronic lymphocytic leukemia / / 22700719 rs2456449 chr8 128192981 A G 6.31E-04 Erectile dysfunction / / 22704111 rs2456449 chr8 128192981 A G 0.0000081 Prostate cancer / / 23555315 rs1021955 chr8 128203973 A G 8.08E-04 Multiple complex diseases / / 17554300 rs1473581 chr8 128204216 C T 4.50E-05 Malaria / / 19465909 rs2466032 chr8 128209820 T C 1.65E-08 Chronic lymphocytic leukemia / / 23770605 rs2466035 chr8 128211229 T C 2.00E-08 Chronic lymphocytic leukemia / / 23770605 rs6651244 chr8 128217462 T G 9.12E-06 Multiple complex diseases / / 17554300 rs10087719 chr8 128228863 A G 2.59E-04 Smoking initiation LOC100507056 intron 24665060 rs283741 chr8 128252993 C T 9.76E-04 Myocardial Infarction / / pha002873 rs6992863 chr8 128269154 C T 3.00E-05 Prostate cancer / / 21743057 rs11777807 chr8 128280808 C T 4.60E-05 Osteosarcoma / / 23727862 rs17378189 chr8 128288920 C T 8.16E-04 Osteosarcoma / / 23727862 rs4871780 chr8 128291578 C T 9.46E-05 Serum metabolites / / 19043545 rs185852 chr8 128293466 A G 4.60E-06 Type 2 diabetes / / 17460697 rs185852 chr8 128293466 A G 9.47E-05 Potassium levels / / pha003086 rs412835 chr8 128295710 C A 6.03E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs412835 chr8 128295710 C A 8.50E-04 Osteosarcoma / / 23727862 rs17378569 chr8 128302639 C T 5.25E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs12216777 chr8 128303372 C T 6.24E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs283728 chr8 128313500 T A 8.17E-05 Serum metabolites / / 19043545 rs16902094 chr8 128320346 A G 6.00E-15 Prostate cancer / / 19767754 rs16902094 chr8 128320346 A G 6.00E-15 Nasopharyngeal carcinoma / / 20512145 rs445114 chr8 128323181 T C 5.00E-10 Prostate cancer / / 19767754 rs445114 chr8 128323181 T C 5.00E-10 Nasopharyngeal carcinoma / / 20512145 rs445114 chr8 128323181 T C 5.00E-07 Prostate cancer / / 21743057 rs445114 chr8 128323181 T C 0.00000059 Prostate cancer / / 23555315 rs445114 chr8 128323181 T C 0.0000018 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs620861 chr8 128335673 G A 4.90E-07 Prostate cancer / / 18264097 rs620861 chr8 128335673 G A 8.80E-05 Prostate cancer (early onset) / / 24740154 rs17464492 chr8 128342866 A G 2.36E-04 Multiple complex diseases / / 17554300 rs673745 chr8 128345269 C T 2.02E-08 Breast cancer (early onset) / / 24493630 rs7826557 chr8 128345731 C A 3.42E-08 Breast cancer (early onset) / / 24493630 rs418269 chr8 128346358 G A 2.13E-08 Breast cancer (early onset) / / 24493630 rs13271658 chr8 128354313 G A 3.73E-05 Height / / 22021425 rs10098985 chr8 128355019 G T 3.72E-08 Breast cancer (early onset) / / 24493630 rs13281615 chr8 128355618 A G 5.00E-12 Breast cancer / / 17529967 rs13281615 chr8 128355618 A G 5.00E-12 Nasopharyngeal carcinoma / / 20512145 rs13281615 chr8 128355618 A G 1.00E-27 Breast cancer / / 23535729 rs7002826 chr8 128364271 G C 9.64E-06 Serum metabolites / / 19043545 rs7002826 chr8 128364271 G C 2.06E-08 Breast cancer (early onset) / / 24493630 rs7007568 chr8 128364906 G C 1.87E-05 Serum metabolites / / 19043545 rs7007568 chr8 128364906 G C 2.23E-08 Breast cancer (early onset) / / 24493630 rs7815100 chr8 128376801 T C 1.32E-05 Serum metabolites / / 19043545 rs7815100 chr8 128376801 T C 2.56E-08 Breast cancer (early onset) / / 24493630 rs1562430 chr8 128387852 T C 6.00E-07 Breast cancer / / 20453838 rs1562430 chr8 128387852 T C 3.00E-11 Breast cancer / / 21263130 rs2392780 chr8 128388025 A G 1.18E-05 Serum metabolites / / 19043545 rs2392780 chr8 128388025 A G 1.00E-08 Breast cancer (early onset) / / 24493630 rs10505477 chr8 128407443 A G 3.00E-11 Colorectal cancer / / 17618283 rs10505477 chr8 128407443 A G 3.73E-14 Colorectal cancer / / 17618284 rs10505477 chr8 128407443 A G 3.16E-08 Prostate cancer / / 18264096 rs10505477 chr8 128407443 A G 3.00E-11 Nasopharyngeal carcinoma / / 20512145 rs10505477 chr8 128407443 A G 5.90E-04 Colorectal cancer / / 20610541 rs10505477 chr8 128407443 A G 2.60E-11 Colorectal cancer / / 23266556 rs10505477 chr8 128407443 A G 0.00000044 Prostate cancer / / 23555315 rs10505477 chr8 128407443 A G 0.00000087 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs10505477 chr8 128407443 A G 0.0000442 Colorectal adenoma (excluding hyperplasic) / / 23677573 rs10505477 chr8 128407443 A G 0.0000442 Colorectal adenoma / / 23677573 rs10505477 chr8 128407443 A G 0.0000442 Colorectal adenoma (including hyperplasic) / / 23677573 rs10505477 chr8 128407443 A G 8.00E-13 Colorectal cancer / / 24737748 rs10505477 chr8 128407443 A G 9.00E-09 Prostate cancer (early onset) / / 24740154 rs10505477 chr8 128407443 A G 3.43E-13 Colorectal cancer / / 24836286 rs10505476 chr8 128408116 C T 3.94E-05 Prostate cancer / / 18264096 rs10808555 chr8 128409511 G A 1.50E-07 Colorectal cancer / / 19011631 rs10808556 chr8 128413147 C T 4.40E-08 Prostate cancer / / 18264097 rs6983267 chr8 128413305 G T 9.00E-13 Prostate cancer / / 17401363 rs6983267 chr8 128413305 G T 5.40E-04 Colorectal cancer / / 17618283 rs6983267 chr8 128413305 G T 1.00E-14 Colorectal cancer / / 17618284 rs6983267 chr8 128413305 G T 7.00E-12 Prostate cancer / / 18264096 rs6983267 chr8 128413305 G T 9.00E-13 Prostate cancer / / 18264097 rs6983267 chr8 128413305 G T 7.00E-11 Colorectal cancer / / 18372905 rs6983267 chr8 128413305 G T 2.10E-14 Colorectal cancer / / 19011631 rs6983267 chr8 128413305 G T 1.00E-14 Nasopharyngeal carcinoma / / 20512145 rs6983267 chr8 128413305 G T 7.00E-04 Colorectal cancer / / 20610541 rs6983267 chr8 128413305 G T 2.00E-08 Colorectal cancer / / 21242260 rs6983267 chr8 128413305 G T 9.00E-06 Prostate cancer / / 21743057 rs6983267 chr8 128413305 G T 1.00E-11 Colorectal cancer / / 23266556 rs6983267 chr8 128413305 G T 0.00000039 Prostate cancer / / 23555315 rs6983267 chr8 128413305 G T 0.0000013 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs6983267 chr8 128413305 G T 1.00E-08 Prostate cancer (early onset) / / 24740154 rs6983267 chr8 128413305 G T 4.00E-15 Prostate cancer / / 24753544 rs6983267 chr8 128413305 G T 5.00E-14 Colorectal cancer / / 24836286 rs10505474 chr8 128417504 T C 1.54E-05 Prostate cancer / / 18264096 rs7837328 chr8 128423127 A G 3.00E-04 Colorectal cancer / / 17618284 rs7837328 chr8 128423127 A G 7.81E-08 Prostate cancer / / 18264096 rs7837328 chr8 128423127 A G 2.00E-08 Prostate cancer / / 18264097 rs7837328 chr8 128423127 A G 1.20E-10 Colorectal cancer / / 19011631 rs7837328 chr8 128423127 A G 2.13E-05 Colorectal cancer / / 21242260 rs10956369 chr8 128423817 T A 4.20E-05 Colorectal cancer / / 20610541 rs7014346 chr8 128424792 A G 2.00E-04 Colorectal cancer / / 17618284 rs7014346 chr8 128424792 A G 9.91E-08 Prostate cancer / / 18264096 rs7014346 chr8 128424792 A G 1.40E-08 Prostate cancer / / 18264097 rs7014346 chr8 128424792 A G 9.00E-26 Colorectal cancer / / 18372901 rs7014346 chr8 128424792 A G 3.00E-13 Colorectal cancer / / 19011631 rs7014346 chr8 128424792 A G 9.00E-26 Nasopharyngeal carcinoma / / 20512145 rs7014346 chr8 128424792 A G 2.50E-04 Colorectal cancer / / 20610541 rs7014346 chr8 128424792 A G 2.52E-10 Colorectal cancer / / 23266556 rs7014346 chr8 128424792 A G 0.00011 Prostate cancer / / 23555315 rs7014346 chr8 128424792 A G 0.00018 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs7014346 chr8 128424792 A G 1.96E-08 Colorectal cancer / / 24836286 rs7005829 chr8 128434944 C T 2.52E-04 Multiple complex diseases / / 17554300 rs6470511 chr8 128435924 A G 5.06E-05 F-cell distribution / / 21326311 rs1447294 chr8 128437686 C T 5.51E-04 Multiple complex diseases / / 17554300 rs1447294 chr8 128437686 C T 6.94E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs12334695 chr8 128453928 T C 6.00E-04 Colorectal cancer / / 17618284 rs4871791 chr8 128458644 C T 2.45E-06 Intelligence LOC727677 intron 21826061 rs7841228 chr8 128460878 A G 3.47E-05 Creatinine levels LOC727677 intron pha003069 rs7841264 chr8 128466814 C T 2.00E-04 Colorectal cancer LOC727677 intron 17618284 rs3999771 chr8 128469498 T C 8.94E-05 Bipolar disorder LOC727677 intron 20451256 rs10555137 chr8 128469590 C T 2.18E-16 Blood pressure LOC727677 intron 21909110 rs1447293 chr8 128472320 C T 1.46E-05 Prostate cancer LOC727677 intron 18264096 rs1447293 chr8 128472320 C T 1.60E-07 Prostate cancer LOC727677 intron 18264097 rs921146 chr8 128475185 G T 9.93E-06 Prostate cancer LOC727677 intron 18264096 rs921146 chr8 128475185 G T 2.00E-08 Prostate cancer LOC727677 intron 18264097 rs7819102 chr8 128481349 C T 4.05E-04 Type 2 diabetes LOC727677 intron 17463246 rs4871799 chr8 128482642 G A 7.20E-06 Prostate cancer LOC727677 intron 18264096 rs4871799 chr8 128482642 G A 8.53E-04 Osteosarcoma LOC727677 intron 23727862 rs1447295 chr8 128485038 A C 2.00E-14 Prostate cancer LOC727677 intron 17401363 rs1447295 chr8 128485038 A C 6.00E-18 Prostate cancer LOC727677 intron 17401366 rs1447295 chr8 128485038 A C 1.36E-17 Prostate cancer LOC727677 intron 18264096 rs1447295 chr8 128485038 A C 1.10E-16 Prostate cancer LOC727677 intron 18264097 rs1447295 chr8 128485038 A C 2.00E-19 Prostate cancer LOC727677 intron 19767754 rs1447295 chr8 128485038 A C 2.00E-19 Nasopharyngeal carcinoma LOC727677 intron 20512145 rs1447295 chr8 128485038 A C 3.61E-09 Prostate cancer LOC727677 intron 22923026 rs1447295 chr8 128485038 A C 1.60E-12 Prostate cancer (non-advanced prostate cancer) LOC727677 intron 23555315 rs1447295 chr8 128485038 A C 9.90E-16 Prostate cancer LOC727677 intron 23555315 rs1447295 chr8 128485038 A C 7.80E-05 Prostate cancer (early onset) LOC727677 intron 24740154 rs1447295 chr8 128485038 A C 6.00E-18 Prostate cancer LOC727677 intron 24753544 rs7836840 chr8 128491792 T G 0.00014 Prostate cancer LOC727677 intron 23555315 rs7831028 chr8 128492029 C G 6.64E-06 Prostate cancer / / 18264096 rs6985504 chr8 128496776 A G 3.16E-06 Prostate cancer / / 18264096 rs17766217 chr8 128504497 T C 3.00E-07 Response to antidepressant treatment / / 22041458 rs4242382 chr8 128517573 A G 1.78E-06 Multiple complex diseases / / 17554300 rs4242382 chr8 128517573 A G 3.00E-19 Prostate cancer / / 18264096 rs4242382 chr8 128517573 A G 5.40E-17 Prostate cancer / / 18264097 rs4242382 chr8 128517573 A G 3.00E-19 Nasopharyngeal carcinoma / / 20512145 rs4242382 chr8 128517573 A G 2.87E-04 Insulin resistance / / 21901158 rs4242382 chr8 128517573 A G 2.93E-13 Prostate cancer / / 22923026 rs4242382 chr8 128517573 A G 1.30E-17 Prostate cancer / / 23555315 rs4242382 chr8 128517573 A G 1.70E-14 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs4242384 chr8 128518554 C A 1.13E-18 Prostate cancer / / 18264096 rs4242384 chr8 128518554 C A 3.00E-16 Prostate cancer / / 18264097 rs4242384 chr8 128518554 C A 2.00E-24 Prostate cancer / / 19767753 rs4242384 chr8 128518554 C A 2.00E-24 Nasopharyngeal carcinoma / / 20512145 rs4242384 chr8 128518554 C A 3.00E-16 Prostate cancer / / 21743057 rs4242384 chr8 128518554 C A 7.37E-13 Prostate cancer / / 22923026 rs4242384 chr8 128518554 C A 0.0000019 Prostate cancer (advanced) / / 23555315 rs4242384 chr8 128518554 C A 1.00E-16 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs4242384 chr8 128518554 C A 6.80E-21 Prostate cancer / / 23555315 rs4242384 chr8 128518554 C A 2.98E-05 Prostate cancer / / pha002877 rs10099413 chr8 128522063 T C 8.44E-04 Type 2 diabetes / / 17463246 rs7017300 chr8 128525268 C A 3.67E-13 Prostate cancer / / 18264096 rs7017300 chr8 128525268 C A 2.20E-11 Prostate cancer / / 18264097 rs7004374 chr8 128525985 T C 1.10E-05 Urinary metabolites / / 21572414 rs11988857 chr8 128531873 G A 8.69E-16 Prostate cancer / / 18264096 rs11988857 chr8 128531873 G A 1.80E-13 Prostate cancer / / 18264097 rs11988857 chr8 128531873 G A 2.85E-05 Prostate cancer / / pha002877 rs10090154 chr8 128532137 T C 3.00E-06 Prostate cancer / / 22923026 rs9656816 chr8 128534654 G A 4.34E-13 Prostate cancer / / 18264096 rs9656816 chr8 128534654 G A 2.10E-14 Prostate cancer / / 18264097 rs12542685 chr8 128537583 A T 7.24E-05 Prostate cancer / / 18264096 rs7837688 chr8 128539360 T G 1.89E-15 Prostate cancer / / 17401363 rs7837688 chr8 128539360 T G 4.63E-17 Prostate cancer / / 18264096 rs7837688 chr8 128539360 T G 5.90E-17 Prostate cancer / / 18264097 rs7837688 chr8 128539360 T G 1.00E-25 Prostate cancer / / 20676098 rs7837688 chr8 128539360 T G 9.15E-13 Prostate cancer / / 22923026 rs7837688 chr8 128539360 T G 0.000000015 Prostate cancer (advanced) / / 23555315 rs7837688 chr8 128539360 T G 4.50E-17 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs7837688 chr8 128539360 T G 6.80E-22 Prostate cancer / / 23555315 rs6991990 chr8 128545383 C T 5.57E-05 Prostate cancer / / 18264096 rs13258742 chr8 128548678 A G 2.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12680265 chr8 128550416 A C 8.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs6470531 chr8 128559157 C T 1.63E-04 Attention deficit hyperactivity disorder / / pha002875 rs4733739 chr8 128578015 T C 4.90E-06 Urinary metabolites / / 21572414 rs4551307 chr8 128599672 A G 3.59E-05 Osteosarcoma / / 23727862 rs4551307 chr8 128599672 A G 8.22E-04 Osteosarcoma / / 23727862 rs4129666 chr8 128603409 T C 1.40E-05 Esophageal cancer (squamous cell) / / 22960999 rs4451272 chr8 128613730 A G 1.84E-04 Age-related macular degeneration / / 22125219 rs10956376 chr8 128624885 T C 0.00023 Breast cancer early age of onset / / 18463975 rs4133274 chr8 128676131 A G 1.70E-06 Acne (severe teenage) / / 24114350 rs13248513 chr8 128691212 T C 2.02E-06 Acne (severe teenage) / / 24114350 rs6470563 chr8 128708570 T G 7.30E-05 Alzheimer's disease / / 22005930 rs16902328 chr8 128713873 T G 3.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9642880 chr8 128718068 G T 9.00E-12 Urinary bladder cancer / / 18794855 rs9642880 chr8 128718068 G T 7.00E-12 Urinary bladder cancer / / 20348956 rs9642880 chr8 128718068 G T 9.00E-12 Nasopharyngeal carcinoma / / 20512145 rs9642880 chr8 128718068 G T 2.00E-18 Bladder cancer / / 20972438 rs9642880 chr8 128718068 G T 4.00E-38 Bladder cancer / / 24163127 rs9642880 chr8 128718068 G T 6.30E-06 Urinary bladder cancer / / 24861552 rs10094872 chr8 128719884 A T 2.00E-07 Urinary bladder cancer / / 24861552 rs10090430 chr8 128724426 C T 2.60E-07 Multiple complex diseases / / 17554300 rs7462301 chr8 128757350 G A 4.87E-04 Response to alcohol consumption (flushing response) / / 24277619 rs12680047 chr8 128758861 T C 0.0000675 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12680047 chr8 128758861 T C 2.79E-05 Abdominal aortic aneurysm / / 24046328 rs6470572 chr8 128768154 A C 3.95E-05 Intracranial aneurysm / / 20613766 rs6981913 chr8 128775635 T C 5.77E-05 Erythrocyte counts / / pha003099 rs4404878 chr8 128798394 T C 3.02E-05 Pancreatic cancer / / pha002874 rs4404878 chr8 128798394 T C 1.19E-05 Pancreatic cancer / / pha002889 rs10956390 chr8 128808839 T C 0.0000128 Primary sclerosing cholangitis PVT1 intron 23603763 rs10956390 chr8 128808839 T C 1.61E-04 Pancreatic cancer PVT1 intron pha002874 rs10956390 chr8 128808839 T C 8.66E-06 Pancreatic cancer PVT1 intron pha002889 rs4410871 chr8 128815029 T C 4.85E-04 Premature ovarian failure PVT1 intron 19508998 rs4410871 chr8 128815029 T C 8.00E-09 Multiple sclerosis PVT1 intron 21833088 rs4410871 chr8 128815029 T C 5.00E-10 Allergic sensitization PVT1 intron 23817571 rs7841347 chr8 128818308 A G 1.56E-06 Malignant pleural mesothelioma PVT1 intron 23626673 rs7841347 chr8 128818308 A G 2.60E-05 Malignant pleural mesothelioma PVT1 intron 23626673 rs7841347 chr8 128818308 A G 3.25E-05 Pancreatic cancer PVT1 intron pha002874 rs7841347 chr8 128818308 A G 1.81E-05 Pancreatic cancer PVT1 intron pha002889 rs2392825 chr8 128875820 G A 9.95E-05 Epilepsy (remission after treatment) PVT1 intron 23962720 rs4427136 chr8 128879839 G A 4.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PVT1 intron 20877124 rs6470586 chr8 128888319 T G 1.76E-04 Coronary heart disease PVT1 intron 21971053 rs6470588 chr8 128889371 A C 5.00E-11 Renal cell carcinoma PVT1 intron 24220699 rs6470588 chr8 128889371 A C 1.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PVT1 intron 20877124 rs9656968 chr8 128890261 C A 1.30E-05 Hypertension PVT1 intron pha003042 rs4733579 chr8 128898169 T G 6.34E-04 Coronary heart disease PVT1 intron 21971053 rs10111989 chr8 128901992 T C 4.06E-05 Post-operative nausea and vomiting PVT1 intron 21694509 rs10111989 chr8 128901992 T C 6.63E-04 Coronary heart disease PVT1 intron 21971053 rs16902460 chr8 128920197 G A 3.00E-06 Psychosis (atypical) PVT1 intron 24132900 rs1365371 chr8 128949223 A G 7.00E-05 Type 2 diabetes PVT1 intron 17903298 rs16902485 chr8 128952554 C T 7.11E-04 Multiple complex diseases PVT1 intron 17554300 rs16902486 chr8 128955065 C G 0.00034 Erectile dysfunction after radiotherapy for prostate cancer PVT1 intron 23021708 rs755521 chr8 128978856 A C 2.68E-05 Systemic lupus erythematosus PVT1 intron pha002867 rs752427 chr8 128980008 C T 6.65E-07 Hodgkin's lymphoma PVT1 intron 24149102 rs4733809 chr8 128989292 C T 1.50E-04 Volumetric brain MRI PVT1 intron 17903297 rs4733809 chr8 128989292 C T 2.74E-07 Hodgkin's lymphoma PVT1 intron 24149102 rs16902507 chr8 129001797 G A 1.40E-06 Lipid traits PVT1 intron 21777205 rs10956403 chr8 129007207 A G 8.28E-05 Cognitive test performance PVT1 intron 20125193 rs1529335 chr8 129016347 C T 4.01E-05 Hodgkin's lymphoma PVT1 intron 24149102 rs6470600 chr8 129043045 G A 8.68E-06 Cardiovascular disease PVT1 intron 18179892 rs1532560 chr8 129051940 G A 1.67E-05 Arthritis (juvenile idiopathic) PVT1 intron 22354554 rs2720709 chr8 129058356 G A 2.10E-05 Type 2 diabetes PVT1 intron 17395743 rs2720709 chr8 129058356 G A 5.81E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) PVT1 intron 17982456 rs2720659 chr8 129060804 G A 1.50E-05 Type 2 diabetes PVT1 intron 17395743 rs2720660 chr8 129061242 A G 1.24E-04 Type 2 diabetes PVT1 intron 17395743 rs2720662 chr8 129063021 C T 3.00E-06 Type 2 diabetes PVT1 intron 17395743 rs1499373 chr8 129064665 C G 3.60E-05 Type 2 diabetes PVT1 intron 17395743 rs2648868 chr8 129064808 G A 4.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PVT1 intron 20877124 rs2648875 chr8 129072161 G A 2.00E-06 End-stage renal disease PVT1 intron 17395743 rs2648876 chr8 129072966 A G 9.67E-06 Hodgkin's lymphoma PVT1 intron 24149102 rs2608053 chr8 129075832 T C 1.00E-07 Hodgkin's lymphoma PVT1 intron 21037568 rs2608053 chr8 129075832 T C 1.92E-06 Hodgkin's lymphoma PVT1 intron 24149102 rs13255292 chr8 129076573 C T 0.0000401 Primary sclerosing cholangitis PVT1 intron 23603763 rs13255292 chr8 129076573 C T 9.81E-08 Hodgkin's lymphoma PVT1 intron 24149102 rs2720666 chr8 129083459 G A 6.93E-05 Response to acetaminophen (hepatotoxicity) PVT1 intron 21177773 rs2720667 chr8 129083584 G A 5.73E-05 Response to acetaminophen (hepatotoxicity) PVT1 intron 21177773 rs2720667 chr8 129083584 G A 1.73E-05 Hodgkin's lymphoma PVT1 intron 24149102 rs2020247 chr8 129085013 G C 3.27E-05 Cervical cancer PVT1 intron 24700089 rs17467140 chr8 129093836 T C 9.13E-05 Alzheimer's disease (age of onset) PVT1 intron 22005931 rs17467140 chr8 129093836 T C 2.93E-04 Lymphocyte counts PVT1 intron 22286170 rs1499368 chr8 129094589 C T 4.43E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PVT1 intron 20877124 rs6470602 chr8 129099503 A G 1.01E-05 Hodgkin's lymphoma PVT1 intron 24149102 rs3931283 chr8 129110733 G A 2.52E-04 Type 2 diabetes PVT1 intron 17395743 rs3931281 chr8 129110843 C T 1.09E-04 Gallstones PVT1 intron 17632509 rs2720672 chr8 129117936 A G 6.71E-04 Eye color / / 23118974 rs4733833 chr8 129124831 C A 3.41E-04 Multiple complex diseases / / 17554300 rs5029317 chr8 129126853 T C 8.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1030102 chr8 129126986 G A 8.31E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2160766 chr8 129138663 C T 4.40E-05 Cognitive function / / 24684796 rs2720683 chr8 129142534 T C 5.99E-04 Type 2 diabetes / / 17463246 rs2608041 chr8 129149171 G A 6.96E-04 Type 2 diabetes / / 17463246 rs2608039 chr8 129151648 T C 3.31E-04 Type 2 diabetes / / 17463246 rs2648836 chr8 129167534 C A,G,T 5.10E-05 Cognitive impairment induced by topiramate / / 22091778 rs2608029 chr8 129170126 C G 0.00000314 Primary biliary cirrhosis / / 22936693 rs2608029 chr8 129170126 C G 0.00000485 Primary biliary cirrhosis (anti-mitochondrial antibody positive) / / 22936693 rs2608029 chr8 129170126 C G 0.00000894 Primary biliary cirrhosis in females / / 22936693 rs2648833 chr8 129174099 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2019960 chr8 129192271 T C 1.00E-13 Hodgkin's lymphoma / / 21037568 rs2019960 chr8 129192271 T C 5.00E-09 Multiple sclerosis / / 21833088 rs2019960 chr8 129192271 T C 6.00E-10 Hodgkin's lymphoma / / 24149102 rs2019960 chr8 129192271 T C 7.00E-08 Hodgkin's lymphoma / / 24920014 rs2909239 chr8 129192349 G A 7.33E-05 Cognitive impairment induced by topiramate / / 22091778 rs11780156 chr8 129194641 C T 3.00E-11 Breast cancer / / 23535729 rs1902779 chr8 129198030 A G 7.36E-04 Multiple complex diseases / / 17554300 rs4288340 chr8 129202654 C T 4.21E-04 Type 2 diabetes / / 17463246 rs10505508 chr8 129215924 C T 6.40E-05 Pancreatic cancer / / pha002889 rs6470612 chr8 129218047 A G 2.41E-06 Cognitive impairment induced by topiramate / / 22091778 rs11995854 chr8 129220073 T G 8.00E-06 Obesity-related traits / / 23251661 rs2111565 chr8 129229700 A G 8.94E-04 Type 2 diabetes / / 17463246 rs2111565 chr8 129229700 A G 2.24E-04 HIV-1 viral setpoint / / 17641165 rs2925879 chr8 129230078 G T 1.67E-04 HIV-1 viral setpoint / / 17641165 rs2909246 chr8 129230194 C T 1.80E-04 HIV-1 viral setpoint / / 17641165 rs16902742 chr8 129235447 G A 5.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs7812998 chr8 129238669 G A 5.53E-04 Suicide attempts in bipolar disorder / / 21041247 rs7840538 chr8 129242275 G C 5.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs10505507 chr8 129242801 T C 5.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs10492294 chr8 129246415 T C 4.00E-06 Immunoglobulin A / / 20694011 rs9693045 chr8 129247376 T C 5.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs16902754 chr8 129249103 C A 5.21E-04 Suicide attempts in bipolar disorder / / 21041247 rs2977035 chr8 129249256 A G 2.49E-04 HIV-1 viral setpoint / / 17641165 rs2977035 chr8 129249256 A G 0.000008 Primary sclerosing cholangitis / / 23603763 rs10808568 chr8 129264060 A C 2.20E-05 Celiac disease / / 22057235 rs10808568 chr8 129264060 A C 0.000022 Celiac disease / / 23143596 rs9792269 chr8 129264589 A G 3.00E-09 Celiac disease / / 20190752 rs9792269 chr8 129264589 A G 3.00E-09 Asthma / / 21150878 rs9792269 chr8 129264589 A G 3.28E-09 Celiac disease and Rheumatoid arthritis / / 21383967 rs9792269 chr8 129264589 A G 3.28E-09 Multiple sclerosis / / 22190364 rs4733852 chr8 129269193 T G 6.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4733601 chr8 129269466 A G 1.31E-04 Type 2 diabetes / / 17463246 rs11775199 chr8 129280949 A G 7.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) / / 23934736 rs9886419 chr8 129284351 A G 7.10E-04 Pulmonary function / / 23932459 rs4733859 chr8 129306423 C A 3.80E-05 Prion diseases / / 22210626 rs2142200 chr8 129313171 T G 5.75E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs976226 chr8 129314766 G A 3.00E-04 Epilepsy / / 22116939 rs975730 chr8 129316014 G A 2.00E-08 Celiac disease and Rheumatoid arthritis / / 21383967 rs975730 chr8 129316014 G A 0.00012 Prostate cancer / / 23555315 rs975730 chr8 129316014 G A 0.00029 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs975729 chr8 129316050 T C 7.42E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs4265149 chr8 129351485 C T 5.03E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs7841408 chr8 129412828 A G 3.57E-04 Type 2 diabetes / / 20818381 rs938646 chr8 129418532 C T 3.31E-04 Type 2 diabetes / / 20818381 rs7815944 chr8 129427518 A G 4.00E-07 Atopic dermatitis / / 23042114 rs16902907 chr8 129428900 G A 7.24E-05 Multiple complex diseases / / 17554300 rs6998301 chr8 129435018 C T 4.13E-04 Type 2 diabetes / / 20818381 rs6470627 chr8 129439051 T G 3.32E-05 Self-reported allergy / / 23817569 rs1516969 chr8 129442568 C T 5.09E-04 Type 2 diabetes / / 20818381 rs2037223 chr8 129454952 A G 2.70E-05 Type 2 diabetes / / 17463246 rs10808570 chr8 129463535 A C 3.49E-04 Alcohol dependence / / 20201924 rs4733871 chr8 129464930 T C 1.07E-04 Type 2 diabetes / / 17463246 rs12543535 chr8 129473012 T G 3.41E-04 Type 2 diabetes / / 17463246 rs6470634 chr8 129492753 T G 5.98E-04 Multiple complex diseases / / 17554300 rs17805924 chr8 129514190 A C 3.56E-04 Multiple complex diseases / / 17554300 rs1400485 chr8 129530492 A G 2.42E-04 Multiple complex diseases / / 17554300 rs10089519 chr8 129532118 A G 2.04E-04 Type 2 diabetes / / 17463246 rs10089519 chr8 129532118 A G 3.87E-04 Osteosarcoma / / 23727862 rs1516971 chr8 129542100 T C 1.00E-10 Rheumatoid arthritis / / 24390342 rs1516971 chr8 129542100 T C 3.00E-11 Rheumatoid arthritis / / 24390342 rs10088218 chr8 129543949 G A 7.62E-04 Type 2 diabetes / / 17463246 rs10088218 chr8 129543949 G A 1.86E-04 Multiple complex diseases / / 17554300 rs10088218 chr8 129543949 G A 3.00E-09 Ovarian cancer / / 20852632 rs10088218 chr8 129543949 G A 1.00E-17 Ovarian cancer / / 23535730 rs10088218 chr8 129543949 G A 3.00E-12 Ovarian cancer / / 23535730 rs1516974 chr8 129548134 A G 7.54E-05 Multiple complex diseases / / 17554300 rs1516975 chr8 129548193 T C 4.42E-05 Multiple complex diseases / / 17554300 rs1516976 chr8 129548258 T C 6.41E-04 Type 2 diabetes / / 17463246 rs1516976 chr8 129548258 T C 9.26E-05 Multiple complex diseases / / 17554300 rs17807628 chr8 129551311 T C 7.30E-04 Type 2 diabetes / / 17463246 rs17807628 chr8 129551311 T C 9.94E-05 Multiple complex diseases / / 17554300 rs938651 chr8 129555443 A C 9.03E-04 Type 2 diabetes / / 17463246 rs938651 chr8 129555443 A C 1.21E-04 Multiple complex diseases / / 17554300 rs2011527 chr8 129555532 T C 5.18E-04 Type 2 diabetes / / 17463246 rs2011527 chr8 129555532 T C 8.98E-05 Multiple complex diseases / / 17554300 rs6470637 chr8 129556163 A G 3.86E-04 Type 2 diabetes / / 17463246 rs6470637 chr8 129556163 A G 1.51E-04 Multiple complex diseases / / 17554300 rs6651252 chr8 129567181 T C 2.61E-04 Multiple complex diseases / / 17554300 rs6651252 chr8 129567181 T C 4.00E-18 Crohn's disease / / 21102463 rs6651252 chr8 129567181 T C 1.00E-16 Crohn's disease / / 23128233 rs1561927 chr8 129568078 C T 1.00E-07 Type 2 diabetes / / 24509480 rs10505528 chr8 129640852 G A 4.14E-05 Orofacial clefts / / 22863734 rs1372995 chr8 129642367 T C 1.58E-08 Orofacial clefts / / 19270707 rs16903544 chr8 129645234 T C 0.000448 Facial morphology / / 23028347 rs10956433 chr8 129659764 C T 2.01E-04 Orofacial clefts / / 22863734 rs4236736 chr8 129691246 C A 2.55E-05 Orofacial clefts / / 22863734 rs11783015 chr8 129695009 T C 4.20E-05 Orofacial clefts / / 19270707 rs1367966 chr8 129697564 C T 8.06E-05 Orofacial clefts / / 19270707 rs7015145 chr8 129709285 A G 4.86E-06 Orofacial clefts / / 19270707 rs7015145 chr8 129709285 A G 2.96E-05 Cleft lip / / 20436469 rs7015145 chr8 129709285 A G 3.38E-12 Orofacial clefts / / 22863734 rs6470648 chr8 129716308 G A 8.98E-05 Orofacial clefts / / 22863734 rs1432017 chr8 129736086 C T 1.76E-09 Orofacial clefts / / 19270707 rs9297775 chr8 129736712 C A 1.44E-05 Orofacial clefts / / 19270707 rs9297775 chr8 129736712 C A 1.98E-05 Cleft lip / / 20436469 rs9297775 chr8 129736712 C A 5.92E-12 Orofacial clefts / / 22863734 rs1030608 chr8 129739752 G A 1.69E-05 Orofacial clefts / / 19270707 rs1030608 chr8 129739752 G A 3.43E-07 Orofacial clefts / / 22863734 rs1030609 chr8 129739877 C A 1.70E-05 Orofacial clefts / / 19270707 rs1030609 chr8 129739877 C A 4.49E-07 Orofacial clefts / / 22863734 rs7017882 chr8 129741536 T C 1.27E-04 Gallstones / / 17632509 rs7017882 chr8 129741536 T C 2.70E-05 Urinary metabolites / / 21572414 rs6996786 chr8 129747986 G T 1.44E-05 Orofacial clefts / / 19270707 rs6996786 chr8 129747986 G T 5.70E-05 Cleft lip / / 20436469 rs6996786 chr8 129747986 G T 4.61E-11 Orofacial clefts / / 22863734 rs6991851 chr8 129770388 A C 1.87E-10 Orofacial clefts / / 19270707 rs10110365 chr8 129773535 G A 6.00E-06 Response to methotrexate in juvenile idiopathic arthritis / / 24709693 rs759944 chr8 129787426 A G 1.65E-04 Attention deficit hyperactivity disorder / / pha002875 rs10956445 chr8 129787976 T C 5.00E-07 Response to methotrexate in juvenile idiopathic arthritis / / 24709693 rs4545057 chr8 129789134 A C 7.80E-05 Orofacial clefts / / 19270707 rs4545057 chr8 129789134 A C 1.80E-05 Urinary metabolites / / 21572414 rs4545057 chr8 129789134 A C 2.30E-08 Orofacial clefts / / 22863734 rs4397367 chr8 129791539 A G 1.12E-04 Orofacial clefts / / 22863734 rs7460492 chr8 129791927 G A 7.54E-07 Orofacial clefts / / 19270707 rs4733649 chr8 129798114 C A 7.78E-06 Orofacial clefts / / 19270707 rs7006281 chr8 129800770 A G 8.70E-07 Orofacial clefts / / 19270707 rs1356761 chr8 129805974 G A 4.16E-05 Orofacial clefts / / 19270707 rs2056312 chr8 129807571 C A 5.52E-04 Multiple complex diseases / / 17554300 rs2060145 chr8 129807905 C T 4.15E-04 Type 2 diabetes / / 17463246 rs2060145 chr8 129807905 C T 6.97E-05 Serum metabolites / / 19043545 rs6999288 chr8 129811911 C G 1.65E-04 Type 2 diabetes / / 17463246 rs3857888 chr8 129824861 G C 7.77E-15 Orofacial clefts / / 19270707 rs16903632 chr8 129826559 G A 4.92E-05 Multiple complex diseases / / 17554300 rs6994324 chr8 129832156 T C 6.53E-04 Multiple complex diseases / / 17554300 rs6996572 chr8 129836728 C T 8.26E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs6983287 chr8 129837224 T A 7.77E-05 Cleft lip / / 20436469 rs2395855 chr8 129840739 T C 5.37E-05 Orofacial clefts / / 19270707 rs2395855 chr8 129840739 T C 8.84E-09 Cleft lip / / 20436469 rs2395855 chr8 129840739 T C 7.18E-14 Orofacial clefts / / 22863734 rs4733653 chr8 129844671 C T 6.12E-05 Orofacial clefts / / 19270707 rs4733653 chr8 129844671 C T 9.84E-09 Orofacial clefts / / 22863734 rs10956448 chr8 129854369 G A 1.99E-05 Type 2 diabetes / / 17463246 rs10216909 chr8 129855465 G A 4.31E-05 Multiple complex diseases / / 17554300 rs17240568 chr8 129861680 G A 2.34E-05 Type 2 diabetes / / 17463246 rs873761 chr8 129863533 T A 4.69E-06 Orofacial clefts / / 19270707 rs17818958 chr8 129864593 C T 1.07E-04 Attention deficit hyperactivity disorder / / pha002875 rs11989880 chr8 129872982 C T 1.99E-06 Orofacial clefts / / 19270707 rs11989880 chr8 129872982 C T 1.19E-05 Cleft lip / / 20436469 rs11989880 chr8 129872982 C T 5.89E-15 Orofacial clefts / / 22863734 rs4733532 chr8 129881299 G A 5.50E-05 Orofacial clefts / / 19270707 rs4733532 chr8 129881299 G A 2.18E-08 Cleft lip / / 20436469 rs4733532 chr8 129881299 G A 2.43E-14 Orofacial clefts / / 22863734 rs10094461 chr8 129887185 C A 4.22E-05 Multiple complex diseases / / 17554300 rs11994831 chr8 129888481 C T 2.88E-09 Orofacial clefts / / 19270707 rs17241253 chr8 129890188 T C 1.11E-23 Orofacial clefts / / 19270707 rs1850889 chr8 129890405 A G 4.02E-05 Orofacial clefts / / 19270707 rs1850889 chr8 129890405 A G 1.12E-10 Cleft lip / / 20436469 rs1850889 chr8 129890405 A G 1.44E-16 Orofacial clefts / / 22863734 rs1155582 chr8 129895021 C G 1.91E-10 Orofacial clefts / / 19270707 rs7815713 chr8 129895473 T C 2.02E-07 Orofacial clefts / / 19270707 rs1519850 chr8 129896821 C T 5.34E-05 Orofacial clefts / / 19270707 rs1519850 chr8 129896821 C T 2.09E-10 Cleft lip / / 20436469 rs1519850 chr8 129896821 C T 3.77E-15 Orofacial clefts / / 22863734 rs1519849 chr8 129896967 T C 5.38E-05 Orofacial clefts / / 19270707 rs1519849 chr8 129896967 T C 1.20E-08 Cleft lip / / 20436469 rs1519849 chr8 129896967 T C 1.49E-14 Orofacial clefts / / 22863734 rs1157136 chr8 129901910 T C 4.18E-06 Orofacial clefts / / 19270707 rs1157136 chr8 129901910 T C 5.11E-06 Cleft lip / / 20436469 rs1157136 chr8 129901910 T C 6.50E-08 Primary tooth development (time to first tooth eruption) / / 23704328 rs10956450 chr8 129902395 C T 3.14E-05 Type 2 diabetes / / 17463246 rs6470670 chr8 129913448 T C 1.22E-06 Orofacial clefts / / 19270707 rs7009139 chr8 129914248 G A 1.22E-11 Orofacial clefts / / 19270707 rs1519847 chr8 129915760 C T 2.42E-05 Orofacial clefts / / 19270707 rs1519847 chr8 129915760 C T 4.61E-13 Cleft lip / / 20436469 rs1519847 chr8 129915760 C T 5.47E-21 Orofacial clefts / / 22863734 rs1530300 chr8 129919458 T C 4.95E-06 Orofacial clefts / / 19270707 rs1530300 chr8 129919458 T C 2.00E-11 Cleft lip / / 20436469 rs1530300 chr8 129919458 T C 6.31E-22 Orofacial clefts / / 22863734 rs1519841 chr8 129919800 T C 1.72E-05 Orofacial clefts / / 19270707 rs1519841 chr8 129919800 T C 7.41E-12 Cleft lip / / 20436469 rs1519841 chr8 129919800 T C 1.80E-20 Orofacial clefts / / 22863734 rs997310 chr8 129920280 C A 1.19E-08 Orofacial clefts / / 19270707 rs12542837 chr8 129926661 T C 2.06E-05 Orofacial clefts / / 19270707 rs12542837 chr8 129926661 T C 2.29E-12 Cleft lip / / 20436469 rs12542837 chr8 129926661 T C 1.02E-20 Orofacial clefts / / 22863734 rs11506137 chr8 129929148 C T 1.51E-12 Orofacial clefts / / 19270707 rs17241866 chr8 129939466 T C 9.08E-05 Orofacial clefts / / 19270707 rs17241908 chr8 129944876 C G 7.82E-04 Multiple complex diseases / / 17554300 rs987525 chr8 129946154 C A 3.00E-24 Orofacial clefts / / 19270707 rs987525 chr8 129946154 C A 9.00E-08 Orofacial clefts / / 19656524 rs987525 chr8 129946154 C A 4.00E-16 Cleft lip / / 20436469 rs987525 chr8 129946154 C A 1.00E-26 Orofacial clefts / / 22863734 rs987525 chr8 129946154 C A 2.00E-11 Orofacial clefts / / 22863734 rs987525 chr8 129946154 C A 5.00E-35 Orofacial clefts / / 22863734 rs987525 chr8 129946154 C A 0.000589 Facial morphology / / 23028347 rs17820135 chr8 129947786 T G 6.03E-14 Orofacial clefts / / 19270707 rs12548036 chr8 129947882 G T 2.08E-06 Orofacial clefts / / 19270707 rs12548036 chr8 129947882 G T 8.20E-12 Cleft lip / / 20436469 rs12548036 chr8 129947882 G T 2.24E-21 Orofacial clefts / / 22863734 rs7012117 chr8 129948108 T C 8.83E-04 Multiple complex diseases / / 17554300 rs12548721 chr8 129948854 C A 2.33E-05 Orofacial clefts / / 19270707 rs10956453 chr8 129949791 G C 4.02E-07 Orofacial clefts / / 19270707 rs12549494 chr8 129950333 C T 1.78E-05 Orofacial clefts / / 19270707 rs1372449 chr8 129950390 G A 1.13E-16 Orofacial clefts / / 19270707 rs7017252 chr8 129950844 C T 6.77E-04 Multiple complex diseases / / 17554300 rs7017252 chr8 129950844 C T 3.22E-07 Orofacial clefts / / 19270707 rs7017252 chr8 129950844 C T 2.31E-10 Cleft lip / / 20436469 rs7017252 chr8 129950844 C T 1.81E-20 Orofacial clefts / / 22863734 rs7815993 chr8 129951769 C T 8.17E-04 Multiple complex diseases / / 17554300 rs7815993 chr8 129951769 C T 2.31E-05 Type 1 diabetes / / 18978792 rs12547241 chr8 129952509 G A 9.94E-07 Orofacial clefts / / 19270707 rs12547241 chr8 129952509 G A 5.52E-09 Cleft lip / / 20436469 rs12547241 chr8 129952509 G A 9.41E-17 Orofacial clefts / / 22863734 rs6995235 chr8 129953936 A G 9.37E-07 Orofacial clefts / / 19270707 rs11784358 chr8 129954008 C T 8.29E-06 Orofacial clefts / / 19270707 rs13265167 chr8 129959316 C T 6.24E-07 Orofacial clefts / / 19270707 rs17242358 chr8 129964873 G A 4.58E-04 Multiple complex diseases / / 17554300 rs17242358 chr8 129964873 G A 1.50E-05 Urinary metabolites / / 21572414 rs1441994 chr8 129969187 T C 3.65E-07 Orofacial clefts / / 19270707 rs12546244 chr8 129970246 G A 4.72E-07 Orofacial clefts / / 19270707 rs16903929 chr8 129970774 A C 3.61E-04 Multiple complex diseases / / 17554300 rs1470206 chr8 129977464 T C 6.67E-06 Orofacial clefts / / 19270707 rs1470206 chr8 129977464 T C 3.74E-10 Cleft lip / / 20436469 rs1470206 chr8 129977464 T C 2.71E-17 Orofacial clefts / / 22863734 rs13274247 chr8 129981468 G A 8.87E-15 Orofacial clefts / / 19270707 rs882083 chr8 129982756 C T 1.60E-08 Orofacial clefts / / 19270707 rs882083 chr8 129982756 C T 2.21E-12 Cleft lip / / 20436469 rs882083 chr8 129982756 C T 6.83E-23 Orofacial clefts / / 22863734 rs894264 chr8 129983232 A T 4.70E-04 Type 2 diabetes / / 17463246 rs11787407 chr8 129985440 A G 4.10E-06 Orofacial clefts / / 19270707 rs11787407 chr8 129985440 A G 2.99E-10 Cleft lip / / 20436469 rs11787407 chr8 129985440 A G 1.39E-18 Orofacial clefts / / 22863734 rs12546523 chr8 129986110 G A 8.73E-07 Orofacial clefts / / 19270707 rs12546523 chr8 129986110 G A 5.24E-10 Cleft lip / / 20436469 rs12546523 chr8 129986110 G A 1.19E-18 Orofacial clefts / / 22863734 rs6990893 chr8 129988219 G A 7.67E-04 Multiple complex diseases / / 17554300 rs7838330 chr8 129993106 T C 2.21E-08 Orofacial clefts / / 19270707 rs2004375 chr8 130002730 C T 1.74E-05 Multiple complex diseases / / 17554300 rs2004375 chr8 130002730 C T 4.91E-11 Orofacial clefts / / 19270707 rs2004375 chr8 130002730 C T 2.95E-11 Orofacial clefts / / 22863734 rs748978 chr8 130003116 G A 4.79E-06 Cleft lip / / 20436469 rs748978 chr8 130003116 G A 1.27E-14 Orofacial clefts / / 22863734 rs766812 chr8 130004704 A G 8.98E-09 Orofacial clefts / / 19270707 rs1441990 chr8 130006472 A G 4.40E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17821251 chr8 130009233 T C 1.15E-13 Orofacial clefts / / 19270707 rs10110974 chr8 130009787 C A 1.26E-06 Orofacial clefts / / 22863734 rs10110974 chr8 130009787 C A 8.29E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2197111 chr8 130015715 A G 4.09E-05 Orofacial clefts / / 19270707 rs2197111 chr8 130015715 A G 1.26E-08 Orofacial clefts / / 22863734 rs7018275 chr8 130016499 C T 4.09E-05 Orofacial clefts / / 19270707 rs7018275 chr8 130016499 C T 1.30E-08 Orofacial clefts / / 22863734 rs7835741 chr8 130017714 T C 7.03E-10 Orofacial clefts / / 19270707 rs10505532 chr8 130021961 A C 3.43E-06 Orofacial clefts / / 22863734 rs1372452 chr8 130029034 A G 9.08E-05 Orofacial clefts / / 19270707 rs1372452 chr8 130029034 A G 5.63E-09 Orofacial clefts / / 22863734 rs12334809 chr8 130031006 T C 9.08E-05 Orofacial clefts / / 19270707 rs12334809 chr8 130031006 T C 5.86E-09 Orofacial clefts / / 22863734 rs7844734 chr8 130042141 T C 4.66E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7844734 chr8 130042141 T C 1.39E-06 Orofacial clefts / / 22863734 rs4487715 chr8 130055981 T C 5.26E-06 Orofacial clefts / / 22863734 rs10808576 chr8 130063971 T G 6.27E-05 Cleft lip / / 20436469 rs10808576 chr8 130063971 T G 2.88E-07 Orofacial clefts / / 22863734 rs11996876 chr8 130087172 T C 1.46E-06 Orofacial clefts / / 19270707 rs11996876 chr8 130087172 T C 3.56E-08 Orofacial clefts / / 22863734 rs11784932 chr8 130095478 C A 1.07E-06 Orofacial clefts / / 22863734 rs4339605 chr8 130112168 T C 2.06E-06 Orofacial clefts / / 22863734 rs6984251 chr8 130117683 C A 5.03E-05 Tunica Media / / pha003036 rs4418312 chr8 130157804 C G 1.05E-05 Orofacial clefts / / 19270707 rs4571700 chr8 130173467 C T 1.10E-05 Orofacial clefts / / 22863734 rs9643245 chr8 130178978 C T 4.77E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3935421 chr8 130203139 A G 4.58E-05 Orofacial clefts / / 19270707 rs3935421 chr8 130203139 A G 4.55E-09 Orofacial clefts / / 22863734 rs4422741 chr8 130211328 T C 5.60E-05 Orofacial clefts / / 19270707 rs4422741 chr8 130211328 T C 6.09E-09 Orofacial clefts / / 22863734 rs4367503 chr8 130220746 T C 8.48E-05 Tunica Media / / pha003036 rs4472475 chr8 130222035 A G 2.96E-09 Orofacial clefts / / 19270707 rs7822386 chr8 130224721 A G 8.69E-05 Orofacial clefts / / 19270707 rs7822386 chr8 130224721 A G 3.33E-07 Orofacial clefts / / 22863734 rs7826130 chr8 130224742 C T 5.12E-09 Orofacial clefts / / 19270707 rs7826294 chr8 130224892 C T 2.76E-09 Orofacial clefts / / 19270707 rs7826688 chr8 130225011 G A 6.02E-05 Orofacial clefts / / 19270707 rs7826688 chr8 130225011 G A 3.22E-07 Orofacial clefts / / 22863734 rs4733688 chr8 130252455 T C 4.61E-04 Type 2 diabetes LOC728724 intron 17463246 rs7846284 chr8 130370235 A G 1.41E-05 Cognitive impairment induced by topiramate / / 22091778 rs7846284 chr8 130370235 A G 0.0000406 Otitis media (children 3 years old or younger) / / 23133572 rs7846684 chr8 130370414 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7846684 chr8 130370414 C T 0.000036 Otitis media (children 3 years old or younger) / / 23133572 rs11990588 chr8 130375804 G A 2.39E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16904056 chr8 130386734 G C 1.81E-04 Attention deficit hyperactivity disorder / / pha002875 rs2568409 chr8 130417624 T G 4.79E-10 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs11783022 chr8 130475638 T C 6.95E-04 Taste perception / / 22132133 rs10464870 chr8 130477823 C T 3.04E-10 Glioma / / 19578367 rs10464870 chr8 130477823 C T 1.49E-11 Glioma / / 21531791 rs12543365 chr8 130483338 C T 0.00006912 Sarcoidosis / / 22952805 rs891835 chr8 130491752 T G 8.00E-11 Glioma / / 19578367 rs891835 chr8 130491752 T G 8.00E-11 Nasopharyngeal carcinoma / / 20512145 rs891835 chr8 130491752 T G 1.54E-12 Glioma / / 21531791 rs1835844 chr8 130500331 C T 0.00006987 Sarcoidosis / / 22952805 rs11786408 chr8 130528077 C A 3.65E-04 Multiple complex diseases / / 17554300 rs4733711 chr8 130545445 G A 4.14E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10505542 chr8 130547253 T C 1.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1025524 chr8 130551963 G A 3.76E-05 Multiple complex diseases / / 17554300 rs10956483 chr8 130572110 G C 2.00E-10 White blood cell types / / 21738478 rs10098310 chr8 130613614 G A 3.00E-20 White blood cell count / / 21738480 rs7005206 chr8 130620813 A G 9.13E-05 Obsessive-compulsive disorder / / 24821223 rs1991866 chr8 130624105 G C 2.00E-09 Inflammatory bowel disease / / 23128233 rs7819128 chr8 130630157 C T 2.23E-05 Post-operative nausea and vomiting / / 21694509 rs4636162 chr8 130639540 G A 2.89E-09 Glioma / / 21531791 rs6470745 chr8 130641921 A G 2.77E-15 Glioma / / 19578367 rs6470745 chr8 130641921 A G 4.02E-17 Glioma / / 21531791 rs10101342 chr8 130643868 G A 3.42E-06 Odorant perception / / 23910658 rs10105319 chr8 130644825 G A 6.37E-04 Multiple complex diseases / / 17554300 rs7018091 chr8 130661901 T G 4.54E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs12544799 chr8 130663510 A G 1.06E-08 Glioma / / 21531791 rs9656979 chr8 130664407 T C 1.08E-06 Glioma / / 19578367 rs9656979 chr8 130664407 T C 6.99E-11 Glioma / / 21531791 rs16904140 chr8 130665643 G A 7.88E-13 Glioma / / 19578367 rs16904140 chr8 130665643 G A 1.87E-14 Glioma / / 21531791 rs9918807 chr8 130676639 T C 5.00E-06 Retinopathy in non-diabetics / / 23393555 rs6985166 chr8 130679176 A G 4.21E-08 Glioma / / 21531791 rs4295627 chr8 130685457 T G 2.00E-18 Glioma / / 19578367 rs4295627 chr8 130685457 T G 2.00E-18 Nasopharyngeal carcinoma / / 20512145 rs4295627 chr8 130685457 T G 5.00E-21 Glioma / / 21531791 rs6470763 chr8 130720646 G C 2.76E-04 Height / / 17255346 rs6470764 chr8 130725665 C T 2.00E-28 Height / / 20881960 rs7461495 chr8 130726025 G A 6.48E-05 Hemoglobin concentration / / 20534544 rs4517087 chr8 130727351 A G 5.00E-04 Osteosarcoma / / 23727862 rs4733731 chr8 130732672 C G 3.65E-04 Multiple complex diseases / / 17554300 rs3885952 chr8 130742744 C T 6.48E-05 Hemoglobin concentration / / 20534544 rs4606023 chr8 130755393 G T 1.84E-04 Hemoglobin concentration / / 20534544 rs4144738 chr8 130760850 A G 1.90E-04 Height GSDMC missense 17255346 rs12681935 chr8 130782993 T C 1.07E-05 Lung function (forced vital capacity) GSDMC intron 24023788 rs1600934 chr8 130786737 A G 1.84E-04 Hemoglobin concentration GSDMC intron 20534544 rs4733741 chr8 130788548 C T 9.00E-05 Major depressive disorder GSDMC intron 21042317 rs2086639 chr8 130809688 T C 2.97E-05 Hemoglobin concentration / / 20534544 rs17276203 chr8 130818030 G C 3.32E-06 Colorectal cancer / / 23266556 rs7014175 chr8 130818636 C G 3.32E-06 Colorectal cancer / / 23266556 rs2128382 chr8 130820039 C T 8.00E-06 Colorectal cancer / / 23266556 rs2170568 chr8 130820375 T A 9.20E-07 Colorectal cancer / / 23266556 rs2128383 chr8 130820635 A G 9.61E-07 Colorectal cancer / / 23266556 rs2894493 chr8 130821049 C T 1.21E-06 Colorectal cancer / / 23266556 rs1482562 chr8 130821073 A C 2.22E-04 Alzheimer's disease (late onset) / / 21379329 rs7006896 chr8 130822194 G A 1.00E-06 Colorectal cancer / / 23266556 rs1825225 chr8 130827576 C A 6.38E-05 Alzheimer's disease (late onset) / / 21379329 rs365713 chr8 130834025 T C 6.27E-05 Alzheimer's disease (late onset) / / 21379329 rs10109713 chr8 130837943 T C 2.46E-04 Colorectal cancer / / 23266556 rs11994702 chr8 130844400 C A 0.00000933 Follicular lymphoma / / 23025665 rs298622 chr8 130849731 A G 4.44E-05 Relative hand skill in reading disability / / 24068947 rs439184 chr8 130864813 G T 6.45E-05 Relative hand skill in reading disability FAM49B intron 24068947 rs2306528 chr8 130868061 G T 3.66E-05 Colorectal cancer FAM49B intron 23266556 rs11783021 chr8 130868212 G A 2.68E-04 HIV-1 viral setpoint FAM49B intron 17641165 rs837083 chr8 130868363 C T 6.60E-05 Relative hand skill in reading disability FAM49B intron 24068947 rs10956502 chr8 130880015 T G 2.25E-05 Longevity FAM49B intron 21612516 rs10956502 chr8 130880015 T G 1.58E-05 Colorectal cancer FAM49B intron 23266556 rs16904166 chr8 130882869 C T 1.58E-05 Colorectal cancer FAM49B intron 23266556 rs4395866 chr8 130885528 A G 1.55E-05 Colorectal cancer FAM49B intron 23266556 rs2086641 chr8 130901909 T C 1.00E-05 Colorectal cancer FAM49B intron 23266556 rs2624810 chr8 130921162 T C 5.98E-05 Relative hand skill in reading disability FAM49B intron 24068947 rs2624809 chr8 130927424 A G 6.07E-05 Relative hand skill in reading disability FAM49B intron 24068947 rs4733750 chr8 130939125 A G 2.01E-05 Migraine FAM49B intron 23793025 rs4733750 chr8 130939125 A G 4.14E-05 Glucose levels FAM49B intron pha003061 rs16904179 chr8 130958951 G A 7.00E-07 Post-traumatic stress disorder (asjusted for relatedness) FAM49B intron 23726511 rs837224 chr8 130971985 G A 8.65E-05 Serum metabolites FAM49B intron 19043545 rs837224 chr8 130971985 G A 3.26E-05 Relative hand skill in reading disability FAM49B intron 24068947 rs10092658 chr8 130980472 C T 6.00E-06 Protein quantitative trait loci FAM49B intron 18464913 rs837231 chr8 130987888 C T 1.64E-04 HIV-1 viral setpoint FAM49B intron 17641165 rs16904185 chr8 130991818 T G 1.57E-04 Multiple complex diseases FAM49B intron 17554300 rs1812141 chr8 130994861 C T 1.06E-04 Multiple complex diseases FAM49B intron 17554300 rs921693 chr8 131005011 G A 2.11E-04 Multiple complex diseases FAM49B intron 17554300 rs6470789 chr8 131015276 A G 2.58E-04 Blood pressure FAM49B intron 17255346 rs750677 chr8 131031801 C G 8.21E-04 Depression (quantitative trait) / / 20800221 rs16904191 chr8 131033496 A G 2.00E-07 Migraine / / 23793025 rs4733566 chr8 131033928 G T 6.24E-04 Depression (quantitative trait) / / 20800221 rs7463674 chr8 131034911 A T 6.19E-04 Depression (quantitative trait) / / 20800221 rs6470790 chr8 131038848 A G 5.78E-04 Depression (quantitative trait) / / 20800221 rs6470791 chr8 131039109 T C 6.12E-04 Depression (quantitative trait) / / 20800221 rs10087217 chr8 131042009 C T 5.50E-04 Multiple complex diseases / / 17554300 rs11774834 chr8 131045893 T C 4.04E-04 Alzheimer's disease / / 22005930 rs11774917 chr8 131046123 T C 4.30E-04 Alzheimer's disease / / 22005930 rs7840640 chr8 131049778 T A 5.33E-05 Multiple complex diseases / / 17554300 rs11774067 chr8 131054622 C T 4.17E-04 Alzheimer's disease / / 22005930 rs10106205 chr8 131080411 T C 3.68E-04 Alzheimer's disease ASAP1 intron 22005930 rs11774131 chr8 131089774 C T 3.39E-04 Alzheimer's disease ASAP1 intron 22005930 rs6984045 chr8 131092413 T C 2.00E-06 Multiple sclerosis ASAP1 intron 19525955 rs13269464 chr8 131099982 C T 3.52E-04 Suicide attempts in bipolar disorder ASAP1 intron 21423239 rs13269464 chr8 131099982 C T 4.43E-04 Alzheimer's disease ASAP1 intron 22005930 rs6470800 chr8 131100960 G T 5.48E-04 Alzheimer's disease ASAP1 intron 22005930 rs10113410 chr8 131101643 G A 2.98E-04 Alzheimer's disease ASAP1 intron 22005930 rs11779191 chr8 131105046 G A 3.21E-04 Alzheimer's disease ASAP1 intron 22005930 rs11782883 chr8 131105414 T C 3.21E-04 Alzheimer's disease ASAP1 intron 22005930 rs7003568 chr8 131110092 G A 3.20E-04 Alzheimer's disease ASAP1 intron 22005930 rs6992305 chr8 131115087 G A 6.79E-04 Suicide attempts in bipolar disorder ASAP1 intron 21423239 rs6992305 chr8 131115087 G A 8.04E-04 Alzheimer's disease ASAP1 intron 22005930 rs11783860 chr8 131115354 C T 3.18E-04 Alzheimer's disease ASAP1 intron 22005930 rs4639572 chr8 131118658 T C 4.20E-05 Creatinine levels ASAP1 intron 20222955 rs4639572 chr8 131118658 T C 3.16E-04 Alzheimer's disease ASAP1 intron 22005930 rs6470802 chr8 131129442 T C 8.15E-04 Suicide attempts in bipolar disorder ASAP1 intron 21423239 rs13249018 chr8 131133695 G A 2.58E-04 Suicide attempts in bipolar disorder ASAP1 intron 21423239 rs7004884 chr8 131135269 A G 9.37E-04 Alcohol dependence ASAP1 intron 21314694 rs6470805 chr8 131161571 A G 8.60E-05 Systemic sclerosis ASAP1 intron 21750679 rs11782152 chr8 131168522 C T 7.35E-04 Alzheimer's disease ASAP1 intron 22005930 rs7464885 chr8 131179235 C T 9.24E-04 Alzheimer's disease ASAP1 intron 22005930 rs10095984 chr8 131188265 T C 8.13E-04 Suicide attempts in bipolar disorder ASAP1 intron 21423239 rs11777289 chr8 131189298 T C 2.25E-05 Diabetes Mellitus ASAP1 intron pha003059 rs7012705 chr8 131189480 C A 1.66E-04 Alzheimer's disease ASAP1 intron 22005930 rs11774690 chr8 131190498 C G 6.01E-04 Alzheimer's disease ASAP1 intron 22005930 rs1118887 chr8 131202021 A T 4.57E-04 Alzheimer's disease ASAP1 intron 22005930 rs17282526 chr8 131207943 T C 3.87E-04 Suicide attempts in bipolar disorder ASAP1 intron 21423239 rs17282526 chr8 131207943 T C 7.34E-04 Alzheimer's disease ASAP1 intron 22005930 rs876575 chr8 131210851 A G 8.59E-04 Alzheimer's disease ASAP1 intron 22005930 rs4733775 chr8 131213570 G A 4.66E-04 Alzheimer's disease ASAP1 intron 22005930 rs2114196 chr8 131225299 G A 6.90E-04 Alzheimer's disease ASAP1 intron 22005930 rs1469288 chr8 131226652 G A 6.79E-04 Alzheimer's disease ASAP1 intron 22005930 rs7834461 chr8 131243949 T C 7.95E-04 Suicide attempts in bipolar disorder ASAP1 intron 21423239 rs2554374 chr8 131256398 T C 2.88E-04 Alzheimer's disease ASAP1 intron 22005930 rs4733777 chr8 131271562 C T 5.75E-04 Alzheimer's disease ASAP1 intron 22005930 rs7839523 chr8 131281826 G T 4.86E-05 Systemic sclerosis ASAP1 intron 21750679 rs17284725 chr8 131282724 A T 6.47E-04 Alzheimer's disease ASAP1 intron 22005930 rs4733571 chr8 131290664 T G 8.92E-04 Alzheimer's disease ASAP1 intron 22005930 rs11778881 chr8 131291187 T C 5.81E-06 Diabetes Mellitus ASAP1 intron pha003059 rs2912194 chr8 131298189 C G 2.38E-04 Suicide attempts in bipolar disorder ASAP1 intron 21423239 rs7839155 chr8 131318869 G A 5.16E-04 Alzheimer's disease ASAP1 intron 22005930 rs7817803 chr8 131319822 A C 4.73E-05 Systemic sclerosis ASAP1 intron 21750679 rs3057 chr8 131329837 C T 2.09E-05 Systemic sclerosis ASAP1 intron 21750679 rs9643252 chr8 131332667 G A 4.40E-04 Alzheimer's disease ASAP1 intron 22005930 rs16904252 chr8 131359644 G A 2.84E-04 Tourette syndrome ASAP1 intron 22889924 rs11778712 chr8 131391700 T C 6.94E-04 Alzheimer's disease ASAP1 intron 22005930 rs7844582 chr8 131391874 T C 4.42E-04 Amyotrophic lateral sclerosis (sporadic) ASAP1 intron 24529757 rs7836273 chr8 131393919 C T 6.75E-04 Alzheimer's disease ASAP1 intron 22005930 rs11784988 chr8 131408709 T C 5.73E-04 Alzheimer's disease ASAP1 intron 22005930 rs11785806 chr8 131409414 T A 5.72E-04 Alzheimer's disease ASAP1 intron 22005930 rs11776262 chr8 131410381 A C 6.19E-04 Alzheimer's disease ASAP1 intron 22005930 rs112765450 chr8 131436649 G A 4.14E-05 Cocaine dependence ASAP1 intron 23958962 rs10956525 chr8 131442851 T C 2.40E-05 Alcoholism (heaviness of drinking) ASAP1 intron 21529783 rs74676837 chr8 131458654 A G 4.18E-05 Cocaine dependence / / 23958962 rs7461215 chr8 131458713 G T 5.19E-04 Smoking initiation / / 24665060 rs10956526 chr8 131467319 G A 4.46E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs868104 chr8 131469692 T C 1.49E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs11774901 chr8 131481319 C T 2.52E-04 Alzheimer's disease / / 22005930 rs11774901 chr8 131481319 C T 6.57E-05 Insulin Resistance / / pha003062 rs7386933 chr8 131504525 G C 5.87E-04 Alzheimer's disease / / 22005930 rs9297810 chr8 131512902 C T 2.28E-05 Bone mineral density / / 19181680 rs10087780 chr8 131517071 T C 8.28E-04 Parkinson's disease / / 17052657 rs7001278 chr8 131517830 G T 8.66E-04 Type 2 diabetes / / 17463246 rs6983828 chr8 131518268 T C 0.0000129 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4529483 chr8 131519202 A G 6.41E-04 Parkinson's disease / / 17052657 rs7835480 chr8 131524621 A G 3.03E-04 Alzheimer's disease / / 17998437 rs10505550 chr8 131528150 G T 4.12E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6981998 chr8 131553214 T G 4.30E-06 Parkinson's disease / / 20711177 rs10956535 chr8 131554761 C T 5.05E-04 Alzheimer's disease / / 22005930 rs13278484 chr8 131555334 G C 1.03E-04 Alzheimer's disease / / 22005930 rs7015252 chr8 131555749 C A 5.09E-04 Alzheimer's disease / / 22005930 rs11994262 chr8 131586429 C T 6.13E-04 Rheumatoid arthritis / / 21452313 rs4397423 chr8 131601975 T A 7.96E-04 Alzheimer's disease / / 17998437 rs10097381 chr8 131604211 C G 9.14E-04 Alzheimer's disease / / 17998437 rs16904316 chr8 131617850 C T 8.14E-15 Multiple complex diseases / / 17554300 rs16904316 chr8 131617850 C T 2.00E-06 Methotrexate phramacokinetics (acute lymphoblastic leukemia) / / 19901119 rs6470831 chr8 131641096 G A 9.23E-04 Multiple complex diseases / / 17554300 rs4236889 chr8 131653407 A G 4.67E-04 Multiple complex diseases / / 17554300 rs10505560 chr8 131744988 T C 7.40E-04 Alcohol dependence / / 21314694 rs6990380 chr8 131780149 G A 5.21E-04 Type 2 diabetes / / 17463246 rs6990427 chr8 131780227 G C 3.99E-04 Type 2 diabetes / / 17463246 rs10097218 chr8 131780258 T C 9.03E-04 Type 2 diabetes / / 17463246 rs963215 chr8 131802718 G A 8.12E-04 Schizophrenia ADCY8 intron 21674006 rs263232 chr8 131808169 C A 6.00E-07 Post-traumatic stress disorder ADCY8 intron 24677629 rs263238 chr8 131812033 G A 2.00E-06 Total ventricular volume ADCY8 intron 21116278 rs2917065 chr8 131814885 T C 5.57E-06 Total ventricular volume ADCY8 intron 21116278 rs17324385 chr8 131819444 T C 7.20E-05 Electrocardiographic conduction measures ADCY8 intron 19389651 rs17324385 chr8 131819444 T C 5.15E-05 Lupus nephritis in systemic lupus erythematosus ADCY8 intron 24925725 rs1435446 chr8 131826621 G A 3.60E-05 Electrocardiographic conduction measures ADCY8 intron 19389651 rs1396980 chr8 131842636 C T 6.68E-04 Response to cytidine analogues (gemcitabine) ADCY8 intron 24483146 rs10108431 chr8 131843238 A G 8.55E-04 Multiple complex diseases ADCY8 intron 17554300 rs3914071 chr8 131855192 T C 3.00E-04 Multiple complex diseases ADCY8 intron 17554300 rs263242 chr8 131862304 T C 7.74E-04 Smoking initiation ADCY8 intron 24665060 rs263239 chr8 131865018 A G 8.13E-04 Coronary heart disease ADCY8 intron 21606135 rs263239 chr8 131865018 A G 6.20E-05 Smoking initiation ADCY8 intron 24665060 rs448852 chr8 131865742 A G 3.04E-05 Femoral neck bone geometry ADCY8 intron 22087292 rs448852 chr8 131865742 A G 5.09E-04 Smoking initiation ADCY8 intron 24665060 rs4130328 chr8 131895923 A G 3.91E-04 Myocardial Infarction ADCY8 intron pha002873 rs6997554 chr8 131945428 T C 1.15E-04 Type 2 diabetes ADCY8 intron 17463246 rs7815277 chr8 131960656 T C 5.54E-04 Fibrinogen ADCY8 intron 17255346 rs12156272 chr8 131972500 C A 4.00E-04 Dietary macronutrient intake ADCY8 intron 23636237 rs17327900 chr8 132000828 G A 8.96E-04 Multiple complex diseases ADCY8 intron 17554300 rs3750889 chr8 132002334 C T 3.68E-05 stroke (ischemic) ADCY8 intron 17434096 rs7845934 chr8 132019515 T C 7.24E-06 Multiple complex diseases ADCY8 intron 17554300 rs1023096 chr8 132035562 C T 6.74E-06 stroke (ischemic) ADCY8 intron 17434096 rs10505568 chr8 132037550 A C 1.30E-05 Urinary metabolites ADCY8 intron 21572414 rs3829210 chr8 132054152 G A 2.07E-05 Response to methotrexate in juvenile idiopathic arthritis / / 24709693 rs7008202 chr8 132074410 C A 9.65E-06 stroke (ischemic) / / 17434096 rs10505569 chr8 132082752 A G 7.61E-04 Multiple complex diseases / / 17554300 rs6980475 chr8 132133864 C A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10099194 chr8 132145040 T C 1.56E-04 Multiple complex diseases / / 17554300 rs4736745 chr8 132163574 G T 4.79E-05 Multiple complex diseases / / 17554300 rs10956576 chr8 132164319 T C 1.02E-04 Attention deficit hyperactivity disorder / / 22420046 rs4736471 chr8 132178085 A G 2.20E-05 Urinary metabolites / / 21572414 rs9785107 chr8 132188511 G A 4.13E-04 Multiple complex diseases / / 17554300 rs11993359 chr8 132235416 C G 1.81E-04 Multiple complex diseases / / 17554300 rs6470909 chr8 132250643 A G 6.10E-05 Multiple complex diseases / / 17554300 rs7461567 chr8 132272181 A C 1.58E-04 Type 2 diabetes / / 17463246 rs7461567 chr8 132272181 A C 4.70E-04 Obesity (extreme) / / 21935397 rs7837225 chr8 132284746 C T 5.30E-04 Obesity (extreme) / / 21935397 rs4736771 chr8 132285068 G A 5.37E-04 Obesity (extreme) / / 21935397 rs4513159 chr8 132292590 T C 1.15E-04 Type 2 diabetes / / 17463246 rs4513159 chr8 132292590 T C 6.67E-04 Obesity (extreme) / / 21935397 rs4527077 chr8 132292717 C A 6.65E-04 Obesity (extreme) / / 21935397 rs10102742 chr8 132304508 T C 6.97E-04 Obesity (extreme) / / 21935397 rs4380914 chr8 132311479 G A 1.20E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4344053 chr8 132317480 T G 7.46E-07 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10108033 chr8 132330716 T C 1.00E-06 IgG glycosylation / / 23382691 rs10108033 chr8 132330716 T C 3.00E-06 IgG glycosylation / / 23382691 rs4260876 chr8 132353414 C G 1.30E-05 Urinary metabolites / / 21572414 rs4596632 chr8 132353735 G A 5.40E-06 Urinary metabolites / / 21572414 rs4596632 chr8 132353735 G A 3.00E-06 Eye color / / 23118974 rs6470954 chr8 132366068 C A 6.42E-04 Multiple complex diseases / / 17554300 rs7837961 chr8 132375417 G A 4.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7840042 chr8 132398682 C T 2.30E-05 Urinary metabolites / / 21572414 rs6991824 chr8 132399833 C A 2.08E-04 Multiple complex diseases / / 17554300 rs1430317 chr8 132441048 T C 3.60E-06 Sickle cell anemia (severity) / / 20029952 rs1346811 chr8 132455575 A T 8.99E-04 Alzheimer's disease / / 17998437 rs273393 chr8 132469052 A G 5.10E-04 Alzheimer's disease / / 24755620 rs10505574 chr8 132472102 A G 8.34E-04 Type 2 diabetes / / 17846124 rs715969 chr8 132473863 A C 2.09E-05 Schizophrenia / / 19197363 rs16904454 chr8 132475200 C T 2.96E-04 Type 2 diabetes / / 17463246 rs10481187 chr8 132479119 G T 8.85E-04 Type 2 diabetes / / 17463246 rs273429 chr8 132479901 C T 1.35E-08 B cell non-Hodgkin lymphoma / / 23749188 rs1395804 chr8 132510680 C T 3.08E-04 Cognitive decline / / 23732972 rs273403 chr8 132511008 G A 5.65E-04 Type 2 diabetes / / 17463246 rs273413 chr8 132531794 G A 7.24E-05 Epilepsy / / 22116939 rs13275290 chr8 132567154 G A 8.21E-04 Alcohol dependence / / 20201924 rs10505576 chr8 132593787 A G 7.35E-04 Type 2 diabetes / / 17846125 rs277047 chr8 132627248 T C 4.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs41528648 chr8 132680422 A G 4.26E-04 Multiple complex diseases / / 17554300 rs1035189 chr8 132682208 G A 6.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17636779 chr8 132711423 G A 5.25E-05 Serum metabolites / / 19043545 rs529894 chr8 132718006 A G 1.78E-05 Orofacial clefts / / 22419666 rs491614 chr8 132719817 C T 4.75E-04 Alzheimer's disease / / 24755620 rs12680149 chr8 132720242 A T 2.31E-04 Multiple complex diseases / / 17554300 rs568950 chr8 132731792 C A 6.99E-04 Rheumatoid arthritis / / 21452313 rs7815383 chr8 132828062 T C 2.01E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs11779646 chr8 132852096 G A 8.09E-05 Parkinson's disease (motor and cognition) / / 22658654 rs11779646 chr8 132852096 G A 8.09E-05 Immune response to anthrax vaccine / / 22658931 rs7832443 chr8 132886443 A G 9.00E-06 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs4388438 chr8 132886840 T C 5.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1995317 chr8 132897862 T C 8.78E-05 Type 2 diabetes / / 17463246 rs12681074 chr8 132910350 A G 4.16E-05 Type 2 diabetes / / 17463246 rs1392872 chr8 132921441 A G 3.74E-04 Amyotrophic lateral sclerosis (sporadic) EFR3A intron 24529757 rs7834499 chr8 132925632 T C 5.40E-04 Type 2 diabetes EFR3A intron 17463246 rs4546642 chr8 132943652 T C 3.84E-04 Type 2 diabetes EFR3A intron 17463246 rs10112200 chr8 132953350 A G 7.85E-05 Lung adenocarcinoma EFR3A intron 19836008 rs9297837 chr8 132958609 A T 6.46E-05 Type 2 diabetes EFR3A intron 17463246 rs16904557 chr8 132966522 A C 1.62E-04 Type 2 diabetes EFR3A intron 17463246 rs16904562 chr8 132985598 G A 7.52E-04 Multiple complex diseases EFR3A intron 17554300 rs2270875 chr8 132999936 A G 9.00E-06 Response to cholinesterase inhibitors in Alzheimer's disease EFR3A cds-synon 23374588 rs4736529 chr8 133023163 G C 5.97E-04 Coronary Artery Disease EFR3A UTR-3 17634449 rs7004288 chr8 133029287 G A 1.46E-04 Type 2 diabetes / / 17463246 rs12542759 chr8 133034837 T G 3.48E-05 Serum metabolites / / 19043545 rs12542759 chr8 133034837 T G 3.97E-06 Smooth-surface caries / / 24556642 rs7007220 chr8 133034922 C T 9.98E-05 Serum metabolites / / 19043545 rs7007939 chr8 133035196 G A 2.30E-05 Serum metabolites / / 19043545 rs7007939 chr8 133035196 G A 4.11E-06 Smooth-surface caries / / 24556642 rs4736532 chr8 133047768 C T 2.54E-04 Multiple complex diseases OC90 intron 17554300 rs10808596 chr8 133047995 G A 2.40E-04 Multiple complex diseases OC90 intron 17554300 rs1472571 chr8 133048593 C T 3.44E-04 Multiple complex diseases OC90 intron 17554300 rs2102103 chr8 133051551 C T 2.26E-04 Multiple complex diseases OC90 intron 17554300 rs16904581 chr8 133067537 G A 9.80E-05 Personality dimensions OC90 intron 18957941 rs16904581 chr8 133067537 G A 7.40E-04 Suicide attempts in bipolar disorder OC90 intron 21423239 rs2014357 chr8 133103290 T C 9.00E-07 Common traits (Other) HHLA1 intron 20585627 rs10111409 chr8 133118482 G A 9.40E-05 HIV-1 control / / 20041166 rs2403732 chr8 133122898 G T 1.70E-05 Urinary metabolites / / 21572414 rs2403735 chr8 133123041 T G 1.70E-05 Urinary metabolites / / 21572414 rs2469634 chr8 133130867 C T 7.52E-04 Multiple complex diseases / / 17554300 rs1437821 chr8 133133080 C T 9.83E-04 Multiple complex diseases KCNQ3 nearGene-3 17554300 rs16904603 chr8 133142973 C T 1.60E-05 Urinary metabolites KCNQ3 intron 21572414 rs2469517 chr8 133156438 A G 6.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNQ3 intron 20877124 rs2469518 chr8 133156467 G A 0.00000706 Alcohol craving with or without dependence KCNQ3 intron 22481050 rs1864772 chr8 133157285 T C 6.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNQ3 intron 20877124 rs1864773 chr8 133158041 A G 6.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNQ3 intron 20877124 rs1595411 chr8 133159425 G A 5.89E-04 Alcohol dependence KCNQ3 intron 20201924 rs1595411 chr8 133159425 G A 0.0000312 Alcohol craving with or without dependence KCNQ3 intron 22481050 rs1991718 chr8 133161324 C T 8.07E-04 Alcohol dependence KCNQ3 intron 20201924 rs1991718 chr8 133161324 C T 0.000016 Alcohol craving with or without dependence KCNQ3 intron 22481050 rs4266631 chr8 133208522 C G 1.90E-05 Urinary metabolites KCNQ3 intron 21572414 rs4388439 chr8 133208622 A G 1.90E-05 Urinary metabolites KCNQ3 intron 21572414 rs17654436 chr8 133209163 C G 7.57E-05 Multiple complex diseases KCNQ3 intron 17554300 rs16904624 chr8 133209243 T C 1.90E-05 Urinary metabolites KCNQ3 intron 21572414 rs17596332 chr8 133250021 G C 6.98E-04 Multiple complex diseases KCNQ3 intron 17554300 rs2403737 chr8 133256442 T C 7.98E-05 Bipolar disorder KCNQ3 intron 18317468 rs1078332 chr8 133260692 G A 2.82E-04 Heart Failure KCNQ3 intron pha002884 rs726576 chr8 133279873 C T 6.63E-05 Bipolar disorder KCNQ3 intron 18317468 rs13258436 chr8 133283634 T C 1.60E-05 Urinary metabolites KCNQ3 intron 21572414 rs2896655 chr8 133284974 G A 6.50E-06 Dietary macronutrient intake KCNQ3 intron 23372041 rs4642625 chr8 133297193 T A 6.25E-05 Bipolar disorder KCNQ3 intron 18317468 rs7818112 chr8 133309703 A C 1.80E-05 Urinary metabolites KCNQ3 intron 21572414 rs7818112 chr8 133309703 A C 5.24E-04 Smoking initiation KCNQ3 intron 24665060 rs1457783 chr8 133313239 T C 3.27E-04 Lung function (forced expiratory volume in 1 second) KCNQ3 intron 24023788 rs1457784 chr8 133313335 C A 1.72E-05 C-Reactive Protein KCNQ3 intron pha003070 rs9649969 chr8 133337663 T G 6.64E-04 Heart Failure KCNQ3 intron pha002884 rs7819140 chr8 133349985 C A 7.70E-04 Smoking cessation KCNQ3 intron 24665060 rs1020740 chr8 133350326 T C 6.01E-04 Coronary Artery Disease KCNQ3 intron 17634449 rs1020740 chr8 133350326 T C 4.62E-05 Cognitive impairment induced by topiramate KCNQ3 intron 22091778 rs978152 chr8 133369094 C G 8.00E-06 Coronary artery calcification KCNQ3 intron 23870195 rs7820317 chr8 133374822 G A 2.77E-05 Alzheimer's disease (late onset) KCNQ3 intron 21379329 rs7821360 chr8 133375731 C T 2.00E-04 Bipolar disorder KCNQ3 intron 18317468 rs2100648 chr8 133377392 C T 7.36E-04 Type 2 diabetes KCNQ3 intron 17463246 rs2100646 chr8 133377440 C T 8.21E-05 Hemoglobin KCNQ3 intron pha003098 rs6992843 chr8 133382498 T C 9.48E-05 Hemoglobin KCNQ3 intron pha003098 rs1457785 chr8 133396175 G A 9.34E-05 Erythrocyte counts KCNQ3 intron pha003101 rs2673567 chr8 133397127 G T 4.30E-04 Alzheimer's disease (late onset) KCNQ3 intron 21379329 rs2597357 chr8 133401831 A G 2.84E-04 Alzheimer's disease (late onset) KCNQ3 intron 21379329 rs2673606 chr8 133409932 C T 2.64E-04 Alzheimer's disease (late onset) KCNQ3 intron 21379329 rs2673604 chr8 133411607 C A 4.07E-06 Alzheimer's disease (late onset) KCNQ3 intron 21379329 rs2721900 chr8 133414630 C T 2.59E-05 Alzheimer's disease (late onset) KCNQ3 intron 21379329 rs2673562 chr8 133416556 G T 9.02E-06 Alzheimer's disease (late onset) KCNQ3 intron 21379329 rs2673593 chr8 133444342 T G 3.94E-06 Height KCNQ3 intron pha003010 rs12549298 chr8 133456657 T A 1.00E-05 Urinary metabolites KCNQ3 intron 21572414 rs2721907 chr8 133463627 G A 2.55E-04 Stroke KCNQ3 intron pha002886 rs2597348 chr8 133471941 C T 3.23E-04 Coronary heart disease KCNQ3 intron 21606135 rs2597348 chr8 133471941 C T 1.63E-05 Brain derived neurotrophic factor levels,in serum KCNQ3 intron 22047184 rs2403775 chr8 133472362 A G 3.36E-04 Coronary heart disease KCNQ3 intron 21606135 rs2403775 chr8 133472362 A G 1.86E-05 Brain derived neurotrophic factor levels,in serum KCNQ3 intron 22047184 rs2673586 chr8 133472585 A G 2.60E-05 Urinary metabolites KCNQ3 intron 21572414 rs2673555 chr8 133476806 T C 7.14E-04 Multiple complex diseases KCNQ3 intron 17554300 rs2673556 chr8 133476930 G C 3.80E-04 Coronary heart disease KCNQ3 intron 21606135 rs2167171 chr8 133487525 C A 8.55E-04 Alzheimer's disease KCNQ3 intron 24755620 rs3914483 chr8 133504481 G C 9.49E-04 Alzheimer's disease / / 22005930 rs2733162 chr8 133528541 G A 7.00E-06 Digit length ratio / / 20303062 rs2673576 chr8 133528579 A G 8.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2673577 chr8 133530355 C T 5.02E-04 Multiple complex diseases / / 17554300 rs7010482 chr8 133530440 A G 4.18E-04 Multiple complex diseases / / 17554300 rs78702510 chr8 133544170 T C 0.00005318 Sarcoidosis / / 22952805 rs12549265 chr8 133553595 A G 9.80E-04 Multiple complex diseases / / 17554300 rs62514468 chr8 133564537 T C 0.00005418 Sarcoidosis / / 22952805 rs2357507 chr8 133580193 T C 3.61E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs62514508 chr8 133625307 A G 0.00006192 Sarcoidosis LRRC6 intron 22952805 rs62514509 chr8 133639191 G C 0.000005061 Sarcoidosis LRRC6 intron 22952805 rs62514514 chr8 133664749 T C 0.000003755 Sarcoidosis LRRC6 intron 22952805 rs10097529 chr8 133704712 C A 8.80E-05 Asthma (bronchodilator response) / / 22792082 rs10097529 chr8 133704712 C A 7.60E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10956677 chr8 133708897 G A 2.60E-05 Urinary metabolites / / 21572414 rs1593398 chr8 133726628 A G 2.96E-04 Coronary heart disease TMEM71 intron 21971053 rs2052701 chr8 133731794 C A 1.79E-04 Coronary heart disease TMEM71 intron 21971053 rs16904724 chr8 133734222 C A 3.04E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) TMEM71 intron 24023788 rs2739024 chr8 133759051 G A 3.53E-07 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM71 intron 20877124 rs2739024 chr8 133759051 G A 4.21E-07 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM71 intron 20877124 rs74775484 chr8 133759318 A G 8.10E-06 Stroke (ischemic) TMEM71 cds-synon 21957438 rs80262555 chr8 133761844 T C 8.17E-06 Stroke (ischemic) TMEM71 intron 21957438 rs113988259 chr8 133761895 T G 7.91E-06 Stroke (ischemic) TMEM71 intron 21957438 rs2433057 chr8 133768658 T A 8.77E-06 Stroke (ischemic) TMEM71 intron 21957438 rs890210 chr8 133774068 C T 7.88E-07 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs890210 chr8 133774068 C T 8.40E-07 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2433051 chr8 133776163 T C 1.18E-05 Osteoarthritis (knee and hip) / / 21177295 rs2433051 chr8 133776163 T C 4.83E-04 Osteoarthritis (knee and hip) / / 21177295 rs2739030 chr8 133777471 G A 4.00E-05 Lung adenocarcinoma / / 22797724 rs56217800 chr8 133793270 T A 4.80E-07 Stroke (ischemic) PHF20L1 intron 21957438 rs2739045 chr8 133805889 T G 6.96E-04 Type 2 diabetes PHF20L1 intron 17463246 rs2739045 chr8 133805889 T G 1.10E-07 Urinary metabolites PHF20L1 intron 21572414 rs2553587 chr8 133808415 A G 2.70E-07 Urinary metabolites PHF20L1 intron 21572414 rs10505600 chr8 133812863 C G 1.36E-05 Bone mass and geometry PHF20L1 intron 17903296 rs235437 chr8 133830633 C T 2.64E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PHF20L1 intron 20877124 rs235437 chr8 133830633 C T 7.06E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PHF20L1 intron 20877124 rs10956683 chr8 133831483 G A 4.22E-04 Alcohol dependence PHF20L1 intron 21314694 rs7009180 chr8 133868674 A G 3.74E-04 Alzheimer's disease (late onset) / / 21379329 rs75188332 chr8 133876153 T G 8.87E-07 Stroke (ischemic) / / 21957438 rs864898 chr8 133904380 G A 1.49E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TG intron 20877124 rs864898 chr8 133904380 G A 5.07E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TG intron 20877124 rs75359268 chr8 133921014 C T 1.29E-06 Stroke (ischemic) TG intron 21957438 rs3847173 chr8 133922914 A G 2.55E-04 Response to taxane treatment (placlitaxel) TG intron 23006423 rs79568178 chr8 133929138 C T 1.35E-06 Stroke (ischemic) TG intron 21957438 rs853308 chr8 133929917 C T 2.00E-08 Vitiligo TG intron 22561518 rs7011493 chr8 133935499 T C 1.03E-04 Response to taxane treatment (placlitaxel) TG intron 23006423 rs2739060 chr8 133947746 T C 4.49E-05 Serum metabolites TG intron 19043545 rs28540916 chr8 133959399 T C 2.34E-06 Stroke (ischemic) TG intron 21957438 rs4736614 chr8 133961011 T C 2.27E-06 Stroke (ischemic) TG intron 21957438 rs7015805 chr8 133965936 T C 2.57E-06 Stroke (ischemic) TG intron 21957438 rs9643296 chr8 133966348 A C 2.49E-06 Stroke (ischemic) TG intron 21957438 rs12677246 chr8 133967395 C G 8.87E-04 Alcohol dependence TG intron 21314694 rs1963138 chr8 133970345 G A 5.97E-06 Stroke (ischemic) TG intron 21957438 rs76745731 chr8 133975183 A G 4.12E-06 Stroke (ischemic) TG intron 21957438 rs6988193 chr8 133980451 A G 7.20E-06 Stroke (ischemic) TG intron 21957438 rs1403488 chr8 133985019 G A 5.70E-06 Urinary metabolites TG intron 21572414 rs1403487 chr8 133985059 A G 9.90E-06 Urinary metabolites TG intron 21572414 rs2222452 chr8 133985395 G A 1.20E-05 Urinary metabolites TG intron 21572414 rs11785501 chr8 133985966 T C 2.07E-04 Type 2 diabetes TG intron 17463246 rs11785501 chr8 133985966 T C 1.10E-05 Urinary metabolites TG intron 21572414 rs6998423 chr8 133989290 C T 6.20E-06 Multiple sclerosis TG intron 21833088 rs7844859 chr8 134003063 C G 2.80E-06 Urinary metabolites TG intron 21572414 rs7844761 chr8 134003128 A G 2.20E-05 Urinary metabolites TG intron 21572414 rs11782322 chr8 134011692 C T 2.30E-05 Urinary metabolites TG intron 21572414 rs16904802 chr8 134014335 C T 1.90E-05 Urinary metabolites TG intron 21572414 rs10505604 chr8 134027588 A G 3.10E-06 Celiac disease TG intron 17558408 rs10505604 chr8 134027588 A G 9.02E-05 Tunica Media TG intron pha003038 rs869769 chr8 134030488 T C 4.78E-04 Depression (quantitative trait) TG intron 20800221 rs16904805 chr8 134032429 G A 4.99E-04 Alzheimer's disease (late onset) TG intron 21379329 rs2702996 chr8 134055485 T C 4.70E-06 Urinary metabolites SLA intron 21572414 rs2687837 chr8 134056899 T C 7.40E-06 Urinary metabolites SLA intron 21572414 rs4736618 chr8 134060459 T C 8.73E-04 Multiple complex diseases SLA intron 17554300 rs2702967 chr8 134068748 G A 4.86E-04 Insulin resistance SLA intron 21901158 rs2741200 chr8 134071833 T C 5.00E-06 Temperament SLA intron 22832960 rs4486183 chr8 134072363 G T 0.000021 Breast cancer SLA missense 23555315 rs4301434 chr8 134087450 A G 4.57E-07 Graves' disease SLA intron 23612905 rs4301434 chr8 134087450 A G 1.58E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SLA intron 24023788 rs2739171 chr8 134098665 G A 0.000104 Oxaliplatin induced nausea/vomiting in response to colorectal cancer treatment SLA intron 22310351 rs7818576 chr8 134105000 C A,G,T 1.10E-09 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) SLA intron 23080225 rs7018140 chr8 134106969 T A 5.66E-05 Multiple complex diseases SLA intron 17554300 rs73354644 chr8 134107312 G A 0.00033 Prostate cancer TG missense 23555315 rs2069568 chr8 134108453 C T 7.80E-06 Urinary metabolites TG cds-synon 21572414 rs1000263 chr8 134109776 C G 1.50E-05 Urinary metabolites SLA intron 21572414 rs1133076 chr8 134125682 G A 1.20E-05 Urinary metabolites TG missense 21572414 rs2958692 chr8 134134673 C T 2.91E-04 Response to cytidine analogues (gemcitabine) TG intron 24483146 rs2958693 chr8 134135095 C T 6.64E-04 Response to cytidine analogues (gemcitabine) TG intron 24483146 rs2294025 chr8 134145512 G A 8.00E-09 Graves' disease TG intron 23612905 rs2294025 chr8 134145512 G A 7.93E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) TG intron 24023788 rs11774513 chr8 134158551 G A 7.82E-04 Type 2 diabetes / / 17463246 rs4736636 chr8 134163440 G A 4.55E-04 Multiple complex diseases / / 17554300 rs11778112 chr8 134167681 G A 5.99E-04 Type 2 diabetes / / 17463246 rs4736437 chr8 134185668 T G 1.14E-08 Graves' disease / / 23612905 rs12156170 chr8 134188778 G A 4.78E-04 Alzheimer's disease (late onset) / / 21379329 rs10956695 chr8 134189138 T C 2.19E-06 Graves' disease / / 23612905 rs10956695 chr8 134189138 T C 1.25E-04 Lung function (forced vital capacity) / / 24023788 rs11777166 chr8 134194568 A G 9.57E-04 Multiple complex diseases / / 17554300 rs4527850 chr8 134196849 T C 0.00052 Endometrial cancer / / 22426144 rs4527850 chr8 134196849 T C 2.00E-06 Type 2 diabetes / / 23300278 rs16904845 chr8 134199776 T C 5.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs3739262 chr8 134205713 G A 4.51E-04 Type 2 diabetes WISP1 intron 17463246 rs3739262 chr8 134205713 G A 2.45E-05 Multiple complex diseases WISP1 intron 17554300 rs16893344 chr8 134206279 C T 2.51E-04 Type 2 diabetes WISP1 intron 17463246 rs16893344 chr8 134206279 C T 4.10E-04 Suicide attempts in bipolar disorder WISP1 intron 21041247 rs16893344 chr8 134206279 C T 1.02E-06 Magnesium levels WISP1 intron pha003092 rs2977527 chr8 134213685 G A 8.21E-04 Suicide attempts in bipolar disorder WISP1 intron 21041247 rs4382455 chr8 134214191 C A 8.40E-04 Suicide attempts in bipolar disorder WISP1 intron 21041247 rs7005834 chr8 134214204 C T 6.36E-05 Graves' disease WISP1 intron 21841780 rs7006080 chr8 134214224 G T 1.39E-04 Multiple complex diseases WISP1 intron 17554300 rs2977530 chr8 134215112 G A 1.70E-05 Urinary metabolites WISP1 intron 21572414 rs2977531 chr8 134215631 A G 5.58E-04 Multiple complex diseases WISP1 intron 17554300 rs753722 chr8 134215946 G C 7.42E-04 Suicide attempts in bipolar disorder WISP1 intron 21041247 rs753722 chr8 134215946 G C 9.40E-06 Urinary metabolites WISP1 intron 21572414 rs1109563 chr8 134219238 G A 7.31E-04 Alzheimer's disease WISP1 intron 22005930 rs10100792 chr8 134219818 C T 5.97E-04 Multiple complex diseases WISP1 intron 17554300 rs2977537 chr8 134220063 G A 4.18E-05 Alzheimer's disease WISP1 intron 22005930 rs2272645 chr8 134227197 A T 5.49E-06 Left ventricular mass WISP1 intron 21212386 rs13263504 chr8 134247127 G A 6.05E-05 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs7843329 chr8 134249223 T C 1.12E-04 Multiple complex diseases NDRG1 nearGene-3 17554300 rs16904873 chr8 134260817 T C 2.58E-04 Blood pressure NDRG1 intron 17255346 rs4590423 chr8 134261296 C T 7.78E-04 Multiple complex diseases NDRG1 intron 17554300 rs7018287 chr8 134264054 G T 1.78E-05 Job-related exhaustion NDRG1 intron 23620144 rs2272651 chr8 134270548 T C 3.00E-06 Post-traumatic stress disorder (asjusted for relatedness) NDRG1 intron 23726511 rs2272651 chr8 134270548 T C 5.36E-05 Post-traumatic stress disorder NDRG1 intron 23726511 rs2977505 chr8 134286193 T C 8.30E-06 Urinary metabolites NDRG1 intron 21572414 rs10956699 chr8 134288583 G A 4.09E-04 Multiple complex diseases NDRG1 intron 17554300 rs4736646 chr8 134320263 A G 9.13E-04 Alzheimer's disease / / 22005930 rs4736648 chr8 134323337 T C 4.31E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16904891 chr8 134332054 G A 8.40E-04 Taste perception / / 22132133 rs11993225 chr8 134335352 A C 1.36E-05 Cardiovascular disease / / pha003064 rs10095018 chr8 134339266 T C 2.04E-04 Multiple complex diseases / / 17554300 rs10093875 chr8 134360780 A C 6.58E-05 Schizophrenia / / 24253340 rs2976545 chr8 134367178 G A 5.50E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs2976562 chr8 134372848 C T 3.35E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10106540 chr8 134461851 A G 7.00E-07 Personality dimensions / / 23903073 rs16904926 chr8 134471062 A T 9.39E-04 Multiple complex diseases ST3GAL1 UTR-3 17554300 rs2736871 chr8 134475077 G A 3.00E-06 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia ST3GAL1 intron 24039173 rs6986303 chr8 134478529 G A 2.33E-05 Male-pattern baldness ST3GAL1 intron 18849994 rs7460764 chr8 134494524 A G 4.13E-04 Multiple complex diseases ST3GAL1 intron 17554300 rs7827061 chr8 134500809 C A,G,T 9.02E-04 Multiple complex diseases ST3GAL1 intron 17554300 rs6995270 chr8 134513219 C T 7.93E-04 Type 2 diabetes ST3GAL1 intron 17463246 rs6989475 chr8 134519265 A G 5.00E-06 Alcohol dependence ST3GAL1 intron 21956439 rs6989914 chr8 134519479 C T 8.46E-04 Amyotrophic lateral sclerosis (sporadic) ST3GAL1 intron 24529757 rs1474113 chr8 134523882 C T 5.86E-04 Smoking cessation ST3GAL1 intron 24665060 rs2978043 chr8 134527871 A G 6.80E-05 Information processing speed ST3GAL1 intron 21130836 rs2978043 chr8 134527871 A G 4.47E-04 Lung function (forced vital capacity) ST3GAL1 intron 24023788 rs7831920 chr8 134531922 C T 5.80E-06 Body mass index ST3GAL1 intron 19557197 rs2978012 chr8 134539196 C T 3.80E-04 Alzheimer's disease ST3GAL1 intron 17998437 rs2978012 chr8 134539196 C T 8.73E-05 Alzheimer's disease ST3GAL1 intron pha002879 rs2978014 chr8 134539636 G A 4.63E-04 Alzheimer's disease ST3GAL1 intron 17998437 rs2978015 chr8 134539879 C T 5.66E-05 Alzheimer's disease ST3GAL1 intron 17998437 rs2978015 chr8 134539879 C T 8.81E-05 Alzheimer's disease ST3GAL1 intron pha002879 rs2945779 chr8 134541542 C T 5.45E-04 Alzheimer's disease ST3GAL1 intron 17998437 rs16904938 chr8 134541623 G A 3.06E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ST3GAL1 intron 24023788 rs2978023 chr8 134548571 T C 1.58E-04 Alzheimer's disease ST3GAL1 intron 17998437 rs2978023 chr8 134548571 T C 2.92E-05 Serum metabolites ST3GAL1 intron 19043545 rs2978023 chr8 134548571 T C 1.50E-06 Urinary metabolites ST3GAL1 intron 21572414 rs2978023 chr8 134548571 T C 1.81E-04 Alzheimer's disease ST3GAL1 intron pha002879 rs7018169 chr8 134555877 T G 4.81E-04 Alzheimer's disease ST3GAL1 intron 17998437 rs7018169 chr8 134555877 T G 4.64E-06 Serum metabolites ST3GAL1 intron 19043545 rs11775725 chr8 134566133 C T 2.45E-05 Vitiligo ST3GAL1 intron 19890347 rs4526340 chr8 134569528 G A 2.30E-05 Urinary metabolites ST3GAL1 intron 21572414 rs2272674 chr8 134579093 C T 1.14E-05 Triglycerides ST3GAL1 intron 19074352 rs2272674 chr8 134579093 C T 1.14E-05 Polyunsaturated fatty acid levels,in plasma ST3GAL1 intron 19148276 rs939024 chr8 134586713 A G 3.95E-04 Type 2 diabetes / / 17463246 rs939024 chr8 134586713 A G 4.11E-04 Multiple complex diseases / / 17554300 rs1464241 chr8 134587501 T C 8.33E-05 Atopic dermatitis / / 23042114 rs2945723 chr8 134587859 C T 3.46E-05 Atopic dermatitis / / 23042114 rs4270941 chr8 134589010 C G,T 3.95E-05 Atopic dermatitis / / 23042114 rs2404005 chr8 134589233 A T 4.64E-05 Atopic dermatitis / / 23042114 rs11984457 chr8 134590311 T A 7.73E-05 Atopic dermatitis / / 23042114 rs11984505 chr8 134590512 T A 8.79E-05 Atopic dermatitis / / 23042114 rs7827748 chr8 134596232 G T 3.80E-04 Type 2 diabetes / / 17463246 rs7827748 chr8 134596232 G T 2.53E-04 Multiple complex diseases / / 17554300 rs7827748 chr8 134596232 G T 3.96E-05 Serum metabolites / / 19043545 rs6471132 chr8 134604069 G A 5.72E-04 Type 2 diabetes / / 17463246 rs6471132 chr8 134604069 G A 1.06E-05 Serum metabolites / / 19043545 rs7016568 chr8 134604864 C T 1.70E-04 Type 2 diabetes / / 17463246 rs7016568 chr8 134604864 C T 7.47E-04 Multiple complex diseases / / 17554300 rs7016568 chr8 134604864 C T 1.82E-05 Serum metabolites / / 19043545 rs6984823 chr8 134606300 G A 3.77E-04 Smoking initiation / / 24665060 rs4736702 chr8 134615729 G C 6.93E-04 Smoking initiation / / 24665060 rs2945733 chr8 134615750 T G 4.00E-06 Intraocular pressure / / 24002674 rs2978048 chr8 134616136 T G 1.00E-06 Response to protease inhibitor treatment in hepatitis c (peak serum total bilirubin levels) / / 24503447 rs11780149 chr8 134667593 T C 2.35E-04 Type 2 diabetes / / 17463246 rs2860223 chr8 134668677 A G 2.00E-06 Schizophrenia (negative symptoms) / / 23382809 rs6981912 chr8 134678117 A G 5.49E-04 Schizophrenia LOC100507162 intron 19197363 rs2945756 chr8 134686065 A G 4.51E-05 LDL lipoproteins LOC100507162 intron pha002902 rs1584448 chr8 134689575 G A 8.66E-04 Multiple complex diseases LOC100507162 intron 17554300 rs74566133 chr8 134778342 C T 7.00E-07 Eating disorders (purging via substances) / / 23568457 rs7814358 chr8 134785709 T C 4.81E-05 Blood Pressure / / pha003048 rs10808617 chr8 134800267 C T 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs4629849 chr8 134800940 G C 2.54E-04 Type 2 diabetes / / 17463246 rs10091359 chr8 134811944 A G 5.08E-04 Type 2 diabetes / / 17463246 rs4897732 chr8 134846732 A G 8.58E-04 Stroke / / pha002887 rs12541947 chr8 134849320 G A,C,T 7.88E-04 Body mass index / / 21701565 rs924769 chr8 134851243 G A 2.70E-05 Urinary metabolites / / 21572414 rs924768 chr8 134851366 C T 7.50E-06 Urinary metabolites / / 21572414 rs6983078 chr8 134871987 G A 4.10E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10086443 chr8 134874391 T C 0.0000023 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) / / 23080225 rs7833866 chr8 134875936 C T 2.95E-04 Multiple complex diseases / / 17554300 rs6471160 chr8 134883783 T C 0.0008376 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6471160 chr8 134883783 T C 8.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7016961 chr8 134994471 G A 6.00E-05 Cognitive function / / 24684796 rs13272716 chr8 134996264 A C 1.10E-04 Cognitive function / / 24684796 rs1125719 chr8 135005442 C A 3.94E-04 Parkinson's disease / / 17052657 rs4897624 chr8 135005873 T G 5.21E-04 Parkinson's disease / / 17052657 rs6982411 chr8 135007667 C T 4.63E-04 Parkinson's disease / / 17052657 rs6982411 chr8 135007667 C T 7.46E-05 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs1840938 chr8 135013432 A C 1.16E-04 Cognitive function / / 24684796 rs1119017 chr8 135013719 C T 4.86E-04 Smoking quantity / / 24665060 rs2896732 chr8 135018253 A C 6.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs1379435 chr8 135018502 C T 6.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs11990927 chr8 135022900 A G 6.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs11998159 chr8 135022916 G A 6.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs11998140 chr8 135023012 C A 5.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs1379440 chr8 135023442 C T 5.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs7819815 chr8 135026160 A G 3.10E-07 Schizophrenia(age at onset) / / 21688384 rs7820063 chr8 135026266 C T 1.13E-05 Schizophrenia(age at onset) / / 21688384 rs16905051 chr8 135029384 C T 7.42E-05 Body Mass Index / / pha003009 rs4897668 chr8 135030615 A G 8.30E-26 Meningococcal disease / / 20694013 rs1158934 chr8 135032242 G A 1.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs16905053 chr8 135039688 T A 2.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs16905054 chr8 135040165 A G 2.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs7840466 chr8 135081282 G T 1.43E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1870126 chr8 135093701 T C 6.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs7842645 chr8 135093903 A G 1.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs6981423 chr8 135094936 C T 7.60E-04 Suicide attempts in bipolar disorder / / 21041247 rs1457463 chr8 135099778 G A 8.45E-06 Suicide attempts in bipolar disorder / / 21041247 rs7830450 chr8 135107375 T C 6.87E-05 Suicide attempts in bipolar disorder / / 21041247 rs1124525 chr8 135122889 G A 9.09E-05 Suicide attempts in bipolar disorder / / 21041247 rs1457473 chr8 135125604 A G 2.48E-04 Suicide attempts in bipolar disorder / / 21041247 rs765847 chr8 135136008 A G 6.26E-04 Parkinson's disease / / 17052657 rs765847 chr8 135136008 A G 8.94E-05 Suicide attempts in bipolar disorder / / 21041247 rs7011020 chr8 135141217 G A 8.98E-05 Suicide attempts in bipolar disorder / / 21041247 rs1446995 chr8 135141848 G T 9.14E-05 Suicide attempts in bipolar disorder / / 21041247 rs4897681 chr8 135143521 C T 4.87E-04 Parkinson's disease / / 17052657 rs4897681 chr8 135143521 C T 9.25E-05 Suicide attempts in bipolar disorder / / 21041247 rs6471191 chr8 135143604 C T 3.06E-04 Age-related macular degeneration / / 22125219 rs6994801 chr8 135145384 G C 9.37E-05 Suicide attempts in bipolar disorder / / 21041247 rs992526 chr8 135147297 T C 4.87E-04 Parkinson's disease / / 17052657 rs992526 chr8 135147297 T C 9.68E-05 Suicide attempts in bipolar disorder / / 21041247 rs7012406 chr8 135149933 T A 4.35E-04 Suicide attempts in bipolar disorder / / 21041247 rs1840936 chr8 135151600 G A 6.58E-04 Parkinson's disease / / 17052657 rs11783369 chr8 135165772 T C 2.35E-04 Type 2 diabetes / / 17463246 rs4389976 chr8 135207136 A T 7.51E-05 Bipolar disorder / / 18317468 rs4897700 chr8 135230161 G A 6.77E-04 Multiple complex diseases / / 17554300 rs2028941 chr8 135253546 C A 5.21E-06 Rheumatoid arthritis / / 19503088 rs4897704 chr8 135262880 G A 2.84E-06 Rheumatoid arthritis / / 19503088 rs4348534 chr8 135272269 C T 6.05E-05 Longevity / / 20304771 rs4385492 chr8 135278125 C G 6.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs4298516 chr8 135283869 G A 2.09E-04 Alzheimer's disease / / 17998437 rs13268776 chr8 135284669 G A 6.12E-05 Serum metabolites / / 19043545 rs11787445 chr8 135319528 C T 1.89E-05 Hypertension (essential hypertension) / / 22184326 rs1584254 chr8 135324352 A C 3.02E-05 Cognitive performance / / 19734545 rs6471216 chr8 135339383 T C 4.38E-04 Obesity (extreme) / / 21935397 rs4412399 chr8 135343419 T C 8.13E-04 Obesity (extreme) / / 21935397 rs7840709 chr8 135371779 A C 1.76E-04 Multiple complex diseases / / 17554300 rs4272415 chr8 135381683 C T 8.54E-04 Obesity (extreme) / / 21935397 rs6989835 chr8 135385500 C T 8.60E-04 Obesity (extreme) / / 21935397 rs4529495 chr8 135386087 G A 8.61E-04 Obesity (extreme) / / 21935397 rs7011517 chr8 135389370 G T 9.38E-04 Obesity (extreme) / / 21935397 rs6471231 chr8 135407780 G A 3.61E-05 Alzheimer's disease / / 17998437 rs6415559 chr8 135460497 T C 8.89E-04 Heart Failure / / pha002884 rs4909616 chr8 135500567 A G 3.91E-05 Melanoma ZFAT intron 21926416 rs754234 chr8 135512875 A G 7.86E-05 Information processing speed ZFAT intron 21130836 rs2083683 chr8 135517527 A G 3.84E-04 Smoking quantity ZFAT intron 24665060 rs13256684 chr8 135530733 G T 4.87E-04 Smoking quantity ZFAT intron 24665060 rs7015197 chr8 135534629 C G 3.10E-06 Urinary metabolites ZFAT intron 21572414 rs7015197 chr8 135534629 C G 5.54E-04 Smoking quantity ZFAT intron 24665060 rs10505624 chr8 135538680 G C 4.90E-04 Breast cancer and prostate cancer ZFAT intron 17903305 rs1550582 chr8 135542084 G A 8.41E-05 Information processing speed ZFAT intron 21130836 rs1020236 chr8 135543194 T C 3.26E-04 Smoking quantity ZFAT intron 24665060 rs7816909 chr8 135551597 T G 5.43E-04 Smoking quantity ZFAT intron 24665060 rs6578231 chr8 135565420 T C 2.52E-04 Smoking quantity ZFAT intron 24665060 rs7827545 chr8 135566567 C T 3.76E-05 Multiple complex diseases ZFAT intron 17554300 rs7827545 chr8 135566567 C T 2.00E-44 Hypertension ZFAT intron 21626137 rs1372662 chr8 135567046 G C 2.00E-44 Hypertension ZFAT intron 21626137 rs2034016 chr8 135570871 T C 3.87E-05 Smoking quantity ZFAT intron 24665060 rs9792264 chr8 135570935 A G 1.10E-04 Schizophrenia(treatment response to risperidone) ZFAT intron 19850283 rs6986489 chr8 135571916 G A 4.70E-04 Smoking quantity ZFAT intron 24665060 rs721000 chr8 135574196 T C 1.53E-05 Amyotrophic lateral sclerosis (sporadic) ZFAT intron 24529757 rs721000 chr8 135574196 T C 7.88E-06 Smoking quantity ZFAT intron 24665060 rs10283108 chr8 135575046 T C 2.66E-04 Smoking quantity ZFAT intron 24665060 rs11786410 chr8 135577099 T C 5.41E-05 Smoking quantity ZFAT intron 24665060 rs6577655 chr8 135593725 C T 5.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio ZFAT intron 22589738 rs11988811 chr8 135598675 G A 4.10E-05 Height ZFAT intron 21998595 rs11778878 chr8 135599220 G A 2.90E-04 Smoking quantity ZFAT intron 24665060 rs1036819 chr8 135611945 A C 8.69E-05 Cognitive performance ZFAT intron 19734545 rs1036819 chr8 135611945 A C 3.57E-21 Pelvic organ prolapse ZFAT intron 22105264 rs894343 chr8 135612595 A G 7.03E-06 Smoking quantity ZFAT intron 24665060 rs3739422 chr8 135614972 A G 3.50E-06 Height ZFAT cds-synon 21998595 rs7012866 chr8 135616959 T G 6.42E-04 Smoking quantity ZFAT intron 24665060 rs7011157 chr8 135629179 T A 5.39E-04 Smoking quantity ZFAT intron 24665060 rs10875385 chr8 135629574 A G 9.79E-05 Smoking quantity ZFAT intron 24665060 rs11985416 chr8 135634005 T C 1.57E-04 Smoking quantity ZFAT intron 24665060 rs11990335 chr8 135635174 G A 6.56E-06 Monocyte chemoattractant protein-1 ZFAT intron pha003071 rs11166629 chr8 135636964 C T 3.00E-06 Smoking quantity ZFAT intron 24665060 rs12680655 chr8 135637337 C G 2.00E-14 Height ZFAT intron 20881960 rs935119 chr8 135638353 A G 4.23E-06 Smoking quantity ZFAT intron 24665060 rs733254 chr8 135638632 C A 2.00E-06 Height ZFAT intron 21998595 rs966659 chr8 135639045 T C 3.04E-06 Smoking quantity ZFAT intron 24665060 rs7818331 chr8 135639653 C T 4.30E-06 Smoking quantity ZFAT intron 24665060 rs1545240 chr8 135642632 A C 1.52E-04 Attention deficit hyperactivity disorder ZFAT intron pha002875 rs4909330 chr8 135644369 T C 1.75E-05 Smoking quantity ZFAT intron 24665060 rs2873014 chr8 135645860 A G 5.25E-04 Insulin resistance ZFAT intron 21901158 rs1036820 chr8 135646571 A G 3.15E-04 Insulin resistance ZFAT intron 21901158 rs2028556 chr8 135648040 T C 2.81E-04 Smoking quantity ZFAT intron 24665060 rs4909338 chr8 135651616 C T 2.76E-05 Waist Circumference ZFAT intron pha003025 rs11166643 chr8 135654340 C T 5.67E-05 Waist Circumference ZFAT intron pha003025 rs17772163 chr8 135655246 T C 7.00E-05 Height ZFAT intron 19396169 rs16905215 chr8 135676891 G A 1.89E-04 Breast cancer ZFAT intron pha002853 rs9785140 chr8 135678804 C T 1.26E-04 Breast cancer ZFAT intron pha002853 rs4243859 chr8 135716089 G T 1.37E-05 Blood pressure (age interaction) ZFAT intron 24954895 rs9969668 chr8 135731578 G A 4.95E-05 Waist Circumference / / pha003025 rs12547792 chr8 135764140 G A 2.30E-06 Urinary metabolites / / 21572414 rs12547840 chr8 135764332 G C 1.40E-05 Urinary metabolites / / 21572414 rs6980776 chr8 135766931 A G 2.90E-06 Urinary metabolites / / 21572414 rs4472470 chr8 135782981 C T 2.60E-05 Urinary metabolites / / 21572414 rs10106201 chr8 135809634 C A 4.40E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10106201 chr8 135809634 C A 1.82E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10095483 chr8 135812548 A C 8.44E-05 Coronary heart disease / / pha003030 rs7017546 chr8 135837130 A G 9.79E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6577889 chr8 135850547 G A 3.01E-05 Serum albumin level / / pha003084 rs731589 chr8 135860401 T C 1.49E-04 Multiple complex diseases / / 17554300 rs2205362 chr8 135864228 C T 2.66E-04 Multiple complex diseases / / 17554300 rs7016743 chr8 135866685 A G 2.65E-04 Multiple complex diseases / / 17554300 rs7016774 chr8 135866758 A T 2.47E-04 Multiple complex diseases / / 17554300 rs12541063 chr8 135869976 A G 2.61E-06 Blood pressure / / 24001895 rs12541063 chr8 135869976 A G 3.00E-06 Blood pressure / / 24001895 rs1000394 chr8 135870334 T C 8.48E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs1000394 chr8 135870334 T C 9.24E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs12542413 chr8 135871032 T C 1.86E-04 Type 2 diabetes / / 17463246 rs4909801 chr8 135879159 T C 3.00E-06 Response to alcohol consumption (flushing response) / / 24277619 rs4243894 chr8 135884188 T C 1.15E-04 Smoking cessation / / 24665060 rs10505632 chr8 135892340 C T 4.07E-04 Multiple complex diseases / / 17554300 rs4909820 chr8 135894058 C A 1.00E-05 Response to alcohol consumption (flushing response) / / 24277619 rs4243899 chr8 135894109 G T 5.50E-04 Smoking cessation / / 24665060 rs11782108 chr8 135899442 A C 8.49E-05 Smoking cessation / / 24665060 rs4266608 chr8 135900198 A G 9.95E-04 HIV-1 viral setpoint / / 17641165 rs7462577 chr8 135908515 G A 1.90E-06 Primary sclerosing cholangitis / / 21151127 rs7459564 chr8 135924612 G T 9.63E-05 Cognitive test performance / / 20125193 rs7465467 chr8 135986892 G A 0.00000796 Asthma / / 22694930 rs7465467 chr8 135986892 G A 4.62E-04 Response to alcohol consumption (flushing response) / / 24277619 rs6578068 chr8 136038123 T G 3.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6987207 chr8 136039314 A G 5.21E-04 Acute lung injury / / 22295056 rs7816532 chr8 136040379 C T 7.18E-04 Multiple complex diseases / / 17554300 rs13253938 chr8 136041144 A G 2.60E-04 Age-related macular degeneration / / 21665990 rs16905271 chr8 136045268 A G 7.00E-05 Response to alcohol consumption (flushing response) / / 24277619 rs7827609 chr8 136045533 G A 3.21E-04 Insulin resistance / / 21901158 rs9324520 chr8 136054247 T C 1.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4909875 chr8 136073003 G A 8.12E-04 Alzheimer's disease / / 17998437 rs1480781 chr8 136073929 T C 6.54E-04 Alzheimer's disease / / 17998437 rs1383474 chr8 136134647 G A 4.10E-05 Memory performance / / 22105620 rs4909886 chr8 136134975 C A 4.90E-05 Memory performance / / 22105620 rs10505634 chr8 136156339 G A 3.53E-04 Multiple complex diseases / / 17554300 rs3924923 chr8 136162227 G A 6.50E-05 HIV-1 control / / 20041166 rs1383469 chr8 136207951 A G 2.25E-04 Stroke / / pha002886 rs964043 chr8 136225944 G A 7.41E-04 Acute lung injury / / 22295056 rs7824666 chr8 136241066 A G 8.80E-06 Urinary metabolites / / 21572414 rs874745 chr8 136415446 G A 9.59E-04 Type 2 diabetes / / 17463246 rs2873417 chr8 136421680 G A 2.17E-05 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs199697033 chr8 136428893 T TGC 1.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs897406 chr8 136428893 T C 1.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10106123 chr8 136449715 G A 4.83E-04 Alzheimer's disease / / 24755620 rs6997956 chr8 136484390 T A 8.48E-06 Nicotine smoking KHDRBS3 intron 19268276 rs6997956 chr8 136484390 T A 1.70E-05 Urinary metabolites KHDRBS3 intron 21572414 rs11779943 chr8 136522558 G A 6.61E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) KHDRBS3 intron 23648065 rs10092358 chr8 136526248 A G 6.61E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) KHDRBS3 intron 23648065 rs16905387 chr8 136539132 T G 4.23E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) KHDRBS3 intron 23648065 rs6577649 chr8 136584525 A G 2.18E-04 Multiple complex diseases KHDRBS3 intron 17554300 rs11787396 chr8 136598801 C T 2.00E-05 Urinary metabolites KHDRBS3 intron 21572414 rs7846379 chr8 136603611 C G 7.10E-04 Multiple complex diseases KHDRBS3 intron 17554300 rs11166605 chr8 136624184 A G 1.40E-05 Urinary metabolites KHDRBS3 intron 21572414 rs11166605 chr8 136624184 A G 4.23E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) KHDRBS3 intron 23648065 rs4909494 chr8 136646548 C T 1.70E-05 Urinary metabolites KHDRBS3 intron 21572414 rs4909498 chr8 136648991 G C 9.40E-06 Urinary metabolites KHDRBS3 intron 21572414 rs10112691 chr8 136649677 A G 2.50E-05 Urinary metabolites KHDRBS3 intron 21572414 rs10099186 chr8 136658491 A G 2.30E-05 Urinary metabolites KHDRBS3 intron 21572414 rs4243848 chr8 136705708 G A 9.54E-04 Multiple complex diseases / / 17554300 rs6984541 chr8 136705975 A G 3.55E-05 Erythrocyte counts / / pha003099 rs4243849 chr8 136713137 A G 2.00E-06 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4243849 chr8 136713137 A G 3.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10875380 chr8 136718900 C G 5.85E-04 Multiple complex diseases / / 17554300 rs10875381 chr8 136719202 A G 2.02E-04 Multiple complex diseases / / 17554300 rs10875381 chr8 136719202 A G 3.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4377995 chr8 136723548 G A 3.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4294215 chr8 136723689 G A 3.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11166611 chr8 136731736 C T 4.39E-04 Multiple complex diseases / / 17554300 rs7460819 chr8 136735506 C T 5.92E-05 Left ventricular hypertrophy / / pha003052 rs6981947 chr8 136739516 C T 4.67E-05 Left ventricular hypertrophy / / pha003052 rs10105839 chr8 136746981 T G 6.23E-04 Multiple complex diseases / / 17554300 rs7822171 chr8 136770869 C T 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4909520 chr8 136788138 T C 3.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7004150 chr8 136789208 G C 1.43E-04 Multiple complex diseases / / 17554300 rs6991363 chr8 136789772 A G 8.26E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4385494 chr8 136850054 T G 4.51E-05 Glaucoma (primary open-angle) / / 22605921 rs4351452 chr8 136850133 G A 2.50E-05 Urinary metabolites / / 21572414 rs12680546 chr8 136871739 A G 4.67E-05 Parkinson's disease / / 17052657 rs12680546 chr8 136871739 A G 3.00E-06 Amyotrophic lateral sclerosis / / 17362836 rs4552942 chr8 136874323 T C 1.30E-05 Amyotrophic Lateral Sclerosis / / 17362836 rs4552942 chr8 136874323 T C 3.60E-05 Serum metabolites / / 19043545 rs4552942 chr8 136874323 T C 1.50E-05 Urinary metabolites / / 21572414 rs11785202 chr8 136887474 T G 4.45E-04 Multiple complex diseases / / 17554300 rs16905419 chr8 136902020 A T 7.70E-04 Acute lung injury / / 22295056 rs13276788 chr8 136902755 C T 3.86E-04 Multiple complex diseases / / 17554300 rs6997347 chr8 136925074 C T 1.13E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs962157 chr8 136941348 G T 1.03E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1448720 chr8 136944174 A G 8.88E-04 Multiple complex diseases / / 17554300 rs1597224 chr8 136948573 T C 6.10E-04 Multiple complex diseases / / 17554300 rs1900819 chr8 136960178 C A 4.89E-04 Multiple complex diseases / / 17554300 rs6577689 chr8 136967817 A G 5.96E-04 Coronary Artery Disease / / 17634449 rs961369 chr8 136984839 A T 3.15E-04 Coronary Artery Disease / / 17634449 rs2922350 chr8 136986018 T C 2.14E-05 Multiple sclerosis / / 17660530 rs6577695 chr8 136987791 G T 7.43E-04 Coronary Artery Disease / / 17634449 rs16905439 chr8 136989204 C T 9.00E-06 Insomnia (caffeine-induced) / / 22754043 rs6985828 chr8 137001427 T C 3.13E-06 Common variable immunodeficiency / / 21497890 rs1868368 chr8 137013447 T C 2.40E-04 Coronary Artery Disease / / 17634449 rs1868368 chr8 137013447 T C 8.52E-05 Multiple sclerosis / / 17660530 rs1448725 chr8 137014864 T C 4.24E-04 Coronary Artery Disease / / 17634449 rs17614890 chr8 137031683 G C 4.69E-04 Type 2 diabetes / / 17463246 rs11994949 chr8 137033779 G A 7.05E-04 Type 2 diabetes / / 17463246 rs6577701 chr8 137036253 C T 8.79E-04 Type 2 diabetes / / 17463246 rs2317355 chr8 137037516 A G 4.00E-06 Urinary metabolites / / 21572414 rs10109871 chr8 137041792 G A 7.47E-04 Type 2 diabetes / / 17463246 rs13266231 chr8 137044357 G A 8.23E-04 Type 2 diabetes / / 17463246 rs9644426 chr8 137049395 G A 9.80E-06 Urinary metabolites / / 21572414 rs1031282 chr8 137054657 G A 1.10E-05 Urinary metabolites / / 21572414 rs10505647 chr8 137056293 G A 1.40E-05 Urinary metabolites / / 21572414 rs6577706 chr8 137071329 T C 1.76E-04 Multiple complex diseases / / 17554300 rs1597223 chr8 137099679 T C 5.12E-05 Glucose levels / / pha003057 rs4398959 chr8 137117712 T G 6.53E-05 Glucose levels / / pha003057 rs17617902 chr8 137118779 G A 8.26E-04 Coronary heart disease / / 21606135 rs16905518 chr8 137177843 A G 6.84E-04 Multiple complex diseases / / 17554300 rs16905518 chr8 137177843 A G 1.23E-04 Smoking initiation / / 24665060 rs4243855 chr8 137193701 C T 7.08E-04 Type 2 diabetes / / 17846124 rs16905524 chr8 137198618 A G 4.08E-04 Smoking initiation / / 24665060 rs4294218 chr8 137226607 G A 2.40E-05 HIV-1 control / / 20041166 rs12682131 chr8 137241965 G A 4.54E-04 Smoking initiation / / 24665060 rs11166639 chr8 137256602 G A 3.30E-04 Smoking initiation / / 24665060 rs1872607 chr8 137275517 T C 1.57E-05 Serum metabolites / / 19043545 rs11993784 chr8 137278827 G A 3.21E-04 Smoking initiation / / 24665060 rs7820305 chr8 137300154 C T 4.53E-06 Serum metabolites / / 19043545 rs1492970 chr8 137313038 T A 2.06E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs923791 chr8 137319350 T G 8.19E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs16905615 chr8 137328144 G A 8.70E-05 HIV-1 control / / 20041166 rs16905615 chr8 137328144 G A 4.11E-04 Alcohol dependence / / 20201924 rs7820587 chr8 137330446 C T 8.47E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs923792 chr8 137337480 T C 8.66E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs992206 chr8 137346544 A T 7.33E-04 Multiple complex diseases / / 17554300 rs7831304 chr8 137349957 C G 9.50E-04 Multiple complex diseases / / 17554300 rs4909342 chr8 137350523 A T 2.10E-05 Urinary metabolites / / 21572414 rs10107806 chr8 137354052 G T 2.20E-05 Urinary metabolites / / 21572414 rs10089197 chr8 137364619 T C 1.70E-05 Urinary metabolites / / 21572414 rs7840440 chr8 137379939 G A,T 5.10E-05 HIV-1 control / / 20041166 rs10505655 chr8 137391277 C T 8.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7828882 chr8 137402348 C T 1.89E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs16905838 chr8 137424467 C T 8.81E-05 Parkinson's disease / / 21738487 rs11782648 chr8 137505400 A G 9.17E-04 Multiple complex diseases / / 17554300 rs2255522 chr8 137523980 G A 7.22E-05 Psoriasis / / 18364390 rs2660664 chr8 137526323 G A 7.91E-05 LDL lipoproteins / / pha002902 rs2660664 chr8 137526323 G A 4.09E-05 Height / / pha003011 rs2581561 chr8 137545148 C T 3.48E-06 Hearing function / / 21493956 rs2119234 chr8 137552803 G T 4.53E-06 Hearing function / / 21493956 rs2587847 chr8 137555575 C T 4.28E-06 Hearing function / / 21493956 rs305261 chr8 137562031 C T 3.98E-06 Hearing function / / 21493956 rs305256 chr8 137568252 T C 2.37E-06 Hearing function / / 21493956 rs305255 chr8 137569002 G A 3.95E-06 Hearing function / / 21493956 rs16906098 chr8 137570047 C T 5.93E-05 Cognitive test performance / / 20125193 rs305290 chr8 137586801 G T 4.40E-06 Hearing function / / 21493956 rs305289 chr8 137587070 C T 4.49E-06 Hearing function / / 21493956 rs305288 chr8 137587374 T C 4.56E-06 Hearing function / / 21493956 rs305286 chr8 137592046 A C,G,T 5.23E-06 Hearing function / / 21493956 rs7815091 chr8 137595285 G A 5.93E-05 Cognitive test performance / / 20125193 rs11774028 chr8 137602505 G A 5.93E-05 Cognitive test performance / / 20125193 rs305231 chr8 137604105 G T 7.76E-06 Hearing function / / 21493956 rs305237 chr8 137607818 A G 8.53E-06 Hearing function / / 21493956 rs305244 chr8 137615206 A C 8.97E-06 Hearing function / / 21493956 rs305249 chr8 137618957 T C 9.68E-06 Hearing function / / 21493956 rs7812739 chr8 137620090 T C 5.93E-05 Cognitive test performance / / 20125193 rs1372067 chr8 137658719 A G 5.93E-05 Cognitive test performance / / 20125193 rs17646599 chr8 137687955 A G 6.38E-04 Type 2 diabetes / / 17463246 rs17647250 chr8 137729204 G C 8.75E-04 Type 2 diabetes / / 17463246 rs17587101 chr8 137734805 G A 8.75E-04 Type 2 diabetes / / 17463246 rs17647461 chr8 137735286 G A 5.96E-04 Type 2 diabetes / / 17463246 rs17587374 chr8 137745571 A G 5.67E-04 Type 2 diabetes / / 17463246 rs3850496 chr8 137754601 C T 6.85E-04 Type 2 diabetes / / 17463246 rs3850497 chr8 137754784 A G 8.99E-04 Type 2 diabetes / / 17463246 rs3850497 chr8 137754784 A G 1.90E-05 Urinary metabolites / / 21572414 rs7813155 chr8 137768473 T A 7.81E-04 Type 2 diabetes / / 17463246 rs16906293 chr8 137768892 C T 8.30E-09 Bilirubin levels,in serum / / 20639394 rs2610080 chr8 137771190 C A 4.43E-05 Cognitive test performance / / 20125193 rs2610084 chr8 137772759 T C 1.72E-05 Cognitive test performance / / 20125193 rs2610084 chr8 137772759 T C 3.38E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs2582478 chr8 137776731 A G 1.72E-05 Cognitive test performance / / 20125193 rs2582478 chr8 137776731 A G 3.38E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs2610088 chr8 137779259 T C 1.72E-05 Cognitive test performance / / 20125193 rs2610088 chr8 137779259 T C 3.19E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs17594878 chr8 137786437 G A 7.65E-04 Type 2 diabetes / / 17463246 rs2610093 chr8 137787569 A G 1.72E-05 Cognitive test performance / / 20125193 rs2610093 chr8 137787569 A G 3.19E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs17648984 chr8 137792371 G A 7.62E-04 Type 2 diabetes / / 17463246 rs17648984 chr8 137792371 G A 2.20E-05 Urinary metabolites / / 21572414 rs4438957 chr8 137805768 C G 3.78E-06 Body mass index / / 19557197 rs4438957 chr8 137805768 C G 2.24E-08 Obesity / / 23563607 rs1841513 chr8 137811069 A G 1.72E-05 Cognitive test performance / / 20125193 rs34216016 chr8 137811069 A AAG 1.72E-05 Cognitive test performance / / 20125193 rs372546711 chr8 137811069 A AG 1.72E-05 Cognitive test performance / / 20125193 rs2610114 chr8 137812540 T C 1.72E-05 Cognitive test performance / / 20125193 rs2610114 chr8 137812540 T C 3.94E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs2610116 chr8 137814067 A G 2.60E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs2649130 chr8 137814585 G A 1.99E-05 Cognitive test performance / / 20125193 rs2649130 chr8 137814585 G A 2.60E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs2649129 chr8 137814742 G A 1.72E-05 Cognitive test performance / / 20125193 rs2649129 chr8 137814742 G A 1.00E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs2649127 chr8 137815685 T C 1.88E-05 Cognitive test performance / / 20125193 rs2649127 chr8 137815685 T C 1.76E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs2649126 chr8 137815729 G A 1.23E-05 Cognitive test performance / / 20125193 rs2649126 chr8 137815729 G A 2.72E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs2582454 chr8 137817574 C T 1.72E-05 Cognitive test performance / / 20125193 rs2582454 chr8 137817574 C T 2.81E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs2649123 chr8 137818388 T G 1.72E-05 Cognitive test performance / / 20125193 rs2649123 chr8 137818388 T G 2.81E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs10505665 chr8 137822965 G A 3.24E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs2613815 chr8 137825180 G A 1.72E-05 Cognitive test performance / / 20125193 rs2613815 chr8 137825180 G A 2.18E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs2610127 chr8 137826173 C T 1.72E-05 Cognitive test performance / / 20125193 rs2610127 chr8 137826173 C T 2.44E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs2613817 chr8 137826900 G T 1.72E-05 Cognitive test performance / / 20125193 rs2613817 chr8 137826900 G T 2.51E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs2610128 chr8 137827853 C T 1.72E-05 Cognitive test performance / / 20125193 rs2610128 chr8 137827853 C T 2.66E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs2582447 chr8 137828862 A G 1.72E-05 Cognitive test performance / / 20125193 rs2582447 chr8 137828862 A G 2.51E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs1979813 chr8 137829950 G T 1.72E-05 Cognitive test performance / / 20125193 rs1979813 chr8 137829950 G T 2.72E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs2582444 chr8 137830784 C T 1.72E-05 Cognitive test performance / / 20125193 rs2582444 chr8 137830784 C T 3.08E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs2582435 chr8 137833740 A G 1.46E-05 Cognitive test performance / / 20125193 rs2582435 chr8 137833740 A G 4.26E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs2610067 chr8 137835656 T C 1.72E-05 Cognitive test performance / / 20125193 rs2610067 chr8 137835656 T C 4.26E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs2582431 chr8 137836277 C T 1.72E-05 Cognitive test performance / / 20125193 rs2582431 chr8 137836277 C T 3.11E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs7842167 chr8 137841734 G C 5.95E-04 Multiple complex diseases / / 17554300 rs16906415 chr8 137850011 A G 3.00E-06 IgG glycosylation / / 23382691 rs16906415 chr8 137850011 A G 6.00E-06 IgG glycosylation / / 23382691 rs4084898 chr8 137863759 T G 6.13E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs6985540 chr8 137934938 A G 6.14E-04 Multiple complex diseases / / 17554300 rs1353851 chr8 137963436 T C 5.27E-05 Post-operative nausea and vomiting / / 21694509 rs1499451 chr8 137977335 T G 3.80E-05 Serum metabolites / / 19043545 rs1499447 chr8 137982289 C T 3.29E-04 Stroke / / pha002887 rs1499449 chr8 137995401 T C 6.10E-04 Major depressive disorder / / 21042317 rs11166680 chr8 137997343 C G 8.60E-04 Major depressive disorder / / 21042317 rs11991861 chr8 138004942 A T 7.79E-08 Metabolite levels / / 23281178 rs7014243 chr8 138008250 T A 6.40E-04 Major depressive disorder / / 21042317 rs4366108 chr8 138018770 C T 4.90E-08 Metabolite levels / / 23281178 rs6995856 chr8 138024322 T C 6.50E-04 Major depressive disorder / / 21042317 rs11780624 chr8 138063213 C T 3.06E-04 Schizophrenia / / 19197363 rs11989063 chr8 138076583 C G 2.60E-04 Major depressive disorder / / 21042317 rs4256627 chr8 138097930 T C 5.40E-04 Major depressive disorder / / 21042317 rs7007075 chr8 138099266 C T 7.70E-06 Lipid traits / / 17903299 rs16906784 chr8 138144102 G A 6.69E-04 Type 2 diabetes / / 17463246 rs16906788 chr8 138146684 G A 2.98E-04 Schizophrenia / / 19197363 rs16906790 chr8 138147252 A C 8.79E-04 Multiple complex diseases / / 17554300 rs2223027 chr8 138155604 A G 4.92E-04 Type 2 diabetes / / 17463246 rs2325910 chr8 138178356 A G 1.70E-05 Type 2 diabetes / / 17463246 rs4272417 chr8 138194722 G A 2.80E-05 Cognitive function / / 24684796 rs2077233 chr8 138194869 G A 7.00E-06 Cognitive function / / 24684796 rs10112576 chr8 138235253 A G 4.96E-04 Smoking initiation / / 24665060 rs16906883 chr8 138236515 T C 2.51E-04 Alzheimer's disease (late onset) / / 21379329 rs7018106 chr8 138264848 A G 1.78E-04 Smoking initiation / / 24665060 rs16906903 chr8 138271557 A G 4.18E-05 Odorant perception / / 23910658 rs7000183 chr8 138286203 C A 6.73E-04 Myocardial Infarction / / pha002873 rs17624373 chr8 138312284 G A 1.00E-05 Urinary metabolites / / 21572414 rs17670205 chr8 138312610 C T 1.40E-05 Urinary metabolites / / 21572414 rs7845766 chr8 138337614 G A 1.80E-04 Lipid levels / / 18193043 rs13279979 chr8 138354352 T C 4.92E-05 Bipolar disorder / / 17486107 rs9324446 chr8 138368191 T C 5.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10505673 chr8 138378521 C T 4.10E-04 Crohn's disease / / 17684544 rs7017772 chr8 138379927 T C 9.25E-05 Multiple complex diseases / / 17554300 rs6990441 chr8 138381900 T C 1.70E-04 Multiple complex diseases / / 17554300 rs4579564 chr8 138382230 C T 1.57E-04 Multiple complex diseases / / 17554300 rs12541665 chr8 138386546 G T 0.000646659 Hypertension (early onset hypertension) / / 22479346 rs6577786 chr8 138390046 T C 0.000820187 Hypertension (early onset hypertension) / / 22479346 rs4909661 chr8 138391403 G A 7.48E-04 Smoking initiation / / 24665060 rs17626729 chr8 138391587 C T 2.46E-04 Multiple complex diseases / / 17554300 rs12544377 chr8 138402047 C T 1.49E-04 Multiple complex diseases / / 17554300 rs4291304 chr8 138412519 A G 1.10E-04 Multiple complex diseases / / 17554300 rs2992721 chr8 138418828 G A 2.93E-04 Multiple complex diseases / / 17554300 rs1514211 chr8 138420450 A G 1.42E-04 Multiple complex diseases / / 17554300 rs2960102 chr8 138420536 G A 6.16E-04 Multiple complex diseases / / 17554300 rs2992719 chr8 138440538 C T 6.72E-04 Multiple complex diseases / / 17554300 rs2992718 chr8 138442904 A G 1.00E-04 Prostate cancer / / 21743057 rs2960109 chr8 138444604 T C 5.56E-04 Parkinson's disease / / 17052657 rs1514194 chr8 138449358 G A 8.13E-04 Parkinson's disease / / 17052657 rs2960110 chr8 138454656 C T 2.34E-05 Coronary heart disease / / pha003055 rs10505678 chr8 138455566 G C 6.07E-04 Multiple complex diseases / / 17554300 rs11166721 chr8 138456312 G A 6.52E-04 Multiple complex diseases / / 17554300 rs16907208 chr8 138463366 A G 6.12E-04 Multiple complex diseases / / 17554300 rs16907216 chr8 138464270 C A 7.84E-04 Multiple complex diseases / / 17554300 rs41373445 chr8 138483302 T C 6.47E-04 Type 2 diabetes / / 17463246 rs4053409 chr8 138505969 A G 8.93E-05 Erythrocyte counts / / pha003101 rs1849692 chr8 138506934 T C 2.01E-04 Vaspin levels / / 22907691 rs1849692 chr8 138506934 T C 0.0002012 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs1399176 chr8 138514170 T C 7.00E-04 Colorectal cancer / / 17618283 rs16907427 chr8 138522685 C T 2.01E-04 Vaspin levels / / 22907691 rs16907427 chr8 138522685 C T 0.0001743 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs16907427 chr8 138522685 C T 0.0002012 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs12541822 chr8 138602460 T A 4.26E-04 Major depressive disorder / / 22472876 rs7833364 chr8 138648600 G A 4.06E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7833364 chr8 138648600 G A 4.10E-04 Lung function (forced vital capacity) / / 24023788 rs6577815 chr8 138657388 C T 8.80E-06 Urinary metabolites / / 21572414 rs12676177 chr8 138669620 T C 4.99E-05 Cognitive impairment induced by topiramate / / 22091778 rs12545584 chr8 138688770 T C 2.56E-04 Coronary heart disease / / 21971053 rs7834617 chr8 138691728 A T 6.94E-05 Multiple complex diseases / / 17554300 rs4503134 chr8 138693985 A G 4.14E-05 Multiple complex diseases / / 17554300 rs7002130 chr8 138695073 C T 3.88E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7002130 chr8 138695073 C T 5.83E-05 Lung function (forced vital capacity) / / 24023788 rs11166746 chr8 138701808 A T 9.76E-04 Alzheimer's disease / / 17998437 rs10481397 chr8 138710637 C A 9.38E-04 Coronary Artery Disease / / 17634449 rs10104327 chr8 138711327 T C 9.31E-05 Bipolar disorder / / 22925353 rs13275514 chr8 138770156 A G 5.07E-04 Smoking initiation / / 24665060 rs10112884 chr8 138777847 A G 6.19E-04 Alzheimer's disease / / 17998437 rs7002489 chr8 138804397 A G 4.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6577840 chr8 138805432 G A 7.10E-06 Left ventricular hypertrophy / / 21828061 rs4909705 chr8 138805788 T C 3.70E-06 Left ventricular hypertrophy / / 21828061 rs7825068 chr8 138807660 T C 5.00E-06 Left ventricular hypertrophy / / 21828061 rs7840530 chr8 138811480 A G 7.30E-06 Left ventricular hypertrophy / / 21828061 rs13282624 chr8 138849473 T G 3.04E-05 Cognitive impairment induced by topiramate FLJ45872 intron 22091778 rs7819359 chr8 138849524 A G 3.09E-04 Type 2 diabetes FLJ45872 intron 17463246 rs7829804 chr8 138855494 G C 3.99E-04 Suicide attempts in bipolar disorder FLJ45872 intron 21423239 rs7826901 chr8 138855983 A G 4.91E-04 Suicide attempts in bipolar disorder FLJ45872 intron 21423239 rs17636604 chr8 138863357 T C 8.70E-04 Suicide attempts in bipolar disorder FLJ45872 intron 21423239 rs7386076 chr8 138864042 C T 5.16E-04 Suicide attempts in bipolar disorder FLJ45872 intron 21423239 rs7386095 chr8 138864096 C T 5.20E-04 Suicide attempts in bipolar disorder FLJ45872 intron 21423239 rs4909709 chr8 138866091 T C 4.62E-04 Suicide attempts in bipolar disorder FLJ45872 intron 21423239 rs11987116 chr8 138866995 G A 2.09E-04 Suicide attempts in bipolar disorder FLJ45872 intron 21423239 rs6997404 chr8 138872643 C T 4.18E-04 Suicide attempts in bipolar disorder FLJ45872 intron 21423239 rs7001067 chr8 138873213 G C 4.08E-04 Suicide attempts in bipolar disorder FLJ45872 intron 21423239 rs907461 chr8 138875499 T C 6.71E-04 Suicide attempts in bipolar disorder FLJ45872 intron 21423239 rs1473083 chr8 138878491 T G 6.67E-04 Suicide attempts in bipolar disorder FLJ45872 intron 21423239 rs9657451 chr8 138905296 A G 2.00E-06 Cognitive performance FLJ45872 intron 20125193 rs62531686 chr8 138909719 T C 8.00E-07 PCA3 expression level FLJ45872 intron 23555189 rs62531686 chr8 138909719 T C 8.04E-07 PCA3 expression level FLJ45872 intron 23555189 rs2668096 chr8 138912997 G A 8.42E-05 Cognitive test performance FLJ45872 intron 20125193 rs17695537 chr8 138914072 C T 8.40E-05 Serum metabolites FLJ45872 intron 19043545 rs2705293 chr8 138918945 C T 7.37E-04 Type 2 diabetes FLJ45872 intron 17463246 rs2705293 chr8 138918945 C T 3.06E-04 Multiple complex diseases FLJ45872 intron 17554300 rs2705293 chr8 138918945 C T 6.00E-06 Neuroticism FLJ45872 intron 18762592 rs2668104 chr8 138919052 C T 3.24E-05 Cognitive test performance FLJ45872 intron 20125193 rs1511829 chr8 138919325 T C 7.37E-04 Type 2 diabetes FLJ45872 intron 17463246 rs2705291 chr8 138919701 G A 7.64E-04 Multiple complex diseases FLJ45872 intron 17554300 rs2705290 chr8 138919757 G A 8.17E-04 Body mass index FLJ45872 intron 21701565 rs2221844 chr8 138927680 C T 1.47E-05 Cognitive test performance FLJ45872 intron 20125193 rs1858367 chr8 138930779 G A 2.00E-10 Smoking behavior FLJ45872 intron 20418888 rs1398034 chr8 138932176 T C 6.26E-04 Esophageal adenocarcinoma FLJ45872 intron 24121790 rs2668117 chr8 138944949 C T 1.69E-04 Insulin resistance FLJ45872 intron 21901158 rs2705276 chr8 138952704 A G 7.18E-04 Insulin resistance FLJ45872 intron 21901158 rs10103652 chr8 139009683 C A 5.08E-06 Parkinson's disease FLJ45872 intron 21738487 rs16908145 chr8 139037973 T A 9.68E-05 Multiple complex diseases FLJ45872 intron 17554300 rs982842 chr8 139069173 A G 7.85E-05 Cognitive test performance FLJ45872 intron 20125193 rs10101858 chr8 139072818 A G 6.78E-04 Coronary heart disease FLJ45872 intron 21971053 rs1028777 chr8 139077206 A C 4.23E-05 Hearing function FLJ45872 intron 17255346 rs984440 chr8 139077728 C T 3.00E-06 Obesity-related traits FLJ45872 intron 23251661 rs873828 chr8 139143419 A G 1.30E-05 Urinary metabolites FAM135B UTR-3 21572414 rs754155 chr8 139143576 A C 1.00E-05 Urinary metabolites FAM135B UTR-3 21572414 rs4620329 chr8 139145308 G A 2.88E-04 Multiple complex diseases FAM135B intron 17554300 rs7459851 chr8 139145752 G A 6.30E-06 Urinary metabolites FAM135B intron 21572414 rs16908342 chr8 139154039 T C 2.64E-05 Receptive language ability FAM135B intron 24687471 rs4338148 chr8 139159028 T C 3.04E-05 Receptive language ability FAM135B intron 24687471 rs7835830 chr8 139165289 T C 9.48E-04 Heart Failure FAM135B missense pha002885 rs6577880 chr8 139173968 C T 4.00E-06 Urinary metabolites FAM135B intron 21572414 rs7007481 chr8 139175059 C A 1.70E-05 Urinary metabolites FAM135B intron 21572414 rs4455890 chr8 139191312 G A 9.11E-06 Triglycerides FAM135B intron pha003081 rs10875418 chr8 139196194 G A 8.48E-04 Type 2 diabetes FAM135B intron 17463246 rs4520207 chr8 139197874 C T 2.00E-04 Information processing speed FAM135B intron 21130836 rs16908507 chr8 139198605 A T 3.03E-04 Type 2 diabetes FAM135B intron 17463246 rs11995943 chr8 139215025 C A 1.00E-04 Cognitive impairment induced by topiramate FAM135B intron 22091778 rs4909759 chr8 139224501 T C 2.00E-04 Cognitive impairment induced by topiramate FAM135B intron 22091778 rs4909761 chr8 139225562 T C 4.25E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) FAM135B intron 24023788 rs7001598 chr8 139228642 A G 1.90E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) FAM135B intron 24023788 rs13280614 chr8 139235599 C T 3.66E-04 Body mass index FAM135B intron 21701565 rs7840115 chr8 139238709 C T 6.48E-04 Multiple complex diseases FAM135B intron 17554300 rs4909764 chr8 139255918 T C 2.00E-06 Inflammatory biomarkers FAM135B intron 22228203 rs7460570 chr8 139261705 T C 8.16E-05 HIV-1 control FAM135B intron 20041166 rs7816995 chr8 139277356 T A 6.59E-04 Suicide attempts in bipolar disorder FAM135B intron 21423239 rs10875422 chr8 139291263 G C 6.09E-06 White blood cell count FAM135B intron 21738479 rs13273961 chr8 139294301 A T 3.30E-06 Urinary metabolites FAM135B intron 21572414 rs10505698 chr8 139298819 A G 2.94E-04 Depression (quantitative trait) FAM135B intron 20800221 rs1512406 chr8 139299165 C T 5.04E-04 Substance dependence FAM135B intron 21818250 rs10875423 chr8 139301378 T A 9.00E-06 Periodontitis (PAL4Q3) FAM135B intron 24024966 rs17721181 chr8 139302480 T C 8.20E-05 Serum metabolites FAM135B intron 19043545 rs1512407 chr8 139303835 T C 7.92E-05 Substance dependence FAM135B intron 21818250 rs1398293 chr8 139309169 G A 7.09E-05 Body Mass Index FAM135B intron pha003006 rs1398293 chr8 139309169 G A 9.74E-05 Body Mass Index FAM135B intron pha003007 rs16908814 chr8 139333627 G A 1.87E-05 Multiple complex diseases FAM135B intron 17554300 rs16908816 chr8 139334720 C T 4.08E-04 Multiple complex diseases FAM135B intron 17554300 rs4909775 chr8 139362117 C T 0.00014 Salmonella-induced pyroptosis FAM135B intron 22837397 rs4909779 chr8 139374614 T C 0.000663 Salmonella-induced pyroptosis FAM135B intron 22837397 rs340707 chr8 139379964 T C 4.05E-04 Epilepsy FAM135B intron 22116939 rs1401608 chr8 139381934 G A 1.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) FAM135B intron 17982456 rs1519369 chr8 139393909 C T 0.000125 Salmonella-induced pyroptosis FAM135B intron 22837397 rs1519370 chr8 139394114 G A 0.000548 Salmonella-induced pyroptosis FAM135B intron 22837397 rs12675397 chr8 139395920 C T 4.04E-04 Type 2 diabetes FAM135B intron 17463246 rs16909084 chr8 139405963 C T 8.64E-04 Type 2 diabetes FAM135B intron 17463246 rs2056412 chr8 139413333 T C 1.41E-08 Autism FAM135B intron 22935194 rs4909788 chr8 139424363 C G 2.93E-04 Cognitive decline FAM135B intron 23732972 rs2139331 chr8 139453108 G A 4.74E-04 Multiple complex diseases FAM135B intron 17554300 rs17674188 chr8 139474561 G A 9.86E-04 Multiple complex diseases FAM135B intron 17554300 rs17725200 chr8 139476477 G A 2.31E-04 Type 2 diabetes FAM135B intron 17463246 rs11166825 chr8 139481671 C T 6.87E-04 Multiple complex diseases FAM135B intron 17554300 rs16909195 chr8 139484985 T C 4.89E-04 Multiple complex diseases FAM135B intron 17554300 rs11166827 chr8 139504270 C T 5.00E-06 Cognitive performance FAM135B intron 20125193 rs11166827 chr8 139504270 C T 2.77E-04 Celiac disease FAM135B intron 23936387 rs7017524 chr8 139593796 C A 4.49E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10091528 chr8 139603111 C T 5.85E-04 HIV-1 viral setpoint COL22A1 intron 17641165 rs4576426 chr8 139634852 T G 2.80E-04 Response to antidepressants COL22A1 intron 19736353 rs4301456 chr8 139642327 A C 2.18E-04 Multiple complex diseases COL22A1 intron 17554300 rs7003632 chr8 139646998 T C 4.00E-04 Multiple complex diseases COL22A1 intron 17554300 rs10091563 chr8 139647262 A G 5.57E-05 Depression (quantitative trait) / / 20800221 rs4909439 chr8 139658747 C T 1.68E-04 Depression (quantitative trait) COL22A1 intron 20800221 rs6577938 chr8 139659232 T G 2.99E-04 Depression (quantitative trait) COL22A1 intron 20800221 rs4909440 chr8 139659737 T C 2.98E-04 Depression (quantitative trait) COL22A1 intron 20800221 rs6982714 chr8 139660353 G T 1.35E-04 Depression (quantitative trait) COL22A1 intron 20800221 rs6984002 chr8 139660425 C G 2.77E-04 Depression (quantitative trait) COL22A1 intron 20800221 rs6982882 chr8 139660473 G C 2.67E-04 Depression (quantitative trait) COL22A1 intron 20800221 rs6988358 chr8 139661487 G C 1.20E-04 Depression (quantitative trait) COL22A1 intron 20800221 rs6577939 chr8 139662751 C G,T 7.64E-05 Depression (quantitative trait) COL22A1 intron 20800221 rs3923549 chr8 139663617 A G 3.96E-04 Depression (quantitative trait) COL22A1 intron 20800221 rs3924863 chr8 139664484 G A 7.25E-05 Depression (quantitative trait) COL22A1 intron 20800221 rs3924862 chr8 139664516 G A 7.29E-05 Depression (quantitative trait) COL22A1 intron 20800221 rs6985495 chr8 139665734 G C 9.30E-05 Depression (quantitative trait) COL22A1 intron 20800221 rs4073447 chr8 139665846 A T 8.46E-05 Depression (quantitative trait) COL22A1 intron 20800221 rs4073446 chr8 139665874 A G 8.48E-05 Depression (quantitative trait) COL22A1 intron 20800221 rs6421014 chr8 139668786 G A 8.81E-05 Depression (quantitative trait) COL22A1 intron 20800221 rs6421014 chr8 139668786 G A 8.20E-05 Epilepsy (remission after treatment) COL22A1 intron 23962720 rs7002247 chr8 139669063 G T 3.27E-04 Depression (quantitative trait) COL22A1 intron 20800221 rs6989017 chr8 139669119 T C 1.16E-04 Depression (quantitative trait) COL22A1 intron 20800221 rs7460303 chr8 139669569 A G 6.06E-05 Depression (quantitative trait) COL22A1 intron 20800221 rs7460303 chr8 139669569 A G 9.16E-05 Epilepsy (remission after treatment) COL22A1 intron 23962720 rs4072881 chr8 139672167 C T 6.40E-05 Depression (quantitative trait) COL22A1 intron 20800221 rs4072506 chr8 139672602 T C 6.43E-05 Depression (quantitative trait) COL22A1 intron 20800221 rs13272198 chr8 139675763 T C 0.0003576 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) COL22A1 intron 23233654 rs13272198 chr8 139675763 T C 3.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) COL22A1 intron 23233662 rs4380981 chr8 139680940 A G 0.0002635 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) COL22A1 intron 23233654 rs4380981 chr8 139680940 A G 2.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) COL22A1 intron 23233662 rs9657455 chr8 139681125 C A 0.0002499 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) COL22A1 intron 23233654 rs9657455 chr8 139681125 C A 2.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) COL22A1 intron 23233662 rs4369035 chr8 139682749 A G 1.53E-04 Multiple complex diseases COL22A1 intron 17554300 rs4369035 chr8 139682749 A G 0.0001341 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) COL22A1 intron 23233654 rs4369035 chr8 139682749 A G 1.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) COL22A1 intron 23233662 rs7844188 chr8 139694420 G A 2.68E-04 Myopia (pathological) COL22A1 intron 21095009 rs3936181 chr8 139706264 G T 2.86E-04 Coronary heart disease COL22A1 intron 21606135 rs4073002 chr8 139707862 C A 8.73E-04 Alzheimer's disease COL22A1 intron 17998437 rs4545143 chr8 139711729 T A 1.34E-04 Alzheimer's disease COL22A1 intron pha002879 rs1573833 chr8 139799772 A G 8.00E-05 Schizophrenia COL22A1 intron 19571809 rs7837787 chr8 139806715 A G 9.22E-05 Serum metabolites COL22A1 intron 19043545 rs12549194 chr8 139826837 A C 8.41E-04 Insulin resistance COL22A1 intron 21901158 rs11166852 chr8 139876185 A G 3.47E-04 Smoking initiation COL22A1 intron 24665060 rs11775756 chr8 139876426 A C 1.00E-05 Urinary metabolites COL22A1 intron 21572414 rs16893548 chr8 139879290 C T 5.07E-04 Aortic root size COL22A1 intron 21223598 rs6988229 chr8 139884509 C T 9.00E-06 Asthma (bronchodilator response) COL22A1 intron 23508266 rs12549200 chr8 139888196 G A 4.20E-06 Major depressive disorder COL22A1 intron 21042317 rs4736229 chr8 139900534 A G 9.01E-05 Body Fat Distribution COL22A1 intron pha003017 rs7816085 chr8 139931564 C T 8.35E-04 Alzheimer's disease / / 17998437 rs6577977 chr8 139975998 C A 6.22E-05 Leukocyte Counts / / pha003091 rs10096648 chr8 139981134 G T 8.03E-04 Smoking initiation / / 24665060 rs1354736 chr8 139986981 G A 4.92E-04 Type 2 diabetes / / 17463246 rs13253216 chr8 139996825 A C 7.43E-05 Hemoglobin / / pha003096 rs1395312 chr8 140007543 C A 3.92E-06 Height / / 22021425 rs951920 chr8 140010100 G A 1.10E-04 Myasthenia gravis / / 23055271 rs7816264 chr8 140014262 G T 2.70E-04 Type 2 diabetes / / 17463246 rs959554 chr8 140014803 A T 2.89E-04 Type 2 diabetes / / 17463246 rs959554 chr8 140014803 A T 5.65E-04 Aortic root size / / 21223598 rs16909936 chr8 140015639 C A 8.49E-04 Type 2 diabetes / / 17463246 rs1506508 chr8 140016398 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7816871 chr8 140028000 A G 9.49E-05 Body Composition / / pha003012 rs2318830 chr8 140028933 T C 7.30E-05 Body Composition / / pha003012 rs12678595 chr8 140033861 G A 7.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12677892 chr8 140037884 G A 6.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10100018 chr8 140047202 C T 2.66E-04 Multiple complex diseases / / 17554300 rs7838977 chr8 140054219 G A 6.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10092007 chr8 140060263 T C 3.07E-04 Multiple complex diseases / / 17554300 rs16910069 chr8 140081806 C A 8.88E-04 Type 2 diabetes / / 17463246 rs16910092 chr8 140093159 T G 2.30E-05 Urinary metabolites / / 21572414 rs4736057 chr8 140127842 A C 2.14E-04 Sudden cardiac arrest / / 21658281 rs11987078 chr8 140132539 A G 4.19E-04 Multiple complex diseases / / 17554300 rs13256020 chr8 140148578 C G 6.22E-04 Multiple complex diseases / / 17554300 rs6981713 chr8 140149457 G A 4.03E-04 Multiple complex diseases / / 17554300 rs6577995 chr8 140158294 C T 5.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4074554 chr8 140163451 C A 1.39E-05 Multiple complex diseases / / 17554300 rs4074243 chr8 140163899 C T 2.15E-05 Multiple complex diseases / / 17554300 rs11166882 chr8 140168640 C T 1.19E-05 Multiple complex diseases / / 17554300 rs6997709 chr8 140180024 G T 7.88E-06 Multiple complex diseases / / 17554300 rs4736061 chr8 140211185 C T 2.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12545058 chr8 140216794 A G 2.78E-04 Hearing function / / 17255346 rs2873891 chr8 140217584 G C 2.81E-04 Hearing function / / 17255346 rs4133282 chr8 140218012 C T 1.99E-04 Hearing function / / 17255346 rs4556079 chr8 140232935 T C 3.96E-04 Parkinson's disease / / 17052657 rs4556079 chr8 140232935 T C 4.79E-06 Parkinson's disease / / pha002868 rs12548929 chr8 140236246 C A 2.97E-04 Hearing function / / 17255346 rs7017449 chr8 140239452 T C 5.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2001907 chr8 140241181 C T 3.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11781101 chr8 140247662 T C 8.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11781101 chr8 140247662 T C 5.31E-06 Parkinson's disease / / pha002868 rs7004938 chr8 140259225 G A 9.32E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7004938 chr8 140259225 G A 2.97E-06 Parkinson's disease / / pha002868 rs7006046 chr8 140259239 C T 5.27E-04 Parkinson's disease / / 17052657 rs7006046 chr8 140259239 C T 2.79E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11783351 chr8 140259539 C T 2.09E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11783351 chr8 140259539 C T 5.51E-06 Parkinson's disease / / pha002868 rs6578017 chr8 140264606 A T 1.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs4440614 chr8 140264728 G A 1.94E-04 Parkinson's disease / / 21248740 rs4440614 chr8 140264728 G A 1.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs2319103 chr8 140265018 T A 1.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs9324505 chr8 140265234 C T 1.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs10216400 chr8 140265381 T C 1.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs7814156 chr8 140265594 A G 1.04E-04 Parkinson's disease / / 21248740 rs7814156 chr8 140265594 A G 8.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs7829971 chr8 140265669 G A 8.51E-05 Suicide attempts in bipolar disorder / / 21423239 rs4577937 chr8 140266003 G A 1.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs7464965 chr8 140266131 G C 7.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs4311640 chr8 140266411 G T 1.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs4477000 chr8 140266704 T C 9.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs11777960 chr8 140266789 G A 8.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs6996249 chr8 140300612 T C 9.74E-05 Bipolar disorder / / 19488044 rs6984036 chr8 140304962 T C 2.51E-04 Scoliosis / / 21216876 rs2873903 chr8 140320084 A G 8.93E-05 Scoliosis / / 21216876 rs10505712 chr8 140375282 C T 7.13E-04 Telomere length / / 23900074 rs972164 chr8 140403873 A G 8.00E-04 Stroke / / pha002887 rs2045856 chr8 140409588 C A 7.58E-06 Lipid levels / / 19016617 rs9324508 chr8 140428805 G A,C,T 6.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs12680834 chr8 140430945 C T 6.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs2447553 chr8 140432773 T C 8.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs2468677 chr8 140519517 G T 8.00E-07 Adiponectin levels / / 21700879 rs2468680 chr8 140521220 G A 6.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2468680 chr8 140521220 G A 6.12E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs11778126 chr8 140532313 C T 1.13E-05 Creatinine levels / / pha003069 rs6993113 chr8 140535461 G A 1.19E-05 Creatinine levels / / pha003069 rs4736281 chr8 140575658 G A 1.36E-05 Creatinine levels / / pha003069 rs2542447 chr8 140590558 G A 0.000167 Salmonella-induced pyroptosis / / 22837397 rs918184 chr8 140594358 A C 0.000519 Salmonella-induced pyroptosis / / 22837397 rs11776727 chr8 140597862 A G 7.14E-04 Parkinson's disease / / 16252231 rs2542436 chr8 140602616 T C 3.30E-04 Response to antidepressants / / 19736353 rs2542435 chr8 140603502 G A 2.99E-04 Alcohol dependence / / 21314694 rs2431300 chr8 140611754 A G 2.80E-05 Urinary metabolites / / 21572414 rs2471087 chr8 140616555 G A 9.35E-04 Type 2 diabetes / / 17463246 rs2542425 chr8 140632384 T C 7.68E-05 Cognitive test performance KCNK9 intron 20125193 rs2542425 chr8 140632384 T C 2.00E-04 Cognitive impairment induced by topiramate KCNK9 intron 22091778 rs2014712 chr8 140640634 C T 8.40E-04 Alcohol dependence KCNK9 intron 21314694 rs10088495 chr8 140641081 C T 5.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNK9 intron 20877124 rs2545462 chr8 140645504 G T 3.25E-04 Blood pressure KCNK9 intron 17255346 rs741463 chr8 140646188 C G 4.34E-04 Type 2 diabetes KCNK9 intron 17463246 rs741463 chr8 140646188 C G 2.30E-04 Multiple complex diseases KCNK9 intron 17554300 rs888349 chr8 140669745 G T 2.34E-04 Hearing function KCNK9 intron 17255346 rs759656 chr8 140669967 A G 4.86E-05 Serum metabolites KCNK9 intron 19043545 rs759656 chr8 140669967 A G 4.30E-06 Urinary metabolites KCNK9 intron 21572414 rs12678141 chr8 140709957 C T 6.15E-04 Myopia (pathological) KCNK9 intron 21095009 rs124672 chr8 140722178 A G 5.52E-04 Coronary heart disease / / 21971053 rs10112809 chr8 140766175 T C 4.20E-08 Health and aging,CVD and cancer age of onset TRAPPC9 intron 22174011 rs11773968 chr8 140771011 G T 8.10E-04 Alcohol dependence TRAPPC9 intron 20201924 rs11773968 chr8 140771011 G T 8.10E-04 Alcohol dependence TRAPPC9 intron 20201924 rs7834010 chr8 140791732 A C 2.80E-05 Parkinson's disease (age of onset) TRAPPC9 intron 19772629 rs12679196 chr8 140812347 C T 3.10E-16 Progranulin levels TRAPPC9 intron 21087763 rs12679196 chr8 140812347 C T 3.10E-16 Myocardial infarction TRAPPC9 intron 21211798 rs7828992 chr8 140826670 A G 8.70E-05 Parkinson's disease (age of onset) TRAPPC9 intron 19772629 rs12682508 chr8 140846871 G A 3.30E-04 Fasting plasma glucose TRAPPC9 intron 19060907 rs4736010 chr8 140907637 A G 1.00E-05 Prostate cancer TRAPPC9 intron 21743057 rs898803 chr8 140908579 A G 1.00E-05 Prostate cancer TRAPPC9 intron 21743057 rs7845933 chr8 140909484 G T 1.00E-05 Prostate cancer TRAPPC9 intron 21743057 rs11166933 chr8 140909760 A G 1.00E-05 Prostate cancer TRAPPC9 intron 21743057 rs2085925 chr8 140934805 C T 4.98E-04 Hemoglobin concentration TRAPPC9 intron 20534544 rs2233224 chr8 140942614 C T 2.00E-05 Urinary metabolites TRAPPC9 intron 21572414 rs1542502 chr8 140962615 G A 7.42E-04 Type 2 diabetes TRAPPC9 intron 17463246 rs2665917 chr8 140963276 T C 7.98E-04 Osteosarcoma TRAPPC9 intron 23727862 rs2035133 chr8 140965303 A G 8.50E-06 Urinary metabolites TRAPPC9 intron 21572414 rs2941572 chr8 140969845 C T 1.30E-05 Urinary metabolites TRAPPC9 intron 21572414 rs2665931 chr8 140977205 A G 2.55E-04 Height TRAPPC9 intron 17255346 rs2614724 chr8 140983203 A G 3.59E-05 Multiple sclerosis TRAPPC9 intron 17660530 rs2614724 chr8 140983203 A G 1.60E-05 Urinary metabolites TRAPPC9 intron 21572414 rs2665952 chr8 140983920 C A 1.20E-05 Urinary metabolites TRAPPC9 intron 21572414 rs1870805 chr8 140995243 A G 3.00E-06 Obesity-related traits TRAPPC9 intron 23251661 rs34129218 chr8 140995243 A AG 3.00E-06 Obesity-related traits TRAPPC9 intron 23251661 rs7013574 chr8 141026556 C T 7.29E-04 Aortic root size TRAPPC9 intron 21223598 rs6578058 chr8 141030338 A T 1.24E-04 Type 2 diabetes TRAPPC9 intron 17463246 rs3815610 chr8 141033483 A T 4.17E-04 Type 2 diabetes TRAPPC9 intron 17463246 rs9987138 chr8 141076623 G C 3.28E-04 Type 2 diabetes TRAPPC9 intron 17463246 rs6985153 chr8 141100742 T C 5.17E-04 Alzheimer's disease TRAPPC9 intron 22005930 rs12547311 chr8 141104817 T C 1.40E-05 Urinary metabolites TRAPPC9 intron 21572414 rs6992848 chr8 141150169 T C 7.00E-06 Response to amphetamines TRAPPC9 intron 22952603 rs4282547 chr8 141152836 T C 2.40E-05 Urinary metabolites TRAPPC9 intron 21572414 rs3935989 chr8 141203709 T C 9.99E-04 Alzheimer's disease TRAPPC9 intron 22005930 rs3935989 chr8 141203709 T C 3.01E-06 Body Mass Index TRAPPC9 intron pha003015 rs11990197 chr8 141207813 A G 1.73E-04 Alzheimer's disease TRAPPC9 intron 22005930 rs13259162 chr8 141210214 G A 6.65E-05 Cortisol secretion,in saliva TRAPPC9 intron 21316860 rs13259162 chr8 141210214 G A 1.74E-04 Alzheimer's disease TRAPPC9 intron 22005930 rs10090220 chr8 141215000 A G 1.79E-04 Alzheimer's disease TRAPPC9 intron 22005930 rs4507747 chr8 141219125 C T 8.03E-04 Alzheimer's disease TRAPPC9 intron 22005930 rs4507747 chr8 141219125 C T 2.32E-06 Femoral neck bone geometry TRAPPC9 intron 22087292 rs7014855 chr8 141257264 C T 5.77E-04 Alcohol dependence TRAPPC9 intron 21314694 rs4078541 chr8 141265687 A G 8.46E-04 Heart Failure TRAPPC9 intron pha002885 rs4078539 chr8 141266513 T C 8.54E-04 Heart Failure TRAPPC9 intron pha002885 rs4736167 chr8 141284382 A G 8.00E-05 Alzheimer's disease (late onset) TRAPPC9 intron 21379329 rs4075647 chr8 141288769 C T 2.78E-04 Insulin resistance TRAPPC9 intron 21901158 rs13282061 chr8 141300377 C T 3.33E-04 Coronary heart disease TRAPPC9 intron 21606135 rs7839705 chr8 141360167 A G 7.18E-04 Type 2 diabetes TRAPPC9 intron 17463246 rs11778051 chr8 141410497 C T 7.05E-04 Alzheimer's disease TRAPPC9 intron 24755620 rs6993904 chr8 141480330 A G 4.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10109589 chr8 141530057 C T 1.06E-05 Triglycerides / / pha003081 rs10109589 chr8 141530057 C T 2.23E-05 Lipid levels / / pha003082 rs2977451 chr8 141534198 A G 2.40E-06 Fasting plasma glucose / / 19060907 rs2977453 chr8 141538846 T C 1.40E-04 Primary sclerosing cholangitis / / 19944697 rs2944755 chr8 141574194 A G 8.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients EIF2C2 intron 23400010 rs2977491 chr8 141574277 G A 8.20E-07 Urinary metabolites EIF2C2 intron 21572414 rs9694342 chr8 141587404 C T 3.97E-04 Multiple complex diseases EIF2C2 intron 17554300 rs7009635 chr8 141594881 T C 2.54E-05 Response to statin treatment (atorvastatin),change in cholesterol levels EIF2C2 intron 20031582 rs7001653 chr8 141621038 G A 2.39E-04 Response to statin treatment (atorvastatin),change in cholesterol levels EIF2C2 intron 20031582 rs2176397 chr8 141622537 C T 8.00E-05 Cognitive test performance EIF2C2 intron 20125193 rs11166986 chr8 141656155 G A 3.94E-04 Multiple complex diseases / / 17554300 rs11166990 chr8 141663972 G A 5.82E-04 Brain structure / / 22504417 rs11166991 chr8 141666413 C T 6.62E-04 Brain structure / / 22504417 rs10088475 chr8 141670266 T C 9.79E-04 Brain structure PTK2 intron 22504417 rs13273096 chr8 141675931 C T 5.60E-04 Brain structure PTK2 intron 22504417 rs7016497 chr8 141677324 T C 8.39E-05 Multiple complex diseases PTK2 intron 17554300 rs11166992 chr8 141677470 C T 5.56E-04 Brain structure PTK2 intron 22504417 rs3639 chr8 141684170 T C 1.16E-05 Brain structure PTK2 intron 22504417 rs4413752 chr8 141688972 C T 4.14E-04 Brain structure PTK2 intron 22504417 rs10089107 chr8 141698451 T C 4.27E-04 Brain structure PTK2 intron 22504417 rs7820179 chr8 141701476 C T 1.61E-04 Brain structure PTK2 intron 22504417 rs11785444 chr8 141704996 G A 6.62E-04 Multiple complex diseases PTK2 intron 17554300 rs11785444 chr8 141704996 G A 2.69E-05 Heart Rate PTK2 intron pha003051 rs4961287 chr8 141706320 G A 1.25E-05 Brain structure PTK2 intron 22504417 rs11166995 chr8 141719251 A G 7.63E-04 Brain structure PTK2 intron 22504417 rs4961230 chr8 141722084 G A 6.34E-04 Brain structure PTK2 intron 22504417 rs13280245 chr8 141727310 T G 7.21E-04 Brain structure PTK2 intron 22504417 rs7839832 chr8 141728474 C T 6.51E-04 Brain structure PTK2 intron 22504417 rs13257090 chr8 141729463 C T 1.89E-05 Brain structure PTK2 intron 22504417 rs11997161 chr8 141738587 T C 1.37E-05 Brain structure PTK2 intron 22504417 rs6994744 chr8 141740868 A C 2.13E-05 Brain structure PTK2 intron 22504417 rs6993266 chr8 141762659 G A 2.02E-05 Brain structure PTK2 intron 22504417 rs6578134 chr8 141778434 C T 7.63E-14 Non-obstructive azoospermia PTK2 intron 22197933 rs6985838 chr8 141801188 G C 0.00012 Coronary artery calcification PTK2 intron 23727086 rs10090774 chr8 141826739 C T 9.92E-04 Brain structure PTK2 intron 22504417 rs9650572 chr8 141831989 C T 9.70E-04 Brain structure PTK2 intron 22504417 rs7001591 chr8 141834000 G A 7.80E-04 Brain structure PTK2 intron 22504417 rs4434666 chr8 141840168 A G 7.81E-04 Brain structure PTK2 intron 22504417 rs4246128 chr8 141840739 G A 7.63E-04 Brain structure PTK2 intron 22504417 rs4961234 chr8 141840881 T C 7.06E-04 Brain structure PTK2 intron 22504417 rs13251663 chr8 141841577 A G 7.71E-04 Brain structure PTK2 intron 22504417 rs7831543 chr8 141847249 T C 5.29E-04 Brain structure PTK2 intron 22504417 rs12156014 chr8 141853518 T G 5.86E-04 Brain structure PTK2 intron 22504417 rs10098086 chr8 141858319 C G 1.00E-06 Parkinson's disease (interaction with coffee consumption) PTK2 intron 21876681 rs4961237 chr8 141902493 G A 8.49E-04 Brain structure PTK2 intron 22504417 rs10111852 chr8 141937541 C T 1.15E-04 Brain structure PTK2 intron 22504417 rs11167021 chr8 142025644 C T 1.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1078671 chr8 142070978 C T 8.20E-04 Multiple complex diseases / / 17554300 rs12115135 chr8 142081677 A G 2.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs12114035 chr8 142081744 T C 2.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs10098724 chr8 142084536 T C 3.00E-07 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs10111473 chr8 142090080 C T 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs12334878 chr8 142094777 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4961252 chr8 142104944 A G 3.00E-08 Response to interferon beta therapy / / 21502966 rs1467073 chr8 142132965 A G 2.45E-04 Celiac disease / / 23936387 rs7815457 chr8 142136963 G C 8.33E-06 Intracerebral hemorrhage / / 24656865 rs7816501 chr8 142136964 C T 7.40E-06 Intracerebral hemorrhage / / 24656865 rs7009780 chr8 142137634 T C 1.97E-06 Intracerebral hemorrhage / / 24656865 rs6988905 chr8 142137704 G A 2.95E-06 Intracerebral hemorrhage / / 24656865 rs3739232 chr8 142138860 C G 4.12E-06 Intracerebral hemorrhage DENND3 UTR-5 24656865 rs3739231 chr8 142139187 C T 4.56E-06 Intracerebral hemorrhage DENND3 intron 24656865 rs6578152 chr8 142139251 T C 6.33E-06 Intracerebral hemorrhage DENND3 intron 24656865 rs307766 chr8 142151713 C T 6.60E-04 Alcohol dependence DENND3 intron 21314694 rs3816063 chr8 142161064 C G,T 2.00E-06 Obesity-related traits DENND3 intron 23251661 rs7001673 chr8 142198596 G T 4.97E-09 Narcolepsy DENND3 intron 19629137 rs7001673 chr8 142198596 G T 7.58E-04 Body mass index DENND3 intron 21701565 rs6988366 chr8 142198682 T C 1.50E-05 Urinary metabolites DENND3 intron 21572414 rs6988366 chr8 142198682 T C 3.09E-04 Body mass index DENND3 intron 21701565 rs6988366 chr8 142198682 T C 3.71E-04 Body mass index DENND3 intron 21701565 rs13270024 chr8 142201477 T C 3.29E-04 Attention deficit hyperactivity disorder DENND3 intron 22012869 rs9792 chr8 142205237 A G 7.98E-04 Body mass index DENND3 UTR-3 21701565 rs6578153 chr8 142209543 C T 4.67E-04 Body mass index / / 21701565 rs3739238 chr8 142222445 T C 8.94E-04 Response to taxane treatment (placlitaxel) SLC45A4 missense 23006423 rs9324542 chr8 142227854 T A 7.04E-04 Response to taxane treatment (placlitaxel) SLC45A4 intron 23006423 rs4961258 chr8 142232878 G A 6.70E-04 Response to taxane treatment (placlitaxel) SLC45A4 intron 23006423 rs10875467 chr8 142233396 C A 9.60E-04 Response to taxane treatment (placlitaxel) SLC45A4 intron 23006423 rs6981564 chr8 142249029 C G 4.20E-10 Health and aging,CVD and cancer age of onset / / 22174011 rs6981564 chr8 142249029 C G 5.20E-07 Health and aging,CVD and cancer age of onset / / 22174011 rs6981564 chr8 142249029 C G 9.90E-07 Health and aging,CVD and cancer age of onset / / 22174011 rs13253108 chr8 142283565 G A 5.02E-05 Bipolar disorder and schizophrenia / / 20889312 rs7827290 chr8 142300315 T G 9.00E-06 Bipolar disorder / / 21926972 rs919873 chr8 142302260 C T 1.01E-09 Metabolite levels / / 23281178 rs11167044 chr8 142304421 C T 3.83E-10 Metabolite levels / / 23281178 rs11776290 chr8 142320537 A G 7.78E-06 Bipolar disorder and schizophrenia / / 20889312 rs11776290 chr8 142320537 A G 0.000788 Salmonella-induced pyroptosis / / 22837397 rs7818687 chr8 142323189 T C 8.35E-04 Multiple complex diseases / / 17554300 rs7818687 chr8 142323189 T C 4.41E-05 Meningococcal disease / / 20694013 rs878422 chr8 142327998 G A 0.000469 Salmonella-induced pyroptosis / / 22837397 rs6985508 chr8 142337734 G A 1.33E-04 Multiple complex diseases / / 17554300 rs11984988 chr8 142342682 T G 1.65E-05 Bipolar disorder and schizophrenia / / 20889312 rs4961372 chr8 142358865 A G 3.22E-06 Bipolar disorder and schizophrenia / / 20889312 rs6578164 chr8 142359262 C T 3.02E-04 Bipolar disorder / / 18317468 rs6578164 chr8 142359262 C T 5.43E-06 Bipolar disorder and schizophrenia / / 20889312 rs7386745 chr8 142359368 T C 1.85E-05 Bipolar disorder and schizophrenia / / 20889312 rs7386474 chr8 142359550 A G 3.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs7830293 chr8 142373509 T C 3.60E-05 Type 2 diabetes GPR20 intron 17463248 rs6578167 chr8 142381292 A C 4.70E-05 Type 2 diabetes / / 17463248 rs7839244 chr8 142388255 G A 6.80E-05 Type 2 diabetes / / 17463248 rs4961268 chr8 142395211 A G 3.70E-05 Type 2 diabetes / / 17463248 rs7836752 chr8 142460693 G A 0.00064 Salmonella-induced pyroptosis FLJ43860 intron 22837397 rs11777747 chr8 142466821 C T 8.00E-06 Coronary artery calcification FLJ43860 intron 23870195 rs7843467 chr8 142470210 T C 0.000662 Salmonella-induced pyroptosis FLJ43860 intron 22837397 rs4907398 chr8 142480610 C T 8.30E-04 Osteosarcoma FLJ43860 intron 23727862 rs2380249 chr8 142497453 C T 4.91E-04 Multiple complex diseases FLJ43860 intron 17554300 rs2380250 chr8 142497614 C G 6.45E-04 Multiple complex diseases FLJ43860 intron 17554300 rs7837045 chr8 142540925 A C 5.00E-06 Breast size / / 22747683 rs1566080 chr8 142556805 A C 6.00E-06 Obesity-related traits / / 23251661 rs4243790 chr8 142570586 T C 1.20E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs10112716 chr8 142572865 T C 1.28E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11787080 chr8 142575600 T C 5.37E-05 Bipolar disorder / / 17486107 rs607831 chr8 142583871 C T 0.0000226 Panic disorder / / 23149450 rs607831 chr8 142583871 C T 2.26E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs11777472 chr8 142604448 T C 4.61E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs898988 chr8 142607549 G A 3.40E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs898987 chr8 142607603 C T 3.45E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs307401 chr8 142609665 G A 5.51E-06 Magnesium levels / / pha003092 rs307412 chr8 142611869 A G 9.80E-08 Iron levels / / 21208937 rs307418 chr8 142619567 A G 1.92E-04 Multiple complex diseases / / 17554300 rs307419 chr8 142619906 G C 9.56E-04 Multiple complex diseases / / 17554300 rs1004380 chr8 142621485 G A 2.80E-05 Urinary metabolites / / 21572414 rs1566084 chr8 142624215 G T 7.30E-07 Urinary metabolites / / 21572414 rs4907362 chr8 142626257 A C 6.20E-06 Urinary metabolites / / 21572414 rs1496863 chr8 142629143 G A 8.50E-06 Urinary metabolites / / 21572414 rs12680513 chr8 142631621 C T 7.10E-06 Urinary metabolites / / 21572414 rs13263959 chr8 142632315 T C 8.00E-07 Hair color / / 20585627 rs13263959 chr8 142632315 T C 1.50E-05 Urinary metabolites / / 21572414 rs9650577 chr8 142637994 T C 3.20E-07 Urinary metabolites / / 21572414 rs4907335 chr8 142645348 G T 5.50E-07 Urinary metabolites / / 21572414 rs10103458 chr8 142646752 A G 4.60E-07 Urinary metabolites / / 21572414 rs903961 chr8 142652560 T A 8.93E-05 Bipolar disorder and schizophrenia / / 20889312 rs6578205 chr8 142653435 A T 9.59E-06 Periodontitis (PAL4Q3) / / 24024966 rs10094253 chr8 142656918 A T 8.80E-06 Urinary metabolites / / 21572414 rs10088430 chr8 142661456 T C 9.87E-05 Bipolar disorder and schizophrenia / / 20889312 rs11779832 chr8 142684947 G A 3.81E-05 Type 2 diabetes / / 17463246 rs1109990 chr8 142704071 G C 5.79E-05 Bipolar disorder and schizophrenia / / 20889312 rs903956 chr8 142705898 A G 2.10E-06 Urinary metabolites / / 21572414 rs11785008 chr8 142728247 T C 6.68E-05 Cognitive test performance / / 20125193 rs12549250 chr8 142729853 A G 9.34E-04 Parkinson's disease / / 17052657 rs12549250 chr8 142729853 A G 5.41E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4072286 chr8 142736531 T G 3.92E-08 Osteoarthritis / / 22763110 rs4072286 chr8 142736531 T G 4.00E-07 Obesity-related traits / / 23251661 rs9324553 chr8 142743811 A G 7.75E-04 Type 2 diabetes / / 17463246 rs9324553 chr8 142743811 A G 9.69E-06 Multiple complex diseases / / 17554300 rs12676599 chr8 142745374 T C 5.66E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs9720679 chr8 142832751 C A 9.93E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12541756 chr8 142876649 G A 8.06E-04 Body mass index / / 21701565 rs9772881 chr8 142878259 G A 8.10E-07 Urinary metabolites / / 21572414 rs11786376 chr8 142893675 G A 2.98E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2121474 chr8 142911466 G A 4.33E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7012875 chr8 142923384 G A 2.43E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1446940 chr8 142924017 A G 3.01E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11988083 chr8 142934184 G T 2.43E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1992805 chr8 142950775 C T 5.42E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs935461 chr8 142980434 C T 9.61E-06 Gallstones / / 17632509 rs6583548 chr8 142986509 G A 7.56E-04 Alzheimer's disease / / 22005930 rs7845056 chr8 143020731 C T 9.00E-06 IgG glycosylation / / 23382691 rs12676273 chr8 143057986 A G 1.18E-06 Common variable immunodeficiency / / 21497890 rs11167112 chr8 143097840 A G 7.19E-04 Multiple complex diseases / / 17554300 rs879430 chr8 143106031 G T 1.80E-04 Multiple complex diseases / / 17554300 rs1388800 chr8 143106264 A G 1.90E-05 Urinary metabolites / / 21572414 rs7816988 chr8 143107657 T G 1.37E-05 Elbow pain / / pha003008 rs7816988 chr8 143107657 T G 1.06E-05 Body Mass Index / / pha003009 rs4917291 chr8 143115093 A G 9.49E-04 Multiple complex diseases / / 17554300 rs2220696 chr8 143118812 C G 9.40E-07 Urinary metabolites / / 21572414 rs4917300 chr8 143121671 T C 2.00E-06 Amyotrophic lateral sclerosis / / 22959728 rs7845034 chr8 143125433 A C 5.20E-06 Urinary metabolites / / 21572414 rs10101202 chr8 143127524 G A 1.70E-05 Urinary metabolites / / 21572414 rs12334475 chr8 143145547 C T 3.29E-04 Celiac disease / / 23936387 rs7826652 chr8 143169755 T C 3.29E-04 Multiple complex diseases / / 17554300 rs7845878 chr8 143184400 T C 1.30E-04 Hearing function / / 17255346 rs11167121 chr8 143191126 T A 1.80E-05 Urinary metabolites / / 21572414 rs728827 chr8 143193540 T C 5.61E-05 Graves' disease / / 21841780 rs11785292 chr8 143198953 G A 3.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs7017932 chr8 143199529 G A 5.32E-04 Aortic root size / / 21223598 rs13253406 chr8 143200557 T G 4.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs6981017 chr8 143202173 T C 4.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs7010981 chr8 143202470 C T 4.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs6996172 chr8 143202634 G T 4.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs7350065 chr8 143203264 A G 5.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs7388555 chr8 143212132 G A 9.64E-05 Autism spectrum disorders (language delay) / / 21519539 rs10099944 chr8 143234817 G A 2.21E-05 Multiple complex diseases / / 17554300 rs7823353 chr8 143249727 G A 1.99E-04 Myocardial Infarction / / pha002873 rs3923878 chr8 143270729 C T 1.10E-05 Urinary metabolites / / 21572414 rs4976961 chr8 143270885 A G 1.36E-04 Multiple complex diseases / / 17554300 rs4977008 chr8 143273372 C T 1.58E-04 Multiple complex diseases / / 17554300 rs7835585 chr8 143298768 G T 9.49E-06 Asthma (childhood onset) TS/RE1 intron 23829686 rs4976952 chr8 143302361 G A 6.47E-06 Multiple complex diseases TS/RE1 intron 17554300 rs11784523 chr8 143307103 A G 1.71E-05 Multiple complex diseases TS/RE1 intron 17554300 rs10098073 chr8 143309504 C A 5.42E-06 Schizophrenia TS/RE1 intron 21926974 rs10098073 chr8 143309504 C A 9.05E-09 Schizophrenia,schizoaffective disorder or bipolar disorder TS/RE1 intron 24166486 rs4129585 chr8 143312933 A C 2.00E-10 Schizophrenia TS/RE1 intron 23974872 rs4129585 chr8 143312933 A C 2.38E-08 Schizophrenia,schizoaffective disorder or bipolar disorder TS/RE1 intron 24166486 rs4129585 chr8 143312933 A C 5.14E-05 Blood Pressure TS/RE1 intron pha003040 rs6583607 chr8 143324399 T C 8.91E-04 Alcohol dependence TS/RE1 intron 21314694 rs6583612 chr8 143347243 G A 4.90E-05 Diabetic retinopathy TS/RE1 intron 21441570 rs4976986 chr8 143350197 A C 3.20E-05 Diabetic retinopathy TS/RE1 intron 21441570 rs4976955 chr8 143350750 T C 3.90E-05 Diabetic retinopathy TS/RE1 intron 21441570 rs4976955 chr8 143350750 T C 1.94E-05 Non-obstructive azoospermia TS/RE1 intron 22541561 rs7000748 chr8 143408785 C T 1.82E-04 Rheumatoid arthritis TS/RE1 intron 21452313 rs7014552 chr8 143410423 A G 4.57E-04 Parkinson's disease TS/RE1 intron 17052657 rs12676425 chr8 143413857 A C 1.70E-05 Urinary metabolites TS/RE1 intron 21572414 rs10109771 chr8 143488721 A G 8.99E-04 Multiple complex diseases / / 17554300 rs7838831 chr8 143489013 G C 9.12E-04 Multiple complex diseases / / 17554300 rs10093944 chr8 143491225 A C 5.99E-04 Multiple complex diseases / / 17554300 rs370172569 chr8 143549588 C CGTGT 6.99E-05 IgE levels BAI1 intron 17255346 rs372803082 chr8 143549588 C CGTGT 6.99E-05 IgE levels BAI1 intron 17255346 rs6583634 chr8 143549588 C T 6.99E-05 IgE levels BAI1 intron 17255346 rs6583635 chr8 143562095 C G 6.16E-04 Suicide attempts in bipolar disorder BAI1 intron 21423239 rs7462966 chr8 143569216 A G 8.00E-04 Suicide attempts in bipolar disorder BAI1 intron 21423239 rs7460047 chr8 143620400 G A 8.51E-05 Height BAI1 intron pha003011 rs7386386 chr8 143637459 C T 6.80E-05 AIDS progression / / 19115949 rs11167148 chr8 143645999 A G 1.00E-04 AIDS progression / / 19115949 rs6996219 chr8 143656021 A G 4.82E-05 Duodenal ulcer / / 22387998 rs4073782 chr8 143660032 C T 2.67E-05 Duodenal ulcer / / 22387998 rs4073410 chr8 143660669 G A 2.77E-05 Duodenal ulcer / / 22387998 rs3934486 chr8 143664312 A G 3.30E-05 Duodenal ulcer / / 22387998 rs10105842 chr8 143671615 C T 2.10E-08 Duodenal ulcer / / 22387998 rs7843869 chr8 143675222 A G 1.20E-04 Schizophrenia / / 19197363 rs11167150 chr8 143681457 A G 8.70E-05 Meningococcal disease / / 20694013 rs7835613 chr8 143682428 G A 9.21E-04 Nicotine dependence / / 17158188 rs7835613 chr8 143682428 G A 5.82E-05 Bipolar disorder and schizophrenia / / 20889312 rs9324593 chr8 143686995 A G 3.14E-04 Premature ovarian failure / / 19508998 rs9324593 chr8 143686995 A G 3.23E-08 Duodenal ulcer / / 22387998 rs10110456 chr8 143690833 G A 6.30E-06 Urinary metabolites / / 21572414 rs7465272 chr8 143691838 T A 9.34E-05 Schizophrenia / / 19571809 rs7465272 chr8 143691838 T A 9.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs10097505 chr8 143694184 G A 2.86E-05 Duodenal ulcer ARC UTR-3 22387998 rs28473387 chr8 143707473 T C 1.31E-10 Duodenal ulcer / / 22387998 rs6984406 chr8 143722537 C T 1.50E-05 Immunoglobulin A / / 20694011 rs4327844 chr8 143733540 T C 2.30E-05 Urinary metabolites / / 21572414 rs6995314 chr8 143749718 A G 2.00E-05 Urinary metabolites JRK intron 21572414 rs2920283 chr8 143757037 T C 2.45E-18 Duodenal ulcer PSCA intron 22387998 rs2978981 chr8 143759137 C T 4.00E-09 Gastric cancer (diffuse-type gastric cancer) PSCA intron 18488030 rs2976387 chr8 143759364 G A 1.20E-10 Gastric cancer (diffuse-type gastric cancer) PSCA intron 18488030 rs13262164 chr8 143761172 C T 1.50E-04 Gastric cancer (diffuse-type gastric cancer) PSCA intron 18488030 rs2294008 chr8 143761931 C T 1.50E-17 Gastric cancer (diffuse-type gastric cancer) PSCA UTR-5 18488030 rs2294008 chr8 143761931 C T 5.10E-04 Gastric cancer (diffuse-type gastric cancer) PSCA UTR-5 18488030 rs2294008 chr8 143761931 C T 2.00E-10 Bladder cancer PSCA UTR-5 19648920 rs2294008 chr8 143761931 C T 2.00E-10 Nasopharyngeal carcinoma PSCA UTR-5 20512145 rs2294008 chr8 143761931 C T 4.00E-11 Bladder cancer PSCA UTR-5 20972438 rs2294008 chr8 143761931 C T 2.00E-33 Duodenal ulcer PSCA UTR-5 22387998 rs2294008 chr8 143761931 C T 0.000346 Height (Pygmy height) PSCA UTR-5 22570615 rs2294010 chr8 143762430 A G 5.10E-09 Gastric cancer (diffuse-type gastric cancer) PSCA intron 18488030 rs2976391 chr8 143762724 C A 1.70E-04 Gastric cancer (diffuse-type gastric cancer) PSCA intron 18488030 rs2976392 chr8 143762932 G A 5.00E-04 Gastric cancer (diffuse-type gastric cancer) PSCA intron 18488030 rs2976392 chr8 143762932 G A 6.40E-18 Gastric cancer (diffuse-type gastric cancer) PSCA intron 18488030 rs2976392 chr8 143762932 G A 0.000346 Height (Pygmy height) PSCA intron 22570615 rs2920298 chr8 143763043 A G 5.00E-09 Gastric cancer (diffuse-type gastric cancer) PSCA intron 18488030 rs2920297 chr8 143763083 A G 4.12E-18 Duodenal ulcer PSCA intron 22387998 rs1045531 chr8 143763547 C A 4.80E-09 Gastric cancer (diffuse-type gastric cancer) PSCA cds-synon 18488030 rs2976394 chr8 143763622 C T 3.50E-09 Gastric cancer (diffuse-type gastric cancer) PSCA UTR-3 18488030 rs10216533 chr8 143763690 G A 3.60E-09 Gastric cancer (diffuse-type gastric cancer) PSCA UTR-3 18488030 rs2976395 chr8 143763750 G A 3.90E-09 Gastric cancer (diffuse-type gastric cancer) PSCA UTR-3 18488030 rs1045574 chr8 143763958 G A 1.34E-18 Duodenal ulcer PSCA UTR-3 22387998 rs2976396 chr8 143764001 G A 4.90E-09 Gastric cancer (diffuse-type gastric cancer) PSCA UTR-3 18488030 rs12155758 chr8 143765885 G A 1.11E-08 Duodenal ulcer / / 22387998 rs2585179 chr8 143774193 G A 0.000123 Height (Pygmy height) / / 22570615 rs2585174 chr8 143782044 A G 2.20E-04 Gastric cancer (diffuse-type gastric cancer) LY6K cds-synon 18488030 rs2244163 chr8 143784500 T G 2.90E-04 Gastric cancer (diffuse-type gastric cancer) LY6K UTR-3 18488030 rs2244163 chr8 143784500 T G 1.40E-08 Duodenal ulcer LY6K UTR-3 22387998 rs2244163 chr8 143784500 T G 2.38E-05 Myopia (severe) LY6K UTR-3 23933737 rs2164308 chr8 143785659 C T 5.56E-07 Duodenal ulcer / / 22387998 rs2572904 chr8 143792193 A C 5.82E-07 Duodenal ulcer LOC100288181 intron 22387998 rs4736372 chr8 143792266 G A 6.43E-04 Tourette syndrome LOC100288181 intron 22889924 rs2572906 chr8 143798269 G A 3.07E-05 Myopia (severe) LOC100288181 intron 23933737 rs6471590 chr8 143798552 G A 5.32E-05 Male fertility LOC100288181 intron 22633400 rs2585146 chr8 143798641 G T 1.77E-04 Alzheimer's disease LOC100288181 intron 17998437 rs2585140 chr8 143806896 A G 5.40E-07 Duodenal ulcer LOC100288181 intron 22387998 rs1036385 chr8 143842901 T C 2.94E-08 Duodenal ulcer / / 22387998 rs1036385 chr8 143842901 T C 2.68E-05 Myopia (severe) / / 23933737 rs1036385 chr8 143842901 T C 2.84E-05 Body Fat Distribution / / pha003017 rs1036385 chr8 143842901 T C 4.34E-05 Body Fat Distribution / / pha003018 rs2572925 chr8 143867905 C T 6.32E-07 Duodenal ulcer LY6D missense 22387998 rs11777634 chr8 143887957 C T 5.98E-06 Duodenal ulcer / / 22387998 rs199911610 chr8 143887957 C CGCT 5.98E-06 Duodenal ulcer / / 22387998 rs6981918 chr8 144007939 C A 1.60E-06 Cystic fibrosis-related diabetes / / 23670970 rs11136286 chr8 144102493 C T 9.36E-05 Stroke LY6E intron pha002887 rs4433125 chr8 144107501 G A 2.68E-04 Stroke / / pha002887 rs7015223 chr8 144132469 A G 6.27E-04 Multiple complex diseases C8orf31 intron 17554300 rs4977127 chr8 144172757 G A 2.08E-04 Multiple complex diseases / / 17554300 rs7846671 chr8 144183966 A G 1.74E-04 Bipolar disorder,schizoaffective / / 19567891 rs7846671 chr8 144183966 A G 8.01E-04 Alcohol dependence / / 21314694 rs4977138 chr8 144231514 A G 0.0000697 post-traumatic stress disorder / / 22869035 rs4977138 chr8 144231514 A G 6.97E-05 Schizophrenia / / 22883433 rs6420183 chr8 144234489 C T 0.0000414 post-traumatic stress disorder / / 22869035 rs6420183 chr8 144234489 C T 4.14E-05 Schizophrenia / / 22883433 rs6420185 chr8 144303071 G A 0.0000453 HDL cholesterol / / 23063622 rs10087900 chr8 144303418 G A 5.36E-05 Stroke (ischemic) / / 22941190 rs10087900 chr8 144303418 G A 0.0000183 HDL cholesterol / / 23063622 rs7388248 chr8 144305353 G C 0.00000517 HDL cholesterol (female) / / 23063622 rs7388248 chr8 144305353 G C 2.93E-09 HDL cholesterol / / 23063622 rs7464066 chr8 144330452 A G 1.35E-05 Parkinson's disease ZFP41 intron 21812969 rs4495442 chr8 144333836 T C 5.61E-05 Multiple complex diseases ZFP41 intron 17554300 rs7815716 chr8 144337356 T G 1.35E-05 Parkinson's disease ZFP41 intron 21812969 rs7824894 chr8 144338990 T C 9.15E-04 Type 2 diabetes ZFP41 intron 17463246 rs10090179 chr8 144339053 G A 1.60E-05 Parkinson's disease ZFP41 intron 21812969 rs4419827 chr8 144363094 C A 1.49E-04 Multiple complex diseases / / 17554300 rs7386102 chr8 144382192 G C 3.21E-04 Multiple complex diseases / / 17554300 rs4874105 chr8 144457328 A G 9.97E-05 Multiple complex diseases RHPN1 intron 17554300 rs879740 chr8 144484673 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4874137 chr8 144543160 G A 3.26E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer ZC3H3 intron 21483023 rs369051 chr8 144548806 A G 1.16E-04 Osteosarcoma ZC3H3 intron 23727862 rs380904 chr8 144565905 A G 5.00E-10 Venous thromboembolism (gene x gene interaction) ZC3H3 intron 23509962 rs11779488 chr8 144573123 G A 7.40E-05 Parkinson's disease (age of onset) ZC3H3 intron 19772629 rs7464822 chr8 144599178 G A 1.70E-25 Progranulin levels ZC3H3 intron 21087763 rs7464822 chr8 144599178 G A 1.70E-25 Myocardial infarction ZC3H3 intron 21211798 rs4874147 chr8 144620183 T C 4.37E-06 Longevity,exceptional ZC3H3 missense 20595579 rs3750209 chr8 144620871 A G 4.02E-04 Multiple complex diseases ZC3H3 cds-synon 17554300 rs4874150 chr8 144636272 G A 7.68E-04 Parkinson's disease GSDMD intron 17052657 rs2290416 chr8 144657600 G A 9.00E-06 Attention deficit hyperactivity disorder /PRT1 cds-synon 18821565 rs1466219 chr8 144673722 C A 8.75E-04 Multiple complex diseases EEF1D intron 17554300 rs1466219 chr8 144673722 C A 7.34E-17 Lymphocyte counts EEF1D intron 22286170 rs2045084 chr8 144693839 C T 3.00E-06 Rhegmatogenous retinal detachment / / 23585552 rs7831300 chr8 144727653 G A 6.99E-04 Body mass index ZNF623 intron 21701565 rs3750204 chr8 144732450 G A,T 3.26E-05 Alcohol consumption ZNF623 cds-synon 23743675 rs12679735 chr8 144733805 C T 3.65E-05 Alcohol consumption ZNF623 UTR-3 23743675 rs12677473 chr8 144756386 T C 4.37E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11778657 chr8 144801681 G A 1.45E-04 Schizophrenia(treatment response to risperidone) MAPK15 intron 19850283 rs35925379 chr8 144802456 C T 2.00E-06 Obesity-related traits MAPK15 missense 23251661 rs12681370 chr8 144814242 G A 6.79E-05 Glucose levels FAM83H intron pha003057 rs138137510 chr8 144942477 C T 0.00024 Prostate cancer EPPK1 missense 23555315 rs200744657 chr8 144945012 G A 0.000065 Prostate cancer (advanced) EPPK1 missense 23555315 rs12543389 chr8 144945191 T C 2.60E-04 Smoking initiation EPPK1 missense 24665060 rs4977188 chr8 144956464 G A 4.42E-04 Type 2 diabetes / / 17463246 rs4073455 chr8 144978607 T G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6995402 chr8 145005561 T C 5.00E-10 Platelet counts PLEC intron 22139419 rs11784762 chr8 145009610 A G 2.37E-04 Lymphocyte counts PLEC intron 22286170 rs7464572 chr8 145021167 C G 1.00E-09 Fibrinogen PLEC intron 23969696 rs11136341 chr8 145043543 A G 4.00E-13 LDL cholesterol PLEC intron 20686565 rs11136341 chr8 145043543 A G 9.00E-10 Cholesterol,total PLEC intron 20686565 rs11136341 chr8 145043543 A G 6.00E-09 Cholesterol,total PLEC intron 24097068 rs11136341 chr8 145043543 A G 7.00E-12 LDL cholesterol PLEC intron 24097068 rs6985603 chr8 145086428 G C 5.80E-05 Lymphocyte counts SPATC1 nearGene-5 22286170 rs11990558 chr8 145132633 T C 2.03E-04 Multiple complex diseases EXOSC4 nearGene-5 17554300 rs6558295 chr8 145139522 C G 2.00E-59 Metabolic traits GPAA1 intron 21886157 rs7822232 chr8 145145687 A C 5.00E-15 Blood metabolite levels / / 24816252 rs12550729 chr8 145155408 C T 6.00E-110 Blood metabolite levels SHARPIN intron 24816252 rs4977219 chr8 145516698 C A 0.0000253 Type 2 diabetes HSF1 intron 22325160 rs4925820 chr8 145637148 T G 0.0000888 Type 2 diabetes / / 22325160 rs2721195 chr8 145677011 T C 8.99E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) CYHR1 intron 23648065 rs750472 chr8 145701453 A C 8.99E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) FOXH1 UTR-5 23648065 rs2360220 chr8 145764544 C T 6.28E-04 Multiple complex diseases ARHGAP39 intron 17554300 rs6996077 chr8 145774287 C T 5.93E-04 Smoking initiation ARHGAP39 intron 24665060 rs2620636 chr8 145778128 C T 4.00E-06 Smoking initiation ARHGAP39 intron 24665060 rs11997133 chr8 145783561 A G 4.57E-04 Smoking initiation ARHGAP39 intron 24665060 rs11997608 chr8 145785009 C T 2.46E-04 Smoking initiation ARHGAP39 intron 24665060 rs11984823 chr8 145808982 T C 2.46E-04 Smoking initiation ARHGAP39 intron 24665060 rs2958483 chr8 145987048 G A 8.01E-06 Left ventricular mass / / 21212386 rs11784860 chr8 146013799 C T 4.83E-16 Lymphocyte counts / / 22286170 rs2735902 chr8 146081370 T A 0.00000876 Sasang constitution (Soeum) / / 22394158 rs2975272 chr8 146148165 C G 2.62E-04 Type 2 diabetes / / 17463246 rs2975282 chr8 146195832 C T 3.55E-04 Lymphocyte counts / / 22286170 rs4237144 chr9 200893 G A 8.00E-05 Personality dimensions / / 18957941 rs669980 chr9 200971 G T 1.54E-76 Multiple complex diseases / / 17554300 rs561921 chr9 216124 G A 4.06E-04 Heart Failure DOCK8 intron pha002884 rs500785 chr9 218183 C G 2.10E-05 Urinary metabolites DOCK8 intron 21572414 rs12555266 chr9 247174 A G 2.80E-04 Lung function (forced expiratory volume in 1 second) DOCK8 intron 17255346 rs11792508 chr9 253594 G T 1.92E-05 Melanoma DOCK8 intron 21926416 rs2274526 chr9 273233 G C 6.08E-05 Response to metformin DOCK8 intron 21186350 rs636918 chr9 274641 T A,C,G 4.47E-06 Cognitive impairment induced by topiramate DOCK8 intron 22091778 rs6476030 chr9 289061 A G 3.00E-06 Obesity-related traits DOCK8 intron 23251661 rs10813156 chr9 307197 T C 1.00E-04 Cognitive impairment induced by topiramate DOCK8 intron 22091778 rs4294238 chr9 318207 C T 6.45E-05 Cognitive impairment induced by topiramate DOCK8 intron 22091778 rs10813766 chr9 331490 T G 4.00E-12 Mean platelet volume DOCK8 intron 22139419 rs10813812 chr9 334016 G T 6.13E-04 Obesity (extreme) DOCK8 intron 21935397 rs12377330 chr9 336026 C T 1.40E-05 Urinary metabolites DOCK8 intron 21572414 rs10971413 chr9 341063 C A 8.49E-04 Multiple complex diseases DOCK8 intron 17554300 rs4741821 chr9 343981 T C 7.21E-05 Meningococcal disease DOCK8 intron 20694013 rs10972266 chr9 359338 C T 6.54E-04 Taste perception DOCK8 intron 22132133 rs750586 chr9 362749 A G 6.92E-04 Longevity DOCK8 intron 22279548 rs12348944 chr9 377066 C T 2.80E-05 Alcohol and nictotine co-dependence DOCK8 cds-synon 20158304 rs3739598 chr9 382810 C G 9.73E-04 Multiple complex diseases DOCK8 intron 17554300 rs2297075 chr9 390512 C T 7.56E-06 Obesity-related traits DOCK8 cds-synon 23251661 rs10814731 chr9 396380 A G 8.46E-04 Amyotrophic Lateral Sclerosis DOCK8 intron 17362836 rs12346176 chr9 398673 A G 6.60E-04 Alcohol dependence DOCK8 intron 21314694 rs6476806 chr9 419399 G A 7.09E-04 Suicide attempts in bipolar disorder DOCK8 intron 21423239 rs2297080 chr9 421860 A G 7.67E-04 Suicide attempts in bipolar disorder DOCK8 intron 21423239 rs6476810 chr9 424327 T G 6.39E-04 Suicide attempts in bipolar disorder DOCK8 intron 21423239 rs12353411 chr9 426215 C T 1.80E-04 Smoking quantity DOCK8 intron 24665060 rs10974366 chr9 426740 G C 5.80E-04 Smoking quantity DOCK8 intron 24665060 rs16906738 chr9 429940 T G 7.10E-04 Smoking quantity DOCK8 intron 24665060 rs10974442 chr9 438779 G A 6.23E-05 Smoking quantity DOCK8 intron 24665060 rs1887958 chr9 442030 C T 3.22E-05 Orofacial clefts DOCK8 intron 20023658 rs713244 chr9 480675 A C 1.20E-07 Health and aging,CVD and cancer age of onset KANK1 intron 22174011 rs713244 chr9 480675 A C 1.90E-10 Health and aging,CVD and cancer age of onset KANK1 intron 22174011 rs10974769 chr9 484850 G C 9.89E-04 Alzheimer's disease KANK1 intron 22005930 rs7036591 chr9 500810 G A 2.00E-04 Cognitive impairment induced by topiramate KANK1 intron 22091778 rs7038366 chr9 515616 C A 0.00000337 Nicotine dependence (smoking) KANK1 intron 22377092 rs1928415 chr9 517715 C T 0.000000602 Nicotine dependence (smoking) KANK1 intron 22377092 rs2026075 chr9 520886 G A 0.00000148 Nicotine dependence (smoking) KANK1 intron 22377092 rs9299011 chr9 541031 C A 6.13E-04 Suicide attempts in bipolar disorder KANK1 intron 21423239 rs10975061 chr9 543631 C T 0.0000066 Nicotine dependence (smoking) KANK1 intron 22377092 rs2804279 chr9 550782 A G 3.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KANK1 intron 20877124 rs9632892 chr9 556399 C T 5.36E-05 Multiple complex diseases KANK1 intron 17554300 rs10975130 chr9 557340 T C 6.14E-04 Multiple complex diseases KANK1 intron 17554300 rs10975130 chr9 557340 T C 1.71E-06 Multiple sclerosis KANK1 intron 17660530 rs2804262 chr9 559714 C A 7.13E-05 Multiple sclerosis KANK1 intron 17660530 rs4740817 chr9 561143 C T 0.000000651 Nicotine dependence (smoking) KANK1 intron 22377092 rs7019523 chr9 564786 A C 2.65E-04 Multiple complex diseases KANK1 intron 17554300 rs7027930 chr9 565917 T C 9.00E-06 Pulmonary function decline KANK1 intron 22424883 rs2804266 chr9 568384 T C 3.79E-05 Alcohol consumption KANK1 intron 23743675 rs10975200 chr9 571085 A G 9.95E-06 Multiple sclerosis KANK1 intron 17660530 rs2641973 chr9 580171 A T 1.51E-04 Alcohol consumption KANK1 intron 23743675 rs2804275 chr9 580319 G A 1.49E-04 Alcohol consumption KANK1 intron 23743675 rs2804276 chr9 580725 T C 1.86E-04 Alcohol consumption KANK1 intron 23743675 rs2361089 chr9 580868 C T 1.54E-04 Alcohol consumption KANK1 intron 23743675 rs2641970 chr9 581453 C T 1.16E-04 Alcohol consumption KANK1 intron 23743675 rs2804280 chr9 589511 C T 7.70E-05 Alcohol consumption KANK1 intron 23743675 rs2642006 chr9 590454 T C 4.50E-05 Response to antidepressants KANK1 intron 19736353 rs2642003 chr9 592229 T C 7.04E-05 Alcohol consumption KANK1 intron 23743675 rs2642002 chr9 592718 C T 1.14E-04 Alcohol consumption KANK1 intron 23743675 rs2804284 chr9 592757 A G 6.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KANK1 intron 20877124 rs10491598 chr9 592889 A G 4.02E-05 Serum metabolites KANK1 intron 19043545 rs2642001 chr9 593229 T C 7.98E-05 Alcohol consumption KANK1 intron 23743675 rs2642000 chr9 593899 G T 6.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KANK1 intron 20877124 rs2641997 chr9 594697 G T 6.69E-05 Alcohol consumption KANK1 intron 23743675 rs2641996 chr9 595756 A C 8.70E-05 Alcohol consumption KANK1 intron 23743675 rs1389563 chr9 596826 C T 6.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KANK1 intron 20877124 rs2642005 chr9 601493 G A 6.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KANK1 intron 20877124 rs1532310 chr9 602986 A G 6.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KANK1 intron 20877124 rs2804297 chr9 603264 C T 5.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KANK1 intron 20877124 rs2804304 chr9 606439 T C 1.14E-04 Alcohol consumption KANK1 intron 23743675 rs2804308 chr9 607382 C G 2.30E-04 Alcohol consumption KANK1 intron 23743675 rs9696204 chr9 607901 G C 8.41E-05 Multiple sclerosis KANK1 intron 17660530 rs10975395 chr9 609829 T C 1.68E-04 Alcohol consumption KANK1 intron 23743675 rs12236704 chr9 612167 A G 7.98E-04 Alzheimer's disease KANK1 intron 17998437 rs1962203 chr9 613215 A G 2.58E-04 Alcohol consumption KANK1 intron 23743675 rs7047247 chr9 613932 G A 2.05E-04 Alcohol consumption KANK1 intron 23743675 rs4610808 chr9 614707 C G 2.21E-04 Alcohol consumption KANK1 intron 23743675 rs7020705 chr9 614803 G C 2.67E-04 Alcohol consumption KANK1 intron 23743675 rs7033109 chr9 614905 C T 2.70E-04 Alcohol consumption KANK1 intron 23743675 rs10975421 chr9 615310 A G 6.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KANK1 intron 20877124 rs10815385 chr9 632131 G A 1.23E-05 Gallstones KANK1 intron 17632509 rs6477055 chr9 634094 A T 9.20E-04 Multiple complex diseases KANK1 intron 17554300 rs16921801 chr9 649616 G C 5.03E-05 Multiple complex diseases KANK1 intron 17554300 rs9407332 chr9 651333 T A 1.30E-05 Progressive supranuclear palsy KANK1 intron 21685912 rs9407334 chr9 651461 C T 8.26E-05 Progressive supranuclear palsy KANK1 intron 21685912 rs2361106 chr9 657244 A G 2.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KANK1 intron 20877124 rs1570477 chr9 657340 G A 2.00E-05 Urinary metabolites KANK1 intron 21572414 rs1570477 chr9 657340 G A 2.32E-07 Esophageal cancer (squamous cell) KANK1 intron 22960999 rs2361107 chr9 663644 C G 0.0000842 Panic disorder KANK1 intron 23149450 rs2361107 chr9 663644 C G 8.42E-05 Serum tamsulosin hydrochloride concentration KANK1 intron 23151678 rs7035770 chr9 668887 A C 8.00E-06 Urinary metabolites KANK1 intron 21572414 rs7024722 chr9 671186 A G 1.64E-04 Aortic root size KANK1 intron 21223598 rs4742225 chr9 677938 G T 1.10E-05 Urinary metabolites KANK1 intron 21572414 rs4742225 chr9 677938 G T 0.000000481 Nicotine dependence (smoking) KANK1 intron 22377092 rs16922480 chr9 678010 A G 5.02E-06 Asthma (childhood onset) KANK1 intron 23829686 rs12352279 chr9 678837 T C 3.00E-06 Migraine - clinic-based KANK1 intron 23793025 rs9408677 chr9 685819 C A 6.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KANK1 intron 20877124 rs4742236 chr9 686753 G A 0.0000186 Nicotine dependence (smoking) KANK1 intron 22377092 rs2361111 chr9 687592 G T 8.62E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KANK1 intron 20877124 rs912162 chr9 694453 C T 1.19E-05 Smoking cessation KANK1 intron 24665060 rs912174 chr9 712156 T G 5.94E-05 Bipolar disorder KANK1 missense 17486107 rs3824420 chr9 712766 G A 1.60E-09 Insulin processing and secretion KANK1 missense 23263489 rs10815562 chr9 732302 T C 0.0000962 Nicotine dependence (smoking) KANK1 intron 22377092 rs10739127 chr9 737436 G T 0.0000546 Nicotine dependence (smoking) KANK1 intron 22377092 rs10491590 chr9 738940 C T 4.22E-04 Suicide attempts in bipolar disorder KANK1 intron 21423239 rs12002416 chr9 739464 C T 9.55E-04 Suicide attempts in bipolar disorder KANK1 intron 21423239 rs16923238 chr9 739892 C G 9.60E-04 Suicide attempts in bipolar disorder KANK1 intron 21423239 rs16923238 chr9 739892 C G 1.50E-05 Urinary metabolites KANK1 intron 21572414 rs7027152 chr9 741001 T C 0.000062 Nicotine dependence (smoking) KANK1 intron 22377092 rs13286166 chr9 741307 G A 0.0000149 Nicotine dependence (smoking) KANK1 intron 22377092 rs10758863 chr9 742642 T G 0.0000388 Nicotine dependence (smoking) KANK1 intron 22377092 rs16923344 chr9 749493 T C 5.52E-04 Type 2 diabetes / / 17463246 rs7865413 chr9 751359 C T 7.14E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1076086 chr9 754655 T G 8.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs7035993 chr9 786996 A G 0.0000437 Nicotine dependence (smoking) / / 22377092 rs12000567 chr9 789499 A C 8.00E-06 Preschool internalizing problems / / 24839885 rs1323267 chr9 801602 T C 7.70E-06 Urinary metabolites / / 21572414 rs10115078 chr9 802053 G A 8.90E-06 Urinary metabolites / / 21572414 rs2370200 chr9 802801 A G 7.91E-08 Testicular germ cell cancer / / 20543847 rs4742419 chr9 804436 T C 2.78E-07 Testicular germ cell cancer / / 20543847 rs4742419 chr9 804436 T C 2.00E-05 Telomere length / / 23900074 rs10976690 chr9 804924 G A 1.10E-05 Urinary metabolites / / 21572414 rs7035551 chr9 811618 G A 7.40E-06 Urinary metabolites / / 21572414 rs7035551 chr9 811618 G A 4.20E-04 Telomere length / / 23900074 rs10815756 chr9 818693 T C 3.05E-08 Testicular germ cell cancer / / 20543847 rs10815756 chr9 818693 T C 3.27E-05 Telomere length / / 23900074 rs4141756 chr9 822594 T C 2.08E-09 Testicular germ cell cancer / / 20543847 rs4141756 chr9 822594 T C 3.30E-04 Telomere length / / 23900074 rs912062 chr9 841152 C A 3.00E-06 Obesity-related traits DMRT1 nearGene-5 23251661 rs7040024 chr9 845516 A C 1.00E-11 Testicular cancer DMRT1 intron 21551455 rs1407808 chr9 847292 G T 4.15E-06 Obesity-related traits DMRT1 intron 23251661 rs4740943 chr9 853004 T C 3.94E-04 Telomere length DMRT1 intron 23900074 rs4740943 chr9 853004 T C 3.46E-05 Hemoglobin DMRT1 intron pha003098 rs7029148 chr9 855091 A G 1.48E-09 Testicular germ cell cancer DMRT1 intron 20543847 rs7029148 chr9 855091 A G 4.30E-04 Telomere length DMRT1 intron 23900074 rs755383 chr9 863635 C T 1.00E-23 Testicular germ cell cancer DMRT1 intron 20543847 rs755383 chr9 863635 C T 9.00E-10 Testicular cancer DMRT1 intron 21551455 rs755383 chr9 863635 C T 4.00E-07 Testicular germ cell tumor DMRT1 intron 23666239 rs755383 chr9 863635 C T 2.00E-26 Testicular germ cell tumor DMRT1 intron 23666240 rs4538942 chr9 870027 G A,T 9.01E-05 Hemoglobin DMRT1 intron pha003098 rs11790408 chr9 876418 G T 4.96E-07 Multiple complex diseases DMRT1 intron 17554300 rs16925404 chr9 893000 T C 6.56E-04 Multiple complex diseases DMRT1 intron 17554300 rs16925457 chr9 894714 C A 5.12E-04 Multiple complex diseases DMRT1 intron 17554300 rs10491585 chr9 938941 T C 6.19E-04 Type 2 diabetes DMRT1 intron 17846125 rs279874 chr9 953057 C G 9.13E-05 Response to acetaminophen (hepatotoxicity) DMRT1 intron 21177773 rs279874 chr9 953057 C G 5.40E-06 Urinary metabolites DMRT1 intron 21572414 rs10759073 chr9 953465 C T 7.30E-06 Urinary metabolites DMRT1 intron 21572414 rs364477 chr9 955794 C T 8.00E-05 Personality dimensions DMRT1 intron 18957941 rs364477 chr9 955794 C T 4.00E-06 Major depressive disorder DMRT1 intron 23377640 rs279903 chr9 962184 A G 5.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DMRT1 intron 20877124 rs12336949 chr9 967606 G T 2.00E-05 Urinary metabolites DMRT1 intron 21572414 rs10977870 chr9 969688 G C 9.66E-06 Periodontitis (Mean PAL) / / 24024966 rs408200 chr9 972476 T C 5.64E-05 Insulin-related traits / / 19902172 rs279888 chr9 978833 G A 4.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DMRT3 intron 20877124 rs7860200 chr9 985979 T C 6.76E-04 Suicide attempts in bipolar disorder DMRT3 intron 21423239 rs279880 chr9 986085 A G 6.70E-05 Personality dimensions DMRT3 intron 18957941 rs279880 chr9 986085 A G 8.28E-05 Asthma DMRT3 intron 23181788 rs279878 chr9 988817 G T 4.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DMRT3 intron 20877124 rs9299104 chr9 1001254 G A 5.40E-05 Personality dimensions / / 18957941 rs12343006 chr9 1002280 T C 7.89E-04 Multiple complex diseases / / 17554300 rs10978129 chr9 1003994 G C 5.16E-04 Multiple complex diseases / / 17554300 rs4740995 chr9 1004958 A G 4.47E-04 Iron levels / / pha002876 rs2279988 chr9 1042166 G T 8.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6474550 chr9 1052722 G T 3.09E-04 Alcohol consumption (maxi-drinks) DMRT2 intron 24277619 rs17641078 chr9 1056959 G C 5.00E-06 Hyperactive-impulsive symptoms DMRT2 missense 18821565 rs9140 chr9 1057318 A G 2.00E-05 Urinary metabolites DMRT2 UTR-3 21572414 rs17795247 chr9 1073148 G T 4.64E-05 Multiple complex diseases / / 17554300 rs4237127 chr9 1129674 G A 6.43E-04 Obesity (extreme) / / 21935397 rs4741117 chr9 1130580 G A 5.58E-04 Obesity (extreme) / / 21935397 rs10959648 chr9 1132880 A G 9.64E-05 Blood Pressure / / pha003050 rs7871304 chr9 1154454 A G 7.54E-04 Obesity (extreme) / / 21935397 rs10119034 chr9 1180987 A G 5.76E-04 Multiple complex diseases / / 17554300 rs12003662 chr9 1183974 A G 4.84E-04 Alzheimer's disease / / 17998437 rs12003662 chr9 1183974 A G 2.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs10125101 chr9 1184213 G A 5.27E-04 Alzheimer's disease / / 17998437 rs10125101 chr9 1184213 G A 2.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs13286896 chr9 1189715 C G 9.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs10809650 chr9 1202371 A G 6.00E-09 Dupuytren's disease / / 21732829 rs10809675 chr9 1210991 G A 1.70E-05 Urinary metabolites / / 21572414 rs1890126 chr9 1214563 C A 2.86E-05 Serum albumin level / / pha003084 rs3920797 chr9 1216635 C T 1.90E-05 Urinary metabolites / / 21572414 rs10809695 chr9 1218440 T C 8.11E-05 Calcium levels / / pha003085 rs10960472 chr9 1218605 G T 4.52E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10960475 chr9 1218816 T C 8.11E-05 Calcium levels / / pha003085 rs6474685 chr9 1221840 T C 1.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs10283579 chr9 1222318 C A 2.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs9298672 chr9 1222804 A G 4.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs4740518 chr9 1229958 G A 1.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs7018922 chr9 1230619 T C 9.63E-05 Alcohol dependence / / 19581569 rs10756345 chr9 1230994 C T 2.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs10511426 chr9 1231372 G A 3.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10511426 chr9 1231372 G A 4.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs10756347 chr9 1231408 T C 2.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs10756348 chr9 1231484 T C 2.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs13293948 chr9 1235507 T G 1.62E-06 Calcium levels / / pha003085 rs10429609 chr9 1235703 C A 3.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs945861 chr9 1235959 G C 5.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs945862 chr9 1235993 G A 8.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs2210980 chr9 1237021 C T 3.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs2225873 chr9 1237380 A G 2.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs1337622 chr9 1238093 C T 2.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs1556786 chr9 1241530 C T 2.11E-05 Serum albumin level / / pha003084 rs12352824 chr9 1267148 C T 2.32E-05 Serum metabolites / / 19043545 rs1538718 chr9 1268294 G A 1.11E-05 Serum metabolites / / 19043545 rs4512431 chr9 1268688 C G 5.79E-05 Serum metabolites / / 19043545 rs885043 chr9 1270931 C A 3.61E-04 Type 2 diabetes / / 17463246 rs885043 chr9 1270931 C A 1.00E-05 Age-related macular degeneration / / 20861866 rs12686237 chr9 1271102 C T 4.03E-04 Multiple complex diseases / / 17554300 rs10960798 chr9 1288255 G T 2.57E-05 Intelligence / / 21826061 rs16927032 chr9 1296827 A G 1.55E-04 Multiple complex diseases / / 17554300 rs1340013 chr9 1298487 C T 8.21E-04 Multiple complex diseases / / 17554300 rs7864098 chr9 1304815 G A 1.44E-09 Multiple complex diseases / / 17554300 rs10960872 chr9 1306855 C A 1.80E-04 Multiple complex diseases / / 17554300 rs10809903 chr9 1319470 C T 2.71E-04 Sudden cardiac arrest / / 21658281 rs11790506 chr9 1320872 A G 8.62E-04 Multiple complex diseases / / 17554300 rs7875774 chr9 1325139 T G 7.63E-05 Panic disorder / / 19165232 rs7875774 chr9 1325139 T G 3.00E-04 Aortic root size / / 21223598 rs4469515 chr9 1339391 A G 4.60E-06 Celiac disease / / 17558408 rs10961025 chr9 1342328 C T 6.73E-04 Type 2 diabetes / / 17463246 rs7871293 chr9 1354036 T C 8.67E-04 Alzheimer's disease / / 24755620 rs955466 chr9 1354499 C A 2.00E-05 Urinary metabolites / / 21572414 rs10961250 chr9 1387505 A G 9.69E-04 Type 2 diabetes / / 17463246 rs677079 chr9 1387954 C A 2.74E-04 Multiple complex diseases / / 17554300 rs590938 chr9 1391887 A G 7.30E-05 Soluble levels of adhesion molecules / / pha003072 rs17744504 chr9 1418670 G A 1.80E-05 Urinary metabolites / / 21572414 rs880013 chr9 1435496 T C 5.28E-05 Male-pattern baldness / / 18849994 rs10121536 chr9 1448017 T C 4.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10491860 chr9 1449360 C G 6.53E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7036822 chr9 1450428 G A 9.16E-05 Diabetes Mellitus / / pha003059 rs1332004 chr9 1453731 G A 4.50E-06 Response to taxane treatment (placlitaxel) / / 23006423 rs4142436 chr9 1454200 T C 5.52E-04 Substance dependence / / 21818250 rs1412259 chr9 1456797 C T 4.00E-06 Response to taxane treatment (docetaxel) / / 23006423 rs10114417 chr9 1459663 T C 5.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2210421 chr9 1460365 A C 5.75E-05 Body mass index / / 22446040 rs10124818 chr9 1463618 A G 7.73E-05 Aging (time to event) / / 21782286 rs16929773 chr9 1468923 A G 5.89E-04 Smoking initiation / / 24665060 rs12002949 chr9 1469317 G A 5.98E-07 Arthritis (juvenile idiopathic) / / 22354554 rs17745803 chr9 1470043 C G 4.90E-05 Cognitive function / / 24684796 rs4741416 chr9 1484527 A G 4.40E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs10810235 chr9 1486005 T C 3.52E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs7864191 chr9 1487108 C T 6.19E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs11789499 chr9 1495011 G C 3.61E-04 Type 2 diabetes / / 17463246 rs1576747 chr9 1503556 G A 9.22E-05 Monocyte counts / / pha003089 rs1412254 chr9 1510230 A C 1.46E-06 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs10491859 chr9 1510299 G A 5.32E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7859562 chr9 1510590 A G 7.94E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10810324 chr9 1510848 G A 6.80E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10810325 chr9 1510881 A G 9.76E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7019932 chr9 1511184 C T 7.94E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6474880 chr9 1513074 T C 1.65E-06 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs9886784 chr9 1521204 A C 1.04E-04 Alzheimer's disease / / 17998437 rs9886784 chr9 1521204 A C 3.20E-04 Alzheimer's disease (late onset) / / 21460841 rs7045593 chr9 1540499 G A 3.15E-05 Coronary heart disease / / pha003031 rs2486443 chr9 1553378 T C,G 2.40E-05 Vitamin D concentrations / / 20600896 rs2486443 chr9 1553378 T C,G 2.40E-05 Vitamin D concentrations / / 20600896 rs689393 chr9 1581084 G C 5.02E-04 Alzheimer's disease / / 17998437 rs553669 chr9 1581287 C G 7.77E-04 Multiple complex diseases / / 17554300 rs10810437 chr9 1582315 A T 1.43E-04 Alzheimer's disease / / 17998437 rs4741531 chr9 1582525 A C 8.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs771909 chr9 1591055 A G 1.65E-04 Alzheimer's disease / / 17998437 rs7873584 chr9 1591888 A C 4.50E-05 Coronary heart disease / / pha003031 rs16931355 chr9 1592353 G A 9.00E-04 Multiple complex diseases / / 17554300 rs1923924 chr9 1592554 C T 1.54E-04 Multiple complex diseases / / 17554300 rs1323247 chr9 1594081 C A 5.17E-05 Coronary heart disease / / pha003031 rs10756712 chr9 1596394 C G 1.00E-04 Alzheimer's disease / / 17998437 rs1923928 chr9 1598885 A G 8.66E-04 Common variable immunodeficiency / / 21497890 rs702160 chr9 1603814 A G 6.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs702162 chr9 1604122 A G 8.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs702167 chr9 1605827 G A 3.00E-04 Alcohol dependence / / 20201924 rs10125227 chr9 1613688 C T 5.38E-05 Coronary heart disease / / pha003031 rs1535593 chr9 1616513 T G 3.57E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs945658 chr9 1616639 T G 6.05E-04 Alzheimer's disease / / 17998437 rs1537966 chr9 1625303 G A 5.95E-05 Bipolar disorder / / 21771265 rs7869423 chr9 1634618 C T 4.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4741565 chr9 1637067 C A 1.50E-05 Urinary metabolites / / 21572414 rs702192 chr9 1646654 C T 4.66E-05 Bipolar disorder / / 21771265 rs4740635 chr9 1670196 G C 5.51E-06 Cardiovascular disease / / 18179892 rs16932397 chr9 1670237 A G 3.18E-04 Type 2 diabetes / / 17463246 rs4741576 chr9 1676825 A G 1.60E-05 Urinary metabolites / / 21572414 rs2093648 chr9 1677474 T C 2.20E-05 Urinary metabolites / / 21572414 rs535825 chr9 1683418 G C 9.90E-05 Schizophrenia / / 19571809 rs652703 chr9 1683781 C G 1.50E-05 Urinary metabolites / / 21572414 rs2760397 chr9 1685649 A G 6.80E-06 Urinary metabolites / / 21572414 rs10810664 chr9 1700043 T A 9.10E-06 Urinary metabolites / / 21572414 rs2485160 chr9 1700930 G C 8.09E-04 Alzheimer's disease / / 17998437 rs7850273 chr9 1709151 C G 3.10E-04 Alzheimer's disease / / 17998437 rs7020507 chr9 1715820 A G 6.90E-05 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) / / 24325915 rs10962856 chr9 1717031 A G 0.0000445 Polycystic ovary syndrome / / 22951595 rs10962856 chr9 1717031 A G 4.45E-05 Intracranial aneurysm / / 22961961 rs2095614 chr9 1717960 G A 7.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs747047 chr9 1718127 C T 8.75E-04 Type 2 diabetes / / 17463246 rs2616839 chr9 1719155 G A 9.07E-04 Type 2 diabetes / / 17463246 rs474015 chr9 1723433 G A 1.99E-04 Type 2 diabetes / / 17463246 rs574852 chr9 1724623 C A 1.52E-04 Type 2 diabetes / / 17463246 rs576652 chr9 1724823 G A 3.13E-04 Type 2 diabetes / / 17463246 rs576684 chr9 1724840 A G 4.78E-04 Type 2 diabetes / / 17463246 rs526771 chr9 1726812 A T 4.91E-04 Type 2 diabetes / / 17463246 rs771061 chr9 1734456 A G 1.90E-04 Type 2 diabetes / / 17463246 rs519864 chr9 1734768 T C 3.87E-04 Type 2 diabetes / / 17463246 rs10963203 chr9 1777553 G A 7.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10117983 chr9 1815727 T C 9.25E-05 AIDS progression / / 19115949 rs7045455 chr9 1823605 C T 2.03E-05 AIDS progression / / 19115949 rs10810919 chr9 1826401 C T 2.00E-05 Prostate cancer / / 23668334 rs10283612 chr9 1830286 C A 3.22E-04 Alzheimer's disease / / 17998437 rs10963540 chr9 1835334 A G 2.00E-05 Prostate cancer / / 23668334 rs973494 chr9 1845111 T C 1.77E-04 Type 2 diabetes / / 17463246 rs7847373 chr9 1845946 A G 6.69E-05 Type 2 diabetes / / 17463246 rs17724855 chr9 1872957 G A 8.84E-04 Multiple complex diseases / / 17554300 rs7862396 chr9 1878648 T C 1.10E-04 Celiac disease / / 23936387 rs4740652 chr9 1882265 C T 2.28E-04 Stroke / / pha002886 rs4741619 chr9 1887124 T G 2.74E-04 Stroke / / pha002886 rs1331297 chr9 1888703 G A 3.23E-04 Stroke / / pha002886 rs4741626 chr9 1894807 C A 5.72E-04 Stroke / / pha002886 rs7857865 chr9 1957974 G A 3.46E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7019322 chr9 1987918 T C 3.07E-04 Multiple complex diseases / / 17554300 rs6475372 chr9 1994204 C A 6.97E-05 Coronary heart disease / / pha003035 rs10115271 chr9 1997594 T G 8.61E-04 Multiple complex diseases / / 17554300 rs10512034 chr9 2000684 G A 1.02E-05 Alcohol and nictotine co-dependence / / 20158304 rs4741636 chr9 2013580 T C 9.05E-05 Elbow pain SMARCA2 nearGene-5 pha003008 rs6475412 chr9 2024076 T C 1.93E-05 Fibrinogen SMARCA2 intron 17255346 rs6475447 chr9 2058133 T C 9.39E-04 Stroke SMARCA2 intron pha002886 rs7035608 chr9 2064507 C T 7.06E-05 Orofacial clefts SMARCA2 intron 22419666 rs7035608 chr9 2064507 C T 8.58E-04 Response to taxane treatment (placlitaxel) SMARCA2 intron 23006423 rs10811366 chr9 2065892 G T 5.42E-05 Orofacial clefts SMARCA2 intron 22419666 rs4741641 chr9 2072356 T G 0.0000448 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SMARCA2 intron 22628534 rs2066111 chr9 2073839 C T 8.20E-05 Schizophrenia (treatment refractory) SMARCA2 intron 22479419 rs2066111 chr9 2073839 C T 3.84E-05 Erythrocyte counts SMARCA2 intron pha003099 rs2066110 chr9 2074070 G A 7.12E-05 Orofacial clefts SMARCA2 intron 22419666 rs3763627 chr9 2076174 A T 1.20E-05 Schizophrenia (treatment refractory) SMARCA2 intron 22479419 rs7035071 chr9 2079250 T C 3.50E-05 Anger SMARCA2 intron 24489884 rs1572745 chr9 2084739 G A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SMARCA2 intron 22628534 rs3793487 chr9 2086352 G A 0.0000448 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SMARCA2 intron 22628534 rs12375895 chr9 2090718 T G 3.85E-05 Orofacial clefts SMARCA2 intron 22419666 rs3793490 chr9 2095958 T G 3.00E-06 Schizophrenia (treatment refractory) SMARCA2 intron 22479419 rs2066109 chr9 2109139 T C 1.12E-04 Type 2 diabetes SMARCA2 intron 17463246 rs2376311 chr9 2116715 G A 1.09E-05 Type 2 diabetes SMARCA2 intron 17463246 rs7048496 chr9 2125231 C A 7.44E-04 Alzheimer's disease SMARCA2 intron 24755620 rs7869436 chr9 2127315 A G 7.44E-04 Alzheimer's disease SMARCA2 intron 24755620 rs12344160 chr9 2136142 T C 1.90E-17 Health and aging,CVD and cancer age of onset SMARCA2 intron 22174011 rs12344160 chr9 2136142 T C 5.70E-16 Health and aging,CVD and cancer age of onset SMARCA2 intron 22174011 rs10757211 chr9 2136820 T G 0.000513 Salmonella-induced pyroptosis SMARCA2 intron 22837397 rs2376305 chr9 2143543 G A 2.44E-04 Glycosylated haemoglobin levels SMARCA2 intron 17255346 rs7032394 chr9 2160378 A G 7.42E-06 Panic disorder SMARCA2 intron 19165232 rs3793508 chr9 2167498 A G 6.52E-05 Body Fat Distribution SMARCA2 intron pha003017 rs10965086 chr9 2172235 A G 8.87E-05 Celiac disease SMARCA2 intron 23936387 rs2376230 chr9 2173752 G A 3.42E-04 Alzheimer's disease (late onset) SMARCA2 intron 21379329 rs2296212 chr9 2191309 C G 5.80E-05 Schizophrenia (treatment refractory) SMARCA2 missense 22479419 rs4741652 chr9 2194227 C T 1.06E-05 Major depressive disorder / / 22472876 rs4741652 chr9 2194227 C T 7.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs6475600 chr9 2203938 C T 2.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) / / 24025145 rs4537352 chr9 2206658 G C,T 5.17E-05 Type 2 diabetes / / 17463246 rs7037884 chr9 2213818 T G 1.55E-04 Smoking initiation / / 24665060 rs7863671 chr9 2226080 A G 5.06E-05 Alzheimer's disease / / 17998437 rs10811679 chr9 2234701 T C 9.53E-06 Aging (time to event) / / 21782286 rs7036632 chr9 2235037 C G 4.06E-04 Type 2 diabetes / / 17463246 rs2376227 chr9 2237390 C A 5.90E-04 Alcohol dependence / / 20201924 rs4741657 chr9 2239429 T C 8.20E-04 Alcohol dependence / / 20201924 rs16938145 chr9 2256092 T C 1.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17405547 chr9 2271325 G T 8.54E-04 Acute lung injury / / 22295056 rs10123149 chr9 2273601 G A 4.24E-06 Alopecia areata / / 22027810 rs16938218 chr9 2273915 G C 4.18E-04 Acute lung injury / / 22295056 rs10123832 chr9 2274082 G C 6.58E-04 Acute lung injury / / 22295056 rs1408328 chr9 2288588 C T 3.63E-05 Alzheimer's disease (late onset) / / 21379329 rs1535837 chr9 2288633 G A 4.48E-05 Alzheimer's disease (late onset) / / 21379329 rs1535837 chr9 2288633 G A 2.91E-04 Lung function (forced vital capacity) / / 24023788 rs7861374 chr9 2289519 C A 0.0000708 post-traumatic stress disorder / / 22869035 rs7861374 chr9 2289519 C A 7.08E-05 Schizophrenia / / 22883433 rs9644866 chr9 2290590 C T 5.61E-05 Alzheimer's disease (late onset) / / 21379329 rs1555644 chr9 2295503 C A 2.75E-04 Myopia (pathological) / / 21095009 rs16938276 chr9 2295572 T C 2.77E-04 White matter integrity / / 22425255 rs10965506 chr9 2299220 T G 0.0000812 post-traumatic stress disorder / / 22869035 rs10965506 chr9 2299220 T G 8.12E-05 Schizophrenia / / 22883433 rs13292475 chr9 2300565 T C 0.0000624 post-traumatic stress disorder / / 22869035 rs13292475 chr9 2300565 T C 6.24E-05 Schizophrenia / / 22883433 rs12684262 chr9 2301610 A G 7.14E-04 White matter integrity / / 22425255 rs10965522 chr9 2301692 C T 3.00E-05 Lung adenocarcinoma / / 22797724 rs13294267 chr9 2301724 A G 0.000044 post-traumatic stress disorder / / 22869035 rs13294267 chr9 2301724 A G 4.40E-05 Schizophrenia / / 22883433 rs10965543 chr9 2305679 G A 1.10E-05 Urinary metabolites / / 21572414 rs7026913 chr9 2305756 C T 7.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9987682 chr9 2306167 C A 2.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7852731 chr9 2320822 C G 4.75E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1002780 chr9 2325739 T C 1.98E-05 Coronary heart disease / / pha003035 rs11788548 chr9 2336621 C T 3.33E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10965761 chr9 2340028 C G 9.33E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs10491707 chr9 2353522 T C 6.27E-04 Myocardial Infarction / / pha002873 rs7033436 chr9 2407784 G T 5.23E-04 Acute lung injury / / 22295056 rs2183807 chr9 2416120 G C 7.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs1537221 chr9 2416439 C T 6.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs1537224 chr9 2416845 C T 6.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs2150831 chr9 2416895 C A 3.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs16906059 chr9 2421084 G A 4.55E-05 Acute lung injury / / 22295056 rs869106 chr9 2421273 G A 2.91E-04 Alzheimer's disease (late onset) / / 21379329 rs869106 chr9 2421273 G A 4.55E-05 Acute lung injury / / 22295056 rs869105 chr9 2421459 G A 5.37E-04 Acute lung injury / / 22295056 rs1023198 chr9 2422211 C G 8.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs10966249 chr9 2425127 A T 4.78E-05 Response to metformin / / 21186350 rs10966253 chr9 2427182 T C 7.53E-06 Multiple complex diseases / / 17554300 rs7039085 chr9 2427960 A G 5.72E-05 Response to metformin / / 21186350 rs2210396 chr9 2429859 T C 6.71E-05 Response to metformin / / 21186350 rs2376118 chr9 2430189 C G 5.93E-05 Response to metformin / / 21186350 rs2889293 chr9 2435209 A G 5.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs10812052 chr9 2456879 A G 4.60E-04 Type 2 diabetes / / 17463246 rs10812052 chr9 2456879 A G 5.04E-04 Multiple complex diseases / / 17554300 rs4741710 chr9 2458456 G T 2.11E-04 Type 2 diabetes / / 17463246 rs2150720 chr9 2469742 A G 8.67E-04 Type 2 diabetes / / 17463246 rs914494 chr9 2469939 A G 7.89E-05 Body Mass Index / / pha003021 rs4741717 chr9 2492466 G A 5.55E-05 Multiple sclerosis / / 17660530 rs1571812 chr9 2495870 C A 3.35E-05 Celiac disease / / 23936387 rs7864942 chr9 2527980 A G 4.81E-04 Aortic root size / / 21223598 rs655568 chr9 2535524 C T 2.35E-04 Parkinson's disease / / 17052657 rs4740693 chr9 2546974 C T 1.48E-04 Type 2 diabetes / / 17463246 rs10812227 chr9 2548556 C T 5.00E-06 Gambling / / 22780124 rs12237653 chr9 2551654 T C 3.00E-06 Gambling / / 22780124 rs11790496 chr9 2572011 A T 4.75E-04 Multiple complex diseases / / 17554300 rs502309 chr9 2572909 C T 5.40E-06 Volumetric brain MRI / / 17903297 rs7860538 chr9 2573499 T G 3.72E-05 Aortic root size / / 21223598 rs2168136 chr9 2594577 C T 1.60E-04 Volumetric brain MRI / / 17903297 rs9969780 chr9 2614294 T C 7.67E-06 Body Mass Index / / pha003014 rs4741746 chr9 2618969 T C 2.98E-06 Nicotine smoking / / 19268276 rs35136375 chr9 2628433 T A 6.24E-10 Cholesterol,total VLDLR intron 23063622 rs34548991 chr9 2628957 C T 1.76E-10 LDL cholesterol VLDLR intron 23063622 rs1454627 chr9 2631738 A G 7.73E-05 Lung function (forced expiratory volume in 1 second) VLDLR intron 24023788 rs1551411 chr9 2631932 C T 4.12E-05 Lung function (forced expiratory volume in 1 second) VLDLR intron 24023788 rs12336893 chr9 2632365 T G 0.000094 Cholesterol,total VLDLR intron 23063622 rs34998951 chr9 2634144 A G 2.41E-15 LDL cholesterol VLDLR intron 23063622 rs34998951 chr9 2634144 A G 7.14E-11 Cholesterol,total VLDLR intron 23063622 rs7024888 chr9 2636992 T C 7.51E-08 LDL cholesterol VLDLR intron 23063622 rs34156497 chr9 2639533 A G 0.0000013 HDL cholesterol VLDLR intron 23063622 rs35464166 chr9 2639745 T C 0.000000858 Cholesterol,total VLDLR intron 23063622 rs2242104 chr9 2640492 A G 2.26E-06 Lung adenocarcinoma VLDLR intron 19836008 rs35486699 chr9 2640605 C T 4.47E-09 LDL cholesterol VLDLR intron 23063622 rs3780181 chr9 2640759 A G 2.00E-09 LDL cholesterol VLDLR intron 24097068 rs3780181 chr9 2640759 A G 7.00E-10 Cholesterol,total VLDLR intron 24097068 rs10967306 chr9 2640805 G A 3.94E-04 Epilepsy VLDLR intron 22116939 rs35466361 chr9 2641107 T A 0.000000302 LDL cholesterol VLDLR intron 23063622 rs35782329 chr9 2643832 T C 3.84E-20 Cholesterol,total VLDLR intron 23063622 rs35782329 chr9 2643832 T C 5.02E-16 LDL cholesterol VLDLR intron 23063622 rs7863951 chr9 2644874 T C 0.000000973 Cholesterol,total VLDLR intron 23063622 rs7863951 chr9 2644874 T C 3.95E-14 LDL cholesterol VLDLR intron 23063622 rs2290465 chr9 2645201 C G 7.15E-04 Obesity (extreme) VLDLR intron 21935397 rs2063570 chr9 2663788 G T 5.45E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4741756 chr9 2668187 A C 1.22E-32 Vascular endothelial growth factor levels / / 21757650 rs1542358 chr9 2673393 C T 2.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs12347630 chr9 2673801 G A 3.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs6475920 chr9 2673933 C A 1.94E-38 Vascular endothelial growth factor levels / / 21757650 rs7859818 chr9 2674110 A G 2.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs6475922 chr9 2674318 T C 8.85E-04 Type 2 diabetes / / 17463246 rs7874073 chr9 2674864 G A 2.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs10967470 chr9 2675698 A G 2.39E-21 Vascular endothelial growth factor levels / / 21757650 rs11793970 chr9 2675728 G A,C 2.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs7029840 chr9 2677429 C A 2.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs55779643 chr9 2677743 GT G 2.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs7029311 chr9 2677743 G A 2.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs7046015 chr9 2677787 A G 2.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs6475926 chr9 2678059 T C 2.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs6475927 chr9 2678077 G A 3.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs7847455 chr9 2678427 A T 3.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs16909038 chr9 2678958 C G 3.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs10967492 chr9 2681175 T A 9.22E-21 Vascular endothelial growth factor levels / / 21757650 rs7870258 chr9 2681397 T G 1.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs7031441 chr9 2683052 G C 8.40E-04 Type 2 diabetes / / 17463246 rs7031441 chr9 2683052 G C 1.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs10738760 chr9 2691186 A G 1.00E-39 Vascular endothelial growth factor levels / / 21757650 rs10122587 chr9 2691951 C T 2.56E-24 Vascular endothelial growth factor levels / / 21757650 rs11788193 chr9 2692393 T A 4.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs2375980 chr9 2692622 C G 4.67E-34 Vascular endothelial growth factor levels / / 21757650 rs748787 chr9 2694201 G A 4.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs930811 chr9 2696555 G A 1.00E-06 Obesity-related traits / / 23251661 rs1454629 chr9 2700620 C T 8.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs1823903 chr9 2707420 A G 5.92E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12345016 chr9 2708258 C G 9.73E-04 Lymphocyte counts / / 22286170 rs11793747 chr9 2715284 G C 5.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs11789876 chr9 2715349 C T 3.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs10812526 chr9 2721249 A G 4.89E-05 Alzheimer's disease (age of onset) KCNV2 intron 22005931 rs10967728 chr9 2721794 G C 4.69E-05 Alzheimer's disease (age of onset) KCNV2 intron 22005931 rs1026355 chr9 2722884 G C 9.90E-05 Alzheimer's disease (age of onset) KCNV2 intron 22005931 rs1007021 chr9 2723657 G A 5.36E-05 Tourette syndrome KCNV2 intron 22889924 rs1007022 chr9 2723761 C A 8.85E-05 Tourette syndrome KCNV2 intron 22889924 rs10967738 chr9 2724151 C T 4.66E-04 Multiple complex diseases KCNV2 intron 17554300 rs1006698 chr9 2725283 A C 8.93E-05 Alzheimer's disease (age of onset) KCNV2 intron 22005931 rs10967755 chr9 2726000 C T 5.74E-04 Multiple complex diseases KCNV2 intron 17554300 rs10967775 chr9 2730988 T G 3.77E-04 Tourette syndrome / / 22889924 rs13294756 chr9 2734038 A G 6.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10733413 chr9 2734710 T C 3.83E-05 Alzheimer's disease (age of onset) / / 22005931 rs7048820 chr9 2735053 T C 3.83E-05 Alzheimer's disease (age of onset) / / 22005931 rs11791696 chr9 2736707 G A 8.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7850096 chr9 2741728 T G 1.36E-05 Alzheimer's disease (age of onset) / / 22005931 rs2034763 chr9 2742608 C T 1.12E-05 Alzheimer's disease (age of onset) / / 22005931 rs2034764 chr9 2742771 T C 4.00E-06 Alzheimer's disease (age of onset) / / 22005931 rs4741761 chr9 2743254 G A 8.97E-06 Alzheimer's disease (age of onset) / / 22005931 rs11788306 chr9 2758335 A G 4.69E-06 Alzheimer's disease (age of onset) / / 22005931 rs10812641 chr9 2777384 T A 3.00E-06 Blood trace element (Se levels) / / 23720494 rs10757686 chr9 2787856 A C 9.30E-06 Obesity-related traits / / 23251661 rs10812738 chr9 2817887 A G 8.76E-06 stroke (ischemic) KIAA0020 intron 17434096 rs6476038 chr9 2823380 G A 8.60E-04 Response to statin treatment (atorvastatin),change in cholesterol levels KIAA0020 intron 20031582 rs2270891 chr9 2828742 C A 1.77E-04 Response to cytadine analogues (cytosine arabinoside) KIAA0020 missense 24483146 rs10968457 chr9 2838470 C T 9.00E-06 Obesity-related traits KIAA0020 missense 23251661 rs10123121 chr9 2848800 A G 8.28E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10968634 chr9 2860773 C G 1.64E-04 Multiple complex diseases / / 17554300 rs10968708 chr9 2875055 C G 2.89E-04 Aortic root size / / 21223598 rs1501572 chr9 2904794 G C 1.10E-04 Lipid traits / / 17903299 rs10511437 chr9 2909111 A G 4.50E-04 Type 2 diabetes / / 17463246 rs10511437 chr9 2909111 A G 3.21E-04 Type 2 diabetes / / 17846125 rs7874472 chr9 2915141 C T 1.28E-04 Type 2 diabetes / / 17463246 rs1501576 chr9 2918656 T C 5.30E-04 Alcohol dependence / / 20201924 rs10969011 chr9 2929376 C T 1.94E-04 Multiple complex diseases / / 17554300 rs7045640 chr9 2978377 A C 8.00E-06 Systolic blood pressure in sickle cell anemia / / 24058526 rs10283729 chr9 2981637 A C 3.50E-10 Multiple complex diseases / / 17554300 rs1393040 chr9 2985743 A G 8.58E-04 Alzheimer's disease / / 17998437 rs7856429 chr9 3011814 C T 7.29E-04 Multiple complex diseases / / 17554300 rs3904459 chr9 3032897 A T 2.40E-06 Urinary metabolites / / 21572414 rs10969596 chr9 3033744 C T 5.87E-04 Multiple complex diseases / / 17554300 rs2376771 chr9 3034146 A C 1.70E-05 Urinary metabolites / / 21572414 rs10738843 chr9 3060291 A C 7.59E-05 Schizophrenia / / 19571811 rs16913918 chr9 3074359 A G 2.57E-04 Multiple complex diseases / / 17554300 rs12335659 chr9 3075020 T G 1.24E-04 Multiple complex diseases / / 17554300 rs10813578 chr9 3153178 G A 9.36E-06 Lung adenocarcinoma / / 19836008 rs1570287 chr9 3154333 C T 8.90E-06 Lung adenocarcinoma / / 19836008 rs10970384 chr9 3158247 A C 1.05E-07 Schizophrenia / / 21926974 rs4740720 chr9 3206279 A G 7.63E-05 Neuroticism / / 23229837 rs73642627 chr9 3280136 C T 1.55E-04 Acne (severe) RFX3 intron 24927181 rs2986687 chr9 3301887 G A 4.28E-04 Amyotrophic lateral sclerosis (sporadic) RFX3 intron 24529757 rs10971465 chr9 3338749 A G 3.44E-06 Sickle cell anemia (severity) RFX3 intron 20029952 rs10971472 chr9 3342398 G C 9.76E-04 Type 2 diabetes RFX3 intron 17463246 rs10971472 chr9 3342398 G C 4.38E-04 Multiple complex diseases RFX3 intron 17554300 rs7036456 chr9 3344786 G A 3.26E-07 Sickle cell anemia (severity) RFX3 intron 20029952 rs7867276 chr9 3345373 G A 9.88E-04 Type 2 diabetes RFX3 intron 17463246 rs7867276 chr9 3345373 G A 5.42E-04 Multiple complex diseases RFX3 intron 17554300 rs17715667 chr9 3397067 T C 4.34E-04 Alzheimer's disease RFX3 intron 24755620 rs4008948 chr9 3473360 A C 2.90E-05 Urinary metabolites RFX3 intron 21572414 rs10814284 chr9 3593961 A G 2.90E-04 Hearing function / / 17255346 rs2380874 chr9 3670864 T C 4.59E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7875055 chr9 3704360 A G 9.90E-04 Multiple complex diseases / / 17554300 rs7872019 chr9 3707775 G A 4.97E-05 Mammographic density / / 22532574 rs7854384 chr9 3743044 C T 8.69E-04 Type 2 diabetes / / 17463246 rs10973337 chr9 3752706 G C 9.65E-04 Aortic root size / / 21223598 rs10973348 chr9 3755197 G A 3.43E-04 Multiple complex diseases / / 17554300 rs13286706 chr9 3757758 A G 3.64E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs13296612 chr9 3758657 T A 1.35E-04 Multiple complex diseases / / 17554300 rs13296612 chr9 3758657 T A 2.49E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1929353 chr9 3759975 A G 8.34E-04 Insulin resistance / / 21901158 rs6476642 chr9 3765395 C T 6.46E-05 Coronary heart disease / / pha003031 rs16919564 chr9 3766183 A T 2.40E-05 Urinary metabolites / / 21572414 rs10973439 chr9 3770847 A C 3.56E-04 Lymphocyte counts / / 22286170 rs7039314 chr9 3781983 C T 0.0000205 Migraine / / 22678113 rs7039314 chr9 3781983 C T 2.05E-05 Migraine / / 22683712 rs4741853 chr9 3797726 G A 5.55E-04 Sarcoidosis / / 19165924 rs7049103 chr9 3824004 G A 6.84E-05 ldl cholesterol GLIS3 nearGene-3 pha003077 rs10116901 chr9 3826440 T A,C,G 4.70E-10 Platelet aggregation(pre- and post-aspirin) GLIS3 UTR-3 20529293 rs17742098 chr9 3828745 G T 1.00E-04 Information processing speed GLIS3 intron 21130836 rs1455173 chr9 3829793 C G 7.82E-04 Insulin resistance GLIS3 intron 21901158 rs10973733 chr9 3838633 G A 1.71E-05 Odorant perception GLIS3 intron 23910658 rs10758488 chr9 3840625 G T 4.64E-04 Response to cytadine analogues (cytosine arabinoside) GLIS3 intron 24483146 rs4612398 chr9 3840882 T C 1.56E-04 Suicide attempts in bipolar disorder GLIS3 intron 21423239 rs4612398 chr9 3840882 T C 2.14E-04 Tourette syndrome GLIS3 intron 22889924 rs4741859 chr9 3841216 T C 8.57E-07 Triglycerides GLIS3 intron pha003081 rs4741859 chr9 3841216 T C 7.59E-06 Lipid levels GLIS3 intron pha003082 rs717423 chr9 3844061 G A 4.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy) GLIS3 intron 24554482 rs10973775 chr9 3847878 G A 2.66E-05 Gallstones GLIS3 intron 17632509 rs6476722 chr9 3866849 G A 2.88E-04 Major depressive disorder GLIS3 intron 22472876 rs9657625 chr9 3893296 G C 1.41E-04 Insulin resistance GLIS3 intron 21901158 rs10974064 chr9 3897225 C T 5.79E-04 Suicide attempts in bipolar disorder GLIS3 intron 21423239 rs10974127 chr9 3915436 C T 2.65E-04 HIV-1 viral setpoint GLIS3 intron 17641165 rs622536 chr9 3927704 T C 4.50E-08 Alzheimer's disease biomarkers GLIS3 intron 23562540 rs622536 chr9 3927704 T C 6.68E-07 Alzheimer's disease biomarkers GLIS3 intron 23562540 rs622951 chr9 3927804 C T 4.50E-08 Alzheimer's disease biomarkers GLIS3 intron 23562540 rs622951 chr9 3927804 C T 6.68E-07 Alzheimer's disease biomarkers GLIS3 intron 23562540 rs623295 chr9 3927841 A C 4.50E-08 Alzheimer's disease biomarkers GLIS3 intron 23562540 rs623295 chr9 3927841 A C 6.68E-07 Alzheimer's disease biomarkers GLIS3 intron 23562540 rs624290 chr9 3928115 C T 4.50E-08 Alzheimer's disease biomarkers GLIS3 intron 23562540 rs624290 chr9 3928115 C T 6.68E-07 Alzheimer's disease biomarkers GLIS3 intron 23562540 rs514716 chr9 3929424 C T 1.00E-08 Alzheimer's disease biomarkers GLIS3 intron 23562540 rs514716 chr9 3929424 C T 3.00E-09 Alzheimer's disease biomarkers GLIS3 intron 23562540 rs16920043 chr9 3931254 G A 1.11E-04 Type 2 diabetes GLIS3 intron 17463246 rs16920090 chr9 3939997 G A 2.93E-04 Type 2 diabetes GLIS3 intron 17463246 rs12344176 chr9 3940862 T C 8.81E-06 Magnesium levels GLIS3 intron pha003092 rs532755 chr9 3942009 G C 1.32E-05 Serum metabolites GLIS3 intron 19043545 rs501631 chr9 3943125 C T 4.13E-05 Serum metabolites GLIS3 intron 19043545 rs1445339 chr9 3943449 C T 1.17E-05 Bone mineral density GLIS3 intron 19181680 rs553012 chr9 3944989 G A 3.38E-05 Serum metabolites GLIS3 intron 19043545 rs1445338 chr9 3946361 C T 1.51E-04 IgE levels GLIS3 intron 17255346 rs10491899 chr9 3946659 T C 1.52E-05 Asthma GLIS3 intron 11022011 rs10491899 chr9 3946659 T C 4.40E-04 Type 2 diabetes and 6 quantitative traits GLIS3 intron 17848626 rs646058 chr9 3974811 G A 6.50E-04 Multiple complex diseases GLIS3 intron 17554300 rs657076 chr9 3983003 G A 4.62E-04 Schizophrenia GLIS3 intron 19197363 rs7850708 chr9 3985549 C A 8.77E-05 Cognitive performance GLIS3 intron 19734545 rs500044 chr9 4002823 G A 0.0002 Migraine GLIS3 intron 22678113 rs16920361 chr9 4009019 C A 3.44E-04 Multiple complex diseases GLIS3 intron 17554300 rs564816 chr9 4015370 C A 3.00E-07 Methotrexate phramacokinetics (acute lymphoblastic leukemia) GLIS3 intron 19901119 rs10114243 chr9 4021656 C A 9.17E-04 Type 2 diabetes GLIS3 intron 17463246 rs10974284 chr9 4028700 T C 1.05E-23 Narcolepsy GLIS3 intron 19629137 rs10124899 chr9 4032095 G A 1.80E-05 Urinary metabolites GLIS3 intron 21572414 rs614782 chr9 4039027 G A 4.10E-04 Amyotrophic Lateral Sclerosis GLIS3 intron 17827064 rs2890547 chr9 4039273 C T 7.99E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GLIS3 intron 20031582 rs616081 chr9 4039286 C T 1.47E-04 Multiple complex diseases GLIS3 intron 17554300 rs501461 chr9 4039727 G T 1.96E-04 Alzheimer's disease (late onset) GLIS3 intron 21379329 rs501461 chr9 4039727 G T 1.24E-05 Paclitaxel-induced neuropathy GLIS3 intron 23776197 rs676472 chr9 4043590 T C 1.13E-05 Common variable immunodeficiency GLIS3 intron 21497890 rs4741881 chr9 4049110 A G 3.94E-05 HIV-1 viral setpoint GLIS3 intron 22174851 rs7863479 chr9 4049372 T C 1.23E-04 Alzheimer's disease (late onset) GLIS3 intron 21379329 rs10123460 chr9 4055211 G T 1.00E-06 Parkinson's disease (interaction with coffee consumption) GLIS3 intron 21876681 rs10974307 chr9 4058403 C T 5.20E-04 Taste perception GLIS3 intron 22132133 rs1417155 chr9 4068946 G A 9.00E-05 Prostate cancer GLIS3 intron 21743057 rs2185405 chr9 4078851 T C 1.35E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GLIS3 intron 20031582 rs4741887 chr9 4079470 G A 7.95E-04 Response to taxane treatment (placlitaxel) GLIS3 intron 23006423 rs7028492 chr9 4080755 G T 1.60E-05 Urinary metabolites GLIS3 intron 21572414 rs7030223 chr9 4083297 T C 4.18E-04 Response to cytadine analogues (cytosine arabinoside) GLIS3 intron 24483146 rs10814831 chr9 4083863 T C 4.18E-04 Response to cytadine analogues (cytosine arabinoside) GLIS3 intron 24483146 rs10814832 chr9 4084390 C T 4.50E-05 Response to statin treatment (atorvastatin),change in cholesterol levels GLIS3 intron 20031582 rs10814832 chr9 4084390 C T 9.56E-04 Response to cytadine analogues (cytosine arabinoside) GLIS3 intron 24483146 rs10758555 chr9 4084467 A G 1.01E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GLIS3 intron 20031582 rs1556987 chr9 4086553 C A 9.71E-04 Response to cytadine analogues (cytosine arabinoside) GLIS3 intron 24483146 rs806034 chr9 4096451 G T 6.68E-05 Lymphocyte counts GLIS3 intron pha003094 rs806034 chr9 4096451 G T 3.21E-05 Neutrophil count GLIS3 intron pha003095 rs806033 chr9 4096642 C A 7.01E-05 Lymphocyte counts GLIS3 intron pha003094 rs806033 chr9 4096642 C A 3.04E-05 Neutrophil count GLIS3 intron pha003095 rs806031 chr9 4100236 C T 9.39E-05 LDL lipoproteins GLIS3 intron pha002902 rs2890548 chr9 4105330 A C 4.77E-05 Eosinophil counts GLIS3 intron pha003088 rs1934661 chr9 4111791 G C 7.90E-07 Red blood cell traits GLIS3 intron 23222517 rs13301186 chr9 4119049 C T 1.92E-05 ldl cholesterol GLIS3 intron pha003076 rs611698 chr9 4136715 C T 8.72E-05 ldl cholesterol GLIS3 intron pha003076 rs526197 chr9 4137610 T G 8.72E-05 ldl cholesterol GLIS3 intron pha003076 rs7851070 chr9 4170457 A G 7.02E-06 Alcohol and nictotine co-dependence GLIS3 intron 20158304 rs7865812 chr9 4170979 C A 9.21E-04 Coronary heart disease GLIS3 intron 21606135 rs4741905 chr9 4176285 A T 9.16E-04 Multiple complex diseases GLIS3 intron 17554300 rs10814860 chr9 4181652 G A 3.23E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) GLIS3 intron 24023788 rs7033243 chr9 4206462 C T 5.88E-04 Multiple complex diseases GLIS3 intron 17554300 rs6476824 chr9 4206769 A G 1.30E-05 Urinary metabolites GLIS3 intron 21572414 rs911488 chr9 4217773 A C 1.12E-04 Sarcoidosis GLIS3 intron 19165924 rs7041962 chr9 4236100 C T 1.07E-04 Response to cholinesterase inhibitors in Alzheimer's disease GLIS3 intron 23374588 rs1571583 chr9 4267209 A G 1.00E-06 Thyroid hormone levels GLIS3 intron 23408906 rs1571583 chr9 4267209 A G 3.00E-08 Thyroid hormone levels GLIS3 intron 23408906 rs7019761 chr9 4268175 C G 9.61E-04 Suicide attempts in bipolar disorder GLIS3 intron 21423239 rs4548236 chr9 4268785 C T 6.39E-04 Suicide attempts in bipolar disorder GLIS3 intron 21423239 rs10974425 chr9 4269636 A C 5.34E-04 Suicide attempts in bipolar disorder GLIS3 intron 21423239 rs10120752 chr9 4270074 C T 5.27E-04 Suicide attempts in bipolar disorder GLIS3 intron 21423239 rs10814906 chr9 4270669 A G 1.91E-04 Hemoglobin concentration GLIS3 intron 20534544 rs10814908 chr9 4272449 T C 3.20E-04 Hemoglobin concentration GLIS3 intron 20534544 rs3892354 chr9 4282942 T G 2.73E-04 Multiple complex diseases GLIS3 intron 17554300 rs3892354 chr9 4282942 T G 7.59E-04 Type 2 diabetes GLIS3 intron 22158537 rs10758591 chr9 4285986 G C 1.28E-05 Type 2 diabetes GLIS3 intron 22158537 rs7024686 chr9 4287211 G C 7.16E-06 Type 2 diabetes GLIS3 intron 22158537 rs7041847 chr9 4287466 A G 2.00E-14 Type 2 diabetes GLIS3 intron 22158537 rs7041847 chr9 4287466 A G 0.00072 Type 2 diabetes GLIS3 intron 22885922 rs7041847 chr9 4287466 A G 1.99E-14 Type 2 diabetes GLIS3 intron 23300278 rs7041847 chr9 4287466 A G 5.00E-06 Type 2 diabetes GLIS3 intron 24509480 rs7034200 chr9 4289050 C A 1.00E-12 Fasting insulin-related traits GLIS3 intron 20081858 rs7034200 chr9 4289050 C A 1.00E-13 Fasting glucose-related traits GLIS3 intron 20081858 rs7034200 chr9 4289050 C A 2.64E-06 Type 2 diabetes GLIS3 intron 22158537 rs7034200 chr9 4289050 C A 7.00E-07 Fasting glucose-related traits (interaction with BMI) GLIS3 intron 22581228 rs7034200 chr9 4289050 C A 0.000092 Fasting blood glucose GLIS3 intron 22885924 rs10814914 chr9 4289196 T C 1.36E-06 Type 2 diabetes GLIS3 intron 22158537 rs2380950 chr9 4289747 G T 2.00E-04 Cognitive impairment induced by topiramate GLIS3 intron 22091778 rs2380950 chr9 4289747 G T 6.75E-05 Cognitive impairment induced by topiramate GLIS3 intron 22091778 rs2380950 chr9 4289747 G T 8.44E-06 Cognitive impairment induced by topiramate GLIS3 intron 22091778 rs4237150 chr9 4290085 G C 6.30E-05 Multiple complex diseases GLIS3 intron 17554300 rs4237150 chr9 4290085 G C 2.51E-06 Type 2 diabetes GLIS3 intron 22158537 rs4237150 chr9 4290085 G C 0.00000028 Fasting blood glucose GLIS3 intron 22885924 rs6476842 chr9 4291268 C T 3.21E-04 Multiple complex diseases GLIS3 intron 17554300 rs7020673 chr9 4291747 C G 1.55E-04 Multiple complex diseases GLIS3 intron 17554300 rs7020673 chr9 4291747 C G 4.88E-05 Type 1 diabetes GLIS3 intron 18978792 rs7020673 chr9 4291747 C G 5.00E-12 Type 1 diabetes GLIS3 intron 19430480 rs7020673 chr9 4291747 C G 5.40E-12 Multiple sclerosis GLIS3 intron 22190364 rs10758593 chr9 4292083 G A 3.00E-06 Type 1 diabetes GLIS3 intron 18840781 rs10758593 chr9 4292083 G A 1.18E-08 Type 1 diabetes GLIS3 intron 21980299 rs10758593 chr9 4292083 G A 0.00000026 Type 2 diabetes GLIS3 intron 22885922 rs10758593 chr9 4292083 G A 0.00000058 Type 2 diabetes (males) GLIS3 intron 22885922 rs10758593 chr9 4292083 G A 0.000013 HOMA-B GLIS3 intron 22885922 rs10758593 chr9 4292083 G A 0.000019 Fasting insulin-related traits GLIS3 intron 22885922 rs10758593 chr9 4292083 G A 1.20E-12 Fasting blood glucose GLIS3 intron 22885922 rs10758593 chr9 4292083 G A 5.10E-07 Type 2 diabetes GLIS3 intron 24509480 rs7867224 chr9 4292152 A G 0.000239 Fasting insulin-related traits GLIS3 intron 22885924 rs7867224 chr9 4292152 A G 3.90E-09 Fasting blood glucose GLIS3 intron 22885924 rs10814916 chr9 4293150 A C 0.000256 Fasting insulin-related traits GLIS3 intron 22885924 rs10814916 chr9 4293150 A C 6.85E-14 Fasting blood glucose GLIS3 intron 22885924 rs10814916 chr9 4293150 A C 6.00E-12 Type 2 diabetes GLIS3 intron 22961080 rs4339696 chr9 4295880 T G 1.56E-04 Multiple complex diseases GLIS3 intron 17554300 rs4339696 chr9 4295880 T G 4.79E-05 Type 1 diabetes GLIS3 intron 18978792 rs10758596 chr9 4301601 G A 6.53E-04 Type 2 diabetes GLIS3 nearGene-5 17463246 rs10758597 chr9 4301782 T G 5.47E-04 Type 2 diabetes GLIS3 nearGene-5 17463246 rs4097545 chr9 4303313 G A 5.84E-04 Type 2 diabetes / / 17463246 rs7018850 chr9 4303517 C T 5.41E-04 Type 2 diabetes / / 17463246 rs1330308 chr9 4305129 A G 8.51E-04 Type 2 diabetes / / 17463246 rs4567095 chr9 4309006 C T 6.12E-05 Relative hand skill in reading disability / / 24068947 rs10758606 chr9 4326425 A G 8.45E-04 Myopia (pathological) / / 21095009 rs12342539 chr9 4327960 C T 2.12E-04 Myopia (pathological) / / 21095009 rs13286735 chr9 4331760 C A 5.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10974480 chr9 4338987 G A 2.20E-04 Multiple complex diseases / / 17554300 rs10814948 chr9 4368838 C T 4.25E-04 Multiple complex diseases / / 17554300 rs10814948 chr9 4368838 C T 1.87E-08 Colorectal cancer vs. adenoma controls / / 22532847 rs10814950 chr9 4370901 C T 5.87E-04 Multiple complex diseases / / 17554300 rs17803219 chr9 4390752 C G 7.73E-07 Type 2 diabetes / / 17463246 rs4740775 chr9 4402216 A T 6.05E-04 Smoking quantity / / 24665060 rs10814969 chr9 4419154 T C 3.00E-06 Smoking quantity / / 24665060 rs10974531 chr9 4426631 C A 5.00E-06 Pancreatic cancer / / 22158540 rs10814970 chr9 4429762 T C 5.57E-05 Cognitive impairment induced by topiramate / / 22091778 rs932948 chr9 4443744 A G 8.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7034118 chr9 4461826 A G 3.30E-05 Bilirubin levels / / 19414484 rs954864 chr9 4476238 G A 5.51E-04 Stroke / / pha002887 rs2150192 chr9 4487024 A G 5.56E-05 Prostate cancer / / 22923026 rs10974573 chr9 4487575 T G 6.06E-04 Aortic root size / / 21223598 rs10814995 chr9 4505544 A C 6.10E-04 Alcohol dependence SLC1A1 intron 20201924 rs10814997 chr9 4516070 C T 2.78E-04 Multiple complex diseases SLC1A1 intron 17554300 rs17812250 chr9 4517894 A G 1.61E-04 Type 2 diabetes SLC1A1 intron 17463246 rs17812250 chr9 4517894 A G 1.20E-04 Alcohol dependence SLC1A1 intron 20201924 rs7022369 chr9 4527752 C G 5.06E-04 Type 2 diabetes SLC1A1 intron 17463246 rs2026828 chr9 4543307 A G 1.06E-04 Type 2 diabetes SLC1A1 intron 17463246 rs7856675 chr9 4555305 A G 8.00E-06 Coronary artery calcification SLC1A1 intron 23870195 rs3780414 chr9 4557165 T C 1.70E-05 Urinary metabolites SLC1A1 intron 21572414 rs2228622 chr9 4564432 G A 1 Drug response to Clozapine SLC1A1 cds-synon 19884611 rs2228622 chr9 4564432 G A 1 Drug response to Olanzapine SLC1A1 cds-synon 19884611 rs2228622 chr9 4564432 G A 1 Drug response to Risperidone SLC1A1 cds-synon 19884611 rs3780413 chr9 4567353 C G 1 Drug response to Clozapine SLC1A1 intron 19884611 rs3780413 chr9 4567353 C G 1 Drug response to Olanzapine SLC1A1 intron 19884611 rs3780413 chr9 4567353 C G 1 Drug response to Risperidone SLC1A1 intron 19884611 rs3780412 chr9 4572480 T C 1 Drug response to Clozapine SLC1A1 intron 19884611 rs3780412 chr9 4572480 T C 1 Drug response to Olanzapine SLC1A1 intron 19884611 rs3780412 chr9 4572480 T C 1 Drug response to Risperidone SLC1A1 intron 19884611 rs7871243 chr9 4573218 G A 1.20E-04 Type 2 diabetes SLC1A1 intron 17463246 rs12682807 chr9 4574022 A C 5.49E-04 Alcohol dependence SLC1A1 intron 21314694 rs6476879 chr9 4577346 A C 7.21E-04 Tourette syndrome SLC1A1 intron 22889924 rs301434 chr9 4582082 C T 9.89E-05 Height SLC1A1 intron pha003010 rs301434 chr9 4582082 C T 9.11E-05 Height SLC1A1 intron pha003011 rs301451 chr9 4602398 C G 2.50E-04 Gastric cancer (diffuse-type gastric cancer) C9orf68 intron 18488030 rs10974676 chr9 4631802 A G 8.29E-04 Acute lung injury C9orf68 intron 22295056 rs4484748 chr9 4643573 C G 6.10E-04 Multiple complex diseases C9orf68 intron 17554300 rs301468 chr9 4645935 A G 8.50E-04 Multiple complex diseases C9orf68 intron 17554300 rs2146423 chr9 4657040 A G 2.88E-06 Osteoarthritis C9orf68 intron 22763110 rs1385452 chr9 4658449 G T 1.56E-04 Multiple complex diseases C9orf68 intron 17554300 rs7874378 chr9 4695068 A G 1.20E-04 Acne (severe) CDC37L1 intron 24927181 rs439660 chr9 4733368 G C 9.06E-04 Lymphocyte counts AK3 intron 22286170 rs10122575 chr9 4734014 T C 8.20E-06 Urinary metabolites AK3 intron 21572414 rs12352353 chr9 4743341 A G 6.57E-07 Schizophrenia AK3 nearGene-5 21926974 rs409801 chr9 4744743 T C 3.00E-49 Platelet counts / / 22139419 rs409801 chr9 4744743 T C 3.00E-05 Platelet counts / / 24026423 rs1756871 chr9 4758022 G A 2.28E-04 Alcohol dependence / / 20201924 rs10815070 chr9 4760538 G C 6.13E-05 Multiple sclerosis / / 17660530 rs385893 chr9 4763176 T C 9.00E-17 Hematological parameters / / 19820697 rs385893 chr9 4763176 T C 2.95E-13 Blood cell counts and other traits / / 20139978 rs385893 chr9 4763176 T C 3.00E-13 Blood cell counts and other traits / / 20139978 rs385893 chr9 4763176 T C 2.95E-13 Hepatitis B / / 21750111 rs385893 chr9 4763176 T C 8.50E-17 Mean platelet volume / / 22423221 rs10974772 chr9 4767677 C T 6.13E-11 Other erythrocyte phenotypes / / 19862010 rs7865442 chr9 4772328 C G 3.11E-10 Other erythrocyte phenotypes / / 19862010 rs296859 chr9 4774015 C T 4.00E-07 Handedness / / 24065183 rs13284412 chr9 4778777 G A 1.77E-11 Other erythrocyte phenotypes / / 19862010 rs423955 chr9 4792339 C T 1.00E-09 Platelet counts / / 24026423 rs17661798 chr9 4793897 C A 6.88E-04 Multiple complex diseases RCL1 intron 17554300 rs13284787 chr9 4811553 A C,G,T 2.84E-11 Other erythrocyte phenotypes RCL1 intron 19862010 rs13284787 chr9 4811553 A C,G,T 2.07E-08 Red blood cell traits RCL1 intron 23222517 rs13300663 chr9 4814948 G C 2.75E-11 Other erythrocyte phenotypes RCL1 intron 19862010 rs13300663 chr9 4814948 G C 1.00E-29 Platelet counts RCL1 intron 22139419 rs13300663 chr9 4814948 G C 2.67E-08 Red blood cell traits RCL1 intron 23222517 rs13300663 chr9 4814948 G C 3.00E-06 Platelet counts RCL1 intron 24026423 rs443934 chr9 4831076 A C 1.12E-04 Response to cytidine analogues (gemcitabine) RCL1 intron 24483146 rs439975 chr9 4832888 T C 9.18E-04 Heart Failure RCL1 intron pha002884 rs457287 chr9 4834394 A G 1.00E-06 Platelet counts RCL1 intron 23263863 rs3780359 chr9 4835574 G A 3.95E-08 Red blood cell traits RCL1 intron 23222517 rs6476915 chr9 4839511 T C 0.0005114 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RCL1 intron 23233654 rs6476915 chr9 4839511 T C 5.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) RCL1 intron 23233662 rs295263 chr9 4840063 C T 0.0000846 Transmission distortion RCL1 intron 22377632 rs10974808 chr9 4840380 A G 1.91E-12 Other erythrocyte phenotypes RCL1 intron 19862010 rs10974808 chr9 4840380 A G 2.86E-09 Red blood cell traits RCL1 intron 23222517 rs7868737 chr9 4843672 C G 1.19E-04 Multiple complex diseases RCL1 intron 17554300 rs7868737 chr9 4843672 C G 5.46E-13 Other erythrocyte phenotypes RCL1 intron 19862010 rs7868737 chr9 4843672 C G 8.32E-13 Red blood cell traits RCL1 intron 23222517 rs2236496 chr9 4844265 T C 6.92E-10 Other erythrocyte phenotypes RCL1 intron 19862010 rs2236496 chr9 4844265 T C 2.50E-14 Blood cell counts and other traits RCL1 intron 20139978 rs2236496 chr9 4844265 T C 5.69E-11 Blood cell counts and other traits RCL1 intron 20139978 rs2236496 chr9 4844265 T C 6.00E-11 Blood cell counts and other traits RCL1 intron 20139978 rs2236496 chr9 4844265 T C 1.00E-19 Red blood cell traits RCL1 intron 23222517 rs2236496 chr9 4844265 T C 2.00E-07 Mean corpuscular volume RCL1 intron 23263863 rs2236497 chr9 4844704 T C 1.46E-12 Other erythrocyte phenotypes RCL1 intron 19862010 rs2236497 chr9 4844704 T C 6.09E-15 Red blood cell traits RCL1 intron 23222517 rs295258 chr9 4845242 G A 7.30E-07 Red blood cell traits RCL1 intron 23222517 rs10815094 chr9 4845520 A G 1.29E-12 Other erythrocyte phenotypes RCL1 intron 19862010 rs10815094 chr9 4845520 A G 3.12E-13 Red blood cell traits RCL1 intron 23222517 rs10815094 chr9 4845520 A G 5.00E-06 Mean corpuscular hemoglobin RCL1 intron 23263863 rs10815095 chr9 4848297 A G 1.19E-04 Multiple complex diseases RCL1 intron 17554300 rs10815095 chr9 4848297 A G 1.23E-12 Other erythrocyte phenotypes RCL1 intron 19862010 rs10815095 chr9 4848297 A G 7.97E-13 Red blood cell traits RCL1 intron 23222517 rs10758656 chr9 4852599 A G 7.11E-13 Other erythrocyte phenotypes RCL1 intron 19862010 rs10758656 chr9 4852599 A G 2.93E-12 Red blood cell traits RCL1 intron 23222517 rs10758657 chr9 4853751 A C,G 4.45E-13 Other erythrocyte phenotypes RCL1 intron 19862010 rs10758657 chr9 4853751 A C,G 1.66E-12 Red blood cell traits RCL1 intron 23222517 rs10974815 chr9 4854253 C T 2.57E-11 Other erythrocyte phenotypes RCL1 intron 19862010 rs10974815 chr9 4854253 C T 1.99E-11 Red blood cell traits RCL1 intron 23222517 rs457417 chr9 4855514 C A 0.000524 Salmonella-induced pyroptosis RCL1 intron 22837397 rs7853365 chr9 4855858 A C 9.86E-05 Multiple complex diseases RCL1 intron 17554300 rs7853365 chr9 4855858 A C 5.38E-13 Other erythrocyte phenotypes RCL1 intron 19862010 rs7853365 chr9 4855858 A C 9.09E-12 Red blood cell traits RCL1 intron 23222517 rs508227 chr9 4855912 C T 2.16E-07 Red blood cell traits RCL1 intron 23222517 rs10758658 chr9 4856877 G A 2.00E-14 Mean corpuscular hemoglobin RCL1 intron 19862010 rs10758658 chr9 4856877 G A 3.00E-20 Mean corpuscular volume RCL1 intron 19862010 rs10758658 chr9 4856877 G A 2.85E-14 Blood cell counts and other traits RCL1 intron 20139978 rs10758658 chr9 4856877 G A 7.13E-11 Blood cell counts and other traits RCL1 intron 20139978 rs10758658 chr9 4856877 G A 1.44E-14 Red blood cell traits RCL1 intron 23222517 rs15583 chr9 4860300 A G 5.44E-10 Red blood cell traits RCL1 UTR-3 23222517 rs1053872 chr9 4860643 G C 1.38E-04 Multiple complex diseases RCL1 UTR-3 17554300 rs1053872 chr9 4860643 G C 6.34E-12 Other erythrocyte phenotypes RCL1 UTR-3 19862010 rs1053872 chr9 4860643 G C 1.72E-11 Red blood cell traits RCL1 UTR-3 23222517 rs1053889 chr9 4860980 G A 9.28E-04 Type 2 diabetes RCL1 UTR-3 17463246 rs1053889 chr9 4860980 G A 3.75E-04 Response to cytidine analogues (gemcitabine) RCL1 UTR-3 24483146 rs4740804 chr9 4861479 C T 2.83E-08 Other erythrocyte phenotypes / / 19862010 rs4740804 chr9 4861479 C T 1.14E-10 Red blood cell traits / / 23222517 rs7867346 chr9 4863670 T C 1.33E-08 Red blood cell traits / / 23222517 rs10758661 chr9 4863952 A G 1.75E-12 Red blood cell traits / / 23222517 rs7044812 chr9 4864885 T C 7.38E-08 Red blood cell traits / / 23222517 rs7041623 chr9 4864891 A G 1.88E-09 Red blood cell traits / / 23222517 rs12554461 chr9 4865256 A G 2.05E-09 Red blood cell traits / / 23222517 rs10815098 chr9 4865338 C T 1.95E-11 Other erythrocyte phenotypes / / 19862010 rs10815098 chr9 4865338 C T 6.09E-09 Red blood cell traits / / 23222517 rs7032487 chr9 4866010 G T 7.15E-07 Red blood cell traits / / 23222517 rs7850837 chr9 4866840 T C 2.20E-04 Primary sclerosing cholangitis / / 19944697 rs10815099 chr9 4876202 C T 0.000327 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10815099 chr9 4876202 C T 3.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs731235 chr9 4877031 T C 1.96E-04 Alzheimer's disease / / 17998437 rs10815105 chr9 4904969 T G 8.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10815111 chr9 4911930 T C 7.10E-06 Carotid intima media thickness / / 21909108 rs10974859 chr9 4930487 A C 8.00E-04 Multiple complex diseases / / 17554300 rs10815124 chr9 4933391 A G 7.87E-04 Multiple complex diseases / / 17554300 rs10815125 chr9 4933667 C T 9.76E-04 Multiple complex diseases / / 17554300 rs1571222 chr9 4935533 G A 4.80E-04 Multiple complex diseases / / 17554300 rs3968 chr9 4941997 G C 2.09E-05 Bipolar disorder / / 21926972 rs4742054 chr9 4947510 C T 1.10E-05 Urinary metabolites / / 21572414 rs6476931 chr9 4959024 C T 7.37E-04 Type 2 diabetes / / 17463246 rs10974892 chr9 4964774 A G 1.84E-05 Self-reported allergy / / 23817569 rs1327495 chr9 4974441 G A 8.59E-04 Crohn's disease / / 23266558 rs7864782 chr9 4976029 A G 7.23E-04 Multiple complex diseases / / 17554300 rs1887427 chr9 4979730 A G 6.43E-04 Crohn's disease / / 23266558 rs10758669 chr9 4981602 C A 3.00E-09 Crohn's disease / / 18587394 rs10758669 chr9 4981602 C A 1.00E-06 Ulcerative colitis / / 20228799 rs10758669 chr9 4981602 C A 1.00E-13 Crohn's disease / / 21102463 rs10758669 chr9 4981602 C A 3.00E-09 Asthma / / 21150878 rs10758669 chr9 4981602 C A 2.00E-25 Ulcerative colitis / / 21297633 rs10758669 chr9 4981602 C A 3.46E-09 Multiple sclerosis / / 22190364 rs10758669 chr9 4981602 C A 8.00E-45 Inflammatory bowel disease / / 23128233 rs10758669 chr9 4981602 C A 3.83E-05 Ulcerative colitis / / 23511034 rs10758669 chr9 4981602 C A 6.59E-05 Ulcerative colitis / / 23511034 rs2274471 chr9 4985879 A G 5.00E-06 Crohn's disease JAK2 intron 23266558 rs7849191 chr9 4988761 C T 4.34E-08 Crohn's disease JAK2 intron 18587394 rs2890618 chr9 4991840 T C 5.23E-04 Depression (quantitative trait) JAK2 intron 20800221 rs1327493 chr9 4993082 C G 5.16E-04 Depression (quantitative trait) JAK2 intron 20800221 rs6476934 chr9 4993267 T G 4.93E-04 Depression (quantitative trait) JAK2 intron 20800221 rs1536800 chr9 5055434 C T 2.79E-04 Alzheimer's disease (late onset) JAK2 intron 21379329 rs10974944 chr9 5070831 C G 4.00E-20 Myeloproliferative neoplasms JAK2 intron 19287384 rs10815160 chr9 5116616 T G 2.08E-04 Alzheimer's disease (late onset) JAK2 intron 21379329 rs10975003 chr9 5213687 T C 1.00E-06 Ulcerative colitis / / 19915573 rs10758678 chr9 5271598 C T 0.0005739 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10758678 chr9 5271598 C T 5.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7848509 chr9 5317534 C T 2.70E-04 Tourette syndrome / / 22889924 rs9299013 chr9 5372724 G T 8.21E-05 Lymphocyte counts C9orf46 intron 22286170 rs10975083 chr9 5377177 A G 8.04E-04 Smoking cessation C9orf46 intron 24665060 rs7027829 chr9 5384832 C A 1.96E-04 Amyotrophic lateral sclerosis C9orf46 intron 23624525 rs10975087 chr9 5386384 T G 7.72E-05 Cognitive test performance C9orf46 intron 20125193 rs10815203 chr9 5389075 T C 3.01E-04 Smoking cessation C9orf46 intron 24665060 rs10975090 chr9 5389652 C T 2.59E-04 Sarcoidosis C9orf46 intron 19165924 rs1535454 chr9 5410723 C T 3.00E-06 Obesity-related traits C9orf46 intron 23251661 rs10815211 chr9 5412546 C T 7.54E-04 Smoking cessation C9orf46 intron 24665060 rs10815213 chr9 5418191 T C 1.82E-04 Smoking cessation C9orf46 intron 24665060 rs10815216 chr9 5420526 A C 2.09E-05 Malignant pleural mesothelioma C9orf46 intron 23626673 rs10815216 chr9 5420526 A C 8.53E-06 Malignant pleural mesothelioma C9orf46 intron 23626673 rs2295870 chr9 5436461 C A 2.03E-04 Smoking cessation C9orf46 intron 24665060 rs911761 chr9 5439946 T A,C,G 6.40E-05 Cognitive test performance / / 20125193 rs4742095 chr9 5445990 G T 9.58E-04 Parkinson's disease / / 17052657 rs4742095 chr9 5445990 G T 6.92E-05 Alzheimer's disease / / 17998437 rs10975121 chr9 5446078 A G 7.00E-07 Urinary metabolites / / 21572414 rs10125854 chr9 5464065 A G 3.12E-04 Alzheimer's disease (late onset) CD274 intron 21379329 rs2890658 chr9 5465130 C A 3.06E-04 Alzheimer's disease CD274 intron 17998437 rs7034893 chr9 5494438 T C 3.23E-05 Endometrial cancer / / 24096698 rs4742104 chr9 5532871 T C 6.05E-04 Parkinson's disease PDCD1LG2 intron 17052657 rs7854413 chr9 5557708 T C 1.11E-04 Body mass index PDCD1LG2 missense 17255346 rs10975179 chr9 5559893 C T 3.28E-05 Body mass index PDCD1LG2 intron 17255346 rs7048870 chr9 5565601 G A 1.09E-04 Body mass index PDCD1LG2 intron 17255346 rs1536927 chr9 5581140 T G 6.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs10815246 chr9 5591035 C G,T 1.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs16923249 chr9 5592145 C A 9.10E-06 Urinary metabolites / / 21572414 rs10815251 chr9 5599565 T A 2.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs7042156 chr9 5609844 A C 7.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs7026868 chr9 5660807 C T 2.89E-04 Parkinson's disease KIAA1432 intron 16252231 rs10975258 chr9 5719116 C A 1.18E-05 Colorectal cancer KIAA1432 intron 21242260 rs10815278 chr9 5747187 C T 5.97E-04 Colorectal cancer KIAA1432 intron 24448986 rs7846809 chr9 5748232 C T 7.79E-04 Endometrial cancer KIAA1432 intron 24096698 rs3739648 chr9 5774225 T G 1.20E-06 Urinary metabolites KIAA1432 cds-synon 21572414 rs10975277 chr9 5774661 G A 4.20E-06 Urinary metabolites KIAA1432 UTR-3 21572414 rs1342854 chr9 5791151 G A 4.90E-04 Obesity (extreme) ERMP1 intron 21935397 rs1014006 chr9 5804276 G A 8.46E-04 Parkinson's disease ERMP1 intron 16252231 rs10815285 chr9 5814424 T G 4.64E-05 Parkinson's disease ERMP1 intron 16252231 rs1776008 chr9 5818970 T C 2.12E-04 Multiple complex diseases ERMP1 intron 17554300 rs17571216 chr9 5830317 T C 9.92E-05 Parkinson's disease ERMP1 intron 16252231 rs4628310 chr9 5840402 G A 1.08E-04 Parkinson's disease / / 16252231 rs1418746 chr9 5854501 T C 5.10E-06 Lipid levels / / 18193043 rs10758713 chr9 5872949 A G 0.00000325 Cytarabine sensitivity / / 23538338 rs7862229 chr9 5875256 C G 1.95E-04 Multiple complex diseases / / 17554300 rs2233176 chr9 5890825 C T 0.0000526 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2233176 chr9 5890825 C T 5.26E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2150702 chr9 5893861 G A,T 3.00E-08 Multiple sclerosis MLA/ intron 22190364 rs2150702 chr9 5893861 G A,T 2.50E-05 Multiple sclerosis MLA/ intron 24234648 rs1411948 chr9 5982797 G A 5.29E-04 Alzheimer's disease KIAA2026 intron 24755620 rs1888703 chr9 5983508 T G 8.90E-04 Alzheimer's disease KIAA2026 intron 24755620 rs1993912 chr9 5987781 A C 6.16E-04 Alcohol dependence KIAA2026 intron 21314694 rs7859471 chr9 6023626 T C 7.48E-04 Obesity (extreme) / / 21935397 rs1094328 chr9 6029644 C T 4.86E-04 Alzheimer's disease / / 24755620 rs10975412 chr9 6049547 A G 2.05E-06 Self-reported allergy LOC100506189 intron 23817569 rs10975413 chr9 6049843 A G 1.93E-06 Self-reported allergy LOC100506189 intron 23817569 rs10975416 chr9 6051924 T G 2.50E-06 Self-reported allergy LOC100506189 intron 23817569 rs1330124 chr9 6053098 A C 1.80E-06 Self-reported allergy LOC100506189 intron 23817569 rs380568 chr9 6055531 T C 1.50E-06 Self-reported allergy LOC100506189 intron 23817569 rs343489 chr9 6064299 C G 6.06E-07 Self-reported allergy LOC100506189 intron 23817569 rs343490 chr9 6064575 A G 4.90E-07 Self-reported allergy LOC100506189 intron 23817569 rs343491 chr9 6064640 G C 4.82E-07 Self-reported allergy LOC100506189 intron 23817569 rs343496 chr9 6068077 A T 4.60E-07 Self-reported allergy / / 23817569 rs343496 chr9 6068077 A T 2.00E-06 Asthma and hay fever / / 24388013 rs343476 chr9 6072597 T C 3.25E-07 Self-reported allergy / / 23817569 rs343475 chr9 6073013 C G 3.54E-07 Self-reported allergy / / 23817569 rs189348 chr9 6073194 T C 3.33E-07 Self-reported allergy / / 23817569 rs343474 chr9 6073843 A G 8.76E-05 Aortic root size / / 21223598 rs343473 chr9 6074936 A G 1.09E-04 Self-reported allergy / / 23817569 rs378952 chr9 6078146 C T 4.48E-07 Self-reported allergy / / 23817569 rs371454 chr9 6078614 C T 3.62E-06 Asthma / / 20860503 rs371454 chr9 6078614 C T 6.24E-07 Self-reported allergy / / 23817569 rs454664 chr9 6078763 A G 1.09E-04 Self-reported allergy / / 23817569 rs340923 chr9 6088628 G A 1.32E-06 Self-reported allergy / / 23817569 rs340921 chr9 6090160 G T 1.59E-06 Self-reported allergy / / 23817569 rs821164 chr9 6090989 C G 1.32E-06 Self-reported allergy / / 23817569 rs340918 chr9 6091048 A C 1.19E-06 Self-reported allergy / / 23817569 rs531759 chr9 6091996 C T 1.20E-06 Self-reported allergy / / 23817569 rs639247 chr9 6092089 T G 1.25E-06 Self-reported allergy / / 23817569 rs420445 chr9 6092154 G A 1.24E-06 Self-reported allergy / / 23817569 rs2150969 chr9 6093990 C G 1.39E-06 Self-reported allergy / / 23817569 rs9408638 chr9 6096931 A G 1.47E-06 Self-reported allergy / / 23817569 rs437389 chr9 6099531 T C 1.74E-06 Self-reported allergy / / 23817569 rs340906 chr9 6106086 T C 1.82E-06 Self-reported allergy / / 23817569 rs340905 chr9 6106169 A C 1.81E-06 Self-reported allergy / / 23817569 rs340904 chr9 6106779 C A 1.33E-06 Self-reported allergy / / 23817569 rs340903 chr9 6107113 C A,G 1.79E-06 Self-reported allergy / / 23817569 rs340901 chr9 6108398 G C 1.83E-06 Self-reported allergy / / 23817569 rs340900 chr9 6108921 T C 5.14E-05 Asthma / / 23181788 rs340898 chr9 6109516 A C 6.16E-04 Self-reported allergy / / 23817569 rs974936 chr9 6111703 A C 1.84E-06 Self-reported allergy / / 23817569 rs7040888 chr9 6113735 T C 1.40E-05 Urinary metabolites / / 21572414 rs441616 chr9 6113940 T C 1.84E-06 Self-reported allergy / / 23817569 rs1556470 chr9 6115538 C T 1.95E-06 Self-reported allergy / / 23817569 rs374672 chr9 6119038 C T 2.43E-06 Self-reported allergy / / 23817569 rs443175 chr9 6123556 T C 1.86E-06 Self-reported allergy / / 23817569 rs1332291 chr9 6124101 T C 1.53E-06 Self-reported allergy / / 23817569 rs1755531 chr9 6124250 T G 1.66E-06 Self-reported allergy / / 23817569 rs1970089 chr9 6124359 T C 1.61E-06 Self-reported allergy / / 23817569 rs1537285 chr9 6124584 T G 1.61E-06 Self-reported allergy / / 23817569 rs1332292 chr9 6124862 T C 2.17E-06 Self-reported allergy / / 23817569 rs7035594 chr9 6125353 A T 1.56E-06 Self-reported allergy / / 23817569 rs7039066 chr9 6125539 T C 1.43E-06 Self-reported allergy / / 23817569 rs340915 chr9 6126588 A G 1.35E-06 Self-reported allergy / / 23817569 rs340914 chr9 6126799 A G 1.27E-06 Self-reported allergy / / 23817569 rs340912 chr9 6127851 A G 1.24E-06 Self-reported allergy / / 23817569 rs340908 chr9 6128897 T C 2.81E-06 Asthma / / 20860503 rs340908 chr9 6128897 T C 3.20E-07 Asthma / / 21907864 rs340908 chr9 6128897 T C 1.15E-06 Self-reported allergy / / 23817569 rs340907 chr9 6129637 A C 1.12E-06 Self-reported allergy / / 23817569 rs10114457 chr9 6130940 A G 5.02E-07 Self-reported allergy / / 23817569 rs4742159 chr9 6131612 A T 9.82E-07 Self-reported allergy / / 23817569 rs376690 chr9 6134926 C T 1.04E-06 Self-reported allergy / / 23817569 rs376382 chr9 6134999 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs413382 chr9 6142948 C A 1.97E-07 Self-reported allergy / / 23817569 rs369756 chr9 6146441 G T 4.76E-08 Self-reported allergy / / 23817569 rs10119713 chr9 6163823 G A 4.86E-05 Schizophrenia / / 20185149 rs2079 chr9 6166653 G A 1.20E-05 Self-reported allergy / / 23817569 rs2381413 chr9 6167017 C G 9.81E-05 Self-reported allergy / / 23817569 rs2381413 chr9 6167017 C G 3.10E-04 Smoking initiation / / 24665060 rs7032572 chr9 6172380 A G 2.00E-09 Self-reported allergy / / 23817569 rs72699186 chr9 6175855 A T 2.00E-09 Asthma and hay fever / / 24388013 rs1412426 chr9 6188652 A C,G,T 1.82E-09 Asthma / / 20860503 rs1412426 chr9 6188652 A C,G,T 1.11E-05 Vitiligo / / 22561518 rs1342326 chr9 6190076 A C 9.00E-10 Asthma / / 20860503 rs1342326 chr9 6190076 A C 9.20E-10 Asthma / / 21907864 rs1342326 chr9 6190076 A C 9.20E-10 Asthma / / 22561531 rs1342326 chr9 6190076 A C 6.00E-09 Self-reported allergy / / 23817569 rs1342326 chr9 6190076 A C 1.10E-10 Asthma (childhood,severe) / / 24241537 rs2095044 chr9 6192796 T C 7.09E-08 Self-reported allergy / / 23817569 rs2381416 chr9 6193455 C A 2.00E-12 Asthma / / 21804549 rs2381416 chr9 6193455 C A 1.23E-07 Self-reported allergy / / 23817569 rs1888909 chr9 6197392 T C 3.97E-07 Asthma / / 21804549 rs1888909 chr9 6197392 T C 6.03E-08 Self-reported allergy / / 23817569 rs992969 chr9 6209697 A G 4.81E-13 Asthma / / 20860503 rs992969 chr9 6209697 A G 1.77E-07 Self-reported allergy / / 23817569 rs3939286 chr9 6210099 T C 4.11E-13 Asthma / / 20860503 rs3939286 chr9 6210099 T C 1.35E-07 Self-reported allergy / / 23817569 rs928413 chr9 6213387 G A 2.17E-13 Asthma / / 20860503 rs928413 chr9 6213387 G A 1.40E-07 Self-reported allergy / / 23817569 rs928413 chr9 6213387 G A 9.00E-13 Asthma (childhood,severe) / / 24241537 rs7848215 chr9 6213468 C T 1.84E-05 Vitiligo / / 22561518 rs7848215 chr9 6213468 C T 3.15E-07 Self-reported allergy / / 23817569 rs2066362 chr9 6219176 G T 9.03E-12 Asthma IL33 intron 20860503 rs2066362 chr9 6219176 G T 2.41E-08 Self-reported allergy IL33 intron 23817569 rs2006682 chr9 6227045 G C 4.53E-06 Self-reported allergy IL33 intron 23817569 rs2210463 chr9 6227752 A G 4.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IL33 intron 20877124 rs2210463 chr9 6227752 A G 5.61E-05 Post-operative nausea and vomiting IL33 intron 21694509 rs4740840 chr9 6229110 A G 8.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IL33 intron 20877124 rs12551256 chr9 6231239 A G 1.54E-05 Self-reported allergy IL33 intron 23817569 rs10815388 chr9 6232242 C T 6.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IL33 intron 20877124 rs12339348 chr9 6233082 A T 9.96E-08 Self-reported allergy IL33 intron 23817569 rs17582919 chr9 6233376 T C 9.53E-08 Self-reported allergy IL33 intron 23817569 rs7033258 chr9 6234131 G A 7.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IL33 intron 20877124 rs10975507 chr9 6236977 A T 4.87E-08 Self-reported allergy IL33 intron 23817569 rs17498196 chr9 6237547 A C 5.06E-07 Asthma IL33 intron 20860503 rs17498196 chr9 6237547 A C 3.73E-08 Self-reported allergy IL33 intron 23817569 rs10815393 chr9 6240324 T C 4.10E-08 Self-reported allergy IL33 intron 23817569 rs10118795 chr9 6240658 T C 1.11E-04 Coronary Artery Disease IL33 intron 17634449 rs10118795 chr9 6240658 T C 6.00E-07 Parkinson's disease (interaction with coffee consumption) IL33 intron 21876681 rs7019575 chr9 6243935 G C 9.20E-07 Self-reported allergy IL33 intron 23817569 rs10975519 chr9 6253571 C T 9.00E-07 Endometriosis IL33 cds-synon 23472165 rs744567 chr9 6292602 C G 8.39E-08 Self-reported allergy / / 23817569 rs17756142 chr9 6301578 A C 5.00E-07 Self-reported allergy / / 23817569 rs17705436 chr9 6310908 C G 3.88E-07 Self-reported allergy / / 23817569 rs4742179 chr9 6324376 A C 1.63E-05 Self-reported allergy / / 23817569 rs10758764 chr9 6326825 T A 1.57E-05 Self-reported allergy / / 23817569 rs2295843 chr9 6328871 G A 3.90E-05 Amyotrophic lateral sclerosis (sporadic) TPD52L3 cds-synon 24529757 rs3847262 chr9 6328947 T C 9.28E-04 Multiple complex diseases / / 17554300 rs1052335 chr9 6330380 A C 2.86E-07 Non-albumin protein levels TPD52L3 UTR-3 22558069 rs10491836 chr9 6331421 C A 1.01E-07 Self-reported allergy TPD52L3 UTR-3 23817569 rs16924356 chr9 6331610 G A 1.25E-07 Self-reported allergy TPD52L3 UTR-3 23817569 rs721352 chr9 6332901 A C 1.11E-05 Self-reported allergy / / 23817569 rs7850988 chr9 6335760 A T 7.10E-08 Self-reported allergy / / 23817569 rs731585 chr9 6342328 G A 1.25E-05 Self-reported allergy / / 23817569 rs16924428 chr9 6351111 A G 2.72E-08 Self-reported allergy / / 23817569 rs10975552 chr9 6351834 T C 8.80E-05 Self-reported allergy / / 23817569 rs10975553 chr9 6352819 T C 8.34E-05 Self-reported allergy / / 23817569 rs7021445 chr9 6356657 C T 8.89E-04 Multiple complex diseases / / 17554300 rs7022186 chr9 6359144 T C 7.59E-05 Self-reported allergy / / 23817569 rs7851246 chr9 6362365 G A 2.12E-08 Self-reported allergy / / 23817569 rs10975558 chr9 6364449 C T 2.34E-08 Self-reported allergy / / 23817569 rs10975558 chr9 6364449 C T 7.90E-05 Erythrocyte counts / / pha003099 rs7875812 chr9 6364533 A T 8.84E-05 Self-reported allergy / / 23817569 rs719725 chr9 6365683 A C 1.32E-05 Colorectal cancer / / 17618283 rs719725 chr9 6365683 A C 8.75E-05 Self-reported allergy / / 23817569 rs4361812 chr9 6365737 C A 9.67E-08 Self-reported allergy / / 23817569 rs7025295 chr9 6395247 T C 1.44E-04 Self-reported allergy / / 23817569 rs7850497 chr9 6395540 A T 2.00E-04 Adverse response to radiation therapy / / 23719583 rs7857628 chr9 6409874 A G 1.22E-04 Self-reported allergy / / 23817569 rs10975580 chr9 6414839 A G 3.57E-06 Rheumatoid arthritis UHRF2 intron 19503088 rs10975587 chr9 6429259 G A 6.99E-05 Cognitive test performance UHRF2 intron 20125193 rs10739103 chr9 6432156 C A 4.92E-04 Multiple complex diseases UHRF2 intron 17554300 rs560059 chr9 6447196 G A 4.89E-07 Non-albumin protein levels UHRF2 intron 22558069 rs7027361 chr9 6451088 G A 2.50E-05 Parkinson's disease (age of onset) UHRF2 intron 19772629 rs7869419 chr9 6469964 T G 9.64E-04 Multiple complex diseases UHRF2 intron 17554300 rs16924631 chr9 6486308 G C 3.00E-06 Periodontal microbiota UHRF2 intron 22699663 rs13290126 chr9 6492715 G A 2.62E-04 Multiple complex diseases UHRF2 intron 17554300 rs1547258 chr9 6523056 T C 6.01E-05 Erythrocyte counts / / pha003099 rs10975629 chr9 6532344 G A 7.89E-05 Erythrocyte counts GLDC nearGene-3 pha003099 rs7848919 chr9 6532477 G A 5.39E-05 Hemoglobin GLDC UTR-3 pha003098 rs7848919 chr9 6532477 G A 7.90E-06 Erythrocyte counts GLDC UTR-3 pha003099 rs1061407 chr9 6532544 G A 1.14E-04 Multiple complex diseases GLDC UTR-3 17554300 rs2282158 chr9 6535057 C T 0.000348 Salmonella-induced pyroptosis GLDC intron 22837397 rs4742211 chr9 6535500 C T 3.58E-06 Self-reported allergy GLDC intron 23817569 rs3902970 chr9 6544734 G A 3.26E-04 Lung function (forced vital capacity) GLDC intron 24023788 rs17591030 chr9 6550024 C T 3.28E-04 Type 2 diabetes GLDC intron 17463246 rs4512434 chr9 6553054 T C 2.90E-06 Urinary metabolites GLDC intron 21572414 rs10125618 chr9 6555311 A G 2.04E-05 Schizophrenia GLDC intron 19571811 rs7035933 chr9 6611609 G T 5.70E-04 Coronary Artery Disease GLDC intron 17634449 rs2773502 chr9 6624259 A G 7.80E-06 Urinary metabolites GLDC intron 21572414 rs2578269 chr9 6624541 C T 1.20E-05 Urinary metabolites GLDC intron 21572414 rs1260460 chr9 6631099 A G 3.98E-04 Type 2 diabetes GLDC intron 17463246 rs1260460 chr9 6631099 A G 5.30E-04 Primary sclerosing cholangitis GLDC intron 19944697 rs934854 chr9 6631611 A G 4.30E-07 Urinary metabolites GLDC intron 21572414 rs934855 chr9 6631702 G T 1.90E-07 Urinary metabolites GLDC intron 21572414 rs7872937 chr9 6638114 C T 7.60E-06 Urinary metabolites GLDC intron 21572414 rs1755606 chr9 6641802 A G 1.70E-04 Primary sclerosing cholangitis GLDC intron 19944697 rs11999442 chr9 6654050 G A 3.15E-04 Response to taxane treatment (placlitaxel) LOC100287623 intron 23006423 rs1759402 chr9 6680477 G T 4.34E-04 Type 2 diabetes / / 17463246 rs1759402 chr9 6680477 G T 8.44E-06 Serum metabolites / / 19043545 rs2381485 chr9 6695986 G A 2.54E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7040131 chr9 6720831 T C 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2990659 chr9 6722212 G A 3.88E-05 Bipolar disorder and schizophrenia KDM4C intron 20889312 rs4742247 chr9 6726613 C T 6.19E-04 Acute lung injury KDM4C intron 22295056 rs2988414 chr9 6741529 G A 8.00E-04 Acute lymphoblastic leukemia (childhood) KDM4C intron 20189245 rs2988414 chr9 6741529 G A 4.80E-05 Bipolar disorder and schizophrenia KDM4C intron 20889312 rs7036872 chr9 6744721 T C 5.18E-04 Smoking cessation KDM4C intron 24665060 rs12346963 chr9 6760217 C T 1.00E-04 Suicide attempts in bipolar disorder KDM4C intron 21423239 rs6477107 chr9 6760919 T C 7.00E-05 Lipoproteins KDM4C intron pha003079 rs10975822 chr9 6762095 C A 1.12E-04 Suicide attempts in bipolar disorder KDM4C intron 21423239 rs10975823 chr9 6764157 T C 6.16E-05 Suicide attempts in bipolar disorder KDM4C intron 21423239 rs13287326 chr9 6765386 T C 8.85E-05 Suicide attempts in bipolar disorder KDM4C intron 21423239 rs3887736 chr9 6769229 G A 6.52E-05 Suicide attempts in bipolar disorder KDM4C intron 21423239 rs7861740 chr9 6769429 A G 1.87E-04 Suicide attempts in bipolar disorder KDM4C intron 21423239 rs7861972 chr9 6769692 A G 2.14E-04 Suicide attempts in bipolar disorder KDM4C intron 21423239 rs13283575 chr9 6773832 T C 9.16E-05 Suicide attempts in bipolar disorder KDM4C intron 21423239 rs4742263 chr9 6782225 G A 1.98E-04 Smoking cessation KDM4C intron 24665060 rs10975827 chr9 6784659 A T 9.23E-05 Suicide attempts in bipolar disorder KDM4C intron 21423239 rs10815468 chr9 6784726 G C 7.00E-06 Bipolar disorder and schizophrenia KDM4C intron 20889312 rs10815468 chr9 6784726 G C 2.73E-04 Smoking cessation KDM4C intron 24665060 rs10815468 chr9 6784726 G C 4.26E-05 Schizophrenia KDM4C intron pha002857 rs10975828 chr9 6786119 G T 1.14E-04 Suicide attempts in bipolar disorder KDM4C intron 21423239 rs10975830 chr9 6790972 T C 2.75E-04 Suicide attempts in bipolar disorder KDM4C intron 21423239 rs10283424 chr9 6791521 T C 6.43E-05 Smoking cessation KDM4C intron 24665060 rs4740858 chr9 6794210 G A 5.82E-04 Smoking cessation KDM4C intron 24665060 rs6477109 chr9 6794938 T C 3.32E-04 Smoking cessation KDM4C intron 24665060 rs11998950 chr9 6811507 C T 8.75E-04 Nicotine smoking KDM4C intron 19268276 rs13299146 chr9 6835060 G A 9.50E-04 Suicide attempts in bipolar disorder KDM4C intron 21423239 rs12553351 chr9 6838348 T G 6.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KDM4C intron 20877124 rs7846927 chr9 6841480 A G 5.83E-04 Heart Failure KDM4C intron pha002885 rs6477117 chr9 6845561 A G 9.13E-05 Serum metabolites KDM4C intron 19043545 rs6477118 chr9 6845630 C T 9.13E-04 Multiple complex diseases KDM4C intron 17554300 rs4742269 chr9 6849317 G A 4.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KDM4C intron 20877124 rs4742269 chr9 6849317 G A 5.00E-06 Radiation response KDM4C intron 20923822 rs4742269 chr9 6849317 G A 4.69E-04 Smoking cessation KDM4C intron 24665060 rs10975856 chr9 6854610 G T 1.32E-04 Smoking cessation KDM4C intron 24665060 rs10975860 chr9 6865386 A G 9.50E-06 Urinary metabolites KDM4C intron 21572414 rs4439184 chr9 6866374 C G 2.10E-04 Primary sclerosing cholangitis KDM4C intron 19944697 rs7043479 chr9 6889799 A G 1.15E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) KDM4C intron 22566498 rs10975883 chr9 6900898 A G 9.20E-06 Urinary metabolites KDM4C intron 21572414 rs1578325 chr9 6917652 G C 8.84E-04 Obesity (extreme) KDM4C intron 21935397 rs12380111 chr9 6924118 T C 5.63E-04 Obesity (extreme) KDM4C intron 21935397 rs2185463 chr9 6924416 A G 5.65E-04 Obesity (extreme) KDM4C intron 21935397 rs2185464 chr9 6924843 C T 7.68E-04 Obesity (extreme) KDM4C intron 21935397 rs7043262 chr9 6926738 G A 7.86E-04 Obesity (extreme) KDM4C intron 21935397 rs7861518 chr9 6936862 C T 7.30E-04 Obesity (extreme) KDM4C intron 21935397 rs10975928 chr9 6950134 A C 2.85E-04 Obesity (extreme) KDM4C intron 21935397 rs7019108 chr9 6953554 T C 2.04E-04 Obesity (extreme) KDM4C intron 21935397 rs7863791 chr9 6957481 T C 8.62E-04 Multiple complex diseases KDM4C intron 17554300 rs10758809 chr9 6958299 A C 1.82E-04 Obesity (extreme) KDM4C intron 21935397 rs7042372 chr9 6959840 A G 7.90E-04 Obesity (extreme) KDM4C intron 21935397 rs7022642 chr9 6960107 A C 4.94E-06 Body mass index KDM4C intron 19557197 rs9657633 chr9 6961871 T C 6.58E-04 Type 2 diabetes KDM4C intron 17463246 rs9657633 chr9 6961871 T C 2.40E-05 Urinary metabolites KDM4C intron 21572414 rs9657633 chr9 6961871 T C 4.59E-05 Obesity (extreme) KDM4C intron 21935397 rs10815490 chr9 6962574 T C 4.39E-05 Obesity (extreme) KDM4C intron 21935397 rs10815491 chr9 6962695 T G 8.30E-06 Urinary metabolites KDM4C intron 21572414 rs10815491 chr9 6962695 T G 4.39E-05 Obesity (extreme) KDM4C intron 21935397 rs1890918 chr9 6965451 C G 5.62E-05 Obesity (extreme) KDM4C intron 21935397 rs10815495 chr9 6966001 A G 5.67E-05 Obesity (extreme) KDM4C intron 21935397 rs10815496 chr9 6966486 T A 1.49E-04 Obesity (extreme) KDM4C intron 21935397 rs7865491 chr9 6967846 C T 5.72E-05 Obesity (extreme) KDM4C intron 21935397 rs702279 chr9 6969634 C A 7.04E-05 Body Composition KDM4C intron pha003012 rs702279 chr9 6969634 C A 6.55E-05 Body Mass Index KDM4C intron pha003021 rs10758814 chr9 6971932 A G 6.44E-05 Obesity (extreme) KDM4C intron 21935397 rs10758815 chr9 6972193 A G 1.53E-04 Obesity (extreme) KDM4C intron 21935397 rs10815498 chr9 6972479 G A 1.53E-04 Obesity (extreme) KDM4C intron 21935397 rs2792235 chr9 6973510 C T 2.45E-05 Body Composition KDM4C intron pha003012 rs2792235 chr9 6973510 C T 6.70E-06 Body Mass Index KDM4C intron pha003021 rs1323398 chr9 6987663 G T 0.00054598 Hypertension (early onset hypertension) KDM4C intron 22479346 rs2760650 chr9 6988475 A G 4.18E-05 HIV-1 viral setpoint KDM4C intron 17641165 rs2760660 chr9 6993848 A C 5.96E-05 HIV-1 viral setpoint KDM4C intron 17641165 rs946929 chr9 6997639 A G 3.84E-04 HIV-1 viral setpoint KDM4C intron 17641165 rs11790877 chr9 6998948 A G 7.28E-04 HIV-1 viral setpoint KDM4C intron 17641165 rs10122718 chr9 6999846 G T 8.31E-04 HIV-1 viral setpoint KDM4C intron 17641165 rs10975965 chr9 7004340 A G 4.12E-04 HIV-1 viral setpoint KDM4C intron 17641165 rs7025832 chr9 7007063 G A 2.59E-04 Lung function (forced expiratory volume in 1 second) KDM4C intron 17255346 rs12380879 chr9 7014867 T C 9.74E-05 Type 2 diabetes KDM4C intron 17463246 rs12379204 chr9 7014879 C T 2.39E-04 HIV-1 viral setpoint KDM4C intron 17641165 rs10975990 chr9 7026716 G A 7.15E-06 Alcohol withdrawal symptoms KDM4C intron 22072270 rs7045222 chr9 7027194 C T 4.19E-05 Lung function (forced expiratory volume in 1 second) KDM4C intron 17255346 rs10758821 chr9 7030268 G T 2.79E-05 Alcohol withdrawal symptoms KDM4C intron 22072270 rs1407862 chr9 7032776 G A 4.93E-05 Alcohol withdrawal symptoms KDM4C intron 22072270 rs2381536 chr9 7035727 G A 2.18E-04 Type 2 diabetes KDM4C intron 17463246 rs1323401 chr9 7042274 T C 1.93E-04 HIV-1 viral setpoint KDM4C intron 17641165 rs16925187 chr9 7043455 C G 5.00E-06 Response to fenofibrate (adiponectin levels) KDM4C intron 23149075 rs7034275 chr9 7067344 G C 9.19E-04 Type 2 diabetes KDM4C intron 17463246 rs7034275 chr9 7067344 G C 3.81E-04 Nicotine smoking KDM4C intron 19268276 rs17456897 chr9 7096061 A G 9.95E-04 Parkinson's disease KDM4C intron 17052657 rs7860305 chr9 7109519 G C 1.15E-04 Cognitive function KDM4C intron 24684796 rs1323404 chr9 7116020 C G 1.06E-04 Cognitive function KDM4C intron 24684796 rs7028357 chr9 7132694 A G 1.70E-04 Multiple complex diseases KDM4C intron 17554300 rs12341169 chr9 7134421 C T 4.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KDM4C intron 20877124 rs12341212 chr9 7134581 C T 6.27E-04 Multiple complex diseases KDM4C intron 17554300 rs10976062 chr9 7138349 T C 5.92E-04 Type 2 diabetes KDM4C intron 17463246 rs10976070 chr9 7150975 C T 1.08E-04 Response to cytadine analogues (cytosine arabinoside) KDM4C intron 24483146 rs913581 chr9 7150997 T C 7.73E-04 Substance dependence KDM4C intron 21818250 rs913581 chr9 7150997 T C 7.74E-04 Response to cytadine analogues (cytosine arabinoside) KDM4C intron 24483146 rs12683056 chr9 7152400 A G 1.16E-04 Response to cytadine analogues (cytosine arabinoside) KDM4C intron 24483146 rs16925503 chr9 7162852 A T 0.00000848 Panic disorder KDM4C intron 23149450 rs16925503 chr9 7162852 A T 8.48E-06 Serum tamsulosin hydrochloride concentration KDM4C intron 23151678 rs10758841 chr9 7163938 C T 1.62E-04 Response to cytadine analogues (cytosine arabinoside) KDM4C intron 24483146 rs1556100 chr9 7164039 A G 3.10E-04 Type 2 diabetes KDM4C intron 17463246 rs10815532 chr9 7164061 C T 5.38E-05 Schizophrenia KDM4C intron 19571811 rs10815532 chr9 7164061 C T 2.38E-04 Response to cytadine analogues (cytosine arabinoside) KDM4C intron 24483146 rs1556099 chr9 7164502 C A 7.76E-05 Multiple sclerosis (age of onset) KDM4C intron 19010793 rs1556099 chr9 7164502 C A 6.41E-04 Response to cytidine analogues (gemcitabine) KDM4C intron 24483146 rs7022345 chr9 7173752 A G 3.54E-05 Interstitial lung disease KDM4C intron 23583980 rs913588 chr9 7174673 G A 6.15E-04 White matter integrity KDM4C missense 22425255 rs913588 chr9 7174673 G A 9.56E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy KDM4C missense 23834954 rs913588 chr9 7174673 G A 3.90E-04 Response to cytadine analogues (cytosine arabinoside) KDM4C missense 24483146 rs10976088 chr9 7174813 T A 1.05E-04 Type 2 diabetes KDM4C UTR-3 17463246 rs913590 chr9 7174898 C A 1.75E-04 White matter integrity KDM4C UTR-3 22425255 rs2770729 chr9 7178197 G A 4.74E-04 Alzheimer's disease (late onset) / / 21379329 rs2770729 chr9 7178197 G A 4.68E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2770730 chr9 7178410 G A 4.09E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs913591 chr9 7184942 C G 7.60E-04 Insulin resistance / / 21901158 rs2820917 chr9 7192313 A G 9.57E-05 Interstitial lung disease / / 23583980 rs2820917 chr9 7192313 A G 9.23E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10815541 chr9 7194214 G A 2.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2820914 chr9 7195408 A G 2.00E-06 Obesity-related traits / / 23251661 rs2770756 chr9 7196816 G A 1.65E-04 Alzheimer's disease (late onset) / / 21379329 rs2820910 chr9 7197796 C T 2.38E-04 Alzheimer's disease (late onset) / / 21379329 rs10815547 chr9 7200905 G A 5.15E-04 Multiple complex diseases / / 17554300 rs7020238 chr9 7209284 T C 2.70E-05 Ulcerative colitis / / 19915572 rs7020238 chr9 7209284 T C 6.76E-05 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs3001093 chr9 7222895 A G 1.54E-05 Alzheimer's disease (late onset) / / 21379329 rs10976131 chr9 7226519 T C 5.39E-08 Schizophrenia / / 21926974 rs10120788 chr9 7231323 G A 4.10E-04 Taste perception / / 22132133 rs2820953 chr9 7233161 A G 4.08E-04 Myocardial Infarction / / pha002883 rs10976143 chr9 7245081 C G 5.22E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs16925655 chr9 7245728 A T 2.94E-06 Response to metformin / / 21186350 rs10976166 chr9 7266283 A G 2.40E-05 Urinary metabolites / / 21572414 rs10733533 chr9 7267702 C T 4.22E-04 Insulin resistance / / 21901158 rs10758849 chr9 7268068 T C 2.80E-05 Triglycerides / / 19074352 rs10815578 chr9 7273950 G A 5.69E-06 Obesity-related traits / / 23251661 rs1887867 chr9 7274696 T C 1.00E-06 Obesity-related traits / / 23251661 rs1887867 chr9 7274696 T C 6.00E-06 Obesity-related traits / / 23251661 rs1928206 chr9 7275202 C G 2.64E-05 Response to metformin / / 21186350 rs7034160 chr9 7276798 A G 7.92E-06 Obesity-related traits / / 23251661 rs10815582 chr9 7284763 T C 8.01E-06 Obesity-related traits / / 23251661 rs4742322 chr9 7286599 G T 4.67E-06 Obesity-related traits / / 23251661 rs16925783 chr9 7288704 G A 1.23E-05 Response to metformin / / 21186350 rs10815590 chr9 7309750 G A 9.03E-05 Heart Rate / / pha003053 rs10511465 chr9 7346029 C T 1.12E-05 Blood Pressure / / pha003048 rs11999183 chr9 7346370 T G 9.79E-06 Blood Pressure / / pha003048 rs2381589 chr9 7356531 A C 1.18E-05 Post-operative nausea and vomiting / / 21694509 rs1926359 chr9 7375925 A G 4.99E-04 Alzheimer's disease / / 22005930 rs2148360 chr9 7385490 T C 0.00000081 Breast cancer(er negative) / / 23555315 rs10511468 chr9 7387977 A C 5.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10511468 chr9 7387977 A C 4.60E-05 Major depressive disorder / / 21042317 rs4742341 chr9 7388656 A G 7.50E-05 Major depressive disorder / / 21042317 rs6477194 chr9 7389700 G C 6.10E-05 Major depressive disorder / / 21042317 rs10481528 chr9 7391401 T C 0.0008264 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10481528 chr9 7391401 T C 8.26E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10481611 chr9 7391541 C T 0.0008203 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10481611 chr9 7391541 C T 8.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10120589 chr9 7391855 G A 9.55E-06 Asthma (childhood onset) / / 23829686 rs7033457 chr9 7393934 T C 2.00E-04 Blood Phenotypes / / 17903294 rs10815607 chr9 7397527 C T 3.40E-05 Major depressive disorder / / 21042317 rs10815607 chr9 7397527 C T 8.96E-05 Heart Rate / / pha003054 rs11793437 chr9 7406526 C G 2.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs2997578 chr9 7408763 A G 7.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1926412 chr9 7415021 C A 5.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs1926410 chr9 7415094 G T 6.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs12685373 chr9 7415760 C G 5.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs13301132 chr9 7415834 T A 5.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs1926409 chr9 7416348 C T 6.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs13302304 chr9 7419069 T C 6.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs11794449 chr9 7466305 G A 6.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs2986278 chr9 7480472 T G 1.00E-05 Major depressive disorder / / 21042317 rs3955044 chr9 7482618 A G 3.00E-05 Major depressive disorder / / 21042317 rs10815615 chr9 7485343 A G 6.30E-06 Major depressive disorder / / 21042317 rs10511473 chr9 7499180 G C 4.72E-04 Multiple complex diseases / / 17554300 rs2890751 chr9 7508444 T C 3.16E-04 Multiple complex diseases / / 17554300 rs2890751 chr9 7508444 T C 2.62E-05 Calcium levels / / pha003085 rs10511474 chr9 7511166 T C 4.45E-05 Calcium levels / / pha003085 rs2381624 chr9 7513175 G A 1.94E-05 Cognitive impairment induced by topiramate / / 22091778 rs6477205 chr9 7516770 T A,C,G 1.12E-04 Follicular lymphoma / / 21533074 rs2381628 chr9 7518656 T C 6.00E-06 IgG glycosylation / / 23382691 rs10124873 chr9 7524720 C G 1.26E-04 Type 2 diabetes / / 17463246 rs10124873 chr9 7524720 C G 5.92E-04 Multiple complex diseases / / 17554300 rs10124892 chr9 7524847 C T 8.14E-05 Type 2 diabetes / / 17463246 rs10124892 chr9 7524847 C T 6.24E-04 Multiple complex diseases / / 17554300 rs10124892 chr9 7524847 C T 7.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs4269591 chr9 7527298 T C 8.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs10758876 chr9 7527476 T G 8.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs10758877 chr9 7527489 C T 8.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs10758879 chr9 7527926 A G 8.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs10758880 chr9 7528098 A C 8.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs2381632 chr9 7528140 G T 1.49E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10815626 chr9 7528239 C T 8.20E-04 Suicide attempts in bipolar disorder / / 21041247 rs10976357 chr9 7530883 C T 2.84E-05 Type 2 diabetes / / 17463246 rs4740893 chr9 7533050 A G 2.71E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2890755 chr9 7539001 A G 5.32E-04 Premature ovarian failure / / 19508998 rs1806697 chr9 7539381 C T 1.35E-04 Type 2 diabetes / / 17463246 rs12349302 chr9 7540496 G T 5.86E-05 Pancreatic cancer / / pha002889 rs10976390 chr9 7550870 C T 8.54E-05 Smoking cessation / / 24665060 rs4400445 chr9 7558261 C T 8.00E-06 Obesity-related traits / / 23251661 rs4400445 chr9 7558261 C T 9.00E-06 Obesity-related traits / / 23251661 rs4740897 chr9 7561271 C T 1.15E-05 Odorant perception / / 23910658 rs2381642 chr9 7563692 A G 6.90E-05 Alcohol dependence / / 24277619 rs2381642 chr9 7563692 A G 2.18E-04 Smoking cessation / / 24665060 rs10976413 chr9 7573504 T C 1.56E-04 Type 2 diabetes / / 17463246 rs10976414 chr9 7573560 A T 1.17E-04 Type 2 diabetes / / 17463246 rs4742378 chr9 7578222 C T 4.14E-04 Alcohol dependence / / 24277619 rs1485184 chr9 7579004 A G 4.87E-04 Premature ovarian failure / / 19508998 rs962092 chr9 7580824 G A 1.60E-06 Urinary metabolites / / 21572414 rs1385447 chr9 7585409 T C 4.94E-05 Cognitive test performance / / 20125193 rs2220184 chr9 7589065 G T 4.80E-04 Type 2 diabetes / / 17463246 rs13285544 chr9 7595558 G A 2.60E-05 Type 2 diabetes / / 17463246 rs3864785 chr9 7603506 G C 0.000000048 Sickle cell anemia / / 22679008 rs10815645 chr9 7604410 C A 6.31E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10124811 chr9 7619582 C T 1.50E-05 Urinary metabolites / / 21572414 rs3912454 chr9 7625060 C A 8.10E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1485187 chr9 7634720 C T 4.90E-09 Platelet aggregation(pre- and post-aspirin) / / 20529293 rs10976492 chr9 7673654 G A 3.44E-05 Aortic root size / / 21223598 rs842304 chr9 7682601 C A 4.00E-06 HIV-1 susceptibility / / 21160409 rs842304 chr9 7682601 C A 1.07E-04 White matter integrity / / 22425255 rs328847 chr9 7684244 C T 6.96E-04 White matter integrity / / 22425255 rs328847 chr9 7684244 C T 8.01E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs328844 chr9 7685999 A G 7.22E-04 Depression (quantitative trait) / / 20800221 rs328843 chr9 7692837 G C 2.03E-04 Depression (quantitative trait) / / 20800221 rs842301 chr9 7694484 T C 8.79E-05 Depression (quantitative trait) / / 20800221 rs328838 chr9 7703280 C A 5.33E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs13292845 chr9 7705998 A C 4.26E-04 Alzheimer's disease (late onset) / / 21379329 rs842305 chr9 7710087 G A 9.11E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs842295 chr9 7720367 A G 9.90E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11792949 chr9 7729207 G C 4.05E-06 Bipolar disorder,affective / / 20528957 rs10758892 chr9 7734250 G A 9.00E-06 Myopia (pathological) / / 23049088 rs7021164 chr9 7757657 A G 4.69E-05 Serum metabolites / / 19043545 rs7863770 chr9 7757891 C T 3.57E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs7863054 chr9 7780159 C T 4.59E-04 Type 2 diabetes / / 17463246 rs10125984 chr9 7786701 C T 6.82E-04 Alcohol dependence / / 21314694 rs327756 chr9 7790940 C T 4.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs327755 chr9 7792599 C A 2.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9407391 chr9 7819715 A G 5.64E-04 Multiple complex diseases / / 17554300 rs17547957 chr9 7834859 T C 4.31E-06 Multiple complex diseases / / 17554300 rs10976613 chr9 7841873 A T 3.77E-04 Multiple complex diseases / / 17554300 rs2381671 chr9 7854722 G A 6.70E-06 Urinary metabolites / / 21572414 rs10815710 chr9 7906830 G A 2.50E-04 Alzheimer's disease (late onset) / / 21379329 rs16926845 chr9 7908874 C T 4.57E-04 Alzheimer's disease (late onset) / / 21379329 rs10976659 chr9 7909429 A G 6.45E-04 White matter integrity / / 22425255 rs7037011 chr9 7911752 T C 6.37E-04 Multiple complex diseases / / 17554300 rs10815714 chr9 7914008 T C 2.96E-04 Multiple complex diseases / / 17554300 rs10815714 chr9 7914008 T C 8.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs12345345 chr9 7915552 C T 3.00E-06 Urinary metabolites / / 21572414 rs1535480 chr9 7925381 T G 4.00E-07 Common traits (Other) / / 20585627 rs10815721 chr9 7945146 A G 6.41E-04 White matter integrity / / 22425255 rs7853641 chr9 7964559 A G 3.37E-04 Smoking initiation / / 24665060 rs10976693 chr9 7970004 C G 9.84E-04 Type 2 diabetes / / 17463246 rs7041304 chr9 7972907 T A 1.30E-05 Urinary metabolites / / 21572414 rs12682851 chr9 8012418 A G 2.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs2146180 chr9 8045606 G A 3.00E-08 Personality dimensions / / 23903073 rs6477258 chr9 8095638 T C 7.19E-06 Alzheimer's disease / / 21059989 rs10815759 chr9 8102543 T G 9.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs7040383 chr9 8110791 C T 6.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs12336338 chr9 8116662 C A 1.32E-05 Brain structure / / 22504417 rs4742453 chr9 8117601 A G 4.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs4742455 chr9 8118541 C T 5.18E-07 Lipid traits / / 21777205 rs986195 chr9 8118871 G C 1.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs6477260 chr9 8119324 T C 3.56E-04 Type 2 diabetes / / 17463246 rs2208700 chr9 8119503 T C 1.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs1160594 chr9 8120381 T C 1.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs1040907 chr9 8120614 A T 1.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs7034109 chr9 8121487 C T 1.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs7030827 chr9 8123227 T C 1.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs10758939 chr9 8125410 A G 4.75E-06 Alzheimer's disease / / 21059989 rs10758939 chr9 8125410 A G 4.78E-04 Alzheimer's disease / / 21059989 rs2208702 chr9 8126058 T A 1.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs10815767 chr9 8131675 T C 1.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs1361317 chr9 8133055 T G 1.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs911763 chr9 8133859 T G 2.61E-06 Brain structure / / 22504417 rs10125582 chr9 8135549 T C 9.98E-07 Brain structure / / 22504417 rs16927158 chr9 8138580 A G 1.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs16927160 chr9 8138709 A G 1.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs964222 chr9 8139013 A G 1.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs1998338 chr9 8140651 A G 4.74E-06 Brain structure / / 22504417 rs747437 chr9 8140889 T C 2.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs911766 chr9 8140904 G A 5.42E-06 Brain structure / / 22504417 rs2224580 chr9 8142291 C A 5.31E-06 Brain structure / / 22504417 rs11787770 chr9 8142694 A G 1.83E-06 Brain structure / / 22504417 rs7466238 chr9 8143773 G T 8.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs10125727 chr9 8145159 C T 6.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs1416595 chr9 8148244 G C 2.27E-06 Brain structure / / 22504417 rs1416595 chr9 8148244 G C 0.000616 Salmonella-induced pyroptosis / / 22837397 rs10815773 chr9 8155698 G C 0.0000197 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10815773 chr9 8155698 G C 1.97E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10976807 chr9 8155727 T C 5.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs16927186 chr9 8155863 A G 0.000063 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16927186 chr9 8155863 A G 6.30E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9696734 chr9 8157022 T C 0.000125 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9696734 chr9 8157022 T C 1.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10815774 chr9 8157313 A G 0.000027 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10815774 chr9 8157313 A G 2.70E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12555637 chr9 8157608 G C 0.0000723 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12555637 chr9 8157608 G C 7.23E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs721905 chr9 8159670 T C 0.0000268 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs721905 chr9 8159670 T C 2.68E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7875560 chr9 8160114 G T 4.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs7862610 chr9 8160552 A C 0.0001349 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7862610 chr9 8160552 A C 1.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13287364 chr9 8160714 A G 0.0000732 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13287364 chr9 8160714 A G 7.32E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17540468 chr9 8160729 C T 6.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs17540468 chr9 8160729 C T 5.88E-07 White blood cell count / / 21738479 rs17540482 chr9 8160778 C G 0.0003807 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17540482 chr9 8160778 C G 3.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4742462 chr9 8161669 A G 0.0000721 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4742462 chr9 8161669 A G 7.21E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7047282 chr9 8162652 T A 0.0000351 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7047282 chr9 8162652 T A 3.51E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7859144 chr9 8163517 G T 7.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs17631170 chr9 8165056 G A 4.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs11795174 chr9 8166202 A G 0.0006471 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11795174 chr9 8166202 A G 6.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9299060 chr9 8167171 C T 3.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs11794801 chr9 8169035 C T 0.0006203 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11794801 chr9 8169035 C T 6.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2185234 chr9 8169192 G C 0.0002161 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2185234 chr9 8169192 G C 2.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13297903 chr9 8170480 T C 0.0004375 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13297903 chr9 8170480 T C 4.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13292463 chr9 8170945 G A 0.0006214 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13292463 chr9 8170945 G A 6.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2066100 chr9 8174664 G T 6.11E-04 Smoking quantity / / 24665060 rs10739150 chr9 8176226 T G 4.80E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10511488 chr9 8189112 G A 8.40E-05 Cognitive performance / / 19734545 rs7044355 chr9 8196511 G A 1.00E-07 Platelet aggregation / / 20526338 rs1538521 chr9 8197045 G A 1.63E-05 Cognitive performance / / 19734545 rs10815781 chr9 8198199 C T 5.82E-04 Smoking quantity / / 24665060 rs1781276 chr9 8206576 C T 5.74E-04 Alcohol dependence / / 20201924 rs1781276 chr9 8206576 C T 0.0002914 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1781276 chr9 8206576 C T 2.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12003978 chr9 8208825 G C 3.34E-04 Multiple complex diseases / / 17554300 rs10815790 chr9 8209809 T C 2.56E-04 Multiple complex diseases / / 17554300 rs10815793 chr9 8226643 A G 6.07E-04 Type 2 diabetes / / 17463246 rs10815793 chr9 8226643 A G 4.94E-04 Multiple complex diseases / / 17554300 rs10815795 chr9 8226716 A G 8.32E-04 Type 2 diabetes / / 17463246 rs10815795 chr9 8226716 A G 4.74E-04 Multiple complex diseases / / 17554300 rs10815796 chr9 8227693 A G 4.79E-04 Type 2 diabetes / / 17463246 rs10815796 chr9 8227693 A G 2.23E-04 Multiple complex diseases / / 17554300 rs10815798 chr9 8235633 A G 6.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs1339289 chr9 8236122 C T 5.42E-04 Prostate cancer mortality / / 20978177 rs9408738 chr9 8239423 A C 2.19E-04 Multiple complex diseases / / 17554300 rs7035222 chr9 8259072 G A 4.97E-04 Multiple complex diseases / / 17554300 rs7045605 chr9 8262469 T G 1.28E-06 Primary biliary cirrhosis / / 21399635 rs10976891 chr9 8263328 G A 5.17E-04 Multiple complex diseases / / 17554300 rs10976892 chr9 8264250 C T 9.81E-04 Acute lung injury / / 22295056 rs1027581 chr9 8267413 G C 9.87E-04 Multiple complex diseases / / 17554300 rs950832 chr9 8268198 C T 5.58E-04 Acute lung injury / / 22295056 rs7025712 chr9 8269073 C T 6.09E-04 Acute lung injury / / 22295056 rs10976910 chr9 8270248 T C 5.08E-04 Acute lung injury / / 22295056 rs7042696 chr9 8271465 C T 5.17E-04 Acute lung injury / / 22295056 rs7031618 chr9 8271892 T C 6.79E-04 Acute lung injury / / 22295056 rs7864066 chr9 8277169 G T 7.65E-04 Acute lung injury / / 22295056 rs7042655 chr9 8278669 C T 1.25E-04 Acute lung injury / / 22295056 rs1500305 chr9 8279817 C A 1.25E-04 Acute lung injury / / 22295056 rs1500306 chr9 8279847 T G 7.65E-04 Acute lung injury / / 22295056 rs16927434 chr9 8280666 C T 7.65E-04 Acute lung injury / / 22295056 rs1875241 chr9 8280788 A T 1.70E-04 Acute lung injury / / 22295056 rs1392507 chr9 8280846 G A 7.20E-04 Acute lung injury / / 22295056 rs1392508 chr9 8280950 A C 1.64E-04 Acute lung injury / / 22295056 rs1392509 chr9 8280981 A G 1.64E-04 Acute lung injury / / 22295056 rs7860372 chr9 8281790 C T 1.64E-04 Acute lung injury / / 22295056 rs7024924 chr9 8282399 T C 1.64E-04 Acute lung injury / / 22295056 rs12551280 chr9 8282895 C T 8.18E-04 Acute lung injury / / 22295056 rs1157099 chr9 8282909 G A 1.63E-04 Acute lung injury / / 22295056 rs10116379 chr9 8284091 C T 9.37E-05 Acute lung injury / / 22295056 rs1472534 chr9 8284398 A G 9.37E-05 Acute lung injury / / 22295056 rs1472536 chr9 8284654 T A 1.60E-04 Acute lung injury / / 22295056 rs7872830 chr9 8284789 C T 9.33E-05 Acute lung injury / / 22295056 rs7872167 chr9 8284955 G A 9.33E-05 Acute lung injury / / 22295056 rs7872172 chr9 8284965 G T 3.62E-04 Acute lung injury / / 22295056 rs1909760 chr9 8287604 C G 1.01E-04 Acute lung injury / / 22295056 rs4084051 chr9 8290220 T C 4.07E-04 Acute lung injury / / 22295056 rs10758950 chr9 8290816 T A 4.07E-04 Acute lung injury / / 22295056 rs7873084 chr9 8319806 C T 4.96E-04 Acute lung injury PTPRD intron 22295056 rs3739578 chr9 8320065 G A 2.44E-04 Acute lung injury PTPRD intron 22295056 rs12001948 chr9 8320837 G C 4.70E-04 Nicotine dependence PTPRD intron 17407593 rs3765142 chr9 8339203 A T 5.00E-05 Prostate cancer PTPRD intron 21743057 rs10511492 chr9 8345959 A G 4.66E-04 Acute lung injury PTPRD intron 22295056 rs12342801 chr9 8348632 A G 5.42E-04 Acute lung injury PTPRD intron 22295056 rs16927608 chr9 8349805 T C 5.42E-04 Acute lung injury PTPRD intron 22295056 rs16927610 chr9 8349851 T G 6.45E-04 Acute lung injury PTPRD intron 22295056 rs12004215 chr9 8357036 T A 1.00E-04 Prostate cancer PTPRD intron 21743057 rs1500319 chr9 8361501 T C 5.94E-04 Acute lung injury PTPRD intron 22295056 rs12552493 chr9 8361934 C T 1.00E-04 Prostate cancer PTPRD intron 21743057 rs7867463 chr9 8371434 G A 7.62E-04 Acute lung injury PTPRD intron 22295056 rs12343024 chr9 8375569 G T 8.35E-04 Acute lung injury PTPRD intron 22295056 rs7030727 chr9 8381926 G A 1.00E-04 Prostate cancer PTPRD intron 21743057 rs12343475 chr9 8383887 T C 8.00E-05 Prostate cancer PTPRD intron 21743057 rs12000147 chr9 8405242 A T 4.00E-05 Prostate cancer PTPRD intron 21743057 rs1875239 chr9 8407583 C T 9.51E-05 Blood Pressure PTPRD intron pha003046 rs2031216 chr9 8428856 A G 2.30E-05 Acute lymphoblastic leukemia (childhood) PTPRD intron 19684603 rs2381798 chr9 8431163 G A 9.43E-04 Alzheimer's disease PTPRD intron 17998437 rs7023863 chr9 8432417 C G 1.00E-04 Prostate cancer PTPRD intron 21743057 rs10758974 chr9 8435925 A G 3.37E-07 Hearing function PTPRD intron 21493956 rs10815873 chr9 8436194 G T 3.35E-07 Hearing function PTPRD intron 21493956 rs10977105 chr9 8437488 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes PTPRD intron 22628534 rs10122691 chr9 8458811 A G 9.71E-04 Type 2 diabetes PTPRD intron 17463246 rs7862199 chr9 8470572 G A 3.16E-05 Parent of origin effect on language impairment (maternal) PTPRD intron 24571439 rs12341185 chr9 8477980 A G 4.71E-04 Obesity (extreme) PTPRD intron 21935397 rs2381804 chr9 8478068 C T 4.58E-04 Obesity (extreme) PTPRD intron 21935397 rs10977149 chr9 8478115 T C 4.86E-04 Obesity (extreme) PTPRD intron 21935397 rs13294270 chr9 8480519 C A 7.78E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PTPRD intron 20031582 rs2296102 chr9 8489105 G T 5.16E-04 Stroke PTPRD intron pha002886 rs10758976 chr9 8498248 G A 6.13E-04 Obesity (extreme) PTPRD intron 21935397 rs7035558 chr9 8500472 C T 3.34E-04 Obesity (extreme) PTPRD intron 21935397 rs10758977 chr9 8504101 G T 3.20E-04 Obesity (extreme) PTPRD intron 21935397 rs1998516 chr9 8508148 G A 6.40E-04 Obesity (extreme) PTPRD intron 21935397 rs6477314 chr9 8522326 G A 4.58E-04 Lung function (forced vital capacity) PTPRD intron 24023788 rs7038093 chr9 8556180 T C 6.64E-04 Multiple complex diseases PTPRD intron 17554300 rs7026937 chr9 8558331 G A 2.96E-04 Alcohol dependence PTPRD intron 24277619 rs10977207 chr9 8569186 C A 6.67E-04 Amyotrophic Lateral Sclerosis PTPRD intron 17827064 rs10977210 chr9 8578261 T C 5.87E-05 Schizophrenia PTPRD intron 19197363 rs7861140 chr9 8585188 T C 1.02E-04 Schizophrenia PTPRD intron 19197363 rs7861140 chr9 8585188 T C 7.60E-05 Coronary heart disease PTPRD intron pha003055 rs7035431 chr9 8595416 C T 5.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTPRD intron 20877124 rs10815921 chr9 8600627 C T 1.59E-05 Personality dimensions PTPRD intron 22628180 rs12685150 chr9 8601881 C G 1.39E-05 Personality dimensions PTPRD intron 22628180 rs16928175 chr9 8602323 G A 1.53E-05 Personality dimensions PTPRD intron 22628180 rs16928179 chr9 8602903 A G 6.73E-06 Personality dimensions PTPRD intron 22628180 rs16928187 chr9 8603393 T C 1.84E-05 Personality dimensions PTPRD intron 22628180 rs9792461 chr9 8603606 G A 1.76E-05 Personality dimensions PTPRD intron 22628180 rs7043072 chr9 8609905 C T 2.77E-05 Personality dimensions PTPRD intron 22628180 rs1337809 chr9 8610298 C T 3.69E-05 Personality dimensions PTPRD intron 22628180 rs1337810 chr9 8610494 C G 1.34E-08 Metabolite levels PTPRD intron 23281178 rs1337808 chr9 8621368 G T 1.35E-05 Serum metabolites PTPRD intron 19043545 rs1512380 chr9 8635791 A G 2.50E-05 Urinary metabolites PTPRD intron 21572414 rs907625 chr9 8660158 C T 5.86E-05 Elbow pain PTPRD intron pha003008 rs1025547 chr9 8664838 G T 5.06E-05 Elbow pain PTPRD intron pha003008 rs10511506 chr9 8682672 A G 7.58E-04 Schizophrenia PTPRD intron 19197363 rs1434265 chr9 8693432 C T 8.40E-06 Urinary metabolites PTPRD intron 21572414 rs10125358 chr9 8694330 G A 7.00E-06 Urinary metabolites PTPRD intron 21572414 rs16928280 chr9 8695233 T C 3.00E-10 Immune response to measles-mumps-rubella vaccine PTPRD intron 24811271 rs1543083 chr9 8703025 T G 8.81E-05 Height PTPRD intron pha003010 rs1543083 chr9 8703025 T G 3.73E-05 Height PTPRD intron pha003011 rs7867247 chr9 8705964 A C,G,T 1.00E-04 Cognitive impairment induced by topiramate PTPRD intron 22091778 rs16928304 chr9 8709838 A G 0.0000653 post-traumatic stress disorder PTPRD intron 22869035 rs16928304 chr9 8709838 A G 6.53E-05 Schizophrenia PTPRD intron 22883433 rs10977260 chr9 8720393 T C 8.12E-04 Iron levels PTPRD intron pha002876 rs6477333 chr9 8737316 A G 2.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) PTPRD intron 23648065 rs10116682 chr9 8761778 C A 1.63E-05 Response to treatment for acute lymphoblastic leukemia PTPRD intron 19176441 rs1036327 chr9 8774025 C T 7.55E-04 Amyotrophic Lateral Sclerosis PTPRD intron 17827064 rs1036327 chr9 8774025 C T 3.47E-04 Myopia (pathological) PTPRD intron 21095009 rs1434276 chr9 8797533 T C 1.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTPRD intron 20877124 rs9299075 chr9 8798347 A G 1 Drug response to Etoposide PTPRD intron 17537913 rs10481625 chr9 8804761 T C 1 Drug response to Etoposide PTPRD intron 17537913 rs4562389 chr9 8805462 T C 1 Drug response to Etoposide PTPRD intron 17537913 rs7872026 chr9 8816665 T C 1.50E-05 Urinary metabolites PTPRD intron 21572414 rs10815964 chr9 8826108 G A 7.01E-08 Metabolite levels PTPRD intron 23281178 rs1434254 chr9 8826278 C T 7.91E-08 Metabolite levels PTPRD intron 23281178 rs10120450 chr9 8826588 T C 7.47E-08 Metabolite levels PTPRD intron 23281178 rs10120501 chr9 8826767 T C 8.81E-08 Metabolite levels PTPRD intron 23281178 rs10758996 chr9 8827077 T G 7.47E-08 Metabolite levels PTPRD intron 23281178 rs10977313 chr9 8828849 G T 4.42E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) PTPRD intron 22566498 rs2053125 chr9 8831162 A G 7.67E-08 Metabolite levels PTPRD intron 23281178 rs7048621 chr9 8832038 C T 7.67E-08 Metabolite levels PTPRD intron 23281178 rs10121203 chr9 8833227 A G 7.67E-08 Metabolite levels PTPRD intron 23281178 rs2570961 chr9 8845429 G A 1.00E-04 Cognitive impairment induced by topiramate PTPRD intron 22091778 rs1975197 chr9 8846955 G A 6.00E-09 Restless legs syndrome PTPRD intron 18660810 rs1975197 chr9 8846955 G A 6.38E-05 Information processing speed PTPRD intron 21130836 rs1975197 chr9 8846955 G A 3.00E-10 Restless legs syndrome PTPRD intron 21779176 rs2117099 chr9 8847233 G A 1.80E-04 Alcohol dependence PTPRD intron 20201924 rs2117099 chr9 8847233 G A 4.90E-04 Alcohol dependence PTPRD intron 20201924 rs10123580 chr9 8850237 C T 6.11E-05 Serum metabolites PTPRD intron 19043545 rs10759003 chr9 8851012 G A 1.06E-05 Cognitive test performance PTPRD intron 20125193 rs7466280 chr9 8854069 A G 9.14E-05 Coronary heart disease PTPRD intron pha003033 rs10815976 chr9 8854489 G T 8.16E-05 Serum metabolites PTPRD intron 19043545 rs12002381 chr9 8870553 C T 3.10E-04 Alcohol dependence PTPRD intron 20201924 rs10759010 chr9 8873659 T C 2.14E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) PTPRD intron 24192120 rs7028784 chr9 8877467 G A 8.99E-05 Erythrocyte counts PTPRD intron pha003101 rs7865131 chr9 8879086 C G 7.60E-05 Parkinson's disease (age of onset) PTPRD intron 19772629 rs17584499 chr9 8879118 C T 9.00E-10 Type 2 diabetes PTPRD intron 20174558 rs17584499 chr9 8879118 C T 9.00E-10 Type 2 diabetes PTPRD intron 21647700 rs17584499 chr9 8879118 C T 9.00E-10 Type 2 diabetes PTPRD intron 23300278 rs2196066 chr9 8894910 C A 2.80E-05 Urinary metabolites PTPRD intron 21572414 rs1433541 chr9 8898464 G A 8.49E-04 Suicide attempts in bipolar disorder PTPRD intron 21423239 rs1433540 chr9 8901682 T G 7.90E-04 Suicide attempts in bipolar disorder PTPRD intron 21423239 rs10977361 chr9 8922089 G A 3.82E-05 Lymphocyte counts PTPRD intron pha003094 rs10977361 chr9 8922089 G A 6.38E-05 Neutrophil count PTPRD intron pha003095 rs7858751 chr9 8923010 C T 1.64E-05 Lung adenocarcinoma PTPRD intron 19836008 rs9299077 chr9 8924197 C T 2.88E-06 Glaucoma (primary open-angle) PTPRD intron 22605921 rs1897676 chr9 8926956 T C 5.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTPRD intron 20877124 rs1433545 chr9 8952346 C G 2.46E-05 Multiple complex diseases PTPRD intron 17554300 rs12555539 chr9 8982866 C T 1.07E-04 Suicide attempts in bipolar disorder PTPRD intron 21423239 rs2039331 chr9 8988375 T C 0.0001 Migraine PTPRD intron 22678113 rs9942952 chr9 8993618 G A 1.13E-04 Heart Failure PTPRD intron pha002884 rs973117 chr9 9000033 C A 5.50E-06 Homocysteine levels,in plasma PTPRD intron 19525478 rs613613 chr9 9014274 C T 9.16E-04 Alzheimer's disease PTPRD intron 22005930 rs78925264 chr9 9015087 T C 9.00E-06 Antibody status in Tripanosoma cruzi seropositivity PTPRD intron 24324551 rs378363 chr9 9020223 T C 8.00E-06 Migraine - clinic-based PTPRD intron 23793025 rs1041506 chr9 9022772 G A 6.34E-04 Type 2 diabetes PTPRD intron 17463246 rs324495 chr9 9029463 G A 7.04E-04 Smoking initiation PTPRD intron 24665060 rs324461 chr9 9032693 G A 4.62E-05 Cognitive test performance PTPRD intron 20125193 rs172862 chr9 9032872 T C 4.56E-04 Coronary heart disease PTPRD intron 21971053 rs324519 chr9 9038430 T C 2.53E-05 Body Mass Index PTPRD intron pha003019 rs324519 chr9 9038430 T C 9.15E-05 Body Mass Index PTPRD intron pha003020 rs1331660 chr9 9039222 A G 7.17E-08 Corneal structure PTPRD intron 22003120 rs172864 chr9 9039395 A T 4.08E-04 Insulin resistance PTPRD intron 21901158 rs13285004 chr9 9048128 T C 6.57E-05 Cognitive test performance PTPRD intron 20125193 rs324457 chr9 9054621 A C 5.76E-04 Type 2 diabetes PTPRD intron 17463246 rs10816041 chr9 9058076 C T 8.63E-04 Type 2 diabetes PTPRD intron 17463246 rs193407 chr9 9059924 C G 4.26E-08 Metabolite levels PTPRD intron 23281178 rs12006155 chr9 9061331 T C 1.87E-05 Body Mass Index PTPRD intron pha003007 rs12006155 chr9 9061331 T C 2.24E-06 Body Mass Index PTPRD intron pha003015 rs10977466 chr9 9065941 C G 7.26E-08 Metabolite levels PTPRD intron 23281178 rs674362 chr9 9085811 C A 1.50E-04 Type 2 diabetes PTPRD intron 17463246 rs7024971 chr9 9098121 A T 5.50E-06 Urinary metabolites PTPRD intron 21572414 rs324542 chr9 9102409 C T 6.82E-04 Type 2 diabetes PTPRD intron 17463246 rs16928942 chr9 9106511 T C 1.30E-05 Urinary metabolites PTPRD intron 21572414 rs17589981 chr9 9119229 T C 1.31E-06 Osteoarthritis (knee and hip) PTPRD intron 21177295 rs17589981 chr9 9119229 T C 2.85E-05 Osteoarthritis (knee and hip) PTPRD intron 21177295 rs17589981 chr9 9119229 T C 5.19E-06 Osteoarthritis (knee and hip) PTPRD intron 21177295 rs957155 chr9 9142828 C T 7.27E-05 Type 2 diabetes PTPRD intron 17463246 rs10816049 chr9 9144085 T C 2.00E-04 Cognitive impairment induced by topiramate PTPRD intron 22091778 rs10977530 chr9 9149546 G A 8.15E-05 Major depressive disorder PTPRD intron 21621269 rs72696835 chr9 9183012 C A 1.27E-06 Stroke (ischemic) PTPRD intron 21957438 rs10511522 chr9 9185515 T A 4.58E-04 Multiple complex diseases PTPRD intron 17554300 rs945464 chr9 9186346 C T 1.71E-05 Orofacial clefts PTPRD intron 22419666 rs1445210 chr9 9192961 G T 1.91E-05 Lipoproteins PTPRD intron pha003079 rs10977564 chr9 9196661 A G 4.35E-04 Smoking initiation PTPRD intron 24665060 rs10435819 chr9 9197298 G A 6.21E-04 Rheumatoid arthritis PTPRD intron 21452313 rs1157067 chr9 9197812 G T 5.59E-05 Monocyte chemoattractant protein-1 PTPRD intron pha003071 rs4357351 chr9 9223809 T C 8.80E-04 Rheumatoid arthritis PTPRD intron 21452313 rs4409444 chr9 9225463 C T 2.24E-07 Cholesterol PTPRD intron pha003073 rs4409444 chr9 9225463 C T 2.65E-07 ldl cholesterol PTPRD intron pha003076 rs4409444 chr9 9225463 C T 3.92E-07 Cholesterol PTPRD intron pha003078 rs12380021 chr9 9229743 C G 6.16E-05 Major depressive disorder PTPRD intron 21621269 rs4742571 chr9 9235372 C A 6.41E-06 Cholesterol PTPRD intron pha003073 rs4742571 chr9 9235372 C A 1.98E-05 ldl cholesterol PTPRD intron pha003076 rs4742571 chr9 9235372 C A 7.35E-06 Cholesterol PTPRD intron pha003078 rs4742577 chr9 9238714 G T 3.40E-04 Type 2 diabetes and 6 quantitative traits PTPRD intron 17848626 rs4742578 chr9 9238929 C A 1.02E-05 Cholesterol PTPRD intron pha003073 rs4742578 chr9 9238929 C A 2.55E-05 ldl cholesterol PTPRD intron pha003076 rs4742578 chr9 9238929 C A 1.28E-05 Cholesterol PTPRD intron pha003078 rs6477383 chr9 9258963 A G 1.89E-04 Smoking initiation PTPRD intron 24665060 rs35041767 chr9 9261737 G GC 8.19E-04 Coronary Artery Disease PTPRD intron 17634449 rs35041767 chr9 9261737 G GC 6.81E-06 Restless legs syndrome PTPRD intron 17637780 rs35041767 chr9 9261737 G GC 6.00E-10 Restless legs syndrome PTPRD intron 18660810 rs4626664 chr9 9261737 G A 8.19E-04 Coronary Artery Disease PTPRD intron 17634449 rs4626664 chr9 9261737 G A 6.81E-06 Restless legs syndrome PTPRD intron 17637780 rs4626664 chr9 9261737 G A 6.00E-10 Restless legs syndrome PTPRD intron 18660810 rs4563945 chr9 9277320 A G 7.10E-05 Post-operative nausea and vomiting PTPRD intron 21694509 rs10122609 chr9 9283557 T C 3.48E-06 Response to tocilizumab in rheumatoid arthritis PTPRD intron 22491018 rs2151324 chr9 9295875 C A 1.59E-06 Cholesterol PTPRD intron pha003073 rs2151324 chr9 9295875 C A 5.96E-06 ldl cholesterol PTPRD intron pha003076 rs2151324 chr9 9295875 C A 2.02E-06 Cholesterol PTPRD intron pha003078 rs1332800 chr9 9337454 A G 2.00E-04 Information processing speed PTPRD intron 21130836 rs1332796 chr9 9338146 T A 7.83E-05 Coronary Artery Disease PTPRD intron 17634449 rs2065511 chr9 9338417 C T 2.00E-04 Information processing speed PTPRD intron 21130836 rs1412881 chr9 9340127 T C 2.72E-04 Coronary Artery Disease PTPRD intron 17634449 rs1412881 chr9 9340127 T C 2.00E-04 Information processing speed PTPRD intron 21130836 rs1889107 chr9 9357065 G A 4.39E-04 Response to taxane treatment (placlitaxel) PTPRD intron 23006423 rs950196 chr9 9361571 T A 2.00E-04 Coronary Artery Disease PTPRD intron 17634449 rs2780078 chr9 9377679 A C 5.33E-05 Diabetes Mellitus PTPRD intron pha003060 rs2151322 chr9 9394684 C T 4.62E-05 Odorant perception PTPRD intron 23910658 rs10759062 chr9 9404584 T C 4.51E-04 Multiple complex diseases PTPRD intron 17554300 rs10816124 chr9 9404896 C A 7.94E-04 Substance dependence PTPRD intron 21818250 rs10759064 chr9 9405003 A G 8.77E-04 Multiple complex diseases PTPRD intron 17554300 rs1475680 chr9 9405316 C T 9.49E-04 Multiple complex diseases PTPRD intron 17554300 rs4142435 chr9 9439700 G A 3.34E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PTPRD intron 20031582 rs1360593 chr9 9440838 A G 4.43E-04 Alzheimer's disease (late onset) PTPRD intron 21379329 rs12350794 chr9 9465857 C T 6.57E-04 Multiple complex diseases PTPRD intron 17554300 rs12350794 chr9 9465857 C T 1.60E-05 Urinary metabolites PTPRD intron 21572414 rs12001482 chr9 9468051 T G 1.90E-05 Urinary metabolites PTPRD intron 21572414 rs11789423 chr9 9476652 C T 1.12E-04 Multiple complex diseases PTPRD intron 17554300 rs11789423 chr9 9476652 C T 2.30E-05 Urinary metabolites PTPRD intron 21572414 rs10117271 chr9 9482268 C T 5.29E-04 Body mass index PTPRD intron 21701565 rs4534173 chr9 9496356 T C 3.92E-05 Bipolar disorder,affective PTPRD intron 20528957 rs11790706 chr9 9504580 T G 6.21E-05 Major depressive disorder PTPRD intron 22472876 rs694959 chr9 9526811 C A 3.24E-04 Fibrinogen PTPRD intron 17255346 rs16929760 chr9 9565335 A G 3.87E-04 Multiple complex diseases PTPRD intron 17554300 rs10491608 chr9 9616646 C T 4.00E-04 Type 2 diabetes and 6 quantitative traits PTPRD intron 17848626 rs10816160 chr9 9662940 A C 6.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTPRD intron 20877124 rs2803366 chr9 9687742 T C 7.73E-05 Information processing speed PTPRD intron 21130836 rs4391483 chr9 9711904 A G 2.32E-05 Intracerebral hemorrhage PTPRD intron 24656865 rs4378017 chr9 9713959 T G 2.46E-05 Intracerebral hemorrhage PTPRD intron 24656865 rs7031298 chr9 9716531 T G 2.70E-05 Intracerebral hemorrhage PTPRD intron 24656865 rs4273904 chr9 9724976 G A 6.62E-04 Multiple complex diseases PTPRD intron 17554300 rs7048068 chr9 9726251 A C 1.86E-05 Serum metabolites PTPRD intron 19043545 rs6477414 chr9 9726850 A T 8.29E-04 Multiple complex diseases PTPRD intron 17554300 rs10816169 chr9 9729134 T C 3.84E-04 Fibrinogen PTPRD intron 17255346 rs1359176 chr9 9750139 C T 5.48E-04 Response to taxane treatment (placlitaxel) PTPRD intron 23006423 rs1174581 chr9 9763352 C T 7.47E-05 Hematocrit PTPRD intron pha003097 rs1174581 chr9 9763352 C T 4.47E-05 Erythrocyte counts PTPRD intron pha003101 rs10977969 chr9 9772431 C T 2.85E-05 Erythrocyte counts PTPRD intron pha003101 rs10977972 chr9 9776856 C G 9.21E-04 Multiple complex diseases PTPRD intron 17554300 rs4740988 chr9 9783693 C T 5.84E-05 Insulin-related traits PTPRD intron pha003063 rs4740988 chr9 9783693 C T 2.05E-05 Erythrocyte counts PTPRD intron pha003101 rs2382056 chr9 9785685 A G 3.49E-05 Hematocrit PTPRD intron pha003097 rs2382056 chr9 9785685 A G 2.93E-05 Erythrocyte counts PTPRD intron pha003101 rs1174590 chr9 9790222 A G 2.16E-05 Erythrocyte counts PTPRD intron pha003101 rs2761734 chr9 9793285 C A 2.40E-04 Heart Failure PTPRD intron pha002885 rs10977990 chr9 9798243 T C 6.78E-04 Suicide attempts in bipolar disorder PTPRD intron 21423239 rs2296171 chr9 9799476 A G 6.53E-04 Multiple complex diseases PTPRD intron 17554300 rs1768881 chr9 9800546 G T 7.30E-04 Iron levels PTPRD intron pha002876 rs1746799 chr9 9800624 T C 7.27E-04 Iron levels PTPRD intron pha002876 rs1613507 chr9 9801755 G A 8.41E-04 Iron levels PTPRD intron pha002876 rs10491919 chr9 9802010 T C 4.21E-04 Multiple complex diseases PTPRD intron 17554300 rs10491919 chr9 9802010 T C 6.07E-07 Paclitaxel sensitivity in NCI60 cancer cell lines PTPRD intron 21314952 rs1408126 chr9 9802058 G A 4.23E-04 Iron levels PTPRD intron pha002876 rs2821490 chr9 9802458 T C 5.64E-04 Iron levels PTPRD intron pha002876 rs4742622 chr9 9805193 A G 6.28E-05 Lung function (forced expiratory volume in 1 second) PTPRD intron pha003103 rs7851330 chr9 9857166 T C 3.72E-04 Multiple complex diseases PTPRD intron 17554300 rs10816216 chr9 9861006 T G 6.08E-04 Multiple complex diseases PTPRD intron 17554300 rs2209192 chr9 9862171 C G 7.44E-04 Alcohol dependence PTPRD intron 21314694 rs10978076 chr9 9907449 T C 4.33E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) PTPRD intron 22566498 rs10759101 chr9 9909726 G A 3.24E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) PTPRD intron 24023788 rs10759102 chr9 9910123 G A 1.00E-06 Airflow obstruction PTPRD intron 22837378 rs4741000 chr9 9910922 C A 2.86E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) PTPRD intron 24023788 rs10816229 chr9 9912827 A C 4.24E-05 Tuberculosis PTPRD intron 24057671 rs10816229 chr9 9912827 A C 8.01E-04 Smoking quantity PTPRD intron 24665060 rs10816230 chr9 9914448 C T 6.80E-06 Urinary metabolites PTPRD intron 21572414 rs4461956 chr9 9915186 C A 1.56E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) PTPRD intron 24023788 rs7849581 chr9 9924724 C T 9.00E-07 Myopia (pathological) PTPRD intron 23049088 rs10978121 chr9 9945648 T C 3.48E-08 Non-obstructive azoospermia PTPRD intron 22197933 rs7470838 chr9 9962381 A G 1.47E-06 Paclitaxel sensitivity in NCI60 cancer cell lines PTPRD intron 21314952 rs7860148 chr9 9970203 T C 2.16E-05 Osteoarthritis (knee and hip) PTPRD intron 21177295 rs7860148 chr9 9970203 T C 2.87E-05 Osteoarthritis (knee and hip) PTPRD intron 21177295 rs2890898 chr9 9974221 A G 5.87E-05 Tunica Media PTPRD intron pha003038 rs2890898 chr9 9974221 A G 4.42E-05 Triglycerides PTPRD intron pha003080 rs7858099 chr9 9974650 G C 6.90E-04 Lipid traits PTPRD intron 17903299 rs7874951 chr9 9978178 C T 1.79E-05 Tunica Media PTPRD intron pha003038 rs7040189 chr9 9984631 T G 7.52E-05 stroke (ischemic) PTPRD intron 17434096 rs7466206 chr9 9993029 A C 2.07E-05 Triglycerides PTPRD intron pha003080 rs10978156 chr9 10000931 C T 2.54E-04 HIV-1 viral setpoint PTPRD intron 17641165 rs10816274 chr9 10004634 C A 9.18E-05 Triglycerides PTPRD intron pha003080 rs10816274 chr9 10004634 C A 2.66E-05 Eosinophil counts PTPRD intron pha003088 rs4497018 chr9 10011571 C A 4.52E-05 Triglycerides PTPRD intron pha003080 rs4497018 chr9 10011571 C A 5.06E-05 Eosinophil counts PTPRD intron pha003088 rs16930836 chr9 10024528 C T 9.64E-06 Multiple complex diseases PTPRD intron 17554300 rs10733202 chr9 10027632 T G 7.32E-04 Alzheimer's disease PTPRD intron 24755620 rs1217007 chr9 10028397 C T 8.81E-05 Alzheimer's disease PTPRD intron 24755620 rs1217003 chr9 10030458 G A 6.18E-05 HDL cholesterol PTPRD intron pha003074 rs291272 chr9 10043014 T G 5.00E-06 Temperament PTPRD intron 22832960 rs291266 chr9 10044857 C T 8.20E-04 Heart Failure PTPRD intron pha002884 rs2136530 chr9 10047844 C T 4.04E-05 Alzheimer's disease (late onset) PTPRD intron 21460841 rs378628 chr9 10054257 T C 7.01E-06 QRS duration in Tripanosoma cruzi seropositivity PTPRD intron 24324551 rs447578 chr9 10054522 T C 6.00E-06 QRS duration in Tripanosoma cruzi seropositivity PTPRD intron 24324551 rs565315 chr9 10064950 C T 4.54E-04 Multiple complex diseases PTPRD intron 17554300 rs832241 chr9 10066100 T C 3.40E-04 Multiple complex diseases PTPRD intron 17554300 rs9298651 chr9 10076276 G A 1.09E-04 Multiple complex diseases PTPRD intron 17554300 rs7023147 chr9 10077180 C A 4.40E-04 Type 2 diabetes PTPRD intron 17463246 rs10511531 chr9 10077962 A G 9.87E-04 Type 2 diabetes PTPRD intron 17463246 rs159224 chr9 10126201 G T 2.45E-04 Prostate cancer mortality PTPRD intron 20978177 rs150409 chr9 10128645 T C 9.75E-04 Prostate cancer mortality PTPRD intron 20978177 rs294845 chr9 10139580 T C 7.00E-06 Obesity-related traits PTPRD intron 23251661 rs294852 chr9 10185596 C T 5.41E-04 Alzheimer's disease PTPRD intron 17998437 rs294856 chr9 10192290 A C 2.00E-06 Anxiety and major depressive disorder PTPRD intron 24047446 rs575932 chr9 10207930 C G 1.20E-05 Urinary metabolites PTPRD intron 21572414 rs2498599 chr9 10216836 G C 2.90E-06 Urinary metabolites PTPRD intron 21572414 rs2498601 chr9 10217017 T C 8.75E-04 Multiple complex diseases PTPRD intron 17554300 rs1322136 chr9 10226620 C A 6.50E-06 Urinary metabolites PTPRD intron 21572414 rs1322137 chr9 10230744 G T 6.68E-05 Triglycerides PTPRD intron pha003080 rs10809041 chr9 10231178 G A 4.99E-05 Triglycerides PTPRD intron pha003080 rs10958969 chr9 10236629 A G 8.50E-04 Multiple complex diseases PTPRD intron 17554300 rs4741020 chr9 10247217 T C 2.50E-04 Alcohol dependence PTPRD intron 20201924 rs4741020 chr9 10247217 T C 2.28E-05 Triglycerides PTPRD intron pha003080 rs2475335 chr9 10260263 C T 7.60E-04 Alcohol dependence PTPRD intron 20201924 rs2475335 chr9 10260263 C T 9.00E-06 Partial epilepsies PTPRD intron 20522523 rs2475357 chr9 10270339 T G 6.10E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) PTPRD intron 23648065 rs1322155 chr9 10270636 A G 5.42E-05 Paget's disease PTPRD intron 20436471 rs10958998 chr9 10275798 A G 2.54E-04 Fibrinogen PTPRD intron 17255346 rs10958998 chr9 10275798 A G 3.84E-06 Smooth-surface caries PTPRD intron 24556642 rs12005579 chr9 10284969 A G 2.08E-05 Cognitive impairment induced by topiramate PTPRD intron 22091778 rs616040 chr9 10295912 G T 7.93E-04 Myopia (pathological) PTPRD intron 21095009 rs600075 chr9 10297519 G A 6.31E-04 Myopia (pathological) PTPRD intron 21095009 rs592682 chr9 10310477 C A 2.10E-05 Urinary metabolites PTPRD intron 21572414 rs605257 chr9 10310942 A T 3.77E-04 Multiple complex diseases PTPRD intron 17554300 rs635858 chr9 10311825 C T 9.71E-04 Myopia (pathological) PTPRD intron 21095009 rs635858 chr9 10311825 C T 1.41E-05 Leukocyte Counts PTPRD intron pha003091 rs680760 chr9 10314941 T C 5.05E-04 Myopia (pathological) PTPRD intron 21095009 rs680760 chr9 10314941 T C 9.49E-06 Leukocyte Counts PTPRD intron pha003091 rs587791 chr9 10318490 G T 0.0000144 Follicular lymphoma PTPRD intron 23025665 rs9987798 chr9 10325044 T C 5.24E-04 Multiple complex diseases PTPRD intron 17554300 rs10809068 chr9 10329917 A T 2.61E-05 Bipolar disorder and schizophrenia PTPRD intron 20889312 rs10114902 chr9 10336364 T C 7.59E-05 Leukocyte Counts PTPRD intron pha003091 rs12551193 chr9 10341449 T C 6.20E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PTPRD intron 20031582 rs12552756 chr9 10342841 A C 7.49E-04 Type 2 diabetes PTPRD intron 17463246 rs10959062 chr9 10348091 T C 5.09E-04 Smoking initiation PTPRD intron 24665060 rs10959064 chr9 10348518 C T 3.95E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PTPRD intron 20031582 rs10511545 chr9 10351048 C T 1.26E-06 Paclitaxel sensitivity in NCI60 cancer cell lines PTPRD intron 21314952 rs10118113 chr9 10354622 C G 7.17E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PTPRD intron 20031582 rs16925863 chr9 10354770 T C 1.78E-05 Asthma PTPRD intron pha003128 rs17625506 chr9 10357405 G C 6.40E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PTPRD intron 20031582 rs12551331 chr9 10366812 T C 6.07E-05 Information processing speed PTPRD intron 21130836 rs1359091 chr9 10367106 T G 1.00E-04 Cognitive impairment induced by topiramate PTPRD intron 22091778 rs10738162 chr9 10369161 T C 2.00E-04 Information processing speed PTPRD intron 21130836 rs4741032 chr9 10408149 A C 3.26E-04 Multiple complex diseases PTPRD intron 17554300 rs1359099 chr9 10411338 A G 6.83E-05 Hemoglobin concentration PTPRD intron 20534544 rs10809092 chr9 10421687 T C 7.05E-05 Information processing speed PTPRD intron 21130836 rs12346029 chr9 10424164 T C 2.00E-04 Information processing speed PTPRD intron 21130836 rs649891 chr9 10430602 T C 6.00E-06 Type 2 diabetes PTPRD intron 21647700 rs2382216 chr9 10463098 A G 8.24E-05 Height PTPRD intron 17255346 rs2784624 chr9 10478387 G A 5.42E-04 Response to cytadine analogues (cytosine arabinoside) PTPRD intron 24483146 rs1853232 chr9 10481205 C T 8.14E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) PTPRD intron 24236485 rs2757867 chr9 10482790 T C 3.05E-05 Epilepsy (remission after treatment) PTPRD intron 23962720 rs7847371 chr9 10486011 T A 1.62E-05 Epilepsy (remission after treatment) PTPRD intron 23962720 rs7847372 chr9 10486015 T G 1.62E-05 Epilepsy (remission after treatment) PTPRD intron 23962720 rs74390789 chr9 10491240 C T 7.46E-05 Epilepsy (remission after treatment) PTPRD intron 23962720 rs77332315 chr9 10504871 G A 3.17E-07 Epilepsy (remission after treatment) PTPRD intron 23962720 rs72700966 chr9 10505224 C T 3.00E-07 Epilepsy (remission after treatment) PTPRD intron 23962720 rs72700967 chr9 10505534 T C 3.28E-07 Epilepsy (remission after treatment) PTPRD intron 23962720 rs57863399 chr9 10505698 A C 1.82E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs72700969 chr9 10506270 A G 3.59E-07 Epilepsy (remission after treatment) PTPRD intron 23962720 rs72700970 chr9 10506702 T A 3.75E-07 Epilepsy (remission after treatment) PTPRD intron 23962720 rs72700971 chr9 10506812 G T 3.80E-07 Epilepsy (remission after treatment) PTPRD intron 23962720 rs72700972 chr9 10506866 A T 3.82E-07 Epilepsy (remission after treatment) PTPRD intron 23962720 rs72700973 chr9 10509738 A G 5.43E-07 Epilepsy (remission after treatment) PTPRD intron 23962720 rs72700974 chr9 10511392 T C 5.81E-07 Epilepsy (remission after treatment) PTPRD intron 23962720 rs116920693 chr9 10511614 T C 5.79E-07 Epilepsy (remission after treatment) PTPRD intron 23962720 rs833402 chr9 10520172 C T 2.16E-04 Type 2 diabetes PTPRD intron 17463246 rs73396228 chr9 10525419 C T 2.72E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs73642005 chr9 10525447 C G,T 2.70E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs833428 chr9 10527999 C T 0.0004448 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PTPRD intron 23233654 rs833428 chr9 10527999 C T 4.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) PTPRD intron 23233662 rs73642006 chr9 10531527 T G 5.49E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs117029051 chr9 10533701 T C 9.69E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs2784609 chr9 10538067 G T 6.40E-05 Epilepsy (remission after treatment) PTPRD intron 23962720 rs1335999 chr9 10538336 A G 4.46E-05 Epilepsy (remission after treatment) PTPRD intron 23962720 rs2484744 chr9 10539386 C T 3.69E-05 Epilepsy (remission after treatment) PTPRD intron 23962720 rs59245244 chr9 10539603 T A 6.82E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs60551430 chr9 10540228 A G 7.34E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs10809117 chr9 10541177 T G 2.27E-05 Tuberculosis PTPRD intron 24057671 rs73396244 chr9 10543802 T C 5.51E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs73396249 chr9 10543846 A G 5.53E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs2181158 chr9 10546257 G T 7.13E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) PTPRD intron 23648065 rs73396250 chr9 10546800 T C 4.91E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs1008981 chr9 10546814 C T 9.98E-04 Multiple complex diseases PTPRD intron 17554300 rs1008981 chr9 10546814 C T 5.04E-06 Response to metformin PTPRD intron 21186350 rs833456 chr9 10547886 T A 1.46E-04 Multiple complex diseases PTPRD intron 17554300 rs73396252 chr9 10547991 G C 4.91E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs73642012 chr9 10551607 C A 2.60E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs75534774 chr9 10552339 T C 7.12E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs76356465 chr9 10553845 C A 1.95E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs73642013 chr9 10555237 C T 3.65E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs56946422 chr9 10555324 T C 3.79E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs10756061 chr9 10561180 T C 7.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) PTPRD intron 23648065 rs56280034 chr9 10562978 A G 3.04E-05 Epilepsy (remission after treatment) PTPRD intron 23962720 rs61527822 chr9 10569533 G C 2.80E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs73642015 chr9 10570215 T C 4.72E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs988954 chr9 10572234 A C 1.81E-05 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia PTPRD intron 24039173 rs17203683 chr9 10572433 T C 4.74E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs73642017 chr9 10573215 C A 2.62E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs73642018 chr9 10573216 T G 2.62E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs17793027 chr9 10575711 G C 3.79E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs73396285 chr9 10576896 C T 4.98E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs59062567 chr9 10578422 T C 5.44E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs10959176 chr9 10581485 A C 4.67E-04 Multiple complex diseases PTPRD intron 17554300 rs79093854 chr9 10582654 T C 6.28E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs117171007 chr9 10583506 C A 6.55E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs4741038 chr9 10583907 T A 4.97E-04 Suicide attempts in bipolar disorder PTPRD intron 21041247 rs13298283 chr9 10586527 A C 2.55E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) PTPRD intron 23648065 rs73398207 chr9 10586911 T G 6.02E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs73398218 chr9 10590224 T C 3.62E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs12005827 chr9 10591017 A C 3.20E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs1322291 chr9 10592492 C T 4.04E-04 Heart Failure PTPRD intron pha002885 rs10809130 chr9 10598429 C T 6.56E-04 Response to cytidine analogues (gemcitabine) PTPRD intron 24483146 rs74378976 chr9 10601754 C T 1.86E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs73398234 chr9 10603286 A G 2.57E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs10959196 chr9 10606301 T C 7.36E-04 Type 2 diabetes PTPRD intron 17463246 rs73398242 chr9 10608509 T C 2.12E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs73398246 chr9 10610094 A G 9.86E-06 Epilepsy (remission after treatment) PTPRD intron 23962720 rs10733210 chr9 10624494 A C 5.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs2146089 chr9 10624748 G A 2.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs7030993 chr9 10626033 A G 2.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs1322294 chr9 10626389 A G 3.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs2890924 chr9 10632596 T G 1.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs10738172 chr9 10634079 A G 3.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs1322300 chr9 10635232 C T 3.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs10756072 chr9 10635939 G A 3.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs4741044 chr9 10639445 G A 7.89E-05 Suicide attempts in bipolar disorder / / 21041247 rs10809144 chr9 10647333 C T 1.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs1923439 chr9 10648898 G T 1.37E-04 Suicide attempts in bipolar disorder / / 21041247 rs1322303 chr9 10649309 G A 1.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs4131202 chr9 10653484 T C 7.16E-05 Suicide attempts in bipolar disorder / / 21041247 rs10809145 chr9 10655189 A G 5.66E-05 Suicide attempts in bipolar disorder / / 21041247 rs10809147 chr9 10655366 T C 5.62E-05 Suicide attempts in bipolar disorder / / 21041247 rs10756076 chr9 10655642 A G 5.42E-05 Suicide attempts in bipolar disorder / / 21041247 rs10756079 chr9 10656211 C T 5.34E-05 Suicide attempts in bipolar disorder / / 21041247 rs4587381 chr9 10657075 G T 5.09E-05 Suicide attempts in bipolar disorder / / 21041247 rs4578000 chr9 10657332 G A 5.06E-05 Suicide attempts in bipolar disorder / / 21041247 rs10756080 chr9 10657559 C T 4.93E-05 Suicide attempts in bipolar disorder / / 21041247 rs4641116 chr9 10659290 T C 4.95E-05 Suicide attempts in bipolar disorder / / 21041247 rs10756088 chr9 10661370 G A 5.17E-05 Suicide attempts in bipolar disorder / / 21041247 rs7030381 chr9 10661622 A G 5.19E-05 Suicide attempts in bipolar disorder / / 21041247 rs7030672 chr9 10661798 C G 5.28E-05 Suicide attempts in bipolar disorder / / 21041247 rs7019756 chr9 10662166 T C 5.42E-05 Suicide attempts in bipolar disorder / / 21041247 rs7034568 chr9 10662358 C T 5.44E-05 Suicide attempts in bipolar disorder / / 21041247 rs4262363 chr9 10664367 A G 5.63E-05 Suicide attempts in bipolar disorder / / 21041247 rs10756092 chr9 10664583 C A 5.85E-05 Suicide attempts in bipolar disorder / / 21041247 rs4272438 chr9 10665040 T A 5.84E-05 Suicide attempts in bipolar disorder / / 21041247 rs35345135 chr9 10665668 AT A 4.95E-05 Suicide attempts in bipolar disorder / / 21041247 rs4380991 chr9 10665668 A T 4.95E-05 Suicide attempts in bipolar disorder / / 21041247 rs7045753 chr9 10668198 T C 6.30E-05 Suicide attempts in bipolar disorder / / 21041247 rs10511552 chr9 10686202 G A 8.77E-04 Type 2 diabetes / / 17846125 rs4623487 chr9 10686696 T C 6.46E-04 Type 2 diabetes / / 17846125 rs4338154 chr9 10694331 C T 1.92E-04 Type 2 diabetes / / 17846125 rs10756104 chr9 10723877 A G 4.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11790055 chr9 10725294 C T 5.10E-04 Multiple complex diseases / / 17554300 rs16926349 chr9 10725719 G A 1.26E-05 Type 2 diabetes / / 17463246 rs16926349 chr9 10725719 G A 2.17E-05 Multiple complex diseases / / 17554300 rs1154842 chr9 10737004 G A 1.34E-04 Type 2 diabetes / / 17463246 rs1154842 chr9 10737004 G A 1.54E-05 Multiple complex diseases / / 17554300 rs1329615 chr9 10737968 T C 3.60E-05 Type 2 diabetes / / 17463246 rs1329615 chr9 10737968 T C 1.52E-04 Multiple complex diseases / / 17554300 rs980351 chr9 10741174 T A 1.61E-04 Type 2 diabetes / / 17463246 rs980351 chr9 10741174 T A 7.95E-04 Multiple complex diseases / / 17554300 rs10511555 chr9 10774641 G C 1.02E-04 Type 2 diabetes / / 17846125 rs7048649 chr9 10778243 A G 1.04E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2225299 chr9 10827792 C T 6.67E-05 Serum metabolites / / 19043545 rs2890930 chr9 10861806 A C 1.17E-05 Alcohol and nictotine co-dependence / / 20158304 rs2890930 chr9 10861806 A C 9.23E-06 Alcohol and nictotine co-dependence / / 20158304 rs12686649 chr9 10880753 C G 2.39E-06 Kawasaki disease / / 21221998 rs10959364 chr9 10913970 C T 6.57E-05 Orofacial clefts / / 22419666 rs7863959 chr9 10928755 C T 7.80E-04 Insulin resistance / / 21901158 rs10809248 chr9 10937761 T C 7.30E-04 Multiple complex diseases / / 17554300 rs4378061 chr9 10940127 C T 6.60E-05 Breast cancer and prostate cancer / / 17903305 rs10738198 chr9 11011600 T C 4.84E-05 Multiple complex diseases / / 17554300 rs10116149 chr9 11033102 T C 7.28E-04 Multiple complex diseases / / 17554300 rs7028285 chr9 11039910 A G 6.10E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1931398 chr9 11085519 A T 4.46E-04 Smoking quantity / / 24665060 rs7044787 chr9 11101956 G A 8.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs10959531 chr9 11108517 A G 6.80E-05 Diabetic retinopathy / / 21441570 rs1577120 chr9 11108586 C A 6.22E-04 Multiple complex diseases / / 17554300 rs2382267 chr9 11117514 C T 3.90E-04 Myasthenia gravis / / 23055271 rs10756202 chr9 11194921 G A 1.27E-04 Multiple complex diseases / / 17554300 rs10809383 chr9 11196439 G C 2.60E-04 Multiple complex diseases / / 17554300 rs7030123 chr9 11224627 T G 6.04E-05 Multiple complex diseases / / 17554300 rs901992 chr9 11241301 G C 4.24E-05 Multiple complex diseases / / 17554300 rs11515055 chr9 11256275 C T 2.60E-06 Response to amphetamines / / 22952603 rs10959672 chr9 11257448 G A 7.88E-05 Bipolar disorder / / 18317468 rs10959672 chr9 11257448 G A 5.00E-07 Response to amphetamines / / 22952603 rs10809441 chr9 11366549 C T 7.73E-04 Multiple complex diseases / / 17554300 rs1160808 chr9 11379133 A G 8.47E-05 Bipolar disorder / / 20451256 rs2065746 chr9 11397008 T G 6.46E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs10809457 chr9 11402319 G T 9.00E-07 Palmitic acid (16:0) plasma levels / / 23362303 rs10809464 chr9 11408193 T A 6.59E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs1335467 chr9 11419061 T G 9.42E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs1335464 chr9 11423524 C G 9.42E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs9406426 chr9 11437634 C T 8.02E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs10809476 chr9 11440848 A C 8.97E-05 Cognitive test performance / / 20125193 rs10756253 chr9 11449567 T C 5.97E-04 Multiple complex diseases / / 17554300 rs2152263 chr9 11450611 G A 3.92E-04 Type 2 diabetes / / 17463246 rs2152263 chr9 11450611 G A 9.51E-05 Bipolar disorder / / 20451256 rs10809491 chr9 11474608 T C 9.95E-04 Type 2 diabetes / / 17463246 rs16927687 chr9 11518390 T C 7.79E-04 Type 2 diabetes / / 17463246 rs10959917 chr9 11549065 G A 5.34E-04 Type 2 diabetes / / 17463246 rs10809523 chr9 11561385 C T 7.78E-05 Cognitive test performance / / 20125193 rs10809527 chr9 11580309 G A 7.15E-05 Cognitive test performance / / 20125193 rs10959964 chr9 11583747 A G 8.44E-04 Type 2 diabetes / / 17463246 rs10959970 chr9 11586357 C A 4.08E-04 Type 2 diabetes / / 17463246 rs10511567 chr9 11606348 T C 1.30E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs7040733 chr9 11609017 G C 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1822387 chr9 11617265 T C 5.46E-05 Hepatocellular carcinoma / / 22807686 rs10960031 chr9 11622644 A G 9.10E-05 Bipolar disorder / / 20451256 rs10809545 chr9 11641257 C T 2.08E-04 Scoliosis / / 21216876 rs2821204 chr9 11683901 C T 2.89E-05 Obsessive-compulsive disorder / / 24821223 rs2821195 chr9 11689891 C G 6.54E-04 Multiple complex diseases / / 17554300 rs2821195 chr9 11689891 C G 7.39E-04 Response to TNF antagonist treatment / / 21061259 rs7033056 chr9 11695757 C T 4.06E-04 Type 2 diabetes / / 17463246 rs7018532 chr9 11695785 T C 3.65E-04 Type 2 diabetes / / 17463246 rs7018532 chr9 11695785 T C 8.44E-05 Bipolar disorder / / 20451256 rs10960101 chr9 11696306 C T 3.87E-04 Type 2 diabetes / / 17463246 rs10960106 chr9 11701727 C A 3.78E-04 Type 2 diabetes / / 17463246 rs13299395 chr9 11704593 G A 3.87E-04 Type 2 diabetes / / 17463246 rs443042 chr9 11709025 A G 6.35E-05 Systemic sclerosis / / 21750679 rs10756265 chr9 11710328 G A 4.80E-05 Systemic sclerosis / / 21750679 rs1486803 chr9 11716862 C T 1.87E-05 Parkinson's disease / / 21738487 rs1471871 chr9 11734178 A G 9.70E-06 Obesity-related traits / / 23251661 rs12380853 chr9 11736515 C A 7.48E-04 Smoking cessation / / 24665060 rs13295519 chr9 11740814 C G 5.27E-04 Type 2 diabetes / / 17463246 rs10960239 chr9 11795556 G A 1.95E-04 Multiple complex diseases / / 17554300 rs10809605 chr9 11807350 C T 8.80E-05 Multiple complex diseases / / 17554300 rs10732328 chr9 11835471 T C 8.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs1386302 chr9 11835950 G A 3.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs1929406 chr9 11839955 G A 1.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs1386301 chr9 11843562 A G 4.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs6474675 chr9 11857464 C A 4.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs962737 chr9 11857869 G A 4.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs10756298 chr9 11861703 G A 3.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs2029209 chr9 11861841 G A 4.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs973330 chr9 11861962 A G 4.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs7049246 chr9 11880391 G T 7.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs1486802 chr9 11885258 C T 5.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs4741188 chr9 11887262 C G 5.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs4401971 chr9 11890045 A G 6.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs4401971 chr9 11890045 A G 4.00E-07 Obsessive-compulsive disorder / / 24821223 rs12683024 chr9 11903938 C T 8.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13297301 chr9 11911621 A T 8.02E-04 Depression (quantitative trait) / / 20800221 rs10809648 chr9 11917701 G A 6.55E-05 Lipid levels / / pha003082 rs10960376 chr9 11929890 C T 8.03E-05 Lipid levels / / pha003082 rs10117492 chr9 11934556 A G 9.94E-05 Lipid levels / / pha003082 rs7039047 chr9 11946421 T C 6.15E-05 Lipid levels / / pha003082 rs1929412 chr9 11951222 C A 8.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4146797 chr9 11951983 A G 9.36E-05 Lipid levels / / pha003082 rs1929408 chr9 11952796 G A 6.70E-05 Lipid levels / / pha003082 rs10960397 chr9 11953279 C T 6.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs7848826 chr9 11979040 T G 5.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs4582647 chr9 11987651 G T 2.57E-04 Multiple complex diseases / / 17554300 rs1023815 chr9 12004095 T G 3.77E-04 Parkinson's disease / / 17052657 rs16922993 chr9 12004346 C G 6.36E-04 Multiple complex diseases / / 17554300 rs16928324 chr9 12007006 T C 1.69E-04 Multiple complex diseases / / 17554300 rs10809674 chr9 12015741 G A 6.17E-04 Parkinson's disease / / 17052657 rs7036903 chr9 12085717 G T 1.05E-04 IgE levels / / 17255346 rs10809694 chr9 12092895 A G 4.05E-05 IgE levels / / 17255346 rs10283652 chr9 12096410 G A 8.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10960477 chr9 12099118 A C 1.36E-04 IgE levels / / 17255346 rs10960478 chr9 12099364 G A,C,T 1.76E-04 IgE levels / / 17255346 rs12351590 chr9 12108916 G A 3.00E-06 Reading and spelling / / 23738518 rs12351590 chr9 12108916 G A 5.00E-06 Word reading / / 23738518 rs10960483 chr9 12110840 G T 3.96E-06 Reading and spelling / / 23738518 rs10960483 chr9 12110840 G T 8.41E-06 Word reading / / 23738518 rs10960488 chr9 12124410 A G 1.28E-05 Word reading / / 23738518 rs10960488 chr9 12124410 A G 5.48E-06 Reading and spelling / / 23738518 rs791775 chr9 12133233 G C 1.15E-05 Word reading / / 23738518 rs791775 chr9 12133233 G C 4.41E-06 Reading and spelling / / 23738518 rs7043331 chr9 12148057 T C 6.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12337214 chr9 12162866 C T 3.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7024763 chr9 12165608 A G 1.15E-05 Word reading / / 23738518 rs7024763 chr9 12165608 A G 4.92E-06 Reading and spelling / / 23738518 rs7025259 chr9 12165758 G T 1.28E-05 Word reading / / 23738518 rs7025259 chr9 12165758 G T 5.48E-06 Reading and spelling / / 23738518 rs10809706 chr9 12165806 C A 4.50E-06 Urinary metabolites / / 21572414 rs17260539 chr9 12182545 G A 2.47E-07 Panic disorder / / 19165232 rs2066097 chr9 12195026 A G 8.68E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10511573 chr9 12204748 G A 2.80E-05 Urinary metabolites / / 21572414 rs17175889 chr9 12206873 T G 7.79E-04 Nicotine dependence / / 17158188 rs17175889 chr9 12206873 T G 7.06E-05 IgE levels / / 17255346 rs10756343 chr9 12215913 A C 9.20E-06 Urinary metabolites / / 21572414 rs10809734 chr9 12220126 A G 7.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1538514 chr9 12224908 G C 6.28E-07 Statin-induced myopathy / / 21826682 rs10116548 chr9 12234642 C T 5.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs946452 chr9 12234969 C T 6.40E-05 IgE levels / / 17255346 rs10960541 chr9 12239604 A G 4.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12341694 chr9 12241908 C T 8.43E-05 IgE levels / / 17255346 rs12348047 chr9 12246667 C T 2.98E-05 IgE levels / / 17255346 rs4008045 chr9 12248419 G T 1.54E-05 IgE levels / / 17255346 rs10960554 chr9 12265588 T C 7.98E-04 Depression (quantitative trait) / / 20800221 rs1538515 chr9 12267378 C T 2.38E-04 IgE levels / / 17255346 rs10809746 chr9 12271768 C T 7.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs6474694 chr9 12272705 G A 4.48E-05 Hemoglobin / / pha003098 rs6474695 chr9 12272803 G A 4.24E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs6474695 chr9 12272803 G A 5.79E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs7872992 chr9 12288083 C G 2.93E-04 Acute lung injury / / 22295056 rs7873941 chr9 12288602 G T 4.43E-04 Acute lung injury / / 22295056 rs10756362 chr9 12344883 G T 0.00000576 Femoral neck bone mineral density / / 22692763 rs1952692 chr9 12382539 A C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10960659 chr9 12396385 C T 7.24E-04 Smoking cessation / / 24665060 rs13289810 chr9 12396731 A G 1.00E-19 Hair color / / 22556244 rs12683218 chr9 12421929 A G 9.37E-06 Lung cancer / / 19654303 rs12683218 chr9 12421929 A G 1.15E-05 Hypertension / / 21082022 rs7856061 chr9 12433463 T G 3.85E-04 Lung function (forced vital capacity) / / 24023788 rs2065367 chr9 12456328 T C 6.03E-04 Smoking cessation / / 24665060 rs1331369 chr9 12465662 C T 1.90E-04 Myocardial infarction / / 21107343 rs791670 chr9 12515949 G T 4.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs10960694 chr9 12521469 T C 3.61E-04 Body mass index / / 21701565 rs10960694 chr9 12521469 T C 3.72E-04 Body mass index / / 21701565 rs16929097 chr9 12521826 G A 8.00E-09 Asthma (childhood onset) / / 23829686 rs1408806 chr9 12531726 C G 6.79E-04 Body mass index / / 21701565 rs10960702 chr9 12540169 T A 7.85E-05 Schizophrenia(age at onset) / / 21688384 rs1325144 chr9 12550516 A G 8.35E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1325149 chr9 12570945 A C 2.09E-05 Stroke (ischemic) / / 22941190 rs190806135 chr9 12573415 G T 2.17E-05 Acne (severe) / / 24927181 rs10738284 chr9 12573829 A G 1.65E-05 Stroke (ischemic) / / 22941190 rs10809797 chr9 12581270 T C 1.31E-04 Telomere length / / 21573004 rs1325154 chr9 12582565 C T 5.00E-06 Attention deficit hyperactivity disorder (time to onset) / / 18937294 rs10124604 chr9 12585186 G A 4.98E-05 Stroke (ischemic) / / 22941190 rs10960719 chr9 12611970 G A 1.24E-04 Acute lymphoblastic leukemia (childhood) / / 22076464 rs10809808 chr9 12624463 T G 4.90E-07 Common traits (Other) / / 20585627 rs10809811 chr9 12650996 C G 3.00E-05 Diabetic nephropathy / / pha002866 rs1121541 chr9 12667049 C T 3.00E-05 Diabetic nephropathy / / pha002866 rs1325127 chr9 12668328 C T 3.09E-07 Common traits (Other) / / 20585627 rs1408799 chr9 12672097 T C 6.00E-17 Blue vs. green eyes / / 18488028 rs1408799 chr9 12672097 T C 3.80E-08 Common traits (Other) / / 20585627 rs1408799 chr9 12672097 T C 4.30E-04 Tanning / / 23548203 rs1408799 chr9 12672097 T C 5.00E-07 Eye color / / 23548203 rs10960751 chr9 12675264 T C 2.88E-08 Common traits (Other) / / 20585627 rs10809826 chr9 12682663 C G 1.60E-05 Diabetic nephropathy / / pha002866 rs2075508 chr9 12698363 T C 2.83E-04 Schizophrenia TYRP1 intron 19197363 rs2733832 chr9 12704725 C T 3.24E-07 Common traits (Other) TYRP1 intron 20585627 rs1137134 chr9 12712157 G A 7.94E-08 Common traits (Other) LOC100506267 intron 20585627 rs12379024 chr9 12717405 G A 3.50E-05 Diabetic nephropathy LOC100506267 intron pha002866 rs13288636 chr9 12721806 G A 8.30E-06 Urinary metabolites LOC100506267 intron 21572414 rs13288636 chr9 12721806 G A 5.70E-05 Diabetic nephropathy LOC100506267 intron pha002866 rs13288681 chr9 12721881 G C 1.20E-05 Urinary metabolites LOC100506267 intron 21572414 rs13288681 chr9 12721881 G C 7.20E-05 Diabetic nephropathy LOC100506267 intron pha002866 rs970946 chr9 12738690 C A 9.50E-06 Urinary metabolites LOC100506267 intron 21572414 rs10738290 chr9 12740906 A C 5.71E-04 Amyotrophic Lateral Sclerosis LOC100506267 intron 17362836 rs10124197 chr9 12746651 T C 1.40E-05 Urinary metabolites LOC100506267 intron 21572414 rs10756405 chr9 12748234 G A 1.90E-05 Urinary metabolites LOC100506267 intron 21572414 rs7019981 chr9 12748818 G A 2.70E-05 Urinary metabolites LOC100506267 intron 21572414 rs927869 chr9 12748962 A G 1.05E-07 Common traits (Other) LOC100506267 intron 20585627 rs10960781 chr9 12762374 G A 9.10E-06 Urinary metabolites LOC100506267 intron 21572414 rs10809838 chr9 12766337 T G 8.78E-04 Alcohol dependence LOC100506267 intron 21314694 rs10491742 chr9 12775488 G A 2.67E-04 Amyotrophic Lateral Sclerosis LURAP1L UTR-5 17362836 rs10960809 chr9 12816001 C T 1.34E-04 Multiple complex diseases LURAP1L intron 17554300 rs652278 chr9 12839484 T C 4.27E-05 Coronary heart disease / / pha003031 rs10491739 chr9 12847826 T C 2.06E-04 Multiple complex diseases / / 17554300 rs13291971 chr9 12861065 G C 3.80E-04 Multiple complex diseases / / 17554300 rs546171 chr9 12879368 C A 6.79E-05 Parkinson's disease / / 17052657 rs7864059 chr9 12893356 A G 3.45E-06 Coronary heart disease / / pha003031 rs1953021 chr9 12914396 G T 1.00E-06 Periodontitis (CDC/AAP) / / 24024966 rs10756426 chr9 12947238 T A,C 3.00E-04 Myasthenia gravis / / 23055271 rs11792350 chr9 12947761 C A,G,T 3.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs10429589 chr9 12954666 G C 7.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs10960866 chr9 12956115 G T 2.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs3932596 chr9 12956761 G T 2.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs10448183 chr9 12957884 G A 2.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs10960868 chr9 12957958 T C 3.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs4741261 chr9 12958649 A G 4.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs10809865 chr9 12959188 C T 4.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs10809866 chr9 12959211 A G 4.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs10809867 chr9 12959245 G T 4.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs10809868 chr9 12959428 G A 4.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs10118051 chr9 12959560 T C 5.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs10809869 chr9 12960282 G T 6.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs10465043 chr9 12960607 T A,C,G 3.52E-04 Multiple complex diseases / / 17554300 rs1332072 chr9 12987911 G T 5.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs1887884 chr9 12995112 C T 4.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs11789175 chr9 12996815 G C 7.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs1360517 chr9 13007129 T C 3.00E-06 AIDS / / 19754311 rs10756438 chr9 13008952 T C 4.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs1412306 chr9 13009715 T G 7.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs1412304 chr9 13010074 G T 5.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs1412303 chr9 13010191 T C 5.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs1332070 chr9 13011565 A G 4.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs7847416 chr9 13012787 C T 5.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs1410777 chr9 13016103 A G 4.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs7022183 chr9 13016817 T C 4.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs7022183 chr9 13016817 T C 6.58E-06 Alopecia areata / / 22027810 rs1328909 chr9 13017271 A T 4.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs10756440 chr9 13018096 T C 4.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs10809873 chr9 13018781 T A 4.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs12351740 chr9 13020010 C T 6.63E-06 AIDS / / 19754311 rs10514822 chr9 13025284 G T 7.02E-05 ldl cholesterol / / pha003076 rs10809876 chr9 13027530 A G 5.34E-04 Type 2 diabetes / / 17463246 rs10809876 chr9 13027530 A G 2.55E-05 Serum metabolites / / 19043545 rs4741269 chr9 13028429 T C 1.75E-05 Serum metabolites / / 19043545 rs9792560 chr9 13029816 G A 4.40E-06 Serum metabolites / / 19043545 rs4741271 chr9 13030211 T C 1.02E-05 Serum metabolites / / 19043545 rs10809889 chr9 13052851 C G 2.46E-05 Hypertension / / 19609347 rs3264 chr9 13106598 T C 8.31E-05 Angioedema in response to angiotensin-converting enzyme inhibitor MPDZ UTR-3 23838604 rs2274647 chr9 13115422 T G 7.42E-05 Antineutrophil cytoplasmic antibody-associated vasculitis MPDZ intron 22808956 rs2274647 chr9 13115422 T G 2.59E-06 Height MPDZ intron pha003011 rs11793993 chr9 13265893 T C 5.21E-06 Cognitive test performance / / 20125193 rs10961005 chr9 13282447 G A 7.02E-05 Cognitive impairment induced by topiramate / / 22091778 rs1185261 chr9 13337242 C T 2.24E-19 Varicose Veins / / pha001416 rs4606154 chr9 13468276 G A 9.40E-05 Bone mineral density (BMD),in women LOC100506304 intron 20164292 rs10809954 chr9 13468616 A G 5.04E-04 Response to cytadine analogues (cytosine arabinoside) LOC100506304 intron 24483146 rs10121700 chr9 13497553 C T 5.63E-05 Type 2 diabetes / / 17463246 rs1333996 chr9 13504924 C T 1.24E-04 Type 2 diabetes / / 17463246 rs3737150 chr9 13508282 A G 1.70E-05 Urinary metabolites / / 21572414 rs3737151 chr9 13508344 T A 1.20E-05 Urinary metabolites / / 21572414 rs3737152 chr9 13508377 C T 2.73E-04 Multiple complex diseases / / 17554300 rs12684544 chr9 13510394 G T 5.72E-04 Alzheimer's disease / / 17998437 rs12684544 chr9 13510394 G T 6.20E-06 Urinary metabolites / / 21572414 rs1324183 chr9 13557491 A C 8.00E-09 Corneal structure / / 23291589 rs10491755 chr9 13559272 A C 3.72E-22 Varicose Veins / / pha001414 rs10961150 chr9 13573724 C T 4.81E-05 Intracerebral hemorrhage / / 24656865 rs7847125 chr9 13577494 T C 3.02E-05 Intracerebral hemorrhage / / 24656865 rs10961154 chr9 13583940 T C 5.09E-04 Multiple complex diseases / / 17554300 rs10809986 chr9 13585061 T A 8.90E-04 Multiple complex diseases / / 17554300 rs10961163 chr9 13594084 A C 3.21E-05 Intracerebral hemorrhage / / 24656865 rs2382400 chr9 13594673 C G 1.38E-05 Intracerebral hemorrhage / / 24656865 rs2382400 chr9 13594673 C G 9.57E-06 Intracerebral hemorrhage / / 24656865 rs1535836 chr9 13616431 G A 1.50E-07 Urinary metabolites / / 21572414 rs10511583 chr9 13618445 A G 9.50E-05 Lung adenocarcinoma / / 19836008 rs13301366 chr9 13639092 C T 4.08E-04 Smoking cessation / / 24665060 rs16930665 chr9 13670365 C T 6.61E-04 Smoking cessation / / 24665060 rs1408314 chr9 13682737 C T 2.99E-04 Coronary Artery Disease / / 17634449 rs627216 chr9 13705568 C G 8.51E-05 Bipolar disorder and schizophrenia / / 20889312 rs10961199 chr9 13714854 A C 1.60E-04 Coronary Artery Disease / / 17634449 rs10810007 chr9 13719314 A T 7.09E-04 Coronary Artery Disease / / 17634449 rs1556494 chr9 13723812 A G 1.55E-04 Coronary Artery Disease / / 17634449 rs10115052 chr9 13725246 G T 2.65E-05 Multiple complex diseases / / 17554300 rs10115052 chr9 13725246 G T 7.49E-05 Bipolar disorder and schizophrenia / / 20889312 rs10810009 chr9 13726331 C G 4.04E-04 Coronary Artery Disease / / 17634449 rs2382407 chr9 13734430 T C 9.49E-05 Blood Pressure / / pha003045 rs1327517 chr9 13743702 G C 1.61E-04 Coronary Artery Disease / / 17634449 rs10733265 chr9 13750811 T C 6.97E-05 Serum metabolites / / 19043545 rs1011531 chr9 13755192 T C 5.21E-04 Coronary Artery Disease / / 17634449 rs1011531 chr9 13755192 T C 3.67E-04 Iron levels / / pha002876 rs10756493 chr9 13756710 C G 1.63E-05 Coronary Artery Disease / / 17634449 rs11789440 chr9 13757664 C G 1.57E-05 Coronary Artery Disease / / 17634449 rs10733267 chr9 13758271 G T 1.52E-05 Coronary Artery Disease / / 17634449 rs12347123 chr9 13759474 T G 9.41E-05 Blood Pressure / / pha003050 rs17216411 chr9 13760986 A G 2.66E-04 Multiple complex diseases / / 17554300 rs17805200 chr9 13764434 T C 1.48E-04 Coronary Artery Disease / / 17634449 rs10756500 chr9 13772055 G A 3.08E-06 Coronary Artery Disease / / 17634449 rs1562044 chr9 13774423 C T 4.38E-06 Coronary Artery Disease / / 17634449 rs10961259 chr9 13799421 A G 5.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs1556489 chr9 13802412 T A 3.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs987416 chr9 13812037 T G 4.26E-04 Smoking initiation / / 24665060 rs7866165 chr9 13812685 G T 3.64E-05 Psoriasis / / 20953190 rs11788150 chr9 13825565 C A 4.73E-05 Psoriasis / / 20953190 rs2078639 chr9 13828594 T C 3.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs10491766 chr9 13846800 C T 9.71E-04 Multiple complex diseases / / 17554300 rs7022974 chr9 13849054 T C 1.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs1813529 chr9 13849122 C T 3.54E-05 Psoriasis / / 20953190 rs17220109 chr9 13850269 T A 1.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs7021837 chr9 13854176 T C 1.02E-05 Psoriasis / / 20953190 rs7021837 chr9 13854176 T C 7.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs7036600 chr9 13854370 A C 9.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs16930996 chr9 13855462 C G 2.91E-04 Multiple complex diseases / / 17554300 rs16931031 chr9 13857580 A G 7.67E-04 Multiple complex diseases / / 17554300 rs12006148 chr9 13871187 A G 1.81E-07 Coronary heart disease / / 22319020 rs1327512 chr9 13891813 G A 7.81E-05 Glucose levels / / pha003058 rs9298693 chr9 13901409 G A 1.60E-05 Sleep and circadian phenotypes / / 17903308 rs10810059 chr9 13930022 A C 7.85E-04 Tourette syndrome C9orf146 intron 22889924 rs12338757 chr9 13932998 C T 5.07E-04 Suicide attempts in bipolar disorder C9orf146 intron 21423239 rs957691 chr9 13934368 G A 3.49E-04 Suicide attempts in bipolar disorder C9orf146 intron 21423239 rs17192194 chr9 13935198 C T 1.20E-04 Suicide attempts in bipolar disorder C9orf146 intron 21423239 rs13285663 chr9 13937519 G A 3.34E-04 Suicide attempts in bipolar disorder C9orf146 intron 21423239 rs17277467 chr9 13939884 C T 2.34E-04 Suicide attempts in bipolar disorder C9orf146 intron 21423239 rs13292270 chr9 13940536 A G 2.84E-04 Suicide attempts in bipolar disorder C9orf146 intron 21423239 rs13292571 chr9 13940704 A T 1.84E-04 Suicide attempts in bipolar disorder C9orf146 intron 21423239 rs13299074 chr9 13941396 T C 2.05E-04 Suicide attempts in bipolar disorder C9orf146 intron 21423239 rs13298062 chr9 13941513 A G 2.82E-04 Suicide attempts in bipolar disorder C9orf146 intron 21423239 rs13283645 chr9 13949666 C T 2.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs17277593 chr9 13950593 G A 2.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs7048074 chr9 13980085 C T 5.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10511587 chr9 13980584 A G 7.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs755267 chr9 13986757 C T 8.83E-05 Hypertension / / pha003042 rs7875700 chr9 13987876 C G 1.90E-05 Urinary metabolites / / 21572414 rs10810080 chr9 14026089 T C 9.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs10810081 chr9 14026183 A G 9.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs7049018 chr9 14033328 C T 4.62E-05 Personality dimensions / / 18957941 rs10116586 chr9 14058548 A C 1.11E-04 Alcohol dependence / / 21314694 rs7039300 chr9 14064741 T G 2.00E-06 Alzheimer's disease biomarkers / / 23419831 rs564854 chr9 14065522 C A 1.80E-04 Response to antidepressants / / 19736353 rs6474816 chr9 14076237 C T 9.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs578720 chr9 14076256 G T 2.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs578809 chr9 14076289 A C 2.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs480700 chr9 14079067 T C 3.81E-05 Brain structure / / 22504417 rs7858 chr9 14087769 C T 1.00E-04 Response to antidepressants NFIB UTR-3 19736353 rs7858 chr9 14087769 C T 1.54E-04 Suicide attempts in bipolar disorder NFIB UTR-3 21423239 rs548824 chr9 14088789 T C 1.29E-04 Suicide attempts in bipolar disorder NFIB intron 21423239 rs12551855 chr9 14093727 A T 1.50E-05 Urinary metabolites NFIB intron 21572414 rs571693 chr9 14110242 T G 9.13E-04 Suicide attempts in bipolar disorder NFIB intron 21423239 rs573057 chr9 14113903 A C 4.06E-04 Suicide attempts in bipolar disorder NFIB intron 21423239 rs498010 chr9 14116484 C T 5.75E-04 Suicide attempts in bipolar disorder NFIB intron 21423239 rs551272 chr9 14118122 A G 7.51E-04 Suicide attempts in bipolar disorder NFIB intron 21423239 rs693566 chr9 14118308 C T 8.81E-04 Suicide attempts in bipolar disorder NFIB intron 21423239 rs7860845 chr9 14119810 A G 9.48E-14 Total IFN-gamma response to smallpox vaccine NFIB intron 22661280 rs2382437 chr9 14139828 T C 2.30E-04 Stroke NFIB intron pha002887 rs6474821 chr9 14172048 G A 3.29E-04 Alzheimer's disease (late onset) NFIB intron 21379329 rs10810105 chr9 14191522 T C 1.00E-04 Information processing speed NFIB intron 21130836 rs10961411 chr9 14192366 A G 2.00E-04 Information processing speed NFIB intron 21130836 rs10961439 chr9 14233159 T G 0.000275333 Hypertension (early onset hypertension) NFIB intron 22479346 rs7040053 chr9 14235002 T C 4.10E-05 Cognitive test performance NFIB intron 20125193 rs10756542 chr9 14237649 C A 7.84E-04 Obesity (extreme) NFIB intron 21935397 rs10810120 chr9 14244376 T C 5.18E-05 Hypertension (early onset hypertension) NFIB intron 22479346 rs1322987 chr9 14244753 T C 1.06E-05 Cognitive test performance NFIB intron 20125193 rs10435726 chr9 14251917 G T 6.42E-06 Age-related macular degeneration NFIB intron pha002869 rs10435726 chr9 14251917 G T 4.14E-05 Age-related macular degeneration NFIB intron pha002890 rs10810121 chr9 14267285 C A 3.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NFIB intron 20877124 rs1061820 chr9 14269556 A G 6.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NFIB intron 20877124 rs1322991 chr9 14270342 G A 7.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NFIB intron 20877124 rs1322991 chr9 14270342 G A 2.12E-06 Sodium levels NFIB intron pha003093 rs1322993 chr9 14276983 C T 2.21E-07 Sodium levels NFIB intron pha003093 rs2382468 chr9 14303061 T G 2.05E-04 Alcohol consumption (maxi-drinks) NFIB intron 24277619 rs4741363 chr9 14339205 C T 4.87E-04 Multiple complex diseases NFIB intron 17554300 rs12379369 chr9 14359000 C T 1.49E-04 Smoking cessation NFIB intron 24665060 rs10491776 chr9 14362390 T C 2.30E-04 Smoking cessation NFIB intron 24665060 rs683474 chr9 14365269 C T 6.98E-05 Lipoproteins NFIB intron pha003079 rs10961490 chr9 14370172 T C 4.41E-05 Oral cancers (chewing tobacco related) NFIB intron 22503698 rs2382469 chr9 14378712 A C 5.07E-05 Cleft lip NFIB intron 20436469 rs630973 chr9 14380945 T G 6.48E-04 HIV-1 viral setpoint NFIB intron 17641165 rs717932 chr9 14389011 C T 4.18E-05 Sudden cardiac arrest NFIB intron 21658281 rs1807429 chr9 14395595 T G 3.68E-05 Fibrinogen NFIB intron 17255346 rs7875762 chr9 14422035 A G 8.28E-05 Type 2 diabetes / / 17846125 rs7846762 chr9 14422276 C T 5.45E-05 Type 2 diabetes / / 17846125 rs1028705 chr9 14426209 C T 2.60E-05 Serum metabolites / / 19043545 rs56037905 chr9 14432026 G A 1.39E-05 Alcohol consumption / / 23743675 rs958957 chr9 14434284 A G 1.24E-04 Type 2 diabetes / / 17846125 rs59677118 chr9 14441677 G A 1.00E-06 Alcohol consumption / / 23743675 rs10491775 chr9 14443784 A C 7.40E-05 Hypothyroidism / / 22493691 rs1556032 chr9 14446001 C T 9.00E-06 AIDS / / 19754311 rs303724 chr9 14468137 A G 1.00E-05 Urinary metabolites / / 21572414 rs10961534 chr9 14470833 A G 7.00E-06 Hypothyroidism / / 22493691 rs56327111 chr9 14481382 A G 6.32E-05 Alcohol consumption / / 23743675 rs13299701 chr9 14482456 C T 3.63E-05 Alcohol consumption / / 23743675 rs35950138 chr9 14483143 C T 3.59E-05 Alcohol consumption / / 23743675 rs35094112 chr9 14483581 G A 3.58E-05 Alcohol consumption / / 23743675 rs13285597 chr9 14483654 C T 3.72E-05 Alcohol consumption / / 23743675 rs303746 chr9 14488904 G C 9.39E-05 Schizophrenia / / pha002859 rs13292512 chr9 14493900 A T 7.89E-05 Bipolar disorder and schizophrenia / / 20889312 rs7023433 chr9 14511645 A C 5.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7023433 chr9 14511645 A C 8.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7023433 chr9 14511645 A C 2.77E-04 Lung function (forced vital capacity) / / 24023788 rs873553 chr9 14518829 A C 1.89E-05 Tunica Media / / pha003034 rs913417 chr9 14520611 G A 4.61E-04 Kawasaki disease / / 21326860 rs913417 chr9 14520611 G A 2.72E-05 Brain structure / / 22504417 rs927969 chr9 14524438 C A 3.99E-05 Asthma / / pha003128 rs6474842 chr9 14533865 C T 1.40E-05 Urinary metabolites / / 21572414 rs1328001 chr9 14535880 T A 2.60E-05 Urinary metabolites / / 21572414 rs17713843 chr9 14537063 G A 6.13E-04 Glycemic traits (pregnancy) / / 23903356 rs7850989 chr9 14541236 C T 4.58E-05 Brain structure / / 22504417 rs12002454 chr9 14547633 T C 3.41E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs12002454 chr9 14547633 T C 9.36E-05 Cortisol secretion,in saliva / / 21316860 rs10491772 chr9 14550138 A G 2.23E-04 Multiple complex diseases / / 17554300 rs16931947 chr9 14552704 A G 0.0000051 Mean arterial pressure / / 22510845 rs7025595 chr9 14554281 A C 9.70E-06 Urinary metabolites / / 21572414 rs10961577 chr9 14562314 C T 7.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs10491771 chr9 14564090 T C 6.19E-05 Triglycerides / / pha003080 rs7040652 chr9 14566406 T G 3.47E-05 Triglycerides / / pha003080 rs10116154 chr9 14573613 T C 2.66E-05 Triglycerides / / pha003080 rs1343705 chr9 14610866 G A 1.93E-04 Vaspin levels / / 22907691 rs1343705 chr9 14610866 G A 0.0001925 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs2382492 chr9 14631836 G T 1.40E-04 Iris characteristics ZDHHC21 intron 21835309 rs10961628 chr9 14633286 G A 9.98E-04 Response to cytidine analogues (gemcitabine) ZDHHC21 intron 24483146 rs4620377 chr9 14633299 T C 4.89E-05 Vaspin levels ZDHHC21 intron 22907691 rs4620377 chr9 14633299 T C 0.0000489 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit ZDHHC21 intron 22907730 rs4620377 chr9 14633299 T C 0.0001717 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit ZDHHC21 intron 22907730 rs4490946 chr9 14635546 A G 9.65E-04 Response to cytidine analogues (gemcitabine) ZDHHC21 intron 24483146 rs10810197 chr9 14637704 A G 4.16E-04 Response to cytidine analogues (gemcitabine) ZDHHC21 intron 24483146 rs6474849 chr9 14640055 C T 5.99E-04 Taste perception ZDHHC21 intron 22132133 rs4740583 chr9 14644737 A G 6.25E-04 Suicide attempts in bipolar disorder ZDHHC21 intron 21423239 rs10120588 chr9 14645813 A G 2.91E-04 Suicide attempts in bipolar disorder ZDHHC21 intron 21423239 rs10961636 chr9 14649728 G A 5.66E-05 Height ZDHHC21 intron 17255346 rs10511594 chr9 14649846 C T 9.00E-05 Kidney function and endocine traits ZDHHC21 intron 17903292 rs11790303 chr9 14651382 T C 6.97E-04 HIV-1 viral setpoint ZDHHC21 intron 17641165 rs7853156 chr9 14654900 C T 2.70E-04 Height ZDHHC21 intron 17255346 rs10756597 chr9 14657139 A C 8.07E-05 Lymphocyte counts ZDHHC21 intron 22286170 rs10481503 chr9 14660700 G A 7.15E-05 Soluble levels of adhesion molecules ZDHHC21 intron pha003072 rs10961640 chr9 14662171 T C 3.50E-05 Height ZDHHC21 intron 17255346 rs6474850 chr9 14662459 A G 0.0000024 Confectionary intake ZDHHC21 intron 23408455 rs2890992 chr9 14672267 C T 0.0000027 Confectionary intake ZDHHC21 intron 23408455 rs10123973 chr9 14672443 C T 4.42E-04 Suicide attempts in bipolar disorder ZDHHC21 intron 21423239 rs10810211 chr9 14676870 G A 0.0000078 Confectionary intake ZDHHC21 intron 23408455 rs9298706 chr9 14678730 T C 3.25E-04 Suicide attempts in bipolar disorder ZDHHC21 intron 21423239 rs7865184 chr9 14687867 A G 3.90E-05 Kidney function and endocine traits ZDHHC21 intron 17903292 rs2382478 chr9 14689745 G C 6.16E-04 Suicide attempts in bipolar disorder ZDHHC21 intron 21423239 rs2890987 chr9 14692219 C G 7.93E-04 Suicide attempts in bipolar disorder ZDHHC21 intron 21423239 rs4326470 chr9 14694536 A C 2.77E-04 Coronary heart disease / / 21606135 rs1858633 chr9 14696674 T G 2.41E-05 Type 2 diabetes / / 17463246 rs1317294 chr9 14697022 G A 6.22E-04 Stroke / / pha002887 rs1317294 chr9 14697022 G A 3.03E-05 Coronary heart disease / / pha003031 rs16932197 chr9 14701851 G C 5.21E-05 Relative hand skill / / 24068947 rs1154781 chr9 14712456 C A 7.29E-05 Relative hand skill / / 24068947 rs7847525 chr9 14714575 T C 8.70E-05 Relative hand skill / / 24068947 rs10115703 chr9 14722616 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) CER1 missense 20708005 rs10961689 chr9 14737506 T G 9.67E-04 Alzheimer's disease FREM1 missense 24755620 rs4741426 chr9 14747412 A G 4.18E-04 Alzheimer's disease FREM1 cds-synon 24755620 rs10117516 chr9 14749434 C T 1.37E-04 Alcohol dependence FREM1 intron 24277619 rs10117516 chr9 14749434 C T 2.61E-04 Alcohol consumption (maxi-drinks) FREM1 intron 24277619 rs10738377 chr9 14757744 C A 7.78E-05 HIV-1 viral setpoint FREM1 intron 17641165 rs7864052 chr9 14757877 A C 6.87E-04 Multiple complex diseases FREM1 intron 17554300 rs2382500 chr9 14764374 G C 3.36E-05 Multiple complex diseases FREM1 intron 17554300 rs923926 chr9 14765030 T C 5.95E-04 Myopia (pathological) FREM1 intron 21095009 rs6474855 chr9 14767916 G A 7.47E-04 Myocardial Infarction FREM1 intron pha002873 rs7852390 chr9 14772384 A C 1.70E-04 Response to taxane treatment (placlitaxel) FREM1 intron 23006423 rs1032474 chr9 14775853 A G 0.0002 Migraine FREM1 cds-synon 22678113 rs10961700 chr9 14776140 C T 2.67E-04 Tourette syndrome FREM1 missense 22889924 rs4415414 chr9 14778244 T G 0.0002 Migraine FREM1 intron 22678113 rs7027322 chr9 14785224 G A 4.15E-04 Multiple complex diseases FREM1 intron 17554300 rs1546135 chr9 14787156 C T 7.87E-04 Tourette syndrome FREM1 intron 22889924 rs7025956 chr9 14788407 T C 9.24E-04 Multiple complex diseases FREM1 intron 17554300 rs1494348 chr9 14790363 C T 1.95E-04 Multiple complex diseases FREM1 intron 17554300 rs2291681 chr9 14790841 G T 1.39E-04 Nicotine smoking FREM1 intron 19268276 rs2291681 chr9 14790841 G T 9.48E-04 Myopia (pathological) FREM1 intron 21095009 rs1389733 chr9 14791715 G T 1.10E-04 Alcohol dependence FREM1 intron 20201924 rs1389733 chr9 14791715 G T 3.36E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FREM1 intron 20877124 rs10046797 chr9 14833003 A C 6.14E-05 Parent of origin effect on language impairment (child trend) FREM1 intron 24571439 rs11506374 chr9 14833401 G A 7.43E-04 Aortic root size FREM1 intron 21223598 rs1552896 chr9 14841387 C G 8.87E-06 Bone mass and geometry FREM1 intron 17903296 rs16932354 chr9 14850256 T C 2.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FREM1 intron 20877124 rs200861231 chr9 14859401 C A 8.69E-12 Body mass index FREM1 missense 23555315 rs16892 chr9 14889834 T C 9.36E-04 Response to taxane treatment (placlitaxel) FREM1 intron 23006423 rs17222108 chr9 14891600 T C 7.11E-04 Response to taxane treatment (placlitaxel) FREM1 intron 23006423 rs10810285 chr9 14891670 C T 0.0000378 fMRI brain tests in schizophrenia FREM1 intron 22440650 rs10961780 chr9 14898161 T G 2.00E-06 Height FREM1 intron 19893584 rs10961780 chr9 14898161 T G 1.15E-05 Blood Pressure FREM1 intron pha003039 rs940120 chr9 14906868 G A 5.48E-05 Bone mineral density FREM1 intron 19181680 rs7861117 chr9 14911082 T A 8.82E-04 Suicide attempts in bipolar disorder FREM1 nearGene-5 21423239 rs1855143 chr9 14929020 T C 8.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs1464608 chr9 14947785 G T 8.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs6415721 chr9 14964952 C T 7.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs10961811 chr9 14968316 C G 7.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs7026072 chr9 14973346 C A 5.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs7857763 chr9 14974080 C T 7.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs7030620 chr9 14974488 C T 7.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs2049291 chr9 14975829 T C 4.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs7870499 chr9 14977169 G C 5.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs9298710 chr9 14978548 G T 6.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs7040444 chr9 15059821 G T 4.77E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs1936718 chr9 15078522 A G 9.64E-05 Cognitive performance / / 19734545 rs7047010 chr9 15087382 T C 7.80E-06 Urinary metabolites / / 21572414 rs10756650 chr9 15104561 G A 5.00E-06 Metabolite levels (Pyroglutamine) / / 23934736 rs10961884 chr9 15111573 T C 1.11E-06 Prostate cancer / / 24185611 rs2800577 chr9 15154607 A C,G,T 1.67E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs1780159 chr9 15157977 T C 6.00E-06 Calcium levels / / 20705733 rs932712 chr9 15159928 A G 8.62E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs7026350 chr9 15165032 T C 3.31E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs17227372 chr9 15189086 T C 2.90E-05 Urinary metabolites TTC39B intron 21572414 rs693196 chr9 15202417 C T 3.87E-04 Common variable immunodeficiency TTC39B intron 21497890 rs693196 chr9 15202417 C T 2.35E-04 Lung function (forced expiratory volume in 1 second) TTC39B intron 24023788 rs569078 chr9 15205014 C T 6.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TTC39B intron 20877124 rs12684860 chr9 15210451 A C 1.89E-05 Cognitive test performance TTC39B intron 20125193 rs12343442 chr9 15212216 T G 3.90E-05 Amyotrophic lateral sclerosis (sporadic) TTC39B intron 24529757 rs10810364 chr9 15218408 G A 6.25E-04 Type 2 diabetes TTC39B intron 17463246 rs7870690 chr9 15218947 C A 7.54E-04 Response to taxane treatment (placlitaxel) TTC39B intron 23006423 rs619105 chr9 15240454 T C 3.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TTC39B intron 20877124 rs519664 chr9 15246652 C T 6.22E-05 Diabetes Mellitus TTC39B intron pha003060 rs12345299 chr9 15247714 G A 3.48E-06 Diabetes Mellitus TTC39B intron pha003060 rs13300482 chr9 15260948 G A 7.77E-04 Suicide attempts in bipolar disorder TTC39B intron 21423239 rs7870745 chr9 15271933 C T 2.36E-04 Lung function (forced expiratory volume in 1 second) TTC39B intron 24023788 rs7870745 chr9 15271933 C T 3.61E-04 Lung function (forced vital capacity) TTC39B intron 24023788 rs10511610 chr9 15272462 C G 2.52E-04 Type 2 diabetes TTC39B intron 17463246 rs10961949 chr9 15276926 T C 7.58E-04 Type 2 diabetes TTC39B intron 17463246 rs12003180 chr9 15283097 C T 5.00E-06 Bipolar disorder and schizophrenia TTC39B intron 20889312 rs471364 chr9 15289578 C T 3.00E-10 HDL cholesterol TTC39B intron 19060906 rs471364 chr9 15289578 C T 3.00E-10 Coronary heart disease TTC39B intron 21347282 rs471364 chr9 15289578 C T 0.000126 Cholesterol,total TTC39B intron 23063622 rs2185938 chr9 15293427 G A 1.50E-04 Lipid levels TTC39B intron 18193043 rs6474902 chr9 15293946 C T 3.22E-28 Metabolite levels TTC39B intron 22286219 rs643531 chr9 15296034 C A 7.00E-09 HDL cholesterol TTC39B intron 20864672 rs581080 chr9 15305378 G C 1.00E-13 HDL cholesterol TTC39B intron 20686565 rs581080 chr9 15305378 G C 3.00E-09 Cholesterol,total TTC39B intron 20686565 rs581080 chr9 15305378 G C 1.00E-13 Cholesterol,total TTC39B intron 24097068 rs581080 chr9 15305378 G C 1.00E-19 HDL cholesterol TTC39B intron 24097068 rs2245641 chr9 15309928 A C 2.00E-06 Bipolar disorder / / 22925353 rs652185 chr9 15321542 A G 5.27E-06 Odorant perception / / 23910658 rs16933006 chr9 15335914 A C 1.00E-06 Obesity-related traits / / 23251661 rs16933006 chr9 15335914 A C 4.00E-06 Obesity-related traits / / 23251661 rs16933006 chr9 15335914 A C 8.00E-08 Obesity-related traits / / 23251661 rs1215130 chr9 15343709 C T 5.08E-04 Alcohol dependence / / 20201924 rs473315 chr9 15349934 A G 7.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs680686 chr9 15351450 A G 2.97E-04 Alcohol dependence / / 20201924 rs681093 chr9 15351505 T C 3.00E-05 Electrocardiographic conduction measures / / 19389651 rs7867510 chr9 15353410 G A 3.66E-04 Alcohol dependence / / 21314694 rs519761 chr9 15357041 T C 4.50E-05 Electrocardiographic conduction measures / / 19389651 rs2805017 chr9 15367719 T A 5.10E-05 Electrocardiographic conduction measures / / 19389651 rs2490866 chr9 15369878 C T 7.00E-05 Electrocardiographic conduction measures / / 19389651 rs2105386 chr9 15383624 T C 5.15E-04 Multiple complex diseases / / 17554300 rs10738397 chr9 15451866 A G 5.80E-05 Schizophrenia S/PC3 intron 19571811 rs9650683 chr9 15457801 G C 6.16E-04 Coronary heart disease S/PC3 intron 21606135 rs13248 chr9 15464286 C T 6.04E-04 Response to cytidine analogues (gemcitabine) PSIP1 UTR-3 24483146 rs7857933 chr9 15516375 G A 9.40E-06 Urinary metabolites / / 21572414 rs10962058 chr9 15534070 C T 0.000517 Salmonella-induced pyroptosis / / 22837397 rs10962061 chr9 15540763 C A 0.000321 Salmonella-induced pyroptosis / / 22837397 rs1041529 chr9 15549731 A C 0.00043 Salmonella-induced pyroptosis / / 22837397 rs10962066 chr9 15555038 C G 5.93E-04 Multiple complex diseases C9orf93 intron 17554300 rs7873152 chr9 15555458 C T 9.68E-04 Multiple complex diseases C9orf93 intron 17554300 rs7024640 chr9 15705955 C T 8.94E-04 Multiple complex diseases C9orf93 intron 17554300 rs7847144 chr9 15714658 C T 9.01E-04 Multiple complex diseases C9orf93 intron 17554300 rs10756697 chr9 15728517 A G 1.23E-04 Multiple complex diseases C9orf93 intron 17554300 rs11792770 chr9 15731398 C T 5.29E-04 Response to taxane treatment (placlitaxel) C9orf93 intron 23006423 rs1396706 chr9 15732420 C A 7.71E-04 Type 2 diabetes C9orf93 intron 17846125 rs6474957 chr9 15735854 A G 0.000482 Salmonella-induced pyroptosis C9orf93 intron 22837397 rs4740624 chr9 15753411 T C 9.65E-04 Multiple complex diseases C9orf93 intron 17554300 rs10810439 chr9 15754393 A G 7.68E-04 Multiple complex diseases C9orf93 intron 17554300 rs1341734 chr9 15763124 A G 3.20E-04 Type 2 diabetes C9orf93 intron 17846125 rs10756704 chr9 15783816 G A 5.05E-04 Multiple complex diseases C9orf93 intron 17554300 rs7866641 chr9 15812396 G A 3.87E-04 Multiple complex diseases C9orf93 intron 17554300 rs2153727 chr9 15829503 T C 8.52E-04 Multiple complex diseases C9orf93 intron 17554300 rs16933858 chr9 15978313 G A 9.16E-04 Multiple complex diseases / / 17554300 rs10962244 chr9 15980320 C T 4.24E-04 Type 2 diabetes / / 17463246 rs1927702 chr9 15986716 T C 6.00E-06 Body mass index / / 19851299 rs79156074 chr9 16000235 C T 2.00E-06 Metabolite levels (5-HIAA/ MHPG Ratio) / / 23319000 rs1887665 chr9 16004012 C G 1.90E-05 Urinary metabolites / / 21572414 rs3124458 chr9 16022186 C T 4.36E-04 Smoking initiation / / 24665060 rs1328280 chr9 16030903 T C 3.31E-04 Multiple complex diseases / / 17554300 rs4741557 chr9 16031080 T C 6.10E-04 Multiple complex diseases / / 17554300 rs3008706 chr9 16034538 G A,C,T 1.47E-09 Bilirubin levels,in serum / / 20639394 rs1887671 chr9 16035672 T C 1.86E-06 Multiple complex diseases / / 17554300 rs1887671 chr9 16035672 T C 8.06E-04 Alcohol dependence / / 21314694 rs7023221 chr9 16085262 T C 2.06E-10 Non-obstructive azoospermia / / 22197933 rs943784 chr9 16096547 T C 3.29E-04 Acute lung injury / / 22295056 rs12005226 chr9 16098105 T C 9.59E-04 Acute lung injury / / 22295056 rs11999853 chr9 16099709 A G 2.78E-04 Acute lung injury / / 22295056 rs1536689 chr9 16129630 A G 1.87E-04 Arthritis (juvenile idiopathic) / / 22354554 rs1536689 chr9 16129630 A G 1.52E-05 Celiac disease / / 23936387 rs7023487 chr9 16152308 C A 2.09E-04 Parkinson's disease / / 17052657 rs729119 chr9 16155596 A C 1.88E-04 Acute lung injury / / 22295056 rs12004737 chr9 16164549 A G 5.98E-04 Acute lung injury / / 22295056 rs16934192 chr9 16185090 G T 2.00E-04 Polycystic ovary syndrome / / 22178785 rs10114001 chr9 16185668 G A 2.27E-04 Bipolar disorder,schizoaffective / / 19567891 rs11999291 chr9 16186212 G A 3.38E-04 Bipolar disorder,schizoaffective / / 19567891 rs4961665 chr9 16191258 G T 1.27E-04 Bipolar disorder,schizoaffective / / 19567891 rs7022294 chr9 16194746 C T 2.30E-05 Urinary metabolites / / 21572414 rs16934222 chr9 16196951 C A 8.99E-04 Multiple complex diseases / / 17554300 rs10114438 chr9 16198488 A G 3.80E-07 Urinary metabolites / / 21572414 rs10117629 chr9 16200201 G C 1.80E-05 Urinary metabolites / / 21572414 rs1108491 chr9 16200331 C G 3.07E-04 Type 2 diabetes / / 17846125 rs1571910 chr9 16204088 A T 2.33E-04 Multiple complex diseases / / 17554300 rs200667799 chr9 16211137 T TAC 4.26E-04 Abdominal aortic aneurysm / / 22055160 rs7044238 chr9 16211137 T C 4.26E-04 Abdominal aortic aneurysm / / 22055160 rs12554091 chr9 16211712 T G 1.21E-04 Bipolar disorder,schizoaffective / / 19567891 rs12554091 chr9 16211712 T G 0.000699422 Hypertension (early onset hypertension) / / 22479346 rs6415726 chr9 16247629 G A 5.87E-04 Tourette syndrome / / 22889924 rs10733309 chr9 16253322 A G 5.89E-04 Type 2 diabetes / / 17463246 rs7040587 chr9 16256964 G A 9.63E-04 Obesity (extreme) / / 21935397 rs7043514 chr9 16257016 C T 9.73E-04 Obesity (extreme) / / 21935397 rs1105358 chr9 16265819 G C 2.43E-22 Narcolepsy / / 19629137 rs869624 chr9 16279444 G C 1.10E-07 Urinary metabolites / / 21572414 rs869624 chr9 16279444 G C 2.62E-04 Alzheimer's disease / / 22005930 rs869625 chr9 16279473 T A 7.79E-04 Multiple complex diseases / / 17554300 rs1332479 chr9 16282340 C T 8.90E-04 Depression (quantitative trait) / / 20800221 rs10962365 chr9 16286344 G A 6.83E-04 Depression (quantitative trait) / / 20800221 rs10962366 chr9 16286587 T C 6.77E-04 Depression (quantitative trait) / / 20800221 rs10810544 chr9 16286870 C T 5.48E-04 Depression (quantitative trait) / / 20800221 rs1114539 chr9 16288875 G A 6.24E-04 Depression (quantitative trait) / / 20800221 rs7850784 chr9 16289910 G A 4.91E-04 Depression (quantitative trait) / / 20800221 rs7861593 chr9 16290697 A G 4.02E-04 Depression (quantitative trait) / / 20800221 rs10810549 chr9 16299425 G A 4.59E-04 Depression (quantitative trait) / / 20800221 rs10962370 chr9 16305538 A G 7.45E-04 Multiple complex diseases / / 17554300 rs10962371 chr9 16305615 A G 1.20E-06 Urinary metabolites / / 21572414 rs7032123 chr9 16309559 A G 8.94E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7851138 chr9 16310620 G A 6.31E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs16934439 chr9 16321578 T G 5.84E-04 Alcohol dependence / / 20201924 rs16934439 chr9 16321578 T G 8.90E-07 Urinary metabolites / / 21572414 rs1888955 chr9 16329537 C T 2.80E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs10962382 chr9 16335469 C A 3.91E-05 Brain structure / / 22504417 rs10810557 chr9 16336250 T C 3.40E-04 Pulmonary function / / 23932459 rs7025710 chr9 16344654 T G 5.43E-05 Insulin Resistance / / pha003062 rs7025710 chr9 16344654 T G 8.91E-05 Insulin-related traits / / pha003063 rs4961706 chr9 16349953 G T 2.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs9407760 chr9 16363460 T C 5.92E-05 HIV-1 viral setpoint / / 17641165 rs7864648 chr9 16368732 G T 2.00E-08 Height / / 20881960 rs9406636 chr9 16385132 C A 9.00E-07 Metabolite levels (Dihydroxy docosatrienoic acid) / / 23934736 rs10810562 chr9 16397155 T C 9.66E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs16934624 chr9 16415302 G A 4.02E-04 Multiple complex diseases BNC2 UTR-3 17554300 rs10511619 chr9 16424985 T C 3.68E-04 Amyotrophic Lateral Sclerosis BNC2 intron 17362836 rs1927620 chr9 16453145 A C 9.47E-05 Height BNC2 intron pha003011 rs1927621 chr9 16453551 T C 3.47E-05 Height BNC2 intron pha003011 rs11999885 chr9 16458254 G T 1.62E-04 Multiple complex diseases BNC2 intron 17554300 rs10733310 chr9 16464980 T G 2.29E-05 Height BNC2 intron pha003011 rs2274557 chr9 16473118 T C 4.13E-05 Weight BNC2 intron pha003026 rs4961721 chr9 16493471 A G 2.56E-04 Multiple complex diseases BNC2 intron 17554300 rs10124550 chr9 16512748 A G 7.00E-07 Metabolite levels (Pyroglutamine) BNC2 intron 23934736 rs10124550 chr9 16512748 A G 5.20E-05 Height BNC2 intron pha003010 rs10124550 chr9 16512748 A G 1.20E-05 Height BNC2 intron pha003011 rs12115663 chr9 16517953 C A 3.60E-05 Social communication problems BNC2 intron 24047820 rs2891071 chr9 16540987 A G 7.27E-04 Amyotrophic Lateral Sclerosis BNC2 intron 17362836 rs10962487 chr9 16561547 G T 3.11E-05 Pulmonary function BNC2 intron 20010835 rs10962494 chr9 16574838 T C 9.30E-05 Femoral neck bone geometry BNC2 intron 22087292 rs10123558 chr9 16578434 G A 1.61E-04 Height BNC2 intron 17255346 rs10511622 chr9 16596071 G A 7.88E-07 Paclitaxel sensitivity in NCI60 cancer cell lines BNC2 intron 21314952 rs10118611 chr9 16597465 G A 0.00000121 LDL cholesterol BNC2 intron 23063622 rs10118611 chr9 16597465 G A 1.83E-09 Triglycerides BNC2 intron 23063622 rs10962504 chr9 16598985 G C 9.05E-05 Femoral neck bone geometry BNC2 intron 22087292 rs4961725 chr9 16599255 T C 5.53E-04 Alzheimer's disease BNC2 intron 17998437 rs7032523 chr9 16603483 A T 3.04E-04 Height BNC2 intron 17255346 rs13290470 chr9 16619529 A G 5.70E-04 Amyotrophic Lateral Sclerosis BNC2 intron 17362836 rs2275256 chr9 16625749 C T 4.41E-04 Amyotrophic Lateral Sclerosis BNC2 intron 17362836 rs7870730 chr9 16649932 T C 5.39E-05 Height BNC2 intron 17255346 rs10733314 chr9 16694836 A G 1.25E-06 Serum metabolites BNC2 intron 19043545 rs1888207 chr9 16696187 G A 1.01E-05 Serum metabolites BNC2 intron 19043545 rs10738446 chr9 16696510 G C 9.90E-06 Serum metabolites BNC2 intron 19043545 rs10962542 chr9 16698234 C A 5.34E-05 Serum metabolites BNC2 intron 19043545 rs10810593 chr9 16699008 A G 1.52E-05 Serum metabolites BNC2 intron 19043545 rs2297176 chr9 16706012 C T 2.05E-05 Serum metabolites BNC2 intron 19043545 rs1856132 chr9 16730653 A G 3.13E-04 Height BNC2 intron 17255346 rs1411429 chr9 16733693 C G 2.65E-04 Type 2 diabetes BNC2 intron 17846125 rs2183408 chr9 16733907 G C 4.22E-04 Type 2 diabetes BNC2 intron 17846125 rs2840290 chr9 16733957 A G 8.47E-04 Type 2 diabetes BNC2 intron 17846125 rs7874791 chr9 16747815 C T 1.00E-04 Type 2 diabetes BNC2 intron 17846125 rs12344698 chr9 16750143 C T 2.03E-04 Height BNC2 intron 17255346 rs6475074 chr9 16753455 T C 3.34E-04 Type 2 diabetes BNC2 intron 17846125 rs1330298 chr9 16755121 A G 9.45E-04 Amyotrophic Lateral Sclerosis BNC2 intron 17362836 rs10810619 chr9 16763140 A G 7.01E-04 Amyotrophic Lateral Sclerosis BNC2 intron 17362836 rs10756811 chr9 16768265 G C 8.85E-04 Multiple complex diseases BNC2 intron 17554300 rs4961755 chr9 16769812 G C 7.00E-05 Type 2 diabetes BNC2 intron 17463248 rs2150089 chr9 16770181 G A 2.64E-04 Height BNC2 intron 17255346 rs10962582 chr9 16772775 A C 5.86E-04 Response to cytadine analogues (cytosine arabinoside) BNC2 intron 24483146 rs10123118 chr9 16778780 G A 2.90E-04 Height BNC2 intron 17255346 rs10810632 chr9 16789024 C T 2.00E-04 Type 1 diabetes BNC2 intron 19875614 rs10810632 chr9 16789024 C T 3.70E-07 Type 1 diabetes BNC2 intron 19875614 rs10810632 chr9 16789024 C T 3.70E-08 Type 1 diabetes BNC2 intron 19875614 rs10810632 chr9 16789024 C T 6.79E-06 Type 1 diabetes BNC2 intron 19875614 rs10810632 chr9 16789024 C T 7.10E-04 Type 1 diabetes BNC2 intron 19875614 rs10810632 chr9 16789024 C T 7.90E-04 Type 1 diabetes BNC2 intron 19875614 rs10810632 chr9 16789024 C T 9.00E-08 Type 1 diabetes BNC2 intron 19875614 rs10756815 chr9 16789081 G A 4.58E-04 Lung function (forced expiratory volume in 1 second) BNC2 intron 24023788 rs6475082 chr9 16789436 G A 1.80E-07 Type 1 diabetes BNC2 intron 19875614 rs6475082 chr9 16789436 G A 2.70E-04 Type 1 diabetes BNC2 intron 19875614 rs6475082 chr9 16789436 G A 7.40E-07 Type 1 diabetes BNC2 intron 19875614 rs6475082 chr9 16789436 G A 8.28E-06 Type 1 diabetes BNC2 intron 19875614 rs4961760 chr9 16789878 C T 1.60E-07 Type 1 diabetes BNC2 intron 19875614 rs4961760 chr9 16789878 C T 2.23E-05 Type 1 diabetes BNC2 intron 19875614 rs4961760 chr9 16789878 C T 7.10E-07 Type 1 diabetes BNC2 intron 19875614 rs10962594 chr9 16791743 T C 8.42E-05 Blood Pressure BNC2 intron pha003040 rs10119731 chr9 16792350 A C 1.81E-04 Height BNC2 intron 17255346 rs10120562 chr9 16793104 A G 1.32E-04 Height BNC2 intron 17255346 rs10962599 chr9 16795286 C T 7.24E-04 Response to cytadine analogues (cytosine arabinoside) BNC2 intron 24483146 rs16935073 chr9 16795790 A C 3.83E-05 Height BNC2 intron 17255346 rs2026804 chr9 16800341 A C 6.25E-04 Response to cytadine analogues (cytosine arabinoside) BNC2 intron 24483146 rs2254193 chr9 16801850 A C 1.10E-06 Type 1 diabetes BNC2 intron 19875614 rs2254193 chr9 16801850 A C 2.00E-07 Type 1 diabetes BNC2 intron 19875614 rs2254193 chr9 16801850 A C 2.26E-04 Type 1 diabetes BNC2 intron 19875614 rs2254193 chr9 16801850 A C 3.50E-04 Type 1 diabetes BNC2 intron 19875614 rs2254193 chr9 16801850 A C 5.32E-04 Type 1 diabetes BNC2 intron 19875614 rs2254193 chr9 16801850 A C 8.95E-04 Type 1 diabetes BNC2 intron 19875614 rs10962612 chr9 16804167 T G 6.25E-04 Response to cytadine analogues (cytosine arabinoside) BNC2 intron 24483146 rs2254468 chr9 16804197 A G 7.79E-04 Type 2 diabetes BNC2 intron 17846125 rs3936215 chr9 16816755 C T 8.60E-07 Asthma BNC2 intron 24406073 rs10810642 chr9 16841515 A G 7.06E-05 Type 2 diabetes BNC2 intron 17463246 rs1339548 chr9 16846323 T C 4.07E-08 Common traits (Other) BNC2 intron 20585627 rs1339552 chr9 16848790 C T 1.58E-04 Multiple complex diseases BNC2 intron 17554300 rs1339552 chr9 16848790 C T 1.28E-10 Ovarian cancer BNC2 intron 19648919 rs4961501 chr9 16851678 T G 8.49E-12 Ovarian cancer BNC2 intron 19648919 rs12379687 chr9 16854367 G T 1.27E-08 Ovarian cancer BNC2 intron 19648919 rs1416742 chr9 16856883 G A 7.85E-04 Multiple complex diseases BNC2 intron 17554300 rs1416742 chr9 16856883 G A 1.74E-09 Ovarian cancer BNC2 intron 19648919 rs10756819 chr9 16858084 G A 4.85E-12 Ovarian cancer BNC2 intron 19648919 rs10756819 chr9 16858084 G A 2.04E-07 Common traits (Other) BNC2 intron 20585627 rs7861573 chr9 16862280 A G 3.61E-10 Ovarian cancer BNC2 intron 19648919 rs2153271 chr9 16864521 C T 4.66E-10 Ovarian cancer BNC2 intron 19648919 rs2153271 chr9 16864521 C T 4.00E-10 Freckling BNC2 intron 20585627 rs367899983 chr9 16864521 CTCTG C 4.66E-10 Ovarian cancer BNC2 intron 19648919 rs367899983 chr9 16864521 CTCTG C 4.00E-10 Freckling BNC2 intron 20585627 rs12379183 chr9 16865699 A G 1.36E-10 Ovarian cancer BNC2 intron 19648919 rs10962656 chr9 16877788 G A 5.88E-09 Ovarian cancer / / 19648919 rs10435764 chr9 16886083 G T 8.38E-04 Insulin resistance / / 21901158 rs3927680 chr9 16887366 T A 1.40E-04 Multiple complex diseases / / 17554300 rs10962668 chr9 16894140 T C 9.69E-04 Type 2 diabetes / / 17463246 rs10962668 chr9 16894140 T C 2.99E-04 Multiple complex diseases / / 17554300 rs3927678 chr9 16895146 C T 1.66E-04 Type 2 diabetes / / 17463246 rs10810661 chr9 16903850 A G 5.03E-05 Multiple complex diseases / / 17554300 rs7032158 chr9 16904047 A G 1.97E-05 Multiple complex diseases / / 17554300 rs7032175 chr9 16904080 A G 1.08E-04 Multiple complex diseases / / 17554300 rs7033354 chr9 16904846 C T 3.47E-07 Common traits (Other) / / 20585627 rs7868583 chr9 16906359 G A 1.19E-04 Multiple complex diseases / / 17554300 rs10810666 chr9 16911666 C T 1.24E-12 Ovarian cancer / / 19648919 rs4445329 chr9 16911757 G A 2.67E-17 Ovarian cancer / / 19648919 rs3814113 chr9 16915021 T C 5.00E-19 Ovarian cancer / / 19648919 rs3814113 chr9 16915021 T C 5.00E-19 Nasopharyngeal carcinoma / / 20512145 rs3814113 chr9 16915021 T C 4.00E-29 Ovarian cancer / / 23535730 rs3814113 chr9 16915021 T C 4.00E-32 Ovarian cancer / / 23535730 rs3814113 chr9 16915021 T C 6.00E-11 Ovarian cancer in BRCA1 mutation carriers / / 23544013 rs7019530 chr9 16936082 G A 2.10E-05 Urinary metabolites / / 21572414 rs7035981 chr9 16936283 T C 1.80E-05 Urinary metabolites / / 21572414 rs10962747 chr9 16942642 A T 2.05E-04 Multiple complex diseases / / 17554300 rs1538589 chr9 16942901 C T 1.35E-04 Multiple complex diseases / / 17554300 rs10441701 chr9 16946016 G A 8.37E-04 Multiple complex diseases / / 17554300 rs6475098 chr9 16948004 T G 6.43E-04 Multiple complex diseases / / 17554300 rs11791614 chr9 16963863 A G 1.82E-05 Diabetes Mellitus / / pha003060 rs10962774 chr9 16968831 G T 0.0000662 Coronary artery disease / / 23202125 rs10511627 chr9 16969642 G A 5.81E-05 Diabetes Mellitus / / pha003060 rs4961511 chr9 16970809 G T 9.00E-06 Corneal astigmatism / / 23322567 rs7042891 chr9 16989246 G A 5.56E-06 Type 2 diabetes / / 17463246 rs986472 chr9 16991622 G A 5.56E-06 Type 2 diabetes / / 17463246 rs10733336 chr9 16992325 C G 8.30E-05 Type 2 diabetes / / 17463246 rs1487505 chr9 17000713 T A 9.90E-04 Type 2 diabetes / / 17463246 rs1487504 chr9 17000855 A G 9.90E-04 Type 2 diabetes / / 17463246 rs2481550 chr9 17000932 G C 9.90E-04 Type 2 diabetes / / 17463246 rs13299954 chr9 17015692 G T 7.99E-05 Blood Pressure / / pha003048 rs263640 chr9 17019121 G A 9.90E-04 Type 2 diabetes / / 17463246 rs263548 chr9 17028235 C A 0.0000532 Nicotine dependence (smoking) / / 22377092 rs263548 chr9 17028235 C A 9.68E-05 Blood Pressure / / pha003048 rs263548 chr9 17028235 C A 3.82E-05 Blood Pressure / / pha003050 rs263576 chr9 17034019 T G 1.75E-05 Hypertension / / pha003042 rs263580 chr9 17039312 T G 7.93E-05 Coronary heart disease / / pha003030 rs263580 chr9 17039312 T G 7.20E-05 Blood Pressure / / pha003048 rs263585 chr9 17041557 A G 5.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs366216 chr9 17053484 C A 1.40E-05 Urinary metabolites / / 21572414 rs914049 chr9 17063068 T C 6.95E-04 Smoking initiation / / 24665060 rs366565 chr9 17063703 T C 8.23E-04 Smoking initiation / / 24665060 rs442431 chr9 17064431 T C 5.94E-04 Smoking initiation / / 24665060 rs2774633 chr9 17070633 A G 0.000043 Asthma / / 22694930 rs2774633 chr9 17070633 A G 3.97E-04 Smoking initiation / / 24665060 rs2774633 chr9 17070633 A G 5.79E-06 Blood Pressure / / pha003050 rs2129626 chr9 17071162 A C 0.0000246 Asthma / / 22694930 rs2129626 chr9 17071162 A C 4.18E-04 Smoking initiation / / 24665060 rs2129626 chr9 17071162 A C 5.78E-06 Blood Pressure / / pha003050 rs10810714 chr9 17087619 C G 9.82E-05 Smoking initiation / / 24665060 rs263606 chr9 17096753 C T 4.44E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs263606 chr9 17096753 C T 9.85E-06 Cardiac Troponin-T levels / / 23247143 rs13289535 chr9 17100003 A G 3.65E-05 Colorectal cancer / / 24448986 rs17754109 chr9 17130156 C T 9.74E-26 Narcolepsy / / 19629137 rs2779772 chr9 17147191 A C 2.79E-07 Type 2 diabetes CNTLN intron 21799836 rs9407787 chr9 17158245 T C 4.69E-04 Alzheimer's disease (late onset) CNTLN intron 21379329 rs10511633 chr9 17161527 G T 2.59E-05 Cardiovascular disease CNTLN intron 17903304 rs10511633 chr9 17161527 G T 8.88E-05 Alzheimer's disease (late onset) CNTLN intron 21379329 rs2815175 chr9 17165698 A G 2.09E-04 Alzheimer's disease (late onset) CNTLN intron 21379329 rs7037191 chr9 17167963 T C 7.77E-04 Smoking initiation CNTLN intron 24665060 rs2210539 chr9 17168867 A G 3.93E-04 Multiple complex diseases CNTLN intron 17554300 rs3119848 chr9 17176955 C T 3.17E-04 Alzheimer's disease (late onset) CNTLN intron 21379329 rs2815173 chr9 17181174 G T 2.74E-04 Alzheimer's disease (late onset) CNTLN intron 21379329 rs16935397 chr9 17186374 T C 7.21E-04 Multiple complex diseases CNTLN intron 17554300 rs4961534 chr9 17208589 G A 2.55E-04 Alzheimer's disease (late onset) CNTLN intron 21379329 rs10962917 chr9 17230086 G A 4.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CNTLN intron 20877124 rs7043703 chr9 17241284 A G 3.54E-04 Multiple complex diseases CNTLN intron 17554300 rs6475122 chr9 17244601 C T 2.25E-04 Multiple complex diseases CNTLN intron 17554300 rs1576958 chr9 17245775 C T 3.19E-04 Multiple complex diseases CNTLN intron 17554300 rs7034768 chr9 17246197 C T 1.45E-04 Multiple complex diseases CNTLN intron 17554300 rs7035525 chr9 17246567 G A 2.38E-04 Multiple complex diseases CNTLN intron 17554300 rs10962939 chr9 17247143 T C 5.01E-04 Multiple complex diseases CNTLN intron 17554300 rs7046327 chr9 17250916 T C 1.31E-04 Multiple complex diseases CNTLN intron 17554300 rs614471 chr9 17296785 T G 3.61E-04 Multiple complex diseases CNTLN intron 17554300 rs613966 chr9 17296926 T C 1.48E-04 Multiple complex diseases CNTLN intron 17554300 rs600133 chr9 17297041 G A 1.89E-04 Multiple complex diseases CNTLN intron 17554300 rs600041 chr9 17297105 T C 2.23E-04 Multiple complex diseases CNTLN intron 17554300 rs6475128 chr9 17309813 A G 2.14E-04 Multiple complex diseases CNTLN intron 17554300 rs6475129 chr9 17309886 T A 2.56E-04 Multiple complex diseases CNTLN intron 17554300 rs1930641 chr9 17316541 T G 2.29E-04 Multiple complex diseases CNTLN intron 17554300 rs17829280 chr9 17324158 G C 7.36E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CNTLN intron 20031582 rs10756867 chr9 17325704 C G 5.94E-04 Multiple complex diseases CNTLN intron 17554300 rs6475141 chr9 17350378 A C 9.68E-04 Multiple complex diseases CNTLN intron 17554300 rs6475143 chr9 17351711 A G 6.60E-04 Multiple complex diseases CNTLN intron 17554300 rs4961551 chr9 17367673 G A 8.69E-04 Multiple complex diseases CNTLN intron 17554300 rs13285126 chr9 17377629 C A 0.000086 Asthma CNTLN intron 22694930 rs7027539 chr9 17380028 G T 1.82E-04 Multiple complex diseases CNTLN intron 17554300 rs4961554 chr9 17380607 A G 1.51E-04 Multiple complex diseases CNTLN intron 17554300 rs7035276 chr9 17394536 C T 1.31E-04 Multiple complex diseases CNTLN missense 17554300 rs10963084 chr9 17404464 C T 4.12E-05 Interstitial lung disease CNTLN intron 23583980 rs10511634 chr9 17418788 A G 4.56E-11 Gout CNTLN intron pha001406 rs1967357 chr9 17436662 C T 2.31E-04 Alzheimer's disease (late onset) CNTLN intron 21379329 rs11792612 chr9 17442000 G A 1.77E-04 Smoking initiation CNTLN intron 24665060 rs11788615 chr9 17442116 A G 4.24E-04 Smoking initiation CNTLN intron 24665060 rs10810790 chr9 17458872 C T 6.00E-06 Response to amphetamines CNTLN intron 22952603 rs10756881 chr9 17463615 T C 4.89E-05 Parkinson's disease CNTLN intron 21738487 rs2441997 chr9 17474085 G A 4.19E-04 Alcohol dependence CNTLN intron 20201924 rs2383024 chr9 17487945 T G 9.00E-06 Pulmonary function decline CNTLN intron 22424883 rs2383025 chr9 17490559 T C 3.61E-05 Parkinson's disease CNTLN intron 21248740 rs2593353 chr9 17504609 G A 2.10E-04 Endometriosis / / 21151130 rs7350278 chr9 17524038 G T 7.72E-04 Stroke / / pha002887 rs2754330 chr9 17554647 G A 2.80E-05 Urinary metabolites / / 21572414 rs2208486 chr9 17599369 A T 2.30E-04 Body mass index SH3GL2 intron 21701565 rs3808770 chr9 17600136 A G 4.88E-04 Multiple complex diseases SH3GL2 intron 17554300 rs1543479 chr9 17604934 T C 6.51E-04 Tourette syndrome SH3GL2 intron 22889924 rs1555422 chr9 17621965 A C 9.20E-05 Creatinine levels SH3GL2 intron pha003069 rs2224447 chr9 17624700 C G 2.40E-05 Urinary metabolites SH3GL2 intron 21572414 rs3808747 chr9 17626616 C T 4.19E-04 Iron levels SH3GL2 intron pha002876 rs4504735 chr9 17630500 C T 1.62E-04 Depression (quantitative trait) SH3GL2 intron 20800221 rs10963171 chr9 17636427 G A 4.02E-04 Multiple complex diseases SH3GL2 intron 17554300 rs3808700 chr9 17697976 G A 7.11E-04 Multiple complex diseases SH3GL2 intron 17554300 rs16935921 chr9 17711155 A C 1.18E-04 Multiple complex diseases SH3GL2 intron 17554300 rs1536076 chr9 17731921 T G 5.00E-07 Parkinson's disease SH3GL2 intron 22451204 rs720269 chr9 17739210 T A 1.50E-05 Urinary metabolites SH3GL2 intron 21572414 rs10491540 chr9 17760097 G A 5.87E-04 Response to cytadine analogues (cytosine arabinoside) SH3GL2 intron 24483146 rs1886589 chr9 17761379 C T 5.13E-06 Leprosy SH3GL2 intron 22019778 rs3808669 chr9 17776205 T A 1.70E-05 Urinary metabolites SH3GL2 intron 21572414 rs9407866 chr9 17779087 A G 1.60E-05 Urinary metabolites SH3GL2 intron 21572414 rs17454653 chr9 17779595 G C 9.90E-06 Urinary metabolites SH3GL2 intron 21572414 rs61551917 chr9 17792927 C T 4.05E-05 Intracerebral hemorrhage SH3GL2 intron 24656865 rs73645334 chr9 17793759 G A 4.07E-05 Intracerebral hemorrhage SH3GL2 intron 24656865 rs12378332 chr9 17796377 G C 6.70E-04 Response to cytadine analogues (cytosine arabinoside) SH3GL2 UTR-3 24483146 rs12000241 chr9 17807508 T C 9.61E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6475175 chr9 17829896 A G 3.84E-05 Intracerebral hemorrhage / / 24656865 rs10963299 chr9 17833057 C T 4.90E-05 Intracerebral hemorrhage / / 24656865 rs4415417 chr9 17837858 A G 1.07E-04 Multiple complex diseases / / 17554300 rs10756918 chr9 17843275 A G 5.67E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17184207 chr9 17856829 C T 5.11E-05 Aortic root size / / 21223598 rs16936038 chr9 17858905 T G 3.47E-04 Multiple complex diseases / / 17554300 rs12347147 chr9 17859223 T C 9.66E-05 Multiple complex diseases / / 17554300 rs7035861 chr9 17869637 T G 1.69E-05 Cognitive performance / / 19734545 rs10511639 chr9 17870918 C T 1.65E-05 Cognitive performance / / 19734545 rs10511639 chr9 17870918 C T 6.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4335230 chr9 17878879 T C 1.79E-05 Cognitive performance / / 19734545 rs10963315 chr9 17880109 G A 1.30E-05 Cognitive performance / / 19734545 rs10810865 chr9 17895105 T C 4.00E-06 Cognitive performance / / 19734545 rs1977882 chr9 17899606 C A,G,T 8.00E-06 Cognitive performance / / 19734545 rs1977882 chr9 17899606 C A,G,T 4.24E-05 F-cell distribution / / 21326311 rs1977882 chr9 17899606 C A,G,T 8.00E-06 Cognitive performance / / 19734545 rs10810866 chr9 17902936 T C 7.83E-06 Cognitive performance / / 19734545 rs1343844 chr9 17907828 A T 3.62E-06 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines / / 21483694 rs12347619 chr9 17910983 T C 7.29E-05 Post-operative nausea and vomiting / / 21694509 rs4129864 chr9 17915215 G C 9.40E-07 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines / / 21483694 rs1755289 chr9 17938351 T C 3.00E-06 Multiple sclerosis / / 19010793 rs1755289 chr9 17938351 T C 9.84E-06 Leprosy / / pha002872 rs1755279 chr9 17942415 T C 2.50E-05 Type 2 diabetes / / 17463246 rs2026766 chr9 17956000 A C 3.92E-06 Obesity-related traits / / 23251661 rs1620986 chr9 17961642 C A 2.70E-06 Obesity-related traits / / 23251661 rs2772686 chr9 17963004 G A 2.76E-06 Obesity-related traits / / 23251661 rs1755271 chr9 17979578 T C 2.00E-06 Obesity-related traits / / 23251661 rs10963391 chr9 18002205 T C 4.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs10511650 chr9 18005255 C T 4.98E-04 Alzheimer's disease / / 22005930 rs953923 chr9 18010619 G A 6.82E-04 Aortic root size / / 21223598 rs10810888 chr9 18023977 A G 3.61E-04 Smoking cessation / / 24665060 rs1284013 chr9 18040586 G C 5.24E-05 Aortic root size / / 21223598 rs1411242 chr9 18056415 T C 8.71E-05 Blood Pressure / / pha002903 rs6475196 chr9 18061140 A C 4.82E-04 Smoking cessation / / 24665060 rs7860016 chr9 18071787 G A 5.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs878951 chr9 18102007 C T 8.56E-05 Cognitive impairment induced by topiramate / / 22091778 rs12353178 chr9 18109156 A C 2.63E-05 Tardive dyskinesia / / 20939080 rs2210327 chr9 18109235 A T 7.00E-07 Heart failure / / 20445134 rs7025435 chr9 18117103 A T 3.99E-05 Sarcoidosis / / 19165924 rs1970064 chr9 18122017 A G 8.19E-05 Cognitive test performance / / 20125193 rs579392 chr9 18125966 C T 0.00065 Breast cancer / / 23555315 rs10810904 chr9 18127068 A G 6.29E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs4364725 chr9 18128201 T C 3.31E-04 Multiple complex diseases / / 17554300 rs4322098 chr9 18128281 A T 2.64E-04 Multiple complex diseases / / 17554300 rs10963462 chr9 18130036 G T 0.0000118 Alcohol dependence / / 23089632 rs10963462 chr9 18130036 G T 6.22E-06 Alcohol dependence / / 23089632 rs763976 chr9 18134914 A C 0.0000074 Alcohol dependence / / 23089632 rs763976 chr9 18134914 A C 0.00001 Alcohol dependence / / 23089632 rs983230 chr9 18140836 G T 4.62E-05 Multiple complex diseases / / 17554300 rs1360414 chr9 18163591 G C 1.60E-06 Lipid traits / / 21777205 rs12006002 chr9 18166899 C T 0.000000487 Alcohol dependence / / 23089632 rs12006002 chr9 18166899 C T 7.24E-06 Alcohol dependence / / 23089632 rs34236855 chr9 18178314 G A 9.49E-06 Alcohol dependence (age at onset) / / 24962325 rs2187455 chr9 18193796 G A 5.71E-05 Bone mineral density / / 19181680 rs1944766 chr9 18215280 C A 2.90E-06 Subcutaneous adipose tissue volume in HIV-infected men / / 21897333 rs1944751 chr9 18224772 A G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10963534 chr9 18243696 C A 3.90E-06 Urinary metabolites / / 21572414 rs10810935 chr9 18251855 A G 2.00E-06 Alcohol dependence (age at onset) / / 24962325 rs7862758 chr9 18267846 G A 1.30E-05 Urinary metabolites / / 21572414 rs7862683 chr9 18267947 C G 4.90E-05 Longevity and age-related phenotypes / / 17903295 rs13289416 chr9 18270885 T G 9.50E-06 Urinary metabolites / / 21572414 rs13288253 chr9 18270920 A G 4.50E-06 Urinary metabolites / / 21572414 rs12353343 chr9 18285249 A G 8.69E-06 Stroke (ischemic) / / 22941190 rs16936539 chr9 18292079 G T 4.36E-04 Multiple complex diseases / / 17554300 rs10511641 chr9 18292118 G A 2.50E-05 Urinary metabolites / / 21572414 rs10963561 chr9 18300883 A G 1.90E-04 Major depressive disorder / / 21042317 rs12235198 chr9 18303984 G A 2.18E-04 Bipolar disorder / / 18317468 rs10963578 chr9 18338649 G A 0.000000068 Myopia (Age of onset) / / 23468642 rs1340048 chr9 18348408 T A,C,G 8.05E-05 Attention deficit hyperactivity disorder / / 23728934 rs10511652 chr9 18362865 A G 5.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10120545 chr9 18386757 C T 4.56E-04 Alcohol dependence / / 21314694 rs1329726 chr9 18430742 A C 1.52E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs6475216 chr9 18444138 C T 9.00E-06 Obesity-related traits / / 23251661 rs1340043 chr9 18458068 T C 9.00E-06 Obesity-related traits / / 23251661 rs3898100 chr9 18468875 C T 3.00E-04 Insulin resistance / / 21901158 rs1281351 chr9 18476171 C A 3.65E-04 Multiple complex diseases ADAMTSL1 intron 17554300 rs7868026 chr9 18527580 A G 9.30E-04 Multiple complex diseases ADAMTSL1 intron 17554300 rs1341058 chr9 18530188 T A 1.91E-04 Coronary Artery Disease ADAMTSL1 intron 17634449 rs6475226 chr9 18531480 T C 7.66E-04 Multiple complex diseases ADAMTSL1 intron 17554300 rs7863071 chr9 18531748 C T 0.00010002 Hypertension (early onset hypertension) ADAMTSL1 intron 22479346 rs6475227 chr9 18538877 G T 0.000064695 Hypertension (early onset hypertension) ADAMTSL1 intron 22479346 rs10756968 chr9 18540841 G A 6.00E-04 Multiple complex diseases ADAMTSL1 intron 17554300 rs7042143 chr9 18545079 G A 7.20E-04 Multiple complex diseases ADAMTSL1 intron 17554300 rs10963642 chr9 18569449 C T 6.10E-05 Coronary Artery Disease ADAMTSL1 intron 17634449 rs10756976 chr9 18574806 A C 2.20E-04 Response to antidepressants ADAMTSL1 intron 19736353 rs1891042 chr9 18575425 A C 9.45E-06 Cognitive impairment induced by topiramate ADAMTSL1 intron 22091778 rs10119114 chr9 18576556 T G 4.85E-06 Cognitive impairment induced by topiramate ADAMTSL1 intron 22091778 rs949682 chr9 18595548 T G 1.10E-04 Multiple complex diseases ADAMTSL1 intron 17554300 rs10963662 chr9 18601139 A C 2.69E-04 Alcohol dependence ADAMTSL1 intron 20201924 rs1539000 chr9 18602403 T C 0.0002 Migraine ADAMTSL1 intron 22678113 rs10963676 chr9 18622043 T G 1.13E-08 Parkinson's disease ADAMTSL1 intron 17052657 rs17229989 chr9 18636986 G A 6.61E-04 Alzheimer's disease ADAMTSL1 intron 24755620 rs702205 chr9 18638211 C G 9.99E-04 Alzheimer's disease ADAMTSL1 intron 24755620 rs702207 chr9 18639484 C T 1.38E-04 Multiple complex diseases ADAMTSL1 intron 17554300 rs11795307 chr9 18640431 T C 6.19E-04 Alzheimer's disease ADAMTSL1 intron 24755620 rs7863100 chr9 18640590 T C 9.15E-04 Multiple complex diseases ADAMTSL1 intron 17554300 rs7863100 chr9 18640590 T C 6.43E-04 Coronary Artery Disease ADAMTSL1 intron 17634449 rs776778 chr9 18657019 G A 2.00E-04 Cognitive impairment induced by topiramate ADAMTSL1 intron 22091778 rs776778 chr9 18657019 G A 4.64E-05 Cognitive impairment induced by topiramate ADAMTSL1 intron 22091778 rs776778 chr9 18657019 G A 5.15E-04 Alzheimer's disease ADAMTSL1 intron 24755620 rs776776 chr9 18657558 A G 2.00E-06 Amyotrophic lateral sclerosis (sporadic) ADAMTSL1 intron 24529757 rs776764 chr9 18676163 A G 8.40E-05 ldl cholesterol ADAMTSL1 intron pha003076 rs10963718 chr9 18679376 G A 8.70E-07 Urinary metabolites ADAMTSL1 intron 21572414 rs1412672 chr9 18680679 C G 6.30E-07 Urinary metabolites ADAMTSL1 intron 21572414 rs2779127 chr9 18682352 A C 6.30E-07 Urinary metabolites ADAMTSL1 intron 21572414 rs4977338 chr9 18718086 G T 0.00000196 Migraine ADAMTSL1 intron 22678113 rs4977338 chr9 18718086 G T 1.96E-06 Migraine ADAMTSL1 intron 22683712 rs10963742 chr9 18742684 A T 9.78E-05 Multiple complex diseases ADAMTSL1 intron 17554300 rs6475242 chr9 18747761 A G 7.50E-04 Alzheimer's disease ADAMTSL1 intron 22005930 rs7021767 chr9 18748247 G T 8.51E-04 Alzheimer's disease ADAMTSL1 intron 22005930 rs563006 chr9 18750076 C T 0.000608372 Hypertension (early onset hypertension) ADAMTSL1 intron 22479346 rs1332702 chr9 18750329 A C 5.86E-04 Alzheimer's disease ADAMTSL1 intron 22005930 rs1332703 chr9 18750420 T G 3.03E-04 Alzheimer's disease ADAMTSL1 intron 22005930 rs7043157 chr9 18751638 G A 4.23E-04 Alzheimer's disease ADAMTSL1 intron 22005930 rs12554232 chr9 18752235 A C 3.83E-04 Alzheimer's disease ADAMTSL1 intron 22005930 rs2164000 chr9 18758205 T C 4.45E-04 Lung function (forced expiratory volume in 1 second) ADAMTSL1 intron 17255346 rs2164000 chr9 18758205 T C 2.34E-05 Type 2 diabetes ADAMTSL1 intron 17846125 rs1978746 chr9 18761099 A C 8.00E-06 QT interval (interaction) ADAMTSL1 intron 23459443 rs10963750 chr9 18769138 T A 3.41E-04 Cognitive decline ADAMTSL1 intron 23732972 rs7869627 chr9 18772370 T C 9.14E-05 Blood Pressure ADAMTSL1 intron pha003043 rs1549986 chr9 18776840 A C 2.00E-05 Major depressive disorder ADAMTSL1 cds-synon 21042317 rs1549986 chr9 18776840 A C 1.23E-05 Relative hand skill ADAMTSL1 cds-synon 24068947 rs2289006 chr9 18778319 C A 4.88E-06 Hypertension ADAMTSL1 intron 21082022 rs11791705 chr9 18778723 T A 3.20E-05 Telomere length ADAMTSL1 intron 20139977 rs16937066 chr9 18783332 C T 9.70E-04 Multiple complex diseases ADAMTSL1 intron 17554300 rs715212 chr9 18786181 A C 6.89E-04 Suicide attempts in bipolar disorder ADAMTSL1 intron 21423239 rs7034696 chr9 18804130 C T 2.20E-08 Glaucoma ADAMTSL1 intron 21532571 rs4977446 chr9 18806927 G T 7.60E-04 Multiple complex diseases ADAMTSL1 intron 17554300 rs4977447 chr9 18806999 A G 5.23E-05 Attention deficit hyperactivity disorder ADAMTSL1 intron 22420046 rs10963779 chr9 18811047 G A 7.43E-04 Suicide attempts in bipolar disorder ADAMTSL1 intron 21423239 rs13302488 chr9 18811169 G A 8.01E-04 Suicide attempts in bipolar disorder ADAMTSL1 intron 21423239 rs10122993 chr9 18811343 C A 7.08E-04 Suicide attempts in bipolar disorder ADAMTSL1 intron 21423239 rs1594806 chr9 18813869 G C 8.59E-04 Alzheimer's disease ADAMTSL1 intron 22005930 rs10156461 chr9 18818890 C T 3.59E-04 Body mass index ADAMTSL1 intron 21701565 rs10963786 chr9 18826610 G A 4.72E-04 Multiple complex diseases ADAMTSL1 intron 17554300 rs2077707 chr9 18827221 A C 6.58E-04 Alzheimer's disease ADAMTSL1 intron 22005930 rs7039188 chr9 18833014 A G 5.11E-04 Multiple complex diseases ADAMTSL1 intron 17554300 rs11791292 chr9 18853327 T G 4.70E-04 Suicide attempts in bipolar disorder ADAMTSL1 intron 21423239 rs1433830 chr9 18868647 T C 1.38E-04 Myocardial Infarction ADAMTSL1 intron pha002883 rs10756997 chr9 18915953 A G 2.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12345835 chr9 18916311 A C 2.34E-06 Odorant perception / / 23910658 rs2182729 chr9 18917347 C T 3.79E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10811063 chr9 18921386 T G 5.45E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs945442 chr9 18927768 C A 2.24E-05 Osteoarthritis (knee and hip) / / 21177295 rs945442 chr9 18927768 C A 8.61E-06 Osteoarthritis (knee and hip) / / 21177295 rs945442 chr9 18927768 C A 1.58E-06 Osteoarthritis / / 22763110 rs150639454 chr9 18928963 G A 0.00000027 Breast cancer(er negative) FAM154A missense 23555315 rs1571228 chr9 18930222 G A 2.00E-07 Non-small cell lung cancer FAM154A intron 23144319 rs4977469 chr9 18930880 T G 1.22E-06 Osteoarthritis (knee and hip) FAM154A intron 21177295 rs4977469 chr9 18930880 T G 3.90E-05 Osteoarthritis (knee and hip) FAM154A intron 21177295 rs6475273 chr9 18950787 G A 8.81E-04 Multiple complex diseases FAM154A missense 17554300 rs7857590 chr9 18989893 T A 8.08E-06 Bone mass and geometry FAM154A intron 17903296 rs7030400 chr9 19014645 C A 6.80E-05 Alcoholism (heaviness of drinking) FAM154A intron 21529783 rs10121144 chr9 19022648 G A 5.00E-07 Parkinson's disease (interaction with coffee consumption) FAM154A intron 21876681 rs10963922 chr9 19033058 C A 8.43E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) FAM154A UTR-5 23648065 rs7875404 chr9 19087154 T C 8.04E-04 Multiple complex diseases HAUS6 cds-synon 17554300 rs12554335 chr9 19108827 G A 6.03E-05 Body Fat Distribution / / pha003017 rs10811128 chr9 19152044 G T 5.29E-04 Multiple complex diseases / / 17554300 rs10811130 chr9 19161145 G C 7.28E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2503349 chr9 19163207 C T 7.30E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs141215807 chr9 19213634 C T 9.00E-06 Metabolite levels (HVA) / / 23319000 rs3802333 chr9 19232135 T C 3.05E-05 Body mass index / / 17255346 rs4977291 chr9 19234830 T G 1.24E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs1854551 chr9 19235270 G A 4.19E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs16937415 chr9 19236489 G A 2.65E-05 Cognitive performance / / 19734545 rs4977517 chr9 19239168 G A 1.70E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs7027485 chr9 19244788 A C 4.98E-04 Parkinson's disease / / 17052657 rs7043344 chr9 19253435 C T 9.07E-05 Body mass index / / 17255346 rs7043344 chr9 19253435 C T 1.63E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10757048 chr9 19281099 G A 6.23E-05 Body mass index / / 17255346 rs41269019 chr9 19290794 A C 0.00073 Prostate cancer DENND4C missense 23555315 rs2772401 chr9 19322931 G A 4.33E-05 Body mass index DENND4C intron 17255346 rs17818670 chr9 19331571 G A 7.07E-04 Multiple complex diseases DENND4C intron 17554300 rs7866416 chr9 19340521 A G 5.25E-04 Smoking quantity DENND4C intron 24665060 rs1129101 chr9 19372990 G A 4.52E-05 Body mass index DENND4C UTR-3 17255346 rs6475326 chr9 19386565 T C 2.16E-04 Body mass index / / 17255346 rs7048650 chr9 19397040 G A 8.50E-04 Parkinson's disease / / 17052657 rs7048650 chr9 19397040 G A 6.73E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10757054 chr9 19402041 G A 7.80E-04 Iris characteristics / / 21835309 rs10757060 chr9 19446853 T C 9.67E-05 Non-alcoholic fatty liver disease histology (other) ACER2 intron 20708005 rs10757060 chr9 19446853 T C 4.02E-05 Glucose levels ACER2 intron pha003058 rs2383096 chr9 19448473 A G 7.77E-05 Gallstones ACER2 intron 17632509 rs960908 chr9 19458939 C T 6.50E-05 Crohn's disease / / 20570966 rs12349140 chr9 19461193 G T 9.01E-05 Blood Pressure LOC392288 missense pha003044 rs1011131 chr9 19484460 C G 2.47E-05 Schizophrenia / / 20832056 rs7858547 chr9 19484869 T C 5.33E-05 Schizophrenia / / 20832056 rs10491556 chr9 19527424 G C 9.15E-05 Schizophrenia SLC24A2 intron 19571809 rs3780218 chr9 19531262 C T 9.54E-05 Body Mass Index SLC24A2 intron pha003006 rs3780218 chr9 19531262 C T 5.36E-05 Waist Circumference SLC24A2 intron pha003024 rs3780218 chr9 19531262 C T 3.37E-06 Weight SLC24A2 intron pha003026 rs7036288 chr9 19570458 A C 9.25E-04 Multiple complex diseases SLC24A2 intron 17554300 rs3780215 chr9 19579427 G A 7.00E-06 Body mass index (asthmatics) SLC24A2 intron 23517042 rs7861864 chr9 19589481 C T 4.65E-04 Type 2 diabetes SLC24A2 intron 17463246 rs2180939 chr9 19606810 G A 2.84E-05 Weight SLC24A2 intron pha003026 rs10964236 chr9 19608329 A G 8.57E-05 Weight SLC24A2 intron pha003026 rs2208552 chr9 19614952 T C 2.79E-04 Multiple complex diseases SLC24A2 intron 17554300 rs4977308 chr9 19622268 T C 4.91E-04 Multiple complex diseases SLC24A2 cds-synon 17554300 rs10757082 chr9 19623126 T C 3.56E-04 Multiple complex diseases SLC24A2 intron 17554300 rs16937677 chr9 19642563 G A 0.000083 Migraine SLC24A2 intron 22678113 rs16937677 chr9 19642563 G A 8.30E-05 Migraine SLC24A2 intron 22683712 rs2208554 chr9 19646058 A G 4.67E-05 Parkinson's disease (motor and cognition) SLC24A2 intron 22658654 rs16937678 chr9 19652765 T C 6.56E-04 Amyotrophic Lateral Sclerosis SLC24A2 intron 17827064 rs16937690 chr9 19656396 A G 1.91E-04 Suicide attempts in bipolar disorder SLC24A2 intron 21041247 rs16937690 chr9 19656396 A G 8.58E-04 Suicide attempts in bipolar disorder SLC24A2 intron 21041247 rs766576 chr9 19660406 A G 9.06E-04 Type 2 diabetes SLC24A2 intron 17463246 rs10811225 chr9 19662307 G A 2.91E-05 Cognitive performance SLC24A2 intron 19734545 rs10811225 chr9 19662307 G A 4.66E-04 Suicide attempts in bipolar disorder SLC24A2 intron 21041247 rs4258076 chr9 19664081 G T 4.00E-06 Cognitive performance SLC24A2 intron 19734545 rs4258076 chr9 19664081 G T 2.82E-04 Suicide attempts in bipolar disorder SLC24A2 intron 21041247 rs13300397 chr9 19670094 C T 3.01E-05 Cognitive performance SLC24A2 intron 19734545 rs2383113 chr9 19678269 A C 9.98E-04 Stroke SLC24A2 intron pha002887 rs12555771 chr9 19691013 T C 6.20E-05 Cognitive performance SLC24A2 intron 19734545 rs7862478 chr9 19698751 T C 6.26E-05 Cognitive performance SLC24A2 intron 19734545 rs7028514 chr9 19702068 T C 9.01E-05 Cognitive performance SLC24A2 intron 19734545 rs7869360 chr9 19712170 G A 3.52E-05 F-cell distribution SLC24A2 intron 21326311 rs10757087 chr9 19740788 C T 2.19E-05 Lipoproteins SLC24A2 intron pha003079 rs1182672 chr9 19751357 C T 1.04E-04 Lung function (forced expiratory volume in 1 second) SLC24A2 intron 17255346 rs16937762 chr9 19756086 C T 1.00E-04 Cognitive impairment induced by topiramate SLC24A2 intron 22091778 rs16937762 chr9 19756086 C T 4.82E-05 Cognitive impairment induced by topiramate SLC24A2 intron 22091778 rs1327409 chr9 19771890 T C 3.19E-04 Lung function (forced expiratory volume in 1 second) SLC24A2 intron 17255346 rs10964284 chr9 19781086 C T 1.03E-04 Major depressive disorder SLC24A2 intron 22472876 rs1831083 chr9 19792882 G A 1.30E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs12347532 chr9 19861417 C A 8.07E-05 Body mass (lean) / / 19268274 rs10511673 chr9 19878076 G A 8.56E-05 Alzheimer's disease / / 22832961 rs16937811 chr9 19879349 C T 8.37E-05 Alzheimer's disease / / 22832961 rs7867866 chr9 19879462 G T 8.04E-05 Alzheimer's disease / / 22832961 rs7042180 chr9 19881100 T C 7.09E-05 Alzheimer's disease / / 22832961 rs7026007 chr9 19881169 G A 7.02E-05 Alzheimer's disease / / 22832961 rs7025940 chr9 19881264 C T 6.86E-05 Alzheimer's disease / / 22832961 rs7026253 chr9 19881314 G C 7.02E-05 Alzheimer's disease / / 22832961 rs7026430 chr9 19881623 C T 6.93E-05 Alzheimer's disease / / 22832961 rs12377344 chr9 19881986 C T 4.83E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10511674 chr9 19882251 C T 6.39E-04 Smoking cessation / / 24665060 rs10811278 chr9 19898792 G A 0.000076 Migraine / / 22678113 rs10811278 chr9 19898792 G A 7.60E-05 Migraine / / 22683712 rs1887392 chr9 19910154 G C 5.20E-04 Multiple complex diseases / / 17554300 rs1887392 chr9 19910154 G C 7.98E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7852773 chr9 19919331 T C 3.92E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17832714 chr9 19932591 A C 8.71E-05 Serum metabolites / / 19043545 rs10811293 chr9 19966165 T C 9.51E-05 Serum metabolites / / 19043545 rs12235874 chr9 19971061 T C 4.23E-05 Serum metabolites / / 19043545 rs12057044 chr9 19982455 T C 2.73E-04 Multiple complex diseases / / 17554300 rs12057044 chr9 19982455 T C 7.87E-05 Serum metabolites / / 19043545 rs41404548 chr9 19989584 C T 2.16E-04 Multiple complex diseases / / 17554300 rs1936449 chr9 20004666 G A 8.95E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7849770 chr9 20005448 C T 5.02E-05 Serum metabolites / / 19043545 rs7870665 chr9 20018445 T C 8.93E-04 Coronary heart disease / / 21971053 rs10964389 chr9 20022425 T C 0.0002 Migraine / / 22678113 rs10964390 chr9 20022916 T C 0.0002 Migraine / / 22678113 rs10964392 chr9 20025247 A C 3.99E-04 Alzheimer's disease (late onset) / / 21379329 rs4073871 chr9 20028452 A C 7.80E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4246835 chr9 20033087 A G 8.32E-05 Left ventricular hypertrophy / / pha003052 rs9792484 chr9 20035364 C T 2.67E-05 Serum metabolites / / 19043545 rs12000170 chr9 20058552 G T 1.17E-04 Multiple complex diseases / / 17554300 rs12335706 chr9 20061257 G C 4.11E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs16937883 chr9 20098711 A G 7.00E-06 Asthma (toluene diisocyanate-induced) / / 19187332 rs6475409 chr9 20125259 C T 4.61E-04 Smoking initiation / / 24665060 rs2039461 chr9 20145988 T C 3.50E-05 Alzheimer's disease (late onset) / / 20885792 rs2039461 chr9 20145988 T C 3.50E-05 Alzheimer's disease (late onset) / / 21460841 rs10811323 chr9 20159175 C T 5.61E-05 Serum metabolites / / 19043545 rs1413258 chr9 20176246 A G 4.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4478647 chr9 20176715 G A 5.17E-04 Schizophrenia / / 19197363 rs1889246 chr9 20180680 T C 1.26E-05 Recombination rate / / 21698098 rs2034875 chr9 20219315 G A 6.64E-04 Epilepsy / / 22116939 rs10511678 chr9 20238152 A G 2.25E-04 Type 2 diabetes / / 17846125 rs10811336 chr9 20242344 A C 5.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs10811336 chr9 20242344 A C 1.14E-05 Intracerebral hemorrhage / / 24656865 rs10964495 chr9 20245283 T C 2.20E-05 Urinary metabolites / / 21572414 rs10964496 chr9 20248264 G A 1.63E-05 Intracerebral hemorrhage / / 24656865 rs10811338 chr9 20248945 G A 1.58E-05 Intracerebral hemorrhage / / 24656865 rs1456962 chr9 20250993 G T 5.00E-05 Cognitive impairment induced by topiramate / / 22091778 rs1551534 chr9 20255355 A G 6.46E-04 Alcohol dependence / / 21314694 rs16923521 chr9 20261635 T C 2.20E-05 Urinary metabolites / / 21572414 rs12345147 chr9 20262063 A C 3.94E-06 Intracerebral hemorrhage / / 24656865 rs12342192 chr9 20263142 T C 6.68E-06 Intracerebral hemorrhage / / 24656865 rs12342261 chr9 20263333 T C 5.56E-06 Intracerebral hemorrhage / / 24656865 rs12341270 chr9 20266189 G A 1.69E-05 Intracerebral hemorrhage / / 24656865 rs72699916 chr9 20267021 C T 1.58E-05 Intracerebral hemorrhage / / 24656865 rs10757128 chr9 20267576 G A 1.44E-05 Intracerebral hemorrhage / / 24656865 rs4977408 chr9 20270743 C T 7.49E-04 Type 2 diabetes / / 17463246 rs12005027 chr9 20271277 A G 3.50E-05 Intracerebral hemorrhage / / 24656865 rs13440226 chr9 20272442 T C 3.56E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7041951 chr9 20275354 C G 1.60E-05 Urinary metabolites / / 21572414 rs16937991 chr9 20275640 T C 7.48E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1531206 chr9 20281390 A G 9.11E-05 Serum metabolites / / 19043545 rs1531206 chr9 20281390 A G 4.42E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4977412 chr9 20282412 T G 9.00E-07 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10511679 chr9 20283265 C T 2.22E-05 stroke (ischemic) / / 17434096 rs10811340 chr9 20283406 A G 1.12E-05 Intracerebral hemorrhage / / 24656865 rs10811341 chr9 20284946 T A 6.92E-05 Serum metabolites / / 19043545 rs7874912 chr9 20285497 T A 5.83E-05 Serum metabolites / / 19043545 rs7859498 chr9 20285667 A G 5.29E-05 Serum metabolites / / 19043545 rs7859498 chr9 20285667 A G 9.65E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4977415 chr9 20286082 T C 4.60E-05 Serum metabolites / / 19043545 rs4977415 chr9 20286082 T C 7.81E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6475425 chr9 20286438 A C 2.29E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12353526 chr9 20286678 C T 1.97E-05 Intracerebral hemorrhage / / 24656865 rs717082 chr9 20287282 G A 3.26E-04 Type 2 diabetes / / 17463246 rs7026582 chr9 20287948 T C 3.30E-05 Serum metabolites / / 19043545 rs7026582 chr9 20287948 T C 1.30E-06 Coronary heart disease / / pha003033 rs897703 chr9 20289426 C T 5.72E-04 White matter integrity / / 22425255 rs7021788 chr9 20295863 A G 8.29E-04 White matter integrity / / 22425255 rs7851959 chr9 20308166 G C 1.25E-15 Gallbladder disease / / pha001404 rs2383137 chr9 20317383 G C 7.57E-05 Type 2 diabetes / / 17463246 rs2383137 chr9 20317383 G C 6.27E-04 Multiple complex diseases / / 17554300 rs7048991 chr9 20322932 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs224013 chr9 20323846 G C 6.82E-04 Schizophrenia / / 21674006 rs10964534 chr9 20327754 A G 2.02E-05 Post-operative nausea and vomiting / / 21694509 rs13296370 chr9 20346912 T C 1.29E-04 Celiac disease MLLT3 intron 23936387 rs7870252 chr9 20351075 A G 1.62E-04 Smoking cessation MLLT3 intron 24665060 rs16938058 chr9 20411354 G A 3.85E-05 HIV-1 viral setpoint MLLT3 intron 22174851 rs7041793 chr9 20428137 A G 2.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MLLT3 intron 20877124 rs7041793 chr9 20428137 A G 6.48E-05 HIV-1 viral setpoint MLLT3 intron 22174851 rs6475430 chr9 20430468 T C 9.99E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MLLT3 intron 20877124 rs13299141 chr9 20461775 T C 3.65E-05 Celiac disease MLLT3 intron 23936387 rs6475431 chr9 20464928 A G 4.69E-05 Duodenal ulcer MLLT3 intron 22387998 rs4571814 chr9 20494511 G T 2.63E-04 Multiple complex diseases MLLT3 intron 17554300 rs6475448 chr9 20497142 G A 8.34E-04 Parkinson's disease MLLT3 intron 17052657 rs10811359 chr9 20514400 C T 2.13E-04 Iron levels MLLT3 intron pha002876 rs1537073 chr9 20528546 A G 6.72E-04 Iron levels MLLT3 intron pha002876 rs7037941 chr9 20536297 T G 9.83E-04 Prostate cancer mortality MLLT3 intron 20978177 rs1360378 chr9 20563799 C T 3.41E-04 Type 2 diabetes MLLT3 intron 17463246 rs12380857 chr9 20578041 T C 6.25E-04 Nicotine smoking MLLT3 intron 19268276 rs7867710 chr9 20602188 T C 6.96E-04 Bone mass and geometry MLLT3 intron 17903296 rs2775264 chr9 20603364 C T 8.84E-06 Glaucoma (primary open-angle) MLLT3 intron 22605921 rs7019271 chr9 20648805 A G 3.77E-04 Alzheimer's disease (late onset) / / 21379329 rs2383145 chr9 20649911 A C 3.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17831954 chr9 20666605 C T 9.99E-06 Glaucoma (primary open-angle) KIAA1797 intron 22605921 rs17758909 chr9 20666639 A C 2.71E-04 Smoking initiation KIAA1797 intron 24665060 rs4596728 chr9 20670187 A G 1.93E-04 Smoking initiation KIAA1797 intron 24665060 rs10429585 chr9 20671212 A G 9.36E-04 Suicide attempts in bipolar disorder KIAA1797 intron 21423239 rs12685818 chr9 20675372 T A 7.62E-04 Smoking initiation KIAA1797 intron 24665060 rs12338810 chr9 20683404 A T 4.21E-04 Smoking initiation KIAA1797 intron 24665060 rs3802504 chr9 20684602 T A 4.72E-04 Smoking initiation KIAA1797 intron 24665060 rs10964661 chr9 20690244 C T 7.63E-04 Smoking initiation KIAA1797 intron 24665060 rs7848159 chr9 20696043 G A 2.80E-05 Urinary metabolites KIAA1797 intron 21572414 rs10964665 chr9 20700838 A G 5.46E-05 AIDS progression KIAA1797 intron 19115949 rs4977831 chr9 20713068 A G 1.91E-04 Alzheimer's disease (late onset) KIAA1797 intron 21379329 rs4977831 chr9 20713068 A G 1.85E-05 Alzheimer's disease KIAA1797 intron 24755620 rs2039391 chr9 20714014 C T 7.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KIAA1797 intron 20877124 rs12684948 chr9 20716880 C T 9.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIAA1797 intron 23233662 rs7867470 chr9 20716955 C T 9.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIAA1797 intron 23233662 rs4977898 chr9 20720599 A C 4.14E-04 Alzheimer's disease KIAA1797 intron 24755620 rs4978017 chr9 20739231 G A 2.60E-05 Urinary metabolites KIAA1797 intron 21572414 rs7021708 chr9 20742210 A G 4.72E-04 Multiple complex diseases KIAA1797 intron 17554300 rs4978111 chr9 20755174 A G 1.62E-04 Glycosylated haemoglobin levels KIAA1797 intron 17255346 rs4978111 chr9 20755174 A G 0.000169872 Hypertension (early onset hypertension) KIAA1797 intron 22479346 rs4978111 chr9 20755174 A G 8.91E-04 Heart Failure KIAA1797 intron pha002885 rs7851363 chr9 20758306 T A 5.70E-05 Pulmonary function KIAA1797 intron 17903307 rs16938162 chr9 20763840 T C 2.63E-04 Type 2 diabetes KIAA1797 intron 17463246 rs10511687 chr9 20764870 T C 1.30E-05 Urinary metabolites KIAA1797 missense 21572414 rs7854443 chr9 20773526 C A 0.000203833 Hypertension (early onset hypertension) KIAA1797 intron 22479346 rs10448161 chr9 20775272 C T 0.00018173 Hypertension (early onset hypertension) KIAA1797 intron 22479346 rs4977732 chr9 20793445 T C 7.69E-06 Hypertension (early onset hypertension) KIAA1797 intron 22479346 rs2039389 chr9 20801595 A G 0.000318712 Hypertension (early onset hypertension) KIAA1797 intron 22479346 rs2151003 chr9 20803597 T C 0.000130906 Hypertension (early onset hypertension) KIAA1797 intron 22479346 rs10511683 chr9 20811210 G A 3.65E-04 Heart Failure KIAA1797 intron pha002885 rs10757149 chr9 20831915 A T 1.10E-05 Urinary metabolites KIAA1797 intron 21572414 rs2026994 chr9 20834837 A G 2.60E-05 Urinary metabolites KIAA1797 intron 21572414 rs10757150 chr9 20844196 A T 7.00E-06 Urinary metabolites KIAA1797 intron 21572414 rs76495380 chr9 20844431 C T 2.00E-07 Age-related nuclear cataracts KIAA1797 intron 24951543 rs1986633 chr9 20876259 G A 1.66E-04 Heart Failure KIAA1797 intron pha002885 rs6475483 chr9 20882525 T C 4.70E-05 Temperament (bipolar disorder) KIAA1797 intron 22365631 rs7049134 chr9 20896938 G A 1.60E-05 Temperament (bipolar disorder) KIAA1797 intron 22365631 rs11531714 chr9 20897266 T C 5.08E-05 Hypertension (early onset hypertension) KIAA1797 intron 22479346 rs6475490 chr9 20945207 G C 9.84E-04 Alcohol dependence KIAA1797 intron 21314694 rs4606148 chr9 20951594 C T 8.14E-04 Multiple complex diseases KIAA1797 intron 17554300 rs10757160 chr9 20960170 T C 3.14E-04 Heart Failure KIAA1797 intron pha002885 rs4977881 chr9 20988426 A G 4.52E-04 Multiple complex diseases KIAA1797 missense 17554300 rs4468020 chr9 20996709 T C 2.58E-04 Multiple complex diseases / / 17554300 rs3884620 chr9 21003372 G A 0.00018664 Hypertension (early onset hypertension) / / 22479346 rs1134090 chr9 21006934 A G 8.90E-05 Coronary heart disease PTPLAD2 UTR-3 pha003030 rs2275887 chr9 21017828 G A 2.77E-04 Aortic root size PTPLAD2 intron 21223598 rs2275887 chr9 21017828 G A 0.000821837 Hypertension (early onset hypertension) PTPLAD2 intron 22479346 rs1112165 chr9 21018574 C T 7.84E-04 Multiple complex diseases PTPLAD2 intron 17554300 rs11789272 chr9 21030851 G A 5.42E-05 Alcohol dependence PTPLAD2 intron 21314694 rs10964808 chr9 21033557 A G 1.82E-05 Bipolar disorder and schizophrenia / / 20889312 rs7867456 chr9 21035307 G T 9.00E-06 Axial length / / 24144296 rs12006112 chr9 21042299 T C 3.92E-05 Bipolar disorder and schizophrenia / / 20889312 rs10964817 chr9 21056085 T C 3.79E-05 Serum metabolites / / 19043545 rs1419373 chr9 21057062 T C 5.04E-04 Multiple complex diseases / / 17554300 rs1419373 chr9 21057062 T C 1.40E-05 Urinary metabolites / / 21572414 rs2383176 chr9 21061642 G A 8.37E-05 Prostate cancer / / 22923026 rs1857652 chr9 21064876 C T 8.98E-05 Multiple sclerosis / / 17660530 rs11999657 chr9 21078936 G A 2.51E-09 HDL cholesterol / / 23063622 rs11999657 chr9 21078936 G A 3.60E-14 Cholesterol,total / / 23063622 rs7033217 chr9 21081432 G A 0.00039 Coronary artery calcification / / 23727086 rs10964832 chr9 21095633 T C 6.81E-04 Smoking quantity / / 24665060 rs4977959 chr9 21105154 A G 8.30E-05 Hemoglobin / / pha003096 rs10964842 chr9 21111840 C A 5.64E-05 Aging (time to event) / / 21782286 rs7046606 chr9 21149963 C T 7.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7855438 chr9 21150650 C A 9.73E-04 Depression (quantitative trait) / / 20800221 rs10964862 chr9 21151553 C A 9.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10125010 chr9 21216028 C T 6.01E-05 HIV-1 control / / 20041166 rs10811525 chr9 21288176 G A 5.29E-05 Lymphocyte counts / / 22286170 rs643070 chr9 21368609 T C 2.01E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1224391 chr9 21391698 T C 3.03E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2104880 chr9 21419723 C T 6.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2104880 chr9 21419723 C T 1.04E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6475535 chr9 21450474 G C 1.49E-04 Coronary heart disease / / 21606135 rs10965002 chr9 21455814 C T 2.08E-05 Bipolar disorder / / 21771265 rs1412396 chr9 21468103 T G 7.29E-04 Insulin resistance MIR31HG intron 21901158 rs2383192 chr9 21471726 C T 4.82E-05 Orofacial clefts MIR31HG intron 22419666 rs4246868 chr9 21478318 C T 5.06E-05 Orofacial clefts MIR31HG intron 22419666 rs7849420 chr9 21499624 A C 5.23E-05 Type 2 diabetes MIR31HG intron 17463246 rs7849420 chr9 21499624 A C 3.90E-05 Personality dimensions MIR31HG intron 18957941 rs7849420 chr9 21499624 A C 1.00E-06 Lipid traits MIR31HG intron 24023261 rs1332182 chr9 21507082 G T 2.10E-05 Urinary metabolites MIR31HG intron 21572414 rs720975 chr9 21520274 T C 4.50E-06 Urinary metabolites MIR31HG intron 21572414 rs1576791 chr9 21521258 T G 1.10E-05 Urinary metabolites MIR31HG intron 21572414 rs2209062 chr9 21548213 C T 2.00E-05 Urinary metabolites MIR31HG intron 21572414 rs10757225 chr9 21555445 G T 7.27E-05 Orofacial clefts MIR31HG intron 22419666 rs4141712 chr9 21557406 A C 9.67E-05 Non-alcoholic fatty liver disease histology (other) MIR31HG intron 20708005 rs7033598 chr9 21565674 C T 1.35E-04 Celiac disease / / 23936387 rs7865428 chr9 21566730 G A 6.85E-04 Parkinson's disease / / 17052657 rs7026552 chr9 21581712 G T 8.02E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs970987 chr9 21585265 C A 3.48E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs2123340 chr9 21589041 G A 2.95E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs12002727 chr9 21596183 G C 2.34E-04 Obesity (extreme) / / 21935397 rs10965079 chr9 21604969 A G 3.30E-04 Obesity (extreme) / / 21935397 rs61302418 chr9 21610679 C A 1.28E-39 Metabolite levels / / 22286219 rs2035205 chr9 21661236 G A 7.15E-06 Body Mass Index / / pha003014 rs4512473 chr9 21663040 G A 3.17E-05 Body Mass Index / / pha003014 rs10119076 chr9 21665604 C A 1.11E-05 Body Mass Index / / pha003014 rs2039585 chr9 21675373 A C 9.34E-04 Myopia (pathological) / / 21095009 rs1377195 chr9 21675545 A G 4.59E-04 Lung function (forced vital capacity) / / 24023788 rs2383200 chr9 21677459 T C 3.19E-04 Myopia (pathological) / / 21095009 rs7866337 chr9 21679452 G A 6.94E-05 Recombination rate / / 21698098 rs10965099 chr9 21682759 A G 1.76E-04 Myopia (pathological) / / 21095009 rs7860632 chr9 21683289 C A 4.53E-04 Myopia (pathological) / / 21095009 rs1377197 chr9 21683805 T C 1.86E-04 Stroke / / pha002887 rs2383201 chr9 21684063 A G 4.50E-04 Myopia (pathological) / / 21095009 rs2197008 chr9 21685404 G A 7.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10811582 chr9 21692017 G A 9.86E-06 Melanoma / / 21926416 rs1889680 chr9 21695460 T C 2.13E-04 Coronary heart disease / / 21606135 rs12380505 chr9 21695893 A G 9.41E-07 Melanoma / / 21926416 rs1452658 chr9 21700795 G A 2.42E-04 Coronary heart disease / / 21606135 rs1452658 chr9 21700795 G A 1.15E-06 Melanoma / / 21926416 rs10811584 chr9 21701005 T G 3.07E-04 Coronary heart disease / / 21606135 rs7848524 chr9 21701432 T C 7.25E-05 Coronary heart disease / / 21606135 rs7848524 chr9 21701432 T C 6.84E-07 Melanoma / / 21926416 rs6475552 chr9 21701674 G A 4.65E-04 Coronary heart disease / / 21606135 rs6475552 chr9 21701674 G A 8.41E-07 Melanoma / / 21926416 rs1987458 chr9 21704873 T C 7.11E-05 Melanoma / / 21926416 rs896655 chr9 21706571 A G 8.25E-05 Melanoma / / 21926416 rs751173 chr9 21707372 C T 5.60E-06 Melanoma / / 21706340 rs2383202 chr9 21710215 C T 8.70E-07 Melanoma / / 21926416 rs1335500 chr9 21711675 G A 1.04E-06 Melanoma / / 21926416 rs10811595 chr9 21715801 T G 7.40E-07 Cutaneous nevi / / 19578365 rs10757236 chr9 21715890 G C 7.40E-07 Cutaneous nevi / / 19578365 rs6475555 chr9 21716997 A G 8.00E-07 Cutaneous nevi / / 19578365 rs6475567 chr9 21733644 T A 1.50E-05 Urinary metabolites / / 21572414 rs1345026 chr9 21745756 T C 2.56E-05 Melanoma / / 21926416 rs4636294 chr9 21747803 A C,G,T 3.00E-15 Cutaneous nevi / / 19578365 rs4636294 chr9 21747803 A C,G,T 3.70E-08 Melanoma / / 21706340 rs17833407 chr9 21748320 A G 3.02E-06 Schizophrenia / / 19571809 rs4375086 chr9 21748332 T C 2.90E-06 Urinary metabolites / / 21572414 rs1414243 chr9 21748433 C G 6.82E-04 Multiple complex diseases / / 17554300 rs1414243 chr9 21748433 C G 1.18E-04 Cognitive decline / / 23732972 rs4543632 chr9 21748618 T G 2.50E-06 Urinary metabolites / / 21572414 rs2165409 chr9 21748962 G A 2.41E-04 Cognitive decline / / 23732972 rs1561650 chr9 21752358 A G 7.38E-05 Melanoma / / 21926416 rs1335509 chr9 21753138 G A 3.06E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2218220 chr9 21756089 C T 4.80E-08 Melanoma / / 21706340 rs7846904 chr9 21757432 C T 2.90E-06 Urinary metabolites / / 21572414 rs1335510 chr9 21757803 T G 1.10E-07 Melanoma / / 21706340 rs7866787 chr9 21760639 A G 9.61E-05 Melanoma / / 21926416 rs7866533 chr9 21767404 G A 2.90E-06 Urinary metabolites / / 21572414 rs10121899 chr9 21770951 T C 3.15E-05 Melanoma / / 21926416 rs1341866 chr9 21771241 T C 6.90E-07 Melanoma / / 21706340 rs1341866 chr9 21771241 T C 2.58E-05 Melanoma / / 21926416 rs6475579 chr9 21771756 A G 8.06E-05 Melanoma / / 21926416 rs10757253 chr9 21772267 T C 9.54E-05 Melanoma / / 21926416 rs9886831 chr9 21773167 C G 7.65E-05 Melanoma / / 21926416 rs10811612 chr9 21774167 C G 1.40E-06 Urinary metabolites / / 21572414 rs10757254 chr9 21775061 A G 9.66E-05 Melanoma / / 21926416 rs7021012 chr9 21775957 G A 8.30E-05 Melanoma / / 21926416 rs1440993 chr9 21778660 G A 9.16E-05 Melanoma / / 21926416 rs10811615 chr9 21782164 G A 9.55E-05 Melanoma / / 21926416 rs7863942 chr9 21784758 A T 2.14E-05 Melanoma / / 21926416 rs1345024 chr9 21785018 C T 2.63E-05 Melanoma / / 21926416 rs1345023 chr9 21785139 T A 2.56E-05 Melanoma / / 21926416 rs7049092 chr9 21787262 C T 1.85E-05 Melanoma / / 21926416 rs7038708 chr9 21788081 T G 8.68E-05 Melanoma / / 21926416 rs7022754 chr9 21788481 A G 2.36E-05 Melanoma / / 21926416 rs7022856 chr9 21788523 A G 9.71E-05 Melanoma / / 21926416 rs10965133 chr9 21788656 C T 2.25E-05 Melanoma / / 21926416 rs10965134 chr9 21788782 G A 1.86E-05 Melanoma / / 21926416 rs6475581 chr9 21788877 T C 1.30E-05 Urinary metabolites / / 21572414 rs10965135 chr9 21789580 C T 7.40E-07 Cutaneous nevi / / 19578365 rs10811617 chr9 21790067 A G 7.53E-05 Melanoma / / 21926416 rs10811618 chr9 21790142 G C 8.69E-05 Melanoma / / 21926416 rs1542075 chr9 21790669 C G 4.63E-05 Melanoma / / 21926416 rs12344842 chr9 21793177 T G 4.06E-05 Melanoma / / 21926416 rs10119693 chr9 21796791 G A 8.25E-06 Melanoma / / 21926416 rs7033503 chr9 21799598 T C 5.50E-07 Melanoma / / 21926416 rs2165408 chr9 21802469 A G 4.35E-05 Melanoma MTAP nearGene-5 21926416 rs871024 chr9 21803880 C A 6.00E-04 Chronic fatigue syndrome MTAP intron 21912186 rs869329 chr9 21804693 A G 3.89E-05 Melanoma MTAP intron 21926416 rs10757257 chr9 21806564 G A 3.10E-08 Melanoma MTAP intron 21706340 rs10757257 chr9 21806564 G A 1.65E-05 Melanoma MTAP intron 21926416 rs10757257 chr9 21806564 G A 3.90E-05 Melanoma MTAP intron 24980573 rs10217379 chr9 21807994 A G 6.30E-06 Urinary metabolites MTAP intron 21572414 rs10965144 chr9 21808913 C T 1.10E-07 Cutaneous nevi MTAP intron 19578365 rs10965144 chr9 21808913 C T 4.46E-05 Melanoma MTAP intron 21926416 rs10965145 chr9 21809077 T A 2.21E-05 Melanoma MTAP intron 21926416 rs12004745 chr9 21812349 T A 6.13E-04 Aortic root size MTAP intron 21223598 rs10811624 chr9 21812720 C T 2.10E-06 Urinary metabolites MTAP intron 21572414 rs10811624 chr9 21812720 C T 5.08E-05 Glaucoma (primary open-angle) MTAP intron 22605921 rs72691561 chr9 21813241 T C 8.27E-05 Melanoma MTAP intron 21926416 rs72691563 chr9 21813495 C T 2.53E-05 Melanoma MTAP intron 21926416 rs72691564 chr9 21813518 C T 7.15E-05 Melanoma MTAP intron 21926416 rs58377678 chr9 21813718 C T 1.08E-05 Melanoma MTAP intron 21926416 rs7023329 chr9 21816528 A G 4.00E-07 Melanoma MTAP intron 19578364 rs7023329 chr9 21816528 A G 4.00E-07 Nasopharyngeal carcinoma MTAP intron 20512145 rs7023329 chr9 21816528 A G 2.70E-07 Melanoma MTAP intron 21706340 rs7023329 chr9 21816528 A G 1.64E-05 Melanoma MTAP intron 21926416 rs7023329 chr9 21816528 A G 7.00E-09 Melanoma MTAP intron 21983787 rs7023329 chr9 21816528 A G 2.30E-05 Melanoma MTAP intron 24980573 rs10114559 chr9 21816637 T C 1.35E-05 Melanoma MTAP intron 21926416 rs7023474 chr9 21816646 A G 8.87E-05 Melanoma MTAP intron 21926416 rs7023954 chr9 21816758 G A 4.90E-07 Cutaneous nevi MTAP missense 19578365 rs7023954 chr9 21816758 G A 1.28E-05 Melanoma MTAP missense 21926416 rs7027989 chr9 21817754 A G 4.00E-07 Cutaneous nevi MTAP intron 19578365 rs4615669 chr9 21818674 A G 2.22E-05 Melanoma MTAP intron 21926416 rs10121449 chr9 21826516 A G 1.43E-05 Melanoma MTAP intron 21926416 rs10811625 chr9 21826840 G A 6.00E-07 Cutaneous nevi MTAP intron 19578365 rs10811626 chr9 21826940 G T 1.45E-05 Melanoma MTAP intron 21926416 rs3922992 chr9 21827406 A G 6.00E-07 Cutaneous nevi MTAP intron 19578365 rs3922992 chr9 21827406 A G 1.82E-05 Melanoma MTAP intron 21926416 rs3927737 chr9 21827992 G A 6.10E-07 Cutaneous nevi MTAP intron 19578365 rs3900787 chr9 21828110 A C 5.50E-07 Cutaneous nevi MTAP intron 19578365 rs3900787 chr9 21828110 A C 1.11E-05 Melanoma MTAP intron 21926416 rs3927738 chr9 21828242 T C 3.28E-05 Melanoma MTAP intron 21926416 rs10811629 chr9 21840298 A G 1.60E-05 Melanoma MTAP intron 21706340 rs7851133 chr9 21846327 C T 1.24E-07 Esophageal cancer (squamous cell) MTAP intron 22960999 rs10965163 chr9 21854740 C T 4.30E-05 Monocyte counts MTAP cds-synon pha003089 rs3935920 chr9 21855687 G A 1.52E-05 Monocyte counts MTAP intron pha003089 rs4607709 chr9 21881338 T C 4.76E-06 Cognitive impairment induced by topiramate / / 22091778 rs10757260 chr9 21953137 G A 2.00E-04 Information processing speed / / 21130836 rs75220302 chr9 21958279 T C 0.0000218 Menopause (age at onset) / / 23424626 rs717326 chr9 21958524 T C 5.64E-04 Multiple complex diseases / / 17554300 rs3731245 chr9 21972445 C T 0.0000218 Menopause (age at onset) CDKN2A intron 23424626 rs3731239 chr9 21974218 A G 2.26E-06 Glaucoma CDKN2A intron 21532571 rs3731239 chr9 21974218 A G 2.12E-06 Coronary artery calcification CDKN2A intron 22144573 rs3731239 chr9 21974218 A G 2.44E-05 Glaucoma (primary open-angle) CDKN2A intron 22419738 rs36228836 chr9 21975141 A T 0.0000218 Menopause (age at onset) CDKN2A intron 23424626 rs3731236 chr9 21976976 G A 5.25E-13 LDL cholesterol CDKN2A intron 23063622 rs2811709 chr9 21980151 A G 3.11E-05 Basophils CDKN2A intron pha003087 rs3731217 chr9 21984661 A C 2.00E-08 Acute lymphoblastic leukemia (B-cell precursor) CDKN2A intron 23996088 rs3731215 chr9 21985771 A G 0.00000174 Triglycerides CDKN2A intron 23063622 rs3731215 chr9 21985771 A G 1.10E-12 Cholesterol,total CDKN2A intron 23063622 rs3731215 chr9 21985771 A G 3.48E-09 HDL cholesterol CDKN2A intron 23063622 rs3731215 chr9 21985771 A G 9.80E-10 LDL cholesterol CDKN2A intron 23063622 rs3731211 chr9 21986847 T A 6.00E-14 Platelet counts CDKN2A intron 22139419 rs3731199 chr9 21989330 T C 2.98E-15 HDL cholesterol CDKN2A intron 23063622 rs2518723 chr9 21995882 C T 0.00000565 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs61271866 chr9 21997015 T A 1.01E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs3218020 chr9 21997872 G A 2.53E-09 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs3218020 chr9 21997872 G A 6.36E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs3218020 chr9 21997872 G A 3.06E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs3218020 chr9 21997872 G A 0.00000165 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs2811712 chr9 21998035 G A 1.14E-06 Acute lymphoblastic leukemia (B-cell precursor) CDKN2B-AS1 intron 23996088 rs3218012 chr9 21998660 G A 0.0000121 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs3218009 chr9 21998757 C G 3.27E-06 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs2811713 chr9 21999328 G A 9.27E-06 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs2811713 chr9 21999328 G A 4.47E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs572101477 chr9 21999328 GTATGT G 9.27E-06 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs572101477 chr9 21999328 GTATGT G 4.47E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs35720900 chr9 22002477 G GA 0.0000778 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs397688611 chr9 22002477 G GA 0.0000778 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs72693618 chr9 22002477 G A 0.0000778 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs3217992 chr9 22003223 C T 2.86E-10 Glioma CDKN2B UTR-3 21531791 rs3217992 chr9 22003223 C T 5.04E-04 Glaucoma CDKN2B UTR-3 21532571 rs3217992 chr9 22003223 C T 5.82E-08 Coronary artery calcification CDKN2B UTR-3 22144573 rs3217992 chr9 22003223 C T 1.48E-11 Glaucoma (primary open-angle) CDKN2B UTR-3 22570617 rs3217992 chr9 22003223 C T 2.55E-06 Glaucoma (primary open-angle) CDKN2B UTR-3 22605921 rs3217992 chr9 22003223 C T 2.75E-07 Glaucoma CDKN2B UTR-3 22792221 rs3217992 chr9 22003223 C T 1.57E-08 Coronary artery disease (CAD) (females) CDKN2B UTR-3 23202125 rs3217992 chr9 22003223 C T 4.66E-48 Coronary artery disease (CAD) (males) CDKN2B UTR-3 23202125 rs3217992 chr9 22003223 C T 5.43E-31 Coronary artery disease (CAD) age <=50 CDKN2B UTR-3 23202125 rs3217992 chr9 22003223 C T 5.69E-41 Coronary artery disease with myocardial infarction CDKN2B UTR-3 23202125 rs3217992 chr9 22003223 C T 6.01E-36 Coronary artery disease (CAD) age >50 CDKN2B UTR-3 23202125 rs3217992 chr9 22003223 C T 0.000000788 Coronary artery calcification CDKN2B UTR-3 23394302 rs3217992 chr9 22003223 C T 2.21E-29 Coronary artery disease CDKN2B UTR-3 24262325 rs1063192 chr9 22003367 G A 7.83E-04 Schizophrenia CDKN2B UTR-3 19197363 rs1063192 chr9 22003367 G A 4.61E-12 Glioma CDKN2B UTR-3 19578367 rs1063192 chr9 22003367 G A 4.00E-15 Vertical cup-disc ratio CDKN2B UTR-3 20548946 rs1063192 chr9 22003367 G A 4.91E-15 Glioma CDKN2B UTR-3 21531791 rs1063192 chr9 22003367 G A 7.46E-10 Glaucoma CDKN2B UTR-3 21532571 rs1063192 chr9 22003367 G A 7.89E-08 Coronary artery calcification CDKN2B UTR-3 22144573 rs1063192 chr9 22003367 G A 3.82E-06 Ankle-brachial index CDKN2B UTR-3 22199011 rs1063192 chr9 22003367 G A 1.66E-05 Longevity CDKN2B UTR-3 22279548 rs1063192 chr9 22003367 G A 5.00E-11 Glaucoma (primary open-angle) CDKN2B UTR-3 22419738 rs1063192 chr9 22003367 G A 9.67E-15 Glaucoma (primary open-angle) CDKN2B UTR-3 22570617 rs1063192 chr9 22003367 G A 0.0000183 Coronary artery calcification CDKN2B UTR-3 23394302 rs3217986 chr9 22005330 T G 4.22E-04 Multiple complex diseases CDKN2B UTR-3 17554300 rs2069418 chr9 22009698 G C 7.39E-07 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs2069418 chr9 22009698 G C 1.08E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs2069418 chr9 22009698 G C 1.96E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs2069418 chr9 22009698 G C 1.31E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs2069418 chr9 22009698 G C 0.0000123 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs2069416 chr9 22010004 T A,G 5.19E-07 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs2069416 chr9 22010004 T A,G 2.37E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs2069416 chr9 22010004 T A,G 5.78E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs2069416 chr9 22010004 T A,G 0.000000138 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs3808845 chr9 22010575 G A 0.0000218 Menopause (age at onset) CDKN2B-AS1 intron 23424626 rs3808846 chr9 22010946 G A 0.0000218 Menopause (age at onset) CDKN2B-AS1 intron 23424626 rs573687 chr9 22011642 G A 6.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDKN2B-AS1 intron 20877124 rs573687 chr9 22011642 G A 1.28E-12 Glioma CDKN2B-AS1 intron 21531791 rs573687 chr9 22011642 G A 2.11E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs573687 chr9 22011642 G A 5.64E-13 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs573687 chr9 22011642 G A 0.00000237 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs13298881 chr9 22012051 T C 1.47E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs545226 chr9 22012422 G A 2.82E-07 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs545226 chr9 22012422 G A 0.00000128 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10811640 chr9 22013411 G T 1.83E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs10811640 chr9 22013411 G T 1.43E-08 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10811640 chr9 22013411 G T 0.00000139 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10757263 chr9 22013805 C T 1.31E-08 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10757263 chr9 22013805 C T 0.00000126 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10811641 chr9 22014137 C G 4.12E-07 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs10811641 chr9 22014137 C G 2.14E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs10811641 chr9 22014137 C G 7.35E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs1101330 chr9 22015465 C A 2.68E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs1101330 chr9 22015465 C A 0.00000209 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1101329 chr9 22015997 C T 1.20E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs62556546 chr9 22016510 C G 3.11E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs2106120 chr9 22017101 G T 1.75E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs2106120 chr9 22017101 G T 1.29E-08 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs2106120 chr9 22017101 G T 0.000000741 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs2106119 chr9 22017550 A G 1.76E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs2106119 chr9 22017550 A G 1.26E-08 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs2106119 chr9 22017550 A G 0.000000603 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs643319 chr9 22017836 C A 3.13E-08 Multiple complex diseases CDKN2B-AS1 intron 17554300 rs643319 chr9 22017836 C A 2.21E-10 Coronary Artery Disease CDKN2B-AS1 intron 17634449 rs643319 chr9 22017836 C A 7.11E-05 Coronary heart disease CDKN2B-AS1 intron 21606135 rs643319 chr9 22017836 C A 1.50E-06 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22428042 rs643319 chr9 22017836 C A 1.08E-08 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs643319 chr9 22017836 C A 5.44E-08 Glaucoma CDKN2B-AS1 intron 22792221 rs7044859 chr9 22018781 T A 4.82E-08 Multiple complex diseases CDKN2B-AS1 intron 17554300 rs7044859 chr9 22018781 T A 2.90E-11 Coronary Artery Disease CDKN2B-AS1 intron 17634449 rs7044859 chr9 22018781 T A 2.03E-05 Coronary heart disease CDKN2B-AS1 intron 21606135 rs7044859 chr9 22018781 T A 1.36E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs7044859 chr9 22018781 T A 2.30E-06 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22428042 rs7044859 chr9 22018781 T A 2.67E-08 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs7044859 chr9 22018781 T A 0.000000758 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs523096 chr9 22019129 A G 1.42E-06 Multiple complex diseases CDKN2B-AS1 intron 17554300 rs523096 chr9 22019129 A G 8.64E-09 Coronary Artery Disease CDKN2B-AS1 intron 17634449 rs523096 chr9 22019129 A G 4.05E-05 Coronary heart disease CDKN2B-AS1 intron 21606135 rs523096 chr9 22019129 A G 7.65E-07 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs523096 chr9 22019129 A G 3.36E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs523096 chr9 22019129 A G 1.43E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs523096 chr9 22019129 A G 3.80E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22428042 rs523096 chr9 22019129 A G 4.40E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs523096 chr9 22019129 A G 5.00E-11 Glaucoma CDKN2B-AS1 intron 22792221 rs523096 chr9 22019129 A G 0.00000564 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs518394 chr9 22019673 G C 1.41E-06 Multiple complex diseases CDKN2B-AS1 intron 17554300 rs518394 chr9 22019673 G C 2.10E-09 Coronary Artery Disease CDKN2B-AS1 intron 17634449 rs518394 chr9 22019673 G C 4.43E-05 Coronary heart disease CDKN2B-AS1 intron 21606135 rs518394 chr9 22019673 G C 3.37E-06 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs518394 chr9 22019673 G C 9.38E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs518394 chr9 22019673 G C 1.41E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs518394 chr9 22019673 G C 5.20E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22428042 rs518394 chr9 22019673 G C 4.40E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs518394 chr9 22019673 G C 6.71E-08 Glaucoma CDKN2B-AS1 intron 22792221 rs518394 chr9 22019673 G C 0.00000805 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10757264 chr9 22019732 A G 1.89E-07 Multiple complex diseases CDKN2B-AS1 intron 17554300 rs10757264 chr9 22019732 A G 3.02E-09 Coronary Artery Disease CDKN2B-AS1 intron 17634449 rs10757264 chr9 22019732 A G 6.99E-06 Coronary heart disease CDKN2B-AS1 intron 21606135 rs10757264 chr9 22019732 A G 1.60E-06 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22428042 rs10757264 chr9 22019732 A G 0.000000475 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs597816 chr9 22021172 T C 1.56E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs597816 chr9 22021172 T C 3.11E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs568447 chr9 22021615 G A 1.38E-08 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs567453 chr9 22021737 G C 9.14E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs581876 chr9 22022376 C T 1.82E-11 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs76774391 chr9 22023775 G C 0.0000218 Menopause (age at onset) CDKN2B-AS1 intron 23424626 rs10965212 chr9 22023795 T A 9.54E-10 Multiple complex diseases CDKN2B-AS1 intron 17554300 rs10965212 chr9 22023795 T A 2.18E-11 Coronary Artery Disease CDKN2B-AS1 intron 17634449 rs10965212 chr9 22023795 T A 1.03E-04 Coronary heart disease CDKN2B-AS1 intron 21606135 rs10965212 chr9 22023795 T A 4.85E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs10965212 chr9 22023795 T A 2.72E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10965212 chr9 22023795 T A 0.000000365 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10965212 chr9 22023795 T A 9.14E-05 Acute lymphoblastic leukemia (childhood) CDKN2B-AS1 intron 23512250 rs504318 chr9 22024023 A T 1.25E-08 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs496892 chr9 22024351 C T 4.93E-09 Multiple complex diseases CDKN2B-AS1 intron 17554300 rs496892 chr9 22024351 C T 6.39E-11 Coronary Artery Disease CDKN2B-AS1 intron 17634449 rs496892 chr9 22024351 C T 6.11E-05 Type 1 diabetes CDKN2B-AS1 intron 18978792 rs496892 chr9 22024351 C T 1.75E-04 Coronary heart disease CDKN2B-AS1 intron 21606135 rs496892 chr9 22024351 C T 1.25E-08 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs496892 chr9 22024351 C T 0.000000277 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10811643 chr9 22024966 A G 1.70E-08 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10811643 chr9 22024966 A G 0.000000283 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10811644 chr9 22025067 A T 6.63E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs10811644 chr9 22025067 A T 1.70E-08 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs7035484 chr9 22025240 C G 6.86E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs7035484 chr9 22025240 C G 8.41E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs7035484 chr9 22025240 C G 0.00000116 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10738604 chr9 22025493 G A 7.40E-09 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs10738604 chr9 22025493 G A 1.71E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs10738604 chr9 22025493 G A 6.64E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs615552 chr9 22026077 T C 2.75E-07 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs615552 chr9 22026077 T C 1.52E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs615552 chr9 22026077 T C 1.91E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs615552 chr9 22026077 T C 4.85E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs615552 chr9 22026077 T C 0.00000622 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs615552 chr9 22026077 T C 4.00E-06 Migraine without aura CDKN2B-AS1 intron 23793025 rs613312 chr9 22026594 G A 1.98E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs613312 chr9 22026594 G A 1.38E-12 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs613312 chr9 22026594 G A 0.00000277 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs543830 chr9 22026639 A T 6.34E-08 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs543830 chr9 22026639 A T 1.14E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs543830 chr9 22026639 A T 2.00E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs543830 chr9 22026639 A T 3.64E-12 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs543830 chr9 22026639 A T 0.00000286 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1591136 chr9 22026834 G C 6.85E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs1591136 chr9 22026834 G C 2.72E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs599452 chr9 22027402 G A 2.06E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs599452 chr9 22027402 G A 3.25E-12 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs599452 chr9 22027402 G A 0.00000255 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs76810097 chr9 22027714 C T 0.0000218 Menopause (age at onset) CDKN2B-AS1 intron 23424626 rs62560774 chr9 22028406 C A 2.20E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs62560774 chr9 22028406 C A 0.0000745 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs7049105 chr9 22028801 A G 1.05E-09 Multiple complex diseases CDKN2B-AS1 intron 17554300 rs7049105 chr9 22028801 A G 9.21E-12 Coronary Artery Disease CDKN2B-AS1 intron 17634449 rs7049105 chr9 22028801 A G 2.16E-10 Glioma CDKN2B-AS1 intron 21531791 rs7049105 chr9 22028801 A G 4.84E-07 Glaucoma CDKN2B-AS1 intron 21532571 rs7049105 chr9 22028801 A G 7.88E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs7049105 chr9 22028801 A G 1.80E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22428042 rs7049105 chr9 22028801 A G 7.38E-14 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs7049105 chr9 22028801 A G 0.000000213 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs7049105 chr9 22028801 A G 4.01E-08 Acute lymphoblastic leukemia (B-cell precursor) CDKN2B-AS1 intron 23996088 rs188234402 chr9 22029057 T A 0.000000209 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs201049435 chr9 22029057 TA T 0.000000209 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs34059530 chr9 22029057 T TA 0.000000209 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs397733626 chr9 22029057 T TA 0.000000209 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs565448157 chr9 22029057 T TA 0.000000209 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs679038 chr9 22029080 G A 5.94E-08 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs679038 chr9 22029080 G A 1.26E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs679038 chr9 22029080 G A 2.23E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs679038 chr9 22029080 G A 3.25E-12 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs679038 chr9 22029080 G A 0.00000215 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10965215 chr9 22029445 G A 5.15E-10 Multiple complex diseases CDKN2B-AS1 intron 17554300 rs10965215 chr9 22029445 G A 8.28E-13 Coronary Artery Disease CDKN2B-AS1 intron 17634449 rs10965215 chr9 22029445 G A 1.85E-04 Coronary heart disease CDKN2B-AS1 intron 21606135 rs10965215 chr9 22029445 G A 2.50E-06 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22428042 rs10965215 chr9 22029445 G A 1.34E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10965215 chr9 22029445 G A 0.000000188 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10965215 chr9 22029445 G A 1.11E-04 Acute lymphoblastic leukemia (childhood) CDKN2B-AS1 intron 23512250 rs564398 chr9 22029547 T C 1.00E-06 Type 2 diabetes CDKN2B-AS1 intron 17463249 rs564398 chr9 22029547 T C 1.78E-08 Multiple complex diseases CDKN2B-AS1 intron 17554300 rs564398 chr9 22029547 T C 8.58E-11 Coronary Artery Disease CDKN2B-AS1 intron 17634449 rs564398 chr9 22029547 T C 1.00E-06 Coronary heart disease CDKN2B-AS1 intron 21347282 rs564398 chr9 22029547 T C 1.82E-04 Coronary heart disease CDKN2B-AS1 intron 21606135 rs564398 chr9 22029547 T C 4.38E-08 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs564398 chr9 22029547 T C 9.83E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs564398 chr9 22029547 T C 2.22E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs564398 chr9 22029547 T C 4.60E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22428042 rs564398 chr9 22029547 T C 1.24E-12 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs564398 chr9 22029547 T C 1.45E-07 Glaucoma CDKN2B-AS1 intron 22792221 rs564398 chr9 22029547 T C 0.00000226 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs4977753 chr9 22030027 C T 1.16E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs4977753 chr9 22030027 C T 0.000000365 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs662463 chr9 22030438 A G 9.82E-06 Acute lymphoblastic leukemia (childhood) CDKN2B-AS1 intron 23512250 rs7865618 chr9 22031005 G A 1.33E-09 Multiple complex diseases CDKN2B-AS1 intron 17554300 rs7865618 chr9 22031005 G A 1.90E-11 Coronary Artery Disease CDKN2B-AS1 intron 17634449 rs7865618 chr9 22031005 G A 2.00E-27 Coronary heart disease CDKN2B-AS1 intron 21606135 rs7865618 chr9 22031005 G A 3.11E-08 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs7865618 chr9 22031005 G A 1.08E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs7865618 chr9 22031005 G A 2.20E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs7865618 chr9 22031005 G A 9.00E-11 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22428042 rs7865618 chr9 22031005 G A 2.48E-13 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs7865618 chr9 22031005 G A 8.85E-08 Glaucoma CDKN2B-AS1 intron 22792221 rs7865618 chr9 22031005 G A 0.000000781 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs77706751 chr9 22031441 C T 0.0000218 Menopause (age at onset) CDKN2B-AS1 intron 23424626 rs74599268 chr9 22031778 A T 0.0000218 Menopause (age at onset) CDKN2B-AS1 intron 23424626 rs10115049 chr9 22032119 A G 4.61E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs10115049 chr9 22032119 A G 2.30E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10115049 chr9 22032119 A G 0.000000132 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs634537 chr9 22032152 T G 5.46E-08 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs634537 chr9 22032152 T G 1.01E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs634537 chr9 22032152 T G 2.18E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs634537 chr9 22032152 T G 1.24E-12 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs634537 chr9 22032152 T G 0.00000116 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs2157719 chr9 22033366 C T 5.89E-04 Schizophrenia CDKN2B-AS1 intron 19197363 rs2157719 chr9 22033366 C T 1.41E-12 Glioma CDKN2B-AS1 intron 19578367 rs2157719 chr9 22033366 C T 1.00E-06 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs2157719 chr9 22033366 C T 5.00E-16 Glioma CDKN2B-AS1 intron 21531791 rs2157719 chr9 22033366 C T 4.30E-08 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs2157719 chr9 22033366 C T 1.21E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs2157719 chr9 22033366 C T 2.09E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs2157719 chr9 22033366 C T 1.00E-12 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs2157719 chr9 22033366 C T 2.00E-18 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs2157719 chr9 22033366 C T 0.000000788 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs2151280 chr9 22034719 G A 6.79E-11 Glioma CDKN2B-AS1 intron 21531791 rs2151280 chr9 22034719 G A 6.73E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs2151280 chr9 22034719 G A 1.87E-13 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs2151280 chr9 22034719 G A 3.00E-10 Basal cell carcinoma CDKN2B-AS1 intron 24403052 rs1008878 chr9 22036112 G T 3.39E-08 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs1008878 chr9 22036112 G T 1.49E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs1008878 chr9 22036112 G T 2.04E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs1008878 chr9 22036112 G T 1.44E-12 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs1008878 chr9 22036112 G T 0.00000103 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1556515 chr9 22036367 C T 4.02E-08 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs1556515 chr9 22036367 C T 2.48E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs1556515 chr9 22036367 C T 2.04E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs1556515 chr9 22036367 C T 1.29E-12 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs1556515 chr9 22036367 C T 0.000000711 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs35975148 chr9 22037071 T A 8.75E-04 Taste perception CDKN2B-AS1 intron 22132133 rs1333037 chr9 22040765 C T 5.38E-08 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs1333037 chr9 22040765 C T 3.60E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs1333037 chr9 22040765 C T 1.96E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs1333037 chr9 22040765 C T 1.29E-12 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs1333037 chr9 22040765 C T 0.00000115 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1360590 chr9 22041443 T C 6.81E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs1360590 chr9 22041443 T C 5.42E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs1360590 chr9 22041443 T C 0.000000141 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1412830 chr9 22043612 C T 1.92E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs1412830 chr9 22043612 C T 2.66E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs1412830 chr9 22043612 C T 0.0000571 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1333036 chr9 22043819 T C 2.24E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs1333036 chr9 22043819 T C 0.000000392 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1412829 chr9 22043926 A G 2.00E-10 Glioma (high-grade) CDKN2B-AS1 intron 19578366 rs1412829 chr9 22043926 A G 6.23E-13 Glioma CDKN2B-AS1 intron 19578367 rs1412829 chr9 22043926 A G 5.00E-07 Nasopharyngeal carcinoma CDKN2B-AS1 intron 20512145 rs1412829 chr9 22043926 A G 5.00E-15 Glioma CDKN2B-AS1 intron 21531791 rs1412829 chr9 22043926 A G 2.93E-10 Glaucoma CDKN2B-AS1 intron 21532571 rs1412829 chr9 22043926 A G 6.63E-08 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs1412829 chr9 22043926 A G 1.95E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs1412829 chr9 22043926 A G 1.91E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs1412829 chr9 22043926 A G 2.95E-15 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs1412829 chr9 22043926 A G 0.00000291 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1412829 chr9 22043926 A G 5.00E-05 Cystic fibrosis-related diabetes CDKN2B-AS1 intron 23670970 rs1333034 chr9 22044122 C T 1.66E-06 Acute lymphoblastic leukemia (B-cell precursor) CDKN2B-AS1 intron 23996088 rs1360589 chr9 22045317 C T 5.54E-08 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs1360589 chr9 22045317 C T 4.62E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs1360589 chr9 22045317 C T 1.90E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs1360589 chr9 22045317 C T 1.14E-11 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10120806 chr9 22047945 T C 5.00E-06 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs10120806 chr9 22047945 T C 8.38E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs7027950 chr9 22048391 C T 8.16E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs7027950 chr9 22048391 C T 0.000000253 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs7028268 chr9 22048414 G A 1.25E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs7028268 chr9 22048414 G A 4.38E-08 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs7028570 chr9 22048683 G A 6.60E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs7028570 chr9 22048683 G A 8.16E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs7028570 chr9 22048683 G A 0.000000257 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10757265 chr9 22048859 T C 8.16E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10757265 chr9 22048859 T C 0.00000031 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10738605 chr9 22049130 C A,G 8.16E-10 Glaucoma (primary open-angle) / / 22570617 rs10738605 chr9 22049130 C A,G 0.000000395 Coronary artery calcification / / 23394302 rs10757266 chr9 22049555 C T 8.16E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10811645 chr9 22049656 G A 5.02E-06 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs10811645 chr9 22049656 G A 8.16E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10811645 chr9 22049656 G A 0.000000315 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs944799 chr9 22050613 A G 8.16E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs944799 chr9 22050613 A G 0.000000132 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs944800 chr9 22050898 A G 1.89E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs944800 chr9 22050898 A G 3.44E-11 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs944800 chr9 22050898 A G 0.000051 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs944801 chr9 22051670 G C 5.78E-08 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs944801 chr9 22051670 G C 5.80E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs944801 chr9 22051670 G C 1.73E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs944801 chr9 22051670 G C 1.27E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs944801 chr9 22051670 G C 2.40E-09 Type 2 diabetes CDKN2B-AS1 intron 22885922 rs944801 chr9 22051670 G C 0.000000476 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs6475604 chr9 22052734 T C 1.88E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs6475604 chr9 22052734 T C 1.45E-11 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs6475604 chr9 22052734 T C 0.000000733 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10757267 chr9 22052810 G C 8.74E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10757267 chr9 22052810 G C 0.000000161 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10965219 chr9 22053687 A G 4.99E-11 Multiple complex diseases CDKN2B-AS1 intron 17554300 rs10965219 chr9 22053687 A G 2.33E-12 Coronary Artery Disease CDKN2B-AS1 intron 17634449 rs10965219 chr9 22053687 A G 2.36E-05 Coronary heart disease CDKN2B-AS1 intron 21606135 rs10965219 chr9 22053687 A G 8.19E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs10965219 chr9 22053687 A G 8.30E-07 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22428042 rs10965219 chr9 22053687 A G 1.23E-08 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10965219 chr9 22053687 A G 2.38E-08 Glaucoma CDKN2B-AS1 intron 22792221 rs10965219 chr9 22053687 A G 0.000000125 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10965219 chr9 22053687 A G 9.50E-05 Acute lymphoblastic leukemia (childhood) CDKN2B-AS1 intron 23512250 rs7027048 chr9 22053709 A G 1.30E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs7027048 chr9 22053709 A G 0.000000281 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs17756311 chr9 22053895 G A 1.37E-05 Acute lymphoblastic leukemia (childhood) CDKN2B-AS1 intron 23512250 rs7030641 chr9 22054040 C T 6.08E-08 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs7030641 chr9 22054040 C T 5.68E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs7030641 chr9 22054040 C T 1.88E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs7030641 chr9 22054040 C T 5.09E-11 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs7030641 chr9 22054040 C T 0.00000103 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs17694572 chr9 22054356 G A 1.24E-05 Acute lymphoblastic leukemia (childhood) CDKN2B-AS1 intron 23512250 rs2383204 chr9 22055048 A G 1.17E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs2383204 chr9 22055048 A G 0.000000166 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs7036489 chr9 22055992 G A 1.89E-16 LDL cholesterol CDKN2B-AS1 intron 23063622 rs7039467 chr9 22056213 A G 3.32E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs7853090 chr9 22056295 T C 2.37E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs7866783 chr9 22056359 A G 1.88E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs7866783 chr9 22056359 A G 5.83E-11 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs7866783 chr9 22056359 A G 0.000000545 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10120688 chr9 22056499 G A 3.07E-11 Glioma CDKN2B-AS1 intron 21531791 rs10120688 chr9 22056499 G A 3.98E-05 Glaucoma CDKN2B-AS1 intron 21532571 rs10120688 chr9 22056499 G A 7.24E-05 Coronary heart disease CDKN2B-AS1 intron 21606135 rs10120688 chr9 22056499 G A 2.41E-06 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs10120688 chr9 22056499 G A 7.19E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs10120688 chr9 22056499 G A 1.42E-13 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10120688 chr9 22056499 G A 3.57E-08 Glaucoma CDKN2B-AS1 intron 22792221 rs10120688 chr9 22056499 G A 2.35E-08 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10120688 chr9 22056499 G A 2.65E-07 Acute lymphoblastic leukemia (B-cell precursor) CDKN2B-AS1 intron 23996088 rs10757268 chr9 22059905 T C 2.44E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs2095144 chr9 22060136 A G 2.45E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs2383205 chr9 22060935 A G 2.45E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs2383205 chr9 22060935 A G 7.52E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs2383205 chr9 22060935 A G 4.34E-08 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs2184061 chr9 22061562 C A 2.66E-07 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs2184061 chr9 22061562 C A 1.35E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs2184061 chr9 22061562 C A 4.24E-08 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1537378 chr9 22061614 A G 2.68E-07 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs1537378 chr9 22061614 A G 8.49E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs1537378 chr9 22061614 A G 2.49E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs1537378 chr9 22061614 A G 1.35E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs1537378 chr9 22061614 A G 5.95E-08 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1011970 chr9 22062134 G T 3.00E-08 Breast cancer CDKN2B-AS1 intron 20453838 rs1011970 chr9 22062134 G T 6.00E-08 Breast cancer CDKN2B-AS1 intron 23535729 rs1011970 chr9 22062134 G T 3.90E-05 Breast cancer CDKN2B-AS1 intron 23535733 rs8181050 chr9 22064391 G A 2.87E-07 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs8181050 chr9 22064391 G A 8.75E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs8181050 chr9 22064391 G A 2.51E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs8181050 chr9 22064391 G A 1.42E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs8181050 chr9 22064391 G A 5.69E-08 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs8181047 chr9 22064465 A G 6.18E-04 Coronary heart disease CDKN2B-AS1 intron 21606135 rs8181047 chr9 22064465 A G 2.15E-06 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs8181047 chr9 22064465 A G 2.51E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs8181047 chr9 22064465 A G 6.50E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22428042 rs8181047 chr9 22064465 A G 9.16E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs8181047 chr9 22064465 A G 9.28E-05 Glaucoma CDKN2B-AS1 intron 22792221 rs8181047 chr9 22064465 A G 0.0000998 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10811647 chr9 22065002 C G 6.98E-12 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs10811647 chr9 22065002 C G 8.39E-08 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs10811647 chr9 22065002 C G 6.07E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10811647 chr9 22065002 C G 2.40E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1333039 chr9 22065657 G C 2.92E-07 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs1333039 chr9 22065657 G C 8.86E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs1333039 chr9 22065657 G C 1.44E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs1333039 chr9 22065657 G C 1.35E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs1333039 chr9 22065657 G C 6.25E-08 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs4977755 chr9 22066363 T A 2.32E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs4977755 chr9 22066363 T A 4.19E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10965223 chr9 22067004 G A 1.39E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs10965224 chr9 22067276 T A 3.63E-06 Coronary Artery Disease CDKN2B-AS1 intron 17634449 rs10965224 chr9 22067276 T A 2.00E-09 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs10965224 chr9 22067276 T A 2.99E-07 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs10965224 chr9 22067276 T A 8.13E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs10965224 chr9 22067276 T A 1.40E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs10965224 chr9 22067276 T A 1.35E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10965224 chr9 22067276 T A 5.93E-04 Glaucoma CDKN2B-AS1 intron 22792221 rs10965224 chr9 22067276 T A 6.65E-08 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10811648 chr9 22067542 C T 1.41E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs10811648 chr9 22067542 C T 4.04E-11 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10811649 chr9 22067554 C T 1.82E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs10811649 chr9 22067554 C T 2.68E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10811650 chr9 22067593 A G 3.00E-12 Myocardial infarction CDKN2B-AS1 intron 17478679 rs10811650 chr9 22067593 A G 7.30E-12 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs10811650 chr9 22067593 A G 9.17E-08 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs10811650 chr9 22067593 A G 6.07E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10811650 chr9 22067593 A G 2.23E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10811651 chr9 22067830 G A 3.07E-07 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs10811651 chr9 22067830 G A 9.22E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs10811651 chr9 22067830 G A 1.42E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs10811651 chr9 22067830 G A 1.32E-10 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10811651 chr9 22067830 G A 4.88E-08 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs4977756 chr9 22068652 G A 7.00E-15 Glioma CDKN2B-AS1 intron 19578367 rs4977756 chr9 22068652 G A 3.00E-09 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs4977756 chr9 22068652 G A 7.00E-15 Nasopharyngeal carcinoma CDKN2B-AS1 intron 20512145 rs4977756 chr9 22068652 G A 7.19E-14 Glioma CDKN2B-AS1 intron 21531791 rs4977756 chr9 22068652 G A 1.00E-14 Glaucoma CDKN2B-AS1 intron 21532571 rs4977756 chr9 22068652 G A 4.02E-07 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs4977756 chr9 22068652 G A 8.82E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs4977756 chr9 22068652 G A 7.97E-06 Longevity CDKN2B-AS1 intron 22279548 rs4977756 chr9 22068652 G A 1.44E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22419738 rs4977756 chr9 22068652 G A 7.34E-16 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs4977756 chr9 22068652 G A 1.00E-08 Glioma CDKN2B-AS1 intron 22886559 rs4977756 chr9 22068652 G A 4.88E-08 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs16905599 chr9 22069144 G A 0.000000103 Coronary artery disease CDKN2B-AS1 intron 23202125 rs4451405 chr9 22071750 C T 0.000000285 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs12555547 chr9 22072040 C G 0.0000969 Menopause (age at onset) CDKN2B-AS1 intron 23424626 rs10757269 chr9 22072264 A G 8.00E-10 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs10757269 chr9 22072264 A G 5.53E-13 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs10757269 chr9 22072264 A G 9.00E-09 ankle-brachial index CDKN2B-AS1 intron 22199011 rs10757269 chr9 22072264 A G 1.80E-08 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10757269 chr9 22072264 A G 0.0000941 Carotid intima media thickness CDKN2B-AS1 intron 23152477 rs10757269 chr9 22072264 A G 1.54E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs9632884 chr9 22072301 G C 3.81E-13 Multiple complex diseases CDKN2B-AS1 intron 17554300 rs9632884 chr9 22072301 G C 4.68E-18 Coronary Artery Disease CDKN2B-AS1 intron 17634449 rs9632884 chr9 22072301 G C 4.00E-10 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs9632884 chr9 22072301 G C 5.92E-13 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs9632884 chr9 22072301 G C 2.89E-08 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs9632884 chr9 22072301 G C 3.40E-04 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22428042 rs9632884 chr9 22072301 G C 1.23E-08 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs9632884 chr9 22072301 G C 2.07E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs9632885 chr9 22072638 G A 3.00E-10 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs9632885 chr9 22072638 G A 9.49E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs9632885 chr9 22072638 G A 6.19E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10757270 chr9 22072719 A G 4.52E-05 Coronary heart disease CDKN2B-AS1 intron 21606135 rs10757270 chr9 22072719 A G 4.35E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10757270 chr9 22072719 A G 5.71E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs16923583 chr9 22073334 T A 1.10E-04 Smoking cessation CDKN2B-AS1 intron 24665060 rs10811652 chr9 22077085 A C 3.50E-08 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs1412832 chr9 22077543 C T 5.00E-07 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs1412832 chr9 22077543 C T 2.30E-08 Glioma CDKN2B-AS1 intron 21531791 rs1412832 chr9 22077543 C T 4.55E-05 Longevity CDKN2B-AS1 intron 22279548 rs1412832 chr9 22077543 C T 2.36E-12 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs1412832 chr9 22077543 C T 5.55E-05 Myocardial infarction CDKN2B-AS1 intron 24916648 rs10116277 chr9 22081397 G T 1.80E-15 Myocardial infarction CDKN2B-AS1 intron 17478679 rs10116277 chr9 22081397 G T 8.00E-10 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs10116277 chr9 22081397 G T 4.48E-10 Glioma CDKN2B-AS1 intron 21531791 rs10116277 chr9 22081397 G T 1.54E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs10116277 chr9 22081397 G T 2.80E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs10116277 chr9 22081397 G T 3.45E-11 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs10116277 chr9 22081397 G T 2.51E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10116277 chr9 22081397 G T 5.23E-05 Abdominal aortic aneurysm CDKN2B-AS1 intron 24046328 rs6475606 chr9 22081850 C T 1.64E-17 Multiple complex diseases CDKN2B-AS1 intron 17554300 rs6475606 chr9 22081850 C T 1.45E-17 Coronary Artery Disease CDKN2B-AS1 intron 17634449 rs6475606 chr9 22081850 C T 8.00E-10 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs6475606 chr9 22081850 C T 9.49E-07 Coronary heart disease CDKN2B-AS1 intron 21606135 rs6475606 chr9 22081850 C T 1.64E-13 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs6475606 chr9 22081850 C T 2.43E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs6475606 chr9 22081850 C T 4.00E-08 Intracranial aneurysm CDKN2B-AS1 intron 22961961 rs6475606 chr9 22081850 C T 2.28E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10965228 chr9 22082380 A G 6.83E-08 Coronary artery disease CDKN2B-AS1 intron 23202125 rs1333040 chr9 22083404 C T 4.10E-15 Myocardial infarction CDKN2B-AS1 intron 17478679 rs1333040 chr9 22083404 C T 1.00E-10 Intracranial aneurysm CDKN2B-AS1 intron 18997786 rs1333040 chr9 22083404 C T 1.00E-07 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs1333040 chr9 22083404 C T 2.00E-22 Intracranial aneurysm CDKN2B-AS1 intron 20364137 rs1333040 chr9 22083404 C T 1.67E-12 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs1333040 chr9 22083404 C T 5.56E-05 Intracranial aneurysm CDKN2B-AS1 intron 22286173 rs1333040 chr9 22083404 C T 4.88E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs1333040 chr9 22083404 C T 0.00000359 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1537370 chr9 22084310 C T 9.00E-10 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs1537370 chr9 22084310 C T 1.26E-14 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs1537370 chr9 22084310 C T 1.79E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs1537370 chr9 22084310 C T 1.39E-05 Stroke CDKN2B-AS1 intron 22306652 rs1537370 chr9 22084310 C T 6.91E-11 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1537370 chr9 22084310 C T 2.00E-11 Coronary artery calcification CDKN2B-AS1 intron 23561647 rs7857345 chr9 22087473 T C 2.64E-08 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs7857345 chr9 22087473 T C 0.0000968 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10738606 chr9 22088090 A T 7.53E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10738607 chr9 22088094 A G 2.10E-19 Myocardial infarction CDKN2B-AS1 intron 17478679 rs10738607 chr9 22088094 A G 4.12E-15 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs10738607 chr9 22088094 A G 1.60E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs10738607 chr9 22088094 A G 7.48E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10757272 chr9 22088260 C T 4.80E-12 Multiple complex diseases CDKN2B-AS1 intron 17554300 rs10757272 chr9 22088260 C T 1.19E-06 Coronary Artery Disease CDKN2B-AS1 intron 17634449 rs10757272 chr9 22088260 C T 2.00E-11 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs10757272 chr9 22088260 C T 4.56E-06 Coronary heart disease CDKN2B-AS1 intron 21606135 rs10757272 chr9 22088260 C T 1.80E-15 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs10757272 chr9 22088260 C T 1.45E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs10757272 chr9 22088260 C T 2.00E-07 Intracranial aneurysm CDKN2B-AS1 intron 22286173 rs10757272 chr9 22088260 C T 9.20E-04 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22428042 rs10757272 chr9 22088260 C T 7.02E-09 Coronary heart disease CDKN2B-AS1 intron 23364394 rs10757272 chr9 22088260 C T 8.10E-11 Coronary artery calcification CDKN2B-AS1 intron 23727086 rs10757274 chr9 22096055 A G 3.70E-06 Coronary heart disease CDKN2B-AS1 intron 17478681 rs10757274 chr9 22096055 A G 7.00E-11 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs10757274 chr9 22096055 A G 8.00E-45 Coronary heart disease CDKN2B-AS1 intron 22751097 rs10757274 chr9 22096055 A G 7.96E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10757274 chr9 22096055 A G 0.000000068 Coronary artery calcification CDKN2B-AS1 intron 23727086 rs4977574 chr9 22098574 A G 1.10E-18 Myocardial infarction CDKN2B-AS1 intron 17478679 rs4977574 chr9 22098574 A G 4.28E-13 Multiple complex diseases CDKN2B-AS1 intron 17554300 rs4977574 chr9 22098574 A G 1.03E-18 Coronary Artery Disease CDKN2B-AS1 intron 17634449 rs4977574 chr9 22098574 A G 3.00E-44 Myocardial infarction (early onset) CDKN2B-AS1 intron 19198609 rs4977574 chr9 22098574 A G 8.00E-11 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs4977574 chr9 22098574 A G 2.98E-27 Cardiovascular disease risk factors CDKN2B-AS1 intron 21239051 rs4977574 chr9 22098574 A G 3.00E-44 Coronary heart disease CDKN2B-AS1 intron 21347282 rs4977574 chr9 22098574 A G 2.00E-25 Coronary heart disease CDKN2B-AS1 intron 21378988 rs4977574 chr9 22098574 A G 1.00E-22 Coronary heart disease CDKN2B-AS1 intron 21378990 rs4977574 chr9 22098574 A G 1.08E-10 Glioma CDKN2B-AS1 intron 21531791 rs4977574 chr9 22098574 A G 5.67E-04 Glaucoma CDKN2B-AS1 intron 21532571 rs4977574 chr9 22098574 A G 2.41E-06 Coronary heart disease CDKN2B-AS1 intron 21606135 rs4977574 chr9 22098574 A G 3.21E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs4977574 chr9 22098574 A G 2.33E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs4977574 chr9 22098574 A G 3.50E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22428042 rs4977574 chr9 22098574 A G 4.33E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs4977574 chr9 22098574 A G 1.35E-22 Pericardial fat CDKN2B-AS1 intron 22589742 rs4977574 chr9 22098574 A G 6.61E-08 Coronary heart disease CDKN2B-AS1 intron 22751097 rs4977574 chr9 22098574 A G 1.36E-08 Coronary heart disease CDKN2B-AS1 intron 23364394 rs4977574 chr9 22098574 A G 1.36E-08 Major depressive disorder CDKN2B-AS1 intron 23377640 rs4977574 chr9 22098574 A G 5.70E-12 Coronary artery calcification CDKN2B-AS1 intron 23727086 rs4977574 chr9 22098574 A G 1.76E-05 Abdominal aortic aneurysm CDKN2B-AS1 intron 24046328 rs4977574 chr9 22098574 A G 8.00E-06 Myocardial infarction CDKN2B-AS1 intron 24916648 rs2891168 chr9 22098619 A G 5.90E-13 Multiple complex diseases CDKN2B-AS1 intron 17554300 rs2891168 chr9 22098619 A G 1.34E-18 Coronary Artery Disease CDKN2B-AS1 intron 17634449 rs2891168 chr9 22098619 A G 6.00E-11 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs2891168 chr9 22098619 A G 2.29E-06 Coronary heart disease CDKN2B-AS1 intron 21606135 rs2891168 chr9 22098619 A G 5.20E-04 Atrial fibrillation CDKN2B-AS1 intron 21846873 rs2891168 chr9 22098619 A G 2.75E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs2891168 chr9 22098619 A G 2.32E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs2891168 chr9 22098619 A G 4.80E-05 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22428042 rs2891168 chr9 22098619 A G 1.83E-08 Coronary heart disease CDKN2B-AS1 intron 23364394 rs2891168 chr9 22098619 A G 4.94E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs2891168 chr9 22098619 A G 7.70E-12 Coronary artery calcification CDKN2B-AS1 intron 23727086 rs1537371 chr9 22099568 C A 1.70E-04 Subclinical atherosclerosis CDKN2B-AS1 intron 17903303 rs1537371 chr9 22099568 C A 1.87E-05 Cardiovascular disease CDKN2B-AS1 intron 17903304 rs1537371 chr9 22099568 C A 2.73E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs1537371 chr9 22099568 C A 1.93E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs1537371 chr9 22099568 C A 5.15E-11 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1556516 chr9 22100176 G C 8.80E-05 Subclinical atherosclerosis CDKN2B-AS1 intron 17903303 rs1556516 chr9 22100176 G C 1.86E-05 Cardiovascular disease CDKN2B-AS1 intron 17903304 rs1556516 chr9 22100176 G C 2.72E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs1556516 chr9 22100176 G C 1.91E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs1556516 chr9 22100176 G C 4.82E-11 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs6475608 chr9 22101702 T C 6.30E-08 Myocardial infarction CDKN2B-AS1 intron 17478679 rs6475608 chr9 22101702 T C 1.11E-09 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs6475608 chr9 22101702 T C 0.0000502 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs7859727 chr9 22102165 C T 4.00E-11 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs7859727 chr9 22102165 C T 2.71E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs7859727 chr9 22102165 C T 2.19E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs7859727 chr9 22102165 C T 4.28E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1537372 chr9 22103183 G T 4.00E-07 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs1537372 chr9 22103183 G T 6.69E-09 Coronary heart disease CDKN2B-AS1 intron 23364394 rs1537372 chr9 22103183 G T 1.76E-09 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1537373 chr9 22103341 T G 2.70E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs1537373 chr9 22103341 T G 2.28E-06 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs1537373 chr9 22103341 T G 4.05E-11 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1333042 chr9 22103813 A G 2.45E-12 Multiple complex diseases CDKN2B-AS1 intron 17554300 rs1333042 chr9 22103813 A G 2.45E-12 Coronary Artery Disease CDKN2B-AS1 intron 17634449 rs1333042 chr9 22103813 A G 1.00E-10 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs1333042 chr9 22103813 A G 2.60E-07 Coronary heart disease CDKN2B-AS1 intron 21606135 rs1333042 chr9 22103813 A G 1.10E-37 Coronary heart disease CDKN2B-AS1 intron 21966275 rs1333042 chr9 22103813 A G 4.54E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs1333042 chr9 22103813 A G 2.15E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs1333042 chr9 22103813 A G 4.40E-04 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22428042 rs1333042 chr9 22103813 A G 1.00E-09 Coronary heart disease CDKN2B-AS1 intron 23364394 rs1333042 chr9 22103813 A G 5.90E-11 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs7859362 chr9 22105927 T C 4.06E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs7859362 chr9 22105927 T C 2.10E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs10757275 chr9 22106225 G A 1.08E-08 Coronary heart disease CDKN2B-AS1 intron 23364394 rs1333043 chr9 22106731 T A 2.36E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs1333043 chr9 22106731 T A 8.00E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs1333043 chr9 22106731 T A 7.22E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1412834 chr9 22110131 T C 4.31E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs1412834 chr9 22110131 T C 2.10E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs1412834 chr9 22110131 T C 7.09E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs7341786 chr9 22112241 A C 4.48E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs7341786 chr9 22112241 A C 1.46E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs7341786 chr9 22112241 A C 2.55E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs7341791 chr9 22112427 A G 3.39E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10511701 chr9 22112599 T C 1.10E-04 Subclinical atherosclerosis CDKN2B-AS1 intron 17903303 rs10511701 chr9 22112599 T C 1.67E-05 Cardiovascular disease CDKN2B-AS1 intron 17903304 rs10511701 chr9 22112599 T C 3.00E-10 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs10511701 chr9 22112599 T C 4.48E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs10511701 chr9 22112599 T C 1.46E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs10511701 chr9 22112599 T C 3.24E-09 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10733376 chr9 22114469 G C 4.50E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs10733376 chr9 22114469 G C 1.79E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs10733376 chr9 22114469 G C 3.37E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10738609 chr9 22114495 A C,G,T 4.50E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs10738609 chr9 22114495 A C,G,T 1.79E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs10738609 chr9 22114495 A C,G,T 3.98E-08 Coronary heart disease CDKN2B-AS1 intron 23364394 rs10738609 chr9 22114495 A C,G,T 0.000000016 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs2383206 chr9 22115026 A G 6.70E-06 Coronary heart disease CDKN2B-AS1 intron 17478681 rs2383206 chr9 22115026 A G 7.00E-10 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs2383206 chr9 22115026 A G 4.51E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs2383206 chr9 22115026 A G 1.77E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs2383206 chr9 22115026 A G 2.11E-08 Coronary heart disease CDKN2B-AS1 intron 23364394 rs2383206 chr9 22115026 A G 1.45E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10965235 chr9 22115105 C A 6.00E-12 Endometriosis CDKN2B-AS1 intron 20601957 rs944797 chr9 22115286 T C 8.00E-10 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs944797 chr9 22115286 T C 2.99E-10 Glioma CDKN2B-AS1 intron 21531791 rs944797 chr9 22115286 T C 5.20E-35 Coronary heart disease CDKN2B-AS1 intron 21966275 rs944797 chr9 22115286 T C 6.00E-16 Coronary heart disease CDKN2B-AS1 intron 21971053 rs944797 chr9 22115286 T C 5.44E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs944797 chr9 22115286 T C 1.45E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs944797 chr9 22115286 T C 5.94E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs944797 chr9 22115286 T C 2.11E-08 Coronary heart disease CDKN2B-AS1 intron 23364394 rs944797 chr9 22115286 T C 1.17E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs944797 chr9 22115286 T C 2.37E-05 Myocardial infarction CDKN2B-AS1 intron 24916648 rs1004638 chr9 22115589 A T 5.28E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs1004638 chr9 22115589 A T 1.43E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs1004638 chr9 22115589 A T 1.90E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs2383207 chr9 22115959 A G 1.00E-16 Myocardial infarction CDKN2B-AS1 intron 17478679 rs2383207 chr9 22115959 A G 1.00E-06 Intracranial aneurysm CDKN2B-AS1 intron 20364137 rs2383207 chr9 22115959 A G 2.00E-08 Abdominal aortic aneurysm CDKN2B-AS1 intron 20622881 rs2383207 chr9 22115959 A G 1.99E-10 Glioma CDKN2B-AS1 intron 21531791 rs2383207 chr9 22115959 A G 8.56E-05 Glaucoma CDKN2B-AS1 intron 21532571 rs2383207 chr9 22115959 A G 5.62E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs2383207 chr9 22115959 A G 1.12E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs2383207 chr9 22115959 A G 2.42E-06 Stroke CDKN2B-AS1 intron 22306652 rs2383207 chr9 22115959 A G 1.20E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs2383207 chr9 22115959 A G 1.89E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1537374 chr9 22116046 A G 6.03E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs1537374 chr9 22116046 A G 1.22E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs1537374 chr9 22116046 A G 1.89E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1537375 chr9 22116071 T C 3.00E-10 Lipoprotein A [Lp(a)] levels and coronary artery disease CDKN2B-AS1 intron 20032323 rs1537375 chr9 22116071 T C 1.56E-10 Glioma CDKN2B-AS1 intron 21531791 rs1537375 chr9 22116071 T C 5.06E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs1537375 chr9 22116071 T C 1.06E-07 Ankle-brachial index CDKN2B-AS1 intron 22199011 rs1537375 chr9 22116071 T C 5.75E-09 Glaucoma (primary open-angle) CDKN2B-AS1 intron 22570617 rs1537375 chr9 22116071 T C 1.58E-09 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1537376 chr9 22116220 T C 2.11E-08 Coronary heart disease CDKN2B-AS1 intron 23364394 rs1537376 chr9 22116220 T C 1.45E-10 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs1333045 chr9 22119195 T C 6.30E-15 Myocardial infarction CDKN2B-AS1 intron 17478679 rs1333045 chr9 22119195 T C 4.21E-16 Coronary artery calcification CDKN2B-AS1 intron 22144573 rs1333045 chr9 22119195 T C 4.28E-10 Coronary heart disease CDKN2B-AS1 intron 23364394 rs1333045 chr9 22119195 T C 0.00000286 Coronary artery calcification CDKN2B-AS1 intron 23394302 rs10217586 chr9 22121349 A T 5.80E-10 Coronary heart disease / / 23364394 rs10217586 chr9 22121349 A T 0.000000357 Coronary artery calcification / / 23394302 rs10738610 chr9 22123766 A C 1.04E-16 Coronary artery calcification / / 22144573 rs10738610 chr9 22123766 A C 1.87E-07 Ankle-brachial index / / 22199011 rs10738610 chr9 22123766 A C 8.73E-10 Coronary heart disease / / 23364394 rs10738610 chr9 22123766 A C 5.34E-10 Coronary artery calcification / / 23394302 rs1333046 chr9 22124123 T A 2.50E-17 Myocardial infarction / / 17478679 rs1333046 chr9 22124123 T A 1.04E-16 Coronary artery calcification / / 22144573 rs1333046 chr9 22124123 T A 1.91E-07 Ankle-brachial index / / 22199011 rs1333046 chr9 22124123 T A 8.73E-10 Coronary heart disease / / 23364394 rs1333046 chr9 22124123 T A 7.06E-10 Coronary artery calcification / / 23394302 rs7857118 chr9 22124140 A T 1.26E-10 Coronary artery calcification / / 23394302 rs10757277 chr9 22124450 A G 8.73E-10 Coronary heart disease / / 23364394 rs10757277 chr9 22124450 A G 8.76E-09 Coronary artery calcification / / 23394302 rs10811656 chr9 22124472 C T 9.46E-09 Coronary artery calcification / / 23394302 rs10757278 chr9 22124477 A G 1.00E-20 Myocardial infarction / / 17478679 rs10757278 chr9 22124477 A G 6.00E-10 Lipoprotein A [Lp(a)] levels and coronary artery disease / / 20032323 rs10757278 chr9 22124477 A G 1.00E-20 Coronary heart disease / / 21347282 rs10757278 chr9 22124477 A G 1.19E-18 Coronary artery calcification / / 22144573 rs10757278 chr9 22124477 A G 4.43E-06 Ankle-brachial index / / 22199011 rs10757278 chr9 22124477 A G 3.34E-08 Coronary heart disease / / 22751097 rs10757278 chr9 22124477 A G 8.73E-10 Coronary heart disease / / 23364394 rs10757278 chr9 22124477 A G 8.73E-10 Major depressive disorder / / 23377640 rs10757278 chr9 22124477 A G 8.73E-09 Coronary artery calcification / / 23394302 rs10757278 chr9 22124477 A G 2.20E-11 Coronary artery calcification / / 23727086 rs1333047 chr9 22124504 A T 2.29E-04 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs1333047 chr9 22124504 A T 1.20E-18 Coronary artery calcification / / 22144573 rs1333047 chr9 22124504 A T 4.47E-06 Ankle-brachial index / / 22199011 rs1333047 chr9 22124504 A T 1.04E-09 Coronary artery calcification / / 23394302 rs1333047 chr9 22124504 A T 1.44E-53 Coronary artery disease / / 24262325 rs1333047 chr9 22124504 A T 2.00E-07 Large artery stroke / / 24262325 rs10757279 chr9 22124630 A G 8.73E-10 Coronary heart disease / / 23364394 rs10757279 chr9 22124630 A G 8.73E-09 Coronary artery calcification / / 23394302 rs4977575 chr9 22124744 C G 9.93E-19 Coronary artery calcification / / 22144573 rs4977575 chr9 22124744 C G 5.47E-06 Ankle-brachial index / / 22199011 rs4977575 chr9 22124744 C G 8.15E-10 Coronary artery calcification / / 23394302 rs1333048 chr9 22125347 A C 6.00E-18 Myocardial infarction / / 17478679 rs1333048 chr9 22125347 A C 9.74E-06 Multiple complex diseases / / 17554300 rs1333048 chr9 22125347 A C 1.28E-13 Coronary Artery Disease / / 17634449 rs1333048 chr9 22125347 A C 2.00E-10 Lipoprotein A [Lp(a)] levels and coronary artery disease / / 20032323 rs1333048 chr9 22125347 A C 4.57E-06 Coronary heart disease / / 21378986 rs1333048 chr9 22125347 A C 1.08E-06 Coronary heart disease / / 21606135 rs1333048 chr9 22125347 A C 7.00E-14 Coronary heart disease / / 21626137 rs1333048 chr9 22125347 A C 4.63E-17 Coronary artery calcification / / 22144573 rs1333048 chr9 22125347 A C 1.50E-06 Ankle-brachial index / / 22199011 rs1333048 chr9 22125347 A C 1.40E-04 Glaucoma (primary open-angle) / / 22428042 rs1333048 chr9 22125347 A C 4.18E-10 Coronary heart disease / / 23364394 rs1333048 chr9 22125347 A C 5.28E-10 Coronary artery calcification / / 23394302 rs1333048 chr9 22125347 A C 3.00E-04 Colorectal cancer / / 24836286 rs1333049 chr9 22125503 G C 1.00E-13 Coronary heart disease / / 17554300 rs1333049 chr9 22125503 G C 3.00E-19 Coronary heart disease / / 17634449 rs1333049 chr9 22125503 G C 8.00E-10 Lipoprotein A [Lp(a)] levels and coronary artery disease / / 20032323 rs1333049 chr9 22125503 G C 2.20E-25 Cardiovascular disease risk factors / / 21239051 rs1333049 chr9 22125503 G C 3.00E-19 Coronary heart disease / / 21347282 rs1333049 chr9 22125503 G C 6.00E-04 Coronary heart disease / / 21378986 rs1333049 chr9 22125503 G C 7.00E-58 Coronary heart disease / / 21606135 rs1333049 chr9 22125503 G C 7.00E-14 Coronary heart disease / / 21626137 rs1333049 chr9 22125503 G C 2.70E-34 Coronary heart disease / / 21966275 rs1333049 chr9 22125503 G C 3.00E-24 Coronary artery calcification / / 22144573 rs1333049 chr9 22125503 G C 5.51E-06 Ankle-brachial index / / 22199011 rs1333049 chr9 22125503 G C 2.91E-32 Coronary heart disease / / 22319020 rs1333049 chr9 22125503 G C 8.30E-05 Glaucoma (primary open-angle) / / 22428042 rs1333049 chr9 22125503 G C 2.63E-08 Coronary heart disease / / 22751097 rs1333049 chr9 22125503 G C 1.39E-52 Coronary artery disease / / 23202125 rs1333049 chr9 22125503 G C 2.57E-80 Coronary artery disease with myocardial infarction / / 23202125 rs1333049 chr9 22125503 G C 3.01E-61 Coronary artery disease (CAD) age <=50 / / 23202125 rs1333049 chr9 22125503 G C 3.93E-88 Coronary artery disease (CAD) (males) / / 23202125 rs1333049 chr9 22125503 G C 4.03E-41 Coronary artery disease (CAD) age >50 / / 23202125 rs1333049 chr9 22125503 G C 4.42E-24 Coronary artery disease (CAD) (females) / / 23202125 rs1333049 chr9 22125503 G C 4.43E-09 Coronary heart disease / / 23364394 rs1333049 chr9 22125503 G C 4.43E-09 Major depressive disorder / / 23377640 rs1333049 chr9 22125503 G C 1.36E-08 Coronary artery calcification / / 23394302 rs1333049 chr9 22125503 G C 0.00016 Coronary artery calcification / / 23727086 rs1333049 chr9 22125503 G C 1.00E-56 Coronary artery disease or ischemic stroke / / 24262325 rs1333049 chr9 22125503 G C 1.00E-59 Coronary artery disease or large artery stroke / / 24262325 rs1333049 chr9 22125503 G C 3.00E-56 Coronary artery disease / / 24262325 rs1333049 chr9 22125503 G C 3.70E-06 Large artery stroke / / 24262325 rs1333050 chr9 22125913 C T 2.82E-13 Coronary artery calcification / / 22144573 rs7020996 chr9 22129579 C T 1.88E-04 Type 2 diabetes / / 17463246 rs7020996 chr9 22129579 C T 2.00E-07 Type 2 diabetes / / 18372903 rs7020996 chr9 22129579 C T 2.00E-07 Coronary heart disease / / 21347282 rs7020996 chr9 22129579 C T 4.45E-10 Type 2 diabetes / / 22158537 rs10965243 chr9 22130065 A G 1.70E-11 Type 2 diabetes / / 22158537 rs10965245 chr9 22130515 G A 1.93E-05 Type 2 diabetes / / 22158537 rs2891169 chr9 22131825 A G 1.36E-04 Multiple complex diseases / / 17554300 rs2383208 chr9 22132076 A G 8.07E-04 Type 2 diabetes / / 17463246 rs2383208 chr9 22132076 A G 7.20E-04 Type 2 diabetes / / 17463248 rs2383208 chr9 22132076 A G 2.60E-06 Type 2 diabetes / / 17463249 rs2383208 chr9 22132076 A G 1.44E-06 Multiple complex diseases / / 17554300 rs2383208 chr9 22132076 A G 2.00E-29 Type 2 diabetes / / 19401414 rs2383208 chr9 22132076 A G 1.45E-11 Type 2 diabetes / / 20818381 rs2383208 chr9 22132076 A G 2.00E-29 Coronary heart disease / / 21347282 rs2383208 chr9 22132076 A G 2.00E-29 Type 2 diabetes / / 21647700 rs2383208 chr9 22132076 A G 6.90E-16 Type 2 diabetes / / 21874001 rs2383208 chr9 22132076 A G 3.03E-25 Type 2 diabetes / / 22158537 rs2383208 chr9 22132076 A G 3.00E-17 Type 2 diabetes / / 22961080 rs2383208 chr9 22132076 A G 3.00E-06 Type 2 diabetes / / 23209189 rs10965250 chr9 22133284 G A 1.00E-10 Type 2 diabetes / / 20581827 rs10965250 chr9 22133284 G A 3.12E-04 Type 2 diabetes / / 22158537 rs10965250 chr9 22133284 G A 1.80E-25 Type 2 diabetes / / 22885922 rs10965250 chr9 22133284 G A 5.70E-16 Type 2 diabetes (females) / / 22885922 rs10965250 chr9 22133284 G A 8.50E-15 Type 2 diabetes (males) / / 22885922 rs10965250 chr9 22133284 G A 1.20E-10 Type 2 diabetes / / 23300278 rs10811659 chr9 22133716 T C 9.90E-06 Urinary metabolites / / 21572414 rs10757282 chr9 22133984 T C 2.41E-10 Type 2 diabetes / / 22325160 rs10811661 chr9 22134094 T C 5.00E-08 Type 2 diabetes / / 17463246 rs10811661 chr9 22134094 T C 8.00E-15 Type 2 diabetes / / 17463248 rs10811661 chr9 22134094 T C 5.00E-06 Type 2 diabetes / / 17463249 rs10811661 chr9 22134094 T C 2.48E-06 Multiple complex diseases / / 17554300 rs10811661 chr9 22134094 T C 1 Drug response to Troglitazone / / 18544707 rs10811661 chr9 22134094 T C 7.00E-07 Type 2 diabetes / / 19056611 rs10811661 chr9 22134094 T C 8.00E-15 Coronary heart disease / / 21347282 rs10811661 chr9 22134094 T C 1.49E-07 Type 2 diabetes / / 22158537 rs10811661 chr9 22134094 T C 4.83E-16 Type 2 diabetes / / 22325160 rs10811661 chr9 22134094 T C 7.00E-06 Fasting glucose-related traits (interaction with BMI) / / 22581228 rs10811661 chr9 22134094 T C 3.70E-27 Type 2 diabetes / / 22885922 rs10811661 chr9 22134094 T C 5.70E-18 Fasting blood glucose / / 22885922 rs10811661 chr9 22134094 T C 0.00008753 2-hour glucose tolerance test / / 22885924 rs10811661 chr9 22134094 T C 5.60E-18 Fasting blood glucose / / 22885924 rs10811661 chr9 22134094 T C 1.00E-18 Type 2 diabetes / / 23945395 rs10811661 chr9 22134094 T C 1.00E-27 Type 2 diabetes / / 24509480 rs10757283 chr9 22134172 C T 1.05E-04 Multiple complex diseases / / 17554300 rs1333051 chr9 22136489 A T 6.78E-06 Multiple complex diseases / / 17554300 rs1333051 chr9 22136489 A T 6.00E-10 Type 2 diabetes / / 21573907 rs7018475 chr9 22137685 T G 3.00E-08 Type 2 diabetes / / 22293688 rs191930498 chr9 22145333 C G 0.0000583 Menopause (age at onset) / / 23424626 rs7042842 chr9 22157512 A G 0.00000113 LDL cholesterol / / 23063622 rs1537377 chr9 22169700 T C 2.00E-09 Endometriosis / / 23104006 rs866666 chr9 22183781 C T 5.94E-05 Cognitive impairment induced by topiramate / / 22091778 rs1751449 chr9 22196863 A G 9.30E-05 Bone mineral density (BMD),in women / / 20164292 rs1679013 chr9 22206987 C T 1.00E-08 Chronic lymphocytic leukemia / / 23770605 rs6475619 chr9 22207255 A T 9.89E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1679023 chr9 22250574 A G 5.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs10121530 chr9 22293166 G T 1.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs10738619 chr9 22298403 C T 2.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs1575971 chr9 22301053 C T 2.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs1575973 chr9 22301383 G T 2.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs2383216 chr9 22329058 A G 5.58E-04 Multiple complex diseases / / 17554300 rs716580 chr9 22336434 G A 1.30E-05 Intelligence (childhood) / / 23358156 rs1359742 chr9 22336996 G C 6.08E-09 Chronic lymphocytic leukemia / / 23770605 rs961831 chr9 22362104 T G 7.00E-06 Personality dimensions / / 20691247 rs10113901 chr9 22374032 C T 1.63E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs944034 chr9 22382145 A G 6.16E-05 Pulmonary function / / 20010835 rs1410978 chr9 22404681 C T 2.06E-05 Tuberculosis / / 24057671 rs476924 chr9 22431172 G A 8.51E-04 Tourette syndrome / / 22889924 rs476924 chr9 22431172 G A 3.80E-04 Lung function (forced vital capacity) / / 24023788 rs6475646 chr9 22454150 G A 1.81E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6475646 chr9 22454150 G A 4.40E-04 Lung function (forced vital capacity) / / 24023788 rs534632 chr9 22458980 G A 9.32E-29 Alcohol consumption / / pha001398 rs586716 chr9 22488678 G A 8.00E-06 Tuberculosis / / 24057671 rs6475653 chr9 22509658 A C 1.14E-04 Multiple complex diseases / / 17554300 rs10965365 chr9 22514989 G T 2.99E-04 Multiple complex diseases / / 17554300 rs10965365 chr9 22514989 G T 9.19E-05 Serum metabolites / / 19043545 rs1392087 chr9 22515738 G C 1.45E-04 Multiple complex diseases / / 17554300 rs1392087 chr9 22515738 G C 9.19E-05 Serum metabolites / / 19043545 rs1392087 chr9 22515738 G C 7.97E-27 Metabolite levels / / 22286219 rs4977586 chr9 22547508 C T 8.91E-05 Blood Pressure / / pha003040 rs6475667 chr9 22608036 G A 1.90E-05 Parkinson's disease / / 21738487 rs1932605 chr9 22625034 T C 6.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs7027354 chr9 22625342 G A 3.61E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7027354 chr9 22625342 G A 7.68E-05 Parkinson's disease / / 21738487 rs1763983 chr9 22627742 G A 6.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs7033988 chr9 22639090 C T 1.20E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1448792 chr9 22641633 A G 2.48E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1448789 chr9 22644110 A G 9.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs2210865 chr9 22669166 A G 1.20E-04 Amyotrophic Lateral Sclerosis FLJ35282 intron 17362836 rs613391 chr9 22670715 C G 5.00E-06 Quantitative traits FLJ35282 intron 19197348 rs636398 chr9 22680915 G T 1.69E-04 Amyotrophic Lateral Sclerosis FLJ35282 intron 17362836 rs17768235 chr9 22683792 T C 9.34E-04 Suicide attempts in bipolar disorder FLJ35282 intron 21423239 rs13289091 chr9 22690588 A G 1.26E-04 Amyotrophic Lateral Sclerosis FLJ35282 intron 17362836 rs11792221 chr9 22690660 T C 9.01E-04 Response to taxane treatment (placlitaxel) FLJ35282 intron 23006423 rs13286221 chr9 22693678 A G 1.74E-04 Amyotrophic Lateral Sclerosis FLJ35282 intron 17362836 rs1667087 chr9 22696345 G A 3.94E-04 Amyotrophic Lateral Sclerosis FLJ35282 intron 17362836 rs524361 chr9 22697535 C T 8.74E-04 Response to taxane treatment (placlitaxel) FLJ35282 intron 23006423 rs593909 chr9 22730877 C A 2.49E-04 Amyotrophic Lateral Sclerosis FLJ35282 intron 17362836 rs687779 chr9 22731757 G A 2.54E-04 Amyotrophic Lateral Sclerosis FLJ35282 intron 17362836 rs521757 chr9 22731784 T C 2.20E-04 Amyotrophic Lateral Sclerosis FLJ35282 intron 17362836 rs528204 chr9 22741961 A T 9.46E-04 Response to taxane treatment (placlitaxel) FLJ35282 intron 23006423 rs7039906 chr9 22746017 C A 2.60E-05 Urinary metabolites FLJ35282 intron 21572414 rs842847 chr9 22748083 C A 1.12E-04 Amyotrophic Lateral Sclerosis FLJ35282 intron 17362836 rs580417 chr9 22749670 A G 1.93E-04 Amyotrophic Lateral Sclerosis FLJ35282 intron 17362836 rs644917 chr9 22749869 G A 6.23E-04 Response to taxane treatment (placlitaxel) FLJ35282 intron 23006423 rs10811771 chr9 22770886 A G 8.00E-07 Response to antipsychotic therapy (extrapyramidal side effects) FLJ35282 intron 19875103 rs10811771 chr9 22770886 A G 2.84E-04 Suicide attempts in bipolar disorder FLJ35282 intron 21423239 rs12341759 chr9 22773567 A G 3.23E-04 Suicide attempts in bipolar disorder FLJ35282 intron 21423239 rs586554 chr9 22796540 T C 5.51E-04 Multiple complex diseases FLJ35282 intron 17554300 rs10117288 chr9 22809847 G A 4.55E-05 Bone mineral density FLJ35282 intron 19181680 rs10757359 chr9 22813898 T C 7.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FLJ35282 intron 20877124 rs7849973 chr9 22819576 G C 2.72E-04 Lung function (forced expiratory volume in 1 second) FLJ35282 intron 17255346 rs7849973 chr9 22819576 G C 8.59E-06 Serum metabolites FLJ35282 intron 19043545 rs7849973 chr9 22819576 G C 8.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) FLJ35282 intron 23453885 rs12554707 chr9 22842202 G A 2.00E-06 Response to amphetamines / / 22952603 rs7860089 chr9 22862795 G A 2.45E-05 Pulmonary function / / 20010835 rs4977798 chr9 22870294 G A 4.55E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1381922 chr9 22909498 C T 2.80E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1463030 chr9 22911864 C T 3.63E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs10511707 chr9 22912324 G A 8.34E-05 Serum metabolites / / 19043545 rs1531482 chr9 22937975 C T 2.70E-05 Urinary metabolites / / 21572414 rs7857311 chr9 22965874 T A 5.36E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10811812 chr9 22985180 T G 8.97E-05 Tunica Media / / pha003034 rs12349792 chr9 22985934 A T 4.46E-05 Glaucoma (primary open-angle) / / 22419738 rs10965553 chr9 22986069 A G 4.14E-04 Multiple complex diseases / / 17554300 rs1350996 chr9 22987182 G A 4.78E-04 Glaucoma (primary open-angle) / / 22419738 rs17696405 chr9 22990235 G A 3.95E-05 Glaucoma (primary open-angle) / / 22419738 rs7023567 chr9 23031321 C G 3.91E-05 Hypertension / / 19609347 rs2383253 chr9 23072095 A G 2.05E-05 Major depressive disorder / / 21621269 rs10511714 chr9 23081563 C G 1.66E-05 Bilirubin levels,in serum / / 19389676 rs16906879 chr9 23171516 T C 6.09E-05 Waist Circumference / / pha003023 rs2039749 chr9 23175657 C G 7.23E-05 Multiple complex diseases / / 17554300 rs7033378 chr9 23176101 C T 4.76E-05 Body Mass Index / / pha003020 rs7038289 chr9 23177606 C A 5.30E-04 Type 2 diabetes / / 17463246 rs1227463 chr9 23182825 A G 4.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7390078 chr9 23189128 A G 2.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10965692 chr9 23193941 G A 4.59E-04 Multiple complex diseases / / 17554300 rs10811868 chr9 23199959 G A 2.07E-04 Multiple complex diseases / / 17554300 rs1339142 chr9 23219125 T C 5.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1339142 chr9 23219125 T C 8.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10965711 chr9 23220531 A G 7.36E-06 White blood cell count / / 21738479 rs1339140 chr9 23222186 C A 5.61E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4400469 chr9 23239149 T C 3.80E-04 Body mass index / / 21701565 rs2225964 chr9 23267111 G T 5.26E-04 Rheumatoid arthritis / / 21452313 rs1538491 chr9 23280475 G A 8.76E-05 Cognitive test performance / / 20125193 rs1361305 chr9 23284312 G A 7.24E-04 Smoking cessation / / 24665060 rs9987819 chr9 23285901 G A 2.47E-05 Body mass index / / 23669352 rs4609278 chr9 23287879 A G 2.74E-04 Rheumatoid arthritis / / 21452313 rs1544161 chr9 23307377 A G 2.66E-05 Suicidal ideation / / 20877300 rs7871745 chr9 23309087 C G 5.31E-04 Coronary heart disease / / 21606135 rs1578105 chr9 23327655 G A 7.70E-04 Insulin resistance / / 21901158 rs6475738 chr9 23353939 C G 9.20E-06 Bipolar disorder / / 21738484 rs10965797 chr9 23359506 T C,G 7.00E-04 Aortic root size / / 21223598 rs2210292 chr9 23361805 G A 9.78E-04 Coronary heart disease / / 21606135 rs2210292 chr9 23361805 G A 6.62E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs1360380 chr9 23378488 G T 5.43E-04 Coronary heart disease / / 21606135 rs1111767 chr9 23380965 A G 8.96E-04 Multiple complex diseases / / 17554300 rs10965823 chr9 23391636 A G 9.50E-04 Multiple complex diseases / / 17554300 rs7873308 chr9 23425710 C T 5.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs12000445 chr9 23426271 A G 7.00E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs10115111 chr9 23433112 T C 1.33E-04 HIV-1 viral setpoint / / 21490045 rs166685 chr9 23486236 A G 5.63E-05 Multiple complex diseases / / 17554300 rs274917 chr9 23512985 A C 1.79E-07 Body Mass Index / / pha003007 rs274917 chr9 23512985 A C 6.16E-05 Weight / / pha003027 rs185678 chr9 23515021 A G 7.88E-07 Body Mass Index / / pha003007 rs16907259 chr9 23517989 C T 1.71E-07 Body Mass Index / / pha003007 rs16907259 chr9 23517989 C T 3.22E-05 Weight / / pha003027 rs274928 chr9 23524441 A C 3.47E-07 Body Mass Index / / pha003007 rs274928 chr9 23524441 A C 6.38E-05 Body Fat Distribution / / pha003017 rs274928 chr9 23524441 A C 6.15E-05 Body Fat Distribution / / pha003018 rs274928 chr9 23524441 A C 4.18E-05 Weight / / pha003027 rs7865248 chr9 23532809 T C 1.23E-05 Body Mass Index / / pha003007 rs12551650 chr9 23543410 G T 4.10E-08 Body Mass Index / / pha003007 rs12551650 chr9 23543410 G T 3.70E-06 Weight / / pha003027 rs7852546 chr9 23545955 C T 7.42E-04 Multiple complex diseases / / 17554300 rs7028484 chr9 23546461 G T 9.43E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10511729 chr9 23557227 T G 7.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs10511730 chr9 23563772 C T 3.10E-05 Blood pressure / / 19114657 rs10511730 chr9 23563772 C T 1.30E-04 Alcohol dependence / / 20201924 rs10511730 chr9 23563772 C T 5.90E-04 Alcohol dependence / / 20201924 rs274960 chr9 23567768 T C 4.67E-04 Multiple complex diseases / / 17554300 rs7852159 chr9 23575805 A G 9.40E-06 Amyotrophic lateral sclerosis / / 20801717 rs10965941 chr9 23583321 G A 1.29E-04 Insulin resistance / / 21901158 rs4977867 chr9 23613083 A G 2.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs2197402 chr9 23638686 C T 1.90E-05 Hypothyroidism / / 22493691 rs10966006 chr9 23644284 G A 8.94E-04 Aortic root size / / 21223598 rs1576287 chr9 23652656 G C 2.60E-05 Urinary metabolites / / 21572414 rs6475752 chr9 23658011 T G 2.31E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs2217504 chr9 23682669 G A 2.40E-05 Urinary metabolites / / 21572414 rs1329028 chr9 23687097 C G 2.50E-05 Urinary metabolites / / 21572414 rs10733392 chr9 23694188 C T 4.20E-05 Parkinson's disease (age of onset) ELAVL2 intron 19772629 rs7859819 chr9 23695179 C T 9.67E-05 Non-alcoholic fatty liver disease histology (other) ELAVL2 intron 20708005 rs16907618 chr9 23698649 T G 7.09E-04 Type 2 diabetes ELAVL2 intron 17463246 rs4977887 chr9 23718520 G T 2.05E-05 Heart Rate ELAVL2 intron pha003054 rs10811962 chr9 23728372 A G 0.0000295 Major depressive disorder ELAVL2 intron 23149448 rs10491817 chr9 23769754 A C 8.70E-04 Schizophrenia ELAVL2 intron 21674006 rs2195731 chr9 23785967 C A 6.00E-05 Body mass index ELAVL2 intron 20818722 rs2195731 chr9 23785967 C A 1.85E-05 Opioid sensitivity ELAVL2 intron 23183491 rs2195731 chr9 23785967 C A 3.32E-04 Lung function (forced vital capacity) ELAVL2 intron 24023788 rs17551174 chr9 23817548 A G 5.13E-05 Prostate cancer ELAVL2 intron pha002877 rs17551174 chr9 23817548 A G 8.95E-05 Prostate cancer ELAVL2 intron pha002878 rs12341793 chr9 23829824 A G 7.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17557796 chr9 23830403 A G 4.56E-05 Serum metabolites / / 19043545 rs512089 chr9 23874047 A C 1.98E-05 Anorexia nervosa / / 21079607 rs1376141 chr9 23887854 A G 0.000013 Major depressive disorder / / 22915352 rs7035943 chr9 23979686 A G 8.39E-05 Coronary heart disease / / pha003030 rs10966189 chr9 24057376 G A 1.96E-04 Smoking initiation / / 24665060 rs41370445 chr9 24088807 T C 6.47E-04 Multiple complex diseases / / 17554300 rs4246856 chr9 24092072 C G 6.00E-06 D-dimer levels / / 21502573 rs2225614 chr9 24111280 C A 3.00E-06 Quantitative traits / / 19197348 rs12376503 chr9 24121196 A G 9.28E-05 Body Mass Index / / pha003009 rs10812030 chr9 24146203 A G 6.80E-04 Heart Failure / / pha002885 rs7850234 chr9 24189914 C T 6.28E-04 Type 2 diabetes / / 17463246 rs17256610 chr9 24246608 T A 5.86E-04 Type 2 diabetes / / 17463246 rs16908149 chr9 24247436 G C 1.75E-04 Smoking quantity / / 24665060 rs17197195 chr9 24247485 G A 3.14E-04 Type 2 diabetes / / 17463246 rs4007541 chr9 24264219 T C 5.86E-04 Type 2 diabetes / / 17463246 rs1410964 chr9 24272883 A G 6.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6475790 chr9 24298508 A C 7.42E-04 Multiple complex diseases / / 17554300 rs829751 chr9 24358469 A G 3.73E-05 Longevity / / 22279548 rs10115440 chr9 24428847 C T 3.96E-05 Heart Rate / / pha003051 rs10966313 chr9 24448683 T C 5.02E-05 Heart Rate / / pha003051 rs1984582 chr9 24477128 G A 4.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs1411216 chr9 24520194 A G 6.71E-04 Parkinson's disease / / 17052657 rs16908561 chr9 24602765 C T 8.04E-152 Multiple complex diseases / / 17554300 rs1759041 chr9 24621944 A G 6.57E-04 Stroke / / pha002886 rs10812071 chr9 24650899 C A,G,T 8.51E-05 Brain lesion load / / 19010793 rs10966380 chr9 24670982 C T 9.06E-04 Insulin resistance / / 21901158 rs12345084 chr9 24675596 C G 5.86E-04 Multiple complex diseases / / 17554300 rs16908747 chr9 24717136 T A 7.20E-05 Electrocardiographic conduction measures / / 19389651 rs144154278 chr9 24718061 G A 8.09E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs10491833 chr9 24720232 T C 8.14E-04 Parkinson's disease / / 17052657 rs10491833 chr9 24720232 T C 6.30E-05 Amyotrophic Lateral Sclerosis / / 17362836 rs10491833 chr9 24720232 T C 4.00E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs10966435 chr9 24722681 G C 1.80E-05 Urinary metabolites / / 21572414 rs7870157 chr9 24725459 T C 7.09E-04 Alzheimer's disease / / 17998437 rs4977950 chr9 24732482 G C 9.10E-08 Blood pressure / / 19114657 rs10757483 chr9 24732824 T C 4.01E-04 Alzheimer's disease / / 17998437 rs4977953 chr9 24741204 G A 3.32E-05 Bilirubin levels,in serum / / 19389676 rs4129728 chr9 24754535 A C 6.00E-05 Post-operative nausea and vomiting / / 21694509 rs1926681 chr9 24802015 A C 6.39E-04 Multiple complex diseases / / 17554300 rs10125310 chr9 24899898 A G 2.43E-04 Blood pressure / / 17255346 rs10966576 chr9 24932377 C T 5.93E-04 Type 2 diabetes / / 17463246 rs7863722 chr9 24933878 C T 6.76E-05 Blood pressure / / 17255346 rs7025715 chr9 24934491 T C 3.70E-04 Blood pressure / / 17255346 rs2126173 chr9 24948958 T C 1.61E-05 Blood pressure / / 17255346 rs2383455 chr9 24953301 A G 1.54E-05 Blood pressure / / 17255346 rs2383454 chr9 24953447 C T 1.51E-05 Blood pressure / / 17255346 rs10966629 chr9 24998099 A G 7.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs1125516 chr9 24999327 C T 8.37E-04 Type 2 diabetes / / 17463246 rs7854529 chr9 25017813 T C,G 3.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13286283 chr9 25029338 G A 4.34E-05 HIV-1 viral setpoint / / 22174851 rs2614163 chr9 25054188 A T 4.43E-04 Multiple complex diseases / / 17554300 rs3126974 chr9 25083867 T C 5.70E-04 Fibrinogen / / 17255346 rs1925484 chr9 25092081 C T 4.43E-04 Multiple complex diseases / / 17554300 rs10116136 chr9 25112596 A G 3.61E-04 Smoking initiation / / 24665060 rs3126975 chr9 25142445 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs3118302 chr9 25149090 A G 4.97E-05 Type 2 diabetes / / 17463246 rs7867236 chr9 25165160 C T 2.04E-04 Type 2 diabetes / / 17463246 rs10966772 chr9 25170008 A G 4.90E-04 Multiple complex diseases / / 17554300 rs12337176 chr9 25178084 C T 7.89E-05 Type 2 diabetes / / 17463246 rs3118339 chr9 25184960 T C 8.21E-04 Type 2 diabetes / / 17463246 rs10118016 chr9 25192085 C T 3.39E-04 Type 2 diabetes / / 17463246 rs9408053 chr9 25192282 C T 9.65E-05 Cognitive test performance / / 20125193 rs181881383 chr9 25192573 C T 2.00E-08 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs7039724 chr9 25195023 A G 2.73E-04 Type 2 diabetes / / 17463246 rs6475838 chr9 25195149 C T 9.64E-05 Cognitive test performance / / 20125193 rs4578051 chr9 25219550 G C 7.64E-05 Type 2 diabetes / / 17463246 rs1999469 chr9 25221244 A T 2.43E-04 Type 2 diabetes / / 17463246 rs1999469 chr9 25221244 A T 1.11E-04 Coronary Artery Disease / / 17634449 rs1999468 chr9 25221407 A G 5.37E-04 Type 2 diabetes / / 17463246 rs10966811 chr9 25233484 G A 3.21E-04 Type 2 diabetes / / 17463246 rs10966811 chr9 25233484 G A 5.57E-06 Male fertility / / 22633400 rs1758734 chr9 25263918 G A 6.55E-05 HDL cholesterol / / pha003075 rs1758743 chr9 25281553 A G 5.84E-04 Multiple complex diseases / / 17554300 rs10966833 chr9 25281912 C T 1.21E-04 Type 2 diabetes / / 17463246 rs10511753 chr9 25286650 G A 2.33E-05 Colorectal cancer / / 21242260 rs4977974 chr9 25294701 T C 5.92E-05 Creatinine levels / / pha003069 rs2443486 chr9 25308251 T C 8.01E-04 Multiple complex diseases / / 17554300 rs2443486 chr9 25308251 T C 8.60E-06 Urinary metabolites / / 21572414 rs1318664 chr9 25349769 A G 1.02E-04 Multiple complex diseases / / 17554300 rs10757521 chr9 25385317 C T 1.06E-04 Bipolar disorder / / 17486107 rs7021404 chr9 25414051 C A,T 8.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) / / 23934736 rs10966900 chr9 25425160 T G 0.00000012 Perception of the odorant androstenone / / 22362865 rs13295352 chr9 25430845 A G 8.11E-05 Cognitive impairment induced by topiramate / / 22091778 rs7035858 chr9 25440872 C T 5.96E-05 Cognitive performance / / 19734545 rs12552736 chr9 25449122 T C 2.00E-06 RR interval (heart rate) / / 20031603 rs13300284 chr9 25452812 G A 4.00E-06 RR interval (heart rate) / / 20031603 rs7861656 chr9 25452963 A G 9.10E-04 Multiple complex diseases / / 17554300 rs10966920 chr9 25455760 A G 6.87E-04 Multiple complex diseases / / 17554300 rs1537269 chr9 25495626 A G 3.49E-04 Type 2 diabetes / / 17463246 rs1537270 chr9 25495652 G A 4.14E-04 Type 2 diabetes / / 17463246 rs1360523 chr9 25499528 T G 2.12E-04 Type 2 diabetes / / 17463246 rs1332173 chr9 25500238 A G 0.000231616 Hypertension (early onset hypertension) / / 22479346 rs2210430 chr9 25501297 T C 9.00E-06 Sleep quality / / 23728906 rs12003047 chr9 25527621 T C 9.38E-05 Longevity / / 20304771 rs17774966 chr9 25551357 C T 8.00E-06 Entorhinal cortical thickness / / 21116278 rs7849571 chr9 25592151 C T 0.000072 Pancreatic cancer and survival / / 22665904 rs7036435 chr9 25618261 C T 7.12E-05 Obesity (extreme) / / 21935397 rs7036435 chr9 25618261 C T 4.03E-05 Blood Pressure / / pha003045 rs7036435 chr9 25618261 C T 2.54E-05 Blood Pressure / / pha003047 rs10511762 chr9 25631130 T C 1.29E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs10511765 chr9 25643333 A C 7.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4144931 chr9 25658150 C T 7.70E-04 Alcohol dependence / / 20201924 rs4977681 chr9 25658483 T C 2.91E-04 Schizophrenia / / 19197363 rs1128957 chr9 25677257 C G 7.76E-05 Height TUSC1 UTR-3 17255346 rs1128957 chr9 25677257 C G 3.75E-05 Multiple complex diseases TUSC1 UTR-3 17554300 rs10738727 chr9 25679024 G C 2.03E-04 Height TUSC1 nearGene-5 17255346 rs10738727 chr9 25679024 G C 4.10E-04 Multiple complex diseases TUSC1 nearGene-5 17554300 rs7031899 chr9 25691032 T C 4.10E-06 Urinary metabolites / / 21572414 rs7851146 chr9 25696292 T C 7.29E-04 Insulin resistance / / 21901158 rs16909643 chr9 25717857 T C 4.72E-04 Insulin resistance / / 21901158 rs1231331 chr9 25718004 T A 7.06E-04 Coronary Artery Disease / / 17634449 rs13286794 chr9 25719190 G A 1.12E-04 Coronary Artery Disease / / 17634449 rs13286794 chr9 25719190 G A 9.25E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7034534 chr9 25723678 G A 3.90E-04 Coronary Artery Disease / / 17634449 rs7034534 chr9 25723678 G A 4.66E-05 Recombination rate / / 21698098 rs12342141 chr9 25734900 C T 8.35E-04 Alzheimer's disease / / 22005930 rs1231339 chr9 25740863 A C 6.96E-05 Hypertension / / pha003042 rs1231343 chr9 25742531 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs13286966 chr9 25749378 G A 7.16E-04 Multiple complex diseases / / 17554300 rs13286966 chr9 25749378 G A 3.10E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1937934 chr9 25757569 C T 1.22E-04 Type 2 diabetes / / 17463246 rs1937934 chr9 25757569 C T 2.58E-05 Height / / 22021425 rs1634404 chr9 25772172 A G 2.23E-04 Alzheimer's disease (late onset) / / 21379329 rs10967072 chr9 25775262 C A 5.24E-04 Smoking initiation / / 24665060 rs1147808 chr9 25775447 C T 3.86E-04 Alzheimer's disease (late onset) / / 21379329 rs1220078 chr9 25794090 A G 7.95E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1782030 chr9 25808485 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1219937 chr9 25901396 G A 3.77E-04 Multiple complex diseases / / 17554300 rs1219937 chr9 25901396 G A 3.46E-05 Socioeconomic Factors / / pha003066 rs1219936 chr9 25901711 G A 6.09E-04 Smoking initiation / / 24665060 rs1219935 chr9 25902763 C T 0.00008247 Sarcoidosis / / 22952805 rs1219942 chr9 25919851 C T 9.96E-05 Socioeconomic Factors / / pha003066 rs546921 chr9 25938342 G A 3.49E-05 Socioeconomic Factors / / pha003066 rs7039123 chr9 25955017 A G 6.56E-12 Multiple complex diseases / / 17554300 rs552317 chr9 25964852 G A 8.26E-04 Multiple complex diseases / / 17554300 rs16909976 chr9 25969885 A T 7.66E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs16910024 chr9 25988972 T C 2.75E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2891276 chr9 25993272 A G 1.02E-05 Multiple complex diseases / / 17554300 rs2891276 chr9 25993272 A G 1.41E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1855030 chr9 25993972 C T 7.83E-04 Multiple complex diseases / / 17554300 rs1332340 chr9 26005487 T C 5.96E-04 Multiple complex diseases / / 17554300 rs7036403 chr9 26037837 C T 2.24E-04 Aortic root size / / 21223598 rs957252 chr9 26059028 A C 1.17E-05 Response to metformin / / 21186350 rs9406901 chr9 26062582 A G 5.22E-05 Response to metformin / / 21186350 rs16910139 chr9 26079978 T G 7.47E-05 Self-reported allergy LOC100506422 intron 23817569 rs16910141 chr9 26080022 A G 1.50E-04 Self-reported allergy LOC100506422 intron 23817569 rs16910176 chr9 26117767 T C 1.87E-04 Epilepsy LOC100506422 UTR-3 22116939 rs10738747 chr9 26184578 G A 5.03E-06 Uric acid levels / / 21294900 rs10738747 chr9 26184578 G A 1.00E-04 Prostate cancer / / 21743057 rs2571519 chr9 26184917 C T 1.00E-04 Prostate cancer / / 21743057 rs1821553 chr9 26187635 G A 2.00E-04 Information processing speed / / 21130836 rs1369211 chr9 26203908 A C 2.04E-04 Scoliosis / / 21216876 rs2217796 chr9 26205694 A G 3.65E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs4978053 chr9 26208857 G C 6.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs2016672 chr9 26226441 A C 3.35E-05 Major depressive disorder (broad) / / 20038947 rs1434866 chr9 26226927 C T 6.25E-05 Major depressive disorder (broad) / / 20038947 rs2060439 chr9 26242136 G A 6.07E-07 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs623893 chr9 26257238 C T 2.72E-04 Alzheimer's disease / / 22005930 rs629448 chr9 26273322 G T 3.14E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs2082714 chr9 26276773 T G 7.46E-05 Orofacial clefts / / 22419666 rs2383643 chr9 26289186 G C 6.96E-04 Multiple complex diseases / / 17554300 rs353435 chr9 26290977 C T 2.75E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10511771 chr9 26298134 C T 1.99E-05 Lung adenocarcinoma / / 19836008 rs17719825 chr9 26302964 A G 3.32E-05 Lung adenocarcinoma / / 19836008 rs10967301 chr9 26313753 A C 1.40E-05 Urinary metabolites / / 21572414 rs989494 chr9 26317242 A C 6.33E-04 Type 2 diabetes / / 17463246 rs1336466 chr9 26333942 T C 6.28E-04 Obesity (extreme) / / 21935397 rs2618000 chr9 26359420 G T 9.70E-04 Depression (quantitative trait) / / 20800221 rs451664 chr9 26370564 G A 9.97E-05 Celiac disease / / 23936387 rs406058 chr9 26371680 G A 5.65E-05 Celiac disease / / 23936387 rs2769970 chr9 26381874 C T 1.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs694150 chr9 26384371 A G 7.55E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10812392 chr9 26410031 C T 7.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1855980 chr9 26414780 T C 1.55E-05 Obesity (extreme) / / 21935397 rs10757609 chr9 26443738 A G 1.20E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10757609 chr9 26443738 A G 5.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10757609 chr9 26443738 A G 6.99E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16910463 chr9 26444299 C A 4.42E-05 Multiple complex diseases / / 17554300 rs3930533 chr9 26466575 C A 4.88E-04 Parkinson's disease / / 17052657 rs4978076 chr9 26524684 C T 6.00E-04 Chronic fatigue syndrome / / 21912186 rs12551856 chr9 26547175 G C 1.40E-05 Urinary metabolites / / 21572414 rs12552748 chr9 26551100 T C 2.10E-05 Urinary metabolites / / 21572414 rs10757612 chr9 26551726 A C 8.86E-04 Schizophrenia / / 19197363 rs10967401 chr9 26553975 T C 9.03E-04 Insulin resistance / / 21901158 rs1328426 chr9 26565214 A C 6.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs1887221 chr9 26565913 A C 4.52E-05 Serum metabolites / / 19043545 rs996414 chr9 26580067 G A 8.76E-07 chronic obstructive pulmonary disease / / 21921092 rs10812425 chr9 26606060 C T 2.20E-06 Drug-induced liver injury (flucloxacillin) / / 19483685 rs10812426 chr9 26609613 T C 5.75E-05 Prostate cancer / / pha002877 rs10812428 chr9 26614847 C T 1.00E-06 Drug-induced liver injury (flucloxacillin) / / 19483685 rs10812428 chr9 26614847 C T 2.57E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7868631 chr9 26624871 T G 8.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs16910638 chr9 26626729 A G 6.26E-06 Type 2 diabetes / / 23300278 rs989947 chr9 26650017 A G 9.81E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10511782 chr9 26674660 A G 2.80E-05 Urinary metabolites / / 21572414 rs12236180 chr9 26675172 T G 4.63E-05 Schizophrenia / / pha002857 rs10967476 chr9 26682007 G A 4.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7871815 chr9 26694184 G A 2.95E-04 Celiac disease / / 23936387 rs13294589 chr9 26694888 A G 2.00E-06 Gallbladder cancer / / 22318345 rs10757623 chr9 26713335 T G 2.28E-05 Bipolar disorder and schizophrenia / / 20889312 rs2060409 chr9 26714614 T C 1.07E-05 Cognitive test performance / / 20125193 rs10812450 chr9 26722838 C T 7.60E-04 Alcohol dependence / / 20201924 rs10967494 chr9 26723522 T C 6.27E-05 Bipolar disorder and schizophrenia / / 20889312 rs4978100 chr9 26751013 T C 7.00E-05 Cholesterol / / pha003073 rs4978100 chr9 26751013 T C 9.53E-05 Cholesterol / / pha003078 rs17693610 chr9 26762105 C T 3.91E-04 Depression (quantitative trait) / / 20800221 rs16910779 chr9 26771916 A C 9.54E-04 Depression (quantitative trait) / / 20800221 rs10812462 chr9 26777178 A G 9.31E-06 Multiple complex diseases / / 17554300 rs10511777 chr9 26783463 C T 1.52E-06 Amyotrophic lateral sclerosis / / 20801718 rs1889899 chr9 26789940 A G 6.00E-06 Smoking behavior / / 19247474 rs17755738 chr9 26798101 G T 5.32E-04 Multiple complex diseases / / 17554300 rs7863308 chr9 26808206 T G 1.01E-05 Cognitive test performance / / 20125193 rs17760657 chr9 26832939 G A 6.55E-04 Multiple complex diseases / / 17554300 rs12344894 chr9 26833141 C G 7.70E-06 Urinary metabolites / / 21572414 rs7032756 chr9 26844843 C T 4.50E-06 Schizophrenia C9orf82 intron 19571808 rs7868158 chr9 26860358 T C 9.90E-06 Schizophrenia C9orf82 intron 19571808 rs10511792 chr9 26901068 A T 6.10E-06 Urinary metabolites / / 21572414 rs7863476 chr9 26915925 G A 3.60E-06 Schizophrenia PLAA intron 19571808 rs7863476 chr9 26915925 G A 6.30E-07 Schizophrenia PLAA intron 21791550 rs7863476 chr9 26915925 G A 0.00000063 Psychosis PLAA intron 23164818 rs7871286 chr9 26917718 C T 9.55E-05 Cognitive test performance PLAA intron 20125193 rs7871286 chr9 26917718 C T 2.68E-08 Metabolite levels PLAA intron 23281178 rs7045881 chr9 26935996 A T 2.00E-06 Schizophrenia PLAA intron 20185149 rs7045881 chr9 26935996 A T 2.10E-06 Schizophrenia (treatment refractory) PLAA intron 22479419 rs7035755 chr9 26945976 A G 9.90E-05 Schizophrenia PLAA intron 19571808 rs7035755 chr9 26945976 A G 2.18E-05 Cognitive test performance PLAA intron 20125193 rs144847384 chr9 27009095 T C 0.000064 Breast cancer(er negative) IFT74 missense 23555315 rs12337896 chr9 27018020 A G 3.70E-07 Schizophrenia IFT74 intron 19571808 rs7390085 chr9 27028947 A G 4.99E-06 Amyotrophic lateral sclerosis IFT74 intron 20801718 rs9644870 chr9 27038948 T G 8.06E-04 Myocardial Infarction IFT74 intron pha002883 rs10812518 chr9 27041676 C T 3.00E-07 Schizophrenia IFT74 intron 19571808 rs16910953 chr9 27047460 T C 8.32E-04 Multiple complex diseases IFT74 intron 17554300 rs620090 chr9 27074233 G T 4.17E-04 Type 2 diabetes / / 17463246 rs1577330 chr9 27075715 A G 4.00E-06 IgG glycosylation / / 23382691 rs2782434 chr9 27095072 C T 8.24E-05 Triglycerides / / pha003080 rs615532 chr9 27104709 G A 2.07E-05 Triglycerides / / pha003080 rs615375 chr9 27112311 G T 9.30E-04 Suicide attempts in bipolar disorder TEK intron 21423239 rs680739 chr9 27114804 T A 8.81E-04 Type 2 diabetes TEK intron 17463246 rs621786 chr9 27118807 A G 9.64E-04 Stroke TEK intron pha002887 rs666812 chr9 27120369 G T 1.31E-05 Cardiovascular disease TEK intron pha003064 rs666812 chr9 27120369 G T 1.32E-06 Triglycerides TEK intron pha003080 rs1334809 chr9 27126415 G T 8.00E-06 IgG glycosylation TEK intron 23382691 rs7044842 chr9 27132514 T C 8.63E-04 Response to statin treatment (atorvastatin),change in cholesterol levels TEK intron 20031582 rs7044842 chr9 27132514 T C 7.95E-05 Amyotrophic lateral sclerosis TEK intron 20801718 rs7032817 chr9 27133385 C T 7.11E-06 Triglycerides TEK intron pha003080 rs12554485 chr9 27137253 A C 3.59E-04 Response to statin treatment (atorvastatin),change in cholesterol levels TEK intron 20031582 rs11789885 chr9 27138898 C T 5.73E-06 Triglycerides TEK intron pha003080 rs10967731 chr9 27139817 G A 6.15E-04 Multiple complex diseases TEK intron 17554300 rs7034505 chr9 27151394 G A 0.000834 Height (Pygmy height) TEK intron 22570615 rs7865623 chr9 27152209 C T 1.14E-04 Smoking cessation TEK intron 18519826 rs628873 chr9 27155544 C T 8.39E-04 HIV-1 viral setpoint TEK intron 17641165 rs628873 chr9 27155544 C T 4.90E-04 Volumetric brain MRI TEK intron 17903297 rs7871318 chr9 27171311 C T 0.00014 Height (Pygmy height) TEK intron 22570615 rs4242670 chr9 27200738 C A 3.23E-04 Alzheimer's disease (late onset) TEK intron 21379329 rs1413829 chr9 27201968 A G 6.40E-04 Crohn's disease TEK intron 17684544 rs1360773 chr9 27202284 G T 8.78E-04 Response to statin treatment (atorvastatin),change in cholesterol levels TEK intron 20031582 rs7024846 chr9 27226947 G T 3.32E-04 Type 2 diabetes TEK intron 17463246 rs7037246 chr9 27229544 C G 5.37E-05 Smoking cessation TEK UTR-3 18519826 rs857 chr9 27229786 G A,C,T 1.73E-04 Smoking cessation TEK UTR-3 18519826 rs1322048 chr9 27232748 C T 2.69E-06 Longevity,exceptional / / 20595579 rs1322048 chr9 27232748 C T 2.94E-06 Longevity / / 22279548 rs1590255 chr9 27233968 G T 3.30E-04 Alcohol dependence / / 20201924 rs1590255 chr9 27233968 G T 8.50E-04 Alcohol dependence / / 20201924 rs7468695 chr9 27234521 G A 4.60E-04 Alcohol dependence / / 20201924 rs2057362 chr9 27247314 T C 3.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00032 intron 20877124 rs10967809 chr9 27248189 C G 3.85E-05 Type 2 diabetes LINC00032 intron 17463246 rs997675 chr9 27258216 G A 1.29E-05 Longevity,exceptional LINC00032 intron 20595579 rs997675 chr9 27258216 G A 1.41E-05 Longevity LINC00032 intron 22279548 rs1126107 chr9 27284363 C T 9.64E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2383722 chr9 27288895 T G 2.24E-04 Longevity C9orf11 intron 22279548 rs12337286 chr9 27292474 T C 0.00026 Breast cancer C9orf11 missense 23555315 rs10967875 chr9 27309659 T C 6.00E-06 Obesity-related traits / / 23251661 rs7848125 chr9 27313439 C T 3.07E-04 Smoking initiation / / 24665060 rs1555453 chr9 27326780 G T 0.0000107 Aging MOB3B UTR-3 22445811 rs2181029 chr9 27326904 A G 4.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MOB3B UTR-3 20877124 rs3739531 chr9 27328964 C T 1.21E-04 Blood pressure MOB3B UTR-3 17255346 rs10967899 chr9 27335339 A G 1.21E-04 Amyotrophic Lateral Sclerosis MOB3B intron 17827064 rs7041639 chr9 27341338 A G 6.48E-05 Celiac disease MOB3B intron 23936387 rs7849799 chr9 27361872 A G 2.36E-04 Iron levels MOB3B intron pha002876 rs7034798 chr9 27364824 A C 2.08E-05 Height MOB3B intron 22021425 rs12346755 chr9 27384204 C T 9.50E-04 Amyotrophic lateral sclerosis (sporadic) MOB3B intron 24529757 rs1110155 chr9 27386505 T G 7.00E-06 Urinary metabolites MOB3B intron 21572414 rs2225389 chr9 27409264 T G 6.47E-05 Psoriasis MOB3B intron 18364390 rs2225389 chr9 27409264 T G 2.88E-08 Amyotrophic lateral sclerosis MOB3B intron 20801718 rs763372 chr9 27428665 A T 6.77E-04 Multiple complex diseases MOB3B intron 17554300 rs1411720 chr9 27433387 A T 2.04E-04 Multiple complex diseases MOB3B intron 17554300 rs2589053 chr9 27441537 C T 2.83E-04 Alcohol dependence MOB3B intron 21314694 rs2764329 chr9 27443374 A T 6.87E-04 Alzheimer's disease MOB3B intron 17998437 rs1058326 chr9 27447089 G A 4.30E-05 Information processing speed MOB3B intron 21130836 rs1058326 chr9 27447089 G A 1.94E-05 Alcohol consumption MOB3B intron pha001397 rs12377254 chr9 27450596 C G 2.90E-05 Urinary metabolites MOB3B intron 21572414 rs4879507 chr9 27451482 C T 6.79E-04 Smoking initiation MOB3B intron 24665060 rs7021551 chr9 27456645 G T 2.60E-05 Urinary metabolites MOB3B intron 21572414 rs7021930 chr9 27456928 G A 8.48E-04 Type 2 diabetes MOB3B intron 17463246 rs10967946 chr9 27461643 C T 2.50E-05 Urinary metabolites MOB3B intron 21572414 rs10511816 chr9 27468461 C A 8.05E-06 Amyotrophic lateral sclerosis MOB3B intron 20801717 rs10511816 chr9 27468461 C A 5.23E-05 Amyotrophic lateral sclerosis MOB3B intron 20801718 rs10511816 chr9 27468461 C A 1.44E-27 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs10511816 chr9 27468461 C A 2.31E-13 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs10511816 chr9 27468461 C A 3.08E-18 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs10967952 chr9 27474214 T C 0.000000866 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs10967952 chr9 27474214 T C 3.49E-11 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs10967952 chr9 27474214 T C 5.31E-05 Erythrocyte counts MOB3B intron pha003101 rs1822723 chr9 27478052 C T 0.000000097 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs1822723 chr9 27478052 C T 4.37E-08 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs10967958 chr9 27481905 C T 0.00000135 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs10967958 chr9 27481905 C T 7.77E-11 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs4879515 chr9 27482235 C T 1.16E-06 Amyotrophic lateral sclerosis MOB3B intron 20801717 rs4879515 chr9 27482235 C T 3.98E-05 Amyotrophic lateral sclerosis MOB3B intron 20801718 rs4879515 chr9 27482235 C T 1.16E-17 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs4879515 chr9 27482235 C T 8.10E-14 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs4879515 chr9 27482235 C T 8.33E-26 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs10967959 chr9 27482967 C T 0.000000132 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs10967959 chr9 27482967 C T 6.58E-11 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs10967959 chr9 27482967 C T 2.05E-06 Erythrocyte counts MOB3B intron pha003101 rs17835770 chr9 27484575 C T 9.89E-04 Multiple complex diseases MOB3B intron 17554300 rs17779457 chr9 27488092 T G 7.00E-07 Urinary symptoms in response to radiotherapy in prostate cancer MOB3B intron 23376709 rs868856 chr9 27489251 A G 3.19E-07 Amyotrophic lateral sclerosis MOB3B intron 20801718 rs7046653 chr9 27490967 A G 5.00E-07 Response to TNF antagonist treatment MOB3B intron 18615156 rs7046653 chr9 27490967 A G 1.17E-05 Amyotrophic lateral sclerosis MOB3B intron 20801717 rs7046653 chr9 27490967 A G 2.03E-07 Amyotrophic lateral sclerosis MOB3B intron 20801718 rs7046653 chr9 27490967 A G 0.0000156 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs7046653 chr9 27490967 A G 5.05E-21 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs7046653 chr9 27490967 A G 6.67E-37 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs7046653 chr9 27490967 A G 6.86E-64 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs10967964 chr9 27495920 C A 8.78E-04 Multiple complex diseases MOB3B intron 17554300 rs10116539 chr9 27498358 C T 2.07E-04 Multiple complex diseases MOB3B intron 17554300 rs1031154 chr9 27498800 A C 7.00E-06 Systemic lupus erythematosus MOB3B intron 20706608 rs1977661 chr9 27502986 C A 0.000000032 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs10812605 chr9 27510360 C T 0.00000238 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs10812605 chr9 27510360 C T 6.75E-23 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs10812605 chr9 27510360 C T 7.93E-57 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs10812605 chr9 27510360 C T 9.75E-30 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs12553951 chr9 27512234 A C 2.50E-04 Systemic lupus erythematosus MOB3B intron 20706608 rs774352 chr9 27516590 T C 2.75E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain MOB3B intron 20154673 rs774352 chr9 27516590 T C 0.0000134 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs774352 chr9 27516590 T C 1.34E-36 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs774352 chr9 27516590 T C 2.10E-21 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs774352 chr9 27516590 T C 3.93E-64 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs774351 chr9 27516640 A C 2.89E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain MOB3B intron 20154673 rs774351 chr9 27516640 A C 0.0000136 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs774351 chr9 27516640 A C 1.35E-36 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs774351 chr9 27516640 A C 2.13E-21 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs774351 chr9 27516640 A C 3.93E-64 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs11792285 chr9 27519173 C T 1.04E-12 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs11792285 chr9 27519173 C T 1.97E-09 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs11792285 chr9 27519173 C T 7.81E-17 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs10967973 chr9 27525751 A G 1.29E-04 Multiple complex diseases IFNK intron 17554300 rs4879540 chr9 27527479 A T 1.19E-04 Multiple complex diseases MOB3B intron 17554300 rs903603 chr9 27529316 G A 8.92E-08 Amyotrophic lateral sclerosis MOB3B intron 20801717 rs903603 chr9 27529316 G A 0.0000187 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs903603 chr9 27529316 G A 2.21E-28 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs903603 chr9 27529316 G A 3.28E-19 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs903603 chr9 27529316 G A 5.98E-16 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs903603 chr9 27529316 G A 7.55E-08 Amyotrophic lateral sclerosis MOB3B intron 23587638 rs903603 chr9 27529316 G A 8.65E-04 Heart Failure MOB3B intron pha002884 rs10812610 chr9 27533984 C A 5.00E-06 Heart failure / / 20445134 rs10812610 chr9 27533984 C A 4.53E-05 Amyotrophic lateral sclerosis / / 20801718 rs10812610 chr9 27533984 C A 3.47E-04 Heart Failure / / pha002884 rs2814707 chr9 27536397 C T 7.00E-09 Amyotrophic lateral sclerosis / / 19734901 rs2814707 chr9 27536397 C T 5.72E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs2814707 chr9 27536397 C T 3.32E-06 Amyotrophic lateral sclerosis / / 20801717 rs2814707 chr9 27536397 C T 1.18E-10 Amyotrophic lateral sclerosis / / 20801718 rs2814707 chr9 27536397 C T 4.72E-10 Prion diseases / / 22210626 rs2814707 chr9 27536397 C T 0.000005 Amyotrophic lateral sclerosis / / 23587638 rs2814707 chr9 27536397 C T 1.00E-20 Amyotrophic lateral sclerosis / / 23587638 rs2814707 chr9 27536397 C T 1.95E-43 Amyotrophic lateral sclerosis / / 23587638 rs2814707 chr9 27536397 C T 3.02E-84 Amyotrophic lateral sclerosis / / 23587638 rs2814707 chr9 27536397 C T 1.35E-08 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs2477523 chr9 27536894 T A 1.06E-08 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs3849941 chr9 27538948 A G 9.54E-09 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs10812611 chr9 27542261 C T 0.0000502 Amyotrophic lateral sclerosis / / 23587638 rs10812611 chr9 27542261 C T 1.50E-52 Amyotrophic lateral sclerosis / / 23587638 rs10812611 chr9 27542261 C T 6.96E-33 Amyotrophic lateral sclerosis / / 23587638 rs10812611 chr9 27542261 C T 7.88E-23 Amyotrophic lateral sclerosis / / 23587638 rs10812611 chr9 27542261 C T 9.82E-08 Amyotrophic lateral sclerosis / / 23587638 rs3849942 chr9 27543281 T C 1.00E-08 Amyotrophic lateral sclerosis / / 19734901 rs3849942 chr9 27543281 T C 1.38E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs3849942 chr9 27543281 T C 8.00E-10 Amyotrophic lateral sclerosis / / 20801717 rs3849942 chr9 27543281 T C 9.00E-11 Amyotrophic lateral sclerosis / / 20801718 rs3849942 chr9 27543281 T C 4.64E-10 Prion diseases / / 22210626 rs3849942 chr9 27543281 T C 4.00E-07 Amyotrophic lateral sclerosis / / 22959728 rs3849942 chr9 27543281 T C 0.00000328 Amyotrophic lateral sclerosis / / 23587638 rs3849942 chr9 27543281 T C 1.35E-43 Amyotrophic lateral sclerosis / / 23587638 rs3849942 chr9 27543281 T C 3.02E-84 Amyotrophic lateral sclerosis / / 23587638 rs3849942 chr9 27543281 T C 5.44E-21 Amyotrophic lateral sclerosis / / 23587638 rs3849942 chr9 27543281 T C 5.80E-06 Amyotrophic lateral sclerosis / / 24234648 rs3849942 chr9 27543281 T C 1.00E-08 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs3849942 chr9 27543281 T C 1.10E-08 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs3849943 chr9 27543382 C T 7.69E-09 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs10967976 chr9 27544943 G A 0.0000363 Amyotrophic lateral sclerosis / / 23587638 rs10967976 chr9 27544943 G A 1.19E-33 Amyotrophic lateral sclerosis / / 23587638 rs10967976 chr9 27544943 G A 1.72E-53 Amyotrophic lateral sclerosis / / 23587638 rs10967976 chr9 27544943 G A 2.69E-23 Amyotrophic lateral sclerosis / / 23587638 rs10967976 chr9 27544943 G A 6.16E-08 Amyotrophic lateral sclerosis / / 23587638 rs13691 chr9 27546890 G A 2.39E-04 Alzheimer's disease C9orf72 UTR-3 22005930 rs13691 chr9 27546890 G A 6.33E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) C9orf72 UTR-3 23648065 rs12349820 chr9 27553876 T C 0.000000253 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs12349820 chr9 27553876 T C 0.000021 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs12349820 chr9 27553876 T C 2.94E-08 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs12349820 chr9 27553876 T C 3.63E-11 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs10122902 chr9 27556780 G A 5.00E-11 Amyotrophic lateral sclerosis C9orf72 cds-synon 20801717 rs10122902 chr9 27556780 G A 0.00000155 Amyotrophic lateral sclerosis C9orf72 cds-synon 23587638 rs10757665 chr9 27557919 T C 1.90E-05 Amyotrophic lateral sclerosis C9orf72 intron 20801717 rs10757665 chr9 27557919 T C 0.000000238 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs10757665 chr9 27557919 T C 0.0000192 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs10757665 chr9 27557919 T C 2.94E-08 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs10757665 chr9 27557919 T C 3.28E-11 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs10812614 chr9 27558238 A T 6.45E-04 Alzheimer's disease C9orf72 intron 22005930 rs147370410 chr9 27558238 A AA,AT 6.45E-04 Alzheimer's disease C9orf72 intron 22005930 rs774356 chr9 27559721 T C 1.07E-08 Amyotrophic lateral sclerosis (sporadic) C9orf72 intron 24256812 rs1565948 chr9 27559733 G A 2.70E-14 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs774357 chr9 27559835 G A 0.00000561 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs774357 chr9 27559835 G A 1.15E-20 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs774357 chr9 27559835 G A 2.03E-43 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs774357 chr9 27559835 G A 7.67E-85 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs3849944 chr9 27560594 T C 5.30E-06 Biomarkers C9orf72 UTR-3 17903293 rs774359 chr9 27561049 T C 3.00E-06 Amyotrophic lateral sclerosis C9orf72 UTR-3 19734901 rs774359 chr9 27561049 T C 7.66E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain C9orf72 UTR-3 20154673 rs774359 chr9 27561049 T C 1.09E-06 Amyotrophic lateral sclerosis C9orf72 UTR-3 20801717 rs774359 chr9 27561049 T C 3.64E-09 Amyotrophic lateral sclerosis C9orf72 UTR-3 20801718 rs774359 chr9 27561049 T C 0.00000123 Amyotrophic lateral sclerosis C9orf72 UTR-3 23587638 rs774359 chr9 27561049 T C 1.29E-74 Amyotrophic lateral sclerosis C9orf72 UTR-3 23587638 rs774359 chr9 27561049 T C 4.48E-23 Amyotrophic lateral sclerosis C9orf72 UTR-3 23587638 rs774359 chr9 27561049 T C 6.62E-43 Amyotrophic lateral sclerosis C9orf72 UTR-3 23587638 rs2453554 chr9 27561800 C T 1.22E-08 Amyotrophic lateral sclerosis (sporadic) C9orf72 intron 24256812 rs2484319 chr9 27563755 A C 1.07E-08 Amyotrophic lateral sclerosis (sporadic) C9orf72 intron 24256812 rs2453555 chr9 27563868 G A 1.07E-08 Amyotrophic lateral sclerosis (sporadic) C9orf72 intron 24256812 rs3849945 chr9 27568817 A G 1.09E-08 Amyotrophic lateral sclerosis (sporadic) C9orf72 intron 24256812 rs13284967 chr9 27569572 C T 5.16E-04 Alzheimer's disease C9orf72 intron 22005930 rs2282241 chr9 27572255 C A 8.42E-05 Type 2 diabetes C9orf72 intron 17463246 rs2282241 chr9 27572255 C A 1.67E-14 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs2282241 chr9 27572255 C A 1.94E-14 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs2282241 chr9 27572255 C A 4.06E-05 Coronary heart disease C9orf72 intron pha003031 rs2282240 chr9 27572634 C T 1.76E-13 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs2282240 chr9 27572634 C T 5.00E-12 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs2282240 chr9 27572634 C T 6.65E-09 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs60242496 chr9 27572634 C CCCCTCCTGGGAAAGTGCAGGACCT 1.76E-13 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs60242496 chr9 27572634 C CCCCTCCTGGGAAAGTGCAGGACCT 5.00E-12 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs60242496 chr9 27572634 C CCCCTCCTGGGAAAGTGCAGGACCT 6.65E-09 Amyotrophic lateral sclerosis C9orf72 intron 23587638 rs11789520 chr9 27574515 C T 1.21E-08 Amyotrophic lateral sclerosis (sporadic) C9orf72 nearGene-5 24256812 rs1982915 chr9 27579560 A G 1.37E-05 Amyotrophic lateral sclerosis / / 20801717 rs1982915 chr9 27579560 A G 0.0000153 Amyotrophic lateral sclerosis / / 23587638 rs1982915 chr9 27579560 A G 1.00E-11 Amyotrophic lateral sclerosis / / 23587638 rs1982915 chr9 27579560 A G 2.35E-18 Amyotrophic lateral sclerosis / / 23587638 rs1982915 chr9 27579560 A G 2.59E-09 Amyotrophic lateral sclerosis / / 23587638 rs12350076 chr9 27580674 A C 3.08E-05 Lymphocyte counts / / 22286170 rs2453556 chr9 27586162 A G 4.67E-05 Amyotrophic lateral sclerosis / / 20801718 rs2453556 chr9 27586162 A G 0.0000339 Amyotrophic lateral sclerosis / / 23587638 rs2453556 chr9 27586162 A G 1.19E-12 Amyotrophic lateral sclerosis / / 23587638 rs2453556 chr9 27586162 A G 2.35E-27 Amyotrophic lateral sclerosis / / 23587638 rs2453556 chr9 27586162 A G 4.62E-22 Amyotrophic lateral sclerosis / / 23587638 rs2477518 chr9 27599746 T C 5.37E-11 Amyotrophic lateral sclerosis / / 23587638 rs10968002 chr9 27600698 C G 1.60E-05 Urinary metabolites / / 21572414 rs810174 chr9 27609514 G A 1.39E-05 Amyotrophic lateral sclerosis / / 20801718 rs2889829 chr9 27610657 A G 2.00E-07 PCA3 expression level / / 23555189 rs2889829 chr9 27610657 A G 2.13E-07 PCA3 expression level / / 23555189 rs504532 chr9 27615794 C T 5.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10812622 chr9 27620642 C A 6.01E-04 Type 2 diabetes / / 17463246 rs12555345 chr9 27630562 T C 5.00E-06 Total ventricular volume / / 21116278 rs7036816 chr9 27678194 A G 3.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2026146 chr9 27723858 G T 4.66E-04 Schizophrenia / / 19197363 rs10812654 chr9 27724226 A G 1.00E-05 Prostate cancer / / 21743057 rs10732349 chr9 27725305 G A 8.81E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10812655 chr9 27725556 G C 1.19E-04 Multiple complex diseases / / 17554300 rs10968085 chr9 27730552 T C 5.80E-04 Multiple complex diseases / / 17554300 rs1857080 chr9 27733456 C A 1.24E-05 Multiple complex diseases / / 17554300 rs1857079 chr9 27733472 T C 4.48E-04 Multiple complex diseases / / 17554300 rs10120133 chr9 27750034 T A 6.89E-04 Obesity (extreme) / / 21935397 rs10968093 chr9 27753227 G A 6.82E-04 Obesity (extreme) / / 21935397 rs7035239 chr9 27753785 C A 6.12E-04 Obesity (extreme) / / 21935397 rs10511807 chr9 27760185 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1330195 chr9 27765416 T C 6.83E-04 Multiple complex diseases / / 17554300 rs1624203 chr9 27766591 A G 4.95E-04 Multiple complex diseases / / 17554300 rs10968110 chr9 27792965 T C 8.76E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4879802 chr9 27795074 A G 0.00009597 Sarcoidosis / / 22952805 rs12685581 chr9 27804977 A G 2.10E-05 Urinary metabolites / / 21572414 rs10812665 chr9 27808093 T A 4.18E-04 Aortic root size / / 21223598 rs10968122 chr9 27808448 G T 0.00002448 Sarcoidosis / / 22952805 rs7020269 chr9 27820493 A G 8.88E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7851811 chr9 27824832 T C 7.41E-04 Multiple complex diseases / / 17554300 rs10812671 chr9 27835640 C G 2.70E-05 Urinary metabolites / / 21572414 rs12376417 chr9 27840808 T C 4.79E-04 White matter integrity / / 22425255 rs7865479 chr9 27845760 T C 9.73E-05 Cognitive impairment induced by topiramate / / 22091778 rs7853855 chr9 27846594 A G 1.98E-04 White matter integrity / / 22425255 rs4581139 chr9 27860390 C T 2.60E-04 White matter integrity / / 22425255 rs6476020 chr9 27864330 T C 1.97E-04 IgE levels / / 17255346 rs10968162 chr9 27871793 T C 4.38E-04 Multiple complex diseases / / 17554300 rs4878610 chr9 27872054 T C 2.60E-04 Insulin resistance / / 21901158 rs10968164 chr9 27872621 C A,G,T 8.71E-05 Multiple complex diseases / / 17554300 rs2383739 chr9 27875069 G A 1.00E-04 Prostate cancer / / 21743057 rs10491820 chr9 27876714 C T 2.37E-04 Type 2 diabetes / / 17846124 rs7029145 chr9 27882653 C T 9.00E-06 Immunoglobulin A / / 20694011 rs1316922 chr9 27894682 G A 4.08E-04 Pemphigus vulgaris / / 22437316 rs10968209 chr9 27934863 T C 2.39E-05 Multiple complex diseases / / 17554300 rs1930046 chr9 27943240 G C,T 2.20E-05 Urinary metabolites / / 21572414 rs4969135 chr9 27964549 C G 4.38E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LINGO2 intron 20031582 rs10968243 chr9 27974789 T C 6.46E-05 Response to taxane treatment (placlitaxel) LINGO2 intron 23006423 rs7034075 chr9 27992871 T A 3.84E-04 Response to taxane treatment (placlitaxel) LINGO2 intron 23006423 rs10968269 chr9 28004402 T C 4.25E-05 Obesity (extreme) LINGO2 intron 21935397 rs10968271 chr9 28005432 T C 4.11E-05 Obesity (extreme) LINGO2 intron 21935397 rs12236967 chr9 28012746 C A 3.70E-05 Obesity (extreme) LINGO2 intron 21935397 rs12235674 chr9 28027694 G A 1.80E-04 Obesity (extreme) LINGO2 intron 21935397 rs10968291 chr9 28031741 G A 1.90E-04 Obesity (extreme) LINGO2 intron 21935397 rs10968296 chr9 28036229 C T 3.81E-04 Obesity (extreme) LINGO2 intron 21935397 rs16912333 chr9 28037486 T C 3.74E-04 Obesity (extreme) LINGO2 intron 21935397 rs2778427 chr9 28042988 T A 3.51E-04 Multiple complex diseases LINGO2 intron 17554300 rs1343456 chr9 28049518 T C 1.75E-04 Type 2 diabetes LINGO2 intron 17463246 rs2123204 chr9 28058435 A G 0.000657 Salmonella-induced pyroptosis LINGO2 intron 22837397 rs2123205 chr9 28064791 C T 6.10E-05 Male fertility LINGO2 intron 22633400 rs7853840 chr9 28068081 T C 7.35E-04 Longevity LINGO2 intron 22279548 rs6476035 chr9 28071285 G C 1.63E-05 Male fertility LINGO2 intron 22633400 rs1869173 chr9 28082001 C T 3.42E-04 Multiple complex diseases LINGO2 intron 17554300 rs17698390 chr9 28083091 C A 1.32E-04 Multiple complex diseases LINGO2 intron 17554300 rs4305993 chr9 28088526 T C 1.83E-04 Amyotrophic lateral sclerosis LINGO2 intron 20801718 rs12339229 chr9 28093232 C T 1.23E-05 Male fertility LINGO2 intron 22633400 rs1060558 chr9 28104320 A T 9.31E-05 Male fertility LINGO2 intron 22633400 rs10124164 chr9 28107917 G C 7.78E-04 Suicide attempts in bipolar disorder LINGO2 intron 21423239 rs17771324 chr9 28111873 T C 9.77E-05 Brain lesion load LINGO2 intron 19010793 rs7850371 chr9 28164681 A G 5.71E-04 Multiple complex diseases LINGO2 intron 17554300 rs1377045 chr9 28168157 G C 3.20E-04 Response to cytidine analogues (gemcitabine) LINGO2 intron 24483146 rs2044962 chr9 28173138 T C 5.87E-04 Parkinson's disease LINGO2 intron 17052657 rs2044962 chr9 28173138 T C 1.01E-05 Coronary heart disease LINGO2 intron pha003032 rs1319535 chr9 28181085 C T 1.88E-04 Alzheimer's disease (late onset) LINGO2 intron 21379329 rs1319535 chr9 28181085 C T 4.00E-06 IgG glycosylation LINGO2 intron 23382691 rs1319535 chr9 28181085 C T 9.00E-06 IgG glycosylation LINGO2 intron 23382691 rs1319535 chr9 28181085 C T 6.43E-04 Response to cytadine analogues (cytosine arabinoside) LINGO2 intron 24483146 rs12686570 chr9 28184627 G A 6.47E-05 Cognitive test performance LINGO2 intron 20125193 rs991849 chr9 28198623 A G 1.70E-04 Lung function (forced vital capacity) LINGO2 intron 24023788 rs991849 chr9 28198623 A G 4.86E-04 Lung function (forced expiratory volume in 1 second) LINGO2 intron 24023788 rs10757716 chr9 28204063 G C 5.90E-04 Multiple complex diseases LINGO2 intron 17554300 rs10757716 chr9 28204063 G C 2.64E-04 Aortic root size LINGO2 intron 21223598 rs4604546 chr9 28215694 C T 4.32E-04 Alzheimer's disease (late onset) LINGO2 intron 21379329 rs10511826 chr9 28221934 A G 7.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINGO2 intron 20877124 rs10968404 chr9 28237928 G A 1.26E-04 Taste perception LINGO2 intron 22132133 rs7038123 chr9 28252086 T G 2.45E-04 Taste perception LINGO2 intron 22132133 rs12057041 chr9 28257665 A G 0.00053465 Hypertension (early onset hypertension) LINGO2 intron 22479346 rs13298436 chr9 28272794 C T 0.000448343 Hypertension (early onset hypertension) LINGO2 intron 22479346 rs13301122 chr9 28276698 G A 3.80E-05 Celiac disease LINGO2 intron 17558408 rs10968432 chr9 28281650 T C 0.000546224 Hypertension (early onset hypertension) LINGO2 intron 22479346 rs4481691 chr9 28295916 T C 7.61E-04 Multiple complex diseases LINGO2 intron 17554300 rs10968465 chr9 28297859 G A 0.000389541 Hypertension (early onset hypertension) LINGO2 intron 22479346 rs981864 chr9 28303495 C A 2.40E-04 Type 2 diabetes LINGO2 intron 17846124 rs1023200 chr9 28332480 T C 7.57E-04 Alzheimer's disease (late onset) LINGO2 intron 21460841 rs13298550 chr9 28337698 G A 1.17E-04 Aortic root size LINGO2 intron 21223598 rs16912725 chr9 28359782 C A 2.00E-06 Obesity-related traits LINGO2 intron 23251661 rs3849955 chr9 28360374 C A 2.73E-04 Response to TNF antagonist treatment LINGO2 intron 21061259 rs16912739 chr9 28364240 G A 2.11E-06 Obesity-related traits LINGO2 intron 23251661 rs1331893 chr9 28388957 A C 2.20E-05 Urinary metabolites LINGO2 intron 21572414 rs10968560 chr9 28398225 C A 1.53E-04 Lung function (forced vital capacity) LINGO2 intron 24023788 rs10968562 chr9 28402043 A G 7.00E-06 Obesity-related traits LINGO2 intron 23251661 rs10968576 chr9 28414339 A G 3.00E-13 Body mass index LINGO2 intron 20935630 rs10968576 chr9 28414339 A G 2.65E-13 Body mass index LINGO2 intron 23001569 rs10968576 chr9 28414339 A G 3.00E-08 Obesity LINGO2 intron 23563607 rs1412239 chr9 28425515 C G 2.00E-10 Obesity LINGO2 intron 23563607 rs374068319 chr9 28425515 CG C 2.00E-10 Obesity LINGO2 intron 23563607 rs1412240 chr9 28425516 G T 4.87E-04 Alzheimer's disease (late onset) LINGO2 intron 21379329 rs7044907 chr9 28463701 G A 1.86E-04 Vaspin levels LINGO2 intron 22907691 rs7044907 chr9 28463701 G A 0.0001855 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks LINGO2 intron 22907730 rs1888814 chr9 28470551 T C 9.62E-04 Myocardial Infarction LINGO2 intron pha002873 rs1888814 chr9 28470551 T C 1.70E-05 Erythrocyte counts LINGO2 intron pha003090 rs1331895 chr9 28473654 G A 6.50E-05 Personality dimensions LINGO2 intron 18957941 rs1331900 chr9 28491651 C G 9.78E-04 Bipolar disorder LINGO2 intron 19259986 rs1331901 chr9 28491679 T C 7.00E-05 Erythrocyte counts LINGO2 intron pha003090 rs9298897 chr9 28492396 G A 1.24E-05 Erythrocyte counts LINGO2 intron pha003090 rs7857758 chr9 28502627 G A 9.04E-04 Tourette syndrome LINGO2 intron 22889924 rs7857851 chr9 28509969 G T 3.71E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LINGO2 intron 24023788 rs12005012 chr9 28539581 T C 2.59E-04 Body mass index LINGO2 intron 21701565 rs12005012 chr9 28539581 T C 2.63E-04 Body mass index LINGO2 intron 21701565 rs12003711 chr9 28542803 T C 2.45E-05 Smoking initiation LINGO2 intron 24665060 rs10968649 chr9 28544375 T G 8.38E-05 Orofacial clefts LINGO2 intron 22419666 rs10491883 chr9 28562256 T C 5.39E-05 Heart Rate LINGO2 intron pha003054 rs1521731 chr9 28570652 A G 2.28E-04 Body mass index LINGO2 intron 21701565 rs1521731 chr9 28570652 A G 2.97E-04 Body mass index LINGO2 intron 21701565 rs2891316 chr9 28587994 G A 1.29E-04 Endometrial cancer LINGO2 intron 24096698 rs2891316 chr9 28587994 G A 3.32E-04 Endometrial cancer LINGO2 intron 24096698 rs2891316 chr9 28587994 G A 9.00E-06 Endometrial cancer LINGO2 intron 24096698 rs12348435 chr9 28600142 A C 2.00E-06 Alcohol dependence (age at onset) LINGO2 intron 24962325 rs10968666 chr9 28603940 A G 2.29E-06 Alcohol dependence (age at onset) LINGO2 intron 24962325 rs12351510 chr9 28651898 T G 0.00000085 Confectionary intake LINGO2 intron 23408455 rs7847762 chr9 28695569 C T 6.38E-05 Cognitive impairment induced by topiramate LINGO2 intron 22091778 rs7021597 chr9 28708151 A C 7.38E-04 Nicotine dependence LINGO2 intron 17158188 rs10968743 chr9 28734248 G A 6.68E-04 Multiple complex diseases LINGO2 intron 17554300 rs7851298 chr9 28736988 C T 2.79E-04 Schizophrenia LINGO2 intron 19197363 rs2478966 chr9 28769188 A G 4.60E-05 Coffee consumption LINGO2 intron 21357676 rs824248 chr9 28772700 A T 8.00E-06 Type 2 diabetes LINGO2 intron 24390345 rs824251 chr9 28773458 A G 3.60E-05 Lung adenocarcinoma LINGO2 intron 22797724 rs1409924 chr9 28778877 A G 8.32E-04 Obesity (extreme) LINGO2 intron 21935397 rs1409925 chr9 28778923 T A 8.13E-04 Obesity (extreme) LINGO2 intron 21935397 rs10968770 chr9 28780795 C T 8.16E-04 Obesity (extreme) LINGO2 intron 21935397 rs10812875 chr9 28781231 C T 7.27E-04 Obesity (extreme) LINGO2 intron 21935397 rs824241 chr9 28786264 C A 2.90E-04 Lung function (forced expiratory volume in 1 second) LINGO2 intron 24023788 rs10968773 chr9 28795700 G A 3.63E-04 Aortic root size LINGO2 intron 21223598 rs1389728 chr9 28817957 T C 4.16E-05 Femoral neck bone geometry LINGO2 intron 22087292 rs824215 chr9 28820101 A G 1.90E-06 Urinary metabolites LINGO2 intron 21572414 rs969715 chr9 28820807 A G 3.06E-05 Femoral neck bone geometry LINGO2 intron 22087292 rs17374075 chr9 28826452 G A 1.70E-06 Urinary metabolites LINGO2 intron 21572414 rs702247 chr9 28841307 C T 1.50E-06 Urinary metabolites LINGO2 intron 21572414 rs1434308 chr9 28851909 T C 1.37E-04 Sarcoidosis LINGO2 intron 21540310 rs16913751 chr9 28853125 C T 1.64E-06 Femoral neck bone geometry LINGO2 intron 22087292 rs10491629 chr9 28855155 G T 2.91E-06 Femoral neck bone geometry LINGO2 intron 22087292 rs7026756 chr9 28855202 C A 2.00E-06 Urinary metabolites LINGO2 intron 21572414 rs824409 chr9 28855511 A G 2.00E-06 Urinary metabolites LINGO2 intron 21572414 rs1327363 chr9 28858580 C T 2.70E-06 Urinary metabolites LINGO2 intron 21572414 rs12005658 chr9 28868243 A G 4.60E-05 Femoral neck bone geometry LINGO2 intron 22087292 rs3849874 chr9 28869369 G C 8.96E-05 Femoral neck bone geometry LINGO2 intron 22087292 rs320947 chr9 28869800 C T 8.28E-04 Response to cytidine analogues (gemcitabine) LINGO2 intron 24483146 rs320950 chr9 28870162 T A 3.20E-06 Urinary metabolites LINGO2 intron 21572414 rs11998784 chr9 28875332 A G 9.41E-05 Femoral neck bone geometry LINGO2 intron 22087292 rs16913782 chr9 28876158 C T 3.37E-05 Femoral neck bone geometry LINGO2 intron 22087292 rs1368998 chr9 28879953 C A 3.18E-05 Femoral neck bone geometry LINGO2 intron 22087292 rs320954 chr9 28880008 T A 1.30E-05 Urinary metabolites LINGO2 intron 21572414 rs184409 chr9 28880052 T C 4.40E-06 Urinary metabolites LINGO2 intron 21572414 rs13299800 chr9 28892211 A G 2.74E-04 Smoking initiation LINGO2 intron 24665060 rs7043927 chr9 28894989 G A 2.10E-05 Urinary metabolites LINGO2 intron 21572414 rs13291151 chr9 28906765 T C 8.17E-06 Malignant mesothelioma LINGO2 intron 23827383 rs10491630 chr9 28911561 T C 8.36E-06 Malignant mesothelioma LINGO2 intron 23827383 rs7018863 chr9 28911619 A G 4.97E-06 Statin-induced myopathy LINGO2 intron 21826682 rs10968823 chr9 28912686 C A 1.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINGO2 intron 20877124 rs13298781 chr9 28914832 T G 8.44E-06 Malignant mesothelioma LINGO2 intron 23827383 rs17325678 chr9 28920151 C T 8.40E-06 Malignant mesothelioma LINGO2 intron 23827383 rs13291623 chr9 28922257 A G 8.40E-06 Malignant mesothelioma LINGO2 intron 23827383 rs13289067 chr9 28925469 C G 8.39E-06 Malignant mesothelioma LINGO2 intron 23827383 rs17326482 chr9 28929720 G A 8.40E-06 Malignant mesothelioma LINGO2 intron 23827383 rs17326517 chr9 28930296 A G 8.40E-06 Malignant mesothelioma LINGO2 intron 23827383 rs1409929 chr9 28936211 G A 8.43E-06 Malignant mesothelioma LINGO2 intron 23827383 rs13299777 chr9 28939554 T C 8.76E-05 Femoral neck bone geometry LINGO2 intron 22087292 rs7871600 chr9 28940111 C T 8.17E-05 Femoral neck bone geometry LINGO2 intron 22087292 rs10491633 chr9 28943695 C T 8.28E-05 Femoral neck bone geometry LINGO2 intron 22087292 rs10491633 chr9 28943695 C T 8.40E-06 Malignant mesothelioma LINGO2 intron 23827383 rs2383784 chr9 28944277 T C 6.58E-04 Sarcoidosis LINGO2 intron 21540310 rs13287752 chr9 28946332 C T 8.09E-06 Malignant mesothelioma LINGO2 intron 23827383 rs13287598 chr9 28960723 A G 8.44E-06 Malignant mesothelioma LINGO2 intron 23827383 rs3860955 chr9 28971082 C A 1.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINGO2 intron 20877124 rs3860955 chr9 28971082 C A 0.0000606 Tuberculosis with late age of onset LINGO2 intron 22551897 rs4879297 chr9 28981481 G A 2.00E-05 Urinary metabolites LINGO2 intron 21572414 rs10968884 chr9 29020053 A C 3.53E-04 Tourette syndrome LINGO2 intron 22889924 rs12376696 chr9 29024733 C T 6.20E-04 Tourette syndrome LINGO2 intron 22889924 rs10491640 chr9 29028380 T C 4.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINGO2 intron 20877124 rs10968899 chr9 29032248 C T 4.82E-04 Tourette syndrome LINGO2 intron 22889924 rs1832877 chr9 29048440 G A 8.61E-05 Serum metabolites LINGO2 intron 19043545 rs1342261 chr9 29052156 C T 6.80E-04 Type 2 diabetes and 6 quantitative traits LINGO2 intron 17848626 rs10968944 chr9 29101432 A G 3.86E-05 Male fertility LINGO2 intron 22633400 rs2000194 chr9 29105290 C A 8.29E-04 Multiple complex diseases LINGO2 intron 17554300 rs2000194 chr9 29105290 C A 1.69E-05 Femoral neck bone geometry LINGO2 intron 22087292 rs7861363 chr9 29105778 G A 8.42E-04 Multiple complex diseases LINGO2 intron 17554300 rs7861363 chr9 29105778 G A 2.57E-05 Femoral neck bone geometry LINGO2 intron 22087292 rs4879315 chr9 29106234 T C 5.04E-05 Femoral neck bone geometry LINGO2 intron 22087292 rs7864992 chr9 29106566 C T 3.86E-05 Male fertility LINGO2 intron 22633400 rs10968960 chr9 29119391 C T 4.27E-05 Male fertility LINGO2 intron 22633400 rs10968961 chr9 29119429 G A 3.87E-05 Male fertility LINGO2 intron 22633400 rs10757800 chr9 29130674 A G,T 3.86E-05 Male fertility LINGO2 intron 22633400 rs2050993 chr9 29136748 G A 4.80E-05 Male fertility LINGO2 intron 22633400 rs16914339 chr9 29145676 T C 1.80E-05 Urinary metabolites LINGO2 intron 21572414 rs10813007 chr9 29146765 G C 3.55E-05 Male fertility LINGO2 intron 22633400 rs10757816 chr9 29168848 T A 4.39E-05 Male fertility LINGO2 intron 22633400 rs2096168 chr9 29181556 C G 8.30E-04 Parkinson's disease LINGO2 intron 16252231 rs10968995 chr9 29183429 T C 6.43E-04 Coronary Artery Disease LINGO2 intron 17634449 rs7024949 chr9 29198980 A G 5.14E-04 Obesity (extreme) LINGO2 intron 21935397 rs7024949 chr9 29198980 A G 9.87E-05 Femoral neck bone geometry LINGO2 intron 22087292 rs10813028 chr9 29223296 C T 4.16E-05 Crohn's disease / / 20570966 rs4879321 chr9 29226705 A C 8.41E-04 Type 2 diabetes / / 17463246 rs10813050 chr9 29308040 C T 2.19E-05 ldl cholesterol / / pha003077 rs1169758 chr9 29317769 A G 3.95E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1169758 chr9 29317769 A G 5.07E-05 Platelet counts / / pha003100 rs1169757 chr9 29318382 G T 4.46E-05 Cholesterol / / pha003083 rs2183831 chr9 29323125 T C 4.61E-05 Cognitive performance / / 19734545 rs2183832 chr9 29323582 A C 4.61E-05 Cognitive performance / / 19734545 rs16914695 chr9 29336303 A G 1.50E-05 Cortisol secretion,in saliva / / 21316860 rs16914695 chr9 29336303 A G 9.61E-06 F-cell distribution / / 21326311 rs9695393 chr9 29349856 G A 1.43E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1929831 chr9 29363582 A G 1.16E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1929825 chr9 29412486 A G 1.30E-05 Urinary metabolites / / 21572414 rs2383811 chr9 29416253 G A 8.38E-04 Stroke / / pha002887 rs1575599 chr9 29431179 T C 5.43E-04 Stroke / / pha002887 rs1888817 chr9 29434257 T A 8.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs1999426 chr9 29435030 C T 8.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs16914891 chr9 29498319 C T 4.86E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10969210 chr9 29504458 C T 1.96E-05 Cortisol secretion,in saliva / / 21316860 rs12376718 chr9 29531579 C A 7.67E-04 HIV(mother-to-child transmission) / / 20487506 rs12376718 chr9 29531579 C A 9.79E-05 HIV(mother-to-child transmission) / / 20487506 rs1889055 chr9 29539919 A G 4.28E-04 HIV(mother-to-child transmission) / / 20487506 rs1889055 chr9 29539919 A G 5.21E-05 HIV(mother-to-child transmission) / / 20487506 rs13290799 chr9 29545875 C T 4.00E-06 Obesity-related traits / / 23251661 rs10491678 chr9 29568686 T C 8.47E-04 Stroke / / pha002887 rs688532 chr9 29569470 G A 2.70E-05 Urinary metabolites / / 21572414 rs521400 chr9 29570820 G A 1.70E-05 Urinary metabolites / / 21572414 rs10491680 chr9 29574928 T C 6.51E-04 Smoking initiation / / 24665060 rs483312 chr9 29575467 G A 1.55E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs12238051 chr9 29587032 A G 1.89E-04 Smoking initiation / / 24665060 rs10969287 chr9 29614435 A G 4.44E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs601162 chr9 29632142 A G 1.00E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs498619 chr9 29632345 G A 2.28E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs602469 chr9 29632433 C T 1.69E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2128184 chr9 29636965 C T 4.72E-04 Insulin resistance / / 21901158 rs583110 chr9 29637044 A C 4.93E-06 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs10969314 chr9 29660792 C A 1.18E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10813151 chr9 29669331 A G 7.46E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10969327 chr9 29693569 C A 4.40E-04 Alzheimer's disease (late onset) / / 21379329 rs10813154 chr9 29697103 T C 6.93E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs953639 chr9 29704495 T C 1.69E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1414030 chr9 29726239 C T 6.83E-04 Coronary heart disease / / 21606135 rs7037008 chr9 29732108 T C 8.74E-05 Femoral neck bone geometry / / 22087292 rs10813159 chr9 29738493 A T 2.81E-04 Coronary heart disease / / 21606135 rs928636 chr9 29739205 A G 8.73E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10511833 chr9 29742444 A G 1.60E-04 Endometriosis / / 21151130 rs13290469 chr9 29772920 G A 7.75E-05 Insulin-related traits / / pha003063 rs10969375 chr9 29783989 T C 6.00E-06 Obesity-related traits / / 23251661 rs10813168 chr9 29788364 C A 2.37E-04 Alzheimer's disease (late onset) / / 21379329 rs10813168 chr9 29788364 C A 7.38E-06 Obesity-related traits / / 23251661 rs6476155 chr9 29817453 A G 1.79E-04 Smoking cessation / / 24665060 rs9408157 chr9 29919131 A G 2.53E-06 Esophageal cancer (squamous cell) / / 22960999 rs10969456 chr9 29934085 A T 9.34E-04 Alzheimer's disease / / 17998437 rs10738830 chr9 29943739 T C 4.10E-04 Multiple complex diseases / / 17554300 rs4620360 chr9 29947473 G T 6.57E-06 Body mass index / / 19557197 rs10813208 chr9 29954848 C T 5.88E-06 Body mass index / / 19557197 rs10813208 chr9 29954848 C T 0.0002 Migraine / / 22678113 rs10969478 chr9 29954934 G A 5.86E-06 Body mass index / / 19557197 rs10969478 chr9 29954934 G A 0.000085 Migraine / / 22678113 rs10969478 chr9 29954934 G A 8.50E-05 Migraine / / 22683712 rs12002080 chr9 29956902 T G 5.91E-06 Body mass index / / 19557197 rs10511835 chr9 29958595 G A 6.12E-06 Body mass index / / 19557197 rs10511835 chr9 29958595 G A 0.0002 Migraine / / 22678113 rs12552329 chr9 29958616 C T 0.0000997 Migraine / / 22678113 rs12552329 chr9 29958616 C T 9.97E-05 Migraine / / 22683712 rs12552329 chr9 29958616 C T 2.99E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4472601 chr9 29966804 G A 7.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10813209 chr9 29969103 G T 2.35E-05 Aortic root size / / 21223598 rs2813927 chr9 29986250 T C 3.55E-05 Body Mass Index / / pha003020 rs2360192 chr9 29989597 A G 1.58E-05 Body Mass Index / / pha003020 rs4540481 chr9 29990455 C T 6.31E-04 Smoking initiation / / 24665060 rs10121528 chr9 29991337 A C 1.96E-05 Body Mass Index / / pha003020 rs10969511 chr9 30010493 A G 4.49E-04 Smoking initiation / / 24665060 rs17774360 chr9 30014366 T G 7.59E-05 Body Mass Index / / pha003020 rs10969535 chr9 30064499 G A 3.85E-05 Insulin resistance / / 21901158 rs1633490 chr9 30094419 C T 5.44E-06 Menarche (age at onset) / / 19282985 rs1633501 chr9 30115718 A G 8.34E-04 Multiple complex diseases / / 17554300 rs10969562 chr9 30119722 T A 7.35E-05 Depression (quantitative trait) / / 20800221 rs1510911 chr9 30119796 A C 2.13E-04 Depression (quantitative trait) / / 20800221 rs4878423 chr9 30119908 C T 1.97E-04 Depression (quantitative trait) / / 20800221 rs1510910 chr9 30122753 C A 2.78E-04 Depression (quantitative trait) / / 20800221 rs1510909 chr9 30122786 C T 8.05E-05 Depression (quantitative trait) / / 20800221 rs7875798 chr9 30125557 T C 1.36E-04 Depression (quantitative trait) / / 20800221 rs7030976 chr9 30128393 T C 9.82E-05 Depression (quantitative trait) / / 20800221 rs9919065 chr9 30130067 A T 2.12E-04 Depression (quantitative trait) / / 20800221 rs9918985 chr9 30130213 G T 1.11E-04 Depression (quantitative trait) / / 20800221 rs1606053 chr9 30137451 T C 8.21E-05 Depression (quantitative trait) / / 20800221 rs4878424 chr9 30138908 A G 3.64E-06 Pancreatic cancer / / 22158540 rs1018254 chr9 30143230 C T 1.87E-05 Depression (quantitative trait) / / 20800221 rs1126081 chr9 30201118 T C 1.40E-04 Multiple complex diseases / / 17554300 rs4879416 chr9 30209421 C T 9.35E-05 HDL particle features / / pha002900 rs12351836 chr9 30413575 G A 2.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs12000753 chr9 30418801 C A 2.69E-06 Personality dimensions / / 22628180 rs10118000 chr9 30460163 G A 2.39E-04 Alcohol consumption / / 23743675 rs13290610 chr9 30460547 A G 2.20E-04 Alcohol consumption / / 23743675 rs10813259 chr9 30467137 A G 5.24E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs4242682 chr9 30520322 G A 1.64E-04 Amyotrophic lateral sclerosis / / 20801718 rs10813281 chr9 30524250 C T 5.83E-05 Cognitive test performance / / 20125193 rs1104787 chr9 30591737 G A 6.92E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs3849883 chr9 30639205 G A 0.00000545 Alcohol craving with or without dependence / / 22481050 rs12552047 chr9 30654170 C G 3.93E-04 Insulin resistance / / 21901158 rs10738852 chr9 30697379 A G 4.79E-04 Multiple complex diseases / / 17554300 rs10813354 chr9 30725869 A T 3.78E-04 Body mass index / / 21701565 rs10969844 chr9 30734467 A T 1.36E-08 Metabolite levels / / 23281178 rs10813357 chr9 30743640 G T 6.27E-08 Metabolite levels / / 23281178 rs4108267 chr9 30746381 A G 1.31E-08 Metabolite levels / / 23281178 rs3914504 chr9 30748943 C T 1.72E-08 Metabolite levels / / 23281178 rs10969853 chr9 30751220 T C 5.00E-06 Alcohol dependence (age at onset) / / 24962325 rs10813367 chr9 30837981 G T 1.36E-04 Cocaine dependence / / 23958962 rs10813367 chr9 30837981 G T 7.63E-04 Cocaine dependence / / 23958962 rs10969918 chr9 30875780 T C 4.97E-04 Multiple complex diseases / / 17554300 rs10813374 chr9 30879675 A G 3.00E-08 Immune response to measles-mumps-rubella vaccine / / 24811271 rs12235303 chr9 30882214 G A 3.10E-08 Immune response to measles-mumps-rubella vaccine / / 24811271 rs10969943 chr9 30889977 C T 3.10E-08 Immune response to measles-mumps-rubella vaccine / / 24811271 rs10969948 chr9 30891914 G T 3.10E-08 Immune response to measles-mumps-rubella vaccine / / 24811271 rs10969950 chr9 30893160 A G 3.10E-08 Immune response to measles-mumps-rubella vaccine / / 24811271 rs2375090 chr9 30894048 G A 3.10E-08 Immune response to measles-mumps-rubella vaccine / / 24811271 rs12554600 chr9 30930783 A G 6.47E-05 Serum metabolites / / 19043545 rs7039161 chr9 30952534 C T 2.16E-04 Multiple complex diseases / / 17554300 rs13291086 chr9 30953009 A G 5.24E-04 Multiple complex diseases / / 17554300 rs7867525 chr9 30970211 G A 6.05E-05 Cognitive test performance / / 20125193 rs2888998 chr9 30979640 A G 7.91E-05 Colorectal cancer / / 19723657 rs2888998 chr9 30979640 A G 2.20E-05 Bipolar disorder / / 22925353 rs7038348 chr9 30982002 C T 4.73E-05 Major depressive disorder / / 22472876 rs7024630 chr9 30982620 T C 4.14E-05 Major depressive disorder / / 22472876 rs10757998 chr9 31024144 G A 8.92E-05 Parkinson's disease / / 21738487 rs10757999 chr9 31027597 G A 5.90E-05 Major depressive disorder / / 22472876 rs1335139 chr9 31083856 A T 4.93E-04 Multiple complex diseases / / 17554300 rs7037780 chr9 31100423 A T 1.00E-04 Prostate cancer / / 21743057 rs13285414 chr9 31100668 G A 4.09E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs12347592 chr9 31102874 A C 3.41E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs12553567 chr9 31165966 A T 0.0000555 Major depressive disorder / / 23149448 rs13283588 chr9 31177957 A G 8.72E-04 Multiple complex diseases / / 17554300 rs1335130 chr9 31183551 T G 8.95E-04 Multiple complex diseases / / 17554300 rs1333614 chr9 31236307 A G 7.00E-05 Parkinson's disease (age of onset) / / 19772629 rs10758044 chr9 31258551 T A 5.81E-04 Multiple complex diseases / / 17554300 rs10813525 chr9 31288508 A G 9.49E-04 Coronary heart disease / / 21971053 rs6476284 chr9 31347460 T C 2.81E-04 Coronary heart disease / / 21971053 rs10217534 chr9 31349953 C T 3.77E-04 Coronary heart disease / / 21971053 rs7873690 chr9 31394275 T C 3.74E-04 Multiple complex diseases / / 17554300 rs7870771 chr9 31397582 A G 8.16E-04 Multiple complex diseases / / 17554300 rs10435736 chr9 31419915 G C 4.00E-07 Metabolite levels (X-11787) / / 23934736 rs10970345 chr9 31450384 C T 3.78E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs148359873 chr9 31450666 C T 1.00E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs148359873 chr9 31450666 C T 5.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs7861900 chr9 31456861 T C 2.42E-04 Multiple complex diseases / / 17554300 rs10970374 chr9 31470393 C T 5.95E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7041035 chr9 31472315 C T 1.72E-04 Type 2 diabetes / / 17463246 rs10813601 chr9 31472633 C T 3.31E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16917027 chr9 31487723 T C 2.38E-05 Alzheimer's disease / / 22005930 rs7042541 chr9 31488411 T C 1.72E-05 Alzheimer's disease / / 22005930 rs7026591 chr9 31488859 A G 2.34E-05 Alzheimer's disease / / 22005930 rs16917038 chr9 31490521 C T 1.48E-05 Alzheimer's disease / / 22005930 rs16917039 chr9 31490611 C T 2.23E-05 Alzheimer's disease / / 22005930 rs7033027 chr9 31491780 T C 2.12E-05 Alzheimer's disease / / 22005930 rs7047689 chr9 31491827 G T 4.66E-05 Alzheimer's disease / / 22005930 rs7020033 chr9 31492009 C G,T 2.08E-05 Alzheimer's disease / / 22005930 rs7020054 chr9 31492130 A G 2.10E-05 Alzheimer's disease / / 22005930 rs7020184 chr9 31492195 C T 2.08E-05 Alzheimer's disease / / 22005930 rs7036821 chr9 31492344 T C 2.06E-05 Alzheimer's disease / / 22005930 rs16917043 chr9 31492927 C A 2.04E-05 Alzheimer's disease / / 22005930 rs16917048 chr9 31493267 C A 2.01E-05 Alzheimer's disease / / 22005930 rs10429621 chr9 31494970 G A 1.31E-05 Alzheimer's disease / / 22005930 rs10429534 chr9 31494993 A G 1.30E-05 Alzheimer's disease / / 22005930 rs10429631 chr9 31495041 G A 1.89E-05 Alzheimer's disease / / 22005930 rs10429539 chr9 31495183 A G 1.87E-05 Alzheimer's disease / / 22005930 rs13286245 chr9 31496532 T A 3.60E-05 Alzheimer's disease / / 22005930 rs10429469 chr9 31497248 G C,T 3.54E-05 Alzheimer's disease / / 22005930 rs13302848 chr9 31499301 T C 4.51E-05 Alzheimer's disease / / 22005930 rs13302825 chr9 31499870 G C 4.48E-05 Alzheimer's disease / / 22005930 rs13297113 chr9 31500197 A C 4.40E-05 Alzheimer's disease / / 22005930 rs13299727 chr9 31500940 T G 4.39E-05 Alzheimer's disease / / 22005930 rs13302490 chr9 31501013 C T 4.09E-05 Alzheimer's disease / / 22005930 rs16917053 chr9 31501598 G A 1.38E-05 Alzheimer's disease / / 22005930 rs13295330 chr9 31503145 T C 3.39E-05 Alzheimer's disease / / 22005930 rs13285154 chr9 31505016 C T 3.68E-05 Alzheimer's disease / / 22005930 rs16917061 chr9 31505681 G T 1.73E-05 Alzheimer's disease / / 22005930 rs10465075 chr9 31523945 G A 5.26E-06 White blood cell count / / 21738479 rs7866101 chr9 31524615 G C 1.64E-05 Alzheimer's disease / / 22005930 rs16917077 chr9 31532212 T C 1.72E-04 Type 2 diabetes / / 17463246 rs2502177 chr9 31532933 T C 1.03E-04 Alzheimer's disease / / 22005930 rs2502176 chr9 31533362 C T 1.74E-05 Alzheimer's disease / / 22005930 rs10758071 chr9 31542987 G A 6.22E-05 Alzheimer's disease / / 22005930 rs10813613 chr9 31543026 C G 6.18E-05 Alzheimer's disease / / 22005930 rs4576506 chr9 31546472 A G 1.00E-06 Alzheimer's disease / / 22005930 rs4629956 chr9 31547115 G A 6.03E-05 Alzheimer's disease / / 22005930 rs7034481 chr9 31553846 A G 5.78E-05 Alzheimer's disease / / 22005930 rs10970420 chr9 31561234 A G 8.24E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4416905 chr9 31563999 G A 6.57E-05 Alzheimer's disease / / 22005930 rs6476296 chr9 31567404 C T 4.09E-06 Alzheimer's disease / / 22005930 rs10758076 chr9 31568379 C T 2.37E-04 Insulin resistance / / 21901158 rs10758076 chr9 31568379 C T 7.70E-05 Alzheimer's disease / / 22005930 rs10732353 chr9 31568897 T C 4.39E-04 Insulin resistance / / 21901158 rs10732353 chr9 31568897 T C 6.97E-05 Alzheimer's disease / / 22005930 rs7870685 chr9 31573188 A G 7.74E-05 Alzheimer's disease / / 22005930 rs4879526 chr9 31575197 A C,T 7.81E-05 Alzheimer's disease / / 22005930 rs7852095 chr9 31584783 T C 2.94E-06 Alzheimer's disease / / 22005930 rs2044401 chr9 31669518 G A 6.60E-04 Biomarkers / / 17903293 rs10511884 chr9 31678988 C T 5.70E-05 Biomarkers / / 17903293 rs7875673 chr9 31808652 T G 7.80E-04 Type 2 diabetes / / 20818381 rs1410707 chr9 31828687 T C 3.04E-21 Multiple complex diseases / / 17554300 rs10511885 chr9 31831043 A G 7.00E-05 Type 2 diabetes / / 17903298 rs10511885 chr9 31831043 A G 1.70E-04 Endometriosis / / 21151130 rs10511886 chr9 31836555 T C 2.00E-05 Type 2 diabetes / / 17903298 rs10511886 chr9 31836555 T C 1.70E-04 Endometriosis / / 21151130 rs10511887 chr9 31837334 A G 8.86E-06 Telomere length / / 20139977 rs959283 chr9 31853754 C T 7.03E-04 Multiple complex diseases / / 17554300 rs10970564 chr9 31862948 T C 7.58E-05 Acne (severe) / / 24927181 rs10813656 chr9 31913150 G T 4.40E-06 Urinary metabolites / / 21572414 rs372957 chr9 31972985 G A 3.82E-04 Multiple complex diseases / / 17554300 rs1038268 chr9 31977623 A G 4.73E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs4146178 chr9 31980998 A C 3.75E-04 Type 2 diabetes / / 17463246 rs287579 chr9 31981125 C G 4.32E-04 Multiple complex diseases / / 17554300 rs287577 chr9 31981377 A G 7.21E-04 Multiple complex diseases / / 17554300 rs3912274 chr9 31983917 T C 8.79E-04 Multiple complex diseases / / 17554300 rs2375811 chr9 31989998 A G 3.17E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs12342755 chr9 31996254 A C 3.09E-05 Non-word repetition / / 23738518 rs201642778 chr9 32007381 T TG,TT 8.30E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs2375814 chr9 32007381 T G 8.30E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs423664 chr9 32020350 G C 4.28E-04 Multiple complex diseases / / 17554300 rs407791 chr9 32022207 G A 8.64E-04 Myopia (pathological) / / 21095009 rs10970695 chr9 32027297 T A 7.35E-05 Response to methylphenidate treatment / / 21130132 rs428416 chr9 32040469 A G 2.67E-04 Multiple complex diseases / / 17554300 rs396708 chr9 32047507 C T 4.50E-04 Multiple complex diseases / / 17554300 rs287558 chr9 32054968 T A 3.63E-04 Multiple complex diseases / / 17554300 rs12685181 chr9 32057858 A G 3.78E-04 Myopia (pathological) / / 21095009 rs439005 chr9 32059777 A G 1.89E-05 Recombination rate / / 21698098 rs476578 chr9 32060229 G A 5.98E-04 Multiple complex diseases / / 17554300 rs7031829 chr9 32072523 A G 9.30E-04 Multiple complex diseases / / 17554300 rs4879555 chr9 32074541 A G 4.85E-04 Multiple complex diseases / / 17554300 rs1508318 chr9 32078175 C T 1.02E-04 Myopia (pathological) / / 21095009 rs10813719 chr9 32079002 C A 3.66E-04 Multiple complex diseases / / 17554300 rs10435795 chr9 32081117 T C 9.08E-05 ldl cholesterol / / pha003076 rs7860693 chr9 32088488 T C 8.70E-04 Multiple complex diseases / / 17554300 rs10813725 chr9 32088857 G A 5.06E-04 Multiple complex diseases / / 17554300 rs7033664 chr9 32097906 C T 1.60E-04 Myopia (pathological) / / 21095009 rs1842636 chr9 32110777 A G 7.00E-04 Myopia (pathological) / / 21095009 rs1842636 chr9 32110777 A G 4.41E-04 Smoking quantity / / 24665060 rs2128033 chr9 32111179 A C 4.37E-04 Smoking quantity / / 24665060 rs7854371 chr9 32111669 A G 5.91E-04 Myopia (pathological) / / 21095009 rs7854371 chr9 32111669 A G 4.56E-04 Smoking quantity / / 24665060 rs10970782 chr9 32112420 G A 3.07E-05 ldl cholesterol / / pha003077 rs10758115 chr9 32115403 A G 2.06E-05 ldl cholesterol / / pha003077 rs16917898 chr9 32116520 G A 7.99E-05 Male fertility / / 22633400 rs7038301 chr9 32117710 T C 2.32E-05 Myopia (pathological) / / 21095009 rs3001896 chr9 32120209 C T 2.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7859572 chr9 32137688 A G 5.45E-04 Myopia (pathological) / / 21095009 rs906585 chr9 32143671 C T 1.07E-04 Myocardial Infarction / / pha002883 rs10813765 chr9 32158851 C T 1.40E-05 Urinary metabolites / / 21572414 rs10511896 chr9 32161992 G T 5.45E-04 Myopia (pathological) / / 21095009 rs10738881 chr9 32163679 C T 2.46E-05 Myocardial Infarction / / pha002883 rs950349 chr9 32191134 A G 8.76E-04 Multiple complex diseases / / 17554300 rs12336318 chr9 32199290 A G 3.83E-04 Multiple complex diseases / / 17554300 rs4272468 chr9 32200997 T G 3.46E-04 Multiple complex diseases / / 17554300 rs1331247 chr9 32223873 G A 2.80E-05 Urinary metabolites / / 21572414 rs1331249 chr9 32239114 A G 2.50E-06 Urinary metabolites / / 21572414 rs16918052 chr9 32242196 C T 3.40E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10970865 chr9 32247145 C T 1.70E-05 Urinary metabolites / / 21572414 rs10970869 chr9 32255125 G A 1.38E-07 Height / / pha003010 rs10970869 chr9 32255125 G A 1.26E-06 Height / / pha003011 rs3928808 chr9 32278891 C T 9.40E-05 Information processing speed / / 21130836 rs12346019 chr9 32305020 G A 9.62E-05 Coronary heart disease / / pha003032 rs16918150 chr9 32323500 G A 5.43E-04 Multiple complex diseases / / 17554300 rs5008140 chr9 32323672 G C 7.49E-04 Multiple complex diseases / / 17554300 rs17215333 chr9 32335139 C T 1 Drug response to Etoposide / / 17537913 rs10511903 chr9 32344825 C T 3.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10511904 chr9 32345295 C A 4.96E-04 Myocardial Infarction / / pha002873 rs10511905 chr9 32348024 A G 3.00E-04 Asthma (bronchodilator response) / / 23508266 rs7857056 chr9 32367887 A G 3.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10970946 chr9 32373513 C T 8.43E-04 Multiple complex diseases / / 17554300 rs1023087 chr9 32376618 G T 8.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7033149 chr9 32398234 G T 2.40E-05 Urinary metabolites ACO1 intron 21572414 rs6476361 chr9 32401610 A G 4.39E-04 Myocardial Infarction ACO1 intron pha002873 rs17288067 chr9 32409046 G A 4.62E-05 Coronary heart disease ACO1 intron pha003030 rs10738886 chr9 32409442 G A 3.74E-05 Myocardial Infarction ACO1 intron pha002873 rs4442231 chr9 32410850 T C 3.88E-04 Myocardial Infarction ACO1 intron pha002873 rs4879584 chr9 32412622 C T 4.30E-04 Heart Failure ACO1 intron pha002885 rs2026739 chr9 32418237 G T 3.68E-04 Type 2 diabetes ACO1 intron 17463246 rs7032871 chr9 32422690 T A 5.00E-06 IgG glycosylation ACO1 intron 23382691 rs12555576 chr9 32431306 G A 1.35E-05 Psoriasis ACO1 intron 20953190 rs10970976 chr9 32433526 T C 4.00E-06 Asthma ACO1 intron 22561531 rs16918276 chr9 32439795 C T 6.12E-09 Multiple complex diseases ACO1 intron 17554300 rs12555727 chr9 32456656 G A 1.91E-05 Psoriasis DDX58 UTR-3 20953190 rs10970997 chr9 32475686 A G 4.94E-04 Smoking initiation DDX58 intron 24665060 rs7034650 chr9 32504316 A G 7.21E-04 Multiple complex diseases DDX58 intron 17554300 rs11795343 chr9 32523737 T C 8.40E-11 Psoriasis DDX58 intron 23143594 rs149817592 chr9 32542016 T C 0.00021 Breast cancer (ER positive) TOPORS missense 23555315 rs17290760 chr9 32556380 A G 1.00E-07 Immune response to smallpox vaccine (IL-6) NDUFB6 intron 22610502 rs10971024 chr9 32561704 T A 4.72E-04 Multiple complex diseases NDUFB6 intron 17554300 rs504896 chr9 32596503 G A 5.90E-05 HIV-1 control / / 20041166 rs750969 chr9 32618915 T C 4.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs10813841 chr9 32619211 C T 4.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs10813842 chr9 32621415 C T 4.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs676932 chr9 32622026 C G 5.72E-06 Acute lymphoblastic leukemia (childhood) / / 22076464 rs10813843 chr9 32625622 C T 3.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs10813843 chr9 32625622 C T 4.85E-04 Stroke / / pha002887 rs10758144 chr9 32627088 C G 3.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs10971047 chr9 32631369 C T 3.68E-04 Suicide attempts in bipolar disorder TAF1L cds-synon 21423239 rs10971048 chr9 32639519 A G 8.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs10971051 chr9 32645735 T C 5.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs10813847 chr9 32648240 T C 5.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs7875015 chr9 32653255 C A 6.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs12683252 chr9 32670045 G A 8.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs4879591 chr9 32696996 T C 3.70E-04 Type 2 diabetes / / 17463246 rs4879604 chr9 32721882 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17220588 chr9 32725528 T C 1.29E-04 HIV-1 viral setpoint / / 17641165 rs1409703 chr9 32744779 T C 1.53E-04 Multiple complex diseases / / 17554300 rs10813871 chr9 32746889 G T 1.39E-04 Multiple complex diseases / / 17554300 rs10738894 chr9 32754979 C G 1.24E-04 Multiple complex diseases / / 17554300 rs10758161 chr9 32755028 C T 8.23E-06 Parkinson's disease (motor and cognition) / / 22658654 rs10758161 chr9 32755028 C T 8.00E-06 Immune response to anthrax vaccine / / 22658931 rs10758161 chr9 32755028 C T 4.03E-05 Coronary heart disease / / pha003032 rs10758162 chr9 32759617 C A 2.32E-05 Parkinson's disease (motor and cognition) / / 22658654 rs10758162 chr9 32759617 C A 2.32E-05 Immune response to anthrax vaccine / / 22658931 rs10813874 chr9 32760620 C T 4.34E-05 Schizophrenia(age at onset) / / 21688384 rs10813874 chr9 32760620 C T 5.85E-05 Parkinson's disease (motor and cognition) / / 22658654 rs10813874 chr9 32760620 C T 5.85E-05 Immune response to anthrax vaccine / / 22658931 rs640747 chr9 32780898 C T 5.04E-04 Multiple complex diseases / / 17554300 rs17221665 chr9 32781475 G T 0.000304 Salmonella-induced pyroptosis / / 22837397 rs300639 chr9 32786553 T C 4.83E-05 Male-pattern baldness TMEM215 UTR-3 18849994 rs300639 chr9 32786553 T C 0.00007961 Sarcoidosis TMEM215 UTR-3 22952805 rs2478564 chr9 32802729 G A 7.09E-04 Multiple complex diseases / / 17554300 rs10971142 chr9 32803092 C A 1.91E-04 Cholesterol / / 17255346 rs642798 chr9 32809306 A G 2.91E-04 Cholesterol / / 17255346 rs688232 chr9 32813551 C T 2.83E-04 Type 2 diabetes / / 17463246 rs654184 chr9 32817120 C G 1.56E-04 Type 2 diabetes / / 17463246 rs664407 chr9 32821061 A G 4.01E-04 Type 2 diabetes / / 17463246 rs630151 chr9 32832112 G A 4.85E-04 Type 2 diabetes / / 17463246 rs12686572 chr9 32850696 A G 9.00E-06 Urinary metabolites / / 21572414 rs12684472 chr9 32850712 C T 1.10E-05 Urinary metabolites / / 21572414 rs16918673 chr9 32853918 A T 1.20E-05 Urinary metabolites / / 21572414 rs1442286 chr9 32855756 C T 3.23E-05 Insulin Resistance / / pha003062 rs1442286 chr9 32855756 C T 2.28E-05 Insulin-related traits / / pha003063 rs6476383 chr9 32865569 A G 5.68E-06 Alcohol and nictotine co-dependence / / 20158304 rs10971169 chr9 32866253 T C 5.12E-04 Smoking quantity / / 24665060 rs7049065 chr9 32866960 C T 5.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs10971170 chr9 32870068 G T 9.00E-06 IgG glycosylation / / 23382691 rs2031675 chr9 32873872 G A 1.39E-05 Blood Pressure / / pha003040 rs2031675 chr9 32873872 G A 8.84E-07 Blood Pressure / / pha003048 rs17314892 chr9 32875606 C T 2.12E-04 Smoking quantity / / 24665060 rs1867027 chr9 32876777 G A 7.05E-04 Multiple complex diseases / / 17554300 rs10813889 chr9 32880568 G A 6.10E-04 Type 2 diabetes / / 17463246 rs10122775 chr9 32884983 C T 7.29E-04 Alcohol dependence / / 20201924 rs1888871 chr9 32886639 G A 9.88E-06 Colorectal cancer / / 21242260 rs1348255 chr9 32886717 T C 9.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs1348255 chr9 32886717 T C 7.56E-05 Blood Pressure / / pha003046 rs1348255 chr9 32886717 T C 8.62E-05 Blood Pressure / / pha003048 rs1348255 chr9 32886717 T C 4.17E-06 Socioeconomic Factors / / pha003066 rs10813891 chr9 32890699 T G 6.25E-05 Multiple complex diseases / / 17554300 rs7862465 chr9 32893302 C T 6.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs4879635 chr9 32899807 G A 4.40E-04 Alcohol dependence / / 20201924 rs4879638 chr9 32908420 T C 9.71E-05 Epilepsy (remission after treatment) / / 23962720 rs7848406 chr9 32909259 G A 8.88E-04 Type 2 diabetes / / 17463246 rs7848406 chr9 32909259 G A 6.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs10971211 chr9 32910292 G A 8.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs12377462 chr9 32914589 C T 2.00E-06 Vitamin B12 levels / / 22367966 rs10971259 chr9 32978806 C T 1.34E-04 Pancreatic cancer APTX intron pha002874 rs10813916 chr9 32990132 T C 9.61E-06 Lymphocyte counts APTX intron 22286170 rs2183870 chr9 32994500 T G 9.84E-05 Response to statin treatment (atorvastatin),change in cholesterol levels APTX intron 20031582 rs10813923 chr9 33023517 G A 1.61E-04 Pancreatic cancer LOC646808 intron pha002874 rs10758179 chr9 33023833 T C 1.40E-04 Pancreatic cancer LOC646808 intron pha002874 rs10813928 chr9 33051685 T C 1.45E-04 Pancreatic cancer SMU1 intron pha002874 rs11789823 chr9 33056299 C T 3.42E-04 Aortic root size SMU1 intron 21223598 rs10813942 chr9 33092835 A C 2.07E-04 Vaspin levels / / 22907691 rs10813942 chr9 33092835 A C 0.0002074 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs10971412 chr9 33113066 G A 6.93E-04 Multiple complex diseases B4GALT1 UTR-3 17554300 rs12379501 chr9 33113970 C T 1.40E-06 Common variable immunodeficiency B4GALT1 intron 21497890 rs12379501 chr9 33113970 C T 4.77E-05 Asthma B4GALT1 intron pha003127 rs2183124 chr9 33115556 A G 3.86E-05 Asthma B4GALT1 intron pha003127 rs2031902 chr9 33117524 C T 6.52E-05 Tetralogy of Fallot B4GALT1 intron 23297363 rs3818593 chr9 33120706 A G 7.55E-04 Multiple complex diseases B4GALT1 intron 17554300 rs10971418 chr9 33122024 C A 5.62E-04 Multiple complex diseases B4GALT1 intron 17554300 rs10113903 chr9 33122645 G C 7.00E-06 IgG glycosylation B4GALT1 intron 23382691 rs12342831 chr9 33124872 T C 1.00E-10 IgG glycosylation B4GALT1 intron 23382691 rs12342831 chr9 33124872 T C 3.00E-10 IgG glycosylation B4GALT1 intron 23382691 rs12342831 chr9 33124872 T C 3.00E-11 IgG glycosylation B4GALT1 intron 23382691 rs12342831 chr9 33124872 T C 3.00E-11 IgG glycosylation B4GALT1 intron 23382691 rs12342831 chr9 33124872 T C 5.00E-07 IgG glycosylation B4GALT1 intron 23382691 rs12342831 chr9 33124872 T C 5.00E-08 IgG glycosylation B4GALT1 intron 23382691 rs4879666 chr9 33125279 G A 5.60E-05 Tetralogy of Fallot B4GALT1 intron 23297363 rs10758189 chr9 33125804 T C 2.00E-06 IgG glycosylation B4GALT1 intron 23382691 rs10813951 chr9 33128021 A G 1.00E-09 IgG glycosylation B4GALT1 intron 23382691 rs10813951 chr9 33128021 A G 3.00E-06 IgG glycosylation B4GALT1 intron 23382691 rs10813951 chr9 33128021 A G 4.00E-07 IgG glycosylation B4GALT1 intron 23382691 rs10813951 chr9 33128021 A G 5.00E-10 IgG glycosylation B4GALT1 intron 23382691 rs10813951 chr9 33128021 A G 7.00E-08 IgG glycosylation B4GALT1 intron 23382691 rs10758192 chr9 33131651 G A 7.25E-05 Cognitive impairment induced by topiramate B4GALT1 intron 22091778 rs3780486 chr9 33139453 C T 1.00E-06 IgG glycosylation B4GALT1 intron 23382691 rs3780486 chr9 33139453 C T 5.00E-11 IgG glycosylation B4GALT1 intron 23382691 rs3780486 chr9 33139453 C T 9.00E-11 IgG glycosylation B4GALT1 intron 23382691 rs2770807 chr9 33141752 G A 6.11E-05 Tetralogy of Fallot B4GALT1 intron 23297363 rs10813957 chr9 33153527 G T 2.00E-09 IgG glycosylation B4GALT1 intron 23382691 rs10813957 chr9 33153527 G T 3.00E-09 IgG glycosylation B4GALT1 intron 23382691 rs10813957 chr9 33153527 G T 5.00E-08 IgG glycosylation B4GALT1 intron 23382691 rs10813957 chr9 33153527 G T 7.00E-06 IgG glycosylation B4GALT1 intron 23382691 rs7860416 chr9 33176426 C T 5.99E-04 Multiple complex diseases / / 17554300 rs11998760 chr9 33177136 C T 5.68E-04 Multiple complex diseases / / 17554300 rs10971438 chr9 33180308 A G 9.62E-06 Cognitive impairment induced by topiramate / / 22091778 rs10813960 chr9 33180362 C T 4.00E-07 Urate levels / / 23263486 rs11792935 chr9 33188609 T C 4.32E-05 Blood pressure / / 17255346 rs11792935 chr9 33188609 T C 9.50E-04 Multiple complex diseases / / 17554300 rs830407 chr9 33217266 G A 3.58E-04 Multiple complex diseases / / 17554300 rs830407 chr9 33217266 G A 8.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs1702645 chr9 33218297 T C 8.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10738912 chr9 33233494 A G 9.54E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs706119 chr9 33259777 G T 4.06E-04 Birth weight BAG1 intron 17255346 rs3758271 chr9 33263208 T C 5.10E-07 Height BAG1 intron 21194676 rs12336160 chr9 33283582 G T 1.00E-06 Erectile dysfunction and prostate cancer treatment / / 20932654 rs706134 chr9 33345616 A G 4.23E-04 Suicide attempts in bipolar disorder NFX1 intron 21423239 rs12237401 chr9 33367088 C T 6.12E-04 Suicide attempts in bipolar disorder NFX1 intron 21423239 rs17251987 chr9 33388289 C T 9.83E-04 Alcohol dependence AQP7 intron 21314694 rs7029953 chr9 33406297 G A 3.78E-25 Narcolepsy / / 19629137 rs17253114 chr9 33416380 G C 9.27E-04 Multiple complex diseases / / 17554300 rs7023320 chr9 33420302 G T 9.43E-05 Hypertension / / pha003042 rs4878538 chr9 33425385 G A 7.06E-05 Iron levels / / 19880490 rs4878538 chr9 33425385 G A 7.06E-05 Iron levels / / pha002876 rs4879704 chr9 33427322 A C 3.55E-05 Orofacial clefts / / 22419666 rs10813982 chr9 33454806 A C 1.30E-05 Urinary metabolites / / 21572414 rs2989936 chr9 33478434 C T 1.96E-04 Myocardial Infarction / / pha002883 rs2381115 chr9 33494160 C T 2.29E-04 Myocardial Infarction / / pha002883 rs10120325 chr9 33527793 T G 3.70E-04 Multiple complex diseases ANKRD18B intron 17554300 rs1856190 chr9 33608615 T C 3.00E-05 Kidney function and endocine traits / / 17903292 rs855495 chr9 33613660 G T 3.25E-04 Type 2 diabetes / / 17463246 rs1832325 chr9 33662389 A G 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1856195 chr9 33696330 G A 2.24E-05 Cervical cancer / / 24700089 rs2734590 chr9 33712471 A T 6.48E-04 Type 2 diabetes / / 17463246 rs10971677 chr9 33750237 C T 0.0000549 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes PRSS3 nearGene-5 22628534 rs3843935 chr9 33787871 C T 9.00E-04 Pulmonary function PRSS3 intron 23932459 rs216345 chr9 33799370 T C 4.00E-06 Bipolar disorder PRSS3 nearGene-3 18711365 rs3814511 chr9 33816476 C T 1.67E-04 Type 2 diabetes / / 17463246 rs10971712 chr9 33820938 C T 1.21E-04 Alzheimer's disease (late onset) UBE2R2 intron 21379329 rs10971733 chr9 33841798 G A 1.89E-04 Type 2 diabetes UBE2R2 intron 17463246 rs13295276 chr9 33853118 G A 2.07E-06 IgE levels UBE2R2 intron 22075330 rs10971750 chr9 33869781 T C 1.21E-04 Alzheimer's disease (late onset) UBE2R2 intron 21379329 rs7856487 chr9 33870940 G A 1.21E-04 Alzheimer's disease (late onset) UBE2R2 intron 21379329 rs6476426 chr9 33873557 C G 4.89E-04 Type 2 diabetes UBE2R2 intron 17463246 rs13302810 chr9 33888000 C A 7.98E-06 IgE levels UBE2R2 intron 22075330 rs10971773 chr9 33898779 G A 1.21E-04 Alzheimer's disease (late onset) UBE2R2 intron 21379329 rs13287325 chr9 33929030 G A 9.02E-06 IgE levels UBAP2 intron 22075330 rs874572 chr9 33933705 A G 1.69E-04 Type 2 diabetes UBAP2 intron 17463246 rs307652 chr9 33935736 A G 9.50E-04 Multiple complex diseases UBAP2 intron 17554300 rs307682 chr9 33973324 A G 8.38E-04 Type 2 diabetes UBAP2 intron 17463246 rs10971833 chr9 33988706 A C,G,T 6.67E-04 Multiple complex diseases UBAP2 intron 17554300 rs12350059 chr9 34040565 G A 4.00E-04 Multiple complex diseases UBAP2 intron 17554300 rs10115407 chr9 34050307 C A 3.11E-04 Multiple complex diseases / / 17554300 rs12376145 chr9 34050406 C T 1.26E-04 Alzheimer's disease (late onset) / / 21379329 rs13296914 chr9 34054826 C T 2.42E-05 IgE levels / / 22075330 rs7871764 chr9 34071541 T G 2.00E-06 Height / / 19343178 rs17341977 chr9 34098257 G C 5.63E-04 Type 2 diabetes DCAF12 intron 17463246 rs10511914 chr9 34107232 T C 6.49E-04 Multiple complex diseases DCAF12 intron 17554300 rs10511915 chr9 34107310 G A 6.97E-04 Type 2 diabetes DCAF12 intron 17463246 rs10971938 chr9 34120720 T C 1.67E-04 Alzheimer's disease (late onset) DCAF12 intron 21379329 rs10814071 chr9 34146645 C T 2.30E-05 Breast cancer / / 22452962 rs10758242 chr9 34146776 G A 7.01E-04 Multiple complex diseases / / 17554300 rs7020934 chr9 34261117 T C 4.64E-04 Atopy KIF24 intron 21625490 rs7862080 chr9 34303922 A G 3.96E-10 Lymphocyte counts KIF24 intron 22286170 rs11788425 chr9 34333855 A G 1.00E-04 Cognitive impairment induced by topiramate NUDT2 intron 22091778 rs10758259 chr9 34392908 G A 3.60E-04 Multiple complex diseases C9orf24 intron 17554300 rs3933343 chr9 34395816 A C 7.45E-05 Cognitive impairment induced by topiramate C9orf24 intron 22091778 rs4879785 chr9 34396346 G A 6.17E-04 Multiple complex diseases C9orf24 intron 17554300 rs946847 chr9 34408204 T G 9.12E-04 Multiple complex diseases FAM219A intron 17554300 rs876222 chr9 34414084 C G 5.41E-04 Multiple complex diseases FAM219A intron 17554300 rs4879786 chr9 34421591 G C 7.31E-04 Multiple complex diseases FAM219A intron 17554300 rs13297645 chr9 34422185 G A 6.82E-04 Type 2 diabetes FAM219A intron 17463246 rs6476445 chr9 34426124 G C 4.70E-04 Multiple complex diseases FAM219A intron 17554300 rs11547035 chr9 34459025 G T 1.11E-04 Alzheimer's disease (late onset) D/I1 missense 21379329 rs10125115 chr9 34464433 T C 3.94E-04 Multiple complex diseases D/I1 intron 17554300 rs4879795 chr9 34469025 G A 4.75E-06 Rheumatoid arthritis D/I1 intron 19503088 rs4879801 chr9 34509746 G A 4.21E-06 Rheumatoid arthritis D/I1 intron 19503088 rs2281997 chr9 34521867 T C 5.31E-06 Rheumatoid arthritis ENHO intron 19503088 rs7857130 chr9 34525976 C G 7.75E-05 Type 1 diabetes / / 21980299 rs4879803 chr9 34545932 T G 5.85E-04 Lymphocyte counts / / 22286170 rs2274592 chr9 34552437 C T 5.50E-08 Rheumatoid arthritis CNTFR intron 19503088 rs7044318 chr9 34554999 T C 2.01E-04 Gallstones CNTFR intron 17632509 rs12553466 chr9 34557313 G A 1.58E-06 Rheumatoid arthritis CNTFR intron 19503088 rs3802428 chr9 34567200 A C 7.63E-05 Alzheimer's disease CNTFR intron 17998437 rs10972162 chr9 34600759 G T 4.30E-05 Coronary heart disease / / pha003032 rs2812357 chr9 34655436 T C 1.47E-06 Rheumatoid arthritis IL11RA intron 19503088 rs2812365 chr9 34663138 C T 2.40E-08 Rheumatoid arthritis CCL27 nearGene-5 19503088 rs913835 chr9 34664488 A G 7.41E-05 Coronary heart disease / / pha003032 rs2772548 chr9 34670988 T G 8.45E-07 Rheumatoid arthritis / / 19503088 rs10972195 chr9 34683607 C A 4.20E-05 Coronary heart disease / / pha003032 rs2812378 chr9 34710260 G A 5.16E-05 Multiple complex diseases / / 17554300 rs2812378 chr9 34710260 G A 3.00E-08 Rheumatoid arthritis / / 18794853 rs2812378 chr9 34710260 G A 5.18E-10 Rheumatoid arthritis (CCP positive) / / 23143596 rs2812378 chr9 34710260 G A 7.20E-10 Rheumatoid arthritis / / 23143596 rs11574914 chr9 34710338 G A 2.00E-15 Rheumatoid arthritis / / 24390342 rs11574914 chr9 34710338 G A 3.00E-15 Rheumatoid arthritis / / 24390342 rs1854574 chr9 34726671 G A 7.46E-04 Multiple complex diseases FAM205A missense 17554300 rs2812344 chr9 34730015 C T 6.32E-04 Multiple complex diseases / / 17554300 rs7024727 chr9 34730395 G T 8.42E-06 Rheumatoid arthritis / / 19503088 rs2492358 chr9 34737828 C T 2.09E-04 Dermatomyositis / / 23983088 rs951005 chr9 34743681 G A 4.00E-10 Rheumatoid arthritis / / 20453842 rs951005 chr9 34743681 G A 3.90E-10 Celiac disease and Rheumatoid arthritis / / 21383967 rs951005 chr9 34743681 G A 3.90E-10 Multiple sclerosis / / 22190364 rs951005 chr9 34743681 G A 0.0000096 Rheumatoid arthritis / / 23143596 rs951005 chr9 34743681 G A 3.17E-04 Dermatomyositis / / 23983088 rs2772525 chr9 34746896 A G 4.49E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs277580 chr9 34771875 A G 9.18E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs277576 chr9 34806065 C T 6.33E-04 Smoking cessation / / 24665060 rs3739876 chr9 34831144 A G 5.26E-04 Smoking cessation / / 24665060 rs3739877 chr9 34831172 G A 7.54E-04 Smoking cessation / / 24665060 rs924566 chr9 34835861 C G 6.01E-04 Smoking cessation / / 24665060 rs3802426 chr9 34836905 A G 7.26E-04 Smoking cessation FAM205B intron 24665060 rs7850519 chr9 34842864 G A 5.29E-04 Smoking cessation / / 24665060 rs13290746 chr9 34868377 C T 1.50E-04 Neuroticism / / 17667963 rs10814178 chr9 34891317 A G 4.59E-04 Type 2 diabetes / / 17463246 rs10814178 chr9 34891317 A G 6.66E-04 Multiple complex diseases / / 17554300 rs12002630 chr9 34919516 T A 2.19E-04 Multiple complex diseases / / 17554300 rs7045765 chr9 34974974 T C 4.01E-04 Response to taxane treatment (placlitaxel) KIAA1045 intron 23006423 rs3739873 chr9 34978431 G A 4.89E-04 Response to taxane treatment (placlitaxel) KIAA1045 UTR-3 23006423 rs3739873 chr9 34978431 G A 8.19E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) KIAA1045 UTR-3 23648065 rs813422 chr9 35046291 T G 8.20E-06 Urinary metabolites / / 21572414 rs556766 chr9 35089048 A C 0.000000119 Cholesterol,total PIGO UTR-3 23063622 rs4593642 chr9 35125947 A G 1.93E-05 Lymphocyte counts / / 22286170 rs4879869 chr9 35141508 T C 6.80E-06 Weight / / 19851299 rs10972341 chr9 35141705 A G 9.00E-06 Weight / / 19851299 rs10972350 chr9 35149831 A G 8.60E-06 Weight / / 19851299 rs4879884 chr9 35227684 A T 5.15E-04 Type 2 diabetes UNC13B intron 17463246 rs10121009 chr9 35269819 T C 3.00E-06 Parkinson's disease UNC13B intron 21812969 rs10814218 chr9 35270675 A G 2.39E-04 Type 2 diabetes UNC13B intron 17463246 rs10972429 chr9 35319634 C T 3.11E-04 Multiple complex diseases UNC13B intron 17554300 rs10972436 chr9 35330294 C G 2.34E-04 Type 2 diabetes UNC13B intron 17463246 rs716359 chr9 35348697 T A 5.62E-04 Bipolar disorder UNC13B intron 19259986 rs1927957 chr9 35349764 C T 2.01E-04 Bipolar disorder UNC13B intron 19259986 rs6476483 chr9 35350085 A G 2.45E-04 Bipolar disorder UNC13B intron 19259986 rs10814234 chr9 35405543 C G 1.64E-04 Arthritis (juvenile idiopathic) / / 22354554 rs17370022 chr9 35424038 A G 4.56E-04 Intraocular pressure ATP8B5P intron 23836780 rs17298052 chr9 35438294 G C 4.56E-04 Intraocular pressure ATP8B5P intron 23836780 rs17370251 chr9 35439386 T C 4.56E-04 Intraocular pressure ATP8B5P intron 23836780 rs7875285 chr9 35482075 T C 6.57E-04 Glycosylated haemoglobin levels / / 17255346 rs7018605 chr9 35482764 T G 1.91E-04 Glycosylated haemoglobin levels / / 17255346 rs16932494 chr9 35557087 G T 9.07E-05 Multiple complex diseases RUSC2 intron 17554300 rs4879907 chr9 35566752 T C 3.11E-04 Multiple complex diseases / / 17554300 rs7389781 chr9 35573942 T A 5.23E-07 Glaucoma (primary open-angle) / / 22605921 rs1890592 chr9 35635683 T G 2.50E-04 Psoriasis / / 20953189 rs3138083 chr9 35648950 A G 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs3750433 chr9 35680564 G A 5.49E-05 Mammographic density CA9 intron 22532574 rs760402 chr9 35686376 G A 9.33E-04 Obesity (extreme) TPM2 intron 21935397 rs3793537 chr9 35687556 G C 8.11E-04 Obesity (extreme) TPM2 intron 21935397 rs4879926 chr9 35700837 C T 8.00E-06 IgE levels in asthmatics TLN1 intron 23967269 rs2295795 chr9 35712003 G A 7.01E-04 Obesity (extreme) TLN1 missense 21935397 rs16932581 chr9 35719940 A G 1.24E-04 Multiple complex diseases TLN1 intron 17554300 rs2295797 chr9 35722282 T C 7.97E-04 Obesity (extreme) TLN1 intron 21935397 rs1534847 chr9 35723712 T C 7.04E-04 Obesity (extreme) TLN1 intron 21935397 rs4142495 chr9 35728494 G A 6.29E-04 Obesity (extreme) TLN1 intron 21935397 rs113785628 chr9 35740902 C A,G,T 0.000066 Breast cancer(er negative) GBA2 missense 23555315 rs10814275 chr9 35758578 A G 1.20E-05 Mammographic density / / 22532574 rs10814275 chr9 35758578 A G 3.00E-04 Stroke / / pha002886 rs10972581 chr9 35779571 C T 9.24E-05 Type 2 diabetes / / 17463246 rs10758325 chr9 35804149 G A 1.17E-04 Type 2 diabetes NPR2 intron 17463246 rs1407295 chr9 35805161 T A 2.71E-05 Mammographic density NPR2 intron 22532574 rs3763631 chr9 35808334 C G 7.87E-04 Type 2 diabetes NPR2 intron 17463246 rs734158 chr9 35823009 T C 0.000427 Salmonella-induced pyroptosis C9orf128 intron 22837397 rs2236294 chr9 35842301 G A 0.000174 Salmonella-induced pyroptosis TMEM8B intron 22837397 rs7854812 chr9 35843080 T A 0.000769 Salmonella-induced pyroptosis TMEM8B intron 22837397 rs17204908 chr9 35854565 C T 9.76E-05 Coronary heart disease TMEM8B UTR-3 pha003032 rs10758328 chr9 35856434 G A 1.34E-05 Type 2 diabetes / / 17463246 rs12554095 chr9 35856634 G A 7.69E-04 White matter integrity / / 22425255 rs11791889 chr9 35860942 G A 9.77E-05 Type 2 diabetes / / 17463246 rs12552435 chr9 35864274 A G 7.24E-04 Mammographic density / / 22532574 rs2181027 chr9 35874516 G T 0.0000496 Salmonella-induced pyroptosis / / 22837397 rs12000024 chr9 35892051 A G 3.68E-05 White matter integrity / / 22425255 rs4271053 chr9 35903398 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10972628 chr9 35937611 G A 1.40E-04 Intelligence (childhood) / / 23358156 rs16932807 chr9 35964766 A G 4.81E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12352266 chr9 35971579 C T 3.39E-04 Smoking quantity / / 24665060 rs1408466 chr9 35992302 T C 9.33E-05 Brain lesion load / / 19010793 rs10511924 chr9 36007605 G C 7.36E-04 Nicotine dependence / / 17158188 rs4314728 chr9 36009389 T C 7.60E-05 White matter hyperintensity burden / / 21681796 rs2077559 chr9 36014850 A G 7.00E-05 White matter hyperintensity burden / / 21681796 rs1111711 chr9 36015653 G A 7.80E-05 White matter hyperintensity burden / / 21681796 rs10972689 chr9 36016167 A G 7.50E-05 White matter hyperintensity burden / / 21681796 rs7029221 chr9 36018310 G T 6.80E-05 White matter hyperintensity burden / / 21681796 rs7029221 chr9 36018310 G T 2.83E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7029143 chr9 36018404 C T 6.90E-05 White matter hyperintensity burden / / 21681796 rs7029349 chr9 36018417 G A 6.70E-05 White matter hyperintensity burden / / 21681796 rs12352029 chr9 36020393 T A 6.70E-05 White matter hyperintensity burden / / 21681796 rs10511925 chr9 36021852 A G 6.40E-05 White matter hyperintensity burden / / 21681796 rs10972691 chr9 36022197 G C 6.30E-05 White matter hyperintensity burden / / 21681796 rs7023581 chr9 36022613 A G 6.40E-05 White matter hyperintensity burden / / 21681796 rs7027417 chr9 36023246 A G 6.50E-05 White matter hyperintensity burden / / 21681796 rs7855775 chr9 36023395 G A 1.30E-05 Urinary metabolites / / 21572414 rs10814320 chr9 36023728 G A 2.30E-06 Urinary metabolites / / 21572414 rs7863810 chr9 36025452 A G 1.30E-05 Urinary metabolites / / 21572414 rs10972695 chr9 36026455 T G 1.20E-05 White matter hyperintensity burden / / 21681796 rs12341524 chr9 36026551 T C 1.20E-05 White matter hyperintensity burden / / 21681796 rs12345899 chr9 36026814 A G 1.20E-05 White matter hyperintensity burden / / 21681796 rs12339284 chr9 36028399 G A 1.00E-05 White matter hyperintensity burden / / 21681796 rs7039651 chr9 36031317 G A 1.00E-05 White matter hyperintensity burden / / 21681796 rs10814323 chr9 36031610 G A 1.70E-06 White matter hyperintensity burden / / 21681796 rs10814323 chr9 36031610 G A 0.000142 white matter hyperintensity burden / / 23674528 rs4879951 chr9 36088648 C G 8.13E-04 Multiple complex diseases RECK intron 17554300 rs4878639 chr9 36099399 T C 1.00E-06 IgG glycosylation RECK intron 23382691 rs4878639 chr9 36099399 T C 4.00E-08 IgG glycosylation RECK intron 23382691 rs4878639 chr9 36099399 T C 6.00E-06 IgG glycosylation RECK intron 23382691 rs4878639 chr9 36099399 T C 6.00E-07 IgG glycosylation RECK intron 23382691 rs11788747 chr9 36105264 A G 2.76E-04 Multiple complex diseases RECK cds-synon 17554300 rs752353 chr9 36137346 A G 5.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GLIPR2 intron 20877124 rs17835038 chr9 36141514 T C 9.69E-05 Blood Pressure GLIPR2 intron pha003039 rs17835038 chr9 36141514 T C 7.13E-06 Blood Pressure GLIPR2 intron pha003045 rs17835038 chr9 36141514 T C 1.73E-05 Blood Pressure GLIPR2 intron pha003047 rs7022784 chr9 36147128 C T 6.28E-04 Multiple complex diseases GLIPR2 intron 17554300 rs10814339 chr9 36154678 A C 5.64E-05 Multiple complex diseases GLIPR2 intron 17554300 rs10814339 chr9 36154678 A C 3.47E-04 Epilepsy GLIPR2 intron 22116939 rs13287406 chr9 36200678 T C 1.38E-04 Insulin resistance CLTA intron 21901158 rs1043313 chr9 36214971 G A 3.83E-05 Lung function (forced expiratory volume in 1 second) GNE UTR-3 pha003102 rs10972827 chr9 36286276 C T 2.10E-05 Urinary metabolites / / 21572414 rs7044830 chr9 36293157 C T 3.53E-04 Alcohol dependence / / 21314694 rs10123040 chr9 36307043 C T 5.90E-05 Schizophrenia / / 19571808 rs10758368 chr9 36310778 T G 2.60E-06 Schizophrenia / / 19571808 rs41449047 chr9 36448070 C G 3.88E-04 Multiple complex diseases / / 17554300 rs10814392 chr9 36481391 C T 5.52E-04 Multiple complex diseases / / 17554300 rs366887 chr9 36542368 A G 3.55E-04 Coronary heart disease / / 21971053 rs10972978 chr9 36576847 A G 3.25E-04 Alcohol dependence MELK intron 21314694 rs2246564 chr9 36638245 A T 8.22E-04 Alcohol dependence MELK intron 21314694 rs4512469 chr9 36659725 T C 2.64E-04 Multiple complex diseases MELK intron 17554300 rs2094394 chr9 36702096 G A 1.30E-04 Coronary heart disease / / 21971053 rs2094394 chr9 36702096 G A 1.33E-05 Lung function (forced vital capacity) / / pha003104 rs10973041 chr9 36723143 C T 5.00E-04 Major depressive disorder / / 21042317 rs12552072 chr9 36727388 T C 0.00000989 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1001159 chr9 36728585 C T 4.01E-08 Metabolite levels / / 23281178 rs10758392 chr9 36730774 T G 3.57E-08 Metabolite levels / / 23281178 rs10814435 chr9 36733156 C T 2.58E-08 Metabolite levels / / 23281178 rs10814436 chr9 36733236 A G 2.58E-08 Metabolite levels / / 23281178 rs10973047 chr9 36733406 A G 2.58E-08 Metabolite levels / / 23281178 rs10973048 chr9 36733478 G A 2.58E-08 Metabolite levels / / 23281178 rs10814437 chr9 36734000 C A 2.58E-08 Metabolite levels / / 23281178 rs10758394 chr9 36734252 A G 2.58E-08 Metabolite levels / / 23281178 rs10973049 chr9 36734287 T C 2.58E-08 Metabolite levels / / 23281178 rs10814438 chr9 36734488 G A 2.58E-08 Metabolite levels / / 23281178 rs7043503 chr9 36734872 C G 1.41E-08 Metabolite levels / / 23281178 rs7043808 chr9 36734901 G A 2.58E-08 Metabolite levels / / 23281178 rs7046618 chr9 36735029 A G 2.58E-08 Metabolite levels / / 23281178 rs10738976 chr9 36736811 T C 5.29E-08 Metabolite levels / / 23281178 rs7857754 chr9 36738641 G A 5.60E-04 Alcohol dependence / / 20201924 rs7857754 chr9 36738641 G A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7873864 chr9 36740957 G A 2.60E-04 Alcohol dependence / / 20201924 rs7873864 chr9 36740957 G A 3.00E-04 Alcohol dependence / / 20201924 rs10116484 chr9 36741027 C T 2.50E-04 Alcohol dependence / / 20201924 rs10116484 chr9 36741027 C T 3.80E-04 Alcohol dependence / / 20201924 rs10125149 chr9 36756876 G C 2.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs10973061 chr9 36765045 G A 8.95E-04 Taste perception / / 22132133 rs13292929 chr9 36798025 C T 5.12E-05 Cholesterol / / pha003073 rs13292929 chr9 36798025 C T 4.61E-05 ldl cholesterol / / pha003076 rs13292929 chr9 36798025 C T 7.04E-05 Cholesterol / / pha003078 rs10758401 chr9 36798742 G A 5.05E-05 Serum metabolites / / 19043545 rs1410011 chr9 36827258 A G 1.65E-04 Birth weight / / 17255346 rs2800252 chr9 36830616 T G 2.04E-05 Birth weight / / 17255346 rs2851697 chr9 36831580 A G 9.01E-05 Multiple complex diseases / / 17554300 rs3780136 chr9 36845973 C A 6.33E-06 Orofacial clefts PAX5 intron 20023658 rs3780136 chr9 36845973 C A 3.65E-04 Orofacial clefts PAX5 intron 22863734 rs10758409 chr9 36869256 C T 0.000244 Breast cancer early age of onset PAX5 intron 18463975 rs2277142 chr9 36881866 T C 2.11E-04 Myocardial Infarction PAX5 intron pha002883 rs3780141 chr9 36885583 G A 1.75E-05 Monocyte counts PAX5 intron pha003089 rs3824339 chr9 36885746 G A 8.68E-06 Aortic root size PAX5 intron 21223598 rs3824339 chr9 36885746 G A 3.27E-04 Alcohol dependence PAX5 intron 21314694 rs3780143 chr9 36885919 C T 7.62E-05 Bipolar disorder and schizophrenia PAX5 intron 20889312 rs4507859 chr9 36887712 C T 6.81E-04 Myocardial Infarction PAX5 intron pha002883 rs9298973 chr9 36888975 C T 3.13E-05 Monocyte counts PAX5 intron pha003089 rs10738979 chr9 36889325 G A 3.13E-05 Monocyte counts PAX5 intron pha003089 rs1573257 chr9 36896143 G A 7.45E-05 Multiple complex diseases PAX5 intron 17554300 rs3780150 chr9 36907255 T C 8.57E-05 Monocyte counts PAX5 intron pha003089 rs2297109 chr9 36922960 T A 2.67E-04 Multiple complex diseases PAX5 intron 17554300 rs4878668 chr9 36928909 G T 1.57E-04 Type 2 diabetes PAX5 intron 17463246 rs4878670 chr9 36932412 G A 2.00E-06 Monocyte counts PAX5 intron pha003089 rs3758165 chr9 36936360 A G 2.53E-05 Monocyte counts PAX5 intron pha003089 rs3780160 chr9 36942624 T C 2.26E-05 Monocyte counts PAX5 intron pha003089 rs4880043 chr9 36950507 C T 5.20E-05 Cholesterol PAX5 intron 17255346 rs4407980 chr9 36952743 A G 2.75E-04 Parkinson's disease PAX5 intron 17052657 rs16933812 chr9 36969205 G T 5.00E-06 Obesity and blood pressure PAX5 intron 22013104 rs16933812 chr9 36969205 G T 9.00E-09 Obesity and blood pressure PAX5 intron 22013104 rs13292007 chr9 36977212 T C 9.18E-04 Acute lung injury PAX5 intron 22295056 rs3758171 chr9 36997417 G A 4.00E-08 Intelligence PAX5 intron 22449649 rs7020413 chr9 37002115 A G 5.35E-04 Multiple complex diseases PAX5 intron 17554300 rs6476606 chr9 37005561 A G 4.39E-04 Multiple complex diseases PAX5 intron 17554300 rs4878672 chr9 37007239 C G 9.86E-04 Multiple complex diseases PAX5 intron 17554300 rs1888018 chr9 37008984 A T 6.42E-04 Multiple complex diseases PAX5 intron 17554300 rs3758175 chr9 37012263 A G 4.22E-04 Multiple complex diseases PAX5 intron 17554300 rs7874488 chr9 37024122 C T 3.50E-04 Multiple complex diseases PAX5 intron 17554300 rs3758179 chr9 37029569 T C 6.46E-04 Multiple complex diseases PAX5 intron 17554300 rs3013739 chr9 37031876 G A 1.14E-04 Multiple complex diseases PAX5 intron 17554300 rs2282079 chr9 37036247 G A 2.76E-05 Breast cancer (survival) LOC100130458 UTR-5 20332263 rs1329568 chr9 37037976 T G 8.00E-07 Response to tocilizumab in rheumatoid arthritis LOC100130458 UTR-3 22491018 rs12378217 chr9 37331605 T G 2.76E-05 Major depressive disorder ZCCHC7 intron 21621269 rs12378217 chr9 37331605 T G 5.00E-05 Major depressive disorder ZCCHC7 intron pha002850 rs12551069 chr9 37353252 C A 3.95E-04 Type 2 diabetes ZCCHC7 intron 17463246 rs7043792 chr9 37354328 G A 5.39E-04 Type 2 diabetes ZCCHC7 intron 17463246 rs309455 chr9 37432264 T C 4.50E-04 Amyotrophic lateral sclerosis (sporadic) GRHPR intron 24529757 rs11789963 chr9 37448509 T C 8.73E-05 Amyotrophic lateral sclerosis (sporadic) ZBTB5 intron 24529757 rs10814556 chr9 37491280 A C 3.92E-05 Lymphocyte counts POLR1E intron 22286170 rs10758435 chr9 37505793 C T 2.05E-05 Lymphocyte counts / / 22286170 rs7039920 chr9 37557720 T C 9.46E-04 White matter integrity FBXO10 intron 22425255 rs10118277 chr9 37558780 C A 5.20E-05 Serum metabolites FBXO10 intron 19043545 rs7042509 chr9 37579553 G T 6.22E-05 Blood Pressure / / pha003048 rs10973441 chr9 37622777 T C 8.17E-07 Schizophrenia / / 21926974 rs10973450 chr9 37642234 T C 7.21E-04 Lymphocyte counts / / 22286170 rs7021824 chr9 37650203 C T 1.09E-05 Blood Pressure / / pha003046 rs7021824 chr9 37650203 C T 1.02E-05 Blood Pressure / / pha003048 rs1886909 chr9 37656212 G A 3.32E-05 Triglycerides FRMPD1 intron pha003081 rs1886909 chr9 37656212 G A 2.52E-05 Lipid levels FRMPD1 intron pha003082 rs1325916 chr9 37660696 T C 1.50E-05 Triglycerides FRMPD1 intron pha003081 rs1325916 chr9 37660696 T C 1.05E-05 Lipid levels FRMPD1 intron pha003082 rs6476656 chr9 37663810 G A 8.48E-05 Triglycerides FRMPD1 intron pha003081 rs6476656 chr9 37663810 G A 5.63E-05 Lipid levels FRMPD1 intron pha003082 rs10973474 chr9 37665824 G C 3.15E-04 Multiple complex diseases FRMPD1 intron 17554300 rs10973475 chr9 37666361 C T 1.51E-04 Smoking initiation FRMPD1 intron 24665060 rs10120945 chr9 37672546 G A 8.95E-04 Multiple complex diseases FRMPD1 intron 17554300 rs10973494 chr9 37692526 G A 8.17E-04 Multiple complex diseases FRMPD1 intron 17554300 rs3827513 chr9 37693006 T C 9.11E-05 Major depressive disorder FRMPD1 intron 19107115 rs576020823 chr9 37693006 TACAC T 9.11E-05 Major depressive disorder FRMPD1 intron 19107115 rs10758452 chr9 37706566 G A 1.54E-04 Multiple complex diseases FRMPD1 intron 17554300 rs2296555 chr9 37708307 A C 1.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FRMPD1 intron 20877124 rs2296553 chr9 37711594 A C 8.26E-04 Stroke FRMPD1 intron pha002887 rs2013458 chr9 37719011 T C 7.50E-05 Major depressive disorder FRMPD1 intron 19107115 rs12345385 chr9 37749508 A G 5.00E-04 Heart rate / / 23583979 rs1409145 chr9 37761044 T C 1.22E-04 Multiple complex diseases RG9MTD3 intron 17554300 rs3208406 chr9 37780831 A G 3.06E-04 Birth weight EXOSC3 missense 17255346 rs3208406 chr9 37780831 A G 8.09E-04 Stroke EXOSC3 missense pha002886 rs3827515 chr9 37781455 G A 1.81E-04 Multiple complex diseases EXOSC3 intron 17554300 rs7049213 chr9 37799031 G C 1.97E-04 Multiple complex diseases / / 17554300 rs966494 chr9 37803210 T C 2.17E-04 Multiple complex diseases DCAF10 intron 17554300 rs16934508 chr9 37858861 C G 1.51E-04 Multiple complex diseases DCAF10 intron 17554300 rs10973596 chr9 37886511 A G 9.42E-04 Multiple complex diseases MCART1 intron 17554300 rs4878724 chr9 37901883 A G 1.44E-04 Body mass index MCART1 intron 17255346 rs3747547 chr9 37916408 T C 5.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) SHB UTR-3 23934736 rs735740 chr9 37944427 G A 9.64E-05 Sodium levels SHB intron pha003093 rs735741 chr9 37944489 G A,C,T 5.40E-04 Type 2 diabetes SHB intron 17463246 rs735741 chr9 37944489 G A,C,T 4.06E-04 Alzheimer's disease (late onset) SHB intron 21379329 rs7048063 chr9 37957229 A G 8.16E-04 Multiple complex diseases SHB intron 17554300 rs1138374 chr9 37974743 T C 5.80E-04 Multiple complex diseases SHB cds-synon 17554300 rs943938 chr9 37983770 C T 2.55E-04 Multiple complex diseases SHB intron 17554300 rs2243893 chr9 37989893 A G 4.62E-04 Multiple complex diseases SHB intron 17554300 rs2243893 chr9 37989893 A G 2.20E-05 Urinary metabolites SHB intron 21572414 rs7028020 chr9 38007747 A G 2.26E-04 Multiple complex diseases SHB intron 17554300 rs10814639 chr9 38009663 A G 3.29E-04 Multiple complex diseases SHB intron 17554300 rs4878733 chr9 38010025 C T 5.81E-04 Multiple complex diseases SHB intron 17554300 rs4878734 chr9 38010085 A T 2.80E-04 Multiple complex diseases SHB intron 17554300 rs2381775 chr9 38024812 G A 1.54E-05 Stroke SHB intron pha002886 rs10814645 chr9 38027524 G T 6.86E-04 Insulin resistance SHB intron 21901158 rs943936 chr9 38027644 C T 1.08E-04 Body mass index SHB intron 17255346 rs67076718 chr9 38035758 C T 0.00001025 Sarcoidosis SHB intron 22952805 rs3763637 chr9 38037956 T A 0.00002118 Sarcoidosis SHB intron 22952805 rs7025303 chr9 38040095 C T 1.21E-06 Brain structure SHB intron 20171287 rs7873102 chr9 38041142 T G 6.00E-07 Brain structure SHB intron 20171287 rs11790106 chr9 38047710 G A 4.80E-05 Cognitive test performance SHB intron 20125193 rs11790106 chr9 38047710 G A 0.00009798 Sarcoidosis SHB intron 22952805 rs72726049 chr9 38049744 C T 0.0000649 Sarcoidosis SHB intron 22952805 rs72726052 chr9 38056290 C T 0.00007059 Sarcoidosis SHB intron 22952805 rs4878743 chr9 38058424 C T 1.79E-04 Alzheimer's disease (late onset) SHB intron 21379329 rs1887879 chr9 38079565 G C 0.000006577 Sarcoidosis / / 22952805 rs11792197 chr9 38086999 C T 0.000006791 Sarcoidosis / / 22952805 rs4878183 chr9 38090221 G A 1.72E-05 Cholesterol / / pha003073 rs4878183 chr9 38090221 G A 9.90E-06 Cholesterol / / pha003078 rs56003262 chr9 38090421 G A,T 0.000009502 Sarcoidosis / / 22952805 rs67026305 chr9 38090421 G GT 0.000009502 Sarcoidosis / / 22952805 rs11794104 chr9 38091723 T C 0.0000181 Sarcoidosis / / 22952805 rs4878749 chr9 38096655 C G 2.90E-05 Urinary metabolites / / 21572414 rs72726067 chr9 38099153 G A 0.000044 Sarcoidosis / / 22952805 rs72726073 chr9 38103439 A G 0.00002929 Sarcoidosis / / 22952805 rs72726074 chr9 38103817 C G 0.00003728 Sarcoidosis / / 22952805 rs72726076 chr9 38104326 C T 0.00002929 Sarcoidosis / / 22952805 rs2381732 chr9 38118280 C T 6.00E-06 Urinary metabolites / / 21572414 rs72726082 chr9 38119334 A G 0.00000651 Sarcoidosis / / 22952805 rs7033592 chr9 38119900 A C 1.30E-05 Urinary metabolites / / 21572414 rs10758472 chr9 38121338 C G 5.70E-06 Urinary metabolites / / 21572414 rs72726087 chr9 38123401 C G 0.00003527 Sarcoidosis / / 22952805 rs72726090 chr9 38124186 T C 0.00003527 Sarcoidosis / / 22952805 rs7859095 chr9 38124273 C T 6.10E-06 Urinary metabolites / / 21572414 rs80125530 chr9 38124382 G C 0.00006337 Sarcoidosis / / 22952805 rs11791354 chr9 38125173 G C 0.00001109 Sarcoidosis / / 22952805 rs11791344 chr9 38125272 C T 0.00005422 Sarcoidosis / / 22952805 rs72726094 chr9 38126746 G T 0.00003349 Sarcoidosis / / 22952805 rs943932 chr9 38132048 C T 0.00001813 Sarcoidosis / / 22952805 rs1928236 chr9 38132477 T C 0.00002207 Sarcoidosis / / 22952805 rs7467749 chr9 38136965 A T 0.00001813 Sarcoidosis / / 22952805 rs7848566 chr9 38137724 T G 1.90E-05 Urinary metabolites / / 21572414 rs943934 chr9 38138880 C T 0.00003376 Sarcoidosis / / 22952805 rs10758475 chr9 38140632 G T 6.20E-06 Urinary metabolites / / 21572414 rs1928239 chr9 38142145 A C 6.40E-06 Urinary metabolites / / 21572414 rs1928242 chr9 38144829 C T 6.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11790887 chr9 38145719 T C 0.00006824 Sarcoidosis / / 22952805 rs943935 chr9 38150167 T G 1.60E-06 Urinary metabolites / / 21572414 rs943935 chr9 38150167 T G 7.07E-04 Acute lung injury / / 22295056 rs1001959 chr9 38151190 C T 2.00E-06 Urinary metabolites / / 21572414 rs10973683 chr9 38151268 A C 4.02E-04 Alzheimer's disease (late onset) / / 21379329 rs10973683 chr9 38151268 A C 2.10E-06 Urinary metabolites / / 21572414 rs7859035 chr9 38154137 G A 8.10E-05 Stroke / / pha002886 rs894520 chr9 38189527 T C 2.86E-05 Hypertension / / 21082022 rs1867181 chr9 38239829 C T 9.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs2810722 chr9 38244416 A G 1.62E-05 Eosinophil counts / / pha003088 rs10973717 chr9 38259732 C A 5.63E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2057374 chr9 38281314 A C 3.68E-05 Cognitive impairment induced by topiramate / / 22091778 rs4878192 chr9 38298804 T C 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs12378970 chr9 38333643 C T 4.58E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1555481 chr9 38337291 G T 5.68E-04 Heart Failure / / pha002884 rs17444315 chr9 38355790 T C 9.91E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs17444315 chr9 38355790 T C 7.64E-06 Coronary heart disease / / pha003032 rs4878791 chr9 38361379 C T 1.73E-04 Insulin resistance / / 21901158 rs4878797 chr9 38380350 C A 8.84E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs4878198 chr9 38382515 G A 6.85E-04 Insulin resistance / / 21901158 rs17451412 chr9 38383549 A G 7.20E-06 Urinary metabolites / / 21572414 rs17451412 chr9 38383549 A G 3.47E-04 Insulin resistance / / 21901158 rs11790480 chr9 38384578 G A 0.000301332 Hypertension (early onset hypertension) / / 22479346 rs1555480 chr9 38386351 C T 6.30E-06 Urinary metabolites / / 21572414 rs4646771 chr9 38394806 C T 3.70E-06 Urinary metabolites ALDH1B1 intron 21572414 rs2073478 chr9 38396065 G T 7.70E-05 ldl cholesterol ALDH1B1 missense pha003077 rs12336048 chr9 38404292 G A 9.63E-04 Multiple complex diseases / / 17554300 rs7865905 chr9 38404352 C T 2.62E-04 Type 2 diabetes / / 17463246 rs10973789 chr9 38406178 C T 1.42E-04 Type 2 diabetes / / 17463246 rs11361 chr9 38406590 G A 6.94E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7857013 chr9 38409037 C A 5.55E-04 Multiple complex diseases IGFBPL1 UTR-3 17554300 rs1467574 chr9 38421975 G A 7.09E-04 Lymphocyte counts IGFBPL1 intron 22286170 rs10973813 chr9 38431667 G A 7.83E-05 Triglycerides / / pha003080 rs10973825 chr9 38445252 G A 1.70E-05 Urinary metabolites / / 21572414 rs12551371 chr9 38445742 G A 5.42E-04 Alzheimer's disease / / 22005930 rs1110183 chr9 38456365 G A 8.00E-06 Hypertension / / 22384028 rs10973834 chr9 38457824 C T 1.01E-05 Hypertension / / 22384028 rs2799146 chr9 38458729 C T 9.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs1891922 chr9 38462319 A G 3.57E-05 Triglycerides / / pha003080 rs2799729 chr9 38466031 A G 6.54E-05 Triglycerides / / pha003080 rs2996368 chr9 38522055 C A 1.02E-04 Multiple complex diseases / / 17554300 rs2993156 chr9 38531889 T C 3.10E-06 Urinary metabolites / / 21572414 rs10814710 chr9 38534411 T G 2.90E-06 Urinary metabolites / / 21572414 rs10973948 chr9 38633652 A G 2.72E-05 Lung adenocarcinoma / / 19836008 rs12340088 chr9 38639318 T G 0.00000497 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs12340088 chr9 38639318 T G 5.04E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10973953 chr9 38639853 G A 4.21E-05 Coronary heart disease / / pha003032 rs7048548 chr9 38640619 C T 8.47E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11792859 chr9 38652961 A G 2.72E-04 Tourette syndrome / / 22889924 rs2993155 chr9 38657638 G T 9.80E-04 Multiple complex diseases / / 17554300 rs4074216 chr9 38671825 C G 4.29E-04 Multiple complex diseases / / 17554300 rs13294686 chr9 38673236 A G 3.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs16931494 chr9 38673912 A C 7.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs7039377 chr9 38675465 G A 8.79E-05 Information processing speed / / 21130836 rs7039377 chr9 38675465 G A 2.00E-06 Obesity-related traits / / 23251661 rs10814736 chr9 38678071 G C 6.47E-04 Obesity (extreme) / / 21935397 rs10120311 chr9 38708965 T A 3.82E-05 Personality dimensions / / 22628180 rs11794651 chr9 38738489 C G,T 9.48E-05 Male fertility / / 22633400 rs184891496 chr9 38750579 T C 7.00E-06 Metabolite levels (HVA/MHPG ratio) / / 23319000 rs7048445 chr9 39008919 A G 9.58E-06 Scoliosis / / 21216876 rs11263335 chr9 44873200 C T 2.52E-04 Multiple complex diseases / / 17554300 rs10120657 chr9 46880341 C A 5.00E-07 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs10120296 chr9 68170421 T C 2.43E-04 Cholesterol / / 17255346 rs10120296 chr9 68170421 T C 3.74E-06 Rheumatoid arthritis / / 19503088 rs2492042 chr9 69088194 A G 1.10E-06 Urinary metabolites PGM5P2 intron 21572414 rs2860101 chr9 71103406 G T 5.60E-04 Alzheimer's disease PGM5 intron 22005930 rs7022220 chr9 71106512 T C 5.21E-04 Alzheimer's disease PGM5 intron 22005930 rs11142650 chr9 71109125 A T 7.58E-04 Alzheimer's disease PGM5 intron 22005930 rs7861495 chr9 71154607 G C 1.17E-05 Schizophrenia C9orf71 intron 19571809 rs10120859 chr9 71156295 T C 5.75E-04 Suicide attempts in bipolar disorder / / 21041247 rs10869020 chr9 71156551 A G 5.42E-04 Multiple complex diseases / / 17554300 rs10869020 chr9 71156551 A G 4.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs10746875 chr9 71156949 T A 4.63E-04 Suicide attempts in bipolar disorder / / 21041247 rs7860486 chr9 71157459 C A 4.81E-04 Suicide attempts in bipolar disorder / / 21041247 rs11795256 chr9 71168012 A G 2.92E-05 Bipolar disorder / / 17486107 rs7036795 chr9 71168318 T C 2.99E-06 Alopecia areata / / 22027810 rs1571825 chr9 71181052 G C 8.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs1571826 chr9 71181100 A T 8.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs1411993 chr9 71186182 T C 0.0001199 Sarcoidosis / / 22952805 rs2183738 chr9 71211200 C T 3.63E-04 Alzheimer's disease / / 17998437 rs2183738 chr9 71211200 C T 8.73E-05 Obsessive-compulsive disorder / / 24821223 rs7032966 chr9 71211602 C T 4.45E-04 Alcohol dependence / / 21314694 rs7864204 chr9 71229179 A G 9.00E-07 Body mass index (interaction) / / 23192594 rs2183737 chr9 71241633 G A 1.21E-06 Blood pressure / / 21378095 rs1888723 chr9 71265112 G A 7.22E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10119024 chr9 71309252 T C 8.22E-04 Multiple complex diseases / / 17554300 rs4534183 chr9 71325908 A G 4.97E-04 Multiple complex diseases PIP5K1B intron 17554300 rs10781117 chr9 71326432 G A 8.48E-08 Metabolite levels PIP5K1B intron 23281178 rs10869225 chr9 71326478 A G 8.48E-08 Metabolite levels PIP5K1B intron 23281178 rs10121993 chr9 71328378 G A 9.31E-08 Metabolite levels PIP5K1B intron 23281178 rs4744685 chr9 71330398 C T 9.44E-08 Metabolite levels PIP5K1B intron 23281178 rs10217316 chr9 71341703 T C 9.44E-08 Metabolite levels PIP5K1B intron 23281178 rs4745230 chr9 71345123 T C 9.30E-08 Metabolite levels PIP5K1B intron 23281178 rs1537885 chr9 71372114 A G 5.74E-04 Type 2 diabetes PIP5K1B intron 17463246 rs4623507 chr9 71392876 G A 1.69E-04 Aortic root size PIP5K1B intron 21223598 rs12552102 chr9 71403821 C T 3.97E-04 Aortic root size PIP5K1B intron 21223598 rs12555728 chr9 71407597 G C 3.82E-04 Aortic root size PIP5K1B intron 21223598 rs11143761 chr9 71415903 A C 7.81E-04 Multiple complex diseases PIP5K1B intron 17554300 rs10869320 chr9 71422770 T C 6.72E-04 Multiple complex diseases PIP5K1B intron 17554300 rs17482797 chr9 71425044 G A 1.18E-04 Type 2 diabetes PIP5K1B intron 17463246 rs1556751 chr9 71433212 G A 2.00E-04 Chronic kidney disease PIP5K1B intron 21931561 rs4744712 chr9 71434707 A C 8.00E-14 Chronic kidney disease PIP5K1B intron 20383146 rs4744712 chr9 71434707 A C 3.00E-04 Chronic kidney disease PIP5K1B intron 21931561 rs4744712 chr9 71434707 A C 7.67E-11 Chronic kidney disease PIP5K1B intron 22479191 rs11143951 chr9 71451982 G A 7.04E-04 Multiple complex diseases PIP5K1B intron 17554300 rs11143976 chr9 71454944 G A 4.20E-04 Multiple complex diseases PIP5K1B intron 17554300 rs10781227 chr9 71455680 A C,G 1.70E-05 Urinary metabolites PIP5K1B intron 21572414 rs6560397 chr9 71471912 C T 2.00E-07 Pit-and-Fissure caries PIP5K1B intron 23470693 rs2039625 chr9 71484439 A T 1.46E-05 Squamous cell carcinoma PIP5K1B intron 23341777 rs10511961 chr9 71497485 G C 7.00E-04 Chronic fatigue syndrome PIP5K1B intron 21912186 rs17058792 chr9 71516542 T C 1.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIP5K1B intron 20877124 rs7859638 chr9 71533367 G A 9.59E-05 Heart Rate PIP5K1B intron pha003054 rs4744737 chr9 71533908 A G 3.81E-04 Multiple complex diseases PIP5K1B intron 17554300 rs10117400 chr9 71549001 A T 1.12E-04 Multiple complex diseases PIP5K1B intron 17554300 rs1056266 chr9 71558545 C T 9.01E-04 Type 2 diabetes PIP5K1B intron 17463246 rs10781329 chr9 71618245 G A 8.34E-05 Asthma PIP5K1B intron 11022011 rs4745520 chr9 71631733 A C 1.83E-04 Alzheimer's disease / / 17998437 rs998215 chr9 71633113 G T 2.30E-05 Urinary metabolites / / 21572414 rs1590944 chr9 71636650 A T 8.97E-05 Multiple complex diseases / / 17554300 rs3763608 chr9 71647375 T C 6.47E-05 Progressive supranuclear palsy / / 21685912 rs7047274 chr9 71662140 C T 1.46E-04 Multiple complex diseases FXN intron 17554300 rs2309393 chr9 71676088 C T 7.10E-05 Progressive supranuclear palsy FXN intron 21685912 rs2498432 chr9 71684369 G A 2.97E-04 Sudden cardiac arrest FXN intron 21658281 rs7870295 chr9 71686476 G A 3.54E-08 Narcolepsy FXN intron 19629137 rs6560551 chr9 71698202 G A 4.49E-04 Multiple complex diseases FXN intron 17554300 rs4069737 chr9 71701174 T C 4.67E-04 Multiple complex diseases FXN intron 17554300 rs10869918 chr9 71745307 C T 4.05E-04 Response to taxane treatment (placlitaxel) TJP2 intron 23006423 rs10122932 chr9 71746053 G C 9.83E-04 Multiple complex diseases TJP2 intron 17554300 rs7034303 chr9 71746871 C T 8.52E-04 Multiple complex diseases TJP2 intron 17554300 rs6560584 chr9 71747172 T C 8.24E-04 Multiple complex diseases TJP2 intron 17554300 rs10781440 chr9 71762766 G A 4.43E-04 Multiple complex diseases TJP2 intron 17554300 rs11145465 chr9 71766593 C A 7.00E-09 Refractive error TJP2 UTR-5 23396134 rs1538583 chr9 71791547 A G 8.47E-04 Multiple complex diseases TJP2 intron 17554300 rs10869975 chr9 71795034 T C 4.31E-04 Multiple complex diseases TJP2 intron 17554300 rs2309424 chr9 71806370 A G 3.73E-04 Multiple complex diseases TJP2 intron 17554300 rs11145746 chr9 71834380 G A 7.33E-04 Multiple complex diseases TJP2 intron 17554300 rs11145746 chr9 71834380 G A 2.30E-11 Myopia (Age of onset) TJP2 intron 23468642 rs7863144 chr9 71839039 A G 3.90E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) TJP2 intron 24023788 rs2309428 chr9 71843023 C A 9.60E-05 Non-alcoholic fatty liver disease histology (other) TJP2 missense 20708005 rs9314671 chr9 71860041 G C 3.47E-04 Blood pressure TJP2 intron 17255346 rs2282335 chr9 71865932 G A 4.00E-06 Renal sinus fat TJP2 intron 22044751 rs7859876 chr9 71923012 A T 4.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs6559453 chr9 71926658 T C 8.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs1572762 chr9 71926960 A G 6.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs1890634 chr9 71930959 T A 6.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs6559467 chr9 71933157 G A 4.29E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10780297 chr9 71935577 C A 2.34E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10780297 chr9 71935577 C A 8.49E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3750552 chr9 71943002 C T 5.00E-06 Bipolar disorder FAM189A2 intron 22925353 rs7027671 chr9 71949468 A G 2.20E-05 Urinary metabolites FAM189A2 intron 21572414 rs7027671 chr9 71949468 A G 9.87E-04 Response to cytidine analogues (gemcitabine) FAM189A2 intron 24483146 rs10867403 chr9 71970080 A G 1.74E-04 Response to cytidine analogues (gemcitabine) FAM189A2 intron 24483146 rs10780336 chr9 72003529 G A 9.71E-04 Response to cytidine analogues (gemcitabine) FAM189A2 intron 24483146 rs11138566 chr9 72036369 C T 2.44E-04 Premature ovarian failure / / 19508998 rs1761293 chr9 72043280 C T 0.00008644 Sarcoidosis APBA1 UTR-3 22952805 rs1217339 chr9 72047599 G A 7.68E-04 Suicide attempts in bipolar disorder APBA1 intron 21041247 rs3737172 chr9 72047635 C T 7.68E-04 Suicide attempts in bipolar disorder APBA1 intron 21041247 rs1217338 chr9 72048098 T C 7.10E-04 Alzheimer's disease APBA1 intron 17998437 rs1217338 chr9 72048098 T C 7.69E-04 Suicide attempts in bipolar disorder APBA1 intron 21041247 rs2781530 chr9 72056397 C T 2.60E-04 Premature ovarian failure APBA1 intron 19508998 rs1831555 chr9 72058021 T C 2.60E-04 Premature ovarian failure APBA1 intron 19508998 rs1977552 chr9 72059114 G T 3.86E-04 Premature ovarian failure APBA1 intron 19508998 rs2781542 chr9 72090806 T G 2.13E-04 Alzheimer's disease APBA1 intron 17998437 rs7866199 chr9 72134427 C T 4.41E-04 Alzheimer's disease APBA1 intron 17998437 rs11139084 chr9 72137536 A G 4.17E-04 Alzheimer's disease APBA1 intron 17998437 rs11139269 chr9 72160248 T C 9.00E-04 Suicide attempts in bipolar disorder APBA1 intron 21423239 rs7019109 chr9 72160392 T C 9.00E-04 Suicide attempts in bipolar disorder APBA1 intron 21423239 rs7033083 chr9 72160492 G C 9.14E-04 Suicide attempts in bipolar disorder APBA1 intron 21423239 rs4330751 chr9 72198400 C T 6.70E-04 Multiple complex diseases APBA1 intron 17554300 rs10780539 chr9 72218613 A G 6.13E-05 Orofacial clefts APBA1 intron 19270707 rs2161056 chr9 72229395 A G 5.91E-05 Orofacial clefts APBA1 intron 19270707 rs10746683 chr9 72231647 T C 6.77E-05 Schizophrenia(age at onset) APBA1 intron 21688384 rs13288998 chr9 72233182 T G 2.74E-04 Alzheimer's disease (late onset) APBA1 intron 21379329 rs10867932 chr9 72322433 A G 5.38E-04 Myopia (pathological) / / 21095009 rs7857137 chr9 72328727 A G 2.39E-04 Longevity PTAR1 UTR-3 22279548 rs10511968 chr9 72345603 G C 5.34E-04 Response to taxane treatment (placlitaxel) PTAR1 intron 23006423 rs10511969 chr9 72362158 C T 0.00000769 Panic disorder PTAR1 intron 23149450 rs10511969 chr9 72362158 C T 7.69E-06 Serum tamsulosin hydrochloride concentration PTAR1 intron 23151678 rs11140297 chr9 72406110 A T 9.35E-04 Multiple complex diseases / / 17554300 rs17517794 chr9 72416913 A G 9.00E-04 Spine bone size / / 21947420 rs7863087 chr9 72429750 T C 4.22E-05 Leukocyte Counts / / pha003091 rs10511973 chr9 72466275 A G 2.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C9orf135 intron 20877124 rs10511973 chr9 72466275 A G 2.97E-05 Parkinson's disease (motor and cognition) C9orf135 intron 22658654 rs7869694 chr9 72484697 A G 6.00E-06 Body mass index C9orf135 intron 20818722 rs7869694 chr9 72484697 A G 3.96E-04 Acute lung injury C9orf135 intron 22295056 rs10780686 chr9 72492959 A G 5.94E-05 Serum metabolites C9orf135 intron 19043545 rs11140842 chr9 72519172 T C 8.77E-04 Response to cytadine analogues (cytosine arabinoside) C9orf135 intron 24483146 rs11140862 chr9 72525212 A T 8.19E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7847934 chr9 72549748 A G 1.83E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs10780718 chr9 72553665 G C 8.12E-04 Type 2 diabetes / / 17463246 rs996375 chr9 72562749 T C 3.70E-04 Multiple complex diseases / / 17554300 rs996375 chr9 72562749 T C 5.25E-05 Type 1 diabetes / / 18978792 rs7025044 chr9 72568187 T A 2.37E-04 Multiple complex diseases / / 17554300 rs7025044 chr9 72568187 T A 3.96E-05 Type 1 diabetes / / 18978792 rs7029606 chr9 72569288 T C 4.61E-04 Multiple complex diseases / / 17554300 rs1873825 chr9 72591055 A G 2.11E-04 Multiple complex diseases / / 17554300 rs1873825 chr9 72591055 A G 5.86E-05 Type 1 diabetes / / 18978792 rs10511978 chr9 72608505 T C 1.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4430153 chr9 72650127 G T 8.32E-05 Type 1 diabetes / / 18978792 rs2997657 chr9 72662689 C T 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes MAMDC2 intron 22628534 rs12685939 chr9 72684034 G A 5.45E-04 Multiple complex diseases MAMDC2 intron 17554300 rs867595 chr9 72694541 T G 8.33E-05 Neuroblastoma MAMDC2 intron pha002895 rs3015182 chr9 72698039 G C 6.25E-05 Bipolar disorder MAMDC2 intron 19488044 rs3015182 chr9 72698039 G C 8.79E-05 Bipolar Disorder MAMDC2 intron pha002863 rs2975866 chr9 72703016 G A 6.39E-05 Bipolar disorder MAMDC2 intron 19488044 rs2975868 chr9 72705607 G C 5.13E-05 Bipolar disorder MAMDC2 intron 19488044 rs2975868 chr9 72705607 G C 8.99E-05 Bipolar Disorder MAMDC2 intron pha002863 rs3015189 chr9 72706347 T G 6.11E-05 Bipolar disorder MAMDC2 intron 19488044 rs10511979 chr9 72720438 G A 5.76E-05 Neuroblastoma MAMDC2 intron pha002895 rs3015216 chr9 72725049 C T 1.54E-04 Multiple complex diseases MAMDC2 intron 17554300 rs17088840 chr9 72753755 C A 5.37E-04 Bipolar disorder,schizoaffective MAMDC2 intron 19567891 rs10780866 chr9 72776664 T G 7.88E-04 Rheumatoid arthritis MAMDC2 intron 21452313 rs2148853 chr9 72809127 C T 3.85E-04 Lung function (forced expiratory volume in 1 second) MAMDC2 intron 17255346 rs2871297 chr9 72813681 A C 2.56E-06 Biliary atresia MAMDC2 intron 20460270 rs1073540 chr9 72829814 A C 8.26E-05 Bipolar disorder,schizoaffective MAMDC2 intron 19567891 rs3858107 chr9 72861693 T G 8.74E-06 Kawasaki disease LOC100507299 intron 21221998 rs1180109 chr9 72885267 T C 4.34E-04 Type 2 diabetes SMC5 intron 17463246 rs17052443 chr9 72891828 G A 3.17E-04 Lung function (forced expiratory volume in 1 second) SMC5 intron 17255346 rs1180117 chr9 72897440 T C 9.65E-04 Rheumatoid arthritis SMC5 missense 21452313 rs11142350 chr9 72902386 A G 6.60E-06 Kawasaki disease SMC5 intron 21221998 rs4745006 chr9 72985886 T C 8.12E-04 Type 2 diabetes / / 17463246 rs11142387 chr9 72998332 A C 1.00E-09 Body mass index / / 22344221 rs11142387 chr9 72998332 A C 3.00E-08 Body mass index / / 24861553 rs963265 chr9 73094535 T C 1.00E-06 Migraine with aura / / 23793025 rs10511983 chr9 73146746 A G 0.00004298 Sarcoidosis / / 22952805 rs10780944 chr9 73157416 G A 8.00E-07 Pubertal anthropometrics TRPM3 intron 23449627 rs2277188 chr9 73164637 C T 5.06E-05 Diabetes (gestational) TRPM3 intron 22233651 rs10511984 chr9 73170295 G A 1.36E-04 Myocardial Infarction TRPM3 intron pha002883 rs17055319 chr9 73184227 C A 5.11E-04 Multiple complex diseases TRPM3 intron 17554300 rs10780950 chr9 73193428 T C 2.74E-04 Multiple complex diseases TRPM3 intron 17554300 rs11790957 chr9 73200907 T C 7.45E-05 Weight TRPM3 intron pha003027 rs10114679 chr9 73224560 C T 5.20E-04 Alcohol dependence TRPM3 intron 20201924 rs2185338 chr9 73227348 G C 1.18E-04 Multiple complex diseases TRPM3 intron 17554300 rs7039780 chr9 73279957 A G 6.06E-05 Multiple complex diseases TRPM3 intron 17554300 rs4744608 chr9 73280977 C G 5.30E-05 Multiple complex diseases TRPM3 intron 17554300 rs10746854 chr9 73283109 C T 3.28E-04 Suicide attempts in bipolar disorder TRPM3 intron 21423239 rs10116210 chr9 73284493 G A 8.44E-05 Multiple complex diseases TRPM3 intron 17554300 rs1934470 chr9 73284766 T C 4.24E-04 Suicide attempts in bipolar disorder TRPM3 intron 21423239 rs17460690 chr9 73285588 T C 8.28E-04 Major depressive disorder TRPM3 intron 22472876 rs17460690 chr9 73285588 T C 8.84E-05 Hypertension (early onset hypertension) TRPM3 intron 22479346 rs4523327 chr9 73285829 T G 3.21E-04 Suicide attempts in bipolar disorder TRPM3 intron 21423239 rs4465028 chr9 73287076 A G 4.09E-04 Suicide attempts in bipolar disorder TRPM3 intron 21423239 rs1317604 chr9 73293066 A G 4.77E-04 Suicide attempts in bipolar disorder TRPM3 intron 21423239 rs1934473 chr9 73293836 A T 4.55E-04 Suicide attempts in bipolar disorder TRPM3 intron 21423239 rs1856655 chr9 73295539 T G 3.76E-04 Suicide attempts in bipolar disorder TRPM3 intron 21423239 rs10868874 chr9 73302000 T C 4.07E-04 Suicide attempts in bipolar disorder TRPM3 intron 21423239 rs1328151 chr9 73303119 G A 5.41E-04 Suicide attempts in bipolar disorder TRPM3 intron 21423239 rs10115622 chr9 73306551 C A 4.06E-04 Multiple complex diseases TRPM3 intron 17554300 rs10780958 chr9 73307217 A G 4.97E-04 Suicide attempts in bipolar disorder TRPM3 intron 21423239 rs10780959 chr9 73307490 G A 4.18E-04 Multiple complex diseases TRPM3 intron 17554300 rs10511985 chr9 73307620 G C 3.18E-04 Multiple complex diseases TRPM3 intron 17554300 rs10123287 chr9 73308567 G C 7.73E-04 Multiple complex diseases TRPM3 intron 17554300 rs3908571 chr9 73315693 A C 2.29E-04 Multiple complex diseases TRPM3 intron 17554300 rs11142566 chr9 73365750 C T 0.000564187 Hypertension (early onset hypertension) TRPM3 intron 22479346 rs10118380 chr9 73405864 T C 7.40E-06 Carotenoid and tocopherol levels TRPM3 intron 19185284 rs1328155 chr9 73410540 G A 6.48E-04 Suicide attempts in bipolar disorder TRPM3 intron 21423239 rs10868893 chr9 73419560 G A 4.19E-04 Multiple complex diseases TRPM3 intron 17554300 rs2275242 chr9 73448055 C T 2.25E-04 Multiple complex diseases TRPM3 intron 17554300 rs2275242 chr9 73448055 C T 4.30E-06 Colorectal cancer TRPM3 intron 21242260 rs2039645 chr9 73452287 G A 3.52E-06 Colorectal cancer TRPM3 intron 21242260 rs6560161 chr9 73459104 G A 2.10E-04 Multiple complex diseases TRPM3 intron 17554300 rs1337028 chr9 73460091 A G 1.69E-04 Multiple complex diseases TRPM3 intron 17554300 rs7847940 chr9 73461900 C G 3.53E-04 Multiple complex diseases TRPM3 intron 17554300 rs7022926 chr9 73462784 G A 1.22E-04 Multiple complex diseases TRPM3 intron 17554300 rs11787887 chr9 73491479 A T 5.10E-05 Asthma TRPM3 intron 23181788 rs4143736 chr9 73517105 G A 1.19E-05 Parkinson's disease (motor and cognition) TRPM3 intron 22658654 rs17056015 chr9 73544829 C T 5.29E-04 Type 2 diabetes TRPM3 intron 17463246 rs2993003 chr9 73577326 A G 1.70E-05 HDL cholesterol TRPM3 intron pha003075 rs7041925 chr9 73585789 T C 7.28E-04 Type 2 diabetes TRPM3 intron 17463246 rs2993008 chr9 73586356 C T 2.46E-06 Common variable immunodeficiency TRPM3 intron 21497890 rs2909295 chr9 73594114 C T 7.68E-04 Stroke TRPM3 intron pha002887 rs17056164 chr9 73610053 C A 4.21E-04 Type 2 diabetes TRPM3 intron 17463246 rs17520103 chr9 73615061 G A 8.11E-05 HDL cholesterol TRPM3 intron pha003074 rs2909292 chr9 73615374 T C 6.35E-06 Intracerebral hemorrhage TRPM3 intron 24656865 rs495259 chr9 73632464 A G 1.73E-05 HDL cholesterol TRPM3 intron pha003074 rs649375 chr9 73639449 C T 8.34E-04 Multiple complex diseases TRPM3 intron 17554300 rs1411164 chr9 73655072 A C 4.46E-05 Asthma TRPM3 intron 20159242 rs688933 chr9 73673159 T C 3.10E-06 Lipid traits TRPM3 intron 17903299 rs7873024 chr9 73696694 C T 2.28E-04 Type 2 diabetes TRPM3 intron 17463246 rs541326 chr9 73706951 G A 3.60E-05 Lipid traits TRPM3 intron 17903299 rs972387 chr9 73722022 A T 2.85E-04 Type 2 diabetes TRPM3 intron 17463246 rs4620343 chr9 73736643 C T 8.34E-05 Osteoarthritis (knee and hip) / / 21177295 rs4620343 chr9 73736643 C T 8.63E-04 Osteoarthritis (knee and hip) / / 21177295 rs4620343 chr9 73736643 C T 4.85E-05 LDL lipoproteins / / pha002902 rs1329778 chr9 73755913 G A 0.000881 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1329778 chr9 73755913 G A 8.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1329776 chr9 73756531 T C 0.0001998 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1329776 chr9 73756531 T C 2.00E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10116502 chr9 73762034 G A 0.0002052 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10116502 chr9 73762034 G A 2.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10116082 chr9 73763985 T C 0.0002072 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10116082 chr9 73763985 T C 2.07E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1329773 chr9 73765153 G A 5.40E-05 Memory performance / / 22105620 rs17056372 chr9 73773253 G A 0.0002329 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17056372 chr9 73773253 G A 2.33E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13284436 chr9 73774529 C G 0.0002398 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13284436 chr9 73774529 C G 2.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11142707 chr9 73775105 T C 0.0002467 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11142707 chr9 73775105 T C 2.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11142708 chr9 73778502 A G 1.30E-05 Intracerebral hemorrhage / / 24656865 rs11142708 chr9 73778502 A G 4.67E-05 Intracerebral hemorrhage / / 24656865 rs4745062 chr9 73784264 C T 1.00E-06 Longevity / / 20834067 rs10512009 chr9 73801266 C T 2.80E-04 Type 2 diabetes / / 17463246 rs1354458 chr9 73827806 G A 4.10E-04 Type 2 diabetes / / 17463246 rs7021834 chr9 73894085 C T 3.00E-05 Lipid traits / / 17903299 rs1394309 chr9 73915535 G A 5.05E-05 Depression (quantitative trait) / / 23290196 rs1504400 chr9 73916583 A T 1.10E-05 Urinary metabolites / / 21572414 rs1504401 chr9 73916953 T C 2.66E-05 Height / / pha003011 rs1847503 chr9 73923662 C T 8.57E-06 Aortic root size / / 21223598 rs10121027 chr9 73926178 G A 7.55E-06 Aortic root size / / 21223598 rs11142815 chr9 74016922 T C 4.30E-04 Multiple complex diseases / / 17554300 rs10869019 chr9 74042353 T C 4.24E-05 Bipolar disorder / / 21771265 rs10746876 chr9 74065947 C T 1.92E-05 Bipolar disorder / / 21771265 rs7034150 chr9 74072841 G A 1.60E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs1891298 chr9 74094529 A G 6.10E-06 Urinary metabolites / / 21572414 rs11142845 chr9 74096528 C T 8.05E-05 Bipolar disorder and schizophrenia / / 20889312 rs7033424 chr9 74098834 A G 7.80E-06 Urinary metabolites / / 21572414 rs6560207 chr9 74106055 G T 1.00E-05 Urinary metabolites / / 21572414 rs10123278 chr9 74107098 T C 1.30E-05 Urinary metabolites / / 21572414 rs531769000 chr9 74107098 TA T 1.30E-05 Urinary metabolites / / 21572414 rs12551709 chr9 74137779 C T 6.30E-04 Myopia (pathological) / / 21095009 rs1935339 chr9 74146455 G C 1.89E-04 Birth weight / / 17255346 rs11142873 chr9 74151806 C T 2.76E-04 Birth weight / / 17255346 rs10512001 chr9 74156121 G A 9.63E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7042172 chr9 74158641 A G 4.12E-05 Bipolar disorder / / 21771265 rs7874847 chr9 74163610 C T 2.55E-04 Birth weight / / 17255346 rs2309979 chr9 74167402 T C 5.72E-05 Rheumatoid arthritis / / 17804836 rs2309979 chr9 74167402 T C 4.12E-05 Bipolar disorder / / 21771265 rs2309982 chr9 74174742 A G 3.70E-04 Asperger disorder / / 21182207 rs2232134 chr9 74176764 C A 8.12E-04 Multiple complex diseases / / 17554300 rs12552904 chr9 74183471 G A 6.59E-04 Myopia (pathological) / / 21095009 rs4606122 chr9 74186310 C T 9.68E-04 Stroke / / pha002886 rs2210016 chr9 74200674 G A 2.78E-04 Schizophrenia / / 19197363 rs11142904 chr9 74202802 T C 7.89E-04 Schizophrenia / / 19197363 rs11142907 chr9 74207521 A C 5.08E-05 Type 2 diabetes / / 17463246 rs2871401 chr9 74257162 A C 9.28E-04 Coronary heart disease / / 21971053 rs10732702 chr9 74264420 T C 3.99E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1410989 chr9 74265535 G A 4.20E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2297089 chr9 74305098 C T 1.22E-04 Glycosylated haemoglobin levels TMEM2 missense 17255346 rs1010434 chr9 74325433 C T 9.50E-04 Multiple complex diseases TMEM2 intron 17554300 rs1010434 chr9 74325433 C T 7.33E-04 Alcohol dependence TMEM2 intron 21314694 rs3739781 chr9 74326961 A G 1.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM2 intron 20877124 rs7037458 chr9 74327419 C A 6.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM2 intron 20877124 rs3780610 chr9 74328922 A G 4.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM2 intron 20877124 rs2310024 chr9 74374194 C T 4.43E-05 Parkinson's disease TMEM2 intron 17052657 rs12379790 chr9 74379259 A G 7.81E-04 Multiple complex diseases TMEM2 intron 17554300 rs4745122 chr9 74392687 A C 5.48E-05 Parkinson's disease / / 21812969 rs11143012 chr9 74436815 C G 8.75E-04 Obesity (extreme) / / 21935397 rs10869073 chr9 74600517 C T 3.34E-04 Rheumatoid arthritis / / 21452313 rs2147240 chr9 74602989 C G 7.75E-05 Multiple complex diseases / / 17554300 rs10869077 chr9 74608292 C T 9.22E-05 Cognitive performance / / 19734545 rs7046711 chr9 74643648 A C 9.00E-06 Urinary metabolites / / 21572414 rs10123272 chr9 74648601 T C 9.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs4745152 chr9 74649339 G A 8.60E-06 Urinary metabolites / / 21572414 rs942395 chr9 74658286 G A 1.70E-05 Urinary metabolites / / 21572414 rs4322076 chr9 74697891 C T 9.61E-04 Alzheimer's disease / / 17998437 rs10746902 chr9 74698289 C A 6.97E-04 Alzheimer's disease / / 17998437 rs11143104 chr9 74701812 T A 0.0000487 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10781066 chr9 74709235 T C 6.10E-05 Multiple complex diseases / / 17554300 rs10781070 chr9 74723330 A G 7.83E-05 Alzheimer's disease / / 17998437 rs9785222 chr9 74726786 T C 2.80E-04 Multiple complex diseases / / 17554300 rs9785222 chr9 74726786 T C 6.19E-04 Alzheimer's disease / / 17998437 rs11788782 chr9 74736147 A T 6.62E-05 Alzheimer's disease GDA intron 17998437 rs9314794 chr9 74737437 C T 3.23E-05 Alzheimer's disease GDA intron 17998437 rs4745159 chr9 74738747 A C 4.38E-06 Alzheimer's disease GDA intron 17998437 rs4237252 chr9 74745216 T G 6.30E-04 Multiple complex diseases GDA intron 17554300 rs4237252 chr9 74745216 T G 5.16E-04 Alzheimer's disease GDA intron 17998437 rs10869127 chr9 74747787 G T 4.36E-04 Multiple complex diseases GDA intron 17554300 rs10511997 chr9 74760556 G A 5.60E-05 Alcohol consumption GDA intron pha001401 rs12338453 chr9 74769532 C T 1.59E-05 Intelligence GDA intron 21826061 rs10869134 chr9 74776701 A G 1.33E-05 Intelligence GDA intron 21826061 rs11143141 chr9 74777184 C T 1.33E-05 Intelligence GDA intron 21826061 rs10869142 chr9 74797309 C T 1.55E-05 Intelligence GDA intron 21826061 rs7867133 chr9 74808010 A G 3.90E-06 Bipolar disorder GDA intron 19416921 rs11143176 chr9 74836085 G T 1.25E-05 Major depressive disorder GDA intron 22472876 rs10869149 chr9 74836247 T C 1.23E-05 Major depressive disorder GDA intron 22472876 rs10781090 chr9 74839689 C T 2.80E-05 Urinary metabolites GDA intron 21572414 rs10869150 chr9 74845989 C A 5.55E-05 Major depressive disorder GDA intron 22472876 rs17057536 chr9 74846104 A G 4.85E-05 Major depressive disorder GDA intron 22472876 rs10869151 chr9 74850932 A C 5.82E-05 Major depressive disorder GDA intron 22472876 rs11143186 chr9 74851035 A G 1.06E-05 Major depressive disorder GDA intron 22472876 rs7854074 chr9 74886897 T C 7.81E-04 Type 2 diabetes / / 17463246 rs11143230 chr9 74887703 A C 7.00E-06 Suicidal ideation / / 20877300 rs11143230 chr9 74887703 A C 8.00E-07 Suicidal ideation / / 20877300 rs17080960 chr9 74916660 G A 4.90E-05 Odorant perception / / 23910658 rs941939 chr9 74921042 T C 4.36E-04 Multiple complex diseases LOC100507540 intron 17554300 rs2146185 chr9 74950213 T C 5.21E-04 Smoking quantity / / 24665060 rs3398 chr9 74969076 G A 5.28E-07 Esophageal cancer (squamous cell) ZFAND5 UTR-3 22960999 rs2809270 chr9 74975136 T C 8.36E-09 HDL cholesterol ZFAND5 cds-synon 23063622 rs2984526 chr9 74987260 C G 2.16E-07 Esophageal cancer (squamous cell) / / 22960999 rs2984526 chr9 74987260 C G 4.00E-04 Smoking quantity / / 24665060 rs2984524 chr9 74989643 C T 4.59E-04 Smoking quantity / / 24665060 rs2758460 chr9 74995813 A G 4.88E-04 Smoking quantity / / 24665060 rs2984519 chr9 74997987 A G 2.82E-04 Smoking quantity / / 24665060 rs3012514 chr9 75016279 T G 3.40E-04 Smoking quantity / / 24665060 rs10869174 chr9 75039005 C T 5.82E-04 Smoking quantity / / 24665060 rs9314797 chr9 75043308 A G 1.22E-04 Smoking quantity / / 24665060 rs7027640 chr9 75044591 G A 1.00E-05 Urinary metabolites / / 21572414 rs10781101 chr9 75046564 T C 1.20E-05 Urinary metabolites / / 21572414 rs10781101 chr9 75046564 T C 1.34E-04 Smoking quantity / / 24665060 rs4526421 chr9 75047061 C G 1.20E-05 Urinary metabolites / / 21572414 rs4526421 chr9 75047061 C G 3.51E-05 Smoking quantity / / 24665060 rs7853275 chr9 75052326 T C 8.80E-06 Urinary metabolites / / 21572414 rs7853275 chr9 75052326 T C 3.74E-04 Smoking quantity / / 24665060 rs13283854 chr9 75059839 C T 6.41E-04 Smoking quantity / / 24665060 rs6560276 chr9 75062692 C T 1.88E-04 Smoking quantity / / 24665060 rs3902975 chr9 75073647 G A 1.19E-04 Smoking quantity / / 24665060 rs10869178 chr9 75077730 G C 7.28E-04 Multiple complex diseases / / 17554300 rs7866546 chr9 75079110 A G 5.74E-04 Smoking quantity / / 24665060 rs7864535 chr9 75084510 T A 5.84E-04 Smoking quantity / / 24665060 rs12004208 chr9 75091769 T C 5.53E-04 Smoking quantity / / 24665060 rs6560277 chr9 75092767 C T 5.92E-04 Smoking quantity / / 24665060 rs4132905 chr9 75097189 C T 1.67E-04 Smoking quantity / / 24665060 rs4304386 chr9 75110311 A C 4.63E-04 Smoking quantity / / 24665060 rs7040392 chr9 75112780 C T 7.29E-04 Smoking quantity / / 24665060 rs12342088 chr9 75117764 A G 1.14E-04 Smoking quantity / / 24665060 rs4073226 chr9 75119753 C A 7.16E-04 Smoking quantity / / 24665060 rs4073227 chr9 75119808 A C 3.22E-04 Smoking quantity / / 24665060 rs10121866 chr9 75121849 A G 3.75E-04 Smoking quantity / / 24665060 rs7857674 chr9 75123453 G T 0.0002 Migraine / / 22678113 rs7044241 chr9 75127543 A T 5.54E-04 Smoking quantity / / 24665060 rs7855743 chr9 75127848 G A 2.40E-04 Smoking quantity / / 24665060 rs4373587 chr9 75130977 T C 4.84E-04 Smoking quantity / / 24665060 rs10869183 chr9 75135825 T C 3.46E-04 Smoking quantity TMC1 nearGene-5 24665060 rs7022441 chr9 75136789 G A 1.40E-07 Esophageal cancer (squamous cell) TMC1 UTR-5 22960999 rs7022441 chr9 75136789 G A 5.16E-04 Smoking quantity TMC1 UTR-5 24665060 rs4129520 chr9 75169376 G T 1.72E-05 Smoking quantity TMC1 intron 24665060 rs28535485 chr9 75181491 G A 1.52E-05 Smoking quantity TMC1 intron 24665060 rs7864744 chr9 75188225 G T 1.31E-05 Smoking quantity TMC1 intron 24665060 rs7851577 chr9 75188290 A G 4.55E-04 Smoking quantity TMC1 intron 24665060 rs12344850 chr9 75193817 C T 4.47E-05 Monocyte chemoattractant protein-1 TMC1 intron pha003071 rs7045535 chr9 75210243 T C 1.17E-04 Smoking quantity TMC1 intron 24665060 rs13285932 chr9 75211603 C T 4.23E-04 Coronary Artery Disease TMC1 intron 17634449 rs13285932 chr9 75211603 C T 2.40E-04 Smoking quantity TMC1 intron 24665060 rs10521449 chr9 75222901 G A 1.82E-04 Smoking quantity TMC1 intron 24665060 rs17080971 chr9 75226110 G A 2.00E-04 Smoking quantity TMC1 intron 24665060 rs970386 chr9 75226846 C T 4.09E-04 Smoking quantity TMC1 intron 24665060 rs12351893 chr9 75227490 G A 4.46E-04 Smoking quantity TMC1 intron 24665060 rs1978991 chr9 75235589 T G 0.0002455 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMC1 intron 23233654 rs1978991 chr9 75235589 T G 2.46E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMC1 intron 23233662 rs140273783 chr9 75241962 T TG 0.0002368 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMC1 intron 23233654 rs140273783 chr9 75241962 T TG 2.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMC1 intron 23233662 rs7032424 chr9 75241962 T G 0.0002368 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMC1 intron 23233654 rs7032424 chr9 75241962 T G 2.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMC1 intron 23233662 rs10869190 chr9 75244284 A G 8.22E-04 Multiple complex diseases TMC1 intron 17554300 rs17058037 chr9 75245546 C T 3.22E-05 Spine bone size TMC1 intron 23207799 rs1444835 chr9 75252221 T C 0.0002321 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMC1 intron 23233654 rs1444835 chr9 75252221 T C 2.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMC1 intron 23233662 rs1037031 chr9 75253729 G A 0.0002316 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMC1 intron 23233654 rs1037031 chr9 75253729 G A 2.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMC1 intron 23233662 rs2310153 chr9 75258936 G C 0.0002289 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMC1 intron 23233654 rs2310153 chr9 75258936 G C 2.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMC1 intron 23233662 rs11143366 chr9 75267687 A C 0.0002222 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMC1 intron 23233654 rs11143366 chr9 75267687 A C 2.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMC1 intron 23233662 rs1663759 chr9 75275064 T C 0.0002203 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMC1 intron 23233654 rs1663759 chr9 75275064 T C 2.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMC1 intron 23233662 rs1663762 chr9 75276898 G A 0.0002174 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMC1 intron 23233654 rs1663762 chr9 75276898 G A 2.17E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMC1 intron 23233662 rs1796999 chr9 75280172 G A 0.0003281 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMC1 intron 23233654 rs1796999 chr9 75280172 G A 3.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMC1 intron 23233662 rs2487471 chr9 75280611 G A 0.0003304 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMC1 intron 23233654 rs2487471 chr9 75280611 G A 3.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMC1 intron 23233662 rs11143369 chr9 75281320 G A 0.000442 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMC1 intron 23233654 rs11143369 chr9 75281320 G A 4.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMC1 intron 23233662 rs1630771 chr9 75282205 G A 0.0004685 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMC1 intron 23233654 rs1630771 chr9 75282205 G A 4.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMC1 intron 23233662 rs186937202 chr9 75318935 A G 7.52E-05 Acne (severe) TMC1 intron 24927181 rs1000668 chr9 75405859 T A 1.09E-07 Esophageal cancer (squamous cell) TMC1 intron 22960999 rs17058153 chr9 75407159 T C 8.30E-05 Response to statin therapy TMC1 missense 20339536 rs17058153 chr9 75407159 T C 9.73E-06 Obesity-related traits TMC1 missense 23251661 rs348479 chr9 75512300 T G 4.45E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs348472 chr9 75521060 A G 0.00000042 Joint damage severity in rheumatoid arthritis ALDH1A1 intron 23696630 rs348472 chr9 75521060 A G 9.13E-05 Height ALDH1A1 intron pha003011 rs348460 chr9 75534760 T G 8.27E-05 Elbow pain ALDH1A1 intron pha003008 rs8187910 chr9 75549810 T C 2.49E-04 Smoking cessation ALDH1A1 intron 24665060 rs348455 chr9 75552899 A G 1.51E-04 Multiple complex diseases ALDH1A1 intron 17554300 rs8187876 chr9 75564954 C T 2.41E-06 Angioedema in response to angiotensin-converting enzyme inhibitor ALDH1A1 intron 23838604 rs10156653 chr9 75586627 C T 4.21E-06 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs7856728 chr9 75602903 A G 6.35E-04 Multiple complex diseases / / 17554300 rs7857814 chr9 75614486 T C 2.30E-05 Urinary metabolites / / 21572414 rs7028573 chr9 75636267 A G 2.90E-05 Urinary metabolites / / 21572414 rs17058421 chr9 75709442 A G 2.17E-05 Orofacial clefts / / 22419666 rs11143479 chr9 75721950 A G 9.59E-04 Acute lung injury / / 22295056 rs11143481 chr9 75735898 C T 6.69E-04 Acute lung injury / / 22295056 rs17652063 chr9 75740818 A G 6.98E-04 Acute lung injury / / 22295056 rs10869227 chr9 75757209 C T 4.15E-05 Orofacial clefts / / 22419666 rs3758354 chr9 75764565 A C 3.00E-06 Schizophrenia,bipolar disorder and depression (combined) / / 20713499 rs2795119 chr9 75780714 G A 9.20E-04 Alzheimer's disease ANXA1 intron 22005930 rs10512015 chr9 75781246 T C 3.70E-07 Cognitive decline ANXA1 intron 22054870 rs2795120 chr9 75781376 T G 6.58E-04 Alzheimer's disease ANXA1 intron 22005930 rs17058570 chr9 75782555 C G 6.57E-06 Cognitive decline ANXA1 intron 22054870 rs11143514 chr9 75789579 G A 8.39E-06 Glucose levels / / pha003057 rs10781126 chr9 75792301 A G 4.40E-05 Asthma (bronchodilator response) / / 22792082 rs11143520 chr9 75792846 G A 1.87E-04 Multiple complex diseases / / 17554300 rs10869233 chr9 75793038 A T 3.13E-04 Blood pressure / / 17255346 rs4581121 chr9 75810393 C T 1.80E-05 Asthma (bronchodilator response) / / 22792082 rs7874116 chr9 75813310 A C 3.70E-06 Asthma (bronchodilator response) / / 22792082 rs13290663 chr9 75819755 C T 2.61E-06 Height / / pha003010 rs13290663 chr9 75819755 C T 8.55E-07 Height / / pha003011 rs12343428 chr9 75900508 G A 1.40E-05 Urinary metabolites / / 21572414 rs7031916 chr9 75938075 A G 7.34E-04 Parkinson's disease / / 16252231 rs7048335 chr9 75971475 A G 4.78E-04 Multiple complex diseases / / 17554300 rs950058 chr9 76050327 T C 3.54E-05 Height / / pha003010 rs950058 chr9 76050327 T C 6.18E-06 Height / / pha003011 rs639446 chr9 76059956 C G 6.39E-04 Alzheimer's disease / / 17998437 rs2310385 chr9 76106790 A G 9.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11143600 chr9 76115057 C T 4.38E-04 Acute lung injury / / 22295056 rs11143600 chr9 76115057 C T 1.14E-04 Attention deficit hyperactivity disorder / / 22420046 rs278712 chr9 76157147 G A 3.71E-04 Multiple complex diseases / / 17554300 rs12555078 chr9 76157700 G A 2.00E-06 Obesity-related traits / / 23251661 rs11143609 chr9 76158682 G A 7.00E-06 HIV-1 control / / 20041166 rs7039235 chr9 76174083 C T 2.90E-04 Multiple complex diseases / / 17554300 rs157113 chr9 76187539 T C 3.40E-04 Alcohol dependence / / 20201924 rs17059048 chr9 76188256 A C 4.54E-05 Type 2 diabetes / / 17463246 rs1505518 chr9 76224560 G A 5.07E-04 Taste perception / / 22132133 rs1398307 chr9 76242155 C T 5.92E-05 Pancreatic cancer / / pha002874 rs156769 chr9 76247590 C A 5.72E-05 Taste perception / / 22132133 rs2493449 chr9 76262425 G A 3.30E-06 Gallstones / / 17632509 rs11143665 chr9 76316341 A G 3.80E-08 Response to citalopram in major depressive disorder / / 20619826 rs11143665 chr9 76316341 A G 5.60E-07 Response to citalopram in major depressive disorder / / 20619826 rs11143665 chr9 76316341 A G 1.18E-04 Coronary heart disease / / 21606135 rs11143677 chr9 76335316 G A 1.80E-04 Coronary heart disease / / 21606135 rs11143678 chr9 76337403 T G 1.90E-07 Response to citalopram in major depressive disorder / / 20619826 rs11143678 chr9 76337403 T G 2.70E-06 Response to citalopram in major depressive disorder / / 20619826 rs11143678 chr9 76337403 T G 1.64E-04 Coronary heart disease / / 21606135 rs11143679 chr9 76337514 C T 1.10E-07 Response to citalopram in major depressive disorder / / 20619826 rs11143679 chr9 76337514 C T 1.60E-06 Response to citalopram in major depressive disorder / / 20619826 rs11143679 chr9 76337514 C T 1.67E-04 Coronary heart disease / / 21606135 rs11143683 chr9 76342406 T C 1.60E-07 Response to citalopram in major depressive disorder / / 20619826 rs11143683 chr9 76342406 T C 2.60E-06 Response to citalopram in major depressive disorder / / 20619826 rs11143683 chr9 76342406 T C 1.21E-04 Coronary heart disease / / 21606135 rs7029105 chr9 76344939 T C 1.52E-04 Coronary heart disease / / 21606135 rs17059327 chr9 76345352 T C 4.53E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs9410714 chr9 76360371 A G 2.47E-05 Tardive dyskinesia / / 20939080 rs2125391 chr9 76389514 A G 4.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10512029 chr9 76412646 A C 4.51E-05 Waist Circumference / / pha003023 rs1458495 chr9 76427979 C A 5.97E-05 Height / / pha003010 rs1458495 chr9 76427979 C A 4.30E-06 Waist Circumference / / pha003023 rs11999227 chr9 76433950 C T 9.19E-04 Heart Failure / / pha002885 rs17059531 chr9 76492427 T C 5.99E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1020772 chr9 76532512 A G 5.86E-04 Multiple complex diseases / / 17554300 rs4745272 chr9 76575541 C T 6.95E-05 Tuberculosis / / 24057671 rs2933021 chr9 76611727 A T 9.17E-04 Multiple complex diseases / / 17554300 rs10781185 chr9 76706362 C T 4.15E-05 Age-related macular degeneration (extreme sampling) / / 23577725 rs7020553 chr9 76710284 A C 6.69E-04 Multiple complex diseases / / 17554300 rs7020553 chr9 76710284 A C 4.66E-05 Age-related macular degeneration (extreme sampling) / / 23577725 rs12551119 chr9 76731402 A G 0.0000148 HDL cholesterol particle diameter / / 23263444 rs4237260 chr9 76741416 G C 4.98E-07 Glaucoma (primary open-angle) / / 22605921 rs2045191 chr9 76793127 T C 8.91E-04 Parkinson's disease / / 17052657 rs1455040 chr9 76849139 T C 1.57E-05 Cognitive impairment induced by topiramate / / 22091778 rs657145 chr9 76888531 T G 5.18E-04 Parkinson's disease / / 17052657 rs7859799 chr9 76897503 C T 9.59E-04 Parkinson's disease / / 17052657 rs5002587 chr9 76898246 C T 9.39E-04 Parkinson's disease / / 17052657 rs2604270 chr9 76925683 C G 3.04E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2991751 chr9 76936998 T C 1.42E-04 Attention deficit hyperactivity disorder / / 22420046 rs11143927 chr9 76951368 A T 7.42E-04 Multiple complex diseases / / 17554300 rs7846903 chr9 77115111 G A 1.22E-04 Nicotine dependence RORB intron 18227835 rs10869409 chr9 77123389 T C 5.53E-05 Nicotine dependence RORB intron 18227835 rs10746959 chr9 77136348 A G 1.69E-04 Body mass index RORB intron 21701565 rs13293006 chr9 77136896 C A 5.92E-04 Nicotine dependence RORB intron 18227835 rs13293006 chr9 77136896 C A 6.12E-05 Body mass index RORB intron 21701565 rs13293006 chr9 77136896 C A 7.92E-04 Body mass index RORB intron 21701565 rs13291991 chr9 77136979 G A 3.93E-05 Body mass index RORB intron 21701565 rs13291991 chr9 77136979 G A 4.53E-04 Body mass index RORB intron 21701565 rs7042950 chr9 77149837 A G 9.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio RORB intron 22589738 rs7042950 chr9 77149837 A G 4.00E-08 Refractive error RORB intron 23396134 rs965897 chr9 77175017 G T 2.30E-05 Urinary metabolites RORB intron 21572414 rs4745348 chr9 77237977 T C 5.15E-05 Longevity RORB intron 20304771 rs10512037 chr9 77253626 A G 2.04E-04 Multiple complex diseases RORB intron 17554300 rs1327827 chr9 77255110 T C 4.02E-04 Coronary heart disease RORB intron 21606135 rs10869433 chr9 77268666 G T 1.83E-04 Lung function (forced expiratory volume in 1 second) RORB intron 24023788 rs523781 chr9 77323239 G C 1.70E-05 Urinary metabolites / / 21572414 rs519067 chr9 77323772 T G 8.90E-05 Aging (time to event) / / 21782286 rs944857 chr9 77352798 A G 1.00E-04 Cognitive impairment induced by topiramate TRPM6 intron 22091778 rs11787707 chr9 77366199 A G 8.83E-04 Amyotrophic lateral sclerosis (sporadic) TRPM6 intron 24529757 rs12551900 chr9 77368117 T C 1.40E-05 Urinary metabolites TRPM6 intron 21572414 rs11144134 chr9 77499796 T C 8.00E-15 magnesium levels TRPM6 intron 20700443 rs12379179 chr9 77535027 T C 3.90E-05 Leukocyte Counts / / pha003091 rs13299921 chr9 77535672 C T 1.00E-04 Information processing speed / / 21130836 rs1176822 chr9 77548909 C A 1.32E-04 Multiple complex diseases / / 17554300 rs1176821 chr9 77549758 T G 2.49E-04 Multiple complex diseases / / 17554300 rs10869460 chr9 77573159 G T 9.75E-04 Multiple complex diseases / / 17554300 rs11144180 chr9 77608459 C G 7.80E-05 Cognitive function C9orf41 intron 24684796 rs4745373 chr9 77612006 G A 6.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C9orf41 intron 20877124 rs911737 chr9 77680812 G A 3.97E-05 Cognitive impairment induced by topiramate C9orf95 intron 22091778 rs2376397 chr9 77690749 C T 1.10E-05 Alcoholism (heaviness of drinking) C9orf95 intron 21529783 rs3780178 chr9 77708152 T C 5.70E-06 Urinary metabolites OSTF1 intron 21572414 rs3780178 chr9 77708152 T C 2.92E-06 Lymphocyte counts OSTF1 intron 22286170 rs1977240 chr9 77710789 T C 9.10E-05 Type 2 diabetes OSTF1 intron 17463246 rs10123421 chr9 77713279 A G 1.36E-04 Multiple complex diseases OSTF1 intron 17554300 rs10123421 chr9 77713279 A G 3.02E-04 Coronary Artery Disease OSTF1 intron 17634449 rs10869501 chr9 77719556 C G 8.25E-04 Multiple complex diseases OSTF1 intron 17554300 rs10869510 chr9 77754734 A T 2.40E-05 Urinary metabolites OSTF1 intron 21572414 rs2273770 chr9 77755469 C T 4.77E-05 Cognitive performance OSTF1 intron 19734545 rs814018 chr9 77770756 T C 5.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs1081875 chr9 77780144 T C 8.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs1081875 chr9 77780144 T C 5.52E-05 Myopia (severe) / / 23933737 rs1081875 chr9 77780144 T C 2.31E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1081877 chr9 77782517 T C 8.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs1081877 chr9 77782517 T C 7.57E-05 Myopia (severe) / / 23933737 rs773014 chr9 77783998 T C 9.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs12350178 chr9 77789226 A C 5.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs10283463 chr9 77789607 G A 8.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs10283465 chr9 77789735 G T 6.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs773005 chr9 77791461 A C 6.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs773007 chr9 77792873 G A 7.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs12341208 chr9 77806643 A G 1.67E-05 Platelet counts / / 21507922 rs1930069 chr9 77830922 T C 1.00E-06 Urinary metabolites / / 21572414 rs1332368 chr9 77831238 A G 2.30E-06 Urinary metabolites / / 21572414 rs7852833 chr9 77851696 C T 9.98E-04 Alzheimer's disease / / 17998437 rs7852833 chr9 77851696 C T 5.96E-05 Body mass (lean) / / 19268274 rs7350256 chr9 77855652 T G 1.80E-05 Urinary metabolites / / 21572414 rs7037086 chr9 77881317 A G 1.48E-06 Coronary heart disease / / pha003030 rs7037086 chr9 77881317 A G 2.06E-05 Coronary heart disease / / pha003031 rs6560438 chr9 77896832 A C 1.20E-04 Coronary heart disease / / 21606135 rs1332353 chr9 77904405 G C 9.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs7874203 chr9 77904911 G C 5.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs6560441 chr9 77910106 C A 6.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs6560442 chr9 77914207 G A 1.40E-05 Coffee consumption / / 21357676 rs6560442 chr9 77914207 G A 3.40E-05 Coronary heart disease / / pha003030 rs6560442 chr9 77914207 G A 9.98E-05 Coronary heart disease / / pha003031 rs7032904 chr9 77934640 A G 9.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs4744746 chr9 77965742 T C 6.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs2376734 chr9 77976700 G A 2.08E-04 Lung function (forced vital capacity) / / 24023788 rs11144408 chr9 77988769 A G 8.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs1409937 chr9 77991404 A G 5.54E-04 Schizophrenia / / 19197363 rs1409937 chr9 77991404 A G 5.00E-05 Tanning / / 19340012 rs12004565 chr9 77992822 G A 2.44E-04 Hearing function / / 17255346 rs10869553 chr9 77996901 A G 8.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs10869553 chr9 77996901 A G 2.70E-05 Urinary metabolites / / 21572414 rs11144417 chr9 77998494 G A 2.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs7867522 chr9 77999354 T G 3.27E-04 Lung function (forced vital capacity) / / 24023788 rs7867522 chr9 77999354 T G 4.21E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10869554 chr9 78005255 C T 5.68E-06 Telomere length / / 23001564 rs10869557 chr9 78020355 T G 7.38E-06 Waist circumference / / 19557197 rs10869558 chr9 78020438 G C 6.71E-06 Waist circumference / / 19557197 rs17061143 chr9 78023923 T C 6.17E-06 Waist circumference / / 19557197 rs17712651 chr9 78027655 G A 2.20E-05 Urinary metabolites / / 21572414 rs10869559 chr9 78027920 G C 5.19E-06 Waist circumference / / 19557197 rs489332 chr9 78028346 C T 6.00E-06 Schizophrenia / / 23212062 rs693895 chr9 78028869 A G 5.00E-06 Waist circumference / / 19557197 rs569406 chr9 78029345 T C 4.67E-06 Waist circumference / / 19557197 rs692953 chr9 78034657 C T 4.02E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs507824 chr9 78034710 G T 4.62E-06 Waist circumference / / 19557197 rs516609 chr9 78069679 C T 1.35E-05 Alcohol dependence / / 23089632 rs2768303 chr9 78107556 A G 2.63E-04 Multiple complex diseases / / 17554300 rs7862621 chr9 78115606 T C 6.46E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs13293903 chr9 78117476 A C 7.23E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10512043 chr9 78120328 G T 1.28E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs990798 chr9 78122762 A G 6.83E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs990797 chr9 78123057 T C 4.75E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4745411 chr9 78124822 T C 6.38E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17643782 chr9 78148907 A G 4.34E-04 Type 2 diabetes / / 17463246 rs979258 chr9 78151228 G A 8.97E-05 Multiple complex diseases / / 17554300 rs11144515 chr9 78226714 C A 1.80E-05 Urinary metabolites / / 21572414 rs11144516 chr9 78228430 C A 3.47E-04 Smoking initiation / / 24665060 rs914660 chr9 78230339 A G 5.11E-04 Type 2 diabetes / / 17463246 rs10869613 chr9 78250260 A C 3.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17061482 chr9 78251083 T C 1.39E-04 Multiple complex diseases / / 17554300 rs1328570 chr9 78251232 T C 5.84E-04 Multiple complex diseases / / 17554300 rs1328565 chr9 78266575 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1328563 chr9 78269417 A G 2.70E-05 Urinary metabolites / / 21572414 rs4745430 chr9 78272025 C T 8.30E-06 Schizophrenia / / 19197363 rs4745430 chr9 78272025 C T 3.80E-05 Schizophrenia / / 19571808 rs4745431 chr9 78272095 T C 3.83E-06 Schizophrenia / / 19197363 rs1014766 chr9 78274889 A G 2.90E-05 Urinary metabolites / / 21572414 rs10512049 chr9 78276675 C T 3.00E-06 Total ventricular volume / / 21116278 rs2094588 chr9 78277767 T C 3.91E-04 Schizophrenia / / 19197363 rs1360003 chr9 78283424 C T 5.30E-05 Bone mineral density (BMD),in women / / 20164292 rs10869631 chr9 78294845 G A 2.16E-04 Multiple complex diseases / / 17554300 rs943868 chr9 78301111 A T 2.50E-05 Urinary metabolites / / 21572414 rs7870138 chr9 78305258 C T 5.12E-04 Smoking cessation / / 24665060 rs7044203 chr9 78315752 C T 7.74E-04 Iron levels / / pha002876 rs17663620 chr9 78331051 G A 8.19E-05 Formal thought disorder in schizophrenia / / 22648509 rs4744765 chr9 78332861 G T 2.60E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17061627 chr9 78336697 C T 2.94E-04 Type 2 diabetes / / 17463246 rs11144603 chr9 78351260 A C 7.72E-05 Lung cancer / / 18978787 rs11144612 chr9 78385634 C T 6.70E-04 Multiple complex diseases / / 17554300 rs12344488 chr9 78425925 G A 5.00E-06 Non-alcoholic fatty liver disease histology (AST) / / 20708005 rs4745450 chr9 78452816 T C 1.86E-05 Cognitive test performance / / 20125193 rs11144641 chr9 78455655 A G 8.64E-05 Lung cancer / / 18978787 rs7030848 chr9 78473260 G A 4.49E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11144657 chr9 78486204 A T 4.31E-05 Bipolar disorder / / 18317468 rs11144672 chr9 78515717 A T 4.57E-04 Multiple complex diseases PCSK5 intron 17554300 rs10869665 chr9 78518999 C T 2.22E-04 Vaspin levels PCSK5 intron 22907691 rs10869665 chr9 78518999 C T 0.0002098 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit PCSK5 intron 22907730 rs10869665 chr9 78518999 C T 0.0002215 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks PCSK5 intron 22907730 rs11144688 chr9 78542286 G A 1.00E-11 Height PCSK5 intron 20881960 rs11144688 chr9 78542286 G A 3.30E-10 Height PCSK5 intron 21194676 rs11144688 chr9 78542286 G A 5.90E-09 Height PCSK5 intron 21194676 rs11144688 chr9 78542286 G A 4.00E-16 Height PCSK5 intron 23563607 rs4584211 chr9 78557137 A C 9.39E-04 Type 2 diabetes PCSK5 intron 17463246 rs7854620 chr9 78559549 C A 2.32E-04 Multiple complex diseases PCSK5 intron 17554300 rs11144692 chr9 78560319 C G 3.05E-04 Multiple complex diseases PCSK5 intron 17554300 rs1340503 chr9 78571504 A G 1.00E-05 Insulin response PCSK5 intron 19430760 rs11144698 chr9 78573139 A G 2.13E-04 Multiple complex diseases PCSK5 intron 17554300 rs11144706 chr9 78590408 A T 1.80E-05 Urinary metabolites PCSK5 intron 21572414 rs4416887 chr9 78597225 A G 3.96E-05 Alcohol and nictotine co-dependence PCSK5 intron 20158304 rs4416887 chr9 78597225 A G 8.61E-05 Height PCSK5 intron pha003010 rs7040589 chr9 78607323 A T 3.85E-04 Multiple complex diseases PCSK5 intron 17554300 rs2225969 chr9 78613471 A G 4.06E-05 Height PCSK5 intron 17255346 rs12342299 chr9 78642228 C T 1.09E-05 Coronary heart disease PCSK5 intron 21606135 rs11144723 chr9 78649934 G A 6.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PCSK5 intron 20877124 rs1029040 chr9 78653823 T C 0.000000553 Cholesterol,total PCSK5 intron 23063622 rs2792224 chr9 78657730 A G 7.76E-04 Nicotine smoking PCSK5 intron 19268276 rs11144728 chr9 78659547 T C 0.00087 Salmonella-induced pyroptosis PCSK5 intron 22837397 rs2185230 chr9 78659798 C T 0.000502 Salmonella-induced pyroptosis PCSK5 intron 22837397 rs7047865 chr9 78665776 T G 7.00E-06 Amyotrophic lateral sclerosis (age of onset) PCSK5 intron 22959728 rs7047865 chr9 78665776 T G 5.00E-06 Metabolite levels (5-HIAA) PCSK5 intron 23319000 rs7024200 chr9 78693232 A G 7.74E-04 Nicotine smoking PCSK5 intron 19268276 rs12001902 chr9 78715080 G T 8.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PCSK5 intron 20877124 rs12001902 chr9 78715080 G T 3.80E-04 Taste perception PCSK5 intron 22132133 rs12006422 chr9 78716551 T A 0.00000183 HDL cholesterol PCSK5 intron 23063622 rs1467773 chr9 78733068 A G 2.12E-04 Suicide attempts in bipolar disorder PCSK5 intron 21041247 rs1467773 chr9 78733068 A G 8.82E-04 Suicide attempts in bipolar disorder PCSK5 intron 21041247 rs2185227 chr9 78733394 A G 2.36E-04 Suicide attempts in bipolar disorder PCSK5 intron 21041247 rs2377524 chr9 78772459 A T 8.90E-05 Response to statin therapy PCSK5 intron 20339536 rs1411956 chr9 78777937 A G 6.80E-05 Parkinson's disease (age of onset) PCSK5 intron 19772629 rs10869717 chr9 78782943 A G 7.00E-04 Atrial fibrillation PCSK5 intron 21846873 rs10124834 chr9 78785098 C T 2.32E-04 Multiple complex diseases PCSK5 intron 17554300 rs17062158 chr9 78786218 A C 5.60E-06 Urinary metabolites PCSK5 intron 21572414 rs17062158 chr9 78786218 A C 1.10E-05 Pericardial fat PCSK5 intron 22589742 rs17062170 chr9 78788033 C T 4.80E-06 Pericardial fat PCSK5 intron 22589742 rs10869720 chr9 78788473 G A 1.00E-05 Pericardial fat PCSK5 intron 22589742 rs17062174 chr9 78788543 C A 7.70E-06 Pericardial fat PCSK5 intron 22589742 rs2377527 chr9 78791189 T G 7.38E-04 Oral cancers (chewing tobacco related) PCSK5 intron 22503698 rs10781344 chr9 78791312 T C 8.43E-04 Multiple complex diseases PCSK5 intron 17554300 rs10869727 chr9 78804842 A C 8.75E-04 Multiple complex diseases PCSK5 intron 17554300 rs7870493 chr9 78812153 C T 7.83E-04 Multiple complex diseases PCSK5 intron 17554300 rs11144790 chr9 78812472 G A 6.45E-06 Male fertility PCSK5 intron 22633400 rs990560 chr9 78823694 G A 3.49E-06 Serum metabolites PCSK5 intron 19043545 rs10781347 chr9 78834472 T C 5.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PCSK5 intron 20877124 rs10746997 chr9 78841401 G T 1.00E-06 Response to fenofibrate (adiponectin levels) PCSK5 intron 23149075 rs1353343 chr9 78851588 C T 4.90E-04 Schizophrenia PCSK5 intron 19197363 rs2007744 chr9 78854312 T G 1.96E-05 Schizophrenia PCSK5 intron 19197363 rs2261722 chr9 78869581 G A 0.00000111 Child behavior checklist/1.5-5 pervasive developmental problems PCSK5 intron 23049896 rs1353342 chr9 78874769 A C 3.34E-07 Ventricular fibrillation in acute MI PCSK5 intron 20622880 rs10115735 chr9 78900161 G T 5.76E-04 Multiple complex diseases PCSK5 intron 17554300 rs10115755 chr9 78900183 G A 4.98E-04 Multiple complex diseases PCSK5 intron 17554300 rs2260411 chr9 78902949 T C 1.29E-05 Multiple sclerosis (age of onset) PCSK5 intron 19010793 rs2842488 chr9 78903526 A G 1.58E-05 Multiple sclerosis (age of onset) PCSK5 intron 19010793 rs903547 chr9 78904508 C A 1.20E-05 Multiple sclerosis (age of onset) PCSK5 intron 19010793 rs17721076 chr9 78904950 T C 4.70E-05 Temporomandibular joint disorders PCSK5 intron 23746317 rs2842485 chr9 78905545 T A 6.62E-04 Multiple complex diseases PCSK5 intron 17554300 rs2842483 chr9 78906150 A G 5.00E-06 Multiple sclerosis (age of onset) PCSK5 intron 19010793 rs7021909 chr9 78907594 G A 5.30E-05 Temporomandibular joint disorders PCSK5 intron 23746317 rs2803418 chr9 78909274 G T 8.32E-06 Multiple sclerosis (age of onset) PCSK5 intron 19010793 rs2803419 chr9 78909550 A T 1.90E-05 Urinary metabolites PCSK5 intron 21572414 rs2803420 chr9 78909569 C T 4.73E-04 Multiple complex diseases PCSK5 intron 17554300 rs10869747 chr9 78910401 G A 2.00E-05 Temporomandibular joint disorders PCSK5 intron 23746317 rs1078868 chr9 78915454 A G 8.58E-04 Type 2 diabetes PCSK5 intron 17463246 rs17062408 chr9 78917814 T C 3.75E-04 Substance dependence PCSK5 intron 21818250 rs2257718 chr9 78924969 A G 4.60E-04 Multiple complex diseases PCSK5 intron 17554300 rs7357776 chr9 78925242 C A 4.96E-04 Multiple complex diseases PCSK5 intron 17554300 rs2257775 chr9 78925814 C A 1.45E-04 Multiple complex diseases PCSK5 intron 17554300 rs2258131 chr9 78931893 A G 1.18E-04 Multiple complex diseases PCSK5 intron 17554300 rs1027384 chr9 78932693 A G 7.36E-05 Coronary heart disease PCSK5 intron 21606135 rs1027383 chr9 78932928 G T 5.00E-06 Urinary metabolites PCSK5 intron 21572414 rs11144827 chr9 78933874 A G 9.12E-04 Coronary heart disease PCSK5 intron 21606135 rs2803439 chr9 78950203 G A 4.86E-05 Blood Pressure PCSK5 intron pha003039 rs13297620 chr9 78958032 A G 2.72E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy PCSK5 intron 24578207 rs13297620 chr9 78958032 A G 2.72E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy PCSK5 intron 24578207 rs2842494 chr9 78959409 G A 1.51E-04 Sudden cardiac arrest PCSK5 intron 21658281 rs11144870 chr9 79004213 C T 1.04E-06 Vaspin levels RFK intron 22907691 rs11144870 chr9 79004213 C T 0.00000104 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks RFK intron 22907730 rs11144870 chr9 79004213 C T 0.00000104 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at minimum 6 weeks RFK intron 22907730 rs11144870 chr9 79004213 C T 0.000037 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit RFK intron 22907730 rs10116800 chr9 79034262 T C 1.05E-04 Vaspin levels / / 22907691 rs10116800 chr9 79034262 T C 0.0001049 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs6560517 chr9 79038170 T G 7.00E-06 Dialysis-related mortality / / 21546767 rs11144905 chr9 79065299 A C 1.43E-06 Vaspin levels GCNT1 intron 22907691 rs11144905 chr9 79065299 A C 0.00000143 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks GCNT1 intron 22907730 rs11144905 chr9 79065299 A C 0.00000143 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at minimum 6 weeks GCNT1 intron 22907730 rs11144905 chr9 79065299 A C 0.000074 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit GCNT1 intron 22907730 rs785936 chr9 79093664 A G 3.00E-05 Schizophrenia GCNT1 intron 20185149 rs785916 chr9 79101006 A G 7.50E-06 Vaspin levels GCNT1 intron 22907691 rs785916 chr9 79101006 A G 0.0000075 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks GCNT1 intron 22907730 rs785916 chr9 79101006 A G 0.0000075 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at minimum 6 weeks GCNT1 intron 22907730 rs785916 chr9 79101006 A G 0.00021 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit GCNT1 intron 22907730 rs4532668 chr9 79115844 A C 7.73E-05 Hypertension GCNT1 UTR-5 pha003042 rs4532668 chr9 79115844 A C 6.80E-05 Blood Pressure GCNT1 UTR-5 pha003050 rs3739517 chr9 79116755 T C 3.53E-04 Response to taxane treatment (placlitaxel) GCNT1 intron 23006423 rs2282683 chr9 79117751 A G 4.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GCNT1 missense 20877124 rs1057406 chr9 79118329 G A 4.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GCNT1 cds-synon 20877124 rs589561 chr9 79120475 A T 3.50E-05 Cognitive function GCNT1 UTR-3 24684796 rs17180166 chr9 79126033 G T 7.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs680448 chr9 79126953 A G 5.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs680448 chr9 79126953 A G 5.64E-05 Vaspin levels / / 22907691 rs680448 chr9 79126953 A G 0.0000564 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs680448 chr9 79126953 A G 0.000163 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs1886268 chr9 79156769 C T 5.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1886268 chr9 79156769 C T 6.68E-06 Blood Pressure / / pha002903 rs13290974 chr9 79164646 G A 9.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs13290974 chr9 79164646 G A 1.38E-04 Amyotrophic lateral sclerosis / / 23624525 rs7029703 chr9 79205349 C T 2.23E-06 Bipolar disorder / / 17486107 rs11144967 chr9 79215237 T C 6.97E-04 Multiple complex diseases / / 17554300 rs812533 chr9 79225259 T C 3.41E-04 Blood pressure / / 17255346 rs812533 chr9 79225259 T C 5.59E-05 Height / / pha003011 rs700800 chr9 79230242 C A 9.66E-07 Height PRUNE2 intron pha003010 rs700800 chr9 79230242 C A 5.93E-06 Height PRUNE2 intron pha003011 rs7865889 chr9 79230395 C T 1.56E-06 Height PRUNE2 intron pha003010 rs7865889 chr9 79230395 C T 1.53E-05 Height PRUNE2 intron pha003011 rs2553211 chr9 79231007 C A 8.49E-05 Height PRUNE2 intron pha003010 rs2553211 chr9 79231007 C A 2.84E-05 Height PRUNE2 intron pha003011 rs7046144 chr9 79231549 C T 4.65E-04 Nicotine dependence PRUNE2 intron 17158188 rs786319 chr9 79233633 G A 4.40E-05 Height PRUNE2 intron pha003011 rs786320 chr9 79236165 G A 6.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) PRUNE2 intron 23648065 rs700809 chr9 79240050 T C 2.61E-05 Response to methylphenidate treatment PRUNE2 intron 21130132 rs11144986 chr9 79246547 T C 5.75E-05 Multiple complex diseases PRUNE2 intron 17554300 rs7045505 chr9 79249761 T A 2.68E-06 Multiple complex diseases PRUNE2 intron 17554300 rs605523 chr9 79254447 T G 2.46E-04 Self-reported allergy PRUNE2 intron 23817569 rs478699 chr9 79258395 T C 3.15E-04 Self-reported allergy PRUNE2 intron 23817569 rs478792 chr9 79258419 G C 3.15E-04 Self-reported allergy PRUNE2 intron 23817569 rs512951 chr9 79259850 A G 1.34E-04 Self-reported allergy PRUNE2 intron 23817569 rs11144992 chr9 79263092 T C 1.21E-04 Multiple complex diseases PRUNE2 intron 17554300 rs526347 chr9 79264147 T C 3.33E-04 Schizophrenia PRUNE2 intron 20832056 rs526347 chr9 79264147 T C 4.91E-04 Self-reported allergy PRUNE2 intron 23817569 rs10521475 chr9 79267872 C A 1.84E-05 Multiple complex diseases PRUNE2 intron 17554300 rs11144996 chr9 79271509 C T 9.45E-06 Multiple complex diseases PRUNE2 intron 17554300 rs17062858 chr9 79272019 T C 1.60E-06 Multiple complex diseases PRUNE2 intron 17554300 rs10869793 chr9 79277117 T C 7.46E-04 Self-reported allergy PRUNE2 intron 23817569 rs11145000 chr9 79278779 T C 6.68E-04 Self-reported allergy PRUNE2 intron 23817569 rs7862059 chr9 79282119 G A 4.73E-04 HIV-1 viral setpoint PRUNE2 intron 17641165 rs7862059 chr9 79282119 G A 5.26E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) PRUNE2 intron 22566498 rs17062868 chr9 79282170 G A 1.06E-04 Response to taxane treatment (placlitaxel) PRUNE2 intron 23006423 rs476612 chr9 79300111 G T 0.00062 Prostate cancer PRUNE2 intron 23555315 rs506965 chr9 79310655 C A 4.56E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PRUNE2 intron 20031582 rs572737 chr9 79311851 T C 1.08E-04 Multiple complex diseases PRUNE2 intron 17554300 rs594498 chr9 79314231 T C 9.89E-04 Multiple complex diseases PRUNE2 intron 17554300 rs561970 chr9 79318677 T C 6.90E-04 Multiple complex diseases PRUNE2 missense 17554300 rs618145 chr9 79319560 A C 4.57E-04 Multiple complex diseases PRUNE2 intron 17554300 rs3739523 chr9 79319874 C A 1.39E-05 Cognitive test performance PRUNE2 missense 20125193 rs615187 chr9 79326505 A T 2.27E-04 Multiple complex diseases PRUNE2 intron 17554300 rs10781372 chr9 79339715 T C 6.92E-05 Response to statin treatment (atorvastatin),change in cholesterol levels PRUNE2 intron 20031582 rs7046452 chr9 79368342 T C 5.18E-04 Multiple complex diseases PRUNE2 intron 17554300 rs10217638 chr9 79368987 A G 9.29E-04 Multiple complex diseases PRUNE2 intron 17554300 rs10217794 chr9 79369163 G A 7.68E-04 Multiple complex diseases PRUNE2 intron 17554300 rs1936283 chr9 79390020 C T 5.51E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PCA3 intron 20031582 rs10781380 chr9 79408144 T C 7.00E-07 Hippocampal atrophy PRUNE2 intron 19668339 rs11145075 chr9 79414574 C A 1.94E-04 Multiple complex diseases PRUNE2 intron 17554300 rs10521470 chr9 79425692 G A 9.37E-05 Blood Pressure PRUNE2 intron pha003043 rs10124357 chr9 79429800 T C 7.46E-04 Type 2 diabetes PRUNE2 intron 17463246 rs11145083 chr9 79434825 G C 1.69E-05 Multiple complex diseases PRUNE2 intron 17554300 rs11145084 chr9 79435471 C A 7.29E-05 Multiple complex diseases PRUNE2 intron 17554300 rs7867090 chr9 79436617 T C 8.39E-05 Alzheimer's disease PRUNE2 intron 17998437 rs10869829 chr9 79438813 C T 9.47E-05 Hippocampal atrophy PRUNE2 intron 19668339 rs11792292 chr9 79440805 C T 8.41E-06 Multiple complex diseases PRUNE2 intron 17554300 rs10869830 chr9 79444014 C T 7.54E-06 Multiple complex diseases PRUNE2 intron 17554300 rs4745588 chr9 79471562 C T 6.50E-07 Urinary metabolites PRUNE2 intron 21572414 rs7031918 chr9 79511499 C T 2.75E-04 Taste perception PRUNE2 intron 22132133 rs12553751 chr9 79513254 G A 2.77E-04 Celiac disease PRUNE2 intron 23936387 rs1888744 chr9 79549339 C G 4.79E-04 Multiple complex diseases / / 17554300 rs1011711 chr9 79550279 C T 8.64E-04 Parkinson's disease / / 16252231 rs1011711 chr9 79550279 C T 5.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7034806 chr9 79573354 T C 2.70E-05 Urinary metabolites / / 21572414 rs7852521 chr9 79576188 T C 2.20E-05 Urinary metabolites / / 21572414 rs12351573 chr9 79576824 A G 1.10E-06 Urinary metabolites / / 21572414 rs7856464 chr9 79577007 T C 1.89E-04 Multiple complex diseases / / 17554300 rs1929539 chr9 79582862 C A 7.94E-04 Premature ovarian failure / / 19508998 rs79460104 chr9 79610628 T C 4.00E-06 Response to amphetamines / / 22952603 rs10781406 chr9 79611959 A G 1.40E-04 Prostate cancer mortality / / 20978177 rs12378793 chr9 79613935 G C 8.61E-05 Gallstones / / 17632509 rs12347891 chr9 79615289 G A 3.63E-04 Multiple complex diseases / / 17554300 rs4745606 chr9 79615596 C T 5.20E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7046182 chr9 79626207 C T 3.40E-04 Type 2 diabetes / / 17463246 rs10869873 chr9 79662945 C A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10435941 chr9 79669104 G A 2.05E-04 Smoking initiation / / 24665060 rs10781417 chr9 79702675 T C 4.30E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11793898 chr9 79706284 A G 2.56E-04 Hearing function / / 17255346 rs11145281 chr9 79709824 A G 8.76E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4142603 chr9 79769394 T C 4.05E-05 Nicotine dependence / / 17158188 rs2377887 chr9 79770398 G C 2.66E-05 Type 2 diabetes / / 17463246 rs10869902 chr9 79772090 G A 1.47E-04 Nicotine dependence / / 17158188 rs12338171 chr9 79772615 G T 3.38E-04 Type 2 diabetes / / 17463246 rs7869194 chr9 79778247 C T 2.34E-04 Height / / 17255346 rs17723837 chr9 79786475 C T 9.99E-06 Type 2 diabetes / / 17463246 rs11790663 chr9 79786834 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17785751 chr9 79790425 T C 2.43E-05 Type 2 diabetes VPS13A nearGene-5 17463246 rs7043951 chr9 79790544 C G 3.12E-04 Height VPS13A nearGene-5 17255346 rs17723855 chr9 79790855 T C 3.91E-04 Height VPS13A nearGene-5 17255346 rs4012480 chr9 79794753 G T 1.02E-04 Celiac disease VPS13A intron 23936387 rs12338283 chr9 79802986 G A 7.98E-05 Celiac disease VPS13A intron 23936387 rs10869910 chr9 79824002 C T 4.91E-04 Nicotine dependence VPS13A intron 17158188 rs2150902 chr9 79826041 A C 1.74E-04 Type 2 diabetes VPS13A intron 17463246 rs11145347 chr9 79846516 T C 8.32E-05 Celiac disease VPS13A intron 23936387 rs10115162 chr9 79862502 T C 1.10E-04 Type 2 diabetes VPS13A intron 17463246 rs10115162 chr9 79862502 T C 1.03E-04 Celiac disease VPS13A intron 23936387 rs2022443 chr9 79869852 T G 2.49E-05 Nicotine dependence VPS13A intron 17158188 rs17337986 chr9 79873081 C T 9.60E-05 Height VPS13A intron 17255346 rs2050831 chr9 79888396 A G 7.30E-05 Type 2 diabetes VPS13A intron 17293876 rs7030802 chr9 79891237 T G 8.65E-05 Celiac disease VPS13A intron 23936387 rs17422967 chr9 79891964 C T 2.59E-04 Height VPS13A intron 17255346 rs17423029 chr9 79895012 T G 2.31E-04 Height VPS13A intron 17255346 rs11145371 chr9 79901742 G A 8.51E-06 Type 2 diabetes VPS13A intron 17463246 rs10125560 chr9 79913120 G A 7.04E-06 Type 2 diabetes VPS13A intron 17463246 rs11145381 chr9 79915141 T C 4.72E-05 Nicotine dependence VPS13A intron 17158188 rs12380218 chr9 79935660 A G 2.09E-05 Nicotine dependence VPS13A intron 17158188 rs17423984 chr9 79936415 A G 9.42E-05 Celiac disease VPS13A cds-synon 23936387 rs6651537 chr9 79938832 G A 5.78E-05 Bipolar disorder VPS13A intron 20451256 rs17424026 chr9 79946961 C T 1.78E-04 Height VPS13A cds-synon 17255346 rs7025532 chr9 79954545 T C 8.36E-05 Celiac disease VPS13A cds-synon 23936387 rs1327544 chr9 79971422 C T 1.90E-04 Height VPS13A intron 17255346 rs10491843 chr9 79980974 A C 9.28E-05 Celiac disease VPS13A intron 23936387 rs10491840 chr9 80010635 A G 6.92E-06 Type 2 diabetes VPS13A intron 17463246 rs11145410 chr9 80012400 G A 7.86E-04 Nicotine dependence VPS13A intron 17158188 rs12342273 chr9 80029750 G C 6.47E-05 Bipolar disorder VPS13A intron 20451256 rs2274486 chr9 80030829 G A,C,T 4.22E-04 Smoking cessation VPS13A intron 24665060 rs17063627 chr9 80039658 A G 1.03E-08 Gallstones G/14 intron 17632509 rs10116050 chr9 80062274 G A 5.25E-05 Cognitive impairment induced by topiramate G/14 intron 22091778 rs1547190 chr9 80075134 C T 1.06E-04 Vaspin levels G/14 intron 22907691 rs1547190 chr9 80075134 C T 0.0001055 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks G/14 intron 22907730 rs3780293 chr9 80076247 G A 9.59E-05 Blood pressure G/14 intron 17255346 rs7875530 chr9 80086190 C T 6.80E-06 Urinary metabolites G/14 intron 21572414 rs3780296 chr9 80137434 C T 8.97E-06 Osteoarthritis G/14 intron 22763110 rs17785979 chr9 80147246 C A 3.54E-04 Smoking cessation G/14 intron 24665060 rs12340660 chr9 80163814 G A 1.60E-05 Pulmonary function G/14 intron 19300500 rs7849646 chr9 80181751 C T 7.92E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) G/14 intron 23648065 rs961572 chr9 80185929 G T 8.59E-04 Amyotrophic Lateral Sclerosis G/14 intron 17362836 rs716080 chr9 80196611 G T 3.15E-05 Serum metabolites G/14 intron 19043545 rs1772921 chr9 80196839 G T 2.61E-04 Multiple complex diseases G/14 intron 17554300 rs1162211 chr9 80201301 T C 3.80E-05 B cell non-Hodgkin lymphoma G/14 intron 23749188 rs3905108 chr9 80226683 C T 1.77E-04 Major depressive disorder G/14 intron 22472876 rs17063814 chr9 80231601 G A 2.28E-04 Multiple complex diseases G/14 intron 17554300 rs13288161 chr9 80236438 C T 3.79E-05 Longevity G/14 intron 20304771 rs7032434 chr9 80251191 A G 7.04E-05 Multiple complex diseases G/14 intron 17554300 rs10869950 chr9 80257000 C T 3.80E-04 Myasthenia gravis G/14 intron 23055271 rs10869954 chr9 80292007 A G 3.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4745661 chr9 80320365 A G 3.00E-06 IgG glycosylation / / 23382691 rs7048503 chr9 80469561 G A 6.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) G/Q intron 20877124 rs7035689 chr9 80561672 G A 1.00E-04 Information processing speed G/Q intron 21130836 rs10781474 chr9 80562978 C T 1.93E-04 Bipolar disorder (mania) G/Q intron 23326512 rs11145629 chr9 80564440 A G 1.54E-04 Bipolar disorder (mania) G/Q intron 23326512 rs4745687 chr9 80619811 A G 9.61E-05 Bipolar disorder (mania) G/Q intron 23326512 rs11145653 chr9 80623095 C A 1.76E-04 Bipolar disorder (mania) G/Q intron 23326512 rs4745690 chr9 80639602 A G 1.26E-04 Bipolar disorder (mania) G/Q intron 23326512 rs950141 chr9 80704731 T G 1.28E-04 HIV-1 viral setpoint / / 21490045 rs11999145 chr9 80740886 A C 8.17E-05 Lung adenocarcinoma / / 19836008 rs7031014 chr9 80778831 C T 9.90E-05 Lung adenocarcinoma / / 19836008 rs998369 chr9 80781401 T C 6.22E-05 Lung adenocarcinoma / / 19836008 rs10870061 chr9 80807783 C T 4.30E-05 Lung adenocarcinoma / / 19836008 rs11145739 chr9 80807868 G A 6.70E-05 Parkinson's disease / / 21738487 rs882510 chr9 80811489 T G 1.40E-05 Urinary metabolites / / 21572414 rs2026390 chr9 80824321 G A 4.13E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7044325 chr9 80826181 A C 3.92E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1929402 chr9 80863088 G A 3.50E-04 Asperger disorder CEP78 intron 21182207 rs11137585 chr9 80900677 C T 8.92E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs41389547 chr9 80903388 A G 1.54E-04 Multiple complex diseases / / 17554300 rs3808906 chr9 80910643 T A 5.50E-05 Brain derived neurotrophic factor levels,in serum PSAT1 nearGene-5 22047184 rs3758201 chr9 80918420 C T 2.80E-04 Osteoarthritis PSAT1 intron 19508968 rs3739474 chr9 80919756 T G 5.00E-04 Male fertility PSAT1 cds-synon 22633400 rs944513 chr9 80921446 G T 8.50E-06 Personality dimensions PSAT1 intron 21173776 rs10116231 chr9 80921599 C T 4.40E-05 Serum metabolites PSAT1 intron 19043545 rs10116267 chr9 80921732 C T 2.38E-05 Serum metabolites PSAT1 intron 19043545 rs11137594 chr9 80922317 G A 5.10E-06 Personality dimensions PSAT1 intron 21173776 rs7018865 chr9 80922394 A G 8.30E-06 Personality dimensions PSAT1 intron 21173776 rs11137606 chr9 80935799 C T 5.79E-05 Inflammation PSAT1 intron pha002897 rs1411916 chr9 80940576 G A 4.00E-06 Visceral fat PSAT1 intron 22589738 rs9697134 chr9 80974407 T C 8.18E-05 Male fertility / / 22633400 rs17197444 chr9 80974524 G A 4.51E-04 Parkinson's disease / / 17052657 rs2989579 chr9 80985742 T C 3.95E-05 Cognitive test performance / / 20125193 rs7030182 chr9 80994786 G T 2.68E-04 Height / / 17255346 rs2989585 chr9 80997705 A G 0.0000738 post-traumatic stress disorder / / 22869035 rs2989585 chr9 80997705 A G 7.38E-05 Schizophrenia / / 22883433 rs10867190 chr9 81004205 G A 5.80E-05 Male fertility / / 22633400 rs7855119 chr9 81011912 C A 9.94E-04 Self-reported allergy / / 23817569 rs10867192 chr9 81013826 T C 8.18E-05 Male fertility / / 22633400 rs10867192 chr9 81013826 T C 7.14E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10867192 chr9 81013826 T C 3.51E-04 Iron levels / / pha002876 rs10867195 chr9 81019406 G A 8.18E-05 Male fertility / / 22633400 rs7867029 chr9 81020418 G C 1.04E-05 Male fertility / / 22633400 rs7047148 chr9 81021662 A G 8.18E-05 Male fertility / / 22633400 rs10780235 chr9 81031994 G C 8.18E-05 Male fertility / / 22633400 rs7872363 chr9 81036713 G C 8.69E-04 Alzheimer's disease / / 22005930 rs7019259 chr9 81038220 A G 8.82E-04 Iron levels / / pha002876 rs12552001 chr9 81062916 C T 4.25E-05 Smoking initiation / / 24665060 rs10125737 chr9 81083897 G A 6.00E-06 Obesity-related traits / / 23251661 rs3010711 chr9 81120420 G A,C 5.94E-04 Multiple complex diseases / / 17554300 rs1032889 chr9 81148338 A G 4.89E-05 Hirschsprung's disease / / 19196962 rs1394926 chr9 81169107 G T 6.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1394924 chr9 81169237 G A 6.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2047995 chr9 81169950 T C 8.71E-05 Multiple sclerosis / / 17660530 rs1394921 chr9 81171783 G T 5.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12551231 chr9 81191252 C A 4.43E-04 Taste perception / / 22132133 rs1505644 chr9 81194214 C T 8.10E-06 Personality dimensions / / 21173776 rs1505642 chr9 81194384 G A 6.80E-07 Personality dimensions / / 21173776 rs1505641 chr9 81194641 A G 6.90E-06 Personality dimensions / / 21173776 rs1505640 chr9 81195046 T C 5.90E-07 Personality dimensions / / 21173776 rs1505639 chr9 81195055 A G 1.10E-06 Personality dimensions / / 21173776 rs10217162 chr9 81196411 C T 1.10E-06 Personality dimensions / / 21173776 rs1505637 chr9 81196948 G A 8.90E-07 Personality dimensions / / 21173776 rs1505636 chr9 81197258 T A 6.60E-07 Personality dimensions / / 21173776 rs6420241 chr9 81200757 C G 3.60E-07 Personality dimensions / / 21173776 rs6559398 chr9 81201598 G A 6.20E-07 Personality dimensions / / 21173776 rs1394937 chr9 81202467 G C 6.40E-07 Personality dimensions / / 21173776 rs1505635 chr9 81206794 A C 3.10E-07 Personality dimensions / / 21173776 rs885007 chr9 81209159 G A 3.20E-06 Personality dimensions / / 21173776 rs1505634 chr9 81209651 A G 3.30E-07 Personality dimensions / / 21173776 rs1505632 chr9 81212385 A G 2.20E-06 Personality dimensions / / 21173776 rs1394936 chr9 81214033 T C 8.30E-07 Personality dimensions / / 21173776 rs6559399 chr9 81217634 C A 5.50E-06 Personality dimensions / / 21173776 rs234802 chr9 81222228 C A 3.00E-06 Personality dimensions / / 21173776 rs234801 chr9 81222360 A C 4.10E-06 Personality dimensions / / 21173776 rs10780240 chr9 81234078 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs570356433 chr9 81234078 T TC 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs234792 chr9 81240595 G A 5.39E-05 Hypertension / / pha003042 rs10867228 chr9 81259195 T C 7.22E-05 Hypertension / / 21082022 rs2905476 chr9 81281915 T C 6.35E-05 Longevity / / 21612516 rs1757948 chr9 81310680 A C 7.00E-06 vWF and FVIII levels / / 21810271 rs1757948 chr9 81310680 A C 3.00E-06 Multiple sclerosis / / 21833088 rs1634352 chr9 81313820 A G 8.00E-06 Multiple sclerosis / / 21833088 rs2521904 chr9 81328432 G A 6.16E-05 Serum metabolites / / 19043545 rs12342805 chr9 81346848 C T 8.60E-04 Schizophrenia / / 19197363 rs117347249 chr9 81368654 A G 3.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs10512079 chr9 81372519 A G 5.62E-04 Type 2 diabetes / / 17463246 rs7030975 chr9 81384105 G A 4.30E-06 Urinary metabolites / / 21572414 rs7849146 chr9 81394337 G T 9.83E-05 Creatinine levels / / pha003069 rs1929871 chr9 81404992 G A 7.34E-04 Stroke / / pha002886 rs4300072 chr9 81407851 C T 7.71E-04 Stroke / / pha002886 rs11137846 chr9 81408592 G T 2.00E-05 Urinary metabolites / / 21572414 rs4128826 chr9 81409261 C T 1.70E-05 Urinary metabolites / / 21572414 rs3897787 chr9 81409486 G T 7.69E-04 Stroke / / pha002886 rs12348374 chr9 81429025 A G 2.20E-05 Urinary metabolites / / 21572414 rs4877953 chr9 81469029 C A 5.66E-05 Waist-Hip Ratio / / pha003013 rs7848659 chr9 81502879 T G 1.93E-04 Multiple complex diseases / / 17554300 rs1371010 chr9 81518790 T C 1.32E-04 Fibrinogen / / 17255346 rs1438805 chr9 81555504 T G 6.67E-04 Alzheimer's disease / / 22005930 rs7850417 chr9 81557850 G A 5.37E-04 Alzheimer's disease / / 22005930 rs10867310 chr9 81560697 C T 7.53E-04 Alzheimer's disease / / 22005930 rs11137965 chr9 81562929 C A 8.14E-04 Alzheimer's disease / / 22005930 rs10512074 chr9 81572766 G A 7.43E-04 Alzheimer's disease / / 22005930 rs1438795 chr9 81582105 A C 2.03E-04 Glycosylated haemoglobin levels / / 17255346 rs10867325 chr9 81591540 A G 2.06E-05 Alzheimer's disease / / 24755620 rs11788493 chr9 81623111 G A,T 8.68E-04 Multiple complex diseases / / 17554300 rs11137996 chr9 81626352 T C 6.66E-04 Alzheimer's disease / / 24755620 rs1036598 chr9 81628944 T C 1.80E-05 Urinary metabolites / / 21572414 rs11137997 chr9 81632244 A C 9.98E-04 Multiple complex diseases / / 17554300 rs7038338 chr9 81634435 A G 4.20E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10867329 chr9 81638004 T A 5.61E-04 Type 2 diabetes / / 17463246 rs6559441 chr9 81646444 C T 6.60E-05 Body Mass Index / / pha003006 rs6559443 chr9 81647793 C A 5.61E-04 Schizophrenia / / 19197363 rs11788042 chr9 81650381 A G 8.97E-04 Response to TNF antagonist treatment / / 21061259 rs10512080 chr9 81657195 A G 6.73E-04 Response to TNF antagonist treatment / / 21061259 rs7871268 chr9 81680914 G A 5.68E-04 Multiple complex diseases / / 17554300 rs7869802 chr9 81684048 T C 3.40E-06 Urinary metabolites / / 21572414 rs10465173 chr9 81764975 C A 2.22E-05 Parkinson's disease / / 21738487 rs7035088 chr9 81773535 G T 9.70E-06 Urinary metabolites / / 21572414 rs1361536 chr9 81782185 A G 5.50E-07 Urinary metabolites / / 21572414 rs6559460 chr9 81782267 A G 6.40E-07 Urinary metabolites / / 21572414 rs6559461 chr9 81783181 C T 1.60E-05 Urinary metabolites / / 21572414 rs902907 chr9 81814564 G A 4.08E-07 Esophageal cancer (squamous cell) / / 22960999 rs10124727 chr9 81815272 C T 5.69E-04 Myopia (pathological) / / 21095009 rs2769965 chr9 81819044 G A 5.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2769965 chr9 81819044 G A 1.10E-05 Volumetric brain MRI / / 17903297 rs2493600 chr9 81821091 C T 9.16E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs273464 chr9 81829336 C T 1.40E-05 Urinary metabolites / / 21572414 rs2479727 chr9 81837892 T A 7.09E-05 Smoking initiation / / 24665060 rs2769958 chr9 81839723 G T 5.12E-04 Myopia (pathological) / / 21095009 rs273452 chr9 81842673 A G 6.78E-04 Myopia (pathological) / / 21095009 rs273431 chr9 81866992 C G 1.76E-04 Multiple complex diseases / / 17554300 rs1887719 chr9 81869419 G A 1.71E-05 Post-operative nausea and vomiting / / 21694509 rs11792810 chr9 81870379 C T 9.95E-05 Myopia (pathological) / / 21095009 rs273472 chr9 81876910 G A 3.41E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs13293121 chr9 81881830 A G 4.26E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4295736 chr9 81882339 G A 1.70E-10 Type 2 diabetes / / 21874001 rs4295736 chr9 81882339 G A 4.26E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4486277 chr9 81882407 A G 7.00E-05 Lung cancer / / 18978790 rs2769967 chr9 81889358 G C 3.00E-06 Inattentive symptoms / / 18821565 rs1118644 chr9 81901856 T G 4.48E-06 Serum metabolites / / 19043545 rs17791513 chr9 81905590 A G 0.00000028 Type 2 diabetes / / 22885922 rs17791513 chr9 81905590 A G 0.0000028 Type 2 diabetes (males) / / 22885922 rs17791513 chr9 81905590 A G 3.00E-08 Type 2 diabetes / / 24509480 rs1688964 chr9 81911067 A G 2.68E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7862285 chr9 81922269 G A 3.04E-04 Multiple complex diseases / / 17554300 rs7045156 chr9 81926265 T C 5.73E-07 Asthma (childhood onset) / / 23829686 rs10867359 chr9 81930694 T C 5.32E-05 Panic disorder / / 19165232 rs13292136 chr9 81952128 C T 3.00E-08 Type 2 diabetes / / 20581827 rs13292136 chr9 81952128 C T 3.00E-08 Type 2 diabetes / / 21647700 rs13292136 chr9 81952128 C T 0.00000085 Type 2 diabetes / / 22885922 rs971986 chr9 81952643 T C 2.50E-05 Urinary metabolites / / 21572414 rs7020903 chr9 81953539 G A 4.97E-05 Lung adenocarcinoma / / 19836008 rs11138152 chr9 81966641 C T 1.70E-05 Urinary metabolites / / 21572414 rs7026908 chr9 81972841 C A 5.65E-05 Height / / pha003011 rs9314677 chr9 82018917 C T 4.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs11138196 chr9 82024440 T A 7.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs2378383 chr9 82039362 A G 7.00E-07 Asthma (childhood onset) / / 19714205 rs12555018 chr9 82042477 G A 2.31E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs12554999 chr9 82042491 C A 2.00E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7848623 chr9 82075292 T C 3.10E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10867388 chr9 82081650 A G 8.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs12339463 chr9 82083592 G A 8.71E-04 Suicide attempts in bipolar disorder / / 21041247 rs9697204 chr9 82105101 G A 5.04E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12337953 chr9 82109255 T C 5.04E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17082505 chr9 82116268 A G 5.04E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7867387 chr9 82116941 A G 2.04E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11138278 chr9 82133538 T C 4.16E-04 Multiple complex diseases LOC100506414 intron 17554300 rs11138278 chr9 82133538 T C 7.46E-05 Personality dimensions LOC100506414 intron 18957941 rs7042201 chr9 82139942 C T 5.81E-05 Personality dimensions LOC100506414 intron 18957941 rs10867401 chr9 82150669 T C 1.16E-05 Personality dimensions / / 22628180 rs1538752 chr9 82152549 T C 1.08E-05 Personality dimensions / / 22628180 rs140141171 chr9 82160138 G C 9.70E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs11138290 chr9 82163313 C T 2.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs13291796 chr9 82165005 A G 8.92E-04 Type 2 diabetes / / 17463246 rs13291796 chr9 82165005 A G 4.83E-05 Postoperative ventricular dysfunction / / 21980348 rs7018813 chr9 82177081 A C 3.20E-05 Erythrocyte counts / / pha003090 rs2807305 chr9 82177290 C T 6.17E-05 Aging (time to event) / / 21782286 rs2807302 chr9 82197735 G A 5.46E-07 Menopause (age at onset) TLE4 intron 19448619 rs2807307 chr9 82233506 T G 1.09E-04 Suicide attempts in bipolar disorder TLE4 intron 21423239 rs2791576 chr9 82234882 G A 2.02E-04 Suicide attempts in bipolar disorder TLE4 intron 21423239 rs4242612 chr9 82237934 C T 2.66E-04 Suicide attempts in bipolar disorder TLE4 intron 21423239 rs12337384 chr9 82243701 T C 3.53E-05 Duodenal ulcer TLE4 intron 22387998 rs2297499 chr9 82267732 C G 7.68E-04 Suicide attempts in bipolar disorder TLE4 intron 21423239 rs4877146 chr9 82280362 C T 5.64E-04 Suicide attempts in bipolar disorder TLE4 intron 21423239 rs10867411 chr9 82297990 A G 8.97E-04 Suicide attempts in bipolar disorder TLE4 intron 21423239 rs201205120 chr9 82297990 A AG 8.97E-04 Suicide attempts in bipolar disorder TLE4 intron 21423239 rs11138329 chr9 82298324 A G 8.05E-04 Suicide attempts in bipolar disorder TLE4 intron 21423239 rs7863550 chr9 82299047 A G 6.42E-04 Suicide attempts in bipolar disorder TLE4 intron 21423239 rs9722721 chr9 82299596 T A 5.47E-04 Suicide attempts in bipolar disorder TLE4 intron 21423239 rs11138331 chr9 82299972 A C 5.55E-04 Suicide attempts in bipolar disorder TLE4 intron 21423239 rs10867413 chr9 82301340 C A 6.89E-04 Suicide attempts in bipolar disorder TLE4 intron 21423239 rs1316823 chr9 82301795 A G 6.21E-04 Suicide attempts in bipolar disorder TLE4 intron 21423239 rs4877501 chr9 82303326 G A 6.08E-04 Suicide attempts in bipolar disorder TLE4 intron 21423239 rs914715 chr9 82310898 T A 2.28E-06 Multiple complex diseases TLE4 intron 17554300 rs914715 chr9 82310898 T A 1.00E-06 Bipolar disorder TLE4 intron 21254220 rs7862187 chr9 82338804 A G 7.95E-05 Waist Circumference TLE4 intron pha003023 rs2151145 chr9 82345881 G A 1.00E-07 Menopause (age at onset) / / 19448619 rs4877504 chr9 82348771 C T 1.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs10867418 chr9 82354524 C T 6.49E-05 Waist-Hip Ratio / / pha003013 rs10867419 chr9 82362167 C T 2.33E-04 Osteoarthritis / / 19508968 rs2183299 chr9 82365757 G A 6.94E-05 Waist-Hip Ratio / / pha003029 rs1888073 chr9 82377443 T G 1.21E-04 Osteoarthritis / / 19508968 rs977219 chr9 82399186 G A 8.33E-05 Waist-Hip Ratio / / pha003029 rs10512091 chr9 82422832 A G 1.45E-05 Response to citalopram treatment / / 19846067 rs10512091 chr9 82422832 A G 7.80E-06 Response to citalopram in major depressive disorder / / 20619826 rs10512091 chr9 82422832 A G 8.00E-06 Response to citalopram in major depressive disorder / / 20619826 rs1384615 chr9 82424032 T G 2.98E-04 Hearing function / / 17255346 rs7025280 chr9 82437195 C A 3.63E-04 Blood pressure / / 17255346 rs4273932 chr9 82439058 T C 3.09E-04 Cholesterol / / 17255346 rs7039360 chr9 82478788 T C 2.18E-05 Waist Circumference / / pha003023 rs12336327 chr9 82488202 G A 8.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs4877518 chr9 82489957 T C 8.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs11790630 chr9 82492741 C T 7.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs267571 chr9 82533026 T C 8.00E-05 Serum metabolites / / 19043545 rs382479 chr9 82546188 C A 4.32E-05 Post-operative nausea and vomiting / / 21694509 rs442485 chr9 82555844 C G 4.08E-04 Body mass index / / 21701565 rs442485 chr9 82555844 C G 7.08E-04 Body mass index / / 21701565 rs1329579 chr9 82559959 T G 6.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4877525 chr9 82583014 T C 4.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2889900 chr9 82641073 C G 5.68E-04 Nicotine dependence / / 17158188 rs10867457 chr9 82666349 C G 7.63E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10867459 chr9 82721529 A G 8.91E-04 Alzheimer's disease / / 22005930 rs971258 chr9 82729842 C T 6.00E-05 Alcoholism (heaviness of drinking) / / 21529783 rs10512096 chr9 82730333 T C 5.60E-05 Alcoholism (heaviness of drinking) / / 21529783 rs4877536 chr9 82732470 C T 8.86E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1576197 chr9 82737410 A G 9.82E-04 Alzheimer's disease / / 22005930 rs1328433 chr9 82743820 A G 5.00E-05 Alcoholism (heaviness of drinking) / / 21529783 rs11138516 chr9 82759502 C T 9.96E-05 Alcohol consumption / / 23953852 rs7044051 chr9 82759818 G A 6.42E-05 Multiple complex diseases / / 17554300 rs7044051 chr9 82759818 G A 5.46E-05 Serum metabolites / / 19043545 rs11138524 chr9 82773990 G A 0.00001 Composite episodic memory score / / 22865056 rs12554086 chr9 82807503 G A 4.00E-07 RR interval (heart rate) / / 20031603 rs11138552 chr9 82816735 C A 3.72E-05 Alcohol consumption / / 23953852 rs11793341 chr9 82922380 G A 4.84E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10735544 chr9 82971428 T C 1.40E-04 Arthritis (juvenile idiopathic) / / 22354554 rs10735544 chr9 82971428 T C 1.87E-04 Cognitive decline / / 23732972 rs1333940 chr9 82971893 A G 2.38E-04 Cognitive decline / / 23732972 rs12686543 chr9 82975578 C T 2.52E-05 Arthritis (juvenile idiopathic) / / 22354554 rs10780387 chr9 82977098 T C 4.21E-05 Serum metabolites / / 19043545 rs7851576 chr9 82980562 G A 7.64E-05 Serum metabolites / / 19043545 rs7851576 chr9 82980562 G A 1.89E-04 Arthritis (juvenile idiopathic) / / 22354554 rs1573228 chr9 82984308 C T 8.60E-05 Serum metabolites / / 19043545 rs4877557 chr9 82991662 T C 1.95E-05 Arthritis (juvenile idiopathic) / / 22354554 rs7047256 chr9 83027012 A C 7.42E-04 Breast cancer / / 20852631 rs7027349 chr9 83052341 A G 2.31E-05 Serum metabolites / / 19043545 rs17083352 chr9 83052940 C A 4.32E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17083391 chr9 83070557 C G 2.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs41431645 chr9 83080199 T C 2.90E-07 Urinary metabolites / / 21572414 rs17083408 chr9 83086421 A T 0.00026 Salmonella-induced pyroptosis / / 22837397 rs10081668 chr9 83104621 G T 9.80E-05 Bipolar disorder and schizophrenia / / 20889312 rs10081668 chr9 83104621 G T 2.40E-05 Urinary metabolites / / 21572414 rs1857471 chr9 83105978 T A 2.40E-06 Urinary metabolites / / 21572414 rs1857471 chr9 83105978 T A 2.72E-04 Substance dependence / / 21818250 rs11138705 chr9 83121545 G C 6.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs9792623 chr9 83122882 C T 4.53E-04 Tourette syndrome / / 22889924 rs13286593 chr9 83155239 G A 8.84E-04 Alzheimer's disease / / 22005930 rs2149343 chr9 83156748 G A 8.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs7872917 chr9 83161877 A G 8.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs7872932 chr9 83161916 A C,T 8.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs7873054 chr9 83161977 A G 9.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs4394477 chr9 83162551 G T 5.91E-05 Intelligence / / 21826061 rs4579606 chr9 83162856 T C 9.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs4376568 chr9 83162920 A G 9.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs10780427 chr9 83163292 A C 5.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs10735552 chr9 83163501 C G 6.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs3904093 chr9 83163547 T C 6.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs1410537 chr9 83164383 G T 8.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs1410536 chr9 83164407 G A 8.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs1410535 chr9 83164591 A G 7.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs12238737 chr9 83167534 T C 3.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs1328501 chr9 83168111 A C 8.93E-08 Metabolite levels / / 23281178 rs2209907 chr9 83169355 A G 3.40E-08 Colorectal cancer / / 20610541 rs10867574 chr9 83169994 G A 3.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs1359986 chr9 83171850 T C 2.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs1328500 chr9 83172180 T G 8.93E-08 Metabolite levels / / 23281178 rs10780429 chr9 83172656 T C 3.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs10867575 chr9 83174096 C T 3.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs1410542 chr9 83217377 A G 1.00E-05 Hypertension / / 22384028 rs41481149 chr9 83219841 T A 7.54E-04 Type 2 diabetes / / 17463246 rs17260223 chr9 83253280 A G 6.05E-04 Alzheimer's disease / / 22005930 rs913504 chr9 83255484 G T 3.69E-04 Insulin resistance / / 21901158 rs6559565 chr9 83263078 A C,G,T 3.63E-05 Bipolar Disorder / / pha002863 rs17266958 chr9 83265249 C T 4.00E-06 Preschool internalizing problems / / 24839885 rs12552136 chr9 83539913 A G 2.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12552136 chr9 83539913 A G 3.96E-04 Taste perception / / 22132133 rs10780471 chr9 83544183 G T 8.16E-04 Taste perception / / 22132133 rs4877627 chr9 83545715 T G 5.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11138921 chr9 83547081 A G 2.43E-05 Serum metabolites / / 19043545 rs11138922 chr9 83547144 C T 4.03E-04 Gallstones / / 17632509 rs1332872 chr9 83551167 G A 5.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11138939 chr9 83567044 T C 7.67E-04 Taste perception / / 22132133 rs7350230 chr9 83572513 C A 4.51E-05 Calcium levels / / pha003085 rs11138942 chr9 83574329 G T 7.94E-05 Taste perception / / 22132133 rs7024926 chr9 83576272 A C 2.87E-05 Calcium levels / / pha003085 rs727435 chr9 83579468 T C 9.60E-06 Blood Phenotypes / / 17903294 rs1332873 chr9 83598302 A G 4.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2378554 chr9 83615318 T C 2.93E-05 Parkinson's disease / / pha002868 rs2378556 chr9 83620771 T C 4.97E-05 Serum metabolites / / 19043545 rs2378557 chr9 83620819 T C 4.97E-05 Serum metabolites / / 19043545 rs400161 chr9 83622926 G A 7.54E-05 Serum metabolites / / 19043545 rs1175332 chr9 83635624 A C 4.97E-05 Serum metabolites / / 19043545 rs1929716 chr9 83637291 G C 6.82E-05 Serum metabolites / / 19043545 rs1556447 chr9 83643410 C A 7.47E-04 Taste perception / / 22132133 rs1556447 chr9 83643410 C A 2.35E-05 Calcium levels / / pha003085 rs7850389 chr9 83649213 T C 6.04E-04 Taste perception / / 22132133 rs12004880 chr9 83653077 A G 2.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11791715 chr9 83667401 C A 6.63E-04 Alzheimer's disease / / 22005930 rs1186145 chr9 83670423 G A 4.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12335799 chr9 83674122 G C 7.66E-04 Obesity (extreme) / / 21935397 rs17268958 chr9 83694231 T C 6.52E-04 Taste perception / / 22132133 rs1929715 chr9 83720918 T C 6.90E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17269854 chr9 83732050 T C,G 5.93E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs997020 chr9 83758648 G A 8.33E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7869606 chr9 83838856 A G 9.33E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs11139109 chr9 83887092 A C 0.00009518 Sarcoidosis / / 22952805 rs11139114 chr9 83895620 T A 2.27E-04 Multiple complex diseases / / 17554300 rs7042916 chr9 83898995 G A 1.01E-04 Alcohol dependence / / 20201924 rs10217627 chr9 83900505 A T 3.55E-04 Smoking initiation / / 24665060 rs10780505 chr9 83906507 T C 3.91E-04 Aortic root size / / 21223598 rs10780505 chr9 83906507 T C 7.09E-04 Smoking initiation / / 24665060 rs13298109 chr9 83909232 C A 5.20E-04 Smoking initiation / / 24665060 rs7869128 chr9 83928740 A C 5.55E-05 Smoking initiation / / 24665060 rs7869544 chr9 83928836 G A 4.45E-04 Smoking initiation / / 24665060 rs7853515 chr9 83932430 G A 8.70E-04 Myopia (pathological) / / 21095009 rs1330210 chr9 83950550 A G 2.46E-05 Myopia (pathological) / / 21095009 rs7876035 chr9 83953443 C T 5.66E-04 Myopia (pathological) / / 21095009 rs12376965 chr9 83998114 T C 9.40E-05 HDL cholesterol / / pha003075 rs7869726 chr9 84007864 T C 9.45E-04 Coronary heart disease / / 21971053 rs10780513 chr9 84012054 T G 1.13E-04 Lung function (forced vital capacity) / / 24023788 rs10121648 chr9 84012442 G C 1.20E-06 Urinary metabolites / / 21572414 rs11794108 chr9 84014898 C T 1.46E-04 Multiple complex diseases / / 17554300 rs10867752 chr9 84015037 C T 3.00E-06 Hippocampal atrophy / / 19668339 rs11139218 chr9 84023250 C T 7.47E-05 Hippocampal atrophy / / 19668339 rs10780514 chr9 84027986 G A 1.92E-05 Lung function (forced vital capacity) / / 24023788 rs7036348 chr9 84034924 A C 2.00E-06 Urinary metabolites / / 21572414 rs11794168 chr9 84035574 C A 4.45E-05 Hippocampal atrophy / / 19668339 rs7864158 chr9 84053765 T G 9.67E-08 Metabolite levels / / 23281178 rs7848770 chr9 84053795 C G 9.67E-08 Metabolite levels / / 23281178 rs10115200 chr9 84066010 T C 8.38E-08 Metabolite levels / / 23281178 rs11139265 chr9 84073624 T C 8.38E-08 Metabolite levels / / 23281178 rs663838 chr9 84088631 T C 4.71E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11139273 chr9 84092123 A G 7.11E-08 Metabolite levels / / 23281178 rs11139275 chr9 84092501 T A 7.11E-08 Metabolite levels / / 23281178 rs11139278 chr9 84093089 T G 7.11E-08 Metabolite levels / / 23281178 rs10121380 chr9 84099480 A C 4.03E-09 Multiple complex diseases / / 17554300 rs12377364 chr9 84103358 G T 6.76E-08 Metabolite levels / / 23281178 rs633096 chr9 84109865 A G 6.40E-05 Statin-induced myopathy / / 21826682 rs10119360 chr9 84130607 T C 5.78E-04 Type 2 diabetes / / 17463246 rs10780518 chr9 84141281 G C 7.38E-04 Type 2 diabetes / / 17463246 rs11139298 chr9 84144714 A C 3.96E-05 Asthma / / pha003128 rs7848966 chr9 84155486 T C 7.48E-04 Type 2 diabetes / / 17463246 rs7029222 chr9 84173486 G A 4.43E-05 Post-operative nausea and vomiting / / 21694509 rs1412224 chr9 84192036 T C 1.64E-05 Rheumatoid arthritis / / 17804836 rs12238375 chr9 84196515 C T 9.50E-05 Pericardial fat / / 22589742 rs2796460 chr9 84201594 C A 1.52E-06 Multiple complex diseases TLE1 intron 17554300 rs2796460 chr9 84201594 C A 4.69E-04 Aortic root size TLE1 intron 21223598 rs7860431 chr9 84210209 C T 3.69E-05 Acute lung injury TLE1 intron 22295056 rs1539377 chr9 84212422 A T 5.26E-06 Blood Pressure and Arterial Stiffness TLE1 intron 17903302 rs2777777 chr9 84213160 C T 9.00E-06 Visceral adipose tissue adjusted for BMI TLE1 intron 22589738 rs815847 chr9 84222618 G A 3.00E-06 Visceral fat TLE1 intron 22589738 rs815846 chr9 84222905 G A 4.89E-04 Multiple complex diseases TLE1 intron 17554300 rs10867787 chr9 84254819 A G 3.09E-05 Waist Circumference TLE1 intron pha003023 rs12551040 chr9 84256984 A G 6.38E-05 Body Mass Index TLE1 intron pha003015 rs10780526 chr9 84262437 A T 1.23E-05 Serum metabolites TLE1 intron 19043545 rs4877669 chr9 84262485 A G 9.86E-05 Waist-Hip Ratio TLE1 intron pha003029 rs10867791 chr9 84262687 T C 3.89E-05 Serum metabolites TLE1 intron 19043545 rs10867791 chr9 84262687 T C 2.90E-06 Urinary metabolites TLE1 intron 21572414 rs2796447 chr9 84268878 A G 5.24E-05 Body Mass Index TLE1 intron pha003015 rs2591 chr9 84288353 C T 5.47E-04 Type 2 diabetes TLE1 intron 17463246 rs10116251 chr9 84306767 G T 9.00E-07 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs2796441 chr9 84308948 G A 2.00E-04 Polycystic ovary syndrome / / 22178785 rs2796441 chr9 84308948 G A 4.90E-09 Type 2 diabetes (males) / / 22885922 rs2796441 chr9 84308948 G A 5.40E-09 Type 2 diabetes / / 22885922 rs2796441 chr9 84308948 G A 2.00E-06 Type 2 diabetes / / 24509480 rs2627013 chr9 84327210 G A 8.15E-04 Myocardial Infarction / / pha002873 rs2129107 chr9 84349621 T C 9.99E-05 Aging (time to event) / / 21782286 rs2129107 chr9 84349621 T C 3.81E-06 Polycystic ovary syndrome / / 22178785 rs1484114 chr9 84363305 G A 6.99E-05 Body Mass Index / / pha003021 rs7854320 chr9 84366478 A G 4.01E-08 Metabolite levels / / 23281178 rs10118133 chr9 84367194 A G 4.01E-08 Metabolite levels / / 23281178 rs17296588 chr9 84370001 G A 5.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1007995 chr9 84371927 A G 4.01E-08 Metabolite levels / / 23281178 rs11139399 chr9 84372741 T C 1.00E-06 Hippocampal atrophy / / 22745009 rs11139399 chr9 84372741 T C 1.86E-08 Metabolite levels / / 23281178 rs7033983 chr9 84380739 C T 7.83E-05 Body Mass Index / / pha003021 rs1010745 chr9 84386712 A G 5.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs1010745 chr9 84386712 A G 5.19E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17085042 chr9 84389168 A C 1.20E-05 Urinary metabolites / / 21572414 rs474179 chr9 84411558 T C 7.09E-05 Body Mass Index / / pha003009 rs669223 chr9 84419758 T G 4.61E-04 Depression (quantitative trait) / / 20800221 rs674084 chr9 84442427 A G 5.95E-06 Blood Pressure / / pha003049 rs4877679 chr9 84452691 T C 4.32E-04 Smoking initiation / / 24665060 rs10867818 chr9 84454027 T C 1.50E-05 Type 2 diabetes / / 23209189 rs17370182 chr9 84461318 C A 7.95E-04 Type 2 diabetes / / 17463246 rs4999155 chr9 84462943 C T 6.17E-07 Prostate cancer / / 22923026 rs11788387 chr9 84470876 G T 1.72E-05 Job-related exhaustion / / 23620144 rs12353488 chr9 84515411 T C 3.57E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs12353488 chr9 84515411 T C 3.57E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs7018590 chr9 84520436 A G 4.02E-04 Alcohol dependence / / 21314694 rs13295552 chr9 84522749 A C 5.00E-06 IgG glycosylation / / 23382691 rs11139465 chr9 84589869 A C 9.37E-04 Multiple complex diseases LOC100652913 intron 17554300 rs11139465 chr9 84589869 A C 5.71E-04 Rheumatoid arthritis LOC100652913 intron 21452313 rs1334760 chr9 84590675 C A 5.58E-04 Rheumatoid arthritis LOC100652913 intron 21452313 rs12342760 chr9 84672279 T C 5.87E-04 Multiple complex diseases / / 17554300 rs1006665 chr9 84727874 C A 7.77E-04 Multiple complex diseases / / 17554300 rs10867840 chr9 84892263 G A 9.59E-05 Schizophrenia / / 19571809 rs1933584 chr9 84948300 C T 7.98E-04 Alzheimer's disease / / 17998437 rs2788110 chr9 84962689 A G 4.24E-05 Schizophrenia / / 19571809 rs10867844 chr9 84986219 A G 5.46E-05 Schizophrenia / / 19571809 rs1330830 chr9 85135643 G A 6.91E-05 Insulin resistance / / 21901158 rs7043482 chr9 85135915 A C 3.00E-06 Insulin resistance / / 21901158 rs10121807 chr9 85136884 A G 9.38E-05 Nicotine smoking / / 19268276 rs12551673 chr9 85158447 T C 1.40E-05 Urinary metabolites / / 21572414 rs12004246 chr9 85167744 A G 1.70E-05 Urinary metabolites / / 21572414 rs868395 chr9 85175793 G T 8.57E-04 Multiple complex diseases / / 17554300 rs7022118 chr9 85187051 T G 2.15E-04 Insulin resistance / / 21901158 rs7035647 chr9 85199256 G A 7.81E-04 Type 2 diabetes / / 17463246 rs7028728 chr9 85209810 A G 8.60E-04 Multiple complex diseases / / 17554300 rs7031058 chr9 85256142 A G 2.12E-04 Multiple complex diseases / / 17554300 rs11139665 chr9 85261201 T G 0.00000784 Uterine leiomyomata / / 23040493 rs11139689 chr9 85303653 G A 1.60E-05 Urinary metabolites / / 21572414 rs668853 chr9 85311147 C T 2.00E-06 Ulcerative colitis / / 19122664 rs609444 chr9 85347613 G T 8.37E-05 Parkinson's disease / / 17052657 rs7869575 chr9 85358903 C T 1.70E-05 Urinary metabolites / / 21572414 rs11139727 chr9 85362958 A G 4.40E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs932638 chr9 85391686 C A 4.66E-05 Hemoglobin concentration / / 20534544 rs932638 chr9 85391686 C A 2.00E-05 Urinary metabolites / / 21572414 rs963727 chr9 85406002 A G 2.17E-04 Hemoglobin concentration / / 20534544 rs1998303 chr9 85414981 A G 1.00E-06 Select biomarker traits / / 17903293 rs4877240 chr9 85440941 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10867902 chr9 85451187 C T 6.16E-04 Body mass index / / 21701565 rs2224524 chr9 85458060 G A 5.02E-05 Lung adenocarcinoma / / 19836008 rs2208622 chr9 85459107 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1417271 chr9 85474844 C T 6.78E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs927353 chr9 85477440 C A 6.78E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs11139845 chr9 85486112 G A 2.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs10867909 chr9 85490188 G A 6.02E-05 Suicide attempts in bipolar disorder / / 21423239 rs12235637 chr9 85492701 C T 3.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs12235637 chr9 85492701 C T 9.15E-06 HDL cholesterol / / pha003074 rs10867910 chr9 85493025 T G 5.89E-05 Suicide attempts in bipolar disorder / / 21423239 rs4357374 chr9 85495552 A G 7.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17733409 chr9 85497840 G C 7.54E-04 Body mass index / / 21701565 rs7038698 chr9 85506296 C A 4.72E-04 Smoking initiation / / 24665060 rs7031458 chr9 85520374 T C 4.46E-05 Suicide attempts in bipolar disorder / / 21423239 rs7026976 chr9 85521271 A G 1.40E-04 Major depressive disorder / / 21042317 rs17672128 chr9 85522366 C G 8.14E-05 Multiple complex diseases / / 17554300 rs11139867 chr9 85524834 A G 9.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs3897456 chr9 85527950 A G 1.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs7872040 chr9 85549831 C G 2.30E-05 Urinary metabolites / / 21572414 rs10117640 chr9 85552823 A T 2.70E-05 Serum metabolites / / 19043545 rs73651015 chr9 85564274 A C 7.27E-05 Cocaine dependence / / 23958962 rs7024799 chr9 85573467 G C 6.85E-04 Multiple complex diseases / / 17554300 rs7024799 chr9 85573467 G C 1.70E-05 Urinary metabolites / / 21572414 rs10867921 chr9 85609781 G A 8.00E-06 Obesity-related traits RASEF intron 23251661 rs952450 chr9 85620008 C T 6.60E-05 Personality dimensions RASEF intron 18957941 rs1948797 chr9 85657836 C T 2.49E-04 Amyotrophic lateral sclerosis (sporadic) RASEF intron 24529757 rs871512 chr9 85689581 A G 7.60E-05 Personality dimensions / / 18957941 rs11139921 chr9 85748119 G A 7.12E-04 Alzheimer's disease / / 17998437 rs6559700 chr9 85751913 A G 7.31E-04 Type 2 diabetes / / 17463246 rs952744 chr9 85766721 C T 9.82E-04 Coronary heart disease / / 21971053 rs1323766 chr9 85811825 A G 6.88E-04 Coronary Artery Disease / / 17634449 rs7043458 chr9 85853917 A G 6.37E-06 Bipolar disorder LOC100506605 intron 20451256 rs1048228 chr9 85859648 T G 9.01E-04 Myocardial Infarction FRMD3 UTR-3 pha002873 rs4877742 chr9 85860771 C G 7.11E-05 Bipolar disorder FRMD3 UTR-3 20451256 rs4877750 chr9 85872664 T C 9.72E-05 Bipolar disorder FRMD3 intron 20451256 rs12339855 chr9 85876399 A G 4.00E-04 Smoking cessation FRMD3 intron 24665060 rs13298532 chr9 85891266 T C 1.20E-05 Urinary metabolites FRMD3 intron 21572414 rs1323780 chr9 85903383 A C 4.92E-06 Bipolar disorder FRMD3 intron 20451256 rs942280 chr9 85905861 C T 1.48E-04 Progressive supranuclear palsy FRMD3 intron 21685912 rs10867977 chr9 85907516 A G 1.40E-04 Progressive supranuclear palsy FRMD3 intron 21685912 rs3889596 chr9 85969893 G A 7.04E-04 Multiple complex diseases FRMD3 intron 17554300 rs3889596 chr9 85969893 G A 6.23E-05 Smoking initiation FRMD3 intron 24665060 rs10780599 chr9 85992977 C T 1.10E-05 Urinary metabolites FRMD3 intron 21572414 rs12337675 chr9 86002493 T C 4.60E-06 Urinary metabolites FRMD3 intron 21572414 rs11140065 chr9 86007259 T C 9.00E-07 Urinary metabolites FRMD3 intron 21572414 rs4242622 chr9 86019168 A C 2.30E-05 Urinary metabolites FRMD3 intron 21572414 rs7035287 chr9 86021132 T C 0.00000179 Sarcoidosis FRMD3 intron 22952805 rs7035287 chr9 86021132 T C 9.58E-05 Waist-Hip Ratio FRMD3 intron pha003013 rs7035287 chr9 86021132 T C 8.94E-05 Waist-Hip Ratio FRMD3 intron pha003028 rs4097498 chr9 86024484 A C 2.52E-05 Waist-Hip Ratio FRMD3 intron pha003013 rs4097498 chr9 86024484 A C 2.21E-05 Waist-Hip Ratio FRMD3 intron pha003028 rs11140077 chr9 86039118 G A 1.66E-06 Lipid traits FRMD3 intron 21777205 rs10217746 chr9 86039845 T C 9.70E-04 Type 2 diabetes FRMD3 intron 17463246 rs11140081 chr9 86041189 C T 8.57E-04 Type 2 diabetes FRMD3 intron 17463246 rs7019130 chr9 86042288 T C 6.75E-06 Waist-Hip Ratio FRMD3 intron pha003013 rs7019130 chr9 86042288 T C 1.67E-05 Waist-Hip Ratio FRMD3 intron pha003028 rs4877761 chr9 86044173 C T 3.25E-05 Waist-Hip Ratio FRMD3 intron pha003013 rs4877761 chr9 86044173 C T 2.87E-05 Waist-Hip Ratio FRMD3 intron pha003028 rs11140087 chr9 86045746 C T 8.78E-05 Waist-Hip Ratio FRMD3 intron pha003013 rs3893399 chr9 86046077 G A 8.57E-04 Type 2 diabetes FRMD3 intron 17463246 rs11140088 chr9 86048288 G A 3.29E-05 Waist-Hip Ratio FRMD3 intron pha003013 rs11140088 chr9 86048288 G A 2.90E-05 Waist-Hip Ratio FRMD3 intron pha003028 rs10868008 chr9 86051269 A C 1.66E-06 Lipid traits FRMD3 intron 21777205 rs2375919 chr9 86055337 T C 5.07E-05 Waist-Hip Ratio FRMD3 intron pha003013 rs2375919 chr9 86055337 T C 4.45E-05 Waist-Hip Ratio FRMD3 intron pha003028 rs7034859 chr9 86055713 T G 0.000548 Salmonella-induced pyroptosis FRMD3 intron 22837397 rs11140092 chr9 86059732 C T 1.66E-06 Lipid traits FRMD3 intron 21777205 rs11140096 chr9 86066034 A G 4.97E-05 Waist-Hip Ratio FRMD3 intron pha003013 rs11140096 chr9 86066034 A G 5.45E-05 Waist-Hip Ratio FRMD3 intron pha003028 rs3860938 chr9 86108027 G T 9.92E-06 Orofacial clefts FRMD3 intron 20023658 rs3860941 chr9 86108665 G A 8.26E-04 Suicide attempts in bipolar disorder FRMD3 intron 21423239 rs4097644 chr9 86110280 G A 6.42E-04 Suicide attempts in bipolar disorder FRMD3 intron 21423239 rs4097643 chr9 86110338 T A 8.31E-04 Suicide attempts in bipolar disorder FRMD3 intron 21423239 rs12552693 chr9 86117401 T C 1.02E-05 Barrett's esophagus FRMD3 intron 24121790 rs4877257 chr9 86117611 T G 7.54E-04 Suicide attempts in bipolar disorder FRMD3 intron 21423239 rs7863215 chr9 86149786 G A 1.10E-05 Urinary metabolites FRMD3 intron 21572414 rs7863215 chr9 86149786 G A 0.000708 Diabetic nephropathy in Type 1 diabetes FRMD3 intron 22721967 rs1888747 chr9 86155551 C G 6.30E-07 Diabetic nephropathy / / 19252134 rs1888747 chr9 86155551 C G 6.70E-04 Diabetic nephropathy / / 19252134 rs1888747 chr9 86155551 C G 0.00000021 Diabetic nephropathy in Type 1 diabetes / / 22721967 rs1999397 chr9 86156196 T C 8.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs2210381 chr9 86156348 G T 9.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs10868025 chr9 86164176 A G 3.10E-05 Diabetic nephropathy / / 19252134 rs10868025 chr9 86164176 A G 4.30E-04 Diabetic nephropathy / / 19252134 rs10868025 chr9 86164176 A G 5.00E-07 Diabetic nephropathy / / 19252134 rs10868025 chr9 86164176 A G 0.00065 Diabetic nephropathy in Type 1 diabetes / / 22721967 rs10868025 chr9 86164176 A G 1.79E-07 Diabetic nephropathy / / pha002852 rs10868025 chr9 86164176 A G 6.46E-07 Diabetic nephropathy / / pha002864 rs13289150 chr9 86164428 A G 0.000648 Diabetic nephropathy in Type 1 diabetes / / 22721967 rs6559732 chr9 86168692 C T 4.17E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs4412434 chr9 86177073 A T 4.41E-04 Major depressive disorder / / 22472876 rs3934902 chr9 86177401 G A 6.26E-05 Schizophrenia / / 19197363 rs4451390 chr9 86179563 T C 2.47E-04 Alzheimer's disease / / 17998437 rs12340511 chr9 86189820 C T 3.78E-04 Multiple complex diseases / / 17554300 rs17086501 chr9 86203301 A G 2.90E-05 Urinary metabolites / / 21572414 rs12339683 chr9 86214149 C T 3.80E-05 Alzheimer's disease (late onset) / / 21460841 rs10113885 chr9 86216008 C T 1.86E-05 Alzheimer's disease (late onset) / / 21460841 rs2780983 chr9 86217430 C T 4.70E-05 Body mass (lean) / / 19268274 rs2780969 chr9 86250804 C T 1.39E-05 Hypertension C9orf103 intron pha003042 rs1052690 chr9 86258685 A C 1.70E-05 Urinary metabolites C9orf103 missense 21572414 rs7045761 chr9 86289460 T C 9.07E-05 Cognitive impairment induced by topiramate UBQLN1 intron 22091778 rs7045761 chr9 86289460 T C 6.73E-05 Orofacial clefts UBQLN1 intron 22419666 rs10746718 chr9 86311783 A G 7.49E-06 Hypertension UBQLN1 intron pha003042 rs12345514 chr9 86324426 G T 9.07E-05 Cognitive impairment induced by topiramate UBQLN1 nearGene-5 22091778 rs12345514 chr9 86324426 G T 5.77E-05 Orofacial clefts UBQLN1 nearGene-5 22419666 rs7853377 chr9 86552205 A G 5.00E-08 Height / / 20881960 rs192705 chr9 86591704 G A 3.25E-06 Primary biliary cirrhosis HNRNPK intron 21399635 rs149512376 chr9 86617349 C T 0.0001 Prostate cancer (advanced) RMI1 missense 23555315 rs6559758 chr9 86625243 A G 4.75E-04 Multiple complex diseases / / 17554300 rs11140355 chr9 86687791 G A 9.15E-04 Rheumatoid arthritis / / 21452313 rs11140355 chr9 86687791 G A 8.86E-05 Stroke / / pha002887 rs7029403 chr9 86707888 G A 3.30E-05 Crohn's disease (need for surgery) / / 23665963 rs1115113 chr9 86732788 G A 1.47E-04 Multiple complex diseases / / 17554300 rs2889956 chr9 86736068 G A 8.96E-06 Molar-incisor hypomineralization / / 23918034 rs10123143 chr9 86740348 T C 9.09E-05 AIDS progression / / 19115949 rs13288553 chr9 86741461 G T 2.00E-06 Molar-incisor hypomineralization / / 23918034 rs7028167 chr9 86743347 A C 6.50E-06 Molar-incisor hypomineralization / / 23918034 rs12377308 chr9 86745026 A C 1.72E-04 Insulin resistance / / 21901158 rs12002481 chr9 86769798 C T 1.55E-04 Multiple complex diseases / / 17554300 rs7874377 chr9 86770193 G C 0.00004857 Sarcoidosis / / 22952805 rs12003072 chr9 86771161 C A 0.00003093 Sarcoidosis / / 22952805 rs74305417 chr9 86779774 G C 0.00005361 Sarcoidosis / / 22952805 rs78456402 chr9 86781900 A C 0.00004433 Sarcoidosis / / 22952805 rs11998981 chr9 86783107 C T 0.00004433 Sarcoidosis / / 22952805 rs7042671 chr9 86791957 A T 4.87E-04 Smoking quantity / / 24665060 rs2265423 chr9 86819736 A G 2.40E-05 Urinary metabolites / / 21572414 rs2184742 chr9 86845034 G C 2.93E-04 Insulin resistance / / 21901158 rs4877824 chr9 86855859 A G 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11793319 chr9 86866915 C T 6.50E-05 Cognitive function / / 24684796 rs1015951 chr9 86868157 C T 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10512145 chr9 86869023 G A 1.24E-07 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs4877830 chr9 86876315 T G 1.09E-05 Suicide attempts in bipolar disorder / / 21041247 rs11790651 chr9 86886897 G T 3.46E-04 Psoriasis / / 20953187 rs17427184 chr9 86913733 G A 1.71E-05 Suicide attempts in bipolar disorder SLC28A3 intron 21041247 rs7861242 chr9 86915542 G A 7.10E-06 Response to statin therapy SLC28A3 intron 20339536 rs10868141 chr9 86921278 C T 6.12E-05 Suicide attempts in bipolar disorder SLC28A3 intron 21041247 rs10868142 chr9 86921615 C T 5.80E-06 Response to statin therapy SLC28A3 intron 20339536 rs10868142 chr9 86921615 C T 0.000138 Transmission distortion SLC28A3 intron 22377632 rs10123041 chr9 86922036 C T 6.00E-06 Response to statin therapy SLC28A3 intron 20339536 rs10780661 chr9 86926307 A G 1.70E-08 Narcolepsy SLC28A3 intron 19629137 rs4877842 chr9 86929380 A G 6.80E-05 Response to statin therapy SLC28A3 intron 20339536 rs7029691 chr9 86931611 G A 8.50E-05 Response to statin therapy SLC28A3 intron 20339536 rs4877844 chr9 86932154 G C 4.30E-05 Response to statin therapy SLC28A3 intron 20339536 rs12000457 chr9 86944425 G A 4.00E-06 Obesity-related traits SLC28A3 intron 23251661 rs17343066 chr9 86946073 G A 6.50E-05 Nicotine smoking SLC28A3 intron 19268276 rs10435946 chr9 86955808 C A 2.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC28A3 intron 20877124 rs12351012 chr9 86960066 T C 4.12E-06 White blood cell count SLC28A3 intron 21738479 rs17087144 chr9 86964718 T A 8.76E-04 Multiple complex diseases SLC28A3 intron 17554300 rs6559804 chr9 87065048 C G 0.000347 Asthma / / 22502797 rs7875211 chr9 87082451 A G 9.07E-05 Alzheimer's disease (late onset) / / 21379329 rs1409705 chr9 87106862 G C 7.20E-08 Insulin-related traits / / 22791750 rs35060039 chr9 87108724 C A 1.85E-07 Insulin-related traits / / 22791750 rs13295556 chr9 87108855 C T 1.85E-07 Insulin-related traits / / 22791750 rs13297129 chr9 87109051 T C 1.85E-07 Insulin-related traits / / 22791750 rs10512148 chr9 87109486 A C 1.85E-07 Insulin-related traits / / 22791750 rs36070690 chr9 87109931 C T 3.58E-06 Insulin-related traits / / 22791750 rs34273676 chr9 87110967 T A 1.80E-07 Insulin-related traits / / 22791750 rs17430135 chr9 87112336 A G 1.66E-07 Insulin-related traits / / 22791750 rs3904480 chr9 87113298 T A 1.53E-07 Insulin-related traits / / 22791750 rs3904481 chr9 87113494 G A 1.55E-07 Insulin-related traits / / 22791750 rs4463503 chr9 87113527 A G 1.55E-07 Insulin-related traits / / 22791750 rs7029848 chr9 87114868 A G 1.53E-07 Insulin-related traits / / 22791750 rs34808171 chr9 87118630 C G 1.53E-07 Insulin-related traits / / 22791750 rs7468189 chr9 87119101 T C 1.53E-07 Insulin-related traits / / 22791750 rs7020767 chr9 87119828 C T 1.53E-07 Insulin-related traits / / 22791750 rs7864887 chr9 87122083 C T 1.53E-07 Insulin-related traits / / 22791750 rs34439305 chr9 87126504 A G 1.53E-07 Insulin-related traits / / 22791750 rs34307009 chr9 87126923 A G 1.53E-07 Insulin-related traits / / 22791750 rs34629677 chr9 87126957 C T 1.53E-07 Insulin-related traits / / 22791750 rs7856875 chr9 87127540 C T 7.76E-07 Insulin-related traits / / 22791750 rs35842364 chr9 87133256 G A 5.26E-08 Insulin-related traits / / 22791750 rs1077625 chr9 87134644 A G 5.17E-08 Insulin-related traits / / 22791750 rs35452829 chr9 87170793 C T 3.10E-06 Insulin-related traits / / 22791750 rs35712893 chr9 87170873 C T 4.53E-06 Insulin-related traits / / 22791750 rs35712377 chr9 87171220 C T 1.87E-06 Insulin-related traits / / 22791750 rs13284056 chr9 87171710 C G 1.40E-06 Insulin-related traits / / 22791750 rs34289003 chr9 87172208 A T 5.17E-08 Insulin-related traits / / 22791750 rs17346028 chr9 87172347 G A 5.17E-08 Insulin-related traits / / 22791750 rs13295359 chr9 87173672 C T 5.17E-08 Insulin-related traits / / 22791750 rs17430887 chr9 87175716 T C 5.17E-08 Insulin-related traits / / 22791750 rs17346170 chr9 87175801 A G 5.17E-08 Insulin-related traits / / 22791750 rs35640669 chr9 87177586 T C 5.17E-08 Insulin-related traits / / 22791750 rs17346477 chr9 87183208 C T 5.17E-08 Insulin-related traits / / 22791750 rs4877280 chr9 87186405 G A 9.00E-06 Waist-to-hip circumference ratio (interaction) / / 23192594 rs2889960 chr9 87193464 T C 8.25E-04 Stroke (pediatric) / / 22990015 rs715243 chr9 87216845 A C 2.34E-04 Alzheimer's disease (late onset) / / 21379329 rs1020120 chr9 87226088 C T 4.63E-05 Alzheimer's disease (late onset) / / 21379329 rs10512152 chr9 87227809 A G 7.60E-05 Volumetric brain MRI / / 17903297 rs1307279 chr9 87281307 C T 6.34E-06 Psoriasis / / 20953187 rs3758317 chr9 87282615 C T 3.34E-04 Alzheimer's disease (late onset) NTRK2 nearGene-5 21379329 rs1211166 chr9 87285992 G A 2.87E-08 Body mass index NTRK2 intron 23001569 rs35085611 chr9 87299715 C T 2.91E-06 Insulin-related traits NTRK2 intron 22791750 rs1187343 chr9 87308783 G A 6.03E-05 Chronic Hepatitis C infection NTRK2 intron 21725309 rs2489162 chr9 87333742 G A 5.69E-04 Multiple complex diseases NTRK2 intron 17554300 rs10116453 chr9 87363201 A T 2.70E-06 Urinary metabolites NTRK2 intron 21572414 rs34811816 chr9 87387192 A G 3.73E-06 Insulin-related traits NTRK2 intron 22791750 rs1573219 chr9 87387622 A G 5.60E-04 Volumetric brain MRI NTRK2 intron 17903297 rs1573219 chr9 87387622 A G 1.71E-04 Psoriasis NTRK2 intron 20953187 rs7038866 chr9 87387907 A G 4.14E-04 Multiple complex diseases NTRK2 intron 17554300 rs7038866 chr9 87387907 A G 3.60E-04 Volumetric brain MRI NTRK2 intron 17903297 rs1539676 chr9 87390167 T C 4.58E-04 Multiple complex diseases NTRK2 intron 17554300 rs1662695 chr9 87405212 G A 5.91E-06 Orofacial clefts NTRK2 intron 22419666 rs1443440 chr9 87406168 C T 1.10E-06 Urinary metabolites NTRK2 intron 21572414 rs3654 chr9 87430491 T C 1.77E-04 Multiple complex diseases NTRK2 UTR-3 17554300 rs10780688 chr9 87446444 A G 6.06E-04 Coronary heart disease NTRK2 intron 21606135 rs10868228 chr9 87447546 A G 7.66E-04 Coronary heart disease NTRK2 intron 21606135 rs1867283 chr9 87450766 G A 4.62E-04 Premature ovarian failure NTRK2 intron 19508998 rs1867283 chr9 87450766 G A 2.73E-04 Myopia (pathological) NTRK2 intron 21095009 rs4877289 chr9 87484613 A G 8.59E-04 Multiple complex diseases NTRK2 intron 17554300 rs3780634 chr9 87488718 A G 2.80E-05 Urinary metabolites NTRK2 UTR-3 21572414 rs10868236 chr9 87508696 G T 9.64E-05 Nicotine smoking NTRK2 intron 19268276 rs2034106 chr9 87531128 T C 0.00000229 Triglycerides NTRK2 intron 23063622 rs1443445 chr9 87534158 G A 7.63E-05 Suicide attempts in bipolar disorder NTRK2 intron 21423239 rs763623 chr9 87539664 G A 6.70E-04 Heroin addiction NTRK2 intron 20520587 rs995861 chr9 87541642 T C 7.37E-04 Suicide attempts in bipolar disorder NTRK2 intron 21423239 rs17087898 chr9 87553211 C T 1.78E-05 Gallstones NTRK2 intron 17632509 rs6559838 chr9 87553563 C T 9.78E-04 Suicide attempts in bipolar disorder NTRK2 intron 21423239 rs7026337 chr9 87568014 G A 4.55E-04 Rheumatoid arthritis NTRK2 intron 21452313 rs2586566 chr9 87570912 G A 3.14E-04 Suicide attempts in bipolar disorder NTRK2 intron 21423239 rs2277193 chr9 87574009 T C 3.14E-04 Multiple complex diseases NTRK2 intron 17554300 rs6559840 chr9 87575500 C T 4.01E-04 Lung function (forced vital capacity) NTRK2 intron 24023788 rs17332552 chr9 87583632 C T 1.34E-04 Suicide attempts in bipolar disorder NTRK2 intron 21423239 rs7026417 chr9 87589165 T C 9.83E-05 Alcohol consumption NTRK2 intron 23953852 rs10746752 chr9 87595716 G A 1.17E-06 Left ventricular mass NTRK2 intron 21212386 rs9802671 chr9 87597827 C A 3.35E-06 Left ventricular mass NTRK2 intron 21212386 rs9802671 chr9 87597827 C A 7.33E-04 Glaucoma (primary open-angle) NTRK2 intron 22605921 rs10115908 chr9 87623385 A G 3.60E-04 Coronary heart disease NTRK2 intron 21606135 rs4877900 chr9 87632318 C T 9.06E-04 Alcohol dependence NTRK2 intron 21314694 rs1586681 chr9 87647434 G T 3.78E-04 Alcohol dependence / / 21314694 rs2200968 chr9 87652112 C T 3.26E-04 Coronary heart disease / / 21606135 rs10118392 chr9 87680401 T C 1.74E-06 Cocaine dependence / / 23958962 rs10118392 chr9 87680401 T C 5.71E-05 Cocaine dependence / / 23958962 rs544862 chr9 87699138 A G 7.59E-05 Serum metabolites / / 19043545 rs1931109 chr9 87734520 T G 7.84E-05 Vascular dementia / / 22116812 rs12348840 chr9 87739737 C T 9.72E-05 Vascular dementia / / 22116812 rs1078815 chr9 87744810 G A 4.60E-04 Myasthenia gravis / / 23055271 rs7849941 chr9 87745233 A T 5.46E-08 Birth weight / / 24950379 rs17088268 chr9 87759493 G A,C,T 9.04E-05 Vascular dementia / / 22116812 rs10868257 chr9 87761907 C T 3.80E-04 Myasthenia gravis / / 23055271 rs12340987 chr9 87770927 A G 1.00E-08 Birth weight / / 24950379 rs620420 chr9 87778956 C T 3.40E-04 Myasthenia gravis / / 23055271 rs1387927 chr9 87788048 A G 7.63E-04 Multiple complex diseases / / 17554300 rs329200 chr9 87795226 A G 9.00E-04 Alcohol dependence / / 20201924 rs12348509 chr9 87795894 T C 5.74E-05 Bipolar disorder and schizophrenia / / 20889312 rs1931113 chr9 87816616 A G 8.15E-05 Depression (quantitative trait) / / 20800221 rs7850866 chr9 87820596 A G 2.22E-04 Multiple complex diseases / / 17554300 rs7850866 chr9 87820596 A G 9.95E-05 Depression (quantitative trait) / / 20800221 rs1931114 chr9 87822415 A C 3.28E-04 Multiple complex diseases / / 17554300 rs1931114 chr9 87822415 A C 3.13E-05 Depression (quantitative trait) / / 20800221 rs1571331 chr9 87823068 A G 3.12E-05 Depression (quantitative trait) / / 20800221 rs10156437 chr9 87823812 A G 3.36E-04 Multiple complex diseases / / 17554300 rs10156437 chr9 87823812 A G 2.95E-05 Depression (quantitative trait) / / 20800221 rs1889250 chr9 87825118 C T 1.99E-04 Multiple complex diseases / / 17554300 rs1889250 chr9 87825118 C T 3.10E-05 Depression (quantitative trait) / / 20800221 rs7045204 chr9 87825889 G A 2.85E-05 Depression (quantitative trait) / / 20800221 rs10868266 chr9 87827039 G A 2.82E-05 Depression (quantitative trait) / / 20800221 rs7859866 chr9 87830448 A T 2.70E-05 Depression (quantitative trait) / / 20800221 rs1931093 chr9 87832469 A G 2.69E-05 Depression (quantitative trait) / / 20800221 rs10868267 chr9 87833517 C T 3.72E-05 Depression (quantitative trait) / / 20800221 rs11140892 chr9 87834342 C T 4.02E-04 Depression (quantitative trait) / / 20800221 rs11140892 chr9 87834342 C T 3.11E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11140893 chr9 87834508 T G 3.95E-05 Depression (quantitative trait) / / 20800221 rs7030902 chr9 87835091 G A 9.94E-04 Depression (quantitative trait) / / 20800221 rs10868268 chr9 87837741 A G 2.97E-04 Depression (quantitative trait) / / 20800221 rs10868268 chr9 87837741 A G 9.10E-05 Cognitive function / / 24684796 rs4147134 chr9 87843840 C T 2.69E-04 Multiple complex diseases / / 17554300 rs4147134 chr9 87843840 C T 3.83E-05 Depression (quantitative trait) / / 20800221 rs11140900 chr9 87844016 C T 3.96E-04 Depression (quantitative trait) / / 20800221 rs11140900 chr9 87844016 C T 2.95E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs11140901 chr9 87844249 G A 9.67E-05 Depression (quantitative trait) / / 20800221 rs11140902 chr9 87845035 C T 2.31E-04 Depression (quantitative trait) / / 20800221 rs11140902 chr9 87845035 C T 9.50E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs11140902 chr9 87845035 C T 8.30E-05 Cognitive function / / 24684796 rs11140903 chr9 87845670 G A 9.01E-05 Depression (quantitative trait) / / 20800221 rs2378682 chr9 87847282 G A 3.34E-05 Depression (quantitative trait) / / 20800221 rs766348 chr9 87847392 G A 9.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12379112 chr9 87851625 C G 5.21E-04 Depression (quantitative trait) / / 20800221 rs992303 chr9 87852583 C T 5.87E-04 Depression (quantitative trait) / / 20800221 rs7040848 chr9 87853360 G A 3.37E-05 ldl cholesterol / / pha003076 rs7039476 chr9 87856534 T C 1.35E-04 Depression (quantitative trait) / / 20800221 rs6559851 chr9 87856663 G C 5.93E-04 Depression (quantitative trait) / / 20800221 rs1931097 chr9 87857686 G C 5.70E-04 Depression (quantitative trait) / / 20800221 rs913444 chr9 87861650 G A 2.09E-05 Rhegmatogenous retinal detachment / / 23585552 rs1034042 chr9 87900094 T C 7.31E-05 Bipolar disorder / / 19488044 rs1034042 chr9 87900094 T C 1.58E-05 Bipolar Disorder / / pha002863 rs2769612 chr9 87909739 T C 7.41E-05 Bipolar disorder / / 19488044 rs2769612 chr9 87909739 T C 1.60E-05 Bipolar Disorder / / pha002863 rs2769609 chr9 87910540 G A 6.73E-04 Multiple complex diseases / / 17554300 rs2769605 chr9 87912671 C T 4.48E-05 Bipolar disorder / / 19488044 rs2769605 chr9 87912671 C T 9.38E-06 Bipolar Disorder / / pha002863 rs2769600 chr9 87915309 C T 6.23E-05 Bipolar disorder / / 19488044 rs2769600 chr9 87915309 C T 1.35E-05 Bipolar Disorder / / pha002863 rs2769596 chr9 87917769 A G 8.33E-04 Multiple complex diseases / / 17554300 rs2769595 chr9 87918231 G A,C,T 4.84E-05 Bipolar disorder / / 19488044 rs2769595 chr9 87918231 G A,C,T 1.17E-05 Bipolar Disorder / / pha002863 rs2841484 chr9 87923891 C T 7.71E-04 Alzheimer's disease / / 17998437 rs2841498 chr9 87930045 A C 4.00E-06 Partial epilepsies / / 20522523 rs2769621 chr9 87930889 C T 1.79E-04 Alzheimer's disease / / 17998437 rs2814734 chr9 87992789 A C 4.43E-06 Partial epilepsies / / 20522523 rs2593018 chr9 88009220 T C 4.29E-05 Partial epilepsies / / 20522523 rs4877928 chr9 88018061 A G 7.57E-04 Taste perception / / 22132133 rs2841457 chr9 88021435 T C 2.10E-06 Urinary metabolites / / 21572414 rs2592997 chr9 88026931 C G 2.00E-06 Urinary metabolites / / 21572414 rs2592998 chr9 88029134 C T 8.45E-05 Waist Circumference / / pha003023 rs2814730 chr9 88030166 C T 8.38E-05 Waist Circumference / / pha003023 rs1545369 chr9 88034682 A T 3.80E-04 Lymphocyte counts / / 22286170 rs7034690 chr9 88128336 T C 1.01E-04 Glycemic traits (pregnancy) / / 23903356 rs11141013 chr9 88144944 T C 2.23E-04 Insulin resistance / / 21901158 rs10115559 chr9 88191184 T G 4.62E-04 Glycemic traits (pregnancy) AGTPBP1 intron 23903356 rs4877950 chr9 88340454 T C 6.76E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) AGTPBP1 intron 20877124 rs3916184 chr9 88353231 T C 1.12E-04 Alzheimer's disease (late onset) AGTPBP1 intron 21379329 rs3812508 chr9 88357495 G A 1.40E-05 Body Mass Index / / pha003019 rs3812508 chr9 88357495 G A 6.04E-06 Body Mass Index / / pha003020 rs12379804 chr9 88365480 G C 6.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs7048878 chr9 88398905 C T 9.89E-05 Asthma / / 11022011 rs665219 chr9 88536916 G A 2.83E-05 Tunica Media / / pha003036 rs511395 chr9 88562392 C T 3.72E-06 Alcohol consumption /A35 intron 23953852 rs11141171 chr9 88603317 G A 6.62E-04 Multiple complex diseases /A35 intron 17554300 rs9410906 chr9 88630786 C T 2.71E-05 Alcohol consumption /A35 intron 23953852 rs7031120 chr9 88669475 T G 0.000078 Migraine GOLM1 intron 22678113 rs7031120 chr9 88669475 T G 7.80E-05 Migraine GOLM1 intron 22683712 rs10115014 chr9 88671087 C T 1.00E-04 Cognitive impairment induced by topiramate GOLM1 intron 22091778 rs7019241 chr9 88693460 C T 2.92E-04 Alzheimer's disease GOLM1 intron 17998437 rs7019241 chr9 88693460 C T 8.67E-05 Femoral neck bone geometry GOLM1 intron 22087292 rs6559900 chr9 88699059 C T 1.91E-04 Alzheimer's disease GOLM1 intron 17998437 rs6559901 chr9 88699276 C T 2.01E-04 Alzheimer's disease GOLM1 intron 17998437 rs6559902 chr9 88699409 G A 2.15E-04 Alzheimer's disease GOLM1 intron 17998437 rs10868366 chr9 88700060 G T 2.43E-04 Alzheimer's disease GOLM1 intron 17998437 rs10868366 chr9 88700060 G T 2.40E-04 Alzheimer's disease (late onset) GOLM1 intron 21460841 rs10868375 chr9 88709104 A G 1.57E-04 Alzheimer's disease GOLM1 intron 17998437 rs7024708 chr9 88719491 A G 1.93E-04 Alzheimer's disease / / 17998437 rs7874443 chr9 88725756 T C 6.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs7867760 chr9 88728064 G C 8.93E-04 Alcohol dependence / / 21314694 rs7867760 chr9 88728064 G C 6.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs7854172 chr9 88728282 T C 9.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs7875522 chr9 88729691 C T 9.92E-05 Suicide attempts in bipolar disorder / / 21423239 rs4877961 chr9 88732829 C T 1.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs11793816 chr9 88733752 A G 8.07E-05 Suicide attempts in bipolar disorder / / 21423239 rs7870162 chr9 88733766 C T 5.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs7870214 chr9 88733933 A G 5.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs7870214 chr9 88733933 A G 4.94E-05 Cognitive impairment induced by topiramate / / 22091778 rs2770811 chr9 88738450 T C 2.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs2812003 chr9 88743556 G A 6.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs12378988 chr9 88755951 T C 5.44E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11141262 chr9 88756246 T C 6.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs4452889 chr9 88758216 A T 2.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs4466477 chr9 88760758 A G 9.77E-04 Multiple complex diseases / / 17554300 rs11526404 chr9 88769857 C T 6.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs4278228 chr9 88778824 A T 6.83E-05 Suicide attempts in bipolar disorder / / 21423239 rs6559907 chr9 88789719 G T 9.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs4378039 chr9 88794978 T G 2.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs1013899 chr9 88822748 G C 4.98E-04 Multiple complex diseases / / 17554300 rs1013899 chr9 88822748 G C 7.10E-06 Urinary metabolites / / 21572414 rs10780752 chr9 88826309 T C 3.49E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs10780752 chr9 88826309 T C 4.90E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs7018642 chr9 88831855 T C 7.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs7851359 chr9 88833143 T A 9.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs4316216 chr9 88833465 A G 7.66E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs942284 chr9 88847477 C T 2.42E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) C9orf153 intron 23648065 rs10118760 chr9 88854546 T G 6.25E-04 Suicide attempts in bipolar disorder C9orf153 intron 21423239 rs7861466 chr9 88855057 C A 9.00E-04 Suicide attempts in bipolar disorder C9orf153 intron 21423239 rs6559916 chr9 88856121 C T 4.49E-04 Multiple complex diseases C9orf153 intron 17554300 rs6559918 chr9 88856534 G A 7.62E-04 Suicide attempts in bipolar disorder C9orf153 intron 21423239 rs10125093 chr9 88857199 C T 3.14E-04 Suicide attempts in bipolar disorder C9orf153 intron 21423239 rs7848944 chr9 88859144 C T 3.07E-04 Suicide attempts in bipolar disorder C9orf153 intron 21423239 rs4439207 chr9 88860649 G T 3.68E-04 Suicide attempts in bipolar disorder C9orf153 intron 21423239 rs4484780 chr9 88860820 C T 3.51E-04 Suicide attempts in bipolar disorder C9orf153 intron 21423239 rs11141316 chr9 88865541 A G 6.43E-04 Suicide attempts in bipolar disorder C9orf153 intron 21423239 rs11141317 chr9 88865698 C T 2.72E-04 Suicide attempts in bipolar disorder C9orf153 intron 21423239 rs12339816 chr9 88866783 C T 2.84E-04 Suicide attempts in bipolar disorder C9orf153 intron 21423239 rs4877314 chr9 88919453 C T 7.18E-04 Amyotrophic lateral sclerosis (sporadic) ZCCHC6 intron 24529757 rs700760 chr9 88934624 G T 1.42E-05 Bone mass and geometry ZCCHC6 intron 17903296 rs10512175 chr9 88952313 A C 6.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) ZCCHC6 intron 17982456 rs791321 chr9 88953554 C T 1.17E-04 Lymphocyte counts ZCCHC6 intron 22286170 rs353810 chr9 89029191 A C 6.52E-05 Body Mass Index / / pha003020 rs187117 chr9 89029703 C T 4.38E-05 Post-operative nausea and vomiting / / 21694509 rs353819 chr9 89059858 G A 6.32E-04 Multiple complex diseases / / 17554300 rs12379293 chr9 89074350 C A 1.20E-06 Primary tooth development (number of teeth) / / 23704328 rs466390 chr9 89083107 C T 7.91E-05 Body Mass Index / / pha003020 rs405761 chr9 89085126 G A 9.76E-05 Body Mass Index / / pha003020 rs1963183 chr9 89109924 T G 1.99E-04 Type 2 diabetes / / 17463246 rs8181166 chr9 89116628 G C 3.00E-12 Height / / 20881960 rs4877984 chr9 89123908 G A 2.46E-04 Telomere length / / 23900074 rs17804667 chr9 89124883 A G 7.40E-04 Obesity (extreme) / / 21935397 rs990327 chr9 89133257 A G 2.50E-04 Telomere length / / 23900074 rs6559935 chr9 89140339 G A 1.91E-04 Telomere length / / 23900074 rs10491846 chr9 89162181 C T 5.66E-05 Response to hepatitis C treatment / / 19684573 rs7850197 chr9 89177743 G A 5.68E-04 Multiple complex diseases / / 17554300 rs10746779 chr9 89189664 G A 2.38E-04 Multiple complex diseases / / 17554300 rs10780771 chr9 89191784 A G 6.04E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs6559938 chr9 89210029 A T 5.08E-04 Aortic root size / / 21223598 rs9696070 chr9 89230779 C T 8.47E-05 LDL lipoproteins / / pha002902 rs1411983 chr9 89236178 A T 9.26E-05 Substance dependence / / 21818250 rs1888714 chr9 89240203 A G 6.62E-04 White matter integrity / / 22425255 rs952834 chr9 89241777 T G 8.22E-04 Type 2 diabetes / / 17463246 rs11141473 chr9 89269261 C A 3.36E-05 Lipid traits / / 24023261 rs11141474 chr9 89272127 T A 2.88E-04 Multiple complex diseases / / 17554300 rs12683318 chr9 89274201 A G 2.30E-04 Self-reported allergy / / 23817569 rs932956 chr9 89280867 A G 1.06E-04 Multiple complex diseases / / 17554300 rs2026340 chr9 89305003 T C 1.30E-05 Urinary metabolites / / 21572414 rs2026340 chr9 89305003 T C 1.16E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1029046 chr9 89314179 C T 8.01E-05 Multiple sclerosis / / 20598377 rs11141495 chr9 89316029 A C 9.06E-04 Multiple complex diseases / / 17554300 rs4878007 chr9 89327192 T C 6.54E-04 Epilepsy / / 22116939 rs2274561 chr9 89372790 A G 2.20E-04 Myasthenia gravis / / 23055271 rs994029 chr9 89375314 C T 0.000000198 Alcohol dependence / / 23691058 rs1887624 chr9 89408044 G A 6.99E-05 Multiple complex diseases / / 17554300 rs11141546 chr9 89409926 G A 1.59E-04 Multiple complex diseases / / 17554300 rs12340912 chr9 89415456 T C 7.04E-04 Multiple complex diseases / / 17554300 rs7874223 chr9 89415913 T C 4.45E-04 Multiple complex diseases / / 17554300 rs7048294 chr9 89419847 C T 3.89E-05 Meningococcal disease / / 20694013 rs10780793 chr9 89438655 C T 1.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs10780795 chr9 89443026 C T 8.99E-04 Type 2 diabetes / / 17463246 rs1952348 chr9 89443726 C A 6.02E-04 Type 2 diabetes / / 17463246 rs10491606 chr9 89472918 G T 8.33E-06 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs10491606 chr9 89472918 G T 8.33E-06 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs10491606 chr9 89472918 G T 8.33E-06 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs1169848 chr9 89481996 G T 7.63E-04 Insulin resistance / / 21901158 rs402644 chr9 89483458 C T 6.55E-04 Insulin resistance / / 21901158 rs7034750 chr9 89487401 A G 4.00E-06 Urinary metabolites / / 21572414 rs10512177 chr9 89519033 C T 4.37E-04 Multiple complex diseases / / 17554300 rs10868504 chr9 89526846 A G 9.85E-05 Bipolar disorder / / 20451256 rs11141597 chr9 89527458 A G 2.00E-06 Asthma (childhood onset) / / 23829686 rs1431848 chr9 89542539 C A 5.06E-04 Body mass index / / 21701565 rs10868506 chr9 89545960 C A 9.82E-05 Serum metabolites / / 19043545 rs17052330 chr9 89552555 C T 2.28E-04 Obesity (extreme) / / 21935397 rs7036455 chr9 89554097 T C 3.55E-04 Insulin resistance / / 21901158 rs7036455 chr9 89554097 T C 8.27E-05 Hepatocellular carcinoma / / 22807686 rs12350534 chr9 89558064 C T 3.73E-06 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs12350534 chr9 89558064 C T 3.73E-06 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs12350534 chr9 89558064 C T 4.00E-06 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs6559957 chr9 89569764 G T 3.10E-04 Body mass index / / 21701565 rs9792548 chr9 89573083 G A 4.00E-06 Insulin resistance / / 21901158 rs9792548 chr9 89573083 G A 8.03E-05 Hepatocellular carcinoma / / 22807686 rs1927084 chr9 89575478 G A 7.97E-05 Hepatocellular carcinoma / / 22807686 rs12555841 chr9 89584572 G A 1.91E-04 Body mass index / / 21701565 rs12554360 chr9 89586340 C T 8.13E-04 Alcohol dependence / / 21314694 rs4878029 chr9 89594294 A G 6.30E-06 Urinary metabolites / / 21572414 rs10114955 chr9 89597085 C T 2.36E-04 Type 2 diabetes / / 17463246 rs10121131 chr9 89597464 A G 2.00E-06 Urinary metabolites / / 21572414 rs729194 chr9 89610795 C T 6.18E-04 Multiple complex diseases / / 17554300 rs4877339 chr9 89611557 A G 3.75E-04 Type 2 diabetes / / 17463246 rs4877339 chr9 89611557 A G 4.20E-04 Multiple complex diseases / / 17554300 rs7027501 chr9 89612224 T C 5.67E-04 Body mass index / / 21701565 rs7027501 chr9 89612224 T C 6.36E-04 Body mass index / / 21701565 rs1927077 chr9 89612554 A G 6.34E-04 Multiple complex diseases / / 17554300 rs4472598 chr9 89613598 C T 6.69E-04 Multiple complex diseases / / 17554300 rs7035400 chr9 89622624 C G 3.63E-04 Insulin resistance / / 21901158 rs1599045 chr9 89641577 T C 4.23E-05 Multiple complex diseases LOC440173 intron 17554300 rs10735582 chr9 89667667 C T 5.53E-04 Body mass index / / 21701565 rs10735582 chr9 89667667 C T 8.33E-04 Body mass index / / 21701565 rs2061430 chr9 89669067 C T 8.53E-04 Body mass index / / 21701565 rs7019492 chr9 89669756 T A 4.60E-05 Body mass index / / 21701565 rs7019492 chr9 89669756 T A 4.82E-05 Body mass index / / 21701565 rs7856774 chr9 89725269 T C 0.0000549 alzheimer's disease (late onset) / / 22785395 rs277743 chr9 89744719 G A 3.01E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2768812 chr9 89819417 G A 1.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs438257 chr9 89820711 T C 1.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs405519 chr9 89820783 G C 1.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs399028 chr9 89820796 G A 1.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs427361 chr9 89820895 A G 1.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs451722 chr9 89821518 G A 1.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs451722 chr9 89821518 G A 4.60E-06 Primary tooth development (number of teeth) / / 23704328 rs11141704 chr9 89822988 A G 9.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs392597 chr9 89823046 G A 1.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs433627 chr9 89827413 T C 2.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs432005 chr9 89827662 C A 1.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs278707 chr9 89830672 C T 1.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs11141709 chr9 89832383 C T 4.18E-04 Multiple complex diseases / / 17554300 rs10868539 chr9 89832951 G A 5.28E-04 Multiple complex diseases / / 17554300 rs10116993 chr9 89843699 T C 5.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs11141715 chr9 89844348 G C 5.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs11141716 chr9 89844462 T G 4.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs11141717 chr9 89844525 G A 6.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs11141723 chr9 89865709 G C 7.02E-04 Body mass index / / 21701565 rs7024533 chr9 89873773 C T 7.38E-04 Multiple complex diseases / / 17554300 rs1969762 chr9 89874932 G A 8.11E-05 Cholesterol / / pha003073 rs1969762 chr9 89874932 G A 5.87E-05 ldl cholesterol / / pha003076 rs10868555 chr9 89924898 C A 3.18E-05 Alcohol consumption / / 23953852 rs2378731 chr9 89945557 T A 1.21E-05 Bone mass and geometry / / 17903296 rs7022187 chr9 89956163 C T 5.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs11141754 chr9 89958743 G A 9.27E-05 Post-operative nausea and vomiting / / 21694509 rs4878061 chr9 89959601 G A 4.64E-04 Crohn's disease / / 17435756 rs11141758 chr9 89964369 A G 7.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs11791306 chr9 89966967 G C 1.43E-05 Bipolar disorder and schizophrenia / / 20889312 rs10868564 chr9 89967771 T C 6.16E-05 Hypertension / / 21082022 rs1930056 chr9 89970895 G T 4.59E-04 Multiple complex diseases / / 17554300 rs1958935 chr9 89975480 G A 9.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1930057 chr9 89979884 C T 9.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1930058 chr9 89980100 A G 9.66E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17052797 chr9 89991700 G C 3.77E-06 Bipolar disorder and schizophrenia / / 20889312 rs17052797 chr9 89991700 G C 2.41E-04 Smoking cessation / / 24665060 rs12376350 chr9 90002911 T C 8.87E-04 Type 2 diabetes / / 17463246 rs12376350 chr9 90002911 T C 7.07E-04 Multiple complex diseases / / 17554300 rs12376350 chr9 90002911 T C 4.63E-04 Alzheimer's disease / / 17998437 rs4427250 chr9 90009393 A G 1.15E-05 Bipolar disorder and schizophrenia / / 20889312 rs960935 chr9 90018433 A G 4.86E-05 Post-operative nausea and vomiting / / 21694509 rs11141788 chr9 90019633 G A 5.98E-04 Type 2 diabetes / / 17463246 rs11141788 chr9 90019633 G A 8.57E-05 Multiple complex diseases / / 17554300 rs1806864 chr9 90031669 G C 1.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs10746806 chr9 90034195 A G 2.21E-04 Smoking cessation / / 24665060 rs10868580 chr9 90040474 G A,C 7.94E-05 Cervical cancer / / 24700089 rs4457416 chr9 90081038 A G 8.15E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4457417 chr9 90081191 A G 6.10E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10780842 chr9 90095024 T G 9.57E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10868605 chr9 90095233 C T 9.57E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs868477 chr9 90121173 A G 4.96E-04 Multiple complex diseases DAPK1 intron 17554300 rs7849249 chr9 90137475 T G 3.46E-05 Type 2 diabetes DAPK1 intron 17463246 rs12378187 chr9 90145115 A G 5.79E-04 Type 2 diabetes DAPK1 intron 17463246 rs11141869 chr9 90147873 A G 9.04E-04 Type 2 diabetes DAPK1 intron 17463246 rs4878097 chr9 90150300 G A 7.90E-04 Type 2 diabetes DAPK1 intron 17463246 rs4877364 chr9 90150679 C T 6.43E-04 Type 2 diabetes DAPK1 intron 17463246 rs4877365 chr9 90155692 G A 3.92E-04 Type 2 diabetes DAPK1 intron 17463246 rs1421001 chr9 90159313 A G 4.00E-06 Cognitive function DAPK1 intron 24684796 rs1421001 chr9 90159313 A G 6.16E-05 Calcium levels DAPK1 intron pha003085 rs10780856 chr9 90159356 A G 8.91E-04 Type 2 diabetes DAPK1 intron 17463246 rs1157645 chr9 90161721 C G 5.50E-05 Cognitive function DAPK1 intron 24684796 rs2026742 chr9 90163255 G A 5.07E-04 Type 2 diabetes DAPK1 intron 17463246 rs11141876 chr9 90166798 C T 1.82E-04 Multiple complex diseases DAPK1 intron 17554300 rs11141876 chr9 90166798 C T 2.88E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) DAPK1 intron 24192120 rs1045211 chr9 90169051 A G 5.76E-04 Multiple complex diseases DAPK1 intron 17554300 rs6560001 chr9 90170231 C T 7.04E-04 Insulin resistance DAPK1 intron 21901158 rs10868625 chr9 90170277 C T 1.05E-04 Type 2 diabetes DAPK1 intron 17463246 rs11141883 chr9 90171439 G A 1.01E-04 Type 2 diabetes DAPK1 intron 17463246 rs7855623 chr9 90171589 T C 8.22E-04 Type 2 diabetes DAPK1 intron 17463246 rs7855635 chr9 90171608 T C 5.69E-04 Type 2 diabetes DAPK1 intron 17463246 rs7869390 chr9 90171672 C T 2.80E-05 Type 2 diabetes DAPK1 intron 17463246 rs17479142 chr9 90172040 C A 5.28E-04 Type 2 diabetes DAPK1 intron 17463246 rs17479142 chr9 90172040 C A 4.96E-05 Personality dimensions DAPK1 intron 18957941 rs17479184 chr9 90173374 A G 8.86E-04 Type 2 diabetes DAPK1 intron 17463246 rs17479184 chr9 90173374 A G 8.21E-05 Personality dimensions DAPK1 intron 18957941 rs4878102 chr9 90173522 C T 9.04E-04 Type 2 diabetes DAPK1 intron 17463246 rs1861832 chr9 90174169 C T 1.29E-04 Type 2 diabetes DAPK1 intron 17463246 rs6560005 chr9 90175393 C T 2.72E-05 Serum metabolites DAPK1 intron 19043545 rs6560005 chr9 90175393 C T 8.00E-05 Cognitive function DAPK1 intron 24684796 rs928114 chr9 90178806 C G 4.88E-04 Type 2 diabetes DAPK1 intron 17463246 rs928114 chr9 90178806 C G 3.83E-05 Personality dimensions DAPK1 intron 18957941 rs928114 chr9 90178806 C G 3.80E-05 Personality dimensions DAPK1 intron 21173776 rs11141896 chr9 90185614 C T 1.69E-04 Type 2 diabetes DAPK1 intron 17463246 rs12685116 chr9 90194227 G A 5.34E-04 Type 2 diabetes DAPK1 intron 17463246 rs7031264 chr9 90194328 C T 1.51E-04 Type 2 diabetes DAPK1 intron 17463246 rs12685372 chr9 90194645 G A 5.62E-04 Type 2 diabetes DAPK1 intron 17463246 rs3095748 chr9 90209137 G A 5.00E-07 Immune reponse to smallpox (secreted IFN-alpha) DAPK1 intron 22610502 rs7869944 chr9 90232402 A G,T 2.99E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) DAPK1 intron 24023788 rs11141915 chr9 90235794 A C 1.00E-06 Response to gemcitabine in pancreatic cancer DAPK1 intron 22293537 rs3118867 chr9 90261695 A G 4.00E-07 Blood pressure DAPK1 intron 24954895 rs3118867 chr9 90261695 A G 4.00E-07 Blood pressure DAPK1 intron 24954895 rs3118867 chr9 90261695 A G 7.00E-06 Blood pressure DAPK1 intron 24954895 rs943855 chr9 90270327 C T 1.00E-04 Cognitive impairment induced by topiramate DAPK1 intron 22091778 rs721936 chr9 90283149 G A 6.13E-04 Multiple complex diseases DAPK1 intron 17554300 rs10868644 chr9 90289936 C T 5.97E-05 Bipolar disorder DAPK1 intron 17486107 rs13283425 chr9 90323220 A G 3.00E-05 Type 2 diabetes DAPK1 UTR-3 23300278 rs4877369 chr9 90324869 C T 0.0006756 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4877369 chr9 90324869 C T 6.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11141951 chr9 90325530 G A 0.0006757 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11141951 chr9 90325530 G A 6.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3128504 chr9 90329781 T C 0.0005943 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs3128504 chr9 90329781 T C 5.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs943856 chr9 90370511 T C 0.00080959 Hypertension (early onset hypertension) / / 22479346 rs10123732 chr9 90395684 A G 6.84E-05 Smoking quantity CTSL3 intron 24665060 rs9410964 chr9 90405210 C A 5.70E-05 HIV-1 control / / 20041166 rs7022568 chr9 90405244 G A 3.27E-04 Smoking quantity / / 24665060 rs7025854 chr9 90405614 A T 3.51E-04 Smoking quantity / / 24665060 rs961391 chr9 90408587 G T 2.01E-04 Smoking quantity / / 24665060 rs12339094 chr9 90410222 T G 3.00E-06 Smoking quantity / / 24665060 rs9410967 chr9 90411001 C G 6.11E-05 Smoking quantity / / 24665060 rs9410970 chr9 90415220 C A 1.39E-04 Smoking quantity / / 24665060 rs4878135 chr9 90436850 A C 8.04E-05 Post-operative nausea and vomiting / / 21694509 rs7045334 chr9 90455686 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7847239 chr9 90456696 C T 7.44E-04 Smoking quantity / / 24665060 rs3935944 chr9 90470780 G A 1.47E-04 Smoking quantity / / 24665060 rs4878138 chr9 90476111 C T 4.39E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10868664 chr9 90482495 G A 9.77E-04 Acute lung injury / / 22295056 rs4072799 chr9 90487924 T G 2.39E-05 Partial epilepsies / / 20522523 rs11142012 chr9 90492678 G T 9.32E-04 Parkinson's disease / / 17052657 rs4072357 chr9 90498210 T C 2.90E-06 Osteoarthritis C9orf79 intron 22763110 rs11142017 chr9 90503451 G A 6.43E-05 Serum metabolites C9orf79 missense 19043545 rs7857434 chr9 90507164 C G 6.96E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs472781 chr9 90526316 C A 2.00E-04 Parkinson's disease / / 17052657 rs1756985 chr9 90562495 A C 6.84E-04 Type 2 diabetes / / 17463246 rs10868677 chr9 90611872 C T 8.79E-05 Behcet's disease / / pha002888 rs590347 chr9 90617141 T C 8.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs11793481 chr9 90629142 T C 9.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs12351691 chr9 90631130 T C 7.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs12553922 chr9 90640761 C T 6.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs10868680 chr9 90641214 G A 5.36E-05 Type 2 diabetes / / 17463246 rs10125370 chr9 90650880 G A 1.99E-04 Type 2 diabetes / / 17463246 rs11142062 chr9 90658749 C T 6.22E-05 Attention deficit hyperactivity disorder / / 22012869 rs529051 chr9 90662755 T C 3.30E-05 Diabetic retinopathy / / 21441570 rs58412084 chr9 90681984 G A 0.00009672 Sarcoidosis / / 22952805 rs9644993 chr9 90700096 C A 7.08E-05 Multiple complex diseases / / 17554300 rs4877406 chr9 90760805 C T 2.92E-04 Hemoglobin concentration / / 20534544 rs10868716 chr9 90762508 A G 9.42E-05 Hemoglobin concentration / / 20534544 rs2150921 chr9 90763539 C T 7.70E-05 IgE levels / / 22075330 rs7027288 chr9 90765292 A G 7.54E-05 IgE levels / / 22075330 rs7025341 chr9 90767826 T A 7.42E-05 IgE levels / / 22075330 rs10125291 chr9 90768827 A G 9.78E-05 IgE levels / / 22075330 rs10125321 chr9 90768886 A G 7.40E-05 IgE levels / / 22075330 rs1929942 chr9 90769826 T C 7.33E-05 IgE levels / / 22075330 rs2150922 chr9 90770845 G A 7.47E-05 IgE levels / / 22075330 rs2150923 chr9 90770949 G A 7.49E-05 IgE levels / / 22075330 rs7038901 chr9 90772892 G A 7.66E-05 IgE levels / / 22075330 rs4877412 chr9 90773906 C T 7.69E-05 IgE levels / / 22075330 rs7029261 chr9 90774440 T A 6.87E-05 IgE levels / / 22075330 rs10868718 chr9 90774496 G A 6.58E-05 IgE levels / / 22075330 rs10868719 chr9 90774570 C G 6.31E-05 IgE levels / / 22075330 rs1888875 chr9 90776494 T G 5.72E-05 IgE levels / / 22075330 rs7847987 chr9 90780765 G C 5.07E-05 IgE levels / / 22075330 rs7020342 chr9 90781499 A G 4.96E-05 IgE levels / / 22075330 rs7039913 chr9 90781568 T C 4.88E-05 IgE levels / / 22075330 rs4877414 chr9 90781661 T C 4.83E-05 IgE levels / / 22075330 rs4877415 chr9 90781782 T C 4.75E-05 IgE levels / / 22075330 rs2183879 chr9 90783625 C T 4.65E-05 IgE levels / / 22075330 rs2183881 chr9 90783792 C A 4.60E-05 IgE levels / / 22075330 rs10780903 chr9 90785170 C T 4.48E-05 IgE levels / / 22075330 rs11142142 chr9 90785547 A G 4.44E-05 IgE levels / / 22075330 rs11142143 chr9 90785654 A G 4.90E-05 IgE levels / / 22075330 rs11142145 chr9 90786554 G T 4.90E-05 IgE levels / / 22075330 rs17053832 chr9 90789164 T A 4.87E-05 IgE levels / / 22075330 rs11142146 chr9 90789775 T G 4.83E-05 IgE levels / / 22075330 rs11142147 chr9 90790039 C T 4.82E-05 IgE levels / / 22075330 rs11142148 chr9 90790154 T A 4.79E-05 IgE levels / / 22075330 rs11142149 chr9 90790331 C T 4.73E-05 IgE levels / / 22075330 rs17053839 chr9 90790713 G A 4.71E-05 IgE levels / / 22075330 rs2814840 chr9 90792249 G A 4.60E-05 IgE levels / / 22075330 rs2778019 chr9 90792863 C T 5.49E-05 Cholesterol / / 17255346 rs2578250 chr9 90794089 A G 4.53E-05 IgE levels / / 22075330 rs7019589 chr9 90801773 T A 7.49E-05 Multiple complex diseases / / 17554300 rs17053864 chr9 90803472 G A 2.72E-04 Multiple complex diseases / / 17554300 rs2814828 chr9 90811182 T C 8.57E-04 Coronary Artery Disease / / 17634449 rs2814828 chr9 90811182 T C 9.00E-07 Height / / 18391951 rs2778031 chr9 90835726 T C 9.00E-13 Height / / 20881960 rs7861008 chr9 90838717 C T 9.69E-04 Alzheimer's disease / / 17998437 rs17053979 chr9 90844063 C G 6.59E-05 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs10868731 chr9 90852317 C G,T 0.0000858 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10868732 chr9 90854093 A G 0.0000938 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10868733 chr9 90854131 T G 0.0000882 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10868734 chr9 90854175 C G 0.0000758 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10046858 chr9 90854389 C G 0.0000757 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10120841 chr9 90854606 G A 0.0000752 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11142192 chr9 90854807 C T 0.0000864 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11142193 chr9 90854820 G A 0.0000649 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11142194 chr9 90854863 G A 0.0000717 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11142195 chr9 90854865 A G 0.000071 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12682957 chr9 90855087 A G 0.0000679 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10868737 chr9 90855223 G A 0.0000646 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10868738 chr9 90855449 A G 0.0000635 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4297119 chr9 90855895 G A 0.0000631 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4297120 chr9 90855918 G A 0.0000629 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4556178 chr9 90856237 T G 0.0000647 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4284121 chr9 90856291 A G 0.0000934 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4628339 chr9 90856685 T C 0.0000603 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7023518 chr9 90856775 T G 0.0000518 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7038272 chr9 90856856 G C 0.0000603 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10868739 chr9 90857315 T A 0.0000596 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7039207 chr9 90857539 G A 0.0000824 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7042191 chr9 90857608 C T 0.0000834 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7042233 chr9 90857756 A T 0.0000571 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7028051 chr9 90857957 T C 0.0000548 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7028051 chr9 90857957 T C 5.63E-05 Body Mass Index / / pha003020 rs10868740 chr9 90858973 C T 0.0000574 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10735594 chr9 90863026 T C 0.0000629 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10124913 chr9 90864733 G A 0.0000634 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7023044 chr9 90865568 C T 0.0000895 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7023896 chr9 90866289 A G 0.0000656 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11142201 chr9 90866397 A G 0.0000659 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11142202 chr9 90866595 G A 0.0000917 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10746837 chr9 90873653 G A 5.41E-05 Platelet counts / / pha003100 rs2083197 chr9 90882058 G A 0.0000994 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10868746 chr9 90896077 G A 1.42E-04 Alcohol dependence / / 20201924 rs7870611 chr9 90905665 C T 2.20E-06 Urinary metabolites / / 21572414 rs7044138 chr9 90906254 A T 9.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs7045192 chr9 91049113 A G 7.81E-04 Response to taxane treatment (placlitaxel) SPIN1 intron 23006423 rs7871303 chr9 91112102 A G 8.46E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10114386 chr9 91143074 G C 1.18E-04 Multiple complex diseases / / 17554300 rs4877453 chr9 91197917 G A 4.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs9410665 chr9 91198886 C G 6.27E-05 Suicide attempts in bipolar disorder / / 21423239 rs4877455 chr9 91200373 A G 6.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs17054251 chr9 91204990 T C 6.80E-06 Urinary metabolites / / 21572414 rs17054265 chr9 91260562 C T 4.00E-06 Obesity-related traits / / 23251661 rs17054266 chr9 91260661 G A 8.30E-05 Electrocardiographic conduction measures / / 19389651 rs7049159 chr9 91266181 C T 9.81E-04 Acute lung injury LOC286238 intron 22295056 rs17054324 chr9 91311230 G C 3.83E-04 Acute lung injury / / 22295056 rs17054326 chr9 91311713 T C 4.15E-04 Acute lung injury / / 22295056 rs17054328 chr9 91311747 T C 4.15E-04 Acute lung injury / / 22295056 rs17054416 chr9 91369335 C A 8.73E-04 Type 2 diabetes / / 17463246 rs4559318 chr9 91371370 C T 9.23E-04 Type 2 diabetes / / 17463246 rs7849560 chr9 91380010 A T 3.87E-04 Gallstones / / 17632509 rs7867530 chr9 91415414 C A 3.62E-04 Multiple complex diseases / / 17554300 rs1288653 chr9 91416748 T C 9.91E-04 Heart Failure / / pha002884 rs2653814 chr9 91423611 T G 7.37E-04 Heart Failure / / pha002884 rs9410395 chr9 91508928 C T 1.30E-05 Urinary metabolites / / 21572414 rs1502707 chr9 91510548 G A 5.20E-06 Urinary metabolites / / 21572414 rs2316799 chr9 91521062 A C 2.10E-04 White blood cell types / / 21738478 rs1875620 chr9 91540059 G A 7.00E-07 Response to statin therapy (LDL-C) / / 22331829 rs9410429 chr9 91563034 C T 1.50E-06 Urinary metabolites / / 21572414 rs6559326 chr9 91581532 C G 1.70E-05 Parkinson's disease (familial) / / 18985386 rs12115280 chr9 91641563 C T 2.61E-06 Personality dimensions SHC3 intron 23658558 rs13295927 chr9 91732709 T C 4.30E-04 Alcohol dependence SHC3 intron 20201924 rs13295927 chr9 91732709 T C 6.30E-06 Alcohol dependence SHC3 intron 20201924 rs13295927 chr9 91732709 T C 6.31E-06 Alcoholism SHC3 intron pha002893 rs9410462 chr9 91750607 C T 3.83E-04 Suicide attempts in bipolar disorder SHC3 intron 21423239 rs11137521 chr9 91760103 A G 1.10E-05 Urinary metabolites SHC3 intron 21572414 rs17527693 chr9 91762628 C T 2.05E-04 Multiple complex diseases SHC3 intron 17554300 rs17054763 chr9 91766733 A G 9.39E-05 Multiple complex diseases SHC3 intron 17554300 rs746357 chr9 91837560 C T 7.90E-08 Warfarin responsiveness (phenprocoumon) / / 21063236 rs11137545 chr9 91841972 A G 3.10E-05 Parkinson's disease (age of onset) / / 19772629 rs12341391 chr9 91848678 A G 2.60E-04 Alcohol dependence / / 20201924 rs12341391 chr9 91848678 A G 5.50E-04 Alcohol dependence / / 20201924 rs17437920 chr9 91864233 G A 2.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs10441779 chr9 91878702 C T 2.90E-04 Alcohol dependence / / 20201924 rs10441779 chr9 91878702 C T 3.60E-04 Alcohol dependence / / 20201924 rs1980889 chr9 91899245 T C 5.30E-08 Warfarin responsiveness (phenprocoumon) / / 21063236 rs13294002 chr9 91906139 T G 2.00E-04 Alcohol dependence / / 20201924 rs13294002 chr9 91906139 T G 7.20E-05 Alcohol dependence / / 20201924 rs13294002 chr9 91906139 T G 7.20E-05 Alcoholism / / pha002893 rs3211663 chr9 91926088 C T 8.15E-05 Coronary heart disease / / pha003032 rs9410319 chr9 92016522 G C 1.03E-04 Alzheimer's disease SEMA4D intron 17998437 rs9410321 chr9 92030186 T C 6.09E-06 Orofacial clefts SEMA4D intron 22863734 rs4132699 chr9 92036427 A C 4.72E-05 Cleft lip SEMA4D intron 20436469 rs4132699 chr9 92036427 A C 5.00E-07 Orofacial clefts SEMA4D intron 22863734 rs11265876 chr9 92039416 T G 1.91E-05 Orofacial clefts SEMA4D intron 22863734 rs10512197 chr9 92040475 C T 4.49E-05 Orofacial clefts SEMA4D intron 22863734 rs7041088 chr9 92052894 G A 3.64E-04 Alzheimer's disease SEMA4D intron 17998437 rs11999884 chr9 92070391 A G 5.67E-05 Orofacial clefts SEMA4D intron 22863734 rs11265908 chr9 92077132 T C 8.60E-05 Obsessive-compulsive disorder SEMA4D intron 24821223 rs4129680 chr9 92081272 G A 6.30E-04 Suicide attempts in bipolar disorder SEMA4D intron 21423239 rs4876986 chr9 92089740 T C 1.40E-05 Urinary metabolites SEMA4D intron 21572414 rs10908927 chr9 92090941 T A 1.40E-05 Urinary metabolites SEMA4D intron 21572414 rs7854120 chr9 92102584 G A 8.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12003997 chr9 92105854 G A 2.90E-05 Urinary metabolites / / 21572414 rs7852744 chr9 92109479 T C 7.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2031970 chr9 92204172 C T 1.95E-05 Orofacial clefts / / 22863734 rs7871395 chr9 92209587 C T 1.75E-05 Orofacial clefts / / 22863734 rs1475537 chr9 92212750 C T 2.01E-05 Orofacial clefts / / 22863734 rs3138512 chr9 92222453 G A 2.22E-06 Orofacial clefts / / 22863734 rs3138513 chr9 92222495 C T 8.64E-05 Orofacial clefts / / 20023658 rs3138513 chr9 92222495 C T 3.45E-05 Orofacial clefts / / 22863734 rs3138513 chr9 92222495 C T 1.77E-04 Myocardial Infarction / / pha002883 rs870926 chr9 92231020 G A 5.24E-05 Hematocrit / / pha003097 rs12551884 chr9 92238514 C A 6.05E-05 Hematocrit / / pha003097 rs17539995 chr9 92241847 G A 7.30E-05 Orofacial clefts / / 22863734 rs10908906 chr9 92242062 T A 2.80E-05 Urinary metabolites / / 21572414 rs12554199 chr9 92247909 G A 6.46E-07 Hemoglobin / / pha003096 rs12554199 chr9 92247909 G A 1.71E-07 Hematocrit / / pha003097 rs10908907 chr9 92249584 G A 6.00E-06 Alcoholism (heaviness of drinking) / / 21529783 rs4877115 chr9 92250365 T G 1.21E-04 Myopia (pathological) / / 21095009 rs4877118 chr9 92258048 T A 7.79E-04 Type 2 diabetes UNQ6494 intron 17463246 rs12555625 chr9 92276715 T G 2.20E-05 Hemoglobin UNQ6494 intron pha003096 rs12555625 chr9 92276715 T G 1.70E-05 Hematocrit UNQ6494 intron pha003097 rs1109998 chr9 92277210 A G 3.22E-04 Orofacial clefts UNQ6494 intron 22863734 rs4877120 chr9 92279448 T G 1.06E-04 Orofacial clefts UNQ6494 intron 22863734 rs4876950 chr9 92290054 T C 2.64E-04 Multiple complex diseases UNQ6494 intron 17554300 rs4077800 chr9 92298168 C T 4.94E-04 Hemoglobin concentration UNQ6494 intron 20534544 rs10908921 chr9 92321289 A G 9.20E-04 Amyotrophic Lateral Sclerosis UNQ6494 intron 17362836 rs10908921 chr9 92321289 A G 2.12E-04 White matter integrity UNQ6494 intron 22425255 rs4877005 chr9 92325852 T C 5.52E-05 Weight UNQ6494 intron pha003027 rs11265930 chr9 92467404 A C 1.57E-04 Stroke / / pha002887 rs11265944 chr9 92478435 C T 2.87E-04 Smoking quantity / / 24665060 rs10116554 chr9 92489679 G A 1.23E-04 Parkinson's disease / / 21248740 rs10116554 chr9 92489679 G A 9.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs11265951 chr9 92493514 C T 9.35E-05 Parkinson's disease / / 21248740 rs9696589 chr9 92494120 C T 6.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs10797132 chr9 92494210 G A 7.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs9330451 chr9 92503272 C T 1.39E-04 Body mass index / / 21701565 rs10820848 chr9 92693510 C T 1.20E-05 Urinary metabolites / / 21572414 rs7025971 chr9 92693881 C T 8.00E-07 Urinary metabolites / / 21572414 rs10992338 chr9 92704074 A G 7.36E-04 Type 2 diabetes / / 17463246 rs7466044 chr9 92711334 G A 1.10E-05 Urinary metabolites / / 21572414 rs2196923 chr9 92711789 A G 8.63E-05 Glucose levels / / pha002899 rs16905942 chr9 92716596 G A 1.66E-05 Substance dependence / / 21818250 rs16905955 chr9 92719592 G A 5.69E-04 Multiple complex diseases / / 17554300 rs10117261 chr9 92726922 G A 1.20E-04 Type 2 diabetes / / 17463246 rs4744515 chr9 92773311 G A 8.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs497510 chr9 92793643 G T 4.00E-04 Suicide attempts in bipolar disorder LOC286370 intron 21041247 rs652593 chr9 92825528 G C 2.04E-04 Multiple complex diseases / / 17554300 rs649527 chr9 92839438 A G 2.43E-04 Type 2 diabetes / / 17463246 rs4744106 chr9 92873665 G A 7.68E-06 LDL lipoproteins / / pha002902 rs10820912 chr9 92875667 G T 6.86E-05 Serum metabolites / / 19043545 rs7867808 chr9 92876028 C T 1.00E-04 Information processing speed / / 21130836 rs7848094 chr9 92876060 T C 8.01E-05 Serum metabolites / / 19043545 rs10992164 chr9 92879883 G A 9.67E-05 Myocardial Infarction / / pha002873 rs2081670 chr9 92887231 C T 3.00E-06 Protein quantitative trait loci / / 18464913 rs7038808 chr9 92891296 C A,G,T 4.90E-06 Urinary metabolites / / 21572414 rs10992247 chr9 92900609 A G 2.47E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7025302 chr9 92903522 G A 1.58E-04 Myocardial Infarction / / pha002883 rs7048754 chr9 92941210 C T 2.74E-04 Blood pressure / / 17255346 rs10992452 chr9 92963339 A C 6.37E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs10821091 chr9 93008041 C T 1.44E-04 Crohn's disease / / 17435756 rs2798060 chr9 93028943 C T 8.10E-05 Cardiovascular disease / / pha003065 rs2798062 chr9 93032607 G A 6.60E-05 Cardiovascular disease / / pha003065 rs1754073 chr9 93033924 C T 5.48E-05 Coronary heart disease / / pha003055 rs10821149 chr9 93039262 A G 2.00E-04 Information processing speed / / 21130836 rs10217176 chr9 93065137 T G 3.60E-05 Information processing speed / / 21130836 rs111556230 chr9 93065137 T TG 3.60E-05 Information processing speed / / 21130836 rs1754069 chr9 93067790 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1754069 chr9 93067790 C T 5.29E-05 Cognitive impairment induced by topiramate / / 22091778 rs1754068 chr9 93068037 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1754068 chr9 93068037 C T 9.06E-05 Cognitive impairment induced by topiramate / / 22091778 rs10993000 chr9 93081685 T C 8.76E-05 Cardiovascular disease / / pha003065 rs10993008 chr9 93085382 G A 2.70E-05 Type 2 diabetes / / 17460697 rs7858079 chr9 93159850 T C 7.10E-05 Bipolar disorder / / 19488044 rs7858079 chr9 93159850 T C 4.34E-05 Bipolar Disorder / / pha002858 rs1576290 chr9 93162602 G A 6.66E-04 Heart Failure / / pha002884 rs10821402 chr9 93170435 T G 7.37E-05 Bipolar disorder / / 19488044 rs10821402 chr9 93170435 T G 4.43E-05 Bipolar Disorder / / pha002858 rs883924 chr9 93181531 G A 2.00E-06 Hepatitis C induced liver fibrosis / / 22841784 rs10761389 chr9 93246553 A G 2.20E-05 Urinary metabolites LOC340515 intron 21572414 rs16906632 chr9 93260040 A G 7.88E-05 Alzheimer's disease LOC340515 intron 22832961 rs12353086 chr9 93265378 A C 9.04E-05 Alzheimer's disease LOC340515 intron 22832961 rs7033803 chr9 93266353 G C 8.97E-05 Alzheimer's disease LOC340515 intron 22832961 rs7033909 chr9 93266402 G C 7.15E-05 Alzheimer's disease LOC340515 intron 22832961 rs690474 chr9 93351272 A G 3.72E-04 Type 2 diabetes / / 17463246 rs7868194 chr9 93369784 A G 2.54E-05 Type 2 diabetes / / 17463246 rs7868194 chr9 93369784 A G 0.000435 Salmonella-induced pyroptosis / / 22837397 rs1017753 chr9 93377901 C T 0.000587 Salmonella-induced pyroptosis DIRAS2 intron 22837397 rs690232 chr9 93382438 G A 1.57E-05 Longevity DIRAS2 intron 20304771 rs563726 chr9 93387516 T C 5.92E-06 Body mass index DIRAS2 intron 19557197 rs497353 chr9 93392890 A G 4.99E-06 Body mass index DIRAS2 intron 19557197 rs4744473 chr9 93402190 G T 6.45E-05 Coronary heart disease DIRAS2 intron pha003030 rs1831521 chr9 93409357 A G 8.00E-06 Cognitive test performance / / 17903297 rs1870661 chr9 93439259 A C 3.90E-05 Coronary heart disease / / pha003030 rs2169237 chr9 93464111 A G 1.84E-04 Multiple complex diseases / / 17554300 rs10993637 chr9 93464206 C T 1.08E-04 Multiple complex diseases / / 17554300 rs10993637 chr9 93464206 C T 1.55E-04 Aortic root size / / 21223598 rs2126054 chr9 93464770 A G 1.49E-04 Multiple complex diseases / / 17554300 rs1172902 chr9 93475945 A G 2.00E-04 Response to interferon beta in multiple sclerosis / / 18195134 rs1172918 chr9 93496948 G A 1.97E-04 Multiple complex diseases / / 17554300 rs12380216 chr9 93514242 G A 2.55E-04 Multiple complex diseases / / 17554300 rs1148853 chr9 93530909 G A 6.25E-04 Bipolar disorder / / 19259986 rs291007 chr9 93539879 A G 1.89E-05 Schizophrenia / / 19197363 rs291005 chr9 93540345 T C 5.88E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs291005 chr9 93540345 T C 5.88E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs290274 chr9 93546913 G A 9.69E-05 Breast cancer / / 21060860 rs290269 chr9 93551997 G C 7.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs290267 chr9 93552550 C T 6.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs290258 chr9 93555739 A G 1.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs10993693 chr9 93557698 A G 2.06E-04 Breast cancer / / 21060860 rs290992 chr9 93561309 T C 9.83E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs290986 chr9 93563536 A G 9.00E-07 Multiple sclerosis SYK nearGene-5 21833088 rs1319677 chr9 93565999 A G 6.85E-05 Breast cancer SYK intron 21060860 rs12553524 chr9 93569646 G T 1.91E-04 Breast cancer SYK intron 21060860 rs7036417 chr9 93570505 C T 6.67E-05 Breast cancer SYK intron 21060860 rs12551275 chr9 93572123 T C 4.33E-05 Multiple complex diseases SYK intron 17554300 rs7032733 chr9 93572345 G A 4.11E-06 Multiple complex diseases SYK intron 17554300 rs2042984 chr9 93573095 C T 8.93E-05 Alcohol consumption SYK intron 23953852 rs290240 chr9 93573542 G A 6.02E-05 Schizophrenia SYK intron 19197363 rs290237 chr9 93574650 C T 1.83E-06 Schizophrenia SYK intron 19197363 rs10993698 chr9 93577781 G T 7.71E-05 Multiple complex diseases SYK intron 17554300 rs4744505 chr9 93579997 A G 8.14E-05 Hypertension SYK intron pha003042 rs1333630 chr9 93581182 C T 7.34E-05 Hypertension SYK intron pha003042 rs914925 chr9 93584793 A G 8.16E-06 Educational attainment SYK intron 21694764 rs290974 chr9 93590403 G A 2.50E-04 Oral cancers (chewing tobacco related) SYK intron 22503698 rs10993706 chr9 93602967 A G 2.67E-05 Multiple complex diseases SYK intron 17554300 rs10993714 chr9 93613106 A T 9.54E-05 Major depressive disorder SYK intron 22472876 rs12001366 chr9 93622150 A C 7.74E-05 Multiple complex diseases SYK intron 17554300 rs10993727 chr9 93622689 T C 1.85E-04 Multiple complex diseases SYK intron 17554300 rs10821515 chr9 93624896 G A 8.41E-10 Esophageal cancer SYK intron 21642993 rs4529574 chr9 93626241 A G 6.13E-04 Alzheimer's disease SYK intron 24755620 rs965892 chr9 93629789 C G 9.67E-04 Multiple complex diseases SYK intron 17554300 rs2613310 chr9 93630445 C T 2.57E-04 Multiple complex diseases SYK intron 17554300 rs10993738 chr9 93633240 A C 5.00E-06 Type 2 diabetes SYK intron 22456796 rs290227 chr9 93636664 G A 7.00E-11 Vascular dementia SYK intron 23480133 rs12344755 chr9 93658952 T C 8.70E-04 Tourette syndrome SYK UTR-3 22889924 rs11794023 chr9 93664706 A G 1.16E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4744521 chr9 93664729 C T 3.86E-05 Cognitive test performance / / 20125193 rs296663 chr9 93710061 A G 2.00E-04 Information processing speed / / 21130836 rs10991722 chr9 93718266 G A 9.16E-06 Smoking cessation / / 18519826 rs426365 chr9 93723833 C T 8.56E-04 Iron levels / / pha002876 rs382847 chr9 93724431 C T 3.92E-05 Personality dimensions / / 18957941 rs12352804 chr9 93731058 G A 7.96E-05 Orofacial clefts / / 22863734 rs10820820 chr9 93731198 C T 5.36E-08 Smoking cessation / / 18519826 rs1155522 chr9 93731484 C G 4.37E-07 White blood cell count / / 21738479 rs7047670 chr9 93752522 A G 3.15E-22 Narcolepsy / / 19629137 rs296648 chr9 93829019 G A 3.50E-04 Iron levels / / pha002876 rs296611 chr9 93834194 G A 6.24E-05 Response to cytadine analogues (cytosine arabinoside) LOC100129316 intron 24483146 rs3853607 chr9 93837497 T C 7.18E-04 Smoking cessation / / 24665060 rs435940 chr9 93847906 G A 4.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs430794 chr9 93852815 G T 8.00E-08 Pelvic organ prolapse / / 22105264 rs10991781 chr9 93909589 A G 8.08E-04 Multiple complex diseases LOC100128909 intron 17554300 rs4743820 chr9 93928416 C T 4.00E-09 Inflammatory bowel disease / / 23128233 rs16907269 chr9 93970272 T C 1.15E-05 Cervical cancer / / 24700089 rs16907273 chr9 93970365 C T 9.57E-06 Cervical cancer / / 24700089 rs773506 chr9 93975471 G A 6.00E-06 Type 2 diabetes nephropathy / / 21150874 rs773506 chr9 93975471 G A 3.27E-04 Type 2 diabetes / / 22238593 rs9785225 chr9 93982492 G A 2.70E-05 Bone mineral density (BMD),in women AUH intron 20164292 rs16907323 chr9 94025459 T C 5.91E-04 Alzheimer's disease AUH intron 17998437 rs12238387 chr9 94034568 A G 9.42E-05 Cervical cancer AUH intron 24700089 rs10512210 chr9 94048529 C T 8.39E-04 Multiple complex diseases AUH intron 17554300 rs10512210 chr9 94048529 C T 8.74E-05 Alzheimer's disease AUH intron 17998437 rs1757659 chr9 94087402 A G 9.90E-04 Acute lung injury AUH intron 22295056 rs10991892 chr9 94102162 A G 2.37E-06 Systemic lupus erythematosus AUH intron pha002867 rs10991892 chr9 94102162 A G 8.01E-04 Myocardial Infarction AUH intron pha002883 rs10512211 chr9 94104260 C G 7.65E-04 Alzheimer's disease AUH intron 17998437 rs4480236 chr9 94107347 G A 7.83E-04 Multiple complex diseases AUH intron 17554300 rs10991906 chr9 94126373 C T 2.70E-05 Urinary metabolites / / 21572414 rs10991911 chr9 94137176 G A 9.56E-05 Triglycerides / / pha003080 rs894962 chr9 94161700 T C 6.81E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7024443 chr9 94164373 C A 5.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1758695 chr9 94165889 G T 3.19E-04 Acute lung injury / / 22295056 rs12683158 chr9 94187265 C T 3.20E-05 Type 2 diabetes / / 17463248 rs13297268 chr9 94188141 G A 3.00E-05 Type 2 diabetes / / 17463248 rs13289738 chr9 94192146 G T 3.30E-05 Type 2 diabetes / / 17463248 rs774227 chr9 94193941 G A 2.34E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs809568 chr9 94199485 A G 6.18E-04 Type 2 diabetes / / 17463246 rs10820857 chr9 94222921 G A 1.29E-04 Alcohol dependence / / 20201924 rs1591068 chr9 94225537 G A 8.21E-05 Alcohol dependence / / 20201924 rs1591068 chr9 94225537 G A 8.21E-05 Alcoholism / / pha002891 rs10820859 chr9 94228244 G A 1.94E-05 Type 2 diabetes / / 17463246 rs1855065 chr9 94235377 T G 6.74E-04 Type 2 diabetes / / 17463246 rs1855065 chr9 94235377 T G 4.28E-05 Alcohol dependence / / 20201924 rs1855065 chr9 94235377 T G 4.28E-05 Alcoholism / / pha002891 rs7038686 chr9 94243567 G A 3.47E-06 Hirschsprung's disease / / 19196962 rs12336222 chr9 94246218 C T 8.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs4743837 chr9 94246772 G A 6.70E-05 Major depressive disorder / / 22472876 rs4743838 chr9 94246879 G A 3.76E-05 Tardive dyskinesia / / 20939080 rs6479347 chr9 94268566 T A 4.50E-04 Breast cancer and prostate cancer / / 17903305 rs10991963 chr9 94276025 C A 1.36E-04 Type 2 diabetes / / 17463246 rs10820871 chr9 94291624 G A 1.30E-04 Type 2 diabetes / / 17463246 rs16907578 chr9 94295659 G A 1.33E-04 Type 2 diabetes / / 17463246 rs7045588 chr9 94297629 C T 2.00E-04 Type 2 diabetes / / 17463246 rs7030790 chr9 94297650 A G 1.96E-04 Type 2 diabetes / / 17463246 rs7030896 chr9 94297697 A G 1.11E-04 Type 2 diabetes / / 17463246 rs10481715 chr9 94310766 G A 8.96E-04 Stroke / / pha002887 rs2131301 chr9 94321069 G T 7.58E-05 Major depressive disorder / / 22472876 rs10991988 chr9 94326186 C T 2.08E-04 Type 2 diabetes / / 17463246 rs7867934 chr9 94326393 C T 2.43E-04 Type 2 diabetes / / 17463246 rs902923 chr9 94333599 C T 4.60E-04 Suicidal ideation / / 22030708 rs902923 chr9 94333599 C T 5.48E-05 Major depressive disorder / / 22472876 rs9409623 chr9 94373806 G A 7.86E-05 Major depressive disorder (broad) / / 20038947 rs9409443 chr9 94376908 T A 5.85E-05 Major depressive disorder (broad) / / 20038947 rs7027715 chr9 94378253 G A 8.82E-05 Major depressive disorder (broad) / / 20038947 rs2131304 chr9 94403445 C A 5.04E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10992029 chr9 94408117 A C 1.09E-04 Colorectal cancer / / 24448986 rs2076773 chr9 94414784 G A 6.11E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs2076773 chr9 94414784 G A 9.85E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs7032274 chr9 94420140 T C 6.40E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs7032274 chr9 94420140 T C 7.08E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs10992039 chr9 94428149 T G 2.92E-05 Cytomegalovirus antibody response / / 21993531 rs2892376 chr9 94445809 A G 9.27E-04 Parkinson's disease / / 17052657 rs10820897 chr9 94447593 G A 2.66E-05 Cytomegalovirus antibody response / / 21993531 rs923769 chr9 94456714 C T 5.01E-05 Blood Pressure / / pha003050 rs4743850 chr9 94463001 C A 7.67E-04 Nicotine dependence / / 17158188 rs4073735 chr9 94488415 C T 7.65E-04 Alcohol dependence ROR2 intron 21314694 rs16907725 chr9 94510145 G A 8.07E-04 Type 2 diabetes ROR2 intron 17463246 rs16907764 chr9 94534917 T G 1.16E-04 Sudden cardiac arrest ROR2 intron 21658281 rs7029673 chr9 94542162 G A 8.62E-04 Tourette syndrome ROR2 intron 22889924 rs3935382 chr9 94546564 C T 7.48E-04 Response to TNF antagonist treatment ROR2 intron 21061259 rs3935382 chr9 94546564 C T 2.02E-05 Kawasaki disease ROR2 intron 22446961 rs12343368 chr9 94578495 T C 1.68E-06 Glycemic traits (pregnancy) ROR2 intron 23903356 rs12343368 chr9 94578495 T C 3.11E-06 Glycemic traits (pregnancy) ROR2 intron 23903356 rs11790808 chr9 94588498 T C 0.0000115 Otitis media (children 3 years old or younger) ROR2 intron 23133572 rs7856144 chr9 94594505 C T 6.02E-04 Aortic root size ROR2 intron 21223598 rs7858435 chr9 94651415 A G 6.13E-04 Type 2 diabetes ROR2 intron 17463246 rs4430151 chr9 94662474 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) ROR2 intron 20708005 rs16907979 chr9 94683050 T C 9.25E-04 Suicide attempts in bipolar disorder ROR2 intron 21423239 rs3858082 chr9 94696219 A C 5.29E-05 Multiple complex diseases ROR2 intron 17554300 rs7871522 chr9 94703861 G A 1.80E-05 Urinary metabolites ROR2 intron 21572414 rs1954599 chr9 94729773 A T 1.26E-04 Sudden cardiac arrest / / 21658281 rs7867394 chr9 94763136 G A 1.31E-04 Multiple complex diseases / / 17554300 rs7872515 chr9 94822540 G A 6.00E-07 Bipolar disorder and schizophrenia SPTLC1 intron 22688191 rs7860518 chr9 94826465 C T 4.64E-05 Coronary heart disease SPTLC1 intron pha003031 rs7856177 chr9 94839342 A G 7.60E-06 Coronary heart disease SPTLC1 intron pha003031 rs1970121 chr9 94870152 C A 4.63E-04 Suicide,with and without major depression SPTLC1 intron 22059935 rs11790991 chr9 94873324 A G 8.90E-06 Urinary metabolites SPTLC1 intron 21572414 rs10992234 chr9 94877836 A G 6.38E-06 Coronary heart disease SPTLC1 nearGene-5 pha003031 rs7023075 chr9 94882079 G A 8.04E-05 Alzheimer's disease / / 17998437 rs7023075 chr9 94882079 G A 1.47E-04 Alzheimer's disease / / pha002879 rs10992241 chr9 94891778 T C 5.31E-06 Male-pattern baldness / / 18849994 rs11794664 chr9 94925680 A C 5.24E-05 Smoking quantity / / 24665060 rs10992260 chr9 94935081 C T 3.52E-05 Serum metabolites / / 19043545 rs13292103 chr9 94945832 C A 1.50E-05 Urinary metabolites / / 21572414 rs556155 chr9 94985637 T C 9.69E-04 Alcohol dependence IARS missense 21314694 rs10761149 chr9 94988945 T C 7.51E-04 Type 2 diabetes IARS intron 17463246 rs10761150 chr9 95006407 G C 4.22E-05 Serum metabolites IARS intron 19043545 rs4743869 chr9 95010216 T C 5.83E-05 Inflammation IARS intron pha002897 rs9299403 chr9 95018903 A G 5.84E-05 Serum metabolites IARS intron 19043545 rs9299403 chr9 95018903 A G 1.80E-05 Urinary metabolites IARS intron 21572414 rs1152757 chr9 95020034 T A 5.87E-04 Type 2 diabetes IARS intron 17463246 rs10120980 chr9 95020914 A G 7.74E-05 Serum metabolites IARS intron 19043545 rs10820964 chr9 95041636 G A 3.50E-05 Elbow pain IARS intron pha003008 rs10739927 chr9 95052081 G T 4.43E-05 Elbow pain IARS intron pha003008 rs710162 chr9 95059790 T A 3.03E-05 Serum metabolites NOL8 UTR-3 19043545 rs710162 chr9 95059790 T A 9.70E-06 Urinary metabolites NOL8 UTR-3 21572414 rs6479417 chr9 95064562 G C 3.54E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines NOL8 intron 21844884 rs9409664 chr9 95070095 A G 5.15E-05 Inflammation NOL8 intron pha002897 rs3758229 chr9 95078852 C A 8.01E-05 Serum metabolites NOL8 intron 19043545 rs7023004 chr9 95098712 A G 3.89E-05 Elbow pain CENPP intron pha003008 rs10820967 chr9 95101729 G C 1.22E-05 Serum metabolites CENPP intron 19043545 rs10820967 chr9 95101729 G C 9.23E-04 Alcohol dependence CENPP intron 21314694 rs10115222 chr9 95128149 T C 2.77E-05 Serum metabolites CENPP intron 19043545 rs7853859 chr9 95151377 T C 8.80E-06 Urinary metabolites OGN intron 21572414 rs9299404 chr9 95170338 G A 2.64E-05 Serum metabolites CENPP intron 19043545 rs9299404 chr9 95170338 G A 1.30E-05 Urinary metabolites CENPP intron 21572414 rs7045409 chr9 95201540 T A 1.14E-05 Serum metabolites CENPP intron 19043545 rs7045409 chr9 95201540 T A 1.00E-05 Urinary metabolites CENPP intron 21572414 rs10820978 chr9 95220601 G T 4.14E-04 Alcohol dependence ASPN intron 21314694 rs331377 chr9 95243549 A G 1.76E-04 Insulin resistance ASPN intron 21901158 rs4744134 chr9 95246833 G A 5.00E-05 Serum metabolites CENPP intron 19043545 rs4744134 chr9 95246833 G A 7.70E-06 Urinary metabolites CENPP intron 21572414 rs7869742 chr9 95256174 A G 4.16E-05 Elbow pain ECM2 UTR-3 pha003008 rs331380 chr9 95256519 C T 6.90E-05 Inflammation ECM2 intron pha002897 rs331379 chr9 95261104 C T 1.80E-04 Insulin resistance ECM2 intron 21901158 rs230222 chr9 95265558 C G 6.79E-04 Type 2 diabetes ECM2 intron 17463246 rs4744136 chr9 95275024 G A 4.74E-05 Serum metabolites ECM2 intron 19043545 rs4744136 chr9 95275024 G A 8.50E-06 Urinary metabolites ECM2 intron 21572414 rs4743874 chr9 95288323 C A 8.98E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ECM2 intron 21844884 rs2104533 chr9 95290456 G A 7.44E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ECM2 intron 21844884 rs2895219 chr9 95300559 T C 7.44E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CENPP intron 21844884 rs10820986 chr9 95312961 T G 4.65E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CENPP intron 21844884 rs10992367 chr9 95323135 C T 2.45E-04 Type 2 diabetes CENPP intron 17463246 rs10820990 chr9 95323297 A G 1.58E-05 Serum metabolites CENPP intron 19043545 rs10820990 chr9 95323297 A G 1.00E-05 Urinary metabolites CENPP intron 21572414 rs7848391 chr9 95337520 C T 9.64E-05 Serum metabolites CENPP intron 19043545 rs7848391 chr9 95337520 C T 1.40E-05 Urinary metabolites CENPP intron 21572414 rs2296669 chr9 95373790 C T 6.34E-05 Serum metabolites CENPP intron 19043545 rs2148537 chr9 95380726 G A 1.21E-04 Type 2 diabetes IPPK intron 17463246 rs7043114 chr9 95387983 C T 4.68E-04 Amyotrophic Lateral Sclerosis IPPK intron 17362836 rs10820998 chr9 95419269 A C 4.45E-05 Type 2 diabetes IPPK intron 17463246 rs7857105 chr9 95427757 C T 1.12E-05 Type 2 diabetes IPPK intron 17463246 rs7857105 chr9 95427757 C T 8.80E-04 Alzheimer's disease IPPK intron 17998437 rs9969804 chr9 95429120 A C 4.68E-04 Amyotrophic Lateral Sclerosis IPPK intron 17362836 rs9969804 chr9 95429120 A C 8.00E-17 Height IPPK intron 20881960 rs912261 chr9 95442033 T C 4.67E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs10821008 chr9 95487497 G A 6.79E-04 Alcohol dependence BICD2 intron 21314694 rs10992447 chr9 95509733 C T 2.21E-04 Type 2 diabetes BICD2 intron 17463246 rs10992448 chr9 95514833 T A 1.58E-04 Type 2 diabetes BICD2 intron 17463246 rs912262 chr9 95525557 A G 9.14E-05 Serum metabolites BICD2 intron 19043545 rs10992460 chr9 95536447 A G 1.46E-04 Type 2 diabetes / / 17463246 rs10992463 chr9 95541775 C T 1.48E-04 Celiac disease / / 23936387 rs12236788 chr9 95542654 G A 8.18E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs7868651 chr9 95555939 T G 2.69E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7855203 chr9 95557334 C T 7.29E-04 Type 2 diabetes / / 17463246 rs10992471 chr9 95559505 G A 2.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs2018717 chr9 95560505 A G 9.95E-04 Multiple complex diseases / / 17554300 rs7049211 chr9 95583518 G C 9.91E-04 Response to cytidine analogues (gemcitabine) ANKRD19P intron 24483146 rs7873259 chr9 95598200 A G 1.18E-05 Longevity ANKRD19P intron 21612516 rs7045305 chr9 95599825 G A 5.40E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4744151 chr9 95630376 T C 1.40E-05 Urinary metabolites ZNF484 intron 21572414 rs6479434 chr9 95630981 A G 2.10E-05 Urinary metabolites ZNF484 intron 21572414 rs1575437 chr9 95669345 T G 1.14E-05 Serum metabolites / / 19043545 rs7872848 chr9 95679388 A G 3.45E-05 Serum metabolites / / 19043545 rs7035868 chr9 95683366 T G 3.22E-05 Serum metabolites / / 19043545 rs10992535 chr9 95688099 T G 2.73E-04 Schizophrenia / / 19197363 rs10821046 chr9 95708192 T C 5.45E-05 Glucose levels / / pha003058 rs6479445 chr9 95766471 A T 8.27E-04 Multiple complex diseases FGD3 intron 17554300 rs10122401 chr9 95772036 T C 5.50E-05 Elbow pain FGD3 intron pha003008 rs10761189 chr9 95772228 A G 3.97E-05 Glucose levels FGD3 intron pha003058 rs10761191 chr9 95781040 T C 3.89E-05 Basophils FGD3 intron pha003087 rs6479446 chr9 95782991 T C 1.67E-04 Multiple complex diseases FGD3 intron 17554300 rs11788432 chr9 95788623 T C 2.84E-04 Multiple complex diseases FGD3 intron 17554300 rs11788432 chr9 95788623 T C 2.10E-05 Urinary metabolites FGD3 intron 21572414 rs10992619 chr9 95823747 T C 2.05E-05 Parkinson's disease SUSD3 intron 21738487 rs10115063 chr9 95824005 A C 4.94E-04 Multiple complex diseases SUSD3 intron 17554300 rs10992622 chr9 95830197 A G 2.99E-04 Amyotrophic Lateral Sclerosis SUSD3 intron 17827064 rs7859109 chr9 95837818 A G 1.07E-04 Amyotrophic Lateral Sclerosis SUSD3 intron 17827064 rs1131773 chr9 95840256 A G 9.39E-04 Amyotrophic Lateral Sclerosis SUSD3 missense 17827064 rs9696357 chr9 95845152 C T 3.63E-07 Longevity,exceptional SUSD3 intron 20595579 rs9696357 chr9 95845152 C T 9.08E-05 Systemic sclerosis SUSD3 intron 21750679 rs4077822 chr9 95859739 T C 2.00E-05 Urinary metabolites C9orf89 intron 21572414 rs4744175 chr9 95869726 G A 5.28E-05 Cognitive impairment induced by topiramate C9orf89 intron 22091778 rs13285107 chr9 95881054 C T 5.69E-04 Alcohol dependence / / 20201924 rs2275848 chr9 95887320 G T 1.00E-06 Obesity (early onset extreme) NINJ1 missense 23563609 rs7875586 chr9 95891998 T C 5.40E-06 Urinary metabolites NINJ1 intron 21572414 rs4743895 chr9 95905750 C T 6.30E-06 Urinary metabolites / / 21572414 rs6479456 chr9 95909429 T C 3.35E-04 Multiple complex diseases / / 17554300 rs6479456 chr9 95909429 T C 6.30E-06 Urinary metabolites / / 21572414 rs10821080 chr9 95930572 C T 4.60E-04 Alzheimer's disease (late onset) / / 21379329 rs4744188 chr9 95950461 C T 7.84E-05 Alzheimer's disease (late onset) WNK2 intron 21379329 rs10992675 chr9 95963316 T C 3.35E-04 Sudden cardiac arrest WNK2 intron 21658281 rs7874101 chr9 95991895 T C 4.53E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) WNK2 intron 24023788 rs2398820 chr9 95996573 G A 6.31E-04 Response to taxane treatment (placlitaxel) WNK2 intron 23006423 rs10761203 chr9 96021312 G A 9.26E-05 Alzheimer's disease (late onset) WNK2 missense 21379329 rs10512233 chr9 96050356 C T 7.90E-04 Type 2 diabetes WNK2 intron 17463246 rs2306183 chr9 96052179 G A,C,T 1.57E-04 Alzheimer's disease (late onset) WNK2 intron 21379329 rs2306183 chr9 96052179 G A,C,T 9.70E-04 Pulmonary function WNK2 intron 23932459 rs16936752 chr9 96063690 T G 1.40E-11 Progranulin levels WNK2 intron 21087763 rs16936752 chr9 96063690 T G 1.40E-11 Myocardial infarction WNK2 intron 21211798 rs3001450 chr9 96085370 C T 3.91E-05 Blood Pressure and Arterial Stiffness C9orf129 intron 17903302 rs4633120 chr9 96093865 G T 2.77E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) C9orf129 intron 24023788 rs2927567 chr9 96096243 A C 1.63E-04 Alzheimer's disease (late onset) C9orf129 intron 21379329 rs1931371 chr9 96138557 A G 1.81E-05 F-cell distribution / / 21326311 rs2086106 chr9 96144349 T C 4.37E-04 Type 2 diabetes / / 17463246 rs2086106 chr9 96144349 T C 8.16E-04 Alcohol dependence / / 21314694 rs4401932 chr9 96147077 T C 1.99E-04 Alzheimer's disease (late onset) / / 21379329 rs2841680 chr9 96161642 G A 9.37E-04 Coronary heart disease / / 21971053 rs2841680 chr9 96161642 G A 9.03E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10992722 chr9 96163761 C A 3.87E-04 Multiple complex diseases / / 17554300 rs3933795 chr9 96185673 T C 9.24E-04 Coronary heart disease / / 21971053 rs10116422 chr9 96357739 A C 0.00001879 Sarcoidosis PHF2 intron 22952805 rs10117691 chr9 96357925 T C 0.0000705 Sarcoidosis PHF2 intron 22952805 rs10114002 chr9 96358030 C T 0.00006833 Sarcoidosis PHF2 intron 22952805 rs2254715 chr9 96363700 C T 3.39E-04 Alzheimer's disease (late onset) PHF2 intron 21379329 rs2994368 chr9 96376900 A G 1.96E-04 Multiple complex diseases PHF2 intron 17554300 rs2250236 chr9 96377797 C T 1.78E-04 Alzheimer's disease (late onset) PHF2 intron 21379329 rs12551314 chr9 96379797 C A 4.30E-05 Osteoarthritis (hip) PHF2 intron 23989986 rs12238738 chr9 96393807 A G 2.08E-05 Formal thought disorder in schizophrenia PHF2 intron 22648509 rs2001589 chr9 96395801 G A 4.14E-05 Formal thought disorder in schizophrenia PHF2 intron 22648509 rs10821191 chr9 96414935 T C 2.13E-05 Formal thought disorder in schizophrenia PHF2 intron 22648509 rs11793637 chr9 96415899 A G 5.55E-04 Alcohol dependence PHF2 intron 21314694 rs7040340 chr9 96443910 G A 2.24E-05 Formal thought disorder in schizophrenia / / 22648509 rs6479503 chr9 96444486 A G 5.79E-04 Taste perception / / 22132133 rs7855940 chr9 96535966 C G 7.14E-04 Type 2 diabetes / / 17463246 rs7027203 chr9 96562563 A C 6.00E-06 DNA methylation (variation) / / 23725790 rs10761280 chr9 96569343 A G 9.17E-04 Type 2 diabetes / / 17463246 rs10821242 chr9 96629896 T C 5.30E-04 Body mass index / / 21701565 rs10114408 chr9 96631134 A T 3.00E-06 Colorectal cancer / / 23300701 rs10117869 chr9 96631796 G A 4.63E-04 Body mass index / / 21701565 rs10821258 chr9 96657324 C T 3.69E-05 Body mass index / / 21701565 rs10821258 chr9 96657324 C T 7.13E-04 Body mass index / / 21701565 rs12684081 chr9 96714981 G A 3.94E-04 Taste perception BARX1 intron 22132133 rs11789015 chr9 96716028 A G 1.00E-09 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) BARX1 intron 24121790 rs11789015 chr9 96716028 A G 2.00E-07 Esophageal adenocarcinoma BARX1 intron 24121790 rs11789015 chr9 96716028 A G 5.00E-06 Barrett's esophagus BARX1 intron 24121790 rs10993006 chr9 96729129 C T 5.29E-04 Stroke / / pha002886 rs1316935 chr9 96729962 C T 5.19E-04 Stroke / / pha002886 rs2153060 chr9 96742545 G A 3.01E-04 Type 2 diabetes / / 17463246 rs1316814 chr9 96742718 A G 7.63E-04 Type 2 diabetes / / 17463246 rs9695457 chr9 96743245 G A 5.41E-05 Insulin resistance / / 21901158 rs1592153 chr9 96745836 A C 8.97E-04 Type 2 diabetes / / 17463246 rs1592153 chr9 96745836 A C 1.80E-04 Insulin resistance / / 21901158 rs2153058 chr9 96746126 G A 8.96E-04 Type 2 diabetes / / 17463246 rs10761309 chr9 96753722 T C 3.04E-04 Insulin resistance / / 21901158 rs2225458 chr9 96756805 T C 3.44E-04 Type 2 diabetes / / 17463246 rs987511 chr9 96757868 G A 7.37E-04 Type 2 diabetes / / 17463246 rs2150624 chr9 96776609 T C 3.19E-04 Schizophrenia / / 19197363 rs1539282 chr9 96827424 T C 6.60E-05 Immunoglobulin A PTPDC1 intron 20694011 rs6479527 chr9 96858411 G A 2.00E-06 Esophageal adenocarcinoma PTPDC1 intron 24121790 rs6479527 chr9 96858411 G A 4.74E-05 Barrett's esophagus PTPDC1 intron 24121790 rs6479527 chr9 96858411 G A 5.84E-08 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) PTPDC1 intron 24121790 rs10821295 chr9 96869147 G A 3.18E-05 Insulin resistance PTPDC1 intron 21901158 rs3909256 chr9 96889505 T C 2.79E-04 Taste perception / / 22132133 rs1257763 chr9 96893945 A G 1.00E-09 Height / / 20881960 rs10512230 chr9 96916230 G T 2.20E-05 Urinary metabolites / / 21572414 rs10993096 chr9 96975306 G T 3.22E-05 Personality dimensions / / 22628180 rs10821317 chr9 96975668 C T 3.11E-05 Personality dimensions / / 22628180 rs7030004 chr9 96986521 T G 2.85E-05 Personality dimensions / / 22628180 rs9409706 chr9 96990968 T C 2.82E-05 Personality dimensions / / 22628180 rs9409498 chr9 96994063 G A 2.94E-05 Personality dimensions / / 22628180 rs9409709 chr9 97007046 T C 2.89E-05 Personality dimensions / / 22628180 rs9409710 chr9 97009024 A G 2.85E-05 Personality dimensions / / 22628180 rs3118756 chr9 97047402 C T 2.55E-04 Multiple complex diseases ZNF169 intron 17554300 rs3131910 chr9 97056183 A C 3.58E-04 Multiple complex diseases ZNF169 intron 17554300 rs10993160 chr9 97068926 A G 6.00E-07 Body mass index / / 22344221 rs1752784 chr9 97177826 C T 7.00E-06 Amyotrophic Lateral Sclerosis HIATL1 intron 17362836 rs4744346 chr9 97211784 C T 6.15E-06 Rheumatoid arthritis HIATL1 intron 19503088 rs9409787 chr9 97261572 G A 6.92E-05 ldl cholesterol / / pha003076 rs7860616 chr9 97265947 A G 7.68E-04 Schizophrenia / / 19197363 rs12342274 chr9 97280338 C T 1.80E-04 Sudden cardiac arrest / / 21658281 rs16910061 chr9 97314741 G A 3.00E-06 Height / / 19893584 rs11998973 chr9 97314815 T A 3.60E-04 Aortic root size / / 21223598 rs600130 chr9 97338996 C T 7.05E-04 Multiple complex diseases FBP2 intron 17554300 rs600130 chr9 97338996 C T 2.14E-04 HIV-1 viral setpoint FBP2 intron 17641165 rs35600708 chr9 97356243 C T 8.73E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2274689 chr9 97365542 A C 7.73E-06 Personality dimensions FBP1 UTR-3 22628180 rs4111369 chr9 97403720 C T 5.37E-05 Major depressive disorder (broad) FBP1 nearGene-5 20038947 rs7864831 chr9 97404594 C T 1.86E-05 Sudden cardiac arrest / / 21658281 rs10761348 chr9 97405262 G C 2.90E-05 Coffee consumption / / 21357676 rs7035325 chr9 97409437 G A 2.55E-05 Suicide attempts in depression or bipolar disorder / / 24964207 rs6479562 chr9 97429160 A G 4.44E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10124091 chr9 97440480 G A 1.27E-04 Type 2 diabetes / / 17463246 rs10124091 chr9 97440480 G A 9.10E-05 Personality dimensions / / 18957941 rs4460442 chr9 97443341 A C 7.51E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs10125337 chr9 97444038 T C 4.00E-06 Obesity-related traits / / 23251661 rs10821383 chr9 97445923 A G 5.37E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10124217 chr9 97447430 C T 1.27E-04 Type 2 diabetes / / 17463246 rs10124217 chr9 97447430 C T 9.10E-05 Personality dimensions / / 18957941 rs12554486 chr9 97463435 G T 6.11E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10120534 chr9 97463801 A C 3.92E-06 Obesity-related traits / / 23251661 rs10117499 chr9 97464447 C A 1.58E-04 Type 2 diabetes / / 17463246 rs12344604 chr9 97466882 C T 4.46E-04 Type 2 diabetes / / 17463246 rs7847004 chr9 97466973 C T 5.95E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7847107 chr9 97467025 C T 4.44E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1016013 chr9 97476484 A G 3.61E-05 Longevity / / 22279548 rs4744370 chr9 97477793 C T 1.63E-12 Polycystic ovary syndrome / / 22885925 rs3887267 chr9 97499184 A T 3.51E-06 Uric acid levels C9orf3 intron 21294900 rs16911678 chr9 97517729 A G 5.84E-04 Multiple complex diseases C9orf3 intron 17554300 rs60120 chr9 97525103 A C 3.51E-06 Uric acid levels C9orf3 intron 21294900 rs438742 chr9 97532364 A G 3.51E-06 Uric acid levels C9orf3 intron 21294900 rs562605 chr9 97536704 G A 6.77E-06 Uric acid levels C9orf3 intron 21294900 rs356148 chr9 97541577 G A 6.77E-06 Uric acid levels C9orf3 intron 21294900 rs10512235 chr9 97549812 A G 2.42E-04 Stroke (pediatric) C9orf3 intron 22990015 rs356135 chr9 97550495 G A 3.50E-04 Aortic root size C9orf3 intron 21223598 rs356128 chr9 97571230 G C 3.47E-06 Uric acid levels C9orf3 intron 21294900 rs7855781 chr9 97578438 A G 3.47E-06 Uric acid levels C9orf3 intron 21294900 rs894425 chr9 97585017 T C 3.47E-06 Uric acid levels C9orf3 intron 21294900 rs1867102 chr9 97627767 A G 1.78E-04 Longevity C9orf3 intron 22279548 rs10761362 chr9 97647314 A G 9.16E-08 Adiponectin levels C9orf3 intron 20887962 rs4385527 chr9 97648587 G A 5.87E-09 Polycystic ovary syndrome C9orf3 intron 22885925 rs10821415 chr9 97713459 C A 4.00E-11 Atrial fibrillation C9orf3 intron 22544366 rs2404295 chr9 97723868 T C 5.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C9orf3 intron 20877124 rs3802458 chr9 97741274 A G 4.06E-04 Multiple complex diseases C9orf3 intron 17554300 rs3802458 chr9 97741274 A G 4.00E-06 Erectile dysfunction and prostate cancer treatment C9orf3 intron 20932654 rs3802457 chr9 97741336 G A 5.00E-14 Polycystic ovary syndrome C9orf3 intron 22885925 rs7042271 chr9 97754447 C A 1.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C9orf3 intron 20877124 rs4744426 chr9 97805062 G A 5.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C9orf3 intron 20877124 rs7862156 chr9 97805164 C T 5.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C9orf3 intron 20877124 rs7033633 chr9 97838781 A G 8.07E-04 Multiple complex diseases C9orf3 intron 17554300 rs4647473 chr9 97955070 A G 5.79E-04 Insulin resistance FANCC intron 21901158 rs356689 chr9 97986694 T C 5.36E-04 Multiple complex diseases FANCC intron 17554300 rs356678 chr9 97991935 T C 7.51E-04 Multiple complex diseases FANCC intron 17554300 rs7039117 chr9 98057180 T C 2.55E-23 Gender FANCC intron 22362730 rs356665 chr9 98060631 T C 1.91E-04 Response to cholinesterase inhibitors in Alzheimer's disease FANCC intron 23374588 rs4647355 chr9 98079143 A G 2.33E-04 Response to radiotherapy in cancer (late toxicity) FANCC intron 24785509 rs4647355 chr9 98079143 A G 2.97E-04 Response to radiotherapy in cancer (late toxicity) FANCC intron 24785509 rs17295583 chr9 98145056 G A 3.47E-04 Multiple complex diseases / / 17554300 rs16909856 chr9 98204493 G A 5.99E-08 Pulmonary function / / 20010835 rs16909859 chr9 98204792 G A 6.74E-08 Pulmonary function PTCH1 nearGene-3 20010835 rs16909865 chr9 98207302 C G 1.16E-06 Pulmonary function PTCH1 UTR-3 20010835 rs16909865 chr9 98207302 C G 4.67E-05 Cognitive test performance PTCH1 UTR-3 20125193 rs2282043 chr9 98212608 C T 1.75E-07 Pulmonary function PTCH1 intron 20010835 rs16909898 chr9 98231008 A G 5.00E-07 Pulmonary function PTCH1 intron 20010835 rs16909898 chr9 98231008 A G 8.00E-12 Pulmonary function (interaction) PTCH1 intron 23284291 rs16909902 chr9 98236202 A G 6.39E-04 Multiple complex diseases PTCH1 intron 17554300 rs3824488 chr9 98236664 C T 8.83E-08 Pulmonary function PTCH1 intron 20010835 rs2282041 chr9 98248387 A G 5.47E-08 Pulmonary function PTCH1 intron 20010835 rs473902 chr9 98256235 T G 2.00E-17 Height PTCH1 intron 20881960 rs10512249 chr9 98256309 G A 2.79E-08 Pulmonary function PTCH1 intron 20010835 rs10512249 chr9 98256309 G A 9.35E-04 White matter integrity PTCH1 intron 22425255 rs10512248 chr9 98259703 T G 4.00E-11 Height PTCH1 intron 18391952 rs10512248 chr9 98259703 T G 1.10E-14 Height PTCH1 intron 21194676 rs10512248 chr9 98259703 T G 2.30E-08 Height PTCH1 intron 21194676 rs10512248 chr9 98259703 T G 9.00E-08 Height PTCH1 intron 21194676 rs10512247 chr9 98296403 C T 2.35E-06 Pulmonary function / / 20010835 rs16909975 chr9 98307129 G A 6.54E-06 Pulmonary function / / 20010835 rs16909978 chr9 98307990 G A 4.00E-06 Pulmonary function / / 20010835 rs16909981 chr9 98313032 G C 7.96E-06 Pulmonary function / / 20010835 rs1932075 chr9 98360116 C T 8.63E-04 Alcohol dependence / / 21314694 rs6478058 chr9 98360213 T C 9.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs7862599 chr9 98360258 T C 4.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs6478060 chr9 98360331 T A 4.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs10985640 chr9 98365343 A G 8.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs10987971 chr9 98371272 G A 2.34E-05 Insulin resistance / / 21901158 rs4743090 chr9 98376367 C T 4.91E-04 Insulin resistance / / 21901158 rs10988802 chr9 98376699 G A 4.00E-06 Chemerin levels / / 20237162 rs10988805 chr9 98376726 A T 9.89E-06 Insulin resistance / / 21901158 rs4743091 chr9 98377191 C T 5.05E-04 Insulin resistance / / 21901158 rs7041767 chr9 98377896 A G 9.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs7854560 chr9 98382950 C T 3.69E-04 Insulin resistance / / 21901158 rs10988997 chr9 98384487 C G 3.23E-05 Insulin resistance / / 21901158 rs10989157 chr9 98388345 G A 8.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs4742700 chr9 98395621 A G 8.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs4743120 chr9 98397459 T C 5.80E-04 Smoking behavior / / 20418888 rs4743120 chr9 98397459 T C 8.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs4743123 chr9 98400242 T C 7.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs10990447 chr9 98412987 G A 4.73E-04 Multiple complex diseases / / 17554300 rs10760968 chr9 98415690 G A 4.01E-04 Multiple complex diseases / / 17554300 rs17299607 chr9 98422513 G A 9.13E-05 Type 2 diabetes / / 17463246 rs10739891 chr9 98427543 C A 6.77E-05 Cognitive test performance / / 20125193 rs11790994 chr9 98429266 C G 2.00E-07 Inattentive symptoms / / 18821565 rs4743148 chr9 98430574 A G 1.00E-05 Type 2 diabetes / / 17460697 rs10820751 chr9 98432200 G A 1.90E-05 White matter hyperintensity burden / / 21681796 rs10991564 chr9 98434305 C T 9.20E-05 White matter hyperintensity burden / / 21681796 rs10991595 chr9 98435028 C G 9.40E-05 White matter hyperintensity burden / / 21681796 rs12552255 chr9 98437158 A G 2.72E-04 Taste perception / / 22132133 rs12552255 chr9 98437158 A G 1.37E-06 Dilated cardiomyopathy / / 23853074 rs1970200 chr9 98439324 C T 6.86E-04 Type 2 diabetes / / 17463246 rs4743181 chr9 98452793 G A 5.83E-04 Myocardial Infarction / / pha002883 rs17372603 chr9 98452966 G A 4.48E-04 Type 2 diabetes / / 17463246 rs369791 chr9 98469778 C A 9.53E-04 Alzheimer's disease / / 17998437 rs1977620 chr9 98475674 C T 9.38E-06 Serum metabolites / / 19043545 rs700976 chr9 98497395 C T 6.67E-04 Coronary heart disease / / 21971053 rs10981787 chr9 98516889 C T 8.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10981895 chr9 98519783 C T 7.91E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7042092 chr9 98533383 A C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC100506667 intron 22628534 rs10759835 chr9 98546523 T G 8.46E-05 Cognitive test performance / / 20125193 rs4743327 chr9 98548528 G A 5.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs12375861 chr9 98556065 C G 8.55E-04 Multiple complex diseases / / 17554300 rs4742763 chr9 98558855 T C 8.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs816677 chr9 98568543 C T 6.93E-04 Heart Failure / / pha002884 rs17303073 chr9 98573990 C G 7.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs4743351 chr9 98576622 C G 7.76E-04 Suicide attempts in bipolar disorder LINC00476 intron 21423239 rs4742769 chr9 98584685 G A 7.40E-04 Suicide attempts in bipolar disorder LINC00476 intron 21423239 rs12551596 chr9 98586889 C T 1.70E-05 Urinary metabolites LINC00476 intron 21572414 rs2149564 chr9 98607989 G T 4.14E-04 Lung function (forced expiratory volume in 1 second) LINC00476 intron 24023788 rs10739632 chr9 98616743 G A 8.20E-04 Multiple complex diseases LINC00476 intron 17554300 rs56108623 chr9 98638306 C T 0.00017 Breast cancer C9orf102 missense 23555315 rs689619 chr9 98683971 G A 7.70E-04 Type 2 diabetes and 6 quantitative traits C9orf102 intron 17848626 rs2274653 chr9 98691257 G A 6.15E-04 Type 2 diabetes C9orf102 intron 17846125 rs10512245 chr9 98691811 A G 1.40E-04 Blood Pressure and Arterial Stiffness C9orf102 intron 17903302 rs689597 chr9 98700071 A G 2.00E-05 Personality dimensions C9orf102 intron 18957941 rs689979 chr9 98718673 T C 1.36E-04 Response to diuretic therapy in hypertension C9orf102 intron 23753411 rs10739787 chr9 98739498 G A 7.64E-05 Femoral neck bone geometry / / 22087292 rs10819695 chr9 98762901 C T 7.44E-05 Coronary heart disease / / 24778558 rs10512243 chr9 98775459 G A 8.70E-05 Inflammation / / pha002897 rs238 chr9 98786276 A G 9.07E-04 Parkinson's disease / / 22438815 rs238 chr9 98786276 A G 9.61E-06 Response to diuretic therapy in hypertension / / 23753411 rs1547201 chr9 98816484 T C 4.00E-06 IgG glycosylation / / 23382691 rs1547201 chr9 98816484 T C 7.00E-06 IgG glycosylation / / 23382691 rs4592147 chr9 98817497 A G 2.15E-04 Alzheimer's disease / / 22005930 rs734631 chr9 98818496 C G 4.22E-04 Telomere length / / 23900074 rs10989076 chr9 98821185 G A 8.60E-04 Alzheimer's disease / / 22005930 rs7867155 chr9 98827814 C T 9.00E-07 Anxiety in major depressive disorder / / 24047446 rs10739797 chr9 98828889 A G 1.14E-04 Alzheimer's disease LOC158435 intron 22005930 rs4562454 chr9 98840796 T C 6.34E-05 Multiple sclerosis LOC158435 intron 17660530 rs4548305 chr9 98845617 C A 8.17E-05 Body Mass Index LOC158435 intron pha003022 rs4424387 chr9 98880157 C T 3.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4743597 chr9 98918219 T C 6.82E-04 Premature ovarian failure / / 19508998 rs4743598 chr9 98918433 A G 1.87E-04 Iron levels / / pha002876 rs12353207 chr9 98928974 G A 1.34E-04 Smoking initiation / / 24665060 rs4743611 chr9 98932408 T C 1.46E-04 Multiple complex diseases / / 17554300 rs10512241 chr9 98937662 T C 8.60E-06 Alopecia areata / / 22027810 rs4743619 chr9 98942575 C T 3.40E-05 Personality dimensions / / 18957941 rs1467608 chr9 98945274 G A 2.00E-04 Smoking initiation / / 24665060 rs1467609 chr9 98945338 T C 1.34E-04 Smoking initiation / / 24665060 rs1467612 chr9 98946557 G A 7.65E-05 Smoking initiation / / 24665060 rs7872270 chr9 98947439 C T 4.60E-05 Information processing speed / / 21130836 rs10512240 chr9 98956488 A G 2.25E-04 Smoking initiation / / 24665060 rs4743638 chr9 98962102 C A 8.30E-05 Personality dimensions / / 18957941 rs4743645 chr9 98970521 C T 2.08E-04 Smoking initiation / / 24665060 rs13285532 chr9 98972002 T C 4.65E-04 Aortic root size / / 21223598 rs10989731 chr9 98977432 T C 4.84E-05 Smoking initiation / / 24665060 rs8190560 chr9 99002185 C T 2.00E-06 Smoking initiation HSD17B3 intron 24665060 rs11788785 chr9 99031628 G A 1.80E-04 Weight loss (gastric bypass surgery) HSD17B3 intron 23643386 rs1927885 chr9 99075386 A G 1.91E-04 Multiple complex diseases / / 17554300 rs10126039 chr9 99085363 A C 0.000526 Internal carotid artery thickness (average of near and far walls) SLC35D2 intron 23487405 rs6479272 chr9 99097527 T C 9.00E-06 Non-small cell lung cancer SLC35D2 intron 23144319 rs10820447 chr9 99132044 C T 6.00E-06 Migraine with aura SLC35D2 intron 23793025 rs2025151 chr9 99161512 C G 2.00E-12 Height ZNF367 intron 23563607 rs12002084 chr9 99165576 T C 7.97E-04 Alzheimer's disease ZNF367 intron 24755620 rs13302712 chr9 99260928 A G 6.02E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10978609 chr9 99452968 T G 3.57E-04 Multiple complex diseases / / 17554300 rs112865199 chr9 99452968 T TG 3.57E-04 Multiple complex diseases / / 17554300 rs1596359 chr9 99487607 C T 1.68E-05 Gallbladder cancer / / 22318345 rs10114863 chr9 99509624 C T 1.68E-05 Gallbladder cancer / / 22318345 rs10816533 chr9 99539138 G C 2.00E-06 Height ZNF510 intron 19030899 rs7040493 chr9 99620277 A G 4.60E-05 Hypothyroidism / / 22493691 rs1046795 chr9 99655358 C T 4.30E-05 Hypothyroidism / / 22493691 rs10980421 chr9 99832473 A G 5.69E-04 Multiple complex diseases / / 17554300 rs4484816 chr9 99862098 A G 8.68E-04 Acute lung injury / / 22295056 rs10046806 chr9 99871795 T C 9.41E-04 Acute lung injury / / 22295056 rs13297375 chr9 99894617 C T 5.54E-04 Insulin resistance / / 21901158 rs2001382 chr9 99895662 C T 8.79E-04 Insulin resistance / / 21901158 rs10817160 chr9 99898794 G C 8.19E-04 Insulin resistance / / 21901158 rs10980992 chr9 99946041 C T 3.31E-04 Alcohol dependence ANKRD18CP intron 24277619 rs7866267 chr9 99949910 T G 1.58E-04 Smoking quantity ANKRD18CP intron 24665060 rs7020393 chr9 99964351 A G 1.86E-05 Orofacial clefts ANKRD18CP intron 22419666 rs7020393 chr9 99964351 A G 3.00E-05 Smoking quantity ANKRD18CP intron 24665060 rs35025387 chr9 100004903 A AG 2.40E-04 Urinary metabolites BDAG1 intron 21572414 rs9299202 chr9 100006537 C T 6.04E-04 Multiple complex diseases BDAG1 intron 17554300 rs752243 chr9 100072467 G C 7.66E-04 Suicide attempts in bipolar disorder BDAG1 intron 21423239 rs10981551 chr9 100074148 A G 6.74E-04 Suicide attempts in bipolar disorder BDAG1 intron 21423239 rs4345679 chr9 100083872 G A 9.57E-04 Suicide attempts in bipolar disorder BDAG1 intron 21423239 rs7855956 chr9 100088143 T C 8.15E-04 Suicide attempts in bipolar disorder BDAG1 intron 21423239 rs7040299 chr9 100088519 C T 1.16E-04 Multiple complex diseases BDAG1 intron 17554300 rs12378350 chr9 100089171 T C 7.31E-04 Smoking quantity BDAG1 intron 24665060 rs7026893 chr9 100092515 C T 8.41E-04 Suicide attempts in bipolar disorder BDAG1 intron 21423239 rs7847332 chr9 100093102 T G 9.02E-04 Suicide attempts in bipolar disorder BDAG1 intron 21423239 rs10817448 chr9 100096570 T C 9.56E-04 Suicide attempts in bipolar disorder BDAG1 intron 21423239 rs10981664 chr9 100097344 C T 1.70E-05 Hypertension BDAG1 intron 22384028 rs12553213 chr9 100105428 G T 6.82E-04 Smoking quantity BDAG1 intron 24665060 rs2061634 chr9 100105782 C G 3.01E-05 Behcet's disease C9orf174 missense 19442274 rs2061634 chr9 100105782 C G 4.20E-05 Behcet's disease C9orf174 missense 19442274 rs2061634 chr9 100105782 C G 6.22E-06 Behcet's disease C9orf174 missense 19442274 rs2061634 chr9 100105782 C G 7.16E-06 Behcet's disease C9orf174 missense 19442274 rs10435866 chr9 100107365 A G 9.85E-04 Suicide attempts in bipolar disorder BDAG1 intron 21423239 rs1462087 chr9 100109254 G A 6.15E-04 Suicide attempts in bipolar disorder BDAG1 intron 21423239 rs2401383 chr9 100109518 C T 2.30E-05 Hypertension BDAG1 intron 22384028 rs1462086 chr9 100110484 C T 4.53E-04 Suicide attempts in bipolar disorder BDAG1 intron 21423239 rs4743080 chr9 100111831 A G 3.83E-04 Suicide attempts in bipolar disorder BDAG1 intron 21423239 rs2401384 chr9 100114652 A C 6.82E-04 Smoking quantity BDAG1 intron 24665060 rs1564048 chr9 100114913 C T 6.82E-04 Smoking quantity BDAG1 intron 24665060 rs12683933 chr9 100115009 C T 3.89E-04 Suicide attempts in bipolar disorder BDAG1 intron 21423239 rs4743082 chr9 100116059 T G 6.82E-04 Smoking quantity BDAG1 intron 24665060 rs10981784 chr9 100121536 C T 6.82E-04 Smoking quantity BDAG1 intron 24665060 rs4743083 chr9 100122006 A C 6.82E-04 Smoking quantity BDAG1 intron 24665060 rs2306090 chr9 100132829 T C 6.82E-04 Smoking quantity BDAG1 intron 24665060 rs2045731 chr9 100134667 G A 4.53E-04 Smoking quantity BDAG1 intron 24665060 rs10817492 chr9 100135384 A C 6.40E-04 Suicide attempts in bipolar disorder BDAG1 intron 21423239 rs898870 chr9 100139396 G A 4.12E-04 Smoking quantity C9orf174 UTR-3 24665060 rs7874652 chr9 100141029 A G 5.88E-04 Smoking quantity / / 24665060 rs10981848 chr9 100143699 T A 4.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs17331748 chr9 100144427 A G 3.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs3747510 chr9 100144682 T C 8.01E-04 Smoking quantity / / 24665060 rs10981889 chr9 100149456 C T 6.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs12115447 chr9 100152684 A G 6.96E-04 Smoking quantity / / 24665060 rs3827485 chr9 100153481 G A 6.96E-04 Smoking quantity / / 24665060 rs10817513 chr9 100153594 C A 5.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs10817515 chr9 100153846 C T 5.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs7030698 chr9 100153904 T A 6.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs12553259 chr9 100154080 A C 4.26E-04 Smoking quantity / / 24665060 rs10981916 chr9 100156757 G A 8.56E-04 Suicide attempts in bipolar disorder LOC286359 intron 21423239 rs7862883 chr9 100279009 A G 3.84E-05 Smoking initiation TMOD1 intron 24665060 rs10982508 chr9 100285653 C T 1.93E-05 Triglycerides TMOD1 intron pha003081 rs10982508 chr9 100285653 C T 9.57E-06 Lipid levels TMOD1 intron pha003082 rs10759765 chr9 100307493 G A 4.20E-05 Pulmonary function TMOD1 intron 23932459 rs4742698 chr9 100312284 T C 9.51E-05 Telomere length TMOD1 intron 21573004 rs1475545 chr9 100316230 C T 5.00E-06 Obesity-related traits TMOD1 intron 23251661 rs6478262 chr9 100319280 C T 8.79E-05 Coronary heart disease TMOD1 intron pha003032 rs913912 chr9 100341038 T C 8.10E-04 Thyroid cancer (papillary,radiation-related) TMOD1 intron 20350937 rs3176734 chr9 100440391 G A 4.95E-04 Multiple complex diseases XPA intron 17554300 rs3176639 chr9 100458109 C A 2.25E-05 Serum metabolites XPA intron 19043545 rs2805831 chr9 100466636 G A 7.11E-04 Smoking cessation / / 24665060 rs2668797 chr9 100482503 G A 6.10E-04 Thyroid cancer (papillary,radiation-related) / / 20350937 rs2668797 chr9 100482503 G A 2.90E-05 Systemic sclerosis / / 21750679 rs953199 chr9 100482976 C A 2.10E-04 Thyroid cancer (papillary,radiation-related) / / 20350937 rs10817988 chr9 100486691 G A 0.00008521 Sarcoidosis / / 22952805 rs2808693 chr9 100490758 A G 5.93E-05 Serum metabolites / / 19043545 rs2805818 chr9 100493631 C T 2.98E-05 Serum metabolites / / 19043545 rs2805815 chr9 100496160 G A 6.08E-05 Systemic sclerosis / / 21750679 rs2805811 chr9 100496474 G C 5.77E-05 Serum metabolites / / 19043545 rs7875482 chr9 100496665 C T 9.84E-06 Obesity-related traits / / 23251661 rs2805809 chr9 100496922 G A 5.93E-05 Serum metabolites / / 19043545 rs2668804 chr9 100497750 C A 6.58E-05 Serum metabolites / / 19043545 rs2805790 chr9 100499206 G A 5.20E-05 Systemic sclerosis / / 21750679 rs2805771 chr9 100504015 C T 3.43E-06 Obesity-related traits / / 23251661 rs2808699 chr9 100505830 C A 4.41E-05 Systemic sclerosis / / 21750679 rs2808699 chr9 100505830 C A 6.02E-06 Obesity-related traits / / 23251661 rs16924016 chr9 100511331 C T 5.00E-06 Parent of origin effect on language impairment (paternal) / / 24571439 rs1512261 chr9 100522530 G T 6.90E-06 Thyroid cancer (papillary,radiation-related) / / 20350937 rs1512261 chr9 100522530 G T 2.40E-05 Hypothyroidism / / 22493691 rs10818037 chr9 100525302 G C 1.68E-06 Obesity-related traits / / 23251661 rs1912995 chr9 100530899 A G 1.00E-06 Obesity-related traits / / 23251661 rs1877431 chr9 100534147 A G 5.50E-08 Obesity-related traits / / 23251661 rs1877431 chr9 100534147 A G 8.00E-05 Cognitive function / / 24684796 rs7045465 chr9 100534823 A T 5.50E-08 Obesity-related traits / / 23251661 rs7030256 chr9 100535203 C G 2.58E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7030256 chr9 100535203 C G 2.51E-09 Obesity-related traits / / 23251661 rs7030280 chr9 100535267 C T 2.80E-09 Thyroid cancer (papillary,radiation-related) / / 20350937 rs7030280 chr9 100535267 C T 4.60E-09 Obesity-related traits / / 23251661 rs10983700 chr9 100537455 T C 2.80E-09 Thyroid cancer (papillary,radiation-related) / / 20350937 rs10983700 chr9 100537455 T C 2.51E-09 Obesity-related traits / / 23251661 rs10983701 chr9 100537577 G A 3.79E-09 Obesity-related traits / / 23251661 rs1588635 chr9 100537802 A C 3.70E-09 Thyroid cancer (papillary,radiation-related) / / 20350937 rs1588635 chr9 100537802 A C 2.51E-09 Obesity-related traits / / 23251661 rs7028661 chr9 100538470 A G 3.59E-09 Obesity-related traits / / 23251661 rs10818050 chr9 100538923 A G 1.17E-07 Thyroid stimulating hormone / / 24852370 rs7021576 chr9 100540541 C T 4.22E-09 Obesity-related traits / / 23251661 rs1877432 chr9 100543880 G A 5.20E-04 Thyroid cancer (papillary,radiation-related) / / 20350937 rs1877432 chr9 100543880 G A 3.90E-06 Hypothyroidism / / 21981779 rs1877432 chr9 100543880 G A 4.40E-09 Hypothyroidism / / 22493691 rs1877432 chr9 100543880 G A 2.93E-05 Thyroid cancer / / 23894154 rs4743130 chr9 100546040 C T 2.96E-09 Obesity-related traits / / 23251661 rs1561962 chr9 100546219 C T 2.86E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1561962 chr9 100546219 C T 4.15E-09 Obesity-related traits / / 23251661 rs925488 chr9 100546391 G A 2.74E-09 Obesity-related traits / / 23251661 rs925489 chr9 100546600 C T 1.70E-09 Thyroid cancer (papillary,radiation-related) / / 20350937 rs925489 chr9 100546600 C T 1.58E-08 Hypothyroidism / / 21981779 rs925489 chr9 100546600 C T 2.00E-19 Hypothyroidism / / 22493691 rs925489 chr9 100546600 C T 2.74E-09 Obesity-related traits / / 23251661 rs925489 chr9 100546600 C T 1.00E-13 Thyroid stimulating hormone / / 24852370 rs7864322 chr9 100548934 C T 3.23E-09 Obesity-related traits / / 23251661 rs7850258 chr9 100549013 A G 1.70E-09 Thyroid cancer (papillary,radiation-related) / / 20350937 rs7850258 chr9 100549013 A G 4.00E-09 Hypothyroidism / / 21981779 rs7850258 chr9 100549013 A G 2.50E-19 Hypothyroidism / / 22493691 rs7850258 chr9 100549013 A G 2.96E-09 Obesity-related traits / / 23251661 rs7850258 chr9 100549013 A G 3.47E-10 Thyroid cancer / / 23894154 rs1443438 chr9 100550028 T C 5.50E-11 Hypothyroidism / / 22493691 rs1443438 chr9 100550028 T C 1.00E-09 Obesity-related traits / / 23251661 rs1443438 chr9 100550028 T C 3.47E-10 Thyroid cancer / / 23894154 rs7030241 chr9 100550375 T A 1.03E-09 Obesity-related traits / / 23251661 rs7027030 chr9 100550455 A C 1.49E-09 Obesity-related traits / / 23251661 rs10739496 chr9 100552559 C T 2.03E-08 Obesity-related traits / / 23251661 rs10983761 chr9 100553957 A C 2.03E-08 Obesity-related traits / / 23251661 rs965513 chr9 100556109 A G 2.00E-27 Thyroid cancer / / 19198613 rs965513 chr9 100556109 A G 2.00E-09 Thyroid cancer (papillary,radiation-related) / / 20350937 rs965513 chr9 100556109 A G 4.80E-12 Thyroid cancer (papillary,radiation-related) / / 20350937 rs965513 chr9 100556109 A G 6.00E-08 Thyroid cancer (papillary,radiation-related) / / 20350937 rs965513 chr9 100556109 A G 2.00E-27 Nasopharyngeal carcinoma / / 20512145 rs965513 chr9 100556109 A G 1.52E-08 Hypothyroidism / / 21981779 rs965513 chr9 100556109 A G 6.90E-15 Thyroid cancer / / 22267200 rs965513 chr9 100556109 A G 4.30E-19 Hypothyroidism / / 22493691 rs965513 chr9 100556109 A G 7.52E-09 Obesity-related traits / / 23251661 rs965513 chr9 100556109 A G 3.00E-10 Thyroid cancer / / 23894154 rs965513 chr9 100556109 A G 1.26E-06 Thyroid stimulating hormone / / 24852370 rs10759944 chr9 100556972 A G 1.70E-19 Thyroid cancer / / 19198613 rs10759944 chr9 100556972 A G 3.50E-09 Thyroid cancer (papillary,radiation-related) / / 20350937 rs10759944 chr9 100556972 A G 2.53E-08 Hypothyroidism / / 21981779 rs10759944 chr9 100556972 A G 5.80E-19 Hypothyroidism / / 22493691 rs10759944 chr9 100556972 A G 2.03E-08 Obesity-related traits / / 23251661 rs10759944 chr9 100556972 A G 2.67E-10 Thyroid cancer / / 23894154 rs10818090 chr9 100561486 C T 2.03E-08 Obesity-related traits / / 23251661 rs7870795 chr9 100574120 T C 3.00E-05 Hypothyroidism / / 22493691 rs7870795 chr9 100574120 T C 0.00000315 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs7870795 chr9 100574120 T C 4.84E-06 Thyroid cancer / / 23894154 rs7859751 chr9 100575888 G A 2.81E-04 Lymphocyte counts / / 22286170 rs7859751 chr9 100575888 G A 0.00000284 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs6478413 chr9 100582024 A G 6.15E-06 Obesity-related traits / / 23251661 rs10124220 chr9 100583074 T C 3.75E-06 Obesity-related traits / / 23251661 rs1443432 chr9 100583195 C T 5.11E-06 Obesity-related traits / / 23251661 rs7037853 chr9 100585131 T C 6.50E-06 Cognitive impairment induced by topiramate / / 22091778 rs7848973 chr9 100588839 A G 2.50E-06 Thyroid cancer (papillary,radiation-related) / / 20350937 rs7848973 chr9 100588839 A G 7.10E-11 Hypothyroidism / / 22493691 rs7848973 chr9 100588839 A G 3.75E-06 Obesity-related traits / / 23251661 rs7848973 chr9 100588839 A G 1.58E-09 Thyroid cancer / / 23894154 rs7045138 chr9 100591463 C T 2.00E-11 Thyroid hormone levels / / 23408906 rs7045138 chr9 100591463 C T 3.00E-06 Thyroid hormone levels / / 23408906 rs7045138 chr9 100591463 C T 5.00E-07 Thyroid hormone levels / / 23408906 rs7024345 chr9 100595238 A G 2.60E-05 Bone mineral density (spine) / / 19079262 rs7024345 chr9 100595238 A G 1.90E-12 Thyroid cancer / / 19198613 rs7024345 chr9 100595238 A G 1.40E-06 Thyroid cancer (papillary,radiation-related) / / 20350937 rs7024345 chr9 100595238 A G 1.00E-08 Hypothyroidism / / 22493691 rs12348691 chr9 100608682 G A 1.45E-08 Thyroid cancer / / 23894154 rs10759960 chr9 100608745 A G 5.60E-05 Hypothyroidism / / 22493691 rs10759960 chr9 100608745 A G 2.41E-06 Thyroid cancer / / 23894154 rs1867277 chr9 100615914 A G 4.50E-07 Thyroid cancer (papillary,radiation-related) FOXE1 UTR-5 20350937 rs1443434 chr9 100617479 G T 2.80E-09 Thyroid cancer FOXE1 UTR-3 19198613 rs1443434 chr9 100617479 G T 2.60E-04 Thyroid cancer (papillary,radiation-related) FOXE1 UTR-3 20350937 rs1443434 chr9 100617479 G T 4.60E-05 Hypothyroidism FOXE1 UTR-3 22493691 rs1443435 chr9 100617583 T C 2.48E-08 Thyroid cancer FOXE1 UTR-3 23894154 rs907580 chr9 100622597 T C 4.40E-05 Bone mineral density (spine) / / 19079262 rs907580 chr9 100622597 T C 1.10E-14 Thyroid cancer / / 19198613 rs907580 chr9 100622597 T C 4.20E-06 Thyroid cancer (papillary,radiation-related) / / 20350937 rs907580 chr9 100622597 T C 4.60E-06 Bone mineral density / / 21927923 rs907580 chr9 100622597 T C 1.20E-08 Hypothyroidism / / 22493691 rs925487 chr9 100636398 C T 2.60E-13 Thyroid cancer / / 19198613 rs925487 chr9 100636398 C T 4.50E-05 Thyroid cancer (papillary,radiation-related) / / 20350937 rs925487 chr9 100636398 C T 4.10E-08 Hypothyroidism / / 22493691 rs925487 chr9 100636398 C T 2.31E-08 Thyroid cancer / / 23894154 rs10984103 chr9 100639275 A C 2.20E-13 Thyroid cancer / / 19198613 rs10984103 chr9 100639275 A C 4.60E-05 Thyroid cancer (papillary,radiation-related) / / 20350937 rs10984103 chr9 100639275 A C 3.90E-08 Hypothyroidism / / 22493691 rs7866436 chr9 100650096 G A 5.20E-05 Thyroid cancer (papillary,radiation-related) / / 20350937 rs7866436 chr9 100650096 G A 2.40E-08 Hypothyroidism / / 22493691 rs7866436 chr9 100650096 G A 4.19E-08 Thyroid cancer / / 23894154 rs755109 chr9 100696203 T C 1.00E-06 Quantitative traits HEMGN intron 19197348 rs4743150 chr9 100740124 C T 5.00E-06 Coronary heart disease / / 21378988 rs4743150 chr9 100740124 C T 9.23E-06 Primary biliary cirrhosis / / 21399635 rs872251 chr9 100757343 A G 1.40E-05 Urinary metabolites ANP32B intron 21572414 rs10283737 chr9 100780063 T G 1.10E-05 Urinary metabolites / / 21572414 rs874610 chr9 100782695 G T 9.34E-06 Primary biliary cirrhosis / / 21399635 rs10984811 chr9 100784050 A C 1.70E-05 Urinary metabolites / / 21572414 rs7870926 chr9 100796945 G A 3.48E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10818454 chr9 100819940 G A 7.53E-06 Height /NS intron pha003011 rs10818468 chr9 100836889 C T 2.88E-05 Height TRIM14 intron pha003011 rs41382249 chr9 100841967 C T 3.25E-04 Multiple complex diseases TRIM14 intron 17554300 rs7022455 chr9 100866872 T C 3.85E-07 Red blood cell traits TRIM14 intron 23222517 rs10985065 chr9 100866903 C T 9.16E-07 Red blood cell traits TRIM14 intron 23222517 rs7855251 chr9 100868189 T C 5.52E-07 Red blood cell traits TRIM14 intron 23222517 rs12337659 chr9 100872589 C T 1.66E-04 Alzheimer's disease (late onset) TRIM14 intron 21379329 rs7875438 chr9 100876284 T C 4.38E-04 Alzheimer's disease (late onset) TRIM14 intron 21379329 rs16912804 chr9 100881740 C T 2.20E-04 Multiple complex diseases / / 17554300 rs16913017 chr9 100896002 C T 1.04E-14 Multiple complex diseases CORO2A intron 17554300 rs2795486 chr9 100903168 A T 2.60E-05 Urinary metabolites CORO2A intron 21572414 rs3780457 chr9 100922407 G A 4.23E-04 Suicide attempts in bipolar disorder CORO2A intron 21423239 rs10118043 chr9 100923472 G A 6.69E-04 Multiple complex diseases CORO2A intron 17554300 rs17202687 chr9 100926475 T C 2.43E-04 Suicide attempts in bipolar disorder CORO2A intron 21423239 rs10818541 chr9 100927161 C T 4.40E-06 Gamma gluatamyl transferase levels (interaction with age) CORO2A intron 22010049 rs10985257 chr9 100927255 A C 3.70E-06 Gamma gluatamyl transferase levels (interaction with age) CORO2A intron 22010049 rs10491723 chr9 100927632 G A 1.00E-04 Information processing speed CORO2A intron 21130836 rs16913432 chr9 100927762 G A 4.17E-04 Suicide attempts in bipolar disorder CORO2A intron 21423239 rs4743176 chr9 100930659 C A 3.82E-04 Multiple complex diseases CORO2A intron 17554300 rs1539290 chr9 100931158 A G 7.41E-04 Suicide attempts in bipolar disorder CORO2A intron 21423239 rs4610873 chr9 100934033 T G 2.90E-06 Gamma gluatamyl transferase levels (interaction with age) CORO2A intron 22010049 rs2231652 chr9 100935754 G C 2.08E-04 Gallstones CORO2A intron 17632509 rs2231652 chr9 100935754 G C 2.10E-05 Urinary metabolites CORO2A intron 21572414 rs10985325 chr9 100938462 C T 7.98E-04 Iron levels CORO2A intron pha002876 rs7870439 chr9 100951838 G T 1.10E-05 Job-related exhaustion CORO2A intron 23620144 rs10985391 chr9 100960607 A G 4.42E-04 Sudden cardiac arrest / / 21658281 rs3780453 chr9 100964651 C T 2.37E-05 Job-related exhaustion TBC1D2 intron 23620144 rs3780452 chr9 100964701 T C 2.03E-05 Job-related exhaustion TBC1D2 intron 23620144 rs11788019 chr9 100966791 C A 5.10E-06 Urinary metabolites TBC1D2 intron 21572414 rs3758257 chr9 100978626 G C 2.60E-05 Urinary metabolites TBC1D2 intron 21572414 rs3758257 chr9 100978626 G C 4.34E-04 Smoking initiation TBC1D2 intron 24665060 rs16914086 chr9 100988477 G A 0.000066 Nicotine dependence (smoking) TBC1D2 intron 22377092 rs4743193 chr9 101008541 C T 9.10E-05 Erythrocyte counts TBC1D2 intron pha003101 rs10115971 chr9 101024887 A G 0.0000337 Alcohol craving with or without dependence / / 22481050 rs16914425 chr9 101035344 C T 9.19E-04 Multiple complex diseases / / 17554300 rs1435261 chr9 101046205 T C 9.85E-05 Hemoglobin / / pha003098 rs1435261 chr9 101046205 T C 1.60E-06 Erythrocyte counts / / pha003099 rs1435261 chr9 101046205 T C 2.37E-05 Erythrocyte counts / / pha003101 rs1435259 chr9 101046441 T C 4.91E-05 Cognitive test performance / / 20125193 rs7869364 chr9 101065212 T G 4.47E-04 Alzheimer's disease (late onset) GABBR2 intron 21379329 rs12551959 chr9 101074701 C A 2.57E-05 Cognitive test performance GABBR2 intron 20125193 rs7020190 chr9 101086941 C T 8.34E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy GABBR2 intron 24578207 rs7020190 chr9 101086941 C T 8.34E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy GABBR2 intron 24578207 rs10818782 chr9 101087286 G A 5.57E-07 HDL cholesterol GABBR2 intron 23726366 rs812855 chr9 101111519 C T 3.44E-04 Smoking initiation GABBR2 intron 24665060 rs10986018 chr9 101123336 T C 2.00E-08 Folate pathway vitamin levels GABBR2 intron 19744961 rs661532 chr9 101137555 C T 3.31E-04 Cognitive impairment induced by topiramate GABBR2 intron 22091778 rs552989 chr9 101137895 C T 5.76E-04 Cognitive impairment induced by topiramate GABBR2 intron 22091778 rs10818845 chr9 101138682 A G 3.48E-04 Type 2 diabetes GABBR2 intron 17463246 rs2900382 chr9 101177852 C T 3.18E-05 Height GABBR2 intron pha003010 rs4743221 chr9 101178629 C A 1.10E-05 Urinary metabolites GABBR2 intron 21572414 rs1537958 chr9 101187760 T G 1.50E-05 Urinary metabolites GABBR2 intron 21572414 rs62574625 chr9 101218552 A G 0.0000375 Nonsyndromic striae distensae (stretch marks) GABBR2 intron 23633020 rs2808554 chr9 101229725 T C 8.98E-04 Suicide attempts in bipolar disorder GABBR2 intron 21423239 rs2779531 chr9 101231892 A G 4.54E-04 Alzheimer's disease (late onset) GABBR2 intron 21379329 rs874278 chr9 101249423 G A 5.21E-04 HIV-1 viral setpoint GABBR2 intron 17641165 rs874278 chr9 101249423 G A 7.01E-04 Alcohol consumption (maxi-drinks) GABBR2 intron 24277619 rs17770838 chr9 101253222 C T 3.88E-05 Coronary heart disease GABBR2 intron pha003035 rs2779551 chr9 101253226 T C 2.00E-06 Post-traumatic stress disorder (asjusted for relatedness) GABBR2 intron 23726511 rs2779552 chr9 101254476 A C 7.08E-05 Coronary heart disease GABBR2 intron pha003035 rs2808560 chr9 101262218 C T 1.52E-04 Alcohol consumption GABBR2 intron 23743675 rs10986439 chr9 101262400 C G 2.36E-04 Type 2 diabetes GABBR2 intron 17463246 rs7023937 chr9 101266451 C A 2.64E-04 Type 2 diabetes GABBR2 intron 17463246 rs2779562 chr9 101277681 T C 1.86E-05 Schizophrenia GABBR2 intron 19571811 rs1930409 chr9 101278541 C T 5.87E-04 Coronary heart disease GABBR2 intron 21971053 rs2779569 chr9 101280384 T C 1.57E-04 Alcohol consumption GABBR2 intron 23743675 rs16916777 chr9 101281175 G A 8.32E-04 Coronary heart disease GABBR2 intron 21971053 rs16916777 chr9 101281175 G A 1.09E-05 Vascular dementia GABBR2 intron 22116812 rs7861460 chr9 101282313 A G 3.14E-04 Amyotrophic Lateral Sclerosis GABBR2 intron 17362836 rs944760 chr9 101283741 G T 1.58E-04 Alcohol consumption GABBR2 intron 23743675 rs2779576 chr9 101284552 A T 1.57E-04 Alcohol consumption GABBR2 intron 23743675 rs2779577 chr9 101285414 C A 3.00E-04 Heroin addiction GABBR2 intron 20520587 rs2779581 chr9 101286985 T C 1.81E-04 Alcohol consumption GABBR2 intron 23743675 rs2779582 chr9 101287117 C T 1.56E-04 Alcohol consumption GABBR2 intron 23743675 rs10521035 chr9 101295352 G T 7.28E-04 Type 2 diabetes GABBR2 intron 17463246 rs12351127 chr9 101295417 C T 4.09E-05 Asthma GABBR2 intron 11022011 rs4237192 chr9 101297144 A G 4.12E-04 Coronary heart disease GABBR2 intron 21971053 rs2808570 chr9 101301655 C G 6.21E-04 Self-reported allergy GABBR2 intron 23817569 rs2808522 chr9 101306446 C A 5.96E-04 Self-reported allergy GABBR2 intron 23817569 rs2808523 chr9 101306621 C T 6.94E-04 Self-reported allergy GABBR2 intron 23817569 rs884886 chr9 101318075 T G 7.87E-04 Coronary heart disease GABBR2 intron 21971053 rs10986740 chr9 101320582 G A 1.66E-05 Orofacial clefts GABBR2 intron 22419666 rs4743235 chr9 101320857 G T 5.71E-04 Type 2 diabetes GABBR2 intron 17463246 rs4743237 chr9 101322880 T C 5.73E-04 Coronary heart disease GABBR2 intron 21971053 rs867762 chr9 101329859 G A 8.50E-04 Type 2 diabetes GABBR2 intron 17463246 rs1167768 chr9 101331392 G A 2.23E-04 Parkinson's disease GABBR2 intron 16252231 rs2779523 chr9 101334945 G T 4.81E-05 Serum metabolites GABBR2 intron 19043545 rs2779524 chr9 101338855 C T 2.38E-04 Hemoglobin concentration GABBR2 intron 20534544 rs2808529 chr9 101338946 T C 5.23E-04 Type 2 diabetes GABBR2 intron 17463246 rs2808538 chr9 101344709 C T 2.38E-04 Hemoglobin concentration GABBR2 intron 20534544 rs2778908 chr9 101345778 A G 2.38E-04 Hemoglobin concentration GABBR2 intron 20534544 rs2808541 chr9 101357407 C T 2.13E-04 Cognitive impairment induced by topiramate GABBR2 intron 22091778 rs2151216 chr9 101359392 T C 3.63E-04 Cognitive impairment induced by topiramate GABBR2 intron 22091778 rs17779442 chr9 101362263 G A 6.82E-05 Prion diseases GABBR2 intron 22210626 rs17779442 chr9 101362263 G A 0.000285 Salmonella-induced pyroptosis GABBR2 intron 22837397 rs17779442 chr9 101362263 G A 1.86E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) GABBR2 intron 24023788 rs4327958 chr9 101377032 G T 3.88E-05 Lung function (forced expiratory volume in 1 second) GABBR2 intron pha003102 rs1167774 chr9 101382838 G T 9.84E-06 Lung function (forced expiratory volume in 1 second) GABBR2 intron pha003102 rs10120452 chr9 101386241 G A 7.31E-07 White blood cell count GABBR2 intron 21738479 rs1930135 chr9 101411132 T C 7.68E-05 Lung function (forced expiratory volume in 1 second) GABBR2 intron pha003102 rs4517239 chr9 101454321 G A 8.10E-05 Lung function (forced expiratory volume in 1 second) GABBR2 intron pha003102 rs337547 chr9 101460267 G A 1.02E-05 Lung function (forced expiratory volume in 1 second) GABBR2 intron pha003102 rs337547 chr9 101460267 G A 9.42E-05 Lung function (forced vital capacity) GABBR2 intron pha003104 rs570138 chr9 101467937 A G 1.31E-05 Lung function (forced expiratory volume in 1 second) GABBR2 intron pha003102 rs173066 chr9 101481866 C T 2.50E-05 Urinary metabolites / / 21572414 rs4078676 chr9 101486073 C A 1.90E-05 Urinary metabolites / / 21572414 rs337572 chr9 101486645 G A 4.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10760475 chr9 101489665 C A 2.50E-05 Urinary metabolites / / 21572414 rs10987602 chr9 101515008 G A 8.40E-07 Urinary metabolites ANKS6 intron 21572414 rs168083 chr9 101516176 G T 4.50E-06 Urinary metabolites ANKS6 intron 21572414 rs580809 chr9 101518442 C T 4.50E-06 Urinary metabolites ANKS6 intron 21572414 rs4743273 chr9 101527875 G A 8.85E-05 Information processing speed ANKS6 intron 21130836 rs7027771 chr9 101552955 T C 9.52E-04 Blood pressure ANKS6 intron 17255346 rs2295924 chr9 101585831 C T 9.11E-08 Non-obstructive azoospermia GALNT12 intron 22197933 rs2295926 chr9 101593825 T C 6.52E-04 Stroke GALNT12 intron pha002887 rs1407503 chr9 101598609 G A 4.00E-05 Lung cancer GALNT12 intron 18978790 rs7855317 chr9 101633298 G A 8.77E-04 Coronary Artery Disease / / 17634449 rs2038621 chr9 101649953 C T 0.00000047 Joint damage severity in rheumatoid arthritis / / 23696630 rs732726 chr9 101663086 C A 0.00000044 Joint damage severity in rheumatoid arthritis / / 23696630 rs4743294 chr9 101673848 A G 4.96E-05 Sarcoidosis / / 19165924 rs7470221 chr9 101678036 T C 2.82E-04 Smoking quantity / / 24665060 rs2151616 chr9 101729103 G A 9.11E-05 Serum metabolites COL15A1 intron 19043545 rs4743300 chr9 101729239 A T 5.77E-04 Multiple complex diseases COL15A1 intron 17554300 rs17711860 chr9 101800106 A G 2.90E-04 Insulin resistance COL15A1 intron 21901158 rs7031588 chr9 101822302 C T 9.41E-04 Nicotine dependence COL15A1 intron 17158188 rs7034716 chr9 101858382 C T 4.40E-06 Urinary metabolites / / 21572414 rs11568746 chr9 101868208 C G 1.52E-15 HDL cholesterol TGFBR1 intron 23063622 rs11568746 chr9 101868208 C G 1.91E-15 LDL cholesterol TGFBR1 intron 23063622 rs11568746 chr9 101868208 C G 5.39E-10 Triglycerides TGFBR1 intron 23063622 rs11568746 chr9 101868208 C G 7.14E-25 Cholesterol,total TGFBR1 intron 23063622 rs10988705 chr9 101868571 G A 4.06E-04 Obesity (extreme) TGFBR1 intron 21935397 rs10760670 chr9 101872163 G A 2.10E-05 Urinary metabolites TGFBR1 intron 21572414 rs1571590 chr9 101883808 A G 7.12E-04 Gallbladder cancer TGFBR1 intron 22318345 rs11568767 chr9 101895272 C T 1.06E-13 LDL cholesterol TGFBR1 intron 23063622 rs11568767 chr9 101895272 C T 8.17E-09 HDL cholesterol TGFBR1 intron 23063622 rs11568778 chr9 101900410 A G 6.66E-04 Smoking cessation TGFBR1 intron 24665060 rs334353 chr9 101908365 T G 3.00E-11 Age-related macular degeneration TGFBR1 intron 23455636 rs868 chr9 101911656 A G 2.60E-05 Urinary metabolites TGFBR1 UTR-3 21572414 rs7035064 chr9 101931740 A G 6.80E-06 Alcohol and nictotine co-dependence / / 22488850 rs12342980 chr9 101939966 A G 9.67E-05 Multiple complex diseases / / 17554300 rs3780616 chr9 101987760 G A 2.00E-05 Blood pressure SEC61B intron 21228793 rs438824 chr9 102016891 A G 4.70E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs410180 chr9 102018148 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs790189 chr9 102032394 T C 6.90E-06 Urinary metabolites / / 21572414 rs790191 chr9 102035838 T G 1.80E-05 Urinary metabolites / / 21572414 rs10819643 chr9 102037970 A G 1.00E-06 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs398704 chr9 102064194 T C 1.01E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs723171 chr9 102071608 A G 3.48E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1323467 chr9 102095381 T C 6.89E-04 Multiple complex diseases / / 17554300 rs188943 chr9 102101765 T C 1.50E-05 Urinary metabolites / / 21572414 rs188941 chr9 102110757 T C 1.72E-04 Multiple complex diseases / / 17554300 rs12551906 chr9 102119090 G A 3.00E-06 Callous-unemotional behaviour / / 23874384 rs10819657 chr9 102128509 C T 8.36E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2281728 chr9 102129789 T A 1.20E-05 Urinary metabolites / / 21572414 rs2281728 chr9 102129789 T A 5.86E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7023945 chr9 102130088 A C 1.20E-05 Urinary metabolites / / 21572414 rs16918536 chr9 102130554 G T 8.46E-04 Multiple complex diseases / / 17554300 rs10988788 chr9 102148318 C G 1.70E-05 Urinary metabolites / / 21572414 rs920771 chr9 102163313 A C 6.50E-05 Serum metabolites / / 19043545 rs7032399 chr9 102171467 G T 8.07E-05 Serum metabolites / / 19043545 rs7040144 chr9 102176403 C G 7.39E-05 Serum metabolites / / 19043545 rs7042668 chr9 102176700 G C 1.20E-05 Urinary metabolites / / 21572414 rs35775808 chr9 102225544 A G 7.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs649057 chr9 102234323 C A 5.00E-06 Dental caries / / 23064961 rs649057 chr9 102234323 C A 8.00E-06 Smooth-surface caries / / 23470693 rs16918616 chr9 102272438 G A 2.02E-04 Insulin resistance / / 21901158 rs10988863 chr9 102331281 A C 9.27E-04 Multiple complex diseases / / 17554300 rs10988863 chr9 102331281 A C 2.20E-05 Urinary metabolites / / 21572414 rs10819686 chr9 102333777 G A 4.05E-04 IgE levels / / 17255346 rs10819686 chr9 102333777 G A 8.72E-04 Multiple complex diseases / / 17554300 rs10122296 chr9 102334338 T C 7.52E-04 Multiple complex diseases / / 17554300 rs1078067 chr9 102334728 C T 4.06E-04 IgE levels / / 17255346 rs10819687 chr9 102346029 C A 0.0007194 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10819687 chr9 102346029 C A 7.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12342850 chr9 102419410 A G 0.0001314 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12342850 chr9 102419410 A G 1.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1578463 chr9 102464577 C T 0.0000452 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1578463 chr9 102464577 C T 4.52E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10988897 chr9 102554038 T A 0.0001316 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10988897 chr9 102554038 T A 1.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs199999066 chr9 102554038 T TA 0.0001316 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs199999066 chr9 102554038 T TA 1.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7029559 chr9 102555087 T G 0.0001317 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7029559 chr9 102555087 T G 1.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10988898 chr9 102559272 A G 4.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10988898 chr9 102559272 A G 0.0001318 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10988898 chr9 102559272 A G 1.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7026022 chr9 102562216 A C 4.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7026022 chr9 102562216 A C 0.0001359 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7026022 chr9 102562216 A C 1.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7034165 chr9 102563494 T G 0.0001067 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7034165 chr9 102563494 T G 1.07E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1526265 chr9 102565953 G C 0.0001365 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1526265 chr9 102565953 G C 1.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1417738 chr9 102569599 A G 0.0001398 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1417738 chr9 102569599 A G 1.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10156557 chr9 102571296 C T 0.0001401 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10156557 chr9 102571296 C T 1.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7047636 chr9 102579467 C G 0.0001409 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7047636 chr9 102579467 C G 1.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1405209 chr9 102585545 T C 4.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NR4A3 intron 20877124 rs1405209 chr9 102585545 T C 0.0001415 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NR4A3 intron 23233654 rs1405209 chr9 102585545 T C 1.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) NR4A3 intron 23233662 rs7022059 chr9 102592688 G A 0.0001423 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NR4A3 intron 23233654 rs7022059 chr9 102592688 G A 1.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) NR4A3 intron 23233662 rs12352835 chr9 102602059 T C 0.0001529 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NR4A3 intron 23233654 rs12352835 chr9 102602059 T C 1.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) NR4A3 intron 23233662 rs7020565 chr9 102617905 T C 4.33E-12 Multiple complex diseases NR4A3 intron 17554300 rs12554558 chr9 102639298 T C 1.40E-05 Urinary metabolites / / 21572414 rs4428721 chr9 102686487 C T 8.93E-05 Blood Pressure STX17 intron pha003040 rs1997368 chr9 102713580 G A 9.94E-05 Amyotrophic lateral sclerosis STX17 intron 20801717 rs10760706 chr9 102723692 C T 4.00E-07 Alopecia areata STX17 intron 20596022 rs10760706 chr9 102723692 C T 9.14E-05 Amyotrophic lateral sclerosis STX17 intron 20801717 rs7873746 chr9 102775717 A C 7.93E-05 HDL cholesterol ERP44 intron pha003075 rs1418267 chr9 102806574 A G 4.56E-04 Tuberculosis ERP44 intron 22239941 rs7028939 chr9 102808685 A G 3.00E-06 Preeclampsia ERP44 intron 23551011 rs7041338 chr9 102820727 G C 5.23E-04 Tuberculosis ERP44 intron 22239941 rs16918878 chr9 102846630 C T 1.84E-05 Cognitive decline ERP44 intron 22054870 rs7849323 chr9 102854188 T C 3.42E-06 Preeclampsia ERP44 intron 23551011 rs846756 chr9 102884176 C T 6.94E-05 HDL cholesterol INVS intron pha003075 rs1415927 chr9 102911706 T C 3.48E-06 Preeclampsia INVS intron 23551011 rs7047693 chr9 102918306 T C 3.31E-06 Preeclampsia INVS intron 23551011 rs10988989 chr9 102922307 T C 3.31E-06 Preeclampsia INVS intron 23551011 rs7020780 chr9 102958736 G A 2.66E-06 Preeclampsia INVS intron 23551011 rs10989019 chr9 102976541 T C 2.00E-06 Preeclampsia INVS intron 23551011 rs11790431 chr9 103046916 G A 8.75E-05 HDL cholesterol INVS intron pha003075 rs2787372 chr9 103050407 C T 2.99E-05 HDL cholesterol INVS intron pha003075 rs7039994 chr9 103051205 C T 3.95E-06 Breast cancer(er negative) INVS intron 21062454 rs7039994 chr9 103051205 C T 9.70E-05 HDL cholesterol INVS intron pha003075 rs2806700 chr9 103055997 G T 2.54E-05 HDL cholesterol INVS intron pha003075 rs3813712 chr9 103060386 T G 4.21E-05 HDL cholesterol INVS intron pha003075 rs10989049 chr9 103064153 A G 7.63E-05 HDL cholesterol TEX10 nearGene-3 pha003075 rs4743392 chr9 103068905 T A,C 2.90E-04 Major depressive disorder TEX10 intron 21042317 rs10989064 chr9 103111965 C T 8.07E-04 Multiple complex diseases TEX10 intron 17554300 rs944710 chr9 103112459 C T 4.52E-05 HDL cholesterol TEX10 intron pha003075 rs7874900 chr9 103116441 C T 4.81E-05 HDL cholesterol / / pha003075 rs13284428 chr9 103149987 T C 8.37E-05 Spine bone size / / 23207799 rs12000794 chr9 103157515 C A 5.40E-06 Breast cancer(er negative) / / 21062454 rs12000794 chr9 103157515 C A 9.79E-05 HDL cholesterol / / pha003074 rs11790432 chr9 103191461 A G 2.41E-05 Anxiety and major depressive disorder MSANTD3 intron 24047446 rs7046408 chr9 103232469 A T 6.17E-04 Multiple complex diseases MSANTD3-TMEFF1 intron 17554300 rs7046408 chr9 103232469 A T 1.02E-04 Smoking initiation MSANTD3-TMEFF1 intron 24665060 rs7865385 chr9 103247581 A C,G,T 1.97E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TMEFF1 intron 24023788 rs10819788 chr9 103262228 G A 3.75E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TMEFF1 intron 24023788 rs1332598 chr9 103278418 C T 3.25E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TMEFF1 intron 24023788 rs41382949 chr9 103281780 G A 7.84E-04 Multiple complex diseases TMEFF1 intron 17554300 rs12683122 chr9 103286465 C T 2.45E-04 Multiple complex diseases TMEFF1 intron 17554300 rs10989145 chr9 103297599 C T 2.30E-04 Multiple complex diseases TMEFF1 intron 17554300 rs10989147 chr9 103300396 G T 6.38E-04 Multiple complex diseases TMEFF1 intron 17554300 rs10465148 chr9 103303033 T C 1.49E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TMEFF1 intron 24023788 rs10989154 chr9 103324394 C T 4.05E-04 Multiple complex diseases TMEFF1 intron 17554300 rs17742650 chr9 103351014 A G 3.67E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10989170 chr9 103362510 T C 3.10E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10819795 chr9 103368363 T A 7.00E-06 Plasma amyloid beta peptide concentrations (ABx-42) / / 24535457 rs10115383 chr9 103370532 A G 7.69E-05 Nicotine smoking / / 19268276 rs10760734 chr9 103384199 G C 6.77E-04 Acute lung injury / / 22295056 rs4113694 chr9 103411554 C G 2.97E-04 Acute lung injury / / 22295056 rs4348565 chr9 103412325 G A 0.0002 Migraine / / 22678113 rs4742788 chr9 103417349 C T 9.86E-04 Acute lung injury / / 22295056 rs4531108 chr9 103424823 G A 2.65E-04 Acute lung injury / / 22295056 rs3901498 chr9 103425281 C T 7.66E-04 Acute lung injury / / 22295056 rs10114244 chr9 103427659 C T 7.24E-04 Acute lung injury / / 22295056 rs4288433 chr9 103435526 C T 4.95E-04 Acute lung injury / / 22295056 rs4237198 chr9 103439145 A G 5.86E-04 Acute lung injury / / 22295056 rs10819808 chr9 103446253 A G 4.24E-04 Spine bone size / / 23207799 rs10123021 chr9 103452068 G T 0.000000313 Stroke / / 23422753 rs10989222 chr9 103479848 A C 9.70E-05 Multiple complex diseases / / 17554300 rs12346541 chr9 103480387 G A 4.39E-04 Iron levels / / pha002876 rs7874083 chr9 103482429 C T 4.39E-04 Iron levels / / pha002876 rs7853739 chr9 103485819 A C 4.17E-04 Iron levels / / pha002876 rs4743420 chr9 103488089 C A 4.47E-04 Iron levels / / pha002876 rs10521051 chr9 103488628 G A 1.08E-15 Varicose Veins / / pha001416 rs13302189 chr9 103493958 A G 9.16E-05 Cognitive impairment induced by topiramate / / 22091778 rs10989249 chr9 103532305 G A 0.000113 Alpha-2-adrenoceptor-mediated vasoconstriction / / 23337848 rs1953805 chr9 103603365 C A 1.09E-04 Myopia (pathological) / / 21095009 rs13285273 chr9 103691860 G A 5.75E-05 Breast cancer / / pha002853 rs16919646 chr9 103694660 A G 4.94E-07 Cognitive impairment induced by topiramate / / 22091778 rs492265 chr9 103719203 C G 9.94E-05 Serum metabolites / / 19043545 rs2417226 chr9 103766537 G A 8.20E-05 Breast cancer / / pha002853 rs10989375 chr9 103835356 A G 4.40E-04 Multiple complex diseases LPPR1 intron 17554300 rs10989383 chr9 103839683 G A 3.52E-04 Multiple complex diseases LPPR1 intron 17554300 rs17761685 chr9 103874419 T A 1.20E-05 Urinary metabolites LPPR1 intron 21572414 rs2993807 chr9 103874937 C T 1.44E-05 Femoral neck bone geometry LPPR1 intron 22087292 rs10760792 chr9 103895161 C T 7.00E-04 Primary sclerosing cholangitis LPPR1 intron 19944697 rs3118941 chr9 103910778 T G 3.20E-04 Alzheimer's disease (late onset) LPPR1 intron 21379329 rs10989419 chr9 103934113 C T 2.20E-06 Urinary metabolites LPPR1 intron 21572414 rs2303980 chr9 103947363 A T 4.45E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LPPR1 intron 20031582 rs1431477 chr9 103954453 T G 7.61E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LPPR1 intron 20031582 rs10989426 chr9 103968464 G T 2.99E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LPPR1 intron 20031582 rs10819917 chr9 104026839 T C 2.71E-04 Myopia (pathological) LPPR1 intron 21095009 rs10122456 chr9 104047966 G A 0.000758 Height (Pygmy height) LPPR1 intron 22570615 rs12337836 chr9 104076596 C A 1.30E-05 Bilirubin levels LPPR1 intron 19414484 rs10989474 chr9 104089494 G A 8.21E-04 Multiple complex diseases / / 17554300 rs4403470 chr9 104094147 T C 3.40E-06 Urinary metabolites / / 21572414 rs1226149 chr9 104147083 T C 0.00026 Height (Pygmy height) BAAT intron 22570615 rs10819926 chr9 104163789 T C 5.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZNF189 intron 20877124 rs10819926 chr9 104163789 T C 4.80E-06 Urinary metabolites ZNF189 intron 21572414 rs61755102 chr9 104171770 G A 0.00083 Prostate cancer ZNF189 missense 23555315 rs475348 chr9 104179478 T G 7.37E-05 Serum metabolites / / 19043545 rs578597 chr9 104185258 C T 7.95E-05 Serum metabolites ALDOB intron 19043545 rs17773076 chr9 104192852 T A,C 5.53E-04 Type 2 diabetes ALDOB intron 17463246 rs573816 chr9 104204614 C T 1.90E-05 Kawasaki disease / / 22081228 rs10989504 chr9 104206096 C T 2.00E-05 Urinary metabolites / / 21572414 rs10989511 chr9 104218656 A G 7.27E-05 Chronic obstructive pulmonary disease / / 19300482 rs10989511 chr9 104218656 A G 7.27E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10819937 chr9 104223233 C G 1.00E-09 Liver enzyme levels (alkaline phosphatase) / / 22001757 rs10989518 chr9 104223252 T C,G 8.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4742814 chr9 104226808 G A 0.000146 Height (Pygmy height) / / 22570615 rs10989523 chr9 104230977 T C 6.19E-04 Type 2 diabetes / / 17463246 rs1929482 chr9 104246779 T C 7.80E-06 Serum metabolites C9orf125 intron 19043545 rs1929496 chr9 104266953 A C 0.0000587 Major depressive disorder / / 23149448 rs1929496 chr9 104266953 A C 5.19E-05 Blood Pressure / / pha003039 rs13290720 chr9 104269009 T C 5.19E-05 Blood Pressure / / pha003039 rs1929487 chr9 104272503 A T 6.60E-05 Serum metabolites / / 19043545 rs12353519 chr9 104339000 C G 8.36E-05 Type 2 diabetes GRIN3A intron 17463246 rs10123961 chr9 104343719 G T 0.000817 Height (Pygmy height) GRIN3A intron 22570615 rs1323432 chr9 104362937 A G 2.50E-08 Lipid levels GRIN3A intron 18193043 rs9792648 chr9 104376601 A G 2.70E-05 Hypothyroidism GRIN3A intron 22493691 rs41337446 chr9 104382026 A G 9.37E-04 Multiple complex diseases GRIN3A intron 17554300 rs1323415 chr9 104426458 G A 2.00E-04 Cognitive impairment induced by topiramate GRIN3A intron 22091778 rs1323434 chr9 104432293 C T 2.00E-04 Cognitive impairment induced by topiramate GRIN3A intron 22091778 rs942142 chr9 104432873 T G 2.00E-04 Cognitive impairment induced by topiramate GRIN3A cds-synon 22091778 rs1535631 chr9 104434146 G A 2.00E-04 Cognitive impairment induced by topiramate GRIN3A intron 22091778 rs2506352 chr9 104443319 T C 0.000669 Height (Pygmy height) GRIN3A intron 22570615 rs10512287 chr9 104458968 A G 2.30E-04 Breast cancer and prostate cancer GRIN3A intron 17903305 rs4743484 chr9 104479480 C T 8.30E-04 Crohn's disease GRIN3A intron 17684544 rs4615635 chr9 104481380 C T 0.000128 Salmonella-induced pyroptosis GRIN3A intron 22837397 rs2225879 chr9 104487475 G A 2.70E-05 Urinary metabolites GRIN3A intron 21572414 rs1415643 chr9 104503963 A C 2.90E-05 Urinary metabolites / / 21572414 rs10512289 chr9 104510458 T C 2.27E-06 Phospholipid levels (plasma) / / 21829377 rs4743487 chr9 104536303 A C 2.10E-04 Crohn's disease / / 17684544 rs4523321 chr9 104537610 C T 1.00E-06 Obesity-related traits / / 23251661 rs4523321 chr9 104537610 C T 2.00E-06 Obesity-related traits / / 23251661 rs11506967 chr9 104538875 T A 2.50E-05 Urinary metabolites / / 21572414 rs11791821 chr9 104543022 T C 7.50E-05 Hypothyroidism / / 22493691 rs1415654 chr9 104555177 A C 7.10E-05 Rheumatoid arthritis / / 21452313 rs1415654 chr9 104555177 A C 3.20E-06 Body Composition / / pha003012 rs1415654 chr9 104555177 A C 1.77E-06 Body Mass Index / / pha003021 rs1337707 chr9 104558885 T C 5.86E-06 Body Composition / / pha003012 rs1337707 chr9 104558885 T C 1.69E-06 Body Mass Index / / pha003021 rs7036602 chr9 104566472 C T 8.96E-05 Body Composition / / pha003012 rs7857093 chr9 104567544 T C 7.96E-04 Taste perception / / 22132133 rs2417297 chr9 104570604 G A 4.22E-05 Body Composition / / pha003012 rs2417297 chr9 104570604 G A 4.04E-05 Body Mass Index / / pha003021 rs10989647 chr9 104595027 T C 9.30E-04 Multiple complex diseases / / 17554300 rs1022749 chr9 104595776 T C 9.12E-06 Coronary artery calcification / / 23870195 rs2786717 chr9 104596969 T G 3.31E-04 Stroke / / pha002887 rs10989661 chr9 104622868 G A 6.00E-06 Smoking behavior / / 19247474 rs12552818 chr9 104623359 G A 3.16E-06 Coronary artery calcification / / 23870195 rs2181038 chr9 104623443 A C 5.72E-05 Stroke / / pha002887 rs1012203 chr9 104626708 A G 1.59E-05 Staphylococcus aureus infection / / 24847357 rs1002665 chr9 104630136 T C 8.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1415649 chr9 104636695 C T 2.69E-06 Asthma (childhood onset) / / 23829686 rs4742834 chr9 104649651 A G 6.34E-05 Lipoproteins / / pha003079 rs10989685 chr9 104655862 A G 7.79E-05 Lipoproteins / / pha003079 rs1033763 chr9 104658851 T C 7.92E-05 Lipoproteins / / pha003079 rs11789634 chr9 104673545 C T 8.84E-05 HIV-1 viral setpoint / / 22174851 rs10989691 chr9 104674217 C T 2.42E-05 Cognitive test performance / / 20125193 rs10989693 chr9 104674729 G A 2.64E-05 Cognitive test performance / / 20125193 rs2995211 chr9 104709020 A G 4.79E-06 Carotenoid and tocopherol levels / / 19185284 rs10123826 chr9 104710163 G A 9.79E-04 Type 2 diabetes / / 17463246 rs1342124 chr9 104742968 A C 5.60E-04 Multiple complex diseases / / 17554300 rs1342124 chr9 104742968 A C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7467889 chr9 104747866 C T 1.06E-04 Self-reported allergy / / 23817569 rs3012588 chr9 104753152 C G 3.75E-05 Self-reported allergy / / 23817569 rs1418242 chr9 104755009 T C 1.21E-04 Self-reported allergy / / 23817569 rs2417312 chr9 104755999 A G 9.49E-05 Self-reported allergy / / 23817569 rs7873386 chr9 104756598 G A 6.00E-04 Multiple complex diseases / / 17554300 rs10820022 chr9 104757230 C G 8.40E-05 Self-reported allergy / / 23817569 rs3012591 chr9 104757385 G C 2.80E-05 Self-reported allergy / / 23817569 rs1935381 chr9 104760482 G A 1.49E-05 Glucose levels / / pha003061 rs10739819 chr9 104762213 A G 8.87E-05 Self-reported allergy / / 23817569 rs10989753 chr9 104763565 A T 9.21E-04 Multiple complex diseases / / 17554300 rs1418247 chr9 104765867 T G 9.65E-05 Self-reported allergy / / 23817569 rs2995190 chr9 104766075 C T 7.44E-04 Multiple complex diseases / / 17554300 rs10820026 chr9 104768040 T C 1.56E-04 Self-reported allergy / / 23817569 rs10820027 chr9 104768230 G A 6.19E-05 Self-reported allergy / / 23817569 rs10989764 chr9 104769896 T C 9.53E-04 Multiple complex diseases / / 17554300 rs10989766 chr9 104771134 G A 1.15E-04 Myocardial Infarction / / pha002883 rs10118278 chr9 104801485 A G 2.60E-05 Urinary metabolites / / 21572414 rs10739825 chr9 104812127 G T 3.75E-04 Aortic root size / / 21223598 rs7847976 chr9 104812738 T G 9.08E-04 Aortic root size / / 21223598 rs7020246 chr9 104813143 T G 9.38E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs10989791 chr9 104817599 G A 9.26E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs320296 chr9 104830117 G T 6.70E-05 Cognitive impairment induced by topiramate / / 22091778 rs10760837 chr9 104839839 C T 9.38E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1449650 chr9 104844038 G T 9.63E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs10820051 chr9 104844220 T G 9.67E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs11791649 chr9 104848262 C T 5.69E-04 Type 2 diabetes / / 17463246 rs17228531 chr9 104848500 T A 5.49E-04 Type 2 diabetes / / 17463246 rs12006073 chr9 104860473 A G 9.77E-04 Type 2 diabetes / / 17463246 rs10989818 chr9 104860673 G A 8.23E-04 Type 2 diabetes / / 17463246 rs10989824 chr9 104867838 C T 7.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs10989825 chr9 104868071 G A 4.63E-05 Type 2 diabetes / / 17463246 rs10989826 chr9 104868110 A G 4.68E-05 Type 2 diabetes / / 17463246 rs10820064 chr9 104869259 T A 8.48E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs10989829 chr9 104869704 C A 8.51E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs10989833 chr9 104870039 G T 8.55E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs10989837 chr9 104870470 T C 8.65E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs2417321 chr9 104873300 T G 4.63E-05 Type 2 diabetes / / 17463246 rs7034610 chr9 104877235 G A 6.99E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1375704 chr9 104878486 C T 5.47E-04 Type 2 diabetes / / 17463246 rs10512293 chr9 104878920 C T 6.74E-04 Type 2 diabetes / / 17463246 rs10989864 chr9 104898358 C A 5.12E-04 Type 2 diabetes / / 17463246 rs113498057 chr9 104898358 C CGGCTTGTA 5.12E-04 Type 2 diabetes / / 17463246 rs371113657 chr9 104898358 C CGGCTTGTA 5.12E-04 Type 2 diabetes / / 17463246 rs320208 chr9 104944494 T C 9.16E-04 Myocardial Infarction / / pha002883 rs7028042 chr9 104944497 A G 0.000457757 Hypertension (early onset hypertension) / / 22479346 rs320209 chr9 104944755 A T 4.00E-07 Response to antipsychotic treatment / / 20195266 rs10760853 chr9 104961860 C G 8.60E-06 Urinary metabolites / / 21572414 rs16921368 chr9 104971300 A C 0.000163164 Hypertension (early onset hypertension) / / 22479346 rs1932165 chr9 104973626 G A 6.27E-05 Hypertension (early onset hypertension) / / 22479346 rs7862708 chr9 104993515 A G 1.17E-04 Aortic root size / / 21223598 rs10512296 chr9 104993672 T C 1.41E-04 Parkinson's disease / / 21248740 rs1535628 chr9 105016749 G A 0.00000681 Gains in maximal O2 uptake response / / 21183627 rs7036669 chr9 105034238 A G 1.33E-06 Height / / pha003010 rs7036669 chr9 105034238 A G 6.47E-07 Height / / pha003011 rs959066 chr9 105041263 G A 0.000135 Gains in maximal O2 uptake response / / 21183627 rs10820123 chr9 105045726 A C 2.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10739837 chr9 105061142 C T 4.76E-04 Alzheimer's disease / / 22005930 rs13440284 chr9 105062326 C A 7.17E-05 Response to hepatitis C treatment / / 19684573 rs13440284 chr9 105062326 C A 1.80E-04 Myopia (pathological) / / 21095009 rs1475214 chr9 105063597 A C 3.49E-04 Alzheimer's disease / / 22005930 rs4355836 chr9 105072512 T G 3.93E-04 Alzheimer's disease / / 22005930 rs2224763 chr9 105072630 A T 3.53E-04 Alzheimer's disease / / 22005930 rs1924014 chr9 105076320 C T 4.17E-04 Alzheimer's disease / / 22005930 rs12005744 chr9 105077400 G A 4.70E-05 Response to hepatitis C treatment / / 19684573 rs12005744 chr9 105077400 G A 5.61E-04 Myopia (pathological) / / 21095009 rs1543533 chr9 105077543 T C 7.35E-05 Coronary heart disease / / pha003031 rs10733719 chr9 105078519 C G 2.77E-04 Alzheimer's disease / / 22005930 rs10990004 chr9 105086690 C A 3.89E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs9409373 chr9 105090815 A G 3.43E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2417352 chr9 105092830 G A 2.72E-04 Alzheimer's disease / / 22005930 rs10114491 chr9 105093304 A G 2.74E-04 Alzheimer's disease / / 22005930 rs1924025 chr9 105096543 C T 5.61E-04 Myopia (pathological) / / 21095009 rs1477531 chr9 105111068 T C 6.97E-04 Smoking quantity / / 24665060 rs10990032 chr9 105116201 G A 7.06E-04 Alzheimer's disease / / 22005930 rs13294497 chr9 105120673 A G 9.29E-04 Alzheimer's disease / / 22005930 rs1425280 chr9 105120779 T C 2.19E-05 Alzheimer's disease / / 22005930 rs17541319 chr9 105121272 A G 8.50E-04 Alzheimer's disease / / 22005930 rs10441769 chr9 105122350 T G 9.28E-04 Alzheimer's disease / / 22005930 rs12377566 chr9 105129880 G A 1.67E-04 Multiple complex diseases / / 17554300 rs10116192 chr9 105134416 C T 8.28E-04 Multiple complex diseases / / 17554300 rs2417361 chr9 105135141 A G 4.39E-04 Multiple complex diseases / / 17554300 rs7021792 chr9 105147065 C A 5.24E-04 Multiple complex diseases / / 17554300 rs10760889 chr9 105147244 C T 3.42E-04 Smoking initiation / / 24665060 rs10512297 chr9 105195907 G T 8.60E-05 Lipid traits / / 17903299 rs10990103 chr9 105214028 C T 8.07E-05 Longevity / / 20304771 rs10760894 chr9 105219505 C T 8.84E-05 Longevity / / 20304771 rs7849848 chr9 105259717 C T 0.0002 Migraine / / 22678113 rs12002921 chr9 105275743 A C 8.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7029589 chr9 105279735 T G 5.91E-05 Multiple complex diseases / / 17554300 rs7868071 chr9 105293652 A C 7.59E-04 Alzheimer's disease / / 22005930 rs1986364 chr9 105309407 T C 5.11E-05 AIDS / / 19754311 rs4521822 chr9 105315604 T G 0.000308872 Hypertension (early onset hypertension) / / 22479346 rs4743564 chr9 105347447 C A 7.55E-05 Cognitive performance / / 19734545 rs1332980 chr9 105376158 A G 0.000821232 Hypertension (early onset hypertension) / / 22479346 rs10820216 chr9 105405415 G A 5.46E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10820217 chr9 105406083 T C 6.62E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13283389 chr9 105414477 A G 5.40E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10990221 chr9 105417046 A C 7.70E-04 Type 2 diabetes / / 22158537 rs7864985 chr9 105435311 T A 1.06E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2210533 chr9 105442117 A G 7.00E-06 Obesity-related traits / / 23251661 rs10820241 chr9 105464554 T G 5.35E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2210531 chr9 105467805 T C 5.45E-04 Tourette syndrome / / 22889924 rs7350197 chr9 105489651 C A,G,T 9.19E-04 Coronary Artery Disease / / 17634449 rs1492592 chr9 105490129 C T 9.88E-04 Type 2 diabetes / / 17463246 rs2017014 chr9 105492552 A G 8.65E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10990265 chr9 105495740 A T 1.60E-05 Urinary metabolites / / 21572414 rs10990268 chr9 105502498 T C 5.00E-06 Tourette syndrome / / 22889924 rs1580650 chr9 105523821 C T 2.61E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7858600 chr9 105526362 G A 2.26E-04 Tourette syndrome / / 22889924 rs860935 chr9 105591958 C T 9.85E-04 Alzheimer's disease / / 17998437 rs10512305 chr9 105595627 A G 6.17E-05 Diabetes Mellitus / / pha003060 rs7035848 chr9 105606018 A G 2.15E-05 Myopia (pathological) / / 23049088 rs843287 chr9 105618519 A T 3.63E-04 Alzheimer's disease / / 17998437 rs10117096 chr9 105620922 A C 8.02E-06 Sodium levels / / pha003093 rs843285 chr9 105623343 G A 6.80E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs843282 chr9 105625399 C T 7.14E-06 Carotenoid and tocopherol levels / / 19185284 rs2797634 chr9 105640651 G A 2.00E-05 Insulin response / / 19430760 rs7467550 chr9 105662920 C T 5.65E-04 Alzheimer's disease / / 17998437 rs10990387 chr9 105706036 T G 1.09E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4268180 chr9 105724993 C G 2.02E-04 Alzheimer's disease / / 17998437 rs10990394 chr9 105725266 C T 1.40E-04 Sudden cardiac arrest / / 21658281 rs2417407 chr9 105726998 G A 3.19E-05 Bipolar disorder and schizophrenia / / 20889312 rs10990401 chr9 105734010 T C 8.85E-05 Bipolar disorder and schizophrenia / / 20889312 rs1342899 chr9 105735195 C T 8.00E-07 Response to antineoplastic agents / / 21659360 rs1934995 chr9 105746701 A G 1.10E-05 Bipolar disorder and schizophrenia / / 20889312 rs10990410 chr9 105751859 C T 1.13E-04 Multiple complex diseases / / 17554300 rs7856348 chr9 105755995 C A 7.90E-05 Type 2 diabetes / / 17463248 rs1417704 chr9 105756213 T C 3.38E-05 Orofacial clefts / / 22419666 rs1572918 chr9 105779916 T A 1.53E-04 Smoking initiation CYLC2 intron 24665060 rs13289480 chr9 105780450 A C 2.70E-04 Smoking initiation CYLC2 intron 24665060 rs1417705 chr9 105781322 C T 8.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10760934 chr9 105783649 G T 8.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12344642 chr9 105794830 A G 8.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10820351 chr9 105797832 G T 1.56E-05 Asthma / / 23181788 rs1375213 chr9 105812345 C A 7.13E-05 Nonalcoholic fatty liver disease / / 21423719 rs1584415 chr9 105825222 C T 6.27E-05 Bladder cancer / / 19648920 rs1584415 chr9 105825222 C T 0.000302987 Hypertension (early onset hypertension) / / 22479346 rs16936133 chr9 105831341 G A 2.00E-05 Bladder cancer / / 19648920 rs10990619 chr9 105965663 A G 0.00000001 Brain microstructure and intellectual performance / / 22723713 rs7045860 chr9 105973033 C T 8.30E-06 Urinary metabolites / / 21572414 rs1448584 chr9 105974754 G T 5.44E-05 Information processing speed / / 21130836 rs10990652 chr9 106008694 A C 1.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10820405 chr9 106010237 G A 1.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1947880 chr9 106014099 G C 1.07E-05 Alzheimer's disease / / 22005930 rs2417428 chr9 106017061 T C 9.58E-06 Alzheimer's disease / / 22005930 rs535341402 chr9 106017061 TATG T 9.58E-06 Alzheimer's disease / / 22005930 rs7038665 chr9 106017317 G A 1.22E-05 Alzheimer's disease / / 22005930 rs960644 chr9 106020984 A G 1.68E-05 Alzheimer's disease / / 22005930 rs16922670 chr9 106024220 T C 7.00E-06 Alzheimer's disease / / 22005930 rs4295718 chr9 106038803 T C 2.00E-04 Information processing speed / / 21130836 rs1456481 chr9 106039608 G A 4.37E-04 Alzheimer's disease / / 22005930 rs1037661 chr9 106041092 G A 3.82E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10990663 chr9 106041760 G A 5.36E-04 Alzheimer's disease / / 22005930 rs1456486 chr9 106045137 C G 5.61E-04 Alzheimer's disease / / 22005930 rs12352683 chr9 106051864 T C 1.02E-04 Type 2 diabetes / / 17463246 rs12352683 chr9 106051864 T C 5.48E-04 Alzheimer's disease / / 22005930 rs12337792 chr9 106052433 G T 6.06E-04 Alzheimer's disease / / 22005930 rs10820412 chr9 106058590 T C 2.15E-05 Alzheimer's disease / / 22005930 rs12343587 chr9 106065184 A G 4.76E-04 Alzheimer's disease / / 22005930 rs7030511 chr9 106066477 A G 4.71E-04 Alzheimer's disease / / 22005930 rs4743641 chr9 106067533 C T 6.47E-04 Myocardial Infarction / / pha002883 rs12342570 chr9 106067811 C T 4.57E-04 Alzheimer's disease / / 22005930 rs16922740 chr9 106076270 A G 2.96E-04 Alzheimer's disease / / 22005930 rs16922746 chr9 106079694 A C 3.93E-04 Alzheimer's disease / / 22005930 rs408323 chr9 106085677 G A 1.00E-04 Information processing speed / / 21130836 rs450441 chr9 106093936 A G 2.00E-04 Information processing speed / / 21130836 rs303575 chr9 106104878 G A 3.23E-05 Information processing speed / / 21130836 rs303577 chr9 106105939 T C 7.34E-05 Information processing speed / / 21130836 rs303578 chr9 106106390 T G 2.74E-05 Information processing speed / / 21130836 rs1904928 chr9 106120670 G A 7.88E-04 Alzheimer's disease / / 17998437 rs303596 chr9 106122565 G A 2.00E-04 Information processing speed / / 21130836 rs303601 chr9 106124075 G A 2.00E-04 Information processing speed / / 21130836 rs6479168 chr9 106177362 C T 3.78E-05 Bone mineral density (BMD),in women / / 20164292 rs1591687 chr9 106179846 C T 3.60E-05 Bone mineral density (BMD),in women / / 20164292 rs12682841 chr9 106205827 G A 1.26E-05 Coronary heart disease / / pha003030 rs12682841 chr9 106205827 G A 6.14E-05 Coronary heart disease / / pha003031 rs12683176 chr9 106207271 G A 1.57E-04 Glycosylated haemoglobin levels / / 17255346 rs10820425 chr9 106244066 C T 1.80E-05 Urinary metabolites / / 21572414 rs12351109 chr9 106248670 G A 1.23E-04 Body mass index / / 17255346 rs10512315 chr9 106255322 G A 2.28E-05 Bone mass and geometry / / 17903296 rs925224 chr9 106264554 T A 1.83E-04 Body mass index / / 17255346 rs10760969 chr9 106287146 G A 2.01E-05 Body mass index / / 17255346 rs2202828 chr9 106289427 C T 5.23E-05 Body mass index / / 17255346 rs10760970 chr9 106295428 C T 2.30E-05 Urinary metabolites / / 21572414 rs10990763 chr9 106302762 T C 5.96E-05 Glucose levels / / pha003057 rs9299372 chr9 106304253 A C 2.97E-05 Body mass index / / 17255346 rs9299372 chr9 106304253 A C 9.40E-05 Alcoholism (heaviness of drinking) / / 21529783 rs10820453 chr9 106310984 A G 3.02E-05 Glucose levels / / pha003057 rs2786798 chr9 106326245 C T 1.43E-04 Body mass index / / 17255346 rs2786797 chr9 106326604 G A 7.36E-05 Body mass index / / 17255346 rs1995788 chr9 106326805 G C 1.28E-05 Body mass index / / 17255346 rs1337755 chr9 106330626 A G 9.40E-05 Body mass index / / 17255346 rs1337753 chr9 106332172 C T 1.73E-04 Body mass index / / 17255346 rs1396554 chr9 106345310 A G 9.80E-05 Alcoholism (heaviness of drinking) / / 21529783 rs925225 chr9 106361108 C T 4.01E-04 Body mass index / / 17255346 rs144649413 chr9 106369944 G A 9.00E-06 Metabolite levels (MHPG) / / 23319000 rs10990836 chr9 106378468 G A 2.48E-04 Body mass index / / 17255346 rs12554273 chr9 106461857 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs403258 chr9 106477496 A G 8.50E-05 Basophils / / pha003087 rs2196799 chr9 106484791 T C 0.00048 Endometrial cancer / / 22426144 rs988692 chr9 106561925 A C 1.35E-04 Blood pressure / / 17255346 rs7046401 chr9 106563455 G T 1.42E-04 Blood pressure / / 17255346 rs10990950 chr9 106579128 A G 5.76E-05 Coronary heart disease / / pha003056 rs7046385 chr9 106604233 T C 9.99E-04 Celiac disease / / 23936387 rs7847020 chr9 106627186 G A 5.46E-04 Type 2 diabetes / / 17463246 rs12682762 chr9 106665293 G A 3.47E-04 Smoking cessation / / 24665060 rs10990991 chr9 106674850 C T 5.30E-04 Smoking cessation / / 24665060 rs3888912 chr9 106705225 A G 8.49E-04 Multiple complex diseases / / 17554300 rs1562042 chr9 106707614 G A 2.10E-04 Type 2 diabetes / / 21874001 rs501434 chr9 106737655 A T 4.21E-04 Aortic root size / / 21223598 rs1867347 chr9 106772759 A G 2.08E-04 Breast cancer / / pha002853 rs666577 chr9 106778807 G T 3.00E-07 Urinary metabolites / / 21572414 rs1536895 chr9 106793726 A G 3.00E-07 Orofacial clefts (interaction) / / 21618603 rs7859895 chr9 106796731 A T 2.75E-04 Aortic root size / / 21223598 rs7859895 chr9 106796731 A T 5.10E-06 Urinary metabolites / / 21572414 rs7857706 chr9 106800121 C A 2.50E-06 Urinary metabolites / / 21572414 rs7855268 chr9 106804809 G C 2.39E-04 Aortic root size / / 21223598 rs7855268 chr9 106804809 G C 2.50E-06 Urinary metabolites / / 21572414 rs4742899 chr9 106822968 A G 7.74E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10991089 chr9 106834309 C A 7.45E-06 Paget's disease / / 20436471 rs1854535 chr9 106844137 G A 9.50E-06 Urinary metabolites / / 21572414 rs1411104 chr9 106850851 G A 1.30E-05 Urinary metabolites / / 21572414 rs10512326 chr9 106854545 G A 1.20E-04 Obesity-related traits / / 17903300 rs10991104 chr9 106854605 G A 8.49E-05 Major depressive disorder (broad) / / 20038947 rs1360176 chr9 106854716 G T 6.91E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1411103 chr9 106854958 C T 3.22E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs41460248 chr9 106875128 G C 4.01E-04 Multiple complex diseases SMC2 intron 17554300 rs10991125 chr9 106917770 A G 3.25E-04 Type 2 diabetes / / 23300278 rs1470704 chr9 106926908 G A 1.80E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1450685 chr9 106937745 A G 1.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1857985 chr9 106987143 T C 2.61E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7854627 chr9 107000392 G T 3.83E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1507508 chr9 107024516 G A 5.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1450679 chr9 107026812 C T 5.00E-07 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10739887 chr9 107039664 C T 8.92E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3012360 chr9 107057576 A T 9.01E-05 Serum metabolites / / 19043545 rs13302718 chr9 107080360 G A 7.39E-04 Insulin resistance / / 21901158 rs10512323 chr9 107114285 A G 2.84E-05 Information processing speed / / 21130836 rs1565606 chr9 107122545 C T 2.20E-05 Urinary metabolites / / 21572414 rs3012352 chr9 107125805 C T 6.70E-06 Urinary metabolites / / 21572414 rs3012352 chr9 107125805 C T 8.26E-04 Coronary heart disease / / 21606135 rs10820639 chr9 107170699 A G 8.52E-05 Waist-Hip Ratio / / pha003013 rs7865150 chr9 107212335 A G 2.60E-05 Urinary metabolites / / 21572414 rs7865150 chr9 107212335 A G 4.79E-04 Coronary heart disease / / 21606135 rs1826375 chr9 107230263 A G 8.80E-04 Type 2 diabetes / / 17463246 rs698458 chr9 107234110 A G 4.20E-06 Urinary metabolites / / 21572414 rs698458 chr9 107234110 A G 8.77E-04 Coronary heart disease / / 21606135 rs698459 chr9 107234158 T G 5.20E-06 Urinary metabolites / / 21572414 rs698459 chr9 107234158 T G 5.06E-04 Coronary heart disease / / 21606135 rs698460 chr9 107234218 C T 4.70E-06 Urinary metabolites / / 21572414 rs698460 chr9 107234218 C T 6.15E-04 Coronary heart disease / / 21606135 rs792260 chr9 107236146 C G 1.90E-05 Urinary metabolites / / 21572414 rs10120811 chr9 107239149 A T 8.72E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1916675 chr9 107246404 A G 6.20E-05 Coronary heart disease / / 21606135 rs41461344 chr9 107249594 C A 7.62E-04 Type 2 diabetes / / 17463246 rs41461344 chr9 107249594 C A 8.68E-04 Alzheimer's disease / / 17998437 rs7032725 chr9 107250205 G C 6.43E-04 Coronary heart disease / / 21606135 rs10820650 chr9 107257406 T C 2.60E-05 Urinary metabolites / / 21572414 rs10820650 chr9 107257406 T C 5.59E-05 Coronary heart disease / / 21606135 rs10820656 chr9 107260599 C T 2.20E-05 Urinary metabolites / / 21572414 rs10820656 chr9 107260599 C T 1.10E-04 Coronary heart disease / / 21606135 rs10820660 chr9 107265490 A G 1.27E-12 Metabolite levels / / 22286219 rs2030625 chr9 107268432 T G 3.10E-06 Urinary metabolites / / 21572414 rs955610 chr9 107268825 G A 3.40E-06 Urinary metabolites / / 21572414 rs7869260 chr9 107280568 G A 6.14E-05 Socioeconomic Factors / / pha003066 rs10761033 chr9 107292001 T C 5.99E-05 Pancreatic cancer / / pha002874 rs1523670 chr9 107292315 T C 6.70E-05 Pancreatic cancer / / pha002874 rs1464666 chr9 107292997 C A 7.04E-05 Pancreatic cancer / / pha002874 rs10761034 chr9 107294722 T G 9.92E-05 IgE levels / / 22075330 rs6479247 chr9 107297337 A C 5.16E-04 Type 2 diabetes / / 17463246 rs6479250 chr9 107300612 T G 8.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13287980 chr9 107324200 G A 1.09E-07 Urate levels / / 20884846 rs13287980 chr9 107324200 G A 1.00E-06 Gout / / 23263486 rs10739897 chr9 107341056 T C 1.43E-04 Type 2 diabetes / / 17463246 rs4145627 chr9 107341313 C T 1.43E-04 Type 2 diabetes / / 17463246 rs4145630 chr9 107341636 G A 1.40E-04 Type 2 diabetes / / 17463246 rs1403821 chr9 107342109 A G 1.35E-04 Type 2 diabetes / / 17463246 rs7036488 chr9 107342361 A C 1.33E-04 Type 2 diabetes / / 17463246 rs1523682 chr9 107358983 T A 8.88E-05 Type 2 diabetes / / 17463246 rs1357561 chr9 107360014 A G 1.82E-04 Type 2 diabetes / / 17463246 rs6479260 chr9 107361599 G C 3.89E-04 Type 2 diabetes OR13C5 missense 17463246 rs7856737 chr9 107361710 G A 3.77E-05 Type 2 diabetes / / 17463246 rs7866945 chr9 107372489 T C 1.96E-04 Type 2 diabetes / / 17463246 rs7848871 chr9 107372578 C T 1.79E-04 Type 2 diabetes / / 17463246 rs10991330 chr9 107384394 A G 2.10E-04 Type 2 diabetes / / 17463246 rs10761068 chr9 107418661 C T 0.000164 Salmonella-induced pyroptosis / / 22837397 rs10739904 chr9 107430962 T A 1.10E-04 Type 2 diabetes / / 17463246 rs10820709 chr9 107457275 A C 4.95E-04 Multiple complex diseases OR13D1 missense 17554300 rs10820709 chr9 107457275 A C 5.90E-05 Malaria OR13D1 missense 19465909 rs10991360 chr9 107459686 C T 6.14E-04 Multiple complex diseases / / 17554300 rs2162115 chr9 107471308 G T 3.87E-04 Type 2 diabetes / / 17846124 rs10512332 chr9 107474463 T C 4.60E-05 Type 2 diabetes / / 17846124 rs10512332 chr9 107474463 T C 4.60E-05 Type 2 diabetes / / 21647700 rs10739905 chr9 107506122 C T 5.53E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10512333 chr9 107512604 A C 1.56E-04 Type 2 diabetes NIPS/P3A intron 17846124 rs2274870 chr9 107515214 G A 4.00E-06 Response to cytidine analogues (gemcitabine) NIPS/P3A missense 24483146 rs10761082 chr9 107516169 C T 1.83E-05 Response to cytidine analogues (gemcitabine) NIPS/P3A intron 24483146 rs10820722 chr9 107517680 G T 3.20E-05 Response to cytidine analogues (gemcitabine) NIPS/P3A intron 24483146 rs10820723 chr9 107519449 A G 1.74E-04 Response to cytidine analogues (gemcitabine) NIPS/P3A intron 24483146 rs12552611 chr9 107527830 T C 3.89E-04 Type 2 diabetes NIPS/P3B intron 17463246 rs2472476 chr9 107531956 C T 3.00E-06 Obesity-related traits NIPS/P3B intron 23251661 rs2472476 chr9 107531956 C T 1.92E-05 Response to cytidine analogues (gemcitabine) NIPS/P3B intron 24483146 rs10820726 chr9 107532317 A G 2.35E-04 Response to cytidine analogues (gemcitabine) NIPS/P3B intron 24483146 rs11789818 chr9 107547230 C T 8.38E-04 Response to taxane treatment (placlitaxel) ABCA1 intron 23006423 rs2740485 chr9 107548493 G T 3.99E-04 Type 2 diabetes ABCA1 intron 17463246 rs2274871 chr9 107549593 C G 4.88E-06 Bipolar disorder ABCA1 intron 19259986 rs4149333 chr9 107552924 A G 5.30E-06 Chronic kidney disease ABCA1 intron 22479191 rs2230808 chr9 107562804 T C 1.00E-04 Coronary Artery Disease ABCA1 missense 17634449 rs2777800 chr9 107563269 T C 0.0000346 Cholesterol,total ABCA1 intron 23063622 rs1999431 chr9 107564676 T C 1.46E-05 Multiple complex diseases ABCA1 intron 17554300 rs2234885 chr9 107578401 C T 4.46E-04 Type 2 diabetes ABCA1 intron 17463246 rs33918808 chr9 107579632 C G 0.0000404 HDL cholesterol ABCA1 missense 23063622 rs3818688 chr9 107580657 G A 4.04E-04 Lung function (forced expiratory volume in 1 second) ABCA1 intron 17255346 rs3818688 chr9 107580657 G A 2.61E-04 Myocardial Infarction ABCA1 intron pha002883 rs2254884 chr9 107581749 A C 0.000117 Schizophrenia ABCA1 intron 23637625 rs2066714 chr9 107586753 T C 8.06E-05 Myopia (pathological) ABCA1 missense 23049088 rs2066714 chr9 107586753 T C 0.000000434 HDL cholesterol ABCA1 missense 23063622 rs35207495 chr9 107586800 C T 4.31E-12 Triglycerides ABCA1 missense 23063622 rs2066715 chr9 107588033 C T 0.0000794 Cholesterol,total ABCA1 missense 23063622 rs3780543 chr9 107588572 A G 0.000000114 HDL cholesterol ABCA1 intron 23063622 rs4149311 chr9 107588777 C T 9.00E-06 Myopia (pathological) ABCA1 intron 23049088 rs4149310 chr9 107589134 A T 2.00E-10 Metabolite levels (atherosclerosis) ABCA1 intron 22916037 rs2066718 chr9 107589255 C G,T 1.98E-11 HDL cholesterol ABCA1 missense 23063622 rs2853579 chr9 107591272 G T 8.00E-06 Myopia (pathological) ABCA1 cds-synon 23049088 rs2853579 chr9 107591272 G T 8.00E-06 Myopia (pathological) ABCA1 cds-synon 23049088 rs2515629 chr9 107594364 A G 5.00E-07 Coronary heart disease ABCA1 intron 21347282 rs2515629 chr9 107594364 A G 0.000000204 HDL cholesterol ABCA1 intron 22629316 rs2515629 chr9 107594364 A G 0.0000252 HDL cholesterol (female) ABCA1 intron 22629316 rs2065412 chr9 107598740 C T 4.74E-05 Schizophrenia ABCA1 intron 22037552 rs2472386 chr9 107601541 G A 8.87E-05 Eosinophil counts ABCA1 intron pha003088 rs2274873 chr9 107602678 G A 2.21E-04 Birth weight ABCA1 cds-synon 17255346 rs2472449 chr9 107604197 G T 0.0000014 HDL cholesterol ABCA1 intron 22629316 rs2487039 chr9 107617433 C T 7.77E-05 Eosinophil counts ABCA1 intron pha003088 rs9282541 chr9 107620835 G A 7.00E-09 HDL cholesterol ABCA1 missense 18193046 rs9282541 chr9 107620835 G A 6.00E-26 HDL cholesterol ABCA1 missense 23505323 rs1929842 chr9 107633623 G C 3.50E-05 Height ABCA1 intron 21998595 rs2000069 chr9 107635869 C T 0.000000503 HDL cholesterol ABCA1 intron 23063622 rs4149274 chr9 107639414 G A 7.40E-08 Lipid levels ABCA1 intron 18193043 rs4149273 chr9 107642211 T C 3.51E-08 Cholesterol,total ABCA1 intron 23063622 rs4149273 chr9 107642211 T C 5.22E-08 HDL cholesterol ABCA1 intron 23063622 rs4149272 chr9 107642287 C T 2.75E-05 Post-operative nausea and vomiting ABCA1 intron 21694509 rs4149272 chr9 107642287 C T 0.000000025 Cholesterol,total ABCA1 intron 23063622 rs4149272 chr9 107642287 C T 4.54E-08 HDL cholesterol ABCA1 intron 23063622 rs11789603 chr9 107647019 C T 0.00000234 HDL cholesterol (male) ABCA1 intron 23063622 rs11789603 chr9 107647019 C T 3.12E-13 HDL cholesterol ABCA1 intron 23063622 rs11789603 chr9 107647019 C T 9.85E-08 HDL cholesterol (female) ABCA1 intron 23063622 rs4149270 chr9 107647077 G A,C,T 1.24E-04 Type 2 diabetes ABCA1 intron 17463246 rs4149269 chr9 107647121 A G 3.95E-04 Type 2 diabetes ABCA1 intron 17463246 rs4149269 chr9 107647121 A G 9.55E-04 Multiple complex diseases ABCA1 intron 17554300 rs4149269 chr9 107647121 A G 0.000000729 HDL cholesterol ABCA1 intron 23063622 rs4149269 chr9 107647121 A G 1.76E-09 Cholesterol,total ABCA1 intron 23063622 rs4149268 chr9 107647220 C T 1.29E-04 Type 2 diabetes ABCA1 intron 17463246 rs4149268 chr9 107647220 C T 1.00E-10 HDL cholesterol ABCA1 intron 18193043 rs4149268 chr9 107647220 C T 1.00E-10 Coronary heart disease ABCA1 intron 21347282 rs4149268 chr9 107647220 C T 3.22E-09 Cholesterol,total ABCA1 intron 23063622 rs3890182 chr9 107647655 G A 4.28E-06 Type 2 diabetes ABCA1 intron 17463246 rs3890182 chr9 107647655 G A 2.09E-06 Cardiovascular disease ABCA1 intron 18179892 rs3890182 chr9 107647655 G A 3.00E-10 HDL cholesterol ABCA1 intron 18193044 rs3890182 chr9 107647655 G A 5.00E-07 HDL cholesterol ABCA1 intron 20864672 rs3890182 chr9 107647655 G A 3.00E-10 Coronary heart disease ABCA1 intron 21347282 rs3890182 chr9 107647655 G A 1.20E-18 HDL cholesterol ABCA1 intron 23063622 rs3890182 chr9 107647655 G A 4.27E-09 Cholesterol,total ABCA1 intron 23063622 rs3847300 chr9 107648430 G A 1.07E-17 HDL cholesterol ABCA1 intron 23063622 rs3847300 chr9 107648430 G A 8.87E-08 Cholesterol,total ABCA1 intron 23063622 rs3847303 chr9 107648652 C T 3.43E-12 Triglycerides ABCA1 intron 19060911 rs3847303 chr9 107648652 C T 9.03E-05 HDL cholesterol ABCA1 intron pha003074 rs3847303 chr9 107648652 C T 4.78E-05 HDL cholesterol ABCA1 intron pha003075 rs13290420 chr9 107648965 T C 1.41E-18 HDL cholesterol ABCA1 intron 23063622 rs13290420 chr9 107648965 T C 3.91E-09 Cholesterol,total ABCA1 intron 23063622 rs10115928 chr9 107650843 C T 5.26E-05 Post-operative nausea and vomiting ABCA1 intron 21694509 rs10115928 chr9 107650843 C T 6.10E-09 Cholesterol,total ABCA1 intron 23063622 rs2275544 chr9 107651212 T C 0.000000104 Cholesterol,total ABCA1 intron 23063622 rs2275544 chr9 107651212 T C 7.04E-17 HDL cholesterol ABCA1 intron 23063622 rs2275545 chr9 107651526 A G 0.00000132 Cholesterol,total ABCA1 intron 23063622 rs2275545 chr9 107651526 A G 2.47E-15 HDL cholesterol ABCA1 intron 23063622 rs12686004 chr9 107653426 G A 5.31E-05 Type 2 diabetes and other traits ABCA1 intron 19734900 rs12686004 chr9 107653426 G A 2.00E-18 HDL cholesterol ABCA1 intron 21909109 rs12686004 chr9 107653426 G A 1.52E-08 HDL cholesterol ABCA1 intron 23063622 rs12686004 chr9 107653426 G A 5.61E-10 Cholesterol,total ABCA1 intron 23063622 rs3858076 chr9 107656122 A C 0.000000429 Cholesterol,total ABCA1 intron 23063622 rs3858076 chr9 107656122 A C 6.43E-14 HDL cholesterol ABCA1 intron 23063622 rs3905000 chr9 107657070 G A 1.62E-05 Type 2 diabetes ABCA1 intron 17463246 rs3905000 chr9 107657070 G A 9.00E-13 HDL cholesterol ABCA1 intron 19060911 rs3905000 chr9 107657070 G A 2.76E-08 Lipid levels ABCA1 intron 19936222 rs3905000 chr9 107657070 G A 9.00E-06 MRI atrophy measures ABCA1 intron 21116278 rs3905000 chr9 107657070 G A 9.00E-13 Coronary heart disease ABCA1 intron 21347282 rs3905000 chr9 107657070 G A 9.10E-05 Blood Pressure ABCA1 intron pha002898 rs3905000 chr9 107657070 G A 8.36E-05 HDL cholesterol ABCA1 intron pha003074 rs3905000 chr9 107657070 G A 6.29E-05 HDL cholesterol ABCA1 intron pha003075 rs3847305 chr9 107657253 G C 0.000000355 Cholesterol,total ABCA1 intron 23063622 rs3847305 chr9 107657253 G C 1.99E-14 HDL cholesterol ABCA1 intron 23063622 rs12341993 chr9 107658910 C A 0.000000379 Cholesterol,total ABCA1 intron 23063622 rs12341993 chr9 107658910 C A 2.02E-12 HDL cholesterol ABCA1 intron 23063622 rs2777784 chr9 107661059 A G 8.00E-05 Response to statin therapy ABCA1 intron 20339536 rs2777784 chr9 107661059 A G 1.53E-09 Cholesterol,total ABCA1 intron 23063622 rs2777784 chr9 107661059 A G 0.00017 Coronary artery calcification ABCA1 intron 23727086 rs10120087 chr9 107661150 C A 5.08E-08 HDL cholesterol ABCA1 intron 23063622 rs2777786 chr9 107661561 C G 2.02E-04 Type 2 diabetes ABCA1 intron 17463246 rs2777786 chr9 107661561 C G 6.30E-05 Response to statin therapy ABCA1 intron 20339536 rs2575875 chr9 107662494 G A 7.83E-10 Cholesterol,total ABCA1 intron 23063622 rs2575875 chr9 107662494 G A 0.00002 Coronary artery calcification ABCA1 intron 23727086 rs2791950 chr9 107662691 T C 5.70E-05 Response to statin therapy ABCA1 intron 20339536 rs2777791 chr9 107663065 C G 4.80E-05 Response to statin therapy ABCA1 intron 20339536 rs2777792 chr9 107663094 C T 7.20E-05 Response to statin therapy ABCA1 intron 20339536 rs1883025 chr9 107664301 C T 1.00E-09 HDL cholesterol ABCA1 intron 19060906 rs1883025 chr9 107664301 C T 4.81E-06 Lipid levels ABCA1 intron 19913121 rs1883025 chr9 107664301 C T 4.98E-04 Lipid levels ABCA1 intron 19913121 rs1883025 chr9 107664301 C T 2.24E-05 Blood cell counts and other traits ABCA1 intron 20139978 rs1883025 chr9 107664301 C T 6.40E-07 Response to statin therapy ABCA1 intron 20339536 rs1883025 chr9 107664301 C T 2.00E-33 HDL cholesterol ABCA1 intron 20686565 rs1883025 chr9 107664301 C T 3.00E-27 Cholesterol,total ABCA1 intron 20686565 rs1883025 chr9 107664301 C T 1.00E-09 Coronary heart disease ABCA1 intron 21347282 rs1883025 chr9 107664301 C T 1.20E-07 Age-related macular degeneration ABCA1 intron 21665990 rs1883025 chr9 107664301 C T 3.04E-11 Metabolite levels ABCA1 intron 22286219 rs1883025 chr9 107664301 C T 6.00E-10 Metabolic syndrome ABCA1 intron 22399527 rs1883025 chr9 107664301 C T 0.000000625 HDL cholesterol ABCA1 intron 22629316 rs1883025 chr9 107664301 C T 0.0000445 HDL cholesterol (male) ABCA1 intron 22629316 rs1883025 chr9 107664301 C T 1.80E-15 Cholesterol,total ABCA1 intron 23063622 rs1883025 chr9 107664301 C T 5.24E-21 HDL cholesterol ABCA1 intron 23063622 rs1883025 chr9 107664301 C T 2.00E-65 HDL cholesterol ABCA1 intron 24097068 rs1883025 chr9 107664301 C T 6.00E-53 Cholesterol,total ABCA1 intron 24097068 rs1883025 chr9 107664301 C T 7.08E-04 Lipid traits ABCA1 intron 24386095 rs2575876 chr9 107665739 G A 7.50E-07 Response to statin therapy ABCA1 intron 20339536 rs2575876 chr9 107665739 G A 1.20E-07 Metabolic syndrome phenotype ABCA1 intron 22022282 rs2575876 chr9 107665739 G A 6.20E-08 Metabolic syndrome phenotype ABCA1 intron 22022282 rs2575876 chr9 107665739 G A 2.00E-11 Lipid metabolism phenotypes ABCA1 intron 22286219 rs2575876 chr9 107665739 G A 1.05E-16 Cholesterol,total ABCA1 intron 23063622 rs2575876 chr9 107665739 G A 4.65E-21 HDL cholesterol ABCA1 intron 23063622 rs2254819 chr9 107666414 T C 3.88E-10 Cholesterol,total ABCA1 intron 23063622 rs2254819 chr9 107666414 T C 9.87E-16 HDL cholesterol ABCA1 intron 23063622 rs2740486 chr9 107666513 T G 2.80E-09 Lipid levels ABCA1 intron 19936222 rs2740486 chr9 107666513 T G 3.38E-05 HDL particle features ABCA1 intron pha002900 rs3905001 chr9 107668064 G C 8.88E-10 HDL cholesterol ABCA1 intron 23063622 rs13284054 chr9 107669073 T C 2.33E-09 Cholesterol,total ABCA1 intron 23063622 rs13284054 chr9 107669073 T C 3.10E-16 HDL cholesterol ABCA1 intron 23063622 rs4100654 chr9 107669241 T C 5.62E-08 Cholesterol,total ABCA1 intron 23063622 rs4100654 chr9 107669241 T C 8.65E-14 HDL cholesterol ABCA1 intron 23063622 rs2777795 chr9 107672365 G A 0.000000331 HDL cholesterol ABCA1 intron 23063622 rs2777795 chr9 107672365 G A 2.28E-09 Cholesterol,total ABCA1 intron 23063622 rs4149263 chr9 107677289 A G 7.00E-06 Periodontitis (Mean PAL) ABCA1 intron 24024966 rs6479284 chr9 107680355 T A 8.60E-06 Urinary metabolites ABCA1 intron 21572414 rs2515616 chr9 107681995 A G 4.61E-05 Coronary heart disease ABCA1 intron 21606135 rs2515614 chr9 107684318 A C 2.30E-08 Lipid levels ABCA1 intron 19936222 rs2515614 chr9 107684318 A C 3.40E-08 Lipid levels ABCA1 intron 19936222 rs2472493 chr9 107695848 G A 6.70E-05 Glaucoma (primary open-angle) / / 20835238 rs2472493 chr9 107695848 G A 2.00E-04 Information processing speed / / 21130836 rs9919066 chr9 107726821 C T 3.63E-05 Lung adenocarcinoma / / 19836008 rs9919066 chr9 107726821 C T 7.09E-04 Tourette syndrome / / 22889924 rs7023634 chr9 107731789 G A 2.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2185414 chr9 107737067 A G 2.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7019610 chr9 107751593 A G 4.34E-04 Multiple complex diseases / / 17554300 rs1983035 chr9 107780384 G T 8.59E-05 Multiple complex diseases / / 17554300 rs13302605 chr9 107830154 C T 5.37E-04 Obesity (extreme) / / 21935397 rs3132119 chr9 107839645 C A 6.49E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs3132119 chr9 107839645 C A 8.04E-05 Lung function (forced vital capacity) / / pha003104 rs1039407 chr9 107856582 C T 3.77E-05 Cognitive test performance / / 20125193 rs3005716 chr9 107858481 C T 7.55E-05 Post-operative nausea and vomiting / / 21694509 rs10991561 chr9 107917632 T C 9.56E-04 Multiple complex diseases / / 17554300 rs7870426 chr9 107920445 T C 2.93E-04 Multiple complex diseases / / 17554300 rs41339744 chr9 107939665 C T 7.14E-04 Multiple complex diseases / / 17554300 rs327963 chr9 107997081 T C 8.28E-04 Multiple complex diseases / / 17554300 rs16924416 chr9 108055478 T A 4.11E-05 Multiple complex diseases SLC44A1 intron 17554300 rs2812314 chr9 108166606 G T 4.08E-05 Multiple sclerosis / / 20598377 rs10991660 chr9 108218852 A G 6.00E-06 Urinary metabolites FSD1L intron 21572414 rs2149592 chr9 108229990 A G 1.17E-05 Alcohol and nictotine co-dependence FSD1L intron 20158304 rs10991669 chr9 108250836 T C 2.54E-04 Cholesterol FSD1L intron 17255346 rs7867012 chr9 108265876 T C 4.90E-06 Urinary metabolites FSD1L intron 21572414 rs10991677 chr9 108271902 G T 9.31E-04 Type 2 diabetes FSD1L intron 17463246 rs2518129 chr9 108371337 A G 0.000598 Salmonella-induced pyroptosis FKTN intron 22837397 rs10816284 chr9 108380004 G A 4.90E-05 Hypothyroidism FKTN intron 22493691 rs635712 chr9 108415556 T C 1.18E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1463984 chr9 108427062 C T 3.00E-06 Cognitive performance / / 20125193 rs9299108 chr9 108434007 A G 5.71E-05 Post-operative nausea and vomiting / / 21694509 rs10120372 chr9 108440542 T C 4.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs7854091 chr9 108620579 A G 6.38E-04 Type 2 diabetes / / 17463246 rs9969729 chr9 108631950 G A 2.00E-06 Alzheimer's disease (late onset) / / 22881374 rs2997728 chr9 108635487 C G 6.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs2997729 chr9 108638708 A G 9.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs2417650 chr9 108640222 A C 8.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs2860257 chr9 108641374 T C 3.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs3010959 chr9 108641808 C T 4.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs10978329 chr9 108642814 G A 9.71E-05 Bipolar disorder and schizophrenia / / 20889312 rs4612407 chr9 108642925 A T 6.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs2417654 chr9 108643176 G T 7.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs2417656 chr9 108644107 C T 5.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs10978330 chr9 108644325 G A 5.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs4742969 chr9 108645172 A G 8.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs10816352 chr9 108647162 C T 8.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs10978332 chr9 108651205 C G 4.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs4742971 chr9 108655096 G T 8.00E-07 Protein quantitative trait loci / / 18464913 rs2417644 chr9 108655192 G T 6.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs4598317 chr9 108656238 C A 1.35E-04 Gallstones / / 17632509 rs4598317 chr9 108656238 C A 5.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs11531799 chr9 108660350 G A 4.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs6477482 chr9 108662277 T C 3.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs10759148 chr9 108662336 C T 2.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs16925032 chr9 108662938 G T 3.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs10117602 chr9 108663208 T C 3.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs10120538 chr9 108663414 A G 3.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs10115085 chr9 108663489 C T 2.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs7025973 chr9 108664158 T C 3.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs7040788 chr9 108664198 G A 3.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs4742973 chr9 108675647 T A 8.88E-04 Multiple complex diseases / / 17554300 rs2417662 chr9 108681706 A G 9.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs1987247 chr9 108683324 G C 8.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs1987248 chr9 108683365 C T 7.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs10816353 chr9 108683600 A G 7.20E-05 Bipolar disorder and schizophrenia / / 20889312 rs10816353 chr9 108683600 A G 3.44E-05 Schizophrenia / / pha002857 rs10117135 chr9 108683829 A G 6.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs10739216 chr9 108684704 G A 8.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs10733556 chr9 108684735 T C 4.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs10124171 chr9 108684951 C T 4.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs7851747 chr9 108686430 T C 7.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs10759154 chr9 108688630 G C,T 2.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs7470829 chr9 108697256 T C 2.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs6477484 chr9 108702415 C G 3.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs7021067 chr9 108706764 C G 4.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs7043049 chr9 108711745 G C 3.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs2417680 chr9 108750147 T G 9.85E-05 Cognitive impairment induced by topiramate / / 22091778 rs12684572 chr9 108757072 A G 0.00007867 Sarcoidosis / / 22952805 rs2417682 chr9 108779678 G A 4.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4255200 chr9 108793429 G A 9.72E-05 Alzheimer's disease / / 24755620 rs10759169 chr9 108820533 C T 7.75E-04 Alzheimer's disease / / 24755620 rs10512343 chr9 108839164 G A 9.08E-04 Multiple complex diseases / / 17554300 rs2138620 chr9 108841099 A G 7.27E-04 Obesity (extreme) / / 21935397 rs2138630 chr9 108864576 A C,G,T 6.58E-04 Obesity (extreme) / / 21935397 rs885578 chr9 108866460 C A 7.29E-04 Multiple complex diseases / / 17554300 rs7020549 chr9 108867432 G A 6.88E-04 Obesity (extreme) / / 21935397 rs7023595 chr9 108867603 C T 6.87E-04 Obesity (extreme) / / 21935397 rs6477492 chr9 108867720 G A 6.87E-04 Obesity (extreme) / / 21935397 rs10759171 chr9 108870106 C T 6.89E-04 Obesity (extreme) / / 21935397 rs1516892 chr9 108873590 T C 8.16E-04 Obesity (extreme) / / 21935397 rs1878368 chr9 108873997 C T 8.26E-04 Obesity (extreme) / / 21935397 rs10521076 chr9 108878562 C T 7.39E-04 Multiple complex diseases / / 17554300 rs1516883 chr9 108907267 G A 4.77E-09 Menarche (age at onset) / / 19448620 rs9409084 chr9 108907646 A G 2.11E-08 Menarche (age at onset) / / 19448620 rs9299121 chr9 108912412 T A 4.55E-09 Menarche (age at onset) / / 19448620 rs1516882 chr9 108912911 A G 5.14E-09 Menarche (age at onset) / / 19448620 rs1516882 chr9 108912911 A G 7.51E-05 Blood Pressure / / pha003044 rs1516881 chr9 108913054 C G 4.42E-09 Menarche (age at onset) / / 19448620 rs2008393 chr9 108914057 A G 4.35E-09 Menarche (age at onset) / / 19448620 rs10978430 chr9 108916009 C T 6.52E-09 Menarche (age at onset) / / 19448620 rs12686569 chr9 108916711 G T 6.11E-09 Menarche (age at onset) / / 19448620 rs12686569 chr9 108916711 G T 5.56E-05 Blood Pressure / / pha003044 rs2222133 chr9 108917072 T C 6.19E-09 Menarche (age at onset) / / 19448620 rs2222133 chr9 108917072 T C 5.56E-05 Blood Pressure / / pha003044 rs12352703 chr9 108917266 G T 4.55E-09 Menarche (age at onset) / / 19448620 rs10453225 chr9 108920220 G T 5.10E-09 Menarche (age at onset) / / 19448620 rs2417687 chr9 108923457 A G 7.71E-04 Type 2 diabetes / / 17463246 rs2417687 chr9 108923457 A G 6.03E-09 Menarche (age at onset) / / 19448620 rs2138628 chr9 108931732 T A,G 3.20E-09 Menarche (age at onset) / / 19448620 rs7861820 chr9 108936674 T C 4.16E-09 Menarche (age at onset) / / 19448620 rs7861820 chr9 108936674 T C 3.00E-09 Menarche and menopause (age at onset) / / 19448621 rs10156597 chr9 108941509 A T 2.89E-09 Menarche (age at onset) / / 19448620 rs2090409 chr9 108967088 C A 2.00E-09 Menarche (age at onset) / / 19448620 rs2090409 chr9 108967088 C A 2.00E-33 Menarche (age at onset) / / 21102462 rs2090409 chr9 108967088 C A 2.00E-06 Pubertal anthropometrics / / 23449627 rs1516890 chr9 108989399 G A 2.48E-09 Menarche (age at onset) / / 19448620 rs966523 chr9 109057447 C G 4.04E-08 Menarche (age at onset) / / 19448620 rs7859875 chr9 109093375 C T 8.94E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12001203 chr9 109140030 T C 1.46E-04 Hearing function / / 17255346 rs718261 chr9 109156100 A T 5.44E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10759180 chr9 109162816 A G 9.79E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17218614 chr9 109177377 G A 3.75E-05 HIV-1 control / / 20041166 rs902144 chr9 109177571 G C 9.70E-06 Urinary metabolites / / 21572414 rs884975 chr9 109177722 G A 9.70E-06 Urinary metabolites / / 21572414 rs4237181 chr9 109178638 C T 9.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs7031747 chr9 109181406 G A 9.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs10113989 chr9 109185446 T C 7.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs7030135 chr9 109186373 C T 7.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs7038016 chr9 109187743 C T 8.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs7042670 chr9 109189050 A G 1.80E-05 Urinary metabolites / / 21572414 rs16925492 chr9 109201514 C T 7.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs7039680 chr9 109243327 A C 3.60E-08 Urinary metabolites / / 21572414 rs16925517 chr9 109247001 G A 1.90E-07 Asthma (childhood onset) / / 23829686 rs1387595 chr9 109252423 G A 1.87E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11794795 chr9 109254458 T C 1.10E-08 Urinary metabolites / / 21572414 rs7849001 chr9 109265040 T C 2.90E-07 Urinary metabolites / / 21572414 rs6477523 chr9 109265076 G T 2.28E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs16925535 chr9 109291197 C T 1.30E-05 Urinary metabolites / / 21572414 rs10978521 chr9 109305426 G A 3.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7865489 chr9 109312922 G T 4.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10124870 chr9 109323036 C T 4.94E-04 Multiple complex diseases / / 17554300 rs6477527 chr9 109323457 G A 1.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs869562 chr9 109324173 C T 3.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1907438 chr9 109348980 G A 1.50E-04 Multiple complex diseases / / 17554300 rs7871327 chr9 109362226 G A 1.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16925649 chr9 109363730 A G 6.95E-04 Insulin resistance / / 21901158 rs10816400 chr9 109365223 G A 6.17E-05 Multiple complex diseases / / 17554300 rs9942977 chr9 109382361 G A 1.13E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs12002108 chr9 109393957 C T 3.18E-04 Birth weight / / 17255346 rs7044278 chr9 109403758 T C 1.13E-04 Birth weight / / 17255346 rs16925721 chr9 109446865 C G 3.33E-05 Multiple complex diseases / / 17554300 rs10978600 chr9 109467965 T A 2.11E-06 Pulmonary function / / 20010835 rs1491103 chr9 109468107 G A 2.15E-06 Pulmonary function / / 20010835 rs1491102 chr9 109468259 C T 1.86E-06 Pulmonary function / / 20010835 rs10816425 chr9 109477710 C A 9.77E-05 Serum metabolites / / 19043545 rs9942941 chr9 109479134 C T 9.77E-05 Serum metabolites / / 19043545 rs3936578 chr9 109482027 A C 6.88E-06 Pulmonary function / / 20010835 rs1491106 chr9 109483517 G T 1.21E-06 Pulmonary function / / 20010835 rs962719 chr9 109490307 G A 1.19E-06 Pulmonary function / / 20010835 rs1491099 chr9 109508320 C A 8.03E-04 Aortic root size / / 21223598 rs1491121 chr9 109515422 T A 4.80E-04 Self-reported allergy / / 23817569 rs2451948 chr9 109518208 A G 0.0002 Migraine / / 22678113 rs10978630 chr9 109530035 C G 3.74E-04 Type 2 diabetes / / 17463246 rs10759199 chr9 109546063 G C 9.45E-05 Asthma / / 11022011 rs10978647 chr9 109566506 G A 5.30E-06 Urinary metabolites / / 21572414 rs7027110 chr9 109599046 G A 2.00E-13 Height / / 20881960 rs10978661 chr9 109618474 T C 3.36E-04 Aortic root size / / 21223598 rs17787921 chr9 109631825 C T 4.49E-04 Alcohol dependence ZNF462 intron 20201924 rs4743034 chr9 109632353 G A 2.00E-08 Height ZNF462 intron 18391951 rs16925920 chr9 109673244 A G 7.86E-05 Response to cytadine analogues (cytosine arabinoside) ZNF462 intron 24483146 rs1858231 chr9 109676893 A G 2.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule) ZNF462 intron 24025145 rs1000152 chr9 109687288 T C 2.53E-04 Type 2 diabetes ZNF462 cds-synon 17463246 rs1000152 chr9 109687288 T C 8.50E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZNF462 cds-synon 20877124 rs6477552 chr9 109728087 A T 1.90E-05 Urinary metabolites ZNF462 intron 21572414 rs12350828 chr9 109729137 A G 1.90E-05 Urinary metabolites ZNF462 intron 21572414 rs7847708 chr9 109730909 T C 6.80E-06 Urinary metabolites ZNF462 intron 21572414 rs696562 chr9 109809366 T C 4.52E-04 Insulin resistance / / 21901158 rs4978664 chr9 109819928 G A 1.67E-05 Crohn's disease / / 17684544 rs17785871 chr9 109860088 C T 0.0002 Migraine / / 22678113 rs16912217 chr9 109876910 C T 5.77E-05 Cervical cancer / / 24700089 rs1007061 chr9 109882332 G A 3.29E-04 Type 2 diabetes / / 17463246 rs12002945 chr9 109890250 A G 2.06E-04 Type 2 diabetes / / 17463246 rs2417773 chr9 109943165 C T 6.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7032927 chr9 109949144 A G 7.27E-04 Tourette syndrome / / 22889924 rs1519039 chr9 109954812 C T 4.68E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12336793 chr9 109960553 G T 2.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2680198 chr9 109971491 T G 1.41E-05 Telomere length / / 20139977 rs2680198 chr9 109971491 T G 2.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2680197 chr9 109972066 T G 1.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13292544 chr9 109986449 G A 4.85E-05 Serum metabolites / / 19043545 rs13292544 chr9 109986449 G A 1.89E-05 Cognitive test performance / / 20125193 rs17724552 chr9 110000354 G A 3.92E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs1323806 chr9 110006085 C T 8.67E-04 Alcohol dependence / / 20201924 rs10816481 chr9 110042484 T C 9.56E-04 Multiple complex diseases / / 17554300 rs7035611 chr9 110049828 C T 3.72E-04 Type 2 diabetes RAD23B intron 17463246 rs7038659 chr9 110055689 G A 8.67E-05 Tunica Media RAD23B intron pha003034 rs942292 chr9 110076032 C T 0.000115 Salmonella-induced pyroptosis RAD23B intron 22837397 rs1805335 chr9 110081018 A G 0.000283 Salmonella-induced pyroptosis RAD23B intron 22837397 rs1805330 chr9 110084261 C T 1.65E-04 Response to taxane treatment (placlitaxel) RAD23B intron 23006423 rs11573711 chr9 110085568 C T 1.30E-05 Urinary metabolites RAD23B intron 21572414 rs817841 chr9 110100252 G A 4.16E-04 Type 2 diabetes / / 17463246 rs10816493 chr9 110100745 C T 4.91E-04 Type 2 diabetes / / 17463246 rs817843 chr9 110100863 A G 2.57E-04 Type 2 diabetes / / 17463246 rs817844 chr9 110101440 T G 3.70E-04 Type 2 diabetes / / 17463246 rs817852 chr9 110106222 C T 1.90E-05 Urinary metabolites / / 21572414 rs817858 chr9 110125811 C G 7.00E-06 Body mass index / / 20966902 rs12375540 chr9 110136208 T C 7.80E-05 Relative hand skill / / 24068947 rs12343115 chr9 110154147 A G 2.27E-08 Multiple complex diseases / / 17554300 rs817826 chr9 110156300 C T 5.00E-14 Prostate cancer / / 23023329 rs10978832 chr9 110165440 A C 4.90E-04 Multiple complex diseases / / 17554300 rs10978836 chr9 110167753 C T 9.10E-04 Multiple complex diseases / / 17554300 rs17789358 chr9 110184254 G A 2.34E-04 Type 2 diabetes / / 17463246 rs17789358 chr9 110184254 G A 4.50E-06 Urinary metabolites / / 21572414 rs947126 chr9 110195358 G A 3.04E-05 Height / / pha003011 rs17725250 chr9 110238361 G A 5.80E-06 Urinary metabolites / / 21572414 rs7041758 chr9 110280496 C T 3.14E-04 Epilepsy / / 22116939 rs10759243 chr9 110306115 C A 1.00E-08 Breast cancer / / 23535729 rs2258083 chr9 110318782 G A 1.99E-06 Odorant perception / / 23910658 rs12336475 chr9 110356677 A C 2.77E-05 Tourette syndrome / / 22889924 rs6477578 chr9 110362000 C G 6.13E-06 Lipid traits / / 21777205 rs10759245 chr9 110384379 C T 1.80E-04 Parkinson's disease / / 21248740 rs7850292 chr9 110406171 A G 2.89E-05 Personality dimensions / / 22628180 rs7849612 chr9 110418574 G A 8.36E-04 Epilepsy / / 22116939 rs7854757 chr9 110428218 T C 3.77E-05 Personality dimensions / / 22628180 rs940288 chr9 110436996 A G 4.23E-05 Cognitive test performance / / 20125193 rs10759250 chr9 110446704 T C 3.42E-05 Myocardial Infarction / / pha002883 rs2149998 chr9 110462930 C T 6.88E-04 Myocardial Infarction / / pha002883 rs4979264 chr9 110466214 T G 8.86E-05 Cognitive test performance / / 20125193 rs4979264 chr9 110466214 T G 2.32E-04 Myocardial Infarction / / pha002883 rs1411355 chr9 110472296 C T 4.30E-04 Asperger disorder / / 21182207 rs6477592 chr9 110489771 C T 7.13E-05 Serum metabolites / / 19043545 rs4979291 chr9 110495044 C A 1.50E-05 Urinary metabolites / / 21572414 rs41319448 chr9 110500421 A G 1.62E-04 Multiple complex diseases / / 17554300 rs1467311 chr9 110536932 G A 1.00E-06 Glycated hemoglobin levels / / 24647736 rs1330150 chr9 110544407 G A 1.20E-05 Urinary metabolites / / 21572414 rs1330146 chr9 110552239 G A 3.70E-05 Type 2 diabetes / / 17463248 rs10816576 chr9 110553667 G A 3.70E-05 Type 2 diabetes / / 17463248 rs10121193 chr9 110581046 A G 8.40E-05 Type 2 diabetes / / 17463248 rs17880007 chr9 110632904 G C 7.61E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4979515 chr9 110634216 A G 5.00E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13289749 chr9 110650482 T C 4.48E-04 Hemoglobin concentration / / 20534544 rs34048749 chr9 110660983 A G 2.90E-04 Multiple complex diseases / / 17554300 rs1929274 chr9 110661235 A T 5.26E-04 Alzheimer's disease / / 17998437 rs1929276 chr9 110666409 A G 3.63E-05 Triglycerides / / pha003080 rs199958676 chr9 110666409 A AG 3.63E-05 Triglycerides / / pha003080 rs2094919 chr9 110666626 C A 4.56E-05 Triglycerides / / pha003080 rs4978649 chr9 110677097 T C 7.92E-05 HDL cholesterol / / pha003074 rs7863573 chr9 110680544 C T 8.10E-04 Alzheimer's disease / / 17998437 rs7023709 chr9 110685767 T C 3.68E-06 Triglycerides / / pha003080 rs10759267 chr9 110687247 C G 7.30E-04 Alzheimer's disease / / 17998437 rs1339761 chr9 110699777 G C 1.00E-04 Prostate cancer / / 21743057 rs10979119 chr9 110704087 T C 1.00E-04 Prostate cancer / / 21743057 rs12340808 chr9 110705341 T A 1.00E-04 Prostate cancer / / 21743057 rs10512376 chr9 110706865 G C 1.00E-04 Prostate cancer / / 21743057 rs10979126 chr9 110712165 G A 1.13E-04 Alcohol dependence / / 20201924 rs11792080 chr9 110718148 G A 8.35E-06 Serum metabolites / / 19043545 rs41342844 chr9 110722187 G C 7.51E-04 Multiple complex diseases / / 17554300 rs648962 chr9 110728697 A G 7.08E-06 Serum metabolites / / 19043545 rs1554279 chr9 110729237 T C 3.56E-06 Serum metabolites / / 19043545 rs10521086 chr9 110738027 G A 8.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs530723 chr9 110739836 A T 4.19E-06 Serum metabolites / / 19043545 rs657659 chr9 110742851 G A 6.04E-06 Serum metabolites / / 19043545 rs7341756 chr9 110762725 G A 1.62E-05 Glycosylated haemoglobin levels / / 17255346 rs10512369 chr9 110765359 G A 1.06E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs10816609 chr9 110779419 C A 5.52E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4979624 chr9 110782512 C G 4.41E-04 Smoking quantity / / 24665060 rs7868720 chr9 110787096 C T 9.47E-05 Asthma / / 11022011 rs7855502 chr9 110787468 T A 3.63E-04 Smoking quantity / / 24665060 rs1995761 chr9 110795237 A G 5.07E-04 Type 2 diabetes / / 17463246 rs10816619 chr9 110807556 A G 4.18E-10 Multiple complex diseases / / 17554300 rs13301510 chr9 110809708 G A 6.67E-04 Type 2 diabetes / / 17463246 rs10979182 chr9 110817020 A G 0.000000023 Psoriasis / / 23143594 rs4978668 chr9 110817549 G T 6.92E-04 Smoking quantity / / 24665060 rs7042864 chr9 110872307 C T 6.00E-06 Tonometry / / 17903302 rs1025571 chr9 110887048 C A 1.49E-05 Osteoarthritis (knee and hip) / / 21177295 rs1025571 chr9 110887048 C A 8.73E-05 Osteoarthritis (knee and hip) / / 21177295 rs865686 chr9 110888478 G T 2.00E-10 Breast cancer / / 21263130 rs865686 chr9 110888478 G T 1.00E-34 Breast cancer / / 23535729 rs1836458 chr9 110898887 A C 6.36E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10979251 chr9 110909319 T C 7.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs10512365 chr9 110911118 C T 5.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs10512364 chr9 110911316 G A 3.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs633082 chr9 110912805 G C 4.00E-05 Type 2 diabetes / / 17903298 rs10816636 chr9 110918637 A C 8.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs4542003 chr9 110923018 T C 1.90E-04 Alcohol dependence / / 20201924 rs2417845 chr9 110931101 G A 1.53E-04 Multiple complex diseases / / 17554300 rs12377951 chr9 110938232 T C 9.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs10979261 chr9 110939138 A G 8.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs1412428 chr9 110940319 G A 3.64E-04 Alcohol dependence / / 20201924 rs1412427 chr9 110940360 C T 5.73E-04 Alcohol dependence / / 20201924 rs556399 chr9 110955288 G A 3.65E-04 Response to alcohol consumption (flushing response) / / 24277619 rs507242 chr9 110969263 A G 9.16E-05 Height / / pha003011 rs838013 chr9 110969574 T C 9.56E-05 Height / / pha003011 rs7026619 chr9 110978841 A C 0.00006941 Sarcoidosis / / 22952805 rs10979285 chr9 110989866 G A 2.20E-05 Urinary metabolites / / 21572414 rs41438046 chr9 111006875 C A,G 2.61E-04 Smoking quantity / / 24665060 rs41424946 chr9 111007033 T A 9.72E-05 Multiple complex diseases / / 17554300 rs1332297 chr9 111012105 G T 1.79E-04 Multiple complex diseases / / 17554300 rs1332299 chr9 111012416 T C 6.10E-05 Multiple complex diseases / / 17554300 rs10739255 chr9 111023899 C T 2.49E-05 Height / / pha003010 rs10739255 chr9 111023899 C T 5.47E-05 Height / / pha003011 rs2778252 chr9 111026158 G A 5.12E-04 Multiple complex diseases / / 17554300 rs1323397 chr9 111034788 G A 5.82E-05 Height / / pha003010 rs1323397 chr9 111034788 G A 3.55E-05 Height / / pha003011 rs1323374 chr9 111037829 A T 4.98E-05 Multiple complex diseases / / 17554300 rs1570504 chr9 111054809 C A 1.72E-04 Smoking initiation / / 24665060 rs1535619 chr9 111055065 A G 3.43E-04 Smoking initiation / / 24665060 rs10816656 chr9 111062515 A G 7.19E-04 Multiple complex diseases / / 17554300 rs7866786 chr9 111062852 T C 8.21E-04 Multiple complex diseases / / 17554300 rs1323381 chr9 111064438 C T 5.25E-04 Multiple complex diseases / / 17554300 rs1407849 chr9 111064598 A T 3.16E-04 Multiple complex diseases / / 17554300 rs1323382 chr9 111064686 G A 9.91E-04 Multiple complex diseases / / 17554300 rs1323382 chr9 111064686 G A 3.02E-04 Smoking initiation / / 24665060 rs1323383 chr9 111065424 G A 5.96E-06 Height / / pha003010 rs1323383 chr9 111065424 G A 1.38E-05 Height / / pha003011 rs10979316 chr9 111075125 A T 4.40E-04 Depression (quantitative trait) / / 20800221 rs7033347 chr9 111077062 T C 4.69E-04 Depression (quantitative trait) / / 20800221 rs7033858 chr9 111077461 T C 5.27E-04 Depression (quantitative trait) / / 20800221 rs4978679 chr9 111078622 T A 4.77E-04 Depression (quantitative trait) / / 20800221 rs1830704 chr9 111079759 T C 4.82E-04 Depression (quantitative trait) / / 20800221 rs13283083 chr9 111080846 T G 6.27E-04 Depression (quantitative trait) / / 20800221 rs1923964 chr9 111081694 C G 8.67E-08 Narcolepsy / / 19629137 rs10979317 chr9 111081801 T C 6.41E-04 Depression (quantitative trait) / / 20800221 rs4978345 chr9 111082271 T G 5.09E-04 Depression (quantitative trait) / / 20800221 rs1323387 chr9 111083964 A G 5.75E-04 Depression (quantitative trait) / / 20800221 rs1407854 chr9 111084515 T C 6.21E-04 Depression (quantitative trait) / / 20800221 rs1323388 chr9 111085427 T C 5.18E-04 Depression (quantitative trait) / / 20800221 rs7860612 chr9 111085981 C T 5.20E-04 Depression (quantitative trait) / / 20800221 rs7860923 chr9 111086120 G T 6.57E-04 Depression (quantitative trait) / / 20800221 rs942136 chr9 111086396 A G 5.22E-04 Depression (quantitative trait) / / 20800221 rs4631545 chr9 111092662 A T 7.18E-04 Depression (quantitative trait) / / 20800221 rs10816659 chr9 111092798 C T 7.19E-04 Depression (quantitative trait) / / 20800221 rs6477632 chr9 111094462 T C 7.27E-04 Depression (quantitative trait) / / 20800221 rs6477634 chr9 111094710 A G 7.29E-04 Depression (quantitative trait) / / 20800221 rs6477635 chr9 111094805 C G 5.95E-04 Depression (quantitative trait) / / 20800221 rs7035490 chr9 111095529 T A 7.32E-04 Depression (quantitative trait) / / 20800221 rs2417854 chr9 111095847 G C 7.36E-04 Depression (quantitative trait) / / 20800221 rs6477639 chr9 111097895 G C 6.25E-04 Depression (quantitative trait) / / 20800221 rs7031855 chr9 111098115 G A 6.81E-04 Depression (quantitative trait) / / 20800221 rs1323389 chr9 111098510 T C 6.28E-04 Depression (quantitative trait) / / 20800221 rs7863237 chr9 111099150 A G 6.23E-04 Depression (quantitative trait) / / 20800221 rs1323391 chr9 111100388 C T 6.17E-04 Depression (quantitative trait) / / 20800221 rs1323393 chr9 111102607 C T 6.69E-04 Depression (quantitative trait) / / 20800221 rs1923966 chr9 111103718 T G 7.61E-04 Depression (quantitative trait) / / 20800221 rs1923967 chr9 111103947 C G 8.41E-04 Depression (quantitative trait) / / 20800221 rs1114278 chr9 111105109 T C 6.15E-04 Depression (quantitative trait) / / 20800221 rs12550936 chr9 111106217 G T 6.66E-04 Depression (quantitative trait) / / 20800221 rs7043512 chr9 111106263 C G 7.50E-04 Depression (quantitative trait) / / 20800221 rs1323396 chr9 111107191 A C 4.29E-04 Depression (quantitative trait) / / 20800221 rs1323396 chr9 111107191 A C 1.02E-04 Smoking initiation / / 24665060 rs7048064 chr9 111107390 C T 4.34E-04 Depression (quantitative trait) / / 20800221 rs4978685 chr9 111108110 G A 5.52E-04 Depression (quantitative trait) / / 20800221 rs7045550 chr9 111109673 T C 4.58E-04 Depression (quantitative trait) / / 20800221 rs4978686 chr9 111110747 T C 4.61E-04 Depression (quantitative trait) / / 20800221 rs2417855 chr9 111113479 G C 5.43E-04 Depression (quantitative trait) / / 20800221 rs2146785 chr9 111114348 C T 6.05E-04 Depression (quantitative trait) / / 20800221 rs12551690 chr9 111118529 C T 6.72E-04 Depression (quantitative trait) / / 20800221 rs1535622 chr9 111119332 T C 6.19E-04 Depression (quantitative trait) / / 20800221 rs10979326 chr9 111120353 A C 3.17E-04 Depression (quantitative trait) / / 20800221 rs12379749 chr9 111123697 T C 5.42E-04 Depression (quantitative trait) / / 20800221 rs10979332 chr9 111128578 T C 1.60E-04 Depression (quantitative trait) / / 20800221 rs7018489 chr9 111132382 C T 1.29E-04 Depression (quantitative trait) / / 20800221 rs7852356 chr9 111135098 T A 6.69E-04 Depression (quantitative trait) / / 20800221 rs10816664 chr9 111139825 G T 7.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs7048793 chr9 111162207 A T 3.10E-05 Personality dimensions / / 18957941 rs1211179 chr9 111163388 A G 7.21E-04 Type 2 diabetes / / 17463246 rs482574 chr9 111165959 G A 8.47E-04 Type 2 diabetes / / 17463246 rs10816668 chr9 111166719 A G 9.21E-04 Type 2 diabetes / / 17463246 rs564597 chr9 111166760 C T 9.21E-04 Type 2 diabetes / / 17463246 rs1535618 chr9 111175607 T C 2.98E-04 Type 2 diabetes / / 17463246 rs593932 chr9 111184155 A G 1.03E-04 Nonalcoholic fatty liver disease / / 21423719 rs10512360 chr9 111256032 T C 5.50E-06 Urinary metabolites / / 21572414 rs2224806 chr9 111256573 C T 8.66E-05 Bipolar disorder / / 20451256 rs2224806 chr9 111256573 C T 1.20E-05 Urinary metabolites / / 21572414 rs2224806 chr9 111256573 C T 9.19E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10979372 chr9 111259345 T G 2.93E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs10979374 chr9 111272976 C G 8.69E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs7030851 chr9 111281164 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs35791994 chr9 111282843 G A 2.82E-04 Multiple complex diseases / / 17554300 rs10816679 chr9 111283188 T C 3.88E-04 Tourette syndrome / / 22889924 rs11794355 chr9 111286817 A C 7.20E-06 Coffee consumption / / 21357676 rs1006116 chr9 111341664 A G 8.26E-05 Alzheimer's disease / / 21098978 rs16913309 chr9 111343154 C T 9.24E-04 Type 2 diabetes / / 17463246 rs1930095 chr9 111354918 T C 1.31E-05 Intracranial aneurysm / / 20613766 rs12338957 chr9 111369098 T C 3.58E-05 Self-reported allergy / / 23817569 rs10120792 chr9 111377888 G A 6.70E-06 Urinary metabolites / / 21572414 rs10979414 chr9 111387353 G A 7.56E-05 Cognitive impairment induced by topiramate / / 22091778 rs10979414 chr9 111387353 G A 3.67E-05 Schizophrenia / / pha002859 rs13289732 chr9 111387462 A G 3.31E-05 Cognitive impairment induced by topiramate / / 22091778 rs4978721 chr9 111401766 T C 1.09E-05 Cognitive impairment induced by topiramate / / 22091778 rs10122628 chr9 111403445 A G 0.000005 Asthma (exacerbation) / / 23706709 rs10816693 chr9 111404834 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10816693 chr9 111404834 G T 4.26E-05 Blood Pressure / / pha002903 rs10979424 chr9 111405228 C T 5.49E-04 Type 2 diabetes / / 17463246 rs2900469 chr9 111410157 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2900469 chr9 111410157 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs937160 chr9 111417991 G A 1.02E-05 Cognitive impairment induced by topiramate / / 22091778 rs2417919 chr9 111427754 T C 1.22E-05 Cognitive impairment induced by topiramate / / 22091778 rs2417920 chr9 111427865 C T 2.60E-05 Urinary metabolites / / 21572414 rs1319974 chr9 111427977 C A 1.40E-05 Cognitive impairment induced by topiramate / / 22091778 rs1994803 chr9 111435611 A T 2.10E-05 Urinary metabolites / / 21572414 rs11794727 chr9 111435632 A G 8.77E-05 Cognitive test performance / / 20125193 rs11794727 chr9 111435632 A G 9.13E-06 Intelligence / / 21826061 rs1319972 chr9 111443828 T G 4.11E-06 Cognitive impairment induced by topiramate / / 22091778 rs1578230 chr9 111447666 G A 1.20E-05 Urinary metabolites / / 21572414 rs2417927 chr9 111447959 A G 1.00E-05 Urinary metabolites / / 21572414 rs1873759 chr9 111448608 T C 4.84E-06 Cognitive impairment induced by topiramate / / 22091778 rs16913434 chr9 111448624 T C 6.55E-07 Cognitive impairment induced by topiramate / / 22091778 rs1339879 chr9 111454904 G T 4.11E-06 Cognitive impairment induced by topiramate / / 22091778 rs10512385 chr9 111455575 A G 6.00E-06 Paclitaxel-induced neuropathy / / 23776197 rs12686293 chr9 111457987 C T 6.70E-06 Urinary metabolites / / 21572414 rs11791687 chr9 111483336 C T 6.68E-05 Intelligence / / 21826061 rs4978732 chr9 111504057 C T 7.13E-04 Aortic root size / / 21223598 rs10816707 chr9 111504523 G A 8.38E-05 Aortic root size / / 21223598 rs10816707 chr9 111504523 G A 2.80E-05 Urinary metabolites / / 21572414 rs10979461 chr9 111504954 C G 1.04E-04 Aortic root size / / 21223598 rs10979461 chr9 111504954 C G 2.10E-05 Urinary metabolites / / 21572414 rs111488248 chr9 111504954 C CG 1.04E-04 Aortic root size / / 21223598 rs111488248 chr9 111504954 C CG 2.10E-05 Urinary metabolites / / 21572414 rs4978733 chr9 111507044 T C 2.90E-06 Urinary metabolites / / 21572414 rs4636276 chr9 111511616 A G 9.87E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2039810 chr9 111511670 G A 8.62E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10816710 chr9 111511992 T C 5.07E-04 Acute lung injury / / 22295056 rs7036502 chr9 111513134 C T 1.60E-06 Urinary metabolites / / 21572414 rs11789156 chr9 111520844 A G 9.40E-06 Stroke (ischemic) / / 22384361 rs4978738 chr9 111545688 G A 4.80E-04 Myasthenia gravis / / 23055271 rs10120268 chr9 111548104 C T 1.00E-04 Type 2 diabetes / / 17463249 rs10120268 chr9 111548104 C T 1.02E-04 Multiple complex diseases / / 17554300 rs1416898 chr9 111552022 C T 2.69E-04 Multiple complex diseases / / 17554300 rs4490911 chr9 111553314 G T 4.14E-04 Multiple complex diseases / / 17554300 rs7869174 chr9 111554749 G T 2.35E-04 Multiple complex diseases / / 17554300 rs10116332 chr9 111555640 A G 3.89E-04 Multiple complex diseases / / 17554300 rs10979498 chr9 111555993 T C 2.38E-04 IgE levels / / 17255346 rs2153354 chr9 111568028 C G 1.30E-04 Multiple complex diseases / / 17554300 rs4474093 chr9 111571869 A C 8.54E-04 Multiple complex diseases / / 17554300 rs10979515 chr9 111574633 C T 3.63E-04 Body mass index / / 17255346 rs10979540 chr9 111598710 G C 2.70E-04 Multiple complex diseases / / 17554300 rs7872727 chr9 111626090 G A 2.32E-04 Multiple complex diseases / / 17554300 rs12351317 chr9 111628667 C T 0.000219 fMRI brain tests in schizophrenia / / 22440650 rs2027433 chr9 111637304 G T 2.07E-04 Prion diseases IKBKAP intron 22210626 rs9299166 chr9 111639682 C T 8.99E-04 Bipolar disorder IKBKAP intron 19259986 rs3818875 chr9 111640524 G C 8.99E-04 Bipolar disorder IKBKAP intron 19259986 rs10435834 chr9 111640631 C T 5.70E-04 Type 2 diabetes IKBKAP intron 17463246 rs7874280 chr9 111642535 T C 9.22E-05 Coronary restenosis IKBKAP intron 21878436 rs7873793 chr9 111643875 G A 5.39E-05 Personality dimensions IKBKAP intron 18957941 rs2275495 chr9 111644396 G A 0.000391 fMRI brain tests in schizophrenia IKBKAP intron 22440650 rs4978374 chr9 111646983 A G 6.17E-04 Multiple complex diseases IKBKAP intron 17554300 rs10816756 chr9 111647581 A C 2.04E-04 Prion diseases IKBKAP intron 22210626 rs10816756 chr9 111647581 A C 0.000514 fMRI brain tests in schizophrenia IKBKAP intron 22440650 rs3204145 chr9 111651620 A T 5.26E-05 Personality dimensions IKBKAP missense 18957941 rs10118853 chr9 111652022 C A 5.11E-05 Personality dimensions IKBKAP intron 18957941 rs3780512 chr9 111654395 C T 3.12E-05 Information processing speed IKBKAP intron 21130836 rs947196 chr9 111655932 A T 4.24E-04 Type 2 diabetes IKBKAP intron 17463246 rs947196 chr9 111655932 A T 1.58E-04 Multiple complex diseases IKBKAP intron 17554300 rs4369056 chr9 111668438 C T 8.56E-04 Multiple complex diseases IKBKAP intron 17554300 rs838827 chr9 111668652 C T 0.000568 fMRI brain tests in schizophrenia IKBKAP missense 22440650 rs1759852 chr9 111670056 T A 5.11E-04 Type 2 diabetes IKBKAP intron 17463246 rs838826 chr9 111670100 C A 2.43E-04 Type 2 diabetes IKBKAP intron 17463246 rs838825 chr9 111670423 A C 6.44E-06 Non-small cell lung cancer IKBKAP intron 21866343 rs1772047 chr9 111679012 A G 6.48E-04 Type 2 diabetes IKBKAP intron 17463246 rs16913693 chr9 111680359 T G 5.72E-14 Fasting blood glucose IKBKAP intron 22885924 rs3750457 chr9 111684989 T C 4.12E-04 Type 2 diabetes IKBKAP intron 17463246 rs10979615 chr9 111698789 C T 4.63E-04 Type 2 diabetes FAM206A intron 17463246 rs12351693 chr9 111711515 A G 4.65E-04 Type 2 diabetes CTN/L1 intron 17463246 rs874863 chr9 111728577 A G 9.08E-05 Information processing speed CTN/L1 intron 21130836 rs2304780 chr9 111732644 G C 7.14E-04 Multiple complex diseases CTN/L1 intron 17554300 rs10979633 chr9 111733282 C T 3.21E-04 Multiple complex diseases CTN/L1 intron 17554300 rs4978765 chr9 111735885 T G 7.23E-04 Type 2 diabetes CTN/L1 intron 17463246 rs10512390 chr9 111753682 T C 8.44E-05 Coronary restenosis CTN/L1 intron 21878436 rs838836 chr9 111754288 T C 0.000543 fMRI brain tests in schizophrenia CTN/L1 intron 22440650 rs4978766 chr9 111762887 A G 8.39E-04 Type 2 diabetes CTN/L1 intron 17463246 rs1772033 chr9 111769543 G A 5.63E-06 Non-small cell lung cancer CTN/L1 intron 21866343 rs10816767 chr9 111782670 G A 0.0000387 Amyotrophic lateral sclerosis TMEM245 UTR-3 23587638 rs10115972 chr9 111786448 A G 0.000568 fMRI brain tests in schizophrenia TMEM245 intron 22440650 rs1537431 chr9 111788228 T C 0.0000479 Amyotrophic lateral sclerosis TMEM245 intron 23587638 rs643410 chr9 111799563 A C 1.00E-06 Schizophrenia (negative symptoms) TMEM245 intron 23382809 rs11787869 chr9 111831600 G A 8.68E-05 Coronary heart disease TMEM245 intron pha003030 rs562982 chr9 111840500 C T 8.16E-04 Stroke TMEM245 intron pha002886 rs10979684 chr9 111845798 G A 8.34E-04 Multiple complex diseases TMEM245 intron 17554300 rs523340 chr9 111854246 G A 2.00E-06 Information processing speed TMEM245 intron 21130836 rs1519466 chr9 111860797 C T 3.52E-06 Information processing speed TMEM245 intron 21130836 rs2805888 chr9 111880736 T C 2.30E-04 Obesity (extreme) TMEM245 intron 21935397 rs7861082 chr9 111888778 C T 7.10E-05 Coronary restenosis / / 21878436 rs1533642 chr9 111903349 C T 2.35E-05 Information processing speed FRRS1L intron 21130836 rs1533641 chr9 111911775 G A 5.10E-04 Obesity (extreme) FRRS1L intron 21935397 rs999729 chr9 111911823 C G 2.30E-05 Non-small cell lung cancer FRRS1L intron 21866343 rs1467242 chr9 111913454 A G 2.30E-05 Non-small cell lung cancer FRRS1L intron 21866343 rs1467242 chr9 111913454 A G 5.47E-05 Coronary heart disease FRRS1L intron pha003031 rs10759330 chr9 111914037 T C 5.17E-04 Obesity (extreme) FRRS1L intron 21935397 rs10979712 chr9 111915474 T C 2.18E-06 Coronary heart disease FRRS1L intron pha003031 rs6477693 chr9 111918365 C A 1.50E-04 Smoking behavior FRRS1L intron 20418888 rs6477693 chr9 111918365 C A 1.45E-04 Obesity (extreme) FRRS1L intron 21935397 rs10979720 chr9 111920745 C A 1.93E-05 Non-small cell lung cancer FRRS1L intron 21866343 rs369572084 chr9 111920745 C CCCCTGTA 1.93E-05 Non-small cell lung cancer FRRS1L intron 21866343 rs544847642 chr9 111920745 C CCCCTGTA 1.93E-05 Non-small cell lung cancer FRRS1L intron 21866343 rs4978774 chr9 111925315 A G 1.18E-04 Obesity (extreme) FRRS1L intron 21935397 rs4978774 chr9 111925315 A G 0.000692561 Primary sclerosing cholangitis FRRS1L intron 23603763 rs2139350 chr9 111928593 A G 9.47E-05 Coronary restenosis FRRS1L intron 21878436 rs6477694 chr9 111932342 C T 8.66E-04 Obesity (extreme) / / 21935397 rs10759332 chr9 111934261 A G 4.95E-04 Nicotine smoking EPB41L4B UTR-3 19268276 rs7858727 chr9 111936128 C A 0.0000185 post-traumatic stress disorder EPB41L4B UTR-3 22869035 rs7858727 chr9 111936128 C A 1.85E-05 Schizophrenia EPB41L4B UTR-3 22883433 rs10979727 chr9 111936788 C T 3.51E-05 Coronary restenosis EPB41L4B UTR-3 21878436 rs4978776 chr9 111937552 C T 1.00E-04 Information processing speed EPB41L4B intron 21130836 rs10119402 chr9 111938125 G T 0.0000132 post-traumatic stress disorder EPB41L4B intron 22869035 rs10119402 chr9 111938125 G T 1.32E-05 Schizophrenia EPB41L4B intron 22883433 rs885505 chr9 111941854 A C 2.73E-05 Coronary restenosis EPB41L4B intron 21878436 rs908859 chr9 111941857 T C 1.86E-05 Information processing speed EPB41L4B intron 21130836 rs10816778 chr9 111943009 C T 9.67E-06 Coronary restenosis EPB41L4B intron 21878436 rs3750450 chr9 111945049 T G 0.0000897 post-traumatic stress disorder EPB41L4B missense 22869035 rs3750450 chr9 111945049 T G 8.97E-05 Schizophrenia EPB41L4B missense 22883433 rs3983526 chr9 111945992 T C 1.69E-05 Coronary restenosis EPB41L4B intron 21878436 rs10116353 chr9 111950088 G T 9.51E-05 Coronary restenosis EPB41L4B intron 21878436 rs6415807 chr9 111958345 G A 0.0000131 post-traumatic stress disorder EPB41L4B intron 22869035 rs6415807 chr9 111958345 G A 1.31E-05 Schizophrenia EPB41L4B intron 22883433 rs4978780 chr9 111967572 C T 1.27E-05 Coronary restenosis EPB41L4B intron 21878436 rs12684047 chr9 111972671 T A 3.22E-04 Nicotine smoking EPB41L4B intron 19268276 rs7858370 chr9 111973020 G A 0.000262 Schizophrenia EPB41L4B intron 22440650 rs4978783 chr9 111978049 C A 7.87E-05 Coronary restenosis EPB41L4B intron 21878436 rs12553631 chr9 111984713 C T 6.93E-04 Insulin resistance EPB41L4B intron 21901158 rs17200841 chr9 111996188 C T 2.77E-04 Amyotrophic lateral sclerosis (sporadic) EPB41L4B intron 24529757 rs2004094 chr9 112021852 T C 0.000504474 Hypertension (early onset hypertension) EPB41L4B intron 22479346 rs10979785 chr9 112032220 T C 6.41E-04 Insulin resistance EPB41L4B intron 21901158 rs4978790 chr9 112033401 C T 5.27E-05 Kawasaki disease EPB41L4B intron 22081228 rs3793552 chr9 112039400 C T 9.59E-05 Cognitive impairment induced by topiramate EPB41L4B intron 22091778 rs4978791 chr9 112040717 C T 0.000634281 Hypertension (early onset hypertension) EPB41L4B intron 22479346 rs999485 chr9 112047495 C A 2.45E-04 Alzheimer's disease (late onset) EPB41L4B intron 21379329 rs10512392 chr9 112056059 C T 7.43E-04 Longevity EPB41L4B intron 22279548 rs3763640 chr9 112070162 G T 7.43E-05 Multiple complex diseases EPB41L4B intron 17554300 rs10122294 chr9 112074707 A G 4.00E-07 Parkinson's disease (interaction with coffee consumption) EPB41L4B intron 21876681 rs10759339 chr9 112094109 G C 0.0003319 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10759339 chr9 112094109 G C 3.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7863010 chr9 112103798 T C 0.0001853 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7863010 chr9 112103798 T C 1.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7847955 chr9 112104111 C A 0.0001817 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7847955 chr9 112104111 C A 1.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12685074 chr9 112115687 C T 7.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs17793521 chr9 112129721 A G 4.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs12551129 chr9 112133083 C T 5.90E-04 Coronary Artery Disease / / 17634449 rs12551129 chr9 112133083 C T 2.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs3793569 chr9 112148314 A G 5.04E-04 Suicide attempts in bipolar disorder PTPN3 intron 21423239 rs7866508 chr9 112179110 G A 0.0006 Erectile dysfunction after radiotherapy for prostate cancer PTPN3 intron 23021708 rs10979861 chr9 112197634 T C 2.00E-04 Cognitive impairment induced by topiramate PTPN3 intron 22091778 rs10979870 chr9 112211392 G A 2.80E-05 Urinary metabolites PTPN3 UTR-5 21572414 rs10979876 chr9 112213363 G A 2.90E-05 Urinary metabolites PTPN3 UTR-5 21572414 rs4978818 chr9 112272229 G C 8.03E-05 Body mass (lean) / / 19268274 rs10759345 chr9 112279045 A G 9.17E-04 Alzheimer's disease / / 17998437 rs7858161 chr9 112325051 G A 8.55E-05 Serum albumin level / / pha003084 rs7020545 chr9 112329589 A C 3.80E-05 Serum albumin level / / pha003084 rs13284716 chr9 112333025 T C 1.93E-05 Serum albumin level / / pha003084 rs13284589 chr9 112348882 C T 7.45E-06 Serum albumin level / / pha003084 rs7044539 chr9 112353128 C T 1.21E-05 Serum albumin level / / pha003084 rs7857453 chr9 112354798 A G 1.00E-05 Serum albumin level / / pha003084 rs7863484 chr9 112378977 C G 9.65E-05 Bipolar disorder and schizophrenia / / 20889312 rs10979965 chr9 112383429 C T 4.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16914315 chr9 112418293 G A 7.22E-05 Intelligence PALM2 intron 21826061 rs10979990 chr9 112429319 C T 6.68E-04 Parkinson's disease PALM2 intron 16252231 rs10816852 chr9 112431958 G A 3.56E-05 Triglycerides PALM2 intron pha003080 rs1358913 chr9 112441911 A G 8.06E-05 Prion diseases PALM2 intron 22210626 rs7035307 chr9 112468586 A T 2.70E-05 Urinary metabolites PALM2 intron 21572414 rs1322275 chr9 112480192 A G 1.03E-04 Prion diseases PALM2 intron 22210626 rs12340768 chr9 112491559 T C 2.90E-05 Cognitive function PALM2 intron 24684796 rs10980019 chr9 112495131 T C 3.40E-05 Cognitive function PALM2 intron 24684796 rs3117682 chr9 112504271 T C 2.34E-04 Cholesterol PALM2 intron 17255346 rs3117682 chr9 112504271 T C 7.78E-06 Cognitive function PALM2 intron 24684796 rs10115465 chr9 112510942 A G 2.90E-05 Cognitive function PALM2 intron 24684796 rs10512400 chr9 112512382 A C 1.90E-04 Cholesterol PALM2 intron 17255346 rs10512400 chr9 112512382 A C 1.50E-05 Cognitive function PALM2 intron 24684796 rs10980026 chr9 112515043 A G 2.90E-05 Cognitive function PALM2 intron 24684796 rs10980027 chr9 112515228 G A 2.90E-05 Cognitive function PALM2 intron 24684796 rs7042004 chr9 112515704 G A 1.90E-04 Cholesterol PALM2 intron 17255346 rs7042004 chr9 112515704 G A 1.50E-05 Cognitive function PALM2 intron 24684796 rs17202497 chr9 112516346 G A 1.50E-05 Cognitive function PALM2 intron 24684796 rs4978846 chr9 112517179 C G 1.69E-04 Cholesterol PALM2 intron 17255346 rs1327788 chr9 112518894 G A 3.10E-05 Cognitive function PALM2 intron 24684796 rs4978848 chr9 112521126 G C 3.00E-06 Cognitive function PALM2 intron 24684796 rs4246875 chr9 112521563 A C 4.90E-05 Cognitive function PALM2 intron 24684796 rs1327796 chr9 112526289 C G 3.00E-06 Type 2 diabetes PALM2 intron 22456796 rs1028867 chr9 112528882 A G 7.29E-05 Blood pressure PALM2 intron 17255346 rs1028867 chr9 112528882 A G 8.48E-05 Alzheimer's disease (late onset) PALM2 intron 23565137 rs2025875 chr9 112596911 G A 8.00E-06 Obesity-related traits PALM2 intron 23251661 rs11794095 chr9 112605138 T C 2.97E-05 Alzheimer's disease (late onset) PALM2 intron 23565137 rs12235555 chr9 112606312 A T 3.94E-05 Alzheimer's disease (late onset) PALM2 intron 23565137 rs10980082 chr9 112606655 A G 1.89E-05 Alzheimer's disease (late onset) PALM2 intron 23565137 rs11789107 chr9 112606832 A G 1.38E-05 Alzheimer's disease (late onset) PALM2 intron 23565137 rs11789107 chr9 112606832 A G 7.09E-04 Alzheimer's disease (late onset) PALM2 intron 23565137 rs13299867 chr9 112607260 C T 6.48E-05 Alzheimer's disease (late onset) PALM2 intron 23565137 rs13300030 chr9 112607376 A G 3.25E-04 Alzheimer's disease (late onset) PALM2 intron 23565137 rs13300030 chr9 112607376 A G 3.32E-06 Alzheimer's disease (late onset) PALM2 intron 23565137 rs2769151 chr9 112608710 A G 6.01E-04 Amyotrophic Lateral Sclerosis PALM2 intron 17827064 rs2769151 chr9 112608710 A G 6.31E-05 Cognitive impairment induced by topiramate PALM2 intron 22091778 rs10816895 chr9 112609522 A C 1.95E-05 Alzheimer's disease (late onset) PALM2 intron 23565137 rs10816895 chr9 112609522 A C 4.60E-04 Alzheimer's disease (late onset) PALM2 intron 23565137 rs913360 chr9 112611379 T G 1.83E-07 Alzheimer's disease (late onset) PALM2 intron 23565137 rs913360 chr9 112611379 T G 2.27E-05 Alzheimer's disease (late onset) PALM2 intron 23565137 rs913360 chr9 112611379 T G 6.60E-06 Alzheimer's disease (late onset) PALM2 intron 23565137 rs913361 chr9 112611525 G A 1.96E-07 Alzheimer's disease (late onset) PALM2 intron 23565137 rs913361 chr9 112611525 G A 2.60E-05 Alzheimer's disease (late onset) PALM2 intron 23565137 rs13283845 chr9 112613183 C T 6.82E-07 Alzheimer's disease (late onset) PALM2 intron 23565137 rs13283845 chr9 112613183 C T 7.64E-05 Alzheimer's disease (late onset) PALM2 intron 23565137 rs34879704 chr9 112619327 G A 6.57E-04 Alzheimer's disease (late onset) PALM2 intron 23565137 rs34879704 chr9 112619327 G A 6.90E-05 Alzheimer's disease (late onset) PALM2 intron 23565137 rs13298370 chr9 112627830 G C 1.02E-05 Alzheimer's disease (late onset) PALM2 intron 23565137 rs13298370 chr9 112627830 G C 4.16E-04 Alzheimer's disease (late onset) PALM2 intron 23565137 rs13299632 chr9 112630042 A G 4.86E-05 Alzheimer's disease (late onset) PALM2 intron 23565137 rs10980112 chr9 112666483 G A 7.58E-04 Glycemic traits (pregnancy) PALM2 intron 23903356 rs12000736 chr9 112691620 T A 3.24E-04 Insulin resistance PALM2 intron 21901158 rs4978866 chr9 112735585 T C 6.99E-04 Suicide attempts in bipolar disorder PALM2-AKAP2 intron 21423239 rs995294 chr9 112739344 C T 3.07E-04 Smoking initiation PALM2-AKAP2 intron 24665060 rs4978411 chr9 112750411 T C 5.70E-05 Smoking initiation PALM2-AKAP2 intron 24665060 rs12337887 chr9 112751907 A T 6.41E-04 Acute lung injury PALM2-AKAP2 intron 22295056 rs7864442 chr9 112757604 C A 1.99E-04 Alzheimer's disease (late onset) PALM2-AKAP2 intron 21379329 rs6477736 chr9 112769632 A G 2.98E-04 Alzheimer's disease (late onset) PALM2-AKAP2 intron 21379329 rs260193 chr9 112783050 A C 2.85E-04 Alzheimer's disease PALM2-AKAP2 intron 17998437 rs260214 chr9 112809494 C G 9.77E-04 Alzheimer's disease PALM2-AKAP2 intron 17998437 rs260214 chr9 112809494 C G 1.43E-04 Acute lung injury PALM2-AKAP2 intron 22295056 rs260221 chr9 112814823 G T 9.66E-05 Acute lung injury AKAP2 intron 22295056 rs260222 chr9 112815188 G A 9.66E-05 Acute lung injury AKAP2 intron 22295056 rs482678 chr9 112820418 A C 1.53E-04 Tourette syndrome AKAP2 intron 22889924 rs10980170 chr9 112822183 G A 5.56E-04 Tourette syndrome AKAP2 intron 22889924 rs545955 chr9 112824301 G C 8.94E-05 Acute lung injury AKAP2 intron 22295056 rs521883 chr9 112826429 A G 9.97E-05 Acute lung injury AKAP2 intron 22295056 rs492649 chr9 112827305 A G 8.51E-05 Acute lung injury AKAP2 intron 22295056 rs491744 chr9 112827405 G A 4.07E-04 Acute lung injury AKAP2 intron 22295056 rs491730 chr9 112832400 T C 2.32E-06 Alzheimer's disease AKAP2 intron 17998437 rs481661 chr9 112839238 G A 5.15E-04 Acute lung injury AKAP2 intron 22295056 rs1980874 chr9 112850080 G A 2.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) AKAP2 intron 17982456 rs7038399 chr9 112853511 G A 1.72E-04 Systemic lupus erythematosus and Systemic sclerosis AKAP2 intron 23740937 rs10980207 chr9 112874028 A G 3.92E-04 Aortic root size AKAP2 intron 21223598 rs17806457 chr9 112891635 C T 6.00E-06 Body mass index (education interaction) AKAP2 intron 24281739 rs3739456 chr9 112900785 A G 9.97E-05 Cognitive test performance AKAP2 cds-synon 20125193 rs4978873 chr9 112902561 G A 8.31E-05 Cognitive test performance AKAP2 intron 20125193 rs10125067 chr9 112933781 A G 8.99E-04 Alcohol dependence AKAP2 UTR-3 20201924 rs7032940 chr9 112945405 G A 3.00E-06 Height / / 19893584 rs10481661 chr9 112953100 T C 2.46E-05 Serum metabolites / / 19043545 rs10512403 chr9 112962809 G A 9.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) C9orf152 UTR-3 17982456 rs9299183 chr9 112981272 C T 8.38E-04 Coronary heart disease / / 21606135 rs10816943 chr9 112983819 A G 8.00E-05 Glaucoma (primary open-angle) / / 20835238 rs10816943 chr9 112983819 A G 4.64E-07 Myocardial Infarction / / pha002883 rs4246880 chr9 112987690 C T 1.26E-04 Birth weight / / 17255346 rs4135168 chr9 113016885 T C 4.95E-06 Phospholipid levels (plasma) TXN intron 21829377 rs2301241 chr9 113019508 G A 5.19E-07 Coronary heart disease / / 22319020 rs10980296 chr9 113032678 G C 1.71E-04 Birth weight / / 17255346 rs1556047 chr9 113043999 G A 0.0000683 Uterine leiomyomata / / 23040493 rs7869617 chr9 113060439 A C 3.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10759405 chr9 113061311 A C 2.08E-04 Acute lung injury / / 22295056 rs7855326 chr9 113068793 G C 3.09E-04 Response to taxane treatment (placlitaxel) TXNDC8 intron 23006423 rs10759407 chr9 113068881 T G 2.87E-04 Acute lung injury TXNDC8 intron 22295056 rs10759408 chr9 113068958 C A 2.52E-04 Acute lung injury TXNDC8 intron 22295056 rs10816965 chr9 113069090 A G 2.22E-04 Acute lung injury TXNDC8 intron 22295056 rs10759409 chr9 113070578 G A 2.48E-04 Acute lung injury TXNDC8 intron 22295056 rs963143 chr9 113112572 G T 0.000185 Breast cancer early age of onset / / 18463975 rs10816985 chr9 113116973 G C 0.000243 Breast cancer early age of onset / / 18463975 rs1327533 chr9 113131163 T G 1.00E-06 Longevity SVEP1 intron 20834067 rs4978927 chr9 113196429 C T 9.92E-05 Multiple complex diseases SVEP1 intron 17554300 rs7042161 chr9 113197263 T C 6.00E-06 Bipolar disorder SVEP1 intron 18711365 rs1931321 chr9 113205702 A G 8.56E-05 Multiple complex diseases SVEP1 intron 17554300 rs4421419 chr9 113213726 A G 9.19E-05 Multiple complex diseases SVEP1 intron 17554300 rs4978928 chr9 113218306 T C 8.55E-05 Multiple complex diseases SVEP1 intron 17554300 rs10817025 chr9 113234507 T C 0.0002 Migraine SVEP1 missense 22678113 rs10512405 chr9 113236797 T C 0.0000121 Migraine SVEP1 intron 22678113 rs10512405 chr9 113236797 T C 1.21E-05 Migraine SVEP1 intron 22683712 rs10980405 chr9 113238870 C G 7.35E-05 Multiple complex diseases SVEP1 intron 17554300 rs10817026 chr9 113239268 C T 0.0000232 Migraine SVEP1 intron 22678113 rs10817026 chr9 113239268 C T 2.32E-05 Migraine SVEP1 intron 22683712 rs10739303 chr9 113250699 G A 1.72E-04 Multiple complex diseases SVEP1 intron 17554300 rs4978934 chr9 113254704 C T 9.23E-04 Multiple complex diseases SVEP1 intron 17554300 rs10817033 chr9 113259152 T G 0.00041 Breast cancer SVEP1 missense 23555315 rs4427239 chr9 113270601 A G 0.0003576 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SVEP1 intron 23233654 rs4427239 chr9 113270601 A G 3.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) SVEP1 intron 23233662 rs4403484 chr9 113279114 A G 7.26E-04 Response to cytadine analogues (cytosine arabinoside) SVEP1 intron 24483146 rs7028943 chr9 113289207 T A 0.0002048 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SVEP1 intron 23233654 rs7028943 chr9 113289207 T A 2.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) SVEP1 intron 23233662 rs4300064 chr9 113296046 T C 3.27E-05 Cognitive test performance SVEP1 intron 20125193 rs1889321 chr9 113300835 C T 7.00E-07 Pulmonary function decline SVEP1 intron 22424883 rs12001338 chr9 113303685 G A 3.85E-05 Cognitive test performance SVEP1 intron 20125193 rs10980437 chr9 113310476 G A 2.13E-04 Type 2 diabetes SVEP1 intron 22158537 rs16915123 chr9 113317662 T C 1.85E-04 Type 2 diabetes SVEP1 intron 22158537 rs11795219 chr9 113328717 C A 5.20E-05 Bone mineral density SVEP1 intron 19181680 rs10980451 chr9 113332268 C T 5.94E-10 Coronary heart disease SVEP1 intron 23364394 rs10817041 chr9 113336728 G C 8.04E-04 Smoking cessation SVEP1 intron 24665060 rs4978947 chr9 113368778 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7470394 chr9 113380772 T A 8.63E-04 Multiple complex diseases / / 17554300 rs10980508 chr9 113419759 A T 1.00E-06 Type 2 diabetes (dietary heme iron intake interaction) / / 23386860 rs4269612 chr9 113423432 A C 5.76E-04 Multiple complex diseases / / 17554300 rs4269612 chr9 113423432 A C 9.91E-04 Response to TNF antagonist treatment / / 21061259 rs10980535 chr9 113472810 A C 8.90E-05 Elbow pain MUSK intron pha003008 rs4336672 chr9 113485961 A C 3.37E-04 Schizophrenia MUSK intron 19197363 rs4259484 chr9 113486002 T C 9.79E-04 Depression (quantitative trait) MUSK intron 20800221 rs4259484 chr9 113486002 T C 1.50E-04 Response to cytidine analogues (gemcitabine) MUSK intron 24483146 rs4332201 chr9 113488684 T C 8.92E-04 Depression (quantitative trait) MUSK intron 20800221 rs4332201 chr9 113488684 T C 1.35E-04 Response to cytidine analogues (gemcitabine) MUSK intron 24483146 rs10817087 chr9 113490776 C T 2.53E-04 Response to cytidine analogues (gemcitabine) MUSK intron 24483146 rs10759465 chr9 113493797 A G 2.62E-05 Odorant perception MUSK intron 23910658 rs4532674 chr9 113503776 C T 5.00E-04 Schizophrenia MUSK intron 19197363 rs10121886 chr9 113518165 T C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes MUSK intron 22628534 rs1940247 chr9 113523032 C T 2.30E-04 Myopia (pathological) MUSK intron 21095009 rs1940247 chr9 113523032 C T 3.70E-06 Urinary metabolites MUSK intron 21572414 rs10817091 chr9 113527226 G A 2.18E-04 Type 2 diabetes MUSK intron 19184112 rs2766984 chr9 113541125 C T 4.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MUSK intron 20877124 rs2767000 chr9 113552214 A G 8.51E-04 Myocardial Infarction MUSK intron pha002883 rs523299 chr9 113560468 T C 1.28E-04 Schizophrenia(treatment response to risperidone) MUSK intron 19850283 rs2821142 chr9 113566357 C T 8.51E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs16915435 chr9 113579789 A G 8.51E-04 Multiple complex diseases / / 17554300 rs509276 chr9 113581359 G A 1.40E-04 Alcohol dependence / / 20201924 rs509276 chr9 113581359 G A 2.50E-05 Alcohol dependence / / 20201924 rs509276 chr9 113581359 G A 2.53E-05 Alcoholism / / pha002892 rs12553421 chr9 113582672 A C 5.75E-04 Type 2 diabetes / / 17463246 rs2767001 chr9 113584012 A G 6.87E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs553219 chr9 113612463 C T 7.71E-05 Glucose levels / / pha003058 rs521522 chr9 113620186 A G 1.20E-05 Urinary metabolites / / 21572414 rs554504 chr9 113621464 T A 1.20E-05 Urinary metabolites / / 21572414 rs556471 chr9 113622213 C G 1.20E-05 Urinary metabolites / / 21572414 rs474186 chr9 113622466 A G 1.20E-05 Urinary metabolites / / 21572414 rs4978964 chr9 113633647 G A 8.77E-05 Glucose levels / / pha003058 rs544276 chr9 113640468 A G 7.59E-04 Type 2 diabetes LPAR1 intron 17463246 rs7029898 chr9 113646892 C A 5.46E-09 Cholesterol,total LPAR1 intron 23063622 rs1536435 chr9 113648839 A G 1.10E-04 Pancreatic cancer LPAR1 intron pha002874 rs1536435 chr9 113648839 A G 9.93E-05 Pancreatic cancer LPAR1 intron pha002889 rs1007000 chr9 113662681 C T 5.00E-12 Corneal structure LPAR1 intron 23291589 rs1409684 chr9 113665254 C T 7.00E-04 Atrial fibrillation LPAR1 intron 21846873 rs1409684 chr9 113665254 C T 1.70E-06 Corneal structure LPAR1 intron 23291589 rs2766987 chr9 113667957 A C 2.40E-05 Urinary metabolites LPAR1 intron 21572414 rs4246883 chr9 113674955 A G 0.0000306 Nonsyndromic striae distensae (stretch marks) LPAR1 intron 23633020 rs1326898 chr9 113675287 T C 0.0000419 Nonsyndromic striae distensae (stretch marks) LPAR1 intron 23633020 rs10980631 chr9 113675950 T C 0.0000447 Nonsyndromic striae distensae (stretch marks) LPAR1 intron 23633020 rs10817110 chr9 113676086 T C 0.0000447 Nonsyndromic striae distensae (stretch marks) LPAR1 intron 23633020 rs62573185 chr9 113676759 A G 0.0000419 Nonsyndromic striae distensae (stretch marks) LPAR1 intron 23633020 rs10817111 chr9 113678725 A T 0.0000933 Nonsyndromic striae distensae (stretch marks) LPAR1 intron 23633020 rs2766996 chr9 113687727 T G 2.40E-05 Urinary metabolites LPAR1 intron 21572414 rs7030789 chr9 113735512 A G 0.0000015 Apnea hypopnea index LPAR1 intron 23155414 rs10980684 chr9 113756464 T C 1.20E-04 Systemic lupus erythematosus(serologic and cytokine profiles in serum) LPAR1 intron 20659327 rs41506255 chr9 113779436 G A 3.72E-04 Multiple complex diseases LPAR1 intron 17554300 rs12353038 chr9 113782852 G A 2.59E-04 Lung function (forced vital capacity) LPAR1 intron 24023788 rs10980699 chr9 113790030 A G 7.47E-05 Waist Circumference LPAR1 intron pha003023 rs4978977 chr9 113791920 A C 2.17E-05 Gaucher disease severity LPAR1 intron 22388998 rs1468758 chr9 113807082 C T 1.00E-09 Height / / 20881960 rs4978434 chr9 113811445 C T 1.38E-05 Coronary heart disease / / pha003030 rs1978302 chr9 113834396 C G 7.53E-04 Depression (quantitative trait) / / 20800221 rs1978305 chr9 113834511 A G 3.77E-04 Type 2 diabetes / / 17463246 rs717890 chr9 113835380 A G 1.82E-04 Bipolar disorder / / 19259986 rs7861175 chr9 113857337 T C 7.98E-06 Cardiovascular disease / / 18179892 rs9299191 chr9 113864545 C T 1.79E-05 Pulmonary function / / 17903307 rs10491533 chr9 113864650 C T 6.59E-04 Multiple complex diseases / / 17554300 rs10980782 chr9 113885694 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7870066 chr9 113911613 T C 1.00E-04 Information processing speed / / 21130836 rs10980800 chr9 113915905 T C 2.00E-22 White blood cell count / / 21738480 rs17207006 chr9 113943573 A C 5.87E-05 Multiple complex diseases / / 17554300 rs7046956 chr9 113957534 C T 3.56E-05 Information processing speed / / 21130836 rs10817162 chr9 113971089 G A 7.90E-05 White matter hyperintensity burden / / 21681796 rs865412 chr9 113974398 T G 3.45E-04 Type 2 diabetes / / 17463246 rs10980827 chr9 113980690 G T 4.00E-04 Type 2 diabetes / / 17463246 rs2570377 chr9 113981087 G A 3.81E-04 Type 2 diabetes / / 17463246 rs2570388 chr9 113992598 G A 5.17E-04 Type 2 diabetes / / 17463246 rs690722 chr9 114044933 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10980854 chr9 114050357 G A 5.76E-04 Coronary heart disease / / 21971053 rs1036281 chr9 114051427 T G 7.17E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs691859 chr9 114071071 A G 2.00E-04 Information processing speed / / 21130836 rs314450 chr9 114079196 T G 1.62E-04 Multiple complex diseases / / 17554300 rs1060736 chr9 114126119 T C 3.24E-04 Type 2 diabetes KIAA0368 intron 17463246 rs12338044 chr9 114153117 T A 5.17E-04 Type 2 diabetes KIAA0368 intron 17463246 rs3737126 chr9 114155811 T C 3.01E-05 Creutzfeldt-Jakob disease (variant) KIAA0368 intron 22137330 rs12350676 chr9 114170130 A G 3.08E-04 Type 2 diabetes KIAA0368 intron 17463246 rs2274899 chr9 114173564 T A 8.70E-05 Longevity KIAA0368 intron 20304771 rs7857003 chr9 114218760 G A 2.46E-04 Type 2 diabetes KIAA0368 intron 17463246 rs7857003 chr9 114218760 G A 8.42E-04 Multiple complex diseases KIAA0368 intron 17554300 rs41465450 chr9 114238515 G A 1.27E-05 Multiple complex diseases KIAA0368 intron 17554300 rs41475647 chr9 114238734 C T 5.82E-06 Esophageal cancer (squamous cell) KIAA0368 intron 22960999 rs7857580 chr9 114276945 G A 3.92E-04 Type 2 diabetes / / 17463246 rs4448355 chr9 114283045 T C 2.39E-04 Type 2 diabetes / / 17463246 rs4448355 chr9 114283045 T C 4.92E-04 Multiple complex diseases / / 17554300 rs10980926 chr9 114293634 A G 4.00E-11 Menarche (age at onset) ZNF483 intron 21102462 rs10980926 chr9 114293634 A G 2.00E-07 Pubertal anthropometrics ZNF483 intron 23449627 rs10980926 chr9 114293634 A G 3.00E-06 Pubertal anthropometrics ZNF483 intron 23449627 rs10441737 chr9 114301585 C T 2.56E-15 Menarche (age at onset) ZNF483 intron 23599027 rs10441737 chr9 114301585 C T 4.00E-15 Menarche (age at onset) ZNF483 intron 23599027 rs7873730 chr9 114303679 A T 2.00E-06 Menarche (age at onset) ZNF483 intron 23599027 rs7873730 chr9 114303679 A T 3.80E-15 Menarche (age at onset) ZNF483 intron 23599027 rs7027778 chr9 114318911 A G 3.64E-04 Type 2 diabetes PTGR1 intron 17463246 rs2146078 chr9 114326505 T G 4.65E-05 Lymphocyte counts PTGR1 intron 22286170 rs10817190 chr9 114344403 G A 8.99E-06 Height PTGR1 intron pha003010 rs10817190 chr9 114344403 G A 1.07E-05 Height PTGR1 intron pha003011 rs2273788 chr9 114348617 C T 5.00E-07 Monocyte counts PTGR1 intron 23314186 rs10980968 chr9 114373275 G A 8.22E-04 Multiple complex diseases LRRC37A5P intron 17554300 rs10121085 chr9 114386599 C T 6.88E-04 Multiple complex diseases / / 17554300 rs10121085 chr9 114386599 C T 4.99E-05 Prostate cancer / / pha002878 rs10125351 chr9 114388307 T C 7.95E-04 Multiple complex diseases / / 17554300 rs1885502 chr9 114399968 C A 2.06E-04 Multiple complex diseases D/JC25 intron 17554300 rs1570304 chr9 114401173 C T 3.01E-04 Insulin resistance D/JC25 intron 21901158 rs2146079 chr9 114406649 A G 6.95E-05 Type 1 diabetes D/JC25 intron 18978792 rs7853362 chr9 114461241 G C 4.16E-04 Type 2 diabetes C9orf84 intron 17463246 rs953536 chr9 114489887 C T 8.20E-06 Obesity-related traits C9orf84 intron 17903300 rs10981043 chr9 114502742 G A 1.70E-06 Height C9orf84 intron 20400458 rs10981043 chr9 114502742 G A 2.54E-04 Bipolar disorder,affective C9orf84 intron 20528957 rs41306457 chr9 114508557 G A 0.000077 Breast cancer(er negative) C9orf84 missense 23555315 rs7029339 chr9 114519599 G C 1.48E-12 Metabolite levels C9orf84 intron 22286219 rs10817215 chr9 114521630 A G 6.57E-05 Bipolar disorder,affective C9orf84 UTR-5 20528957 rs315711 chr9 114548451 G A 6.70E-04 Type 2 diabetes / / 17463246 rs315711 chr9 114548451 G A 5.40E-05 Obesity-related traits / / 17903300 rs10283479 chr9 114558001 A G 1.73E-04 Bipolar disorder,affective / / 20528957 rs446465 chr9 114562289 T G 6.21E-04 Type 2 diabetes / / 17463246 rs10981079 chr9 114563069 C A 1.13E-04 Bipolar disorder,affective / / 20528957 rs667463 chr9 114567760 T C 7.00E-05 Obesity-related traits / / 17903300 rs315701 chr9 114568897 T C 7.93E-04 Type 2 diabetes / / 17463246 rs7875230 chr9 114572011 C T 9.30E-05 Bipolar disorder,affective / / 20528957 rs17735670 chr9 114572504 G C 1.69E-05 Bipolar disorder,affective / / 20528957 rs7036787 chr9 114591865 A G 2.17E-04 Hearing function / / 17255346 rs7036787 chr9 114591865 A G 2.00E-05 Urinary metabolites / / 21572414 rs4978466 chr9 114599048 G A 5.08E-05 Information processing speed / / 21130836 rs1547308 chr9 114603240 C T 5.34E-04 Multiple complex diseases / / 17554300 rs10817224 chr9 114606949 G A 4.26E-05 Multiple complex diseases / / 17554300 rs11788458 chr9 114618021 A G 0.000000542 Femoral neck bone mineral density / / 22692763 rs11788458 chr9 114618021 A G 0.000054 Femoral neck bone mineral density (females) / / 22692763 rs12379047 chr9 114629162 G A 2.55E-04 Alzheimer's disease / / 24755620 rs7858428 chr9 114632873 C T 9.98E-04 Alzheimer's disease / / 24755620 rs2418192 chr9 114643893 T C 1.57E-05 Elbow pain / / pha003008 rs10981136 chr9 114645077 C T 1.60E-05 Urinary metabolites / / 21572414 rs1813202 chr9 114688103 A G 8.84E-05 Elbow pain UGCG intron pha003008 rs7860208 chr9 114699757 T C 2.03E-05 Elbow pain / / pha003008 rs7854170 chr9 114702514 G A 5.56E-05 Elbow pain / / pha003008 rs10817244 chr9 114706886 T A 6.00E-05 Prostate cancer / / 21743057 rs10817245 chr9 114706973 C T 2.77E-05 Serum metabolites / / 19043545 rs10817245 chr9 114706973 C T 4.00E-05 Prostate cancer / / 21743057 rs10817246 chr9 114707212 T C 4.00E-05 Prostate cancer / / 21743057 rs10981171 chr9 114707438 T C 4.00E-05 Prostate cancer / / 21743057 rs7028129 chr9 114707622 G A 4.00E-05 Prostate cancer / / 21743057 rs10513152 chr9 114708331 A G 5.00E-05 Prostate cancer / / 21743057 rs419097 chr9 114711743 C T 2.62E-04 Hearing function / / 17255346 rs1105564 chr9 114722246 G T 1.08E-05 Lymphocyte counts / / 22286170 rs4401941 chr9 114778046 C T 4.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs10981210 chr9 114780290 T C 4.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs10125054 chr9 114798037 G A 4.00E-06 Obesity-related traits / / 23251661 rs7854368 chr9 114807641 A G 4.72E-06 Serum dimethylarginine levels (symmetric) SUSD1 intron 24159190 rs1864357 chr9 114812743 G A 6.36E-06 Serum dimethylarginine levels (symmetric) SUSD1 intron 24159190 rs4979078 chr9 114823121 T C 3.00E-06 Venous thromboembolism SUSD1 intron 23650146 rs9695757 chr9 114826645 A G 2.50E-06 Serum dimethylarginine levels (symmetric) SUSD1 intron 24159190 rs9695214 chr9 114826794 T C 2.49E-06 Serum dimethylarginine levels (symmetric) SUSD1 intron 24159190 rs10817260 chr9 114828332 C T 2.33E-06 Serum dimethylarginine levels (symmetric) SUSD1 intron 24159190 rs13290725 chr9 114839134 G A 5.84E-04 Suicide attempts in bipolar disorder SUSD1 intron 21423239 rs7862743 chr9 114839679 G T 6.74E-04 Suicide attempts in bipolar disorder SUSD1 intron 21423239 rs16916637 chr9 114841632 C G 6.50E-04 Suicide attempts in bipolar disorder SUSD1 intron 21423239 rs16916643 chr9 114843661 C T 7.85E-04 Suicide attempts in bipolar disorder SUSD1 intron 21423239 rs3849119 chr9 114844254 A G 8.10E-04 Suicide attempts in bipolar disorder SUSD1 intron 21423239 rs12344697 chr9 114844813 A T 9.42E-04 Suicide attempts in bipolar disorder SUSD1 intron 21423239 rs12353280 chr9 114849482 C T 4.30E-04 Suicide attempts in bipolar disorder SUSD1 intron 21423239 rs2782931 chr9 114850190 C T 6.00E-06 Amyotrophic lateral sclerosis SUSD1 intron 17362836 rs4979082 chr9 114864734 C G 9.02E-04 Suicide attempts in bipolar disorder SUSD1 intron 21423239 rs12686374 chr9 114868037 G A 9.37E-04 Suicide attempts in bipolar disorder SUSD1 intron 21423239 rs7040124 chr9 114871202 C T 8.76E-04 Suicide attempts in bipolar disorder SUSD1 intron 21423239 rs2476934 chr9 114875617 T C 2.14E-05 Serum metabolites SUSD1 intron 19043545 rs7849584 chr9 114876846 G A 7.84E-04 Suicide attempts in bipolar disorder SUSD1 intron 21423239 rs10981291 chr9 114924720 T C 6.46E-04 Response to cytadine analogues (cytosine arabinoside) SUSD1 intron 24483146 rs781621 chr9 114927397 G A 8.52E-04 Suicide attempts in bipolar disorder SUSD1 intron 21423239 rs10759528 chr9 114929943 G T 9.98E-04 Multiple complex diseases SUSD1 intron 17554300 rs4979085 chr9 114931106 G T 7.75E-04 Iron levels SUSD1 intron pha002876 rs10739335 chr9 114934114 C A 3.80E-04 Suicide attempts in bipolar disorder SUSD1 intron 21423239 rs7043510 chr9 114935040 G A 9.57E-04 Suicide attempts in bipolar disorder SUSD1 intron 21423239 rs10114892 chr9 114935976 G A 9.56E-04 Suicide attempts in bipolar disorder SUSD1 intron 21423239 rs943617 chr9 114937852 A G 3.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs10125827 chr9 114944506 C T 5.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs1887518 chr9 114957457 A G 9.05E-04 Rheumatoid arthritis / / 21452313 rs14255 chr9 114981378 T G 3.07E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) PTBP3 UTR-3 23648065 rs1534069 chr9 114985497 T C 1.97E-04 Amyotrophic lateral sclerosis (sporadic) PTBP3 UTR-3 24529757 rs6477900 chr9 114989616 A G 1.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) PTBP3 intron 23648065 rs7026917 chr9 114990872 C T 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer PTBP3 intron 21245432 rs7026917 chr9 114990872 C T 5.84E-04 Rheumatoid arthritis PTBP3 intron 21452313 rs6477901 chr9 114992714 C T 0.00000113 Primary sclerosing cholangitis PTBP3 intron 23603763 rs2027384 chr9 115000234 G A 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer PTBP3 intron 21245432 rs1359878 chr9 115011317 G A 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer PTBP3 intron 21245432 rs10817301 chr9 115015710 G A 3.83E-05 Osteoarthritis (knee and hip) PTBP3 intron 21177295 rs10817301 chr9 115015710 G A 8.46E-04 Osteoarthritis (knee and hip) PTBP3 intron 21177295 rs6477905 chr9 115023661 C T 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer PTBP3 intron 21245432 rs7870866 chr9 115030570 C T 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer PTBP3 intron 21245432 rs7875779 chr9 115039845 T C 1.86E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) PTBP3 intron 23648065 rs2148991 chr9 115070928 T A 2.23E-04 Smoking initiation PTBP3 intron 24665060 rs4542000 chr9 115088669 T C 1.38E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) PTBP3 intron 23648065 rs946816 chr9 115091259 T C 9.34E-04 Multiple complex diseases PTBP3 intron 17554300 rs7040447 chr9 115095743 T C 1.37E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) PTBP3 intron 23648065 rs10817323 chr9 115111709 G A 7.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs4098492 chr9 115125172 A G 0.0008768 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4098492 chr9 115125172 A G 8.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10739347 chr9 115131672 G A 9.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7024102 chr9 115132897 G C 9.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4979106 chr9 115134357 C T 9.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4273920 chr9 115134789 T A 9.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7862690 chr9 115137476 T C 6.14E-04 Age-related macular degeneration / / 22125219 rs4422838 chr9 115138478 C T 9.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7858897 chr9 115139882 A G 9.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3813857 chr9 115141833 A G 9.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6477924 chr9 115141946 A G 9.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4979110 chr9 115142134 A G 9.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2418206 chr9 115144581 C T 9.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) HSDL2 intron 23233662 rs7039649 chr9 115147463 G A 9.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) HSDL2 intron 23233662 rs7852741 chr9 115156389 C T 7.91E-04 Suicide attempts in bipolar disorder HSDL2 intron 21423239 rs4978489 chr9 115167146 T C 1.51E-06 Creatinine levels HSDL2 intron pha003069 rs10817341 chr9 115196558 A G 8.14E-05 Blood pressure (response to angiotensin II receptor blocker) HSDL2 intron 24192120 rs10817344 chr9 115205042 T G 4.96E-07 Creatinine levels HSDL2 intron pha003069 rs16916995 chr9 115213702 G A 7.39E-07 Creatinine levels HSDL2 intron pha003069 rs3849130 chr9 115218388 T C 1.00E-04 Postoperative ventricular dysfunction HSDL2 intron 21980348 rs3849130 chr9 115218388 T C 0.0005445 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) HSDL2 intron 23233654 rs3849130 chr9 115218388 T C 5.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) HSDL2 intron 23233662 rs10759566 chr9 115219141 T C 9.71E-05 Postoperative ventricular dysfunction HSDL2 intron 21980348 rs7846977 chr9 115220067 A G 9.71E-05 Postoperative ventricular dysfunction HSDL2 intron 21980348 rs7032579 chr9 115223298 G A 9.71E-05 Postoperative ventricular dysfunction HSDL2 intron 21980348 rs2900543 chr9 115224399 T C 9.71E-05 Postoperative ventricular dysfunction HSDL2 intron 21980348 rs10981416 chr9 115228455 T C 9.71E-05 Postoperative ventricular dysfunction HSDL2 intron 21980348 rs10283468 chr9 115243683 T C 9.71E-05 Postoperative ventricular dysfunction / / 21980348 rs7023765 chr9 115244422 A G 9.71E-05 Postoperative ventricular dysfunction / / 21980348 rs6477941 chr9 115252349 T C 5.26E-05 Postoperative ventricular dysfunction KIAA1958 intron 21980348 rs3849131 chr9 115258710 T C 8.30E-05 Postoperative ventricular dysfunction KIAA1958 intron 21980348 rs10739360 chr9 115272992 G A 9.71E-05 Postoperative ventricular dysfunction KIAA1958 intron 21980348 rs4979128 chr9 115289605 T C 2.96E-06 Creatinine levels KIAA1958 intron pha003069 rs3983387 chr9 115320787 T C 8.09E-06 Creatinine levels KIAA1958 intron pha003069 rs2593684 chr9 115347088 G A 2.15E-05 Creatinine levels KIAA1958 intron pha003069 rs2676624 chr9 115359049 T C 5.30E-06 Creatinine levels KIAA1958 intron pha003069 rs11789059 chr9 115397206 C T 5.16E-05 Schizophrenia(age at onset) KIAA1958 intron 21688384 rs2798311 chr9 115399594 C T 3.84E-06 Obesity (extreme) KIAA1958 intron 21935397 rs10513167 chr9 115405798 C T 1.34E-04 Aortic root size KIAA1958 intron 21223598 rs786990 chr9 115416257 A G 8.12E-05 Breast cancer KIAA1958 intron 21060860 rs4979141 chr9 115417171 G A 4.56E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KIAA1958 intron 20877124 rs4979142 chr9 115421424 G A 7.23E-04 Parkinson's disease KIAA1958 intron 17052657 rs786965 chr9 115448195 A C 2.41E-05 Obesity (extreme) / / 21935397 rs786965 chr9 115448195 A C 6.69E-04 Smoking initiation / / 24665060 rs786966 chr9 115448341 T G 2.38E-05 Obesity (extreme) / / 21935397 rs786969 chr9 115449556 C G 2.46E-04 Obesity (extreme) C9orf80 UTR-3 21935397 rs1711746 chr9 115452656 A G 2.07E-05 Obesity (extreme) C9orf80 intron 21935397 rs1711746 chr9 115452656 A G 6.66E-05 Brain derived neurotrophic factor levels,in serum C9orf80 intron 22047184 rs1711745 chr9 115452909 C A 2.09E-05 Obesity (extreme) C9orf80 intron 21935397 rs1711744 chr9 115453484 T A 5.41E-05 Smoking initiation C9orf80 intron 24665060 rs786977 chr9 115459708 A G 2.11E-05 Obesity (extreme) C9orf80 intron 21935397 rs786977 chr9 115459708 A G 1.56E-05 Brain derived neurotrophic factor levels,in serum C9orf80 intron 22047184 rs786978 chr9 115460239 G A 8.41E-04 Multiple complex diseases C9orf80 intron 17554300 rs786978 chr9 115460239 G A 2.11E-05 Obesity (extreme) C9orf80 intron 21935397 rs2798316 chr9 115462552 T C 6.16E-04 Obesity (extreme) C9orf80 intron 21935397 rs2185769 chr9 115462594 A G 7.38E-05 Obesity (extreme) C9orf80 intron 21935397 rs2185769 chr9 115462594 A G 1.52E-05 Brain derived neurotrophic factor levels,in serum C9orf80 intron 22047184 rs2185768 chr9 115462645 C T 6.17E-04 Obesity (extreme) C9orf80 intron 21935397 rs2153837 chr9 115463001 T A 7.41E-05 Obesity (extreme) C9orf80 intron 21935397 rs1711739 chr9 115464474 G A 7.45E-05 Obesity (extreme) C9orf80 intron 21935397 rs1418410 chr9 115465282 A G 7.49E-05 Obesity (extreme) C9orf80 intron 21935397 rs1418410 chr9 115465282 A G 8.59E-05 Brain derived neurotrophic factor levels,in serum C9orf80 intron 22047184 rs786961 chr9 115471346 T C 7.51E-05 Obesity (extreme) C9orf80 intron 21935397 rs787278 chr9 115473531 C A 7.62E-05 Obesity (extreme) C9orf80 intron 21935397 rs2645994 chr9 115483322 G A 7.55E-05 Obesity (extreme) / / 21935397 rs9409123 chr9 115507165 G A,T 2.14E-04 Obesity (extreme) / / 21935397 rs2796032 chr9 115519904 T C 2.27E-04 Obesity (extreme) SNX30 intron 21935397 rs1891403 chr9 115527183 C T 2.25E-04 Obesity (extreme) SNX30 intron 21935397 rs2796028 chr9 115528755 T C 2.25E-04 Obesity (extreme) SNX30 intron 21935397 rs813101 chr9 115532907 C G 2.25E-04 Obesity (extreme) SNX30 intron 21935397 rs787287 chr9 115534245 T C 2.25E-04 Obesity (extreme) SNX30 intron 21935397 rs1361720 chr9 115535579 G A 2.25E-04 Obesity (extreme) SNX30 intron 21935397 rs2645993 chr9 115536267 T A 2.25E-04 Obesity (extreme) SNX30 intron 21935397 rs787284 chr9 115538040 A G 2.25E-04 Obesity (extreme) SNX30 intron 21935397 rs787280 chr9 115539085 G A 2.25E-04 Obesity (extreme) SNX30 intron 21935397 rs787294 chr9 115540424 T C 2.25E-04 Obesity (extreme) SNX30 intron 21935397 rs787295 chr9 115541606 C G 2.25E-04 Obesity (extreme) SNX30 intron 21935397 rs787297 chr9 115542133 C A 2.25E-04 Obesity (extreme) SNX30 intron 21935397 rs787298 chr9 115542206 C T 2.25E-04 Obesity (extreme) SNX30 intron 21935397 rs787299 chr9 115542369 T C 2.25E-04 Obesity (extreme) SNX30 intron 21935397 rs787301 chr9 115542737 A C 2.26E-04 Obesity (extreme) SNX30 intron 21935397 rs787302 chr9 115543839 G A 2.26E-04 Obesity (extreme) SNX30 intron 21935397 rs787271 chr9 115549463 C T 2.26E-04 Obesity (extreme) SNX30 intron 21935397 rs787272 chr9 115549547 T C 3.23E-04 Obesity (extreme) SNX30 intron 21935397 rs787274 chr9 115550363 A C 3.22E-04 Obesity (extreme) SNX30 intron 21935397 rs787275 chr9 115550523 C G 3.22E-04 Obesity (extreme) SNX30 intron 21935397 rs700122 chr9 115551847 A G 2.26E-04 Obesity (extreme) SNX30 intron 21935397 rs787276 chr9 115551891 T C 2.26E-04 Obesity (extreme) SNX30 intron 21935397 rs10733594 chr9 115552630 T G 2.26E-04 Obesity (extreme) SNX30 intron 21935397 rs6477959 chr9 115554296 G A 2.26E-04 Obesity (extreme) SNX30 intron 21935397 rs4979153 chr9 115554984 G A 2.26E-04 Obesity (extreme) SNX30 intron 21935397 rs4979154 chr9 115555031 A G 2.27E-04 Obesity (extreme) SNX30 intron 21935397 rs10739370 chr9 115556941 A G 2.26E-04 Obesity (extreme) SNX30 intron 21935397 rs11794493 chr9 115557614 G A 8.85E-04 Obesity (extreme) SNX30 intron 21935397 rs7030795 chr9 115558962 G A 2.28E-04 Obesity (extreme) SNX30 intron 21935397 rs10124260 chr9 115559341 T C 2.32E-04 Obesity (extreme) SNX30 intron 21935397 rs1891402 chr9 115567184 T C 2.48E-04 Obesity (extreme) SNX30 cds-synon 21935397 rs4979157 chr9 115571791 T C 2.54E-04 Obesity (extreme) SNX30 intron 21935397 rs1418409 chr9 115573707 T C 2.59E-04 Obesity (extreme) SNX30 intron 21935397 rs7868830 chr9 115577125 G A 2.59E-04 Obesity (extreme) SNX30 intron 21935397 rs12555600 chr9 115585109 T G 1.20E-05 Urinary metabolites SNX30 intron 21572414 rs1539338 chr9 115586187 A G 2.58E-04 Obesity (extreme) SNX30 intron 21935397 rs7859175 chr9 115587160 G A 2.58E-04 Obesity (extreme) SNX30 intron 21935397 rs4246892 chr9 115588649 G A 2.58E-04 Obesity (extreme) SNX30 intron 21935397 rs10739373 chr9 115593239 G A 2.56E-04 Obesity (extreme) SNX30 intron 21935397 rs885387 chr9 115596390 G A 2.38E-04 Obesity (extreme) SNX30 intron 21935397 rs4978507 chr9 115609376 G A 2.45E-04 Obesity (extreme) SNX30 intron 21935397 rs4979165 chr9 115609539 T C 2.45E-04 Obesity (extreme) SNX30 intron 21935397 rs4979166 chr9 115610148 T C 5.68E-05 Brain derived neurotrophic factor levels,in serum SNX30 intron 22047184 rs10759589 chr9 115610429 G A 6.66E-05 Brain derived neurotrophic factor levels,in serum SNX30 intron 22047184 rs10759590 chr9 115610567 G C 9.52E-04 Obesity (extreme) SNX30 intron 21935397 rs912661 chr9 115611114 T A 5.73E-05 Brain derived neurotrophic factor levels,in serum SNX30 intron 22047184 rs9299211 chr9 115612797 G A 5.77E-05 Brain derived neurotrophic factor levels,in serum SNX30 intron 22047184 rs9299212 chr9 115612829 T G 5.77E-05 Brain derived neurotrophic factor levels,in serum SNX30 intron 22047184 rs10759592 chr9 115613915 A G 5.76E-05 Brain derived neurotrophic factor levels,in serum SNX30 intron 22047184 rs10759593 chr9 115614403 C T 5.75E-05 Brain derived neurotrophic factor levels,in serum SNX30 intron 22047184 rs4366151 chr9 115614693 T C 5.74E-05 Brain derived neurotrophic factor levels,in serum SNX30 intron 22047184 rs10817397 chr9 115614925 G A 5.72E-05 Brain derived neurotrophic factor levels,in serum SNX30 intron 22047184 rs10759596 chr9 115615025 C G 7.84E-05 Brain derived neurotrophic factor levels,in serum SNX30 intron 22047184 rs10733596 chr9 115615241 T G 5.80E-07 Urinary metabolites SNX30 intron 21572414 rs10733596 chr9 115615241 T G 5.69E-05 Brain derived neurotrophic factor levels,in serum SNX30 intron 22047184 rs10733597 chr9 115615251 C T 2.30E-06 Urinary metabolites SNX30 intron 21572414 rs10759598 chr9 115615580 T C 2.20E-06 Urinary metabolites SNX30 intron 21572414 rs10759598 chr9 115615580 T C 5.79E-05 Brain derived neurotrophic factor levels,in serum SNX30 intron 22047184 rs1970528 chr9 115615754 A G 1.40E-06 Urinary metabolites SNX30 intron 21572414 rs1970528 chr9 115615754 A G 6.68E-05 Brain derived neurotrophic factor levels,in serum SNX30 intron 22047184 rs1539342 chr9 115615955 A G 2.00E-06 Urinary metabolites SNX30 intron 21572414 rs1539342 chr9 115615955 A G 7.39E-05 Brain derived neurotrophic factor levels,in serum SNX30 intron 22047184 rs1970527 chr9 115615985 G C 5.80E-05 Brain derived neurotrophic factor levels,in serum SNX30 intron 22047184 rs1539340 chr9 115616152 C T 5.82E-05 Brain derived neurotrophic factor levels,in serum SNX30 intron 22047184 rs10817398 chr9 115616388 T A,C,G 5.86E-05 Brain derived neurotrophic factor levels,in serum SNX30 intron 22047184 rs10759599 chr9 115616408 C T 5.85E-05 Brain derived neurotrophic factor levels,in serum SNX30 intron 22047184 rs10817399 chr9 115616434 C T 5.85E-05 Brain derived neurotrophic factor levels,in serum SNX30 intron 22047184 rs10759600 chr9 115616447 T C 5.85E-05 Brain derived neurotrophic factor levels,in serum SNX30 intron 22047184 rs1475293 chr9 115619587 A G 6.61E-04 Multiple complex diseases SNX30 intron 17554300 rs10481638 chr9 115619906 T C 3.30E-06 Urinary metabolites SNX30 intron 21572414 rs6415814 chr9 115623779 T A 2.46E-04 Obesity (extreme) SNX30 intron 21935397 rs2182046 chr9 115625699 C T 1.87E-04 Obesity (extreme) SNX30 intron 21935397 rs4979170 chr9 115626918 C G 1.40E-05 Urinary metabolites SNX30 intron 21572414 rs10739377 chr9 115631598 C T 1.10E-05 Urinary metabolites SNX30 UTR-3 21572414 rs16917417 chr9 115632898 G A 1.70E-06 Urinary metabolites SNX30 UTR-3 21572414 rs2025544 chr9 115632969 A G 2.30E-06 Urinary metabolites SNX30 UTR-3 21572414 rs2025544 chr9 115632969 A G 8.40E-04 Obesity (extreme) SNX30 UTR-3 21935397 rs1324932 chr9 115634198 A G 0.00026 Height (Pygmy height) SNX30 UTR-3 22570615 rs10733599 chr9 115634234 A T 8.26E-04 Obesity (extreme) SNX30 UTR-3 21935397 rs1324931 chr9 115634282 C T 8.25E-04 Obesity (extreme) SNX30 UTR-3 21935397 rs1324930 chr9 115634639 C T 4.62E-04 Multiple complex diseases SNX30 UTR-3 17554300 rs1324930 chr9 115634639 C T 1.10E-05 Urinary metabolites SNX30 UTR-3 21572414 rs7032763 chr9 115635252 A T 3.98E-05 Brain derived neurotrophic factor levels,in serum SNX30 UTR-3 22047184 rs7873289 chr9 115638386 G A 8.25E-04 Obesity (extreme) / / 21935397 rs10759603 chr9 115639581 C G 8.25E-04 Obesity (extreme) / / 21935397 rs10739378 chr9 115639631 C T 8.25E-04 Obesity (extreme) / / 21935397 rs10759604 chr9 115639748 G A 8.25E-04 Obesity (extreme) / / 21935397 rs10759604 chr9 115639748 G A 0.00016 Height (Pygmy height) / / 22570615 rs4979176 chr9 115641181 G A 1.90E-05 Urinary metabolites / / 21572414 rs4979176 chr9 115641181 G A 8.25E-04 Obesity (extreme) / / 21935397 rs4979176 chr9 115641181 G A 0.00037 Height (Pygmy height) / / 22570615 rs4978510 chr9 115643795 G C 3.80E-06 Urinary metabolites SLC46A2 intron 21572414 rs4978510 chr9 115643795 G C 6.28E-04 Obesity (extreme) SLC46A2 intron 21935397 rs4979178 chr9 115644335 G C 9.40E-04 Obesity (extreme) SLC46A2 intron 21935397 rs10124939 chr9 115654683 T C 9.00E-04 Obesity (extreme) / / 21935397 rs10124979 chr9 115654843 T G 9.43E-04 Obesity (extreme) / / 21935397 rs10115711 chr9 115655263 A G 9.74E-04 Obesity (extreme) / / 21935397 rs11793236 chr9 115655849 G A 2.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17823832 chr9 115666267 C T 8.28E-04 Coronary Artery Disease / / 17634449 rs10981540 chr9 115666561 G T 5.98E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11794662 chr9 115669458 G T 8.68E-04 Obesity (extreme) / / 21935397 rs10981543 chr9 115670988 T C 4.73E-04 Obesity (extreme) / / 21935397 rs11789893 chr9 115671309 T C 5.50E-04 Obesity (extreme) / / 21935397 rs4978518 chr9 115673588 G A 5.90E-05 Memory performance / / 22105620 rs7854949 chr9 115674130 A G 8.24E-04 Obesity (extreme) / / 21935397 rs1952004 chr9 115674281 G A 8.20E-04 Obesity (extreme) / / 21935397 rs1952005 chr9 115674313 C G 8.20E-04 Obesity (extreme) / / 21935397 rs7855402 chr9 115674426 C G 8.03E-04 Obesity (extreme) / / 21935397 rs11789944 chr9 115674592 G A 3.54E-04 Obesity (extreme) / / 21935397 rs10981545 chr9 115675086 G A 6.03E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10981545 chr9 115675086 G A 3.56E-04 Obesity (extreme) / / 21935397 rs12004372 chr9 115679298 A G 3.20E-04 Alzheimer's disease / / 17998437 rs10817405 chr9 115679419 A G 9.79E-04 Alzheimer's disease / / 17998437 rs10817408 chr9 115687735 T C 6.00E-06 IgG glycosylation / / 23382691 rs10817408 chr9 115687735 T C 6.00E-06 IgG glycosylation / / 23382691 rs10817408 chr9 115687735 T C 7.00E-06 IgG glycosylation / / 23382691 rs10759615 chr9 115691913 G A 8.52E-04 Alzheimer's disease / / 17998437 rs7022919 chr9 115694221 T C 2.70E-07 Health and aging,CVD and cancer age of onset / / 22174011 rs7022919 chr9 115694221 T C 6.80E-08 Health and aging,CVD and cancer age of onset / / 22174011 rs747066 chr9 115698346 C T 1.50E-04 Crohn's disease / / 17684544 rs4246894 chr9 115777556 T C 2.11E-05 Personality dimensions / / 22628180 rs13294922 chr9 115864525 C A 2.54E-04 Type 2 diabetes / / 17463246 rs13294922 chr9 115864525 C A 5.96E-07 Serum metabolites / / 19043545 rs10981635 chr9 115888112 C T 1.07E-06 Type 2 diabetes / / 17463246 rs4457406 chr9 115893544 C T 2.59E-04 Type 2 diabetes / / 17463246 rs4457406 chr9 115893544 C T 9.95E-06 Type 2 diabetes / / 21490949 rs7867889 chr9 115894240 G A 3.50E-05 Alcoholism (heaviness of drinking) / / 21529783 rs10981639 chr9 115897653 C T 5.64E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs4979215 chr9 115904129 C T 5.30E-05 Alcoholism (heaviness of drinking) / / 21529783 rs3810909 chr9 115931692 A G 2.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FKBP15 cds-synon 20877124 rs3810909 chr9 115931692 A G 5.63E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FKBP15 cds-synon 20877124 rs17762660 chr9 115952414 C T 1.78E-07 Multiple complex diseases FKBP15 intron 17554300 rs16926630 chr9 115955271 T C 5.17E-04 Lymphocyte counts FKBP15 intron 22286170 rs4979224 chr9 115982278 A G 7.80E-04 Coronary heart disease FKBP15 intron 21606135 rs10981693 chr9 115985417 T C 6.24E-04 Coronary heart disease SLC31A1 intron 21606135 rs10513189 chr9 115990221 T C 2.20E-05 Urinary metabolites SLC31A1 intron 21572414 rs6477998 chr9 115997249 C A 8.00E-06 Hematology traits SLC31A1 intron 23303382 rs10817478 chr9 116078520 T C 4.40E-05 Parkinson's disease (age of onset) WDR31 UTR-3 19772629 rs1077636 chr9 116122326 T C 6.49E-05 Erythrocyte counts BSPRY intron pha003099 rs6478009 chr9 116123671 A G 9.33E-04 Multiple complex diseases BSPRY intron 17554300 rs6478009 chr9 116123671 A G 7.00E-05 Serum metabolites BSPRY intron 19043545 rs7037201 chr9 116123917 A G 6.89E-04 Multiple complex diseases BSPRY intron 17554300 rs7038037 chr9 116124325 G A 2.70E-06 Primary sclerosing cholangitis BSPRY intron 21151127 rs10981769 chr9 116125789 T C 3.50E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) BSPRY intron 23648065 rs7857932 chr9 116130924 T C 9.31E-05 Smoking initiation BSPRY intron 24665060 rs818710 chr9 116131453 C A 9.77E-05 Erythrocyte counts BSPRY intron pha003099 rs3088235 chr9 116132334 C T 0.00065 Breast cancer BSPRY missense 23555315 rs818702 chr9 116144973 G A 5.85E-04 Lymphocyte counts / / 22286170 rs818704 chr9 116148316 G A 2.79E-04 Response to cytidine analogues (gemcitabine) ALAD nearGene-3 24483146 rs1139488 chr9 116153900 A G 2.77E-05 Male-pattern baldness ALAD cds-synon 18849994 rs2792818 chr9 116159099 C T 0.0005932 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ALAD intron 23233654 rs2792818 chr9 116159099 C T 5.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) ALAD intron 23233662 rs818691 chr9 116165396 T G 3.25E-05 Basophils ALAD nearGene-5 pha003087 rs14419 chr9 116170559 G A 2.54E-04 Type 2 diabetes POLE3 UTR-3 17846124 rs7870912 chr9 116188725 G T 0.0000485 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) C9orf43 intron 23233654 rs7870912 chr9 116188725 G T 4.85E-05 Methotrexate clearance (acute lymphoblastic leukemia) C9orf43 intron 23233662 rs1578592 chr9 116194436 A G 8.56E-04 HIV-1 viral setpoint / / 17641165 rs12338788 chr9 116214058 G A 3.67E-04 Multiple complex diseases RGS3 intron 17554300 rs12338788 chr9 116214058 G A 0.0001395 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs12338788 chr9 116214058 G A 1.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs10217750 chr9 116234304 G A 9.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7864467 chr9 116236432 G A 0.0000781 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7864467 chr9 116236432 G A 7.81E-05 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7864816 chr9 116236890 C T 0.0001302 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7864816 chr9 116236890 C T 1.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs10981793 chr9 116238296 T C 0.0001291 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs10981793 chr9 116238296 T C 1.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs10981794 chr9 116240245 A G 9.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7021491 chr9 116241707 T C 9.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs12335991 chr9 116246535 C G 9.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs6478012 chr9 116246885 T C 9.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs12344964 chr9 116250083 T C 9.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs12339851 chr9 116255225 G A 9.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs12346939 chr9 116256673 T C 9.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7860673 chr9 116258555 G A 9.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7027340 chr9 116260765 T G 9.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7020623 chr9 116263270 G A 9.83E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7023661 chr9 116263404 C T 9.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7040031 chr9 116263454 T C 9.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs6478016 chr9 116264014 T C 9.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7028327 chr9 116264616 C T 9.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7856689 chr9 116264875 G A 4.71E-04 Multiple complex diseases RGS3 intron 17554300 rs7856689 chr9 116264875 G A 0.0001101 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7856689 chr9 116264875 G A 1.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7872283 chr9 116265088 T C 9.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7857217 chr9 116265360 G A 0.0000666 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7857217 chr9 116265360 G A 6.66E-05 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs17186238 chr9 116265583 C G 0.00042 Coronary artery calcification RGS3 intron 23727086 rs7033679 chr9 116266165 G C 9.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs6478017 chr9 116269094 G A 5.40E-05 Bipolar disorder RGS3 intron 19488044 rs6478017 chr9 116269094 G A 0.0008998 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs6478017 chr9 116269094 G A 9.00E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7870265 chr9 116269520 T G 0.0008982 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7870265 chr9 116269520 T G 8.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs10125960 chr9 116270976 C A 9.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs10481676 chr9 116272681 T C 9.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs9299215 chr9 116272901 C A 9.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs4596719 chr9 116278104 C T 9.12E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7026656 chr9 116280103 C T 9.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7043140 chr9 116280204 T C 9.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7027024 chr9 116280214 G A 9.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs12351728 chr9 116281977 A G 0.0000593 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs12351728 chr9 116281977 A G 5.93E-05 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs12342699 chr9 116282114 G A 5.69E-05 Multiple complex diseases RGS3 intron 17554300 rs12342699 chr9 116282114 G A 0.0008951 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs12342699 chr9 116282114 G A 8.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs12336719 chr9 116282306 C T 0.0008922 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs12336719 chr9 116282306 C T 8.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7867353 chr9 116283367 G T 0.0008911 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7867353 chr9 116283367 G T 8.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs12339617 chr9 116284893 C G 0.0008881 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs12339617 chr9 116284893 C G 8.88E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs12344578 chr9 116285083 T C 0.0008862 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs12344578 chr9 116285083 T C 8.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7037441 chr9 116285429 T C 0.0008845 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7037441 chr9 116285429 T C 8.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7041833 chr9 116286469 T C 0.0008819 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7041833 chr9 116286469 T C 8.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7042695 chr9 116287100 T A 0.0006441 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7042695 chr9 116287100 T A 6.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7042968 chr9 116287351 T C 0.0001086 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7042968 chr9 116287351 T C 1.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7855325 chr9 116288473 T C 0.000875 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7855325 chr9 116288473 T C 8.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7855434 chr9 116288537 T C 0.0000557 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs10981808 chr9 116288943 G A 0.0008695 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs10981808 chr9 116288943 G A 8.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7046427 chr9 116289417 G A 0.0008676 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7046427 chr9 116289417 G A 8.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs12346076 chr9 116289916 C G 0.0008646 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs12346076 chr9 116289916 C G 8.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs12343141 chr9 116293017 C G 0.0008569 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs12343141 chr9 116293017 C G 8.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs12345524 chr9 116294517 C T 0.0008553 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs12345524 chr9 116294517 C T 8.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7049221 chr9 116302382 G C 0.0000762 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7049221 chr9 116302382 G C 7.62E-05 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7018783 chr9 116302815 C T 0.0008379 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7018783 chr9 116302815 C T 8.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs10981814 chr9 116302976 G T 0.0008356 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs10981814 chr9 116302976 G T 8.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs10981815 chr9 116303037 A G 0.0000508 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs10981815 chr9 116303037 A G 5.08E-05 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs10981816 chr9 116303064 G A 0.0008319 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs10981816 chr9 116303064 G A 8.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7851718 chr9 116304165 G A 0.0008315 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 UTR-3 23233654 rs7851718 chr9 116304165 G A 8.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 UTR-3 23233662 rs7851937 chr9 116304304 G A 0.000045 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 UTR-3 23233654 rs7851937 chr9 116304304 G A 4.50E-05 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 UTR-3 23233662 rs10981817 chr9 116304952 G A 0.0008281 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs10981817 chr9 116304952 G A 8.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7853792 chr9 116309418 G T 0.0008269 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7853792 chr9 116309418 G T 8.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7854197 chr9 116309773 G A 0.0008248 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7854197 chr9 116309773 G A 8.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs10981819 chr9 116310993 C T 0.000824 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs10981819 chr9 116310993 C T 8.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs1890992 chr9 116319660 A G 3.45E-04 Multiple complex diseases RGS3 intron 17554300 rs1890992 chr9 116319660 A G 0.000822 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs1890992 chr9 116319660 A G 8.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs3983381 chr9 116319794 T C 0.0008211 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs3983381 chr9 116319794 T C 8.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7024612 chr9 116321695 G A 0.00082 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7024612 chr9 116321695 G A 8.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7024445 chr9 116321844 A G 0.0008183 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7024445 chr9 116321844 A G 8.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7024996 chr9 116321980 G A 0.0008176 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7024996 chr9 116321980 G A 8.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs6478022 chr9 116325892 G C 0.0008145 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs6478022 chr9 116325892 G C 8.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs6478023 chr9 116328053 A G 0.0008125 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs6478023 chr9 116328053 A G 8.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs12337340 chr9 116328950 T C 0.0008114 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs12337340 chr9 116328950 T C 8.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs944346 chr9 116329408 A G 0.0008102 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs944346 chr9 116329408 A G 8.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs12338697 chr9 116329986 T C 0.0008085 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs12338697 chr9 116329986 T C 8.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs12338701 chr9 116330033 T G 0.0008073 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs12338701 chr9 116330033 T G 8.07E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs884898 chr9 116330970 A G 5.33E-04 Multiple complex diseases RGS3 intron 17554300 rs884898 chr9 116330970 A G 0.0000185 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs884898 chr9 116330970 A G 1.85E-05 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs12341332 chr9 116332171 T C 0.0008058 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs12341332 chr9 116332171 T C 8.06E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs9657641 chr9 116333311 T C 0.0007969 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs9657641 chr9 116333311 T C 7.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs9657658 chr9 116333409 C T 0.0007957 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs9657658 chr9 116333409 C T 7.96E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs9657659 chr9 116333514 A G 0.0007945 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs9657659 chr9 116333514 A G 7.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs9785299 chr9 116335172 C T 0.0000162 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs9785299 chr9 116335172 C T 1.62E-05 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs10981830 chr9 116336035 G A 0.0000136 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs10981830 chr9 116336035 G A 1.36E-05 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7863159 chr9 116336574 C T 0.0007853 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7863159 chr9 116336574 C T 7.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7048208 chr9 116337759 G A 0.0007839 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7048208 chr9 116337759 G A 7.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7854524 chr9 116340326 A G 0.000012 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7854524 chr9 116340326 A G 1.20E-05 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7857943 chr9 116340571 G T 0.0007772 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7857943 chr9 116340571 G T 7.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs12346087 chr9 116341002 T G 0.0007494 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs12346087 chr9 116341002 T G 7.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7047062 chr9 116341116 T C 0.0007751 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7047062 chr9 116341116 T C 7.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs7871186 chr9 116344213 G A 0.0007714 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs7871186 chr9 116344213 G A 7.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs12347895 chr9 116345471 T C 0.0007702 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs12347895 chr9 116345471 T C 7.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs12343129 chr9 116345565 C A 0.0007682 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs12343129 chr9 116345565 C A 7.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs10981835 chr9 116349298 G A 2.69E-04 Multiple complex diseases RGS3 intron 17554300 rs10981835 chr9 116349298 G A 0.0000135 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RGS3 intron 23233654 rs10981835 chr9 116349298 G A 1.35E-05 Methotrexate clearance (acute lymphoblastic leukemia) RGS3 intron 23233662 rs12341266 chr9 116356516 A G 0.000000132 Hypertrophic cardiomyopathy RGS3 missense 23255317 rs17187621 chr9 116362738 A G 0.0001361 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17187621 chr9 116362738 A G 1.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs670719 chr9 116388816 G A 5.67E-04 Type 2 diabetes / / 17846124 rs479766 chr9 116389289 G A 3.60E-05 Type 2 diabetes / / 17463246 rs589248 chr9 116397397 G T 6.91E-04 Tourette syndrome / / 22889924 rs10817496 chr9 116398343 T C 3.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs16907354 chr9 116398896 C A 3.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs584190 chr9 116404703 C T 5.76E-05 Elbow pain / / pha003008 rs2622266 chr9 116420246 C T 5.22E-04 Smoking initiation / / 24665060 rs10981870 chr9 116422276 A G 2.98E-05 Bipolar disorder / / 19488044 rs10981874 chr9 116422664 C A 3.98E-05 Bipolar disorder / / 19488044 rs7031666 chr9 116423629 C T 4.32E-05 Bipolar disorder / / 19488044 rs4979274 chr9 116444269 C A 7.40E-05 Diabetic retinopathy / / 21441570 rs16908104 chr9 116459907 A T 2.52E-04 Multiple complex diseases / / 17554300 rs2170226 chr9 116464160 C T 2.65E-04 Osteoarthritis / / 19508968 rs2170226 chr9 116464160 C T 2.68E-04 Heart Failure / / pha002884 rs7852801 chr9 116470121 A G 2.66E-04 Smoking initiation / / 24665060 rs10817517 chr9 116499027 C T 1.80E-05 Lung adenocarcinoma / / 22797724 rs7341836 chr9 116503850 T C 7.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16908769 chr9 116509161 T C 4.79E-04 Type 2 diabetes / / 17463246 rs16908826 chr9 116513339 A G 1.15E-04 Type 2 diabetes / / 17463246 rs10513213 chr9 116519285 A G 5.03E-06 Statin-induced myopathy / / 21826682 rs7029499 chr9 116527080 T C 2.13E-04 Multiple complex diseases / / 17554300 rs1359637 chr9 116535410 C T 9.25E-05 Amyotrophic lateral sclerosis / / 20801717 rs987282 chr9 116561225 T C 3.24E-04 Acute lung injury / / 22295056 rs12683246 chr9 116561612 G A 3.26E-04 Acute lung injury / / 22295056 rs988015 chr9 116564763 T C 2.96E-04 Acute lung injury / / 22295056 rs10981934 chr9 116565746 A G 2.96E-04 Acute lung injury / / 22295056 rs2418253 chr9 116566190 A G 2.76E-04 Acute lung injury / / 22295056 rs10116566 chr9 116664845 T C 8.00E-07 Parkinson's disease (interaction with coffee consumption) ZNF618 intron 21876681 rs10817542 chr9 116725481 G A 2.06E-04 Taste perception ZNF618 intron 22132133 rs10513224 chr9 116741439 A C 8.26E-04 Alcohol dependence ZNF618 intron 21314694 rs12682865 chr9 116742214 T C 0.00000022 Asthma ZNF618 intron 23040885 rs1408113 chr9 116742833 A G 2.54E-05 Blood Pressure and Arterial Stiffness ZNF618 intron 17903302 rs4979311 chr9 116749530 G C 0.00000061 Asthma ZNF618 intron 23040885 rs10982031 chr9 116776289 T C 5.38E-04 Type 2 diabetes ZNF618 intron 17463246 rs4979326 chr9 116780465 G A 7.76E-04 Type 2 diabetes ZNF618 intron 17463246 rs10982035 chr9 116782921 T C 8.58E-04 Depression (quantitative trait) ZNF618 intron 20800221 rs1359172 chr9 116785558 C T 9.27E-05 Cognitive test performance ZNF618 intron 20125193 rs4574916 chr9 116794037 G C 1.91E-04 Depression (quantitative trait) ZNF618 intron 20800221 rs752035 chr9 116794078 C G 4.75E-04 Depression (quantitative trait) ZNF618 intron 20800221 rs4979333 chr9 116798141 A G 5.38E-04 Depression (quantitative trait) ZNF618 intron 20800221 rs10121424 chr9 116800606 T C 5.36E-04 Depression (quantitative trait) ZNF618 intron 20800221 rs10124293 chr9 116800860 A G 5.40E-04 Depression (quantitative trait) ZNF618 intron 20800221 rs12555049 chr9 116805634 A G 6.88E-05 Cognitive test performance ZNF618 intron 20125193 rs12555049 chr9 116805634 A G 5.53E-05 Orofacial clefts ZNF618 intron 22419666 rs3810928 chr9 116815777 C T 5.74E-04 Multiple complex diseases ZNF618 UTR-3 17554300 rs10739400 chr9 116816816 G A 3.20E-05 Temporomandibular joint disorders ZNF618 UTR-3 23746317 rs2269454 chr9 116822650 T C 4.12E-04 Schizophrenia AMBP intron 24043878 rs12344124 chr9 116837745 G T 9.03E-06 Body Mass Index AMBP intron pha003006 rs12344124 chr9 116837745 G T 4.11E-05 Waist Circumference AMBP intron pha003024 rs3762058 chr9 116842333 C T 0.0008569 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs891725 chr9 116847201 C T 3.06E-04 Scoliosis / / 21216876 rs891724 chr9 116847365 G A 8.50E-04 Type 2 diabetes / / 17463246 rs7048737 chr9 116852145 C T 5.52E-10 Coronary heart disease / / 23364394 rs12347081 chr9 116855285 G C 6.43E-10 Coronary heart disease KIF12 intron 23364394 rs1570589 chr9 116874355 A G 6.10E-04 Alcohol dependence / / 20201924 rs7856967 chr9 116887405 C A 1.27E-23 Narcolepsy / / 19629137 rs9792636 chr9 116887682 G A,C 6.17E-04 Smoking initiation / / 24665060 rs2839874 chr9 116890163 C G 6.00E-06 Social communication problems / / 24564958 rs10982078 chr9 116891486 G A 9.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs891720 chr9 116897213 C A 1.30E-04 Hearing function / / 17255346 rs12338900 chr9 116898696 G C 5.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7868176 chr9 116902782 A G 5.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10817573 chr9 116907448 G A 2.91E-06 Corneal structure / / 22003120 rs10739403 chr9 116913145 C T 6.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs4979351 chr9 116945025 T C 4.11E-09 Multiple complex diseases COL27A1 intron 17554300 rs10739406 chr9 116945547 T C 8.03E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) COL27A1 intron 24023788 rs4979352 chr9 116957958 G A 4.51E-04 Schizophrenia COL27A1 intron 19197363 rs2567714 chr9 116964061 T C 4.89E-04 Lung function (forced expiratory volume in 1 second) COL27A1 intron 24023788 rs2567719 chr9 116967263 T G 2.60E-05 Multiple sclerosis COL27A1 intron 19525955 rs10982107 chr9 116972955 G T 5.70E-05 Post-operative nausea and vomiting COL27A1 intron 21694509 rs7024508 chr9 116985310 T C 7.80E-04 Amyotrophic Lateral Sclerosis COL27A1 intron 17362836 rs7868992 chr9 116991071 G A 3.00E-08 Tourette syndrome COL27A1 intron 22889924 rs1078851 chr9 116993669 A G 5.60E-05 Tourette syndrome COL27A1 intron 22889924 rs1249718 chr9 116998789 C T 2.14E-04 Tourette syndrome COL27A1 intron 22889924 rs1122517 chr9 116999628 A G 8.38E-04 Tourette syndrome COL27A1 intron 22889924 rs2029522 chr9 117009953 G A 1.49E-04 Response to alcohol consumption (flushing response) COL27A1 intron 24277619 rs999599 chr9 117011595 C T 3.24E-05 Serum metabolites COL27A1 intron 19043545 rs999599 chr9 117011595 C T 9.70E-05 HDL particle features COL27A1 intron pha002900 rs2418268 chr9 117023606 C T 1.44E-05 Triglycerides COL27A1 intron pha003081 rs2418268 chr9 117023606 C T 3.94E-05 Lipid levels COL27A1 intron pha003082 rs7032231 chr9 117025771 C A 2.93E-05 Triglycerides COL27A1 intron pha003081 rs7032231 chr9 117025771 C A 4.91E-05 Lipid levels COL27A1 intron pha003082 rs2636859 chr9 117029422 G C 9.05E-06 Brain structure COL27A1 intron 22504417 rs2636860 chr9 117030582 G A 4.40E-05 Brain structure COL27A1 intron 22504417 rs5003737 chr9 117032189 G A 1.10E-05 HDL cholesterol COL27A1 intron pha003075 rs5003737 chr9 117032189 G A 1.71E-05 Lipid levels COL27A1 intron pha003082 rs2636864 chr9 117032448 T C 2.02E-05 HDL cholesterol COL27A1 intron pha003075 rs2636864 chr9 117032448 T C 1.90E-05 Lipid levels COL27A1 intron pha003082 rs1249721 chr9 117036760 A G 1.70E-05 Iron levels COL27A1 intron 21208937 rs1766059 chr9 117039111 A G 4.64E-05 Serum metabolites COL27A1 intron 19043545 rs16927834 chr9 117048473 G A 0.00000111 LDL cholesterol particle diameter COL27A1 intron 23263444 rs16927834 chr9 117048473 G A 0.00000756 HDL cholesterol particle diameter COL27A1 intron 23263444 rs4978577 chr9 117048609 C T 0.000000898 LDL cholesterol particle diameter COL27A1 intron 23263444 rs4978577 chr9 117048609 C T 0.00000671 HDL cholesterol particle diameter COL27A1 intron 23263444 rs946053 chr9 117049891 T G 2.00E-07 Height COL27A1 intron 18391951 rs10982134 chr9 117050998 G A 7.52E-04 Schizophrenia COL27A1 missense 19197363 rs1687410 chr9 117051020 A G 0.00000122 LDL cholesterol particle diameter COL27A1 cds-synon 23263444 rs1687410 chr9 117051020 A G 0.00000798 HDL cholesterol particle diameter COL27A1 cds-synon 23263444 rs10817583 chr9 117051271 C A 0.00000105 LDL cholesterol particle diameter COL27A1 intron 23263444 rs10817583 chr9 117051271 C A 0.00000733 HDL cholesterol particle diameter COL27A1 intron 23263444 rs1249742 chr9 117051614 A G 0.000000465 LDL cholesterol particle diameter COL27A1 intron 23263444 rs1249742 chr9 117051614 A G 0.0000143 HDL cholesterol particle diameter COL27A1 intron 23263444 rs1249740 chr9 117052039 G A 0.00000272 LDL cholesterol particle diameter COL27A1 intron 23263444 rs1249740 chr9 117052039 G A 0.00000825 HDL cholesterol particle diameter COL27A1 intron 23263444 rs1249738 chr9 117053215 A G 6.07E-04 Schizophrenia COL27A1 intron 19197363 rs1249730 chr9 117056851 A G 2.15E-04 Obesity (extreme) COL27A1 intron 21935397 rs10982136 chr9 117058723 A G 3.71E-04 Obesity (extreme) COL27A1 intron 21935397 rs4979365 chr9 117060746 T C 8.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL27A1 intron 20877124 rs7031311 chr9 117061251 A G 4.89E-04 Obesity (extreme) COL27A1 intron 21935397 rs11537824 chr9 117073588 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7851482 chr9 117078286 T G 1.20E-04 Endometriosis / / 21151130 rs150611042 chr9 117083803 C A,T 7.00E-15 Thrombin generation potential phenotypes ORM1 nearGene-5 24357727 rs150611042 chr9 117083803 C A,T 8.00E-06 Thrombin generation potential phenotypes ORM1 nearGene-5 24357727 rs116994374 chr9 117084672 G A 5.81E-07 Thrombin generation potential phenotypes ORM1 nearGene-5 24357727 rs116994374 chr9 117084672 G A 7.32E-07 Thrombin generation potential phenotypes ORM1 nearGene-5 24357727 rs113354603 chr9 117086241 G A 9.58E-07 Thrombin generation potential phenotypes ORM1 intron 24357727 rs113354603 chr9 117086241 G A 9.96E-07 Thrombin generation potential phenotypes ORM1 intron 24357727 rs10982156 chr9 117088064 T A 2.00E-10 End-stage coagulation ORM1 intron 23381943 rs10982156 chr9 117088064 T A 6.05E-07 Thrombin generation potential phenotypes ORM1 intron 24357727 rs10982156 chr9 117088064 T A 9.65E-07 Thrombin generation potential phenotypes ORM1 intron 24357727 rs1687390 chr9 117089888 G A 1 Drug response to Warfarin / / 19794411 rs1038776 chr9 117101245 G A 5.68E-04 Type 2 diabetes AK/ intron 17463246 rs2636870 chr9 117102046 G A 3.41E-04 Type 2 diabetes AK/ intron 17463246 rs2636870 chr9 117102046 G A 9.06E-04 Response to TNF antagonist treatment AK/ intron 21061259 rs1490744 chr9 117111592 T C 8.80E-04 Type 2 diabetes AK/ intron 17463246 rs1490744 chr9 117111592 T C 7.18E-04 Response to TNF antagonist treatment AK/ intron 21061259 rs1249726 chr9 117113786 T G 1.08E-04 Coronary heart disease AK/ intron 21971053 rs10982177 chr9 117114168 C T 9.58E-05 Coronary heart disease AK/ intron 21971053 rs10982177 chr9 117114168 C T 8.24E-04 Response to cytidine analogues (gemcitabine) AK/ intron 24483146 rs7866925 chr9 117120680 C T 5.01E-04 Epilepsy AK/ intron 22116939 rs2274159 chr9 117166246 A G 7.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) DFNB31 missense 21239504 rs942519 chr9 117169033 A G 7.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) DFNB31 missense 21239504 rs12339210 chr9 117170241 G C 5.94E-04 Multiple complex diseases DFNB31 missense 17554300 rs2274160 chr9 117170310 C T 9.00E-05 Prostate cancer DFNB31 intron 21743057 rs7046973 chr9 117193206 G A 4.05E-04 Multiple complex diseases DFNB31 intron 17554300 rs4979391 chr9 117200079 T C 1.72E-05 Serum metabolites DFNB31 intron 19043545 rs10817611 chr9 117201399 T C 5.00E-04 Pancreatic cancer DFNB31 intron 23180869 rs4979397 chr9 117219888 T C 9.56E-05 Hypothyroidism DFNB31 intron 21981779 rs1408528 chr9 117220773 C T 1.01E-04 Hypothyroidism DFNB31 intron 21981779 rs4979402 chr9 117222675 G A 6.76E-05 Hypothyroidism DFNB31 intron 21981779 rs1535971 chr9 117229400 T G 5.53E-04 Schizophrenia DFNB31 intron 21747397 rs1535971 chr9 117229400 T G 1.73E-04 Hypothyroidism DFNB31 intron 21981779 rs79509430 chr9 117240906 C T 2.00E-08 Obesity-related traits DFNB31 missense 23251661 rs11787667 chr9 117242845 C T 4.39E-04 Multiple complex diseases DFNB31 intron 17554300 rs11787667 chr9 117242845 C T 2.68E-04 Bipolar disorder,schizoaffective DFNB31 intron 19567891 rs10982239 chr9 117245086 A C 6.25E-04 Type 2 diabetes DFNB31 intron 17463246 rs10982246 chr9 117250393 A G 2.58E-05 Multiple complex diseases DFNB31 intron 17554300 rs10982246 chr9 117250393 A G 3.78E-05 Bipolar disorder,schizoaffective DFNB31 intron 19567891 rs10982256 chr9 117260834 C T 6.76E-06 Multiple complex diseases DFNB31 intron 17554300 rs10982256 chr9 117260834 C T 2.27E-04 Bipolar disorder,schizoaffective DFNB31 intron 19567891 rs10982256 chr9 117260834 C T 9.00E-06 Bipolar disorder DFNB31 intron 21254220 rs4979416 chr9 117262877 G A 1.07E-04 Bipolar disorder DFNB31 intron 18317468 rs4979418 chr9 117264083 G A 4.83E-04 Hemoglobin concentration DFNB31 intron 20534544 rs1535964 chr9 117272439 G C 1.89E-04 Multiple complex diseases / / 17554300 rs942518 chr9 117272858 G A 1.00E-04 Bipolar disorder / / 17486107 rs998548 chr9 117275182 G A 4.48E-04 Type 2 diabetes / / 17463246 rs998548 chr9 117275182 G A 4.30E-04 Multiple complex diseases / / 17554300 rs998548 chr9 117275182 G A 5.13E-04 Bipolar disorder,schizoaffective / / 19567891 rs10513248 chr9 117278844 T C 5.87E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10513248 chr9 117278844 T C 2.08E-05 Hypertension / / pha003042 rs4978596 chr9 117294617 G A 2.70E-04 White matter integrity / / 22425255 rs4979424 chr9 117309052 C T 9.15E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs16930000 chr9 117311703 A C 4.33E-04 Multiple complex diseases / / 17554300 rs10982289 chr9 117314774 G A 1.20E-04 Alcohol dependence / / 20201924 rs10982289 chr9 117314774 G A 1.40E-04 Alcohol dependence / / 20201924 rs10982292 chr9 117325291 G A 6.81E-06 Bipolar disorder / / 18317468 rs7868842 chr9 117360729 T C 6.96E-04 Stroke ATP6V1G1 UTR-3 pha002886 rs10115585 chr9 117370196 A C 5.80E-05 Lung adenocarcinoma / / 19836008 rs10982330 chr9 117376286 C A 8.98E-04 Suicide attempts in bipolar disorder C9orf91 intron 21423239 rs7027695 chr9 117383919 G A 5.90E-04 Smoking initiation C9orf91 intron 24665060 rs7036626 chr9 117385992 G A 1.82E-04 Smoking initiation C9orf91 intron 24665060 rs7866902 chr9 117392088 G A 4.16E-05 Bipolar disorder C9orf91 intron 18317468 rs10982355 chr9 117411420 A G 4.31E-04 Multiple complex diseases / / 17554300 rs752858 chr9 117414981 C T 7.47E-04 Type 2 diabetes / / 17463246 rs2274598 chr9 117420132 A G 8.50E-05 Crohn's disease / / 16221758 rs2274598 chr9 117420132 A G 7.04E-06 Bipolar disorder / / 18317468 rs2296947 chr9 117430524 G A 1.10E-04 Multiple complex diseases LOC100505478 missense 17554300 rs2296947 chr9 117430524 G A 2.20E-05 Urinary metabolites LOC100505478 missense 21572414 rs1359992 chr9 117430611 A T 2.44E-04 Alcohol dependence LOC100505478 missense 21314694 rs7847092 chr9 117433041 T C 9.72E-04 Multiple complex diseases LOC100505478 intron 17554300 rs7869653 chr9 117435306 G A 1.70E-05 Urinary metabolites LOC100505478 intron 21572414 rs1075371 chr9 117444370 C A 1.45E-04 Crohn's disease / / 16221758 rs2900591 chr9 117445279 C T 6.66E-06 Bipolar disorder / / 18317468 rs16931058 chr9 117467553 G A 2.34E-06 Bipolar disorder / / 18317468 rs1410561 chr9 117473992 G A 9.90E-04 Type 2 diabetes / / 17463246 rs10817669 chr9 117483015 G A 2.96E-04 Crohn's disease / / 23266558 rs10982385 chr9 117493017 T G 8.73E-08 Leprosy / / 20018961 rs10759734 chr9 117496650 G A 3.73E-04 Insulin resistance / / 21901158 rs2185935 chr9 117502242 C T 9.63E-05 Multiple complex diseases / / 17554300 rs2185935 chr9 117502242 C T 8.26E-05 Rheumatoid arthritis / / 17804836 rs2185935 chr9 117502242 C T 2.81E-05 Heart Rate / / pha003053 rs2068955 chr9 117504798 A G 2.72E-05 Crohn's disease / / 23266558 rs7038398 chr9 117516418 C A 2.80E-05 Crohn's disease / / 23266558 rs12552933 chr9 117521582 C T 7.23E-04 Taste perception / / 22132133 rs12552933 chr9 117521582 C T 3.76E-08 Crohn's disease / / 23266558 rs10817674 chr9 117522580 C A 4.20E-05 Type 2 diabetes / / 17463249 rs10817674 chr9 117522580 C A 4.23E-05 Multiple complex diseases / / 17554300 rs4978609 chr9 117530319 A G 3.34E-05 Crohn's disease / / 23266558 rs4574921 chr9 117538334 C T 7.76E-11 Crohn's disease / / 16221758 rs4574921 chr9 117538334 C T 2.17E-16 Leprosy / / 20018961 rs4574921 chr9 117538334 C T 4.71E-05 Hypertension / / 22384028 rs4574921 chr9 117538334 C T 1.83E-06 Crohn's disease / / 23266558 rs7860414 chr9 117541450 T C 7.99E-04 Multiple complex diseases / / 17554300 rs6478106 chr9 117545666 C T 7.76E-07 Crohn's disease / / 16221758 rs6478106 chr9 117545666 C T 1.37E-10 Primary biliary cirrhosis / / 23000144 rs6478106 chr9 117545666 C T 5.00E-46 Crohn's disease / / 23266558 rs10114470 chr9 117547772 T C 5.42E-14 Leprosy TNFSF15 UTR-3 20018961 rs10114470 chr9 117547772 T C 4.82E-11 Crohn's disease TNFSF15 UTR-3 23266558 rs10114470 chr9 117547772 T C 4.08E-06 Leprosy TNFSF15 UTR-3 pha002872 rs7853287 chr9 117549327 G A 3.00E-10 IgA levels TNFSF15 UTR-3 24676358 rs10117785 chr9 117551603 T A 2.51E-12 Crohn's disease TNFSF15 UTR-3 16221758 rs3810936 chr9 117552885 T C 3.89E-11 Crohn's disease TNFSF15 cds-synon 16221758 rs3810936 chr9 117552885 T C 1.00E-15 Crohn's disease TNFSF15 cds-synon 21102463 rs4246905 chr9 117553249 T C 3.02E-06 Crohn's disease TNFSF15 intron 16221758 rs4246905 chr9 117553249 T C 6.00E-12 Ulcerative colitis TNFSF15 intron 21297633 rs4246905 chr9 117553249 T C 3.00E-32 Inflammatory bowel disease TNFSF15 intron 23128233 rs6478108 chr9 117558703 C T 5.62E-14 Crohn's disease TNFSF15 intron 16221758 rs6478108 chr9 117558703 C T 2.46E-05 Multiple complex diseases TNFSF15 intron 17554300 rs6478108 chr9 117558703 C T 3.00E-21 Leprosy TNFSF15 intron 20018961 rs6478108 chr9 117558703 C T 7.01E-09 Leprosy TNFSF15 intron 22019778 rs6478108 chr9 117558703 C T 3.68E-09 Primary biliary cirrhosis TNFSF15 intron 23000144 rs6478108 chr9 117558703 C T 1.53E-12 Crohn's disease TNFSF15 intron 23266558 rs6478108 chr9 117558703 C T 4.11E-07 Leprosy TNFSF15 intron pha002872 rs4372078 chr9 117563687 T G 6.46E-10 Crohn's disease TNFSF15 intron 16221758 rs4263839 chr9 117566440 A G 1.49E-05 Multiple complex diseases TNFSF15 intron 17554300 rs4263839 chr9 117566440 A G 3.00E-10 Crohn's disease TNFSF15 intron 18587394 rs4263839 chr9 117566440 A G 3.00E-10 Asthma TNFSF15 intron 21150878 rs4263839 chr9 117566440 A G 2.60E-10 Multiple sclerosis TNFSF15 intron 22190364 rs4979462 chr9 117567013 C T 3.38E-13 Crohn's disease TNFSF15 intron 16221758 rs4979462 chr9 117567013 C T 3.00E-14 Primary biliary cirrhosis TNFSF15 intron 23000144 rs6478109 chr9 117568766 A G 1.17E-11 Crohn's disease TNFSF15 nearGene-5 16221758 rs6478109 chr9 117568766 A G 3.67E-09 Crohn's disease TNFSF15 nearGene-5 18587394 rs6478109 chr9 117568766 A G 3.00E-08 Inflammatory bowel disease TNFSF15 nearGene-5 18758464 rs6478109 chr9 117568766 A G 6.84E-12 Crohn's disease TNFSF15 nearGene-5 23266558 rs6478109 chr9 117568766 A G 9.12E-08 Leprosy TNFSF15 nearGene-5 pha002872 rs7848647 chr9 117569046 T C 4.43E-11 Crohn's disease TNFSF15 nearGene-5 16221758 rs7865494 chr9 117576479 C T 8.53E-04 Type 2 diabetes / / 17463246 rs7869487 chr9 117580914 C T 3.24E-11 Crohn's disease / / 16221758 rs7869487 chr9 117580914 C T 4.72E-06 Multiple complex diseases / / 17554300 rs2006996 chr9 117592638 T C 4.00E-13 Inflammatory bowel disease / / 21699788 rs2006996 chr9 117592638 T C 4.00E-16 Inflammatory bowel disease / / 21699788 rs2006996 chr9 117592638 T C 4.68E-13 Primary biliary cirrhosis / / 23000144 rs2006996 chr9 117592638 T C 1.22E-10 Crohn's disease / / 23266558 rs11554257 chr9 117605070 T C 1.39E-06 Ulcerative colitis,refractory / / 20848476 rs2093403 chr9 117611913 T C 6.08E-04 Body mass index / / 21701565 rs10114224 chr9 117613032 T C 5.92E-04 Type 2 diabetes / / 17463246 rs10982427 chr9 117613696 T C 7.41E-04 Type 2 diabetes / / 17463246 rs16931910 chr9 117618309 A C 5.50E-08 Crohn's disease / / 16221758 rs7040029 chr9 117619214 T C 5.99E-08 Primary biliary cirrhosis / / 23000144 rs998410 chr9 117622674 G T 4.82E-13 Primary biliary cirrhosis / / 23000144 rs7866342 chr9 117627569 G T 1.80E-04 Multiple complex diseases / / 17554300 rs7866342 chr9 117627569 G T 1.48E-09 Primary biliary cirrhosis / / 23000144 rs7866342 chr9 117627569 G T 2.69E-06 Crohn's disease / / 23266558 rs7866342 chr9 117627569 G T 1.01E-05 Leprosy / / pha002872 rs4979467 chr9 117630043 C T 6.72E-09 Crohn's disease / / 23266558 rs7863183 chr9 117642418 T C 3.13E-09 Primary biliary cirrhosis / / 23000144 rs7863183 chr9 117642418 T C 1.33E-07 Crohn's disease / / 23266558 rs13300483 chr9 117643362 C T 4.51E-14 Primary biliary cirrhosis / / 23000144 rs13300483 chr9 117643362 C T 5.18E-10 IgA levels / / 24676358 rs7028891 chr9 117645015 A G 9.82E-11 Primary biliary cirrhosis / / 23000144 rs7028891 chr9 117645015 A G 1.30E-06 Crohn's disease / / 23266558 rs1407309 chr9 117651780 G A 4.13E-10 Primary biliary cirrhosis / / 23000144 rs911605 chr9 117654990 G A 4.36E-04 Multiple complex diseases / / 17554300 rs10982445 chr9 117659691 T C 9.24E-08 Primary biliary cirrhosis TNFSF8 intron 23000144 rs5003740 chr9 117660601 G C 2.00E-05 Urinary metabolites TNFSF8 intron 21572414 rs5003740 chr9 117660601 G C 2.86E-11 Primary biliary cirrhosis TNFSF8 intron 23000144 rs3181201 chr9 117663800 G C 3.13E-10 Primary biliary cirrhosis TNFSF8 UTR-3 23000144 rs2974 chr9 117664172 T C 1.97E-07 Crohn's disease TNFSF8 UTR-3 16221758 rs2295800 chr9 117664211 T C 3.06E-08 Crohn's disease TNFSF8 UTR-3 16221758 rs2295800 chr9 117664211 T C 1.79E-04 Crohn's disease TNFSF8 UTR-3 23266558 rs2295800 chr9 117664211 T C 6.62E-05 Blood Pressure TNFSF8 UTR-3 pha003049 rs3181372 chr9 117665435 A G 3.69E-08 Primary biliary cirrhosis TNFSF8 UTR-3 23000144 rs3181367 chr9 117666678 G A 3.26E-08 Primary biliary cirrhosis TNFSF8 intron 23000144 rs3181362 chr9 117667443 T C 2.75E-04 Crohn's disease TNFSF8 intron 16221758 rs3181362 chr9 117667443 T C 6.38E-10 Crohn's disease TNFSF8 intron 23266558 rs3181196 chr9 117667937 G A,C,T 2.75E-06 Crohn's disease TNFSF8 intron 16221758 rs3827818 chr9 117669270 C T 5.62E-05 Crohn's disease TNFSF8 intron 16221758 rs1322054 chr9 117669299 A G 9.13E-09 Crohn's disease TNFSF8 intron 16221758 rs3789882 chr9 117669699 A T 4.45E-09 Crohn's disease TNFSF8 intron 16221758 rs3789879 chr9 117678236 T C 3.70E-09 Crohn's disease TNFSF8 intron 16221758 rs1885383 chr9 117679802 G A 1.61E-09 Crohn's disease TNFSF8 intron 16221758 rs2181032 chr9 117690864 C T 4.37E-05 Crohn's disease TNFSF8 intron 16221758 rs4978612 chr9 117691364 T A 5.50E-05 Crohn's disease TNFSF8 intron 16221758 rs3181360 chr9 117691558 C A,G,T 8.13E-05 Crohn's disease TNFSF8 intron 16221758 rs3181360 chr9 117691558 C A,G,T 4.52E-04 Longevity TNFSF8 intron 22279548 rs3181360 chr9 117691558 C A,G,T 7.94E-10 Crohn's disease TNFSF8 intron 23266558 rs3181357 chr9 117692344 G A 2.88E-06 Crohn's disease TNFSF8 intron 16221758 rs2075533 chr9 117693631 G A 9.54E-08 Primary biliary cirrhosis / / 23000144 rs3181348 chr9 117694184 G A 2.33E-04 Crohn's disease / / 23266558 rs3181348 chr9 117694184 G A 2.21E-05 Blood Pressure / / pha003049 rs10817689 chr9 117708099 T C 8.33E-05 Pulmonary function / / 19300500 rs10982467 chr9 117711707 C T 8.43E-05 Pulmonary function / / 19300500 rs881172 chr9 117714838 C T 8.40E-05 Pulmonary function / / 19300500 rs1322061 chr9 117715175 A C 5.82E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6478121 chr9 117716520 G C 8.90E-05 Pulmonary function / / 19300500 rs10817691 chr9 117720262 A C 9.83E-05 Pulmonary function / / 19300500 rs16932015 chr9 117751528 C G 2.20E-06 Urinary metabolites / / 21572414 rs16932027 chr9 117754106 C T 3.77E-04 Crohn's disease / / 23266558 rs4979485 chr9 117755204 C T 9.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs17239197 chr9 117756853 G T 9.69E-04 Type 2 diabetes / / 17463246 rs17817825 chr9 117757075 A C 5.34E-04 Crohn's disease / / 23266558 rs10982485 chr9 117758148 G A 7.30E-06 Urinary metabolites / / 21572414 rs10739430 chr9 117764088 T A 4.30E-06 Urinary metabolites / / 21572414 rs4978617 chr9 117764849 C T 7.30E-06 Urinary metabolites / / 21572414 rs7045562 chr9 117766421 C T 1.80E-05 Urinary metabolites / / 21572414 rs12006094 chr9 117771310 T C 4.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs13321 chr9 117792583 C G 2.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) TNC missense 21239504 rs2104772 chr9 117808785 T A 2.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) TNC missense 21239504 rs12349585 chr9 117813364 G A 8.35E-04 Obesity (extreme) TNC intron 21935397 rs17819305 chr9 117816230 C T 1.74E-07 Cardiovascular disease TNC intron 18179892 rs7859478 chr9 117817405 T G 8.36E-04 Obesity (extreme) TNC intron 21935397 rs1537011 chr9 117820549 G C 1.50E-06 Urinary metabolites TNC intron 21572414 rs17241442 chr9 117825085 G A 6.49E-08 Gallstones TNC intron 17632509 rs16932160 chr9 117829987 C A 4.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TNC intron 20877124 rs7847271 chr9 117830812 G A 4.00E-06 Prostate cancer (gene x gene interaction) TNC intron 22219177 rs1330349 chr9 117840742 G C 9.40E-05 Bipolar disorder TNC intron 19488044 rs1513 chr9 117856130 T G 1.10E-05 Urinary metabolites TNC intron 21572414 rs10982542 chr9 117875777 C G 1.80E-05 Urinary metabolites TNC intron 21572414 rs10982543 chr9 117876080 G A 1.90E-05 Urinary metabolites TNC intron 21572414 rs10125663 chr9 117886416 C T 6.34E-04 Type 2 diabetes / / 17463246 rs2012775 chr9 117903848 T C 9.43E-04 Multiple complex diseases DEC1 nearGene-5 17554300 rs2012566 chr9 117903975 G A 8.79E-04 Multiple complex diseases DEC1 nearGene-5 17554300 rs4978621 chr9 117909576 A G 3.27E-04 Multiple complex diseases DEC1 intron 17554300 rs6478141 chr9 117924671 G A 8.70E-06 Urinary metabolites DEC1 intron 21572414 rs7862558 chr9 117925922 T C 1.10E-05 Urinary metabolites DEC1 intron 21572414 rs7866181 chr9 117928419 C T 6.81E-05 Hypertension (early onset hypertension) DEC1 intron 22479346 rs7860900 chr9 117930567 T G 8.84E-05 Multiple complex diseases DEC1 intron 17554300 rs10982592 chr9 117932692 T C 9.56E-05 Cognitive performance DEC1 intron 19734545 rs10982597 chr9 117944988 A G 1.70E-05 Urinary metabolites DEC1 intron 21572414 rs4978628 chr9 117964656 A G 8.07E-04 Multiple complex diseases DEC1 intron 17554300 rs1335355 chr9 117970796 A C 9.99E-05 Cognitive impairment induced by topiramate DEC1 intron 22091778 rs10982611 chr9 117975864 A G 6.34E-05 Coronary heart disease DEC1 intron pha003032 rs10982611 chr9 117975864 A G 3.30E-05 Coronary heart disease DEC1 intron pha003033 rs10982614 chr9 117981057 C T 0.000885524 Hypertension (early onset hypertension) DEC1 intron 22479346 rs10982618 chr9 117987615 G T 6.43E-06 Kawasaki disease DEC1 intron 21221998 rs2989505 chr9 117996224 T C 2.67E-06 Pancreatic cancer DEC1 intron 23180869 rs2225749 chr9 118030920 A G 6.50E-04 Response to taxane treatment (placlitaxel) DEC1 intron 23006423 rs1414153 chr9 118042353 A C 1.42E-05 Pancreatic cancer DEC1 intron 23180869 rs7853844 chr9 118050414 G A 2.00E-06 Pancreatic cancer DEC1 intron 23180869 rs2418327 chr9 118052341 A G 6.31E-04 Bipolar disorder DEC1 intron 19259986 rs1414141 chr9 118052746 C T 1.70E-04 Type 2 diabetes and 6 quantitative traits DEC1 intron 17848626 rs10982662 chr9 118064892 G A 8.33E-05 Alzheimer's disease DEC1 intron 21098978 rs10982663 chr9 118066578 G C 8.34E-05 Alzheimer's disease DEC1 intron 21098978 rs1157836 chr9 118068722 C T 1.64E-04 Smoking initiation DEC1 intron 24665060 rs4978633 chr9 118124242 T C 9.64E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer DEC1 intron 21483023 rs974691 chr9 118125362 A G 9.64E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer DEC1 intron 21483023 rs972449 chr9 118126265 C T 3.26E-04 Type 2 diabetes DEC1 intron 17463246 rs9409143 chr9 118129604 C G 0.000028 Salmonella-induced pyroptosis DEC1 intron 22837397 rs9409144 chr9 118129621 T C 0.000024 Salmonella-induced pyroptosis DEC1 intron 22837397 rs9409145 chr9 118129747 T C 0.000323 Salmonella-induced pyroptosis DEC1 intron 22837397 rs10817755 chr9 118130427 T C 0.000134 Salmonella-induced pyroptosis DEC1 intron 22837397 rs10982716 chr9 118137199 C T 2.58E-04 Type 2 diabetes DEC1 intron 17463246 rs10982717 chr9 118139774 G A 0.00038 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DEC1 intron 23233654 rs10982717 chr9 118139774 G A 3.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) DEC1 intron 23233662 rs10817758 chr9 118143933 C T 2.52E-05 Cognitive impairment induced by topiramate DEC1 intron 22091778 rs7037974 chr9 118174830 T C 9.19E-04 Type 2 diabetes / / 17463246 rs7037974 chr9 118174830 T C 3.27E-04 Alzheimer's disease (late onset) / / 21379329 rs7037974 chr9 118174830 T C 9.29E-05 Cognitive impairment induced by topiramate / / 22091778 rs959486 chr9 118178057 C G 0.0002092 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs959486 chr9 118178057 C G 2.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10982735 chr9 118183158 A G 1.07E-04 Body mass index / / 17255346 rs9409154 chr9 118202716 T C 2.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs2157663 chr9 118213502 C T 2.50E-05 Urinary metabolites / / 21572414 rs1632812 chr9 118223430 G A 1.85E-04 Body mass index / / 17255346 rs1632812 chr9 118223430 G A 7.90E-04 Alcohol dependence / / 20201924 rs12341727 chr9 118244107 C T 2.73E-05 Cognitive impairment induced by topiramate / / 22091778 rs10982769 chr9 118254988 T C 2.55E-05 Body mass index / / 17255346 rs10982769 chr9 118254988 T C 2.90E-04 Alcohol dependence / / 20201924 rs12003493 chr9 118277283 C T 0.0004997 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12003493 chr9 118277283 C T 5.00E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1018845 chr9 118311164 G A 5.59E-04 Type 2 diabetes / / 17463246 rs10982794 chr9 118312655 T G 9.17E-04 Type 2 diabetes / / 17463246 rs4979552 chr9 118314283 A G 6.69E-04 Type 2 diabetes / / 17463246 rs4979554 chr9 118314378 A G 6.88E-04 Type 2 diabetes / / 17463246 rs12000608 chr9 118352592 T C 9.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs875069 chr9 118357126 C T 2.20E-05 Bipolar disorder / / 21771265 rs12115665 chr9 118368761 G A 1.63E-05 Blood Pressure / / pha003040 rs10817804 chr9 118387316 C A 1.12E-04 Type 2 diabetes / / 17463246 rs374050628 chr9 118387316 CA C 1.12E-04 Type 2 diabetes / / 17463246 rs7850229 chr9 118397913 C A 3.20E-05 Blood Pressure / / pha003040 rs10817805 chr9 118404041 G A 5.23E-04 Type 2 diabetes / / 17463246 rs10982853 chr9 118405173 C T 4.63E-05 Bipolar disorder / / 21771265 rs12006166 chr9 118424987 A T 9.00E-07 Migraine / / 23793025 rs10817809 chr9 118433442 T C 2.25E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs10119510 chr9 118447297 A G 5.00E-06 Urinary metabolites / / 21572414 rs10982874 chr9 118448207 T C 8.19E-04 Rheumatoid arthritis / / 21452313 rs10982874 chr9 118448207 T C 8.55E-05 Post-operative nausea and vomiting / / 21694509 rs10120612 chr9 118449091 A G 4.30E-06 Urinary metabolites / / 21572414 rs10817817 chr9 118451241 A G 3.18E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs7852660 chr9 118461823 T C 6.85E-05 Post-operative nausea and vomiting / / 21694509 rs12380012 chr9 118475932 C T 2.40E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs7045079 chr9 118485764 C T 0.000668 Salmonella-induced pyroptosis / / 22837397 rs11788382 chr9 118539497 G A 3.50E-05 Blood Pressure / / pha003039 rs7029464 chr9 118587823 A T 4.67E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs7029464 chr9 118587823 A T 4.67E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs10982946 chr9 118599720 T C 5.67E-05 Monocyte counts / / pha003089 rs10982957 chr9 118617531 A C 4.14E-05 Monocyte counts / / pha003089 rs10982970 chr9 118624384 T G 7.87E-05 Monocyte counts / / pha003089 rs10982990 chr9 118658716 A G 2.00E-06 Amyotrophic lateral sclerosis (sporadic) LINC00474 intron 24529757 rs7467853 chr9 118664276 T C 0.0000091 Mean arterial pressure LINC00474 intron 22510845 rs7862674 chr9 118674021 G A 9.26E-04 Type 2 diabetes LINC00474 intron 17463246 rs10983013 chr9 118683862 C T 9.90E-06 Stroke (ischemic) LINC00474 intron 21957438 rs7027312 chr9 118694535 A G 2.18E-04 Tourette syndrome / / 22889924 rs9408887 chr9 118713227 G A 9.78E-06 Stroke (ischemic) / / 21957438 rs12115454 chr9 118720050 G A 0.0000774 Gains in maximal O2 uptake response / / 21183627 rs7467015 chr9 118720418 T C 9.88E-06 Stroke (ischemic) / / 21957438 rs1349323 chr9 118741718 C T 9.33E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1901069 chr9 118744545 C A 1.25E-04 Parkinson's disease / / 17052657 rs7468478 chr9 118856835 A G 4.96E-04 Multiple complex diseases / / 17554300 rs7869233 chr9 118863701 C T 1.20E-04 Multiple complex diseases / / 17554300 rs436582 chr9 118956668 A G 3.00E-06 Conotruncal heart defects PAPPA intron 24800985 rs756624 chr9 118992381 C T 5.66E-05 Schizophrenia PAPPA intron 19571811 rs10435873 chr9 119038034 T G 5.41E-04 Smoking initiation PAPPA intron 24665060 rs11791847 chr9 119064292 T C 3.11E-11 Metabolite levels PAPPA intron 22286219 rs2418441 chr9 119074837 A G 3.03E-05 Multiple complex diseases PAPPA intron 17554300 rs2418444 chr9 119105667 T G 9.39E-04 Heart Failure PAPPA intron pha002884 rs7020782 chr9 119106881 C A 9.20E-06 Height PAPPA missense 21194676 rs751543 chr9 119122342 C T 7.00E-10 Height PAPPA intron 20881960 rs12353147 chr9 119130627 T C 2.92E-04 Fibrinogen PAPPA intron 17255346 rs7869550 chr9 119134796 A G 1.00E-06 Height PAPPA intron 18391950 rs10983127 chr9 119145200 T C 3.30E-05 Height PAPPA intron pha003010 rs16933484 chr9 119154200 A G 8.78E-04 Amyotrophic lateral sclerosis (sporadic) PAPPA intron 24529757 rs16933502 chr9 119163576 A C 1.29E-04 Amyotrophic lateral sclerosis (sporadic) PAPPA UTR-3 24529757 rs10983139 chr9 119168426 T G 3.69E-04 Hearing function / / 17255346 rs17302884 chr9 119172047 A G 5.16E-05 Behcet's disease / / pha002888 rs17303101 chr9 119181794 G A 1.04E-05 Behcet's disease / / 23291587 rs17303101 chr9 119181794 G A 2.52E-05 Migraine - clinic-based / / 23793025 rs17303101 chr9 119181794 G A 3.46E-04 Migraine without aura / / 23793025 rs17303101 chr9 119181794 G A 4.00E-07 Migraine / / 23793025 rs1507909 chr9 119187459 G A 6.84E-04 Type 2 diabetes ASTN2 nearGene-3 17846124 rs6478237 chr9 119192516 A C 8.30E-04 Type 2 diabetes and 6 quantitative traits ASTN2 intron 17848626 rs7850952 chr9 119200847 C A 9.90E-06 Gamma gluatamyl transferase levels (interaction with age) ASTN2 intron 22010049 rs888401 chr9 119207606 T C 2.51E-04 Hearing function ASTN2 intron 17255346 rs12057009 chr9 119226730 G A 7.48E-05 Cognitive test performance ASTN2 intron 20125193 rs4837545 chr9 119229246 C T 2.81E-04 Hearing function ASTN2 intron 17255346 rs10759842 chr9 119236373 C T 5.56E-04 Suicide attempts in bipolar disorder ASTN2 intron 21423239 rs10759842 chr9 119236373 C T 6.69E-04 Lymphocyte counts ASTN2 intron 22286170 rs7030607 chr9 119245183 G A 1.50E-07 Hippocampal volume ASTN2 intron 22504421 rs7020341 chr9 119247974 G C 1.80E-07 Hippocampal volume ASTN2 intron 22504421 rs17220352 chr9 119248059 A G 6.61E-06 Behcet's disease ASTN2 intron 23291587 rs7040792 chr9 119248993 T C 1.10E-07 Hippocampal volume ASTN2 intron 22504421 rs6478240 chr9 119249198 A G 1.10E-07 Hippocampal volume ASTN2 intron 22504421 rs10759844 chr9 119249326 T A 1.10E-07 Hippocampal volume ASTN2 intron 22504421 rs7852872 chr9 119249339 C G 1.00E-07 Hippocampal volume ASTN2 intron 22504421 rs6478241 chr9 119252629 A G 4.00E-08 Migraine ASTN2 intron 22683712 rs6478241 chr9 119252629 A G 1.00E-07 Migraine without aura ASTN2 intron 23793025 rs6478241 chr9 119252629 A G 1.00E-09 Migraine - clinic-based ASTN2 intron 23793025 rs6478241 chr9 119252629 A G 1.45E-07 Migraine without aura ASTN2 intron 23793025 rs6478241 chr9 119252629 A G 4.43E-07 Migraine ASTN2 intron 23793025 rs1876475 chr9 119253472 T A 1.10E-05 Urinary metabolites ASTN2 intron 21572414 rs11794318 chr9 119254123 G C 1.30E-07 Hippocampal volume ASTN2 intron 22504421 rs12353303 chr9 119255634 C T 2.50E-07 Hippocampal volume ASTN2 intron 22504421 rs767432 chr9 119258187 C T 4.60E-04 Aortic root size ASTN2 intron 21223598 rs767432 chr9 119258187 C T 2.30E-07 Hippocampal volume ASTN2 intron 22504421 rs1475057 chr9 119261166 C T 5.37E-04 Coronary Artery Disease ASTN2 intron 17634449 rs4836732 chr9 119266695 C T 2.48E-06 Osteoarthritis ASTN2 intron 22763110 rs12379128 chr9 119300567 G A 7.75E-04 Response to cytidine analogues (gemcitabine) ASTN2 intron 24483146 rs13290997 chr9 119314217 A G 5.00E-07 Pulmonary function (interaction) ASTN2 intron 23284291 rs10983238 chr9 119333683 C G 1.00E-07 Attention deficit hyperactivity disorder ASTN2 intron 18839057 rs10983238 chr9 119333683 C G 5.29E-04 Sarcoidosis ASTN2 intron 19165924 rs10983238 chr9 119333683 C G 3.26E-04 Smoking initiation ASTN2 intron 24665060 rs1885241 chr9 119355134 A G 1.52E-05 Blood Pressure ASTN2 intron pha003044 rs10983260 chr9 119365260 G T 9.67E-04 Coronary Artery Disease ASTN2 intron 17634449 rs10983260 chr9 119365260 G T 4.86E-04 Smoking initiation ASTN2 intron 24665060 rs4837659 chr9 119365292 A C 6.54E-04 Multiple complex diseases ASTN2 intron 17554300 rs1885243 chr9 119384592 T C 1.91E-05 Blood Pressure ASTN2 intron pha003044 rs1885245 chr9 119392413 G C 8.61E-05 Diabetes (gestational) ASTN2 intron 22233651 rs1596101 chr9 119401227 T C 8.37E-05 Multiple complex diseases ASTN2 intron 17554300 rs803929 chr9 119406661 A G 3.97E-04 Coronary Artery Disease ASTN2 intron 17634449 rs10983304 chr9 119448979 C T 3.47E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ASTN2 missense 20031582 rs3019 chr9 119462112 C T 3.90E-04 Coronary heart disease TRIM32 UTR-3 21966275 rs803917 chr9 119467660 G A 1 Drug response to Etoposide ASTN2 intron 17537913 rs803916 chr9 119469941 T A 3.38E-04 Multiple complex diseases ASTN2 intron 17554300 rs10983314 chr9 119475072 A T 2.26E-04 Multiple complex diseases ASTN2 intron 17554300 rs719535 chr9 119476270 T C 9.02E-06 Osteoarthritis ASTN2 intron 22763110 rs10983320 chr9 119483689 C T 1 Drug response to Etoposide ASTN2 intron 17537913 rs10817928 chr9 119489376 C T 3.23E-05 Osteoarthritis (knee and hip) ASTN2 intron 21177295 rs10817928 chr9 119489376 C T 3.60E-05 Osteoarthritis (knee and hip) ASTN2 intron 21177295 rs10817928 chr9 119489376 C T 8.17E-05 Hypertension ASTN2 intron pha003041 rs10983328 chr9 119490338 G A 6.72E-05 Alzheimer's disease ASTN2 intron 21098978 rs10491577 chr9 119490474 T C 3.20E-05 Response to statin therapy ASTN2 intron 20339536 rs7028544 chr9 119490572 A G 6.63E-05 Alzheimer's disease ASTN2 intron 21098978 rs7028544 chr9 119490572 A G 4.65E-07 Coronary heart disease ASTN2 intron pha003031 rs2416570 chr9 119508795 G A 6.43E-04 Type 2 diabetes ASTN2 intron 17463246 rs2416570 chr9 119508795 G A 1.60E-05 Urinary metabolites ASTN2 intron 21572414 rs894207 chr9 119510166 G A 1.40E-05 Urinary metabolites ASTN2 intron 21572414 rs10732383 chr9 119513100 C T 1.60E-05 Urinary metabolites ASTN2 intron 21572414 rs10983338 chr9 119518570 A C 2.35E-04 Multiple complex diseases ASTN2 intron 17554300 rs1372330 chr9 119519588 G A 7.46E-05 Response to taxane treatment (placlitaxel) ASTN2 intron 23006423 rs10759854 chr9 119522445 C A 3.76E-05 Lupus nephritis in systemic lupus erythematosus ASTN2 intron 24925725 rs930465 chr9 119525465 T C 9.82E-04 Multiple complex diseases ASTN2 intron 17554300 rs930465 chr9 119525465 T C 5.61E-05 Lupus nephritis in systemic lupus erythematosus ASTN2 intron 24925725 rs930466 chr9 119525840 T C 3.57E-05 Lupus nephritis in systemic lupus erythematosus ASTN2 intron 24925725 rs4836849 chr9 119526375 C T 3.50E-05 Information processing speed ASTN2 intron 21130836 rs4837838 chr9 119526538 C T 3.00E-05 Response to statin therapy ASTN2 intron 20339536 rs10759855 chr9 119528478 A C 4.64E-05 Lupus nephritis in systemic lupus erythematosus ASTN2 intron 24925725 rs1372332 chr9 119532775 C G 2.31E-05 Multiple complex diseases ASTN2 intron 17554300 rs10817931 chr9 119533257 C A 2.75E-04 Body mass index ASTN2 intron 21701565 rs10817931 chr9 119533257 C A 8.92E-04 Body mass index ASTN2 intron 21701565 rs41518847 chr9 119565556 T G 4.60E-04 Type 2 diabetes ASTN2 intron 17463246 rs7853590 chr9 119567708 A G 8.19E-04 Type 2 diabetes ASTN2 intron 17463246 rs1465918 chr9 119572876 G T 3.16E-04 Osteoarthritis ASTN2 intron 19508968 rs13287008 chr9 119579003 T C 6.64E-04 Depression (quantitative trait) ASTN2 intron 20800221 rs13285982 chr9 119579244 A G 5.78E-04 Depression (quantitative trait) ASTN2 intron 20800221 rs13285982 chr9 119579244 A G 2.10E-06 Urinary metabolites ASTN2 intron 21572414 rs3818501 chr9 119582648 T G 6.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ASTN2 intron 20877124 rs10733623 chr9 119584505 A G 3.50E-04 Primary sclerosing cholangitis ASTN2 intron 19944697 rs1326807 chr9 119585852 C T 1.59E-06 Non-obstructive azoospermia ASTN2 intron 22541561 rs7866077 chr9 119598413 C T 1.86E-05 Multiple complex diseases ASTN2 intron 17554300 rs7852640 chr9 119598595 T C 1.79E-05 Multiple complex diseases ASTN2 intron 17554300 rs7849242 chr9 119601401 A C 4.85E-06 Multiple complex diseases ASTN2 intron 17554300 rs1969918 chr9 119603853 G C 9.52E-04 Multiple complex diseases ASTN2 intron 17554300 rs12335373 chr9 119604993 C G 6.65E-04 Depression (quantitative trait) ASTN2 intron 20800221 rs1326814 chr9 119612028 C T 1.90E-04 Alcohol dependence ASTN2 intron 20201924 rs1536428 chr9 119616042 A G 1.80E-04 Alcohol dependence ASTN2 intron 20201924 rs1326816 chr9 119618184 G A 6.49E-04 Response to cytidine analogues (gemcitabine) ASTN2 intron 24483146 rs10491574 chr9 119622438 C T 2.12E-04 Multiple complex diseases ASTN2 intron 17554300 rs2026586 chr9 119622762 T C 8.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ASTN2 intron 20877124 rs2026587 chr9 119626289 G A 9.73E-05 Alzheimer's disease ASTN2 intron 17998437 rs1359703 chr9 119630787 A T 7.11E-05 Schizophrenia ASTN2 intron 19571809 rs10817947 chr9 119633124 G A 8.98E-04 Depression (quantitative trait) ASTN2 intron 20800221 rs4333683 chr9 119638009 G A 9.44E-04 Depression (quantitative trait) ASTN2 intron 20800221 rs1326818 chr9 119639180 G A 5.70E-05 HIV-1 control ASTN2 intron 20041166 rs10817951 chr9 119639424 C T 4.50E-04 Depression (quantitative trait) ASTN2 intron 20800221 rs7868701 chr9 119641530 C T 3.23E-04 Depression (quantitative trait) ASTN2 intron 20800221 rs7042673 chr9 119642094 G A 2.89E-04 Depression (quantitative trait) ASTN2 intron 20800221 rs12336175 chr9 119645481 G A 4.03E-05 Depression (quantitative trait) ASTN2 intron 20800221 rs16934016 chr9 119652372 T A 1.93E-04 Insulin resistance ASTN2 intron 21901158 rs7035794 chr9 119652497 C T 2.88E-04 Depression (quantitative trait) ASTN2 intron 20800221 rs16934021 chr9 119653328 G A 4.62E-04 Depression (quantitative trait) ASTN2 intron 20800221 rs4091697 chr9 119654521 T C 2.00E-05 Smoking behavior ASTN2 intron 20418888 rs3843826 chr9 119659689 G C 5.17E-04 Insulin resistance ASTN2 intron 21901158 rs11788987 chr9 119677554 G A 6.41E-05 Bipolar disorder and schizophrenia ASTN2 intron 20889312 rs11792136 chr9 119679456 T C 4.27E-05 Bipolar disorder and schizophrenia ASTN2 intron 20889312 rs11792136 chr9 119679456 T C 8.53E-04 Alzheimer's disease ASTN2 intron 22005930 rs4838020 chr9 119685232 G A 3.32E-04 Depression (quantitative trait) ASTN2 intron 20800221 rs12337270 chr9 119706269 G A 8.09E-04 Multiple complex diseases ASTN2 intron 17554300 rs10116120 chr9 119707772 G T 4.72E-05 Cholesterol ASTN2 intron 17255346 rs13288277 chr9 119709428 A G 7.50E-04 Alcohol dependence ASTN2 intron 20201924 rs12552544 chr9 119710188 G A 1.21E-04 Cholesterol ASTN2 intron 17255346 rs3849144 chr9 119712333 C A 3.97E-05 Cognitive test performance ASTN2 intron 20125193 rs16934119 chr9 119722707 T C 9.09E-04 Multiple complex diseases ASTN2 intron 17554300 rs2150199 chr9 119725725 A G 3.49E-04 Lung function (forced vital capacity) ASTN2 intron 24023788 rs1928980 chr9 119729943 C T 2.93E-04 Cholesterol ASTN2 intron 17255346 rs1928980 chr9 119729943 C T 5.61E-04 Insulin resistance ASTN2 intron 21901158 rs16934138 chr9 119730256 C A 4.51E-04 Alzheimer's disease ASTN2 intron 17998437 rs10759878 chr9 119730709 A G 7.02E-05 Lung function (forced vital capacity) ASTN2 intron 24023788 rs10759879 chr9 119732360 A G 1.06E-04 Lung function (forced vital capacity) ASTN2 intron 24023788 rs1928984 chr9 119733957 C G 2.06E-04 Cholesterol ASTN2 intron 17255346 rs1928991 chr9 119740845 T C 1.19E-04 Insulin resistance ASTN2 intron 21901158 rs7871473 chr9 119742375 C T 3.23E-05 Lung function (forced vital capacity) ASTN2 intron 24023788 rs7871473 chr9 119742375 C T 3.30E-04 Lung function (forced expiratory volume in 1 second) ASTN2 intron 24023788 rs7341922 chr9 119748559 G A 3.15E-04 Lung function (forced vital capacity) ASTN2 intron 24023788 rs7042036 chr9 119766969 C T 3.43E-04 Substance dependence ASTN2 intron 21818250 rs10817972 chr9 119768572 A G 4.64E-05 Cognitive test performance ASTN2 intron 20125193 rs1537528 chr9 119771893 G A 5.45E-04 Taste perception ASTN2 intron 22132133 rs6478269 chr9 119774374 G A 3.25E-04 Schizophrenia ASTN2 intron 19197363 rs10817974 chr9 119775606 C A 4.97E-04 Parkinson's disease ASTN2 intron 17052657 rs10759889 chr9 119789033 G T 1.85E-04 Multiple complex diseases ASTN2 intron 17554300 rs11792541 chr9 119789507 G A 3.40E-06 Urinary metabolites ASTN2 intron 21572414 rs7857377 chr9 119792250 A G 1.19E-05 Serum metabolites ASTN2 intron 19043545 rs9697211 chr9 119799692 G C 5.75E-04 Suicide attempts in bipolar disorder ASTN2 intron 21423239 rs10983467 chr9 119801737 T G 2.88E-04 Suicide attempts in bipolar disorder ASTN2 intron 21423239 rs1931302 chr9 119802441 G A 2.08E-04 Smoking initiation ASTN2 intron 24665060 rs10983479 chr9 119816239 T C 5.42E-05 Glucose levels ASTN2 intron pha003061 rs871126 chr9 119816793 C G 4.22E-04 Parkinson's disease ASTN2 intron 16252231 rs944976 chr9 119817038 G A 6.60E-04 Type 2 diabetes and 6 quantitative traits ASTN2 intron 17848626 rs10983487 chr9 119824051 C T 9.70E-05 Hemoglobin concentration ASTN2 intron 20534544 rs10121565 chr9 119825237 G A 2.08E-05 Glycosylated haemoglobin levels ASTN2 intron 17255346 rs10121565 chr9 119825237 G A 5.39E-04 Coronary heart disease ASTN2 intron 21606135 rs4497044 chr9 119827440 G C 6.68E-04 Suicide attempts in bipolar disorder ASTN2 intron 21423239 rs10983490 chr9 119827816 T A 5.73E-04 Suicide attempts in bipolar disorder ASTN2 intron 21423239 rs10118188 chr9 119836771 T G 1.20E-05 Urinary metabolites ASTN2 intron 21572414 rs10983510 chr9 119837918 T A 7.65E-04 Suicide attempts in bipolar disorder ASTN2 intron 21423239 rs16934284 chr9 119839328 T C 2.00E-06 Obesity-related traits ASTN2 intron 23251661 rs7034790 chr9 119840730 A G 8.02E-04 Multiple complex diseases ASTN2 intron 17554300 rs1889318 chr9 119843051 T C 3.20E-05 Asthma (bronchodilator response) ASTN2 intron 22792082 rs1334086 chr9 119850813 G A 4.20E-05 Asthma (bronchodilator response) ASTN2 intron 22792082 rs944981 chr9 119870092 G T 7.34E-05 Lupus nephritis in systemic lupus erythematosus ASTN2 intron 24925725 rs3923774 chr9 119880993 T C 5.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ASTN2 intron 20877124 rs4614069 chr9 119901641 G A 2.23E-04 Glycosylated haemoglobin levels ASTN2 intron 17255346 rs6478282 chr9 119925095 G T 6.88E-04 Coronary heart disease ASTN2 intron 21971053 rs6478282 chr9 119925095 G T 5.59E-06 Parkinson's disease (motor and cognition) ASTN2 intron 22658654 rs6478282 chr9 119925095 G T 6.00E-06 Immune response to anthrax vaccine ASTN2 intron 22658931 rs4838255 chr9 119926426 T A 3.00E-07 Response to antipsychotic treatment ASTN2 intron 20195266 rs928641 chr9 119927510 C T 8.29E-05 Cognitive performance ASTN2 intron 19734545 rs928641 chr9 119927510 C T 9.99E-04 Coronary heart disease ASTN2 intron 21971053 rs12683718 chr9 119942472 A G 7.25E-06 Parkinson's disease (motor and cognition) ASTN2 intron 22658654 rs12683718 chr9 119942472 A G 7.25E-06 Immune response to anthrax vaccine ASTN2 intron 22658931 rs977937 chr9 119942649 C T 4.42E-05 Cognitive performance ASTN2 intron 19734545 rs10983560 chr9 119943791 G C 7.04E-04 Multiple complex diseases ASTN2 intron 17554300 rs7856971 chr9 119977051 G T 5.67E-05 Serum metabolites ASTN2 intron 19043545 rs1160245 chr9 119992920 T A 4.40E-05 Anger ASTN2 intron 24489884 rs1335405 chr9 119993022 C T 4.44E-04 Suicide attempts in bipolar disorder ASTN2 intron 21041247 rs12237890 chr9 119993788 T A 4.37E-04 Suicide attempts in bipolar disorder ASTN2 intron 21041247 rs1335406 chr9 119995964 A T 4.99E-04 Suicide attempts in bipolar disorder ASTN2 intron 21041247 rs10465132 chr9 120007625 T C 2.00E-05 Urinary metabolites ASTN2 intron 21572414 rs10983587 chr9 120022061 C T 3.31E-04 Multiple complex diseases ASTN2 intron 17554300 rs4837062 chr9 120031365 G A 1.31E-04 Epilepsy ASTN2 intron 22116939 rs6478300 chr9 120035769 C A 1.32E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) ASTN2 intron 23648065 rs7026789 chr9 120043171 T C 1.35E-04 Epilepsy ASTN2 intron 22116939 rs10983605 chr9 120047430 G A 0.0005117 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ASTN2 intron 23233654 rs10983605 chr9 120047430 G A 5.12E-04 Methotrexate clearance (acute lymphoblastic leukemia) ASTN2 intron 23233662 rs10513297 chr9 120050463 T C 3.15E-05 Insulin-related traits ASTN2 intron pha002901 rs10818018 chr9 120052954 A T 0.0004852 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ASTN2 intron 23233654 rs10818018 chr9 120052954 A T 4.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) ASTN2 intron 23233662 rs10983608 chr9 120053100 C T 0.0004854 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ASTN2 intron 23233654 rs10983608 chr9 120053100 C T 4.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) ASTN2 intron 23233662 rs7862566 chr9 120054021 C T 3.15E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) ASTN2 intron 23648065 rs7862566 chr9 120054021 C T 5.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) ASTN2 intron 23648065 rs2416594 chr9 120060374 A G 0.0005776 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ASTN2 intron 23233654 rs2416594 chr9 120060374 A G 5.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) ASTN2 intron 23233662 rs2416594 chr9 120060374 A G 8.35E-05 Insulin-related traits ASTN2 intron pha002901 rs7046849 chr9 120061790 G A 0.0005501 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ASTN2 intron 23233654 rs7046849 chr9 120061790 G A 5.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) ASTN2 intron 23233662 rs10983613 chr9 120065787 C T 3.13E-05 Post-operative nausea and vomiting ASTN2 intron 21694509 rs10733628 chr9 120068354 C G 3.40E-06 Urinary metabolites ASTN2 intron 21572414 rs7022764 chr9 120068520 A G 9.00E-05 Prostate cancer ASTN2 intron 21743057 rs10983614 chr9 120069153 T C 7.00E-04 Pancreatic cancer ASTN2 intron 23180869 rs1416941 chr9 120074715 G C 6.00E-04 Pancreatic cancer ASTN2 intron 23180869 rs10818020 chr9 120078303 A T 4.91E-05 Pancreatic cancer ASTN2 intron 23180869 rs11790950 chr9 120078941 T G 8.00E-04 Pancreatic cancer ASTN2 intron 23180869 rs7866774 chr9 120082773 C T 2.90E-05 Urinary metabolites ASTN2 intron 21572414 rs10818022 chr9 120083882 G A 6.00E-04 Pancreatic cancer ASTN2 intron 23180869 rs10983619 chr9 120086176 A C 4.00E-04 Pancreatic cancer ASTN2 intron 23180869 rs7850624 chr9 120086232 C T 8.00E-04 Pancreatic cancer ASTN2 intron 23180869 rs3924642 chr9 120099585 T C 1.25E-05 Coronary heart disease ASTN2 intron pha003031 rs10983627 chr9 120102138 T C 6.78E-05 Cholesterol ASTN2 intron pha003073 rs3924100 chr9 120104077 A G 9.87E-04 Insulin resistance ASTN2 intron 21901158 rs4240415 chr9 120109509 T C 5.89E-05 Orofacial clefts ASTN2 intron 22419666 rs12552343 chr9 120110290 G A 1.73E-05 Serum metabolites ASTN2 intron 19043545 rs10818027 chr9 120111419 C A 6.11E-04 Multiple complex diseases ASTN2 intron 17554300 rs1934486 chr9 120135313 T C 6.35E-04 Obesity (extreme) ASTN2 intron 21935397 rs16934591 chr9 120136086 C T 9.62E-04 Insulin resistance ASTN2 intron 21901158 rs2226006 chr9 120137758 C T 6.00E-06 Economic and political preferences (fairness) ASTN2 intron 22566634 rs7875709 chr9 120145345 C T 5.02E-04 Obesity (extreme) ASTN2 intron 21935397 rs16905573 chr9 120146521 A T 9.49E-04 Suicide attempts in bipolar disorder ASTN2 intron 21423239 rs1416942 chr9 120154849 G T 1.39E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ASTN2 intron 20031582 rs1416942 chr9 120154849 G T 7.77E-04 Suicide attempts in bipolar disorder ASTN2 intron 21423239 rs16905611 chr9 120181980 A C 5.80E-04 Nicotine smoking / / 19268276 rs13288296 chr9 120182690 T C 3.22E-04 Insulin resistance / / 21901158 rs9695439 chr9 120184863 C T 8.10E-05 Cognitive function / / 24684796 rs1415377 chr9 120191973 A G 8.40E-05 Cognitive function / / 24684796 rs1337212 chr9 120199350 G A 4.00E-05 Lung function (forced vital capacity) / / pha003104 rs1339923 chr9 120217688 A G 1.40E-04 Coronary Artery Disease / / 17634449 rs1339923 chr9 120217688 A G 2.58E-05 Intracerebral hemorrhage / / 24656865 rs7040495 chr9 120219151 A T 2.51E-05 Intracerebral hemorrhage / / 24656865 rs7029721 chr9 120219553 T C 9.66E-06 Intracerebral hemorrhage / / 24656865 rs7044380 chr9 120219813 A G 2.36E-05 Intracerebral hemorrhage / / 24656865 rs7021038 chr9 120224826 T C 2.00E-05 Intracerebral hemorrhage / / 24656865 rs7025237 chr9 120225715 T G 1.83E-05 Intracerebral hemorrhage / / 24656865 rs1337216 chr9 120232342 T C 2.85E-05 Intracerebral hemorrhage / / 24656865 rs72766168 chr9 120236853 G A 2.60E-05 Intracerebral hemorrhage / / 24656865 rs1541155 chr9 120253907 A G 8.29E-04 Type 2 diabetes / / 17463246 rs534178 chr9 120256050 C T 9.72E-04 Type 2 diabetes / / 17463246 rs10983677 chr9 120275073 T G 3.00E-05 Prostate cancer / / 21743057 rs12337381 chr9 120275159 T C 3.00E-05 Prostate cancer / / 21743057 rs10983678 chr9 120275407 C G 3.00E-05 Prostate cancer / / 21743057 rs10983680 chr9 120275665 A G 3.00E-05 Prostate cancer / / 21743057 rs549493 chr9 120277096 T C 4.73E-05 Neutrophil count / / pha003095 rs2771051 chr9 120287708 G T 4.00E-09 Venous thromboembolism (gene x gene interaction) / / 23509962 rs1985317 chr9 120292334 C T 1.00E-09 Venous thromboembolism (gene x gene interaction) / / 23509962 rs476999 chr9 120327559 C A 7.49E-05 Tunica Media / / pha003037 rs10983710 chr9 120366614 C T 7.31E-14 Metabolite levels / / 22286219 rs1329055 chr9 120372882 C T 1.74E-05 Body Mass Index / / pha003019 rs1329055 chr9 120372882 C T 3.71E-06 Body Mass Index / / pha003020 rs2039126 chr9 120373921 G A 2.90E-05 Urinary metabolites / / 21572414 rs1329053 chr9 120376121 A G 2.80E-05 Urinary metabolites / / 21572414 rs1329053 chr9 120376121 A G 2.71E-04 Coronary heart disease / / 21606135 rs4837494 chr9 120436141 T C 5.21E-05 Prion diseases / / 22210626 rs1252041 chr9 120444797 A G 2.03E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs5030717 chr9 120473834 A G 1.00E-06 Plasma omega-6 polyunsaturated fatty acid levels TLR4 intron 24823311 rs4986791 chr9 120475602 C T 2.69E-04 Alzheimer's disease TLR4 missense 24755620 rs913930 chr9 120484009 G A 0.0002198 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs913930 chr9 120484009 G A 2.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7034482 chr9 120500533 G A 9.91E-04 Type 2 diabetes / / 17463246 rs7870814 chr9 120503274 A G 6.92E-04 Coronary Artery Disease / / 17634449 rs7860332 chr9 120503508 T G 6.90E-04 Coronary Artery Disease / / 17634449 rs10759938 chr9 120504213 G C 6.15E-04 Coronary Artery Disease / / 17634449 rs10818080 chr9 120510180 C T 9.93E-05 Intelligence / / 21826061 rs16906152 chr9 120521952 A G 6.80E-04 Multiple complex diseases / / 17554300 rs16906169 chr9 120525502 A C 0.000018 Mean arterial pressure / / 22510845 rs10983777 chr9 120525980 C G 9.87E-04 Alzheimer's disease / / 17998437 rs10983782 chr9 120533505 C A 3.17E-07 Glaucoma-related traits / / 22058429 rs10115586 chr9 120559011 T C 5.00E-07 IgG glycosylation / / 23382691 rs16906273 chr9 120599426 T C 1.00E-04 Prostate cancer / / 21743057 rs11793751 chr9 120614014 T C 2.60E-05 Urinary metabolites / / 21572414 rs1828887 chr9 120623523 C T 9.03E-05 Major depressive disorder (broad) / / 20038947 rs10818097 chr9 120626599 C T 1.50E-05 Serum metabolites / / 19043545 rs2048741 chr9 120637262 G A 2.40E-05 Bone mass and geometry / / 17903296 rs12378218 chr9 120648450 C A 1.63E-04 Attention deficit hyperactivity disorder / / 23728934 rs1514773 chr9 120650670 A G 1.63E-05 Serum metabolites / / 19043545 rs7047242 chr9 120651594 C G 1.74E-05 Serum metabolites / / 19043545 rs4837521 chr9 120654461 T C 2.31E-05 Serum metabolites / / 19043545 rs1271480 chr9 120688923 G A 1.74E-04 Multiple complex diseases / / 17554300 rs643215 chr9 120697951 T G 1.59E-04 Multiple complex diseases / / 17554300 rs2466429 chr9 120701293 C G 9.01E-05 Multiple complex diseases / / 17554300 rs488101 chr9 120707625 C T 1.04E-10 Multiple complex diseases / / 17554300 rs2225602 chr9 120734599 A G 5.88E-04 Major depressive disorder / / 22472876 rs9408905 chr9 120751155 G A 7.84E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2245960 chr9 120757370 C T 9.39E-04 Heart Failure / / pha002884 rs2780246 chr9 120769844 T C 9.11E-06 Obesity-related traits / / 23251661 rs2809420 chr9 120787025 T C 7.90E-04 Type 2 diabetes / / 17463246 rs2416604 chr9 120795990 T C 3.00E-06 Obesity-related traits / / 23251661 rs2806096 chr9 120806401 A G 7.58E-05 Intelligence / / 21826061 rs2806096 chr9 120806401 A G 5.01E-04 Coronary heart disease / / 21971053 rs2900142 chr9 120831882 C T 1.33E-04 Bipolar disorder / / 19259986 rs2416614 chr9 120836861 C G 9.96E-04 Type 2 diabetes / / 17463246 rs2809381 chr9 120852000 T C 7.78E-04 Multiple complex diseases / / 17554300 rs2806105 chr9 120852522 C T 8.87E-04 Multiple complex diseases / / 17554300 rs10122244 chr9 120904826 A G 8.44E-04 Multiple complex diseases / / 17554300 rs10123191 chr9 120906200 A T 5.00E-07 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs10983890 chr9 120913368 C T 7.22E-04 Multiple complex diseases / / 17554300 rs2769186 chr9 120929609 G A 1.20E-04 Multiple complex diseases / / 17554300 rs10513326 chr9 120978387 A C 6.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs876347 chr9 121031029 A G 2.00E-06 Response to antipsychotic therapy (extrapyramidal side effects) / / 19875103 rs12345715 chr9 121080656 G T 3.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs10115823 chr9 121092696 A C 1.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs12552282 chr9 121106909 G T 2.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs10983996 chr9 121117742 G A 2.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs10983996 chr9 121117742 G A 6.20E-06 Urinary metabolites / / 21572414 rs10124472 chr9 121125496 C A 6.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs3893408 chr9 121127354 C T 2.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs3893408 chr9 121127354 C T 6.20E-06 Urinary metabolites / / 21572414 rs1342510 chr9 121130268 C A 2.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs1342510 chr9 121130268 C A 6.20E-06 Urinary metabolites / / 21572414 rs10283930 chr9 121143176 G A 3.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs10818151 chr9 121182554 T C 4.86E-04 Multiple complex diseases / / 17554300 rs7022505 chr9 121213149 C T 3.70E-06 Urinary metabolites / / 21572414 rs7860140 chr9 121223808 T C 5.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs7864139 chr9 121224731 T C 9.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs10984029 chr9 121227711 C T 4.75E-04 Multiple complex diseases / / 17554300 rs7031212 chr9 121266166 T C 2.80E-05 Urinary metabolites / / 21572414 rs4404982 chr9 121326894 A G 3.06E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs1335258 chr9 121327323 C A 3.56E-05 Multiple complex diseases / / 17554300 rs1335258 chr9 121327323 C A 1.06E-06 Bipolar disorder and schizophrenia / / 20889312 rs1335258 chr9 121327323 C A 1.77E-05 Schizophrenia / / pha002857 rs7874294 chr9 121332922 T G 3.79E-05 Multiple complex diseases / / 17554300 rs7874294 chr9 121332922 T G 7.37E-06 Bipolar disorder and schizophrenia / / 20889312 rs10984096 chr9 121339090 A G 7.54E-05 Bipolar disorder / / 17486107 rs10984096 chr9 121339090 A G 8.74E-05 Triglycerides / / pha002904 rs1572299 chr9 121346417 T C 6.50E-04 Schizophrenia / / 19197363 rs1572299 chr9 121346417 T C 4.00E-06 Schizophrenia / / 19571808 rs1572299 chr9 121346417 T C 3.10E-06 Schizophrenia / / 21791550 rs1572299 chr9 121346417 T C 0.0000031 Psychosis / / 23164818 rs10984107 chr9 121355679 G A 3.10E-05 Bipolar disorder / / 19488044 rs10984107 chr9 121355679 G A 3.40E-06 Bipolar disorder and schizophrenia / / 20889312 rs10984107 chr9 121355679 G A 4.62E-05 Bipolar Disorder / / pha002858 rs11789399 chr9 121359286 G A 2.29E-06 Bipolar disorder / / 19488044 rs11789399 chr9 121359286 G A 6.00E-09 Bipolar disorder and schizophrenia / / 20889312 rs11789399 chr9 121359286 G A 1.60E-06 Schizophrenia / / pha002857 rs11789399 chr9 121359286 G A 4.30E-06 Bipolar Disorder / / pha002858 rs11789407 chr9 121359546 C A 6.60E-06 Multiple complex diseases / / 17554300 rs11789407 chr9 121359546 C A 8.67E-06 Bipolar disorder / / 19488044 rs11789407 chr9 121359546 C A 1.55E-08 Bipolar disorder and schizophrenia / / 20889312 rs11789407 chr9 121359546 C A 2.17E-06 Schizophrenia / / pha002857 rs11789407 chr9 121359546 C A 1.69E-05 Bipolar Disorder / / pha002858 rs1414097 chr9 121359692 T C 7.66E-05 Bipolar disorder / / 19488044 rs1414097 chr9 121359692 T C 9.11E-06 Bipolar disorder and schizophrenia / / 20889312 rs10759986 chr9 121363428 A C 2.26E-06 Bipolar disorder and schizophrenia / / 20889312 rs10759986 chr9 121363428 A C 2.89E-05 Schizophrenia / / pha002857 rs10733631 chr9 121364057 A C 2.25E-06 Bipolar disorder and schizophrenia / / 20889312 rs10733631 chr9 121364057 A C 2.07E-05 Schizophrenia / / pha002857 rs10759987 chr9 121364134 A C 8.94E-05 Multiple complex diseases / / 17554300 rs10759987 chr9 121364134 A C 4.95E-06 Bipolar disorder and schizophrenia / / 20889312 rs10759987 chr9 121364134 A C 3.57E-05 Schizophrenia / / pha002857 rs7866602 chr9 121364803 A C 4.62E-04 Multiple complex diseases / / 17554300 rs7866602 chr9 121364803 A C 7.80E-06 Bipolar disorder and schizophrenia / / 20889312 rs7866602 chr9 121364803 A C 5.24E-05 Schizophrenia / / pha002857 rs13285333 chr9 121378164 G A 9.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs13289435 chr9 121378413 C T 8.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs16907429 chr9 121383979 T C 4.79E-04 Aortic root size / / 21223598 rs1508376 chr9 121412214 G A 9.12E-04 Multiple complex diseases / / 17554300 rs10759994 chr9 121418763 G A 4.79E-04 Intracranial aneurysm / / 22286173 rs10114818 chr9 121422538 G A 6.71E-05 Longevity / / 20304771 rs16907501 chr9 121433254 G A 1.49E-04 Multiple complex diseases / / 17554300 rs10984174 chr9 121452706 G A 6.30E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs13288491 chr9 121463210 C T 5.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs7846997 chr9 121472600 A G 4.44E-04 Multiple complex diseases / / 17554300 rs12235164 chr9 121481298 C T 1.08E-05 Cognitive impairment induced by topiramate / / 22091778 rs12235164 chr9 121481298 C T 7.35E-06 Cognitive impairment induced by topiramate / / 22091778 rs1546442 chr9 121485160 G C 8.90E-04 Multiple complex diseases / / 17554300 rs4433214 chr9 121502691 A G 2.70E-05 Urinary metabolites / / 21572414 rs1355029 chr9 121505346 G A 7.90E-06 Urinary metabolites / / 21572414 rs10984205 chr9 121505836 G C 1.70E-05 Urinary metabolites / / 21572414 rs9644906 chr9 121519904 C G 6.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs9632909 chr9 121522885 C T 2.53E-04 Birth weight / / 17255346 rs2416686 chr9 121529204 C T 2.95E-04 Birth weight / / 17255346 rs2416688 chr9 121529334 C A 2.95E-04 Birth weight / / 17255346 rs17466586 chr9 121539628 C T 1.00E-05 Bipolar disorder and schizophrenia / / 20889312 rs961959 chr9 121550035 A C 2.38E-04 Multiple complex diseases / / 17554300 rs10984229 chr9 121559353 T C 1.16E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2148473 chr9 121604646 A G 6.39E-05 Depression (quantitative trait) / / 23290196 rs10984257 chr9 121607349 T C 5.72E-05 Depression (quantitative trait) / / 23290196 rs10984272 chr9 121636934 A T 6.57E-05 Depression (quantitative trait) / / 23290196 rs7467375 chr9 121650692 G T 7.20E-05 Depression (quantitative trait) / / 23290196 rs10984285 chr9 121651958 C T 6.61E-05 Depression (quantitative trait) / / 23290196 rs12237612 chr9 121698714 T C 5.17E-05 Parkinson's disease / / 17052657 rs10984338 chr9 121718918 C A 9.44E-06 Magnesium levels / / pha003092 rs10984339 chr9 121719114 T C 4.71E-04 Obesity (extreme) / / 21935397 rs10984340 chr9 121719628 G A 2.68E-04 Obesity (extreme) / / 21935397 rs724975 chr9 121788712 G A 0.000135 Oxaliplatin induced nausea/vomiting in response to colorectal cancer treatment / / 22310351 rs2191625 chr9 121790959 G T 6.42E-05 Serum metabolites / / 19043545 rs10117035 chr9 121796354 C T 3.02E-05 Taste perception / / 22132133 rs11794075 chr9 121803081 A G 6.98E-05 Suicide attempts in bipolar disorder / / 21041247 rs10122991 chr9 121808496 G A 3.16E-05 Taste perception / / 22132133 rs1158810 chr9 121809519 T C 3.53E-07 Primary biliary cirrhosis / / 23000144 rs1158810 chr9 121809519 T C 0.000000353 Facial morphology / / 23028347 rs6478394 chr9 121836674 A G 8.10E-04 Taste perception / / 22132133 rs6478394 chr9 121836674 A G 4.66E-07 Primary biliary cirrhosis / / 23000144 rs6478394 chr9 121836674 A G 0.000000466 Facial morphology / / 23028347 rs17134 chr9 121877596 G T 2.90E-04 Heart Failure / / pha002884 rs10984415 chr9 121884167 G A 6.82E-05 Response to metformin / / 21186350 rs7468009 chr9 121905152 G A 0.00003 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer / / 21245432 rs7468009 chr9 121905152 G A 2.00E-04 Heart Failure / / pha002884 rs230117 chr9 121916856 G A 6.84E-05 Panic disorder / / 19165232 rs230150 chr9 121946510 G C 2.66E-05 Response to metformin DBC1 intron 21186350 rs230089 chr9 121956076 G A 2.12E-05 Response to metformin DBC1 intron 21186350 rs1332450 chr9 121963214 A G 3.41E-04 Multiple complex diseases DBC1 intron 17554300 rs10760025 chr9 121967957 G A 1.95E-04 Multiple complex diseases DBC1 intron 17554300 rs10984440 chr9 121969350 G T 1.20E-05 Hemoglobin concentration DBC1 intron 20534544 rs9696959 chr9 121973842 A G 3.67E-04 Multiple complex diseases DBC1 intron 17554300 rs2183963 chr9 121974018 C T 2.69E-04 Multiple complex diseases DBC1 intron 17554300 rs7849611 chr9 121975207 C T 3.04E-04 Multiple complex diseases DBC1 intron 17554300 rs10984447 chr9 121984553 A G 8.00E-06 Multiple sclerosis DBC1 intron 17660530 rs10818288 chr9 121988899 T G 4.09E-04 Hemoglobin concentration DBC1 intron 20534544 rs10818288 chr9 121988899 T G 6.51E-04 Alzheimer's disease DBC1 intron 24755620 rs1332445 chr9 121992274 T C 2.41E-05 Hemoglobin concentration DBC1 intron 20534544 rs10818289 chr9 121993508 T C 3.08E-04 Hemoglobin concentration DBC1 intron 20534544 rs1332448 chr9 122033466 C T 3.25E-04 Hemoglobin concentration DBC1 intron 20534544 rs17534 chr9 122035038 C T 3.25E-04 Hemoglobin concentration DBC1 intron 20534544 rs487240 chr9 122036135 A G 2.68E-04 Type 2 diabetes DBC1 intron 17463246 rs914651 chr9 122036993 C T 3.08E-04 Suicide attempts in bipolar disorder DBC1 intron 21423239 rs914650 chr9 122037126 G T 3.16E-04 Suicide attempts in bipolar disorder DBC1 intron 21423239 rs914648 chr9 122037678 C G 2.47E-04 Suicide attempts in bipolar disorder DBC1 intron 21423239 rs1221140 chr9 122038177 G A 3.76E-04 Suicide attempts in bipolar disorder DBC1 intron 21423239 rs1332447 chr9 122038494 A G 9.70E-04 Suicide attempts in bipolar disorder DBC1 intron 21423239 rs10760031 chr9 122038860 G A 4.15E-04 Type 2 diabetes DBC1 intron 17463246 rs679134 chr9 122039397 G A 5.31E-04 Suicide attempts in bipolar disorder DBC1 intron 21423239 rs731133 chr9 122039862 G A 4.85E-04 Suicide attempts in bipolar disorder DBC1 intron 21423239 rs1221144 chr9 122042511 G C 6.23E-04 Suicide attempts in bipolar disorder DBC1 intron 21423239 rs471215 chr9 122043556 T C 8.38E-04 Suicide attempts in bipolar disorder DBC1 intron 21423239 rs4837628 chr9 122059709 T C 1.00E-06 Parkinson's disease DBC1 intron 20070850 rs41489644 chr9 122113823 G A 2.12E-04 Multiple complex diseases DBC1 intron 17554300 rs7039577 chr9 122118114 C T 1.69E-04 Multiple complex diseases DBC1 intron 17554300 rs7039577 chr9 122118114 C T 3.46E-04 Lung function (forced vital capacity) DBC1 intron 24023788 rs10760035 chr9 122120109 T G 4.47E-04 Multiple complex diseases DBC1 intron 17554300 rs17635892 chr9 122166761 A C 8.34E-05 Cholesterol / / pha003078 rs1888736 chr9 122175586 T G 1.23E-04 Multiple complex diseases / / 17554300 rs10491527 chr9 122176793 A G 7.45E-04 Myocardial Infarction / / pha002883 rs11792112 chr9 122198457 T C 4.50E-05 Osteoarthritis (knee and hip) / / 21177295 rs11792112 chr9 122198457 T C 5.79E-05 Osteoarthritis (knee and hip) / / 21177295 rs11792112 chr9 122198457 T C 7.56E-04 Osteoarthritis (knee and hip) / / 21177295 rs9299260 chr9 122222874 C T 7.12E-06 Cognitive decline / / 23207651 rs6478407 chr9 122230569 C T 7.92E-05 Serum metabolites / / 19043545 rs6478407 chr9 122230569 C T 1.80E-05 Urinary metabolites / / 21572414 rs10760040 chr9 122243097 T C 1.40E-05 Urinary metabolites / / 21572414 rs10760041 chr9 122243410 T C 7.60E-06 Urinary metabolites / / 21572414 rs1412055 chr9 122249965 G A 1.62E-04 Fibrinogen / / 17255346 rs6478412 chr9 122253667 C T 5.02E-04 Multiple complex diseases / / 17554300 rs12555385 chr9 122254248 T C 4.10E-04 Type 2 diabetes / / 17463246 rs10984560 chr9 122257627 C T 1.10E-05 Urinary metabolites / / 21572414 rs10984561 chr9 122258577 C T 3.00E-06 Pulmonary function decline / / 22424883 rs10984568 chr9 122260749 G A 2.79E-05 Heart Failure / / pha002884 rs10120423 chr9 122273279 T C 5.82E-04 Multiple complex diseases / / 17554300 rs2109664 chr9 122301156 C T 4.57E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs4644327 chr9 122303614 G A 5.68E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs1331614 chr9 122307847 C T 7.53E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs10818337 chr9 122352721 T G 3.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10818362 chr9 122431650 C T 3.94E-05 Serum metabolites / / 19043545 rs10125439 chr9 122436623 C T 6.10E-06 Urinary metabolites / / 21572414 rs960322 chr9 122445351 C G 2.60E-05 Urinary metabolites / / 21572414 rs10984642 chr9 122450340 C T 2.80E-05 Urinary metabolites / / 21572414 rs4642724 chr9 122481907 T G 2.69E-04 Parkinson's disease / / 17052657 rs12343913 chr9 122486004 T C 6.48E-04 Type 2 diabetes / / 17463246 rs17388019 chr9 122510675 C T 2.72E-04 Type 2 diabetes / / 17463246 rs10984680 chr9 122520487 G T 5.50E-06 Urinary metabolites / / 21572414 rs10984684 chr9 122522318 G A 5.39E-04 Type 2 diabetes / / 17463246 rs2809901 chr9 122543369 G T 8.76E-05 Serum metabolites / / 19043545 rs16909059 chr9 122556023 G A 2.00E-05 Urinary metabolites / / 21572414 rs10818386 chr9 122564129 C T 8.14E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs944961 chr9 122572896 C T 9.92E-06 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs4378028 chr9 122574527 G A 4.22E-05 Cognitive test performance / / 20125193 rs4378028 chr9 122574527 G A 4.69E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4469535 chr9 122577120 G T 3.64E-05 Cognitive test performance / / 20125193 rs1333920 chr9 122581960 G C 9.74E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1333916 chr9 122596036 G A 4.15E-05 Cognitive test performance / / 20125193 rs6478444 chr9 122681580 A G 5.60E-06 Melanoma / / 21983785 rs4837687 chr9 122708292 A G 1.73E-05 Serum metabolites / / 19043545 rs1333886 chr9 122711751 C A 2.87E-05 Serum metabolites / / 19043545 rs6651527 chr9 122716626 T G 6.80E-06 Serum metabolites / / 19043545 rs2900163 chr9 122720528 A G 1.06E-05 Serum metabolites / / 19043545 rs2416726 chr9 122723348 T C 5.84E-06 Serum metabolites / / 19043545 rs10818415 chr9 122771568 C T 9.08E-04 Multiple complex diseases / / 17554300 rs16909317 chr9 122774519 C T 6.07E-04 Multiple complex diseases / / 17554300 rs2416740 chr9 122777336 G A 3.84E-04 Multiple complex diseases / / 17554300 rs2416745 chr9 122781254 T G 1.00E-06 Preschool internalizing problems / / 24839885 rs6478452 chr9 122788060 A G 5.14E-04 Smoking initiation / / 24665060 rs945247 chr9 122803658 G T 4.94E-04 Multiple complex diseases / / 17554300 rs945249 chr9 122842260 C T 9.63E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs870777 chr9 122844943 T C 3.10E-05 Response to statin therapy / / 20339536 rs4837700 chr9 122846710 T C 3.70E-05 Response to statin therapy / / 20339536 rs1335214 chr9 122847182 G C 3.40E-05 Response to statin therapy / / 20339536 rs4837702 chr9 122848409 A G 3.50E-05 Response to statin therapy / / 20339536 rs4590508 chr9 122849119 T C 3.50E-05 Response to statin therapy / / 20339536 rs1335215 chr9 122850531 A G 3.50E-05 Response to statin therapy / / 20339536 rs7018996 chr9 122852635 C T 7.50E-05 Response to statin therapy / / 20339536 rs12235613 chr9 122852849 T C 9.51E-05 Orofacial clefts / / 22419666 rs945244 chr9 122858134 C T 4.10E-05 Response to statin therapy / / 20339536 rs945244 chr9 122858134 C T 8.85E-05 Orofacial clefts / / 22419666 rs7022811 chr9 122859248 C T 5.00E-05 Response to statin therapy / / 20339536 rs9299270 chr9 122860171 G A 4.80E-05 Response to statin therapy / / 20339536 rs16909449 chr9 122861297 T C 1.00E-06 Response to statin therapy / / 20339536 rs10984840 chr9 122868788 A G 1.87E-04 Cognitive decline / / 23732972 rs945246 chr9 122874156 T C 9.95E-04 Parkinson's disease / / 17052657 rs10760078 chr9 122894800 C T 2.43E-04 Type 2 diabetes / / 17463246 rs1154869 chr9 122905627 T G 8.59E-04 Multiple complex diseases / / 17554300 rs4837735 chr9 122978928 C T 9.27E-04 Multiple complex diseases / / 17554300 rs4837752 chr9 123056637 G A 6.00E-06 Response to antipsychotic therapy (extrapyramidal side effects) / / 19875103 rs4837752 chr9 123056637 G A 3.38E-04 Smoking initiation / / 24665060 rs983525 chr9 123103019 C T 5.81E-04 Multiple complex diseases / / 17554300 rs727661 chr9 123110320 T C 9.48E-06 Multiple complex diseases / / 17554300 rs1112863 chr9 123122187 G A 6.00E-05 Prostate cancer / / 21743057 rs1537282 chr9 123124504 C T 8.87E-06 Glucose levels / / pha003058 rs1332252 chr9 123130657 A G 1.42E-04 Multiple complex diseases / / 17554300 rs7849538 chr9 123132935 T C 8.54E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4836815 chr9 123134544 G C 7.62E-06 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12379034 chr9 123162666 A G 1.00E-12 Rheumatoid arthritis CDK5RAP2 intron 24782177 rs12379034 chr9 123162666 A G 1.00E-16 Rheumatoid arthritis CDK5RAP2 intron 24782177 rs3780674 chr9 123166919 C T 9.70E-05 Bone mineral density (spine) CDK5RAP2 intron 19079262 rs3780674 chr9 123166919 C T 7.10E-06 Bone mineral density CDK5RAP2 intron 21927923 rs2297454 chr9 123171755 T C 4.47E-05 Cognitive test performance CDK5RAP2 intron 20125193 rs7857382 chr9 123341189 T G 6.94E-04 Response to taxane treatment (placlitaxel) CDK5RAP2 intron 23006423 rs1359328 chr9 123370822 T C 9.16E-05 Intelligence MEGF9 intron 21826061 rs41417544 chr9 123415462 T C 3.35E-04 Multiple complex diseases MEGF9 intron 17554300 rs2274144 chr9 123421879 A G 9.03E-04 Depression (quantitative trait) MEGF9 intron 20800221 rs78876922 chr9 123453605 T G 3.81E-05 Intracerebral hemorrhage MEGF9 intron 24656865 rs80112840 chr9 123454085 G T 3.20E-05 Intracerebral hemorrhage MEGF9 intron 24656865 rs10984991 chr9 123473242 G A 3.00E-04 Renal function-related traits (urea) MEGF9 intron 22797727 rs10985070 chr9 123636121 C A 4.00E-09 Rheumatoid arthritis PHF19 intron 24390342 rs10985070 chr9 123636121 C A 5.00E-11 Rheumatoid arthritis PHF19 intron 24390342 rs1953126 chr9 123640500 T C 3.43E-08 Rheumatoid arthritis / / 17804836 rs1953126 chr9 123640500 T C 7.86E-10 Rheumatoid arthritis / / 19503088 rs1953126 chr9 123640500 T C 4.00E-11 Celiac disease and Rheumatoid arthritis / / 21383967 rs1953126 chr9 123640500 T C 6.03E-04 Rheumatoid arthritis / / 21452313 rs1953126 chr9 123640500 T C 0.00000208 Rheumatoid arthritis / / 23143596 rs10985073 chr9 123643855 T C 1.80E-08 Rheumatoid arthritis / / 17804836 rs10985073 chr9 123643855 T C 9.10E-11 Rheumatoid arthritis / / 19503088 rs2072438 chr9 123651301 T C 3.00E-09 Rheumatoid arthritis / / 24782177 rs881375 chr9 123652898 T C 1.40E-08 Rheumatoid arthritis / / 17804836 rs881375 chr9 123652898 T C 4.00E-08 Rheumatoid arthritis / / 19503088 rs881375 chr9 123652898 T C 4.00E-08 Asthma / / 21907864 rs7046108 chr9 123660339 G A 9.18E-04 Multiple complex diseases / / 17554300 rs7046108 chr9 123660339 G A 2.30E-05 Urinary metabolites / / 21572414 rs10985085 chr9 123665297 C T 9.94E-05 Hypertension (essential hypertension) TRAF1 UTR-3 22184326 rs2239657 chr9 123671520 G A 5.73E-04 Multiple complex diseases TRAF1 cds-synon 17554300 rs2239657 chr9 123671520 G A 9.30E-05 HIV-1 control TRAF1 cds-synon 20041166 rs2239657 chr9 123671520 G A 1.10E-05 Urinary metabolites TRAF1 cds-synon 21572414 rs2239658 chr9 123671837 T C 9.63E-04 Multiple complex diseases TRAF1 intron 17554300 rs6478488 chr9 123675133 C T 3.59E-04 Multiple complex diseases TRAF1 intron 17554300 rs758959 chr9 123676699 C T 2.60E-04 Atrial fibrillation TRAF1 intron 21846873 rs2109895 chr9 123677827 C T 7.20E-05 HIV-1 control TRAF1 intron 20041166 rs2269060 chr9 123683569 C T 0.000000371 Rheumatoid arthritis TRAF1 intron 23143596 rs2269060 chr9 123683569 C T 1.73E-08 Rheumatoid arthritis (CCP positive) TRAF1 intron 23143596 rs7021206 chr9 123684157 G A 2.70E-05 Urinary metabolites TRAF1 intron 21572414 rs12376966 chr9 123684195 C T 3.39E-04 Multiple complex diseases TRAF1 intron 17554300 rs1930780 chr9 123686219 C G 8.64E-04 Multiple complex diseases TRAF1 intron 17554300 rs2301334 chr9 123689104 C A 6.54E-09 Triglycerides TRAF1 UTR-5 23063622 rs2301334 chr9 123689104 C A 0.00039 Coronary artery calcification TRAF1 UTR-5 23727086 rs3761847 chr9 123690239 G A 4.00E-14 Rheumatoid arthritis TRAF1 intron 17804836 rs3761847 chr9 123690239 G A 6.99E-10 Rheumatoid arthritis TRAF1 intron 19503088 rs3761847 chr9 123690239 G A 2.00E-07 Rheumatoid arthritis TRAF1 intron 20453842 rs3761847 chr9 123690239 G A 4.00E-14 Celiac disease and Rheumatoid arthritis TRAF1 intron 21383967 rs3761847 chr9 123690239 G A 4.00E-14 Multiple sclerosis TRAF1 intron 22190364 rs3761847 chr9 123690239 G A 0.00000021 Rheumatoid arthritis TRAF1 intron 23143596 rs10739580 chr9 123695282 C T 0.0000017 Rheumatoid arthritis / / 23143596 rs6478491 chr9 123698490 G C 2.73E-04 Multiple complex diseases / / 17554300 rs7044444 chr9 123699909 G C 6.70E-04 Multiple complex diseases / / 17554300 rs10985098 chr9 123705289 C G 6.36E-04 Multiple complex diseases / / 17554300 rs2900180 chr9 123706382 T C 8.00E-14 Rheumatoid arthritis / / 17804836 rs10985104 chr9 123709586 A G 2.27E-04 Multiple complex diseases / / 17554300 rs7045519 chr9 123717840 C A 0.0000383 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes C5 intron 22628534 rs7867511 chr9 123723390 C A 3.65E-04 Multiple complex diseases C5 intron 17554300 rs7035682 chr9 123727994 C T 0.0000322 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes C5 intron 22628534 rs10985112 chr9 123731408 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes C5 intron 22628534 rs7026551 chr9 123733133 A C 2.00E-08 Rheumatoid arthritis C5 intron 17804836 rs7026551 chr9 123733133 A C 6.84E-06 Rheumatoid arthritis C5 intron 19503088 rs7026551 chr9 123733133 A C 4.16E-04 Hemoglobin concentration C5 intron 20534544 rs2269066 chr9 123737018 C T 6.39E-06 Rheumatoid arthritis C5 intron 17804836 rs7037673 chr9 123740484 C T 1.57E-06 Rheumatoid arthritis C5 intron 17804836 rs7037673 chr9 123740484 C T 4.60E-08 Rheumatoid arthritis C5 intron 19503088 rs7046909 chr9 123763880 T C 2.85E-04 Coronary heart disease C5 intron 21606135 rs7027797 chr9 123771799 T C 1.14E-05 Lung adenocarcinoma C5 intron 19836008 rs2416810 chr9 123785200 G A 2.40E-05 Rheumatoid arthritis C5 intron 17804836 rs2416810 chr9 123785200 G A 9.01E-06 Rheumatoid arthritis C5 intron 19503088 rs17216529 chr9 123800218 C T 0.000015 Stroke C5 missense 23422753 rs1468673 chr9 123809890 C T 6.03E-05 Rheumatoid arthritis C5 intron 17804836 rs1468673 chr9 123809890 C T 9.39E-06 Rheumatoid arthritis C5 intron 19503088 rs2300939 chr9 123811717 C T 8.08E-04 Bipolar disorder C5 intron 19259986 rs2300939 chr9 123811717 C T 3.19E-05 Lung adenocarcinoma C5 intron 19836008 rs10985140 chr9 123822837 G A 7.50E-05 HIV-1 control / / 20041166 rs10733651 chr9 123858194 G T 8.40E-05 HIV-1 control CNTRL intron 20041166 rs10081760 chr9 123884306 A G 8.40E-05 HIV-1 control CNTRL intron 20041166 rs10818509 chr9 123886733 G C 3.02E-04 Multiple complex diseases CNTRL intron 17554300 rs1407912 chr9 123906001 A C 8.40E-05 HIV-1 control CNTRL intron 20041166 rs7023214 chr9 123908345 G A 8.40E-05 HIV-1 control CNTRL intron 20041166 rs9408926 chr9 123914874 C T 4.00E-08 Immune reponse to smallpox (secreted IFN-alpha) CNTRL cds-synon 22610502 rs2057465 chr9 123926837 A C 0.0000706 Primary sclerosing cholangitis CNTRL intron 23603763 rs2057466 chr9 123926930 T C 3.79E-05 Multiple complex diseases CNTRL intron 17554300 rs2273988 chr9 123928486 T C 8.40E-05 HIV-1 control CNTRL intron 20041166 rs10760153 chr9 123948375 T C 4.00E-04 Asthma (childhood onset) RAB14 intron 21359210 rs942152 chr9 123951685 C T 1.30E-07 Rheumatoid arthritis RAB14 intron 19503088 rs9408928 chr9 123951917 T C 4.00E-09 Immune reponse to smallpox (secreted IFN-alpha) RAB14 intron 22610502 rs9792437 chr9 123964901 A G 3.70E-05 HIV-1 control / / 20041166 rs10513365 chr9 124020925 C T 3.06E-04 Bipolar disorder / / 19259986 rs10985207 chr9 124083948 A G 3.95E-04 Multiple complex diseases GSN intron 17554300 rs306772 chr9 124092355 C T 6.17E-06 Rheumatoid arthritis GSN intron 19503088 rs767770 chr9 124098535 C T 6.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs16910559 chr9 124106209 G A 1.38E-05 Iron levels STOM intron 19880490 rs16910559 chr9 124106209 G A 2.85E-05 Cognitive test performance STOM intron 20125193 rs16910559 chr9 124106209 G A 1.38E-05 Iron levels STOM intron pha002876 rs3761853 chr9 124135334 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs41424949 chr9 124138683 G T 6.75E-12 Multiple complex diseases / / 17554300 rs2196311 chr9 124170490 C A 5.01E-05 Cognitive impairment induced by topiramate / / 22091778 rs2196311 chr9 124170490 C A 6.12E-05 Hypertension (early onset hypertension) / / 22479346 rs2196311 chr9 124170490 C A 2.56E-04 Iron levels / / pha002876 rs2043520 chr9 124174857 A G 8.86E-05 Hypertension (early onset hypertension) / / 22479346 rs4837853 chr9 124213962 C T 9.08E-05 Hypertension (early onset hypertension) / / 22479346 rs769012 chr9 124234021 G A 9.80E-05 Hypertension (early onset hypertension) GGTA1P intron 22479346 rs12551209 chr9 124283089 G A 9.48E-05 Lung adenocarcinoma / / 19836008 rs7042758 chr9 124328194 T C 9.57E-06 Obesity-related traits / / 23251661 rs1757321 chr9 124331759 C T 1.56E-04 Alcohol dependence DAB2IP intron 21314694 rs4310275 chr9 124339034 G T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes DAB2IP intron 22628534 rs10818568 chr9 124339349 G A 0.0000131 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes DAB2IP intron 22628534 rs10513376 chr9 124354826 T C 5.00E-04 Obesity,menopause DAB2IP intron 21424828 rs7025486 chr9 124422403 G A 5.00E-10 Abdominal aortic aneurysm DAB2IP intron 20622881 rs1571801 chr9 124427373 G T 2.84E-05 Prostate cancer DAB2IP intron 18073375 rs35061590 chr9 124476013 G T 9.00E-06 Heart rate DAB2IP intron 23534349 rs13290547 chr9 124487495 C T 3.62E-05 Ankle-brachial index DAB2IP intron 22199011 rs13290547 chr9 124487495 C T 9.45E-06 Heart rate DAB2IP intron 23534349 rs3747851 chr9 124521260 G A 6.00E-07 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) DAB2IP cds-synon 23648065 rs10985375 chr9 124549642 C A 2.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs10818593 chr9 124560853 C T 9.00E-06 Metabolite levels (X-11787) / / 23934736 rs10760187 chr9 124565820 T C 5.00E-07 Periodontal microbiota / / 22699663 rs10760193 chr9 124605896 C T 4.76E-04 Obesity (extreme) TTLL11 intron 21935397 rs10818604 chr9 124608609 T A 4.80E-04 Obesity (extreme) TTLL11 intron 21935397 rs10760197 chr9 124610491 A G 4.90E-04 Obesity (extreme) TTLL11 intron 21935397 rs10760198 chr9 124610536 G A 4.95E-04 Obesity (extreme) TTLL11 intron 21935397 rs10760198 chr9 124610536 G A 8.83E-05 Glucose levels TTLL11 intron pha003057 rs10985423 chr9 124623193 G A 7.23E-05 Lupus nephritis in systemic lupus erythematosus TTLL11 intron 24925725 rs4390017 chr9 124633711 C T 6.71E-04 Multiple complex diseases TTLL11 intron 17554300 rs10121618 chr9 124639787 C T 9.33E-04 Multiple complex diseases TTLL11 intron 17554300 rs7033700 chr9 124643095 C T 2.10E-04 Hearing function TTLL11 intron 17255346 rs4271039 chr9 124661100 G A 5.99E-05 Body Mass Index TTLL11 intron pha003020 rs13295747 chr9 124685499 C T 4.90E-09 Schizophrenia TTLL11 intron 22037555 rs7022103 chr9 124693113 C T 9.49E-04 Aortic root size TTLL11 intron 21223598 rs7022103 chr9 124693113 C T 3.63E-04 Smoking quantity TTLL11 intron 24665060 rs13295532 chr9 124697877 T C 5.72E-04 Smoking quantity TTLL11 intron 24665060 rs2416841 chr9 124701103 T C 4.34E-04 Multiple complex diseases TTLL11 intron 17554300 rs2416841 chr9 124701103 T C 4.39E-04 Alzheimer's disease TTLL11 intron 17998437 rs10985458 chr9 124701165 C G 3.92E-04 Smoking quantity TTLL11 intron 24665060 rs7869913 chr9 124703298 C T 1.82E-04 Smoking quantity TTLL11 intron 24665060 rs10985459 chr9 124703332 C T 3.41E-04 Smoking quantity TTLL11 intron 24665060 rs12379136 chr9 124716151 G A 8.65E-05 Smoking quantity TTLL11 intron 24665060 rs7867048 chr9 124720206 C G 1.04E-04 Alzheimer's disease TTLL11 intron 17998437 rs7867807 chr9 124737687 C A 6.41E-04 Aortic root size TTLL11 intron 21223598 rs7867807 chr9 124737687 C A 5.08E-04 Smoking quantity TTLL11 intron 24665060 rs16911180 chr9 124738711 T C 2.70E-04 Alzheimer's disease TTLL11 intron 17998437 rs13299260 chr9 124741069 T C 5.45E-04 Suicide attempts in bipolar disorder TTLL11 intron 21041247 rs7855045 chr9 124741658 A G 5.98E-04 Suicide attempts in bipolar disorder TTLL11 intron 21041247 rs16911292 chr9 124781549 C T 6.53E-04 Nicotine smoking TTLL11 intron 19268276 rs12551572 chr9 124864385 T G 4.62E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs944214 chr9 124872011 T C 8.39E-05 Coronary heart disease / / pha003033 rs944217 chr9 124873472 G A 2.00E-05 Urinary metabolites / / 21572414 rs10985535 chr9 124878182 C T 8.27E-07 Recombination rate / / 21698098 rs7038781 chr9 124885254 G A 2.47E-05 Myopia (pathological) / / 21095009 rs7042153 chr9 124885596 C A 7.05E-04 Myopia (pathological) / / 21095009 rs3818638 chr9 124906723 T C 6.00E-06 Obesity-related traits NDUFA8 intron 23251661 rs7037705 chr9 124907534 A C 1.63E-04 Response to radiotherapy in cancer (late toxicity) NDUFA8 intron 24785509 rs7037705 chr9 124907534 A C 3.02E-05 Response to radiotherapy in cancer (late toxicity) NDUFA8 intron 24785509 rs7873816 chr9 124909632 G A 8.64E-04 Multiple complex diseases NDUFA8 intron 17554300 rs10818641 chr9 124933017 C T 7.60E-04 Tourette syndrome MORN5 intron 22889924 rs7856367 chr9 124942544 A T 5.00E-06 Smoking initiation MORN5 intron 24665060 rs16911551 chr9 124950477 C T 6.20E-06 Prostate cancer (early onset) MORN5 intron 24740154 rs1105993 chr9 124954697 A G 5.19E-04 Sarcoidosis MORN5 intron 19165924 rs7859776 chr9 124955922 G T 3.67E-04 Sarcoidosis MORN5 intron 19165924 rs10818649 chr9 124969315 C T 9.80E-06 Age-related nuclear cataracts LHX6 intron 24951543 rs10818651 chr9 124974419 G A 9.82E-05 Type 2 diabetes LHX6 intron 17463246 rs10760213 chr9 124980130 G A 2.19E-05 Type 2 diabetes LHX6 intron 17463246 rs12237553 chr9 124981393 G T 5.00E-04 Gamma gluatamyl transferase levels (interaction with age) LHX6 intron 22010049 rs3808900 chr9 124992764 A G 2.89E-06 Personality dimensions LHX6 nearGene-5 22628180 rs3808900 chr9 124992764 A G 7.06E-05 Myopia (pathological) LHX6 nearGene-5 23049088 rs10733657 chr9 125001985 C T 1.80E-04 Alcohol dependence RBM18 UTR-3 20201924 rs10818655 chr9 125002275 T C 6.02E-04 Type 2 diabetes RBM18 UTR-3 17463246 rs3829097 chr9 125003196 T A 6.00E-05 Type 2 diabetes and 6 quantitative traits RBM18 UTR-3 17848626 rs7042018 chr9 125003528 A G 4.70E-04 Alcohol dependence RBM18 UTR-3 20201924 rs1060586 chr9 125003679 G A 3.70E-04 Type 2 diabetes and 6 quantitative traits RBM18 UTR-3 17848626 rs1060586 chr9 125003679 G A 8.92E-05 Eosinophil counts RBM18 UTR-3 pha003088 rs1888218 chr9 125014475 C T 1.20E-05 Urinary metabolites RBM18 intron 21572414 rs7019478 chr9 125065423 A C 8.02E-05 Tuberculosis MRRF intron 20694014 rs3842787 chr9 125133507 C T 0.00017 Coronary artery calcification PTGS1 missense 23727086 rs10306121 chr9 125134648 A T 3.29E-09 LDL cholesterol PTGS1 intron 23063622 rs10306137 chr9 125138464 C T 0.000000653 Cholesterol,total PTGS1 intron 23063622 rs10306137 chr9 125138464 C T 3.74E-09 LDL cholesterol PTGS1 intron 23063622 rs10306227 chr9 125140500 G A 5.84E-05 Amyotrophic lateral sclerosis (sporadic) PTGS1 intron 24529757 rs10306145 chr9 125143061 C T 2.13E-06 White blood cell count PTGS1 intron 21738479 rs10306146 chr9 125143147 T C 3.65E-06 White blood cell count PTGS1 intron 21738479 rs10306148 chr9 125143384 C G 3.75E-06 White blood cell count PTGS1 intron 21738479 rs5788 chr9 125143792 C A 5.80E-06 White blood cell count PTGS1 cds-synon 21738479 rs4836886 chr9 125146895 C T 5.97E-06 White blood cell count PTGS1 intron 21738479 rs4836887 chr9 125146943 C T 5.97E-06 White blood cell count PTGS1 intron 21738479 rs4836888 chr9 125146980 T G 2.89E-06 White blood cell count PTGS1 intron 21738479 rs9299280 chr9 125147687 G A 2.63E-06 White blood cell count PTGS1 intron 21738479 rs9299281 chr9 125147871 A G 2.74E-06 White blood cell count PTGS1 intron 21738479 rs6478565 chr9 125148632 A G 8.62E-06 White blood cell count PTGS1 intron 21738479 rs10513402 chr9 125164936 T C 3.28E-05 Weight / / pha003026 rs950104 chr9 125165225 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1832744 chr9 125179075 A G 2.94E-04 Multiple complex diseases / / 17554300 rs2778624 chr9 125209061 T C 3.41E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10818702 chr9 125245724 C T 0.00000219 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs12380552 chr9 125266798 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10985667 chr9 125282970 T G 3.65E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4837973 chr9 125284773 A G 2.31E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10818708 chr9 125289521 G A 2.86E-04 Body mass index OR1N1 missense 21701565 rs10818708 chr9 125289521 G A 7.92E-04 Body mass index OR1N1 missense 21701565 rs374849660 chr9 125289521 GC GAT,GGC 2.86E-04 Body mass index OR1N1 missense 21701565 rs374849660 chr9 125289521 GC GAT,GGC 7.92E-04 Body mass index OR1N1 missense 21701565 rs10739610 chr9 125307018 C T 7.25E-04 Body mass index / / 21701565 rs7026744 chr9 125313720 C T 4.05E-04 Body mass index / / 21701565 rs10760239 chr9 125317485 G T 5.50E-06 Urinary metabolites / / 21572414 rs1024287 chr9 125317726 G T 1.00E-05 Urinary metabolites / / 21572414 rs4836895 chr9 125328145 C T 8.60E-06 Urinary metabolites / / 21572414 rs2000112 chr9 125328520 G A 6.06E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1831367 chr9 125331047 T C 2.29E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1934924 chr9 125331386 C A 8.60E-06 Urinary metabolites / / 21572414 rs7874877 chr9 125338028 T C 6.20E-07 Urinary metabolites / / 21572414 rs10985712 chr9 125339499 C T 4.20E-06 Urinary metabolites / / 21572414 rs10985712 chr9 125339499 C T 9.81E-04 Coronary heart disease / / 21606135 rs7867785 chr9 125340264 C T 1.70E-07 Urinary metabolites / / 21572414 rs7867785 chr9 125340264 C T 9.23E-04 Coronary heart disease / / 21606135 rs913855 chr9 125370383 T G 8.03E-04 Hearing function / / 17255346 rs1467715 chr9 125372908 A G 1.65E-04 Hearing function / / 17255346 rs972925 chr9 125377087 A G 7.44E-05 Age-related macular degeneration OR1Q1 missense 21197116 rs1329957 chr9 125377505 A G 2.60E-04 Alcohol dependence OR1Q1 missense 20201924 rs10739616 chr9 125384788 A G 2.19E-04 Alcohol dependence / / 20201924 rs12000807 chr9 125386182 T C 0.000692 Salmonella-induced pyroptosis / / 22837397 rs10491516 chr9 125388326 A G 2.73E-05 Iron status biomarkers / / 19084217 rs237625 chr9 125397012 G T 7.10E-05 Parkinson's disease (age of onset) / / 19772629 rs237625 chr9 125397012 G T 1.53E-04 Alzheimer's disease (late onset) / / 21379329 rs237625 chr9 125397012 G T 8.32E-04 Acute lung injury / / 22295056 rs16912081 chr9 125435311 C A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs16912107 chr9 125439777 G A 1.09E-04 Multiple complex diseases / / 17554300 rs41440452 chr9 125480240 G A 3.66E-11 Gallstones / / 17632509 rs16912163 chr9 125498680 T C 3.95E-04 Multiple complex diseases / / 17554300 rs10985760 chr9 125512770 T C 8.79E-07 Alcohol and nictotine co-dependence OR1L6 missense 20158304 rs16912238 chr9 125573030 A G 5.00E-06 Obesity-related traits / / 23251661 rs143503466 chr9 125589057 G A 0.000029 Prostate cancer (advanced) PDCL missense 23555315 rs12981 chr9 125607011 T C 0.00027 Coronary artery calcification / / 23727086 rs2241064 chr9 125680547 C T 8.00E-04 Type 2 diabetes / / 17463246 rs11793023 chr9 125847894 G A 6.60E-06 Urinary metabolites RABGAP1 intron 21572414 rs7021257 chr9 125990358 G T 3.57E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) STRBP intron 24023788 rs2488597 chr9 125992073 A G 0.00045 Coronary artery calcification STRBP intron 23727086 rs12352446 chr9 126011460 C T 4.10E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) STRBP intron 22566498 rs3739839 chr9 126031850 T C 1.49E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs10818803 chr9 126056464 C T 3.19E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10818803 chr9 126056464 C T 8.01E-04 Iron levels / / pha002876 rs10985950 chr9 126063065 G A 3.57E-05 Iron levels / / 19880490 rs10985950 chr9 126063065 G A 3.57E-05 Iron levels / / pha002876 rs10985950 chr9 126063065 G A 9.36E-05 Lipoproteins / / pha003079 rs10739625 chr9 126073680 G T 9.92E-04 Response to TNF antagonist treatment / / 21061259 rs3927757 chr9 126087359 G A 4.00E-04 Type 2 diabetes / / 17463246 rs10818810 chr9 126096522 G A 1.20E-06 Urinary metabolites / / 21572414 rs2491351 chr9 126153310 A G 5.50E-05 Multiple complex diseases DENND1A intron 17554300 rs872863 chr9 126154354 C T 2.00E-11 Myopia (pathological) DENND1A intron 23049088 rs7047077 chr9 126196925 C T 1.40E-05 Urinary metabolites DENND1A intron 21572414 rs3829851 chr9 126219706 A G 4.86E-04 Multiple complex diseases DENND1A cds-synon 17554300 rs17212242 chr9 126233829 G C 2.87E-04 Type 2 diabetes DENND1A intron 17463246 rs17212403 chr9 126247269 G A 6.76E-05 Type 2 diabetes DENND1A intron 17463246 rs2808399 chr9 126262232 G A 5.40E-06 Urinary metabolites DENND1A intron 21572414 rs2772206 chr9 126268302 T C 4.08E-04 Amyotrophic lateral sclerosis (sporadic) DENND1A intron 24529757 rs2808400 chr9 126271574 C T 9.50E-07 Urinary metabolites DENND1A intron 21572414 rs2808401 chr9 126275713 C T 1.40E-05 Urinary metabolites DENND1A intron 21572414 rs7026921 chr9 126297895 A G 1.50E-05 Urinary metabolites DENND1A intron 21572414 rs10513428 chr9 126304553 C T 3.01E-04 Fibrinogen DENND1A intron 17255346 rs10513428 chr9 126304553 C T 8.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) DENND1A intron 23648065 rs7037102 chr9 126317639 G A 1.68E-05 Cognitive performance DENND1A intron 19734545 rs10986053 chr9 126321003 C T 2.10E-06 Body mass index (non-asthmatics) DENND1A intron 23517042 rs1560264 chr9 126332230 C T 1.80E-06 Urinary metabolites DENND1A intron 21572414 rs17286621 chr9 126343077 C T 5.60E-05 Temperament (bipolar disorder) DENND1A intron 22365631 rs7852296 chr9 126352218 G A 9.00E-06 Personality dimensions DENND1A intron 20691247 rs17287018 chr9 126366667 T C 1.60E-05 Temperament (bipolar disorder) DENND1A intron 22365631 rs10818854 chr9 126446778 G A 9.00E-18 Polycystic ovary syndrome DENND1A intron 21151128 rs10818854 chr9 126446778 G A 2.50E-04 Polycystic ovary syndrome DENND1A intron 22885925 rs10818854 chr9 126446778 G A 2.00E-07 Body mass index (non-asthmatics) DENND1A intron 23517042 rs10818858 chr9 126458540 C T 2.99E-05 Multiple sclerosis (brain glutamate levels) DENND1A intron 20802204 rs17288605 chr9 126488059 G C 7.24E-05 Femoral neck bone geometry DENND1A intron 22087292 rs7857605 chr9 126507613 T C 2.44E-05 Multiple complex diseases DENND1A intron 17554300 rs7857605 chr9 126507613 T C 1.33E-07 Polycystic ovary syndrome DENND1A intron 21151128 rs16926797 chr9 126513838 T G 3.08E-04 Fibrinogen DENND1A intron 17255346 rs16926797 chr9 126513838 T G 6.83E-05 Coronary heart disease DENND1A intron pha003056 rs9785285 chr9 126520068 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes DENND1A cds-synon 22628534 rs2479106 chr9 126525212 A G 4.00E-04 Acute lymphoblastic leukemia (childhood) DENND1A intron 20189245 rs2479106 chr9 126525212 A G 8.00E-19 Polycystic ovary syndrome DENND1A intron 21151128 rs2479106 chr9 126525212 A G 5.00E-10 Polycystic ovary syndrome DENND1A intron 22885925 rs1778890 chr9 126531755 T C 6.00E-04 Acute lymphoblastic leukemia (childhood) DENND1A intron 20189245 rs1778890 chr9 126531755 T C 2.79E-09 Polycystic ovary syndrome DENND1A intron 21151128 rs7044210 chr9 126537668 A C 7.65E-04 Obesity (extreme) DENND1A intron 21935397 rs1627536 chr9 126542704 A T 1.00E-04 Acute lymphoblastic leukemia (childhood) DENND1A intron 20189245 rs1627536 chr9 126542704 A T 3.27E-07 Polycystic ovary syndrome DENND1A intron 21151128 rs1627536 chr9 126542704 A T 4.90E-06 Urinary metabolites DENND1A intron 21572414 rs2799465 chr9 126544609 T C 0.0000221 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes DENND1A intron 22628534 rs10986105 chr9 126549955 T G 6.13E-09 Polycystic ovary syndrome DENND1A intron 21151128 rs10986105 chr9 126549955 T G 1.44E-06 Polycystic ovary syndrome DENND1A intron 22885925 rs1752164 chr9 126558537 T C 6.14E-04 Obesity (extreme) DENND1A intron 21935397 rs1752165 chr9 126558810 T C 4.96E-04 Obesity (extreme) DENND1A intron 21935397 rs1752166 chr9 126558843 T G 4.97E-04 Obesity (extreme) DENND1A intron 21935397 rs2479104 chr9 126585101 T C 0.0000269 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes DENND1A intron 22628534 rs1927239 chr9 126595883 G T 0.0000269 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes DENND1A intron 22628534 rs4836945 chr9 126609778 A G 0.0000269 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes DENND1A intron 22628534 rs617162 chr9 126623024 C T 9.96E-04 Multiple complex diseases DENND1A intron 17554300 rs670961 chr9 126637361 C T 5.56E-04 Type 2 diabetes DENND1A intron 17463246 rs2536951 chr9 126646519 A G 9.00E-04 Acute lymphoblastic leukemia (childhood) DENND1A intron 20189245 rs2536951 chr9 126646519 A G 1.90E-06 Urinary metabolites DENND1A intron 21572414 rs2041545 chr9 126650515 C T 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes DENND1A intron 22628534 rs677987 chr9 126656997 C T 6.60E-06 Urinary metabolites DENND1A intron 21572414 rs12115297 chr9 126685609 C T 8.57E-05 Femoral neck bone geometry DENND1A intron 22087292 rs10986139 chr9 126689150 C G 2.10E-06 Urinary metabolites DENND1A intron 21572414 rs3739827 chr9 126690157 G A 6.10E-07 Urinary metabolites DENND1A intron 21572414 rs10818894 chr9 126695770 G A 3.80E-07 Urinary metabolites / / 21572414 rs10818894 chr9 126695770 G A 1.86E-05 Odorant perception / / 23910658 rs10818894 chr9 126695770 G A 2.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) / / 24025145 rs7039823 chr9 126719501 C T 1.91E-04 Multiple complex diseases / / 17554300 rs10760302 chr9 126722647 G A 1.54E-04 Multiple complex diseases / / 17554300 rs1887341 chr9 126769291 T C 6.29E-04 Multiple complex diseases / / 17554300 rs2025952 chr9 126783104 C T 3.57E-04 Multiple complex diseases LHX2 intron 17554300 rs2075064 chr9 126783847 C T 2.00E-08 Waist circumference LHX2 intron 23966867 rs10818911 chr9 126814204 C A 0.000191 Ovarian cancer / / 22794196 rs7857883 chr9 126817862 C T 1.30E-05 Urinary metabolites / / 21572414 rs10986189 chr9 126818497 A G 1.10E-05 Urinary metabolites / / 21572414 rs10986190 chr9 126818818 A G 3.15E-05 Brain structure / / 22504417 rs943486 chr9 126840586 C T 2.90E-05 Urinary metabolites / / 21572414 rs16927115 chr9 126840768 C T 3.84E-04 Multiple complex diseases / / 17554300 rs7858299 chr9 126855342 G T 5.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs7040016 chr9 126858551 T A 4.51E-05 Brain structure / / 22504417 rs7860363 chr9 126860775 C T 6.73E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs7868364 chr9 126862478 G T 7.47E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs12001303 chr9 126863718 G C 2.56E-04 Multiple complex diseases / / 17554300 rs2478894 chr9 126905188 G A 6.32E-05 Lymphocyte counts / / 22286170 rs2807584 chr9 126918033 A G 7.87E-06 Cognitive test performance / / 20125193 rs7018646 chr9 126926031 T C 6.69E-05 Rheumatoid arthritis / / 19503088 rs2807580 chr9 126926107 T C 3.00E-06 Cognitive performance / / 20125193 rs12001349 chr9 126939311 T C 7.85E-04 Rheumatoid arthritis / / 21452313 rs7042608 chr9 126951284 G A 1.80E-05 Colorectal cancer / / 21242260 rs10986266 chr9 126957987 T C 3.11E-04 Body mass index / / 17255346 rs4838122 chr9 126958966 T G 1.30E-04 Body mass index / / 17255346 rs12005728 chr9 126959784 A C 1.73E-04 Body mass index / / 17255346 rs4838124 chr9 126960231 G A 1.89E-04 Body mass index / / 17255346 rs16927249 chr9 126960974 T C 2.72E-04 Body mass index / / 17255346 rs4838126 chr9 126961902 A G 1.76E-04 Body mass index / / 17255346 rs10119810 chr9 126962448 T C 1.93E-04 Body mass index / / 17255346 rs16927260 chr9 126963082 G A 2.46E-04 Body mass index / / 17255346 rs1106489 chr9 126965396 T C 8.18E-05 Cognitive test performance / / 20125193 rs7021104 chr9 126970838 C A 8.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7861578 chr9 127001421 C T 8.89E-05 Major depressive disorder / / 21621269 rs4838140 chr9 127010114 T C 4.93E-05 Multiple complex diseases / / 17554300 rs4838140 chr9 127010114 T C 5.84E-04 Taste perception / / 22132133 rs2282085 chr9 127025040 A G 3.70E-05 Height NEK6 intron pha003010 rs7853472 chr9 127036667 G A 6.04E-04 Type 2 diabetes NEK6 intron 17463246 rs10760345 chr9 127037796 A G 2.68E-05 Height NEK6 intron pha003010 rs16927327 chr9 127047450 G A 9.95E-05 Multiple complex diseases NEK6 intron 17554300 rs4838159 chr9 127069629 T G 3.67E-04 Stroke NEK6 intron 22306652 rs2274782 chr9 127084074 C T 5.67E-05 Height NEK6 intron pha003010 rs912355 chr9 127090966 T C 4.08E-06 Vitiligo NEK6 intron 22561518 rs10760361 chr9 127178266 G T 5.99E-04 Type 2 diabetes / / 17463246 rs10986339 chr9 127195873 G A 4.53E-05 Major depressive disorder (broad) / / 20038947 rs10986339 chr9 127195873 G A 3.26E-04 Major depressive disorder / / 22472876 rs16927477 chr9 127221205 G A 3.01E-04 Multiple complex diseases GPR144 intron 17554300 rs4838179 chr9 127221424 C T 2.42E-04 Bipolar disorder (mania) GPR144 intron 23326512 rs7041730 chr9 127222239 G A 4.66E-04 Lymphocyte counts GPR144 intron 22286170 rs7041730 chr9 127222239 G A 1.80E-04 Bipolar disorder (mania) GPR144 intron 23326512 rs7851429 chr9 127224772 G A 5.71E-05 Bipolar disorder (mania) GPR144 intron 23326512 rs7851555 chr9 127224865 G A 1.35E-04 Bipolar disorder (mania) GPR144 intron 23326512 rs10818977 chr9 127230118 C T 7.28E-05 Response to cytidine analogues (gemcitabine) GPR144 intron 24483146 rs10760365 chr9 127230891 G A 5.30E-05 Response to cytidine analogues (gemcitabine) GPR144 missense 24483146 rs10760365 chr9 127230891 G A 8.44E-04 Response to cytadine analogues (cytosine arabinoside) GPR144 missense 24483146 rs10114038 chr9 127327763 A G 2.00E-06 Follicle stimulating hormone NR6A1 intron 24049095 rs4076333 chr9 127385609 T C 7.13E-04 Multiple complex diseases NR6A1 intron 17554300 rs10986391 chr9 127428235 C T 9.83E-04 Multiple complex diseases NR6A1 intron 17554300 rs4144630 chr9 127439200 T C 4.64E-04 Multiple complex diseases NR6A1 intron 17554300 rs721862 chr9 127535992 G A 4.21E-04 Multiple complex diseases / / 17554300 rs721863 chr9 127536267 T A 6.56E-04 Multiple complex diseases / / 17554300 rs4838210 chr9 127546183 G A 6.35E-04 Multiple complex diseases OLFML2A intron 17554300 rs750692 chr9 127562619 C G 5.75E-04 Multiple complex diseases OLFML2A intron 17554300 rs12683929 chr9 127613385 C T 5.70E-05 Tooth agenesis (maxillary third molar) / / 24172245 rs2304957 chr9 127643946 A G 8.78E-05 Creatinine levels GOLGA1 intron pha003069 rs13299805 chr9 127710312 T C 3.62E-05 Insulin-related traits SCAI UTR-3 pha003063 rs13299805 chr9 127710312 T C 3.73E-05 Leukocyte Counts SCAI UTR-3 pha003091 rs7040520 chr9 127711321 A G 2.40E-04 Alzheimer's disease (late onset) SCAI UTR-3 21379329 rs10819014 chr9 127713478 G T 9.82E-05 Prion diseases SCAI UTR-3 22210626 rs12001999 chr9 127746648 T C 5.99E-05 Tunica Media SCAI intron pha003038 rs41422453 chr9 127812131 A C 3.74E-05 Multiple complex diseases SCAI intron 17554300 rs11789451 chr9 127825903 A G 3.58E-05 Insulin Resistance SCAI intron pha003062 rs11789451 chr9 127825903 A G 6.43E-05 Insulin-related traits SCAI intron pha003063 rs7860360 chr9 127886915 C T 9.92E-04 Multiple complex diseases SCAI intron 17554300 rs6744 chr9 127909069 C T 1.05E-05 Bone mass and geometry PPP6C UTR-3 17903296 rs1364372 chr9 127938486 T C 4.96E-04 Multiple complex diseases PPP6C intron 17554300 rs10986703 chr9 128087011 G C 4.93E-04 Multiple complex diseases GAPVD1 intron 17554300 rs2841334 chr9 128122320 A G 8.32E-05 Potassium levels GAPVD1 intron pha003086 rs2291858 chr9 128128782 A G 5.35E-04 Stroke (pediatric) / / 22990015 rs1463837 chr9 128135215 T C 7.27E-05 Tunica Media / / pha003038 rs4837016 chr9 128141809 G A 1.90E-04 Stroke (pediatric) / / 22990015 rs7023669 chr9 128204759 G C 9.51E-06 Smoking cessation MAPKAP1 intron 18519826 rs10986769 chr9 128222340 A G 2.80E-10 Progranulin levels MAPKAP1 intron 21087763 rs10986769 chr9 128222340 A G 2.80E-10 Myocardial infarction MAPKAP1 intron 21211798 rs1891034 chr9 128232399 A G 2.56E-05 Smoking cessation MAPKAP1 intron 18519826 rs522894 chr9 128299605 G A 1.22E-04 Type 2 diabetes MAPKAP1 intron 17463246 rs522894 chr9 128299605 G A 8.38E-05 Smoking cessation MAPKAP1 intron 18519826 rs829179 chr9 128316645 G A 6.37E-05 Bipolar disorder MAPKAP1 intron 21771265 rs530628 chr9 128325934 G C 5.91E-04 Type 2 diabetes MAPKAP1 intron 22158537 rs476819 chr9 128362737 A G 4.74E-05 Multiple complex diseases MAPKAP1 intron 17554300 rs476819 chr9 128362737 A G 2.73E-04 Type 2 diabetes MAPKAP1 intron 22158537 rs534214 chr9 128369224 G A 4.07E-04 Type 2 diabetes MAPKAP1 intron 22158537 rs829312 chr9 128377873 T C 5.52E-04 Type 2 diabetes MAPKAP1 intron 22158537 rs10986881 chr9 128519086 C T 0.000000281 Triglycerides PBX3 intron 23063622 rs10986881 chr9 128519086 C T 0.000000728 LDL cholesterol PBX3 intron 23063622 rs11999260 chr9 128521473 C T 6.74E-04 Schizophrenia PBX3 intron 19197363 rs1339496 chr9 128523068 A G 1.33E-09 Triglycerides PBX3 intron 23063622 rs12341976 chr9 128546359 G T 8.56E-04 Schizophrenia PBX3 intron 19197363 rs10986953 chr9 128585381 G A 1.32E-08 Triglycerides PBX3 intron 23063622 rs4489409 chr9 128587065 C T 8.30E-04 Multiple complex diseases PBX3 intron 17554300 rs10986986 chr9 128621951 A G 4.53E-07 Multiple complex diseases PBX3 intron 17554300 rs4838298 chr9 128629488 C T 4.24E-04 Schizophrenia PBX3 intron 19197363 rs10986994 chr9 128629537 G A 1.51E-08 Triglycerides PBX3 intron 23063622 rs7865684 chr9 128635669 T C 5.88E-04 Multiple complex diseases PBX3 intron 17554300 rs10987019 chr9 128669493 C T 1.55E-09 Triglycerides PBX3 intron 23063622 rs10513454 chr9 128673226 T G 3.45E-04 Schizophrenia PBX3 intron 19197363 rs10987048 chr9 128699100 A G 0.000000177 Triglycerides PBX3 intron 23063622 rs10760405 chr9 128711455 T G 8.03E-04 Multiple complex diseases PBX3 intron 17554300 rs7024493 chr9 128712242 A G 4.70E-05 Potassium levels PBX3 intron pha003086 rs7871599 chr9 128721828 C G 5.38E-04 Multiple complex diseases PBX3 intron 17554300 rs888230 chr9 128724304 A C 1.26E-04 Multiple complex diseases PBX3 intron 17554300 rs2111358 chr9 128724683 A C 4.70E-05 Potassium levels PBX3 intron pha003086 rs7026855 chr9 128724831 C T 5.75E-04 Multiple complex diseases PBX3 intron 17554300 rs1105727 chr9 128725543 T C 8.22E-04 Multiple complex diseases PBX3 intron 17554300 rs3829098 chr9 128727035 T C 7.64E-04 Multiple complex diseases PBX3 intron 17554300 rs3793622 chr9 128727170 C T 5.17E-04 Multiple complex diseases PBX3 intron 17554300 rs2058850 chr9 128731818 A G 3.04E-04 Multiple complex diseases / / 17554300 rs12336219 chr9 128732275 C T 4.29E-04 Multiple complex diseases / / 17554300 rs1477147 chr9 128736511 C G 2.75E-04 Multiple complex diseases / / 17554300 rs2149992 chr9 128738591 G A 8.47E-05 Potassium levels / / pha003086 rs10987080 chr9 128748401 G A 4.10E-05 Asthma / / 20698975 rs10987099 chr9 128772507 A C 6.52E-04 Multiple complex diseases / / 17554300 rs12003988 chr9 128812103 C T 9.44E-05 Glucose levels / / pha003057 rs4838320 chr9 128831097 T C 9.00E-06 Economic and political preferences (immigration/crime) / / 22566634 rs10987149 chr9 128857851 G A 5.00E-06 Response to mTOR inhibitor (everolimus) / / 24009623 rs11787836 chr9 128858597 T C 1.40E-05 Cognitive test performance / / 20125193 rs7852920 chr9 128860354 G A 2.47E-04 Type 2 diabetes / / 17463246 rs2080558 chr9 128860704 A C 3.84E-04 Multiple complex diseases / / 17554300 rs2080558 chr9 128860704 A C 6.60E-05 Creatinine levels / / 20222955 rs2080558 chr9 128860704 A C 0.000399032 Hypertension (early onset hypertension) / / 22479346 rs6478724 chr9 128876516 G A 4.97E-04 Myocardial Infarction / / pha002883 rs4595229 chr9 128879934 A G 6.90E-04 Myocardial Infarction / / pha002883 rs10819125 chr9 128882136 C T 0.0008922 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10819125 chr9 128882136 C T 8.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17355806 chr9 128914544 T C 0.0008245 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17355806 chr9 128914544 T C 8.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13290757 chr9 128928438 C T 4.60E-06 Migraine / / 21666692 rs13290757 chr9 128928438 C T 9.74E-05 Tunica Media / / pha003037 rs11999582 chr9 128928958 C T 4.68E-04 Alzheimer's disease (late onset) / / 21379329 rs888219 chr9 128929023 A C 2.00E-07 Response to antipsychotic treatment / / 19721433 rs10987191 chr9 128957168 C A 1.41E-04 Celiac disease / / 23936387 rs10819136 chr9 128966109 G A 7.50E-05 Personality dimensions / / 18957941 rs2773395 chr9 128969465 T G 5.67E-04 Coronary Artery Disease / / 17634449 rs2809430 chr9 129007969 T C 1.27E-04 Multiple complex diseases / / 17554300 rs4836535 chr9 129046512 G T 5.69E-04 Smoking initiation / / 24665060 rs10987232 chr9 129051009 A G 3.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10987232 chr9 129051009 A G 7.84E-05 Smoking initiation / / 24665060 rs1536959 chr9 129053531 G A 8.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1536959 chr9 129053531 G A 5.96E-04 Smoking initiation / / 24665060 rs41377047 chr9 129054988 C T 4.83E-04 Multiple complex diseases / / 17554300 rs17292288 chr9 129058500 C T 8.95E-06 Hearing function / / 21493956 rs569313 chr9 129072443 C T 7.84E-07 Lymphocyte counts / / 22286170 rs10491514 chr9 129102018 C G 5.93E-04 Suicide attempts in bipolar disorder FAM125B intron 21423239 rs1888156 chr9 129102840 G A 6.18E-04 Suicide attempts in bipolar disorder FAM125B cds-synon 21423239 rs10987251 chr9 129102994 G A 7.59E-04 Suicide attempts in bipolar disorder FAM125B intron 21423239 rs10760426 chr9 129103584 G A 6.93E-04 Suicide attempts in bipolar disorder FAM125B intron 21423239 rs1360289 chr9 129115717 T C 6.49E-04 Suicide attempts in bipolar disorder FAM125B intron 21423239 rs10987253 chr9 129120430 C A 8.72E-04 Suicide attempts in bipolar disorder FAM125B intron 21423239 rs2041544 chr9 129129505 T C 2.59E-05 Schizophrenia FAM125B intron 21747397 rs2286889 chr9 129143435 A G 7.19E-05 Dental caries FAM125B cds-synon 21940522 rs758970 chr9 129194773 A G 6.00E-07 Obesity-related traits FAM125B intron 23251661 rs887656 chr9 129197516 T C 6.37E-04 Schizophrenia FAM125B intron 19197363 rs2286885 chr9 129246487 A C 6.00E-06 Intraocular pressure FAM125B intron 24518671 rs3814127 chr9 129265742 A G 4.14E-05 Parkinson's disease FAM125B UTR-3 21738487 rs3814127 chr9 129265742 A G 4.61E-05 Orofacial clefts FAM125B UTR-3 22863734 rs3739567 chr9 129266141 T C 4.60E-05 Parkinson's disease FAM125B UTR-3 21738487 rs10819174 chr9 129268065 C T 3.95E-05 Parkinson's disease FAM125B UTR-3 21738487 rs10819174 chr9 129268065 C T 7.08E-05 Orofacial clefts FAM125B UTR-3 22863734 rs4837098 chr9 129278855 C G 3.92E-04 Type 2 diabetes / / 17463246 rs885618 chr9 129282357 G A 5.36E-04 Iron levels / / pha002876 rs10819182 chr9 129320566 A G 2.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs13287122 chr9 129325783 A G 2.94E-04 Type 2 diabetes / / 17463246 rs4083650 chr9 129353178 A T 9.49E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10819188 chr9 129370955 G A 4.39E-04 Obesity (extreme) / / 21935397 rs10819189 chr9 129379518 G A 4.53E-04 Obesity (extreme) LMX1B intron 21935397 rs1536907 chr9 129382560 A G 2.80E-05 Urinary metabolites LMX1B intron 21572414 rs10760444 chr9 129396434 G A 1.90E-05 Urinary metabolites LMX1B intron 21572414 rs10448285 chr9 129397014 C T 1.90E-05 Urinary metabolites LMX1B intron 21572414 rs12377679 chr9 129397755 G A 5.84E-04 Obesity (extreme) LMX1B intron 21935397 rs7859156 chr9 129400028 T C 6.01E-04 Obesity (extreme) LMX1B intron 21935397 rs12342373 chr9 129402567 G A 3.00E-06 Social communication problems LMX1B intron 24564958 rs11793373 chr9 129407543 G A 4.80E-04 Primary sclerosing cholangitis LMX1B intron 19944697 rs11793373 chr9 129407543 G A 1.31E-04 Obesity (extreme) LMX1B intron 21935397 rs10760446 chr9 129408445 G C 1.79E-04 Obesity (extreme) LMX1B intron 21935397 rs3814120 chr9 129414929 G A 1.40E-05 Type 2 diabetes LMX1B intron 17460697 rs4322101 chr9 129428677 A G 1.70E-04 Obesity (extreme) LMX1B intron 21935397 rs10121527 chr9 129431213 C T 1.59E-04 Obesity (extreme) LMX1B intron 21935397 rs4339739 chr9 129448131 T G 1.79E-04 Obesity (extreme) LMX1B intron 21935397 rs10987411 chr9 129450439 T C 2.18E-04 Obesity (extreme) LMX1B intron 21935397 rs2277158 chr9 129453229 A G 1.89E-04 Obesity (extreme) LMX1B cds-synon 21935397 rs13295990 chr9 129455587 G C 6.64E-05 Obesity (extreme) LMX1B cds-synon 21935397 rs10987413 chr9 129459438 G A 1.80E-04 Obesity (extreme) LMX1B UTR-3 21935397 rs10987414 chr9 129459478 C T 1.82E-04 Obesity (extreme) LMX1B UTR-3 21935397 rs10760450 chr9 129459628 C T 1.29E-04 Obesity (extreme) LMX1B UTR-3 21935397 rs10733682 chr9 129460914 A G 6.26E-06 Obesity (extreme) LMX1B UTR-3 21935397 rs4083644 chr9 129461714 C T 8.25E-04 Multiple complex diseases LMX1B UTR-3 17554300 rs3861878 chr9 129461912 A G 2.22E-04 Multiple complex diseases LMX1B UTR-3 17554300 rs3861878 chr9 129461912 A G 7.35E-04 Obesity (extreme) LMX1B UTR-3 21935397 rs10987417 chr9 129462501 G T 5.14E-06 Obesity (extreme) LMX1B UTR-3 21935397 rs3906146 chr9 129463613 C T 5.89E-05 Obesity (extreme) LMX1B nearGene-3 21935397 rs3906146 chr9 129463613 C T 2.60E-04 Longevity LMX1B nearGene-3 22279548 rs4358894 chr9 129464802 C G 5.41E-05 Obesity (extreme) / / 21935397 rs867560 chr9 129465233 C G 5.33E-05 Obesity (extreme) / / 21935397 rs867560 chr9 129465233 C G 4.82E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs867559 chr9 129465325 A G 7.00E-06 Smoking behavior / / 20418888 rs867559 chr9 129465325 A G 1.00E-07 Body mass index / / 20935630 rs13287548 chr9 129466456 C T 4.56E-05 Obesity (extreme) / / 21935397 rs13292976 chr9 129467340 C T 4.28E-05 Obesity (extreme) / / 21935397 rs12684797 chr9 129469539 G C 3.22E-05 Obesity (extreme) / / 21935397 rs7870976 chr9 129471897 C A 3.26E-05 Obesity (extreme) / / 21935397 rs2417032 chr9 129473302 A G 6.47E-04 Body mass index / / 21701565 rs2417033 chr9 129473576 G A 3.24E-04 Obesity (extreme) / / 21935397 rs10760452 chr9 129478908 C T 1.28E-04 Multiple complex diseases / / 17554300 rs10760452 chr9 129478908 C T 3.81E-04 Obesity (extreme) / / 21935397 rs10987447 chr9 129508612 A G 9.89E-04 Obesity (extreme) / / 21935397 rs10987448 chr9 129508659 G A,T 8.74E-04 Obesity (extreme) / / 21935397 rs10819218 chr9 129510823 T C 7.88E-04 Obesity (extreme) / / 21935397 rs10819220 chr9 129511442 C T 7.71E-04 Obesity (extreme) / / 21935397 rs10114029 chr9 129512251 G A 7.52E-04 Obesity (extreme) / / 21935397 rs10819224 chr9 129513186 G A 5.59E-04 Obesity (extreme) / / 21935397 rs555991595 chr9 129513186 G GA 5.59E-04 Obesity (extreme) / / 21935397 rs1005918 chr9 129513586 G T 7.83E-04 Acute lung injury / / 22295056 rs1005919 chr9 129513663 C G 5.49E-04 Obesity (extreme) / / 21935397 rs2417038 chr9 129551466 A G 1.33E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7856497 chr9 129575594 A G 0.0008821 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ZBTB43 intron 23233654 rs7856497 chr9 129575594 A G 8.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) ZBTB43 intron 23233662 rs516104 chr9 129580187 A G 0.0008819 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ZBTB43 intron 23233654 rs516104 chr9 129580187 A G 8.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) ZBTB43 intron 23233662 rs7048973 chr9 129609857 T C 4.97E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7035535 chr9 129613696 T C 8.34E-04 Insulin resistance / / 21901158 rs7035535 chr9 129613696 T C 9.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3120029 chr9 129649356 A G 2.70E-05 Urinary metabolites / / 21572414 rs610116 chr9 129655445 A C 7.20E-06 Urinary metabolites / / 21572414 rs610116 chr9 129655445 A C 2.37E-04 Lymphocyte counts / / 22286170 rs10819250 chr9 129670864 C T 2.00E-04 Information processing speed / / 21130836 rs10819250 chr9 129670864 C T 1.39E-04 Smoking initiation / / 24665060 rs11787970 chr9 129684583 T C 7.44E-06 Serum metabolites RALGPS1 intron 19043545 rs687642 chr9 129686974 G A 6.90E-05 Multiple complex diseases RALGPS1 intron 17554300 rs518170 chr9 129687028 A G 1.64E-04 Multiple complex diseases RALGPS1 intron 17554300 rs535025 chr9 129696332 T A 4.91E-04 Multiple complex diseases RALGPS1 intron 17554300 rs526893 chr9 129702033 G C 6.54E-05 Multiple complex diseases RALGPS1 intron 17554300 rs694735 chr9 129729233 A C 1.27E-05 Multiple complex diseases RALGPS1 intron 17554300 rs7040080 chr9 129742041 C T 4.77E-06 Serum metabolites RALGPS1 intron 19043545 rs943803 chr9 129770237 G A 4.77E-06 Serum metabolites RALGPS1 intron 19043545 rs17368205 chr9 129798221 A G 8.93E-04 Multiple complex diseases RALGPS1 intron 17554300 rs10987552 chr9 129811401 G T 1.78E-05 Serum metabolites RALGPS1 intron 19043545 rs12349534 chr9 129814903 G A 4.54E-06 Serum metabolites RALGPS1 intron 19043545 rs7023617 chr9 129820741 A G 2.06E-05 Body Mass Index RALGPS1 intron pha003007 rs11794686 chr9 129837564 T C 5.56E-06 Serum metabolites RALGPS1 intron 19043545 rs2297866 chr9 129854199 G A 4.87E-06 Serum metabolites ANGPTL2 cds-synon 19043545 rs11792699 chr9 129865851 A G 5.73E-06 Serum metabolites RALGPS1 intron 19043545 rs1766227 chr9 129877889 C A 6.94E-04 Multiple complex diseases RALGPS1 intron 17554300 rs1556889 chr9 129886905 G A 6.92E-04 Multiple complex diseases RALGPS1 intron 17554300 rs2789508 chr9 129887348 T G 7.93E-04 Multiple complex diseases RALGPS1 intron 17554300 rs12551115 chr9 129906656 A C 4.52E-06 Serum metabolites RALGPS1 intron 19043545 rs7044613 chr9 129909750 T G 4.95E-04 Multiple complex diseases RALGPS1 intron 17554300 rs16929617 chr9 129910207 A G 1.56E-04 Multiple complex diseases RALGPS1 intron 17554300 rs12350252 chr9 129915631 C A 5.69E-06 Serum metabolites RALGPS1 intron 19043545 rs11789486 chr9 129921983 G A 2.54E-06 Serum metabolites RALGPS1 intron 19043545 rs1028865 chr9 129933324 G A 4.90E-06 Serum metabolites RALGPS1 intron 19043545 rs3739555 chr9 129940416 T G 5.95E-05 Coronary heart disease RALGPS1 UTR-3 21971053 rs3739554 chr9 129940645 A G 6.51E-05 Information processing speed RALGPS1 UTR-3 21130836 rs1333005 chr9 130042369 G A 3.98E-04 Prostate cancer mortality GARNL3 intron 20978177 rs17378510 chr9 130060326 C T 9.84E-04 Type 2 diabetes GARNL3 intron 17463246 rs11792519 chr9 130061054 A G 1.05E-04 Coronary heart disease GARNL3 intron 21971053 rs10819274 chr9 130093904 C T 2.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GARNL3 intron 20877124 rs10119132 chr9 130096344 T A 1.60E-04 Multiple complex diseases GARNL3 intron 17554300 rs10987598 chr9 130102939 T G 1.12E-04 Multiple complex diseases GARNL3 intron 17554300 rs9650750 chr9 130105122 G A 7.98E-05 Multiple complex diseases GARNL3 intron 17554300 rs10987600 chr9 130105618 G A 1.26E-04 Multiple complex diseases GARNL3 intron 17554300 rs10760481 chr9 130106066 A G 5.37E-05 Multiple complex diseases GARNL3 intron 17554300 rs4130590 chr9 130107964 A G 3.00E-06 Bipolar disorder GARNL3 intron 18711365 rs4130590 chr9 130107964 A G 4.20E-05 Bipolar disorder and major depressive disorder (combined) GARNL3 intron 20351715 rs4130590 chr9 130107964 A G 0.000732455 Hypertension (early onset hypertension) GARNL3 intron 22479346 rs7041940 chr9 130109746 T C 4.20E-05 Bipolar disorder and major depressive disorder (combined) GARNL3 intron 20351715 rs7029536 chr9 130110411 C T 5.00E-06 Metabolite levels (HVA) GARNL3 intron 23319000 rs6478770 chr9 130112231 T C 4.30E-05 Bipolar disorder and major depressive disorder (combined) GARNL3 intron 20351715 rs34447382 chr9 130123425 A AG 7.76E-04 Multiple complex diseases GARNL3 intron 17554300 rs4454390 chr9 130123425 A G 7.76E-04 Multiple complex diseases GARNL3 intron 17554300 rs4837146 chr9 130124951 T C 8.30E-04 Multiple complex diseases GARNL3 intron 17554300 rs3808838 chr9 130157934 A G 6.95E-05 Multiple complex diseases / / 17554300 rs3808838 chr9 130157934 A G 2.62E-04 Lymphocyte counts / / 22286170 rs1138740 chr9 130165995 C T 5.28E-04 Coronary heart disease SLC2A8 cds-synon 21971053 rs10819291 chr9 130186700 C T 0.0000034 Breast cancer ZNF79 UTR-5 23555315 rs2248025 chr9 130206762 C T 4.95E-04 Multiple complex diseases ZNF79 cds-synon 17554300 rs2491101 chr9 130215249 C T 4.43E-04 Multiple complex diseases LRSAM1 intron 17554300 rs150292099 chr9 130224593 A G 0.00000035 Prostate cancer (advanced) LRSAM1 missense 23555315 rs2798429 chr9 130257191 G A 3.91E-04 Multiple complex diseases LRSAM1 intron 17554300 rs2247374 chr9 130297246 C T 1.10E-06 Coronary heart disease FAM129B intron 22319020 rs2246653 chr9 130303385 G C 8.65E-04 Multiple complex diseases FAM129B intron 17554300 rs2243950 chr9 130303750 G C 6.01E-04 Multiple complex diseases FAM129B intron 17554300 rs2257055 chr9 130311404 A C 4.57E-05 Educational attainment FAM129B intron 21694764 rs2253112 chr9 130320119 T C 5.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM129B intron 20877124 rs10987687 chr9 130330131 C T 0.000255 Height (Pygmy height) FAM129B intron 22570615 rs4532699 chr9 130338333 A G,T 7.30E-04 Response to statin treatment (atorvastatin),change in cholesterol levels FAM129B intron 20031582 rs4532699 chr9 130338333 A G,T 3.30E-04 Alzheimer's disease (late onset) FAM129B intron 21379329 rs2287116 chr9 130420813 G T 2.38E-04 Type 2 diabetes STXBP1 intron 17463246 rs2287116 chr9 130420813 G T 4.97E-04 Multiple complex diseases STXBP1 intron 17554300 rs12171699 chr9 130455691 C T 1.77E-04 Type 2 diabetes / / 17463246 rs118012211 chr9 130475480 C T 0.0006 Breast cancer C9orf117 missense 23555315 rs1999224 chr9 130498120 T G 8.04E-04 Type 2 diabetes TOR2A nearGene-5 17463246 rs514024 chr9 130504070 G A 3.64E-04 Alzheimer's disease (late onset) SH2D3C cds-synon 21379329 rs514024 chr9 130504070 G A 5.00E-06 Eating disorders (purging via substances) SH2D3C cds-synon 23568457 rs10739694 chr9 130526605 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) SH2D3C intron 20708005 rs1544105 chr9 130562725 C T 1 Drug response to Methotrexate / / 19902562 rs116330805 chr9 130580575 C T 0.00001 Prostate cancer (advanced) ENG missense 23555315 rs7034078 chr9 130596098 C T 3.96E-22 Triglycerides ENG intron 23063622 rs10987759 chr9 130618377 T C 9.97E-05 ldl cholesterol ENG nearGene-5 pha003076 rs7865146 chr9 130619637 C T 1.00E-06 Metabolic syndrome / / 20694148 rs1571142 chr9 130660810 A G 1.31E-05 Iron status biomarkers ST6GAL/C6 intron 19084217 rs2417061 chr9 130663557 A C 5.13E-04 Multiple complex diseases / / 17554300 rs3818509 chr9 130670532 C T 5.45E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3780668 chr9 130673419 C T 6.45E-05 Serum metabolites ST6GAL/C4 intron 19043545 rs141670007 chr9 130687485 C T 0.00058 Prostate cancer (non-advanced prostate cancer) PIP5KL1 missense 23555315 rs10987807 chr9 130753031 T C 1.71E-04 Multiple complex diseases / / 17554300 rs4837218 chr9 130755693 G A 6.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7874186 chr9 130770031 G A 9.92E-05 Cognitive test performance / / 20125193 rs947625 chr9 130774524 T C 9.08E-04 Multiple complex diseases / / 17554300 rs4837223 chr9 130776407 C T 7.81E-04 Alcohol dependence / / 21314694 rs878400 chr9 130908044 G A 9.99E-04 Myopia (pathological) / / 21095009 rs2417115 chr9 130932993 A G 8.90E-04 Suicide attempts in bipolar disorder CIZ1 intron 21423239 rs2502731 chr9 130976557 C T 1.62E-04 Height DNM1 intron 17255346 rs2502731 chr9 130976557 C T 2.00E-06 Attention deficit hyperactivity disorder DNM1 intron 18839057 rs2502731 chr9 130976557 C T 7.50E-05 Parkinson's disease (age of onset) DNM1 intron 19772629 rs3003602 chr9 130981064 C T 1.00E-05 Parkinson's disease (age of onset) DNM1 intron 19772629 rs3003609 chr9 130984755 C T 3.00E-04 Multiple complex diseases DNM1 cds-synon 17554300 rs3003609 chr9 130984755 C T 4.60E-06 Coronary heart disease DNM1 cds-synon 21971053 rs3003609 chr9 130984755 C T 1.89E-04 Lymphocyte counts DNM1 cds-synon 22286170 rs9644916 chr9 130998850 C T 1.92E-04 Suicide attempts in bipolar disorder DNM1 intron 21423239 rs9644952 chr9 130999152 C A 5.10E-04 Suicide attempts in bipolar disorder DNM1 intron 21423239 rs7022174 chr9 130999472 G C 2.66E-04 Suicide attempts in bipolar disorder DNM1 intron 21423239 rs7854612 chr9 131000860 A G 2.80E-04 Suicide attempts in bipolar disorder DNM1 intron 21423239 rs10987942 chr9 131001692 G C 3.42E-04 Suicide attempts in bipolar disorder DNM1 intron 21423239 rs2240956 chr9 131048760 T C 5.25E-05 Asthma SWI5 intron 23181788 rs11539570 chr9 131084628 C A,T 7.00E-06 Obesity-related traits TRUB2 cds-synon 23251661 rs2286814 chr9 131133983 C A 1.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) URM1 intron 20877124 rs1009850 chr9 131193665 A C 7.55E-05 Bipolar disorder and schizophrenia CERCAM intron 20889312 rs1009850 chr9 131193665 A C 5.21E-05 Schizophrenia CERCAM intron pha002857 rs4837271 chr9 131241808 A G 1.54E-04 Type 2 diabetes ODF2 intron 17463246 rs869455 chr9 131289600 G T 1.47E-04 Type 2 diabetes GLE1 intron 17463246 rs7871140 chr9 131299228 C T 4.53E-04 Type 2 diabetes GLE1 intron 17463246 rs4836614 chr9 131301651 T C 2.77E-04 Type 2 diabetes GLE1 intron 17463246 rs10760563 chr9 131303522 G A 3.04E-04 Type 2 diabetes GLE1 UTR-3 17463246 rs12380424 chr9 131403221 G T 6.00E-06 Axial length WDR34 intron 24144296 rs2298038 chr9 131419422 C T 1.68E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2298038 chr9 131419422 C T 5.80E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4836618 chr9 131455903 C T 5.41E-06 Age-related macular degeneration SET intron pha000001 rs72758841 chr9 131475583 G C 6.00E-06 Obesity-related traits PKN3 missense 23251661 rs10739734 chr9 131527676 T G 6.24E-04 Multiple complex diseases ZER1 intron 17554300 rs11560592 chr9 131532694 C T 0.0001422 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ZER1 intron 23233654 rs11560592 chr9 131532694 C T 1.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) ZER1 intron 23233662 rs10113946 chr9 131534333 C T 0.0001418 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10113946 chr9 131534333 C T 1.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs15676 chr9 131572027 G A 1.00E-12 Blood metabolite levels TBC1D13 UTR-3 24816252 rs10988125 chr9 131572903 A G 5.96E-04 Lymphocyte counts / / 22286170 rs2280845 chr9 131583170 T A,C,G 0.00000064 Cholesterol,total C9orf114 UTR-3 23063622 rs2280845 chr9 131583170 T A,C,G 0.0000286 LDL cholesterol C9orf114 UTR-3 23063622 rs3750320 chr9 131670457 T C 6.64E-04 Iron levels LRRC8A cds-synon pha002876 rs10113912 chr9 131700209 C T 6.69E-04 Multiple complex diseases PHYHD1 intron 17554300 rs548662390 chr9 131700209 CCT C 6.69E-04 Multiple complex diseases PHYHD1 intron 17554300 rs719703 chr9 131745548 T C 4.15E-04 Lymphocyte counts NUP188 intron 22286170 rs73624835 chr9 131762080 A G 0.000052 Breast cancer(er negative) NUP188 missense 23555315 rs3750340 chr9 131772389 T G 3.20E-04 Myasthenia gravis SH3GLB2 intron 23055271 rs7042889 chr9 131795361 A C 0.0003769 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7042889 chr9 131795361 A C 3.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7873667 chr9 131795955 A T 0.0003535 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7873667 chr9 131795955 A T 3.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7863575 chr9 131798561 A G 0.000352 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7863575 chr9 131798561 A G 3.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10513506 chr9 131799139 C T 0.0003502 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10513506 chr9 131799139 C T 3.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11564101 chr9 131799261 C T 0.0002015 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FAM73B UTR-5 23233654 rs11564101 chr9 131799261 C T 2.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) FAM73B UTR-5 23233662 rs7867379 chr9 131803330 T C 0.0001516 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FAM73B intron 23233654 rs7867379 chr9 131803330 T C 1.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) FAM73B intron 23233662 rs11544968 chr9 131804785 T C 0.0004591 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FAM73B missense 23233654 rs11544968 chr9 131804785 T C 4.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) FAM73B missense 23233662 rs7046961 chr9 131849036 C T 1.28E-04 Cognitive decline DOLPP1 cds-synon 23732972 rs10988209 chr9 131871927 A G 7.14E-05 Alzheimer's disease (late onset) CRAT intron 21379329 rs7849270 chr9 131874641 A G 3.00E-21 Blood metabolite ratios PPP2R4 intron 24816252 rs2541164 chr9 131876908 G A 9.20E-05 Serum metabolites PPP2R4 intron 19043545 rs2541161 chr9 131884802 C T 7.28E-05 Serum metabolites PPP2R4 intron 19043545 rs3124505 chr9 131887856 C A 8.00E-06 Axial length PPP2R4 intron 24144296 rs10988217 chr9 131888116 A G 3.00E-06 Hypersomnia (HLA-DQB1*06:02 negative) PPP2R4 intron 23646285 rs10988217 chr9 131888116 A G 1.00E-18 Blood metabolite levels PPP2R4 intron 24816252 rs10819471 chr9 131896325 T G 4.79E-05 Serum metabolites PPP2R4 intron 19043545 rs10760593 chr9 131953598 C T 2.20E-04 Epilepsy / / 22116939 rs4836643 chr9 131960131 G A 2.71E-04 Scoliosis / / 21216876 rs2417135 chr9 131960870 C T 4.08E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs4836644 chr9 131984706 G T 8.00E-05 Neuroticism / / 23229837 rs4837349 chr9 131984729 G A,C 6.42E-05 Neuroticism / / 23229837 rs2479028 chr9 131986809 C T 7.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6478876 chr9 131991826 G C 6.33E-04 Acute lung injury / / 22295056 rs2480451 chr9 131992120 T C 4.21E-04 Acute lung injury / / 22295056 rs12057017 chr9 131992434 C T 2.45E-04 Acute lung injury / / 22295056 rs4837352 chr9 131992485 G A 2.45E-04 Acute lung injury / / 22295056 rs716548 chr9 131992861 C A 2.45E-04 Acute lung injury / / 22295056 rs12375476 chr9 131993971 A G 5.31E-04 Acute lung injury / / 22295056 rs395119 chr9 131996071 C T 3.10E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs2480448 chr9 131996715 T G 8.70E-04 Acute lung injury / / 22295056 rs10733695 chr9 131997207 T C 6.90E-04 Acute lung injury / / 22295056 rs7023548 chr9 132008768 C T 1.34E-07 Malaria / / 23717212 rs17440544 chr9 132014175 A G 5.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs11564091 chr9 132018506 C T 8.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs11564091 chr9 132018506 C T 1.69E-04 Celiac disease / / 23936387 rs1556144 chr9 132022766 T C 3.96E-04 Multiple complex diseases / / 17554300 rs1556143 chr9 132022788 C T 2.12E-04 Multiple complex diseases / / 17554300 rs13283950 chr9 132024109 G T 7.86E-04 Acute lung injury / / 22295056 rs7865327 chr9 132037024 C T 7.27E-05 Multiple complex diseases / / 17554300 rs7865327 chr9 132037024 C T 2.80E-05 Urinary metabolites / / 21572414 rs10988298 chr9 132042502 A G 2.66E-04 Multiple complex diseases / / 17554300 rs4836648 chr9 132048664 G A 3.27E-04 Alzheimer's disease / / 17998437 rs913770 chr9 132084621 G A 6.56E-04 Amyotrophic lateral sclerosis (sporadic) C9orf106 missense 24529757 rs7034728 chr9 132085293 T C 5.58E-04 Myocardial Infarction / / pha002873 rs883335 chr9 132085965 C G 2.10E-05 Urinary metabolites / / 21572414 rs10988323 chr9 132093466 T C 4.58E-04 Multiple complex diseases / / 17554300 rs147641655 chr9 132110445 G A 0.0000076 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10988341 chr9 132115179 A G 7.85E-05 Triglycerides / / pha002904 rs10988346 chr9 132131098 G A 3.36E-05 Orofacial clefts / / 22419666 rs10760614 chr9 132146405 C T 7.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs10819508 chr9 132147913 T C 2.60E-05 Erythrocyte counts / / pha003101 rs7869228 chr9 132148519 C T 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10988348 chr9 132152548 T A 9.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs10121772 chr9 132162453 T C 3.05E-05 Erythrocyte counts / / pha003101 rs10124706 chr9 132162828 A C 5.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4837362 chr9 132163254 A C 2.50E-04 Alcohol dependence / / 24277619 rs4837366 chr9 132192986 A G 2.83E-04 Iron levels / / pha002876 rs1616208 chr9 132298733 G A 1.17E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs1616208 chr9 132298733 G A 2.03E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs10988428 chr9 132339070 G T 8.00E-06 Metabolite levels (Pyroglutamine) / / 23934736 rs73628692 chr9 132349597 A T 7.00E-06 Metabolite levels (HVA/5-HIAA ratio) / / 23319000 rs10988439 chr9 132352219 G T 1.40E-04 Alcohol dependence / / 20201924 rs1220652 chr9 132358827 T C 9.01E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10988446 chr9 132360176 T C 6.72E-05 Erythrocyte counts / / pha003101 rs2542242 chr9 132366836 A G 7.37E-05 Body mass (lean) / / 19268274 rs10988449 chr9 132370360 C T 3.00E-06 Response to antidepressant treatment / / 22041458 rs4509442 chr9 132386835 A G 9.68E-05 Glycosylated haemoglobin levels / / 17255346 rs4837394 chr9 132389419 A G 9.33E-05 Glycosylated haemoglobin levels METTL11A intron 17255346 rs1861783 chr9 132390226 T C 5.85E-05 Glycosylated haemoglobin levels METTL11A intron 17255346 rs2900277 chr9 132394270 G T 8.44E-06 Osteoarthritis METTL11A intron 22763110 rs10114250 chr9 132395338 G A 4.55E-06 Glycosylated haemoglobin levels METTL11A intron 17255346 rs10739754 chr9 132420439 T C 3.45E-05 Hypertension / / pha003041 rs7866070 chr9 132444099 A G 7.00E-07 Common traits (Other) PRRX2 intron 20585627 rs10125991 chr9 132448019 A G 6.55E-04 Response to taxane treatment (placlitaxel) PRRX2 intron 23006423 rs1867099 chr9 132449529 C G 3.59E-04 Response to taxane treatment (placlitaxel) PRRX2 intron 23006423 rs10819557 chr9 132449756 G A 0.000161418 Hypertension (early onset hypertension) PRRX2 intron 22479346 rs3844046 chr9 132465237 C T 1.42E-04 Blood pressure PRRX2 intron 17255346 rs4836667 chr9 132465556 C T 8.23E-04 Multiple complex diseases PRRX2 intron 17554300 rs12683018 chr9 132467024 C T 1.02E-04 Blood pressure PRRX2 intron 17255346 rs12553596 chr9 132504668 T C 1.01E-04 Glycosylated haemoglobin levels PTGES intron 17255346 rs10819563 chr9 132505202 A G 3.42E-04 Nicotine dependence PTGES intron 17158188 rs10739757 chr9 132507910 T C 1.79E-05 Glycosylated haemoglobin levels PTGES intron 17255346 rs10988492 chr9 132511199 C T 3.13E-05 Glycosylated haemoglobin levels PTGES intron 17255346 rs10988493 chr9 132511956 G T 8.25E-05 Glycosylated haemoglobin levels PTGES intron 17255346 rs920658 chr9 132512235 C T 1.22E-04 Glycosylated haemoglobin levels PTGES intron 17255346 rs4837408 chr9 132514140 C T 6.36E-04 Nicotine dependence PTGES intron 17158188 rs4837413 chr9 132539425 T C 7.81E-04 Tourette syndrome / / 22889924 rs11998910 chr9 132541344 T C 1.67E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7873555 chr9 132546316 C T 3.60E-04 Schizophrenia / / 19197363 rs9722212 chr9 132553024 C G 5.27E-04 Lymphocyte counts / / 22286170 rs7029757 chr9 132566666 G A 8.42E-05 Coronary heart disease TOR1B intron pha003031 rs10116248 chr9 132568500 C T 3.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TOR1B intron 20877124 rs371980130 chr9 132579110 TT TCG,TTT 5.05E-05 Coronary heart disease TOR1A intron pha003031 rs3780697 chr9 132579110 T C 5.05E-05 Coronary heart disease TOR1A intron pha003031 rs7858348 chr9 132617888 G A 9.83E-04 Alcohol dependence USP20 intron 21314694 rs913320 chr9 132627723 G A 8.75E-04 Multiple complex diseases USP20 intron 17554300 rs880242 chr9 132629832 G A 7.80E-05 Coffee consumption USP20 intron 21357676 rs2528 chr9 132669500 G C 3.06E-04 Multiple complex diseases FNBP1 intron 17554300 rs7865287 chr9 132720132 C G 4.48E-04 Multiple complex diseases FNBP1 intron 17554300 rs1322671 chr9 132759808 A C 1.69E-04 Multiple complex diseases FNBP1 intron 17554300 rs806861 chr9 132787528 G A 8.35E-04 Amyotrophic Lateral Sclerosis FNBP1 intron 17827064 rs12351312 chr9 132919843 C T 4.11E-04 Acute lung injury / / 22295056 rs41354949 chr9 132930037 G A 2.20E-08 Urinary metabolites / / 21572414 rs12376641 chr9 132930078 C G 2.00E-08 Urinary metabolites / / 21572414 rs4836694 chr9 132939792 G C 7.00E-07 Alzheimer's disease (cognitive decline) NCS1 intron 23535033 rs3780711 chr9 132943043 T C 6.47E-04 Coronary heart disease NCS1 intron 21971053 rs1342043 chr9 132958305 C T 2.42E-04 Alzheimer's disease NCS1 intron 24755620 rs7024495 chr9 132967196 A G 9.25E-04 Iron levels NCS1 intron pha002876 rs868964 chr9 132971820 G A 1.67E-04 Alzheimer's disease NCS1 intron 24755620 rs947513 chr9 132973988 G A,C 1.17E-04 Vitiligo NCS1 intron 22561518 rs947513 chr9 132973988 G A,C 2.27E-04 Iron levels NCS1 intron pha002876 rs7868152 chr9 133003943 G A 9.52E-06 Vascular dementia / / 22116812 rs10988653 chr9 133006474 T C 9.15E-04 Iron levels / / pha002876 rs7026795 chr9 133013233 G A 1.03E-06 Common variable immunodeficiency / / 21497890 rs2417162 chr9 133013563 G A 6.36E-04 Acute lung injury / / 22295056 rs13302591 chr9 133014637 G A 8.20E-08 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs13302591 chr9 133014637 G A 8.33E-04 Iron levels / / pha002876 rs7045878 chr9 133019198 T C 3.10E-08 Platelet aggregation(pre- and post-aspirin) / / 20529293 rs7045878 chr9 133019198 T C 6.10E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs7028995 chr9 133025949 C T 5.78E-04 Heart Failure / / pha002885 rs6478959 chr9 133050571 C G 0.0007579 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100289200 intron 23233654 rs6478959 chr9 133050571 C G 7.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100289200 intron 23233662 rs113125285 chr9 133071918 CG C 0.0007352 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100289200 intron 23233654 rs113125285 chr9 133071918 CG C 7.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100289200 intron 23233662 rs373454125 chr9 133071918 CG C 0.0007352 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100289200 intron 23233654 rs373454125 chr9 133071918 CG C 7.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100289200 intron 23233662 rs576115930 chr9 133071918 C CG 0.0007352 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100289200 intron 23233654 rs576115930 chr9 133071918 C CG 7.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100289200 intron 23233662 rs6478961 chr9 133071918 C T 0.0007352 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100289200 intron 23233654 rs6478961 chr9 133071918 C T 7.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100289200 intron 23233662 rs914981 chr9 133245991 G A 3.82E-04 Myocardial Infarction HMCN2 intron pha002873 rs11243875 chr9 133246381 C T 1.10E-05 Urinary metabolites HMCN2 missense 21572414 rs7855331 chr9 133262821 G A 5.00E-05 Multiple complex diseases HMCN2 intron 17554300 rs11244127 chr9 133264096 G A 4.17E-05 Prostate cancer HMCN2 intron 18264096 rs4372050 chr9 133271928 T C 2.32E-05 Cognitive impairment induced by topiramate HMCN2 intron 22091778 rs10736862 chr9 133283255 A G 4.23E-05 HIV-1 viral setpoint HMCN2 intron 17641165 rs10736862 chr9 133283255 A G 5.40E-04 Response to cytadine analogues (cytosine arabinoside) HMCN2 intron 24483146 rs10793975 chr9 133284310 G A 1.24E-05 HIV-1 viral setpoint HMCN2 missense 17641165 rs7861815 chr9 133286172 C T 8.17E-04 Amyotrophic Lateral Sclerosis HMCN2 intron 17362836 rs4740391 chr9 133287097 G A 3.99E-05 Longevity HMCN2 intron 21612516 rs17146951 chr9 133299131 T C 9.20E-05 HIV-1 control HMCN2 intron 20041166 rs12342208 chr9 133310815 T C 3.80E-04 Acute lung injury / / 22295056 rs928516 chr9 133315271 A T 1.80E-05 Urinary metabolites / / 21572414 rs7860909 chr9 133331226 A G 2.30E-05 Urinary metabolites ASS1 intron 21572414 rs7860909 chr9 133331226 A G 2.16E-05 Sudden cardiac arrest ASS1 intron 21658281 rs11243474 chr9 133358199 G T 6.00E-05 Prostate cancer ASS1 intron 21743057 rs10901080 chr9 133358656 G T 6.00E-05 Prostate cancer ASS1 intron 21743057 rs12005118 chr9 133359756 G C 1.00E-04 Prostate cancer ASS1 intron 21743057 rs10901158 chr9 133419664 A G 6.52E-05 Lipoproteins / / pha003079 rs7030440 chr9 133440620 G A 2.00E-05 Height / / 18391952 rs7466269 chr9 133464084 A G 8.00E-07 Height FUBP3 intron 18391950 rs7466269 chr9 133464084 A G 3.00E-17 Height FUBP3 intron 20881960 rs7466269 chr9 133464084 A G 2.00E-10 Height FUBP3 intron 23563607 rs7466269 chr9 133464084 A G 2.00E-08 Bone mineral density (paediatric,lower limb) FUBP3 intron 24945404 rs7466269 chr9 133464084 A G 3.00E-08 Bone mineral density (paediatric,total body less head) FUBP3 intron 24945404 rs7466269 chr9 133464084 A G 5.00E-06 Bone mineral density (paediatric,lower limb) FUBP3 intron 24945404 rs7851693 chr9 133478827 C G 3.00E-22 Bone mineral density FUBP3 intron 22504420 rs7851693 chr9 133478827 C G 0.000634 Femoral neck bone mineral density (premenopausal) FUBP3 intron 23074152 rs7851693 chr9 133478827 C G 6.08E-04 Bone mineral density FUBP3 intron 24249740 rs10793963 chr9 133518456 G A 1.90E-05 Urinary metabolites / / 21572414 rs3802344 chr9 133534279 G A 2.14E-05 Fractional exhaled nitric oxide (childhood) / / 24315451 rs3802344 chr9 133534279 G A 5.00E-06 Fractional exhaled nitric oxide (childhood) / / 24315451 rs3802344 chr9 133534279 G A 1.20E-05 Blood Pressure / / pha003040 rs11244096 chr9 133551344 G A 2.38E-05 Alcohol and nictotine co-dependence PRDM12 intron 20158304 rs17147185 chr9 133571204 G A 4.93E-05 Bone mineral density EXOSC2 intron 24249740 rs2269337 chr9 133572684 G A 7.24E-08 Bilirubin levels,in serum EXOSC2 intron 19389676 rs2789764 chr9 133620998 T A 1.20E-05 Urinary metabolites ABL1 intron 21572414 rs4740363 chr9 133629184 A G 9.30E-05 Neutrophil count ABL1 intron pha003095 rs4740366 chr9 133630622 A G 9.84E-05 Neutrophil count ABL1 intron pha003095 rs4740203 chr9 133636808 C T 8.62E-05 Lymphocyte counts ABL1 intron pha003094 rs4740203 chr9 133636808 C T 4.23E-05 Neutrophil count ABL1 intron pha003095 rs11244146 chr9 133675143 G A 2.40E-05 Personality dimensions ABL1 intron 18957941 rs2260323 chr9 133700786 T C 4.82E-08 Coronary heart disease ABL1 intron 23364394 rs2855190 chr9 133708361 T C 7.60E-05 Personality dimensions ABL1 intron 18957941 rs2855190 chr9 133708361 T C 7.80E-05 Age-related macular degeneration ABL1 intron 20861866 rs6597642 chr9 133725767 G A 8.00E-05 Personality dimensions ABL1 intron 18957941 rs1800609 chr9 133731184 T C 6.10E-05 Personality dimensions ABL1 intron 18957941 rs1800609 chr9 133731184 T C 1.44E-08 Coronary heart disease ABL1 intron 23364394 rs3824400 chr9 133734075 C T 6.50E-05 Personality dimensions ABL1 intron 18957941 rs6597645 chr9 133745487 A G 9.85E-06 Response to amphetamines ABL1 intron 22952603 rs3808816 chr9 133746117 T C 8.10E-04 Multiple complex diseases ABL1 intron 17554300 rs4740376 chr9 133747734 C T 9.11E-06 Response to amphetamines ABL1 intron 22952603 rs2070997 chr9 133748083 A G 8.00E-06 Response to amphetamines ABL1 intron 22952603 rs4740377 chr9 133754220 T C 3.04E-04 Multiple complex diseases ABL1 intron 17554300 rs10901296 chr9 133765656 G A 2.44E-10 Bilirubin levels,in serum / / 20639394 rs10901296 chr9 133765656 G A 0.0000237 Aging / / 22445811 rs7040543 chr9 133770017 A C 1.16E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs12343454 chr9 133816023 G A 0.000327 Trichophyton tonsurans susceptibility / / 22704677 rs7026302 chr9 133828475 G A 1.49E-04 Parkinson's disease / / 17052657 rs11244216 chr9 133843861 G A 5.74E-04 Type 2 diabetes / / 17463246 rs2178107 chr9 133858122 G A 2.00E-04 Information processing speed / / 21130836 rs11244239 chr9 133877304 G A 9.51E-05 Bipolar disorder and schizophrenia / / 20889312 rs915401 chr9 133888771 A G 3.23E-04 Myopia (pathological) LAMC3 intron 21095009 rs8181067 chr9 133897781 C T 6.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LAMC3 intron 20877124 rs8181067 chr9 133897781 C T 4.57E-04 Alzheimer's disease LAMC3 intron 22005930 rs3780280 chr9 133906250 G A 2.87E-05 IgE levels LAMC3 intron 17255346 rs3808810 chr9 133908753 G A 9.20E-05 Cognitive test performance LAMC3 intron 20125193 rs4740396 chr9 133917807 T C 3.86E-04 Response to taxane treatment (placlitaxel) LAMC3 intron 23006423 rs4740399 chr9 133931262 A G 1.98E-04 Heart Failure LAMC3 intron pha002884 rs4740401 chr9 133938676 A C 5.26E-04 Type 2 diabetes LAMC3 intron 17463246 rs4740401 chr9 133938676 A C 2.70E-05 Urinary metabolites LAMC3 intron 21572414 rs10901343 chr9 133945955 G A 4.90E-05 Intracerebral hemorrhage LAMC3 intron 24656865 rs7045991 chr9 133960768 C T 4.88E-05 Intracerebral hemorrhage LAMC3 intron 24656865 rs36035484 chr9 133960773 T C 4.87E-05 Intracerebral hemorrhage LAMC3 intron 24656865 rs7045998 chr9 133960777 C T 4.87E-05 Intracerebral hemorrhage LAMC3 intron 24656865 rs353541 chr9 134014941 C T 8.17E-05 Type 2 diabetes NUP214 intron 17463246 rs11244305 chr9 134025595 A G 4.07E-04 Smoking initiation NUP214 intron 24665060 rs719854 chr9 134045534 A G 3.68E-04 Smoking initiation NUP214 intron 24665060 rs10901364 chr9 134157342 C T 6.41E-04 Lymphocyte counts / / 22286170 rs7041276 chr9 134165248 C T 4.80E-05 Telomere length PPAPDC3 UTR-5 23001564 rs4740438 chr9 134212002 G A 7.84E-04 White matter integrity / / 22425255 rs7852711 chr9 134233268 A G 0.000484765 Hypertension (early onset hypertension) / / 22479346 rs542305 chr9 134258779 A G 3.02E-04 Heart Failure / / pha002884 rs4740238 chr9 134308491 G A 1.68E-04 Depression (quantitative trait) PRRC2B intron 20800221 rs2994066 chr9 134326950 G A 2.87E-04 Lung function (forced vital capacity) PRRC2B intron 24023788 rs12553392 chr9 134348723 G A 7.59E-05 Schizophrenia PRRC2B intron 21926974 rs3808830 chr9 134408434 C T 6.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs6597505 chr9 134420144 C T 3.03E-04 Alzheimer's disease / / 17998437 rs4740266 chr9 134420163 A G 9.41E-05 Multiple complex diseases / / 17554300 rs4740170 chr9 134436280 T C 5.84E-05 Cognitive impairment induced by topiramate / / 22091778 rs11243434 chr9 134448487 A G 8.92E-06 Response to amphetamines / / 22952603 rs11243436 chr9 134449467 T C 8.61E-06 Response to amphetamines / / 22952603 rs11243437 chr9 134450073 G C 7.00E-06 Response to amphetamines / / 22952603 rs3765542 chr9 134458378 T C 6.90E-05 Proinsulin levels RAPGEF1 intron 21873549 rs3808803 chr9 134471153 C T 2.86E-04 Multiple complex diseases RAPGEF1 intron 17554300 rs4740294 chr9 134473021 C G 1.30E-05 Type 2 diabetes RAPGEF1 intron 17463246 rs7034356 chr9 134479017 A G 1.32E-05 Type 2 diabetes RAPGEF1 intron 17463246 rs4237112 chr9 134479939 G A 3.97E-05 Type 2 diabetes RAPGEF1 intron 17463246 rs12236783 chr9 134483325 G A 2.81E-04 Alzheimer's disease RAPGEF1 intron 22005930 rs11243452 chr9 134488061 T A 2.74E-04 Alzheimer's disease RAPGEF1 intron 22005930 rs2026006 chr9 134501124 G A 1.86E-04 Alzheimer's disease RAPGEF1 intron 22005930 rs17148121 chr9 134503810 C T 8.02E-06 Alcohol consumption RAPGEF1 intron 23953852 rs4740173 chr9 134505215 T C 2.68E-04 Body mass index RAPGEF1 intron 21701565 rs4740173 chr9 134505215 T C 3.32E-04 Body mass index RAPGEF1 intron 21701565 rs10901077 chr9 134508882 A G 3.33E-06 Cognitive impairment induced by topiramate RAPGEF1 intron 22091778 rs4474069 chr9 134511386 T C 8.22E-07 Smoking cessation RAPGEF1 intron 18519826 rs7858724 chr9 134511815 C T 3.66E-04 Alzheimer's disease RAPGEF1 intron 22005930 rs11243461 chr9 134514251 C T 3.52E-04 Alzheimer's disease RAPGEF1 intron 22005930 rs6597515 chr9 134532412 C T 1.10E-05 Urinary metabolites RAPGEF1 intron 21572414 rs6597515 chr9 134532412 C T 3.55E-04 Alzheimer's disease RAPGEF1 intron 22005930 rs7035496 chr9 134533880 G A 2.98E-05 Smoking cessation RAPGEF1 intron 18519826 rs1772 chr9 134538963 G A 7.09E-04 Suicide attempts in bipolar disorder RAPGEF1 intron 21423239 rs2026007 chr9 134543402 T C 4.36E-04 Alzheimer's disease RAPGEF1 intron 22005930 rs7030497 chr9 134544975 C T 4.52E-04 Alzheimer's disease RAPGEF1 intron 22005930 rs12551187 chr9 134545448 T C 4.39E-04 Suicide attempts in bipolar disorder RAPGEF1 intron 21423239 rs12238418 chr9 134547178 C T 4.63E-04 Alzheimer's disease RAPGEF1 intron 22005930 rs12551879 chr9 134547718 T G 5.96E-04 Suicide attempts in bipolar disorder RAPGEF1 intron 21423239 rs13299737 chr9 134548084 C T 4.78E-04 Alzheimer's disease RAPGEF1 intron 22005930 rs11243471 chr9 134553535 G A 5.23E-04 Alzheimer's disease RAPGEF1 intron 22005930 rs12001816 chr9 134555186 T C 2.84E-05 Post-operative nausea and vomiting RAPGEF1 intron 21694509 rs10120010 chr9 134561197 C T 5.96E-04 Suicide attempts in bipolar disorder RAPGEF1 intron 21423239 rs10120010 chr9 134561197 C T 4.34E-05 Alcohol consumption RAPGEF1 intron 23953852 rs11243473 chr9 134567960 C T 5.27E-04 Alzheimer's disease RAPGEF1 intron 22005930 rs11243477 chr9 134581547 G C 5.05E-04 Alzheimer's disease RAPGEF1 intron 22005930 rs11243479 chr9 134582408 A C 5.97E-04 Alzheimer's disease RAPGEF1 intron 22005930 rs12336419 chr9 134592328 G C 6.02E-04 Suicide attempts in bipolar disorder RAPGEF1 intron 21423239 rs11243485 chr9 134594229 T A 6.71E-06 Kawasaki disease RAPGEF1 intron 21221998 rs11243485 chr9 134594229 T A 3.05E-04 Alzheimer's disease RAPGEF1 intron 22005930 rs11243486 chr9 134596359 T C 5.91E-04 Suicide attempts in bipolar disorder RAPGEF1 intron 21423239 rs11243489 chr9 134602956 T C 8.82E-04 Suicide attempts in bipolar disorder RAPGEF1 intron 21423239 rs4991743 chr9 134607747 A G 1.73E-04 Type 2 diabetes RAPGEF1 intron 17463246 rs11243494 chr9 134611544 A G 4.05E-04 Body mass index RAPGEF1 intron 21701565 rs1041264 chr9 134617340 C T 3.07E-06 Alcohol consumption / / 23953852 rs1123551 chr9 134621809 G T 5.00E-04 Alzheimer's disease / / 22005930 rs10901083 chr9 134626207 T A 7.24E-04 Alzheimer's disease / / 22005930 rs4740183 chr9 134627123 G A 7.42E-04 Alzheimer's disease / / 22005930 rs12340210 chr9 134633824 C T 1.37E-05 Alcohol consumption / / 23953852 rs17553657 chr9 134638891 G A 1.99E-06 Body Mass Index / / pha003009 rs17553657 chr9 134638891 G A 9.01E-05 Waist Circumference / / pha003025 rs17553657 chr9 134638891 G A 7.50E-06 Weight / / pha003027 rs3012719 chr9 134641427 C T 9.00E-06 Hypertension / / 22384028 rs2031872 chr9 134645218 T C 7.15E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2031872 chr9 134645218 T C 2.84E-04 Schizophrenia / / 20832056 rs3012738 chr9 134652749 G A 3.08E-05 Blood Pressure / / pha003043 rs11243525 chr9 134656710 A T 1.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs10793897 chr9 134657367 C T 1.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs7851410 chr9 134658090 T C 1.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs11243536 chr9 134675670 A G 4.54E-04 Type 2 diabetes / / 17463246 rs10901103 chr9 134693169 A G 2.89E-04 Alzheimer's disease (late onset) / / 21379329 rs716738 chr9 134696326 T C 3.75E-04 Alzheimer's disease (late onset) / / 21379329 rs7865643 chr9 134729345 C A 3.97E-05 Serum metabolites / / 19043545 rs4579577 chr9 134767080 A C 9.16E-05 Serum metabolites MED27 intron 19043545 rs11243557 chr9 134771080 C T 8.50E-05 Iron levels MED27 intron 21208937 rs7029454 chr9 134778509 A C 6.99E-05 Coronary Artery Disease MED27 intron 17634449 rs11243562 chr9 134788048 C T 7.63E-06 Multiple complex diseases MED27 intron 17554300 rs6597536 chr9 134791779 C T 3.62E-05 Periodontitis (Chronic) MED27 intron 25008200 rs7047055 chr9 134799366 T C 0.0000026 Apolipoprotein B levels response after 40mg daily simvastatin treatment MED27 intron 23100282 rs7047055 chr9 134799366 T C 0.000053 LDL cholesterol response after 40mg daily simvastatin treatment MED27 intron 23100282 rs4128956 chr9 134818509 T C 3.60E-05 Kidney function and endocine traits MED27 intron 17903292 rs6597539 chr9 134826121 A C 8.26E-05 Attention deficit hyperactivity disorder MED27 intron 23728934 rs7032759 chr9 134836197 T C 1.19E-05 Type 2 diabetes MED27 intron 20818381 rs7032759 chr9 134836197 T C 2.19E-05 F-cell distribution MED27 intron 21326311 rs4564007 chr9 134854280 T C 3.37E-05 Waist Circumference MED27 intron pha003023 rs4363310 chr9 134890430 T C 4.65E-05 Waist Circumference MED27 intron pha003023 rs9411334 chr9 134896887 C T 4.89E-05 Waist Circumference MED27 intron pha003023 rs7026534 chr9 134907263 T G 1.85E-05 Waist Circumference MED27 intron pha003023 rs10512416 chr9 134913378 A G 3.56E-05 Attention deficit hyperactivity disorder MED27 intron 23728934 rs9411438 chr9 134946805 A G 9.28E-05 Waist Circumference MED27 intron pha003023 rs7858174 chr9 135009024 T C 8.49E-04 Myopia (pathological) / / 21095009 rs6597546 chr9 135029391 C G 8.53E-05 Serum metabolites / / 19043545 rs7862560 chr9 135030039 C T 1.66E-05 Serum metabolites / / 19043545 rs883318 chr9 135042885 A G 6.48E-04 Multiple complex diseases NTNG2 intron 17554300 rs7851167 chr9 135051942 C A 1.28E-05 Creatinine levels NTNG2 intron pha003069 rs7039329 chr9 135053756 C T 1.53E-05 Creatinine levels NTNG2 intron pha003069 rs10116759 chr9 135055814 A C 7.71E-05 Creatinine levels NTNG2 intron pha003069 rs870591 chr9 135062771 G A 0.0008283 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NTNG2 intron 23233654 rs870591 chr9 135062771 G A 8.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) NTNG2 intron 23233662 rs11243656 chr9 135064702 G C 0.000832 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NTNG2 intron 23233654 rs11243656 chr9 135064702 G C 8.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) NTNG2 intron 23233662 rs11243657 chr9 135064788 C T 9.06E-04 Methotrexate clearance (acute lymphoblastic leukemia) NTNG2 intron 23233662 rs7870760 chr9 135070104 A G 0.0008786 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NTNG2 intron 23233654 rs7870760 chr9 135070104 A G 8.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) NTNG2 intron 23233662 rs3739930 chr9 135073967 C T 9.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) NTNG2 cds-synon 23233662 rs3739929 chr9 135074063 T C 9.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) NTNG2 intron 23233662 rs11243667 chr9 135080098 A G 2.02E-04 Multiple complex diseases NTNG2 intron 17554300 rs11243676 chr9 135096767 G A 3.00E-06 Systemic lupus erythematosus NTNG2 intron 18204098 rs6597562 chr9 135099486 C T 1.10E-05 Urinary metabolites NTNG2 intron 21572414 rs2274853 chr9 135114365 G A 6.63E-04 Alcohol dependence NTNG2 intron 20201924 rs3739927 chr9 135139826 T C 8.25E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) SETX missense 23648065 rs12340860 chr9 135151461 A G 7.69E-04 Multiple complex diseases SETX intron 17554300 rs3780825 chr9 135156270 C T 7.00E-04 Type 2 diabetes SETX intron 17846125 rs744133 chr9 135185355 A G 3.68E-04 Multiple complex diseases SETX intron 17554300 rs1185995 chr9 135245867 A G 1.06E-05 Systemic lupus erythematosus / / pha002867 rs7470548 chr9 135298675 C T 4.53E-05 Cognitive impairment induced by topiramate C9orf171 intron 22091778 rs1412272 chr9 135298917 C T 9.78E-05 Psoriasis C9orf171 intron 18364390 rs558356 chr9 135329771 C T 7.93E-05 Coronary restenosis C9orf171 intron 21878436 rs569434 chr9 135344407 G A 9.00E-06 Obesity-related traits C9orf171 intron 23251661 rs569434 chr9 135344407 G A 6.18E-04 Amyotrophic lateral sclerosis (sporadic) C9orf171 intron 24529757 rs559127 chr9 135365590 G A 5.08E-05 Cognitive test performance C9orf171 intron 20125193 rs562350 chr9 135374898 T C 7.15E-05 Cognitive test performance / / 20125193 rs787904 chr9 135379520 A C 6.60E-05 Cognitive test performance C9orf171 intron 20125193 rs10901182 chr9 135395961 G C 3.65E-04 Type 2 diabetes C9orf171 intron 17463246 rs7024593 chr9 135396373 T C 6.35E-04 Response to statin treatment (atorvastatin),change in cholesterol levels C9orf171 intron 20031582 rs944805 chr9 135398088 C T 0.00000578 Panic disorder C9orf171 intron 23149450 rs944805 chr9 135398088 C T 6.79E-06 Serum tamsulosin hydrochloride concentration C9orf171 intron 23151678 rs7864953 chr9 135399370 T C 7.23E-04 Myocardial Infarction C9orf171 intron pha002883 rs7864953 chr9 135399370 T C 2.84E-04 Heart Failure C9orf171 intron pha002885 rs12376178 chr9 135401128 C T 4.79E-04 Response to cytadine analogues (cytosine arabinoside) C9orf171 intron 24483146 rs306549 chr9 135470176 C G 7.90E-05 Proinsulin levels DDX31 UTR-3 21873549 rs306542 chr9 135473647 A C 1.80E-05 Urinary metabolites DDX31 intron 21572414 rs306540 chr9 135478811 T C 4.89E-04 Type 2 diabetes DDX31 intron 17463246 rs523071 chr9 135481269 C A 3.84E-04 Type 2 diabetes DDX31 intron 17463246 rs11243840 chr9 135481357 G A 2.41E-04 Type 2 diabetes DDX31 intron 17463246 rs445990 chr9 135483721 G T 9.93E-05 Osteoarthritis DDX31 intron 19508968 rs445990 chr9 135483721 G T 2.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DDX31 intron 20877124 rs445990 chr9 135483721 G T 1.49E-05 Intelligence DDX31 intron 21826061 rs445990 chr9 135483721 G T 1.23E-05 Amyotrophic lateral sclerosis DDX31 intron 23624525 rs403679 chr9 135488035 C T 3.21E-04 Type 2 diabetes DDX31 intron 17463246 rs306567 chr9 135493451 G C 2.13E-04 Type 2 diabetes DDX31 intron 17463246 rs11243851 chr9 135508282 C G 3.73E-04 Multiple complex diseases DDX31 intron 17554300 rs17149424 chr9 135533884 A C 8.00E-06 Schizophrenia DDX31 intron 19571809 rs17149424 chr9 135533884 A C 3.64E-05 Schizophrenia DDX31 intron pha002859 rs2583805 chr9 135538807 G C 7.38E-04 Multiple complex diseases DDX31 intron 17554300 rs96153 chr9 135550093 A G 5.87E-04 Multiple complex diseases GTF3C4 intron 17554300 rs455764 chr9 135556791 C T 4.18E-04 Multiple complex diseases GTF3C4 intron 17554300 rs17149524 chr9 135556807 A G 9.59E-06 Schizophrenia GTF3C4 intron 19571809 rs17149524 chr9 135556807 A G 4.12E-05 Schizophrenia GTF3C4 intron pha002859 rs444197 chr9 135558503 A C 3.80E-04 Multiple complex diseases GTF3C4 intron 17554300 rs10901198 chr9 135559249 C T 8.74E-04 Type 2 diabetes GTF3C4 intron 17463246 rs787240 chr9 135560139 T C 4.00E-04 Multiple complex diseases GTF3C4 intron 17554300 rs567423 chr9 135561770 T C 3.21E-04 Multiple complex diseases GTF3C4 intron 17554300 rs2772006 chr9 135567388 T G 3.44E-04 Multiple complex diseases / / 17554300 rs302923 chr9 135572647 T C 3.00E-04 HIV(mother-to-child transmission) / / 20487506 rs302925 chr9 135573396 G T 8.09E-20 Multiple complex diseases / / 17554300 rs7466085 chr9 135588382 G A 4.41E-05 Intelligence / / 21826061 rs10124697 chr9 135589689 A T 2.82E-04 Obesity (extreme) / / 21935397 rs2772000 chr9 135590998 A C 2.50E-04 Obesity (extreme) / / 21935397 rs457298 chr9 135593035 C G 2.19E-04 Obesity (extreme) / / 21935397 rs12550888 chr9 135605439 C T 9.91E-04 Obesity (extreme) AK8 intron 21935397 rs913705 chr9 135616700 C T 7.41E-04 Amyotrophic Lateral Sclerosis AK8 intron 17362836 rs11243897 chr9 135618283 A G 6.00E-08 Attention deficit hyperactivity disorder AK8 intron 18839057 rs10901207 chr9 135618325 G A 4.76E-05 Biliary atresia AK8 intron 20460270 rs12552369 chr9 135632493 G A 8.00E-06 Major depressive disorder AK8 intron 23377640 rs10901212 chr9 135647021 C A 5.00E-06 Obesity-related traits AK8 intron 23251661 rs2772008 chr9 135664166 T G 2.70E-05 Urinary metabolites AK8 intron 21572414 rs2809253 chr9 135692783 G T 6.74E-04 Amyotrophic lateral sclerosis AK8 intron 23624525 rs2771994 chr9 135724901 T C 6.05E-05 Aspirin exacerbated respiratory disease in asthmatics AK8 intron 23180272 rs2254289 chr9 135727409 A G 7.51E-04 Amyotrophic lateral sclerosis AK8 intron 23624525 rs7025767 chr9 135742669 G A 7.73E-04 Type 2 diabetes AK8 intron 17463246 rs2072058 chr9 135750073 G A 2.90E-04 Primary sclerosing cholangitis AK8 intron 19944697 rs1050700 chr9 135767943 C T 1.12E-04 Aspirin exacerbated respiratory disease in asthmatics TSC1 UTR-3 23180272 rs11243929 chr9 135774164 T C 2.35E-05 Aspirin exacerbated respiratory disease in asthmatics TSC1 intron 23180272 rs1076160 chr9 135776034 C T 6.00E-06 Psoriasis TSC1 intron 19169254 rs1076160 chr9 135776034 C T 2.10E-04 Primary sclerosing cholangitis TSC1 intron 19944697 rs1076160 chr9 135776034 C T 6.00E-06 Psoriasis TSC1 intron 20953187 rs7020438 chr9 135776341 C A 2.07E-05 Aspirin exacerbated respiratory disease in asthmatics TSC1 intron 23180272 rs10901219 chr9 135778827 C T 2.09E-05 Aspirin exacerbated respiratory disease in asthmatics TSC1 intron 23180272 rs12345576 chr9 135779530 T C 2.01E-05 Aspirin exacerbated respiratory disease in asthmatics TSC1 intron 23180272 rs10901220 chr9 135781563 G A 2.01E-05 Aspirin exacerbated respiratory disease in asthmatics TSC1 intron 23180272 rs1073123 chr9 135786904 A G 2.06E-05 Aspirin exacerbated respiratory disease in asthmatics TSC1 missense 23180272 rs13295430 chr9 135799776 G A 4.08E-04 Lung function (forced vital capacity) TSC1 intron 24023788 rs7874234 chr9 135813001 C T 6.70E-05 Aspirin exacerbated respiratory disease in asthmatics TSC1 intron 23180272 rs7874234 chr9 135813001 C T 3.32E-04 Smoking initiation TSC1 intron 24665060 rs4962083 chr9 135820608 C T 5.01E-04 Smoking initiation TSC1 nearGene-5 24665060 rs4962225 chr9 135820731 A C 3.94E-04 Smoking initiation TSC1 nearGene-5 24665060 rs7035308 chr9 135822290 G A 4.65E-04 Smoking initiation / / 24665060 rs11998995 chr9 135841420 C T 2.10E-06 Urinary metabolites / / 21572414 rs2905077 chr9 135841437 G A 9.76E-04 Multiple complex diseases / / 17554300 rs2905072 chr9 135845035 G A 6.00E-06 Bipolar disorder / / 19416921 rs2905072 chr9 135845035 G A 6.44E-04 Smoking initiation / / 24665060 rs2773822 chr9 135861033 C T 1.40E-06 Carotid intima media thickness GFI1B intron 21909108 rs2773822 chr9 135861033 C T 2.92E-04 Attention deficit hyperactivity disorder GFI1B intron 22012869 rs7019702 chr9 135867989 A C 3.45E-06 Alzheimer's disease (late onset) / / 20885792 rs886017 chr9 135974100 G A 1.43E-05 Crohn's disease and psoriasis RALGDS cds-synon 22482804 rs7036096 chr9 135998623 G A 5.43E-04 Response to taxane treatment (placlitaxel) RALGDS intron 23006423 rs2073927 chr9 136031346 A G 2.90E-05 Hypertension (essential hypertension) GBGT1 intron 22184326 rs4962095 chr9 136031751 G T 2.89E-05 Hypertension (essential hypertension) GBGT1 intron 22184326 rs7868232 chr9 136042264 T C 2.86E-07 Red blood cell traits / / 23222517 rs7849542 chr9 136042530 G A 6.95E-09 Red blood cell traits / / 23222517 rs7849887 chr9 136042782 G A 1.22E-08 Red blood cell traits / / 23222517 rs2039184 chr9 136047393 A G 9.26E-07 Red blood cell traits / / 23222517 rs6597604 chr9 136049780 A G 1.20E-14 Soluble ICAM-1 / / 21533024 rs6597604 chr9 136049780 A G 4.22E-08 Red blood cell traits / / 23222517 rs4962099 chr9 136054274 T C 5.12E-08 Red blood cell traits / / 23222517 rs10751500 chr9 136057106 A G 5.87E-08 Red blood cell traits / / 23222517 rs11795315 chr9 136064766 G A 4.76E-11 Red blood cell traits / / 23222517 rs4128808 chr9 136065229 G C 4.73E-11 Red blood cell traits / / 23222517 rs13295207 chr9 136075679 C A 2.19E-09 Red blood cell traits / / 23222517 rs10901243 chr9 136078375 G C 8.57E-10 Red blood cell traits / / 23222517 rs10901244 chr9 136079463 C T 9.83E-05 Coronary Artery Disease / / 17634449 rs4489379 chr9 136084941 C T 3.59E-07 Red blood cell traits OBP2B nearGene-5 23222517 rs3761821 chr9 136085783 T C 1.00E-08 Red blood cell traits OBP2B nearGene-5 23222517 rs3761823 chr9 136086812 C G 8.75E-10 Red blood cell traits / / 23222517 rs4962104 chr9 136087047 T C 2.51E-10 Red blood cell traits / / 23222517 rs10793957 chr9 136087931 G T 3.41E-08 Red blood cell traits / / 23222517 rs6597610 chr9 136091096 G A 5.86E-09 Red blood cell traits / / 23222517 rs10793959 chr9 136093199 G A 3.47E-09 Red blood cell traits / / 23222517 rs4246169 chr9 136094150 C A 8.90E-09 Red blood cell traits / / 23222517 rs13300535 chr9 136097813 A G 2.25E-07 Red blood cell traits / / 23222517 rs4322078 chr9 136098479 A C 4.74E-07 Red blood cell traits / / 23222517 rs4379511 chr9 136101557 T C 5.01E-09 Red blood cell traits / / 23222517 rs886082 chr9 136101999 T G 1.89E-10 Red blood cell traits / / 23222517 rs4507838 chr9 136102199 T C 7.17E-04 IgE levels / / 17255346 rs4507838 chr9 136102199 T C 9.85E-09 Red blood cell traits / / 23222517 rs9411463 chr9 136105515 C T 4.84E-15 Red blood cell traits / / 23222517 rs9411463 chr9 136105515 C T 3.19E-13 End-stage coagulation / / 23381943 rs7852396 chr9 136108670 G A 1.06E-08 Red blood cell traits / / 23222517 rs9411464 chr9 136109165 C T 3.80E-09 Red blood cell traits / / 23222517 rs9411464 chr9 136109165 C T 2.18E-11 End-stage coagulation / / 23381943 rs4246170 chr9 136112413 A G 2.16E-13 Red blood cell traits / / 23222517 rs4246170 chr9 136112413 A G 1.77E-12 End-stage coagulation / / 23381943 rs4962039 chr9 136112570 C T 9.12E-14 Red blood cell traits / / 23222517 rs4962039 chr9 136112570 C T 1.75E-12 End-stage coagulation / / 23381943 rs4424335 chr9 136113559 C G 1.60E-13 Red blood cell traits / / 23222517 rs4424335 chr9 136113559 C G 2.86E-12 End-stage coagulation / / 23381943 rs12339451 chr9 136115310 C G 5.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs13301148 chr9 136115440 C T 8.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs7469576 chr9 136117964 G A 3.33E-05 Duodenal ulcer / / 22387998 rs9411367 chr9 136118513 C T 1.44E-05 Duodenal ulcer / / 22387998 rs9411367 chr9 136118513 C T 8.20E-09 Red blood cell traits / / 23222517 rs9919007 chr9 136119527 C T 9.30E-05 Amyotrophic Lateral Sclerosis / / 17362836 rs9919007 chr9 136119527 C T 3.18E-07 Duodenal ulcer / / 22387998 rs9919007 chr9 136119527 C T 2.76E-08 Red blood cell traits / / 23222517 rs9411468 chr9 136119888 G A 3.49E-07 Red blood cell traits / / 23222517 rs9411471 chr9 136120091 G A 3.22E-07 Duodenal ulcer / / 22387998 rs9411471 chr9 136120091 G A 9.24E-07 Red blood cell traits / / 23222517 rs7855466 chr9 136121303 C T 1.80E-07 Duodenal ulcer / / 22387998 rs7855466 chr9 136121303 C T 3.09E-08 Red blood cell traits / / 23222517 rs7855466 chr9 136121303 C T 5.51E-07 Malaria / / 23717212 rs7046863 chr9 136121441 T C 3.34E-07 Duodenal ulcer / / 22387998 rs10901250 chr9 136121626 G A 1.09E-13 Tumor biomarkers / / 23300138 rs4363269 chr9 136123840 A G 6.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4363269 chr9 136123840 A G 2.94E-10 Tumor biomarkers / / 23300138 rs7025839 chr9 136124190 G A 7.90E-14 Tumor biomarkers / / 23300138 rs9411475 chr9 136127268 T C 5.99E-09 Tumor biomarkers / / 23300138 rs62574565 chr9 136128259 G A 5.97E-09 Venous thrombosis / / 22675575 rs58081338 chr9 136128329 T C 6.33E-09 Venous thrombosis / / 22675575 rs62574567 chr9 136128421 C G 6.33E-09 Venous thrombosis / / 22675575 rs7857390 chr9 136128546 A G 8.13E-11 Venous thrombosis / / 22675575 rs12554336 chr9 136128663 A G 7.96E-09 Venous thrombosis / / 22675575 rs12554339 chr9 136128737 A C 6.58E-09 Venous thrombosis / / 22675575 rs10901253 chr9 136128772 T C 7.12E-09 Venous thrombosis / / 22675575 rs10901253 chr9 136128772 T C 9.12E-06 Obesity-related traits / / 23251661 rs11244052 chr9 136129125 C A 5.57E-09 Venous thrombosis / / 22675575 rs11244053 chr9 136129360 A G 5.90E-09 Venous thrombosis / / 22675575 rs4962114 chr9 136129611 G A 6.04E-09 Venous thrombosis / / 22675575 rs4962116 chr9 136129716 G A 6.55E-09 Venous thrombosis / / 22675575 rs8176751 chr9 136131022 C T 1.06E-09 Malaria ABO UTR-3 23717212 rs8176749 chr9 136131188 C T 2.59E-05 Graves' disease ABO cds-synon 21841780 rs8176749 chr9 136131188 C T 1.09E-17 Red blood cell traits ABO cds-synon 23222517 rs8176749 chr9 136131188 C T 3.30E-05 Platelet counts ABO cds-synon 23263863 rs8176749 chr9 136131188 C T 4.00E-98 Coagulation factor levels ABO cds-synon 23267103 rs8176749 chr9 136131188 C T 7.00E-105 Tumor biomarkers ABO cds-synon 23300138 rs8176749 chr9 136131188 C T 1.59E-17 End-stage coagulation ABO cds-synon 23381943 rs8176749 chr9 136131188 C T 1.20E-07 Malaria ABO cds-synon 23717212 rs8176749 chr9 136131188 C T 4.00E-12 Urinary metabolites (H-NMR features) ABO cds-synon 24586186 rs8176749 chr9 136131188 C T 2.59E-23 Elevated serum carcinoembryonic antigen levels ABO cds-synon 24941225 rs8176748 chr9 136131289 C T 4.57E-09 Venous thrombosis ABO missense 22675575 rs8176748 chr9 136131289 C T 7.52E-09 End-stage coagulation ABO missense 23381943 rs8176747 chr9 136131315 C G 5.71E-11 Red blood cell traits ABO missense 23222517 rs8176747 chr9 136131315 C G 2.79E-33 Tumor biomarkers ABO missense 23300138 rs8176747 chr9 136131315 C G 2.42E-13 End-stage coagulation ABO missense 23381943 rs8176746 chr9 136131322 G T 4.00E-08 Blood cell counts and other traits ABO missense 20139978 rs8176746 chr9 136131322 G T 4.32E-08 Blood cell counts and other traits ABO missense 20139978 rs8176746 chr9 136131322 G T 4.56E-05 Graves' disease ABO missense 21841780 rs8176746 chr9 136131322 G T 2.20E-16 Red blood cell traits ABO missense 23222517 rs8176746 chr9 136131322 G T 4.70E-36 Tumor biomarkers ABO missense 23300138 rs8176746 chr9 136131322 G T 1.59E-17 End-stage coagulation ABO missense 23381943 rs8176746 chr9 136131322 G T 4.00E-06 Graves' disease ABO missense 23612905 rs8176746 chr9 136131322 G T 1.14E-07 Malaria ABO missense 23717212 rs8176746 chr9 136131322 G T 6.10E-24 Elevated serum carcinoembryonic antigen levels ABO missense 24941225 rs8176743 chr9 136131415 C T 4.58E-16 Red blood cell traits ABO missense 23222517 rs8176743 chr9 136131415 C T 4.77E-36 Tumor biomarkers ABO missense 23300138 rs8176743 chr9 136131415 C T 2.00E-17 End-stage coagulation ABO missense 23381943 rs8176743 chr9 136131415 C T 8.29E-08 Malaria ABO missense 23717212 rs8176743 chr9 136131415 C T 1.82E-23 Elevated serum carcinoembryonic antigen levels ABO missense 24941225 rs8176742 chr9 136131437 C T 3.10E-12 Soluble ICAM-1 ABO cds-synon 21533024 rs8176742 chr9 136131437 C T 7.73E-09 Venous thrombosis ABO cds-synon 22675575 rs8176741 chr9 136131461 G A 8.29E-28 Tumor biomarkers ABO cds-synon 23300138 rs8176741 chr9 136131461 G A 2.00E-24 Elevated serum carcinoembryonic antigen levels ABO cds-synon 24941225 rs8176740 chr9 136131472 A T 1.40E-12 Soluble ICAM-1 ABO missense 21533024 rs8176740 chr9 136131472 A T 8.03E-34 vWF levels,in plasma ABO missense 21534939 rs8176740 chr9 136131472 A T 5.10E-08 Protein biomarker ABO missense 23056639 rs8176740 chr9 136131472 A T 1.45E-08 End-stage coagulation ABO missense 23381943 rs7853989 chr9 136131592 G C 1.06E-17 Red blood cell traits ABO missense 23222517 rs7853989 chr9 136131592 G C 4.06E-36 Tumor biomarkers ABO missense 23300138 rs7853989 chr9 136131592 G C 2.92E-10 End-stage coagulation ABO missense 23381943 rs7873522 chr9 136131905 T C 4.80E-22 Soluble ICAM-1 ABO intron 21533024 rs7873522 chr9 136131905 T C 1.83E-12 Tumor biomarkers ABO intron 23300138 rs7873522 chr9 136131905 T C 5.12E-12 Elevated serum carcinoembryonic antigen levels ABO intron 24941225 rs7873635 chr9 136132012 T C 1.22E-11 Venous thrombosis ABO intron 22675575 rs8176732 chr9 136132303 A G 1.20E-12 Soluble ICAM-1 ABO intron 21533024 rs8176732 chr9 136132303 A G 1.38E-08 Venous thromboembolism ABO intron 21980494 rs8176732 chr9 136132303 A G 3.19E-04 Type 2 diabetes ABO intron 22158537 rs8176732 chr9 136132303 A G 5.51E-08 Protein biomarker ABO intron 23056639 rs8176732 chr9 136132303 A G 1.45E-08 End-stage coagulation ABO intron 23381943 rs8176731 chr9 136132350 T C 4.50E-21 Soluble ICAM-1 ABO intron 21533024 rs8176731 chr9 136132350 T C 9.28E-12 Red blood cell traits ABO intron 23222517 rs8176731 chr9 136132350 T C 7.96E-17 Tumor biomarkers ABO intron 23300138 rs2073823 chr9 136132516 G A 6.12E-36 Tumor biomarkers ABO intron 23300138 rs8176730 chr9 136132525 T C 1.29E-17 Red blood cell traits ABO intron 23222517 rs8176730 chr9 136132525 T C 3.59E-35 Tumor biomarkers ABO intron 23300138 rs8176730 chr9 136132525 T C 2.92E-10 End-stage coagulation ABO intron 23381943 rs8176728 chr9 136132561 G C 1.05E-08 Venous thromboembolism ABO intron 21980494 rs8176728 chr9 136132561 G C 5.51E-08 Protein biomarker ABO intron 23056639 rs8176728 chr9 136132561 G C 1.45E-08 End-stage coagulation ABO intron 23381943 rs8176726 chr9 136132608 C T 7.52E-09 Venous thrombosis ABO intron 22675575 rs8176725 chr9 136132617 G A 1.45E-17 Red blood cell traits ABO intron 23222517 rs8176725 chr9 136132617 G A 3.51E-18 Tumor biomarkers ABO intron 23300138 rs8176725 chr9 136132617 G A 2.92E-10 End-stage coagulation ABO intron 23381943 rs8176725 chr9 136132617 G A 6.61E-11 Elevated serum carcinoembryonic antigen levels ABO intron 24941225 rs2073824 chr9 136132633 A G 3.70E-21 Soluble ICAM-1 ABO intron 21533024 rs2073824 chr9 136132633 A G 2.27E-11 Red blood cell traits ABO intron 23222517 rs2073824 chr9 136132633 A G 8.03E-10 Tumor biomarkers ABO intron 23300138 rs2073825 chr9 136132707 A T 7.90E-13 Soluble ICAM-1 ABO intron 21533024 rs2073825 chr9 136132707 A T 1.15E-08 Venous thromboembolism ABO intron 21980494 rs2073825 chr9 136132707 A T 5.75E-08 Protein biomarker ABO intron 23056639 rs2073825 chr9 136132707 A T 1.45E-08 End-stage coagulation ABO intron 23381943 rs8176722 chr9 136132754 C A 9.07E-42 vWF levels,in plasma ABO intron 21534939 rs8176722 chr9 136132754 C A 1.06E-17 Red blood cell traits ABO intron 23222517 rs8176722 chr9 136132754 C A 7.90E-36 Tumor biomarkers ABO intron 23300138 rs8176722 chr9 136132754 C A 2.92E-10 End-stage coagulation ABO intron 23381943 rs8176722 chr9 136132754 C A 9.00E-10 Malaria ABO intron 23717212 rs8176722 chr9 136132754 C A 1.17E-23 Elevated serum carcinoembryonic antigen levels ABO intron 24941225 rs8176720 chr9 136132873 T C 1.30E-21 Soluble ICAM-1 ABO cds-synon 21533024 rs8176720 chr9 136132873 T C 1.37E-12 Red blood cell traits ABO cds-synon 23222517 rs8176720 chr9 136132873 T C 7.59E-17 Tumor biomarkers ABO cds-synon 23300138 rs8176720 chr9 136132873 T C 3.00E-21 Serum alkaline phosphatase levels ABO cds-synon 24094242 rs8176720 chr9 136132873 T C 7.38E-12 Elevated serum carcinoembryonic antigen levels ABO cds-synon 24941225 rs77641731 chr9 136132908 T C 2.16E-08 Obesity-related traits ABO missense 23251661 rs77641731 chr9 136132908 T C 6.00E-12 Venous thromboembolism / / 22672568 rs77641731 chr9 136132908 T C 4.00E-21 Malaria / / 22895189 rs8176719 chr9 136132908 T TC 2.16E-08 Obesity-related traits ABO missense 23251661 rs8176719 chr9 136132908 T TC 6.00E-12 Venous thromboembolism / / 22672568 rs8176719 chr9 136132908 T TC 4.00E-21 Malaria / / 22895189 rs8176717 chr9 136133034 G T 1.20E-08 Venous thromboembolism ABO intron 21980494 rs8176717 chr9 136133034 G T 5.50E-08 Protein biomarker ABO intron 23056639 rs8176717 chr9 136133034 G T 1.38E-08 End-stage coagulation ABO intron 23381943 rs8176715 chr9 136133148 T C 1.20E-11 Soluble ICAM-1 ABO intron 21533024 rs8176715 chr9 136133148 T C 7.96E-12 Venous thrombosis ABO intron 22675575 rs8176714 chr9 136133178 G A 1.17E-08 Venous thromboembolism ABO intron 21980494 rs8176714 chr9 136133178 G A 5.64E-09 Venous thrombosis ABO intron 22675575 rs8176714 chr9 136133178 G A 5.66E-08 Protein biomarker ABO intron 23056639 rs8176714 chr9 136133178 G A 1.74E-08 End-stage coagulation ABO intron 23381943 rs512770 chr9 136133506 A G 2.90E-10 Soluble ICAM-1 ABO missense 21533024 rs512770 chr9 136133506 A G 1.21E-24 vWF levels,in plasma ABO missense 21534939 rs512770 chr9 136133506 A G 1.41E-08 Protein biomarker ABO missense 23056639 rs4962040 chr9 136133531 A G 5.70E-14 Soluble ICAM-1 ABO intron 21533024 rs4962040 chr9 136133531 A G 1.07E-10 Venous thrombosis ABO intron 22675575 rs641959 chr9 136133699 C A 6.40E-12 Venous thromboembolism ABO intron 21980494 rs641959 chr9 136133699 C A 1.04E-11 Venous thrombosis ABO intron 22675575 rs641959 chr9 136133699 C A 4.36E-08 Protein biomarker ABO intron 23056639 rs641959 chr9 136133699 C A 2.15E-09 End-stage coagulation ABO intron 23381943 rs641943 chr9 136133714 G A 3.70E-16 Soluble ICAM-1 ABO intron 21533024 rs641943 chr9 136133714 G A 6.94E-12 Venous thromboembolism ABO intron 21980494 rs641943 chr9 136133714 G A 1.46E-11 Venous thrombosis ABO intron 22675575 rs641943 chr9 136133714 G A 4.56E-08 Protein biomarker ABO intron 23056639 rs641943 chr9 136133714 G A 2.15E-09 End-stage coagulation ABO intron 23381943 rs514708 chr9 136133743 T C 6.40E-16 Soluble ICAM-1 ABO intron 21533024 rs514708 chr9 136133743 T C 7.18E-12 Venous thromboembolism ABO intron 21980494 rs514708 chr9 136133743 T C 1.46E-11 Venous thrombosis ABO intron 22675575 rs514708 chr9 136133743 T C 4.57E-08 Protein biomarker ABO intron 23056639 rs514708 chr9 136133743 T C 2.15E-09 End-stage coagulation ABO intron 23381943 rs517414 chr9 136134034 A G 1.32E-08 Venous thromboembolism ABO intron 21980494 rs517414 chr9 136134034 A G 4.39E-08 Protein biomarker ABO intron 23056639 rs517414 chr9 136134034 A G 1.74E-08 End-stage coagulation ABO intron 23381943 rs638756 chr9 136134472 C A 5.38E-33 vWF levels,in plasma ABO intron 21534939 rs638756 chr9 136134472 C A 1.16E-09 Venous thromboembolism ABO intron 21980494 rs638756 chr9 136134472 C A 7.86E-09 End-stage coagulation ABO intron 23381943 rs626035 chr9 136134994 G T 1.39E-08 Venous thromboembolism ABO intron 21980494 rs626035 chr9 136134994 G T 3.19E-09 Venous thrombosis ABO intron 22675575 rs626035 chr9 136134994 G T 4.41E-08 Protein biomarker ABO intron 23056639 rs626035 chr9 136134994 G T 1.82E-08 End-stage coagulation ABO intron 23381943 rs547495 chr9 136134995 C T 5.42E-09 Venous thrombosis ABO intron 22675575 rs547643 chr9 136135047 T C 1.39E-08 Venous thromboembolism ABO intron 21980494 rs547643 chr9 136135047 T C 4.48E-08 Protein biomarker ABO intron 23056639 rs547643 chr9 136135047 T C 1.82E-08 End-stage coagulation ABO intron 23381943 rs625593 chr9 136135096 A G 1.43E-08 Venous thromboembolism ABO intron 21980494 rs625593 chr9 136135096 A G 1.82E-08 End-stage coagulation ABO intron 23381943 rs8176707 chr9 136135108 G T 4.32E-04 Multiple complex diseases ABO intron 17554300 rs549331 chr9 136135195 G C 1.52E-08 Venous thromboembolism ABO intron 21980494 rs549331 chr9 136135195 G C 4.50E-08 Protein biomarker ABO intron 23056639 rs549331 chr9 136135195 G C 1.82E-08 End-stage coagulation ABO intron 23381943 rs549446 chr9 136135238 T C 1.10E-12 Soluble ICAM-1 ABO missense 21533024 rs549446 chr9 136135238 T C 3.57E-32 vWF levels,in plasma ABO missense 21534939 rs549446 chr9 136135238 T C 1.52E-08 Venous thromboembolism ABO missense 21980494 rs549446 chr9 136135238 T C 4.47E-08 Protein biomarker ABO missense 23056639 rs549446 chr9 136135238 T C 1.82E-08 End-stage coagulation ABO missense 23381943 rs624601 chr9 136135365 A G 1.56E-08 Venous thromboembolism ABO intron 21980494 rs624601 chr9 136135365 A G 4.44E-08 Protein biomarker ABO intron 23056639 rs624601 chr9 136135365 A G 1.83E-08 End-stage coagulation ABO intron 23381943 rs613423 chr9 136135478 A G 1.71E-08 Venous thromboembolism ABO intron 21980494 rs613423 chr9 136135478 A G 4.43E-08 Protein biomarker ABO intron 23056639 rs613423 chr9 136135478 A G 1.83E-08 End-stage coagulation ABO intron 23381943 rs8176704 chr9 136135552 G A 4.00E-34 Coagulation factor levels ABO intron 23267103 rs8176704 chr9 136135552 G A 0.0000872 Interleukin-6 (IL-6) levels ABO intron 23505291 rs574347 chr9 136135659 C T 6.20E-13 Soluble ICAM-1 ABO intron 21533024 rs574347 chr9 136135659 C T 1.81E-08 Venous thromboembolism ABO intron 21980494 rs574347 chr9 136135659 C T 4.55E-08 Protein biomarker ABO intron 23056639 rs574347 chr9 136135659 C T 1.49E-08 End-stage coagulation ABO intron 23381943 rs8176703 chr9 136135863 G T 2.10E-12 Malaria ABO intron 22895189 rs8176702 chr9 136136146 G A 1.10E-13 Soluble ICAM-1 ABO intron 21533024 rs8176702 chr9 136136146 G A 1.05E-10 Venous thrombosis ABO intron 22675575 rs579483 chr9 136136196 A T 1.50E-08 Venous thromboembolism ABO intron 21980494 rs579483 chr9 136136196 A T 4.71E-08 Protein biomarker ABO intron 23056639 rs579483 chr9 136136196 A T 1.85E-08 End-stage coagulation ABO intron 23381943 rs579622 chr9 136136242 A G 1.28E-08 Venous thromboembolism ABO intron 21980494 rs579622 chr9 136136242 A G 4.86E-08 Protein biomarker ABO intron 23056639 rs579622 chr9 136136242 A G 1.86E-08 End-stage coagulation ABO intron 23381943 rs493211 chr9 136136516 A G 5.78E-08 Protein biomarker ABO intron 23056639 rs688976 chr9 136136770 A C 8.05E-31 vWF levels,in plasma ABO missense 21534939 rs688976 chr9 136136770 A C 9.25E-09 Venous thromboembolism ABO missense 21980494 rs688976 chr9 136136770 A C 4.89E-08 Protein biomarker ABO missense 23056639 rs688976 chr9 136136770 A C 1.88E-08 End-stage coagulation ABO missense 23381943 rs2073826 chr9 136136963 G A,C,T 5.70E-17 Soluble ICAM-1 ABO intron 21533024 rs2073826 chr9 136136963 G A,C,T 7.10E-14 Venous thrombosis ABO intron 22675575 rs687621 chr9 136137065 A G 7.81E-09 Cardiovascular disease risk factors ABO intron 21239051 rs687621 chr9 136137065 A G 7.00E-06 D-dimer levels ABO intron 21502573 rs687621 chr9 136137065 A G 4.20E-52 Soluble ICAM-1 ABO intron 21533024 rs687621 chr9 136137065 A G 3.27E-34 Venous thromboembolism ABO intron 21980494 rs687621 chr9 136137065 A G 4.90E-04 Metabolic syndrome phenotype ABO intron 22022282 rs687621 chr9 136137065 A G 9.70E-48 Metabolic syndrome phenotype ABO intron 22022282 rs687621 chr9 136137065 A G 2.35E-19 Inflammatory biomarkers ABO intron 22291609 rs687621 chr9 136137065 A G 7.58E-14 Venous thromboembolism ABO intron 22672568 rs687621 chr9 136137065 A G 4.35E-34 Venous thrombosis ABO intron 22675575 rs687621 chr9 136137065 A G 9.00E-100 Activated partial thromboplastin time ABO intron 22703881 rs687621 chr9 136137065 A G 1.09E-17 Protein biomarker ABO intron 23056639 rs687621 chr9 136137065 A G 3.73E-07 Red blood cell traits ABO intron 23222517 rs687621 chr9 136137065 A G 4.03E-10 Metabolite levels ABO intron 23281178 rs687621 chr9 136137065 A G 1.15E-55 End-stage coagulation ABO intron 23381943 rs687621 chr9 136137065 A G 2.00E-52 Venous thromboembolism ABO intron 23650146 rs687289 chr9 136137106 G A 7.75E-09 Cardiovascular disease risk factors ABO intron 21239051 rs687289 chr9 136137106 G A 1.60E-52 Soluble ICAM-1 ABO intron 21533024 rs687289 chr9 136137106 G A 2.80E-34 Venous thromboembolism ABO intron 21980494 rs687289 chr9 136137106 G A 2.36E-19 Inflammatory biomarkers ABO intron 22291609 rs687289 chr9 136137106 G A 7.42E-14 Venous thromboembolism ABO intron 22672568 rs687289 chr9 136137106 G A 1.63E-34 Venous thrombosis ABO intron 22675575 rs687289 chr9 136137106 G A 1.10E-17 Protein biomarker ABO intron 23056639 rs687289 chr9 136137106 G A 2.94E-08 Obesity-related traits ABO intron 23251661 rs687289 chr9 136137106 G A 1.00E-128 Coagulation factor levels ABO intron 23267103 rs687289 chr9 136137106 G A 4.03E-10 Metabolite levels ABO intron 23281178 rs687289 chr9 136137106 G A 1.15E-55 End-stage coagulation ABO intron 23381943 rs687289 chr9 136137106 G A 1.00E-12 Urinary metabolites (H-NMR features) ABO intron 24586186 rs687289 chr9 136137106 G A 2.00E-12 Urinary metabolites (H-NMR features) ABO intron 24586186 rs2073827 chr9 136137133 G C 2.80E-17 Soluble ICAM-1 ABO intron 21533024 rs2073827 chr9 136137133 G C 7.38E-14 Venous thromboembolism ABO intron 21980494 rs2073827 chr9 136137133 G C 4.34E-06 Venous thromboembolism ABO intron 22672568 rs2073827 chr9 136137133 G C 5.38E-14 Venous thrombosis ABO intron 22675575 rs2073827 chr9 136137133 G C 6.12E-22 End-stage coagulation ABO intron 23381943 rs2073828 chr9 136137140 G A,C,T 4.30E-17 Soluble ICAM-1 ABO intron 21533024 rs2073828 chr9 136137140 G A,C,T 5.89E-14 Venous thrombosis ABO intron 22675575 rs2073828 chr9 136137140 G A,C,T 5.64E-07 Pancreatic cancer ABO intron pha002889 rs8176694 chr9 136137646 T C 3.40E-12 Soluble ICAM-1 ABO intron 21533024 rs8176694 chr9 136137646 T C 3.13E-22 vWF levels,in plasma ABO intron 21534939 rs8176693 chr9 136137657 C T 6.10E-75 Metabolic syndrome phenotype ABO intron 22022282 rs8176693 chr9 136137657 C T 7.57E-08 Protein biomarker ABO intron 23056639 rs8176693 chr9 136137657 C T 1.48E-17 Red blood cell traits ABO intron 23222517 rs8176693 chr9 136137657 C T 1.30E-35 Tumor biomarkers ABO intron 23300138 rs8176693 chr9 136137657 C T 1.30E-35 Type 2 diabetes ABO intron 23300278 rs8176693 chr9 136137657 C T 1.59E-17 End-stage coagulation ABO intron 23381943 rs8176693 chr9 136137657 C T 3.73E-08 Malaria ABO intron 23717212 rs673578 chr9 136137857 G A,C,T 4.30E-12 Venous thrombosis ABO intron 22675575 rs672316 chr9 136138125 G A,C,T 3.40E-12 Venous thromboembolism ABO intron 21980494 rs672316 chr9 136138125 G A,C,T 5.76E-12 Venous thrombosis ABO intron 22675575 rs672316 chr9 136138125 G A,C,T 2.27E-09 End-stage coagulation ABO intron 23381943 rs8176691 chr9 136138229 C T 9.13E-11 Venous thrombosis ABO intron 22675575 rs8176690 chr9 136138317 A G 4.03E-14 Venous thrombosis ABO intron 22675575 rs8176686 chr9 136138776 T C 4.29E-11 Venous thrombosis ABO intron 22675575 rs657152 chr9 136139265 C A 2.00E-30 Liver enzyme levels ABO intron 18940312 rs657152 chr9 136139265 C A 1.35E-38 Blood cell counts and other traits ABO intron 20139978 rs657152 chr9 136139265 C A 9.00E-13 Phytosterol levels ABO intron 20529992 rs657152 chr9 136139265 C A 4.11E-08 Cardiovascular disease risk factors ABO intron 21239051 rs657152 chr9 136139265 C A 4.10E-05 Alcoholism (heaviness of drinking) ABO intron 21529783 rs657152 chr9 136139265 C A 3.20E-44 Soluble ICAM-1 ABO intron 21533024 rs657152 chr9 136139265 C A 9.73E-223 vWF levels,in plasma ABO intron 21534939 rs657152 chr9 136139265 C A 3.35E-05 Graves' disease ABO intron 21841780 rs657152 chr9 136139265 C A 5.46E-28 Venous thromboembolism ABO intron 21980494 rs657152 chr9 136139265 C A 6.04E-21 Inflammatory biomarkers ABO intron 22291609 rs657152 chr9 136139265 C A 6.05E-08 Duodenal ulcer ABO intron 22387998 rs657152 chr9 136139265 C A 1.21E-12 Venous thromboembolism ABO intron 22672568 rs657152 chr9 136139265 C A 5.14E-28 Venous thrombosis ABO intron 22675575 rs657152 chr9 136139265 C A 6.01E-18 Protein biomarker ABO intron 23056639 rs657152 chr9 136139265 C A 9.72E-09 Cholesterol,total ABO intron 23063622 rs657152 chr9 136139265 C A 2.45E-11 Activated partial thromboplastin time ABO intron 23188048 rs657152 chr9 136139265 C A 2.00E-08 Obesity-related traits ABO intron 23251661 rs657152 chr9 136139265 C A 4.33E-09 Metabolite levels ABO intron 23281178 rs657152 chr9 136139265 C A 2.65E-50 End-stage coagulation ABO intron 23381943 rs657152 chr9 136139265 C A 1.00E-06 Thyroid hormone levels ABO intron 23408906 rs657152 chr9 136139265 C A 4.00E-10 Thyroid hormone levels ABO intron 23408906 rs657152 chr9 136139265 C A 4.00E-08 Serum alkaline phosphatase levels ABO intron 24094242 rs657152 chr9 136139265 C A 1.00E-19 Urinary metabolites (H-NMR features) ABO intron 24586186 rs657152 chr9 136139265 C A 2.06E-05 Pancreatic cancer ABO intron pha002874 rs657152 chr9 136139265 C A 5.59E-07 Pancreatic cancer ABO intron pha002889 rs8176682 chr9 136139297 C A,G,T 1.02E-10 Venous thromboembolism ABO intron 21980494 rs8176682 chr9 136139297 C A,G,T 8.70E-11 Venous thrombosis ABO intron 22675575 rs8176682 chr9 136139297 C A,G,T 2.39E-20 End-stage coagulation ABO intron 23381943 rs474279 chr9 136139617 T C 5.96E-09 Venous thromboembolism ABO intron 21980494 rs474279 chr9 136139617 T C 1.56E-08 End-stage coagulation ABO intron 23381943 rs8176681 chr9 136139754 T C 6.43E-04 Multiple complex diseases ABO intron 17554300 rs8176681 chr9 136139754 T C 8.39E-14 Venous thromboembolism ABO intron 21980494 rs8176681 chr9 136139754 T C 4.15E-06 Venous thromboembolism ABO intron 22672568 rs8176681 chr9 136139754 T C 1.89E-13 Venous thrombosis ABO intron 22675575 rs8176681 chr9 136139754 T C 6.06E-22 End-stage coagulation ABO intron 23381943 rs1633513 chr9 136140462 C T 5.18E-12 Venous thrombosis ABO intron 22675575 rs1752339 chr9 136141135 C T 5.55E-09 Venous thrombosis ABO intron 22675575 rs2519093 chr9 136141870 C T 8.00E-16 Venous thromboembolism ABO intron 22672568 rs2519093 chr9 136141870 C T 6.86E-29 Venous thrombosis ABO intron 22675575 rs2519093 chr9 136141870 C T 3.00E-05 Lipid traits ABO intron 24023260 rs8176672 chr9 136142185 C T 1.03E-09 Tumor biomarkers ABO intron 23300138 rs8176672 chr9 136142185 C T 4.85E-08 Malaria ABO intron 23717212 rs514659 chr9 136142203 A C 8.00E-09 Coronary heart disease ABO intron 21239051 rs514659 chr9 136142203 A C 2.23E-34 Venous thromboembolism ABO intron 21980494 rs514659 chr9 136142203 A C 9.04E-20 Inflammatory biomarkers ABO intron 22291609 rs514659 chr9 136142203 A C 6.26E-14 Venous thromboembolism ABO intron 22672568 rs514659 chr9 136142203 A C 6.32E-34 Venous thrombosis ABO intron 22675575 rs514659 chr9 136142203 A C 5.99E-18 Protein biomarker ABO intron 23056639 rs514659 chr9 136142203 A C 7.02E-07 Red blood cell traits ABO intron 23222517 rs514659 chr9 136142203 A C 4.45E-10 Metabolite levels ABO intron 23281178 rs514659 chr9 136142203 A C 2.26E-55 End-stage coagulation ABO intron 23381943 rs514659 chr9 136142203 A C 1.16E-04 Self-reported allergy ABO intron 23817569 rs644234 chr9 136142217 T G 1.57E-08 Cardiovascular disease risk factors ABO intron 21239051 rs644234 chr9 136142217 T G 4.39E-28 Venous thromboembolism ABO intron 21980494 rs644234 chr9 136142217 T G 2.69E-21 Inflammatory biomarkers ABO intron 22291609 rs644234 chr9 136142217 T G 1.16E-12 Venous thromboembolism ABO intron 22672568 rs644234 chr9 136142217 T G 1.81E-27 Venous thrombosis ABO intron 22675575 rs644234 chr9 136142217 T G 4.00E-47 Protein biomarker ABO intron 23056639 rs644234 chr9 136142217 T G 1.23E-09 Metabolite levels ABO intron 23281178 rs644234 chr9 136142217 T G 1.10E-49 End-stage coagulation ABO intron 23381943 rs643434 chr9 136142355 G A 1.64E-08 Cardiovascular disease risk factors ABO intron 21239051 rs643434 chr9 136142355 G A 4.70E-28 Venous thromboembolism ABO intron 21980494 rs643434 chr9 136142355 G A 9.00E-25 Inflammatory biomarkers ABO intron 22291609 rs643434 chr9 136142355 G A 1.16E-12 Venous thromboembolism ABO intron 22672568 rs643434 chr9 136142355 G A 3.35E-28 Venous thrombosis ABO intron 22675575 rs643434 chr9 136142355 G A 5.65E-18 Protein biomarker ABO intron 23056639 rs643434 chr9 136142355 G A 1.23E-09 Metabolite levels ABO intron 23281178 rs643434 chr9 136142355 G A 1.00E-49 End-stage coagulation ABO intron 23381943 rs543040 chr9 136143000 A T 4.56E-34 Venous thrombosis ABO intron 22675575 rs613534 chr9 136143120 A G 6.58E-23 Venous thrombosis ABO intron 22675575 rs543968 chr9 136143121 T C 2.23E-24 Venous thrombosis ABO intron 22675575 rs544873 chr9 136143212 G A 3.20E-28 Venous thrombosis ABO intron 22675575 rs545971 chr9 136143372 C T 8.96E-09 Cardiovascular disease risk factors ABO intron 21239051 rs545971 chr9 136143372 C T 2.59E-34 Venous thromboembolism ABO intron 21980494 rs545971 chr9 136143372 C T 8.99E-20 Inflammatory biomarkers ABO intron 22291609 rs545971 chr9 136143372 C T 6.38E-14 Venous thromboembolism ABO intron 22672568 rs545971 chr9 136143372 C T 1.64E-34 Venous thrombosis ABO intron 22675575 rs545971 chr9 136143372 C T 8.82E-18 Protein biomarker ABO intron 23056639 rs545971 chr9 136143372 C T 7.26E-07 Red blood cell traits ABO intron 23222517 rs545971 chr9 136143372 C T 4.45E-10 Metabolite levels ABO intron 23281178 rs545971 chr9 136143372 C T 2.27E-55 End-stage coagulation ABO intron 23381943 rs612169 chr9 136143442 A G 3.66E-08 Cardiovascular disease risk factors ABO intron 21239051 rs612169 chr9 136143442 A G 9.00E-40 Metabolic traits ABO intron 21886157 rs612169 chr9 136143442 A G 2.39E-34 Venous thromboembolism ABO intron 21980494 rs612169 chr9 136143442 A G 8.99E-20 Inflammatory biomarkers ABO intron 22291609 rs612169 chr9 136143442 A G 7.21E-14 Venous thromboembolism ABO intron 22672568 rs612169 chr9 136143442 A G 3.24E-34 Venous thrombosis ABO intron 22675575 rs612169 chr9 136143442 A G 8.92E-18 Protein biomarker ABO intron 23056639 rs612169 chr9 136143442 A G 7.85E-07 Red blood cell traits ABO intron 23222517 rs612169 chr9 136143442 A G 4.45E-10 Metabolite levels ABO intron 23281178 rs612169 chr9 136143442 A G 2.27E-55 End-stage coagulation ABO intron 23381943 rs8176668 chr9 136144059 A T 7.75E-11 Venous thrombosis ABO intron 22675575 rs597988 chr9 136144284 T A 8.88E-34 Venous thrombosis ABO intron 22675575 rs597974 chr9 136144297 A G 1.56E-33 Venous thrombosis ABO intron 22675575 rs576125 chr9 136144309 G A 3.54E-33 Venous thrombosis ABO intron 22675575 rs8176663 chr9 136144427 T C 5.27E-34 Venous thrombosis ABO intron 22675575 rs488775 chr9 136144534 G A 7.73E-09 Venous thrombosis ABO intron 22675575 rs7036642 chr9 136144626 G A 7.37E-11 Venous thrombosis ABO intron 22675575 rs596141 chr9 136144689 T G 1.99E-09 Venous thrombosis ABO intron 22675575 rs491626 chr9 136144873 C T 6.98E-35 Venous thrombosis ABO intron 22675575 rs492488 chr9 136144960 G A 1.29E-34 Venous thrombosis ABO intron 22675575 rs493246 chr9 136144994 G A 1.29E-34 Venous thrombosis ABO intron 22675575 rs494242 chr9 136145118 C T 2.51E-28 Venous thrombosis ABO intron 22675575 rs495203 chr9 136145240 C T 1.29E-34 Venous thrombosis ABO intron 22675575 rs582118 chr9 136145471 A G 1.29E-34 Venous thrombosis ABO intron 22675575 rs582094 chr9 136145484 A T 1.29E-34 Venous thrombosis ABO intron 22675575 rs2769071 chr9 136145974 A G 4.30E-34 Venous thrombosis ABO intron 22675575 rs677355 chr9 136146046 G A 3.05E-34 Venous thrombosis ABO intron 22675575 rs676457 chr9 136146227 A T 4.30E-34 Venous thrombosis ABO intron 22675575 rs527210 chr9 136146431 C T 6.79E-33 Venous thrombosis ABO intron 22675575 rs675201 chr9 136146466 A G 7.10E-09 Venous thrombosis ABO intron 22675575 rs550057 chr9 136146597 C T 1.81E-24 Venous thrombosis ABO intron 22675575 rs674302 chr9 136146664 T A 9.59E-09 Cardiovascular disease risk factors ABO intron 21239051 rs674302 chr9 136146664 T A 2.58E-34 Venous thromboembolism ABO intron 21980494 rs674302 chr9 136146664 T A 8.41E-20 Inflammatory biomarkers ABO intron 22291609 rs674302 chr9 136146664 T A 8.14E-14 Venous thromboembolism ABO intron 22672568 rs674302 chr9 136146664 T A 8.13E-35 Venous thrombosis ABO intron 22675575 rs674302 chr9 136146664 T A 8.37E-18 Protein biomarker ABO intron 23056639 rs674302 chr9 136146664 T A 9.60E-07 Red blood cell traits ABO intron 23222517 rs674302 chr9 136146664 T A 4.45E-10 Metabolite levels ABO intron 23281178 rs674302 chr9 136146664 T A 2.17E-55 End-stage coagulation ABO intron 23381943 rs551100 chr9 136146740 T C 7.10E-09 Venous thrombosis ABO intron 22675575 rs663054 chr9 136146920 T G 1.08E-11 Venous thrombosis ABO intron 22675575 rs7046674 chr9 136147012 C T 1.02E-10 Venous thrombosis ABO intron 22675575 rs554833 chr9 136147160 C T 1.19E-34 Venous thrombosis ABO intron 22675575 rs8176649 chr9 136147295 G A 4.89E-11 Venous thrombosis ABO intron 22675575 rs660340 chr9 136147553 A G 1.13E-06 Venous thromboembolism ABO intron 22672568 rs660340 chr9 136147553 A G 9.88E-21 Venous thrombosis ABO intron 22675575 rs581107 chr9 136147702 C T 1.94E-20 Venous thrombosis ABO intron 22675575 rs659104 chr9 136147823 T G 1.28E-06 Venous thromboembolism ABO intron 22672568 rs659104 chr9 136147823 T G 9.90E-21 Venous thrombosis ABO intron 22675575 rs647800 chr9 136148000 A G 2.09E-17 Venous thrombosis ABO intron 22675575 rs473533 chr9 136148035 T C 1.69E-20 Venous thrombosis ABO intron 22675575 rs475419 chr9 136148231 C T 2.55E-20 Venous thrombosis ABO intron 22675575 rs476410 chr9 136148368 G C 2.55E-20 Venous thrombosis ABO intron 22675575 rs500498 chr9 136148647 T C 8.00E-33 Soluble ICAM-1 ABO intron 21533024 rs500498 chr9 136148647 T C 2.70E-20 Venous thrombosis ABO intron 22675575 rs500498 chr9 136148647 T C 5.36E-14 End-stage coagulation ABO intron 23381943 rs500499 chr9 136148648 G C 2.70E-20 Venous thrombosis ABO intron 22675575 rs505922 chr9 136149229 T C 7.00E-40 Protein quantitative trait loci ABO intron 18464913 rs505922 chr9 136149229 T C 4.00E-15 Venous thromboembolism ABO intron 19278955 rs505922 chr9 136149229 T C 5.00E-08 Pancreatic cancer ABO intron 19648918 rs505922 chr9 136149229 T C 5.00E-08 Nasopharyngeal carcinoma ABO intron 20512145 rs505922 chr9 136149229 T C 1.03E-08 Cardiovascular disease risk factors ABO intron 21239051 rs505922 chr9 136149229 T C 3.90E-52 Soluble ICAM-1 ABO intron 21533024 rs505922 chr9 136149229 T C 8.00E-06 Graves' disease ABO intron 21841780 rs505922 chr9 136149229 T C 7.00E-04 Pancreatic cancer ABO intron 21849791 rs505922 chr9 136149229 T C 1.00E-34 Venous thromboembolism ABO intron 21980494 rs505922 chr9 136149229 T C 7.71E-20 Inflammatory biomarkers ABO intron 22291609 rs505922 chr9 136149229 T C 1.00E-10 Duodenal ulcer ABO intron 22387998 rs505922 chr9 136149229 T C 1.00E-300 ABO system O blood type ABO intron 22611595 rs505922 chr9 136149229 T C 9.39E-14 Venous thromboembolism ABO intron 22672568 rs505922 chr9 136149229 T C 1.61E-34 Venous thrombosis ABO intron 22675575 rs505922 chr9 136149229 T C 8.43E-18 Protein biomarker ABO intron 23056639 rs505922 chr9 136149229 T C 3.80E-09 Insulin processing and secretion ABO intron 23263489 rs505922 chr9 136149229 T C 4.45E-10 Metabolite levels ABO intron 23281178 rs505922 chr9 136149229 T C 5.00E-57 End-stage coagulation ABO intron 23381943 rs505922 chr9 136149229 T C 2.00E-10 Graves' disease ABO intron 23612905 rs505922 chr9 136149229 T C 2.32E-08 Malaria ABO intron 23717212 rs505922 chr9 136149229 T C 2.48E-06 Pancreatic cancer ABO intron pha002874 rs505922 chr9 136149229 T C 3.77E-08 Pancreatic cancer ABO intron pha002889 rs507666 chr9 136149399 G A,C,T 5.00E-29 Soluble ICAM-1 ABO intron 18604267 rs507666 chr9 136149399 G A,C,T 1.00E-09 Lipid levels ABO intron 19936222 rs507666 chr9 136149399 G A,C,T 2.49E-13 Lipid levels ABO intron 19936222 rs507666 chr9 136149399 G A,C,T 4.40E-08 Lipid levels ABO intron 19936222 rs507666 chr9 136149399 G A,C,T 4.50E-10 Lipid levels ABO intron 19936222 rs507666 chr9 136149399 G A,C,T 5.30E-13 Lipid levels ABO intron 19936222 rs507666 chr9 136149399 G A,C,T 7.65E-10 Lipid levels ABO intron 19936222 rs507666 chr9 136149399 G A,C,T 3.00E-91 Soluble ICAM-1 ABO intron 21533024 rs507666 chr9 136149399 G A,C,T 5.57E-29 Venous thrombosis ABO intron 22675575 rs507666 chr9 136149399 G A,C,T 2.07E-07 Obesity-related traits ABO intron 23251661 rs507666 chr9 136149399 G A,C,T 9.75E-19 Tumor biomarkers ABO intron 23300138 rs507666 chr9 136149399 G A,C,T 2.00E-11 Lipid traits ABO intron 24386095 rs507666 chr9 136149399 G A,C,T 4.00E-11 Lipid traits ABO intron 24386095 rs507666 chr9 136149399 G A,C,T 7.39E-19 Elevated serum carcinoembryonic antigen levels ABO intron 24941225 rs529565 chr9 136149500 T C 1.08E-08 Cardiovascular disease risk factors ABO intron 21239051 rs529565 chr9 136149500 T C 1.39E-34 Venous thromboembolism ABO intron 21980494 rs529565 chr9 136149500 T C 6.25E-05 Hypertension (essential hypertension) ABO intron 22184326 rs529565 chr9 136149500 T C 3.85E-20 Inflammatory biomarkers ABO intron 22291609 rs529565 chr9 136149500 T C 9.45E-14 Venous thromboembolism ABO intron 22672568 rs529565 chr9 136149500 T C 4.96E-35 Venous thrombosis ABO intron 22675575 rs529565 chr9 136149500 T C 8.57E-18 Protein biomarker ABO intron 23056639 rs529565 chr9 136149500 T C 7.21E-07 Red blood cell traits ABO intron 23222517 rs529565 chr9 136149500 T C 4.45E-10 Metabolite levels ABO intron 23281178 rs529565 chr9 136149500 T C 5.05E-56 End-stage coagulation ABO intron 23381943 rs630510 chr9 136149581 A G 2.86E-19 Venous thrombosis ABO intron 22675575 rs630014 chr9 136149722 A G 1.50E-22 Soluble ICAM-1 ABO intron 21533024 rs630014 chr9 136149722 A G 6.72E-87 vWF levels,in plasma ABO intron 21534939 rs630014 chr9 136149722 A G 7.10E-05 Graves' disease ABO intron 21841780 rs630014 chr9 136149722 A G 2.54E-19 Venous thromboembolism ABO intron 21980494 rs630014 chr9 136149722 A G 1.08E-09 Inflammatory biomarkers ABO intron 22291609 rs630014 chr9 136149722 A G 3.85E-08 Venous thromboembolism ABO intron 22672568 rs630014 chr9 136149722 A G 3.02E-19 Venous thrombosis ABO intron 22675575 rs630014 chr9 136149722 A G 2.81E-08 Protein biomarker ABO intron 23056639 rs630014 chr9 136149722 A G 0.000000116 Cholesterol,total ABO intron 23063622 rs630014 chr9 136149722 A G 0.000000445 LDL cholesterol ABO intron 23063622 rs630014 chr9 136149722 A G 3.70E-08 Red blood cell traits ABO intron 23222517 rs630014 chr9 136149722 A G 5.99E-24 End-stage coagulation ABO intron 23381943 rs630014 chr9 136149722 A G 2.40E-18 Urinary metabolites (H-NMR features) ABO intron 24586186 rs630014 chr9 136149722 A G 8.59E-04 Myocardial infarction ABO intron 24916648 rs630014 chr9 136149722 A G 4.28E-05 Pancreatic cancer ABO intron pha002874 rs630014 chr9 136149722 A G 4.70E-06 Pancreatic cancer ABO intron pha002889 rs532436 chr9 136149830 G A 5.57E-29 Venous thrombosis ABO intron 22675575 rs537895 chr9 136150403 A G 6.26E-09 Venous thrombosis ABO intron 22675575 rs616154 chr9 136150466 C T 2.86E-19 Venous thrombosis ABO intron 22675575 rs559723 chr9 136150484 A G 1.00E-18 Venous thrombosis ABO intron 22675575 rs566183 chr9 136151198 A G 6.02E-09 Venous thrombosis ABO nearGene-5 22675575 rs568203 chr9 136151445 A C 1.40E-12 Soluble ICAM-1 ABO nearGene-5 21533024 rs568203 chr9 136151445 A C 4.83E-09 Venous thromboembolism ABO nearGene-5 21980494 rs568203 chr9 136151445 A C 6.02E-09 Venous thrombosis ABO nearGene-5 22675575 rs568203 chr9 136151445 A C 2.08E-08 End-stage coagulation ABO nearGene-5 23381943 rs600038 chr9 136151806 T C 6.90E-22 Venous thrombosis ABO nearGene-5 22675575 rs8176635 chr9 136152009 G A 1.50E-12 Soluble ICAM-1 ABO nearGene-5 21533024 rs8176634 chr9 136152070 G C 1.30E-09 Soluble ICAM-1 ABO nearGene-5 21533024 rs663367 chr9 136153451 A G 7.55E-09 Venous thrombosis / / 22675575 rs552148 chr9 136153481 T C 4.51E-09 Venous thromboembolism / / 21980494 rs552148 chr9 136153481 T C 7.85E-06 Obesity-related traits / / 23251661 rs552148 chr9 136153481 T C 1.92E-08 End-stage coagulation / / 23381943 rs651007 chr9 136153875 C T 2.00E-82 E-selectin levels / / 20147318 rs651007 chr9 136153875 C T 2.36E-13 Coronary heart disease / / 21378990 rs651007 chr9 136153875 C T 1.35E-161 vWF levels,in plasma / / 21534939 rs651007 chr9 136153875 C T 6.00E-09 Metabolite levels / / 21909109 rs651007 chr9 136153875 C T 1.30E-07 Coronary heart disease / / 21966275 rs651007 chr9 136153875 C T 8.96E-21 Venous thromboembolism / / 21980494 rs651007 chr9 136153875 C T 3.35E-12 Inflammatory biomarkers / / 22291609 rs651007 chr9 136153875 C T 2.20E-14 Venous thromboembolism / / 22672568 rs651007 chr9 136153875 C T 1.45E-21 Venous thrombosis / / 22675575 rs651007 chr9 136153875 C T 7.10E-11 Cholesterol,total / / 23063622 rs651007 chr9 136153875 C T 5.97E-09 Activated partial thromboplastin time / / 23188048 rs651007 chr9 136153875 C T 3.82E-14 Red blood cell traits / / 23222517 rs651007 chr9 136153875 C T 1.31E-09 Metabolite levels / / 23281178 rs651007 chr9 136153875 C T 2.12E-18 Tumor biomarkers / / 23300138 rs651007 chr9 136153875 C T 2.12E-18 Type 2 diabetes / / 23300278 rs651007 chr9 136153875 C T 2.00E-25 End-stage coagulation / / 23381943 rs651007 chr9 136153875 C T 1.00E-56 Serum alkaline phosphatase levels / / 24094242 rs651007 chr9 136153875 C T 6.00E-20 Blood metabolite levels / / 24816252 rs11244061 chr9 136153981 C T 3.20E-14 Venous thrombosis / / 22675575 rs579459 chr9 136154168 T C 1.00E-29 Soluble E-selectin levels / / 19729612 rs579459 chr9 136154168 T C 2.00E-41 Soluble levels of adhesion molecules / / 20167578 rs579459 chr9 136154168 T C 4.00E-14 Coronary heart disease / / 21378990 rs579459 chr9 136154168 T C 3.34E-21 Venous thromboembolism / / 21980494 rs579459 chr9 136154168 T C 3.00E-123 Liver enzyme levels (alkaline phosphatase) / / 22001757 rs579459 chr9 136154168 T C 3.63E-13 Inflammatory biomarkers / / 22291609 rs579459 chr9 136154168 T C 4.08E-14 Pericardial fat / / 22589742 rs579459 chr9 136154168 T C 3.85E-16 Venous thromboembolism / / 22672568 rs579459 chr9 136154168 T C 1.45E-21 Venous thrombosis / / 22675575 rs579459 chr9 136154168 T C 1.91E-10 Protein biomarker / / 23056639 rs579459 chr9 136154168 T C 0.000000217 Coronary artery disease with myocardial infarction / / 23202125 rs579459 chr9 136154168 T C 0.000122 Coronary artery disease (CAD) age <=50 / / 23202125 rs579459 chr9 136154168 T C 0.000215 Coronary artery disease (CAD) age >50 / / 23202125 rs579459 chr9 136154168 T C 2.36E-21 LDL cholesterol / / 23202125 rs579459 chr9 136154168 T C 2.82E-08 Coronary artery disease (CAD) (males) / / 23202125 rs579459 chr9 136154168 T C 4.03E-20 Cholesterol,total / / 23202125 rs579459 chr9 136154168 T C 9.00E-18 Red blood cell traits / / 23222517 rs579459 chr9 136154168 T C 1.66E-07 Obesity-related traits / / 23251661 rs579459 chr9 136154168 T C 3.08E-10 Metabolite levels / / 23281178 rs579459 chr9 136154168 T C 3.00E-21 Tumor biomarkers / / 23300138 rs579459 chr9 136154168 T C 3.00E-21 Type 2 diabetes / / 23300278 rs579459 chr9 136154168 T C 9.85E-13 End-stage coagulation / / 23381943 rs579459 chr9 136154168 T C 1.77E-04 Self-reported allergy / / 23817569 rs579459 chr9 136154168 T C 2.00E-07 Coronary artery disease / / 24262325 rs579459 chr9 136154168 T C 2.00E-09 Coronary artery disease or ischemic stroke / / 24262325 rs579459 chr9 136154168 T C 2.60E-04 Stroke (ischemic) / / 24262325 rs579459 chr9 136154168 T C 3.00E-08 Coronary artery disease or large artery stroke / / 24262325 rs579459 chr9 136154168 T C 1.00E-28 Urinary metabolites (H-NMR features) / / 24586186 rs579459 chr9 136154168 T C 2.00E-32 Urinary metabolites (H-NMR features) / / 24586186 rs579459 chr9 136154168 T C 1.00E-28 Blood metabolite ratios / / 24816252 rs579459 chr9 136154168 T C 4.44E-19 Elevated serum carcinoembryonic antigen levels / / 24941225 rs9411488 chr9 136154246 G T 3.20E-13 Protein biomarker / / 23056639 rs9411488 chr9 136154246 G T 4.73E-09 End-stage coagulation / / 23381943 rs649129 chr9 136154304 C A,G,T 1.00E-15 Soluble levels of adhesion molecules / / 20167578 rs649129 chr9 136154304 C A,G,T 3.56E-21 Venous thromboembolism / / 21980494 rs649129 chr9 136154304 C A,G,T 7.81E-13 Inflammatory biomarkers / / 22291609 rs649129 chr9 136154304 C A,G,T 2.94E-16 Venous thromboembolism / / 22672568 rs649129 chr9 136154304 C A,G,T 1.17E-21 Venous thrombosis / / 22675575 rs649129 chr9 136154304 C A,G,T 1.74E-10 Protein biomarker / / 23056639 rs649129 chr9 136154304 C A,G,T 1.46E-15 Red blood cell traits / / 23222517 rs649129 chr9 136154304 C A,G,T 3.08E-10 Metabolite levels / / 23281178 rs649129 chr9 136154304 C A,G,T 3.13E-21 Tumor biomarkers / / 23300138 rs649129 chr9 136154304 C A,G,T 3.13E-21 Type 2 diabetes / / 23300278 rs649129 chr9 136154304 C A,G,T 9.91E-13 End-stage coagulation / / 23381943 rs649129 chr9 136154304 C A,G,T 1.68E-04 Self-reported allergy / / 23817569 rs649129 chr9 136154304 C A,G,T 9.00E-37 Blood metabolite ratios / / 24816252 rs495828 chr9 136154867 G T 3.00E-08 Angiotensin-converting enzyme activity / / 20066004 rs495828 chr9 136154867 G T 1.18E-11 Blood cell counts and other traits / / 20139978 rs495828 chr9 136154867 G T 3.33E-12 Blood cell counts and other traits / / 20139978 rs495828 chr9 136154867 G T 4.00E-59 Blood cell counts and other traits / / 20139978 rs495828 chr9 136154867 G T 4.23E-59 Blood cell counts and other traits / / 20139978 rs495828 chr9 136154867 G T 6.06E-10 Blood cell counts and other traits / / 20139978 rs495828 chr9 136154867 G T 4.00E-21 Venous thromboembolism / / 21980494 rs495828 chr9 136154867 G T 1.30E-12 Inflammatory biomarkers / / 22291609 rs495828 chr9 136154867 G T 3.00E-16 Venous thromboembolism / / 22672568 rs495828 chr9 136154867 G T 1.59E-21 Venous thrombosis / / 22675575 rs495828 chr9 136154867 G T 1.94E-10 Protein biomarker / / 23056639 rs495828 chr9 136154867 G T 1.59E-15 Red blood cell traits / / 23222517 rs495828 chr9 136154867 G T 3.08E-10 Metabolite levels / / 23281178 rs495828 chr9 136154867 G T 1.83E-21 Tumor biomarkers / / 23300138 rs495828 chr9 136154867 G T 1.83E-21 Type 2 diabetes / / 23300278 rs495828 chr9 136154867 G T 9.41E-13 End-stage coagulation / / 23381943 rs495828 chr9 136154867 G T 1.82E-04 Self-reported allergy / / 23817569 rs495828 chr9 136154867 G T 6.00E-34 Blood metabolite ratios / / 24816252 rs635634 chr9 136155000 C T 8.00E-22 LDL cholesterol / / 20686565 rs635634 chr9 136155000 C T 9.00E-21 Cholesterol,total / / 20686565 rs635634 chr9 136155000 C T 6.03E-28 Venous thromboembolism / / 21980494 rs635634 chr9 136155000 C T 1.50E-28 Venous thrombosis / / 22675575 rs635634 chr9 136155000 C T 2.68E-10 Protein biomarker / / 23056639 rs635634 chr9 136155000 C T 4.07E-11 Metabolite levels / / 23281178 rs635634 chr9 136155000 C T 2.00E-41 LDL cholesterol / / 24097068 rs635634 chr9 136155000 C T 3.00E-35 Cholesterol,total / / 24097068 rs12683493 chr9 136155063 C T 1.30E-08 End-stage coagulation / / 23381943 rs13298002 chr9 136155127 G A 3.25E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs13298002 chr9 136155127 G A 1.22E-10 Protein biomarker / / 23056639 rs500428 chr9 136155343 A G 2.16E-09 Venous thromboembolism / / 21980494 rs500428 chr9 136155343 A G 7.17E-09 Venous thrombosis / / 22675575 rs7030248 chr9 136155359 G A 8.35E-07 Red blood cell traits / / 23222517 rs7030248 chr9 136155359 G A 4.21E-22 Tumor biomarkers / / 23300138 rs7030248 chr9 136155359 G A 4.00E-15 Elevated serum carcinoembryonic antigen levels / / 24941225 rs633862 chr9 136155444 C A,G,T 8.10E-21 Venous thromboembolism / / 21980494 rs633862 chr9 136155444 C A,G,T 1.68E-07 Venous thromboembolism / / 22672568 rs633862 chr9 136155444 C A,G,T 2.44E-20 Venous thrombosis / / 22675575 rs633862 chr9 136155444 C A,G,T 1.75E-06 Obesity-related traits / / 23251661 rs633862 chr9 136155444 C A,G,T 8.04E-24 End-stage coagulation / / 23381943 rs633862 chr9 136155444 C A,G,T 2.40E-18 Urinary metabolites (H-NMR features) / / 24586186 rs633862 chr9 136155444 C A,G,T 5.80E-14 Urinary metabolites (H-NMR features) / / 24586186 rs502361 chr9 136155589 C G 2.22E-09 Venous thromboembolism / / 21980494 rs502361 chr9 136155589 C G 7.07E-09 Venous thrombosis / / 22675575 rs502361 chr9 136155589 C G 2.88E-08 End-stage coagulation / / 23381943 rs9411491 chr9 136156015 T C 2.47E-13 Protein biomarker / / 23056639 rs9411491 chr9 136156015 T C 4.56E-09 End-stage coagulation / / 23381943 rs9411381 chr9 136156067 T C 4.56E-09 End-stage coagulation / / 23381943 rs557317 chr9 136157037 C A 4.98E-12 Venous thrombosis / / 22675575 rs558240 chr9 136157133 G A 5.54E-12 Venous thromboembolism / / 21980494 rs558240 chr9 136157133 G A 6.55E-12 Venous thrombosis / / 22675575 rs176694 chr9 136164593 T G 1.11E-09 Venous thrombosis / / 22675575 rs7025162 chr9 136166346 C T 2.00E-09 Soluble ICAM-1 / / 21533024 rs7025162 chr9 136166346 C T 2.81E-13 Protein biomarker / / 23056639 rs7025162 chr9 136166346 C T 7.12E-10 Tumor biomarkers / / 23300138 rs7025162 chr9 136166346 C T 7.12E-10 Type 2 diabetes / / 23300278 rs7025162 chr9 136166346 C T 3.58E-08 End-stage coagulation / / 23381943 rs7025162 chr9 136166346 C T 3.00E-27 Serum alkaline phosphatase levels / / 24094242 rs624960 chr9 136175051 T C 7.98E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs62574648 chr9 136178623 G A 3.18E-09 Venous thrombosis / / 22675575 rs590485 chr9 136178942 C T 8.20E-05 Metabolic syndrome phenotype / / 22022282 rs62574650 chr9 136179241 G A 2.55E-09 Venous thrombosis / / 22675575 rs62574651 chr9 136179306 C G 2.55E-09 Venous thrombosis / / 22675575 rs62574652 chr9 136179508 G A 2.60E-09 Venous thrombosis / / 22675575 rs117134629 chr9 136179726 A G 2.71E-09 Venous thrombosis / / 22675575 rs62574654 chr9 136179808 G A 2.71E-09 Venous thrombosis / / 22675575 rs62574655 chr9 136179862 G A 2.71E-09 Venous thrombosis / / 22675575 rs62574656 chr9 136180912 G A 2.78E-09 Venous thrombosis / / 22675575 rs554710 chr9 136181848 C T 2.10E-04 Suicidal ideation / / 22030708 rs62574657 chr9 136184312 G T 4.66E-09 Venous thrombosis / / 22675575 rs11244079 chr9 136184526 G A 6.09E-10 Red blood cell traits / / 23222517 rs11244079 chr9 136184526 G A 3.29E-15 End-stage coagulation / / 23381943 rs11244079 chr9 136184526 G A 8.66E-06 Parkinson's disease / / pha002868 rs11789139 chr9 136185324 C G 4.52E-09 Venous thrombosis / / 22675575 rs493014 chr9 136187163 G T 6.00E-11 Venous thromboembolism (gene x gene interaction) / / 23509962 rs10901263 chr9 136192872 G A 6.73E-08 Tumor biomarkers / / 23300138 rs10901263 chr9 136192872 G A 6.60E-04 Thyroid stimulating hormone / / 24852370 rs10751505 chr9 136195374 A G 5.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs886089 chr9 136199466 G A,C,T 6.80E-04 Parkinson's disease SURF6 missense 17052657 rs886090 chr9 136199503 G A 8.29E-04 Parkinson's disease SURF6 missense 17052657 rs2296809 chr9 136227017 G A 2.69E-11 vWF levels,in plasma SURF2 intron 21534939 rs28374096 chr9 136235100 G C 4.66E-04 Response to taxane treatment (placlitaxel) SURF4 intron 23006423 rs56343119 chr9 136237672 C A 5.60E-13 Venous thrombosis SURF4 intron 22675575 rs1179037 chr9 136238509 G A 8.91E-07 Lymphocyte counts SURF4 intron 22286170 rs3758348 chr9 136239399 G C 6.46E-72 vWF levels,in plasma SURF4 intron 21534939 rs3758348 chr9 136239399 G C 3.86E-17 Venous thromboembolism SURF4 intron 21980494 rs3758348 chr9 136239399 G C 1.22E-07 Inflammatory biomarkers SURF4 intron 22291609 rs3758348 chr9 136239399 G C 1.79E-06 Venous thromboembolism SURF4 intron 22672568 rs3758348 chr9 136239399 G C 9.89E-13 Venous thrombosis SURF4 intron 22675575 rs3758348 chr9 136239399 G C 1.41E-11 Red blood cell traits SURF4 intron 23222517 rs17474001 chr9 136267149 C T 7.33E-12 Venous thrombosis C9orf96 intron 22675575 rs3124747 chr9 136268084 A G 2.90E-04 Metabolic syndrome phenotype C9orf96 missense 22022282 rs3124747 chr9 136268084 A G 4.56E-07 Red blood cell traits C9orf96 missense 23222517 rs3124747 chr9 136268084 A G 4.39E-10 End-stage coagulation C9orf96 missense 23381943 rs2285487 chr9 136277482 T C 4.00E-05 Lung cancer REXO4 missense 18978790 rs2285487 chr9 136277482 T C 1.60E-05 Bicuspid aortic valve REXO4 missense 20098615 rs3118663 chr9 136281753 G A 2.45E-04 Stroke ADAMTS13 intron pha002886 rs75039118 chr9 136304461 A G 0.0000219 Menopause (age at onset) ADAMTS13 intron 23424626 rs4962153 chr9 136323754 A G 8.00E-21 Liver enzyme levels ADAMTS13 intron 18940312 rs4962153 chr9 136323754 A G 1.20E-06 Biliary atresia ADAMTS13 intron 20460270 rs4962153 chr9 136323754 A G 5.46E-15 Venous thromboembolism ADAMTS13 intron 21980494 rs4962153 chr9 136323754 A G 9.10E-06 Venous thromboembolism ADAMTS13 intron 22672568 rs4962153 chr9 136323754 A G 7.46E-08 Red blood cell traits ADAMTS13 intron 23222517 rs739468 chr9 136326248 T G 5.38E-15 Venous thromboembolism CACFD1 intron 21980494 rs739468 chr9 136326248 T G 9.28E-06 Venous thromboembolism CACFD1 intron 22672568 rs739468 chr9 136326248 T G 4.11E-07 Red blood cell traits CACFD1 intron 23222517 rs3124765 chr9 136328657 T C,G 8.44E-06 Venous thromboembolism CACFD1 missense 22672568 rs3094379 chr9 136334910 T C 2.56E-07 Red blood cell traits CACFD1 UTR-3 23222517 rs28615587 chr9 136365146 T G 2.00E-04 Polycystic ovary syndrome / / 22178785 rs28666751 chr9 136454105 C T 8.49E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs10821577 chr9 136460220 G A 4.04E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs3025343 chr9 136478355 G A 4.00E-08 Smoking behavior / / 20418890 rs3025343 chr9 136478355 G A 3.60E-08 Smoking behavior / / 22832964 rs1029372 chr9 136478442 G A 5.60E-06 Urinary metabolites / / 21572414 rs1029372 chr9 136478442 G A 3.93E-06 Diabetes Mellitus / / pha003060 rs7867984 chr9 136485598 G A 8.06E-04 Aortic root size / / 21223598 rs1076153 chr9 136498143 G T 6.25E-05 Stroke / / pha002886 rs77273740 chr9 136501728 C T 0.000093 Prostate cancer (advanced) DBH missense 23555315 rs2519155 chr9 136504598 T C 8.06E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) DBH intron 24023788 rs2873804 chr9 136505644 T C 7.98E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) DBH intron 24023788 rs3025393 chr9 136506594 G A 0.00000153 Triglycerides DBH intron 23063622 rs3025393 chr9 136506594 G A 1.86E-09 HDL cholesterol DBH intron 23063622 rs5321 chr9 136507559 G C 1.10E-22 Health and aging,CVD and cancer age of onset DBH missense 22174011 rs5321 chr9 136507559 G C 3.20E-08 Health and aging,CVD and cancer age of onset DBH missense 22174011 rs5321 chr9 136507559 G C 6.20E-08 Health and aging,CVD and cancer age of onset DBH missense 22174011 rs5324 chr9 136508658 G A 0.0000016 HDL cholesterol DBH missense 23063622 rs1611123 chr9 136509083 C T 1.39E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) DBH intron 24023788 rs1611125 chr9 136509312 C T 2.90E-05 vWF levels,in plasma DBH intron 21534939 rs1541332 chr9 136511516 G A 8.04E-05 vWF levels,in plasma DBH intron 21534939 rs129886 chr9 136528721 C T 1.80E-07 Urinary metabolites SARDH UTR-3 21572414 rs2519126 chr9 136550670 C T 7.01E-05 Waist Circumference SARDH intron pha003023 rs129901 chr9 136552263 A G 0.0000383 Amyotrophic lateral sclerosis SARDH intron 23587638 rs129901 chr9 136552263 A G 0.0000417 Amyotrophic lateral sclerosis SARDH intron 23587638 rs886016 chr9 136555629 T C 0.0000407 Amyotrophic lateral sclerosis SARDH missense 23587638 rs886016 chr9 136555629 T C 0.0000445 Amyotrophic lateral sclerosis SARDH missense 23587638 rs2073817 chr9 136559460 C T 0.0000205 Amyotrophic lateral sclerosis SARDH missense 23587638 rs2073817 chr9 136559460 C T 0.00003 Amyotrophic lateral sclerosis SARDH missense 23587638 rs2073817 chr9 136559460 C T 7.94E-05 Waist Circumference SARDH missense pha003023 rs2502740 chr9 136561367 G A 2.61E-04 Obesity (extreme) SARDH cds-synon 21935397 rs10993768 chr9 136563926 C T 2.96E-05 Type 2 diabetes SARDH intron 17463246 rs694821 chr9 136570740 C T 2.70E-05 Obesity (extreme) SARDH intron 21935397 rs7040170 chr9 136586367 A G 1.67E-04 Type 2 diabetes SARDH intron 17463246 rs916620 chr9 136596750 C T 1.91E-04 Attention deficit hyperactivity disorder SARDH intron 22420046 rs147006467 chr9 136599026 C G 0.00015 Prostate cancer SARDH missense 23555315 rs147006467 chr9 136599026 C G 0.00037 Prostate cancer (non-advanced prostate cancer) SARDH missense 23555315 rs642193 chr9 136626906 C A 1.63E-05 Myopia (severe) VAV2 nearGene-3 23933737 rs622035 chr9 136632662 A C 8.78E-04 Parkinson's disease VAV2 intron 17052657 rs669443 chr9 136641713 C T 4.00E-05 Adiposity VAV2 intron 19461586 rs602990 chr9 136643994 T C 1.00E-04 Information processing speed VAV2 missense 21130836 rs2073888 chr9 136658816 T C 0.0000736 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes VAV2 intron 22628534 rs10993803 chr9 136658987 C T 0.0000736 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes VAV2 intron 22628534 rs7021663 chr9 136676014 T C 3.00E-06 IgG glycosylation VAV2 intron 23382691 rs756777 chr9 136679080 A G 1.00E-06 IgG glycosylation VAV2 intron 23382691 rs12344583 chr9 136723520 A G 8.00E-06 vWF and FVIII levels VAV2 intron 21810271 rs12115818 chr9 136745163 G A 6.56E-05 Multiple complex diseases VAV2 intron 17554300 rs2073883 chr9 136754076 C T 4.90E-06 Urinary metabolites VAV2 intron 21572414 rs2810545 chr9 136759046 A C 1.44E-05 Age-related macular degeneration VAV2 intron pha000001 rs2157834 chr9 136767301 A C 1.00E-04 Information processing speed VAV2 intron 21130836 rs2157835 chr9 136767346 G T 1.00E-04 Information processing speed VAV2 intron 21130836 rs2265520 chr9 136790282 T C 3.81E-04 Fibrinogen VAV2 intron 17255346 rs2519818 chr9 136797140 G A 9.96E-06 Type 2 diabetes VAV2 intron 17463246 rs2519808 chr9 136802291 A T 4.48E-04 Aortic root size VAV2 intron 21223598 rs3780786 chr9 136816065 C G 1.23E-24 Narcolepsy VAV2 intron 19629137 rs3780792 chr9 136835343 A G 1.00E-06 Multiple sclerosis VAV2 intron 20598377 rs3847320 chr9 136906752 G A 2.93E-04 Alzheimer's disease (late onset) BRD3 intron 21379329 rs12345376 chr9 136919523 A G 7.15E-05 Multiple complex diseases BRD3 intron 17554300 rs2810489 chr9 136922700 G A 2.50E-05 Urinary metabolites BRD3 intron 21572414 rs11789898 chr9 136925663 G T 2.00E-10 Platelet counts BRD3 intron 22139419 rs10993907 chr9 136928644 T C 1.59E-04 Self-reported allergy BRD3 intron 23817569 rs10821544 chr9 136933982 C G 2.02E-04 Self-reported allergy / / 23817569 rs734500 chr9 136937514 G T 2.08E-04 Self-reported allergy / / 23817569 rs2078778 chr9 136938961 G A 2.14E-04 Self-reported allergy / / 23817569 rs2078779 chr9 136939231 C G 2.29E-04 Self-reported allergy / / 23817569 rs7872110 chr9 137098042 T C 8.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs7027150 chr9 137103126 T C 9.98E-04 Alzheimer's disease / / 17998437 rs7043538 chr9 137109051 C T 8.14E-05 Bipolar disorder / / 20451256 rs7873963 chr9 137112655 T C 5.42E-05 Cognitive impairment induced by topiramate / / 22091778 rs7873963 chr9 137112655 T C 7.49E-06 Cognitive impairment induced by topiramate / / 22091778 rs7028191 chr9 137117496 C T 0.0002 Migraine / / 22678113 rs7848481 chr9 137120661 T C 8.60E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs10785877 chr9 137125501 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10785877 chr9 137125501 G A 7.00E-07 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs1889151 chr9 137160637 T G 8.21E-05 Coronary heart disease / / pha003055 rs1889151 chr9 137160637 T G 9.83E-05 Triglycerides / / pha003080 rs1930788 chr9 137163718 C T 2.10E-05 Urinary metabolites / / 21572414 rs1930788 chr9 137163718 C T 4.38E-05 Triglycerides / / pha003080 rs4917350 chr9 137230790 C G 2.70E-05 Urinary metabolites RXRA intron 21572414 rs4917352 chr9 137232030 T C 2.00E-05 Urinary metabolites RXRA intron 21572414 rs12351482 chr9 137261632 C T 2.11E-04 Smoking initiation RXRA intron 24665060 rs34312136 chr9 137269456 T C 8.00E-08 Intelligence RXRA intron 22449649 rs34090729 chr9 137293845 C T 1.27E-22 Cholesterol,total RXRA intron 23063622 rs34090729 chr9 137293845 C T 1.96E-11 Triglycerides RXRA intron 23063622 rs34090729 chr9 137293845 C T 1.97E-18 LDL cholesterol RXRA intron 23063622 rs34090729 chr9 137293845 C T 3.12E-26 HDL cholesterol RXRA intron 23063622 rs10125024 chr9 137298977 C T 0.000000514 Triglycerides RXRA intron 23063622 rs34186206 chr9 137301904 C T 0.000000614 Triglycerides RXRA intron 23063622 rs35738419 chr9 137303790 C T 1.01E-30 HDL cholesterol RXRA intron 23063622 rs35738419 chr9 137303790 C T 1.88E-11 LDL cholesterol RXRA intron 23063622 rs35738419 chr9 137303790 C T 6.75E-25 Cholesterol,total RXRA intron 23063622 rs10120653 chr9 137307083 G T 1.01E-12 Triglycerides RXRA intron 23063622 rs10120653 chr9 137307083 G T 5.64E-12 HDL cholesterol RXRA intron 23063622 rs34986018 chr9 137325462 G A 1.37E-08 HDL cholesterol RXRA intron 23063622 rs1045570 chr9 137332311 T G 6.05E-04 Amyotrophic Lateral Sclerosis RXRA UTR-3 17362836 rs3118526 chr9 137337357 T C 1.07E-05 Coronary heart disease / / pha003056 rs3132288 chr9 137341498 G A 7.41E-04 Response to TNF antagonist treatment / / 21061259 rs11103603 chr9 137341600 T C 4.07E-05 Alcohol consumption / / 23743675 rs9409930 chr9 137342468 T C 6.65E-05 Alcohol consumption / / 23743675 rs9409931 chr9 137342757 T C 1.05E-04 Alcohol consumption / / 23743675 rs4565533 chr9 137345126 G A 5.88E-05 Alzheimer's disease / / 24755620 rs3118545 chr9 137348592 G T 8.48E-04 Heart Failure / / pha002885 rs7033624 chr9 137352272 G A 3.75E-05 Smoking initiation / / 24665060 rs3118548 chr9 137353294 A G 4.07E-04 Alzheimer's disease / / 24755620 rs875434 chr9 137353696 C T 7.03E-05 Type 2 diabetes / / 17463246 rs3118549 chr9 137353958 A G 6.15E-04 Alzheimer's disease / / 24755620 rs3118551 chr9 137354604 T C 7.51E-04 Alzheimer's disease / / 24755620 rs3132278 chr9 137360240 T C 8.18E-04 Alzheimer's disease / / 24755620 rs7033608 chr9 137373598 T C 6.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4842022 chr9 137408941 G A 1.11E-04 Multiple complex diseases / / 17554300 rs1536479 chr9 137412655 A G 7.24E-05 Bipolar disorder / / 18317468 rs1536479 chr9 137412655 A G 1.78E-06 Central corneal thickness / / 21098505 rs2148702 chr9 137422319 G A 1.91E-06 Central corneal thickness LOC100506532 intron 21098505 rs4841895 chr9 137424042 G A 8.00E-07 Blood pressure LOC100506532 intron 24954895 rs3118593 chr9 137426334 C A 2.36E-06 Central corneal thickness LOC100506532 intron 21098505 rs1006418 chr9 137426935 G A 1.73E-06 Type 2 diabetes LOC100506532 intron 21573907 rs1409832 chr9 137428425 T G 2.30E-08 Central corneal thickness LOC100506532 intron 21098505 rs4842040 chr9 137430010 G A 2.55E-06 Central corneal thickness LOC100506532 intron 21098505 rs4842044 chr9 137431904 C T 2.53E-09 Central corneal thickness LOC100506532 intron 21098505 rs3132307 chr9 137436214 G C 1.27E-04 Bipolar disorder LOC100506532 intron 18317468 rs3118515 chr9 137436314 G A 8.00E-10 Central corneal thickness LOC100506532 intron 23493294 rs943423 chr9 137437183 G A 1.17E-05 Platelet counts / / pha003100 rs3118516 chr9 137439792 G A 9.49E-07 Central corneal thickness / / 20719862 rs3118516 chr9 137439792 G A 1.94E-19 Corneal structure / / 23291589 rs3132306 chr9 137440212 T C 9.40E-07 Central corneal thickness / / 20719862 rs3132306 chr9 137440212 T C 3.00E-10 Central corneal thickness / / 22814818 rs3132306 chr9 137440212 T C 8.89E-20 Corneal structure / / 23291589 rs1536482 chr9 137440528 G A 9.29E-07 Central corneal thickness / / 20719862 rs1536482 chr9 137440528 G A 4.62E-09 Central corneal thickness / / 21098505 rs1536482 chr9 137440528 G A 4.40E-10 Central corneal thickness / / 22814818 rs1536482 chr9 137440528 G A 3.00E-22 Corneal structure / / 23291589 rs1536482 chr9 137440528 G A 6.00E-08 Central corneal thickness / / 23493294 rs1536483 chr9 137440684 C T 2.05E-06 Central corneal thickness / / 20719862 rs1536484 chr9 137440708 G C 6.19E-07 Central corneal thickness / / 20719862 rs3118520 chr9 137441595 A G 2.66E-07 Central corneal thickness / / 20719862 rs3118520 chr9 137441595 A G 3.37E-20 Corneal structure / / 23291589 rs11103407 chr9 137477402 G A 1.68E-04 Multiple complex diseases / / 17554300 rs11103429 chr9 137506578 A G 6.00E-06 Crohn's disease (need for surgery) / / 23665963 rs4424343 chr9 137515158 G A 7.88E-05 Coronary heart disease / / pha003030 rs11103451 chr9 137529221 T C 2.00E-04 Information processing speed / / 21130836 rs6537942 chr9 137559556 A G 6.85E-11 Corneal structure COL5A1 intron 23291589 rs7044529 chr9 137568051 C T 9.30E-06 Central corneal thickness COL5A1 intron 20485516 rs7044529 chr9 137568051 C T 5.00E-08 Central corneal thickness COL5A1 intron 20719862 rs7044529 chr9 137568051 C T 1.50E-09 Central corneal thickness COL5A1 intron 21098505 rs7044529 chr9 137568051 C T 5.00E-12 Corneal structure COL5A1 intron 23291589 rs12554842 chr9 137573407 C T 4.54E-09 Corneal structure COL5A1 intron 23291589 rs12554098 chr9 137573609 G A 2.57E-10 Corneal structure COL5A1 intron 23291589 rs4077962 chr9 137585003 C A 6.65E-05 Tunica Media COL5A1 intron pha003038 rs3922982 chr9 137586995 T C 5.88E-04 Type 2 diabetes COL5A1 intron 17463246 rs4341231 chr9 137592961 T C 6.02E-04 Response to taxane treatment (placlitaxel) COL5A1 intron 23006423 rs4341231 chr9 137592961 T C 2.85E-04 Self-reported allergy COL5A1 intron 23817569 rs7028769 chr9 137594233 C T 0.00007164 Sarcoidosis COL5A1 intron 22952805 rs6537946 chr9 137594494 G A 9.50E-05 Diabetic retinopathy COL5A1 intron 21441570 rs4529530 chr9 137594829 C T 8.90E-04 Diabetic nephropathy COL5A1 intron 20347642 rs4529530 chr9 137594829 C T 9.70E-05 Diabetic retinopathy COL5A1 intron 21441570 rs3109671 chr9 137595066 C T 1.20E-05 Urinary metabolites COL5A1 intron 21572414 rs4240703 chr9 137595928 A G 2.21E-05 Colorectal cancer COL5A1 intron 21242260 rs3935335 chr9 137596166 G A 1.85E-05 Colorectal cancer COL5A1 intron 21242260 rs4841926 chr9 137601285 C T 7.07E-06 Colorectal cancer COL5A1 intron 21242260 rs3128591 chr9 137602119 G A 1.45E-05 Colorectal cancer COL5A1 intron 21242260 rs3128591 chr9 137602119 G A 3.64E-06 Aging (time to event) COL5A1 intron 21782286 rs4842157 chr9 137658608 A G 0.000622283 Hypertension (early onset hypertension) COL5A1 intron 22479346 rs7861012 chr9 137672541 C G 6.70E-05 Diabetic retinopathy COL5A1 intron 21441570 rs35491424 chr9 137673861 T TG 4.70E-05 Diabetic retinopathy COL5A1 intron 21441570 rs6537949 chr9 137673861 T G 4.70E-05 Diabetic retinopathy COL5A1 intron 21441570 rs13294483 chr9 137675994 G A 4.70E-05 Diabetic retinopathy COL5A1 intron 21441570 rs12005196 chr9 137677090 T G 4.70E-05 Diabetic retinopathy COL5A1 intron 21441570 rs12005720 chr9 137678020 T C 4.80E-05 Diabetic retinopathy COL5A1 intron 21441570 rs3124934 chr9 137678038 T C 7.40E-04 Aortic root size COL5A1 intron 21223598 rs11103527 chr9 137681673 G A 1.13E-04 Multiple complex diseases COL5A1 intron 17554300 rs7874142 chr9 137704782 G A 4.82E-04 Multiple complex diseases COL5A1 intron 17554300 rs7874142 chr9 137704782 G A 1.00E-06 Longevity COL5A1 intron 20834067 rs3811149 chr9 137708803 A G 2.16E-04 Multiple complex diseases COL5A1 intron 17554300 rs10776910 chr9 137708960 A C 7.60E-05 Personality dimensions COL5A1 intron 18957941 rs9410002 chr9 137730956 G A 7.23E-04 Response to taxane treatment (placlitaxel) COL5A1 intron 23006423 rs4504708 chr9 137736544 G T 2.54E-04 Alcohol dependence COL5A1 UTR-3 21314694 rs11103562 chr9 137773787 T A 3.51E-04 Multiple complex diseases FCN2 intron 17554300 rs7851236 chr9 137789468 G T 4.13E-04 Aortic root size / / 21223598 rs4841944 chr9 137790376 C T 4.16E-05 Cognitive impairment induced by topiramate / / 22091778 rs2094962 chr9 137816459 C T 5.00E-06 IgG glycosylation / / 23382691 rs7044453 chr9 137818970 T G 4.25E-04 Aortic root size / / 21223598 rs10858300 chr9 137842500 C T 1.56E-08 Coronary heart disease / / 23364394 rs10858313 chr9 137902809 C T 5.99E-04 Type 2 diabetes / / 17463246 rs4842213 chr9 137928371 T A 3.77E-05 Chronic obstructive pulmonary disease / / 19300482 rs4842213 chr9 137928371 T A 3.77E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs607223 chr9 137932668 A G 4.49E-04 Type 2 diabetes / / 17463246 rs638891 chr9 137935184 C A,G,T 2.00E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs568358 chr9 137935300 T C 3.09E-04 Type 2 diabetes / / 17463246 rs17039645 chr9 137939262 T C 5.74E-04 Multiple complex diseases / / 17554300 rs472048 chr9 137971918 C T 4.19E-04 Obesity (extreme) OLFM1 intron 21935397 rs665748 chr9 137973428 A C 4.18E-04 Obesity (extreme) OLFM1 intron 21935397 rs563961 chr9 137975041 C T 1.23E-04 Acute lung injury OLFM1 intron 22295056 rs475440 chr9 137975129 A C 1.59E-04 Acute lung injury OLFM1 intron 22295056 rs500461 chr9 137982127 T C 2.69E-05 Obesity (extreme) OLFM1 cds-synon 21935397 rs542172 chr9 137987233 A G 2.52E-05 Obesity (extreme) OLFM1 intron 21935397 rs9969691 chr9 137998806 A G 4.99E-04 Iron levels OLFM1 intron pha002876 rs1815366 chr9 138004273 G A 1.90E-06 Urinary metabolites OLFM1 intron 21572414 rs10858336 chr9 138005168 T C 7.90E-06 Urinary metabolites OLFM1 intron 21572414 rs11103686 chr9 138013709 C G 4.00E-06 Urinary metabolites / / 21572414 rs11103687 chr9 138013927 A G 2.80E-06 Urinary metabolites / / 21572414 rs899838 chr9 138015107 A G 9.65E-05 Alzheimer's disease (late onset) / / 21379329 rs899839 chr9 138015312 A G 1.15E-04 Alzheimer's disease (late onset) / / 21379329 rs647128 chr9 138015713 A G 9.20E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1609671 chr9 138026014 T A 1.20E-06 Urinary metabolites / / 21572414 rs3860249 chr9 138027657 G A 5.70E-05 Response to statin therapy / / 20339536 rs3849221 chr9 138028677 A C 1.00E-06 Obesity-related traits / / 23251661 rs10776934 chr9 138029701 T G 1.00E-06 Response to hepatitis C treatment / / 22095909 rs11103712 chr9 138037372 G A 1.25E-04 Multiple complex diseases / / 17554300 rs17495030 chr9 138038093 C T 4.98E-04 Smoking initiation / / 24665060 rs12555792 chr9 138066092 G A 6.22E-04 Obesity (extreme) / / 21935397 rs7870302 chr9 138094758 T C 2.60E-06 Urinary metabolites / / 21572414 rs17581058 chr9 138099285 G C 5.60E-07 Urinary metabolites / / 21572414 rs1891981 chr9 138104497 A G 5.64E-05 Post-operative nausea and vomiting / / 21694509 rs7043655 chr9 138125763 A C 2.60E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs7041883 chr9 138126715 C A 6.57E-04 Type 2 diabetes / / 17463246 rs1106256 chr9 138133689 T C 6.78E-06 Personality dimensions / / 18957941 rs2298247 chr9 138139779 T A 2.58E-04 Type 2 diabetes / / 17463246 rs11103778 chr9 138151672 G A 4.59E-05 Type 2 diabetes / / 17463246 rs11103778 chr9 138151672 G A 5.82E-04 Multiple complex diseases / / 17554300 rs11103778 chr9 138151672 G A 7.40E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4841962 chr9 138195203 A C 8.67E-04 Alcohol dependence / / 24277619 rs7032559 chr9 138202418 C T 3.20E-05 White matter hyperintensity burden / / 21681796 rs11103814 chr9 138217857 A T 1.40E-05 White matter hyperintensity burden / / 21681796 rs4841966 chr9 138219716 C T 1.75E-04 Multiple complex diseases / / 17554300 rs11103815 chr9 138219857 C T 2.10E-05 White matter hyperintensity burden / / 21681796 rs9410016 chr9 138220702 C G 9.70E-06 White matter hyperintensity burden / / 21681796 rs4842252 chr9 138221411 G A 7.60E-05 White matter hyperintensity burden / / 21681796 rs10115665 chr9 138234799 A G 2.20E-05 White matter hyperintensity burden / / 21681796 rs11789038 chr9 138245050 G T 6.65E-04 Coronary Artery Disease / / 17634449 rs11789038 chr9 138245050 G T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11103845 chr9 138252603 G A 6.19E-04 Multiple complex diseases / / 17554300 rs12238007 chr9 138274187 A G 3.11E-04 Insulin resistance / / 21901158 rs10858396 chr9 138275776 G A 6.00E-06 Attention deficit hyperactivity disorder / / 21784300 rs17499507 chr9 138310423 G A 3.41E-04 Multiple complex diseases / / 17554300 rs7855598 chr9 138314255 A G 0.0000406 Uterine leiomyomata / / 23040493 rs2384794 chr9 138332606 C T 9.16E-04 Coronary heart disease / / 21606135 rs2590504 chr9 138365495 C T 8.84E-05 Multiple complex diseases / / 17554300 rs12238018 chr9 138365624 G C 1.81E-05 Multiple complex diseases / / 17554300 rs13284515 chr9 138417830 C T 3.36E-04 Atopy LCN1 intron 21625490 rs462537 chr9 138437163 C T 1.19E-05 Word reading OBP2A nearGene-5 23738518 rs465208 chr9 138437272 A G 1.19E-05 Word reading OBP2A nearGene-5 23738518 rs7045084 chr9 138437736 C T 4.18E-05 Cytomegalovirus antibody response OBP2A nearGene-5 21993531 rs7045084 chr9 138437736 C T 0.0000992 Nicotine dependence (smoking) OBP2A nearGene-5 22377092 rs464177 chr9 138437774 A G 4.35E-04 Type 2 diabetes OBP2A nearGene-5 17463246 rs705669 chr9 138468394 C T 2.52E-05 Wegener's granulomatosis LOC100130954 intron 23740775 rs4842007 chr9 138474785 T C 6.72E-04 Celiac disease / / 23936387 rs2151376 chr9 138482453 C T 8.03E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs200428393 chr9 138516420 G T 0.000006 Prostate cancer (advanced) GLT6D1 missense 23555315 rs1537415 chr9 138529722 G C 6.00E-09 Periodontitis GLT6D1 intron 19897590 rs4842019 chr9 138547454 G T 6.87E-06 Cognitive test performance / / 20125193 rs541131 chr9 138552234 G A 1.63E-05 Systemic sclerosis / / 21750679 rs488709 chr9 138559891 G A 2.80E-05 Behcet's disease / / 23291587 rs480422 chr9 138580775 A G 9.29E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10858151 chr9 138582650 G A 1.95E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs540018 chr9 138584921 G A 5.20E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs505391 chr9 138589985 A G 4.09E-04 Multiple complex diseases SOHLH1 intron 17554300 rs487750 chr9 138603740 C T 2.11E-04 Response to cytadine analogues (cytosine arabinoside) KCNT1 intron 24483146 rs12684310 chr9 138638382 C T 1.72E-04 Alzheimer's disease (late onset) KCNT1 intron 21379329 rs10776851 chr9 138718121 A G 0.0000213 Otitis media (children 3 years old or younger) CAMSAP1 intron 23133572 rs884072 chr9 138816346 C T 6.76E-04 Schizophrenia / / 19197363 rs7869795 chr9 138893874 T C 4.47E-05 Post-operative nausea and vomiting / / 21694509 rs4842080 chr9 138924023 A T 4.56E-06 Serum metabolites /CC2 intron 19043545 rs11103291 chr9 138947799 G A 3.46E-05 Tuberculosis /CC2 intron 24057671 rs871095 chr9 138955246 C T 8.53E-04 Alzheimer's disease /CC2 intron 24755620 rs10776875 chr9 138964892 A G 3.28E-04 Smoking initiation /CC2 intron 24665060 rs10858226 chr9 139025615 T C 5.03E-05 Birth weight / / 17255346 rs750761 chr9 139050647 A G 8.40E-06 Nasopharyngeal carcinoma / / 23209447 rs748751 chr9 139051174 A G 1.70E-05 Ankylosing spondylitis / / 20062062 rs11103372 chr9 139083019 G A 2.10E-04 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs11103372 chr9 139083019 G A 2.20E-04 Fasting insulin (interaction) / / 24204828 rs7860634 chr9 139089679 G A 2.00E-08 Thyroid hormone levels LHX3 intron 23408906 rs7860634 chr9 139089679 G A 2.00E-14 Thyroid hormone levels LHX3 intron 23408906 rs7860634 chr9 139089679 G A 5.00E-08 Thyroid hormone levels LHX3 intron 23408906 rs7849585 chr9 139111870 G T 5.00E-14 Height QSOX2 intron 20881960 rs10858250 chr9 139119215 A G 4.94E-04 Smoking initiation QSOX2 intron 24665060 rs7861829 chr9 139120043 C G 1.34E-04 Smoking initiation QSOX2 intron 24665060 rs11103390 chr9 139120828 T C 4.99E-05 Smoking initiation QSOX2 intron 24665060 rs12338076 chr9 139121740 A C 2.00E-08 Height QSOX2 intron 20189936 rs60980157 chr9 139235415 C T 0.000000014 Insulin processing and secretion GPSM1 missense 23263489 rs11787792 chr9 139252148 G A 2.00E-10 Type 2 diabetes GPSM1 intron 23945395 rs3829109 chr9 139256766 G A 1.10E-10 Fasting blood glucose DNLZ intron 22885924 rs34971035 chr9 139265596 G A 5.00E-08 Monocyte chemoattractant protein-1 CARD9 cds-synon 23017229 rs34971035 chr9 139265596 G A 5.00E-06 Obesity-related traits CARD9 cds-synon 23251661 rs10781499 chr9 139266405 G A 3.00E-19 Ulcerative colitis CARD9 cds-synon 21297633 rs10781499 chr9 139266405 G A 4.00E-56 Inflammatory bowel disease CARD9 cds-synon 23128233 rs10781499 chr9 139266405 G A 0.000693321 Primary sclerosing cholangitis CARD9 cds-synon 23603763 rs4077515 chr9 139266496 C T 5.00E-08 Ulcerative colitis CARD9 missense 20228799 rs4077515 chr9 139266496 C T 1.00E-36 Crohn's disease CARD9 missense 21102463 rs4077515 chr9 139266496 C T 0.000076 Primary sclerosing cholangitis CARD9 missense 22521342 rs4077515 chr9 139266496 C T 4.00E-06 Crohn's disease CARD9 missense 22936669 rs10781500 chr9 139269338 C T 7.00E-06 Ulcerative colitis CARD9 nearGene-5 19915572 rs10781500 chr9 139269338 C T 1.00E-06 Ankylosing spondylitis CARD9 nearGene-5 21743469 rs10781500 chr9 139269338 C T 1.10E-04 Thyroid cancer CARD9 nearGene-5 23894154 rs3812561 chr9 139270876 G A 1.16E-06 Coronary Artery Disease S/PC4 missense 17634449 rs3812561 chr9 139270876 G A 1.29E-28 Lymphocyte counts S/PC4 missense 22286170 rs3124994 chr9 139295282 A G 1.61E-05 Multiple complex diseases / / 17554300 rs3812581 chr9 139311471 C T 3.25E-08 Metabolite levels PMPCA cds-synon 23281178 rs11145974 chr9 139316744 C T 1.44E-04 Multiple complex diseases PMPCA intron 17554300 rs10870166 chr9 139316916 G C 4.45E-05 Multiple complex diseases PMPCA intron 17554300 rs10870166 chr9 139316916 G C 3.25E-08 Metabolite levels PMPCA intron 23281178 rs1130635 chr9 139317869 T C 3.25E-08 Metabolite levels PMPCA UTR-3 23281178 rs10747044 chr9 139319129 G T 2.77E-05 Multiple complex diseases / / 17554300 rs10747044 chr9 139319129 G T 3.64E-04 Coronary Artery Disease / / 17634449 rs10747044 chr9 139319129 G T 3.23E-08 Metabolite levels / / 23281178 rs10448340 chr9 139320069 T G 6.97E-06 Multiple complex diseases / / 17554300 rs10448340 chr9 139320069 T G 2.05E-08 Metabolite levels / / 23281178 rs1128877 chr9 139323201 A G 5.81E-05 Orofacial clefts INPP5E UTR-3 22419666 rs1127162 chr9 139335206 T C 2.17E-05 Orofacial clefts SEC16A UTR-3 22419666 rs3812591 chr9 139341612 T C 2.36E-05 Multiple complex diseases SEC16A intron 17554300 rs11145756 chr9 139364585 A G 5.75E-05 Multiple complex diseases SEC16A intron 17554300 rs3812594 chr9 139368953 G A 5.00E-05 Type 2 diabetes SEC16A missense 23209189 rs10870070 chr9 139374952 C A 1.24E-04 Amyotrophic lateral sclerosis (sporadic) SEC16A intron 24529757 rs4379550 chr9 139376426 A G 6.79E-05 Multiple complex diseases SEC16A intron 17554300 rs4379550 chr9 139376426 A G 1.57E-10 Lymphocyte counts SEC16A intron 22286170 rs11574906 chr9 139396113 T A 2.74E-07 Crohn's disease and psoriasis NOTCH1 intron 22482804 rs4880055 chr9 139487092 C T 6.14E-05 Coronary heart disease / / 21971053 rs10735657 chr9 139535714 G T 1.92E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs7871194 chr9 139544437 A C 3.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) LOC100505976 intron 23648065 rs1332793 chr9 139556771 C T 7.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EGFL7 intron 20877124 rs7041558 chr9 139559127 A G 9.81E-04 Alcohol dependence EGFL7 intron 24277619 rs9411216 chr9 139575487 G A 8.39E-05 Celiac disease AGPAT2 intron 23936387 rs945384 chr9 139616742 A G 2.90E-05 Type 2 diabetes FAM69B missense 17293876 rs945384 chr9 139616742 A G 2.90E-05 Type 2 diabetes FAM69B missense 19184112 rs9886752 chr9 139634495 G A 2.79E-04 Response to taxane treatment (placlitaxel) LCN10 STOP-GAIN 23006423 rs2811749 chr9 139725227 C T 6.60E-05 Personality dimensions C9orf86 intron 18957941 rs10123375 chr9 139746992 G A 1.97E-04 Self-reported allergy MAMDC4 intron 23817569 rs7869864 chr9 139749067 C T 2.34E-04 Self-reported allergy MAMDC4 cds-synon 23817569 rs2236544 chr9 139754110 G A 1.87E-04 Self-reported allergy MAMDC4 intron 23817569 rs945385 chr9 139756477 G A 1.10E-06 Urinary metabolites EDF1 nearGene-3 21572414 rs945385 chr9 139756477 G A 2.07E-04 Self-reported allergy EDF1 nearGene-3 23817569 rs36097075 chr9 139765276 G C 4.22E-04 Beta-trace protein levels / / 23328707 rs10747037 chr9 139774381 T A 2.30E-06 Urinary metabolites / / 21572414 rs10747037 chr9 139774381 T A 2.49E-04 Self-reported allergy / / 23817569 rs7048473 chr9 139775146 C T 2.17E-04 Self-reported allergy / / 23817569 rs3739943 chr9 139776194 G C 2.26E-04 Self-reported allergy / / 23817569 rs3739942 chr9 139776400 C T 2.28E-04 Self-reported allergy / / 23817569 rs4880153 chr9 139776649 T C 2.52E-04 Self-reported allergy / / 23817569 rs10781520 chr9 139779462 G A 3.39E-04 Self-reported allergy / / 23817569 rs17243641 chr9 139781438 G T 1.82E-09 LDL cholesterol TRAF2 intron 23063622 rs17243641 chr9 139781438 G T 2.83E-13 Cholesterol,total TRAF2 intron 23063622 rs17243641 chr9 139781438 G T 6.22E-11 HDL cholesterol TRAF2 intron 23063622 rs56079415 chr9 139794565 G A 3.27E-04 Beta-trace protein levels TRAF2 intron 23328707 rs4880160 chr9 139808639 T C 2.70E-06 Urinary metabolites TRAF2 intron 21572414 rs17250539 chr9 139812457 C T 8.12E-04 Beta-trace protein levels TRAF2 intron 23328707 rs17244159 chr9 139814656 G T 9.32E-04 Beta-trace protein levels TRAF2 intron 23328707 rs17244243 chr9 139817545 C A,G,T 0.00000231 Cholesterol,total TRAF2 intron 23063622 rs2386140 chr9 139823622 A G 7.49E-04 Alcohol dependence / / 21314694 rs7045803 chr9 139830733 G C 2.20E-10 Beta-trace protein levels / / 23328707 rs6560652 chr9 139830940 T C 1.08E-04 Alcohol dependence / / 21314694 rs6560652 chr9 139830940 T C 2.30E-10 Beta-trace protein levels / / 23328707 rs10116414 chr9 139831696 C T 2.00E-10 Beta-trace protein levels / / 23328707 rs10118333 chr9 139832005 A G 3.90E-11 Beta-trace protein levels / / 23328707 rs2090626 chr9 139833425 T A,G 1.90E-16 Beta-trace protein levels / / 23328707 rs2090627 chr9 139833441 C T 7.10E-14 Beta-trace protein levels / / 23328707 rs7040705 chr9 139836362 G A 2.90E-14 Beta-trace protein levels FBXW5 intron 23328707 rs2271872 chr9 139837990 G C 3.70E-14 Beta-trace protein levels FBXW5 intron 23328707 rs28578007 chr9 139838690 T C 3.20E-14 Beta-trace protein levels FBXW5 intron 23328707 rs7859131 chr9 139838918 C A 3.40E-09 Beta-trace protein levels FBXW5 intron 23328707 rs2271870 chr9 139839297 A G 2.50E-09 Beta-trace protein levels C8G nearGene-5 23328707 rs2071006 chr9 139839904 T G 2.90E-14 Beta-trace protein levels C8G cds-synon 23328707 rs7862602 chr9 139840471 G T 1.20E-14 Beta-trace protein levels C8G intron 23328707 rs4880172 chr9 139844151 C A 2.20E-08 Beta-trace protein levels / / 23328707 rs10870148 chr9 139844504 T C 3.10E-09 Beta-trace protein levels / / 23328707 rs4880078 chr9 139844953 G A 4.70E-18 Beta-trace protein levels / / 23328707 rs11792444 chr9 139845356 G A 4.32E-05 Beta-trace protein levels / / 23328707 rs925936 chr9 139845672 C T 2.80E-16 Beta-trace protein levels / / 23328707 rs13301993 chr9 139845678 T A 1.18E-05 Beta-trace protein levels / / 23328707 rs13289108 chr9 139845691 C T 3.70E-05 Beta-trace protein levels / / 23328707 rs12551078 chr9 139846002 T C 2.94E-05 Beta-trace protein levels / / 23328707 rs12551097 chr9 139846131 T G 2.54E-05 Beta-trace protein levels / / 23328707 rs13301994 chr9 139846292 A G 2.32E-05 Beta-trace protein levels / / 23328707 rs13283724 chr9 139847089 G C 2.79E-05 Beta-trace protein levels LCN12 intron 23328707 rs34635210 chr9 139847500 G A 2.99E-04 Beta-trace protein levels LCN12 intron 23328707 rs884218 chr9 139847570 T C 1.80E-10 Beta-trace protein levels LCN12 intron 23328707 rs4880079 chr9 139847737 T C 2.20E-16 Beta-trace protein levels LCN12 intron 23328707 rs2271869 chr9 139848273 A G 7.80E-19 Beta-trace protein levels LCN12 intron 23328707 rs2271868 chr9 139848278 T C 5.40E-19 Beta-trace protein levels LCN12 intron 23328707 rs4880175 chr9 139848688 C T 2.30E-10 Beta-trace protein levels LCN12 cds-synon 23328707 rs4880081 chr9 139849285 C T 3.00E-18 Beta-trace protein levels LCN12 intron 23328707 rs868102 chr9 139850119 G A 7.80E-19 Beta-trace protein levels / / 23328707 rs883108 chr9 139850256 C G 6.00E-05 Beta-trace protein levels / / 23328707 rs908833 chr9 139850675 G T 7.80E-19 Beta-trace protein levels / / 23328707 rs62641809 chr9 139851937 A G 9.71E-05 Beta-trace protein levels / / 23328707 rs10781527 chr9 139852224 T C 7.10E-10 Beta-trace protein levels / / 23328707 rs76584589 chr9 139852708 A G 5.79E-04 Beta-trace protein levels / / 23328707 rs4514077 chr9 139853234 A G 5.20E-10 Beta-trace protein levels / / 23328707 rs4242708 chr9 139853341 C G 3.70E-10 Beta-trace protein levels / / 23328707 rs10781528 chr9 139854099 A G 7.20E-10 Beta-trace protein levels / / 23328707 rs13294373 chr9 139854256 T A 7.53E-07 Beta-trace protein levels / / 23328707 rs12555781 chr9 139855524 T C 1.73E-06 Beta-trace protein levels / / 23328707 rs11145945 chr9 139855606 A G 2.60E-16 Beta-trace protein levels / / 23328707 rs908837 chr9 139856328 A G 3.20E-16 Beta-trace protein levels / / 23328707 rs908839 chr9 139856639 C G 1.83E-08 Corneal structure / / 23291589 rs908839 chr9 139856639 C G 2.20E-17 Beta-trace protein levels / / 23328707 rs885070 chr9 139856810 A G 7.70E-19 Beta-trace protein levels / / 23328707 rs13302411 chr9 139857136 G A 4.98E-06 Beta-trace protein levels / / 23328707 rs11145946 chr9 139857140 G T 3.20E-16 Beta-trace protein levels / / 23328707 rs11145947 chr9 139857529 T C 2.80E-16 Beta-trace protein levels / / 23328707 rs35692357 chr9 139857830 C A 4.06E-06 Beta-trace protein levels / / 23328707 rs11145948 chr9 139857912 G A 2.52E-04 Alcohol dependence / / 21314694 rs11145948 chr9 139857912 G A 2.10E-23 Beta-trace protein levels / / 23328707 rs11145949 chr9 139857958 A G 1.90E-23 Beta-trace protein levels / / 23328707 rs4542025 chr9 139858834 A G 1.90E-23 Beta-trace protein levels / / 23328707 rs13292961 chr9 139858866 A G 2.00E-23 Beta-trace protein levels / / 23328707 rs13289286 chr9 139858880 G T 2.00E-23 Beta-trace protein levels / / 23328707 rs7040970 chr9 139859013 T C 3.91E-11 Corneal structure / / 23291589 rs7040970 chr9 139859013 T C 8.00E-18 Beta-trace protein levels / / 23328707 rs12379667 chr9 139859954 C T 4.10E-23 Beta-trace protein levels / / 23328707 rs7868669 chr9 139860100 A G 1.50E-23 Beta-trace protein levels / / 23328707 rs11145951 chr9 139860264 T C 6.00E-12 Corneal structure / / 23291589 rs11145951 chr9 139860264 T C 2.30E-17 Beta-trace protein levels / / 23328707 rs11793787 chr9 139860631 C T 3.37E-07 Beta-trace protein levels / / 23328707 rs13290780 chr9 139861076 C G 1.26E-05 Beta-trace protein levels / / 23328707 rs13295095 chr9 139861113 G A 3.18E-07 Beta-trace protein levels / / 23328707 rs4880178 chr9 139861395 T A 3.80E-23 Beta-trace protein levels / / 23328707 rs7019538 chr9 139861470 T C 1.50E-23 Beta-trace protein levels / / 23328707 rs2386138 chr9 139862324 T C 8.10E-15 Beta-trace protein levels / / 23328707 rs60414152 chr9 139862389 T C 3.76E-06 Beta-trace protein levels / / 23328707 rs61641581 chr9 139862439 T C 1.87E-06 Beta-trace protein levels / / 23328707 rs57024841 chr9 139862633 G A 1.00E-23 Beta-trace protein levels / / 23328707 rs11145954 chr9 139862898 C T 2.50E-23 Beta-trace protein levels / / 23328707 rs11145955 chr9 139862954 C T 1.10E-14 Beta-trace protein levels / / 23328707 rs908829 chr9 139863732 G C 2.00E-23 Beta-trace protein levels / / 23328707 rs11793934 chr9 139863777 G A 1.27E-05 Beta-trace protein levels / / 23328707 rs11787585 chr9 139863841 C T 2.51E-07 Beta-trace protein levels / / 23328707 rs11787588 chr9 139863909 C T 1.61E-07 Beta-trace protein levels / / 23328707 rs2386137 chr9 139864033 G A 1.10E-14 Beta-trace protein levels / / 23328707 rs11788014 chr9 139864087 C A 1.13E-05 Beta-trace protein levels / / 23328707 rs11789276 chr9 139864107 T C 1.13E-05 Beta-trace protein levels / / 23328707 rs2386136 chr9 139864341 A G 6.00E-17 Beta-trace protein levels / / 23328707 rs12351283 chr9 139864438 G C 1.57E-07 Beta-trace protein levels / / 23328707 rs13301523 chr9 139864593 T C 1.01E-05 Beta-trace protein levels / / 23328707 rs7868723 chr9 139864732 G A 1.71E-05 Beta-trace protein levels / / 23328707 rs7860696 chr9 139864896 T C 1.70E-05 Beta-trace protein levels / / 23328707 rs7851235 chr9 139864911 C G 1.71E-05 Beta-trace protein levels / / 23328707 rs7868892 chr9 139864916 G A 1.70E-05 Beta-trace protein levels / / 23328707 rs7872382 chr9 139865239 G A 1.75E-05 Beta-trace protein levels / / 23328707 rs11145959 chr9 139865775 C T 5.85E-06 Beta-trace protein levels / / 23328707 rs7033713 chr9 139865825 A C 1.85E-05 Beta-trace protein levels / / 23328707 rs11790360 chr9 139866247 T G 3.95E-10 Corneal structure / / 23291589 rs11790360 chr9 139866247 T G 1.10E-16 Beta-trace protein levels / / 23328707 rs13300320 chr9 139866743 C G 2.76E-07 Beta-trace protein levels / / 23328707 rs7851828 chr9 139867698 G A 2.80E-11 Beta-trace protein levels / / 23328707 rs10870152 chr9 139867726 T A 4.00E-11 Beta-trace protein levels / / 23328707 rs10117314 chr9 139867752 C T 1.10E-08 Beta-trace protein levels / / 23328707 rs10124249 chr9 139869556 G A 4.50E-11 Beta-trace protein levels / / 23328707 rs10114487 chr9 139869600 C T 1.70E-08 Beta-trace protein levels / / 23328707 rs867250 chr9 139870445 T C 6.20E-11 Beta-trace protein levels / / 23328707 rs867251 chr9 139870710 T C 6.20E-11 Beta-trace protein levels / / 23328707 rs56030643 chr9 139873088 C A 5.20E-10 Beta-trace protein levels PTGDS intron 23328707 rs28609008 chr9 139878622 T C 9.30E-11 Beta-trace protein levels LCNL1 intron 23328707 rs17578859 chr9 139879170 G A 4.00E-08 Beta-trace protein levels LCNL1 missense 23328707 rs12343591 chr9 139880415 C A 1.60E-10 Beta-trace protein levels / / 23328707 rs12343713 chr9 139883020 G C 1.60E-10 Beta-trace protein levels / / 23328707 rs12350318 chr9 139883188 T C 1.60E-10 Beta-trace protein levels / / 23328707 rs3829902 chr9 139892629 G T 2.00E-09 Beta-trace protein levels / / 23328707 rs11999781 chr9 139895468 C T 1.80E-09 Beta-trace protein levels / / 23328707 rs62585806 chr9 139897384 A T 1.70E-09 Beta-trace protein levels / / 23328707 rs10114463 chr9 139899588 C T 2.00E-09 Beta-trace protein levels / / 23328707 rs41306732 chr9 139902166 G A 1.80E-09 Beta-trace protein levels ABCA2 UTR-3 23328707 rs2176675 chr9 139914219 C T 1.80E-08 Beta-trace protein levels ABCA2 intron 23328707 rs140319041 chr9 139914819 G A 0.00012 Prostate cancer ABCA2 missense 23555315 rs66526117 chr9 139924470 G C 8.15E-05 Beta-trace protein levels C9orf139 intron 23328707 rs13301354 chr9 139924637 T C 4.10E-15 Progranulin levels FUT7 UTR-3 21087763 rs13301354 chr9 139924637 T C 4.10E-15 Myocardial infarction FUT7 UTR-3 21211798 rs141846761 chr9 139925490 C T 0.00024 Breast cancer FUT7 missense 23555315 rs41317014 chr9 139929080 C T 4.40E-08 Beta-trace protein levels C9orf139 intron 23328707 rs9411240 chr9 139931311 G A 3.00E-08 Beta-trace protein levels C9orf139 nearGene-3 23328707 rs1138628 chr9 139932211 C A 3.20E-08 Beta-trace protein levels / / 23328707 rs9411241 chr9 139932918 T C 3.20E-08 Beta-trace protein levels / / 23328707 rs6605 chr9 139934020 G A 3.20E-08 Beta-trace protein levels NPDC1 UTR-3 23328707 rs9411299 chr9 139938793 G C 0.0000558 Nonsyndromic striae distensae (stretch marks) NPDC1 intron 23633020 rs3814504 chr9 139941948 G C 0.0000558 Nonsyndromic striae distensae (stretch marks) NPDC1 nearGene-5 23633020 rs17853460 chr9 139943112 A G 0.0000456 Nonsyndromic striae distensae (stretch marks) ENTPD2 cds-synon 23633020 rs2292925 chr9 139945363 G A 0.000048 Nonsyndromic striae distensae (stretch marks) ENTPD2 cds-synon 23633020 rs4880084 chr9 139946327 C T 0.0000488 Nonsyndromic striae distensae (stretch marks) ENTPD2 intron 23633020 rs9411242 chr9 139950008 G A 0.0000693 Nonsyndromic striae distensae (stretch marks) ENTPD2 nearGene-5 23633020 rs3763662 chr9 139950351 G A 4.60E-08 Beta-trace protein levels ENTPD2 nearGene-5 23328707 rs3763662 chr9 139950351 G A 0.0000643 Nonsyndromic striae distensae (stretch marks) ENTPD2 nearGene-5 23633020 rs3763663 chr9 139950597 G A 0.0000726 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4880085 chr9 139955227 T C 4.70E-08 Beta-trace protein levels / / 23328707 rs4880085 chr9 139955227 T C 0.0000761 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17065341 chr9 139978619 A G 5.66E-04 Alcohol dependence UAP1L1 UTR-3 21314694 rs3750518 chr9 139982868 C T 1 Drug response to Daunorubicin MAN1B1 intron 18451141 rs10870177 chr9 139987350 C T 1.99E-05 Response to mTOR inhibitor (everolimus) MAN1B1 intron 24009623 rs10870177 chr9 139987350 C T 8.04E-05 Response to mTOR inhibitor (rapamycin) MAN1B1 intron 24009623 rs9411307 chr9 139994947 C T 7.39E-05 Personality dimensions MAN1B1 intron 18957941 rs7856589 chr9 140003921 G A 5.44E-05 Personality dimensions MAN1B1 nearGene-3 18957941 rs28417902 chr9 140088630 G A 7.00E-06 Obesity-related traits TPRN intron 23251661 rs9330200 chr9 140137651 T A 1.70E-45 Health and aging,CVD and cancer age of onset TUBB4B missense 22174011 rs9330200 chr9 140137651 T A 1.80E-10 Health and aging,CVD and cancer age of onset TUBB4B missense 22174011 rs9330200 chr9 140137651 T A 2.20E-35 Health and aging,CVD and cancer age of onset TUBB4B missense 22174011 rs9330200 chr9 140137651 T A 2.50E-16 Health and aging,CVD and cancer age of onset TUBB4B missense 22174011 rs9330200 chr9 140137651 T A 6.50E-53 Health and aging,CVD and cancer age of onset TUBB4B missense 22174011 rs9330200 chr9 140137651 T A 8.20E-05 Health and aging,CVD and cancer age of onset TUBB4B missense 22174011 rs9330200 chr9 140137651 T A 8.20E-13 Health and aging,CVD and cancer age of onset TUBB4B missense 22174011 rs9775457 chr9 140266929 A C 3.15E-06 Vaspin levels EXD3 intron 22907691 rs9775457 chr9 140266929 A C 0.00000315 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks EXD3 intron 22907730 rs9775457 chr9 140266929 A C 0.0001026 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit EXD3 intron 22907730 rs7469429 chr9 140291708 C T 2.00E-04 Cognitive impairment induced by topiramate EXD3 intron 22091778 rs10116708 chr9 140376668 A G 4.45E-04 Multiple complex diseases PNPLA7 intron 17554300 rs11137410 chr9 140414410 C T 1.77E-04 Type 2 diabetes PNPLA7 missense 17463246 rs11137410 chr9 140414410 C T 1.49E-05 Cognitive test performance PNPLA7 missense 20125193 rs13296028 chr9 140560544 T C 4.25E-04 Response to cytadine analogues (cytosine arabinoside) EHMT1 intron 24483146 rs17496354 chr9 140566936 T C 1.99E-04 Response to cytadine analogues (cytosine arabinoside) EHMT1 intron 24483146 rs2501557 chr9 140569260 C T 1.55E-04 Cholesterol EHMT1 intron 17255346 rs3849856 chr9 140573788 C T 2.44E-04 Response to cytadine analogues (cytosine arabinoside) EHMT1 intron 24483146 rs3895387 chr9 140573808 C T 7.65E-05 Lupus nephritis in systemic lupus erythematosus EHMT1 intron 24925725 rs4979657 chr9 140591260 A G 9.99E-04 Response to cytadine analogues (cytosine arabinoside) EHMT1 intron 24483146 rs10780183 chr9 140594915 A G 1.43E-04 Response to cytadine analogues (cytosine arabinoside) EHMT1 intron 24483146 rs3123510 chr9 140636333 G A 5.36E-04 Multiple complex diseases EHMT1 intron 17554300 rs4876902 chr9 140710603 C T 8.46E-04 Suicide attempts in bipolar disorder EHMT1 intron 21423239 rs7862101 chr9 140756825 T C 4.20E-06 Urinary metabolites / / 21572414 rs7023346 chr9 140895241 G A 9.22E-04 Multiple complex diseases CAC/1B intron 17554300 rs2168526 chr9 140899600 G A 6.19E-04 Multiple complex diseases CAC/1B intron 17554300 rs10780196 chr9 140899682 G A 7.84E-04 Multiple complex diseases CAC/1B intron 17554300 rs7852253 chr9 140928615 A G 6.43E-05 Cognitive performance CAC/1B intron 19734545 rs7865267 chr9 140938075 C T 2.93E-04 Smoking quantity CAC/1B intron 24665060 rs7021328 chr9 140938957 T A,C 1.48E-04 Smoking quantity CAC/1B intron 24665060 rs7020939 chr9 140942815 A G 5.75E-04 Smoking quantity CAC/1B intron 24665060 rs7853637 chr9 140944123 A C 7.26E-04 Smoking quantity CAC/1B intron 24665060 rs6559263 chr9 140956338 T C 3.89E-04 Smoking quantity CAC/1B intron 24665060 rs11137360 chr9 140957557 A G 3.86E-04 Smoking quantity CAC/1B intron 24665060 rs7023278 chr9 140961469 A G 3.80E-04 Smoking quantity CAC/1B intron 24665060 rs10867099 chr9 140962305 A G 3.86E-04 Smoking quantity CAC/1B intron 24665060 rs10867100 chr9 140962687 G T 2.76E-04 Smoking quantity CAC/1B intron 24665060 rs6559264 chr9 140964281 T C 4.60E-04 Smoking quantity CAC/1B intron 24665060 rs10114026 chr9 140965392 C T 2.92E-04 Smoking quantity CAC/1B intron 24665060 rs11137364 chr9 140969445 A G 6.00E-05 Smoking quantity CAC/1B intron 24665060 rs4066674 chr9 140978576 T A,C,G 5.38E-07 Delayed encephalopathy in acute carbon monoxide poisoning CAC/1B intron 24265751 rs4066674 chr9 140978576 T A,C,G 6.84E-07 Delayed encephalopathy in acute carbon monoxide poisoning CAC/1B intron 24265751 rs7906287 chr10 135853 A G 1.00E-04 Prostate cancer / / 21743057 rs4287273 chr10 137186 C G 1.00E-04 Prostate cancer / / 21743057 rs4495823 chr10 143543 G A 2.11E-04 Smoking initiation / / 24665060 rs11253478 chr10 144847 C T 2.30E-05 Urinary metabolites / / 21572414 rs11253478 chr10 144847 C T 2.59E-04 Smoking initiation / / 24665060 rs9419560 chr10 152201 A G 1.53E-04 Multiple complex diseases / / 17554300 rs4881552 chr10 159299 A T 5.00E-05 Prostate cancer / / 21743057 rs1105116 chr10 240788 T G 2.73E-04 Type 2 diabetes ZMYND11 intron 17463246 rs2448378 chr10 273344 A C 7.99E-05 Myopia (pathological) ZMYND11 intron 23049088 rs7919162 chr10 285002 T C 8.84E-04 Alzheimer's disease ZMYND11 intron 22005930 rs7919436 chr10 285200 T G 6.21E-04 Alzheimer's disease ZMYND11 intron 22005930 rs3125037 chr10 297633 A G 2.58E-04 Myocardial Infarction ZMYND11 intron pha002873 rs2060138 chr10 307807 C T 6.55E-04 Type 2 diabetes / / 17463246 rs12246027 chr10 318076 G A 1.00E-10 Blood metabolite levels / / 24816252 rs3740304 chr10 323283 A G 9.82E-05 Information processing speed DIP2C cds-synon 21130836 rs3125028 chr10 331398 G A 2.56E-05 Triglycerides DIP2C intron pha003081 rs3125028 chr10 331398 G A 5.52E-05 Lipid levels DIP2C intron pha003082 rs2288681 chr10 373048 T C 3.76E-04 Type 2 diabetes DIP2C cds-synon 17463246 rs2288681 chr10 373048 T C 8.27E-04 Multiple complex diseases DIP2C cds-synon 17554300 rs7070654 chr10 377161 C T 9.59E-04 Suicide attempts in bipolar disorder DIP2C intron 21423239 rs3922851 chr10 407584 G A 8.49E-04 Suicide attempts in bipolar disorder DIP2C intron 21423239 rs3922851 chr10 407584 G A 3.53E-05 Alzheimer's disease DIP2C intron 22005930 rs10904172 chr10 462298 A G 8.32E-04 Alzheimer's disease DIP2C intron 22005930 rs10904173 chr10 462885 G A 1.78E-04 Alzheimer's disease DIP2C intron 22005930 rs11252332 chr10 467318 T A 1.46E-04 Alzheimer's disease DIP2C intron 22005930 rs17159588 chr10 537748 G A,C,T 4.81E-05 Multiple complex diseases DIP2C intron 17554300 rs816590 chr10 551086 C T 1.30E-05 Multiple complex diseases DIP2C intron 17554300 rs816589 chr10 551157 C T 8.48E-13 Multiple complex diseases DIP2C intron 17554300 rs11252923 chr10 566195 G A 8.79E-06 Alzheimer's disease DIP2C intron 22005930 rs11252926 chr10 566379 C T 8.00E-06 Alzheimer's disease DIP2C intron 22005930 rs12358336 chr10 566981 A T 6.86E-05 Alzheimer's disease DIP2C intron 22005930 rs4881399 chr10 567325 A G 1.64E-05 Alzheimer's disease DIP2C intron 22005930 rs11253065 chr10 583548 G A 9.14E-04 Myocardial Infarction DIP2C intron pha002883 rs11593378 chr10 592873 C G 2.03E-04 Alzheimer's disease DIP2C intron 22005930 rs17221323 chr10 618685 T C 1.00E-07 Immune reponse to smallpox (secreted IFN-alpha) DIP2C intron 22610502 rs17159691 chr10 619316 A G 2.40E-06 Multiple complex diseases DIP2C intron 17554300 rs17293454 chr10 633495 T C 1.20E-05 Information processing speed DIP2C intron 21130836 rs17159711 chr10 636509 C A 4.33E-05 Multiple complex diseases DIP2C intron 17554300 rs4881498 chr10 690039 G A 1.16E-04 Multiple complex diseases DIP2C intron 17554300 rs7916968 chr10 759268 A G 7.00E-06 Migraine / / 23793025 rs527970 chr10 759276 C T 2.20E-04 Aortic root size / / 21223598 rs816314 chr10 762872 A G 1.27E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs877282 chr10 771532 G A 5.00E-08 Uric acid levels / / 23703922 rs1409399 chr10 773939 C T 1.09E-05 Multiple complex diseases / / 17554300 rs754037 chr10 778091 C T 2.78E-04 Multiple complex diseases / / 17554300 rs11253424 chr10 813426 C T 0.000103 Breast cancer early age of onset / / 18463975 rs11253424 chr10 813426 C T 3.23E-05 Vascular dementia / / 22116812 rs11253424 chr10 813426 C T 1.13E-05 Inflammation / / pha002897 rs9971028 chr10 814216 C T 2.97E-05 Smoking initiation / / 24665060 rs10752019 chr10 820868 C T 3.05E-05 Smoking initiation / / 24665060 rs17159892 chr10 821035 G A 1.75E-04 Multiple complex diseases / / 17554300 rs1555895 chr10 837407 A G 1.26E-04 Taste perception / / 22132133 rs765867 chr10 869901 G T 8.68E-04 Taste perception LARP4B intron 22132133 rs12249828 chr10 894838 C T 1.37E-04 Taste perception LARP4B intron 22132133 rs11253475 chr10 907262 C A 5.46E-04 Taste perception LARP4B intron 22132133 rs11253489 chr10 927331 G A 7.89E-04 Smoking cessation LARP4B intron 24665060 rs1904671 chr10 1014603 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12356612 chr10 1055055 C T 4.90E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GTPBP4 intron 22566498 rs4880751 chr10 1055866 A T 0.00001349 Sarcoidosis GTPBP4 intron 22952805 rs17293608 chr10 1056252 C T 4.92E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GTPBP4 intron 22566498 rs17221491 chr10 1065191 A G 5.64E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) IDI2 UTR-3 22566498 rs3750729 chr10 1068802 G A 7.00E-04 Acute lymphoblastic leukemia (childhood) IDI2-AS1 intron 20189245 rs10508206 chr10 1075777 T G 8.03E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) IDI2-AS1 intron 22566498 rs12762955 chr10 1078782 A C 8.00E-06 Response to angiotensin II receptor blocker therapy IDI2-AS1 intron 22566498 rs12784928 chr10 1083617 A C 2.22E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) IDI2-AS1 intron 22566498 rs4880758 chr10 1085572 C G 0.00004186 Sarcoidosis IDI2-AS1 intron 22952805 rs7075188 chr10 1088746 T G 5.05E-05 Cognitive impairment induced by topiramate IDI1 intron 22091778 rs7075188 chr10 1088746 T G 2.42E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) IDI1 intron 22566498 rs7072554 chr10 1090988 C T 2.43E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) IDI1 intron 22566498 rs4519019 chr10 1116294 G A 5.14E-04 Alzheimer's disease WDR37 intron 17998437 rs10508203 chr10 1119203 A G 3.13E-04 Suicide attempts in bipolar disorder WDR37 intron 21423239 rs7080500 chr10 1129814 G A 7.69E-06 Suicide attempts in bipolar disorder WDR37 intron 21423239 rs1871625 chr10 1133628 A T 0.00006758 Sarcoidosis WDR37 intron 22952805 rs10159718 chr10 1139183 A G 6.18E-05 Schizophrenia (cytomegalovirus infection interaction) WDR37 intron 23358160 rs10794720 chr10 1156165 T C 1.00E-08 Chronic kidney disease WDR37 intron 20383146 rs10794720 chr10 1156165 T C 4.96E-08 Chronic kidney disease WDR37 intron 22479191 rs11250268 chr10 1159566 C A 1.10E-05 Urinary metabolites WDR37 intron 21572414 rs11250298 chr10 1206798 C T 1.33E-04 Smoking initiation LINC00200 intron 24665060 rs2387301 chr10 1212635 A C 6.86E-04 Smoking initiation / / 24665060 rs6560716 chr10 1224336 T C 4.52E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ADARB2 UTR-3 24023788 rs10903399 chr10 1227868 T C 0.0000768 Migraine ADARB2 UTR-3 22678113 rs10903399 chr10 1227868 T C 7.68E-05 Migraine ADARB2 UTR-3 22683712 rs1046914 chr10 1228206 T C 0.0000343 Migraine ADARB2 UTR-3 22678113 rs1046914 chr10 1228206 T C 3.43E-05 Migraine ADARB2 UTR-3 22683712 rs2271275 chr10 1230968 C T 0.0000267 Migraine ADARB2 missense 22678113 rs2271275 chr10 1230968 C T 2.67E-05 Migraine ADARB2 missense 22683712 rs7087154 chr10 1244020 T G 4.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADARB2 intron 20877124 rs4880487 chr10 1246883 C T 3.00E-06 Migraine ADARB2 intron 23793025 rs10794730 chr10 1247022 T C 6.03E-04 Common variable immunodeficiency ADARB2 intron 21497890 rs883248 chr10 1250184 C T 0.00000383 Migraine ADARB2 intron 22678113 rs883248 chr10 1250184 C T 3.83E-06 Migraine ADARB2 intron 22683712 rs3793735 chr10 1282828 T C 2.04E-05 Hirschsprung's disease ADARB2 intron 19196962 rs7900341 chr10 1286740 C T 1.50E-05 Urinary metabolites ADARB2 intron 21572414 rs3849973 chr10 1306220 T G 7.23E-05 Elbow pain ADARB2 intron pha003008 rs4880807 chr10 1306745 G A 7.23E-05 Elbow pain ADARB2 intron pha003008 rs11250378 chr10 1316520 G A 4.42E-04 Multiple complex diseases ADARB2 intron 17554300 rs11250378 chr10 1316520 G A 2.04E-05 Serum metabolites ADARB2 intron 19043545 rs2804102 chr10 1325411 T C 8.58E-04 Stroke ADARB2 intron pha002887 rs2651486 chr10 1327807 C T 4.10E-04 Multiple complex diseases ADARB2 intron 17554300 rs11250386 chr10 1334277 T G 1.58E-08 Multiple complex diseases ADARB2 intron 17554300 rs7900500 chr10 1334563 G T 9.65E-04 Multiple complex diseases ADARB2 intron 17554300 rs11599315 chr10 1343017 C T 9.28E-04 Aortic root size ADARB2 intron 21223598 rs11599315 chr10 1343017 C T 5.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients ADARB2 intron 23400010 rs17293755 chr10 1353714 C T 9.74E-05 Response to mTOR inhibitor (rapamycin) ADARB2 intron 24009623 rs7073579 chr10 1374007 G A 1.40E-05 Sleep and circadian phenotypes ADARB2 intron 17903308 rs2892333 chr10 1396155 C T 4.32E-05 Response to mTOR inhibitor (everolimus) ADARB2 intron 24009623 rs7901983 chr10 1399941 C T 2.76E-04 Response to cytadine analogues (cytosine arabinoside) ADARB2 intron 24483146 rs4880498 chr10 1402884 T G 2.67E-05 Esophageal adenocarcinoma ADARB2 intron 24121790 rs11250464 chr10 1406364 T C 6.00E-06 Radiation response ADARB2 intron 20923822 rs2387653 chr10 1407826 C T 5.79E-04 Type 2 diabetes ADARB2 intron 17463246 rs2387653 chr10 1407826 C T 6.28E-06 Lipid traits ADARB2 intron 24023261 rs11250483 chr10 1416962 C T 1.99E-04 Celiac disease ADARB2 intron 23936387 rs11598577 chr10 1433926 A C 6.83E-04 Insomnia ADARB2 intron 23728906 rs2805522 chr10 1444645 G A 1.46E-04 Tourette syndrome ADARB2 intron 22889924 rs34174118 chr10 1452537 G A 2.67E-06 Ejection fraction in Tripanosoma cruzi seropositivity ADARB2 intron 24324551 rs17293817 chr10 1452786 G A 2.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity ADARB2 intron 24324551 rs34510805 chr10 1453878 G A 5.36E-06 Ejection fraction in Tripanosoma cruzi seropositivity ADARB2 intron 24324551 rs2387673 chr10 1459379 G A 7.28E-05 Coronary restenosis ADARB2 intron 21878436 rs2805535 chr10 1460432 T C 8.59E-05 Coronary restenosis ADARB2 intron 21878436 rs2997983 chr10 1461116 T C 6.68E-05 Coronary restenosis ADARB2 intron 21878436 rs2805543 chr10 1464892 T C 5.86E-04 Multiple complex diseases ADARB2 intron 17554300 rs2820651 chr10 1471765 C A 4.00E-07 Migraine with aura ADARB2 intron 23793025 rs2820651 chr10 1471765 C A 4.13E-04 Migraine ADARB2 intron 23793025 rs2820651 chr10 1471765 C A 9.97E-04 Migraine - clinic-based ADARB2 intron 23793025 rs10794750 chr10 1477202 C G 6.27E-04 Depression (quantitative trait) ADARB2 intron 20800221 rs17156334 chr10 1477677 G A 4.12E-04 Alzheimer's disease (late onset) ADARB2 intron 21379329 rs4880851 chr10 1478154 T C 3.34E-04 Depression (quantitative trait) ADARB2 intron 20800221 rs12267070 chr10 1478171 C A 3.36E-04 Depression (quantitative trait) ADARB2 intron 20800221 rs17156341 chr10 1478227 C A,G,T 1.46E-04 Alzheimer's disease (late onset) ADARB2 intron 21379329 rs17156347 chr10 1478900 T A 8.52E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) ADARB2 intron 24236485 rs10508209 chr10 1479049 A G 4.44E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ADARB2 intron 22566498 rs3898610 chr10 1484759 T C 6.44E-04 Bipolar disorder ADARB2 intron 19259986 rs2820623 chr10 1491872 T G 7.82E-04 Sleep duration ADARB2 intron 23728906 rs2820623 chr10 1491872 T G 4.17E-04 Smoking quantity ADARB2 intron 24665060 rs12782764 chr10 1509658 G A 1.39E-04 Osteoarthritis (knee and hip) ADARB2 intron 21177295 rs12782764 chr10 1509658 G A 5.23E-05 Osteoarthritis (knee and hip) ADARB2 intron 21177295 rs12782764 chr10 1509658 G A 7.97E-04 Osteoarthritis (knee and hip) ADARB2 intron 21177295 rs2813404 chr10 1521858 G T 6.31E-04 Amyotrophic Lateral Sclerosis ADARB2 intron 17827064 rs2176377 chr10 1524409 C A 3.75E-04 Suicide attempts in bipolar disorder ADARB2 intron 21423239 rs2138688 chr10 1524465 T C 6.52E-04 Suicide attempts in bipolar disorder ADARB2 intron 21423239 rs10794753 chr10 1532171 A C,T 1.77E-04 Amyotrophic Lateral Sclerosis ADARB2 intron 17362836 rs10794753 chr10 1532171 A C,T 4.63E-04 Suicide attempts in bipolar disorder ADARB2 intron 21423239 rs10903467 chr10 1535739 C T 8.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADARB2 intron 20877124 rs17221736 chr10 1542204 G A 1.28E-04 Suicide attempts in bipolar disorder ADARB2 intron 21423239 rs2813428 chr10 1542887 C A 1.42E-04 Suicide attempts in bipolar disorder ADARB2 intron 21423239 rs2820624 chr10 1542940 G A 1.44E-04 Suicide attempts in bipolar disorder ADARB2 intron 21423239 rs17293852 chr10 1544231 T A 1.25E-04 Suicide attempts in bipolar disorder ADARB2 intron 21423239 rs2813432 chr10 1546669 T C 1.56E-04 Suicide attempts in bipolar disorder ADARB2 intron 21423239 rs2813433 chr10 1546782 C T 2.34E-05 Cognitive test performance ADARB2 intron 20125193 rs2813433 chr10 1546782 C T 1.84E-04 Suicide attempts in bipolar disorder ADARB2 intron 21423239 rs10508211 chr10 1563135 G A 3.96E-05 Blood Pressure ADARB2 intron pha003043 rs2813354 chr10 1592517 C G,T 9.17E-05 Pulmonary function ADARB2 intron 20010835 rs10903481 chr10 1594022 A C 5.11E-04 Multiple complex diseases ADARB2 intron 17554300 rs10508213 chr10 1611165 G T 0.0000185 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ADARB2 intron 22628534 rs2676760 chr10 1612952 G A 9.01E-04 Response to alcohol consumption (flushing response) ADARB2 intron 24277619 rs2813383 chr10 1621800 T C 9.37E-11 Multiple complex diseases ADARB2 intron 17554300 rs7894920 chr10 1621911 C T 9.81E-04 Depression (quantitative trait) ADARB2 intron 20800221 rs11250641 chr10 1622632 G C 4.09E-04 Smoking quantity ADARB2 intron 24665060 rs10903497 chr10 1624900 T C 5.99E-04 Response to cytadine analogues (cytosine arabinoside) ADARB2 intron 24483146 rs10794765 chr10 1625294 C T 0.0000151 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ADARB2 intron 22628534 rs2999399 chr10 1630821 C T 6.00E-06 Emphysema-related traits ADARB2 intron 20709820 rs7090242 chr10 1638527 G A 1.20E-04 Height ADARB2 intron 17255346 rs1909437 chr10 1664242 A G 4.05E-04 Alzheimer's disease ADARB2 intron 22005930 rs10794773 chr10 1665029 T C 9.06E-04 Multiple complex diseases ADARB2 intron 17554300 rs11250672 chr10 1665466 G A 4.99E-05 Alcohol withdrawal symptoms ADARB2 intron 22072270 rs7086346 chr10 1665821 G A 4.99E-05 Alcohol withdrawal symptoms ADARB2 intron 22072270 rs2387952 chr10 1667365 A G 8.79E-04 Multiple complex diseases ADARB2 intron 17554300 rs12572078 chr10 1669110 C T 4.09E-04 Alzheimer's disease ADARB2 intron 22005930 rs12253295 chr10 1672126 C G 5.64E-04 Obesity (extreme) ADARB2 intron 21935397 rs7078498 chr10 1672408 A G 6.02E-04 Obesity (extreme) ADARB2 intron 21935397 rs1909440 chr10 1674132 G A 1.10E-05 Inflammatory demyelinating disease ADARB2 intron 19850125 rs12267329 chr10 1675548 A G 6.71E-05 Response to acetaminophen (hepatotoxicity) ADARB2 intron 21177773 rs12267329 chr10 1675548 A G 4.97E-04 Coronary heart disease ADARB2 intron 21971053 rs6560749 chr10 1676531 T G 2.00E-06 Quantitative traits ADARB2 intron 19197348 rs6560749 chr10 1676531 T G 8.00E-06 Quantitative traits ADARB2 intron 19197348 rs4880897 chr10 1684797 G T 1.20E-05 Inflammatory demyelinating disease ADARB2 intron 19850125 rs10903528 chr10 1685508 A G 1.63E-05 Systemic lupus erythematosus and Systemic sclerosis ADARB2 intron 23740937 rs7072699 chr10 1692796 C T 2.76E-04 Celiac disease ADARB2 intron 23936387 rs1909428 chr10 1705247 A G 7.40E-06 Inflammatory demyelinating disease ADARB2 intron 19850125 rs1909428 chr10 1705247 A G 0.000592 Salmonella-induced pyroptosis ADARB2 intron 22837397 rs9787605 chr10 1765792 T C 0.000018 Mean arterial pressure ADARB2 intron 22510845 rs4076747 chr10 1830815 C A 2.89E-05 Serum metabolites / / 19043545 rs11250787 chr10 1831994 C T 1.93E-04 Arthritis (juvenile idiopathic) / / 22354554 rs4367871 chr10 1845059 C T 7.00E-05 Arthritis (juvenile idiopathic) / / 22354554 rs12570407 chr10 1854773 C T 8.80E-04 Alcohol dependence / / 20201924 rs6560771 chr10 1872265 G A 4.31E-04 Type 2 diabetes / / 17463246 rs11250815 chr10 1875945 G A 2.72E-04 Type 2 diabetes / / 17463246 rs12360000 chr10 1897978 G A 6.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) / / 23934736 rs4077784 chr10 1902429 G A 8.98E-04 Multiple complex diseases / / 17554300 rs9919410 chr10 1902486 C T 0.000107 Height (Pygmy height) / / 22570615 rs9919410 chr10 1902486 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10794793 chr10 1902639 C T 9.08E-04 Multiple complex diseases / / 17554300 rs10794794 chr10 1902670 C T 9.42E-04 Multiple complex diseases / / 17554300 rs7098283 chr10 1921530 C T 8.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2492866 chr10 1922296 C T 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs962760 chr10 1923557 T C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7073281 chr10 1923792 G T 5.51E-05 Leukocyte Counts / / pha003091 rs10903586 chr10 1925702 A G 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs17222231 chr10 1953471 A G 3.20E-06 Urinary metabolites / / 21572414 rs11250936 chr10 1977970 G C 3.47E-04 Alzheimer's disease / / 17998437 rs7912369 chr10 2005604 A G 6.42E-05 Body Mass Index / / pha003014 rs7915592 chr10 2027751 C T 6.38E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs1414128 chr10 2045821 T C 0.000679 Salmonella-induced pyroptosis / / 22837397 rs1414125 chr10 2055591 C A 9.40E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs870041 chr10 2085671 C T 2.99E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10794839 chr10 2086923 A G 7.64E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10903646 chr10 2087959 A G 4.69E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10794843 chr10 2089841 C A 4.06E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10903651 chr10 2089982 A G 3.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2388121 chr10 2104415 G A 4.72E-05 Blood Pressure / / pha003049 rs11251048 chr10 2120407 G A 6.58E-05 Waist-Hip Ratio / / pha003029 rs11251055 chr10 2128355 C T 3.55E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12242400 chr10 2131363 T A 2.86E-05 Formal thought disorder in schizophrenia / / 22648509 rs17155620 chr10 2131439 A G 9.19E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7101173 chr10 2135810 G T 1.67E-04 Coronary heart disease / / 21971053 rs959702 chr10 2149260 A G 1.40E-05 Longevity and age-related phenotypes / / 17903295 rs12776254 chr10 2154862 A G 1.82E-06 Alcohol dependence / / 20202923 rs12776254 chr10 2154862 A G 6.81E-05 Alcohol dependence / / 21703634 rs10794854 chr10 2159703 G A 7.09E-04 Type 2 diabetes / / 17463246 rs4357617 chr10 2165880 C T 1.24E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7071544 chr10 2167727 A G 8.74E-04 Type 2 diabetes / / 17463246 rs12413439 chr10 2168400 G T 5.30E-06 Uric acid levels / / 21294900 rs12412835 chr10 2169025 T C 5.98E-06 Uric acid levels / / 21294900 rs11592097 chr10 2176806 C A 0.000285 Ovarian cancer / / 22794196 rs2210553 chr10 2177862 C T 3.68E-04 Type 2 diabetes / / 17463246 rs2210553 chr10 2177862 C T 2.50E-05 Urinary metabolites / / 21572414 rs17157751 chr10 2184599 A G 4.33E-04 Type 2 diabetes / / 17463246 rs17157751 chr10 2184599 A G 8.47E-05 Multiple complex diseases / / 17554300 rs1333201 chr10 2208519 T C 7.39E-05 Hematocrit / / pha003097 rs1475704 chr10 2213781 C T 8.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs17157831 chr10 2220505 A G 1.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs7075621 chr10 2221296 A T 1.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs10751855 chr10 2224013 T C 1.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs7918296 chr10 2225271 A T 9.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs7923239 chr10 2226705 A T 4.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs6560803 chr10 2226860 A C 1.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs10903694 chr10 2227746 C T 1.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs7920690 chr10 2229969 C G 8.13E-05 Suicide attempts in bipolar disorder / / 21423239 rs4477372 chr10 2235341 T C 8.51E-05 Suicide attempts in bipolar disorder / / 21423239 rs1930658 chr10 2247438 G C 4.80E-05 Suicide attempts in bipolar disorder / / 21423239 rs7086528 chr10 2248228 A G 6.36E-05 Suicide attempts in bipolar disorder / / 21423239 rs1412915 chr10 2249005 C T 5.46E-05 Suicide attempts in bipolar disorder / / 21423239 rs1333206 chr10 2255779 T C 2.64E-05 Suicide attempts in bipolar disorder / / 21423239 rs10903698 chr10 2256452 C A 9.98E-04 Alzheimer's disease / / 17998437 rs1537409 chr10 2257286 C T 2.54E-05 Suicide attempts in bipolar disorder / / 21423239 rs7079734 chr10 2259074 A G 3.61E-05 Suicide attempts in bipolar disorder / / 21423239 rs914817 chr10 2260774 T C 1.41E-05 Suicide attempts in bipolar disorder / / 21423239 rs943041 chr10 2264355 A C 7.20E-05 Suicide attempts in bipolar disorder / / 21423239 rs10794876 chr10 2265337 T C 1.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs10903700 chr10 2265952 C T 6.79E-05 Suicide attempts in bipolar disorder / / 21423239 rs10903702 chr10 2267433 C T 4.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs9651405 chr10 2269560 C A 6.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs3750590 chr10 2270812 A T 2.38E-04 Depression (quantitative trait) / / 20800221 rs2014892 chr10 2281519 T C 2.18E-04 Depression (quantitative trait) / / 20800221 rs10751858 chr10 2285333 T C 3.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs7914519 chr10 2286053 G A 9.60E-05 Personality dimensions / / 18957941 rs7916063 chr10 2286495 C A 6.99E-05 Cognitive performance / / 19734545 rs12359244 chr10 2287367 T G 2.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs12358911 chr10 2287475 A C 2.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs1547290 chr10 2287865 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1041598 chr10 2290492 C A 3.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs7910363 chr10 2290566 C T 8.86E-08 Metabolite levels / / 23281178 rs1041599 chr10 2290618 A C 2.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs11817443 chr10 2291522 T C 2.91E-04 Depression (quantitative trait) / / 20800221 rs11817443 chr10 2291522 T C 2.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs2065528 chr10 2291574 G A 2.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs2065528 chr10 2291574 G A 3.55E-05 Cognitive impairment induced by topiramate / / 22091778 rs10903713 chr10 2292180 A G 4.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs7923214 chr10 2293989 G C 6.22E-04 Diabetic retinopathy / / 20871662 rs10903717 chr10 2296183 C T 6.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs7902529 chr10 2298418 T A 6.14E-06 Hypertension / / 19609347 rs7087032 chr10 2306308 A C 4.61E-05 Cognitive performance / / 19734545 rs12413244 chr10 2311002 T C 2.34E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12413244 chr10 2311002 T C 3.28E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs11251129 chr10 2312933 C T 2.49E-04 Smoking quantity / / 24665060 rs12243279 chr10 2319476 G T 0.0000616 Salmonella-induced pyroptosis / / 22837397 rs6560806 chr10 2321752 C T 5.13E-05 Cognitive performance / / 19734545 rs10903729 chr10 2324132 G A 5.35E-05 Platelet counts / / pha003100 rs2025685 chr10 2331425 C T 5.00E-04 Spine bone size / / 21947420 rs7093372 chr10 2334742 G T 9.91E-05 Platelet counts / / pha003100 rs7919956 chr10 2340038 C T 9.47E-05 Platelet counts / / pha003100 rs768628 chr10 2351833 T C 6.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) LOC399708 intron 23648065 rs11251161 chr10 2363481 G A 6.90E-06 Urinary metabolites / / 21572414 rs7099701 chr10 2363832 C A 7.20E-05 Cognitive test performance / / 20125193 rs10444195 chr10 2383782 C A 4.79E-05 Basophils / / pha003087 rs12779267 chr10 2387282 G A 1.00E-04 Prostate cancer / / 21743057 rs17158208 chr10 2395177 G T 7.30E-06 Iron levels / / 21208937 rs11813772 chr10 2404079 T C 1.00E-04 Prostate cancer / / 21743057 rs12772107 chr10 2421536 C T 8.82E-04 Type 2 diabetes / / 17463246 rs12571964 chr10 2424556 C T 6.77E-04 Type 2 diabetes / / 17463246 rs12571964 chr10 2424556 C T 4.17E-04 Multiple complex diseases / / 17554300 rs12571964 chr10 2424556 C T 9.00E-06 Obesity-related traits / / 23251661 rs11251231 chr10 2454195 G A 1.43E-04 Alzheimer's disease / / 24755620 rs10903760 chr10 2455493 C G,T 4.51E-04 Multiple complex diseases / / 17554300 rs10903760 chr10 2455493 C G,T 3.29E-06 Acute lymphoblastic leukemia (childhood) / / 19684603 rs10903762 chr10 2461205 T C 5.88E-04 Type 2 diabetes / / 17463246 rs17158375 chr10 2510476 T C 7.48E-04 Multiple complex diseases / / 17554300 rs9423540 chr10 2524045 A C 5.50E-05 Response to statin therapy / / 20339536 rs4881000 chr10 2525769 T G 5.50E-05 Response to statin therapy / / 20339536 rs9419515 chr10 2526060 C G 5.50E-05 Response to statin therapy / / 20339536 rs9419443 chr10 2527011 C T 7.00E-05 Response to statin therapy / / 20339536 rs9419444 chr10 2527177 A G 6.50E-05 Response to statin therapy / / 20339536 rs9419445 chr10 2529326 T C 9.70E-05 Response to statin therapy / / 20339536 rs729397 chr10 2532019 G C 8.00E-06 Response to statin therapy / / 20339536 rs2452200 chr10 2536538 C T 7.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2452199 chr10 2537042 G A 7.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2458705 chr10 2541377 A G 5.86E-04 Multiple complex diseases / / 17554300 rs2388097 chr10 2566085 C T 1.09E-04 Pancreatic cancer / / pha002874 rs7093049 chr10 2593077 A G 5.45E-04 Coronary heart disease / / 21606135 rs17179961 chr10 2605786 A G 4.96E-04 Multiple complex diseases / / 17554300 rs10903809 chr10 2610523 G A 8.89E-05 Bipolar disorder / / 18317468 rs10903809 chr10 2610523 G A 1.58E-05 Bipolar disorder and schizophrenia / / 20889312 rs4881003 chr10 2614863 T A 4.80E-05 Cognitive function / / 24684796 rs7920309 chr10 2619695 G A 4.80E-05 Cognitive function / / 24684796 rs2388251 chr10 2620997 G A 9.96E-06 Basophils / / pha003087 rs2388252 chr10 2623568 C T 7.01E-06 Basophils / / pha003087 rs2388288 chr10 2627161 A G 5.90E-05 Cognitive function / / 24684796 rs11251392 chr10 2635863 C T 2.60E-05 Cognitive function / / 24684796 rs10794929 chr10 2653147 C T 5.07E-04 Insulin resistance / / 21901158 rs12570182 chr10 2669310 T C 7.90E-04 Insulin resistance / / 21901158 rs10903834 chr10 2676299 A G 1.51E-04 Insulin resistance / / 21901158 rs11251410 chr10 2688094 T A 2.50E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs7074375 chr10 2691576 C T 9.30E-06 Urinary metabolites / / 21572414 rs7899257 chr10 2695158 A G 5.26E-05 Insulin resistance / / 21901158 rs4391734 chr10 2695566 C T 7.49E-08 Multiple complex diseases / / 17554300 rs11592860 chr10 2702805 G A 3.74E-04 Insulin resistance / / 21901158 rs17158770 chr10 2703572 C T 9.89E-04 Alcohol dependence / / 24277619 rs884289 chr10 2714749 A G 9.43E-05 Coronary heart disease / / pha003032 rs11597478 chr10 2715418 G A 1.25E-04 Alcohol dependence / / 24277619 rs10903843 chr10 2722162 A G 6.10E-04 Alcohol dependence / / 24277619 rs11251448 chr10 2757555 T G 7.13E-05 Personality dimensions / / 18957941 rs79619559 chr10 2776698 A T 3.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs17158961 chr10 2780813 C T 2.32E-04 Type 2 diabetes / / 17463246 rs11599371 chr10 2781027 C T 6.13E-04 Type 2 diabetes / / 17463246 rs11593350 chr10 2781146 T A 2.97E-04 Type 2 diabetes / / 17463246 rs7922357 chr10 2782179 T G 3.16E-04 Type 2 diabetes / / 17463246 rs7922626 chr10 2782413 T G 3.16E-04 Type 2 diabetes / / 17463246 rs7093144 chr10 2783069 C T 4.62E-04 Type 2 diabetes / / 17463246 rs9329300 chr10 2789594 A C 2.00E-09 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2388395 chr10 2792650 A G 1.40E-04 Body mass index / / 18325910 rs2388397 chr10 2792863 A T 4.80E-04 Body mass index / / 18325910 rs2388399 chr10 2792892 G A 4.20E-04 Body mass index / / 18325910 rs1108028 chr10 2808756 G A 5.39E-06 Sodium levels / / pha003093 rs7895748 chr10 2817535 A C 7.78E-04 Type 2 diabetes / / 17463246 rs11251504 chr10 2818244 G A 8.62E-04 Type 2 diabetes / / 17463246 rs11251505 chr10 2818320 A T 7.75E-04 Type 2 diabetes / / 17463246 rs7898310 chr10 2819460 C T 4.83E-04 Multiple complex diseases / / 17554300 rs7898310 chr10 2819460 C T 6.20E-05 Cognitive function / / 24684796 rs10736960 chr10 2831743 A G 3.87E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1334700 chr10 2834346 T C 2.03E-04 Multiple complex diseases / / 17554300 rs1577249 chr10 2836854 G A 4.00E-04 Multiple complex diseases / / 17554300 rs1577249 chr10 2836854 G A 1.80E-05 Urinary metabolites / / 21572414 rs2388507 chr10 2848009 A G 2.00E-05 Urinary metabolites / / 21572414 rs7080882 chr10 2864447 G A 1.57E-04 Eye color / / 23118974 rs7079321 chr10 2876604 G C 9.75E-04 Response to TNF antagonist treatment / / 21061259 rs7093545 chr10 2901275 C T 1.90E-05 Urinary metabolites / / 21572414 rs4370836 chr10 2914753 A C 5.96E-05 Progressive supranuclear palsy / / 21685912 rs4382808 chr10 2916558 A G 5.96E-05 Progressive supranuclear palsy / / 21685912 rs11251566 chr10 2959731 G A 8.07E-04 Multiple complex diseases / / 17554300 rs1574317 chr10 2967402 A G 8.55E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs1875166 chr10 2967851 G T 1.98E-05 Multiple complex diseases / / 17554300 rs1875171 chr10 2971075 T A 3.68E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1875173 chr10 2971405 C T 3.65E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1875174 chr10 2971488 C T 1.04E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2454829 chr10 2972144 G A 3.68E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2936896 chr10 2972261 A G 3.68E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3003514 chr10 2973425 G A 3.68E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11251588 chr10 2986450 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11251588 chr10 2986450 A G 6.78E-05 Cognitive impairment induced by topiramate / / 22091778 rs11251588 chr10 2986450 A G 7.81E-05 Cognitive impairment induced by topiramate / / 22091778 rs4408225 chr10 2987064 T C 5.74E-04 Type 2 diabetes / / 17463246 rs10794975 chr10 2988202 C T 2.81E-05 Cognitive impairment induced by topiramate / / 22091778 rs10794975 chr10 2988202 C T 6.00E-05 Cognitive impairment induced by topiramate / / 22091778 rs10794975 chr10 2988202 C T 6.37E-05 Cognitive impairment induced by topiramate / / 22091778 rs12220191 chr10 2989572 A G 8.30E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1909675 chr10 2990680 C T 6.78E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11251596 chr10 2993191 C T 2.05E-05 Nephrolithiasis / / 22396660 rs12359642 chr10 2993411 G C 3.70E-05 Bipolar disorder and schizophrenia / / 20889312 rs12769869 chr10 3004796 T C 4.45E-04 Smoking quantity / / 24665060 rs7080980 chr10 3009063 C T 2.10E-05 Cognitive function / / 24684796 rs12782126 chr10 3036072 T A 1.00E-05 Cognitive function / / 24684796 rs17135074 chr10 3075076 G A 8.42E-04 Multiple complex diseases / / 17554300 rs3814585 chr10 3095185 G A 5.90E-04 HIV-1 viral setpoint / / 17641165 rs7087613 chr10 3096702 G A 4.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs10732921 chr10 3097212 T C 6.12E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10903959 chr10 3133648 T G 5.02E-05 Waist Circumference PFKP intron pha003023 rs2388595 chr10 3138009 C T 9.42E-04 Type 2 diabetes PFKP intron 17463246 rs10903962 chr10 3138339 A G 6.29E-04 Type 2 diabetes PFKP intron 17463246 rs4271292 chr10 3147456 C T 1.99E-04 Type 2 diabetes PFKP intron 17463246 rs7907949 chr10 3148056 G A 1.10E-05 Obesity-related traits PFKP intron 17658951 rs4881084 chr10 3150371 G A 1.43E-05 Alcohol dependence PFKP intron 23089632 rs7896691 chr10 3155173 C T 2.00E-06 Disc degeneration (lumbar) PFKP intron 22993228 rs6602024 chr10 3155237 A G 4.90E-06 Obesity-related traits PFKP intron 17658951 rs9423462 chr10 3160726 T C 4.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PFKP intron 20877124 rs6602026 chr10 3162423 G A 9.99E-04 Amyotrophic Lateral Sclerosis PFKP intron 17362836 rs6602026 chr10 3162423 G A 1.70E-05 Hypothyroidism PFKP intron 22493691 rs7080240 chr10 3169803 C T 4.83E-04 Alzheimer's disease (late onset) PFKP intron 21379329 rs2306311 chr10 3176389 C T 4.73E-04 Alcohol dependence PFKP intron 21314694 rs2306311 chr10 3176389 C T 3.72E-05 Insulin Resistance PFKP intron pha003062 rs2306311 chr10 3176389 C T 3.56E-05 Insulin-related traits PFKP intron pha003063 rs2306311 chr10 3176389 C T 6.06E-05 Triglycerides PFKP intron pha003080 rs1053000 chr10 3178881 C T 1.11E-05 Insulin Resistance PFKP UTR-3 pha003062 rs1053000 chr10 3178881 C T 8.50E-06 Insulin-related traits PFKP UTR-3 pha003063 rs2279216 chr10 3180951 G A 5.71E-05 Waist-Hip Ratio PITRM1 intron pha003013 rs2279216 chr10 3180951 G A 4.08E-05 Waist-Hip Ratio PITRM1 intron pha003028 rs2279216 chr10 3180951 G A 8.38E-06 Insulin Resistance PITRM1 intron pha003062 rs2279216 chr10 3180951 G A 5.06E-06 Insulin-related traits PITRM1 intron pha003063 rs7094698 chr10 3183747 A G 4.90E-09 Progranulin levels PITRM1 intron 21087763 rs7094698 chr10 3183747 A G 4.90E-09 Myocardial infarction PITRM1 intron 21211798 rs7898695 chr10 3184507 A G 3.50E-05 White matter hyperintensity burden PITRM1 intron 21681796 rs7097793 chr10 3186943 G C 1.10E-04 Alcohol dependence PITRM1 intron 21314694 rs2291103 chr10 3190797 T C 4.80E-05 Insulin-related traits PITRM1 intron pha003063 rs17287235 chr10 3193292 C G 4.22E-04 Suicide attempts in bipolar disorder PITRM1 intron 21423239 rs3765099 chr10 3197592 G A 5.31E-05 Insulin-related traits PITRM1 intron pha003063 rs9423709 chr10 3202682 G A 4.79E-04 Multiple complex diseases PITRM1 intron 17554300 rs7912487 chr10 3204561 C T 3.20E-04 Osteoarthritis PITRM1 intron 19508968 rs7070745 chr10 3205745 T C 7.62E-06 Alzheimer's disease (late onset) PITRM1 intron 21379329 rs17133550 chr10 3212244 C T 7.26E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PITRM1 intron 20877124 rs7078068 chr10 3219445 T C 9.00E-05 Waist Circumference / / pha003025 rs7093944 chr10 3230052 C A 2.21E-04 Celiac disease / / 23936387 rs4375352 chr10 3245325 T C 1.11E-04 Cholesterol / / 17255346 rs9423522 chr10 3264448 T C 4.05E-04 Multiple complex diseases / / 17554300 rs2814918 chr10 3266295 C T 2.16E-05 Cholesterol / / pha003073 rs2814918 chr10 3266295 C T 4.83E-05 ldl cholesterol / / pha003076 rs2814918 chr10 3266295 C T 3.99E-05 Cholesterol / / pha003078 rs2764980 chr10 3284007 A G 9.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs10508250 chr10 3290142 C T 7.62E-05 Major depressive disorder / / 19107115 rs4881131 chr10 3295673 G A 7.06E-05 Cognitive impairment induced by topiramate / / 22091778 rs912832 chr10 3305354 A G 1.55E-04 Multiple complex diseases / / 17554300 rs2296465 chr10 3309647 A G 1.50E-05 Obesity-related traits / / 17903300 rs17135017 chr10 3333530 G A 4.30E-06 Alcohol dependence / / 20201924 rs17135017 chr10 3333530 G A 4.32E-06 Alcoholism / / pha002892 rs12766986 chr10 3335061 T C 4.86E-04 Multiple complex diseases / / 17554300 rs11251836 chr10 3335447 G T 2.90E-05 Alcohol dependence / / 20201924 rs11251836 chr10 3335447 G T 2.88E-05 Alcoholism / / pha002892 rs7069744 chr10 3390506 T C 7.96E-04 Type 2 diabetes / / 17463246 rs2182195 chr10 3395216 A C 4.08E-06 Reading and spelling / / 23738518 rs12415036 chr10 3399934 G A 4.08E-06 Reading and spelling / / 23738518 rs4271299 chr10 3400516 A G 1.74E-05 Reading and spelling / / 23738518 rs11251863 chr10 3401059 A G 4.08E-06 Reading and spelling / / 23738518 rs2209500 chr10 3402334 A G 1.69E-05 Reading and spelling / / 23738518 rs10508252 chr10 3402591 T C 1.69E-05 Reading and spelling / / 23738518 rs11251866 chr10 3407280 T C 1.42E-05 Reading and spelling / / 23738518 rs12773260 chr10 3407329 C T 1.42E-05 Reading and spelling / / 23738518 rs10904027 chr10 3408316 C A 7.04E-06 Reading and spelling / / 23738518 rs17135159 chr10 3408947 A C 2.00E-06 Reading and spelling / / 23738518 rs11251868 chr10 3411423 C T 3.40E-06 Reading and spelling / / 23738518 rs7090790 chr10 3416737 A G 3.51E-05 Non-word repetition / / 23738518 rs7090790 chr10 3416737 A G 6.40E-06 Reading and spelling / / 23738518 rs1570854 chr10 3418124 C T 7.00E-06 Economic and political preferences (environmentalism) / / 22566634 rs7085371 chr10 3419952 G A 3.51E-05 Non-word repetition / / 23738518 rs7085371 chr10 3419952 G A 7.91E-06 Reading and spelling / / 23738518 rs10904029 chr10 3429289 G T 6.00E-04 Multiple complex diseases / / 17554300 rs10904029 chr10 3429289 G T 3.51E-05 Non-word repetition / / 23738518 rs10904029 chr10 3429289 G T 7.91E-06 Reading and spelling / / 23738518 rs10508253 chr10 3430951 T G 1.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10508253 chr10 3430951 T G 3.77E-06 Reading and spelling / / 23738518 rs11251873 chr10 3436109 A G 6.64E-06 Reading and spelling / / 23738518 rs7079024 chr10 3445668 C T 0.00000303 Migraine / / 22678113 rs7079024 chr10 3445668 C T 3.03E-06 Migraine / / 22683712 rs10795033 chr10 3447072 C T 0.0000172 Migraine / / 22678113 rs10795033 chr10 3447072 C T 1.72E-05 Migraine / / 22683712 rs4881165 chr10 3457097 C T 3.82E-04 Multiple complex diseases / / 17554300 rs883634 chr10 3488484 A G 3.74E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4881177 chr10 3507739 G T 2.85E-04 Smoking cessation / / 24665060 rs2165468 chr10 3516105 C A 1.00E-06 Bone mineral density / / 17903296 rs11251910 chr10 3518880 G A 4.22E-04 Smoking cessation / / 24665060 rs622898 chr10 3522302 A G 4.21E-04 Smoking initiation / / 24665060 rs1962663 chr10 3524893 T G 9.53E-04 Alzheimer's disease / / 17998437 rs17135292 chr10 3526096 G A 1.10E-05 Urinary metabolites / / 21572414 rs11251914 chr10 3526686 C T 7.81E-05 Hemoglobin / / pha003096 rs11251914 chr10 3526686 C T 7.46E-05 Hemoglobin / / pha003098 rs10904050 chr10 3531982 G C 2.72E-04 Smoking initiation / / 24665060 rs959509 chr10 3536296 C T 3.63E-06 Coronary artery calcification / / 23870195 rs7074352 chr10 3538749 G T 6.68E-05 Erythrocyte counts / / pha003099 rs7092929 chr10 3538794 A C 3.00E-07 Coronary artery calcification / / 23870195 rs7092929 chr10 3538794 A C 4.16E-04 Smoking initiation / / 24665060 rs7097515 chr10 3539690 A G 6.92E-06 Coronary artery calcification / / 23870195 rs11251918 chr10 3545288 T G 0.0000529 Skin naphthyl-keratin adduct (NKA) levels in workers exposed to naphthalene / / 22391508 rs12264969 chr10 3550613 T C 2.57E-06 Panic disorder / / 19165232 rs12264969 chr10 3550613 T C 1.69E-23 Narcolepsy / / 19629137 rs615019 chr10 3563318 T C 2.93E-04 Alzheimer's disease (late onset) / / 21379329 rs715094 chr10 3584566 T C 7.99E-05 Hemoglobin / / pha003098 rs715094 chr10 3584566 T C 8.71E-05 Erythrocyte counts / / pha003099 rs1890583 chr10 3590269 T C 1.90E-04 Alzheimer's disease (late onset) / / 21379329 rs10795059 chr10 3592082 G A 7.99E-05 Hemoglobin / / pha003098 rs10795059 chr10 3592082 G A 8.71E-05 Erythrocyte counts / / pha003099 rs7086377 chr10 3596526 T G 0.0002 Migraine / / 22678113 rs7086377 chr10 3596526 T G 5.85E-05 Erythrocyte counts / / pha003099 rs558212 chr10 3601124 G A 8.34E-04 Insulin resistance / / 21901158 rs705464 chr10 3643035 G A 1.07E-09 Breast cancer / / 20852631 rs705469 chr10 3658919 T C 7.00E-06 Capecitabine sensitivity / / 22864933 rs705471 chr10 3667726 A G 7.00E-06 Capecitabine sensitivity / / 22864933 rs7897954 chr10 3668898 G T 0.000823 Salmonella-induced pyroptosis / / 22837397 rs7098140 chr10 3682002 T C 0.00054 Salmonella-induced pyroptosis / / 22837397 rs10508257 chr10 3699729 G A 9.05E-05 Longevity / / 20304771 rs6601745 chr10 3719164 C T 1.70E-05 Urinary metabolites / / 21572414 rs10904077 chr10 3720304 G T 3.57E-05 Migraine / / 23793025 rs11252020 chr10 3723609 G T 2.24E-06 Lipid traits / / 21777205 rs7100211 chr10 3727947 T C 6.34E-04 Nicotine dependence / / 17158188 rs7077025 chr10 3769785 C G 2.62E-05 Serum metabolites / / 19043545 rs11252061 chr10 3774779 A G 4.37E-04 Type 2 diabetes / / 17463246 rs12254418 chr10 3785290 C T 3.59E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2171304 chr10 3787961 G C 7.27E-05 Serum metabolites / / 19043545 rs10508264 chr10 3804257 G A 2.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4259743 chr10 3807852 G A 7.38E-05 Relative hand skill in reading disability / / 24068947 rs1043003 chr10 3820787 T C 3.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KLF6 UTR-3 20877124 rs1043003 chr10 3820787 T C 9.82E-05 Cholesterol KLF6 UTR-3 pha003078 rs7919841 chr10 3839642 T C 4.39E-04 Parkinson's disease / / 16252231 rs7897562 chr10 3844242 G A 2.65E-05 Hypertension / / 19609347 rs11252110 chr10 3848340 A G 4.31E-05 Glucose levels / / pha003058 rs12358872 chr10 3854018 C T 4.21E-04 Prostate cancer mortality / / 20978177 rs6601764 chr10 3862542 C T 9.00E-06 Crohn's disease / / 17554300 rs12266938 chr10 3862940 T C 0.0002 Migraine / / 22678113 rs11594834 chr10 3867784 G T 3.40E-05 Response to statin therapy / / 20339536 rs11594834 chr10 3867784 G T 5.32E-06 Major depressive disorder / / 22472876 rs7901658 chr10 3887605 C T 7.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7904986 chr10 3888519 G A 8.30E-07 Urinary metabolites / / 21572414 rs7906433 chr10 3888845 C T 1.30E-06 Urinary metabolites / / 21572414 rs7897383 chr10 3893980 C T 2.38E-05 Height / / pha003011 rs10904109 chr10 3896686 C G 9.00E-04 Multiple complex diseases / / 17554300 rs17135903 chr10 3898018 C T 2.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs17135906 chr10 3899157 T G 2.65E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6601770 chr10 3913700 C T 9.12E-04 Multiple complex diseases / / 17554300 rs6601770 chr10 3913700 C T 2.36E-04 Coronary heart disease / / 21971053 rs6601770 chr10 3913700 C T 6.37E-05 Height / / pha003011 rs12771235 chr10 3926920 G A 8.99E-06 White blood cell count / / 21738479 rs7075364 chr10 3927451 C T 6.73E-06 White blood cell count / / 21738479 rs17251434 chr10 3932531 A G 6.30E-05 HIV-1 control / / 20041166 rs12414586 chr10 3935291 G A 8.18E-04 Multiple complex diseases / / 17554300 rs7915142 chr10 3948429 C T 6.96E-04 Acute lung injury / / 22295056 rs9651513 chr10 3949166 G A 9.90E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs11252191 chr10 3964161 C T 1.30E-07 Asthma / / 24406073 rs7915818 chr10 3966574 G T 8.10E-04 Multiple complex diseases / / 17554300 rs7901977 chr10 3966869 A G 5.55E-04 Multiple complex diseases / / 17554300 rs7086533 chr10 3968713 A C 3.80E-07 Asthma / / 24406073 rs7921993 chr10 3983598 A G 3.40E-06 Urinary metabolites / / 21572414 rs2031574 chr10 3985194 A G 8.96E-04 Obesity (extreme) / / 21935397 rs4600113 chr10 3989450 T G 2.13E-05 Word reading / / 23738518 rs2031573 chr10 4001897 C T 7.00E-06 Word reading / / 23738518 rs2148189 chr10 4028083 G A 7.40E-05 Triglycerides / / 19074352 rs4242768 chr10 4029755 T G 3.10E-04 Type 2 diabetes / / 17463246 rs11252249 chr10 4037207 C T 4.66E-04 Stroke / / pha002886 rs2031577 chr10 4050003 A G 1.00E-06 Longevity / / 20834067 rs2291788 chr10 4070444 G A 2.38E-05 Coronary heart disease / / pha003032 rs41344344 chr10 4091271 A G 2.46E-04 Alzheimer's disease / / 17998437 rs17341098 chr10 4092430 G A 2.55E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs17341098 chr10 4092430 G A 8.02E-04 Alzheimer's disease / / 17998437 rs4881276 chr10 4094454 T A 8.34E-04 Body mass index / / 21701565 rs7904836 chr10 4097880 A G 4.70E-04 Body mass index / / 21701565 rs7904836 chr10 4097880 A G 5.63E-04 Body mass index / / 21701565 rs2645210 chr10 4098453 A G 5.88E-04 Body mass index / / 21701565 rs7087387 chr10 4138794 T C 2.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs7091317 chr10 4139153 T A 2.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs17132103 chr10 4147131 T C 3.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs4881291 chr10 4151051 G A 3.21E-04 Alzheimer's disease (late onset) / / 21379329 rs10795130 chr10 4151121 T G 7.00E-06 Sex hormone-binding globulin levels / / 22675492 rs10904191 chr10 4157015 C T 2.76E-05 Heart Rate / / pha003053 rs10508273 chr10 4208924 C A 4.56E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11252385 chr10 4217047 A G 6.24E-05 Telomere length / / 21573004 rs7094715 chr10 4225127 C T 7.27E-05 Multiple complex diseases / / 17554300 rs7907704 chr10 4226411 A G 7.40E-05 Multiple complex diseases / / 17554300 rs7922038 chr10 4233037 C T 1.42E-05 Triglycerides / / 19074352 rs7922038 chr10 4233037 C T 1.42E-05 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs11252394 chr10 4240870 G A 4.30E-05 Asthma (bronchodilator response) / / 22792082 rs11252394 chr10 4240870 G A 2.00E-07 Asthma (bronchodilator response) / / 23508266 rs10508277 chr10 4259123 T C 7.87E-06 Premature ovarian failure / / 19508998 rs10508277 chr10 4259123 T C 7.87E-06 Other erythrocyte phenotypes / / 19862010 rs10904204 chr10 4284196 G A 8.49E-04 Suicide attempts in bipolar disorder LOC100652988 intron 21423239 rs10904207 chr10 4286897 A G 2.28E-04 Multiple complex diseases / / 17554300 rs11252439 chr10 4325994 T A 7.79E-04 Multiple complex diseases / / 17554300 rs2225080 chr10 4352413 C A 8.21E-04 Multiple complex diseases / / 17554300 rs10904233 chr10 4365399 T C 9.25E-05 HIV-1 viral setpoint / / 22174851 rs10904233 chr10 4365399 T C 3.80E-04 White matter integrity / / 22425255 rs10904234 chr10 4374838 A G 6.73E-04 White matter integrity / / 22425255 rs9988693 chr10 4379270 G T 8.42E-04 White matter integrity / / 22425255 rs4261192 chr10 4380623 G T 5.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs10795158 chr10 4382152 T C 5.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs9633757 chr10 4384056 C T 5.88E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs11252477 chr10 4390097 A G 5.88E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs6601838 chr10 4390460 C T 9.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs11252479 chr10 4392931 T A 3.76E-04 Acute lung injury / / 22295056 rs1926810 chr10 4398913 C T 2.81E-04 Acute lung injury / / 22295056 rs1571130 chr10 4399135 C T 4.27E-04 Acute lung injury / / 22295056 rs11252483 chr10 4402242 A G 3.59E-04 Acute lung injury / / 22295056 rs2182586 chr10 4418953 C T 5.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs10904245 chr10 4420505 T C 4.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs17271524 chr10 4420709 T C 7.00E-05 Lupus / / 17911428 rs1468064 chr10 4434165 G A 9.73E-04 White matter integrity / / 22425255 rs1679444 chr10 4484135 C T 5.82E-05 Hemoglobin / / pha003098 rs1751295 chr10 4496292 G A 6.44E-05 Creatinine levels / / pha003069 rs11252550 chr10 4512899 A G 4.81E-05 Serum metabolites / / 19043545 rs10795171 chr10 4524207 A G 0.000125 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10795171 chr10 4524207 A G 1.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1871617 chr10 4525983 A G 0.0001215 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1871617 chr10 4525983 A G 1.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1871618 chr10 4526111 C T 0.0001216 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1871618 chr10 4526111 C T 1.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10904265 chr10 4526368 A G 0.0001216 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10904265 chr10 4526368 A G 1.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10751969 chr10 4527027 T C 0.0004706 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10751969 chr10 4527027 T C 4.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12572015 chr10 4527345 T C 0.0006611 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12572015 chr10 4527345 T C 6.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10795174 chr10 4527869 G T 0.0007029 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10795174 chr10 4527869 G T 7.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10751970 chr10 4528146 T C 0.0006907 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10751970 chr10 4528146 T C 6.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs398012690 chr10 4528146 T TC 0.0006907 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs398012690 chr10 4528146 T TC 6.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs577269150 chr10 4528146 T TC 0.0006907 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs577269150 chr10 4528146 T TC 6.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs71391947 chr10 4528146 T TC 0.0006907 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs71391947 chr10 4528146 T TC 6.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4584478 chr10 4529068 C T 0.0006932 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4584478 chr10 4529068 C T 6.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1079110 chr10 4529263 A G 0.0007989 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1079110 chr10 4529263 A G 7.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7917711 chr10 4534369 T A 1.56E-04 Aortic root size / / 21223598 rs10795177 chr10 4535585 G A 4.79E-05 Personality dimensions / / 18957941 rs10904269 chr10 4535623 G C 4.78E-05 Personality dimensions / / 18957941 rs4551658 chr10 4538492 C A 5.48E-05 Coronary heart disease / / pha003031 rs10751977 chr10 4542299 A G 3.34E-05 Personality dimensions / / 18957941 rs4313471 chr10 4543335 A G 5.86E-05 Coronary heart disease / / pha003031 rs12573114 chr10 4558326 G A 5.30E-06 Glycemic traits (pregnancy) / / 23903356 rs12573114 chr10 4558326 G A 6.77E-06 Glycemic traits (pregnancy) / / 23903356 rs12573114 chr10 4558326 G A 2.03E-04 Smoking quantity / / 24665060 rs1904667 chr10 4564553 A G 1.00E-05 Malaria / / 19465909 rs10795184 chr10 4570425 T C 1.04E-05 Coronary heart disease / / pha003031 rs313476 chr10 4586302 G A 2.68E-05 Body Mass Index / / pha003019 rs715987 chr10 4598903 T C 1.59E-04 Type 2 diabetes / / 22158537 rs7098007 chr10 4615355 G A 8.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10795189 chr10 4619787 T G 5.50E-07 Response to lithium treatment in bipolar disorder / / 19448189 rs109882 chr10 4624233 T C 1.21E-04 Schizophrenia / / 19197363 rs11252601 chr10 4627405 T C 6.10E-05 Attention deficit hyperactivity disorder / / 22420046 rs386560 chr10 4633815 C T 9.20E-05 White matter hyperintensity burden / / 21681796 rs10458787 chr10 4655565 A G 1.00E-06 Body mass index / / 20397748 rs11252631 chr10 4672037 G A 3.25E-05 Schizophrenia / / 20185149 rs7086888 chr10 4676196 A G 8.00E-06 Multiple myeloma (IgH translocation) / / 23502783 rs313445 chr10 4680910 G A 5.29E-05 Prion diseases / / 22210626 rs313437 chr10 4684042 G A 1.82E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2165953 chr10 4716542 G A 9.00E-06 Obesity-related traits LOC100216001 intron 23251661 rs1391511 chr10 4719796 A G 7.00E-06 Neonatal lupus LOC100216001 intron 20662065 rs1391511 chr10 4719796 A G 0.0007482 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100216001 intron 23233654 rs1391511 chr10 4719796 A G 7.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100216001 intron 23233662 rs7080649 chr10 4731081 C T 4.93E-04 Alzheimer's disease / / 17998437 rs1498272 chr10 4731224 G A 5.86E-04 Alzheimer's disease / / 17998437 rs7099504 chr10 4748776 T G 2.36E-04 Multiple complex diseases / / 17554300 rs17133449 chr10 4758118 T C 4.00E-06 Asthma / / 21790008 rs11252694 chr10 4784070 G T 8.68E-04 Alzheimer's disease / / 17998437 rs7074452 chr10 4793816 A C 5.97E-04 Multiple complex diseases / / 17554300 rs10795201 chr10 4802626 T C 6.40E-04 Myocardial infarction / / 21107343 rs1901632 chr10 4813211 C A 2.89E-04 Coronary Artery Disease / / 17634449 rs1901632 chr10 4813211 C A 7.20E-05 Parkinson's disease / / 21738487 rs2397990 chr10 4829103 C T 2.29E-04 Alcohol dependence / / 20201924 rs11595123 chr10 4832920 A G 9.58E-04 Multiple complex diseases / / 17554300 rs2167704 chr10 4845062 C T 1.31E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2397989 chr10 4846626 G A 7.14E-04 Coronary Artery Disease / / 17634449 rs2397989 chr10 4846626 G A 8.37E-05 Major depressive disorder (broad) / / 20038947 rs2397989 chr10 4846626 G A 2.00E-05 ldl cholesterol / / pha003077 rs2397988 chr10 4846866 T G 8.22E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7475463 chr10 4874794 A G 3.68E-04 Multiple complex diseases AKR1E2 intron 17554300 rs2924269 chr10 4884784 T C 3.88E-06 Type 2 diabetes AKR1E2 intron 17463246 rs2167702 chr10 4887470 G A 8.91E-04 Type 2 diabetes AKR1E2 intron 17463246 rs10795202 chr10 4893318 C T 9.70E-04 Type 2 diabetes / / 17463246 rs4880699 chr10 4916614 T C 9.87E-04 Type 2 diabetes tAKR intron 17463246 rs4460716 chr10 4919641 G T 9.10E-04 Type 2 diabetes tAKR intron 17463246 rs4545440 chr10 4919845 G A 7.82E-04 Type 2 diabetes tAKR intron 17463246 rs10904363 chr10 4920413 G C 3.24E-06 Body mass index tAKR intron 24827717 rs7922213 chr10 4923545 C T 9.90E-04 Type 2 diabetes tAKR intron 17463246 rs7071257 chr10 4926008 T C 8.22E-04 Type 2 diabetes tAKR intron 17463246 rs10904368 chr10 4932085 G A 2.28E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs12268038 chr10 4990993 A G 4.79E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs2904804 chr10 5009759 G T 6.00E-06 Economic and political preferences (immigration/crime) AKR1C1 intron 22566634 rs7909924 chr10 5026680 G A 8.09E-04 Multiple complex diseases / / 17554300 rs12249281 chr10 5075493 G A 4.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10736995 chr10 5091201 G A 3.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) AKR1C3 intron 20877124 rs4881388 chr10 5101104 C T 1.39E-04 Progressive supranuclear palsy AKR1C3 intron 21685912 rs7082806 chr10 5101653 A C 5.57E-04 Obesity (extreme) AKR1C3 intron 21935397 rs7099555 chr10 5101963 C G 3.06E-05 Multiple complex diseases AKR1C3 intron 17554300 rs7099555 chr10 5101963 C G 6.58E-04 Obesity (extreme) AKR1C3 intron 21935397 rs4881394 chr10 5113711 T C 4.00E-04 Suicidal ideation AKR1C3 intron 22030708 rs2105450 chr10 5115907 T G 2.40E-05 Urinary metabolites AKR1C3 intron 21572414 rs7901781 chr10 5119544 C T 3.35E-05 Tuberculosis AKR1C3 intron 24057671 rs10904411 chr10 5124755 T C 9.24E-05 Cytomegalovirus antibody response AKR1C3 intron 21993531 rs1937849 chr10 5133839 A C 8.27E-05 Cytomegalovirus antibody response AKR1C3 intron 21993531 rs1937848 chr10 5134043 G A 8.25E-05 Cytomegalovirus antibody response AKR1C3 intron 21993531 rs11252934 chr10 5134416 T C 3.99E-04 Coronary heart disease AKR1C3 intron 21606135 rs1937847 chr10 5134511 A C 8.21E-05 Cytomegalovirus antibody response AKR1C3 intron 21993531 rs2518047 chr10 5136360 A C 8.07E-05 Cytomegalovirus antibody response AKR1C3 intron 21993531 rs1937843 chr10 5136915 A G 5.57E-04 Coronary heart disease AKR1C3 intron 21606135 rs2518049 chr10 5138036 A G 7.00E-13 Metabolic traits AKR1C3 intron 21886157 rs2518049 chr10 5138036 A G 7.93E-05 Cytomegalovirus antibody response AKR1C3 intron 21993531 rs7741 chr10 5138607 G A 3.25E-04 Coronary heart disease AKR1C3 cds-synon 21606135 rs12387 chr10 5139685 G A 7.86E-05 Cytomegalovirus antibody response AKR1C3 missense 21993531 rs2275928 chr10 5147909 G A 2.20E-04 Alcohol dependence AKR1C3 intron 20201924 rs7917079 chr10 5158475 G A 6.58E-05 Cytomegalovirus antibody response / / 21993531 rs2398195 chr10 5158609 A G 6.46E-05 Cytomegalovirus antibody response / / 21993531 rs2211630 chr10 5159796 A T 6.34E-05 Cytomegalovirus antibody response / / 21993531 rs1937920 chr10 5161955 A G 7.67E-04 Coronary heart disease / / 21606135 rs7920135 chr10 5162308 A T 6.05E-05 Cytomegalovirus antibody response / / 21993531 rs12776280 chr10 5168153 G A 4.45E-04 Coronary heart disease / / 21606135 rs4448597 chr10 5174475 A G 3.00E-04 Coronary heart disease / / 21606135 rs1781929 chr10 5196119 C T 7.24E-05 Cytomegalovirus antibody response / / 21993531 rs1781930 chr10 5196273 A G 7.24E-05 Cytomegalovirus antibody response / / 21993531 rs1761603 chr10 5199216 T C 7.24E-05 Cytomegalovirus antibody response AKR1CL1 intron 21993531 rs1781935 chr10 5199934 G C 6.93E-05 Coronary heart disease / / 21606135 rs1781935 chr10 5199934 G C 4.64E-04 Body mass index / / 21701565 rs11253019 chr10 5200076 A G 3.40E-04 Coronary heart disease AKR1CL1 intron 21606135 rs1781937 chr10 5200638 G A 4.13E-04 Body mass index AKR1CL1 intron 21701565 rs1334467 chr10 5201219 G A 9.04E-04 Coronary heart disease AKR1CL1 intron 21606135 rs4881406 chr10 5203296 A G 2.34E-04 Coronary heart disease AKR1CL1 intron 21606135 rs11253022 chr10 5206049 C T 7.47E-04 Coronary heart disease AKR1CL1 intron 21606135 rs2398103 chr10 5206096 C T 1.35E-04 Coronary heart disease AKR1CL1 intron 21606135 rs11253036 chr10 5226718 T C 3.43E-04 Coronary heart disease AKR1CL1 intron 21606135 rs3750571 chr10 5247434 C A 8.09E-06 Smoking cessation AKR1C4 intron 18519826 rs1832007 chr10 5254847 A G 2.00E-12 Triglycerides AKR1C4 intron 24097068 rs17134585 chr10 5256272 T C 3.00E-38 Blood metabolite ratios AKR1C4 intron 24816252 rs4881413 chr10 5258450 T G 7.31E-05 Smoking cessation AKR1C4 intron 18519826 rs2104994 chr10 5273767 G A 7.88E-04 Smoking cessation / / 24665060 rs7911824 chr10 5295247 T A 6.88E-06 Hearing function / / 21493956 rs7921115 chr10 5297642 T C 6.41E-06 Hearing function / / 21493956 rs1107822 chr10 5304823 C G 6.47E-06 Hearing function / / 21493956 rs2398234 chr10 5310533 A G 4.46E-06 Hearing function / / 21493956 rs7087937 chr10 5313492 A G 9.78E-06 Hearing function / / 21493956 rs2398236 chr10 5331159 A G 0.00000907 Alcohol dependence / / 23691058 rs9423593 chr10 5332349 C T 0.00000832 Alcohol dependence / / 23691058 rs7076488 chr10 5333008 G A 4.20E-04 Alcohol dependence / / 20201924 rs7076488 chr10 5333008 G A 0.00000213 Alcohol dependence / / 23691058 rs1987511 chr10 5348337 T C 9.00E-08 Intelligence / / 22449649 rs9423407 chr10 5355712 C T 9.00E-04 Alcohol dependence / / 20201924 rs7894961 chr10 5356862 T C 7.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7895335 chr10 5357328 A G 3.29E-04 Multiple complex diseases / / 17554300 rs12570234 chr10 5382676 T G 6.71E-05 Prion diseases / / 22210626 rs11253116 chr10 5383254 T C 8.52E-04 Alzheimer's disease / / 22005930 rs12098412 chr10 5383888 T C 8.72E-04 Alzheimer's disease / / 22005930 rs12098413 chr10 5383980 T C 8.50E-04 Alzheimer's disease / / 22005930 rs11253119 chr10 5384777 T G 9.48E-04 Alzheimer's disease / / 22005930 rs11253121 chr10 5389223 C T 1.21E-04 Prion diseases / / 22210626 rs12784234 chr10 5404261 T G 7.10E-04 Type 2 diabetes / / 17463246 rs12784234 chr10 5404261 T G 1.25E-05 Hypertension / / pha003042 rs12783734 chr10 5405265 G A 1.26E-05 Hypertension / / pha003042 rs10904487 chr10 5424465 C T 4.29E-07 Autism / / 22843504 rs12258526 chr10 5433973 C A 3.07E-04 Alzheimer's disease (late onset) / / 21379329 rs11592540 chr10 5529329 G A 8.00E-05 Prostate cancer / / 21743057 rs12357686 chr10 5550673 G A 5.41E-04 Coronary heart disease / / 21606135 rs9423641 chr10 5554141 T G 6.63E-04 Aortic root size / / 21223598 rs11816050 chr10 5557041 C T 9.32E-04 Coronary heart disease / / 21606135 rs4077511 chr10 5578172 G A 1.90E-05 Urinary metabolites / / 21572414 rs7922769 chr10 5596392 C A 1.52E-05 Cognitive impairment induced by topiramate / / 22091778 rs4242799 chr10 5598603 T A 1.36E-04 Type 2 diabetes / / 17463246 rs7899101 chr10 5608202 C T 3.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12098712 chr10 5611911 C T 2.21E-05 Femoral neck bone geometry / / 22087292 rs12098712 chr10 5611911 C T 1.80E-04 Heart rate / / 23583979 rs7074607 chr10 5633371 G A 8.04E-06 White blood cell count / / 21738479 rs7075917 chr10 5633549 C T 3.44E-05 Orofacial clefts / / 22419666 rs7915861 chr10 5641348 T C 7.74E-04 Multiple complex diseases / / 17554300 rs11595011 chr10 5645477 C T 2.59E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4750500 chr10 5645758 A C 9.40E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4750514 chr10 5645895 G A 2.34E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4750519 chr10 5645947 T G 1.21E-05 Serum metabolites / / 19043545 rs7076013 chr10 5646103 G T 1.49E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11259742 chr10 5647078 C T 1.16E-04 Multiple complex diseases / / 17554300 rs11259742 chr10 5647078 C T 4.83E-05 Serum metabolites / / 19043545 rs4748301 chr10 5648019 G C 6.87E-05 Serum metabolites / / 19043545 rs4748304 chr10 5648101 C G 2.60E-05 Serum metabolites / / 19043545 rs4747358 chr10 5650193 C T 1.42E-05 Serum metabolites / / 19043545 rs7924096 chr10 5652237 G C 8.27E-04 Multiple complex diseases / / 17554300 rs7924096 chr10 5652237 G C 3.39E-05 Serum metabolites / / 19043545 rs7924096 chr10 5652237 G C 4.40E-05 Malaria / / 19465909 rs17141741 chr10 5665774 C G 5.00E-06 Breast cancer / / 23468962 rs7909299 chr10 5685301 C T 6.47E-04 Rheumatoid arthritis ASB13 intron 21452313 rs11256831 chr10 5689058 G T 7.15E-05 Alcohol dependence ASB13 intron 21703634 rs2386646 chr10 5694612 T C 3.46E-04 Multiple complex diseases ASB13 intron 17554300 rs9423896 chr10 5716858 T C 2.03E-04 Multiple complex diseases / / 17554300 rs11258725 chr10 5720424 T A 7.55E-04 Multiple complex diseases / / 17554300 rs1578743 chr10 5722784 A C 6.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11259192 chr10 5726821 G A 5.38E-04 Multiple complex diseases FAM208B UTR-5 17554300 rs9423936 chr10 5734358 A C 6.79E-04 Multiple complex diseases FAM208B intron 17554300 rs3209286 chr10 5753516 G A 2.70E-04 Lung function (forced vital capacity) FAM208B intron 24023788 rs2890365 chr10 5773876 C A 2.73E-04 Lung function (forced expiratory volume in 1 second) FAM208B intron 24023788 rs2890365 chr10 5773876 C A 4.59E-04 Lung function (forced vital capacity) FAM208B intron 24023788 rs2797501 chr10 5804531 G A 8.00E-06 Osteosarcoma FAM208B missense 23727862 rs6602240 chr10 5816751 C A 6.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GDI2 intron 20877124 rs6602240 chr10 5816751 C A 2.91E-04 Lung function (forced expiratory volume in 1 second) GDI2 intron 24023788 rs6602240 chr10 5816751 C A 3.67E-04 Lung function (forced vital capacity) GDI2 intron 24023788 rs10795544 chr10 5820897 C A 3.08E-04 Lung function (forced vital capacity) GDI2 intron 24023788 rs10795544 chr10 5820897 C A 3.68E-04 Lung function (forced expiratory volume in 1 second) GDI2 intron 24023788 rs11255164 chr10 5825699 G T 3.04E-05 Multiple complex diseases GDI2 intron 17554300 rs6602259 chr10 5844628 C T 4.07E-04 Lung function (forced expiratory volume in 1 second) GDI2 intron 24023788 rs7098372 chr10 5886149 T C 3.50E-06 Breast cancer / / 20453838 rs7098372 chr10 5886149 T C 3.86E-05 Age-related macular degeneration / / 22125219 rs7098372 chr10 5886149 T C 2.13E-04 Vaspin levels / / 22907691 rs7098372 chr10 5886149 T C 0.0002125 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs2380205 chr10 5886734 C T 5.00E-07 Breast cancer / / 20453838 rs2380205 chr10 5886734 C T 3.86E-05 Age-related macular degeneration / / 22125219 rs2380205 chr10 5886734 C T 1.33E-04 Vaspin levels / / 22907691 rs2380205 chr10 5886734 C T 0.0001326 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs2380205 chr10 5886734 C T 1.97E-04 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs713588 chr10 5886962 A G 4.00E-06 Breast cancer / / 20453838 rs867052 chr10 5887183 A G 4.00E-06 Breast cancer / / 20453838 rs7897260 chr10 5888427 C G 4.30E-06 Breast cancer / / 20453838 rs7894083 chr10 5893268 A C 4.60E-06 Breast cancer / / 20453838 rs7894083 chr10 5893268 A C 3.25E-05 Age-related macular degeneration / / 22125219 rs7894083 chr10 5893268 A C 8.90E-05 Vaspin levels / / 22907691 rs7894083 chr10 5893268 A C 0.000089 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs9663697 chr10 5897906 C T 4.60E-06 Breast cancer / / 20453838 rs12774966 chr10 5898098 G T 4.70E-06 Breast cancer / / 20453838 rs4293038 chr10 5898159 G A 5.80E-06 Breast cancer / / 20453838 rs4330991 chr10 5898180 A C 5.90E-06 Breast cancer / / 20453838 rs12780246 chr10 5898205 G A 8.50E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7072174 chr10 5898802 T C 6.60E-06 Breast cancer / / 20453838 rs7072174 chr10 5898802 T C 5.17E-05 Age-related macular degeneration / / 22125219 rs7072174 chr10 5898802 T C 8.90E-05 Vaspin levels / / 22907691 rs7072174 chr10 5898802 T C 0.000089 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs7099029 chr10 5899188 C A 6.40E-06 Breast cancer / / 20453838 rs2380208 chr10 5900032 C G 6.30E-06 Breast cancer / / 20453838 rs907685 chr10 5900332 A G 6.20E-06 Breast cancer / / 20453838 rs907685 chr10 5900332 A G 5.17E-05 Age-related macular degeneration / / 22125219 rs907685 chr10 5900332 A G 8.90E-05 Vaspin levels / / 22907691 rs907685 chr10 5900332 A G 0.000089 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs907686 chr10 5900693 G A 6.60E-06 Breast cancer / / 20453838 rs907686 chr10 5900693 G A 3.77E-05 Age-related macular degeneration / / 22125219 rs907686 chr10 5900693 G A 8.90E-05 Vaspin levels / / 22907691 rs907686 chr10 5900693 G A 0.000089 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs907688 chr10 5900822 A G 7.10E-06 Breast cancer / / 20453838 rs907688 chr10 5900822 A G 3.77E-05 Age-related macular degeneration / / 22125219 rs907688 chr10 5900822 A G 8.90E-05 Vaspin levels / / 22907691 rs907688 chr10 5900822 A G 0.000089 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs907689 chr10 5900973 T C 7.10E-06 Breast cancer / / 20453838 rs907689 chr10 5900973 T C 4.70E-05 Age-related macular degeneration / / 22125219 rs907689 chr10 5900973 T C 1.32E-04 Vaspin levels / / 22907691 rs907689 chr10 5900973 T C 0.0001316 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs12359234 chr10 5902711 A C,G,T 2.92E-04 Age-related macular degeneration / / 22125219 rs2203197 chr10 5904918 C T 3.84E-05 Age-related macular degeneration ANKRD16 intron 22125219 rs2203197 chr10 5904918 C T 1.48E-04 Vaspin levels ANKRD16 intron 22907691 rs2203197 chr10 5904918 C T 0.000148 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks ANKRD16 intron 22907730 rs1323659 chr10 5916926 C G 3.70E-06 Urinary metabolites ANKRD16 intron 21572414 rs17145612 chr10 5918432 G A 6.00E-06 Obesity-related traits ANKRD16 intron 23251661 rs662701 chr10 5918732 T C 7.40E-06 Urinary metabolites ANKRD16 intron 21572414 rs6602322 chr10 5930579 G A 1.96E-04 Age-related macular degeneration ANKRD16 intron 22125219 rs6602330 chr10 5944233 T C 7.06E-04 Response to cytadine analogues (cytosine arabinoside) FBXO18 intron 24483146 rs1998521 chr10 5992119 T C 6.57E-04 Endometrial cancer / / 24096698 rs7910212 chr10 6009126 C T 6.18E-04 Multiple complex diseases IL15RA intron 17554300 rs8177772 chr10 6015057 G A 1.01E-04 Smoking initiation IL15RA intron 24665060 rs8177617 chr10 6022795 G A 8.56E-05 Atopic dermatitis / / 23042114 rs7077401 chr10 6025878 A G 7.94E-04 Type 2 diabetes / / 17463246 rs6602360 chr10 6029726 G A 2.30E-05 Urinary metabolites / / 21572414 rs1323651 chr10 6033301 T G 0.000169065 Hypertension (early onset hypertension) / / 22479346 rs7911500 chr10 6037726 C T 5.00E-09 Inflammatory biomarkers / / 22228203 rs12359875 chr10 6051107 C T 7.23E-05 Self-reported allergy / / 23817569 rs12722605 chr10 6053163 T A 3.00E-07 Inflammatory biomarkers IL2RA UTR-3 22228203 rs9663421 chr10 6055604 C T 5.22E-04 Response to statin treatment (atorvastatin),change in cholesterol levels IL2RA intron 20031582 rs9663421 chr10 6055604 C T 6.62E-05 Self-reported allergy IL2RA intron 23817569 rs2076846 chr10 6063253 A G 1.98E-05 Self-reported allergy IL2RA intron 23817569 rs2025345 chr10 6067688 A G 5.38E-05 Serum metabolites IL2RA intron 19043545 rs2025345 chr10 6067688 A G 3.00E-06 Self-reported allergy IL2RA intron 23817569 rs7910961 chr10 6077796 T C 3.45E-05 Self-reported allergy IL2RA intron 23817569 rs11256448 chr10 6079479 A G 3.55E-04 Multiple complex diseases IL2RA intron 17554300 rs7072398 chr10 6079846 G A 5.30E-06 Self-reported allergy IL2RA intron 23817569 rs12722515 chr10 6081230 C A 4.00E-10 Inflammatory bowel disease IL2RA intron 23128233 rs4749924 chr10 6082396 A C 2.30E-04 Self-reported allergy IL2RA intron 23817569 rs6602398 chr10 6082953 G T 2.36E-04 Self-reported allergy IL2RA intron 23817569 rs4749926 chr10 6085312 G A 5.29E-05 Nicotine smoking IL2RA intron 19268276 rs10905656 chr10 6086093 C A 4.65E-05 Serum metabolites IL2RA intron 19043545 rs942201 chr10 6086292 G T 8.67E-04 Multiple complex diseases IL2RA intron 17554300 rs706781 chr10 6086385 C T 3.79E-04 Multiple complex diseases IL2RA intron 17554300 rs11256497 chr10 6087794 G A 1.33E-05 Multiple sclerosis IL2RA intron 19525953 rs791587 chr10 6088699 A G 3.03E-06 Multiple sclerosis IL2RA intron 17660530 rs12722508 chr10 6088743 A T 0.0000201 Rheumatoid arthritis (CCP positive) IL2RA intron 23143596 rs7909519 chr10 6089841 T G 0.000000984 Oligoarticular juvenile idiopathic arthritis IL2RA intron 23603761 rs7909519 chr10 6089841 T G 0.0000341 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis IL2RA intron 23603761 rs7909519 chr10 6089841 T G 8.00E-10 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) IL2RA intron 23603761 rs10905668 chr10 6092055 C T 6.19E-05 Multiple complex diseases IL2RA intron 17554300 rs10905669 chr10 6092093 C T 8.83E-05 Multiple complex diseases IL2RA intron 17554300 rs61839660 chr10 6094697 C T 5.00E-09 Type 1 diabetes IL2RA intron 22293688 rs12722495 chr10 6097283 T C 1.00E-38 Type 1 diabetes autoantibodies IL2RA intron 21829393 rs706779 chr10 6098824 T C 3.00E-09 Vitiligo IL2RA intron 20410501 rs706779 chr10 6098824 T C 1.14E-09 Vitiligo IL2RA intron 21326295 rs706779 chr10 6098824 T C 7.20E-05 Hypothyroidism IL2RA intron 22493691 rs706779 chr10 6098824 T C 4.98E-14 Vitiligo IL2RA intron 22561518 rs706779 chr10 6098824 T C 0.000000269 Graves' disease and Hashimoto's thyroiditis IL2RA intron 22922229 rs706779 chr10 6098824 T C 0.00000227 Graves' disease IL2RA intron 22922229 rs706778 chr10 6098949 C T 1.00E-11 Rheumatoid arthritis IL2RA intron 20453842 rs706778 chr10 6098949 C T 5.40E-06 Primary sclerosing cholangitis IL2RA intron 21151127 rs706778 chr10 6098949 C T 1.40E-11 Celiac disease and Rheumatoid arthritis IL2RA intron 21383967 rs706778 chr10 6098949 C T 1.40E-11 Multiple sclerosis IL2RA intron 22190364 rs706778 chr10 6098949 C T 5.00E-14 Rheumatoid arthritis IL2RA intron 24390342 rs706778 chr10 6098949 C T 5.00E-15 Rheumatoid arthritis IL2RA intron 24390342 rs2104286 chr10 6099045 T C 5.92E-08 Multiple complex diseases IL2RA intron 17554300 rs2104286 chr10 6099045 T C 2.16E-07 Multiple sclerosis IL2RA intron 17660530 rs2104286 chr10 6099045 T C 9.00E-08 Multiple sclerosis IL2RA intron 19525953 rs2104286 chr10 6099045 T C 7.00E-06 Multiple sclerosis IL2RA intron 19525955 rs2104286 chr10 6099045 T C 1.90E-05 Multiple sclerosis IL2RA intron 21833088 rs2104286 chr10 6099045 T C 3.52E-10 Multiple sclerosis IL2RA intron 22190364 rs2104286 chr10 6099045 T C 4.41E-10 Rheumatoid arthritis IL2RA intron 23143596 rs2104286 chr10 6099045 T C 1.00E-06 Rheumatoid arthritis IL2RA intron 24449572 rs3134883 chr10 6100725 G A 8.50E-07 Primary sclerosing cholangitis IL2RA intron 21151127 rs3118470 chr10 6101713 T C 2.00E-12 Alopecia areata IL2RA intron 20596022 rs3118470 chr10 6101713 T C 3.00E-11 Multiple sclerosis IL2RA intron 21833088 rs3118470 chr10 6101713 T C 7.80E-04 Multiple sclerosis IL2RA intron 24234648 rs17149458 chr10 6101860 T A 0.000000949 Triglycerides IL2RA intron 23063622 rs12722489 chr10 6102012 C T 5.30E-04 Multiple complex diseases IL2RA intron 17554300 rs12722489 chr10 6102012 C T 3.00E-08 Multiple sclerosis IL2RA intron 17660530 rs12722489 chr10 6102012 C T 3.00E-09 Crohn's disease IL2RA intron 21102463 rs12722489 chr10 6102012 C T 4.00E-08 Multiple sclerosis IL2RA intron 22190364 rs12722486 chr10 6103762 C T 2.00E-09 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) IL2RA intron 24554482 rs10795791 chr10 6108340 A G 1.26E-08 Multiple complex diseases / / 17554300 rs10795791 chr10 6108340 A G 1.60E-04 Arthritis (juvenile idiopathic) / / 22354554 rs10795791 chr10 6108340 A G 1.11E-09 Rheumatoid arthritis / / 23143596 rs10795791 chr10 6108340 A G 1.19E-09 Rheumatoid arthritis (CCP positive) / / 23143596 rs4147359 chr10 6108439 G A 4.70E-06 Primary sclerosing cholangitis / / 21151127 rs4147359 chr10 6108439 G A 8.19E-17 Primary sclerosing cholangitis / / 23603763 rs7089861 chr10 6110326 C G 3.38E-07 Multiple sclerosis / / 19525953 rs7089861 chr10 6110326 C G 4.34E-04 Multiple sclerosis / / 22190364 rs7090512 chr10 6110829 C T 5.00E-20 Multiple sclerosis / / 21833088 rs7090530 chr10 6110875 C A 3.40E-04 Vitiligo / / 20410501 rs7090530 chr10 6110875 C A 2.93E-15 Type 1 diabetes / / 21980299 rs7090530 chr10 6110875 C A 5.80E-05 Hypothyroidism / / 22493691 rs1887027 chr10 6113782 C T 2.60E-04 Biomarkers / / 17903293 rs10905718 chr10 6114856 A G 2.40E-07 Primary sclerosing cholangitis / / 21151127 rs12251307 chr10 6123495 C T 4.24E-06 Multiple complex diseases / / 17554300 rs12251307 chr10 6123495 C T 2.00E-06 Type 1 diabetes / / 18978792 rs12251307 chr10 6123495 C T 1.00E-13 Type 1 diabetes / / 19430480 rs12251307 chr10 6123495 C T 4.71E-05 Vitiligo / / 20410501 rs12251307 chr10 6123495 C T 4.40E-06 Urinary metabolites / / 21572414 rs41295115 chr10 6124621 T C 5.00E-07 Asthma and hay fever / / 24388013 rs8463 chr10 6158412 A G 2.16E-04 Multiple complex diseases RBM17 UTR-3 17554300 rs4750005 chr10 6169685 T C 5.30E-04 Vitiligo / / 20410501 rs3920615 chr10 6176780 T C 1.05E-04 Vitiligo / / 20410501 rs3920615 chr10 6176780 T C 2.59E-05 Orofacial clefts / / 22419666 rs10905879 chr10 6177083 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4747887 chr10 6177682 T C 1.07E-04 Vitiligo / / 20410501 rs4747887 chr10 6177682 T C 3.92E-05 Orofacial clefts / / 22419666 rs4750012 chr10 6177794 C T 1.10E-04 Vitiligo / / 20410501 rs4750012 chr10 6177794 C T 3.37E-05 Orofacial clefts / / 22419666 rs7099083 chr10 6178236 G A 8.84E-05 Vitiligo / / 20410501 rs7099083 chr10 6178236 G A 4.37E-05 Orofacial clefts / / 22419666 rs11598494 chr10 6178941 T C 2.00E-05 Multiple complex diseases / / 17554300 rs11257010 chr10 6197536 T G 2.60E-04 Multiple complex diseases PFKFB3 intron 17554300 rs674430 chr10 6220360 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) PFKFB3 intron 20708005 rs678395 chr10 6221318 A G 2.37E-04 Multiple complex diseases PFKFB3 intron 17554300 rs2516618 chr10 6253983 G A 8.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PFKFB3 intron 20877124 rs2148294 chr10 6258052 G A 8.56E-05 Aging (time to event) PFKFB3 intron 21782286 rs1064891 chr10 6276574 T C 2.70E-06 Celiac disease PFKFB3 UTR-3 17558408 rs1539234 chr10 6276743 G A 4.60E-06 Celiac disease PFKFB3 UTR-3 17558408 rs7916923 chr10 6286839 T C 1.18E-04 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs7916923 chr10 6286839 T C 6.91E-05 Esophageal adenocarcinoma / / 24121790 rs2185691 chr10 6292607 T C 1.30E-04 Alcohol dependence / / 20201924 rs2185691 chr10 6292607 T C 9.67E-05 Major depressive disorder / / pha002850 rs4750200 chr10 6308646 A G 2.12E-05 Bladder cancer / / 19648920 rs11257726 chr10 6311749 A G 9.66E-04 Type 2 diabetes / / 17463246 rs11257726 chr10 6311749 A G 6.71E-04 Multiple complex diseases / / 17554300 rs11257741 chr10 6314722 G A 6.72E-04 Type 2 diabetes / / 17463246 rs11257741 chr10 6314722 G A 6.54E-04 Multiple complex diseases / / 17554300 rs7077335 chr10 6315794 C A 2.00E-12 Myopia (pathological) / / 23049088 rs7896455 chr10 6322167 G T 4.24E-05 Type 2 diabetes LOC399715 intron 17463246 rs7896594 chr10 6322229 G A 4.49E-05 Type 2 diabetes LOC399715 intron 17463246 rs11257854 chr10 6329997 T C 2.11E-05 Type 2 diabetes LOC399715 intron 17463246 rs7906792 chr10 6347698 T A 3.68E-05 Type 2 diabetes LOC399715 intron 17463246 rs7906792 chr10 6347698 T A 4.37E-04 Multiple complex diseases LOC399715 intron 17554300 rs7906792 chr10 6347698 T A 6.17E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LOC399715 intron 20031582 rs12262851 chr10 6350590 C T 7.48E-04 Multiple complex diseases LOC399715 intron 17554300 rs7913723 chr10 6351150 C G 1 Drug response to Etoposide LOC399715 intron 17537913 rs764189 chr10 6356210 C T 6.63E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LOC399715 intron 20031582 rs12779447 chr10 6364754 G A 5.89E-05 Stroke LOC399715 intron pha002887 rs10795992 chr10 6367728 A G 1.46E-04 Type 2 diabetes LOC399715 intron 17463246 rs7087682 chr10 6368760 C T 6.56E-05 Type 2 diabetes LOC399715 intron 17463246 rs947470 chr10 6389605 A G 8.05E-04 Schizophrenia / / 19197363 rs947471 chr10 6389672 T C 8.05E-04 Schizophrenia / / 19197363 rs947473 chr10 6389914 A C 4.75E-06 Personality dimensions / / 21173776 rs2387397 chr10 6390192 G C 1.90E-08 Celiac disease / / 22057235 rs2387397 chr10 6390192 G C 0.000000019 Celiac disease / / 23143596 rs947474 chr10 6390450 G A 1.74E-05 Multiple complex diseases / / 17554300 rs947474 chr10 6390450 G A 4.00E-09 Type 1 diabetes / / 18978792 rs947474 chr10 6390450 G A 4.00E-09 Multiple sclerosis / / 22190364 rs947474 chr10 6390450 G A 0.000025 Rheumatoid arthritis / / 23143596 rs947474 chr10 6390450 G A 3.00E-10 Rheumatoid arthritis / / 24390342 rs947474 chr10 6390450 G A 4.00E-10 Rheumatoid arthritis / / 24390342 rs12416248 chr10 6391031 G C 1.61E-05 Alzheimer's disease (late onset) / / 21460841 rs2181622 chr10 6391061 G A 5.68E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs744254 chr10 6392848 G A 2.41E-04 Multiple complex diseases / / 17554300 rs744253 chr10 6393009 A G 1.59E-04 Multiple complex diseases / / 17554300 rs4750316 chr10 6393260 C G 5.55E-05 Multiple complex diseases / / 17554300 rs4750316 chr10 6393260 C G 4.00E-06 Rheumatoid arthritis / / 18794853 rs4750316 chr10 6393260 C G 2.00E-06 Rheumatoid arthritis / / 20453842 rs4750316 chr10 6393260 C G 1.30E-08 Celiac disease and Rheumatoid arthritis / / 21383967 rs4750316 chr10 6393260 C G 1.30E-08 Multiple sclerosis / / 22190364 rs4750316 chr10 6393260 C G 4.22E-08 Rheumatoid arthritis / / 23143596 rs4750316 chr10 6393260 C G 1.55E-04 Rheumatoid arthritis / / 24449572 rs725206 chr10 6394995 C T 5.94E-06 Alzheimer's disease (late onset) / / 21460841 rs4558075 chr10 6401625 C T 5.89E-04 Taste perception / / 22132133 rs4558075 chr10 6401625 C T 2.00E-07 Celiac disease / / 24999842 rs10796045 chr10 6402741 G T 8.46E-04 Taste perception / / 22132133 rs10796045 chr10 6402741 G T 4.63E-07 Celiac disease / / 24999842 rs1570527 chr10 6404700 T G 1.45E-05 Multiple complex diseases / / 17554300 rs11258317 chr10 6407737 G A 6.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs11258317 chr10 6407737 G A 5.61E-06 Schizophrenia / / pha002857 rs592456 chr10 6435374 C T 2.43E-04 Taste perception / / 22132133 rs2296125 chr10 6441591 G A 0.00008598 Sarcoidosis / / 22952805 rs11258500 chr10 6442854 T C 0.00006691 Sarcoidosis / / 22952805 rs11258501 chr10 6443214 T C 0.00006691 Sarcoidosis / / 22952805 rs11258515 chr10 6445110 C T 0.0000961 Sarcoidosis / / 22952805 rs7095942 chr10 6445160 T C 6.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs79708044 chr10 6445223 A G 0.0000961 Sarcoidosis / / 22952805 rs9633784 chr10 6453002 C T 0.00007973 Sarcoidosis / / 22952805 rs11258589 chr10 6454687 G A 0.00007973 Sarcoidosis / / 22952805 rs11258612 chr10 6456434 C T 0.00009714 Sarcoidosis / / 22952805 rs4750439 chr10 6469324 C T 8.24E-04 Suicide attempts in bipolar disorder PRKCQ UTR-3 21423239 rs2236380 chr10 6469817 A G 3.04E-04 Suicide attempts in bipolar disorder PRKCQ UTR-3 21423239 rs2236380 chr10 6469817 A G 1.87E-06 Type 1 diabetes PRKCQ UTR-3 21980299 rs681023 chr10 6471318 C T 1.56E-04 Multiple complex diseases PRKCQ intron 17554300 rs11596750 chr10 6471816 T C 2.29E-04 Suicide attempts in bipolar disorder PRKCQ intron 21423239 rs11258747 chr10 6472891 G T 1.00E-07 Type 1 diabetes PRKCQ cds-synon 19430480 rs602419 chr10 6473216 T G 3.58E-07 FVII levels PRKCQ intron 21676895 rs10796145 chr10 6474027 G A 5.32E-04 Suicide attempts in bipolar disorder PRKCQ intron 21423239 rs944714 chr10 6475157 A G 5.49E-04 Suicide attempts in bipolar disorder PRKCQ intron 21423239 rs631968 chr10 6475296 T C 4.03E-04 Suicide attempts in bipolar disorder PRKCQ intron 21423239 rs677986 chr10 6477267 G A 8.83E-04 Suicide attempts in bipolar disorder PRKCQ intron 21423239 rs944715 chr10 6479156 C T 4.36E-04 Suicide attempts in bipolar disorder PRKCQ intron 21423239 rs11258802 chr10 6479507 G C 1.21E-04 Suicide attempts in bipolar disorder PRKCQ intron 21423239 rs12358161 chr10 6481227 G A 2.05E-04 Suicide attempts in bipolar disorder PRKCQ intron 21423239 rs6602705 chr10 6487428 T C 2.89E-05 Suicide attempts in bipolar disorder PRKCQ intron 21423239 rs7918923 chr10 6500718 C T 3.00E-04 Coronary Artery Disease PRKCQ intron 17634449 rs618020 chr10 6503450 T A 5.84E-04 Insulin resistance PRKCQ intron 21901158 rs604663 chr10 6504126 T C 3.58E-04 Suicide attempts in bipolar disorder PRKCQ intron 21041247 rs678304 chr10 6504136 C G 4.31E-04 Suicide attempts in bipolar disorder PRKCQ intron 21041247 rs591441 chr10 6511386 G A 0.0000823 Salmonella-induced pyroptosis PRKCQ intron 22837397 rs7080157 chr10 6512559 G A 5.56E-05 Lupus nephritis in systemic lupus erythematosus PRKCQ intron 24925725 rs12269156 chr10 6512580 A G 1.49E-08 Cholesterol,total PRKCQ intron 23063622 rs12269156 chr10 6512580 A G 3.49E-10 LDL cholesterol PRKCQ intron 23063622 rs11597105 chr10 6512581 G A 9.85E-05 Caffeine consumption PRKCQ intron 21490707 rs6602745 chr10 6536552 C T 5.91E-04 Amyotrophic Lateral Sclerosis PRKCQ intron 17362836 rs4748099 chr10 6536608 C T 6.29E-04 Multiple complex diseases PRKCQ intron 17554300 rs500766 chr10 6550590 C T 2.97E-05 Angioedema in response to angiotensin-converting enzyme inhibitor PRKCQ intron 23838604 rs667254 chr10 6564775 C T 2.97E-05 Angioedema in response to angiotensin-converting enzyme inhibitor PRKCQ intron 23838604 rs11259403 chr10 6572225 C T 7.00E-06 Body mass index (asthmatics) PRKCQ intron 23517042 rs11259425 chr10 6577673 C G 5.10E-06 Urinary metabolites PRKCQ intron 21572414 rs6602820 chr10 6596242 G A 4.99E-04 Multiple complex diseases PRKCQ intron 17554300 rs4748153 chr10 6606541 C T 3.00E-08 Immune response to smallpox vaccine (IL-6) PRKCQ intron 22542470 rs7072496 chr10 6608313 C T 1.03E-05 Odorant perception PRKCQ intron 23910658 rs10906888 chr10 6611326 G A 7.74E-04 Multiple complex diseases PRKCQ intron 17554300 rs10906922 chr10 6629225 G A 0.0000329 Tuberculosis with early age of onset / / 22551897 rs10737105 chr10 6631223 C G 3.90E-05 Psoriasis / / 20953189 rs2435587 chr10 6631867 G A 1.49E-04 Celiac disease / / 23936387 rs1041227 chr10 6643803 C T 3.00E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1041226 chr10 6643851 G A 1.60E-04 Taste perception / / 22132133 rs975167 chr10 6650991 T G 1.44E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1327249 chr10 6651563 G A 8.30E-05 Tooth agenesis (third molar) / / 24172245 rs2387587 chr10 6653936 G T 5.13E-04 Multiple complex diseases / / 17554300 rs6602060 chr10 6662657 T C 8.82E-05 Taste perception / / 22132133 rs1475418 chr10 6690147 T C 6.98E-05 Hypertension / / pha003041 rs11253857 chr10 6700116 A G 5.30E-05 Rheumatoid arthritis / / 21673997 rs10795360 chr10 6701714 G C 6.57E-04 Alzheimer's disease / / 22005930 rs11253894 chr10 6706872 C T 9.90E-05 Coronary heart disease / / pha003031 rs2026628 chr10 6709658 A G 1.60E-05 Rheumatoid arthritis / / 21673997 rs4747272 chr10 6713760 T C 6.48E-04 Alzheimer's disease / / 22005930 rs7071132 chr10 6714060 A T 7.59E-04 Alzheimer's disease / / 22005930 rs10904722 chr10 6714424 T C 8.13E-04 Taste perception / / 22132133 rs7893320 chr10 6717515 T C 5.70E-04 Alzheimer's disease / / 22005930 rs3928770 chr10 6717865 C T 6.52E-04 Alzheimer's disease / / 22005930 rs11254023 chr10 6726703 A G 7.30E-04 Aortic root size / / 21223598 rs2387595 chr10 6727538 C T 9.12E-06 Soluble levels of adhesion molecules / / pha003072 rs11254047 chr10 6729497 C T 9.90E-05 Cognitive performance / / 19734545 rs11254048 chr10 6729511 G A 5.84E-04 Multiple complex diseases / / 17554300 rs10508311 chr10 6731456 C G 0.0000215 Panic disorder / / 23149450 rs10508311 chr10 6731456 C G 3.19E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs4237341 chr10 6737384 T G 1.53E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs12573122 chr10 6738313 A G 0.0000593 Panic disorder / / 23149450 rs12573122 chr10 6738313 A G 5.93E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs7099454 chr10 6756983 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1442721 chr10 6771957 C T 2.50E-06 Urinary metabolites / / 21572414 rs1442721 chr10 6771957 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7096622 chr10 6781338 T G 7.03E-04 Type 2 diabetes / / 17463246 rs12570744 chr10 6789463 C T 1.92E-07 Response to anti-TNF treatment in rheumatoid arthritis / / 23555300 rs12570744 chr10 6789463 C T 2.00E-07 Response to anti-TNF treatment in rheumatoid arthritis / / 23555300 rs12570744 chr10 6789463 C T 3.05E-05 Response to anti-TNF treatment in rheumatoid arthritis / / 23555300 rs12570744 chr10 6789463 C T 5.50E-04 Response to anti-TNF treatment in rheumatoid arthritis / / 23555300 rs7920034 chr10 6791192 G A 3.10E-04 Type 2 diabetes / / 17463246 rs12764177 chr10 6792567 A C 8.61E-04 Response to TNF antagonist treatment / / 21061259 rs413721 chr10 6796079 T C 9.42E-04 Type 2 diabetes / / 17463246 rs353186 chr10 6797935 C G 1.88E-04 Response to TNF antagonist treatment / / 21061259 rs17141724 chr10 6797972 G A 9.99E-05 Alzheimer's disease / / 17998437 rs353188 chr10 6799130 T A 4.32E-04 Aortic root size / / 21223598 rs353189 chr10 6799269 A G 5.84E-05 Metabolite levels (MHPG) / / 23319000 rs12218200 chr10 6801162 G A 5.84E-05 Metabolite levels (MHPG) / / 23319000 rs11254492 chr10 6805486 G A 5.06E-04 Iron levels / / pha002876 rs11254499 chr10 6806600 G T 6.84E-04 Multiple complex diseases / / 17554300 rs11254580 chr10 6818583 C T 6.71E-04 Multiple complex diseases LOC100652997 intron 17554300 rs10904957 chr10 6826024 T A 5.18E-04 Multiple complex diseases LOC100507127 intron 17554300 rs10904966 chr10 6830962 A G 4.02E-05 Multiple complex diseases LOC100507127 intron 17554300 rs2387742 chr10 6836687 C T 3.45E-04 Iron levels LOC100507127 intron pha002876 rs2892347 chr10 6838849 G T 7.63E-04 Response to TNF antagonist treatment LOC100507127 intron 21061259 rs11254686 chr10 6838942 C T 7.15E-04 Response to TNF antagonist treatment LOC100507127 intron 21061259 rs11254759 chr10 6857307 G A 2.35E-04 Breast cancer LOC100507127 intron 21060860 rs7895644 chr10 6858920 T G 2.27E-04 Breast cancer LOC100507127 intron 21060860 rs11254771 chr10 6862055 A G 1.66E-04 Breast cancer LOC100507127 intron 21060860 rs17400327 chr10 6884134 C T 4.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs1013250 chr10 6893264 G A 6.82E-04 Suicide attempts in bipolar disorder / / 21041247 rs17142092 chr10 6914071 C T 8.39E-04 Prostate cancer mortality / / 20978177 rs2791408 chr10 6922340 A G 1.11E-04 Coronary heart disease / / 21606135 rs11816922 chr10 6924444 C A 2.06E-04 Migraine with aura / / 23793025 rs11816922 chr10 6924444 C A 5.00E-06 Migraine / / 23793025 rs17142139 chr10 6926362 G A 1.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs546899 chr10 6929145 C T 5.98E-05 Coronary heart disease / / 21606135 rs10508315 chr10 6934645 T C 7.71E-04 Alzheimer's disease / / 17998437 rs2892352 chr10 6942102 G A 3.52E-05 Glucose levels / / pha003058 rs2892352 chr10 6942102 G A 9.65E-05 Glucose levels / / pha003061 rs4378289 chr10 6945985 G A 9.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs6602217 chr10 6946263 T C 2.32E-05 Lung adenocarcinoma / / 19836008 rs6602217 chr10 6946263 T C 4.58E-05 Schizophrenia / / 21926974 rs6602217 chr10 6946263 T C 2.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs6602217 chr10 6946263 T C 0.0000229 Schizophrenia / / 23637625 rs2501677 chr10 6946752 A T 3.00E-06 Fasting insulin-related traits (interaction with BMI) / / 22581228 rs2387751 chr10 6955430 C A 5.39E-05 Orofacial clefts / / 22419666 rs2490689 chr10 6969816 T C 1.52E-05 Stroke (ischemic) / / 22941190 rs17404332 chr10 6975531 T C 5.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs1417019 chr10 6977902 T C 2.18E-04 Glycosylated haemoglobin levels / / 17255346 rs2490696 chr10 6983811 A G 5.53E-05 Stroke / / pha002887 rs946785 chr10 7001654 A G 2.26E-05 Parkinson's disease / / 21738487 rs946785 chr10 7001654 A G 7.80E-04 Type 2 diabetes / / 23209189 rs2490699 chr10 7006906 T C 9.73E-04 Multiple complex diseases / / 17554300 rs11254908 chr10 7007088 T C 9.98E-04 Multiple complex diseases / / 17554300 rs1417017 chr10 7009116 T A 6.98E-04 Acute lung injury / / 22295056 rs1417032 chr10 7012462 T C 1.94E-04 Alzheimer's disease / / pha002879 rs2486866 chr10 7013216 C T 1.53E-04 Alzheimer's disease / / pha002879 rs7078447 chr10 7015194 T C 1.54E-04 Taste perception / / 22132133 rs7917304 chr10 7021234 G A 3.29E-06 Cognitive test performance / / 20125193 rs2804110 chr10 7023565 C T 7.73E-04 Metabolite levels (MHPG) / / 23319000 rs2804108 chr10 7023888 C T 8.51E-04 Metabolite levels (MHPG) / / 23319000 rs2804134 chr10 7038660 G A,C,T 6.72E-05 HDL cholesterol / / pha003075 rs2804134 chr10 7038660 G A,C,T 1.01E-05 Lipid levels / / pha003082 rs2804133 chr10 7039552 A G 1.39E-05 Lipid levels / / pha003082 rs2788628 chr10 7042852 T C 8.45E-04 Type 2 diabetes / / 17463246 rs946287 chr10 7086473 T C 1.20E-05 Cognitive test performance / / 20125193 rs10905099 chr10 7089016 A G 8.00E-06 Orofacial clefts / / 22419666 rs946284 chr10 7089312 T C 4.15E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7074704 chr10 7108989 A G 7.46E-05 Orofacial clefts / / 22419666 rs9423765 chr10 7112076 G A 9.00E-05 Prostate cancer / / 21743057 rs2387906 chr10 7116005 G A 9.56E-04 Type 2 diabetes / / 17846125 rs7067992 chr10 7127076 A G 8.36E-04 Type 2 diabetes / / 17846125 rs2462692 chr10 7144255 T A,C,G 5.15E-06 Leprosy / / 20018961 rs2462692 chr10 7144255 T A,C,G 2.33E-19 Sickle cell anemia (severity) / / 20029952 rs2462692 chr10 7144255 T A,C,G 1.57E-06 Leprosy / / pha002872 rs2388027 chr10 7148302 A G 2.21E-04 Myocardial Infarction / / pha002883 rs942432 chr10 7162564 T C 6.70E-04 Taste perception / / 22132133 rs2247498 chr10 7193364 C T 7.25E-05 Body Mass Index / / pha003015 rs2462696 chr10 7208862 G A 1.86E-04 Smoking cessation SFMBT2 intron 18519826 rs7081404 chr10 7219457 G A 4.72E-04 Multiple complex diseases SFMBT2 intron 17554300 rs1969825 chr10 7221320 G A 6.84E-05 Body Mass Index SFMBT2 intron pha003009 rs2762608 chr10 7229439 T C 3.21E-04 Multiple complex diseases SFMBT2 intron 17554300 rs2762608 chr10 7229439 T C 2.62E-04 Smoking cessation SFMBT2 intron 18519826 rs2762607 chr10 7230824 A C 1.74E-04 Multiple complex diseases SFMBT2 intron 17554300 rs2277225 chr10 7244675 G A 8.42E-04 Acute lung injury SFMBT2 intron 22295056 rs10905117 chr10 7249734 T G 0.0000619 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SFMBT2 intron 22628534 rs7920088 chr10 7250148 C T 4.35E-04 Acute lung injury SFMBT2 intron 22295056 rs2692824 chr10 7253461 C T 1.37E-04 Type 2 diabetes SFMBT2 intron 17463246 rs2692840 chr10 7259446 C T 1.63E-05 Smoking cessation SFMBT2 intron 18519826 rs2692840 chr10 7259446 C T 3.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) SFMBT2 intron 23648065 rs2692812 chr10 7265468 T C 3.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) SFMBT2 intron 23648065 rs2025463 chr10 7273601 A G 9.50E-04 Type 2 diabetes and 6 quantitative traits SFMBT2 intron 17848626 rs10905124 chr10 7276215 G A 3.41E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) SFMBT2 intron 23648065 rs10905129 chr10 7280550 T C 3.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) SFMBT2 intron 23648065 rs1535863 chr10 7286614 A C 9.20E-04 Type 2 diabetes SFMBT2 intron 17463246 rs12256404 chr10 7287771 G A 5.18E-04 Smoking initiation SFMBT2 intron 24665060 rs10905136 chr10 7301457 T C 2.24E-04 Type 2 diabetes SFMBT2 intron 17463246 rs2767696 chr10 7301591 C T 7.30E-04 Type 2 diabetes SFMBT2 intron 17463246 rs2692780 chr10 7305696 A G 9.26E-05 Cardiovascular disease SFMBT2 intron pha003065 rs10508328 chr10 7310004 T C 7.00E-05 Prostate cancer SFMBT2 intron 22923026 rs12776457 chr10 7396604 G C 2.00E-04 Response to cytidine analogues (gemcitabine) SFMBT2 intron 24483146 rs719810 chr10 7460252 A G 8.02E-04 Type 2 diabetes / / 17463246 rs7077972 chr10 7480692 A C 7.61E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs4748940 chr10 7508499 A G 3.09E-08 Systemic lupus erythematosus / / pha002867 rs11255149 chr10 7511603 T C 2.86E-04 Stroke / / pha002887 rs7911580 chr10 7516306 G T 3.34E-05 Bipolar disorder / / 17486107 rs2245352 chr10 7523155 C T 7.66E-04 Body mass index / / 21701565 rs2245977 chr10 7528721 A C 2.92E-04 Type 2 diabetes / / 17463246 rs873930 chr10 7529974 A G 4.40E-06 Speech perception in dyslexia / / 19786962 rs12414739 chr10 7531747 C T 3.88E-04 Body mass index / / 21701565 rs12414739 chr10 7531747 C T 6.24E-04 Body mass index / / 21701565 rs11591777 chr10 7549849 A G 2.30E-06 Urinary metabolites / / 21572414 rs11255178 chr10 7565716 T C 1.40E-05 Urinary metabolites / / 21572414 rs11596759 chr10 7585013 G A 4.81E-04 Multiple complex diseases / / 17554300 rs12416004 chr10 7610213 C T 8.61E-05 Smoking cessation ITIH5 intron 18519826 rs1537625 chr10 7610506 C A 3.18E-04 Type 2 diabetes ITIH5 intron 17463246 rs12247601 chr10 7611498 T C 8.10E-05 Alcoholism (heaviness of drinking) ITIH5 intron 21529783 rs12774458 chr10 7623127 G A 1.92E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) ITIH5 intron 24236485 rs11255224 chr10 7639932 G T 9.33E-04 Myopia (pathological) ITIH5 intron 21095009 rs11255226 chr10 7642284 C T 2.29E-04 Multiple complex diseases ITIH5 intron 17554300 rs4623795 chr10 7651909 C G 6.60E-04 Multiple complex diseases ITIH5 intron 17554300 rs4623795 chr10 7651909 C G 7.80E-05 Personality dimensions ITIH5 intron 18957941 rs11255241 chr10 7660490 C A 1.18E-04 Smoking cessation ITIH5 intron 18519826 rs7904081 chr10 7661011 C T 7.11E-05 Cognitive test performance ITIH5 intron 20125193 rs7904081 chr10 7661011 C T 1.95E-05 Height ITIH5 intron pha003010 rs7904081 chr10 7661011 C T 1.82E-05 Height ITIH5 intron pha003011 rs11255242 chr10 7661114 C G 1.22E-04 Smoking cessation ITIH5 intron 18519826 rs1970183 chr10 7661453 T C 9.44E-04 Myocardial Infarction ITIH5 intron pha002873 rs10795560 chr10 7667975 T C 7.59E-04 Metabolite levels (MHPG) ITIH5 intron 23319000 rs10905203 chr10 7668637 C T 2.48E-04 Multiple complex diseases ITIH5 intron 17554300 rs17347867 chr10 7673498 T G 6.75E-05 Height ITIH5 intron pha003011 rs17142881 chr10 7677416 A G 1.59E-04 Multiple complex diseases ITIH5 intron 17554300 rs6602256 chr10 7679393 C T 5.69E-04 Multiple complex diseases ITIH5 cds-synon 17554300 rs12769926 chr10 7684323 G A 6.43E-04 Multiple complex diseases ITIH5 intron 17554300 rs9732111 chr10 7688458 C T 7.10E-06 Urinary metabolites ITIH5 intron 21572414 rs11255267 chr10 7697504 G A 3.67E-04 Type 2 diabetes ITIH5 intron 17463246 rs11255272 chr10 7700795 C T 2.63E-04 Multiple complex diseases ITIH5 intron 17554300 rs7908119 chr10 7716687 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7068417 chr10 7718254 C T 3.63E-04 Multiple complex diseases / / 17554300 rs11812109 chr10 7730983 C T 9.63E-05 Cognitive test performance / / 20125193 rs11255291 chr10 7736904 C T 2.00E-06 Ovarian reserve / / 22116950 rs7474871 chr10 7741956 G A 6.59E-05 Multiple complex diseases / / 17554300 rs4747574 chr10 7755623 G T 3.81E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ITIH2 intron 24023788 rs7090433 chr10 7759865 A G 0.00063254 Hypertension (early onset hypertension) ITIH2 intron 22479346 rs6602267 chr10 7759926 T C 0.000607869 Hypertension (early onset hypertension) ITIH2 intron 22479346 rs7912641 chr10 7768221 G T 9.11E-04 Response to taxane treatment (placlitaxel) ITIH2 intron 23006423 rs7074068 chr10 7768781 A G 0.000782786 Hypertension (early onset hypertension) ITIH2 intron 22479346 rs3736966 chr10 7785087 G A 8.76E-04 Metabolite levels (MHPG) ITIH2 intron 23319000 rs11255338 chr10 7796891 A G 8.67E-04 Response to taxane treatment (placlitaxel) KIN UTR-3 23006423 rs12761309 chr10 7810017 A G 2.45E-04 Hearing function KIN intron 17255346 rs7095166 chr10 7821081 A G,T 3.98E-04 Alzheimer's disease KIN intron 24755620 rs4363498 chr10 7825530 T C 4.64E-05 Monocyte chemoattractant protein-1 KIN intron pha003071 rs1244416 chr10 7837189 T A 1.80E-05 Urinary metabolites ATP5C1 intron 21572414 rs1244432 chr10 7845298 T A 8.80E-06 Urinary metabolites ATP5C1 intron 21572414 rs1244434 chr10 7846974 C T 7.80E-06 Urinary metabolites ATP5C1 intron 21572414 rs1244444 chr10 7852454 T C 1.30E-05 Urinary metabolites / / 21572414 rs1244456 chr10 7859107 C T 1.80E-05 Urinary metabolites / / 21572414 rs1244506 chr10 7873271 G A 1.90E-05 Urinary metabolites TAF3 intron 21572414 rs11255400 chr10 7887621 G A 7.00E-06 IgG glycosylation TAF3 intron 23382691 rs6602275 chr10 7903733 C T 4.24E-04 Oral cancers (chewing tobacco related) TAF3 intron 22503698 rs10905240 chr10 7908552 G A 5.78E-06 Post-operative nausea and vomiting TAF3 intron 21694509 rs11594292 chr10 7947548 T C 3.62E-05 Post-operative nausea and vomiting TAF3 intron 21694509 rs11255455 chr10 7991452 C A 1.57E-05 Post-operative nausea and vomiting TAF3 intron 21694509 rs7101294 chr10 8022873 A G 3.81E-05 Post-operative nausea and vomiting TAF3 intron 21694509 rs4749442 chr10 8028388 T C 2.13E-05 Post-operative nausea and vomiting TAF3 intron 21694509 rs11593082 chr10 8040431 T C 3.69E-05 Serum alpha1-antitrypsin levels TAF3 intron 23990791 rs10905267 chr10 8056495 C T 4.30E-04 Multiple complex diseases TAF3 intron 17554300 rs430753 chr10 8074437 A C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10795588 chr10 8086170 A G 2.99E-05 Erythrocyte counts / / pha003101 rs263425 chr10 8088277 C T 4.32E-04 Multiple complex diseases / / 17554300 rs4143094 chr10 8089136 T G 9.00E-09 Colorectal cancer (diet interaction) / / 24743840 rs403029 chr10 8090001 G C 1 Drug response to Etoposide / / 17537913 rs403029 chr10 8090001 G C 5.54E-04 Multiple complex diseases / / 17554300 rs1244181 chr10 8091377 A C,G,T 1.71E-06 Migraine with aura / / 23793025 rs1244186 chr10 8092683 T C 2.97E-08 Hodgkin's lymphoma / / 24149102 rs501764 chr10 8093034 G T 7.00E-08 Hodgkin's lymphoma FLJ45983 intron 21037568 rs501764 chr10 8093034 G T 4.00E-10 Hodgkin's lymphoma FLJ45983 intron 24149102 rs485411 chr10 8093185 T C 4.93E-06 Hodgkin's lymphoma FLJ45983 intron 21037568 rs485411 chr10 8093185 T C 6.61E-06 Non-small cell lung cancer (survival) FLJ45983 intron 23704207 rs485411 chr10 8093185 T C 1.52E-08 Hodgkin's lymphoma FLJ45983 intron 24149102 rs485411 chr10 8093185 T C 1.72E-08 Colorectal cancer (diet interaction) FLJ45983 intron 24743840 rs2275806 chr10 8095340 G A 0.000000046 Rheumatoid arthritis / / 23143596 rs2275806 chr10 8095340 G A 4.58E-08 Rheumatoid arthritis (CCP positive) / / 23143596 rs1269486 chr10 8096199 A G 7.53E-08 Colorectal cancer (diet interaction) GATA3 nearGene-5 24743840 rs1399180 chr10 8098719 T C 1 Drug response to Etoposide GATA3 intron 17537913 rs3781094 chr10 8101427 A C 0.0000976 Primary sclerosing cholangitis GATA3 intron 23603763 rs3781093 chr10 8101927 T C 4.09E-04 Suicide attempts in bipolar disorder GATA3 intron 21423239 rs3781093 chr10 8101927 T C 2.62E-07 Acute lymphoblastic leukemia (childhood) GATA3 intron 24141364 rs3781093 chr10 8101927 T C 4.94E-12 Acute lymphoblastic leukemia (childhood) GATA3 intron 24141364 rs3802604 chr10 8102272 G A 0.00000368 Rheumatoid arthritis (CCP positive) GATA3 intron 23143596 rs3802604 chr10 8102272 G A 0.0000507 Rheumatoid arthritis GATA3 intron 23143596 rs376397 chr10 8103298 A G 7.48E-04 Suicide attempts in bipolar disorder GATA3 intron 21423239 rs3824662 chr10 8104208 C A 9.00E-12 Acute lymphoblastic leukemia (B-cell precursor) GATA3 intron 23996088 rs3824662 chr10 8104208 C A 1.05E-08 Acute lymphoblastic leukemia (childhood) GATA3 intron 24141364 rs3824662 chr10 8104208 C A 2.17E-14 Acute lymphoblastic leukemia (childhood) GATA3 intron 24141364 rs3824660 chr10 8104722 C T 2.00E-08 Rheumatoid arthritis GATA3 intron 24390342 rs3824660 chr10 8104722 C T 3.00E-09 Rheumatoid arthritis GATA3 intron 24390342 rs2277228 chr10 8105745 G A 8.99E-04 Suicide attempts in bipolar disorder GATA3 intron 21423239 rs3781092 chr10 8106353 G A 2.31E-04 Suicide attempts in bipolar disorder GATA3 intron 21423239 rs570613 chr10 8106502 C T 2.26E-04 Suicide attempts in bipolar disorder GATA3 intron 21423239 rs568727 chr10 8106701 A C 2.62E-04 Suicide attempts in bipolar disorder GATA3 intron 21423239 rs10752126 chr10 8106747 G C 8.98E-04 Suicide attempts in bipolar disorder GATA3 intron 21423239 rs569421 chr10 8108592 T C 4.33E-07 Acute lymphoblastic leukemia (B-cell precursor) GATA3 intron 23996088 rs444929 chr10 8110024 C T 1.79E-04 Alzheimer's disease GATA3 intron 17998437 rs444929 chr10 8110024 C T 3.00E-06 Hodgkin's lymphoma GATA3 intron 24920014 rs422628 chr10 8111409 C T 3.95E-04 Alzheimer's disease GATA3 intron 17998437 rs9746 chr10 8116503 A G 1.24E-06 Acute lymphoblastic leukemia (B-cell precursor) GATA3 UTR-3 23996088 rs2798841 chr10 8132972 C T 6.84E-05 Sodium levels / / pha003093 rs1244157 chr10 8137356 A G 3.69E-05 Sodium levels / / pha003093 rs10508343 chr10 8150713 C A 8.00E-06 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs11255526 chr10 8153348 G C 4.96E-05 Serum metabolites / / 19043545 rs7901847 chr10 8164215 T C 6.10E-04 Smoking initiation / / 24665060 rs11593940 chr10 8164599 G A 1.30E-05 Urinary metabolites / / 21572414 rs17448111 chr10 8177161 C G 3.84E-04 Multiple complex diseases / / 17554300 rs17143250 chr10 8177255 C T 1.76E-04 Multiple complex diseases / / 17554300 rs12268153 chr10 8186268 T C 7.57E-05 Hypertension / / 19609347 rs541945 chr10 8192239 C A 4.79E-04 Type 2 diabetes / / 17463246 rs17376977 chr10 8202956 C A 5.61E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs17449720 chr10 8219241 A G 8.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs10905311 chr10 8224786 C T 1.66E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1416560 chr10 8231720 G A 7.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs10508346 chr10 8231982 G C 5.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs11255560 chr10 8232008 A G 4.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs10508347 chr10 8232422 G T 5.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs11255563 chr10 8232965 G C 2.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs10905312 chr10 8233252 G A 2.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs1779643 chr10 8233615 A C 1.79E-05 Suicide attempts in bipolar disorder / / 21423239 rs2489248 chr10 8234457 T A 1.82E-05 Suicide attempts in bipolar disorder / / 21423239 rs10905315 chr10 8251307 G A 4.57E-04 IgE levels / / 17255346 rs17379473 chr10 8260821 G A 7.99E-04 Type 2 diabetes / / 17463246 rs1779630 chr10 8293266 C T 2.40E-05 Urinary metabolites / / 21572414 rs6602296 chr10 8324716 G T 6.70E-05 Response to statin therapy / / 20339536 rs6602296 chr10 8324716 G T 0.000745036 Hypertension (early onset hypertension) / / 22479346 rs11255615 chr10 8324889 T C 5.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule) / / 24025145 rs17466705 chr10 8326554 G T 2.10E-05 Urinary metabolites / / 21572414 rs10795615 chr10 8329986 T C 2.59E-05 Gaucher disease severity / / 22388998 rs4749728 chr10 8331078 G T 2.82E-04 Schizophrenia / / 19197363 rs10159927 chr10 8334463 G A 1.22E-11 Metabolite levels / / 22286219 rs1892063 chr10 8337245 A G 6.67E-04 Depression (quantitative trait) / / 20800221 rs11255628 chr10 8350343 T C 5.74E-04 Depression (quantitative trait) / / 20800221 rs1999872 chr10 8353494 C A 5.01E-05 Hirschsprung's disease / / 19196962 rs1538246 chr10 8367870 A C 4.18E-05 Asthma / / pha003128 rs11255635 chr10 8370629 T C 7.50E-05 Hemoglobin concentration / / 20534544 rs10508350 chr10 8378782 C T 9.22E-06 Schizophrenia / / 24253340 rs2388712 chr10 8382503 A G 9.10E-06 Stroke (ischemic) / / 22384361 rs7088565 chr10 8390131 T C 1.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs12781482 chr10 8393925 G A 1.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs11598970 chr10 8397816 A T 0.00054 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11598970 chr10 8397816 A T 5.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7081521 chr10 8398914 C T 7.10E-06 Urinary metabolites / / 21572414 rs11255657 chr10 8406819 C T 9.27E-05 Hypertension / / pha003041 rs11255657 chr10 8406819 C T 8.92E-05 Diabetes Mellitus / / pha003059 rs11255665 chr10 8416139 G A 0.0008912 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11255665 chr10 8416139 G A 8.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12265137 chr10 8416256 A G 0.0006601 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12265137 chr10 8416256 A G 6.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2787140 chr10 8442856 C T 8.94E-05 Coronary Artery Disease / / 17634449 rs1361153 chr10 8458317 C T 1.03E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2993385 chr10 8462439 T C 5.94E-06 Prostate cancer / / 24185611 rs2646425 chr10 8470387 C T 2.70E-05 Urinary metabolites / / 21572414 rs7918885 chr10 8474595 T G 1.29E-07 Prostate cancer / / 24185611 rs12251624 chr10 8479257 T C 2.62E-06 Prostate cancer / / 24185611 rs7090925 chr10 8479868 A G 2.62E-06 Prostate cancer / / 24185611 rs10905371 chr10 8480044 A G 2.77E-07 Prostate cancer / / 24185611 rs10905374 chr10 8481486 G A 4.43E-07 Prostate cancer / / 24185611 rs17143655 chr10 8483560 A G 2.50E-04 Multiple complex diseases / / 17554300 rs17143655 chr10 8483560 A G 8.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7096374 chr10 8484113 C T 5.16E-07 Prostate cancer / / 24185611 rs7896254 chr10 8486161 G A 3.27E-07 Prostate cancer / / 24185611 rs17143668 chr10 8486444 T C 1.88E-04 Smoking initiation / / 24665060 rs7090191 chr10 8486590 A G 0.000769 Salmonella-induced pyroptosis / / 22837397 rs7079888 chr10 8498892 C T 8.51E-05 Erythrocyte counts / / pha003099 rs7904468 chr10 8523708 G T 2.15E-04 Stroke / / pha002886 rs4749765 chr10 8529115 G A 1.40E-05 Urinary metabolites / / 21572414 rs4749765 chr10 8529115 G A 3.90E-05 Insulin resistance / / 21901158 rs10795640 chr10 8529752 C T 3.58E-04 Insulin resistance / / 21901158 rs10795641 chr10 8529815 G C 3.13E-04 Insulin resistance / / 21901158 rs10905386 chr10 8531676 A G 1.50E-05 Urinary metabolites / / 21572414 rs10795645 chr10 8532635 C T 2.60E-05 Urinary metabolites / / 21572414 rs10795645 chr10 8532635 C T 9.02E-04 Stroke / / pha002886 rs7074625 chr10 8534953 C A 8.25E-04 Multiple complex diseases / / 17554300 rs4749770 chr10 8536278 T C 6.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10795650 chr10 8545524 A G 4.54E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs2388741 chr10 8553444 C T 9.88E-04 Rheumatoid arthritis / / 21452313 rs2646388 chr10 8562000 C T 8.83E-05 Cognitive test performance / / 20125193 rs2646437 chr10 8566311 G A 2.41E-04 Multiple complex diseases / / 17554300 rs7894791 chr10 8591369 C A 7.05E-04 Obesity (extreme) / / 21935397 rs1325881 chr10 8613894 T C 7.04E-05 Eosinophil counts / / pha003088 rs10905409 chr10 8623589 T C 4.00E-04 Multiple complex diseases / / 17554300 rs10508359 chr10 8631309 A C 8.91E-05 Waist Circumference / / pha003025 rs4749791 chr10 8633861 C T 8.00E-06 Obesity-related traits / / 23251661 rs10752143 chr10 8646048 T C 0.0000496 Colorectal adenoma (excluding hyperplasic) / / 23677573 rs10752143 chr10 8646048 T C 0.0000496 Colorectal adenoma (including hyperplasic) / / 23677573 rs827411 chr10 8691594 C A 1.97E-05 Response to TNF antagonist treatment / / 21061259 rs827411 chr10 8691594 C A 0.0000235 Panic disorder / / 23149450 rs827411 chr10 8691594 C A 2.35E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs827392 chr10 8700934 A G 2.20E-04 Response to TNF antagonist treatment / / 21061259 rs827392 chr10 8700934 A G 0.0000102 Panic disorder / / 23149450 rs827392 chr10 8700934 A G 1.02E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs10795668 chr10 8701219 G A 3.00E-13 Colorectal cancer / / 18372905 rs10795668 chr10 8701219 G A 3.00E-13 Nasopharyngeal carcinoma / / 20512145 rs10795668 chr10 8701219 G A 5.00E-15 Colorectal cancer / / 24836286 rs2483924 chr10 8708668 A C 0.0000479 Panic disorder / / 23149450 rs2483924 chr10 8708668 A C 4.79E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs4508106 chr10 8709338 T G 1.83E-04 Response to TNF antagonist treatment / / 21061259 rs4749806 chr10 8711723 C T 1.30E-04 Response to TNF antagonist treatment / / 21061259 rs4749806 chr10 8711723 C T 0.0000204 Panic disorder / / 23149450 rs4749806 chr10 8711723 C T 2.04E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs2184380 chr10 8714074 G C,T 4.30E-07 Breast cancer / / 17529974 rs2184380 chr10 8714074 G C,T 1.76E-05 Odorant perception / / 23910658 rs827382 chr10 8719269 C T 1.26E-04 Migraine without aura / / 23793025 rs827382 chr10 8719269 C T 9.00E-08 Migraine / / 23793025 rs827382 chr10 8719269 C T 9.64E-04 Migraine - clinic-based / / 23793025 rs11255841 chr10 8739580 T A 7.00E-11 Colorectal cancer / / 24737748 rs7071899 chr10 8780484 C T 8.10E-06 Urinary metabolites / / 21572414 rs7071899 chr10 8780484 C T 5.74E-05 Attention deficit hyperactivity disorder / / 22420046 rs7923068 chr10 8786826 G A 2.70E-05 Urinary metabolites / / 21572414 rs12220656 chr10 8789461 C T 2.40E-05 Urinary metabolites / / 21572414 rs12220668 chr10 8789510 C T 2.40E-05 Urinary metabolites / / 21572414 rs7912638 chr10 8789577 G C 2.40E-05 Urinary metabolites / / 21572414 rs7914614 chr10 8792274 T A 1.20E-05 Urinary metabolites / / 21572414 rs979534 chr10 8796596 C T 7.80E-06 Urinary metabolites / / 21572414 rs979534 chr10 8796596 C T 2.38E-05 Attention deficit hyperactivity disorder / / 22420046 rs4749821 chr10 8801845 C T 2.29E-05 Attention deficit hyperactivity disorder / / 22420046 rs10508367 chr10 8802308 C A,G 1.40E-05 Urinary metabolites / / 21572414 rs11255908 chr10 8802912 T G 1.40E-05 Urinary metabolites / / 21572414 rs11255920 chr10 8823759 A G 4.43E-05 Attention deficit hyperactivity disorder / / 22420046 rs2991815 chr10 8829183 A G 4.45E-04 Multiple complex diseases / / 17554300 rs17502419 chr10 8834391 C T 7.30E-06 Urinary metabolites / / 21572414 rs1080653 chr10 8835046 A T 2.88E-04 Body mass index / / 21701565 rs2025758 chr10 8841669 T C 1.30E-04 Self-reported allergy / / 23817569 rs7091279 chr10 8843004 G A 1.61E-05 Attention deficit hyperactivity disorder / / 22420046 rs406742 chr10 8845941 A G 1.49E-05 Attention deficit hyperactivity disorder / / 22420046 rs1444774 chr10 8926700 G A 9.64E-04 Asthma / / 21804548 rs11255965 chr10 8931793 G A 9.62E-08 Self-reported allergy / / 23817569 rs11255967 chr10 8933411 G A 2.63E-07 Self-reported allergy / / 23817569 rs290903 chr10 8936140 A G 1.17E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs290903 chr10 8936140 A G 4.55E-04 Lung function (forced vital capacity) / / 24023788 rs2388896 chr10 8954224 A G 9.00E-08 Tetralogy of Fallot / / 23297363 rs11255975 chr10 8958587 T C 0.000849 Asthma / / 23666277 rs12261421 chr10 8958811 C T 7.94E-08 Self-reported allergy / / 23817569 rs1857231 chr10 8961614 G A 1.87E-07 Tetralogy of Fallot / / 23297363 rs290923 chr10 8965476 G A 2.27E-04 Multiple complex diseases / / 17554300 rs895068 chr10 8966406 G T 4.45E-06 Alzheimer's disease (late onset) / / 23565137 rs895068 chr10 8966406 G T 5.90E-05 Alzheimer's disease (late onset) / / 23565137 rs1243418 chr10 8966800 T G 3.37E-06 Alzheimer's disease (late onset) / / 23565137 rs1243418 chr10 8966800 T G 4.70E-05 Alzheimer's disease (late onset) / / 23565137 rs1243417 chr10 8967379 A T 3.10E-06 Alzheimer's disease (late onset) / / 23565137 rs1243417 chr10 8967379 A T 4.18E-05 Alzheimer's disease (late onset) / / 23565137 rs1273007 chr10 8967522 C T 2.20E-04 Alzheimer's disease (late onset) / / 23565137 rs1273007 chr10 8967522 C T 3.08E-06 Alzheimer's disease (late onset) / / 23565137 rs1273007 chr10 8967522 C T 4.17E-05 Alzheimer's disease (late onset) / / 23565137 rs1243416 chr10 8967716 G A 3.09E-06 Alzheimer's disease (late onset) / / 23565137 rs1243416 chr10 8967716 G A 4.18E-05 Alzheimer's disease (late onset) / / 23565137 rs1243413 chr10 8969083 A G 3.66E-06 Alzheimer's disease (late onset) / / 23565137 rs1243413 chr10 8969083 A G 4.50E-05 Alzheimer's disease (late onset) / / 23565137 rs11255979 chr10 8969452 T C 1.66E-04 Self-reported allergy / / 23817569 rs10508372 chr10 8972018 G A 2.00E-15 Asthma / / 21804548 rs10508372 chr10 8972018 G A 1.92E-04 Self-reported allergy / / 23817569 rs10905488 chr10 8976044 T C 1.76E-04 Self-reported allergy / / 23817569 rs1243400 chr10 8976658 A G 4.80E-06 Kidney function and endocine traits / / 17903292 rs10905490 chr10 8982416 G A 1.88E-05 Self-reported allergy / / 23817569 rs827640 chr10 8988011 C T 1.50E-05 Kidney function and endocine traits / / 17903292 rs12247401 chr10 8991873 T C 3.86E-05 Self-reported allergy / / 23817569 rs827637 chr10 9010624 A G 4.14E-04 Tourette syndrome / / 22889924 rs827637 chr10 9010624 A G 1.79E-05 Blood Pressure / / pha003043 rs10430791 chr10 9013198 T C 6.12E-05 Asthma / / 21804548 rs11255998 chr10 9013834 C T 8.61E-06 Self-reported allergy / / 23817569 rs827628 chr10 9020234 T C 3.19E-04 Alcohol dependence / / 20201924 rs41341945 chr10 9022838 G C 1.30E-05 Urinary metabolites / / 21572414 rs930579 chr10 9037492 G T 7.52E-04 Multiple complex diseases / / 17554300 rs4116669 chr10 9040700 C T 2.15E-06 Self-reported allergy / / 23817569 rs2589561 chr10 9046645 A G 5.22E-07 Self-reported allergy / / 23817569 rs11256022 chr10 9048172 A G 4.33E-07 Multiple complex diseases / / 17554300 rs12413578 chr10 9049253 C T 5.00E-08 Rheumatoid arthritis / / 24390342 rs12413578 chr10 9049253 C T 8.00E-08 Rheumatoid arthritis / / 24390342 rs7898135 chr10 9052036 C A 1.89E-06 Self-reported allergy / / 23817569 rs1775550 chr10 9052742 G A 7.37E-07 Self-reported allergy / / 23817569 rs1775551 chr10 9053043 C A 7.41E-07 Self-reported allergy / / 23817569 rs962993 chr10 9053132 C T 2.00E-08 Self-reported allergy / / 23817569 rs2797288 chr10 9053173 G A 1.37E-06 Self-reported allergy / / 23817569 rs2589562 chr10 9053672 G A 9.92E-04 Self-reported allergy / / 23817569 rs1775553 chr10 9054325 C T 2.44E-08 Self-reported allergy / / 23817569 rs1663687 chr10 9054787 G A 2.19E-08 Self-reported allergy / / 23817569 rs1663680 chr10 9057245 T C 2.04E-08 Self-reported allergy / / 23817569 rs1031163 chr10 9057422 G T 2.05E-08 Self-reported allergy / / 23817569 rs2589559 chr10 9061370 C T 1.33E-06 Self-reported allergy / / 23817569 rs6602349 chr10 9061798 G C 1.37E-06 Self-reported allergy / / 23817569 rs2589563 chr10 9062283 C T 1.44E-06 Self-reported allergy / / 23817569 rs2197415 chr10 9062856 T G 3.04E-08 Self-reported allergy / / 23817569 rs1444787 chr10 9063530 G A 1.75E-06 Self-reported allergy / / 23817569 rs725861 chr10 9063776 A G 3.37E-04 Type 2 diabetes / / 17846125 rs725861 chr10 9063776 A G 1.44E-06 Self-reported allergy / / 23817569 rs1444788 chr10 9064120 T C 1.48E-06 Self-reported allergy / / 23817569 rs1612986 chr10 9064716 T C 8.13E-07 Self-reported allergy / / 23817569 rs1342773 chr10 9064955 T A 4.18E-04 Self-reported allergy / / 23817569 rs1149909 chr10 9067197 A C 6.84E-04 Self-reported allergy / / 23817569 rs1444791 chr10 9071014 T G 9.74E-04 Self-reported allergy / / 23817569 rs2259672 chr10 9071314 C T 8.83E-04 Self-reported allergy / / 23817569 rs1342767 chr10 9074903 C T 9.35E-04 Self-reported allergy / / 23817569 rs1663665 chr10 9075034 A C 8.52E-04 Self-reported allergy / / 23817569 rs2797272 chr10 9085303 T C 4.68E-05 Melanoma / / 21926416 rs2797270 chr10 9085626 A T 1.52E-05 Self-reported allergy / / 23817569 rs2093625 chr10 9086792 A G 2.98E-05 Self-reported allergy / / 23817569 rs2093626 chr10 9086882 C T 1.43E-05 Self-reported allergy / / 23817569 rs1857230 chr10 9087240 T G 1.62E-05 Self-reported allergy / / 23817569 rs2797266 chr10 9089160 G A 1.38E-05 Self-reported allergy / / 23817569 rs2057442 chr10 9089934 C T 1.20E-05 Self-reported allergy / / 23817569 rs860418 chr10 9091900 T C 1.64E-05 Self-reported allergy / / 23817569 rs861172 chr10 9093426 C T 1.44E-05 Self-reported allergy / / 23817569 rs852273 chr10 9093639 T G 1.07E-05 Self-reported allergy / / 23817569 rs1573110 chr10 9095495 T C 0.0000141 Ovarian cancer / / 22794196 rs2760204 chr10 9099975 C T 1.50E-05 Self-reported allergy / / 23817569 rs2146602 chr10 9101185 T A 6.05E-06 Self-reported allergy / / 23817569 rs2760206 chr10 9101436 A G 3.38E-06 Self-reported allergy / / 23817569 rs4550140 chr10 9105847 G A 1.70E-05 Self-reported allergy / / 23817569 rs2397336 chr10 9107914 G A 2.42E-05 Self-reported allergy / / 23817569 rs17145188 chr10 9108518 G A 8.87E-06 Self-reported allergy / / 23817569 rs17434960 chr10 9108558 C T 4.69E-06 Heart Rate / / pha003053 rs11256045 chr10 9117233 T C 1.09E-05 Self-reported allergy / / 23817569 rs10905509 chr10 9120362 T A 4.05E-04 Self-reported allergy / / 23817569 rs17363282 chr10 9120894 A G 3.76E-04 Type 2 diabetes / / 17463246 rs11256049 chr10 9125534 A G 4.23E-05 Self-reported allergy / / 23817569 rs11256050 chr10 9126840 A C 4.38E-05 Self-reported allergy / / 23817569 rs10905511 chr10 9135110 G A 4.43E-05 Self-reported allergy / / 23817569 rs10905515 chr10 9140585 C T 2.90E-05 Self-reported allergy / / 23817569 rs11256061 chr10 9140808 A G 2.90E-05 Self-reported allergy / / 23817569 rs11256063 chr10 9142272 C T 2.79E-05 Self-reported allergy / / 23817569 rs11256065 chr10 9143333 G A 2.69E-05 Self-reported allergy / / 23817569 rs10490944 chr10 9143511 C T 5.42E-05 Self-reported allergy / / 23817569 rs10490945 chr10 9143721 T G 2.60E-05 Self-reported allergy / / 23817569 rs17436267 chr10 9146876 G A 2.46E-05 Self-reported allergy / / 23817569 rs11256068 chr10 9147609 C T 2.46E-05 Self-reported allergy / / 23817569 rs11256070 chr10 9148600 T C 2.42E-05 Self-reported allergy / / 23817569 rs11256071 chr10 9148749 A G 1.85E-05 Self-reported allergy / / 23817569 rs11256073 chr10 9152268 T C 3.13E-05 Self-reported allergy / / 23817569 rs11256074 chr10 9155986 T C,G 4.82E-05 Self-reported allergy / / 23817569 rs10905518 chr10 9168739 A G 1.71E-05 Self-reported allergy / / 23817569 rs1149915 chr10 9172233 T C 1.13E-05 Self-reported allergy / / 23817569 rs17145278 chr10 9172291 A G 2.23E-05 Self-reported allergy / / 23817569 rs3118110 chr10 9174598 T C 2.83E-05 Self-reported allergy / / 23817569 rs1263695 chr10 9175242 A G 2.42E-05 Self-reported allergy / / 23817569 rs1149917 chr10 9175560 A G 2.06E-05 Self-reported allergy / / 23817569 rs1149919 chr10 9176002 G A 3.27E-05 Self-reported allergy / / 23817569 rs4749838 chr10 9222404 T C 9.45E-04 Multiple complex diseases / / 17554300 rs11256115 chr10 9244586 C A 2.60E-05 Urinary metabolites / / 21572414 rs1242969 chr10 9251679 T G 8.23E-05 Breast cancer / / pha002853 rs10905530 chr10 9268122 A G 2.50E-04 Serum selenium levels / / 23698163 rs1149958 chr10 9279084 A G 1.98E-04 Serum selenium levels / / 23698163 rs17145627 chr10 9296840 G A 0.000022 Carotid intima media thickness / / 23152477 rs17145627 chr10 9296840 G A 8.82E-05 Erythrocyte counts / / pha003090 rs7909586 chr10 9302751 C G 6.53E-04 Multiple complex diseases / / 17554300 rs11256134 chr10 9303950 G A 4.09E-05 Odorant perception / / 23910658 rs10795699 chr10 9311739 A C 2.31E-07 Glaucoma-related traits / / 22058429 rs11256141 chr10 9326101 T C 0.00000321 Carotid intima media thickness LOC100507163 intron 23152477 rs10491003 chr10 9328651 C T 5.00E-09 Calcium levels / / 24068962 rs12247397 chr10 9363877 A G 3.00E-09 Immune reponse to smallpox (secreted IL-1beta) / / 22610502 rs1150039 chr10 9372367 A G 1.06E-05 Cognitive impairment induced by topiramate / / 22091778 rs10905548 chr10 9428807 C A 9.75E-05 Coronary heart disease / / pha003030 rs972701 chr10 9471974 T C 1.88E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs10508394 chr10 9481842 C A 6.54E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs7091813 chr10 9518670 A T 9.65E-04 Metabolite levels (MHPG) / / 23319000 rs12252220 chr10 9545307 C T 4.85E-04 Fibrinogen / / 17255346 rs17515642 chr10 9568910 C A 2.00E-06 IgG glycosylation / / 23382691 rs733431 chr10 9577710 T C 3.96E-04 Fibrinogen / / 17255346 rs12255084 chr10 9578574 A G 7.22E-04 Body mass index / / 21701565 rs7901214 chr10 9601929 C T 3.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs12779266 chr10 9678512 G A 5.91E-04 Acute lung injury / / 22295056 rs17517988 chr10 9698647 A C 5.59E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs10508390 chr10 9769257 C T 1.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10508390 chr10 9769257 C T 6.82E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11256318 chr10 9778028 C G 8.95E-04 Alzheimer's disease / / 17998437 rs12413970 chr10 9791834 A G 8.22E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12413970 chr10 9791834 A G 8.84E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10905617 chr10 9795653 T C 5.53E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10905617 chr10 9795653 T C 9.32E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10905617 chr10 9795653 T C 1.86E-05 Coronary heart disease / / pha003056 rs3740218 chr10 9801169 T C 1.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3740218 chr10 9801169 T C 1.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs766610 chr10 9807278 T C 1.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs766610 chr10 9807278 T C 3.52E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10508388 chr10 9807832 C A 3.70E-05 Intelligence / / 21826061 rs11256338 chr10 9823594 A G 4.53E-05 Erythrocyte counts / / pha003090 rs2038922 chr10 9867908 T C 4.36E-04 Coronary heart disease / / 21606135 rs12414220 chr10 9886680 T C 4.08E-05 IgE levels / / 22075330 rs10795749 chr10 9917445 C T 3.70E-06 Kawasaki disease / / 22446962 rs2050778 chr10 9933991 G A 5.95E-05 Cognitive test performance / / 20125193 rs4142060 chr10 9938980 C T 5.80E-06 Kawasaki disease / / 22446962 rs10508383 chr10 9962704 G A 8.04E-04 Parkinson's disease / / 17052657 rs10508381 chr10 9963634 A G 8.39E-04 Schizophrenia / / 19197363 rs9329330 chr10 9983853 T A 3.17E-05 Personality dimensions / / 18957941 rs10218944 chr10 9987130 G A 3.70E-06 Iron levels / / 21208937 rs12263766 chr10 9996990 A G 3.00E-06 Obesity-related traits / / 23251661 rs10905646 chr10 10011994 T C 6.00E-05 Prostate cancer / / 21743057 rs10905647 chr10 10012257 T C 4.00E-05 Prostate cancer / / 21743057 rs12249528 chr10 10014581 A G 4.00E-05 Prostate cancer / / 21743057 rs7918807 chr10 10020194 T C 4.00E-05 Prostate cancer / / 21743057 rs7915591 chr10 10020278 A G 1.00E-05 Prostate cancer / / 21743057 rs1591891 chr10 10022005 A G 4.00E-05 Prostate cancer / / 21743057 rs1339681 chr10 10023340 A G 4.00E-05 Prostate cancer / / 21743057 rs1339683 chr10 10023597 G T 4.00E-05 Prostate cancer / / 21743057 rs1995578 chr10 10024686 A G 4.00E-05 Prostate cancer / / 21743057 rs1339685 chr10 10025584 C A,T 4.00E-05 Prostate cancer / / 21743057 rs6602387 chr10 10034807 G A 5.00E-05 Prostate cancer / / 21743057 rs6602388 chr10 10035016 G A 5.00E-05 Prostate cancer / / 21743057 rs7074507 chr10 10035465 T C 5.00E-05 Prostate cancer / / 21743057 rs4437940 chr10 10065243 G A,T 7.06E-08 Metabolite levels / / 23281178 rs10905651 chr10 10073544 G A 8.00E-06 Dental caries / / 23259602 rs17147135 chr10 10084566 T C 8.00E-06 Obesity-related traits / / 23251661 rs1540956 chr10 10087031 G A 2.23E-04 Multiple complex diseases / / 17554300 rs2762637 chr10 10094837 G A 9.52E-04 Multiple complex diseases / / 17554300 rs2762637 chr10 10094837 G A 9.79E-05 Coronary heart disease / / pha003030 rs2762637 chr10 10094837 G A 6.29E-05 Coronary heart disease / / pha003032 rs2804069 chr10 10105587 G A 5.25E-05 Coronary heart disease / / pha003032 rs2657513 chr10 10134319 C A 4.02E-05 Bipolar disorder and schizophrenia / / 20889312 rs2804058 chr10 10134434 G A 9.99E-04 Multiple complex diseases / / 17554300 rs12356435 chr10 10136473 G A 1.90E-05 Coronary heart disease / / pha003032 rs7073292 chr10 10139363 A G 1.21E-05 Coronary heart disease / / pha003030 rs7070083 chr10 10142911 G A 1.83E-05 Coronary heart disease / / pha003032 rs10905663 chr10 10144990 G T 6.41E-06 Glaucoma (primary open-angle) / / 22605921 rs2209299 chr10 10148233 A G 3.09E-05 Coronary heart disease / / pha003032 rs4749929 chr10 10158656 G T 2.61E-04 Multiple complex diseases / / 17554300 rs10752181 chr10 10187940 G A 8.39E-04 Acute lung injury / / 22295056 rs7904679 chr10 10188711 A C 8.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs7086978 chr10 10193981 C A 2.74E-04 Type 2 diabetes / / 17463246 rs17651582 chr10 10198304 T C 2.89E-04 Multiple complex diseases / / 17554300 rs10752182 chr10 10198962 T C 4.74E-05 Bladder cancer / / 19648920 rs2819049 chr10 10212040 A G 4.67E-05 Bladder cancer / / 19648920 rs7083994 chr10 10228684 G A 2.15E-04 Type 2 diabetes / / 17463246 rs7907470 chr10 10268989 G A 7.71E-04 Type 2 diabetes / / 22158537 rs7907578 chr10 10269019 G T 7.66E-04 Multiple complex diseases / / 17554300 rs7915918 chr10 10270679 G A 8.23E-04 Type 2 diabetes / / 22158537 rs6602417 chr10 10272553 C G 5.93E-04 Type 2 diabetes / / 22158537 rs10795772 chr10 10274206 T C 4.70E-04 Type 2 diabetes / / 22158537 rs17527069 chr10 10277345 T C 5.10E-04 Alcohol dependence / / 20201924 rs2151595 chr10 10284445 T C 2.64E-05 Multiple complex diseases / / 17554300 rs7094706 chr10 10295747 C G 6.45E-04 Type 2 diabetes / / 22158537 rs7097577 chr10 10296119 G T 6.00E-06 Obesity-related traits / / 23251661 rs7088313 chr10 10299580 C G 2.49E-04 Type 2 diabetes / / 22158537 rs7072070 chr10 10299710 A T 6.81E-04 Type 2 diabetes / / 22158537 rs10795780 chr10 10301888 T G 2.69E-04 Type 2 diabetes / / 22158537 rs10905699 chr10 10302664 G C 7.14E-04 Type 2 diabetes / / 22158537 rs2398212 chr10 10303080 G A 7.40E-04 Type 2 diabetes / / 22158537 rs2398213 chr10 10303213 A G 7.35E-04 Type 2 diabetes / / 22158537 rs10795782 chr10 10303896 T C 7.01E-04 Type 2 diabetes / / 22158537 rs10795783 chr10 10303947 A C 6.03E-05 Glaucoma (primary open-angle) / / 22605921 rs2065592 chr10 10304151 C A 4.01E-04 Type 2 diabetes / / 22158537 rs2065591 chr10 10304197 C T 4.23E-04 Type 2 diabetes / / 22158537 rs2151593 chr10 10304577 T C 2.63E-04 Type 2 diabetes / / 22158537 rs7923025 chr10 10305100 T A 9.37E-04 Type 2 diabetes / / 22158537 rs10905700 chr10 10305221 A G 3.38E-04 Type 2 diabetes / / 22158537 rs1333833 chr10 10307518 A T 7.18E-04 Type 2 diabetes / / 22158537 rs10466299 chr10 10309804 G A 7.50E-04 Type 2 diabetes / / 22158537 rs10458805 chr10 10310319 A G 9.99E-04 Type 2 diabetes / / 22158537 rs369639724 chr10 10310319 A AG 9.99E-04 Type 2 diabetes / / 22158537 rs10458818 chr10 10310375 T C 7.10E-04 Type 2 diabetes / / 22158537 rs4749944 chr10 10310509 T C 7.72E-04 Type 2 diabetes / / 22158537 rs12260727 chr10 10338329 G A 2.57E-04 IgE levels / / 17255346 rs12260727 chr10 10338329 G A 4.14E-05 Basophils / / pha003087 rs11816779 chr10 10349735 C T 7.21E-04 Multiple complex diseases / / 17554300 rs7917005 chr10 10358556 C T 1.26E-04 Multiple complex diseases / / 17554300 rs4747853 chr10 10372907 C T 5.96E-04 Metabolite levels (MHPG) / / 23319000 rs7087371 chr10 10385009 T C 2.80E-05 Urinary metabolites / / 21572414 rs2050252 chr10 10385079 G A 6.45E-04 Multiple complex diseases / / 17554300 rs7092703 chr10 10388195 C T 3.00E-06 Corneal astigmatism / / 23322567 rs10905715 chr10 10402541 A G 9.43E-06 Multiple complex diseases / / 17554300 rs928520 chr10 10407029 G A 0.00000125 LDL cholesterol / / 23063622 rs11256583 chr10 10423558 G A 8.95E-05 Orofacial clefts / / 19270707 rs1418405 chr10 10456217 C T 8.73E-05 Diabetes Mellitus / / pha003059 rs7894041 chr10 10463201 T G 9.23E-04 Type 2 diabetes / / 17463246 rs17502349 chr10 10466430 T G 7.67E-04 Multiple complex diseases / / 17554300 rs2251525 chr10 10467761 C T 2.05E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2494993 chr10 10489373 T C 6.83E-04 Alzheimer's disease / / 22005930 rs2104348 chr10 10489449 A T 7.11E-04 Alzheimer's disease / / 22005930 rs2093850 chr10 10489643 G A 6.83E-04 Alzheimer's disease / / 22005930 rs1324315 chr10 10490403 C A 7.21E-04 Alzheimer's disease / / 22005930 rs960873 chr10 10491159 A C 7.25E-04 Alzheimer's disease / / 22005930 rs2488172 chr10 10495544 G T 7.41E-04 Alzheimer's disease / / 22005930 rs2477031 chr10 10500875 G T 8.55E-04 Alzheimer's disease / / 22005930 rs7895315 chr10 10503251 C A 2.20E-05 Urinary metabolites / / 21572414 rs1575561 chr10 10514599 T C 8.67E-04 Type 2 diabetes / / 17463246 rs11256627 chr10 10535954 G A 5.17E-04 Obesity (extreme) / / 21935397 rs4747860 chr10 10540164 C T 8.76E-04 Obesity (extreme) / / 21935397 rs4747862 chr10 10542851 A C 3.64E-04 Multiple complex diseases / / 17554300 rs2243413 chr10 10546494 A C 8.51E-04 Type 2 diabetes / / 17463246 rs2398243 chr10 10552597 T G 2.27E-05 Blood Pressure / / pha003045 rs2398243 chr10 10552597 T G 5.33E-05 Blood Pressure / / pha003047 rs2477041 chr10 10556217 C A 8.21E-04 Type 2 diabetes / / 17463246 rs2252120 chr10 10558886 G A 2.15E-05 Blood Pressure / / pha003045 rs2252120 chr10 10558886 G A 2.83E-05 Blood Pressure / / pha003047 rs12412511 chr10 10559645 T G 6.80E-05 Blood Pressure / / pha003039 rs12412511 chr10 10559645 T G 2.72E-05 Blood Pressure / / pha003045 rs10508404 chr10 10565427 T C 6.57E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10508404 chr10 10565427 T C 2.07E-04 Scoliosis / / 21216876 rs11256663 chr10 10587244 A T 5.90E-06 Urinary metabolites / / 21572414 rs10905739 chr10 10587506 G A 1.80E-05 Urinary metabolites / / 21572414 rs7923400 chr10 10591016 C T 9.38E-04 Metabolite levels (MHPG) / / 23319000 rs11256676 chr10 10601860 A G 5.00E-06 Dental caries / / 23064961 rs7085082 chr10 10602446 T C 2.39E-04 Intracranial aneurysm / / 20613766 rs7918560 chr10 10610969 A G 2.00E-04 Information processing speed / / 21130836 rs1410241 chr10 10639742 T C 6.23E-04 Smoking initiation / / 24665060 rs10905765 chr10 10650798 C T 2.64E-05 Orofacial clefts / / 22419666 rs4747870 chr10 10655180 G C 4.72E-04 Blood pressure (response to calcium channel blocker) / / 24192120 rs12098617 chr10 10659405 A G 7.45E-05 Information processing speed / / 21130836 rs12098617 chr10 10659405 A G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs11256710 chr10 10660861 A G 5.67E-04 Smoking initiation / / 24665060 rs17148521 chr10 10663937 A G 3.99E-05 Hypertension / / 19609347 rs17515754 chr10 10668932 A G 3.73E-04 Smoking initiation / / 24665060 rs10508412 chr10 10673076 T C 5.93E-04 Smoking initiation / / 24665060 rs7092313 chr10 10689602 C T 2.00E-06 Smoking initiation / / 24665060 rs1410237 chr10 10691040 C T 5.12E-05 Smoking initiation / / 24665060 rs11597845 chr10 10691985 A G 4.16E-05 Smoking initiation / / 24665060 rs10905778 chr10 10699419 G A 7.01E-06 Smoking initiation / / 24665060 rs10508417 chr10 10793853 A T 8.59E-04 Alzheimer's disease / / 17998437 rs10905822 chr10 10812788 G A 3.49E-04 Body mass index / / 17255346 rs998789 chr10 10818087 A G 1.15E-04 Multiple complex diseases / / 17554300 rs11256826 chr10 10818374 C T 6.36E-05 Body mass index / / 17255346 rs11256826 chr10 10818374 C T 3.17E-05 Intelligence / / 21826061 rs7088716 chr10 10850258 A G 4.70E-04 Type 2 diabetes / / 17463246 rs7099044 chr10 10852874 A C 9.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10905835 chr10 10859858 A G 2.70E-05 Urinary metabolites / / 21572414 rs10905838 chr10 10861405 G A 7.60E-04 Stroke / / pha002887 rs2038663 chr10 10865213 G C 2.40E-05 Urinary metabolites / / 21572414 rs4749995 chr10 10874408 G A 2.00E-06 Urinary metabolites / / 21572414 rs4749995 chr10 10874408 G A 1.36E-05 Glaucoma (primary open-angle) / / 22605921 rs4565798 chr10 10874803 T C 7.70E-07 Urinary metabolites / / 21572414 rs968561 chr10 10885882 A G 6.79E-04 Stroke / / pha002887 rs10752209 chr10 10886244 T C 8.00E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12257036 chr10 10889014 T C 6.36E-04 Parkinson's disease / / 16252231 rs6602459 chr10 10910560 G C 1.10E-04 Self-reported allergy / / 23817569 rs4749999 chr10 10915790 C A 9.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2224693 chr10 10923851 T A 8.69E-04 Obesity (extreme) / / 21935397 rs7070614 chr10 10925174 T A 7.00E-04 Obesity (extreme) / / 21935397 rs7087274 chr10 10926211 G A 7.58E-04 Obesity (extreme) / / 21935397 rs1018573 chr10 10928268 T G 8.56E-04 Obesity (extreme) / / 21935397 rs7895452 chr10 10930856 T A 8.91E-04 Obesity (extreme) / / 21935397 rs1018574 chr10 10933573 T C 3.72E-05 Self-reported allergy / / 23817569 rs7085558 chr10 10934757 A G 8.08E-04 Obesity (extreme) / / 21935397 rs9424113 chr10 10942921 C T 1.51E-05 Adverse response to lamotrigine and phenytoin / / 22379998 rs10795832 chr10 10946610 G T 5.67E-04 Multiple complex diseases / / 17554300 rs1015087 chr10 10948223 T G 6.19E-04 Multiple complex diseases / / 17554300 rs1015087 chr10 10948223 T G 1.78E-05 Adverse response to lamotrigine and phenytoin / / 22379998 rs4750004 chr10 10950730 A G 1.31E-04 Smoking initiation / / 24665060 rs7898939 chr10 10951618 G A 1.18E-04 Smoking initiation / / 24665060 rs12253020 chr10 10952307 A G 6.95E-04 Multiple complex diseases / / 17554300 rs7067649 chr10 10953351 A G 5.15E-04 Smoking initiation / / 24665060 rs7893924 chr10 10953819 A G 5.15E-04 Smoking initiation / / 24665060 rs7097329 chr10 10956220 G A 1.95E-04 Smoking initiation / / 24665060 rs9804384 chr10 10969223 A G 3.04E-04 Multiple complex diseases / / 17554300 rs10905868 chr10 10974256 A G 4.00E-06 Obesity-related traits / / 23251661 rs17149140 chr10 10977601 A C 7.80E-06 Urinary metabolites LOC254312 intron 21572414 rs1928722 chr10 10985316 A G 2.33E-04 Myopia (pathological) LOC254312 intron 21095009 rs201062 chr10 10985932 A T 6.09E-04 Alzheimer's disease LOC254312 intron 17998437 rs7093099 chr10 10990942 C T 3.13E-04 Alzheimer's disease (late onset) LOC254312 intron 21460841 rs17444979 chr10 10994159 C T 2.41E-04 Alzheimer's disease (late onset) / / 21460841 rs62209 chr10 11000339 G T 2.00E-07 Alzheimer's disease (late onset) / / 21379329 rs201099 chr10 11024559 A G 8.33E-08 Alzheimer's disease (late onset) / / 21379329 rs201109 chr10 11041967 C T 4.29E-07 Alzheimer's disease (late onset) / / 21379329 rs201119 chr10 11049977 T C 1.52E-08 Alzheimer's disease (late onset) CELF2 intron 21379329 rs201124 chr10 11053049 A C 1.31E-06 Alzheimer's disease (late onset) CELF2 intron 21379329 rs7099713 chr10 11053143 A C 2.30E-04 Alzheimer's disease (late onset) CELF2 intron 21379329 rs1547221 chr10 11055589 T C 4.35E-05 Alzheimer's disease (late onset) CELF2 intron 21379329 rs1999207 chr10 11078390 T C 9.43E-05 Non-alcoholic fatty liver disease histology (other) CELF2 intron 20708005 rs1291870 chr10 11085164 G C 9.02E-04 Multiple complex diseases CELF2 intron 17554300 rs1291880 chr10 11091162 T C 5.70E-05 Personality dimensions CELF2 intron 18957941 rs1291882 chr10 11091325 G A 4.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CELF2 intron 20877124 rs1291836 chr10 11101276 A G 1.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CELF2 intron 20877124 rs1291846 chr10 11107195 A G 9.00E-06 Attention deficit hyperactivity disorder and conduct disorder CELF2 intron 18951430 rs1291851 chr10 11109077 C T 6.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CELF2 intron 20877124 rs1291854 chr10 11110195 T C 5.40E-05 Personality dimensions CELF2 intron 18957941 rs7083575 chr10 11122007 T C 1.09E-14 Metabolite levels CELF2 intron 22286219 rs7907550 chr10 11131552 G A 8.91E-05 Smoking cessation CELF2 intron 18519826 rs1291818 chr10 11132190 T C 7.77E-05 Type 2 diabetes CELF2 intron 17463246 rs1750731 chr10 11154164 G A 1.62E-04 Response to alcohol consumption (flushing response) CELF2 intron 24277619 rs1750734 chr10 11161978 A G 3.20E-05 Rheumatoid arthritis CELF2 intron 22446963 rs1750734 chr10 11161978 A G 4.60E-04 Response to alcohol consumption (flushing response) CELF2 intron 24277619 rs17375715 chr10 11162787 T G 6.09E-04 Type 2 diabetes CELF2 intron 17463246 rs11256991 chr10 11166455 T G 8.12E-04 HIV-1 viral setpoint CELF2 intron 17641165 rs7093401 chr10 11174096 C T 4.71E-06 White blood cell count CELF2 intron 21738479 rs17149616 chr10 11175462 G A 8.96E-04 Suicide attempts in bipolar disorder CELF2 intron 21423239 rs675870 chr10 11192163 T C 2.70E-04 Heart Failure CELF2 intron pha002884 rs17449532 chr10 11192455 G A 6.62E-04 Type 2 diabetes CELF2 intron 17463246 rs7899835 chr10 11208761 A T 4.43E-04 Multiple complex diseases CELF2 intron 17554300 rs682970 chr10 11209955 T C 1.29E-05 Multiple complex diseases CELF2 intron 17554300 rs660676 chr10 11215311 T C 9.85E-05 Serum metabolites CELF2 intron 19043545 rs2759642 chr10 11215946 T C 8.28E-05 Serum metabolites CELF2 intron 19043545 rs583818 chr10 11217632 T G 9.16E-05 Serum metabolites CELF2 intron 19043545 rs584228 chr10 11217722 T G 9.24E-05 Serum metabolites CELF2 intron 19043545 rs636416 chr10 11219490 C G 9.48E-05 Smoking cessation CELF2 intron 18519826 rs658469 chr10 11221366 T C 1.89E-04 Smoking cessation CELF2 intron 18519826 rs596406 chr10 11224665 T C 4.00E-07 Liver enzyme levels (aspartate transaminase) CELF2 intron 24124411 rs596406 chr10 11224665 T C 9.00E-06 Liver enzyme levels (alanine transaminase) CELF2 intron 24124411 rs624907 chr10 11225239 T A 9.33E-04 Type 2 diabetes CELF2 intron 17463246 rs2399659 chr10 11238195 G A 8.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CELF2 intron 20877124 rs2399659 chr10 11238195 G A 8.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CELF2 intron 20877124 rs10795851 chr10 11249240 C T 0.0000228 Transmission distortion CELF2 intron 22377632 rs17149878 chr10 11257076 A G 6.03E-04 Type 2 diabetes CELF2 intron 17463246 rs2653523 chr10 11288390 C G 4.32E-04 Multiple complex diseases CELF2 intron 17554300 rs2765974 chr10 11288418 C A 7.02E-04 Multiple complex diseases CELF2 intron 17554300 rs2653522 chr10 11290997 A C 6.40E-04 Multiple complex diseases CELF2 intron 17554300 rs2765981 chr10 11294546 C T 2.80E-04 Cardiovascular disease adverse events in renal patients treated with calcineurin inhibitors CELF2 intron 16155738 rs1058349 chr10 11302377 T A 2.32E-05 Smoking cessation CELF2 intron 18519826 rs17150017 chr10 11319244 A G 1.78E-10 Multiple complex diseases CELF2 intron 17554300 rs11257046 chr10 11327285 C T 6.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CELF2 intron 20877124 rs12262014 chr10 11339009 A G 9.20E-04 Tourette syndrome CELF2 intron 22889924 rs17150094 chr10 11341596 G A 4.75E-05 Coronary heart disease CELF2 intron pha003031 rs10795859 chr10 11345706 A G 1.34E-06 Smoking cessation CELF2 intron 18519826 rs10795859 chr10 11345706 A G 4.30E-04 Smoking cessation CELF2 intron 18519826 rs10905930 chr10 11367447 C T 6.03E-04 Multiple complex diseases CELF2 intron 17554300 rs9329334 chr10 11369870 C T 1.51E-05 Gallstones CELF2 intron 17632509 rs7893689 chr10 11381946 G A,C 8.43E-04 Response to alcohol consumption (flushing response) / / 24277619 rs7071449 chr10 11387870 G C 7.97E-04 Body mass index / / 21701565 rs3905634 chr10 11389400 A G 8.45E-05 HDL cholesterol / / pha003075 rs3905634 chr10 11389400 A G 5.39E-05 Lipid levels / / pha003082 rs3847424 chr10 11394809 A G 6.17E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs7899892 chr10 11395211 G A 2.42E-04 Multiple complex diseases / / 17554300 rs7917066 chr10 11395224 A G 6.28E-05 Multiple complex diseases / / 17554300 rs12245515 chr10 11396152 G A 6.17E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs12245515 chr10 11396152 G A 4.55E-04 Acne (severe) / / 24927181 rs7088943 chr10 11433996 G A 5.21E-04 Body mass index / / 21701565 rs17150296 chr10 11437683 C G 4.57E-04 Body mass index / / 21701565 rs17150296 chr10 11437683 C G 8.14E-04 Body mass index / / 21701565 rs2454788 chr10 11444622 G A 6.79E-04 Multiple complex diseases / / 17554300 rs4750058 chr10 11468441 G A 6.11E-05 Response to metformin / / 21186350 rs1530375 chr10 11491077 C T 1.50E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs10508422 chr10 11513242 T C 1.00E-04 Cognitive impairment induced by topiramate USP6NL intron 22091778 rs11257120 chr10 11522930 C G 7.91E-04 Type 2 diabetes USP6NL intron 17463246 rs7085769 chr10 11543661 G A 1.11E-04 Breast cancer USP6NL intron pha002853 rs17458263 chr10 11553640 G A 6.40E-05 Response to statin therapy USP6NL intron 20339536 rs4445554 chr10 11564421 C T 7.16E-05 Breast cancer USP6NL intron pha002853 rs10508425 chr10 11579546 G A 1.56E-04 Breast cancer USP6NL intron pha002853 rs17537423 chr10 11579836 C T 1.09E-04 Multiple complex diseases USP6NL intron 17554300 rs17150540 chr10 11580354 C T 4.72E-05 Sudden cardiac arrest USP6NL intron 21658281 rs754426 chr10 11629403 C A 0.0001624 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) USP6NL intron 23233654 rs754426 chr10 11629403 C A 1.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) USP6NL intron 23233662 rs11592006 chr10 11656600 T C 7.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6602504 chr10 11658594 G A 3.04E-05 Coronary heart disease / / pha003035 rs7094839 chr10 11671268 T G 6.75E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs10795870 chr10 11680543 T C 2.62E-05 Alzheimer's disease (late onset) / / 21379329 rs10905985 chr10 11703136 G A 2.52E-04 Alzheimer's disease (late onset) / / 21379329 rs12784561 chr10 11712965 G A 5.33E-04 Smoking initiation / / 24665060 rs12265836 chr10 11719010 T G 8.00E-06 Obesity-related traits LOC100507228 intron 23251661 rs11257241 chr10 11719655 G A 4.22E-05 Cognitive test performance LOC100507228 intron 20125193 rs7920721 chr10 11720308 A G 9.32E-06 Alzheimer's disease (late onset) LOC100507228 intron 21379329 rs7920721 chr10 11720308 A G 3.00E-07 Alzheimer's disease (late onset) LOC100507228 intron 24162737 rs7094380 chr10 11723257 C T 2.13E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2399726 chr10 11736956 C T 3.92E-04 Tourette syndrome / / 22889924 rs12773964 chr10 11742632 G A 6.44E-05 Alzheimer's disease (late onset) / / 21460841 rs6602515 chr10 11742673 G A 7.09E-05 Alzheimer's disease (late onset) / / 21460841 rs12776405 chr10 11742710 A G 6.65E-05 Alzheimer's disease (late onset) / / 21460841 rs11592515 chr10 11743103 C T 6.72E-05 Alzheimer's disease (late onset) / / 21460841 rs11597245 chr10 11743514 G A 6.69E-05 Alzheimer's disease (late onset) / / 21460841 rs12764640 chr10 11743944 T C 7.61E-05 Alzheimer's disease (late onset) / / 21460841 rs7895883 chr10 11767337 A G 8.61E-04 Type 2 diabetes / / 17463246 rs7895883 chr10 11767337 A G 9.40E-06 Urinary metabolites / / 21572414 rs3829154 chr10 11782753 A G 5.67E-11 Lymphocyte counts / / 22286170 rs4750099 chr10 11795575 G T 4.87E-04 Alcohol dependence ECHDC3 intron 21314694 rs7900369 chr10 11798419 A G 9.06E-04 Insulin resistance ECHDC3 intron 21901158 rs7085191 chr10 11800518 A T 9.06E-04 Insulin resistance ECHDC3 intron 21901158 rs10752235 chr10 11804104 A G 1.96E-04 Multiple complex diseases ECHDC3 intron 17554300 rs7101167 chr10 11815455 T C 7.50E-04 Insulin resistance / / 21901158 rs1359363 chr10 11846021 C T 9.11E-04 Stroke / / pha002886 rs12358475 chr10 11848792 G A 7.50E-04 Myocardial Infarction / / pha002873 rs2147441 chr10 11873047 C G,T 3.81E-04 Type 2 diabetes C10orf47 intron 17463246 rs11257350 chr10 11874754 C T 4.50E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) C10orf47 intron 24236485 rs942539 chr10 11879926 C T 8.66E-04 Alzheimer's disease C10orf47 intron 22005930 rs10795906 chr10 11931749 G A 2.63E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LOC219731 intron 22566498 rs12252853 chr10 11932326 T C 1.38E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LOC219731 intron 22566498 rs12255292 chr10 11934137 A G 4.39E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LOC219731 intron 22566498 rs12356904 chr10 11936420 C T 7.11E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11257397 chr10 11936590 G A 1.41E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4620613 chr10 11971453 T C 3.59E-04 Response to TNF antagonist treatment UPF2 intron 21061259 rs17151073 chr10 11984424 A G 1.19E-04 Multiple complex diseases UPF2 intron 17554300 rs7080355 chr10 12006358 T C 8.45E-04 Alzheimer's disease UPF2 intron 22005930 rs7899260 chr10 12051574 A G 4.04E-05 Amyotrophic Lateral Sclerosis UPF2 intron 18057069 rs10795917 chr10 12051816 G A 7.00E-07 Prostate cancer (gene x gene interaction) UPF2 intron 22219177 rs11257489 chr10 12069476 A G 9.86E-04 Type 2 diabetes UPF2 intron 17463246 rs1279134 chr10 12070561 C T 9.71E-04 Alzheimer's disease UPF2 intron 22005930 rs4237420 chr10 12076043 A G 7.84E-04 Alzheimer's disease UPF2 intron 22005930 rs1300033 chr10 12084190 A C 8.81E-04 Alzheimer's disease UPF2 intron 22005930 rs2399768 chr10 12089961 G C 6.94E-04 Alzheimer's disease / / 22005930 rs11257556 chr10 12177704 C A 1.03E-05 Lymphocyte counts SEC61A2 intron 22286170 rs34863826 chr10 12215734 A G 0.000018 Prostate cancer (advanced) NUDT5 missense 23555315 rs2399788 chr10 12239118 A G 5.26E-04 Smoking cessation CDC123 intron 24665060 rs1878798 chr10 12243483 G C 1.78E-06 Pulmonary function CDC123 intron 20010835 rs10906097 chr10 12243821 T G 1.79E-06 Pulmonary function CDC123 intron 20010835 rs10508438 chr10 12244079 G A 5.71E-06 Pulmonary function CDC123 intron 20010835 rs10508438 chr10 12244079 G A 2.07E-08 Type 2 diabetes CDC123 intron 22158537 rs2895504 chr10 12244612 A G 3.80E-05 Pulmonary function CDC123 intron 20010835 rs1317549 chr10 12245314 T G 5.52E-04 Multiple complex diseases CDC123 intron 17554300 rs1317549 chr10 12245314 T G 3.99E-05 Pulmonary function CDC123 intron 20010835 rs35048815 chr10 12245496 G GC 1.10E-16 Urinary metabolites CDC123 intron 21572414 rs1317548 chr10 12245520 G A 4.44E-04 Multiple complex diseases CDC123 intron 17554300 rs1317548 chr10 12245520 G A 3.71E-05 Pulmonary function CDC123 intron 20010835 rs12773913 chr10 12249224 G T 6.32E-05 Pulmonary function CDC123 intron 20010835 rs12413792 chr10 12249289 T C 6.14E-05 Pulmonary function CDC123 intron 20010835 rs12775830 chr10 12249445 C G 6.33E-05 Pulmonary function CDC123 intron 20010835 rs4747968 chr10 12249797 C T 5.99E-05 Pulmonary function CDC123 intron 20010835 rs7895525 chr10 12250620 T C 7.26E-05 Pulmonary function CDC123 intron 20010835 rs7100710 chr10 12250861 A G 3.35E-05 Pulmonary function CDC123 intron 20010835 rs7100710 chr10 12250861 A G 1.12E-08 Type 2 diabetes CDC123 intron 22158537 rs2271804 chr10 12252217 G A 1.73E-06 Pulmonary function CDC123 intron 20010835 rs12221133 chr10 12253597 G A 5.76E-05 Pulmonary function CDC123 intron 20010835 rs12221133 chr10 12253597 G A 3.18E-08 Type 2 diabetes CDC123 intron 22158537 rs7896600 chr10 12255175 G C 5.67E-05 Pulmonary function CDC123 intron 20010835 rs7896600 chr10 12255175 G C 3.29E-11 Type 2 diabetes CDC123 intron 22158537 rs11257600 chr10 12255657 G T 3.45E-05 Pulmonary function CDC123 intron 20010835 rs11257600 chr10 12255657 G T 6.75E-11 Type 2 diabetes CDC123 intron 22158537 rs2399796 chr10 12256559 A G 8.92E-06 Pulmonary function CDC123 intron 20010835 rs4478891 chr10 12267654 A G 5.89E-06 Pulmonary function CDC123 intron 20010835 rs4478891 chr10 12267654 A G 3.33E-07 Type 2 diabetes CDC123 intron 22158537 rs11257608 chr10 12269343 C T 4.54E-05 Pulmonary function CDC123 intron 20010835 rs11598305 chr10 12269400 C A 2.05E-05 Pulmonary function CDC123 intron 19300500 rs11598305 chr10 12269400 C A 2.96E-07 Pulmonary function CDC123 intron 20010835 rs12413646 chr10 12274759 A G 6.47E-06 Pulmonary function CDC123 intron 20010835 rs7068966 chr10 12277992 C T 6.42E-05 Pulmonary function CDC123 intron 19300500 rs7068966 chr10 12277992 C T 6.51E-07 Pulmonary function CDC123 intron 20010835 rs7068966 chr10 12277992 C T 3.00E-12 Pulmonary function CDC123 intron 21946350 rs7068966 chr10 12277992 C T 6.00E-13 Pulmonary function CDC123 intron 21946350 rs7068966 chr10 12277992 C T 2.00E-11 Pulmonary function (interaction) CDC123 intron 23284291 rs10906104 chr10 12280296 A G 4.17E-05 Pulmonary function CDC123 intron 20010835 rs10906104 chr10 12280296 A G 8.84E-06 Non-small cell lung cancer (survival) CDC123 intron 23704207 rs7075724 chr10 12282461 A G 4.08E-05 Pulmonary function CDC123 intron 20010835 rs11257613 chr10 12284392 G A 6.63E-05 Pulmonary function CDC123 intron 19300500 rs11257613 chr10 12284392 G A 6.09E-07 Pulmonary function CDC123 intron 20010835 rs4469792 chr10 12288780 A G 5.01E-06 Pulmonary function CDC123 intron 20010835 rs2399797 chr10 12289618 C T 5.06E-06 Pulmonary function CDC123 intron 20010835 rs1051055 chr10 12292454 A G 2.92E-04 Multiple complex diseases CDC123 UTR-3 17554300 rs1051055 chr10 12292454 A G 1.99E-05 Pulmonary function CDC123 UTR-3 20010835 rs11257622 chr10 12295339 T C 7.70E-05 Pulmonary function / / 20010835 rs11257622 chr10 12295339 T C 5.60E-05 Type 2 diabetes / / 21874001 rs4747969 chr10 12297230 C T 4.31E-04 Multiple complex diseases / / 17554300 rs4747969 chr10 12297230 C T 9.38E-05 Pulmonary function / / 20010835 rs11819728 chr10 12298194 A G 2.56E-06 Pulmonary function / / 20010835 rs11817797 chr10 12298444 C T 2.44E-06 Pulmonary function / / 20010835 rs11593214 chr10 12298595 G C 2.03E-06 Pulmonary function / / 20010835 rs7916879 chr10 12300790 G A 5.65E-06 Pulmonary function / / 20010835 rs7916879 chr10 12300790 G A 1.43E-07 Type 2 diabetes / / 22158537 rs10906111 chr10 12302357 C T 2.80E-05 Pulmonary function / / 20010835 rs10906111 chr10 12302357 C T 8.52E-09 Type 2 diabetes / / 22158537 rs4747972 chr10 12305648 G C 9.31E-07 Pulmonary function / / 20010835 rs11257654 chr10 12307611 C T 5.05E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11257655 chr10 12307894 C T 4.34E-05 Pulmonary function / / 20010835 rs11257655 chr10 12307894 C T 0.00000044 Fasting blood glucose / / 22885922 rs11257655 chr10 12307894 C T 0.0000021 Type 2 diabetes / / 22885922 rs11257655 chr10 12307894 C T 0.000059 Type 2 diabetes (females) / / 22885922 rs11257655 chr10 12307894 C T 0.00083 Type 2 diabetes (males) / / 22885922 rs11257655 chr10 12307894 C T 7.00E-09 Type 2 diabetes / / 22961080 rs11257655 chr10 12307894 C T 3.00E-09 Type 2 diabetes / / 24509480 rs11593567 chr10 12307963 A G 2.85E-05 Pulmonary function / / 19300500 rs11593567 chr10 12307963 A G 1.36E-06 Pulmonary function / / 20010835 rs7895410 chr10 12310737 T C 2.50E-05 Pulmonary function / / 20010835 rs10906115 chr10 12314997 A G 8.44E-04 Multiple complex diseases / / 17554300 rs10906115 chr10 12314997 A G 1.00E-08 Type 2 diabetes / / 20862305 rs10906115 chr10 12314997 A G 1.65E-05 Type 2 diabetes / / 22158537 rs11257679 chr10 12318284 C T 4.05E-05 Pulmonary function / / 20010835 rs7069060 chr10 12323464 A G 3.82E-05 Multiple complex diseases / / 17554300 rs12779790 chr10 12328010 A G 1.00E-10 Type 2 diabetes / / 18372903 rs12779790 chr10 12328010 A G 1.00E-10 Coronary heart disease / / 21347282 rs12779790 chr10 12328010 A G 1.00E-10 Type 2 diabetes / / 21647700 rs12779790 chr10 12328010 A G 1.00E-10 Type 2 diabetes / / 23300278 rs10752261 chr10 12330713 G A,T 2.00E-05 Urinary metabolites / / 21572414 rs11257707 chr10 12364206 A G 2.70E-09 Urinary metabolites / / 21572414 rs11257727 chr10 12385344 A G 5.68E-04 Alzheimer's disease / / 17998437 rs12773845 chr10 12416629 A G 9.60E-04 Metabolite levels (MHPG) CAMK1D intron 23319000 rs35692499 chr10 12416661 A G 9.60E-04 Metabolite levels (MHPG) CAMK1D intron 23319000 rs11257765 chr10 12434742 T C 5.04E-04 Taste perception CAMK1D intron 22132133 rs4750211 chr10 12435379 C T 6.00E-07 Obesity-related traits CAMK1D intron 23251661 rs4747982 chr10 12435395 G A 9.48E-07 Obesity-related traits CAMK1D intron 23251661 rs4747983 chr10 12436580 C T 2.00E-04 Information processing speed CAMK1D intron 21130836 rs10906142 chr10 12438783 G A 1.00E-06 Obesity-related traits CAMK1D intron 23251661 rs10906142 chr10 12438783 G A 1.00E-06 Obesity-related traits CAMK1D intron 23251661 rs10906142 chr10 12438783 G A 4.00E-06 Obesity-related traits CAMK1D intron 23251661 rs1892302 chr10 12446572 T C 9.38E-05 Progressive supranuclear palsy CAMK1D intron 21685912 rs1574114 chr10 12448888 C T 4.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAMK1D intron 20877124 rs1125791 chr10 12475837 T G 7.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAMK1D intron 20877124 rs11595633 chr10 12478476 G A 1.00E-04 Information processing speed CAMK1D intron 21130836 rs2801493 chr10 12480633 C T 9.75E-04 Type 2 diabetes CAMK1D intron 17463246 rs12763487 chr10 12490818 A G 3.73E-04 Type 2 diabetes CAMK1D intron 17463246 rs1077685 chr10 12492379 G A 1.96E-05 Paget's disease CAMK1D intron 20436471 rs4620627 chr10 12517891 A G 4.17E-04 Depression (quantitative trait) CAMK1D intron 20800221 rs2768428 chr10 12523129 T C 4.90E-05 Psychosis (methamphetamine induced) CAMK1D intron 23594818 rs7078980 chr10 12538491 G A 6.10E-04 Multiple complex diseases CAMK1D intron 17554300 rs7078980 chr10 12538491 G A 1.40E-04 Lung cancer CAMK1D intron 19414679 rs11257835 chr10 12544852 G A 2.35E-05 Bipolar disorder and schizophrenia CAMK1D intron 20889312 rs2768447 chr10 12549961 T C 2.51E-05 Hematocrit CAMK1D intron pha003097 rs11595316 chr10 12551331 A G 7.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAMK1D intron 20877124 rs7911448 chr10 12552998 G A 3.75E-04 Type 2 diabetes CAMK1D intron 17463246 rs7078672 chr10 12558701 T G 6.23E-04 Suicide attempts in bipolar disorder CAMK1D intron 21423239 rs7084330 chr10 12569272 C G 6.56E-04 Suicide attempts in bipolar disorder CAMK1D intron 21423239 rs7902362 chr10 12580163 C G 6.36E-04 Suicide attempts in bipolar disorder CAMK1D intron 21423239 rs11257872 chr10 12580664 C T 8.33E-04 Suicide attempts in bipolar disorder CAMK1D intron 21423239 rs11257877 chr10 12582713 A G 7.70E-04 Suicide attempts in bipolar disorder CAMK1D intron 21423239 rs7078960 chr10 12589150 A G 3.54E-04 Rheumatoid arthritis CAMK1D intron 21452313 rs4747989 chr10 12590175 C T 2.74E-05 Attention deficit hyperactivity disorder CAMK1D intron 20732625 rs2815627 chr10 12597490 G T 5.78E-04 Coronary heart disease CAMK1D intron 21606135 rs10906170 chr10 12598308 A G 1.94E-04 Response to cholinesterase inhibitors in Alzheimer's disease CAMK1D intron 23374588 rs11257888 chr10 12601504 C T 9.61E-04 Coronary heart disease CAMK1D intron 21606135 rs11257897 chr10 12615252 T C 6.39E-04 Acute lung injury CAMK1D intron 22295056 rs2895527 chr10 12626977 A G 8.50E-05 Personality dimensions CAMK1D intron 18957941 rs12414386 chr10 12644580 C T 9.16E-05 Coronary heart disease CAMK1D intron pha003033 rs11596728 chr10 12645887 C T 4.45E-05 Parkinson's disease CAMK1D intron 17052657 rs17152001 chr10 12658870 G T 6.19E-04 Multiple complex diseases CAMK1D intron 17554300 rs12260523 chr10 12672884 A G 8.44E-04 Response to cytadine analogues (cytosine arabinoside) CAMK1D intron 24483146 rs10906189 chr10 12675061 G A 6.00E-06 QT interval (interaction) CAMK1D intron 23459443 rs10450540 chr10 12682845 C G 2.00E-05 Urinary metabolites CAMK1D intron 21572414 rs11818088 chr10 12695316 G T 7.37E-04 Aortic root size CAMK1D intron 21223598 rs75263140 chr10 12702569 A G 6.00E-06 Anorexia nervosa CAMK1D intron 23568457 rs12251362 chr10 12714269 G A 5.86E-05 Height CAMK1D intron pha003010 rs12251362 chr10 12714269 G A 9.10E-06 Height CAMK1D intron pha003011 rs4750249 chr10 12748816 C T 2.50E-06 Urinary metabolites CAMK1D intron 21572414 rs1007553 chr10 12750412 A G 8.30E-05 Diabetic retinopathy CAMK1D intron 21441570 rs1008032 chr10 12752102 A C 8.40E-05 Diabetic retinopathy CAMK1D intron 21441570 rs12240912 chr10 12757293 T C 9.40E-05 Diabetic retinopathy CAMK1D intron 21441570 rs17152137 chr10 12757582 C T 9.40E-05 Diabetic retinopathy CAMK1D intron 21441570 rs5002377 chr10 12762178 G C 5.78E-04 Multiple complex diseases CAMK1D intron 17554300 rs11596618 chr10 12793946 G A 1.90E-05 Urinary metabolites CAMK1D intron 21572414 rs4335437 chr10 12796923 A G 5.85E-04 Parkinson's disease CAMK1D intron 17052657 rs4132050 chr10 12797758 G A 3.30E-04 Alzheimer's disease CAMK1D intron 24755620 rs928337 chr10 12835045 A G 3.29E-04 Coronary heart disease CAMK1D intron 21606135 rs17152268 chr10 12836482 A C 9.99E-04 Response to taxane treatment (placlitaxel) CAMK1D intron 23006423 rs11258005 chr10 12853462 A G 4.95E-04 Coronary heart disease CAMK1D intron 21606135 rs11258009 chr10 12855156 T C 6.83E-04 Multiple complex diseases CAMK1D intron 17554300 rs1627294 chr10 12862336 C A 4.46E-04 Amyotrophic Lateral Sclerosis CAMK1D intron 17362836 rs1644391 chr10 12868304 A C 4.76E-05 Smoking cessation CAMK1D intron 18519826 rs1644392 chr10 12869000 A G 0.00008 Asthma (exacerbation) CAMK1D intron 23706709 rs2431623 chr10 12872880 A G 9.00E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs17152343 chr10 12873276 C T 1.95E-04 Multiple complex diseases / / 17554300 rs10906233 chr10 12875208 C T 4.00E-06 Eating disorders / / 23568457 rs1757070 chr10 12878354 G C 8.09E-05 Smoking cessation / / 18519826 rs1644412 chr10 12882041 C T 0.000037 Asthma (exacerbation) / / 23706709 rs17152389 chr10 12892220 G C 0.00003191 Sarcoidosis / / 22952805 rs7909670 chr10 12918764 C T 3.00E-09 Height / / 20881960 rs4748011 chr10 12941157 T C 1.16E-04 Oral cancers (chewing tobacco related) CCDC3 intron 22503698 rs281849 chr10 12959026 G T 3.24E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) CCDC3 intron 23648065 rs281851 chr10 12966495 A C 7.28E-05 Post-operative nausea and vomiting CCDC3 intron 21694509 rs1251009 chr10 12975907 C T 7.80E-06 Bladder cancer CCDC3 intron 19648920 rs10906258 chr10 12976723 G T 8.20E-06 Stroke (ischemic) CCDC3 intron 22941190 rs1757056 chr10 12979422 C T 7.60E-05 Post-operative nausea and vomiting CCDC3 intron 21694509 rs1475610 chr10 12979699 A G 4.55E-05 Bladder cancer CCDC3 intron 19648920 rs10906261 chr10 12983627 A G 5.13E-05 Body Mass Index CCDC3 intron pha003015 rs928339 chr10 12984272 G A 5.48E-05 Bladder cancer CCDC3 intron 19648920 rs10906263 chr10 12987176 A G 6.75E-05 Body Mass Index CCDC3 intron pha003007 rs10906263 chr10 12987176 A G 5.49E-05 Body Mass Index CCDC3 intron pha003015 rs1251005 chr10 12987730 G A 1.50E-05 Urinary metabolites CCDC3 intron 21572414 rs2668922 chr10 12995969 A G 6.28E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CCDC3 intron 20031582 rs13377047 chr10 13000495 G A 4.10E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) CCDC3 intron 23648065 rs10508451 chr10 13004213 T C 7.91E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CCDC3 intron 20031582 rs10508452 chr10 13005288 T G 4.81E-04 Alzheimer's disease (late onset) CCDC3 intron 21379329 rs557264 chr10 13022684 C T 9.18E-04 Amyotrophic Lateral Sclerosis CCDC3 intron 17827064 rs11258100 chr10 13023690 G T 2.42E-06 Personality dimensions CCDC3 intron 23658558 rs920409 chr10 13033757 T G 2.23E-04 Amyotrophic Lateral Sclerosis CCDC3 intron 17827064 rs11593010 chr10 13088856 G C 1.91E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs637440 chr10 13099342 A G 2.29E-05 Multiple sclerosis / / 17660530 rs11258164 chr10 13103202 A G 9.42E-05 Multiple sclerosis / / 17660530 rs525455 chr10 13103285 G A 7.00E-07 Platelet aggregation / / 20526338 rs7079869 chr10 13121352 A G 6.78E-04 Myopia (pathological) / / 21095009 rs10796021 chr10 13135046 T C 4.01E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs532411611 chr10 13135046 T TC 4.01E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs641113 chr10 13137865 A G 3.66E-06 Hearing function / / 21493956 rs11258186 chr10 13145649 A G 3.49E-04 Multiple complex diseases OPTN intron 17554300 rs7921853 chr10 13152666 T G 4.78E-05 Paget's disease OPTN intron 20436471 rs1561570 chr10 13155726 T C 6.00E-13 Paget's disease OPTN intron 20436471 rs1561570 chr10 13155726 T C 4.00E-38 Paget's disease OPTN intron 21623375 rs825411 chr10 13169374 A G 7.82E-08 Paget's disease OPTN intron 20436471 rs2095388 chr10 13184045 A G 3.08E-06 Paget's disease / / 20436471 rs2895550 chr10 13185726 A G 8.52E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12779658 chr10 13252832 T C 7.89E-05 Hematocrit MCM10 UTR-3 pha003097 rs17152980 chr10 13276751 G C 6.80E-04 Metabolite levels (MHPG) / / 23319000 rs10906326 chr10 13279827 A G 3.27E-04 Height / / 17255346 rs2476980 chr10 13284032 C A 8.57E-05 Self-reported allergy / / 23817569 rs533672 chr10 13289784 A T 8.82E-04 Alzheimer's disease / / 22005930 rs4750333 chr10 13295039 T C 8.37E-04 Alzheimer's disease / / 22005930 rs10796051 chr10 13310071 T C 7.00E-06 Self-reported allergy / / 23817569 rs10906338 chr10 13310204 C T 7.14E-06 Self-reported allergy / / 23817569 rs500800 chr10 13328248 T C 1.02E-04 Lymphocyte counts PHYH intron 22286170 rs11258312 chr10 13336952 A G 7.97E-04 Suicide attempts in bipolar disorder PHYH intron 21423239 rs505081 chr10 13338202 G A 4.07E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PHYH intron 20877124 rs1095368 chr10 13355131 T C 7.00E-07 IgG glycosylation / / 23382691 rs1747683 chr10 13361976 A G 1.00E-07 IgG glycosylation SEPHS1 intron 23382691 rs1747683 chr10 13361976 A G 2.00E-07 IgG glycosylation SEPHS1 intron 23382691 rs1747683 chr10 13361976 A G 3.00E-07 IgG glycosylation SEPHS1 intron 23382691 rs1747683 chr10 13361976 A G 4.00E-07 IgG glycosylation SEPHS1 intron 23382691 rs1747683 chr10 13361976 A G 4.00E-07 IgG glycosylation SEPHS1 intron 23382691 rs1747683 chr10 13361976 A G 6.00E-07 IgG glycosylation SEPHS1 intron 23382691 rs10508459 chr10 13363046 A T 2.00E-06 IgG glycosylation SEPHS1 intron 23382691 rs2181839 chr10 13363624 C T 6.31E-05 Lung function (forced expiratory volume in 1 second) SEPHS1 intron pha003102 rs7914142 chr10 13381392 T C 2.92E-04 Multiple complex diseases SEPHS1 intron 17554300 rs1004621 chr10 13388584 G C 3.26E-06 Leprosy SEPHS1 intron 22019778 rs11258348 chr10 13410002 T C 1.71E-05 Parkinson's disease (motor and cognition) / / 22658654 rs2000064 chr10 13416918 C T 7.40E-06 Urinary metabolites / / 21572414 rs7099743 chr10 13447195 A G 3.53E-04 Obesity (extreme) / / 21935397 rs17531080 chr10 13448279 C T 8.42E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10906369 chr10 13465158 A G 4.42E-04 Aortic root size / / 21223598 rs9651539 chr10 13479496 A G 7.06E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2277222 chr10 13494594 T C 0.0000355 Tuberculosis with early age of onset BEND7 cds-synon 22551897 rs7074617 chr10 13495416 G A 0.0000765 Tuberculosis with early age of onset BEND7 intron 22551897 rs17533373 chr10 13518273 C T 6.22E-05 Elbow pain BEND7 intron pha003008 rs17153352 chr10 13530217 T A 7.00E-06 IgG glycosylation BEND7 intron 23382691 rs11258432 chr10 13560871 A T 3.65E-04 Multiple complex diseases / / 17554300 rs2478106 chr10 13628528 T C 1.42E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2399985 chr10 13645210 C T 1.16E-05 Lupus nephritis in systemic lupus erythematosus PRPF18 intron 24925725 rs2478118 chr10 13650032 C T 5.00E-06 Lupus nephritis in systemic lupus erythematosus PRPF18 intron 24925725 rs2478126 chr10 13659738 A C 2.70E-05 Crohn's disease PRPF18 intron 17684544 rs7098174 chr10 13666931 T G 7.19E-04 Iron levels PRPF18 intron pha002876 rs7089227 chr10 13667731 G T 7.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU) PRPF18 intron 24025145 rs12255911 chr10 13685247 T C 7.37E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs56161216 chr10 13688798 A G 6.00E-06 Parasitemia in Tripanosoma cruzi seropositivity FRMD4A UTR-3 24324551 rs7075997 chr10 13689761 G T 3.00E-04 Acute lymphoblastic leukemia (childhood) FRMD4A intron 20189245 rs74123095 chr10 13698078 T A 7.35E-06 Parasitemia in Tripanosoma cruzi seropositivity FRMD4A intron 24324551 rs11818229 chr10 13700805 A C 8.39E-06 Parasitemia in Tripanosoma cruzi seropositivity FRMD4A intron 24324551 rs943101 chr10 13729426 A C 2.66E-05 Serum metabolites FRMD4A intron 19043545 rs943102 chr10 13729505 C T 2.92E-05 Serum metabolites FRMD4A intron 19043545 rs10906447 chr10 13729647 C G 9.97E-05 Serum metabolites FRMD4A intron 19043545 rs2077150 chr10 13734850 T C 5.62E-05 Serum metabolites FRMD4A intron 19043545 rs2296596 chr10 13735947 A G 2.20E-05 Bone mineral density (BMD),in women FRMD4A cds-synon 20164292 rs2296596 chr10 13735947 A G 1.70E-05 Hypertension FRMD4A cds-synon 22384028 rs4314962 chr10 13737029 C A 5.20E-05 Bone mineral density (BMD),in women FRMD4A intron 20164292 rs1541010 chr10 13755544 C T 1.00E-06 RR interval (heart rate) FRMD4A intron 20031603 rs12220591 chr10 13762483 G A 7.48E-05 Amyotrophic lateral sclerosis (sporadic) FRMD4A intron 24529757 rs10796116 chr10 13762786 A G 8.84E-04 Body mass index FRMD4A intron 21701565 rs10796116 chr10 13762786 A G 0.0000999 Panic disorder FRMD4A intron 23149450 rs10796116 chr10 13762786 A G 9.99E-05 Serum tamsulosin hydrochloride concentration FRMD4A intron 23151678 rs17153802 chr10 13765323 T C 1.30E-05 Multiple complex diseases FRMD4A intron 17554300 rs7900357 chr10 13777194 G A 3.58E-05 IgE levels in asthmatics (D.p. specific) FRMD4A intron 23967269 rs9633782 chr10 13780118 G A 0.00060512 Hypertension (early onset hypertension) FRMD4A intron 22479346 rs6602681 chr10 13783685 T A,G 3.20E-04 Multiple complex diseases FRMD4A intron 17554300 rs10737079 chr10 13785400 C T 7.08E-04 Multiple complex diseases FRMD4A intron 17554300 rs10906466 chr10 13790265 A G 8.00E-06 Migraine FRMD4A intron 23793025 rs12257410 chr10 13792522 A C 0.0000377 Aging FRMD4A intron 22445811 rs7095537 chr10 13796225 T C 3.57E-06 Dental caries FRMD4A intron 21940522 rs7095537 chr10 13796225 T C 3.04E-04 Smoking initiation FRMD4A intron 24665060 rs4424567 chr10 13801269 A G 6.87E-05 Multiple complex diseases FRMD4A intron 17554300 rs34778395 chr10 13801432 C T 1.85E-05 Multiple complex diseases FRMD4A intron 17554300 rs10906467 chr10 13801636 C T 6.89E-05 Multiple complex diseases FRMD4A intron 17554300 rs10796119 chr10 13820420 C A 1.00E-04 Prostate cancer FRMD4A intron 21743057 rs17153983 chr10 13820804 G C 2.58E-04 Multiple complex diseases FRMD4A intron 17554300 rs1881584 chr10 13831712 A G 0.000804314 Hypertension (early onset hypertension) FRMD4A intron 22479346 rs4145934 chr10 13835616 G A 1.07E-04 Hearing function FRMD4A intron 17255346 rs7088455 chr10 13853852 A G 8.14E-04 Multiple complex diseases FRMD4A intron 17554300 rs1343002 chr10 13854997 G A 7.09E-05 Cognitive test performance FRMD4A intron 20125193 rs11258651 chr10 13867888 T C 6.24E-04 Type 2 diabetes FRMD4A intron 17463246 rs11258658 chr10 13869323 G A,C 6.33E-04 Type 2 diabetes FRMD4A intron 17463246 rs10906506 chr10 13874453 T C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FRMD4A intron 22628534 rs7899777 chr10 13875590 A G 4.97E-04 Multiple complex diseases FRMD4A intron 17554300 rs41506144 chr10 13876687 C G 4.03E-08 Gallstones FRMD4A intron 17632509 rs10906510 chr10 13883136 T C 4.96E-04 Type 2 diabetes FRMD4A intron 17463246 rs7894550 chr10 13883460 G T 4.39E-04 Stroke FRMD4A intron pha002886 rs7088464 chr10 13883951 A G 3.15E-04 Type 2 diabetes FRMD4A intron 17463246 rs12779769 chr10 13893998 T C 2.93E-04 Cholesterol FRMD4A intron 17255346 rs10906523 chr10 13908001 C G 5.12E-04 Multiple complex diseases FRMD4A intron 17554300 rs10508468 chr10 13918753 T C 7.00E-05 Breast cancer FRMD4A intron 17529967 rs2698127 chr10 13931134 G A 1.21E-04 Body mass index FRMD4A intron 21701565 rs2698127 chr10 13931134 G A 3.61E-04 Body mass index FRMD4A intron 21701565 rs1547834 chr10 13936554 G A 1.22E-05 Cholesterol FRMD4A intron 17255346 rs2797877 chr10 13937073 C A 2.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FRMD4A intron 20877124 rs17154204 chr10 13965414 T G 7.79E-04 Multiple complex diseases FRMD4A intron 17554300 rs2995648 chr10 13967259 G A 2.32E-05 Blood Pressure FRMD4A intron pha003049 rs2995648 chr10 13967259 G A 3.81E-05 Blood Pressure FRMD4A intron pha003050 rs1406467 chr10 13967533 G A 3.11E-05 Blood Pressure FRMD4A intron pha003049 rs1406467 chr10 13967533 G A 3.74E-05 Blood Pressure FRMD4A intron pha003050 rs17632029 chr10 13968125 C T 8.92E-05 Parkinson's disease FRMD4A intron 21738487 rs17632029 chr10 13968125 C T 3.58E-05 Intelligence FRMD4A intron 21826061 rs2797887 chr10 13971656 T C 5.96E-06 Multiple complex diseases FRMD4A intron 17554300 rs7904694 chr10 13973579 C T 1.34E-05 Major depression (suicidal thoughts and behavior) FRMD4A intron 21750702 rs2797891 chr10 13974452 T G 6.90E-05 Serum metabolites FRMD4A intron 19043545 rs10906545 chr10 13978235 A G 3.24E-04 Multiple complex diseases FRMD4A intron 17554300 rs2797878 chr10 13986063 T C 9.85E-04 Type 2 diabetes FRMD4A intron 17463246 rs12240404 chr10 13988898 C T 1.36E-05 Intelligence FRMD4A intron 21826061 rs12240404 chr10 13988898 C T 1.67E-05 Blood Pressure FRMD4A intron pha003050 rs7081208 chr10 13991865 G A 1.00E-10 Alzheimer's disease FRMD4A intron 22430674 rs2447027 chr10 14003363 C T 9.82E-05 Hemoglobin FRMD4A intron pha003098 rs2457861 chr10 14006391 G A 3.64E-04 Nicotine smoking FRMD4A intron 19268276 rs12358733 chr10 14016290 G A 7.38E-04 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs10906555 chr10 14016879 G A 7.50E-04 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs4237437 chr10 14018711 G A 8.83E-04 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs4237438 chr10 14018768 A C 6.33E-04 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs11258770 chr10 14018910 G T 8.83E-04 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs4503425 chr10 14019034 C G 8.83E-04 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs10508470 chr10 14021822 G A 5.84E-04 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs7909279 chr10 14026046 A G 7.45E-04 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs1574583 chr10 14026870 G C 7.40E-04 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs2446585 chr10 14028086 G A 9.59E-04 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs4748066 chr10 14029313 T A 8.79E-05 Major depressive disorder (broad) FRMD4A intron 20038947 rs4748066 chr10 14029313 T A 8.19E-04 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs4748066 chr10 14029313 T A 6.58E-06 Odorant perception FRMD4A intron 23910658 rs7917296 chr10 14029639 G A 7.10E-05 Major depressive disorder (broad) FRMD4A intron 20038947 rs7917296 chr10 14029639 G A 1.01E-04 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs7917314 chr10 14029682 G A 1.03E-04 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs11258774 chr10 14029701 G A 9.31E-05 Major depressive disorder (broad) FRMD4A intron 20038947 rs11258774 chr10 14029701 G A 1.10E-04 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs11258775 chr10 14029742 T C 9.32E-05 Major depressive disorder (broad) FRMD4A intron 20038947 rs11258775 chr10 14029742 T C 1.09E-04 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs7917812 chr10 14030067 G A 9.30E-05 Major depressive disorder (broad) FRMD4A intron 20038947 rs7917812 chr10 14030067 G A 1.14E-04 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs7921866 chr10 14030161 C T 5.58E-04 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs4750446 chr10 14030319 T G 9.32E-05 Major depressive disorder (broad) FRMD4A intron 20038947 rs4750446 chr10 14030319 T G 5.25E-04 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs4748068 chr10 14030692 T A 6.21E-05 Major depressive disorder (broad) FRMD4A intron 20038947 rs4748068 chr10 14030692 T A 1.01E-04 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs7922870 chr10 14030921 C T 6.14E-05 Major depressive disorder (broad) FRMD4A intron 20038947 rs7922870 chr10 14030921 C T 9.29E-05 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs2447011 chr10 14032199 C T 4.61E-04 Multiple complex diseases FRMD4A intron 17554300 rs4748075 chr10 14038517 T C 9.40E-05 Major depressive disorder (broad) FRMD4A intron 20038947 rs2457837 chr10 14051456 C T 5.47E-05 Elbow pain FRMD4A intron pha003008 rs12777331 chr10 14052850 G A 2.68E-04 Response to statin treatment (atorvastatin),change in cholesterol levels FRMD4A intron 20031582 rs2457857 chr10 14060679 C A 8.38E-05 Lung function (forced expiratory volume in 1 second) FRMD4A intron 17255346 rs17154458 chr10 14068500 T C 1.18E-04 Lung function (forced expiratory volume in 1 second) FRMD4A intron 17255346 rs17154458 chr10 14068500 T C 9.74E-05 Lipoprotein-associated phospholipase A2 activity and mass FRMD4A intron 20442857 rs2447038 chr10 14071061 C T 5.00E-05 Prostate cancer FRMD4A intron 21743057 rs2457855 chr10 14071783 A G 6.34E-04 White matter integrity FRMD4A intron 22425255 rs1599944 chr10 14072183 G A 4.10E-07 Urinary metabolites FRMD4A intron 21572414 rs7901829 chr10 14073201 G T 1.20E-04 Parkinson's disease FRMD4A intron 17052657 rs1020857 chr10 14073753 T G 2.35E-04 Lung function (forced expiratory volume in 1 second) FRMD4A intron 17255346 rs1020857 chr10 14073753 T G 3.70E-04 White matter integrity FRMD4A intron 22425255 rs1975887 chr10 14079512 C T 1.50E-05 Urinary metabolites FRMD4A intron 21572414 rs11258834 chr10 14093180 C T 8.50E-06 Urinary metabolites FRMD4A intron 21572414 rs4750458 chr10 14101367 T C 1.87E-04 Lung function (forced expiratory volume in 1 second) FRMD4A intron 17255346 rs7898303 chr10 14102945 G A 1.10E-06 Urinary metabolites FRMD4A intron 21572414 rs7898303 chr10 14102945 G A 2.57E-04 White matter integrity FRMD4A intron 22425255 rs11258845 chr10 14104135 C T 2.57E-04 Lung function (forced expiratory volume in 1 second) FRMD4A intron 17255346 rs11258845 chr10 14104135 C T 1.00E-05 Urinary metabolites FRMD4A intron 21572414 rs1870746 chr10 14117154 T A 1.98E-04 Body mass index FRMD4A intron 21701565 rs1870746 chr10 14117154 T A 3.04E-05 Body mass index FRMD4A intron 21701565 rs7095572 chr10 14118084 C T 1.07E-04 Multiple complex diseases FRMD4A intron 17554300 rs7095572 chr10 14118084 C T 1.76E-05 Body mass index FRMD4A intron 21701565 rs3101357 chr10 14119720 G T 2.71E-06 Colorectal cancer FRMD4A intron 21242260 rs3101357 chr10 14119720 G T 6.81E-04 Body mass index FRMD4A intron 21701565 rs7920328 chr10 14121089 T G 1.20E-08 Urinary metabolites FRMD4A intron 21572414 rs2614143 chr10 14123459 G A 4.39E-06 Colorectal cancer FRMD4A intron 21242260 rs1359731 chr10 14125252 C T 7.62E-04 Suicide attempts in bipolar disorder FRMD4A intron 21423239 rs922239 chr10 14125635 A T 3.05E-04 Body mass index FRMD4A intron 21701565 rs922239 chr10 14125635 A T 4.30E-05 Body mass index FRMD4A intron 21701565 rs2767288 chr10 14129851 T C 3.27E-04 Birth weight FRMD4A intron 17255346 rs7893591 chr10 14131761 G A 5.20E-06 Urinary metabolites FRMD4A intron 21572414 rs1327003 chr10 14148412 T G 1.24E-05 Amyotrophic lateral sclerosis (sporadic) FRMD4A intron 24529757 rs7893529 chr10 14149703 T C 5.90E-04 Type 2 diabetes FRMD4A intron 17463246 rs17154656 chr10 14151277 A C 7.78E-05 Creatinine levels FRMD4A intron pha003069 rs1327000 chr10 14157261 G A 2.59E-04 Type 2 diabetes FRMD4A intron 17463246 rs10906599 chr10 14158126 C T 2.56E-04 Lung function (forced expiratory volume in 1 second) FRMD4A intron 17255346 rs1409747 chr10 14160000 C T 2.96E-04 Lung function (forced expiratory volume in 1 second) FRMD4A intron 17255346 rs17325064 chr10 14160295 G A 6.15E-05 Cognitive test performance FRMD4A intron 20125193 rs1359728 chr10 14161500 C T 2.54E-04 Lung function (forced expiratory volume in 1 second) FRMD4A intron 17255346 rs10796157 chr10 14162322 T C 3.33E-04 Lung function (forced expiratory volume in 1 second) FRMD4A intron 17255346 rs2104551 chr10 14162577 C T 8.59E-04 Multiple complex diseases FRMD4A intron 17554300 rs7088695 chr10 14163648 C T 3.33E-04 Lung function (forced expiratory volume in 1 second) FRMD4A intron 17255346 rs11258880 chr10 14172634 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FRMD4A intron 22628534 rs6602707 chr10 14174921 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FRMD4A intron 22628534 rs9663251 chr10 14182045 A G 5.30E-05 Temporomandibular joint disorders FRMD4A intron 23746317 rs11258903 chr10 14196780 C T 1.90E-04 Suicidal ideation FRMD4A intron 22030708 rs17154765 chr10 14208611 T C 7.33E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FRMD4A intron 24023788 rs17154771 chr10 14214910 G C 9.11E-04 Obesity (extreme) FRMD4A intron 21935397 rs11258918 chr10 14218291 C T 4.85E-04 Lung function (forced expiratory volume in 1 second) FRMD4A intron 24023788 rs4750480 chr10 14227416 G C 4.69E-04 Type 2 diabetes FRMD4A intron 17463246 rs4750480 chr10 14227416 G C 8.88E-05 Serum metabolites FRMD4A intron 19043545 rs7905928 chr10 14227908 G T 3.24E-04 Lung function (forced expiratory volume in 1 second) FRMD4A intron 24023788 rs7919543 chr10 14230471 C T 4.20E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FRMD4A intron 24023788 rs11591602 chr10 14232324 G A 2.61E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FRMD4A intron 24023788 rs4750489 chr10 14251892 A G 3.39E-04 Type 2 diabetes FRMD4A intron 17463246 rs1983907 chr10 14262019 G A 3.44E-04 Lung function (forced expiratory volume in 1 second) FRMD4A intron 24023788 rs7906363 chr10 14262438 C A 3.44E-04 Lung function (forced expiratory volume in 1 second) FRMD4A intron 24023788 rs7898553 chr10 14278130 C A 9.43E-05 Prostate cancer FRMD4A intron 22923026 rs1218401 chr10 14284089 T C 1.18E-04 Multiple complex diseases FRMD4A intron 17554300 rs11258977 chr10 14291542 G A 2.84E-05 Prostate cancer FRMD4A intron 22923026 rs1218374 chr10 14295301 T G 3.93E-05 Prostate cancer FRMD4A intron 22923026 rs1218373 chr10 14296716 T G 1.55E-04 Multiple complex diseases FRMD4A intron 17554300 rs17154969 chr10 14305544 C T 1.60E-04 Multiple complex diseases FRMD4A intron 17554300 rs1218355 chr10 14318773 T C 6.61E-05 Prostate cancer FRMD4A intron 22923026 rs1228333 chr10 14329226 C T 3.41E-04 Multiple complex diseases FRMD4A intron 17554300 rs1041337 chr10 14350730 C A 1.57E-04 Multiple complex diseases FRMD4A intron 17554300 rs1218412 chr10 14352706 C T 1.16E-13 Metabolite levels FRMD4A intron 22286219 rs1218430 chr10 14362718 A G 2.17E-04 Sarcoidosis FRMD4A intron 19165924 rs7082219 chr10 14375259 G T 1.14E-04 Substance dependence / / 21818250 rs12264410 chr10 14377852 T A 4.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs1717513 chr10 14378508 G A 5.82E-04 Multiple complex diseases / / 17554300 rs17337006 chr10 14382164 T C 7.68E-05 Body mass index / / 21701565 rs1218486 chr10 14385265 T G 3.03E-04 Substance dependence / / 21818250 rs7918657 chr10 14395828 C T 2.12E-04 Alzheimer's disease / / 24755620 rs7083480 chr10 14398225 C T 1.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7083480 chr10 14398225 C T 2.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12265618 chr10 14400359 G T 2.62E-04 Alzheimer's disease / / 24755620 rs11259039 chr10 14422809 G A 7.14E-05 Calcium intake levels and metabolic syndrome / / 22170361 rs2895598 chr10 14432535 A C 4.06E-04 Multiple complex diseases / / 17554300 rs7905868 chr10 14488967 T C 6.64E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs11259112 chr10 14500795 T C 3.09E-04 Coronary Artery Disease / / 17634449 rs11259131 chr10 14514061 T G 8.78E-05 Bipolar disorder and schizophrenia / / 20889312 rs7083394 chr10 14523377 C T 2.16E-04 Coronary Artery Disease / / 17634449 rs7087856 chr10 14524880 G A 4.96E-05 Coronary Artery Disease / / 17634449 rs10508474 chr10 14531530 T C 1.02E-05 Triglycerides / / 19074352 rs10508474 chr10 14531530 T C 1.02E-05 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs10906692 chr10 14583701 C G 4.96E-04 Multiple complex diseases FAM107B intron 17554300 rs4543882 chr10 14603299 G A 1.69E-04 Multiple complex diseases FAM107B intron 17554300 rs7096086 chr10 14610085 T C 2.03E-04 Multiple complex diseases FAM107B intron 17554300 rs10906701 chr10 14619045 T C 7.11E-05 Bipolar disorder and schizophrenia FAM107B intron 20889312 rs17155499 chr10 14622448 T C 1.30E-06 Coronary heart disease FAM107B intron 21971053 rs12777920 chr10 14625920 T C 4.36E-09 Multiple complex diseases FAM107B intron 17554300 rs1409391 chr10 14627825 T C 3.67E-04 Birth weight FAM107B intron 17255346 rs1409390 chr10 14627846 T C 2.25E-04 Alcohol consumption (maxi-drinks) FAM107B intron 24277619 rs11259207 chr10 14630069 G A 6.27E-05 Bipolar disorder and schizophrenia FAM107B intron 20889312 rs11259210 chr10 14633723 T C 7.75E-04 Alcohol consumption (maxi-drinks) FAM107B intron 24277619 rs35375469 chr10 14638939 C T 2.67E-04 Type 2 diabetes FAM107B intron 17463246 rs7921651 chr10 14660199 C T 7.97E-05 Cholesterol FAM107B intron pha003078 rs12770153 chr10 14662775 G A 2.10E-05 Urinary metabolites FAM107B intron 21572414 rs4750542 chr10 14663944 A T 1.20E-05 Urinary metabolites FAM107B intron 21572414 rs7916569 chr10 14666538 G A 1.76E-04 Metabolite levels (MHPG) FAM107B intron 23319000 rs17155611 chr10 14667353 C T 8.81E-05 Cocaine dependence FAM107B intron 23958962 rs10906720 chr10 14675475 G C 8.04E-05 Breast cancer FAM107B intron 21060860 rs7089802 chr10 14696000 C T 6.88E-04 Response to alcohol consumption (flushing response) FAM107B intron 24277619 rs7922166 chr10 14698549 T A 4.00E-04 Gamma gluatamyl transferase levels (interaction with age) FAM107B intron 22010049 rs7903263 chr10 14698952 C A 1.76E-04 Multiple complex diseases FAM107B intron 17554300 rs17155703 chr10 14701678 T C 5.20E-04 Amyotrophic lateral sclerosis (sporadic) FAM107B intron 24529757 rs1410077 chr10 14734699 T C 0.000645 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FAM107B intron 23233654 rs1410077 chr10 14734699 T C 6.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) FAM107B intron 23233662 rs11259283 chr10 14740813 T G 6.70E-04 Type 2 diabetes FAM107B intron 17463246 rs12412629 chr10 14743063 T C 6.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM107B intron 20877124 rs1001004 chr10 14748752 A G 7.29E-06 Aortic root size FAM107B intron 21223598 rs4748109 chr10 14757779 A G 3.98E-04 Aortic root size FAM107B intron 21223598 rs2688858 chr10 14764993 C T 8.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM107B intron 20877124 rs913293 chr10 14776244 T A 4.01E-04 Suicide attempts in bipolar disorder FAM107B intron 21423239 rs913292 chr10 14776323 G T 1.87E-04 Suicide attempts in bipolar disorder FAM107B intron 21423239 rs7921961 chr10 14778352 C T 6.72E-04 Suicide attempts in bipolar disorder FAM107B intron 21423239 rs7921286 chr10 14778533 G A 6.38E-04 Suicide attempts in bipolar disorder FAM107B intron 21423239 rs2688864 chr10 14779154 T C 4.20E-04 Suicide attempts in bipolar disorder FAM107B intron 21423239 rs2768702 chr10 14779689 C T 5.55E-04 Suicide attempts in bipolar disorder FAM107B intron 21423239 rs2768703 chr10 14780316 C T 7.78E-04 Suicide attempts in bipolar disorder FAM107B intron 21423239 rs1955196 chr10 14780739 T C 9.79E-04 Suicide attempts in bipolar disorder FAM107B intron 21423239 rs1955195 chr10 14780788 A T 8.45E-04 Suicide attempts in bipolar disorder FAM107B intron 21423239 rs2601749 chr10 14781330 T C 9.75E-04 Suicide attempts in bipolar disorder FAM107B intron 21423239 rs1555989 chr10 14784086 C T 8.83E-04 Suicide attempts in bipolar disorder FAM107B intron 21423239 rs2609811 chr10 14784890 C A,G,T 8.94E-04 Suicide attempts in bipolar disorder FAM107B intron 21423239 rs12256790 chr10 14818870 A G 1.56E-04 Birth weight / / 17255346 rs10906756 chr10 14827228 T A 2.60E-05 Urinary metabolites / / 21572414 rs10796221 chr10 14839071 T G 3.35E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2609839 chr10 14846174 G A 4.24E-04 Body mass index / / 21701565 rs7076860 chr10 14847704 A G 7.88E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7900873 chr10 14863864 G A 7.73E-06 Rheumatoid arthritis CDNF intron 19503088 rs7094179 chr10 14872427 C A 0.000371 5-fluorouracil induced nausea/vomiting in response to colorectal cancer treatment CDNF intron 22310351 rs7894284 chr10 14894901 T C 7.03E-06 Rheumatoid arthritis HSPA14 intron 19503088 rs7894284 chr10 14894901 T C 6.09E-06 QRS duration in Tripanosoma cruzi seropositivity HSPA14 intron 24324551 rs17156034 chr10 14932239 A G 2.57E-04 Multiple complex diseases SUV39H2 intron 17554300 rs11594111 chr10 14945406 A G 1.00E-07 Migraine SUV39H2 UTR-3 23793025 rs11594111 chr10 14945406 A G 1.25E-04 Migraine without aura SUV39H2 UTR-3 23793025 rs12572872 chr10 14954024 G A 2.87E-06 Rheumatoid arthritis DCLRE1C intron 19503088 rs4276994 chr10 15020847 T G 9.90E-05 Orofacial clefts / / 22419666 rs12241793 chr10 15025223 T C 8.36E-04 Metabolite levels (MHPG) / / 23319000 rs7092900 chr10 15090511 C T 2.39E-12 Metabolite levels OLAH intron 22286219 rs12781344 chr10 15095449 G A 9.47E-06 Hemoglobin OLAH intron pha003098 rs12781344 chr10 15095449 G A 6.24E-07 Erythrocyte counts OLAH intron pha003099 rs7082022 chr10 15100883 C G 0.0000369 Nonsyndromic striae distensae (stretch marks) OLAH intron 23633020 rs7917664 chr10 15115515 C T 0.0000832 Nonsyndromic striae distensae (stretch marks) OLAH UTR-3 23633020 rs11259474 chr10 15129402 T C 5.00E-06 Obesity-related traits ACBD7 intron 23251661 rs9663982 chr10 15136259 T G 5.69E-04 Multiple complex diseases / / 17554300 rs11819275 chr10 15149165 C T 5.64E-06 Lymphocyte counts NMT2 UTR-3 22286170 rs7915262 chr10 15198584 T C 2.80E-06 Parkinson's disease NMT2 intron 20711177 rs7096608 chr10 15199753 T C 2.90E-06 Parkinson's disease NMT2 intron 20711177 rs17156361 chr10 15202337 A T 1.60E-05 Urinary metabolites NMT2 intron 21572414 rs7902390 chr10 15203310 A C 4.18E-04 Multiple complex diseases NMT2 intron 17554300 rs7091245 chr10 15211739 A G 2.21E-04 Multiple complex diseases / / 17554300 rs6602821 chr10 15248166 T C 5.61E-05 Multiple complex diseases / / 17554300 rs10906865 chr10 15274522 C G 2.93E-04 Multiple complex diseases FAM171A1 intron 17554300 rs2138929 chr10 15294548 C A 8.27E-05 Hemoglobin FAM171A1 intron pha003096 rs7920144 chr10 15304786 G A 5.20E-06 Urinary metabolites FAM171A1 intron 21572414 rs17156509 chr10 15325014 C A 1.10E-05 Urinary metabolites FAM171A1 intron 21572414 rs11259612 chr10 15382469 A G 9.10E-04 Age-related macular degeneration FAM171A1 intron 21909106 rs4750624 chr10 15383780 A G 2.09E-34 Narcolepsy FAM171A1 intron 19629137 rs4387250 chr10 15388889 C T 7.67E-05 Bipolar disorder,affective FAM171A1 intron 20528957 rs4750628 chr10 15391182 G A 5.00E-05 Asperger disorder FAM171A1 intron 21182207 rs10796285 chr10 15393309 G A 2.00E-05 Asperger disorder FAM171A1 intron 21182207 rs11599615 chr10 15395181 T C 7.00E-05 Asperger disorder FAM171A1 intron 21182207 rs10508485 chr10 15437159 G A 2.94E-05 Duodenal ulcer / / 22387998 rs11259663 chr10 15484342 C A 5.42E-04 Parkinson's disease / / 17052657 rs11598126 chr10 15493251 T C 3.96E-04 Type 2 diabetes / / 17463246 rs10752384 chr10 15524141 T C 6.75E-04 Smoking initiation / / 24665060 rs2014821 chr10 15548747 A G 4.20E-06 Dietary macronutrient intake / / 23372041 rs11259718 chr10 15549894 A G 4.65E-04 Aortic root size / / 21223598 rs7077361 chr10 15561543 T C 5.00E-06 Parkinson's disease ITGA8 intron 19915575 rs7077361 chr10 15561543 T C 1.51E-08 Parkinson's disease ITGA8 intron 22438815 rs28643277 chr10 15600671 C A 9.00E-06 Periodontitis (CDC/AAP) ITGA8 intron 24024966 rs1057970 chr10 15638706 G T 4.34E-05 Multiple complex diseases ITGA8 intron 17554300 rs2282384 chr10 15648104 G A 9.32E-05 Taste perception ITGA8 intron 22132133 rs2044892 chr10 15648648 C T 9.96E-04 Type 2 diabetes ITGA8 intron 17463246 rs1376690 chr10 15680073 C T 5.85E-05 Taste perception ITGA8 intron 22132133 rs11253593 chr10 15696654 A T 5.19E-04 Suicide attempts in bipolar disorder ITGA8 intron 21423239 rs9333117 chr10 15702585 A G 7.96E-04 Suicide attempts in bipolar disorder ITGA8 intron 21423239 rs11253602 chr10 15712178 T C 9.08E-04 Suicide attempts in bipolar disorder ITGA8 intron 21423239 rs9333105 chr10 15714431 C A 5.08E-06 Multiple complex diseases ITGA8 intron 17554300 rs7895372 chr10 15719621 C G 6.00E-06 Quantitative traits ITGA8 missense 19197348 rs9333092 chr10 15725723 C T 7.84E-04 Coronary heart disease ITGA8 intron 21971053 rs1417658 chr10 15734374 A G 1.94E-04 Glycosylated haemoglobin levels ITGA8 intron 17255346 rs11253609 chr10 15744892 A G 9.60E-04 Insulin resistance ITGA8 intron 21901158 rs1557040 chr10 15745323 A G 1.09E-04 Glycosylated haemoglobin levels ITGA8 intron 17255346 rs7086410 chr10 15745650 C T 1.73E-04 Glycosylated haemoglobin levels ITGA8 intron 17255346 rs10752027 chr10 15745968 T C 1.73E-04 Glycosylated haemoglobin levels ITGA8 intron 17255346 rs9333260 chr10 15761209 A C 1.54E-04 Type 2 diabetes ITGA8 intron 17463246 rs2487488 chr10 15764723 C T 2.07E-07 Glycosylated haemoglobin levels / / 17255346 rs1934935 chr10 15777408 T C 9.06E-06 Glycosylated haemoglobin levels / / 17255346 rs1557035 chr10 15777763 G A 6.10E-07 Glycosylated haemoglobin levels / / 17255346 rs1557034 chr10 15777861 A G 2.07E-07 Glycosylated haemoglobin levels / / 17255346 rs1361538 chr10 15786462 C T 2.07E-07 Glycosylated haemoglobin levels / / 17255346 rs6602056 chr10 15787971 A G 2.94E-07 Glycosylated haemoglobin levels / / 17255346 rs7093307 chr10 15795051 C T 1.06E-04 Glycosylated haemoglobin levels / / 17255346 rs7905319 chr10 15797198 A G 2.32E-04 Glycosylated haemoglobin levels / / 17255346 rs7905686 chr10 15797400 C T 7.42E-06 Glycosylated haemoglobin levels / / 17255346 rs11818485 chr10 15806371 C T 5.40E-04 Diabetic nephropathy / / 20347642 rs10508494 chr10 15821778 C G 8.20E-04 Crohn's disease FAM188A intron 17684544 rs12262809 chr10 15835277 G A 8.13E-05 Serum metabolites FAM188A intron 19043545 rs12262809 chr10 15835277 G A 8.09E-04 Depression (quantitative trait) FAM188A intron 20800221 rs4387254 chr10 15850183 C G 5.98E-04 Depression (quantitative trait) FAM188A intron 20800221 rs11253656 chr10 15858620 A T 8.88E-04 Depression (quantitative trait) FAM188A intron 20800221 rs10795321 chr10 15861275 C G 3.45E-05 Serum metabolites FAM188A intron 19043545 rs10795321 chr10 15861275 C G 1.55E-04 Depression (quantitative trait) FAM188A intron 20800221 rs10795322 chr10 15861576 A G 4.57E-04 Depression (quantitative trait) FAM188A intron 20800221 rs10904631 chr10 15868012 C A 5.18E-04 Depression (quantitative trait) FAM188A intron 20800221 rs12264533 chr10 15869590 A G 2.26E-04 Depression (quantitative trait) FAM188A intron 20800221 rs7923528 chr10 15889372 C T 1.96E-04 Depression (quantitative trait) FAM188A intron 20800221 rs35785910 chr10 15934272 C CAG 2.99E-04 Depression (quantitative trait) / / 20800221 rs7903674 chr10 15934272 C G 2.99E-04 Depression (quantitative trait) / / 20800221 rs11253684 chr10 15943346 G A 0.00047 Breast cancer / / 23555315 rs7919133 chr10 15944137 T C 2.80E-05 Urinary metabolites / / 21572414 rs11253713 chr10 16015463 C T 3.98E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7080090 chr10 16022844 A T 0.00004 Mean arterial pressure / / 22510845 rs7098245 chr10 16022924 T A 0.00004 Mean arterial pressure / / 22510845 rs11253727 chr10 16035541 G T 4.39E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11812670 chr10 16043948 A G 4.60E-05 Height / / pha003010 rs11812670 chr10 16043948 A G 9.99E-05 Height / / pha003011 rs1341562 chr10 16057887 G A 9.62E-04 Alzheimer's disease / / 24755620 rs870551 chr10 16061788 G A 6.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs870551 chr10 16061788 G A 6.42E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10904665 chr10 16068563 G A 8.83E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs947335 chr10 16070792 T C 6.72E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs2015326 chr10 16070912 T G 7.41E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs7899730 chr10 16100127 T C 8.60E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4748242 chr10 16101247 A G 1.35E-05 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4307622 chr10 16102103 G T 1.02E-05 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11253760 chr10 16109238 T C 9.37E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11253762 chr10 16112933 T C 3.51E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs11253762 chr10 16112933 T C 1.00E-05 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10795344 chr10 16113883 G A 9.92E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2069036 chr10 16116747 T C 8.00E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4748245 chr10 16118555 A G 0.000407 Breast cancer early age of onset / / 18463975 rs11253773 chr10 16131289 T C 6.85E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs11253779 chr10 16138489 C T 2.01E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs11253779 chr10 16138489 C T 3.36E-05 Pulmonary function in asthmatics / / 23541324 rs7098374 chr10 16145787 T C 8.62E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs7098374 chr10 16145787 T C 5.11E-05 Pulmonary function in asthmatics / / 23541324 rs1417096 chr10 16147479 A G 3.11E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs1340151 chr10 16148908 G A 7.93E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs6602078 chr10 16151893 C A 2.87E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs1340145 chr10 16156836 G A 7.52E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs4747260 chr10 16157874 G T 1.18E-05 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7342092 chr10 16158312 G T 1.23E-05 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11253799 chr10 16158680 G A 1.16E-05 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10795348 chr10 16158880 C T 3.40E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs10795348 chr10 16158880 C T 5.07E-05 Pulmonary function in asthmatics / / 23541324 rs11253822 chr10 16197267 C A 1.50E-05 Urinary metabolites / / 21572414 rs11253825 chr10 16197573 A C 1.50E-05 Urinary metabolites / / 21572414 rs2226024 chr10 16198980 A G 3.51E-04 Diabetic retinopathy / / 20871662 rs11593981 chr10 16230372 G T 6.27E-04 Obesity (extreme) / / 21935397 rs2355244 chr10 16232391 A G 2.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4748263 chr10 16233175 A G 8.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1340143 chr10 16243408 A C 7.13E-04 Orofacial clefts / / 22419666 rs7080187 chr10 16254369 T A 4.52E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1340142 chr10 16255006 A G 6.75E-04 Smoking cessation / / 24665060 rs17136428 chr10 16268673 T C 1.60E-05 Urinary metabolites / / 21572414 rs2991895 chr10 16276206 T C 2.23E-05 Multiple complex diseases / / 17554300 rs7902512 chr10 16281080 C T 2.30E-05 Urinary metabolites / / 21572414 rs11253863 chr10 16284825 C T 2.80E-05 Urinary metabolites / / 21572414 rs10508503 chr10 16299951 C T 2.00E-07 Obesity / / 19151714 rs10508503 chr10 16299951 C T 1.00E-07 Smoking behavior / / 20418888 rs12217463 chr10 16318694 T C 4.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs12217463 chr10 16318694 T C 3.37E-04 Insulin resistance / / 21901158 rs11253896 chr10 16343798 C A 2.00E-05 Urinary metabolites / / 21572414 rs10795368 chr10 16344054 C T 1.30E-05 Urinary metabolites / / 21572414 rs10904714 chr10 16346741 A G 0.000765 Salmonella-induced pyroptosis / / 22837397 rs12269329 chr10 16349018 A G 6.60E-19 Multiple complex diseases / / 17554300 rs2225702 chr10 16366811 G T 9.95E-06 Cognitive impairment induced by topiramate / / 22091778 rs11253924 chr10 16383771 G T 9.98E-04 Coronary heart disease / / 21606135 rs7090427 chr10 16383931 A G 8.37E-04 Coronary heart disease / / 21606135 rs7910788 chr10 16421596 T C 8.09E-05 Femoral neck bone geometry / / 22087292 rs11597943 chr10 16449109 T C 1.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs11253982 chr10 16467242 C A 1.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs10904739 chr10 16478392 A G 4.18E-05 Suicide attempts in bipolar disorder / / 21423239 rs11818351 chr10 16484042 C T 4.29E-05 Suicide attempts in bipolar disorder PTER intron 21423239 rs17138622 chr10 16488056 G A 4.64E-05 Suicide attempts in bipolar disorder PTER intron 21423239 rs2171730 chr10 16509960 C A 1.25E-04 Suicide attempts in bipolar disorder PTER intron 21423239 rs11254007 chr10 16514198 T C 1.24E-04 Suicide attempts in bipolar disorder PTER intron 21423239 rs7076592 chr10 16514215 T C 1.24E-04 Suicide attempts in bipolar disorder PTER intron 21423239 rs7097849 chr10 16515689 A G 1.72E-04 Suicide attempts in bipolar disorder PTER intron 21423239 rs11254008 chr10 16517273 A G 1.04E-04 Suicide attempts in bipolar disorder PTER intron 21423239 rs11254009 chr10 16517784 T C 1.75E-04 Suicide attempts in bipolar disorder PTER intron 21423239 rs11254010 chr10 16518407 T C 9.48E-05 Suicide attempts in bipolar disorder PTER intron 21423239 rs17138721 chr10 16535251 T C 8.05E-04 Multiple complex diseases PTER intron 17554300 rs11254031 chr10 16541771 A G 2.36E-04 Suicide attempts in bipolar disorder PTER intron 21423239 rs7909832 chr10 16556710 T C 5.13E-04 Smoking initiation C1QL3 intron 24665060 rs17138777 chr10 16574358 A C 6.73E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs7086455 chr10 16583249 C T 2.17E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs10400085 chr10 16586339 A C 4.83E-13 Multiple complex diseases / / 17554300 rs7084722 chr10 16595396 A G 0.0000612 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7084722 chr10 16595396 A G 6.12E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11254085 chr10 16610995 G A 0.0003238 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11254085 chr10 16610995 G A 3.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11254088 chr10 16614035 C T 0.0003294 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11254088 chr10 16614035 C T 3.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11254089 chr10 16614193 T C 0.0002402 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11254089 chr10 16614193 T C 2.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11254091 chr10 16615689 G A 0.000239 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11254091 chr10 16615689 G A 2.39E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12221265 chr10 16617359 T G 0.0002366 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12221265 chr10 16617359 T G 2.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7068341 chr10 16634299 C T 2.00E-06 Migraine RSU1 UTR-3 23793025 rs17138910 chr10 16682602 T C 3.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RSU1 intron 20877124 rs7902142 chr10 16687244 A G 2.51E-04 IgE levels RSU1 intron 17255346 rs7087965 chr10 16689683 G A 4.93E-06 Information processing speed RSU1 intron 21130836 rs4412660 chr10 16691950 C T 3.44E-04 Alzheimer's disease RSU1 intron 22005930 rs7920932 chr10 16692015 C G 3.46E-04 Alzheimer's disease RSU1 intron 22005930 rs7089460 chr10 16698600 T G 3.07E-04 Alzheimer's disease RSU1 intron 22005930 rs7089460 chr10 16698600 T G 6.12E-07 Lymphocyte counts RSU1 intron 22286170 rs7090316 chr10 16702330 C T 7.53E-05 Myopia (severe) RSU1 intron 23933737 rs10795410 chr10 16704314 G A 2.31E-05 Information processing speed RSU1 intron 21130836 rs10795410 chr10 16704314 G A 1.30E-05 Urinary metabolites RSU1 intron 21572414 rs12780474 chr10 16716432 A C 1.00E-04 Information processing speed RSU1 intron 21130836 rs12572686 chr10 16719088 A G 5.08E-05 Colorectal cancer RSU1 intron 19723657 rs10904792 chr10 16738162 C G 1.83E-04 Acute lung injury RSU1 intron 22295056 rs10795417 chr10 16743672 A G 2.85E-04 Acute lung injury RSU1 intron 22295056 rs11254160 chr10 16744523 G A 6.00E-06 Obesity-related traits RSU1 intron 23251661 rs11254160 chr10 16744523 G A 8.00E-06 Obesity-related traits RSU1 intron 23251661 rs7916663 chr10 16748610 G A 2.00E-06 Obesity-related traits RSU1 intron 23251661 rs7916663 chr10 16748610 G A 4.00E-07 Obesity-related traits RSU1 intron 23251661 rs7916663 chr10 16748610 G A 5.00E-06 Obesity-related traits RSU1 intron 23251661 rs2356378 chr10 16762215 G A 2.50E-05 Urinary metabolites RSU1 intron 21572414 rs12261652 chr10 16767461 T G 1.82E-05 Amyotrophic lateral sclerosis (sporadic) RSU1 intron 24529757 rs17156937 chr10 16807745 C T 0.0000113 Sarcoidosis RSU1 intron 22952805 rs34613695 chr10 16810590 G T 0.00005245 Sarcoidosis RSU1 intron 22952805 rs2004489 chr10 16810847 G A 4.97E-04 Response to taxane treatment (placlitaxel) RSU1 intron 23006423 rs3780974 chr10 16821021 T C 6.04E-05 Serum metabolites RSU1 intron 19043545 rs115664995 chr10 16838592 G T 2.08E-04 Cocaine dependence RSU1 intron 23958962 rs7068881 chr10 16838866 A G 9.10E-04 Response to taxane treatment (placlitaxel) RSU1 intron 23006423 rs12253979 chr10 16853415 T C 6.76E-04 Amyotrophic lateral sclerosis (sporadic) RSU1 intron 24529757 rs7074293 chr10 16857203 A C 6.13E-04 Metabolite levels (MHPG) RSU1 intron 23319000 rs3808925 chr10 16860239 A G 2.00E-04 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs780633 chr10 16863161 G A 2.51E-04 Stroke / / pha002887 rs4747284 chr10 16863652 A G 6.13E-04 Metabolite levels (MHPG) / / 23319000 rs17139292 chr10 16870080 G A 3.22E-12 LDL cholesterol CUBN intron 23063622 rs17139292 chr10 16870080 G A 5.67E-09 Cholesterol,total CUBN intron 23063622 rs7087360 chr10 16872337 C A 7.44E-04 HIV-1 viral setpoint CUBN intron 17641165 rs3740169 chr10 16873547 G A 5.13E-04 Alcohol dependence CUBN intron 21314694 rs703058 chr10 16876052 G T 3.20E-06 Dietary macronutrient intake CUBN intron 23372041 rs7898873 chr10 16877080 G C 8.84E-10 HDL cholesterol CUBN missense 23063622 rs1891473 chr10 16903080 T C 0.000000283 LDL cholesterol CUBN intron 23063622 rs11591606 chr10 16911115 C T 9.47E-04 Tourette syndrome CUBN intron 22889924 rs1801239 chr10 16919052 T C 1.00E-11 Urinary albumin excretion CUBN missense 21355061 rs780849 chr10 16926733 G T 0.00000009 Joint damage severity in rheumatoid arthritis CUBN intron 23696630 rs11254269 chr10 16939840 G A 0.0000878 LDL cholesterol CUBN intron 23063622 rs10752063 chr10 16955198 T G 6.81E-04 Multiple complex diseases CUBN intron 17554300 rs11254275 chr10 16962352 A G 2.51E-04 Multiple complex diseases CUBN intron 17554300 rs1849381 chr10 16964698 T C 2.96E-04 Multiple complex diseases CUBN intron 17554300 rs2271461 chr10 16975078 G A 2.03E-06 Hypertension CUBN intron pha003041 rs2271463 chr10 16982244 G T 7.00E-06 Ovarian response to FSH stimulation in IVF CUBN intron 21316307 rs10904842 chr10 16984582 T C 8.44E-04 Aortic root size CUBN intron 21223598 rs3934024 chr10 16986810 C T 2.92E-04 Aortic root size CUBN intron 21223598 rs10508517 chr10 16997891 G A 6.00E-06 Quantitative traits CUBN intron 19197348 rs10508517 chr10 16997891 G A 3.36E-04 Aortic root size CUBN intron 21223598 rs7071576 chr10 16999350 G A 1.61E-05 Hypertension CUBN intron pha003041 rs2942359 chr10 17008422 C T 4.57E-06 Hypertension CUBN intron pha003041 rs12244831 chr10 17009523 T C 4.84E-05 Hypertension CUBN intron pha003041 rs7895900 chr10 17011989 G C 2.21E-04 Multiple complex diseases CUBN intron 17554300 rs11254305 chr10 17014984 G A 9.99E-05 Hypertension CUBN intron pha003041 rs12249562 chr10 17015405 G A 0.0000303 Alcohol consumption (Heavy) CUBN intron 23422394 rs3012501 chr10 17018678 G C 1.40E-05 Urinary metabolites CUBN intron 21572414 rs3012480 chr10 17023564 T C 4.25E-07 Facial morphology CUBN intron 22341974 rs3012482 chr10 17023657 C T 4.05E-07 Facial morphology CUBN intron 22341974 rs1512702 chr10 17023668 T G 3.85E-07 Facial morphology CUBN intron 22341974 rs2942364 chr10 17024025 T C 3.76E-07 Facial morphology CUBN intron 22341974 rs2942365 chr10 17024217 A C 3.68E-07 Facial morphology CUBN intron 22341974 rs2932895 chr10 17024375 A T 3.55E-07 Facial morphology CUBN intron 22341974 rs3012484 chr10 17024404 C T 3.51E-07 Facial morphology CUBN intron 22341974 rs1801231 chr10 17024503 G A 3.25E-07 Facial morphology CUBN missense 22341974 rs1801229 chr10 17024615 A T 3.19E-07 Facial morphology CUBN cds-synon 22341974 rs3012485 chr10 17024849 A G 3.14E-07 Facial morphology CUBN intron 22341974 rs3012486 chr10 17024959 C T 3.14E-07 Facial morphology CUBN intron 22341974 rs3012487 chr10 17024994 C T 3.15E-07 Facial morphology CUBN intron 22341974 rs3012488 chr10 17025107 T A 3.15E-07 Facial morphology CUBN intron 22341974 rs3012490 chr10 17025645 C T 3.15E-07 Facial morphology CUBN intron 22341974 rs3012491 chr10 17025666 T C 3.16E-07 Facial morphology CUBN intron 22341974 rs3012493 chr10 17025828 C T 3.19E-07 Facial morphology CUBN intron 22341974 rs3012494 chr10 17026384 A G 4.02E-07 Facial morphology CUBN intron 22341974 rs10904861 chr10 17030775 C T 1.11E-05 Hypertension CUBN intron pha003041 rs2291521 chr10 17032281 C T 5.24E-05 Hypertension CUBN intron pha003041 rs3012479 chr10 17035822 A C 6.15E-05 Hypertension CUBN intron pha003041 rs1276711 chr10 17038701 C A 5.74E-05 Aortic root size CUBN intron 21223598 rs7904146 chr10 17041163 G A 7.40E-06 Urinary metabolites CUBN intron 21572414 rs10508518 chr10 17041473 T G 3.90E-05 Lipid traits CUBN intron 17903299 rs11254327 chr10 17048708 C T 7.02E-07 Esophageal cancer (squamous cell) CUBN intron 22960999 rs4082518 chr10 17063026 C T 2.17E-06 Reading disability and language impairment CUBN intron 24024963 rs12257093 chr10 17064991 G A 8.05E-09 HDL cholesterol CUBN intron 23063622 rs3902042 chr10 17065067 T C 7.71E-05 Obsessive-compulsive disorder CUBN intron 24821223 rs3902042 chr10 17065067 T C 7.71E-05 Obsessive-compulsive disorder CUBN intron 24821223 rs12357285 chr10 17068128 C G 6.42E-04 Obesity (extreme) CUBN intron 21935397 rs12146414 chr10 17068251 A G 8.96E-05 Waist Circumference CUBN intron pha003023 rs2356215 chr10 17073900 T C 0.0002 Migraine CUBN intron 22678113 rs17139666 chr10 17077440 G A 4.62E-04 Multiple complex diseases CUBN intron 17554300 rs2356731 chr10 17078569 C T 0.00000102 LDL cholesterol CUBN intron 23063622 rs10508520 chr10 17126878 C T 9.50E-06 Urinary metabolites CUBN intron 21572414 rs11254363 chr10 17130693 A G 1.00E-06 Folate pathway vitamin levels CUBN intron 19303062 rs1907364 chr10 17131072 C T 6.48E-04 Acute lung injury CUBN intron 22295056 rs2356825 chr10 17135164 T C 3.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CUBN intron 20877124 rs2356827 chr10 17135294 C T 3.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CUBN intron 20877124 rs11254370 chr10 17140234 A T 5.70E-04 Coronary heart disease CUBN intron 21966275 rs1033765 chr10 17141952 C A 4.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CUBN intron 20877124 rs6602175 chr10 17142526 G T 4.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CUBN intron 20877124 rs6602175 chr10 17142526 G T 3.00E-06 MRI atrophy measures CUBN intron 21116278 rs1801224 chr10 17147521 G T 4.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CUBN missense 20877124 rs10752067 chr10 17148892 C T 0.000079 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 CUBN intron 21873659 rs1801222 chr10 17156151 A G 3.00E-09 Folate pathway vitamin levels CUBN missense 19744961 rs1801222 chr10 17156151 A G 8.00E-10 Homocysteine levels CUBN missense 23824729 rs7900434 chr10 17158728 C T 5.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CUBN intron 20877124 rs7078169 chr10 17162314 T C 0.000053 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 CUBN intron 21873659 rs10795449 chr10 17163081 G T 5.88E-04 Obesity (extreme) CUBN intron 21935397 rs7921488 chr10 17169077 A G 7.92E-07 Type 2 diabetes CUBN intron 23945395 rs7923464 chr10 17172221 T A 6.95E-06 Gallstones CUBN nearGene-5 17632509 rs11819350 chr10 17175942 C T 2.51E-17 HDL cholesterol / / 23063622 rs10904884 chr10 17180100 T C 2.35E-04 Bipolar disorder,schizoaffective / / 19567891 rs10904887 chr10 17188641 T C 4.00E-06 Telomere length TRDMT1 UTR-3 24478790 rs3780962 chr10 17193346 A G 8.66E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRDMT1 intron 20877124 rs10904893 chr10 17204944 T C 4.23E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRDMT1 intron 20877124 rs12780845 chr10 17223244 A G 8.00E-10 Homocysteine levels TRDMT1 intron 23824729 rs11254435 chr10 17224426 A T 2.82E-04 Bipolar disorder,schizoaffective TRDMT1 intron 19567891 rs10904896 chr10 17225826 G A 7.49E-06 Telomere length TRDMT1 intron 24478790 rs10490959 chr10 17230836 A T 2.96E-04 Bipolar disorder,schizoaffective TRDMT1 intron 19567891 rs3824632 chr10 17230999 G A 3.99E-04 Bipolar disorder,schizoaffective TRDMT1 intron 19567891 rs7901017 chr10 17234392 T C 1.02E-08 HDL cholesterol TRDMT1 intron 23063622 rs2038574 chr10 17241705 C T 4.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRDMT1 intron 20877124 rs2038574 chr10 17241705 C T 6.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRDMT1 intron 20877124 rs17381591 chr10 17244048 T C 3.09E-04 Bipolar disorder TRDMT1 UTR-5 18317468 rs17381591 chr10 17244048 T C 2.90E-20 Progranulin levels TRDMT1 UTR-5 21087763 rs17381591 chr10 17244048 T C 2.90E-20 Myocardial infarction TRDMT1 UTR-5 21211798 rs7099222 chr10 17251430 C G 3.37E-04 Bipolar disorder / / 18317468 rs1470379 chr10 17258799 C T 1.45E-04 Celiac disease LOC100507347 intron 23936387 rs10904908 chr10 17260290 A G 3.00E-11 Cholesterol,total LOC100507347 intron 24097068 rs3249 chr10 17279517 C T 1.55E-04 Celiac disease VIM UTR-3 23936387 rs243013 chr10 17285064 A C 1.52E-04 Celiac disease / / 23936387 rs911607 chr10 17302891 G A 2.56E-04 Celiac disease / / 23936387 rs359294 chr10 17333310 A G 5.27E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs359295 chr10 17333514 A G 6.64E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs359297 chr10 17333680 G A 5.27E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12262718 chr10 17343706 G A 2.19E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs12262718 chr10 17343706 G A 1.88E-05 Lung function (forced vital capacity) / / pha003104 rs2986704 chr10 17344225 T C 4.96E-05 Lung function (forced vital capacity) / / pha003104 rs400333 chr10 17351794 A G 4.82E-04 Alcohol dependence / / 21314694 rs10904929 chr10 17354581 G A 2.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs10904930 chr10 17372524 T A,C,G 8.22E-04 Lymphocyte counts ST8SIA6 intron 22286170 rs17436666 chr10 17381190 G A 7.91E-05 Postoperative ventricular dysfunction ST8SIA6 intron 21980348 rs12355902 chr10 17385954 C T 6.10E-06 Urinary metabolites ST8SIA6 intron 21572414 rs11254539 chr10 17387944 G A 3.03E-04 Cholesterol ST8SIA6 intron 17255346 rs359312 chr10 17388143 C T 9.00E-08 Response to treatment for acute lymphoblastic leukemia ST8SIA6 intron 19176441 rs4146638 chr10 17396213 C T 9.10E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ST8SIA6 intron 21844884 rs10904949 chr10 17439939 A G 2.82E-04 Multiple complex diseases ST8SIA6 intron 17554300 rs4561106 chr10 17456574 T C 4.04E-05 Bladder cancer ST8SIA6 intron 19648920 rs12570539 chr10 17461723 G A 6.34E-05 Bladder cancer ST8SIA6 intron 19648920 rs12246530 chr10 17476686 T C 5.99E-05 Cognitive impairment induced by topiramate ST8SIA6 intron 22091778 rs79811438 chr10 17529243 T G 1.02E-04 Metabolite levels (MHPG) / / 23319000 rs12413737 chr10 17529889 C T 1.02E-04 Metabolite levels (MHPG) / / 23319000 rs12414094 chr10 17530411 C T 2.91E-04 Metabolite levels (MHPG) / / 23319000 rs10508537 chr10 17530464 A G 1.02E-04 Metabolite levels (MHPG) / / 23319000 rs78527042 chr10 17531035 G C 1.02E-04 Metabolite levels (MHPG) / / 23319000 rs75554140 chr10 17531143 T G 1.02E-04 Metabolite levels (MHPG) / / 23319000 rs113483787 chr10 17531574 T C 1.02E-04 Metabolite levels (MHPG) / / 23319000 rs11597931 chr10 17544516 C G 3.95E-04 Metabolite levels (MHPG) / / 23319000 rs11593604 chr10 17544529 A G 8.99E-04 Type 2 diabetes / / 17463246 rs11593604 chr10 17544529 A G 3.95E-04 Metabolite levels (MHPG) / / 23319000 rs11254636 chr10 17550121 T C 5.01E-04 Metabolite levels (MHPG) / / 23319000 rs11254637 chr10 17550122 C A 5.01E-04 Metabolite levels (MHPG) / / 23319000 rs10904964 chr10 17568492 C G 6.98E-04 Insulin resistance / / 21901158 rs75611188 chr10 17569504 C T 3.16E-04 Metabolite levels (MHPG) / / 23319000 rs2884127 chr10 17578161 G A 1.99E-04 Endometrial cancer / / 24096698 rs2884127 chr10 17578161 G A 7.57E-05 Endometrial cancer / / 24096698 rs7918325 chr10 17581693 C T 3.05E-04 Metabolite levels (MHPG) / / 23319000 rs74120443 chr10 17584120 A C 3.05E-04 Metabolite levels (MHPG) / / 23319000 rs6602203 chr10 17596121 C T 8.74E-04 Alcohol dependence / / 21314694 rs12256421 chr10 17614097 A G 7.10E-06 Personality dimensions / / 21173776 rs2154257 chr10 17627137 C G 5.10E-06 Personality dimensions / / 21173776 rs17141364 chr10 17628797 A G 4.35E-04 Multiple complex diseases / / 17554300 rs4748387 chr10 17634637 A G 1.80E-05 Serum metabolites PTPLA intron 19043545 rs17141401 chr10 17642806 C T 4.69E-04 Multiple complex diseases PTPLA intron 17554300 rs7921895 chr10 17731025 A T 1.80E-05 Urinary metabolites STAM intron 21572414 rs2182158 chr10 17731272 T C 4.52E-04 Multiple complex diseases STAM intron 17554300 rs17141517 chr10 17746301 C A 8.11E-05 Multiple complex diseases STAM intron 17554300 rs17141517 chr10 17746301 C A 2.10E-05 Biliary atresia STAM intron 20460270 rs7912011 chr10 17759871 T G 8.04E-05 Multiple complex diseases / / 17554300 rs544313 chr10 17962530 G A 1.70E-04 Alcohol dependence / / 20201924 rs10827981 chr10 18268222 C T 8.68E-04 Multiple complex diseases SLC39A12 intron 17554300 rs2437271 chr10 18276761 G T 2.00E-04 Cognitive impairment induced by topiramate SLC39A12 intron 22091778 rs2497755 chr10 18282667 A T 4.40E-06 Urinary metabolites SLC39A12 intron 21572414 rs7099037 chr10 18286593 A G 2.75E-05 Height SLC39A12 intron pha003010 rs7099037 chr10 18286593 A G 6.56E-05 Height SLC39A12 intron pha003011 rs7099037 chr10 18286593 A G 1.89E-05 Waist Circumference SLC39A12 intron pha003023 rs2478574 chr10 18288632 G C 5.20E-06 Urinary metabolites SLC39A12 intron 21572414 rs7893893 chr10 18305697 C T 2.50E-05 Urinary metabolites SLC39A12 intron 21572414 rs2497782 chr10 18319041 G A 9.44E-05 Pulmonary function SLC39A12 intron 19300500 rs16916785 chr10 18328899 G A 1.80E-05 Urinary metabolites SLC39A12 intron 21572414 rs2488132 chr10 18329818 C T 4.72E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SLC39A12 intron 24023788 rs16916794 chr10 18331480 A T 1.80E-05 Urinary metabolites SLC39A12 intron 21572414 rs2488135 chr10 18333144 T C 6.70E-05 Pulmonary function / / 19300500 rs16916797 chr10 18333790 A C 8.81E-04 Multiple complex diseases / / 17554300 rs2488136 chr10 18334521 A G 7.33E-05 Pulmonary function / / 19300500 rs2488140 chr10 18338686 A G 6.10E-05 Height / / 17255346 rs2488140 chr10 18338686 A G 5.32E-05 Triglycerides / / pha003081 rs2488140 chr10 18338686 A G 3.61E-05 Lipid levels / / pha003082 rs2488148 chr10 18344187 G A 9.54E-05 Height / / 17255346 rs2497802 chr10 18352614 C G 9.85E-04 Obesity (extreme) / / 21935397 rs2185765 chr10 18355646 A G 7.32E-04 Obesity (extreme) / / 21935397 rs2497806 chr10 18358259 T C 2.74E-04 Obesity (extreme) / / 21935397 rs2497808 chr10 18358603 G A 7.27E-04 Multiple complex diseases / / 17554300 rs2488154 chr10 18360306 C A 6.13E-04 Obesity (extreme) / / 21935397 rs2497810 chr10 18360504 C G 8.91E-04 Multiple complex diseases / / 17554300 rs2488155 chr10 18361329 T G 8.14E-04 Obesity (extreme) / / 21935397 rs11012580 chr10 18371713 T G 7.28E-04 Multiple complex diseases / / 17554300 rs12255303 chr10 18372986 A G 1.21E-04 Alcohol dependence / / 24277619 rs10508558 chr10 18388434 A C 4.86E-04 Multiple complex diseases / / 17554300 rs10508558 chr10 18388434 A C 9.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs17661538 chr10 18397247 G C 1.00E-06 Response to antipsychotic treatment / / 20195266 rs4373814 chr10 18419972 G C 3.01E-04 Blood pressure / / 21909110 rs4373814 chr10 18419972 G C 4.00E-10 Diastolic blood pressure / / 21909115 rs4373814 chr10 18419972 G C 5.00E-11 Systolic blood pressure / / 21909115 rs4373814 chr10 18419972 G C 9.00E-08 Hypertension / / 21909115 rs1571787 chr10 18433986 G A 6.13E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs10740993 chr10 18442482 C T 0.000815714 Hypertension (early onset hypertension) CACNB2 intron 22479346 rs10740993 chr10 18442482 C T 2.00E-07 Primary tooth development (time to first tooth eruption) CACNB2 intron 23704328 rs10740993 chr10 18442482 C T 2.00E-09 Primary tooth development (number of teeth) CACNB2 intron 23704328 rs10764326 chr10 18448062 T C 0.00050632 Hypertension (early onset hypertension) CACNB2 intron 22479346 rs2068357 chr10 18449089 G A,T 9.90E-04 Stroke CACNB2 intron pha002887 rs11012850 chr10 18456162 G A 3.70E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs73593770 chr10 18456816 G A 3.70E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs7090118 chr10 18459282 G A 4.32E-04 Suicide attempts in bipolar disorder CACNB2 intron 21423239 rs12412532 chr10 18463335 T C 8.85E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs12411638 chr10 18463338 C T 8.85E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs16916922 chr10 18467744 A T 6.55E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs16916925 chr10 18468211 A G 4.00E-05 Diastolic blood pressure CACNB2 intron 19430483 rs16916925 chr10 18468211 A G 6.55E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs12777936 chr10 18469956 C T 1.56E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs16916928 chr10 18470153 G A 1.56E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs12413195 chr10 18470329 T C 2.24E-05 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1779235 chr10 18471274 A G 1.56E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs111512190 chr10 18471553 C T 3.70E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1757211 chr10 18471620 G A 2.92E-05 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1757210 chr10 18472566 A G 1.18E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1757209 chr10 18472842 C T 5.42E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs71507259 chr10 18472842 CA CCA,CTG 5.42E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1757208 chr10 18472843 A G 6.88E-05 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1757207 chr10 18472861 T C 6.76E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1779226 chr10 18472977 A G 1.59E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1779227 chr10 18473271 T C 6.76E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1757206 chr10 18473370 T C 6.76E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1757205 chr10 18473693 G T 8.38E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1779228 chr10 18474727 T C 5.33E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs7067916 chr10 18475075 A G 1.59E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1779238 chr10 18475974 G A 6.76E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs16916932 chr10 18476276 C T 8.40E-06 Paclitaxel-induced neuropathy CACNB2 intron 23776197 rs1779240 chr10 18476313 G A 1.14E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs11592084 chr10 18477286 G A 5.51E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs78011406 chr10 18477990 A C 5.30E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs996861 chr10 18478008 C A 7.74E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs11593318 chr10 18479198 G A 0.0000831 Circulating PCSK9 levels CACNB2 intron 22460556 rs11593318 chr10 18479198 G A 5.30E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs12413079 chr10 18480425 G A 5.30E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs12414674 chr10 18480653 A G 5.30E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs16916944 chr10 18481044 C T 5.30E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1475613 chr10 18492187 A G 9.37E-04 Multiple complex diseases CACNB2 intron 17554300 rs1277762 chr10 18494666 C T 5.47E-05 Multiple complex diseases CACNB2 intron 17554300 rs11013005 chr10 18496985 T C 2.38E-05 Hypertension CACNB2 intron 19609347 rs12355606 chr10 18497821 T C 2.40E-09 Multiple complex diseases CACNB2 intron 17554300 rs1277769 chr10 18499794 C A 0.00000679 Nicotine dependence (smoking) CACNB2 intron 23643383 rs2482119 chr10 18503661 C T 8.30E-04 Acute lung injury CACNB2 intron 22295056 rs1757217 chr10 18506467 T C 7.07E-04 Multiple complex diseases CACNB2 intron 17554300 rs2489204 chr10 18508434 G C 5.29E-05 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1631911 chr10 18512884 T C 3.33E-05 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1631891 chr10 18512890 C A 3.33E-05 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1628528 chr10 18513289 T G 4.66E-05 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1779214 chr10 18513677 T C 9.57E-05 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1779213 chr10 18513698 G A 3.94E-05 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1779212 chr10 18513733 T C 2.14E-05 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1613804 chr10 18515834 A G 2.07E-05 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1757224 chr10 18516411 C G 9.87E-06 Metabolite levels (MHPG) CACNB2 intron 23319000 rs2250999 chr10 18517084 A G 2.07E-05 Metabolite levels (MHPG) CACNB2 intron 23319000 rs2482111 chr10 18517644 G A 4.41E-05 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1277744 chr10 18519612 C T 7.92E-06 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1277752 chr10 18522475 G A 5.41E-05 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1277753 chr10 18522975 T C 2.05E-05 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1277755 chr10 18523848 A G 5.60E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1277756 chr10 18524089 C T 3.31E-05 Metabolite levels (MHPG) CACNB2 intron 23319000 rs2482109 chr10 18525170 G A 3.00E-06 Metabolite levels (HVA/MHPG ratio) CACNB2 intron 23319000 rs2489199 chr10 18525290 A G 3.37E-06 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1757199 chr10 18533494 C T 1.46E-04 Metabolite levels (MHPG) CACNB2 intron 23319000 rs1757214 chr10 18534850 G A 9.49E-04 HIV-1 viral setpoint CACNB2 intron 17641165 rs2357928 chr10 18549641 G A 5.24E-04 Aortic root size CACNB2 UTR-5 21223598 rs9633647 chr10 18565470 C A 4.54E-04 White matter integrity CACNB2 intron 22425255 rs17609633 chr10 18585358 T C 5.94E-05 Heart rate CACNB2 intron 23583979 rs2799573 chr10 18601928 T C 4.00E-08 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) CACNB2 intron 23453885 rs7093791 chr10 18623463 A G 7.81E-05 Cognitive test performance CACNB2 intron 20125193 rs7093791 chr10 18623463 A G 5.96E-05 Major depressive disorder CACNB2 intron 22472876 rs11013700 chr10 18626566 G T 1.00E-04 Cognitive impairment induced by topiramate CACNB2 intron 22091778 rs7083127 chr10 18631445 A G 5.32E-05 Major depressive disorder CACNB2 intron 22472876 rs7083127 chr10 18631445 A G 0.00014 Bipolar disorder CACNB2 intron 23637625 rs12240995 chr10 18637232 A C 1.33E-05 Alcohol and nictotine co-dependence CACNB2 intron 20158304 rs16917194 chr10 18645447 T C 6.82E-04 Multiple complex diseases CACNB2 intron 17554300 rs16917194 chr10 18645447 T C 9.60E-05 Information processing speed CACNB2 intron 21130836 rs12780039 chr10 18678987 G C 1.80E-06 Urinary metabolites CACNB2 intron 21572414 rs10828623 chr10 18680935 T C 1.29E-04 Schizophrenia (cytomegalovirus infection interaction) CACNB2 intron 23358160 rs1570940 chr10 18685765 C T 2.00E-04 Cognitive impairment induced by topiramate CACNB2 intron 22091778 rs12247217 chr10 18700276 A G 5.50E-06 Urinary metabolites CACNB2 intron 21572414 rs997264 chr10 18703895 C A 2.67E-04 Response to taxane treatment (placlitaxel) CACNB2 intron 23006423 rs1813353 chr10 18707448 T C 7.01E-15 Blood pressure CACNB2 intron 21909110 rs1813353 chr10 18707448 T C 2.30E-15 Systolic blood pressure CACNB2 intron 21909115 rs11014166 chr10 18708798 A T 1.00E-08 Diastolic blood pressure CACNB2 intron 19430479 rs11014166 chr10 18708798 A T 6.00E-08 Hypertension CACNB2 intron 19430479 rs11014166 chr10 18708798 A T 7.00E-07 Systolic blood pressure CACNB2 intron 19430479 rs11014166 chr10 18708798 A T 1.00E-08 Coronary heart disease CACNB2 intron 21347282 rs11014166 chr10 18708798 A T 4.59E-14 Blood pressure CACNB2 intron 21909110 rs16917330 chr10 18711046 C G 2.30E-05 Urinary metabolites CACNB2 intron 21572414 rs10828679 chr10 18711288 G A 8.72E-04 Multiple complex diseases CACNB2 intron 17554300 rs10828679 chr10 18711288 G A 3.22E-05 Response to taxane treatment (placlitaxel) CACNB2 intron 23006423 rs1575836 chr10 18714705 G T 6.02E-05 Response to taxane treatment (placlitaxel) CACNB2 intron 23006423 rs10741058 chr10 18716145 T C 2.82E-05 Response to taxane treatment (placlitaxel) CACNB2 intron 23006423 rs10741058 chr10 18716145 T C 3.50E-04 Schizophrenia (cytomegalovirus infection interaction) CACNB2 intron 23358160 rs10741058 chr10 18716145 T C 3.50E-04 Drinking behavior CACNB2 intron 23364009 rs10764483 chr10 18716346 A G 9.70E-04 Multiple complex diseases CACNB2 intron 17554300 rs10764483 chr10 18716346 A G 1.71E-05 Response to taxane treatment (placlitaxel) CACNB2 intron 23006423 rs7077248 chr10 18719441 T C 5.49E-05 Response to taxane treatment (placlitaxel) CACNB2 intron 23006423 rs10741061 chr10 18721204 A G 7.62E-05 Response to taxane treatment (placlitaxel) CACNB2 intron 23006423 rs3908476 chr10 18722759 T A 7.41E-04 Multiple complex diseases CACNB2 intron 17554300 rs1926026 chr10 18725659 G A 8.96E-05 Response to taxane treatment (placlitaxel) CACNB2 intron 23006423 rs7917206 chr10 18727919 C G 9.78E-05 Serum metabolites CACNB2 intron 19043545 rs12258967 chr10 18727959 C G 2.00E-16 Blood pressure CACNB2 intron 21909110 rs7069923 chr10 18730368 C T 1.00E-06 Quantitative traits CACNB2 intron 19197348 rs17691888 chr10 18734528 G A 1.00E-10 Schizophrenia CACNB2 intron 23974872 rs1325988 chr10 18740606 C T 1.39E-05 Information processing speed CACNB2 intron 21130836 rs7923938 chr10 18744719 T C 2.23E-04 Response to taxane treatment (placlitaxel) CACNB2 intron 23006423 rs7893279 chr10 18745105 T G 5.56E-05 Blood Pressure CACNB2 intron pha002898 rs1998822 chr10 18755664 A G 9.84E-05 Heart Rate CACNB2 intron pha003053 rs7076247 chr10 18759629 T C 6.00E-06 Protein quantitative trait loci CACNB2 intron 18464913 rs7076247 chr10 18759629 T C 9.49E-05 Response to hepatitis C treatment CACNB2 intron 19684573 rs7076247 chr10 18759629 T C 4.29E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CACNB2 intron 24023788 rs7895467 chr10 18762948 G A 1.19E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CACNB2 intron 24023788 rs8181477 chr10 18782880 A C 1.00E-06 Obesity-related traits CACNB2 intron 23251661 rs10828779 chr10 18787821 A T 0.000309 Salmonella-induced pyroptosis CACNB2 intron 22837397 rs4485000 chr10 18789724 T G 4.30E-07 Urinary metabolites CACNB2 intron 21572414 rs4237348 chr10 18798203 T C 3.93E-04 Multiple complex diseases CACNB2 intron 17554300 rs4628581 chr10 18799890 A C 5.45E-04 Multiple complex diseases CACNB2 intron 17554300 rs7099307 chr10 18901770 C T 5.15E-04 Multiple complex diseases NSUN6 intron 17554300 rs7095666 chr10 18939467 T A 2.60E-05 Urinary metabolites NSUN6 intron 21572414 rs11015416 chr10 18946297 A C 3.45E-04 Smoking initiation / / 24665060 rs10829156 chr10 18950555 T C 4.00E-07 Sudden cardiac arrest ARL5B intron 21658281 rs7072963 chr10 18960064 A C 7.65E-05 C-Reactive Protein ARL5B intron pha003070 rs10829186 chr10 18962541 A G 2.13E-06 Personality dimensions ARL5B intron 21173776 rs1542727 chr10 18990315 A G 6.89E-05 Bipolar disorder / / 22925353 rs1542727 chr10 18990315 A G 4.81E-05 Depression (quantitative trait) / / 23290196 rs16917736 chr10 19026307 G A 1.62E-04 Multiple complex diseases / / 17554300 rs7096907 chr10 19026841 T C 5.73E-05 Response to metformin / / 21186350 rs16917742 chr10 19027478 G A 1.69E-05 Multiple complex diseases / / 17554300 rs16917745 chr10 19027696 G A 9.16E-05 Multiple complex diseases / / 17554300 rs1410921 chr10 19074770 A T 6.97E-05 Multiple complex diseases / / 17554300 rs913655 chr10 19090812 T C 1.45E-04 Lung function (forced vital capacity) / / 24023788 rs2451504 chr10 19092987 A C 7.69E-05 Response to methylphenidate treatment / / 21130132 rs16917919 chr10 19160029 A G 7.67E-06 Temporal lobe volumes / / 20197096 rs16917924 chr10 19174999 A C 9.83E-04 Multiple complex diseases / / 17554300 rs9888029 chr10 19212287 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10826750 chr10 19253137 A C 4.40E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10763789 chr10 19293206 G C 3.35E-04 Suicide attempts in bipolar disorder / / 21041247 rs12355180 chr10 19303448 C A 9.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs10763810 chr10 19317044 G A 3.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2789310 chr10 19328435 A C 4.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs2789310 chr10 19328435 A C 5.52E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs2813787 chr10 19332184 T C 4.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs2789311 chr10 19332252 C T 5.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs2813788 chr10 19332318 T C 5.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs2813789 chr10 19332408 A G 4.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs1999956 chr10 19334637 G A 5.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1934050 chr10 19340959 G C 4.19E-05 Orofacial clefts / / 22419666 rs7083348 chr10 19342086 G A 6.04E-04 Multiple complex diseases / / 17554300 rs10826891 chr10 19343525 C T 3.75E-04 White matter integrity / / 22425255 rs16918253 chr10 19405531 G T 8.00E-06 Obesity-related traits LOC100652979 intron 23251661 rs12252665 chr10 19406306 G A 4.93E-05 Body Mass Index LOC100652979 intron pha003020 rs11008573 chr10 19417181 T C 1.16E-04 Birth weight LOC100652979 cds-synon 17255346 rs10826986 chr10 19425704 A G 2.20E-05 Urinary metabolites LOC100652979 missense 21572414 rs4748559 chr10 19467440 C T 0.00015112 Hypertension (early onset hypertension) LOC100652979 intron 22479346 rs16918323 chr10 19471726 C T 2.89E-04 Amyotrophic Lateral Sclerosis LOC100652979 intron 17362836 rs10827035 chr10 19478110 A G 0.00028634 Hypertension (early onset hypertension) LOC100652979 intron 22479346 rs116994217 chr10 19490381 G A 2.21E-05 Intracerebral hemorrhage LOC100652979 intron 24656865 rs17721294 chr10 19492968 C G 9.00E-06 Urinary metabolites LOC100652979 intron 21572414 rs16918359 chr10 19506293 T C 2.02E-04 Amyotrophic Lateral Sclerosis LOC100652979 intron 17362836 rs1889515 chr10 19509564 G A 1.42E-04 Amyotrophic Lateral Sclerosis LOC100652979 intron 17362836 rs1889515 chr10 19509564 G A 2.10E-05 Urinary metabolites LOC100652979 intron 21572414 rs4278424 chr10 19511109 C T 0.000275762 Hypertension (early onset hypertension) LOC100652979 intron 22479346 rs11009093 chr10 19532355 T G 1.27E-04 Multiple complex diseases LOC100652979 intron 17554300 rs16918386 chr10 19534099 G A 2.99E-04 Multiple complex diseases LOC100652979 intron 17554300 rs2499065 chr10 19572729 T C 3.19E-04 Suicide attempts in bipolar disorder LOC100652979 intron 21423239 rs2499063 chr10 19576720 C T 4.43E-04 Suicide attempts in bipolar disorder LOC100652979 intron 21423239 rs7068857 chr10 19582264 G A 7.55E-05 Heart Failure / / pha002884 rs7068857 chr10 19582264 G A 3.12E-05 Diabetes Mellitus / / pha003060 rs2496057 chr10 19583668 A G 5.31E-04 Multiple complex diseases / / 17554300 rs11009346 chr10 19583989 C G 7.15E-04 Type 2 diabetes / / 17463246 rs2499081 chr10 19592466 A G 3.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12221388 chr10 19593301 A G 1.25E-05 Smoking initiation / / 24665060 rs12221388 chr10 19593301 A G 7.37E-05 Diabetes Mellitus / / pha003060 rs11009391 chr10 19596431 C G 0.0000314 Panic disorder / / 23149450 rs11009391 chr10 19596431 C G 3.14E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs1582061 chr10 19600689 T G 6.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16915702 chr10 19601686 T G 5.32E-04 Multiple complex diseases / / 17554300 rs7101338 chr10 19624631 G C 9.57E-04 Multiple complex diseases C10orf112 intron 17554300 rs1577307 chr10 19637088 G A,C,T 4.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C10orf112 intron 20877124 rs1591345 chr10 19645239 A G 6.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C10orf112 intron 20877124 rs11009626 chr10 19654670 G C 4.36E-04 Smoking initiation C10orf112 intron 24665060 rs10763968 chr10 19661995 G T 1.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C10orf112 intron 20877124 rs12761627 chr10 19664446 G A 2.80E-05 Urinary metabolites C10orf112 intron 21572414 rs10827335 chr10 19671136 A C 8.31E-04 Multiple complex diseases C10orf112 intron 17554300 rs17670074 chr10 19705383 A C,G,T 8.10E-06 Diabetic retinopathy C10orf112 intron 21441570 rs12249309 chr10 19707805 T G 2.80E-05 Urinary metabolites C10orf112 intron 21572414 rs11009826 chr10 19710091 T C 4.15E-04 Multiple complex diseases C10orf112 intron 17554300 rs12267418 chr10 19714554 G A 8.20E-06 Diabetic retinopathy C10orf112 intron 21441570 rs9888035 chr10 19715018 T C 9.30E-06 Diabetic retinopathy C10orf112 intron 21441570 rs7082614 chr10 19715844 T G 2.10E-05 Diabetic retinopathy C10orf112 intron 21441570 rs7094477 chr10 19715913 G A 7.20E-05 Diabetic retinopathy C10orf112 intron 21441570 rs7094477 chr10 19715913 G A 0.0006497 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) C10orf112 intron 23233654 rs7094477 chr10 19715913 G A 6.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) C10orf112 intron 23233662 rs10827388 chr10 19716189 C G 8.10E-05 Diabetic retinopathy C10orf112 intron 21441570 rs10827388 chr10 19716189 C G 0.0006515 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) C10orf112 intron 23233654 rs10827388 chr10 19716189 C G 6.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) C10orf112 intron 23233662 rs11009849 chr10 19716826 T A 8.40E-06 Urinary metabolites C10orf112 intron 21572414 rs7080525 chr10 19719746 C G 2.10E-05 Urinary metabolites C10orf112 intron 21572414 rs2358395 chr10 19721013 A G 0.000205 Salmonella-induced pyroptosis C10orf112 intron 22837397 rs10827414 chr10 19725665 C T 2.00E-05 Prostate cancer C10orf112 intron 21743057 rs3864829 chr10 19740447 A G 3.81E-04 Type 2 diabetes C10orf112 intron 17463246 rs3852458 chr10 19767401 G A 5.64E-04 Type 2 diabetes C10orf112 intron 17463246 rs3904887 chr10 19768895 T C 6.42E-04 Type 2 diabetes C10orf112 intron 17463246 rs6481942 chr10 19769118 C T 5.61E-04 Type 2 diabetes C10orf112 intron 17463246 rs3852459 chr10 19770716 A G 6.68E-04 Type 2 diabetes C10orf112 intron 17463246 rs1332926 chr10 19776636 G A 7.04E-07 Cognitive test performance C10orf112 intron 20125193 rs6481955 chr10 19795045 A G 7.40E-04 Alcohol dependence C10orf112 intron 20201924 rs3852465 chr10 19796430 T C 6.90E-04 Alcohol dependence C10orf112 intron 20201924 rs10494868 chr10 19807875 C A 6.40E-04 Alcohol dependence C10orf112 intron 20201924 rs12776128 chr10 19813583 T G 2.30E-05 Urinary metabolites C10orf112 intron 21572414 rs3852471 chr10 19822313 T A 2.88E-06 Phospholipid levels (plasma) C10orf112 intron 21829377 rs7076844 chr10 19826238 A G 2.40E-06 Phospholipid levels (plasma) C10orf112 intron 21829377 rs10764059 chr10 19831958 G T 4.95E-06 Phospholipid levels (plasma) C10orf112 intron 21829377 rs3844357 chr10 19834795 C T 4.54E-05 Hypertension C10orf112 intron pha003041 rs3904891 chr10 19851833 C G 1.75E-04 Alzheimer's disease C10orf112 intron 17998437 rs1537352 chr10 19859090 C A 5.75E-05 Hypertension C10orf112 intron pha003041 rs7082385 chr10 19861290 G T 3.04E-05 HIV-1 viral setpoint C10orf112 intron 22174851 rs7080370 chr10 19869633 A T 4.11E-04 Alzheimer's disease C10orf112 intron 17998437 rs1409737 chr10 19886330 G A 8.86E-04 Type 2 diabetes C10orf112 intron 17846124 rs7898799 chr10 19889467 C T 1.80E-06 Aortic stiffness C10orf112 intron 22068335 rs3852482 chr10 19897194 T C 4.82E-06 Phospholipid levels (plasma) C10orf112 intron 21829377 rs4748602 chr10 19897622 A G 4.40E-04 Type 2 diabetes C10orf112 intron 22158537 rs4406722 chr10 19901013 C G 2.00E-05 Urinary metabolites C10orf112 intron 21572414 rs4406722 chr10 19901013 C G 2.57E-06 Phospholipid levels (plasma) C10orf112 intron 21829377 rs4406722 chr10 19901013 C G 8.33E-05 Bipolar disorder C10orf112 intron 22925353 rs10827645 chr10 19902779 A G 5.00E-06 Prostate cancer C10orf112 intron 21743057 rs10827649 chr10 19909770 A G 8.90E-06 Aortic stiffness C10orf112 intron 22068335 rs10764094 chr10 19910538 T C 3.90E-07 Aortic stiffness C10orf112 intron 22068335 rs1326986 chr10 19929513 T C 6.22E-04 Amyotrophic Lateral Sclerosis C10orf112 intron 17362836 rs1326986 chr10 19929513 T C 4.00E-06 Ankylosing spondylitis C10orf112 intron 20062062 rs1326986 chr10 19929513 T C 2.00E-07 Smoking behavior C10orf112 intron 20418888 rs10827735 chr10 19936149 G A,T 3.62E-04 Response to cytadine analogues (cytosine arabinoside) C10orf112 intron 24483146 rs10827735 chr10 19936149 G A,T 4.72E-04 Response to cytidine analogues (gemcitabine) C10orf112 intron 24483146 rs10764114 chr10 19937986 A G 6.82E-04 Alzheimer's disease C10orf112 intron 17998437 rs7099812 chr10 19978398 T G 1.35E-07 Alopecia areata C10orf112 intron 22027810 rs11011636 chr10 20110335 C T 7.25E-04 Multiple complex diseases PLXDC2 intron 17554300 rs1331148 chr10 20142655 A G 8.30E-05 Acute lymphoblastic leukemia (childhood) PLXDC2 intron 19684603 rs12571401 chr10 20149180 C T 9.33E-05 Monocyte counts PLXDC2 intron pha003089 rs11011649 chr10 20151213 T C 2.06E-04 Alzheimer's disease PLXDC2 intron 17998437 rs11593584 chr10 20153694 G A 5.33E-05 Tunica Media PLXDC2 intron pha003038 rs752318 chr10 20163833 T C 2.02E-04 Premature ovarian failure PLXDC2 intron 19508998 rs752318 chr10 20163833 T C 5.33E-05 Tunica Media PLXDC2 intron pha003038 rs10508600 chr10 20167823 G A 1.58E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) PLXDC2 intron 24023788 rs2358650 chr10 20168505 A T 4.60E-06 Urinary metabolites PLXDC2 intron 21572414 rs11011658 chr10 20176963 C T 9.61E-05 Response to statin treatment (atorvastatin),change in cholesterol levels PLXDC2 intron 20031582 rs11011661 chr10 20180225 C T 5.00E-07 Tunica Media PLXDC2 intron pha003037 rs11011663 chr10 20186425 C T 0.00002585 Sarcoidosis PLXDC2 intron 22952805 rs7904103 chr10 20187467 T C 2.51E-05 Tunica Media PLXDC2 intron pha003037 rs965788 chr10 20201551 C T 3.23E-06 Tunica Media PLXDC2 intron pha003037 rs11011669 chr10 20203516 G C 0.00005156 Sarcoidosis PLXDC2 intron 22952805 rs1326238 chr10 20207674 C G 1.70E-05 Urinary metabolites PLXDC2 intron 21572414 rs2148299 chr10 20225654 T G 5.24E-05 Serum metabolites PLXDC2 intron 19043545 rs6482071 chr10 20229749 T C 6.50E-05 Pulmonary function in asthmatics PLXDC2 intron 23541324 rs719041 chr10 20267492 C G 2.30E-05 Urinary metabolites PLXDC2 intron 21572414 rs1111367 chr10 20273583 C T 6.95E-05 Triglycerides PLXDC2 intron pha003080 rs1111367 chr10 20273583 C T 6.37E-05 Triglycerides PLXDC2 intron pha003081 rs10508606 chr10 20276131 T G 6.39E-05 Premature ovarian failure PLXDC2 intron 19508998 rs10508606 chr10 20276131 T G 6.39E-05 Other erythrocyte phenotypes PLXDC2 intron 19862010 rs16919668 chr10 20279158 A G 0.0000205 Otitis media (children 3 years old or younger) PLXDC2 intron 23133572 rs11597892 chr10 20284083 C T 5.39E-04 Response to taxane treatment (placlitaxel) PLXDC2 intron 23006423 rs1326246 chr10 20290021 G A 9.97E-04 Response to taxane treatment (placlitaxel) PLXDC2 intron 23006423 rs768654 chr10 20291113 G A 4.15E-04 Response to taxane treatment (placlitaxel) PLXDC2 intron 23006423 rs17760485 chr10 20294036 G A 1.17E-05 Monocyte chemoattractant protein-1 PLXDC2 intron pha003071 rs7077535 chr10 20309308 C T 8.14E-04 Response to taxane treatment (placlitaxel) PLXDC2 intron 23006423 rs1986577 chr10 20311243 C T 1.38E-04 Alzheimer's disease PLXDC2 intron 22005930 rs1986635 chr10 20317656 T C 3.60E-06 Urinary metabolites PLXDC2 intron 21572414 rs10740959 chr10 20319845 T G 2.10E-05 Urinary metabolites PLXDC2 intron 21572414 rs10508608 chr10 20332952 G T 1.07E-04 Alzheimer's disease PLXDC2 intron 24755620 rs2884576 chr10 20337118 G T 4.20E-06 Urinary metabolites PLXDC2 intron 21572414 rs10764194 chr10 20351417 G A 6.50E-07 Urinary metabolites PLXDC2 intron 21572414 rs16919789 chr10 20351869 C T 9.37E-04 Alzheimer's disease PLXDC2 intron 24755620 rs10827949 chr10 20354407 G A 2.22E-04 Alzheimer's disease PLXDC2 intron 24755620 rs16919795 chr10 20364445 A G 4.44E-04 Multiple complex diseases PLXDC2 intron 17554300 rs10827955 chr10 20364995 G T 2.95E-04 Alzheimer's disease PLXDC2 intron 24755620 rs4336923 chr10 20368998 A G 6.40E-06 Bronchopulmonary dysplasia PLXDC2 intron 23897914 rs4336923 chr10 20368998 A G 1.54E-04 Alzheimer's disease PLXDC2 intron 24755620 rs10764197 chr10 20370401 T C 5.61E-04 Alzheimer's disease PLXDC2 intron 24755620 rs10827959 chr10 20370579 A G 1.90E-05 Urinary metabolites PLXDC2 intron 21572414 rs10827959 chr10 20370579 A G 5.90E-04 Alzheimer's disease PLXDC2 intron 24755620 rs10827963 chr10 20380428 C A 1.42E-04 Smoking cessation PLXDC2 intron 24665060 rs7098330 chr10 20383783 G T 6.64E-04 Smoking cessation PLXDC2 intron 24665060 rs2460582 chr10 20407763 G C 5.68E-04 Smoking cessation PLXDC2 intron 24665060 rs4634985 chr10 20434780 T C 3.00E-06 Bronchopulmonary dysplasia PLXDC2 intron 23897914 rs7086733 chr10 20447821 A G 2.55E-04 Taste perception PLXDC2 intron 22132133 rs12356363 chr10 20448286 C T 8.59E-05 Orofacial clefts PLXDC2 intron 22863734 rs4338432 chr10 20458202 C T 7.10E-04 Heart Failure PLXDC2 intron pha002885 rs7098999 chr10 20484628 C T 2.59E-04 Taste perception PLXDC2 intron 22132133 rs10508619 chr10 20501152 T C 3.45E-04 Multiple complex diseases PLXDC2 intron 17554300 rs10508619 chr10 20501152 T C 1.80E-05 Coronary heart disease PLXDC2 intron pha003031 rs16920111 chr10 20503267 G T 2.64E-05 Cognitive performance PLXDC2 intron 19734545 rs12356314 chr10 20523207 T A 2.60E-06 Iron levels PLXDC2 intron 21208937 rs11011907 chr10 20539426 T A 9.74E-05 Bipolar disorder PLXDC2 intron 18317468 rs1571942 chr10 20542634 A G 3.00E-07 Diabetic retinopathy PLXDC2 intron 21310492 rs966569 chr10 20568507 A C 9.20E-04 Type 2 diabetes and 6 quantitative traits PLXDC2 intron 17848626 rs955429 chr10 20578530 T C 3.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11011941 chr10 20586485 A G 1.75E-06 Coronary heart disease / / pha003031 rs11011942 chr10 20587022 C T 8.16E-05 Coronary heart disease / / pha003030 rs11011942 chr10 20587022 C T 1.51E-05 Coronary heart disease / / pha003031 rs12219125 chr10 20593087 G T 9.00E-09 Diabetic retinopathy / / 21310492 rs10764218 chr10 20597771 T C 2.69E-05 Coronary heart disease / / pha003030 rs10764218 chr10 20597771 T C 3.28E-05 Coronary heart disease / / pha003031 rs1571944 chr10 20605188 G T 9.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs11011964 chr10 20622881 G A 1.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs10828018 chr10 20622924 C T 3.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs11011986 chr10 20632313 T A 1.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs11011987 chr10 20632877 A G 9.19E-05 Suicide attempts in bipolar disorder / / 21423239 rs11011990 chr10 20633483 T C 9.21E-05 Suicide attempts in bipolar disorder / / 21423239 rs10828025 chr10 20633912 T G 9.59E-05 Suicide attempts in bipolar disorder / / 21423239 rs10828026 chr10 20633949 T A 9.29E-05 Suicide attempts in bipolar disorder / / 21423239 rs10828027 chr10 20634155 G C 1.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs1984056 chr10 20634493 C A 1.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs1984057 chr10 20634526 A G 1.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs12570880 chr10 20636897 G A 5.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs10828029 chr10 20637499 C T 5.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs2884681 chr10 20638066 G A 9.09E-04 Bipolar disorder / / 19259986 rs7081455 chr10 20638885 G T 1.00E-05 Glaucoma (primary open-angle) / / 19625618 rs10828032 chr10 20639507 T C 2.22E-04 Multiple complex diseases / / 17554300 rs7090902 chr10 20644506 A G 5.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs10508621 chr10 20646439 C G 8.20E-04 Crohn's disease / / 17684544 rs10508621 chr10 20646439 C G 1.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs883580 chr10 20648411 T C 1.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs11012000 chr10 20649284 G A 9.83E-04 Multiple complex diseases / / 17554300 rs11012006 chr10 20660356 C A 3.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs7909914 chr10 20673452 A C 3.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs12772794 chr10 20674653 A G 7.00E-06 Neutrophil count / / 21507922 rs16920492 chr10 20707062 T C 8.65E-04 Multiple complex diseases / / 17554300 rs10508626 chr10 20717789 C T 8.93E-04 Myopia (pathological) / / 21095009 rs7094012 chr10 20719281 C G 4.89E-05 Suicide attempts in bipolar disorder / / 21423239 rs11012039 chr10 20722097 A G 5.81E-05 Suicide attempts in bipolar disorder / / 21423239 rs11012055 chr10 20755710 C G 2.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs6482125 chr10 20761804 C A 8.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs11012068 chr10 20763305 T A 3.43E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11012077 chr10 20768098 G A 4.50E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10764235 chr10 20773880 C G 4.46E-04 Alzheimer's disease / / 24755620 rs12358819 chr10 20777943 G C 3.28E-05 Sudden cardiac arrest / / 21658281 rs10764238 chr10 20778441 T G 8.70E-04 Tourette syndrome / / 22889924 rs7897194 chr10 20792334 G A 8.00E-06 Bipolar disorder / / 22925353 rs1361360 chr10 20795797 C T 1.30E-05 Urinary metabolites / / 21572414 rs16920587 chr10 20806400 C G 1.98E-06 Response to antidepressants / / 20360315 rs16920589 chr10 20806529 T A 1.85E-06 Response to antidepressants / / 20360315 rs7910350 chr10 20808390 T A 1.68E-06 Response to antidepressants / / 20360315 rs16920624 chr10 20810525 T G 7.00E-07 Response to antidepressants / / 20360315 rs1339653 chr10 20813062 G A 1.65E-06 Response to antidepressants / / 20360315 rs1339654 chr10 20813456 A T 2.26E-06 Response to antidepressants / / 20360315 rs1416803 chr10 20821931 T C 2.70E-05 Urinary metabolites / / 21572414 rs2486567 chr10 20837373 C T 2.87E-04 Alzheimer's disease / / 17998437 rs1339657 chr10 20840874 T C 3.34E-04 Alzheimer's disease / / 17998437 rs7081156 chr10 20842031 T C 1.01E-06 Response to antidepressants / / 20360315 rs11595329 chr10 20857219 C G 2.33E-06 Response to antidepressants / / 20360315 rs11012167 chr10 20862401 C T 6.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs7092971 chr10 20862427 T C 9.64E-04 Multiple complex diseases / / 17554300 rs12247444 chr10 20864492 A G 2.33E-06 Response to antidepressants / / 20360315 rs16920681 chr10 20864666 A G 5.78E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs11819199 chr10 20865157 A G 2.33E-06 Response to antidepressants / / 20360315 rs10508629 chr10 20877781 G A 2.90E-05 Urinary metabolites / / 21572414 rs11594336 chr10 20880496 C T 2.76E-06 Response to antidepressants / / 20360315 rs10740978 chr10 20883275 G C 6.76E-05 Aortic root size / / 21223598 rs10734034 chr10 20883413 T C 3.53E-04 Aortic root size / / 21223598 rs16920700 chr10 20895806 A C 2.14E-06 Response to antidepressants / / 20360315 rs11598280 chr10 20897254 C T 1.85E-06 Response to antidepressants / / 20360315 rs11598341 chr10 20897541 C T 2.51E-06 Response to antidepressants / / 20360315 rs11598854 chr10 20897903 C T 7.67E-07 Response to antidepressants / / 20360315 rs2359536 chr10 20899608 T C 2.00E-06 Peripheral artery disease / / 20610895 rs11593835 chr10 20904153 C T 1.85E-06 Response to antidepressants / / 20360315 rs2359537 chr10 20907665 C T 2.27E-06 Response to antidepressants / / 20360315 rs12415669 chr10 20924940 G A 8.08E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7899755 chr10 20933127 C T 2.60E-05 Urinary metabolites / / 21572414 rs2359580 chr10 20934310 C T 9.81E-04 Tourette syndrome / / 22889924 rs11012220 chr10 20936507 A G 2.98E-04 Multiple complex diseases / / 17554300 rs10508633 chr10 20955050 G C 5.05E-04 Type 2 diabetes / / 17463246 rs9663276 chr10 20967946 A C 7.79E-04 Multiple complex diseases / / 17554300 rs11012270 chr10 20977155 T C 3.67E-04 Body mass index / / 17255346 rs9645521 chr10 20980016 G A 8.80E-05 Body mass index / / 20818722 rs4748699 chr10 20984907 G A 6.78E-05 LDL lipoproteins / / pha002902 rs7095613 chr10 20993102 T C 5.32E-05 Orofacial clefts / / 22419666 rs7070319 chr10 21015343 C T 1.69E-04 Type 2 diabetes / / 17463246 rs7923404 chr10 21017050 T A 9.15E-04 Multiple complex diseases / / 17554300 rs3781490 chr10 21081843 G A 7.02E-04 Multiple complex diseases NEBL intron 17554300 rs16921139 chr10 21136444 G A 6.97E-04 Multiple complex diseases NEBL intron 17554300 rs703088 chr10 21140255 A C 9.01E-06 Major depression (suicidal thoughts and behavior) NEBL intron 21750702 rs788994 chr10 21152030 G A 8.24E-05 Lymphocyte counts NEBL intron pha003094 rs697160 chr10 21160952 C T 9.15E-04 Multiple complex diseases NEBL intron 17554300 rs3791202 chr10 21174672 T G 3.52E-04 Multiple complex diseases NEBL intron 17554300 rs788970 chr10 21185661 G A 7.58E-05 Lymphocyte counts NEBL intron pha003094 rs10159961 chr10 21205008 A C 7.97E-05 Lymphocyte counts NEBL intron pha003094 rs12356048 chr10 21210283 G A 3.14E-04 Alzheimer's disease NEBL intron 22005930 rs4748734 chr10 21210538 G T 9.89E-04 Alzheimer's disease NEBL intron 22005930 rs4748737 chr10 21218979 C T 4.69E-04 Alzheimer's disease NEBL intron 22005930 rs4748738 chr10 21219406 T C 1.72E-04 Alzheimer's disease NEBL intron 22005930 rs12770568 chr10 21219902 C T 7.75E-04 Alzheimer's disease NEBL intron 22005930 rs10828155 chr10 21219928 G A 1.74E-04 Alzheimer's disease NEBL intron 22005930 rs10828156 chr10 21219958 G A 1.76E-04 Alzheimer's disease NEBL intron 22005930 rs4748739 chr10 21220491 T G 1.81E-04 Alzheimer's disease NEBL intron 22005930 rs10828157 chr10 21224046 T C 6.24E-04 Coronary Artery Disease NEBL intron 17634449 rs6415963 chr10 21240343 T C 4.69E-04 Multiple complex diseases NEBL intron 17554300 rs11012433 chr10 21263447 G A 3.56E-04 Response to platinum-based chemotherapy in small-cell lung cancer NEBL intron 20463552 rs11012443 chr10 21267842 T C 2.48E-04 Multiple complex diseases NEBL intron 17554300 rs11012463 chr10 21276652 A G 8.51E-05 Multiple complex diseases NEBL intron 17554300 rs11012463 chr10 21276652 A G 1.90E-04 Response to platinum-based chemotherapy in small-cell lung cancer NEBL intron 20463552 rs16921408 chr10 21295815 G A 4.82E-04 Multiple complex diseases NEBL intron 17554300 rs597837 chr10 21302821 A C 2.14E-05 Caffeine consumption NEBL intron 21490707 rs604251 chr10 21323423 A G 3.72E-05 Multiple complex diseases NEBL intron 17554300 rs604251 chr10 21323423 A G 5.30E-04 Smoking initiation NEBL intron 24665060 rs649734 chr10 21326720 G A 2.97E-05 Multiple complex diseases NEBL intron 17554300 rs641632 chr10 21329425 A C 3.16E-05 Multiple complex diseases NEBL intron 17554300 rs631361 chr10 21336002 C T 2.06E-05 Multiple complex diseases NEBL intron 17554300 rs611992 chr10 21337438 T G 2.16E-05 Multiple complex diseases NEBL intron 17554300 rs611992 chr10 21337438 T G 2.78E-04 Smoking initiation NEBL intron 24665060 rs491386 chr10 21341618 A G 4.04E-05 Multiple complex diseases NEBL intron 17554300 rs491386 chr10 21341618 A G 1.87E-04 Smoking initiation NEBL intron 24665060 rs2119242 chr10 21344773 G A 3.83E-04 Multiple complex diseases NEBL intron 17554300 rs893881 chr10 21349368 A G 1.52E-05 Multiple complex diseases NEBL intron 17554300 rs11599453 chr10 21353120 C A 1.67E-04 Vaspin levels NEBL intron 22907691 rs11599453 chr10 21353120 C A 0.0001671 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks NEBL intron 22907730 rs11599453 chr10 21353120 C A 0.0001866 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit NEBL intron 22907730 rs9665295 chr10 21356592 C A 4.89E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) NEBL intron 22566498 rs7088409 chr10 21363030 T C 1.58E-05 Multiple complex diseases NEBL intron 17554300 rs9633625 chr10 21366778 C T 7.30E-04 Response to statin treatment (atorvastatin),change in cholesterol levels NEBL intron 20031582 rs11817725 chr10 21368072 G T 7.61E-04 Type 2 diabetes NEBL intron 17463246 rs11817725 chr10 21368072 G T 1.42E-05 Multiple complex diseases NEBL intron 17554300 rs11012514 chr10 21368442 A T 1.77E-05 Multiple complex diseases NEBL intron 17554300 rs11012515 chr10 21369034 C T 5.45E-04 Type 2 diabetes NEBL intron 17463246 rs11012515 chr10 21369034 C T 2.55E-05 Multiple complex diseases NEBL intron 17554300 rs7097035 chr10 21370420 T C 9.10E-06 Multiple complex diseases NEBL intron 17554300 rs1870706 chr10 21377768 G T 1.73E-04 Multiple complex diseases NEBL intron 17554300 rs605715 chr10 21377866 C T 9.10E-04 Multiple complex diseases NEBL intron 17554300 rs10828188 chr10 21390313 C A 4.12E-04 Type 2 diabetes NEBL intron 17463246 rs12243039 chr10 21436222 C A 6.00E-06 Response to radiotherapy in cancer (late toxicity) NEBL intron 24785509 rs12243039 chr10 21436222 C A 8.00E-06 Response to radiotherapy in cancer (late toxicity) NEBL intron 24785509 rs1751915 chr10 21444603 G A 2.90E-05 Vaspin levels NEBL intron 22907691 rs1751915 chr10 21444603 G A 0.000029 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit NEBL intron 22907730 rs11012548 chr10 21446033 G T 5.18E-04 Multiple complex diseases NEBL intron 17554300 rs11599589 chr10 21449777 A G 1.62E-04 Vaspin levels NEBL intron 22907691 rs11599589 chr10 21449777 A G 0.0001624 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit NEBL intron 22907730 rs10828201 chr10 21461860 C T 1.00E-04 Cognitive impairment induced by topiramate NEBL intron 22091778 rs10828206 chr10 21479885 A T 4.44E-04 Coronary Artery Disease / / 17634449 rs1841530 chr10 21480273 A G 3.27E-04 Coronary Artery Disease / / 17634449 rs12412833 chr10 21495362 A G 0.000476 Salmonella-induced pyroptosis / / 22837397 rs10828213 chr10 21510840 T G 6.30E-04 Myocardial Infarction / / pha002873 rs3847375 chr10 21567565 C A 1.00E-06 Schizophrenia / / 22885689 rs3847375 chr10 21567565 C A 7.08E-05 Coronary heart disease / / pha003055 rs11012683 chr10 21672276 A T 8.50E-04 Multiple complex diseases / / 17554300 rs11012732 chr10 21830104 A G 2.00E-14 Meningioma MLLT10 intron 21804547 rs1243180 chr10 21915619 T A 1.00E-07 Ovarian cancer MLLT10 intron 23535730 rs1243180 chr10 21915619 T A 2.00E-08 Ovarian cancer MLLT10 intron 23535730 rs16921893 chr10 21961864 C G 3.24E-04 Cognitive decline MLLT10 intron 23732972 rs370104096 chr10 21961864 C CAG 3.24E-04 Cognitive decline MLLT10 intron 23732972 rs1243192 chr10 21983960 C A 5.39E-05 Smoking initiation MLLT10 intron 24665060 rs7072776 chr10 22032942 A G 4.00E-14 Breast cancer MLLT10 nearGene-3 23535729 rs2666781 chr10 22205676 C A 5.83E-08 Parkinson's disease D/JC1 intron 17052657 rs2666781 chr10 22205676 C A 4.00E-06 Asthma (childhood onset) D/JC1 intron 17611496 rs10740997 chr10 22269847 T C 7.51E-04 Type 2 diabetes D/JC1 intron 17463246 rs11814448 chr10 22315843 A C 9.00E-16 Breast cancer / / 23535729 rs4529807 chr10 22318101 T C 1.10E-05 Volumetric brain MRI / / 17903297 rs6482199 chr10 22337752 A G 2.80E-06 Urinary metabolites / / 21572414 rs4266962 chr10 22341574 C G 2.39E-08 Acute lymphoblastic leukemia (childhood) / / 23512250 rs11812890 chr10 22341895 T C 1.89E-04 Alcohol dependence / / 21314694 rs4748793 chr10 22483011 A G 8.40E-09 Acute lymphoblastic leukemia (childhood) / / 23512250 rs4748793 chr10 22483011 A G 4.22E-04 Smoking initiation / / 24665060 rs2148959 chr10 22504189 C T 7.45E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7069551 chr10 22603318 G A 8.40E-04 Multiple complex diseases / / 17554300 rs11012962 chr10 22641914 C T 1.63E-04 Multiple complex diseases SPAG6 intron 17554300 rs7893132 chr10 22648080 C G 6.03E-04 Multiple complex diseases SPAG6 intron 17554300 rs7920038 chr10 22654430 C T 1.15E-05 Multiple complex diseases SPAG6 intron 17554300 rs16922235 chr10 22683351 G T 3.22E-04 Multiple complex diseases SPAG6 intron 17554300 rs3004 chr10 22724472 A G 5.95E-04 Multiple complex diseases / / 17554300 rs10828309 chr10 22758198 G T 2.59E-04 Multiple complex diseases / / 17554300 rs7904708 chr10 22781046 C T 2.04E-04 Multiple complex diseases / / 17554300 rs11593715 chr10 22790884 C A 9.65E-05 Myocardial Infarction / / pha002883 rs7901152 chr10 22833153 G A 1.89E-08 Acute lymphoblastic leukemia (childhood) PIP4K2A intron 23512250 rs2230469 chr10 22839628 T C 2.00E-09 Acute lymphoblastic leukemia (B-cell precursor) PIP4K2A missense 23996088 rs11013046 chr10 22840583 C T 2.92E-09 Acute lymphoblastic leukemia (childhood) PIP4K2A intron 23512250 rs12146350 chr10 22843111 C G 8.35E-04 Suicide attempts in bipolar disorder PIP4K2A intron 21041247 rs7094131 chr10 22847439 C T 9.00E-06 Obesity-related traits PIP4K2A intron 23251661 rs7088318 chr10 22852948 C A 1.13E-11 Acute lymphoblastic leukemia (childhood) PIP4K2A intron 23512250 rs7075634 chr10 22853102 T C 2.06E-10 Acute lymphoblastic leukemia (childhood) PIP4K2A intron 23512250 rs1062190 chr10 22863491 C T 2.12E-04 Stroke PIP4K2A intron pha002887 rs1627983 chr10 22913051 C T 2.05E-04 Birth weight PIP4K2A intron 17255346 rs7902016 chr10 22916114 C G 7.03E-04 Multiple complex diseases PIP4K2A intron 17554300 rs1631873 chr10 22917990 T A 3.88E-04 Birth weight PIP4K2A intron 17255346 rs1631873 chr10 22917990 T A 8.71E-04 Multiple complex diseases PIP4K2A intron 17554300 rs16922539 chr10 22926129 T A 1.82E-04 Multiple complex diseases PIP4K2A intron 17554300 rs943196 chr10 22928514 G A 3.56E-04 Response to taxane treatment (placlitaxel) PIP4K2A intron 23006423 rs2559534 chr10 22928868 T G 6.18E-04 Response to taxane treatment (placlitaxel) PIP4K2A intron 23006423 rs1778335 chr10 22932148 T C 6.04E-05 Response to taxane treatment (placlitaxel) PIP4K2A intron 23006423 rs1614387 chr10 22937071 A C 1.72E-04 Response to taxane treatment (placlitaxel) PIP4K2A intron 23006423 rs1171492 chr10 22941037 A C 1.55E-04 Response to taxane treatment (placlitaxel) PIP4K2A intron 23006423 rs6482228 chr10 22974261 G A 9.60E-06 Urinary metabolites PIP4K2A intron 21572414 rs1891877 chr10 22978029 T C 9.80E-04 Suicidal ideation PIP4K2A intron 22030708 rs7084115 chr10 22991590 A G 1.47E-04 Coronary heart disease PIP4K2A intron 21971053 rs17527491 chr10 23027581 G A 8.44E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs7072301 chr10 23033291 G C 4.68E-04 Multiple complex diseases / / 17554300 rs11013118 chr10 23039451 G T 2.16E-04 Rheumatoid arthritis / / 21452313 rs946961 chr10 23094828 G C 6.90E-06 Malaria / / 19465909 rs4748822 chr10 23096354 G A 4.51E-04 Type 2 diabetes / / 17463246 rs11013140 chr10 23098092 T C 5.60E-06 Malaria / / 19465909 rs16922724 chr10 23099423 T A 1.28E-04 Multiple complex diseases / / 17554300 rs12252439 chr10 23107272 T G 6.02E-05 Serum metabolites / / 19043545 rs10828342 chr10 23117969 C T 1.64E-06 Multiple complex diseases / / 17554300 rs2222870 chr10 23151064 T C 1.77E-04 Multiple complex diseases / / 17554300 rs7070284 chr10 23153350 T C 2.50E-06 White blood cell count / / 21738479 rs1578343 chr10 23167848 G A 5.51E-06 White blood cell count / / 21738479 rs10764354 chr10 23168728 T C 3.28E-06 White blood cell count / / 21738479 rs10764362 chr10 23186527 T C 9.40E-06 White blood cell count / / 21738479 rs10828368 chr10 23187710 A T 3.70E-06 White blood cell count / / 21738479 rs4601662 chr10 23195209 C A 4.90E-06 White blood cell count / / 21738479 rs10764363 chr10 23195889 A T 4.90E-06 White blood cell count / / 21738479 rs1922123 chr10 23199219 A C 8.02E-06 White blood cell count / / 21738479 rs1922124 chr10 23206446 A G 6.61E-07 White blood cell count / / 21738479 rs7100326 chr10 23249878 C T 2.80E-05 Urinary metabolites ARMC3 intron 21572414 rs1054052 chr10 23303253 T A 2.00E-06 IgG glycosylation ARMC3 intron 23382691 rs1054052 chr10 23303253 T A 3.00E-06 IgG glycosylation ARMC3 intron 23382691 rs1054052 chr10 23303253 T A 6.00E-06 IgG glycosylation ARMC3 intron 23382691 rs1054052 chr10 23303253 T A 6.00E-07 IgG glycosylation ARMC3 intron 23382691 rs10764372 chr10 23307046 G T 3.44E-05 Alzheimer's disease (late onset) ARMC3 intron 21379329 rs4237359 chr10 23342159 G A 1.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs722258 chr10 23369421 C T 3.00E-06 Sleep time / / 23728906 rs7073142 chr10 23372022 T C 8.90E-04 Taste perception / / 22132133 rs11593017 chr10 23375723 A T 5.47E-04 Multiple complex diseases / / 17554300 rs1478911 chr10 23377556 G C 3.73E-04 Multiple complex diseases / / 17554300 rs12413082 chr10 23381422 C T 1.50E-06 Longevity / / 21612516 rs7094224 chr10 23394202 T C 1.70E-05 Urinary metabolites MSRB2 intron 21572414 rs7094823 chr10 23394654 T C 1.50E-05 Urinary metabolites MSRB2 intron 21572414 rs11013291 chr10 23400191 T C 9.80E-05 Alcohol consumption (maxi-drinks) MSRB2 intron 24277619 rs7893600 chr10 23434744 A C 3.00E-06 Obesity-related traits / / 23251661 rs4748846 chr10 23508023 G A 5.43E-05 Odorant perception / / 23910658 rs10734046 chr10 23664096 G T 6.23E-05 Pancreatic cancer / / pha002889 rs1398024 chr10 23665438 G T 4.00E-06 Crohn's disease and sarcoidosis (combined) / / 18723019 rs4747475 chr10 23743462 T C 0.000015 Mean arterial pressure / / 22510845 rs7898730 chr10 23813455 C T 2.59E-04 Aortic root size / / 21223598 rs16923476 chr10 23858211 G A 1.00E-07 Obesity (early onset extreme) / / 23563609 rs16923535 chr10 23896359 G A 0.000493 Salmonella-induced pyroptosis / / 22837397 rs10828520 chr10 23901835 G A 0.000674 Salmonella-induced pyroptosis / / 22837397 rs1337322 chr10 23936020 G A 1.50E-05 Urinary metabolites / / 21572414 rs12259862 chr10 23963671 C T 0.000469 Salmonella-induced pyroptosis / / 22837397 rs11013643 chr10 23968383 A G 2.57E-04 Alcohol consumption / / 23743675 rs11013645 chr10 23969208 A G 2.57E-04 Alcohol consumption / / 23743675 rs962184 chr10 23998944 A C 0.000369 Salmonella-induced pyroptosis KIAA1217 intron 22837397 rs4748908 chr10 24014122 A G 6.63E-04 Alcohol dependence KIAA1217 intron 21314694 rs6482335 chr10 24029291 T G 6.14E-04 Heart Failure KIAA1217 intron pha002885 rs16924015 chr10 24166782 G T 2.33E-04 Multiple complex diseases KIAA1217 intron 17554300 rs16924036 chr10 24196086 T C 7.07E-05 Multiple complex diseases KIAA1217 intron 17554300 rs10828575 chr10 24229446 T C 7.10E-04 Aortic root size KIAA1217 intron 21223598 rs11013804 chr10 24230240 C T 2.38E-04 Celiac disease KIAA1217 intron 23936387 rs4420167 chr10 24233614 A G 2.60E-04 Celiac disease KIAA1217 intron 23936387 rs4748918 chr10 24234777 G A 9.39E-05 Aortic root size KIAA1217 intron 21223598 rs4748919 chr10 24234829 A T 1.25E-04 Aortic root size KIAA1217 intron 21223598 rs7893502 chr10 24244061 T C 7.00E-04 Aortic root size KIAA1217 intron 21223598 rs4748922 chr10 24277063 G A,C 9.88E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KIAA1217 intron 20877124 rs1970288 chr10 24294611 T C 2.70E-04 Osteoarthritis (knee and hip) KIAA1217 intron 21177295 rs1970288 chr10 24294611 T C 4.39E-04 Osteoarthritis (knee and hip) KIAA1217 intron 21177295 rs1970288 chr10 24294611 T C 6.11E-05 Osteoarthritis (knee and hip) KIAA1217 intron 21177295 rs11013847 chr10 24296765 T C 4.48E-04 Tourette syndrome KIAA1217 intron 22889924 rs12146261 chr10 24299354 T G 4.27E-05 Body mass index KIAA1217 intron 22446040 rs6482358 chr10 24322810 T G 1.19E-04 Tourette syndrome KIAA1217 intron 22889924 rs7100869 chr10 24484615 C A 2.00E-04 Information processing speed KIAA1217 intron 21130836 rs10741048 chr10 24485269 C T 2.00E-04 Information processing speed KIAA1217 intron 21130836 rs7089962 chr10 24487557 C A 9.01E-05 Triglycerides KIAA1217 intron pha003080 rs11013962 chr10 24495586 A G 3.00E-07 Common traits (Other) KIAA1217 intron 20585627 rs17504419 chr10 24507819 G A 5.64E-04 Multiple complex diseases KIAA1217 intron 17554300 rs12412151 chr10 24518064 G A 9.43E-04 Acute lung injury KIAA1217 intron 22295056 rs12414014 chr10 24522830 G A 6.19E-04 Acute lung injury KIAA1217 intron 22295056 rs12413189 chr10 24523789 A C 8.61E-04 Acute lung injury KIAA1217 intron 22295056 rs17582653 chr10 24524783 T C 8.61E-04 Acute lung injury KIAA1217 intron 22295056 rs3814686 chr10 24539039 G A 9.83E-06 C-Reactive Protein KIAA1217 intron pha003070 rs1138002 chr10 24542519 A G 7.70E-06 Urinary metabolites KIAA1217 intron 21572414 rs1336188 chr10 24562990 T C 3.69E-05 Post-operative nausea and vomiting KIAA1217 intron 21694509 rs220341 chr10 24567595 A G 4.00E-04 Smoking quantity KIAA1217 intron 24665060 rs220355 chr10 24576622 C A 0.000691 Salmonella-induced pyroptosis KIAA1217 intron 22837397 rs220370 chr10 24588243 T C 5.54E-04 Aortic root size KIAA1217 intron 21223598 rs7917252 chr10 24596982 A T 4.27E-04 Type 2 diabetes KIAA1217 intron 17463246 rs12258036 chr10 24600008 G A 5.00E-04 Polycystic ovary syndrome KIAA1217 intron 22178785 rs10741050 chr10 24600547 G T 2.73E-04 Multiple complex diseases KIAA1217 intron 17554300 rs17384657 chr10 24621080 G A 7.00E-05 Prostate cancer KIAA1217 intron 21743057 rs7897007 chr10 24621169 G A 1.04E-04 Suicide attempts in bipolar disorder KIAA1217 intron 21041247 rs10741051 chr10 24622329 A G 1.05E-04 Suicide attempts in bipolar disorder KIAA1217 intron 21041247 rs7094782 chr10 24625405 A G 9.91E-04 Lymphocyte counts KIAA1217 intron 22286170 rs10828629 chr10 24632135 A C 7.18E-07 Post-operative nausea and vomiting KIAA1217 intron 21694509 rs2484873 chr10 24634956 A G 4.00E-07 Cognitive performance KIAA1217 intron 20125193 rs11014058 chr10 24653308 G A 6.43E-05 Pancreatic cancer KIAA1217 intron pha002889 rs7068808 chr10 24693571 T A 1.20E-05 Urinary metabolites KIAA1217 intron 21572414 rs12781952 chr10 24701692 G A 1.00E-04 Information processing speed KIAA1217 intron 21130836 rs2366915 chr10 24707669 C T 9.66E-04 Alcohol dependence KIAA1217 intron 24277619 rs10508674 chr10 24720825 A G 5.50E-04 Type 2 diabetes KIAA1217 intron 17463246 rs10508674 chr10 24720825 A G 3.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KIAA1217 intron 20877124 rs1537170 chr10 24729218 A G 1.95E-05 Type 2 diabetes KIAA1217 intron 17463246 rs11014094 chr10 24742828 C T 1.45E-04 Premature ovarian failure KIAA1217 intron 19508998 rs1556406 chr10 24789614 T C 1.00E-05 Major depressive disorder KIAA1217 intron 22472876 rs2183696 chr10 24791381 A G 9.94E-06 Major depressive disorder KIAA1217 intron 22472876 rs7899691 chr10 24792171 C G 1.76E-06 C-reactive protein KIAA1217 intron 22492993 rs10508679 chr10 24793880 G A 1.43E-06 C-reactive protein KIAA1217 intron 22492993 rs4748949 chr10 24803057 G A 7.70E-05 Alcoholism (heaviness of drinking) KIAA1217 intron 21529783 rs7090837 chr10 24806631 G A 1.61E-05 Major depressive disorder KIAA1217 intron 22472876 rs2297330 chr10 24810663 C A 1.54E-04 Multiple complex diseases KIAA1217 intron 17554300 rs2297330 chr10 24810663 C A 9.96E-06 Iron status biomarkers KIAA1217 intron 19084217 rs151027148 chr10 24813550 G A 0.00089 Breast cancer KIAA1217 missense 23555315 rs12268215 chr10 24814142 A G 9.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) KIAA1217 intron 22566498 rs10828664 chr10 24814503 G A 5.55E-05 Major depressive disorder KIAA1217 intron 22472876 rs10828664 chr10 24814503 G A 9.08E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) KIAA1217 intron 22566498 rs7904181 chr10 24828744 T G 1.97E-04 Amyotrophic lateral sclerosis (sporadic) KIAA1217 intron 24529757 rs3748218 chr10 24832885 C T 8.64E-04 Suicide attempts in bipolar disorder KIAA1217 cds-synon 21423239 rs1888656 chr10 24833705 A G 2.94E-04 Suicide attempts in bipolar disorder KIAA1217 intron 21423239 rs11014149 chr10 24838797 A G 8.14E-06 Bipolar disorder / / 20451256 rs7074909 chr10 24841274 A G 7.39E-06 Bipolar disorder / / 20451256 rs16924894 chr10 24845525 T A 6.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs11014158 chr10 24847050 C T 2.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs2256766 chr10 24852071 A T 8.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs7082393 chr10 24927447 C A 2.00E-04 IgE levels ARHGAP21 intron 17255346 rs7090524 chr10 24929141 G A 1.33E-04 Response to alcohol consumption (flushing response) ARHGAP21 intron 24277619 rs7070456 chr10 24967092 C T 8.15E-05 Panic disorder ARHGAP21 intron 19165232 rs7087801 chr10 25005932 C T 1.95E-04 IgE levels ARHGAP21 intron 17255346 rs11593521 chr10 25081855 T C 1.09E-04 Self-reported allergy / / 23817569 rs11014249 chr10 25111910 T G 3.00E-06 Obesity-related traits / / 23251661 rs11014249 chr10 25111910 T G 2.76E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs2077710 chr10 25124247 C G 7.85E-04 Lymphocyte counts / / 22286170 rs3827855 chr10 25143819 G C 3.66E-04 Multiple complex diseases PRTFDC1 intron 17554300 rs10741068 chr10 25144730 C T 9.09E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) PRTFDC1 intron 23648065 rs2484650 chr10 25156642 G A 1.97E-04 Smoking initiation PRTFDC1 intron 24665060 rs1971470 chr10 25158221 G T 7.86E-05 Smoking initiation PRTFDC1 intron 24665060 rs7078551 chr10 25174726 C T 6.10E-04 Alcohol dependence PRTFDC1 intron 20201924 rs11595185 chr10 25191370 A G 1.93E-05 Parkinson's disease PRTFDC1 intron 19915575 rs7908585 chr10 25206554 C T 9.84E-04 Response to alcohol consumption (flushing response) PRTFDC1 intron 24277619 rs11014306 chr10 25224462 T C 4.00E-06 Metabolite levels (Pyroglutamine) PRTFDC1 intron 23934736 rs7393543 chr10 25319146 C G 6.50E-06 Urinary metabolites / / 21572414 rs11014357 chr10 25321589 A T 3.35E-04 Coronary Artery Disease / / 17634449 rs11014357 chr10 25321589 A T 6.40E-06 Urinary metabolites / / 21572414 rs10508687 chr10 25325937 T C 8.45E-05 Diabetic nephropathy / / pha002852 rs1124017 chr10 25326104 A G 2.04E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11014365 chr10 25345720 A G 9.43E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12773782 chr10 25364115 A G 5.17E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10508682 chr10 25376990 C G 1.50E-05 Urinary metabolites / / 21572414 rs11014393 chr10 25377295 C G,T 9.72E-04 Type 2 diabetes / / 17463246 rs943043 chr10 25394337 T C 7.08E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7904193 chr10 25446245 C T 2.14E-04 Type 2 diabetes / / 17463246 rs11014431 chr10 25459750 A G 5.19E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) LOC100128811 intron 23648065 rs11014431 chr10 25459750 A G 7.34E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) LOC100128811 intron 23648065 rs1340000 chr10 25460763 G A 1.73E-20 Alcohol consumption LOC100128811 intron pha001400 rs2807241 chr10 25500532 T C 8.79E-04 Coronary Artery Disease GPR158 intron 17634449 rs2807231 chr10 25515067 A G 5.04E-04 Coronary Artery Disease GPR158 intron 17634449 rs2807231 chr10 25515067 A G 1.22E-05 Cognitive impairment induced by topiramate GPR158 intron 22091778 rs10508689 chr10 25522280 A G 6.30E-05 Cognitive impairment induced by topiramate GPR158 intron 22091778 rs915028 chr10 25531636 A C 8.64E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) GPR158 intron 23648065 rs1339999 chr10 25532099 C T 1.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) GPR158 intron 23648065 rs1339999 chr10 25532099 C T 7.82E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) GPR158 intron 23648065 rs1416995 chr10 25533536 T C 5.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) GPR158 intron 23648065 rs2807256 chr10 25555314 A G 2.90E-04 Multiple complex diseases GPR158 intron 17554300 rs7902135 chr10 25576492 G A 5.56E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) GPR158 intron 23648065 rs59132240 chr10 25591153 A G 6.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity GPR158 intron 24324551 rs55801305 chr10 25591409 T C 6.90E-06 Ejection fraction in Tripanosoma cruzi seropositivity GPR158 intron 24324551 rs10450325 chr10 25636849 A G 8.62E-04 Alzheimer's disease GPR158 intron 17998437 rs2807255 chr10 25637528 A G 9.48E-05 Cognitive test performance GPR158 intron 20125193 rs10828777 chr10 25653017 A G 7.24E-05 Cognitive test performance GPR158 intron 20125193 rs959751 chr10 25656838 T C 2.80E-05 Coronary heart disease GPR158 intron pha003030 rs1760767 chr10 25668632 T G 8.90E-05 Coronary heart disease GPR158 intron pha003030 rs1773625 chr10 25668687 G A 8.90E-05 Coronary heart disease GPR158 intron pha003030 rs12762462 chr10 25668778 G A,C,T 6.09E-05 Brain derived neurotrophic factor levels,in serum GPR158 intron 22047184 rs1628986 chr10 25671025 A G 7.73E-05 Coronary heart disease GPR158 intron pha003030 rs1754253 chr10 25671382 A C 2.13E-05 Coronary heart disease GPR158 intron pha003030 rs1591250 chr10 25674081 G A 5.38E-05 Cognitive test performance GPR158 intron 20125193 rs11014525 chr10 25689276 G T 2.00E-05 Multiple complex diseases GPR158 intron 17554300 rs1773691 chr10 25702556 A G 3.99E-05 Coronary heart disease GPR158 intron pha003031 rs72786268 chr10 25770025 G C 4.00E-07 QRS duration in Tripanosoma cruzi seropositivity GPR158 intron 24324551 rs3005191 chr10 25776176 A G 4.54E-04 Alcohol dependence GPR158 intron 20201924 rs1329255 chr10 25781407 G A 7.12E-05 Lung adenocarcinoma GPR158 intron 19836008 rs3005182 chr10 25784552 G A 6.73E-05 Lung adenocarcinoma GPR158 intron 19836008 rs7072700 chr10 25788635 G A 5.60E-05 Cognitive function GPR158 intron 24684796 rs1329252 chr10 25791843 T G 2.90E-05 Urinary metabolites GPR158 intron 21572414 rs10047266 chr10 25811835 T G 5.70E-06 Urinary metabolites GPR158 intron 21572414 rs10741092 chr10 25814527 G T 1.06E-04 Cognitive function GPR158 intron 24684796 rs10508699 chr10 25821161 A G 1.70E-05 Urinary metabolites GPR158 intron 21572414 rs7100942 chr10 25823753 C A 4.80E-05 Major depressive disorder GPR158 intron 21042317 rs1414040 chr10 25853401 T C 2.50E-06 Urinary metabolites GPR158 intron 21572414 rs17558301 chr10 25880459 C G 7.00E-06 IgG glycosylation GPR158 intron 23382691 rs12775535 chr10 25918879 C T 4.00E-09 Immune response to smallpox vaccine (IL-6) / / 22542470 rs16926212 chr10 25920808 C A 7.09E-04 Multiple complex diseases / / 17554300 rs10741097 chr10 25926559 T G 1.12E-04 Type 2 diabetes / / 17463246 rs10764571 chr10 25927191 T G 1.12E-04 Type 2 diabetes / / 17463246 rs10764581 chr10 25996101 T C 6.50E-04 Alcohol dependence / / 20201924 rs2442901 chr10 25996795 G A 9.40E-06 Urinary metabolites / / 21572414 rs10828853 chr10 25997959 A G 3.34E-05 Soluble levels of adhesion molecules / / pha003072 rs10828854 chr10 25998218 A G 3.34E-05 Soluble levels of adhesion molecules / / pha003072 rs11014702 chr10 26001670 T C 3.45E-05 Bipolar disorder and schizophrenia / / 20889312 rs2504183 chr10 26002248 G A 7.00E-06 IgG glycosylation / / 23382691 rs2504192 chr10 26007962 A T 4.79E-05 Bipolar disorder and schizophrenia / / 20889312 rs2505449 chr10 26019605 G A 1.16E-04 Vaspin levels / / 22907691 rs2505449 chr10 26019605 G A 0.0001155 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs2442868 chr10 26023841 C T 2.30E-05 Urinary metabolites / / 21572414 rs2263000 chr10 26026785 T C 6.40E-06 Urinary metabolites / / 21572414 rs7100843 chr10 26028475 G A 1.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs723370 chr10 26043071 A G 4.18E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2437382 chr10 26055631 G A 8.46E-05 Lung adenocarcinoma / / 19836008 rs2263002 chr10 26058758 A T 9.79E-04 Alzheimer's disease / / 22005930 rs17664916 chr10 26072818 C T 5.76E-04 Type 2 diabetes / / 17463246 rs2505491 chr10 26095196 A G 3.28E-04 Parkinson's disease / / 17052657 rs2505437 chr10 26117821 T C 8.83E-04 Parkinson's disease / / 17052657 rs7896386 chr10 26129395 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs3006269 chr10 26133639 T G 2.27E-04 Multiple complex diseases / / 17554300 rs3006252 chr10 26147060 A C 2.74E-04 Multiple complex diseases / / 17554300 rs4749080 chr10 26162766 A G 4.00E-07 Obesity-related traits / / 23251661 rs7078573 chr10 26164407 A G 7.05E-04 Acute lung injury / / 22295056 rs12572559 chr10 26166232 A G 6.43E-05 Acute lung injury / / 22295056 rs12413953 chr10 26173695 G A 1.98E-06 Obesity-related traits / / 23251661 rs7086207 chr10 26187677 T G 3.90E-05 Adiposity / / 19461586 rs11014841 chr10 26187923 T C 1.10E-05 Urinary metabolites / / 21572414 rs9787562 chr10 26252005 A G 4.71E-06 Obesity-related traits MYO3A intron 23251661 rs12257119 chr10 26286159 G T 2.30E-05 Urinary metabolites MYO3A cds-synon 21572414 rs16926523 chr10 26294828 G A 4.00E-06 PR interval MYO3A intron 23534349 rs4749090 chr10 26304072 A C 9.70E-06 Urinary metabolites MYO3A intron 21572414 rs12573019 chr10 26314305 G A 8.20E-06 Obesity-related traits MYO3A intron 23251661 rs1339811 chr10 26318337 A G 8.86E-06 Obesity-related traits MYO3A intron 23251661 rs11593128 chr10 26352952 C A 0.0000604 Uterine leiomyomata MYO3A intron 23040493 rs1521032 chr10 26353592 G A 0.0000541 Uterine leiomyomata MYO3A intron 23040493 rs3824700 chr10 26355906 G A 0.0000492 Uterine leiomyomata MYO3A missense 23040493 rs1521033 chr10 26382351 T C 0.0000889 Uterine leiomyomata MYO3A intron 23040493 rs41279910 chr10 26409601 T G 6.00E-06 Parkinson's disease MYO3A intron 20711177 rs2096176 chr10 26433366 C T 5.00E-06 Obesity-related traits MYO3A intron 23251661 rs7085103 chr10 26433673 G A 8.18E-04 Stroke (pediatric) MYO3A intron 22990015 rs1999240 chr10 26463130 C A 5.69E-04 Suicide,with and without major depression MYO3A missense 22059935 rs1999240 chr10 26463130 C A 7.96E-04 Suicide,with and without major depression MYO3A missense 22059935 rs11014993 chr10 26483183 T C 2.70E-04 Colorectal cancer MYO3A intron 20610541 rs12764197 chr10 26484154 A G 6.00E-06 Obesity-related traits MYO3A intron 23251661 rs16926664 chr10 26485613 T C 5.73E-04 Multiple complex diseases MYO3A intron 17554300 rs2839670 chr10 26504340 C A 5.54E-05 Coronary heart disease / / pha003030 rs2839671 chr10 26505822 G A 0.000860521 Fasting blood glucose GAD2 intron 22885924 rs8190645 chr10 26520487 G A 2.41E-05 Stroke (ischemic) GAD2 intron 22941190 rs11015008 chr10 26527590 G A 1.95E-05 Body Mass Index GAD2 intron pha003007 rs11015008 chr10 26527590 G A 5.02E-05 Body Mass Index GAD2 intron pha003015 rs11015008 chr10 26527590 G A 2.38E-05 Body Fat Distribution GAD2 intron pha003016 rs11015008 chr10 26527590 G A 7.23E-06 Waist Circumference GAD2 intron pha003025 rs11015008 chr10 26527590 G A 2.75E-06 Weight GAD2 intron pha003027 rs8190650 chr10 26530667 A G 7.09E-04 Amyotrophic lateral sclerosis (sporadic) GAD2 intron 24529757 rs16926761 chr10 26564368 G A 0.00032 Coronary artery calcification GAD2 intron 23727086 rs1999241 chr10 26566427 A G 1.68E-04 Arthritis (juvenile idiopathic) GAD2 intron 22354554 rs11015025 chr10 26566456 C T 2.87E-04 Type 2 diabetes GAD2 intron 17463246 rs11015025 chr10 26566456 C T 7.59E-04 Multiple complex diseases GAD2 intron 17554300 rs11015025 chr10 26566456 C T 2.59E-04 Suicide attempts in bipolar disorder GAD2 intron 21041247 rs7903552 chr10 26606312 A G 2.90E-06 Common variable immunodeficiency / / 21497890 rs4749114 chr10 26630030 G A 3.51E-04 Multiple complex diseases / / 17554300 rs3006801 chr10 26654660 G T 6.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10828979 chr10 26655039 A C 7.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4749118 chr10 26660883 T C 2.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4749118 chr10 26660883 T C 6.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4749119 chr10 26663922 A G 4.21E-05 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs945294 chr10 26697294 G T 3.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs868093 chr10 26705832 T C 2.00E-06 Urinary metabolites / / 21572414 rs3006819 chr10 26718561 A G 2.50E-05 Urinary metabolites / / 21572414 rs1889692 chr10 26718723 A C 9.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs1889692 chr10 26718723 A C 5.05E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9299819 chr10 26719882 T C 8.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs3006818 chr10 26721012 A C 8.08E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9299820 chr10 26722622 G A 9.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs1335551 chr10 26724205 C G 4.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs1335552 chr10 26725355 T C 6.32E-04 Type 2 diabetes / / 17463246 rs1335552 chr10 26725355 T C 7.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs1335552 chr10 26725355 T C 1.80E-05 Urinary metabolites / / 21572414 rs3006805 chr10 26732831 A G 4.90E-07 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) APBB1IP intron 22566498 rs2992257 chr10 26734587 C T 3.00E-07 Response to angiotensin II receptor blocker therapy APBB1IP intron 22566498 rs2992258 chr10 26737883 C A 4.78E-07 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) APBB1IP intron 22566498 rs2992262 chr10 26741174 C T 6.77E-04 Type 2 diabetes APBB1IP intron 17463246 rs703003 chr10 26758867 C A 3.27E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) APBB1IP intron 22566498 rs7085145 chr10 26764577 G A 6.86E-05 Monocyte chemoattractant protein-1 APBB1IP intron pha003071 rs786870 chr10 26774694 T C 5.00E-07 Inflammatory biomarkers APBB1IP intron 22228203 rs12412826 chr10 26778606 G A 2.04E-06 Colorectal cancer APBB1IP intron 21242260 rs10508719 chr10 26782711 A G 1.40E-05 Age-related macular degeneration APBB1IP intron pha000002 rs12783959 chr10 26802361 C T 8.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) APBB1IP intron 20877124 rs702988 chr10 26814452 T C 1.76E-05 Multiple sclerosis (brain glutamate levels) APBB1IP intron 20802204 rs10764631 chr10 26827600 A G 4.42E-05 Cytomegalovirus antibody response APBB1IP intron 21993531 rs10764631 chr10 26827600 A G 2.95E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) APBB1IP intron 24023788 rs10764631 chr10 26827600 A G 4.15E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) APBB1IP intron 24023788 rs10741114 chr10 26845247 A G 5.97E-05 Cytomegalovirus antibody response APBB1IP intron 21993531 rs10741114 chr10 26845247 A G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes APBB1IP intron 22628534 rs12219836 chr10 26858860 G A 9.01E-05 Weight / / pha003027 rs4747570 chr10 26866420 G A 3.37E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs9665670 chr10 26910726 C T 1.05E-04 Multiple complex diseases / / 17554300 rs7074054 chr10 26914881 C G 3.70E-04 Multiple complex diseases / / 17554300 rs1748326 chr10 26948937 A G 1.89E-04 Taste perception / / 22132133 rs1853682 chr10 26950217 G A 2.85E-04 Taste perception / / 22132133 rs2489568 chr10 26952415 A G 8.05E-05 Taste perception / / 22132133 rs1009273 chr10 26955598 A G 2.96E-04 Alcohol dependence / / 21314694 rs12415035 chr10 26971879 C T 1.05E-05 Type 2 diabetes / / 17463246 rs1677732 chr10 26981625 T C 9.30E-06 Urinary metabolites / / 21572414 rs11015231 chr10 26985149 C G 1.53E-04 Insulin resistance PDSS1 nearGene-5 21901158 rs7896301 chr10 26988258 A T 6.47E-05 Type 2 diabetes PDSS1 intron 17463246 rs3802609 chr10 27025659 A G 5.56E-04 Acute lung injury PDSS1 intron 22295056 rs10764638 chr10 27031214 A G 8.31E-05 Acute lung injury PDSS1 intron 22295056 rs6482573 chr10 27033193 G A 6.06E-05 Bone mineral density PDSS1 intron 19181680 rs10741117 chr10 27034320 A G 6.89E-04 Acute lung injury PDSS1 intron 22295056 rs3802612 chr10 27037893 C G 6.87E-05 Acute lung injury ABI1 intron 22295056 rs2368184 chr10 27039517 T G 6.52E-05 Acute lung injury ABI1 intron 22295056 rs1031858 chr10 27045387 C T 7.51E-05 Acute lung injury ABI1 intron 22295056 rs1998634 chr10 27047593 G A 3.37E-05 Acute lung injury ABI1 intron 22295056 rs1998632 chr10 27047739 G A 7.03E-05 Acute lung injury ABI1 intron 22295056 rs1324637 chr10 27059608 C T 8.36E-05 Acute lung injury ABI1 intron 22295056 rs1590445 chr10 27071250 A G 6.64E-05 Acute lung injury ABI1 intron 22295056 rs10829064 chr10 27072989 G T 6.64E-05 Acute lung injury ABI1 intron 22295056 rs10741118 chr10 27074012 C T 1.32E-04 Acute lung injury ABI1 intron 22295056 rs4463751 chr10 27085246 T C 8.73E-04 Type 2 diabetes ABI1 intron 17463246 rs4463751 chr10 27085246 T C 5.06E-04 Schizophrenia ABI1 intron 20832056 rs10829071 chr10 27101718 T C 1.14E-04 Acute lung injury ABI1 intron 22295056 rs4749185 chr10 27102668 C T 1.14E-04 Acute lung injury ABI1 intron 22295056 rs3916988 chr10 27102957 G A 8.33E-05 Acute lung injury ABI1 intron 22295056 rs2182293 chr10 27119082 C A 9.03E-05 Acute lung injury ABI1 intron 22295056 rs4376804 chr10 27131645 A G 9.19E-05 Acute lung injury ABI1 intron 22295056 rs140301952 chr10 27137334 A AC 1.02E-04 Acute lung injury ABI1 intron 22295056 rs16927348 chr10 27137334 A C 1.02E-04 Acute lung injury ABI1 intron 22295056 rs1409130 chr10 27143872 G C 1.26E-04 Acute lung injury ABI1 intron 22295056 rs1409128 chr10 27150093 G T 1.20E-04 Acute lung injury ABI1 nearGene-5 22295056 rs2031562 chr10 27150873 A G 1.16E-04 Acute lung injury ABI1 nearGene-5 22295056 rs1815323 chr10 27204531 T C 9.47E-04 Insulin resistance / / 21901158 rs12572726 chr10 27227681 A T 7.24E-04 Type 2 diabetes LINC00202 intron 17463246 rs12573020 chr10 27228421 T C 4.71E-04 Type 2 diabetes / / 17463246 rs7914382 chr10 27265641 C T 1.00E-04 Information processing speed / / 21130836 rs7911508 chr10 27277408 G A 1.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12779247 chr10 27290090 T C 7.44E-05 Body Composition / / pha003012 rs3781098 chr10 27304609 G T 2.82E-04 Multiple complex diseases ANKRD26 intron 17554300 rs4747583 chr10 27344697 T C 6.50E-05 Hypothyroidism ANKRD26 intron 22493691 rs11015508 chr10 27369987 A G 8.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ANKRD26 intron 20877124 rs10829174 chr10 27371647 T C 8.00E-05 Parkinson's disease (age of onset) ANKRD26 intron 19772629 rs2297145 chr10 27381349 T C 5.40E-04 Type 2 diabetes ANKRD26 cds-synon 17463246 rs6482596 chr10 27416747 T G 6.34E-08 Metabolite levels YME1L1 intron 23281178 rs7091723 chr10 27466165 C A 8.08E-05 Alcohol consumption MASTL intron pha001399 rs4749233 chr10 27467967 G A 7.76E-05 Intelligence MASTL intron 21826061 rs7918793 chr10 27497191 G A 2.96E-04 Multiple complex diseases ACBD5 missense 17554300 rs11812283 chr10 27532690 A G 4.18E-04 Multiple complex diseases / / 17554300 rs10829219 chr10 27560120 C T 2.55E-05 Pancreatic cancer / / pha002889 rs2483499 chr10 27569521 C T 8.78E-05 Stroke (ischemic) / / 22941190 rs2483499 chr10 27569521 C T 1.25E-05 Body Composition / / pha003012 rs2483499 chr10 27569521 C T 1.33E-05 Body Mass Index / / pha003021 rs572646 chr10 27632038 T A 4.27E-05 Multiple complex diseases / / 17554300 rs237566 chr10 27653762 G C 1.50E-05 Urinary metabolites / / 21572414 rs532473 chr10 27669655 G A 1.33E-04 Multiple complex diseases / / 17554300 rs525103 chr10 27675406 C T 1.05E-04 Multiple complex diseases / / 17554300 rs527914 chr10 27675704 G A 1.14E-04 Multiple complex diseases / / 17554300 rs506659 chr10 27678534 T C 9.77E-05 Common variable immunodeficiency / / 21497890 rs567829 chr10 27680581 G C 6.58E-05 Multiple complex diseases / / 17554300 rs490734 chr10 27681953 G T 5.52E-05 Multiple complex diseases / / 17554300 rs517060 chr10 27682489 T C 5.32E-05 Multiple complex diseases / / 17554300 rs615948 chr10 27682737 C T 5.13E-05 Multiple complex diseases / / 17554300 rs616814 chr10 27682911 A G 3.07E-04 Multiple complex diseases / / 17554300 rs579323 chr10 27683351 G A 8.56E-05 Multiple complex diseases / / 17554300 rs1762105 chr10 27683565 A C 8.03E-05 Multiple complex diseases / / 17554300 rs630295 chr10 27683616 T C 7.47E-05 Multiple complex diseases / / 17554300 rs2429490 chr10 27691271 C T 1.15E-04 Response to platinum-based chemotherapy in small-cell lung cancer PTCHD3 intron 20463552 rs2484180 chr10 27692279 A C,G 4.02E-04 Alzheimer's disease (late onset) PTCHD3 missense 21379329 rs1334893 chr10 27693305 G A 5.00E-06 Fasting insulin-related traits (interaction with BMI) PTCHD3 intron 22581228 rs2477341 chr10 27713525 A G 2.15E-04 Alzheimer's disease (late onset) / / 21379329 rs11015796 chr10 27745470 A G 6.57E-04 Type 2 diabetes / / 17463246 rs11015882 chr10 27861940 T C 1.70E-06 Urinary metabolites / / 21572414 rs4598563 chr10 27865573 A G 4.39E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2368246 chr10 27868459 A T 7.58E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs7069985 chr10 27890831 A G 9.98E-04 Type 2 diabetes / / 17463246 rs1908274 chr10 27906212 C T 4.19E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1908275 chr10 27906348 T C 5.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs980135 chr10 27908124 C G 3.25E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11015914 chr10 27911671 C A 5.01E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1494207 chr10 27912301 C T 4.91E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1687721 chr10 27944386 C T 3.67E-06 Waist-hip ratio / / 20935629 rs10508727 chr10 28025771 C T 3.27E-04 Body mass index MKX intron 17255346 rs10508727 chr10 28025771 C T 1.00E-10 Immune response to smallpox vaccine (IL-6) MKX intron 22542470 rs12355413 chr10 28120745 T C 4.39E-05 Serum metabolites ARMC4 intron 19043545 rs6481484 chr10 28123071 A C 5.90E-05 Serum metabolites ARMC4 intron 19043545 rs915175 chr10 28133687 C T 5.09E-04 Nicotine smoking ARMC4 intron 19268276 rs1889522 chr10 28142838 G A 5.47E-05 Serum metabolites ARMC4 intron 19043545 rs11006747 chr10 28150935 A C 8.00E-06 Obesity-related traits ARMC4 intron 23251661 rs2152019 chr10 28156285 T C 2.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARMC4 intron 20877124 rs16928376 chr10 28159133 C G 8.63E-04 Multiple complex diseases ARMC4 intron 17554300 rs12356262 chr10 28172558 C T 9.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) ARMC4 intron 23233662 rs1334719 chr10 28183423 A C 2.34E-04 Response to platinum-based chemotherapy in small-cell lung cancer ARMC4 intron 20463552 rs7897553 chr10 28201966 C T 6.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARMC4 intron 20877124 rs2297646 chr10 28225897 G T 2.34E-04 Response to platinum-based chemotherapy in small-cell lung cancer ARMC4 intron 20463552 rs1970631 chr10 28231735 G A 1.91E-04 Response to platinum-based chemotherapy in small-cell lung cancer ARMC4 intron 20463552 rs3802517 chr10 28233469 T A 5.57E-06 Response to platinum-based chemotherapy in small-cell lung cancer ARMC4 intron 20463552 rs11596400 chr10 28245420 A G 1.97E-04 Response to platinum-based chemotherapy in small-cell lung cancer ARMC4 intron 20463552 rs4405206 chr10 28260151 A G 1.53E-05 Soluble levels of adhesion molecules ARMC4 missense pha003072 rs12218330 chr10 28260543 A G 1.00E-04 Iris characteristics ARMC4 intron 21835309 rs12218330 chr10 28260543 A G 4.70E-05 Cognitive impairment induced by topiramate ARMC4 intron 22091778 rs12415087 chr10 28271283 A G 0.000348313 Hypertension (early onset hypertension) ARMC4 intron 22479346 rs10763636 chr10 28314473 C T 0.0000524 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10763637 chr10 28314843 G T 0.0000538 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7920857 chr10 28346035 G C 3.27E-04 Insulin resistance MPP7 intron 21901158 rs2252206 chr10 28347988 A G 0.000795 Salmonella-induced pyroptosis MPP7 intron 22837397 rs7909706 chr10 28353751 T C 6.30E-05 Response to platinum-based chemotherapy in small-cell lung cancer MPP7 intron 20463552 rs4749301 chr10 28373644 T C 5.80E-04 Alcohol dependence MPP7 intron 20201924 rs927675 chr10 28382933 A C 2.00E-06 MRI atrophy measures MPP7 intron 21116278 rs10763642 chr10 28388150 G A 7.00E-06 Obesity-related traits MPP7 intron 23251661 rs4749306 chr10 28391617 C G 1.49E-04 Response to platinum-based chemotherapy in small-cell lung cancer MPP7 intron 20463552 rs10826398 chr10 28393824 G T 9.81E-05 Multiple complex diseases MPP7 intron 17554300 rs10826398 chr10 28393824 G T 1.67E-05 Response to platinum-based chemotherapy in small-cell lung cancer MPP7 intron 20463552 rs12776665 chr10 28400835 C A 2.57E-06 Total ventricular volume MPP7 intron 21116278 rs2490062 chr10 28415164 A T 0.0000612 Nonsyndromic striae distensae (stretch marks) MPP7 intron 23633020 rs4317882 chr10 28424177 G A 7.51E-05 Response to platinum-based chemotherapy in small-cell lung cancer MPP7 intron 20463552 rs4506531 chr10 28432044 C G 9.96E-04 Type 2 diabetes MPP7 intron 17463246 rs4506531 chr10 28432044 C G 7.51E-05 Response to platinum-based chemotherapy in small-cell lung cancer MPP7 intron 20463552 rs147999424 chr10 28438930 G A 0.000038 Breast cancer (ER positive) MPP7 missense 23555315 rs9299597 chr10 28442841 G A 0.000634026 Hypertension (early onset hypertension) MPP7 intron 22479346 rs2985532 chr10 28446745 T C 0.0000556 Nonsyndromic striae distensae (stretch marks) MPP7 intron 23633020 rs7081378 chr10 28449974 G A 8.74E-04 Alzheimer's disease MPP7 intron 24755620 rs2985523 chr10 28450599 T G 3.16E-04 Response to platinum-based chemotherapy in small-cell lung cancer MPP7 intron 20463552 rs2985523 chr10 28450599 T G 0.0000632 Nonsyndromic striae distensae (stretch marks) MPP7 intron 23633020 rs12254584 chr10 28451249 C A 4.04E-04 Alzheimer's disease MPP7 intron 24755620 rs2985522 chr10 28451289 T C 0.0000343 Nonsyndromic striae distensae (stretch marks) MPP7 intron 23633020 rs1626856 chr10 28451524 T A 0.0000665 Nonsyndromic striae distensae (stretch marks) MPP7 intron 23633020 rs1781832 chr10 28452867 T C 0.0000677 Nonsyndromic striae distensae (stretch marks) MPP7 intron 23633020 rs2763316 chr10 28453046 A G 0.0000684 Nonsyndromic striae distensae (stretch marks) MPP7 intron 23633020 rs1781833 chr10 28453145 G C 0.0000685 Nonsyndromic striae distensae (stretch marks) MPP7 intron 23633020 rs1781834 chr10 28453225 T C 0.0000684 Nonsyndromic striae distensae (stretch marks) MPP7 intron 23633020 rs1781835 chr10 28453354 T C 0.0000684 Nonsyndromic striae distensae (stretch marks) MPP7 intron 23633020 rs1748484 chr10 28453677 T A 0.000074 Nonsyndromic striae distensae (stretch marks) MPP7 intron 23633020 rs2801843 chr10 28453966 A C,G,T 0.0000895 Nonsyndromic striae distensae (stretch marks) MPP7 intron 23633020 rs2801844 chr10 28453981 G T 0.0000688 Nonsyndromic striae distensae (stretch marks) MPP7 intron 23633020 rs2801845 chr10 28454152 A T 8.20E-04 Multiple complex diseases MPP7 intron 17554300 rs7085245 chr10 28454533 T G 3.52E-04 Alzheimer's disease MPP7 intron 24755620 rs7101051 chr10 28454570 C A 9.33E-04 Alzheimer's disease MPP7 intron 24755620 rs2985517 chr10 28455529 T C 0.0000673 Nonsyndromic striae distensae (stretch marks) MPP7 intron 23633020 rs2887214 chr10 28462933 T A 3.55E-04 Multiple complex diseases MPP7 intron 17554300 rs7914949 chr10 28466013 T C 2.00E-04 Multiple complex diseases MPP7 intron 17554300 rs35494924 chr10 28466881 T C 2.68E-06 Bone mineral density MPP7 intron 24249740 rs11006913 chr10 28470732 A G 6.39E-05 Response to platinum-based chemotherapy in small-cell lung cancer MPP7 intron 20463552 rs2985535 chr10 28475495 C T 2.75E-04 Response to platinum-based chemotherapy in small-cell lung cancer MPP7 intron 20463552 rs1937809 chr10 28476148 C T 3.36E-04 Type 2 diabetes MPP7 intron 17463246 rs1937809 chr10 28476148 C T 2.75E-04 Response to platinum-based chemotherapy in small-cell lung cancer MPP7 intron 20463552 rs3905706 chr10 28479942 C T 2.00E-16 Bone mineral density MPP7 intron 22504420 rs3905706 chr10 28479942 C T 8.00E-06 Bone mineral density MPP7 intron 24249740 rs3905706 chr10 28479942 C T 2.93E-06 Bone mineral density (paediatric,skull) MPP7 intron 24945404 rs3905706 chr10 28479942 C T 3.00E-06 Bone mineral density (paediatric,skull) MPP7 intron 24945404 rs7922685 chr10 28489647 C G 1.02E-04 Response to platinum-based chemotherapy in small-cell lung cancer MPP7 intron 20463552 rs11006923 chr10 28504944 T C 9.00E-06 Alzheimer's disease MPP7 intron 22005930 rs11006928 chr10 28514249 A T 1.04E-05 Alzheimer's disease MPP7 intron 22005930 rs17831816 chr10 28515799 G A 9.19E-06 Alzheimer's disease MPP7 intron 22005930 rs11006950 chr10 28540477 C G 1.02E-04 Alzheimer's disease MPP7 intron 22005930 rs1870097 chr10 28541472 T C 8.31E-04 Response to statin treatment (atorvastatin),change in cholesterol levels MPP7 intron 20031582 rs11006958 chr10 28544070 A C 1.32E-05 Alzheimer's disease MPP7 intron 22005930 rs7086943 chr10 28560451 T C 6.14E-04 Insulin resistance MPP7 intron 21901158 rs7905490 chr10 28567807 C T 3.22E-04 Acute lung injury MPP7 intron 22295056 rs10826442 chr10 28576515 T G 1.86E-04 Acute lung injury / / 22295056 rs3936496 chr10 28579751 C T 1.92E-04 Acute lung injury / / 22295056 rs3936497 chr10 28579969 A G 1.87E-04 Multiple complex diseases / / 17554300 rs3936497 chr10 28579969 A G 1.38E-04 Acute lung injury / / 22295056 rs3936497 chr10 28579969 A G 0.0000634 Uterine leiomyomata / / 23040493 rs3936499 chr10 28580010 A C 8.76E-05 Acute lung injury / / 22295056 rs11006992 chr10 28582697 G C 3.85E-04 Alzheimer's disease / / 22005930 rs11006993 chr10 28582881 G C 1.69E-05 Alzheimer's disease / / 22005930 rs11006995 chr10 28585496 C T 3.23E-04 Alzheimer's disease / / 22005930 rs10826445 chr10 28589942 G A 3.33E-04 Alzheimer's disease / / 22005930 rs11007003 chr10 28597308 A C 1.98E-04 Multiple complex diseases / / 17554300 rs786399 chr10 28605526 A G 3.20E-04 Iron levels / / pha002876 rs1148186 chr10 28617635 C G 7.00E-06 Pulmonary function decline / / 22424883 rs1676780 chr10 28617810 T C 2.70E-07 Platelet aggregation(pre- and post-aspirin) / / 20529293 rs1776122 chr10 28633217 C T 3.10E-07 Platelet aggregation(pre- and post-aspirin) / / 20529293 rs1626487 chr10 28634770 A G 2.62E-04 Coronary Artery Disease / / 17634449 rs11007107 chr10 28722502 G A 5.00E-05 Bipolar disorder,affective / / 20528957 rs7085106 chr10 28734355 C T 1.70E-05 Alcohol and nictotine co-dependence / / 20158304 rs7085106 chr10 28734355 C T 5.94E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs7085106 chr10 28734355 C T 5.52E-05 HDL cholesterol / / pha003075 rs16928895 chr10 28734655 C T 2.79E-04 Type 2 diabetes / / 17463246 rs2807753 chr10 28748532 T C 3.99E-04 Type 2 diabetes / / 17463246 rs12762979 chr10 28748824 G A 4.59E-05 Chronic obstructive pulmonary disease / / 19300482 rs2153299 chr10 28752106 T C 3.00E-06 Obesity-related traits / / 23251661 rs332139 chr10 28859079 C T 8.22E-04 Response to statin treatment (atorvastatin),change in cholesterol levels WAC intron 20031582 rs624032 chr10 28958376 T C 6.01E-05 Parkinson's disease / / 21738487 rs663378 chr10 28975214 G A 4.40E-04 Intelligence (childhood) / / 23358156 rs17832466 chr10 28975522 C T 6.70E-05 White matter hyperintensity burden / / 21681796 rs11592762 chr10 28994376 T C 1.50E-05 White matter hyperintensity burden / / 21681796 rs12569910 chr10 28995563 A G 4.40E-05 White matter hyperintensity burden / / 21681796 rs12569910 chr10 28995563 A G 1.60E-05 Height / / pha003010 rs12772296 chr10 28995651 A T 1.80E-05 White matter hyperintensity burden / / 21681796 rs117783414 chr10 29005814 C T 4.17E-04 Telomere length / / 24478790 rs10826503 chr10 29010588 C T 1.38E-04 Vaspin levels / / 22907691 rs10826503 chr10 29010588 C T 0.0001378 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs1360761 chr10 29011821 C T 2.21E-04 Vaspin levels / / 22907691 rs1360761 chr10 29011821 C T 0.0002206 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs1762004 chr10 29015323 C T 2.00E-05 Cognitive performance / / 19734545 rs1248993 chr10 29027223 A G 6.00E-06 Preeclampsia / / 23551011 rs11007230 chr10 29043820 G A 3.14E-04 Multiple complex diseases / / 17554300 rs17692054 chr10 29052912 C T 5.84E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs787111 chr10 29056628 C A 3.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs1334750 chr10 29085551 G T 2.44E-05 Lung adenocarcinoma / / 19836008 rs1334750 chr10 29085551 G T 2.60E-05 Bipolar disorder / / 20451256 rs2797463 chr10 29086106 A G 2.28E-05 Lung adenocarcinoma / / 19836008 rs787112 chr10 29089970 C T 9.31E-05 Bipolar disorder / / 20451256 rs7910778 chr10 29091958 T A 8.70E-04 Type 2 diabetes / / 17463246 rs4747633 chr10 29156072 A G 1.00E-04 Prostate cancer / / 21743057 rs1775929 chr10 29159348 G T 2.69E-05 HIV-1 progression / / 20064070 rs7088136 chr10 29159490 G A 1.00E-04 Prostate cancer / / 21743057 rs1691946 chr10 29160457 T G 1.70E-05 HIV-1 progression / / 20064070 rs1691943 chr10 29160836 A G 2.69E-05 HIV-1 progression / / 20064070 rs1775933 chr10 29160876 A G 3.10E-05 HIV-1 progression / / 20064070 rs1495673 chr10 29204927 C A 1.90E-05 Major depressive disorder / / 21042317 rs10508741 chr10 29252309 T A,C,G 7.90E-04 Major depressive disorder / / 21042317 rs12765463 chr10 29260154 C T 7.70E-04 Depression (quantitative trait) / / 20800221 rs788063 chr10 29261497 A G 1.06E-04 Telomere length / / 23900074 rs12768785 chr10 29264304 A G 7.40E-04 Depression (quantitative trait) / / 20800221 rs11007347 chr10 29286539 A T 3.17E-05 Major depressive disorder (broad) / / 20038947 rs11007350 chr10 29289031 C T 3.00E-06 Cannabis dependence / / 21668797 rs6481557 chr10 29290203 A G 7.63E-05 Major depressive disorder (broad) / / 20038947 rs2250970 chr10 29290352 C T 7.30E-05 Major depressive disorder (broad) / / 20038947 rs1773860 chr10 29291556 C T 1.42E-05 Major depressive disorder (broad) / / 20038947 rs1773860 chr10 29291556 C T 8.73E-05 Major depressive disorder / / 22472876 rs1612122 chr10 29291898 A T 7.00E-06 Major depressive disorder (broad) / / 20038947 rs11007381 chr10 29310947 T C 4.06E-05 Multiple complex diseases / / 17554300 rs2887372 chr10 29316537 A G 3.88E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs2368950 chr10 29316770 A G 3.80E-04 Depression (quantitative trait) / / 20800221 rs11007409 chr10 29328462 C T 8.00E-05 Coffee consumption / / 21357676 rs788076 chr10 29336849 G A 2.00E-06 Palmitoleic acid (16:1n-7) plasma levels / / 23362303 rs4749381 chr10 29342810 A G 7.53E-04 Type 2 diabetes / / 17463246 rs1773842 chr10 29349286 G A 9.32E-05 Ulcerative colitis / / 19915573 rs12767581 chr10 29357507 A G 6.01E-04 HIV-1 viral setpoint / / 17641165 rs7073795 chr10 29360636 T C 4.88E-04 HIV-1 viral setpoint / / 17641165 rs2211055 chr10 29363556 G A 6.76E-04 HIV-1 viral setpoint / / 17641165 rs10826566 chr10 29364697 G A 4.00E-06 Migraine with aura / / 23793025 rs530410 chr10 29370022 A G 8.20E-06 HDL cholesterol / / pha003074 rs1338541 chr10 29378718 C T 5.99E-04 HIV-1 viral setpoint / / 17641165 rs12243277 chr10 29421591 G A 4.53E-04 Multiple complex diseases / / 17554300 rs10508742 chr10 29424176 G T 3.42E-04 Hearing function / / 17255346 rs478229 chr10 29434036 A G 2.65E-04 Hearing function / / 17255346 rs486397 chr10 29457157 G A 9.86E-05 Glycosylated haemoglobin levels / / 17255346 rs571678 chr10 29470909 C T 1.51E-04 Multiple complex diseases / / 17554300 rs4387258 chr10 29487365 G A 4.00E-06 Methotrexate phramacokinetics (acute lymphoblastic leukemia) / / 19901119 rs575156 chr10 29498209 C T 3.49E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs887339 chr10 29505124 T C 0.0000108 5-fluorouracil induced diarrhoea in response to colorectal cancer treatment / / 22310351 rs7094704 chr10 29509590 G T 2.73E-04 HIV-1 viral setpoint / / 17641165 rs2532774 chr10 29512320 T G 9.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs2796304 chr10 29565983 C A 3.65E-05 Attention deficit hyperactivity disorder / / 20732627 rs2817837 chr10 29605338 G A 2.00E-04 Information processing speed / / 21130836 rs16930174 chr10 29615116 A G 8.11E-06 Spine bone size / / 23207799 rs789920 chr10 29628094 C T 7.87E-07 Gaucher disease severity / / 22388998 rs17222441 chr10 29630311 A G 4.55E-04 Insulin resistance / / 21901158 rs7094201 chr10 29632242 A G 5.26E-05 Body Mass Index / / pha003014 rs12220989 chr10 29659521 C A 6.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2796337 chr10 29661144 C T 4.02E-04 Multiple complex diseases / / 17554300 rs2368416 chr10 29696985 T C 7.02E-05 Vaspin levels / / 22907691 rs7096194 chr10 29768353 C G 8.94E-04 Response to taxane treatment (placlitaxel) SVIL intron 23006423 rs10826649 chr10 29792539 C A 0.00000238 Platelet thrombus as measured by PFA-100ColA closure time upon shear stress SVIL intron 22550155 rs2505914 chr10 29800484 A T 6.13E-04 Multiple complex diseases SVIL intron 17554300 rs7910521 chr10 29803661 C T 0.00000183 Platelet thrombus as measured by PFA-100ColA closure time upon shear stress SVIL intron 22550155 rs7070678 chr10 29812602 G T 3.58E-08 Platelet thrombus as measured by PFA-100ColA closure time upon shear stress SVIL cds-synon 22550155 rs10826650 chr10 29814284 T C 4.43E-08 Platelet thrombus as measured by PFA-100ColA closure time upon shear stress SVIL intron 22550155 rs10160013 chr10 29839787 A G 6.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SVIL missense 20877124 rs1270874 chr10 29839864 A C 1.40E-04 Type 2 diabetes SVIL cds-synon 17463248 rs3740002 chr10 29840164 A G 5.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SVIL cds-synon 20877124 rs7919539 chr10 29856023 G A 6.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SVIL intron 20877124 rs7919539 chr10 29856023 G A 8.30E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SVIL intron 20877124 rs7919539 chr10 29856023 G A 3.62E-05 Height SVIL intron pha003011 rs7903861 chr10 29864741 A G 4.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SVIL intron 20877124 rs7903861 chr10 29864741 A G 6.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SVIL intron 20877124 rs7079620 chr10 29871949 G A 9.86E-04 Alcohol dependence SVIL intron 21314694 rs2368369 chr10 29874502 A C 6.80E-05 Height SVIL intron pha003011 rs4572039 chr10 29874633 G A 7.77E-05 Height SVIL intron pha003011 rs2488683 chr10 29889249 C G 4.30E-07 Urinary metabolites SVIL intron 21572414 rs2488682 chr10 29889441 A G 3.00E-07 Urinary metabolites SVIL intron 21572414 rs2505900 chr10 29890267 C A 2.10E-07 Urinary metabolites SVIL intron 21572414 rs2505903 chr10 29892296 T C 2.90E-06 Cognitive impairment induced by topiramate SVIL intron 22091778 rs2488676 chr10 29892525 A T 7.20E-07 Urinary metabolites SVIL intron 21572414 rs2505905 chr10 29893504 T C 1.80E-06 Urinary metabolites SVIL intron 21572414 rs7904156 chr10 29902184 C A 1.41E-06 Diabetes Mellitus SVIL intron pha003060 rs1777329 chr10 29911568 G A 6.54E-09 Diabetes Mellitus SVIL intron pha003060 rs1777331 chr10 29917503 A G 6.54E-09 Diabetes Mellitus SVIL intron pha003060 rs12412148 chr10 29938853 G A 2.86E-05 F-cell distribution SVIL intron 21326311 rs3858235 chr10 29973953 G T 0.000400424 Hypertension (early onset hypertension) SVIL intron 22479346 rs3847395 chr10 29974097 G A 0.000315422 Hypertension (early onset hypertension) SVIL intron 22479346 rs17294599 chr10 29975117 G T 7.18E-06 Diabetes Mellitus SVIL intron pha003060 rs1777334 chr10 29993344 T C 9.47E-04 Alzheimer's disease SVIL intron 17998437 rs7898486 chr10 30001433 A G 8.54E-04 Response to cytidine analogues (gemcitabine) SVIL intron 24483146 rs1927457 chr10 30008663 T C 8.00E-06 Normalized brain volume SVIL intron 19010793 rs11007712 chr10 30009340 A G 1.60E-06 Soluble levels of adhesion molecules SVIL intron pha003072 rs7100022 chr10 30011958 A G 3.20E-05 Diabetic retinopathy SVIL intron 21441570 rs12264622 chr10 30019642 G A 1.93E-04 Multiple complex diseases SVIL intron 17554300 rs2096249 chr10 30054255 G A 3.69E-04 Type 2 diabetes / / 17463246 rs10763757 chr10 30079533 C T 0.0000957 Carotid intima media thickness / / 23152477 rs2986961 chr10 30087359 C T 5.00E-07 Migraine with aura / / 23793025 rs2986971 chr10 30096628 A G 3.00E-06 Non-alcoholic fatty liver disease histology (lobular) / / 20708005 rs2986974 chr10 30099778 A G 9.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs7920851 chr10 30111971 G A 5.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs11007764 chr10 30116104 C G 3.44E-06 Asthma (childhood onset) / / 23829686 rs1929239 chr10 30124617 G A 9.62E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1109609 chr10 30170992 T C 2.98E-04 Cholesterol / / 17255346 rs3006564 chr10 30177888 T C 5.00E-06 Orofacial clefts / / 22419666 rs2989426 chr10 30188995 C T 8.00E-06 Urinary metabolites / / 21572414 rs2989426 chr10 30188995 C T 3.16E-05 Orofacial clefts / / 22419666 rs2989430 chr10 30194164 G A 3.53E-05 Orofacial clefts / / 22419666 rs1610357 chr10 30194393 T G 2.46E-05 Orofacial clefts / / 22419666 rs1573027 chr10 30201353 A G 2.10E-05 Urinary metabolites / / 21572414 rs1573027 chr10 30201353 A G 2.49E-05 Orofacial clefts / / 22419666 rs2989436 chr10 30207593 C T 5.43E-04 Coronary Artery Disease / / 17634449 rs11007809 chr10 30209706 C T 5.61E-04 Multiple complex diseases / / 17554300 rs2776632 chr10 30212755 A G 5.85E-05 Schizophrenia / / 19571811 rs1246758 chr10 30214703 C A 5.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs10826731 chr10 30215448 T C 1.38E-05 Post-operative nausea and vomiting / / 21694509 rs11007812 chr10 30215811 C T 5.18E-06 Common variable immunodeficiency / / 21497890 rs2776630 chr10 30216397 T C 7.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs1270449 chr10 30216662 C T 7.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs1774234 chr10 30217515 C T 1.69E-05 Intelligence / / 21826061 rs11007820 chr10 30222053 A G 6.37E-04 Multiple complex diseases / / 17554300 rs7078452 chr10 30230765 C T 5.19E-05 Breast cancer / / 21060860 rs10508754 chr10 30246742 G A 0.0007572 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10508754 chr10 30246742 G A 7.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2795623 chr10 30250437 A G 9.40E-06 White blood cell count / / 21738479 rs10508752 chr10 30253972 T G 4.33E-04 Diabetic retinopathy / / 20871662 rs11007836 chr10 30264550 G A 5.33E-05 Multiple complex diseases / / 17554300 rs10826745 chr10 30277487 G A 8.51E-05 Post-operative nausea and vomiting / / 21694509 rs12779954 chr10 30292293 A T 5.63E-04 Suicide attempts in bipolar disorder / / 21041247 rs12780390 chr10 30292474 C T 5.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs11007851 chr10 30292597 C T 8.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11007851 chr10 30292597 C T 6.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs4749520 chr10 30296358 G A 8.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs1418276 chr10 30297987 T C 8.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs1418278 chr10 30298078 A G 8.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs10826749 chr10 30298522 T C 8.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs3739998 chr10 30316072 C G 1.00E-11 Coronary heart disease KIAA1462 missense 21088011 rs7920682 chr10 30317826 A G 1.44E-04 Coronary heart disease KIAA1462 cds-synon 21378990 rs2487928 chr10 30323892 G A 8.98E-04 Coronary Artery Disease KIAA1462 intron 17634449 rs10826753 chr10 30326776 C T 7.72E-04 Depression (quantitative trait) KIAA1462 intron 20800221 rs2505083 chr10 30335122 T C 4.00E-08 Coronary heart disease KIAA1462 intron 21378988 rs2505083 chr10 30335122 T C 0.00000191 Coronary artery disease (CAD) age >50 KIAA1462 intron 23202125 rs2505083 chr10 30335122 T C 0.00000574 Coronary artery disease (CAD) age <=50 KIAA1462 intron 23202125 rs2505083 chr10 30335122 T C 0.000214 Coronary artery disease with myocardial infarction KIAA1462 intron 23202125 rs2505083 chr10 30335122 T C 4.16E-08 Coronary artery disease (CAD) (males) KIAA1462 intron 23202125 rs2505083 chr10 30335122 T C 4.97E-12 Coronary artery disease KIAA1462 intron 23202125 rs2505083 chr10 30335122 T C 2.40E-05 Coronary artery disease KIAA1462 intron 24262325 rs72810797 chr10 30336672 C T 0.00015 Breast cancer (ER positive) KIAA1462 missense 23555315 rs2255515 chr10 30355193 A G 1.98E-05 Odorant perception / / 23910658 rs2478830 chr10 30366521 C A 9.87E-05 Coronary heart disease / / pha003031 rs3847404 chr10 30389213 C T 3.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs3847404 chr10 30389213 C T 5.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs7915293 chr10 30394177 A G 6.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs17295031 chr10 30397456 A G 7.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs17295031 chr10 30397456 A G 8.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs12220219 chr10 30397839 T C 7.48E-04 Suicide attempts in bipolar disorder / / 21041247 rs12220246 chr10 30398119 T C 7.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs2505115 chr10 30398791 T G 1.83E-06 Recombination rate / / 21698098 rs12243598 chr10 30400471 A G 6.96E-04 Insulin resistance / / 21901158 rs2505089 chr10 30405405 A C 5.92E-06 Recombination rate / / 21698098 rs10826765 chr10 30407984 T C 2.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2478836 chr10 30414750 T C 1.99E-04 Multiple complex diseases / / 17554300 rs3121293 chr10 30420194 G A 4.29E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11007912 chr10 30421289 G C 6.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs11007913 chr10 30423885 G A 3.71E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11007913 chr10 30423885 G A 6.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs7896890 chr10 30430477 C T 6.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs10508745 chr10 30430806 T C 6.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs3004184 chr10 30435492 G A 1.40E-11 Metabolite levels / / 22286219 rs2488034 chr10 30454233 A G 3.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs2488034 chr10 30454233 A G 3.74E-05 Suicide attempts in bipolar disorder / / 21041247 rs2488035 chr10 30457133 A C 2.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs2488035 chr10 30457133 A C 3.26E-05 Suicide attempts in bipolar disorder / / 21041247 rs2482828 chr10 30460206 A G 2.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs2482828 chr10 30460206 A G 3.29E-05 Suicide attempts in bipolar disorder / / 21041247 rs2488003 chr10 30467805 G A 1.56E-05 Suicide attempts in bipolar disorder / / 21041247 rs2488003 chr10 30467805 G A 1.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs2505109 chr10 30468505 T C 3.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs2505109 chr10 30468505 T C 3.56E-05 Suicide attempts in bipolar disorder / / 21041247 rs1571957 chr10 30469934 C T 4.14E-05 Suicide attempts in bipolar disorder / / 21041247 rs1571957 chr10 30469934 C T 4.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs473195 chr10 30470826 C T 1.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs473195 chr10 30470826 C T 5.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs2505110 chr10 30470900 A G 3.46E-05 Suicide attempts in bipolar disorder / / 21041247 rs2505110 chr10 30470900 A G 4.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs2795857 chr10 30472064 C G 3.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs2795857 chr10 30472064 C G 4.85E-05 Suicide attempts in bipolar disorder / / 21041247 rs2795858 chr10 30472203 G A 2.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs2795858 chr10 30472203 G A 3.41E-05 Suicide attempts in bipolar disorder / / 21041247 rs1977583 chr10 30472392 A G 2.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs1977583 chr10 30472392 A G 3.42E-05 Suicide attempts in bipolar disorder / / 21041247 rs2798907 chr10 30472773 G A 2.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs2798907 chr10 30472773 G A 3.54E-05 Suicide attempts in bipolar disorder / / 21041247 rs2795859 chr10 30474487 T C 2.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs2795859 chr10 30474487 T C 4.28E-05 Suicide attempts in bipolar disorder / / 21041247 rs2798906 chr10 30474586 A G 2.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs2798906 chr10 30474586 A G 4.27E-05 Suicide attempts in bipolar disorder / / 21041247 rs2798920 chr10 30475643 A G 2.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs2798920 chr10 30475643 A G 4.86E-05 Suicide attempts in bipolar disorder / / 21041247 rs576505 chr10 30476606 T C 2.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs576505 chr10 30476606 T C 8.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs2505112 chr10 30477204 C T 1.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs2505112 chr10 30477204 C T 5.43E-05 Suicide attempts in bipolar disorder / / 21041247 rs2482824 chr10 30477775 T C 1.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs2482824 chr10 30477775 T C 3.51E-05 Suicide attempts in bipolar disorder / / 21041247 rs6481661 chr10 30480519 C T 1.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs6481661 chr10 30480519 C T 5.75E-04 Suicide attempts in bipolar disorder / / 21041247 rs11007929 chr10 30486784 C T 1.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs11007929 chr10 30486784 C T 5.95E-04 Suicide attempts in bipolar disorder / / 21041247 rs1360550 chr10 30487760 G A 8.49E-05 Suicide attempts in bipolar disorder / / 21041247 rs1360550 chr10 30487760 G A 8.95E-06 Suicide attempts in bipolar disorder / / 21041247 rs2462021 chr10 30490704 C T 8.30E-06 Suicide attempts in bipolar disorder / / 21041247 rs2462021 chr10 30490704 C T 9.06E-05 Suicide attempts in bipolar disorder / / 21041247 rs2488010 chr10 30491407 A G 1.00E-05 Suicide attempts in bipolar disorder / / 21041247 rs2488010 chr10 30491407 A G 1.37E-04 Suicide attempts in bipolar disorder / / 21041247 rs2151114 chr10 30492605 G A 1.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs2151114 chr10 30492605 G A 7.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs10826770 chr10 30495051 A G 1.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs10826770 chr10 30495051 A G 7.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs503598 chr10 30496125 G A 1.04E-05 Suicide attempts in bipolar disorder / / 21041247 rs503598 chr10 30496125 G A 1.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs560559 chr10 30497350 G A 1.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs560559 chr10 30497350 G A 6.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs2795863 chr10 30500267 G A 2.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs2795863 chr10 30500267 G A 2.54E-05 Suicide attempts in bipolar disorder / / 21041247 rs616881 chr10 30500418 G A 7.46E-04 Multiple complex diseases / / 17554300 rs2779068 chr10 30503579 G T 3.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs2779068 chr10 30503579 G T 4.93E-05 Suicide attempts in bipolar disorder / / 21041247 rs2689216 chr10 30503955 G A 3.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs2689216 chr10 30503955 G A 5.21E-05 Suicide attempts in bipolar disorder / / 21041247 rs2995271 chr10 30519832 C T 8.00E-07 Pancreatitis / / 23143602 rs10763777 chr10 30589393 G T 8.88E-04 Coronary Artery Disease / / 17634449 rs2480296 chr10 30609810 T G 8.75E-04 Taste perception MTPAP intron 22132133 rs11008005 chr10 30639220 A G 7.19E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) MTPAP nearGene-5 23648065 rs2484290 chr10 30650941 T C 0.000445647 Hypertension (early onset hypertension) / / 22479346 rs2489857 chr10 30651481 A G 5.90E-04 Taste perception / / 22132133 rs10826795 chr10 30661341 T G 3.62E-04 Amyotrophic lateral sclerosis (sporadic) LOC729668 intron 24529757 rs111797426 chr10 30662555 T C 2.20E-11 Metabolite levels LOC729668 intron 22286219 rs7917535 chr10 30676016 G A 3.68E-04 Multiple complex diseases / / 17554300 rs1042058 chr10 30728101 T C 6.00E-11 Inflammatory bowel disease MAP3K8 cds-synon 23128233 rs303436 chr10 30731893 C A 8.81E-04 Parkinson's disease MAP3K8 intron 17052657 rs303436 chr10 30731893 C A 7.33E-04 Type 2 diabetes MAP3K8 intron 17846125 rs8177029 chr10 30748498 T C 3.41E-04 Type 2 diabetes MAP3K8 intron 17463246 rs619864 chr10 30750950 C T 8.68E-05 Hematocrit MAP3K8 nearGene-3 pha003097 rs3124199 chr10 30789588 T C 2.00E-04 HIV(mother-to-child transmission) / / 20487506 rs3118600 chr10 30791330 T G 9.65E-04 Alzheimer's disease / / 17998437 rs728975 chr10 30792776 A G 2.98E-04 Alzheimer's disease / / 17998437 rs16931583 chr10 30795848 A G 7.67E-04 Multiple complex diseases / / 17554300 rs6481686 chr10 30798642 G C 3.82E-04 Multiple complex diseases / / 17554300 rs7905629 chr10 30816383 A G 9.68E-04 Acute lung injury / / 22295056 rs16931597 chr10 30821312 G A 9.99E-04 Insulin resistance / / 21901158 rs7922109 chr10 30830220 C A 5.13E-04 Insulin resistance / / 21901158 rs7921998 chr10 30830248 A G 5.37E-06 Multiple complex diseases / / 17554300 rs3124177 chr10 30830475 C G 3.24E-05 Bipolar disorder / / 19488044 rs3124177 chr10 30830475 C G 2.70E-05 Bipolar Disorder / / pha002863 rs12251865 chr10 30833410 G A 1.22E-04 Insulin resistance / / 21901158 rs11008099 chr10 30834632 G A 9.00E-06 QT interval / / 23166209 rs10763801 chr10 30848725 C A 6.87E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11008110 chr10 30849466 T A 5.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1567101 chr10 30861083 T C 4.42E-04 Insulin resistance / / 21901158 rs7092615 chr10 30862180 T C 8.38E-04 Insulin resistance / / 21901158 rs366620 chr10 30898870 C T 7.30E-04 Multiple complex diseases / / 17554300 rs7087001 chr10 30899705 G T 9.55E-04 Insulin resistance / / 21901158 rs2814637 chr10 30902048 A G 1.26E-04 Multiple complex diseases LYZL2 intron 17554300 rs1506784 chr10 30909900 G T 2.70E-04 Primary sclerosing cholangitis LYZL2 intron 19944697 rs399593 chr10 30912030 G T 9.00E-09 Dental caries LYZL2 intron 23064961 rs113331708 chr10 30929975 C T 0.00002012 Sarcoidosis / / 22952805 rs113251490 chr10 30931652 A T 0.00001163 Sarcoidosis / / 22952805 rs151026869 chr10 30936041 A C,G 0.00002675 Sarcoidosis / / 22952805 rs3104001 chr10 30937904 G A 1.04E-04 Myopia (pathological) / / 21095009 rs11008171 chr10 30965085 G A 7.96E-05 Age-related macular degeneration / / pha002890 rs16930258 chr10 30997507 G C 1.57E-04 Sarcoidosis / / 19165924 rs7910154 chr10 31000393 A G 2.17E-04 Type 2 diabetes / / 17463246 rs10763821 chr10 31000901 G A 1.75E-04 Type 2 diabetes / / 17463246 rs12217435 chr10 31014074 C G 1.44E-04 Breast cancer / / 21060860 rs1494134 chr10 31017872 C T 5.69E-04 Type 2 diabetes / / 17463246 rs2047142 chr10 31024081 A C 5.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7916670 chr10 31086001 T C 9.90E-04 Multiple complex diseases / / 17554300 rs12098549 chr10 31113477 C T 9.86E-06 Height / / 22021425 rs2994652 chr10 31124111 G A 8.31E-04 Alzheimer's disease / / 22005930 rs2994654 chr10 31125306 T A 3.09E-04 Multiple complex diseases / / 17554300 rs11008285 chr10 31130983 T G 7.95E-04 Parkinson's disease / / 17052657 rs7475857 chr10 31186791 G A 5.67E-04 Multiple complex diseases ZNF438 intron 17554300 rs7915093 chr10 31215977 T C 1.04E-04 Multiple complex diseases ZNF438 intron 17554300 rs1771645 chr10 31314469 G T 1.76E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) ZNF438 intron 17982456 rs12572002 chr10 31365828 G A 3.26E-04 Multiple complex diseases / / 17554300 rs2994684 chr10 31366271 T C 3.00E-07 Response to antipsychotic treatment / / 20195266 rs947113 chr10 31375355 T G 2.72E-05 Personality dimensions / / 22628180 rs2793108 chr10 31379105 C T 2.03E-05 Personality dimensions / / 22628180 rs2793109 chr10 31379846 T A 1.47E-06 Personality dimensions / / 22628180 rs793096 chr10 31385449 C T 6.22E-04 Multiple complex diseases / / 17554300 rs793096 chr10 31385449 C T 2.52E-05 Personality dimensions / / 22628180 rs793094 chr10 31386822 G A 2.21E-05 Personality dimensions / / 22628180 rs7080444 chr10 31388250 C T 8.36E-04 Renal cell carcinoma / / 22010048 rs867991 chr10 31389265 T G 6.36E-06 Personality dimensions / / 22628180 rs867992 chr10 31389313 A T 6.36E-06 Personality dimensions / / 22628180 rs2066250 chr10 31412936 C A 9.36E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2066250 chr10 31412936 C A 1.30E-04 Multiple complex diseases / / 17554300 rs793108 chr10 31415106 C T 3.00E-06 Multiple sclerosis / / 21833088 rs793108 chr10 31415106 C T 1.29E-04 Renal cell carcinoma / / 22010048 rs793108 chr10 31415106 C T 1.00E-09 Rheumatoid arthritis / / 24390342 rs793108 chr10 31415106 C T 4.40E-04 Rheumatoid arthritis / / 24390342 rs793108 chr10 31415106 C T 6.00E-07 Rheumatoid arthritis / / 24390342 rs2994673 chr10 31418052 T A 5.36E-04 Multiple complex diseases / / 17554300 rs1340991 chr10 31418463 A G 6.45E-04 Renal cell carcinoma / / 22010048 rs1771641 chr10 31434499 T C 1.01E-04 Multiple complex diseases / / 17554300 rs7903482 chr10 31458151 C T 1.13E-04 Aortic root size / / 21223598 rs1764437 chr10 31475114 C T 3.66E-05 Height / / pha003010 rs1250307 chr10 31495974 G A 4.00E-06 Disc degeneration (lumbar) / / 22993228 rs2484992 chr10 31512098 T C 5.00E-06 Disc degeneration (lumbar) / / 22993228 rs2484990 chr10 31515132 T C 4.00E-06 Disc degeneration (lumbar) / / 22993228 rs3123688 chr10 31528802 T G 9.05E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs1314014 chr10 31565621 A G 4.85E-09 Narcolepsy / / 19629137 rs16932309 chr10 31580605 C A 6.91E-04 Alcohol dependence / / 21314694 rs7894459 chr10 31611256 C T 7.83E-05 Asthma ZEB1 intron 23181788 rs2839657 chr10 31655768 C T 5.23E-05 Colorectal cancer ZEB1 intron 19723657 rs11812734 chr10 31673851 G A 1.95E-05 Multiple complex diseases ZEB1 intron 17554300 rs141194628 chr10 31810679 A G 0.00013 Prostate cancer (advanced) ZEB1 missense 23555315 rs10490929 chr10 31816596 C T 5.23E-05 Multiple complex diseases ZEB1 UTR-3 17554300 rs10826967 chr10 31862850 C T 9.21E-04 Multiple complex diseases / / 17554300 rs11008538 chr10 31886634 G C 4.47E-04 Multiple complex diseases / / 17554300 rs11008540 chr10 31894818 C T 5.48E-04 Multiple complex diseases / / 17554300 rs7909221 chr10 31902801 G A 8.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs703068 chr10 31903180 C A,T 9.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs6481753 chr10 31903976 C A 9.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs11008546 chr10 31905494 T G 5.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs4313476 chr10 31916689 T C 3.63E-05 Schizophrenia / / 20185149 rs796082 chr10 31920291 G A 3.91E-05 C-reactive protein / / 24763700 rs703069 chr10 31933997 A C 5.54E-04 Type 2 diabetes / / 17463246 rs11591307 chr10 31949411 G A 5.92E-06 Erythrocyte counts / / pha003099 rs796143 chr10 31950753 T C 9.55E-05 Cognitive performance / / 19734545 rs11008578 chr10 31955906 G A 5.92E-06 Erythrocyte counts / / pha003099 rs1775437 chr10 31964226 T C 4.50E-06 C-reactive protein / / 24763700 rs796130 chr10 31966507 G A 3.99E-04 Type 2 diabetes / / 17463246 rs796130 chr10 31966507 G A 5.64E-06 C-reactive protein / / 24763700 rs796127 chr10 31968729 T C 5.50E-04 Type 2 diabetes / / 17463246 rs796127 chr10 31968729 T C 3.00E-06 C-reactive protein / / 24763700 rs796126 chr10 31968759 T C 3.99E-04 Type 2 diabetes / / 17463246 rs796126 chr10 31968759 T C 3.26E-06 C-reactive protein / / 24763700 rs10508765 chr10 31968783 A G 4.99E-06 Erythrocyte counts / / pha003099 rs2488384 chr10 31973767 T C 5.31E-06 C-reactive protein / / 24763700 rs796153 chr10 31985518 G A 6.28E-05 Erythrocyte counts / / pha003099 rs10826979 chr10 31987246 T C 3.61E-05 Height / / pha003011 rs7081678 chr10 31990623 G A 6.00E-06 Waist-hip ratio / / 20935629 rs2383975 chr10 31998573 C T 9.84E-05 Serum metabolites / / 19043545 rs11008612 chr10 32016090 G A 7.96E-04 Type 2 diabetes / / 17463246 rs10826987 chr10 32038493 C T 4.70E-05 Prostate cancer / / pha002878 rs2778646 chr10 32044641 A C 3.73E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs7090529 chr10 32067712 C G 4.75E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2797130 chr10 32086304 T C 1.14E-04 Bipolar disorder,schizoaffective / / 19567891 rs2799019 chr10 32142850 G A 6.00E-04 Bipolar disorder,schizoaffective ARHGAP12 intron 19567891 rs2799019 chr10 32142850 G A 5.10E-07 Urinary metabolites ARHGAP12 intron 21572414 rs2808081 chr10 32162342 A G 1.10E-06 Urinary metabolites ARHGAP12 intron 21572414 rs2808079 chr10 32167385 C T 3.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARHGAP12 intron 20877124 rs2808073 chr10 32179275 T C 2.60E-07 Urinary metabolites ARHGAP12 intron 21572414 rs2808061 chr10 32190612 A G 3.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARHGAP12 intron 20877124 rs16932781 chr10 32202933 T C 2.97E-04 Gallstones ARHGAP12 intron 17632509 rs12256714 chr10 32216262 G A 3.10E-07 Urinary metabolites ARHGAP12 intron 21572414 rs11818816 chr10 32216766 T G 2.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARHGAP12 intron 20877124 rs3847414 chr10 32219176 T C 2.45E-04 Multiple complex diseases LOC100652968 intron 17554300 rs3847414 chr10 32219176 T C 8.30E-07 Urinary metabolites LOC100652968 intron 21572414 rs1251400 chr10 32235145 T C 2.56E-04 Multiple complex diseases / / 17554300 rs1251400 chr10 32235145 T C 8.30E-07 Urinary metabolites / / 21572414 rs7095322 chr10 32248491 T C 3.40E-04 Multiple complex diseases / / 17554300 rs7095322 chr10 32248491 T C 4.10E-07 Urinary metabolites / / 21572414 rs1419168 chr10 32257332 T G 4.50E-07 Urinary metabolites / / 21572414 rs10827003 chr10 32266216 C T 2.30E-07 Urinary metabolites / / 21572414 rs11818697 chr10 32273277 A G 2.47E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1251389 chr10 32288746 G A 7.34E-05 Waist-Hip Ratio / / pha003013 rs1251355 chr10 32290146 C G 4.60E-06 Urinary metabolites / / 21572414 rs211388 chr10 32293449 G C 6.36E-04 Type 2 diabetes / / 17463246 rs211389 chr10 32294011 T G 6.36E-04 Type 2 diabetes / / 17463246 rs1775715 chr10 32309005 A G 5.00E-06 Bipolar disorder (mood-incongruent) KIF5B intron 23092984 rs172431 chr10 32326037 G A 5.51E-05 Waist-Hip Ratio KIF5B intron pha003013 rs806813 chr10 32353837 A G 8.31E-04 Bipolar disorder,schizoaffective / / 19567891 rs4747764 chr10 32357556 G A 8.10E-04 Alcohol dependence / / 20201924 rs16932874 chr10 32358438 T C 1.27E-04 Depression (quantitative trait) / / 20800221 rs11008755 chr10 32360053 T C 1.77E-04 Depression (quantitative trait) / / 20800221 rs211315 chr10 32360188 C T 2.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs11008756 chr10 32363137 A G 1.77E-04 Depression (quantitative trait) / / 20800221 rs1251370 chr10 32366761 A G 1.58E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs211329 chr10 32368532 A T 2.51E-04 Type 2 diabetes / / 17463246 rs211330 chr10 32368589 A G 2.45E-04 Type 2 diabetes / / 17463246 rs1262077 chr10 32369189 G T 3.44E-04 Type 2 diabetes / / 17463246 rs12357161 chr10 32384983 C T 9.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs11595629 chr10 32386385 G A 1.00E-05 Urinary metabolites / / 21572414 rs211409 chr10 32393213 T C 8.20E-04 Alcohol dependence / / 20201924 rs211409 chr10 32393213 T C 7.29E-05 Lipoproteins / / pha003079 rs211413 chr10 32396902 C A 6.86E-04 Depression (quantitative trait) / / 20800221 rs211415 chr10 32397358 C T 6.87E-04 Depression (quantitative trait) / / 20800221 rs211416 chr10 32397591 T A 6.90E-04 Depression (quantitative trait) / / 20800221 rs211424 chr10 32398895 T C 7.90E-04 Alcohol dependence / / 20201924 rs73477 chr10 32400396 G A 1.40E-04 Alcohol dependence / / 20201924 rs2907799 chr10 32408084 G C 4.70E-06 Urinary metabolites / / 21572414 rs7095123 chr10 32412615 G A 5.36E-05 Pulmonary function / / 20010835 rs11008779 chr10 32413987 C T 9.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs3006632 chr10 32415789 A G 2.00E-05 Urinary metabolites / / 21572414 rs10827014 chr10 32432000 T C 8.67E-04 Multiple complex diseases / / 17554300 rs7083956 chr10 32450551 C A 6.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs3006679 chr10 32460069 C T 6.86E-05 Serum metabolites / / 19043545 rs2998067 chr10 32479621 G A 0.0000835 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity / / 22945461 rs11008826 chr10 32482049 C T 7.16E-05 Multiple complex diseases / / 17554300 rs7900894 chr10 32487505 T C 9.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2998081 chr10 32493108 A C 9.48E-06 Telomere length / / 23900074 rs2031791 chr10 32531607 T C 1.18E-04 Schizophrenia / / 19197363 rs1410232 chr10 32566313 C T 4.75E-04 Depression (quantitative trait) EPC1 intron 20800221 rs2986928 chr10 32568388 T C 3.77E-04 Schizophrenia EPC1 intron 19197363 rs1041231 chr10 32569039 C G 4.04E-04 Depression (quantitative trait) EPC1 intron 20800221 rs143713361 chr10 32625018 C T 8.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) EPC1 intron 24159190 rs2370759 chr10 32634972 G A 2.00E-06 Sexual dysfunction (female) EPC1 intron 22509378 rs2505373 chr10 32638416 C T 9.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs12258353 chr10 32653282 G A 6.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11008902 chr10 32664993 T C 4.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7922515 chr10 32684126 G A 3.11E-04 Alzheimer's disease (late onset) / / 21379329 rs7099897 chr10 32684427 G A 4.32E-04 Alzheimer's disease (late onset) / / 21379329 rs7072959 chr10 32687497 T C 2.10E-05 Information processing speed / / 21130836 rs17296100 chr10 32687828 G C 5.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs11813606 chr10 32692720 T A 7.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs17296114 chr10 32693485 C T 6.90E-05 Personality dimensions / / 18957941 rs17296114 chr10 32693485 C T 3.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs7474572 chr10 32695523 A T 7.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs4394741 chr10 32696496 G A 3.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs12256829 chr10 32700382 A T 3.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs12256905 chr10 32700539 A C 4.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs2370773 chr10 32723831 A T 3.25E-04 Multiple complex diseases / / 17554300 rs2490503 chr10 32740019 G A 0.000729 Salmonella-induced pyroptosis CCDC7 intron 22837397 rs1759666 chr10 32919407 A G 0.000165 Salmonella-induced pyroptosis C10orf68 intron 22837397 rs7908644 chr10 32923722 G A 2.72E-04 White matter integrity C10orf68 intron 22425255 rs11592907 chr10 32972770 G A 2.49E-04 White matter integrity C10orf68 intron 22425255 rs1763783 chr10 32981827 G A 0.000188 Salmonella-induced pyroptosis C10orf68 intron 22837397 rs11595683 chr10 33009569 T C 2.23E-04 White matter integrity C10orf68 intron 22425255 rs7075648 chr10 33010304 C A 2.23E-04 White matter integrity C10orf68 intron 22425255 rs16933650 chr10 33016278 T C 2.23E-04 White matter integrity C10orf68 intron 22425255 rs10827123 chr10 33042613 T G 1.69E-04 Multiple complex diseases C10orf68 intron 17554300 rs1932506 chr10 33058310 G T 4.12E-04 White matter integrity C10orf68 intron 22425255 rs7910994 chr10 33096734 T G 8.15E-06 Multiple complex diseases C10orf68 intron 17554300 rs1342548 chr10 33188102 G A 0.000598 Salmonella-induced pyroptosis / / 22837397 rs10508776 chr10 33189027 T C 4.64E-04 Suicide attempts in bipolar disorder ITGB1 nearGene-3 21423239 rs2153875 chr10 33190567 C A 1.00E-04 Cognitive impairment induced by topiramate ITGB1 intron 22091778 rs4587680 chr10 33200782 C T 2.95E-04 White matter integrity ITGB1 intron 22425255 rs2488326 chr10 33207497 T A,C 0.000331 Salmonella-induced pyroptosis ITGB1 intron 22837397 rs2230396 chr10 33209266 G T 0.000389 Salmonella-induced pyroptosis ITGB1 cds-synon 22837397 rs9417094 chr10 33227380 T C 9.63E-04 Multiple complex diseases ITGB1 intron 17554300 rs2488336 chr10 33236305 T C 5.92E-05 LDL lipoproteins ITGB1 intron pha002902 rs10827166 chr10 33256863 G T 1.07E-04 Depression (quantitative trait) / / 20800221 rs17296289 chr10 33260699 G A 5.40E-05 Breast cancer (survival) / / 20332263 rs11009161 chr10 33263267 T C 3.44E-05 Depression (quantitative trait) / / 20800221 rs722432 chr10 33263864 G A 4.64E-04 Multiple complex diseases / / 17554300 rs1187102 chr10 33264032 C G 1.64E-06 Schizophrenia / / 19571811 rs11009162 chr10 33264180 A G 2.70E-05 Depression (quantitative trait) / / 20800221 rs1187098 chr10 33265555 T C 0.000101 Salmonella-induced pyroptosis / / 22837397 rs17296310 chr10 33276301 G C 4.93E-04 Multiple complex diseases LOC100505562 intron 17554300 rs10827167 chr10 33277782 C T 6.16E-05 LDL lipoproteins LOC100505562 intron pha002902 rs11591508 chr10 33284653 C T 3.27E-06 Breast cancer (survival) LOC100505562 intron 20332263 rs10827170 chr10 33290343 G A,C 4.75E-04 Depression (quantitative trait) LOC100505562 intron 20800221 rs11009175 chr10 33294775 G A 5.00E-06 Depression (quantitative trait) LOC100505562 intron 20800221 rs11009175 chr10 33294775 G A 5.40E-06 Depression (quantitative trait) LOC100505562 intron 23290196 rs6481818 chr10 33299356 C A 6.32E-04 Depression (quantitative trait) LOC100505562 intron 20800221 rs6481819 chr10 33299459 T C 6.33E-04 Depression (quantitative trait) LOC100505562 intron 20800221 rs11009183 chr10 33306309 A C 2.10E-04 Depression (quantitative trait) LOC100505562 intron 20800221 rs12146170 chr10 33311032 T C 1.61E-05 Depression (quantitative trait) LOC100505562 intron 20800221 rs941831 chr10 33324516 A G 1.31E-04 White matter integrity LOC100505562 intron 22425255 rs10827173 chr10 33328779 T A 7.45E-04 Depression (quantitative trait) LOC100505562 intron 20800221 rs11009195 chr10 33334273 T C 6.89E-04 Amyotrophic Lateral Sclerosis LOC100505562 intron 17362836 rs11009195 chr10 33334273 T C 7.04E-04 Depression (quantitative trait) LOC100505562 intron 20800221 rs10430560 chr10 33340331 T C 2.33E-04 Depression (quantitative trait) LOC100505562 intron 20800221 rs10430572 chr10 33340399 C T 1.73E-04 Depression (quantitative trait) LOC100505562 intron 20800221 rs11009198 chr10 33342307 C A 1.78E-04 Depression (quantitative trait) LOC100505562 intron 20800221 rs11009199 chr10 33342328 T C 1.79E-04 Depression (quantitative trait) LOC100505562 intron 20800221 rs11009199 chr10 33342328 T C 1.05E-04 Bipolar disorder (mania) LOC100505562 intron 23326512 rs11009200 chr10 33342384 G C 1.79E-04 Depression (quantitative trait) LOC100505562 intron 20800221 rs7094668 chr10 33343357 G A 1.79E-04 Depression (quantitative trait) LOC100505562 intron 20800221 rs7078479 chr10 33345201 C G 1.82E-04 Depression (quantitative trait) LOC100505562 intron 20800221 rs17230579 chr10 33348045 G A 9.33E-04 Depression (quantitative trait) LOC100505562 intron 20800221 rs17230579 chr10 33348045 G A 4.45E-04 Bipolar disorder (mania) LOC100505562 intron 23326512 rs11009203 chr10 33348133 C G 7.70E-04 Depression (quantitative trait) LOC100505562 intron 20800221 rs10827177 chr10 33349390 A T 2.27E-05 Depression (quantitative trait) LOC100505562 intron 20800221 rs10827178 chr10 33351101 C T 3.60E-05 Depression (quantitative trait) LOC100505562 intron 20800221 rs2666261 chr10 33356139 T C 3.44E-05 Hepatocellular carcinoma LOC100505562 intron 22807686 rs11009208 chr10 33356713 T A 3.45E-05 Depression (quantitative trait) LOC100505562 intron 20800221 rs12355459 chr10 33357713 T C 4.89E-05 Depression (quantitative trait) LOC100505562 intron 20800221 rs12359953 chr10 33358070 C T 4.88E-05 Depression (quantitative trait) LOC100505562 intron 20800221 rs10827179 chr10 33362132 C A 2.85E-04 Depression (quantitative trait) LOC100505562 intron 20800221 rs2666279 chr10 33364859 G T 5.89E-05 Serum metabolites LOC100505562 intron 19043545 rs11009213 chr10 33365939 C T 6.97E-05 Depression (quantitative trait) LOC100505562 intron 20800221 rs11009216 chr10 33366959 A T 9.15E-05 Depression (quantitative trait) LOC100505562 intron 20800221 rs2666275 chr10 33367804 C G 9.08E-05 Serum metabolites LOC100505562 intron 19043545 rs7088801 chr10 33368644 T C 0.000700636 Hypertension (early onset hypertension) LOC100505562 intron 22479346 rs10827183 chr10 33369393 G A 5.18E-05 Depression (quantitative trait) LOC100505562 intron 20800221 rs12571443 chr10 33371103 G A 4.94E-05 Depression (quantitative trait) / / 20800221 rs10827185 chr10 33372725 G A 9.32E-05 Monocyte counts / / pha003089 rs10827186 chr10 33373750 T C 8.81E-04 Depression (quantitative trait) / / 20800221 rs16933929 chr10 33374204 G C 8.82E-04 Depression (quantitative trait) / / 20800221 rs11009222 chr10 33374735 A G 9.46E-04 Multiple complex diseases / / 17554300 rs11009222 chr10 33374735 A G 8.81E-04 Depression (quantitative trait) / / 20800221 rs17296373 chr10 33375914 G A 4.73E-05 Depression (quantitative trait) / / 20800221 rs17296387 chr10 33384007 C T 5.03E-04 Multiple complex diseases / / 17554300 rs2666265 chr10 33388942 G T 4.61E-04 Multiple complex diseases / / 17554300 rs11009228 chr10 33393854 G A 4.61E-04 Multiple complex diseases / / 17554300 rs11009231 chr10 33402524 G A 6.80E-04 Multiple complex diseases / / 17554300 rs10827201 chr10 33404728 G C 5.98E-04 Multiple complex diseases / / 17554300 rs7902627 chr10 33405087 A C 8.00E-06 IgG glycosylation / / 23382691 rs2666236 chr10 33418872 G A 2.13E-05 Multiple complex diseases / / 17554300 rs2666236 chr10 33418872 G A 2.12E-05 Type 1 diabetes / / 18978792 rs2093055 chr10 33423693 A G 3.04E-05 Multiple complex diseases / / 17554300 rs722987 chr10 33426239 G C 1.47E-04 Multiple complex diseases / / 17554300 rs2383983 chr10 33426814 A G 2.72E-06 Multiple complex diseases / / 17554300 rs11009243 chr10 33427220 A G 6.28E-04 Multiple complex diseases / / 17554300 rs16934073 chr10 33427603 G T 2.47E-04 Type 2 diabetes / / 17463246 rs2506134 chr10 33464952 A G 5.85E-05 Alzheimer's disease / / 24755620 rs2506135 chr10 33465037 T C 9.85E-06 Alzheimer's disease / / 24755620 rs2506137 chr10 33466043 C T 1.02E-05 Alzheimer's disease NRP1 nearGene-3 24755620 rs10080 chr10 33467108 G A 6.59E-05 Alzheimer's disease NRP1 UTR-3 24755620 rs1044210 chr10 33467321 G T 1.36E-05 Alzheimer's disease NRP1 UTR-3 24755620 rs2506141 chr10 33468014 T C 2.96E-04 Alzheimer's disease NRP1 UTR-3 24755620 rs16915674 chr10 33470100 C T 5.17E-05 Multiple complex diseases NRP1 intron 17554300 rs2228638 chr10 33475282 C T 2.00E-07 Tetralogy of Fallot NRP1 missense 23297363 rs734186 chr10 33484829 G A 2.52E-05 Tetralogy of Fallot NRP1 intron 23297363 rs2250706 chr10 33493307 C T 2.90E-05 Immunoglobulin A NRP1 intron 20694011 rs2474714 chr10 33495983 A G 7.56E-06 Osteoarthritis NRP1 intron 22763110 rs2506155 chr10 33503179 C A 3.00E-06 Migraine NRP1 intron 23793025 rs927099 chr10 33525836 T C 8.50E-06 Urinary metabolites NRP1 intron 21572414 rs17413155 chr10 33532755 T G 1.40E-04 Endometriosis NRP1 intron 21151130 rs1888690 chr10 33535796 G C 3.38E-08 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines NRP1 intron 21483694 rs16934292 chr10 33549468 G A 1.84E-05 Left ventricular hypertrophy NRP1 intron pha003052 rs2070296 chr10 33552695 C T 3.04E-05 Cognitive performance NRP1 cds-synon 19734545 rs10827224 chr10 33557279 A C 3.39E-05 Cognitive performance NRP1 intron 19734545 rs10827227 chr10 33561788 C T 8.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NRP1 intron 20877124 rs1952983 chr10 33568935 G T 0.000146187 Hypertension (early onset hypertension) NRP1 intron 22479346 rs4934871 chr10 33583089 G A 1.63E-05 F-cell distribution NRP1 intron 21326311 rs7086456 chr10 33602412 C T 3.29E-04 Obesity (extreme) NRP1 intron 21935397 rs11009338 chr10 33606306 A T 8.91E-04 Obesity (extreme) NRP1 intron 21935397 rs2804498 chr10 33620707 C T 9.25E-04 Type 2 diabetes NRP1 intron 17846126 rs11812929 chr10 33637243 C T 3.03E-05 HIV-1 viral setpoint / / 22174851 rs10827246 chr10 33642629 C T 9.98E-05 Femoral neck bone geometry / / 22087292 rs11009357 chr10 33648920 C A 7.32E-05 Femoral neck bone geometry / / 22087292 rs2150686 chr10 33649023 T C 6.09E-05 Femoral neck bone geometry / / 22087292 rs12267895 chr10 33654111 G A 9.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs17296526 chr10 33656119 T C 2.70E-05 Triglycerides / / pha003080 rs2804455 chr10 33669666 A G 3.56E-04 Multiple complex diseases / / 17554300 rs11009370 chr10 33679029 A T 2.97E-04 Multiple complex diseases / / 17554300 rs7910887 chr10 33690581 C T 6.80E-05 Triglycerides / / 19074352 rs2804463 chr10 33691764 A G 8.23E-04 Multiple complex diseases / / 17554300 rs2785279 chr10 33709876 T C 1.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs945583 chr10 33735135 A G 4.20E-06 Urinary metabolites / / 21572414 rs41463050 chr10 33752378 G A 7.95E-04 Smoking cessation / / 24665060 rs1902411 chr10 33785475 C T 8.21E-04 Multiple complex diseases / / 17554300 rs2785250 chr10 33816271 C T 3.20E-04 Multiple complex diseases / / 17554300 rs11009439 chr10 33851177 A G 6.40E-06 Urinary metabolites / / 21572414 rs12247441 chr10 33851964 A C 5.10E-06 Urinary metabolites / / 21572414 rs7088857 chr10 33852455 T C 5.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7081539 chr10 33855696 T G 8.02E-05 Blood Pressure / / pha003047 rs11009462 chr10 33885610 C T 4.31E-04 Schizophrenia / / 19197363 rs10827274 chr10 33901538 A C 1.55E-05 QT interval / / 22726844 rs16934693 chr10 33909902 A T 4.11E-04 Multiple complex diseases / / 17554300 rs12784577 chr10 33990742 T A 6.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs11009507 chr10 34025041 G A 3.35E-05 Multiple complex diseases / / 17554300 rs11009507 chr10 34025041 G A 1.30E-04 Aortic root size / / 21223598 rs7073701 chr10 34028762 A C 7.24E-05 Cognitive test performance / / 20125193 rs9663087 chr10 34044457 C T 7.69E-05 Serum metabolites / / 19043545 rs2039334 chr10 34063999 A T 4.75E-05 Serum metabolites / / 19043545 rs10827283 chr10 34064066 A G 3.99E-05 Serum metabolites / / 19043545 rs17231134 chr10 34078973 G T 7.48E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2777515 chr10 34079819 T C 1.89E-04 Taste perception / / 22132133 rs7896318 chr10 34083209 G A 9.11E-04 Multiple complex diseases / / 17554300 rs1412115 chr10 34088053 T C 6.00E-06 Schizophrenia / / 21682944 rs2777525 chr10 34091207 C A 4.35E-05 Taste perception / / 22132133 rs2812646 chr10 34114285 T C 4.40E-04 Multiple complex diseases / / 17554300 rs12413603 chr10 34131163 C T 1.47E-04 Alzheimer's disease / / 24755620 rs2210382 chr10 34132999 G T 3.72E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs867214 chr10 34148669 T A,C 8.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs41441548 chr10 34150821 G A 2.66E-06 Schizophrenia / / 21926974 rs41441548 chr10 34150821 G A 6.74E-05 Alzheimer's disease / / 24755620 rs7082110 chr10 34161048 A G 6.14E-04 Depression (quantitative trait) / / 20800221 rs16934897 chr10 34186525 C G 7.02E-04 Multiple complex diseases / / 17554300 rs1740721 chr10 34189978 A G 1.95E-04 Parkinson's disease / / 21248740 rs17414370 chr10 34206477 C T 0.0003031 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17414370 chr10 34206477 C T 3.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1160769 chr10 34210538 T C 4.00E-05 Erythrocyte counts / / pha003090 rs7894891 chr10 34213499 A G 2.00E-04 Multiple complex diseases / / 17554300 rs10763962 chr10 34216753 C T 3.26E-04 Multiple complex diseases / / 17554300 rs999142 chr10 34229323 G A,C,T 9.75E-05 Height / / pha003011 rs7905537 chr10 34231275 A C 2.94E-04 Hemoglobin concentration / / 20534544 rs7905537 chr10 34231275 A C 8.00E-07 Emphysema-related traits / / 20709820 rs11009601 chr10 34237166 G A 0.00089 Breast cancer / / 23555315 rs1780436 chr10 34257612 G A 8.00E-06 Major depressive disorder / / 19065144 rs1780436 chr10 34257612 G A 3.00E-06 Major depressive disorder / / 21621269 rs1780436 chr10 34257612 G A 2.41E-06 Major depressive disorder / / pha002850 rs224714 chr10 34266223 G A 8.01E-05 Schizophrenia / / 24253340 rs10827318 chr10 34275113 C T 8.64E-05 Schizophrenia / / 24253340 rs224767 chr10 34281430 C T 7.67E-04 Multiple complex diseases / / 17554300 rs16935007 chr10 34329445 T C 2.48E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs7909281 chr10 34379682 C T 2.46E-04 Multiple complex diseases / / 17554300 rs7074105 chr10 34380866 T C 3.62E-04 Telomere length / / 23900074 rs117955912 chr10 34389275 T G 0.0000624 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1660622 chr10 34456509 C G 1.11E-05 Smoking cessation PARD3 intron 18519826 rs1290002 chr10 34466656 G A 3.03E-06 Obesity PARD3 intron 22484627 rs629039 chr10 34488364 G A 1.21E-04 Smoking cessation PARD3 intron 18519826 rs629039 chr10 34488364 G A 3.75E-05 Parkinson's disease (motor and cognition) PARD3 intron 22658654 rs629039 chr10 34488364 G A 3.75E-05 Immune response to anthrax vaccine PARD3 intron 22658931 rs1660643 chr10 34493123 C T 7.11E-05 Parkinson's disease (motor and cognition) PARD3 intron 22658654 rs1660643 chr10 34493123 C T 7.11E-05 Immune response to anthrax vaccine PARD3 intron 22658931 rs678188 chr10 34495289 A G 5.45E-05 Smoking cessation PARD3 intron 18519826 rs2570326 chr10 34513830 C T 3.09E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) PARD3 intron 22566498 rs1778871 chr10 34535021 C G 2.18E-05 Multiple complex diseases PARD3 intron 17554300 rs1778871 chr10 34535021 C G 2.32E-06 Smoking cessation PARD3 intron 18519826 rs1778871 chr10 34535021 C G 1.80E-05 Urinary metabolites PARD3 intron 21572414 rs11009696 chr10 34538563 T C 3.36E-04 Multiple complex diseases PARD3 intron 17554300 rs658885 chr10 34563925 A G 8.93E-05 Orofacial clefts PARD3 intron 22419666 rs10827344 chr10 34569737 T G 7.97E-04 Multiple complex diseases PARD3 intron 17554300 rs1778870 chr10 34575279 C T 8.41E-06 Smoking cessation PARD3 intron 18519826 rs1660644 chr10 34579747 G C 9.18E-04 Multiple complex diseases PARD3 intron 17554300 rs1660644 chr10 34579747 G C 4.40E-06 Urinary metabolites PARD3 intron 21572414 rs3891844 chr10 34580891 G A 1.32E-04 Multiple complex diseases PARD3 intron 17554300 rs3891844 chr10 34580891 G A 4.20E-06 Urinary metabolites PARD3 intron 21572414 rs2582860 chr10 34582534 C T 7.59E-04 Multiple complex diseases PARD3 intron 17554300 rs2582860 chr10 34582534 C T 4.30E-06 Urinary metabolites PARD3 intron 21572414 rs16935300 chr10 34588467 A G 4.70E-06 Urinary metabolites PARD3 intron 21572414 rs16935302 chr10 34589742 G A 1.07E-04 Smoking cessation PARD3 intron 18519826 rs12241064 chr10 34599342 A G 9.67E-05 Cognitive test performance PARD3 intron 20125193 rs16935315 chr10 34616456 A G 8.91E-04 Multiple complex diseases PARD3 intron 17554300 rs7094027 chr10 34678932 T C 1.49E-04 Multiple complex diseases PARD3 intron 17554300 rs16935403 chr10 34719764 C A 8.63E-04 Multiple complex diseases PARD3 intron 17554300 rs11009804 chr10 34774296 G A 2.20E-04 Aortic root size PARD3 intron 21223598 rs773985 chr10 34782752 C T 1.05E-05 Bone mass and geometry PARD3 intron 17903296 rs4934636 chr10 34786691 G A 1.67E-04 Aortic root size PARD3 intron 21223598 rs1030841 chr10 34812291 T C 1.56E-04 Multiple complex diseases PARD3 intron 17554300 rs563507 chr10 34817988 G A 9.00E-06 Acute lymphoblastic leukemia (childhood) PARD3 intron 19684603 rs563507 chr10 34817988 G A 9.00E-06 Nasopharyngeal carcinoma PARD3 intron 20512145 rs2985303 chr10 34974831 T A 4.70E-04 Schizophrenia PARD3 intron 20832056 rs2985303 chr10 34974831 T A 2.10E-05 Urinary metabolites PARD3 intron 21572414 rs11009892 chr10 35016575 T C 0.000324 Salmonella-induced pyroptosis PARD3 intron 22837397 rs11010007 chr10 35165095 G A 3.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs11010007 chr10 35165095 G A 9.75E-15 Gallbladder disease / / pha001404 rs16935780 chr10 35173730 A G 2.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs11010015 chr10 35173919 C T 2.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs4244991 chr10 35174635 T C 5.50E-06 Urinary metabolites / / 21572414 rs4244992 chr10 35174755 A T 5.00E-06 Urinary metabolites / / 21572414 rs12269653 chr10 35176153 G A 8.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs2492448 chr10 35195406 G A 8.49E-04 Type 2 diabetes / / 17463246 rs2492448 chr10 35195406 G A 3.84E-06 Parkinson's disease / / pha002868 rs11591754 chr10 35207153 C T 1.68E-06 Parkinson's disease / / pha002868 rs10827467 chr10 35223482 C A 5.37E-06 Odorant perception / / 23910658 rs7897198 chr10 35237731 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11010056 chr10 35250203 G T 0.000807842 Hypertension (early onset hypertension) / / 22479346 rs9787643 chr10 35267810 C A 8.19E-05 Insulin resistance / / 21901158 rs17582416 chr10 35287650 T G 3.12E-05 Multiple complex diseases / / 17554300 rs17582416 chr10 35287650 T G 2.00E-09 Crohn's disease / / 18587394 rs17582416 chr10 35287650 T G 2.00E-09 Asthma / / 21150878 rs17582416 chr10 35287650 T G 1.79E-09 Multiple sclerosis / / 22190364 rs11010067 chr10 35295431 C G 1.04E-04 Multiple complex diseases / / 17554300 rs11010067 chr10 35295431 C G 2.00E-25 Inflammatory bowel disease / / 23128233 rs7920095 chr10 35303334 G A 2.20E-05 Parkinson's disease CUL2 intron pha002868 rs7923172 chr10 35309367 G A 1.43E-05 Parkinson's disease CUL2 intron pha002868 rs11595898 chr10 35326263 T C 2.31E-05 Parkinson's disease CUL2 intron pha002868 rs11010077 chr10 35328088 A G 8.06E-05 Multiple complex diseases CUL2 intron 17554300 rs4934704 chr10 35332164 C T 1.48E-05 Parkinson's disease CUL2 intron pha002868 rs7897024 chr10 35338673 C T 6.21E-04 Multiple complex diseases CUL2 cds-synon 17554300 rs7900480 chr10 35338699 G A 1.10E-04 Multiple complex diseases CUL2 intron 17554300 rs4934709 chr10 35339324 C A 9.19E-05 Multiple complex diseases CUL2 intron 17554300 rs1926554 chr10 35344969 C T 3.32E-05 Parkinson's disease CUL2 intron pha002868 rs7099036 chr10 35349574 C T 2.13E-05 Parkinson's disease CUL2 intron pha002868 rs13377158 chr10 35370465 G T 1.82E-04 Multiple complex diseases CUL2 intron 17554300 rs4934719 chr10 35376769 T C 2.68E-05 Parkinson's disease CUL2 intron pha002868 rs4934721 chr10 35377715 A G 1.39E-04 Multiple complex diseases CUL2 intron 17554300 rs11593858 chr10 35381373 G A 2.14E-05 Parkinson's disease / / pha002868 rs11596502 chr10 35387187 T G 1.43E-04 Multiple complex diseases / / 17554300 rs12768019 chr10 35389843 T C 2.31E-05 Parkinson's disease / / pha002868 rs4934724 chr10 35393669 C T 3.21E-05 Parkinson's disease / / pha002868 rs2126984 chr10 35410291 A G 1.79E-04 Multiple complex diseases / / 17554300 rs10827492 chr10 35429825 C T 1.69E-05 Parkinson's disease CREM intron pha002868 rs12761675 chr10 35438337 T C 1.52E-04 Multiple complex diseases CREM intron 17554300 rs2505639 chr10 35474421 A G 3.83E-05 Multiple complex diseases CREM intron 17554300 rs4934540 chr10 35474699 T C 1.83E-05 Parkinson's disease CREM intron pha002868 rs7077242 chr10 35481965 G T 1.78E-04 Multiple complex diseases CREM intron 17554300 rs4934735 chr10 35496730 A G 4.75E-04 Multiple complex diseases CREM intron 17554300 rs17591857 chr10 35499043 G A 1.83E-04 Multiple complex diseases CREM intron 17554300 rs12242110 chr10 35535695 A G 1.00E-09 Crohn's disease / / 21102463 rs3936503 chr10 35549257 G A 1.60E-05 Multiple complex diseases CCNY intron 17554300 rs3936503 chr10 35549257 G A 8.04E-09 Crohn's disease CCNY intron 18587394 rs16935948 chr10 35549748 G C 1.78E-05 Multiple complex diseases CCNY intron 17554300 rs12261843 chr10 35554054 T G 7.00E-10 Ulcerative colitis CCNY intron 21297633 rs12261843 chr10 35554054 T G 8.33E-04 Ulcerative colitis CCNY intron 23511034 rs12261843 chr10 35554054 T G 4.05E-05 Parkinson's disease CCNY intron pha002868 rs11010152 chr10 35567127 T C 9.87E-04 Multiple complex diseases CCNY intron 17554300 rs12242002 chr10 35569606 T C 8.91E-04 Multiple complex diseases CCNY intron 17554300 rs2474518 chr10 35639721 A G 5.13E-05 Orofacial clefts CCNY intron 22419666 rs3003981 chr10 35718212 C T 5.75E-04 Multiple complex diseases CCNY intron 17554300 rs4934753 chr10 35755345 C A 9.95E-04 Multiple complex diseases CCNY intron 17554300 rs7902346 chr10 35783056 G A 6.27E-04 Multiple complex diseases CCNY intron 17554300 rs11595699 chr10 35796354 C G 8.92E-04 Multiple complex diseases CCNY intron 17554300 rs10827512 chr10 35815727 G A 5.56E-04 Multiple complex diseases CCNY intron 17554300 rs11010228 chr10 35852015 C T 7.16E-05 Multiple complex diseases CCNY intron 17554300 rs10827519 chr10 35912391 G A 1.36E-04 Telomere length / / 21573004 rs11010237 chr10 35914178 C T 1.70E-05 Urinary metabolites / / 21572414 rs114088342 chr10 35918232 A G 2.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs910967 chr10 35922904 T G 5.40E-06 Urinary metabolites / / 21572414 rs11010245 chr10 35924020 C T 2.90E-05 Urinary metabolites / / 21572414 rs11010252 chr10 35947551 C T 2.23E-04 Multiple complex diseases / / 17554300 rs11010252 chr10 35947551 C T 1.00E-04 Information processing speed / / 21130836 rs618443 chr10 35948710 A G 3.17E-05 Information processing speed / / 21130836 rs2474743 chr10 35961247 A G 0.0000095 Mean arterial pressure / / 22510845 rs11815242 chr10 35995340 G C 3.55E-04 Height / / 17255346 rs11815242 chr10 35995340 G C 3.08E-04 Multiple complex diseases / / 17554300 rs16936260 chr10 36008493 A G 7.30E-04 Smoking initiation / / 24665060 rs17510785 chr10 36024653 C T 9.20E-06 Urinary metabolites / / 21572414 rs875655 chr10 36029626 G A 8.28E-06 White blood cell count / / 21738479 rs17511194 chr10 36036780 A C 9.39E-04 Type 2 diabetes / / 17463246 rs12411410 chr10 36037466 C T 6.00E-04 Type 2 diabetes / / 17463246 rs12411410 chr10 36037466 C T 2.72E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs7079134 chr10 36042424 G T 5.11E-05 Body Fat Distribution / / pha003017 rs7079134 chr10 36042424 G T 4.72E-05 Body Fat Distribution / / pha003018 rs2152541 chr10 36045994 G A 9.88E-04 Type 2 diabetes / / 17463246 rs587003 chr10 36046482 T C 2.95E-05 Body Fat Distribution / / pha003016 rs587003 chr10 36046482 T C 4.78E-06 Body Fat Distribution / / pha003017 rs587003 chr10 36046482 T C 4.59E-06 Body Fat Distribution / / pha003018 rs625092 chr10 36049656 C T 2.95E-05 Body Fat Distribution / / pha003016 rs625092 chr10 36049656 C T 4.78E-06 Body Fat Distribution / / pha003017 rs625092 chr10 36049656 C T 4.59E-06 Body Fat Distribution / / pha003018 rs588210 chr10 36050302 T C 6.58E-04 Multiple complex diseases / / 17554300 rs11818072 chr10 36053660 C T 4.43E-05 Multiple complex diseases / / 17554300 rs11010290 chr10 36060309 A G 3.20E-04 Obesity,menopause / / 21424828 rs11010290 chr10 36060309 A G 9.00E-06 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs2845920 chr10 36061143 G A 4.03E-04 Multiple complex diseases / / 17554300 rs2804817 chr10 36061337 C A 5.36E-04 Multiple complex diseases / / 17554300 rs2804814 chr10 36071555 G A 2.75E-04 Multiple complex diseases / / 17554300 rs4934765 chr10 36074474 C T 7.70E-06 Urinary metabolites / / 21572414 rs10508819 chr10 36079293 C T 9.69E-05 HIV-1 viral setpoint / / 22174851 rs2804834 chr10 36129521 A G 8.10E-05 HIV-1 control / / 20041166 rs1475386 chr10 36134109 T C 7.30E-05 HIV-1 control / / 20041166 rs2209688 chr10 36136605 G A 7.90E-05 HIV-1 control / / 20041166 rs487446 chr10 36161981 G A 4.66E-04 Multiple complex diseases / / 17554300 rs11010324 chr10 36201437 C T 1.00E-04 Hypothyroidism / / 22493691 rs10740915 chr10 36208419 C G 8.29E-04 Multiple complex diseases / / 17554300 rs10764062 chr10 36209003 A C 8.10E-04 Multiple complex diseases / / 17554300 rs708435 chr10 36212146 C A 8.08E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs708414 chr10 36249483 A G 9.32E-05 Attention deficit hyperactivity disorder / / 22420046 rs708414 chr10 36249483 A G 2.86E-04 Alzheimer's disease / / 24755620 rs16936504 chr10 36283073 C T 1.51E-05 Bipolar disorder and schizophrenia / / 20889312 rs16936504 chr10 36283073 C T 2.56E-05 Schizophrenia / / pha002857 rs2891526 chr10 36288359 G A 4.17E-04 Alzheimer's disease / / 24755620 rs1528006 chr10 36294152 G A 9.55E-04 Multiple complex diseases / / 17554300 rs10508825 chr10 36316812 T C 8.86E-05 ldl cholesterol / / pha003076 rs11010390 chr10 36346759 C T 8.86E-05 ldl cholesterol / / pha003076 rs315644 chr10 36455895 C A 1.20E-05 Intraocular pressure / / 24002674 rs1451193 chr10 36461567 G A 2.09E-05 Taste perception / / 22132133 rs7067812 chr10 36462292 T C 2.67E-05 Taste perception / / 22132133 rs7092191 chr10 36469499 A C 3.50E-04 Taste perception / / 22132133 rs10827617 chr10 36471685 C A 7.78E-04 Multiple complex diseases / / 17554300 rs899865 chr10 36473044 T C 1.91E-04 Taste perception / / 22132133 rs315630 chr10 36474822 C A 3.37E-04 Blood pressure / / 17255346 rs315604 chr10 36495749 C T 6.50E-06 Iron levels / / 21208937 rs11010572 chr10 36511451 G A 3.56E-04 Barrett's esophagus / / 24121790 rs11010572 chr10 36511451 G A 8.36E-04 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs11815387 chr10 36514772 C T 5.57E-04 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs10508839 chr10 36570120 A T 2.40E-05 Urinary metabolites / / 21572414 rs2796780 chr10 36587545 C T 1.90E-05 Urinary metabolites / / 21572414 rs4934805 chr10 36594471 G A 4.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs12571128 chr10 36597203 A G 5.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs1779874 chr10 36600257 G A 4.08E-05 Lipoproteins / / pha003079 rs1775167 chr10 36608920 C A 2.90E-05 Urinary metabolites / / 21572414 rs2800092 chr10 36613554 C T 5.52E-05 Body Mass Index / / pha003007 rs2800092 chr10 36613554 C T 4.38E-05 Body Mass Index / / pha003014 rs2800092 chr10 36613554 C T 6.28E-05 Weight / / pha003027 rs11010623 chr10 36625162 C T 3.18E-04 Birth weight / / 17255346 rs1624144 chr10 36627135 G A 8.50E-05 Lipoproteins / / pha003079 rs1775178 chr10 36627345 G A 8.50E-05 Lipoproteins / / pha003079 rs11010631 chr10 36635494 C T 3.03E-04 Birth weight / / 17255346 rs11010633 chr10 36637021 G T 5.11E-05 Asthma / / 11022011 rs7894832 chr10 36642075 G A 6.50E-04 Multiple complex diseases / / 17554300 rs7894832 chr10 36642075 G A 9.88E-06 Lipid traits / / 22028671 rs7916089 chr10 36643454 T C 2.39E-04 Parkinson's disease / / 17052657 rs11593579 chr10 36647770 G A 1.82E-04 Suicide attempts in bipolar disorder / / 21041247 rs1779876 chr10 36648040 T G 3.00E-06 Protein quantitative trait loci / / 18464913 rs7911097 chr10 36651214 C A 6.49E-04 Alzheimer's disease / / 17998437 rs2796771 chr10 36702570 C T 5.89E-04 Taste perception / / 22132133 rs1539398 chr10 36710530 G T 5.74E-04 Multiple complex diseases / / 17554300 rs16937007 chr10 36722047 G A 4.97E-04 Multiple complex diseases / / 17554300 rs2245729 chr10 36726681 T A 3.40E-04 Aortic root size / / 21223598 rs2503040 chr10 36746633 G A 5.01E-04 Taste perception / / 22132133 rs2505613 chr10 36747362 A C 1.74E-05 Body Mass Index / / pha003014 rs3924753 chr10 36753213 G A 5.00E-04 Alzheimer's disease / / 17998437 rs2505574 chr10 36828518 C T 3.09E-04 Tourette syndrome / / 22889924 rs17629831 chr10 36842708 T C 5.59E-04 Myopia (pathological) / / 21095009 rs2483021 chr10 36847132 C T 6.39E-05 Diabetic retinopathy / / 20871662 rs1889031 chr10 36847253 A C 3.64E-05 Diabetic retinopathy / / 20871662 rs2505585 chr10 36848993 G A 5.08E-05 Diabetic retinopathy / / 20871662 rs1537328 chr10 36849592 A C 6.39E-05 Diabetic retinopathy / / 20871662 rs1332770 chr10 36862892 T C 9.94E-04 Myopia (pathological) / / 21095009 rs2505593 chr10 36863975 T A 9.93E-04 Diabetic retinopathy / / 20871662 rs1360573 chr10 36885921 A G 2.00E-06 Periodontal microbiota / / 22699663 rs4934825 chr10 36890519 A C 5.65E-04 Multiple complex diseases / / 17554300 rs4934826 chr10 36890536 A G 3.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2483003 chr10 36890663 C T 1.91E-04 Multiple complex diseases / / 17554300 rs1332772 chr10 36891028 A G 2.25E-04 Multiple complex diseases / / 17554300 rs1332773 chr10 36892217 A G 8.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7082117 chr10 36893210 A G 6.88E-04 Acute lung injury / / 22295056 rs10827651 chr10 36895284 C T 8.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11593196 chr10 36898886 T G 1.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11593196 chr10 36898886 T G 9.25E-04 Acute lung injury / / 22295056 rs10827678 chr10 36920321 T C 9.06E-05 HIV-1 viral setpoint / / 22174851 rs7091681 chr10 36943725 T C 1.09E-04 Multiple complex diseases / / 17554300 rs17551460 chr10 37005752 T C 2.71E-04 Multiple complex diseases / / 17554300 rs2185863 chr10 37063692 G T 7.45E-04 Heart Failure / / pha002884 rs11010872 chr10 37066341 T C 3.98E-04 Multiple complex diseases / / 17554300 rs1537671 chr10 37093779 G C 6.10E-05 Parkinson's disease (familial) / / 18985386 rs11010891 chr10 37093820 G T 8.54E-04 Type 2 diabetes / / 17463246 rs11010891 chr10 37093820 G T 8.81E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11010892 chr10 37094227 T C 6.10E-05 Parkinson's disease (familial) / / 18985386 rs199513858 chr10 37094227 T TGC 6.10E-05 Parkinson's disease (familial) / / 18985386 rs2103249 chr10 37130758 G A 8.62E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11010921 chr10 37155513 C T 6.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs11010945 chr10 37196005 T A 9.45E-04 Type 2 diabetes / / 17463246 rs10764116 chr10 37239565 T C 3.20E-04 Multiple complex diseases / / 17554300 rs11813269 chr10 37243242 A G 8.29E-05 Bipolar disorder / / 19488044 rs11010965 chr10 37258105 C T 0.0002 Migraine / / 22678113 rs10508857 chr10 37304120 T C 7.89E-04 Multiple complex diseases / / 17554300 rs2459425 chr10 37306985 A G 2.87E-04 Scoliosis / / 21216876 rs11010995 chr10 37315221 T C 3.62E-04 Multiple complex diseases / / 17554300 rs1914170 chr10 37342776 G A 6.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs1200909 chr10 37364068 C T 6.79E-05 Suicide attempts in bipolar disorder / / 21423239 rs1200910 chr10 37364259 C T 4.56E-05 Suicide attempts in bipolar disorder / / 21423239 rs1782076 chr10 37479884 A G 6.91E-06 Serum metabolites ANKRD30A intron 19043545 rs1148259 chr10 37508450 A C 3.00E-09 Metabolite levels ANKRD30A cds-synon 19043545 rs1148263 chr10 37525896 A T 6.59E-04 Type 2 diabetes / / 17463246 rs1148263 chr10 37525896 A T 9.32E-07 Serum metabolites / / 19043545 rs1200818 chr10 37559338 C T 6.71E-05 Suicide attempts in bipolar disorder / / 21423239 rs1200820 chr10 37559479 C A,G 3.48E-04 Type 2 diabetes / / 17463246 rs1200821 chr10 37559580 A G 6.00E-06 Hemostatic factors and hematological phenotypes / / 17903294 rs1200826 chr10 37564987 T C 2.44E-04 Type 2 diabetes / / 17463246 rs1200826 chr10 37564987 T C 5.14E-08 Serum metabolites / / 19043545 rs7096155 chr10 37579117 A C 4.84E-04 Multiple complex diseases / / 17554300 rs1938417 chr10 37687520 A C 6.29E-06 Serum metabolites / / 19043545 rs10827805 chr10 37894260 C A 2.48E-05 Coronary heart disease / / 21606135 rs11011299 chr10 37934966 G A 7.75E-04 Multiple complex diseases / / 17554300 rs4934888 chr10 37939165 G T 3.44E-04 Multiple complex diseases / / 17554300 rs17660144 chr10 37943214 C T 2.50E-04 Coronary heart disease / / 21606135 rs12266900 chr10 37954353 G A 8.40E-04 Multiple complex diseases / / 17554300 rs289647 chr10 37968278 A G 1.26E-05 Serum metabolites / / 19043545 rs11011334 chr10 37973151 T C 9.97E-04 Type 2 diabetes / / 17463246 rs7474896 chr10 37982097 C T 9.00E-07 Obesity (extreme) / / 19553259 rs7090858 chr10 38003670 C A 1.14E-05 Serum metabolites / / 19043545 rs11011346 chr10 38009483 C T 6.70E-04 Asthma / / 20698975 rs11011366 chr10 38074158 A G 3.27E-04 Multiple complex diseases / / 17554300 rs1208681 chr10 38092975 C T 1.89E-05 Serum metabolites / / 19043545 rs3824585 chr10 38109421 T C 8.92E-04 Multiple complex diseases / / 17554300 rs11011415 chr10 38264389 T C 8.07E-04 Multiple complex diseases ZNF25 intron 17554300 rs11011417 chr10 38271117 C G 1.34E-05 Multiple complex diseases / / 17554300 rs633400 chr10 38329421 G C 5.80E-04 Multiple complex diseases ZNF33A intron 17554300 rs645064 chr10 38334341 C T 1.87E-05 Serum metabolites ZNF33A intron 19043545 rs496627 chr10 38350398 G A 2.56E-05 Serum metabolites / / 19043545 rs12357256 chr10 38359501 T C 7.30E-05 Multiple complex diseases / / 17554300 rs2505192 chr10 38395023 G A 7.41E-05 Suicide attempts in bipolar disorder ZNF37A intron 21423239 rs16937688 chr10 38416473 C T 7.20E-04 Alcohol dependence / / 21314694 rs2474598 chr10 38430296 T C 4.39E-05 Sarcoidosis / / 19165924 rs2505244 chr10 38456047 A G 5.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs11011491 chr10 38491972 C T 4.77E-04 Multiple complex diseases LOC100129055 intron 17554300 rs2749647 chr10 38549612 A G 2.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs2996580 chr10 38556338 T G 9.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs2983854 chr10 38579088 C T 8.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs2754426 chr10 38623469 A G 1.73E-04 Sarcoidosis / / 19165924 rs41359444 chr10 38645824 A G 3.57E-04 Multiple complex diseases HSD17B7P2 intron 17554300 rs2804672 chr10 38656887 G A 8.00E-06 Height HSD17B7P2 intron 22021425 rs2754361 chr10 38677789 T G 7.14E-04 Suicide attempts in bipolar disorder SEPT7L intron 21423239 rs7078894 chr10 38776846 T A 2.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs61848000 chr10 42598530 C T 2.15E-11 Metabolite levels / / 22286219 rs11239623 chr10 42636467 G A 1.77E-04 Bipolar disorder / / 18317468 rs2505821 chr10 42816861 T A 4.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs2505838 chr10 42827951 G A 5.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs2505838 chr10 42827951 G A 9.10E-05 Parkinson's disease / / 21738487 rs531646281 chr10 42827951 GC G 5.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs531646281 chr10 42827951 GC G 9.10E-05 Parkinson's disease / / 21738487 rs2954824 chr10 42836036 G C 5.31E-04 Suicide attempts in bipolar disorder LOC441666 intron 21423239 rs2466475 chr10 42856143 A C 4.78E-04 Suicide attempts in bipolar disorder LOC441666 intron 21423239 rs2466481 chr10 42859628 A G 4.82E-04 Suicide attempts in bipolar disorder LOC441666 intron 21423239 rs2489684 chr10 42862079 T C 5.60E-04 Suicide attempts in bipolar disorder LOC441666 intron 21423239 rs2505803 chr10 42864101 A C 5.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs2505807 chr10 42868071 T C 7.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs2801943 chr10 42947627 T C 3.17E-05 Parkinson's disease CCNYL2 intron 21738487 rs7076849 chr10 42975859 T C 6.60E-04 Suicide attempts in bipolar disorder LOC84856 intron 21423239 rs1255410 chr10 42981321 A G 8.29E-04 Type 2 diabetes LOC84856 intron 17463246 rs1889310 chr10 42981695 A T 8.46E-04 Alcohol dependence LOC84856 intron 20201924 rs1889310 chr10 42981695 A T 7.11E-04 Suicide attempts in bipolar disorder LOC84856 intron 21423239 rs11239614 chr10 42982518 G A 7.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs11499092 chr10 42982645 T C 6.67E-04 Suicide attempts in bipolar disorder LOC84856 intron 21423239 rs11499095 chr10 42983525 G T 8.43E-04 Suicide attempts in bipolar disorder LOC84856 intron 21423239 rs1855450 chr10 42983707 G T 8.25E-04 Suicide attempts in bipolar disorder LOC84856 intron 21423239 rs6593349 chr10 42985292 G A 7.93E-04 Suicide attempts in bipolar disorder LOC84856 intron 21423239 rs1813564 chr10 42998764 C T 8.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs210270 chr10 43000810 T C 2.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs210269 chr10 43001447 A G 2.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs12218023 chr10 43006384 A C,T 1.55E-04 Multiple complex diseases / / 17554300 rs210236 chr10 43012693 T C 9.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs210260 chr10 43037887 A T 9.46E-04 Suicide attempts in bipolar disorder ZNF37BP intron 21423239 rs210222 chr10 43057076 T C 9.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs17157312 chr10 43060329 C T 3.33E-04 Bipolar disorder,schizoaffective / / 19567891 rs1255413 chr10 43066414 C T 4.34E-04 Type 2 diabetes / / 17463246 rs12218051 chr10 43072767 C T 3.64E-04 Bipolar disorder,schizoaffective / / 19567891 rs7921658 chr10 43075288 T C 7.06E-04 Bipolar disorder,schizoaffective / / 19567891 rs158391 chr10 43143078 T G 9.92E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs603671 chr10 43157138 C T 3.55E-04 Alzheimer's disease / / 17998437 rs12413418 chr10 43173569 T C 3.89E-05 Vaspin levels / / 22907691 rs12413418 chr10 43173569 T C 0.0000389 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs17158044 chr10 43185136 G C 8.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs11499099 chr10 43214703 T C 6.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs12245652 chr10 43218331 C T 9.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs2506101 chr10 43225806 T C 9.40E-05 Serum metabolites / / 19043545 rs1592158 chr10 43273356 G A 1.70E-06 Nonalcoholic fatty liver disease / / 21423719 rs7913831 chr10 43273866 T C 2.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs11239788 chr10 43327972 T G 1.27E-04 Suicide attempts in bipolar disorder BMS1 UTR-3 21423239 rs2142991 chr10 43341105 C T 3.00E-07 Progressive supranuclear palsy / / 21685912 rs11239809 chr10 43384178 C A 9.49E-05 Diabetic nephropathy / / pha002852 rs11239832 chr10 43419367 C A 9.71E-04 Coronary Artery Disease / / 17634449 rs702373 chr10 43422802 A G 1.90E-05 Urinary metabolites / / 21572414 rs788261 chr10 43437970 T C 4.93E-05 Multiple complex diseases / / 17554300 rs3123719 chr10 43440029 C T 5.93E-05 Post-operative nausea and vomiting / / 21694509 rs2256432 chr10 43474623 C T 8.11E-06 Neuroblastoma / / pha002895 rs12572318 chr10 43483490 T C 4.30E-05 Tooth agenesis (third molar) / / 24172245 rs2506038 chr10 43488908 C A 2.60E-04 Smoking initiation / / 24665060 rs947699 chr10 43493897 C T 3.66E-05 Post-operative nausea and vomiting / / 21694509 rs2506039 chr10 43499398 G A 3.28E-04 Smoking initiation / / 24665060 rs1271546 chr10 43505098 A G 6.92E-05 Hypertension / / pha003041 rs2565191 chr10 43529926 A G 8.73E-04 Multiple complex diseases / / 17554300 rs2565190 chr10 43530071 A C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2565190 chr10 43530071 A C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2565190 chr10 43530071 A C 6.82E-05 Cognitive impairment induced by topiramate / / 22091778 rs7088902 chr10 43549708 T C 2.74E-05 Gaucher disease severity / / 22388998 rs2435367 chr10 43566614 C T 1.50E-05 Urinary metabolites / / 21572414 rs2505995 chr10 43569653 A G 3.00E-15 Hirschsprung's disease / / 19196962 rs2506011 chr10 43574936 T C 5.98E-16 Hirschsprung's disease RET intron 19196962 rs2435356 chr10 43583150 A G 6.08E-04 Multiple complex diseases RET intron 17554300 rs2435356 chr10 43583150 A G 1.53E-16 Hirschsprung's disease RET intron 19196962 rs2506021 chr10 43584148 C T 2.37E-14 Hirschsprung's disease RET intron 19196962 rs2435342 chr10 43584256 T C 1.03E-14 Hirschsprung's disease RET intron 19196962 rs12247456 chr10 43588196 G A 5.21E-05 Hypertension RET intron 19609347 rs2505538 chr10 43591403 A G 1.44E-15 Hirschsprung's disease RET intron 19196962 rs2505533 chr10 43594453 T C 3.78E-17 Hirschsprung's disease RET intron 19196962 rs3123655 chr10 43595194 C G 2.43E-14 Hirschsprung's disease RET intron 19196962 rs1864403 chr10 43604950 A G 2.31E-15 Hirschsprung's disease RET intron 19196962 rs1864403 chr10 43604950 A G 4.06E-04 Smoking initiation RET intron 24665060 rs3026762 chr10 43610671 G T 6.00E-07 Smoking behavior RET intron 20418888 rs2742234 chr10 43612609 C T 4.00E-18 Hirschsprung's disease RET intron 19196962 rs2742236 chr10 43620551 G A 3.89E-09 Hirschsprung's disease RET intron 19196962 rs2565200 chr10 43622933 T C 1.89E-17 Hirschsprung's disease RET UTR-3 19196962 rs17028 chr10 43623812 C T 1.42E-06 Hirschsprung's disease RET UTR-3 19196962 rs17028 chr10 43623812 C T 2.97E-05 Cognitive test performance RET UTR-3 20125193 rs3026785 chr10 43625686 T C 3.46E-04 Alzheimer's disease (late onset) RET UTR-3 21379329 rs3004214 chr10 43631698 C T 1.94E-15 Hirschsprung's disease / / 19196962 rs2505513 chr10 43633537 C G 3.50E-05 Parkinson's disease / / 17052657 rs2505506 chr10 43645854 C T 7.53E-17 Hirschsprung's disease CSGAL/CT2 intron 19196962 rs7476512 chr10 43649563 T G 2.44E-05 Monocyte counts CSGAL/CT2 intron pha003089 rs2505557 chr10 43666016 C T 3.85E-04 Tourette syndrome CSGAL/CT2 intron 22889924 rs2505556 chr10 43666623 T C 1.37E-05 Monocyte counts CSGAL/CT2 intron pha003089 rs2503848 chr10 43672785 G A 4.09E-04 Tourette syndrome CSGAL/CT2 intron 22889924 rs2435377 chr10 43683600 C T 5.29E-17 Hirschsprung's disease / / 19196962 rs1254964 chr10 43695049 T C 3.18E-05 Monocyte counts RASGEF1A intron pha003089 rs12241923 chr10 43713047 T C 7.98E-04 Tourette syndrome RASGEF1A intron 22889924 rs12220534 chr10 43734306 T G 1.93E-16 Hirschsprung's disease RASGEF1A intron 19196962 rs1879310 chr10 43734775 T C 1.67E-16 Hirschsprung's disease RASGEF1A intron 19196962 rs7093409 chr10 43740067 A G 1.31E-16 Hirschsprung's disease RASGEF1A intron 19196962 rs10899786 chr10 43744583 G A 2.65E-04 Tourette syndrome RASGEF1A intron 22889924 rs12244413 chr10 43747330 G T 8.48E-04 Coronary heart disease RASGEF1A intron 21971053 rs7090455 chr10 43753532 C T 1.65E-11 Hirschsprung's disease RASGEF1A intron 19196962 rs28461806 chr10 43755754 T C 2.00E-06 Obesity-related traits RASGEF1A intron 23251661 rs28461806 chr10 43755754 T C 5.00E-08 Obesity-related traits RASGEF1A intron 23251661 rs1879307 chr10 43757943 G A 2.28E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) RASGEF1A intron 24023788 rs11816932 chr10 43767816 A G 8.89E-04 Alzheimer's disease / / 24755620 rs11816932 chr10 43767816 A G 9.92E-06 Heart Rate / / pha003051 rs1879316 chr10 43769444 T C 1.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2505526 chr10 43769891 A G 4.49E-09 Hirschsprung's disease / / 19196962 rs56080575 chr10 43788778 G A 1.52E-04 Telomere length / / 24478790 rs2503872 chr10 43793625 C T 9.52E-05 Prostate cancer / / pha002878 rs11238510 chr10 43813185 C T 7.70E-05 Cognitive function / / 24684796 rs2503875 chr10 43814049 G A 2.00E-07 Multiple sclerosis / / 20598377 rs2503876 chr10 43814896 A G 4.02E-06 Multiple sclerosis / / 20598377 rs2460535 chr10 43821380 C T 3.95E-05 Serum alpha1-antitrypsin levels / / 23990791 rs2460535 chr10 43821380 C T 4.33E-04 Telomere length / / 24478790 rs59383062 chr10 43847135 C A 1.46E-04 Telomere length / / 24478790 rs10466239 chr10 43849827 C T 5.62E-06 Telomere length / / 24478790 rs10466239 chr10 43849827 C T 7.00E-06 Telomere length / / 24478790 rs11814409 chr10 43852721 A C 3.39E-04 Telomere length / / 24478790 rs17366560 chr10 43856612 A T 7.33E-04 Obesity (extreme) / / 21935397 rs4514358 chr10 43861924 G A 9.87E-04 Multiple complex diseases / / 17554300 rs80027918 chr10 43881183 G A 1.91E-04 Telomere length HNRNPF UTR-3 24478790 rs13376803 chr10 43881355 A G 2.07E-04 Telomere length HNRNPF UTR-3 24478790 rs10409 chr10 43881921 A C,G 1.99E-04 Telomere length HNRNPF UTR-3 24478790 rs10899803 chr10 43940898 T C 1.85E-04 Telomere length ZNF487P intron 24478790 rs10899803 chr10 43940898 T C 1.85E-04 Telomere length ZNF487P intron 24478790 rs12775610 chr10 43981371 A G 4.94E-05 Smoking quantity / / 24665060 rs11813634 chr10 43987135 A G 2.50E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs3122227 chr10 43988273 C T 5.12E-04 Type 2 diabetes / / 17463246 rs1856398 chr10 44008335 A G 1.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12240317 chr10 44013866 A C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2393949 chr10 44014299 T C 9.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2999237 chr10 44017449 G C 2.26E-04 Multiple complex diseases / / 17554300 rs2999237 chr10 44017449 G C 3.78E-05 Insulin resistance / / 21901158 rs3006389 chr10 44017472 A G 6.18E-04 Multiple complex diseases / / 17554300 rs3006389 chr10 44017472 A G 8.98E-05 Insulin resistance / / 21901158 rs1338567 chr10 44020467 G A 3.51E-04 Multiple complex diseases / / 17554300 rs1338567 chr10 44020467 G A 6.17E-05 Insulin resistance / / 21901158 rs2999241 chr10 44021769 G A 8.94E-04 Type 2 diabetes / / 17463246 rs2999241 chr10 44021769 G A 3.37E-04 Multiple complex diseases / / 17554300 rs2999241 chr10 44021769 G A 1.23E-04 Insulin resistance / / 21901158 rs3122231 chr10 44027356 T C 3.22E-04 Multiple complex diseases / / 17554300 rs3122231 chr10 44027356 T C 9.95E-05 Insulin resistance / / 21901158 rs1338559 chr10 44030617 A G 3.86E-04 Insulin resistance / / 21901158 rs7099038 chr10 44038096 A C 2.08E-04 Multiple complex diseases / / 17554300 rs3006381 chr10 44046172 C T 1.25E-04 Multiple complex diseases / / 17554300 rs7893169 chr10 44050715 A G 7.64E-06 Alcohol and nictotine co-dependence / / 20158304 rs10793442 chr10 44051819 C A 7.64E-06 Alcohol and nictotine co-dependence ZNF239 UTR-3 20158304 rs7894102 chr10 44054967 G A 7.64E-06 Alcohol and nictotine co-dependence ZNF239 intron 20158304 rs2393938 chr10 44063812 T C 7.13E-06 Alcohol and nictotine co-dependence ZNF239 UTR-5 20158304 rs9326506 chr10 44068558 A C 7.80E-06 Type 2 diabetes ZNF239 intron 17463249 rs9326506 chr10 44068558 A C 7.03E-06 Multiple complex diseases ZNF239 intron 17554300 rs9422545 chr10 44070754 A G 9.94E-06 Multiple complex diseases / / 17554300 rs2066046 chr10 44099347 G A 1.10E-04 Insulin resistance / / 21901158 rs2039723 chr10 44109024 T C 3.97E-04 Insulin resistance ZNF485 intron 21901158 rs10899838 chr10 44109759 T C 6.63E-05 Blood Pressure ZNF485 intron pha003049 rs11238599 chr10 44114107 A T 7.12E-04 Insulin resistance / / 21901158 rs10793454 chr10 44115713 C T 6.22E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4078412 chr10 44124361 G A 4.05E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10899855 chr10 44182772 C G 1.25E-05 Multiple complex diseases / / 17554300 rs10751332 chr10 44196101 C T 4.97E-04 Premature ovarian failure / / 19508998 rs11238645 chr10 44207259 C T 3.41E-04 HIV-1 viral setpoint / / 17641165 rs11238646 chr10 44207375 C T 5.81E-05 HIV-1 viral setpoint / / 17641165 rs11238646 chr10 44207375 C T 3.88E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7903170 chr10 44223180 T C 2.46E-05 Body Mass Index / / pha003019 rs7903170 chr10 44223180 T C 2.81E-05 Body Mass Index / / pha003020 rs11238679 chr10 44233628 T C 5.33E-05 Body Mass Index / / pha003015 rs11238680 chr10 44234466 A G 9.68E-05 Body Mass Index / / pha003019 rs11238680 chr10 44234466 A G 1.76E-05 Body Mass Index / / pha003020 rs10793484 chr10 44254509 G T 2.10E-05 Body Mass Index / / pha003019 rs10793484 chr10 44254509 G T 2.20E-05 Body Mass Index / / pha003020 rs17154388 chr10 44283774 T G 1.73E-04 Multiple complex diseases / / 17554300 rs1540967 chr10 44303930 C T 8.64E-05 Prion diseases / / 22210626 rs7906426 chr10 44307607 A G 7.08E-04 Heart Failure / / pha002884 rs7079939 chr10 44312106 A C 5.63E-05 Gallstones / / 17632509 rs17154467 chr10 44312301 C T 7.10E-05 IgE levels / / 17255346 rs11238722 chr10 44315371 A G 1.00E-04 Information processing speed / / 21130836 rs7086449 chr10 44317118 C A 1.28E-07 Multiple complex diseases / / 17554300 rs11238724 chr10 44320547 G A 4.06E-06 Multiple complex diseases / / 17554300 rs10793500 chr10 44322048 T C 5.19E-05 Information processing speed / / 21130836 rs748715 chr10 44343087 C T 1.00E-04 Information processing speed C10orf136 intron 21130836 rs10899929 chr10 44373192 G A 1.00E-04 Information processing speed LOC100506835 intron 21130836 rs11238765 chr10 44375912 G T 2.80E-05 Urinary metabolites LOC100506835 intron 21572414 rs10899949 chr10 44406205 A G 2.25E-05 Vascular dementia LOC283033 intron 22116812 rs10899952 chr10 44427021 G T 4.75E-05 Vascular dementia LOC283033 intron 22116812 rs11238781 chr10 44428985 A G 4.24E-05 Vascular dementia LOC283033 intron 22116812 rs6593372 chr10 44433340 A G 5.31E-04 Smoking cessation LOC283033 intron 24665060 rs4948582 chr10 44435246 C T 2.70E-05 Urinary metabolites LOC283033 intron 21572414 rs10899953 chr10 44435882 T A 2.00E-05 Urinary metabolites LOC283033 intron 21572414 rs4948792 chr10 44437325 C T 1.60E-05 Urinary metabolites LOC283033 intron 21572414 rs1254860 chr10 44448020 C T 9.69E-05 Systemic sclerosis LOC283033 intron 21750679 rs1254671 chr10 44453049 T C 2.81E-04 Coronary Artery Disease LOC283033 intron 17634449 rs7924201 chr10 44456029 G T 9.09E-06 Obesity-related traits LOC283033 intron 23251661 rs1570846 chr10 44456480 G A 7.10E-04 Pulmonary function LOC283033 intron 23932459 rs1532232 chr10 44456716 G A 8.13E-04 Multiple complex diseases LOC283033 intron 17554300 rs898549 chr10 44458714 C T 6.00E-06 Obesity-related traits LOC283033 intron 23251661 rs2862856 chr10 44483397 G A 7.12E-05 HDL cholesterol / / pha003074 rs2862856 chr10 44483397 G A 1.31E-05 HDL cholesterol / / pha003075 rs10793513 chr10 44494546 G A 7.63E-04 Multiple complex diseases / / 17554300 rs10793514 chr10 44496971 T C 3.09E-04 Multiple complex diseases / / 17554300 rs35639687 chr10 44500807 CG C 6.96E-04 Coronary Artery Disease / / 17634449 rs7478408 chr10 44500807 C T 6.96E-04 Coronary Artery Disease / / 17634449 rs6593393 chr10 44520658 C T 6.56E-04 Type 2 diabetes / / 17463246 rs17154929 chr10 44524675 C T 1.00E-07 HIV-associated dementia / / 22628157 rs2047009 chr10 44539913 T G 0.000000035 Coronary artery disease (CAD) age <=50 / / 23202125 rs2047009 chr10 44539913 T G 0.000000824 Coronary artery disease with myocardial infarction / / 23202125 rs2047009 chr10 44539913 T G 0.00000343 Coronary artery disease (CAD) age >50 / / 23202125 rs2047009 chr10 44539913 T G 6.83E-10 Coronary artery disease / / 23202125 rs2047009 chr10 44539913 T G 9.41E-11 Coronary artery disease (CAD) (males) / / 23202125 rs2047009 chr10 44539913 T G 8.86E-06 Obesity-related traits / / 23251661 rs2047009 chr10 44539913 T G 4.79E-06 Coronary artery disease / / 24262325 rs10508881 chr10 44541565 A G 4.00E-07 Endometriosis / / 23472165 rs268322 chr10 44556602 C T 7.60E-05 Coronary heart disease / / pha003031 rs2639463 chr10 44566061 T C 4.75E-04 Coronary Artery Disease / / 17634449 rs268300 chr10 44580839 G A 8.21E-05 Intracranial aneurysm / / 20613766 rs11238863 chr10 44607426 A G 5.51E-06 Waist-hip ratio / / 20935629 rs268274 chr10 44632262 T C 5.82E-05 Waist Circumference / / pha003025 rs2802485 chr10 44670587 C T 1.62E-04 Multiple complex diseases / / 17554300 rs11238891 chr10 44670992 G T 2.64E-04 Insulin resistance / / 21901158 rs11238892 chr10 44671194 C T 2.20E-04 Type 2 diabetes / / 17463246 rs11238892 chr10 44671194 C T 9.15E-04 Insulin resistance / / 21901158 rs11238892 chr10 44671194 C T 2.48E-06 Glaucoma (primary open-angle) / / 22605921 rs3892077 chr10 44672151 T C 3.87E-05 Type 2 diabetes / / 17463246 rs1704228 chr10 44673050 C T 2.51E-04 Insulin resistance / / 21901158 rs1680635 chr10 44673148 G A 5.23E-05 Type 2 diabetes / / 17463246 rs1623851 chr10 44691241 A G 5.91E-04 Coronary Artery Disease / / 17634449 rs1627329 chr10 44691633 T C 6.58E-05 Coronary Artery Disease / / 17634449 rs11238911 chr10 44695862 G A 4.13E-04 Coronary Artery Disease / / 17634449 rs768676 chr10 44702681 T A 3.90E-04 Type 2 diabetes / / 17846126 rs88796 chr10 44737036 T C 9.52E-04 Type 2 diabetes / / 17463246 rs583489 chr10 44738688 C G 2.58E-05 Coronary Artery Disease / / 17634449 rs535176 chr10 44747059 C T 2.04E-05 Coronary Artery Disease / / 17634449 rs622472 chr10 44749211 A C 1.84E-06 Coronary Artery Disease / / 17634449 rs513391 chr10 44749708 A C 5.29E-05 Coronary Artery Disease / / 17634449 rs11238956 chr10 44749854 T C 0.000159 Coronary artery disease / / 23202125 rs687175 chr10 44751910 T C 9.73E-04 Multiple complex diseases / / 17554300 rs687175 chr10 44751910 T C 4.77E-07 Coronary Artery Disease / / 17634449 rs559580 chr10 44752078 T C 7.80E-04 Multiple complex diseases / / 17554300 rs559469 chr10 44752118 T C 7.75E-04 Multiple complex diseases / / 17554300 rs535949 chr10 44752330 G T 4.06E-07 Coronary Artery Disease / / 17634449 rs17155842 chr10 44752633 C T 0.000324 Coronary artery disease / / 23202125 rs671765 chr10 44752976 A G 9.38E-04 Multiple complex diseases / / 17554300 rs671765 chr10 44752976 A G 5.10E-07 Coronary Artery Disease / / 17634449 rs501120 chr10 44753867 T C 3.12E-04 Multiple complex diseases / / 17554300 rs501120 chr10 44753867 T C 9.00E-08 Coronary heart disease / / 17634449 rs501120 chr10 44753867 T C 9.00E-08 Coronary heart disease / / 21347282 rs501120 chr10 44753867 T C 9.58E-07 Coronary heart disease / / 22319020 rs501120 chr10 44753867 T C 0.000000318 Coronary artery disease (CAD) age >50 / / 23202125 rs501120 chr10 44753867 T C 0.0000125 Coronary artery disease (CAD) (males) / / 23202125 rs501120 chr10 44753867 T C 0.000139 Coronary artery disease (CAD) (females) / / 23202125 rs501120 chr10 44753867 T C 1.37E-08 Coronary artery disease / / 23202125 rs501120 chr10 44753867 T C 6.49E-08 Coronary artery disease (CAD) age <=50 / / 23202125 rs501120 chr10 44753867 T C 8.56E-11 Coronary artery disease with myocardial infarction / / 23202125 rs501120 chr10 44753867 T C 2.00E-06 Coronary artery disease / / 24262325 rs1746048 chr10 44775824 C T 8.39E-04 Multiple complex diseases / / 17554300 rs1746048 chr10 44775824 C T 5.73E-07 Coronary Artery Disease / / 17634449 rs1746048 chr10 44775824 C T 7.00E-09 Myocardial infarction (early onset) / / 19198609 rs1746048 chr10 44775824 C T 7.00E-09 Coronary heart disease / / 21347282 rs1746048 chr10 44775824 C T 3.00E-10 Coronary heart disease / / 21378990 rs1746048 chr10 44775824 C T 2.93E-10 Pericardial fat / / 22589742 rs1746049 chr10 44776310 C T 3.88E-04 Type 2 diabetes / / 17463246 rs1746049 chr10 44776310 C T 7.54E-04 Multiple complex diseases / / 17554300 rs1746049 chr10 44776310 C T 8.77E-07 Coronary Artery Disease / / 17634449 rs2862116 chr10 44795943 A G 5.49E-05 Heart Failure / / pha002885 rs1159931 chr10 44806042 G A 7.18E-04 Coronary Artery Disease / / 17634449 rs1159931 chr10 44806042 G A 7.19E-06 Post-operative nausea and vomiting / / 21694509 rs2146807 chr10 44813738 T C 5.39E-04 Multiple complex diseases / / 17554300 rs7082209 chr10 44814336 A G 9.47E-04 Multiple complex diseases / / 17554300 rs977754 chr10 44817419 G T 2.13E-04 Multiple complex diseases / / 17554300 rs1436931 chr10 44826733 G C 1.75E-04 Multiple complex diseases / / 17554300 rs1836982 chr10 44827164 G C 1.95E-04 Multiple complex diseases / / 17554300 rs10900020 chr10 44827197 A T 3.00E-06 Schizophrenia / / 23212062 rs12360225 chr10 44838832 A G 4.68E-04 Smoking quantity / / 24665060 rs11238999 chr10 44840479 G C 5.80E-33 Narcolepsy / / 19629137 rs17156166 chr10 44849429 A G 5.87E-04 Multiple complex diseases / / 17554300 rs266099 chr10 44860013 T C 1.77E-04 Multiple complex diseases / / 17554300 rs266095 chr10 44864168 C T 8.00E-09 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) / / 24554482 rs266089 chr10 44869427 A G 5.20E-18 Progranulin levels CXCL12 intron 21087763 rs266089 chr10 44869427 A G 5.20E-18 Myocardial infarction CXCL12 intron 21211798 rs3780891 chr10 44878713 G A 7.73E-05 Tunica Media CXCL12 intron pha003036 rs11239035 chr10 44911999 C T 7.13E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs1253941 chr10 44914035 C T 5.87E-04 Type 2 diabetes / / 17463246 rs1253933 chr10 44914384 G C 6.15E-04 Type 2 diabetes / / 17463246 rs1253932 chr10 44914499 G A 6.82E-04 Type 2 diabetes / / 17463246 rs1253928 chr10 44914953 C A 6.15E-04 Type 2 diabetes / / 17463246 rs1253743 chr10 44952832 A G 8.97E-04 Type 2 diabetes / / 17463246 rs10900040 chr10 44953571 T C 8.10E-04 Aortic root size / / 21223598 rs10900045 chr10 44972203 C T 0.000272 Salmonella-induced pyroptosis / / 22837397 rs1124063 chr10 44992284 C T 0.000231 Salmonella-induced pyroptosis / / 22837397 rs10900053 chr10 44998792 A G 0.000328 Salmonella-induced pyroptosis / / 22837397 rs7086617 chr10 45007607 C T 5.80E-04 Type 2 diabetes / / 17463246 rs11239104 chr10 45010296 C T 0.0000022 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment / / 23392654 rs11239104 chr10 45010296 C T 2.20E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs17485517 chr10 45011597 A G 0.000254 Salmonella-induced pyroptosis / / 22837397 rs10900058 chr10 45026907 A G 2.64E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7072122 chr10 45034672 C T 6.00E-07 Estradiol plasma levels (breast cancer) / / 23518928 rs2184770 chr10 45049680 G A 3.91E-04 Multiple complex diseases / / 17554300 rs11597734 chr10 45053522 G A 0.00026 Salmonella-induced pyroptosis / / 22837397 rs10159760 chr10 45059741 C A 1.27E-04 Smoking quantity / / 24665060 rs10159976 chr10 45059905 T C 3.10E-04 Smoking quantity / / 24665060 rs10793544 chr10 45060304 G A 1.64E-04 Smoking quantity / / 24665060 rs10047358 chr10 45060874 A C 3.19E-04 Smoking quantity / / 24665060 rs10047393 chr10 45061109 G A 9.70E-05 Bipolar disorder and schizophrenia / / 20889312 rs10047393 chr10 45061109 G A 3.74E-04 Smoking quantity / / 24665060 rs11239139 chr10 45062495 G A 4.14E-04 Smoking quantity / / 24665060 rs11239141 chr10 45063228 G A 3.22E-04 Smoking quantity / / 24665060 rs10793548 chr10 45064764 C T 3.66E-04 Smoking quantity / / 24665060 rs10900072 chr10 45066922 T G 3.45E-04 Smoking quantity / / 24665060 rs10900073 chr10 45066992 T C 3.04E-04 Smoking quantity / / 24665060 rs7083920 chr10 45071890 C T 1.80E-05 Attention deficit hyperactivity disorder / / 20732627 rs7083920 chr10 45071890 C T 7.84E-06 Bipolar disorder and schizophrenia / / 20889312 rs899889 chr10 45072819 G A 1.32E-05 Attention deficit hyperactivity disorder / / 20732627 rs1021055 chr10 45073211 G A 1.27E-05 Attention deficit hyperactivity disorder / / 20732627 rs10900075 chr10 45073383 T C 1.50E-05 Attention deficit hyperactivity disorder / / 20732627 rs10900075 chr10 45073383 T C 9.21E-06 Bipolar disorder and schizophrenia / / 20889312 rs11239157 chr10 45078170 C T 1.52E-05 Attention deficit hyperactivity disorder / / 20732627 rs11239157 chr10 45078170 C T 5.18E-06 Bipolar disorder and schizophrenia / / 20889312 rs7893928 chr10 45078943 C T 2.30E-05 Alzheimer's disease (late onset) / / 20885792 rs7893928 chr10 45078943 C T 2.30E-05 Alzheimer's disease (late onset) / / 21460841 rs1999774 chr10 45081394 T A 1.25E-05 Attention deficit hyperactivity disorder / / 20732627 rs1999774 chr10 45081394 T A 3.15E-06 Bipolar disorder and schizophrenia / / 20889312 rs17487074 chr10 45081692 C A 6.48E-05 Bipolar disorder and schizophrenia / / 20889312 rs17487074 chr10 45081692 C A 0.000112 Salmonella-induced pyroptosis / / 22837397 rs2061971 chr10 45089053 A G 2.42E-05 Attention deficit hyperactivity disorder / / 20732627 rs2061971 chr10 45089053 A G 8.02E-04 Smoking quantity / / 24665060 rs10900077 chr10 45103728 G A 6.08E-05 Bipolar disorder and schizophrenia / / 20889312 rs10900077 chr10 45103728 G A 0.000385 Salmonella-induced pyroptosis / / 22837397 rs7069381 chr10 45104415 G T 1.50E-05 Attention deficit hyperactivity disorder / / 20732627 rs7069381 chr10 45104415 G T 4.04E-06 Bipolar disorder and schizophrenia / / 20889312 rs1904837 chr10 45117466 G A 2.79E-06 Bipolar disorder and schizophrenia / / 20889312 rs1585913 chr10 45117976 G A 2.50E-06 Bipolar disorder / / 21738484 rs11239177 chr10 45123379 T C 3.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs1002589 chr10 45126887 T C 3.13E-06 Bipolar disorder and schizophrenia / / 20889312 rs7897295 chr10 45152612 C T 0.0006853 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7897295 chr10 45152612 C T 6.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7912000 chr10 45161042 G C 0.0007584 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7912000 chr10 45161042 G C 7.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1480597 chr10 45161109 C T 2.00E-06 Parkinson's disease / / 17052657 rs1480597 chr10 45161109 C T 3.76E-05 Bilirubin levels,in serum / / 19389676 rs4356177 chr10 45163568 T C 1.87E-05 Parkinson's disease / / 17052657 rs11239202 chr10 45171582 C T 6.00E-05 Prostate cancer / / 21743057 rs2170227 chr10 45174519 T C 0.0007879 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2170227 chr10 45174519 T C 7.88E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12358198 chr10 45176482 G C 1.50E-05 Urinary metabolites / / 21572414 rs7897547 chr10 45177654 G A 5.70E-04 Multiple complex diseases / / 17554300 rs7897547 chr10 45177654 G A 9.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7903994 chr10 45177834 A G 6.87E-04 Multiple complex diseases / / 17554300 rs7903994 chr10 45177834 A G 9.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7919204 chr10 45177853 C T 9.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12768956 chr10 45179743 T A 0.0008962 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12768956 chr10 45179743 T A 8.96E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12771080 chr10 45181334 C T 9.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs899888 chr10 45181550 A C 9.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs999473 chr10 45182316 A G 8.00E-06 Parkinson's disease / / 17052657 rs7077918 chr10 45183876 T C 6.00E-05 Prostate cancer / / 21743057 rs17501869 chr10 45184927 A G 0.0008592 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17501869 chr10 45184927 A G 8.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17501883 chr10 45186774 T G 0.0008533 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17501883 chr10 45186774 T G 8.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12571148 chr10 45186817 A G 9.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11239209 chr10 45187031 G A 6.00E-05 Prostate cancer / / 21743057 rs10900094 chr10 45193060 G A 6.00E-05 Prostate cancer / / 21743057 rs17156787 chr10 45193851 C A 0.0008218 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17156787 chr10 45193851 C A 8.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7071236 chr10 45194727 T C 6.00E-05 Prostate cancer / / 21743057 rs7083361 chr10 45194916 G A 6.00E-05 Prostate cancer / / 21743057 rs10508887 chr10 45195541 C T 6.00E-05 Prostate cancer / / 21743057 rs11239212 chr10 45195716 T A 6.00E-05 Prostate cancer / / 21743057 rs7902711 chr10 45197293 A G 1.00E-04 Prostate cancer / / 21743057 rs10793554 chr10 45199031 C T 6.00E-05 Prostate cancer / / 21743057 rs7082194 chr10 45200119 G A,C 1.00E-04 Prostate cancer / / 21743057 rs12569566 chr10 45206624 A G 9.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10900097 chr10 45208025 G A 9.65E-04 Multiple complex diseases / / 17554300 rs10900097 chr10 45208025 G A 6.00E-05 Prostate cancer / / 21743057 rs10508888 chr10 45208225 C T 0.000723 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10508888 chr10 45208225 C T 7.23E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12772796 chr10 45209441 A G 0.0007215 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12772796 chr10 45209441 A G 7.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7097094 chr10 45210690 T G 8.00E-06 Parkinson's disease / / 17052657 rs7097094 chr10 45210690 T G 7.94E-05 Serum metabolites / / 19043545 rs7097094 chr10 45210690 T G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17156829 chr10 45212097 C T 0.0007107 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17156829 chr10 45212097 C T 7.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10900098 chr10 45213993 G A 5.00E-05 Prostate cancer / / 21743057 rs9326520 chr10 45214296 T C 7.00E-05 Prostate cancer / / 21743057 rs7912289 chr10 45216720 A G 0.0006975 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7912289 chr10 45216720 A G 6.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11239222 chr10 45216984 C G 0.0007154 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11239222 chr10 45216984 C G 7.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17502557 chr10 45218392 T C 0.0006881 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17502557 chr10 45218392 T C 6.88E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10900099 chr10 45221505 G A 4.23E-04 Multiple complex diseases / / 17554300 rs10900099 chr10 45221505 G A 5.00E-05 Prostate cancer / / 21743057 rs10900107 chr10 45243171 T C 4.57E-04 Multiple complex diseases / / 17554300 rs2256688 chr10 45264421 A G 2.96E-04 HIV-1 progression to AIDS and death / / 21811574 rs2256688 chr10 45264421 A G 4.43E-05 HIV-1 progression to AIDS and death / / 21811574 rs10900114 chr10 45307205 T C 8.40E-06 Emphysema-related traits / / 20709820 rs7911712 chr10 45319654 G A 6.00E-06 Emphysema-related traits TMEM72-AS1 intron 20709820 rs17157105 chr10 45342116 C T 1.60E-04 Multiple complex diseases TMEM72-AS1 intron 17554300 rs1977324 chr10 45374098 T C 8.67E-07 Red blood cell traits TMEM72-AS1 intron 23222517 rs3740086 chr10 45375296 G A 7.54E-08 Red blood cell traits TMEM72-AS1 intron 23222517 rs11239271 chr10 45376294 T C 4.93E-09 Red blood cell traits TMEM72-AS1 intron 23222517 rs10900123 chr10 45376574 C T 2.42E-08 Red blood cell traits TMEM72-AS1 intron 23222517 rs914699 chr10 45377066 A C 8.66E-09 Red blood cell traits TMEM72-AS1 intron 23222517 rs12250074 chr10 45378289 G A 5.65E-04 Multiple complex diseases TMEM72-AS1 intron 17554300 rs4948643 chr10 45379759 T C 9.05E-07 Red blood cell traits TMEM72-AS1 intron 23222517 rs10793562 chr10 45380472 A G 5.14E-07 Red blood cell traits TMEM72-AS1 intron 23222517 rs5000415 chr10 45383674 C T 3.25E-09 Red blood cell traits TMEM72-AS1 intron 23222517 rs2065466 chr10 45384047 T C 6.28E-09 Red blood cell traits TMEM72-AS1 intron 23222517 rs1570985 chr10 45384409 G A 9.64E-04 Alzheimer's disease TMEM72-AS1 intron 22005930 rs4506594 chr10 45384811 A G 3.11E-07 Red blood cell traits TMEM72-AS1 intron 23222517 rs4439464 chr10 45384876 T G 1.02E-07 Red blood cell traits TMEM72-AS1 intron 23222517 rs4948922 chr10 45385828 A C 7.99E-08 Red blood cell traits TMEM72-AS1 intron 23222517 rs4948924 chr10 45386046 T C 9.83E-08 Red blood cell traits TMEM72-AS1 intron 23222517 rs10900126 chr10 45386322 G T 2.75E-09 Red blood cell traits TMEM72-AS1 intron 23222517 rs10793564 chr10 45386352 C A 5.36E-09 Red blood cell traits TMEM72-AS1 intron 23222517 rs10793565 chr10 45388231 G C 7.48E-10 Red blood cell traits TMEM72-AS1 intron 23222517 rs2026428 chr10 45389452 T C 6.44E-10 Red blood cell traits TMEM72-AS1 intron 23222517 rs2183994 chr10 45389940 T C 3.65E-07 Red blood cell traits TMEM72-AS1 intron 23222517 rs10900127 chr10 45390103 C A 1.47E-07 Red blood cell traits TMEM72-AS1 intron 23222517 rs4948645 chr10 45391481 A G 2.68E-09 Red blood cell traits TMEM72-AS1 intron 23222517 rs4948925 chr10 45392455 G A 4.31E-10 Red blood cell traits TMEM72-AS1 intron 23222517 rs4948926 chr10 45392604 G C 5.92E-07 Red blood cell traits TMEM72-AS1 intron 23222517 rs10900128 chr10 45393201 G T 3.87E-09 Red blood cell traits TMEM72-AS1 intron 23222517 rs12777258 chr10 45394961 C T 5.27E-07 Red blood cell traits TMEM72-AS1 intron 23222517 rs7909074 chr10 45395839 G A 1.86E-10 Red blood cell traits TMEM72-AS1 intron 23222517 rs10751360 chr10 45396971 G A 5.00E-10 Red blood cell traits TMEM72-AS1 intron 23222517 rs10751361 chr10 45398186 C A 3.35E-07 Red blood cell traits TMEM72-AS1 intron 23222517 rs879074 chr10 45400053 G A 7.87E-10 Red blood cell traits TMEM72-AS1 intron 23222517 rs6593447 chr10 45400235 G A 4.10E-07 Red blood cell traits TMEM72-AS1 intron 23222517 rs7079573 chr10 45400406 G A 2.05E-08 Red blood cell traits TMEM72-AS1 intron 23222517 rs879344 chr10 45400667 G C 2.66E-07 Red blood cell traits TMEM72-AS1 intron 23222517 rs4268464 chr10 45401081 T A 4.13E-10 Red blood cell traits TMEM72-AS1 intron 23222517 rs10736831 chr10 45402311 G A 1.28E-08 Red blood cell traits TMEM72-AS1 intron 23222517 rs1332624 chr10 45402325 G A 3.06E-04 Smoking cessation TMEM72-AS1 intron 24665060 rs2281840 chr10 45406291 G A 2.40E-07 Red blood cell traits TMEM72-AS1 intron 23222517 rs2281841 chr10 45406608 T C 4.57E-08 Red blood cell traits TMEM72-AS1 intron 23222517 rs4147126 chr10 45407333 G T 4.87E-08 Red blood cell traits TMEM72-AS1 intron 23222517 rs869156 chr10 45479052 C A 4.84E-06 Response to lithium treatment in bipolar disorder RASSF4 intron 21961650 rs2297492 chr10 45491371 T C 2.81E-04 Multiple complex diseases / / 17554300 rs10751363 chr10 45528928 A T 7.72E-04 Type 2 diabetes / / 17463246 rs2311846 chr10 45545941 C G 7.72E-04 Type 2 diabetes / / 17463246 rs1936394 chr10 45547962 G A 1.00E-05 Urinary metabolites / / 21572414 rs12413425 chr10 45551814 T G 9.60E-06 Cognitive decline (age-related) / / 24468470 rs12358699 chr10 45553729 G A 9.00E-06 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs12358699 chr10 45553729 G A 9.47E-06 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4948954 chr10 45668241 C T 8.29E-04 Parkinson's disease LOC338579 intron 17052657 rs1815630 chr10 45715369 C T 3.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs2000017 chr10 45718996 C A 2.49E-05 Magnesium levels / / pha003092 rs7912637 chr10 45723417 T C 8.49E-05 Magnesium levels / / pha003092 rs10900189 chr10 45731301 C G,T 3.45E-06 Squamous cell carcinoma / / 23341777 rs17441991 chr10 45736643 A G 9.00E-04 Endometrial cancer / / 24096698 rs7919239 chr10 45898356 C A 7.55E-05 Personality dimensions ALOX5 intron 18957941 rs2115819 chr10 45901089 A G 1 Drug response to Montelukast ALOX5 intron 16293801 rs7090328 chr10 45918076 A G 1.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ALOX5 intron 20877124 rs3740107 chr10 45923770 A G 1.85E-07 Coronary heart disease ALOX5 intron 22319020 rs3780909 chr10 45925215 T A 5.90E-04 Coronary heart disease ALOX5 intron 21966275 rs1059696 chr10 45934437 G A 8.76E-05 Rheumatoid arthritis ALOX5 intron 21452313 rs2288619 chr10 45939818 C T 1.45E-11 Red blood cell traits ALOX5 intron 23222517 rs7089063 chr10 45946389 C A 2.57E-08 Other erythrocyte phenotypes / / 19862010 rs7089063 chr10 45946389 C A 2.42E-08 Red blood cell traits / / 23222517 rs17523413 chr10 45948175 C G,T 1.57E-11 Red blood cell traits / / 23222517 rs3740111 chr10 45951716 G A 5.85E-11 Red blood cell traits / / 23222517 rs3824618 chr10 45952433 C T 1.55E-11 Red blood cell traits MARCH8 nearGene-3 23222517 rs3824616 chr10 45952929 T C 3.67E-11 Red blood cell traits MARCH8 UTR-3 23222517 rs7908745 chr10 45953767 A G 4.54E-07 Red blood cell traits MARCH8 missense 23222517 rs2279433 chr10 45954807 A G 1.14E-11 Red blood cell traits MARCH8 intron 23222517 rs2279434 chr10 45955064 C T 2.60E-11 Blood cell counts and other traits MARCH8 intron 20139978 rs2279434 chr10 45955064 C T 3.82E-12 Blood cell counts and other traits MARCH8 intron 20139978 rs2279434 chr10 45955064 C T 4.00E-12 Blood cell counts and other traits MARCH8 intron 20139978 rs2279434 chr10 45955064 C T 2.90E-07 Red blood cell traits MARCH8 intron 23222517 rs3764990 chr10 45956828 G A 7.44E-12 Red blood cell traits MARCH8 missense 23222517 rs17157825 chr10 45958676 G A 7.69E-12 Red blood cell traits MARCH8 intron 23222517 rs2291429 chr10 45958881 A C,G 9.00E-11 Blood metabolite levels MARCH8 intron 24816252 rs12769244 chr10 45959385 G A 3.43E-09 Red blood cell traits MARCH8 intron 23222517 rs12771275 chr10 45959652 C A 7.90E-12 Red blood cell traits MARCH8 intron 23222517 rs10900218 chr10 45961422 A G 2.45E-08 Other erythrocyte phenotypes MARCH8 intron 19862010 rs10900218 chr10 45961422 A G 1.88E-09 Red blood cell traits MARCH8 intron 23222517 rs17157832 chr10 45961761 T G 2.01E-11 Red blood cell traits MARCH8 intron 23222517 rs963029 chr10 45963387 C T 2.39E-08 Other erythrocyte phenotypes MARCH8 intron 19862010 rs963029 chr10 45963387 C T 5.74E-07 Red blood cell traits MARCH8 intron 23222517 rs17157836 chr10 45963586 T C 5.16E-12 Red blood cell traits MARCH8 intron 23222517 rs17157839 chr10 45963777 T C 5.58E-11 Red blood cell traits MARCH8 intron 23222517 rs901682 chr10 45965861 C T 1.22E-11 Red blood cell traits MARCH8 intron 23222517 rs901683 chr10 45966422 G A 2.00E-16 Red blood cell traits MARCH8 intron 23222517 rs901684 chr10 45966628 G A 3.32E-12 Red blood cell traits MARCH8 intron 23222517 rs768673 chr10 45966749 G A 3.01E-12 Red blood cell traits MARCH8 intron 23222517 rs10508895 chr10 45967768 C T 1.54E-11 Red blood cell traits MARCH8 intron 23222517 rs17157852 chr10 45967801 C G 1.17E-09 Red blood cell traits MARCH8 intron 23222517 rs12779281 chr10 45977447 T C 2.54E-12 Red blood cell traits MARCH8 intron 23222517 rs11239535 chr10 45978387 C T 8.81E-09 Red blood cell traits MARCH8 intron 23222517 rs10900220 chr10 45983922 A G 6.21E-09 Red blood cell traits MARCH8 intron 23222517 rs12774690 chr10 45989745 G T 3.84E-11 Red blood cell traits MARCH8 intron 23222517 rs12764652 chr10 45991978 G A 1.52E-09 Red blood cell traits MARCH8 intron 23222517 rs10900222 chr10 45997366 G T 8.60E-09 Red blood cell traits MARCH8 intron 23222517 rs11239541 chr10 46001866 C T 4.81E-09 Red blood cell traits MARCH8 intron 23222517 rs12773463 chr10 46003631 A C 7.00E-12 Red blood cell traits MARCH8 intron 23222517 rs12766550 chr10 46011355 C G 1.22E-11 Red blood cell traits MARCH8 intron 23222517 rs12772485 chr10 46011421 T C 1.58E-09 Red blood cell traits MARCH8 intron 23222517 rs970548 chr10 46013277 A C 2.00E-10 HDL cholesterol MARCH8 intron 24097068 rs970548 chr10 46013277 A C 8.00E-09 Cholesterol,total MARCH8 intron 24097068 rs12781186 chr10 46013438 A G 5.90E-12 Red blood cell traits MARCH8 intron 23222517 rs12779198 chr10 46013547 G A 5.77E-09 Red blood cell traits MARCH8 intron 23222517 rs12762495 chr10 46013615 T C 9.37E-09 Red blood cell traits MARCH8 intron 23222517 rs17157880 chr10 46014488 A G 4.52E-12 Red blood cell traits MARCH8 intron 23222517 rs12257537 chr10 46014671 T C 4.53E-05 Rheumatoid arthritis MARCH8 intron 21452313 rs17157884 chr10 46015942 C T 5.82E-12 Red blood cell traits MARCH8 intron 23222517 rs11239548 chr10 46018168 T A 2.49E-08 Red blood cell traits MARCH8 intron 23222517 rs1073525 chr10 46024620 G A 4.80E-05 Personality dimensions MARCH8 intron 18957941 rs11239550 chr10 46024729 A G 1.00E-10 Mean corpuscular volume MARCH8 intron 19862010 rs11239550 chr10 46024729 A G 4.01E-09 Blood cell counts and other traits MARCH8 intron 20139978 rs11239550 chr10 46024729 A G 8.84E-10 Red blood cell traits MARCH8 intron 23222517 rs10508896 chr10 46030643 A G 5.67E-12 Red blood cell traits MARCH8 intron 23222517 rs10466245 chr10 46031747 G A 2.36E-05 Rheumatoid arthritis MARCH8 intron 21452313 rs17157898 chr10 46037209 C G 8.76E-09 Red blood cell traits MARCH8 intron 23222517 rs12776291 chr10 46038507 T C 1.08E-08 Red blood cell traits MARCH8 intron 23222517 rs12781506 chr10 46038702 T C 1.42E-08 Red blood cell traits MARCH8 intron 23222517 rs12774453 chr10 46038921 G A 1.68E-10 Red blood cell traits MARCH8 intron 23222517 rs9422439 chr10 46040473 C T 5.94E-12 Red blood cell traits MARCH8 intron 23222517 rs1982796 chr10 46042573 G A 2.00E-07 Red blood cell traits MARCH8 intron 23222517 rs12779976 chr10 46042932 A G 2.67E-09 Red blood cell traits MARCH8 intron 23222517 rs17157919 chr10 46044092 G T 1.62E-09 Red blood cell traits MARCH8 intron 23222517 rs9422440 chr10 46045125 C T 7.01E-11 Red blood cell traits MARCH8 intron 23222517 rs9422650 chr10 46045761 G T 2.62E-09 Red blood cell traits MARCH8 intron 23222517 rs9422651 chr10 46047456 G A 3.24E-08 Red blood cell traits MARCH8 intron 23222517 rs9422441 chr10 46048053 A G 6.83E-11 Red blood cell traits MARCH8 intron 23222517 rs9422442 chr10 46048078 C A 8.59E-07 Red blood cell traits MARCH8 intron 23222517 rs17157928 chr10 46048229 C T 8.93E-11 Red blood cell traits MARCH8 intron 23222517 rs9422653 chr10 46048918 G A 3.58E-08 Red blood cell traits MARCH8 intron 23222517 rs9422655 chr10 46051408 T C 1.52E-09 Red blood cell traits MARCH8 intron 23222517 rs17451208 chr10 46051905 C G 1.25E-10 Red blood cell traits MARCH8 intron 23222517 rs9422657 chr10 46053061 G A 1.10E-09 Red blood cell traits MARCH8 intron 23222517 rs17157931 chr10 46054359 T C 9.85E-07 Red blood cell traits MARCH8 intron 23222517 rs7086046 chr10 46076235 G A 2.41E-05 Rheumatoid arthritis MARCH8 intron 21452313 rs12779637 chr10 46081096 T C 1.83E-09 Red blood cell traits MARCH8 intron 23222517 rs1060848 chr10 46111950 A G 1.23E-07 Red blood cell traits ZFAND4 cds-synon 23222517 rs34082391 chr10 46121704 T C 0.00065 Breast cancer ZFAND4 missense 23555315 rs12267385 chr10 46122199 G A 2.38E-04 Rheumatoid arthritis ZFAND4 missense 21452313 rs10793621 chr10 46122794 G A 8.00E-06 Prostate cancer ZFAND4 intron 21743057 rs11239577 chr10 46129300 A C 8.00E-06 Prostate cancer ZFAND4 intron 21743057 rs17157944 chr10 46148266 A G 1.37E-07 Red blood cell traits ZFAND4 intron 23222517 rs17157945 chr10 46148301 T A 1.14E-07 Red blood cell traits ZFAND4 intron 23222517 rs17696005 chr10 46148750 C T 5.23E-04 Type 2 diabetes ZFAND4 intron 17463246 rs17696005 chr10 46148750 C T 1.20E-07 Red blood cell traits ZFAND4 intron 23222517 rs11239587 chr10 46158519 T C 8.00E-06 Prostate cancer ZFAND4 intron 21743057 rs17159090 chr10 46207801 C T 7.26E-04 Type 2 diabetes / / 17463246 rs17159090 chr10 46207801 C T 5.54E-07 Red blood cell traits / / 23222517 rs11239591 chr10 46208186 G A 1.00E-04 Prostate cancer / / 21743057 rs17696112 chr10 46210751 C T 4.89E-04 Type 2 diabetes / / 17463246 rs17696112 chr10 46210751 C T 1.31E-07 Red blood cell traits / / 23222517 rs17159119 chr10 46215766 C T 2.04E-07 Red blood cell traits / / 23222517 rs17158898 chr10 46220450 T A 5.84E-07 Red blood cell traits / / 23222517 rs1475815 chr10 46977566 C T 3.22E-04 Multiple complex diseases / / 17554300 rs1336003 chr10 46994321 G A 1.40E-05 Urinary metabolites GPRIN2 intron 21572414 rs1105347 chr10 46995474 A G 2.60E-05 Urinary metabolites GPRIN2 intron 21572414 rs7895435 chr10 47600464 G A 6.59E-04 Multiple complex diseases / / 17554300 rs7088096 chr10 47609552 G T 3.57E-05 Serum metabolites / / 19043545 rs12761764 chr10 47665412 C G 3.70E-04 Suicide attempts in bipolar disorder ANTXRL intron 21423239 rs4076960 chr10 47667164 C T 2.30E-04 HIV-1 viral setpoint ANTXRL intron 17641165 rs7081666 chr10 47673801 C T 9.09E-05 Multiple complex diseases ANTXRL intron 17554300 rs7081666 chr10 47673801 C T 4.91E-04 Acute lung injury ANTXRL intron 22295056 rs3013795 chr10 47684875 T G 1.37E-05 Hirschsprung's disease ANTXRL intron 19196962 rs3013794 chr10 47685591 C T 7.31E-04 Response to taxane treatment (placlitaxel) ANTXRL intron 23006423 rs7090464 chr10 48353676 T C 7.29E-04 Alcohol dependence / / 21314694 rs4922517 chr10 48368856 C A 7.48E-05 Post-operative nausea and vomiting ZNF488 intron 21694509 rs3814160 chr10 48371277 C T 3.12E-04 Suicide attempts in bipolar disorder ZNF488 missense 21041247 rs17457528 chr10 48380049 A G 3.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs11204213 chr10 48388228 C T 1.00E-13 Corneal curvature RBP3 missense 24963161 rs3758494 chr10 48392070 C G 1.59E-04 Parkinson's disease RBP3 nearGene-5 16252231 rs3781226 chr10 48416258 C T 2.34E-05 Blood Pressure GDF2 intron pha003048 rs7093975 chr10 48424759 T C 6.54E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs762454 chr10 48427246 T C 4.76E-05 Socioeconomic Factors GDF10 intron pha003067 rs11593867 chr10 48443093 G A 1.20E-05 Urinary metabolites / / 21572414 rs732315 chr10 48452661 A G 1.25E-23 Narcolepsy / / 19629137 rs10082400 chr10 48463136 C T 7.66E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12414155 chr10 48471020 T C 6.59E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs11204227 chr10 48471360 C T 1.70E-05 Urinary metabolites / / 21572414 rs9421819 chr10 48482576 G C 7.21E-04 Alzheimer's disease / / 17998437 rs4584515 chr10 48517085 G A 8.46E-04 Type 2 diabetes / / 17463246 rs9421758 chr10 48533604 G T 1.93E-04 Alzheimer's disease (late onset) / / 21379329 rs4545491 chr10 48551702 G A 2.80E-05 Urinary metabolites / / 21572414 rs12218639 chr10 48573990 G A 3.25E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs896570 chr10 48593635 G A 3.88E-07 Esophageal cancer (squamous cell) / / 22960999 rs9422352 chr10 48607823 T C 5.80E-05 Hypothyroidism / / 22493691 rs786792 chr10 48628441 T C 4.13E-04 Premature ovarian failure / / 19508998 rs930739 chr10 48628790 A G 9.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs786806 chr10 48637416 C T 3.87E-05 Premature ovarian failure / / 19508998 rs786806 chr10 48637416 C T 3.87E-05 Other erythrocyte phenotypes / / 19862010 rs2790937 chr10 48639880 A G 9.73E-05 Premature ovarian failure / / 19508998 rs2790937 chr10 48639880 A G 9.73E-05 Other erythrocyte phenotypes / / 19862010 rs786781 chr10 48658479 G A 1.14E-05 Premature ovarian failure / / 19508998 rs786781 chr10 48658479 G A 1.14E-05 Other erythrocyte phenotypes / / 19862010 rs17011052 chr10 49422750 C A,G,T 1.20E-06 Urinary metabolites FRMPD2 intron 21572414 rs7076472 chr10 49426489 T C 9.30E-05 Type 2 diabetes FRMPD2 intron 17463246 rs745708 chr10 49445675 A G 3.36E-04 Type 2 diabetes FRMPD2 intron 17463246 rs745708 chr10 49445675 A G 1.23E-22 Narcolepsy FRMPD2 intron 19629137 rs905184 chr10 49446204 T C 9.73E-04 Type 2 diabetes FRMPD2 intron 17463246 rs169439 chr10 49450675 C A 1.30E-05 Alcohol and nictotine co-dependence FRMPD2 intron 20158304 rs11101297 chr10 49550128 A T 9.02E-05 Multiple complex diseases / / 17554300 rs2440861 chr10 49605139 T C 0.000713 Salmonella-induced pyroptosis / / 22837397 rs10857561 chr10 49608638 G A 0.000761 Salmonella-induced pyroptosis MAPK8 nearGene-5 22837397 rs2289805 chr10 49627912 T G 6.80E-06 Urinary metabolites MAPK8 intron 21572414 rs11101326 chr10 49662490 A G 3.23E-04 Aortic root size ARHGAP22 intron 21223598 rs11598657 chr10 49679917 C T 3.34E-04 Menopause (age at onset) ARHGAP22 intron 22267201 rs1077960 chr10 49698113 T G 7.91E-04 Response to taxane treatment (placlitaxel) ARHGAP22 intron 23006423 rs4838605 chr10 49699957 C T 2.00E-09 Diabetic retinopathy ARHGAP22 intron 21310492 rs12768718 chr10 49706201 A G 4.43E-05 Bipolar disorder ARHGAP22 intron 18317468 rs6537565 chr10 49712072 C T 1.17E-04 Bipolar disorder ARHGAP22 intron 18317468 rs7098760 chr10 49714842 A G 7.21E-05 Bipolar disorder ARHGAP22 intron 18317468 rs11101349 chr10 49715108 A C 5.63E-05 Bipolar disorder ARHGAP22 intron 18317468 rs10776612 chr10 49735563 C T 2.00E-06 Conduct disorder (symptom count) ARHGAP22 intron 20585324 rs747533 chr10 49756258 G A 1.14E-05 Self-employment ARHGAP22 intron 23593239 rs747532 chr10 49756362 C T 9.38E-05 Vaspin levels ARHGAP22 intron 22907691 rs747532 chr10 49756362 C T 0.0000938 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit ARHGAP22 intron 22907730 rs10776614 chr10 49763166 T C 7.00E-06 Self-employment ARHGAP22 intron 23593239 rs7098855 chr10 49787078 C T 8.98E-05 Parent of origin effect on language impairment (paternal) ARHGAP22 intron 24571439 rs12218054 chr10 49801239 C T 1.48E-05 Parent of origin effect on language impairment (paternal) ARHGAP22 intron 24571439 rs12218054 chr10 49801239 C T 9.65E-05 Body Mass Index ARHGAP22 intron pha003014 rs7914253 chr10 49807631 C A 2.20E-05 Personality dimensions ARHGAP22 intron 18957941 rs4562728 chr10 49857197 G C 9.02E-05 Serum metabolites ARHGAP22 intron 19043545 rs1057549 chr10 49867327 G A 1.29E-04 Osteoarthritis (knee and hip) / / 21177295 rs1057549 chr10 49867327 G A 7.83E-05 Osteoarthritis (knee and hip) / / 21177295 rs10857619 chr10 49907313 A G 3.11E-05 Cholesterol WDFY4 intron pha003083 rs7897333 chr10 49910210 A G 1.78E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WDFY4 intron 20877124 rs7897333 chr10 49910210 A G 6.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WDFY4 intron 20877124 rs7897333 chr10 49910210 A G 7.12E-05 Cholesterol WDFY4 intron pha003083 rs1871608 chr10 49918427 C T 3.58E-04 Schizophrenia WDFY4 intron 20832056 rs1871608 chr10 49918427 C T 1.90E-05 Urinary metabolites WDFY4 intron 21572414 rs10776638 chr10 49920031 T A 4.67E-04 Schizophrenia WDFY4 intron 20832056 rs1904601 chr10 49920608 G T 2.89E-04 Schizophrenia WDFY4 intron 20832056 rs1904601 chr10 49920608 G T 1.90E-05 Urinary metabolites WDFY4 intron 21572414 rs7069001 chr10 49927163 A T 8.84E-04 Multiple complex diseases WDFY4 intron 17554300 rs17781278 chr10 49930541 G A 6.32E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) WDFY4 intron 23648065 rs11101442 chr10 49936336 C T 3.00E-06 Systemic lupus erythematosus WDFY4 intron 19165918 rs2620902 chr10 49970226 G A 1.50E-05 Urinary metabolites WDFY4 intron 21572414 rs11101474 chr10 49981436 A G 4.19E-06 Obesity and osteoporosis WDFY4 intron 19714249 rs10857636 chr10 49985110 C T 2.00E-07 Response to antidepressant treatment WDFY4 intron 22041458 rs2663037 chr10 50010018 C T 1.50E-05 Urinary metabolites WDFY4 intron 21572414 rs2448539 chr10 50015211 T G 9.85E-05 Cognitive test performance WDFY4 intron 20125193 rs7097397 chr10 50025396 G A 8.00E-12 Systemic lupus erythematosus WDFY4 missense 20169177 rs12264297 chr10 50025604 C T 3.66E-04 Schizophrenia WDFY4 intron 19197363 rs7098906 chr10 50027770 C T 1.00E-05 Urinary metabolites WDFY4 intron 21572414 rs10857650 chr10 50030023 G A 1.00E-05 Urinary metabolites WDFY4 intron 21572414 rs3747878 chr10 50030242 G C 1.10E-05 Urinary metabolites WDFY4 intron 21572414 rs12248218 chr10 50035284 G A 3.26E-05 Cognitive test performance WDFY4 intron 20125193 rs877819 chr10 50042951 A G 8.00E-09 Systemic lupus erythematosus WDFY4 intron 23273568 rs7922169 chr10 50045456 T G 2.67E-05 Cognitive test performance WDFY4 intron 20125193 rs11101533 chr10 50058563 C T 5.76E-06 Brachial circumference WDFY4 intron 22479309 rs11101535 chr10 50064431 T C 2.40E-06 Urinary metabolites WDFY4 intron 21572414 rs17836494 chr10 50080669 G A 3.50E-06 Urinary metabolites WDFY4 intron 21572414 rs12777007 chr10 50082108 C T 8.66E-05 Cognitive test performance WDFY4 intron 20125193 rs2671692 chr10 50097819 G A 2.60E-05 Rheumatoid arthritis WDFY4 intron 24390342 rs2671692 chr10 50097819 G A 3.00E-09 Rheumatoid arthritis WDFY4 intron 24390342 rs2671692 chr10 50097819 G A 9.90E-06 Rheumatoid arthritis WDFY4 intron 24390342 rs2943244 chr10 50100889 A C 4.34E-06 Rheumatoid arthritis WDFY4 intron 19503088 rs12252129 chr10 50103072 A G 5.28E-04 Multiple complex diseases WDFY4 intron 17554300 rs2663041 chr10 50107537 T C 7.83E-05 Rheumatoid arthritis WDFY4 intron 17804836 rs3849150 chr10 50109223 C T 2.00E-06 Subclinical atherosclerosis WDFY4 intron 17903303 rs3849150 chr10 50109223 C T 5.51E-04 Schizophrenia WDFY4 intron 19197363 rs3849150 chr10 50109223 C T 2.73E-05 Behcet's disease WDFY4 intron pha002888 rs1913517 chr10 50119054 A G 5.67E-06 Rheumatoid arthritis WDFY4 intron 17804836 rs1913517 chr10 50119054 A G 1.70E-08 Rheumatoid arthritis WDFY4 intron 19503088 rs1913517 chr10 50119054 A G 7.00E-12 Systemic lupus erythematosus WDFY4 intron 19838193 rs1913517 chr10 50119054 A G 3.10E-06 Systemic lupus erythematosus WDFY4 intron 23273568 rs17772611 chr10 50122109 C T 7.12E-05 Cognitive test performance LRRC18 missense 20125193 rs7094610 chr10 50122181 C A 5.70E-10 Systemic lupus erythematosus LRRC18 missense 19838193 rs11101565 chr10 50126875 C T 7.72E-05 Cervical cancer WDFY4 intron 24700089 rs2671702 chr10 50135158 A G 7.72E-05 Cervical cancer WDFY4 intron 24700089 rs2663018 chr10 50147024 C T 2.82E-04 Cholesterol WDFY4 intron 17255346 rs1317894 chr10 50183737 T C 2.60E-05 Body Mass Index WDFY4 intron pha003009 rs1317894 chr10 50183737 T C 6.01E-05 Glucose levels WDFY4 intron pha003057 rs2252811 chr10 50192120 A C 1.11E-04 Alzheimer's disease (late onset) / / 20885792 rs6537587 chr10 50194408 C T 5.57E-04 Multiple complex diseases / / 17554300 rs2249294 chr10 50197484 G A 4.98E-04 Multiple complex diseases / / 17554300 rs883017 chr10 50217438 T C 4.04E-05 Body Mass Index / / pha003021 rs883016 chr10 50217522 T C 4.00E-04 Multiple complex diseases / / 17554300 rs17700388 chr10 50218092 A G 7.89E-04 Multiple complex diseases / / 17554300 rs2244967 chr10 50224766 C T 5.00E-06 Uric acid levels VSTM4 UTR-3 21294900 rs2137920 chr10 50229638 T A 1.00E-06 Migraine with aura VSTM4 intron 23793025 rs2254410 chr10 50238355 A G 1.74E-06 Uric acid levels VSTM4 intron 21294900 rs12776211 chr10 50249026 T C 2.45E-04 Height VSTM4 intron 17255346 rs7082096 chr10 50250604 G T 1.22E-04 Height VSTM4 intron 17255346 rs2250146 chr10 50250732 A C 1.56E-04 Height VSTM4 intron 17255346 rs7897289 chr10 50268763 T C 3.31E-06 Multiple complex diseases VSTM4 intron 17554300 rs17011757 chr10 50287798 G A 2.38E-04 Multiple complex diseases VSTM4 intron 17554300 rs12776460 chr10 50288931 G T 1.63E-04 Multiple complex diseases VSTM4 intron 17554300 rs12269023 chr10 50293456 A G 1.80E-05 Multiple complex diseases VSTM4 intron 17554300 rs10508910 chr10 50293567 G A 3.96E-04 Coronary Artery Disease VSTM4 intron 17634449 rs4508127 chr10 50294263 A G 1.27E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) VSTM4 intron 17982456 rs4317904 chr10 50294670 G A 3.00E-05 Multiple complex diseases VSTM4 intron 17554300 rs4317904 chr10 50294670 G A 2.80E-04 Crohn's disease and Celiac disease VSTM4 intron 21298027 rs4129035 chr10 50295011 A C 6.64E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) VSTM4 intron 17982456 rs7097933 chr10 50302895 A G 1.44E-05 Multiple complex diseases VSTM4 intron 17554300 rs10508911 chr10 50306386 C T 6.86E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) VSTM4 intron 17982456 rs4298825 chr10 50307302 A G 4.55E-04 Coronary Artery Disease VSTM4 intron 17634449 rs12245255 chr10 50315080 C G 5.02E-05 Body mass index VSTM4 intron 19584900 rs12245255 chr10 50315080 C G 6.17E-05 Body mass index VSTM4 intron 19584900 rs4838446 chr10 50317778 C T 6.67E-05 Multiple complex diseases VSTM4 intron 17554300 rs12255055 chr10 50318484 G A 1.68E-04 Multiple complex diseases VSTM4 intron 17554300 rs4558091 chr10 50321918 C T 4.94E-05 Multiple complex diseases VSTM4 intron 17554300 rs11100990 chr10 50325055 C G 2.19E-05 Multiple complex diseases / / 17554300 rs4350286 chr10 50327100 T C 5.69E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs7100655 chr10 50338363 T C 2.20E-04 Multiple complex diseases LOC100506733 intron 17554300 rs6537499 chr10 50340749 T A 1.30E-04 Multiple complex diseases FAM170B intron 17554300 rs10218995 chr10 50343022 G A 2.00E-04 Information processing speed LOC100506733 intron 21130836 rs4319434 chr10 50345140 A G 8.93E-05 Multiple complex diseases LOC100506733 intron 17554300 rs2725190 chr10 50357789 C A 1.50E-04 Multiple complex diseases LOC100506733 intron 17554300 rs2725191 chr10 50357832 G T 1.02E-04 Multiple complex diseases LOC100506733 intron 17554300 rs2804938 chr10 50365546 A G 1.35E-04 Multiple complex diseases C10orf128 intron 17554300 rs2725181 chr10 50369372 A T 2.16E-05 Multiple complex diseases C10orf128 intron 17554300 rs2725180 chr10 50369395 A G 1.55E-04 Multiple complex diseases C10orf128 intron 17554300 rs2725180 chr10 50369395 A G 8.60E-05 Information processing speed C10orf128 intron 21130836 rs10857437 chr10 50381921 G A 1.73E-05 Psoriasis C10orf128 intron 18364390 rs17701543 chr10 50426613 G A 4.44E-05 Cognitive impairment induced by topiramate / / 22091778 rs2377990 chr10 50436199 G A 9.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2377990 chr10 50436199 G A 9.80E-05 Personality dimensions / / 18957941 rs10857448 chr10 50436863 T A 3.60E-05 Personality dimensions / / 18957941 rs17774280 chr10 50447244 A G 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12776010 chr10 50453668 A G 2.20E-06 Urinary metabolites / / 21572414 rs17009617 chr10 50453933 G A 5.00E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11812365 chr10 50469281 T C 1.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6537521 chr10 50496662 A G 6.43E-05 Cognitive test performance / / 20125193 rs1001338 chr10 50498449 T G 5.66E-05 Cognitive test performance / / 20125193 rs17774576 chr10 50500459 C G 5.00E-06 Oleic acid (18:1n-9) plasma levels / / 23362303 rs4838493 chr10 50512384 C T 4.11E-04 Multiple complex diseases C10orf71 intron 17554300 rs11101084 chr10 50519197 T C 6.93E-04 Type 2 diabetes C10orf71 intron 17463246 rs190417157 chr10 50532542 A G 0.00012 Prostate cancer (advanced) C10orf71 missense 23555315 rs4838508 chr10 50561507 T C 2.00E-06 HIV-1 control / / 20041166 rs12220898 chr10 50576633 C T 1.00E-06 Inflammatory biomarkers DRGX intron 22228203 rs1924490 chr10 50643498 T C 2.75E-04 White matter integrity / / 22425255 rs1924490 chr10 50643498 T C 8.48E-04 Heart Failure / / pha002885 rs7076173 chr10 50693350 C T 8.51E-05 White matter integrity ERCC6 intron 22425255 rs4838524 chr10 50710123 C T 1.58E-04 White matter integrity ERCC6 intron 22425255 rs958967 chr10 50710620 G A 1.58E-04 White matter integrity ERCC6 intron 22425255 rs4253038 chr10 50736979 A G 7.72E-04 Multiple complex diseases ERCC6 intron 17554300 rs17177717 chr10 50764503 A G 2.68E-04 Type 2 diabetes / / 17463246 rs1949884 chr10 50771419 A G 2.70E-05 Urinary metabolites / / 21572414 rs10857508 chr10 50773264 G C 3.64E-05 Postoperative ventricular dysfunction / / 21980348 rs10857512 chr10 50790190 G T 1.96E-04 Type 2 diabetes / / 17463246 rs11527800 chr10 50794437 A C 2.27E-05 Postoperative ventricular dysfunction / / 21980348 rs11101175 chr10 50798560 A C 5.66E-05 Postoperative ventricular dysfunction / / 21980348 rs1917805 chr10 50805983 A G 6.09E-07 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs3729496 chr10 50821191 G T 1.50E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma CHAT UTR-5 22205395 rs1880676 chr10 50824117 G A 4.20E-04 Type 2 diabetes CHAT missense 17463246 rs78925077 chr10 50830155 C G 0.0001 Breast cancer CHAT missense 23555315 rs8178990 chr10 50830171 C T 6.77E-04 Acute lung injury CHAT missense 22295056 rs3793791 chr10 50841704 C T 4.09E-04 Multiple complex diseases CHAT intron 17554300 rs4838544 chr10 50856652 G A 1.95E-10 LDL cholesterol / / 23063622 rs1343772 chr10 50884948 T C 3.00E-06 Smoking behavior / / 20418888 rs1258192 chr10 50994547 T C 2.62E-05 Cognitive performance / / 19734545 rs1438928 chr10 51043786 T C 7.21E-04 Multiple complex diseases / / 17554300 rs1438929 chr10 51043865 G A 6.12E-04 Multiple complex diseases / / 17554300 rs2611512 chr10 51515534 A G 2.70E-12 Prostate cancer / / 18264097 rs2926494 chr10 51517356 T C 3.00E-07 PCA3 expression level / / 23555189 rs7077830 chr10 51522276 C G 1.82E-04 Type 2 diabetes / / 17463246 rs3123078 chr10 51524971 C T 1.20E-15 Prostate cancer / / 18264097 rs3123078 chr10 51524971 C T 1.00E-19 Prostate cancer / / 19767753 rs3123078 chr10 51524971 C T 1.00E-19 Nasopharyngeal carcinoma / / 20512145 rs7920517 chr10 51532621 G A 1.30E-19 Prostate cancer / / 18264097 rs11006207 chr10 51538176 T C 2.81E-08 Prostate cancer / / 18264096 rs11006207 chr10 51538176 T C 3.90E-14 Prostate cancer / / 18264097 rs10993994 chr10 51549496 T C 7.00E-13 Prostate cancer MSMB nearGene-5 18264096 rs10993994 chr10 51549496 T C 9.00E-29 Prostate cancer MSMB nearGene-5 18264097 rs10993994 chr10 51549496 T C 9.00E-29 Nasopharyngeal carcinoma MSMB nearGene-5 20512145 rs10993994 chr10 51549496 T C 3.00E-08 Prostate cancer MSMB nearGene-5 20676098 rs10993994 chr10 51549496 T C 7.00E-13 Prostate-specific antigen levels MSMB nearGene-5 21160077 rs10993994 chr10 51549496 T C 5.00E-06 Prostate cancer MSMB nearGene-5 21743057 rs10993994 chr10 51549496 T C 5.00E-17 Prostate-specific antigen levels MSMB nearGene-5 23269536 rs10993994 chr10 51549496 T C 1.00E-09 PCA3 expression level MSMB nearGene-5 23555189 rs10993994 chr10 51549496 T C 1.90E-07 Prostate cancer (early onset) MSMB nearGene-5 24740154 rs10993994 chr10 51549496 T C 2.00E-07 Prostate cancer (early onset) MSMB nearGene-5 24740154 rs10993994 chr10 51549496 T C 3.00E-26 Prostate cancer MSMB nearGene-5 24753544 rs17178655 chr10 51561799 G A 7.78E-06 Alcohol and nictotine co-dependence MSMB intron 20158304 rs10994675 chr10 51563993 G A 3.99E-04 Lymphocyte counts NCOA4 nearGene-5 22286170 rs10740051 chr10 51570152 G A 9.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) NCOA4 intron 23648065 rs7085433 chr10 51593354 G A 6.00E-10 Blood cell counts and other traits TIMM23 intron 20139978 rs7085433 chr10 51593354 G A 6.42E-10 Blood cell counts and other traits TIMM23 intron 20139978 rs7085433 chr10 51593354 G A 6.73E-09 Blood cell counts and other traits TIMM23 intron 20139978 rs2002129 chr10 51787804 G A,C,T 8.02E-05 Bone mineral density FLJ31813 intron 19181680 rs7098222 chr10 51792797 A G 6.99E-04 Multiple complex diseases FLJ31813 intron 17554300 rs3964873 chr10 51822906 C T 1.22E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines FLJ31813 intron 21844884 rs10825492 chr10 52008730 G A 1.57E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs2196463 chr10 52008748 G A 5.83E-04 Follicle stimulating hormone / / 24049095 rs1898198 chr10 52009648 A G 1.28E-05 Opioid sensitivity / / 23183491 rs10508921 chr10 52010708 C T 4.30E-04 Crohn's disease / / 17684544 rs10508921 chr10 52010708 C T 9.00E-07 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1865749 chr10 52013434 A C 4.06E-05 Post-operative nausea and vomiting / / 21694509 rs1865749 chr10 52013434 A C 2.04E-04 Dental caries / / 21940522 rs11004819 chr10 52013640 C T 1.29E-05 Opioid sensitivity / / 23183491 rs2574983 chr10 52019288 A G 2.83E-04 Dental caries / / 21940522 rs7082758 chr10 52032084 A G 2.96E-06 Post-operative nausea and vomiting / / 21694509 rs10508925 chr10 52036514 G A 2.78E-04 Renal cell carcinoma / / 22010048 rs2813323 chr10 52039157 G A 7.79E-04 Alcohol dependence / / 20201924 rs12358176 chr10 52088004 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SGMS1 intron 22628534 rs2574975 chr10 52119297 T C 5.00E-06 Response to amphetamines SGMS1 intron 22952603 rs10508927 chr10 52127451 A G 1.02E-04 Smoking initiation SGMS1 intron 24665060 rs11005387 chr10 52132743 C T 7.90E-05 Coffee consumption SGMS1 intron 21357676 rs12355439 chr10 52135089 A G 1.02E-04 Bipolar disorder SGMS1 intron 17486107 rs7477280 chr10 52157935 C T 7.15E-04 Parkinson's disease SGMS1 intron 17052657 rs11005626 chr10 52188013 C T 6.67E-04 Tourette syndrome SGMS1 intron 22889924 rs12251514 chr10 52259794 A C 5.00E-06 QRS duration in Tripanosoma cruzi seropositivity SGMS1 intron 24324551 rs7904833 chr10 52279428 C A 5.76E-04 Amyotrophic Lateral Sclerosis SGMS1 intron 17827064 rs3011777 chr10 52285511 A G 3.47E-05 Lung adenocarcinoma SGMS1 intron 19836008 rs3011777 chr10 52285511 A G 4.16E-05 Pancreatic cancer SGMS1 intron pha002874 rs10826161 chr10 52296835 T C 5.29E-04 Type 2 diabetes SGMS1 intron 17463246 rs10826161 chr10 52296835 T C 9.75E-05 Amyotrophic Lateral Sclerosis SGMS1 intron 17827064 rs12415817 chr10 52297002 C T 5.47E-04 Type 2 diabetes SGMS1 intron 17463246 rs11006084 chr10 52301532 C T 9.75E-05 Amyotrophic Lateral Sclerosis SGMS1 intron 17827064 rs2144861 chr10 52309756 C G,T 6.12E-04 Type 2 diabetes SGMS1 intron 17463246 rs2144861 chr10 52309756 C G,T 4.71E-05 Tuberculosis SGMS1 intron 24057671 rs7921226 chr10 52336656 A T 4.71E-05 Odorant perception SGMS1 intron 23910658 rs10763566 chr10 52341930 G A 4.20E-04 Amyotrophic Lateral Sclerosis SGMS1 intron 17827064 rs6481433 chr10 52353186 G C 9.10E-05 Personality dimensions SGMS1 intron 18957941 rs12358192 chr10 52364839 C T 2.51E-04 Multiple complex diseases SGMS1 intron 17554300 rs4935737 chr10 52370312 T G 4.91E-05 Lymphocyte counts SGMS1 intron pha003094 rs4935737 chr10 52370312 T G 8.41E-05 Neutrophil count SGMS1 intron pha003095 rs7093195 chr10 52393270 A G 3.43E-04 Multiple complex diseases / / 17554300 rs17582633 chr10 52418427 A G 2.37E-04 Multiple complex diseases / / 17554300 rs3011759 chr10 52446582 T C 6.73E-04 Type 2 diabetes / / 17463246 rs3011759 chr10 52446582 T C 3.41E-04 Smoking initiation / / 24665060 rs7073683 chr10 52491639 C T 1.20E-05 Urinary metabolites / / 21572414 rs11815391 chr10 52578738 A G 9.50E-04 Suicide attempts in bipolar disorder A1CF intron 21423239 rs11815391 chr10 52578738 A G 1.13E-10 Urate levels A1CF intron 23263486 rs12413118 chr10 52581892 A G 1.98E-05 Orofacial clefts A1CF intron 22419666 rs10821871 chr10 52584110 T C 5.60E-04 Suicide attempts in bipolar disorder A1CF intron 21423239 rs10821871 chr10 52584110 T C 4.30E-04 Type 2 diabetes A1CF intron 22158537 rs10821871 chr10 52584110 T C 4.26E-10 Urate levels A1CF intron 23263486 rs10821871 chr10 52584110 T C 6.40E-05 Height A1CF intron pha003010 rs10821877 chr10 52603659 C T 4.80E-04 Suicide attempts in bipolar disorder A1CF intron 21423239 rs10821877 chr10 52603659 C T 2.98E-08 Urate levels A1CF intron 23263486 rs10994720 chr10 52612101 G A 9.09E-04 Suicide attempts in bipolar disorder A1CF intron 21423239 rs10994720 chr10 52612101 G A 1.78E-11 Urate levels A1CF intron 23263486 rs10994731 chr10 52614189 A G 1.10E-08 Urate levels A1CF intron 23263486 rs4567398 chr10 52616922 C T 6.75E-09 Urate levels A1CF intron 23263486 rs12768968 chr10 52621752 G C 5.53E-04 Suicide attempts in bipolar disorder A1CF intron 21423239 rs12768968 chr10 52621752 G C 7.66E-09 Urate levels A1CF intron 23263486 rs17592117 chr10 52643038 T C 3.65E-09 Urate levels A1CF intron 23263486 rs7901497 chr10 52643822 A G 9.35E-04 Multiple complex diseases A1CF intron 17554300 rs10994856 chr10 52645248 G A 5.20E-12 Urate levels A1CF intron 23263486 rs10994860 chr10 52645424 C T 6.62E-12 Urate levels A1CF UTR-5 23263486 rs10821905 chr10 52646093 G A 7.00E-17 Urate levels A1CF nearGene-5 23263486 rs3808919 chr10 52646344 A G 2.08E-08 Urate levels A1CF nearGene-5 23263486 rs10761587 chr10 52649193 T C 9.58E-11 Urate levels / / 23263486 rs4290173 chr10 52649771 C T 2.32E-08 Urate levels / / 23263486 rs10761599 chr10 52678031 C T 2.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1546501 chr10 52679867 G A 2.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7097894 chr10 52717885 A G 6.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6479812 chr10 52724799 A G 4.87E-04 Coronary heart disease / / 21971053 rs10995225 chr10 52739809 T A 4.58E-04 Type 2 diabetes / / 17463246 rs10995319 chr10 52762887 T C 6.55E-04 Type 2 diabetes PRKG1 intron 17463246 rs10995322 chr10 52763285 C T 1.25E-05 Coronary heart disease PRKG1 intron 21971053 rs2339686 chr10 52766038 G A 5.28E-04 Type 2 diabetes PRKG1 intron 17463246 rs2339686 chr10 52766038 G A 9.58E-04 Multiple complex diseases PRKG1 intron 17554300 rs2339686 chr10 52766038 G A 1.80E-04 Coronary heart disease PRKG1 intron 21971053 rs10822117 chr10 52786701 A G 2.08E-04 Coronary heart disease PRKG1 intron 21971053 rs6479874 chr10 52789355 T C 3.00E-07 Migraine PRKG1 intron 23793025 rs10822139 chr10 52792194 A G 1.04E-07 Facial morphology PRKG1 intron 22341974 rs10822139 chr10 52792194 A G 2.70E-04 Response to taxane treatment (placlitaxel) PRKG1 intron 23006423 rs10761738 chr10 52809354 G A 2.30E-06 Urinary metabolites PRKG1 intron 21572414 rs9414810 chr10 52839660 C G 7.70E-07 Urinary metabolites PRKG1 intron 21572414 rs9415711 chr10 52839673 T C 3.90E-07 Urinary metabolites PRKG1 intron 21572414 rs16913685 chr10 52848799 C T 6.25E-04 Myopia (pathological) PRKG1 intron 21095009 rs10995620 chr10 52858289 C T 2.60E-05 Urinary metabolites PRKG1 intron 21572414 rs10822229 chr10 52866170 C T 6.30E-06 Urinary metabolites PRKG1 intron 21572414 rs10508935 chr10 52866503 A G 2.80E-05 Urinary metabolites PRKG1 intron 21572414 rs1904694 chr10 52905494 A G 2.70E-05 Urinary metabolites PRKG1 intron 21572414 rs1904694 chr10 52905494 A G 8.17E-05 Hypertension,salt-sensitive PRKG1 intron 21573014 rs10508937 chr10 52913970 C T 1.75E-04 Scoliosis PRKG1 intron 21216876 rs1904683 chr10 52949162 G T 2.20E-05 Urinary metabolites PRKG1 intron 21572414 rs7897633 chr10 52957721 C A 1.28E-05 Hypertension,salt-sensitive PRKG1 intron 21573014 rs7905063 chr10 52964590 C T 1.90E-05 Hypertension,salt-sensitive PRKG1 intron 21573014 rs16915935 chr10 53015583 C T 4.05E-04 Multiple complex diseases PRKG1 intron 17554300 rs10490975 chr10 53020936 G T 7.21E-04 Alcohol dependence PRKG1 intron 20201924 rs12247775 chr10 53021623 C T 8.01E-04 Response to cytadine analogues (cytosine arabinoside) PRKG1 intron 24483146 rs3844131 chr10 53035096 C T 2.25E-04 Type 2 diabetes PRKG1 intron 17463246 rs11594220 chr10 53035622 G A 2.25E-04 Type 2 diabetes PRKG1 intron 17463246 rs10996555 chr10 53042298 G A 4.64E-04 Multiple complex diseases PRKG1 intron 17554300 rs10082503 chr10 53048204 T A 1.45E-04 Type 2 diabetes PRKG1 intron 17463246 rs10082503 chr10 53048204 T A 3.50E-04 Multiple complex diseases PRKG1 intron 17554300 rs2339710 chr10 53048551 G T 3.03E-04 Type 2 diabetes PRKG1 intron 17463246 rs10082353 chr10 53049844 A T 3.36E-04 Multiple complex diseases PRKG1 intron 17554300 rs12251902 chr10 53058385 C T 1.46E-05 Platelet counts PRKG1 intron 21507922 rs12261736 chr10 53068604 C T 3.50E-07 Parkinson's disease (age of onset) PRKG1 intron 19772629 rs16916799 chr10 53079432 T C 1.02E-04 Multiple complex diseases PRKG1 intron 17554300 rs211070 chr10 53080272 G C 5.15E-05 Multiple complex diseases PRKG1 intron 17554300 rs211072 chr10 53081072 A T 5.05E-05 Multiple complex diseases PRKG1 intron 17554300 rs293244 chr10 53199410 A C 8.56E-04 Response to taxane treatment (placlitaxel) PRKG1 intron 23006423 rs1348542 chr10 53218458 T G 9.71E-04 Response to taxane treatment (placlitaxel) PRKG1 intron 23006423 rs10508940 chr10 53218926 C T 6.23E-04 Response to taxane treatment (placlitaxel) PRKG1 intron 23006423 rs293300 chr10 53231446 C T 1.45E-04 Alzheimer's disease PRKG1 intron 22005930 rs1822689 chr10 53232902 A G 1.30E-04 Alzheimer's disease PRKG1 intron 22005930 rs7099012 chr10 53234048 C T 9.89E-04 Alzheimer's disease PRKG1 intron 22005930 rs1444400 chr10 53234155 G A 1.69E-04 Alzheimer's disease PRKG1 intron 22005930 rs1444401 chr10 53234928 T A,C,G 2.03E-04 Alzheimer's disease PRKG1 intron 22005930 rs10762173 chr10 53236736 A G 1.11E-04 Alzheimer's disease PRKG1 intron 22005930 rs6480276 chr10 53237452 G A 2.90E-04 Alzheimer's disease PRKG1 intron 22005930 rs293303 chr10 53237721 T G 1.36E-04 Alzheimer's disease PRKG1 intron 22005930 rs293305 chr10 53240557 T C 4.41E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer PRKG1 intron 21483023 rs293314 chr10 53242703 C T 7.00E-06 Obesity-related traits PRKG1 intron 23251661 rs2879571 chr10 53246907 C G 8.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) PRKG1 intron 17982456 rs10997790 chr10 53253450 T G 8.30E-05 Insulin-related traits PRKG1 intron pha002901 rs1952138 chr10 53262633 C T 3.00E-06 IgG glycosylation PRKG1 intron 23382691 rs1033968 chr10 53269467 G A 6.79E-04 Stroke PRKG1 intron pha002886 rs10128493 chr10 53276747 C A 9.93E-04 Amyotrophic lateral sclerosis (sporadic) PRKG1 intron 24529757 rs2038918 chr10 53291813 A G 8.33E-05 Cognitive performance PRKG1 intron 19734545 rs10998087 chr10 53316743 C G 1.17E-04 Attention deficit hyperactivity disorder PRKG1 intron 23728934 rs7923153 chr10 53350411 C A 8.68E-05 Major depressive disorder PRKG1 intron 21621269 rs11596256 chr10 53358808 A G 5.39E-04 Multiple complex diseases PRKG1 intron 17554300 rs7077665 chr10 53365208 G A 1.03E-04 Orofacial clefts PRKG1 intron 22419666 rs2339794 chr10 53375420 C T 5.69E-04 Alzheimer's disease PRKG1 intron 22005930 rs3829170 chr10 53393098 C T 5.80E-05 Major depressive disorder PRKG1 intron 21621269 rs4486574 chr10 53399900 T C 6.83E-05 Height PRKG1 intron pha003010 rs4486574 chr10 53399900 T C 7.37E-05 Height PRKG1 intron pha003011 rs7079618 chr10 53404013 A C 3.11E-04 Type 2 diabetes PRKG1 intron 17463246 rs1922131 chr10 53415680 C T 1.85E-05 Height PRKG1 intron pha003010 rs1922131 chr10 53415680 C T 2.10E-05 Height PRKG1 intron pha003011 rs4575213 chr10 53425328 C A 0.0000465 Otitis media (children 3 years old or younger) PRKG1 intron 23133572 rs4630239 chr10 53441007 T C 6.10E-05 Erythrocyte counts PRKG1 intron pha003099 rs10999076 chr10 53480225 G A 1.70E-05 Urinary metabolites PRKG1 intron 21572414 rs10762328 chr10 53480628 T A 9.90E-06 Urinary metabolites PRKG1 intron 21572414 rs11594325 chr10 53482734 C T 4.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PRKG1 intron 20877124 rs7922491 chr10 53493473 G A 5.00E-07 Asthma PRKG1 intron 21907864 rs1937690 chr10 53584234 A G 3.11E-04 Bipolar disorder PRKG1 intron 18317468 rs10508958 chr10 53588040 A C 3.20E-06 Selenium resistance in NCI60 cancer cell lines PRKG1 intron 20830292 rs12247820 chr10 53602190 A G 4.20E-06 Asthma PRKG1 intron 20698975 rs1937701 chr10 53608977 C T 1.51E-04 Alcohol dependence PRKG1 intron 20201924 rs1937701 chr10 53608977 C T 3.73E-04 White matter integrity PRKG1 intron 22425255 rs7080306 chr10 53613913 C T 9.57E-05 Alcohol dependence PRKG1 intron 20201924 rs7080306 chr10 53613913 C T 9.57E-05 Alcoholism PRKG1 intron pha002891 rs7080306 chr10 53613913 C T 1.19E-05 Heart Rate PRKG1 intron pha003051 rs7071831 chr10 53627833 T C 6.91E-04 Type 2 diabetes PRKG1 intron 17463246 rs4595495 chr10 53673286 A G 7.59E-04 Coronary heart disease PRKG1 intron 21606135 rs11000137 chr10 53681794 G T 3.00E-06 Migraine PRKG1 intron 23793025 rs11000189 chr10 53694448 G T 0.0003 Salmonella-induced pyroptosis PRKG1 intron 22837397 rs11000193 chr10 53695204 C A 0.000382 Salmonella-induced pyroptosis PRKG1 intron 22837397 rs7092969 chr10 53707749 T A 2.57E-06 Attention deficit hyperactivity disorder PRKG1 intron 20732627 rs2339898 chr10 53709352 T C 2.85E-05 Multiple complex diseases PRKG1 intron 17554300 rs17639165 chr10 53709427 C T 3.92E-04 Insulin resistance PRKG1 intron 21901158 rs7093940 chr10 53710220 C T 5.06E-05 Multiple complex diseases PRKG1 intron 17554300 rs7073794 chr10 53713519 G A 1.94E-04 Multiple complex diseases PRKG1 intron 17554300 rs1903960 chr10 53721176 T G 1.24E-05 Attention deficit hyperactivity disorder PRKG1 intron 20732627 rs1904033 chr10 53730294 C T 1.95E-04 Fibrinogen PRKG1 intron 17255346 rs2454568 chr10 53732919 C T 6.34E-05 Fibrinogen PRKG1 intron 17255346 rs1904046 chr10 53742120 C T 2.04E-04 Fibrinogen PRKG1 intron 17255346 rs11000404 chr10 53753066 C T 3.25E-04 Multiple complex diseases PRKG1 intron 17554300 rs4275567 chr10 53758289 A C 7.80E-04 Parkinson's disease PRKG1 intron 17052657 rs4935303 chr10 53769608 A G 3.49E-04 Sudden cardiac arrest PRKG1 intron 21658281 rs7893146 chr10 53772799 T C 2.87E-05 Attention deficit hyperactivity disorder PRKG1 intron 20732627 rs10823954 chr10 53773365 G A 3.01E-05 Attention deficit hyperactivity disorder PRKG1 intron 20732627 rs10762524 chr10 53773912 T G 9.89E-07 Attention deficit hyperactivity disorder PRKG1 intron 20732627 rs1903979 chr10 53774826 C T 1.21E-05 Attention deficit hyperactivity disorder PRKG1 intron 20732627 rs11000467 chr10 53775072 G C 1.67E-04 Multiple complex diseases PRKG1 intron 17554300 rs1903977 chr10 53776286 T A 1.50E-05 Attention deficit hyperactivity disorder PRKG1 intron 20732627 rs10823964 chr10 53777043 T G 7.84E-07 Attention deficit hyperactivity disorder PRKG1 intron 20732627 rs10823973 chr10 53779480 C G 6.32E-07 Attention deficit hyperactivity disorder PRKG1 intron 20732627 rs10823978 chr10 53787957 G A 3.51E-05 Attention deficit hyperactivity disorder PRKG1 intron 20732627 rs10762539 chr10 53788881 T G 7.12E-05 Serum metabolites PRKG1 intron 19043545 rs10762539 chr10 53788881 T G 3.24E-05 Attention deficit hyperactivity disorder PRKG1 intron 20732627 rs7901487 chr10 53789388 C T 3.42E-05 Attention deficit hyperactivity disorder PRKG1 intron 20732627 rs10762540 chr10 53789667 A C 1.28E-05 Serum metabolites PRKG1 intron 19043545 rs10762540 chr10 53789667 A C 3.62E-05 Attention deficit hyperactivity disorder PRKG1 intron 20732627 rs10823981 chr10 53792294 A T 0.0008126 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PRKG1 intron 23233654 rs10823981 chr10 53792294 A T 8.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) PRKG1 intron 23233662 rs11000542 chr10 53799265 G A 7.04E-05 Multiple complex diseases PRKG1 intron 17554300 rs17560636 chr10 53803755 A C 4.04E-04 Amyotrophic lateral sclerosis (sporadic) PRKG1 intron 24529757 rs17641137 chr10 53806602 C T 2.33E-04 Nicotine smoking PRKG1 intron 19268276 rs17641137 chr10 53806602 C T 5.35E-04 Alcohol dependence PRKG1 intron 20201924 rs17641202 chr10 53809894 A G 8.31E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PRKG1 intron 21844884 rs4411238 chr10 53821238 T C 3.24E-05 Type 2 diabetes PRKG1 intron 22158537 rs4935027 chr10 53838761 G A 3.04E-05 Type 2 diabetes PRKG1 intron 22158537 rs12255651 chr10 53841105 T C 5.94E-04 Response to cytadine analogues (cytosine arabinoside) PRKG1 intron 24483146 rs1904017 chr10 53853542 A G 3.39E-04 Telomere length PRKG1 intron 24478790 rs1904013 chr10 53859440 G T 7.40E-05 Telomere length PRKG1 intron 24478790 rs16926524 chr10 53859626 A G 3.54E-04 Type 2 diabetes PRKG1 intron 17463246 rs60830257 chr10 53867534 G A 6.90E-05 Telomere length PRKG1 intron 24478790 rs61448551 chr10 53874705 T C 4.70E-05 Telomere length PRKG1 intron 24478790 rs16927026 chr10 53887029 A G 6.50E-05 Telomere length PRKG1 intron 24478790 rs10458658 chr10 53891853 G A 3.13E-05 Multiple complex diseases PRKG1 intron 17554300 rs58118931 chr10 53893871 T C 7.10E-05 Telomere length PRKG1 intron 24478790 rs7911524 chr10 53895450 A C 8.16E-04 Type 2 diabetes PRKG1 intron 17463246 rs9415080 chr10 53946014 A T 9.23E-04 Multiple complex diseases PRKG1 intron 17554300 rs9416044 chr10 53959055 A T 5.85E-04 Multiple complex diseases PRKG1 intron 17554300 rs1194491 chr10 53966124 C A 5.64E-05 Parkinson's disease PRKG1 intron 21812969 rs10508964 chr10 53969988 C T 1.61E-04 Multiple complex diseases PRKG1 intron 17554300 rs1406476 chr10 53975769 A G 4.73E-04 Premature ovarian failure PRKG1 intron 19508998 rs1729581 chr10 53981353 T C 9.78E-04 Suicide attempts in bipolar disorder PRKG1 intron 21423239 rs1729578 chr10 53983258 T C 9.66E-04 Suicide attempts in bipolar disorder PRKG1 intron 21423239 rs10824262 chr10 53986505 G T 1.11E-04 Suicide attempts in bipolar disorder PRKG1 intron 21423239 rs2339954 chr10 53992507 G A 6.91E-05 Suicide attempts in bipolar disorder PRKG1 intron 21423239 rs7909144 chr10 54000704 A G 3.73E-04 Suicide attempts in bipolar disorder PRKG1 intron 21423239 rs1875792 chr10 54002801 A G 5.98E-04 Suicide attempts in bipolar disorder PRKG1 intron 21423239 rs1406473 chr10 54032702 G T 8.13E-05 Type 2 diabetes PRKG1 intron 17463246 rs7916242 chr10 54048234 G A 3.99E-04 Suicide attempts in bipolar disorder PRKG1 intron 21423239 rs1896373 chr10 54094359 T C 3.46E-04 Tourette syndrome / / 22889924 rs11001702 chr10 54103425 T C 1.37E-05 Melanoma / / 21926416 rs16929715 chr10 54117138 A G 7.34E-04 Type 2 diabetes / / 17463246 rs146295628 chr10 54125312 G T 9.40E-06 Periodontitis (Mean PAL) / / 24024966 rs112125027 chr10 54130753 A G 5.00E-06 Periodontitis (Mean PAL) / / 24024966 rs138374901 chr10 54133021 G T 4.75E-06 Periodontitis (Mean PAL) / / 24024966 rs1194671 chr10 54147789 C T 4.37E-04 Type 2 diabetes / / 17463246 rs1194670 chr10 54148044 A C 3.12E-04 Type 2 diabetes / / 17463246 rs1194668 chr10 54148626 G A 4.87E-04 Type 2 diabetes / / 17463246 rs1194659 chr10 54153551 C T 8.95E-04 Type 2 diabetes / / 17463246 rs16913607 chr10 54154221 C T 4.40E-04 Lung function (forced vital capacity) / / 24023788 rs1733706 chr10 54158576 A G 4.47E-05 Multiple sclerosis (age of onset) / / 19010793 rs1733706 chr10 54158576 A G 9.98E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7080407 chr10 54168713 C T 5.19E-04 Multiple complex diseases / / 17554300 rs10824464 chr10 54169153 T C 6.16E-04 Multiple complex diseases / / 17554300 rs11002016 chr10 54190471 C T 8.77E-04 Multiple complex diseases / / 17554300 rs1194713 chr10 54197690 G A 9.98E-05 Cervical cancer / / 24700089 rs7072401 chr10 54222700 T C 4.19E-04 Multiple complex diseases / / 17554300 rs1733724 chr10 54223977 A G 7.00E-08 Electrocardiographic traits / / 20062063 rs1733724 chr10 54223977 A G 3.00E-08 QRS duration / / 21076409 rs4935325 chr10 54240004 T C 3.76E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1660801 chr10 54263577 T C 8.53E-04 Tourette syndrome / / 22889924 rs1733717 chr10 54287113 C T 8.05E-06 Multiple complex diseases / / 17554300 rs10824621 chr10 54337021 C T 7.17E-05 IgE levels / / 17255346 rs2222800 chr10 54341873 A C 4.00E-06 Metabolite levels (X-11787) / / 23934736 rs10824650 chr10 54361898 A G 8.77E-04 Alcohol dependence / / 20201924 rs2136892 chr10 54370006 A T 8.90E-06 Urinary metabolites / / 21572414 rs2384019 chr10 54374214 A G 8.50E-06 Urinary metabolites / / 21572414 rs1912609 chr10 54379638 A G 2.80E-05 Urinary metabolites / / 21572414 rs11002799 chr10 54385382 C T 4.62E-05 Rheumatoid arthritis / / 17804836 rs2222801 chr10 54388248 G A 1.70E-05 Urinary metabolites / / 21572414 rs12414500 chr10 54389414 T C 1.40E-05 Urinary metabolites / / 21572414 rs959781 chr10 54399802 C T 1.67E-04 Alcohol dependence / / 20201924 rs7907873 chr10 54405190 G A 7.82E-04 Acute lung injury / / 22295056 rs7897096 chr10 54405286 T C 9.74E-04 Acute lung injury / / 22295056 rs1348350 chr10 54410202 C A 3.10E-06 Emphysema-related traits / / 20709820 rs1373004 chr10 54427825 T G 8.17E-04 Multiple complex diseases / / 17554300 rs1373004 chr10 54427825 T G 2.00E-12 Bone mineral density / / 22504420 rs1373004 chr10 54427825 T G 0.000149 Lumbar spine bone mineral density (premenopausal) / / 23074152 rs12262251 chr10 54431330 C T 6.79E-04 Multiple complex diseases / / 17554300 rs1373003 chr10 54431543 A G 5.19E-04 Multiple complex diseases / / 17554300 rs11003040 chr10 54433608 G A 4.43E-04 Multiple complex diseases / / 17554300 rs7902708 chr10 54439728 G C 1.00E-08 Bone properties (heel) / / 24430505 rs7902708 chr10 54439728 G C 5.00E-15 Bone properties (heel) / / 24430505 rs2218330 chr10 54440485 C T 1.70E-05 Urinary metabolites / / 21572414 rs11814440 chr10 54467459 C A 8.58E-04 Type 2 diabetes / / 17463246 rs10824773 chr10 54473501 C T 3.82E-07 Multiple complex diseases / / 17554300 rs11003074 chr10 54483538 C A 2.20E-05 Urinary metabolites / / 21572414 rs10824779 chr10 54488855 A G 1.45E-04 Type 2 diabetes / / 17463246 rs12385751 chr10 54499040 C T 3.80E-05 Bipolar disorder / / 17486107 rs12571712 chr10 54501332 T C 2.30E-04 Type 2 diabetes / / 17463246 rs1975458 chr10 54501717 C T 2.36E-04 Type 2 diabetes / / 17463246 rs1992529 chr10 54504049 C T 9.74E-04 Myocardial Infarction / / pha002873 rs10824787 chr10 54507871 T G 8.62E-04 Rheumatoid arthritis / / 21452313 rs3829168 chr10 54515590 A G 5.97E-04 Rheumatoid arthritis / / 21452313 rs10508975 chr10 54516331 A G 9.81E-04 Myocardial Infarction / / pha002873 rs16933073 chr10 54521090 C T 9.38E-04 Type 2 diabetes / / 17463246 rs10450310 chr10 54524658 G A 2.53E-04 Rheumatoid arthritis MBL2 nearGene-3 21452313 rs2120132 chr10 54526040 T C 9.67E-04 Rheumatoid arthritis MBL2 UTR-3 21452313 rs10082466 chr10 54526622 A G 2.50E-04 Rheumatoid arthritis MBL2 UTR-3 21452313 rs1982266 chr10 54530636 A G 6.09E-04 Cocaine dependence MBL2 intron 23958962 rs1800450 chr10 54531235 C T 7.03E-05 Stroke (ischemic) MBL2 missense 22941190 rs7899547 chr10 54536839 T G 5.27E-05 Depression (quantitative trait) / / 23290196 rs7083840 chr10 54544665 A C,T 1.90E-05 Urinary metabolites / / 21572414 rs12247509 chr10 54544685 G A 1.50E-05 Urinary metabolites / / 21572414 rs11003145 chr10 54559322 A G 0.0006152 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11003145 chr10 54559322 A G 6.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11003156 chr10 54559910 T C 0.0006155 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11003156 chr10 54559910 T C 6.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12412781 chr10 54560250 G A 0.0006144 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12412781 chr10 54560250 G A 6.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12771335 chr10 54561347 C G 0.0006155 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12771335 chr10 54561347 C G 6.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12771797 chr10 54561593 C T 0.0006164 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12771797 chr10 54561593 C T 6.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12772543 chr10 54561614 A G 0.0006166 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12772543 chr10 54561614 A G 6.17E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12772757 chr10 54561699 A T 0.0006277 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12772757 chr10 54561699 A T 6.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7922029 chr10 54562515 T A 0.0006357 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7922029 chr10 54562515 T A 6.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7901707 chr10 54562524 G A 0.0006381 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7901707 chr10 54562524 G A 6.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6480967 chr10 54562961 C T 0.0006428 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6480967 chr10 54562961 C T 6.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7478412 chr10 54563025 A G 0.0006459 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7478412 chr10 54563025 A G 6.46E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11003159 chr10 54563148 T C 0.0006471 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11003159 chr10 54563148 T C 6.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11003163 chr10 54563566 T C 0.0006619 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11003163 chr10 54563566 T C 6.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7918389 chr10 54570951 C A 5.88E-04 Alzheimer's disease / / 24755620 rs11003177 chr10 54571607 C T 5.67E-04 Alzheimer's disease / / 24755620 rs6480975 chr10 54574996 G C 2.00E-06 Age-related macular degeneration / / 23326517 rs6480975 chr10 54574996 G C 3.00E-06 Age-related macular degeneration / / 23326517 rs11817079 chr10 54583109 C T 1.80E-05 Urinary metabolites / / 21572414 rs4098805 chr10 54586048 T C 1.80E-05 Urinary metabolites / / 21572414 rs12777905 chr10 54617058 G A 2.10E-05 Urinary metabolites / / 21572414 rs11003231 chr10 54629374 G A 0.000862542 Hypertension (early onset hypertension) / / 22479346 rs10508976 chr10 54632299 T C 5.49E-04 Multiple complex diseases / / 17554300 rs4935369 chr10 54633231 C T 3.08E-04 Smoking quantity / / 24665060 rs11003240 chr10 54641214 C T 7.12E-04 Multiple complex diseases / / 17554300 rs16935229 chr10 54665583 T G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7907283 chr10 54669056 G A 8.30E-05 Depression (quantitative trait) / / 23290196 rs17590583 chr10 54669514 T C 1.82E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1343065 chr10 54676411 G A 4.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10508977 chr10 54684217 G A 0.0005 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs16935489 chr10 54695965 G A 9.90E-04 Type 2 diabetes / / 17463246 rs12571703 chr10 54697623 A G 5.75E-04 White matter integrity / / 22425255 rs10824843 chr10 54715100 A G 5.18E-04 Multiple complex diseases / / 17554300 rs10824843 chr10 54715100 A G 2.44E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs11003283 chr10 54717081 C T 2.19E-04 Type 2 diabetes / / 17463246 rs11003285 chr10 54717187 G T 1.92E-04 Type 2 diabetes / / 17463246 rs7900326 chr10 54756889 C T 4.80E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2249003 chr10 54765608 A C 2.70E-05 Asthma / / pha003127 rs12412945 chr10 54798107 C T 5.62E-05 Parkinson's disease / / 17052657 rs12412945 chr10 54798107 C T 7.66E-05 Body mass index / / 22446040 rs10824861 chr10 54799497 A G 1.31E-04 Multiple complex diseases / / 17554300 rs1917186 chr10 54799931 C T 2.73E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10508985 chr10 54830893 G A 2.71E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7090905 chr10 54831160 G A 1.84E-04 Multiple complex diseases / / 17554300 rs11003389 chr10 54865961 G A 2.89E-04 Multiple complex diseases / / 17554300 rs11003389 chr10 54865961 G A 6.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2384167 chr10 54955296 A G 4.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17678511 chr10 55000332 C T 1.42E-05 Glaucoma (primary open-angle) / / 22605921 rs4935411 chr10 55034244 G A 2.00E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10824975 chr10 55038946 A G 6.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs9664298 chr10 55104497 A G 3.57E-05 Prion diseases / / 22210626 rs2133469 chr10 55137245 G A 7.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10508995 chr10 55137361 C G 9.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12412561 chr10 55169541 T C 8.39E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs435882 chr10 55199970 T G 3.61E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs17693434 chr10 55216150 T C 4.30E-06 Urinary metabolites / / 21572414 rs187076 chr10 55228462 G A 0.0004553 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs187076 chr10 55228462 G A 4.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12762519 chr10 55268839 T G 9.50E-04 Glycemic traits (pregnancy) / / 23903356 rs10762991 chr10 55289571 T G 4.06E-05 Biliary atresia / / 20460270 rs431788 chr10 55294564 C A 7.51E-04 Multiple complex diseases / / 17554300 rs583012 chr10 55294874 G A 2.00E-06 Select biomarker traits / / 17903293 rs401030 chr10 55301556 C T 1.54E-05 Personality dimensions / / 22628180 rs452019 chr10 55329523 G A 8.27E-05 Parkinson's disease / / 21738487 rs17622628 chr10 55341602 T A 1.48E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs3120130 chr10 55343454 A G 9.58E-04 HIV-1 viral setpoint / / 17641165 rs3120130 chr10 55343454 A G 5.09E-04 Alcohol dependence / / 20201924 rs351847 chr10 55344712 T C 4.54E-04 Alcohol dependence / / 20201924 rs1932011 chr10 55357136 A C 8.49E-05 Alcohol dependence / / 20201924 rs1932011 chr10 55357136 A C 8.49E-05 Alcoholism / / pha002891 rs7904493 chr10 55365419 C A 3.89E-04 Alcohol dependence / / 20201924 rs7076633 chr10 55367359 T C 1.77E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1489843 chr10 55367569 G A 4.58E-04 Alcohol dependence / / 20201924 rs10825073 chr10 55371601 C T 1.13E-05 Colorectal cancer / / 21242260 rs6481026 chr10 55371788 G A 1.22E-05 Colorectal cancer / / 21242260 rs9416285 chr10 55381191 C T 4.19E-04 Alcohol dependence / / 20201924 rs12256830 chr10 55384743 C T 2.00E-10 Immune response to smallpox vaccine (IL-6) / / 22542470 rs7095328 chr10 55385962 C T 8.80E-06 Colorectal cancer / / 21242260 rs7095328 chr10 55385962 C T 2.29E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs9416286 chr10 55389030 T C 2.34E-05 Colorectal cancer / / 21242260 rs7906396 chr10 55391609 T C 1.90E-05 Colorectal cancer / / 21242260 rs11003722 chr10 55394615 A G 2.82E-06 Colorectal cancer / / 21242260 rs7078645 chr10 55395318 G A 1.70E-05 Colorectal cancer / / 21242260 rs7097226 chr10 55395380 A C 1.36E-05 Colorectal cancer / / 21242260 rs1565344 chr10 55405976 T C 6.88E-04 Multiple complex diseases / / 17554300 rs7077606 chr10 55407091 C T 5.00E-07 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs9416295 chr10 55413116 T C 9.93E-05 Alcohol dependence / / 20201924 rs9416295 chr10 55413116 T C 9.93E-05 Alcoholism / / pha002891 rs7923617 chr10 55417490 C A 1.64E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs11003740 chr10 55418087 C A 2.26E-05 Colorectal cancer / / 21242260 rs825820 chr10 55421304 T C 1.11E-04 Alcohol dependence / / 20201924 rs2130372 chr10 55421933 G A 1.43E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs17697015 chr10 55422701 A G 1.39E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs825809 chr10 55439533 C A 9.43E-05 Hemoglobin / / pha003096 rs7904689 chr10 55448875 T C 5.61E-07 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs10508997 chr10 55482641 A G 4.10E-04 Lipid traits / / 17903299 rs1578774 chr10 55488274 G A 0.00000828 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment / / 23392654 rs1578774 chr10 55488274 G A 8.28E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs7068100 chr10 55488573 G A 0.0000024 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment / / 23392654 rs7068100 chr10 55488573 G A 2.40E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1994576 chr10 55493719 G A 6.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10825102 chr10 55496705 G A 0.00000327 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment / / 23392654 rs10825102 chr10 55496705 G A 3.27E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs7085943 chr10 55496887 C G 0.00000367 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment / / 23392654 rs7085943 chr10 55496887 C G 3.67E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1387657 chr10 55497584 C T 0.00000234 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment / / 23392654 rs1387657 chr10 55497584 C T 2.34E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs11813807 chr10 55540590 G T 2.60E-06 Vitiligo / / 22561518 rs1954342 chr10 55551074 A C 1.13E-06 Vitiligo / / 22561518 rs79854148 chr10 55581779 T C 0.0009 Prostate cancer PCDH15 missense 23555315 rs1900418 chr10 55594810 A G 9.99E-04 Coronary heart disease PCDH15 intron 21971053 rs10825123 chr10 55611160 T G 1.34E-05 Cervical cancer PCDH15 intron 24700089 rs4478893 chr10 55635024 G A 2.75E-06 Post-operative nausea and vomiting PCDH15 intron 21694509 rs10825150 chr10 55645953 C T 2.00E-04 Cognitive impairment induced by topiramate PCDH15 intron 22091778 rs41487044 chr10 55646644 G A 8.22E-04 Multiple complex diseases PCDH15 intron 17554300 rs2921923 chr10 55662089 G A 5.71E-05 Post-operative nausea and vomiting PCDH15 intron 21694509 rs1900451 chr10 55677700 A G 3.00E-05 Lactate dehydrogenase levels PCDH15 intron 20981236 rs12412902 chr10 55685073 A G 6.65E-05 Melanoma PCDH15 intron 21926416 rs2121526 chr10 55686763 A G 2.11E-49 Multiple complex diseases PCDH15 intron 17554300 rs139087859 chr10 55721531 T C 0.0001 Breast cancer (ER positive) PCDH15 missense 23555315 rs1900438 chr10 55722449 G A 6.15E-05 Post-operative nausea and vomiting PCDH15 intron 21694509 rs2255126 chr10 55747471 G A 9.89E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PCDH15 intron 21844884 rs2926404 chr10 55753531 G A 8.59E-06 Hearing function PCDH15 intron 21493956 rs2660178 chr10 55766507 A G 6.54E-06 Hearing function PCDH15 intron 21493956 rs10509003 chr10 55767622 C T 7.10E-05 Lactate dehydrogenase levels PCDH15 intron 20981236 rs2384366 chr10 55777289 A C 7.06E-05 Multiple complex diseases PCDH15 intron 17554300 rs2221567 chr10 55825695 G T 8.70E-05 Triglycerides PCDH15 intron pha003080 rs11004071 chr10 55868485 G A,C 0.00000483 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment PCDH15 intron 23392654 rs11004071 chr10 55868485 G A,C 4.83E-06 Thiazide-induced adverse metabolic effects in hypertensive patients PCDH15 intron 23400010 rs7100992 chr10 55881882 C G 8.00E-05 Prostate cancer PCDH15 intron 21743057 rs7907790 chr10 55903108 C T 3.00E-05 Hypothyroidism PCDH15 intron 22493691 rs10825264 chr10 55947954 T G 1 Drug response to Etoposide PCDH15 intron 17537913 rs1561674 chr10 55948714 T C 4.69E-05 Bipolar disorder PCDH15 intron 21771265 rs16905691 chr10 55949899 T C 1 Drug response to Etoposide PCDH15 intron 17537913 rs7078920 chr10 55951173 A G 4.69E-05 Bipolar disorder PCDH15 intron 21771265 rs4935502 chr10 55955444 T G 3.62E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) PCDH15 missense 23648065 rs10825269 chr10 55955610 C T 5.00E-06 Irritable bowel syndrome PCDH15 missense 24797007 rs11004142 chr10 55972031 A C 3.24E-04 Amyotrophic Lateral Sclerosis PCDH15 intron 17362836 rs7099893 chr10 56027431 T C 6.44E-04 Multiple complex diseases PCDH15 intron 17554300 rs12255610 chr10 56028635 C T 4.09E-04 Multiple complex diseases PCDH15 intron 17554300 rs857374 chr10 56073081 C T 2.93E-04 Multiple complex diseases PCDH15 intron 17554300 rs1342281 chr10 56076760 T C 6.95E-04 Multiple complex diseases PCDH15 intron 17554300 rs865091 chr10 56080908 C T 5.65E-04 Multiple complex diseases PCDH15 intron 17554300 rs1935468 chr10 56083725 T C 1.58E-05 Alcohol and nictotine co-dependence PCDH15 intron 20158304 rs1342287 chr10 56093271 C T 7.01E-04 Multiple complex diseases PCDH15 intron 17554300 rs4592338 chr10 56098424 C A 4.01E-04 Alzheimer's disease (late onset) PCDH15 intron 21379329 rs978674 chr10 56119975 G A 4.01E-04 Alzheimer's disease (late onset) PCDH15 intron 21379329 rs1573045 chr10 56131150 A T 6.14E-04 Alzheimer's disease PCDH15 intron 17998437 rs12761151 chr10 56137187 C T 3.44E-04 Alzheimer's disease (late onset) PCDH15 intron 21379329 rs10825324 chr10 56170113 G A 1.63E-04 Smoking cessation PCDH15 intron 18519826 rs10825324 chr10 56170113 G A 3.36E-05 Serum metabolites PCDH15 intron 19043545 rs12146398 chr10 56172854 G A 7.34E-05 IgE levels PCDH15 intron 17255346 rs12146398 chr10 56172854 G A 4.45E-05 Smoking cessation PCDH15 intron 18519826 rs12146398 chr10 56172854 G A 2.50E-05 Serum metabolites PCDH15 intron 19043545 rs11004281 chr10 56173059 C T 7.34E-05 IgE levels PCDH15 intron 17255346 rs11004281 chr10 56173059 C T 1.25E-04 Smoking cessation PCDH15 intron 18519826 rs11004281 chr10 56173059 C T 2.57E-05 Serum metabolites PCDH15 intron 19043545 rs11004282 chr10 56173100 G A 6.97E-05 IgE levels PCDH15 intron 17255346 rs11004282 chr10 56173100 G A 2.50E-05 Serum metabolites PCDH15 intron 19043545 rs11004283 chr10 56173151 T G 4.68E-05 IgE levels PCDH15 intron 17255346 rs11004284 chr10 56173236 T G 7.34E-05 IgE levels PCDH15 intron 17255346 rs11004284 chr10 56173236 T G 2.50E-05 Serum metabolites PCDH15 intron 19043545 rs4935107 chr10 56173800 T C 1.93E-05 IgE levels PCDH15 intron 17255346 rs6481096 chr10 56174370 C T 6.54E-05 IgE levels PCDH15 intron 17255346 rs6481096 chr10 56174370 C T 4.06E-05 Serum metabolites PCDH15 intron 19043545 rs2795918 chr10 56177015 C T 2.45E-05 Odorant perception PCDH15 intron 23910658 rs2891523 chr10 56185901 T C 1.52E-04 IgE levels PCDH15 intron 17255346 rs2891523 chr10 56185901 T C 3.23E-05 Serum metabolites PCDH15 intron 19043545 rs2151077 chr10 56194868 C A 1.47E-04 IgE levels PCDH15 intron 17255346 rs2151078 chr10 56194959 T C 4.68E-04 IgE levels PCDH15 intron 17255346 rs7070060 chr10 56196319 G C 4.35E-04 IgE levels PCDH15 intron 17255346 rs7070060 chr10 56196319 G C 4.01E-05 Serum metabolites PCDH15 intron 19043545 rs1888972 chr10 56196942 C G 4.58E-04 IgE levels PCDH15 intron 17255346 rs1888972 chr10 56196942 C G 3.31E-05 Serum metabolites PCDH15 intron 19043545 rs1888973 chr10 56197191 C T 4.50E-04 IgE levels PCDH15 intron 17255346 rs1888973 chr10 56197191 C T 3.31E-05 Serum metabolites PCDH15 intron 19043545 rs11597868 chr10 56197903 T C 2.90E-05 Serum metabolites PCDH15 intron 19043545 rs7476422 chr10 56204291 G T 3.00E-07 Adverse response to chemotherapy in breast cancer (alopecia) PCDH15 intron 24025145 rs1930149 chr10 56208967 T C 8.75E-05 IgE levels in asthmatics (D.f. specific) PCDH15 intron 23967269 rs11004335 chr10 56245720 A G 4.17E-05 Erythrocyte counts PCDH15 intron pha003099 rs1930143 chr10 56262173 C G 5.56E-04 Type 2 diabetes PCDH15 intron 17463246 rs11004359 chr10 56301550 G A 1.97E-04 Cholesterol PCDH15 intron 17255346 rs11004359 chr10 56301550 G A 5.25E-05 Breast cancer PCDH15 intron pha002853 rs1930165 chr10 56301930 G A 9.86E-08 Autism PCDH15 intron 22843504 rs11004362 chr10 56302374 C T 2.81E-04 Cholesterol PCDH15 intron 17255346 rs12769874 chr10 56331169 T C 6.32E-04 Response to cytadine analogues (cytosine arabinoside) PCDH15 intron 24483146 rs1930158 chr10 56337555 G A 7.08E-04 Response to cytadine analogues (cytosine arabinoside) PCDH15 intron 24483146 rs2026410 chr10 56345511 A G 9.79E-05 Response to cytadine analogues (cytosine arabinoside) PCDH15 intron 24483146 rs11492307 chr10 56354771 C G 6.03E-04 Smoking quantity PCDH15 intron 24665060 rs7913327 chr10 56366524 T C 2.06E-04 Lung function (forced expiratory volume in 1 second) PCDH15 intron 17255346 rs1937395 chr10 56391303 G A 1.00E-06 Pulmonary function decline PCDH15 intron 22424883 rs10509016 chr10 56411394 A G 6.85E-04 Bipolar disorder PCDH15 intron 19259986 rs1414686 chr10 56411659 T C 7.00E-04 Bipolar disorder PCDH15 intron 19259986 rs1414686 chr10 56411659 T C 3.14E-04 Epilepsy PCDH15 intron 22116939 rs11004437 chr10 56417062 C T 2.30E-04 Alzheimer's disease (late onset) PCDH15 intron 21379329 rs11004439 chr10 56423968 A C 4.33E-04 Parkinson's disease PCDH15 missense 17052657 rs7902184 chr10 56428277 C T 1.80E-05 HDL particle features PCDH15 intron pha002900 rs10763126 chr10 56462471 A C 5.32E-04 Myopia (pathological) PCDH15 intron 21095009 rs11004473 chr10 56474910 G A 1.30E-04 Multiple complex diseases PCDH15 intron 17554300 rs10825386 chr10 56487598 A C 4.79E-04 Myopia (pathological) PCDH15 intron 21095009 rs953128 chr10 56502386 G A 5.49E-04 Multiple complex diseases PCDH15 intron 17554300 rs16906501 chr10 56504782 A G 8.47E-05 Multiple complex diseases PCDH15 intron 17554300 rs10763141 chr10 56517410 A G 4.71E-05 Pulmonary function in asthmatics PCDH15 intron 23541324 rs10825405 chr10 56592865 C T 1.60E-06 Urinary metabolites / / 21572414 rs7474541 chr10 56617957 A C 8.97E-04 Type 2 diabetes / / 17463246 rs3902590 chr10 56618052 A G 8.40E-04 Type 2 diabetes / / 17463246 rs12415187 chr10 56619339 G T 1.00E-04 Information processing speed / / 21130836 rs7079654 chr10 56625124 T C 2.00E-04 Information processing speed / / 21130836 rs2061049 chr10 56626798 C T 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs11004624 chr10 56652749 T C 4.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs11004628 chr10 56669640 C A,T 2.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs11004629 chr10 56669928 C T 2.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs2168108 chr10 56685218 A G 2.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs1733795 chr10 56691305 G A 1.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs1670815 chr10 56693368 A G 1.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs1598178 chr10 56695884 T C 1.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs1670820 chr10 56696364 A G 1.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs1733767 chr10 56696751 T A,G 1.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs1733766 chr10 56697083 C T 8.88E-05 Suicide attempts in bipolar disorder / / 21423239 rs1670825 chr10 56697737 T A 8.97E-05 Suicide attempts in bipolar disorder / / 21423239 rs1304466 chr10 56701420 G T 9.80E-05 Suicide attempts in bipolar disorder / / 21423239 rs1349893 chr10 56701951 C T 8.66E-04 HIV-1 viral setpoint / / 17641165 rs1454481 chr10 56704254 A C 1.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs1922168 chr10 56704545 C T 1.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs1670829 chr10 56705323 A G 1.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs1670837 chr10 56709224 T C 1.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs2045145 chr10 56716972 G A 4.17E-05 Orofacial clefts / / 19270707 rs2045145 chr10 56716972 G A 9.96E-05 ldl cholesterol / / pha003076 rs1219525 chr10 56742013 A G 8.50E-05 Graves' disease / / 21841780 rs11004662 chr10 56757641 C T 1.64E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6481134 chr10 56763586 G T 3.32E-04 Type 2 diabetes / / 17463246 rs2141841 chr10 56768101 A G 6.93E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16906812 chr10 56775106 A G 4.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs1922150 chr10 56775782 A C 5.96E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10740609 chr10 56790969 T A 5.00E-06 Weight / / 20966902 rs1922159 chr10 56819932 T C 8.76E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs10430541 chr10 56824247 G A 1.10E-05 Urinary metabolites / / 21572414 rs16906916 chr10 56848985 A C 8.00E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs11004745 chr10 56888128 T C 2.01E-04 Coronary heart disease / / 21971053 rs1857446 chr10 56897103 A G 8.43E-05 Multiple complex diseases / / 17554300 rs1936458 chr10 56898304 G A 2.59E-05 Personality dimensions / / 18957941 rs10825471 chr10 56900638 A G 8.36E-04 Alcohol dependence / / 20201924 rs1444672 chr10 56907899 C A 7.72E-04 Multiple complex diseases / / 17554300 rs2680312 chr10 56927420 C T 5.56E-05 Insulin-related traits / / pha003063 rs9299558 chr10 56933921 C A 9.92E-06 Osteoarthritis / / 22763110 rs7901317 chr10 56942953 T A 2.50E-05 Urinary metabolites / / 21572414 rs2680324 chr10 56970071 T G 9.77E-07 Educational attainment / / 21694764 rs2247977 chr10 56972812 G A 6.50E-05 Alcoholism (heaviness of drinking) / / 21529783 rs10763188 chr10 57011352 G T 6.68E-05 Response to metformin / / 21186350 rs10763188 chr10 57011352 G T 5.50E-06 Urinary metabolites / / 21572414 rs11004806 chr10 57077831 C T 3.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs10825494 chr10 57077849 G A 1.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs1900472 chr10 57095253 C T 2.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs1900474 chr10 57095400 T C 2.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs6481156 chr10 57098859 A T 3.29E-04 Cognitive decline / / 23732972 rs6481157 chr10 57099471 T C 1.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs2218582 chr10 57103360 A G 1.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs1900482 chr10 57108195 C T 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs10825499 chr10 57109317 A T 1.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs1900493 chr10 57113620 T C 2.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs7897491 chr10 57117502 C T 2.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs1900491 chr10 57118292 G T 2.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs12778882 chr10 57119747 T G 7.62E-04 Heart Failure / / pha002885 rs7094690 chr10 57120766 G A 2.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs11004830 chr10 57125900 G C 3.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs7089355 chr10 57126578 G A 3.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs1992822 chr10 57128108 T C 3.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs1992821 chr10 57128289 C A 6.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs1992820 chr10 57128307 G C 2.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs1777675 chr10 57139743 T G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7073734 chr10 57208210 T G 2.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10825522 chr10 57231656 T C 9.77E-04 Myocardial Infarction / / pha002873 rs12412734 chr10 57246802 C T 1.52E-04 Amyotrophic lateral sclerosis / / 20801718 rs10509034 chr10 57292460 T C 6.97E-05 C-Reactive Protein / / pha003070 rs41517949 chr10 57358716 C T 3.33E-05 Response to citalopram treatment / / 19846067 rs2463946 chr10 57384713 G A 6.37E-04 Smoking initiation / / 24665060 rs1916521 chr10 57416961 C T 5.00E-07 Cardiac hypertrophy / / 21348951 rs2392951 chr10 57439221 C T 5.27E-04 Smoking cessation / / 24665060 rs7100189 chr10 57475759 G T 4.39E-04 Smoking initiation / / 24665060 rs7909089 chr10 57484637 C G 4.75E-04 Smoking initiation / / 24665060 rs7096970 chr10 57499910 T A 5.18E-04 Smoking initiation / / 24665060 rs4572048 chr10 57501624 G A 1.47E-04 Smoking initiation / / 24665060 rs10763254 chr10 57502078 G C 3.42E-04 Smoking initiation / / 24665060 rs10763255 chr10 57505066 G A 3.39E-04 Multiple complex diseases / / 17554300 rs1916551 chr10 57506658 T G 6.96E-04 Smoking initiation / / 24665060 rs7915549 chr10 57521574 G T 4.78E-04 Smoking initiation / / 24665060 rs11005017 chr10 57537162 A G 4.87E-04 Smoking initiation / / 24665060 rs16907840 chr10 57549296 C T 8.00E-06 Post-traumatic stress disorder (asjusted for relatedness) / / 23726511 rs7898484 chr10 57560172 T C 5.86E-06 Post-operative nausea and vomiting / / 21694509 rs7898484 chr10 57560172 T C 1.38E-04 Smoking initiation / / 24665060 rs4935610 chr10 57578424 G T 2.14E-05 Epilepsy / / 22116939 rs2893663 chr10 57593097 C T 2.90E-04 Coronary heart disease / / 21606135 rs10825636 chr10 57601680 G A 6.19E-04 Myocardial Infarction / / pha002873 rs12248518 chr10 57736009 C T 1.86E-04 Amyotrophic lateral sclerosis / / 20801718 rs12248518 chr10 57736009 C T 7.95E-05 Cardiovascular disease / / pha003064 rs10763296 chr10 57774135 C G 9.51E-06 Migraine / / 23793025 rs1392715 chr10 57788090 G A 9.17E-04 Myocardial Infarction / / pha002873 rs7100758 chr10 57790400 A G 8.22E-04 Type 2 diabetes / / 17463246 rs9415368 chr10 57792128 A G 6.80E-05 Blood Pressure / / pha003044 rs9415372 chr10 57794104 T C 2.95E-05 Blood Pressure / / pha003044 rs10825739 chr10 57806382 T G 4.02E-05 Blood Pressure / / pha003044 rs11005196 chr10 57809031 G T 3.65E-05 Pancreatic cancer / / pha002874 rs7078466 chr10 57819376 C T 8.99E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7078466 chr10 57819376 C T 1.93E-05 Blood Pressure / / pha003044 rs2101782 chr10 57823358 C T 5.47E-04 Response to TNF antagonist treatment / / 21061259 rs10763312 chr10 57841516 G A 7.36E-05 Blood Pressure / / pha003044 rs9416489 chr10 57861481 A G 3.30E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9416489 chr10 57861481 A G 5.89E-05 Blood Pressure / / pha003044 rs9415422 chr10 57864809 C T 6.08E-04 Type 2 diabetes / / 17463246 rs1908351 chr10 57877118 T C 9.86E-04 Type 2 diabetes / / 17463246 rs3104871 chr10 57878503 C T 2.29E-04 Type 2 diabetes / / 17463246 rs3125651 chr10 57878684 C A 6.10E-04 Type 2 diabetes / / 17463246 rs16908337 chr10 57882586 G A 3.11E-04 Multiple complex diseases / / 17554300 rs2250944 chr10 57893217 A C 1.80E-05 Urinary metabolites / / 21572414 rs11005240 chr10 57928768 C T 4.15E-05 Pancreatic cancer / / pha002874 rs7350417 chr10 57932693 C T 2.30E-05 Urinary metabolites / / 21572414 rs2462443 chr10 58005632 C T 2.29E-05 Body Mass Index / / pha003006 rs2462443 chr10 58005632 C T 4.74E-05 Waist Circumference / / pha003024 rs2435872 chr10 58029209 C T 2.95E-05 Body Mass Index / / pha003006 rs2435872 chr10 58029209 C T 6.07E-05 Waist Circumference / / pha003024 rs12571653 chr10 58060921 C T 4.33E-05 Weight / / pha003026 rs3861048 chr10 58078921 A C 4.44E-06 Body Mass Index / / pha003006 rs3861048 chr10 58078921 A C 5.00E-05 Body Fat Distribution / / pha003017 rs3861048 chr10 58078921 A C 2.74E-05 Body Mass Index / / pha003019 rs3861048 chr10 58078921 A C 4.98E-05 Body Mass Index / / pha003020 rs3861048 chr10 58078921 A C 3.12E-06 Waist Circumference / / pha003024 rs3861048 chr10 58078921 A C 2.12E-05 Waist Circumference / / pha003025 rs3861048 chr10 58078921 A C 6.30E-05 Weight / / pha003026 rs7909011 chr10 58109847 G C 2.04E-04 Type 2 diabetes / / 17463246 rs2393069 chr10 58118905 C G 8.44E-08 Scoliosis ZWINT intron 22019779 rs4935649 chr10 58239664 C T 5.37E-04 Multiple complex diseases / / 17554300 rs4935649 chr10 58239664 C T 9.06E-05 Body Mass Index / / pha003006 rs4935649 chr10 58239664 C T 4.15E-05 Weight / / pha003026 rs7086393 chr10 58250470 G A 7.52E-04 Type 2 diabetes / / 17463246 rs10825805 chr10 58250679 T G 1.27E-05 Blood Pressure / / pha003044 rs1907911 chr10 58252790 A G,T 1.27E-05 Blood Pressure / / pha003044 rs1907912 chr10 58266235 C A 9.47E-06 Blood Pressure / / pha003044 rs1907913 chr10 58267121 T C 9.47E-06 Blood Pressure / / pha003044 rs10825816 chr10 58282168 G T 7.14E-04 Type 2 diabetes / / 17463246 rs10825817 chr10 58283134 C G 7.35E-04 Type 2 diabetes / / 17463246 rs10825819 chr10 58296254 A G 0.0000892 Migraine / / 22678113 rs10825819 chr10 58296254 A G 8.92E-05 Migraine / / 22683712 rs1907926 chr10 58339241 T C 2.00E-07 Nicotine use / / 23942779 rs7474843 chr10 58340191 A G 7.61E-05 Body Mass Index / / pha003006 rs17577849 chr10 58354925 A C 2.60E-05 Urinary metabolites / / 21572414 rs17584858 chr10 58367904 A G 2.40E-05 Urinary metabolites / / 21572414 rs16909104 chr10 58368498 T G 6.41E-04 Acute lung injury / / 22295056 rs1996435 chr10 58485885 A C 8.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1914570 chr10 58492254 A G 8.17E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11005497 chr10 58509938 A C 5.47E-09 Adiponectin levels / / 20887962 rs11005510 chr10 58532989 C A 1.67E-07 Multiple complex diseases / / 17554300 rs12262474 chr10 58540286 A G 8.80E-06 Urinary metabolites / / 21572414 rs10509060 chr10 58541436 G C 9.60E-04 Type 2 diabetes / / 17846125 rs10509060 chr10 58541436 G C 4.84E-04 Diabetic retinopathy / / 20871662 rs10509061 chr10 58541887 A G 5.04E-04 Diabetic retinopathy / / 20871662 rs7921283 chr10 58549887 A G 1.93E-04 Diabetic retinopathy / / 20871662 rs1925315 chr10 58591477 T A 9.90E-06 Urinary metabolites / / 21572414 rs1033924 chr10 58607343 G C 7.70E-07 Lipid levels / / 18193043 rs1925293 chr10 58639245 G A 2.43E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs2818851 chr10 58677838 C T 6.09E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs12414237 chr10 58697216 A C 0.0000013 Perception of the odorant galaxolide / / 22362865 rs12762470 chr10 58702033 A C 8.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11005601 chr10 58751570 A T 9.72E-04 Multiple complex diseases / / 17554300 rs10763449 chr10 58775175 C G 3.15E-04 Multiple complex diseases / / 17554300 rs16909960 chr10 58778561 T A 8.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs2393172 chr10 58781418 G A 1.70E-05 Urinary metabolites / / 21572414 rs12242066 chr10 58782324 G A 6.08E-04 Multiple complex diseases / / 17554300 rs2393128 chr10 58795236 T C 5.62E-04 Type 2 diabetes / / 17463246 rs11814572 chr10 58803817 C G 1.50E-05 Urinary metabolites / / 21572414 rs1394108 chr10 58846575 T C 7.29E-04 Type 2 diabetes / / 17463246 rs1394108 chr10 58846575 T C 3.26E-05 Myopia (pathological) / / 23049088 rs4589208 chr10 58853784 A G 5.28E-05 Myopia (pathological) / / 23049088 rs7906620 chr10 58906049 C T 1.50E-04 Obesity,menopause / / 21424828 rs11005665 chr10 58913651 A G 2.55E-05 Myopia (pathological) / / 23049088 rs7082897 chr10 58936492 C A 3.88E-38 Metabolite levels / / 22286219 rs6481257 chr10 58938552 C A 3.52E-05 Pulmonary function / / 17903307 rs10825991 chr10 58943359 C T 6.04E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10825992 chr10 58948207 T G 2.17E-05 Myopia (pathological) / / 23049088 rs6481260 chr10 58963458 T C 5.73E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs2055552 chr10 58966671 G A 1.56E-04 Schizophrenia / / 20832056 rs7083404 chr10 58972355 T A 5.77E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs11005694 chr10 58974808 C G 6.00E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs3907688 chr10 58995294 A G 1.56E-04 Schizophrenia / / 20832056 rs7908694 chr10 58997325 T C 9.73E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs10826010 chr10 59004770 G T 9.59E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs7917615 chr10 59005472 A G 1.69E-04 Schizophrenia / / 20832056 rs1717532 chr10 59017026 A C 9.20E-04 Multiple complex diseases / / 17554300 rs1275282 chr10 59066251 G A 3.05E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1275277 chr10 59069786 A G 3.54E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12259466 chr10 59071887 G T 2.50E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7915278 chr10 59084209 G T 3.30E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7906235 chr10 59085846 A G 5.71E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4935699 chr10 59092325 G A 2.04E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12244977 chr10 59092682 T G 1.03E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12249388 chr10 59095288 A C 9.64E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs12249393 chr10 59095331 A G 7.67E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs12241948 chr10 59095454 C G 7.67E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs10509072 chr10 59095567 T C 2.04E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12256364 chr10 59095688 G A 1.03E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs16910529 chr10 59095842 T C 9.40E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2928464 chr10 59095942 C A 1.83E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2928465 chr10 59095976 A G 3.65E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs16910534 chr10 59097328 C T 1.36E-09 Common variable immunodeficiency / / 21497890 rs2928472 chr10 59097794 G C 7.23E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs3008767 chr10 59111746 T C 3.99E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs3008769 chr10 59122829 T C 5.18E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs3008770 chr10 59123217 G A 2.36E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2928426 chr10 59131353 A C 2.76E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs3008784 chr10 59139949 G A 2.49E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2928442 chr10 59146466 T C 8.68E-07 Asthma (childhood onset) / / 23829686 rs2928445 chr10 59146776 T C 2.76E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs2127615 chr10 59154057 C T 9.55E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4564252 chr10 59175140 C T 3.49E-04 Type 2 diabetes / / 17463246 rs4462262 chr10 59189178 T C 9.00E-08 Diabetic retinopathy / / 21310492 rs10763492 chr10 59282980 G A 2.86E-05 Major depressive disorder / / 20516156 rs2393283 chr10 59300009 C T 1.05E-05 Erythrocyte counts / / pha003099 rs2393369 chr10 59305355 A G 2.90E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs35866326 chr10 59316923 C G 3.65E-05 Parkinson's disease / / 16252231 rs2893745 chr10 59327130 C T 5.90E-05 HIV-1 control / / 20041166 rs6481297 chr10 59333310 T C 7.10E-04 Multiple complex diseases / / 17554300 rs6481298 chr10 59340730 C G 8.98E-04 Multiple complex diseases / / 17554300 rs7894146 chr10 59371321 A G 0.00000275 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs11005876 chr10 59378803 T C 0.00000275 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4501916 chr10 59388098 C A 2.56E-04 Taste perception / / 22132133 rs7912876 chr10 59402469 G A 7.71E-04 Multiple complex diseases / / 17554300 rs7089259 chr10 59423191 A G 7.50E-06 Urinary metabolites / / 21572414 rs6481309 chr10 59441244 A C 8.41E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4428991 chr10 59447321 G C 1.60E-05 Urinary metabolites / / 21572414 rs9416609 chr10 59472580 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs11598894 chr10 59502591 T A 7.80E-04 Type 2 diabetes / / 17463246 rs1395048 chr10 59507814 A T 5.94E-04 Type 2 diabetes / / 17463246 rs1395041 chr10 59514608 G C 6.17E-04 Type 2 diabetes / / 17463246 rs10826108 chr10 59521428 G A 8.41E-04 Rheumatoid arthritis / / 21452313 rs10826108 chr10 59521428 G A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7475779 chr10 59537773 C A 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6481338 chr10 59545176 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs17625002 chr10 59559120 T G 3.93E-06 Alcohol dependence (age at onset) / / 24962325 rs56299213 chr10 59559319 C T 3.93E-06 Alcohol dependence (age at onset) / / 24962325 rs1605148 chr10 59559554 C T 0.0008367 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1605148 chr10 59559554 C T 8.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1395043 chr10 59559737 T G 7.60E-06 Urinary metabolites / / 21572414 rs11594537 chr10 59560685 T C 5.36E-06 Alcohol dependence (age at onset) / / 24962325 rs9415506 chr10 59563420 G A 8.68E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1505923 chr10 59569726 C G 5.20E-05 Multiple complex diseases / / 17554300 rs7909889 chr10 59572370 C T 3.29E-06 Alcohol dependence (age at onset) / / 24962325 rs16911099 chr10 59572683 G C 2.80E-05 Urinary metabolites / / 21572414 rs17625382 chr10 59572708 G A 3.00E-06 Alcohol dependence (age at onset) / / 24962325 rs7918536 chr10 59582091 T C 5.45E-05 Bipolar disorder,affective / / 20528957 rs7087114 chr10 59605344 T C 1.54E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12772513 chr10 59677013 C A 6.08E-05 Chronic obstructive pulmonary disease / / 19300482 rs12772513 chr10 59677013 C A 6.08E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7070038 chr10 59724388 G A 7.00E-06 Coronary artery calcification / / 23870195 rs7088591 chr10 59724403 A T 8.81E-07 Blood pressure / / 24001895 rs7088591 chr10 59724403 A T 9.00E-07 Blood pressure / / 24001895 rs11005987 chr10 59732432 T C 1.65E-05 Coronary heart disease / / 21606135 rs16911440 chr10 59733269 A C 6.88E-05 Coronary heart disease / / 21606135 rs7897320 chr10 59733318 A G 1.56E-04 Coronary heart disease / / 21606135 rs1999504 chr10 59743071 G T 9.64E-04 Alzheimer's disease / / 22005930 rs16911518 chr10 59752987 G A 8.59E-04 Alzheimer's disease / / 22005930 rs16911550 chr10 59758506 T C 7.71E-04 Alzheimer's disease / / 22005930 rs7909606 chr10 59762965 T C 7.53E-04 Alzheimer's disease / / 22005930 rs1930472 chr10 59768050 G A 2.46E-04 Vaspin levels / / 22907691 rs1930472 chr10 59768050 G A 0.0002457 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs11006011 chr10 59770449 G A 1.89E-04 Vaspin levels / / 22907691 rs11006011 chr10 59770449 G A 0.0001885 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs1930489 chr10 59785181 C T 2.35E-04 Vaspin levels / / 22907691 rs1930489 chr10 59785181 C T 0.0002348 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs77751818 chr10 59785350 C T 2.42E-05 Tuberculosis / / 22306650 rs871682 chr10 59788494 C T 2.35E-04 Vaspin levels / / 22907691 rs871682 chr10 59788494 C T 0.0002348 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs11006039 chr10 59825472 T C 9.14E-08 Multiple complex diseases / / 17554300 rs1759361 chr10 59826399 C T 9.19E-04 Type 2 diabetes / / 17463246 rs1759360 chr10 59826491 A G 7.27E-04 Type 2 diabetes / / 17463246 rs1910221 chr10 59834955 G A 9.34E-04 Type 2 diabetes / / 17463246 rs1630415 chr10 59836488 C G 9.72E-04 Type 2 diabetes / / 17463246 rs1759328 chr10 59840216 G T 8.26E-04 Type 2 diabetes / / 17463246 rs1759328 chr10 59840216 G T 2.42E-04 Smoking initiation / / 24665060 rs1759329 chr10 59840295 C T 5.70E-04 Type 2 diabetes / / 17463246 rs1910224 chr10 59840683 C T 8.42E-04 Type 2 diabetes / / 17463246 rs1698470 chr10 59854977 G C 8.94E-04 Alzheimer's disease / / 22005930 rs11817349 chr10 59892940 G A 5.19E-04 Alzheimer's disease / / 22005930 rs1819658 chr10 59913151 C T 9.00E-17 Crohn's disease / / 21102463 rs1199085 chr10 59927277 A G 4.45E-05 Cardiovascular disease / / pha003065 rs1622669 chr10 59932498 A G 7.36E-04 Nicotine dependence / / 17158188 rs1622626 chr10 59932512 A C 7.36E-04 Nicotine dependence / / 17158188 rs1199094 chr10 59952630 A T 2.15E-04 Smoking quantity IPMK UTR-3 24665060 rs1630731 chr10 59959530 T G 2.35E-06 Statin-induced myopathy IPMK intron 21826682 rs12261547 chr10 59969111 G C 2.05E-04 Alcohol dependence IPMK intron 21314694 rs2590307 chr10 59977161 C T 1.26E-07 Statin-induced myopathy IPMK intron 21826682 rs2790232 chr10 59985671 C T 8.00E-06 Obesity-related traits IPMK intron 23251661 rs2790216 chr10 59997926 G A 1.60E-04 Statin-induced myopathy IPMK intron 21826682 rs2790216 chr10 59997926 G A 8.00E-09 Inflammatory bowel disease IPMK intron 23128233 rs2590339 chr10 60012231 T C 1.30E-05 Urinary metabolites IPMK intron 21572414 rs2790168 chr10 60025448 C T 1.30E-04 Statin-induced myopathy IPMK intron 21826682 rs7899961 chr10 60026425 G T 5.32E-04 Myocardial Infarction IPMK intron pha002873 rs2275442 chr10 60035152 C T 2.27E-04 Myocardial Infarction CISD1 intron pha002873 rs16851 chr10 60073590 T C 6.47E-04 Smoking quantity / / 24665060 rs10826172 chr10 60118681 T C 3.30E-06 Urinary metabolites UBE2D1 intron 21572414 rs11006122 chr10 60125877 C T 3.80E-06 Urinary metabolites UBE2D1 intron 21572414 rs11006130 chr10 60150445 A G 8.36E-04 Insulin resistance TFAM intron 21901158 rs11006132 chr10 60156166 A G 1.70E-05 Urinary metabolites / / 21572414 rs7901463 chr10 60172378 C T 2.00E-04 Suicidal ideation / / 22030708 rs7916849 chr10 60201928 A G 1.78E-05 Hemoglobin / / pha003096 rs7085387 chr10 60204602 G A 2.00E-06 Migraine without aura / / 23793025 rs7085387 chr10 60204602 G A 1.78E-05 Hemoglobin / / pha003096 rs10509091 chr10 60210790 T G 6.00E-06 Height / / 23456168 rs11006159 chr10 60242465 G A 4.87E-04 Insulin resistance / / 21901158 rs2033149 chr10 60264741 A T 5.25E-05 Insulin resistance / / 21901158 rs7084402 chr10 60265404 A G 2.00E-13 Refractive error / / 23396134 rs1346301 chr10 60267310 G A 0.0000257 Primary sclerosing cholangitis / / 23603763 rs12264028 chr10 60278140 C T 6.98E-04 Insulin resistance BICC1 intron 21901158 rs3001712 chr10 60281516 A G 3.11E-04 Hearing function BICC1 intron 17255346 rs12571250 chr10 60285619 G A 3.31E-05 Bronchopulmonary dysplasia BICC1 intron 23897914 rs1658469 chr10 60292402 A G 7.51E-04 Insulin resistance BICC1 intron 21901158 rs1658442 chr10 60318897 G A 3.00E-06 Corneal astigmatism BICC1 intron 23322567 rs1649053 chr10 60321487 T C 1.00E-04 Blood Phenotypes BICC1 intron 17903294 rs2098962 chr10 60322587 G C 9.33E-04 Aortic root size BICC1 intron 21223598 rs1649048 chr10 60324282 G A 7.29E-04 Insulin resistance BICC1 intron 21901158 rs1866168 chr10 60361562 T C 1.77E-05 Myopia (severe) BICC1 intron 23933737 rs4245599 chr10 60365755 A G 0.00000069 Myopia (Age of onset) BICC1 intron 23468642 rs17694070 chr10 60370872 A T 8.65E-04 Alzheimer's disease BICC1 intron 17998437 rs10740739 chr10 60382381 C G 1.76E-04 Multiple complex diseases BICC1 intron 17554300 rs7101281 chr10 60421738 T A 2.23E-04 Nicotine dependence BICC1 intron 17158188 rs11006230 chr10 60460821 C T 1.60E-06 Urinary metabolites BICC1 intron 21572414 rs4418750 chr10 60461051 C G 1.82E-04 Self-reported allergy BICC1 intron 23817569 rs2393469 chr10 60461322 C T 1.40E-05 Urinary metabolites BICC1 intron 21572414 rs2393469 chr10 60461322 C T 1.87E-04 Self-reported allergy BICC1 intron 23817569 rs2393471 chr10 60462707 C T 1.61E-04 Self-reported allergy BICC1 intron 23817569 rs4367897 chr10 60464393 C A 6.22E-04 Type 2 diabetes BICC1 intron 17463246 rs4367897 chr10 60464393 C A 1.80E-05 Urinary metabolites BICC1 intron 21572414 rs4367897 chr10 60464393 C A 1.61E-04 Self-reported allergy BICC1 intron 23817569 rs11006251 chr10 60514349 T C 9.14E-05 Acute lung injury BICC1 intron 22295056 rs7094271 chr10 60515022 T C 4.78E-05 Prostate cancer BICC1 intron 22923026 rs7903712 chr10 60516806 C G 1.59E-04 Acute lung injury BICC1 intron 22295056 rs7087186 chr10 60523725 C G 2.17E-04 Acute lung injury BICC1 intron 22295056 rs6481435 chr10 60528473 G C 1.50E-04 Acute lung injury BICC1 intron 22295056 rs2393479 chr10 60531282 G A 1.45E-04 Acute lung injury BICC1 intron 22295056 rs2393478 chr10 60531312 G A 1.50E-04 Acute lung injury BICC1 intron 22295056 rs2393477 chr10 60532733 G A 1.50E-04 Acute lung injury BICC1 intron 22295056 rs10740761 chr10 60532986 C A 1.50E-04 Acute lung injury BICC1 intron 22295056 rs7920393 chr10 60534150 A G 2.63E-04 Acute lung injury BICC1 intron 22295056 rs999846 chr10 60535677 A G 2.63E-04 Acute lung injury BICC1 intron 22295056 rs999845 chr10 60535920 T C 3.80E-08 Major depressive disorder BICC1 intron 20516156 rs999845 chr10 60535920 T C 2.63E-04 Acute lung injury BICC1 intron 22295056 rs999845 chr10 60535920 T C 0.000000312 Major depressive disorder BICC1 intron 22915352 rs12777552 chr10 60537141 C T 1.12E-04 Acute lung injury BICC1 intron 22295056 rs11006260 chr10 60540038 A C 1.74E-04 Acute lung injury BICC1 intron 22295056 rs4948546 chr10 60540878 G A 1.02E-04 Acute lung injury BICC1 intron 22295056 rs9416742 chr10 60542694 G A 1.82E-08 Major depressive disorder BICC1 intron 20516156 rs9416742 chr10 60542694 G A 1.44E-04 Acute lung injury BICC1 intron 22295056 rs9416742 chr10 60542694 G A 0.00000097 Major depressive disorder age at onset<30 BICC1 intron 22915352 rs9416742 chr10 60542694 G A 0.00000152 Major depressive disorder age at onset<35 BICC1 intron 22915352 rs7081819 chr10 60543624 A G 1.44E-04 Acute lung injury BICC1 intron 22295056 rs11006263 chr10 60555578 A G 7.00E-06 Obesity-related traits BICC1 intron 23251661 rs11006267 chr10 60563634 A C,G,T 0.000126541 Primary sclerosing cholangitis BICC1 intron 23603763 rs4948317 chr10 60571435 C T 7.00E-08 Colorectal cancer BICC1 intron 24836286 rs9416746 chr10 60573753 G T 6.22E-05 Cardiovascular disease BICC1 intron pha003065 rs4344442 chr10 60577393 T C 4.35E-05 Cardiovascular disease BICC1 cds-synon pha003065 rs1992657 chr10 60581614 G A 2.87E-05 Cardiovascular disease BICC1 intron pha003065 rs4948550 chr10 60588553 T C 4.14E-05 Cardiovascular disease BICC1 missense pha003065 rs3125452 chr10 60606990 G A 5.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7910260 chr10 60610919 C T 2.90E-05 Lung cancer / / 18385738 rs3125447 chr10 60626234 A G 4.77E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs282674 chr10 60643336 A G 1.17E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs282674 chr10 60643336 A G 6.92E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs282673 chr10 60643617 G A 1.82E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs3910871 chr10 60657501 C T 4.48E-04 Sudden cardiac arrest / / 21658281 rs7086860 chr10 60667535 A G 8.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs7068552 chr10 60667652 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10740763 chr10 60668547 T C 7.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs61458523 chr10 60668571 G A 2.00E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs3910869 chr10 60671677 T C 7.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs10740764 chr10 60675285 G T 6.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs7069997 chr10 60676010 A G 6.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs282694 chr10 60678820 A G 5.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs7906427 chr10 60683190 T C 5.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs12255479 chr10 60684468 A T 8.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs10826250 chr10 60686269 T C 8.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs11006299 chr10 60686420 G C 8.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs10826251 chr10 60686497 A T 6.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs4948553 chr10 60686891 C T 7.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs4948554 chr10 60686939 A G 7.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs4948556 chr10 60686990 G A 6.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs4948322 chr10 60687520 T G 5.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs7080010 chr10 60687773 G A 6.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs6481445 chr10 60688982 C T 6.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs3910873 chr10 60690078 A C,G 7.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs10826252 chr10 60690239 G T 7.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs3851254 chr10 60690457 A C 7.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs7896874 chr10 60694063 A G 6.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs11006313 chr10 60695295 T A 4.41E-05 Bipolar disorder and schizophrenia / / 20889312 rs10763591 chr10 60705156 G A 4.86E-05 Bipolar disorder and schizophrenia / / 20889312 rs3910877 chr10 60711247 G A 3.82E-05 Bipolar disorder and schizophrenia / / 20889312 rs3910876 chr10 60711341 C T 1.15E-05 Bipolar disorder and schizophrenia / / 20889312 rs12252934 chr10 60712592 T C 5.30E-05 Bipolar disorder and schizophrenia / / 20889312 rs7089764 chr10 60712676 G C 4.46E-05 Bipolar disorder and schizophrenia / / 20889312 rs3851235 chr10 60715067 C T 4.64E-04 Alzheimer's disease / / 24755620 rs10826258 chr10 60724306 A G 7.26E-05 Multiple complex diseases / / 17554300 rs3894101 chr10 60739778 C T 3.58E-04 Depression (quantitative trait) / / 20800221 rs204940 chr10 60740316 C T 3.29E-05 Myopia (pathological) / / 23049088 rs1904756 chr10 60793994 T G 7.42E-10 Type 2 diabetes / / 17463246 rs12761351 chr10 60859410 T C 2.44E-05 Blood Pressure / / pha003044 rs919827 chr10 60885300 C T 9.26E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs16913289 chr10 60956904 T C 9.37E-04 Type 2 diabetes PHYHIPL intron 17463246 rs1380555 chr10 61009696 C G 0.00007873 Sarcoidosis FAM13C intron 22952805 rs2452503 chr10 61016633 T C 9.94E-05 Cardiovascular disease FAM13C intron 17903304 rs2251968 chr10 61016778 C T 0.00009287 Sarcoidosis FAM13C intron 22952805 rs284624 chr10 61034019 G C 0.00007041 Sarcoidosis FAM13C intron 22952805 rs284622 chr10 61034908 T C 0.00008719 Sarcoidosis FAM13C intron 22952805 rs419515 chr10 61042524 C T 0.00006705 Sarcoidosis FAM13C intron 22952805 rs284617 chr10 61044036 T C 0.00008864 Sarcoidosis FAM13C intron 22952805 rs16913417 chr10 61097761 C T 2.90E-05 Urinary metabolites FAM13C intron 21572414 rs284613 chr10 61109730 T C 5.83E-04 Multiple complex diseases FAM13C intron 17554300 rs284613 chr10 61109730 T C 1.30E-05 Urinary metabolites FAM13C intron 21572414 rs284609 chr10 61113993 G A 8.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) FAM13C intron 23648065 rs7903982 chr10 61118672 C T 1.22E-04 Multiple complex diseases FAM13C intron 17554300 rs10509101 chr10 61134335 G A 7.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10509101 chr10 61134335 G A 3.95E-05 Stroke / / pha002887 rs11006464 chr10 61146582 T C 5.00E-06 Oleic acid (18:1n-9) plasma levels / / 23362303 rs11006468 chr10 61148750 G A 6.59E-05 Bipolar disorder and schizophrenia / / 20889312 rs7099568 chr10 61220923 C T 6.78E-05 Cognitive performance / / 19734545 rs12762262 chr10 61237122 C T 4.47E-04 IgE levels / / 17255346 rs10509103 chr10 61247710 A G 7.37E-05 Coronary heart disease / / pha003035 rs1763893 chr10 61285319 G C 3.95E-04 Multiple complex diseases / / 17554300 rs11006554 chr10 61286904 C T 1.77E-04 Gallstones / / 17632509 rs1763887 chr10 61297547 C T 2.80E-05 Urinary metabolites / / 21572414 rs1763895 chr10 61303675 T C 7.17E-04 Alzheimer's disease / / 24755620 rs1763895 chr10 61303675 T C 4.91E-05 Monocyte counts / / pha003089 rs12354621 chr10 61309703 A C 5.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11006576 chr10 61322015 G A 1.20E-06 Urinary metabolites / / 21572414 rs11813512 chr10 61336292 A G 2.96E-05 Glaucoma (primary open-angle) / / 22419738 rs1909638 chr10 61338267 T C 5.90E-07 Urinary metabolites / / 21572414 rs1875148 chr10 61341991 T C 2.02E-05 Tuberculosis / / 20694014 rs11598299 chr10 61347537 G A 1.30E-06 Urinary metabolites / / 21572414 rs11815662 chr10 61370043 C T 8.95E-04 Type 2 diabetes / / 17463246 rs11815662 chr10 61370043 C T 5.40E-06 Urinary metabolites / / 21572414 rs10826332 chr10 61380266 T A 2.68E-04 Fibrinogen / / 17255346 rs10826334 chr10 61380482 C G 1.00E-08 Systolic blood pressure (alcohol consumption interaction) / / 24376456 rs10826334 chr10 61380482 C G 4.00E-08 Systolic blood pressure (alcohol consumption interaction) / / 24376456 rs10826334 chr10 61380482 C G 9.00E-07 Mean arterial pressure (alcohol consumption interaction) / / 24376456 rs2126771 chr10 61380753 T C 2.48E-04 Fibrinogen / / 17255346 rs2126771 chr10 61380753 T C 1.56E-04 Schizophrenia / / 21674006 rs16913885 chr10 61388368 G A 4.00E-06 Insulin response / / 19430760 rs12252838 chr10 61394078 C T 1.39E-04 Multiple complex diseases / / 17554300 rs11599171 chr10 61394137 G A 1.52E-13 Urate levels / / 23263486 rs2893807 chr10 61399990 T C 8.04E-15 Urate levels / / 23263486 rs11006640 chr10 61406386 T C 1.21E-11 Multiple complex diseases / / 17554300 rs3763747 chr10 61412335 A G 1.77E-13 Urate levels SLC16A9 UTR-3 23263486 rs12356193 chr10 61413353 A G 1.00E-08 Uric acid levels SLC16A9 intron 19503597 rs12356193 chr10 61413353 A G 3.90E-19 Urate levels SLC16A9 intron 23263486 rs12356193 chr10 61413353 A G 2.00E-33 Blood metabolite levels SLC16A9 intron 24816252 rs12356193 chr10 61413353 A G 4.00E-63 Blood metabolite levels SLC16A9 intron 24816252 rs12356193 chr10 61413353 A G 8.00E-20 Blood metabolite levels SLC16A9 intron 24816252 rs2242206 chr10 61414011 G T 1.52E-14 Urate levels SLC16A9 missense 23263486 rs1904071 chr10 61418691 T G 4.71E-15 Urate levels SLC16A9 intron 23263486 rs4948351 chr10 61425189 C T 3.30E-11 Urate levels SLC16A9 intron 23263486 rs4948351 chr10 61425189 C T 7.14E-05 Hemoglobin SLC16A9 intron pha003098 rs4948351 chr10 61425189 C T 1.07E-05 Erythrocyte counts SLC16A9 intron pha003099 rs11006679 chr10 61428646 A G 2.14E-15 Urate levels SLC16A9 intron 23263486 rs10826342 chr10 61433292 T G 1.06E-15 Urate levels SLC16A9 intron 23263486 rs1171606 chr10 61434519 G A 1.03E-15 Urate levels SLC16A9 intron 23263486 rs12772586 chr10 61440304 T C 6.53E-15 Urate levels SLC16A9 intron 23263486 rs1171660 chr10 61443808 A G 7.40E-16 Urate levels SLC16A9 intron 23263486 rs1171659 chr10 61444364 A G 1.53E-15 Urate levels SLC16A9 intron 23263486 rs1171658 chr10 61444748 A G 3.39E-10 Urate levels SLC16A9 intron 23263486 rs746228 chr10 61445173 T C 1.97E-05 Diabetes Mellitus SLC16A9 intron pha003060 rs753763 chr10 61445412 T C 3.81E-08 Urate levels SLC16A9 intron 23263486 rs753762 chr10 61445594 G A 2.25E-15 Urate levels SLC16A9 intron 23263486 rs1171652 chr10 61449512 T C 2.79E-13 Urate levels SLC16A9 intron 23263486 rs1171652 chr10 61449512 T C 8.68E-06 Erythrocyte counts SLC16A9 intron pha003099 rs7094971 chr10 61449564 A G 3.80E-20 Serum metabolites SLC16A9 intron 20037589 rs7094971 chr10 61449564 A G 2.70E-05 Urinary metabolites SLC16A9 intron 21572414 rs7094971 chr10 61449564 A G 3.00E-14 Metabolic traits SLC16A9 intron 21886157 rs7094971 chr10 61449564 A G 6.94E-16 Urate levels SLC16A9 intron 23263486 rs1171650 chr10 61450153 C T 1.79E-13 Urate levels SLC16A9 intron 23263486 rs1171648 chr10 61450932 C T 2.41E-13 Urate levels SLC16A9 intron 23263486 rs1171647 chr10 61452002 A G 6.08E-13 Urate levels SLC16A9 intron 23263486 rs1171645 chr10 61452592 A T 2.18E-13 Urate levels SLC16A9 intron 23263486 rs1171643 chr10 61452752 A G 1.87E-13 Urate levels SLC16A9 intron 23263486 rs1171620 chr10 61464507 C G 2.70E-19 Urate levels SLC16A9 intron 23263486 rs1171619 chr10 61465838 A G 3.72E-19 Urate levels SLC16A9 intron 23263486 rs1171618 chr10 61465941 T C 1.70E-07 Urate levels SLC16A9 intron 20884846 rs1171618 chr10 61465941 T C 5.26E-14 Urate levels SLC16A9 intron 23263486 rs1171617 chr10 61467182 G T 1.14E-22 Urate levels SLC16A9 intron 23263486 rs1171617 chr10 61467182 G T 2.00E-14 Blood metabolite levels SLC16A9 intron 24816252 rs1171616 chr10 61468589 G T 1.15E-22 Urate levels SLC16A9 intron 23263486 rs1171615 chr10 61469090 C T 8.01E-23 Urate levels SLC16A9 intron 23263486 rs1171615 chr10 61469090 C T 2.00E-95 Blood metabolite ratios SLC16A9 intron 24816252 rs1171615 chr10 61469090 C T 3.00E-34 Blood metabolite levels SLC16A9 intron 24816252 rs1171615 chr10 61469090 C T 4.00E-11 Blood metabolite levels SLC16A9 intron 24816252 rs1171614 chr10 61469538 T C 2.00E-28 Urate levels SLC16A9 UTR-5 23263486 rs1171614 chr10 61469538 T C 3.00E-23 Blood metabolite levels SLC16A9 UTR-5 24816252 rs1171614 chr10 61469538 T C 7.00E-14 Blood metabolite levels SLC16A9 UTR-5 24816252 rs1171610 chr10 61477697 C T 2.48E-09 Urate levels / / 23263486 rs1171609 chr10 61479385 A G 3.87E-08 Urate levels / / 23263486 rs2671613 chr10 61486286 T C 1.01E-10 Urate levels / / 23263486 rs1171582 chr10 61494037 C T 2.89E-10 Urate levels / / 23263486 rs10821585 chr10 61516587 G A 8.29E-05 Coronary heart disease / / pha003033 rs9943397 chr10 61522319 G A 5.15E-05 Coronary heart disease / / pha003033 rs2090123 chr10 61525567 A G 1.26E-08 Urate levels / / 23263486 rs10994023 chr10 61562977 A G 4.05E-05 HIV-1 viral setpoint CCDC6 intron 22174851 rs4948367 chr10 61573386 C A 7.98E-04 Response to taxane treatment (placlitaxel) CCDC6 intron 23006423 rs17791484 chr10 61612159 C T 3.35E-04 Response to taxane treatment (placlitaxel) CCDC6 intron 23006423 rs1149660 chr10 61619983 C A 6.44E-05 Coronary heart disease CCDC6 intron pha003033 rs1664260 chr10 61632854 T C 9.85E-04 Multiple complex diseases CCDC6 intron 17554300 rs7076972 chr10 61653220 G A 0.00009968 Sarcoidosis CCDC6 intron 22952805 rs1684889 chr10 61662767 T C 1.99E-05 Multiple complex diseases CCDC6 intron 17554300 rs1171826 chr10 61663637 G A 1.30E-05 Triglycerides CCDC6 intron 19074352 rs1171826 chr10 61663637 G A 1.30E-05 Polyunsaturated fatty acid levels,in plasma CCDC6 intron 19148276 rs1171834 chr10 61668952 G A 5.86E-04 Multiple complex diseases / / 17554300 rs7894427 chr10 61669228 G T 4.19E-05 Major depressive disorder / / 22472876 rs2440915 chr10 61673772 G A 4.38E-05 Major depressive disorder / / 22472876 rs1684918 chr10 61688953 A G 2.45E-04 Multiple complex diseases / / 17554300 rs1684918 chr10 61688953 A G 5.91E-05 Major depressive disorder / / 22472876 rs6479671 chr10 61697877 G A 1.35E-11 Alcohol consumption / / pha001398 rs7095688 chr10 61709983 C T 5.30E-04 Multiple complex diseases / / 17554300 rs7095688 chr10 61709983 C T 3.07E-05 Major depressive disorder / / 22472876 rs7094419 chr10 61713218 T C 1.82E-05 Crohn's disease / / 23266558 rs12776262 chr10 61719385 T G 4.20E-04 Alzheimer's disease / / 24755620 rs7078432 chr10 61722273 T G 5.00E-05 Alzheimer's disease / / 24755620 rs968626 chr10 61722957 T C 7.72E-04 Type 2 diabetes / / 17463246 rs723212 chr10 61725913 A G 6.81E-04 Insulin resistance / / 21901158 rs1684895 chr10 61726870 C A 5.39E-05 Cognitive test performance / / 20125193 rs10821624 chr10 61737287 C T 2.23E-04 Alzheimer's disease / / 24755620 rs10821633 chr10 61749766 G A 8.27E-04 Schizophrenia / / 19197363 rs10509116 chr10 61754080 G T 2.30E-05 Urinary metabolites / / 21572414 rs6479686 chr10 61773358 C T 7.61E-04 Alzheimer's disease / / 17998437 rs16914571 chr10 61793446 T C 8.71E-05 Cognitive decline ANK3 intron 22054870 rs1002442 chr10 61803062 T G 3.00E-07 Amyotrophic lateral sclerosis (sporadic) ANK3 intron 24529757 rs7893313 chr10 61820631 T C 1.01E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) ANK3 intron 23648065 rs7902905 chr10 61826411 C T 9.58E-06 Cognitive test performance ANK3 intron 20125193 rs7902905 chr10 61826411 C T 4.44E-05 Intelligence ANK3 intron 21826061 rs140463162 chr10 61833684 C T 0.000038 Breast cancer ANK3 missense 23555315 rs9804190 chr10 61839831 C T 1.00E-04 Information processing speed ANK3 intron 21130836 rs9804190 chr10 61839831 C T 3.06E-05 Bipolar disorder ANK3 intron 21926972 rs9804190 chr10 61839831 C T 0.000736 Bipolar disorder ANK3 intron 23070075 rs10994198 chr10 61856035 C A 7.61E-04 Response to cytadine analogues (cytosine arabinoside) ANK3 intron 24483146 rs12761450 chr10 61885892 G T 1.00E-06 Plasma amyloid beta peptide concentrations (ABx-42) ANK3 intron 24535457 rs10740011 chr10 61890937 G T 7.90E-05 Cognitive test performance ANK3 intron 20125193 rs10509123 chr10 61893145 T G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ANK3 intron 22628534 rs10509124 chr10 61893733 T C 0.00000147 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ANK3 intron 22628534 rs3213829 chr10 61893898 T G 3.04E-04 Alzheimer's disease ANK3 intron 17998437 rs2288359 chr10 61902023 T C 3.64E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) ANK3 intron 23648065 rs16914582 chr10 61941275 T G 8.10E-04 Multiple complex diseases ANK3 intron 17554300 rs10159800 chr10 61945611 C G 1.96E-04 Suicide attempts in bipolar disorder ANK3 intron 21423239 rs10821700 chr10 61959061 C A,G,T 1.60E-04 Multiple complex diseases ANK3 intron 17554300 rs10994250 chr10 61961795 G A 2.88E-05 Acne (severe) ANK3 intron 24927181 rs2297979 chr10 61965625 A G,T 1.86E-04 Multiple complex diseases ANK3 cds-synon 17554300 rs7908312 chr10 61997885 A C 1.40E-04 Multiple complex diseases ANK3 intron 17554300 rs10821707 chr10 61997956 A G 1.56E-04 Multiple complex diseases ANK3 intron 17554300 rs10821707 chr10 61997956 A G 1.64E-05 Acne (severe) ANK3 intron 24927181 rs16914663 chr10 62017320 A G 2.91E-04 Insulin resistance ANK3 intron 21901158 rs10821709 chr10 62041591 T C 8.92E-04 Schizophrenia ANK3 intron 19197363 rs12782806 chr10 62042711 T C 4.53E-05 Suicidal ideation ANK3 intron 20877300 rs10761473 chr10 62060382 C G 2.26E-07 Bipolar disorder ANK3 intron 24618891 rs10821716 chr10 62070753 C T 6.33E-04 Alcohol dependence ANK3 intron 21314694 rs10509129 chr10 62071041 G T 4.77E-08 Bipolar disorder ANK3 intron 24618891 rs10761482 chr10 62085337 T C 8.00E-06 Schizophrenia ANK3 intron 20185149 rs10761482 chr10 62085337 T C 7.70E-06 Schizophrenia (treatment refractory) ANK3 intron 22479419 rs1380459 chr10 62097331 C T 1.70E-05 Bipolar disorder and major depressive disorder (combined) ANK3 intron 20351715 rs1380459 chr10 62097331 C T 7.59E-04 Major depressive disorder ANK3 intron 22472876 rs1380459 chr10 62097331 C T 2.71E-08 Bipolar disorder ANK3 intron 24618891 rs10994308 chr10 62098952 G A 1.80E-05 Bipolar disorder and major depressive disorder (combined) ANK3 intron 20351715 rs10994308 chr10 62098952 G A 3.60E-08 Bipolar disorder ANK3 intron 24618891 rs10821736 chr10 62105053 C T 1.55E-08 Bipolar disorder ANK3 intron 24618891 rs7084499 chr10 62106882 T C 0.000174 Schizophrenia ANK3 intron 23637625 rs1981251 chr10 62127927 A G 7.94E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ANK3 intron 20031582 rs10821745 chr10 62136206 T G 4.29E-04 Major depressive disorder ANK3 intron 22472876 rs10821745 chr10 62136206 T G 1.26E-08 Bipolar disorder ANK3 intron 24618891 rs10821745 chr10 62136206 T G 6.54E-05 Coronary heart disease ANK3 intron pha003035 rs10994322 chr10 62136279 C T 2.00E-05 Bipolar disorder and major depressive disorder (combined) ANK3 intron 20351715 rs10994322 chr10 62136279 C T 3.30E-08 Bipolar disorder ANK3 intron 24618891 rs7895653 chr10 62143348 C T 4.53E-04 Suicide attempts in bipolar disorder ANK3 intron 21041247 rs4948412 chr10 62146576 T C 7.80E-06 Bipolar disorder and major depressive disorder (combined) ANK3 intron 20351715 rs4948412 chr10 62146576 T C 8.77E-04 Major depressive disorder ANK3 intron 22472876 rs4948412 chr10 62146576 T C 2.99E-08 Bipolar disorder ANK3 intron 24618891 rs3808943 chr10 62151015 C T 3.10E-05 Bipolar disorder and major depressive disorder (combined) ANK3 intron 20351715 rs3808943 chr10 62151015 C T 3.71E-08 Bipolar disorder ANK3 intron 24618891 rs10821748 chr10 62152938 G C 1.29E-07 Bipolar disorder ANK3 intron 24618891 rs12416380 chr10 62156154 A G 9.80E-06 Bipolar disorder and major depressive disorder (combined) ANK3 intron 20351715 rs12416380 chr10 62156154 A G 3.78E-08 Bipolar disorder ANK3 intron 24618891 rs4948417 chr10 62161618 A G 9.50E-06 Bipolar disorder and major depressive disorder (combined) ANK3 intron 20351715 rs4948417 chr10 62161618 A G 6.69E-04 Major depressive disorder ANK3 intron 22472876 rs4948417 chr10 62161618 A G 3.40E-08 Bipolar disorder ANK3 intron 24618891 rs10994329 chr10 62163327 C A 6.57E-04 Major depressive disorder ANK3 intron 22472876 rs10821758 chr10 62176632 G A 2.92E-05 Odorant perception ANK3 intron 23910658 rs10994336 chr10 62179812 C T 9.00E-09 Bipolar disorder ANK3 intron 18711365 rs10994336 chr10 62179812 C T 5.00E-07 Bipolar disorder and major depressive disorder (combined) ANK3 intron 20351715 rs10994336 chr10 62179812 C T 2.34E-08 Bipolar disorder ANK3 intron 24618891 rs10994338 chr10 62181128 G A 5.00E-07 Bipolar disorder and major depressive disorder (combined) ANK3 intron 20351715 rs10994338 chr10 62181128 G A 3.44E-08 Bipolar disorder ANK3 intron 24618891 rs4948418 chr10 62185494 C T 2.40E-06 Bipolar disorder and major depressive disorder (combined) ANK3 intron 20351715 rs4948418 chr10 62185494 C T 4.00E-10 Bipolar disorder ANK3 intron 22182935 rs4948418 chr10 62185494 C T 8.88E-04 Major depressive disorder ANK3 intron 22472876 rs4948418 chr10 62185494 C T 5.60E-07 Bipolar disorder ANK3 intron 24618891 rs4948418 chr10 62185494 C T 9.44E-05 Coronary heart disease ANK3 intron pha003035 rs10994359 chr10 62222107 T C 2.45E-08 Schizophrenia ANK3 intron 21926974 rs10994359 chr10 62222107 T C 3.09E-04 Major depressive disorder ANK3 intron 22472876 rs10994359 chr10 62222107 T C 3.00E-09 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) ANK3 intron 23453885 rs10994359 chr10 62222107 T C 8.12E-10 Bipolar disorder ANK3 intron 23637625 rs10994364 chr10 62228327 C T 2.93E-04 Multiple complex diseases ANK3 intron 17554300 rs10761510 chr10 62270037 G T 2.20E-04 Multiple complex diseases ANK3 intron 17554300 rs9633553 chr10 62274737 T G 5.10E-05 Bipolar disorder and major depressive disorder (combined) ANK3 intron 20351715 rs9633553 chr10 62274737 T G 2.96E-10 Bipolar disorder ANK3 intron 24618891 rs2153522 chr10 62278812 G A 0.0000915 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ANK3 intron 22628534 rs2153522 chr10 62278812 G A 0.000792 Schizophrenia ANK3 intron 23637625 rs10994397 chr10 62279124 C T 1.50E-05 Bipolar disorder and major depressive disorder (combined) ANK3 intron 20351715 rs10994397 chr10 62279124 C T 3.00E-07 Bipolar disorder ANK3 intron 21926972 rs10994397 chr10 62279124 C T 7.50E-04 Major depressive disorder ANK3 intron 22472876 rs10994397 chr10 62279124 C T 0.00000215 Bipolar disorder ANK3 intron 23070075 rs10994397 chr10 62279124 C T 7.00E-09 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) ANK3 intron 23453885 rs10994397 chr10 62279124 C T 2.86E-10 Bipolar disorder ANK3 intron 24618891 rs1340586 chr10 62279594 C T 2.39E-05 Serum metabolites ANK3 intron 19043545 rs12269538 chr10 62280236 C T 3.91E-04 Sudden cardiac arrest ANK3 intron 21658281 rs12412135 chr10 62282834 C T 2.60E-05 Bipolar disorder and major depressive disorder (combined) ANK3 intron 20351715 rs12412135 chr10 62282834 C T 3.33E-09 Bipolar disorder ANK3 intron 24618891 rs10821789 chr10 62285338 G A 2.60E-05 Bipolar disorder and major depressive disorder (combined) ANK3 intron 20351715 rs10821789 chr10 62285338 G A 3.72E-09 Bipolar disorder ANK3 intron 24618891 rs10994404 chr10 62288445 T C 2.70E-05 Bipolar disorder and major depressive disorder (combined) ANK3 intron 20351715 rs10994404 chr10 62288445 T C 4.41E-09 Bipolar disorder ANK3 intron 24618891 rs1938541 chr10 62292032 G A 5.98E-04 Type 2 diabetes ANK3 intron 17463246 rs1938541 chr10 62292032 G A 8.28E-04 Multiple complex diseases ANK3 intron 17554300 rs1938540 chr10 62294814 C T 8.80E-06 Bipolar disorder and major depressive disorder (combined) ANK3 intron 20351715 rs1938540 chr10 62294814 C T 8.22E-10 Bipolar disorder ANK3 intron 24618891 rs10821792 chr10 62298616 C T 4.33E-04 Multiple complex diseases ANK3 intron 17554300 rs10821792 chr10 62298616 C T 4.30E-06 Bipolar disorder and major depressive disorder (combined) ANK3 intron 20351715 rs10821792 chr10 62298616 C T 8.34E-10 Bipolar disorder ANK3 intron 24618891 rs1938526 chr10 62300383 A G 8.00E-07 Bipolar disorder and major depressive disorder (combined) ANK3 intron 20351715 rs1938526 chr10 62300383 A G 8.55E-10 Bipolar disorder ANK3 intron 24618891 rs1938525 chr10 62300929 C T 0.00000107 Joint damage severity in rheumatoid arthritis ANK3 intron 23696630 rs2186251 chr10 62304870 G A 8.07E-05 Bipolar disorder ANK3 intron 22925353 rs7085315 chr10 62313241 T C 1.76E-04 Type 2 diabetes ANK3 intron 17463246 rs7085315 chr10 62313241 T C 8.11E-05 Serum metabolites ANK3 intron 19043545 rs10994415 chr10 62322034 T C 5.40E-05 Bipolar disorder and major depressive disorder (combined) ANK3 intron 20351715 rs10994415 chr10 62322034 T C 7.00E-11 Bipolar disorder ANK3 intron 24618891 rs2154393 chr10 62326687 C T 6.70E-05 Bipolar disorder and major depressive disorder (combined) ANK3 intron 20351715 rs2154393 chr10 62326687 C T 3.03E-10 Bipolar disorder ANK3 intron 24618891 rs7072678 chr10 62344769 A G 6.41E-04 Type 2 diabetes ANK3 intron 17463246 rs6479719 chr10 62346137 C T 6.09E-05 Serum metabolites ANK3 intron 19043545 rs16915157 chr10 62346638 C T 5.00E-06 Schizophrenia ANK3 intron 21926974 rs16915157 chr10 62346638 C T 7.00E-07 Schizophrenia ANK3 intron 22688191 rs2393673 chr10 62350366 A T 5.60E-05 Serum metabolites ANK3 intron 19043545 rs10740035 chr10 62352606 G T 7.36E-04 Type 2 diabetes ANK3 intron 17463246 rs1348281 chr10 62356233 T C 5.83E-04 Type 2 diabetes ANK3 intron 17463246 rs16915196 chr10 62359859 A G 3.04E-08 Bipolar disorder ANK3 intron 24618891 rs10761528 chr10 62367660 T C 5.38E-04 Type 2 diabetes ANK3 intron 17463246 rs1006956 chr10 62367976 C T 5.41E-04 Type 2 diabetes ANK3 intron 17463246 rs1006956 chr10 62367976 C T 9.51E-05 Serum metabolites ANK3 intron 19043545 rs10994429 chr10 62371079 C T 2.22E-08 Bipolar disorder ANK3 intron 24618891 rs10994430 chr10 62371953 G T 2.14E-08 Bipolar disorder ANK3 intron 24618891 rs16915231 chr10 62375046 G A 2.49E-08 Bipolar disorder ANK3 intron 24618891 rs10994435 chr10 62385605 C T 4.36E-06 Bipolar disorder ANK3 intron 24618891 rs10994443 chr10 62395518 G A 8.26E-07 Prion diseases ANK3 intron 22210626 rs10994443 chr10 62395518 G A 6.51E-08 Bipolar disorder ANK3 intron 24618891 rs10994465 chr10 62420405 G A 5.32E-06 Bipolar disorder ANK3 intron 24618891 rs10509136 chr10 62425124 C T 2.85E-06 Bipolar disorder ANK3 intron 24618891 rs12218617 chr10 62433440 A T 6.28E-06 Bipolar disorder ANK3 intron 24618891 rs2028563 chr10 62436897 A G 5.96E-04 Type 2 diabetes ANK3 intron 17463246 rs10509138 chr10 62437910 A C 5.56E-06 Bipolar disorder ANK3 intron 24618891 rs1837950 chr10 62444965 T C 5.03E-04 Type 2 diabetes ANK3 intron 17463246 rs1837950 chr10 62444965 T C 6.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ANK3 intron 20877124 rs894384 chr10 62452293 G C 2.19E-04 Type 2 diabetes ANK3 intron 17463246 rs1904418 chr10 62488381 A G 1.71E-05 Bone mineral traits,in men ANK3 intron 21427758 rs1904418 chr10 62488381 A G 4.44E-04 Bone mineral traits,in men ANK3 intron 21427758 rs1904418 chr10 62488381 A G 7.68E-05 Bone mineral traits,in men ANK3 intron 21427758 rs1904397 chr10 62493860 C A 4.81E-05 Cocaine dependence ANK3 nearGene-5 23958962 rs2170005 chr10 62500600 T C 1.19E-05 Type 2 diabetes / / 17463246 rs1904402 chr10 62501994 G A 0.00009015 Sarcoidosis / / 22952805 rs1904403 chr10 62502026 G C 0.00009015 Sarcoidosis / / 22952805 rs1904405 chr10 62504332 G A 0.00009762 Sarcoidosis / / 22952805 rs9415614 chr10 62514136 A G 4.57E-05 Type 2 diabetes / / 17463246 rs10994499 chr10 62516545 G C 1.56E-05 Type 2 diabetes / / 17463246 rs10761556 chr10 62517763 T A 8.43E-06 Type 2 diabetes / / 17463246 rs10761556 chr10 62517763 T A 4.11E-04 Insulin resistance / / 21901158 rs12354450 chr10 62518611 G T 1.78E-04 Multiple complex diseases / / 17554300 rs7087628 chr10 62518655 A C 1.48E-05 Type 2 diabetes / / 17463246 rs720600 chr10 62519731 G A 1.33E-04 Type 2 diabetes / / 17463246 rs10761558 chr10 62523470 G A 1.63E-05 Type 2 diabetes and other traits / / 19734900 rs2170006 chr10 62534614 G A 7.23E-04 Type 2 diabetes / / 17463246 rs744383 chr10 62536778 T C 2.00E-04 Cocaine dependence CDK1 nearGene-5 23958962 rs3213056 chr10 62548390 G A 3.00E-06 Reading and spelling CDK1 intron 23738518 rs2939950 chr10 62549422 C T 1.93E-06 Odorant perception CDK1 intron 23910658 rs2448363 chr10 62550719 C T 1.77E-05 Cocaine dependence CDK1 intron 23958962 rs2448363 chr10 62550719 C T 6.13E-04 Cocaine dependence CDK1 intron 23958962 rs2456778 chr10 62551890 A T 3.00E-06 Cocaine dependence CDK1 intron 23958962 rs2456778 chr10 62551890 A T 5.00E-06 Cocaine dependence CDK1 intron 23958962 rs2456769 chr10 62558842 T C 5.15E-05 Cocaine dependence / / 23958962 rs2127356 chr10 62561695 C A 6.76E-04 Type 2 diabetes / / 17463246 rs4145643 chr10 62562855 G C 5.32E-04 Type 2 diabetes / / 17463246 rs10821843 chr10 62564936 C G 6.43E-04 Type 2 diabetes / / 17463246 rs7093851 chr10 62565144 C G 6.28E-04 Type 2 diabetes / / 17463246 rs12255873 chr10 62594554 A G 3.02E-07 Monocyte chemoattractant protein-1 / / pha003071 rs12242535 chr10 62600239 G T 4.78E-06 Hemoglobin / / pha003098 rs12242535 chr10 62600239 G T 1.92E-06 Erythrocyte counts / / pha003099 rs4132554 chr10 62600287 A G 7.66E-05 Schizophrenia / / pha002859 rs2893863 chr10 62606784 T C 5.93E-04 Multiple complex diseases / / 17554300 rs7080835 chr10 62617283 C A 2.04E-04 Multiple complex diseases / / 17554300 rs10994548 chr10 62624576 A G 6.62E-05 Multiple complex diseases / / 17554300 rs2279942 chr10 62634621 C T 5.54E-04 Fibrinogen RHOBTB1 intron 17255346 rs10821850 chr10 62640118 C G 2.53E-04 Fibrinogen RHOBTB1 intron 17255346 rs16915679 chr10 62650130 G A 9.26E-05 Height RHOBTB1 intron pha003011 rs7898435 chr10 62652165 T C 8.76E-05 Non-alcoholic fatty liver disease histology (other) RHOBTB1 intron 20708005 rs750593 chr10 62662314 A G 2.00E-05 Urinary metabolites RHOBTB1 intron 21572414 rs4437981 chr10 62662503 T C 2.00E-05 Urinary metabolites RHOBTB1 intron 21572414 rs7922793 chr10 62826952 C T 0.0000023 Chronic obstructive pulmonary disease (moderate to severe) / / 22986903 rs16915841 chr10 62864271 G C 4.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs2077850 chr10 62906299 T C 8.20E-06 Urinary metabolites / / 21572414 rs10761570 chr10 62906955 T G 0.00000006 Chronic obstructive pulmonary disease (moderate to severe) / / 22986903 rs10761571 chr10 62907028 A C 0.000000037 Chronic obstructive pulmonary disease (moderate to severe) / / 22986903 rs7896712 chr10 62907185 T A 0.000000037 Chronic obstructive pulmonary disease (moderate to severe) / / 22986903 rs7911302 chr10 62907226 A C,G,T 0.000000044 Chronic obstructive pulmonary disease (moderate to severe) / / 22986903 rs4948444 chr10 62929997 G A 0.00000036 Chronic obstructive pulmonary disease (moderate to severe) / / 22986903 rs12261015 chr10 63003765 A G 4.96E-04 Type 2 diabetes / / 17463246 rs1906470 chr10 63005871 C T 8.27E-04 Multiple complex diseases / / 17554300 rs4145320 chr10 63023314 A G 0.0000236 Carotid intima media thickness / / 23152477 rs10994701 chr10 63035242 G A 8.43E-04 Rheumatoid arthritis / / 21452313 rs1915446 chr10 63063518 T C 4.71E-04 Multiple complex diseases / / 17554300 rs10509145 chr10 63099550 C T 7.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2176929 chr10 63167132 G A 4.09E-04 Amyotrophic lateral sclerosis (sporadic) TMEM26 UTR-3 24529757 rs2139780 chr10 63167404 A G 7.98E-04 Coronary heart disease TMEM26 UTR-3 21971053 rs1915433 chr10 63183583 C A 5.33E-04 Alzheimer's disease TMEM26 intron 22005930 rs2204016 chr10 63187490 G A 6.04E-04 Alzheimer's disease TMEM26 intron 22005930 rs12764963 chr10 63189317 G A 7.36E-04 Suicide attempts in bipolar disorder TMEM26 intron 21423239 rs201128562 chr10 63192414 TA T 7.00E-06 Serum dimethylarginine levels (asymmetric) TMEM26 intron 24159190 rs7088627 chr10 63192414 T A 7.00E-06 Serum dimethylarginine levels (asymmetric) TMEM26 intron 24159190 rs12265711 chr10 63199094 C G 4.24E-04 Suicide attempts in bipolar disorder TMEM26 intron 21423239 rs12244298 chr10 63199519 T C 4.22E-04 Suicide attempts in bipolar disorder TMEM26 intron 21423239 rs12244720 chr10 63203341 C T 4.25E-04 Suicide attempts in bipolar disorder TMEM26 intron 21423239 rs7893857 chr10 63204073 C T 4.19E-04 Suicide attempts in bipolar disorder TMEM26 intron 21423239 rs7910719 chr10 63204403 T A 4.28E-04 Suicide attempts in bipolar disorder TMEM26 intron 21423239 rs7894812 chr10 63204662 G T 4.20E-04 Suicide attempts in bipolar disorder TMEM26 intron 21423239 rs7894601 chr10 63204693 C T 3.99E-04 Suicide attempts in bipolar disorder TMEM26 intron 21423239 rs12766973 chr10 63205435 T C 5.85E-04 Suicide attempts in bipolar disorder TMEM26 intron 21423239 rs12246267 chr10 63209131 G A 5.89E-04 Suicide attempts in bipolar disorder TMEM26 intron 21423239 rs10994766 chr10 63210601 G C 1.65E-04 Multiple complex diseases TMEM26 intron 17554300 rs10994766 chr10 63210601 G C 7.23E-04 Suicide attempts in bipolar disorder TMEM26 intron 21423239 rs7915534 chr10 63214596 G A 4.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs7919173 chr10 63215166 C T 5.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs7920053 chr10 63215731 G A 5.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs7919848 chr10 63215769 A G 5.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs2787702 chr10 63307475 T C 9.00E-06 Response to taxane treatment (placlitaxel) / / 23006423 rs2650717 chr10 63308069 C G 2.46E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2254096 chr10 63308159 G A 3.03E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2787703 chr10 63308714 T C 2.46E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1869927 chr10 63314472 C T 2.32E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2257189 chr10 63318019 G C 2.91E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2787713 chr10 63318204 A T 7.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1378884 chr10 63319932 G C 2.05E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2787716 chr10 63323353 C T 6.15E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2606094 chr10 63324847 T C 3.53E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2814033 chr10 63331594 G T 1.77E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2650741 chr10 63332127 A G 1.76E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2814032 chr10 63336683 G A 3.43E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2814030 chr10 63337793 G A 9.87E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2650731 chr10 63339655 C A 4.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2814027 chr10 63342112 A G 4.32E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs753246 chr10 63342487 G A 4.12E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2606104 chr10 63342861 C T 4.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2787720 chr10 63348465 T C 1.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1350172 chr10 63348767 G T 4.00E-07 Response to taxane treatment (placlitaxel) / / 23006423 rs2606117 chr10 63351803 C A 4.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2814022 chr10 63360811 A G 4.82E-05 Alzheimer's disease (late onset) / / 21460841 rs2814021 chr10 63361987 C T 7.00E-06 Obesity-related traits / / 23251661 rs2814020 chr10 63362545 T C 6.79E-05 Alzheimer's disease (late onset) / / 21460841 rs2251363 chr10 63366958 C A 8.61E-05 Alzheimer's disease / / 24755620 rs2606098 chr10 63367308 A G 5.10E-04 Alzheimer's disease / / 24755620 rs2787723 chr10 63367517 T G 6.94E-05 Alzheimer's disease (late onset) / / 21460841 rs12357683 chr10 63371933 A G 1.18E-04 Alzheimer's disease (late onset) / / 21460841 rs12356284 chr10 63372028 T A 1.15E-04 Alzheimer's disease (late onset) / / 21460841 rs1869928 chr10 63382567 A G 5.60E-05 Cognitive impairment induced by topiramate / / 22091778 rs2034855 chr10 63387362 C A 2.07E-04 Alzheimer's disease / / 24755620 rs7087202 chr10 63389580 A G 5.60E-05 Cognitive impairment induced by topiramate / / 22091778 rs1993415 chr10 63400853 C G 1.71E-05 Serum metabolites / / 19043545 rs7085297 chr10 63401422 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10994852 chr10 63410166 A G 7.69E-04 Common variable immunodeficiency / / 21497890 rs12414729 chr10 63421242 C A 4.16E-04 Alzheimer's disease / / 24755620 rs10994864 chr10 63424459 G A 4.16E-04 Alzheimer's disease C10orf107 intron 24755620 rs2068755 chr10 63433281 A G 7.65E-04 Multiple complex diseases C10orf107 intron 17554300 rs12781009 chr10 63437986 G A 5.45E-04 Multiple complex diseases C10orf107 intron 17554300 rs16916501 chr10 63452146 G A 5.35E-05 Smoking cessation C10orf107 intron 18519826 rs16916501 chr10 63452146 G A 3.60E-04 Alzheimer's disease C10orf107 intron 24755620 rs4590817 chr10 63467553 G C 2.00E-18 Blood pressure C10orf107 intron 21909110 rs4590817 chr10 63467553 G C 1.29E-12 Systolic blood pressure C10orf107 intron 21909115 rs7070977 chr10 63488218 G A 7.30E-04 Alzheimer's disease C10orf107 intron 24755620 rs11598771 chr10 63495134 A T 5.77E-04 Alzheimer's disease C10orf107 intron 24755620 rs2248518 chr10 63511789 G A 5.01E-04 Multiple complex diseases C10orf107 intron 17554300 rs10761593 chr10 63520252 C T 7.27E-04 Multiple complex diseases C10orf107 intron 17554300 rs1530440 chr10 63524591 C T 1.00E-09 Diastolic blood pressure C10orf107 intron 19430483 rs1530440 chr10 63524591 C T 1.00E-09 Coronary heart disease C10orf107 intron 21347282 rs1530440 chr10 63524591 C T 1.00E-09 Blood pressure C10orf107 intron 21378095 rs1530440 chr10 63524591 C T 4.50E-17 Blood pressure C10orf107 intron 21909110 rs117670064 chr10 63525288 G C 0.00000191 Inter-adventitial common carotid artery diameter C10orf107 intron 23246012 rs2448396 chr10 63529738 T C 1.05E-09 Smoking cessation / / 18519826 rs2448396 chr10 63529738 T C 4.99E-04 Smoking cessation / / 18519826 rs10821923 chr10 63561316 G A 5.99E-06 Alzheimer's disease (late onset) / / 21460841 rs10994923 chr10 63564428 T C 5.80E-06 Alzheimer's disease (late onset) / / 21460841 rs10994924 chr10 63564860 G C 5.86E-06 Alzheimer's disease (late onset) / / 21460841 rs1470374 chr10 63580867 C G 7.60E-06 Alzheimer's disease (late onset) / / 21460841 rs12572650 chr10 63593841 A G 8.32E-04 Insulin resistance / / 21901158 rs2588962 chr10 63606492 G A 5.74E-05 Tardive dyskinesia / / 20939080 rs2588962 chr10 63606492 G A 1.96E-06 Alzheimer's disease (late onset) / / 21460841 rs4948479 chr10 63606890 G A 1.06E-05 Alzheimer's disease (late onset) / / 21460841 rs2588963 chr10 63607143 C A 1.12E-06 Alzheimer's disease (late onset) / / 21460841 rs2588964 chr10 63607206 T A 2.88E-05 Tardive dyskinesia / / 20939080 rs2588964 chr10 63607206 T A 1.65E-06 Alzheimer's disease (late onset) / / 21460841 rs2675655 chr10 63607744 C G 1.12E-05 Alzheimer's disease (late onset) / / 21460841 rs4948482 chr10 63609408 C A 1.76E-06 Alzheimer's disease (late onset) / / 21460841 rs2588966 chr10 63609810 C T 1.77E-06 Alzheimer's disease (late onset) / / 21460841 rs2588966 chr10 63609810 C T 1.69E-06 Intelligence / / 21826061 rs1373522 chr10 63610605 C T 1.87E-06 Alzheimer's disease (late onset) / / 21460841 rs2588969 chr10 63611354 C A 6.90E-07 Alzheimer's disease (late onset) / / 21460841 rs2675592 chr10 63611534 A T 5.17E-05 Alzheimer's disease (late onset) / / 21460841 rs10821926 chr10 63613870 T C 5.30E-06 Diabetes (gestational) / / 22233651 rs2588929 chr10 63624500 T C 8.06E-04 Type 2 diabetes / / 17463246 rs2675609 chr10 63636531 T C 2.00E-06 Serum total protein level / / 23022100 rs4948486 chr10 63646610 G A 9.76E-05 Blood Pressure / / pha003049 rs7093142 chr10 63649483 G A 9.15E-05 Blood Pressure / / pha003049 rs77968426 chr10 63678484 C T 0.0000435 post-traumatic stress disorder ARID5B intron 22869035 rs77968426 chr10 63678484 C T 4.35E-05 Schizophrenia ARID5B intron 22883433 rs4948488 chr10 63685154 C T 3.70E-05 Acute lymphoblastic leukemia (childhood) ARID5B intron 23512250 rs2893881 chr10 63688672 G A 8.20E-04 Multiple complex diseases ARID5B intron 17554300 rs2893881 chr10 63688672 G A 3.26E-06 Acute lymphoblastic leukemia (childhood) ARID5B intron 23512250 rs17215180 chr10 63688728 C T 4.60E-07 Urinary metabolites ARID5B intron 21572414 rs6479778 chr10 63689077 T C 9.66E-04 Multiple complex diseases ARID5B intron 17554300 rs6479778 chr10 63689077 T C 7.27E-05 Acute lymphoblastic leukemia (childhood) ARID5B intron 23512250 rs6479779 chr10 63695048 C G 2.40E-05 Urinary metabolites ARID5B intron 21572414 rs6479779 chr10 63695048 C G 1.00E-06 IgG glycosylation ARID5B intron 23382691 rs6479779 chr10 63695048 C G 2.00E-06 IgG glycosylation ARID5B intron 23382691 rs6479779 chr10 63695048 C G 3.19E-05 Acute lymphoblastic leukemia (childhood) ARID5B intron 23512250 rs4948491 chr10 63696889 G A 8.26E-11 Acute lymphoblastic leukemia (B-cell precursor) ARID5B intron 23996088 rs7073837 chr10 63699895 A C 9.30E-31 Acute lymphoblastic leukemia (childhood) ARID5B intron 23512250 rs7073837 chr10 63699895 A C 4.12E-34 Acute lymphoblastic leukemia (B-cell precursor) ARID5B intron 23996088 rs10994982 chr10 63710104 A G 9.01E-09 Acute lymphoblastic leukemia (childhood) ARID5B intron 19684603 rs10994982 chr10 63710104 A G 2.15E-20 Acute lymphoblastic leukemia (childhood) ARID5B intron 23512250 rs10994983 chr10 63712827 G C 2.04E-04 Acute lymphoblastic leukemia (childhood) ARID5B intron 23512250 rs7090445 chr10 63721176 C T 5.00E-54 Acute lymphoblastic leukemia (B-cell precursor) ARID5B intron 23996088 rs7923074 chr10 63723440 A C 1.13E-32 Acute lymphoblastic leukemia (childhood) ARID5B intron 23512250 rs10821936 chr10 63723577 C T 1.00E-15 Acute lymphoblastic leukemia (childhood) ARID5B intron 19684603 rs10821936 chr10 63723577 C T 1.00E-15 Nasopharyngeal carcinoma ARID5B intron 20512145 rs10821936 chr10 63723577 C T 5.88E-46 Acute lymphoblastic leukemia (childhood) ARID5B intron 23512250 rs10821936 chr10 63723577 C T 6.00E-46 Acute lymphoblastic leukemia (childhood) ARID5B intron 23512250 rs7896246 chr10 63724390 A G 7.40E-43 Acute lymphoblastic leukemia (childhood) ARID5B intron 23512250 rs10821938 chr10 63724773 A C 2.05E-31 Acute lymphoblastic leukemia (childhood) ARID5B intron 23512250 rs10821938 chr10 63724773 A C 6.44E-36 Acute lymphoblastic leukemia (B-cell precursor) ARID5B intron 23996088 rs4506592 chr10 63727187 A G 2.68E-46 Acute lymphoblastic leukemia (B-cell precursor) ARID5B intron 23996088 rs7089424 chr10 63752159 T G 7.00E-19 Acute lymphoblastic leukemia (childhood) ARID5B intron 19684604 rs7089424 chr10 63752159 T G 7.00E-19 Nasopharyngeal carcinoma ARID5B intron 20512145 rs7089424 chr10 63752159 T G 8.41E-51 Acute lymphoblastic leukemia (B-cell precursor) ARID5B intron 23996088 rs9971170 chr10 63754798 A C 7.10E-04 Type 2 diabetes ARID5B intron 22158537 rs7894504 chr10 63769839 C T 9.60E-05 Non-alcoholic fatty liver disease histology (other) ARID5B intron 20708005 rs7894504 chr10 63769839 C T 1.87E-10 Acute lymphoblastic leukemia (B-cell precursor) ARID5B intron 23996088 rs7087125 chr10 63773039 C T 6.76E-05 Bone mineral density ARID5B intron 19181680 rs7087125 chr10 63773039 C T 1.59E-11 Acute lymphoblastic leukemia (childhood) ARID5B intron 23512250 rs7087125 chr10 63773039 C T 4.27E-13 Acute lymphoblastic leukemia (B-cell precursor) ARID5B intron 23996088 rs71508903 chr10 63779871 C T 1.00E-08 Rheumatoid arthritis ARID5B intron 24390342 rs71508903 chr10 63779871 C T 3.00E-15 Rheumatoid arthritis ARID5B intron 24390342 rs71508903 chr10 63779871 C T 5.00E-22 Rheumatoid arthritis ARID5B intron 24390342 rs10821944 chr10 63785089 G T 6.00E-18 Rheumatoid arthritis ARID5B intron 22446963 rs12764378 chr10 63800004 G A 4.45E-10 Rheumatoid arthritis (CCP positive) ARID5B intron 23143596 rs12764378 chr10 63800004 G A 4.50E-10 Rheumatoid arthritis ARID5B intron 23143596 rs12357548 chr10 63803472 G A 4.34E-04 Rheumatoid arthritis ARID5B intron 21452313 rs4948496 chr10 63805617 T C 4.59E-04 Rheumatoid arthritis ARID5B intron 21452313 rs4948496 chr10 63805617 T C 5.00E-11 Systemic lupus erythematosus ARID5B intron 23273568 rs9415636 chr10 63826186 G T 2.68E-04 Acute lymphoblastic leukemia (childhood) ARID5B intron 23512250 rs397962420 chr10 63829811 C CT 2.00E-04 Cognitive impairment induced by topiramate ARID5B intron 22091778 rs4948294 chr10 63829811 C T 2.00E-04 Cognitive impairment induced by topiramate ARID5B intron 22091778 rs7090871 chr10 63830286 T C 6.00E-10 Corneal structure ARID5B intron 23291589 rs4948502 chr10 63839417 T C 7.10E-07 Corneal structure ARID5B intron 23291589 rs9415637 chr10 63840265 T G 3.32E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ARID5B intron 20031582 rs9415637 chr10 63840265 T G 1.91E-05 Sudden cardiac arrest ARID5B intron 21658281 rs2278305 chr10 63843112 A G 4.43E-04 Alzheimer's disease (late onset) ARID5B intron 21379329 rs7906079 chr10 63844810 G C 6.62E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ARID5B intron 20031582 rs9414761 chr10 63848656 C T 7.05E-04 Taste perception ARID5B intron 22132133 rs7916978 chr10 63856856 C T 2.61E-04 Alzheimer's disease (late onset) ARID5B nearGene-3 21379329 rs1122157 chr10 63861600 C T 1.90E-05 Urinary metabolites / / 21572414 rs10821956 chr10 63862634 G A 3.50E-05 Cognitive impairment induced by topiramate / / 22091778 rs7896430 chr10 63890959 T G 9.10E-06 Urinary metabolites / / 21572414 rs4979758 chr10 63905989 A C 7.06E-05 Serum metabolites / / 19043545 rs7912580 chr10 63915972 G A 1.00E-06 Response to haloperidol in psychosis / / 24751813 rs12248974 chr10 63942850 A G 9.40E-05 Rheumatoid arthritis / / 23028356 rs3125734 chr10 63958112 T C 5.00E-09 Rheumatoid arthritis RTKN2 missense 23028356 rs10995090 chr10 63974229 T G 1.60E-05 Urinary metabolites RTKN2 intron 21572414 rs10733769 chr10 63974255 G T 5.80E-05 Rheumatoid arthritis RTKN2 intron 21673997 rs4147233 chr10 63982668 A G 6.60E-05 Rheumatoid arthritis RTKN2 intron 21673997 rs4147233 chr10 63982668 A G 6.49E-05 Graves' disease RTKN2 intron 21841780 rs7923556 chr10 64024648 A G 2.10E-07 Colorectal cancer RTKN2 intron 24448986 rs6479800 chr10 64036881 G C 1.40E-04 Rheumatoid arthritis / / 24390342 rs6479800 chr10 64036881 G C 4.00E-06 Rheumatoid arthritis / / 24390342 rs6479800 chr10 64036881 G C 4.00E-08 Rheumatoid arthritis / / 24390342 rs3852412 chr10 64050288 C T 9.90E-05 Hypothyroidism / / 22493691 rs6479805 chr10 64059261 C T 5.40E-05 Rheumatoid arthritis / / 21673997 rs3910172 chr10 64067508 C T 4.40E-05 Rheumatoid arthritis / / 21673997 rs3910172 chr10 64067508 C T 9.12E-05 Graves' disease / / 21841780 rs3864806 chr10 64069035 T G 7.63E-04 Graves' disease / / 21841780 rs3852421 chr10 64069979 T G 6.94E-04 Acute lung injury / / 22295056 rs10761622 chr10 64085701 A T 4.40E-06 Urinary metabolites / / 21572414 rs11593322 chr10 64095507 C T 9.20E-06 Urinary metabolites / / 21572414 rs4746442 chr10 64112473 A G 9.00E-06 Urinary metabolites / / 21572414 rs10761625 chr10 64119397 C T 1.60E-05 Urinary metabolites / / 21572414 rs10740076 chr10 64156110 C T 8.41E-04 Tourette syndrome ZNF365 intron 22889924 rs10995146 chr10 64156773 G A 1.20E-05 Urinary metabolites ZNF365 intron 21572414 rs3758490 chr10 64159333 G T 6.28E-05 Psoriasis ZNF365 missense 18364390 rs7089814 chr10 64187564 C T 3.00E-09 Breast size ZNF365 intron 22747683 rs11598789 chr10 64211640 T G 1.28E-04 Bipolar disorder,schizoaffective ZNF365 intron 19567891 rs2138556 chr10 64214282 A G 3.08E-04 Multiple complex diseases ZNF365 intron 17554300 rs10995170 chr10 64223383 T C 3.00E-07 Intelligence ZNF365 intron 22449649 rs6479815 chr10 64224100 A G 1.38E-04 Alzheimer's disease (late onset) ZNF365 intron 21379329 rs2077316 chr10 64225448 A C 3.64E-08 Sudden cardiac death ZNF365 intron 23593153 rs10822013 chr10 64251977 C T 6.00E-09 Breast cancer ZNF365 intron 21908515 rs6479821 chr10 64252883 G A 9.44E-04 Obesity (extreme) ZNF365 intron 21935397 rs7083750 chr10 64256830 A G 5.81E-04 Multiple complex diseases ZNF365 intron 17554300 rs12245332 chr10 64260847 T C 2.03E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) ZNF365 intron 23648065 rs16917302 chr10 64261198 A C 1.77E-05 Breast cancer ZNF365 intron 21060860 rs16917302 chr10 64261198 A C 4.53E-04 Obesity (extreme) ZNF365 intron 21935397 rs11819137 chr10 64261656 C T 7.80E-04 Obesity (extreme) ZNF365 intron 21935397 rs4746409 chr10 64263402 C G 1.40E-06 Breast cancer ZNF365 intron 20453838 rs4746419 chr10 64275261 C G 5.20E-09 Breast cancer ZNF365 intron 20453838 rs10995189 chr10 64278181 G A 4.70E-09 Breast cancer ZNF365 intron 20453838 rs10995190 chr10 64278682 G A 5.00E-15 Breast cancer ZNF365 intron 20453838 rs10995190 chr10 64278682 G A 1.00E-09 Mammographic density ZNF365 intron 21278746 rs10995190 chr10 64278682 G A 1.00E-36 Breast cancer ZNF365 intron 23535729 rs10995190 chr10 64278682 G A 1.00E-07 Breast cancer ZNF365 intron 23535733 rs10995191 chr10 64278874 C T 4.20E-09 Breast cancer ZNF365 intron 20453838 rs10995194 chr10 64288130 G C 1.50E-09 Breast cancer ZNF365 intron 20453838 rs10995195 chr10 64288389 T C 4.30E-09 Breast cancer ZNF365 intron 20453838 rs16917398 chr10 64301817 C T 9.78E-05 Cognitive impairment induced by topiramate ZNF365 intron 22091778 rs2138564 chr10 64307317 C T 7.90E-04 Alcohol dependence ZNF365 intron 20201924 rs16917442 chr10 64313404 T A 1.34E-04 Arthritis (juvenile idiopathic) ZNF365 intron 22354554 rs7903566 chr10 64315820 G A 5.53E-05 Erythrocyte counts ZNF365 intron pha003090 rs10822026 chr10 64320658 T C 6.50E-05 Erythrocyte counts ZNF365 intron pha003090 rs2393902 chr10 64369001 T C 2.00E-04 Atopic dermatitis ZNF365 intron 23886662 rs12781740 chr10 64377967 C T 2.68E-05 Type 2 diabetes and other traits ZNF365 intron 19734900 rs2393903 chr10 64380336 T C 1.05E-07 Atopic dermatitis ZNF365 intron 21666691 rs10761650 chr10 64384782 G A 2.90E-05 Atopic dermatitis ZNF365 intron 21666691 rs10995238 chr10 64387108 C T 1.20E-04 Multiple complex diseases ZNF365 intron 17554300 rs10995245 chr10 64391375 G A 0.000000324 Narcolepsy (non-HLA narcolepsy) ZNF365 intron 23459209 rs10995245 chr10 64391375 G A 1.00E-11 Narcolepsy ZNF365 intron 24204295 rs12098699 chr10 64396790 A G 0.0000363 Narcolepsy (non-HLA narcolepsy) ZNF365 intron 23459209 rs10995251 chr10 64398466 C T 6.00E-20 Atopic dermatitis ZNF365 intron 23042114 rs10761653 chr10 64404034 T A 0.0000386 Narcolepsy (non-HLA narcolepsy) ZNF365 intron 23459209 rs10761654 chr10 64405646 A G 0.000069 Narcolepsy (non-HLA narcolepsy) ZNF365 intron 23459209 rs2393907 chr10 64407359 C G 0.0000854 Narcolepsy (non-HLA narcolepsy) ZNF365 intron 23459209 rs4237305 chr10 64407851 T A 0.0000578 Narcolepsy (non-HLA narcolepsy) ZNF365 intron 23459209 rs4745874 chr10 64413809 T A 1.81E-04 Multiple complex diseases ZNF365 intron 17554300 rs4745874 chr10 64413809 T A 0.0000493 Narcolepsy (non-HLA narcolepsy) ZNF365 intron 23459209 rs7071642 chr10 64414060 G A 3.41E-08 Crohn's disease and psoriasis ZNF365 intron 22482804 rs7076156 chr10 64415184 A G 7.00E-09 Crohn's disease ZNF365 intron 22412388 rs7915131 chr10 64418656 C T 4.77E-04 Multiple complex diseases ZNF365 intron 17554300 rs6479830 chr10 64418739 T C 0.0000728 Narcolepsy (non-HLA narcolepsy) ZNF365 intron 23459209 rs7090073 chr10 64423505 G A,T 1.91E-04 Multiple complex diseases ZNF365 intron 17554300 rs7075349 chr10 64427649 G A 0.0000128 Narcolepsy (non-HLA narcolepsy) ZNF365 intron 23459209 rs729738 chr10 64430265 C A 2.72E-04 Multiple complex diseases ZNF365 UTR-3 17554300 rs10995271 chr10 64438486 G C 9.47E-09 Multiple complex diseases / / 17554300 rs10995271 chr10 64438486 G C 4.00E-20 Crohn's disease / / 18587394 rs10995271 chr10 64438486 G C 4.00E-20 Asthma / / 21150878 rs10995271 chr10 64438486 G C 4.46E-20 Multiple sclerosis / / 22190364 rs10761659 chr10 64445564 A G 2.00E-06 Crohn's disease / / 17554300 rs10761659 chr10 64445564 A G 4.00E-22 Crohn's disease / / 21102463 rs10761659 chr10 64445564 A G 5.00E-06 Crohn's disease / / 22936669 rs10761659 chr10 64445564 A G 6.00E-46 Inflammatory bowel disease / / 23128233 rs10995278 chr10 64454497 C T 5.46E-04 Type 2 diabetes / / 17463246 rs224126 chr10 64460929 G A 3.53E-05 Multiple complex diseases / / 17554300 rs224127 chr10 64461273 A G 2.50E-05 Multiple complex diseases / / 17554300 rs224135 chr10 64466802 A G 2.84E-04 Crohn's disease / / 23266558 rs224136 chr10 64470675 C T 1.00E-10 Crohn's disease / / 17435756 rs224136 chr10 64470675 C T 1.95E-05 Multiple complex diseases / / 17554300 rs224136 chr10 64470675 C T 1.00E-10 Asthma / / 21907864 rs7088266 chr10 64481048 C T 7.07E-05 Multiple complex diseases / / 17554300 rs224147 chr10 64485815 C G 7.62E-05 Multiple complex diseases / / 17554300 rs224149 chr10 64487073 T C 2.70E-04 Myasthenia gravis / / 23055271 rs224053 chr10 64494790 T G 7.68E-04 Multiple complex diseases / / 17554300 rs224058 chr10 64498865 G A 3.71E-04 Multiple complex diseases / / 17554300 rs224063 chr10 64503349 G T 8.03E-05 Multiple complex diseases / / 17554300 rs224067 chr10 64506971 C T 8.48E-05 Multiple complex diseases / / 17554300 rs224073 chr10 64510104 C G 3.11E-04 Type 2 diabetes / / 17463246 rs224079 chr10 64513230 C T 3.11E-04 Type 2 diabetes / / 17463246 rs10822056 chr10 64514111 C T 1.75E-04 Type 2 diabetes / / 17463246 rs377859 chr10 64516065 G T 2.39E-04 Type 2 diabetes / / 17463246 rs10761660 chr10 64516306 T C 2.90E-04 Myasthenia gravis / / 23055271 rs224029 chr10 64519299 T C 1.82E-04 Type 2 diabetes / / 17463246 rs224030 chr10 64520135 A G 3.79E-04 Type 2 diabetes / / 17463246 rs224031 chr10 64521356 T G 5.64E-04 Fibrinogen / / 17255346 rs224031 chr10 64521356 T G 5.90E-04 Multiple complex diseases / / 17554300 rs224035 chr10 64522411 A G 1.82E-05 Multiple complex diseases / / 17554300 rs224042 chr10 64524290 G A 3.79E-04 Type 2 diabetes / / 17463246 rs224090 chr10 64541319 T C 9.94E-05 Multiple complex diseases / / 17554300 rs224091 chr10 64541373 C T 5.11E-04 Smoking initiation / / 24665060 rs224092 chr10 64541404 A G 1.80E-04 Multiple complex diseases / / 17554300 rs224110 chr10 64551577 A T 7.21E-04 Type 2 diabetes / / 17463246 rs224110 chr10 64551577 A T 2.56E-04 Multiple complex diseases / / 17554300 rs1509966 chr10 64552607 G A 1.30E-05 Ewing sarcoma / / 22327514 rs1848797 chr10 64552934 A G 2.10E-05 Ewing sarcoma / / 22327514 rs7922917 chr10 64559027 G C 5.14E-04 Multiple complex diseases / / 17554300 rs1444418 chr10 64560470 A G 2.00E-07 Atopic dermatitis / / 23042114 rs10995309 chr10 64560878 G A 8.00E-04 Multiple complex diseases / / 17554300 rs9971328 chr10 64561869 A G 5.58E-04 Multiple complex diseases / / 17554300 rs10995312 chr10 64566572 T C 2.31E-04 Multiple complex diseases ADO UTR-3 17554300 rs224278 chr10 64580575 C T 4.00E-17 Ewing sarcoma EGR2 nearGene-5 22327514 rs224292 chr10 64588424 G A 8.60E-06 Ewing sarcoma / / 22327514 rs1475084 chr10 64605734 G A 1.09E-05 Cleft lip / / 20436469 rs1509957 chr10 64610718 T C 8.40E-04 Type 2 diabetes / / 17846124 rs10822065 chr10 64610932 T G 3.58E-05 Cleft lip / / 20436469 rs10509173 chr10 64611889 A G 1.21E-05 Cleft lip / / 20436469 rs12252317 chr10 64646868 C T 2.83E-06 Rheumatoid arthritis / / 17804836 rs9633562 chr10 64647504 A C 2.00E-06 Ewing sarcoma / / 22327514 rs10995356 chr10 64655913 G A 6.25E-04 Alzheimer's disease / / 22005930 rs10995356 chr10 64655913 G A 3.00E-06 Temperament / / 22832960 rs931977 chr10 64657978 C T 2.90E-05 Parkinson's disease (familial) / / 18985386 rs931977 chr10 64657978 C T 7.11E-04 Alzheimer's disease / / 22005930 rs7922141 chr10 64659642 C T 2.97E-05 Multiple complex diseases / / 17554300 rs10509177 chr10 64668048 C T 9.60E-05 Alcoholism (heaviness of drinking) / / 21529783 rs944684 chr10 64676376 C T 8.00E-07 Ewing sarcoma / / 22327514 rs10822082 chr10 64677307 T C 1.30E-05 Parkinson's disease (familial) / / 18985386 rs17797274 chr10 64677390 T G 0.0006835 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17797274 chr10 64677390 T G 6.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7068751 chr10 64697148 C T 9.00E-06 Rheumatoid arthritis / / 17804836 rs2893914 chr10 64702183 A G 1.25E-04 Multiple complex diseases / / 17554300 rs10509178 chr10 64725655 T G 5.40E-05 Tooth agenesis (mandibular third molar) / / 24172245 rs16917994 chr10 64740148 C T 3.87E-04 Multiple complex diseases / / 17554300 rs6479860 chr10 64745865 C T 1.10E-05 Ewing sarcoma / / 22327514 rs2842284 chr10 64769628 G A 4.11E-06 Monocyte chemoattractant protein-1 / / pha003071 rs2495012 chr10 64816444 A G 8.93E-06 Monocyte chemoattractant protein-1 / / pha003071 rs10733785 chr10 64846332 T C 3.23E-04 Type 2 diabetes / / 17463246 rs11594009 chr10 64861870 G T 4.15E-04 Coronary Artery Disease / / 17634449 rs10995439 chr10 64866912 G A 1.00E-07 IgG glycosylation / / 23382691 rs10995439 chr10 64866912 G A 3.00E-06 IgG glycosylation / / 23382691 rs10822136 chr10 64872411 C T 5.00E-07 IgG glycosylation / / 23382691 rs10822136 chr10 64872411 C T 7.00E-07 IgG glycosylation / / 23382691 rs10995450 chr10 64888911 T C 8.31E-04 Coronary Artery Disease / / 17634449 rs12416113 chr10 64896477 T A 2.39E-07 Arthritis (juvenile idiopathic) NRBF2 intron 22354554 rs7073746 chr10 64904071 A G 1.04E-07 Plasma omega-6 polyunsaturated fatty acid levels NRBF2 intron 24823311 rs7073746 chr10 64904071 A G 2.80E-06 Plasma omega-6 polyunsaturated fatty acid levels NRBF2 intron 24823311 rs1009984 chr10 64916469 T G 2.60E-06 Arthritis (juvenile idiopathic) / / 22354554 rs11817689 chr10 64924217 T C 9.77E-08 Arthritis (juvenile idiopathic) / / 22354554 rs1935 chr10 64927823 C G 7.42E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C missense 24823311 rs10733789 chr10 64948684 T C 2.09E-04 Alzheimer's disease JMJD1C intron 24755620 rs4379723 chr10 64963449 T C 7.00E-07 Platelet counts JMJD1C intron 23263863 rs4379723 chr10 64963449 T C 3.00E-16 Mean platelet volume JMJD1C intron 24026423 rs4379723 chr10 64963449 T C 8.05E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs7082090 chr10 64999012 A G 2.20E-07 Arthritis (juvenile idiopathic) JMJD1C intron 22354554 rs9414780 chr10 65001433 A C 5.95E-07 Arthritis (juvenile idiopathic) JMJD1C intron 22354554 rs6479891 chr10 65006456 T C 2.00E-07 Arthritis (juvenile idiopathic) JMJD1C intron 22354554 rs4454603 chr10 65012750 C T 3.80E-06 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs4454603 chr10 65012750 C T 4.25E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs10995485 chr10 65026858 G C 2.00E-06 Response to fenofibrate JMJD1C intron 22890011 rs10761731 chr10 65027610 A T 3.00E-12 Triglycerides JMJD1C intron 20686565 rs10761731 chr10 65027610 A T 2.00E-24 Platelet counts JMJD1C intron 22139419 rs10761731 chr10 65027610 A T 2.00E-06 Platelet counts JMJD1C intron 24026423 rs10761731 chr10 65027610 A T 8.00E-12 Triglycerides JMJD1C intron 24097068 rs10761731 chr10 65027610 A T 9.10E-09 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs7080386 chr10 65048306 C A 6.80E-09 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs7075195 chr10 65050659 A G 2.00E-44 Mean platelet volume JMJD1C intron 22139419 rs7075195 chr10 65050659 A G 3.00E-18 Mean platelet volume JMJD1C intron 24026423 rs7075195 chr10 65050659 A G 9.02E-09 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs9414788 chr10 65056712 A G 2.48E-07 Arthritis (juvenile idiopathic) JMJD1C intron 22354554 rs10761739 chr10 65062008 G C 9.78E-09 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs10761741 chr10 65066186 G T 8.77E-09 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs7070296 chr10 65070438 T A 7.01E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs10761742 chr10 65085048 A G 2.39E-06 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs10761742 chr10 65085048 A G 4.98E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs10995505 chr10 65091159 A G 1.14E-05 Serum metabolites JMJD1C intron 19043545 rs10761744 chr10 65101026 C G 2.56E-07 Arthritis (juvenile idiopathic) JMJD1C intron 22354554 rs10761745 chr10 65101071 G C 2.23E-07 Arthritis (juvenile idiopathic) JMJD1C intron 22354554 rs10740118 chr10 65101207 G C 8.00E-09 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs7896518 chr10 65104500 A G 2.00E-12 Mean platelet volume JMJD1C intron 22423221 rs7896518 chr10 65104500 A G 1.07E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs10761747 chr10 65108156 G C 9.93E-06 Serum metabolites JMJD1C intron 19043545 rs12355784 chr10 65121565 C A 2.38E-04 Type 2 diabetes JMJD1C intron 17463246 rs12355784 chr10 65121565 C A 5.00E-10 Liver enzyme levels JMJD1C intron 18940312 rs12355784 chr10 65121565 C A 8.77E-04 Coronary heart disease JMJD1C intron 21606135 rs12355784 chr10 65121565 C A 4.84E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs10822163 chr10 65124098 C G 3.91E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs6479896 chr10 65126832 T C 5.98E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs2393967 chr10 65133156 A C 3.00E-21 Mean platelet volume JMJD1C intron 19820697 rs2393967 chr10 65133156 A C 3.30E-21 Mean platelet volume JMJD1C intron 22423221 rs2393967 chr10 65133156 A C 4.53E-06 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs7923609 chr10 65133822 A G 5.20E-09 Lipid levels JMJD1C intron 19936222 rs7923609 chr10 65133822 A G 6.00E-23 Liver enzyme levels (alkaline phosphatase) JMJD1C intron 22001757 rs7923609 chr10 65133822 A G 8.38E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs2893919 chr10 65134778 G A 7.83E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs2393966 chr10 65134814 T G 7.85E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs7076310 chr10 65135672 C A 7.69E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs7910927 chr10 65138910 T G 1.00E-25 Sex hormone-binding globulin levels JMJD1C intron 22829776 rs7910927 chr10 65138910 T G 2.00E-13 Sex hormone-binding globulin levels JMJD1C intron 22829776 rs7910927 chr10 65138910 T G 6.00E-35 Sex hormone-binding globulin levels JMJD1C intron 22829776 rs7910927 chr10 65138910 T G 9.09E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs2393969 chr10 65140440 A C 1.17E-07 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs9415699 chr10 65143558 T C 1.72E-07 Arthritis (juvenile idiopathic) JMJD1C intron 22354554 rs7095571 chr10 65150959 T G 8.57E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs10761752 chr10 65160321 T C 8.61E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs9415705 chr10 65161550 T G 1.84E-07 Arthritis (juvenile idiopathic) JMJD1C intron 22354554 rs7912893 chr10 65162000 T A 7.50E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs7896783 chr10 65162153 G A 9.00E-22 Fibrinogen JMJD1C intron 23969696 rs7896783 chr10 65162153 G A 7.89E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs10761756 chr10 65172328 C T 5.76E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs7923544 chr10 65182256 T G 5.70E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs10761762 chr10 65184717 T C 6.52E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs10761766 chr10 65190327 G A 5.65E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs3740331 chr10 65192288 G A 7.03E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs3999089 chr10 65203808 A G 5.42E-04 Type 2 diabetes JMJD1C intron 17463246 rs3999089 chr10 65203808 A G 8.72E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs10509186 chr10 65207018 C T 6.64E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs7085621 chr10 65208926 T C 6.32E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs10740125 chr10 65209609 T C 7.22E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs10740126 chr10 65210935 A G 6.94E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs7092784 chr10 65214749 C T 5.82E-08 Plasma omega-6 polyunsaturated fatty acid levels JMJD1C intron 24823311 rs10761771 chr10 65230164 T C 3.69E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10761771 chr10 65230164 T C 5.81E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7909960 chr10 65239177 T A 4.07E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7909960 chr10 65239177 T A 6.77E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7915779 chr10 65244244 G A,C 3.43E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2893922 chr10 65247019 T G 3.19E-07 Arthritis (juvenile idiopathic) / / 22354554 rs2393977 chr10 65247609 A C 4.04E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10740129 chr10 65250808 G A 4.65E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2893923 chr10 65261184 C T 5.00E-08 Platelet aggregation / / 20526338 rs2893923 chr10 65261184 C T 2.10E-04 Alzheimer's disease / / 24755620 rs2893923 chr10 65261184 C T 3.70E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10509189 chr10 65264126 T C 4.69E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4486511 chr10 65264266 C T 4.68E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs9971352 chr10 65265108 A T 4.70E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10761779 chr10 65274927 A G 5.45E-04 Type 2 diabetes / / 17463246 rs10761779 chr10 65274927 A G 7.00E-10 Liver enzyme levels / / 18940312 rs10761779 chr10 65274927 A G 4.67E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7082470 chr10 65277026 G A 1.15E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10761781 chr10 65284603 T C 3.95E-05 Arthritis (juvenile idiopathic) REEP3 intron 22354554 rs7904459 chr10 65285485 T C 3.80E-05 Multiple complex diseases REEP3 intron 17554300 rs7085018 chr10 65286667 T C 3.16E-08 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs7920036 chr10 65293860 T C 3.59E-08 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs16918575 chr10 65301325 A G 1.67E-07 Arthritis (juvenile idiopathic) REEP3 intron 22354554 rs7897379 chr10 65301725 T C 2.46E-06 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs7897379 chr10 65301725 T C 9.67E-09 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs10761784 chr10 65308750 A T 3.01E-08 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs10761784 chr10 65308750 A T 3.10E-06 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs2163188 chr10 65314711 G C 1.17E-06 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs2163188 chr10 65314711 G C 2.25E-07 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs6479905 chr10 65315231 A G 1.24E-06 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs6479905 chr10 65315231 A G 2.23E-07 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs12411988 chr10 65315397 G C 3.00E-07 Arthritis (juvenile idiopathic) REEP3 intron 22354554 rs10740134 chr10 65315433 T C 2.87E-08 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs10740134 chr10 65315433 T C 3.44E-06 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs7919685 chr10 65315800 G T 1.13E-06 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs7919685 chr10 65315800 G T 2.06E-07 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs12247907 chr10 65317045 G C 1.12E-06 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs12247907 chr10 65317045 G C 2.15E-07 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs7070761 chr10 65317056 A T 1.06E-06 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs7070761 chr10 65317056 A T 2.03E-07 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs10761785 chr10 65318766 G T 3.02E-07 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs10761785 chr10 65318766 G T 7.00E-07 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs2393986 chr10 65320006 A T 2.67E-08 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs2393986 chr10 65320006 A T 2.81E-06 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs4746201 chr10 65322381 G T 1.01E-07 Arthritis (juvenile idiopathic) REEP3 intron 22354554 rs10733793 chr10 65323809 T G 1.03E-06 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs4746203 chr10 65323997 G A,C,T 4.23E-06 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs10822181 chr10 65325126 G A 3.66E-06 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs10822182 chr10 65325478 G A 5.80E-07 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs3847326 chr10 65331859 A G 3.77E-06 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs10761786 chr10 65336207 T C 1.21E-06 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs10822184 chr10 65337153 T C 1.00E-08 Androgen levels REEP3 intron 22936694 rs12768534 chr10 65340897 G A 2.80E-08 Lipid levels REEP3 intron 19936222 rs12768534 chr10 65340897 G A 9.85E-04 Alzheimer's disease REEP3 intron 24755620 rs10822186 chr10 65350383 A G 4.78E-04 Alzheimer's disease REEP3 intron 24755620 rs10822186 chr10 65350383 A G 1.77E-06 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs6479911 chr10 65351581 G A 2.35E-05 Intracerebral hemorrhage REEP3 intron 24656865 rs10761787 chr10 65353755 A T 1.76E-06 Plasma omega-6 polyunsaturated fatty acid levels REEP3 intron 24823311 rs2565186 chr10 65392030 A G 1.67E-04 Myocardial Infarction / / pha002883 rs3858120 chr10 65399851 T C 0.000529 Salmonella-induced pyroptosis / / 22837397 rs10995587 chr10 65461793 G A 5.80E-06 Urinary metabolites / / 21572414 rs4543877 chr10 65502021 C G 7.70E-06 Type 2 diabetes / / 17463248 rs3864799 chr10 65502382 G C 7.50E-06 Type 2 diabetes / / 17463248 rs3912165 chr10 65517691 A G 4.50E-06 Type 2 diabetes / / 17463248 rs10740140 chr10 65519754 A G 2.50E-05 Type 2 diabetes / / 17463248 rs10509195 chr10 65523366 G T 3.30E-05 Type 2 diabetes / / 17846126 rs4746396 chr10 65524123 G C 3.10E-05 Type 2 diabetes / / 17463248 rs3847331 chr10 65547431 C T 8.60E-04 Type 2 diabetes / / 17846126 rs16918864 chr10 65558761 C G 3.40E-05 Type 2 diabetes / / 17463248 rs4427464 chr10 65587937 T G 6.28E-04 Alcohol dependence / / 24277619 rs4107879 chr10 65610953 A T 5.31E-05 Recombination rate / / 21698098 rs1916434 chr10 65622494 C T 3.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10509199 chr10 65625814 C A 1.68E-05 Type 2 diabetes / / 17846126 rs10509200 chr10 65626561 T C 7.00E-05 Longevity and age-related phenotypes / / 17903295 rs884242 chr10 65650779 C T 3.15E-04 Alcohol dependence / / 24277619 rs884243 chr10 65651104 T A 7.13E-05 Multiple complex diseases / / 17554300 rs938036 chr10 65658744 T C 8.00E-06 Tooth agenesis (mandibular third molar) / / 24172245 rs1916412 chr10 65670795 A G 8.35E-05 Type 2 diabetes / / 17846126 rs1916411 chr10 65670833 G C 8.48E-05 Type 2 diabetes / / 17846126 rs1916410 chr10 65671109 T A 0.000505 Salmonella-induced pyroptosis / / 22837397 rs10509201 chr10 65672242 C T 8.80E-05 Type 2 diabetes / / 17846126 rs2252306 chr10 65700555 T G 7.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7911391 chr10 65714950 A G 6.75E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs2250844 chr10 65747473 T A 1.23E-04 Multiple complex diseases / / 17554300 rs736883 chr10 65771002 G A 7.53E-04 Coronary heart disease / / 21606135 rs2671507 chr10 65774014 A G 8.73E-04 Multiple complex diseases / / 17554300 rs2671507 chr10 65774014 A G 7.27E-04 Coronary heart disease / / 21606135 rs16919273 chr10 65796339 T G 7.22E-05 Multiple complex diseases / / 17554300 rs10491072 chr10 65817792 C T 1.39E-05 Major depressive disorder / / 19107115 rs2578018 chr10 65839970 A C 5.21E-04 Type 2 diabetes / / 17463246 rs2578024 chr10 65848106 A G 6.54E-04 Type 2 diabetes / / 17463246 rs2671523 chr10 65855881 A G 4.14E-04 Parkinson's disease / / 17052657 rs10740149 chr10 65887214 A G 2.95E-04 Premature ovarian failure / / 19508998 rs10995835 chr10 65947970 A T 9.59E-04 Multiple complex diseases / / 17554300 rs7080690 chr10 66081084 T C 2.70E-04 Multiple complex diseases / / 17554300 rs7080690 chr10 66081084 T C 2.95E-05 Alzheimer's disease (late onset) / / 21379329 rs2818044 chr10 66142148 G C 4.02E-04 Multiple complex diseases / / 17554300 rs2660109 chr10 66179036 A C 7.52E-05 Serum metabolites / / 19043545 rs7920723 chr10 66206804 G A 7.52E-05 Multiple complex diseases / / 17554300 rs7920723 chr10 66206804 G A 9.94E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7913086 chr10 66222693 C T 9.94E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16919914 chr10 66289103 C T 2.44E-04 Multiple complex diseases / / 17554300 rs10509208 chr10 66289282 G T 4.13E-04 Multiple complex diseases / / 17554300 rs721378 chr10 66320442 T C 4.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10822318 chr10 66340742 G A 2.43E-05 Personality dimensions / / 22628180 rs10822320 chr10 66364116 C T 4.46E-04 Endometrial cancer / / 24096698 rs10822320 chr10 66364116 C T 9.30E-05 Endometrial cancer / / 24096698 rs2394086 chr10 66364463 C A 1.21E-05 Personality dimensions / / 22628180 rs2394085 chr10 66369826 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10995927 chr10 66371941 T C 1.45E-05 Magnesium levels / / pha003092 rs10995932 chr10 66375794 T C 4.78E-04 Type 2 diabetes / / 17463246 rs10995932 chr10 66375794 T C 9.52E-04 Multiple complex diseases / / 17554300 rs10995932 chr10 66375794 T C 6.12E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10995933 chr10 66375958 T C 3.12E-04 Type 2 diabetes / / 17463246 rs2683581 chr10 66378372 A G 6.40E-05 Magnesium levels / / pha003092 rs2394078 chr10 66381103 T C 5.69E-05 Urinary albumin excretion rate in type 1 diabetes / / 24595857 rs2893959 chr10 66383366 G A 2.73E-05 Magnesium levels / / pha003092 rs10761855 chr10 66417543 C T 8.00E-05 Response to statin therapy / / 20339536 rs7895566 chr10 66422746 T G 1.10E-05 Response to statin therapy / / 20339536 rs4746459 chr10 66424808 G T 4.50E-05 Response to statin therapy / / 20339536 rs7093406 chr10 66427078 T C 1.20E-05 Response to statin therapy / / 20339536 rs1915648 chr10 66432099 G A 5.40E-05 Response to statin therapy / / 20339536 rs1915647 chr10 66432626 G C 5.60E-05 Type 2 diabetes / / 17463246 rs12412838 chr10 66435199 T C 1.30E-05 Response to statin therapy / / 20339536 rs2139905 chr10 66438993 A C 5.80E-05 Response to statin therapy / / 20339536 rs10995964 chr10 66440499 G A 1.30E-05 Response to statin therapy / / 20339536 rs10761859 chr10 66441658 G A 3.00E-05 Response to statin therapy / / 20339536 rs7900909 chr10 66448472 T C 8.00E-06 Response to statin therapy / / 20339536 rs11816713 chr10 66452715 C T 1.50E-05 Response to statin therapy / / 20339536 rs10995982 chr10 66453375 C T 1.40E-05 Response to statin therapy / / 20339536 rs1915601 chr10 66454238 G A 1.30E-05 Response to statin therapy / / 20339536 rs7907064 chr10 66461969 C T 2.20E-05 Response to statin therapy / / 20339536 rs12779528 chr10 66462259 G A 1.10E-05 Response to statin therapy / / 20339536 rs12779886 chr10 66462669 A G 1.00E-05 Response to statin therapy / / 20339536 rs9702259 chr10 66465860 G A 8.60E-06 Response to statin therapy / / 20339536 rs1915616 chr10 66486541 G T 9.82E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4559573 chr10 66492416 G C 9.67E-04 Type 2 diabetes / / 17463246 rs1915622 chr10 66493222 A G 8.81E-04 Type 2 diabetes / / 17463246 rs16920273 chr10 66494077 T C 1.23E-04 Hearing function / / 17255346 rs16913136 chr10 66497194 G T 1.50E-04 Multiple complex diseases / / 17554300 rs1915637 chr10 66504223 C A 1.00E-04 Information processing speed / / 21130836 rs2177022 chr10 66506098 T G 1.00E-04 Information processing speed / / 21130836 rs1319115 chr10 66508002 T C 6.60E-04 Type 2 diabetes / / 17463246 rs1879603 chr10 66509895 T C 3.65E-04 Obesity (extreme) / / 21935397 rs2177023 chr10 66515337 C A 0.000777178 Hypertension (early onset hypertension) / / 22479346 rs16920360 chr10 66536501 A C 7.38E-04 Multiple complex diseases / / 17554300 rs16920381 chr10 66549894 T C 0.000442839 Hypertension (early onset hypertension) / / 22479346 rs1227223 chr10 66578207 A C 6.95E-05 Multiple complex diseases / / 17554300 rs10491062 chr10 66605132 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2452420 chr10 66694248 A G 7.00E-05 Prostate cancer / / 21743057 rs10761888 chr10 66730110 A T 5.74E-04 Coronary Artery Disease / / 17634449 rs10761892 chr10 66760408 G T 3.82E-04 Alzheimer's disease / / 24755620 rs7904001 chr10 66762723 G A 9.07E-06 HIV-1 control / / 20041166 rs7904001 chr10 66762723 G A 6.55E-04 Alcohol dependence / / 20201924 rs10822395 chr10 66769220 T A 4.21E-04 Alzheimer's disease / / 24755620 rs147252700 chr10 66797350 G A 0.0000756 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10740186 chr10 66842344 C T 2.79E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs12248645 chr10 66885915 A G 3.16E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12243390 chr10 66892227 T G 6.20E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7922070 chr10 66972788 G T 2.20E-05 Urinary metabolites / / 21572414 rs9415799 chr10 66982405 T C 4.78E-05 Recombination rate / / 21698098 rs9415802 chr10 66995942 G A 8.01E-04 Aortic root size / / 21223598 rs12573629 chr10 67029555 G T 6.30E-05 Schizophrenia / / 19571809 rs1509937 chr10 67055905 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7082281 chr10 67060185 T C 1.60E-05 Urinary metabolites / / 21572414 rs2394136 chr10 67154098 T C 2.10E-05 Urinary metabolites / / 21572414 rs1113930 chr10 67154646 C T 9.74E-05 Lipoproteins / / pha003079 rs2015967 chr10 67172664 A G 6.79E-05 Lipoproteins / / pha003079 rs1857611 chr10 67176848 G A 6.21E-05 Lipoproteins / / pha003079 rs10996409 chr10 67192390 T C 0.0000299 Amyotrophic lateral sclerosis / / 23587638 rs10822550 chr10 67193137 G A 1.71E-05 Multiple sclerosis / / 19525953 rs10509225 chr10 67199769 G A 4.96E-06 Lipoproteins / / pha003079 rs10761982 chr10 67214229 C T 1.14E-05 Lipoproteins / / pha003079 rs7087756 chr10 67253807 A G 5.67E-08 Lipoproteins / / pha003079 rs2394147 chr10 67263249 T C 1.76E-07 Lipoproteins / / pha003079 rs10996496 chr10 67279572 T A 1.90E-05 Urinary metabolites / / 21572414 rs1902367 chr10 67303155 T C 2.71E-05 Lipoproteins / / pha003079 rs1902369 chr10 67304009 T C 4.77E-08 Lipoproteins / / pha003079 rs9787501 chr10 67362269 A G 1.92E-04 Multiple complex diseases / / 17554300 rs11592725 chr10 67408976 C A 3.57E-04 Multiple complex diseases / / 17554300 rs17808573 chr10 67476731 A C 2.15E-05 Bipolar disorder,affective / / 20528957 rs9633568 chr10 67493413 C A 3.05E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12359685 chr10 67512471 G A 5.33E-05 Weight / / pha003026 rs1670170 chr10 67536564 T A 0.000606 Salmonella-induced pyroptosis / / 22837397 rs4609494 chr10 67549939 A G 0.000398 Salmonella-induced pyroptosis / / 22837397 rs7094641 chr10 67598745 G A 2.70E-05 Urinary metabolites / / 21572414 rs7090646 chr10 67598906 T G 2.80E-05 Urinary metabolites / / 21572414 rs10996721 chr10 67611745 G A 6.28E-04 Smoking initiation / / 24665060 rs10996746 chr10 67630123 A G 1.06E-05 Odorant perception / / 23910658 rs4578268 chr10 67640402 T C 3.00E-04 Adverse response to radiation therapy / / 23719583 rs1942006 chr10 67653901 C T 2.12E-05 Partial epilepsies / / 20522523 rs1942006 chr10 67653901 C T 4.07E-05 Epilepsy / / 22116939 rs1941999 chr10 67670598 G A 8.40E-06 Urinary metabolites / / 21572414 rs17239966 chr10 67671031 T C 6.69E-05 Partial epilepsies / / 20522523 rs766031 chr10 67677739 C T 2.60E-05 Cortisol secretion,in saliva / / 21316860 rs1941996 chr10 67679568 G T 3.30E-06 Bronchopulmonary dysplasia / / 23897914 rs1786923 chr10 67689189 G A 4.98E-04 Response to taxane treatment (placlitaxel) CTN/3 intron 23006423 rs1670136 chr10 67701548 A C 5.70E-04 Response to taxane treatment (placlitaxel) CTN/3 intron 23006423 rs10996785 chr10 67706852 T G 7.60E-06 Bronchopulmonary dysplasia CTN/3 intron 23897914 rs1786933 chr10 67707663 C T 4.40E-06 Bronchopulmonary dysplasia CTN/3 intron 23897914 rs1670140 chr10 67708359 T C 4.76E-05 Blood Pressure CTN/3 intron pha003048 rs1786921 chr10 67709586 G A 3.02E-04 Type 2 diabetes CTN/3 intron 17463246 rs1941988 chr10 67721021 T C 1.80E-06 Bronchopulmonary dysplasia CTN/3 intron 23897914 rs2105702 chr10 67726514 A C 7.25E-04 Alzheimer's disease CTN/3 intron 24755620 rs1670137 chr10 67727223 T C 1.90E-06 Bronchopulmonary dysplasia CTN/3 intron 23897914 rs1670138 chr10 67727355 A C 4.41E-04 Alzheimer's disease CTN/3 intron 24755620 rs3017064 chr10 67729575 G A 2.93E-04 Alzheimer's disease (late onset) CTN/3 intron 21379329 rs3017064 chr10 67729575 G A 1.70E-06 Bronchopulmonary dysplasia CTN/3 intron 23897914 rs3017064 chr10 67729575 G A 6.85E-05 Blood Pressure CTN/3 intron pha003048 rs12761845 chr10 67736152 C T 1.36E-04 Type 2 diabetes CTN/3 intron 17463246 rs2394155 chr10 67737130 C T 4.63E-04 Alzheimer's disease (late onset) CTN/3 intron 21379329 rs2394155 chr10 67737130 C T 7.69E-04 Myocardial Infarction CTN/3 intron pha002883 rs72791417 chr10 67743654 A T 1.00E-06 Bronchopulmonary dysplasia CTN/3 intron 23897914 rs2212719 chr10 67743819 A G 7.90E-06 Bronchopulmonary dysplasia CTN/3 intron 23897914 rs6480123 chr10 67747744 G A,C,T 4.70E-06 Bronchopulmonary dysplasia CTN/3 intron 23897914 rs12356475 chr10 67761720 T C 1.54E-06 Bronchopulmonary dysplasia CTN/3 intron 23897914 rs10996824 chr10 67767418 C T 3.11E-04 Suicide attempts in bipolar disorder CTN/3 intron 21423239 rs1993853 chr10 67773309 G A 2.68E-04 Suicide attempts in bipolar disorder CTN/3 intron 21423239 rs1993852 chr10 67773481 T G 7.44E-04 Suicide attempts in bipolar disorder CTN/3 intron 21423239 rs10822694 chr10 67780727 G A 7.48E-04 Suicide attempts in bipolar disorder CTN/3 intron 21423239 rs10822694 chr10 67780727 G A 9.91E-05 Left ventricular hypertrophy CTN/3 intron pha003052 rs10996832 chr10 67782695 T A 7.18E-04 Suicide attempts in bipolar disorder CTN/3 intron 21423239 rs10509257 chr10 67784429 C A 5.36E-04 Insulin resistance CTN/3 intron 21901158 rs2394187 chr10 67784809 C T 7.70E-04 Suicide attempts in bipolar disorder CTN/3 intron 21423239 rs10996834 chr10 67785037 G T 5.02E-04 Suicide attempts in bipolar disorder CTN/3 intron 21423239 rs7076094 chr10 67786048 T C 7.35E-04 Suicide attempts in bipolar disorder CTN/3 intron 21423239 rs6480129 chr10 67793231 A T 5.66E-05 Aging (time to event) CTN/3 intron 21782286 rs3847338 chr10 67793534 A C 5.37E-04 Suicide attempts in bipolar disorder CTN/3 intron 21423239 rs1893388 chr10 67797938 T C 4.98E-04 Suicide attempts in bipolar disorder CTN/3 intron 21423239 rs17243212 chr10 67801719 T C 5.84E-04 Suicide attempts in bipolar disorder CTN/3 intron 21423239 rs10996847 chr10 67803602 C T 7.50E-04 Suicide attempts in bipolar disorder CTN/3 intron 21423239 rs10996862 chr10 67812810 G A 4.12E-04 Suicide attempts in bipolar disorder CTN/3 intron 21423239 rs12573209 chr10 67812861 C G 7.01E-05 Insulin resistance CTN/3 intron 21901158 rs10443938 chr10 67813824 T C 6.71E-04 Suicide attempts in bipolar disorder CTN/3 intron 21423239 rs2394189 chr10 67837498 G A 3.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CTN/3 intron 20877124 rs2394189 chr10 67837498 G A 8.17E-05 Left ventricular hypertrophy CTN/3 intron pha003052 rs1903881 chr10 67846555 A T 2.66E-04 Type 2 diabetes CTN/3 intron 17463246 rs7916078 chr10 67849839 G A 3.41E-05 Left ventricular hypertrophy CTN/3 intron pha003052 rs7895803 chr10 67894481 G A 0.00076 Prostate cancer CTN/3 intron 23555315 rs6480141 chr10 67894819 T C 2.76E-04 Type 2 diabetes CTN/3 intron 17463246 rs7905595 chr10 67914345 A G 2.34E-04 Lung function (forced vital capacity) CTN/3 intron 24023788 rs10996948 chr10 67930295 A G 8.22E-05 Left ventricular hypertrophy CTN/3 intron pha003052 rs10822736 chr10 67935471 T C 1.77E-04 Myopia (pathological) CTN/3 intron 21095009 rs4746553 chr10 67940419 T C 1.07E-04 Lung function (forced vital capacity) CTN/3 intron 24023788 rs4746554 chr10 67960463 C T 3.95E-06 Lung function (forced vital capacity) CTN/3 intron 24023788 rs4746554 chr10 67960463 C T 1.83E-05 Left ventricular hypertrophy CTN/3 intron pha003052 rs1471384 chr10 67964373 G T 4.00E-06 Lung function (forced vital capacity) CTN/3 intron 24023788 rs12251332 chr10 67966574 G C 5.00E-08 Metabolite levels (Pyroglutamine) CTN/3 intron 23934736 rs10996973 chr10 67969980 G A 7.10E-06 Urinary metabolites CTN/3 intron 21572414 rs10996977 chr10 67970573 G T 5.93E-04 Multiple complex diseases CTN/3 intron 17554300 rs10762029 chr10 67974293 C T 2.53E-05 Brain structure CTN/3 intron 22504417 rs10762033 chr10 67996275 A G 2.62E-05 Left ventricular hypertrophy CTN/3 intron pha003052 rs10762034 chr10 67996290 T C 2.62E-05 Left ventricular hypertrophy CTN/3 intron pha003052 rs7907321 chr10 67997193 G T 2.08E-04 Lung function (forced vital capacity) CTN/3 intron 24023788 rs4745895 chr10 67998370 G A 2.53E-05 Left ventricular hypertrophy CTN/3 intron pha003052 rs10996997 chr10 68000700 A G 9.54E-05 Left ventricular hypertrophy CTN/3 intron pha003052 rs12414364 chr10 68004614 G C 7.97E-04 Multiple complex diseases CTN/3 intron 17554300 rs7070883 chr10 68006871 A G 2.01E-04 Lung function (forced vital capacity) CTN/3 intron 24023788 rs7912066 chr10 68028720 C T 5.89E-05 Left ventricular hypertrophy CTN/3 intron pha003052 rs10740231 chr10 68051031 G A 6.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CTN/3 intron 20877124 rs10997044 chr10 68057443 G A 3.50E-04 Suicidal ideation CTN/3 intron 22030708 rs16922823 chr10 68085162 A G 9.12E-04 Multiple complex diseases CTN/3 intron 17554300 rs10762058 chr10 68088508 C G 6.00E-06 Asthma (toluene diisocyanate-induced) CTN/3 intron 19187332 rs7914106 chr10 68125841 T G 9.59E-05 Diabetes (gestational) CTN/3 intron 22233651 rs10509269 chr10 68137773 C T 2.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) CTN/3 intron 17982456 rs2007116 chr10 68140020 G A 3.70E-04 Type 2 diabetes CTN/3 intron 17463246 rs2441725 chr10 68150939 G C 5.99E-06 Statin-induced myopathy CTN/3 intron 21826682 rs10509262 chr10 68154831 A G 3.78E-04 Amyotrophic Lateral Sclerosis CTN/3 intron 17827064 rs2441755 chr10 68165267 C T 4.00E-06 Dental caries CTN/3 intron 23064961 rs1948946 chr10 68168954 T C 2.98E-05 Systemic lupus erythematosus CTN/3 intron pha002867 rs10997139 chr10 68219764 T G 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CTN/3 intron 22628534 rs10822834 chr10 68224205 A G 6.79E-04 Multiple complex diseases CTN/3 intron 17554300 rs2441727 chr10 68224886 A G 1.00E-06 Interstitial lung disease CTN/3 intron 23583980 rs2441727 chr10 68224886 A G 7.33E-05 Interstitial lung disease CTN/3 intron 23583980 rs16923179 chr10 68255323 A C 2.26E-06 Multiple complex diseases CTN/3 intron 17554300 rs16923187 chr10 68258076 G A 6.50E-05 Multiple complex diseases CTN/3 intron 17554300 rs2441748 chr10 68262571 C T 8.67E-05 Response to cholinesterase inhibitors in Alzheimer's disease CTN/3 intron 23374588 rs7914675 chr10 68274967 C A,T 7.31E-05 Multiple complex diseases CTN/3 intron 17554300 rs1386141 chr10 68283545 T G 4.96E-04 Multiple complex diseases CTN/3 intron 17554300 rs2660006 chr10 68299895 T C 2.75E-05 Multiple complex diseases CTN/3 intron 17554300 rs1015484 chr10 68317410 C T 1.77E-04 Multiple complex diseases CTN/3 intron 17554300 rs11595197 chr10 68330414 T C 1.32E-04 Type 2 diabetes CTN/3 intron 17463246 rs7909235 chr10 68374084 G T 8.00E-06 Obesity-related traits CTN/3 intron 23251661 rs10822852 chr10 68375800 C G 2.40E-05 Urinary metabolites CTN/3 intron 21572414 rs7893164 chr10 68395570 C G 7.79E-04 Type 2 diabetes CTN/3 intron 17463246 rs10997287 chr10 68418846 T C 1.70E-05 Urinary metabolites CTN/3 intron 21572414 rs10997287 chr10 68418846 T C 6.35E-05 Smoking cessation CTN/3 intron 24665060 rs10997295 chr10 68437615 C T 2.51E-04 Smoking cessation CTN/3 intron 24665060 rs4990414 chr10 68442048 A G 1.93E-05 Waist Circumference CTN/3 intron pha003023 rs10997306 chr10 68449231 C T 6.14E-04 Type 2 diabetes CTN/3 intron 17463246 rs10822887 chr10 68454810 C T 6.14E-04 Type 2 diabetes CTN/3 intron 17463246 rs7893145 chr10 68461866 T C 1.43E-05 Bipolar disorder and schizophrenia CTN/3 intron 20889312 rs7089600 chr10 68463520 G A 2.34E-04 Smoking cessation CTN/3 intron 24665060 rs4745916 chr10 68463784 T A 1.80E-05 Urinary metabolites CTN/3 intron 21572414 rs10997361 chr10 68482454 C T 2.94E-04 Alcohol dependence CTN/3 intron 20201924 rs10822904 chr10 68486374 G T 8.03E-04 Smoking cessation CTN/3 intron 24665060 rs10509277 chr10 68490976 C T 7.36E-05 Bipolar disorder and schizophrenia CTN/3 intron 20889312 rs10822908 chr10 68505930 T C 1.46E-04 Type 2 diabetes CTN/3 intron 17463246 rs10733830 chr10 68593916 T C 5.29E-05 Information processing speed CTN/3 intron 21130836 rs10733830 chr10 68593916 T C 1.51E-04 Lung function (forced vital capacity) CTN/3 intron 24023788 rs12257423 chr10 68594795 G A 2.39E-05 Lung function (forced vital capacity) CTN/3 intron 24023788 rs12257423 chr10 68594795 G A 7.39E-05 Lung function (forced expiratory volume in 1 second) CTN/3 intron 24023788 rs7902091 chr10 68598292 C A 7.00E-07 Schizophrenia (cytomegalovirus infection interaction) CTN/3 intron 23358160 rs7918698 chr10 68600221 C T 2.00E-04 Information processing speed CTN/3 intron 21130836 rs7919083 chr10 68600498 C A 1.00E-04 Information processing speed CTN/3 intron 21130836 rs4237311 chr10 68607338 A G 1.00E-04 Information processing speed CTN/3 intron 21130836 rs7902209 chr10 68621346 A G 2.33E-04 Body mass index CTN/3 intron 17255346 rs9415866 chr10 68626568 A G 9.00E-05 Parkinson's disease (familial) CTN/3 intron 18985386 rs1880046 chr10 68637811 C T 5.02E-04 Nicotine dependence CTN/3 intron 17158188 rs10997427 chr10 68639036 A T 9.31E-04 Type 2 diabetes CTN/3 intron 17463246 rs4746647 chr10 68639475 T C 2.96E-05 Multiple complex diseases CTN/3 intron 17554300 rs4142041 chr10 68640951 A G 6.00E-06 Nicotine dependence CTN/3 intron 17158188 rs4142041 chr10 68640951 A G 6.00E-06 Coronary heart disease CTN/3 intron 21347282 rs12242171 chr10 68651913 C A 7.54E-04 Suicide attempts in bipolar disorder CTN/3 intron 21423239 rs10762120 chr10 68668627 C T 5.93E-04 Multiple complex diseases CTN/3 intron 17554300 rs9332406 chr10 68670199 C A 9.71E-05 Nicotine dependence CTN/3 intron 17158188 rs2140380 chr10 68678211 C A 3.62E-04 Suicide attempts in bipolar disorder CTN/3 intron 21423239 rs16923756 chr10 68679080 T C 4.60E-04 Suicide attempts in bipolar disorder CTN/3 intron 21423239 rs7897388 chr10 68681780 T C 5.52E-04 Suicide attempts in bipolar disorder CTN/3 intron 21423239 rs12258954 chr10 68683007 A T 3.30E-04 Suicide attempts in bipolar disorder CTN/3 intron 21423239 rs942784 chr10 68710596 C T 2.02E-05 Multiple complex diseases CTN/3 intron 17554300 rs942782 chr10 68712161 G A 8.15E-04 Multiple complex diseases CTN/3 intron 17554300 rs10997457 chr10 68726829 T C 8.59E-04 Multiple complex diseases CTN/3 intron 17554300 rs7082306 chr10 68750755 G A 2.42E-04 Multiple complex diseases CTN/3 intron 17554300 rs4484988 chr10 68785544 T C 2.60E-05 Urinary metabolites CTN/3 intron 21572414 rs2764810 chr10 68824626 A C 8.92E-06 Cognitive impairment induced by topiramate CTN/3 intron 22091778 rs67645977 chr10 68824626 AG AAG,ACA 8.92E-06 Cognitive impairment induced by topiramate CTN/3 intron 22091778 rs10509279 chr10 68824793 C T 4.70E-04 Myasthenia gravis CTN/3 intron 23055271 rs2764813 chr10 68835496 G A 8.48E-06 Cognitive impairment induced by topiramate CTN/3 intron 22091778 rs2619656 chr10 68839714 G A 8.83E-05 Cognitive impairment induced by topiramate CTN/3 intron 22091778 rs10822976 chr10 68857184 A G 2.00E-04 Cognitive impairment induced by topiramate CTN/3 intron 22091778 rs2394340 chr10 68861272 T C 8.03E-04 Alcohol dependence CTN/3 intron 21314694 rs10997510 chr10 68865796 T C 5.40E-06 Urinary metabolites CTN/3 intron 21572414 rs10762139 chr10 68871113 C T 2.00E-04 Cognitive impairment induced by topiramate CTN/3 intron 22091778 rs10997517 chr10 68879803 T C 4.53E-04 Response to TNF antagonist treatment CTN/3 intron 21061259 rs10997517 chr10 68879803 T C 1.05E-04 Migraine CTN/3 intron 23793025 rs10997517 chr10 68879803 T C 6.00E-06 Migraine without aura CTN/3 intron 23793025 rs1014329 chr10 68898342 G A 5.51E-05 Cognitive impairment induced by topiramate CTN/3 intron 22091778 rs4256882 chr10 68907816 A C 5.51E-05 Cognitive impairment induced by topiramate CTN/3 intron 22091778 rs2394354 chr10 68921106 C T 9.54E-06 Thiazide-induced adverse metabolic effects in hypertensive patients CTN/3 intron 23400010 rs10466008 chr10 68922029 T C 3.56E-04 Schizophrenia CTN/3 intron 19197363 rs4746673 chr10 68935700 A G 4.52E-04 Schizophrenia CTN/3 intron 19197363 rs7091927 chr10 68949597 T C 7.44E-04 Schizophrenia CTN/3 intron 19197363 rs4746675 chr10 68952058 C A 9.11E-08 Parkinson's disease CTN/3 intron 17052657 rs10997577 chr10 68974583 T A 9.78E-04 Multiple complex diseases CTN/3 intron 17554300 rs16924375 chr10 69079735 T C 5.75E-04 Smoking initiation CTN/3 intron 24665060 rs2394381 chr10 69141544 C T 1.74E-04 Smoking initiation CTN/3 intron 24665060 rs2394375 chr10 69155636 T C 2.24E-05 Body mass index CTN/3 intron 22446040 rs10997637 chr10 69193601 C T 3.30E-06 Soluble leptin receptor levels CTN/3 intron 20167575 rs7907340 chr10 69194237 G C 4.70E-06 Soluble leptin receptor levels CTN/3 intron 20167575 rs7907588 chr10 69194368 G C 5.10E-06 Soluble leptin receptor levels CTN/3 intron 20167575 rs7915595 chr10 69196030 A T 5.20E-06 Soluble leptin receptor levels CTN/3 intron 20167575 rs7900877 chr10 69204857 G T 6.30E-06 Soluble leptin receptor levels CTN/3 intron 20167575 rs7900696 chr10 69205011 A C 6.40E-06 Soluble leptin receptor levels CTN/3 intron 20167575 rs10997651 chr10 69222470 A C 2.08E-04 Alcohol dependence CTN/3 intron 20201924 rs10997656 chr10 69240768 G A 5.81E-04 Smoking initiation CTN/3 intron 24665060 rs10458635 chr10 69251616 G C 7.42E-04 Alzheimer's disease CTN/3 intron 22005930 rs10823051 chr10 69264597 G C 2.38E-08 Multiple sclerosis CTN/3 intron 17660530 rs10823051 chr10 69264597 G C 1.27E-06 Cervical cancer CTN/3 intron 21716314 rs10997688 chr10 69274676 G A 9.00E-06 Soluble leptin receptor levels CTN/3 intron 20167575 rs16924635 chr10 69313152 T A 6.73E-04 Multiple complex diseases CTN/3 intron 17554300 rs10762174 chr10 69336091 G A 4.55E-06 Blood pressure CTN/3 intron 21909110 rs12251222 chr10 69348758 G A 5.75E-04 Smoking quantity CTN/3 intron 24665060 rs7084028 chr10 69370832 A C 7.69E-04 Smoking quantity CTN/3 intron 24665060 rs7097855 chr10 69373374 C T 8.71E-05 Brain lesion load CTN/3 intron 19010793 rs3125316 chr10 69405242 C T 1.51E-05 Brain lesion load CTN/3 intron 19010793 rs7073410 chr10 69435340 G T 1.14E-04 Smoking quantity CTN/3 intron 24665060 rs12415227 chr10 69539850 A T 4.69E-04 Smoking quantity / / 24665060 rs4746711 chr10 69547057 A G 9.20E-05 Malaria / / 19465909 rs11596401 chr10 69656037 C T 9.16E-04 Type 2 diabetes SIRT1 intron 17463246 rs11596401 chr10 69656037 C T 1.50E-04 Multiple complex diseases SIRT1 intron 17554300 rs116040871 chr10 69672479 G A 0.000061 Breast cancer(er negative) SIRT1 missense 23555315 rs7894163 chr10 69692989 A C 3.71E-04 Multiple complex diseases HERC4 intron 17554300 rs10997908 chr10 69781196 G A 5.13E-04 Bipolar disorder,schizoaffective HERC4 intron 19567891 rs471962 chr10 69846726 T A 6.38E-04 Multiple complex diseases / / 17554300 rs6480305 chr10 69879709 C T 8.50E-05 HIV-1 control MYPN intron 20041166 rs10509295 chr10 69881103 A T 8.24E-04 Suicide attempts in bipolar disorder MYPN intron 21423239 rs1906719 chr10 69914581 G A 4.33E-04 Smoking cessation MYPN intron 18519826 rs1906719 chr10 69914581 G A 7.16E-05 Smoking cessation MYPN intron 18519826 rs2634711 chr10 69925933 T C 6.91E-04 Type 2 diabetes MYPN intron 17463246 rs10823148 chr10 69926334 C G 2.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) MYPN missense 21239504 rs7916821 chr10 69933969 G A 2.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) MYPN missense 21239504 rs58180147 chr10 69943634 C T 7.00E-06 Parasitemia in Tripanosoma cruzi seropositivity MYPN intron 24324551 rs7079385 chr10 69958975 G T 1.07E-04 Smoking cessation MYPN intron 18519826 rs7079481 chr10 69959242 C A 2.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) MYPN missense 21239504 rs10509300 chr10 69960835 G C 9.46E-05 Schizophrenia MYPN intron 19571809 rs6480314 chr10 69967447 G A 2.00E-07 optic disc size (disc) MYPN intron 20395239 rs10998021 chr10 69968189 G A 1.81E-05 Smoking cessation MYPN intron 18519826 rs10998021 chr10 69968189 G A 4.23E-04 Smoking cessation MYPN intron 18519826 rs10998022 chr10 69969986 C T 2.16E-10 Gallstones MYPN intron 17632509 rs7916697 chr10 69991853 A G 2.00E-15 Optic disc parameters ATOH7 UTR-5 21307088 rs1900005 chr10 69998055 A C 8.84E-07 Glaucoma-related traits / / 22058429 rs1900004 chr10 70000881 C T 2.00E-08 Vertical cup-disc ratio / / 20548946 rs1900004 chr10 70000881 C T 3.00E-35 Optic disc parameters / / 20548946 rs1900004 chr10 70000881 C T 7.16E-07 Glaucoma-related traits / / 22058429 rs1900004 chr10 70000881 C T 8.87E-07 Glaucoma-related traits / / 22058429 rs3858145 chr10 70011838 A G 2.00E-07 optic disc size (cup) / / 20395239 rs3858145 chr10 70011838 A G 3.00E-10 optic disc size (disc) / / 20395239 rs10998035 chr10 70014230 C T 4.00E-06 Eating disorders (purging via substances) / / 23568457 rs12571093 chr10 70019371 G A 2.00E-10 optic disc size (disc) / / 20395239 rs10762210 chr10 70050617 G T 7.66E-05 Type 2 diabetes PBLD intron 17463246 rs10733842 chr10 70059043 G A,T 3.81E-04 Type 2 diabetes PBLD intron 17463246 rs10047355 chr10 70060078 T C 8.17E-05 Type 2 diabetes PBLD intron 17463246 rs10047388 chr10 70060213 A C 1.31E-04 Type 2 diabetes PBLD intron 17463246 rs10740294 chr10 70061352 T C 1.35E-04 Type 2 diabetes PBLD intron 17463246 rs7893969 chr10 70085529 T C 3.28E-04 Lung function (forced vital capacity) PBLD intron 24023788 rs16925318 chr10 70086956 A G 3.53E-04 Multiple complex diseases PBLD intron 17554300 rs12217591 chr10 70251287 G A 4.07E-08 Lymphocyte counts SLC25A16 intron 22286170 rs149577882 chr10 70292666 T A 0.000009789 Sarcoidosis / / 22952805 rs10998266 chr10 70303515 A G 3.59E-04 Multiple complex diseases / / 17554300 rs5030881 chr10 70304269 G A 2.56E-04 Musician's dystonia / / 24375517 rs2795876 chr10 70373380 A G 7.49E-04 Alzheimer's disease TET1 intron 24755620 rs2664421 chr10 70375991 C T 7.49E-04 Alzheimer's disease TET1 intron 24755620 rs7896856 chr10 70408726 A G 7.93E-04 Alzheimer's disease TET1 intron 24755620 rs7913568 chr10 70410630 C T 1.40E-04 Alzheimer's disease TET1 intron 24755620 rs2173369 chr10 70428142 C T 9.00E-06 Urinary metabolites TET1 intron 21572414 rs10762236 chr10 70431420 G T 9.36E-04 Amyotrophic lateral sclerosis (sporadic) TET1 intron 24529757 rs7901888 chr10 70455490 A C 9.40E-06 Urinary metabolites / / 21572414 rs7902023 chr10 70455594 A C 1.10E-05 Urinary metabolites / / 21572414 rs7902140 chr10 70455614 C G 3.50E-06 Urinary metabolites / / 21572414 rs10998399 chr10 70475978 A G 8.27E-04 Depression (quantitative trait) / / 20800221 rs10998401 chr10 70482800 C G 6.89E-04 Depression (quantitative trait) CCAR1 intron 20800221 rs1300252 chr10 70502426 T C 0.00000134 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment CCAR1 intron 23392654 rs1300252 chr10 70502426 T C 1.34E-06 Thiazide-induced adverse metabolic effects in hypertensive patients CCAR1 intron 23400010 rs17462632 chr10 70513217 G A 6.92E-04 Alzheimer's disease CCAR1 intron 24755620 rs16925839 chr10 70607861 T C 5.80E-05 Blood Pressure STOX1 intron pha003040 rs10998462 chr10 70618380 C G 8.50E-04 Depression (quantitative trait) STOX1 intron 20800221 rs1417941 chr10 70618859 G A 8.58E-04 Depression (quantitative trait) STOX1 intron 20800221 rs12766549 chr10 70620026 T G 8.74E-04 Depression (quantitative trait) STOX1 intron 20800221 rs10823260 chr10 70620366 T C 8.67E-04 Depression (quantitative trait) STOX1 intron 20800221 rs10998464 chr10 70620429 T C 8.62E-04 Depression (quantitative trait) STOX1 intron 20800221 rs7078797 chr10 70621501 C A 8.54E-04 Depression (quantitative trait) STOX1 intron 20800221 rs7087811 chr10 70622904 G A 8.39E-04 Depression (quantitative trait) STOX1 intron 20800221 rs7088251 chr10 70623185 G A 8.49E-04 Depression (quantitative trait) STOX1 intron 20800221 rs12412524 chr10 70626293 C G 8.19E-04 Depression (quantitative trait) STOX1 intron 20800221 rs10823263 chr10 70626330 A G 8.15E-04 Depression (quantitative trait) STOX1 intron 20800221 rs10998466 chr10 70626429 A G 4.00E-06 Disc degeneration (lumbar) STOX1 intron 22993228 rs7086993 chr10 70626596 T C 6.76E-04 Depression (quantitative trait) STOX1 intron 20800221 rs7903209 chr10 70628582 C T 6.33E-04 Depression (quantitative trait) STOX1 intron 20800221 rs7915930 chr10 70629705 G A 6.00E-04 Depression (quantitative trait) STOX1 intron 20800221 rs10082399 chr10 70631783 G T 5.96E-04 Depression (quantitative trait) STOX1 intron 20800221 rs10509305 chr10 70645376 A C 4.41E-04 Depression (quantitative trait) STOX1 missense 20800221 rs10509305 chr10 70645376 A C 7.64E-05 Lipid levels STOX1 missense pha003082 rs10509306 chr10 70645697 C T 6.50E-04 Smoking quantity STOX1 cds-synon 24665060 rs17470673 chr10 70649244 A G 1.75E-04 Smoking quantity STOX1 intron 24665060 rs10998476 chr10 70657078 G A 5.33E-04 Type 2 diabetes / / 17463246 rs17555825 chr10 70670573 C G 3.99E-04 Smoking quantity DDX50 intron 24665060 rs3740596 chr10 70674178 A G 9.48E-06 Depression (quantitative trait) DDX50 intron 20800221 rs10740315 chr10 70681378 C G 0.00000153 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment DDX50 intron 23392654 rs10740315 chr10 70681378 C G 1.53E-06 Thiazide-induced adverse metabolic effects in hypertensive patients DDX50 intron 23400010 rs10509307 chr10 70710358 G T 2.85E-04 Smoking quantity / / 24665060 rs2017305 chr10 70712062 A G 9.00E-06 Depression (quantitative trait) / / 20800221 rs2017305 chr10 70712062 A G 9.00E-06 Depression (quantitative trait) / / 23290196 rs1539163 chr10 70739630 C T 1.44E-05 Depression (quantitative trait) DDX21 intron 20800221 rs7907661 chr10 70740091 G A 1.17E-04 Smoking quantity DDX21 intron 24665060 rs12412103 chr10 70742931 A G 8.75E-06 Gallstones DDX21 UTR-3 17632509 rs17471932 chr10 70751024 G A 2.53E-05 Depression (quantitative trait) KIAA1279 intron 20800221 rs2487707 chr10 70765092 G T 8.47E-05 Blood Pressure KIAA1279 intron pha003040 rs2491015 chr10 70766813 C T 1.76E-05 Parkinson's disease KIAA1279 intron pha002868 rs12250707 chr10 70779436 C T 1.21E-04 Depression (quantitative trait) / / 20800221 rs2487710 chr10 70782126 C A 3.02E-04 Depression (quantitative trait) / / 20800221 rs12266901 chr10 70783522 T C 2.20E-04 Depression (quantitative trait) / / 20800221 rs12244293 chr10 70783580 A G 1.76E-04 Depression (quantitative trait) / / 20800221 rs7476854 chr10 70788552 A G 1.94E-04 Depression (quantitative trait) / / 20800221 rs12249735 chr10 70791235 A G 7.14E-04 Depression (quantitative trait) / / 20800221 rs6480377 chr10 70793668 T C 5.83E-04 Multiple complex diseases / / 17554300 rs146830092 chr10 70863698 C T 0.00021 Prostate cancer SRGN missense 23555315 rs4746818 chr10 70884687 G T 0.0000053 Amygdala reactivity VPS26A intron 22856363 rs1802295 chr10 70931474 C T 4.00E-08 Type 2 diabetes VPS26A UTR-3 21874001 rs1802295 chr10 70931474 C T 4.10E-08 Type 2 diabetes VPS26A UTR-3 23300278 rs1802295 chr10 70931474 C T 1.18E-04 Glycemic traits (pregnancy) VPS26A UTR-3 23903356 rs1802295 chr10 70931474 C T 6.42E-05 Glycemic traits (pregnancy) VPS26A UTR-3 23903356 rs10998624 chr10 70939801 G A 1.00E-09 Immune reponse to smallpox (secreted IL-1beta) / / 22610502 rs10998634 chr10 70952182 G A 1.15E-08 Multiple complex diseases SUPV3L1 intron 17554300 rs7893492 chr10 70960448 A G 6.65E-05 Bipolar disorder SUPV3L1 intron 19488044 rs10823315 chr10 70960529 C T 6.34E-04 Smoking cessation SUPV3L1 intron 24665060 rs7091695 chr10 70964997 G A 6.08E-05 Bipolar disorder SUPV3L1 intron 19488044 rs4746821 chr10 70968199 G T 9.60E-06 Type 2 diabetes SUPV3L1 intron 21874001 rs5030933 chr10 70975239 T C 4.19E-06 Glycemic traits (pregnancy) / / 23903356 rs5030937 chr10 70975897 C T 1.50E-12 Glycemic traits (pregnancy) / / 23903356 rs5030937 chr10 70975897 C T 6.74E-12 Glycemic traits (pregnancy) / / 23903356 rs5030938 chr10 70975916 C T 1.53E-12 Glycemic traits (pregnancy) / / 23903356 rs5030938 chr10 70975916 C T 7.91E-12 Glycemic traits (pregnancy) / / 23903356 rs10998646 chr10 70976702 G T 5.56E-10 Glycemic traits (pregnancy) / / 23903356 rs10998646 chr10 70976702 G T 9.05E-10 Glycemic traits (pregnancy) / / 23903356 rs10998647 chr10 70977308 T G 1.01E-12 Glycemic traits (pregnancy) / / 23903356 rs10998647 chr10 70977308 T G 6.00E-13 Glycemic traits (pregnancy) / / 23903356 rs17566087 chr10 70978956 A G 1.21E-07 Glycemic traits (pregnancy) / / 23903356 rs17566087 chr10 70978956 A G 1.45E-09 Glycemic traits (pregnancy) / / 23903356 rs5030941 chr10 70982730 C T 3.52E-06 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs5030941 chr10 70982730 C T 7.89E-07 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs4746822 chr10 70982941 C T 1.00E-22 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs4746822 chr10 70982941 C T 1.51E-06 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs4746822 chr10 70982941 C T 4.73E-19 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs4746822 chr10 70982941 C T 6.98E-19 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs4746822 chr10 70982941 C T 8.34E-07 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs2394529 chr10 70985267 G C 1.29E-05 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs2394529 chr10 70985267 G C 2.27E-05 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs4746825 chr10 70985645 C T 2.66E-06 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs4746825 chr10 70985645 C T 3.45E-06 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs9645499 chr10 70986610 G A 1.79E-08 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs9645499 chr10 70986610 G A 2.30E-08 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs9645500 chr10 70986723 T G 0.0001235 2-hour glucose tolerance test HKDC1 intron 22885924 rs9645500 chr10 70986723 T G 4.10E-12 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs9645500 chr10 70986723 T G 5.67E-12 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs9645501 chr10 70986766 G A 3.36E-06 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs9645501 chr10 70986766 G A 4.37E-06 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs10823320 chr10 70987060 A G 3.43E-05 Partial epilepsies HKDC1 missense 20522523 rs10823320 chr10 70987060 A G 1.41E-06 Glycemic traits (pregnancy) HKDC1 missense 23903356 rs10823320 chr10 70987060 A G 3.84E-06 Glycemic traits (pregnancy) HKDC1 missense 23903356 rs10762266 chr10 70987319 G T 6.75E-07 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs10762266 chr10 70987319 G T 8.90E-07 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs7923953 chr10 70988036 T C 1.82E-06 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs7923953 chr10 70988036 T C 3.10E-06 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs1983127 chr10 70989901 G T 0.000000814 Fasting blood glucose HKDC1 intron 22885924 rs1983127 chr10 70989901 G T 1.40E-10 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs1983127 chr10 70989901 G T 5.19E-10 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs4746827 chr10 70992046 G A 1.05E-05 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs4746827 chr10 70992046 G A 6.17E-06 Glycemic traits (pregnancy) HKDC1 intron 23903356 rs10998679 chr10 71024782 C T 1.95E-04 Smoking initiation HKDC1 intron 24665060 rs906219 chr10 71026510 C A 3.73E-05 Attention deficit hyperactivity disorder HKDC1 missense 20732627 rs2394534 chr10 71029302 T G 1.04E-05 Attention deficit hyperactivity disorder HK1 nearGene-5 20732627 rs2394538 chr10 71033697 T C 2.77E-05 Attention deficit hyperactivity disorder HK1 intron 20732627 rs10762275 chr10 71040619 G A 6.43E-05 Parent of origin effect on language impairment (paternal) HK1 intron 24571439 rs4746834 chr10 71041806 G T 8.12E-05 Parent of origin effect on language impairment (paternal) HK1 intron 24571439 rs10998696 chr10 71043781 T C 1.82E-05 Parent of origin effect on language impairment (paternal) HK1 intron 24571439 rs5030916 chr10 71049098 T C 2.51E-05 Parent of origin effect on language impairment (paternal) HK1 intron 24571439 rs10762277 chr10 71052508 G A 8.23E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) HK1 intron 23648065 rs7897621 chr10 71056150 G A 3.31E-05 Information processing speed HK1 intron 21130836 rs4746839 chr10 71062762 G A 1.41E-04 Type 2 diabetes HK1 intron 17463246 rs7898060 chr10 71079286 G A 0.000486 Salmonella-induced pyroptosis HK1 intron 22837397 rs4745982 chr10 71089843 T G 1.64E-09 Other erythrocyte phenotypes HK1 intron 19862010 rs16926246 chr10 71093392 C T 1.00E-13 Hematocrit HK1 intron 19862010 rs16926246 chr10 71093392 C T 2.00E-11 Hemoglobin HK1 intron 19862010 rs16926246 chr10 71093392 C T 3.00E-54 Glycated Hemoglobin levels HK1 intron 20858683 rs16926246 chr10 71093392 C T 6.04E-19 Red blood cell traits HK1 intron 23222517 rs10998724 chr10 71098376 T G 6.91E-05 Pulmonary function HK1 intron 19300500 rs10159477 chr10 71099888 G A 2.98E-08 Other erythrocyte phenotypes HK1 intron 19862010 rs10159477 chr10 71099888 G A 3.19E-25 Glycated hemoglobin levels HK1 intron 22885924 rs10159477 chr10 71099888 G A 4.00E-20 Red blood cell traits HK1 intron 23222517 rs7072268 chr10 71099913 T C 2.00E-25 Glycated Hemoglobin levels HK1 intron 19096518 rs1133189 chr10 71103597 C G 7.88E-08 Red blood cell traits HK1 cds-synon 23222517 rs4589168 chr10 71130217 A C 4.40E-04 Type 2 diabetes HK1 intron 17463246 rs10128513 chr10 71136391 A G 7.19E-04 Type 2 diabetes HK1 intron 17463246 rs1867971 chr10 71145486 A G 2.48E-05 Blood pressure (response to angiotensin II receptor blocker) HK1 intron 24192120 rs12416320 chr10 71148728 G A 7.85E-05 Aging (time to event) HK1 intron 21782286 rs1227938 chr10 71158268 C T 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes HK1 intron 22628534 rs11597682 chr10 71179110 A G 8.40E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12414186 chr10 71179614 T C 8.08E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs5030922 chr10 71182418 A G 5.26E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12772559 chr10 71184356 G C 6.74E-04 Type 2 diabetes / / 17463246 rs12772559 chr10 71184356 G C 9.34E-05 Alzheimer's disease / / 17998437 rs10823372 chr10 71190499 T C 4.77E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12242391 chr10 71201504 C T 4.45E-04 Stroke / / pha002887 rs1867969 chr10 71208084 G A 5.10E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17490626 chr10 71218646 G C 9.56E-06 Venous thromboembolism TSPAN15 intron 22672568 rs10762297 chr10 71218926 T C 8.68E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines TSPAN15 intron 21844884 rs10823384 chr10 71222399 G A 8.74E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines TSPAN15 intron 21844884 rs10998796 chr10 71224244 C T 8.37E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines TSPAN15 intron 21844884 rs10998818 chr10 71231068 C T 6.15E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines TSPAN15 intron 21844884 rs17569412 chr10 71237536 C A 4.03E-05 Type 2 diabetes TSPAN15 intron 17463246 rs2305201 chr10 71244832 C A 6.31E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines TSPAN15 intron 21844884 rs1227937 chr10 71245617 A G 6.82E-04 Multiple complex diseases TSPAN15 intron 17554300 rs1227937 chr10 71245617 A G 2.86E-05 Blood pressure (response to angiotensin II receptor blocker) TSPAN15 intron 24192120 rs3793837 chr10 71246635 G A 4.28E-04 Multiple complex diseases TSPAN15 intron 17554300 rs716788 chr10 71247063 C T 4.94E-04 Multiple complex diseases TSPAN15 intron 17554300 rs1430882 chr10 71252206 C A 6.16E-05 Femoral neck bone geometry TSPAN15 intron 22087292 rs1227969 chr10 71263264 C T 6.00E-07 Response to taxane treatment (placlitaxel) TSPAN15 intron 23006423 rs1652804 chr10 71264325 G A,C,T 6.11E-06 Response to taxane treatment (placlitaxel) TSPAN15 intron 23006423 rs1652804 chr10 71264325 G A,C,T 6.67E-04 Smoking cessation TSPAN15 intron 24665060 rs1052179 chr10 71267010 G A 3.80E-04 Smoking cessation TSPAN15 UTR-3 24665060 rs1236904 chr10 71267849 A C 5.07E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs972570 chr10 71272018 C T 3.79E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10509313 chr10 71272134 A G 4.31E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs891562 chr10 71274737 G T 5.13E-04 Multiple complex diseases / / 17554300 rs891562 chr10 71274737 G T 7.96E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs12416010 chr10 71293704 C T 5.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1227960 chr10 71305156 C G 8.61E-04 Type 2 diabetes / / 17463246 rs10823406 chr10 71312023 G A 2.90E-05 Type 2 diabetes / / 17293876 rs10823406 chr10 71312023 G A 2.90E-05 Type 2 diabetes / / 19184112 rs297044 chr10 71312949 A T 7.86E-04 Multiple complex diseases / / 17554300 rs3903038 chr10 71324931 C T 8.59E-04 Coronary Artery Disease / / 17634449 rs4536103 chr10 71332204 A G 3.35E-04 Response to cytidine analogues (gemcitabine) NEUROG3 missense 24483146 rs4536103 chr10 71332204 A G 3.50E-04 Smoking initiation NEUROG3 missense 24665060 rs4746864 chr10 71341200 C T 5.02E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs922369 chr10 71350131 T C 2.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs922369 chr10 71350131 T C 3.03E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs10509320 chr10 71351011 T C 2.97E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12252820 chr10 71351990 C T 3.65E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12252832 chr10 71352026 C T 1.51E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12252832 chr10 71352026 C T 2.61E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs12252986 chr10 71352056 G A 3.65E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs731573 chr10 71357954 T C 8.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1463058 chr10 71362650 C T 6.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs931028 chr10 71373767 G A 5.16E-05 Schizophrenia / / 20185149 rs4553261 chr10 71375789 A G 9.00E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1903791 chr10 71376076 C T 5.49E-05 Neutrophil count / / pha003095 rs4746874 chr10 71378767 G A 4.99E-05 Coronary heart disease / / pha003030 rs12020 chr10 71392557 C T 7.44E-05 stroke (ischemic) C10orf35 cds-synon 17434096 rs1052152 chr10 71392692 T C 2.47E-04 Multiple complex diseases C10orf35 cds-synon 17554300 rs1132075 chr10 71393025 A G 8.21E-05 stroke (ischemic) C10orf35 UTR-3 17434096 rs1132075 chr10 71393025 A G 3.72E-04 Multiple complex diseases C10orf35 UTR-3 17554300 rs899022 chr10 71393496 A T 2.64E-04 Multiple complex diseases / / 17554300 rs1870960 chr10 71401017 C A 8.30E-06 Urinary metabolites / / 21572414 rs12782802 chr10 71409843 A G 6.28E-05 Lung adenocarcinoma / / 19836008 rs17578395 chr10 71415241 A C 5.00E-06 Type 2 diabetes / / 24509480 rs10823416 chr10 71417394 A G 1.40E-05 Urinary metabolites / / 21572414 rs9783205 chr10 71426938 A C 4.24E-05 Left ventricular hypertrophy / / pha003052 rs2616069 chr10 71427798 G A 4.24E-05 Left ventricular hypertrophy / / pha003052 rs12780021 chr10 71428687 G T 7.80E-04 Type 2 diabetes / / 21874001 rs10509316 chr10 71432279 T C 6.77E-05 Left ventricular hypertrophy / / pha003052 rs12761954 chr10 71437979 C T 8.53E-05 Left ventricular hypertrophy / / pha003052 rs12774027 chr10 71445318 A C 5.70E-04 Type 2 diabetes / / 21874001 rs3847345 chr10 71448900 A G 8.50E-05 Type 2 diabetes / / 21874001 rs2812533 chr10 71452285 T C 5.00E-06 Type 2 diabetes / / 24509480 rs3907199 chr10 71452871 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10823422 chr10 71469137 T C 3.20E-04 Alzheimer's disease / / 22005930 rs12570556 chr10 71469678 G C 2.44E-04 Alzheimer's disease / / 22005930 rs3847347 chr10 71470629 C G 6.53E-04 Alzheimer's disease / / 22005930 rs3858150 chr10 71470674 A G 4.32E-04 Alzheimer's disease / / 22005930 rs10998929 chr10 71471811 T A 2.65E-04 Alzheimer's disease / / 22005930 rs3847349 chr10 71474493 G A 2.27E-04 Smoking initiation / / 24665060 rs2394581 chr10 71482299 A G 3.38E-04 Smoking initiation / / 24665060 rs3104056 chr10 71510039 A G 6.30E-05 Type 2 diabetes / / 17463248 rs10998951 chr10 71521597 C A 1.38E-04 Multiple complex diseases / / 17554300 rs2704517 chr10 71521878 G T 8.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs2704517 chr10 71521878 G T 9.97E-05 Prion diseases / / 22210626 rs2255667 chr10 71525084 A T 0.0006384 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2255667 chr10 71525084 A T 6.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2704465 chr10 71527530 G A 6.33E-05 Systemic lupus erythematosus / / 19838193 rs2252421 chr10 71528724 A G 0.0000514 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2252421 chr10 71528724 A G 5.14E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10998957 chr10 71528930 T C 0.000222 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10998957 chr10 71528930 T C 2.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2252324 chr10 71529084 T C 0.0000515 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2252324 chr10 71529084 T C 5.15E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs750116 chr10 71529945 G A 0.0000515 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs750116 chr10 71529945 G A 5.15E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9919438 chr10 71533042 G A 8.03E-04 Alzheimer's disease / / 22005930 rs2704471 chr10 71535081 T C 1.40E-05 Height / / 21998595 rs731016 chr10 71536447 G A 6.10E-04 Type 2 diabetes / / 21874001 rs4746003 chr10 71538292 C T 6.00E-06 Alzheimer's disease / / 22005930 rs2394597 chr10 71540024 G A 2.80E-04 Type 2 diabetes / / 21874001 rs2247549 chr10 71546573 A G 3.20E-05 Longevity / / 22279548 rs2642572 chr10 71549168 G A 8.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs768505 chr10 71554474 C T 5.30E-05 Primary sclerosing cholangitis / / 19944697 rs768505 chr10 71554474 C T 4.92E-05 Cognitive test performance / / 20125193 rs768505 chr10 71554474 C T 2.29E-04 Smoking quantity / / 24665060 rs12411657 chr10 71556310 C T 8.80E-05 Primary sclerosing cholangitis / / 19944697 rs12411657 chr10 71556310 C T 7.64E-04 Smoking quantity / / 24665060 rs2642609 chr10 71559089 G A 9.80E-05 Bipolar disorder / / 19488044 rs2704503 chr10 71564500 C T 7.55E-04 Type 2 diabetes COL13A1 intron 17463246 rs2763342 chr10 71568578 G A 3.23E-05 Bipolar disorder COL13A1 intron 21771265 rs2763352 chr10 71571595 G A 6.00E-05 Prostate cancer COL13A1 intron 21743057 rs1227771 chr10 71577902 C T 8.06E-04 Parkinson's disease COL13A1 intron 17052657 rs17497526 chr10 71580120 T C 6.00E-07 Parkinson's disease COL13A1 intron 23793441 rs7076867 chr10 71582996 C T 9.78E-06 Bladder cancer COL13A1 intron 24163127 rs7077164 chr10 71583198 C T 7.00E-06 Non-alcoholic fatty liver disease histology (lobular) COL13A1 intron 20708005 rs11598684 chr10 71583757 C T 8.97E-04 Type 2 diabetes COL13A1 intron 17463246 rs1227756 chr10 71588504 G A 2.00E-07 Non-alcoholic fatty liver disease histology (lobular) COL13A1 intron 20708005 rs1227763 chr10 71593257 A C 1.58E-04 Height COL13A1 intron 17255346 rs2704486 chr10 71594301 C A 0.000695993 Hypertension (early onset hypertension) COL13A1 intron 22479346 rs10823439 chr10 71595494 G C 1.80E-05 Response to statin therapy COL13A1 intron 20339536 rs3998144 chr10 71601313 T C 7.19E-05 Cognitive impairment induced by topiramate COL13A1 intron 22091778 rs12357925 chr10 71609313 C G 7.89E-05 Sudden cardiac arrest COL13A1 intron 21658281 rs2763356 chr10 71628602 G T 4.11E-04 Lung function (forced expiratory volume in 1 second) COL13A1 intron 24023788 rs2894300 chr10 71637227 A G 2.58E-05 Personality dimensions COL13A1 intron 22628180 rs1227783 chr10 71640491 C T 1.11E-04 Type 2 diabetes COL13A1 intron 17463246 rs2763366 chr10 71650837 G T 1.03E-04 Vaspin levels COL13A1 intron 22907691 rs2763366 chr10 71650837 G T 0.000103 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit COL13A1 intron 22907730 rs942568 chr10 71657621 G T 3.06E-04 Nicotine smoking COL13A1 intron 19268276 rs942568 chr10 71657621 G T 0.000621 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) COL13A1 intron 23233654 rs942568 chr10 71657621 G T 6.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) COL13A1 intron 23233662 rs942576 chr10 71662783 G T 6.66E-04 Multiple complex diseases COL13A1 intron 17554300 rs942576 chr10 71662783 G T 8.40E-14 Progranulin levels COL13A1 intron 21087763 rs942576 chr10 71662783 G T 8.40E-14 Myocardial infarction COL13A1 intron 21211798 rs4082516 chr10 71704656 C G 1.27E-05 Type 2 diabetes COL13A1 intron 17846126 rs10999042 chr10 71707415 C T 5.99E-04 Smoking initiation COL13A1 intron 24665060 rs10823448 chr10 71708405 A G 4.87E-05 Information processing speed COL13A1 intron 21130836 rs4746014 chr10 71712029 G A 1.91E-04 Lung function (forced expiratory volume in 1 second) COL13A1 intron 24023788 rs4746014 chr10 71712029 G A 4.86E-04 Lung function (forced vital capacity) COL13A1 intron 24023788 rs3750779 chr10 71712502 C T 1.51E-04 Lung function (forced vital capacity) COL13A1 intron 24023788 rs3750779 chr10 71712502 C T 9.66E-05 Lung function (forced expiratory volume in 1 second) COL13A1 intron 24023788 rs2394615 chr10 71713924 T C 7.28E-06 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines COL13A1 intron 21483694 rs1149692 chr10 71716152 G C 3.13E-05 Telomere length COL13A1 intron 20139977 rs4096393 chr10 71717420 A G 3.26E-04 Lung function (forced vital capacity) COL13A1 intron 24023788 rs4096393 chr10 71717420 A G 9.07E-05 Lung function (forced expiratory volume in 1 second) COL13A1 intron 24023788 rs10999059 chr10 71729538 G A 2.70E-07 Urinary metabolites / / 21572414 rs10823454 chr10 71730827 C T 7.40E-07 Urinary metabolites / / 21572414 rs10509314 chr10 71731851 A G 6.51E-05 Smoking initiation / / 24665060 rs10999064 chr10 71742701 A C,G,T 6.85E-04 Major depressive disorder / / 22472876 rs113808744 chr10 71749675 T C 4.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs10999100 chr10 71802746 G A 7.40E-05 ldl cholesterol / / pha003076 rs16927208 chr10 71808518 C T 3.39E-04 Aortic root size / / 21223598 rs12570165 chr10 71811812 A G 5.49E-04 Smoking initiation / / 24665060 rs16927231 chr10 71823229 A T 8.82E-04 Multiple complex diseases H2AFY2 intron 17554300 rs2310992 chr10 71823567 C T 6.33E-04 Insulin resistance H2AFY2 intron 21901158 rs3750768 chr10 71859747 T G 9.42E-04 Acute lung injury H2AFY2 intron 22295056 rs3750769 chr10 71859866 A G 6.07E-04 Suicide attempts in bipolar disorder H2AFY2 intron 21423239 rs10762338 chr10 71863910 C T 8.25E-04 Acute lung injury H2AFY2 intron 22295056 rs1053495 chr10 71874048 G A 0.000866 Ovarian cancer AIFM2 cds-synon 22794196 rs2394656 chr10 71876382 C T 9.40E-04 Type 2 diabetes AIFM2 cds-synon 21874001 rs2280201 chr10 71880190 T C 4.43E-05 Response to mTOR inhibitor (rapamycin) AIFM2 intron 24009623 rs4746965 chr10 71895746 C T 6.87E-04 Depression (quantitative trait) / / 20800221 rs1053105 chr10 71897998 C T 1.92E-04 Vaspin levels TYSND1 UTR-3 22907691 rs1053105 chr10 71897998 C T 0.0001919 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks TYSND1 UTR-3 22907730 rs7087051 chr10 71907200 T G 7.61E-06 Cortisol secretion,in saliva / / 21316860 rs1046747 chr10 71910630 G A 1.28E-06 Lymphocyte counts SAR1A UTR-3 22286170 rs9971029 chr10 71916461 G A 9.20E-05 Creatinine levels SAR1A intron pha003069 rs9971030 chr10 71916826 C T 3.00E-06 Parkinson's disease (interaction with coffee consumption) SAR1A intron 21876681 rs10740329 chr10 71941253 A T 7.60E-04 Depression (quantitative trait) / / 20800221 rs7919014 chr10 71944577 T C 8.45E-04 Depression (quantitative trait) / / 20800221 rs10762348 chr10 71952322 C A 9.16E-04 Depression (quantitative trait) / / 20800221 rs6480445 chr10 71952447 C T 8.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2244916 chr10 71969133 T C 7.23E-04 Multiple complex diseases PPA1 intron 17554300 rs10509321 chr10 71985733 G A 1.93E-05 Lymphocyte counts PPA1 intron 22286170 rs3812696 chr10 72025954 G A 2.90E-05 Urinary metabolites NPFFR1 cds-synon 21572414 rs10823503 chr10 72030710 T A 3.87E-04 Suicide attempts in bipolar disorder NPFFR1 intron 21423239 rs10762355 chr10 72030784 G C 4.70E-04 Suicide attempts in bipolar disorder NPFFR1 intron 21423239 rs10823505 chr10 72035056 A G 2.30E-04 Suicide attempts in bipolar disorder NPFFR1 intron 21423239 rs41322152 chr10 72040805 G C 8.00E-06 Acute lymphoblastic leukemia (childhood) NPFFR1 intron 23007406 rs10762360 chr10 72059506 G C 1.60E-04 Systemic lupus erythematosus(serologic and cytokine profiles in serum) LRRC20 UTR-3 20659327 rs10762361 chr10 72062862 C T 4.26E-04 Response to taxane treatment (placlitaxel) LRRC20 intron 23006423 rs3861040 chr10 72084299 G A 4.88E-05 Coronary heart disease LRRC20 intron pha003031 rs10509322 chr10 72111848 C T 5.11E-04 Multiple complex diseases LRRC20 intron 17554300 rs4747011 chr10 72114378 T C 9.00E-10 Brain connectivity LRRC20 intron 23471985 rs10823529 chr10 72118655 G A 1.00E-04 Cognitive impairment induced by topiramate LRRC20 intron 22091778 rs4747015 chr10 72124462 A G 7.92E-06 Multiple complex diseases LRRC20 intron 17554300 rs10732417 chr10 72135967 A G 1.66E-05 Alzheimer's disease LRRC20 intron 17998437 rs7068419 chr10 72139485 T C 7.74E-06 Multiple complex diseases LRRC20 intron 17554300 rs7918386 chr10 72169625 G A 6.39E-06 Parkinson's disease EIF4EBP2 intron 21248740 rs7072552 chr10 72204961 T C 6.76E-04 Lymphocyte counts / / 22286170 rs7097412 chr10 72261128 T C 7.02E-04 Amyotrophic Lateral Sclerosis KIAA1274 intron 17362836 rs10762386 chr10 72263643 T C 3.06E-04 Multiple complex diseases KIAA1274 intron 17554300 rs4747042 chr10 72263690 G A 2.94E-04 Multiple complex diseases KIAA1274 intron 17554300 rs1001124 chr10 72272453 C T 5.48E-04 Lymphocyte counts KIAA1274 intron 22286170 rs7073737 chr10 72272659 C T 7.74E-04 Amyotrophic Lateral Sclerosis KIAA1274 intron 17362836 rs4746046 chr10 72273357 A G 5.85E-04 Multiple complex diseases KIAA1274 intron 17554300 rs7099027 chr10 72279151 T C 2.54E-05 Elbow pain KIAA1274 intron pha003008 rs11819622 chr10 72287444 G T 2.30E-05 Partial epilepsies KIAA1274 intron 20522523 rs11818368 chr10 72290607 C T 7.07E-04 Amyotrophic Lateral Sclerosis KIAA1274 intron 17362836 rs10999379 chr10 72294836 C T 2.64E-05 Elbow pain KIAA1274 intron pha003008 rs7086704 chr10 72310565 G T 8.00E-04 Dietary macronutrient intake KIAA1274 intron 23636237 rs10740354 chr10 72319022 C T 7.37E-05 Intelligence KIAA1274 intron 21826061 rs10762393 chr10 72331540 A G 2.43E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs10999409 chr10 72332440 T C 5.00E-06 Obesity (extreme) / / 19553259 rs10823577 chr10 72343117 T C 1.53E-05 Lymphocyte counts / / pha003094 rs10823577 chr10 72343117 T C 3.31E-05 Neutrophil count / / pha003095 rs2894125 chr10 72344579 A G 9.71E-05 Body Mass Index / / pha003020 rs2894125 chr10 72344579 A G 5.38E-05 Weight / / pha003026 rs4747064 chr10 72348756 C T 5.54E-05 Lymphocyte counts / / pha003094 rs7080373 chr10 72356766 C T 3.66E-06 Parkinson's disease PRF1 nearGene-3 21738487 rs10999432 chr10 72370724 T G 3.26E-05 Type 1 diabetes / / 21980299 rs10999432 chr10 72370724 T G 7.40E-04 Sleep time / / 23728906 rs826443 chr10 72375542 T C 5.25E-05 Multiple complex diseases / / 17554300 rs10999435 chr10 72375801 G A 1.81E-06 Parkinson's disease / / 21738487 rs608234 chr10 72424312 C T 5.19E-05 Multiple complex diseases / / 17554300 rs17528058 chr10 72424452 C T 5.97E-05 Leukocyte Counts / / pha003091 rs1079351 chr10 72453332 C A 3.39E-04 Smoking quantity ADAMTS14 intron 24665060 rs12775317 chr10 72462283 G A 6.00E-06 Alcohol dependence ADAMTS14 intron 21956439 rs17600642 chr10 72462994 C A 4.03E-06 Multiple complex diseases ADAMTS14 intron 17554300 rs17600642 chr10 72462994 C A 5.00E-06 Bipolar disorder ADAMTS14 intron 21254220 rs10999475 chr10 72469781 A G 3.07E-04 Smoking quantity ADAMTS14 intron 24665060 rs10762399 chr10 72471207 G A 3.97E-04 Smoking quantity ADAMTS14 intron 24665060 rs748343 chr10 72473079 A G 1.88E-05 Cognitive impairment induced by topiramate ADAMTS14 intron 22091778 rs1816002 chr10 72483010 T C 8.00E-06 Weight ADAMTS14 intron 19851299 rs10999486 chr10 72485081 C T 1.98E-06 Left ventricular mass ADAMTS14 intron 21212386 rs10999487 chr10 72485180 T A 1.76E-06 Left ventricular mass ADAMTS14 intron 21212386 rs4746061 chr10 72498841 G A 3.12E-04 Amyotrophic Lateral Sclerosis ADAMTS14 intron 17362836 rs10823607 chr10 72500763 T C 5.00E-06 Sleep duration ADAMTS14 missense 23728906 rs10999501 chr10 72501359 C T 9.75E-06 Parkinson's disease ADAMTS14 intron 21812969 rs12221267 chr10 72505766 G A 5.07E-05 Parkinson's disease ADAMTS14 intron 21812969 rs12784847 chr10 72511528 G A 7.00E-05 Nephrolithiasis ADAMTS14 intron 21283782 rs4747095 chr10 72513272 G A 8.37E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) ADAMTS14 intron 24236485 rs946742 chr10 72515691 C A 0.0000178 Asthma ADAMTS14 intron 22694930 rs2791189 chr10 72517206 T C 0.000000456 Asthma ADAMTS14 intron 22694930 rs4747097 chr10 72518075 C T 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer ADAMTS14 intron 21245432 rs2541232 chr10 72520930 G A 0.0000859 Asthma ADAMTS14 UTR-3 22694930 rs3740434 chr10 72522189 A G 8.00E-05 Nephrolithiasis ADAMTS14 UTR-3 21283782 rs12761224 chr10 72527517 G T 6.00E-06 Prion diseases / / 22210626 rs11591930 chr10 72528564 T A 3.00E-05 Nephrolithiasis / / 21283782 rs2791195 chr10 72531400 C T 6.69E-04 Aortic root size C10orf27 intron 21223598 rs2791196 chr10 72531697 A G 0.0000824 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes C10orf27 intron 22628534 rs7088513 chr10 72536697 C T 4.38E-05 Serum metabolites C10orf27 intron 19043545 rs1880055 chr10 72540847 C G 2.36E-04 Multiple complex diseases C10orf27 intron 17554300 rs1880055 chr10 72540847 C G 2.20E-05 Urinary metabolites C10orf27 intron 21572414 rs16927981 chr10 72546583 C A 6.99E-06 Intelligence / / 21826061 rs12775092 chr10 72550184 C T 1.29E-05 Intelligence / / 21826061 rs11594622 chr10 72580603 A G 4.19E-04 Acute lung injury SGPL1 intron 22295056 rs7894181 chr10 72590090 C T 0.000393398 Hypertension (early onset hypertension) SGPL1 intron 22479346 rs10823627 chr10 72590824 G A 0.000234393 Hypertension (early onset hypertension) SGPL1 intron 22479346 rs3781306 chr10 72592987 G T 0.000608656 Hypertension (early onset hypertension) SGPL1 intron 22479346 rs11595680 chr10 72594745 G T 1.73E-04 Acute lung injury SGPL1 intron 22295056 rs4746069 chr10 72599497 A G 0.000259974 Hypertension (early onset hypertension) SGPL1 intron 22479346 rs11594636 chr10 72610767 A T 1.73E-04 Acute lung injury SGPL1 intron 22295056 rs11596997 chr10 72614271 A G 1.73E-04 Acute lung injury SGPL1 intron 22295056 rs11597050 chr10 72614524 A G 1.38E-04 Acute lung injury SGPL1 cds-synon 22295056 rs11597530 chr10 72614891 A G 1.39E-04 Acute lung injury SGPL1 intron 22295056 rs1997008 chr10 72616064 C T 5.37E-04 Spine bone size SGPL1 intron 23207799 rs11597890 chr10 72624367 T A 1.49E-04 Acute lung injury SGPL1 intron 22295056 rs11595407 chr10 72629255 G A 1.49E-04 Acute lung injury SGPL1 intron 22295056 rs11591712 chr10 72630329 A T 1.49E-04 Acute lung injury SGPL1 intron 22295056 rs865832 chr10 72631626 C T 6.53E-05 Lung function (forced expiratory volume in 1 second) SGPL1 cds-synon 17255346 rs2691148 chr10 72650574 G A 8.86E-04 Type 2 diabetes / / 17463246 rs12259664 chr10 72654424 A G 1.75E-04 Acute lung injury / / 22295056 rs12252993 chr10 72654600 T C 1.84E-04 Acute lung injury / / 22295056 rs7096028 chr10 72656844 T C 6.61E-04 HIV-1 viral setpoint / / 17641165 rs4746070 chr10 72673607 T C 4.46E-04 Iron levels / / pha002876 rs12415816 chr10 72674489 C T 4.53E-04 Iron levels / / pha002876 rs827330 chr10 72677592 A C 8.85E-04 Nicotine dependence / / 17158188 rs1466576 chr10 72688371 T C 8.00E-06 Obesity-related traits / / 23251661 rs827305 chr10 72690361 G A 9.60E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs827294 chr10 72701888 A G 7.04E-05 Cognitive impairment induced by topiramate / / 22091778 rs10823644 chr10 72714280 C T 3.79E-04 Hearing function / / 17255346 rs1538373 chr10 72718265 C T 7.87E-05 Cognitive test performance / / 20125193 rs827267 chr10 72729308 A G 0.00000746 HDL cholesterol particle diameter / / 23263444 rs1471824 chr10 72735740 T C 8.14E-05 stroke (ischemic) / / 17434096 rs827259 chr10 72740379 G A 6.06E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16928236 chr10 72750257 G A 9.51E-04 Multiple complex diseases / / 17554300 rs16928239 chr10 72750636 G A 1.08E-04 Orofacial clefts / / 22863734 rs10509328 chr10 72767409 T C 1.00E-06 Multiple myeloma (IgH translocation) / / 23502783 rs17542297 chr10 72774908 G A 7.84E-05 Orofacial clefts / / 22863734 rs10999637 chr10 72778812 G A 7.46E-05 Diabetic nephropathy / / pha002852 rs4746077 chr10 72780118 T A 3.35E-05 Diabetic nephropathy / / pha002852 rs4456181 chr10 72780680 G A 6.13E-05 Diabetic nephropathy / / pha002852 rs4456181 chr10 72780680 G A 7.32E-05 Diabetic nephropathy / / pha002864 rs1891159 chr10 72795877 A G 3.00E-06 Obesity-related traits / / 23251661 rs9804372 chr10 72847233 A G 8.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs12250762 chr10 72847783 G A 8.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs11497787 chr10 72859876 A G 9.58E-05 Psoriasis / / 20953190 rs10218991 chr10 72870290 G A 2.12E-05 Sleep duration / / 22105623 rs4620642 chr10 72902027 G C 6.05E-05 Formal thought disorder in schizophrenia / / 22648509 rs2153711 chr10 72902948 G C 5.62E-04 Type 2 diabetes / / 17463246 rs2153711 chr10 72902948 G C 1.40E-05 Urinary metabolites / / 21572414 rs7911205 chr10 72907766 A C 7.67E-04 Type 2 diabetes / / 17463246 rs7911205 chr10 72907766 A C 2.50E-05 Urinary metabolites / / 21572414 rs7900002 chr10 72907951 T G 1.50E-05 Urinary metabolites / / 21572414 rs12220332 chr10 72908983 G T 4.93E-05 Formal thought disorder in schizophrenia / / 22648509 rs1417918 chr10 72909867 G T 7.83E-04 Type 2 diabetes / / 17463246 rs1417918 chr10 72909867 G T 1.40E-05 Urinary metabolites / / 21572414 rs1935154 chr10 72910633 C A 6.69E-05 Formal thought disorder in schizophrenia / / 22648509 rs10509330 chr10 72918300 G A 5.21E-05 Formal thought disorder in schizophrenia / / 22648509 rs10823699 chr10 72926445 T A 1.40E-05 Urinary metabolites / / 21572414 rs1539136 chr10 72928131 A G 6.56E-04 Type 2 diabetes / / 17463246 rs1539136 chr10 72928131 A G 1.60E-05 Urinary metabolites / / 21572414 rs1539135 chr10 72929567 C T 2.79E-05 Self-reported allergy / / 23817569 rs7089900 chr10 72943250 A T 8.71E-04 Multiple complex diseases / / 17554300 rs1124754 chr10 72956842 A G 2.33E-05 Self-reported allergy / / 23817569 rs16928529 chr10 72982985 G T 4.00E-06 Attention deficit hyperactivity disorder UNC5B intron 18839057 rs10450286 chr10 72986492 A G 1.10E-05 Urinary metabolites UNC5B intron 21572414 rs12766963 chr10 72996234 C T 9.73E-04 Alcohol dependence UNC5B intron 21314694 rs17545059 chr10 73005037 G A 5.00E-06 Urinary metabolites UNC5B intron 21572414 rs10999746 chr10 73007924 A G 8.29E-04 Type 2 diabetes UNC5B intron 17463246 rs16928560 chr10 73012084 G A 3.55E-04 Response to cytadine analogues (cytosine arabinoside) UNC5B intron 24483146 rs16928574 chr10 73022488 C G 1.26E-04 Type 2 diabetes UNC5B intron 17463246 rs10823717 chr10 73046177 G T 9.91E-05 Multiple sclerosis UNC5B intron 17660530 rs7095433 chr10 73058372 T A 2.90E-05 Pericardial fat UNC5B intron 22589742 rs3740458 chr10 73060277 G A 5.22E-04 Smoking initiation UNC5B UTR-3 24665060 rs6480507 chr10 73063438 C T 6.26E-04 Lymphocyte counts / / 22286170 rs10509333 chr10 73067652 T A 3.70E-04 Blood Pressure and Arterial Stiffness / / 17903302 rs2252996 chr10 73115942 G A 3.00E-06 Systemic lupus erythematosus SLC29A3 missense 23273568 rs703257 chr10 73119135 C T 7.41E-04 Suicide attempts in bipolar disorder SLC29A3 intron 21423239 rs780655 chr10 73119489 G A 6.96E-04 Suicide attempts in bipolar disorder SLC29A3 intron 21423239 rs1084004 chr10 73121945 T C 2.00E-06 Obesity-related traits SLC29A3 cds-synon 23251661 rs1084004 chr10 73121945 T C 8.00E-07 Obesity-related traits SLC29A3 cds-synon 23251661 rs1417210 chr10 73135919 G A,C,T 2.00E-08 Vitiligo / / 22951725 rs9663746 chr10 73148834 G A 4.94E-04 Multiple complex diseases / / 17554300 rs4491141 chr10 73162237 A G 2.85E-04 Blood pressure CDH23 intron 17255346 rs4491141 chr10 73162237 A G 6.75E-05 Cognitive test performance CDH23 intron 20125193 rs10823753 chr10 73203100 C T 5.38E-04 Type 2 diabetes CDH23 intron 17463246 rs16928875 chr10 73212532 T C 5.15E-04 Type 2 diabetes CDH23 intron 17463246 rs7918636 chr10 73215525 A G 7.73E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) CDH23 intron 17982456 rs10999845 chr10 73240361 A G 5.81E-05 Nicotine smoking CDH23 intron 19268276 rs7088556 chr10 73253988 A T 7.70E-06 Urinary metabolites CDH23 intron 21572414 rs10999854 chr10 73266336 C T 7.54E-05 Response to mTOR inhibitor (everolimus) CDH23 intron 24009623 rs10740382 chr10 73269296 G A 2.20E-05 Urinary metabolites CDH23 intron 21572414 rs11594082 chr10 73299253 G T 1.13E-04 Multiple complex diseases CDH23 intron 17554300 rs877783 chr10 73315940 A G 7.38E-04 Amyotrophic Lateral Sclerosis CDH23 intron 17362836 rs877783 chr10 73315940 A G 5.71E-05 Insulin-related traits CDH23 intron pha002901 rs10999882 chr10 73326340 C T 1.23E-04 Alcohol dependence CDH23 intron 20201924 rs885014 chr10 73327821 C T 5.95E-05 Insulin-related traits CDH23 intron pha002901 rs10999892 chr10 73336877 T C 3.85E-05 Brain derived neurotrophic factor levels,in serum CDH23 intron 22047184 rs10999893 chr10 73337158 A T 4.50E-05 Brain derived neurotrophic factor levels,in serum CDH23 intron 22047184 rs12266801 chr10 73337454 C T 4.49E-05 Brain derived neurotrophic factor levels,in serum CDH23 intron 22047184 rs10509336 chr10 73344838 C T 4.35E-04 Multiple complex diseases CDH23 intron 17554300 rs17635977 chr10 73346264 A C 1.14E-05 Personality dimensions CDH23 intron 18957941 rs17635977 chr10 73346264 A C 1.10E-05 Personality dimensions CDH23 intron 21173776 rs7915479 chr10 73351781 T C 1.47E-05 Longevity CDH23 intron 21612516 rs10999907 chr10 73353569 G A 7.80E-05 Personality dimensions CDH23 intron 18957941 rs10999907 chr10 73353569 G A 4.80E-04 Response to cytadine analogues (cytosine arabinoside) CDH23 intron 24483146 rs754726 chr10 73378411 G A 3.05E-04 Lung function (forced expiratory volume in 1 second) CDH23 intron 17255346 rs7907819 chr10 73408096 C T 3.40E-05 HIV-1 control CDH23 intron 20041166 rs12573587 chr10 73413824 G T 8.30E-05 HIV-1 control CDH23 intron 20041166 rs7087554 chr10 73414577 A G 2.45E-05 Common variable immunodeficiency CDH23 intron 21497890 rs1625975 chr10 73422284 A G 3.00E-06 Bipolar disorder (body mass index interaction) CDH23 intron 24322204 rs723274 chr10 73431570 G C 1.60E-04 Spine bone size CDH23 intron 23207799 rs10999949 chr10 73442053 G A 2.49E-04 Alzheimer's disease CDH23 intron 17998437 rs1227087 chr10 73447281 G A 4.96E-05 Serum metabolites CDH23 intron 19043545 rs1227081 chr10 73451573 C T 9.44E-05 Bipolar disorder CDH23 intron 20451256 rs1234326 chr10 73454483 A G 1.70E-05 Parkinson's disease (age of onset) CDH23 intron 19772629 rs10823825 chr10 73454637 T C 5.52E-04 Alcohol dependence CDH23 intron 20201924 rs1227073 chr10 73455821 C T 6.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDH23 intron 20877124 rs7094761 chr10 73456555 C T 2.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CDH23 intron 22566498 rs10999965 chr10 73467457 G A 7.74E-04 Insulin resistance CDH23 intron 21901158 rs7072160 chr10 73469442 A G 9.32E-05 Waist Circumference CDH23 intron pha003023 rs2394838 chr10 73472868 C G 4.63E-04 Taste perception C10orf105 UTR-3 22132133 rs2166631 chr10 73472882 C T 5.82E-04 Taste perception C10orf105 UTR-3 22132133 rs2166631 chr10 73472882 C T 9.34E-05 Waist Circumference C10orf105 UTR-3 pha003023 rs16929266 chr10 73487127 A G 7.17E-04 Alzheimer's disease CDH23 intron 24755620 rs1227056 chr10 73500034 A G 7.59E-04 Parkinson's disease CDH23 intron 16252231 rs3747869 chr10 73520632 A C 1.22E-08 Delayed encephalopathy in acute carbon monoxide poisoning C10orf54 missense 24265751 rs3747869 chr10 73520632 A C 1.34E-07 Delayed encephalopathy in acute carbon monoxide poisoning C10orf54 missense 24265751 rs9415039 chr10 73522694 T C 2.58E-06 Telomere length CDH23 intron 20139977 rs9415039 chr10 73522694 T C 2.35E-04 Lymphocyte counts CDH23 intron 22286170 rs9415996 chr10 73524368 G A 3.02E-05 Post-operative nausea and vomiting CDH23 intron 21694509 rs1867982 chr10 73527047 A G 6.00E-06 Pulmonary function decline CDH23 intron 22424883 rs17712523 chr10 73537614 G A 8.52E-04 Insulin resistance CDH23 missense 21901158 rs4747194 chr10 73558886 G A 3.51E-04 Myocardial Infarction CDH23 missense pha002883 rs4747195 chr10 73558952 C T 4.37E-04 Myocardial Infarction CDH23 missense pha002883 rs7076717 chr10 73565189 G A 4.33E-04 IgE levels CDH23 intron 17255346 rs2854992 chr10 73586585 A G 3.81E-05 Alcohol withdrawal symptoms PSAP intron 22072270 rs11000019 chr10 73591530 G A 8.00E-08 Asthma (childhood onset) PSAP intron 23829686 rs4747204 chr10 73598889 A G 8.97E-05 Alcohol withdrawal symptoms PSAP intron 22072270 rs2394846 chr10 73609059 G C 6.66E-04 Alzheimer's disease PSAP intron 17998437 rs11597008 chr10 73619171 T C 1.50E-06 Urinary metabolites / / 21572414 rs10762485 chr10 73619428 C T 2.05E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs11000067 chr10 73656481 T A,C,G 3.18E-04 Multiple complex diseases / / 17554300 rs10823878 chr10 73673114 G A 9.11E-04 Multiple complex diseases / / 17554300 rs7919939 chr10 73680382 G A 3.12E-05 Waist Circumference / / pha003023 rs7919639 chr10 73680393 A G 1.95E-05 Insulin-related traits / / pha002901 rs4319439 chr10 73706254 C T 8.76E-06 Insulin-related traits / / pha002901 rs11527412 chr10 73717915 C T 6.81E-04 Parkinson's disease / / 17052657 rs7086629 chr10 73729228 T C 5.11E-05 Cocaine dependence CHST3 intron 23958962 rs4148912 chr10 73729498 C T 8.01E-05 Pancreatic cancer CHST3 intron pha002874 rs7894516 chr10 73729650 A C 7.63E-05 Information processing speed CHST3 intron 21130836 rs4148913 chr10 73729752 A G 6.82E-05 Bronchopulmonary dysplasia CHST3 intron 23897914 rs4148917 chr10 73731442 G A 9.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) CHST3 intron 23233662 rs4148941 chr10 73768992 C A 0.000000039 GLP-1-stimulated insulin secretion during hyperglycemic clamps in nondiabetics CHST3 UTR-3 23674605 rs4148943 chr10 73769507 C T 1 Drug response to Docetaxel CHST3 UTR-3 20038957 rs4148943 chr10 73769507 C T 1 Drug response to Thalidomide CHST3 UTR-3 20038957 rs4148945 chr10 73769590 C T 1 Drug response to Docetaxel CHST3 UTR-3 20038957 rs4148945 chr10 73769590 C T 1 Drug response to Thalidomide CHST3 UTR-3 20038957 rs4148947 chr10 73770117 T C 1 Drug response to Docetaxel CHST3 UTR-3 20038957 rs4148947 chr10 73770117 T C 1 Drug response to Thalidomide CHST3 UTR-3 20038957 rs4148950 chr10 73771706 G A 1 Drug response to Docetaxel CHST3 UTR-3 20038957 rs4148950 chr10 73771706 G A 1 Drug response to Thalidomide CHST3 UTR-3 20038957 rs1871450 chr10 73772014 G A 1 Drug response to Docetaxel CHST3 UTR-3 20038957 rs1871450 chr10 73772014 G A 1 Drug response to Thalidomide CHST3 UTR-3 20038957 rs731027 chr10 73772336 T C 1.04E-04 Multiple complex diseases CHST3 UTR-3 17554300 rs730720 chr10 73772762 C T 1 Drug response to Docetaxel CHST3 UTR-3 20038957 rs730720 chr10 73772762 C T 1 Drug response to Thalidomide CHST3 UTR-3 20038957 rs730720 chr10 73772762 C T 2.01E-04 Myocardial Infarction CHST3 UTR-3 pha002873 rs12418 chr10 73773014 G A 1 Drug response to Docetaxel CHST3 UTR-3 20038957 rs12418 chr10 73773014 G A 1 Drug response to Thalidomide CHST3 UTR-3 20038957 rs896076 chr10 73775707 A G 7.21E-04 Myocardial Infarction / / pha002873 rs61852240 chr10 73776614 A G 0.00001888 Sarcoidosis / / 22952805 rs1245582 chr10 73778267 C T 1.00E-06 Disc degeneration (lumbar) / / 24216480 rs1245582 chr10 73778267 C T 4.00E-08 Disc degeneration (lumbar) / / 24216480 rs1245519 chr10 73784791 T C 7.61E-04 Myocardial Infarction / / pha002873 rs1245531 chr10 73790819 G A 5.17E-04 Myocardial Infarction / / pha002873 rs61852247 chr10 73800991 C T 0.00007377 Sarcoidosis / / 22952805 rs1678618 chr10 73806288 A G 8.00E-07 Smoking behavior / / 22832964 rs11000150 chr10 73809941 T G 5.86E-05 Multiple complex diseases / / 17554300 rs11000151 chr10 73810167 T A 4.83E-04 Multiple complex diseases / / 17554300 rs11000152 chr10 73810402 G A 1.60E-04 Multiple complex diseases / / 17554300 rs1049269 chr10 73820001 A G 4.40E-09 Bronchopulmonary dysplasia SPOCK2 UTR-3 21836138 rs7902637 chr10 73825952 G A 1.04E-04 HIV-1 viral setpoint SPOCK2 intron 17641165 rs1245560 chr10 73837420 A C 1.66E-07 Bronchopulmonary dysplasia SPOCK2 intron 21836138 rs1245541 chr10 73849639 G A 5.00E-07 Insulin-like growth factors / / 21216879 rs61853769 chr10 73858832 G A 0.000003783 Sarcoidosis ASCC1 intron 22952805 rs75843515 chr10 73872115 G T 0.00000416 Sarcoidosis ASCC1 intron 22952805 rs145687366 chr10 73882940 A T 0.000001938 Sarcoidosis ASCC1 intron 22952805 rs7090665 chr10 74043803 T C 1.73E-05 Telomere length / / 20139977 rs7893285 chr10 74130388 G A 0.00000764 HDL cholesterol particle diameter MICU1 intron 23263444 rs11000295 chr10 74182400 G A 4.38E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) MICU1 intron 23648065 rs7069357 chr10 74183251 G A 4.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) MICU1 intron 23648065 rs1004256 chr10 74204929 G A 4.38E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) MICU1 intron 23648065 rs140098617 chr10 74210727 G A 0.000002039 Sarcoidosis MICU1 intron 22952805 rs4561121 chr10 74224647 C T 4.38E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) MICU1 intron 23648065 rs10823929 chr10 74251138 G A 8.91E-04 Multiple complex diseases MICU1 intron 17554300 rs12356915 chr10 74261317 C T 5.45E-04 Suicide attempts in bipolar disorder MICU1 intron 21423239 rs61865729 chr10 74322271 C T 0.000008315 Sarcoidosis MICU1 intron 22952805 rs61865731 chr10 74343955 C T 0.00009903 Sarcoidosis MICU1 intron 22952805 rs3009547 chr10 74482123 T C 9.08E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) MCU intron 23648065 rs11818126 chr10 74661041 C T 9.56E-04 Suicide attempts in bipolar disorder OIT3 intron 21423239 rs3829126 chr10 74714177 G T 6.63E-04 Amyotrophic Lateral Sclerosis PLA2G12B intron 17827064 rs7904721 chr10 74731598 T C 3.20E-05 Cognitive impairment induced by topiramate / / 22091778 rs12573768 chr10 74764074 G A 5.90E-04 Alcohol dependence / / 20201924 rs16930262 chr10 74767695 C T 4.90E-04 Alcohol dependence P4HA1 UTR-3 20201924 rs7085141 chr10 74776781 A G 7.20E-04 Alcohol dependence P4HA1 intron 20201924 rs17737927 chr10 74963270 A G 2.04E-07 Heart Rate FAM149B1 intron pha003053 rs11000557 chr10 74987394 A G 5.48E-04 Multiple complex diseases FAM149B1 intron 17554300 rs7079020 chr10 75058601 G C 1.80E-05 Urinary metabolites TTC18 intron 21572414 rs11000607 chr10 75089778 A G 8.09E-04 Multiple complex diseases TTC18 intron 17554300 rs11000621 chr10 75117604 C G 2.41E-04 Multiple complex diseases TTC18 intron 17554300 rs73272348 chr10 75135891 C G 0.000057 Breast cancer(er negative) ANXA7 missense 23555315 rs148945182 chr10 75156284 G T 0.000099 Prostate cancer (advanced) ANXA7 missense 23555315 rs11000671 chr10 75239977 C T 1.02E-05 Alcohol and nictotine co-dependence PPP3CB intron 20158304 rs10824026 chr10 75421208 G A 4.00E-09 Atrial fibrillation / / 22544366 rs10128354 chr10 75470045 T C 8.11E-04 Multiple complex diseases BMS1P4 intron 17554300 rs12413039 chr10 75524759 C G 2.80E-04 Multiple complex diseases SEC24C intron 17554300 rs3849969 chr10 75525999 A G 4.43E-04 Multiple complex diseases SEC24C intron 17554300 rs150846687 chr10 75565704 C T 0.0000049 Prostate cancer (advanced) NDST2 missense 23555315 rs2664280 chr10 75617344 A T 4.50E-04 Multiple complex diseases CAMK2G intron 17554300 rs2664283 chr10 75626373 T C 6.87E-04 Stroke (pediatric) CAMK2G intron 22990015 rs2675671 chr10 75632760 C T 4.34E-04 Multiple complex diseases CAMK2G cds-synon 17554300 rs2675671 chr10 75632760 C T 3.89E-06 Crohn's disease and psoriasis CAMK2G cds-synon 22482804 rs2688610 chr10 75654931 G A 8.32E-04 Multiple complex diseases / / 17554300 rs2688610 chr10 75654931 G A 3.32E-05 Crohn's disease / / 18587394 rs2688608 chr10 75658349 G T 6.00E-04 Multiple complex diseases / / 17554300 rs2227551 chr10 75669190 G T 0.0000813 Type 2 diabetes PLAU nearGene-5 22325160 rs2227564 chr10 75673101 T C 7.00E-10 Inflammatory bowel disease C10orf55 intron 23128233 rs16931023 chr10 75683793 G A 9.31E-05 Heart Rate / / pha003053 rs2633320 chr10 75693306 T C 5.37E-04 Multiple complex diseases / / 17554300 rs2633321 chr10 75693695 G A 1.88E-05 Multiple complex diseases / / 17554300 rs11000831 chr10 75740069 A G 1.02E-04 Attention deficit hyperactivity disorder / / 23728934 rs10824051 chr10 75743618 T C 1.02E-04 Attention deficit hyperactivity disorder / / 23728934 rs7914469 chr10 75786395 C A 2.28E-04 Premature ovarian failure VCL intron 19508998 rs4745730 chr10 75793372 C T 7.06E-04 Alzheimer's disease VCL intron 17998437 rs4745730 chr10 75793372 C T 4.52E-04 Premature ovarian failure VCL intron 19508998 rs4745730 chr10 75793372 C T 1.05E-04 Aortic root size VCL intron 21223598 rs4414157 chr10 75808313 A G 5.34E-04 Premature ovarian failure VCL intron 19508998 rs17743339 chr10 75860098 A G 7.15E-04 Coronary Artery Disease VCL intron 17634449 rs16931177 chr10 75870890 C G 7.49E-05 Serum metabolites VCL intron 19043545 rs1874148 chr10 75874415 A G 1.26E-18 LDL cholesterol VCL intron 23063622 rs1874148 chr10 75874415 A G 1.86E-13 Triglycerides VCL intron 23063622 rs1874148 chr10 75874415 A G 2.11E-25 HDL cholesterol VCL intron 23063622 rs1874148 chr10 75874415 A G 4.69E-18 Cholesterol,total VCL intron 23063622 rs7922894 chr10 75876009 C T 7.49E-05 Serum metabolites VCL intron 19043545 rs10740420 chr10 75919690 G A 8.37E-05 Serum metabolites ADK intron 19043545 rs7079515 chr10 76032411 A C 8.28E-05 Multiple complex diseases ADK intron 17554300 rs4746196 chr10 76079016 G A 9.96E-04 Coronary Artery Disease ADK intron 17634449 rs10824161 chr10 76133762 C G 7.44E-04 Multiple complex diseases ADK intron 17554300 rs7913606 chr10 76150389 A G 9.02E-04 Coronary Artery Disease ADK intron 17634449 rs10762618 chr10 76208811 T C 9.67E-04 Coronary Artery Disease ADK intron 17634449 rs10762622 chr10 76222754 A G 5.55E-04 Coronary Artery Disease ADK intron 17634449 rs7100550 chr10 76237498 C T 8.59E-04 Coronary Artery Disease ADK intron 17634449 rs7924176 chr10 76295789 A G 6.00E-18 Permanent tooth development ADK intron 21931568 rs7924176 chr10 76295789 A G 2.00E-08 Primary tooth development (time to first tooth eruption) ADK intron 23704328 rs7924176 chr10 76295789 A G 8.00E-16 Primary tooth development (number of teeth) ADK intron 23704328 rs10824218 chr10 76421216 A T 2.00E-06 Primary tooth development (time to first tooth eruption) ADK intron 23704328 rs10824226 chr10 76481311 A G 1.60E-05 Cognitive impairment induced by topiramate / / 22091778 rs2153041 chr10 76500841 C T 4.00E-04 Alzheimer's disease (late onset) / / 21379329 rs2153041 chr10 76500841 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11001133 chr10 76503545 C T 4.27E-04 Alzheimer's disease (late onset) / / 21379329 rs10824233 chr10 76505571 G A 4.60E-04 Alcohol dependence / / 20201924 rs10824233 chr10 76505571 G A 3.96E-04 Alzheimer's disease (late onset) / / 21379329 rs3862556 chr10 76540987 C T 8.47E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs951308 chr10 76617479 T C 6.70E-04 Crohn's disease KAT6B intron 17684544 rs11001192 chr10 76643827 G A 8.58E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) KAT6B intron 23648065 rs2001245 chr10 76664836 C T 4.01E-04 Suicide attempts in bipolar disorder KAT6B intron 21423239 rs7899137 chr10 76668462 A C 4.85E-04 Suicide attempts in bipolar disorder KAT6B intron 21423239 rs7092435 chr10 76670311 G C 1.90E-04 Crohn's disease KAT6B intron 17684544 rs11001204 chr10 76685101 A G 6.41E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) KAT6B intron 23648065 rs10466033 chr10 76703006 A G 6.00E-06 Breast size KAT6B intron 22747683 rs16931925 chr10 76769078 A G 2.23E-04 Alzheimer's disease KAT6B intron 17998437 rs7919006 chr10 76808760 C T 4.00E-06 Weight DUPD1 intron 19851299 rs7917231 chr10 76813362 C T 7.43E-05 Lung function (forced expiratory volume in 1 second) DUPD1 intron 17255346 rs10824259 chr10 76820310 A G 4.28E-05 Serum metabolites / / 19043545 rs11001281 chr10 76831010 G A 5.06E-05 Cognitive decline / / 23732972 rs7896442 chr10 76833561 C T 2.45E-06 Age-related macular degeneration / / pha000001 rs7896442 chr10 76833561 C T 7.84E-05 Age-related macular degeneration / / pha002856 rs4745763 chr10 76834921 A C 5.36E-05 Serum metabolites / / 19043545 rs11001286 chr10 76834982 C T 8.10E-05 Cognitive decline / / 23732972 rs7475340 chr10 76839355 A G 2.39E-04 Multiple complex diseases / / 17554300 rs4746261 chr10 76845632 T C 5.90E-05 Multiple complex diseases / / 17554300 rs2804535 chr10 76971844 C T 9.71E-04 Multiple complex diseases VDAC2 intron 17554300 rs2804535 chr10 76971844 C T 6.00E-05 Serum metabolites VDAC2 intron 19043545 rs10824293 chr10 77004792 C T 1.09E-04 Acne (severe) / / 24927181 rs1113313 chr10 77013701 C T 0.0000042 Negative cognition (anxiety related behavioral questionnaire) in children / / 23565138 rs10509357 chr10 77029174 A G 1.20E-04 Crohn's disease / / 17684544 rs11001366 chr10 77067318 T C 3.43E-04 Multiple complex diseases ZNF503-AS1 intron 17554300 rs1259578 chr10 77092026 A G 2.60E-05 Pulmonary function ZNF503-AS1 intron 19300500 rs2435884 chr10 77094218 A G 2.60E-05 Pulmonary function ZNF503-AS1 intron 19300500 rs12267051 chr10 77106637 C T 1.23E-05 Alcohol consumption ZNF503-AS1 intron 23743675 rs1259594 chr10 77108687 A G 4.91E-05 Pulmonary function ZNF503-AS1 intron 19300500 rs1652713 chr10 77112300 C T 2.07E-04 Multiple complex diseases ZNF503-AS1 intron 17554300 rs1652713 chr10 77112300 C T 2.30E-04 Alzheimer's disease ZNF503-AS1 intron 17998437 rs1652713 chr10 77112300 C T 8.13E-05 Pulmonary function ZNF503-AS1 intron 19300500 rs1267723 chr10 77125854 C T 6.54E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs1259589 chr10 77127233 G A 9.42E-04 Multiple complex diseases / / 17554300 rs1259590 chr10 77128000 C T 3.90E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs2488704 chr10 77138624 T C 8.72E-04 Myopia (pathological) / / 21095009 rs7072873 chr10 77210191 C T 2.03E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11001399 chr10 77221744 A C 4.55E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11001401 chr10 77225753 A G 1.76E-04 Type 2 diabetes / / 20818381 rs9416061 chr10 77242061 G A 3.28E-04 Alzheimer's disease / / 24755620 rs2915032 chr10 77249629 A G 6.02E-04 Parkinson's disease / / 16252231 rs2915032 chr10 77249629 A G 1.40E-05 Urinary metabolites / / 21572414 rs2043090 chr10 77298609 A G 3.00E-06 Anorexia nervosa / / 23568457 rs10509359 chr10 77330842 T G 1.48E-04 Stroke (pediatric) / / 22990015 rs10458641 chr10 77406954 C T 5.83E-06 Multiple complex diseases / / 17554300 rs16932464 chr10 77410361 A C 7.96E-05 White matter integrity / / 22425255 rs10824324 chr10 77410782 T C 3.66E-06 Multiple complex diseases / / 17554300 rs7073851 chr10 77417967 A G 7.96E-05 White matter integrity / / 22425255 rs7082404 chr10 77446065 T C 3.05E-06 Multiple complex diseases / / 17554300 rs11001471 chr10 77453942 T G 9.67E-04 Type 2 diabetes / / 17463246 rs11001471 chr10 77453942 T G 3.56E-04 Multiple complex diseases / / 17554300 rs11001475 chr10 77459075 C T 4.58E-04 Multiple complex diseases / / 17554300 rs7898903 chr10 77469230 C T 2.38E-04 Multiple complex diseases / / 17554300 rs7097617 chr10 77504287 A G 3.30E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12242030 chr10 77529218 T C 5.87E-05 Multiple complex diseases / / 17554300 rs10509361 chr10 77553186 A G 5.20E-05 Obesity-related traits C10orf11 intron 17903300 rs7915846 chr10 77564560 T C 8.07E-04 Response to taxane treatment (placlitaxel) C10orf11 intron 23006423 rs1997364 chr10 77572804 A G 1.90E-05 Urinary metabolites C10orf11 intron 21572414 rs7918784 chr10 77577699 T C 8.30E-06 Urinary metabolites C10orf11 intron 21572414 rs1885822 chr10 77614004 T C 5.16E-05 Response to taxane treatment (placlitaxel) C10orf11 intron 23006423 rs12778915 chr10 77617557 G A 9.18E-04 Response to taxane treatment (placlitaxel) C10orf11 intron 23006423 rs1323076 chr10 77622692 G C 1.60E-05 Urinary metabolites C10orf11 intron 21572414 rs7082211 chr10 77631656 A G 8.40E-05 Cognitive impairment induced by topiramate C10orf11 intron 22091778 rs1885824 chr10 77632534 A G 5.01E-05 Cognitive impairment induced by topiramate C10orf11 intron 22091778 rs2181443 chr10 77634338 G A 3.31E-04 Lung function (forced expiratory volume in 1 second) C10orf11 intron 24023788 rs7082215 chr10 77666528 A G 1.10E-04 Type 2 diabetes C10orf11 intron 17463246 rs11001545 chr10 77672153 A G 1.03E-05 Type 2 diabetes C10orf11 intron 17463246 rs11816174 chr10 77673629 A G 7.37E-04 Multiple complex diseases C10orf11 intron 17554300 rs1359037 chr10 77690754 T C 7.99E-04 Acute lung injury C10orf11 intron 22295056 rs2395336 chr10 77736622 A G 4.03E-04 Type 2 diabetes C10orf11 intron 17463246 rs7092693 chr10 77746258 A G 4.11E-04 Type 2 diabetes C10orf11 intron 17463246 rs7097530 chr10 77750742 C T 3.62E-04 Suicide attempts in bipolar disorder C10orf11 intron 21423239 rs2057437 chr10 77752061 A G 4.63E-05 Type 2 diabetes C10orf11 intron 17463246 rs2057440 chr10 77758013 A C 7.79E-04 Suicide attempts in bipolar disorder C10orf11 intron 21423239 rs7920628 chr10 77866732 T C 4.62E-05 Fibrinogen C10orf11 intron 17255346 rs10740455 chr10 77911032 A T 7.00E-06 Methotrexate phramacokinetics (acute lymphoblastic leukemia) C10orf11 intron 19901119 rs12253494 chr10 77920235 G T 7.60E-07 Urinary metabolites C10orf11 intron 21572414 rs17445672 chr10 77921085 C T 5.64E-04 Type 2 diabetes C10orf11 intron 17463246 rs11001649 chr10 77922119 A C 1.28E-05 Erythrocyte counts C10orf11 intron pha003099 rs11001655 chr10 77927556 A G 2.96E-05 Schizophrenia (cytomegalovirus infection interaction) C10orf11 intron 23358160 rs10824378 chr10 77929739 G A 7.44E-04 Type 2 diabetes C10orf11 intron 17463246 rs16932960 chr10 77935521 A G 4.80E-07 Urinary metabolites C10orf11 intron 21572414 rs4746372 chr10 77938242 G A 0.000048 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes C10orf11 intron 22628534 rs10509365 chr10 77939234 T G 1.50E-05 Urinary metabolites C10orf11 intron 21572414 rs1865640 chr10 77943258 T C 8.79E-05 Coronary heart disease C10orf11 intron pha003031 rs12161701 chr10 77991493 G A 5.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C10orf11 intron 20877124 rs12161701 chr10 77991493 G A 8.39E-05 Schizophrenia (cytomegalovirus infection interaction) C10orf11 intron 23358160 rs1247495 chr10 78001359 T G 1.00E-05 Urinary metabolites C10orf11 intron 21572414 rs1247489 chr10 78003580 T G 3.80E-06 Urinary metabolites C10orf11 intron 21572414 rs1247488 chr10 78005230 C T 1.20E-05 Urinary metabolites C10orf11 intron 21572414 rs10762705 chr10 78028463 G A 0.000013483 Alcohol dependence C10orf11 intron 23089632 rs16933137 chr10 78031378 G T 2.20E-04 Multiple complex diseases C10orf11 intron 17554300 rs16933163 chr10 78040993 A G 2.94E-04 Myopia (pathological) C10orf11 intron 21095009 rs17376438 chr10 78055260 G A 4.30E-05 Cognitive function C10orf11 intron 24684796 rs11001722 chr10 78057746 G A 7.64E-04 Response to cytidine analogues (gemcitabine) C10orf11 intron 24483146 rs2573555 chr10 78062571 A G 6.48E-05 Partial epilepsies C10orf11 intron 20522523 rs10824393 chr10 78072371 C A 4.91E-04 Type 2 diabetes C10orf11 intron 17463246 rs2758988 chr10 78088071 A T 3.74E-04 Response to cytadine analogues (cytosine arabinoside) C10orf11 intron 24483146 rs10762714 chr10 78094581 C T 3.44E-04 Type 2 diabetes C10orf11 intron 17463246 rs7086222 chr10 78098791 G A 4.17E-04 Type 2 diabetes C10orf11 intron 17463246 rs17450685 chr10 78106937 C T 8.73E-05 Pulmonary function in asthmatics C10orf11 intron 23541324 rs17450685 chr10 78106937 C T 8.12E-05 Coronary heart disease C10orf11 intron pha003031 rs12413026 chr10 78108661 G A 7.67E-05 Schizophrenia(age at onset) C10orf11 intron 21688384 rs7900522 chr10 78109971 T C 9.49E-09 Systemic lupus erythematosus and Systemic sclerosis C10orf11 intron 23740937 rs7920287 chr10 78111620 A G 6.03E-04 Type 2 diabetes C10orf11 intron 17463246 rs11599008 chr10 78148240 T G 8.76E-06 Lung adenocarcinoma C10orf11 intron 19836008 rs1907335 chr10 78150685 C T 5.38E-05 Iron status biomarkers C10orf11 intron 19084217 rs10509373 chr10 78157572 T C 6.00E-08 Response to tamoxifen in breast cancer C10orf11 intron 22180457 rs10824415 chr10 78174967 T C 7.91E-04 Suicide attempts in bipolar disorder C10orf11 intron 21423239 rs11001775 chr10 78184711 C A 0.0002 Migraine C10orf11 intron 22678113 rs16933537 chr10 78189096 C T 4.22E-04 Multiple complex diseases C10orf11 intron 17554300 rs2579740 chr10 78282773 G A 0.0000016 Mean arterial pressure C10orf11 intron 22510845 rs16933641 chr10 78297974 T C 5.75E-04 Response to taxane treatment (placlitaxel) C10orf11 intron 23006423 rs11001819 chr10 78315224 G A 3.00E-12 Pulmonary function C10orf11 intron 21946350 rs11001819 chr10 78315224 G A 5.00E-08 Pulmonary function (interaction) C10orf11 intron 23284291 rs2256413 chr10 78315334 A G 4.67E-04 Pulmonary function C10orf11 intron 23932459 rs2637260 chr10 78320346 T C 6.34E-07 Pulmonary function / / 23932459 rs2637260 chr10 78320346 T C 7.50E-06 Pulmonary function / / 23932459 rs2637261 chr10 78320593 C T 6.34E-07 Pulmonary function / / 23932459 rs2637261 chr10 78320593 C T 7.50E-06 Pulmonary function / / 23932459 rs2637266 chr10 78331318 A G 2.00E-06 Pulmonary function / / 23932459 rs2637266 chr10 78331318 A G 2.43E-07 Pulmonary function / / 23932459 rs10824425 chr10 78340310 G C 8.20E-06 Pulmonary function / / 23932459 rs10824425 chr10 78340310 G C 8.98E-07 Pulmonary function / / 23932459 rs4633402 chr10 78414244 C A 6.43E-04 Alzheimer's disease / / 22005930 rs11001846 chr10 78418056 A C 6.23E-04 Alzheimer's disease / / 22005930 rs11001850 chr10 78425431 C T 6.54E-04 Alzheimer's disease / / 22005930 rs10824434 chr10 78441162 T C 3.65E-04 Alzheimer's disease / / 22005930 rs11001852 chr10 78445987 G C 3.64E-04 Alzheimer's disease / / 22005930 rs11001862 chr10 78474147 C T 4.18E-04 Alzheimer's disease / / 22005930 rs10824440 chr10 78489079 C T 2.53E-04 Alzheimer's disease / / 22005930 rs10824441 chr10 78490195 G A 2.46E-04 Alzheimer's disease / / 22005930 rs11001867 chr10 78491455 T A 1.20E-04 Alzheimer's disease / / 22005930 rs7090852 chr10 78499053 A G 2.79E-04 Alzheimer's disease / / 22005930 rs11492375 chr10 78513974 T C 6.43E-04 Alzheimer's disease / / 22005930 rs17297628 chr10 78521238 G C 5.29E-04 Type 2 diabetes / / 17463246 rs7912068 chr10 78523559 C T 5.30E-04 Type 2 diabetes / / 17463246 rs10824445 chr10 78530050 T C 5.23E-04 Alzheimer's disease / / 22005930 rs17231884 chr10 78536425 C T 6.48E-04 Alzheimer's disease / / 22005930 rs17231898 chr10 78549057 G A 1.81E-04 Type 2 diabetes / / 17463246 rs11001882 chr10 78556140 C T 6.95E-04 Alzheimer's disease / / 22005930 rs10491077 chr10 78586317 C T 5.57E-04 Multiple complex diseases / / 17554300 rs10824456 chr10 78615458 C G 8.71E-04 Multiple complex diseases / / 17554300 rs2116830 chr10 78646536 G T 3.00E-10 Obesity KCNMA1 UTR-3 21708048 rs2288840 chr10 78649399 C T 7.59E-04 Coronary Artery Disease KCNMA1 intron 17634449 rs7067873 chr10 78654796 C G 9.83E-04 Coronary Artery Disease KCNMA1 intron 17634449 rs7086316 chr10 78688152 G A 6.72E-04 Multiple complex diseases KCNMA1 intron 17554300 rs1865020 chr10 78688976 G A 4.15E-06 Stroke (ischemic) KCNMA1 intron 21957438 rs1907744 chr10 78724050 C T 1.43E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) KCNMA1 intron 24023788 rs7912269 chr10 78727604 T C 1.40E-05 Multiple sclerosis KCNMA1 intron 21833088 rs7915877 chr10 78727967 T C 1.14E-04 Bipolar disorder KCNMA1 intron 18317468 rs11001960 chr10 78746062 A G 7.23E-04 Suicide attempts in bipolar disorder KCNMA1 intron 21423239 rs10740464 chr10 78752289 G T 1.60E-05 Urinary metabolites KCNMA1 intron 21572414 rs7922133 chr10 78784075 C T 4.59E-05 Brain structure KCNMA1 intron 22504417 rs4980123 chr10 78788660 T G 9.21E-06 Brain structure KCNMA1 intron 22504417 rs11001980 chr10 78792829 A G 5.46E-04 Suicide attempts in bipolar disorder KCNMA1 intron 21423239 rs1247755 chr10 78797670 C G 7.47E-05 Diabetic nephropathy KCNMA1 intron pha002852 rs7907270 chr10 78880943 A G 2.35E-06 Hypertension (essential hypertension) KCNMA1 intron 22184326 rs2616646 chr10 78889417 C T 4.00E-04 Type 2 diabetes KCNMA1 intron 21874001 rs11002043 chr10 78902405 C T 7.53E-04 Suicide attempts in bipolar disorder KCNMA1 intron 21423239 rs12359742 chr10 78908581 T C 4.89E-04 Suicide attempts in bipolar disorder KCNMA1 intron 21423239 rs10824494 chr10 78918297 C A,G 8.58E-04 Alcohol dependence KCNMA1 intron 24277619 rs573712 chr10 78919640 T C 7.15E-05 Sleep duration KCNMA1 intron 23728906 rs558828 chr10 78923773 C A 6.25E-04 Multiple complex diseases KCNMA1 intron 17554300 rs527458 chr10 78924624 A G 7.42E-06 Serum metabolites KCNMA1 intron 19043545 rs547212 chr10 78995918 C T 1.11E-04 Response to platinum-based chemotherapy in small-cell lung cancer KCNMA1 intron 20463552 rs547163 chr10 78995938 G A 1.33E-04 Response to platinum-based chemotherapy in small-cell lung cancer KCNMA1 intron 20463552 rs1968485 chr10 79003559 C T 1.04E-04 Response to platinum-based chemotherapy in small-cell lung cancer KCNMA1 intron 20463552 rs547144 chr10 79012469 G C 2.85E-04 Response to statin treatment (atorvastatin),change in cholesterol levels KCNMA1 intron 20031582 rs10509384 chr10 79023182 A G 1.90E-04 Lipid traits KCNMA1 intron 17903299 rs10509384 chr10 79023182 A G 6.04E-06 Serum metabolites KCNMA1 intron 19043545 rs10824509 chr10 79030031 T C 6.00E-06 Urinary metabolites KCNMA1 intron 21572414 rs10824510 chr10 79031563 C T 5.77E-04 Type 2 diabetes KCNMA1 intron 17463246 rs717207 chr10 79043364 G T 2.17E-05 Alcohol dependence KCNMA1 intron 21314694 rs717207 chr10 79043364 G T 6.15E-05 Cortisol secretion,in saliva KCNMA1 intron 21316860 rs479033 chr10 79043499 A C 6.63E-04 Multiple complex diseases KCNMA1 intron 17554300 rs523611 chr10 79050448 G C 7.09E-05 Bipolar disorder KCNMA1 intron 19259986 rs592676 chr10 79053957 T A 8.91E-05 Alcohol and nictotine co-dependence KCNMA1 intron 20158304 rs872794 chr10 79059483 T C 2.20E-04 Alzheimer's disease KCNMA1 intron 17998437 rs583507 chr10 79065329 G A 9.54E-04 Amyotrophic Lateral Sclerosis KCNMA1 intron 17362836 rs12220179 chr10 79068074 A G 5.66E-04 Multiple complex diseases KCNMA1 intron 17554300 rs16934560 chr10 79069953 T A 4.10E-05 Multiple complex diseases KCNMA1 intron 17554300 rs611519 chr10 79077095 C T 2.54E-04 Iron levels KCNMA1 intron pha002876 rs540783 chr10 79077713 C T 3.73E-04 Iron levels KCNMA1 intron pha002876 rs655487 chr10 79080057 G A 6.96E-04 Myocardial Infarction KCNMA1 intron pha002883 rs6480859 chr10 79081948 C A,G,T 0.000000012 Myopia (Age of onset) KCNMA1 intron 23468642 rs591485 chr10 79082890 A G 3.38E-04 Taste perception KCNMA1 intron 22132133 rs12359379 chr10 79083609 T C 3.42E-04 Amyotrophic Lateral Sclerosis KCNMA1 intron 17362836 rs1457523 chr10 79096398 A G 8.00E-05 Response to statin therapy KCNMA1 intron 20339536 rs585620 chr10 79103327 A G 8.13E-04 Multiple complex diseases KCNMA1 intron 17554300 rs207676 chr10 79107134 C T 9.48E-04 Multiple complex diseases KCNMA1 intron 17554300 rs10762756 chr10 79109206 T A 6.50E-05 Response to statin therapy KCNMA1 intron 20339536 rs1659789 chr10 79113564 C T 7.50E-05 Response to statin therapy KCNMA1 intron 20339536 rs35772 chr10 79119449 C T 7.90E-05 Response to statin therapy KCNMA1 intron 20339536 rs620803 chr10 79122481 G C 7.80E-05 Response to statin therapy KCNMA1 intron 20339536 rs1439789 chr10 79123672 A C 5.50E-05 Response to statin therapy KCNMA1 intron 20339536 rs35778 chr10 79125540 C G 7.90E-05 Response to statin therapy KCNMA1 intron 20339536 rs42453 chr10 79126530 A C 8.40E-05 Response to statin therapy KCNMA1 intron 20339536 rs35781 chr10 79126869 G A 9.40E-05 Response to statin therapy KCNMA1 intron 20339536 rs250712 chr10 79127539 A C 9.30E-05 Response to statin therapy KCNMA1 intron 20339536 rs250711 chr10 79127895 A G 9.70E-05 Response to statin therapy KCNMA1 intron 20339536 rs10762757 chr10 79128571 G T 9.30E-05 Response to statin therapy KCNMA1 intron 20339536 rs1866591 chr10 79130855 T C 9.40E-05 Response to statin therapy KCNMA1 intron 20339536 rs1439785 chr10 79131282 T G 9.40E-05 Response to statin therapy KCNMA1 intron 20339536 rs35774 chr10 79133348 G A 9.00E-05 Response to statin therapy KCNMA1 intron 20339536 rs35773 chr10 79133733 T C 9.30E-05 Response to statin therapy KCNMA1 intron 20339536 rs2077641 chr10 79146116 G C 7.92E-04 Alcohol dependence KCNMA1 intron 21314694 rs12219105 chr10 79173540 T C 1.50E-04 Alcohol dependence KCNMA1 intron 20201924 rs12219105 chr10 79173540 T C 9.70E-05 Alcohol dependence KCNMA1 intron 20201924 rs12219105 chr10 79173540 T C 9.68E-05 Alcoholism KCNMA1 intron pha002893 rs10740466 chr10 79176278 T C 6.15E-05 Orofacial clefts KCNMA1 intron 20023658 rs10740467 chr10 79176594 C A 3.86E-05 Anxiety and major depressive disorder KCNMA1 intron 24047446 rs3862501 chr10 79183152 G C 6.45E-04 Multiple complex diseases KCNMA1 intron 17554300 rs660465 chr10 79185111 T C 8.61E-04 Multiple complex diseases KCNMA1 intron 17554300 rs660465 chr10 79185111 T C 9.95E-05 Alzheimer's disease KCNMA1 intron 17998437 rs10824541 chr10 79186259 G C 8.89E-04 Multiple complex diseases KCNMA1 intron 17554300 rs10824541 chr10 79186259 G C 4.99E-05 Bipolar disorder and schizophrenia KCNMA1 intron 20889312 rs584141 chr10 79190354 T G 9.74E-05 Alzheimer's disease KCNMA1 intron 17998437 rs10762759 chr10 79200117 A G 1.23E-04 Osteosarcoma KCNMA1 intron 23727862 rs10762759 chr10 79200117 A G 9.43E-04 Insomnia KCNMA1 intron 23728906 rs7895934 chr10 79204191 G A 9.81E-05 Orofacial clefts KCNMA1 intron 22419666 rs16934799 chr10 79208056 A C 5.30E-05 Personality dimensions KCNMA1 intron 18957941 rs603788 chr10 79211262 G C 9.00E-07 Blood pressure KCNMA1 intron 24954895 rs603788 chr10 79211262 G C 9.00E-07 Blood pressure KCNMA1 intron 24954895 rs289265 chr10 79228709 G A 8.46E-04 Iron levels KCNMA1 intron pha002876 rs681088 chr10 79232842 G A 1.48E-05 Heart Rate KCNMA1 intron pha003054 rs35798 chr10 79234693 T G 9.52E-04 Iron levels KCNMA1 intron pha002876 rs42311 chr10 79235196 C T 7.24E-05 Information processing speed KCNMA1 intron 21130836 rs682275 chr10 79239338 T C 6.60E-06 Heart Rate KCNMA1 intron pha003054 rs682275 chr10 79239338 T C 9.74E-05 Glucose levels KCNMA1 intron pha003057 rs1866587 chr10 79242092 C T 3.79E-06 Heart Rate KCNMA1 intron pha003054 rs843835 chr10 79315725 G A 6.38E-04 Suicide attempts in bipolar disorder KCNMA1 intron 21423239 rs1248572 chr10 79316529 G A 4.81E-04 Suicide attempts in bipolar disorder KCNMA1 intron 21423239 rs3851040 chr10 79318685 C T 4.59E-04 Multiple complex diseases KCNMA1 intron 17554300 rs2673434 chr10 79320152 T C 6.22E-04 Suicide attempts in bipolar disorder KCNMA1 intron 21423239 rs2673462 chr10 79320615 T C 6.46E-04 Suicide attempts in bipolar disorder KCNMA1 intron 21423239 rs2619641 chr10 79322453 A C 2.96E-08 Selenium resistance in NCI60 cancer cell lines KCNMA1 intron 20830292 rs2619641 chr10 79322453 A C 6.05E-04 Suicide attempts in bipolar disorder KCNMA1 intron 21423239 rs2719996 chr10 79322957 T C 8.30E-04 Suicide attempts in bipolar disorder KCNMA1 intron 21423239 rs2719979 chr10 79325831 C T 8.16E-04 Suicide attempts in bipolar disorder KCNMA1 intron 21423239 rs2619607 chr10 79334199 A C 8.07E-04 Type 2 diabetes KCNMA1 intron 17463246 rs2670115 chr10 79335095 A C 2.29E-04 Schizophrenia KCNMA1 intron 18282107 rs2670117 chr10 79354471 A G 9.61E-08 Multiple sclerosis KCNMA1 intron 17660530 rs4979902 chr10 79399946 T C 6.80E-06 Urinary metabolites / / 21572414 rs7071206 chr10 79401316 T C 5.00E-19 Bone mineral density / / 22504420 rs7071206 chr10 79401316 T C 0.000216 Lumbar spine bone mineral density (premenopausal) / / 23074152 rs2673474 chr10 79411445 A G 8.19E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs1877998 chr10 79411740 G A 1.00E-04 Information processing speed / / 21130836 rs1877998 chr10 79411740 G A 3.02E-04 Alzheimer's disease (late onset) / / 21379329 rs1877998 chr10 79411740 G A 1.50E-05 Urinary metabolites / / 21572414 rs2670109 chr10 79413659 G A 2.49E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs716255 chr10 79419679 A T 1.30E-05 Urinary metabolites / / 21572414 rs2254094 chr10 79421244 G A 4.18E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs10509391 chr10 79422369 G A 1.00E-04 Information processing speed / / 21130836 rs10509391 chr10 79422369 G A 2.08E-04 Alzheimer's disease (late onset) / / 21379329 rs2670106 chr10 79441713 T C 3.74E-05 Bone mineral density / / 24249740 rs2619649 chr10 79442104 T C 2.72E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12254219 chr10 79443520 C T 2.66E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4979906 chr10 79444753 A G 7.00E-06 Heart failure / / 20400778 rs12264636 chr10 79448539 G C 2.10E-05 Urinary metabolites / / 21572414 rs1609790 chr10 79464078 C T 8.31E-05 Body Mass Index / / pha003022 rs2673432 chr10 79479119 A G 2.24E-04 Hemoglobin concentration / / 20534544 rs12780841 chr10 79492827 C A 1.09E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs12761718 chr10 79492970 C T 1.09E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs12761718 chr10 79492970 C T 9.99E-04 Coronary Artery Disease / / 17634449 rs12761718 chr10 79492970 C T 4.77E-05 Antisocial behavior / / 20345837 rs12761718 chr10 79492970 C T 4.45E-04 Hemoglobin concentration / / 20534544 rs17417617 chr10 79493346 A C 4.45E-04 Hemoglobin concentration / / 20534544 rs1465865 chr10 79498790 A G 1.17E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1965792 chr10 79498981 T C 5.57E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs11002284 chr10 79525505 C T 8.33E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs1866437 chr10 79526766 T C 4.94E-05 Multiple complex diseases / / 17554300 rs1866437 chr10 79526766 T C 1.12E-07 Blood Pressure / / pha003046 rs1866437 chr10 79526766 T C 3.51E-05 Blood Pressure / / pha003048 rs2579178 chr10 79529215 G A 2.02E-04 Multiple complex diseases / / 17554300 rs2579177 chr10 79529245 C T 1.55E-04 Multiple complex diseases / / 17554300 rs2579176 chr10 79529350 A G 3.94E-05 Multiple complex diseases / / 17554300 rs2579175 chr10 79529533 T C 5.20E-06 Urinary metabolites / / 21572414 rs2579174 chr10 79530213 C T 2.70E-05 Urinary metabolites / / 21572414 rs2579171 chr10 79531561 G A 2.60E-05 Urinary metabolites / / 21572414 rs2579170 chr10 79531976 A G 5.20E-06 Urinary metabolites / / 21572414 rs12261589 chr10 79540835 C T 4.00E-06 Obesity-related traits / / 23251661 rs2579159 chr10 79543077 G A 5.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2812437 chr10 79544075 A G 5.20E-06 Urinary metabolites / / 21572414 rs2812431 chr10 79549242 C T 1.42E-04 Alcohol dependence / / 21314694 rs7922683 chr10 79553592 T C 2.25E-04 Multiple complex diseases DLG5 intron 17554300 rs10762763 chr10 79560803 C G 2.09E-04 Multiple complex diseases DLG5 intron 17554300 rs2579147 chr10 79560861 T C 5.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DLG5 intron 20877124 rs10824579 chr10 79590685 C T 5.99E-07 Blood Pressure DLG5 intron pha003046 rs10824579 chr10 79590685 C T 5.80E-05 Blood Pressure DLG5 intron pha003048 rs539418253 chr10 79590685 CGCGTAACG C 5.99E-07 Blood Pressure DLG5 intron pha003046 rs539418253 chr10 79590685 CGCGTAACG C 5.80E-05 Blood Pressure DLG5 intron pha003048 rs11002306 chr10 79591519 A T 5.00E-04 Multiple complex diseases DLG5 intron 17554300 rs10824582 chr10 79603688 T C 4.00E-07 Blood Pressure DLG5 intron pha003046 rs10824582 chr10 79603688 T C 6.26E-05 Blood Pressure DLG5 intron pha003048 rs1248686 chr10 79610926 T C 7.10E-06 Urinary metabolites DLG5 intron 21572414 rs754466 chr10 79680434 A T 6.00E-10 Liver enzyme levels (gamma-glutamyl transferase) DLG5 intron 22001757 rs10824586 chr10 79716458 A G 2.29E-05 Alzheimer's disease (late onset) / / 21460841 rs201197793 chr10 79719611 CAGAT C 1.66E-05 Personality dimensions / / 22628180 rs2559669 chr10 79719611 C T 1.66E-05 Personality dimensions / / 22628180 rs377445614 chr10 79719611 CAGAT C 1.66E-05 Personality dimensions / / 22628180 rs4979931 chr10 79720746 C T 1.60E-06 Urinary metabolites / / 21572414 rs2042867 chr10 79722242 C T 8.35E-04 Alzheimer's disease / / 17998437 rs12572510 chr10 79726273 T C 1.73E-05 Personality dimensions / / 22628180 rs735638 chr10 79732721 A G 7.77E-06 Personality dimensions / / 22628180 rs2241546 chr10 79735271 T C 7.45E-06 Personality dimensions POLR3A UTR-3 22628180 rs16935486 chr10 79735647 C T 6.60E-04 Multiple complex diseases POLR3A UTR-3 17554300 rs3088264 chr10 79735775 T C 6.37E-06 Personality dimensions POLR3A UTR-3 22628180 rs2241547 chr10 79736964 C G 6.31E-06 Personality dimensions POLR3A UTR-3 22628180 rs2241548 chr10 79737613 A C 2.57E-05 Personality dimensions POLR3A intron 22628180 rs12245010 chr10 79737998 T C 2.56E-05 Personality dimensions POLR3A intron 22628180 rs7905170 chr10 79738238 A G 5.32E-06 Personality dimensions POLR3A intron 22628180 rs4979936 chr10 79739531 C T 5.57E-06 Personality dimensions POLR3A intron 22628180 rs4979937 chr10 79739600 A T 5.76E-06 Personality dimensions POLR3A intron 22628180 rs10824587 chr10 79740262 T C 2.18E-05 Personality dimensions POLR3A intron 22628180 rs1529426 chr10 79770550 C T 1.50E-04 Multiple complex diseases POLR3A intron 17554300 rs3213833 chr10 79785172 C A 1.69E-26 HDL cholesterol POLR3A intron 23063622 rs12267420 chr10 79789657 C A 9.15E-04 Response to taxane treatment (placlitaxel) POLR3A nearGene-5 23006423 rs16935567 chr10 79798919 G A 6.74E-04 Response to taxane treatment (placlitaxel) RPS24 intron 23006423 rs7899453 chr10 79799959 C A 0.000000296 HDL cholesterol RPS24 intron 23063622 rs4979938 chr10 79836619 G A 6.85E-05 Myocardial Infarction / / pha002873 rs12265766 chr10 79908472 G A 4.25E-04 Insulin resistance / / 21901158 rs7911917 chr10 79961222 A T 2.40E-05 Response to statin therapy / / 20339536 rs751284 chr10 79964084 G A 2.70E-05 Response to statin therapy / / 20339536 rs10159695 chr10 79965198 C T 2.60E-05 Response to statin therapy / / 20339536 rs7089561 chr10 79969839 T G 4.05E-05 Erythrocyte counts / / pha003099 rs1249149 chr10 79980725 T C 2.52E-04 Coronary heart disease / / 21606135 rs1249148 chr10 79980813 G T 8.37E-04 HIV-1 viral setpoint / / 17641165 rs1149731 chr10 79988080 A G 2.95E-04 Coronary heart disease / / 21606135 rs2448388 chr10 79988583 G A 2.98E-04 Coronary heart disease / / 21606135 rs1720285 chr10 79997370 C A 5.82E-04 HIV-1 viral setpoint / / 17641165 rs1720296 chr10 80023894 C T 1.58E-04 IgE levels / / 17255346 rs11002475 chr10 80031020 T C 1.66E-04 Cognitive decline / / 23732972 rs10762777 chr10 80052507 T C 8.61E-08 Metabolite levels / / 23281178 rs7902136 chr10 80066799 A G 9.52E-05 Serum metabolites / / 19043545 rs16935812 chr10 80080664 C T 0.0000418 Panic disorder / / 23149450 rs16935812 chr10 80080664 C T 4.18E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs7920472 chr10 80080866 C T 0.000037 Panic disorder / / 23149450 rs7920472 chr10 80080866 C T 3.70E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs1916400 chr10 80091338 T C 1.80E-04 Breast cancer / / pha002853 rs2395528 chr10 80100861 T C 6.00E-06 Conduct disorder (interaction) / / 18846501 rs10490996 chr10 80131442 G A 4.20E-04 Alcohol dependence / / 20201924 rs10490996 chr10 80131442 G A 8.99E-04 Substance dependence / / 21818250 rs719871 chr10 80145435 C T 8.20E-04 Alcohol dependence / / 20201924 rs7900379 chr10 80159210 C T 4.95E-04 Multiple complex diseases / / 17554300 rs989905 chr10 80203388 C T 6.80E-05 Lung adenocarcinoma / / 22797724 rs11002554 chr10 80203825 G A 5.77E-05 Receptive language ability / / 24687471 rs11002555 chr10 80203900 G T 8.04E-05 Receptive language ability / / 24687471 rs11002556 chr10 80204152 A C 6.15E-05 Receptive language ability / / 24687471 rs530106322 chr10 80204152 A AGG 6.15E-05 Receptive language ability / / 24687471 rs11002558 chr10 80205413 A G 7.39E-05 Receptive language ability / / 24687471 rs10824609 chr10 80206903 G A 8.07E-05 Receptive language ability / / 24687471 rs11002559 chr10 80207743 C A 6.64E-05 Receptive language ability / / 24687471 rs2578120 chr10 80212868 A G 6.39E-04 Multiple complex diseases / / 17554300 rs919888 chr10 80215287 C G 2.17E-04 Nicotine dependence / / 17158188 rs2670200 chr10 80222411 C A 2.66E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11597465 chr10 80230590 A G 2.71E-04 Type 2 diabetes / / 17463246 rs2570548 chr10 80231107 C T 4.33E-05 Receptive language ability / / 24687471 rs7074960 chr10 80259796 G A 1.82E-05 Osteoarthritis (knee and hip) / / 21177295 rs10509399 chr10 80312035 T C 8.12E-04 Alzheimer's disease / / 24755620 rs2019432 chr10 80312407 G A 9.50E-04 Alzheimer's disease / / 24755620 rs844429 chr10 80346386 T G 4.50E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs844429 chr10 80346386 T G 2.20E-04 Bipolar disorder / / 19259986 rs288444 chr10 80348121 G A 2.42E-04 Smoking initiation / / 24665060 rs16936151 chr10 80353927 A G 3.71E-04 Multiple complex diseases / / 17554300 rs16936151 chr10 80353927 A G 9.74E-04 Alzheimer's disease / / 17998437 rs1434432 chr10 80396850 T C 2.30E-05 Urinary metabolites / / 21572414 rs1434449 chr10 80401458 C A 1.70E-05 Urinary metabolites / / 21572414 rs10762795 chr10 80405937 G A 3.67E-04 Multiple complex diseases / / 17554300 rs10762795 chr10 80405937 G A 6.15E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs3916024 chr10 80465353 C A 9.63E-04 Acute lung injury / / 22295056 rs6480902 chr10 80487312 G A 3.90E-04 Obesity-related traits / / 17903300 rs7917285 chr10 80494182 G T 2.93E-05 Cardiovascular disease / / pha003065 rs892542 chr10 80498057 G A 8.90E-04 Aortic root size / / 21223598 rs35648 chr10 80501859 C T 9.65E-05 Schizophrenia / / 19571809 rs35648 chr10 80501859 C T 2.10E-05 Urinary metabolites / / 21572414 rs35648 chr10 80501859 C T 3.27E-05 Schizophrenia / / pha002857 rs2894386 chr10 80502208 C A 4.73E-04 Alzheimer's disease (late onset) / / 21379329 rs7900239 chr10 80515081 A G 9.00E-06 Migraine / / 23793025 rs10762798 chr10 80516313 G A 3.72E-04 Body mass index / / 21701565 rs638755 chr10 80530474 G A 5.95E-04 Parkinson's disease / / 17052657 rs637446 chr10 80530708 T C 3.23E-05 Gaucher disease severity / / 22388998 rs12783362 chr10 80540503 G A 2.50E-05 Urinary metabolites / / 21572414 rs12783362 chr10 80540503 G A 0.00042 Salmonella-induced pyroptosis / / 22837397 rs7913285 chr10 80558801 A C 0.000778091 Hypertension (early onset hypertension) / / 22479346 rs11002681 chr10 80560968 C T 0.000853852 Hypertension (early onset hypertension) / / 22479346 rs3910603 chr10 80600853 C A 1.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs11002703 chr10 80603677 G A 6.34E-04 Multiple complex diseases / / 17554300 rs570677 chr10 80622356 C T 7.80E-04 Atrial fibrillation / / 21846873 rs16936534 chr10 80628966 A C 5.69E-04 Multiple complex diseases / / 17554300 rs522549 chr10 80635863 G A 5.80E-05 Major depressive disorder / / 21621269 rs579958 chr10 80653442 T C 8.66E-04 Type 2 diabetes / / 17463246 rs10824663 chr10 80667478 T C 5.24E-04 Myopia (pathological) / / 21095009 rs11002726 chr10 80669894 C T 5.24E-04 Myopia (pathological) / / 21095009 rs11819353 chr10 80674984 G A 0.000391 Salmonella-induced pyroptosis / / 22837397 rs17463021 chr10 80693615 C T 2.23E-05 Alzheimer's disease (late onset) / / 21460841 rs1439037 chr10 80693725 T C 2.30E-05 Alzheimer's disease (late onset) / / 21460841 rs6480910 chr10 80694154 A T 2.13E-05 Alzheimer's disease (late onset) / / 21460841 rs11002743 chr10 80694496 G A 1.74E-05 Alzheimer's disease (late onset) / / 21460841 rs7918719 chr10 80695125 G C 7.90E-05 Response to citalopram treatment / / 19846067 rs7903856 chr10 80695173 T C 5.00E-05 Response to citalopram treatment / / 19846067 rs117450696 chr10 80702012 G A 1.98E-04 Acne (severe) / / 24927181 rs10824694 chr10 80758155 C T 3.58E-04 Response to alcohol consumption (flushing response) LOC283050 intron 24277619 rs10762827 chr10 80762481 C G 1.33E-05 Body mass index LOC283050 intron 23669352 rs10762833 chr10 80771220 A G 6.23E-05 Autism spectrum disorders (language delay) LOC283050 intron 21519539 rs7068603 chr10 80772541 C T 1.24E-04 Autism spectrum disorders (language delay) LOC283050 intron 21519539 rs7068603 chr10 80772541 C T 1.12E-05 Ankylosing spondylitis LOC283050 intron 22138694 rs16936710 chr10 80773372 G A 1.33E-04 Coronary heart disease LOC283050 intron 21606135 rs16936718 chr10 80779004 G A 6.15E-04 Coronary heart disease LOC283050 intron 21606135 rs10824705 chr10 80792528 C A 9.30E-08 Red blood cell traits LOC283050 intron 23222517 rs10762836 chr10 80793869 T G 5.28E-04 Coronary heart disease LOC283050 intron 21606135 rs3910578 chr10 80795378 A G 2.92E-04 Coronary heart disease LOC283050 intron 21606135 rs1946842 chr10 80797439 C T 3.47E-07 Red blood cell traits LOC283050 intron 23222517 rs10824708 chr10 80797523 A G 2.39E-04 Coronary heart disease LOC283050 intron 21606135 rs1946843 chr10 80797577 C A 2.41E-04 Coronary heart disease LOC283050 intron 21606135 rs1946844 chr10 80797602 C G 3.04E-04 Coronary heart disease LOC283050 intron 21606135 rs1439034 chr10 80798973 C A 2.39E-04 Coronary heart disease LOC283050 intron 21606135 rs11002792 chr10 80800377 G C 9.45E-05 Autism spectrum disorders (language delay) LOC283050 intron 21519539 rs10762840 chr10 80813333 G C 2.00E-05 Urinary metabolites LOC283050 intron 21572414 rs946719 chr10 80818256 T A 2.20E-05 Urinary metabolites LOC283050 intron 21572414 rs704017 chr10 80819132 A G 2.00E-08 Colorectal cancer LOC283050 intron 24836286 rs4980022 chr10 80834685 C T 4.95E-04 Smoking initiation ZMIZ1 intron 24665060 rs704010 chr10 80841148 T C 4.00E-09 Breast cancer ZMIZ1 intron 20453838 rs704010 chr10 80841148 T C 7.00E-22 Breast cancer ZMIZ1 intron 23535729 rs4980027 chr10 80843548 C A 7.51E-04 Response to TNF antagonist treatment ZMIZ1 intron 21061259 rs1250009 chr10 80845411 G A 1.60E-06 Breast cancer ZMIZ1 intron 20453838 rs1250005 chr10 80846608 T C 1.60E-06 Breast cancer ZMIZ1 intron 20453838 rs1250003 chr10 80846814 C T 1.60E-06 Breast cancer ZMIZ1 intron 20453838 rs1250000 chr10 80849336 A G 1.80E-06 Breast cancer ZMIZ1 intron 20453838 rs719338 chr10 80851257 G T 2.10E-06 Breast cancer ZMIZ1 intron 20453838 rs873823 chr10 80852602 G A 4.40E-06 Breast cancer ZMIZ1 intron 20453838 rs1250013 chr10 80853508 C T 3.56E-04 Amyotrophic lateral sclerosis (sporadic) ZMIZ1 intron 24529757 rs10762844 chr10 80855423 G A 8.50E-06 Breast cancer ZMIZ1 intron 20453838 rs11002811 chr10 80855650 G A 2.60E-06 Breast cancer ZMIZ1 intron 20453838 rs11002813 chr10 80857533 C T 3.40E-06 Breast cancer ZMIZ1 intron 20453838 rs11002813 chr10 80857533 C T 6.76E-04 Smoking cessation ZMIZ1 intron 24665060 rs11002814 chr10 80858473 G A 3.30E-06 Breast cancer ZMIZ1 intron 20453838 rs11002816 chr10 80858592 G A 3.30E-06 Breast cancer ZMIZ1 intron 20453838 rs11002824 chr10 80872483 C G 4.00E-06 Breast cancer ZMIZ1 intron 20453838 rs16936863 chr10 80873443 T G 4.00E-06 Breast cancer ZMIZ1 intron 20453838 rs17557872 chr10 80873608 A G 3.90E-06 Breast cancer ZMIZ1 intron 20453838 rs11002825 chr10 80873883 C A 4.00E-06 Breast cancer ZMIZ1 intron 20453838 rs11002826 chr10 80874092 G A 3.90E-06 Breast cancer ZMIZ1 intron 20453838 rs4336976 chr10 80878219 T C 4.18E-04 Type 2 diabetes ZMIZ1 intron 17463246 rs11002832 chr10 80880435 C G 5.10E-04 Type 2 diabetes ZMIZ1 intron 17463246 rs11002835 chr10 80880900 C A 7.78E-04 Type 2 diabetes ZMIZ1 intron 17463246 rs780153 chr10 80916381 C G 7.60E-06 Urinary metabolites ZMIZ1 intron 21572414 rs779932 chr10 80918572 G A 1.50E-06 Urinary metabolites ZMIZ1 intron 21572414 rs749821 chr10 80919442 G T 1.43E-04 Multiple complex diseases ZMIZ1 intron 17554300 rs749821 chr10 80919442 G T 0.000436 fMRI brain tests in schizophrenia ZMIZ1 intron 22440650 rs4980038 chr10 80920370 A G 0.000436 fMRI brain tests in schizophrenia ZMIZ1 intron 22440650 rs697241 chr10 80921864 A G 1.90E-05 Urinary metabolites ZMIZ1 UTR-5 21572414 rs1749824 chr10 80923862 C A 8.10E-05 End-stage renal disease ZMIZ1 intron 19929986 rs1749824 chr10 80923862 C A 6.50E-13 Meningococcal disease ZMIZ1 intron 20694013 rs1749824 chr10 80923862 C A 8.91E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZMIZ1 intron 20877124 rs7916441 chr10 80925577 G C 6.00E-10 Height ZMIZ1 intron 20881960 rs703992 chr10 80927651 C G 7.00E-07 Urinary metabolites ZMIZ1 intron 21572414 rs1815314 chr10 80928793 G A 2.20E-05 Urinary metabolites ZMIZ1 intron 21572414 rs703991 chr10 80929130 G A 1.80E-05 Urinary metabolites ZMIZ1 intron 21572414 rs703989 chr10 80931240 T A 8.74E-04 Multiple complex diseases ZMIZ1 intron 17554300 rs703989 chr10 80931240 T A 3.40E-06 Urinary metabolites ZMIZ1 intron 21572414 rs780151 chr10 80931481 G A 2.00E-09 Height ZMIZ1 intron 23563607 rs780151 chr10 80931481 G A 3.86E-05 Weight ZMIZ1 intron pha003026 rs10824726 chr10 80932607 T G 8.16E-05 Osteoarthritis (knee and hip) ZMIZ1 intron 21177295 rs10824726 chr10 80932607 T G 8.35E-06 Osteoarthritis (knee and hip) ZMIZ1 intron 21177295 rs780149 chr10 80934948 G C 9.00E-04 Multiple complex diseases ZMIZ1 intron 17554300 rs780148 chr10 80935083 G C 5.67E-05 Multiple complex diseases ZMIZ1 intron 17554300 rs780148 chr10 80935083 G C 4.66E-05 Bipolar disorder ZMIZ1 intron 21926972 rs810517 chr10 80942620 C T 1.79E-05 Multiple complex diseases ZMIZ1 intron 17554300 rs12571751 chr10 80942631 A G 0.00000064 Type 2 diabetes (males) ZMIZ1 intron 22885922 rs12571751 chr10 80942631 A G 0.0000012 Type 2 diabetes (females) ZMIZ1 intron 22885922 rs12571751 chr10 80942631 A G 1.00E-10 Type 2 diabetes ZMIZ1 intron 22885922 rs12571751 chr10 80942631 A G 2.00E-10 Type 2 diabetes ZMIZ1 intron 24509480 rs703982 chr10 80942721 A G 2.72E-05 Multiple complex diseases ZMIZ1 intron 17554300 rs703979 chr10 80944095 T C 1.27E-04 Osteoarthritis (knee and hip) ZMIZ1 intron 21177295 rs703979 chr10 80944095 T C 1.68E-06 Osteoarthritis (knee and hip) ZMIZ1 intron 21177295 rs703979 chr10 80944095 T C 2.15E-04 Osteoarthritis (knee and hip) ZMIZ1 intron 21177295 rs703979 chr10 80944095 T C 3.92E-04 Osteoarthritis (knee and hip) ZMIZ1 intron 21177295 rs703972 chr10 80952826 G C 1.72E-04 Attention deficit hyperactivity disorder ZMIZ1 intron pha002875 rs703970 chr10 80953136 A C 5.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) ZMIZ1 intron 23453885 rs703969 chr10 80953393 G C 6.09E-05 Serum metabolites ZMIZ1 intron 19043545 rs703965 chr10 80955067 C T 8.00E-06 Bipolar disorder ZMIZ1 intron 18711365 rs10128264 chr10 80959973 T C 1.00E-06 Response to methotrexate in juvenile idiopathic arthritis ZMIZ1 intron 24709693 rs2802369 chr10 80960828 C A 7.00E-06 Response to methotrexate in juvenile idiopathic arthritis ZMIZ1 intron 24709693 rs2490275 chr10 80962411 C T 1.53E-04 Multiple complex diseases ZMIZ1 intron 17554300 rs942794 chr10 80965109 T C 1.06E-05 Response to methotrexate in juvenile idiopathic arthritis ZMIZ1 intron 24709693 rs745417 chr10 80966678 C T 1.97E-04 Multiple complex diseases ZMIZ1 intron 17554300 rs1250590 chr10 80983786 C A 0.000641686 Hypertension (early onset hypertension) ZMIZ1 intron 22479346 rs1250592 chr10 80986678 A G 5.85E-04 Multiple complex diseases ZMIZ1 intron 17554300 rs11002892 chr10 81011589 C T 3.50E-05 Lipoprotein-associated phospholipase A2 activity and mass ZMIZ1 intron 20442857 rs11593576 chr10 81015896 C T 8.00E-07 Vitiligo ZMIZ1 intron 20526339 rs1250546 chr10 81032532 A G 3.00E-18 Inflammatory bowel disease ZMIZ1 intron 23128233 rs1250546 chr10 81032532 A G 0.00000068 Psoriasis ZMIZ1 intron 23143594 rs1250544 chr10 81032885 G A 7.00E-14 Crohn's disease and psoriasis ZMIZ1 intron 22482804 rs1250542 chr10 81034670 G A 4.00E-07 Multiple sclerosis ZMIZ1 intron 22190364 rs1250541 chr10 81034913 G C 1.07E-04 Multiple complex diseases ZMIZ1 intron 17554300 rs1250540 chr10 81036007 A G 2.00E-06 Multiple sclerosis ZMIZ1 intron 19525953 rs1250540 chr10 81036007 A G 3.90E-04 Multiple sclerosis ZMIZ1 intron 21833088 rs1250538 chr10 81037800 G T 1.32E-04 Multiple complex diseases ZMIZ1 intron 17554300 rs1892497 chr10 81043707 C T 5.42E-04 Multiple complex diseases ZMIZ1 intron 17554300 rs1250564 chr10 81047342 A C 2.25E-04 Multiple complex diseases ZMIZ1 intron 17554300 rs12355688 chr10 81055626 C T 6.00E-06 Breast cancer ZMIZ1 intron 23468962 rs7905321 chr10 81057833 G A 5.73E-04 Response to alcohol consumption (flushing response) ZMIZ1 intron 24277619 rs1250552 chr10 81058027 A G 7.34E-05 Cognitive test performance ZMIZ1 intron 20125193 rs1250552 chr10 81058027 A G 9.00E-10 Celiac disease ZMIZ1 intron 20190752 rs1250552 chr10 81058027 A G 9.00E-10 Asthma ZMIZ1 intron 21150878 rs1250552 chr10 81058027 A G 9.09E-10 Celiac disease and Rheumatoid arthritis ZMIZ1 intron 21383967 rs1250552 chr10 81058027 A G 8.00E-17 Celiac disease ZMIZ1 intron 22057235 rs1250552 chr10 81058027 A G 9.09E-10 Multiple sclerosis ZMIZ1 intron 22190364 rs1250552 chr10 81058027 A G 3.13E-06 Osteoarthritis ZMIZ1 intron 22763110 rs4246943 chr10 81060005 G A 3.21E-04 Multiple complex diseases ZMIZ1 intron 17554300 rs1250550 chr10 81060317 C A 6.00E-09 Inflammatory bowel disease (early onset) ZMIZ1 intron 19915574 rs1250550 chr10 81060317 C A 1.00E-30 Crohn's disease ZMIZ1 intron 21102463 rs1250550 chr10 81060317 C A 6.00E-09 Multiple sclerosis ZMIZ1 intron 21833088 rs1250550 chr10 81060317 C A 6.00E-09 Multiple sclerosis ZMIZ1 intron 22190364 rs12784800 chr10 81076941 C T 3.71E-06 Liver disease in chronic hepatitis B virus infection / / 24065354 rs11002926 chr10 81082290 A C 3.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs11002932 chr10 81094290 T G 8.17E-05 Elbow pain / / pha003008 rs16937080 chr10 81094702 T A 4.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs10762858 chr10 81100834 T C 3.70E-06 Urinary metabolites / / 21572414 rs2145998 chr10 81121696 T A 4.00E-13 Height / / 20881960 rs941873 chr10 81139462 G A 4.00E-07 Height / / 21998595 rs10824749 chr10 81159038 C T 8.27E-04 Multiple complex diseases ZCCHC24 intron 17554300 rs4980075 chr10 81163159 C G 2.62E-04 Type 2 diabetes ZCCHC24 intron 17463246 rs4980075 chr10 81163159 C G 8.43E-04 Multiple complex diseases ZCCHC24 intron 17554300 rs10824752 chr10 81169345 A G 2.39E-04 Insulin resistance ZCCHC24 intron 21901158 rs139656641 chr10 81185217 G A 3.46E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) ZCCHC24 intron 24159190 rs181715218 chr10 81185314 T C 3.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) ZCCHC24 intron 24159190 rs1885433 chr10 81191488 T C 9.04E-05 Cognitive test performance ZCCHC24 intron 20125193 rs7906077 chr10 81199376 C G 7.96E-04 Multiple complex diseases ZCCHC24 intron 17554300 rs1650169 chr10 81388196 G T 8.11E-04 Rheumatoid arthritis / / 21452313 rs7089956 chr10 81447620 T C 6.63E-04 Cognition,early reading ability / / 17684495 rs927452 chr10 81652266 G A 9.54E-04 Type 2 diabetes / / 17463246 rs927453 chr10 81652369 C T 8.39E-04 Type 2 diabetes / / 17463246 rs7911085 chr10 81685270 G A 6.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100288974 intron 20877124 rs7911085 chr10 81685270 G A 4.30E-05 Bipolar disorder and schizophrenia LOC100288974 intron 20889312 rs7911085 chr10 81685270 G A 8.30E-06 Urinary metabolites LOC100288974 intron 21572414 rs7911085 chr10 81685270 G A 9.56E-05 Coronary heart disease LOC100288974 intron 21606135 rs7911085 chr10 81685270 G A 1.40E-04 Rheumatoid arthritis LOC100288974 intron 22446963 rs12256689 chr10 81685656 C T 7.67E-05 Bipolar disorder and schizophrenia LOC100288974 intron 20889312 rs2758556 chr10 81690985 A C 4.84E-04 Type 2 diabetes LOC100288974 intron 17463246 rs1923539 chr10 81694950 G A 5.00E-09 Chronic obstructive pulmonary disease-related biomarkers / / 23144326 rs4469829 chr10 81697811 C T 0.000028 Coronary artery calcification SFTPD missense 23727086 rs7078012 chr10 81705433 C T 5.00E-09 Chronic obstructive pulmonary disease-related biomarkers SFTPD intron 23144326 rs721917 chr10 81706324 A G 0.000023 Coronary artery calcification SFTPD missense 23727086 rs726288 chr10 81706973 C T 1.60E-05 Rheumatoid arthritis SFTPD intron 24390342 rs726288 chr10 81706973 C T 9.00E-09 Rheumatoid arthritis SFTPD intron 24390342 rs12770776 chr10 81709544 A G 6.27E-04 Alzheimer's disease / / 24755620 rs10887233 chr10 81715352 C G 2.69E-04 Parkinson's disease / / 16252231 rs11200982 chr10 81732349 A T 6.42E-04 Multiple complex diseases / / 17554300 rs10788338 chr10 81733022 A C 4.63E-04 Type 2 diabetes / / 17463246 rs4255480 chr10 81735888 T C 4.69E-05 Multiple complex diseases / / 17554300 rs3923564 chr10 81735981 A G 2.00E-27 Chronic obstructive pulmonary disease-related biomarkers / / 23144326 rs2341958 chr10 81759954 G A 4.52E-04 Type 2 diabetes / / 17463246 rs7070394 chr10 81767388 A G 4.92E-04 Alzheimer's disease (late onset) / / 21379329 rs12220777 chr10 81788104 T C 7.00E-11 Chronic obstructive pulmonary disease-related biomarkers / / 23144326 rs7083625 chr10 81788837 C A 6.02E-05 Alzheimer's disease (late onset) / / 21379329 rs2342606 chr10 81794163 T C 3.92E-04 Alzheimer's disease (late onset) / / 21379329 rs7087123 chr10 81805246 T C 1.05E-04 Alzheimer's disease (late onset) / / 21379329 rs12146166 chr10 81811580 G A 1.60E-06 Alzheimer's disease (late onset) LOC219347 intron 21379329 rs4478933 chr10 81811672 A G 4.02E-04 Alzheimer's disease (late onset) LOC219347 intron 21379329 rs10887432 chr10 81812036 A G 3.73E-04 Alzheimer's disease (late onset) LOC219347 intron 21379329 rs10887450 chr10 81816940 T C 3.61E-04 Alzheimer's disease (late onset) LOC219347 intron 21379329 rs10788432 chr10 81817843 G A 3.61E-04 Alzheimer's disease (late onset) LOC219347 intron 21379329 rs10887466 chr10 81828410 A G 3.85E-04 Alzheimer's disease (late onset) LOC219347 intron 21379329 rs728616 chr10 81847914 G T 2.00E-12 Chronic obstructive pulmonary disease-related biomarkers C10orf57 intron 23144326 rs2342610 chr10 81859756 A G 1.06E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3851050 chr10 81882370 T C 1.00E-11 Chronic obstructive pulmonary disease-related biomarkers / / 23144326 rs2789698 chr10 81895970 A G 6.79E-05 Sarcoidosis PLAC9 intron 19165924 rs2819878 chr10 81900893 T C 1.25E-05 Sarcoidosis PLAC9 intron 19165924 rs3762097 chr10 81901375 C A 0.0000904 Sarcoidosis PLAC9 intron 22952805 rs745182 chr10 81901722 C T 1.12E-06 Sarcoidosis PLAC9 intron 19165924 rs2789648 chr10 81902315 G A 0.0000477 Sarcoidosis PLAC9 intron 22952805 rs2784770 chr10 81907268 C T 0.00006158 Sarcoidosis / / 22952805 rs2789679 chr10 81907884 A T 3.02E-13 Sarcoidosis / / 19165924 rs2789679 chr10 81907884 A T 0.00003604 Sarcoidosis / / 22952805 rs2789681 chr10 81908130 C G 2.80E-06 Type 2 diabetes / / 21647700 rs7071579 chr10 81910278 A G 4.65E-07 Sarcoidosis / / 19165924 rs1953600 chr10 81911725 C T 2.90E-14 Sarcoidosis / / 19165924 rs1953600 chr10 81911725 C T 1.00E-06 Sarcoidosis / / 22936702 rs1953600 chr10 81911725 C T 0.00008153 Sarcoidosis / / 22952805 rs7091565 chr10 81913561 C T 2.70E-07 Sarcoidosis / / 19165924 rs3748242 chr10 81914787 C T 0.000000519 Coronary artery disease / / 23202125 rs2789686 chr10 81915136 T C 8.47E-07 Multiple complex diseases ANXA11 UTR-3 17554300 rs2789686 chr10 81915136 T C 9.97E-05 Sarcoidosis ANXA11 UTR-3 19165924 rs2789686 chr10 81915136 T C 1.40E-05 Alcoholism (heaviness of drinking) ANXA11 UTR-3 21529783 rs2573346 chr10 81918041 G A 9.99E-16 Sarcoidosis ANXA11 intron 19165924 rs2784773 chr10 81919800 T C 3.17E-07 Sarcoidosis ANXA11 intron 19165924 rs2245168 chr10 81921918 T C 0.0000227 Sarcoidosis ANXA11 intron 22952805 rs2236557 chr10 81923961 G A 0.00002332 Sarcoidosis ANXA11 intron 22952805 rs1049550 chr10 81926702 G A 1.04E-12 Sarcoidosis ANXA11 missense 19165924 rs1049550 chr10 81926702 G A 9.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) ANXA11 missense 21239504 rs1049550 chr10 81926702 G A 0.000023 Sarcoidosis ANXA11 missense 22952805 rs2236556 chr10 81932790 T C 0.00002479 Sarcoidosis ANXA11 intron 22952805 rs6585424 chr10 81933748 A G 1.00E-10 Chronic obstructive pulmonary disease-related biomarkers ANXA11 intron 23144326 rs2819952 chr10 81934324 T C 0.00002479 Sarcoidosis ANXA11 intron 22952805 rs2788296 chr10 81937889 G A 0.00001886 Sarcoidosis ANXA11 intron 22952805 rs2789690 chr10 81938204 G T 0.00002055 Sarcoidosis ANXA11 intron 22952805 rs2573352 chr10 81939813 T C 0.00002055 Sarcoidosis ANXA11 intron 22952805 rs2573353 chr10 81940917 C A 0.00002055 Sarcoidosis ANXA11 intron 22952805 rs2788295 chr10 81941007 C G 0.00002055 Sarcoidosis ANXA11 intron 22952805 rs2789695 chr10 81946840 C T 0.00002633 Sarcoidosis ANXA11 intron 22952805 rs2573356 chr10 81949363 C T 0.00002633 Sarcoidosis ANXA11 intron 22952805 rs2573370 chr10 81951366 C T 0.00002633 Sarcoidosis ANXA11 intron 22952805 rs2819946 chr10 81951635 G A 0.00003663 Sarcoidosis ANXA11 intron 22952805 rs3098105 chr10 81953266 C T 0.00004245 Sarcoidosis ANXA11 intron 22952805 rs11202051 chr10 81953371 A G 0.00003695 Sarcoidosis ANXA11 intron 22952805 rs12770550 chr10 81953451 G T 0.00004586 Sarcoidosis ANXA11 intron 22952805 rs2573338 chr10 81996971 T C 4.25E-04 Alzheimer's disease (late onset) / / 21379329 rs1556893 chr10 82024042 A C 2.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3851059 chr10 82030658 G A 3.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3827869 chr10 82031278 C T 3.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAT1A nearGene-3 20877124 rs7087728 chr10 82033470 G A 2.10E-04 Height MAT1A UTR-3 21194676 rs7087728 chr10 82033470 G A 9.10E-07 Height MAT1A UTR-3 21194676 rs4934027 chr10 82035560 C T 4.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAT1A intron 20877124 rs2282367 chr10 82040346 A G 3.52E-04 Alzheimer's disease (late onset) MAT1A intron 21379329 rs756208 chr10 82041751 A G 3.61E-04 Alzheimer's disease (late onset) MAT1A intron 21379329 rs7901686 chr10 82051123 G A 4.08E-08 Cholesterol,total MAT1A nearGene-5 23063622 rs7096757 chr10 82075993 G A 6.47E-04 Alzheimer's disease / / 22005930 rs17103728 chr10 82118408 G A 7.58E-04 Alzheimer's disease DYDC2 intron 22005930 rs4934134 chr10 82160582 C T 6.76E-04 Multiple complex diseases / / 17554300 rs7916618 chr10 82189686 T C 5.92E-04 Type 2 diabetes FAM213A intron 17463246 rs10887933 chr10 82223767 A G 7.64E-04 Multiple complex diseases TSPAN14 intron 17554300 rs6586030 chr10 82254047 A G 9.00E-16 Inflammatory bowel disease TSPAN14 intron 23128233 rs9633740 chr10 82265271 A G 9.20E-04 Alzheimer's disease TSPAN14 intron 22005930 rs1870137 chr10 82269848 C G 9.20E-04 Alzheimer's disease TSPAN14 intron 22005930 rs10748526 chr10 82273079 T C 4.45E-04 Alzheimer's disease TSPAN14 intron 22005930 rs1878036 chr10 82280137 T G 4.76E-04 Alzheimer's disease TSPAN14 UTR-3 22005930 rs17106475 chr10 82284306 A G 1.11E-04 Ovarian cancer in BRCA1 mutation carriers / / 23544013 rs7096909 chr10 82284512 A T 3.59E-04 Multiple complex diseases / / 17554300 rs7096909 chr10 82284512 A T 1.50E-04 Alzheimer's disease / / 22005930 rs6586051 chr10 82288177 A G 6.65E-05 Lung adenocarcinoma / / 19836008 rs6586051 chr10 82288177 A G 3.00E-04 Polycystic ovary syndrome / / 22178785 rs1870136 chr10 82307117 C T 1.43E-04 Birth weight SH2D4B intron 17255346 rs12257493 chr10 82331231 T C 0.00056 Breast cancer SH2D4B missense 23555315 rs77983942 chr10 82331296 G T 0.00056 Breast cancer SH2D4B missense 23555315 rs7894923 chr10 82338336 G T 9.79E-05 Lung adenocarcinoma SH2D4B intron 19836008 rs11186149 chr10 82340707 T C 9.47E-04 Multiple complex diseases SH2D4B intron 17554300 rs11186149 chr10 82340707 T C 6.46E-07 Gallstones SH2D4B intron 17632509 rs6586091 chr10 82347954 T A 7.72E-04 Alzheimer's disease SH2D4B intron 17998437 rs11186218 chr10 82355975 G A 5.79E-04 Multiple complex diseases SH2D4B intron 17554300 rs17693104 chr10 82368221 T C 6.89E-05 Smoking initiation SH2D4B intron 24665060 rs4933462 chr10 82372612 A G 8.78E-04 Type 2 diabetes SH2D4B intron 17463246 rs4934371 chr10 82372795 C T 9.21E-04 Type 2 diabetes SH2D4B intron 17463246 rs6586111 chr10 82377590 T C 7.00E-06 Capecitabine sensitivity SH2D4B intron 22864933 rs12220111 chr10 82379403 A G 1.98E-04 Myopia (pathological) SH2D4B intron 21095009 rs7067934 chr10 82380665 A G 3.46E-04 Alzheimer's disease (late onset) SH2D4B intron 21379329 rs6586112 chr10 82381181 T G 1.93E-04 Prostate cancer mortality SH2D4B intron 20978177 rs7099231 chr10 82389526 G T 9.62E-04 Prostate cancer mortality SH2D4B intron 20978177 rs7099231 chr10 82389526 G T 1.39E-05 Receptive language ability SH2D4B intron 24687471 rs1157794 chr10 82423260 A G 1.49E-04 Multiple complex diseases / / 17554300 rs7904536 chr10 82424127 A C 1.25E-05 Cognitive performance / / 19734545 rs17107480 chr10 82427223 G A 5.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs7079135 chr10 82428121 G T 4.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs12255425 chr10 82431413 A G 3.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs9971172 chr10 82431787 G A 1.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs17107524 chr10 82448181 A G 1.43E-04 Multiple complex diseases / / 17554300 rs4934419 chr10 82454295 A G 2.13E-04 Body mass index / / 17255346 rs4934419 chr10 82454295 A G 5.23E-05 Cortisol secretion,in saliva / / 21316860 rs4934419 chr10 82454295 A G 7.20E-05 Body Mass Index / / pha003006 rs10509415 chr10 82473065 A C 4.24E-04 Alzheimer's disease / / 17998437 rs4454661 chr10 82476615 A T 3.14E-04 Alzheimer's disease / / 17998437 rs1647210 chr10 82497699 A C 1.36E-04 Alzheimer's disease / / 17998437 rs1647219 chr10 82510802 C T 1.97E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs11598010 chr10 82545771 A G 5.55E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs11592834 chr10 82561348 T C 2.82E-06 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7922583 chr10 82633595 G A 2.91E-05 Multiple complex diseases / / 17554300 rs1876331 chr10 82655429 A G 2.40E-05 Urinary metabolites / / 21572414 rs7898653 chr10 82671815 A T 1.50E-05 Urinary metabolites / / 21572414 rs4933622 chr10 82672226 G A 3.96E-05 Serum metabolites / / 19043545 rs17622849 chr10 82673802 A G 1.70E-05 Urinary metabolites / / 21572414 rs10882367 chr10 82694988 A G 9.61E-04 Alzheimer's disease / / 17998437 rs1484170 chr10 82699491 T C 1.00E-06 Cardiac hypertrophy / / 21348951 rs10509420 chr10 82706117 T C 8.37E-04 Multiple complex diseases / / 17554300 rs12772949 chr10 82708724 A G 2.14E-06 Ankle-brachial index / / 22199011 rs12770949 chr10 82708869 G A 1.70E-05 Iron levels / / 21208937 rs10786153 chr10 82715718 C G 7.26E-08 Metabolite levels / / 23281178 rs9988765 chr10 82715797 T C 0.0000682 Polycystic ovary syndrome / / 22951595 rs9988765 chr10 82715797 T C 6.82E-05 Intracranial aneurysm / / 22961961 rs11187807 chr10 82721134 C A 5.90E-08 Metabolite levels / / 23281178 rs10786160 chr10 82736947 T G 2.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10882485 chr10 82764392 T C 2.83E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10882485 chr10 82764392 T C 5.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6583803 chr10 82796630 G C 2.17E-04 Multiple complex diseases / / 17554300 rs6583816 chr10 82829441 G A 1.39E-04 Type 2 diabetes / / 17463246 rs264322 chr10 82843509 A G 6.80E-04 Aortic root size / / 21223598 rs7068956 chr10 82863294 G A 1.90E-04 Lung function (forced vital capacity) / / 24023788 rs17097249 chr10 82868149 G A 2.03E-04 Lung function (forced vital capacity) / / 24023788 rs7922505 chr10 82946940 C A 9.41E-05 Response to methotrexate in juvenile idiopathic arthritis / / 24709693 rs7922505 chr10 82946940 C A 7.46E-05 Elbow pain / / pha003008 rs1932904 chr10 82965745 A T 5.85E-04 Multiple complex diseases / / 17554300 rs10882846 chr10 82984432 T C 1.17E-05 Cognitive performance / / 19734545 rs11189017 chr10 83018377 T G 8.19E-09 Narcolepsy / / 19629137 rs7072513 chr10 83018714 G T 1.46E-05 Cognitive performance / / 19734545 rs11189305 chr10 83066431 G A 8.57E-05 Blood pressure / / 17255346 rs11189443 chr10 83095232 A G 1.63E-04 Multiple complex diseases / / 17554300 rs510550 chr10 83127985 A G 3.48E-05 Alcohol consumption / / 23743675 rs1854463 chr10 83131664 G T 2.53E-04 Blood pressure / / 17255346 rs1854463 chr10 83131664 G T 4.25E-04 Multiple complex diseases / / 17554300 rs265499 chr10 83144287 A T 2.67E-04 Blood pressure / / 17255346 rs588517 chr10 83153246 T C 1.55E-04 Blood pressure / / 17255346 rs588517 chr10 83153246 T C 8.00E-06 Carotid atherosclerosis in HIV infection / / 20009918 rs1576305 chr10 83172809 T C 3.16E-05 Lactate dehydrogenase levels / / 20981236 rs1329202 chr10 83188768 T C 9.76E-05 Cognitive test performance / / 20125193 rs1329202 chr10 83188768 T C 8.30E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1329202 chr10 83188768 T C 9.12E-06 Retinopathy in non-diabetics / / 23393555 rs1329201 chr10 83188953 C T 8.00E-06 Retinopathy in non-diabetics / / 23393555 rs4933782 chr10 83189180 C T 4.84E-05 Body Mass Index / / pha002896 rs12260387 chr10 83191741 A T 8.56E-06 Retinopathy in non-diabetics / / 23393555 rs11189862 chr10 83192498 G A 1.59E-04 Blood pressure / / 17255346 rs1329198 chr10 83194773 T C 8.82E-04 Depression (quantitative trait) / / 20800221 rs10883236 chr10 83199854 A G 2.54E-05 Cognitive test performance / / 20125193 rs11813825 chr10 83204099 T C 4.93E-06 Serum metabolites / / 19043545 rs4933784 chr10 83212826 C T 0.000223155 Hypertension (early onset hypertension) / / 22479346 rs11190001 chr10 83219473 G A 1.33E-05 Serum metabolites / / 19043545 rs10453985 chr10 83240443 C T 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11190089 chr10 83245222 T C 6.18E-05 Body Mass Index / / pha002896 rs11190089 chr10 83245222 T C 2.04E-05 HDL cholesterol / / pha003074 rs10883392 chr10 83266874 C T 0.000770443 Hypertension (early onset hypertension) / / 22479346 rs9332404 chr10 83273315 C T 0.000899808 Hypertension (early onset hypertension) / / 22479346 rs7917905 chr10 83287387 C A 3.85E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7918647 chr10 83392668 C T 7.60E-04 Premature ovarian failure / / 19508998 rs17710692 chr10 83393187 G A 5.46E-04 Multiple complex diseases / / 17554300 rs9787485 chr10 83566686 C T 4.00E-08 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs9787485 chr10 83566686 C T 5.00E-08 Fasting insulin (interaction) / / 24204828 rs2207657 chr10 83602560 T C 8.22E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs2207658 chr10 83602603 A G 4.22E-04 Sudden cardiac arrest / / 21658281 rs10883825 chr10 83608508 T C 3.43E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs6584391 chr10 83653738 T C 1.41E-04 Sudden cardiac arrest NRG3 intron 21658281 rs10883934 chr10 83689496 A G 3.10E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) NRG3 intron 24023788 rs12241007 chr10 83689509 C G 9.97E-04 Multiple complex diseases NRG3 intron 17554300 rs12241007 chr10 83689509 C G 4.10E-05 Bipolar disorder and schizophrenia NRG3 intron 20889312 rs2281471 chr10 83690009 G A 5.83E-04 Multiple complex diseases NRG3 intron 17554300 rs982245 chr10 83696599 A G 3.50E-04 Taste perception NRG3 intron 22132133 rs10786787 chr10 83730893 G A 6.39E-04 Taste perception NRG3 intron 22132133 rs2224109 chr10 83734145 A G 7.08E-04 Taste perception NRG3 intron 22132133 rs1121444 chr10 83734262 C T 7.97E-04 Taste perception NRG3 intron 22132133 rs10509440 chr10 83736634 G A 2.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) NRG3 intron 17982456 rs7069222 chr10 83756102 G A 5.46E-04 Taste perception NRG3 intron 22132133 rs10884019 chr10 83757021 G A 8.01E-05 Multiple complex diseases NRG3 intron 17554300 rs6584459 chr10 83764504 T C 2.74E-04 Self-reported allergy NRG3 intron 23817569 rs4933819 chr10 83764742 A G 9.22E-04 Alzheimer's disease NRG3 intron 22005930 rs932521 chr10 83764903 T C 2.20E-04 Self-reported allergy NRG3 intron 23817569 rs11192141 chr10 83765599 G A 5.56E-08 LDL cholesterol NRG3 intron 23063622 rs10736168 chr10 83766645 A C 1.95E-04 Self-reported allergy NRG3 intron 23817569 rs2207780 chr10 83767771 G A 7.97E-04 Alzheimer's disease NRG3 intron 22005930 rs7083860 chr10 83769291 C A 2.72E-04 Self-reported allergy NRG3 intron 23817569 rs12258934 chr10 83774835 T C 1.44E-11 LDL cholesterol NRG3 intron 23063622 rs12258934 chr10 83774835 T C 4.07E-15 Cholesterol,total NRG3 intron 23063622 rs12258934 chr10 83774835 T C 9.05E-12 Triglycerides NRG3 intron 23063622 rs2207775 chr10 83774998 G A 9.80E-04 Alzheimer's disease NRG3 intron 22005930 rs3903435 chr10 83776457 C A 5.59E-04 Alzheimer's disease NRG3 intron 22005930 rs9664256 chr10 83777755 C T 1.08E-04 Alzheimer's disease NRG3 intron 22005930 rs10748870 chr10 83784431 T A 7.68E-05 Self-reported allergy NRG3 intron 23817569 rs7068239 chr10 83786851 A G 6.29E-05 Self-reported allergy NRG3 intron 23817569 rs2207774 chr10 83787964 C G 4.87E-05 Self-reported allergy NRG3 intron 23817569 rs10786833 chr10 83789289 A G,T 4.59E-05 Self-reported allergy NRG3 intron 23817569 rs10884059 chr10 83789442 G A 6.13E-04 Alzheimer's disease NRG3 intron 22005930 rs17727747 chr10 83790082 A G 6.73E-04 Alzheimer's disease NRG3 intron 22005930 rs7342133 chr10 83790207 G A 6.67E-04 Alzheimer's disease NRG3 intron 22005930 rs12248199 chr10 83792229 G A 1.14E-09 LDL cholesterol NRG3 intron 23063622 rs12248199 chr10 83792229 G A 8.35E-09 Cholesterol,total NRG3 intron 23063622 rs2207773 chr10 83793043 C T 9.08E-04 Alzheimer's disease NRG3 intron 22005930 rs7072061 chr10 83796554 G C 4.74E-04 Multiple complex diseases NRG3 intron 17554300 rs4933824 chr10 83819125 T G 2.00E-06 Response to iloperidone treatment (QT prolongation) NRG3 intron 18521091 rs7091584 chr10 83821235 T C 0.00041 Coronary artery calcification NRG3 intron 23727086 rs17099306 chr10 83823289 A C 6.69E-04 Suicide attempts in bipolar disorder NRG3 intron 21423239 rs2347335 chr10 83824273 A G 1.99E-04 Response to cytadine analogues (cytosine arabinoside) NRG3 intron 24483146 rs2347335 chr10 83824273 A G 3.97E-06 Erythrocyte counts NRG3 intron pha003090 rs7074858 chr10 83829870 T G 8.31E-07 Erythrocyte counts NRG3 intron pha003090 rs11192402 chr10 83835232 C A 7.00E-06 Asthma NRG3 intron 21790008 rs11192402 chr10 83835232 C A 3.81E-05 Erythrocyte counts NRG3 intron pha003090 rs1884361 chr10 83840542 C T 7.56E-06 Erythrocyte counts NRG3 intron pha003090 rs926929 chr10 83847988 A G 9.30E-04 Response to cytadine analogues (cytosine arabinoside) NRG3 intron 24483146 rs7895300 chr10 83850959 C G,T 9.02E-10 HDL cholesterol NRG3 intron 23063622 rs2144393 chr10 83851010 G A 7.95E-05 Response to cytadine analogues (cytosine arabinoside) NRG3 intron 24483146 rs1024192 chr10 83852193 C T 3.01E-05 Erythrocyte counts NRG3 intron pha003090 rs10490935 chr10 83853792 C T 4.88E-05 Cognitive impairment induced by topiramate NRG3 intron 22091778 rs1649947 chr10 83874965 T G 2.00E-04 Cognitive impairment induced by topiramate NRG3 intron 22091778 rs1649947 chr10 83874965 T G 2.60E-05 Cognitive impairment induced by topiramate NRG3 intron 22091778 rs765833 chr10 83880748 G C 3.29E-05 Type 2 diabetes NRG3 intron 17463246 rs765833 chr10 83880748 G C 4.00E-05 Prostate cancer NRG3 intron 21743057 rs2434065 chr10 83893143 A C 4.00E-05 Prostate cancer NRG3 intron 21743057 rs1649949 chr10 83916424 T C 3.75E-04 Endometrial cancer NRG3 intron 24096698 rs1649949 chr10 83916424 T C 7.85E-05 Endometrial cancer NRG3 intron 24096698 rs7081526 chr10 83922404 G A 9.96E-08 HDL cholesterol NRG3 intron 23063622 rs7908131 chr10 83966320 A G 6.45E-05 Serum metabolites NRG3 intron 19043545 rs12255719 chr10 83974087 T C 2.60E-05 Urinary metabolites NRG3 intron 21572414 rs10884342 chr10 83974586 G A 2.80E-04 Suicide attempts in bipolar disorder NRG3 intron 21423239 rs1474 chr10 83974642 C G 5.22E-04 Suicide attempts in bipolar disorder NRG3 intron 21423239 rs7084937 chr10 83993404 G A 1.55E-04 Smoking initiation NRG3 intron 24665060 rs12250735 chr10 83993705 G A 1.96E-04 Smoking quantity NRG3 intron 24665060 rs17099655 chr10 84003687 G A 9.00E-04 Coronary heart disease NRG3 intron 21966275 rs17657851 chr10 84013849 A G 0.0000292 Triglycerides NRG3 intron 23063622 rs1336274 chr10 84028864 A G 0.0000711 Triglycerides NRG3 intron 23063622 rs4329625 chr10 84035428 C T 2.92E-05 Rheumatoid arthritis (ACPA-negative) NRG3 intron 24532677 rs10884461 chr10 84039976 G A 7.91E-04 Multiple complex diseases NRG3 intron 17554300 rs2225809 chr10 84051375 G A 2.65E-04 Multiple complex diseases NRG3 intron 17554300 rs2225809 chr10 84051375 G A 8.18E-05 Asthma NRG3 intron pha003128 rs1414760 chr10 84054575 C T 2.85E-04 Multiple complex diseases NRG3 intron 17554300 rs10787027 chr10 84055311 G T 3.28E-04 Multiple complex diseases NRG3 intron 17554300 rs7921512 chr10 84056017 G A 3.24E-04 Multiple complex diseases NRG3 intron 17554300 rs7921512 chr10 84056017 G A 3.00E-04 Pancreatic cancer NRG3 intron 20484958 rs7097003 chr10 84065840 G A 8.00E-05 Prostate cancer NRG3 intron 21743057 rs3908834 chr10 84078217 C T 9.48E-04 Type 2 diabetes NRG3 intron 17463246 rs11193681 chr10 84078992 C T 9.19E-04 Type 2 diabetes NRG3 intron 17463246 rs12265675 chr10 84079745 A G 8.24E-04 Multiple complex diseases NRG3 intron 17554300 rs11193797 chr10 84093995 C T 5.39E-04 Multiple complex diseases NRG3 intron 17554300 rs4933836 chr10 84137873 C T 9.50E-05 Erythrocyte counts NRG3 intron pha003099 rs1317008 chr10 84149290 C T 7.11E-05 Glucose levels NRG3 intron pha002899 rs1937984 chr10 84152990 A G 8.14E-05 Glucose levels NRG3 intron pha002899 rs7095137 chr10 84158548 A G 8.28E-04 Diabetic retinopathy NRG3 intron 20871662 rs7069578 chr10 84179887 G A 8.09E-05 Glucose levels NRG3 intron pha002899 rs7909484 chr10 84206002 C T 4.73E-05 Hemoglobin NRG3 intron pha003098 rs7909484 chr10 84206002 C T 1.65E-05 Erythrocyte counts NRG3 intron pha003099 rs7909484 chr10 84206002 C T 4.94E-05 Asthma NRG3 intron pha003128 rs1937970 chr10 84223466 A G 7.37E-04 Alcohol dependence NRG3 intron 24277619 rs4480481 chr10 84249319 C G 2.70E-05 Urinary metabolites NRG3 intron 21572414 rs612371 chr10 84290562 T C 4.67E-04 Obesity (extreme) NRG3 intron 21935397 rs1481126 chr10 84300443 T C 8.63E-04 Obesity (extreme) NRG3 intron 21935397 rs664183 chr10 84307038 T C 7.55E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) NRG3 intron 24023788 rs661469 chr10 84386093 G A 3.26E-04 Cholesterol NRG3 intron 17255346 rs673049 chr10 84386973 T C 9.68E-04 Suicide attempts in bipolar disorder NRG3 intron 21423239 rs10885058 chr10 84389839 G A 5.07E-04 Suicide attempts in bipolar disorder NRG3 intron 21423239 rs10787290 chr10 84392385 G A 5.05E-04 Suicide attempts in bipolar disorder NRG3 intron 21423239 rs2219938 chr10 84395383 C T 2.85E-04 Suicide attempts in bipolar disorder NRG3 intron 21423239 rs10736213 chr10 84397271 G T 5.57E-04 Suicide attempts in bipolar disorder NRG3 intron 21423239 rs10787305 chr10 84411902 G A 6.03E-04 Suicide attempts in bipolar disorder NRG3 intron 21423239 rs11195424 chr10 84412303 G T 4.40E-04 Suicide attempts in bipolar disorder NRG3 intron 21423239 rs2219937 chr10 84419410 G A 4.00E-06 IgG glycosylation NRG3 intron 23382691 rs12358612 chr10 84429842 C T 3.65E-04 Alzheimer's disease NRG3 intron 24755620 rs6584870 chr10 84431179 C T 7.31E-04 Suicide attempts in bipolar disorder NRG3 intron 21423239 rs2783418 chr10 84488447 C G 2.50E-06 Urinary metabolites NRG3 intron 21572414 rs914818 chr10 84579357 G C 9.64E-06 Glycemic traits (pregnancy) NRG3 intron 23903356 rs4360649 chr10 84661601 A G 5.53E-06 Elbow pain NRG3 intron pha003008 rs7079963 chr10 84666953 T G 1.16E-05 Elbow pain NRG3 intron pha003008 rs11819224 chr10 84669803 T C 6.72E-06 Elbow pain NRG3 intron pha003008 rs580293 chr10 84678303 T C 4.42E-05 Magnesium levels NRG3 intron pha003092 rs17101073 chr10 84679680 A G 8.36E-05 Alzheimer's disease NRG3 intron 21098978 rs12416404 chr10 84685218 C T 5.61E-05 Response to tocilizumab in rheumatoid arthritis NRG3 intron 22491018 rs7078771 chr10 84689060 G A 4.27E-108 Multiple complex diseases NRG3 intron 17554300 rs11814517 chr10 84691965 A T 5.67E-05 Alzheimer's disease NRG3 intron 21098978 rs17101125 chr10 84693490 G A 5.45E-05 Alzheimer's disease NRG3 intron 21098978 rs10509462 chr10 84698205 C T 4.35E-05 Alzheimer's disease NRG3 intron 21098978 rs17101130 chr10 84698466 C A 4.31E-05 Alzheimer's disease NRG3 intron 21098978 rs7069185 chr10 84716523 C T 2.31E-05 Alzheimer's disease NRG3 intron 21098978 rs17101139 chr10 84718677 A G 2.28E-05 Alzheimer's disease NRG3 intron 21098978 rs11815363 chr10 84722658 T C 2.25E-05 Alzheimer's disease NRG3 intron 21098978 rs11816685 chr10 84722879 G A 2.23E-05 Alzheimer's disease NRG3 intron 21098978 rs6585083 chr10 84732356 T G 5.09E-04 Suicide attempts in bipolar disorder NRG3 intron 21423239 rs6585084 chr10 84733869 T C 6.37E-04 Suicide attempts in bipolar disorder NRG3 intron 21423239 rs11819041 chr10 84734829 T C 1.85E-05 Alzheimer's disease NRG3 intron 21098978 rs17101164 chr10 84737404 A C 1.70E-05 Alzheimer's disease NRG3 intron 21098978 rs4259774 chr10 84737559 T C 6.74E-04 Suicide attempts in bipolar disorder NRG3 intron 21423239 rs999799 chr10 84738992 T C 1.61E-05 Alzheimer's disease NRG3 intron 21098978 rs17101193 chr10 84744926 C A 1.62E-05 Alzheimer's disease NRG3 missense 21098978 rs17101196 chr10 84745040 A G 1.62E-05 Alzheimer's disease NRG3 cds-synon 21098978 rs3763704 chr10 84746576 C T 7.53E-04 Suicide attempts in bipolar disorder NRG3 UTR-3 21423239 rs4332464 chr10 84748031 A G 7.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs6585104 chr10 84749512 A G 7.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs7909420 chr10 84751592 A G 1.63E-05 Alzheimer's disease / / 21098978 rs11196770 chr10 84752873 A C 6.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs17101209 chr10 84755180 A G 1.63E-05 Alzheimer's disease / / 21098978 rs17689242 chr10 84758939 G T 5.66E-05 Pancreatic cancer / / pha002874 rs17101227 chr10 84767618 C G 1.80E-05 Alzheimer's disease / / 21098978 rs4365000 chr10 84790455 C T 6.50E-06 Urinary metabolites / / 21572414 rs11197065 chr10 84813142 T C 5.20E-06 Urinary metabolites / / 21572414 rs11197175 chr10 84837238 A G 3.30E-06 Urinary metabolites / / 21572414 rs2348756 chr10 84855798 C T 2.50E-06 Urinary metabolites / / 21572414 rs1416871 chr10 84863668 A G 5.20E-06 Urinary metabolites / / 21572414 rs11197372 chr10 84867059 T C 9.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs7915137 chr10 84870076 T C 7.00E-06 Obesity-related traits / / 23251661 rs17101335 chr10 84875705 G A 1.00E-05 Urinary metabolites / / 21572414 rs4298845 chr10 84899356 G C 5.33E-06 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines / / 21483694 rs7070132 chr10 84914054 A G 8.00E-06 Urinary metabolites / / 21572414 rs1856611 chr10 84918842 C A 8.60E-06 Urinary metabolites / / 21572414 rs12415878 chr10 84938932 C T 1.30E-05 Urinary metabolites / / 21572414 rs10509471 chr10 84947422 A C 1.69E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1112434 chr10 84959384 G A 6.50E-06 Urinary metabolites / / 21572414 rs11197830 chr10 84984421 T C 4.26E-04 Taste perception / / 22132133 rs10886053 chr10 85030145 G A 4.27E-04 Taste perception / / 22132133 rs4433516 chr10 85032258 C T 6.44E-04 Multiple complex diseases / / 17554300 rs10886067 chr10 85039715 G A 3.29E-05 Hypertension / / pha003041 rs10886114 chr10 85072264 A G 9.22E-05 Meningococcal disease / / 20694013 rs4617529 chr10 85074636 A G 5.58E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4617529 chr10 85074636 A G 9.11E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11198083 chr10 85077373 A G 8.89E-04 Multiple complex diseases / / 17554300 rs11198250 chr10 85108139 A G 1.70E-05 Multiple complex diseases / / 17554300 rs10736265 chr10 85124375 G A 2.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10736265 chr10 85124375 G A 3.85E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10886223 chr10 85135261 T G 3.15E-04 Multiple complex diseases / / 17554300 rs4076319 chr10 85139142 A G 1.74E-05 Multiple complex diseases / / 17554300 rs17218375 chr10 85155213 A G 1.85E-05 Multiple complex diseases / / 17554300 rs11198481 chr10 85157900 C T 4.45E-04 Multiple complex diseases / / 17554300 rs4145635 chr10 85195657 A G 8.04E-04 Multiple complex diseases / / 17554300 rs1591565 chr10 85202437 G C 4.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs945554 chr10 85244601 A G 3.55E-04 Type 2 diabetes / / 17463246 rs1414874 chr10 85253681 C A 9.00E-06 Self-reported allergy / / 23817569 rs17102034 chr10 85259461 C T 1.46E-05 Self-reported allergy / / 23817569 rs12241147 chr10 85263782 G A 9.22E-04 White matter integrity / / 22425255 rs11593985 chr10 85268375 G T 3.05E-05 Self-reported allergy / / 23817569 rs602012 chr10 85317970 T C 1.34E-04 Depression (quantitative trait) / / 20800221 rs1359265 chr10 85329966 G A 6.15E-04 Type 2 diabetes / / 17463246 rs7085643 chr10 85340174 G A 2.93E-04 Multiple complex diseases / / 17554300 rs11199316 chr10 85343296 C T 5.71E-04 Depression (quantitative trait) / / 20800221 rs10788088 chr10 85346520 T C 5.87E-04 Depression (quantitative trait) / / 20800221 rs10788092 chr10 85349062 G C 5.89E-04 Depression (quantitative trait) / / 20800221 rs1324250 chr10 85359998 G A 9.56E-04 Depression (quantitative trait) / / 20800221 rs17096051 chr10 85378525 C T 6.13E-04 Type 2 diabetes / / 17463246 rs10160047 chr10 85402655 C A 6.53E-04 Type 2 diabetes / / 17463246 rs570446406 chr10 85402655 CTG C 6.53E-04 Type 2 diabetes / / 17463246 rs11199722 chr10 85405884 G A 9.97E-04 Type 2 diabetes / / 17463246 rs11199745 chr10 85409232 G A 8.66E-04 Type 2 diabetes / / 17463246 rs11199745 chr10 85409232 G A 5.86E-04 Multiple complex diseases / / 17554300 rs11199748 chr10 85409341 G A 5.58E-04 Type 2 diabetes / / 17463246 rs11199748 chr10 85409341 G A 6.87E-05 Multiple complex diseases / / 17554300 rs602840 chr10 85418969 G C 5.77E-05 Depression (quantitative trait) / / 20800221 rs2224865 chr10 85422854 G T 9.00E-06 Eosinophilic esophagitis (pediatric) / / 20208534 rs2224865 chr10 85422854 G T 9.98E-04 Heart Failure / / pha002884 rs7092918 chr10 85454812 T C 4.57E-04 Multiple complex diseases / / 17554300 rs4933300 chr10 85456184 T C 1.26E-06 Heart Rate / / pha003053 rs11199997 chr10 85456824 C T 6.29E-04 Multiple complex diseases / / 17554300 rs1041626 chr10 85458703 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2103203 chr10 85459984 A T 2.80E-05 Response to statin therapy / / 20339536 rs2103203 chr10 85459984 A T 1.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs609749 chr10 85461469 G A 8.78E-05 Serum metabolites / / 19043545 rs609267 chr10 85461610 G C 8.78E-05 Serum metabolites / / 19043545 rs608803 chr10 85461728 G A 9.64E-05 Serum metabolites / / 19043545 rs495019 chr10 85462107 C T 8.78E-05 Serum metabolites / / 19043545 rs524265 chr10 85463010 G T 2.50E-05 Response to statin therapy / / 20339536 rs871957 chr10 85463963 G C 5.10E-05 Response to statin therapy / / 20339536 rs871955 chr10 85464038 G T 5.40E-05 Response to statin therapy / / 20339536 rs11200166 chr10 85482256 C T 3.11E-04 Telomere length / / 23900074 rs482596 chr10 85491822 G A 1.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11200376 chr10 85509413 G A 6.80E-05 Diabetic nephropathy / / pha002852 rs612715 chr10 85509615 A C 1.78E-04 Type 2 diabetes / / 17463246 rs612715 chr10 85509615 A C 9.70E-06 Urinary metabolites / / 21572414 rs523558 chr10 85510328 A G 9.70E-06 Urinary metabolites / / 21572414 rs11200394 chr10 85511895 C T 6.80E-05 Diabetic nephropathy / / pha002852 rs501385 chr10 85519590 G T 7.14E-06 Type 2 diabetes / / 21573907 rs12220373 chr10 85524095 A C 6.80E-05 Diabetic nephropathy / / pha002852 rs11200545 chr10 85533422 C T 2.21E-04 IgE levels / / 17255346 rs11200547 chr10 85533498 T C 2.36E-04 IgE levels / / 17255346 rs11200642 chr10 85549244 G A 1.62E-04 IgE levels / / 17255346 rs11200661 chr10 85566843 T C 3.50E-07 Urinary metabolites / / 21572414 rs481826 chr10 85569231 G C 5.83E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs607428 chr10 85576823 G A 5.58E-04 Alzheimer's disease / / 17998437 rs12355819 chr10 85600447 T G 4.95E-04 Multiple complex diseases / / 17554300 rs11200686 chr10 85600523 T C 4.89E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10887165 chr10 85601079 T C 6.89E-04 Multiple complex diseases / / 17554300 rs11200700 chr10 85613835 A G 1.00E-04 Alcohol dependence / / 20201924 rs11200700 chr10 85613835 A G 1.00E-04 Alcoholism / / pha002891 rs1113145 chr10 85618324 T C 3.00E-05 Schizophrenia / / 19571811 rs11200708 chr10 85622112 C A 7.93E-04 Multiple complex diseases / / 17554300 rs1110421 chr10 85632532 T C 3.18E-05 Serum metabolites / / 19043545 rs12411363 chr10 85636495 C T 1.42E-04 Smoking initiation / / 24665060 rs10887181 chr10 85642482 C T 3.17E-05 Serum metabolites / / 19043545 rs7906586 chr10 85645501 G T 1.40E-05 Urinary metabolites / / 21572414 rs7906586 chr10 85645501 G T 8.74E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1833044 chr10 85655442 C A 2.68E-06 Cognitive decline / / 23207651 rs7094672 chr10 85714409 T C 6.20E-05 Kawasaki disease / / 22446961 rs72837991 chr10 85726676 A G 0.0000961 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11200763 chr10 85730810 G A 5.86E-04 Multiple complex diseases / / 17554300 rs10887192 chr10 85731122 C G 1.50E-05 Urinary metabolites / / 21572414 rs10887195 chr10 85750023 T C 4.79E-05 Rheumatoid arthritis / / 17804836 rs7909859 chr10 85759155 C T 5.60E-04 Multiple complex diseases / / 17554300 rs10736313 chr10 85761914 A C 4.90E-06 Urinary metabolites / / 21572414 rs12247436 chr10 85770975 T C 4.04E-04 Blood pressure / / 17255346 rs12247436 chr10 85770975 T C 6.84E-04 Multiple complex diseases / / 17554300 rs11200792 chr10 85773325 T C 3.01E-04 Blood pressure / / 17255346 rs10509487 chr10 85775671 A T 2.86E-04 Blood pressure / / 17255346 rs11200799 chr10 85775899 T A 2.84E-04 Blood pressure / / 17255346 rs7092579 chr10 85776035 C T 4.47E-04 HIV-1 viral setpoint / / 17641165 rs12247093 chr10 85776327 T A 2.86E-04 Blood pressure / / 17255346 rs10509488 chr10 85776737 T C 2.61E-04 Blood pressure / / 17255346 rs10509488 chr10 85776737 T C 2.61E-04 Multiple complex diseases / / 17554300 rs11200801 chr10 85777258 A G 2.44E-04 Blood pressure / / 17255346 rs11200801 chr10 85777258 A G 7.45E-04 Multiple complex diseases / / 17554300 rs6585783 chr10 85789310 T C 3.40E-04 Alcohol dependence / / 20201924 rs6585783 chr10 85789310 T C 4.40E-04 Alcohol dependence / / 20201924 rs6585783 chr10 85789310 T C 8.02E-06 Alcohol dependence / / 20202923 rs7908652 chr10 85791923 C T 3.59E-06 Alzheimer's disease / / 21059989 rs7908652 chr10 85791923 C T 4.51E-04 Alzheimer's disease / / 21059989 rs7068193 chr10 85795618 G A 1.10E-04 Alcohol dependence / / 20201924 rs7068193 chr10 85795618 G A 6.40E-05 Alcohol dependence / / 20201924 rs7068193 chr10 85795618 G A 6.40E-05 Alcoholism / / pha002893 rs6585795 chr10 85796190 A C 0.000711 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6585795 chr10 85796190 A C 7.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4615965 chr10 85798580 C T 1.70E-04 Alcohol dependence / / 20201924 rs4615965 chr10 85798580 C T 8.60E-05 Alcohol dependence / / 20201924 rs4615965 chr10 85798580 C T 8.65E-05 Alcoholism / / pha002893 rs11200819 chr10 85800304 T C 2.59E-04 Multiple complex diseases / / 17554300 rs7076979 chr10 85802965 G T 1.50E-04 Alcohol dependence / / 20201924 rs7076979 chr10 85802965 G T 7.40E-04 Alcohol dependence / / 20201924 rs7906877 chr10 85803792 C T 1.40E-04 Alcohol dependence / / 20201924 rs7906877 chr10 85803792 C T 8.90E-05 Alcohol dependence / / 20201924 rs7906877 chr10 85803792 C T 8.92E-05 Alcoholism / / pha002893 rs12415325 chr10 85823761 T C 8.20E-04 Alzheimer's disease / / 22005930 rs7903045 chr10 85828077 G A 1.20E-06 Urinary metabolites / / 21572414 rs4933309 chr10 85860671 T C 1.93E-04 Longevity / / 22279548 rs7089039 chr10 85879028 A G 3.78E-04 Smoking initiation / / 24665060 rs11200878 chr10 85892211 T C 2.40E-04 Primary sclerosing cholangitis / / 19944697 rs4315004 chr10 85939551 G T 5.02E-04 Type 2 diabetes C10orf99 intron 17463246 rs7099098 chr10 85950406 C T 1.38E-04 Smoking initiation / / 24665060 rs11200916 chr10 85958126 C T 2.40E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDHR1 intron 20877124 rs11200916 chr10 85958126 C T 5.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDHR1 intron 20877124 rs11200916 chr10 85958126 C T 1.74E-05 Brain structure CDHR1 intron 22504417 rs11200917 chr10 85958739 T C 1.32E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDHR1 intron 20877124 rs11200917 chr10 85958739 T C 2.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDHR1 intron 20877124 rs11200917 chr10 85958739 T C 3.96E-05 Cholesterol CDHR1 intron pha003073 rs11200917 chr10 85958739 T C 4.62E-05 Cholesterol CDHR1 intron pha003078 rs4933973 chr10 85959253 C T 7.80E-06 Urinary metabolites CDHR1 intron 21572414 rs7073756 chr10 85963075 T C 5.56E-04 Suicide attempts in bipolar disorder CDHR1 intron 21041247 rs7092674 chr10 85966873 T G 5.42E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDHR1 intron 20877124 rs11200924 chr10 85971124 T C 1.66E-05 Odorant perception CDHR1 intron 23910658 rs4933978 chr10 85971347 G A 6.82E-04 Suicide attempts in bipolar disorder CDHR1 intron 21041247 rs10887255 chr10 85972598 T C 7.16E-04 Suicide attempts in bipolar disorder CDHR1 intron 21041247 rs10887256 chr10 85973415 G C 7.33E-04 Suicide attempts in bipolar disorder CDHR1 intron 21041247 rs7908753 chr10 85974880 C T 9.08E-04 Multiple complex diseases CDHR1 UTR-3 17554300 rs11817531 chr10 85981351 G A 3.94E-05 Brain structure LRIT2 UTR-3 22504417 rs11200925 chr10 85984323 G A 3.53E-05 Brain structure LRIT2 missense 22504417 rs7898778 chr10 85985331 C T 6.61E-04 Multiple complex diseases / / 17554300 rs4933984 chr10 85985508 A G 3.90E-05 Brain structure / / 22504417 rs745480 chr10 85986554 G C 2.50E-10 Myopia (Age of onset) / / 23468642 rs4933991 chr10 86000027 C T 1.66E-04 Multiple complex diseases LRIT1 intron 17554300 rs10887261 chr10 86004269 C T 5.72E-05 Neutrophil count RGR nearGene-5 pha003095 rs17103281 chr10 86011743 G T 6.06E-04 Amyotrophic lateral sclerosis (sporadic) RGR intron 24529757 rs4568951 chr10 86024973 C T 1.90E-05 Urinary metabolites / / 21572414 rs12569977 chr10 86030567 A G 6.50E-04 Type 2 diabetes / / 22158537 rs12414938 chr10 86056141 G T 1.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11200975 chr10 86058209 G A 9.56E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs11200981 chr10 86059232 G A 4.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7477048 chr10 86130626 C T 6.43E-05 Lung function (forced expiratory volume in 1 second) FAM190B intron 24023788 rs3814205 chr10 86131059 A G 3.20E-04 Lung function (forced expiratory volume in 1 second) FAM190B missense 24023788 rs10491033 chr10 86186241 G A 7.00E-10 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) FAM190B intron 17982456 rs1572430 chr10 86199507 A G 3.94E-04 Response to cytidine analogues (gemcitabine) FAM190B intron 24483146 rs1572430 chr10 86199507 A G 1.95E-04 Amyotrophic lateral sclerosis (sporadic) FAM190B intron 24529757 rs11557865 chr10 86273249 T C 9.46E-05 Lung function (forced expiratory volume in 1 second) FAM190B missense 24023788 rs2784849 chr10 86282334 A G 1.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12776667 chr10 86286605 G C 2.16E-04 Multiple complex diseases / / 17554300 rs1188777 chr10 86291949 A G 4.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1211188 chr10 86296621 C T 1.60E-05 Urinary metabolites / / 21572414 rs2488634 chr10 86351634 G A 8.47E-04 Multiple complex diseases / / 17554300 rs2505759 chr10 86352411 C T 2.40E-06 Urinary metabolites / / 21572414 rs11597975 chr10 86355239 A G 7.72E-04 Alcohol dependence / / 24277619 rs2505757 chr10 86358190 C T 0.00007791 Sarcoidosis / / 22952805 rs11818762 chr10 86359796 C T 1.20E-06 Urinary metabolites / / 21572414 rs12268100 chr10 86360942 C T 2.20E-06 Urinary metabolites / / 21572414 rs111209750 chr10 86362642 C T 0.00007654 Sarcoidosis / / 22952805 rs2505748 chr10 86364142 A G 0.00007799 Sarcoidosis / / 22952805 rs2505749 chr10 86364155 T C 0.00007799 Sarcoidosis / / 22952805 rs10128239 chr10 86365673 G C 1.90E-05 Urinary metabolites / / 21572414 rs2488655 chr10 86366368 C T 0.0000648 Sarcoidosis / / 22952805 rs10128100 chr10 86367417 C T 2.50E-06 Urinary metabolites / / 21572414 rs1573154 chr10 86367915 G A 0.00005492 Sarcoidosis / / 22952805 rs11201124 chr10 86370809 T G 6.00E-06 Urinary metabolites / / 21572414 rs2505753 chr10 86376297 C T 2.00E-05 Urinary metabolites / / 21572414 rs2488641 chr10 86378849 G C 0.00002485 Sarcoidosis / / 22952805 rs2488642 chr10 86380086 A C 0.00002083 Sarcoidosis / / 22952805 rs2488650 chr10 86386200 T G 2.95E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2488651 chr10 86386367 G A 0.00001335 Sarcoidosis / / 22952805 rs1891656 chr10 86386578 A T 2.20E-05 Urinary metabolites / / 21572414 rs2488652 chr10 86388423 T C 0.00001335 Sarcoidosis / / 22952805 rs2505781 chr10 86391930 T G 0.00001262 Sarcoidosis / / 22952805 rs2505782 chr10 86392391 A G 1.70E-05 Urinary metabolites / / 21572414 rs11819576 chr10 86393307 A G 3.90E-06 Urinary metabolites / / 21572414 rs9420354 chr10 86398843 T A 0.000003379 Sarcoidosis / / 22952805 rs4477385 chr10 86400969 G A 0.000003379 Sarcoidosis / / 22952805 rs4480475 chr10 86401332 G A 0.000003379 Sarcoidosis / / 22952805 rs4601703 chr10 86405335 T C 0.000003379 Sarcoidosis / / 22952805 rs4388817 chr10 86410057 A G 2.10E-06 Urinary metabolites / / 21572414 rs3922702 chr10 86426609 A G 5.07E-04 Coronary Artery Disease / / 17634449 rs17103805 chr10 86428477 A G 7.69E-04 Type 2 diabetes / / 17463246 rs17103805 chr10 86428477 A G 1.15E-05 Diabetic nephropathy / / 21150874 rs17103805 chr10 86428477 A G 3.09E-04 Type 2 diabetes / / 22238593 rs11201163 chr10 86430735 G A 2.70E-05 Anger / / 24489884 rs2505780 chr10 86460169 C T 3.60E-05 Bone mineral density (BMD),in women / / 20164292 rs2505779 chr10 86464652 A G 4.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs7080844 chr10 86466518 A T 5.35E-04 Insulin resistance / / 21901158 rs4589231 chr10 86467707 G A 1.46E-04 Insulin resistance / / 21901158 rs2484072 chr10 86468447 A G 5.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs871893 chr10 86471855 C T 5.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs17104004 chr10 86480665 C A,T 1.79E-04 Insulin resistance / / 21901158 rs1577279 chr10 86481319 T C 6.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs2505788 chr10 86481602 T C 1.48E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1577280 chr10 86485090 T C 6.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs1577281 chr10 86485179 G T 6.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs1591323 chr10 86486351 T C 4.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs10887382 chr10 86571942 G A 2.13E-05 HDL cholesterol / / pha003074 rs2991921 chr10 86588447 A T 6.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs11201253 chr10 86588902 C T 6.00E-06 Obesity-related traits / / 23251661 rs1577272 chr10 86603486 T C 3.25E-05 Glucose levels / / pha003058 rs1577272 chr10 86603486 T C 2.33E-05 Glucose levels / / pha003061 rs6585903 chr10 86648725 C A 2.91E-05 Cognitive impairment induced by topiramate / / 22091778 rs12767486 chr10 86649647 C T 7.37E-05 Breast cancer / / pha002853 rs4934051 chr10 86658855 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4244961 chr10 86665044 T C 2.70E-05 Cognitive impairment induced by topiramate / / 22091778 rs1933938 chr10 86706681 T C 9.14E-05 Cognitive impairment induced by topiramate / / 22091778 rs12266096 chr10 86721181 C T 6.00E-06 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4934061 chr10 86751781 T C 6.24E-05 Multiple complex diseases / / 17554300 rs10788392 chr10 86752345 A G 1.35E-05 Smoking behavior / / 19188921 rs10788392 chr10 86752345 A G 3.42E-05 Cognitive impairment induced by topiramate / / 22091778 rs1416356 chr10 86754488 C T 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1538431 chr10 86758509 C T 8.87E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17104558 chr10 86804635 C G 8.62E-04 Multiple complex diseases / / 17554300 rs2211084 chr10 86806057 A G 1.44E-05 Cognitive impairment induced by topiramate / / 22091778 rs10509507 chr10 86814194 A G 1.44E-05 Cognitive impairment induced by topiramate / / 22091778 rs949809 chr10 86814737 A G 5.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs6585918 chr10 86839668 G C 3.48E-04 Multiple complex diseases / / 17554300 rs12771765 chr10 86858279 G A 8.33E-05 Smoking quantity / / 24665060 rs11201403 chr10 86900524 A T 5.02E-04 Multiple complex diseases / / 17554300 rs12098564 chr10 86953327 A G 4.00E-07 Stearic acid (18:0) plasma levels / / 23362303 rs7075770 chr10 86972838 A C 9.48E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12354899 chr10 86987636 G C 1.74E-04 Multiple complex diseases / / 17554300 rs7474887 chr10 86988157 G A 2.62E-04 Multiple complex diseases / / 17554300 rs7920704 chr10 86989303 T A 4.95E-05 Multiple complex diseases / / 17554300 rs932091 chr10 86993890 C T 7.70E-04 Bipolar disorder / / 19259986 rs1514461 chr10 86994750 C G 3.44E-04 Multiple complex diseases / / 17554300 rs7100450 chr10 86995047 T C 6.61E-04 Multiple complex diseases / / 17554300 rs12412169 chr10 87002220 T C 4.80E-04 Smoking initiation / / 24665060 rs1399268 chr10 87006464 A G 7.66E-04 Multiple complex diseases / / 17554300 rs883800 chr10 87015549 C T 8.54E-04 Multiple complex diseases / / 17554300 rs7074418 chr10 87018734 G A 1.32E-04 Multiple complex diseases / / 17554300 rs11201527 chr10 87022887 G A 9.57E-04 Multiple complex diseases / / 17554300 rs11201528 chr10 87023113 C A 5.91E-04 Multiple complex diseases / / 17554300 rs7915119 chr10 87033137 G A 3.35E-04 Smoking initiation / / 24665060 rs7919899 chr10 87033725 C T 3.46E-04 Smoking initiation / / 24665060 rs4934076 chr10 87034096 C T 2.20E-04 Smoking initiation / / 24665060 rs9665518 chr10 87044960 G A 9.84E-04 Multiple complex diseases / / 17554300 rs9665518 chr10 87044960 G A 2.01E-04 Smoking initiation / / 24665060 rs11201540 chr10 87054850 A G 7.38E-04 Smoking initiation / / 24665060 rs17105271 chr10 87065901 T A 6.19E-05 Multiple complex diseases / / 17554300 rs7898418 chr10 87071981 T C 3.50E-04 Smoking initiation / / 24665060 rs12356160 chr10 87074304 T C 1.25E-04 Smoking initiation / / 24665060 rs12146219 chr10 87074877 A G 2.79E-05 Smoking initiation / / 24665060 rs2037065 chr10 87075046 A G 6.41E-05 Smoking initiation / / 24665060 rs4344432 chr10 87075221 G A 1.22E-04 Smoking initiation / / 24665060 rs7905918 chr10 87078269 C T 6.07E-05 Smoking initiation / / 24665060 rs17105340 chr10 87078592 C T 1.61E-04 Smoking initiation / / 24665060 rs41319548 chr10 87078603 A G 9.61E-10 Multiple complex diseases / / 17554300 rs10887473 chr10 87079234 G C 7.96E-05 Smoking initiation / / 24665060 rs2037066 chr10 87081768 C T 1.20E-04 Smoking initiation / / 24665060 rs11201567 chr10 87090654 T C 4.89E-04 Smoking initiation / / 24665060 rs9888054 chr10 87092573 C T 9.31E-05 Smoking initiation / / 24665060 rs9888110 chr10 87092792 T C 7.46E-05 Smoking initiation / / 24665060 rs7068955 chr10 87108770 A G 4.89E-04 Smoking initiation / / 24665060 rs11201578 chr10 87114864 C T 7.84E-05 Smoking initiation / / 24665060 rs11591666 chr10 87121466 A G 7.40E-05 Smoking initiation / / 24665060 rs17173655 chr10 87135504 C A 5.32E-04 Type 2 diabetes / / 17463246 rs4934085 chr10 87136082 G A 5.58E-04 Type 2 diabetes / / 17463246 rs11201609 chr10 87167533 C T 3.23E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs41373046 chr10 87197945 A G 7.30E-04 Multiple complex diseases / / 17554300 rs11812719 chr10 87252226 G A 3.45E-04 IgE levels / / 17255346 rs4543926 chr10 87266072 A G 2.00E-04 Information processing speed / / 21130836 rs10788454 chr10 87288497 C T 8.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs1912297 chr10 87301535 G A 6.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs10788455 chr10 87302021 C T 6.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs4934119 chr10 87312326 C G 1.57E-04 Nicotine dependence / / 17158188 rs1876887 chr10 87320572 G T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2664395 chr10 87340685 A G 1.00E-04 Cognitive impairment induced by topiramate LOC100507470 intron 22091778 rs1912274 chr10 87341247 C T 6.67E-05 Femoral neck bone geometry LOC100507470 intron 22087292 rs2664405 chr10 87359826 A G 4.17E-05 Cognitive impairment induced by topiramate GRID1 UTR-3 22091778 rs10509523 chr10 87383486 C T 3.68E-04 Gallstones GRID1 intron 17632509 rs7068714 chr10 87401397 C A 6.03E-04 Response to cytadine analogues (cytosine arabinoside) GRID1 intron 24483146 rs17105747 chr10 87407163 C G 8.40E-04 Multiple complex diseases GRID1 intron 17554300 rs10788461 chr10 87407363 C T 2.00E-04 Cognitive impairment induced by topiramate GRID1 intron 22091778 rs11201716 chr10 87409973 G C 1.88E-06 Schizophrenia GRID1 intron 19571811 rs7899106 chr10 87410904 A G 5.86E-04 Multiple complex diseases GRID1 intron 17554300 rs2928011 chr10 87439651 T C 2.60E-05 Urinary metabolites GRID1 intron 21572414 rs4488140 chr10 87455683 T C 3.97E-08 Metabolite levels GRID1 intron 23281178 rs10749528 chr10 87460984 T C 7.28E-08 Metabolite levels GRID1 intron 23281178 rs10736336 chr10 87480709 C T 1.83E-08 Metabolite levels GRID1 intron 23281178 rs4418740 chr10 87481980 A G 3.91E-05 Telomere length GRID1 intron 20139977 rs10159528 chr10 87485417 T C 5.49E-08 Metabolite levels GRID1 intron 23281178 rs12773880 chr10 87495534 G A 8.61E-04 Response to cytadine analogues (cytosine arabinoside) GRID1 intron 24483146 rs12359579 chr10 87511021 C G 7.06E-04 Multiple complex diseases GRID1 intron 17554300 rs1880381 chr10 87521968 C T 7.95E-05 Multiple complex diseases GRID1 intron 17554300 rs1880381 chr10 87521968 C T 9.96E-26 Narcolepsy GRID1 intron 19629137 rs3011695 chr10 87545173 C T 9.40E-05 Major depressive disorder (broad) GRID1 intron 20038947 rs7076096 chr10 87608460 C T 5.00E-06 Post-traumatic stress disorder (asjusted for relatedness) GRID1 intron 23726511 rs1970525 chr10 87634924 C G 4.00E-06 Periodontal microbiota GRID1 intron 22699663 rs7895098 chr10 87650378 G A 5.04E-05 adolescent idiopathic scoliosis GRID1 intron 24023777 rs10788469 chr10 87687231 A G 3.32E-05 Waist-Hip Ratio GRID1 intron pha003029 rs76765968 chr10 87694292 T C 2.00E-06 Anorexia nervosa GRID1 intron 23568457 rs7923188 chr10 87694914 G A 6.27E-05 Waist-Hip Ratio GRID1 intron pha003029 rs1418396 chr10 87700825 A C 5.24E-04 Multiple complex diseases GRID1 intron 17554300 rs7899222 chr10 87701735 G A 6.36E-04 Multiple complex diseases GRID1 intron 17554300 rs10887538 chr10 87711856 C T 1.90E-05 Urinary metabolites GRID1 intron 21572414 rs2001417 chr10 87737195 T C 6.76E-04 Multiple complex diseases GRID1 intron 17554300 rs10788473 chr10 87740753 C T 2.50E-05 Urinary metabolites GRID1 intron 21572414 rs10788473 chr10 87740753 C T 3.00E-06 Pancreatic cancer GRID1 intron 23180869 rs4393254 chr10 87744398 C T 4.56E-05 stroke (ischemic) GRID1 intron 17434096 rs17318292 chr10 87750258 T C 6.14E-05 Partial epilepsies GRID1 intron 20522523 rs11201867 chr10 87762136 G A 2.81E-04 Suicide attempts in bipolar disorder GRID1 intron 21423239 rs10887544 chr10 87764778 A C 4.59E-04 Gallbladder cancer GRID1 intron 22318345 rs11201872 chr10 87781002 C T 5.53E-05 Multiple complex diseases GRID1 intron 17554300 rs12765150 chr10 87798502 C T 2.59E-04 Multiple complex diseases GRID1 intron 17554300 rs10788478 chr10 87807390 G A 2.02E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) GRID1 intron 24023788 rs10788478 chr10 87807390 G A 3.79E-04 Lung function (forced expiratory volume in 1 second) GRID1 intron 24023788 rs1806590 chr10 87845799 A G 2.43E-04 Nicotine dependence GRID1 intron 17158188 rs7910620 chr10 87846959 C G 7.00E-07 Cardiac structure and function GRID1 intron 19584346 rs12573606 chr10 87882302 G A 1 Drug response to Etoposide GRID1 intron 17537913 rs11201887 chr10 87884110 T C 1 Drug response to Etoposide GRID1 intron 17537913 rs5003944 chr10 87890326 A G 2.42E-04 Alzheimer's disease (late onset) GRID1 intron 21379329 rs12777819 chr10 87893788 C T 3.30E-05 Waist circumference GRID1 intron 23966867 rs11595188 chr10 87906836 C T 9.02E-05 Weight GRID1 intron pha003027 rs11201909 chr10 87908652 C A 6.62E-04 Taste perception GRID1 intron 22132133 rs7915663 chr10 87914036 T A 1 Drug response to Etoposide GRID1 intron 17537913 rs7912161 chr10 87923404 G A 1 Drug response to Etoposide GRID1 intron 17537913 rs12257526 chr10 87928843 T C 1 Drug response to Etoposide GRID1 intron 17537913 rs12262754 chr10 87929082 G A 1 Drug response to Etoposide GRID1 intron 17537913 rs11817682 chr10 87931072 T C 9.34E-04 Multiple complex diseases GRID1 intron 17554300 rs6586000 chr10 87948294 G A 7.34E-05 Cognitive impairment induced by topiramate GRID1 intron 22091778 rs11201942 chr10 87967080 T C 4.48E-05 Lipid traits GRID1 intron 24023261 rs2607830 chr10 87967102 T C 3.10E-04 Primary sclerosing cholangitis GRID1 intron 19944697 rs11201943 chr10 87969162 T A 4.22E-05 Lipid traits GRID1 intron 24023261 rs11201944 chr10 87971273 G C 4.82E-07 Breast cancer GRID1 intron 20852631 rs17106434 chr10 87974029 C T 5.32E-04 Type 2 diabetes GRID1 intron 17463246 rs2607839 chr10 87991916 C A 1 Drug response to Etoposide GRID1 intron 17537913 rs11817097 chr10 88003449 G A 7.80E-06 Urinary metabolites GRID1 intron 21572414 rs2607833 chr10 88051103 G A,T 3.91E-05 Type 2 diabetes GRID1 intron 17463246 rs1902692 chr10 88057777 A G 2.73E-04 Multiple complex diseases GRID1 intron 17554300 rs2814320 chr10 88061803 A G 7.00E-05 Lung cancer GRID1 intron 18978790 rs7914291 chr10 88063915 C T 5.25E-04 Multiple complex diseases GRID1 intron 17554300 rs7918205 chr10 88065156 G A 5.27E-04 Multiple complex diseases GRID1 intron 17554300 rs11201974 chr10 88067925 T C 9.98E-05 Major depressive disorder GRID1 intron 19107115 rs17106584 chr10 88090889 C A 1.56E-04 Type 2 diabetes GRID1 intron 17463246 rs7904985 chr10 88116479 G A 2.09E-04 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) GRID1 intron 24121790 rs7904985 chr10 88116479 G A 6.00E-06 Barrett's esophagus GRID1 intron 24121790 rs2114824 chr10 88119015 A G 8.52E-05 Body Mass Index GRID1 intron pha003014 rs17106692 chr10 88153763 A G 6.64E-05 IgE levels / / 22075330 rs10788500 chr10 88156839 A G 6.77E-06 IgE levels / / 22075330 rs10458771 chr10 88162238 A G 6.37E-06 IgE levels / / 22075330 rs10458771 chr10 88162238 A G 3.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs731171 chr10 88162682 G A 1.35E-08 Narcolepsy / / 19629137 rs2018507 chr10 88163251 G A 3.88E-04 Alzheimer's disease / / 17998437 rs7083506 chr10 88199668 C T 1.19E-05 Serum metabolites WAPAL intron 19043545 rs7075426 chr10 88216402 G A 6.00E-07 Migraine without aura WAPAL intron 23793025 rs2588288 chr10 88311713 G T 6.09E-04 Multiple complex diseases / / 17554300 rs2803546 chr10 88407055 G A 2.79E-04 Anorexia nervosa / / 23568457 rs11202121 chr10 88432328 A G 2.94E-04 Tourette syndrome LDB3 intron 22889924 rs2803566 chr10 88435818 C T 7.03E-05 Body Mass Index LDB3 intron pha003014 rs7917572 chr10 88496015 C A 4.04E-04 Alzheimer's disease (late onset) LDB3 nearGene-3 21379329 rs12772861 chr10 88528362 T C 1.00E-05 Intraocular pressure BMPR1A intron 22570627 rs4933411 chr10 88558471 C T 5.55E-05 Post-operative nausea and vomiting BMPR1A intron 21694509 rs17232010 chr10 88581433 A G 1.37E-05 Smoking initiation BMPR1A intron 24665060 rs4114847 chr10 88601610 G A 7.20E-06 Intraocular pressure BMPR1A intron 22570627 rs12762647 chr10 88603145 C G 7.20E-06 Intraocular pressure BMPR1A intron 22570627 rs17107098 chr10 88603966 T G 3.74E-05 Intelligence BMPR1A intron 21826061 rs17107107 chr10 88605242 C T 5.60E-06 Intraocular pressure BMPR1A intron 22570627 rs11814254 chr10 88606938 G A 7.10E-06 Intraocular pressure BMPR1A intron 22570627 rs12243345 chr10 88613110 A G 8.00E-06 Intraocular pressure BMPR1A intron 22570627 rs12778494 chr10 88616531 T C 8.50E-06 Intraocular pressure BMPR1A intron 22570627 rs7894966 chr10 88618624 T G 3.00E-06 Intraocular pressure BMPR1A intron 22570627 rs10749542 chr10 88631628 T A 9.17E-04 Suicide attempts in bipolar disorder BMPR1A intron 21423239 rs2125053 chr10 88637677 G A 9.77E-06 Sickle cell anemia (severity) BMPR1A intron 20029952 rs7074064 chr10 88683122 T C 0.0000881 Coronary artery disease BMPR1A intron 23202125 rs4447076 chr10 88696381 A G 1.70E-05 Urinary metabolites MMRN2 UTR-3 21572414 rs4447076 chr10 88696381 A G 7.25E-05 Height MMRN2 UTR-3 pha003011 rs11202285 chr10 88743691 A G 1.00E-04 Information processing speed AGAP11 UTR-5 21130836 rs7080675 chr10 88945341 T C 2.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM35A intron 20877124 rs7080675 chr10 88945341 T C 6.36E-05 Psoriasis FAM35A intron 20953190 rs41324346 chr10 89070745 C T 5.66E-05 Schizophrenia LOC728190 intron 19571809 rs4275528 chr10 89164708 T C 2.30E-06 Urinary metabolites LOC728218 intron 21572414 rs3758478 chr10 89262717 A G 1.94E-04 Type 2 diabetes MINPP1 nearGene-5 17463246 rs11202448 chr10 89324356 C A 6.80E-04 Multiple complex diseases / / 17554300 rs1575559 chr10 89325729 C A 4.50E-05 Response to statin therapy / / 20339536 rs9664222 chr10 89338633 A C 7.00E-07 Longevity / / 20304771 rs12771728 chr10 89355313 T C 1.01E-05 Prostate cancer / / 18264096 rs7093316 chr10 89358672 G A 7.86E-05 Coronary restenosis / / 21878436 rs12782065 chr10 89360938 C T 8.46E-05 Hepatocellular carcinoma / / 22807686 rs12570629 chr10 89384666 C T 9.12E-05 Schizophrenia / / pha002859 rs4934353 chr10 89389578 A G 6.30E-05 Height / / 18391952 rs791887 chr10 89411554 T C 5.04E-04 Alcohol dependence / / 21314694 rs2755427 chr10 89417472 A G 3.54E-05 Orofacial clefts / / 22863734 rs10887741 chr10 89443310 T C 4.00E-06 Exercise (leisure time) PAPSS2 intron 19727025 rs12770141 chr10 89455789 A T 6.54E-04 Acute lung injury PAPSS2 intron 22295056 rs3781191 chr10 89462990 A G 6.27E-05 Psoriasis PAPSS2 intron 20953190 rs3781187 chr10 89477221 T C 6.15E-04 Multiple complex diseases PAPSS2 intron 17554300 rs10887746 chr10 89482833 C T 7.20E-04 Multiple complex diseases PAPSS2 intron 17554300 rs4934366 chr10 89485262 G T 7.64E-04 Multiple complex diseases PAPSS2 intron 17554300 rs4934367 chr10 89485295 T C 6.70E-04 Multiple complex diseases PAPSS2 intron 17554300 rs10887748 chr10 89485395 T C 7.40E-04 Multiple complex diseases PAPSS2 intron 17554300 rs7904344 chr10 89501928 G A 0.000488 Salmonella-induced pyroptosis PAPSS2 intron 22837397 rs12765184 chr10 89510229 C T 0.000774 Salmonella-induced pyroptosis / / 22837397 rs2038554 chr10 89534244 G T 0.000314 Salmonella-induced pyroptosis ATAD1 intron 22837397 rs1993845 chr10 89547048 T C 0.000839 Salmonella-induced pyroptosis ATAD1 intron 22837397 rs11816798 chr10 89555714 T C 0.0000773 Salmonella-induced pyroptosis ATAD1 intron 22837397 rs12775017 chr10 89565088 T C 0.000865 Salmonella-induced pyroptosis ATAD1 intron 22837397 rs12781171 chr10 89565700 T C 0.000838 Salmonella-induced pyroptosis ATAD1 intron 22837397 rs12780237 chr10 89570249 A C 0.0000648 Salmonella-induced pyroptosis ATAD1 intron 22837397 rs7900225 chr10 89583792 G C 1.14E-04 Cognitive function CFL1P1 intron 24684796 rs11202576 chr10 89584284 A G 7.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CFL1P1 intron 20877124 rs1871057 chr10 89584676 C T 3.94E-04 Lung function (forced expiratory volume in 1 second) CFL1P1 intron 24023788 rs10509412 chr10 89599354 A C 3.00E-04 Chronic fatigue syndrome CFL1P1 intron 21912186 rs7076964 chr10 89599576 A G 3.06E-05 Warfarin maintenance dose CFL1P1 intron 19300499 rs1234212 chr10 89608892 C T 5.92E-05 Type 2 diabetes / / 22158537 rs1903858 chr10 89653686 A G 5.44E-05 Type 2 diabetes PTEN intron 22158537 rs1234225 chr10 89673569 C T 3.72E-04 Type 2 diabetes PTEN intron 22158537 rs1234224 chr10 89675296 A G 7.30E-04 Type 2 diabetes PTEN intron 22158537 rs12357281 chr10 89700671 G C 1.70E-05 Urinary metabolites PTEN intron 21572414 rs12242772 chr10 89704394 A G 0.000000179 Cholesterol,total PTEN intron 23063622 rs12242772 chr10 89704394 A G 8.38E-08 HDL cholesterol PTEN intron 23063622 rs2248293 chr10 89707265 T C 2.08E-05 Type 2 diabetes PTEN intron 22158537 rs2673832 chr10 89712473 G A 3.71E-04 HIV-1 viral setpoint PTEN intron 17641165 rs149784093 chr10 89752211 C T 3.00E-06 Periodontitis (Mean PAL) / / 24024966 rs2142136 chr10 89763070 C G 8.10E-06 Lipid traits / / 17903299 rs10887774 chr10 89766043 G A 3.65E-05 Type 2 diabetes / / 22158537 rs10788575 chr10 89768584 G A 0.00000215 Body mass index / / 22885924 rs10788575 chr10 89768584 G A 9.00E-06 Type 2 diabetes / / 24509480 rs7908382 chr10 89788638 T C 2.90E-05 Urinary metabolites / / 21572414 rs2248456 chr10 89792371 G A 3.45E-04 Multiple complex diseases / / 17554300 rs2673822 chr10 89793086 G C 2.42E-04 Multiple complex diseases / / 17554300 rs621891 chr10 89797624 C T 9.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs692788 chr10 89799613 A G 9.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs17405354 chr10 89799809 G T 4.60E-06 Urinary metabolites / / 21572414 rs2673814 chr10 89800871 C T 4.81E-04 Multiple complex diseases / / 17554300 rs2673813 chr10 89801899 G T 7.58E-04 Multiple complex diseases / / 17554300 rs559783 chr10 89810463 A G 4.05E-05 Serum metabolites / / 19043545 rs677422 chr10 89812909 T A 2.93E-05 Serum metabolites / / 19043545 rs7096511 chr10 89819111 G A 0.000264 Salmonella-induced pyroptosis / / 22837397 rs945559 chr10 89823147 A G 3.13E-04 Gallstones / / 17632509 rs945559 chr10 89823147 A G 2.21E-05 LDL lipoproteins / / pha002902 rs4933466 chr10 89849519 A G 8.74E-05 LDL lipoproteins / / pha002902 rs11202656 chr10 89866649 C T 7.38E-04 Multiple complex diseases / / 17554300 rs9325599 chr10 89893614 T C 2.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10887787 chr10 89896224 T C 0.000565 Salmonella-induced pyroptosis / / 22837397 rs10509536 chr10 89906286 G T 6.10E-07 Urinary metabolites / / 21572414 rs575865 chr10 89919005 C T 2.90E-05 Urinary metabolites / / 21572414 rs505384 chr10 89923849 A G 1.80E-05 Urinary metabolites / / 21572414 rs868872 chr10 89950581 C T 6.42E-05 Creatinine levels / / pha003069 rs12776142 chr10 90008568 T G 9.51E-04 Multiple complex diseases / / 17554300 rs10887794 chr10 90015274 G A 6.93E-04 Multiple complex diseases / / 17554300 rs286493 chr10 90021251 T C 6.56E-05 Type 1 diabetes / / 18978792 rs10509540 chr10 90023033 T C 1.00E-28 Type 1 diabetes / / 19430480 rs10509540 chr10 90023033 T C 2.83E-06 Type 1 diabetes / / 21980299 rs10509540 chr10 90023033 T C 1.30E-28 Multiple sclerosis / / 22190364 rs10509540 chr10 90023033 T C 0.000393569 Primary sclerosing cholangitis / / 23603763 rs7089186 chr10 90039024 A G 3.82E-04 Multiple complex diseases RNLS intron 17554300 rs2162361 chr10 90047709 C T 9.19E-06 Schizophrenia RNLS intron 19571809 rs2162361 chr10 90047709 C T 4.54E-06 Schizophrenia RNLS intron pha002859 rs11202702 chr10 90054268 G A 5.97E-04 Suicide attempts in bipolar disorder RNLS intron 21423239 rs1426618 chr10 90076715 T C 8.05E-05 Type 2 diabetes RNLS intron 17463246 rs10887801 chr10 90079714 G T 9.61E-05 Cognitive test performance RNLS intron 20125193 rs10887801 chr10 90079714 G T 1.57E-04 Suicide attempts in bipolar disorder RNLS intron 21423239 rs11202719 chr10 90091325 C G 1.27E-04 Type 2 diabetes RNLS intron 17463246 rs1426619 chr10 90091540 C T 1.33E-04 Suicide attempts in bipolar disorder RNLS intron 21423239 rs1426619 chr10 90091540 C T 5.78E-05 Arthritis (juvenile idiopathic) RNLS intron 22354554 rs7089911 chr10 90093514 G A,C 1.47E-04 Suicide attempts in bipolar disorder RNLS intron 21423239 rs792234 chr10 90151021 A G 8.46E-04 Suicide attempts in bipolar disorder RNLS intron 21423239 rs1774977 chr10 90156447 T C 2.99E-04 Smoking initiation RNLS intron 24665060 rs792231 chr10 90161745 C A 2.22E-04 Smoking initiation RNLS intron 24665060 rs17334741 chr10 90178456 A C 6.73E-04 Smoking initiation RNLS intron 24665060 rs10749590 chr10 90211164 C T 5.09E-04 Schizophrenia RNLS intron 20832056 rs10749590 chr10 90211164 C T 9.10E-04 Suicide attempts in bipolar disorder RNLS intron 21423239 rs2437878 chr10 90229234 C T 4.40E-04 Type 2 diabetes RNLS intron 17463246 rs10887831 chr10 90268918 C T 4.77E-04 Endometrial cancer RNLS intron 24096698 rs10887831 chr10 90268918 C T 4.93E-05 Endometrial cancer RNLS intron 24096698 rs10887831 chr10 90268918 C T 8.27E-04 Endometrial cancer RNLS intron 24096698 rs1325904 chr10 90280938 T C 8.00E-04 Chronic fatigue syndrome RNLS intron 21912186 rs11202766 chr10 90295773 C T 8.30E-05 Heart Rate RNLS intron pha003054 rs6586140 chr10 90311151 T G 3.69E-05 Glycemic traits (pregnancy) RNLS intron 23903356 rs12247690 chr10 90329787 C T 4.18E-05 Blood Pressure RNLS intron pha003040 rs10509552 chr10 90352539 C T 4.58E-04 Type 2 diabetes LIPJ intron 17463246 rs17286937 chr10 90423525 G T 3.54E-30 Triglycerides / / 23063622 rs12254574 chr10 90431938 G A 4.37E-04 Alzheimer's disease (late onset) LIPF intron 21379329 rs3858282 chr10 90434411 T C 2.92E-05 Pulmonary function LIPF intron 17903307 rs3858282 chr10 90434411 T C 9.20E-05 Blood Pressure LIPF intron pha003040 rs12776048 chr10 90477590 A C 1.70E-05 Urinary metabolites / / 21572414 rs17112186 chr10 90485369 C G 1.62E-04 Alzheimer's disease LIPK intron 17998437 rs12357879 chr10 90498121 G A 9.10E-05 Vascular dementia LIPK intron 22116812 rs2790702 chr10 90498722 A G 4.90E-04 Primary sclerosing cholangitis LIPK intron 19944697 rs11202849 chr10 90534759 G A 6.19E-05 Serum metabolites LIPN intron 19043545 rs303478 chr10 90545972 T G 1.27E-04 Pancreatic cancer / / pha002874 rs303499 chr10 90553051 A G 4.14E-06 Pancreatic cancer / / pha002874 rs303502 chr10 90554113 T C 1.54E-04 Pancreatic cancer / / pha002874 rs11202868 chr10 90592544 T G 1.43E-04 Acne (severe) ANKRD22 intron 24927181 rs17113606 chr10 90609134 A G 2.37E-05 Pulmonary function ANKRD22 intron 19300500 rs2439707 chr10 90609573 C T 9.79E-06 Post-operative nausea and vomiting ANKRD22 intron 21694509 rs1214547 chr10 90624346 G C 9.78E-04 Multiple complex diseases / / 17554300 rs1214546 chr10 90624386 C T 4.36E-04 Alzheimer's disease (late onset) / / 21379329 rs11202874 chr10 90628315 A G 4.98E-04 Multiple complex diseases / / 17554300 rs1926185 chr10 90642542 A C 3.14E-05 Pulmonary function STAMBPL1 intron 19300500 rs12269097 chr10 90644735 G T 3.26E-05 Pulmonary function STAMBPL1 intron 19300500 rs7097946 chr10 90645341 G A 3.37E-04 Alzheimer's disease (late onset) STAMBPL1 intron 21379329 rs7097946 chr10 90645341 G A 6.52E-04 Heart Failure STAMBPL1 intron pha002885 rs11202880 chr10 90647642 A G 3.78E-05 Pulmonary function STAMBPL1 intron 19300500 rs11202881 chr10 90651701 A C 4.08E-05 Pulmonary function STAMBPL1 intron 19300500 rs7076879 chr10 90652512 C G 4.33E-05 Pulmonary function STAMBPL1 intron 19300500 rs7910708 chr10 90654660 C T 4.33E-05 Pulmonary function STAMBPL1 intron 19300500 rs7075596 chr10 90659586 G A 4.23E-05 Pulmonary function STAMBPL1 intron 19300500 rs755049 chr10 90670810 A G 6.24E-05 Pulmonary function STAMBPL1 intron 19300500 rs12254856 chr10 90673024 G A 5.53E-07 Post-operative nausea and vomiting STAMBPL1 missense 21694509 rs7085698 chr10 90686043 A G 5.82E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11202900 chr10 90690465 G A 3.72E-04 Alzheimer's disease (late onset) / / 21379329 rs1372325 chr10 90693569 T C 7.60E-05 Alcoholism (heaviness of drinking) / / 21529783 rs1372325 chr10 90693569 T C 1.60E-05 Heart Rate / / pha003051 rs1441734 chr10 90716837 G A 6.41E-05 Serum metabolites ACTA2 intron 19043545 rs1926203 chr10 90727334 C A 9.91E-06 Lung cancer ACTA2 intron 18978787 rs1926203 chr10 90727334 C A 1.00E-06 Lung cancer ACTA2 intron 19654303 rs1926203 chr10 90727334 C A 1.00E-06 Nasopharyngeal carcinoma ACTA2 intron 20512145 rs4934433 chr10 90740953 C A 6.44E-05 Heart Rate ACTA2 intron pha003051 rs983751 chr10 90746693 A C 1.97E-08 Total IFN-gamma response to smallpox vaccine ACTA2 intron 22661280 rs3758483 chr10 90748736 C T 7.42E-04 Acute lung injury ACTA2 intron 22295056 rs3758483 chr10 90748736 C T 1.97E-08 Total IFN-gamma response to smallpox vaccine ACTA2 intron 22661280 rs1800682 chr10 90749963 A G 2.00E-08 Chronic lymphocytic leukemia ACTA2 intron 24292274 rs7097572 chr10 90753260 T C 3.51E-06 Lymphocyte counts FAS intron 22286170 rs9658691 chr10 90756163 T C 1.63E-09 Total IFN-gamma response to smallpox vaccine FAS intron 22661280 rs2147420 chr10 90759613 A G 3.10E-13 Chronic lymphocytic leukemia FAS intron 23770605 rs4406737 chr10 90759724 A G 1.00E-14 Chronic lymphocytic leukemia FAS intron 23770605 rs7069750 chr10 90762376 G C,T 0.00000694 Oligoarticular juvenile idiopathic arthritis FAS intron 23603761 rs7069750 chr10 90762376 G C,T 0.00014 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis FAS intron 23603761 rs7069750 chr10 90762376 G C,T 2.93E-08 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) FAS intron 23603761 rs9658736 chr10 90763917 T C 8.89E-16 LDL cholesterol FAS intron 23063622 rs9658736 chr10 90763917 T C 9.08E-65 Triglycerides FAS intron 23063622 rs982764 chr10 90769998 T C 3.35E-04 Longevity FAS intron 22279548 rs982764 chr10 90769998 T C 7.79E-05 Heart Rate FAS intron pha003051 rs2234978 chr10 90771829 T C 6.00E-06 Immunoglobulin A FAS cds-synon 20694011 rs7089946 chr10 90783935 G C 3.34E-04 Type 2 diabetes / / 17463246 rs11202937 chr10 90790007 G A 6.45E-04 Multiple complex diseases / / 17554300 rs17449853 chr10 90790466 T C 3.53E-04 Multiple complex diseases / / 17554300 rs11202938 chr10 90790476 A G 1.25E-09 Multiple complex diseases / / 17554300 rs7898005 chr10 90796151 A G 7.87E-04 Multiple complex diseases / / 17554300 rs7085850 chr10 90811299 A G 4.00E-06 Amyotrophic Lateral Sclerosis / / 17362836 rs7085850 chr10 90811299 A G 3.93E-04 Multiple complex diseases / / 17554300 rs2226247 chr10 90818155 G A 3.44E-04 Smoking initiation / / 24665060 rs7920888 chr10 90818377 T C 5.00E-06 Obesity-related traits / / 23251661 rs7920888 chr10 90818377 T C 7.00E-06 Obesity-related traits / / 23251661 rs7920888 chr10 90818377 T C 7.00E-06 Obesity-related traits / / 23251661 rs7920888 chr10 90818377 T C 9.00E-06 Obesity-related traits / / 23251661 rs1937332 chr10 90826779 A G 7.00E-07 Atrioventricular conduction / / 21041692 rs11595318 chr10 90840317 C T 5.53E-04 Multiple complex diseases / / 17554300 rs2801535 chr10 90855419 A G 6.96E-04 Smoking initiation / / 24665060 rs2841027 chr10 90871172 A C 5.32E-04 Smoking initiation / / 24665060 rs2253503 chr10 90874029 C T 7.47E-05 Glucose levels / / pha003057 rs1317361 chr10 90879304 A G 1.25E-05 Suicidal ideation / / 20877300 rs11203032 chr10 90964614 T G 8.00E-06 Heart failure / / 20445134 rs3802656 chr10 90975649 G A 2.90E-05 Urinary metabolites LIPA intron 21572414 rs17117501 chr10 90979093 A G 2.93E-04 Aortic root size LIPA intron 21223598 rs2254747 chr10 90985948 C T 0.0000635 post-traumatic stress disorder LIPA intron 22869035 rs2254747 chr10 90985948 C T 6.35E-05 Schizophrenia LIPA intron 22883433 rs2071510 chr10 90987564 T G 6.99E-04 Schizophrenia LIPA intron 19197363 rs11203042 chr10 90989109 T C 0.000000309 Coronary artery disease with myocardial infarction LIPA intron 23202125 rs11203042 chr10 90989109 T C 0.00000386 Coronary artery disease (CAD) age <=50 LIPA intron 23202125 rs11203042 chr10 90989109 T C 0.00000608 Coronary artery disease LIPA intron 23202125 rs11203042 chr10 90989109 T C 0.0000825 Coronary artery disease (CAD) age >50 LIPA intron 23202125 rs11203042 chr10 90989109 T C 0.000423 Coronary artery disease (CAD) (males) LIPA intron 23202125 rs11203042 chr10 90989109 T C 6.51E-05 Coronary artery disease LIPA intron 24262325 rs2902563 chr10 90999939 T C 9.07E-04 Type 2 diabetes LIPA intron 17463246 rs1412444 chr10 91002927 C T 3.00E-13 Coronary heart disease LIPA intron 21378988 rs1412444 chr10 91002927 C T 4.00E-08 Coronary heart disease LIPA intron 21606135 rs2246942 chr10 91004886 A G 5.00E-04 Atrial fibrillation LIPA intron 21846873 rs2246942 chr10 91004886 A G 1.01E-124 Coronary heart disease LIPA intron 21966275 rs2246942 chr10 91004886 A G 4.30E-09 Coronary heart disease LIPA intron 21966275 rs2246833 chr10 91005854 C T 6.78E-04 Coronary heart disease LIPA intron 21606135 rs2246833 chr10 91005854 C T 0.000000686 Coronary artery disease (CAD) age <=50 LIPA intron 23202125 rs2246833 chr10 91005854 C T 0.00000239 Coronary artery disease (CAD) (males) LIPA intron 23202125 rs2246833 chr10 91005854 C T 0.00000626 Coronary artery disease LIPA intron 23202125 rs2246833 chr10 91005854 C T 0.000246 Coronary artery disease (CAD) age >50 LIPA intron 23202125 rs2246833 chr10 91005854 C T 2.29E-08 Coronary artery disease with myocardial infarction LIPA intron 23202125 rs2246833 chr10 91005854 C T 5.28E-05 Coronary artery disease LIPA intron 24262325 rs2250781 chr10 91007470 C A 1.54E-96 Coronary heart disease LIPA intron 21966275 rs2250781 chr10 91007470 C A 2.31E-05 Coronary heart disease LIPA intron 21966275 rs2243547 chr10 91010479 A C 1.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LIPA intron 20877124 rs11203054 chr10 91022025 C A 8.44E-04 Depression (quantitative trait) / / 20800221 rs11203054 chr10 91022025 C A 6.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs4934464 chr10 91046899 C A 6.71E-04 Body mass index / / 21701565 rs954439 chr10 91066460 T A 9.56E-04 Multiple complex diseases IFIT2 cds-synon 17554300 rs4630205 chr10 91092706 T C 4.57E-05 Intracerebral hemorrhage IFIT3 intron 24656865 rs4630205 chr10 91092706 T C 4.71E-05 Intracerebral hemorrhage IFIT3 intron 24656865 rs627524 chr10 91116790 A C 1.83E-05 Eating disorders / / 23568457 rs2863759 chr10 91140508 G A 1.12E-06 Statin-induced myopathy IFIT1B intron 21826682 rs303211 chr10 91162497 A G 7.10E-06 Waist circumference / / 19557197 rs303211 chr10 91162497 A G 3.01E-04 Myocardial Infarction / / pha002883 rs2026912 chr10 91212595 C A 7.15E-04 Parkinson's disease SLC16A12 intron 17052657 rs303186 chr10 91251013 A G 6.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC16A12 intron 20877124 rs11185734 chr10 91263864 A G 2.29E-10 Multiple complex diseases SLC16A12 intron 17554300 rs7093575 chr10 91286442 C A 2.71E-04 Parkinson's disease SLC16A12 intron 17052657 rs17479692 chr10 91288459 T G 3.30E-09 Alopecia areata SLC16A12 intron 22027810 rs17480179 chr10 91326387 A C 7.81E-04 Insulin resistance / / 21901158 rs7095066 chr10 91349758 A G 1.70E-05 Urinary metabolites PANK1 intron 21572414 rs7089984 chr10 91357991 G A 7.30E-04 Type 2 diabetes PANK1 intron 17463246 rs11185790 chr10 91372533 G A 3.00E-07 Metabolic traits PANK1 intron 19060910 rs11185790 chr10 91372533 G A 9.73E-05 Insulin-related traits PANK1 intron pha002901 rs10881613 chr10 91389225 T G 6.82E-04 Obesity (extreme) PANK1 intron 21935397 rs927907 chr10 91389738 G A 6.88E-04 Obesity (extreme) PANK1 intron 21935397 rs11185822 chr10 91393013 C T 5.81E-04 Aortic root size PANK1 intron 21223598 rs11185824 chr10 91393712 A G 5.92E-04 Type 2 diabetes PANK1 intron 17463246 rs10727 chr10 91394107 A G 9.91E-04 Multiple complex diseases PANK1 intron 17554300 rs1359624 chr10 91395428 T C 7.51E-04 Obesity (extreme) PANK1 intron 21935397 rs7073802 chr10 91398449 A G 1.90E-05 Urinary metabolites PANK1 intron 21572414 rs997456 chr10 91403980 G A 2.02E-04 Prion diseases PANK1 intron 22210626 rs78765440 chr10 91414563 T C 5.40E-04 Crohn's disease / / 23266558 rs4933510 chr10 91425621 T A 5.34E-04 Multiple complex diseases / / 17554300 rs4933510 chr10 91425621 T A 0.000858 Salmonella-induced pyroptosis / / 22837397 rs943128 chr10 91428221 T C 0.000742 Salmonella-induced pyroptosis / / 22837397 rs7073626 chr10 91428404 A G 1.80E-05 Urinary metabolites / / 21572414 rs7073626 chr10 91428404 A G 0.000244 Salmonella-induced pyroptosis / / 22837397 rs11599335 chr10 91440056 G A 1.89E-04 Prion diseases / / 22210626 rs1326259 chr10 91449996 G T 0.000573 Salmonella-induced pyroptosis / / 22837397 rs6586215 chr10 91450988 G A 0.000592 Salmonella-induced pyroptosis / / 22837397 rs10159959 chr10 91451706 G A 3.73E-05 Aortic root size / / 21223598 rs2104499 chr10 91453196 G A 0.000632 Salmonella-induced pyroptosis / / 22837397 rs7069937 chr10 91479889 A C 1.74E-04 Prion diseases KIF20B intron 22210626 rs1886996 chr10 91498127 T C 1.72E-04 Prion diseases KIF20B missense 22210626 rs10509580 chr10 91506704 T C 2.50E-05 Urinary metabolites KIF20B intron 21572414 rs4934499 chr10 91550544 T C 2.60E-05 Urinary metabolites / / 21572414 rs1998646 chr10 91567696 T C 6.40E-05 Aortic root size / / 21223598 rs1326196 chr10 91571921 G A 1.94E-04 Prion diseases / / 22210626 rs10881696 chr10 91614005 T A 1.13E-04 Multiple complex diseases / / 17554300 rs10509582 chr10 91617124 A G 4.59E-05 Elbow pain / / pha003008 rs1408584 chr10 91626071 A G 2.59E-05 Relative hand skill / / 24068947 rs1924704 chr10 91630960 A G 8.30E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1324705 chr10 91643607 C T 0.00009 Asthma / / 18401594 rs11185930 chr10 91680402 T C 2.30E-05 Urinary metabolites / / 21572414 rs1419112 chr10 91699671 A G 4.02E-06 Cardiovascular disease / / 18179892 rs17129662 chr10 91740936 C T 3.51E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs10509586 chr10 91741437 G T 4.00E-07 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy) / / 24554482 rs12262992 chr10 91744333 C T 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7077721 chr10 91749112 C T 8.35E-04 Multiple complex diseases / / 17554300 rs4933526 chr10 91782521 G A 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10881735 chr10 91792841 T C 1.51E-05 Odorant perception / / 23910658 rs7070137 chr10 91822938 G A 2.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4933541 chr10 91832066 C T 7.00E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2182239 chr10 91835290 C T 1.63E-04 Multiple complex diseases / / 17554300 rs4933173 chr10 91846691 T C 5.32E-04 Multiple complex diseases / / 17554300 rs7084467 chr10 91855982 G A 5.23E-04 Multiple complex diseases / / 17554300 rs10881747 chr10 91860537 A T 4.46E-04 Multiple complex diseases / / 17554300 rs17130391 chr10 91860600 T C 5.28E-04 Multiple complex diseases / / 17554300 rs4933174 chr10 91869383 C T 5.57E-04 Multiple complex diseases / / 17554300 rs4933174 chr10 91869383 C T 0.0000404 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10881750 chr10 91869843 G A 8.81E-04 Multiple complex diseases / / 17554300 rs10509592 chr10 91892863 C G 6.14E-04 Multiple complex diseases / / 17554300 rs1360116 chr10 91901330 G A 5.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1329156 chr10 91905015 A C 5.82E-05 Smoking cessation / / 24665060 rs7096150 chr10 91911223 G A 7.47E-04 Multiple complex diseases / / 17554300 rs1329154 chr10 91912493 A G 1.18E-04 Multiple complex diseases / / 17554300 rs11186048 chr10 91926859 T C 4.55E-04 Multiple complex diseases / / 17554300 rs985604 chr10 91927403 A G 1.22E-04 Multiple complex diseases / / 17554300 rs999903 chr10 91928041 G A 4.84E-04 Multiple complex diseases / / 17554300 rs986222 chr10 91930887 G A 4.91E-04 Multiple complex diseases / / 17554300 rs992139 chr10 91932058 G A 1.82E-04 Multiple complex diseases / / 17554300 rs1329179 chr10 91934453 C G 5.70E-04 Alzheimer's disease / / 17998437 rs2148554 chr10 91951170 T C 1.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs10430648 chr10 91956928 A G 7.40E-04 Multiple complex diseases / / 17554300 rs2250245 chr10 91962670 A G 2.00E-06 Economic and political preferences (feminism/equality) / / 22566634 rs2250149 chr10 91963463 T C 1.00E-06 Economic and political preferences (feminism/equality) / / 22566634 rs699213 chr10 91970688 C G 9.06E-05 Bipolar Disorder / / pha002863 rs17092763 chr10 92027459 A G 0.0005986 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17092763 chr10 92027459 A G 5.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10785952 chr10 92048792 C G 6.93E-04 Multiple complex diseases / / 17554300 rs2104483 chr10 92078697 C T 6.31E-04 Stroke / / pha002887 rs1326162 chr10 92082250 C T 2.20E-05 Receptive language ability / / 24687471 rs11186126 chr10 92087653 G A 1.17E-05 Receptive language ability / / 24687471 rs11186132 chr10 92095687 A G 6.66E-05 Receptive language ability / / 24687471 rs1326167 chr10 92101026 T C 9.59E-07 Receptive language ability / / 24687471 rs10881789 chr10 92148449 T C 2.83E-04 Type 2 diabetes / / 17463246 rs12355470 chr10 92150962 C T 7.10E-04 Iron levels / / pha002876 rs11186154 chr10 92153461 T C 3.97E-04 Type 2 diabetes / / 17463246 rs1106067 chr10 92153836 T A 1.28E-04 Multiple complex diseases / / 17554300 rs1572991 chr10 92155657 G A 4.69E-04 Type 2 diabetes / / 17463246 rs10509601 chr10 92162800 C T 8.03E-04 Heart Failure / / pha002885 rs10785957 chr10 92167112 G T 4.50E-04 Heart Failure / / pha002885 rs12414191 chr10 92167756 T C 1.86E-05 Serum metabolites / / 19043545 rs11186165 chr10 92168375 A G 3.35E-05 Type 2 diabetes / / 17463246 rs7915941 chr10 92168557 C T 1.93E-05 Serum metabolites / / 19043545 rs1935258 chr10 92203605 A G 7.80E-05 Type 2 diabetes / / 17463246 rs7914851 chr10 92211107 C G 7.24E-05 Multiple complex diseases / / 17554300 rs10881798 chr10 92211214 C T 5.88E-05 Type 2 diabetes / / 17463246 rs11186191 chr10 92217631 C G 2.60E-04 Type 2 diabetes / / 17463246 rs7914817 chr10 92234041 A G 0.0004138 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7914817 chr10 92234041 A G 4.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4633363 chr10 92238515 A T 0.0005177 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4633363 chr10 92238515 A T 5.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17096180 chr10 92248698 T C 0.0005388 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17096180 chr10 92248698 T C 5.39E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7905637 chr10 92263444 T C 0.0005601 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7905637 chr10 92263444 T C 5.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1274337 chr10 92263503 T C 9.57E-04 Multiple complex diseases / / 17554300 rs1341817 chr10 92290213 G A 1.14E-04 Type 2 diabetes / / 17463246 rs1341817 chr10 92290213 G A 1.90E-05 Urinary metabolites / / 21572414 rs11186215 chr10 92295630 T C 6.26E-04 Multiple complex diseases / / 17554300 rs17096993 chr10 92299474 G C 0.000631 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17096993 chr10 92299474 G C 6.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1892532 chr10 92333448 T G 8.78E-05 Type 2 diabetes / / 17463246 rs7090090 chr10 92334196 C G,T 1.23E-04 Type 2 diabetes / / 17463246 rs7090119 chr10 92334314 A G 1.23E-04 Type 2 diabetes / / 17463246 rs2420185 chr10 92334588 G A 1.42E-04 Type 2 diabetes / / 17463246 rs2901084 chr10 92335233 A G 1.11E-04 Type 2 diabetes / / 17463246 rs10047335 chr10 92342511 A G 1.03E-04 Type 2 diabetes / / 17463246 rs1274411 chr10 92346977 T C 4.62E-04 Multiple complex diseases / / 17554300 rs11186233 chr10 92350389 T A 6.69E-04 Type 2 diabetes / / 17463246 rs1274394 chr10 92353890 T C 7.54E-05 Epilepsy (remission after treatment) / / 23962720 rs1343651 chr10 92356740 T C 7.83E-05 Epilepsy (remission after treatment) / / 23962720 rs1274400 chr10 92357671 A C 7.12E-05 Epilepsy (remission after treatment) / / 23962720 rs1274401 chr10 92358016 C A 7.22E-05 Epilepsy (remission after treatment) / / 23962720 rs1299939 chr10 92363094 C T 8.07E-05 Epilepsy (remission after treatment) / / 23962720 rs1779941 chr10 92363203 C T 8.10E-05 Epilepsy (remission after treatment) / / 23962720 rs2710717 chr10 92365241 C T 8.23E-05 Epilepsy (remission after treatment) / / 23962720 rs2710725 chr10 92366690 G A 8.35E-05 Epilepsy (remission after treatment) / / 23962720 rs2710726 chr10 92366700 T C 8.35E-05 Epilepsy (remission after treatment) / / 23962720 rs2710728 chr10 92371952 A G 8.70E-05 Epilepsy (remission after treatment) / / 23962720 rs1573252 chr10 92374615 G A 6.28E-04 Multiple complex diseases / / 17554300 rs1972397 chr10 92374955 A G 1.49E-04 Type 2 diabetes / / 17463246 rs1936589 chr10 92376278 T C 4.83E-04 Multiple complex diseases / / 17554300 rs2800123 chr10 92390728 G T 4.29E-04 Multiple complex diseases / / 17554300 rs1592353 chr10 92417767 C T 2.72E-04 Type 2 diabetes / / 17463246 rs2800159 chr10 92433409 C G 6.33E-05 Epilepsy (remission after treatment) / / 23962720 rs7076271 chr10 92434544 T C 6.89E-05 Type 2 diabetes / / 17463246 rs2710767 chr10 92434907 C A 1.81E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1936613 chr10 92435453 T G 5.99E-05 Kawasaki disease / / 22081228 rs1936613 chr10 92435453 T G 7.98E-05 Prion diseases / / 22210626 rs7097710 chr10 92435851 G C 4.21E-05 Type 2 diabetes / / 17463246 rs2901088 chr10 92441553 C T 3.40E-05 Interstitial lung disease / / 23583980 rs1936606 chr10 92442656 C T 3.23E-05 Interstitial lung disease / / 23583980 rs1936602 chr10 92445253 C T 6.25E-05 Interstitial lung disease / / 23583980 rs2800146 chr10 92456074 C T 5.07E-06 Glucose levels / / pha003058 rs2800143 chr10 92463214 T C 0.0002 Migraine / / 22678113 rs1857586 chr10 92470777 G A 7.18E-06 Glucose levels / / pha003058 rs12259754 chr10 92472510 G A,C,T 3.59E-05 Diabetic nephropathy / / pha002864 rs2800135 chr10 92473603 A G 8.58E-05 Serum metabolites / / 19043545 rs11186286 chr10 92477076 T C 3.84E-05 Diabetic nephropathy / / pha002852 rs11186286 chr10 92477076 T C 7.40E-06 Diabetic nephropathy / / pha002864 rs2465115 chr10 92486835 G T 4.95E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs11817364 chr10 92498026 G A 6.36E-05 Diabetic nephropathy / / pha002864 rs3740046 chr10 92501468 C T 2.83E-04 Alcohol consumption (maxi-drinks) HTR7 UTR-3 24277619 rs11186300 chr10 92514739 A C 3.76E-06 Glucose levels HTR7 intron pha003058 rs7086484 chr10 92533729 G A 4.24E-05 Glucose levels HTR7 intron pha003058 rs10881832 chr10 92548763 C T 6.12E-05 Major depressive disorder HTR7 intron 22472876 rs10881832 chr10 92548763 C T 4.98E-06 Glucose levels HTR7 intron pha003058 rs7916403 chr10 92559908 G T 8.46E-04 Type 2 diabetes HTR7 intron 17463246 rs7916403 chr10 92559908 G T 8.17E-06 Glucose levels HTR7 intron pha003058 rs7916403 chr10 92559908 G T 9.30E-05 Glucose levels HTR7 intron pha003061 rs12775181 chr10 92564457 G C 6.49E-05 Femoral neck bone geometry HTR7 intron 22087292 rs11186320 chr10 92576448 T C 7.92E-04 Alcohol dependence HTR7 intron 21314694 rs11186320 chr10 92576448 T C 6.30E-04 Alcohol consumption (maxi-drinks) HTR7 intron 24277619 rs6583735 chr10 92587500 C A 2.83E-05 Major depressive disorder HTR7 intron 22472876 rs10881838 chr10 92590233 A G 6.30E-04 Alcohol consumption (maxi-drinks) HTR7 intron 24277619 rs12249377 chr10 92592956 C A 3.00E-10 White matter microstructure (global fractional anisotropy) HTR7 intron 24736177 rs1935349 chr10 92594343 C T 1 Drug response to Atorvastatin HTR7 intron 17600820 rs1935349 chr10 92594343 C T 1 Drug response to Pravastatin HTR7 intron 17600820 rs1935349 chr10 92594343 C T 1 Drug response to Simvastatin HTR7 intron 17600820 rs2901127 chr10 92595066 C T 5.73E-04 Type 2 diabetes HTR7 intron 17463246 rs10785973 chr10 92598171 C A 0.0008809 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) HTR7 intron 23233654 rs10785973 chr10 92598171 C A 8.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) HTR7 intron 23233662 rs11597471 chr10 92598767 C G 7.42E-04 Type 2 diabetes HTR7 intron 17463246 rs11599902 chr10 92598823 T C 5.55E-04 Type 2 diabetes HTR7 intron 17463246 rs2226116 chr10 92600239 G T 0.0005402 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) HTR7 intron 23233654 rs2226116 chr10 92600239 G T 5.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) HTR7 intron 23233662 rs11186333 chr10 92605119 G A 2.75E-04 Type 2 diabetes HTR7 intron 17463246 rs12259062 chr10 92610045 A G 6.30E-04 Alcohol consumption (maxi-drinks) HTR7 intron 24277619 rs4586057 chr10 92632899 T G 5.00E-06 Economic and political preferences (time) RPP30 intron 22566634 rs7909232 chr10 92651479 G A 5.54E-05 Glucose levels RPP30 intron pha003058 rs4933618 chr10 92652571 C T 7.37E-04 Alcohol consumption (maxi-drinks) RPP30 intron 24277619 rs10509613 chr10 92653119 C T 4.90E-04 Type 2 diabetes and 6 quantitative traits RPP30 intron 17848626 rs1539479 chr10 92688298 A G 1.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs4933624 chr10 92698251 C T 1.79E-04 Multiple complex diseases / / 17554300 rs7897603 chr10 92708759 G C 4.03E-05 Serum metabolites / / 19043545 rs4411211 chr10 92716619 C T 3.84E-05 Serum metabolites / / 19043545 rs7099299 chr10 92719584 C T 8.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs1334583 chr10 92720630 A G 8.75E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs11186398 chr10 92723864 A G 3.84E-05 Serum metabolites / / 19043545 rs12218436 chr10 92739374 T C 4.31E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7096430 chr10 92764460 A G 6.60E-05 Serum metabolites / / 19043545 rs4933637 chr10 92770051 A C 2.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs3852489 chr10 92779223 C T 2.60E-05 Urinary metabolites / / 21572414 rs4933203 chr10 92779580 T C 6.94E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs116858348 chr10 92780623 T G 8.44E-05 Epilepsy (remission after treatment) / / 23962720 rs10509615 chr10 92791516 G A 7.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs7894018 chr10 92817279 T C 1.22E-08 Multiple complex diseases / / 17554300 rs4528226 chr10 92832246 G T 1.10E-07 Effectiveness of iloperidone treatment in schizophrenia / / 18521090 rs10509619 chr10 92869911 T C 8.05E-04 Alzheimer's disease / / 17998437 rs10881889 chr10 92888908 T A 4.34E-05 Multiple complex diseases / / 17554300 rs7067899 chr10 92891064 A G 4.08E-04 Multiple complex diseases / / 17554300 rs6583755 chr10 92891750 T A 5.23E-04 Multiple complex diseases / / 17554300 rs10881890 chr10 92894740 C T 8.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs1992245 chr10 92899856 T C 7.25E-04 Multiple complex diseases / / 17554300 rs7088963 chr10 92905682 G A 6.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6583757 chr10 92905814 C T 4.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6583759 chr10 92976570 A C 9.10E-08 Platelet aggregation(pre- and post-aspirin) PCGF5 intron 20529293 rs12768356 chr10 92982238 G A 7.48E-04 Multiple complex diseases PCGF5 intron 17554300 rs7071503 chr10 92984783 G A 2.50E-04 Multiple complex diseases PCGF5 intron 17554300 rs6583762 chr10 93014953 A C 2.18E-04 Multiple complex diseases PCGF5 intron 17554300 rs7903610 chr10 93028684 G A 7.17E-04 Multiple complex diseases PCGF5 intron 17554300 rs10509625 chr10 93050333 G A 5.82E-06 stroke (ischemic) / / 17434096 rs2631686 chr10 93053537 T C 3.80E-05 Non-small cell lung cancer,hypertriglyceridemia with bexarotene treatment of / / 21737656 rs7076439 chr10 93286842 G A 7.98E-04 Suicide attempts in bipolar disorder LOC100188947 intron 21423239 rs11186608 chr10 93300327 G T 1.50E-05 Urinary metabolites LOC100188947 intron 21572414 rs1329650 chr10 93348120 G T 6.00E-10 Smoking behavior LOC100188947 intron 20418890 rs1329650 chr10 93348120 G T 5.70E-10 Smoking behavior LOC100188947 intron 22832964 rs1329650 chr10 93348120 G T 0.00053 Prostate cancer (non-advanced prostate cancer) LOC100188947 intron 23555315 rs1028936 chr10 93349797 A C 1.30E-09 Smoking behavior LOC100188947 intron 22832964 rs11186622 chr10 93360331 G A 4.00E-05 Post-operative nausea and vomiting LOC100188947 intron 21694509 rs11186629 chr10 93373099 A T 8.36E-04 Type 2 diabetes / / 17463246 rs11186642 chr10 93403068 G T 4.26E-04 Heart Failure / / pha002885 rs2000177 chr10 93412994 T G 7.74E-05 Fasting blood glucose / / 22885924 rs12762813 chr10 93461648 G A 7.71E-05 Serum albumin level / / pha003084 rs147689733 chr10 93592703 C T 2.43E-09 Type 2 diabetes TNKS2 intron 23945395 rs10881990 chr10 93657436 G A 5.26E-04 Type 2 diabetes / / 17463246 rs10881990 chr10 93657436 G A 1.70E-05 Urinary metabolites / / 21572414 rs10881991 chr10 93660359 A G 7.67E-04 Type 2 diabetes / / 17463246 rs200280119 chr10 93668692 G A 0.0000025 Breast cancer FGFBP3 missense 23555315 rs200280119 chr10 93668692 G A 0.00015 Prostate cancer FGFBP3 missense 23555315 rs10748574 chr10 93713363 A G 1.17E-04 Multiple complex diseases BTAF1 intron 17554300 rs4642987 chr10 93721025 A G 6.01E-05 Personality dimensions BTAF1 intron 23903073 rs11186774 chr10 93725487 A T 3.26E-05 Bipolar disorder BTAF1 intron 19488044 rs11186792 chr10 93766315 C A 8.57E-05 Schizophrenia BTAF1 intron 19571809 rs11186792 chr10 93766315 C A 6.28E-05 Schizophrenia BTAF1 intron pha002859 rs10882018 chr10 93812405 T C 4.40E-05 Calcium levels CPEB3 intron pha003085 rs701846 chr10 93871066 G A 2.21E-05 Body Mass Index CPEB3 intron pha003019 rs701846 chr10 93871066 G A 2.18E-05 Body Mass Index CPEB3 intron pha003020 rs189118455 chr10 93919672 C T 1.29E-07 Type 2 diabetes CPEB3 intron 23945395 rs7087501 chr10 93930279 T C 2.45E-05 Body Mass Index CPEB3 intron pha003019 rs7087501 chr10 93930279 T C 2.45E-05 Body Mass Index CPEB3 intron pha003020 rs2182647 chr10 93935344 C T 8.36E-04 Myopia (pathological) CPEB3 intron 21095009 rs17107487 chr10 93973279 G A 3.12E-12 Multiple complex diseases CPEB3 intron 17554300 rs11186898 chr10 94049988 G T 7.86E-04 Multiple complex diseases CPEB3 intron 17554300 rs12411618 chr10 94052164 C T 4.54E-04 Smoking cessation MARCH5 intron 24665060 rs913649 chr10 94091067 A G 8.41E-06 Body Mass Index MARCH5 intron pha003019 rs913649 chr10 94091067 A G 1.35E-05 Body Mass Index MARCH5 intron pha003020 rs11186926 chr10 94098321 G C 6.35E-05 Bipolar disorder MARCH5 intron 19488044 rs11186926 chr10 94098321 G C 3.40E-05 Bipolar Disorder MARCH5 intron pha002863 rs2255718 chr10 94109877 G T 8.78E-06 Body Mass Index MARCH5 intron pha003019 rs2255718 chr10 94109877 G T 1.35E-05 Body Mass Index MARCH5 intron pha003020 rs1057848 chr10 94112156 G C 1.19E-05 Bipolar disorder MARCH5 UTR-3 19488044 rs1057848 chr10 94112156 G C 5.80E-06 Bipolar Disorder MARCH5 UTR-3 pha002863 rs2342694 chr10 94121095 T C 7.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs11186960 chr10 94142607 C A 8.88E-05 Bipolar disorder / / 19488044 rs11186960 chr10 94142607 C A 8.74E-05 Bipolar Disorder / / pha002863 rs7897267 chr10 94148800 C T 7.60E-04 Myopia (pathological) / / 21095009 rs2259049 chr10 94155499 C T 8.44E-05 Body Mass Index / / pha003020 rs2263638 chr10 94168797 G A 3.00E-06 Airflow obstruction / / 22837378 rs2798253 chr10 94202905 G C 1.93E-06 Alcohol and nictotine co-dependence / / 20158304 rs7910977 chr10 94209876 C T 6.32E-04 Myopia (pathological) / / 21095009 rs6583813 chr10 94209939 C T 9.62E-04 Type 2 diabetes / / 22158537 rs2251101 chr10 94211304 C T 6.20E-06 Type 2 diabetes IDE nearGene-3 22158537 rs11187007 chr10 94214580 A G 1.48E-05 Type 2 diabetes IDE intron 22158537 rs551266 chr10 94222624 C T 5.88E-06 Type 2 diabetes IDE intron 22158537 rs1887922 chr10 94224165 C T 4.62E-06 Type 2 diabetes IDE intron 22158537 rs1887922 chr10 94224165 C T 9.74E-05 Ankle-brachial index IDE intron 22199011 rs10882066 chr10 94224746 A G 1.95E-04 Type 2 diabetes IDE intron 17463246 rs4646957 chr10 94229912 C T 6.06E-04 Type 2 diabetes IDE intron 17463246 rs2149632 chr10 94232247 T C 3.88E-06 Type 2 diabetes IDE intron 22158537 rs7910605 chr10 94239793 A G 1.19E-04 Heart rate IDE intron 23583979 rs7093418 chr10 94249769 T G 6.69E-05 Ankle-brachial index IDE intron 22199011 rs1855916 chr10 94254283 A G 5.87E-05 Ankle-brachial index IDE intron 22199011 rs7084090 chr10 94257218 A T 9.59E-06 Type 2 diabetes IDE intron 22158537 rs7084090 chr10 94257218 A T 5.93E-05 Ankle-brachial index IDE intron 22199011 rs11187033 chr10 94262359 T A 1.12E-05 Type 2 diabetes IDE intron 22158537 rs11187037 chr10 94263361 T C 1.75E-04 Type 2 diabetes IDE intron 17463246 rs10509645 chr10 94277866 C A 8.85E-04 Multiple complex diseases IDE intron 17554300 rs10509645 chr10 94277866 C A 1.27E-05 Type 2 diabetes IDE intron 22158537 rs7898493 chr10 94295316 C G 7.14E-06 Type 2 diabetes IDE intron 22158537 rs7898493 chr10 94295316 C G 3.67E-05 Ankle-brachial index IDE intron 22199011 rs1832197 chr10 94298331 G A 1.04E-04 Type 2 diabetes IDE intron 17463246 rs11187061 chr10 94305409 T C 4.47E-06 Type 2 diabetes IDE intron 22158537 rs2421943 chr10 94311815 G A 9.10E-07 Type 2 diabetes IDE intron 17460697 rs2421943 chr10 94311815 G A 3.62E-06 Type 2 diabetes IDE intron 22158537 rs7908111 chr10 94314804 A G 6.23E-06 Type 2 diabetes IDE intron 22158537 rs7908111 chr10 94314804 A G 3.22E-05 Ankle-brachial index IDE intron 22199011 rs11187074 chr10 94326946 C G 2.95E-05 Type 2 diabetes IDE intron 22158537 rs11187074 chr10 94326946 C G 5.64E-05 Ankle-brachial index IDE intron 22199011 rs7100623 chr10 94327156 T C 1.89E-05 Ankle-brachial index IDE intron 22199011 rs6583823 chr10 94344415 C T 1.04E-04 Type 2 diabetes / / 22158537 rs6583826 chr10 94347830 G A 2.00E-05 Type 2 diabetes / / 17460697 rs6583826 chr10 94347830 G A 7.00E-06 Type 2 diabetes / / 21490949 rs6583826 chr10 94347830 G A 3.14E-07 Type 2 diabetes / / 22158537 rs11187083 chr10 94352505 A T 4.43E-05 Type 2 diabetes KIF11 nearGene-5 22158537 rs11187084 chr10 94352618 C T 4.62E-06 Type 2 diabetes KIF11 nearGene-5 22158537 rs11818332 chr10 94353438 T C 1.12E-05 Type 2 diabetes KIF11 intron 22158537 rs3781236 chr10 94353863 A G 7.07E-06 Type 2 diabetes KIF11 intron 22158537 rs3824735 chr10 94354204 T G 2.13E-07 Type 2 diabetes KIF11 intron 22158537 rs4604791 chr10 94356912 C T 1.73E-05 Type 2 diabetes KIF11 intron 22158537 rs17107758 chr10 94367033 A G 1.21E-05 Type 2 diabetes KIF11 intron 22158537 rs12261518 chr10 94367917 A G 9.69E-07 Type 2 diabetes KIF11 intron 22158537 rs11187094 chr10 94368178 G A 2.19E-05 Type 2 diabetes KIF11 intron 22158537 rs11187096 chr10 94369588 G T 4.41E-08 Type 2 diabetes KIF11 intron 22158537 rs10882091 chr10 94374377 C T 2.40E-06 Type 2 diabetes KIF11 intron 17460697 rs12260688 chr10 94379714 C T 2.45E-04 Type 2 diabetes KIF11 intron 17463246 rs12260688 chr10 94379714 C T 9.10E-06 Type 2 diabetes KIF11 intron 22158537 rs7914814 chr10 94382950 T C 2.50E-06 Type 2 diabetes KIF11 intron 17460697 rs7898506 chr10 94382966 G A 5.57E-05 Type 2 diabetes KIF11 intron 22158537 rs7073868 chr10 94383444 C T 4.72E-06 Type 2 diabetes KIF11 intron 22158537 rs7087860 chr10 94386154 A G 5.39E-06 Type 2 diabetes KIF11 intron 22158537 rs17107764 chr10 94392459 A T 2.01E-05 Type 2 diabetes KIF11 intron 22158537 rs11818705 chr10 94392728 C T 5.77E-06 Type 2 diabetes KIF11 intron 22158537 rs11818708 chr10 94392781 C G 4.44E-06 Type 2 diabetes KIF11 intron 22158537 rs11818750 chr10 94392830 G T 4.76E-06 Type 2 diabetes KIF11 intron 22158537 rs11819351 chr10 94394330 C T 8.38E-05 Type 2 diabetes KIF11 intron 22158537 rs10882095 chr10 94394402 T G 2.58E-08 Type 2 diabetes KIF11 intron 22158537 rs7070990 chr10 94394600 C T 3.76E-04 Type 2 diabetes KIF11 intron 22158537 rs7069680 chr10 94397761 T A 3.69E-06 Type 2 diabetes KIF11 intron 22158537 rs6583830 chr10 94398118 A G 2.40E-06 Type 2 diabetes KIF11 intron 17460697 rs6583832 chr10 94401372 T G 8.14E-04 Nicotine dependence KIF11 intron 17158188 rs7079583 chr10 94401893 C G 5.40E-04 Type 2 diabetes KIF11 intron 22158537 rs7079602 chr10 94401970 A G 4.77E-06 Type 2 diabetes KIF11 intron 22158537 rs7088685 chr10 94403598 A T 9.79E-04 Type 2 diabetes KIF11 intron 17463246 rs7088685 chr10 94403598 A T 1.56E-05 Type 2 diabetes KIF11 intron 22158537 rs7902436 chr10 94404697 T A 3.84E-05 Type 2 diabetes KIF11 intron 22158537 rs7917359 chr10 94404824 C T 3.22E-06 Type 2 diabetes KIF11 intron 22158537 rs11187114 chr10 94406237 A T 6.83E-09 Type 2 diabetes KIF11 intron 22158537 rs12264712 chr10 94408408 T C 3.23E-06 Type 2 diabetes KIF11 intron 22158537 rs7067733 chr10 94409749 T C 1.34E-11 Triglycerides KIF11 intron 23063622 rs7067733 chr10 94409749 T C 5.93E-09 Cholesterol,total KIF11 intron 23063622 rs6583833 chr10 94409800 C T 2.34E-04 Type 2 diabetes KIF11 intron 22158537 rs7078243 chr10 94414263 A C 2.07E-04 Type 2 diabetes KIF11 UTR-3 22158537 rs6583834 chr10 94419296 G A 5.49E-05 Type 2 diabetes / / 22158537 rs7914504 chr10 94422018 A T 2.57E-05 Type 2 diabetes / / 22158537 rs7079361 chr10 94422714 T C 1.57E-04 Type 2 diabetes / / 17463246 rs7096187 chr10 94423426 A C 4.07E-05 Type 2 diabetes / / 22158537 rs7899695 chr10 94429094 T C 8.30E-06 Myopia (pathological) / / 21640322 rs7911264 chr10 94436851 T C 3.00E-08 Inflammatory bowel disease / / 23128233 rs2488087 chr10 94446041 G A 1.37E-04 Type 2 diabetes / / 22158537 rs10882100 chr10 94460687 C G 8.83E-04 Alzheimer's disease / / 22005930 rs10882100 chr10 94460687 C G 9.75E-05 Type 2 diabetes / / 22158537 rs1111875 chr10 94462882 C T 3.00E-06 Type 2 diabetes / / 17293876 rs1111875 chr10 94462882 C T 6.00E-10 Type 2 diabetes / / 17463246 rs1111875 chr10 94462882 C T 6.00E-10 Type 2 diabetes / / 17463248 rs1111875 chr10 94462882 C T 5.70E-10 Type 2 diabetes / / 17463249 rs1111875 chr10 94462882 C T 7.30E-06 Type 2 diabetes / / 19184112 rs1111875 chr10 94462882 C T 7.00E-12 Type 2 diabetes / / 19401414 rs1111875 chr10 94462882 C T 7.00E-12 Coronary heart disease / / 21347282 rs1111875 chr10 94462882 C T 7.00E-12 Type 2 diabetes / / 21647700 rs1111875 chr10 94462882 C T 8.67E-05 Type 2 diabetes / / 22158537 rs1111875 chr10 94462882 C T 2.00E-19 Type 2 diabetes / / 22885922 rs1111875 chr10 94462882 C T 4.90E-12 Type 2 diabetes (males) / / 22885922 rs1111875 chr10 94462882 C T 6.70E-13 Type 2 diabetes (females) / / 22885922 rs1111875 chr10 94462882 C T 2.00E-08 Type 2 diabetes / / 23945395 rs1111875 chr10 94462882 C T 3.00E-19 Type 2 diabetes / / 24509480 rs5015480 chr10 94465559 C T 5.00E-06 Type 2 diabetes / / 17463249 rs5015480 chr10 94465559 C T 5.41E-06 Multiple complex diseases / / 17554300 rs5015480 chr10 94465559 C T 7.00E-08 Type 2 diabetes / / 18372903 rs5015480 chr10 94465559 C T 1.00E-15 Type 2 diabetes / / 20581827 rs5015480 chr10 94465559 C T 9.00E-06 Type 2 diabetes / / 20862305 rs5015480 chr10 94465559 C T 7.00E-08 Coronary heart disease / / 21347282 rs5015480 chr10 94465559 C T 1.40E-10 Type 2 diabetes / / 22158537 rs5015480 chr10 94465559 C T 2.68E-14 Type 2 diabetes / / 22325160 rs5015480 chr10 94465559 C T 2.00E-09 Type 2 diabetes / / 22693455 rs5015480 chr10 94465559 C T 2.20E-16 Type 2 diabetes / / 22885922 rs5015480 chr10 94465559 C T 1.30E-15 Type 2 diabetes / / 23300278 rs10882102 chr10 94466495 G C 1.69E-10 Type 2 diabetes / / 22158537 rs10748582 chr10 94477219 T A 3.00E-05 Type 2 diabetes / / 17463249 rs10748582 chr10 94477219 T A 6.51E-06 Multiple complex diseases / / 17554300 rs10748582 chr10 94477219 T A 2.16E-06 Type 2 diabetes / / 22158537 rs7923837 chr10 94481917 G A 2.53E-06 Type 2 diabetes / / 17293876 rs7923837 chr10 94481917 G A 5.80E-04 Type 2 diabetes / / 17460697 rs7923837 chr10 94481917 G A 2.50E-06 Type 2 diabetes / / 19184112 rs7923837 chr10 94481917 G A 5.00E-09 Multiple sclerosis / / 21833088 rs7923837 chr10 94481917 G A 8.03E-07 Type 2 diabetes / / 22158537 rs7923837 chr10 94481917 G A 0.0000375 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7923837 chr10 94481917 G A 6.40E-10 Type 2 diabetes / / 22885922 rs7923837 chr10 94481917 G A 0.00000421 Primary sclerosing cholangitis / / 23603763 rs7923866 chr10 94482076 C T 8.17E-06 Multiple complex diseases / / 17554300 rs7923866 chr10 94482076 C T 6.55E-07 Type 2 diabetes / / 22158537 rs2497306 chr10 94485211 A C 5.00E-09 Dehydroepiandrosterone sulphate levels / / 21533175 rs2488075 chr10 94490174 T C 5.79E-09 Dehydroepiandrosterone sulphate levels / / 21533175 rs2497304 chr10 94492716 C T 2.51E-04 Type 2 diabetes / / 17460697 rs2497304 chr10 94492716 C T 1.63E-08 Dehydroepiandrosterone sulphate levels / / 21533175 rs2497304 chr10 94492716 C T 2.70E-12 Type 2 diabetes / / 21874001 rs947591 chr10 94495753 C A 2.30E-05 Type 2 diabetes / / 17460697 rs947591 chr10 94495753 C A 4.03E-08 Dehydroepiandrosterone sulphate levels / / 21533175 rs4933236 chr10 94498436 T C 4.65E-09 Dehydroepiandrosterone sulphate levels / / 21533175 rs2488073 chr10 94498975 A G 3.68E-08 Dehydroepiandrosterone sulphate levels / / 21533175 rs2488071 chr10 94499577 A G 2.45E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10509646 chr10 94520669 C T 2.74E-05 Coronary heart disease / / pha003032 rs2488084 chr10 94535853 G C 2.74E-04 Multiple complex diseases / / 17554300 rs2488053 chr10 94541649 G A 5.57E-05 Serum metabolites / / 19043545 rs7896131 chr10 94549675 G A 4.65E-05 Multiple complex diseases / / 17554300 rs12241770 chr10 94560521 C T 1.85E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11187182 chr10 94562677 A G 1.38E-07 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2422067 chr10 94565784 G T 4.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2422070 chr10 94578344 C T 9.43E-04 Type 2 diabetes / / 17463246 rs3740380 chr10 94598259 C T 4.90E-05 Major depressive disorder EXOC6 intron 21042317 rs2497348 chr10 94604747 A T 5.28E-04 Type 2 diabetes EXOC6 intron 17463246 rs11516919 chr10 94618925 C T 2.70E-05 Major depressive disorder EXOC6 intron 21042317 rs1409387 chr10 94636367 G A 5.56E-04 Type 2 diabetes EXOC6 intron 17463246 rs1409387 chr10 94636367 G A 4.59E-05 Serum metabolites EXOC6 intron 19043545 rs7094393 chr10 94656941 T C 4.70E-05 Major depressive disorder EXOC6 intron 21042317 rs17377483 chr10 94660133 T C 7.01E-04 Multiple complex diseases EXOC6 intron 17554300 rs7914571 chr10 94663308 G A 4.10E-05 Major depressive disorder EXOC6 intron 21042317 rs7070025 chr10 94665632 A G 6.50E-04 Type 2 diabetes EXOC6 intron 17463246 rs7070025 chr10 94665632 A G 9.65E-05 Serum metabolites EXOC6 intron 19043545 rs7089179 chr10 94705357 G A 8.89E-04 Type 2 diabetes EXOC6 intron 17463246 rs7089179 chr10 94705357 G A 7.10E-05 Serum metabolites EXOC6 intron 19043545 rs2031616 chr10 94736967 G A 9.10E-06 Major depressive disorder EXOC6 intron 21042317 rs7082214 chr10 94740527 A G 9.50E-06 Major depressive disorder EXOC6 intron 21042317 rs835247 chr10 94744904 T G 1.00E-05 Major depressive disorder EXOC6 intron 21042317 rs865612 chr10 94750863 A C 5.84E-04 Multiple complex diseases EXOC6 intron 17554300 rs835238 chr10 94755208 T C 1.10E-05 Major depressive disorder EXOC6 intron 21042317 rs7081888 chr10 94764660 T G 6.24E-05 HDL cholesterol EXOC6 intron pha003075 rs835265 chr10 94786259 A G 2.50E-05 Urinary metabolites EXOC6 intron 21572414 rs7089188 chr10 94787521 A T 7.10E-06 Urinary metabolites EXOC6 intron 21572414 rs9420608 chr10 94800903 C G 2.20E-05 Urinary metabolites EXOC6 intron 21572414 rs2068888 chr10 94839642 G A 2.00E-08 Triglycerides / / 20686565 rs2068888 chr10 94839642 G A 6.70E-05 Information processing speed / / 21130836 rs2068888 chr10 94839642 G A 2.12E-05 Asthma / / 22561531 rs2068888 chr10 94839642 G A 2.00E-11 Triglycerides / / 24097068 rs4418728 chr10 94839724 G T 0.00003 HDL cholesterol / / 23063622 rs4418728 chr10 94839724 G T 3.46E-09 Triglycerides / / 23063622 rs11187273 chr10 94845875 C T 1.42E-04 Multiple complex diseases / / 17554300 rs913422 chr10 94847115 A G 1.82E-04 Smoking cessation / / 24665060 rs10882144 chr10 94852448 C T 0.000215 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10882144 chr10 94852448 C T 2.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17108174 chr10 94852579 C T 0.0002145 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17108174 chr10 94852579 C T 2.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11187277 chr10 94855135 T G 0.000162 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11187277 chr10 94855135 T G 1.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7899052 chr10 94857383 C G 0.0002361 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7899052 chr10 94857383 C G 2.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2182859 chr10 94868976 G T 0.00000813 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2182859 chr10 94868976 G T 8.13E-06 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7081031 chr10 94874319 C G 0.0002445 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7081031 chr10 94874319 C G 2.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7069114 chr10 94874767 T G 0.0002439 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7069114 chr10 94874767 T G 2.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1927464 chr10 94877164 A G 4.94E-04 Type 2 diabetes / / 17463246 rs1927464 chr10 94877164 A G 0.0002378 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1927464 chr10 94877164 A G 2.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10882147 chr10 94877718 A G 4.25E-04 Type 2 diabetes / / 17463246 rs10882147 chr10 94877718 A G 0.0002361 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10882147 chr10 94877718 A G 2.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10748592 chr10 94878355 T A,G 0.0002583 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10748592 chr10 94878355 T A,G 2.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17466628 chr10 94893454 C G 8.09E-04 Type 2 diabetes / / 17463246 rs4918446 chr10 94902664 A C,G 5.48E-04 Schizophrenia / / 19197363 rs10786074 chr10 94920094 G T 7.78E-04 Alzheimer's disease / / 24755620 rs11187300 chr10 94920291 T C 1.98E-04 Gallstones / / 17632509 rs10882165 chr10 94924324 A T 1.00E-11 Refractive error / / 23396134 rs17382981 chr10 94953258 C T 1.60E-05 Serum metabolites / / 19043545 rs7894625 chr10 94962714 T G 1.55E-05 Serum metabolites / / 19043545 rs7894625 chr10 94962714 T G 4.41E-04 Lymphocyte counts / / 22286170 rs11187334 chr10 94985501 C T 6.04E-06 Serum metabolites / / 19043545 rs7081443 chr10 95007493 T G 4.27E-07 Serum metabolites / / 19043545 rs12765326 chr10 95014938 G A 2.34E-07 Serum metabolites / / 19043545 rs7068778 chr10 95022590 T C 1.41E-05 Cytomegalovirus antibody response / / 21993531 rs7085507 chr10 95023142 A G 1.47E-05 Cytomegalovirus antibody response / / 21993531 rs7085808 chr10 95023363 A G 1.47E-05 Cytomegalovirus antibody response / / 21993531 rs7913670 chr10 95023936 A G 1.41E-05 Cytomegalovirus antibody response / / 21993531 rs4593939 chr10 95025150 A G 1.47E-05 Cytomegalovirus antibody response / / 21993531 rs12221227 chr10 95025901 C A 1.47E-05 Cytomegalovirus antibody response / / 21993531 rs11187354 chr10 95025979 C G 1.47E-05 Cytomegalovirus antibody response / / 21993531 rs11187355 chr10 95026006 C A 1.47E-05 Cytomegalovirus antibody response / / 21993531 rs11187356 chr10 95026023 C T 1.48E-05 Cytomegalovirus antibody response / / 21993531 rs11187357 chr10 95026048 A T 1.48E-05 Cytomegalovirus antibody response / / 21993531 rs7070169 chr10 95026500 G A 1.48E-05 Cytomegalovirus antibody response / / 21993531 rs7070620 chr10 95026783 G A 1.31E-05 Cytomegalovirus antibody response / / 21993531 rs7070533 chr10 95026950 A G 1.48E-05 Cytomegalovirus antibody response / / 21993531 rs7070935 chr10 95027167 C T 1.41E-05 Cytomegalovirus antibody response / / 21993531 rs7070944 chr10 95027198 C A 1.48E-05 Cytomegalovirus antibody response / / 21993531 rs7070837 chr10 95027218 A G 1.47E-05 Cytomegalovirus antibody response / / 21993531 rs6583876 chr10 95028069 C G 1.48E-05 Cytomegalovirus antibody response / / 21993531 rs7900460 chr10 95028099 C T 1.48E-05 Cytomegalovirus antibody response / / 21993531 rs7075911 chr10 95028378 C T 1.48E-05 Cytomegalovirus antibody response / / 21993531 rs7097393 chr10 95028466 T C 1.47E-05 Cytomegalovirus antibody response / / 21993531 rs4503467 chr10 95029520 C T 1.41E-05 Cytomegalovirus antibody response / / 21993531 rs77677819 chr10 95030453 A AC 1.47E-05 Cytomegalovirus antibody response / / 21993531 rs7912796 chr10 95030453 A C 1.47E-05 Cytomegalovirus antibody response / / 21993531 rs6583878 chr10 95030573 A G 1.41E-05 Cytomegalovirus antibody response / / 21993531 rs7089791 chr10 95030938 C T 1.47E-05 Cytomegalovirus antibody response / / 21993531 rs4143256 chr10 95031062 A G 1.47E-05 Cytomegalovirus antibody response / / 21993531 rs10882204 chr10 95032483 T G 1.25E-05 Cytomegalovirus antibody response / / 21993531 rs11813813 chr10 95035334 G A 2.60E-06 Cytomegalovirus antibody response / / 21993531 rs7911844 chr10 95035522 G A 2.62E-06 Cytomegalovirus antibody response / / 21993531 rs787652 chr10 95036575 G A 9.76E-05 Cytomegalovirus antibody response / / 21993531 rs10786086 chr10 95038188 T G 2.05E-06 Cytomegalovirus antibody response / / 21993531 rs1323688 chr10 95040595 C T 2.60E-06 Cytomegalovirus antibody response / / 21993531 rs1323689 chr10 95040769 G A 2.30E-06 Cytomegalovirus antibody response / / 21993531 rs10882207 chr10 95043470 G C 1.06E-06 Cytomegalovirus antibody response / / 21993531 rs2761303 chr10 95044356 T C 6.95E-05 Cytomegalovirus antibody response / / 21993531 rs7358204 chr10 95044582 T C 2.53E-06 Cytomegalovirus antibody response / / 21993531 rs11187368 chr10 95044909 G A 2.57E-06 Cytomegalovirus antibody response / / 21993531 rs4917720 chr10 95045413 G A 2.56E-06 Cytomegalovirus antibody response / / 21993531 rs10882209 chr10 95045992 C T 6.11E-07 Cytomegalovirus antibody response / / 21993531 rs2761304 chr10 95046048 C T 5.78E-05 Cytomegalovirus antibody response / / 21993531 rs2797571 chr10 95046375 A G 5.17E-05 Cytomegalovirus antibody response / / 21993531 rs1776067 chr10 95047402 G C 6.22E-05 Cytomegalovirus antibody response / / 21993531 rs2797572 chr10 95047600 C T 6.23E-05 Cytomegalovirus antibody response / / 21993531 rs1776069 chr10 95048686 T C 6.27E-05 Cytomegalovirus antibody response / / 21993531 rs1776070 chr10 95048925 A G 5.32E-05 Cytomegalovirus antibody response / / 21993531 rs1746485 chr10 95048965 A G 5.80E-05 Cytomegalovirus antibody response / / 21993531 rs1776071 chr10 95049058 A G 5.62E-05 Cytomegalovirus antibody response / / 21993531 rs2761305 chr10 95049330 A G 5.51E-05 Cytomegalovirus antibody response / / 21993531 rs1746486 chr10 95049415 C A 5.39E-05 Cytomegalovirus antibody response / / 21993531 rs2761308 chr10 95050819 A G 4.98E-05 Cytomegalovirus antibody response / / 21993531 rs2761309 chr10 95051032 C T 4.90E-05 Cytomegalovirus antibody response / / 21993531 rs2761312 chr10 95052262 T C 1.87E-05 Serum metabolites / / 19043545 rs3850694 chr10 95054039 A C 2.11E-06 Cytomegalovirus antibody response / / 21993531 rs10882215 chr10 95064137 G T 8.40E-04 Alcohol dependence / / 20201924 rs2797581 chr10 95070080 C T 1.60E-05 Platelet counts MYOF intron pha003100 rs10509650 chr10 95091023 A G 9.82E-04 Multiple complex diseases MYOF intron 17554300 rs4917747 chr10 95102202 A G 3.20E-05 Parkinson's disease (age of onset) MYOF intron 19772629 rs787633 chr10 95119248 T C 5.51E-05 Cognitive impairment induced by topiramate MYOF intron 22091778 rs787640 chr10 95124673 G A 1.00E-04 Cognitive impairment induced by topiramate MYOF intron 22091778 rs787640 chr10 95124673 G A 9.23E-07 Osteoarthritis MYOF intron 22763110 rs10509653 chr10 95126591 T C 9.54E-04 Type 2 diabetes MYOF intron 17846124 rs11187403 chr10 95133085 G A 7.85E-04 Multiple complex diseases MYOF intron 17554300 rs696179 chr10 95150259 A G 0.00001285 Sarcoidosis MYOF intron 22952805 rs701863 chr10 95162248 C G 2.33E-05 Bipolar disorder MYOF intron 19488044 rs1617402 chr10 95167741 A G 3.53E-04 Multiple complex diseases MYOF intron 17554300 rs788086 chr10 95178246 C T 9.48E-04 Multiple complex diseases MYOF intron 17554300 rs7091625 chr10 95194711 C T 2.50E-05 Urinary metabolites MYOF intron 21572414 rs701866 chr10 95211586 G A 6.77E-04 Coronary heart disease MYOF intron 21606135 rs17482340 chr10 95225157 G A 4.18E-05 Height MYOF intron 22021425 rs4919163 chr10 95230807 A C 4.30E-07 Urinary metabolites MYOF intron 21572414 rs871427 chr10 95233393 T G 1.20E-06 Urinary metabolites MYOF intron 21572414 rs2004558 chr10 95234482 T C 2.10E-05 Urinary metabolites MYOF intron 21572414 rs17391661 chr10 95235933 C T 4.64E-05 Height MYOF intron 22021425 rs7913010 chr10 95249382 G A 2.02E-05 Height / / 22021425 rs947599 chr10 95266683 A G 3.60E-04 Obesity-related traits CEP55 intron 17903300 rs10882256 chr10 95272834 C T 2.35E-04 HIV-1 viral setpoint CEP55 intron 17641165 rs10882259 chr10 95274972 C A 1.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CEP55 intron 20877124 rs4919224 chr10 95276673 G A 2.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CEP55 intron 20877124 rs17483894 chr10 95303332 A G 7.53E-04 Multiple complex diseases / / 17554300 rs17483894 chr10 95303332 A G 6.92E-05 Bipolar disorder,affective / / 20528957 rs17483970 chr10 95303862 T C 5.00E-04 Multiple complex diseases / / 17554300 rs17483970 chr10 95303862 T C 6.49E-05 Bipolar disorder,affective / / 20528957 rs10882267 chr10 95324503 C A 7.72E-05 Tunica Media O3FAR1 nearGene-5 pha003038 rs17484310 chr10 95326096 T A 8.27E-05 Bipolar disorder,affective O3FAR1 nearGene-5 20528957 rs12415204 chr10 95330890 C A 1.11E-04 Celiac disease O3FAR1 intron 23936387 rs12219199 chr10 95332517 C T 7.00E-04 Parkinson's disease O3FAR1 intron 16252231 rs8181419 chr10 95340811 T G 9.47E-05 Non-alcoholic fatty liver disease histology (other) O3FAR1 intron 20708005 rs11187528 chr10 95343742 C T 0.0000558 HDL cholesterol O3FAR1 intron 23063622 rs17108968 chr10 95346555 G A 8.76E-05 Non-alcoholic fatty liver disease histology (other) O3FAR1 intron 20708005 rs10882272 chr10 95348182 T C 7.00E-15 Retinol levels O3FAR1 UTR-3 21878437 rs10882272 chr10 95348182 T C 6.87E-04 Acute lung injury O3FAR1 UTR-3 22295056 rs10882273 chr10 95348905 T C 4.10E-04 Taste perception O3FAR1 UTR-3 22132133 rs10882273 chr10 95348905 T C 5.78E-04 Acute lung injury O3FAR1 UTR-3 22295056 rs7094671 chr10 95355617 G A 5.80E-05 Hypothyroidism RBP4 intron 22493691 rs17108993 chr10 95364033 C G 8.04E-06 Lipid levels / / 19913121 rs12252137 chr10 95372209 G A 4.46E-04 Taste perception PDE6C nearGene-5 22132133 rs1223306 chr10 95380790 G A,C,T 1.50E-04 Coronary heart disease PDE6C intron 21966275 rs1223306 chr10 95380790 G A,C,T 7.75E-04 Taste perception PDE6C intron 22132133 rs2785137 chr10 95386207 G A 2.50E-05 Fasting plasma glucose PDE6C intron 19060907 rs2785137 chr10 95386207 G A 1.14E-05 Glucose levels PDE6C intron pha002899 rs7080485 chr10 95387629 G A 0.000097 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes PDE6C intron 22628534 rs7080650 chr10 95387857 C T 0.000097 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes PDE6C intron 22628534 rs716333 chr10 95390741 T A 6.79E-04 Alzheimer's disease PDE6C intron 17998437 rs716333 chr10 95390741 T A 2.73E-05 Serum metabolites PDE6C intron 19043545 rs716333 chr10 95390741 T A 8.95E-04 Type 2 diabetes PDE6C intron 22158537 rs7903947 chr10 95391072 T C 0.0000506 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes PDE6C intron 22628534 rs640090 chr10 95392585 G C 5.00E-07 Preschool internalizing problems PDE6C intron 24839885 rs616522 chr10 95395247 A G 5.79E-05 Glucose levels PDE6C intron pha002899 rs3781273 chr10 95402973 A G 9.07E-05 Cognitive performance PDE6C intron 19734545 rs1409332 chr10 95405814 C A 3.92E-05 Cognitive performance PDE6C intron 19734545 rs11187571 chr10 95408651 G A 2.20E-05 Urinary metabolites PDE6C intron 21572414 rs11187573 chr10 95409762 A G 1.35E-05 Prion diseases PDE6C intron 22210626 rs2422324 chr10 95421683 G C 5.33E-04 Parkinson's disease PDE6C intron 16252231 rs1326214 chr10 95433124 A G 1.93E-05 Prion diseases FRA10AC1 intron 22210626 rs10882303 chr10 95449259 G A 1.08E-05 Arthritis (juvenile idiopathic) FRA10AC1 intron 22354554 rs10882306 chr10 95456171 T C 5.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FRA10AC1 intron 20877124 rs10882306 chr10 95456171 T C 1.93E-05 Prion diseases FRA10AC1 intron 22210626 rs11187597 chr10 95458141 A G 1.93E-05 Prion diseases FRA10AC1 cds-synon 22210626 rs726817 chr10 95459817 C T 6.00E-04 Chronic fatigue syndrome FRA10AC1 missense 21912186 rs863800 chr10 95480267 G T 1.52E-05 Prion diseases / / 22210626 rs11187629 chr10 95489435 A G 8.43E-04 Multiple complex diseases / / 17554300 rs1555870 chr10 95519577 A C 2.18E-05 Fibrinogen LGI1 intron pha003068 rs7897575 chr10 95521752 A G 6.30E-05 Fibrinogen LGI1 intron pha003068 rs17109335 chr10 95522608 G A 6.50E-04 Coronary Artery Disease LGI1 intron 17634449 rs7915994 chr10 95526168 C T 2.60E-05 Urinary metabolites LGI1 intron 21572414 rs10509665 chr10 95528442 G A 5.99E-06 Ankle-brachial index LGI1 intron 22199011 rs17109405 chr10 95543430 G T 6.00E-05 Cognitive test performance LGI1 intron 20125193 rs10736083 chr10 95550601 T C 8.60E-04 Multiple complex diseases LGI1 intron 17554300 rs12264508 chr10 95554073 C T 3.58E-04 Alzheimer's disease (late onset) LGI1 intron 21379329 rs10786147 chr10 95640551 T C 9.74E-04 Depression (quantitative trait) / / 20800221 rs4917958 chr10 95641393 G A 9.75E-04 Depression (quantitative trait) / / 20800221 rs7906044 chr10 95641985 G C 9.77E-04 Depression (quantitative trait) / / 20800221 rs12098741 chr10 95650961 A G 9.91E-04 Depression (quantitative trait) / / 20800221 rs7088236 chr10 95652130 T A 9.56E-04 Depression (quantitative trait) / / 20800221 rs7898970 chr10 95652487 A G 8.78E-04 Depression (quantitative trait) / / 20800221 rs10786148 chr10 95655566 T A 8.42E-04 Depression (quantitative trait) SLC35G1 intron 20800221 rs7917744 chr10 95656960 G T 8.42E-04 Depression (quantitative trait) SLC35G1 intron 20800221 rs11187724 chr10 95658258 C G 8.42E-04 Depression (quantitative trait) SLC35G1 intron 20800221 rs11187725 chr10 95659370 C T 8.42E-04 Depression (quantitative trait) SLC35G1 intron 20800221 rs3088126 chr10 95663285 G A 8.46E-04 Depression (quantitative trait) / / 20800221 rs10882364 chr10 95664966 A T 6.91E-04 Depression (quantitative trait) / / 20800221 rs10882364 chr10 95664966 A T 3.82E-05 QT interval / / 22726844 rs829228 chr10 95769344 C T 9.64E-04 Multiple complex diseases PLCE1 intron 17554300 rs1935961 chr10 95783242 G A 4.46E-05 Multiple complex diseases PLCE1 intron 17554300 rs17415514 chr10 95804582 T C 2.63E-05 Hearing impairment PLCE1 intron 19047183 rs7909098 chr10 95838070 G A 9.35E-05 Femoral neck bone geometry PLCE1 intron 22087292 rs7909098 chr10 95838070 G A 5.17E-05 Smoking initiation PLCE1 intron 24665060 rs9663362 chr10 95895177 G C 5.00E-09 Blood pressure PLCE1 intron 21909110 rs932764 chr10 95895940 A G 6.00E-07 Systolic blood pressure PLCE1 intron 19430483 rs932764 chr10 95895940 A G 6.08E-08 Blood pressure PLCE1 intron 21909110 rs932764 chr10 95895940 A G 7.00E-16 Systolic blood pressure PLCE1 intron 21909115 rs932764 chr10 95895940 A G 8.00E-07 Diastolic blood pressure PLCE1 intron 21909115 rs932764 chr10 95895940 A G 9.00E-09 Hypertension PLCE1 intron 21909115 rs11187795 chr10 95913708 C T 0.0000693 Menopause (age at onset) PLCE1 intron 23424626 rs1776946 chr10 95933801 C T 0.0000331 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes PLCE1 intron 22628534 rs9419788 chr10 96013705 G A 4.00E-08 Personality dimensions PLCE1 intron 21368711 rs10786156 chr10 96014622 C G 9.29E-05 Multiple complex diseases PLCE1 intron 17554300 rs3740360 chr10 96025491 A C 6.71E-10 Esophageal cancer (squamous cell) PLCE1 intron 22323360 rs11187837 chr10 96035980 T C 4.00E-07 Sudden cardiac arrest PLCE1 intron 21658281 rs12258052 chr10 96036696 G A 1.06E-04 Multiple complex diseases PLCE1 intron 17554300 rs12263737 chr10 96044913 G A 3.92E-54 Esophageal cancer (squamous cell) PLCE1 intron 20729853 rs12263737 chr10 96044913 G A 5.84E-40 Esophageal cancer (squamous cell) PLCE1 intron 20729853 rs12263737 chr10 96044913 G A 4.43E-13 Esophageal cancer (squamous cell) PLCE1 intron 22323360 rs12263737 chr10 96044913 G A 7.87E-04 Stroke PLCE1 intron pha002886 rs753724 chr10 96051417 G A,C,T 1.10E-10 Esophageal cancer (squamous cell) PLCE1 intron 22323360 rs11187842 chr10 96052511 C T 4.09E-08 Esophageal cancer (squamous cell) PLCE1 intron 22323360 rs11187844 chr10 96056629 C A 3.53E-08 Esophageal cancer PLCE1 intron 21642993 rs3765524 chr10 96058298 C T 2.00E-09 Esophageal cancer and gastric cancer PLCE1 missense 20729852 rs3765524 chr10 96058298 C T 3.00E-10 Dengue shock syndrome PLCE1 missense 22001756 rs3765524 chr10 96058298 C T 3.15E-14 Esophageal cancer (squamous cell) PLCE1 missense 22323360 rs117607728 chr10 96058636 G T 4.00E-07 Chronic obstructive pulmonary disease PLCE1 intron 21685187 rs2274223 chr10 96066341 A G 1.74E-39 Esophageal cancer (squamous cell) PLCE1 missense 20729853 rs2274223 chr10 96066341 A G 7.46E-56 Esophageal cancer (squamous cell) PLCE1 missense 20729853 rs2274223 chr10 96066341 A G 4.00E-20 Esophageal cancer PLCE1 missense 21642993 rs2274223 chr10 96066341 A G 1.19E-07 Dengue shock syndrome PLCE1 missense 22001756 rs2274223 chr10 96066341 A G 1.44E-13 Esophageal cancer (squamous cell) PLCE1 missense 22323360 rs10509671 chr10 96069054 T G 4.31E-04 Type 2 diabetes PLCE1 intron 17463246 rs3781264 chr10 96070375 A G 4.32E-04 Type 2 diabetes PLCE1 intron 17463246 rs3781264 chr10 96070375 A G 4.00E-09 Esophageal cancer and gastric cancer PLCE1 intron 20729852 rs3781264 chr10 96070375 A G 3.43E-07 Dengue shock syndrome PLCE1 intron 22001756 rs3781264 chr10 96070375 A G 5.77E-11 Esophageal cancer (squamous cell) PLCE1 intron 22323360 rs3781264 chr10 96070375 A G 2.31E-04 Stroke PLCE1 intron pha002886 rs11187853 chr10 96072228 G A 2.11E-08 Esophageal cancer PLCE1 intron 21642993 rs6583937 chr10 96083452 A G 1.88E-08 Esophageal cancer PLCE1 intron 21642993 rs10882424 chr10 96086078 T G 1.70E-08 Esophageal cancer PLCE1 intron 21642993 rs17438706 chr10 96087056 A C 8.40E-06 Urinary metabolites PLCE1 intron 21572414 rs11187876 chr10 96090139 C T 1.70E-08 Esophageal cancer / / 21642993 rs10882430 chr10 96090672 A G 1.70E-08 Esophageal cancer / / 21642993 rs17517515 chr10 96098025 G A 5.40E-06 Urinary metabolites NOC3L intron 21572414 rs10786161 chr10 96107671 C T 1.08E-08 Esophageal cancer NOC3L intron 21642993 rs12780491 chr10 96121022 A G 6.80E-05 Prion diseases NOC3L intron 22210626 rs12780491 chr10 96121022 A G 2.03E-04 Stroke NOC3L intron pha002886 rs11187919 chr10 96143498 G A 3.80E-06 Urinary metabolites / / 21572414 rs12785155 chr10 96184641 C T 5.60E-06 Urinary metabolites TBC1D12 intron 21572414 rs11187969 chr10 96231169 G A 8.85E-04 Multiple complex diseases TBC1D12 intron 17554300 rs1969815 chr10 96324151 A G 1.60E-05 Urinary metabolites HELLS intron 21572414 rs11188040 chr10 96355066 C T 2.00E-05 Urinary metabolites HELLS intron 21572414 rs1065026 chr10 96369266 C T 6.00E-06 Urinary metabolites / / 21572414 rs1047625 chr10 96370853 T G 6.10E-06 Urinary metabolites / / 21572414 rs11188044 chr10 96387079 A G 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12772169 chr10 96405329 C T 8.00E-12 Acenocoumarol maintenance dosage / / 19578179 rs12777823 chr10 96405502 G A 2.00E-13 Response to clopidogrel therapy / / 19706858 rs12777823 chr10 96405502 G A 5.00E-12 Warfarin maintenance dose / / 23755828 rs12777823 chr10 96405502 G A 9.63E-06 Metabolite levels (X-11787) / / 23934736 rs749745 chr10 96406516 C T 8.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs10882487 chr10 96407511 C T 2.60E-05 Urinary metabolites / / 21572414 rs1998591 chr10 96407978 G A 8.06E-09 Acenocoumarol maintenance dosage / / 19578179 rs12782132 chr10 96409503 T C 9.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs12765793 chr10 96413072 A G 7.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs12784245 chr10 96427951 G A 7.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs2104543 chr10 96429971 C T 1.09E-08 Acenocoumarol maintenance dosage / / 19578179 rs717238 chr10 96441300 C T 6.15E-04 Suicide attempts in bipolar disorder CYP2C18 nearGene-5 21423239 rs2860838 chr10 96453039 C G 5.95E-04 Suicide attempts in bipolar disorder CYP2C18 intron 21423239 rs12243416 chr10 96454156 G A 5.54E-05 Cognitive performance CYP2C18 intron 19734545 rs7100783 chr10 96464293 G A 7.20E-04 Suicide attempts in bipolar disorder CYP2C18 intron 21423239 rs7896133 chr10 96464730 G A 8.19E-12 Acenocoumarol maintenance dosage CYP2C18 intron 19578179 rs7900135 chr10 96465616 A G 6.14E-04 Suicide attempts in bipolar disorder CYP2C18 intron 21423239 rs2296680 chr10 96466938 G A 5.91E-04 Suicide attempts in bipolar disorder CYP2C18 intron 21423239 rs7085890 chr10 96468119 G C 5.56E-04 Suicide attempts in bipolar disorder CYP2C18 intron 21423239 rs1926712 chr10 96477854 T C 4.87E-04 Suicide attempts in bipolar disorder CYP2C18 intron 21423239 rs1326832 chr10 96485584 A G 4.62E-04 Suicide attempts in bipolar disorder CYP2C18 intron 21423239 rs932809 chr10 96488469 C T 5.80E-04 Suicide attempts in bipolar disorder CYP2C18 intron 21423239 rs7085563 chr10 96488997 T A 5.76E-04 Suicide attempts in bipolar disorder CYP2C18 intron 21423239 rs1126545 chr10 96493058 C T 5.54E-04 Suicide attempts in bipolar disorder CYP2C18 missense 21423239 rs2281890 chr10 96493328 C T 5.44E-04 Suicide attempts in bipolar disorder CYP2C18 intron 21423239 rs1042192 chr10 96495284 G A,C 5.80E-04 Suicide attempts in bipolar disorder CYP2C18 UTR-3 21423239 rs1042194 chr10 96495484 G T 5.72E-04 Suicide attempts in bipolar disorder CYP2C18 UTR-3 21423239 rs1326830 chr10 96495793 C A 4.00E-04 Multiple complex diseases CYP2C18 UTR-3 17554300 rs12572499 chr10 96502802 C T 5.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs11188072 chr10 96519061 C T 1 Drug response to Amitriptyline / / 16413245 rs11188072 chr10 96519061 C T 1 Drug response to Citalopram / / 16413245 rs11188072 chr10 96519061 C T 1 Drug response to Clomipramine / / 16413245 rs11188072 chr10 96519061 C T 1 Drug response to Escitalopram / / 16413245 rs11188072 chr10 96519061 C T 1 Drug response to Omeprazole / / 16413245 rs11188072 chr10 96519061 C T 1 Drug response to Proguanil / / 16413245 rs11188072 chr10 96519061 C T 1 Drug response to Tamoxifen / / 16413245 rs11188072 chr10 96519061 C T 1 Drug response to Amitriptyline / / 17625515 rs11188072 chr10 96519061 C T 1 Drug response to Citalopram / / 17625515 rs11188072 chr10 96519061 C T 1 Drug response to Clomipramine / / 17625515 rs11188072 chr10 96519061 C T 1 Drug response to Escitalopram / / 17625515 rs11188072 chr10 96519061 C T 1 Drug response to Omeprazole / / 17625515 rs11188072 chr10 96519061 C T 1 Drug response to Proguanil / / 17625515 rs11188072 chr10 96519061 C T 1 Drug response to Tamoxifen / / 17625515 rs11188072 chr10 96519061 C T 1 Drug response to Amitriptyline / / 18294333 rs11188072 chr10 96519061 C T 1 Drug response to Citalopram / / 18294333 rs11188072 chr10 96519061 C T 1 Drug response to Clomipramine / / 18294333 rs11188072 chr10 96519061 C T 1 Drug response to Escitalopram / / 18294333 rs11188072 chr10 96519061 C T 1 Drug response to Omeprazole / / 18294333 rs11188072 chr10 96519061 C T 1 Drug response to Proguanil / / 18294333 rs11188072 chr10 96519061 C T 1 Drug response to Tamoxifen / / 18294333 rs11188072 chr10 96519061 C T 1 Drug response to Imipramine / / 19884907 rs4532967 chr10 96519197 G T 7.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs12248560 chr10 96521657 C A,T 1 Drug response to Amitriptyline CYP2C19 nearGene-5 16413245 rs12248560 chr10 96521657 C A,T 1 Drug response to Citalopram CYP2C19 nearGene-5 16413245 rs12248560 chr10 96521657 C A,T 1 Drug response to Clomipramine CYP2C19 nearGene-5 16413245 rs12248560 chr10 96521657 C A,T 1 Drug response to Escitalopram CYP2C19 nearGene-5 16413245 rs12248560 chr10 96521657 C A,T 1 Drug response to Omeprazole CYP2C19 nearGene-5 16413245 rs12248560 chr10 96521657 C A,T 1 Drug response to Proguanil CYP2C19 nearGene-5 16413245 rs12248560 chr10 96521657 C A,T 1 Drug response to Tamoxifen CYP2C19 nearGene-5 16413245 rs12248560 chr10 96521657 C A,T 1 Drug response to Amitriptyline CYP2C19 nearGene-5 18024866 rs12248560 chr10 96521657 C A,T 1 Drug response to Citalopram CYP2C19 nearGene-5 18024866 rs12248560 chr10 96521657 C A,T 1 Drug response to Clomipramine CYP2C19 nearGene-5 18024866 rs12248560 chr10 96521657 C A,T 1 Drug response to Escitalopram CYP2C19 nearGene-5 18024866 rs12248560 chr10 96521657 C A,T 1 Drug response to Omeprazole CYP2C19 nearGene-5 18024866 rs12248560 chr10 96521657 C A,T 1 Drug response to Proguanil CYP2C19 nearGene-5 18024866 rs12248560 chr10 96521657 C A,T 1 Drug response to Tamoxifen CYP2C19 nearGene-5 18024866 rs12248560 chr10 96521657 C A,T 1 Drug response to Clopidogrel CYP2C19 nearGene-5 19106083 rs12248560 chr10 96521657 C A,T 1 Drug response to Clopidogrel CYP2C19 nearGene-5 19106084 rs12248560 chr10 96521657 C A,T 1 Drug response to Imipramine CYP2C19 nearGene-5 19884907 rs4986894 chr10 96522365 T C 9.36E-04 Suicide attempts in bipolar disorder CYP2C19 nearGene-5 21423239 rs4986894 chr10 96522365 T C 6.00E-12 Blood metabolite levels CYP2C19 nearGene-5 24816252 rs28399504 chr10 96522463 A G 1 Drug response to Clopidogrel CYP2C19 missense 19106083 rs28399504 chr10 96522463 A G 1 Drug response to Clopidogrel CYP2C19 missense 19106084 rs28399504 chr10 96522463 A G 1 Drug response to Mephenytoin CYP2C19 missense 9435198 rs10509676 chr10 96523045 A T 5.89E-04 Suicide attempts in bipolar disorder CYP2C19 intron 21423239 rs17882066 chr10 96523073 G A 1.15E-08 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) CYP2C19 intron 24528284 rs17882066 chr10 96523073 G A 2.00E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) CYP2C19 intron 24528284 rs12773342 chr10 96523083 T C 5.87E-04 Suicide attempts in bipolar disorder CYP2C19 intron 21423239 rs12773342 chr10 96523083 T C 1.18E-08 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) CYP2C19 intron 24528284 rs12773342 chr10 96523083 T C 2.00E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) CYP2C19 intron 24528284 rs12768009 chr10 96525865 G A 5.85E-04 Suicide attempts in bipolar disorder CYP2C19 intron 21423239 rs6583954 chr10 96534263 C T 5.85E-04 Suicide attempts in bipolar disorder CYP2C19 intron 21423239 rs6583954 chr10 96534263 C T 4.00E-06 Migraine CYP2C19 intron 23793025 rs41291556 chr10 96535173 T C 1 Drug response to Mephenytoin CYP2C19 missense 10411572 rs41291556 chr10 96535173 T C 1 Drug response to Tolbutamide CYP2C19 missense 10411572 rs41291556 chr10 96535173 T C 1 Drug response to Clopidogrel CYP2C19 missense 19106083 rs41291556 chr10 96535173 T C 1 Drug response to Clopidogrel CYP2C19 missense 19106084 rs17884712 chr10 96535246 G A 1 Drug response to Mephenytoin CYP2C19 missense 12464799 rs4388808 chr10 96536056 A G 9.97E-05 Amyotrophic lateral sclerosis (sporadic) CYP2C19 intron 24529757 rs12778026 chr10 96536227 T A 5.87E-04 Suicide attempts in bipolar disorder CYP2C19 intron 21423239 rs4986893 chr10 96540410 G A 1 Drug response to Clopidogrel CYP2C19 STOP-GAIN 11264478 rs4986893 chr10 96540410 G A 1 Drug response to Esomeprazole CYP2C19 STOP-GAIN 16338278 rs4986893 chr10 96540410 G A 1 Drug response to Clopidogrel CYP2C19 STOP-GAIN 19106083 rs4986893 chr10 96540410 G A 1 Drug response to Clopidogrel CYP2C19 STOP-GAIN 19106084 rs4986893 chr10 96540410 G A 1 Drug response to Clopidogrel CYP2C19 STOP-GAIN 19108880 rs4986893 chr10 96540410 G A 1 Drug response to Clopidogrel CYP2C19 STOP-GAIN 19258584 rs4986893 chr10 96540410 G A 1 Drug response to Clopidogrel CYP2C19 STOP-GAIN 19576352 rs4986893 chr10 96540410 G A 1 Drug response to Clopidogrel CYP2C19 STOP-GAIN 7969038 rs4986893 chr10 96540410 G A 1 Drug response to Clopidogrel CYP2C19 STOP-GAIN 8195181 rs6413438 chr10 96541615 C T 1 Drug response to Mephenytoin CYP2C19 missense 12464799 rs6413438 chr10 96541615 C T 0.00037 Breast cancer (ER positive) CYP2C19 missense 23555315 rs4244285 chr10 96541616 G A,C 1 Drug response to Clopidogrel CYP2C19 cds-synon 11264478 rs4244285 chr10 96541616 G A,C 1 Drug response to Esomeprazole CYP2C19 cds-synon 16338278 rs4244285 chr10 96541616 G A,C 1 Drug response to Clopidogrel CYP2C19 cds-synon 19106083 rs4244285 chr10 96541616 G A,C 1 Drug response to Clopidogrel CYP2C19 cds-synon 19106084 rs4244285 chr10 96541616 G A,C 1 Drug response to Clopidogrel CYP2C19 cds-synon 19108880 rs4244285 chr10 96541616 G A,C 1 Drug response to Clopidogrel CYP2C19 cds-synon 19258584 rs4244285 chr10 96541616 G A,C 1 Drug response to Clopidogrel CYP2C19 cds-synon 19576352 rs4244285 chr10 96541616 G A,C 5.87E-04 Suicide attempts in bipolar disorder CYP2C19 cds-synon 21423239 rs4244285 chr10 96541616 G A,C 1 Drug response to Clopidogrel CYP2C19 cds-synon 7969038 rs4244285 chr10 96541616 G A,C 1 Drug response to Clopidogrel CYP2C19 cds-synon 8195181 rs12571421 chr10 96541982 A G 5.89E-04 Suicide attempts in bipolar disorder CYP2C19 intron 21423239 rs12571421 chr10 96541982 A G 1.24E-08 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) CYP2C19 intron 24528284 rs12571421 chr10 96541982 A G 2.00E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) CYP2C19 intron 24528284 rs12767583 chr10 96547463 C T 3.00E-07 Acenocoumarol maintenance dosage CYP2C19 intron 19578179 rs12767583 chr10 96547463 C T 5.86E-04 Suicide attempts in bipolar disorder CYP2C19 intron 21423239 rs1853205 chr10 96575069 C G 5.86E-04 Suicide attempts in bipolar disorder CYP2C19 intron 21423239 rs1322179 chr10 96575242 C T 9.53E-04 Suicide attempts in bipolar disorder CYP2C19 intron 21423239 rs10509678 chr10 96576190 A C 5.02E-11 Acenocoumarol maintenance dosage CYP2C19 intron 19578179 rs4417205 chr10 96580202 C G 5.87E-04 Suicide attempts in bipolar disorder CYP2C19 intron 21423239 rs3758580 chr10 96602622 C T 7.14E-04 Suicide attempts in bipolar disorder CYP2C19 cds-synon 21423239 rs56337013 chr10 96612495 C T 1 Drug response to Mephenytoin CYP2C19 missense 10022751 rs56337013 chr10 96612495 C T 1 Drug response to Tolbutamide CYP2C19 missense 10022751 rs35709381 chr10 96614725 G T 2.00E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs35709381 chr10 96614725 G T 9.04E-09 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs3862009 chr10 96619025 C T 1.31E-11 Acenocoumarol maintenance dosage / / 19578179 rs733115 chr10 96619086 G T 1.31E-11 Acenocoumarol maintenance dosage / / 19578179 rs12569735 chr10 96621103 A G 2.00E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs12569735 chr10 96621103 A G 8.65E-09 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs12573074 chr10 96626202 T C 7.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs12573074 chr10 96626202 T C 2.00E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs12573074 chr10 96626202 T C 8.66E-09 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs4589212 chr10 96628105 A T 2.00E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs4589212 chr10 96628105 A T 8.83E-09 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs12763230 chr10 96629341 G A 2.00E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs12763230 chr10 96629341 G A 9.54E-09 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs12775707 chr10 96645380 A C 8.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs9888067 chr10 96648224 T G 6.96E-06 Brain structure / / 22504417 rs4110517 chr10 96650328 A G 6.37E-06 Brain structure / / 22504417 rs4110518 chr10 96650570 C T 1.66E-04 Hearing function / / 17255346 rs1853207 chr10 96665937 C T 1.00E-12 Blood metabolite levels / / 24816252 rs2181097 chr10 96681000 G A 2.00E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs2181097 chr10 96681000 G A 4.51E-09 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs1074145 chr10 96681846 G A 9.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs1074145 chr10 96681846 G A 2.00E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs1074145 chr10 96681846 G A 4.00E-09 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs2253635 chr10 96700537 C T 3.19E-09 Acenocoumarol maintenance dosage CYP2C9 intron 19578179 rs2253635 chr10 96700537 C T 7.36E-05 Schizophrenia CYP2C9 intron 21926974 rs1799853 chr10 96702047 C T 1 Drug response to Warfarin CYP2C9 missense 10073515 rs1799853 chr10 96702047 C T 1 Drug response to Warfarin CYP2C9 missense 15001971 rs1799853 chr10 96702047 C T 1 Drug response to Warfarin CYP2C9 missense 15284536 rs1799853 chr10 96702047 C T 1 Drug response to Warfarin CYP2C9 missense 15714076 rs1799853 chr10 96702047 C T 1 Drug response to Warfarin CYP2C9 missense 15947090 rs1799853 chr10 96702047 C T 1 Drug response to Warfarin CYP2C9 missense 16580898 rs1799853 chr10 96702047 C T 1 Drug response to Warfarin CYP2C9 missense 17635701 rs1799853 chr10 96702047 C T 1 Drug response to Warfarin CYP2C9 missense 17846394 rs1799853 chr10 96702047 C T 1 Drug response to Warfarin CYP2C9 missense 17906972 rs1799853 chr10 96702047 C T 1 Drug response to Warfarin CYP2C9 missense 18056659 rs1799853 chr10 96702047 C T 1 Drug response to Warfarin CYP2C9 missense 18250228 rs1799853 chr10 96702047 C T 1 Drug response to Warfarin CYP2C9 missense 18281915 rs1799853 chr10 96702047 C T 1 Drug response to Warfarin CYP2C9 missense 18305455 rs1799853 chr10 96702047 C T 1 Drug response to Warfarin CYP2C9 missense 18855533 rs1799853 chr10 96702047 C T 1 Drug response to Warfarin CYP2C9 missense 19228618 rs1799853 chr10 96702047 C T 1.00E-31 Warfarin maintenance dose CYP2C9 missense 19300499 rs1799853 chr10 96702047 C T 1 Drug response to Warfarin CYP2C9 missense 19794411 rs1799853 chr10 96702047 C T 1 Drug response to Glibenclamide CYP2C9 missense 19794412 rs1799853 chr10 96702047 C T 1 Drug response to Gliclazide CYP2C9 missense 19794412 rs1799853 chr10 96702047 C T 1 Drug response to Glimepiride CYP2C9 missense 19794412 rs1799853 chr10 96702047 C T 1 Drug response to Glipizide CYP2C9 missense 19794412 rs1799853 chr10 96702047 C T 1 Drug response to Metformin CYP2C9 missense 19794412 rs7900194 chr10 96702066 G A,C,T 1 Drug response to Warfarin CYP2C9 missense 20072124 rs7089580 chr10 96705223 A T 1.60E-04 Type 2 diabetes CYP2C9 intron 17463246 rs4086116 chr10 96707202 C T 6.00E-12 Warfarin maintenance dose CYP2C9 intron 18535201 rs4086116 chr10 96707202 C T 3.29E-24 Acenocoumarol maintenance dosage CYP2C9 intron 19578179 rs4918766 chr10 96711884 G A 1.82E-21 Acenocoumarol maintenance dosage CYP2C9 intron 19578179 rs2475376 chr10 96712400 A G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CYP2C9 intron 22628534 rs4917639 chr10 96725535 A C 8.02E-24 Acenocoumarol maintenance dosage CYP2C9 intron 19578179 rs4917639 chr10 96725535 A C 5.40E-04 Suicidal ideation CYP2C9 intron 22030708 rs4917639 chr10 96725535 A C 6.19E-04 Smoking quantity CYP2C9 intron 24665060 rs9332169 chr10 96731310 A G 8.34E-12 Acenocoumarol maintenance dosage CYP2C9 intron 19578179 rs9332172 chr10 96731788 A G 4.60E-04 Suicidal ideation CYP2C9 intron 22030708 rs10509680 chr10 96734339 G T 8.34E-12 Acenocoumarol maintenance dosage CYP2C9 intron 19578179 rs10509680 chr10 96734339 G T 4.00E-07 Warfarin maintenance dose CYP2C9 intron 20833655 rs1934963 chr10 96734676 T C 9.00E-65 Blood metabolite levels CYP2C9 intron 24816252 rs28371685 chr10 96740981 C T 1 Drug response to Warfarin CYP2C9 missense 20072124 rs1057910 chr10 96741053 A C 1 Drug response to Warfarin CYP2C9 missense 10073515 rs1057910 chr10 96741053 A C 1 Drug response to Losartan CYP2C9 missense 11408373 rs1057910 chr10 96741053 A C 1 Drug response to Losartan CYP2C9 missense 11823761 rs1057910 chr10 96741053 A C 1 Drug response to Celecoxib CYP2C9 missense 12893985 rs1057910 chr10 96741053 A C 1 Drug response to Warfarin CYP2C9 missense 15001971 rs1057910 chr10 96741053 A C 1 Drug response to Acenocoumarol CYP2C9 missense 15116053 rs1057910 chr10 96741053 A C 1 Drug response to Warfarin CYP2C9 missense 15284536 rs1057910 chr10 96741053 A C 1 Drug response to Warfarin CYP2C9 missense 15714076 rs1057910 chr10 96741053 A C 1 Drug response to Warfarin CYP2C9 missense 15947090 rs1057910 chr10 96741053 A C 1 Drug response to Warfarin CYP2C9 missense 16580898 rs1057910 chr10 96741053 A C 1 Drug response to Warfarin CYP2C9 missense 17635701 rs1057910 chr10 96741053 A C 1 Drug response to Warfarin CYP2C9 missense 17846394 rs1057910 chr10 96741053 A C 1 Drug response to Warfarin CYP2C9 missense 17906972 rs1057910 chr10 96741053 A C 1 Drug response to Warfarin CYP2C9 missense 18056659 rs1057910 chr10 96741053 A C 1 Drug response to Warfarin CYP2C9 missense 18250228 rs1057910 chr10 96741053 A C 1 Drug response to Warfarin CYP2C9 missense 18281915 rs1057910 chr10 96741053 A C 1 Drug response to Warfarin CYP2C9 missense 18305455 rs1057910 chr10 96741053 A C 1 Drug response to Warfarin CYP2C9 missense 18855533 rs1057910 chr10 96741053 A C 1 Drug response to Warfarin CYP2C9 missense 19228618 rs1057910 chr10 96741053 A C 3.00E-79 Warfarin maintenance dose CYP2C9 missense 19300499 rs1057910 chr10 96741053 A C 6.44E-12 Acenocoumarol maintenance dosage CYP2C9 missense 19578179 rs1057910 chr10 96741053 A C 1 Drug response to Warfarin CYP2C9 missense 19794411 rs1057910 chr10 96741053 A C 1 Drug response to Glibenclamide CYP2C9 missense 19794412 rs1057910 chr10 96741053 A C 1 Drug response to Gliclazide CYP2C9 missense 19794412 rs1057910 chr10 96741053 A C 1 Drug response to Glimepiride CYP2C9 missense 19794412 rs1057910 chr10 96741053 A C 1 Drug response to Glipizide CYP2C9 missense 19794412 rs1057910 chr10 96741053 A C 1 Drug response to Metformin CYP2C9 missense 19794412 rs28371686 chr10 96741058 C G 1 Drug response to Warfarin CYP2C9 missense 20072124 rs9332214 chr10 96743108 T C 8.34E-12 Acenocoumarol maintenance dosage CYP2C9 intron 19578179 rs28371688 chr10 96748492 G GA,GG 5.02E-04 Smoking quantity CYP2C9 intron 24665060 rs9332238 chr10 96748492 G A 5.02E-04 Smoking quantity CYP2C9 intron 24665060 rs2185570 chr10 96751270 T C 4.72E-12 Acenocoumarol maintenance dosage / / 19578179 rs2185570 chr10 96751270 T C 2.00E-08 Dehydroepiandrosterone sulphate levels / / 21533175 rs2860975 chr10 96766934 A C 1.43E-04 HIV-1 viral setpoint / / 17641165 rs2860975 chr10 96766934 A C 2.00E-07 Immune response to smallpox vaccine (IL-6) / / 22542470 rs1934975 chr10 96769769 A G 6.79E-06 Hepatitis B / / 21750111 rs1934955 chr10 96788561 A G 7.00E-05 Prostate cancer / / 21743057 rs1934955 chr10 96788561 A G 3.00E-16 Blood metabolite levels / / 24816252 rs1934954 chr10 96792202 T C 3.00E-06 Tuberculosis / / 24057671 rs1592037 chr10 96792328 G A 7.00E-05 Prostate cancer / / 21743057 rs10882517 chr10 96794734 G A 9.48E-05 Sarcoidosis / / 19165924 rs11572177 chr10 96797270 T C 1 Drug response to Amiodarone CYP2C8 intron 15618689 rs1934953 chr10 96797470 C T 5.00E-07 Immune response to smallpox vaccine (IL-6) CYP2C8 intron 22542470 rs11572174 chr10 96797571 G A 7.89E-09 Acenocoumarol maintenance dosage CYP2C8 intron 19578179 rs1934951 chr10 96798548 C T 1.00E-06 Osteonecrosis of the jaw CYP2C8 intron 18594024 rs10509681 chr10 96798749 T C 1 Drug response to Paclitaxel CYP2C8 missense 11668219 rs10509681 chr10 96798749 T C 1 Drug response to Repaglinide CYP2C8 missense 14534525 rs10509681 chr10 96798749 T C 1 Drug response to Rosiglitazone CYP2C8 missense 14534525 rs10509681 chr10 96798749 T C 1 Drug response to Repaglinide CYP2C8 missense 17178266 rs10509681 chr10 96798749 T C 1 Drug response to Rosiglitazone CYP2C8 missense 17178266 rs10509681 chr10 96798749 T C 2.17E-04 Multiple complex diseases CYP2C8 missense 17554300 rs10509681 chr10 96798749 T C 1 Drug response to Amodiaquine CYP2C8 missense 18855526 rs10509681 chr10 96798749 T C 8.60E-09 Acenocoumarol maintenance dosage CYP2C8 missense 19578179 rs11572169 chr10 96799774 T C 4.18E-08 Dehydroepiandrosterone sulphate levels CYP2C8 intron 21533175 rs1934982 chr10 96802124 A C 3.00E-05 Prostate cancer CYP2C8 intron 21743057 rs11572103 chr10 96818106 T A 1 Drug response to Paclitaxel CYP2C8 missense 11668219 rs1058930 chr10 96818119 G C 1 Drug response to Paclitaxel CYP2C8 missense 12429347 rs2185571 chr10 96824975 C T 7.00E-05 Prostate cancer CYP2C8 intron 21743057 rs11572080 chr10 96827030 C T 1 Drug response to Paclitaxel CYP2C8 missense 11668219 rs11572080 chr10 96827030 C T 1 Drug response to Repaglinide CYP2C8 missense 14534525 rs11572080 chr10 96827030 C T 1 Drug response to Rosiglitazone CYP2C8 missense 14534525 rs11572080 chr10 96827030 C T 1 Drug response to Repaglinide CYP2C8 missense 17178266 rs11572080 chr10 96827030 C T 1 Drug response to Rosiglitazone CYP2C8 missense 17178266 rs11572080 chr10 96827030 C T 1 Drug response to Amodiaquine CYP2C8 missense 18855526 rs2071426 chr10 96828323 T C 4.00E-14 Blood metabolite levels CYP2C8 splice-3 24816252 rs2071426 chr10 96828323 T C 7.00E-14 Blood metabolite levels CYP2C8 splice-3 24816252 rs72820627 chr10 96852690 T A 7.00E-06 Response to amphetamines / / 22952603 rs7097340 chr10 96864595 G A 3.26E-05 Hemoglobin / / pha003096 rs7097340 chr10 96864595 G A 3.17E-05 Hematocrit / / pha003097 rs11188203 chr10 96902153 T A 8.42E-05 Multiple complex diseases / / 17554300 rs601746 chr10 96942283 T C 1.60E-05 Subclinical atherosclerosis / / 17903303 rs626465 chr10 96949586 A G 4.59E-05 Hemoglobin / / pha003096 rs626465 chr10 96949586 A G 5.02E-05 Hematocrit / / pha003097 rs12413028 chr10 97000900 A G 4.51E-04 Type 2 diabetes PDLIM1 intron 17463246 rs12413028 chr10 97000900 A G 1.58E-04 Response to alcohol consumption (flushing response) PDLIM1 intron 24277619 rs12415795 chr10 97001343 C T 1.64E-04 Type 2 diabetes PDLIM1 intron 17463246 rs7912686 chr10 97026458 T C 3.99E-04 Alcohol dependence PDLIM1 intron 21314694 rs11188258 chr10 97043960 G A 1.00E-04 Cognitive impairment induced by topiramate PDLIM1 intron 22091778 rs7084752 chr10 97070115 A G 9.01E-05 Weight / / pha003026 rs3193970 chr10 97072008 T C 1.00E-04 Sudden cardiac arrest SORBS1 UTR-3 21738491 rs4542335 chr10 97086375 C G 5.59E-05 Suicide attempts in bipolar disorder SORBS1 intron 21041247 rs10882583 chr10 97109019 A G 3.56E-05 Obsessive-compulsive disorder SORBS1 intron 24821223 rs6583995 chr10 97110879 C T 1.22E-04 Suicide attempts in bipolar disorder SORBS1 intron 21041247 rs6583995 chr10 97110879 C T 5.62E-04 Suicide attempts in bipolar disorder SORBS1 intron 21041247 rs7076888 chr10 97116219 C T 6.08E-04 Suicide attempts in bipolar disorder SORBS1 intron 21041247 rs7076888 chr10 97116219 C T 8.62E-06 Suicide attempts in bipolar disorder SORBS1 intron 21041247 rs7900095 chr10 97119049 T C 2.05E-04 Suicide attempts in bipolar disorder SORBS1 intron 21041247 rs7900095 chr10 97119049 T C 5.58E-06 Suicide attempts in bipolar disorder SORBS1 intron 21041247 rs7079293 chr10 97119593 T C 2.05E-04 Suicide attempts in bipolar disorder SORBS1 intron 21041247 rs7079293 chr10 97119593 T C 6.19E-06 Suicide attempts in bipolar disorder SORBS1 intron 21041247 rs4918918 chr10 97122241 T C 1.49E-04 Suicide attempts in bipolar disorder SORBS1 intron 21041247 rs4918918 chr10 97122241 T C 3.28E-06 Suicide attempts in bipolar disorder SORBS1 intron 21041247 rs4917686 chr10 97122377 T C 5.70E-06 Multiple complex diseases SORBS1 intron 17554300 rs955760 chr10 97123885 G A 3.63E-04 Suicide attempts in bipolar disorder SORBS1 intron 21041247 rs955760 chr10 97123885 G A 4.87E-06 Suicide attempts in bipolar disorder SORBS1 intron 21041247 rs6583997 chr10 97127264 T C 5.04E-04 Suicide attempts in bipolar disorder SORBS1 intron 21041247 rs12269572 chr10 97130450 T C 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SORBS1 intron 22628534 rs2274491 chr10 97196978 T A 7.00E-06 Migraine - clinic-based SORBS1 intron 23793025 rs2274491 chr10 97196978 T A 7.88E-04 Migraine with aura SORBS1 intron 23793025 rs11592098 chr10 97210983 G A 2.67E-05 Coronary heart disease SORBS1 intron pha003032 rs10882599 chr10 97217591 T A 2.97E-04 Suicide attempts in bipolar disorder SORBS1 intron 21423239 rs7089696 chr10 97218911 G A 2.59E-04 Suicide attempts in bipolar disorder SORBS1 intron 21423239 rs2148893 chr10 97220990 C A 2.33E-04 Suicide attempts in bipolar disorder SORBS1 intron 21423239 rs579342 chr10 97229762 G A 4.00E-06 Obesity-related traits SORBS1 intron 23251661 rs1536558 chr10 97232268 G T 4.77E-05 Type 2 diabetes SORBS1 intron 17846124 rs1536558 chr10 97232268 G T 4.80E-05 Type 2 diabetes SORBS1 intron 21647700 rs7071071 chr10 97239708 A G 4.50E-06 Diabetic nephropathy SORBS1 intron 20347642 rs12247897 chr10 97251762 C T 9.74E-06 Obesity-related traits SORBS1 intron 23251661 rs1536447 chr10 97260564 A G 1.40E-04 Type 2 diabetes and 6 quantitative traits SORBS1 intron 17848626 rs11188337 chr10 97266574 G A 2.64E-04 Smoking initiation SORBS1 intron 24665060 rs12776562 chr10 97269933 C A 7.98E-06 Leukocyte Counts SORBS1 intron pha003091 rs17110879 chr10 97272372 G A 8.96E-04 Suicide attempts in bipolar disorder SORBS1 intron 21423239 rs10882607 chr10 97274838 A C 8.83E-04 Suicide attempts in bipolar disorder SORBS1 intron 21423239 rs943347 chr10 97278123 T C 8.87E-05 Cognitive test performance SORBS1 intron 20125193 rs17110913 chr10 97283567 C T 5.76E-04 Smoking initiation SORBS1 intron 24665060 rs1326934 chr10 97284081 C T 6.21E-05 Leukocyte Counts SORBS1 intron pha003091 rs1326934 chr10 97284081 C T 8.97E-05 Platelet counts SORBS1 intron pha003100 rs11188346 chr10 97289992 G A 2.83E-05 Leukocyte Counts SORBS1 intron pha003091 rs10882611 chr10 97294813 G A 1.31E-05 Leukocyte Counts SORBS1 intron pha003091 rs10882612 chr10 97295395 T C 8.24E-04 Suicide attempts in bipolar disorder SORBS1 intron 21423239 rs12772243 chr10 97295589 A G 5.00E-06 IgG glycosylation SORBS1 intron 23382691 rs1536442 chr10 97295922 T G 7.55E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SORBS1 intron 20031582 rs17458865 chr10 97296254 G A 1.20E-05 Urinary metabolites SORBS1 intron 21572414 rs11188352 chr10 97301004 T G 3.00E-06 IgG glycosylation SORBS1 intron 23382691 rs11188352 chr10 97301004 T G 5.00E-06 IgG glycosylation SORBS1 intron 23382691 rs11188352 chr10 97301004 T G 6.00E-06 IgG glycosylation SORBS1 intron 23382691 rs11188356 chr10 97309704 G A 1.25E-04 Suicide attempts in bipolar disorder SORBS1 intron 21423239 rs12255572 chr10 97328227 A G 2.80E-05 Cortisol secretion,in saliva / / 21316860 rs17110984 chr10 97332195 C T 3.18E-04 HIV-1 viral setpoint / / 17641165 rs10509689 chr10 97345469 G A 2.19E-04 HIV-1 viral setpoint / / 17641165 rs10882635 chr10 97348845 G A 8.63E-05 Cortisol secretion,in saliva / / 21316860 rs487077 chr10 97349492 G A 5.37E-04 Insulin resistance / / 21901158 rs10882639 chr10 97368990 G A 3.54E-04 HIV-1 viral setpoint ALDH18A1 intron 17641165 rs1409709 chr10 97372559 A G 4.39E-05 Multiple complex diseases ALDH18A1 intron 17554300 rs11188403 chr10 97375268 G A 9.73E-06 Migraine ALDH18A1 intron 23793025 rs501819 chr10 97383926 A C 5.39E-05 Major depressive disorder ALDH18A1 intron 19107115 rs2275272 chr10 97388162 G A 2.28E-04 Vaspin levels ALDH18A1 missense 22907691 rs2275272 chr10 97388162 G A 0.0002276 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks ALDH18A1 missense 22907730 rs11188409 chr10 97393475 C T 1.42E-04 Arthritis (juvenile idiopathic) ALDH18A1 intron 22354554 rs56322409 chr10 97395962 T C 8.00E-11 Blood metabolite levels ALDH18A1 intron 24816252 rs11188412 chr10 97401996 G A 3.24E-06 Osteoarthritis ALDH18A1 intron 22763110 rs2282305 chr10 97421345 G A 7.17E-04 Stroke (pediatric) / / 22990015 rs10882651 chr10 97438823 C T 4.91E-05 Major depressive disorder TCTN3 intron 19107115 rs10748638 chr10 97451518 T C 9.58E-05 Coronary heart disease TCTN3 intron pha003031 rs3949478 chr10 97473214 A G 3.20E-05 Nicotine smoking ENTPD1 intron 19268276 rs10748643 chr10 97516764 A G 6.41E-04 Multiple complex diseases ENTPD1 intron 17554300 rs4551688 chr10 97523780 A G 6.53E-04 Multiple complex diseases ENTPD1 intron 17554300 rs4431963 chr10 97529271 T C 4.47E-04 Multiple complex diseases ENTPD1 intron 17554300 rs7096248 chr10 97539087 C T 9.29E-04 Type 2 diabetes ENTPD1 intron 17463246 rs2185818 chr10 97550740 G A 7.07E-04 Multiple complex diseases ENTPD1 intron 17554300 rs4396219 chr10 97561941 C A 7.25E-04 Multiple complex diseases ENTPD1 intron 17554300 rs1891536 chr10 97591297 T C 2.22E-11 Lymphocyte counts ENTPD1 intron 22286170 rs7074403 chr10 97605057 C G 8.23E-04 Multiple complex diseases ENTPD1 intron 17554300 rs10786240 chr10 97666538 C T 3.20E-05 Serum metabolites LOC728558 intron 19043545 rs7922216 chr10 97728428 G A 9.15E-04 Amyotrophic lateral sclerosis (sporadic) LOC728558 intron 24529757 rs7900838 chr10 97748040 G A 5.46E-05 Schizophrenia LOC728558 intron 19571809 rs2039617 chr10 97759203 G A 1.40E-05 Alcohol dependence LOC728558 intron 21956439 rs6584044 chr10 97767386 C T 8.41E-04 Insulin resistance CC2D2B intron 21901158 rs7084542 chr10 97843348 A G 6.69E-05 Schizophrenia LOC728558 intron 19571809 rs12263592 chr10 97851432 G A 3.47E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1172943 chr10 97870781 A G 2.41E-05 Schizophrenia / / 19571809 rs10509700 chr10 97894531 G C 4.20E-05 Electrocardiographic traits and heart rate variability ZNF518A intron 17903306 rs1177749 chr10 97897991 G A 1.29E-05 Schizophrenia ZNF518A intron 19571809 rs3762090 chr10 97913378 A G 4.36E-05 Schizophrenia ZNF518A intron 19571809 rs11188634 chr10 97915182 C T 1.32E-05 Schizophrenia ZNF518A intron 19571809 rs10509703 chr10 97924440 G T 1.26E-06 Statin-induced myopathy / / 21826682 rs11188655 chr10 97947937 A G 5.47E-05 Schizophrenia / / 19571809 rs10882742 chr10 97948589 T G 3.78E-05 Schizophrenia / / 19571809 rs17111453 chr10 97974194 T G 4.12E-04 Multiple complex diseases BLNK intron 17554300 rs10491067 chr10 97982240 T C 5.17E-05 Coronary heart disease BLNK intron 21606135 rs4917723 chr10 97982575 A C 2.17E-04 Multiple complex diseases BLNK intron 17554300 rs10882754 chr10 97993942 C T 3.04E-04 Smoking initiation BLNK intron 24665060 rs10748668 chr10 98019584 T C 6.09E-04 Multiple complex diseases BLNK intron 17554300 rs17111536 chr10 98019690 T C 7.97E-04 Multiple complex diseases BLNK intron 17554300 rs147702836 chr10 98095688 G A 0.000017 Breast cancer (ER positive) DNTT missense 23555315 rs147702836 chr10 98095688 G A 0.00024 Breast cancer DNTT missense 23555315 rs7096643 chr10 98098616 C T 1.90E-05 Urinary metabolites / / 21572414 rs1923704 chr10 98102398 T C 2.20E-05 Urinary metabolites / / 21572414 rs11188724 chr10 98104703 C T 8.13E-04 Response to statin treatment (atorvastatin),change in cholesterol levels OPALIN UTR-3 20031582 rs12571241 chr10 98113333 T C 2.90E-05 Urinary metabolites OPALIN intron 21572414 rs11188734 chr10 98117931 C T 1.97E-04 Weight loss (gastric bypass surgery) OPALIN intron 23643386 rs17479671 chr10 98132016 C T 2.86E-04 Major depressive disorder TLL2 intron 22472876 rs10786284 chr10 98135505 A T 2.00E-06 Attention deficit hyperactivity disorder TLL2 intron 18839057 rs11188739 chr10 98135631 C A 9.36E-04 Multiple complex diseases TLL2 intron 17554300 rs4919008 chr10 98148557 C G 2.96E-04 Alzheimer's disease TLL2 intron 17998437 rs7915341 chr10 98157460 G T 1.00E-04 Cognitive impairment induced by topiramate TLL2 intron 22091778 rs10509709 chr10 98164357 C G 5.82E-04 Alzheimer's disease TLL2 intron 17998437 rs4917737 chr10 98168154 T C 5.79E-04 Multiple complex diseases TLL2 intron 17554300 rs10509710 chr10 98181737 A G 5.40E-06 Urinary metabolites TLL2 intron 21572414 rs7096410 chr10 98183120 T A 7.20E-06 Urinary metabolites TLL2 intron 21572414 rs9988781 chr10 98196029 T C 1.50E-05 Urinary metabolites TLL2 intron 21572414 rs2861579 chr10 98207301 C T 4.01E-04 Multiple complex diseases TLL2 intron 17554300 rs7083245 chr10 98221417 C T 5.22E-04 Multiple complex diseases TLL2 intron 17554300 rs10786291 chr10 98223002 A T 6.43E-04 Multiple complex diseases TLL2 intron 17554300 rs10736109 chr10 98227947 C T 4.84E-04 Taste perception TLL2 intron 22132133 rs11188782 chr10 98236565 T G 3.00E-04 Multiple complex diseases TLL2 intron 17554300 rs11188799 chr10 98260206 T C 6.60E-04 Taste perception TLL2 intron 22132133 rs9633703 chr10 98327266 T C 8.73E-05 Inflammation TM9SF3 intron pha002897 rs7910750 chr10 98380379 C T 9.86E-04 Multiple complex diseases PIK3AP1 intron 17554300 rs4320890 chr10 98384807 C T 4.41E-24 Narcolepsy PIK3AP1 intron 19629137 rs3748232 chr10 98410901 A G 6.00E-04 Multiple complex diseases PIK3AP1 intron 17554300 rs3827867 chr10 98416324 C A 2.60E-05 Urinary metabolites PIK3AP1 intron 21572414 rs7098785 chr10 98417930 A G 5.00E-06 Orthostatic hypotension PIK3AP1 intron 24124408 rs7895244 chr10 98432703 T A 5.00E-06 IgG glycosylation PIK3AP1 intron 23382691 rs17112076 chr10 98469693 C T 4.46E-05 Intracerebral hemorrhage PIK3AP1 missense 24656865 rs61856809 chr10 98469854 G A 4.03E-05 Intracerebral hemorrhage PIK3AP1 intron 24656865 rs12573330 chr10 98470341 A C 4.68E-05 Intracerebral hemorrhage PIK3AP1 intron 24656865 rs12572297 chr10 98470371 T C 4.67E-05 Intracerebral hemorrhage PIK3AP1 intron 24656865 rs57710486 chr10 98470865 T C 4.65E-05 Intracerebral hemorrhage PIK3AP1 intron 24656865 rs59343228 chr10 98470886 C G 4.65E-05 Intracerebral hemorrhage PIK3AP1 intron 24656865 rs61288415 chr10 98470969 C T 3.88E-05 Intracerebral hemorrhage PIK3AP1 intron 24656865 rs61856814 chr10 98471805 C T 4.26E-05 Intracerebral hemorrhage PIK3AP1 intron 24656865 rs1172479 chr10 98481307 T A 4.35E-04 Type 2 diabetes / / 17463246 rs1172464 chr10 98504184 G A 7.77E-05 Hypertension (early onset hypertension) / / 22479346 rs12571935 chr10 98508321 G A 4.75E-05 Bipolar disorder / / 22925353 rs482482 chr10 98514548 C A 9.40E-05 Multiple complex diseases / / 17554300 rs505010 chr10 98521516 C T 1.19E-04 Atopy / / 21625490 rs6584099 chr10 98556785 A T 4.33E-05 Asthma / / 11022011 rs6584099 chr10 98556785 A T 0.000847 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6584099 chr10 98556785 A T 8.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10882842 chr10 98557448 C T 0.0008564 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10882842 chr10 98557448 C T 8.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17112190 chr10 98639846 G A 9.00E-07 Multiple myeloma (IgH translocation) LCOR intron 23502783 rs12268272 chr10 98642248 A G 2.92E-04 Smoking initiation LCOR intron 24665060 rs11815437 chr10 98667529 T C 9.21E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LCOR intron 20877124 rs3829856 chr10 98742750 A C 1.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C10orf12 missense 20877124 rs11188984 chr10 98766221 C T 3.20E-04 Alcohol dependence SLIT1 intron 20201924 rs4919062 chr10 98786856 A C 1.35E-05 Type 2 diabetes SLIT1 intron 17463246 rs7896883 chr10 98787354 T C 6.44E-04 Obesity (extreme) SLIT1 intron 21935397 rs12773465 chr10 98794059 A G 2.00E-07 Mean arterial pressure (alcohol consumption interaction) SLIT1 intron 24376456 rs12268044 chr10 98794615 C T 3.48E-04 Depression (quantitative trait) SLIT1 intron 20800221 rs12268044 chr10 98794615 C T 5.99E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLIT1 intron 20877124 rs12268044 chr10 98794615 C T 7.22E-04 Smoking initiation SLIT1 intron 24665060 rs3824789 chr10 98800099 G A 6.00E-06 Obesity-related traits SLIT1 intron 23251661 rs7902871 chr10 98809703 A G 1.00E-06 Diastolic blood pressure (alcohol consumption interaction) SLIT1 intron 24376456 rs2255174 chr10 98816373 C A 3.95E-04 Depression (quantitative trait) SLIT1 intron 20800221 rs1490688 chr10 98860474 C T 8.20E-05 Pericardial fat SLIT1 intron 22589742 rs4919069 chr10 98861084 C T 9.60E-05 Pericardial fat SLIT1 intron 22589742 rs2279510 chr10 98863189 C T 7.80E-05 Pericardial fat SLIT1 intron 22589742 rs4917756 chr10 98875408 G A 8.10E-05 Pericardial fat SLIT1 intron 22589742 rs2636788 chr10 98876941 G A 2.74E-05 Attention deficit hyperactivity disorder SLIT1 intron 22420046 rs2817708 chr10 98889713 T C 5.38E-05 Attention deficit hyperactivity disorder SLIT1 intron 22420046 rs2817713 chr10 98896779 C A 2.13E-05 Smoking initiation SLIT1 intron 24665060 rs2817647 chr10 98897237 G A 7.22E-04 Smoking initiation SLIT1 intron 24665060 rs7072055 chr10 98908733 C A 2.00E-06 IgG glycosylation SLIT1 intron 23382691 rs2784920 chr10 98913628 G T 1.55E-04 Cognitive decline SLIT1 intron 23732972 rs17502307 chr10 98920840 G A 1.00E-04 Prostate cancer SLIT1 intron 21743057 rs12360055 chr10 98924818 C T 1.32E-04 Prion diseases SLIT1 intron 22210626 rs2784917 chr10 98928942 A G 1 Drug response to Etoposide SLIT1 intron 17537913 rs2636802 chr10 98930392 T C 1 Drug response to Etoposide SLIT1 intron 17537913 rs2636797 chr10 98931738 T C 1 Drug response to Etoposide SLIT1 intron 17537913 rs2817666 chr10 98933853 G A 6.29E-04 Multiple complex diseases SLIT1 intron 17554300 rs701803 chr10 98948671 C T 8.84E-06 Cognitive decline ARHGAP19-SLIT1 intron 23207651 rs701808 chr10 98958034 G A 2.13E-04 Response to cytadine analogues (cytosine arabinoside) ARHGAP19-SLIT1 intron 24483146 rs701814 chr10 98975719 G A 6.06E-04 Multiple complex diseases ARHGAP19-SLIT1 intron 17554300 rs953097 chr10 98981914 T C 2.91E-04 Alzheimer's disease ARHGAP19-SLIT1 intron 24755620 rs10748691 chr10 98983955 G A 1.58E-04 Multiple complex diseases ARHGAP19 UTR-3 17554300 rs793517 chr10 98987522 T C 8.11E-04 Multiple complex diseases ARHGAP19 intron 17554300 rs793515 chr10 98988469 A C 2.50E-04 Crohn's disease ARHGAP19 intron 17684544 rs2297987 chr10 98989454 A G 4.61E-04 Multiple complex diseases ARHGAP19 intron 17554300 rs2861875 chr10 98990139 G C 1.14E-04 Multiple complex diseases ARHGAP19 intron 17554300 rs2861875 chr10 98990139 G C 5.29E-04 Alzheimer's disease ARHGAP19 intron 24755620 rs7074678 chr10 99015364 A G 8.08E-04 Alzheimer's disease ARHGAP19 intron 24755620 rs3740522 chr10 99019144 C T 4.38E-04 Alzheimer's disease ARHGAP19 intron 24755620 rs793523 chr10 99023546 G T 7.34E-04 Alzheimer's disease ARHGAP19 intron 24755620 rs10786321 chr10 99026112 T C 1.38E-04 Alzheimer's disease ARHGAP19 intron 24755620 rs10736115 chr10 99031685 T C 1.46E-04 Alzheimer's disease ARHGAP19 intron 24755620 rs701821 chr10 99038562 G A 0.0000189 HDL cholesterol particle diameter ARHGAP19 intron 23263444 rs1253401 chr10 99050270 G A 0.0000167 HDL cholesterol particle diameter ARHGAP19 intron 23263444 rs10882891 chr10 99059645 C A 2.76E-04 Alzheimer's disease / / 24755620 rs11189119 chr10 99067289 C T 4.96E-04 Longevity / / 22279548 rs10786327 chr10 99071408 C T 2.69E-04 Alzheimer's disease / / 24755620 rs3781373 chr10 99080585 C T 3.27E-04 Alzheimer's disease FRAT1 UTR-3 24755620 rs7901853 chr10 99082360 T C 4.25E-04 Alzheimer's disease / / 24755620 rs11189131 chr10 99085835 G A 4.08E-04 Alzheimer's disease / / 24755620 rs7078288 chr10 99086361 C T 4.30E-04 Alzheimer's disease / / 24755620 rs10882898 chr10 99087330 G A 4.30E-04 Alzheimer's disease / / 24755620 rs4919089 chr10 99087905 G A 4.30E-04 Alzheimer's disease / / 24755620 rs4919091 chr10 99088682 T A 4.13E-04 Alzheimer's disease / / 24755620 rs915196 chr10 99092586 A G 6.30E-06 Age-related macular degeneration FRAT2 UTR-3 pha000001 rs4917766 chr10 99097191 G A 4.68E-04 Alzheimer's disease / / 24755620 rs1048445 chr10 99116903 C T 6.67E-04 Alzheimer's disease RRP12 missense 24755620 rs2275581 chr10 99126249 G A 1.74E-04 Alzheimer's disease RRP12 cds-synon 24755620 rs7895695 chr10 99167255 G A 0.0000357 Schizophrenia / / 23637625 rs2236575 chr10 99225738 T A 4.53E-04 Heart rate MMS19 intron 23583979 rs7915501 chr10 99257815 T G 4.63E-05 Lung Cancer (DNA repair capacity) MMS19 intron 23108145 rs10786352 chr10 99271281 C T 2.47E-04 Hemoglobin concentration UBTD1 intron 20534544 rs7908417 chr10 99278820 T C 2.39E-04 Amyotrophic lateral sclerosis (sporadic) UBTD1 intron 24529757 rs4917774 chr10 99281872 A G 6.15E-05 Serum metabolites UBTD1 intron 19043545 rs11592144 chr10 99283062 T G 4.98E-04 Hemoglobin concentration UBTD1 intron 20534544 rs12767760 chr10 99294797 G A 7.00E-06 Obesity-related traits UBTD1 intron 23251661 rs2185512 chr10 99317388 A G 3.42E-04 Insulin resistance UBTD1 intron 21901158 rs7094973 chr10 99337572 G A 2.79E-04 Alzheimer's disease (late onset) ANKRD2 missense 21379329 rs2282372 chr10 99342970 G A 4.49E-04 Alzheimer's disease (late onset) ANKRD2 intron 21379329 rs61863282 chr10 99351004 C T 3.10E-11 Metabolite levels HOGA1 intron 22286219 rs2861970 chr10 99352084 A G 1.13E-10 Metabolite levels HOGA1 intron 22286219 rs7068278 chr10 99357142 G T 7.02E-12 Metabolite levels HOGA1 intron 22286219 rs7913812 chr10 99357631 T C 6.07E-12 Metabolite levels HOGA1 intron 22286219 rs11817730 chr10 99358511 A G 2.33E-11 Metabolite levels HOGA1 intron 22286219 rs7078003 chr10 99359412 C T 1.00E-12 Metabolite levels HOGA1 intron 22286219 rs2297644 chr10 99359739 T C 1.00E-12 Metabolite levels HOGA1 intron 22286219 rs1105999 chr10 99360533 G T 6.02E-04 Obesity (extreme) HOGA1 intron 21935397 rs4086677 chr10 99360967 G A 0.00003733 Sarcoidosis HOGA1 intron 22952805 rs17108141 chr10 99360990 G A 0.00004015 Sarcoidosis HOGA1 intron 22952805 rs11189312 chr10 99424242 T C 3.76E-04 Type 2 diabetes PI4K2A intron 17463246 rs1046221 chr10 99435487 A C 8.59E-04 Alzheimer's disease PI4K2A UTR-3 24755620 rs1046249 chr10 99435730 A G 8.29E-04 Alzheimer's disease PI4K2A UTR-3 24755620 rs3750564 chr10 99437822 A G 8.29E-04 Alzheimer's disease / / 24755620 rs2151932 chr10 99439901 G A 7.99E-04 Alzheimer's disease / / 24755620 rs7895426 chr10 99440245 G A 7.99E-04 Alzheimer's disease / / 24755620 rs10882986 chr10 99440516 T C 7.99E-04 Alzheimer's disease / / 24755620 rs1253027 chr10 99491948 A G 5.57E-04 Smoking cessation / / 24665060 rs12251897 chr10 99557701 T C 2.69E-05 Height / / pha003010 rs1417006 chr10 99558000 G A 1.10E-05 Urinary metabolites / / 21572414 rs10509714 chr10 99558738 G A 1.84E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11816631 chr10 99562572 A G 3.00E-07 Blood pressure / / 24954895 rs11189381 chr10 99563198 T C 0.00000817 Bisphosphonate-induced osteonecrosis of the jaw / / 22267851 rs4919146 chr10 99570333 G A 4.10E-05 Personality dimensions / / 18957941 rs1010006 chr10 99572296 T C 4.50E-04 Pulmonary function / / 23932459 rs4300338 chr10 99596664 G C 5.15E-04 Multiple complex diseases LOC100505561 intron 17554300 rs4300338 chr10 99596664 G C 9.15E-05 Panic disorder LOC100505561 intron 19165232 rs872570 chr10 99600367 G A 9.21E-05 Serum metabolites LOC100505561 intron 19043545 rs531676 chr10 99637578 G A 9.00E-06 Metabolic syndrome CRTAC1 intron 20694148 rs11189425 chr10 99659374 C T 5.50E-04 Primary sclerosing cholangitis CRTAC1 intron 19944697 rs11189426 chr10 99659467 G A 6.73E-04 Multiple complex diseases CRTAC1 intron 17554300 rs556474 chr10 99703805 C T 0.0000846 Cognitive impairment (no dementia) CRTAC1 intron 23042215 rs508001 chr10 99754973 A C 4.66E-05 Hemoglobin concentration CRTAC1 intron 20534544 rs508001 chr10 99754973 A C 4.15E-05 Cognitive impairment induced by topiramate CRTAC1 intron 22091778 rs12242465 chr10 99763166 G A 1.61E-04 Multiple complex diseases CRTAC1 intron 17554300 rs12242465 chr10 99763166 G A 3.66E-05 Serum metabolites CRTAC1 intron 19043545 rs557334 chr10 99765397 T C 7.91E-05 Multiple complex diseases CRTAC1 intron 17554300 rs557334 chr10 99765397 T C 1.47E-06 Serum metabolites CRTAC1 intron 19043545 rs560100 chr10 99765695 A G 1.21E-04 Multiple complex diseases CRTAC1 intron 17554300 rs560100 chr10 99765695 A G 1.84E-05 Serum metabolites CRTAC1 intron 19043545 rs561111 chr10 99765816 G A 1.16E-04 Multiple complex diseases CRTAC1 intron 17554300 rs561111 chr10 99765816 G A 2.63E-05 Serum metabolites CRTAC1 intron 19043545 rs11591797 chr10 99770333 A G 1.08E-04 Attention deficit hyperactivity disorder CRTAC1 intron 22420046 rs505699 chr10 99774076 C T 2.90E-04 Type 2 diabetes CRTAC1 intron 17463249 rs505699 chr10 99774076 C T 1.29E-05 Multiple complex diseases CRTAC1 intron 17554300 rs505699 chr10 99774076 C T 4.33E-05 Serum metabolites CRTAC1 intron 19043545 rs7922066 chr10 99785636 A G 4.20E-06 Personality dimensions CRTAC1 intron 21173776 rs1867075 chr10 99799824 G A 2.47E-04 Hemoglobin concentration / / 20534544 rs10786379 chr10 99802426 T G 6.99E-04 Multiple complex diseases / / 17554300 rs10736121 chr10 99806748 C T 4.47E-04 Multiple complex diseases / / 17554300 rs17521795 chr10 99817180 T G 3.54E-05 Serum metabolites / / 19043545 rs930479 chr10 99821880 G A 9.93E-05 Serum metabolites / / 19043545 rs920643 chr10 99822587 A C 5.49E-05 Serum metabolites / / 19043545 rs1334463 chr10 99829630 C G 7.35E-05 Serum metabolites / / 19043545 rs3850697 chr10 99832904 G T 4.71E-05 Serum metabolites / / 19043545 rs4917802 chr10 99835094 A G 6.00E-05 Personality dimensions / / 18957941 rs4917802 chr10 99835094 A G 3.31E-05 Coronary heart disease / / pha003032 rs11189479 chr10 99836031 A G 4.71E-05 Serum metabolites / / 19043545 rs10509717 chr10 99836291 A G 4.71E-05 Serum metabolites / / 19043545 rs2225693 chr10 99837301 T C 2.78E-05 Serum metabolites / / 19043545 rs10883041 chr10 99852148 G A 6.51E-05 Serum metabolites / / 19043545 rs4112273 chr10 99863227 C T 9.31E-05 Serum metabolites / / 19043545 rs987793 chr10 99868961 G A 7.93E-05 Serum metabolites / / 19043545 rs4522104 chr10 99887032 A C 8.47E-12 Lymphocyte counts / / 22286170 rs6584171 chr10 99898133 A T 3.92E-05 Serum metabolites C10orf28 intron 19043545 rs10748715 chr10 99914261 C T 6.35E-05 Serum metabolites C10orf28 intron 19043545 rs111537405 chr10 99928045 A G 0.000078 Nonsyndromic striae distensae (stretch marks) C10orf28 intron 23633020 rs1252920 chr10 99947771 G A 6.35E-05 Serum metabolites C10orf28 intron 19043545 rs7898565 chr10 99975727 A G 4.00E-05 Multiple complex diseases C10orf28 intron 17554300 rs7078393 chr10 99976739 A G 3.47E-05 Serum metabolites C10orf28 intron 19043545 rs1048757 chr10 100004441 G C 6.13E-05 Serum metabolites C10orf28 UTR-3 19043545 rs11189528 chr10 100023957 T G 7.03E-05 Serum metabolites LOXL4 intron 19043545 rs10786408 chr10 100031394 T C 8.31E-05 Serum metabolites / / 19043545 rs7905091 chr10 100046078 T G 4.23E-05 Brain structure / / 22504417 rs10748724 chr10 100047975 A C 5.37E-04 Prostate cancer mortality / / 20978177 rs10748724 chr10 100047975 A C 4.60E-06 Urinary metabolites / / 21572414 rs11189552 chr10 100083404 G T 3.75E-08 Metabolite levels / / 23281178 rs7075856 chr10 100089210 C A 7.98E-04 Alcohol dependence / / 21314694 rs12264514 chr10 100102731 A G 1.99E-04 Parkinson's disease / / 21248740 rs11189574 chr10 100118596 G A 5.91E-08 Metabolite levels / / 23281178 rs7894393 chr10 100120872 T C 7.86E-08 Metabolite levels / / 23281178 rs7894393 chr10 100120872 T C 1.90E-04 Heart Failure / / pha002885 rs11814584 chr10 100123612 T C 4.63E-09 Metabolite levels / / 23281178 rs6584190 chr10 100124075 T C 9.30E-13 Metabolite levels / / 23281178 rs6584190 chr10 100124075 T C 6.40E-30 Urinary metabolites (H-NMR features) / / 24586186 rs17109506 chr10 100126386 C T 3.39E-09 Metabolite levels / / 23281178 rs17109512 chr10 100127551 G A 3.00E-14 Aspartate aminotransferase / / 21900944 rs17109550 chr10 100133931 C A,T 1.16E-09 Metabolite levels / / 23281178 rs7096654 chr10 100134036 C T 2.14E-30 Metabolite levels / / 23281178 rs7075655 chr10 100142068 A G 1.65E-17 Metabolite levels / / 23281178 rs17109597 chr10 100142154 G A 9.33E-13 Metabolite levels / / 23281178 rs17109605 chr10 100145129 T C 3.29E-27 Narcolepsy PYROXD2 intron 19629137 rs2296439 chr10 100146771 C G 1.16E-09 Metabolite levels PYROXD2 intron 23281178 rs4345897 chr10 100147060 A G 2.00E-91 Metabolite levels PYROXD2 cds-synon 23281178 rs4345897 chr10 100147060 A G 2.00E-19 Urinary metabolites (H-NMR features) PYROXD2 cds-synon 24586186 rs4345897 chr10 100147060 A G 4.00E-12 Urinary metabolites (H-NMR features) PYROXD2 cds-synon 24586186 rs4400721 chr10 100147097 G A 1.76E-17 Metabolite levels PYROXD2 intron 23281178 rs2147897 chr10 100147813 G T 1.50E-31 Metabolite levels PYROXD2 intron 23281178 rs4539242 chr10 100148058 T C 2.04E-35 Metabolite levels PYROXD2 intron 23281178 rs4539242 chr10 100148058 T C 2.00E-20 Urinary metabolites (H-NMR features) PYROXD2 intron 24586186 rs2147896 chr10 100148176 A G 2.04E-35 Metabolite levels PYROXD2 missense 23281178 rs2147896 chr10 100148176 A G 2.00E-55 Urinary metabolites (H-NMR features) PYROXD2 missense 24586186 rs2147896 chr10 100148176 A G 3.00E-164 Urinary metabolites (H-NMR features) PYROXD2 missense 24586186 rs2147896 chr10 100148176 A G 4.00E-34 Urinary metabolites (H-NMR features) PYROXD2 missense 24586186 rs2147896 chr10 100148176 A G 4.20E-34 Urinary metabolites (H-NMR features) PYROXD2 missense 24586186 rs2147896 chr10 100148176 A G 6.00E-19 Urinary metabolites (H-NMR features) PYROXD2 missense 24586186 rs2147896 chr10 100148176 A G 8.00E-30 Urinary metabolites (H-NMR features) PYROXD2 missense 24586186 rs2182168 chr10 100148353 C G 6.25E-33 Metabolite levels PYROXD2 intron 23281178 rs2274249 chr10 100148415 C T 1.91E-10 Metabolite levels PYROXD2 intron 23281178 rs2274248 chr10 100148542 C T 6.38E-13 Metabolite levels PYROXD2 intron 23281178 rs755126 chr10 100148951 G A 6.25E-33 Metabolite levels PYROXD2 intron 23281178 rs2274247 chr10 100150148 G C 6.25E-33 Metabolite levels PYROXD2 intron 23281178 rs17109620 chr10 100150938 G A 1.16E-09 Metabolite levels PYROXD2 intron 23281178 rs10883084 chr10 100151189 T C 6.25E-33 Metabolite levels PYROXD2 intron 23281178 rs10786415 chr10 100151266 A G 5.29E-34 Metabolite levels PYROXD2 intron 23281178 rs942814 chr10 100151305 A G 2.04E-35 Metabolite levels PYROXD2 intron 23281178 rs7097824 chr10 100151799 A T 6.25E-33 Metabolite levels PYROXD2 intron 23281178 rs7082192 chr10 100151844 T C 6.25E-33 Metabolite levels PYROXD2 intron 23281178 rs6584192 chr10 100152373 T G 1.17E-30 Metabolite levels PYROXD2 intron 23281178 rs11189586 chr10 100154096 A G 1.64E-25 Metabolite levels PYROXD2 intron 23281178 rs11597425 chr10 100154202 G T 4.01E-25 Metabolite levels PYROXD2 intron 23281178 rs11597428 chr10 100154247 G C 4.01E-25 Metabolite levels PYROXD2 intron 23281178 rs11189590 chr10 100154605 T G 4.01E-25 Metabolite levels PYROXD2 intron 23281178 rs10883085 chr10 100155613 A T 4.01E-25 Metabolite levels PYROXD2 intron 23281178 rs11189592 chr10 100155642 C A 2.69E-12 Metabolite levels PYROXD2 intron 23281178 rs17109634 chr10 100155793 C T 1.86E-10 Metabolite levels PYROXD2 intron 23281178 rs7907555 chr10 100155810 C T 4.01E-25 Metabolite levels PYROXD2 intron 23281178 rs7924209 chr10 100155927 T C 4.01E-25 Metabolite levels PYROXD2 intron 23281178 rs7924303 chr10 100155963 T C 4.01E-25 Metabolite levels PYROXD2 intron 23281178 rs7908310 chr10 100156227 G A 4.01E-25 Metabolite levels PYROXD2 intron 23281178 rs7072216 chr10 100156853 T C 8.00E-15 Metabolite levels PYROXD2 intron 21931564 rs7072216 chr10 100156853 T C 7.88E-34 Metabolite levels PYROXD2 intron 23281178 rs10883087 chr10 100156990 T A 4.01E-25 Metabolite levels PYROXD2 intron 23281178 rs10786418 chr10 100157368 C T 4.01E-25 Metabolite levels PYROXD2 intron 23281178 rs200666086 chr10 100157368 C CGCT 4.01E-25 Metabolite levels PYROXD2 intron 23281178 rs4551689 chr10 100157593 T C 2.63E-25 Metabolite levels PYROXD2 intron 23281178 rs4488133 chr10 100159136 A T 3.87E-33 Metabolite levels PYROXD2 intron 23281178 rs4488133 chr10 100159136 A T 1.00E-48 Blood metabolite levels PYROXD2 intron 24816252 rs4488133 chr10 100159136 A T 3E-860 Blood metabolite levels PYROXD2 intron 24816252 rs17109650 chr10 100159373 T C 2.39E-10 Metabolite levels PYROXD2 intron 23281178 rs6584194 chr10 100160399 T C 1.26E-33 Metabolite levels PYROXD2 intron 23281178 rs17109653 chr10 100162151 T C 1.17E-10 Metabolite levels PYROXD2 intron 23281178 rs17109657 chr10 100162695 G C 1.20E-10 Metabolite levels PYROXD2 intron 23281178 rs10883089 chr10 100163120 A C 2.36E-17 Metabolite levels PYROXD2 intron 23281178 rs7897357 chr10 100163597 C T 1.37E-33 Metabolite levels PYROXD2 intron 23281178 rs7914401 chr10 100163928 T C 4.23E-04 Multiple complex diseases PYROXD2 intron 17554300 rs7914401 chr10 100163928 T C 6.76E-19 Metabolite levels PYROXD2 intron 23281178 rs733345 chr10 100164215 G T 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs4474372 chr10 100164571 C T 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs4475861 chr10 100164989 C T 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs2147901 chr10 100165496 C A 4.70E-04 Multiple complex diseases PYROXD2 intron 17554300 rs2147901 chr10 100165496 C A 1.32E-06 Obesity-related traits PYROXD2 intron 23251661 rs2147901 chr10 100165496 C A 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs17109662 chr10 100165967 C A 6.96E-10 Metabolite levels PYROXD2 intron 23281178 rs17455577 chr10 100165997 C T 3.00E-22 Urinary metabolites (H-NMR features) PYROXD2 intron 24586186 rs7910973 chr10 100166732 G A 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs7911036 chr10 100167015 A T 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs10883092 chr10 100167276 A C 1.14E-15 Metabolite levels PYROXD2 intron 23281178 rs12763326 chr10 100167396 G A 3.55E-06 Obesity-related traits PYROXD2 cds-synon 23251661 rs12763326 chr10 100167396 G A 1.29E-17 Metabolite levels PYROXD2 cds-synon 23281178 rs12763379 chr10 100167466 G A 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs942810 chr10 100167860 G C 1.37E-33 Metabolite levels PYROXD2 intron 23281178 rs17109675 chr10 100167951 T C 6.96E-10 Metabolite levels PYROXD2 intron 23281178 rs942809 chr10 100168001 G A 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs942808 chr10 100168102 C A 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs942807 chr10 100168219 G A 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs942806 chr10 100168248 G A 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs942805 chr10 100168372 G A 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs942804 chr10 100168499 C A 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs942803 chr10 100168631 G T 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs9787550 chr10 100169051 C T 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs7923729 chr10 100169465 C T 2.64E-06 Obesity-related traits PYROXD2 intron 23251661 rs7923729 chr10 100169465 C T 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs9804285 chr10 100169472 C T 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs6584200 chr10 100170037 A G 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs6584202 chr10 100170383 G A 4.00E-07 Obesity-related traits PYROXD2 intron 23251661 rs6584202 chr10 100170383 G A 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs7896828 chr10 100170507 A T 1.37E-33 Metabolite levels PYROXD2 intron 23281178 rs3814140 chr10 100170762 C T 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs17109738 chr10 100170895 C T 2.42E-04 Multiple complex diseases PYROXD2 intron 17554300 rs3814141 chr10 100171028 G A 1.83E-13 Metabolite levels PYROXD2 intron 23281178 rs3814142 chr10 100171104 C G 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs10748729 chr10 100171371 G C 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs7909131 chr10 100171471 A G 1.37E-33 Metabolite levels PYROXD2 intron 23281178 rs7910247 chr10 100172252 C T 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs6584204 chr10 100173580 C G 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs3750601 chr10 100174561 C A 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs2147900 chr10 100174721 T C 2.20E-06 Obesity-related traits PYROXD2 intron 23251661 rs2147900 chr10 100174721 T C 1.29E-17 Metabolite levels PYROXD2 intron 23281178 rs2274244 chr10 100175218 A G 1.29E-17 Metabolite levels PYROXD2 nearGene-5 23281178 rs8181292 chr10 100175477 A G 1.29E-17 Metabolite levels / / 23281178 rs3750604 chr10 100175581 G A 1.83E-13 Metabolite levels / / 23281178 rs3750605 chr10 100175654 C T 1.83E-13 Metabolite levels / / 23281178 rs1061437 chr10 100176154 C T 8.57E-04 Multiple complex diseases HPS1 UTR-3 17554300 rs1061437 chr10 100176154 C T 4.54E-06 Obesity-related traits HPS1 UTR-3 23251661 rs1061437 chr10 100176154 C T 1.29E-17 Metabolite levels HPS1 UTR-3 23281178 rs1739 chr10 100176339 A G 2.77E-33 Metabolite levels HPS1 UTR-3 23281178 rs3830020 chr10 100176615 G C 3.24E-34 Metabolite levels HPS1 UTR-3 23281178 rs3830019 chr10 100176848 C T 9.28E-11 Metabolite levels HPS1 UTR-3 23281178 rs701801 chr10 100176869 C T 5.80E-05 Kidney function and endocine traits HPS1 UTR-3 17903292 rs701801 chr10 100176869 C T 1.34E-25 Metabolite levels HPS1 UTR-3 23281178 rs11189600 chr10 100179274 C T 1.59E-32 Metabolite levels HPS1 intron 23281178 rs2296436 chr10 100179851 T C 1.26E-12 Metabolite levels HPS1 missense 23281178 rs17109834 chr10 100181847 T C 1.26E-12 Metabolite levels HPS1 intron 23281178 rs2296435 chr10 100182285 T C 2.54E-13 Metabolite levels HPS1 intron 23281178 rs2296434 chr10 100183570 G C 1.26E-12 Metabolite levels HPS1 missense 23281178 rs7921146 chr10 100186601 G A 4.21E-06 Obesity-related traits HPS1 intron 23251661 rs7921146 chr10 100186601 G A 2.54E-13 Metabolite levels HPS1 intron 23281178 rs10883094 chr10 100188106 G A 5.01E-13 Metabolite levels HPS1 intron 23281178 rs1061135 chr10 100189138 A G 1.41E-04 Suicide attempts in bipolar disorder HPS1 UTR-3 21423239 rs1998757 chr10 100229506 G C 6.47E-04 Type 2 diabetes HPSE2 intron 17463246 rs10748732 chr10 100242039 T C 0.000147 fMRI brain tests in schizophrenia HPSE2 intron 22440650 rs11189629 chr10 100242195 C T 3.18E-04 Taste perception HPSE2 intron 22132133 rs12358472 chr10 100290770 C A 7.47E-04 Taste perception HPSE2 intron 22132133 rs577969 chr10 100291176 C T 4.00E-06 Migraine HPSE2 intron 23793025 rs577969 chr10 100291176 C T 8.96E-04 Migraine without aura HPSE2 intron 23793025 rs10786436 chr10 100300182 C T 8.00E-07 Type 1 diabetes HPSE2 intron 21980299 rs621644 chr10 100311667 G A 5.22E-04 Multiple complex diseases HPSE2 intron 17554300 rs7907389 chr10 100314339 G A 6.18E-04 Taste perception HPSE2 intron 22132133 rs489611 chr10 100318793 T C 5.14E-04 Multiple complex diseases HPSE2 intron 17554300 rs477950 chr10 100322658 T C 5.53E-06 Paget's disease HPSE2 intron 20436471 rs535182 chr10 100324333 T C 1.33E-05 Paget's disease HPSE2 intron 20436471 rs551674 chr10 100332296 C T 4.65E-05 Paget's disease HPSE2 intron 20436471 rs527822 chr10 100332616 G C 1.43E-04 Smoking initiation HPSE2 intron 24665060 rs605591 chr10 100334239 G A 3.09E-05 Paget's disease HPSE2 intron 20436471 rs3936941 chr10 100339741 G T 9.48E-04 Amyotrophic lateral sclerosis (sporadic) HPSE2 intron 24529757 rs11189692 chr10 100344136 T C 9.04E-04 Type 2 diabetes HPSE2 intron 17463246 rs10883141 chr10 100344439 C T 2.66E-04 Multiple complex diseases HPSE2 intron 17554300 rs10883141 chr10 100344439 C T 8.12E-05 Serum metabolites HPSE2 intron 19043545 rs11189693 chr10 100344692 G C 3.56E-04 Type 2 diabetes HPSE2 intron 17463246 rs10883146 chr10 100350338 C T 2.59E-04 Type 2 diabetes HPSE2 intron 17463246 rs12357870 chr10 100364827 G A 4.30E-04 Type 2 diabetes HPSE2 intron 17463246 rs688501 chr10 100378911 T C 4.54E-04 Multiple complex diseases HPSE2 intron 17554300 rs483952 chr10 100383999 C G,T 8.73E-05 Crohn's disease HPSE2 intron 17684544 rs11189719 chr10 100389807 T A 9.83E-04 Type 2 diabetes HPSE2 intron 17463246 rs1159006 chr10 100406283 T C 4.01E-05 Type 2 diabetes HPSE2 intron 17846124 rs1159006 chr10 100406283 T C 4.00E-05 Type 2 diabetes HPSE2 intron 21647700 rs17110576 chr10 100409977 G A 7.35E-04 Type 2 diabetes HPSE2 intron 17463246 rs548976 chr10 100415065 C T 3.67E-04 Multiple complex diseases HPSE2 intron 17554300 rs1360960 chr10 100444301 A G 5.63E-04 Type 2 diabetes HPSE2 intron 17463246 rs2152652 chr10 100473651 T C 8.89E-04 Multiple complex diseases HPSE2 intron 17554300 rs1011617 chr10 100478680 T C 6.07E-04 Multiple complex diseases HPSE2 intron 17554300 rs1414957 chr10 100537024 A G 9.43E-04 Type 2 diabetes HPSE2 intron 17463246 rs11189821 chr10 100557307 G C 1.98E-04 Type 2 diabetes HPSE2 intron 17463246 rs17470570 chr10 100580123 A G 3.00E-06 Migraine without aura HPSE2 intron 23793025 rs11189836 chr10 100583772 G A 1.62E-04 Multiple complex diseases HPSE2 intron 17554300 rs2801405 chr10 100583915 C T 9.00E-06 Obesity-related traits HPSE2 intron 23251661 rs837727 chr10 100592176 A G 2.90E-05 Type 2 diabetes HPSE2 intron 17463246 rs11189842 chr10 100602080 T G 3.45E-05 Multiple complex diseases HPSE2 intron 17554300 rs7922976 chr10 100641594 A C 9.16E-04 Type 2 diabetes HPSE2 intron 17463246 rs10786481 chr10 100641875 T C 5.63E-04 Type 2 diabetes HPSE2 intron 17463246 rs11189853 chr10 100646181 A G 2.00E-06 Migraine without aura HPSE2 intron 23793025 rs11189853 chr10 100646181 A G 6.44E-05 Migraine HPSE2 intron 23793025 rs2018913 chr10 100654000 C A 7.89E-04 Stroke HPSE2 intron pha002886 rs11189867 chr10 100682448 T C 7.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy) HPSE2 intron 24554482 rs10786489 chr10 100704597 G T 2.81E-04 Stroke HPSE2 intron pha002886 rs10883237 chr10 100740475 G A 1.86E-04 Multiple complex diseases HPSE2 intron 17554300 rs11189926 chr10 100751620 T C 7.89E-05 Cognitive test performance HPSE2 intron 20125193 rs10786497 chr10 100794359 T C 1.44E-04 Celiac disease HPSE2 intron 23936387 rs2487891 chr10 100799832 T C 1.48E-05 Alcohol and nictotine co-dependence HPSE2 intron 20158304 rs11189959 chr10 100839676 G T 4.86E-04 Multiple complex diseases HPSE2 intron 17554300 rs12570188 chr10 100855702 C T 5.00E-08 Asthma (childhood onset) HPSE2 intron 23829686 rs7094333 chr10 100981547 C T 1.04E-08 Secreted IFN-gamma response to smallpox vaccine HPSE2 intron 22661280 rs12764454 chr10 100991374 T C 2.36E-05 Lung adenocarcinoma HPSE2 intron 19836008 rs3814146 chr10 100997041 C T 2.55E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) HPSE2 nearGene-5 24023788 rs10786538 chr10 101104712 G A 2.50E-05 Malaria CNNM1 intron 19465909 rs11190062 chr10 101105002 A G 1.30E-05 Malaria CNNM1 intron 19465909 rs11190065 chr10 101115457 C T 3.33E-04 Alzheimer's disease CNNM1 intron 17998437 rs41444048 chr10 101125176 G C 7.24E-04 Multiple complex diseases CNNM1 intron 17554300 rs10509735 chr10 101132282 A C 4.28E-04 Stroke CNNM1 intron pha002886 rs4917864 chr10 101149298 C T 4.24E-04 Suicide attempts in bipolar disorder CNNM1 intron 21423239 rs3793931 chr10 101150256 A G 4.38E-04 Schizophrenia(treatment response to risperidone) CNNM1 intron 19850283 rs3793931 chr10 101150256 A G 2.88E-04 Stroke CNNM1 intron pha002886 rs3793932 chr10 101150347 C A 5.09E-05 Platelet counts CNNM1 intron pha003100 rs2862610 chr10 101154296 A T 1.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs2642 chr10 101156749 T C 0.000000345 Coronary artery disease (CAD) age >50 GOT1 UTR-3 23202125 rs2642 chr10 101156749 T C 0.000000539 Coronary artery disease (CAD) (males) GOT1 UTR-3 23202125 rs2642 chr10 101156749 T C 0.00000604 Coronary artery disease (CAD) age <=50 GOT1 UTR-3 23202125 rs2642 chr10 101156749 T C 7.38E-08 Coronary artery disease with myocardial infarction GOT1 UTR-3 23202125 rs76850691 chr10 101157438 G C 9.00E-07 Liver enzyme levels (aspartate transaminase) GOT1 missense 24124411 rs3750897 chr10 101157817 C G 2.29E-04 Suicide attempts in bipolar disorder GOT1 intron 21423239 rs2234971 chr10 101166544 C T 9.05E-04 Type 2 diabetes GOT1 cds-synon 17463246 rs2234971 chr10 101166544 C T 1.60E-04 Suicide attempts in bipolar disorder GOT1 cds-synon 21423239 rs11190083 chr10 101170989 A G 9.94E-05 Multiple complex diseases GOT1 intron 17554300 rs11594790 chr10 101178156 A G 6.74E-04 Type 2 diabetes GOT1 intron 17463246 rs11594790 chr10 101178156 A G 5.95E-05 Suicide attempts in bipolar disorder GOT1 intron 21423239 rs41436049 chr10 101179865 T A 9.64E-04 Type 2 diabetes GOT1 intron 17463246 rs11190088 chr10 101187482 C G 1.45E-04 Suicide attempts in bipolar disorder GOT1 intron 21423239 rs17570065 chr10 101204371 G C 2.17E-04 Smoking quantity / / 24665060 rs2862595 chr10 101211257 C T 1.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs2490288 chr10 101213253 T C 7.73E-04 Heart Failure / / pha002885 rs7919837 chr10 101220073 G A 1.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs4919316 chr10 101222143 C G 9.86E-05 Suicide attempts in bipolar disorder / / 21423239 rs11593108 chr10 101222490 C T 1.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs10883348 chr10 101227302 T C 1.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs10883350 chr10 101227579 T C 1.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs2862596 chr10 101229527 C T 1.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs4568942 chr10 101229734 G A 1.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs4919321 chr10 101230461 G C 2.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs7077930 chr10 101233574 A C 3.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs7912109 chr10 101235813 G C 3.77E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4919328 chr10 101237244 G A 2.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs2902267 chr10 101237890 C A 2.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs11190106 chr10 101242926 T C 3.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs2490292 chr10 101244382 T C 6.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs2494660 chr10 101244527 A G 8.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs12355928 chr10 101247551 C T 4.76E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11190117 chr10 101256578 G T 1.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs11190120 chr10 101260443 C A 4.32E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10509737 chr10 101263128 T G 7.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4595481 chr10 101264162 A G 1.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10883359 chr10 101274033 A G 8.22E-05 Multiple complex diseases / / 17554300 rs7095491 chr10 101274058 T C 1.53E-09 Multiple complex diseases / / 17554300 rs7095491 chr10 101274058 T C 9.42E-07 Red blood cell traits / / 23222517 rs7078219 chr10 101274365 G A 2.92E-08 Multiple complex diseases / / 17554300 rs7078219 chr10 101274365 G A 6.00E-06 Dental caries / / 23064961 rs7078219 chr10 101274365 G A 3.76E-07 Red blood cell traits / / 23222517 rs7081330 chr10 101274465 A G 2.84E-08 Multiple complex diseases / / 17554300 rs11190134 chr10 101282200 G A 1.00E-10 Red blood cell traits / / 23222517 rs4409764 chr10 101284237 T G 2.00E-20 Crohn's disease / / 21102463 rs4409764 chr10 101284237 T G 1.00E-54 Inflammatory bowel disease / / 23128233 rs10883365 chr10 101287764 G A 4.00E-10 Crohn's disease / / 17554261 rs10883365 chr10 101287764 G A 6.00E-08 Crohn's disease / / 17554300 rs11190137 chr10 101287944 A C 2.90E-04 Multiple complex diseases / / 17554300 rs10883367 chr10 101287990 T C 1.89E-09 Multiple complex diseases / / 17554300 rs11190139 chr10 101288099 C G 5.77E-05 Multiple complex diseases / / 17554300 rs12412391 chr10 101288935 A G 7.00E-07 Colorectal cancer / / 24836286 rs1548964 chr10 101289653 G C 1.22E-09 Multiple complex diseases / / 17554300 rs1548962 chr10 101289735 G C 1.34E-09 Multiple complex diseases / / 17554300 rs6584283 chr10 101290301 T C 7.63E-09 Multiple complex diseases / / 17554300 rs6584283 chr10 101290301 T C 2.00E-07 Ulcerative colitis / / 19915572 rs6584283 chr10 101290301 T C 2.00E-06 Ulcerative colitis / / 20228798 rs6584283 chr10 101290301 T C 8.00E-21 Ulcerative colitis / / 21297633 rs11190140 chr10 101291593 T C 3.00E-16 Crohn's disease NKX2-3 nearGene-5 18587394 rs11190140 chr10 101291593 T C 1.00E-08 Ulcerative colitis NKX2-3 nearGene-5 20228799 rs11190140 chr10 101291593 T C 3.00E-16 Asthma NKX2-3 nearGene-5 21150878 rs11190140 chr10 101291593 T C 3.06E-16 Multiple sclerosis NKX2-3 nearGene-5 22190364 rs11190140 chr10 101291593 T C 4.40E-04 Myasthenia gravis NKX2-3 nearGene-5 23055271 rs11190141 chr10 101292390 C T 5.00E-07 Crohn's disease NKX2-3 nearGene-5 22412388 rs10883371 chr10 101292455 C A 1.23E-09 Multiple complex diseases NKX2-3 nearGene-5 17554300 rs10883371 chr10 101292455 C A 0.000000501 Primary sclerosing cholangitis NKX2-3 nearGene-5 23603763 rs7903232 chr10 101298802 G C 4.03E-04 Multiple complex diseases / / 17554300 rs10786559 chr10 101308890 G C 2.41E-07 Red blood cell traits / / 23222517 rs10883376 chr10 101316142 G A 8.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs989979 chr10 101322423 G C 1.84E-06 Multiple complex diseases / / 17554300 rs989978 chr10 101322555 A G 1.10E-05 Urinary metabolites / / 21572414 rs2902288 chr10 101324365 C G 2.48E-05 Multiple complex diseases / / 17554300 rs1332102 chr10 101324436 T A 5.28E-08 Multiple complex diseases / / 17554300 rs1360522 chr10 101325797 C T 1.35E-06 Multiple complex diseases / / 17554300 rs7091572 chr10 101327851 T C 2.79E-05 Multiple complex diseases / / 17554300 rs878939 chr10 101342941 A G 4.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs878940 chr10 101343026 C T 3.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs1035209 chr10 101345366 C T 5.00E-11 Colorectal cancer / / 24737748 rs11190179 chr10 101365313 G A 2.00E-06 beta2-Glycoprotein I (beta2-GPI) plasma levels / / 23279374 rs11813439 chr10 101452369 G A 3.15E-05 Alcohol dependence ENTPD7 intron 20201924 rs11813439 chr10 101452369 G A 3.15E-05 Alcoholism ENTPD7 intron pha002891 rs2281636 chr10 101492403 T G 6.00E-06 Obesity-related traits COX15 UTR-5 23251661 rs17112202 chr10 101494991 T C 8.74E-05 Alcohol dependence CUTC intron 20201924 rs17112202 chr10 101494991 T C 8.74E-05 Alcoholism CUTC intron pha002891 rs7913190 chr10 101498396 T G 7.46E-06 Obesity-related traits CUTC intron 23251661 rs2756115 chr10 101508622 T C 9.09E-04 Type 2 diabetes CUTC intron 17463246 rs2804419 chr10 101509113 A G 7.77E-06 Obesity-related traits CUTC intron 23251661 rs2804402 chr10 101541583 A G 1 Drug response to Irinotecan ABCC2 nearGene-5 19940846 rs717620 chr10 101542578 C T 1 Drug response to Cyclosporine ABCC2 UTR-5 19890249 rs717620 chr10 101542578 C T 1 Drug response to Mycophenolate Mofetil ABCC2 UTR-5 19890249 rs717620 chr10 101542578 C T 1 Drug response to Mycophenolic Acid ABCC2 UTR-5 19890249 rs717620 chr10 101542578 C T 1 Drug response to Irinotecan ABCC2 UTR-5 19940846 rs717620 chr10 101542578 C T 1 Drug response to SN-38 ABCC2 UTR-5 19940846 rs2273697 chr10 101563815 G A 1 Drug response to Talinolol ABCC2 missense 18334920 rs2002042 chr10 101587931 C T 0.000075 Apolipoprotein B levels response after 40mg daily simvastatin treatment ABCC2 intron 23100282 rs2002042 chr10 101587931 C T 0.000082 LDL cholesterol response after 40mg daily simvastatin treatment ABCC2 intron 23100282 rs2002042 chr10 101587931 C T 8.20E-05 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) ABCC2 intron 23103227 rs4362077 chr10 101588421 C T 2.58E-08 HDL cholesterol ABCC2 intron 23063622 rs3740066 chr10 101604207 C T 1 Drug response to Irinotecan ABCC2 cds-synon 19940846 rs3740066 chr10 101604207 C T 1 Drug response to SN-38 ABCC2 cds-synon 19940846 rs8187710 chr10 101611294 G A 1 Drug response to Lopinavir ABCC2 missense 19842932 rs12762549 chr10 101620771 C G 1 Drug response to Docetaxel / / 18294295 rs11190298 chr10 101620948 A G 2.38E-04 Body mass index / / 17255346 rs11190310 chr10 101659519 C T 1.41E-04 IgE levels DNMBP intron 17255346 rs7896859 chr10 101663438 G T 2.20E-05 Endometriosis DNMBP intron 21151130 rs113923285 chr10 101781773 G A 8.73E-05 Epilepsy (remission after treatment) / / 23962720 rs9794330 chr10 101784131 T C 9.50E-05 Epilepsy (remission after treatment) / / 23962720 rs7089847 chr10 101784816 A G 6.07E-05 Epilepsy (remission after treatment) / / 23962720 rs10883437 chr10 101795361 T A 4.00E-09 Liver enzyme levels (alanine transaminase) / / 22001757 rs11190376 chr10 101798628 G T 2.00E-05 Multiple complex diseases / / 17554300 rs11599750 chr10 101805442 C T 2.50E-05 Bone mineral density (spine) CPN1 intron 19079262 rs11599750 chr10 101805442 C T 2.00E-13 Height CPN1 intron 20881960 rs11593916 chr10 101809659 G A 1.67E-04 Bipolar disorder CPN1 intron 18317468 rs7084921 chr10 101813802 C T 9.00E-10 Bone mineral density CPN1 intron 22504420 rs61871700 chr10 101828261 C T 4.18E-08 Creatine phosphokinase CPN1 intron 23696881 rs12775433 chr10 101834092 C T 3.80E-05 Bone mineral density (spine) CPN1 intron 19079262 rs7921462 chr10 101843140 T C 7.75E-04 Iron levels CPN1 nearGene-5 pha002876 rs1408580 chr10 101860631 C T 7.72E-04 Iron levels / / pha002876 rs11597390 chr10 101861435 G A 2.00E-08 Liver enzyme levels / / 18940312 rs11594333 chr10 101880700 C T 9.70E-06 Urinary metabolites / / 21572414 rs11595928 chr10 101888640 C T 0.000000787 Fatty liver and alanine aminotransferase (ALT) levels / / 23477746 rs11595928 chr10 101888640 C T 0.00000914 Alanine aminotransferase levels / / 23477746 rs1324692 chr10 101890330 C G 0.000000305 Fatty liver and alanine aminotransferase (ALT) levels / / 23477746 rs1324692 chr10 101890330 C G 0.00000699 Alanine aminotransferase levels / / 23477746 rs7893985 chr10 101893418 G A 0.000000248 Fatty liver and alanine aminotransferase (ALT) levels / / 23477746 rs7893985 chr10 101893418 G A 0.00000645 Alanine aminotransferase levels / / 23477746 rs10883446 chr10 101894606 C G 0.000000312 Fatty liver and alanine aminotransferase (ALT) levels / / 23477746 rs10883446 chr10 101894606 C G 0.00000693 Alanine aminotransferase levels / / 23477746 rs2104368 chr10 101900579 C T 0.000000606 Fatty liver and alanine aminotransferase (ALT) levels / / 23477746 rs2104368 chr10 101900579 C T 0.0000104 Alanine aminotransferase levels / / 23477746 rs2025507 chr10 101901775 C T 0.000000628 Fatty liver and alanine aminotransferase (ALT) levels / / 23477746 rs2025507 chr10 101901775 C T 0.0000108 Alanine aminotransferase levels / / 23477746 rs11190401 chr10 101903412 T C 0.000000635 Fatty liver and alanine aminotransferase (ALT) levels / / 23477746 rs11190401 chr10 101903412 T C 0.000011 Alanine aminotransferase levels / / 23477746 rs10883447 chr10 101903906 T G 1.70E-04 Bone mineral density / / 21927923 rs10883447 chr10 101903906 T G 2.30E-04 Bone mineral density / / 21927923 rs10883447 chr10 101903906 T G 0.000000296 Fatty liver and alanine aminotransferase (ALT) levels / / 23477746 rs10883447 chr10 101903906 T G 0.0000395 Alanine aminotransferase levels / / 23477746 rs10883447 chr10 101903906 T G 0.000488 Fatty liver disease / / 23477746 rs2862954 chr10 101912064 T C 0.000000866 Alanine aminotransferase levels ERLIN1 missense 23477746 rs2862954 chr10 101912064 T C 0.00000459 Fatty liver disease ERLIN1 missense 23477746 rs2862954 chr10 101912064 T C 3.03E-10 Fatty liver and alanine aminotransferase (ALT) levels ERLIN1 missense 23477746 rs1408579 chr10 101912194 C T 8.87E-04 Multiple complex diseases ERLIN1 intron 17554300 rs1408579 chr10 101912194 C T 0.000000869 Alanine aminotransferase levels ERLIN1 intron 23477746 rs1408579 chr10 101912194 C T 0.00000419 Fatty liver disease ERLIN1 intron 23477746 rs1408579 chr10 101912194 C T 2.75E-10 Fatty liver and alanine aminotransferase (ALT) levels ERLIN1 intron 23477746 rs10883451 chr10 101924418 T C 0.000000873 Alanine aminotransferase levels ERLIN1 intron 23477746 rs10883451 chr10 101924418 T C 0.00000385 Fatty liver disease ERLIN1 intron 23477746 rs10883451 chr10 101924418 T C 2.52E-10 Fatty liver and alanine aminotransferase (ALT) levels ERLIN1 intron 23477746 rs11595238 chr10 101930409 A G 1.11E-05 Response to radiotherapy in cancer (late toxicity) ERLIN1 intron 24785509 rs11595238 chr10 101930409 A G 2.00E-06 Response to radiotherapy in cancer (late toxicity) ERLIN1 intron 24785509 rs11190412 chr10 101932318 A G 3.85E-04 Multiple complex diseases ERLIN1 intron 17554300 rs17112705 chr10 101937194 T C 0.000000692 Creatine phosphokinase ERLIN1 intron 23696881 rs1324694 chr10 101946445 C T 2.80E-22 Progranulin levels / / 21087763 rs1324694 chr10 101946445 C T 2.80E-22 Myocardial infarction / / 21211798 rs11597086 chr10 101953705 A C 8.00E-06 Type 2 diabetes CHUK intron 17463249 rs11597086 chr10 101953705 A C 1.38E-04 Multiple complex diseases CHUK intron 17554300 rs11597086 chr10 101953705 A C 2.99E-09 Cholesterol,total CHUK intron 23063622 rs11597086 chr10 101953705 A C 0.00000196 Fatty liver disease CHUK intron 23477746 rs11597086 chr10 101953705 A C 0.00000839 Alanine aminotransferase levels CHUK intron 23477746 rs11597086 chr10 101953705 A C 7.71E-10 Fatty liver and alanine aminotransferase (ALT) levels CHUK intron 23477746 rs7358099 chr10 101955002 A T 8.39E-06 Odorant perception CHUK intron 23910658 rs3818411 chr10 101960966 C T 0.000000686 Fatty liver and alanine aminotransferase (ALT) levels CHUK intron 23477746 rs3818411 chr10 101960966 C T 0.0000439 Alanine aminotransferase levels CHUK intron 23477746 rs7923726 chr10 101963299 G T 0.000000464 Fatty liver and alanine aminotransferase (ALT) levels CHUK intron 23477746 rs7923726 chr10 101963299 G T 0.000037 Alanine aminotransferase levels CHUK intron 23477746 rs7923726 chr10 101963299 G T 0.000805 Fatty liver disease CHUK intron 23477746 rs7909855 chr10 101967212 C G 0.000000464 Fatty liver and alanine aminotransferase (ALT) levels CHUK intron 23477746 rs7909855 chr10 101967212 C G 0.0000369 Alanine aminotransferase levels CHUK intron 23477746 rs7909855 chr10 101967212 C G 0.000805 Fatty liver disease CHUK intron 23477746 rs17112737 chr10 101970821 G A 1.70E-04 HDL particle features CHUK intron 21283740 rs17112737 chr10 101970821 G A 5.70E-05 HDL particle features CHUK intron 21283740 rs12269373 chr10 101972378 T C 0.000000459 Fatty liver and alanine aminotransferase (ALT) levels CHUK intron 23477746 rs12269373 chr10 101972378 T C 0.0000371 Alanine aminotransferase levels CHUK intron 23477746 rs12269373 chr10 101972378 T C 0.000795 Fatty liver disease CHUK intron 23477746 rs11591741 chr10 101976501 G C 3.16E-04 Multiple complex diseases CHUK intron 17554300 rs11591741 chr10 101976501 G C 0.00000271 Fatty liver disease CHUK intron 23477746 rs11591741 chr10 101976501 G C 0.00000852 Alanine aminotransferase levels CHUK intron 23477746 rs11591741 chr10 101976501 G C 1.01E-09 Fatty liver and alanine aminotransferase (ALT) levels CHUK intron 23477746 rs17883880 chr10 101990347 T A 1.35E-15 LDL cholesterol CHUK nearGene-5 23063622 rs17883880 chr10 101990347 T A 1.35E-19 Cholesterol,total CHUK nearGene-5 23063622 rs17883880 chr10 101990347 T A 4.85E-16 Triglycerides CHUK nearGene-5 23063622 rs17729876 chr10 101999746 G A 0.0000026 Fatty liver disease CWF19L1 intron 23477746 rs17729876 chr10 101999746 G A 0.00000914 Alanine aminotransferase levels CWF19L1 intron 23477746 rs17729876 chr10 101999746 G A 1.04E-09 Fatty liver and alanine aminotransferase (ALT) levels CWF19L1 intron 23477746 rs17668255 chr10 102000701 C T 0.00000253 Fatty liver disease CWF19L1 intron 23477746 rs17668255 chr10 102000701 C T 0.00000944 Alanine aminotransferase levels CWF19L1 intron 23477746 rs17668255 chr10 102000701 C T 1.04E-09 Fatty liver and alanine aminotransferase (ALT) levels CWF19L1 intron 23477746 rs17668357 chr10 102003906 G C 0.00000229 Fatty liver disease CWF19L1 intron 23477746 rs17668357 chr10 102003906 G C 0.00000976 Alanine aminotransferase levels CWF19L1 intron 23477746 rs17668357 chr10 102003906 G C 9.97E-10 Fatty liver and alanine aminotransferase (ALT) levels CWF19L1 intron 23477746 rs4919438 chr10 102006429 T C,G 0.000000408 Fatty liver and alanine aminotransferase (ALT) levels CWF19L1 intron 23477746 rs4919438 chr10 102006429 T C,G 0.0000396 Alanine aminotransferase levels CWF19L1 intron 23477746 rs4919438 chr10 102006429 T C,G 0.00067 Fatty liver disease CWF19L1 intron 23477746 rs6584354 chr10 102007714 A C 0.000000513 Fatty liver and alanine aminotransferase (ALT) levels CWF19L1 intron 23477746 rs6584354 chr10 102007714 A C 0.0000488 Alanine aminotransferase levels CWF19L1 intron 23477746 rs6584354 chr10 102007714 A C 0.000706 Fatty liver disease CWF19L1 intron 23477746 rs7079072 chr10 102008169 C G 0.000000509 Fatty liver and alanine aminotransferase (ALT) levels CWF19L1 intron 23477746 rs7079072 chr10 102008169 C G 0.0000484 Alanine aminotransferase levels CWF19L1 intron 23477746 rs7079072 chr10 102008169 C G 0.000705 Fatty liver disease CWF19L1 intron 23477746 rs2270962 chr10 102016044 C T 4.61E-05 Major depressive disorder CWF19L1 missense pha002850 rs2270961 chr10 102016268 G A 0.000000606 Fatty liver and alanine aminotransferase (ALT) levels CWF19L1 intron 23477746 rs2270961 chr10 102016268 G A 0.0000415 Alanine aminotransferase levels CWF19L1 intron 23477746 rs7924284 chr10 102018089 C T 8.00E-06 Upper aerodigestive tract cancers CWF19L1 intron 21437268 rs7922807 chr10 102023006 C T 0.000000432 Fatty liver and alanine aminotransferase (ALT) levels CWF19L1 intron 23477746 rs7922807 chr10 102023006 C T 0.0000674 Alanine aminotransferase levels CWF19L1 intron 23477746 rs7922807 chr10 102023006 C T 0.000449 Fatty liver disease CWF19L1 intron 23477746 rs12784396 chr10 102027407 C T 0.00000272 Fatty liver disease CWF19L1 UTR-5 23477746 rs12784396 chr10 102027407 C T 0.000013 Alanine aminotransferase levels CWF19L1 UTR-5 23477746 rs12784396 chr10 102027407 C T 1.86E-09 Fatty liver and alanine aminotransferase (ALT) levels CWF19L1 UTR-5 23477746 rs12242503 chr10 102028467 T C 0.000000366 Fatty liver and alanine aminotransferase (ALT) levels / / 23477746 rs12242503 chr10 102028467 T C 0.0000604 Alanine aminotransferase levels / / 23477746 rs12242503 chr10 102028467 T C 0.000419 Fatty liver disease / / 23477746 rs12254005 chr10 102038685 T A 0.000000443 Fatty liver and alanine aminotransferase (ALT) levels BLOC1S2 intron 23477746 rs12254005 chr10 102038685 T A 0.0000706 Alanine aminotransferase levels BLOC1S2 intron 23477746 rs12254005 chr10 102038685 T A 0.000442 Fatty liver disease BLOC1S2 intron 23477746 rs17112875 chr10 102048515 T C 7.32E-04 Alzheimer's disease PKD2L1 intron 24755620 rs7904983 chr10 102056016 G A 0.000000159 Triglycerides PKD2L1 STOP-GAIN 23063622 rs12767633 chr10 102056440 C T 4.21E-04 Blood pressure PKD2L1 intron 17255346 rs2278842 chr10 102056745 C T 1.66E-04 Blood pressure PKD2L1 missense 17255346 rs2278842 chr10 102056745 C T 3.45E-06 Obesity-related traits PKD2L1 missense 23251661 rs7909153 chr10 102056790 G A 1.89E-09 Triglycerides PKD2L1 missense 23063622 rs12781019 chr10 102057568 T C 1.93E-04 Blood pressure PKD2L1 intron 17255346 rs17112901 chr10 102066185 C T 2.00E-06 Obesity-related traits PKD2L1 intron 23251661 rs603424 chr10 102075479 G A 1.50E-17 Serum metabolites PKD2L1 intron 20037589 rs603424 chr10 102075479 G A 3.00E-57 Metabolic traits PKD2L1 intron 21886157 rs603424 chr10 102075479 G A 6.00E-14 Phospholipid levels (plasma) PKD2L1 intron 22359512 rs603424 chr10 102075479 G A 2.00E-07 Palmitic acid (16:0) plasma levels PKD2L1 intron 23362303 rs603424 chr10 102075479 G A 6.00E-15 Palmitoleic acid (16:1n-7) plasma levels PKD2L1 intron 23362303 rs603424 chr10 102075479 G A 1.00E-11 Metabolite levels PKD2L1 intron 24625756 rs603424 chr10 102075479 G A 1.00E-115 Blood metabolite ratios PKD2L1 intron 24816252 rs603424 chr10 102075479 G A 1.00E-14 Blood metabolite levels PKD2L1 intron 24816252 rs603424 chr10 102075479 G A 2.00E-14 Blood metabolite levels PKD2L1 intron 24816252 rs603424 chr10 102075479 G A 6.00E-21 Blood metabolite levels PKD2L1 intron 24816252 rs603424 chr10 102075479 G A 7.00E-16 Blood metabolite levels PKD2L1 intron 24816252 rs10883460 chr10 102092422 A G 8.25E-04 Depression (quantitative trait) / / 20800221 rs2060792 chr10 102097695 T C 7.97E-04 Depression (quantitative trait) / / 20800221 rs3978768 chr10 102121579 A G 3.61E-05 Depression (quantitative trait) SCD UTR-3 20800221 rs11817557 chr10 102185084 A G 3.68E-05 Multiple complex diseases / / 17554300 rs2298075 chr10 102247408 C A 2.00E-04 Breast cancer SEC31B missense 17529967 rs9420790 chr10 102256197 G A 2.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients SEC31B intron 23400010 rs2273696 chr10 102259706 T G 5.20E-04 Type 2 diabetes and 6 quantitative traits SEC31B intron 17848626 rs3750631 chr10 102279294 A G 4.78E-05 Heart rate SEC31B intron 23583979 rs11190604 chr10 102302457 A G 6.00E-09 Palmitoleic acid (16:1n-7) plasma levels HIF1AN intron 23362303 rs2495726 chr10 102362543 T C 4.86E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2495725 chr10 102364004 A G 2.88E-04 Lung function (forced vital capacity) / / 24023788 rs2495725 chr10 102364004 A G 6.42E-05 Coronary heart disease / / pha003030 rs2495718 chr10 102379297 C T 1.94E-04 Body mass index / / 17255346 rs2495718 chr10 102379297 C T 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2489020 chr10 102385066 T C 6.00E-04 Atrial fibrillation / / 21846873 rs4630219 chr10 102482184 C T 1.97E-04 Multiple complex diseases / / 17554300 rs4509693 chr10 102501571 C T 6.00E-06 Alzheimer's Disease / / 20061627 rs10883543 chr10 102552752 G T 6.53E-05 Type 2 diabetes and other traits PAX2 intron 19734900 rs2902399 chr10 102554029 G A 4.00E-05 Prostate cancer PAX2 intron 21743057 rs2495702 chr10 102592975 C T 7.41E-05 Longevity / / 20304771 rs2476964 chr10 102593621 A G 4.70E-05 Cognitive function / / 24684796 rs4545488 chr10 102612773 A G 6.63E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs912477 chr10 102615168 A G 2.33E-05 Post-operative nausea and vomiting / / 21694509 rs12359797 chr10 102618653 G A 9.62E-05 Post-operative nausea and vomiting / / 21694509 rs4919504 chr10 102620497 T C 1.14E-05 Coronary restenosis / / 21878436 rs11595116 chr10 102642707 G A 0.0000871 Paraoxonase activity / / 23160181 rs7899336 chr10 102647686 T G 7.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs7899638 chr10 102647872 T A 5.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs57214420 chr10 102664608 G A 5.29E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs56317403 chr10 102670196 T G 6.29E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs3802724 chr10 102672718 T C 3.37E-04 Alcohol dependence FAM178A UTR-5 20201924 rs3802724 chr10 102672718 T C 6.31E-06 Ejection fraction in Tripanosoma cruzi seropositivity FAM178A UTR-5 24324551 rs4917916 chr10 102673292 G A 4.69E-04 Alcohol dependence FAM178A UTR-3 20201924 rs4917916 chr10 102673292 G A 4.39E-20 Lymphocyte counts FAM178A UTR-3 22286170 rs4917916 chr10 102673292 G A 6.31E-06 Ejection fraction in Tripanosoma cruzi seropositivity FAM178A UTR-3 24324551 rs12241232 chr10 102692604 T C 4.89E-04 Alcohol dependence FAM178A intron 20201924 rs12241232 chr10 102692604 T C 2.55E-06 Ejection fraction in Tripanosoma cruzi seropositivity FAM178A intron 24324551 rs55942016 chr10 102692643 G A 2.55E-06 Ejection fraction in Tripanosoma cruzi seropositivity FAM178A intron 24324551 rs7911957 chr10 102692970 A G 3.37E-04 Alcohol dependence FAM178A intron 20201924 rs7911957 chr10 102692970 A G 2.54E-06 Ejection fraction in Tripanosoma cruzi seropositivity FAM178A intron 24324551 rs2863094 chr10 102695909 C T 2.13E-06 Ejection fraction in Tripanosoma cruzi seropositivity FAM178A intron 24324551 rs10883565 chr10 102703434 T C 1.67E-06 Ejection fraction in Tripanosoma cruzi seropositivity FAM178A intron 24324551 rs12780429 chr10 102707526 A G 3.13E-05 Body Fat Distribution FAM178A cds-synon pha003016 rs12780429 chr10 102707526 A G 1.96E-05 Waist Circumference FAM178A cds-synon pha003025 rs12780429 chr10 102707526 A G 6.92E-06 Weight FAM178A cds-synon pha003027 rs4919509 chr10 102714887 C T 4.43E-06 Ejection fraction in Tripanosoma cruzi seropositivity FAM178A intron 24324551 rs1056295 chr10 102715183 T C 1.69E-06 Ejection fraction in Tripanosoma cruzi seropositivity FAM178A intron 24324551 rs11190773 chr10 102722428 G C 4.08E-06 Ejection fraction in Tripanosoma cruzi seropositivity FAM178A UTR-3 24324551 rs927302 chr10 102722916 G C 1.62E-06 Ejection fraction in Tripanosoma cruzi seropositivity FAM178A UTR-3 24324551 rs1570171 chr10 102731759 T A 1.43E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs41291460 chr10 102732813 A C 2.81E-06 Ejection fraction in Tripanosoma cruzi seropositivity SEMA4G intron 24324551 rs41291462 chr10 102733407 C A 3.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity SEMA4G intron 24324551 rs111981433 chr10 102733776 C T 7.89E-07 Ejection fraction in Tripanosoma cruzi seropositivity SEMA4G intron 24324551 rs12253241 chr10 102733779 T C 2.42E-06 Ejection fraction in Tripanosoma cruzi seropositivity SEMA4G intron 24324551 rs4919510 chr10 102734778 C G 1.69E-06 Ejection fraction in Tripanosoma cruzi seropositivity SEMA4G intron 24324551 rs735137 chr10 102735835 C G 2.05E-06 Ejection fraction in Tripanosoma cruzi seropositivity SEMA4G intron 24324551 rs28663309 chr10 102736717 G A 9.92E-06 PR interval in Tripanosoma cruzi seropositivity SEMA4G intron 24324551 rs67813203 chr10 102738551 A G 2.52E-06 Ejection fraction in Tripanosoma cruzi seropositivity MRPL43 UTR-3 24324551 rs67692077 chr10 102740271 T C 3.20E-06 Ejection fraction in Tripanosoma cruzi seropositivity SEMA4G intron 24324551 rs12571302 chr10 102742763 C A 3.11E-06 Ejection fraction in Tripanosoma cruzi seropositivity SEMA4G intron 24324551 rs2295716 chr10 102744214 T C 2.27E-06 Ejection fraction in Tripanosoma cruzi seropositivity SEMA4G UTR-3 24324551 rs2863095 chr10 102746503 C T 2.98E-06 Ejection fraction in Tripanosoma cruzi seropositivity MRPL43 cds-synon 24324551 rs3740485 chr10 102750621 C T 7.32E-06 Ejection fraction in Tripanosoma cruzi seropositivity C10orf2 intron 24324551 rs3740486 chr10 102750623 T C 7.32E-06 Ejection fraction in Tripanosoma cruzi seropositivity C10orf2 intron 24324551 rs3740487 chr10 102750783 C A 7.37E-06 Ejection fraction in Tripanosoma cruzi seropositivity C10orf2 UTR-3 24324551 rs3824783 chr10 102750851 G A 7.47E-06 Ejection fraction in Tripanosoma cruzi seropositivity C10orf2 intron 24324551 rs112309064 chr10 102751706 G A 2.07E-06 Ejection fraction in Tripanosoma cruzi seropositivity C10orf2 intron 24324551 rs111545834 chr10 102752162 C T 9.30E-06 Ejection fraction in Tripanosoma cruzi seropositivity C10orf2 intron 24324551 rs4919511 chr10 102752745 G A 2.73E-06 Ejection fraction in Tripanosoma cruzi seropositivity C10orf2 intron 24324551 rs3740488 chr10 102754033 A T 8.25E-06 Ejection fraction in Tripanosoma cruzi seropositivity C10orf2 UTR-3 24324551 rs3740489 chr10 102754238 A G 5.83E-06 Ejection fraction in Tripanosoma cruzi seropositivity C10orf2 nearGene-3 24324551 rs3740490 chr10 102756743 G C 3.61E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs11190786 chr10 102757442 A G 2.17E-06 Ejection fraction in Tripanosoma cruzi seropositivity LZTS2 intron 24324551 rs7902510 chr10 102757934 C T 3.30E-06 Ejection fraction in Tripanosoma cruzi seropositivity LZTS2 intron 24324551 rs7903239 chr10 102758337 G T 3.42E-06 Ejection fraction in Tripanosoma cruzi seropositivity LZTS2 intron 24324551 rs55646950 chr10 102760996 C T 3.16E-06 Ejection fraction in Tripanosoma cruzi seropositivity LZTS2 intron 24324551 rs750866 chr10 102761458 A G 3.03E-06 Ejection fraction in Tripanosoma cruzi seropositivity LZTS2 intron 24324551 rs701834 chr10 102761801 C T 3.01E-06 Ejection fraction in Tripanosoma cruzi seropositivity LZTS2 intron 24324551 rs701835 chr10 102762127 A G 3.05E-06 Ejection fraction in Tripanosoma cruzi seropositivity LZTS2 intron 24324551 rs807029 chr10 102764047 C T 1.86E-04 Eating disorders LZTS2 intron 23568457 rs807029 chr10 102764047 C T 4.00E-07 Ejection fraction in Tripanosoma cruzi seropositivity LZTS2 intron 24324551 rs807028 chr10 102764511 G A 2.34E-04 Suicide attempts in bipolar disorder LZTS2 intron 21423239 rs807027 chr10 102764607 T A 3.50E-06 Ejection fraction in Tripanosoma cruzi seropositivity LZTS2 intron 24324551 rs807025 chr10 102764821 C T 8.59E-06 Ejection fraction in Tripanosoma cruzi seropositivity LZTS2 intron 24324551 rs11190790 chr10 102772283 A C 2.02E-04 Anorexia nervosa PDZD7 intron 23568457 rs701837 chr10 102775205 T C 1.20E-06 Alcohol dependence PDZD7 intron 20201924 rs701837 chr10 102775205 T C 1.19E-06 Alcoholism PDZD7 intron pha002892 rs6584411 chr10 102832925 G A 5.17E-04 Multiple complex diseases / / 17554300 rs10786617 chr10 102835254 C T 4.71E-05 Multiple complex diseases / / 17554300 rs10748804 chr10 102841029 A G 7.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11190818 chr10 102842961 T C 7.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4919513 chr10 102846510 T C 7.89E-05 Multiple complex diseases / / 17554300 rs10883580 chr10 102848834 G A 6.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs72842033 chr10 102858150 G A 0.0000998 Nonsyndromic striae distensae (stretch marks) TLX1NB intron 23633020 rs11190823 chr10 102860730 C T 5.57E-05 Multiple complex diseases TLX1NB intron 17554300 rs4265537 chr10 102861256 C T 1.48E-04 Multiple complex diseases TLX1NB intron 17554300 rs7085631 chr10 102863097 G A 7.71E-05 Multiple complex diseases TLX1NB intron 17554300 rs11190828 chr10 102863307 A T 8.05E-05 Multiple complex diseases TLX1NB intron 17554300 rs10786621 chr10 102880793 A G 4.73E-05 Information processing speed TLX1NB intron 21130836 rs10786621 chr10 102880793 A G 3.17E-05 Hypertension (early onset hypertension) TLX1NB intron 22479346 rs1111350 chr10 102890421 G A 7.07E-05 Hypertension (early onset hypertension) TLX1NB intron 22479346 rs12415670 chr10 102893840 G A 8.82E-05 Hypertension (early onset hypertension) TLX1 intron 22479346 rs2859746 chr10 102896031 C T 0.00000249 HDL cholesterol particle diameter TLX1 intron 23263444 rs2235128 chr10 102896801 G A 4.79E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TLX1 UTR-3 20877124 rs2742042 chr10 102897868 C T 2.34E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100652756 intron 20877124 rs2742042 chr10 102897868 C T 8.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100652756 intron 20877124 rs701840 chr10 102912649 C A 2.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs792720 chr10 102919101 C G 2.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1743829 chr10 102928131 T C 3.61E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12570663 chr10 102930854 C T 4.49E-05 Cognitive impairment induced by topiramate / / 22091778 rs11598564 chr10 102964604 G A 8.19E-05 Scoliosis / / 21216876 rs11598564 chr10 102964604 G A 9.77E-12 adolescent idiopathic scoliosis / / 24023777 rs1535462 chr10 102973872 A G 3.92E-08 Scoliosis / / 22019779 rs3950032 chr10 102974109 A C 3.14E-09 Scoliosis / / 22019779 rs76319884 chr10 102976006 C G 3.24E-09 Scoliosis / / 22019779 rs200590764 chr10 102976661 C CT 3.24E-09 Scoliosis / / 22019779 rs7914775 chr10 102976661 C T 3.24E-09 Scoliosis / / 22019779 rs11190870 chr10 102979207 T C 1.00E-19 Scoliosis / / 22019779 rs11190870 chr10 102979207 T C 2.80E-18 adolescent idiopathic scoliosis / / 24023777 rs11598177 chr10 102980156 T C 3.44E-08 Scoliosis / / 22019779 rs1322332 chr10 102982648 T C 3.50E-08 Scoliosis / / 22019779 rs1407409 chr10 102985407 T C 3.24E-09 Scoliosis / / 22019779 rs1322331 chr10 102986589 A C 3.75E-08 Scoliosis LBX1 nearGene-3 22019779 rs1322330 chr10 102991659 A G 5.18E-09 Scoliosis FLJ41350 intron 22019779 rs625039 chr10 102993649 G A 1.28E-15 adolescent idiopathic scoliosis FLJ41350 intron 24023777 rs625039 chr10 102993649 G A 6.19E-05 Lung function (forced vital capacity) FLJ41350 intron pha003104 rs594791 chr10 102995796 T C 5.65E-09 Scoliosis FLJ41350 intron 22019779 rs678741 chr10 102997581 G A 9.61E-08 Scoliosis FLJ41350 intron 22019779 rs17113827 chr10 103009461 C T 5.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs17113829 chr10 103019884 G A 5.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs2078059 chr10 103024641 T C 1.39E-05 Waist-Hip Ratio / / pha003013 rs2078059 chr10 103024641 T C 2.13E-06 Waist-Hip Ratio / / pha003028 rs12569599 chr10 103033126 G A 2.49E-05 Waist-Hip Ratio / / pha003013 rs12569599 chr10 103033126 G A 6.75E-06 Waist-Hip Ratio / / pha003028 rs12781083 chr10 103101769 T C 4.54E-05 Magnesium levels / / pha003092 rs7916830 chr10 103111057 T C 8.13E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs10883617 chr10 103113035 T C 3.03E-05 Response to gemcitabine in pancreatic cancer BTRC nearGene-5 22142827 rs7090670 chr10 103124457 A C 4.47E-04 Parkinson's disease BTRC intron 17052657 rs7090670 chr10 103124457 A C 8.64E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) BTRC intron 23648065 rs10450405 chr10 103133249 T C 8.13E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) BTRC intron 23648065 rs17760784 chr10 103156416 G C 4.10E-04 Nicotine smoking BTRC intron 19268276 rs7901883 chr10 103186838 G A 8.13E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) BTRC intron 23648065 rs4612729 chr10 103198642 T C 4.48E-04 Parkinson's disease BTRC intron 17052657 rs7900462 chr10 103199218 A G 4.33E-04 Parkinson's disease BTRC intron 17052657 rs7900747 chr10 103199432 A C 4.48E-04 Parkinson's disease BTRC intron 17052657 rs12765602 chr10 103207180 T A 5.49E-04 Obesity (extreme) BTRC intron 21935397 rs10786637 chr10 103228836 C T 4.48E-04 Parkinson's disease BTRC intron 17052657 rs9420843 chr10 103264187 T C 1.60E-05 Bipolar disorder BTRC intron 17486107 rs3095802 chr10 103331644 G T 1.40E-05 Urinary metabolites / / 21572414 rs12769144 chr10 103369554 A C 2.38E-08 Metabolite levels DPCD nearGene-3 23281178 rs17697512 chr10 103527782 A G 8.39E-05 Height / / 17255346 rs17697512 chr10 103527782 A G 6.50E-23 Narcolepsy / / 19629137 rs17698975 chr10 103667483 C A 2.55E-04 Height C10orf76 intron 17255346 rs7913468 chr10 103679314 C T 3.28E-05 Cognitive impairment induced by topiramate C10orf76 intron 22091778 rs11191150 chr10 103690570 C T 2.00E-04 Cognitive impairment induced by topiramate C10orf76 intron 22091778 rs34014631 chr10 103698705 G A 4.00E-06 Coronary artery calcification C10orf76 intron 23870195 rs17700149 chr10 103807817 A G 2.02E-04 Height C10orf76 intron 17255346 rs7090600 chr10 103844935 A G 9.21E-04 Multiple complex diseases / / 17554300 rs4919611 chr10 103894939 C A 4.83E-05 Brain structure PPRC1 intron 22504417 rs11191224 chr10 103920344 G T 0.000026 Prostate cancer (advanced) NOLC1 missense 23555315 rs1049466 chr10 103922063 G C 5.14E-04 Multiple complex diseases NOLC1 UTR-3 17554300 rs7072336 chr10 103930606 C T 7.41E-05 Bipolar disorder / / 17486107 rs10883712 chr10 103939305 G T 2.80E-07 Urinary metabolites / / 21572414 rs10883717 chr10 103967590 T C 1.33E-04 Multiple complex diseases / / 17554300 rs10883717 chr10 103967590 T C 1.20E-06 Urinary metabolites / / 21572414 rs79332175 chr10 104050840 A C 1.90E-04 Acne (severe) GBF1 intron 24927181 rs17780667 chr10 104076231 G A 4.90E-05 Multiple complex diseases GBF1 intron 17554300 rs945781 chr10 104085921 C T 1.40E-06 Urinary metabolites GBF1 intron 21572414 rs3802678 chr10 104115395 A T 9.60E-05 Type 2 diabetes GBF1 intron 17463249 rs3802678 chr10 104115395 A T 2.27E-05 Multiple complex diseases GBF1 intron 17554300 rs12572826 chr10 104132535 A G 3.60E-06 Urinary metabolites GBF1 intron 21572414 rs144256363 chr10 104176384 T G 0.00035 Breast cancer (ER positive) PSD missense 23555315 rs7086205 chr10 104202729 C T 3.67E-06 Social autistic-like traits / / 24133439 rs927821 chr10 104207799 C A 3.00E-06 Social autistic-like traits / / 24133439 rs10883723 chr10 104225832 T C 2.40E-05 Pericardial fat TMEM180 UTR-5 22589742 rs1056738 chr10 104236481 G A 2.40E-05 Pericardial fat TMEM180 UTR-3 22589742 rs1056739 chr10 104236542 T C 2.40E-05 Pericardial fat TMEM180 UTR-3 22589742 rs5870 chr10 104239100 T C 2.02E-04 Multiple complex diseases ACTR1A UTR-3 17554300 rs1056857 chr10 104240003 C T 2.80E-05 Pericardial fat ACTR1A UTR-3 22589742 rs13287 chr10 104240438 A G 2.70E-05 Pericardial fat ACTR1A UTR-3 22589742 rs2296579 chr10 104241375 A G 2.60E-05 Pericardial fat ACTR1A intron 22589742 rs2296581 chr10 104242886 G A 2.50E-05 Pericardial fat ACTR1A intron 22589742 rs2296582 chr10 104244139 G T 2.60E-05 Pericardial fat ACTR1A intron 22589742 rs2296583 chr10 104244322 T G 2.40E-05 Pericardial fat ACTR1A intron 22589742 rs3781290 chr10 104244948 G C 6.10E-05 Pericardial fat ACTR1A intron 22589742 rs2296586 chr10 104245575 G A 2.40E-05 Pericardial fat ACTR1A intron 22589742 rs7917158 chr10 104246471 C A 2.40E-05 Pericardial fat ACTR1A intron 22589742 rs2296588 chr10 104248087 T C 1.60E-05 Pericardial fat ACTR1A intron 22589742 rs2296589 chr10 104248106 T A 2.40E-05 Pericardial fat ACTR1A intron 22589742 rs6584504 chr10 104253507 T C 2.40E-05 Pericardial fat ACTR1A intron 22589742 rs6584508 chr10 104258567 A G 2.60E-05 Pericardial fat ACTR1A intron 22589742 rs7092248 chr10 104262342 A G 1.27E-06 Body mass index ACTR1A intron 19584900 rs7092248 chr10 104262342 A G 1.82E-06 Body mass index ACTR1A intron 19584900 rs2296590 chr10 104262628 G A 2.60E-05 Pericardial fat ACTR1A nearGene-5 22589742 rs3808934 chr10 104264280 C T 2.60E-05 Pericardial fat SUFU intron 22589742 rs2281879 chr10 104268877 G C 2.70E-05 Pericardial fat SUFU intron 22589742 rs10883728 chr10 104269301 G A 2.70E-05 Pericardial fat SUFU intron 22589742 rs10786671 chr10 104271303 G A 2.70E-05 Pericardial fat SUFU intron 22589742 rs10883729 chr10 104273943 A G 2.70E-05 Pericardial fat SUFU intron 22589742 rs4919652 chr10 104274157 C A 1.30E-04 Smoking cessation SUFU intron 18519826 rs7094366 chr10 104274730 C G 2.70E-05 Pericardial fat SUFU intron 22589742 rs1884929 chr10 104275418 C T 2.70E-05 Pericardial fat SUFU intron 22589742 rs11191312 chr10 104278601 T C 2.60E-05 Pericardial fat SUFU intron 22589742 rs10786673 chr10 104280537 G A 2.60E-05 Pericardial fat SUFU intron 22589742 rs7090034 chr10 104281155 C G 2.60E-05 Pericardial fat SUFU intron 22589742 rs1409311 chr10 104282160 G A 2.50E-05 Pericardial fat SUFU intron 22589742 rs1409310 chr10 104282265 T C 2.50E-05 Pericardial fat SUFU intron 22589742 rs7087665 chr10 104282418 T C 2.50E-05 Pericardial fat SUFU intron 22589742 rs7074343 chr10 104283165 G A 2.50E-05 Pericardial fat SUFU intron 22589742 rs12572775 chr10 104285594 A T 4.08E-04 Multiple complex diseases SUFU intron 17554300 rs17114641 chr10 104287359 T G 5.20E-04 Lymphocyte counts SUFU intron 22286170 rs11191321 chr10 104293412 C T 2.00E-05 Pericardial fat SUFU intron 22589742 rs10883732 chr10 104293461 G A 1.90E-05 Pericardial fat SUFU intron 22589742 rs10748825 chr10 104293609 A G 1.90E-05 Pericardial fat SUFU intron 22589742 rs7096072 chr10 104299976 C T 1.90E-05 Pericardial fat SUFU intron 22589742 rs11191325 chr10 104302933 G A 1.80E-05 Pericardial fat SUFU intron 22589742 rs11191326 chr10 104302959 C T 1.80E-05 Pericardial fat SUFU intron 22589742 rs11191330 chr10 104306160 G T 1.80E-05 Pericardial fat SUFU intron 22589742 rs11594073 chr10 104308193 T C 2.50E-05 Pericardial fat SUFU intron 22589742 rs11594073 chr10 104308193 T C 4.98E-04 Self-reported allergy SUFU intron 23817569 rs10786679 chr10 104315667 G A 2.20E-05 Pericardial fat SUFU intron 22589742 rs10786680 chr10 104317192 T C 1.31E-04 Multiple complex diseases SUFU intron 17554300 rs10786680 chr10 104317192 T C 2.40E-05 Pericardial fat SUFU intron 22589742 rs10786680 chr10 104317192 T C 3.53E-04 Self-reported allergy SUFU intron 23817569 rs10786682 chr10 104318322 G T 9.82E-05 Multiple complex diseases SUFU intron 17554300 rs10786682 chr10 104318322 G T 2.90E-05 Pericardial fat SUFU intron 22589742 rs10786682 chr10 104318322 G T 3.52E-04 Self-reported allergy SUFU intron 23817569 rs10883736 chr10 104320029 G T 5.18E-05 Multiple complex diseases SUFU intron 17554300 rs10883736 chr10 104320029 G T 2.20E-05 Pericardial fat SUFU intron 22589742 rs10883736 chr10 104320029 G T 3.40E-04 Self-reported allergy SUFU intron 23817569 rs10883738 chr10 104321721 T C 2.30E-05 Pericardial fat SUFU intron 22589742 rs10883738 chr10 104321721 T C 3.32E-04 Self-reported allergy SUFU intron 23817569 rs10786684 chr10 104323028 G T 4.17E-05 Multiple complex diseases SUFU intron 17554300 rs10786684 chr10 104323028 G T 2.68E-05 Smoking cessation SUFU intron 18519826 rs10786684 chr10 104323028 G T 2.60E-05 Pericardial fat SUFU intron 22589742 rs10786684 chr10 104323028 G T 3.32E-04 Self-reported allergy SUFU intron 23817569 rs10786685 chr10 104323103 G A 1.18E-04 Multiple complex diseases SUFU intron 17554300 rs10786685 chr10 104323103 G A 2.79E-05 Smoking cessation SUFU intron 18519826 rs10786685 chr10 104323103 G A 7.50E-05 Pericardial fat SUFU intron 22589742 rs10786685 chr10 104323103 G A 3.28E-04 Self-reported allergy SUFU intron 23817569 rs7906115 chr10 104327164 A G 3.21E-04 Self-reported allergy SUFU intron 23817569 rs3862030 chr10 104327584 A G 2.30E-05 Pericardial fat SUFU intron 22589742 rs3862030 chr10 104327584 A G 3.21E-04 Self-reported allergy SUFU intron 23817569 rs4917973 chr10 104333700 C T 2.20E-05 Pericardial fat SUFU intron 22589742 rs4917973 chr10 104333700 C T 3.30E-04 Self-reported allergy SUFU intron 23817569 rs12784963 chr10 104336986 G A 2.10E-05 Pericardial fat SUFU intron 22589742 rs12784963 chr10 104336986 G A 3.20E-04 Self-reported allergy SUFU intron 23817569 rs7899004 chr10 104341435 T C 2.00E-05 Pericardial fat SUFU intron 22589742 rs7899004 chr10 104341435 T C 5.50E-04 Self-reported allergy SUFU intron 23817569 rs729023 chr10 104341887 C T 3.33E-05 Multiple complex diseases SUFU intron 17554300 rs729023 chr10 104341887 C T 2.10E-05 Pericardial fat SUFU intron 22589742 rs729023 chr10 104341887 C T 3.06E-04 Self-reported allergy SUFU intron 23817569 rs746552 chr10 104342501 A G 7.40E-06 Pericardial fat SUFU intron 22589742 rs7907760 chr10 104345197 C T 2.10E-05 Pericardial fat SUFU intron 22589742 rs7907760 chr10 104345197 C T 3.42E-04 Self-reported allergy SUFU intron 23817569 rs7068535 chr10 104349127 C T 7.50E-06 Pericardial fat SUFU intron 22589742 rs11191347 chr10 104351617 G A 9.90E-06 Pericardial fat SUFU intron 22589742 rs10748826 chr10 104354804 T C 2.10E-05 Pericardial fat SUFU intron 22589742 rs10748826 chr10 104354804 T C 3.51E-04 Self-reported allergy SUFU intron 23817569 rs3934960 chr10 104355275 A G 2.10E-05 Pericardial fat SUFU intron 22589742 rs3934960 chr10 104355275 A G 3.43E-04 Self-reported allergy SUFU intron 23817569 rs4917976 chr10 104360518 C T 4.25E-05 Multiple complex diseases SUFU intron 17554300 rs4917976 chr10 104360518 C T 1.53E-04 Smoking cessation SUFU intron 18519826 rs4917976 chr10 104360518 C T 2.30E-05 Pericardial fat SUFU intron 22589742 rs4917976 chr10 104360518 C T 3.54E-04 Self-reported allergy SUFU intron 23817569 rs10786691 chr10 104364652 G A 2.10E-05 Pericardial fat SUFU intron 22589742 rs10786691 chr10 104364652 G A 3.54E-04 Self-reported allergy SUFU intron 23817569 rs7075269 chr10 104365724 G A 6.79E-05 Multiple complex diseases SUFU intron 17554300 rs7075269 chr10 104365724 G A 9.12E-05 Smoking cessation SUFU intron 18519826 rs7075269 chr10 104365724 G A 2.10E-05 Pericardial fat SUFU intron 22589742 rs7075269 chr10 104365724 G A 3.25E-04 Self-reported allergy SUFU intron 23817569 rs4919665 chr10 104366042 T C 8.04E-05 Multiple complex diseases SUFU intron 17554300 rs4919665 chr10 104366042 T C 2.30E-05 Pericardial fat SUFU intron 22589742 rs4919665 chr10 104366042 T C 3.05E-04 Self-reported allergy SUFU intron 23817569 rs4917978 chr10 104366353 T C 1.03E-04 Multiple complex diseases SUFU intron 17554300 rs4917978 chr10 104366353 T C 2.20E-05 Pericardial fat SUFU intron 22589742 rs4917978 chr10 104366353 T C 3.55E-04 Self-reported allergy SUFU intron 23817569 rs12782153 chr10 104368294 A G 2.72E-04 Self-reported allergy SUFU intron 23817569 rs10748827 chr10 104368336 G T 8.20E-06 Pericardial fat SUFU intron 22589742 rs7907417 chr10 104370662 T C 4.29E-05 Multiple complex diseases SUFU intron 17554300 rs7907417 chr10 104370662 T C 1.28E-04 Smoking cessation SUFU intron 18519826 rs7907417 chr10 104370662 T C 2.30E-05 Pericardial fat SUFU intron 22589742 rs7907417 chr10 104370662 T C 3.59E-04 Self-reported allergy SUFU intron 23817569 rs11191352 chr10 104372244 A G 2.10E-05 Pericardial fat SUFU intron 22589742 rs11191352 chr10 104372244 A G 3.64E-04 Self-reported allergy SUFU intron 23817569 rs10883753 chr10 104372441 C T 2.10E-05 Pericardial fat SUFU intron 22589742 rs10883753 chr10 104372441 C T 3.67E-04 Self-reported allergy SUFU intron 23817569 rs7908249 chr10 104373300 A G 2.10E-05 Pericardial fat SUFU intron 22589742 rs7908249 chr10 104373300 A G 3.58E-04 Self-reported allergy SUFU intron 23817569 rs7912339 chr10 104373758 G C 3.72E-04 Self-reported allergy SUFU intron 23817569 rs554210843 chr10 104374815 G GC 9.20E-06 Pericardial fat SUFU intron 22589742 rs7093285 chr10 104374815 G C 9.20E-06 Pericardial fat SUFU intron 22589742 rs10786696 chr10 104378134 A G 2.40E-05 Pericardial fat SUFU intron 22589742 rs10786696 chr10 104378134 A G 3.89E-04 Self-reported allergy SUFU intron 23817569 rs7087984 chr10 104380686 G A 2.50E-05 Pericardial fat SUFU intron 22589742 rs7087984 chr10 104380686 G A 3.65E-04 Self-reported allergy SUFU intron 23817569 rs4285804 chr10 104386309 T A 3.60E-05 Pericardial fat SUFU intron 22589742 rs4285804 chr10 104386309 T A 5.39E-04 Self-reported allergy SUFU intron 23817569 rs17114803 chr10 104386934 T C 4.93E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SUFU cds-synon 24023788 rs12414407 chr10 104387019 T C 2.10E-05 Pericardial fat SUFU intron 22589742 rs12357172 chr10 104388549 C A,G,T 5.00E-05 Pericardial fat SUFU intron 22589742 rs11191355 chr10 104392497 T C 1.99E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SUFU UTR-3 24023788 rs12764388 chr10 104413385 G A 1.25E-04 Stroke TRIM8 intron pha002886 rs3850699 chr10 104414221 A G 1.04E-04 Bipolar disorder TRIM8 intron 17486107 rs3850699 chr10 104414221 A G 5.00E-10 Prostate cancer TRIM8 intron 23535732 rs7077678 chr10 104438565 C T 2.92E-06 Coronary heart disease ARL3 intron pha003030 rs17115100 chr10 104591393 G T 7.00E-08 Parkinson's disease CYP17A1-AS1 splice-5 19915575 rs17115100 chr10 104591393 G T 2.46E-05 Parkinson's disease CYP17A1-AS1 splice-5 pha002868 rs1004467 chr10 104594507 A G 1.00E-10 Systolic blood pressure CYP17A1 intron 19430479 rs1004467 chr10 104594507 A G 1.00E-10 Coronary heart disease CYP17A1 intron 21347282 rs1004467 chr10 104594507 A G 6.47E-10 Blood pressure CYP17A1 intron 21909110 rs3824755 chr10 104595849 G C 7.33E-10 Blood pressure CYP17A1 intron 21909110 rs3824755 chr10 104595849 G C 1.20E-07 Coronary heart disease CYP17A1 intron 21966275 rs3824755 chr10 104595849 G C 3.84E-04 Blood pressure CYP17A1 intron 22100073 rs3824755 chr10 104595849 G C 0.0000365 Body mass index CYP17A1 intron 23001569 rs3824755 chr10 104595849 G C 1.00E-06 Blood pressure CYP17A1 intron 24001895 rs3824755 chr10 104595849 G C 1.21E-06 Blood pressure CYP17A1 intron 24001895 rs7089422 chr10 104605328 C T 5.70E-05 White matter hyperintensity burden / / 21681796 rs17724534 chr10 104605521 C T 8.20E-06 White matter hyperintensity burden / / 21681796 rs4290163 chr10 104610926 G T 0.0000229 Arsenic metabolism and toxicity / / 22383894 rs4290163 chr10 104610926 G T 0.00005 Arsenic metabolism and toxicity / / 22383894 rs4290163 chr10 104610926 G T 0.00007 Urinary concentrations of arsenic metabolites (percentage monomethylarsonic acid) / / 22383894 rs4290163 chr10 104610926 G T 1.12E-11 Arsenic metabolism and toxicity / / 22383894 rs3824754 chr10 104614350 C T 1.27E-06 Parkinson's disease C10orf32 intron 19915575 rs3824754 chr10 104614350 C T 3.92E-05 Parkinson's disease C10orf32 intron pha002868 rs4409766 chr10 104616663 T C 9.92E-07 Parkinson's disease C10orf32 intron 19915575 rs7096169 chr10 104618695 A G 7.87E-12 Arsenic metabolism and toxicity C10orf32 intron 22383894 rs9527 chr10 104623578 C T 2.79E-06 Post-operative nausea and vomiting C10orf32 UTR-3 21694509 rs9527 chr10 104623578 C T 0.00000811 Urinary concentrations of arsenic metabolites (percentage monomethylarsonic acid) C10orf32 UTR-3 22383894 rs9527 chr10 104623578 C T 0.0000266 Arsenic metabolism and toxicity C10orf32 UTR-3 22383894 rs9527 chr10 104623578 C T 0.0005 Arsenical skin lesion risk C10orf32 UTR-3 22383894 rs9527 chr10 104623578 C T 0.0009 Urinary concentrations of arsenic metabolites (percentage inorganic arsenic) C10orf32 UTR-3 22383894 rs9527 chr10 104623578 C T 1.96E-12 Arsenic metabolism and toxicity C10orf32 UTR-3 22383894 rs9527 chr10 104623578 C T 2.60E-41 Arsenic metabolism and toxicity C10orf32 UTR-3 22383894 rs9527 chr10 104623578 C T 2.70E-09 Urinary concentrations of arsenic metabolites (percentage dimethylarsinic acid) C10orf32 UTR-3 22383894 rs11191425 chr10 104625970 C T 2.46E-07 Parkinson's disease C10orf32-AS3MT intron 19915575 rs11191425 chr10 104625970 C T 3.96E-05 Parkinson's disease C10orf32-AS3MT intron pha002868 rs7085104 chr10 104628873 A G 4.00E-13 Schizophrenia C10orf32-AS3MT intron 23974872 rs12416687 chr10 104629011 T C 4.00E-09 Blood pressure C10orf32-AS3MT intron 24954895 rs11191439 chr10 104638723 T C 0.00000058 Urinary concentrations of arsenic metabolites (percentage monomethylarsonic acid) AS3MT missense 22383894 rs11191439 chr10 104638723 T C 0.0000042 Urinary concentrations of arsenic metabolites (percentage dimethylarsinic acid) AS3MT missense 22383894 rs11191447 chr10 104652323 C T 6.98E-10 Coronary artery disease AS3MT intron 23202125 rs11191454 chr10 104660004 A G 1.00E-08 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) AS3MT intron 23453885 rs1046778 chr10 104661484 T C 6.00E-07 Schizophrenia AS3MT UTR-3 21791550 rs1046778 chr10 104661484 T C 0.00000089 Urinary concentrations of arsenic metabolites (percentage dimethylarsinic acid) AS3MT UTR-3 22383894 rs1046778 chr10 104661484 T C 0.000000943 Urinary concentrations of arsenic metabolites (percentage monomethylarsonic acid) AS3MT UTR-3 22383894 rs1046778 chr10 104661484 T C 0.0000039 Psychosis AS3MT UTR-3 23164818 rs7897654 chr10 104662458 T C 3.00E-07 Schizophrenia / / 23894747 rs12411886 chr10 104685299 C A 7.79E-07 Parkinson's disease CNNM2 intron 19915575 rs12411886 chr10 104685299 C A 9.50E-08 Intracranial aneurysm CNNM2 intron 20364137 rs12411886 chr10 104685299 C A 5.59E-09 Coronary heart disease CNNM2 intron 21378990 rs4919694 chr10 104698978 T C 0.000000029 Urinary concentrations of arsenic metabolites (percentage monomethylarsonic acid) CNNM2 intron 22383894 rs4919694 chr10 104698978 T C 0.00000236 Arsenic metabolism and toxicity CNNM2 intron 22383894 rs4919694 chr10 104698978 T C 0.00000252 Arsenic metabolism and toxicity CNNM2 intron 22383894 rs4919694 chr10 104698978 T C 8.69E-21 Arsenic metabolism and toxicity CNNM2 intron 22383894 rs12413409 chr10 104719096 G A 6.85E-07 Parkinson's disease CNNM2 intron 19915575 rs12413409 chr10 104719096 G A 1.00E-09 Intracranial aneurysm CNNM2 intron 20364137 rs12413409 chr10 104719096 G A 4.00E-06 Coronary heart disease CNNM2 intron 21378988 rs12413409 chr10 104719096 G A 1.00E-09 Coronary heart disease CNNM2 intron 21378990 rs12413409 chr10 104719096 G A 1.03E-09 Pericardial fat CNNM2 intron 22589742 rs12413409 chr10 104719096 G A 0.000000002 Systolic blood pressure CNNM2 intron 23202125 rs12413409 chr10 104719096 G A 0.000000136 Coronary artery disease (CAD) age >50 CNNM2 intron 23202125 rs12413409 chr10 104719096 G A 0.00000167 Coronary artery disease (CAD) age <=50 CNNM2 intron 23202125 rs12413409 chr10 104719096 G A 0.0000022 Coronary artery disease (CAD) (females) CNNM2 intron 23202125 rs12413409 chr10 104719096 G A 0.00000881 Diastolic blood pressure CNNM2 intron 23202125 rs12413409 chr10 104719096 G A 0.0000111 Coronary artery disease (CAD) (males) CNNM2 intron 23202125 rs12413409 chr10 104719096 G A 0.0000475 Body mass index CNNM2 intron 23202125 rs12413409 chr10 104719096 G A 5.33E-08 Coronary artery disease with myocardial infarction CNNM2 intron 23202125 rs12413409 chr10 104719096 G A 1.00E-06 Coronary artery disease CNNM2 intron 24262325 rs12413409 chr10 104719096 G A 2.00E-08 Coronary artery disease or large artery stroke CNNM2 intron 24262325 rs12413409 chr10 104719096 G A 4.90E-04 Large artery stroke CNNM2 intron 24262325 rs1890185 chr10 104748718 A G 4.00E-07 Migraine CNNM2 intron 23793025 rs10883817 chr10 104755431 G A 0.0000113 Schizophrenia CNNM2 intron 23637625 rs11191514 chr10 104773364 C T 1.03E-04 Intracranial aneurysm CNNM2 intron 22286173 rs7914558 chr10 104775908 G A 2.00E-08 Schizophrenia CNNM2 intron 21926974 rs7914558 chr10 104775908 G A 2.00E-09 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) CNNM2 intron 23453885 rs11191527 chr10 104795134 C T 0.00000008 Urinary concentrations of arsenic metabolites (percentage dimethylarsinic acid) CNNM2 intron 22383894 rs11191527 chr10 104795134 C T 0.0000109 Arsenic metabolism and toxicity CNNM2 intron 22383894 rs11191527 chr10 104795134 C T 0.0000116 Arsenic metabolism and toxicity CNNM2 intron 22383894 rs2296569 chr10 104836511 A G 2.50E-05 White matter hyperintensity burden CNNM2 intron 21681796 rs11191548 chr10 104846178 T C 7.00E-24 Systolic blood pressure NT5C2 UTR-3 19430483 rs11191548 chr10 104846178 T C 7.00E-24 Coronary heart disease NT5C2 UTR-3 21347282 rs11191548 chr10 104846178 T C 7.00E-24 Blood pressure NT5C2 UTR-3 21378095 rs11191548 chr10 104846178 T C 4.00E-17 Blood pressure NT5C2 UTR-3 21572416 rs11191548 chr10 104846178 T C 7.00E-12 Blood pressure NT5C2 UTR-3 21572416 rs11191548 chr10 104846178 T C 8.00E-11 Blood pressure NT5C2 UTR-3 21909110 rs11191548 chr10 104846178 T C 7.00E-26 Systolic blood pressure NT5C2 UTR-3 21909115 rs2274341 chr10 104853503 A T 7.20E-05 White matter hyperintensity burden NT5C2 intron 21681796 rs11598702 chr10 104897985 T C 5.60E-06 White matter hyperintensity burden NT5C2 intron 21681796 rs11598702 chr10 104897985 T C 0.000251 white matter hyperintensity burden NT5C2 intron 23674528 rs11191580 chr10 104906211 T C 3.00E-08 Schizophrenia NT5C2 intron 21926974 rs11191580 chr10 104906211 T C 2.00E-09 Schizophrenia NT5C2 intron 22688191 rs11191580 chr10 104906211 T C 1.00E-08 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) NT5C2 intron 23453885 rs11191580 chr10 104906211 T C 0.00000171 Schizophrenia NT5C2 intron 23637625 rs11191580 chr10 104906211 T C 4.00E-08 Body mass index NT5C2 intron 24861553 rs11191593 chr10 104939215 T C 1.00E-15 Blood pressure NT5C2 intron 21909110 rs11191593 chr10 104939215 T C 1.00E-06 Blood pressure NT5C2 intron 24001895 rs11191593 chr10 104939215 T C 1.13E-06 Blood pressure NT5C2 intron 24001895 rs12240508 chr10 104939232 G A 1.94E-04 Fibrinogen NT5C2 intron 17255346 rs1163238 chr10 104943993 G A 4.80E-06 White matter hyperintensity burden NT5C2 intron 21681796 rs1163238 chr10 104943993 G A 0.000827 white matter hyperintensity burden NT5C2 intron 23674528 rs11191612 chr10 104969578 A G 8.10E-06 White matter hyperintensity burden / / 21681796 rs11191612 chr10 104969578 A G 0.00057 white matter hyperintensity burden / / 23674528 rs4918001 chr10 105013147 A C 0.000000815 Urinary concentrations of arsenic metabolites (percentage dimethylarsinic acid) / / 22383894 rs4918001 chr10 105013147 A C 0.000008 Urinary concentrations of arsenic metabolites (percentage monomethylarsonic acid) / / 22383894 rs1163073 chr10 105022934 T C 4.36E-31 Lymphocyte counts / / 22286170 rs1712517 chr10 105033015 C T 7.79E-04 Type 2 diabetes / / 17463246 rs1712517 chr10 105033015 C T 9.00E-06 Migraine / / 22683712 rs12220267 chr10 105075712 C T 1.00E-213 Arsenic metabolism and toxicity PCGF6 intron 22383894 rs7093667 chr10 105080575 T C 8.90E-05 White matter hyperintensity burden PCGF6 intron 21681796 rs10883855 chr10 105092447 T C 7.70E-05 White matter hyperintensity burden PCGF6 intron 21681796 rs11191659 chr10 105101701 C T 0.0009 Urinary concentrations of arsenic metabolites (percentage monomethylarsonic acid) PCGF6 intron 22383894 rs11191659 chr10 105101701 C T 1.04E-12 Arsenic metabolism and toxicity PCGF6 intron 22383894 rs11191659 chr10 105101701 C T 3.29E-12 Arsenic metabolism and toxicity PCGF6 intron 22383894 rs11191666 chr10 105127278 A G 4.45E-05 Brain structure / / 22504417 rs10883857 chr10 105127587 G T 5.14E-05 Brain structure / / 22504417 rs10883858 chr10 105127708 G A 4.68E-05 Brain structure / / 22504417 rs7905968 chr10 105135319 C T 4.95E-05 Brain structure TAF5 intron 22504417 rs11191672 chr10 105138961 C T 3.97E-05 Brain structure TAF5 intron 22504417 rs11191676 chr10 105155066 C A 4.32E-05 Brain structure USMG5 intron 22504417 rs2292807 chr10 105155645 T C 4.28E-05 Brain structure USMG5 UTR-5 22504417 rs12414609 chr10 105162141 A G 3.85E-05 Brain structure PDCD11 intron 22504417 rs552466648 chr10 105162141 ATG A 3.85E-05 Brain structure PDCD11 intron 22504417 rs7894407 chr10 105176179 T C 6.10E-07 White matter hyperintensity burden PDCD11 intron 21681796 rs2986014 chr10 105194086 C T 4.20E-15 Leukemia(T-cell recognition in patients) PDCD11 missense 21062987 rs2281860 chr10 105201577 C T 4.20E-15 Leukemia(T-cell recognition in patients) PDCD11 intron 21062987 rs6580 chr10 105206874 T C 4.20E-15 Leukemia(T-cell recognition in patients) CALHM2 UTR-3 21062987 rs2232662 chr10 105207301 C T 2.70E-10 Sphingolipid levels CALHM2 missense 22359512 rs10883869 chr10 105211432 G T 4.50E-05 Brain structure CALHM2 intron 22504417 rs140773785 chr10 105211432 G GAGGAGGAGT 4.50E-05 Brain structure CALHM2 intron 22504417 rs729211 chr10 105214932 T C 1.40E-05 White matter hyperintensity burden CALHM1 UTR-3 21681796 rs200456472 chr10 105215062 C T 0.000026 Breast cancer(er negative) CALHM1 missense 23555315 rs755577 chr10 105224066 G A 9.20E-05 White matter hyperintensity burden / / 21681796 rs17736358 chr10 105226538 T C 5.20E-05 White matter hyperintensity burden / / 21681796 rs2986038 chr10 105248507 C T 2.80E-06 Urinary metabolites / / 21572414 rs7071247 chr10 105257786 G T 2.00E-07 Platelet aggregation NEURL intron 20526338 rs7069733 chr10 105297770 C G 7.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) NEURL intron 23453885 rs11191732 chr10 105331761 G A 2.26E-07 Schizophrenia NEURL intron 21926974 rs11191732 chr10 105331761 G A 8.06E-04 Obesity (extreme) NEURL intron 21935397 rs902991 chr10 105342900 C T 2.30E-05 Urinary metabolites NEURL intron 21572414 rs2236211 chr10 105349816 G A 3.63E-04 Major depressive disorder NEURL intron 22472876 rs7918186 chr10 105350447 C T 3.82E-04 Major depressive disorder NEURL UTR-3 22472876 rs729952 chr10 105352990 G T 3.42E-04 Major depressive disorder / / 22472876 rs17738042 chr10 105356031 G A 1.31E-05 Vascular dementia SH3PXD2A UTR-3 22116812 rs3824782 chr10 105360773 C G 3.80E-04 Blood pressure SH3PXD2A UTR-3 17255346 rs3824782 chr10 105360773 C G 4.78E-04 Multiple complex diseases SH3PXD2A UTR-3 17554300 rs11191741 chr10 105362104 G A 3.53E-04 Major depressive disorder SH3PXD2A cds-synon 22472876 rs2281587 chr10 105377349 C T 1.96E-05 Bipolar disorder SH3PXD2A intron 21926972 rs11191749 chr10 105378840 A G 8.18E-04 Obesity (extreme) SH3PXD2A intron 21935397 rs10883890 chr10 105390021 G C 1.59E-05 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia SH3PXD2A intron 24039173 rs12359556 chr10 105390677 C T 9.41E-04 Obesity (extreme) SH3PXD2A intron 21935397 rs3824774 chr10 105438751 C T 9.09E-05 Cardiovascular disease SH3PXD2A intron pha003065 rs10159569 chr10 105472452 T C 8.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SH3PXD2A intron 20877124 rs11191779 chr10 105473580 A G 4.32E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SH3PXD2A intron 20031582 rs879543 chr10 105500857 T C 4.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SH3PXD2A intron 20877124 rs12257568 chr10 105522875 C T 8.70E-05 White matter hyperintensity burden SH3PXD2A intron 21681796 rs2236279 chr10 105531761 C A 1.50E-05 Urinary metabolites SH3PXD2A intron 21572414 rs1107300 chr10 105537349 T C 7.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SH3PXD2A intron 20877124 rs17115967 chr10 105539643 C T 7.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SH3PXD2A intron 20877124 rs4415684 chr10 105540007 C T 8.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SH3PXD2A intron 20877124 rs17115979 chr10 105544691 A T 1.70E-05 Urinary metabolites SH3PXD2A intron 21572414 rs11191818 chr10 105591779 T A,C,G 1.70E-05 Urinary metabolites SH3PXD2A intron 21572414 rs12573437 chr10 105603163 C A 6.76E-04 Alcohol dependence SH3PXD2A intron 20201924 rs2902638 chr10 105636989 T C 2.50E-05 Interstitial lung disease / / 23583980 rs10748858 chr10 105639514 T G 1.55E-06 Telomere length OBFC1 UTR-3 23001564 rs10748858 chr10 105639514 T G 1.24E-05 Interstitial lung disease OBFC1 UTR-3 23583980 rs2067832 chr10 105643134 G A 4.73E-07 Interstitial lung disease OBFC1 intron 23583980 rs4918068 chr10 105644736 T G 9.38E-04 Type 2 diabetes OBFC1 intron 17463246 rs4918068 chr10 105644736 T G 2.54E-09 Multiple complex diseases OBFC1 intron 17554300 rs3814219 chr10 105647095 G A 9.00E-07 Endothelial function traits OBFC1 intron 17903301 rs1980653 chr10 105654164 A G 4.65E-07 Interstitial lung disease OBFC1 intron 23583980 rs10786775 chr10 105657316 G C 1.31E-04 Type 2 diabetes OBFC1 missense 17463246 rs2487999 chr10 105659826 T C 4.22E-14 Telomere length OBFC1 missense 23900074 rs12765878 chr10 105669622 T C 0.00000146 Coronary artery disease OBFC1 intron 23202125 rs2488000 chr10 105671109 T G 1.81E-04 Type 2 diabetes OBFC1 intron 17463246 rs2756116 chr10 105671804 T C 1.81E-04 Type 2 diabetes OBFC1 intron 17463246 rs11191865 chr10 105672842 G A 2.00E-08 Interstitial lung disease OBFC1 intron 23583980 rs11191865 chr10 105672842 G A 2.82E-07 Interstitial lung disease OBFC1 intron 23583980 rs1265164 chr10 105674854 A G 7.50E-12 Telomere length OBFC1 intron 23900074 rs9419958 chr10 105675946 T C 2.61E-05 Lung adenocarcinoma OBFC1 intron 19836008 rs9419958 chr10 105675946 T C 9.00E-11 Telomere length OBFC1 intron 23001564 rs9419958 chr10 105675946 T C 8.46E-05 Interstitial lung disease OBFC1 intron 23583980 rs9419958 chr10 105675946 T C 3.26E-12 Telomere length OBFC1 intron 23900074 rs9420907 chr10 105676465 C A 2.91E-05 Lung adenocarcinoma OBFC1 intron 19836008 rs9420907 chr10 105676465 C A 6.90E-11 Telomere length OBFC1 intron 23535734 rs9420907 chr10 105676465 C A 7.00E-11 Telomere length OBFC1 intron 23535734 rs9420907 chr10 105676465 C A 9.32E-05 Interstitial lung disease OBFC1 intron 23583980 rs4387287 chr10 105677897 A C 2.00E-11 Telomere length OBFC1 UTR-5 20421499 rs3850673 chr10 105679051 C T 2.92E-05 Telomere length / / 23001564 rs4917406 chr10 105688341 A G 7.10E-05 Major depressive disorder (broad) / / 20038947 rs7074532 chr10 105702042 T G 6.47E-05 Interstitial lung disease / / 23583980 rs7073827 chr10 105708793 T C 4.01E-05 Interstitial lung disease / / 23583980 rs7913069 chr10 105714399 C T 8.61E-04 Type 2 diabetes / / 17463246 rs7913069 chr10 105714399 C T 9.00E-14 Uterine fibroids / / 21460842 rs2476950 chr10 105751410 C T 4.81E-04 Response to cytadine analogues (cytosine arabinoside) SLK intron 24483146 rs2476953 chr10 105752503 C T 3.25E-04 Response to cytadine analogues (cytosine arabinoside) SLK intron 24483146 rs805647 chr10 105771009 A C 8.72E-04 Response to cytadine analogues (cytosine arabinoside) SLK intron 24483146 rs805683 chr10 105784123 G T 6.96E-04 Response to cytadine analogues (cytosine arabinoside) SLK intron 24483146 rs805688 chr10 105792077 A G 9.46E-04 Type 2 diabetes COL17A1 intron 17463246 rs2147268 chr10 105793459 C T 1.19E-04 Amyotrophic lateral sclerosis (sporadic) COL17A1 intron 24529757 rs805722 chr10 105810400 T C 3.97E-08 Primary biliary cirrhosis COL17A1 missense 23000144 rs805722 chr10 105810400 T C 3.97E-08 Facial morphology COL17A1 missense 23028347 rs11191909 chr10 105813001 C T 4.61E-08 Primary biliary cirrhosis COL17A1 intron 23000144 rs11191909 chr10 105813001 C T 4.61E-08 Facial morphology COL17A1 intron 23028347 rs1747677 chr10 105815241 A C 2.41E-07 Primary biliary cirrhosis COL17A1 intron 23000144 rs1747677 chr10 105815241 A C 0.000000241 Facial morphology COL17A1 intron 23028347 rs61376250 chr10 105815241 A AC 2.41E-07 Primary biliary cirrhosis COL17A1 intron 23000144 rs61376250 chr10 105815241 A AC 0.000000241 Facial morphology COL17A1 intron 23028347 rs805693 chr10 105815324 A G 2.98E-07 Primary biliary cirrhosis COL17A1 intron 23000144 rs805693 chr10 105815324 A G 0.000000298 Facial morphology COL17A1 intron 23028347 rs805694 chr10 105815454 G A 2.66E-07 Primary biliary cirrhosis COL17A1 intron 23000144 rs805694 chr10 105815454 G A 0.000000266 Facial morphology COL17A1 intron 23028347 rs9971100 chr10 105826419 A C 4.95E-07 Primary biliary cirrhosis COL17A1 intron 23000144 rs9971100 chr10 105826419 A C 0.000000495 Facial morphology COL17A1 intron 23028347 rs9971100 chr10 105826419 A C 6.63E-05 Lupus nephritis in systemic lupus erythematosus COL17A1 intron 24925725 rs11591291 chr10 105829492 C A,T 3.71E-05 Lupus nephritis in systemic lupus erythematosus COL17A1 intron 24925725 rs2274107 chr10 105838703 G A 4.20E-07 Primary biliary cirrhosis COL17A1 intron 23000144 rs2274107 chr10 105838703 G A 0.00000042 Facial morphology COL17A1 intron 23028347 rs2274107 chr10 105838703 G A 3.77E-05 Lupus nephritis in systemic lupus erythematosus COL17A1 intron 24925725 rs1320448 chr10 105846074 A G 2.00E-08 Cardiac hypertrophy COL17A1 nearGene-5 21348951 rs942410 chr10 105847342 C T 7.24E-05 Schizophrenia COL17A1 nearGene-5 19571809 rs12358982 chr10 105854329 A G 4.15E-07 Primary biliary cirrhosis / / 23000144 rs12358982 chr10 105854329 A G 0.000000415 Facial morphology / / 23028347 rs12358982 chr10 105854329 A G 2.38E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs11191924 chr10 105869782 T A 6.95E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10883969 chr10 105884116 C T 3.00E-06 Preeclampsia SFR1 intron 23551011 rs75941862 chr10 105891932 T C 0.0007 Breast cancer WDR96 missense 23555315 rs2289964 chr10 105905161 C T 5.52E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines WDR96 intron 21844884 rs17823267 chr10 105908063 C T 3.24E-04 Hearing function WDR96 intron 17255346 rs11191942 chr10 105941240 C T 6.18E-05 Alzheimer's disease WDR96 intron 17998437 rs10883978 chr10 105950516 C T 9.58E-05 Alzheimer's disease WDR96 intron 17998437 rs11191946 chr10 105962291 G A 2.01E-04 Alzheimer's disease WDR96 intron 17998437 rs7907367 chr10 105966362 A T 8.20E-05 Alzheimer's disease WDR96 intron 17998437 rs515910 chr10 105966404 A G 4.00E-06 Attention deficit hyperactivity disorder WDR96 intron 18839057 rs10883983 chr10 105977766 G C 1.50E-04 Alzheimer's disease WDR96 intron 17998437 rs11191952 chr10 105979638 T C 1.02E-04 Alzheimer's disease WDR96 intron 17998437 rs10883984 chr10 105982620 G C 5.74E-05 Alzheimer's disease WDR96 intron 17998437 rs958118 chr10 105985410 T C 1.54E-04 Alzheimer's disease WDR96 intron 17998437 rs11191962 chr10 105993301 G C 4.01E-04 Alzheimer's disease / / 17998437 rs522148 chr10 105993530 G A 3.15E-04 Alzheimer's disease / / 17998437 rs4925 chr10 106022789 C A 1.26E-04 Endometrial cancer GSTO1 missense 24096698 rs4925 chr10 106022789 C A 2.16E-04 Endometrial cancer GSTO1 missense 24096698 rs7096068 chr10 106025386 T C 3.94E-07 Multiple complex diseases GSTO1 intron 17554300 rs116993524 chr10 106025864 C T 0.00016 Prostate cancer (non-advanced prostate cancer) GSTO1 missense 23555315 rs116993524 chr10 106025864 C T 0.00042 Prostate cancer GSTO1 missense 23555315 rs34400162 chr10 106035070 G A 1.94E-09 Triglycerides GSTO2 missense 23063622 rs34400162 chr10 106035070 G A 8.68E-10 HDL cholesterol GSTO2 missense 23063622 rs156697 chr10 106039185 A G 9.78E-06 Pulmonary function GSTO2 missense 17903307 rs17116834 chr10 106058382 T C 0.000036 Mean arterial pressure GSTO2 intron 22510845 rs276214 chr10 106090787 A G 1.80E-05 Bipolar disorder ITPRIP intron 19259986 rs276213 chr10 106091095 G A 3.17E-04 Bipolar disorder ITPRIP intron 19259986 rs276213 chr10 106091095 G A 4.64E-05 Bilirubin levels,in serum ITPRIP intron 19389676 rs12267798 chr10 106135117 G A 7.13E-04 Tourette syndrome CCDC147 intron 22889924 rs7917394 chr10 106191792 C T 4.48E-05 Cognitive impairment induced by topiramate CCDC147 intron 22091778 rs7915473 chr10 106203605 C T 1.00E-04 Cognitive impairment induced by topiramate CCDC147 intron 22091778 rs9651453 chr10 106207209 T G 5.20E-06 Hodgkin's lymphoma CCDC147 intron 24149102 rs7095475 chr10 106207933 T C 3.63E-04 Smoking cessation CCDC147 intron 24665060 rs1028915 chr10 106265362 T C 9.75E-04 Myopia (pathological) / / 21095009 rs950128 chr10 106270450 T C 9.65E-04 Bipolar disorder / / 19259986 rs962139 chr10 106275865 G A 8.88E-05 Coronary heart disease / / pha003030 rs884672 chr10 106342559 T C 8.11E-05 Multiple complex diseases / / 17554300 rs7917635 chr10 106347094 G A 5.77E-06 White blood cell count / / 21738479 rs11192129 chr10 106354417 C T 0.000403664 Hypertension (early onset hypertension) / / 22479346 rs10786805 chr10 106357532 C T 0.000514421 Hypertension (early onset hypertension) / / 22479346 rs1334616 chr10 106359063 A G 0.000440016 Hypertension (early onset hypertension) / / 22479346 rs1855581 chr10 106371784 A G 0.000184805 Hypertension (early onset hypertension) / / 22479346 rs1413712 chr10 106377686 G A 0.000288558 Hypertension (early onset hypertension) / / 22479346 rs11192137 chr10 106377705 T C 0.000784468 Hypertension (early onset hypertension) / / 22479346 rs4918120 chr10 106382358 C T 0.000487872 Hypertension (early onset hypertension) / / 22479346 rs7084834 chr10 106403209 C T 7.32E-04 Oral cancers (chewing tobacco related) SORCS3 intron 22503698 rs11192148 chr10 106414631 A G 4.10E-05 Parkinson's disease (age of onset) SORCS3 intron 19772629 rs11192152 chr10 106421057 G T 4.51E-05 Anxiety in major depressive disorder SORCS3 intron 24047446 rs10509774 chr10 106427566 C T 9.07E-05 Coronary heart disease SORCS3 intron pha003055 rs10509774 chr10 106427566 C T 3.41E-05 Coronary heart disease SORCS3 intron pha003056 rs951896 chr10 106428784 G C 6.26E-06 Sleep latency SORCS3 intron 23728906 rs872774 chr10 106437380 T C 9.53E-06 White blood cell count SORCS3 intron 21738479 rs11599236 chr10 106454672 T C 1.89E-04 Multiple complex diseases SORCS3 intron 17554300 rs17117599 chr10 106498131 G A 1.30E-05 Multiple complex diseases SORCS3 intron 17554300 rs10884043 chr10 106531703 A G 0.0000274 Otitis media (children 3 years old or younger) SORCS3 intron 23133572 rs745947 chr10 106532960 C T 5.73E-05 Myopia (pathological) SORCS3 intron 23049088 rs11192190 chr10 106552640 G A 5.43E-04 Multiple complex diseases SORCS3 intron 17554300 rs4556466 chr10 106558025 A G 0.0000247 Otitis media (children 3 years old or younger) SORCS3 intron 23133572 rs11192197 chr10 106584753 C T 2.50E-05 Urinary metabolites SORCS3 intron 21572414 rs2451472 chr10 106603824 G A 8.33E-04 Alzheimer's disease SORCS3 intron 17998437 rs2451471 chr10 106606428 A G 8.54E-04 Spine bone size SORCS3 intron 23207799 rs1873306 chr10 106607780 C T 7.17E-04 Spine bone size SORCS3 intron 23207799 rs1907034 chr10 106612425 T A 2.28E-04 Spine bone size SORCS3 intron 23207799 rs2491377 chr10 106624348 A G 2.89E-04 Spine bone size SORCS3 intron 23207799 rs2451495 chr10 106630962 T C 8.20E-04 Spine bone size SORCS3 intron 23207799 rs1979636 chr10 106631707 T G 2.98E-04 Spine bone size SORCS3 intron 23207799 rs3001931 chr10 106640653 T C 6.05E-04 Spine bone size SORCS3 intron 23207799 rs10509779 chr10 106668148 A G 6.35E-05 Coronary heart disease SORCS3 intron pha003055 rs10509779 chr10 106668148 A G 4.91E-07 Coronary heart disease SORCS3 intron pha003056 rs6584641 chr10 106691096 A G 1.80E-05 Urinary metabolites SORCS3 intron 21572414 rs6584646 chr10 106709239 C T 5.10E-06 Urinary metabolites SORCS3 intron 21572414 rs7912844 chr10 106726428 T C 4.43E-04 Multiple complex diseases SORCS3 intron 17554300 rs10884071 chr10 106731970 G A 4.12E-05 Coronary heart disease SORCS3 intron pha003056 rs7914674 chr10 106738675 T C 4.12E-05 Coronary heart disease SORCS3 intron pha003056 rs1404786 chr10 106740404 G A 5.42E-04 Multiple complex diseases SORCS3 intron 17554300 rs961770 chr10 106750257 A G 4.00E-05 Coronary heart disease SORCS3 intron pha003055 rs961770 chr10 106750257 A G 6.88E-07 Coronary heart disease SORCS3 intron pha003056 rs9783155 chr10 106766194 T C 1.88E-05 Coronary heart disease SORCS3 intron pha003055 rs9783155 chr10 106766194 T C 3.87E-07 Coronary heart disease SORCS3 intron pha003056 rs9783190 chr10 106766267 A G 9.24E-05 Coronary heart disease SORCS3 intron pha003055 rs9783190 chr10 106766267 A G 5.00E-05 Coronary heart disease SORCS3 intron pha003056 rs9783122 chr10 106766398 G A 6.76E-04 Multiple complex diseases SORCS3 intron 17554300 rs790647 chr10 106776484 C A 5.70E-04 Alzheimer's disease SORCS3 intron 24755620 rs790647 chr10 106776484 C A 7.04E-06 Cardiovascular disease SORCS3 intron pha003065 rs790647 chr10 106776484 C A 6.96E-05 HDL cholesterol SORCS3 intron pha003075 rs790646 chr10 106777588 T C 6.95E-04 Multiple complex diseases SORCS3 intron 17554300 rs2864037 chr10 106780753 G T 4.05E-05 Cardiovascular disease SORCS3 intron pha003065 rs790640 chr10 106783551 G A 4.05E-05 Cardiovascular disease SORCS3 intron pha003065 rs790638 chr10 106784021 A G 1.90E-05 Urinary metabolites SORCS3 intron 21572414 rs2791461 chr10 106791365 C T 5.25E-06 Cardiovascular disease SORCS3 intron pha003065 rs1670008 chr10 106802229 G C 5.80E-06 Urinary metabolites SORCS3 intron 21572414 rs1361800 chr10 106812116 T G 8.09E-05 Cardiovascular disease SORCS3 intron pha003065 rs790742 chr10 106833971 G A 5.02E-04 Type 2 diabetes SORCS3 intron 17463246 rs790741 chr10 106834164 G A 5.27E-04 Type 2 diabetes SORCS3 intron 17463246 rs768731 chr10 106834450 C A 5.39E-04 Type 2 diabetes SORCS3 intron 17463246 rs768732 chr10 106834574 A G 4.18E-04 Type 2 diabetes SORCS3 intron 17463246 rs790738 chr10 106835688 C T 6.29E-04 Type 2 diabetes SORCS3 intron 17463246 rs745358 chr10 106836499 C T 7.98E-04 Type 2 diabetes SORCS3 intron 17463246 rs790733 chr10 106838655 C T 5.77E-04 Type 2 diabetes SORCS3 intron 17463246 rs790732 chr10 106838809 A G 4.98E-04 Type 2 diabetes SORCS3 intron 17463246 rs1470804 chr10 106842041 G A 6.57E-04 Type 2 diabetes SORCS3 intron 17463246 rs703462 chr10 106843424 G C 7.84E-04 Type 2 diabetes SORCS3 intron 17463246 rs17790008 chr10 106845381 A G 3.14E-05 Post-operative nausea and vomiting SORCS3 intron 21694509 rs10509783 chr10 106903981 G A 9.50E-04 Type 2 diabetes and 6 quantitative traits SORCS3 intron 17848626 rs697190 chr10 106916651 C G 4.31E-05 Hirschsprung's disease SORCS3 intron 19196962 rs11192347 chr10 106929313 G A 2.10E-05 Urinary metabolites SORCS3 intron 21572414 rs11192368 chr10 106979363 A G 6.50E-06 Urinary metabolites SORCS3 intron 21572414 rs2220139 chr10 107021332 C T 7.01E-06 Soluble levels of adhesion molecules SORCS3 intron pha003072 rs10884127 chr10 107027306 A G 1.30E-05 Urinary metabolites / / 21572414 rs2926458 chr10 107248846 T C 6.92E-05 Personality dimensions / / 18957941 rs1870461 chr10 107252462 T C 8.54E-05 Hypertension (essential hypertension) / / 22184326 rs1993643 chr10 107257029 T C 6.14E-05 Hypertension (essential hypertension) / / 22184326 rs7087931 chr10 107282135 G A 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7089194 chr10 107328195 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10786886 chr10 107369270 G A 0.0000917 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs17119214 chr10 107371475 G C 6.21E-04 Type 2 diabetes / / 17463246 rs1421495 chr10 107411813 G A 9.19E-05 Myopia (pathological) / / 23049088 rs10884207 chr10 107423259 T C 5.91E-14 Metabolite levels / / 22286219 rs11192557 chr10 107452683 T C 2.36E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11192557 chr10 107452683 T C 9.59E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10509794 chr10 107460228 T C 8.48E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs10884218 chr10 107486680 G C 8.38E-04 Type 2 diabetes / / 17463246 rs17119461 chr10 107516352 T C 7.00E-12 Melanoma / / 21706340 rs17119496 chr10 107523565 T C 7.67E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs2418774 chr10 107530680 T C 9.13E-05 Prion diseases / / 22210626 rs11593552 chr10 107543300 A G 8.74E-05 Prion diseases / / 22210626 rs7906443 chr10 107573124 T C 1.90E-04 Multiple complex diseases / / 17554300 rs11192617 chr10 107582247 C A 6.04E-06 Bipolar disorder / / 21771265 rs11192617 chr10 107582247 C A 0.00000758 Amyotrophic lateral sclerosis / / 23587638 rs11192617 chr10 107582247 C A 0.0000356 Amyotrophic lateral sclerosis / / 23587638 rs951030 chr10 107589359 G A 6.04E-06 Bipolar disorder / / 21771265 rs951030 chr10 107589359 G A 0.00000753 Amyotrophic lateral sclerosis / / 23587638 rs951030 chr10 107589359 G A 0.0000355 Amyotrophic lateral sclerosis / / 23587638 rs4568931 chr10 107612556 A G 4.49E-05 Cognitive impairment induced by topiramate / / 22091778 rs2683672 chr10 107690520 A G 9.94E-04 Multiple complex diseases / / 17554300 rs1032537 chr10 107739028 G A 8.33E-05 Body Composition / / pha003012 rs1361356 chr10 107763233 A G 2.92E-05 Pure-tone audiometry / / pha001963 rs7905911 chr10 107764638 G A 3.56E-07 Multiple complex diseases / / 17554300 rs11192688 chr10 107810250 T C 2.86E-04 Insulin resistance / / 21901158 rs10736184 chr10 107891602 C T 1.17E-04 Migraine without aura / / 23793025 rs10736184 chr10 107891602 C T 1.68E-05 Migraine / / 23793025 rs2150602 chr10 107941877 T C 1.29E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7918637 chr10 107942299 T C 5.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs766857 chr10 107978172 G A 9.14E-05 HIV-1 viral setpoint / / 21490045 rs962392 chr10 108014282 C T 5.31E-05 Formal thought disorder in schizophrenia / / 22648509 rs12773693 chr10 108016370 G A 9.96E-05 Formal thought disorder in schizophrenia / / 22648509 rs10786939 chr10 108045070 G A 5.63E-04 Type 2 diabetes / / 17463246 rs7894703 chr10 108053365 C T 9.34E-04 Iron levels / / pha002876 rs1724045 chr10 108062863 C T 2.00E-05 Urinary metabolites / / 21572414 rs6584741 chr10 108104853 A G 1.84E-08 Multiple complex diseases / / 17554300 rs821693 chr10 108120190 A G 4.48E-10 Non-obstructive azoospermia / / 22197933 rs1358030 chr10 108123599 G A 1.00E-04 Type 1 diabetes / / 19875614 rs1358030 chr10 108123599 G A 1.40E-04 Type 1 diabetes / / 19875614 rs1358030 chr10 108123599 G A 1.50E-06 Type 1 diabetes / / 19875614 rs1358030 chr10 108123599 G A 2.00E-09 Type 1 diabetes / / 19875614 rs1358030 chr10 108123599 G A 2.20E-09 Type 1 diabetes / / 19875614 rs1358030 chr10 108123599 G A 3.80E-10 Type 1 diabetes / / 19875614 rs1358030 chr10 108123599 G A 5.50E-04 Type 1 diabetes / / 19875614 rs821683 chr10 108142861 G A 1.80E-05 Urinary metabolites / / 21572414 rs2418804 chr10 108182513 A G 1.22E-05 Prostate cancer / / pha002878 rs952965 chr10 108197128 G A 0.000511 Salmonella-induced pyroptosis / / 22837397 rs2177828 chr10 108202638 A C 0.000391 Salmonella-induced pyroptosis / / 22837397 rs376614634 chr10 108202638 A AC 0.000391 Salmonella-induced pyroptosis / / 22837397 rs11192883 chr10 108214136 A G 0.000806 Salmonella-induced pyroptosis / / 22837397 rs12217685 chr10 108225658 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12217685 chr10 108225658 C T 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12262411 chr10 108244976 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2039964 chr10 108254464 G A 7.00E-06 Metabolite levels (MHPG) / / 23319000 rs17297851 chr10 108299424 G A 2.31E-09 Adiponectin levels / / 20887962 rs2181019 chr10 108311696 G A 9.95E-06 Iron status biomarkers / / 19084217 rs12415344 chr10 108332996 G A 9.38E-05 Crohn's disease and psoriasis SORCS1 nearGene-3 22482804 rs12359404 chr10 108334189 C T 3.10E-06 Asthma (childhood onset) SORCS1 UTR-3 23829686 rs11192967 chr10 108339332 T C 5.01E-05 Hypertension SORCS1 intron 19609347 rs7910584 chr10 108367728 C A 7.14E-07 Autism SORCS1 intron 22843504 rs7074484 chr10 108381257 T C 9.52E-05 Cognitive test performance SORCS1 intron 20125193 rs10491052 chr10 108394614 C A 8.08E-05 Cognitive test performance SORCS1 intron 20125193 rs11192998 chr10 108410585 C T 8.56E-05 Cognitive test performance SORCS1 intron 20125193 rs1252031 chr10 108416572 C T 3.50E-04 Atrial fibrillation SORCS1 intron 21846873 rs2756231 chr10 108466412 C T 0.00000012 Triglycerides SORCS1 intron 23063622 rs2486152 chr10 108498078 A G 7.00E-06 Metabolite levels (Pyroglutamine) SORCS1 intron 23934736 rs7903481 chr10 108499902 T G 5.43E-04 Type 2 diabetes SORCS1 intron 17463246 rs10458732 chr10 108500404 C T 0.000000461 Secreted IFN-gamma response to smallpox vaccine SORCS1 intron 22661280 rs4918255 chr10 108564718 T C 6.31E-04 Longevity SORCS1 intron 22279548 rs4918256 chr10 108565036 C A 8.00E-05 Prostate cancer SORCS1 intron 21743057 rs11193085 chr10 108633606 G A 0.000000294 Triglycerides SORCS1 intron 23063622 rs11193085 chr10 108633606 G A 9.06E-08 LDL cholesterol SORCS1 intron 23063622 rs7098073 chr10 108641449 C T 2.52E-04 Multiple complex diseases SORCS1 intron 17554300 rs10884374 chr10 108672793 C T 1.65E-04 Lung function (forced expiratory volume in 1 second) SORCS1 intron 24023788 rs11193096 chr10 108676910 A G 9.56E-04 Alzheimer's disease SORCS1 intron 22005930 rs7079264 chr10 108679892 A G 2.72E-04 Celiac disease SORCS1 intron 23936387 rs11193102 chr10 108680389 C A 7.45E-04 Alzheimer's disease SORCS1 intron 22005930 rs1336621 chr10 108681291 G A 6.61E-04 Alzheimer's disease SORCS1 intron 22005930 rs7097380 chr10 108681669 G A 1.51E-04 Alzheimer's disease SORCS1 intron 22005930 rs7097380 chr10 108681669 G A 2.27E-05 Celiac disease SORCS1 intron 23936387 rs10786981 chr10 108681730 A G 7.01E-04 Alzheimer's disease SORCS1 intron 22005930 rs1889961 chr10 108682573 G A 7.69E-04 Alzheimer's disease SORCS1 intron 22005930 rs1889962 chr10 108682594 G A 6.82E-04 Alzheimer's disease SORCS1 intron 22005930 rs10786983 chr10 108683158 C T 6.68E-04 Alzheimer's disease SORCS1 intron 22005930 rs11193105 chr10 108683420 A G 7.42E-04 Alzheimer's disease SORCS1 intron 22005930 rs11193108 chr10 108684508 A G 6.42E-04 Alzheimer's disease SORCS1 intron 22005930 rs10748929 chr10 108684718 C A 6.37E-04 Alzheimer's disease SORCS1 intron 22005930 rs10509825 chr10 108685212 T C 2.40E-04 Celiac disease SORCS1 intron 23936387 rs10884376 chr10 108685440 A G 6.13E-04 Alzheimer's disease SORCS1 intron 22005930 rs10884380 chr10 108685665 C T 6.01E-04 Alzheimer's disease SORCS1 intron 22005930 rs12355643 chr10 108685765 G A 5.99E-04 Alzheimer's disease SORCS1 intron 22005930 rs10884381 chr10 108686065 C T 1.58E-04 Alzheimer's disease SORCS1 intron 22005930 rs10884381 chr10 108686065 C T 7.30E-05 Celiac disease SORCS1 intron 23936387 rs10786989 chr10 108686158 C T 6.65E-04 Alzheimer's disease SORCS1 intron 22005930 rs10786991 chr10 108686861 A G 5.73E-04 Alzheimer's disease SORCS1 intron 22005930 rs11193118 chr10 108688435 G A 6.54E-04 Alzheimer's disease SORCS1 intron 22005930 rs11193120 chr10 108688778 G A 4.72E-04 Alzheimer's disease SORCS1 intron 22005930 rs11193120 chr10 108688778 G A 5.72E-05 Celiac disease SORCS1 intron 23936387 rs10884387 chr10 108692152 C T 1.37E-04 Alzheimer's disease SORCS1 intron 22005930 rs10884387 chr10 108692152 C T 6.78E-05 Celiac disease SORCS1 intron 23936387 rs10884388 chr10 108692797 G C 9.53E-04 Alzheimer's disease SORCS1 intron 22005930 rs822076 chr10 108698509 C T 7.47E-04 Alzheimer's disease SORCS1 intron 22005930 rs822076 chr10 108698509 C T 1.41E-04 Celiac disease SORCS1 intron 23936387 rs822077 chr10 108698842 A G 7.49E-04 Alzheimer's disease SORCS1 intron 22005930 rs822080 chr10 108704358 G A 6.00E-04 Alzheimer's disease SORCS1 intron 22005930 rs822095 chr10 108709195 A G 2.81E-04 Alzheimer's disease SORCS1 intron 22005930 rs822095 chr10 108709195 A G 9.46E-05 Celiac disease SORCS1 intron 23936387 rs10786998 chr10 108710127 A C 7.61E-05 Vitiligo SORCS1 intron 22561518 rs10786998 chr10 108710127 A C 2.30E-04 Celiac disease SORCS1 intron 23936387 rs822097 chr10 108711579 T C 9.04E-05 Body Mass Index SORCS1 intron pha003020 rs822084 chr10 108714457 T C 5.91E-04 Alzheimer's disease SORCS1 intron 22005930 rs822088 chr10 108715646 A G 4.31E-04 Alzheimer's disease SORCS1 intron 22005930 rs764934 chr10 108717792 T C 5.01E-04 Alzheimer's disease SORCS1 intron 22005930 rs11193130 chr10 108718454 C T 3.52E-04 Schizophrenia SORCS1 intron 20832056 rs11193130 chr10 108718454 C T 9.37E-05 Cognitive impairment induced by topiramate SORCS1 intron 22091778 rs11193130 chr10 108718454 C T 6.99E-05 Vitiligo SORCS1 intron 22561518 rs10786999 chr10 108720972 G A 3.57E-04 Alzheimer's disease SORCS1 intron 22005930 rs1977467 chr10 108723199 G T 2.00E-04 Alzheimer's disease SORCS1 intron 22005930 rs4918273 chr10 108725495 C T 1.06E-04 Clubfoot SORCS1 intron 24667120 rs1023025 chr10 108726124 A G 1.22E-04 Alzheimer's disease SORCS1 intron 22005930 rs1023024 chr10 108726430 A G 3.34E-04 Alzheimer's disease SORCS1 intron 22005930 rs7897726 chr10 108743550 G A 9.74E-05 Lipoproteins SORCS1 intron pha003079 rs12247406 chr10 108756504 G A 0.00000198 Triglycerides SORCS1 intron 23063622 rs12247406 chr10 108756504 G A 2.37E-14 HDL cholesterol SORCS1 intron 23063622 rs12247406 chr10 108756504 G A 4.72E-08 Cholesterol,total SORCS1 intron 23063622 rs6584786 chr10 108789005 G A 8.80E-05 Major depressive disorder SORCS1 intron 21042317 rs17121941 chr10 108798092 A G 7.34E-05 Celiac disease SORCS1 intron 23936387 rs717751 chr10 108803311 G A 2.54E-05 Coronary heart disease SORCS1 intron pha003032 rs717751 chr10 108803311 G A 7.25E-05 Coronary heart disease SORCS1 intron pha003033 rs10509826 chr10 108804840 A G 6.00E-04 Type 2 diabetes and 6 quantitative traits SORCS1 intron 17848626 rs1328230 chr10 108823700 A G 0.00000227 Cholesterol,total SORCS1 intron 23063622 rs12240854 chr10 108843475 C T 3.57E-04 Amyotrophic lateral sclerosis (sporadic) SORCS1 intron 24529757 rs1556758 chr10 108851556 C T 3.47E-05 Longevity SORCS1 intron 21612516 rs2225176 chr10 108855428 C T 2.30E-05 Urinary metabolites SORCS1 intron 21572414 rs11813704 chr10 108861872 G T 7.33E-08 LDL cholesterol SORCS1 intron 23063622 rs11193198 chr10 108861967 G A 7.54E-04 Alcohol dependence SORCS1 intron 21314694 rs12781860 chr10 108908351 A C 3.58E-05 Cognitive impairment induced by topiramate SORCS1 intron 22091778 rs661319 chr10 108910338 T C 7.56E-05 Cognitive test performance SORCS1 intron 20125193 rs601883 chr10 108914445 C G 6.69E-05 Alzheimer's disease SORCS1 intron 17998437 rs17122417 chr10 109035425 C A 3.51E-04 Blood pressure / / 17255346 rs12219216 chr10 109078493 A G 8.01E-05 Cognitive decline / / 22054870 rs7080002 chr10 109129262 A G 2.95E-04 Type 2 diabetes / / 17463246 rs11193407 chr10 109161645 A C 7.37E-06 Narcolepsy / / 20711174 rs10787024 chr10 109171971 T C 7.03E-04 Type 2 diabetes / / 17463246 rs10787024 chr10 109171971 T C 7.32E-06 Narcolepsy / / 20711174 rs11193432 chr10 109196909 C T 8.32E-04 Body mass index / / 21701565 rs12767204 chr10 109197523 T A 4.25E-04 Multiple complex diseases / / 17554300 rs11193447 chr10 109215161 A G 9.68E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs11193448 chr10 109215192 G A 5.61E-04 Multiple complex diseases / / 17554300 rs11193503 chr10 109233322 T C 3.86E-04 Coronary heart disease / / 21606135 rs1903905 chr10 109271687 C T 2.00E-05 Bipolar disorder / / 21771265 rs17291402 chr10 109283156 C T 4.97E-05 Bipolar disorder / / 21771265 rs11591564 chr10 109285928 A G 5.08E-05 Bipolar disorder / / 21771265 rs10884475 chr10 109333696 T C 9.52E-04 Coronary Artery Disease / / 17634449 rs1441273 chr10 109335303 A G 2.60E-05 Urinary metabolites / / 21572414 rs12766593 chr10 109340642 G A 2.75E-04 Tourette syndrome / / 22889924 rs4917504 chr10 109347602 A G 2.32E-04 Prostate cancer mortality / / 20978177 rs17122872 chr10 109358096 T C 3.36E-04 Multiple complex diseases / / 17554300 rs17122872 chr10 109358096 T C 1.99E-04 Cognitive decline / / 23732972 rs4918309 chr10 109361624 C T 3.49E-04 Smoking initiation / / 24665060 rs11193561 chr10 109374384 C T 6.00E-06 Endometriosis / / 23472165 rs7894460 chr10 109379996 G A 3.15E-04 Alzheimer's disease / / 24755620 rs10884483 chr10 109380524 G C 3.15E-04 Alzheimer's disease / / 24755620 rs7914264 chr10 109395356 C T 9.07E-05 Alzheimer's disease / / 24755620 rs17220921 chr10 109396541 C T 3.50E-06 Urinary metabolites / / 21572414 rs1902737 chr10 109405754 A G 8.74E-04 Multiple complex diseases / / 17554300 rs1902738 chr10 109405963 C T 6.91E-04 Multiple complex diseases / / 17554300 rs7894245 chr10 109453932 T C 9.00E-04 Type 2 diabetes / / 17463246 rs7091009 chr10 109474406 T C 1.36E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs1870183 chr10 109492928 A C 4.34E-04 Multiple complex diseases / / 17554300 rs11193670 chr10 109514980 G A 5.60E-05 Endometriosis / / 21151130 rs11193684 chr10 109536094 G T 8.74E-04 Type 2 diabetes / / 17463246 rs2900781 chr10 109542795 C T 2.40E-05 Urinary metabolites / / 21572414 rs7908795 chr10 109548708 G A 9.40E-05 Hypothyroidism / / 22493691 rs2900784 chr10 109549467 C A 8.80E-05 Hypothyroidism / / 22493691 rs4344419 chr10 109555429 T C 7.10E-05 Hypothyroidism / / 22493691 rs12570947 chr10 109569850 T C 4.00E-06 Prion diseases / / 22210626 rs10509852 chr10 109575094 C T 2.09E-04 Parkinson's disease / / 17052657 rs10509853 chr10 109575301 A G 3.44E-04 Parkinson's disease / / 17052657 rs17123393 chr10 109575858 C T 3.96E-05 Response to metformin / / 21186350 rs10884551 chr10 109580795 T C 8.49E-05 Multiple complex diseases / / 17554300 rs12258384 chr10 109587865 C G 4.97E-04 Multiple complex diseases / / 17554300 rs11193730 chr10 109593621 A G 7.65E-05 Blood Pressure / / pha003044 rs1411291 chr10 109599452 A T 8.84E-04 Multiple complex diseases / / 17554300 rs11193742 chr10 109604105 T C 5.37E-04 Multiple complex diseases / / 17554300 rs11193743 chr10 109604419 T C 7.18E-04 Multiple complex diseases / / 17554300 rs7096859 chr10 109614801 G A 3.86E-04 Type 2 diabetes / / 17463246 rs4918326 chr10 109617557 C T 2.42E-04 Type 2 diabetes / / 17463246 rs1834180 chr10 109626066 G A 5.00E-07 Social communication problems / / 24047820 rs10884557 chr10 109629119 A G 6.53E-04 Type 2 diabetes / / 17463246 rs10884573 chr10 109693792 C T 2.38E-04 Alzheimer's disease / / 24755620 rs12356982 chr10 109740297 G A 7.47E-04 Acute lung injury / / 22295056 rs11193831 chr10 109749174 C T 5.60E-04 Alzheimer's disease / / 24755620 rs1931605 chr10 109789833 G T 1.68E-04 Alzheimer's disease / / pha002879 rs7082958 chr10 109794993 G A 5.71E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7082958 chr10 109794993 G A 3.50E-04 Alzheimer's disease / / 24755620 rs12764054 chr10 109805032 G A 3.62E-04 Smoking initiation / / 24665060 rs12572750 chr10 109821919 T C 4.99E-05 Serum metabolites / / 19043545 rs7919012 chr10 109840180 G A 8.02E-04 Smoking initiation / / 24665060 rs11193889 chr10 109856486 G A 2.47E-04 Multiple complex diseases / / 17554300 rs10884597 chr10 109865613 T A 5.83E-04 Acute lung injury / / 22295056 rs17250227 chr10 109867337 T C 1.48E-04 Acute lung injury / / 22295056 rs17250276 chr10 109868977 G A 3.87E-04 Acute lung injury / / 22295056 rs17123786 chr10 109870291 G C 6.70E-05 Acute lung injury / / 22295056 rs12217601 chr10 109881982 G A 2.19E-04 Alzheimer's disease / / 24755620 rs11193900 chr10 109883659 C A 4.43E-05 Cognitive test performance / / 20125193 rs11193901 chr10 109884711 T G 3.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11193910 chr10 109895038 G A 1.12E-05 Cognitive test performance / / 20125193 rs1936488 chr10 109909743 T G 1.09E-05 Cognitive test performance / / 20125193 rs2772129 chr10 109985710 G A 0.000000868 Social anxiety (ARBQ) in children / / 23565138 rs4917516 chr10 110016545 A G 2.50E-06 Urinary metabolites / / 21572414 rs10884620 chr10 110111704 C T 9.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10884621 chr10 110111975 C T 3.20E-06 Urinary metabolites / / 21572414 rs4244271 chr10 110115634 C A 1.20E-05 Urinary metabolites / / 21572414 rs10884627 chr10 110118187 T G 1.40E-05 Urinary metabolites / / 21572414 rs1329482 chr10 110146869 T C 3.96E-04 Myopia (pathological) / / 21095009 rs7924069 chr10 110170385 C T 4.05E-04 Type 2 diabetes / / 17463246 rs1754614 chr10 110172512 T C 4.31E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1762059 chr10 110172699 G A 4.31E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1831286 chr10 110174837 G A 4.97E-04 Smoking quantity / / 24665060 rs1329508 chr10 110194423 T C 0.0000726 Skin naphthyl-keratin adduct (NKA) levels in workers exposed to naphthalene / / 22391508 rs7094475 chr10 110234241 C A 5.92E-05 Serum metabolites / / 19043545 rs10748985 chr10 110270804 T C 6.90E-04 Aortic root size / / 21223598 rs10748985 chr10 110270804 T C 4.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1332280 chr10 110271335 A G 6.90E-04 Aortic root size / / 21223598 rs1332281 chr10 110272296 C G 1.74E-04 Aortic root size / / 21223598 rs17124731 chr10 110283878 C A 1.43E-05 Odorant perception / / 23910658 rs11194147 chr10 110286149 C T 9.22E-05 Celiac disease / / 23936387 rs1888902 chr10 110337386 G A 5.48E-04 Schizophrenia / / 19197363 rs11194172 chr10 110337787 T C 9.06E-04 Insulin resistance / / 21901158 rs17124813 chr10 110347465 T C 9.06E-04 Insulin resistance / / 21901158 rs17124822 chr10 110351462 C G 5.67E-04 Type 2 diabetes / / 17463246 rs11194183 chr10 110354293 G A 1.55E-04 Multiple complex diseases / / 17554300 rs2225535 chr10 110354980 C T 7.89E-05 Body mass index / / 17255346 rs2225535 chr10 110354980 C T 8.38E-05 Attention deficit hyperactivity disorder / / 22420046 rs2482596 chr10 110356935 G A 1.91E-05 Body mass index / / 17255346 rs12767064 chr10 110404272 G T 5.67E-04 Schizophrenia / / 19197363 rs11592212 chr10 110417393 T C 5.16E-05 Parkinson's disease / / pha002865 rs10884686 chr10 110503788 C T 2.42E-04 Hearing function / / 17255346 rs7922390 chr10 110505926 G A 0.00014 Endometrial cancer / / 22426144 rs11194258 chr10 110511224 A G 6.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs12256452 chr10 110513301 C G 6.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs10509877 chr10 110513543 A G 6.57E-04 Suicide attempts in bipolar disorder / / 21041247 rs12258219 chr10 110513656 G T 6.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs17769395 chr10 110515098 C T 8.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs17769443 chr10 110516193 A G 8.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs17769499 chr10 110516335 C A 8.95E-04 Suicide attempts in bipolar disorder / / 21041247 rs7091393 chr10 110522018 C T 5.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs11591352 chr10 110524741 G T 4.69E-04 Suicide attempts in bipolar disorder / / 21041247 rs17697405 chr10 110527358 T C 8.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs12250102 chr10 110635362 C T 8.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs2461320 chr10 110636462 A G 3.95E-05 Cholesterol / / 17255346 rs17778423 chr10 110654579 C G 7.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs17700240 chr10 110654610 A G 7.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs11596191 chr10 110669664 T C 8.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs7096350 chr10 110670900 A G 8.73E-05 Cholesterol / / 17255346 rs7096350 chr10 110670900 A G 1.10E-04 Lung function (forced vital capacity) / / 24023788 rs7096350 chr10 110670900 A G 8.49E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs3934875 chr10 110684551 A G 4.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs17700354 chr10 110689329 C T 4.63E-04 Suicide attempts in bipolar disorder / / 21041247 rs17700389 chr10 110690303 G T 4.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs12258030 chr10 110696498 A G 4.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs11592721 chr10 110697497 G A 5.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs6584909 chr10 110697601 A G 5.19E-04 Suicide attempts in bipolar disorder / / 21041247 rs11595032 chr10 110697968 T A 5.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs11596345 chr10 110702426 A G 5.71E-04 Suicide attempts in bipolar disorder / / 21041247 rs7070406 chr10 110707825 A T 5.60E-04 Suicide attempts in bipolar disorder / / 21041247 rs17778715 chr10 110717247 T C 5.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs17700585 chr10 110718004 C T 6.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs7917300 chr10 110718286 C T 8.09E-04 Multiple complex diseases / / 17554300 rs11593385 chr10 110719772 T C 6.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs9971196 chr10 110720053 A T 8.69E-04 Multiple complex diseases / / 17554300 rs17779016 chr10 110724061 A G 6.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs11599609 chr10 110724493 C T 6.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs17779136 chr10 110727710 T C 6.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs11596823 chr10 110732731 A G 2.70E-05 Glaucoma (primary open-angle) / / 20835238 rs11596823 chr10 110732731 A G 6.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs17779320 chr10 110733336 A G 6.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs4314990 chr10 110734697 T C 6.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs10509884 chr10 110735747 C G 6.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10509885 chr10 110739765 C T 2.70E-05 Glaucoma (primary open-angle) / / 20835238 rs10509885 chr10 110739765 C T 6.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs7098249 chr10 110740060 T C 5.72E-04 Multiple complex diseases / / 17554300 rs12269679 chr10 110741229 T G 7.16E-04 Multiple complex diseases / / 17554300 rs11596046 chr10 110744036 G A 5.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs17701356 chr10 110744467 G A 5.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs17779611 chr10 110744937 T C 6.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs11597293 chr10 110746036 C A 6.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs7920626 chr10 110748658 C T 7.80E-04 Multiple complex diseases / / 17554300 rs11593900 chr10 110750510 T C 6.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs11593939 chr10 110750746 T C 6.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs11592575 chr10 110758783 T C 8.63E-04 Suicide attempts in bipolar disorder / / 21041247 rs4430440 chr10 110759695 T C 2.04E-04 Multiple complex diseases / / 17554300 rs723483 chr10 110814528 T C 1.90E-05 Cholesterol / / 17255346 rs7917648 chr10 110871390 C T 7.98E-04 Multiple complex diseases / / 17554300 rs11194423 chr10 110905211 A G 1.01E-04 Cholesterol / / 17255346 rs473244 chr10 110948284 A G 2.10E-04 Taste perception / / 22132133 rs473244 chr10 110948284 A G 6.91E-05 Socioeconomic Factors / / pha003067 rs12359789 chr10 110949314 C A 2.58E-04 Multiple complex diseases / / 17554300 rs17783561 chr10 110971435 A T 6.00E-06 IgG glycosylation / / 23382691 rs7900798 chr10 111010159 A G 5.66E-04 Multiple complex diseases / / 17554300 rs3903870 chr10 111012936 G A 6.26E-04 Multiple complex diseases / / 17554300 rs3887148 chr10 111013003 T C 6.34E-04 Multiple complex diseases / / 17554300 rs12763648 chr10 111017531 G A 7.74E-04 Multiple complex diseases / / 17554300 rs7087336 chr10 111023009 C T 5.60E-05 Waist Circumference / / pha003023 rs4295978 chr10 111024910 C T 8.49E-04 Multiple complex diseases / / 17554300 rs4268446 chr10 111025185 T C 4.40E-04 Multiple complex diseases / / 17554300 rs830064 chr10 111030369 C T 6.93E-04 Multiple complex diseases / / 17554300 rs10884732 chr10 111039537 A C 1.95E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9651462 chr10 111042873 T C 2.26E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11194610 chr10 111137444 T C 2.11E-04 Type 2 diabetes / / 17463246 rs17126322 chr10 111188992 T C 8.06E-04 Type 2 diabetes / / 17463246 rs7904521 chr10 111192085 G A 5.03E-04 Coronary Artery Disease / / 17634449 rs7092048 chr10 111197730 T C 2.33E-06 Alcohol dependence / / 23089632 rs1354299 chr10 111241216 G A 6.37E-04 Bipolar disorder / / 19259986 rs10884796 chr10 111268887 A G 2.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10884796 chr10 111268887 A G 5.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10884798 chr10 111303358 G A 1.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10884798 chr10 111303358 G A 9.35E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4579865 chr10 111333964 G A 2.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11816884 chr10 111335883 C T 7.80E-05 Iron levels / / 21208937 rs1891750 chr10 111378221 C G 5.77E-04 Multiple complex diseases / / 17554300 rs11194826 chr10 111485427 G C 3.49E-04 Schizophrenia / / 20832056 rs4918458 chr10 111505407 T C 4.11E-06 Kawasaki disease / / 21221998 rs1245911 chr10 111533009 A C 3.62E-04 Multiple complex diseases / / 17554300 rs626198 chr10 111550272 T C 2.50E-04 Multiple complex diseases / / 17554300 rs10787217 chr10 111621103 T A 0.0000998 Negative affect (anxiety related behavioral questionnaire) in children / / 23565138 rs492943 chr10 111629030 T A 2.81E-04 Birth weight XPNPEP1 intron 17255346 rs612155 chr10 111630731 G C 2.16E-04 Multiple complex diseases XPNPEP1 intron 17554300 rs2475277 chr10 111639730 C T 7.20E-05 White matter hyperintensity burden XPNPEP1 intron 21681796 rs588160 chr10 111641538 C T 6.90E-05 White matter hyperintensity burden XPNPEP1 intron 21681796 rs575802 chr10 111644208 G A 3.10E-05 White matter hyperintensity burden XPNPEP1 intron 21681796 rs623980 chr10 111646147 A G 4.26E-04 Multiple complex diseases XPNPEP1 intron 17554300 rs623980 chr10 111646147 A G 6.20E-05 White matter hyperintensity burden XPNPEP1 intron 21681796 rs734165 chr10 111697789 C T 9.01E-06 Biliary atresia / / 20460270 rs734163 chr10 111698192 T C 7.19E-04 Multiple complex diseases / / 17554300 rs11194926 chr10 111700922 C T 2.81E-04 Multiple complex diseases / / 17554300 rs11194926 chr10 111700922 C T 6.52E-06 Biliary atresia / / 20460270 rs921351 chr10 111704715 T C 4.11E-04 Multiple complex diseases / / 17554300 rs921351 chr10 111704715 T C 8.68E-06 Biliary atresia / / 20460270 rs17126902 chr10 111710381 G A 6.15E-04 Type 2 diabetes LOC100505933 intron 17463246 rs17126902 chr10 111710381 G A 5.00E-04 Multiple complex diseases LOC100505933 intron 17554300 rs7080576 chr10 111710817 T C 2.56E-04 Multiple complex diseases LOC100505933 intron 17554300 rs7080576 chr10 111710817 T C 1.01E-05 Biliary atresia LOC100505933 intron 20460270 rs7085888 chr10 111713930 G A 2.22E-04 Multiple complex diseases LOC100505933 intron 17554300 rs731793 chr10 111716667 G C 2.98E-04 Multiple complex diseases LOC100505933 intron 17554300 rs731793 chr10 111716667 G C 5.72E-06 Biliary atresia LOC100505933 intron 20460270 rs12571674 chr10 111717608 A G 3.82E-06 Biliary atresia LOC100505933 intron 20460270 rs12570612 chr10 111717685 T C 4.82E-04 Multiple complex diseases LOC100505933 intron 17554300 rs7098407 chr10 111721778 C T 0.0000015 Mean arterial pressure LOC100505933 intron 22510845 rs17095355 chr10 111735750 C T 2.18E-04 Multiple complex diseases LOC100505933 intron 17554300 rs17095355 chr10 111735750 C T 7.00E-09 Biliary atresia LOC100505933 intron 20460270 rs3862006 chr10 111750764 G A 3.38E-04 Multiple complex diseases LOC100505933 intron 17554300 rs3862006 chr10 111750764 G A 3.15E-05 Biliary atresia LOC100505933 intron 20460270 rs10509906 chr10 111757674 G C 2.36E-06 Stroke (ischemic) LOC100505933 intron 21957438 rs2501577 chr10 111846687 A G 3.22E-05 Biliary atresia ADD3 intron 20460270 rs6584970 chr10 111847820 T C 3.59E-05 Biliary atresia ADD3 intron 20460270 rs2501575 chr10 111849864 G A 5.78E-05 Biliary atresia ADD3 intron 20460270 rs2501574 chr10 111850503 A G 3.69E-04 Birth weight ADD3 intron 17255346 rs7090030 chr10 111860673 T G 7.39E-07 Age-related macular degeneration ADD3 intron pha000001 rs11194981 chr10 111861054 T C 3.40E-05 Biliary atresia ADD3 intron 20460270 rs11194995 chr10 111888130 C T 7.62E-07 Age-related macular degeneration ADD3 intron pha000001 rs11194996 chr10 111889725 C G 7.62E-07 Age-related macular degeneration ADD3 intron pha000001 rs11195001 chr10 111894653 T C 7.19E-07 Age-related macular degeneration ADD3 UTR-3 pha000001 rs6584971 chr10 111898217 T G 8.66E-05 Bipolar disorder and schizophrenia / / 20889312 rs7917994 chr10 111904370 A G 8.56E-05 Age-related macular degeneration / / pha000002 rs7921757 chr10 111904880 C T 8.56E-05 Age-related macular degeneration / / pha000002 rs1891374 chr10 111966844 C T 2.70E-05 Urinary metabolites MXI1 nearGene-5 21572414 rs716595 chr10 112006486 G A 8.00E-06 Normalized brain volume MXI1 intron 19010793 rs716595 chr10 112006486 G A 8.93E-04 Suicide attempts in bipolar disorder MXI1 intron 21041247 rs2010327 chr10 112011484 G A 5.61E-04 Multiple complex diseases MXI1 intron 17554300 rs10884942 chr10 112016926 A G 7.10E-04 Type 2 diabetes MXI1 intron 17463246 rs3793889 chr10 112027656 A G 8.56E-04 Suicide attempts in bipolar disorder MXI1 intron 21041247 rs12357528 chr10 112031057 G A 1.20E-05 Urinary metabolites MXI1 intron 21572414 rs11195062 chr10 112036975 C A 3.00E-06 Multiple myeloma MXI1 intron 23955597 rs11195062 chr10 112036975 C A 1.17E-04 Amyotrophic lateral sclerosis (sporadic) MXI1 intron 24529757 rs1673666 chr10 112070393 G A 8.29E-06 Glycemic traits (pregnancy) / / 23903356 rs6584984 chr10 112082992 T C 2.00E-04 Information processing speed / / 21130836 rs4918496 chr10 112087579 G A 3.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs877115 chr10 112104806 G A 7.15E-04 Rheumatoid arthritis / / 21452313 rs1342275 chr10 112116232 C A,G,T 8.61E-05 Cognitive test performance / / 20125193 rs17127275 chr10 112117300 T C 3.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs1762279 chr10 112117596 C T 1.98E-05 Cognitive test performance / / 20125193 rs17127283 chr10 112122958 T C 9.30E-06 Urinary metabolites / / 21572414 rs7077476 chr10 112125785 A G 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs7078092 chr10 112126226 A T 1.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs11195096 chr10 112126336 G A 1.60E-05 Urinary metabolites / / 21572414 rs11195097 chr10 112126945 A G 1.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs12246208 chr10 112127251 C T 1.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs12246208 chr10 112127251 C T 3.95E-04 White matter integrity / / 22425255 rs12255728 chr10 112127705 T C 1.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs7088083 chr10 112128207 G A 1.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs12252135 chr10 112129539 G A 2.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs12252135 chr10 112129539 G A 3.95E-04 White matter integrity / / 22425255 rs10787232 chr10 112159478 G A 1.90E-05 Urinary metabolites / / 21572414 rs7083193 chr10 112175889 T C 2.34E-04 Cognitive decline / / 23732972 rs11195128 chr10 112186148 C T 2.00E-10 Crohn's disease / / 23850713 rs11195130 chr10 112191224 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10884970 chr10 112194168 A G 8.37E-05 Cognitive test performance / / 20125193 rs10884971 chr10 112206255 G A 8.00E-05 Cognitive test performance / / 20125193 rs10884981 chr10 112217707 G A 3.70E-04 Fibrinogen / / 17255346 rs1870188 chr10 112223286 A C 4.00E-07 Urinary metabolites / / 21572414 rs915216 chr10 112271467 C T 6.80E-04 Multiple complex diseases / / 17554300 rs11195166 chr10 112285813 G T 1.00E-05 Urinary metabolites / / 21572414 rs882486 chr10 112294424 G A 4.81E-04 Endometrial cancer / / 24096698 rs10509921 chr10 112299298 G A 8.33E-04 Alzheimer's disease / / 22005930 rs4918534 chr10 112299671 G A 3.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1107442 chr10 112303595 C T 4.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11195177 chr10 112311842 A G 8.50E-04 Alzheimer's disease / / 22005930 rs1832687 chr10 112313537 A C 9.71E-04 Alzheimer's disease / / 22005930 rs7901527 chr10 112313903 G A 3.81E-04 Suicide attempts in bipolar disorder / / 21041247 rs6584993 chr10 112314670 A G 1.90E-04 Alzheimer's disease (late onset) / / 21379329 rs6584994 chr10 112318524 G C 3.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs11195192 chr10 112336364 T G 9.60E-04 Type 2 diabetes SMC3 intron 17463246 rs4350299 chr10 112380329 T C 8.30E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1856801 chr10 112392162 G T 3.79E-05 Nicotine smoking / / 19268276 rs10509923 chr10 112419189 A G 9.00E-04 Type 2 diabetes and 6 quantitative traits RBM20 intron 17848626 rs12358914 chr10 112425178 T C 1.18E-04 Sudden cardiac arrest RBM20 intron 21658281 rs7082195 chr10 112427449 C T 4.37E-05 Nicotine smoking RBM20 intron 19268276 rs7082195 chr10 112427449 C T 1.98E-04 Amyotrophic lateral sclerosis (sporadic) RBM20 intron 24529757 rs7082097 chr10 112427507 A G 0.000501 fMRI brain tests in schizophrenia RBM20 intron 22440650 rs2039876 chr10 112435308 G C 8.04E-04 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs17828651 chr10 112436222 T G 8.17E-04 Multiple complex diseases RBM20 intron 17554300 rs7342050 chr10 112436300 T C 9.58E-04 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs10885012 chr10 112436971 T C 5.69E-04 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs1417633 chr10 112438525 T C 6.44E-05 stroke (ischemic) RBM20 intron 17434096 rs1417633 chr10 112438525 T C 8.18E-04 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs1954179 chr10 112452132 A G 7.42E-05 Periodontitis (Chronic) RBM20 intron 25008200 rs11195266 chr10 112453917 G A 3.47E-05 stroke (ischemic) RBM20 intron 17434096 rs12413726 chr10 112455828 T C 8.22E-04 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs11195267 chr10 112457584 C A 9.66E-04 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs4918562 chr10 112458179 C T 8.57E-04 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs4918563 chr10 112458494 T C 8.20E-04 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs11195271 chr10 112459293 G T 9.46E-04 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs11195272 chr10 112459430 C T 3.42E-04 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs11593879 chr10 112463230 C T 5.58E-04 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs11195275 chr10 112464824 C T 6.25E-04 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs11195276 chr10 112464845 T G 5.65E-04 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs12220181 chr10 112465311 T C 7.62E-04 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs4918569 chr10 112465910 A C 8.43E-04 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs4918572 chr10 112468875 T C 4.55E-04 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs4918573 chr10 112468929 C T 4.55E-04 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs4918574 chr10 112469088 G A 3.77E-04 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs7090826 chr10 112469659 C A 3.46E-04 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs10509927 chr10 112472062 T C 2.62E-05 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs10509928 chr10 112472103 C A 9.07E-05 stroke (ischemic) RBM20 intron 17434096 rs10509928 chr10 112472103 C A 4.30E-04 Type 2 diabetes and 6 quantitative traits RBM20 intron 17848626 rs10509928 chr10 112472103 C A 2.80E-05 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs17829478 chr10 112474254 C A 1.57E-05 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs17829496 chr10 112474599 G A 1.53E-05 Suicide attempts in bipolar disorder RBM20 intron 21423239 rs17829675 chr10 112484152 G A 2.00E-05 Urinary metabolites RBM20 intron 21572414 rs11195297 chr10 112498838 C A 8.38E-06 White blood cell count RBM20 intron 21738479 rs7077757 chr10 112544655 C T 5.71E-04 Alzheimer's disease RBM20 intron 24755620 rs10787281 chr10 112547206 G A 2.24E-05 Orofacial clefts RBM20 intron 22419666 rs11594321 chr10 112564458 C T 1.16E-05 Blood Pressure RBM20 intron pha003049 rs4918606 chr10 112609973 T G 1.40E-05 Body mass index (education interaction) / / 24281739 rs4917589 chr10 112612802 A G 8.98E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10787287 chr10 112647195 C T 1.20E-05 Body mass index (education interaction) PDCD4 intron 24281739 rs9703807 chr10 112741551 C T 9.10E-05 Coffee consumption SHOC2 intron 21357676 rs11195397 chr10 112750629 C T 3.30E-04 Alcohol dependence SHOC2 intron 20201924 rs6585026 chr10 112753721 C T 2.70E-05 Urinary metabolites SHOC2 intron 21572414 rs10885079 chr10 112797803 G A 2.11E-04 Lymphocyte counts / / 22286170 rs17186196 chr10 112831787 A G 2.32E-04 Fibrinogen / / 17255346 rs11195417 chr10 112831994 C A 7.55E-05 Type 1 diabetes / / 21980299 rs745557 chr10 112846298 G A 7.35E-05 Coronary heart disease / / pha003031 rs11593780 chr10 112858575 C T 5.39E-04 Alcohol dependence / / 21314694 rs945333 chr10 112862029 T C 2.06E-06 Alcohol dependence / / 23089632 rs1556716 chr10 112867412 C T 3.06E-05 Recombination rate / / 21698098 rs2065779 chr10 112877801 G C 3.00E-06 Insomnia (caffeine-induced) / / 22754043 rs7079291 chr10 112882768 T G 5.50E-09 Platelet aggregation(pre- and post-aspirin) / / 20529293 rs10437458 chr10 112883379 G C 6.10E-05 Response to statin therapy / / 20339536 rs945335 chr10 112887549 C T 1.51E-04 Intracranial aneurysm / / 20613766 rs10885090 chr10 112890917 G C 2.62E-05 Brain structure / / 22504417 rs7069564 chr10 112897070 C T 2.48E-04 Cocaine dependence / / 23958962 rs7069564 chr10 112897070 C T 7.88E-05 Cocaine dependence / / 23958962 rs869244 chr10 112909105 G A 3.00E-12 Platelet aggregation / / 20526338 rs1335706 chr10 112914772 C T 1.27E-04 Attention deficit hyperactivity disorder / / pha002875 rs7910277 chr10 112918429 G A 4.39E-04 Telomere length / / 23900074 rs10885102 chr10 112929753 G A 9.90E-04 Insulin resistance / / 21901158 rs1537768 chr10 112969627 A C 3.15E-05 Tunica Media / / pha003037 rs1889744 chr10 112970743 T C 5.25E-05 Tunica Media / / pha003037 rs118137427 chr10 112977008 A G 3.60E-09 Fasting blood glucose / / 22885924 rs12240818 chr10 112979757 C T 2.77E-05 Tunica Media / / pha003037 rs1335715 chr10 112982077 C T 2.10E-05 Urinary metabolites / / 21572414 rs1360864 chr10 112985425 T C 1.60E-05 Tunica Media / / pha003037 rs1832112 chr10 112986039 A G 1.60E-05 Tunica Media / / pha003037 rs12244315 chr10 112986661 G T 1.37E-06 Type 2 diabetes / / 21573907 rs17775850 chr10 112994448 C A 3.15E-05 Tunica Media / / pha003037 rs11195485 chr10 113003817 C T 0.000000963 Menopause (age at onset) / / 23424626 rs11195502 chr10 113039667 C T 9.00E-20 Fasting blood glucose / / 22885924 rs10885122 chr10 113042093 T G 2.00E-06 Fasting glucose-related traits / / 20081858 rs10885122 chr10 113042093 T G 3.00E-16 Fasting insulin-related traits / / 20081858 rs10885122 chr10 113042093 T G 9.00E-08 Fasting glucose-related traits (interaction with BMI) / / 22581228 rs10885122 chr10 113042093 T G 6.32E-17 Fasting blood glucose / / 22885924 rs12261976 chr10 113070996 C T 3.23E-04 Cholesterol / / 17255346 rs10749071 chr10 113094037 A G 1.23E-16 Meningococcal disease / / 20694013 rs10787335 chr10 113102038 A G 9.87E-04 Multiple complex diseases / / 17554300 rs10787345 chr10 113139813 C T 1.70E-05 Urinary metabolites / / 21572414 rs7067594 chr10 113144672 G A 4.70E-06 Urinary metabolites / / 21572414 rs7905487 chr10 113152964 G A 5.70E-06 Urinary metabolites / / 21572414 rs6585073 chr10 113166034 A G 0.0006386 Sarcoidosis / / 22952805 rs10885163 chr10 113166714 C G 0.0005497 Sarcoidosis / / 22952805 rs7896658 chr10 113176902 T C 9.96E-04 Multiple complex diseases / / 17554300 rs7896658 chr10 113176902 T C 0.0003045 Sarcoidosis / / 22952805 rs9421099 chr10 113178455 A G 0.0008268 Sarcoidosis / / 22952805 rs4364989 chr10 113179200 C T 2.60E-05 Urinary metabolites / / 21572414 rs4130310 chr10 113179529 C T 1.50E-05 Urinary metabolites / / 21572414 rs4130312 chr10 113179565 T C 2.10E-05 Urinary metabolites / / 21572414 rs4414149 chr10 113181016 G C 1.20E-05 Urinary metabolites / / 21572414 rs7914767 chr10 113181217 T C 1.10E-05 Urinary metabolites / / 21572414 rs4077364 chr10 113185495 C T 1.70E-05 Urinary metabolites / / 21572414 rs4918648 chr10 113193007 C G 2.50E-05 Urinary metabolites / / 21572414 rs4342958 chr10 113194673 G T 1.55E-04 Obesity (extreme) / / 21935397 rs4342958 chr10 113194673 G T 7.51E-05 Schizophrenia / / pha002859 rs4590798 chr10 113194854 A G 1.70E-05 Urinary metabolites / / 21572414 rs4506568 chr10 113196479 A T 1.80E-05 Urinary metabolites / / 21572414 rs11195592 chr10 113199395 G A 6.86E-04 Multiple complex diseases / / 17554300 rs11195594 chr10 113199690 C T 1.80E-05 Urinary metabolites / / 21572414 rs7920368 chr10 113201886 C T 1.60E-05 Urinary metabolites / / 21572414 rs4451644 chr10 113202321 A G 1.30E-05 Urinary metabolites / / 21572414 rs10885191 chr10 113222522 T C 5.74E-04 Multiple complex diseases / / 17554300 rs10885191 chr10 113222522 T C 6.60E-06 Urinary metabolites / / 21572414 rs1914139 chr10 113225853 G A 3.27E-04 Multiple complex diseases / / 17554300 rs1878244 chr10 113226818 A G 4.66E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1878241 chr10 113227548 C T 4.59E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs10885193 chr10 113229580 C T 4.45E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs4917611 chr10 113241074 C T 9.80E-06 Urinary metabolites / / 21572414 rs4917611 chr10 113241074 C T 0.0000223 Panic disorder / / 23149450 rs4917611 chr10 113241074 C T 2.23E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs2900933 chr10 113243166 T A 1.10E-05 Urinary metabolites / / 21572414 rs8181297 chr10 113246288 A G 3.80E-06 Urinary metabolites / / 21572414 rs3107347 chr10 113257439 A G 8.80E-06 Urinary metabolites / / 21572414 rs1914106 chr10 113265762 T C 7.30E-06 Urinary metabolites / / 21572414 rs10885200 chr10 113269350 T C 4.79E-05 Multiple complex diseases / / 17554300 rs1914102 chr10 113273136 A G 8.86E-05 Major depressive disorder / / 21621269 rs7896606 chr10 113281043 C A 2.40E-05 Urinary metabolites / / 21572414 rs1914101 chr10 113282615 G C 1.02E-04 Multiple complex diseases / / 17554300 rs17790693 chr10 113284330 T C 0.00000184 Tuberculosis with late age of onset / / 22551897 rs10787374 chr10 113287596 A G 4.08E-05 Multiple complex diseases / / 17554300 rs7916268 chr10 113295975 G T 7.35E-05 Body Mass Index / / pha003015 rs4918666 chr10 113322597 C T 4.88E-04 Multiple complex diseases / / 17554300 rs10885211 chr10 113324302 C T 7.73E-04 Multiple complex diseases / / 17554300 rs1914080 chr10 113327791 C T 1.82E-04 Multiple complex diseases / / 17554300 rs7072377 chr10 113328552 G T 8.56E-04 Multiple complex diseases / / 17554300 rs7090642 chr10 113328934 T G 1.50E-05 Urinary metabolites / / 21572414 rs4918668 chr10 113329590 C T 5.45E-04 Multiple complex diseases / / 17554300 rs4918669 chr10 113329634 C A 4.76E-04 Multiple complex diseases / / 17554300 rs1577659 chr10 113341262 C T 5.79E-04 Multiple complex diseases / / 17554300 rs10885216 chr10 113341475 A T 5.28E-04 Multiple complex diseases / / 17554300 rs7084286 chr10 113341835 G A 2.85E-04 Multiple complex diseases / / 17554300 rs10736216 chr10 113378792 G C 1.55E-04 Multiple complex diseases / / 17554300 rs1336414 chr10 113394570 C T 2.81E-04 Multiple complex diseases / / 17554300 rs10885223 chr10 113396689 C T 1.00E-04 Serum albumin level / / pha003084 rs11195665 chr10 113415191 A G 3.27E-04 Multiple complex diseases / / 17554300 rs11195680 chr10 113449034 T C 6.06E-05 Multiple sclerosis / / 20598377 rs11195702 chr10 113496395 C G 2.10E-04 Multiple complex diseases / / 17554300 rs12098793 chr10 113502538 C T 1.87E-05 Odorant perception / / 23910658 rs4304698 chr10 113512966 C T 1.03E-05 Left ventricular hypertrophy / / pha003052 rs1337992 chr10 113514382 A G 6.00E-06 Iron levels / / 21208937 rs11195714 chr10 113517330 G A 4.16E-05 Left ventricular hypertrophy / / pha003052 rs6585111 chr10 113524371 T C 3.61E-05 Bipolar disorder / / 19488044 rs6585111 chr10 113524371 T C 9.04E-05 IgE levels / / 22075330 rs6585111 chr10 113524371 T C 3.85E-05 Bipolar Disorder / / pha002863 rs12569902 chr10 113536366 C T 5.01E-04 Multiple complex diseases / / 17554300 rs1415847 chr10 113536606 A G 9.24E-04 Insulin resistance / / 21901158 rs6585114 chr10 113537652 A G 6.19E-04 Body mass index / / 21701565 rs1923655 chr10 113565450 T A 1.49E-04 Multiple complex diseases / / 17554300 rs959127 chr10 113611569 A G 6.88E-06 Blood Pressure / / pha002903 rs12412337 chr10 113652642 G A 5.87E-04 Multiple complex diseases / / 17554300 rs588908 chr10 113668177 A C,G 5.39E-04 Multiple complex diseases / / 17554300 rs10885292 chr10 113689700 T C 7.91E-04 Taste perception / / 22132133 rs10787418 chr10 113694290 T C 5.34E-05 Multiple complex diseases / / 17554300 rs2111639 chr10 113696371 T C 2.00E-05 Multiple complex diseases / / 17554300 rs6585126 chr10 113700809 T C 3.33E-04 Multiple complex diseases / / 17554300 rs6585131 chr10 113723647 C A 3.39E-04 Multiple complex diseases / / 17554300 rs918216 chr10 113731523 A C 9.55E-04 Multiple complex diseases / / 17554300 rs7902500 chr10 113733379 T C 1.06E-08 Multiple complex diseases / / 17554300 rs952500 chr10 113735304 T C 5.98E-04 Multiple complex diseases / / 17554300 rs2249846 chr10 113816801 G A 2.25E-04 Multiple complex diseases / / 17554300 rs2804609 chr10 113847037 T C 8.60E-04 Type 2 diabetes / / 17463246 rs2804619 chr10 113857979 C T 4.24E-23 Narcolepsy / / 19629137 rs11195815 chr10 113859224 C A 7.91E-04 Multiple complex diseases / / 17554300 rs2419603 chr10 113903867 C T 1.99E-04 Multiple complex diseases / / 17554300 rs2792742 chr10 113905522 A T 8.01E-04 Insulin resistance / / 21901158 rs3824627 chr10 113908060 T C 9.26E-05 Serum metabolites / / 19043545 rs2297991 chr10 113913222 T C 6.79E-04 Type 2 diabetes GPAM UTR-3 17463246 rs1807800 chr10 113913552 A T 9.73E-04 Type 2 diabetes GPAM intron 17463246 rs3824626 chr10 113920652 T C 9.25E-05 Serum metabolites GPAM intron 19043545 rs2792735 chr10 113921825 G A 9.73E-04 Type 2 diabetes GPAM intron 17463246 rs2251579 chr10 113928487 A C 9.44E-05 Serum metabolites GPAM intron 19043545 rs2803616 chr10 113928903 A C 9.44E-05 Serum metabolites GPAM intron 19043545 rs2255141 chr10 113933886 A G 2.00E-09 LDL cholesterol GPAM intron 20686565 rs2255141 chr10 113933886 A G 2.00E-10 Cholesterol,total GPAM intron 20686565 rs2255141 chr10 113933886 A G 1.00E-13 LDL cholesterol GPAM intron 24097068 rs2255141 chr10 113933886 A G 7.00E-16 Cholesterol,total GPAM intron 24097068 rs4306236 chr10 113980294 G T 1.32E-04 Age-related macular degeneration / / 22125219 rs17129638 chr10 113981435 T C 9.10E-05 Parkinson's disease (age of onset) / / 19772629 rs2419613 chr10 114028538 A G 3.51E-04 Major depressive disorder / / 22472876 rs10885322 chr10 114036820 C T 8.98E-04 Multiple complex diseases / / 17554300 rs7075065 chr10 114054572 G A 2.25E-04 Multiple complex diseases TECTB intron 17554300 rs7075065 chr10 114054572 G A 3.88E-05 Serum metabolites TECTB intron 19043545 rs10509958 chr10 114054601 A G 4.00E-04 Chronic fatigue syndrome TECTB intron 21912186 rs12414024 chr10 114071348 A G 3.40E-05 Obesity,menopause GUCY2GP intron 21424828 rs7097428 chr10 114105294 G A 1.30E-05 Urinary metabolites GUCY2GP intron 21572414 rs11195917 chr10 114110893 G A 5.56E-05 Response to citalopram treatment GUCY2GP intron 19846067 rs12255316 chr10 114148689 C T 8.47E-04 Multiple complex diseases ACSL5 intron 17554300 rs7904386 chr10 114150782 C T 8.09E-04 Aortic root size ACSL5 intron 21223598 rs10885343 chr10 114159452 G A 1.83E-04 Multiple complex diseases ACSL5 intron 17554300 rs10885343 chr10 114159452 G A 6.67E-04 Aortic root size ACSL5 intron 21223598 rs4351741 chr10 114159812 G C 1.15E-04 Multiple complex diseases ACSL5 intron 17554300 rs4351741 chr10 114159812 G C 6.67E-04 Aortic root size ACSL5 intron 21223598 rs11195949 chr10 114164146 T G 1.29E-04 Multiple complex diseases ACSL5 intron 17554300 rs7919710 chr10 114169552 G A 6.16E-04 Alcohol consumption (maxi-drinks) ACSL5 intron 24277619 rs7904918 chr10 114169664 T G 8.03E-04 Myopia (pathological) ACSL5 intron 21095009 rs7904918 chr10 114169664 T G 0.00039 Coronary artery calcification ACSL5 intron 23727086 rs2306158 chr10 114192285 G A 6.40E-04 Multiple complex diseases ZDHHC6 intron 17554300 rs12355831 chr10 114202526 A G 2.00E-06 Migraine ZDHHC6 intron 23793025 rs2306160 chr10 114203542 A G 4.00E-04 Gamma gluatamyl transferase levels (interaction with age) ZDHHC6 intron 22010049 rs6421364 chr10 114206121 A G 7.16E-04 Aortic root size ZDHHC6 intron 21223598 rs17129806 chr10 114224639 C T 2.58E-05 Bipolar disorder VTI1A intron 22925353 rs10509963 chr10 114236865 A G 5.92E-04 Type 2 diabetes VTI1A intron 17463246 rs9645551 chr10 114381113 T C 9.45E-04 Insulin resistance VTI1A intron 21901158 rs6585163 chr10 114381720 A C 7.23E-04 Tourette syndrome VTI1A intron 22889924 rs17267338 chr10 114388272 A G 8.00E-06 Multiple sclerosis VTI1A intron 23412934 rs1033922 chr10 114388316 A G 5.08E-05 LDL lipoproteins VTI1A intron pha002902 rs10885362 chr10 114388945 A G 3.55E-04 Lung function (forced expiratory volume in 1 second) VTI1A intron 17255346 rs703332 chr10 114393576 T G 6.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VTI1A intron 20877124 rs77409651 chr10 114401974 T A 1.91E-04 Cocaine dependence VTI1A intron 23958962 rs11196032 chr10 114407099 G A 3.66E-04 Multiple complex diseases VTI1A intron 17554300 rs7092136 chr10 114425842 T A 6.12E-05 Multiple complex diseases VTI1A intron 17554300 rs7092136 chr10 114425842 T A 8.66E-05 Acute lymphoblastic leukemia (childhood) VTI1A intron 19684603 rs10885371 chr10 114436066 G A 3.07E-04 Multiple complex diseases VTI1A intron 17554300 rs17130008 chr10 114439565 A G 2.48E-04 Multiple complex diseases VTI1A intron 17554300 rs17130008 chr10 114439565 A G 4.55E-05 Acute lymphoblastic leukemia (childhood) VTI1A intron 19684603 rs7342028 chr10 114479262 G T 5.00E-10 Ventricular conduction VTI1A intron 21076409 rs10885378 chr10 114491924 T C 2.25E-05 Body mass index VTI1A intron 24827717 rs1885281 chr10 114492898 A G 5.60E-05 Hypothyroidism VTI1A intron 22493691 rs7086803 chr10 114498476 G A 4.00E-18 Lung cancer VTI1A intron 23143601 rs1047468 chr10 114576753 C T 5.35E-05 Prostate cancer VTI1A UTR-3 pha002877 rs1047468 chr10 114576753 C T 7.92E-05 Prostate cancer VTI1A UTR-3 pha002878 rs12358731 chr10 114581193 G A 0.000681 Salmonella-induced pyroptosis / / 22837397 rs12359794 chr10 114581490 A G 8.19E-04 Taste perception / / 22132133 rs12359794 chr10 114581490 A G 0.0000651 Salmonella-induced pyroptosis / / 22837397 rs2003083 chr10 114601712 G T 6.69E-05 Cognitive test performance / / 20125193 rs10787469 chr10 114604007 C G 4.12E-04 Body mass index / / 17255346 rs1547191 chr10 114612972 C T 6.33E-05 Multiple complex diseases / / 17554300 rs1547191 chr10 114612972 C T 3.40E-05 Electrocardiographic conduction measures / / 19389651 rs1327694 chr10 114637545 G T 3.42E-06 Multiple complex diseases / / 17554300 rs17746501 chr10 114649467 A G 3.35E-04 Multiple complex diseases / / 17554300 rs17130133 chr10 114650424 T C 3.23E-04 Multiple complex diseases / / 17554300 rs1556014 chr10 114654197 T C 4.55E-04 Multiple complex diseases / / 17554300 rs10509967 chr10 114695932 A C 4.60E-05 HIV-1 control / / 20041166 rs10047299 chr10 114701410 G T 1.80E-05 HIV-1 control / / 20041166 rs3814570 chr10 114708510 C T 1.80E-05 HIV-1 control TCF7L2 nearGene-5 20041166 rs11196172 chr10 114726843 G A 1.00E-12 Colorectal cancer TCF7L2 intron 24836286 rs1006725 chr10 114730203 A G 0.000000617 LDL cholesterol TCF7L2 intron 23063622 rs7917983 chr10 114732882 T C 4.80E-10 Multiple complex diseases TCF7L2 intron 17554300 rs7901275 chr10 114732906 A C 3.74E-10 Multiple complex diseases TCF7L2 intron 17554300 rs11196174 chr10 114734096 A G 2.10E-04 Breast Cancer in BRCA1 mutation carriers TCF7L2 intron 23544013 rs11196174 chr10 114734096 A G 7.48E-07 Breast Cancer in BRCA1 mutation carriers TCF7L2 intron 23544013 rs11196174 chr10 114734096 A G 8.00E-07 Breast Cancer in BRCA1 mutation carriers TCF7L2 intron 23544013 rs11196174 chr10 114734096 A G 9.55E-06 Breast Cancer in BRCA1 mutation carriers TCF7L2 intron 23544013 rs11196175 chr10 114736614 T C 1.00E-06 Breast Cancer in BRCA1 mutation carriers TCF7L2 intron 23544013 rs11196175 chr10 114736614 T C 1.15E-06 Breast Cancer in BRCA1 mutation carriers TCF7L2 intron 23544013 rs11196175 chr10 114736614 T C 1.21E-05 Breast Cancer in BRCA1 mutation carriers TCF7L2 intron 23544013 rs11196175 chr10 114736614 T C 3.08E-04 Breast Cancer in BRCA1 mutation carriers TCF7L2 intron 23544013 rs4074720 chr10 114748497 C T 5.19E-11 Multiple complex diseases TCF7L2 intron 17554300 rs17747324 chr10 114752503 T C 3.00E-05 Type 2 diabetes TCF7L2 intron 17463248 rs7901695 chr10 114754088 T C 5.97E-06 Type 2 diabetes TCF7L2 intron 17463246 rs7901695 chr10 114754088 T C 1.00E-48 Type 2 diabetes TCF7L2 intron 17463249 rs7901695 chr10 114754088 T C 6.71E-13 Multiple complex diseases TCF7L2 intron 17554300 rs7901695 chr10 114754088 T C 3.42E-07 Type 2 diabetes TCF7L2 intron 17668382 rs7901695 chr10 114754088 T C 4.53E-09 Type 2 diabetes TCF7L2 intron 20818381 rs7901695 chr10 114754088 T C 1.00E-06 Coronary heart disease TCF7L2 intron 21347282 rs7901695 chr10 114754088 T C 4.37E-05 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) TCF7L2 intron 21541012 rs7901695 chr10 114754088 T C 6.00E-07 Cystic fibrosis-related diabetes TCF7L2 intron 23670970 rs4506565 chr10 114756041 A T 2.30E-31 Type 2 diabetes TCF7L2 intron 17463246 rs4506565 chr10 114756041 A T 6.40E-05 Type 2 diabetes TCF7L2 intron 17463248 rs4506565 chr10 114756041 A T 5.00E-12 Type 2 diabetes TCF7L2 intron 17554300 rs4506565 chr10 114756041 A T 1.00E-08 Fasting glucose-related traits TCF7L2 intron 20081858 rs4506565 chr10 114756041 A T 5.00E-12 Coronary heart disease TCF7L2 intron 21347282 rs4506565 chr10 114756041 A T 5.00E-12 Type 2 diabetes TCF7L2 intron 21647700 rs4506565 chr10 114756041 A T 0.0000107 Glycated hemoglobin levels TCF7L2 intron 22885924 rs4506565 chr10 114756041 A T 1.26E-22 Fasting blood glucose TCF7L2 intron 22885924 rs4506565 chr10 114756041 A T 4.66E-13 2-hour glucose tolerance test TCF7L2 intron 22885924 rs4506565 chr10 114756041 A T 9.34E-10 Fasting insulin-related traits TCF7L2 intron 22885924 rs7903146 chr10 114758349 C T 2.00E-34 Type 2 diabetes TCF7L2 intron 17293876 rs7903146 chr10 114758349 C T 2.00E-10 Type 2 diabetes TCF7L2 intron 17460697 rs7903146 chr10 114758349 C T 2.00E-31 Type 2 diabetes TCF7L2 intron 17463246 rs7903146 chr10 114758349 C T 1.00E-08 Type 2 diabetes TCF7L2 intron 17463248 rs7903146 chr10 114758349 C T 5.00E-08 Type 2 diabetes TCF7L2 intron 17668382 rs7903146 chr10 114758349 C T 3.00E-23 Type 2 diabetes TCF7L2 intron 18372903 rs7903146 chr10 114758349 C T 6.00E-16 Type 2 diabetes TCF7L2 intron 19056611 rs7903146 chr10 114758349 C T 9.00E-30 Type 2 diabetes TCF7L2 intron 19056611 rs7903146 chr10 114758349 C T 3.10E-07 Fasting plasma glucose TCF7L2 intron 19060907 rs7903146 chr10 114758349 C T 3.20E-17 Type 2 diabetes TCF7L2 intron 19184112 rs7903146 chr10 114758349 C T 8.00E-12 Type 2 diabetes TCF7L2 intron 19401414 rs7903146 chr10 114758349 C T 1.00E-30 Type 2 diabetes and other traits TCF7L2 intron 19734900 rs7903146 chr10 114758349 C T 2.00E-51 Type 2 diabetes TCF7L2 intron 20581827 rs7903146 chr10 114758349 C T 7.00E-07 Metabolic syndrome TCF7L2 intron 20694148 rs7903146 chr10 114758349 C T 1.57E-08 Type 2 diabetes TCF7L2 intron 20818381 rs7903146 chr10 114758349 C T 1.00E-07 Glycated hemoglobin levels TCF7L2 intron 20849430 rs7903146 chr10 114758349 C T 2.00E-34 Coronary heart disease TCF7L2 intron 21347282 rs7903146 chr10 114758349 C T 4.27E-06 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) TCF7L2 intron 21541012 rs7903146 chr10 114758349 C T 2.00E-20 Proinsulin levels TCF7L2 intron 21873549 rs7903146 chr10 114758349 C T 5.10E-68 Type 2 diabetes TCF7L2 intron 21874001 rs7903146 chr10 114758349 C T 2.00E-15 Type 2 diabetes TCF7L2 intron 22101970 rs7903146 chr10 114758349 C T 5.28E-125 Type 2 diabetes TCF7L2 intron 22325160 rs7903146 chr10 114758349 C T 2.00E-14 Fasting glucose-related traits (interaction with BMI) TCF7L2 intron 22581228 rs7903146 chr10 114758349 C T 3.00E-06 Fasting insulin-related traits (interaction with BMI) TCF7L2 intron 22581228 rs7903146 chr10 114758349 C T 2.00E-40 Type 2 diabetes TCF7L2 intron 22693455 rs7903146 chr10 114758349 C T 4.00E-21 Type 2 diabetes TCF7L2 intron 22693455 rs7903146 chr10 114758349 C T 0.00000014 HOMA-B TCF7L2 intron 22885922 rs7903146 chr10 114758349 C T 1.20E-139 Type 2 diabetes TCF7L2 intron 22885922 rs7903146 chr10 114758349 C T 2.70E-20 Fasting blood glucose TCF7L2 intron 22885922 rs7903146 chr10 114758349 C T 4.00E-73 Type 2 diabetes (females) TCF7L2 intron 22885922 rs7903146 chr10 114758349 C T 5.60E-92 Type 2 diabetes (males) TCF7L2 intron 22885922 rs7903146 chr10 114758349 C T 6.10E-11 Fasting insulin-related traits TCF7L2 intron 22885922 rs7903146 chr10 114758349 C T 0.0001891 Glycated hemoglobin levels TCF7L2 intron 22885924 rs7903146 chr10 114758349 C T 1.32E-25 Fasting blood glucose TCF7L2 intron 22885924 rs7903146 chr10 114758349 C T 2.49E-14 2-hour glucose tolerance test TCF7L2 intron 22885924 rs7903146 chr10 114758349 C T 6.10E-11 Fasting insulin-related traits TCF7L2 intron 22885924 rs7903146 chr10 114758349 C T 1.00E-35 Type 2 diabetes TCF7L2 intron 23209189 rs7903146 chr10 114758349 C T 0.00003 Insulin processing and secretion TCF7L2 intron 23263489 rs7903146 chr10 114758349 C T 2.00E-38 Type 2 diabetes TCF7L2 intron 23300278 rs7903146 chr10 114758349 C T 3.00E-19 Type 2 diabetes TCF7L2 intron 23300278 rs7903146 chr10 114758349 C T 3.00E-35 Type 2 diabetes TCF7L2 intron 23300278 rs7903146 chr10 114758349 C T 6.00E-22 Type 2 diabetes TCF7L2 intron 23300278 rs7903146 chr10 114758349 C T 9.00E-75 Type 2 diabetes TCF7L2 intron 23300278 rs7903146 chr10 114758349 C T 4.00E-06 Cystic fibrosis-related diabetes TCF7L2 intron 23670970 rs7903146 chr10 114758349 C T 2.00E-15 Type 2 diabetes TCF7L2 intron 23945395 rs7903146 chr10 114758349 C T 1.00E-14 Type 2 diabetes TCF7L2 intron 24390345 rs7903146 chr10 114758349 C T 8.00E-75 Type 2 diabetes TCF7L2 intron 24509480 rs4132670 chr10 114767771 G A 9.17E-06 Type 2 diabetes TCF7L2 intron 17463246 rs4132670 chr10 114767771 G A 1.87E-12 Multiple complex diseases TCF7L2 intron 17554300 rs7904519 chr10 114773927 A G 2.70E-10 Type 2 diabetes TCF7L2 intron 17293876 rs7904519 chr10 114773927 A G 2.60E-06 Type 2 diabetes TCF7L2 intron 17460697 rs7904519 chr10 114773927 A G 2.70E-10 Type 2 diabetes TCF7L2 intron 19184112 rs7904519 chr10 114773927 A G 3.00E-08 Breast cancer TCF7L2 intron 23535729 rs7904519 chr10 114773927 A G 2.90E-04 Breast cancer TCF7L2 intron 23535733 rs7904519 chr10 114773927 A G 9.95E-04 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) TCF7L2 intron 24325915 rs34950775 chr10 114780081 C A 1.75E-05 Melanoma TCF7L2 intron 21926416 rs10787472 chr10 114781297 A C 2.00E-11 Multiple complex diseases TCF7L2 intron 17554300 rs11196192 chr10 114782287 T G 9.23E-07 Type 2 diabetes TCF7L2 intron 20818381 rs12243326 chr10 114788815 T C 6.28E-05 Type 2 diabetes TCF7L2 intron 17463246 rs12243326 chr10 114788815 T C 5.00E-06 Type 2 diabetes TCF7L2 intron 17463248 rs12243326 chr10 114788815 T C 1.78E-10 Multiple complex diseases TCF7L2 intron 17554300 rs12243326 chr10 114788815 T C 1.00E-07 Two-hour glucose challenge TCF7L2 intron 20081857 rs12243326 chr10 114788815 T C 1.60E-04 Coronary heart disease TCF7L2 intron 21966275 rs12243326 chr10 114788815 T C 0.000003 2-hour glucose tolerance test TCF7L2 intron 22885924 rs7077039 chr10 114789077 T C 2.83E-12 Multiple complex diseases TCF7L2 intron 17554300 rs7900150 chr10 114793823 T A 2.10E-08 Type 2 diabetes TCF7L2 intron 17293876 rs4367880 chr10 114795256 G C 0.00000037 Myopia (Age of onset) TCF7L2 intron 23468642 rs7100927 chr10 114796048 A G 2.10E-08 Type 2 diabetes TCF7L2 intron 17293876 rs11196205 chr10 114807047 G C 6.98E-11 Multiple complex diseases TCF7L2 intron 17554300 rs10885409 chr10 114808072 T C 1.80E-10 Type 2 diabetes TCF7L2 intron 17293876 rs10885409 chr10 114808072 T C 6.00E-06 Type 2 diabetes TCF7L2 intron 17460697 rs10885409 chr10 114808072 T C 8.44E-11 Multiple complex diseases TCF7L2 intron 17554300 rs10885409 chr10 114808072 T C 1.80E-10 Type 2 diabetes TCF7L2 intron 19184112 rs12255372 chr10 114808902 G T 1.40E-13 Type 2 diabetes TCF7L2 intron 17293876 rs12255372 chr10 114808902 G T 1.60E-07 Type 2 diabetes TCF7L2 intron 17460697 rs12255372 chr10 114808902 G T 3.60E-07 Type 2 diabetes TCF7L2 intron 17463248 rs12255372 chr10 114808902 G T 5.31E-07 Type 2 diabetes TCF7L2 intron 17668382 rs12255372 chr10 114808902 G T 1.40E-13 Type 2 diabetes TCF7L2 intron 19184112 rs12255372 chr10 114808902 G T 4.00E-06 Type 2 diabetes TCF7L2 intron 20818381 rs12255372 chr10 114808902 G T 0.00000536 Glycated hemoglobin levels TCF7L2 intron 22885924 rs12255372 chr10 114808902 G T 1.18E-14 2-hour glucose tolerance test TCF7L2 intron 22885924 rs12255372 chr10 114808902 G T 1.97E-18 Fasting blood glucose TCF7L2 intron 22885924 rs12255372 chr10 114808902 G T 3.67E-09 Fasting insulin-related traits TCF7L2 intron 22885924 rs11196208 chr10 114811316 T C 5.51E-11 Multiple complex diseases TCF7L2 intron 17554300 rs11196212 chr10 114821249 T C 1.09E-05 Multiple complex diseases TCF7L2 intron 17554300 rs4918789 chr10 114821807 T G 2.40E-06 Type 2 diabetes TCF7L2 intron 17293876 rs4918789 chr10 114821807 T G 2.40E-06 Type 2 diabetes TCF7L2 intron 19184112 rs3829191 chr10 114846920 T C 6.28E-12 Triglycerides TCF7L2 intron 23063622 rs7085532 chr10 114859463 G A 8.82E-04 Oral cancers (chewing tobacco related) TCF7L2 intron 22503698 rs290475 chr10 114874019 C T 3.00E-07 Bipolar disorder (body mass index interaction) TCF7L2 intron 24322204 rs74157220 chr10 114877867 G T 6.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) TCF7L2 intron 24159190 rs4918796 chr10 114880342 T C 1.23E-04 Multiple complex diseases TCF7L2 intron 17554300 rs12772424 chr10 114880551 A T 3.00E-08 Bipolar disorder (body mass index interaction) TCF7L2 intron 24322204 rs7080044 chr10 114899115 A T 2.50E-04 Multiple complex diseases TCF7L2 intron 17554300 rs290487 chr10 114909731 C T 1 Drug response to Repaglinide TCF7L2 intron 20054294 rs290483 chr10 114915214 G T 5.30E-06 Type 2 diabetes TCF7L2 intron 17293876 rs290483 chr10 114915214 G T 5.30E-06 Type 2 diabetes TCF7L2 intron 19184112 rs290481 chr10 114923825 C T 0.000000701 Ankle-brachial index TCF7L2 intron 22361517 rs290481 chr10 114923825 C T 0.0001 Ankle-brachial index in diabetics TCF7L2 intron 22361517 rs290481 chr10 114923825 C T 6.94E-05 Cognitive decline TCF7L2 intron 23732972 rs290481 chr10 114923825 C T 5.10E-05 Blood Pressure TCF7L2 intron pha003044 rs7100692 chr10 114971602 A C 9.20E-04 Major depressive disorder / / 21042317 rs12257761 chr10 115016408 C T 7.25E-06 Schizophrenia / / 19571809 rs4265536 chr10 115018340 T C 8.64E-05 Asthma / / 11022011 rs4265536 chr10 115018340 T C 9.32E-04 Alzheimer's disease / / 17998437 rs4918805 chr10 115033944 G A 1.74E-04 Multiple complex diseases / / 17554300 rs2039709 chr10 115062480 G T 4.55E-04 Parkinson's disease / / 17052657 rs499832 chr10 115070140 T G 8.61E-05 Orofacial clefts / / 19270707 rs579848 chr10 115070484 C T 3.32E-04 Birth weight / / 17255346 rs550770 chr10 115071357 T C 2.66E-04 Birth weight / / 17255346 rs536280 chr10 115075044 T C 8.69E-05 Birth weight / / 17255346 rs564782 chr10 115113013 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs884507 chr10 115118856 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1338428 chr10 115125108 G A 3.98E-06 Serum metabolites / / 19043545 rs12250948 chr10 115128491 T C 7.26E-04 Type 2 diabetes / / 17463246 rs12250948 chr10 115128491 T C 1.43E-05 Serum metabolites / / 19043545 rs486759 chr10 115132537 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10885439 chr10 115135422 G A 7.46E-06 Serum metabolites / / 19043545 rs557549 chr10 115138169 T C 1.12E-04 Multiple complex diseases / / 17554300 rs767798 chr10 115139721 A T 5.54E-04 Type 2 diabetes / / 17463246 rs1338426 chr10 115139774 G C 1.90E-05 Urinary metabolites / / 21572414 rs17130335 chr10 115140256 A G 2.75E-05 Cognitive test performance / / 20125193 rs7089082 chr10 115142260 G C 2.30E-05 Urinary metabolites / / 21572414 rs519241 chr10 115146944 G A 2.08E-05 Serum metabolites / / 19043545 rs12763961 chr10 115149323 C T 1.40E-05 Urinary metabolites / / 21572414 rs529334 chr10 115150037 T A,C,G 3.82E-06 Serum metabolites / / 19043545 rs12769650 chr10 115153192 G A 2.00E-05 Urinary metabolites / / 21572414 rs1124096 chr10 115156226 C T 1.46E-06 Serum metabolites / / 19043545 rs1933627 chr10 115172120 A G 7.22E-04 Multiple complex diseases / / 17554300 rs4917653 chr10 115198443 A G 5.80E-04 Multiple complex diseases / / 17554300 rs17130395 chr10 115212165 G C 2.00E-04 Multiple complex diseases / / 17554300 rs35616138 chr10 115220012 A T 2.64E-05 Alcohol consumption / / 23743675 rs1472750 chr10 115235114 T C 5.00E-09 Myopia (pathological) / / 23049088 rs10749132 chr10 115237428 A G 6.56E-05 Coronary heart disease / / pha003033 rs17770015 chr10 115238764 C G 3.00E-06 Migraine without aura / / 23793025 rs1046528 chr10 115242531 T G 3.08E-04 Multiple complex diseases / / 17554300 rs7075094 chr10 115251615 G A 2.59E-04 Multiple complex diseases / / 17554300 rs7919248 chr10 115275365 T G 1.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7919248 chr10 115275365 T G 5.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7919248 chr10 115275365 T G 1.70E-06 Urinary metabolites / / 21572414 rs2419830 chr10 115281218 G A 1.00E-05 Urinary metabolites / / 21572414 rs2419831 chr10 115281857 G A 7.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11592949 chr10 115285308 T G 8.49E-04 Sleep time / / 23728906 rs1570269 chr10 115287202 T G 3.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4261225 chr10 115289375 G T 3.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4918833 chr10 115290564 T C 6.20E-05 Multiple complex diseases / / 17554300 rs7088233 chr10 115294705 C T 1.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1853204 chr10 115308456 G A 5.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10509980 chr10 115314498 A C 6.75E-05 Orofacial clefts HABP2 intron 22419666 rs4918842 chr10 115316812 T C 6.26E-04 Type 2 diabetes HABP2 intron 17463246 rs11575624 chr10 115317262 C T 8.41E-04 Depression (quantitative trait) HABP2 intron 20800221 rs11575625 chr10 115317711 G A 8.41E-04 Depression (quantitative trait) HABP2 intron 20800221 rs11575631 chr10 115319661 C T 7.94E-04 Depression (quantitative trait) HABP2 intron 20800221 rs7094824 chr10 115321129 C T 5.30E-05 Coffee consumption HABP2 intron 21357676 rs11575634 chr10 115321824 C T 8.31E-04 Depression (quantitative trait) HABP2 intron 20800221 rs11575668 chr10 115327084 A G 6.57E-05 Blood Pressure HABP2 intron pha003043 rs4918853 chr10 115330130 T C 6.92E-04 Alcohol dependence HABP2 intron 21314694 rs11575741 chr10 115333651 C T 3.30E-07 Plasminogen activator inhibitor-1 (PAI1) levels,in plasma HABP2 intron 20558613 rs2286744 chr10 115338305 T C 8.71E-05 Serum metabolites HABP2 intron 19043545 rs2302373 chr10 115343287 C T 4.01E-04 Smoking cessation HABP2 intron 24665060 rs911704 chr10 115343700 G A 4.43E-05 Amyotrophic lateral sclerosis HABP2 intron 20801718 rs2419842 chr10 115346999 G C 1.59E-05 Multiple complex diseases HABP2 intron 17554300 rs2419842 chr10 115346999 G C 2.50E-05 Urinary metabolites HABP2 intron 21572414 rs932650 chr10 115347359 T C 2.50E-05 Sleep and circadian phenotypes HABP2 intron 17903308 rs3121454 chr10 115375947 T C 2.30E-06 Urinary metabolites NRAP intron 21572414 rs868738 chr10 115381747 G A 3.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NRAP missense 20877124 rs3189030 chr10 115393929 G A 2.00E-04 Cognitive impairment induced by topiramate NRAP missense 22091778 rs3121466 chr10 115401365 A G 8.41E-04 Multiple complex diseases NRAP intron 17554300 rs3121491 chr10 115421996 G A 5.00E-04 Alcohol dependence NRAP intron 20201924 rs17773680 chr10 115424373 C T 5.23E-05 Elbow pain / / pha003008 rs12415607 chr10 115438204 C A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs3124743 chr10 115464171 A G 2.20E-04 Alcohol dependence CASP7 intron 20201924 rs3124743 chr10 115464171 A G 3.20E-04 Alcohol dependence CASP7 intron 20201924 rs17090911 chr10 115478980 G A 8.69E-05 Multiple complex diseases CASP7 intron 17554300 rs11196449 chr10 115480582 T C 4.90E-04 Alcohol dependence CASP7 intron 20201924 rs11196449 chr10 115480582 T C 9.00E-04 Alcohol dependence CASP7 intron 20201924 rs11196449 chr10 115480582 T C 5.41E-06 Progressive supranuclear palsy CASP7 intron 21685912 rs3814231 chr10 115481018 C T 6.84E-05 Cognitive impairment induced by topiramate CASP7 intron 22091778 rs3814231 chr10 115481018 C T 4.00E-08 Vitiligo CASP7 intron 22561518 rs12769185 chr10 115484200 T G 2.71E-05 Cognitive impairment induced by topiramate CASP7 intron 22091778 rs11196455 chr10 115496883 T C 3.05E-07 Magnesium levels / / pha003092 rs3124736 chr10 115497112 A G 1.41E-05 Longevity / / 20304771 rs12572757 chr10 115512895 G A 5.12E-04 Type 2 diabetes C10orf81 intron 17463246 rs3981351 chr10 115515120 G A 1.00E-06 Obesity-related traits C10orf81 UTR-5 23251661 rs11196479 chr10 115532291 T C 8.07E-05 Blood pressure (response to calcium channel blocker) C10orf81 intron 24192120 rs17090991 chr10 115553092 T C 8.03E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2419863 chr10 115554650 T C 5.24E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12267244 chr10 115581913 T C 2.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7895170 chr10 115587010 C T 1.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7084835 chr10 115590412 C T 6.29E-05 Elbow pain / / pha003008 rs10567 chr10 115594725 C T 1.12E-05 Alcohol and nictotine co-dependence DCLRE1A UTR-3 20158304 rs2301180 chr10 115618246 T C 1.87E-05 Alzheimer's disease NHLRC2 intron 22005930 rs17091067 chr10 115620108 C G 6.13E-05 Alzheimer's disease NHLRC2 intron 22005930 rs7913176 chr10 115644040 G A 2.96E-05 Alzheimer's disease NHLRC2 missense 22005930 rs6585251 chr10 115651253 C A 2.37E-05 Alzheimer's disease NHLRC2 intron 22005930 rs7919159 chr10 115661333 T A 6.74E-04 Insulin resistance NHLRC2 intron 21901158 rs1576479 chr10 115679965 A G 4.58E-04 Alzheimer's disease / / 22005930 rs12244033 chr10 115682099 A G 5.39E-04 Alzheimer's disease / / 22005930 rs10885516 chr10 115682956 G A 5.67E-04 Alzheimer's disease / / 22005930 rs239865 chr10 115685187 G A 1.25E-04 Insulin resistance / / 21901158 rs10885518 chr10 115687103 A G 2.30E-05 Urinary metabolites / / 21572414 rs7894582 chr10 115704458 C A 7.41E-05 HIV-1 viral setpoint / / 17641165 rs180950 chr10 115707967 G T 5.16E-06 Reading disability and language impairment / / 24024963 rs180945 chr10 115710213 G A 5.93E-04 Type 2 diabetes / / 17463246 rs151599 chr10 115724039 G A 9.78E-04 Coronary Artery Disease / / 17634449 rs11196571 chr10 115730237 A T 4.68E-04 Multiple complex diseases / / 17554300 rs17091145 chr10 115734800 A G 7.83E-05 Multiple complex diseases / / 17554300 rs17653278 chr10 115738502 C G 1.03E-05 Suicide attempts in bipolar disorder / / 21041247 rs17653278 chr10 115738502 C G 6.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs17574901 chr10 115739409 C T 1.41E-05 Suicide attempts in bipolar disorder / / 21041247 rs17574901 chr10 115739409 C T 6.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs17653713 chr10 115746419 C A,G,T 2.07E-05 Suicide attempts in bipolar disorder / / 21041247 rs17653713 chr10 115746419 C A,G,T 6.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs17653713 chr10 115746419 C A,G,T 3.54E-04 Alcohol dependence / / 24277619 rs10787511 chr10 115747997 A G 8.00E-04 Acute lung injury / / 22295056 rs82625 chr10 115756130 T C 2.00E-06 Gaucher disease severity / / 22388998 rs413920 chr10 115760082 G C 2.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs7917932 chr10 115768177 A G 8.57E-04 Coronary heart disease / / 21606135 rs623499 chr10 115780369 G T 3.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs2782980 chr10 115781527 T C 2.00E-09 Blood pressure / / 21909110 rs7076938 chr10 115789375 C T 2.72E-04 Blood pressure / / 22100073 rs1801252 chr10 115804036 A G 1 Drug response to Metoprolol ADRB1 missense 12844134 rs1801252 chr10 115804036 A G 1 Drug response to Atenolol ADRB1 missense 18615004 rs1801252 chr10 115804036 A G 1 Drug response to Verapamil ADRB1 missense 18615004 rs1801253 chr10 115805056 G C 1 Drug response to Beta Blockers ADRB1 missense 16844790 rs1801253 chr10 115805056 G C 1 Drug response to Atenolol ADRB1 missense 18615004 rs1801253 chr10 115805056 G C 1 Drug response to Verapamil ADRB1 missense 18615004 rs1801253 chr10 115805056 G C 2.85E-04 Blood pressure ADRB1 missense 22100073 rs1801253 chr10 115805056 G C 4.00E-09 Birth weight ADRB1 missense 23202124 rs10885531 chr10 115814392 C T 4.00E-06 Adiponectin levels / / 22479202 rs4918889 chr10 115830718 C G 1.32E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17776203 chr10 115848372 A C 6.30E-05 Hemoglobin / / pha003098 rs657497 chr10 115899972 G A 1.69E-04 Kawasaki disease C10orf118 intron 21326860 rs10510001 chr10 115972382 G A 2.00E-04 ECG dimensions,brachial artery endothelial function,treadmill exercise responses TDRD1 intron 17903301 rs642602 chr10 115978429 C T 6.78E-04 Kawasaki disease TDRD1 intron 21326860 rs7069675 chr10 116026606 T G 7.95E-04 Obesity (extreme) VWA2 intron 21935397 rs2530322 chr10 116028335 G A 1.53E-08 Metabolite levels VWA2 intron 23281178 rs11196686 chr10 116050008 A G 6.23E-04 Myocardial Infarction / / pha002883 rs17586071 chr10 116079535 T C 7.50E-06 Urinary metabolites AFAP1L2 intron 21572414 rs6585275 chr10 116125988 A G 2.20E-05 Urinary metabolites AFAP1L2 intron 21572414 rs10437496 chr10 116131841 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes AFAP1L2 intron 22628534 rs610315 chr10 116131915 T A 3.00E-05 Cognitive decline AFAP1L2 intron 22054870 rs4751674 chr10 116139029 T C 4.00E-06 Cognitive performance AFAP1L2 intron 20125193 rs1535388 chr10 116165248 A C 7.18E-04 Alzheimer's disease / / 22005930 rs7088109 chr10 116167927 C A 6.58E-04 Alzheimer's disease / / 22005930 rs11196730 chr10 116168638 G A 6.17E-05 Brain lesion load / / 19010793 rs941855 chr10 116169841 T C 1.17E-04 Multiple complex diseases / / 17554300 rs941856 chr10 116170025 G A 6.60E-04 Alzheimer's disease / / 22005930 rs4751864 chr10 116171627 C T 6.54E-04 Alzheimer's disease / / 22005930 rs4752638 chr10 116171691 A G 6.83E-04 Alzheimer's disease / / 22005930 rs7910088 chr10 116172486 C T 6.46E-04 Multiple complex diseases / / 17554300 rs10885564 chr10 116177246 C T 7.04E-04 Alzheimer's disease / / 22005930 rs1575232 chr10 116180247 G A 6.79E-04 Alzheimer's disease / / 22005930 rs7075375 chr10 116183068 A G 3.24E-05 Brain lesion load / / 19010793 rs6585278 chr10 116186382 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11196739 chr10 116188485 C T 4.91E-04 Depression (quantitative trait) / / 20800221 rs11196739 chr10 116188485 C T 1.38E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4752727 chr10 116189070 G A 1.55E-04 Depression (quantitative trait) / / 20800221 rs4752728 chr10 116189170 G A 1.48E-04 Depression (quantitative trait) / / 20800221 rs4752729 chr10 116189190 T C 7.01E-04 Alzheimer's disease / / 22005930 rs11812741 chr10 116189930 G A 4.80E-04 Depression (quantitative trait) / / 20800221 rs11812741 chr10 116189930 G A 7.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11196740 chr10 116190274 G A 8.94E-05 Personality dimensions / / 18957941 rs11196740 chr10 116190274 G A 4.66E-04 Depression (quantitative trait) / / 20800221 rs11196740 chr10 116190274 G A 1.80E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7920422 chr10 116190598 T C 5.87E-04 Multiple complex diseases ABLIM1 nearGene-3 17554300 rs7920422 chr10 116190598 T C 2.44E-04 Depression (quantitative trait) ABLIM1 nearGene-3 20800221 rs4751905 chr10 116190741 T C 2.43E-04 Depression (quantitative trait) ABLIM1 nearGene-3 20800221 rs12218918 chr10 116190816 T C 3.91E-04 Depression (quantitative trait) ABLIM1 nearGene-3 20800221 rs11551242 chr10 116192120 T C 1.39E-04 Response to taxane treatment (placlitaxel) ABLIM1 UTR-3 23006423 rs3750820 chr10 116192626 T C 3.70E-04 Depression (quantitative trait) ABLIM1 UTR-3 20800221 rs7906164 chr10 116192831 T G 5.84E-04 Alzheimer's disease ABLIM1 UTR-3 22005930 rs17091846 chr10 116193167 T G 8.50E-04 Depression (quantitative trait) ABLIM1 UTR-3 20800221 rs10787530 chr10 116193917 A G 5.63E-06 Elbow pain ABLIM1 UTR-3 pha003008 rs941853 chr10 116199175 G A 6.00E-06 Obesity-related traits ABLIM1 intron 23251661 rs12268190 chr10 116218384 C T 7.12E-06 Bipolar disorder ABLIM1 intron 17486107 rs10885570 chr10 116222167 G A 7.10E-06 Urinary metabolites ABLIM1 intron 21572414 rs6585284 chr10 116231620 T G 5.53E-05 Personality dimensions ABLIM1 intron 18957941 rs1535386 chr10 116233234 T C 8.13E-05 Cognitive impairment induced by topiramate ABLIM1 intron 22091778 rs1535386 chr10 116233234 T C 3.25E-04 Stroke ABLIM1 intron pha002887 rs17717312 chr10 116257905 G A 1.30E-05 Bladder cancer ABLIM1 intron 21824976 rs2475230 chr10 116259930 A G 6.55E-05 Elbow pain ABLIM1 intron pha003008 rs10510006 chr10 116260627 A C 2.94E-04 Alzheimer's disease (late onset) ABLIM1 intron 21379329 rs2497707 chr10 116277525 A G 4.35E-06 White blood cell count ABLIM1 intron 21738479 rs2497708 chr10 116281550 A C 1.00E-04 IgE levels in asthmatics (D.f. specific) ABLIM1 intron 23967269 rs2497714 chr10 116292561 A G 4.66E-05 Pulmonary function in asthmatics ABLIM1 intron 23541324 rs7913199 chr10 116294497 T C 4.69E-04 Alzheimer's disease (late onset) ABLIM1 intron 21379329 rs2483596 chr10 116305041 A G 4.76E-06 Hirschsprung's disease ABLIM1 intron 19196962 rs10749170 chr10 116312110 T C 1.19E-05 Elbow pain ABLIM1 intron pha003008 rs7923449 chr10 116323720 A G 1.24E-04 Intracranial aneurysm ABLIM1 intron 20613766 rs10885582 chr10 116327550 T C 4.00E-06 Prostate cancer (gene x gene interaction) ABLIM1 intron 22219177 rs2497663 chr10 116356428 G A 4.34E-04 Alzheimer's disease (late onset) ABLIM1 intron 21379329 rs10787540 chr10 116364424 G A 5.06E-05 Height ABLIM1 intron pha003010 rs10787540 chr10 116364424 G A 1.69E-05 Height ABLIM1 intron pha003011 rs11196802 chr10 116367729 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ABLIM1 intron 22628534 rs17719089 chr10 116383343 G T 4.62E-04 Major depressive disorder ABLIM1 intron 22472876 rs17719647 chr10 116417143 G A 4.92E-05 Multiple complex diseases ABLIM1 intron 17554300 rs11196841 chr10 116417367 T G 2.34E-05 Multiple complex diseases ABLIM1 intron 17554300 rs808338 chr10 116494544 T C 5.47E-04 Stroke / / pha002887 rs7910860 chr10 116494904 T C,G 1.09E-04 Multiple complex diseases / / 17554300 rs808276 chr10 116565387 A G 6.41E-04 Stroke / / pha002887 rs2181563 chr10 116604344 T C 6.72E-05 Pulmonary function in asthmatics FAM160B1 intron 23541324 rs10885616 chr10 116617680 A G 6.64E-05 Height FAM160B1 intron pha003010 rs10885616 chr10 116617680 A G 4.07E-06 Height FAM160B1 intron pha003011 rs951585 chr10 116681477 G A 6.36E-04 Multiple complex diseases / / 17554300 rs6585309 chr10 116730337 G A 8.17E-04 Multiple complex diseases TRUB1 intron 17554300 rs12772737 chr10 116741501 C G 4.96E-05 Attention deficit hyperactivity disorder / / 18980221 rs7082007 chr10 116849734 T C 2.24E-04 Multiple complex diseases / / 17554300 rs1268917 chr10 116874477 A G 2.02E-04 Multiple complex diseases ATRNL1 intron 17554300 rs1314595 chr10 116908479 T C 6.91E-07 Asthma (childhood onset) ATRNL1 intron 23829686 rs2065719 chr10 116920090 A C 6.11E-04 Response to cytidine analogues (gemcitabine) ATRNL1 intron 24483146 rs35990212 chr10 116920090 AT A 6.11E-04 Response to cytidine analogues (gemcitabine) ATRNL1 intron 24483146 rs10885701 chr10 117147589 C T 4.26E-04 Oral cancers (chewing tobacco related) ATRNL1 intron 22503698 rs1414636 chr10 117223605 A G 5.36E-04 Alzheimer's disease ATRNL1 intron 17998437 rs1572396 chr10 117325021 T C 1.40E-05 Endometriosis ATRNL1 intron 21151130 rs1572396 chr10 117325021 T C 1.50E-06 Endometriosis ATRNL1 intron 23104006 rs10509992 chr10 117350004 A G 8.67E-05 Crohn's disease ATRNL1 intron 17684544 rs2804200 chr10 117350297 C G 2.60E-04 Crohn's disease ATRNL1 intron 17684544 rs10509991 chr10 117350560 A G 3.70E-04 Crohn's disease ATRNL1 intron 17684544 rs1590736 chr10 117358809 A G 1.60E-04 Crohn's disease ATRNL1 intron 17684544 rs1590734 chr10 117358919 G C 5.57E-05 Crohn's disease ATRNL1 intron 17684544 rs2769423 chr10 117390995 T G 2.00E-04 Information processing speed ATRNL1 intron 21130836 rs2769422 chr10 117393524 T C 8.20E-06 Endometriosis ATRNL1 intron 23104006 rs2804250 chr10 117396288 C T 7.60E-06 Endometriosis ATRNL1 intron 23104006 rs2769417 chr10 117398195 G A 6.90E-06 Endometriosis ATRNL1 intron 23104006 rs2532726 chr10 117432329 A G 2.01E-05 Glucose levels ATRNL1 intron pha003061 rs4751927 chr10 117481431 A G 8.30E-04 Tourette syndrome ATRNL1 intron 22889924 rs2804167 chr10 117495807 T G 4.97E-04 Multiple complex diseases ATRNL1 intron 17554300 rs2804174 chr10 117501897 T G 4.96E-04 Multiple complex diseases ATRNL1 intron 17554300 rs11197430 chr10 117505905 A G 3.19E-04 Multiple complex diseases ATRNL1 intron 17554300 rs2907535 chr10 117507223 C T 3.77E-04 Multiple complex diseases ATRNL1 intron 17554300 rs10490919 chr10 117512588 T G 2.00E-06 Information processing speed ATRNL1 intron 21130836 rs10490918 chr10 117531155 G A 3.06E-04 Statin-induced myopathy ATRNL1 intron 21826682 rs4447088 chr10 117546809 G C 2.73E-04 Multiple complex diseases ATRNL1 intron 17554300 rs2960660 chr10 117575036 A G 5.73E-04 Multiple complex diseases ATRNL1 intron 17554300 rs2907559 chr10 117592887 C T 6.87E-04 Multiple complex diseases ATRNL1 intron 17554300 rs2420125 chr10 117598733 C G,T 3.28E-04 Multiple complex diseases ATRNL1 intron 17554300 rs875377 chr10 117598833 G A 5.47E-04 Multiple complex diseases ATRNL1 intron 17554300 rs2907573 chr10 117617447 C G 6.09E-04 Multiple complex diseases ATRNL1 intron 17554300 rs2907572 chr10 117617518 A G 4.09E-04 Multiple complex diseases ATRNL1 intron 17554300 rs2615891 chr10 117640316 G A 6.18E-04 Nicotine dependence ATRNL1 intron 17158188 rs2054533 chr10 117690999 C A 5.31E-04 Parkinson's disease ATRNL1 intron 17052657 rs3740571 chr10 117705146 T C 3.09E-04 Suicide attempts in bipolar disorder ATRNL1 UTR-3 21423239 rs10885833 chr10 117707733 T C 2.32E-04 Suicide attempts in bipolar disorder ATRNL1 UTR-3 21423239 rs4751939 chr10 117708868 G A 3.12E-04 Coronary heart disease / / 21971053 rs7093038 chr10 117779496 G A 9.53E-06 Multiple complex diseases / / 17554300 rs11197512 chr10 117811415 G A 5.78E-04 Taste perception / / 22132133 rs11197515 chr10 117817683 C A,G,T 4.80E-05 Waist-hip ratio GFRA1 UTR-3 23966867 rs2072277 chr10 117823204 T C 4.33E-04 Taste perception GFRA1 UTR-3 22132133 rs2302105 chr10 117824888 C G 4.00E-06 IgG glycosylation GFRA1 intron 23382691 rs4751949 chr10 117842360 C T 5.27E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) GFRA1 intron 23648065 rs7087152 chr10 117844044 C T 3.10E-04 Taste perception GFRA1 intron 22132133 rs7087152 chr10 117844044 C T 6.09E-05 Leukocyte Counts GFRA1 intron pha003091 rs7087213 chr10 117844216 A G 3.52E-04 Multiple complex diseases GFRA1 intron 17554300 rs17668282 chr10 117844511 A G 9.31E-04 Multiple complex diseases GFRA1 intron 17554300 rs7070180 chr10 117852470 C T 2.24E-04 Response to TNF antagonist treatment GFRA1 intron 21061259 rs17094083 chr10 117860851 T C 5.08E-04 Response to TNF antagonist treatment GFRA1 intron 21061259 rs17094083 chr10 117860851 T C 2.35E-05 Celiac disease GFRA1 intron 23936387 rs3781514 chr10 117861297 G A 6.33E-05 Celiac disease GFRA1 intron 23936387 rs2694814 chr10 117876408 G A 1.50E-05 Urinary metabolites GFRA1 intron 21572414 rs3843600 chr10 117881996 T C 6.74E-04 Suicide attempts in bipolar disorder GFRA1 intron 21423239 rs3781523 chr10 117885260 G A 3.59E-06 Socioeconomic Factors GFRA1 intron pha003066 rs952918 chr10 117885616 C T 5.31E-04 Body mass index GFRA1 intron 21701565 rs11197545 chr10 117892640 C T 1.11E-05 Socioeconomic Factors GFRA1 intron pha003066 rs2901098 chr10 117894117 T C 1.30E-05 Urinary metabolites GFRA1 intron 21572414 rs2901098 chr10 117894117 T C 2.11E-05 Socioeconomic Factors GFRA1 intron pha003066 rs4237493 chr10 117894381 C T 1.90E-05 Urinary metabolites GFRA1 intron 21572414 rs3781533 chr10 117895639 C T 1.90E-05 Urinary metabolites GFRA1 intron 21572414 rs10885864 chr10 117905705 G A 1.54E-05 Socioeconomic Factors GFRA1 intron pha003066 rs7090606 chr10 117915108 C T 1.91E-05 Socioeconomic Factors GFRA1 intron pha003066 rs10749189 chr10 117918311 T C 7.20E-04 Amyotrophic Lateral Sclerosis GFRA1 intron 17362836 rs10749189 chr10 117918311 T C 9.36E-04 Suicide attempts in bipolar disorder GFRA1 intron 21423239 rs10510015 chr10 117920341 T C 3.97E-05 Bipolar disorder and schizophrenia GFRA1 intron 20889312 rs4751955 chr10 117923225 A G 9.16E-04 Type 2 diabetes GFRA1 intron 17463246 rs4751955 chr10 117923225 A G 7.75E-07 Major depression (suicidal thoughts and behavior) GFRA1 intron 21750702 rs2270181 chr10 117928218 C T 9.67E-04 Response to taxane treatment (placlitaxel) GFRA1 intron 23006423 rs11197567 chr10 117932193 G A 3.99E-04 Eye color GFRA1 intron 23118974 rs2420244 chr10 117935065 C A 5.65E-04 Response to taxane treatment (placlitaxel) GFRA1 intron 23006423 rs11197571 chr10 117942634 A G 8.08E-16 Hirschsprung's disease GFRA1 intron 19196962 rs11197571 chr10 117942634 A G 3.30E-04 Asperger disorder GFRA1 intron 21182207 rs11197571 chr10 117942634 A G 4.06E-04 Taste perception GFRA1 intron 22132133 rs953920 chr10 117947143 T C 8.08E-04 HIV-1 viral setpoint GFRA1 intron 17641165 rs953920 chr10 117947143 T C 3.33E-05 Taste perception GFRA1 intron 22132133 rs2251545 chr10 117954139 C A 8.96E-04 Multiple complex diseases GFRA1 intron 17554300 rs2694764 chr10 117967499 T C 3.60E-05 Personality dimensions GFRA1 intron 18957941 rs12413355 chr10 117973597 A G 3.00E-06 Migraine with aura GFRA1 intron 23793025 rs4562724 chr10 117977650 C T 9.45E-05 Personality dimensions GFRA1 intron 18957941 rs2901099 chr10 117977665 G A 3.30E-05 Personality dimensions GFRA1 intron 18957941 rs1107030 chr10 117978324 T G 2.00E-04 Cognitive impairment induced by topiramate GFRA1 intron 22091778 rs12570087 chr10 117983261 G T 2.60E-05 Personality dimensions GFRA1 intron 18957941 rs10885879 chr10 117984424 T C 3.60E-05 Personality dimensions GFRA1 intron 18957941 rs7894329 chr10 117987546 C A 3.60E-05 Personality dimensions GFRA1 intron 18957941 rs11816383 chr10 118018805 G T 1.50E-05 Urinary metabolites GFRA1 intron 21572414 rs12774375 chr10 118020066 A C 3.30E-05 Memory performance GFRA1 intron 22105620 rs11197611 chr10 118021745 T C 3.90E-05 Memory performance GFRA1 intron 22105620 rs11197612 chr10 118024319 C T 5.30E-05 Memory performance GFRA1 intron 22105620 rs10787639 chr10 118024351 G A 5.70E-05 Memory performance GFRA1 intron 22105620 rs2074986 chr10 118028614 T C 6.50E-06 Urinary metabolites GFRA1 intron 21572414 rs2532688 chr10 118035824 T A 8.20E-06 Urinary metabolites / / 21572414 rs11197620 chr10 118040571 A G 1.30E-05 Memory performance / / 22105620 rs41384349 chr10 118080890 G C 9.30E-07 Urinary metabolites / / 21572414 rs6585390 chr10 118081100 T C 7.10E-06 Urinary metabolites / / 21572414 rs41386650 chr10 118084468 A G 4.60E-06 Urinary metabolites C10orf96 UTR-5 21572414 rs12416239 chr10 118087220 A T 9.90E-07 Urinary metabolites C10orf96 intron 21572414 rs4636575 chr10 118099580 A G 8.80E-04 Iron levels C10orf96 intron pha002876 rs4751584 chr10 118114344 A G 6.15E-04 Multiple complex diseases C10orf96 intron 17554300 rs12218543 chr10 118116034 C T 8.99E-04 Taste perception C10orf96 intron 22132133 rs10885917 chr10 118119387 T C 3.53E-04 Taste perception C10orf96 intron 22132133 rs11197638 chr10 118122444 T A 6.22E-04 Multiple complex diseases C10orf96 intron 17554300 rs11197640 chr10 118131382 A G 1.33E-04 Multiple complex diseases C10orf96 intron 17554300 rs17094718 chr10 118185663 G A 1.35E-04 Smoking cessation / / 18519826 rs1897511 chr10 118186269 C T 6.25E-05 Smoking cessation / / 18519826 rs10885929 chr10 118187528 C T 6.38E-04 Multiple complex diseases PNLIPRP3 missense 17554300 rs7906587 chr10 118231666 C T 1.78E-26 Multiple complex diseases PNLIPRP3 intron 17554300 rs7906587 chr10 118231666 C T 0.000028 Mean arterial pressure PNLIPRP3 intron 22510845 rs10787677 chr10 118238417 C A 5.60E-04 Intracranial aneurysm / / 20613766 rs10787677 chr10 118238417 C A 3.70E-05 Myasthenia gravis / / 23055271 rs10787680 chr10 118246772 G T 0.000035 Mean arterial pressure / / 22510845 rs6585406 chr10 118255297 G T 0.000032 Mean arterial pressure / / 22510845 rs10787687 chr10 118264921 T A 0.000027 Mean arterial pressure / / 22510845 rs10787704 chr10 118278528 G A 0.00003 Mean arterial pressure / / 22510845 rs10787704 chr10 118278528 G A 3.30E-05 Myasthenia gravis / / 23055271 rs10885981 chr10 118286605 C T 0.00002 Mean arterial pressure / / 22510845 rs12249434 chr10 118298706 C T 4.00E-06 Anger / / 24489884 rs3010493 chr10 118326896 C T 3.81E-05 Neuroblastoma PNLIP intron pha002895 rs1049125 chr10 118368606 T C 6.73E-04 Body mass index PNLIPRP1 missense 17255346 rs4523611 chr10 118371262 G C 4.11E-04 Body mass index / / 17255346 rs10510024 chr10 118379953 G C 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10885997 chr10 118397971 A G 8.00E-09 Phospholipid levels (plasma) PNLIPRP2 cds-synon 22359512 rs2420318 chr10 118407568 G A 5.36E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs2420318 chr10 118407568 G A 3.00E-05 Lung function (forced vital capacity) / / pha003104 rs12571521 chr10 118412310 G T 8.74E-04 Type 2 diabetes / / 17463246 rs880977 chr10 118419231 C T 7.90E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2420323 chr10 118427540 C T 4.13E-04 Multiple complex diseases C10orf82 intron 17554300 rs12247542 chr10 118473607 C T 0.00008585 Sarcoidosis HSPA12A intron 22952805 rs758367 chr10 118485201 C T 6.22E-04 Alzheimer's disease HSPA12A intron 17998437 rs1665650 chr10 118487100 T C 9.00E-07 Colorectal cancer HSPA12A intron 23263487 rs1638419 chr10 118493063 G T 7.63E-05 Body Mass Index HSPA12A intron pha003009 rs740599 chr10 118506755 G A 3.26E-04 Tourette syndrome / / 22889924 rs887195 chr10 118507976 G A 4.43E-04 Tourette syndrome / / 22889924 rs1630816 chr10 118528593 A G 1.34E-04 Premature ovarian failure / / 19508998 rs17095224 chr10 118539243 A G 5.08E-08 Red blood cell traits / / 23222517 rs3125617 chr10 118546743 T C 1.83E-04 Type 2 diabetes / / 17463246 rs6585419 chr10 118556539 A G 7.53E-05 Cognitive test performance / / 20125193 rs7097645 chr10 118560477 A G 8.47E-04 Alcohol dependence / / 21314694 rs1681748 chr10 118572521 T C 1.83E-04 Breast cancer / / pha002853 rs740363 chr10 118575606 G A 9.00E-06 Heart failure / / 17903304 rs17095303 chr10 118589566 G T 1.71E-04 Multiple complex diseases / / 17554300 rs2170862 chr10 118620996 G A 4.30E-05 Type 2 diabetes ENO4 intron 17460697 rs11197843 chr10 118641396 G T 2.97E-05 Orofacial clefts ENO4 UTR-3 22863734 rs2257791 chr10 118643670 G A 3.56E-05 Orofacial clefts KIAA1598 UTR-3 22863734 rs1905544 chr10 118704077 A T 4.88E-04 Type 2 diabetes KIAA1598 intron 17463246 rs10886031 chr10 118804993 C T 4.48E-05 Orofacial clefts KIAA1598 intron 20023658 rs10886031 chr10 118804993 C T 1.89E-06 Orofacial clefts KIAA1598 intron 22863734 rs7078160 chr10 118827560 G A 2.00E-08 Orofacial clefts KIAA1598 intron 20023658 rs7078160 chr10 118827560 G A 9.66E-08 Cleft lip KIAA1598 intron 20436469 rs7078160 chr10 118827560 G A 4.00E-11 Orofacial clefts KIAA1598 intron 22863734 rs7078160 chr10 118827560 G A 6.00E-10 Orofacial clefts KIAA1598 intron 22863734 rs1898355 chr10 118828369 A G 3.53E-05 Orofacial clefts KIAA1598 intron 20023658 rs1898355 chr10 118828369 A G 7.46E-06 Orofacial clefts KIAA1598 intron 22863734 rs4752028 chr10 118834991 C T 2.67E-06 Orofacial clefts KIAA1598 intron 20023658 rs4752028 chr10 118834991 C T 7.56E-06 Cleft lip KIAA1598 intron 20436469 rs4752028 chr10 118834991 C T 1.71E-10 Orofacial clefts KIAA1598 intron 22863734 rs10787760 chr10 118890693 G A 1.70E-05 Type 2 diabetes VAX1 UTR-3 17460697 rs716183 chr10 118904495 C T 3.31E-06 Follicular lymphoma / / 21533074 rs11819305 chr10 118908050 A G 1.97E-05 Follicular lymphoma / / 21533074 rs11197915 chr10 118918183 G A 9.05E-04 Type 2 diabetes / / 17463246 rs17095758 chr10 118918519 G C 2.33E-04 Coronary Artery Disease / / 17634449 rs41463449 chr10 118918589 A T 2.26E-04 Coronary Artery Disease / / 17634449 rs963975 chr10 118962873 G C 1.78E-04 Alcohol dependence KCNK18 intron 21314694 rs363341 chr10 119010465 C T 4.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC18A2 intron 20877124 rs929493 chr10 119019126 C T 7.41E-04 Type 2 diabetes SLC18A2 intron 17463246 rs363271 chr10 119027411 G T 3.96E-04 Type 2 diabetes SLC18A2 intron 17463246 rs363271 chr10 119027411 G T 2.42E-08 Narcolepsy SLC18A2 intron 19629137 rs363278 chr10 119035068 A G 6.38E-04 Type 2 diabetes SLC18A2 intron 17463246 rs363294 chr10 119043554 C T 5.56E-05 Alcohol dependence PDZD8 missense 21703634 rs2532812 chr10 119051788 G A 3.63E-05 Alcohol dependence PDZD8 intron 21703634 rs2532841 chr10 119069842 A C 2.68E-05 Suicide attempts in bipolar disorder PDZD8 intron 21423239 rs2794436 chr10 119072166 A G 5.86E-04 Type 2 diabetes PDZD8 intron 17463246 rs2532783 chr10 119072190 C T 6.11E-04 Type 2 diabetes PDZD8 intron 17463246 rs2532839 chr10 119072518 T A 6.48E-04 Type 2 diabetes PDZD8 intron 17463246 rs2532785 chr10 119079053 G A 5.86E-04 Type 2 diabetes PDZD8 intron 17463246 rs1008448 chr10 119082710 G C 2.98E-05 Suicide attempts in bipolar disorder PDZD8 intron 21423239 rs2532844 chr10 119098898 A G 5.44E-04 Type 2 diabetes PDZD8 intron 17463246 rs2532795 chr10 119104729 C T 7.34E-04 Type 2 diabetes PDZD8 intron 17463246 rs17096145 chr10 119107883 C T 2.03E-04 Hearing function PDZD8 intron 17255346 rs11815112 chr10 119107982 C T 5.01E-05 Smoking initiation PDZD8 intron 24665060 rs10886062 chr10 119118509 T C 5.25E-04 Type 2 diabetes PDZD8 intron 17463246 rs7902237 chr10 119141161 G A 2.25E-05 Suicide attempts in bipolar disorder / / 21423239 rs7072493 chr10 119167736 G A 7.55E-04 Multiple complex diseases / / 17554300 rs1638662 chr10 119177760 G A 0.0008404 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1638662 chr10 119177760 G A 8.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs730080 chr10 119180751 C T 3.31E-05 Multiple sclerosis (age of onset) / / 19010793 rs181500 chr10 119181871 G T 5.00E-06 Bipolar disorder and schizophrenia / / 22688191 rs758569 chr10 119193153 C A 3.93E-06 Smooth-surface caries / / 24556642 rs2768336 chr10 119195881 A G 6.54E-06 Smooth-surface caries / / 24556642 rs2254317 chr10 119198158 T A 1.80E-05 Urinary metabolites / / 21572414 rs17096254 chr10 119207027 G A 3.99E-04 Multiple complex diseases / / 17554300 rs6585436 chr10 119210375 T C 6.00E-06 Cardiac repolarization / / 22683750 rs4752066 chr10 119227342 G T 6.00E-07 Pulmonary function in asthmatics / / 23541324 rs242967 chr10 119233375 A G 1.09E-04 Body mass index / / 20818722 rs242966 chr10 119234786 T C 8.02E-06 Pulmonary function in asthmatics / / 23541324 rs11198013 chr10 119253738 C T 4.00E-06 QT interval in Tripanosoma cruzi seropositivity EMX2OS intron 24324551 rs2532660 chr10 119256143 T C 5.04E-05 Hypertension EMX2OS intron 19609347 rs149745931 chr10 119289027 G C 1.35E-04 Acne (severe) EMX2OS intron 24927181 rs855775 chr10 119329341 G A 4.37E-05 Post-operative nausea and vomiting / / 21694509 rs384627 chr10 119336746 C T 1.18E-04 Multiple complex diseases / / 17554300 rs384627 chr10 119336746 C T 5.00E-06 Obesity-related traits / / 23251661 rs703361 chr10 119341820 C T 2.09E-04 Iron levels / / pha002876 rs703363 chr10 119343484 T G 3.40E-07 Post-operative nausea and vomiting / / 21694509 rs703363 chr10 119343484 T G 2.12E-04 Iron levels / / pha002876 rs181601 chr10 119345838 G A 8.37E-04 Multiple complex diseases / / 17554300 rs181601 chr10 119345838 G A 1.07E-05 Post-operative nausea and vomiting / / 21694509 rs10886103 chr10 119367420 A G 1.30E-05 Bipolar disorder / / 20451256 rs181644 chr10 119372658 T G 1.28E-04 Type 2 diabetes / / 17463246 rs181654 chr10 119379656 A G 1.00E-07 Airflow obstruction / / 22837378 rs11198060 chr10 119414894 T C 8.54E-04 Coronary heart disease / / 21606135 rs2184898 chr10 119418104 G A 3.00E-06 Conduct disorder (symptom count) / / 20585324 rs17551306 chr10 119424140 G C 6.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs1538080 chr10 119462812 T G 4.62E-05 Dengue shock syndrome / / 22001756 rs7919329 chr10 119479361 C A 1.90E-05 Dengue shock syndrome / / 22001756 rs2147744 chr10 119489575 G A 2.88E-06 Dengue shock syndrome / / 22001756 rs10749247 chr10 119508643 A C 2.99E-05 Basophils / / pha003087 rs1006285 chr10 119519323 A G 1.39E-04 Body mass index / / 17255346 rs7077625 chr10 119522943 A G 2.51E-04 Smoking initiation / / 24665060 rs7088969 chr10 119533757 T C 3.00E-08 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs4752112 chr10 119547678 T C 1.47E-05 Coronary heart disease / / pha003031 rs11198125 chr10 119582073 A G 9.98E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6585463 chr10 119584861 G A 1.00E-04 Information processing speed / / 21130836 rs11198131 chr10 119589313 G C 2.30E-05 Urinary metabolites / / 21572414 rs7098136 chr10 119601436 T G 8.60E-05 Information processing speed / / 21130836 rs1925265 chr10 119604938 A G 5.00E-06 Metabolite levels (MHPG) / / 23319000 rs17641472 chr10 119611130 C T 4.41E-05 Cholesterol / / pha003073 rs12784400 chr10 119611204 G A 1.18E-05 Tunica Media / / pha003036 rs10886159 chr10 119613610 T C 7.00E-07 Celiac disease / / 23936387 rs4752123 chr10 119613633 T C 2.17E-04 Celiac disease / / 23936387 rs10787803 chr10 119614258 C T 8.02E-05 Type 2 diabetes / / 17463246 rs12571753 chr10 119616877 A G 2.23E-05 Aging (time to event) / / 21782286 rs4612716 chr10 119619382 C T 1.73E-04 Type 2 diabetes / / 17463246 rs6585465 chr10 119620559 T C 1.39E-05 Hodgkin's lymphoma / / 24149102 rs12242357 chr10 119622509 C T 9.74E-05 Cognitive performance / / 19734545 rs12414011 chr10 119628641 C T 2.17E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17096980 chr10 119643073 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17642749 chr10 119647256 T G 4.00E-07 Asthma (sex interaction) / / 24824216 rs11198174 chr10 119660512 G A 7.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs2243483 chr10 119660814 C A 0.000624 Salmonella-induced pyroptosis / / 22837397 rs1936295 chr10 119662092 T C 6.64E-07 Autism / / 22843504 rs2246493 chr10 119663968 T C 2.90E-05 Information processing speed / / 21130836 rs2246493 chr10 119663968 T C 6.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs2249690 chr10 119668388 G T 6.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs2250044 chr10 119671282 G A 6.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs2250290 chr10 119673188 C G 6.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs2250397 chr10 119673905 G C 9.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs2253424 chr10 119676051 G C 4.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs2253808 chr10 119679106 A T 8.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs2253812 chr10 119679259 T C 0.000064 Follicular lymphoma / / 23025665 rs2253812 chr10 119679259 T C 7.08E-05 Body Mass Index / / pha003014 rs2254426 chr10 119683609 G A 2.00E-04 Information processing speed / / 21130836 rs2254432 chr10 119683636 A G 8.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs17097082 chr10 119685916 G A 6.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs11198182 chr10 119686573 A G 6.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs11198183 chr10 119688129 C T 2.30E-05 Information processing speed / / 21130836 rs11198183 chr10 119688129 C T 8.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs12242976 chr10 119688325 G A 7.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs4752130 chr10 119688700 C T 4.34E-05 Weight / / pha003026 rs12259281 chr10 119688722 A C 7.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs10787805 chr10 119691032 T C 8.82E-05 Serum metabolites / / 19043545 rs11198184 chr10 119691133 A G 9.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs11198185 chr10 119691399 T A,C,G 2.80E-05 Information processing speed / / 21130836 rs7069291 chr10 119692335 C T 4.08E-05 Serum metabolites / / 19043545 rs7069291 chr10 119692335 C T 2.91E-05 Weight / / pha003026 rs1419141 chr10 119694504 G A 5.80E-06 Information processing speed / / 21130836 rs4752135 chr10 119695314 A G 8.46E-04 Type 2 diabetes / / 17463246 rs10886189 chr10 119753963 T C 1.35E-05 Adverse response to lamotrigine and phenytoin / / 22379998 rs2928127 chr10 119756876 A G 8.84E-04 Multiple complex diseases / / 17554300 rs853577 chr10 119821336 A G 1.25E-05 Adverse response to lamotrigine and phenytoin CASC2 intron 22379998 rs7906694 chr10 119840532 T C 4.28E-05 Lung function (forced expiratory volume in 1 second) CASC2 intron pha003103 rs1932644 chr10 119849144 A C 2.16E-04 Amyotrophic lateral sclerosis (sporadic) CASC2 intron 24529757 rs2907598 chr10 119860441 A T 5.68E-04 Multiple complex diseases CASC2 intron 17554300 rs853600 chr10 119899147 C A 7.48E-05 Lung function (forced expiratory volume in 1 second) CASC2 intron pha003103 rs2210604 chr10 120001191 A G 5.29E-05 Coronary heart disease / / 21606135 rs11198323 chr10 120008097 G A 8.70E-04 Depression (quantitative trait) / / 20800221 rs11594800 chr10 120020264 T C 8.07E-04 Depression (quantitative trait) / / 20800221 rs11198334 chr10 120021686 C T 3.00E-04 Coronary heart disease / / 21606135 rs11198338 chr10 120025435 G T 9.47E-04 Type 2 diabetes / / 17463246 rs7087553 chr10 120032416 G C 1.00E-04 Prostate cancer / / 21743057 rs12249758 chr10 120032904 C T 1.00E-04 Prostate cancer / / 21743057 rs10886222 chr10 120082538 T C 8.60E-05 Diabetic retinopathy FAM204A intron 21441570 rs236200 chr10 120136970 G A 7.69E-04 Multiple complex diseases / / 17554300 rs853921 chr10 120151128 G A 4.35E-04 Aortic root size / / 21223598 rs7923757 chr10 120163406 G T 2.67E-04 Parkinson's disease / / 17052657 rs853943 chr10 120164251 C T 1.10E-05 Urinary metabolites / / 21572414 rs766478 chr10 120164906 T C 7.35E-04 Parkinson's disease / / 17052657 rs2010654 chr10 120165167 A T 7.35E-04 Parkinson's disease / / 17052657 rs1857269 chr10 120172638 G T 3.70E-04 Parkinson's disease / / 17052657 rs11594463 chr10 120192347 A G 6.20E-06 Urinary metabolites / / 21572414 rs12253411 chr10 120199975 C T 9.10E-06 Urinary metabolites / / 21572414 rs877013 chr10 120205289 T C 1.70E-05 Urinary metabolites / / 21572414 rs7073917 chr10 120206904 G A 1.20E-05 Urinary metabolites / / 21572414 rs17097692 chr10 120218189 A G 5.65E-05 Major depressive disorder / / 21621269 rs6585491 chr10 120222264 T C 4.21E-04 Multiple complex diseases / / 17554300 rs1932547 chr10 120222502 C T 4.38E-04 Multiple complex diseases / / 17554300 rs10430690 chr10 120227834 A G 4.28E-04 Multiple complex diseases / / 17554300 rs12263039 chr10 120239987 C T 4.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs11198446 chr10 120242212 C T 7.49E-05 Pancreatic cancer / / pha002874 rs945491 chr10 120252855 G A 4.34E-05 Multiple complex diseases / / 17554300 rs11198463 chr10 120267079 C G 7.35E-04 Multiple complex diseases / / 17554300 rs1316856 chr10 120267557 G C 3.72E-04 Multiple complex diseases / / 17554300 rs667335 chr10 120277577 G A 6.02E-04 Multiple complex diseases / / 17554300 rs12413624 chr10 120278944 T A 2.53E-04 Multiple complex diseases / / 17554300 rs12413624 chr10 120278944 T A 5.00E-11 Pancreatic cancer / / 22158540 rs12413624 chr10 120278944 T A 2.61E-07 Esophageal cancer (squamous cell) / / 22960999 rs880964 chr10 120282397 A G 1.63E-04 Multiple complex diseases / / 17554300 rs488722 chr10 120298753 T C 5.15E-04 Multiple complex diseases / / 17554300 rs17097790 chr10 120301859 G A 7.73E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs477874 chr10 120311534 C T 2.90E-05 Urinary metabolites / / 21572414 rs1711880 chr10 120331936 A C 6.19E-06 White blood cell count / / 21738479 rs12767507 chr10 120361816 G T 6.44E-04 Smoking initiation / / 24665060 rs1338174 chr10 120363973 T C 4.62E-05 Sarcoidosis / / 19165924 rs10510045 chr10 120436448 T C 2.95E-04 Heart Failure / / pha002884 rs17662895 chr10 120442882 T C 3.30E-06 Urinary metabolites C10orf46 UTR-3 21572414 rs10886289 chr10 120463720 G T 6.41E-05 Asthma C10orf46 intron 11022011 rs17097984 chr10 120479437 T C 9.06E-04 Multiple complex diseases C10orf46 intron 17554300 rs11198591 chr10 120515892 G A 4.51E-04 Multiple complex diseases / / 17554300 rs10886299 chr10 120530731 C T 5.68E-04 Aortic root size / / 21223598 rs11198625 chr10 120571789 C T 5.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs927824 chr10 120580853 C A 1.13E-05 Potassium levels / / pha003086 rs11198640 chr10 120583354 A C 1.32E-05 Potassium levels / / pha003086 rs10886319 chr10 120595466 T G 9.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4752219 chr10 120615561 C T 5.01E-04 Rheumatoid arthritis / / 21452313 rs1409314 chr10 120615752 A G 6.46E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10886328 chr10 120618793 A G 1.12E-04 Rheumatoid arthritis / / 21452313 rs7087205 chr10 120621489 G A 1.27E-25 Narcolepsy / / 19629137 rs10510051 chr10 120663220 T C 5.90E-04 Rheumatoid arthritis / / 21452313 rs10886341 chr10 120687787 A G 1.96E-05 Tunica Media / / pha003036 rs2104529 chr10 120688258 G A 1.96E-05 Tunica Media / / pha003036 rs10787882 chr10 120695832 C T 9.29E-04 Multiple complex diseases / / 17554300 rs7905194 chr10 120697691 C T 5.91E-04 Type 2 diabetes / / 17463246 rs7905194 chr10 120697691 C T 6.05E-05 Alcohol dependence / / 21314694 rs10787884 chr10 120698967 A G 6.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs11198686 chr10 120706575 C T 7.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs7069995 chr10 120708167 A G 5.55E-05 Tunica Media / / pha003036 rs11198706 chr10 120741516 C T 1.40E-04 Birth weight / / 17255346 rs11198717 chr10 120751372 A C 1.40E-04 Birth weight / / 17255346 rs11198720 chr10 120751789 A G 1.40E-04 Birth weight / / 17255346 rs11198721 chr10 120752687 G T 2.08E-04 Birth weight / / 17255346 rs10749282 chr10 120773279 T G 3.14E-08 Multiple complex diseases / / 17554300 rs10886369 chr10 120783641 A G 7.75E-04 Multiple complex diseases / / 17554300 rs10886369 chr10 120783641 A G 5.73E-08 Lymphocyte counts / / 22286170 rs494469 chr10 120784977 A G 3.68E-04 Myopia (pathological) / / 21095009 rs494469 chr10 120784977 A G 0.0000317 Tuberculosis with late age of onset / / 22551897 rs608660 chr10 120785463 C T 7.83E-04 Myopia (pathological) / / 21095009 rs10787899 chr10 120798655 G A 8.17E-05 Cognitive test performance EIF3A intron 20125193 rs10787899 chr10 120798655 G A 0.00000693 Tuberculosis with late age of onset EIF3A intron 22551897 rs4751691 chr10 120850164 A G 5.39E-05 Cognitive test performance / / 20125193 rs9645587 chr10 120859921 C A 1.25E-04 Birth weight / / 17255346 rs2271359 chr10 120864601 G A 8.15E-05 Cognitive test performance FAM45A intron 20125193 rs2271359 chr10 120864601 G A 9.00E-04 Myopia (pathological) FAM45A intron 21095009 rs3858336 chr10 120877710 C T 2.04E-04 Myopia (pathological) FAM45A intron 21095009 rs3858336 chr10 120877710 C T 0.00000552 Tuberculosis with late age of onset FAM45A intron 22551897 rs3802739 chr10 120889022 T C 7.27E-05 Myopia (pathological) FAM45A intron 21095009 rs915272 chr10 120892542 T C 7.05E-05 Myopia (pathological) FAM45A intron 21095009 rs915272 chr10 120892542 T C 0.0000294 Tuberculosis with late age of onset FAM45A intron 22551897 rs6585536 chr10 120904013 T C 5.89E-05 Cognitive test performance SFXN4 intron 20125193 rs6585536 chr10 120904013 T C 5.74E-04 Myopia (pathological) SFXN4 intron 21095009 rs11198804 chr10 120909785 C T 0.000194 Asthma SFXN4 intron 22502797 rs2275111 chr10 120917445 G A 6.08E-05 Lung function (forced expiratory volume in 1 second) SFXN4 intron pha003103 rs10886416 chr10 120952674 C A 4.59E-04 Alcohol dependence / / 24277619 rs10510054 chr10 120957680 C A 5.77E-04 Acute lung injury / / 22295056 rs10749299 chr10 120959450 C T 8.50E-04 Type 2 diabetes / / 17463246 rs10749299 chr10 120959450 C T 5.39E-04 Acute lung injury / / 22295056 rs7923896 chr10 120965995 C T 9.90E-04 Acute lung injury / / 22295056 rs1397615 chr10 120966339 T C 2.00E-06 Obesity-related traits / / 23251661 rs7078228 chr10 120976743 T C 8.56E-05 Pulmonary function GRK5 intron 19300500 rs17098556 chr10 120978183 A G 9.50E-05 Pulmonary function GRK5 intron 19300500 rs17098576 chr10 120998250 A G 9.98E-04 Multiple complex diseases GRK5 intron 17554300 rs17098576 chr10 120998250 A G 7.02E-05 Pulmonary function GRK5 intron 19300500 rs17098586 chr10 121006227 T A 1.26E-04 Type 2 diabetes GRK5 intron 17463246 rs17606601 chr10 121011187 A G 5.70E-05 Personality dimensions GRK5 intron 18957941 rs7095989 chr10 121025097 A C 6.47E-04 Alcohol consumption (maxi-drinks) GRK5 intron 24277619 rs12358835 chr10 121034914 G A 6.00E-06 Personality dimensions GRK5 intron 18957941 rs4752269 chr10 121037952 C T 3.69E-04 Multiple complex diseases GRK5 intron 17554300 rs4752276 chr10 121050018 C T 4.00E-06 Personality dimensions GRK5 intron 18957941 rs11198863 chr10 121050776 C T 2.80E-05 Personality dimensions GRK5 intron 18957941 rs915391 chr10 121065385 A G 5.86E-04 Response to taxane treatment (placlitaxel) GRK5 intron 23006423 rs1563287 chr10 121065940 G C 2.98E-05 Relative hand skill GRK5 intron 24068947 rs871196 chr10 121069074 A G 5.52E-05 Prion diseases GRK5 intron 22210626 rs1556714 chr10 121077191 T G 0.00043 Coronary artery calcification GRK5 intron 23727086 rs1020672 chr10 121084734 C T 6.77E-05 Relative hand skill GRK5 intron 24068947 rs2230345 chr10 121086097 A T 1 Drug response to Beta Blockers GRK5 missense 18425130 rs11198886 chr10 121098290 C T 1.18E-04 Multiple complex diseases GRK5 intron 17554300 rs10886462 chr10 121105311 A G 9.55E-07 Crohn's disease GRK5 intron 17804789 rs11198891 chr10 121107447 C T 5.74E-04 Multiple complex diseases GRK5 intron 17554300 rs11198893 chr10 121107900 G A 9.00E-06 Osteoarthritis (knee and hip) GRK5 intron 21177295 rs11198893 chr10 121107900 G A 9.27E-05 Osteoarthritis (knee and hip) GRK5 intron 21177295 rs11198893 chr10 121107900 G A 9.32E-06 Osteoarthritis (knee and hip) GRK5 intron 21177295 rs915113 chr10 121110785 T G 6.73E-04 Type 2 diabetes GRK5 intron 17463246 rs291979 chr10 121129797 G A 3.10E-07 Height GRK5 intron 21194676 rs291979 chr10 121129797 G A 2.30E-04 Coronary heart disease GRK5 intron 21966275 rs17098787 chr10 121130578 G A 2.70E-05 Urinary metabolites GRK5 intron 21572414 rs17098790 chr10 121133897 C T 1.36E-04 Multiple complex diseases GRK5 intron 17554300 rs1248077 chr10 121139045 G A 3.97E-06 Retinopathy in non-diabetics GRK5 intron 23393555 rs4751714 chr10 121140511 A G 9.16E-06 Retinopathy in non-diabetics GRK5 intron 23393555 rs2275037 chr10 121140534 C G 9.82E-06 Retinopathy in non-diabetics GRK5 intron 23393555 rs3818779 chr10 121140671 A G 9.89E-06 Retinopathy in non-diabetics GRK5 intron 23393555 rs11813472 chr10 121146899 G A 8.54E-06 Retinopathy in non-diabetics GRK5 intron 23393555 rs10886471 chr10 121149403 C T 7.00E-09 Type 2 diabetes GRK5 intron 22961080 rs12254134 chr10 121171882 C A 1.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRK5 intron 20877124 rs12254134 chr10 121171882 C A 4.24E-05 Vaspin levels GRK5 intron 22907691 rs12254134 chr10 121171882 C A 0.0000424 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks GRK5 intron 22907730 rs12254134 chr10 121171882 C A 0.0000424 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at minimum 6 weeks GRK5 intron 22907730 rs17098857 chr10 121175674 C T 8.33E-05 Vaspin levels GRK5 intron 22907691 rs17098857 chr10 121175674 C T 0.0000833 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks GRK5 intron 22907730 rs17098857 chr10 121175674 C T 0.0000833 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at minimum 6 weeks GRK5 intron 22907730 rs7076555 chr10 121180765 G T 5.86E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRK5 intron 20877124 rs1889432 chr10 121186001 A G 7.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) GRK5 intron 23648065 rs915120 chr10 121190113 T C 9.52E-05 Warfarin maintenance dose GRK5 intron 19300499 rs915120 chr10 121190113 T C 3.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRK5 intron 20877124 rs915120 chr10 121190113 T C 1.15E-05 Vaspin levels GRK5 intron 22907691 rs915120 chr10 121190113 T C 0.0000115 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks GRK5 intron 22907730 rs915120 chr10 121190113 T C 0.0000115 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at minimum 6 weeks GRK5 intron 22907730 rs915120 chr10 121190113 T C 0.0003308 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit GRK5 intron 22907730 rs11198927 chr10 121202677 G A 9.67E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) GRK5 intron 23648065 rs2297641 chr10 121212405 C T 1.20E-04 Alcohol dependence GRK5 intron 20201924 rs1999627 chr10 121216923 G A 1.90E-04 Alcohol dependence / / 20201924 rs1999628 chr10 121217061 T A 1.30E-04 Alcohol dependence / / 20201924 rs11198934 chr10 121217683 C T 1.90E-04 Alcohol dependence / / 20201924 rs10886486 chr10 121218572 A C 3.10E-04 Alcohol dependence / / 20201924 rs3009874 chr10 121225352 G A 9.90E-05 Cognitive performance / / 19734545 rs3009874 chr10 121225352 G A 1.13E-05 Mammographic density / / 22532574 rs10886492 chr10 121225476 G A 9.20E-05 Parkinson's disease (familial) / / 18985386 rs10886492 chr10 121225476 G A 7.15E-05 Neuroblastoma / / pha002895 rs10886493 chr10 121225535 G C 9.20E-05 Parkinson's disease (familial) / / 18985386 rs2991769 chr10 121231439 A G 1.00E-04 Information processing speed / / 21130836 rs2991769 chr10 121231439 A G 3.09E-05 Neuroblastoma / / pha002895 rs2991770 chr10 121234063 C T 1.76E-05 Neuroblastoma / / pha002895 rs3009892 chr10 121249171 G A 8.90E-05 Calcium levels / / pha003085 rs2901213 chr10 121281362 T C 6.07E-04 Type 2 diabetes RGS10 intron 22158537 rs4752324 chr10 121290571 T C 2.30E-04 Celiac disease RGS10 intron 23936387 rs10886515 chr10 121343589 T C 6.26E-05 Cognitive test performance TIAL1 intron 20125193 rs10886515 chr10 121343589 T C 5.86E-06 Parkinson's disease TIAL1 intron 21738487 rs3816145 chr10 121347329 T C 6.56E-05 Parkinson's disease TIAL1 intron 21738487 rs12569630 chr10 121362660 A G 6.36E-05 Parkinson's disease / / 21738487 rs12569630 chr10 121362660 A G 1.31E-04 Mammographic density / / 22532574 rs7908484 chr10 121370544 A G 2.85E-05 Lymphocyte counts / / 22286170 rs2577335 chr10 121375181 A G 4.39E-05 HIV-1 viral setpoint / / 17641165 rs196313 chr10 121383036 G A 4.20E-04 Alcohol dependence / / 20201924 rs196290 chr10 121408071 T C 2.81E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs196335 chr10 121411861 C T 4.71E-04 Lung function (forced expiratory volume in 1 second) BAG3 intron 17255346 rs196335 chr10 121411861 C T 1.30E-04 Alcohol dependence BAG3 intron 20201924 rs196342 chr10 121417358 A G 7.09E-05 Atopy BAG3 intron 21625490 rs2234962 chr10 121429633 T C 4.00E-12 Dilated cardiomyopathy BAG3 missense 21459883 rs2234962 chr10 121429633 T C 7.50E-04 Response to taxane treatment (placlitaxel) BAG3 missense 23006423 rs2234962 chr10 121429633 T C 9.62E-04 Stroke BAG3 missense pha002887 rs10787989 chr10 121473817 A G 5.44E-06 Magnesium levels / / pha003092 rs196223 chr10 121493752 G A 2.54E-05 Magnesium levels INPP5F intron pha003092 rs1265536 chr10 121538525 A G 7.83E-05 Magnesium levels INPP5F intron pha003092 rs10787993 chr10 121580883 C T 2.71E-05 Blood Pressure INPP5F intron pha003046 rs12785053 chr10 121583965 A G 2.20E-05 Urinary metabolites INPP5F intron 21572414 rs3188055 chr10 121586882 A G 7.03E-05 Cognitive test performance INPP5F missense 20125193 rs7088166 chr10 121601977 C G 3.17E-04 Lymphocyte counts MCMBP intron 22286170 rs2252156 chr10 121631543 G A 2.10E-05 Blood Pressure MCMBP intron pha003046 rs2475298 chr10 121679013 A G 1.32E-05 Cognitive test performance SEC23IP missense 20125193 rs10788000 chr10 121686097 A C 1.10E-06 Urinary metabolites SEC23IP intron 21572414 rs7907207 chr10 121695636 G T 4.58E-05 Blood Pressure SEC23IP intron pha003046 rs3981102 chr10 121701774 T G 2.30E-06 Urinary metabolites SEC23IP UTR-3 21572414 rs10749330 chr10 121711232 T C 9.85E-05 Cognitive test performance / / 20125193 rs10736277 chr10 121715908 T C 3.75E-05 Multiple complex diseases / / 17554300 rs7912574 chr10 121727414 G C 9.27E-05 Multiple complex diseases / / 17554300 rs6650147 chr10 121741746 C G 2.05E-05 Personality dimensions / / 22628180 rs2420656 chr10 121744448 C T 7.32E-04 Multiple complex diseases / / 17554300 rs10788010 chr10 121748671 A G 7.52E-04 Multiple complex diseases / / 17554300 rs2095363 chr10 121750353 A G 5.72E-04 Multiple complex diseases / / 17554300 rs10886559 chr10 121759478 A G 4.41E-04 Multiple complex diseases / / 17554300 rs10886560 chr10 121759608 C T 4.31E-04 Multiple complex diseases / / 17554300 rs2065660 chr10 121764195 C T 9.12E-04 Multiple complex diseases / / 17554300 rs2151888 chr10 121769435 A C 5.95E-04 Multiple complex diseases / / 17554300 rs10749338 chr10 121774205 C T 9.98E-04 Multiple complex diseases / / 17554300 rs4322307 chr10 121777328 G A 3.50E-04 Multiple complex diseases / / 17554300 rs7917670 chr10 121780861 A C 3.21E-04 Multiple complex diseases / / 17554300 rs2225692 chr10 121785471 G A 6.31E-04 Multiple complex diseases / / 17554300 rs2210673 chr10 121785511 T A 4.44E-04 Multiple complex diseases / / 17554300 rs11199152 chr10 121790576 C A 3.16E-05 Post-operative nausea and vomiting / / 21694509 rs10886572 chr10 121790887 C T 6.72E-04 Multiple complex diseases / / 17554300 rs11594689 chr10 121792404 G A 7.26E-05 Cognitive impairment induced by topiramate / / 22091778 rs10886576 chr10 121794372 T C 9.33E-05 Cognitive impairment induced by topiramate / / 22091778 rs4751761 chr10 121796742 G T 9.90E-04 Multiple complex diseases / / 17554300 rs12359805 chr10 121798593 C G 8.76E-04 Multiple complex diseases / / 17554300 rs4288683 chr10 121814553 C T 7.42E-04 Multiple complex diseases / / 17554300 rs4288683 chr10 121814553 C T 8.90E-04 Taste perception / / 22132133 rs10886586 chr10 121819920 A G 7.95E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17621444 chr10 121821538 C T 3.00E-06 IgG glycosylation / / 23382691 rs4751762 chr10 121822578 T C 7.95E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9919356 chr10 121827515 T C 7.86E-04 Response to TNF antagonist treatment / / 21061259 rs9919356 chr10 121827515 T C 4.48E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1577207 chr10 121827835 A T 8.00E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12263787 chr10 121833090 C G 5.14E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2151886 chr10 121834819 C T 5.84E-04 Multiple complex diseases / / 17554300 rs10788034 chr10 121855554 G T 5.14E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1467785 chr10 121859814 T C 8.56E-05 Crohn's disease / / 20570966 rs1929675 chr10 121865185 G T 2.40E-04 Response to antidepressants / / 19736353 rs4611123 chr10 121875531 G A 9.94E-04 Coronary Artery Disease / / 17634449 rs10788038 chr10 121876520 T C 9.45E-08 Birth weight / / 17255346 rs928382 chr10 121881681 C G 3.19E-07 Asthma (childhood onset) / / 23829686 rs4752394 chr10 121906667 C T 7.14E-04 Multiple complex diseases / / 17554300 rs10736285 chr10 121908852 G A 5.86E-04 Multiple complex diseases / / 17554300 rs7076024 chr10 121919707 A G 2.35E-04 Depression (quantitative trait) / / 20800221 rs6585587 chr10 121922404 T A 8.89E-04 Multiple complex diseases / / 17554300 rs7909474 chr10 121927156 G A 6.47E-04 Depression (quantitative trait) / / 20800221 rs3901860 chr10 121931822 A G 3.68E-04 Schizophrenia / / 19197363 rs9633684 chr10 121934910 T C 7.43E-04 Multiple complex diseases / / 17554300 rs7915835 chr10 121940717 C T 3.03E-05 Multiple complex diseases / / 17554300 rs17099753 chr10 121942694 G C 1.49E-04 Depression (quantitative trait) / / 20800221 rs9943309 chr10 121968479 T C 2.31E-05 Cytomegalovirus antibody response / / 21993531 rs12243526 chr10 122008230 C T 2.12E-05 Orofacial clefts / / 22419666 rs12243526 chr10 122008230 C T 1.75E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs12243526 chr10 122008230 C T 4.69E-05 Body Mass Index / / pha003019 rs12243526 chr10 122008230 C T 3.91E-05 Body Mass Index / / pha003022 rs12243526 chr10 122008230 C T 6.14E-05 Waist-Hip Ratio / / pha003029 rs2026959 chr10 122008352 A G 8.26E-05 Orofacial clefts / / 22419666 rs10886648 chr10 122015574 A G 1.12E-05 Orofacial clefts / / 22419666 rs10886648 chr10 122015574 A G 3.76E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs10886648 chr10 122015574 A G 2.69E-05 Body Mass Index / / pha003019 rs10886648 chr10 122015574 A G 2.79E-05 Body Mass Index / / pha003022 rs10886648 chr10 122015574 A G 5.11E-05 Waist-Hip Ratio / / pha003029 rs11199254 chr10 122043489 C T 2.00E-06 IgG glycosylation / / 23382691 rs11199254 chr10 122043489 C T 3.00E-06 IgG glycosylation / / 23382691 rs10886654 chr10 122046508 C A 2.84E-04 Obesity (extreme) / / 21935397 rs7917723 chr10 122046828 C G 2.54E-04 Obesity (extreme) / / 21935397 rs10749367 chr10 122047355 T C 1.09E-04 Obesity (extreme) / / 21935397 rs10510067 chr10 122047475 T C 2.37E-04 Obesity (extreme) / / 21935397 rs10430700 chr10 122049925 G A 1.21E-04 Obesity (extreme) / / 21935397 rs2420694 chr10 122050139 T C 1.24E-04 Obesity (extreme) / / 21935397 rs41526846 chr10 122051957 C T 5.72E-04 Type 2 diabetes / / 17846124 rs11199264 chr10 122057157 A G 4.50E-04 Obesity (extreme) / / 21935397 rs11199266 chr10 122061612 A G 2.08E-04 Obesity (extreme) / / 21935397 rs2901224 chr10 122062871 G A 6.29E-04 Obesity (extreme) / / 21935397 rs10886660 chr10 122063356 A G 5.99E-04 Multiple complex diseases / / 17554300 rs10886660 chr10 122063356 A G 6.36E-04 Obesity (extreme) / / 21935397 rs2420686 chr10 122064580 C T 6.39E-04 Obesity (extreme) / / 21935397 rs2103332 chr10 122065032 G A 6.56E-04 Obesity (extreme) / / 21935397 rs10749368 chr10 122066481 A C,G 2.98E-04 Obesity (extreme) / / 21935397 rs10749368 chr10 122066481 A C,G 7.47E-05 Body Mass Index / / pha003022 rs11199268 chr10 122066549 G A 9.69E-04 Obesity (extreme) / / 21935397 rs2010946 chr10 122067179 A T 3.03E-04 Obesity (extreme) / / 21935397 rs10886662 chr10 122069164 G A 9.65E-04 Obesity (extreme) / / 21935397 rs2420678 chr10 122076765 G A 3.39E-04 Multiple complex diseases / / 17554300 rs12246499 chr10 122085050 C T 9.23E-04 Multiple complex diseases / / 17554300 rs11199279 chr10 122085113 T C 2.04E-04 Multiple complex diseases / / 17554300 rs7068990 chr10 122088912 G A 1.92E-05 Multiple sclerosis / / 17660530 rs2420698 chr10 122095184 T C 7.43E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs2420698 chr10 122095184 T C 7.43E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs10788067 chr10 122095519 A G 6.69E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs10788067 chr10 122095519 A G 6.69E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs10788068 chr10 122102422 T C 5.43E-05 Tuberculosis / / 20694014 rs7900924 chr10 122152296 T C 3.57E-08 Red blood cell traits / / 23222517 rs2148476 chr10 122175555 A T 3.19E-04 Type 2 diabetes / / 17463246 rs2420717 chr10 122175979 A G 1.78E-04 Type 2 diabetes / / 17463246 rs1326663 chr10 122179526 A G 6.83E-04 Type 2 diabetes / / 17463246 rs10886686 chr10 122197211 G A 4.50E-06 Urinary metabolites / / 21572414 rs6585625 chr10 122199895 C A 9.99E-04 Type 2 diabetes / / 17463246 rs2463134 chr10 122203467 G C 1.20E-05 Urinary metabolites / / 21572414 rs10886690 chr10 122213646 G A 8.69E-04 Type 2 diabetes / / 17463246 rs1041168 chr10 122218655 C T 2.22E-04 Type 2 diabetes PPAPDC1A intron 17463246 rs41387648 chr10 122220293 T C 6.85E-04 Multiple complex diseases PPAPDC1A intron 17554300 rs1536389 chr10 122264200 G A 7.99E-05 Orofacial clefts PPAPDC1A intron 22419666 rs1571099 chr10 122266614 C T 2.57E-87 Interventricular septal wall thickness PPAPDC1A intron 23275298 rs17100287 chr10 122267906 G A 0.000714 Salmonella-induced pyroptosis PPAPDC1A intron 22837397 rs118048115 chr10 122279476 A T 6.00E-07 Alzheimer's disease (cognitive decline) PPAPDC1A intron 23535033 rs11199375 chr10 122282340 G A 0.000358 Salmonella-induced pyroptosis PPAPDC1A intron 22837397 rs7910507 chr10 122303500 G A 1.61E-05 stroke (ischemic) PPAPDC1A intron 17434096 rs4752432 chr10 122307101 T C 7.73E-04 Alzheimer's disease PPAPDC1A intron 22005930 rs11199401 chr10 122316317 G T 8.33E-04 Type 2 diabetes PPAPDC1A intron 17463246 rs11199414 chr10 122333429 G T 5.94E-04 Smoking quantity PPAPDC1A intron 24665060 rs12775329 chr10 122345126 G A 0.0006427 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PPAPDC1A intron 23233654 rs12775329 chr10 122345126 G A 6.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) PPAPDC1A intron 23233662 rs11596736 chr10 122345193 C G 0.0006565 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PPAPDC1A intron 23233654 rs11596736 chr10 122345193 C G 6.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) PPAPDC1A intron 23233662 rs11592921 chr10 122345484 A G 0.0007299 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PPAPDC1A intron 23233654 rs11592921 chr10 122345484 A G 7.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) PPAPDC1A intron 23233662 rs2420791 chr10 122345895 G A 0.0007465 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PPAPDC1A intron 23233654 rs2420791 chr10 122345895 G A 7.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) PPAPDC1A intron 23233662 rs11597338 chr10 122346065 C A 0.0007638 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PPAPDC1A intron 23233654 rs11597338 chr10 122346065 C A 7.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) PPAPDC1A intron 23233662 rs10510076 chr10 122384283 T C 3.48E-04 Parkinson's disease / / 16252231 rs11199449 chr10 122389712 T C 1.10E-04 Type 2 diabetes / / 17463246 rs7068008 chr10 122395310 A G 2.61E-05 Bipolar disorder / / 19488044 rs7068008 chr10 122395310 A G 9.91E-05 Bipolar disorder and schizophrenia / / 20889312 rs7068008 chr10 122395310 A G 1.76E-05 Bipolar Disorder / / pha002858 rs7085988 chr10 122411422 G A 9.19E-04 Type 2 diabetes / / 17463246 rs4405228 chr10 122415470 A G 5.62E-05 Multiple complex diseases / / 17554300 rs7069039 chr10 122419869 G A 9.50E-04 Type 2 diabetes / / 17463246 rs11199512 chr10 122481088 C T 2.67E-06 Stroke (ischemic) / / 22941190 rs10510079 chr10 122483111 A T 7.27E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs2997228 chr10 122489318 A G 4.76E-05 Cognitive impairment induced by topiramate / / 22091778 rs2997228 chr10 122489318 A G 5.87E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3011399 chr10 122501487 T C 5.19E-04 Multiple complex diseases / / 17554300 rs3011399 chr10 122501487 T C 1.62E-04 Schizophrenia / / 21674006 rs2997242 chr10 122505008 G C 3.55E-04 Multiple complex diseases / / 17554300 rs3011410 chr10 122505613 G T 1.55E-04 Multiple complex diseases / / 17554300 rs11199530 chr10 122512230 A G 9.65E-05 Suicide attempts in bipolar disorder / / 21041247 rs11199581 chr10 122581396 A C 1.37E-04 Progressive supranuclear palsy LOC283089 intron 21685912 rs10510082 chr10 122582461 G T 2.03E-04 Type 2 diabetes LOC283089 intron 17463246 rs10510082 chr10 122582461 G T 5.57E-04 Insulin resistance LOC283089 intron 21901158 rs1254152 chr10 122582613 G A 1.14E-04 Progressive supranuclear palsy LOC283089 intron 21685912 rs1254152 chr10 122582613 G A 4.80E-06 Hippocampal volume in schizophrenia LOC283089 intron 23805179 rs1254184 chr10 122590550 A G 3.14E-04 Type 2 diabetes LOC283089 intron 17463246 rs2919009 chr10 122591373 C T 3.52E-05 Cognitive performance LOC283089 intron 19734545 rs2919009 chr10 122591373 C T 5.00E-06 Obesity-related traits LOC283089 intron 23251661 rs11199588 chr10 122593020 G A 1.01E-04 Taste perception LOC283089 intron 22132133 rs12360470 chr10 122596231 G A 5.25E-05 Suicide attempts in bipolar disorder LOC283089 intron 21041247 rs12355703 chr10 122599391 G C 5.22E-05 Suicide attempts in bipolar disorder LOC283089 intron 21041247 rs11199590 chr10 122603284 T C 5.76E-05 Suicide attempts in bipolar disorder LOC283089 intron 21041247 rs11199603 chr10 122617341 A G 8.31E-05 Suicide attempts in bipolar disorder WDR11 intron 21041247 rs11199612 chr10 122631105 C T 8.72E-05 Suicide attempts in bipolar disorder WDR11 intron 21041247 rs11199613 chr10 122632418 T C 8.75E-05 Suicide attempts in bipolar disorder WDR11 intron 21041247 rs12355108 chr10 122633421 C T 8.78E-05 Suicide attempts in bipolar disorder WDR11 cds-synon 21041247 rs12355961 chr10 122634987 G A 8.87E-05 Suicide attempts in bipolar disorder WDR11 intron 21041247 rs2289337 chr10 122649482 A G 1.00E-05 Cognitive performance WDR11 cds-synon 19734545 rs11199632 chr10 122655472 C T 9.51E-05 Suicide attempts in bipolar disorder WDR11 intron 21041247 rs12355611 chr10 122656643 A C 9.66E-05 Suicide attempts in bipolar disorder WDR11 intron 21041247 rs10788126 chr10 122657199 A G 1.15E-07 Smoking cessation WDR11 intron 18519826 rs6585674 chr10 122658017 C T 2.55E-05 Smoking cessation WDR11 intron 18519826 rs3740307 chr10 122665459 C G 5.99E-05 Taste perception WDR11 cds-synon 22132133 rs1530116 chr10 122667022 T G 1.10E-04 Smoking cessation WDR11 intron 18519826 rs11199656 chr10 122684548 T C 6.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs12359177 chr10 122688194 G A 1.21E-04 Suicide attempts in bipolar disorder / / 21041247 rs11199659 chr10 122688953 T A 1.21E-04 Suicide attempts in bipolar disorder / / 21041247 rs11199660 chr10 122689412 G A 1.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs11199661 chr10 122689568 G A 1.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs1652728 chr10 122689964 C T 2.93E-05 Coronary heart disease / / pha003055 rs12357022 chr10 122690439 A G 1.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs11199663 chr10 122692104 G A 1.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs12355094 chr10 122698278 C T 1.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs4751815 chr10 122701505 G A 2.40E-05 Height / / 19396169 rs934320 chr10 122704013 C T 4.85E-05 Follicular lymphoma / / 21533074 rs17101184 chr10 122712944 T C 1.10E-05 Urinary metabolites / / 21572414 rs11199677 chr10 122715152 C A 4.75E-05 Suicide attempts in bipolar disorder / / 21041247 rs10788135 chr10 122717207 G A 2.86E-04 Type 2 diabetes / / 17463246 rs10788135 chr10 122717207 G A 1.22E-04 Coronary Artery Disease / / 17634449 rs11815121 chr10 122719834 A G 4.12E-05 Kawasaki disease / / 22081228 rs7906032 chr10 122720309 T C 7.26E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4752485 chr10 122720974 C T 7.00E-06 Pulmonary function decline / / 22424883 rs4752487 chr10 122736421 C T 3.18E-04 Taste perception / / 22132133 rs6585682 chr10 122754609 T C 5.01E-04 QT interval / / 16648850 rs11199696 chr10 122755774 G A 0.0000865 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11199696 chr10 122755774 G A 8.65E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10510086 chr10 122756274 C A 3.31E-05 QT interval / / 16648850 rs17595871 chr10 122759783 G C 0.0001257 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17595871 chr10 122759783 G C 1.26E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11199701 chr10 122767313 A G 0.0001633 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11199701 chr10 122767313 A G 1.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10886837 chr10 122771258 C G 1.70E-05 Urinary metabolites / / 21572414 rs10886837 chr10 122771258 C G 0.0001805 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10886837 chr10 122771258 C G 1.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12412522 chr10 122799926 G A 9.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7907901 chr10 122805269 G C 3.18E-04 Multiple complex diseases / / 17554300 rs7911360 chr10 122805547 G A 7.00E-06 Chronic kidney disease / / 22479191 rs11199746 chr10 122829617 A G 2.40E-05 Atopy / / 21625490 rs10886848 chr10 122841270 C A 1.77E-05 Alcohol and nictotine co-dependence / / 20158304 rs10886849 chr10 122857963 C T 2.81E-05 Atopy / / 21625490 rs2254189 chr10 122874617 C T 7.43E-04 Multiple complex diseases / / 17554300 rs2130779 chr10 122879732 G T 4.90E-06 Coffee consumption / / 21357676 rs2901286 chr10 122900623 C A 4.00E-06 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs1907244 chr10 122901064 A G 3.48E-04 Smoking quantity / / 24665060 rs10510089 chr10 122908219 T C 8.15E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs7077280 chr10 122925371 T C 3.64E-05 Brain structure / / 22504417 rs7085142 chr10 122939374 T C 6.00E-06 Visceral fat / / 22589738 rs3943077 chr10 122945086 A G 3.00E-14 Adiponectin levels / / 24105470 rs10788146 chr10 122952977 T G 4.79E-04 Multiple complex diseases / / 17554300 rs11593067 chr10 122972358 T C 8.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs11199835 chr10 122977157 A G 9.29E-04 Type 2 diabetes / / 17463246 rs4575197 chr10 123032168 G A 4.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs11199874 chr10 123032519 G A 3.00E-10 Prostate cancer / / 22130093 rs10788160 chr10 123033549 G A 5.00E-15 Prostate-specific antigen levels / / 21160077 rs12413088 chr10 123052728 C T 3.00E-06 Prostate-specific antigen levels / / 21160077 rs7085073 chr10 123057268 T C 5.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs7071101 chr10 123057781 A G 2.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs12570783 chr10 123059899 A G 2.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs7085506 chr10 123064139 G C 5.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs4254007 chr10 123081390 A T 9.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs7900630 chr10 123083104 T C 9.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs2420925 chr10 123087186 C T 6.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs4752534 chr10 123088199 C T 5.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs1896420 chr10 123088853 T C 3.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs1896419 chr10 123089079 C A 3.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs4752536 chr10 123092807 A G 1.06E-05 Pulmonary function in asthmatics / / 23541324 rs11199914 chr10 123093901 C T 2.00E-08 Breast cancer / / 23535729 rs11199916 chr10 123094861 A C 1.37E-05 Pulmonary function in asthmatics / / 23541324 rs7089943 chr10 123094884 G A 1.36E-06 Glycemic traits (pregnancy) / / 23903356 rs7913828 chr10 123095255 A G 8.89E-04 Glycemic traits (pregnancy) / / 23903356 rs7895870 chr10 123098249 C T 8.80E-06 Urinary metabolites / / 21572414 rs10886918 chr10 123117653 A G 1.90E-05 Hypertension / / 22384028 rs10886929 chr10 123135724 T C 4.75E-04 White matter integrity / / 22425255 rs9421422 chr10 123154188 C G 4.54E-05 Sarcoidosis / / 19165924 rs2420926 chr10 123188264 T C 5.88E-05 Body Mass Index / / pha003009 rs11199964 chr10 123193998 T C 1.30E-06 Aortic stiffness / / 22068335 rs7084101 chr10 123194255 G A 4.20E-06 Aortic stiffness / / 22068335 rs7911028 chr10 123198286 T G 2.43E-05 Body Mass Index / / pha003009 rs7918550 chr10 123205203 T C 2.97E-04 Multiple complex diseases / / 17554300 rs7902280 chr10 123205281 G A 1.83E-04 Multiple complex diseases / / 17554300 rs11199974 chr10 123214477 T G 8.88E-04 Multiple complex diseases / / 17554300 rs6585737 chr10 123215273 C T 3.74E-06 Esophageal cancer (squamous cell) / / 22960999 rs3135819 chr10 123241122 C G 2.50E-05 Urinary metabolites FGFR2 intron 21572414 rs2912753 chr10 123257402 A C 2.60E-05 Urinary metabolites FGFR2 intron 21572414 rs4752566 chr10 123267631 G T 9.99E-05 ldl cholesterol FGFR2 intron pha003076 rs3135753 chr10 123280658 T C 9.00E-07 Gout FGFR2 intron 23263486 rs11814493 chr10 123317185 T C 3.95E-04 Response to taxane treatment (placlitaxel) FGFR2 intron 23006423 rs2912787 chr10 123325538 T C 1.62E-05 Orofacial clefts FGFR2 intron 19270707 rs3135730 chr10 123325794 T C 9.27E-06 Orofacial clefts FGFR2 intron 19270707 rs4752569 chr10 123331690 A T 3.00E-05 Breast cancer FGFR2 intron 17529967 rs11200012 chr10 123332415 T A 1.00E-04 Breast cancer FGFR2 intron 17529967 rs3750817 chr10 123332577 C T 1.00E-04 Breast cancer FGFR2 intron 17529967 rs3750817 chr10 123332577 C T 8.00E-08 Breast cancer FGFR2 intron 22951594 rs3750817 chr10 123332577 C T 3.39E-16 Breast cancer (early onset) FGFR2 intron 24493630 rs10736303 chr10 123334457 G A 5.00E-14 Breast cancer FGFR2 intron 17529967 rs11200014 chr10 123334930 G A 1.00E-05 Breast cancer FGFR2 intron 17529973 rs11200014 chr10 123334930 G A 4.05E-04 Hemoglobin concentration FGFR2 intron 20534544 rs11200014 chr10 123334930 G A 9.14E-05 Breast cancer FGFR2 intron pha002853 rs2981579 chr10 123337335 A G 5.60E-06 Breast cancer FGFR2 intron 17529973 rs2981579 chr10 123337335 A G 2.00E-10 Breast cancer FGFR2 intron 19330030 rs2981579 chr10 123337335 A G 4.00E-31 Breast cancer FGFR2 intron 20453838 rs2981579 chr10 123337335 A G 2.00E-10 Nasopharyngeal carcinoma FGFR2 intron 20512145 rs2981579 chr10 123337335 A G 2.00E-170 Breast cancer FGFR2 intron 23535729 rs2981579 chr10 123337335 A G 0.0000072 Breast cancer FGFR2 intron 23555315 rs2981579 chr10 123337335 A G 0.00015 Breast cancer (ER positive) FGFR2 intron 23555315 rs2981579 chr10 123337335 A G 4.36E-05 Breast cancer FGFR2 intron pha002853 rs17542768 chr10 123337814 A G 1.00E-04 Breast cancer FGFR2 intron 17529967 rs1078806 chr10 123338975 A G 1.65E-04 Multiple complex diseases FGFR2 intron 17554300 rs1078806 chr10 123338975 A G 2.00E-06 Breast cancer FGFR2 intron 23354978 rs2981578 chr10 123340311 C T 1.00E-15 Breast cancer FGFR2 intron 17529967 rs2981578 chr10 123340311 C T 7.39E-05 Endometrial cancer FGFR2 intron 24096698 rs2981578 chr10 123340311 C T 7.42E-05 Endometrial cancer FGFR2 intron 24096698 rs2981578 chr10 123340311 C T 1.00E-12 Breast cancer FGFR2 intron 24143190 rs4752571 chr10 123342567 T C 1.00E-05 Breast cancer FGFR2 intron 17529967 rs2981575 chr10 123346116 G A 9.00E-16 Breast cancer FGFR2 intron 17529967 rs2981575 chr10 123346116 G A 1.00E-08 Breast cancer in BRCA2 mutation carriers FGFR2 intron 21060860 rs2981575 chr10 123346116 G A 0.00001 Breast cancer FGFR2 intron 23555315 rs2981575 chr10 123346116 G A 0.00013 Breast cancer (ER positive) FGFR2 intron 23555315 rs1219648 chr10 123346190 A G 1.00E-10 Breast cancer FGFR2 intron 17529973 rs1219648 chr10 123346190 A G 1.00E-10 Nasopharyngeal carcinoma FGFR2 intron 20512145 rs1219648 chr10 123346190 A G 2.00E-13 Breast cancer FGFR2 intron 20872241 rs1219648 chr10 123346190 A G 1.00E-30 Breast cancer FGFR2 intron 21263130 rs1219648 chr10 123346190 A G 0.000014 Breast cancer FGFR2 intron 23555315 rs1219648 chr10 123346190 A G 0.00011 Breast cancer (ER positive) FGFR2 intron 23555315 rs1219648 chr10 123346190 A G 9.85E-06 Breast cancer FGFR2 intron 24143190 rs1219648 chr10 123346190 A G 1.34E-05 Breast cancer FGFR2 intron pha002853 rs1219642 chr10 123348389 T C 3.00E-16 Breast cancer FGFR2 intron 17529967 rs2912774 chr10 123348662 T G 3.00E-15 Breast cancer FGFR2 intron 17529967 rs2912774 chr10 123348662 T G 3.00E-27 Breast cancer (early onset) FGFR2 intron 24493630 rs2936870 chr10 123348902 T C 5.00E-15 Breast cancer FGFR2 intron 17529967 rs17102287 chr10 123350191 T C 1.00E-04 Breast cancer FGFR2 intron 17529967 rs17102287 chr10 123350191 T C 3.05E-09 Breast cancer (early onset) FGFR2 intron 24493630 rs2420946 chr10 123351324 T C 5.00E-16 Breast cancer FGFR2 intron 17529967 rs2420946 chr10 123351324 T C 2.00E-10 Breast cancer FGFR2 intron 17529973 rs2420946 chr10 123351324 T C 1.74E-05 Breast cancer FGFR2 intron pha002853 rs2981582 chr10 123352317 A G 2.00E-76 Breast cancer FGFR2 intron 17529967 rs2981582 chr10 123352317 A G 2.00E-76 Nasopharyngeal carcinoma FGFR2 intron 20512145 rs2981582 chr10 123352317 A G 0.000081 Breast cancer FGFR2 intron 23555315 rs3135718 chr10 123353869 C T 7.00E-05 Breast cancer FGFR2 intron 17529967 rs3135715 chr10 123354726 T G 8.20E-04 Multiple complex diseases FGFR2 intron 17554300 rs1649181 chr10 123375856 C T 6.56E-04 Multiple complex diseases / / 17554300 rs11200051 chr10 123402175 G A 9.72E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10749423 chr10 123405021 A T 7.60E-04 Multiple complex diseases / / 17554300 rs7906816 chr10 123412399 A G 2.89E-04 Alzheimer's disease / / 22005930 rs11200059 chr10 123415590 T C 6.81E-05 Cleft lip / / 20436469 rs2936853 chr10 123422004 T C 7.42E-04 Alzheimer's disease / / 22005930 rs1696803 chr10 123436950 T C 2.25E-06 Primary nonsyndromic vesicoureteric reflex / / 19959718 rs2935718 chr10 123437453 C T 8.56E-05 stroke (ischemic) / / 17434096 rs10788197 chr10 123452085 G A 1.46E-05 stroke (ischemic) / / 17434096 rs4751848 chr10 123456270 G A 2.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1219504 chr10 123460141 A G 3.52E-04 Multiple complex diseases / / 17554300 rs4752586 chr10 123468677 C A 6.40E-05 Parkinson's disease (familial) / / 18985386 rs2935689 chr10 123486626 G T 7.19E-06 Rheumatoid arthritis / / 17804836 rs11200107 chr10 123488039 C T 2.40E-05 Urinary metabolites / / 21572414 rs2936875 chr10 123491643 T G 9.05E-05 Prostate cancer / / 22923026 rs1693669 chr10 123498222 G A 5.52E-06 Lipid traits / / 21777205 rs4751855 chr10 123540315 T C 2.26E-04 Multiple complex diseases ATE1 intron 17554300 rs2132911 chr10 123552966 C T 7.46E-05 Coronary Artery Disease ATE1 intron 17634449 rs7078196 chr10 123589267 G T 7.10E-06 Urinary metabolites ATE1 intron 21572414 rs4486560 chr10 123604355 G A 1.40E-05 Urinary metabolites ATE1 intron 21572414 rs6585765 chr10 123606502 G A 4.71E-04 Response to taxane treatment (placlitaxel) ATE1 intron 23006423 rs7092052 chr10 123615028 A G 1.59E-05 Duodenal ulcer ATE1 intron 22387998 rs10510103 chr10 123624510 T C 3.30E-04 Heart Failure ATE1 intron pha002885 rs10510102 chr10 123625190 T C 2.00E-06 Breast cancer ATE1 intron 21263130 rs4429006 chr10 123626578 A G 1.59E-05 Duodenal ulcer ATE1 intron 22387998 rs10732824 chr10 123654025 A G 9.70E-06 Urinary metabolites ATE1 intron 21572414 rs11200240 chr10 123662780 C T 1.70E-04 Type 2 diabetes ATE1 intron 17463246 rs11200240 chr10 123662780 C T 8.24E-04 Multiple complex diseases ATE1 intron 17554300 rs11200251 chr10 123673206 C T 9.86E-04 Acute lung injury ATE1 intron 22295056 rs10749435 chr10 123673339 T C 1.50E-05 Duodenal ulcer / / 22387998 rs7914615 chr10 123685227 A C 9.30E-04 Suicide attempts in bipolar disorder ATE1 intron 21423239 rs4752630 chr10 123750955 C G 3.04E-04 Alzheimer's disease TACC2 intron 17998437 rs12762668 chr10 123766854 G A 6.10E-06 Urinary metabolites TACC2 intron 21572414 rs10887040 chr10 123767296 A G 2.20E-06 Urinary metabolites TACC2 intron 21572414 rs10887040 chr10 123767296 A G 3.61E-04 Age-related macular degeneration TACC2 intron 22125219 rs11200324 chr10 123769514 C T 5.01E-04 Alzheimer's disease TACC2 intron 17998437 rs12571870 chr10 123771303 C A 8.26E-04 Type 2 diabetes TACC2 intron 17463246 rs11596204 chr10 123782413 C T 1.21E-04 Alzheimer's disease TACC2 intron 24755620 rs2459068 chr10 123795293 T G 1.03E-04 Alzheimer's disease TACC2 intron 24755620 rs2459069 chr10 123795611 C G 2.29E-06 Hirschsprung's disease TACC2 intron 19196962 rs10887056 chr10 123800550 A G 3.79E-04 Response to cytadine analogues (cytosine arabinoside) TACC2 intron 24483146 rs2459091 chr10 123819539 C T 2.29E-04 Alzheimer's disease TACC2 intron 17998437 rs11200392 chr10 123851827 C T 3.00E-06 Obesity-related traits TACC2 intron 23251661 rs2420993 chr10 123857029 T G 1.20E-05 Urinary metabolites TACC2 intron 21572414 rs17103093 chr10 123887925 A G 9.33E-04 Multiple complex diseases TACC2 intron 17554300 rs1113263 chr10 123889001 C G 2.75E-04 Lung function (forced expiratory volume in 1 second) TACC2 intron 17255346 rs17638681 chr10 123908811 T C 5.77E-05 Tunica Media TACC2 intron pha003034 rs7078373 chr10 123911345 T C 5.20E-04 Prostate cancer mortality TACC2 intron 20978177 rs7078373 chr10 123911345 T C 8.30E-06 Urinary metabolites TACC2 intron 21572414 rs4752659 chr10 123911886 C A 4.76E-04 Rheumatoid arthritis TACC2 intron 21452313 rs4752662 chr10 123912338 G A 8.94E-05 Parkinson's disease TACC2 intron 16252231 rs17103138 chr10 123913330 T C 3.44E-05 Meningococcal disease TACC2 intron 20694013 rs17103138 chr10 123913330 T C 2.00E-07 Myopia (pathological) TACC2 intron 23049088 rs10788255 chr10 123927299 C T 3.74E-04 Smoking cessation TACC2 intron 24665060 rs11200450 chr10 123931300 C G 9.62E-04 Type 2 diabetes TACC2 intron 17463246 rs1923449 chr10 123934456 C A 6.90E-08 Urinary metabolites TACC2 intron 21572414 rs7078370 chr10 123937461 A C 1.71E-04 Response to platinum-based chemotherapy in small-cell lung cancer TACC2 intron 20463552 rs4752666 chr10 123948200 A G 8.53E-04 Multiple complex diseases TACC2 intron 17554300 rs10887101 chr10 123958805 T C 2.27E-04 Multiple complex diseases TACC2 intron 17554300 rs6585804 chr10 123980108 G A 5.33E-06 Hearing function TACC2 intron 21493956 rs11592039 chr10 123980945 T C 8.56E-04 Response to TNF antagonist treatment TACC2 intron 21061259 rs1548270 chr10 123993909 T C 9.11E-05 Multiple complex diseases TACC2 intron 17554300 rs1555488 chr10 123994498 T A 9.44E-04 Response to TNF antagonist treatment TACC2 intron 21061259 rs10887108 chr10 124000331 G A 4.59E-06 Serum metabolites TACC2 intron 19043545 rs11200497 chr10 124001794 T C 2.56E-05 Amyotrophic Lateral Sclerosis TACC2 intron 17827064 rs911783 chr10 124007108 A T 3.45E-06 Serum metabolites TACC2 intron 19043545 rs10510106 chr10 124009293 A G 4.10E-06 Serum metabolites TACC2 intron 19043545 rs7086990 chr10 124009670 C G 8.01E-06 Serum metabolites TACC2 intron 19043545 rs7078328 chr10 124029259 T C 7.93E-04 Multiple complex diseases / / 17554300 rs10510107 chr10 124029471 A G 6.65E-04 Multiple complex diseases / / 17554300 rs7893461 chr10 124035694 G T 1.92E-06 Age-related macular degeneration BTBD16 intron pha002869 rs7893461 chr10 124035694 G T 1.65E-06 Age-related macular degeneration BTBD16 intron pha002890 rs6585810 chr10 124041447 A G 3.78E-05 Amyotrophic lateral sclerosis (sporadic) BTBD16 intron 24529757 rs11200528 chr10 124042994 A G 7.94E-04 Multiple complex diseases BTBD16 intron 17554300 rs1028631 chr10 124044674 A G 5.23E-05 Age-related macular degeneration BTBD16 intron pha002890 rs911774 chr10 124045887 A G 8.90E-05 Age-related macular degeneration BTBD16 intron pha002890 rs11592545 chr10 124050575 G A 3.95E-04 Lung function (forced expiratory volume in 1 second) BTBD16 intron 17255346 rs7907952 chr10 124056774 A G 1.51E-05 Age-related macular degeneration BTBD16 intron pha002890 rs10788275 chr10 124061501 C T 3.74E-04 Amyotrophic Lateral Sclerosis BTBD16 intron 17827064 rs1022782 chr10 124068634 T C 6.28E-04 Multiple complex diseases BTBD16 intron 17554300 rs10887122 chr10 124071345 C T 6.10E-04 Multiple complex diseases BTBD16 intron 17554300 rs10887131 chr10 124093199 G C 3.12E-05 Suicide attempts in bipolar disorder BTBD16 intron 21041247 rs10887132 chr10 124093273 T C 3.10E-05 Suicide attempts in bipolar disorder BTBD16 intron 21041247 rs3817285 chr10 124096306 T C 5.21E-10 Age-related macular degeneration BTBD16 intron pha002869 rs3817285 chr10 124096306 T C 4.13E-09 Age-related macular degeneration BTBD16 intron pha002890 rs11200559 chr10 124097427 G T 8.33E-05 Alcoholism BTBD16 intron pha002893 rs7091160 chr10 124103876 G A 1.81E-05 Age-related macular degeneration / / pha002890 rs6585818 chr10 124104924 A G 1.92E-05 Age-related macular degeneration / / pha002890 rs11598094 chr10 124107045 T C 5.64E-07 Age-related macular degeneration / / pha002869 rs11598094 chr10 124107045 T C 2.21E-06 Age-related macular degeneration / / pha002890 rs10887142 chr10 124107484 G A 1.46E-10 Age-related macular degeneration / / 23577725 rs10887142 chr10 124107484 G A 7.22E-11 Age-related macular degeneration (extreme sampling) / / 23577725 rs11200576 chr10 124117550 A T 2.60E-09 Age-related macular degeneration / / 23326517 rs10510109 chr10 124120457 G T 0.000649 Asthma / / 22502797 rs10510109 chr10 124120457 G T 1.05E-07 Age-related macular degeneration (extreme sampling) / / 23577725 rs7080960 chr10 124122632 T C 5.76E-12 Age-related macular degeneration / / pha002869 rs7080960 chr10 124122632 T C 4.24E-11 Age-related macular degeneration / / pha002890 rs7097844 chr10 124123270 C T 8.44E-04 Acute lung injury / / 22295056 rs11200583 chr10 124123470 A C 2.10E-09 Age-related macular degeneration / / 23326517 rs11200583 chr10 124123470 A C 5.76E-16 Age-related macular degeneration / / pha002869 rs11200583 chr10 124123470 A C 8.67E-16 Age-related macular degeneration / / pha002890 rs4751889 chr10 124132188 T C 2.30E-08 Age-related macular degeneration PLEKHA1 nearGene-5 23326517 rs4751889 chr10 124132188 T C 2.26E-15 Age-related macular degeneration PLEKHA1 nearGene-5 pha002869 rs4751889 chr10 124132188 T C 1.73E-14 Age-related macular degeneration PLEKHA1 nearGene-5 pha002890 rs10749466 chr10 124138804 A G 0.00016 Asthma PLEKHA1 intron 22502797 rs10749466 chr10 124138804 A G 1.30E-08 Age-related macular degeneration (extreme sampling) PLEKHA1 intron 23577725 rs10749466 chr10 124138804 A G 6.13E-08 Age-related macular degeneration PLEKHA1 intron 23577725 rs11200594 chr10 124139393 C T 1.40E-09 Age-related macular degeneration PLEKHA1 intron 23326517 rs11200595 chr10 124142629 T C 1.50E-09 Age-related macular degeneration PLEKHA1 intron 23326517 rs7084349 chr10 124145140 G A 2.90E-08 Age-related macular degeneration PLEKHA1 intron 23326517 rs7068487 chr10 124145212 C T 0.000275 Asthma PLEKHA1 intron 22502797 rs7068487 chr10 124145212 C T 3.00E-08 Age-related macular degeneration PLEKHA1 intron 23326517 rs7068487 chr10 124145212 C T 4.01E-08 Age-related macular degeneration PLEKHA1 intron 23577725 rs7068487 chr10 124145212 C T 7.00E-09 Age-related macular degeneration (extreme sampling) PLEKHA1 intron 23577725 rs7902176 chr10 124146691 A T 3.20E-08 Age-related macular degeneration PLEKHA1 intron 23326517 rs11200604 chr10 124147639 G A 1.50E-09 Age-related macular degeneration PLEKHA1 intron 23326517 rs2421017 chr10 124148167 A G 2.00E-09 Age-related macular degeneration PLEKHA1 intron 23326517 rs2421018 chr10 124148264 A G 3.10E-08 Age-related macular degeneration PLEKHA1 intron 23326517 rs7088058 chr10 124149352 C T 0.000177 Asthma PLEKHA1 intron 22502797 rs7088058 chr10 124149352 C T 3.10E-08 Age-related macular degeneration PLEKHA1 intron 23326517 rs7088058 chr10 124149352 C T 1.26E-08 Age-related macular degeneration PLEKHA1 intron 23577725 rs7088058 chr10 124149352 C T 3.23E-09 Age-related macular degeneration (extreme sampling) PLEKHA1 intron 23577725 rs10788284 chr10 124149917 T C 2.00E-09 Age-related macular degeneration PLEKHA1 intron 23326517 rs2421019 chr10 124150586 C T 3.10E-08 Age-related macular degeneration PLEKHA1 intron 23326517 rs2421020 chr10 124150962 G C 4.60E-08 Age-related macular degeneration PLEKHA1 intron 23326517 rs17103488 chr10 124154169 T C 4.46E-04 Suicide attempts in bipolar disorder PLEKHA1 intron 21041247 rs17103488 chr10 124154169 T C 1.80E-09 Age-related macular degeneration PLEKHA1 intron 23326517 rs4146894 chr10 124155381 C T 2.50E-09 Age-related macular degeneration PLEKHA1 intron 23326517 rs4565845 chr10 124159050 A C 2.60E-05 Age-related macular degeneration PLEKHA1 intron 20861866 rs4565845 chr10 124159050 A C 4.40E-04 Suicide attempts in bipolar disorder PLEKHA1 intron 21041247 rs4565845 chr10 124159050 A C 1.90E-09 Age-related macular degeneration PLEKHA1 intron 23326517 rs8181474 chr10 124160581 G A 4.50E-08 Age-related macular degeneration PLEKHA1 intron 23326517 rs4751890 chr10 124161791 T C 0.00025 Glomerular filtration rate PLEKHA1 intron 22962313 rs4751890 chr10 124161791 T C 4.80E-08 Age-related macular degeneration PLEKHA1 intron 23326517 rs4751890 chr10 124161791 T C 2.15E-16 Age-related macular degeneration PLEKHA1 intron pha002869 rs4751890 chr10 124161791 T C 1.61E-15 Age-related macular degeneration PLEKHA1 intron pha002890 rs6585827 chr10 124165615 G A 2.00E-06 Height PLEKHA1 intron 20189936 rs6585827 chr10 124165615 G A 6.41E-07 Celiac disease and Rheumatoid arthritis PLEKHA1 intron 21383967 rs6585827 chr10 124165615 G A 3.20E-09 Age-related macular degeneration PLEKHA1 intron 23326517 rs6585827 chr10 124165615 G A 1.42E-23 Age-related macular degeneration PLEKHA1 intron pha002869 rs6585827 chr10 124165615 G A 1.12E-21 Age-related macular degeneration PLEKHA1 intron pha002890 rs10887149 chr10 124167004 G A 0.000888 Asthma PLEKHA1 intron 22502797 rs10887149 chr10 124167004 G A 7.76E-07 Age-related macular degeneration (extreme sampling) PLEKHA1 intron 23577725 rs10887149 chr10 124167004 G A 2.25E-05 Reading disability and language impairment PLEKHA1 intron 24024963 rs2421016 chr10 124167512 C T 0.00000356 Asthma PLEKHA1 intron 22502797 rs2421016 chr10 124167512 C T 3.00E-09 Age-related macular degeneration PLEKHA1 intron 23326517 rs2421016 chr10 124167512 C T 1.93E-11 Age-related macular degeneration (extreme sampling) PLEKHA1 intron 23577725 rs2421016 chr10 124167512 C T 8.88E-12 Age-related macular degeneration PLEKHA1 intron 23577725 rs2421016 chr10 124167512 C T 1.10E-07 Type 2 diabetes PLEKHA1 intron 24509480 rs7097701 chr10 124171857 T C 2.70E-09 Age-related macular degeneration PLEKHA1 intron 23326517 rs7079976 chr10 124172108 A G 2.70E-09 Age-related macular degeneration PLEKHA1 intron 23326517 rs4612730 chr10 124176452 G A 7.30E-09 Age-related macular degeneration PLEKHA1 intron 23326517 rs17103522 chr10 124177879 T C 4.32E-04 Suicide attempts in bipolar disorder PLEKHA1 intron 21041247 rs17103522 chr10 124177879 T C 1.50E-09 Age-related macular degeneration PLEKHA1 intron 23326517 rs4311997 chr10 124179299 C T 2.90E-09 Age-related macular degeneration PLEKHA1 intron 23326517 rs10887150 chr10 124180578 C A 2.90E-09 Age-related macular degeneration PLEKHA1 intron 23326517 rs10887151 chr10 124180766 C T 2.90E-09 Age-related macular degeneration PLEKHA1 intron 23326517 rs2292626 chr10 124186714 C T 3.00E-09 Age-related macular degeneration PLEKHA1 intron 23326517 rs1045216 chr10 124189197 A G 3.10E-08 Age-related macular degeneration PLEKHA1 missense 23326517 rs17103541 chr10 124190121 A G 3.16E-05 Multiple complex diseases PLEKHA1 UTR-3 17554300 rs10510110 chr10 124192430 T C 0.0000517 Asthma / / 22502797 rs10510110 chr10 124192430 T C 2.60E-09 Age-related macular degeneration / / 23326517 rs10510110 chr10 124192430 T C 1.31E-10 Age-related macular degeneration (extreme sampling) / / 23577725 rs10510110 chr10 124192430 T C 1.84E-10 Age-related macular degeneration / / 23577725 rs10510110 chr10 124192430 T C 1.00E-07 Type 2 diabetes / / 24509480 rs2280141 chr10 124193181 T G 8.26E-07 Celiac disease and Rheumatoid arthritis / / 21383967 rs2280141 chr10 124193181 T G 0.0000461 Asthma / / 22502797 rs2280141 chr10 124193181 T G 2.70E-09 Age-related macular degeneration / / 23326517 rs2280141 chr10 124193181 T G 1.07E-10 Age-related macular degeneration (extreme sampling) / / 23577725 rs2280141 chr10 124193181 T G 1.36E-10 Age-related macular degeneration / / 23577725 rs2280141 chr10 124193181 T G 1.37E-23 Age-related macular degeneration / / pha002869 rs2280141 chr10 124193181 T G 1.06E-21 Age-related macular degeneration / / pha002890 rs7072204 chr10 124195485 A G 3.30E-11 Age-related macular degeneration / / 23326517 rs11200629 chr10 124198585 A G 2.80E-09 Age-related macular degeneration / / 23326517 rs2292627 chr10 124201665 T G 2.80E-09 Age-related macular degeneration / / 23326517 rs2292627 chr10 124201665 T G 1.51E-12 Age-related macular degeneration (extreme sampling) / / 23577725 rs2292627 chr10 124201665 T G 3.04E-12 Age-related macular degeneration / / 23577725 rs2292627 chr10 124201665 T G 4.68E-18 Age-related macular degeneration / / pha002869 rs2292627 chr10 124201665 T G 2.68E-17 Age-related macular degeneration / / pha002890 rs1882907 chr10 124208399 T C 6.27E-06 Age-related macular degeneration / / pha002869 rs1882907 chr10 124208399 T C 4.02E-06 Age-related macular degeneration / / pha002890 rs2223089 chr10 124210160 G C 9.70E-05 White matter hyperintensity burden / / 21681796 rs10490922 chr10 124214034 A T 3.71E-04 Multiple complex diseases ARMS2 nearGene-5 17554300 rs2736911 chr10 124214355 C T 1.03E-05 Lymphocyte counts ARMS2 STOP-GAIN 22286170 rs10490924 chr10 124214448 G T 4.08E-12 Age-related macular degeneration (wet) ARMS2 missense 17053108 rs10490924 chr10 124214448 G T 1.80E-05 Bone mass and geometry ARMS2 missense 17903296 rs10490924 chr10 124214448 G T 5.00E-119 Age-related macular degeneration ARMS2 missense 20385826 rs10490924 chr10 124214448 G T 1.00E-60 Age-related macular degeneration ARMS2 missense 20861866 rs10490924 chr10 124214448 G T 4E-322 Age-related macular degeneration ARMS2 missense 21665990 rs10490924 chr10 124214448 G T 8.67E-29 Age-related macular degeneration ARMS2 missense 21909106 rs10490924 chr10 124214448 G T 3.00E-72 Age-related macular degeneration ARMS2 missense 22694956 rs10490924 chr10 124214448 G T 2.00E-138 Age-related macular degeneration (CNV) ARMS2 missense 22705344 rs10490924 chr10 124214448 G T 7.00E-14 Age-related macular degeneration (CNV vs. GA) ARMS2 missense 22705344 rs10490924 chr10 124214448 G T 7.00E-47 Age-related macular degeneration (GA) ARMS2 missense 22705344 rs10490924 chr10 124214448 G T 9.10E-24 Age-related macular degeneration ARMS2 missense 23326517 rs10490924 chr10 124214448 G T 4E-540 Age-related macular degeneration ARMS2 missense 23455636 rs10490924 chr10 124214448 G T 4.55E-29 Age-related macular degeneration (extreme sampling) ARMS2 missense 23577725 rs10490924 chr10 124214448 G T 8.00E-27 Age-related macular degeneration ARMS2 missense 23577725 rs10490924 chr10 124214448 G T 9.55E-15 Age-related macular degeneration ARMS2 missense pha000002 rs17623531 chr10 124214921 C T 4.08E-04 Multiple complex diseases ARMS2 intron 17554300 rs3750848 chr10 124215315 T G 9.40E-24 Age-related macular degeneration ARMS2 intron 23326517 rs3750848 chr10 124215315 T G 1.45E-26 Age-related macular degeneration ARMS2 intron 23577725 rs3750848 chr10 124215315 T G 3.00E-29 Age-related macular degeneration (extreme sampling) ARMS2 intron 23577725 rs3750847 chr10 124215421 C T 1.66E-06 Age-related macular degeneration ARMS2 intron 22125219 rs3750847 chr10 124215421 C T 9.50E-24 Age-related macular degeneration ARMS2 intron 23326517 rs2014307 chr10 124217632 T G 4.50E-07 Age-related macular degeneration / / 20861866 rs2014307 chr10 124217632 T G 7.48E-08 Age-related macular degeneration / / 21197116 rs2014307 chr10 124217632 T G 4.35E-08 Age-related macular degeneration / / pha000001 rs2014307 chr10 124217632 T G 5.43E-07 Age-related macular degeneration / / pha002856 rs2014307 chr10 124217632 T G 1.48E-23 Age-related macular degeneration / / pha002869 rs2014307 chr10 124217632 T G 4.49E-21 Age-related macular degeneration / / pha002890 rs3793917 chr10 124219275 C G 4.00E-60 Age-related macular degeneration HTRA1 nearGene-5 20385819 rs3793917 chr10 124219275 C G 1.00E-25 Age-related macular degeneration HTRA1 nearGene-5 23326517 rs3793917 chr10 124219275 C G 4.00E-24 Age-related macular degeneration HTRA1 nearGene-5 23326517 rs3793917 chr10 124219275 C G 0.00081 Breast cancer HTRA1 nearGene-5 23555315 rs11200638 chr10 124220544 G A 8.00E-12 Age-related macular degeneration (wet) HTRA1 nearGene-5 17053108 rs2248799 chr10 124223944 C T 7.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HTRA1 intron 20877124 rs2248799 chr10 124223944 C T 3.36E-12 Age-related macular degeneration HTRA1 intron 23577725 rs2248799 chr10 124223944 C T 8.95E-16 Age-related macular degeneration (extreme sampling) HTRA1 intron 23577725 rs2248799 chr10 124223944 C T 2.92E-32 Age-related macular degeneration HTRA1 intron pha002869 rs2248799 chr10 124223944 C T 1.89E-28 Age-related macular degeneration HTRA1 intron pha002890 rs2249049 chr10 124226215 A G 2.70E-05 Urinary metabolites HTRA1 intron 21572414 rs2284665 chr10 124226630 G T 4.75E-28 Age-related macular degeneration (extreme sampling) HTRA1 intron 23577725 rs2284665 chr10 124226630 G T 7.95E-26 Age-related macular degeneration HTRA1 intron 23577725 rs932275 chr10 124231464 G A 3.58E-06 Age-related macular degeneration HTRA1 intron 22125219 rs932275 chr10 124231464 G A 9.70E-23 Age-related macular degeneration HTRA1 intron 23326517 rs4752699 chr10 124234320 G A 8.45E-05 Age-related macular degeneration HTRA1 intron pha002890 rs7093894 chr10 124234880 C A 3.08E-04 Multiple complex diseases HTRA1 intron 17554300 rs17696741 chr10 124235059 G A 4.91E-04 Multiple complex diseases HTRA1 intron 17554300 rs2672588 chr10 124235296 T C 5.39E-05 Alzheimer's disease (late onset) HTRA1 intron 21379329 rs2672587 chr10 124235355 G C 1.30E-17 Age-related macular degeneration HTRA1 intron 23326517 rs2672587 chr10 124235355 G C 3.10E-19 Age-related macular degeneration HTRA1 intron 23577725 rs2672587 chr10 124235355 G C 3.17E-20 Age-related macular degeneration (extreme sampling) HTRA1 intron 23577725 rs4752700 chr10 124237612 A G 2.70E-10 Age-related macular degeneration HTRA1 intron pha002869 rs4752700 chr10 124237612 A G 1.40E-08 Age-related macular degeneration HTRA1 intron pha002890 rs2284666 chr10 124240785 C T 9.47E-04 HIV-1 viral setpoint HTRA1 intron 17641165 rs2284666 chr10 124240785 C T 2.88E-04 Suicide attempts in bipolar disorder HTRA1 intron 21423239 rs2284666 chr10 124240785 C T 1.47E-05 Age-related macular degeneration HTRA1 intron pha002890 rs574413177 chr10 124240785 CT C 9.47E-04 HIV-1 viral setpoint HTRA1 intron 17641165 rs574413177 chr10 124240785 CT C 2.88E-04 Suicide attempts in bipolar disorder HTRA1 intron 21423239 rs574413177 chr10 124240785 CT C 1.47E-05 Age-related macular degeneration HTRA1 intron pha002890 rs2284668 chr10 124240852 T C 3.50E-04 Suicide attempts in bipolar disorder HTRA1 intron 21423239 rs2253755 chr10 124241557 A G 1.50E-08 Age-related macular degeneration HTRA1 intron 23326517 rs2253755 chr10 124241557 A G 3.13E-09 Age-related macular degeneration HTRA1 intron 23577725 rs2253755 chr10 124241557 A G 4.12E-08 Age-related macular degeneration (extreme sampling) HTRA1 intron 23577725 rs11200649 chr10 124241847 C T 3.17E-04 Suicide attempts in bipolar disorder HTRA1 intron 21423239 rs2300431 chr10 124242817 G A 1.14E-08 Age-related macular degeneration HTRA1 intron pha002869 rs2300431 chr10 124242817 G A 1.74E-08 Age-related macular degeneration HTRA1 intron pha002890 rs2300432 chr10 124243189 T C 2.79E-04 Suicide attempts in bipolar disorder HTRA1 intron 21423239 rs2268344 chr10 124244969 T C 2.94E-04 Suicide attempts in bipolar disorder HTRA1 intron 21423239 rs2268345 chr10 124245483 G T 2.59E-04 Suicide attempts in bipolar disorder HTRA1 intron 21423239 rs878107 chr10 124245867 T C 2.82E-04 Suicide attempts in bipolar disorder HTRA1 intron 21423239 rs11200651 chr10 124246002 A G 2.67E-04 Suicide attempts in bipolar disorder HTRA1 intron 21423239 rs2247541 chr10 124260739 C T 1.78E-04 Sudden cardiac arrest HTRA1 intron 21658281 rs763720 chr10 124262444 G A 3.53E-12 Age-related macular degeneration HTRA1 intron pha002869 rs763720 chr10 124262444 G A 2.29E-11 Age-related macular degeneration HTRA1 intron pha002890 rs2268356 chr10 124265326 C T 9.18E-04 Multiple complex diseases HTRA1 intron 17554300 rs7902878 chr10 124288724 G A 9.49E-06 Age-related macular degeneration / / pha002890 rs3013215 chr10 124294174 C A 8.06E-05 Bipolar disorder,affective / / 20528957 rs4752712 chr10 124393339 G A 0.0000941 Sarcoidosis DMBT1 intron 22952805 rs7921534 chr10 124414739 C G 2.80E-05 Urinary metabolites / / 21572414 rs2421031 chr10 124422108 T C 4.62E-04 Anorexia nervosa / / 23568457 rs2177831 chr10 124431063 G A 3.76E-05 Nephrolithiasis / / 22396660 rs4980250 chr10 124456562 C T 5.96E-05 Nephrolithiasis / / 22396660 rs1917847 chr10 124470089 A C 6.10E-05 Body mass index / / 24827717 rs10902851 chr10 124481043 T C 7.67E-05 Post-operative nausea and vomiting / / 21694509 rs2901344 chr10 124488143 T C 6.30E-06 Nephrolithiasis / / 22396660 rs17104017 chr10 124491040 G A 6.69E-06 Nephrolithiasis / / 22396660 rs13376724 chr10 124504595 A G 5.80E-06 Urinary metabolites / / 21572414 rs13376724 chr10 124504595 A G 1.57E-06 Nephrolithiasis / / 22396660 rs4980182 chr10 124506648 A C 9.84E-06 Nephrolithiasis / / 22396660 rs947260 chr10 124528930 C T 4.30E-14 Metabolite levels FLJ46361 intron 22286219 rs11248601 chr10 124544811 C T 7.31E-05 Multiple complex diseases / / 17554300 rs7896663 chr10 124548859 C T 6.11E-04 Multiple complex diseases FLJ46361 intron 17554300 rs7895725 chr10 124575373 T C 8.22E-04 Schizophrenia / / 19197363 rs7915165 chr10 124660458 G A 1.47E-04 Celiac disease / / 23936387 rs7921647 chr10 124671655 C T 1.30E-04 Celiac disease FAM24A intron 23936387 rs11248332 chr10 124676335 T C 1.46E-04 Celiac disease / / 23936387 rs2421162 chr10 124680929 C A 1.46E-04 Celiac disease / / 23936387 rs17653439 chr10 124690291 G A 7.50E-04 Alcohol dependence / / 20201924 rs17653439 chr10 124690291 G A 8.90E-04 Alcohol dependence / / 20201924 rs4980169 chr10 124692586 A G 2.00E-04 Cognitive impairment induced by topiramate C10orf88 intron 22091778 rs4980169 chr10 124692586 A G 9.56E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) C10orf88 intron 23648065 rs12268329 chr10 124720263 T G 7.79E-04 Type 2 diabetes / / 17463246 rs7069346 chr10 124729876 T A 3.00E-06 Migraine without aura / / 23793025 rs9423236 chr10 124734152 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs113921892 chr10 124748926 C T 0.00007768 Sarcoidosis PSTK intron 22952805 rs3736580 chr10 124749965 C T 1.26E-04 Intraocular pressure / / 23836780 rs13353058 chr10 124750722 A G 4.78E-07 Hypertension / / 21082022 rs9423302 chr10 124753060 G A 4.25E-04 Intraocular pressure / / 23836780 rs9328842 chr10 124765857 T C 6.63E-05 Sarcoidosis IKZF5 intron 19165924 rs1898462 chr10 124811466 C T 2.88E-04 White matter integrity ACADSB intron 22425255 rs1898463 chr10 124819217 C T 5.82E-05 White matter integrity / / 22425255 rs7919446 chr10 124823991 C T 1.46E-05 White matter integrity / / 22425255 rs4980248 chr10 124827165 C A 7.61E-05 White matter integrity / / 22425255 rs10902873 chr10 124836815 G A 5.76E-05 White matter integrity / / 22425255 rs11248389 chr10 124850994 T C 6.76E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17104648 chr10 124869903 C G 3.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs17104653 chr10 124873444 C G 3.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs10794595 chr10 124881502 T C 4.33E-06 Nicotine smoking / / 19268276 rs61862032 chr10 124887125 T C 9.00E-06 Periodontitis (Mean PAL) / / 24024966 rs10751752 chr10 124887244 C T 4.25E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17104692 chr10 124891137 C T 3.05E-04 Myopia (pathological) / / 21095009 rs2495774 chr10 124932086 C A 1.10E-04 Type 2 diabetes / / 17460697 rs10902886 chr10 124936077 A G 7.82E-04 Type 2 diabetes / / 17463246 rs4980268 chr10 124941951 A G 3.62E-04 Type 2 diabetes / / 17463246 rs4980270 chr10 124951379 C T 9.77E-05 Amyotrophic lateral sclerosis / / 20801717 rs12784903 chr10 124956180 G A 0.000000771 VLDL cholesterol particle diameter / / 23263444 rs11248439 chr10 124956706 A G 0.00000106 VLDL cholesterol particle diameter / / 23263444 rs11248440 chr10 124957154 G A 0.00000233 VLDL cholesterol particle diameter / / 23263444 rs2495767 chr10 124958574 T C 4.69E-04 Alzheimer's disease (late onset) / / 21379329 rs11248442 chr10 124959614 C T 1.58E-05 Alzheimer's disease (late onset) / / 21379329 rs11248442 chr10 124959614 C T 0.000000488 VLDL cholesterol particle diameter / / 23263444 rs2421177 chr10 124960383 C T 0.000000538 VLDL cholesterol particle diameter / / 23263444 rs10902900 chr10 124964919 C A 0.00000436 VLDL cholesterol particle diameter / / 23263444 rs9423256 chr10 124966517 A G 4.50E-05 Soluble levels of adhesion molecules / / pha003072 rs1114742 chr10 124967595 A G 0.000000498 VLDL cholesterol particle diameter / / 23263444 rs10902901 chr10 124967722 G A 0.00000507 VLDL cholesterol particle diameter / / 23263444 rs12763035 chr10 124967778 T G 0.000000387 VLDL cholesterol particle diameter / / 23263444 rs752920 chr10 124972035 T A 0.0000049 VLDL cholesterol particle diameter / / 23263444 rs17663304 chr10 124973104 T C 1.03E-04 Alzheimer's disease (late onset) / / 21379329 rs17663304 chr10 124973104 T C 0.0000119 VLDL cholesterol particle diameter / / 23263444 rs11248451 chr10 124973893 G A,T 5.96E-04 Multiple complex diseases / / 17554300 rs11248451 chr10 124973893 G A,T 0.000000169 VLDL cholesterol particle diameter / / 23263444 rs10902902 chr10 124974017 C A 0.0000117 VLDL cholesterol particle diameter / / 23263444 rs10902903 chr10 124975939 T G 0.0000117 VLDL cholesterol particle diameter / / 23263444 rs10902904 chr10 124976696 G A 0.0000117 VLDL cholesterol particle diameter / / 23263444 rs11248455 chr10 124977157 C T 0.000000286 VLDL cholesterol particle diameter / / 23263444 rs11248456 chr10 124978379 G A 1.24E-05 Alzheimer's disease (late onset) / / 21379329 rs11248456 chr10 124978379 G A 0.000000286 VLDL cholesterol particle diameter / / 23263444 rs12356367 chr10 124978881 C T 0.0000116 VLDL cholesterol particle diameter / / 23263444 rs7083581 chr10 124979929 A G 0.0000111 VLDL cholesterol particle diameter / / 23263444 rs17663410 chr10 124980896 C T 0.000000163 VLDL cholesterol particle diameter / / 23263444 rs10902906 chr10 124981330 A T 0.0000116 VLDL cholesterol particle diameter / / 23263444 rs10902907 chr10 124982500 C T 1.78E-04 Alzheimer's disease (late onset) / / 21379329 rs10902907 chr10 124982500 C T 0.00000965 VLDL cholesterol particle diameter / / 23263444 rs11597068 chr10 124988153 A G 1.00E-07 Menopause (age at onset) / / 24045676 rs12773354 chr10 124993940 C T 8.95E-04 Alcohol dependence / / 21314694 rs10902911 chr10 124994243 A G 2.57E-04 Alzheimer's disease / / 22005930 rs34048663 chr10 124995307 AG A 5.28E-04 Coronary heart disease / / 21606135 rs6599671 chr10 124995307 A G 5.28E-04 Coronary heart disease / / 21606135 rs11248472 chr10 124999294 T C 7.69E-04 White matter integrity / / 22425255 rs10510126 chr10 125002485 C T 7.10E-07 Breast cancer / / 17529973 rs10510126 chr10 125002485 C T 1.35E-04 Alzheimer's disease / / 22005930 rs10510126 chr10 125002485 C T 2.57E-06 Breast cancer / / pha002853 rs17663924 chr10 125003770 C A 9.93E-04 Alzheimer's disease / / 22005930 rs17663978 chr10 125005193 C T 9.71E-04 Alzheimer's disease / / 22005930 rs17663978 chr10 125005193 C T 4.84E-05 Breast cancer / / pha002853 rs11248473 chr10 125005268 C T 9.59E-04 Alzheimer's disease / / 22005930 rs4980271 chr10 125015706 C A 5.32E-04 Coronary heart disease / / 21606135 rs7916600 chr10 125031183 C T 7.53E-04 Alzheimer's disease / / 22005930 rs7916600 chr10 125031183 C T 1.16E-04 Breast cancer / / pha002853 rs7916610 chr10 125031206 C T 5.91E-04 Alzheimer's disease / / 22005930 rs11248481 chr10 125039016 C G 2.59E-04 Birth weight / / 17255346 rs10902920 chr10 125043537 G A 1.43E-04 Multiple complex diseases / / 17554300 rs11595707 chr10 125045846 A G 2.99E-04 Birth weight / / 17255346 rs17104935 chr10 125046630 G A 4.54E-04 Alzheimer's disease / / 22005930 rs17104938 chr10 125046980 G A 2.30E-04 Alzheimer's disease / / 22005930 rs11248490 chr10 125057297 G A 2.64E-04 Multiple complex diseases / / 17554300 rs11593744 chr10 125057319 G A 1.99E-04 Birth weight / / 17255346 rs11593744 chr10 125057319 G A 2.61E-04 Multiple complex diseases / / 17554300 rs7918922 chr10 125058270 A G 4.79E-04 Multiple complex diseases / / 17554300 rs7091930 chr10 125082162 A T 5.23E-04 Multiple complex diseases / / 17554300 rs913524 chr10 125084639 G A 5.52E-04 Multiple complex diseases / / 17554300 rs4980190 chr10 125086064 C T 4.14E-04 Multiple complex diseases / / 17554300 rs17588065 chr10 125086471 C T 3.68E-04 Birth weight / / 17255346 rs17588065 chr10 125086471 C T 2.04E-04 Multiple complex diseases / / 17554300 rs7908317 chr10 125087397 C T 5.22E-04 Multiple complex diseases / / 17554300 rs12572353 chr10 125087580 T C 4.06E-04 Type 2 diabetes / / 17463246 rs4508144 chr10 125088282 A G 4.73E-04 Multiple complex diseases / / 17554300 rs11248496 chr10 125090399 T C 9.60E-04 Multiple complex diseases / / 17554300 rs6599688 chr10 125098566 A G 8.52E-04 Multiple complex diseases / / 17554300 rs11248499 chr10 125100531 G T 9.49E-04 Multiple complex diseases / / 17554300 rs11593654 chr10 125114667 C T 3.96E-04 Birth weight / / 17255346 rs7894765 chr10 125125151 A G 1.29E-04 Multiple complex diseases / / 17554300 rs7894765 chr10 125125151 A G 6.43E-05 Waist Circumference / / pha003023 rs12264884 chr10 125130306 G A 3.31E-04 Birth weight / / 17255346 rs1328600 chr10 125160933 C A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11248521 chr10 125174371 A T 8.31E-04 Multiple complex diseases / / 17554300 rs845104 chr10 125182983 A T 7.22E-04 Nicotine dependence / / 17158188 rs943879 chr10 125199524 C T 6.20E-06 Urinary metabolites / / 21572414 rs12242236 chr10 125206483 C T 2.46E-05 Orofacial clefts / / 22419666 rs17666963 chr10 125207501 C T 9.00E-06 Cardiac Troponin-T levels / / 23247143 rs845086 chr10 125213800 A C 9.80E-06 Diabetic nephropathy / / 20347642 rs705137 chr10 125215290 G A 9.16E-04 White matter integrity / / 22425255 rs2282015 chr10 125222037 T G 8.00E-10 Venous thromboembolism (gene x gene interaction) / / 23509962 rs845080 chr10 125225057 C T 4.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs705159 chr10 125233053 G A 4.86E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7921636 chr10 125238487 C G 1.50E-05 Urinary metabolites / / 21572414 rs705162 chr10 125251675 G A 1.71E-04 Migraine - clinic-based / / 23793025 rs705162 chr10 125251675 G A 1.99E-05 Migraine without aura / / 23793025 rs705162 chr10 125251675 G A 3.00E-06 Migraine / / 23793025 rs10902935 chr10 125258337 T G 6.10E-06 Blood Pressure / / pha003039 rs17105399 chr10 125259919 A G 2.76E-04 Aortic root size / / 21223598 rs7897598 chr10 125260923 A C 6.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1627852 chr10 125265804 C T 1.70E-05 Tunica Media / / pha003036 rs10902940 chr10 125274226 G A 6.33E-04 Alzheimer's disease / / 17998437 rs1974283 chr10 125308282 A G 7.70E-05 Serum metabolites / / 19043545 rs7908279 chr10 125310660 T C 5.24E-04 Type 2 diabetes / / 17463246 rs2459348 chr10 125320304 A G 3.87E-04 Multiple complex diseases / / 17554300 rs10510133 chr10 125346991 G T 5.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1623484 chr10 125348194 A G 4.28E-04 Smoking initiation / / 24665060 rs17606668 chr10 125371138 C A 9.21E-05 Longevity / / 20304771 rs6599708 chr10 125372707 C T 9.96E-04 Parkinson's disease / / 17052657 rs6599708 chr10 125372707 C T 9.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1219800 chr10 125397907 G A 1.83E-04 Multiple complex diseases / / 17554300 rs705185 chr10 125407194 G A 4.81E-04 Alzheimer's disease / / 22005930 rs10794629 chr10 125450492 A T 2.70E-05 Urinary metabolites GPR26 UTR-3 21572414 rs4980201 chr10 125463571 C T 5.69E-04 Multiple complex diseases / / 17554300 rs4980202 chr10 125463604 A C 2.14E-04 Type 2 diabetes / / 17463246 rs732712 chr10 125466915 C T 2.55E-04 Multiple complex diseases / / 17554300 rs11248245 chr10 125469612 G A 8.81E-05 Type 2 diabetes / / 17463246 rs2362962 chr10 125483540 T A 8.69E-04 Type 2 diabetes / / 17463246 rs2362962 chr10 125483540 T A 3.09E-04 Multiple complex diseases / / 17554300 rs1896384 chr10 125486119 C T 3.65E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12358957 chr10 125487915 C T 3.75E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1863735 chr10 125488140 G A 6.24E-05 Major depressive disorder / / 19107115 rs8181355 chr10 125491860 G A 1.86E-04 IgE levels / / 17255346 rs1955107 chr10 125492465 G C 3.72E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11248268 chr10 125500587 A G 1.36E-04 IgE levels / / 17255346 rs727416 chr10 125530746 C T 1.50E-05 Urinary metabolites CPXM2 intron 21572414 rs1219713 chr10 125541494 G A 9.44E-04 Type 2 diabetes CPXM2 intron 17463246 rs7909921 chr10 125564742 A T 6.37E-04 Alzheimer's disease CPXM2 intron 22005930 rs7913161 chr10 125564900 A G 5.63E-04 Alzheimer's disease CPXM2 intron 22005930 rs8181453 chr10 125575939 G A 7.45E-04 Alzheimer's disease CPXM2 intron 22005930 rs1219705 chr10 125585034 G A 4.11E-06 Cognitive decline CPXM2 intron 23732972 rs1219704 chr10 125585163 G A 3.05E-05 Cognitive decline CPXM2 intron 23732972 rs7902258 chr10 125587730 A T 7.40E-05 Suicide attempts in bipolar disorder CPXM2 intron 21423239 rs11248292 chr10 125590186 T C 6.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CPXM2 intron 20877124 rs7900253 chr10 125599464 A G 1.47E-05 Cognitive decline CPXM2 intron 23732972 rs2176488 chr10 125601148 G C 2.48E-05 Cognitive decline CPXM2 intron 23732972 rs7920094 chr10 125608590 T C 2.48E-05 Cognitive decline CPXM2 intron 23732972 rs6599627 chr10 125609811 T C 1.49E-05 Cognitive decline CPXM2 intron 23732972 rs7067790 chr10 125677037 G C 6.37E-27 Multiple complex diseases / / 17554300 rs1914533 chr10 125681274 T G 1.84E-04 Celiac disease / / 23936387 rs7919381 chr10 125702371 T C 9.03E-05 Aging (time to event) / / 21782286 rs3934463 chr10 125728064 G A 2.82E-04 Multiple complex diseases / / 17554300 rs3934463 chr10 125728064 G A 7.26E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7394262 chr10 125741845 A G 6.35E-04 Multiple complex diseases / / 17554300 rs7067701 chr10 125772419 C G 1.37E-04 Multiple complex diseases CHST15 intron 17554300 rs4929821 chr10 125824450 C T 2.87E-04 Migraine CHST15 intron 23793025 rs11245116 chr10 125921963 A G 7.68E-04 Alzheimer's disease / / 17998437 rs7905355 chr10 125924595 A G 1.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11245493 chr10 126003837 T C 8.28E-04 Body mass index / / 21701565 rs11245493 chr10 126003837 T C 2.57E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11244450 chr10 126036778 C T 2.14E-04 Atopy / / 21094521 rs11244450 chr10 126036778 C T 6.50E-06 Atopy / / 21094521 rs1105778 chr10 126053047 C T 3.31E-05 Coronary heart disease / / pha003030 rs2674329 chr10 126054197 C A 5.92E-04 Smoking quantity / / 24665060 rs2361610 chr10 126056539 G A 7.11E-04 Multiple complex diseases / / 17554300 rs12218361 chr10 126070149 A G 6.15E-06 Schizophrenia / / 20832056 rs870209 chr10 126073849 C T 0.0000757 post-traumatic stress disorder / / 22869035 rs870209 chr10 126073849 C T 7.57E-05 Schizophrenia / / 22883433 rs9422807 chr10 126093991 T C 3.21E-04 Type 2 diabetes OAT intron 17463246 rs1710563 chr10 126128552 T C 6.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1710563 chr10 126128552 T C 1.33E-05 HIV-1 viral setpoint / / 22174851 rs2459210 chr10 126144179 A C 9.00E-06 Hemostatic factors and hematological phenotypes / / 22443383 rs908366 chr10 126144839 C T 7.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs4315021 chr10 126175039 T C 3.06E-05 Cholesterol LHPP intron pha003083 rs7090933 chr10 126192376 A G 4.00E-05 Prostate cancer LHPP intron 21743057 rs11245267 chr10 126219694 T C 8.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LHPP intron 20877124 rs11245268 chr10 126220647 C T 1.90E-05 Urinary metabolites LHPP intron 21572414 rs7922543 chr10 126220834 T G 2.40E-05 Urinary metabolites LHPP intron 21572414 rs12265012 chr10 126224704 C T 6.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LHPP intron 20877124 rs1869660 chr10 126227537 A G 7.52E-05 Hemoglobin LHPP intron pha003096 rs2085175 chr10 126241886 T C 9.15E-05 Type 2 diabetes LHPP intron 17463246 rs11245291 chr10 126248607 A C 2.20E-05 Urinary metabolites LHPP intron 21572414 rs10794150 chr10 126258034 G A 2.60E-05 Urinary metabolites LHPP intron 21572414 rs10794152 chr10 126258162 C T 2.90E-05 Urinary metabolites LHPP intron 21572414 rs12269470 chr10 126260223 T C 7.08E-04 Type 2 diabetes LHPP intron 17463246 rs12269470 chr10 126260223 T C 8.14E-05 Height LHPP intron pha003010 rs12264692 chr10 126260246 C T 7.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LHPP intron 20877124 rs12260583 chr10 126260613 G A 7.02E-04 Type 2 diabetes LHPP intron 17463246 rs12260583 chr10 126260613 G A 7.52E-05 Height LHPP intron pha003010 rs4962651 chr10 126261541 A G 9.57E-04 Response to taxane treatment (placlitaxel) LHPP intron 23006423 rs4962653 chr10 126262395 A G 9.04E-04 Response to taxane treatment (placlitaxel) LHPP intron 23006423 rs17152064 chr10 126267759 C T 5.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LHPP intron 20877124 rs17152064 chr10 126267759 C T 0.00000736 Nicotine dependence (smoking) LHPP intron 23643383 rs12773846 chr10 126275914 G A 7.00E-06 Subcutaneous adipose tissue LHPP intron 22589738 rs12773846 chr10 126275914 G A 1.30E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) LHPP intron 23648065 rs11595762 chr10 126278458 G T 7.82E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LHPP intron 20877124 rs10430737 chr10 126278648 T C 8.00E-05 Major depressive disorder LHPP intron 19107115 rs942014 chr10 126290070 G A 1.60E-05 Urinary metabolites LHPP intron 21572414 rs3740540 chr10 126294167 G A 5.00E-06 Obesity-related traits LHPP intron 23251661 rs7076268 chr10 126338444 C T 1.60E-05 Malaria FAM53B intron 19465909 rs3781458 chr10 126343931 C T 0.00000427 Alcohol dependence FAM53B intron 23691058 rs1006368 chr10 126346603 C T 5.00E-07 Central corneal thickness FAM53B intron 20485516 rs3781452 chr10 126355129 C T 0.00000686 Alcohol dependence FAM53B intron 23691058 rs4962397 chr10 126359100 C A 9.06E-04 Alzheimer's disease FAM53B intron 24755620 rs10901803 chr10 126362648 C G 6.47E-04 Multiple complex diseases FAM53B intron 17554300 rs4962398 chr10 126375196 G T 3.79E-04 Alzheimer's disease FAM53B intron 17998437 rs11245330 chr10 126380338 G A 4.60E-07 Central corneal thickness FAM53B intron 20485516 rs4962686 chr10 126399566 T C 7.30E-05 Malaria FAM53B intron 19465909 rs17624662 chr10 126408146 A C 3.21E-05 Body Mass Index FAM53B intron pha003022 rs10901809 chr10 126410804 C T 9.76E-06 Personality dimensions FAM53B intron 23658558 rs4962692 chr10 126424823 G A 1.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM53B intron 20877124 rs2629540 chr10 126426148 G C 1.00E-06 Cocaine dependence FAM53B intron 23958962 rs2629540 chr10 126426148 G C 1.38E-06 Cocaine dependence FAM53B intron 23958962 rs2629540 chr10 126426148 G C 4.00E-08 Cocaine dependence FAM53B intron 23958962 rs2629540 chr10 126426148 G C 4.28E-08 Cocaine dependence FAM53B intron 23958962 rs10510138 chr10 126438019 C T 8.00E-06 Obesity-related traits / / 23251661 rs12570348 chr10 126438963 G T 1.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2306702 chr10 126446473 A C 7.64E-06 Obesity-related traits / / 23251661 rs10901827 chr10 126505969 T G 1.35E-04 Parkinson's disease FAM175B intron 17052657 rs10901827 chr10 126505969 T G 7.70E-07 Central corneal thickness FAM175B intron 20485516 rs11245376 chr10 126508069 C T 2.98E-04 Insulin resistance FAM175B intron 21901158 rs7914368 chr10 126569993 C T 1.94E-04 Celiac disease / / 23936387 rs11245405 chr10 126572654 T C 6.51E-04 Acute lung injury / / 22295056 rs11245406 chr10 126572672 T C 3.90E-04 Acute lung injury / / 22295056 rs11245407 chr10 126572693 T C 2.08E-04 Acute lung injury / / 22295056 rs10901833 chr10 126572728 A G 2.82E-04 Acute lung injury / / 22295056 rs12355063 chr10 126572860 G C 1.63E-04 Acute lung injury / / 22295056 rs12247671 chr10 126575210 G A 1.63E-04 Acute lung injury / / 22295056 rs7923382 chr10 126576503 T C 1.63E-04 Acute lung injury / / 22295056 rs7900929 chr10 126584999 A C 1.88E-04 Multiple complex diseases / / 17554300 rs17152346 chr10 126585066 A C 5.38E-04 Multiple complex diseases / / 17554300 rs7086128 chr10 126587373 A G 2.51E-04 Multiple complex diseases / / 17554300 rs7086128 chr10 126587373 A G 4.63E-05 Bipolar disorder and schizophrenia / / 20889312 rs7083336 chr10 126590771 T C 5.31E-05 Fibrinogen / / pha003068 rs17152377 chr10 126592852 T G 6.18E-05 Fibrinogen / / pha003068 rs4962708 chr10 126617169 T C 2.03E-06 Prostate cancer / / 18264096 rs10901838 chr10 126623542 A C 7.14E-05 Intelligence / / 21826061 rs2114835 chr10 126630557 C T 2.04E-17 Lymphocyte counts / / 22286170 rs17152402 chr10 126641872 A G 1.13E-04 Multiple complex diseases ZRANB1 intron 17554300 rs4962711 chr10 126644482 T C 3.37E-05 Brain structure ZRANB1 intron 22504417 rs17152408 chr10 126649007 G A 7.80E-04 Multiple complex diseases ZRANB1 intron 17554300 rs11245446 chr10 126650696 A G 1.22E-06 Prostate cancer ZRANB1 intron 18264096 rs4246208 chr10 126654898 C T 2.61E-05 Brain structure ZRANB1 intron 22504417 rs17152433 chr10 126670356 G A 5.63E-05 Fibrinogen ZRANB1 cds-synon pha003068 rs11596226 chr10 126675365 T G 8.19E-05 Alcohol dependence ZRANB1 UTR-3 21314694 rs12243975 chr10 126688047 T C 1.58E-05 Personality dimensions CTBP2 intron 22628180 rs4962413 chr10 126689398 T C 2.38E-04 Smoking initiation CTBP2 intron 24665060 rs3781436 chr10 126695269 C T 3.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CTBP2 intron 20877124 rs1561589 chr10 126695673 G A 6.86E-05 Prostate cancer CTBP2 intron 18264096 rs3781433 chr10 126695847 G A 5.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CTBP2 intron 20877124 rs4962416 chr10 126696872 T C 2.00E-07 Prostate cancer CTBP2 intron 18264096 rs4962416 chr10 126696872 T C 5.50E-04 Alcohol dependence CTBP2 intron 20201924 rs4962416 chr10 126696872 T C 2.00E-07 Nasopharyngeal carcinoma CTBP2 intron 20512145 rs4962416 chr10 126696872 T C 6.76E-05 Prostate cancer CTBP2 intron pha002877 rs7077275 chr10 126697210 T C 1.65E-06 Prostate cancer CTBP2 intron 18264096 rs11245462 chr10 126697962 A G 8.96E-04 Alzheimer's disease CTBP2 intron 17998437 rs12781214 chr10 126702049 C T 5.50E-04 Alcohol dependence CTBP2 intron 20201924 rs11595908 chr10 126706676 C T 8.59E-04 Alcohol dependence CTBP2 intron 21314694 rs35728204 chr10 126712694 C T 0.0000833 Nonsyndromic striae distensae (stretch marks) CTBP2 intron 23633020 rs2949368 chr10 126726080 T C 2.20E-05 Urinary metabolites CTBP2 intron 21572414 rs2949368 chr10 126726080 T C 3.81E-05 Odorant perception CTBP2 intron 23910658 rs3012063 chr10 126732932 C T 3.85E-04 Alzheimer's disease CTBP2 intron 17998437 rs11245482 chr10 126733546 T C 7.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CTBP2 intron 20877124 rs2936540 chr10 126747542 C A 2.95E-04 Hemoglobin concentration CTBP2 intron 20534544 rs2936540 chr10 126747542 C A 7.50E-05 Blood Pressure CTBP2 intron pha003046 rs3889706 chr10 126761534 C T 6.42E-04 Obesity (extreme) CTBP2 intron 21935397 rs12761801 chr10 126772981 C T 3.91E-07 Alcohol and nictotine co-dependence CTBP2 intron 20158304 rs12761801 chr10 126772981 C T 7.89E-07 Alcohol and nictotine co-dependence CTBP2 intron 20158304 rs11245496 chr10 126773746 A G 1.40E-06 Urinary metabolites CTBP2 intron 21572414 rs1152659 chr10 126776488 A G 8.56E-05 Hemoglobin CTBP2 intron pha003098 rs1152661 chr10 126777042 C T 2.50E-05 Urinary metabolites CTBP2 intron 21572414 rs1996667 chr10 126785827 G A 4.50E-04 Depression (quantitative trait) CTBP2 intron 20800221 rs1152684 chr10 126787770 G C 8.60E-06 Urinary metabolites CTBP2 intron 21572414 rs744451 chr10 126792365 C T 1.70E-06 Urinary metabolites CTBP2 intron 21572414 rs913165 chr10 126793086 T C 7.80E-07 Urinary metabolites CTBP2 intron 21572414 rs1152699 chr10 126808031 T C 6.51E-04 White matter integrity CTBP2 intron 22425255 rs1254698 chr10 126811672 T C 4.03E-04 Type 2 diabetes CTBP2 intron 17463246 rs6597883 chr10 126837944 T C 7.16E-04 Response to taxane treatment (placlitaxel) CTBP2 intron 23006423 rs1715859 chr10 126844847 T C 1.81E-04 Insulin resistance CTBP2 intron 21901158 rs11245533 chr10 126863721 C T 1.51E-04 Body mass index / / 17255346 rs1693665 chr10 126873203 C G 3.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs1715869 chr10 126875920 A G 8.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs1693661 chr10 126878751 G A 7.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs17152730 chr10 126911566 T C 2.52E-06 Asthma (childhood onset) / / 23829686 rs17152738 chr10 126914896 C T 4.94E-04 Coronary heart disease / / 21971053 rs9422860 chr10 126916123 G A 7.37E-04 Multiple complex diseases / / 17554300 rs3851566 chr10 126981173 A G 7.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1471228 chr10 127076503 T C 1.29E-04 Stroke / / pha002887 rs17725710 chr10 127081682 A G 8.29E-05 Major depressive disorder / / 21621269 rs17725710 chr10 127081682 A G 4.00E-05 Major depressive disorder / / pha002850 rs17152891 chr10 127087265 T C 7.46E-04 Multiple complex diseases / / 17554300 rs6597703 chr10 127097031 A C 6.18E-05 Major depressive disorder / / 21621269 rs6597703 chr10 127097031 A C 1.78E-05 Major depressive disorder / / pha002850 rs7897813 chr10 127115598 G A 8.42E-05 Neutrophil count / / pha003095 rs7896776 chr10 127118333 T C 8.26E-05 Neutrophil count / / pha003095 rs769160 chr10 127133264 G C 6.12E-05 Migraine / / 23793025 rs989507 chr10 127135838 T C 2.00E-06 Obesity-related traits / / 23251661 rs10510143 chr10 127155823 T G 2.11E-04 Smoking cessation / / 24665060 rs10901382 chr10 127165979 G A 7.10E-05 White matter hyperintensity burden / / 21681796 rs10793998 chr10 127166504 A G 6.50E-05 White matter hyperintensity burden / / 21681796 rs11244514 chr10 127171394 C A 6.30E-05 White matter hyperintensity burden / / 21681796 rs7068573 chr10 127172816 G T 5.30E-05 White matter hyperintensity burden / / 21681796 rs10901384 chr10 127173642 A G 5.20E-05 White matter hyperintensity burden / / 21681796 rs10793999 chr10 127174084 G C 5.20E-05 White matter hyperintensity burden / / 21681796 rs4962461 chr10 127175202 A G 4.60E-05 White matter hyperintensity burden / / 21681796 rs4962462 chr10 127175276 G A 4.60E-05 White matter hyperintensity burden / / 21681796 rs11244517 chr10 127176891 A T 5.70E-05 White matter hyperintensity burden / / 21681796 rs7897631 chr10 127176961 A G 5.70E-05 White matter hyperintensity burden / / 21681796 rs10794002 chr10 127177966 T C 5.60E-05 White matter hyperintensity burden / / 21681796 rs10901385 chr10 127178315 T C 5.70E-05 White matter hyperintensity burden / / 21681796 rs10794003 chr10 127178487 C T 5.70E-05 White matter hyperintensity burden / / 21681796 rs10510144 chr10 127179847 G A 5.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11244519 chr10 127182267 T C 6.50E-05 White matter hyperintensity burden / / 21681796 rs9422889 chr10 127195639 G A 4.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs9422892 chr10 127200863 G A 4.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs9422893 chr10 127204167 G T 4.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs3952616 chr10 127208244 G A 4.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs6597713 chr10 127215932 T C 4.00E-04 Premature ovarian failure / / 19508998 rs7350425 chr10 127218286 C G 7.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs10511206 chr10 127219375 C T 2.40E-05 Breast cancer and prostate cancer / / 17903305 rs748001 chr10 127220601 C T 4.55E-08 Transmission distortion / / 22377632 rs17654476 chr10 127221732 A G 8.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs11244543 chr10 127236574 C T 5.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs11244546 chr10 127241221 A G 6.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs11244547 chr10 127241477 G T 8.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs4962473 chr10 127243627 T C 6.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs11244557 chr10 127248552 A C 6.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs11244559 chr10 127249877 G T 6.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs12777662 chr10 127250034 A G 6.69E-05 Aging (time to event) / / 21782286 rs11244562 chr10 127252997 C T 9.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs7084502 chr10 127258691 G A 8.53E-07 Post-operative nausea and vomiting / / 21694509 rs17153200 chr10 127262447 G A 8.76E-04 Multiple complex diseases / / 17554300 rs11244568 chr10 127265374 T C 0.000782 Salmonella-induced pyroptosis LOC100169752 intron 22837397 rs17153249 chr10 127288290 C T 9.03E-07 Schizophrenia / / 21926974 rs9422897 chr10 127296145 G A,C,T 7.00E-06 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs9422897 chr10 127296145 G A,C,T 7.00E-06 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12254965 chr10 127297038 A G 6.43E-04 Coronary heart disease / / 21606135 rs7075103 chr10 127309825 G A,C,T 3.61E-05 Multiple complex diseases / / 17554300 rs10901411 chr10 127325562 T C 7.84E-05 Coronary heart disease / / pha003032 rs9422913 chr10 127345607 C T 9.89E-05 Male fertility C10orf122 intron 22633400 rs10794012 chr10 127349999 A C 9.67E-05 Coronary heart disease C10orf122 intron pha003032 rs9422915 chr10 127350486 C G 7.36E-04 Multiple complex diseases C10orf122 missense 17554300 rs7895499 chr10 127356109 C T 2.17E-04 Multiple complex diseases C10orf122 intron 17554300 rs9422789 chr10 127356378 T C 1.56E-06 Multiple complex diseases C10orf122 intron 17554300 rs17153404 chr10 127375863 G C 5.29E-04 Coronary heart disease LOC283038 intron 21606135 rs6597720 chr10 127385304 A G 6.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC283038 intron 20877124 rs1471666 chr10 127386603 A T 6.01E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LOC283038 intron 20031582 rs7909932 chr10 127400433 G A 3.05E-04 Alzheimer's disease (late onset) FLJ37035 intron 21379329 rs11244624 chr10 127410627 T C 1.99E-04 Response to statin treatment (atorvastatin),change in cholesterol levels C10orf137 intron 20031582 rs2170643 chr10 127465348 T C 7.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10901450 chr10 127509294 G C 2.26E-12 Lymphocyte counts UROS intron 22286170 rs7320 chr10 127525072 A C 4.51E-04 Taste perception DHX32 UTR-3 22132133 rs3781058 chr10 127528267 T C 6.43E-04 Taste perception DHX32 intron 22132133 rs12356233 chr10 127534930 A G 9.93E-05 Body Mass Index DHX32 intron pha003007 rs12356233 chr10 127534930 A G 3.67E-05 Waist Circumference DHX32 intron pha003025 rs12356233 chr10 127534930 A G 7.47E-05 Coronary heart disease DHX32 intron pha003031 rs7070013 chr10 127626702 C T 4.70E-05 Waist Circumference FANK1 intron pha003025 rs12573823 chr10 127640167 C T 3.62E-05 Waist Circumference FANK1 intron pha003025 rs4403725 chr10 127642276 A G 6.75E-05 Waist Circumference FANK1 intron pha003025 rs4403725 chr10 127642276 A G 1.98E-05 Coronary heart disease FANK1 intron pha003031 rs10901476 chr10 127642617 A G 4.63E-04 Taste perception FANK1 intron 22132133 rs7907300 chr10 127656067 A G 7.42E-04 Multiple complex diseases FANK1 intron 17554300 rs7907300 chr10 127656067 A G 3.80E-05 Waist Circumference FANK1 intron pha003025 rs17153882 chr10 127668854 G C 5.00E-05 Bipolar disorder FANK1 missense 19488044 rs17153882 chr10 127668854 G C 2.91E-05 Bipolar Disorder FANK1 missense pha002858 rs10901513 chr10 127699936 T C 6.00E-06 Visceral fat / / 22589738 rs11244777 chr10 127719213 A G 2.96E-05 Gaucher disease severity ADAM12 intron 22388998 rs11244778 chr10 127722122 T C 3.63E-05 Serum metabolites ADAM12 intron 19043545 rs7920091 chr10 127722422 A G 8.43E-05 Serum metabolites ADAM12 intron 19043545 rs7920091 chr10 127722422 A G 1.11E-05 Gaucher disease severity ADAM12 intron 22388998 rs4732 chr10 127730144 T A 4.97E-04 Type 2 diabetes ADAM12 UTR-3 17463246 rs7920207 chr10 127731309 C A 1.94E-04 Smoking cessation ADAM12 intron 18519826 rs3816602 chr10 127734329 T C 5.76E-04 Multiple complex diseases ADAM12 intron 17554300 rs12765977 chr10 127736306 G A 9.90E-05 Serum metabolites ADAM12 intron 19043545 rs2292692 chr10 127737930 G A 6.90E-05 Smoking cessation ADAM12 cds-synon 18519826 rs1710278 chr10 127738918 G A 5.49E-05 Epilepsy ADAM12 intron 22116939 rs1710288 chr10 127741286 C G 1.82E-04 Smoking cessation ADAM12 intron 18519826 rs1710293 chr10 127744829 A C 1.67E-06 Epilepsy ADAM12 intron 22116939 rs2459113 chr10 127745094 T C 6.10E-04 Type 2 diabetes ADAM12 intron 23209189 rs7076519 chr10 127748839 T C 6.00E-07 Parkinson's disease (age of onset) ADAM12 intron 19772629 rs1278280 chr10 127755544 T G 6.67E-05 Epilepsy ADAM12 intron 22116939 rs7084390 chr10 127761758 A G 7.05E-07 Red blood cell traits ADAM12 intron 23222517 rs12415903 chr10 127762886 C T 1.86E-04 Multiple complex diseases ADAM12 intron 17554300 rs1380439 chr10 127768110 C T 2.80E-04 Multiple complex diseases ADAM12 intron 17554300 rs1878030 chr10 127786509 T C 2.00E-04 Information processing speed ADAM12 intron 21130836 rs35025137 chr10 127789783 C T 0.000000283 Cholesterol,total ADAM12 missense 23063622 rs7079180 chr10 127790305 T C 5.77E-05 Calcium levels ADAM12 intron pha003085 rs1278329 chr10 127823151 T G 8.00E-06 Metabolite levels (5-HIAA/ MHPG Ratio) ADAM12 intron 23319000 rs10901533 chr10 127825388 T A 2.70E-05 Urinary metabolites ADAM12 intron 21572414 rs7896870 chr10 127827684 C T 7.32E-04 Parkinson's disease ADAM12 intron 17052657 rs7896870 chr10 127827684 C T 2.34E-04 Multiple complex diseases ADAM12 intron 17554300 rs1551678 chr10 127829012 C G 9.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients ADAM12 intron 23400010 rs12247230 chr10 127829322 T C 6.37E-05 Multiple complex diseases ADAM12 intron 17554300 rs11244833 chr10 127830266 G C 7.60E-04 Type 2 diabetes ADAM12 intron 17463246 rs10901534 chr10 127830613 A G 9.12E-05 Body Mass Index ADAM12 intron pha003022 rs11244836 chr10 127833499 C T 2.40E-04 Multiple complex diseases ADAM12 intron 17554300 rs4962509 chr10 127835568 T C 2.39E-04 Multiple complex diseases ADAM12 intron 17554300 rs7085290 chr10 127836109 C T 2.35E-04 Multiple complex diseases ADAM12 intron 17554300 rs11244843 chr10 127836991 A G 3.33E-04 Multiple complex diseases ADAM12 intron 17554300 rs11244843 chr10 127836991 A G 8.18E-05 Body Mass Index ADAM12 intron pha003019 rs11244843 chr10 127836991 A G 7.01E-05 Body Mass Index ADAM12 intron pha003022 rs34135052 chr10 127846158 C T 0.00002604 Sarcoidosis ADAM12 intron 22952805 rs12778749 chr10 127846669 C T 1.01E-05 Endometrial cancer ADAM12 intron 24096698 rs12778749 chr10 127846669 C T 8.00E-06 Endometrial cancer ADAM12 intron 24096698 rs12778749 chr10 127846669 C T 9.00E-06 Endometrial cancer ADAM12 intron 24096698 rs2169076 chr10 127849127 C T 1.00E-04 Cognitive impairment induced by topiramate ADAM12 intron 22091778 rs1676734 chr10 127849558 T C 9.99E-05 Body Mass Index ADAM12 intron pha003019 rs11244857 chr10 127851943 G A 6.18E-05 Blood Pressure ADAM12 intron pha003050 rs1380442 chr10 127859655 T G 3.50E-05 Height ADAM12 intron 21998595 rs1380444 chr10 127859846 G T 2.28E-04 Response to alcohol consumption (flushing response) ADAM12 intron 24277619 rs1459709 chr10 127872828 G A 3.32E-04 Parkinson's disease ADAM12 intron 17052657 rs7920519 chr10 127894885 A T 7.66E-04 Multiple complex diseases ADAM12 intron 17554300 rs6597744 chr10 127895003 G A 5.24E-04 Multiple complex diseases ADAM12 intron 17554300 rs7920920 chr10 127895219 A G 5.16E-04 Multiple complex diseases ADAM12 intron 17554300 rs17154535 chr10 127910440 C T 2.44E-05 Type 2 diabetes ADAM12 intron 17463246 rs4962533 chr10 127939770 T C 3.21E-04 Multiple complex diseases ADAM12 intron 17554300 rs11244927 chr10 127957086 T C 3.32E-05 Intracerebral hemorrhage ADAM12 intron 24656865 rs12218815 chr10 127960395 T C 3.08E-05 Intracerebral hemorrhage ADAM12 intron 24656865 rs75316572 chr10 127967532 C T 3.53E-05 Intracerebral hemorrhage ADAM12 missense 24656865 rs10794077 chr10 127971058 G A 7.45E-04 Nicotine dependence ADAM12 intron 17158188 rs2366698 chr10 127975335 T C 9.42E-05 Bipolar disorder ADAM12 intron 17486107 rs12571269 chr10 127982738 G A 3.85E-05 Intracerebral hemorrhage ADAM12 intron 24656865 rs77465468 chr10 127983434 G C 2.55E-05 Intracerebral hemorrhage ADAM12 intron 24656865 rs12571178 chr10 127985372 T G 2.55E-05 Intracerebral hemorrhage ADAM12 intron 24656865 rs79222073 chr10 127988202 C T 4.66E-05 Intracerebral hemorrhage ADAM12 intron 24656865 rs79435014 chr10 127988911 G A,C 4.95E-05 Intracerebral hemorrhage ADAM12 intron 24656865 rs9783128 chr10 127990196 C G 4.20E-06 Urinary metabolites ADAM12 intron 21572414 rs7084896 chr10 128008864 C G 4.49E-05 Serum metabolites ADAM12 intron 19043545 rs10901593 chr10 128016929 C T 5.89E-05 Insulin resistance ADAM12 intron 21901158 rs17759651 chr10 128066982 T C 2.18E-04 Age-related macular degeneration ADAM12 intron 22125219 rs4474359 chr10 128072363 T C 4.06E-05 Intracerebral hemorrhage ADAM12 intron 24656865 rs7919486 chr10 128094493 T C 7.00E-05 Parkinson's disease (familial) / / 18985386 rs4962558 chr10 128141955 T C 6.04E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) C10orf90 intron 23648065 rs10751556 chr10 128143338 C A 8.10E-04 Alzheimer's disease C10orf90 intron 24755620 rs7079392 chr10 128153623 G A 5.20E-05 Coronary heart disease C10orf90 intron pha003030 rs7079392 chr10 128153623 G A 5.00E-06 Coronary heart disease C10orf90 intron pha003031 rs7079561 chr10 128153755 G A 8.54E-06 Body Mass Index C10orf90 intron pha003007 rs12573737 chr10 128201636 G A 2.90E-05 Urinary metabolites C10orf90 intron 21572414 rs1370108 chr10 128213658 C T 1.50E-05 Malaria / / 19465909 rs2366854 chr10 128228042 G T 3.58E-04 Multiple complex diseases / / 17554300 rs7916733 chr10 128240277 T C 5.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2164587 chr10 128244826 T C 3.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4962345 chr10 128246606 G A 2.66E-04 Multiple complex diseases / / 17554300 rs7093782 chr10 128249738 C T 1.18E-04 Multiple complex diseases / / 17554300 rs11245052 chr10 128267640 T A 2.00E-06 Metabolite levels (MHPG) / / 23319000 rs145344173 chr10 128267640 T TA 2.00E-06 Metabolite levels (MHPG) / / 23319000 rs12264765 chr10 128268275 A G 5.21E-04 Multiple complex diseases / / 17554300 rs10128487 chr10 128273179 T C 8.22E-04 Multiple complex diseases / / 17554300 rs2576022 chr10 128287185 T C 5.36E-04 Multiple complex diseases / / 17554300 rs1025641 chr10 128307192 T C 8.28E-07 Schizophrenia / / 21926974 rs2842169 chr10 128330713 T C 2.66E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2842169 chr10 128330713 T C 4.60E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12354898 chr10 128356095 C T 7.13E-05 Blood Pressure / / pha003045 rs11245103 chr10 128387149 C T 7.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs10901662 chr10 128390393 G A 8.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs11245105 chr10 128390546 C A 8.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs10901663 chr10 128390819 G T 1.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs2886794 chr10 128392906 C G 1.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs4962593 chr10 128397041 C T 6.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs7916667 chr10 128405238 G A 9.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs2366878 chr10 128405932 C T 3.16E-05 Body Composition / / pha003012 rs2366878 chr10 128405932 C T 3.96E-05 Body Mass Index / / pha003021 rs12771596 chr10 128413223 C T 2.99E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs7078439 chr10 128419984 T C 8.05E-06 Rheumatoid arthritis / / 19503088 rs10794108 chr10 128423873 G T 4.27E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs10901683 chr10 128431056 C T 3.23E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10219075 chr10 128438264 A C 1.28E-05 Cognitive impairment induced by topiramate / / 22091778 rs2005556 chr10 128445385 A G 1.80E-05 Urinary metabolites / / 21572414 rs10901703 chr10 128470148 G A 8.50E-05 Hypothyroidism / / 22493691 rs11599718 chr10 128476069 A G 9.00E-05 Hypothyroidism / / 22493691 rs7909809 chr10 128485923 C T 2.13E-05 Cognitive performance / / 19734545 rs7090934 chr10 128487203 C T 3.55E-05 Cognitive performance / / 19734545 rs12357398 chr10 128534122 A G 2.88E-04 Alzheimer's disease (late onset) LOC728065 intron 21379329 rs10901726 chr10 128541675 T C 6.46E-04 Smoking initiation LOC728065 intron 24665060 rs7920965 chr10 128542106 T C 7.70E-04 Smoking initiation LOC728065 intron 24665060 rs7894577 chr10 128543452 T C 1.85E-04 Smoking initiation LOC728065 intron 24665060 rs10901727 chr10 128543943 C T 1.60E-04 Smoking initiation LOC728065 intron 24665060 rs4278436 chr10 128549074 A T 1.70E-05 Urinary metabolites LOC728065 intron 21572414 rs7897646 chr10 128549611 A T 7.41E-04 Smoking initiation LOC728065 intron 24665060 rs10751587 chr10 128553305 C T 2.20E-05 Urinary metabolites LOC728065 intron 21572414 rs11598954 chr10 128554136 C T 1.60E-05 Urinary metabolites LOC728065 intron 21572414 rs11594538 chr10 128562169 T C 9.73E-06 Metabolite levels (MHPG) LOC728065 intron 23319000 rs4589200 chr10 128565096 T C 1.14E-05 Personality dimensions LOC728065 intron 22628180 rs11599217 chr10 128566964 G T 3.96E-07 Primary nonsyndromic vesicoureteric reflex LOC728065 intron 19959718 rs7073422 chr10 128580277 A G 2.54E-04 Body mass index LOC728065 intron 17255346 rs12783987 chr10 128581683 C T 1.70E-05 Personality dimensions LOC728065 intron 22628180 rs7091210 chr10 128592809 G A 3.47E-05 Alzheimer's disease (late onset) / / 21379329 rs8181424 chr10 128602101 A C,G,T 3.12E-05 Serum metabolites / / 19043545 rs9733352 chr10 128777390 G C 4.00E-08 Apolipoprotein Levels DOCK1 intron 23031429 rs10741150 chr10 128779958 C T 3.89E-04 Premature ovarian failure DOCK1 intron 19508998 rs10741150 chr10 128779958 C T 9.22E-05 Hypertension (essential hypertension) DOCK1 intron 22184326 rs2275540 chr10 128797717 T C 4.00E-06 Response to cytidine analogues (gemcitabine) DOCK1 intron 24483146 rs2275540 chr10 128797717 T C 5.41E-04 Response to cytadine analogues (cytosine arabinoside) DOCK1 intron 24483146 rs9418753 chr10 128799999 A G 9.51E-04 Response to cytidine analogues (gemcitabine) DOCK1 intron 24483146 rs7912111 chr10 128808908 T C 7.13E-04 Stroke DOCK1 intron pha002886 rs4751175 chr10 128809541 A G 1.60E-05 Urinary metabolites DOCK1 intron 21572414 rs2050812 chr10 128821415 G A 3.82E-04 Smoking quantity DOCK1 intron 24665060 rs4635002 chr10 128862679 A C 3.60E-06 Urinary metabolites DOCK1 intron 21572414 rs9418834 chr10 128871301 T C 2.00E-06 Urinary metabolites DOCK1 intron 21572414 rs12264769 chr10 128881176 A G 6.60E-04 Multiple complex diseases DOCK1 intron 17554300 rs928572 chr10 128890191 C T 6.28E-04 Multiple complex diseases DOCK1 intron 17554300 rs7923977 chr10 128901414 G A 1.10E-05 Cognitive test performance DOCK1 intron 20125193 rs2489401 chr10 128911984 G A 7.24E-04 Multiple complex diseases DOCK1 intron 17554300 rs1060561 chr10 128926013 A G 9.92E-04 Coronary Artery Disease DOCK1 cds-synon 17634449 rs2486968 chr10 128931208 A G 1.06E-05 Cognitive test performance DOCK1 intron 20125193 rs2483853 chr10 128940306 A G 9.00E-05 Response to statin therapy DOCK1 intron 20339536 rs2483865 chr10 129005367 A G 1.70E-05 Iron levels DOCK1 intron 21208937 rs2050305 chr10 129019678 C T 4.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DOCK1 intron 20877124 rs10829607 chr10 129030343 T C 9.70E-04 Oral cancers (chewing tobacco related) DOCK1 intron 22503698 rs11819364 chr10 129043310 A C 9.00E-06 Social communication problems DOCK1 intron 24564958 rs11016909 chr10 129043897 G A 6.92E-04 Multiple complex diseases DOCK1 intron 17554300 rs2498947 chr10 129070585 G A 3.64E-04 Stroke DOCK1 intron pha002887 rs11017083 chr10 129080739 A G 0.000549 Height (Pygmy height) DOCK1 intron 22570615 rs2720972 chr10 129118884 T C 3.87E-04 Coronary heart disease DOCK1 intron 21971053 rs2720967 chr10 129121108 G A 7.89E-04 Coronary heart disease DOCK1 intron 21971053 rs1006217 chr10 129149464 T C 6.31E-04 Prostate cancer mortality DOCK1 intron 20978177 rs1006217 chr10 129149464 T C 0.000324 Salmonella-induced pyroptosis DOCK1 intron 22837397 rs12570609 chr10 129168150 T G 1.75E-05 Alzheimer's disease DOCK1 intron 21098978 rs7914006 chr10 129169432 C A 2.44E-05 Alzheimer's disease DOCK1 intron 21098978 rs10829893 chr10 129176268 G A 8.27E-04 Multiple complex diseases DOCK1 intron 17554300 rs2296630 chr10 129202729 G T 3.13E-05 Response to mTOR inhibitor (everolimus) DOCK1 intron 24009623 rs2229599 chr10 129207429 C T 7.43E-04 Multiple complex diseases DOCK1 cds-synon 17554300 rs2229599 chr10 129207429 C T 7.53E-04 Coronary heart disease DOCK1 cds-synon 21606135 rs7895671 chr10 129208186 G A 3.40E-05 Magnesium levels DOCK1 intron pha003092 rs7920698 chr10 129210751 C A 4.87E-05 Magnesium levels DOCK1 intron pha003092 rs11017990 chr10 129216162 G C 1.06E-04 Alzheimer's disease DOCK1 intron 24755620 rs1078336 chr10 129222061 G T 9.23E-05 Post-operative nausea and vomiting DOCK1 intron 21694509 rs1078336 chr10 129222061 G T 5.95E-04 White matter integrity DOCK1 intron 22425255 rs10765093 chr10 129225796 C T 6.35E-05 Weight DOCK1 intron pha003026 rs11018077 chr10 129227488 G A 7.60E-04 Alcohol dependence DOCK1 intron 20201924 rs7095670 chr10 129230909 G A 1.33E-05 Magnesium levels DOCK1 intron pha003092 rs1931702 chr10 129245244 G A 9.44E-05 Cognitive test performance DOCK1 intron 20125193 rs10830067 chr10 129247480 T C 4.00E-06 Urinary metabolites DOCK1 intron 21572414 rs11018104 chr10 129248044 T A 2.33E-04 Body mass index DOCK1 intron 21701565 rs7904011 chr10 129248480 A C 9.46E-04 Alzheimer's disease DOCK1 intron 24755620 rs10218871 chr10 129255836 G A 2.44E-05 Type 2 diabetes / / 17463246 rs11018112 chr10 129259385 C T 1.14E-05 Type 2 diabetes / / 17463246 rs11018113 chr10 129259434 C A 1.53E-05 Type 2 diabetes / / 17463246 rs10830078 chr10 129261583 A G 1.59E-05 Type 2 diabetes / / 17463246 rs10741271 chr10 129265798 A C 7.98E-08 Metabolite levels / / 23281178 rs868567 chr10 129266910 T G 6.18E-04 Parkinson's disease / / 17052657 rs11018125 chr10 129267759 G A 7.54E-05 Cognitive test performance / / 20125193 rs9651385 chr10 129268539 A G 7.98E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9651385 chr10 129268539 A G 8.03E-05 Triglycerides / / pha003080 rs10765110 chr10 129271850 C A 5.45E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4363506 chr10 129274503 T C 7.00E-07 Amyotrophic lateral sclerosis / / 17362836 rs4363506 chr10 129274503 T C 6.80E-07 Amyotrophic lateral sclerosis (sporadic) / / 19740415 rs11018140 chr10 129276819 T G 9.28E-04 Multiple complex diseases / / 17554300 rs1931737 chr10 129281900 G T 1.07E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10830098 chr10 129284226 T C 5.59E-04 Type 2 diabetes / / 17463246 rs10830099 chr10 129284365 C T 9.77E-04 Parkinson's disease / / 17052657 rs10830099 chr10 129284365 C T 3.40E-06 Amyotrophic Lateral Sclerosis / / 17362836 rs10830100 chr10 129284413 T C 9.29E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10830100 chr10 129284413 T C 6.63E-04 Type 2 diabetes / / 17463246 rs10765118 chr10 129285183 G A 1.60E-06 Amyotrophic Lateral Sclerosis / / 17362836 rs7090712 chr10 129289558 T C 6.25E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7090712 chr10 129289558 T C 6.26E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10830107 chr10 129304075 A G 4.38E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10830109 chr10 129305535 A C 3.80E-04 Alzheimer's disease (late onset) / / 21379329 rs7907561 chr10 129311165 G A 1.44E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4237482 chr10 129320374 A G 1.21E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4237482 chr10 129320374 A G 8.44E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7077676 chr10 129325429 A C 4.91E-04 Parkinson's disease / / 17052657 rs7094852 chr10 129333397 T C 7.91E-04 Parkinson's disease / / 17052657 rs1931704 chr10 129339809 G A 9.69E-04 Parkinson's disease / / 17052657 rs11594494 chr10 129340882 G C 4.91E-05 Alzheimer's disease (age of onset) / / 22005931 rs11597503 chr10 129345622 G A 2.24E-05 Alzheimer's disease (age of onset) / / 22005931 rs10734107 chr10 129353132 T G 1.13E-05 Sleep time / / 23728906 rs10765132 chr10 129353415 G A 7.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12252756 chr10 129381096 G A 4.49E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7077174 chr10 129382253 T C 2.47E-05 Tunica Media / / pha003036 rs12774813 chr10 129384543 G A 3.00E-06 Waist Circumference / / pha003023 rs12267188 chr10 129385588 C T 1.10E-05 Urinary metabolites / / 21572414 rs10765137 chr10 129388646 T C 2.16E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4751459 chr10 129389743 G A 3.80E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs868869 chr10 129395753 C G 7.09E-04 Type 2 diabetes / / 17463246 rs915147 chr10 129401774 C G 8.48E-04 Type 2 diabetes / / 17463246 rs7901816 chr10 129401906 C T 5.27E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10830140 chr10 129408764 G A 3.89E-04 Multiple complex diseases / / 17554300 rs12261126 chr10 129415436 G A 9.10E-06 Urinary metabolites / / 21572414 rs2154175 chr10 129425524 G T 6.31E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2154175 chr10 129425524 G T 1.50E-05 Vitamin D concentrations / / 20600896 rs2154175 chr10 129425524 G T 1.50E-05 Vitamin D concentrations / / 20600896 rs1936875 chr10 129455346 A T 6.32E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7896359 chr10 129481452 T C 3.30E-04 Blood pressure / / 17255346 rs7082808 chr10 129495696 T C 8.80E-04 Alzheimer's disease / / 17998437 rs12784644 chr10 129553772 T C 1.12E-04 Glycosylated haemoglobin levels / / 17255346 rs12784644 chr10 129553772 T C 8.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12784644 chr10 129553772 T C 3.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs12778881 chr10 129580978 T C 8.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs2094209 chr10 129585004 T C 7.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs1926177 chr10 129594161 C A 1.20E-05 Body mass index (non-asthmatics) / / 23517042 rs12780271 chr10 129596555 G A 6.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs12775160 chr10 129596576 C G 3.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs12762583 chr10 129597382 G A 7.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs4751522 chr10 129597478 T C 4.73E-06 Multiple complex diseases / / 17554300 rs11816297 chr10 129604375 A G 1.00E-05 Body mass index (non-asthmatics) / / 23517042 rs12768053 chr10 129613617 A C 9.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs7093392 chr10 129614354 G A 1.10E-05 Body mass index (non-asthmatics) / / 23517042 rs12764292 chr10 129615948 T C 4.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs633114 chr10 129621112 C T 9.63E-06 Eosinophil counts / / pha003088 rs7905689 chr10 129623851 G A 1.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs12778554 chr10 129624632 G A 8.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs729598 chr10 129625357 C T 2.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs7069806 chr10 129628500 T C 4.03E-06 Multiple sclerosis / / 17660530 rs618870 chr10 129628584 A G 5.53E-05 Eosinophil counts / / pha003088 rs6482992 chr10 129678674 T C 4.00E-06 Parkinson's disease (motor and cognition) CLRN3 intron 22658654 rs12413939 chr10 129688467 G A 3.53E-05 Odorant perception CLRN3 intron 23910658 rs2148895 chr10 129692293 C T 2.96E-04 Multiple complex diseases / / 17554300 rs11018401 chr10 129713541 G T 2.43E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) PTPRE intron 23648065 rs10830197 chr10 129725646 C T 8.04E-06 Response to amphetamines PTPRE intron 22952603 rs11018407 chr10 129729992 G C 9.53E-06 Response to amphetamines PTPRE intron 22952603 rs932837 chr10 129736477 G A 7.27E-06 Response to amphetamines PTPRE intron 22952603 rs12049671 chr10 129737631 C T 7.00E-06 Response to amphetamines PTPRE intron 22952603 rs11018410 chr10 129737824 A G 7.50E-06 Response to amphetamines PTPRE intron 22952603 rs7900735 chr10 129748903 A G 8.01E-06 Response to amphetamines PTPRE intron 22952603 rs7084584 chr10 129769546 C T 5.65E-05 Coronary heart disease PTPRE intron pha003056 rs7076228 chr10 129770754 G A 4.38E-04 Multiple complex diseases PTPRE intron 17554300 rs7076348 chr10 129770829 G C 8.58E-04 Multiple complex diseases PTPRE intron 17554300 rs11015999 chr10 129784473 G A 0.000492 Salmonella-induced pyroptosis PTPRE intron 22837397 rs7904367 chr10 129792021 T C 5.00E-04 Primary nonsyndromic vesicoureteric reflex PTPRE intron 19959718 rs11016013 chr10 129814581 T C 5.90E-04 Multiple complex diseases PTPRE intron 17554300 rs10829321 chr10 129851621 A G 1.50E-05 Urinary metabolites PTPRE intron 21572414 rs4750934 chr10 129856876 A T 4.43E-04 Multiple complex diseases PTPRE intron 17554300 rs10764742 chr10 129858897 T C 3.84E-04 Smoking initiation PTPRE intron 24665060 rs4601676 chr10 129860234 G A 4.03E-04 Multiple complex diseases PTPRE intron 17554300 rs12254566 chr10 129873277 G A 4.56E-04 Type 2 diabetes PTPRE intron 17463246 rs2096285 chr10 129879700 A G 4.64E-05 Multiple complex diseases PTPRE intron 17554300 rs7896426 chr10 129888273 G C 8.38E-04 Multiple complex diseases / / 17554300 rs3781305 chr10 129898890 T C 5.00E-07 Urinary metabolites MKI67 intron 21572414 rs8473 chr10 129899578 T C 1.20E-06 Urinary metabolites MKI67 missense 21572414 rs61729197 chr10 129901717 G A 0.0000024 Prostate cancer (advanced) MKI67 missense 23555315 rs2387327 chr10 129930349 C T 7.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs2387326 chr10 129933456 C T 1.00E-06 Select biomarker traits / / 17903293 rs9783135 chr10 129937722 A C 4.36E-04 Alzheimer's disease (late onset) / / 21379329 rs9783135 chr10 129937722 A C 1.21E-04 Smoking initiation / / 24665060 rs7912288 chr10 129954773 A G 9.64E-05 Alzheimer's disease (late onset) / / 21379329 rs12572759 chr10 129954972 C T 1.83E-04 Alzheimer's disease (late onset) / / 21379329 rs6482659 chr10 129958964 A C,T 2.48E-04 Suicide attempts in bipolar disorder / / 21041247 rs6482660 chr10 129959058 A G 1.48E-04 Suicide attempts in bipolar disorder / / 21041247 rs11016113 chr10 129967995 T A 1.00E-05 Urinary metabolites / / 21572414 rs1329189 chr10 129998372 T C 5.00E-06 Orofacial clefts / / 22419666 rs11016132 chr10 130018555 A G 7.68E-06 Lipid traits / / 21777205 rs12244690 chr10 130069115 G C 9.63E-04 Type 2 diabetes / / 17463246 rs7900125 chr10 130074063 G A 5.48E-05 Osteoarthritis (knee and hip) / / 21177295 rs2254606 chr10 130107905 T C 3.28E-05 Hypertension / / pha003042 rs2799403 chr10 130110468 T C 3.53E-05 Hypertension / / pha003042 rs1255135 chr10 130117637 T G 5.36E-04 HIV-1 viral setpoint / / 17641165 rs1754234 chr10 130118585 C G 3.69E-04 Multiple complex diseases / / 17554300 rs1314589 chr10 130130066 A T 3.95E-05 Diabetic nephropathy / / pha002852 rs1314589 chr10 130130066 A T 8.76E-05 Diabetic nephropathy / / pha002864 rs11818629 chr10 130137105 C T 3.00E-06 HIV-1 control / / 20041166 rs10764772 chr10 130142305 G A 9.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10829385 chr10 130144139 A G 9.65E-04 Multiple complex diseases / / 17554300 rs10829385 chr10 130144139 A G 5.00E-05 Prostate cancer / / 21743057 rs1936420 chr10 130147655 T A 5.00E-05 Prostate cancer / / 21743057 rs4348813 chr10 130151410 T G 4.54E-06 Carotenoid and tocopherol levels / / 19185284 rs1857384 chr10 130154470 T C 2.00E-05 Prostate cancer / / 21743057 rs2387611 chr10 130154533 T C 2.00E-05 Prostate cancer / / 21743057 rs7894663 chr10 130163817 A G 3.55E-05 Osteoarthritis (knee and hip) / / 21177295 rs7894663 chr10 130163817 A G 7.51E-05 Osteoarthritis (knee and hip) / / 21177295 rs1339521 chr10 130223257 G A 2.58E-06 Hearing function / / 21493956 rs1890631 chr10 130230448 C G 7.18E-04 Multiple complex diseases / / 17554300 rs10764775 chr10 130233808 T C 6.00E-06 IgG glycosylation / / 23382691 rs11016249 chr10 130248338 G A 9.43E-04 Multiple complex diseases / / 17554300 rs9804317 chr10 130248926 T G 7.00E-06 Cognitive performance / / 20125193 rs7475176 chr10 130251523 T C 4.82E-05 Coronary heart disease / / pha003031 rs881079 chr10 130257967 C A 7.82E-04 Multiple complex diseases / / 17554300 rs10829409 chr10 130260943 G C 3.38E-04 Smoking initiation / / 24665060 rs7096455 chr10 130272033 G T 2.94E-05 Psoriasis / / 18364390 rs2009253 chr10 130300472 T C 1.03E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs10829419 chr10 130318217 A G 1.70E-05 Urinary metabolites / / 21572414 rs11016297 chr10 130318458 C T 4.90E-06 Urinary metabolites / / 21572414 rs8181344 chr10 130354366 T C 6.09E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs79735473 chr10 130354441 G A 5.77E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs76864453 chr10 130355888 G A 6.65E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs75288748 chr10 130357910 G A 7.26E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs117283143 chr10 130361659 G A 7.74E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs118138070 chr10 130361821 G C 7.79E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs75432636 chr10 130362941 T G 8.78E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs12250049 chr10 130363032 G A 1.65E-04 Taste perception / / 22132133 rs1004343 chr10 130363150 T C 6.89E-04 Multiple complex diseases / / 17554300 rs1004344 chr10 130363238 G T 4.07E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs60587785 chr10 130368746 C T 8.94E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs749141 chr10 130369490 T C 4.00E-07 Serum dimethylarginine levels (symmetric) / / 24159190 rs7096235 chr10 130372201 C G 1.87E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs7087654 chr10 130372799 T C 1.91E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs193189882 chr10 130383238 G A 2.00E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12358786 chr10 130383831 G C 5.31E-05 Multiple complex diseases / / 17554300 rs11016359 chr10 130388805 A T 3.98E-04 Multiple complex diseases / / 17554300 rs10829446 chr10 130409727 A G 1.80E-05 Urinary metabolites / / 21572414 rs10829447 chr10 130409857 A G 1.50E-05 Urinary metabolites / / 21572414 rs11016422 chr10 130458369 G A 7.97E-05 Receptive language ability / / 24687471 rs4750990 chr10 130488026 T C 3.91E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10829474 chr10 130497115 C A 2.31E-05 Non-word repetition / / 23738518 rs10829475 chr10 130499303 C T 2.60E-04 Coronary Artery Disease / / 17634449 rs1887244 chr10 130504906 G A 2.30E-06 Prostate cancer / / pha002878 rs7078934 chr10 130509103 C A 2.17E-05 Blood Pressure / / pha003040 rs4750993 chr10 130518039 A G 2.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs913170 chr10 130518417 A G 4.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs913170 chr10 130518417 A G 7.22E-04 Myocardial Infarction / / pha002883 rs10829485 chr10 130549553 T G 1.11E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1327013 chr10 130573275 A G 6.87E-04 Multiple complex diseases / / 17554300 rs1327013 chr10 130573275 A G 5.90E-06 Asthma (childhood onset) / / 23829686 rs11016479 chr10 130574247 A T 1.45E-04 Multiple complex diseases / / 17554300 rs12217982 chr10 130580208 A C 2.77E-04 Acute lung injury / / 22295056 rs12219067 chr10 130580251 G T 8.12E-04 Acute lung injury / / 22295056 rs10829494 chr10 130587426 C T 3.37E-05 Multiple complex diseases / / 17554300 rs10829495 chr10 130588415 C T 1.18E-05 Multiple complex diseases / / 17554300 rs10741165 chr10 130611022 T G 7.87E-05 Serum metabolites / / 19043545 rs10741165 chr10 130611022 T G 8.22E-04 Response to TNF antagonist treatment / / 21061259 rs12250988 chr10 130612534 A T 7.63E-05 Serum metabolites / / 19043545 rs61863454 chr10 130614959 A G 1.40E-11 Metabolite levels / / 22286219 rs942524 chr10 130617815 C G 6.71E-05 Serum metabolites / / 19043545 rs5026308 chr10 130619367 A G 5.44E-05 Serum metabolites / / 19043545 rs7895542 chr10 130619712 C G 9.44E-05 Serum metabolites / / 19043545 rs7895542 chr10 130619712 C G 9.36E-04 Response to TNF antagonist treatment / / 21061259 rs11016498 chr10 130622295 A G 1.27E-04 Cognitive decline / / 23732972 rs1555702 chr10 130622498 C T 2.10E-06 Cognitive decline / / 23732972 rs7084354 chr10 130623222 G A 7.15E-04 Response to TNF antagonist treatment / / 21061259 rs942525 chr10 130624838 C T 1.42E-04 Cognitive decline / / 23732972 rs750986 chr10 130625219 T C 3.71E-04 Response to TNF antagonist treatment / / 21061259 rs750985 chr10 130625249 A G 3.54E-04 Response to TNF antagonist treatment / / 21061259 rs4146168 chr10 130625738 G T 3.56E-04 Response to TNF antagonist treatment / / 21061259 rs3940168 chr10 130635614 G A 5.18E-05 Bipolar disorder and schizophrenia / / 20889312 rs1408536 chr10 130677746 A G 9.86E-04 Multiple complex diseases / / 17554300 rs1408536 chr10 130677746 A G 4.00E-04 Pancreatic cancer / / 23180869 rs11016536 chr10 130684713 G A 7.12E-05 Cognitive impairment induced by topiramate / / 22091778 rs10829514 chr10 130686075 T C 5.24E-04 Multiple complex diseases / / 17554300 rs10764826 chr10 130686476 A G 9.00E-04 Pancreatic cancer / / 23180869 rs1556663 chr10 130714694 C A 0.000856548 Hypertension (early onset hypertension) / / 22479346 rs4751029 chr10 130728264 G A 2.90E-05 Parkinson's disease (age of onset) / / 19772629 rs4751032 chr10 130741803 G A 1.56E-04 Multiple complex diseases / / 17554300 rs7093351 chr10 130755222 C T 6.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs2060893 chr10 130757504 A G 1.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs2060894 chr10 130757816 C T 8.21E-05 Suicide attempts in bipolar disorder / / 21423239 rs713271 chr10 130758998 T C 9.66E-05 Suicide attempts in bipolar disorder / / 21423239 rs1556664 chr10 130812761 T C 9.05E-04 Multiple complex diseases / / 17554300 rs7099795 chr10 130826981 C T 5.30E-05 Hearing function / / 17255346 rs7099795 chr10 130826981 C T 2.53E-05 Body Mass Index / / pha003009 rs7084245 chr10 130894033 C T 8.83E-04 Type 2 diabetes / / 17463246 rs2039371 chr10 130900206 C T 4.78E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2039372 chr10 130900389 T C 3.86E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12778834 chr10 130902337 C A 3.75E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11597093 chr10 130903024 G A 4.63E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12774599 chr10 130905792 G T 6.42E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12766913 chr10 130930938 A G 3.02E-05 Odorant perception / / 23910658 rs7916199 chr10 130939105 T C 3.01E-04 Multiple complex diseases / / 17554300 rs7909469 chr10 130941790 C G 4.29E-05 Multiple complex diseases / / 17554300 rs10829580 chr10 130941884 G A 4.84E-05 Multiple complex diseases / / 17554300 rs997161 chr10 130986137 G A 8.60E-05 Longevity and age-related phenotypes / / 17903295 rs1078389 chr10 131010772 G C 4.77E-04 Multiple complex diseases / / 17554300 rs522855 chr10 131037638 T C 8.10E-07 Urinary metabolites / / 21572414 rs496646 chr10 131038717 A G 1.40E-06 Urinary metabolites / / 21572414 rs540879 chr10 131039408 G A 7.76E-05 Alzheimer's disease / / 17998437 rs538186 chr10 131039698 C T 7.33E-04 Common variable immunodeficiency / / 21497890 rs481105 chr10 131041310 T C 8.10E-07 Urinary metabolites / / 21572414 rs473925 chr10 131041379 C T 7.30E-07 Urinary metabolites / / 21572414 rs527384 chr10 131048255 C A 9.79E-05 Alzheimer's disease / / 17998437 rs541392 chr10 131051177 C T 2.76E-05 Alzheimer's disease / / 17998437 rs541392 chr10 131051177 C T 6.05E-05 Alzheimer's disease / / pha002879 rs1421041 chr10 131074866 A G 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1421041 chr10 131074866 A G 9.56E-05 Cognitive impairment induced by topiramate / / 22091778 rs2542625 chr10 131078144 C T 5.70E-05 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs11818005 chr10 131147906 T C 7.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs1547979 chr10 131180639 T C 3.20E-04 Multiple complex diseases / / 17554300 rs11016778 chr10 131195759 G T 4.12E-04 Type 2 diabetes / / 17463246 rs2792980 chr10 131200443 T C 0.00047 Prostate cancer / / 23555315 rs1978392 chr10 131215389 T G 9.36E-05 Stroke (ischemic) / / 22941190 rs2388328 chr10 131234372 C G 5.00E-06 Metabolite levels (X-11787) / / 23934736 rs3864859 chr10 131237179 T C 0.0004696 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs3864859 chr10 131237179 T C 4.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs868527 chr10 131237968 C A 0.00047 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs868527 chr10 131237968 C A 4.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1626983 chr10 131239375 C T 0.0004709 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1626983 chr10 131239375 C T 4.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11016797 chr10 131250070 G C 3.62E-08 Lymphocyte counts / / 22286170 rs11016798 chr10 131256585 C T 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs11016798 chr10 131256585 C T 1.30E-05 Urinary metabolites / / 21572414 rs10764881 chr10 131263831 G A 1.43E-09 Multiple complex diseases / / 17554300 rs12259379 chr10 131303340 G T 2.70E-05 Urinary metabolites MGMT intron 21572414 rs4751095 chr10 131322781 G A 6.31E-04 Taste perception MGMT intron 22132133 rs556253 chr10 131355781 G A 7.39E-04 Suicide attempts in bipolar disorder MGMT intron 21423239 rs579325 chr10 131363688 C T 6.99E-04 Suicide attempts in bipolar disorder MGMT intron 21423239 rs511361 chr10 131365052 C T 7.36E-04 Suicide attempts in bipolar disorder MGMT intron 21423239 rs551491 chr10 131397821 G A 3.44E-04 Cognition,early reading ability MGMT intron 17684495 rs553371 chr10 131413676 T C 2.17E-05 Bipolar disorder MGMT intron 17486107 rs477692 chr10 131426022 T C 1.00E-08 Response to temozolomide MGMT intron 23047291 rs75322567 chr10 131460488 T C 0.00004224 Sarcoidosis MGMT intron 22952805 rs56383940 chr10 131464342 T A 0.00003302 Sarcoidosis MGMT intron 22952805 rs55673219 chr10 131464731 G A,C 0.00003302 Sarcoidosis MGMT intron 22952805 rs12414229 chr10 131465371 A T 0.00003302 Sarcoidosis MGMT intron 22952805 rs12412879 chr10 131465740 C T 0.00003155 Sarcoidosis MGMT intron 22952805 rs10829618 chr10 131490420 G C 7.89E-04 Multiple complex diseases MGMT intron 17554300 rs11016883 chr10 131500940 G C 9.00E-07 Waist-to-hip circumference ratio (interaction) MGMT intron 23192594 rs4751115 chr10 131510293 T C 4.86E-04 Alcohol dependence MGMT intron 21314694 rs10829622 chr10 131519512 T C 4.58E-04 Alcohol dependence MGMT intron 21314694 rs7097039 chr10 131555074 A C 3.36E-04 Suicide attempts in bipolar disorder MGMT intron 21423239 rs2308321 chr10 131565064 A G 7.42E-04 Suicide attempts in bipolar disorder MGMT missense 21423239 rs10829627 chr10 131567549 C T 4.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs10829630 chr10 131572285 G A 3.75E-05 Serum metabolites / / 19043545 rs4750773 chr10 131583388 G A 7.44E-05 Magnesium levels / / pha003092 rs7911165 chr10 131626650 C T 1.05E-05 Menarche (age at onset) / / 23599027 rs7100028 chr10 131648687 A G 6.89E-05 Post-operative nausea and vomiting EBF3 intron 21694509 rs12783441 chr10 131648947 T C 8.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EBF3 intron 20877124 rs4751138 chr10 131655212 C T 6.62E-04 Suicide attempts in bipolar disorder EBF3 intron 21041247 rs4751140 chr10 131664108 T C 2.69E-04 Longevity EBF3 intron 22279548 rs9804200 chr10 131673986 C T 6.00E-06 Sleep time EBF3 intron 23728906 rs4142058 chr10 131679393 T C 3.99E-05 Cognitive impairment induced by topiramate EBF3 intron 22091778 rs1334011 chr10 131685672 T C 4.21E-04 Multiple complex diseases EBF3 intron 17554300 rs12776159 chr10 131697627 C T 1.76E-05 Multiple complex diseases EBF3 intron 17554300 rs4751144 chr10 131702075 T C 2.83E-06 Post-operative nausea and vomiting EBF3 intron 21694509 rs11597635 chr10 131711365 G A 3.73E-04 Response to taxane treatment (placlitaxel) EBF3 intron 23006423 rs11598130 chr10 131721056 A G 2.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EBF3 intron 20877124 rs7904588 chr10 131731004 C T 1.61E-04 Multiple complex diseases EBF3 intron 17554300 rs12247065 chr10 131736062 C T 7.63E-04 Smoking initiation EBF3 intron 24665060 rs4750780 chr10 131737885 C T 4.50E-05 Lung adenocarcinoma EBF3 intron 19836008 rs658534 chr10 131747646 G C 3.91E-04 Multiple complex diseases EBF3 intron 17554300 rs7099076 chr10 131772971 T C 4.10E-04 Alcohol dependence / / 20201924 rs7099076 chr10 131772971 T C 4.40E-04 Alcohol dependence / / 20201924 rs11017044 chr10 131800501 C T 6.32E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7910342 chr10 131802533 C T 3.56E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4751158 chr10 131810153 A T 8.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7069452 chr10 131815454 A G 6.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs942950 chr10 131815674 T C 5.96E-04 Alcohol dependence / / 21314694 rs7899076 chr10 131833065 T C 5.29E-04 Aortic root size / / 21223598 rs12412485 chr10 131841600 G T 1.11E-05 Body Fat Distribution / / pha003016 rs647216 chr10 131850891 T C 3.62E-04 Multiple complex diseases / / 17554300 rs10829685 chr10 131856651 G T 2.39E-04 Celiac disease / / 23936387 rs4751162 chr10 131908606 G A 2.21E-05 Blood Pressure LOC387723 intron pha003044 rs585030 chr10 131915486 G A 3.44E-04 Type 2 diabetes / / 17463246 rs2031466 chr10 131925017 G A 0.0000338 Circulating PCSK9 levels / / 22460556 rs4750788 chr10 131925850 C T 6.26E-04 Type 2 diabetes / / 17463246 rs4750788 chr10 131925850 C T 3.24E-05 Smoking cessation / / 18519826 rs2147753 chr10 131925912 G A 3.97E-05 Type 2 diabetes / / 17463246 rs17232143 chr10 131926442 T A 5.63E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs17232143 chr10 131926442 T A 5.63E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs12414821 chr10 131928643 G A 6.88E-04 Multiple complex diseases / / 17554300 rs12414821 chr10 131928643 G A 2.11E-05 Left ventricular hypertrophy / / pha003052 rs11017104 chr10 131938395 T C 0.000011 Erectile dysfunction after radiotherapy for prostate cancer GLRX3 intron 23021708 rs12765489 chr10 131945421 T A 2.32E-04 Multiple complex diseases GLRX3 intron 17554300 rs7087901 chr10 131946350 G C 1.25E-04 Multiple complex diseases GLRX3 intron 17554300 rs16910144 chr10 131948558 G A 1.60E-04 Smoking cessation GLRX3 intron 18519826 rs12415867 chr10 131949021 C T 1.47E-04 Multiple complex diseases GLRX3 intron 17554300 rs12415867 chr10 131949021 C T 8.60E-05 Left ventricular hypertrophy GLRX3 intron pha003052 rs10829695 chr10 131953435 G A 0.000014 Erectile dysfunction after radiotherapy for prostate cancer GLRX3 intron 23021708 rs10764930 chr10 131953466 C T 0.0000093 Erectile dysfunction after radiotherapy for prostate cancer GLRX3 intron 23021708 rs10829696 chr10 131953624 G A 0.000015 Erectile dysfunction after radiotherapy for prostate cancer GLRX3 intron 23021708 rs12245251 chr10 131958985 C T 5.86E-05 White matter integrity GLRX3 intron 22425255 rs1570797 chr10 131971337 G T 8.33E-05 Alzheimer's disease GLRX3 intron 24755620 rs4751178 chr10 131992245 A G 7.00E-06 Speech perception in dyslexia / / 19786962 rs4751178 chr10 131992245 A G 9.22E-05 Hypertension / / pha003041 rs12771415 chr10 131995361 T A 3.96E-04 Multiple complex diseases / / 17554300 rs12771415 chr10 131995361 T A 6.02E-07 Inflammatory biomarkers / / 22291609 rs9633655 chr10 132013847 C G 6.30E-05 Memory performance / / 22105620 rs7092451 chr10 132017441 C A 1.51E-04 Multiple complex diseases / / 17554300 rs10829717 chr10 132023402 T G 2.40E-05 Urinary metabolites / / 21572414 rs7094199 chr10 132043419 T C 8.38E-04 HIV-1 viral setpoint / / 17641165 rs11017159 chr10 132048398 T A 1.56E-04 Type 2 diabetes / / 17463246 rs4751185 chr10 132056415 T C 7.00E-06 HIV-1 susceptibility / / 21160409 rs4751185 chr10 132056415 T C 0.0000169 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10829721 chr10 132058449 G A 5.82E-04 Insulin resistance / / 21901158 rs2771226 chr10 132061768 A C 0.0000169 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2628152 chr10 132063889 A G 3.14E-04 Insulin resistance / / 21901158 rs7909507 chr10 132072271 A G 8.92E-04 Myopia (pathological) / / 21095009 rs2480270 chr10 132074935 C A 1.26E-04 Insulin resistance / / 21901158 rs318934 chr10 132087860 G C 1.31E-04 Insulin resistance / / 21901158 rs11017185 chr10 132096167 G A 4.05E-04 Myopia (pathological) / / 21095009 rs11017194 chr10 132111137 G A 2.75E-04 Myopia (pathological) / / 21095009 rs11017211 chr10 132144804 G A 7.84E-05 Hypertension / / pha003041 rs11017212 chr10 132146355 C G 2.49E-04 Multiple complex diseases / / 17554300 rs7914348 chr10 132147366 C T 4.55E-05 Cytomegalovirus antibody response / / 21993531 rs11017221 chr10 132168065 C T 1.00E-07 Migraine / / 23793025 rs1001694 chr10 132168849 G A 3.39E-05 Cognitive impairment induced by topiramate / / 22091778 rs7082417 chr10 132171060 T G 5.79E-04 Type 2 diabetes / / 17463246 rs7086460 chr10 132171541 T C 5.02E-04 Type 2 diabetes / / 17463246 rs7084769 chr10 132179205 C T 1.86E-04 Multiple complex diseases / / 17554300 rs440075 chr10 132190059 C T 7.05E-05 Cognitive impairment induced by topiramate / / 22091778 rs396186 chr10 132193177 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11017236 chr10 132199481 T A 4.36E-04 Type 2 diabetes / / 17463246 rs11017236 chr10 132199481 T A 5.67E-07 Cardiovascular disease / / 18179892 rs11017236 chr10 132199481 T A 6.30E-06 Urinary metabolites / / 21572414 rs11017238 chr10 132199570 G C 6.30E-06 Urinary metabolites / / 21572414 rs10430606 chr10 132202054 C T 6.30E-06 Urinary metabolites / / 21572414 rs424881 chr10 132207985 G A 8.50E-05 Lung adenocarcinoma / / 22797724 rs67585843 chr10 132207985 GA GAT,GGA 8.50E-05 Lung adenocarcinoma / / 22797724 rs7082179 chr10 132221435 G A 2.10E-05 Urinary metabolites / / 21572414 rs4750806 chr10 132224722 G A 2.10E-05 Urinary metabolites / / 21572414 rs4750806 chr10 132224722 G A 0.000573 Salmonella-induced pyroptosis / / 22837397 rs3120134 chr10 132246154 T C 7.00E-04 Multiple complex diseases / / 17554300 rs3120134 chr10 132246154 T C 6.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs10829748 chr10 132254561 G A 1.40E-05 Urinary metabolites / / 21572414 rs326596 chr10 132274767 C T 2.60E-05 Urinary metabolites / / 21572414 rs12411435 chr10 132292622 C T 2.50E-05 Urinary metabolites / / 21572414 rs10764960 chr10 132297773 C A 1.30E-05 Urinary metabolites / / 21572414 rs10829755 chr10 132298888 A G 1.60E-05 Urinary metabolites / / 21572414 rs10450336 chr10 132300782 A C 2.70E-06 Urinary metabolites / / 21572414 rs10450330 chr10 132300871 A G 1.20E-06 Urinary metabolites / / 21572414 rs10450337 chr10 132300883 T C 1.90E-05 Urinary metabolites / / 21572414 rs4751221 chr10 132323344 G T 4.00E-05 Prostate cancer / / 21743057 rs11017302 chr10 132323975 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11017313 chr10 132328529 G A 1.80E-05 Urinary metabolites / / 21572414 rs4750814 chr10 132345497 T C 2.60E-06 Urinary metabolites / / 21572414 rs1334911 chr10 132345679 C T 6.63E-05 Migraine / / 23793025 rs11017328 chr10 132347100 C T 3.00E-07 Conotruncal heart defects / / 24800985 rs7900051 chr10 132370494 T C,G 0.000437783 Hypertension (early onset hypertension) / / 22479346 rs7900051 chr10 132370494 T C,G 7.07E-05 Heart Rate / / pha003053 rs7900051 chr10 132370494 T C,G 4.24E-05 Heart Rate / / pha003054 rs11597303 chr10 132373205 T C 0.000484214 Hypertension (early onset hypertension) / / 22479346 rs11597303 chr10 132373205 T C 3.67E-05 Heart Rate / / pha003053 rs11597303 chr10 132373205 T C 7.27E-05 Heart Rate / / pha003054 rs12220213 chr10 132374190 A G 4.93E-05 Heart Rate / / pha003053 rs12220213 chr10 132374190 A G 4.59E-05 Heart Rate / / pha003054 rs6482814 chr10 132405917 A G 8.61E-04 Alzheimer's disease / / 17998437 rs1177844 chr10 132423915 T C 2.48E-04 Schizophrenia / / 18282107 rs1176486 chr10 132425539 A G 1.49E-04 Cardiovascular disease / / 17903304 rs16911018 chr10 132431119 G A 1.93E-04 Alcohol dependence / / 20201924 rs1176461 chr10 132483929 T C 5.30E-05 Hypertension / / pha003042 rs1185023 chr10 132489040 C T 3.74E-05 Hypertension / / pha003042 rs2939924 chr10 132491701 C T 3.20E-05 Chronic Hepatitis C infection / / 21725309 rs1176449 chr10 132493179 G A 1.28E-05 Hypertension / / pha003042 rs1911372 chr10 132498722 T A 0.0000737 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10741220 chr10 132502902 G C 0.0000709 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7908624 chr10 132509961 C T 4.47E-06 Asthma (childhood onset) / / 23829686 rs12769508 chr10 132520422 A G 0.0000937 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4278438 chr10 132529553 C G 5.50E-06 Urinary metabolites / / 21572414 rs1014637 chr10 132529833 T C 4.72E-05 Telomere length / / 20139977 rs1876319 chr10 132538195 G A 1.20E-05 Urinary metabolites / / 21572414 rs4751264 chr10 132538574 G A 1.97E-04 Stroke / / pha002887 rs7088736 chr10 132540666 C A 1.74E-04 Insulin resistance / / 21901158 rs12240927 chr10 132543489 T C 6.51E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4750827 chr10 132547184 T C 5.18E-06 Obesity-related traits / / 23251661 rs4750829 chr10 132547261 A G 4.00E-06 Obesity-related traits / / 23251661 rs4750829 chr10 132547261 A G 9.00E-06 Obesity-related traits / / 23251661 rs2663006 chr10 132561685 G T 2.96E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7070213 chr10 132561994 G A 8.35E-06 Obesity-related traits / / 23251661 rs875452 chr10 132583607 C T 3.63E-05 Personality dimensions / / 22628180 rs12245366 chr10 132596435 T C 7.65E-04 Myopia (pathological) / / 21095009 rs11816024 chr10 132601324 T C 2.30E-05 Urinary metabolites / / 21572414 rs10829802 chr10 132604292 G A 1.80E-05 Urinary metabolites / / 21572414 rs11017491 chr10 132607399 T C 1.80E-05 Urinary metabolites / / 21572414 rs4751277 chr10 132618483 C T 1.09E-04 Amyotrophic lateral sclerosis / / 23624525 rs12242470 chr10 132620849 A G 3.13E-05 Elbow pain / / pha003008 rs7088120 chr10 132626327 T G 2.92E-04 Parkinson's disease / / 17052657 rs10829816 chr10 132629742 C G 1.83E-04 Multiple complex diseases / / 17554300 rs10829816 chr10 132629742 C G 2.60E-06 Urinary metabolites / / 21572414 rs1617928 chr10 132633344 G A 9.81E-04 Type 2 diabetes / / 17463246 rs7094308 chr10 132637305 C T 6.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs1433522 chr10 132652555 G T 9.01E-05 Multiple complex diseases / / 17554300 rs1703703 chr10 132659360 T C 3.50E-04 Multiple complex diseases / / 17554300 rs4751295 chr10 132682729 T C 9.03E-05 Blood Pressure / / pha002903 rs1655124 chr10 132691725 G A 5.30E-04 Nicotine dependence / / 17158188 rs1655129 chr10 132694161 A G 9.48E-04 Nicotine dependence / / 17158188 rs7074195 chr10 132721236 G C 1.75E-05 Migraine / / 23793025 rs10829844 chr10 132721599 G A 2.98E-05 Cognitive test performance / / 20125193 rs7893744 chr10 132723132 A G 4.78E-05 Orofacial clefts / / 22419666 rs2397395 chr10 132727601 G A 2.71E-05 Cognitive test performance / / 20125193 rs3125594 chr10 132747399 A T 4.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs10829848 chr10 132747887 C T 1.00E-07 Insulin-related traits / / 22791750 rs10829848 chr10 132747887 C T 3.00E-08 Insulin-related traits / / 22791750 rs3125598 chr10 132748033 A C 6.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs7069620 chr10 132749766 C T 4.89E-06 Insulin-related traits / / 22791750 rs10829849 chr10 132749948 T C 4.89E-06 Insulin-related traits / / 22791750 rs10829850 chr10 132750111 T C 4.66E-06 Insulin-related traits / / 22791750 rs10829851 chr10 132750124 C T 4.66E-06 Insulin-related traits / / 22791750 rs10829852 chr10 132750558 G A 4.66E-06 Insulin-related traits / / 22791750 rs10829853 chr10 132750629 G A 4.66E-06 Insulin-related traits / / 22791750 rs6482830 chr10 132751060 T C 4.66E-06 Insulin-related traits / / 22791750 rs7077836 chr10 132751498 G A 3.26E-07 Insulin-related traits / / 22791750 rs11017608 chr10 132751594 G A 4.66E-06 Insulin-related traits / / 22791750 rs10829854 chr10 132751918 T A 4.66E-06 Insulin-related traits / / 22791750 rs7079104 chr10 132759582 T C 2.77E-06 Insulin-related traits / / 22791750 rs7075487 chr10 132759618 A G 2.77E-06 Insulin-related traits / / 22791750 rs35818140 chr10 132760592 C G 2.77E-06 Insulin-related traits / / 22791750 rs7096489 chr10 132761119 G C 2.77E-06 Insulin-related traits / / 22791750 rs12245340 chr10 132789123 C T 1.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs11017649 chr10 132802206 C T 1.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs7092194 chr10 132803392 T C 1.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs12252519 chr10 132805155 G A 1.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs7068387 chr10 132807517 C T 1.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs10458719 chr10 132814714 C A 4.36E-04 Multiple complex diseases / / 17554300 rs7073330 chr10 132815843 C T 3.70E-05 Orofacial clefts / / 22419666 rs2051113 chr10 132822263 C T 1.88E-05 Orofacial clefts / / 22419666 rs12764951 chr10 132847790 C T 0.000000284 CD8+ T cell IFN-gamma response to smallpox vaccine / / 22661280 rs7910464 chr10 132854084 C T 5.55E-05 Post-operative nausea and vomiting / / 21694509 rs1419108 chr10 132859258 C T 1.84E-05 Cognitive test performance / / 20125193 rs7098146 chr10 132879852 T C 7.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3902786 chr10 132881848 A T 1.31E-04 Alcohol dependence / / 21314694 rs7088377 chr10 132891026 A G 1.62E-04 Schizophrenia(treatment response to risperidone) TCERG1L UTR-3 19850283 rs6482849 chr10 132903779 T A 1.04E-05 Hirschsprung's disease TCERG1L intron 19196962 rs12414474 chr10 132926440 T C 9.37E-05 Suicide attempts in bipolar disorder TCERG1L intron 21423239 rs12250538 chr10 132927646 C T 8.00E-05 Suicide attempts in bipolar disorder TCERG1L intron 21423239 rs7923325 chr10 132928393 T G 4.55E-04 Suicide attempts in bipolar disorder TCERG1L intron 21423239 rs7895423 chr10 132928542 T G 5.23E-04 Suicide attempts in bipolar disorder TCERG1L intron 21423239 rs10829911 chr10 132931188 T G 3.88E-05 Suicide attempts in bipolar disorder TCERG1L intron 21423239 rs10829912 chr10 132931236 C T 3.99E-05 Suicide attempts in bipolar disorder TCERG1L intron 21423239 rs10829913 chr10 132931252 A C 4.40E-05 Suicide attempts in bipolar disorder TCERG1L intron 21423239 rs11017741 chr10 132931331 C T 3.80E-05 Suicide attempts in bipolar disorder TCERG1L intron 21423239 rs7920711 chr10 132931710 C T 3.97E-05 Suicide attempts in bipolar disorder TCERG1L intron 21423239 rs7905619 chr10 132931776 A G 2.78E-05 Suicide attempts in bipolar disorder TCERG1L intron 21423239 rs7920843 chr10 132931812 C G,T 2.40E-05 Suicide attempts in bipolar disorder TCERG1L intron 21423239 rs7905749 chr10 132931857 A G 2.42E-05 Suicide attempts in bipolar disorder TCERG1L intron 21423239 rs6482862 chr10 132931959 G A 2.82E-05 Suicide attempts in bipolar disorder TCERG1L intron 21423239 rs6482863 chr10 132932077 G A 2.41E-05 Suicide attempts in bipolar disorder TCERG1L intron 21423239 rs12255578 chr10 132942607 G T 2.42E-04 Nicotine smoking TCERG1L intron 19268276 rs10741243 chr10 132947962 C G 5.00E-06 Type 2 diabetes TCERG1L intron 21490949 rs2397752 chr10 132983821 C T 1.33E-05 Attention deficit hyperactivity disorder TCERG1L intron 20732627 rs1583670 chr10 132984214 T C 1.94E-05 Attention deficit hyperactivity disorder TCERG1L intron 20732627 rs1370868 chr10 132984356 G A 1.07E-05 Attention deficit hyperactivity disorder TCERG1L intron 20732627 rs11593241 chr10 132986646 T C 5.73E-06 Attention deficit hyperactivity disorder TCERG1L intron 20732627 rs2033791 chr10 132993403 G A 7.66E-06 Attention deficit hyperactivity disorder TCERG1L intron 20732627 rs10829947 chr10 133001706 T C 5.31E-04 White matter integrity TCERG1L intron 22425255 rs11017838 chr10 133045646 G T 5.72E-04 Suicide attempts in bipolar disorder TCERG1L intron 21423239 rs1968517 chr10 133048749 T C 6.70E-04 Suicide attempts in bipolar disorder TCERG1L intron 21423239 rs2918092 chr10 133057479 G A 2.00E-06 Iron levels TCERG1L intron 21208937 rs7080842 chr10 133114209 T C 4.58E-05 Serum metabolites / / 19043545 rs10734104 chr10 133141257 T C 1.69E-06 Type 2 diabetes / / 21573907 rs11594412 chr10 133143956 T C 1.90E-05 Urinary metabolites / / 21572414 rs7898539 chr10 133146930 C T 5.93E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11017902 chr10 133147185 G T 7.03E-04 Alzheimer's disease / / 24755620 rs7099724 chr10 133150638 G A 7.68E-04 Alzheimer's disease / / 24755620 rs10734105 chr10 133172119 G A 3.00E-08 Crohn's disease / / 22412388 rs10829998 chr10 133178201 C T 1.69E-04 Multiple complex diseases / / 17554300 rs3123221 chr10 133178622 A G 3.19E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3123209 chr10 133189191 G A 2.29E-05 Bipolar disorder / / 21771265 rs4075537 chr10 133200384 T C 3.98E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs3125524 chr10 133214941 C T 0.0000383 Aging / / 22445811 rs3922590 chr10 133231622 C T 5.00E-04 Crohn's disease / / 17684544 rs4347298 chr10 133234551 G A 5.97E-04 Type 2 diabetes / / 17463246 rs4077607 chr10 133238622 A G 9.60E-06 Urinary metabolites / / 21572414 rs6482891 chr10 133262176 A G 1.60E-05 Urinary metabolites / / 21572414 rs10830010 chr10 133270077 A G 1.60E-05 Urinary metabolites / / 21572414 rs7091184 chr10 133273781 C T 9.10E-06 Urinary metabolites / / 21572414 rs4750869 chr10 133275948 T C 6.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10765074 chr10 133296653 C T 8.90E-05 Body Mass Index / / pha003019 rs4074863 chr10 133298189 G A 1.75E-04 Coronary Artery Disease / / 17634449 rs10765075 chr10 133300258 T C 8.43E-05 Telomere length / / 21573004 rs11018007 chr10 133301918 G A 0.00007256 Sarcoidosis / / 22952805 rs7922424 chr10 133316452 G A 4.37E-05 Left ventricular hypertrophy / / pha003052 rs11813611 chr10 133326894 C T 6.58E-08 Metabolite levels / / 23281178 rs11018023 chr10 133330026 G A 7.00E-06 Temperament / / 22832960 rs11818320 chr10 133335089 C T 4.46E-04 HIV-1 viral setpoint / / 17641165 rs4342938 chr10 133355477 A G 9.36E-07 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs10830046 chr10 133369314 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11156442 chr10 133441851 A C 9.52E-05 Major depressive disorder / / 21621269 rs9419596 chr10 133448637 C T 9.18E-04 Stroke / / pha002887 rs10782374 chr10 133461663 T G 4.24E-05 Major depressive disorder / / 21621269 rs6571245 chr10 133466045 A C 5.44E-06 Acute lymphoblastic leukemia (B-cell precursor) / / 23996088 rs7903080 chr10 133466347 G T 0.000882 Salmonella-induced pyroptosis / / 22837397 rs7913359 chr10 133500681 A G 2.02E-04 Alzheimer's disease / / 17998437 rs7913359 chr10 133500681 A G 1.30E-05 Urinary metabolites / / 21572414 rs7913359 chr10 133500681 A G 2.75E-04 Insulin resistance / / 21901158 rs4472854 chr10 133506259 G T 2.95E-04 Alzheimer's disease / / 17998437 rs4472854 chr10 133506259 G T 1.10E-05 Urinary metabolites / / 21572414 rs9419695 chr10 133515519 A C 1.94E-04 Multiple complex diseases / / 17554300 rs7067998 chr10 133533887 G C 7.00E-04 Depression (quantitative trait) / / 20800221 rs9322838 chr10 133539334 A G 7.20E-04 Alzheimer's disease / / 17998437 rs9322838 chr10 133539334 A G 4.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs9419648 chr10 133560927 T C 2.46E-05 Bipolar disorder / / 18317468 rs9419649 chr10 133561098 A G 1.97E-05 Bipolar disorder / / 18317468 rs9419651 chr10 133561666 A G 1.87E-05 Bipolar disorder / / 18317468 rs4307646 chr10 133569448 C T 2.23E-05 Bipolar disorder / / 18317468 rs4243517 chr10 133578066 A G 6.50E-04 Taste perception / / 22132133 rs4897783 chr10 133608237 G A 0.00035 Prostate cancer / / 23555315 rs12263358 chr10 133647132 G C 2.00E-05 Urinary metabolites / / 21572414 rs7904594 chr10 133734671 C T 2.19E-05 Amyotrophic lateral sclerosis / / 20801717 rs4131689 chr10 133744328 C A 5.18E-05 Cervical cancer / / 24700089 rs7072006 chr10 133745628 C T 4.15E-04 Coronary heart disease / / 21971053 rs10870270 chr10 133754334 G A 2.25E-05 Amyotrophic lateral sclerosis / / 20801717 rs9419390 chr10 133790872 T A,G 8.72E-05 Type 2 diabetes BNIP3 intron 17463246 rs1970005 chr10 133863091 T C 4.90E-04 Lymphocyte counts / / 22286170 rs9419329 chr10 133863665 A G 9.58E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs2172130 chr10 133909957 G A 2.20E-05 Multiple complex diseases / / 17554300 rs9419187 chr10 133911932 T C 1.11E-05 Alopecia areata / / 22027810 rs1491192 chr10 133942779 A G 9.63E-05 Multiple complex diseases JAKMIP3 intron 17554300 rs2814184 chr10 133945696 T C 9.66E-06 Multiple complex diseases JAKMIP3 intron 17554300 rs954820 chr10 133957761 G A 4.00E-06 Chronic obstructive pulmonary disease-related biomarkers JAKMIP3 intron 23144326 rs4880341 chr10 133992689 C T 1.85E-11 Lymphocyte counts JAKMIP3 intron 22286170 rs2637648 chr10 133996225 G A 1.98E-05 Hodgkin's lymphoma JAKMIP3 UTR-3 24149102 rs1046577 chr10 134021149 T C 6.67E-04 Taste perception STK32C UTR-3 22132133 rs2890337 chr10 134023630 T C 5.19E-05 Multiple complex diseases STK32C intron 17554300 rs11146253 chr10 134026212 G A 5.36E-04 Response to taxane treatment (placlitaxel) STK32C intron 23006423 rs2035804 chr10 134034379 A G 7.55E-05 Male fertility STK32C intron 22633400 rs1038799 chr10 134047530 G A 1.69E-04 Multiple complex diseases STK32C intron 17554300 rs7910485 chr10 134049333 T C 8.00E-06 Type 2 diabetes STK32C intron 17668382 rs2814191 chr10 134071848 A G 7.70E-05 Cervical cancer STK32C intron 24700089 rs11146273 chr10 134073393 A G 9.26E-04 Obesity (extreme) STK32C intron 21935397 rs11146313 chr10 134100004 C T 5.90E-04 Obesity (extreme) STK32C intron 21935397 rs7897895 chr10 134101674 A G 2.37E-04 Obesity (extreme) STK32C intron 21935397 rs7911172 chr10 134102055 G T 4.84E-04 Obesity (extreme) STK32C intron 21935397 rs10781566 chr10 134104861 A G 4.83E-04 Obesity (extreme) STK32C intron 21935397 rs10870287 chr10 134105044 C T 4.91E-04 Obesity (extreme) STK32C intron 21935397 rs11818502 chr10 134107027 C T 5.28E-04 Obesity (extreme) STK32C intron 21935397 rs7074272 chr10 134108692 C T 5.40E-04 Obesity (extreme) STK32C intron 21935397 rs2260876 chr10 134158316 A C 5.53E-04 Coronary heart disease LRRC27 intron 21606135 rs4437956 chr10 134181061 G A 3.48E-05 Cognitive impairment induced by topiramate LRRC27 intron 22091778 rs148966337 chr10 134261392 G A 0.0000076 Breast cancer(er negative) C10orf91 missense 23555315 rs12772482 chr10 134294859 G A 6.89E-04 Body mass index / / 21701565 rs73389468 chr10 134295815 C T 9.00E-06 Periodontitis (CDC/AAP) / / 24024966 rs4880264 chr10 134339400 A C 7.57E-04 Multiple complex diseases / / 17554300 rs7091957 chr10 134439478 T C 0.000669 Salmonella-induced pyroptosis INPP5A intron 22837397 rs11146457 chr10 134482349 A G 4.88E-04 Smoking cessation INPP5A intron 24665060 rs913193 chr10 134544247 T C 2.00E-04 Cognitive impairment induced by topiramate INPP5A intron 22091778 rs2148666 chr10 134553785 C T 9.50E-05 Personality dimensions INPP5A intron 18957941 rs12267364 chr10 134554926 C T 5.48E-05 Partial epilepsies INPP5A intron 20522523 rs2803989 chr10 134560596 G A 2.00E-04 Cognitive impairment induced by topiramate INPP5A intron 22091778 rs7092049 chr10 134609699 G A 1.60E-05 Urinary metabolites / / 21572414 rs4880277 chr10 134633353 A G 2.81E-04 Lung function (forced expiratory volume in 1 second) TTC40 intron 17255346 rs11817093 chr10 134644160 T C 2.50E-04 Smoking initiation TTC40 intron 24665060 rs4880433 chr10 134646988 C T 3.96E-04 Lung function (forced expiratory volume in 1 second) TTC40 missense 17255346 rs11146539 chr10 134656513 G C 8.84E-05 Multiple complex diseases TTC40 intron 17554300 rs7090577 chr10 134665329 A G 2.96E-04 Lung function (forced expiratory volume in 1 second) TTC40 intron 17255346 rs2001323 chr10 134672852 T C 2.47E-04 Lung function (forced expiratory volume in 1 second) TTC40 intron 17255346 rs10870347 chr10 134681932 C T 4.74E-05 Cognitive test performance TTC40 intron 20125193 rs7907613 chr10 134705373 T C 1.91E-04 Lung function (forced expiratory volume in 1 second) TTC40 intron 17255346 rs4242712 chr10 134754297 A G 4.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TTC40 intron 20877124 rs12413155 chr10 134810401 G A 3.12E-04 Alzheimer's disease (late onset) / / 21379329 rs4294501 chr10 134873188 A C 2.48E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4271313 chr10 134884595 G A 5.84E-06 Rheumatoid arthritis / / 17804836 rs7086622 chr10 134911489 G C 5.30E-04 Multiple complex diseases GPR123 intron 17554300 rs7918862 chr10 134916121 T A 5.61E-04 Multiple complex diseases GPR123 intron 17554300 rs736017 chr10 134917297 G A 4.90E-04 Type 2 diabetes GPR123 intron 17463246 rs736017 chr10 134917297 G A 9.32E-04 Multiple complex diseases GPR123 intron 17554300 rs7070794 chr10 134917834 T C 3.33E-04 Lung function (forced expiratory volume in 1 second) GPR123 intron 17255346 rs9419015 chr10 134954376 T C 7.52E-04 Parkinson's disease / / 17052657 rs11101601 chr10 134984721 T A 3.60E-04 Multiple complex diseases KNDC1 intron 17554300 rs11101606 chr10 134987060 G A 3.26E-04 Multiple complex diseases KNDC1 intron 17554300 rs9418943 chr10 135023586 G A 3.36E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) KNDC1 intron 24023788 rs2995295 chr10 135068670 C G 9.79E-06 Multiple complex diseases / / 17554300 rs11101694 chr10 135146714 T C 3.39E-04 Schizophrenia CALY intron 19197363 rs2864417 chr10 135159200 A G 1.64E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7100433 chr10 135183802 T C 0.000000141 Triglycerides ECHS1 intron 23063622 rs7100433 chr10 135183802 T C 1.96E-10 LDL cholesterol ECHS1 intron 23063622 rs11101722 chr10 135190429 T C 1.80E-11 Biliary atresia / / 20460270 rs11101727 chr10 135194938 C T 3.48E-04 Multiple complex diseases PAOX intron 17554300 rs11101730 chr10 135197336 A T 3.00E-13 Blood metabolite levels PAOX intron 24816252 rs7901735 chr10 135214344 G A 9.62E-04 Insulin resistance MTG1 intron 21901158 rs10857712 chr10 135225666 T C 3.00E-06 Systemic lupus erythematosus MTG1 intron 24871463 rs2252728 chr10 135275358 T G 5.50E-04 Type 2 diabetes and 6 quantitative traits LOC619207 intron 17848626 rs2243909 chr10 135279810 T G 0.000876514 Hypertension (early onset hypertension) / / 22479346 rs10857722 chr10 135281744 A T 9.26E-04 Multiple complex diseases / / 17554300 rs2814209 chr10 135282201 T C 4.44E-04 Multiple complex diseases / / 17554300 rs2814209 chr10 135282201 T C 4.79E-04 Alcohol dependence / / 21314694 rs1536827 chr10 135306158 C T 4.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs10776686 chr10 135332931 C T 4.98E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs915909 chr10 135347397 T C 0.00033 Coronary artery calcification / / 23727086 rs2515642 chr10 135352013 C T 4.45E-05 Information processing speed CYP2E1 intron 21130836 rs2480259 chr10 135352076 A G 5.46E-05 Information processing speed CYP2E1 intron 21130836 rs2480258 chr10 135352100 T C 4.86E-05 Information processing speed CYP2E1 intron 21130836 rs2249694 chr10 135352153 A G 4.88E-05 Information processing speed CYP2E1 intron 21130836 rs2249694 chr10 135352153 A G 3.00E-06 Obesity-related traits CYP2E1 intron 23251661 rs2249695 chr10 135352168 T C 5.21E-05 Information processing speed CYP2E1 intron 21130836 rs2249695 chr10 135352168 T C 9.53E-06 Obesity-related traits CYP2E1 intron 23251661 rs1952467 chr10 135353499 T G 4.87E-05 Information processing speed / / 21130836 rs8192781 chr10 135354251 T G 4.86E-05 Information processing speed / / 21130836 rs1536826 chr10 135357239 A C 5.54E-05 Information processing speed / / 21130836 rs2987799 chr10 135380499 T G 1.20E-05 Response to antidepressants SYCE1 intron 19736353 rs11602954 chr11 202856 G A 1.00E-14 Mean platelet volume / / 19820697 rs11602954 chr11 202856 G A 1.10E-12 Mean platelet volume / / 22423221 rs11602954 chr11 202856 G A 2.00E-06 Bone mineral density / / 22504420 rs11602954 chr11 202856 G A 5.00E-12 Platelet counts / / 24026423 rs2280543 chr11 203788 C T 4.00E-12 Uterine fibroids BET1L UTR-3 21460842 rs2280543 chr11 203788 C T 3.00E-06 Intracranial aneurysm BET1L UTR-3 22286173 rs2280544 chr11 204062 T C 1.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BET1L UTR-3 20877124 rs2280544 chr11 204062 T C 7.38E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BET1L UTR-3 20877124 rs11246007 chr11 221584 C T 5.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SIRT3 intron 20877124 rs11246007 chr11 221584 C T 6.50E-05 Information processing speed SIRT3 intron 21130836 rs1023430 chr11 224393 A G 2.00E-04 Information processing speed SIRT3 intron 21130836 rs505404 chr11 243268 T G 7.00E-25 Platelet counts PSMD13 intron 22139419 rs505404 chr11 243268 T G 2.00E-11 Platelet counts PSMD13 intron 24026423 rs7116130 chr11 244129 C T 3.77E-04 Alzheimer's disease PSMD13 missense 17998437 rs540078 chr11 254256 C T 3.20E-05 Glycated hemoglobin levels / / 24647736 rs879872 chr11 256714 C T 1.14E-11 Colorectal cancer / / 22532847 rs17655730 chr11 270715 T C 2.00E-15 Mean platelet volume / / 22139419 rs142448057 chr11 284328 G C 0.0000043 Breast cancer(er negative) NLRP6 missense 23555315 rs3809112 chr11 307036 T C 1.18E-05 Sleep duration / / 22105623 rs11246067 chr11 326564 A T 1.62E-05 Sleep duration / / 22105623 rs11246074 chr11 336332 A G 6.71E-05 Lymphocyte counts / / 22286170 rs11246089 chr11 344351 A G 2.38E-04 Body mass index / / 21701565 rs11246089 chr11 344351 A G 7.63E-04 Body mass index / / 21701565 rs11246090 chr11 344368 C A 1.25E-04 Body mass index / / 21701565 rs11246090 chr11 344368 C A 2.92E-04 Body mass index / / 21701565 rs11246094 chr11 345515 A G 2.09E-04 Body mass index / / 21701565 rs11246094 chr11 345515 A G 7.14E-04 Body mass index / / 21701565 rs3210908 chr11 406483 T C 1.83E-05 Post-operative nausea and vomiting SIGIRR missense 21694509 rs10794323 chr11 428385 A G 6.50E-04 Response to cytadine analogues (cytosine arabinoside) ANO9 missense 24483146 rs7935013 chr11 467339 A G 1.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTDSS2 intron 20877124 rs4963194 chr11 484204 A G 7.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTDSS2 intron 20877124 rs7930593 chr11 502013 G A 1.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RNH1 intron 20877124 rs7944548 chr11 502217 C T 9.77E-05 Urate levels RNH1 UTR-5 23263486 rs139348192 chr11 551741 C T 0.000039 Prostate cancer (advanced) LRRC56 missense 23555315 rs936466 chr11 557342 T C 2.73E-07 Left ventricular hypertrophy C11orf35 intron pha003052 rs4963128 chr11 589564 T C 3.00E-10 Systemic lupus erythematosus PHRF1 intron 18204446 rs4963128 chr11 589564 T C 4.00E-06 Systemic lupus erythematosus PHRF1 intron 21408207 rs4963128 chr11 589564 T C 4.90E-09 Multiple sclerosis PHRF1 intron 22190364 rs4963128 chr11 589564 T C 2.50E-05 Systemic lupus erythematosus PHRF1 intron 24871463 rs2396545 chr11 601785 T C 8.00E-06 Systemic lupus erythematosus and Systemic sclerosis PHRF1 intron 23740937 rs936469 chr11 606749 G A 9.64E-07 Systemic lupus erythematosus and Systemic sclerosis PHRF1 intron 23740937 rs936469 chr11 606749 G A 9.33E-05 Coronary heart disease PHRF1 intron pha003033 rs3758650 chr11 616865 G A 6.80E-05 Left ventricular hypertrophy CDHR5 UTR-3 pha003052 rs3758650 chr11 616865 G A 4.28E-05 Diabetes Mellitus CDHR5 UTR-3 pha003060 rs6598008 chr11 618172 A G 4.41E-04 Alzheimer's disease CDHR5 intron 24755620 rs11246255 chr11 672443 C T 1.10E-05 Urinary metabolites DEAF1 intron 21572414 rs10902190 chr11 678561 C T 2.80E-04 Lymphocyte counts DEAF1 intron 22286170 rs12293143 chr11 705404 A G 1.45E-05 Weight / / pha003026 rs11246281 chr11 709861 A G 8.39E-06 Lymphocyte counts EPS8L2 intron 22286170 rs7942569 chr11 710139 G A 6.07E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) EPS8L2 intron 23648065 rs11246286 chr11 715420 G A 0.0000015 Primary sclerosing cholangitis EPS8L2 intron 23603763 rs7930569 chr11 771034 A G 6.92E-04 Alcohol dependence PDDC1 cds-synon 20201924 rs11823172 chr11 772982 G A 4.07E-04 Multiple complex diseases PDDC1 intron 17554300 rs35694355 chr11 831883 G A 3.00E-06 Obesity-related traits EFCAB4A UTR-3 23251661 rs11246327 chr11 840034 C A 5.87E-05 Multiple complex diseases POLR2L UTR-3 17554300 rs11246327 chr11 840034 C A 3.60E-04 Alcohol dependence POLR2L UTR-3 20201924 rs12577694 chr11 888150 T C 3.08E-04 Alzheimer's disease CHID1 intron 17998437 rs11246340 chr11 900809 G A 4.08E-05 Lymphocyte counts CHID1 intron 22286170 rs10751667 chr11 941941 A T 6.00E-07 Alzheimer's disease (late onset) AP2A2 intron 24162737 rs10794350 chr11 946070 A G 7.42E-04 Schizophrenia AP2A2 intron 19197363 rs10902239 chr11 946484 G A 8.86E-04 Multiple complex diseases AP2A2 intron 17554300 rs6421967 chr11 983966 T C 0.0000035 Glomerular filtration rate AP2A2 intron 22962313 rs7950955 chr11 1011490 G A 9.10E-05 Intelligence AP2A2 UTR-3 21826061 rs10902269 chr11 1018116 T G 1.50E-09 Health and aging,CVD and cancer age of onset MUC6 missense 22174011 rs10902269 chr11 1018116 T G 3.00E-21 Health and aging,CVD and cancer age of onset MUC6 missense 22174011 rs10902269 chr11 1018116 T G 3.90E-29 Health and aging,CVD and cancer age of onset MUC6 missense 22174011 rs10902269 chr11 1018116 T G 7.20E-12 Health and aging,CVD and cancer age of onset MUC6 missense 22174011 rs7481521 chr11 1027811 C T 5.52E-04 Schizophrenia MUC6 missense 19197363 rs11246386 chr11 1044938 T C 1.00E-05 Bone mineral density (spine) / / 19079262 rs10902073 chr11 1060934 C A 3.62E-14 Interstitial lung disease / / 23583980 rs10794278 chr11 1061718 G T 5.08E-14 Interstitial lung disease / / 23583980 rs10794279 chr11 1061781 C T 5.06E-14 Interstitial lung disease / / 23583980 rs10794280 chr11 1062867 C T 1.30E-14 Interstitial lung disease / / 23583980 rs10751635 chr11 1062990 A G 1.86E-07 Interstitial lung disease / / 23583980 rs10794281 chr11 1063149 T C 7.04E-05 Serum metabolites / / 19043545 rs2301160 chr11 1063767 T C 9.19E-05 Serum metabolites / / 19043545 rs2301160 chr11 1063767 T C 1.90E-07 Interstitial lung disease / / 23583980 rs10794284 chr11 1067011 G A 2.36E-14 Interstitial lung disease / / 23583980 rs12146505 chr11 1068233 T G 3.68E-05 Alcohol dependence / / 20201924 rs12146505 chr11 1068233 T G 3.68E-05 Alcoholism / / pha002891 rs7942850 chr11 1068900 T C 7.16E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7942850 chr11 1068900 T C 2.03E-14 Interstitial lung disease / / 23583980 rs7942850 chr11 1068900 T C 9.29E-14 Interstitial lung disease / / 23583980 rs2071174 chr11 1073712 T C 3.10E-07 Interstitial lung disease / / 23583980 rs41345745 chr11 1081112 G C 0.00058 Prostate cancer / / 23555315 rs7396030 chr11 1083364 G A 5.09E-04 Oral cancers (chewing tobacco related) / / 22503698 rs7396030 chr11 1083364 G A 2.47E-08 Interstitial lung disease / / 23583980 rs7396030 chr11 1083364 G A 5.90E-08 Interstitial lung disease / / 23583980 rs11245936 chr11 1084362 G A 0.0000146 Tuberculosis with early age of onset / / 22551897 rs10902088 chr11 1087972 C T 9.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10902088 chr11 1087972 C T 7.99E-09 Interstitial lung disease / / 23583980 rs10902088 chr11 1087972 C T 8.00E-09 Interstitial lung disease / / 23583980 rs7103978 chr11 1088815 A G 1.69E-05 Interstitial lung disease / / 23583980 rs7934606 chr11 1093945 T C 4.27E-24 Interstitial lung disease / / 23583980 rs7934606 chr11 1093945 T C 5.46E-22 Interstitial lung disease / / 23583980 rs7934606 chr11 1093945 T C 7.00E-34 Interstitial lung disease / / 23583980 rs6421972 chr11 1096494 T C 1.62E-21 Interstitial lung disease / / 23583980 rs6421972 chr11 1096494 T C 1.92E-23 Interstitial lung disease / / 23583980 rs7480563 chr11 1101649 T C 4.68E-05 Asthma / / 22561531 rs7480563 chr11 1101649 T C 2.68E-18 Interstitial lung disease / / 23583980 rs7480563 chr11 1101649 T C 4.17E-18 Interstitial lung disease / / 23583980 rs7927765 chr11 1104626 G A 6.26E-08 Metabolite levels / / 23281178 rs4077757 chr11 1105834 T A 7.10E-08 Metabolite levels / / 23281178 rs4077759 chr11 1105976 C T 3.23E-12 Interstitial lung disease / / 23583980 rs4077759 chr11 1105976 C T 8.47E-13 Interstitial lung disease / / 23583980 rs10902095 chr11 1115911 T C 3.00E-04 Iris characteristics / / 21835309 rs6421966 chr11 1126979 G T 4.73E-05 Interstitial lung disease / / 23583980 rs2672794 chr11 1241005 T C 7.07E-11 Interstitial lung disease / / 23583980 rs35705950 chr11 1241221 G A,T 2.00E-50 Idiopathic pulmonary fibrosis / / 24429156 rs868903 chr11 1242690 T C 1.26E-22 Interstitial lung disease MUC5B nearGene-5 23583980 rs868903 chr11 1242690 T C 1.31E-25 Interstitial lung disease MUC5B nearGene-5 23583980 rs2672812 chr11 1249372 G A 4.93E-10 Interstitial lung disease MUC5B intron 23583980 rs2075859 chr11 1250488 C T 1.20E-12 Interstitial lung disease MUC5B cds-synon 23583980 rs2075859 chr11 1250488 C T 4.72E-04 Self-reported allergy MUC5B cds-synon 23817569 rs2075859 chr11 1250488 C T 8.09E-05 Serum albumin level MUC5B cds-synon pha003084 rs201500908 chr11 1251368 T A 0.00012 Breast cancer (ER positive) MUC5B missense 23555315 rs2735727 chr11 1257459 G A 1.17E-08 Interstitial lung disease MUC5B intron 23583980 rs2735727 chr11 1257459 G A 8.58E-06 Interstitial lung disease MUC5B intron 23583980 rs2735727 chr11 1257459 G A 6.84E-06 Serum albumin level MUC5B intron pha003084 rs2014486 chr11 1258803 A G 1.22E-09 Interstitial lung disease MUC5B intron 23583980 rs2735733 chr11 1261640 C T 2.43E-09 Interstitial lung disease MUC5B intron 23583980 rs2735733 chr11 1261640 C T 9.75E-04 Self-reported allergy MUC5B intron 23817569 rs4963059 chr11 1272858 C T 1.54E-09 Interstitial lung disease MUC5B cds-synon 23583980 rs2857476 chr11 1281134 T C 1.10E-09 Interstitial lung disease MUC5B intron 23583980 rs2857476 chr11 1281134 T C 1.62E-06 Interstitial lung disease MUC5B intron 23583980 rs2857476 chr11 1281134 T C 1.65E-05 Serum albumin level MUC5B intron pha003084 rs12417955 chr11 1284227 A G 1.48E-06 Interstitial lung disease / / 23583980 rs12417955 chr11 1284227 A G 8.40E-10 Interstitial lung disease / / 23583980 rs12417955 chr11 1284227 A G 8.53E-06 Serum albumin level / / pha003084 rs5744034 chr11 1296237 A G 1.15E-19 Interstitial lung disease TOLLIP UTR-3 23583980 rs3168046 chr11 1296649 G A 1.21E-12 Interstitial lung disease TOLLIP UTR-3 23583980 rs3829223 chr11 1300406 C T 1.40E-09 Interstitial lung disease TOLLIP intron 23583980 rs3829223 chr11 1300406 C T 7.52E-07 Interstitial lung disease TOLLIP intron 23583980 rs3793964 chr11 1301982 T C 1.65E-09 Interstitial lung disease TOLLIP intron 23583980 rs3793964 chr11 1301982 T C 7.77E-07 Interstitial lung disease TOLLIP intron 23583980 rs3750920 chr11 1309956 C T 1.22E-10 Interstitial lung disease TOLLIP cds-synon 23583980 rs111521887 chr11 1312706 C G 2.20E-12 Idiopathic pulmonary fibrosis TOLLIP intron 24429156 rs5743894 chr11 1324772 T C 1.00E-12 Idiopathic pulmonary fibrosis TOLLIP intron 24429156 rs5743890 chr11 1325829 T C 3.00E-11 Idiopathic pulmonary fibrosis TOLLIP intron 24429156 rs5743863 chr11 1328912 G A 5.70E-05 Multiple complex diseases TOLLIP intron 17554300 rs1033198 chr11 1346802 T G 3.12E-08 Interstitial lung disease / / 23583980 rs7118481 chr11 1348338 G C 5.13E-04 Prostate cancer mortality / / 20978177 rs7118481 chr11 1348338 G C 3.44E-08 Interstitial lung disease / / 23583980 rs2334659 chr11 1357063 G A 1.22E-08 Interstitial lung disease / / 23583980 rs2334659 chr11 1357063 G A 4.71E-09 Interstitial lung disease / / 23583980 rs7122936 chr11 1374456 C A 1.78E-10 Interstitial lung disease / / 23583980 rs7122936 chr11 1374456 C A 3.69E-08 Interstitial lung disease / / 23583980 rs7122936 chr11 1374456 C A 1.77E-05 Serum albumin level / / pha003084 rs11023590 chr11 1375960 C T 5.97E-10 Interstitial lung disease / / 23583980 rs10832483 chr11 1377230 C T 2.91E-05 Serum albumin level / / pha003084 rs3925133 chr11 1393709 A G 3.60E-05 Serum albumin level / / pha003084 rs10832840 chr11 1397897 C T 5.11E-04 Body mass index / / 21701565 rs10832840 chr11 1397897 C T 0.00000468 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs10832843 chr11 1398019 G A 4.31E-04 Body mass index / / 21701565 rs4881745 chr11 1398316 C T 0.0000037 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs7944761 chr11 1404838 C T 3.98E-05 Interstitial lung disease / / 23583980 rs7944761 chr11 1404838 C T 3.53E-07 Serum albumin level / / pha003084 rs7941517 chr11 1429616 G A 4.44E-05 Potassium levels BRSK2 intron pha003086 rs10766906 chr11 1440776 G T 6.03E-04 Suicide attempts in bipolar disorder BRSK2 intron 21423239 rs10833693 chr11 1441553 T C 5.90E-04 Suicide attempts in bipolar disorder BRSK2 intron 21423239 rs10833701 chr11 1441996 C T 8.41E-04 Suicide attempts in bipolar disorder BRSK2 intron 21423239 rs10833703 chr11 1442226 C T 4.19E-04 Suicide attempts in bipolar disorder BRSK2 intron 21423239 rs12803212 chr11 1443314 C T 4.00E-04 Suicide attempts in bipolar disorder BRSK2 intron 21423239 rs1317780 chr11 1444328 C G 3.15E-04 Suicide attempts in bipolar disorder BRSK2 intron 21423239 rs11602013 chr11 1473931 G A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes BRSK2 intron 22628534 rs7944983 chr11 1596246 G A 1.95E-04 Body mass index LOC338651 intron 21701565 rs11034930 chr11 1608229 A C 1.20E-05 Urinary metabolites LOC338651 intron 21572414 rs2334501 chr11 1620784 C T 3.52E-04 Body mass index / / 21701565 rs10837407 chr11 1625363 T C 6.04E-05 Serum metabolites / / 19043545 rs7108647 chr11 1629747 T C 3.14E-04 Body mass index / / 21701565 rs12792005 chr11 1630177 G A 8.63E-10 Interstitial lung disease / / 23583980 rs10768666 chr11 1632411 A G 1.19E-04 Body mass index / / 21701565 rs10837645 chr11 1635812 T C 2.74E-04 Body mass index / / 21701565 rs11036478 chr11 1637213 G A 4.75E-04 Body mass index / / 21701565 rs12273868 chr11 1637881 G A 4.46E-04 Body mass index / / 21701565 rs35678986 chr11 1642602 T G 7.61E-14 Interstitial lung disease / / 23583980 rs10837859 chr11 1645966 G A 5.83E-04 Body mass index / / 21701565 rs12365311 chr11 1649887 C G 6.03E-04 Body mass index / / 21701565 rs11601290 chr11 1666298 A T 8.57E-04 Type 2 diabetes / / 17463246 rs11038129 chr11 1671224 G A 3.77E-04 Multiple complex diseases / / 17554300 rs10769146 chr11 1678014 T G 7.36E-05 Cognitive performance / / 19734545 rs17173843 chr11 1679711 C T 8.46E-05 Bladder cancer / / 19648920 rs7110331 chr11 1683564 G T 2.19E-04 Birth weight / / 17255346 rs12806058 chr11 1693052 C T 6.01E-04 Body mass index / / 21701565 rs748541 chr11 1696016 G A 0.000000551 LDL cholesterol particle diameter / / 23263444 rs748541 chr11 1696016 G A 0.00000652 HDL cholesterol particle diameter / / 23263444 rs2334499 chr11 1696849 C T 0.00085 Type 2 diabetes (males) / / 22885922 rs11039428 chr11 1702321 T C 2.66E-04 Alzheimer's disease (late onset) / / 21379329 rs10839220 chr11 1714736 A C 6.19E-04 Type 2 diabetes / / 17463246 rs4752744 chr11 1718266 G A 4.42E-05 Interstitial lung disease / / 23583980 rs6578748 chr11 1732010 G A 7.15E-04 Myopia (pathological) / / 21095009 rs3740627 chr11 1754400 G A 9.78E-05 Triglycerides IFITM10 UTR-3 pha003080 rs7938305 chr11 1760556 G T 1.52E-04 Multiple complex diseases IFITM10 intron 17554300 rs17571 chr11 1782594 G A 6.75E-05 Waist Circumference CTSD missense pha003025 rs10839714 chr11 1822481 A G 5.78E-04 Heart Failure / / pha002885 rs7932087 chr11 1838366 G C 2.43E-06 Multiple complex diseases / / 17554300 rs10839756 chr11 1841555 T C 8.44E-06 Multiple complex diseases / / 17554300 rs11041294 chr11 1841827 T G 4.01E-04 Coronary Artery Disease / / 17634449 rs907609 chr11 1857270 C T 1.30E-04 Alcohol dependence SYT8 intron 20201924 rs907611 chr11 1874072 G A 1.00E-10 Ulcerative colitis LSP1 nearGene-5 21297633 rs907611 chr11 1874072 G A 3.00E-10 Inflammatory bowel disease LSP1 nearGene-5 23128233 rs907611 chr11 1874072 G A 4.00E-08 Bladder cancer LSP1 nearGene-5 24163127 rs2137320 chr11 1884342 G A 4.80E-04 White matter integrity LSP1 intron 22425255 rs2137320 chr11 1884342 G A 4.58E-04 Response to taxane treatment (placlitaxel) LSP1 intron 23006423 rs622173 chr11 1886147 G A 1.36E-04 Alzheimer's disease (late onset) LSP1 intron 21379329 rs11041553 chr11 1888955 G A 2.86E-05 Alcohol dependence LSP1 intron 20201924 rs11041553 chr11 1888955 G A 2.86E-05 Alcoholism LSP1 intron pha002891 rs592373 chr11 1890990 G A 7.50E-06 Blood pressure LSP1 intron 22100073 rs661348 chr11 1905292 T C 2.22E-09 Blood pressure LSP1 intron 22100073 rs661348 chr11 1905292 T C 2.42E-05 Blood pressure LSP1 intron 22100073 rs661348 chr11 1905292 T C 2.98E-11 Blood pressure LSP1 intron 22100073 rs661348 chr11 1905292 T C 4.32E-11 Blood pressure LSP1 intron 22100073 rs661348 chr11 1905292 T C 5.78E-09 Blood pressure LSP1 intron 22100073 rs661348 chr11 1905292 T C 6.09E-04 Alzheimer's disease LSP1 intron 24755620 rs3817197 chr11 1906174 G A 3.10E-04 Blood pressure LSP1 intron 22100073 rs3817198 chr11 1909006 T C 3.00E-09 Breast cancer LSP1 intron 17529967 rs3817198 chr11 1909006 T C 3.00E-09 Nasopharyngeal carcinoma LSP1 intron 20512145 rs3817198 chr11 1909006 T C 2.00E-11 Breast cancer LSP1 intron 23535729 rs7102920 chr11 1917872 G A 3.43E-05 Alzheimer's disease / / 24755620 rs7120258 chr11 1938523 C A 4.01E-04 Alzheimer's disease / / 24755620 rs56840816 chr11 1940357 C T 6.60E-14 Mean platelet volume TNNT3 nearGene-5 22423221 rs73413011 chr11 1941481 T C 1.22E-06 Personality dimensions TNNT3 intron 23658558 rs909116 chr11 1941946 T C 7.00E-07 Breast cancer TNNT3 intron 20453838 rs909116 chr11 1941946 T C 1.80E-04 Blood pressure TNNT3 intron 22100073 rs909116 chr11 1941946 T C 9.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) TNNT3 intron 23648065 rs965912 chr11 1944202 A G 8.50E-05 Hypothyroidism TNNT3 intron 22493691 rs2734495 chr11 1958996 C T 3.34E-04 Suicide attempts in bipolar disorder TNNT3 intron 21423239 rs12812 chr11 1977552 G A 5.35E-05 Response to mTOR inhibitor (rapamycin) MRPL23 missense 24009623 rs10769945 chr11 1985127 C T 2.94E-04 Lymphocyte counts / / 22286170 rs10769945 chr11 1985127 C T 5.00E-07 DNA methylation (variation) / / 23725790 rs10769945 chr11 1985127 C T 4.07E-04 Alzheimer's disease / / 24755620 rs2285935 chr11 2014646 G A 2.00E-11 DNA methylation (parent-of-origin) / / 23725790 rs2285935 chr11 2014646 G A 4.00E-09 DNA methylation (variation) / / 23725790 rs217228 chr11 2014709 T C 2.87E-04 Alzheimer's disease (late onset) / / 21379329 rs217228 chr11 2014709 T C 4.51E-09 DNA methylation (variation) / / 23725790 rs217228 chr11 2014709 T C 5.37E-06 Alzheimer's disease / / 24755620 rs2067051 chr11 2018168 C T 1.00E-08 DNA methylation (parent-of-origin) / / 23725790 rs2067051 chr11 2018168 C T 1.46E-14 DNA methylation (variation) / / 23725790 rs2067051 chr11 2018168 C T 7.00E-08 DNA methylation (parent-of-origin) / / 23725790 rs2107425 chr11 2021075 C T 7.00E-06 Breast cancer / / 17529967 rs4930103 chr11 2024544 G A 1.00E-14 DNA methylation (variation) / / 23725790 rs4930103 chr11 2024544 G A 5.00E-16 DNA methylation (parent-of-origin) / / 23725790 rs4930103 chr11 2024544 G A 6.34E-04 Alzheimer's disease / / 24755620 rs7950932 chr11 2029278 C T 2.20E-05 Urinary metabolites / / 21572414 rs4930144 chr11 2048488 A G 7.00E-06 Celiac disease / / 23936387 rs7928968 chr11 2050299 A T 2.23E-06 Multiple complex diseases / / 17554300 rs7928968 chr11 2050299 A T 1.18E-05 Type 1 diabetes / / 18978792 rs7928968 chr11 2050299 A T 2.78E-14 Type 1 diabetes / / 21980299 rs7940766 chr11 2050558 G A 6.91E-04 Premature ovarian failure / / 19508998 rs7479065 chr11 2068717 A G 7.69E-04 Premature ovarian failure / / 19508998 rs7932964 chr11 2070570 C T 4.90E-05 HDL particle features / / pha002900 rs7925515 chr11 2073913 A G 8.78E-04 Coronary heart disease / / 21971053 rs4930030 chr11 2087220 T C 6.88E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10840303 chr11 2092983 G C 5.27E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4930034 chr11 2096707 G A 7.98E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7924768 chr11 2108072 G A 5.00E-04 Coronary heart disease / / 21971053 rs11042594 chr11 2117403 A G 2.23E-04 Coronary heart disease / / 21971053 rs4929957 chr11 2128309 G A 6.26E-06 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs6578985 chr11 2138139 A G 4.19E-05 Coronary heart disease / / 21971053 rs6578985 chr11 2138139 A G 3.00E-06 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs6578985 chr11 2138139 A G 6.00E-06 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs6578986 chr11 2138152 A G 6.81E-06 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs7115054 chr11 2140255 A G 4.85E-05 Coronary heart disease / / 21971053 rs6578987 chr11 2141586 C T 2.96E-06 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs4341514 chr11 2141603 A G 5.28E-05 Coronary heart disease / / 21971053 rs11042753 chr11 2149995 C T 0.00035 Height (Pygmy height) IGF2 nearGene-3 22570615 rs734351 chr11 2156213 G A 2.70E-05 Urinary metabolites IGF2 intron 21572414 rs3213221 chr11 2157044 C G 1.70E-05 Urinary metabolites IGF2 intron 21572414 rs4244808 chr11 2163110 T G 7.58E-05 Coronary heart disease IGF2 intron 21971053 rs1003483 chr11 2167543 T G 9.67E-05 Parkinson's disease IGF2 intron 17052657 rs10770125 chr11 2169014 A G 7.58E-05 Parkinson's disease INS-IGF2 missense 17052657 rs10770125 chr11 2169014 A G 0.00011 Breast cancer INS-IGF2 missense 23555315 rs3741208 chr11 2169774 A G 2.00E-07 Type 1 diabetes IGF2 intron 17554260 rs1004446 chr11 2170143 G A 4.00E-09 Type 1 diabetes IGF2 intron 17632545 rs1004446 chr11 2170143 G A 3.00E-23 Type 1 diabetes autoantibodies IGF2 intron 21829393 rs1004446 chr11 2170143 G A 4.00E-09 Multiple sclerosis IGF2 intron 22190364 rs1004446 chr11 2170143 G A 0.000002518 Fasting blood glucose IGF2 intron 22885924 rs4320932 chr11 2171601 T C 1.76E-04 Coronary heart disease INS-IGF2 intron 21971053 rs7924316 chr11 2173447 T G 2.01E-05 Parkinson's disease INS-IGF2 intron 17052657 rs7924316 chr11 2173447 T G 4.31E-04 Amyotrophic Lateral Sclerosis INS-IGF2 intron 17362836 rs7924316 chr11 2173447 T G 2.81E-04 Coronary heart disease INS-IGF2 intron 21971053 rs689 chr11 2182224 A T 5.00E-196 Type 1 diabetes autoantibodies INS UTR-5 21829393 rs2070762 chr11 2186335 A G 3.38E-04 Coronary heart disease TH intron 21971053 rs6356 chr11 2190951 C T 2.70E-09 Type 1 diabetes TH missense 17632545 rs7950050 chr11 2190982 A G 0.00000183 LDL cholesterol TH cds-synon 23063622 rs10770141 chr11 2193840 A G 2.95E-08 Type 1 diabetes TH nearGene-5 17632545 rs10770141 chr11 2193840 A G 0.00000157 Type 2 diabetes TH nearGene-5 22325160 rs10743152 chr11 2195981 T C 7.53E-08 Type 1 diabetes / / 17632545 rs7111341 chr11 2213166 C T 6.90E-08 Type 1 diabetes / / 17632545 rs7111341 chr11 2213166 C T 4.00E-48 Type 1 diabetes / / 19430480 rs7946543 chr11 2220558 A G 0.0003772 Sarcoidosis / / 22952805 rs7478680 chr11 2223360 C T 3.58E-04 Multiple complex diseases / / 17554300 rs7126629 chr11 2228952 C A 1.80E-04 Iris characteristics / / 21835309 rs7126629 chr11 2228952 C A 2.00E-08 Prostate cancer (early onset) / / 24740154 rs7127900 chr11 2233574 A C,G 3.00E-33 Prostate cancer / / 19767753 rs7127900 chr11 2233574 A C,G 3.00E-33 Nasopharyngeal carcinoma / / 20512145 rs7127900 chr11 2233574 A C,G 1.00E-07 Prostate cancer (early onset) / / 24740154 rs10840606 chr11 2234690 A G 8.51E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11606404 chr11 2241215 A G 3.87E-04 Type 2 diabetes / / 17463246 rs11021732 chr11 2241272 T C 4.42E-04 Type 2 diabetes / / 17463246 rs7949253 chr11 2253079 A G 6.21E-05 Self-reported allergy / / 23817569 rs6578252 chr11 2270241 G T 5.87E-05 Multiple complex diseases / / 17554300 rs739545 chr11 2271323 G A 5.32E-05 Left ventricular hypertrophy / / pha003052 rs17659078 chr11 2284590 C A 5.33E-04 Common variable immunodeficiency / / 21497890 rs17659078 chr11 2284590 C A 6.83E-06 Height / / pha003010 rs17659078 chr11 2284590 C A 1.65E-05 Height / / pha003011 rs12417933 chr11 2288303 A G 1.05E-04 Smoking initiation / / 24665060 rs4929971 chr11 2298259 G A 5.10E-05 Multiple complex diseases / / 17554300 rs4929971 chr11 2298259 G A 8.71E-04 Alzheimer's disease / / 17998437 rs1011476 chr11 2299035 G T 3.66E-04 Hemoglobin concentration / / 20534544 rs1011476 chr11 2299035 G T 1.14E-05 Height / / pha003010 rs1011476 chr11 2299035 G T 4.68E-05 Height / / pha003011 rs1011476 chr11 2299035 G T 5.03E-05 Lung function (forced vital capacity) / / pha003104 rs4930073 chr11 2302734 G A 6.91E-04 Coronary heart disease / / 21971053 rs10831703 chr11 2304554 T C 7.90E-04 Coronary heart disease / / 21971053 rs7104332 chr11 2305799 C A 8.24E-05 Cognitive test performance / / 20125193 rs7104332 chr11 2305799 C A 4.95E-05 Height / / pha003010 rs10831706 chr11 2306026 A G 2.19E-04 Age-related macular degeneration / / 22125219 rs10831706 chr11 2306026 A G 6.50E-05 Height / / pha003011 rs2521263 chr11 2308762 A G 5.00E-06 Obesity-related traits / / 23251661 rs2074018 chr11 2309634 A T 4.35E-04 Multiple complex diseases / / 17554300 rs2074018 chr11 2309634 A T 5.15E-06 Obesity-related traits / / 23251661 rs1029409 chr11 2309898 G A 3.49E-05 Height / / pha003010 rs1029409 chr11 2309898 G A 8.27E-07 Height / / pha003011 rs756919 chr11 2310605 G T 2.95E-04 Multiple complex diseases / / 17554300 rs756920 chr11 2310870 G C 4.13E-05 Multiple complex diseases / / 17554300 rs7944004 chr11 2311152 T G 2.00E-10 Chronic lymphocytic leukemia / / 23770605 rs7944004 chr11 2311152 T G 2.87E-05 Height / / pha003010 rs7944004 chr11 2311152 T G 1.52E-06 Height / / pha003011 rs2244891 chr11 2319355 C T 1.37E-04 QT interval C11orf21 intron 19305409 rs2521269 chr11 2321095 C A,G,T 7.23E-09 Chronic lymphocytic leukemia C11orf21 intron 23770605 rs11022157 chr11 2322829 C A 3.00E-06 Chronic lymphocytic leukemia C11orf21 intron 24292274 rs2074021 chr11 2323528 T C 5.02E-05 Schizophrenia TSPAN32 intron 19197363 rs2521285 chr11 2341836 A G 8.70E-05 Pericardial fat / / 22589742 rs11022291 chr11 2345621 T C 3.66E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs800350 chr11 2415964 G A 0.000006508 Sarcoidosis CD81 intron 22952805 rs2301698 chr11 2437425 T G 9.46E-05 Heart Rate TRPM5 intron pha003054 rs886277 chr11 2439767 T C 0.00000242 Alcohol consumption TRPM5 missense 23555315 rs2074238 chr11 2484803 T C 3.00E-17 QT interval KCNQ1 intron 19305408 rs16928297 chr11 2486120 T G 1.02E-08 QT interval KCNQ1 intron 19305409 rs16928297 chr11 2486120 T G 2.00E-06 QT interval KCNQ1 intron 23166209 rs7122937 chr11 2486550 C T 6.74E-06 QT interval KCNQ1 intron 23166209 rs12296050 chr11 2489342 C T 3.00E-17 QT interval KCNQ1 intron 19305409 rs12296050 chr11 2489342 C T 8.00E-11 Electrocardiographic traits KCNQ1 intron 20062063 rs12576156 chr11 2498818 A G 2.21E-04 Type 2 diabetes KCNQ1 intron 17463246 rs12576239 chr11 2502319 C T 1.00E-15 QT interval KCNQ1 intron 19305408 rs10832134 chr11 2502486 C T 8.95E-04 Coronary Artery Disease KCNQ1 intron 17634449 rs179407 chr11 2526898 T C 2.87E-04 Cholesterol KCNQ1 intron 17255346 rs16928363 chr11 2533291 C T 6.95E-04 Multiple complex diseases KCNQ1 intron 17554300 rs736609 chr11 2538580 C T 4.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNQ1 intron 20877124 rs2283149 chr11 2543430 T C,G 3.10E-04 Cholesterol KCNQ1 intron 17255346 rs179429 chr11 2550730 A G 7.00E-06 Platelet aggregation KCNQ1 intron 20526338 rs2188198 chr11 2568846 T A 8.70E-05 Orofacial clefts KCNQ1 intron 22419666 rs4539307 chr11 2573121 G A 1.44E-04 Response to alcohol consumption (flushing response) KCNQ1 intron 24277619 rs4539307 chr11 2573121 G A 4.99E-05 Coronary heart disease KCNQ1 intron pha003035 rs7946012 chr11 2592531 C T 0.000000177 Triglycerides KCNQ1 intron 23063622 rs16924843 chr11 2605189 T C 5.42E-04 Smoking quantity KCNQ1 intron 24665060 rs10400286 chr11 2616053 T C 3.44E-06 Asthma (childhood onset) KCNQ1 intron 23829686 rs10741669 chr11 2643480 G A 4.60E-04 Obesity (extreme) KCNQ1 intron 21935397 rs7118939 chr11 2646620 A G 9.17E-04 Obesity (extreme) KCNQ1 intron 21935397 rs10832405 chr11 2648519 A C 7.62E-04 Obesity (extreme) KCNQ1 intron 21935397 rs4271371 chr11 2651410 T C 7.84E-04 Obesity (extreme) KCNQ1 intron 21935397 rs10832417 chr11 2652657 T G 1.00E-06 Blood pressure measurement (high sodium intervention) KCNQ1 intron 24165912 rs10832417 chr11 2652657 T G 2.85E-05 Blood pressure measurement (high sodium intervention) KCNQ1 intron 24165912 rs10832417 chr11 2652657 T G 4.00E-07 Blood pressure measurement (high sodium intervention) KCNQ1 intron 24165912 rs231347 chr11 2674436 G A 8.08E-04 Obesity (extreme) KCNQ1 intron 21935397 rs231343 chr11 2678653 A C 7.45E-04 Obesity (extreme) KCNQ1 intron 21935397 rs151216 chr11 2680815 C T 5.48E-04 Obesity (extreme) KCNQ1 intron 21935397 rs12574151 chr11 2681118 T G 4.50E-04 Alcohol dependence KCNQ1 intron 20201924 rs12574151 chr11 2681118 T G 4.60E-04 Alcohol dependence KCNQ1 intron 20201924 rs231362 chr11 2691471 A G 3.00E-13 Type 2 diabetes KCNQ1 intron 20581827 rs231362 chr11 2691471 A G 0.000000198 Type 2 diabetes KCNQ1 intron 22325160 rs231362 chr11 2691471 A G 1.70E-09 Type 2 diabetes KCNQ1 intron 22885922 rs231362 chr11 2691471 A G 3.00E-13 Type 2 diabetes KCNQ1 intron 23300278 rs231361 chr11 2691500 G A 4.22E-06 Type 2 diabetes KCNQ1 intron 22158537 rs231361 chr11 2691500 G A 0.0000029 Type 2 diabetes (females) KCNQ1 intron 22885922 rs231361 chr11 2691500 G A 0.0000029 Type 2 diabetes (males) KCNQ1 intron 22885922 rs231361 chr11 2691500 G A 1.20E-09 Type 2 diabetes KCNQ1 intron 22885922 rs231359 chr11 2694606 C A 9.95E-06 Type 2 diabetes KCNQ1 intron 22158537 rs231355 chr11 2706327 G C 7.89E-04 Suicide attempts in bipolar disorder KCNQ1 intron 21423239 rs231351 chr11 2711142 T C 8.91E-04 Suicide attempts in bipolar disorder KCNQ1 intron 21423239 rs231841 chr11 2723604 G T 4.40E-05 Response to statin therapy KCNQ1 intron 20339536 rs231841 chr11 2723604 G T 4.91E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines KCNQ1 intron 21844884 rs231841 chr11 2723604 G T 2.06E-04 Amyotrophic lateral sclerosis (sporadic) KCNQ1 intron 24529757 rs129074 chr11 2734125 G A 6.92E-05 Type 2 diabetes KCNQ1 intron 22158537 rs200254903 chr11 2734125 G GA 6.92E-05 Type 2 diabetes KCNQ1 intron 22158537 rs231888 chr11 2739110 C T 7.90E-04 Response to taxane treatment (placlitaxel) KCNQ1 intron 23006423 rs2283205 chr11 2741327 C T 3.98E-05 Fibrinogen KCNQ1 intron pha003068 rs231917 chr11 2745107 C T 4.64E-05 Platelet counts KCNQ1 intron pha003100 rs2283210 chr11 2747905 C G 3.10E-06 Blood pressure KCNQ1 intron 21060006 rs2283210 chr11 2747905 C G 5.00E-04 Blood pressure KCNQ1 intron 21060006 rs2283210 chr11 2747905 C G 7.20E-05 Blood pressure KCNQ1 intron 21060006 rs2283210 chr11 2747905 C G 7.90E-05 Blood pressure KCNQ1 intron 21060006 rs2283214 chr11 2750720 G A 4.53E-05 Alcohol and nictotine co-dependence KCNQ1 intron 20158304 rs231910 chr11 2751285 A G 5.10E-05 Alcohol and nictotine co-dependence KCNQ1 intron 20158304 rs17743926 chr11 2752593 G A 9.67E-05 Non-alcoholic fatty liver disease histology (other) KCNQ1 intron 20708005 rs231906 chr11 2752609 G A 2.00E-06 QT interval KCNQ1 intron 23166209 rs11023937 chr11 2755573 C G 0.00014 Cognitive impairment (no dementia) KCNQ1 intron 23042215 rs108961 chr11 2757985 C T 6.29E-05 Amyotrophic Lateral Sclerosis KCNQ1 intron 17827064 rs108961 chr11 2757985 C T 9.00E-06 Plasma amyloid beta peptide concentrations (ABx-40) KCNQ1 intron 24535457 rs185476610 chr11 2758192 A C 0.0000624 Menopause (age at onset) KCNQ1 intron 23424626 rs7114479 chr11 2763228 T C 6.40E-04 Atrial fibrillation KCNQ1 intron 21846873 rs2237875 chr11 2764118 A G 0.000000121 Total IFN-gamma response to smallpox vaccine KCNQ1 intron 22661280 rs2237878 chr11 2766282 G A 1.00E-06 Protein quantitative trait loci KCNQ1 intron 18464913 rs179785 chr11 2781519 G A 2.00E-04 Cognitive impairment induced by topiramate KCNQ1 intron 22091778 rs463535 chr11 2781670 T C 5.36E-05 Atrial fibrillation KCNQ1 intron 21846873 rs231872 chr11 2787061 G T 3.72E-05 Alcohol and nictotine co-dependence KCNQ1 intron 20158304 rs2075870 chr11 2790019 G A 3.00E-05 Height KCNQ1 intron 21194676 rs2075870 chr11 2790019 G A 6.30E-07 Height KCNQ1 intron 21194676 rs2075870 chr11 2790019 G A 9.80E-11 Height KCNQ1 intron 21194676 rs11024034 chr11 2790163 T C 0.0000092 Mean arterial pressure KCNQ1 intron 22510845 rs81204 chr11 2798305 T C 3.60E-04 Chronic kidney disease KCNQ1 intron 21931561 rs2237886 chr11 2810731 C T 2.00E-13 Height KCNQ1 intron 20881960 rs163171 chr11 2821065 T C 3.12E-12 Type 2 diabetes KCNQ1 intron 20818381 rs163171 chr11 2821065 T C 9.31E-12 Type 2 diabetes KCNQ1 intron 22158537 rs114702513 chr11 2821968 T C 0.000056 Menopause (age at onset) KCNQ1 intron 23424626 rs17744869 chr11 2823862 G C 4.02E-04 Multiple complex diseases KCNQ1 intron 17554300 rs79972789 chr11 2824573 C G 0.00000019 Menopause (age at onset) KCNQ1 intron 23424626 rs8181588 chr11 2831541 T C 5.00E-09 Type 2 diabetes KCNQ1 intron 24101674 rs2237888 chr11 2832905 C T 1.30E-12 Type 2 diabetes KCNQ1 intron 22158537 rs12285496 chr11 2837741 G C 6.57E-04 Suicide attempts in bipolar disorder KCNQ1 intron 21041247 rs163177 chr11 2838413 T C 5.30E-08 Type 2 diabetes KCNQ1 intron 20174558 rs2237892 chr11 2839751 C T 2.00E-42 Type 2 diabetes KCNQ1 intron 18711367 rs2237892 chr11 2839751 C T 1.00E-26 Type 2 diabetes KCNQ1 intron 19401414 rs2237892 chr11 2839751 C T 6.66E-18 Type 2 diabetes KCNQ1 intron 20818381 rs2237892 chr11 2839751 C T 2.00E-42 Coronary heart disease KCNQ1 intron 21347282 rs2237892 chr11 2839751 C T 4.00E-06 Type 2 diabetes KCNQ1 intron 21573907 rs2237892 chr11 2839751 C T 1.00E-26 Type 2 diabetes KCNQ1 intron 21647700 rs2237892 chr11 2839751 C T 3.62E-18 Type 2 diabetes KCNQ1 intron 22158537 rs2237892 chr11 2839751 C T 1.00E-07 Type 2 diabetes KCNQ1 intron 22961080 rs2237892 chr11 2839751 C T 4.00E-29 Type 2 diabetes KCNQ1 intron 23945395 rs2237892 chr11 2839751 C T 9.00E-13 Body mass index KCNQ1 intron 24861553 rs12294675 chr11 2842547 G A 8.37E-04 Suicide attempts in bipolar disorder KCNQ1 intron 21041247 rs163182 chr11 2844216 G C 4.32E-05 Lipid levels KCNQ1 intron 19913121 rs163182 chr11 2844216 G C 1.50E-05 Type 2 diabetes KCNQ1 intron 20174558 rs163182 chr11 2844216 G C 2.00E-17 Type 2 diabetes KCNQ1 intron 21799836 rs163182 chr11 2844216 G C 2.00E-17 Type 2 diabetes KCNQ1 intron 23300278 rs7111394 chr11 2845082 T C 3.61E-06 Chronic kidney disease KCNQ1 intron 21931561 rs163184 chr11 2847069 T G 2.91E-05 Lipid levels KCNQ1 intron 19913121 rs163184 chr11 2847069 T G 1.89E-12 Type 2 diabetes KCNQ1 intron 20818381 rs163184 chr11 2847069 T G 2.82E-05 Type 2 diabetes KCNQ1 intron 21799836 rs163184 chr11 2847069 T G 1.45E-13 Type 2 diabetes KCNQ1 intron 22158537 rs163184 chr11 2847069 T G 0.000000608 Type 2 diabetes KCNQ1 intron 22325160 rs163184 chr11 2847069 T G 0.00035 Fasting blood glucose KCNQ1 intron 22885922 rs163184 chr11 2847069 T G 2.40E-15 Type 2 diabetes KCNQ1 intron 22885922 rs163184 chr11 2847069 T G 8.50E-15 Type 2 diabetes (males) KCNQ1 intron 22885922 rs163184 chr11 2847069 T G 6.80E-05 Type 2 diabetes KCNQ1 intron 23300278 rs163184 chr11 2847069 T G 2.00E-14 Type 2 diabetes KCNQ1 intron 24509480 rs2283228 chr11 2849530 A C 3.80E-04 Type 2 diabetes KCNQ1 intron 20174558 rs234852 chr11 2850782 T C 4.23E-10 Type 2 diabetes KCNQ1 intron 22158537 rs234853 chr11 2850828 G A 4.94E-12 Type 2 diabetes KCNQ1 intron 20818381 rs234853 chr11 2850828 G A 5.49E-13 Type 2 diabetes KCNQ1 intron 22158537 rs234857 chr11 2852529 T C 4.00E-07 Type 2 diabetes KCNQ1 intron 21874001 rs2237895 chr11 2857194 A C 1.00E-09 Type 2 diabetes KCNQ1 intron 20174558 rs234865 chr11 2857618 G C 5.24E-05 Multiple complex diseases KCNQ1 intron 17554300 rs2237896 chr11 2858440 G A 1.42E-19 Type 2 diabetes KCNQ1 intron 22158537 rs2237896 chr11 2858440 G A 4.70E-11 Type 2 diabetes KCNQ1 intron 22885922 rs2237897 chr11 2858546 C T 1.00E-16 Type 2 diabetes KCNQ1 intron 18711366 rs2237897 chr11 2858546 C T 1.60E-07 Type 2 diabetes KCNQ1 intron 20174558 rs2237897 chr11 2858546 C T 1.00E-16 Coronary heart disease KCNQ1 intron 21347282 rs2237897 chr11 2858546 C T 9.00E-15 Type 2 diabetes KCNQ1 intron 24390345 rs2005833 chr11 2863287 G A 0.00013 Coronary artery calcification KCNQ1 intron 23727086 rs2078786 chr11 2896128 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2078786 chr11 2896128 A G 9.55E-06 Neuroblastoma / / pha002895 rs12786533 chr11 2896313 G A 2.14E-04 Multiple complex diseases / / 17554300 rs452338 chr11 2908195 G T 2.96E-04 Alzheimer's disease CDKN1C nearGene-5 22005930 rs450563 chr11 2908965 A G 4.59E-04 Alzheimer's disease / / 22005930 rs10832869 chr11 2910621 T C 5.73E-05 Neuroblastoma SLC22A18AS intron pha002895 rs10832897 chr11 2932535 G A,C 2.00E-04 Pancreatic cancer SLC22A18 intron 20484958 rs440150 chr11 2936657 G A 1.40E-06 Bilirubin levels SLC22A18 intron 19414484 rs16928809 chr11 2936952 G A 1.00E-07 Bilirubin levels SLC22A18 intron 19414484 rs3847646 chr11 2953723 C T 5.00E-06 Calcium levels / / 20705733 rs2583442 chr11 2956166 T C 1.20E-04 Alcohol dependence / / 20201924 rs2583442 chr11 2956166 T C 8.20E-04 Alcohol dependence / / 20201924 rs2583435 chr11 2958818 T C 1.00E-04 Alcohol dependence / / 20201924 rs2583435 chr11 2958818 T C 7.10E-04 Alcohol dependence / / 20201924 rs4758576 chr11 2973880 G A 8.90E-05 HIV-1 control /P1L4 intron 20041166 rs7940694 chr11 2979798 G T 8.90E-05 HIV-1 control /P1L4 intron 20041166 rs16928945 chr11 2992160 A C 2.36E-04 White matter integrity /P1L4 intron 22425255 rs3814964 chr11 2999507 G T 7.20E-04 Alcohol dependence /P1L4 intron 20201924 rs3814964 chr11 2999507 G T 7.40E-05 Alcohol dependence /P1L4 intron 20201924 rs3814964 chr11 2999507 G T 7.45E-05 Alcoholism /P1L4 intron pha002892 rs4758621 chr11 3009640 A G 3.70E-04 Alcohol dependence /P1L4 intron 20201924 rs4758622 chr11 3009921 A G 2.95E-04 Type 2 diabetes /P1L4 intron 17463246 rs4758622 chr11 3009921 A G 7.97E-08 Fetal hemoglobin levels /P1L4 intron 18245381 rs7112509 chr11 3010861 T C 4.84E-04 White matter integrity /P1L4 intron 22425255 rs12805661 chr11 3020740 C T 1.50E-04 Alcohol dependence / / 20201924 rs12805661 chr11 3020740 C T 6.80E-04 Alcohol dependence / / 20201924 rs729662 chr11 3028140 G A 3.70E-04 Alcohol dependence CARS cds-synon 20201924 rs729662 chr11 3028140 G A 8.50E-05 Alcohol dependence CARS cds-synon 20201924 rs729662 chr11 3028140 G A 5.40E-06 Calcium levels CARS cds-synon 20705733 rs729662 chr11 3028140 G A 8.52E-05 Alcoholism CARS cds-synon pha002892 rs7481584 chr11 3029089 G A 4.70E-04 Alcohol dependence CARS intron 20201924 rs7481584 chr11 3029089 G A 9.50E-05 Alcohol dependence CARS intron 20201924 rs7481584 chr11 3029089 G A 5.40E-06 Calcium levels CARS intron 20705733 rs7481584 chr11 3029089 G A 1.00E-10 Calcium levels CARS intron 24068962 rs7481584 chr11 3029089 G A 9.54E-05 Alcoholism CARS intron pha002892 rs739401 chr11 3036324 C T 6.40E-06 Diabetic nephropathy CARS intron 19252134 rs739401 chr11 3036324 C T 8.00E-06 Diabetic nephropathy CARS intron 19252134 rs739401 chr11 3036324 C T 1.00E-06 Longevity CARS intron 20834067 rs739401 chr11 3036324 C T 4.55E-05 Diabetic nephropathy CARS intron pha002852 rs739401 chr11 3036324 C T 7.54E-06 Diabetic nephropathy CARS intron pha002864 rs739401 chr11 3036324 C T 2.50E-05 Diabetic nephropathy CARS intron pha002866 rs438384 chr11 3045651 T C 1.07E-04 Diabetic nephropathy CARS intron pha002866 rs428726 chr11 3046201 G A 4.40E-04 Alcohol dependence CARS intron 20201924 rs428726 chr11 3046201 G A 4.80E-04 Alcohol dependence CARS intron 20201924 rs377765 chr11 3046298 C T 4.60E-04 Alcohol dependence CARS intron 20201924 rs377765 chr11 3046298 C T 5.20E-04 Alcohol dependence CARS intron 20201924 rs12281847 chr11 3048245 C T 1.67E-04 White matter integrity CARS intron 22425255 rs434114 chr11 3050210 A G 7.00E-04 Alcohol dependence CARS intron 20201924 rs434114 chr11 3050210 A G 8.40E-04 Alcohol dependence CARS intron 20201924 rs451041 chr11 3060725 A G 3.10E-06 Diabetic nephropathy CARS intron 19252134 rs451041 chr11 3060725 A G 4.30E-06 Diabetic nephropathy CARS intron 19252134 rs451041 chr11 3060725 A G 1.10E-04 Alcohol dependence CARS intron 20201924 rs451041 chr11 3060725 A G 3.80E-04 Alcohol dependence CARS intron 20201924 rs451041 chr11 3060725 A G 0.0000064 Diabetic nephropathy in Type 1 diabetes CARS intron 22721967 rs451041 chr11 3060725 A G 2.60E-05 Diabetic nephropathy CARS intron pha002852 rs451041 chr11 3060725 A G 3.06E-06 Diabetic nephropathy CARS intron pha002864 rs451041 chr11 3060725 A G 9.80E-05 Diabetic nephropathy CARS intron pha002866 rs369461 chr11 3061992 T C 4.80E-04 Alcohol dependence CARS intron 20201924 rs369461 chr11 3061992 T C 5.70E-04 Alcohol dependence CARS intron 20201924 rs369461 chr11 3061992 T C 7.87E-05 Diabetic nephropathy CARS intron pha002864 rs369461 chr11 3061992 T C 2.50E-05 Diabetic nephropathy CARS intron pha002866 rs406598 chr11 3076285 G A 4.80E-04 Alcohol dependence CARS intron 20201924 rs406598 chr11 3076285 G A 5.20E-04 Alcohol dependence CARS intron 20201924 rs1900372 chr11 3130708 C A 1.81E-04 Response to statin treatment (atorvastatin),change in cholesterol levels OSBPL5 intron 20031582 rs7925089 chr11 3131418 G T 1.84E-04 Hemoglobin concentration OSBPL5 intron 20534544 rs6578322 chr11 3143030 T C 7.10E-04 Alcohol dependence OSBPL5 intron 20201924 rs4758533 chr11 3150086 A G 4.80E-05 Alcohol dependence OSBPL5 intron 20201924 rs4758533 chr11 3150086 A G 4.82E-05 Alcoholism OSBPL5 intron pha002892 rs4758538 chr11 3162394 C T 7.28E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines OSBPL5 intron 21844884 rs4468331 chr11 3165412 G A 6.90E-04 Alcohol dependence OSBPL5 intron 20201924 rs11025773 chr11 3197290 G T 2.80E-06 Urinary metabolites / / 21572414 rs9971622 chr11 3211112 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7950446 chr11 3213147 G A 2.88E-04 Multiple complex diseases / / 17554300 rs7106188 chr11 3220148 G A 8.49E-04 Tourette syndrome / / 22889924 rs12577685 chr11 3220364 C A 6.19E-04 Tourette syndrome / / 22889924 rs10766764 chr11 3221364 C T 1.52E-04 Height / / 17255346 rs10766764 chr11 3221364 C T 6.67E-05 Serum metabolites / / 19043545 rs4758483 chr11 3222869 G T 1.20E-04 Height / / 17255346 rs6578334 chr11 3242223 C T 0.000015 VLDL cholesterol particle diameter C11orf36 intron 23263444 rs11602633 chr11 3247976 G A 6.05E-05 Smoking initiation / / 24665060 rs11026055 chr11 3252320 G A 5.15E-04 HIV-1 viral setpoint MRGPRE intron 17641165 rs11026055 chr11 3252320 G A 4.32E-05 Hypertension MRGPRE intron 22384028 rs10741878 chr11 3257511 G A 1.05E-04 Multiple complex diseases / / 17554300 rs10833533 chr11 3257836 A G 1.08E-04 Multiple complex diseases / / 17554300 rs10833533 chr11 3257836 A G 5.68E-04 HIV-1 viral setpoint / / 17641165 rs11026091 chr11 3259809 G A 2.00E-06 Multiple sclerosis / / 23412934 rs10766825 chr11 3266133 T C 9.90E-04 Alcohol dependence / / 21314694 rs41410949 chr11 3367553 G A 3.59E-04 Type 2 diabetes / / 17463246 rs11026661 chr11 3371687 C T 6.08E-04 Aortic root size / / 21223598 rs10766960 chr11 3377944 C T 8.67E-05 Bipolar disorder / / 19488044 rs11026708 chr11 3378063 G A 3.84E-05 Multiple complex diseases / / 17554300 rs6578339 chr11 3386412 T C 1.26E-04 Multiple complex diseases ZNF195 intron 17554300 rs6578341 chr11 3397074 A G 1.98E-04 Multiple complex diseases ZNF195 intron 17554300 rs7106076 chr11 3397834 G C 2.91E-04 Multiple complex diseases ZNF195 intron 17554300 rs4758578 chr11 3398067 T C 4.76E-05 Bipolar disorder ZNF195 intron 19488044 rs10766972 chr11 3398429 A G 2.29E-04 Multiple complex diseases ZNF195 intron 17554300 rs956453 chr11 3407529 T C 8.95E-04 Type 2 diabetes LOC650368 intron 17463246 rs956453 chr11 3407529 T C 1.70E-05 Urinary metabolites LOC650368 intron 21572414 rs10430923 chr11 3568044 T C 3.29E-05 Coronary heart disease / / pha003031 rs10834615 chr11 3631189 G T 4.25E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10767349 chr11 3641399 G A,T 9.12E-04 Coronary Artery Disease / / 17634449 rs6578401 chr11 3645133 G A 4.60E-06 Urinary metabolites / / 21572414 rs10834648 chr11 3645345 G A 3.00E-05 Iris characteristics / / 21835309 rs2271580 chr11 3648133 C T 2.11E-04 Multiple complex diseases TRPC2 intron 17554300 rs2271580 chr11 3648133 C T 9.40E-06 Urinary metabolites TRPC2 intron 21572414 rs2271586 chr11 3659993 G T 5.90E-04 Type 2 diabetes ART5 missense 17460697 rs16925378 chr11 3677096 C G 7.82E-05 Coronary heart disease ART1 intron 21606135 rs10834744 chr11 3681850 A G 4.10E-07 Multiple complex diseases ART1 intron 17554300 rs10834744 chr11 3681850 A G 8.38E-04 Suicide attempts in bipolar disorder ART1 intron 21041247 rs10834744 chr11 3681850 A G 1.10E-05 Urinary metabolites ART1 intron 21572414 rs2672213 chr11 3691417 C T 8.80E-04 Alcohol dependence CHR/10 intron 20201924 rs2672215 chr11 3691649 A C 6.92E-04 Smoking initiation CHR/10 intron 24665060 rs685782 chr11 3722304 T C 7.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) NUP98 intron 23934736 rs16929785 chr11 3732642 A G 3.67E-04 Suicide attempts in bipolar disorder NUP98 intron 21423239 rs4910665 chr11 3734278 C G 3.19E-04 Suicide attempts in bipolar disorder NUP98 intron 21423239 rs276892 chr11 3776371 C T 2.20E-05 Celiac disease NUP98 intron 17558408 rs1567923 chr11 3784632 G A 3.05E-04 Suicide attempts in bipolar disorder NUP98 intron 21423239 rs4910549 chr11 3796158 A C,T 3.16E-04 Suicide attempts in bipolar disorder NUP98 intron 21423239 rs276885 chr11 3796406 G A,C,T 3.00E-05 Celiac disease NUP98 intron 17558408 rs10767587 chr11 3808138 T G 3.30E-04 Premature ovarian failure NUP98 intron 19508998 rs16929762 chr11 3809349 C T 3.29E-04 Suicide attempts in bipolar disorder NUP98 intron 21423239 rs4910810 chr11 3813961 T C 3.22E-04 Suicide attempts in bipolar disorder NUP98 intron 21423239 rs4910811 chr11 3814004 A G 7.71E-04 Suicide attempts in bipolar disorder NUP98 intron 21423239 rs7122294 chr11 3816102 T C 3.36E-04 Suicide attempts in bipolar disorder NUP98 intron 21423239 rs4910818 chr11 3820785 C T 1.00E-04 Information processing speed PGAP2 intron 21130836 rs15820 chr11 3847430 C T 6.56E-04 Alzheimer's disease PGAP2 UTR-3 24755620 rs7929197 chr11 3849840 C T 8.80E-04 Alzheimer's disease RHOG intron 24755620 rs7101788 chr11 3855757 C T 2.91E-04 Smoking initiation RHOG intron 24665060 rs1451722 chr11 3856553 C T 4.35E-06 Alcohol dependence RHOG intron 23089632 rs1451724 chr11 3856668 G A 6.68E-07 Alcohol dependence RHOG intron 23089632 rs10835182 chr11 3859856 T A 5.92E-05 Femoral neck bone geometry RHOG intron 22087292 rs11030043 chr11 3867350 A G 9.89E-05 Cognitive test performance / / 20125193 rs4367942 chr11 3876433 A G 1.74E-05 Cognitive test performance / / 20125193 rs7126870 chr11 3890059 C T 7.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) STIM1 intron 20877124 rs10160703 chr11 3893213 T G 1.04E-04 Sarcoidosis STIM1 intron 19165924 rs750525 chr11 3948894 G A 0.000748 fMRI brain tests in schizophrenia STIM1 intron 22440650 rs10835333 chr11 3957766 A G 0.000479 fMRI brain tests in schizophrenia STIM1 intron 22440650 rs10835337 chr11 3958828 C T 2.64E-04 Type 2 diabetes STIM1 intron 17463246 rs10835340 chr11 3960420 G A 6.26E-04 Type 2 diabetes STIM1 intron 17463246 rs10500591 chr11 3964805 C A 5.30E-04 Type 2 diabetes STIM1 intron 17463246 rs6578423 chr11 3969444 G A 4.05E-04 Type 2 diabetes STIM1 intron 17463246 rs17279635 chr11 3973083 G T 9.36E-04 Type 2 diabetes STIM1 intron 17463246 rs7924984 chr11 3974588 G A 1.80E-04 Type 2 diabetes STIM1 intron 17463246 rs10835390 chr11 3981488 A G 0.000523 fMRI brain tests in schizophrenia STIM1 intron 22440650 rs17081 chr11 3987830 G A 6.85E-04 Type 2 diabetes STIM1 intron 17463246 rs10835403 chr11 3990941 G T 9.04E-04 Type 2 diabetes STIM1 intron 17463246 rs10835407 chr11 3993231 A G 3.48E-04 Type 2 diabetes STIM1 intron 17463246 rs2959056 chr11 4019401 T A 1.95E-08 Narcolepsy STIM1 intron 19629137 rs963998 chr11 4062803 T C 9.22E-04 Type 2 diabetes STIM1 intron 17463246 rs2920137 chr11 4079318 C T 8.42E-04 Multiple complex diseases STIM1 intron 17554300 rs11030796 chr11 4088776 G A 2.24E-04 Coronary Artery Disease STIM1 intron 17634449 rs11030841 chr11 4099013 A G 1.86E-08 Fetal hemoglobin levels STIM1 intron 18245381 rs11030918 chr11 4115487 T C 3.63E-04 Acute lung injury RRM1 nearGene-5 22295056 rs10835611 chr11 4117730 G C 6.94E-04 Acute lung injury RRM1 intron 22295056 rs1474500 chr11 4124112 T C 2.22E-04 Stroke (pediatric) RRM1 intron 22990015 rs7940013 chr11 4138304 C T 7.70E-04 Acute lung injury RRM1 intron 22295056 rs720106 chr11 4139978 T C 1.24E-08 Fetal hemoglobin levels RRM1 intron 18245381 rs2268168 chr11 4142069 C T 7.70E-04 Acute lung injury RRM1 intron 22295056 rs2056853 chr11 4142172 C T 7.70E-04 Acute lung injury RRM1 intron 22295056 rs3817657 chr11 4142592 T C 7.73E-04 Acute lung injury RRM1 intron 22295056 rs9937 chr11 4159457 A G 1 Drug response to Gemcitabine RRM1 cds-synon 17602053 rs1042858 chr11 4159466 G A 1 Drug response to Gemcitabine RRM1 cds-synon 17602053 rs4910897 chr11 4162477 T C 3.00E-05 Temperament (bipolar disorder) / / 22365631 rs11031110 chr11 4162652 G C 7.30E-04 Acute lung injury / / 22295056 rs4910903 chr11 4165488 C T 4.30E-05 Temperament (bipolar disorder) / / 22365631 rs10835679 chr11 4167432 A G 3.80E-05 Temperament (bipolar disorder) / / 22365631 rs6578446 chr11 4168641 T C 3.40E-05 Temperament (bipolar disorder) / / 22365631 rs7104032 chr11 4222978 G A 7.80E-05 Temperament (bipolar disorder) LOC100506082 intron 22365631 rs7105300 chr11 4223185 C T 8.30E-05 Temperament (bipolar disorder) LOC100506082 intron 22365631 rs10734408 chr11 4231103 T C 6.80E-05 Temperament (bipolar disorder) / / 22365631 rs1822285 chr11 4232627 C T 6.40E-05 Volumetric brain MRI / / 17903297 rs1823636 chr11 4276004 C T 2.03E-12 Fetal hemoglobin levels / / 18245381 rs11031481 chr11 4296219 G C 9.38E-09 Bipolar disorder,affective / / 20528957 rs10835979 chr11 4396185 G A 3.01E-14 Fetal hemoglobin levels / / 18245381 rs13353061 chr11 4398799 T C 6.27E-05 Bipolar disorder,affective / / 20528957 rs765421 chr11 4401792 C G 1.69E-04 Bipolar disorder,affective / / 20528957 rs2052731 chr11 4404192 A G 7.01E-05 Bipolar disorder,affective / / 20528957 rs2269330 chr11 4406483 A G 9.05E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) TRIM21 UTR-3 23648065 rs12365876 chr11 4415064 T C 2.50E-07 Platelet aggregation(pre- and post-aspirin) / / 20529293 rs11032080 chr11 4415079 T C 2.10E-07 Platelet aggregation(pre- and post-aspirin) / / 20529293 rs1823634 chr11 4440838 T C 7.87E-05 Lymphocyte counts / / 22286170 rs7122384 chr11 4452824 A G 9.00E-05 Prostate cancer / / 21743057 rs78887935 chr11 4466434 A G 0.00004442 Sarcoidosis / / 22952805 rs331538 chr11 4466833 T A 9.86E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11032304 chr11 4472880 T C 7.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11032381 chr11 4492529 C G 4.11E-04 Type 2 diabetes / / 17463246 rs890416 chr11 4493334 C A 9.47E-04 Type 2 diabetes / / 17463246 rs9633905 chr11 4496613 C A 5.92E-04 Type 2 diabetes / / 17463246 rs2278170 chr11 4496846 C T 7.00E-06 Amyotrophic lateral sclerosis / / 22470424 rs2278171 chr11 4496916 C T 4.85E-04 Type 2 diabetes / / 17463246 rs96489 chr11 4510285 A G 4.80E-04 Smoking cessation OR52K1 missense 24665060 rs10160399 chr11 4516576 C T 2.00E-06 Obesity-related traits / / 23251661 rs2566243 chr11 4532115 G A 1.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2566231 chr11 4535082 A G 1.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2566221 chr11 4536230 C T 1.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16906358 chr11 4537019 T A 4.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs12279728 chr11 4540077 G T 1.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12279728 chr11 4540077 G T 6.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7131138 chr11 4542813 A G 3.01E-05 Lung function (forced vital capacity) / / pha003104 rs2641426 chr11 4552102 C A 2.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2641426 chr11 4552102 C A 8.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17311688 chr11 4562644 A G 2.52E-04 Tourette syndrome / / 22889924 rs12416860 chr11 4563218 A G 4.00E-06 Obesity-related traits / / 23251661 rs2641412 chr11 4565490 G A 5.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2641412 chr11 4565490 G A 8.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12282912 chr11 4577217 G T 2.02E-05 Lung function (forced vital capacity) / / pha003104 rs1505216 chr11 4578709 G A 3.21E-04 Type 2 diabetes / / 17463246 rs1505209 chr11 4592277 A G 2.01E-08 Malaria / / 23717212 rs12795289 chr11 4594545 A G 6.98E-06 Calcium levels C11orf40 missense pha003085 rs35230615 chr11 4594739 C CT 3.60E-06 Calcium levels C11orf40 intron pha003085 rs919519 chr11 4594739 C T 3.60E-06 Calcium levels C11orf40 intron pha003085 rs2641396 chr11 4597649 G A 2.33E-04 Aortic root size C11orf40 intron 21223598 rs7128702 chr11 4608116 T C 1.58E-12 Fetal hemoglobin levels OR52I2 missense 18245381 rs7951206 chr11 4611654 G A 2.56E-13 Fetal hemoglobin levels / / 18245381 rs905872 chr11 4613366 C T 2.97E-05 Calcium levels / / pha003085 rs4910511 chr11 4615234 A G 1.27E-04 Multiple complex diseases / / 17554300 rs2231963 chr11 4625020 A C 2.12E-04 Multiple complex diseases TRIM68 intron 17554300 rs3861787 chr11 4647770 T G 7.14E-04 Parkinson's disease / / 17052657 rs3861787 chr11 4647770 T G 1.16E-13 Fetal hemoglobin levels / / 18245381 rs3844036 chr11 4649449 A G 3.29E-14 Fetal hemoglobin levels / / 18245381 rs7937180 chr11 4667693 C A 3.22E-05 Cholesterol OR51E1 intron pha003083 rs10500609 chr11 4675379 A G 9.98E-04 Type 2 diabetes OR51E1 UTR-3 17846125 rs12574901 chr11 4677509 A G 8.27E-05 Type 2 diabetes / / 17463246 rs4910663 chr11 4692979 A C 2.50E-05 Urinary metabolites / / 21572414 rs1123991 chr11 4703165 C A 1.63E-09 Fetal hemoglobin levels OR51E2 cds-synon 18245381 rs10836470 chr11 4707571 C T 2.45E-04 Celiac disease OR51E2 intron 23936387 rs1505210 chr11 4713811 A G 5.80E-06 Urinary metabolites OR51E2 intron 21572414 rs1505210 chr11 4713811 A G 4.61E-05 Parent of origin effect on language impairment (maternal) OR51E2 intron 24571439 rs7480497 chr11 4714050 C T 2.80E-06 Urinary metabolites OR51E2 intron 21572414 rs7105156 chr11 4715946 A G 2.02E-04 Multiple complex diseases OR51E2 intron 17554300 rs7105156 chr11 4715946 A G 7.10E-06 Malaria OR51E2 intron 19465909 rs10500614 chr11 4718526 G A 9.77E-06 White blood cell count OR51E2 intron 21738479 rs12271916 chr11 4726878 G A 4.78E-08 Fetal hemoglobin levels / / 18245381 rs4436535 chr11 4731468 G A 2.70E-05 Urinary metabolites / / 21572414 rs4436535 chr11 4731468 G A 8.93E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs7104808 chr11 4752849 G A 4.14E-04 Response to alcohol consumption (flushing response) / / 24277619 rs7952595 chr11 4772797 T C 4.56E-04 Tourette syndrome / / 22889924 rs12788102 chr11 4790575 A G 1.45E-14 Fetal hemoglobin levels OR51F1 cds-synon 18245381 rs12788102 chr11 4790575 A G 2.00E-16 Malaria OR51F1 cds-synon 23717212 rs17227393 chr11 4793549 T C 3.29E-14 Fetal hemoglobin levels / / 18245381 rs17227484 chr11 4793882 A G 1.81E-14 Fetal hemoglobin levels / / 18245381 rs12789492 chr11 4794119 C T 1.09E-14 Fetal hemoglobin levels / / 18245381 rs12789492 chr11 4794119 C T 3.89E-16 Malaria / / 23717212 rs17227547 chr11 4794193 A G 8.64E-14 Fetal hemoglobin levels / / 18245381 rs1594812 chr11 4799209 T G 1.32E-15 Malaria / / 23717212 rs12806476 chr11 4806872 T G 4.40E-16 Malaria / / 23717212 rs12801757 chr11 4807054 A G 2.11E-15 Malaria / / 23717212 rs12808215 chr11 4807972 A G 9.20E-15 Malaria / / 23717212 rs17325567 chr11 4808133 T C 4.23E-14 Fetal hemoglobin levels / / 18245381 rs17325567 chr11 4808133 T C 4.06E-16 Malaria / / 23717212 rs17227978 chr11 4808425 G A 4.50E-14 Fetal hemoglobin levels / / 18245381 rs17227978 chr11 4808425 G A 4.26E-16 Malaria / / 23717212 rs1433907 chr11 4809047 C T 8.89E-05 Insulin-related traits / / pha003063 rs17325742 chr11 4809272 T C 3.11E-11 Fetal hemoglobin levels / / 18245381 rs17228092 chr11 4810364 T C 2.78E-11 Fetal hemoglobin levels / / 18245381 rs17228092 chr11 4810364 T C 4.51E-16 Malaria / / 23717212 rs12224171 chr11 4811083 A G 3.00E-04 Smoking initiation / / 24665060 rs17228176 chr11 4811800 A G 3.69E-14 Fetal hemoglobin levels / / 18245381 rs17228176 chr11 4811800 A G 7.03E-16 Malaria / / 23717212 rs17228183 chr11 4811883 G A 6.01E-14 Fetal hemoglobin levels / / 18245381 rs17228183 chr11 4811883 G A 7.05E-16 Malaria / / 23717212 rs12805337 chr11 4814850 G A 1.94E-04 Smoking initiation / / 24665060 rs7939275 chr11 4821120 C T 3.09E-08 Fetal hemoglobin levels / / 18245381 rs7941731 chr11 4825225 A G 2.53E-04 Smoking initiation OR52R1 missense 24665060 rs1865282 chr11 4830652 T G 0.0000149 Oxaliplatin induced diarrhea in response to colorectal cancer treatment / / 22310351 rs4910686 chr11 4838968 T C 3.75E-12 Fetal hemoglobin levels / / 18245381 rs17328191 chr11 4844040 C T 1.25E-09 Fetal hemoglobin levels / / 18245381 rs12277512 chr11 4849038 A T 2.95E-09 Fetal hemoglobin levels / / 18245381 rs11034106 chr11 4850008 A G 4.21E-05 Body Fat Distribution / / pha003016 rs11034106 chr11 4850008 A G 3.86E-06 Body Fat Distribution / / pha003017 rs11034106 chr11 4850008 A G 8.08E-05 Body Fat Distribution / / pha003018 rs17328565 chr11 4851537 A G 2.20E-12 Fetal hemoglobin levels / / 18245381 rs17328663 chr11 4852715 A G 4.94E-05 Body Fat Distribution / / pha003017 rs4373916 chr11 4853259 C A 1.43E-09 Fetal hemoglobin levels / / 18245381 rs4373916 chr11 4853259 C A 5.27E-04 Alzheimer's disease / / 24755620 rs12279647 chr11 4853334 C T 5.26E-05 Multiple complex diseases / / 17554300 rs12279647 chr11 4853334 C T 7.25E-09 Fetal hemoglobin levels / / 18245381 rs12279647 chr11 4853334 C T 5.09E-04 Alzheimer's disease / / 24755620 rs2412395 chr11 4871036 C T 4.47E-12 Fetal hemoglobin levels / / 18245381 rs17329242 chr11 4885150 A G 4.43E-12 Fetal hemoglobin levels / / 18245381 rs2196122 chr11 4885548 G C 7.00E-07 Blood pressure / / 24954895 rs1155740 chr11 4897339 A G 2.75E-04 Multiple complex diseases / / 17554300 rs10768350 chr11 4918235 A G 8.17E-04 Aortic root size / / 21223598 rs7935375 chr11 4923182 T C 3.43E-27 Narcolepsy / / 19629137 rs10742412 chr11 4926193 G T 9.88E-04 Rheumatoid arthritis / / 21452313 rs10500629 chr11 4926685 G A 7.63E-04 Rheumatoid arthritis / / 21452313 rs10500629 chr11 4926685 G A 7.96E-05 Coronary heart disease / / pha003056 rs11034596 chr11 4928621 G A 4.00E-04 Rheumatoid arthritis OR51A7 missense 21452313 rs11034602 chr11 4930566 T C 4.60E-04 Rheumatoid arthritis / / 21452313 rs16907254 chr11 4931083 C T 1.80E-09 Fetal hemoglobin levels / / 18245381 rs7112101 chr11 4935470 T C 3.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12802922 chr11 4935610 C T 3.27E-15 Fetal hemoglobin levels / / 18245381 rs919900 chr11 4937138 C T 3.08E-04 Type 2 diabetes / / 17463246 rs919900 chr11 4937138 C T 8.76E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10836955 chr11 4945631 G A 8.94E-04 Type 2 diabetes / / 17463246 rs10836955 chr11 4945631 G A 7.13E-11 Fetal hemoglobin levels / / 18245381 rs11034685 chr11 4946345 C T 5.56E-04 Type 2 diabetes / / 17463246 rs12807322 chr11 4948160 G A 3.94E-04 Aortic root size / / 21223598 rs10500624 chr11 4948560 T C 3.97E-04 Aortic root size / / 21223598 rs11034705 chr11 4952941 G C 6.18E-04 Multiple complex diseases / / 17554300 rs840716 chr11 4953462 G T 9.06E-26 Fetal hemoglobin levels / / 18245381 rs840716 chr11 4953462 G T 9.30E-09 F-cell distribution / / 21326311 rs840716 chr11 4953462 G T 2.66E-04 Epilepsy / / 22116939 rs10500622 chr11 4954607 A G 3.09E-04 Multiple complex diseases / / 17554300 rs2605298 chr11 4962632 A T 2.30E-05 Urinary metabolites / / 21572414 rs11034822 chr11 4967061 A G 7.60E-05 Multiple complex diseases / / 17554300 rs7105981 chr11 4980153 A G 7.70E-05 Body Mass Index / / pha003019 rs7105981 chr11 4980153 A G 2.23E-05 Body Mass Index / / pha003022 rs2124447 chr11 4995989 A G 7.95E-09 Fetal hemoglobin levels / / 18245381 rs7104839 chr11 5001255 C G 2.67E-10 Fetal hemoglobin levels / / 18245381 rs7108624 chr11 5001831 C T 4.78E-12 Fetal hemoglobin levels / / 18245381 rs11035019 chr11 5009563 C T 0.000000342 HDL cholesterol MMP26 intron 23063622 rs2499953 chr11 5010905 A G 1.70E-05 Type 2 diabetes MMP26 missense 17293876 rs16908114 chr11 5013466 A G 4.90E-07 Blood cell counts and traits,in red and white blood cells MMP26 missense 21153663 rs11035045 chr11 5015941 C T 2.75E-11 Fetal hemoglobin levels / / 18245381 rs11035046 chr11 5016269 G A 1.31E-10 Fetal hemoglobin levels / / 18245381 rs10837104 chr11 5019217 C G 5.28E-11 Fetal hemoglobin levels / / 18245381 rs10837104 chr11 5019217 C G 7.67E-05 Serum metabolites / / 19043545 rs10837107 chr11 5019357 T C 2.55E-10 Fetal hemoglobin levels / / 18245381 rs10837107 chr11 5019357 T C 5.93E-05 Serum metabolites / / 19043545 rs16908208 chr11 5019985 T C 1.40E-05 Malaria / / 19465909 rs10837108 chr11 5020117 C G 1.12E-10 Fetal hemoglobin levels / / 18245381 rs11035064 chr11 5020189 C T 1.01E-10 Fetal hemoglobin levels / / 18245381 rs11035102 chr11 5029457 A G 4.37E-06 Alcohol dependence / / 23089632 rs2445284 chr11 5029703 C T 1.00E-29 Sickle cell anemia (haemolysis) / / 23406172 rs2499957 chr11 5036384 C G 3.60E-11 Fetal hemoglobin levels / / 18245381 rs2445248 chr11 5048058 G A 2.23E-09 Fetal hemoglobin levels / / 18245381 rs2445252 chr11 5051462 G A 1.73E-09 Fetal hemoglobin levels / / 18245381 rs2445271 chr11 5059064 T G 1.80E-10 Fetal hemoglobin levels / / 18245381 rs2034836 chr11 5060791 A G 1.18E-10 Fetal hemoglobin levels / / 18245381 rs2034839 chr11 5060941 G A 7.16E-11 Fetal hemoglobin levels / / 18245381 rs2034839 chr11 5060941 G A 4.30E-05 Malaria / / 19465909 rs2499983 chr11 5061435 C T 8.25E-11 Fetal hemoglobin levels / / 18245381 rs2499984 chr11 5061541 A G 1.12E-10 Fetal hemoglobin levels / / 18245381 rs2499984 chr11 5061541 A G 7.70E-05 Malaria / / 19465909 rs2499984 chr11 5061541 A G 8.62E-05 Response to lithium treatment in bipolar disorder / / 21961650 rs2499984 chr11 5061541 A G 8.70E-04 Response to lithium treatment in bipolar disorder / / 21961650 rs2500012 chr11 5067358 C T 8.39E-11 Fetal hemoglobin levels / / 18245381 rs2500012 chr11 5067358 C T 4.40E-05 Malaria / / 19465909 rs2500013 chr11 5067389 G T 8.39E-11 Fetal hemoglobin levels / / 18245381 rs2500013 chr11 5067389 G T 8.30E-05 Malaria / / 19465909 rs2959184 chr11 5072835 C T 4.68E-11 Fetal hemoglobin levels / / 18245381 rs2959184 chr11 5072835 C T 2.90E-05 Malaria / / 19465909 rs16909440 chr11 5080844 T C 5.51E-04 Response to lithium treatment in bipolar disorder OR52E2 missense 21961650 rs16909440 chr11 5080844 T C 7.45E-05 Response to lithium treatment in bipolar disorder OR52E2 missense 21961650 rs2445335 chr11 5081630 A T 6.77E-11 Fetal hemoglobin levels / / 18245381 rs16909520 chr11 5085254 C T 3.81E-05 Asthma / / 20159242 rs1817207 chr11 5087712 G A 3.83E-04 Smoking initiation / / 24665060 rs1455965 chr11 5090181 T G 7.40E-04 Multiple complex diseases / / 17554300 rs4144715 chr11 5096331 A G 6.07E-06 Malaria / / 23717212 rs10768550 chr11 5098714 C T 2.30E-05 Urinary metabolites / / 21572414 rs2499935 chr11 5109894 C G 1.20E-14 Fetal hemoglobin levels / / 18245381 rs10500616 chr11 5109946 A C 1.50E-05 Urinary metabolites / / 21572414 rs12294758 chr11 5115192 G A 9.32E-12 Fetal hemoglobin levels / / 18245381 rs12282135 chr11 5116128 T C 8.45E-12 Fetal hemoglobin levels / / 18245381 rs1455958 chr11 5127177 C A 1.51E-09 Fetal hemoglobin levels / / 18245381 rs7944388 chr11 5142671 A G 5.70E-06 Alcohol and nictotine co-dependence / / 22488850 rs7120612 chr11 5154157 A G 7.97E-05 Cognitive test performance / / 20125193 rs10768611 chr11 5172786 A G 6.16E-04 Aortic root size OR52A1 missense 21223598 rs10742552 chr11 5188827 G T 0.00000003 Brain microstructure and intellectual performance / / 22723713 rs6578563 chr11 5199708 T A 1.01E-27 Fetal hemoglobin levels / / 18245381 rs7948698 chr11 5200346 G A 2.09E-24 Fetal hemoglobin levels / / 18245381 rs10837513 chr11 5200640 G T 2.52E-26 Fetal hemoglobin levels / / 18245381 rs7938161 chr11 5213276 A G 1.61E-10 Fetal hemoglobin levels / / 18245381 rs10837540 chr11 5214413 T A 5.10E-13 Fetal hemoglobin levels / / 18245381 rs10837540 chr11 5214413 T A 1.80E-07 F-cell distribution / / 21326311 rs7945652 chr11 5220743 A G 1.92E-14 Fetal hemoglobin levels / / 18245381 rs7937649 chr11 5222379 G A 1.44E-14 Fetal hemoglobin levels / / 18245381 rs7937649 chr11 5222379 G A 7.30E-08 F-cell distribution / / 21326311 rs7950726 chr11 5225447 C A 1.00E-11 HbA2 levels / / 23043469 rs11036238 chr11 5225635 G C 2.52E-04 Type 2 diabetes / / 17463246 rs11036238 chr11 5225635 G C 6.51E-15 Fetal hemoglobin levels / / 18245381 rs11036238 chr11 5225635 G C 4.00E-11 Malaria / / 19465909 rs12805212 chr11 5226318 G A 1.00E-19 Fetal hemoglobin levels / / 18245381 rs201286260 chr11 5226318 G GA 1.00E-19 Fetal hemoglobin levels / / 18245381 rs7120391 chr11 5230907 T C 5.00E-09 Red blood cell traits / / 23696099 rs10837593 chr11 5231897 C T 1.17E-12 Fetal hemoglobin levels / / 18245381 rs6578583 chr11 5233643 G C 5.79E-04 Type 2 diabetes / / 17463246 rs10837628 chr11 5244404 A G 1.78E-04 Rheumatoid arthritis / / 21452313 rs281864519 chr11 5248232 TCA T 1.30E-28 Malaria HBB frameshift 19465909 rs281864519 chr11 5248232 TCA T 1.40E-38 Malaria HBB frameshift 22895189 rs334 chr11 5248232 T A,C,G 1.30E-28 Malaria HBB frameshift 19465909 rs334 chr11 5248232 T A,C,G 1.40E-38 Malaria HBB frameshift 22895189 rs1003586 chr11 5249370 C T 7.54E-25 Fetal hemoglobin levels HBB nearGene-5 18245381 rs6578588 chr11 5252251 T C 3.32E-11 Fetal hemoglobin levels / / 18245381 rs7948668 chr11 5256647 A G 3.70E-04 Response to cytadine analogues (cytosine arabinoside) HBD nearGene-5 24483146 rs16911998 chr11 5257700 G A 5.27E-05 Multiple complex diseases HBD nearGene-5 17554300 rs4283007 chr11 5258490 A T 3.37E-08 Fetal hemoglobin levels / / 18245381 rs2105819 chr11 5259727 G C 7.39E-09 Fetal hemoglobin levels / / 18245381 rs968856 chr11 5260576 T C 2.30E-13 Fetal hemoglobin levels / / 18245381 rs968856 chr11 5260576 T C 6.70E-07 F-cell distribution / / 21326311 rs16912210 chr11 5263853 A G 1.00E-06 Obesity-related traits HBBP1 intron 23251661 rs16912210 chr11 5263853 A G 1.00E-06 Obesity-related traits HBBP1 intron 23251661 rs16912210 chr11 5263853 A G 4.00E-07 Obesity-related traits HBBP1 intron 23251661 rs2071348 chr11 5264146 T G 3.00E-15 Beta thalassemia/Hemoglobin E disease HBBP1 intron 20183929 rs6578592 chr11 5269140 C A 2.60E-18 Fetal hemoglobin levels HBG1 nearGene-3 18245381 rs2855039 chr11 5271671 C T 0.00000224 Fetal hemoglobin levels HBG1 nearGene-5 22936743 rs2855126 chr11 5273147 C G 4.55E-09 Fetal hemoglobin levels / / 18245381 rs11036476 chr11 5275343 C T 3.08E-06 Uric acid levels HBG2 intron 21294900 rs7482144 chr11 5276169 G A 2.40E-38 F-cell distribution LOC100653006 intron 17767159 rs7482144 chr11 5276169 G A 2.40E-38 F-cell distribution LOC100653006 intron 21326311 rs2855123 chr11 5277078 A T 1.18E-09 Fetal hemoglobin levels LOC100653006 intron 18245381 rs5010979 chr11 5279153 T C 6.89E-17 Fetal hemoglobin levels LOC100653006 intron 18245381 rs5010979 chr11 5279153 T C 8.08E-05 Vitiligo LOC100653006 intron 22951725 rs4348933 chr11 5284978 A G 1.61E-09 Fetal hemoglobin levels LOC100653006 intron 18245381 rs7479652 chr11 5293113 T C 1.00E-04 Response to cytadine analogues (cytosine arabinoside) HBE1 nearGene-5 24483146 rs10488675 chr11 5298030 A G 3.38E-05 Telomere length / / 20139977 rs2213169 chr11 5303063 G A 1.00E-13 Mean corpuscular hemoglobin concentration / / 23263863 rs2213169 chr11 5303063 G A 5.00E-11 Hematology traits / / 23263863 rs4910742 chr11 5306509 G A 1.00E-21 Fetal Hemoglobin levels / / 18245381 rs4910742 chr11 5306509 G A 1.20E-21 F-cell distribution / / 21326311 rs4910742 chr11 5306509 G A 2.00E-09 Inflammatory biomarkers / / 22291609 rs11036635 chr11 5308896 G A 4.80E-06 Malaria / / 19465909 rs10837767 chr11 5317553 T G 2.60E-11 Fetal hemoglobin levels / / 18245381 rs10082566 chr11 5328707 C T 1.63E-04 Taste perception / / 22132133 rs11036766 chr11 5335943 T C 3.25E-05 Height / / pha003010 rs11036814 chr11 5344592 A C 3.55E-05 Cognitive impairment induced by topiramate OR51B2 missense 22091778 rs10837814 chr11 5345128 G A 0.00000295 Fetal hemoglobin levels OR51B2 missense 22936743 rs2723381 chr11 5347875 A G 6.94E-04 Alzheimer's disease / / 17998437 rs10837853 chr11 5360615 A G 1.46E-05 Serum albumin level / / pha003084 rs4910752 chr11 5370955 C T 0.00000124 Fetal hemoglobin levels OR51B5 intron 22936743 rs4439540 chr11 5372147 A G 7.06E-05 Amyotrophic lateral sclerosis (sporadic) OR51B5 intron 24529757 rs4373970 chr11 5372690 A G 6.70E-06 Malaria OR51B5 intron 19465909 rs4910755 chr11 5372751 A C 0.00000171 Fetal hemoglobin levels OR51B6 missense 22936743 rs4910756 chr11 5372856 A G 0.00000337 Fetal hemoglobin levels OR51B6 missense 22936743 rs7483122 chr11 5373006 T C 9.30E-04 Rheumatoid arthritis OR51B6 missense 21452313 rs7483122 chr11 5373006 T C 0.00000271 Fetal hemoglobin levels OR51B6 missense 22936743 rs5006887 chr11 5373129 C T 4.76E-05 Amyotrophic lateral sclerosis (sporadic) OR51B6 missense 24529757 rs5006884 chr11 5373251 C T 3.00E-08 Fetal hemoglobin levels OR51B6 missense 20018918 rs5006884 chr11 5373251 C T 2.72E-08 F-cell distribution OR51B6 missense 21326311 rs5006884 chr11 5373251 C T 9.30E-04 Rheumatoid arthritis OR51B6 missense 21452313 rs5006884 chr11 5373251 C T 3.82E-08 Fetal hemoglobin levels OR51B6 missense 22936743 rs5024042 chr11 5373562 C A 0.00000106 Fetal hemoglobin levels OR51B6 missense 22936743 rs4492850 chr11 5374857 C T 7.39E-05 Height OR51B5 intron pha003011 rs16913820 chr11 5382734 C T 1.46E-05 Height OR51B5 intron pha003010 rs16913820 chr11 5382734 C T 7.67E-07 Height OR51B5 intron pha003011 rs10500635 chr11 5386668 G A 0.00000194 Fetal hemoglobin levels OR51B5 intron 22936743 rs728925 chr11 5392484 T C 7.47E-04 Premature ovarian failure OR51B5 intron 19508998 rs728925 chr11 5392484 T C 1.40E-05 Height OR51B5 intron pha003010 rs728925 chr11 5392484 T C 6.50E-07 Height OR51B5 intron pha003011 rs11037068 chr11 5393787 T G 5.81E-04 Suicide attempts in bipolar disorder OR51B5 intron 21041247 rs2736544 chr11 5401260 A G 1.28E-09 Fetal hemoglobin levels OR51B5 intron 18245381 rs12364011 chr11 5403033 A G 9.61E-04 Type 2 diabetes OR51B5 intron 17463246 rs12364011 chr11 5403033 A G 7.92E-04 Response to cytidine analogues (gemcitabine) OR51B5 intron 24483146 rs10837965 chr11 5403334 T A 7.92E-04 Response to cytidine analogues (gemcitabine) OR51B5 intron 24483146 rs12360697 chr11 5405205 G A 5.92E-04 Response to cytidine analogues (gemcitabine) OR51B5 intron 24483146 rs4910780 chr11 5406123 T C 2.30E-05 Malaria OR51B5 intron 19465909 rs11037178 chr11 5409750 T C 8.52E-04 Response to cytidine analogues (gemcitabine) OR51B5 intron 24483146 rs114517600 chr11 5411122 C T 0.00016 Prostate cancer OR51M1 missense 23555315 rs11037191 chr11 5412072 A G 1.94E-31 Fetal hemoglobin levels OR51B5 intron 18245381 rs11037193 chr11 5412543 A G 2.50E-05 Cognitive function OR51B5 intron 24684796 rs6578634 chr11 5420909 G T 9.06E-05 Cognitive impairment induced by topiramate OR51B5 intron 22091778 rs2647579 chr11 5440287 A G 2.32E-18 Fetal hemoglobin levels OR51B5 intron 18245381 rs2647579 chr11 5440287 A G 8.10E-05 Lymphocyte counts OR51B5 intron 22286170 rs1498477 chr11 5440620 G A 2.10E-05 Urinary metabolites OR51B5 intron 21572414 rs2471991 chr11 5441623 A G 1.06E-18 Fetal hemoglobin levels OR51B5 intron 18245381 rs2471991 chr11 5441623 A G 7.38E-05 Lymphocyte counts OR51B5 intron 22286170 rs17359438 chr11 5442226 T C 3.31E-08 Fetal hemoglobin levels OR51B5 intron 18245381 rs17359438 chr11 5442226 T C 1.10E-05 Malaria OR51B5 intron 19465909 rs16930671 chr11 5444886 T G 1.76E-04 Multiple complex diseases OR51B5 intron 17554300 rs11037417 chr11 5448543 G A 5.38E-08 Fetal hemoglobin levels OR51B5 intron 18245381 rs1353735 chr11 5451197 G A 2.22E-08 Fetal hemoglobin levels OR51B5 intron 18245381 rs2340653 chr11 5451761 G A 5.85E-17 Fetal hemoglobin levels OR51B5 intron 18245381 rs2340349 chr11 5455546 C T 9.28E-09 Fetal hemoglobin levels OR51B5 intron 18245381 rs1391619 chr11 5455929 G A 9.46E-24 Fetal hemoglobin levels OR51B5 intron 18245381 rs1391619 chr11 5455929 G A 1.10E-09 F-cell distribution OR51B5 intron 21326311 rs11037444 chr11 5462085 G A 5.05E-09 Fetal hemoglobin levels OR51I1 cds-synon 18245381 rs16931041 chr11 5463425 T C 1.10E-05 Malaria OR51B5 intron 19465909 rs7948471 chr11 5471746 G A 3.00E-10 Sickle cell anemia (haemolysis) OR51B5 intron 23406172 rs7948471 chr11 5471746 G A 6.75E-05 Waist-Hip Ratio OR51B5 intron pha003029 rs7938426 chr11 5471832 A G 6.75E-05 Waist-Hip Ratio OR51B5 intron pha003029 rs6578647 chr11 5472822 G A 2.03E-04 Insulin resistance OR51B5 intron 21901158 rs7104300 chr11 5472989 G A 1.10E-04 Insulin resistance OR51B5 intron 21901158 rs10838134 chr11 5473889 T C 9.83E-05 Waist Circumference OR51B5 intron pha003024 rs10838134 chr11 5473889 T C 7.82E-05 Waist-Hip Ratio OR51B5 intron pha003029 rs7942825 chr11 5481973 C T 8.01E-05 Response to citalopram treatment OR51B5 intron 19846067 rs1391617 chr11 5483825 C T 6.40E-05 Hypertension (early onset hypertension) OR51B5 intron 22479346 rs2647595 chr11 5484249 T C 1.27E-04 Multiple complex diseases OR51B5 intron 17554300 rs2647593 chr11 5487596 G A 5.38E-15 Fetal hemoglobin levels OR51B5 intron 18245381 rs454465 chr11 5488840 C T 4.58E-05 Hypertension (early onset hypertension) OR51B5 intron 22479346 rs449937 chr11 5490345 G A 5.33E-05 Hypertension (early onset hypertension) OR51B5 intron 22479346 rs10768978 chr11 5490529 G A 9.87E-05 Hypertension (early onset hypertension) OR51B5 intron 22479346 rs366257 chr11 5490543 C T 7.08E-05 Hypertension (early onset hypertension) OR51B5 intron 22479346 rs7106553 chr11 5491568 G A 8.62E-09 Fetal hemoglobin levels OR51B5 intron 18245381 rs10768980 chr11 5492033 C G 2.06E-08 Fetal hemoglobin levels OR51B5 intron 18245381 rs16931459 chr11 5493309 C T 5.78E-04 Type 2 diabetes OR51B5 intron 17463246 rs411732 chr11 5493384 A G 2.98E-08 Fetal hemoglobin levels OR51B5 intron 18245381 rs2647543 chr11 5496811 A C 4.49E-05 Hypertension (early onset hypertension) OR51B5 intron 22479346 rs365943 chr11 5497799 G A 7.05E-05 Hypertension (early onset hypertension) OR51B5 intron 22479346 rs404280 chr11 5510341 C T 8.97E-05 Hypertension (early onset hypertension) OR52D1 cds-synon 22479346 rs2879747 chr11 5514892 C A 3.77E-04 Type 2 diabetes OR51B5 intron 17463246 rs2879747 chr11 5514892 C A 4.54E-04 Multiple complex diseases OR51B5 intron 17554300 rs366533 chr11 5517485 G A 9.05E-05 Nicotine smoking OR51B5 intron 19268276 rs366533 chr11 5517485 G A 0.000483659 Hypertension (early onset hypertension) OR51B5 intron 22479346 rs372091 chr11 5518156 A G 6.00E-14 Malaria OR51B5 intron 22895189 rs435810 chr11 5518978 C T 1.20E-09 Fetal hemoglobin levels OR51B5 intron 18245381 rs435810 chr11 5518978 C T 0.000160541 Hypertension (early onset hypertension) OR51B5 intron 22479346 rs371288 chr11 5519006 A G 1.84E-04 Multiple complex diseases OR51B5 intron 17554300 rs414154 chr11 5520572 A G 1.35E-04 Multiple complex diseases OR51B5 intron 17554300 rs11037866 chr11 5525871 C T 1.04E-15 Fetal hemoglobin levels OR51B5 intron 18245381 rs172748 chr11 5533839 T C 2.99E-13 Fetal hemoglobin levels / / 18245381 rs4910812 chr11 5535007 G A 2.23E-11 Fetal hemoglobin levels / / 18245381 rs934460 chr11 5535182 A C 6.61E-13 Fetal hemoglobin levels / / 18245381 rs10838245 chr11 5535529 G T 1.78E-17 Fetal hemoglobin levels / / 18245381 rs10838245 chr11 5535529 G T 1.05E-05 Alzheimer's disease / / 21627779 rs1044392 chr11 5535671 A G 3.20E-18 Fetal hemoglobin levels UBQLNL UTR-3 18245381 rs11547558 chr11 5535671 A AA,AG 3.20E-18 Fetal hemoglobin levels UBQLNL UTR-3 18245381 rs2047456 chr11 5537161 A G 9.28E-04 Common variable immunodeficiency UBQLNL missense 21497890 rs1809862 chr11 5537780 C A 3.86E-19 Fetal hemoglobin levels UBQLNL UTR-5 18245381 rs979752 chr11 5539139 G A 1.20E-04 Type 2 diabetes / / 17846124 rs12286144 chr11 5543019 T C 6.86E-21 Fetal hemoglobin levels / / 18245381 rs2010794 chr11 5545822 A T 4.80E-06 Malaria / / 19465909 rs317775 chr11 5546650 A T 4.84E-04 Smoking initiation / / 24665060 rs7125848 chr11 5556055 T C 9.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs1995158 chr11 5566030 A G 5.37E-04 Stroke (pediatric) OR52H1 missense 22990015 rs1995158 chr11 5566030 A G 4.53E-04 Smoking initiation OR52H1 missense 24665060 rs1566275 chr11 5566365 T C 4.48E-04 Smoking initiation OR52H1 missense 24665060 rs431702 chr11 5569452 T C 5.42E-05 Serum metabolites / / 19043545 rs411933 chr11 5570043 C T 2.46E-13 Fetal hemoglobin levels / / 18245381 rs2647602 chr11 5573701 A C 1.94E-13 Fetal hemoglobin levels / / 18245381 rs1694676 chr11 5573831 T A 2.21E-13 Fetal hemoglobin levels / / 18245381 rs431117 chr11 5574280 A C 1.53E-13 Fetal hemoglobin levels / / 18245381 rs446099 chr11 5574493 C T 2.13E-13 Fetal hemoglobin levels / / 18245381 rs430197 chr11 5574641 T C 2.10E-13 Fetal hemoglobin levels / / 18245381 rs407487 chr11 5575382 G A 5.49E-11 Fetal hemoglobin levels / / 18245381 rs1368697 chr11 5578992 C T 4.79E-17 Fetal hemoglobin levels / / 18245381 rs16932923 chr11 5583915 T G 8.00E-05 Prostate cancer / / 21743057 rs16932932 chr11 5584786 A T 8.00E-05 Prostate cancer / / 21743057 rs10742718 chr11 5586168 C G 9.00E-05 Depression (quantitative trait) / / 23290196 rs10742719 chr11 5586252 A C 6.13E-05 Depression (quantitative trait) / / 23290196 rs10742719 chr11 5586252 A C 2.20E-05 Height / / pha003010 rs10742719 chr11 5586252 A C 8.91E-05 Height / / pha003011 rs10742725 chr11 5586545 C T 9.07E-05 Depression (quantitative trait) / / 23290196 rs4547126 chr11 5587014 C G 4.15E-09 Fetal hemoglobin levels / / 18245381 rs4604918 chr11 5587111 C A 1.80E-05 Height / / pha003010 rs4604918 chr11 5587111 C A 7.98E-05 Height / / pha003011 rs4604918 chr11 5587111 C A 8.79E-05 Lung function (forced vital capacity) / / pha003104 rs9804698 chr11 5588174 T C 2.10E-05 Height / / pha003010 rs9804698 chr11 5588174 T C 4.65E-06 Height / / pha003011 rs2341430 chr11 5589862 T C 9.01E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs3910245 chr11 5593467 A G 9.75E-06 Uric acid levels / / 21294900 rs7124406 chr11 5598243 T C 2.78E-05 Height / / pha003010 rs7124406 chr11 5598243 T C 2.78E-05 Height / / pha003011 rs4910571 chr11 5598864 T G 2.28E-05 Height / / pha003010 rs4910571 chr11 5598864 T G 2.25E-05 Height / / pha003011 rs10838371 chr11 5600486 C T 6.32E-05 Cognitive performance / / 19734545 rs2341434 chr11 5602615 A G 1.89E-05 Height OR52B6 missense pha003010 rs2341434 chr11 5602615 A G 8.84E-05 Height OR52B6 missense pha003011 rs2341434 chr11 5602615 A G 7.10E-05 Lung function (forced vital capacity) OR52B6 missense pha003104 rs2163946 chr11 5602790 A G 9.57E-05 Depression (quantitative trait) OR52B6 cds-synon 23290196 rs7930681 chr11 5603975 C T 9.45E-05 Depression (quantitative trait) / / 23290196 rs7930681 chr11 5603975 C T 1.89E-05 Height / / pha003010 rs7930681 chr11 5603975 C T 8.84E-05 Height / / pha003011 rs7930681 chr11 5603975 C T 7.10E-05 Lung function (forced vital capacity) / / pha003104 rs11038193 chr11 5604713 A T 6.91E-05 Depression (quantitative trait) / / 23290196 rs10769092 chr11 5605154 T G 8.42E-05 Depression (quantitative trait) / / 23290196 rs4910820 chr11 5606219 C T 5.48E-05 Height / / pha003010 rs4910820 chr11 5606219 C T 4.81E-05 Height / / pha003011 rs4910821 chr11 5606639 C T 2.60E-08 Fetal hemoglobin levels / / 18245381 rs4910822 chr11 5608274 G A 1.72E-05 Height / / pha003010 rs4910822 chr11 5608274 G A 7.80E-05 Height / / pha003011 rs4910822 chr11 5608274 G A 7.12E-05 Lung function (forced vital capacity) / / pha003104 rs7108470 chr11 5625603 A G 3.00E-06 IgG glycosylation TRIM6 intron 23382691 rs17304278 chr11 5625988 T C 4.58E-04 Suicide attempts in bipolar disorder TRIM6 intron 21423239 rs1074353 chr11 5626241 G A 3.13E-05 Parent of origin effect on language impairment (maternal) TRIM6 intron 24571439 rs4910828 chr11 5630635 T C 1.40E-05 Calcium levels TRIM6 intron pha003085 rs7939159 chr11 5642001 T C 1.46E-04 Lymphocyte counts TRIM34 intron 22286170 rs10838441 chr11 5645003 G C 2.15E-04 Type 2 diabetes TRIM34 intron 17463246 rs12274893 chr11 5647033 C T 1.36E-04 Type 2 diabetes TRIM34 intron 17463246 rs7127863 chr11 5654481 C T 3.53E-04 Smoking cessation TRIM34 intron 24665060 rs10838475 chr11 5660023 T C 4.38E-04 Type 2 diabetes TRIM34 intron 17463246 rs11820502 chr11 5688024 G C 1.00E-06 IgG glycosylation TRIM5 intron 23382691 rs11820502 chr11 5688024 G C 2.00E-06 IgG glycosylation TRIM5 intron 23382691 rs11820502 chr11 5688024 G C 3.00E-06 IgG glycosylation TRIM5 intron 23382691 rs12808061 chr11 5689975 C A 5.26E-04 Obesity (extreme) TRIM5 intron 21935397 rs10838517 chr11 5695743 T C 4.54E-04 Multiple complex diseases TRIM5 intron 17554300 rs3824949 chr11 5701409 G C 1.64E-04 Type 2 diabetes TRIM5 UTR-5 17463246 rs17305868 chr11 5701883 A G 1.51E-04 Type 2 diabetes TRIM5 intron 17463246 rs2291844 chr11 5719835 T C 9.39E-05 Blood Pressure TRIM22 intron pha003044 rs2291845 chr11 5729580 T C 5.23E-04 Response to taxane treatment (placlitaxel) TRIM22 intron 23006423 rs7113258 chr11 5731455 T A 2.38E-04 Blood pressure TRIM22 UTR-3 17255346 rs7113258 chr11 5731455 T A 1.41E-04 Response to taxane treatment (placlitaxel) TRIM22 UTR-3 23006423 rs4910841 chr11 5733594 A G 5.52E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2047458 chr11 5745637 T G 3.78E-06 Coronary Artery Disease / / 17634449 rs7933860 chr11 5748222 T C 9.25E-06 White blood cell count / / 21738479 rs7928052 chr11 5758833 T C 4.85E-04 Obesity (extreme) / / 21935397 rs2133266 chr11 5770388 T G 6.14E-04 Obesity (extreme) / / 21935397 rs7948009 chr11 5809548 G A 6.19E-04 Telomere length OR52N1 missense 23900074 rs11039100 chr11 5827003 T C 9.10E-04 Multiple complex diseases / / 17554300 rs11039100 chr11 5827003 T C 7.01E-08 Fetal hemoglobin levels / / 18245381 rs11039101 chr11 5827080 G A 7.01E-08 Fetal hemoglobin levels / / 18245381 rs12279684 chr11 5827317 G C 9.50E-05 Serum metabolites / / 19043545 rs9630186 chr11 5830288 G A 5.22E-04 Multiple complex diseases / / 17554300 rs1993225 chr11 5841068 C T 2.51E-08 Fetal hemoglobin levels / / 18245381 rs4758435 chr11 5841856 C T 2.50E-05 Anger OR52N2 cds-synon 24489884 rs8181512 chr11 5842356 A G 5.58E-05 Serum metabolites OR52N2 missense 19043545 rs11039164 chr11 5843138 G A 1.39E-09 Fetal hemoglobin levels / / 18245381 rs10742809 chr11 5862532 A C 6.77E-05 Multiple complex diseases OR52E6 missense 17554300 rs7944871 chr11 5866333 C T 2.08E-04 Height / / 17255346 rs7944507 chr11 5866730 G C 1.96E-04 Height / / 17255346 rs7937528 chr11 5866902 T C 2.04E-04 Height / / 17255346 rs11039274 chr11 5866953 T G 2.22E-09 Fetal hemoglobin levels / / 18245381 rs1869376 chr11 5867626 C G 1.64E-04 Height / / 17255346 rs4578420 chr11 5867685 T G 1.56E-04 Height / / 17255346 rs935959 chr11 5867977 T C 1.56E-04 Height / / 17255346 rs10769276 chr11 5868020 G T 6.77E-05 Multiple complex diseases / / 17554300 rs935960 chr11 5868055 T C 1.56E-04 Height / / 17255346 rs10769277 chr11 5868161 G A 1.15E-04 Height / / 17255346 rs11039351 chr11 5885846 C T 1.56E-11 Fetal hemoglobin levels / / 18245381 rs10838750 chr11 5886246 T C 1.87E-04 Multiple complex diseases / / 17554300 rs10500657 chr11 5904497 T C 3.56E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs4758168 chr11 5906048 G A 3.57E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) OR52E4 missense 23648065 rs4757986 chr11 5906073 G T 3.58E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) OR52E4 missense 23648065 rs1453435 chr11 5906192 A C 3.58E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) OR52E4 cds-synon 23648065 rs11039508 chr11 5920697 A G 5.91E-14 Fetal hemoglobin levels / / 18245381 rs10160336 chr11 5922222 T C 7.87E-05 Bipolar disorder / / 19488044 rs7106300 chr11 5922707 C T 3.70E-04 Alcohol dependence / / 20201924 rs4601752 chr11 5923297 A G 3.60E-04 Alcohol dependence / / 20201924 rs7129741 chr11 5924061 A G 4.60E-04 Alcohol dependence / / 20201924 rs12793767 chr11 5924210 T C 4.51E-08 Metabolite levels / / 23281178 rs10838807 chr11 5925649 G T 1.20E-09 Fetal hemoglobin levels / / 18245381 rs3858526 chr11 5959757 A C 3.00E-06 DNA methylation (variation) / / 23725790 rs10742907 chr11 6002820 A G 8.24E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs4237768 chr11 6007272 A G 1.07E-05 Lung function (forced expiratory volume in 1 second) OR52L1 missense pha003102 rs4388872 chr11 6013529 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17809378 chr11 6019813 T C 3.25E-04 Coronary Artery Disease / / 17634449 rs7947235 chr11 6019989 C A 5.90E-09 Fetal hemoglobin levels / / 18245381 rs11040248 chr11 6023581 A G 7.72E-06 Non-obstructive azoospermia OR56A4 cds-synon 22541561 rs10839221 chr11 6023818 G A 6.44E-04 Coronary Artery Disease OR56A4 cds-synon 17634449 rs12362690 chr11 6025297 T C 5.86E-04 Coronary Artery Disease / / 17634449 rs4573661 chr11 6026661 G A 4.35E-04 Atopy / / 21625490 rs4494290 chr11 6030442 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10734595 chr11 6032767 C T 2.60E-05 Urinary metabolites / / 21572414 rs10734595 chr11 6032767 C T 1.01E-05 Cognitive decline / / 22054870 rs7128982 chr11 6033291 C T 2.70E-05 Urinary metabolites / / 21572414 rs10769565 chr11 6034259 C T 9.09E-06 Cognitive decline / / 22054870 rs6578720 chr11 6035889 T C 2.40E-05 Urinary metabolites / / 21572414 rs4758362 chr11 6037108 C T 1.16E-05 Cognitive decline / / 22054870 rs4237774 chr11 6041346 G A 6.38E-04 Longevity / / 22279548 rs4420239 chr11 6063985 A G 0.00003131 Sarcoidosis / / 22952805 rs4370913 chr11 6070014 T A 0.000009513 Sarcoidosis / / 22952805 rs4620703 chr11 6070157 G A 0.00002113 Sarcoidosis / / 22952805 rs4491198 chr11 6070345 C T 0.00000859 Sarcoidosis / / 22952805 rs5015541 chr11 6070462 C T 0.000009352 Sarcoidosis / / 22952805 rs7481034 chr11 6070499 G A 0.00002094 Sarcoidosis / / 22952805 rs12365575 chr11 6075274 G A 0.00002352 Sarcoidosis / / 22952805 rs10839311 chr11 6075446 C T 0.00003923 Sarcoidosis / / 22952805 rs10839311 chr11 6075446 C T 5.97E-05 Hemoglobin / / pha003098 rs11040466 chr11 6081408 G C 0.00002519 Sarcoidosis / / 22952805 rs11040741 chr11 6121006 A G 2.70E-05 Parkinson's disease (age of onset) / / 19772629 rs10839512 chr11 6121432 C T 3.30E-05 Parkinson's disease (age of onset) / / 19772629 rs11603622 chr11 6132758 A T 2.80E-05 Urinary metabolites / / 21572414 rs1381911 chr11 6134006 A G 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs325640 chr11 6149047 A G 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs325661 chr11 6161724 G A 2.47E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11602249 chr11 6164387 T C 2.20E-05 Urinary metabolites / / 21572414 rs325664 chr11 6164700 G A 7.01E-04 Insulin resistance / / 21901158 rs325687 chr11 6179462 T C 4.56E-04 Depression (quantitative trait) / / 20800221 rs12226204 chr11 6189514 A G 3.82E-04 Type 2 diabetes / / 17463246 rs11040780 chr11 6193544 T C 2.01E-04 Type 2 diabetes / / 17463246 rs325648 chr11 6204316 C A 7.23E-05 Pancreatic cancer / / pha002874 rs17237706 chr11 6215571 G C 7.99E-04 Type 2 diabetes / / 17463246 rs1381914 chr11 6219515 C T 9.17E-04 Type 2 diabetes / / 17463246 rs1824685 chr11 6219620 C T 5.16E-04 Type 2 diabetes / / 17463246 rs17238860 chr11 6242337 T C 4.84E-06 Bipolar disorder FAM160A2 intron 20451256 rs325608 chr11 6245555 C T 2.00E-04 Cognitive impairment induced by topiramate FAM160A2 intron 22091778 rs7104040 chr11 6311226 G A 2.83E-04 Multiple complex diseases / / 17554300 rs10769684 chr11 6313741 G A 7.23E-06 Height / / 22021425 rs17818478 chr11 6319002 A G 2.80E-05 Urinary metabolites / / 21572414 rs10839548 chr11 6322284 A C 2.48E-05 Vascular dementia / / 22116812 rs4758405 chr11 6324634 G A 8.41E-06 Nicotine smoking / / 19268276 rs2344350 chr11 6324678 T C 5.28E-04 Schizophrenia / / 19197363 rs1051992 chr11 6340706 A G 9.60E-05 Carotid intima media thickness PRKCDBP missense 19679847 rs1488864 chr11 6342329 T G 1.00E-06 Smooth-surface caries / / 24556642 rs1488864 chr11 6342329 T G 1.02E-06 Smooth-surface caries / / 24556642 rs4758096 chr11 6348614 C G 9.65E-06 Smooth-surface caries / / 24556642 rs4758408 chr11 6348639 T C 1.12E-06 Smooth-surface caries / / 24556642 rs10839553 chr11 6350791 A C 0.000025 Coronary artery calcification / / 23727086 rs2634205 chr11 6374273 A C 7.39E-04 Stroke / / pha002887 rs2101469 chr11 6397336 T C 5.60E-04 Alcohol dependence / / 20201924 rs11040883 chr11 6409790 G A 1.80E-04 Coronary heart disease SMPD1 nearGene-5 21966275 rs4758417 chr11 6459938 A G 1.44E-05 Atrial fibrillation HPX intron 21846873 rs1004154 chr11 6466091 A C 9.37E-04 Parkinson's disease / / 17052657 rs2555155 chr11 6522804 G A 5.00E-06 DNA methylation (variation) DNHD1 intron 23725790 rs17244263 chr11 6532778 A T 7.22E-05 Lymphocyte counts DNHD1 intron 22286170 rs7103810 chr11 6555365 A G 9.11E-05 Myopia (pathological) DNHD1 missense 23049088 rs2344929 chr11 6556895 C T 8.62E-04 Premature ovarian failure DNHD1 intron 19508998 rs6578761 chr11 6564634 G C 2.86E-05 Serum metabolites DNHD1 intron 19043545 rs11606889 chr11 6569896 G A 9.45E-04 Response to taxane treatment (placlitaxel) DNHD1 missense 23006423 rs2345345 chr11 6577577 T C 5.37E-05 Personality dimensions DNHD1 intron 23903073 rs16915415 chr11 6583928 C A 4.78E-05 Lymphocyte counts DNHD1 intron 22286170 rs11040923 chr11 6585007 G A 0.00071863 Hypertension (early onset hypertension) DNHD1 missense 22479346 rs1800732 chr11 6640753 A G 7.39E-04 Multiple complex diseases TPP1 nearGene-5 17554300 rs150834672 chr11 6661352 C T 0.00069 Prostate cancer DCHS1 missense 23555315 rs10160659 chr11 6665694 A C 2.40E-04 Multiple complex diseases DCHS1 intron 17554300 rs10160659 chr11 6665694 A C 6.17E-23 Narcolepsy DCHS1 intron 19629137 rs2063082 chr11 6668328 A G 4.19E-05 Amyotrophic lateral sclerosis DCHS1 intron 20801718 rs2063082 chr11 6668328 A G 6.24E-04 Suicide attempts in bipolar disorder DCHS1 intron 21423239 rs2063082 chr11 6668328 A G 2.42E-05 Coronary heart disease DCHS1 intron pha003031 rs10500664 chr11 6685558 G A 9.96E-05 Multiple complex diseases / / 17554300 rs10769706 chr11 6693054 T A 8.10E-04 Multiple complex diseases / / 17554300 rs3741277 chr11 6702409 C T 6.46E-06 Longevity,exceptional MRPL17 UTR-3 20595579 rs10839595 chr11 6720186 G A 8.40E-04 Alcohol dependence / / 20201924 rs11825966 chr11 6734161 C T 1.42E-04 Smoking initiation / / 24665060 rs12284429 chr11 6739407 A G 4.84E-05 Cardiovascular disease / / pha003064 rs7114441 chr11 6739814 C T 1.93E-04 Smoking initiation / / 24665060 rs16917433 chr11 6743665 T C 9.23E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7942744 chr11 6743890 C T 7.14E-05 Major depressive disorder (broad) / / 20038947 rs10742983 chr11 6749583 A G 6.69E-06 Lymphocyte counts / / 22286170 rs12799172 chr11 6750057 C T 5.00E-06 Periodontal disease-related phenotypes / / 24347629 rs949901 chr11 6756331 T C 7.45E-04 Smoking initiation / / 24665060 rs10769720 chr11 6756925 A T 4.77E-04 Smoking initiation / / 24665060 rs937854 chr11 6769401 A G 2.79E-04 Smoking initiation / / 24665060 rs7928685 chr11 6773439 T C 4.65E-04 Multiple complex diseases / / 17554300 rs6578777 chr11 6774502 A G 4.57E-04 Smoking initiation / / 24665060 rs7948350 chr11 6778205 T C 4.45E-04 Smoking initiation / / 24665060 rs4758132 chr11 6783401 G A 6.82E-04 Smoking initiation / / 24665060 rs11041009 chr11 6792058 G A 5.57E-04 Smoking initiation / / 24665060 rs10839617 chr11 6793070 G C 2.43E-04 Smoking initiation / / 24665060 rs565506 chr11 6823713 G A,C 6.26E-05 Serum metabolites / / 19043545 rs609433 chr11 6833747 C T 5.66E-05 Serum metabolites / / 19043545 rs2167018 chr11 6842021 G C 1.77E-05 Serum metabolites / / 19043545 rs2100197 chr11 6877875 C T 5.18E-05 Serum metabolites / / 19043545 rs6578784 chr11 6882090 T C 3.34E-05 Serum metabolites / / 19043545 rs11041061 chr11 6883626 G A 6.45E-05 Serum metabolites / / 19043545 rs3110011 chr11 6888862 A G 7.94E-04 Insulin resistance / / 21901158 rs6578789 chr11 6894705 C T 9.63E-06 Serum metabolites / / 19043545 rs10839633 chr11 6895344 G T 2.48E-05 Serum metabolites / / 19043545 rs7930493 chr11 6895857 C A 6.08E-05 Serum metabolites / / 19043545 rs12284359 chr11 6896825 G A 8.62E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs112511001 chr11 6898587 C A 0.00087 Prostate cancer OR10A4 missense 23555315 rs17275066 chr11 6905805 C T 1.06E-06 Serum metabolites / / 19043545 rs721120 chr11 6911272 G T 5.36E-07 Serum metabolites / / 19043545 rs10769732 chr11 6924754 T C 2.30E-05 Urinary metabolites / / 21572414 rs7110568 chr11 6932396 G A 6.25E-04 Smoking initiation / / 24665060 rs7118671 chr11 6934002 G C 1.25E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7118671 chr11 6934002 G C 9.73E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs994710 chr11 6944529 G A 2.07E-04 Smoking initiation / / 24665060 rs2279533 chr11 6947965 G A 2.52E-04 Smoking initiation ZNF215 intron 24665060 rs2857891 chr11 6962957 C T 2.00E-06 Response to cytadine analogues (cytosine arabinoside) ZNF215 intron 24483146 rs2857891 chr11 6962957 C T 2.37E-05 Response to cytidine analogues (gemcitabine) ZNF215 intron 24483146 rs2595500 chr11 6963165 A G 9.37E-05 Lymphocyte counts ZNF215 intron 22286170 rs2595500 chr11 6963165 A G 1.75E-06 Response to cytadine analogues (cytosine arabinoside) ZNF215 intron 24483146 rs2595500 chr11 6963165 A G 2.37E-05 Response to cytidine analogues (gemcitabine) ZNF215 intron 24483146 rs2638100 chr11 6969676 G C 4.11E-04 Response to cytidine analogues (gemcitabine) ZNF215 intron 24483146 rs2638100 chr11 6969676 G C 7.19E-04 Response to cytadine analogues (cytosine arabinoside) ZNF215 intron 24483146 rs2857901 chr11 6980511 A G 5.98E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2857901 chr11 6980511 A G 7.43E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2638094 chr11 6981488 A G 1.72E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs2638094 chr11 6981488 A G 2.91E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2638087 chr11 6990516 C T 8.89E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs980159 chr11 6993077 A C 6.02E-05 Cognitive performance / / 19734545 rs2468989 chr11 7015268 A C 0.0002503 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2468989 chr11 7015268 A C 2.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1156526 chr11 7022717 T C 8.10E-04 Major depressive disorder ZNF214 missense 21042317 rs10769750 chr11 7023541 A G 6.93E-04 Type 2 diabetes ZNF214 intron 17463246 rs10769750 chr11 7023541 A G 6.60E-04 Major depressive disorder ZNF214 intron 21042317 rs7932579 chr11 7023688 A G 5.10E-04 Major depressive disorder ZNF214 intron 21042317 rs10839684 chr11 7032973 G A 7.80E-04 Type 2 diabetes ZNF214 intron 17463246 rs2035845 chr11 7038250 C G 6.89E-04 Type 2 diabetes ZNF214 intron 17463246 rs10839691 chr11 7038451 G A 6.00E-04 Gamma gluatamyl transferase levels (interaction with age) ZNF214 intron 22010049 rs7936892 chr11 7046477 T A 8.20E-04 Type 2 diabetes NLRP14 intron 17463246 rs10839695 chr11 7054167 C T 4.41E-04 Type 2 diabetes NLRP14 intron 17463246 rs16921772 chr11 7066689 C G 9.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) NLRP14 intron 23233662 rs16921939 chr11 7078804 A C 0.0001472 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NLRP14 intron 23233654 rs16921939 chr11 7078804 A C 1.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) NLRP14 intron 23233662 rs11041162 chr11 7096032 G T 2.90E-05 Urinary metabolites / / 21572414 rs4758160 chr11 7114755 A G 8.60E-06 Urinary metabolites / / 21572414 rs11041175 chr11 7118692 G A 7.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7114581 chr11 7119801 A C 7.40E-04 Multiple complex diseases / / 17554300 rs9804633 chr11 7132515 T C 2.60E-05 Urinary metabolites / / 21572414 rs7102031 chr11 7133804 T C 4.66E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7119917 chr11 7144852 C T 8.00E-06 Urinary metabolites / / 21572414 rs17281232 chr11 7153289 C T 2.90E-05 Urinary metabolites / / 21572414 rs10500679 chr11 7156363 C G 7.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs3105717 chr11 7177827 G T 9.05E-05 Platelet counts / / pha003100 rs3905311 chr11 7213503 T C 2.10E-04 Smoking initiation / / 24665060 rs1552463 chr11 7262943 C T 7.56E-05 Height / / pha003010 rs11041292 chr11 7290794 A C 4.17E-04 Alzheimer's disease (late onset) SYT9 intron 21379329 rs10839761 chr11 7311898 T C 4.52E-04 Gallstones SYT9 intron 17632509 rs7948390 chr11 7325445 G A 7.08E-05 Alzheimer's disease (age of onset) SYT9 intron 22005931 rs7938503 chr11 7325520 T A 7.21E-05 Alzheimer's disease (age of onset) SYT9 intron 22005931 rs16924601 chr11 7327394 A G 9.21E-05 Alzheimer's disease (age of onset) SYT9 intron 22005931 rs1017940 chr11 7343638 T C 6.30E-06 Urinary metabolites SYT9 intron 21572414 rs1017939 chr11 7343762 A G 1.49E-04 Type 2 diabetes SYT9 intron 17463246 rs1017939 chr11 7343762 A G 3.06E-04 Alzheimer's disease (late onset) SYT9 intron 21379329 rs10769780 chr11 7367095 T C 3.00E-08 Phospholipid levels (plasma) SYT9 intron 22359512 rs977749 chr11 7384411 T C 7.50E-05 Alcoholism (heaviness of drinking) SYT9 intron 21529783 rs10769782 chr11 7390571 G C 6.28E-06 QRS duration in Tripanosoma cruzi seropositivity SYT9 intron 24324551 rs10769783 chr11 7396191 A G 2.00E-07 QRS duration in Tripanosoma cruzi seropositivity SYT9 intron 24324551 rs10769783 chr11 7396191 A G 6.00E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity SYT9 intron 24324551 rs7944830 chr11 7403207 A T 5.76E-04 Multiple complex diseases SYT9 intron 17554300 rs72846013 chr11 7408743 G A 5.64E-06 QRS duration in Tripanosoma cruzi seropositivity SYT9 intron 24324551 rs7104549 chr11 7418466 A G 4.71E-04 Type 2 diabetes SYT9 intron 17463246 rs7108499 chr11 7419150 A G 2.75E-04 Type 2 diabetes SYT9 intron 17463246 rs11041350 chr11 7419377 A G 8.54E-04 Multiple complex diseases SYT9 intron 17554300 rs2346833 chr11 7432446 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SYT9 intron 22628534 rs7946653 chr11 7437599 C T 3.72E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) SYT9 intron 24192120 rs11601238 chr11 7443183 A G 5.24E-04 Suicide attempts in bipolar disorder SYT9 intron 21423239 rs4369384 chr11 7443897 A G 6.20E-07 Fetal hemoglobin levels SYT9 intron 18245381 rs4297440 chr11 7455385 C A 4.58E-04 Suicide attempts in bipolar disorder SYT9 intron 21423239 rs11041381 chr11 7456827 T G 2.13E-04 Suicide attempts in bipolar disorder SYT9 intron 21423239 rs4072103 chr11 7460958 G A 1.13E-04 Suicide attempts in bipolar disorder SYT9 intron 21423239 rs4076555 chr11 7464372 T C 7.00E-06 IgG glycosylation SYT9 intron 23382691 rs4073620 chr11 7491018 G T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6578865 chr11 7504504 C T 5.99E-05 Tunica Media / / pha003034 rs12805648 chr11 7509566 A T 1.35E-05 Alcohol and nictotine co-dependence OLFML1 missense 20158304 rs3923015 chr11 7520533 C T 2.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OLFML1 intron 20877124 rs4758192 chr11 7521640 C G 2.82E-04 Type 2 diabetes OLFML1 intron 17463246 rs3884596 chr11 7532175 T G 2.34E-04 Type 2 diabetes OLFML1 UTR-3 17463246 rs4370912 chr11 7533228 A G 6.09E-05 Type 2 diabetes / / 17463246 rs12791447 chr11 7556577 A G 1.73E-05 Cognitive impairment induced by topiramate PPFIBP2 intron 22091778 rs6578869 chr11 7561198 T C 5.35E-04 Multiple complex diseases PPFIBP2 intron 17554300 rs10839804 chr11 7571210 A G 6.69E-05 Hemoglobin PPFIBP2 intron pha003098 rs10839804 chr11 7571210 A G 2.43E-05 Erythrocyte counts PPFIBP2 intron pha003099 rs6578872 chr11 7571764 T C 8.04E-05 Hemoglobin PPFIBP2 intron pha003098 rs6578872 chr11 7571764 T C 3.12E-05 Erythrocyte counts PPFIBP2 intron pha003099 rs10839805 chr11 7572567 G A 4.29E-05 Hemoglobin PPFIBP2 intron pha003098 rs10839805 chr11 7572567 G A 1.07E-05 Erythrocyte counts PPFIBP2 intron pha003099 rs7115639 chr11 7588239 G A 7.49E-05 Fibrinogen PPFIBP2 intron 17255346 rs7115639 chr11 7588239 G A 7.80E-05 Type 2 diabetes PPFIBP2 intron 17463246 rs7115929 chr11 7588466 G A 1.93E-04 Fibrinogen PPFIBP2 intron 17255346 rs7115929 chr11 7588466 G A 3.47E-04 Type 2 diabetes PPFIBP2 intron 17463246 rs10839814 chr11 7588591 G A 1.40E-04 Fibrinogen PPFIBP2 intron 17255346 rs10839814 chr11 7588591 G A 5.10E-04 Type 2 diabetes PPFIBP2 intron 17463246 rs7120154 chr11 7594803 C T 8.52E-05 Multiple complex diseases PPFIBP2 intron 17554300 rs7120154 chr11 7594803 C T 5.88E-05 Response to taxane treatment (placlitaxel) PPFIBP2 intron 23006423 rs6578882 chr11 7599391 C A 5.48E-04 Nicotine dependence PPFIBP2 intron 17158188 rs7933428 chr11 7607536 T C 2.27E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) PPFIBP2 intron 24023788 rs4472926 chr11 7613349 A G 6.56E-04 Alcohol dependence PPFIBP2 intron 21314694 rs11041474 chr11 7621867 G T 8.21E-04 Insulin resistance PPFIBP2 intron 21901158 rs10769813 chr11 7642031 G A 8.54E-05 Chronic obstructive pulmonary disease PPFIBP2 intron 19300482 rs4130354 chr11 7652385 T A 4.06E-05 Glaucoma (primary open-angle) PPFIBP2 intron 22605921 rs12708352 chr11 7653090 A G 6.48E-04 Smoking cessation PPFIBP2 intron 24665060 rs4643071 chr11 7662732 C T 3.86E-04 Schizophrenia(treatment response to risperidone) PPFIBP2 cds-synon 19850283 rs4758009 chr11 7670353 A C 5.17E-04 Suicide attempts in bipolar disorder PPFIBP2 intron 21423239 rs5864 chr11 7673015 G A 3.51E-05 Bipolar disorder,affective PPFIBP2 cds-synon 20528957 rs12292013 chr11 7696338 G T 7.73E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs11041530 chr11 7701503 G C 6.00E-06 Blood pressure / / 23972371 rs11041530 chr11 7701503 G C 7.60E-04 Blood pressure / / 23972371 rs4758212 chr11 7702063 T C 4.07E-04 Type 2 diabetes / / 17463246 rs4098360 chr11 7702666 C T 7.92E-06 Waist circumference / / 19557197 rs4758213 chr11 7705666 T A 5.85E-06 Waist circumference / / 19557197 rs12274672 chr11 7706857 G A 5.93E-06 Waist circumference / / 19557197 rs12271537 chr11 7707101 T C 6.12E-06 Waist circumference / / 19557197 rs7110070 chr11 7707768 T G 6.17E-06 Waist circumference / / 19557197 rs7932813 chr11 7708281 A G 5.00E-06 Waist circumference / / 19557197 rs4758215 chr11 7708493 A C,G 9.67E-06 Waist circumference / / 19557197 rs527885056 chr11 7708493 AT A 9.67E-06 Waist circumference / / 19557197 rs12792768 chr11 7708857 G A 9.47E-06 Waist circumference / / 19557197 rs1459826 chr11 7746352 T C 7.50E-05 Amyotrophic lateral sclerosis / / 20801718 rs1600970 chr11 7754959 G A 9.30E-05 Amyotrophic lateral sclerosis / / 20801718 rs10839860 chr11 7770281 A G 3.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1482783 chr11 7784279 G T 3.85E-04 Multiple complex diseases / / 17554300 rs7945517 chr11 7808434 C G 1.10E-04 Type 2 diabetes / / 17463246 rs4758021 chr11 7843773 A G 2.19E-04 Lung function (forced vital capacity) / / 24023788 rs4758021 chr11 7843773 A G 3.16E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs16932488 chr11 7846506 G C 3.10E-05 Type 2 diabetes / / 17463246 rs1482795 chr11 7850345 T C 6.71E-04 Smoking initiation / / 24665060 rs1482796 chr11 7850753 G A 1.60E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1482796 chr11 7850753 G A 8.48E-05 Lung function (forced vital capacity) / / 24023788 rs10769834 chr11 7853238 C T 4.28E-04 Smoking initiation / / 24665060 rs7947347 chr11 7854519 C T 1.01E-04 Lung function (forced vital capacity) / / 24023788 rs7947347 chr11 7854519 C T 1.49E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1828459 chr11 7854578 C T 3.28E-05 Lung function (forced vital capacity) / / 24023788 rs1828459 chr11 7854578 C T 5.33E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2048430 chr11 7855047 C T 2.32E-05 Type 2 diabetes / / 17463246 rs1466365 chr11 7860750 C T 9.40E-04 HIV-1 viral setpoint / / 17641165 rs11602552 chr11 7866442 C T 2.79E-05 Type 2 diabetes / / 17463246 rs1994123 chr11 7869748 T C 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs7112002 chr11 7879176 A C 7.60E-04 Rheumatoid arthritis LOC283299 intron 21452313 rs7112002 chr11 7879176 A C 2.71E-05 Anxiety in major depressive disorder LOC283299 intron 24047446 rs720892 chr11 7879804 C T 9.13E-04 Type 2 diabetes LOC283299 intron 17463246 rs720892 chr11 7879804 C T 1.26E-04 Amyotrophic lateral sclerosis (sporadic) LOC283299 intron 24529757 rs16933056 chr11 7882544 A G 1.19E-04 Lung function (forced expiratory volume in 1 second) LOC283299 intron 24023788 rs16933056 chr11 7882544 A G 2.40E-05 Lung function (forced vital capacity) LOC283299 intron 24023788 rs7950307 chr11 7890697 C T 8.87E-05 Cognitive performance LOC283299 intron 19734545 rs17222598 chr11 7891131 T G 8.53E-05 Lung function (forced vital capacity) LOC283299 intron 24023788 rs6578910 chr11 7899352 G A 2.06E-04 Lung function (forced vital capacity) LOC283299 intron 24023788 rs6578910 chr11 7899352 G A 4.45E-04 Lung function (forced expiratory volume in 1 second) LOC283299 intron 24023788 rs2361065 chr11 7901368 C T 1.82E-04 Lung function (forced vital capacity) LOC283299 intron 24023788 rs2361069 chr11 7908627 C T 2.86E-04 Lung function (forced vital capacity) LOC283299 intron 24023788 rs17315588 chr11 7913911 C A 4.47E-05 Alcohol consumption LOC283299 intron 23953852 rs17315616 chr11 7913940 T C 5.34E-05 Alcohol consumption LOC283299 intron 23953852 rs10769847 chr11 7922651 T C 2.28E-06 Alcohol consumption LOC283299 intron 23953852 rs7933807 chr11 7949791 A C 5.40E-05 Alcohol consumption OR10A6 missense 23953852 rs7928451 chr11 7949860 G A 2.55E-05 Alcohol consumption OR10A6 missense 23953852 rs11041670 chr11 7952920 T G 5.03E-05 Alcohol consumption / / 23953852 rs7941078 chr11 7953355 G T 2.18E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs10839942 chr11 7953550 C A 4.54E-05 Alcohol consumption / / 23953852 rs3930459 chr11 7953958 T C 4.07E-05 Alcohol consumption / / 23953852 rs10839947 chr11 7957953 G A 8.37E-05 Alcohol consumption / / 23953852 rs1397598 chr11 7958828 A G 5.50E-05 Alcohol consumption / / 23953852 rs4758259 chr11 7961130 C T 7.86E-05 Alcohol consumption / / 23953852 rs11041679 chr11 7961752 C A 7.42E-05 Alcohol consumption / / 23953852 rs11041680 chr11 7961797 G A 4.61E-05 Alcohol consumption / / 23953852 rs7942511 chr11 7961931 A G 7.40E-05 Alcohol consumption / / 23953852 rs1355384 chr11 7963498 T C 5.20E-04 Depression (quantitative trait) / / 20800221 rs11041683 chr11 7964667 G A 7.87E-04 Depression (quantitative trait) / / 20800221 rs7931076 chr11 7966642 A C 1.37E-04 Multiple complex diseases / / 17554300 rs7947377 chr11 7967214 G A 4.37E-04 Alzheimer's disease (late onset) / / 21379329 rs878860 chr11 7968359 C T 2.00E-22 Atopic dermatitis / / 23042114 rs6578916 chr11 7989181 A G 4.84E-05 Alzheimer's disease (late onset) / / 21379329 rs6578916 chr11 7989181 A G 7.19E-05 Glucose levels / / pha003058 rs4758263 chr11 8005424 T C 3.88E-04 Multiple complex diseases / / 17554300 rs7125891 chr11 8010307 T G 4.21E-04 Alzheimer's disease EIF3F intron 22005930 rs7951923 chr11 8012077 A C 1.05E-05 Osteoarthritis (knee and hip) EIF3F intron 21177295 rs7951923 chr11 8012077 A C 4.84E-04 Osteoarthritis (knee and hip) EIF3F intron 21177295 rs7951923 chr11 8012077 A C 5.89E-06 Osteoarthritis (knee and hip) EIF3F intron 21177295 rs12420464 chr11 8014777 G T 3.00E-06 Depression (quantitative trait) EIF3F intron 20800221 rs12420464 chr11 8014777 G T 3.30E-06 Depression (quantitative trait) EIF3F intron 23290196 rs6578918 chr11 8019790 C A 7.27E-04 Multiple complex diseases / / 17554300 rs11601274 chr11 8034175 T C 9.07E-05 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs11601274 chr11 8034175 T C 9.50E-05 Fasting insulin (interaction) / / 24204828 rs11041718 chr11 8055268 G A 1.10E-05 Coronary heart disease / / 21966275 rs7113729 chr11 8089121 C T 0.0000102 C-reactive protein TUB intron 23505291 rs7114018 chr11 8089946 T C 0.0000141 C-reactive protein TUB intron 23505291 rs1406095 chr11 8094682 T C 8.00E-06 Alcohol and nictotine co-dependence TUB intron 22488850 rs4758287 chr11 8099913 A C 4.91E-05 Smoking cessation TUB intron 18519826 rs11041740 chr11 8117518 G T 1.97E-05 Smoking cessation TUB intron 18519826 rs11041740 chr11 8117518 G T 5.27E-06 Height TUB intron pha003011 rs145905715 chr11 8122234 G GTA 0.00000139 LDL cholesterol TUB intron 23063622 rs145905715 chr11 8122234 G GTA 7.12E-16 Cholesterol,total TUB intron 23063622 rs7394561 chr11 8122234 G A 0.00000139 LDL cholesterol TUB intron 23063622 rs7394561 chr11 8122234 G A 7.12E-16 Cholesterol,total TUB intron 23063622 rs16935849 chr11 8127196 G A 9.74E-04 Multiple complex diseases TUB UTR-3 17554300 rs1055233 chr11 8127495 T C 7.94E-05 Smoking cessation TUB UTR-3 18519826 rs4343012 chr11 8133175 T C 1.33E-05 Smoking cessation RIC3 intron 18519826 rs10839984 chr11 8180894 A G 2.90E-05 Smoking cessation RIC3 intron 18519826 rs10734629 chr11 8186677 A G 1.77E-06 Smoking cessation RIC3 intron 18519826 rs7112519 chr11 8212769 G A 4.27E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs146103307 chr11 8219178 A G 2.85E-04 Acne (severe) / / 24927181 rs4758051 chr11 8238639 G A 2.83E-08 Neuroblastoma / / pha002895 rs10840002 chr11 8243026 A G 2.39E-05 Orofacial clefts / / 20023658 rs10840002 chr11 8243026 A G 6.01E-06 Neuroblastoma / / pha002895 rs11041816 chr11 8243798 A G 7.10E-05 Personality dimensions / / 18957941 rs11041816 chr11 8243798 A G 2.00E-07 Fasting glucose-related traits (interaction with BMI) / / 22581228 rs1042359 chr11 8246181 A G 4.36E-04 Multiple complex diseases LMO1 cds-synon 17554300 rs2290451 chr11 8248440 C G 2.22E-05 Alcohol consumption LMO1 intron 23743675 rs2290450 chr11 8248482 C T 2.52E-05 Alcohol consumption LMO1 intron 23743675 rs4758317 chr11 8250811 C A 7.00E-07 Alcohol consumption LMO1 intron 23743675 rs11041820 chr11 8251438 G A 2.31E-05 Alcohol consumption LMO1 intron 23743675 rs12807001 chr11 8252441 A G 1.47E-04 Multiple complex diseases LMO1 intron 17554300 rs110419 chr11 8252853 A G 5.00E-16 Neuroblastoma LMO1 intron 21124317 rs110419 chr11 8252853 A G 1.00E-13 Neuroblastoma LMO1 intron 22941191 rs110419 chr11 8252853 A G 5.12E-10 Neuroblastoma LMO1 intron pha002895 rs110420 chr11 8253049 T C 1.03E-04 Alcohol consumption LMO1 intron 23743675 rs12574271 chr11 8254503 G T 1.81E-05 Alcohol consumption LMO1 intron 23743675 rs204926 chr11 8255106 G A 1.66E-05 Alcohol consumption LMO1 intron 23743675 rs3849994 chr11 8262401 A G 9.09E-05 Angioedema in response to angiotensin-converting enzyme inhibitor LMO1 intron 23838604 rs12277079 chr11 8265652 A G 7.73E-04 Response to taxane treatment (placlitaxel) LMO1 intron 23006423 rs2061036 chr11 8266559 C T 5.05E-06 Angioedema in response to angiotensin-converting enzyme inhibitor LMO1 intron 23838604 rs11041826 chr11 8271402 G A 0.0000126 HDL cholesterol particle diameter LMO1 intron 23263444 rs7949134 chr11 8273973 G A 5.94E-05 Coronary heart disease LMO1 intron pha003035 rs7949134 chr11 8273973 G A 4.04E-06 Diabetes Mellitus LMO1 intron pha003059 rs204938 chr11 8278197 C T 1.15E-05 Neuroblastoma LMO1 intron pha002895 rs11041833 chr11 8282786 G A 4.39E-04 Type 2 diabetes LMO1 intron 17463246 rs7932099 chr11 8302806 T C 1.41E-04 Multiple complex diseases / / 17554300 rs7481229 chr11 8313789 C A 8.82E-04 Type 2 diabetes / / 17463246 rs4606466 chr11 8314155 C A 0.0000106 HDL cholesterol particle diameter / / 23263444 rs6578951 chr11 8321128 T C 2.75E-04 Aortic root size / / 21223598 rs7112171 chr11 8321802 A G 1.40E-04 Type 2 diabetes / / 17463246 rs11041862 chr11 8328066 T C 0.00000338 HDL cholesterol particle diameter / / 23263444 rs10840015 chr11 8328097 G A 0.00000238 HDL cholesterol particle diameter / / 23263444 rs7947764 chr11 8328634 C G 0.000015 HDL cholesterol particle diameter / / 23263444 rs7936966 chr11 8328654 T C 0.000015 HDL cholesterol particle diameter / / 23263444 rs4758330 chr11 8329193 C T 0.000015 HDL cholesterol particle diameter / / 23263444 rs4363584 chr11 8329618 T C 0.0000306 alzheimer's disease (late onset) / / 22785395 rs4363584 chr11 8329618 T C 0.0000162 HDL cholesterol particle diameter / / 23263444 rs4758332 chr11 8329840 T C 0.0000121 HDL cholesterol particle diameter / / 23263444 rs897102 chr11 8331494 C T 0.000000008 Brain microstructure and intellectual performance / / 22723713 rs10840025 chr11 8348725 C T 1.20E-04 Celiac disease / / 23936387 rs11041882 chr11 8348837 C T 8.29E-04 Multiple complex diseases / / 17554300 rs7938031 chr11 8366148 C T 2.57E-04 Depression (quantitative trait) / / 20800221 rs6578959 chr11 8366256 G A 4.21E-04 Depression (quantitative trait) / / 20800221 rs7123904 chr11 8368246 G A 5.36E-04 Depression (quantitative trait) / / 20800221 rs7113611 chr11 8368490 T G 4.36E-04 Depression (quantitative trait) / / 20800221 rs7113611 chr11 8368490 T G 2.93E-04 Taste perception / / 22132133 rs897109 chr11 8369292 C A 1.42E-04 Depression (quantitative trait) / / 20800221 rs897111 chr11 8369415 G A 1.42E-04 Depression (quantitative trait) / / 20800221 rs897111 chr11 8369415 G A 1.47E-04 Celiac disease / / 23936387 rs10840028 chr11 8374548 C A 3.51E-04 Depression (quantitative trait) / / 20800221 rs7931324 chr11 8382106 C T 2.30E-05 Urinary metabolites / / 21572414 rs7927814 chr11 8388703 C T 0.0008924 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7927814 chr11 8388703 C T 8.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4586151 chr11 8388951 T C 7.16E-05 Multiple complex diseases / / 17554300 rs1466235 chr11 8389454 A C 4.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs897105 chr11 8391230 A G 2.99E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7106385 chr11 8394169 G A 9.66E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7112091 chr11 8403392 T C 1.73E-05 Blood Pressure / / pha003040 rs10840031 chr11 8410621 G A 5.52E-05 Serum metabolites / / 19043545 rs16938066 chr11 8431949 T G 3.48E-04 Multiple complex diseases STK33 intron 17554300 rs10840037 chr11 8434693 C T 3.76E-04 Coronary heart disease STK33 intron 21971053 rs7939568 chr11 8442054 C T 3.27E-04 Coronary heart disease STK33 intron 21971053 rs1374262 chr11 8458749 G A 6.39E-04 Smoking cessation STK33 intron 24665060 rs7101471 chr11 8463622 G A 6.90E-04 Smoking cessation STK33 intron 24665060 rs10769908 chr11 8484089 C T 1.00E-06 Body mass index STK33 intron 19079261 rs10769908 chr11 8484089 C T 4.60E-07 Smoking behavior STK33 intron 20418888 rs725502 chr11 8503743 C T 5.51E-04 Coronary heart disease STK33 intron 21971053 rs2028882 chr11 8504854 A C 5.77E-04 Smoking cessation STK33 intron 24665060 rs10840065 chr11 8526643 A G 2.99E-04 Coronary heart disease STK33 intron 21971053 rs7105027 chr11 8551916 G T 1.56E-04 Coronary heart disease STK33 intron 21971053 rs11041966 chr11 8561002 T C 2.06E-04 Coronary heart disease STK33 intron 21971053 rs11041978 chr11 8578150 T C 6.63E-04 Smoking cessation STK33 intron 24665060 rs11041987 chr11 8584103 T C 3.55E-04 Multiple complex diseases STK33 intron 17554300 rs9300089 chr11 8585152 G A 7.56E-05 Coronary heart disease STK33 intron 21971053 rs9300092 chr11 8590492 G A 5.35E-04 Smoking cessation STK33 intron 24665060 rs12361165 chr11 8599718 A C 1.89E-04 Depression (quantitative trait) STK33 intron 20800221 rs10160804 chr11 8600240 C A 3.50E-05 Body mass index STK33 intron 24861553 rs4929949 chr11 8604593 T C 3.00E-09 Body mass index STK33 intron 20935630 rs4929949 chr11 8604593 T C 2.80E-09 Body mass index STK33 intron 23001569 rs4929923 chr11 8639200 T C 1.00E-08 Menarche (age at onset) TRIM66 UTR-3 21102462 rs4929947 chr11 8639994 G C 3.10E-04 Multiple complex diseases TRIM66 intron 17554300 rs10840096 chr11 8643989 T C 4.64E-04 Suicide attempts in bipolar disorder TRIM66 intron 21423239 rs9633894 chr11 8653359 T C 6.69E-04 Suicide attempts in bipolar disorder TRIM66 intron 21423239 rs144204188 chr11 8654671 C T 0.0000939 Menopause (age at onset) TRIM66 intron 23424626 rs10743085 chr11 8659134 G A 5.77E-04 Suicide attempts in bipolar disorder TRIM66 intron 21423239 rs11042023 chr11 8662516 T C 1.00E-11 Obesity TRIM66 missense 23563607 rs7934978 chr11 8663098 C T 4.37E-04 Suicide attempts in bipolar disorder TRIM66 intron 21423239 rs10840100 chr11 8669437 A G 6.67E-04 Multiple complex diseases TRIM66 intron 17554300 rs10769938 chr11 8671547 G A 4.37E-04 Multiple complex diseases TRIM66 intron 17554300 rs12575252 chr11 8694073 G C 4.27E-04 Multiple complex diseases LOC100652906 intron 17554300 rs12575252 chr11 8694073 G C 9.90E-04 Menarche (age at onset) LOC100652906 intron 23599027 rs7121168 chr11 8694999 C A 9.24E-04 Depression (quantitative trait) LOC100652906 intron 20800221 rs3942866 chr11 8698328 T C 1.00E-04 Information processing speed LOC100652906 intron 21130836 rs10840110 chr11 8704091 C T 9.91E-04 Alcohol dependence RPL27A UTR-5 21314694 rs2270955 chr11 8716968 T A 1.20E-05 Urinary metabolites ST5 intron 21572414 rs7928370 chr11 8725268 A G 2.90E-05 Urinary metabolites ST5 intron 21572414 rs4370937 chr11 8745081 T C 1.65E-04 Depression (quantitative trait) ST5 intron 20800221 rs11042052 chr11 8750553 C T 6.98E-04 Depression (quantitative trait) ST5 intron 20800221 rs6484007 chr11 8753717 C T 7.17E-04 Depression (quantitative trait) ST5 intron 20800221 rs12296005 chr11 8762162 T G 3.83E-05 Myopia (pathological) ST5 intron 23049088 rs10743086 chr11 8774923 G A 6.68E-04 Depression (quantitative trait) ST5 intron 20800221 rs11042064 chr11 8799749 G A 6.64E-04 Depression (quantitative trait) ST5 intron 20800221 rs3913547 chr11 8800504 A G 6.64E-04 Depression (quantitative trait) ST5 intron 20800221 rs10840120 chr11 8801618 A T 6.65E-04 Depression (quantitative trait) ST5 intron 20800221 rs11042078 chr11 8826700 G T 9.34E-08 Red blood cell traits ST5 intron 23222517 rs10840128 chr11 8826779 A G 3.22E-04 Depression (quantitative trait) ST5 intron 20800221 rs11603841 chr11 8834680 T C 4.84E-07 Red blood cell traits ST5 intron 23222517 rs4929918 chr11 8838660 G A 8.74E-04 Depression (quantitative trait) ST5 intron 20800221 rs2316863 chr11 8838828 G T 8.74E-04 Depression (quantitative trait) ST5 intron 20800221 rs6484606 chr11 8842273 G A 7.90E-04 Depression (quantitative trait) ST5 intron 20800221 rs7131166 chr11 8848463 T G 8.13E-04 Depression (quantitative trait) ST5 intron 20800221 rs2568090 chr11 8849495 T C 3.67E-08 Red blood cell traits ST5 intron 23222517 rs10769967 chr11 8858730 G C 1.98E-08 Red blood cell traits ST5 intron 23222517 rs4910062 chr11 8862188 A C 8.20E-07 Red blood cell traits ST5 intron 23222517 rs7945705 chr11 8862530 G A 1.01E-08 Red blood cell traits ST5 intron 23222517 rs2568043 chr11 8863550 T C 4.29E-09 Red blood cell traits ST5 intron 23222517 rs1529641 chr11 8864138 T G 1.92E-07 Red blood cell traits ST5 intron 23222517 rs10840134 chr11 8865363 T C 1.30E-08 Red blood cell traits ST5 intron 23222517 rs7123429 chr11 8866808 C G 5.50E-09 Red blood cell traits ST5 intron 23222517 rs7937298 chr11 8867509 G C 6.33E-09 Red blood cell traits ST5 intron 23222517 rs10743093 chr11 8869129 A G 3.20E-09 Red blood cell traits ST5 intron 23222517 rs2742552 chr11 8876852 C T 3.93E-08 Red blood cell traits ST5 intron 23222517 rs2742552 chr11 8876852 C T 0.00075 Breast cancer ST5 intron 23555315 rs2742545 chr11 8884308 C G 4.35E-08 Red blood cell traits ST5 intron 23222517 rs2568061 chr11 8886260 A G 5.08E-09 Red blood cell traits ST5 intron 23222517 rs11042103 chr11 8888700 C T 1.37E-08 Red blood cell traits ST5 intron 23222517 rs2742540 chr11 8899528 A G 1.20E-07 Red blood cell traits ST5 intron 23222517 rs10840141 chr11 8902218 T C 1.08E-08 Red blood cell traits ST5 intron 23222517 rs10840142 chr11 8906078 A G 1.19E-08 Red blood cell traits ST5 intron 23222517 rs10769970 chr11 8917937 A G 1.16E-08 Red blood cell traits ST5 intron 23222517 rs10840147 chr11 8920704 A G 6.53E-08 Red blood cell traits ST5 intron 23222517 rs10840148 chr11 8923528 C T 5.75E-09 Red blood cell traits ST5 intron 23222517 rs10769971 chr11 8925276 C T 3.73E-07 Red blood cell traits ST5 intron 23222517 rs10769973 chr11 8928615 C G 1.70E-08 Red blood cell traits ST5 intron 23222517 rs11042125 chr11 8938049 A T 1.45E-09 Red blood cell traits AKIP1 intron 23222517 rs2016942 chr11 8938787 A G 1.40E-08 Red blood cell traits AKIP1 intron 23222517 rs1560569 chr11 8939887 A G 1.32E-08 Red blood cell traits AKIP1 intron 23222517 rs4909952 chr11 8963946 A G 1.52E-07 Red blood cell traits ASCL3 intron 23222517 rs4929922 chr11 8975776 G A 1.86E-07 Red blood cell traits TMEM9B intron 23222517 rs2653570 chr11 8987823 A G 4.07E-08 Red blood cell traits / / 23222517 rs2742480 chr11 8993130 A G 3.43E-07 Red blood cell traits / / 23222517 rs1123936 chr11 9003306 A G 6.18E-07 Red blood cell traits NRIP3 UTR-3 23222517 rs1980429 chr11 9010474 C A 3.90E-07 Red blood cell traits NRIP3 intron 23222517 rs1980428 chr11 9010497 C T 3.61E-07 Red blood cell traits NRIP3 intron 23222517 rs10769979 chr11 9010659 G A 3.53E-08 Red blood cell traits NRIP3 intron 23222517 rs11042149 chr11 9010737 T C 9.05E-07 Red blood cell traits NRIP3 intron 23222517 rs7925728 chr11 9013002 A G 6.51E-08 Red blood cell traits NRIP3 intron 23222517 rs7930026 chr11 9013639 T C 8.97E-08 Red blood cell traits NRIP3 intron 23222517 rs6486060 chr11 9024630 G A 5.07E-08 Red blood cell traits NRIP3 intron 23222517 rs11042154 chr11 9029700 G A 5.57E-08 Red blood cell traits / / 23222517 rs7112378 chr11 9081926 C T 6.53E-04 Parkinson's disease SCUBE2 intron 17052657 rs2647528 chr11 9109287 G A 3.00E-07 beta2-Glycoprotein I (beta2-GPI) plasma levels SCUBE2 intron 23279374 rs963167 chr11 9111558 A G 1.00E-07 beta2-Glycoprotein I (beta2-GPI) plasma levels SCUBE2 intron 23279374 rs1121629 chr11 9127130 T C 7.77E-04 Tourette syndrome / / 22889924 rs1827011 chr11 9138129 G A 9.94E-05 Serum albumin level / / pha003084 rs1353729 chr11 9159818 A G 8.16E-04 Tourette syndrome / / 22889924 rs2291840 chr11 9167114 C A 2.54E-04 Suicide attempts in bipolar disorder DENND5A intron 21041247 rs10770010 chr11 9312034 C A 9.60E-05 Multiple complex diseases TMEM41B intron 17554300 rs4396289 chr11 9316730 T C 2.77E-04 Suicide attempts in bipolar disorder TMEM41B UTR-3 21041247 rs4627080 chr11 9336349 T G 7.66E-04 Multiple complex diseases / / 17554300 rs4910048 chr11 9389875 C T 7.33E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs6486307 chr11 9406023 C T 1.93E-04 Obesity (extreme) / / 21935397 rs12795344 chr11 9423541 C T 2.95E-04 Obesity (extreme) IPO7 intron 21935397 rs7115477 chr11 9429619 C T 2.78E-04 Obesity (extreme) IPO7 intron 21935397 rs7480643 chr11 9431886 G A 1.67E-04 Obesity (extreme) IPO7 intron 21935397 rs12279202 chr11 9432090 C T 4.80E-08 Blood pressure IPO7 intron 21378095 rs12279202 chr11 9432090 C T 1.80E-08 Interleukin levels (IL10,IL1Ra,IL6),in plasma IPO7 intron 22205395 rs2290423 chr11 9450377 T G 2.98E-04 Obesity (extreme) IPO7 intron 21935397 rs7122252 chr11 9451800 G A 2.99E-04 Obesity (extreme) IPO7 intron 21935397 rs4910052 chr11 9455374 T C 3.31E-05 HIV-1 progression IPO7 cds-synon 20064070 rs36048375 chr11 9463317 G C 3.31E-05 HIV-1 progression IPO7 intron 20064070 rs8785 chr11 9468454 G A 3.37E-04 Obesity (extreme) IPO7 UTR-3 21935397 rs1020621 chr11 9469863 G T 5.30E-04 Obesity (extreme) / / 21935397 rs12418104 chr11 9492137 A G 8.71E-04 Multiple complex diseases ZNF143 intron 17554300 rs4910466 chr11 9509352 G C 8.28E-05 HIV-1 progression ZNF143 intron 20064070 rs10082685 chr11 9543916 G A 7.89E-05 HIV-1 progression ZNF143 intron 20064070 rs7102407 chr11 9556117 T C 2.32E-05 HIV-1 progression / / 20064070 rs12272194 chr11 9559481 T C 8.70E-06 Iris characteristics / / 21835309 rs11042427 chr11 9588853 G C 7.77E-04 Lymphocyte counts / / 22286170 rs11042439 chr11 9622254 G C 1.70E-05 Urinary metabolites / / 21572414 rs11042440 chr11 9622414 G A 2.60E-05 Urinary metabolites / / 21572414 rs11042441 chr11 9622677 C T 1.70E-05 Urinary metabolites / / 21572414 rs10770043 chr11 9627471 A G 5.90E-04 Taste perception / / 22132133 rs10840269 chr11 9628802 G A 3.27E-05 Lymphocyte counts / / 22286170 rs2082807 chr11 9672763 T C 6.13E-05 Taste perception / / 22132133 rs12807017 chr11 9679145 T C 3.72E-04 Taste perception / / 22132133 rs12283521 chr11 9723375 G A 7.87E-04 Taste perception SWAP70 intron 22132133 rs1390679 chr11 9734945 A G 2.58E-04 Rheumatoid arthritis SWAP70 intron 21452313 rs1390679 chr11 9734945 A G 7.73E-04 Taste perception SWAP70 intron 22132133 rs920081 chr11 9735608 A G 4.14E-11 Narcolepsy SWAP70 intron 19629137 rs920081 chr11 9735608 A G 4.08E-04 Rheumatoid arthritis SWAP70 intron 21452313 rs397250 chr11 9737574 A G 6.62E-04 Taste perception SWAP70 intron 22132133 rs1695613 chr11 9746201 G A 5.12E-04 Rheumatoid arthritis SWAP70 intron 21452313 rs1695613 chr11 9746201 G A 6.62E-04 Taste perception SWAP70 intron 22132133 rs93139 chr11 9759608 T C 0.0000481 Coronary artery disease SWAP70 intron 23202125 rs360136 chr11 9773517 C A 7.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) SWAP70 UTR-3 17982456 rs3763862 chr11 9802952 A C 3.47E-04 Smoking initiation SBF2 intron 24665060 rs1032550 chr11 9813308 T C 6.73E-05 Serum metabolites SBF2 intron 19043545 rs11042498 chr11 9815426 G A 2.89E-04 Smoking initiation SBF2 intron 24665060 rs6483726 chr11 9825447 C T 9.84E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) SBF2 intron 23648065 rs11042500 chr11 9830595 G A 4.70E-05 Smoking initiation SBF2 intron 24665060 rs11042500 chr11 9830595 G A 8.22E-05 Body Composition SBF2 intron pha003012 rs17268414 chr11 9839856 A C 1.02E-05 Smoking initiation SBF2 intron 24665060 rs360118 chr11 9846278 C G 5.14E-04 Suicide attempts in bipolar disorder SBF2 intron 21041247 rs17268632 chr11 9851731 C T 1.33E-04 Smoking initiation SBF2 intron 24665060 rs2403221 chr11 9852475 G A 5.00E-06 Smoking initiation SBF2 intron 24665060 rs10840311 chr11 9854857 C T 1.95E-05 Smoking initiation SBF2 intron 24665060 rs958875 chr11 9857326 C T 8.18E-05 Basophils SBF2 intron pha003087 rs11042511 chr11 9870622 C T 3.97E-04 Smoking initiation SBF2 intron 24665060 rs7122293 chr11 9874505 T G 3.69E-05 Pancreatic cancer SBF2 intron 23180869 rs360169 chr11 9875519 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) SBF2 intron 20708005 rs2017503 chr11 9881629 G A 4.89E-05 Pancreatic cancer SBF2 intron 23180869 rs4910067 chr11 9885849 C T 1.74E-05 Pancreatic cancer SBF2 intron 23180869 rs12577195 chr11 9890714 C T 3.80E-04 Smoking initiation SBF2 intron 24665060 rs7929434 chr11 9896103 A T 5.97E-04 Type 2 diabetes SBF2 intron 17463246 rs10500712 chr11 9902797 G A 1.88E-04 Smoking initiation SBF2 intron 24665060 rs12800780 chr11 9904748 A T 2.24E-05 Pancreatic cancer SBF2 intron 23180869 rs10743120 chr11 9912052 C T 4.39E-05 Cognitive impairment induced by topiramate SBF2 intron 22091778 rs10840316 chr11 9912131 T C 2.66E-06 Pancreatic cancer SBF2 intron 23180869 rs9300100 chr11 9923830 T G 1.14E-06 Pancreatic cancer SBF2 intron 23180869 rs6483805 chr11 9928979 C T 3.16E-05 Cognitive impairment induced by topiramate SBF2 intron 22091778 rs12362504 chr11 9929542 T C 8.64E-07 Pancreatic cancer SBF2 intron 23180869 rs12418989 chr11 9930234 T G 6.27E-06 Basophils SBF2 intron pha003087 rs368242902 chr11 9930234 T TTGC 6.27E-06 Basophils SBF2 intron pha003087 rs71034745 chr11 9930234 T TTGTTGTTGC 6.27E-06 Basophils SBF2 intron pha003087 rs76933706 chr11 9930234 T TTGTTGC 6.27E-06 Basophils SBF2 intron pha003087 rs7945309 chr11 9942432 C T 8.14E-05 Multiple complex diseases SBF2 intron 17554300 rs10500715 chr11 9973062 T G 2.00E-07 Pancreatic cancer SBF2 intron 23180869 rs7106914 chr11 9977971 T C 1.72E-07 Pancreatic cancer SBF2 intron 23180869 rs4910092 chr11 10003622 T C 8.42E-04 Multiple complex diseases SBF2 intron 17554300 rs7107916 chr11 10012511 A G 3.39E-07 Red blood cell traits SBF2 intron 23222517 rs2403261 chr11 10021791 T C 9.89E-07 Red blood cell traits SBF2 intron 23222517 rs7932484 chr11 10024883 T C 2.34E-07 Red blood cell traits SBF2 intron 23222517 rs2896513 chr11 10027543 G C 2.47E-04 Multiple complex diseases SBF2 intron 17554300 rs2896514 chr11 10027901 T C 1.55E-07 Red blood cell traits SBF2 intron 23222517 rs7936461 chr11 10040886 C T 1.88E-08 Red blood cell traits SBF2 intron 23222517 rs7130610 chr11 10044104 C G 3.41E-08 Red blood cell traits SBF2 intron 23222517 rs7938647 chr11 10061423 T C 9.70E-10 Lipid levels SBF2 intron 19936222 rs12288355 chr11 10072849 G C 8.63E-04 Multiple complex diseases SBF2 intron 17554300 rs12288355 chr11 10072849 G C 1.14E-05 Height SBF2 intron 19039035 rs7114303 chr11 10095687 G C 1.68E-05 Serum metabolites SBF2 intron 19043545 rs7119000 chr11 10096240 C T 8.34E-04 Multiple complex diseases SBF2 intron 17554300 rs7119000 chr11 10096240 C T 3.68E-06 Height SBF2 intron 19039035 rs11042617 chr11 10108484 G A 9.08E-04 Multiple complex diseases SBF2 intron 17554300 rs11042617 chr11 10108484 G A 3.33E-06 Height SBF2 intron 19039035 rs12421096 chr11 10111991 T C 9.00E-05 Prostate cancer SBF2 intron 21743057 rs11042623 chr11 10117334 T G 9.00E-05 Prostate cancer SBF2 intron 21743057 rs11042624 chr11 10117388 G A 1.56E-05 Bipolar disorder,affective SBF2 intron 20528957 rs1442732 chr11 10141219 T C 1.79E-05 Bipolar disorder,affective SBF2 intron 20528957 rs7950447 chr11 10144825 G C 2.78E-05 Serum metabolites SBF2 intron 19043545 rs10734652 chr11 10150212 C T 2.70E-06 Height SBF2 intron 19039035 rs4323860 chr11 10159883 T C 7.54E-05 Height SBF2 intron 19039035 rs11821308 chr11 10162445 T G 3.02E-08 Red blood cell traits SBF2 intron 23222517 rs16907505 chr11 10172545 A G 5.99E-07 Red blood cell traits SBF2 intron 23222517 rs7129531 chr11 10174447 C T 3.32E-08 Red blood cell traits SBF2 intron 23222517 rs2278634 chr11 10184463 C A 6.72E-08 Red blood cell traits SBF2 intron 23222517 rs12360783 chr11 10185365 T C 1.48E-04 Lipid traits SBF2 intron 22028671 rs17293593 chr11 10186289 G A 9.73E-07 Red blood cell traits SBF2 intron 23222517 rs10500721 chr11 10203610 A G 9.68E-09 Red blood cell traits SBF2 intron 23222517 rs12286927 chr11 10205211 A T 5.77E-04 Multiple complex diseases SBF2 intron 17554300 rs16907568 chr11 10212202 A G 2.48E-04 Multiple complex diseases SBF2 intron 17554300 rs11042656 chr11 10214455 C T 5.08E-29 Multiple complex diseases SBF2 intron 17554300 rs11042666 chr11 10227393 A T 8.59E-06 Height SBF2 intron 19039035 rs1867138 chr11 10228728 A G 2.15E-06 Height SBF2 intron 19039035 rs7938543 chr11 10229851 G A 1.09E-07 Red blood cell traits SBF2 intron 23222517 rs1822295 chr11 10233156 T C 7.22E-05 Multiple complex diseases SBF2 intron 17554300 rs1822295 chr11 10233156 T C 8.06E-04 Insulin resistance SBF2 intron 21901158 rs10500722 chr11 10235358 T G 2.02E-08 Red blood cell traits SBF2 intron 23222517 rs1372809 chr11 10244105 C G 6.67E-05 Height SBF2 intron 19039035 rs4910107 chr11 10255403 A G 6.38E-07 Red blood cell traits SBF2 intron 23222517 rs7112413 chr11 10265500 C T 4.00E-06 Systolic blood pressure SBF2 intron 19430483 rs7112413 chr11 10265500 C T 6.87E-07 Red blood cell traits SBF2 intron 23222517 rs7947059 chr11 10268814 C T 7.75E-07 Red blood cell traits SBF2 intron 23222517 rs4910115 chr11 10269375 A T 4.32E-08 Red blood cell traits SBF2 intron 23222517 rs1470260 chr11 10275120 T C 9.17E-08 Red blood cell traits SBF2 intron 23222517 rs1470259 chr11 10275174 T C 1.58E-07 Red blood cell traits SBF2 intron 23222517 rs1442740 chr11 10275343 T G 1.94E-07 Red blood cell traits SBF2 intron 23222517 rs1442739 chr11 10278431 C T 7.06E-07 Red blood cell traits SBF2 intron 23222517 rs1442738 chr11 10278772 C G 2.49E-07 Red blood cell traits SBF2 intron 23222517 rs7115944 chr11 10279712 T C 4.31E-07 Red blood cell traits SBF2 intron 23222517 rs726102 chr11 10283978 G A 2.76E-08 Red blood cell traits SBF2 intron 23222517 rs7118500 chr11 10284762 C A 3.80E-08 Red blood cell traits SBF2 intron 23222517 rs11042702 chr11 10287988 G A 2.70E-05 Height SBF2 intron 19039035 rs11042702 chr11 10287988 G A 3.17E-08 Red blood cell traits SBF2 intron 23222517 rs4597056 chr11 10290923 C T 6.14E-08 Red blood cell traits SBF2 intron 23222517 rs7108358 chr11 10294840 C G 1.62E-05 Height SBF2 intron 19039035 rs7108358 chr11 10294840 C G 5.69E-08 Red blood cell traits SBF2 intron 23222517 rs7110652 chr11 10294902 G C 2.20E-08 Red blood cell traits SBF2 intron 23222517 rs6484147 chr11 10295103 T C 2.31E-05 Height SBF2 intron 19039035 rs6484147 chr11 10295103 T C 4.38E-08 Red blood cell traits SBF2 intron 23222517 rs6484148 chr11 10295144 T C 6.05E-07 Red blood cell traits SBF2 intron 23222517 rs11042714 chr11 10295651 T G 4.29E-05 Height SBF2 intron 19039035 rs11042714 chr11 10295651 T G 2.38E-08 Red blood cell traits SBF2 intron 23222517 rs2920150 chr11 10296653 C T 8.25E-07 Red blood cell traits SBF2 intron 23222517 rs2920151 chr11 10296667 C T 1.58E-06 Height SBF2 intron 19039035 rs2920151 chr11 10296667 C T 4.93E-08 Red blood cell traits SBF2 intron 23222517 rs6484152 chr11 10298452 G A 1.76E-08 Red blood cell traits SBF2 intron 23222517 rs10500724 chr11 10302016 C T 2.00E-04 Subclinical atherosclerosis SBF2 intron 17903303 rs10500724 chr11 10302016 C T 2.01E-05 Height SBF2 intron 19039035 rs10500724 chr11 10302016 C T 5.80E-08 Red blood cell traits SBF2 intron 23222517 rs11042717 chr11 10303939 T C 7.90E-04 Type 2 diabetes SBF2 intron 17463246 rs11042717 chr11 10303939 T C 4.59E-04 Multiple complex diseases SBF2 intron 17554300 rs11042717 chr11 10303939 T C 1.76E-05 Height SBF2 intron 19039035 rs7947666 chr11 10305095 A T 1.95E-08 Red blood cell traits SBF2 intron 23222517 rs11607174 chr11 10306028 C T 8.84E-06 Height SBF2 intron 19039035 rs11607174 chr11 10306028 C T 1.52E-08 Red blood cell traits SBF2 intron 23222517 rs11042725 chr11 10325325 C A 1 Drug response to Paroxetine / / 19636336 rs5010 chr11 10329244 T C 8.92E-04 Obesity (extreme) / / 21935397 rs7944706 chr11 10331311 G A 5.54E-07 Red blood cell traits / / 23222517 rs4444073 chr11 10331664 A C 5.00E-04 Subclinical atherosclerosis / / 17903303 rs17296765 chr11 10332289 G T 6.05E-07 Blood pressure / / 21909110 rs2060658 chr11 10333849 T C 1.88E-07 Red blood cell traits / / 23222517 rs2923126 chr11 10343040 T C 7.66E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs16907654 chr11 10345436 A G 2.15E-05 Height / / 19039035 rs7129220 chr11 10350538 G A 2.76E-05 Height / / 19039035 rs7129220 chr11 10350538 G A 4.00E-07 Blood pressure / / 21909110 rs7129220 chr11 10350538 G A 3.00E-12 Systolic blood pressure / / 21909115 rs7129220 chr11 10350538 G A 6.00E-08 Diastolic blood pressure / / 21909115 rs2957692 chr11 10368119 A G 1.00E-12 Circulating vasoactive peptide levels / / 23381795 rs2923099 chr11 10369340 C A 3.84E-04 Multiple complex diseases / / 17554300 rs2923084 chr11 10388782 A G 5.00E-08 HDL cholesterol / / 20686565 rs2923084 chr11 10388782 A G 5.00E-08 HDL cholesterol / / 24097068 rs6484218 chr11 10390581 G A 4.00E-08 Schizophrenia,bipolar disorder and depression (combined) / / 20713499 rs7119983 chr11 10390692 C T 6.27E-04 Multiple complex diseases / / 17554300 rs10770107 chr11 10391880 C T 1.60E-04 Obesity,menopause / / 21424828 rs11042761 chr11 10397043 C G 6.31E-05 Height / / 17255346 rs2957661 chr11 10397518 C T 2.56E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10840399 chr11 10399121 C T 4.34E-05 Height / / 17255346 rs2198009 chr11 10403577 A G 0.0000228 Gains in maximal O2 uptake response / / 21183627 rs16907765 chr11 10410261 G T 7.19E-05 Height / / 17255346 rs11042775 chr11 10410316 G A 7.85E-04 Lymphocyte counts / / 22286170 rs10743138 chr11 10422929 C A 3.18E-04 Type 2 diabetes / / 17463246 rs10743138 chr11 10422929 C A 7.80E-05 Body Fat Distribution / / pha003017 rs960078 chr11 10424107 T A 5.75E-06 Multiple complex diseases / / 17554300 rs960078 chr11 10424107 T A 2.70E-06 Type 2 diabetes / / 21647700 rs10840403 chr11 10424939 T C 7.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10743139 chr11 10425327 G A 5.97E-04 Type 2 diabetes / / 17463246 rs10743140 chr11 10425417 A G 7.54E-05 Type 2 diabetes / / 17463246 rs10743140 chr11 10425417 A G 4.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7119964 chr11 10425510 C T 1.28E-04 Type 2 diabetes / / 17463246 rs7119964 chr11 10425510 C T 1.83E-04 Multiple complex diseases / / 17554300 rs10160667 chr11 10426578 G A 2.76E-04 Type 2 diabetes / / 17463246 rs11604905 chr11 10428457 A G 0.0004529 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11604905 chr11 10428457 A G 4.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11607345 chr11 10429346 G A 0.0004523 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11607345 chr11 10429346 G A 4.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12801986 chr11 10429998 C T 0.0004546 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12801986 chr11 10429998 C T 4.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11606151 chr11 10430637 A G 0.0004547 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11606153 chr11 10430641 A C 0.0005061 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11606153 chr11 10430641 A C 5.06E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7119498 chr11 10463108 T C 7.59E-04 Schizophrenia / / 19197363 rs3802917 chr11 10508938 T C 7.29E-04 Major depressive disorder AMPD3 intron 22472876 rs3802917 chr11 10508938 T C 7.92E-04 Tourette syndrome AMPD3 intron 22889924 rs7125606 chr11 10510064 T C 5.76E-08 Metabolite levels AMPD3 intron 23281178 rs11042851 chr11 10514260 G A 5.72E-04 Type 2 diabetes AMPD3 intron 17463246 rs1001118 chr11 10514707 A G 6.09E-05 Lung adenocarcinoma AMPD3 intron 19836008 rs16907909 chr11 10520036 G C 6.70E-05 Response to statin therapy AMPD3 intron 20339536 rs16907917 chr11 10520575 G C 4.40E-05 Response to statin therapy AMPD3 intron 20339536 rs10840431 chr11 10524606 C G 9.59E-04 Multiple complex diseases AMPD3 intron 17554300 rs11826750 chr11 10525919 A G 0.0007521 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) AMPD3 intron 23233654 rs11826750 chr11 10525919 A G 7.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) AMPD3 intron 23233662 rs4910150 chr11 10533173 C T 0.0008278 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4910150 chr11 10533173 C T 8.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10770123 chr11 10534866 C T 9.31E-04 Prostate cancer mortality RNF141 UTR-3 20978177 rs1993819 chr11 10540343 A G 4.96E-04 Prostate cancer mortality RNF141 intron 20978177 rs12278433 chr11 10563823 C T 1.10E-05 Urinary metabolites MRVI1-AS1 intron 21572414 rs1964537 chr11 10571351 C T 9.53E-04 Alzheimer's disease MRVI1-AS1 intron 17998437 rs17403795 chr11 10581217 G A 1.22E-05 Schizophrenia LYVE1 intron 19571811 rs7111477 chr11 10596411 G A 4.24E-04 Suicide attempts in bipolar disorder MRVI1 UTR-3 21423239 rs11042902 chr11 10655623 C T 7.04E-04 Alzheimer's disease MRVI1 intron 24755620 rs1035691 chr11 10658735 A G 1.96E-04 Alzheimer's disease (late onset) MRVI1 intron 21379329 rs7940646 chr11 10669228 T C 1.00E-06 Platelet aggregation MRVI1 intron 20526338 rs12421547 chr11 10672895 T C 7.27E-04 Suicide attempts in bipolar disorder MRVI1 intron 21423239 rs4909945 chr11 10673739 T C 1.22E-04 Migraine with aura MRVI1 missense 23793025 rs4909945 chr11 10673739 T C 2.00E-07 Migraine MRVI1 missense 23793025 rs4909945 chr11 10673739 T C 4.72E-04 Migraine - clinic-based MRVI1 missense 23793025 rs1874445 chr11 10691721 T C 6.80E-05 Endometriosis MRVI1 intron 21151130 rs4910167 chr11 10702379 C A 2.65E-05 Major depressive disorder (broad) MRVI1 intron 20038947 rs10743145 chr11 10705420 A G 5.41E-05 Bipolar disorder and schizophrenia MRVI1 intron 20889312 rs6484465 chr11 10711321 G A 6.40E-05 Bipolar disorder and schizophrenia MRVI1 intron 20889312 rs10770137 chr11 10717812 G A 2.00E-05 Bipolar disorder and schizophrenia / / 20889312 rs7122100 chr11 10732560 C A 3.77E-04 Gallstones / / 17632509 rs10840478 chr11 10737001 T G 9.48E-06 Bipolar disorder and schizophrenia / / 20889312 rs753002 chr11 10739243 A G 1.06E-05 Bipolar disorder and schizophrenia / / 20889312 rs2018368 chr11 10740366 C G 1.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs10840479 chr11 10740549 G A 4.97E-05 Bipolar disorder and schizophrenia / / 20889312 rs11042937 chr11 10745394 G T 2.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs7107377 chr11 10748612 C G 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs11042940 chr11 10755268 C T 8.43E-04 Lymphocyte counts / / 22286170 rs924111 chr11 10764618 A G 5.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs4258372 chr11 10782467 C T 3.00E-05 Coronary heart disease CTR9 intron pha003056 rs10500731 chr11 10792326 A G 7.57E-05 Major depressive disorder (broad) CTR9 intron 20038947 rs4909953 chr11 10820384 A C 1.19E-04 Suicide attempts in bipolar disorder EIF4G2 intron 21041247 rs7103202 chr11 10823038 G A 1.19E-04 Suicide attempts in bipolar disorder EIF4G2 intron 21041247 rs10743150 chr11 10824540 G A 1.20E-04 Suicide attempts in bipolar disorder EIF4G2 intron 21041247 rs7932171 chr11 10826920 T C 1.21E-04 Suicide attempts in bipolar disorder EIF4G2 intron 21041247 rs16908350 chr11 10835878 T C 2.55E-04 Coronary heart disease / / 21606135 rs7937695 chr11 10846117 T C 1.65E-04 Coronary heart disease / / 21606135 rs4243917 chr11 10848199 C T 7.51E-05 Suicide attempts in bipolar disorder / / 21041247 rs2132521 chr11 10850522 G A 1.79E-04 Coronary heart disease / / 21606135 rs1908705 chr11 10854722 A T 2.16E-04 Coronary heart disease / / 21606135 rs771377 chr11 10867949 C G 2.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs2687489 chr11 10869909 A G 2.20E-04 Suicide attempts in bipolar disorder / / 21041247 rs7925687 chr11 10873182 T C 2.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs2232928 chr11 10874594 A G 2.31E-04 Suicide attempts in bipolar disorder ZBED5 cds-synon 21041247 rs2232919 chr11 10876353 T C 2.49E-04 Suicide attempts in bipolar disorder ZBED5 missense 21041247 rs2232918 chr11 10876443 G A 2.51E-04 Suicide attempts in bipolar disorder ZBED5 missense 21041247 rs11042997 chr11 10900584 C A 1.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs11042998 chr11 10900912 T G 1.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs2403431 chr11 10902221 C A 2.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs1589596 chr11 10904758 T G 2.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs10840506 chr11 10909038 T C 3.37E-04 Suicide attempts in bipolar disorder / / 21041247 rs16908503 chr11 10912861 A G 3.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs7110417 chr11 10915244 T C 4.79E-04 Type 2 diabetes / / 17463246 rs11043009 chr11 10925016 C T 2.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs11603305 chr11 10997949 A G 1.35E-05 Tourette syndrome / / 22889924 rs7125526 chr11 11000761 A G 8.81E-04 Type 2 diabetes / / 17463246 rs17333772 chr11 11005007 T A 7.25E-04 Multiple complex diseases / / 17554300 rs17333828 chr11 11005165 G A 6.40E-05 Tourette syndrome / / 22889924 rs4910213 chr11 11005510 C G 1.31E-04 Type 2 diabetes / / 17463246 rs12804195 chr11 11005895 G T 1.89E-04 Multiple complex diseases / / 17554300 rs732392 chr11 11007971 T G 4.30E-04 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs6484593 chr11 11017331 G A 8.52E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7928255 chr11 11024584 G A 0.000304 Breast cancer early age of onset / / 18463975 rs12790086 chr11 11024608 C G 7.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs10500737 chr11 11046259 C T 3.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10500737 chr11 11046259 C T 2.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs41352246 chr11 11062350 T C 2.13E-04 Multiple complex diseases / / 17554300 rs1486535 chr11 11091092 G A 7.83E-04 Type 2 diabetes / / 17463246 rs274502 chr11 11102376 A T 8.79E-04 Type 2 diabetes / / 17463246 rs11043079 chr11 11116025 T G 4.13E-05 Odorant perception / / 23910658 rs745231 chr11 11116592 C T 1.95E-04 Suicide attempts in bipolar disorder / / 21041247 rs745231 chr11 11116592 C T 7.69E-04 Suicide attempts in bipolar disorder / / 21041247 rs4500482 chr11 11122180 T C 5.76E-05 Multiple complex diseases / / 17554300 rs10770174 chr11 11124988 A C 2.43E-04 Multiple complex diseases / / 17554300 rs9783382 chr11 11125360 G C 6.77E-04 Multiple complex diseases / / 17554300 rs9783384 chr11 11125419 G A 6.15E-04 Multiple complex diseases / / 17554300 rs9783367 chr11 11125476 T C 1.26E-04 Multiple complex diseases / / 17554300 rs17429652 chr11 11126872 A T 7.01E-06 Lipid traits / / 21777205 rs11043097 chr11 11135795 T C 2.04E-07 Celiac disease and Rheumatoid arthritis / / 21383967 rs10840563 chr11 11140081 C T 3.11E-04 Multiple complex diseases / / 17554300 rs7482222 chr11 11158105 G A,T 3.82E-04 Multiple complex diseases / / 17554300 rs7110986 chr11 11161248 G A 0.00056 Salmonella-induced pyroptosis / / 22837397 rs11825199 chr11 11165473 A G 4.82E-04 Multiple complex diseases / / 17554300 rs1875775 chr11 11172701 T C 1.97E-04 Sudden cardiac arrest / / 21658281 rs2403456 chr11 11177814 A G 5.92E-05 Hypertension / / pha003041 rs113860410 chr11 11178327 G A 0.0000876 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs113443480 chr11 11178332 A C 0.000086 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs113193734 chr11 11178356 G T 0.0000854 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12276646 chr11 11182230 G A 3.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs111259459 chr11 11186368 G A 0.000065 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs885117 chr11 11189537 A G 3.24E-05 Otosclerosis / / 19230858 rs75606920 chr11 11190050 T C 0.0000445 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs16909066 chr11 11191673 C T 1.55E-04 Multiple complex diseases / / 17554300 rs76980452 chr11 11193226 A G 0.0000384 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4910266 chr11 11196633 T A 0.0000105 Placental abruption / / 23205182 rs17431107 chr11 11198784 C T 7.69E-05 Bipolar disorder and schizophrenia / / 20889312 rs112600179 chr11 11199092 T C 0.0000318 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs113176780 chr11 11200804 A C 0.0000504 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2722773 chr11 11205054 T C 6.44E-05 Bipolar disorder and schizophrenia / / 20889312 rs2655084 chr11 11205281 G A 3.89E-05 Bipolar disorder and schizophrenia / / 20889312 rs7930700 chr11 11209609 A G 0.000436 Salmonella-induced pyroptosis / / 22837397 rs7125662 chr11 11210169 G A 0.000531 Salmonella-induced pyroptosis / / 22837397 rs4910274 chr11 11215592 A T 5.78E-05 Bipolar disorder and schizophrenia / / 20889312 rs7948621 chr11 11226112 A C 6.29E-05 Waist-Hip Ratio / / pha003013 rs7948621 chr11 11226112 A C 4.86E-05 Waist-Hip Ratio / / pha003028 rs17347113 chr11 11226136 G A 5.16E-06 Waist-Hip Ratio / / pha003013 rs17347113 chr11 11226136 G A 1.53E-06 Waist-Hip Ratio / / pha003028 rs2722769 chr11 11228374 C G 7.32E-05 Diabetic nephropathy / / 21150874 rs2722769 chr11 11228374 C G 2.00E-06 Type 2 diabetes / / 22238593 rs4341525 chr11 11246376 T C 3.90E-05 Body Mass Index / / pha003019 rs4341525 chr11 11246376 T C 7.08E-05 Body Mass Index / / pha003022 rs17347854 chr11 11247842 T C 2.47E-04 Alzheimer's disease / / 22005930 rs17347854 chr11 11247842 T C 8.64E-05 Blood Pressure / / pha003040 rs11021712 chr11 11251630 C T 2.42E-04 Spine bone size / / 23207799 rs12420184 chr11 11252257 A G 1.14E-04 Alzheimer's disease / / 22005930 rs7114848 chr11 11253466 A C 4.42E-05 Body Mass Index / / pha003019 rs7114848 chr11 11253466 A C 8.81E-05 Body Mass Index / / pha003022 rs7129572 chr11 11253542 C T 4.42E-05 Body Mass Index / / pha003019 rs7129572 chr11 11253542 C T 8.81E-05 Body Mass Index / / pha003022 rs7120631 chr11 11259129 T C 5.72E-04 Spine bone size / / 23207799 rs4910287 chr11 11260163 T C 2.00E-04 Rheumatoid arthritis / / 23918589 rs4076941 chr11 11261567 T C 1.74E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4441010 chr11 11269086 G T 3.20E-06 Urinary metabolites / / 21572414 rs4077525 chr11 11270201 G A 5.20E-05 Multiple complex diseases / / 17554300 rs4910291 chr11 11290071 G A 8.01E-04 Alcohol dependence / / 20201924 rs11602638 chr11 11290399 C T 7.11E-05 Coronary heart disease / / pha003032 rs4909977 chr11 11310634 G A 1.36E-04 Smoking initiation GALNTL4 intron 24665060 rs11021762 chr11 11316074 A C 1.12E-04 Parkinson's disease GALNTL4 intron 21248740 rs4567449 chr11 11318399 T C 4.86E-05 Response to statin treatment (atorvastatin),change in cholesterol levels GALNTL4 intron 20031582 rs4375432 chr11 11321819 T C 1.29E-06 Type 2 diabetes GALNTL4 intron 21799836 rs4910306 chr11 11325713 A G 1.45E-05 Type 2 diabetes GALNTL4 intron 21799836 rs12797711 chr11 11326558 C T 6.34E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) GALNTL4 intron 24023788 rs10741542 chr11 11332507 C T 2.63E-04 Alzheimer's disease GALNTL4 intron 24755620 rs6484805 chr11 11337963 G A 8.80E-05 Response to lithium treatment in bipolar disorder GALNTL4 intron 19448189 rs1471895 chr11 11341186 G A 3.90E-06 Brain infarcts,covert MRI-defined GALNTL4 intron 20044523 rs34376390 chr11 11350393 G C 9.34E-04 Type 2 diabetes GALNTL4 intron 17463246 rs9888256 chr11 11363248 T C 9.11E-05 Bladder cancer GALNTL4 intron 19648920 rs4910326 chr11 11386188 G C 6.56E-04 Response to cytadine analogues (cytosine arabinoside) GALNTL4 intron 24483146 rs12787100 chr11 11386340 A G 9.19E-04 Response to taxane treatment (placlitaxel) GALNTL4 intron 23006423 rs12787100 chr11 11386340 A G 7.20E-04 Response to cytadine analogues (cytosine arabinoside) GALNTL4 intron 24483146 rs1843784 chr11 11386594 T A 3.63E-04 Response to taxane treatment (placlitaxel) GALNTL4 intron 23006423 rs12794600 chr11 11387713 A C 3.27E-04 Response to taxane treatment (placlitaxel) GALNTL4 intron 23006423 rs17436486 chr11 11387855 A G 3.54E-04 Response to taxane treatment (placlitaxel) GALNTL4 intron 23006423 rs16909529 chr11 11388125 A C 8.16E-04 Type 2 diabetes GALNTL4 intron 17463246 rs10047474 chr11 11395489 C T 4.81E-04 Response to taxane treatment (placlitaxel) GALNTL4 intron 23006423 rs11021824 chr11 11395983 T G 4.89E-04 Obesity (extreme) GALNTL4 intron 21935397 rs12294127 chr11 11397472 A G 6.83E-05 Response to taxane treatment (placlitaxel) GALNTL4 intron 23006423 rs10444245 chr11 11398698 G A 7.82E-04 Response to taxane treatment (placlitaxel) GALNTL4 intron 23006423 rs4910328 chr11 11400518 T C 3.13E-04 Obesity (extreme) GALNTL4 intron 21935397 rs4453231 chr11 11403077 C G 4.75E-04 Obesity (extreme) GALNTL4 intron 21935397 rs4453231 chr11 11403077 C G 1.72E-04 Arthritis (juvenile idiopathic) GALNTL4 intron 22354554 rs10765844 chr11 11403717 A G 2.35E-04 Obesity (extreme) GALNTL4 intron 21935397 rs4910331 chr11 11412180 C T 4.60E-04 Multiple complex diseases GALNTL4 intron 17554300 rs4910331 chr11 11412180 C T 7.82E-04 Response to TNF antagonist treatment GALNTL4 intron 21061259 rs111886526 chr11 11415767 G T 2.63E-11 Metabolite levels GALNTL4 intron 22286219 rs12574825 chr11 11419394 G A 2.49E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GALNTL4 intron 22566498 rs4909996 chr11 11426198 G A 8.38E-04 Multiple complex diseases GALNTL4 intron 17554300 rs4910341 chr11 11426298 C A 7.95E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GALNTL4 intron 22566498 rs2129529 chr11 11428031 C T 5.33E-04 Type 2 diabetes GALNTL4 intron 17463246 rs2171344 chr11 11428085 G A 1.20E-05 Urinary metabolites GALNTL4 intron 21572414 rs2171344 chr11 11428085 G A 4.92E-04 Taste perception GALNTL4 intron 22132133 rs4406819 chr11 11428106 C T 9.32E-04 Type 2 diabetes GALNTL4 intron 17463246 rs10831609 chr11 11434451 C T 5.20E-04 Multiple complex diseases GALNTL4 intron 17554300 rs7113315 chr11 11435068 T A 2.60E-05 Urinary metabolites GALNTL4 intron 21572414 rs11021844 chr11 11441428 A G 8.24E-04 Type 2 diabetes GALNTL4 intron 17463246 rs745469 chr11 11443451 G T 3.22E-04 Suicide attempts in bipolar disorder GALNTL4 intron 21423239 rs12578026 chr11 11445760 G T 2.50E-05 Urinary metabolites GALNTL4 intron 21572414 rs7927545 chr11 11446464 A T 4.69E-05 Intracerebral hemorrhage GALNTL4 intron 24656865 rs4910001 chr11 11461222 A G 2.20E-04 Body mass index GALNTL4 intron 17255346 rs4910002 chr11 11461388 A G 1.50E-05 Urinary metabolites GALNTL4 intron 21572414 rs7396111 chr11 11464163 C T 7.65E-04 Type 2 diabetes GALNTL4 intron 17463246 rs7940423 chr11 11504228 G A 1.00E-07 Response to tocilizumab in rheumatoid arthritis GALNTL4 intron 22491018 rs12293824 chr11 11505004 G A 6.67E-05 Leukocyte Counts GALNTL4 intron pha003091 rs9888252 chr11 11507780 G A 0.0000455 Major depressive disorder GALNTL4 intron 23149448 rs2403515 chr11 11507915 T C 3.00E-05 Breast cancer GALNTL4 intron 17529974 rs2403515 chr11 11507915 T C 2.00E-05 Body Composition GALNTL4 intron pha003012 rs2403515 chr11 11507915 T C 2.07E-06 Body Mass Index GALNTL4 intron pha003021 rs7130159 chr11 11512274 G T 4.20E-04 Primary sclerosing cholangitis GALNTL4 intron 19944697 rs9943596 chr11 11530118 C T 1.60E-05 Potassium levels GALNTL4 intron pha003086 rs4910382 chr11 11562006 A G 3.20E-05 Response to statin treatment (atorvastatin),change in cholesterol levels GALNTL4 intron 20031582 rs4910382 chr11 11562006 A G 9.80E-04 Suicide attempts in bipolar disorder GALNTL4 intron 21423239 rs11607888 chr11 11575562 G A 2.18E-04 Alzheimer's disease GALNTL4 intron 22005930 rs11607888 chr11 11575562 G A 9.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) GALNTL4 intron 23233662 rs10741554 chr11 11576727 T A 8.84E-04 Suicide attempts in bipolar disorder GALNTL4 intron 21423239 rs4076181 chr11 11582522 C T 6.81E-04 Suicide attempts in bipolar disorder GALNTL4 intron 21423239 rs6484998 chr11 11590761 C T 2.31E-05 Personality dimensions GALNTL4 intron 18957941 rs7121652 chr11 11590846 T A 4.49E-05 Personality dimensions GALNTL4 intron 18957941 rs11021941 chr11 11596478 T C 5.94E-05 Angioedema in response to angiotensin-converting enzyme inhibitor GALNTL4 intron 23838604 rs10765871 chr11 11615837 C T 8.33E-05 Cognitive impairment induced by topiramate GALNTL4 intron 22091778 rs11021961 chr11 11654893 G A 8.11E-06 Stroke (ischemic) / / 21957438 rs4910407 chr11 11700694 A C 3.35E-04 Tourette syndrome / / 22889924 rs4910407 chr11 11700694 A C 5.66E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11021985 chr11 11700746 C T 9.39E-04 Multiple complex diseases / / 17554300 rs10831663 chr11 11701969 T C 3.08E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4910411 chr11 11719619 G A 2.46E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1869698 chr11 11730938 A C 1.96E-04 Multiple complex diseases / / 17554300 rs1869699 chr11 11731002 C A 9.74E-04 Multiple complex diseases / / 17554300 rs1471014 chr11 11741075 C T 1.80E-06 Urinary metabolites / / 21572414 rs17446021 chr11 11761070 C T 5.36E-04 Multiple complex diseases / / 17554300 rs17446021 chr11 11761070 C T 4.90E-06 Left ventricular hypertrophy / / 21828061 rs11022014 chr11 11766709 T C 4.90E-05 Malaria / / 19465909 rs874651 chr11 11779374 C T 7.93E-04 Schizophrenia / / 19197363 rs874651 chr11 11779374 C T 7.90E-05 Alcoholism (heaviness of drinking) / / 21529783 rs1378357 chr11 11802361 A G 5.81E-04 Schizophrenia / / 19197363 rs16910122 chr11 11808547 C T 2.72E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs16910189 chr11 11836394 A T 7.21E-04 Type 2 diabetes / / 17463246 rs12790557 chr11 11840925 T G 4.54E-04 Acute lung injury / / 22295056 rs10831680 chr11 11840965 C T 1.40E-05 Lung adenocarcinoma / / 22797724 rs12418890 chr11 11893217 G A 6.74E-04 Oral cancers (chewing tobacco related) USP47 intron 22503698 rs10831690 chr11 11898743 T G 2.36E-04 Scoliosis USP47 intron 21216876 rs4360694 chr11 11918698 T C 3.73E-05 Pulmonary function in asthmatics USP47 intron 23541324 rs4910031 chr11 11922325 T C 4.54E-05 Pulmonary function in asthmatics USP47 intron 23541324 rs12225231 chr11 11939811 T C 9.68E-06 Metabolite levels (Dihydroxy docosatrienoic acid) USP47 intron 23934736 rs1472189 chr11 11983885 C T 8.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) / / 23934736 rs3206824 chr11 11986061 T C 2.20E-04 Scoliosis DKK3 missense 21216876 rs10734190 chr11 12001587 T C 7.32E-04 Smoking quantity DKK3 intron 24665060 rs7478946 chr11 12002139 C T 4.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DKK3 intron 20877124 rs12290406 chr11 12004132 G A 3.10E-04 Multiple complex diseases DKK3 intron 17554300 rs7104941 chr11 12020616 C T 7.32E-04 Obesity (extreme) DKK3 intron 21935397 rs7104941 chr11 12020616 C T 9.04E-07 Response to tocilizumab in rheumatoid arthritis DKK3 intron 22491018 rs903014 chr11 12020724 T C 7.79E-04 Obesity (extreme) DKK3 intron 21935397 rs2896594 chr11 12021660 A T 8.26E-04 Obesity (extreme) DKK3 intron 21935397 rs3750940 chr11 12022898 A G 2.01E-06 Response to tocilizumab in rheumatoid arthritis DKK3 intron 22491018 rs4500466 chr11 12041496 A G 2.03E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs11022119 chr11 12050652 G A 2.23E-04 Type 2 diabetes / / 17463246 rs16910421 chr11 12070665 G A 4.00E-06 Visceral fat / / 22589738 rs923175 chr11 12072503 G C 7.00E-06 Response to taxane treatment (docetaxel) / / 23006423 rs6485416 chr11 12073518 G A 6.36E-05 Body Mass Index / / pha003009 rs2131492 chr11 12073761 G T 8.28E-04 Type 2 diabetes / / 17463246 rs7946686 chr11 12076162 A G 5.17E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7946686 chr11 12076162 A G 4.04E-04 Taste perception / / 22132133 rs1872561 chr11 12080552 C T 8.77E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12146494 chr11 12097072 C A 2.99E-04 Sarcoidosis / / 19165924 rs10831728 chr11 12110677 C T 1.50E-05 Cognitive function / / 24684796 rs1485964 chr11 12131800 T G 8.09E-06 Personality dimensions / / 23658558 rs1159649 chr11 12135604 C G 1.53E-05 Lymphocyte counts MICAL2 intron 22286170 rs2013486 chr11 12149531 C T 6.28E-04 Stroke MICAL2 intron pha002887 rs1843546 chr11 12153863 A T 1.12E-04 Aortic root size MICAL2 intron 21223598 rs7105164 chr11 12154093 A G 5.43E-24 Narcolepsy MICAL2 intron 19629137 rs1485957 chr11 12156853 C T 5.59E-04 Aortic root size MICAL2 intron 21223598 rs4414199 chr11 12157942 C T 2.55E-04 Multiple complex diseases MICAL2 intron 17554300 rs1994318 chr11 12159661 C A 2.00E-06 PR interval MICAL2 intron 23534349 rs10831742 chr11 12170325 A G 1.96E-06 Personality dimensions MICAL2 intron 23658558 rs11022211 chr11 12170434 T C 6.10E-16 Multiple complex diseases MICAL2 intron 17554300 rs11822285 chr11 12192623 C T 4.55E-05 Alzheimer's disease MICAL2 intron 17998437 rs11822285 chr11 12192623 C T 6.68E-05 Breast cancer MICAL2 intron 21060860 rs11022222 chr11 12194758 C T 3.13E-04 Type 2 diabetes MICAL2 intron 17463246 rs10831757 chr11 12215182 C A 8.48E-05 Erythrocyte counts MICAL2 intron pha003090 rs10741569 chr11 12216979 A G 3.20E-06 Parkinson's disease MICAL2 intron 20711177 rs17477949 chr11 12219203 C T 3.73E-05 Nicotine smoking MICAL2 intron 19268276 rs10831759 chr11 12221382 A G 4.48E-05 Alcohol and nictotine co-dependence MICAL2 intron 20158304 rs10500753 chr11 12228679 G C 5.40E-04 Cognition,early reading ability MICAL2 intron 17684495 rs16910765 chr11 12229437 C T 4.83E-06 Common variable immunodeficiency MICAL2 intron 21497890 rs6485587 chr11 12245343 T C 8.10E-05 Asthma MICAL2 intron pha003127 rs2279614 chr11 12263047 A G 1.54E-04 Myocardial Infarction MICAL2 intron pha002883 rs12294434 chr11 12265083 G A 1.47E-04 Multiple complex diseases MICAL2 intron 17554300 rs2270511 chr11 12265542 A G 2.00E-05 Urinary metabolites MICAL2 cds-synon 21572414 rs1493959 chr11 12274395 T C 7.54E-04 Multiple complex diseases MICAL2 intron 17554300 rs10831775 chr11 12297327 G A 2.57E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10831775 chr11 12297327 G A 6.06E-05 Waist Circumference / / pha003023 rs10741577 chr11 12305051 A G 8.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs1493953 chr11 12315891 G A 5.83E-04 Multiple complex diseases MICALCL missense 17554300 rs11022288 chr11 12329243 G A 5.17E-04 Alzheimer's disease MICALCL intron 17998437 rs10831798 chr11 12367806 T C 2.78E-05 Alcohol dependence MICALCL intron 20201924 rs10831798 chr11 12367806 T C 2.78E-05 Alcoholism MICALCL intron pha002891 rs4757381 chr11 12368645 G A 8.95E-05 Alcohol dependence MICALCL intron 20201924 rs4757381 chr11 12368645 G A 8.95E-05 Alcoholism MICALCL intron pha002891 rs10219167 chr11 12403836 G A 8.27E-04 Iron levels PARVA intron pha002876 rs10219167 chr11 12403836 G A 4.13E-05 Lung function (forced expiratory volume in 1 second) PARVA intron pha003102 rs4757420 chr11 12415077 G T 6.20E-06 Osteoarthritis PARVA intron 22763110 rs7941793 chr11 12425638 G A 5.10E-06 Urinary metabolites PARVA intron 21572414 rs10831809 chr11 12429376 G A 8.87E-04 Type 2 diabetes PARVA intron 17463246 rs4485089 chr11 12431361 A G 4.43E-05 Coronary heart disease PARVA intron pha003035 rs11022344 chr11 12434458 C T 1.59E-04 Multiple complex diseases PARVA intron 17554300 rs11022346 chr11 12434945 A G 9.84E-04 Multiple complex diseases PARVA intron 17554300 rs11022347 chr11 12434982 G T 4.45E-04 Myopia (pathological) PARVA intron 21095009 rs1002316 chr11 12440284 T G 7.82E-05 Cognitive impairment induced by topiramate PARVA intron 22091778 rs10500757 chr11 12442597 G A 5.12E-04 Sleep depth PARVA intron 23728906 rs73411566 chr11 12454744 T C 1.75E-08 Opioid sensitivity PARVA intron 24143882 rs7120489 chr11 12469397 A G 7.00E-06 Heart failure PARVA intron 20400778 rs7930590 chr11 12470201 G A 1.68E-04 Multiple complex diseases PARVA intron 17554300 rs1426576 chr11 12482568 C T 4.36E-04 Type 2 diabetes PARVA intron 17463246 rs1426576 chr11 12482568 C T 6.55E-04 Multiple complex diseases PARVA intron 17554300 rs10765951 chr11 12484122 G T 3.91E-04 Type 2 diabetes PARVA intron 17463246 rs1991320 chr11 12490545 C T 7.13E-05 Schizophrenia PARVA intron 19197363 rs2288292 chr11 12495699 C T 1.70E-05 Sleep and circadian phenotypes PARVA intron 17903308 rs10765955 chr11 12517482 T C 8.47E-05 Cytomegalovirus antibody response PARVA intron 21993531 rs7126366 chr11 12526896 G A 4.82E-20 Multiple complex diseases PARVA intron 17554300 rs4756903 chr11 12529707 T G 6.98E-04 Multiple complex diseases PARVA intron 17554300 rs2243707 chr11 12534707 G A 6.64E-04 Suicide attempts in bipolar disorder PARVA intron 21423239 rs3812760 chr11 12557016 T G 1.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10831848 chr11 12565464 C T 2.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs10765961 chr11 12566207 A G 4.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs7939385 chr11 12567391 C T 8.33E-05 Suicide attempts in bipolar disorder / / 21423239 rs7925151 chr11 12569119 G C 1.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs4453218 chr11 12569367 A G 1.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs4353252 chr11 12569384 G A 7.48E-05 Suicide attempts in bipolar disorder / / 21423239 rs7106819 chr11 12570446 G C 8.47E-05 Suicide attempts in bipolar disorder / / 21423239 rs1863584 chr11 12575039 G A 2.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs5023635 chr11 12578118 T C 9.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs12417360 chr11 12579507 G A 2.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs7948132 chr11 12580213 G C 2.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs10831854 chr11 12590116 T G 1.70E-05 Urinary metabolites / / 21572414 rs6485859 chr11 12594663 A G 4.60E-06 Urinary metabolites / / 21572414 rs11022424 chr11 12598929 C T 5.07E-04 Smoking initiation / / 24665060 rs10765970 chr11 12611849 T G 1.30E-05 Urinary metabolites / / 21572414 rs11022428 chr11 12616210 C T 8.20E-04 Adiposity / / 19461586 rs7124295 chr11 12619919 G A 1.54E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6485968 chr11 12660201 G A 0.000445 Salmonella-induced pyroptosis / / 22837397 rs7926971 chr11 12698040 A G 4.00E-10 Height TEAD1 intron 20881960 rs4454698 chr11 12720560 G A 4.37E-04 Prostate cancer mortality TEAD1 intron 20978177 rs4636653 chr11 12738650 G A 6.36E-04 Multiple complex diseases TEAD1 intron 17554300 rs4553350 chr11 12759834 C T 9.40E-05 Tooth agenesis (third molar) TEAD1 intron 24172245 rs16911620 chr11 12827351 A T 4.92E-04 Multiple complex diseases TEAD1 intron 17554300 rs2033908 chr11 12838286 C A 6.69E-05 Serum metabolites TEAD1 intron 19043545 rs10500762 chr11 12847833 T C 4.93E-04 Multiple complex diseases TEAD1 intron 17554300 rs16911654 chr11 12855639 G A 2.76E-04 Type 2 diabetes TEAD1 intron 17463246 rs1899068 chr11 12872156 A T 1.71E-05 Serum metabolites TEAD1 intron 19043545 rs4757953 chr11 12874513 A G 3.85E-05 Serum metabolites TEAD1 intron 19043545 rs4757957 chr11 12881398 G C 3.82E-05 Serum metabolites TEAD1 intron 19043545 rs4757064 chr11 12909146 A G 9.66E-05 Schizophrenia TEAD1 intron 20185149 rs4757064 chr11 12909146 A G 5.03E-05 Alzheimer's disease (late onset) TEAD1 intron 21379329 rs10831916 chr11 12911236 C T 4.74E-04 Alcohol dependence TEAD1 intron 20201924 rs10831916 chr11 12911236 C T 1.56E-04 Response to taxane treatment (placlitaxel) TEAD1 intron 23006423 rs4757963 chr11 12912067 G T 4.60E-04 Alzheimer's disease TEAD1 intron 24755620 rs12291037 chr11 12925527 G C 1.54E-04 Multiple complex diseases TEAD1 intron 17554300 rs11605871 chr11 12929383 G A 7.82E-04 Multiple complex diseases TEAD1 intron 17554300 rs6486069 chr11 12932899 A G 2.98E-04 Alzheimer's disease (late onset) TEAD1 intron 21379329 rs11022544 chr11 12933341 T C 9.55E-04 Multiple complex diseases TEAD1 intron 17554300 rs7130663 chr11 12940392 G A 1.00E-04 Information processing speed TEAD1 intron 21130836 rs12790829 chr11 12944946 C T 9.21E-05 Information processing speed TEAD1 intron 21130836 rs11022559 chr11 12945249 A G 1.84E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) TEAD1 intron 22566498 rs4369386 chr11 12957618 A C 8.48E-05 Information processing speed TEAD1 intron 21130836 rs10500767 chr11 12962397 C A 1.77E-04 Response to statin treatment (atorvastatin),change in cholesterol levels TEAD1 UTR-3 20031582 rs16911839 chr11 12963122 C G 4.47E-04 Multiple complex diseases TEAD1 UTR-3 17554300 rs4450153 chr11 12987192 G A 6.78E-04 Lipid levels / / 19016617 rs4450153 chr11 12987192 G A 7.11E-04 Lipid levels / / 19016617 rs4453219 chr11 12987581 G A 6.78E-04 Lipid levels / / 19016617 rs4453219 chr11 12987581 G A 7.11E-04 Lipid levels / / 19016617 rs4453220 chr11 12987701 G A 6.78E-04 Lipid levels / / 19016617 rs4453220 chr11 12987701 G A 6.92E-04 Lipid levels / / 19016617 rs12295437 chr11 12994339 T C 1.35E-04 Alzheimer's disease / / 22005930 rs12295437 chr11 12994339 T C 9.20E-06 Retinopathy in non-diabetics / / 23393555 rs12275206 chr11 12994372 A T 1.41E-04 Alzheimer's disease / / 22005930 rs11022581 chr11 12995412 G T 6.80E-06 Retinopathy in non-diabetics / / 23393555 rs7943015 chr11 12995535 T C 1.40E-04 Alzheimer's disease / / 22005930 rs7943370 chr11 12995875 T C 1.37E-04 Alzheimer's disease / / 22005930 rs7946317 chr11 12995901 T C 1.63E-04 Alzheimer's disease / / 22005930 rs12284323 chr11 12997363 G A 1.34E-04 Alzheimer's disease / / 22005930 rs12271168 chr11 12997787 A G 1.31E-04 Alzheimer's disease / / 22005930 rs12291531 chr11 12998050 T C 1.29E-04 Alzheimer's disease / / 22005930 rs12293390 chr11 12999045 T C 1.25E-04 Alzheimer's disease / / 22005930 rs12288026 chr11 12999445 G A 1.20E-04 Alzheimer's disease / / 22005930 rs12276434 chr11 13000156 A C 1.19E-04 Alzheimer's disease / / 22005930 rs4582959 chr11 13000755 T A 1.11E-04 Alzheimer's disease / / 22005930 rs12278640 chr11 13001679 A G 1.06E-04 Alzheimer's disease / / 22005930 rs7926628 chr11 13002109 A G 1.05E-04 Alzheimer's disease / / 22005930 rs7929650 chr11 13002186 T G 4.83E-04 Alzheimer's disease / / 22005930 rs7102071 chr11 13014088 A C 7.97E-06 Retinopathy in non-diabetics / / 23393555 rs10831936 chr11 13020242 T C 1.74E-04 Multiple complex diseases / / 17554300 rs10160217 chr11 13021824 A G 3.84E-04 Coronary heart disease LOC100506352 intron 21606135 rs4483574 chr11 13022404 A G 3.51E-04 Coronary heart disease LOC100506352 intron 21606135 rs4506627 chr11 13022818 T C 3.25E-04 Coronary heart disease LOC100506352 intron 21606135 rs4757085 chr11 13023643 C T 3.19E-04 Coronary heart disease LOC100506352 intron 21606135 rs12273457 chr11 13057028 G T 8.29E-05 Tunica Media / / pha003034 rs2727405 chr11 13090942 G A 8.00E-06 Obesity-related traits / / 23251661 rs2583125 chr11 13095393 G T 7.05E-05 Longevity / / 20304771 rs2583125 chr11 13095393 G T 2.09E-08 Metabolite levels / / 23281178 rs2583124 chr11 13095907 C T 6.98E-05 Longevity / / 20304771 rs2583124 chr11 13095907 C T 2.09E-08 Metabolite levels / / 23281178 rs10500770 chr11 13096474 A T 3.90E-04 Lipid traits / / 17903299 rs2119563 chr11 13098963 A T 2.09E-08 Metabolite levels / / 23281178 rs1031028 chr11 13099230 C T 2.09E-08 Metabolite levels / / 23281178 rs10831954 chr11 13099336 T C 8.54E-04 Intracranial aneurysm / / 20613766 rs2583134 chr11 13099460 G A 2.09E-08 Metabolite levels / / 23281178 rs10831955 chr11 13099858 G A 6.16E-04 Multiple complex diseases / / 17554300 rs1441344 chr11 13100080 G T 4.44E-04 Type 2 diabetes / / 17463246 rs1441344 chr11 13100080 G T 2.09E-08 Metabolite levels / / 23281178 rs1542084 chr11 13100883 G A 2.09E-08 Metabolite levels / / 23281178 rs2727394 chr11 13103113 G A 3.11E-08 Metabolite levels / / 23281178 rs2583129 chr11 13104010 C A,G,T 2.09E-08 Metabolite levels / / 23281178 rs3109942 chr11 13105467 C A 8.14E-04 Type 2 diabetes / / 17463246 rs3109942 chr11 13105467 C A 3.11E-08 Metabolite levels / / 23281178 rs3098750 chr11 13105564 T A 3.11E-08 Metabolite levels / / 23281178 rs1841845 chr11 13105737 C T 2.09E-08 Metabolite levels / / 23281178 rs2727364 chr11 13111731 C G 2.09E-08 Metabolite levels / / 23281178 rs10766035 chr11 13115117 C G 2.09E-08 Metabolite levels / / 23281178 rs930456 chr11 13121093 A G 6.35E-04 Type 2 diabetes / / 17463246 rs930456 chr11 13121093 A G 2.38E-08 Metabolite levels / / 23281178 rs4757104 chr11 13122200 C A 3.69E-08 Metabolite levels / / 23281178 rs3849154 chr11 13124524 G T 9.08E-04 Multiple complex diseases / / 17554300 rs6486089 chr11 13127942 A T 2.94E-04 Multiple complex diseases / / 17554300 rs117020818 chr11 13129163 G A 7.00E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs79847705 chr11 13134780 G A 7.07E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs7123819 chr11 13139447 G C 7.09E-04 Multiple complex diseases / / 17554300 rs7944511 chr11 13146079 G A 9.68E-05 Body Mass Index / / pha003022 rs10831977 chr11 13154569 C T 7.02E-05 Body Mass Index / / pha003022 rs7109452 chr11 13155778 G T 4.70E-06 Urinary metabolites / / 21572414 rs2086545 chr11 13208379 G C 0.000655 Ovarian cancer / / 22794196 rs10734211 chr11 13228736 C A 9.00E-06 Urinary metabolites / / 21572414 rs7947920 chr11 13230633 T A,C,G 7.57E-04 Body mass index / / 21701565 rs7938000 chr11 13232487 C T 8.30E-06 Personality dimensions / / 21173776 rs10766061 chr11 13235206 T A 9.40E-06 Personality dimensions / / 21173776 rs11022710 chr11 13237709 T C 7.30E-04 Alcohol dependence / / 20201924 rs11022711 chr11 13238162 A G 8.90E-06 Personality dimensions / / 21173776 rs11022712 chr11 13239311 G A 8.80E-06 Personality dimensions / / 21173776 rs7112005 chr11 13239500 T C 3.50E-04 Alcohol dependence / / 20201924 rs7108752 chr11 13239559 A G 3.20E-04 Alcohol dependence / / 20201924 rs7108752 chr11 13239559 A G 7.60E-06 Personality dimensions / / 21173776 rs11022714 chr11 13241425 G T 9.60E-06 Personality dimensions / / 21173776 rs7124156 chr11 13241926 T C 9.60E-06 Personality dimensions / / 21173776 rs10832000 chr11 13250399 A G 5.20E-04 Alcohol dependence / / 20201924 rs12805064 chr11 13258381 G A 1.02E-05 Serum metabolites / / 19043545 rs1531755 chr11 13259778 G A 9.84E-06 Serum metabolites / / 19043545 rs1531754 chr11 13260181 T C 4.96E-04 Multiple complex diseases / / 17554300 rs4372426 chr11 13275240 C T 4.39E-04 Multiple complex diseases / / 17554300 rs10766065 chr11 13277961 C T 1.75E-04 Acute lung injury / / 22295056 rs900145 chr11 13293905 C T 2.00E-08 Menarche (age at onset) / / 21102462 rs1481892 chr11 13301921 G C 9.30E-04 Multiple complex diseases ARNTL intron 17554300 rs2403662 chr11 13302822 A G 8.95E-04 Acute lung injury ARNTL intron 22295056 rs4414197 chr11 13306311 T G 5.71E-04 Acute lung injury ARNTL intron 22295056 rs4146387 chr11 13306648 A G 7.04E-05 Vaspin levels ARNTL intron 22907691 rs4757141 chr11 13307095 A G 7.71E-04 Multiple complex diseases ARNTL intron 17554300 rs11022750 chr11 13307594 G A 7.72E-04 Multiple complex diseases ARNTL intron 17554300 rs1481891 chr11 13310718 T C 5.70E-04 Acute lung injury ARNTL intron 22295056 rs11022753 chr11 13310854 T C 8.49E-04 Multiple complex diseases ARNTL intron 17554300 rs7107287 chr11 13312969 G T 9.40E-05 Tuberculosis ARNTL intron 20694014 rs12290622 chr11 13314307 G A 5.87E-04 Acute lung injury ARNTL intron 22295056 rs11022756 chr11 13315439 A C 5.96E-04 Acute lung injury ARNTL intron 22295056 rs10500779 chr11 13317553 T C 4.01E-04 Multiple complex diseases ARNTL intron 17554300 rs10766073 chr11 13317964 G A 7.72E-04 Multiple complex diseases ARNTL intron 17554300 rs4757144 chr11 13331226 G A 5.00E-06 Schizophrenia ARNTL intron 23358160 rs2166693 chr11 13337828 G A 0.0000611 Cholesterol,total ARNTL intron 23063622 rs6486121 chr11 13355770 C T 1.34E-04 Heart Failure ARNTL intron pha002884 rs6486122 chr11 13361524 C T 2.00E-10 Plasminogen activator inhibitor type 1 levels (PAI-1) ARNTL intron 22990020 rs3816360 chr11 13367750 T C 9.90E-08 Plasminogen activator inhibitor type 1 levels (PAI-1) ARNTL intron 22990020 rs3816360 chr11 13367750 T C 6.80E-06 Triglycerides ARNTL intron pha003080 rs7126303 chr11 13370535 C T 3.26E-04 Heart Failure ARNTL intron pha002884 rs1868049 chr11 13383682 C T 1.20E-05 Urinary metabolites ARNTL intron 21572414 rs2290035 chr11 13407771 T A 0.0000146 Type 2 diabetes ARNTL intron 22325160 rs10832032 chr11 13411344 G T 7.61E-05 Bone mineral density BTBD10 intron 19874204 rs7103068 chr11 13429961 G C 1.53E-04 Type 2 diabetes BTBD10 intron 17463246 rs10832036 chr11 13462853 C A 8.07E-05 Bone mineral density BTBD10 intron 19874204 rs2593579 chr11 13478839 C A 0.000551 Salmonella-induced pyroptosis BTBD10 intron 22837397 rs307245 chr11 13481999 G T 0.000214 Salmonella-induced pyroptosis BTBD10 intron 22837397 rs307246 chr11 13483227 G A 5.88E-05 Bone mineral density BTBD10 intron 19874204 rs12418886 chr11 13500778 T C 9.56E-04 Type 2 diabetes / / 17463246 rs6254 chr11 13514263 C T 6.84E-04 Suicide attempts in bipolar disorder PTH intron 21041247 rs11022858 chr11 13526633 T C 7.70E-04 Type 2 diabetes / / 17463246 rs307223 chr11 13534350 T A 5.34E-04 Type 2 diabetes / / 17463246 rs7931255 chr11 13547617 A C 8.03E-04 Type 2 diabetes / / 17463246 rs12365099 chr11 13548100 A G 5.28E-04 Type 2 diabetes / / 17463246 rs11608098 chr11 13559954 T C 7.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs10500784 chr11 13573825 A C 7.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs1903102 chr11 13574652 C A 7.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs10500786 chr11 13583784 G A 4.01E-05 Brain structure / / 22504417 rs2018354 chr11 13583866 T G 5.02E-04 Type 2 diabetes / / 17463246 rs11022887 chr11 13584776 T A 8.74E-04 Type 2 diabetes / / 17463246 rs11022887 chr11 13584776 T A 9.87E-05 Serum metabolites / / 19043545 rs1870411 chr11 13588943 G A 5.18E-04 Type 2 diabetes / / 17463246 rs1870411 chr11 13588943 G A 6.16E-05 Serum metabolites / / 19043545 rs1870413 chr11 13589155 T G 8.71E-04 Type 2 diabetes / / 17463246 rs1870413 chr11 13589155 T G 9.87E-05 Serum metabolites / / 19043545 rs898148 chr11 13598416 G C 6.93E-04 Type 2 diabetes / / 17463246 rs898148 chr11 13598416 G C 9.87E-05 Serum metabolites / / 19043545 rs2036417 chr11 13617608 A G 9.52E-06 Bone mineral density / / 19874204 rs7125774 chr11 13618804 C T 1.05E-05 Bone mineral density / / 19874204 rs9630182 chr11 13620172 T C 4.00E-07 Bone mineral density / / 19874204 rs11022897 chr11 13620921 C T 6.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs1502243 chr11 13625439 G A 5.62E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs1502243 chr11 13625439 G A 7.18E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs1502242 chr11 13625619 C A 1.33E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1816775 chr11 13783230 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7949225 chr11 13800622 G A 1.50E-05 Urinary metabolites / / 21572414 rs7949225 chr11 13800622 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7112044 chr11 13806012 T C 1.50E-05 Urinary metabolites / / 21572414 rs12804856 chr11 13823917 G A 1.70E-05 Urinary metabolites / / 21572414 rs10832116 chr11 13824801 T G 2.37E-05 Serum metabolites / / 19043545 rs1699031 chr11 13824827 A G 9.65E-05 Alzheimer's disease / / 22832961 rs1583931 chr11 13826331 A G 4.82E-05 Serum metabolites / / 19043545 rs767445 chr11 13839719 A G 7.84E-04 Myopia (pathological) / / 21095009 rs1911597 chr11 13846413 G T 7.84E-04 Myopia (pathological) / / 21095009 rs11022982 chr11 13862705 T C 2.90E-07 Iron levels / / 21208937 rs4756770 chr11 13869220 A T 3.74E-05 Serum metabolites / / 19043545 rs11604879 chr11 13876596 A G 2.20E-05 Urinary metabolites / / 21572414 rs11022987 chr11 13877711 A C 1.32E-04 Multiple complex diseases / / 17554300 rs9651632 chr11 13909116 A C 4.00E-05 Prostate cancer / / 21743057 rs1393878 chr11 13912746 A G 9.94E-05 Orofacial clefts / / 22863734 rs1876427 chr11 13921101 C T 9.16E-04 Type 2 diabetes / / 17463246 rs12271425 chr11 13925559 G C 2.10E-05 Ulcerative colitis / / 19915572 rs1507527 chr11 13926079 G A 5.20E-04 Type 2 diabetes / / 17463246 rs2174146 chr11 13926912 G A 4.61E-04 Type 2 diabetes / / 17463246 rs2174146 chr11 13926912 G A 9.88E-05 Receptive language ability / / 24687471 rs10766122 chr11 13953569 A G 6.51E-04 Type 2 diabetes / / 17463246 rs1830391 chr11 13970363 C G 2.80E-06 Urinary metabolites / / 21572414 rs1528657 chr11 13990544 T G 3.83E-05 Response to taxane treatment (placlitaxel) SPON1 intron 23006423 rs1881516 chr11 13993498 C T 4.76E-04 Multiple complex diseases SPON1 intron 17554300 rs1881516 chr11 13993498 C T 2.70E-06 Urinary metabolites SPON1 intron 21572414 rs1819084 chr11 13996155 C A 9.00E-06 Tuberculosis SPON1 intron 24057671 rs12575169 chr11 13997808 A C 9.34E-04 Alcohol dependence SPON1 intron 21314694 rs2618511 chr11 14006744 A G 9.43E-04 Response to alcohol consumption (flushing response) SPON1 intron 24277619 rs2618516 chr11 14021639 T C 6.00E-10 Brain connectivity SPON1 intron 23471985 rs1528667 chr11 14033524 A G 9.43E-04 Response to alcohol consumption (flushing response) SPON1 intron 24277619 rs7116230 chr11 14035580 G A 1.23E-04 Multiple complex diseases SPON1 intron 17554300 rs7116230 chr11 14035580 G A 1.01E-04 Smoking cessation SPON1 intron 18519826 rs11023051 chr11 14035961 T C 6.99E-05 Multiple complex diseases SPON1 intron 17554300 rs11023051 chr11 14035961 T C 5.26E-05 Smoking cessation SPON1 intron 18519826 rs1528668 chr11 14037478 T C 5.88E-05 Multiple complex diseases SPON1 intron 17554300 rs10832163 chr11 14048303 C T 1.76E-04 Multiple complex diseases SPON1 intron 17554300 rs10832164 chr11 14048480 C T 5.52E-05 Bipolar disorder and schizophrenia SPON1 intron 20889312 rs11023054 chr11 14048654 G A 1.57E-04 Multiple complex diseases SPON1 intron 17554300 rs11023054 chr11 14048654 G A 1.38E-04 Smoking cessation SPON1 intron 18519826 rs11023054 chr11 14048654 G A 2.62E-04 Smoking cessation SPON1 intron 18519826 rs10832165 chr11 14048684 G A 2.37E-04 Multiple complex diseases SPON1 intron 17554300 rs10832165 chr11 14048684 G A 1.02E-04 Smoking cessation SPON1 intron 18519826 rs10832165 chr11 14048684 G A 7.01E-06 Smoking cessation SPON1 intron 18519826 rs11023055 chr11 14049169 A G 1.24E-04 Multiple complex diseases SPON1 intron 17554300 rs11023055 chr11 14049169 A G 1.55E-07 Smoking cessation SPON1 intron 18519826 rs7112850 chr11 14052199 G A 2.10E-04 Multiple complex diseases SPON1 intron 17554300 rs10766134 chr11 14058186 T G 8.19E-05 Multiple complex diseases SPON1 intron 17554300 rs12283632 chr11 14058278 G A 1.96E-04 Multiple complex diseases SPON1 intron 17554300 rs11023059 chr11 14064392 A G 2.94E-05 Multiple complex diseases SPON1 intron 17554300 rs11023059 chr11 14064392 A G 7.80E-05 Smoking cessation SPON1 intron 18519826 rs11023059 chr11 14064392 A G 6.01E-05 Bipolar disorder and schizophrenia SPON1 intron 20889312 rs10832169 chr11 14066486 G A 8.61E-04 Response to alcohol consumption (flushing response) SPON1 intron 24277619 rs10832170 chr11 14066549 A T 3.81E-05 Multiple complex diseases SPON1 intron 17554300 rs10832170 chr11 14066549 A T 3.63E-05 Bipolar disorder and schizophrenia SPON1 intron 20889312 rs4757219 chr11 14066800 T G 5.58E-04 Multiple complex diseases SPON1 intron 17554300 rs4756773 chr11 14068251 T C 8.61E-04 Response to alcohol consumption (flushing response) SPON1 intron 24277619 rs1919295 chr11 14070567 C T 5.26E-05 Crohn's disease SPON1 intron 20570966 rs1528640 chr11 14070828 A G 2.56E-05 Multiple complex diseases SPON1 intron 17554300 rs1528640 chr11 14070828 A G 2.19E-05 Smoking cessation SPON1 intron 18519826 rs1528640 chr11 14070828 A G 6.14E-05 Bipolar disorder and schizophrenia SPON1 intron 20889312 rs2403708 chr11 14072663 G A 3.93E-04 Multiple complex diseases SPON1 intron 17554300 rs11023067 chr11 14075260 C G 1.65E-04 Multiple complex diseases SPON1 intron 17554300 rs11023067 chr11 14075260 C G 9.35E-05 Smoking cessation SPON1 intron 18519826 rs1406356 chr11 14077511 T A 6.48E-05 Multiple complex diseases SPON1 intron 17554300 rs1406356 chr11 14077511 T A 4.63E-05 Smoking cessation SPON1 intron 18519826 rs1406356 chr11 14077511 T A 5.18E-05 Bipolar disorder and schizophrenia SPON1 intron 20889312 rs2049724 chr11 14078151 A G 1.89E-04 Multiple complex diseases SPON1 intron 17554300 rs2049724 chr11 14078151 A G 2.26E-05 Bipolar disorder and schizophrenia SPON1 intron 20889312 rs7104613 chr11 14079931 C T 6.80E-05 Pain relief with opioid treatment SPON1 intron 21622719 rs1528641 chr11 14086458 A T 5.16E-04 Multiple complex diseases SPON1 intron 17554300 rs1919297 chr11 14089499 T G 2.79E-04 Multiple complex diseases SPON1 intron 17554300 rs17556665 chr11 14098482 G T 1.00E-06 Inflammatory biomarkers SPON1 intron 22228203 rs7116296 chr11 14113759 T C 2.37E-04 Multiple complex diseases SPON1 intron 17554300 rs11023088 chr11 14119101 T C 1.77E-04 Multiple complex diseases SPON1 intron 17554300 rs1919302 chr11 14133293 G A 4.95E-05 Prostate cancer SPON1 intron 23023329 rs11023100 chr11 14160504 G A 1 Drug response to Etoposide SPON1 intron 17537913 rs9804490 chr11 14204192 G A 3.99E-10 Multiple complex diseases SPON1 intron 17554300 rs11023139 chr11 14224346 G A 7.00E-11 Alzheimer's disease (cognitive decline) SPON1 intron 23535033 rs1025412 chr11 14246296 G A 9.33E-04 Multiple complex diseases SPON1 intron 17554300 rs7127495 chr11 14249149 G A 8.93E-04 Multiple complex diseases SPON1 intron 17554300 rs731274 chr11 14273677 G A 1.58E-04 Alcohol dependence SPON1 intron 20201924 rs11023163 chr11 14276931 G A 8.92E-04 Suicide attempts in bipolar disorder SPON1 intron 21423239 rs2303975 chr11 14276999 G A 1.60E-04 Alcohol dependence SPON1 intron 20201924 rs2163460 chr11 14313504 T C 1.01E-04 Type 2 diabetes RRAS2 intron 17846124 rs11023182 chr11 14318830 G T 3.00E-04 Alcohol dependence RRAS2 intron 20201924 rs11023186 chr11 14342761 G A 9.66E-05 Alcohol dependence RRAS2 intron 20201924 rs11023186 chr11 14342761 G A 9.66E-05 Alcoholism RRAS2 intron pha002891 rs2915409 chr11 14355732 C T 2.82E-05 Body Mass Index RRAS2 intron pha003022 rs4756788 chr11 14362060 T C 5.69E-04 Alzheimer's disease RRAS2 intron 22005930 rs2349300 chr11 14373662 T C 2.75E-04 Alcohol dependence RRAS2 intron 20201924 rs11023197 chr11 14380998 G A 1 Drug response to Tamoxifen RRAS2 intron 19047159 rs7125877 chr11 14410383 A G 2.10E-06 Urinary metabolites / / 21572414 rs10832249 chr11 14416189 C A 2.50E-07 Urinary metabolites / / 21572414 rs4382869 chr11 14436733 C T 7.84E-04 Myopia (pathological) / / 21095009 rs12804549 chr11 14437758 T A 1.76E-04 Type 2 diabetes / / 17463246 rs7926861 chr11 14442428 A G 0.000795 Breast cancer / / 22228098 rs4369365 chr11 14444515 C G 0.000872 Breast cancer / / 22228098 rs4403769 chr11 14450176 C T 0.00054 Breast cancer / / 22228098 rs7131590 chr11 14453382 T C 0.000589 Breast cancer / / 22228098 rs7112755 chr11 14453387 C T 0.000593 Breast cancer / / 22228098 rs2034480 chr11 14466923 G A 0.000765 Breast cancer / / 22228098 rs2575847 chr11 14471172 C T 0.000765 Breast cancer / / 22228098 rs2575825 chr11 14472096 T C 0.000765 Breast cancer / / 22228098 rs2597208 chr11 14472329 A C 0.000674 Breast cancer / / 22228098 rs2597207 chr11 14472679 T C 0.00076 Breast cancer / / 22228098 rs2575827 chr11 14475515 A G 0.00077 Breast cancer / / 22228098 rs2256884 chr11 14476402 A T 0.000778 Breast cancer / / 22228098 rs2597206 chr11 14477538 A C 0.000779 Breast cancer / / 22228098 rs2575828 chr11 14484192 T C 0.000832 Breast cancer COPB1 intron 22228098 rs2575829 chr11 14485021 C T 0.000812 Breast cancer COPB1 intron 22228098 rs2597201 chr11 14485404 T C 0.0008 Breast cancer COPB1 intron 22228098 rs2597200 chr11 14485600 A G 0.000769 Breast cancer COPB1 intron 22228098 rs2575830 chr11 14485602 C A 0.000803 Breast cancer COPB1 intron 22228098 rs2575831 chr11 14486194 A T 0.00081 Breast cancer COPB1 intron 22228098 rs2575832 chr11 14488810 A G 0.000804 Breast cancer COPB1 intron 22228098 rs2597197 chr11 14489832 G A 0.000792 Breast cancer COPB1 intron 22228098 rs2597196 chr11 14491601 T C 0.000817 Breast cancer COPB1 intron 22228098 rs2575834 chr11 14494684 C G 0.000777 Breast cancer COPB1 intron 22228098 rs2575835 chr11 14496665 A G 0.000264 Breast cancer COPB1 intron 22228098 rs2575836 chr11 14497864 T G 0.000561 Breast cancer COPB1 intron 22228098 rs2575837 chr11 14498001 A G 0.00056 Breast cancer COPB1 intron 22228098 rs2575838 chr11 14498221 C G 0.00055 Breast cancer COPB1 intron 22228098 rs2575857 chr11 14501296 C T 0.000549 Breast cancer COPB1 intron 22228098 rs2597192 chr11 14507236 C T 0.000543 Breast cancer COPB1 intron 22228098 rs2167160 chr11 14507449 C A 0.000526 Breast cancer COPB1 intron 22228098 rs11023238 chr11 14508698 T C 2.50E-04 Iris characteristics COPB1 intron 21835309 rs2575855 chr11 14508976 G A 0.000522 Breast cancer COPB1 intron 22228098 rs2575859 chr11 14510736 C T 0.000512 Breast cancer COPB1 intron 22228098 rs2575864 chr11 14514641 G A 0.000482 Breast cancer COPB1 intron 22228098 rs10832279 chr11 14516003 T A 0.000272 Breast cancer COPB1 intron 22228098 rs565684578 chr11 14516003 T TA 0.000272 Breast cancer COPB1 intron 22228098 rs2597188 chr11 14516906 G A 0.000479 Breast cancer COPB1 intron 22228098 rs2597187 chr11 14517019 C G 0.00048 Breast cancer COPB1 intron 22228098 rs2575822 chr11 14519851 C A 0.000475 Breast cancer COPB1 intron 22228098 rs2575823 chr11 14521354 C A 0.000468 Breast cancer COPB1 UTR-5 22228098 rs2597184 chr11 14524333 G A 0.00044 Breast cancer / / 22228098 rs2597183 chr11 14524366 T C 0.000429 Breast cancer / / 22228098 rs2597221 chr11 14527075 C T 0.000455 Breast cancer PSMA1 intron 22228098 rs6486197 chr11 14529874 C G 0.00045 Breast cancer PSMA1 intron 22228098 rs2597219 chr11 14530866 C G 0.000449 Breast cancer PSMA1 intron 22228098 rs10766183 chr11 14531236 T C 0.000416 Breast cancer PSMA1 intron 22228098 rs11023245 chr11 14531459 T C 0.000448 Breast cancer PSMA1 intron 22228098 rs2597217 chr11 14532883 A G 0.000512 Breast cancer PSMA1 intron 22228098 rs2575852 chr11 14533368 G A 0.000493 Breast cancer PSMA1 intron 22228098 rs2597216 chr11 14533916 G A 0.000491 Breast cancer PSMA1 intron 22228098 rs2575853 chr11 14533963 T C 0.000454 Breast cancer PSMA1 intron 22228098 rs2597215 chr11 14534378 A T 0.000489 Breast cancer PSMA1 intron 22228098 rs1548074 chr11 14534825 A G 0.000488 Breast cancer PSMA1 intron 22228098 rs112169102 chr11 14539639 T TA 0.000469 Breast cancer PSMA1 intron 22228098 rs2575849 chr11 14539639 T A 0.000469 Breast cancer PSMA1 intron 22228098 rs10766184 chr11 14542577 A G 0.000419 Breast cancer PSMA1 intron 22228098 rs2597214 chr11 14547641 G A 0.000434 Breast cancer PSMA1 intron 22228098 rs7112765 chr11 14548439 C T 0.000393 Breast cancer PSMA1 intron 22228098 rs2575840 chr11 14552231 T C 0.000455 Breast cancer PSMA1 intron 22228098 rs2575841 chr11 14552361 C T 0.000429 Breast cancer PSMA1 intron 22228098 rs2575842 chr11 14554146 G A 0.000502 Breast cancer PSMA1 intron 22228098 rs4463820 chr11 14556342 A G 0.000504 Breast cancer PSMA1 intron 22228098 rs10832289 chr11 14669496 A T 2.10E-05 Urinary metabolites PDE3B intron 21572414 rs1403248 chr11 14679017 A C 2.30E-05 Urinary metabolites PDE3B intron 21572414 rs11826363 chr11 14756272 C T 2.25E-05 Odorant perception PDE3B intron 23910658 rs11023332 chr11 14784110 G C 7.00E-06 Adiponectin levels PDE3B intron 22479202 rs6486202 chr11 14798806 A C 2.30E-04 Iris characteristics PDE3B intron 21835309 rs4757268 chr11 14810762 A G 1.60E-05 Urinary metabolites PDE3B cds-synon 21572414 rs1993116 chr11 14910234 A G 3.00E-17 Vitamin D levels CYP2R1 intron 20418485 rs12794714 chr11 14913575 G A 1.48E-05 Follicle stimulating hormone CYP2R1 cds-synon 24049095 rs10741657 chr11 14914878 A G 3.00E-20 Vitamin D insufficiency CYP2R1 nearGene-5 20541252 rs2060793 chr11 14915310 A G 3.00E-17 Vitamin D levels CYP2R1 nearGene-5 20418485 rs1562902 chr11 14918216 C T 7.36E-04 Alcohol dependence / / 24277619 rs16930625 chr11 14918308 A G 4.54E-04 Alcohol dependence / / 24277619 rs1553006 chr11 14922950 A G 1.79E-04 Type 2 diabetes / / 17463246 rs7925191 chr11 14991802 A G 3.79E-05 Femoral neck bone geometry CALCA intron 22087292 rs11821055 chr11 14998603 G A 7.15E-04 Type 2 diabetes / / 17463246 rs11821055 chr11 14998603 G A 5.18E-04 Multiple complex diseases / / 17554300 rs16924840 chr11 15029950 G A 7.23E-05 Multiple complex diseases / / 17554300 rs6486219 chr11 15062177 A T 3.13E-08 Breast cancer / / 20852631 rs11023415 chr11 15072633 G T 6.54E-04 Multiple complex diseases / / 17554300 rs11023415 chr11 15072633 G T 8.13E-05 Serum metabolites / / 19043545 rs1894129 chr11 15098082 A G 2.50E-06 Serum metabolites CALCB intron 19043545 rs11023437 chr11 15130313 A G 2.10E-05 Urinary metabolites / / 21572414 rs2105794 chr11 15144450 C T 5.82E-05 Multiple complex diseases INSC intron 17554300 rs12226609 chr11 15166201 C T 2.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) INSC intron 23648065 rs1714348 chr11 15177259 G A 6.13E-04 Alzheimer's disease INSC intron 22005930 rs1792544 chr11 15180533 G A 2.49E-05 Height INSC intron 17255346 rs1792544 chr11 15180533 G A 1.47E-04 Lung function (forced expiratory volume in 1 second) INSC intron 24023788 rs1792544 chr11 15180533 G A 2.63E-04 Lung function (forced vital capacity) INSC intron 24023788 rs1109328 chr11 15182729 T C 2.63E-05 Psoriasis INSC intron 18364390 rs1540157 chr11 15189409 G A 8.41E-04 Coronary heart disease INSC intron 21606135 rs1627802 chr11 15191961 A G 2.97E-04 Coronary heart disease INSC intron 21606135 rs10160390 chr11 15201160 C T 5.71E-04 Suicide attempts in bipolar disorder INSC intron 21041247 rs1108010 chr11 15216692 C T 1.10E-05 Urinary metabolites INSC intron 21572414 rs1108011 chr11 15216785 T C 1.60E-05 Urinary metabolites INSC intron 21572414 rs1540153 chr11 15221017 A G 3.01E-04 Coronary Artery Disease INSC intron 17634449 rs1540153 chr11 15221017 A G 7.90E-06 Urinary metabolites INSC intron 21572414 rs1945628 chr11 15227989 C T 8.33E-05 Lung function (forced expiratory volume in 1 second) INSC intron pha003102 rs1792551 chr11 15228450 T C 9.10E-06 Urinary metabolites INSC intron 21572414 rs16931216 chr11 15231853 A G 7.89E-04 Suicide attempts in bipolar disorder INSC intron 21041247 rs16931218 chr11 15235052 T C 8.46E-04 Suicide attempts in bipolar disorder INSC intron 21041247 rs1792556 chr11 15244521 T G 5.49E-04 Suicide attempts in bipolar disorder INSC intron 21041247 rs1714336 chr11 15245118 C T 5.48E-04 Suicide attempts in bipolar disorder INSC intron 21041247 rs1714337 chr11 15246886 A G 5.65E-04 Suicide attempts in bipolar disorder INSC intron 21041247 rs1792543 chr11 15252444 A G 6.91E-04 Response to taxane treatment (placlitaxel) INSC intron 23006423 rs16931268 chr11 15258031 C T 5.63E-04 Acute lung injury INSC intron 22295056 rs11023482 chr11 15258289 G A 3.49E-04 Response to taxane treatment (placlitaxel) INSC intron 23006423 rs7116710 chr11 15262321 C G 9.00E-06 Urinary metabolites INSC intron 21572414 rs7116710 chr11 15262321 C G 9.06E-05 Response to mTOR inhibitor (rapamycin) INSC intron 24009623 rs1945602 chr11 15273177 A C 4.70E-06 Urinary metabolites / / 21572414 rs10766220 chr11 15273729 T G 1.40E-05 Urinary metabolites / / 21572414 rs939046 chr11 15275242 A G 9.98E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10500812 chr11 15275559 G A 5.86E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs1945607 chr11 15279421 C A 7.06E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10766222 chr11 15279663 C T 5.20E-06 Urinary metabolites / / 21572414 rs1540138 chr11 15282324 A G 5.14E-05 Prostate cancer / / 22923026 rs1945608 chr11 15282598 A G 9.20E-06 Urinary metabolites / / 21572414 rs2350983 chr11 15284845 G T 5.14E-05 Prostate cancer / / 22923026 rs4291658 chr11 15294201 C A 7.60E-06 Urinary metabolites / / 21572414 rs4291659 chr11 15294368 C A 9.20E-06 Urinary metabolites / / 21572414 rs7940545 chr11 15296168 A C 1.10E-05 Urinary metabolites / / 21572414 rs1343841 chr11 15319228 G A 5.01E-04 Taste perception / / 22132133 rs11023518 chr11 15330115 A G 3.58E-04 Obesity (extreme) / / 21935397 rs4614430 chr11 15337027 G C 8.42E-04 Alzheimer's disease / / 17998437 rs9645645 chr11 15341624 C G 1.74E-04 Obesity (extreme) / / 21935397 rs11605083 chr11 15355246 T C 4.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs11023543 chr11 15375869 T A 3.55E-04 Obesity (extreme) / / 21935397 rs12577240 chr11 15377609 G C 3.55E-04 Obesity (extreme) / / 21935397 rs4500467 chr11 15401144 A G 4.10E-07 Fetal hemoglobin levels / / 18245381 rs11023568 chr11 15439281 T C 3.85E-04 Obesity (extreme) / / 21935397 rs7930647 chr11 15443281 C T 3.92E-05 Non-word repetition / / 23738518 rs4756808 chr11 15455777 G T 5.27E-05 Body mass index / / 21701565 rs4756808 chr11 15455777 G T 7.49E-05 Body mass index / / 21701565 rs7126053 chr11 15455965 A C 6.26E-04 Body mass index / / 21701565 rs11023571 chr11 15456468 G A 8.79E-04 Alcohol dependence / / 24277619 rs7114467 chr11 15457467 G A 9.00E-06 Menarche (age at onset) / / 23667675 rs10734234 chr11 15465860 C T 4.99E-04 Smoking initiation / / 24665060 rs7949682 chr11 15471048 G A 6.33E-05 Multiple complex diseases / / 17554300 rs6486251 chr11 15521553 T G 0.0000844 Panic disorder / / 23149450 rs6486251 chr11 15521553 T G 8.44E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs16931632 chr11 15619943 A G 7.34E-06 Obesity-related traits / / 23251661 rs17439299 chr11 15620586 A G 6.00E-06 Obesity-related traits / / 23251661 rs2351059 chr11 15620907 T G 7.34E-06 Obesity-related traits / / 23251661 rs10500817 chr11 15648135 T C 3.61E-09 Multiple sclerosis / / 17660530 rs7932838 chr11 15677986 A G 2.43E-04 Smoking quantity / / 24665060 rs7117858 chr11 15694462 G A 6.00E-10 Bone mineral density (hip) / / 19801982 rs7117858 chr11 15694462 G A 0.00000619 Femoral neck bone mineral density (premenopausal) / / 23074152 rs7108738 chr11 15710084 T G 1.00E-32 Bone mineral density / / 22504420 rs7108738 chr11 15710084 T G 0.0000132 Femoral neck bone mineral density (premenopausal) / / 23074152 rs7108738 chr11 15710084 T G 1.00E-15 Bone mineral density / / 24249740 rs7108738 chr11 15710084 T G 6.73E-09 Bone mineral density / / 24249740 rs7108738 chr11 15710084 T G 6.73E-09 Bone mineral density / / 24249740 rs7108738 chr11 15710084 T G 8.93E-08 Bone mineral density / / 24249740 rs11023689 chr11 15720177 A T 4.31E-04 Multiple complex diseases / / 17554300 rs7942222 chr11 15725398 T C 5.21E-04 Multiple complex diseases / / 17554300 rs900865 chr11 15729843 C G 4.18E-04 Multiple complex diseases / / 17554300 rs1994214 chr11 15730356 C A 5.39E-04 Multiple complex diseases / / 17554300 rs4426098 chr11 15730752 A T 8.24E-04 Multiple complex diseases / / 17554300 rs3886607 chr11 15735653 A G 7.01E-04 Multiple complex diseases / / 17554300 rs7130751 chr11 15737746 C T 9.81E-04 Multiple complex diseases / / 17554300 rs1011824 chr11 15746997 C T 1.11E-04 Glycosylated haemoglobin levels / / 17255346 rs11023692 chr11 15748289 G A 2.09E-05 Glycosylated haemoglobin levels / / 17255346 rs7943117 chr11 15749254 A T 1.57E-04 Glycosylated haemoglobin levels / / 17255346 rs7107341 chr11 15752353 T A 2.49E-04 Glycosylated haemoglobin levels / / 17255346 rs1484445 chr11 15755276 A G 1.38E-04 Type 2 diabetes / / 17463246 rs11023694 chr11 15757543 G A 4.28E-05 Glycosylated haemoglobin levels / / 17255346 rs7129609 chr11 15758129 A G 5.28E-05 Glycosylated haemoglobin levels / / 17255346 rs11023698 chr11 15760125 C T 1.68E-04 Glycosylated haemoglobin levels / / 17255346 rs11023700 chr11 15761041 A G 1.37E-04 Glycosylated haemoglobin levels / / 17255346 rs1385165 chr11 15763070 G A 1.92E-04 Vaspin levels / / 22907691 rs1385165 chr11 15763070 G A 0.0001922 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs1484433 chr11 15799460 G T 2.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10832519 chr11 15811930 T C 1.50E-05 Bone mineral density (BMD),in women / / 20164292 rs326686 chr11 15824138 G A 1.82E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1920676 chr11 15832747 G T 2.20E-05 Breast cancer and prostate cancer / / 17903305 rs1440714 chr11 15833823 A T 3.70E-05 Breast cancer and prostate cancer / / 17903305 rs1882130 chr11 15844374 A T 1.90E-05 Urinary metabolites / / 21572414 rs1920668 chr11 15846536 G C 1.90E-05 Urinary metabolites / / 21572414 rs1440708 chr11 15848847 T C 1.00E-05 Urinary metabolites / / 21572414 rs12800617 chr11 15850555 T A 1.30E-05 Urinary metabolites / / 21572414 rs7947977 chr11 15854788 C T 6.00E-05 Response to statin therapy / / 20339536 rs7948085 chr11 15854842 C G 5.50E-05 Response to statin therapy / / 20339536 rs11821667 chr11 15856450 T C 5.50E-05 Response to statin therapy / / 20339536 rs11821691 chr11 15856462 T C 5.90E-05 Response to statin therapy / / 20339536 rs7113024 chr11 15858407 C T 7.90E-05 Response to statin therapy / / 20339536 rs6486265 chr11 15858496 G A 7.90E-05 Response to statin therapy / / 20339536 rs12272146 chr11 15858804 C T 1.70E-05 Urinary metabolites / / 21572414 rs7945894 chr11 15859026 C T 8.00E-05 Response to statin therapy / / 20339536 rs1837604 chr11 15861538 A G 7.30E-05 Response to statin therapy / / 20339536 rs7111705 chr11 15863386 C T 8.30E-05 Response to statin therapy / / 20339536 rs12281263 chr11 15886388 A G 0.000452 Salmonella-induced pyroptosis / / 22837397 rs11823900 chr11 15887004 A G 0.000635 Salmonella-induced pyroptosis / / 22837397 rs12287547 chr11 15907288 G A 7.61E-04 Multiple complex diseases / / 17554300 rs11023771 chr11 15922161 A G 3.27E-04 Sudden cardiac arrest / / 21658281 rs894006 chr11 15924743 A G 5.86E-04 Multiple complex diseases / / 17554300 rs11023787 chr11 15952294 C T 5.00E-06 Bone mineral density / / 21104366 rs11023787 chr11 15952294 C T 5.00E-16 Wrist bone mass / / 21104366 rs2615016 chr11 15952543 G C 0.0000677 Cognitive impairment (no dementia) / / 23042215 rs1866822 chr11 15962351 A C 8.84E-04 Type 2 diabetes / / 17463246 rs16932353 chr11 15972672 C T 4.56E-04 Smoking initiation / / 24665060 rs730993 chr11 15985264 A G 7.80E-05 Lung adenocarcinoma / / 22797724 rs730992 chr11 15985282 A C 5.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10832542 chr11 16006473 T C 9.52E-04 Multiple complex diseases SOX6 intron 17554300 rs3922559 chr11 16008235 T C 7.83E-05 Self-reported allergy SOX6 intron 23817569 rs4757378 chr11 16008988 C A 7.38E-05 Self-reported allergy SOX6 intron 23817569 rs11023821 chr11 16022866 G A 4.70E-04 Insulin resistance SOX6 intron 21901158 rs16932416 chr11 16023324 A G 5.72E-04 Multiple complex diseases SOX6 intron 17554300 rs12574862 chr11 16026174 G C 2.23E-04 Multiple complex diseases SOX6 intron 17554300 rs12574859 chr11 16026291 C A 4.77E-04 Multiple complex diseases SOX6 intron 17554300 rs7942659 chr11 16026663 T C 6.10E-04 Multiple complex diseases SOX6 intron 17554300 rs7924380 chr11 16026816 G T 2.90E-04 Multiple complex diseases SOX6 intron 17554300 rs4478958 chr11 16028675 C T 3.09E-04 Multiple complex diseases SOX6 intron 17554300 rs16932455 chr11 16040175 A T 2.00E-06 Capecitabine sensitivity SOX6 intron 22864933 rs16932458 chr11 16040473 G T 3.06E-04 Multiple complex diseases SOX6 intron 17554300 rs10766295 chr11 16105390 T C 2.10E-05 Melanoma SOX6 intron 21983785 rs1401454 chr11 16250183 C T 1.00E-06 Blood pressure SOX6 intron 23972371 rs1401454 chr11 16250183 C T 5.00E-10 Blood pressure SOX6 intron 23972371 rs1949481 chr11 16259405 C T 2.71E-04 Height SOX6 intron 17255346 rs17539593 chr11 16261098 C A 3.04E-04 Multiple complex diseases SOX6 intron 17554300 rs1837096 chr11 16262874 C T 2.36E-04 Multiple complex diseases SOX6 intron 17554300 rs11822790 chr11 16263355 A G 4.07E-04 Multiple complex diseases SOX6 intron 17554300 rs11023888 chr11 16263727 T G 9.88E-04 Multiple complex diseases SOX6 intron 17554300 rs10766312 chr11 16265883 A T 2.77E-04 Multiple complex diseases SOX6 intron 17554300 rs1595373 chr11 16266740 G A 4.59E-07 Blood pressure SOX6 intron 21909110 rs10832576 chr11 16280304 A T 4.99E-04 Multiple complex diseases SOX6 intron 17554300 rs1347677 chr11 16296412 C A 2.18E-04 Multiple complex diseases SOX6 intron 17554300 rs1156725 chr11 16307700 C T 1.30E-07 Blood pressure SOX6 intron 21909110 rs11023907 chr11 16324449 G T 2.92E-04 Multiple complex diseases SOX6 intron 17554300 rs297367 chr11 16329009 T C 8.70E-05 Multiple complex diseases SOX6 intron 17554300 rs190929 chr11 16335038 A G 3.15E-04 Height SOX6 intron 17255346 rs1437635 chr11 16358722 C A 2.51E-08 Secreted IFN-gamma response to smallpox vaccine SOX6 intron 22661280 rs2014408 chr11 16365282 C T 2.99E-06 Blood pressure SOX6 intron 22100073 rs2014408 chr11 16365282 C T 3.20E-05 Blood pressure SOX6 intron 22100073 rs2014408 chr11 16365282 C T 3.50E-07 Blood pressure SOX6 intron 22100073 rs2014408 chr11 16365282 C T 6.46E-04 Blood pressure SOX6 intron 22100073 rs2014408 chr11 16365282 C T 8.11E-07 Blood pressure SOX6 intron 22100073 rs297325 chr11 16389594 T C 4.00E-07 Obesity and osteoporosis SOX6 intron 19714249 rs1370465 chr11 16394068 G A 4.10E-04 Alcohol dependence SOX6 intron 20201924 rs7925853 chr11 16396402 A T 0.000000763 LDL cholesterol SOX6 intron 23063622 rs7925853 chr11 16396402 A T 4.72E-27 HDL cholesterol SOX6 intron 23063622 rs4756846 chr11 16403511 T C 5.00E-07 Obesity and osteoporosis SOX6 intron 19714249 rs11603071 chr11 16408248 T C 3.30E-04 Alcohol dependence SOX6 intron 20201924 rs1393926 chr11 16418711 G A 6.89E-04 Multiple complex diseases SOX6 intron 17554300 rs1503442 chr11 16425782 T C 4.78E-05 Tuberculosis SOX6 intron 20694014 rs11023934 chr11 16425958 T A 9.12E-05 Postoperative ventricular dysfunction SOX6 intron 21980348 rs1503452 chr11 16452132 C T 1.20E-04 Alcohol dependence SOX6 intron 20201924 rs1503452 chr11 16452132 C T 0.00000321 Alcohol dependence SOX6 intron 23691058 rs10832607 chr11 16462767 C T 8.51E-05 Postoperative ventricular dysfunction SOX6 intron 21980348 rs16933105 chr11 16464678 T A 2.51E-06 Obesity and osteoporosis SOX6 intron 19714249 rs10500830 chr11 16485251 G A 2.34E-04 Postoperative ventricular dysfunction SOX6 intron 21980348 rs6486291 chr11 16486894 G A 3.49E-08 HDL cholesterol SOX6 intron 23063622 rs12802656 chr11 16534415 A C 6.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4132991 chr11 16568206 G A 8.85E-05 Postoperative ventricular dysfunction / / 21980348 rs10832653 chr11 16638042 T A 2.86E-04 Multiple complex diseases / / 17554300 rs11024021 chr11 16735491 G A 3.28E-04 Endometrial cancer / / 24096698 rs1392998 chr11 16745643 C T 7.93E-04 Multiple complex diseases / / 17554300 rs10734249 chr11 16775254 G A 8.24E-05 Multiple complex diseases C11orf58 intron 17554300 rs7110136 chr11 16778787 C T 5.41E-05 Multiple complex diseases C11orf58 UTR-3 17554300 rs4757432 chr11 16789155 T C 3.69E-04 Multiple complex diseases / / 17554300 rs217756 chr11 16806160 G T 7.40E-06 Urinary metabolites / / 21572414 rs201660932 chr11 16816195 G A 0.00013 Breast cancer PLEKHA7 missense 23555315 rs183358 chr11 16827720 A G 6.04E-04 Suicide attempts in bipolar disorder PLEKHA7 intron 21423239 rs10832683 chr11 16833461 G A 6.55E-05 Alzheimer's disease PLEKHA7 intron 21098978 rs10832683 chr11 16833461 G A 5.07E-05 ldl cholesterol PLEKHA7 intron pha003077 rs10832683 chr11 16833461 G A 4.84E-05 Cholesterol PLEKHA7 intron pha003083 rs216493 chr11 16834031 A G 9.51E-04 Amyotrophic Lateral Sclerosis PLEKHA7 intron 17362836 rs216495 chr11 16834510 G A 2.88E-05 Alcohol and nictotine co-dependence PLEKHA7 intron 20158304 rs10832684 chr11 16837874 A G 9.66E-05 Major depressive disorder PLEKHA7 intron 21621269 rs10832689 chr11 16846313 C A,G,T 5.75E-05 Major depressive disorder (broad) PLEKHA7 intron 20038947 rs1615979 chr11 16855379 C G 1.22E-04 Multiple complex diseases PLEKHA7 intron 17554300 rs11024054 chr11 16864694 C A 1.11E-04 Multiple complex diseases PLEKHA7 intron 17554300 rs417406 chr11 16873799 C T 3.93E-05 Major depressive disorder (broad) PLEKHA7 intron 20038947 rs11024058 chr11 16877497 C T 7.05E-04 Multiple complex diseases PLEKHA7 intron 17554300 rs11024058 chr11 16877497 C T 1.99E-04 Prostate cancer mortality PLEKHA7 intron 20978177 rs11024061 chr11 16882049 C T 6.06E-04 Multiple complex diseases PLEKHA7 intron 17554300 rs11024061 chr11 16882049 C T 2.45E-04 Prostate cancer mortality PLEKHA7 intron 20978177 rs382734 chr11 16889397 C T 9.80E-05 Hematology traits PLEKHA7 intron 23303382 rs415300 chr11 16889745 G A 4.91E-04 Myopia (pathological) PLEKHA7 intron 21095009 rs415300 chr11 16889745 G A 7.80E-05 Hematology traits PLEKHA7 intron 23303382 rs414992 chr11 16894090 C T 7.42E-05 Major depressive disorder (broad) PLEKHA7 intron 20038947 rs428840 chr11 16896218 A G 3.99E-05 Major depressive disorder (broad) PLEKHA7 intron 20038947 rs11024066 chr11 16897496 C T 4.53E-04 Myopia (pathological) PLEKHA7 intron 21095009 rs12795133 chr11 16897595 C A 8.12E-05 Amyotrophic lateral sclerosis (sporadic) PLEKHA7 intron 24529757 rs414219 chr11 16900362 C G 9.26E-05 Major depressive disorder (broad) PLEKHA7 intron 20038947 rs381815 chr11 16902268 C T 2.00E-09 Systolic blood pressure PLEKHA7 intron 19430479 rs381815 chr11 16902268 C T 2.05E-05 Major depressive disorder (broad) PLEKHA7 intron 20038947 rs381815 chr11 16902268 C T 2.00E-09 Coronary heart disease PLEKHA7 intron 21347282 rs381815 chr11 16902268 C T 3.00E-08 Blood pressure PLEKHA7 intron 21909110 rs381815 chr11 16902268 C T 7.00E-06 Blood pressure PLEKHA7 intron 21909110 rs381815 chr11 16902268 C T 5.27E-11 Systolic blood pressure PLEKHA7 intron 21909115 rs435206 chr11 16903178 C A 3.20E-05 Major depressive disorder (broad) PLEKHA7 intron 20038947 rs378755 chr11 16912251 A C 9.19E-04 Myopia (pathological) PLEKHA7 intron 21095009 rs388968 chr11 16912986 A G 3.26E-05 Major depressive disorder (broad) PLEKHA7 intron 20038947 rs10741712 chr11 16915272 G T 9.16E-04 Multiple complex diseases PLEKHA7 intron 17554300 rs11024074 chr11 16917219 T C 1.00E-06 Diastolic blood pressure PLEKHA7 intron 19430479 rs11024074 chr11 16917219 T C 1.42E-05 Major depressive disorder (broad) PLEKHA7 intron 20038947 rs11024074 chr11 16917219 T C 1.00E-06 Coronary heart disease PLEKHA7 intron 21347282 rs11024074 chr11 16917219 T C 4.03E-04 Acute lung injury PLEKHA7 intron 22295056 rs11024074 chr11 16917219 T C 6.90E-06 Hematology traits PLEKHA7 intron 23303382 rs12418111 chr11 16917430 C T 3.45E-05 Major depressive disorder (broad) PLEKHA7 intron 20038947 rs7926335 chr11 16917869 C T 2.07E-05 Major depressive disorder (broad) PLEKHA7 intron 20038947 rs16933675 chr11 16919677 A C 3.72E-05 Major depressive disorder (broad) PLEKHA7 intron 20038947 rs177544 chr11 16925046 C T 9.89E-05 Major depressive disorder (broad) PLEKHA7 intron 20038947 rs10766358 chr11 16934149 G C 9.50E-05 Hematology traits PLEKHA7 intron 23303382 rs16933680 chr11 16935949 C T 2.36E-04 Type 2 diabetes PLEKHA7 intron 17463246 rs16933680 chr11 16935949 C T 3.15E-04 Multiple complex diseases PLEKHA7 intron 17554300 rs2215085 chr11 16944512 T C 1.70E-05 Hematology traits PLEKHA7 intron 23303382 rs4757446 chr11 16948199 C T 1.90E-05 Hematology traits PLEKHA7 intron 23303382 rs4756875 chr11 16957341 A G 6.16E-04 Type 2 diabetes PLEKHA7 intron 17463246 rs177562 chr11 16957667 T C 3.35E-04 Type 2 diabetes PLEKHA7 intron 17463246 rs4757449 chr11 16963550 A C 9.81E-04 Type 2 diabetes PLEKHA7 intron 17463246 rs4756876 chr11 16963663 C T 2.35E-06 Osteoarthritis PLEKHA7 intron 19508968 rs10766360 chr11 16969754 T A 3.37E-04 Type 2 diabetes PLEKHA7 intron 17463246 rs10766360 chr11 16969754 T A 4.90E-05 Lipid levels PLEKHA7 intron 18193043 rs2883150 chr11 16974786 A G 3.81E-04 Type 2 diabetes PLEKHA7 intron 17463246 rs7121911 chr11 16980153 G A 7.60E-06 Hematology traits PLEKHA7 intron 23303382 rs4757456 chr11 16985391 T A,C,G 3.63E-04 Type 2 diabetes PLEKHA7 intron 17463246 rs4757456 chr11 16985391 T A,C,G 8.03E-04 Multiple complex diseases PLEKHA7 intron 17554300 rs4757457 chr11 16985620 C T 5.32E-04 Type 2 diabetes PLEKHA7 intron 17463246 rs7939987 chr11 16986103 C T 7.01E-04 Type 2 diabetes PLEKHA7 intron 17463246 rs7396552 chr11 16988268 G A 4.29E-04 Type 2 diabetes PLEKHA7 intron 17463246 rs11024097 chr11 16999029 C T 0.000042 Pancreatic cancer and survival PLEKHA7 intron 22665904 rs11024102 chr11 17008605 T C 5.00E-12 Glaucoma (primary open-angle) PLEKHA7 intron 22922875 rs6486334 chr11 17015557 T C 9.07E-08 Glaucoma (primary open-angle) PLEKHA7 intron 22922875 rs6486334 chr11 17015557 T C 6.52E-06 Prostate cancer PLEKHA7 intron pha002878 rs7949405 chr11 17085192 A C 9.48E-06 Triglycerides / / 19074352 rs7949405 chr11 17085192 A C 9.48E-06 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs11024142 chr11 17086632 C T 0.000682 Breast cancer / / 22228098 rs11024145 chr11 17089005 G A 0.000886 Breast cancer / / 22228098 rs11024146 chr11 17093408 C T 0.00068 Breast cancer / / 22228098 rs72632986 chr11 17094121 G A 0.000678 Breast cancer / / 22228098 rs10832730 chr11 17095131 A C 0.000674 Breast cancer / / 22228098 rs11024147 chr11 17095565 T G 0.000825 Breast cancer / / 22228098 rs11024150 chr11 17100265 C G 0.000734 Breast cancer / / 22228098 rs146200696 chr11 17105942 G A 0.000629 Breast cancer / / 22228098 rs149877011 chr11 17106183 C T 0.000607 Breast cancer / / 22228098 rs17560341 chr11 17107163 G A 5.00E-04 Iris characteristics / / 21835309 rs11024152 chr11 17107816 A G 0.000571 Breast cancer / / 22228098 rs11024153 chr11 17110249 T C 0.000783 Breast cancer PIK3C2A UTR-3 22228098 rs17847728 chr11 17116027 T C 0.000793 Breast cancer PIK3C2A intron 22228098 rs72632987 chr11 17121089 T A 0.000666 Breast cancer PIK3C2A intron 22228098 rs6486349 chr11 17126038 T C 0.000728 Breast cancer PIK3C2A intron 22228098 rs3950680 chr11 17138666 G A 1.10E-04 Type 2 diabetes PIK3C2A intron 22158537 rs4356203 chr11 17160148 A G 1.00E-07 Schizophrenia PIK3C2A intron 21926974 rs4356203 chr11 17160148 A G 0.0000548 Schizophrenia PIK3C2A intron 23637625 rs4356203 chr11 17160148 A G 2.14E-05 Bipolar disorder and schizophrenia PIK3C2A intron 24280982 rs4356203 chr11 17160148 A G 6.00E-09 Bipolar disorder and schizophrenia PIK3C2A intron 24280982 rs4356203 chr11 17160148 A G 7.36E-05 Bipolar disorder and schizophrenia PIK3C2A intron 24280982 rs7946010 chr11 17176057 G A 8.27E-04 Schizophrenia PIK3C2A intron 19197363 rs621246 chr11 17203765 G T 6.07E-04 Schizophrenia / / 19197363 rs621246 chr11 17203765 G T 6.38E-05 Body Composition / / pha003012 rs621246 chr11 17203765 G T 6.14E-05 Body Mass Index / / pha003021 rs10766381 chr11 17257045 T A 9.53E-05 Lymphocyte counts / / 22286170 rs12577525 chr11 17260116 G A 2.56E-04 Type 2 diabetes / / 22158537 rs1488933 chr11 17267029 C T 7.70E-04 Schizophrenia / / 19197363 rs7108315 chr11 17267164 C T 7.40E-04 Iris characteristics / / 21835309 rs214097 chr11 17291499 G T 1.33E-04 Schizophrenia / / 19197363 rs214105 chr11 17313521 A G 1.48E-04 Type 2 diabetes NUCB2 intron 22158537 rs1330 chr11 17316029 C T 5.00E-09 Height NUCB2 intron 20881960 rs10766383 chr11 17329798 G T 1.16E-04 Schizophrenia NUCB2 intron 19197363 rs10832757 chr11 17336331 G A 4.60E-05 Lung adenocarcinoma NUCB2 intron 21242121 rs757081 chr11 17351683 C G 8.40E-04 Atrial fibrillation NUCB2 missense 21846873 rs180751580 chr11 17352482 C G 0.000023 Menopause (age at onset) NUCB2 missense 23424626 rs7484027 chr11 17368381 T A 1.10E-05 Type 2 diabetes / / 22158537 rs7928810 chr11 17372443 C A 2.41E-05 Type 2 diabetes / / 22158537 rs2214285 chr11 17380928 C T 1.64E-04 Cholesterol B7H6 intron 17255346 rs9633836 chr11 17401087 T C 3.22E-04 Type 2 diabetes / / 22158537 rs3741203 chr11 17403163 A T 8.08E-04 Type 2 diabetes / / 17463246 rs3741203 chr11 17403163 A T 2.89E-04 Type 2 diabetes / / 22158537 rs1557765 chr11 17403639 T C 1.35E-06 Type 2 diabetes / / 22158537 rs1557765 chr11 17403639 T C 7.00E-06 Social communication problems / / 24564958 rs10766393 chr11 17404652 G A 7.28E-04 Type 2 diabetes / / 17463246 rs1002227 chr11 17405347 C A 6.06E-04 Type 2 diabetes / / 17463246 rs2285676 chr11 17408025 A G 6.50E-06 Schizophrenia KCNJ11 UTR-3 19197363 rs5215 chr11 17408630 C T 5.00E-11 Type 2 diabetes KCNJ11 missense 17463249 rs5215 chr11 17408630 C T 4.00E-07 Type 2 diabetes KCNJ11 missense 18372903 rs5215 chr11 17408630 C T 5.00E-11 Coronary heart disease KCNJ11 missense 21347282 rs5215 chr11 17408630 C T 4.00E-07 Type 2 diabetes KCNJ11 missense 21647700 rs5215 chr11 17408630 C T 2.28E-07 Type 2 diabetes KCNJ11 missense 22158537 rs5215 chr11 17408630 C T 1.03E-09 Type 2 diabetes KCNJ11 missense 22325160 rs5215 chr11 17408630 C T 8.50E-10 Type 2 diabetes KCNJ11 missense 22885922 rs5215 chr11 17408630 C T 5.00E-11 Type 2 diabetes KCNJ11 missense 23300278 rs5215 chr11 17408630 C T 3.00E-11 Type 2 diabetes KCNJ11 missense 24509480 rs5215 chr11 17408630 C T 9.24E-05 Calcium levels KCNJ11 missense pha003085 rs5219 chr11 17409572 T C 1.00E-07 Type 2 diabetes KCNJ11 STOP-GAIN 17463246 rs5219 chr11 17409572 T C 7.00E-11 Type 2 diabetes KCNJ11 STOP-GAIN 17463248 rs5219 chr11 17409572 T C 1.00E-09 Type 2 diabetes KCNJ11 STOP-GAIN 19056611 rs5219 chr11 17409572 T C 5.00E-07 Type 2 diabetes KCNJ11 STOP-GAIN 19056611 rs5219 chr11 17409572 T C 1 Drug response to Repaglinide KCNJ11 STOP-GAIN 20054294 rs5219 chr11 17409572 T C 7.00E-11 Coronary heart disease KCNJ11 STOP-GAIN 21347282 rs886288 chr11 17411163 A G 2.01E-05 Type 2 diabetes KCNJ11 nearGene-5 22158537 rs2074314 chr11 17411821 C T 3.48E-07 Type 2 diabetes KCNJ11 nearGene-5 22158537 rs11024273 chr11 17412717 G T 4.98E-04 Type 2 diabetes / / 17463246 rs7124355 chr11 17412960 A G 1.78E-04 Multiple complex diseases / / 17554300 rs7124355 chr11 17412960 A G 4.00E-07 Type 2 diabetes / / 22158537 rs757110 chr11 17418477 C A 8.38E-06 Type 2 diabetes ABCC8 missense 22158537 rs757110 chr11 17418477 C A 0.0000025 Type 2 diabetes (males) ABCC8 missense 22885922 rs757110 chr11 17418477 C A 0.0000097 Type 2 diabetes (females) ABCC8 missense 22885922 rs4148641 chr11 17421473 G A 8.98E-07 Esophageal cancer (squamous cell) ABCC8 intron 22960999 rs2074311 chr11 17421860 A G 1.03E-04 Blood pressure ABCC8 intron 22100073 rs2074311 chr11 17421860 A G 1.73E-05 Blood pressure ABCC8 intron 22100073 rs2074311 chr11 17421860 A G 2.60E-06 Blood pressure ABCC8 intron 22100073 rs2067043 chr11 17424711 C T 6.33E-04 Type 2 diabetes ABCC8 intron 17463246 rs2067043 chr11 17424711 C T 1.03E-04 Schizophrenia ABCC8 intron 19197363 rs4148634 chr11 17429872 G A 3.48E-05 Pulmonary function in asthmatics ABCC8 intron 23541324 rs7926934 chr11 17433088 A C 2.64E-05 Pulmonary function in asthmatics ABCC8 intron 23541324 rs2299642 chr11 17440868 C T 3.26E-05 Response to Vitamin E supplementation ABCC8 intron 22437554 rs10832786 chr11 17446962 T A 2.44E-04 Type 2 diabetes ABCC8 intron 17463246 rs4148621 chr11 17451427 C A 1.24E-04 Celiac disease ABCC8 intron 23936387 rs4148617 chr11 17455371 G A 5.44E-05 Serum metabolites ABCC8 intron 19043545 rs7106053 chr11 17458730 A G 1.10E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ABCC8 intron 24023788 rs11024286 chr11 17459107 G A 1.58E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ABCC8 intron 24023788 rs12417170 chr11 17460084 T A 2.66E-04 Smoking initiation ABCC8 intron 24665060 rs2237981 chr11 17460899 T C 2.25E-04 Smoking initiation ABCC8 intron 24665060 rs757109 chr11 17462727 G A 2.87E-04 Smoking initiation ABCC8 intron 24665060 rs4459286 chr11 17469466 T C 7.26E-04 Smoking initiation ABCC8 intron 24665060 rs2073586 chr11 17475283 G A 8.15E-05 Longevity ABCC8 intron 21612516 rs4148613 chr11 17476460 C G 0.000000487 Cholesterol,total ABCC8 intron 23063622 rs3758953 chr11 17499547 A G 9.44E-05 Serum albumin level ABCC8 nearGene-5 pha003084 rs2188966 chr11 17499885 C T 5.80E-04 Primary sclerosing cholangitis ABCC8 nearGene-5 19944697 rs12278956 chr11 17508213 G A 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2073584 chr11 17524018 A G 8.22E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) USH1C intron 24192120 rs7104083 chr11 17530484 G A 4.43E-04 Alzheimer's disease (late onset) USH1C intron 21379329 rs17714673 chr11 17534851 G C 7.58E-04 Multiple complex diseases USH1C intron 17554300 rs7129173 chr11 17541798 G A 2.30E-05 Urinary metabolites USH1C intron 21572414 rs7102246 chr11 17562638 T C 2.11E-04 Response to cytidine analogues (gemcitabine) USH1C intron 24483146 rs7113935 chr11 17562722 C T 3.83E-05 Response to cytidine analogues (gemcitabine) USH1C intron 24483146 rs7106302 chr11 17563489 T C 2.95E-04 Response to cytidine analogues (gemcitabine) USH1C intron 24483146 rs4757541 chr11 17567371 A C,T 8.84E-04 Multiple complex diseases USH1C nearGene-5 17554300 rs7130051 chr11 17580050 A C 5.60E-06 Parkinson's disease OTOG intron 17052657 rs11024327 chr11 17601219 G A 1.07E-07 Multiple complex diseases OTOG intron 17554300 rs734640 chr11 17613348 A G 4.00E-04 Chronic fatigue syndrome OTOG intron 21912186 rs11024349 chr11 17656148 A G 7.07E-05 Hemoglobin OTOG intron pha003098 rs11024357 chr11 17667439 G C 2.48E-05 stroke (ischemic) OTOG missense 17434096 rs11024358 chr11 17667561 G T 2.48E-05 stroke (ischemic) / / 17434096 rs869108 chr11 17672112 G A 2.48E-05 stroke (ischemic) / / 17434096 rs4757574 chr11 17726374 A G 1.00E-04 Alcoholism (heaviness of drinking) / / 21529783 rs16934691 chr11 17768545 T C 8.59E-04 Multiple complex diseases KCNC1 intron 17554300 rs17718902 chr11 17784707 G A 0.000179 Oxaliplatin induced neuropathy in response to colorectal cancer treatment KCNC1 intron 22310351 rs60349741 chr11 17796111 A C 5.00E-07 Opioid sensitivity KCNC1 UTR-3 24143882 rs1003921 chr11 17800336 G A 3.39E-05 HIV-1 viral setpoint KCNC1 intron 17641165 rs149628273 chr11 17809762 T C 0.0006 Breast cancer SERGEF missense 23555315 rs12793095 chr11 17812540 T G 5.33E-05 Hemoglobin SERGEF intron pha003096 rs12793095 chr11 17812540 T G 1.39E-05 Hematocrit SERGEF intron pha003097 rs2299634 chr11 17815982 G T 6.03E-04 Type 2 diabetes SERGEF intron 17463246 rs2299634 chr11 17815982 G T 6.22E-04 Coronary Artery Disease SERGEF intron 17634449 rs4756919 chr11 17816412 G A 1.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SERGEF intron 20877124 rs3802970 chr11 17821182 G A 0.000391 Salmonella-induced pyroptosis SERGEF intron 22837397 rs11024408 chr11 17823296 T C 4.75E-04 Response to taxane treatment (placlitaxel) SERGEF intron 23006423 rs4044329 chr11 17888903 G A 0.000793 Salmonella-induced pyroptosis SERGEF intron 22837397 rs2237930 chr11 17897324 A G 8.14E-04 Schizophrenia SERGEF intron 19197363 rs2107426 chr11 17904501 T C 1.89E-04 Type 2 diabetes SERGEF intron 17463246 rs550460 chr11 17923676 A G 5.18E-04 Schizophrenia SERGEF intron 19197363 rs549485 chr11 17923764 T C 8.76E-04 Schizophrenia SERGEF intron 19197363 rs549485 chr11 17923764 T C 2.76E-08 Amyloid A levels SERGEF intron 21124955 rs3993323 chr11 17954082 G A 2.79E-05 Post-operative nausea and vomiting SERGEF intron 21694509 rs2283238 chr11 17978206 T G 9.44E-04 Multiple complex diseases SERGEF intron 17554300 rs211146 chr11 17981047 C T 6.99E-05 Height SERGEF cds-synon pha003011 rs211141 chr11 17994314 G A 6.99E-05 Height SERGEF intron pha003011 rs10741734 chr11 18044648 A G 3.72E-06 Multiple complex diseases TPH1 intron 17554300 rs1800532 chr11 18047816 G T 7.86E-04 Insulin resistance TPH1 intron 21901158 rs7130929 chr11 18068163 C A 2.22E-04 Lung function (forced vital capacity) / / 24023788 rs1079785 chr11 18072273 C T 7.92E-04 Body mass index / / 21701565 rs7950928 chr11 18073212 C G 8.24E-04 Body mass index / / 21701565 rs7937368 chr11 18073429 A T 5.74E-04 Body mass index / / 21701565 rs7131255 chr11 18117362 A G 1.46E-04 Smoking initiation SAAL1 intron 24665060 rs11024491 chr11 18126491 G A 6.97E-04 Alzheimer's disease SAAL1 intron 22005930 rs10832890 chr11 18172814 T A 7.52E-05 Arthritis (juvenile idiopathic) / / 22354554 rs2445149 chr11 18214518 T C 5.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2445147 chr11 18216160 T C 9.85E-04 Multiple complex diseases / / 17554300 rs12282742 chr11 18265799 C T 1.00E-06 Bipolar disorder and schizophrenia SAA2 intron 20889312 rs2468844 chr11 18267027 C A,T 3.21E-05 Type 1 diabetes SAA2 missense 21980299 rs7113375 chr11 18267997 A T 9.98E-04 Suicide attempts in bipolar disorder SAA2 intron 21423239 rs7113375 chr11 18267997 A T 2.88E-04 Response to taxane treatment (placlitaxel) SAA2 intron 23006423 rs3825023 chr11 18270669 C T 3.14E-06 Hepatocellular carcinoma / / 22807686 rs10832911 chr11 18275661 G A 1.62E-04 Multiple complex diseases / / 17554300 rs11024585 chr11 18276223 C T 9.70E-06 Bipolar disorder and schizophrenia / / 20889312 rs11024586 chr11 18276336 A G 8.73E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2045272 chr11 18278098 T G 4.09E-17 Amyloid A Levels / / 21124955 rs7950019 chr11 18278912 G A 1.40E-48 Amyloid A Levels / / 21124955 rs7950019 chr11 18278912 G A 5.04E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1993373 chr11 18280635 A G 4.21E-49 Amyloid A Levels / / 21124955 rs7112278 chr11 18281916 C T 2.09E-48 Amyloid A Levels / / 21124955 rs7112278 chr11 18281916 C T 8.84E-06 Squamous cell carcinoma / / 23341777 rs11024591 chr11 18285205 C T 9.59E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4638289 chr11 18285774 A T 3.00E-53 Amyloid A Levels / / 21124955 rs12218 chr11 18291321 T C 2.18E-18 Amyloid A Levels SAA1 cds-synon 21124955 rs7131332 chr11 18295523 A G 3.22E-15 Amyloid A Levels / / 21124955 rs11024600 chr11 18295810 T C 8.22E-15 Amyloid A Levels / / 21124955 rs1046615 chr11 18300954 G A 2.95E-09 Amyloid A Levels HPS5 UTR-3 21124955 rs1046615 chr11 18300954 G A 4.28E-04 Smoking initiation HPS5 UTR-3 24665060 rs12416821 chr11 18301129 A G 3.07E-09 Amyloid A Levels HPS5 UTR-3 21124955 rs201668750 chr11 18301129 AG A 3.07E-09 Amyloid A Levels HPS5 UTR-3 21124955 rs12419588 chr11 18301130 G A 3.07E-09 Amyloid A Levels HPS5 UTR-3 21124955 rs2271997 chr11 18303404 C T 8.67E-19 Amyloid A Levels HPS5 intron 21124955 rs2049129 chr11 18305333 T C 1.12E-08 Amyloid A Levels HPS5 intron 21124955 rs12291480 chr11 18305757 G C 3.57E-10 Amyloid A Levels HPS5 intron 21124955 rs3781945 chr11 18306272 G A 3.89E-22 Amyloid A Levels HPS5 intron 21124955 rs11024603 chr11 18306399 G A 8.05E-13 Amyloid A Levels HPS5 intron 21124955 rs4757637 chr11 18307575 C A 2.10E-35 Amyloid A Levels HPS5 intron 21124955 rs1520884 chr11 18309700 A G 3.03E-49 Amyloid A Levels HPS5 intron 21124955 rs7117069 chr11 18311607 G A 1.10E-04 Multiple complex diseases HPS5 intron 17554300 rs11024605 chr11 18311701 T C 2.64E-04 Colorectal cancer HPS5 intron 24737748 rs4757638 chr11 18312953 G A 1.12E-46 Amyloid A Levels HPS5 intron 21124955 rs2305564 chr11 18317458 T A 3.76E-34 Amyloid A Levels HPS5 intron 21124955 rs4353250 chr11 18323517 T C 2.00E-51 Amyloid A Levels HPS5 intron 21124955 rs2403254 chr11 18325146 C T 6.07E-36 Amyloid A Levels HPS5 intron 21124955 rs2403254 chr11 18325146 C T 1.00E-20 Metabolic traits HPS5 intron 21886157 rs2403254 chr11 18325146 C T 1.00E-30 Blood metabolite levels HPS5 intron 24816252 rs11024613 chr11 18326542 T C 3.74E-36 Amyloid A Levels HPS5 intron 21124955 rs11024614 chr11 18326758 C T 5.05E-42 Amyloid A Levels HPS5 intron 21124955 rs1140047 chr11 18327684 G T 2.27E-51 Amyloid A levels HPS5 cds-synon 21124955 rs1140047 chr11 18327684 G T 2.27E-51 Amyloid A Levels HPS5 cds-synon 21124955 rs2061164 chr11 18329006 T C 1.92E-51 Amyloid A Levels HPS5 intron 21124955 rs10832918 chr11 18335684 G A 1.09E-24 Amyloid A Levels HPS5 intron 21124955 rs10832920 chr11 18341869 A G 6.35E-36 Amyloid A Levels HPS5 intron 21124955 rs10741741 chr11 18342081 T C 1.96E-49 Amyloid A Levels HPS5 intron 21124955 rs3825025 chr11 18343822 C G 5.32E-51 Amyloid A Levels GTF2H1 UTR-5 21124955 rs3802967 chr11 18344064 T C 5.18E-36 Amyloid A Levels GTF2H1 UTR-5 21124955 rs4150550 chr11 18350898 C G 9.77E-51 Amyloid A Levels GTF2H1 intron 21124955 rs4150550 chr11 18350898 C G 1.13E-05 Pancreatic cancer GTF2H1 intron 23180869 rs4150561 chr11 18354877 T C 1.54E-50 Amyloid A Levels GTF2H1 intron 21124955 rs4150561 chr11 18354877 T C 1.12E-05 Pancreatic cancer GTF2H1 intron 23180869 rs4150562 chr11 18354995 A G 1.58E-50 Amyloid A Levels GTF2H1 intron 21124955 rs4150562 chr11 18354995 A G 1.12E-05 Pancreatic cancer GTF2H1 intron 23180869 rs4150563 chr11 18355102 T G 2.15E-18 Amyloid A Levels GTF2H1 intron 21124955 rs4150564 chr11 18355308 G A 1.66E-50 Amyloid A Levels GTF2H1 intron 21124955 rs4150564 chr11 18355308 G A 1.08E-05 Pancreatic cancer GTF2H1 intron 23180869 rs4150575 chr11 18356466 C T 2.06E-50 Amyloid A Levels GTF2H1 intron 21124955 rs4150575 chr11 18356466 C T 1.08E-05 Pancreatic cancer GTF2H1 intron 23180869 rs4150579 chr11 18357180 A G 2.63E-46 Amyloid A Levels GTF2H1 intron 21124955 rs4150579 chr11 18357180 A G 1.08E-05 Pancreatic cancer GTF2H1 intron 23180869 rs4150581 chr11 18357270 A G 7.68E-32 Amyloid A Levels GTF2H1 intron 21124955 rs4150581 chr11 18357270 A G 2.00E-37 Blood metabolite ratios GTF2H1 intron 24816252 rs4150606 chr11 18363569 C A 3.54E-41 Amyloid A Levels GTF2H1 intron 21124955 rs4150610 chr11 18364140 A G 1.83E-50 Amyloid A Levels GTF2H1 intron 21124955 rs4150610 chr11 18364140 A G 1.10E-05 Pancreatic cancer GTF2H1 intron 23180869 rs4150612 chr11 18364358 G T 1.82E-50 Amyloid A Levels GTF2H1 intron 21124955 rs4150612 chr11 18364358 G T 1.10E-05 Pancreatic cancer GTF2H1 intron 23180869 rs4150615 chr11 18365028 C T 8.49E-49 Amyloid A Levels GTF2H1 intron 21124955 rs4150615 chr11 18365028 C T 1.09E-05 Pancreatic cancer GTF2H1 intron 23180869 rs4150616 chr11 18365114 A T 1.79E-50 Amyloid A Levels GTF2H1 intron 21124955 rs4150616 chr11 18365114 A T 1.10E-05 Pancreatic cancer GTF2H1 intron 23180869 rs4150622 chr11 18365710 A G 8.67E-47 Amyloid A Levels GTF2H1 intron 21124955 rs4150622 chr11 18365710 A G 1.40E-05 Pancreatic cancer GTF2H1 intron 23180869 rs4150628 chr11 18365868 G A 3.44E-41 Amyloid A Levels GTF2H1 intron 21124955 rs4150641 chr11 18370739 C A 1.79E-50 Amyloid A Levels GTF2H1 intron 21124955 rs4150642 chr11 18370898 G C 3.00E-111 Amyloid A levels GTF2H1 intron 21124955 rs4150642 chr11 18370898 G C 3.20E-111 Amyloid A Levels GTF2H1 intron 21124955 rs11024625 chr11 18371560 A C 1.31E-08 Lymphocyte counts GTF2H1 intron 22286170 rs4150650 chr11 18374279 G A 1.79E-50 Amyloid A Levels GTF2H1 intron 21124955 rs4150651 chr11 18374425 T C 1.79E-50 Amyloid A Levels GTF2H1 intron 21124955 rs4150655 chr11 18375164 A T 3.99E-47 Amyloid A Levels GTF2H1 intron 21124955 rs7103375 chr11 18375533 G A 3.26E-111 Amyloid A Levels GTF2H1 intron 21124955 rs4150661 chr11 18379629 C A 1.80E-50 Amyloid A Levels GTF2H1 intron 21124955 rs3740711 chr11 18379839 T C 1.81E-50 Amyloid A Levels GTF2H1 intron 21124955 rs2037867 chr11 18382021 A G 2.17E-35 Amyloid A Levels GTF2H1 intron 21124955 rs4150667 chr11 18382911 C A,T 2.31E-16 Amyloid A Levels GTF2H1 intron 21124955 rs4150673 chr11 18383449 T G 1.26E-44 Amyloid A Levels GTF2H1 intron 21124955 rs4150673 chr11 18383449 T G 1.17E-05 Pancreatic cancer GTF2H1 intron 23180869 rs9783347 chr11 18384938 A G 2.08E-50 Amyloid A Levels GTF2H1 intron 21124955 rs9783347 chr11 18384938 A G 9.00E-06 Pancreatic cancer GTF2H1 intron 23180869 rs4596 chr11 18388128 G C 2.17E-35 Amyloid A Levels GTF2H1 UTR-3 21124955 rs4596 chr11 18388128 G C 1.00E-04 Pancreatic cancer GTF2H1 UTR-3 23180869 rs9988866 chr11 18392983 T A 3.68E-50 Amyloid A Levels / / 21124955 rs4757645 chr11 18393845 C G 3.26E-37 Amyloid A Levels / / 21124955 rs4757645 chr11 18393845 C G 7.00E-04 Pancreatic cancer / / 23180869 rs7112492 chr11 18405510 G T 3.87E-13 Lymphocyte counts / / 22286170 rs2896526 chr11 18419806 A G 4.00E-22 Amyloid A Levels LDHA intron 21124955 rs2056781 chr11 18444989 G A 1.98E-16 Amyloid A Levels LDHC intron 21124955 rs3740713 chr11 18451096 A C 2.84E-15 Amyloid A Levels LDHC intron 21124955 rs3740713 chr11 18451096 A C 9.00E-06 Amyotrophic lateral sclerosis (sporadic) LDHC intron 24529757 rs16935424 chr11 18456737 A T 2.13E-16 Amyloid A Levels LDHC intron 21124955 rs35593189 chr11 18468378 G A 4.66E-12 Amyloid A Levels LDHC intron 21124955 rs16935432 chr11 18470487 G A 2.28E-16 Amyloid A Levels LDHC intron 21124955 rs12289603 chr11 18471370 T C 2.29E-16 Amyloid A Levels LDHC intron 21124955 rs11024665 chr11 18488219 G A 7.70E-08 Platelet aggregation(pre- and post-aspirin) LDHAL6A intron 20529293 rs59530834 chr11 18488219 G GAA 7.70E-08 Platelet aggregation(pre- and post-aspirin) LDHAL6A intron 20529293 rs16935476 chr11 18509993 C T 8.63E-05 Platelet counts TSG101 intron pha003100 rs11024717 chr11 18591571 A G 1.78E-06 Lymphocyte counts UEVLD intron 22286170 rs10128711 chr11 18632984 T C 3.00E-08 Cholesterol,total SPTY2D1 intron 20686565 rs10128711 chr11 18632984 T C 1.00E-11 Cholesterol,total SPTY2D1 intron 24097068 rs10500833 chr11 18638853 T C 3.49E-04 Stroke SPTY2D1 intron pha002886 rs11024739 chr11 18645843 C A 2.70E-05 Height SPTY2D1 intron 21194676 rs11024739 chr11 18645843 C A 2.70E-07 Height SPTY2D1 intron 21194676 rs11024739 chr11 18645843 C A 3.80E-11 Height SPTY2D1 intron 21194676 rs11024739 chr11 18645843 C A 0.0000134 Cholesterol,total SPTY2D1 intron 23063622 rs11024739 chr11 18645843 C A 6.04E-10 LDL cholesterol SPTY2D1 intron 23063622 rs12295403 chr11 18689653 C A 5.00E-06 Ovarian reserve / / 22116950 rs4757695 chr11 18690219 C T 7.31E-05 Coronary heart disease / / pha003030 rs7129477 chr11 18721491 C T 2.41E-04 Multiple complex diseases TMEM86A intron 17554300 rs10832973 chr11 18738784 T C 4.81E-05 Cognitive test performance IGSF22 intron 20125193 rs1550871 chr11 18750886 G A 7.01E-04 Alzheimer's disease PTPN5 intron 24755620 rs11024789 chr11 18785042 C A 1.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTPN5 intron 20877124 rs4074853 chr11 18792880 T C 1.03E-04 Vaspin levels PTPN5 intron 22907691 rs4074853 chr11 18792880 T C 0.0001026 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks PTPN5 intron 22907730 rs4274187 chr11 18794248 G C 6.80E-06 Urinary metabolites PTPN5 intron 21572414 rs7117716 chr11 18808355 C T 6.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTPN5 intron 20877124 rs7932938 chr11 18815295 T G 7.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4627050 chr11 18822037 A G 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs4756971 chr11 18843233 T C 1.63E-04 Type 2 diabetes / / 17463246 rs4414194 chr11 18859517 C T 6.87E-04 Multiple complex diseases / / 17554300 rs10766509 chr11 18864417 C A 7.45E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11024832 chr11 18866075 T C 2.50E-06 Digit length ratio / / 20303062 rs7931749 chr11 18866730 C A 2.43E-04 Type 2 diabetes / / 17463246 rs6483541 chr11 18866999 A G 9.17E-04 Multiple complex diseases / / 17554300 rs4756973 chr11 18870823 A G 3.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs4325289 chr11 18887459 C G 5.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs1384641 chr11 18888866 G C 4.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs1384642 chr11 18889441 A G 4.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs12804599 chr11 18893337 A T 3.79E-04 Alzheimer's disease / / 17998437 rs4757732 chr11 18901853 T C 5.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs7946938 chr11 18903604 C T 5.98E-05 Bipolar disorder / / 18317468 rs7946938 chr11 18903604 C T 6.42E-05 Schizophrenia / / 19571809 rs7946938 chr11 18903604 C T 9.86E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs2200174 chr11 18921030 A G 6.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs2896547 chr11 18927720 A G 7.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs6483549 chr11 18928285 G C 7.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs1384648 chr11 18929432 T C 7.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs1973238 chr11 18932026 G C 7.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs1842921 chr11 18974860 G A 3.95E-04 Premature ovarian failure / / 19508998 rs6483561 chr11 19009495 T C 6.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2170655 chr11 19021421 C T 4.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7114488 chr11 19038151 A G 6.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1483103 chr11 19044149 C T 5.94E-04 Multiple complex diseases / / 17554300 rs7121852 chr11 19045102 C A 8.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7111562 chr11 19051872 T C 2.00E-06 IgG glycosylation / / 23382691 rs7111562 chr11 19051872 T C 4.00E-07 IgG glycosylation / / 23382691 rs11024968 chr11 19075627 T C 3.83E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7104797 chr11 19078468 G T 2.90E-06 Urinary metabolites MRGPRX2 intron 21572414 rs7104554 chr11 19078514 A G 2.60E-05 Urinary metabolites MRGPRX2 intron 21572414 rs1503504 chr11 19079033 G T 1.60E-05 Urinary metabolites MRGPRX2 intron 21572414 rs905553 chr11 19082979 A G 5.30E-04 Coronary heart disease / / 21606135 rs1503502 chr11 19083477 C T 2.44E-04 Coronary heart disease / / 21606135 rs12222200 chr11 19084116 T C 1.47E-04 Coronary heart disease / / 21606135 rs11024975 chr11 19092070 A G 3.17E-04 Coronary heart disease / / 21606135 rs878256 chr11 19094434 A C 8.68E-04 Coronary heart disease / / 21606135 rs2062819 chr11 19097685 G A 6.58E-04 Multiple complex diseases / / 17554300 rs10766527 chr11 19100736 G A 0.000071 Asthma / / 22694930 rs11024979 chr11 19106045 C T 0.0000454 Asthma / / 22694930 rs16936115 chr11 19108683 T C 0.0000679 Asthma / / 22694930 rs10500839 chr11 19113320 C G 2.66E-04 Type 2 diabetes / / 17463246 rs11025001 chr11 19118317 T C 1.92E-05 Hemoglobin / / pha003096 rs4757753 chr11 19118703 T C 9.56E-05 Cognitive test performance / / 20125193 rs4757753 chr11 19118703 T C 1.92E-05 Hemoglobin / / pha003096 rs1962511 chr11 19120676 C T 9.53E-04 Type 2 diabetes / / 17463246 rs11025033 chr11 19163451 C T 7.60E-04 Amyotrophic Lateral Sclerosis ZDHHC13 intron 17827064 rs1393957 chr11 19172911 C T 7.90E-04 Stroke ZDHHC13 intron pha002887 rs2042688 chr11 19186294 C A 6.34E-05 Serum metabolites ZDHHC13 intron 19043545 rs3781799 chr11 19208319 A G 8.93E-05 Magnesium levels CSRP3 intron pha003092 rs12290313 chr11 19218090 G A 3.09E-04 Multiple complex diseases CSRP3 intron 17554300 rs7951347 chr11 19219578 T A 0.000000655 LDL cholesterol CSRP3 intron 23063622 rs7951347 chr11 19219578 T A 1.44E-13 Triglycerides CSRP3 intron 23063622 rs2553974 chr11 19238380 A C 2.00E-04 Information processing speed / / 21130836 rs924693 chr11 19244377 C T 6.51E-04 Coronary heart disease / / 21971053 rs924693 chr11 19244377 C T 9.97E-06 Response to antidepressant treatment (citalopram) / / 23726668 rs1698892 chr11 19244495 C T 4.71E-04 Multiple complex diseases / / 17554300 rs12273001 chr11 19251289 C G 3.57E-05 Relative hand skill E2F8 cds-synon 24068947 rs12273302 chr11 19251704 G A 3.40E-05 Relative hand skill E2F8 intron 24068947 rs201855427 chr11 19256365 A G 0.00037 Breast cancer (ER positive) E2F8 missense 23555315 rs11025082 chr11 19297062 G A 5.10E-05 Malaria / / 19465909 rs1024081 chr11 19371616 A T 3.40E-05 Multiple complex diseases /V2 nearGene-5 17554300 rs11025105 chr11 19373169 C T 0.00045 Breast cancer /V2 intron 22228098 rs11025105 chr11 19373169 C T 8.89E-04 Acute lung injury /V2 intron 22295056 rs2202233 chr11 19383023 C A 3.08E-04 Multiple complex diseases /V2 intron 17554300 rs16936620 chr11 19389534 C T 1.26E-04 Multiple complex diseases /V2 intron 17554300 rs2729894 chr11 19389561 A G 3.08E-04 Multiple complex diseases /V2 intron 17554300 rs4757794 chr11 19410320 T C 4.80E-04 Insulin resistance /V2 intron 21901158 rs2702662 chr11 19414291 G A 5.01E-05 Insulin resistance /V2 intron 21901158 rs10766548 chr11 19416865 T C 2.29E-04 Insulin resistance /V2 intron 21901158 rs2729908 chr11 19422480 G A 1.40E-04 Type 2 diabetes /V2 intron 17463246 rs2729910 chr11 19423117 T C 1.58E-05 Adverse response to lamotrigine and phenytoin /V2 intron 22379998 rs10833107 chr11 19431413 G T 4.95E-04 Tourette syndrome /V2 intron 22889924 rs11025134 chr11 19450627 G T 2.50E-05 Urinary metabolites /V2 intron 21572414 rs11025134 chr11 19450627 G T 8.11E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines /V2 intron 21844884 rs11025135 chr11 19451020 C T 2.36E-05 Major depressive disorder /V2 intron 22472876 rs11025135 chr11 19451020 C T 9.59E-04 Response to cytadine analogues (cytosine arabinoside) /V2 intron 24483146 rs10500847 chr11 19451505 T A 3.91E-05 Major depressive disorder /V2 intron 22472876 rs10766559 chr11 19464246 G A 8.61E-04 Tourette syndrome /V2 intron 22889924 rs2632010 chr11 19466720 G A 6.20E-05 Major depressive disorder /V2 intron 22472876 rs2046575 chr11 19467431 T C 9.82E-05 Major depressive disorder /V2 intron 22472876 rs1386449 chr11 19488083 A G 5.68E-06 Alcohol dependence /V2 intron 20202923 rs1386449 chr11 19488083 A G 4.20E-05 Alcohol dependence /V2 intron 21956439 rs16936804 chr11 19492345 G C 5.69E-04 Multiple complex diseases /V2 intron 17554300 rs10833118 chr11 19493206 A G 9.85E-04 Multiple complex diseases /V2 intron 17554300 rs2729881 chr11 19494407 A C 4.88E-04 Type 2 diabetes /V2 intron 17463246 rs2702719 chr11 19501671 A G 7.71E-04 Multiple complex diseases /V2 intron 17554300 rs1055543 chr11 19532506 T C 8.47E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) /V2 intron 23648065 rs2013380 chr11 19536099 A G 2.21E-04 Myocardial Infarction /V2 intron pha002883 rs2632057 chr11 19541784 T C 9.52E-05 Asthma /V2 intron pha003127 rs2702646 chr11 19546520 T G 0.0000525 Asthma /V2 intron 22694930 rs2702628 chr11 19546842 C T 0.0000524 Asthma /V2 intron 22694930 rs1906217 chr11 19549934 A G 1.70E-05 Urinary metabolites /V2 intron 21572414 rs7117077 chr11 19554417 T C 4.60E-04 Type 2 diabetes /V2 intron 17463246 rs717195 chr11 19565769 A C 5.90E-04 Type 2 diabetes and 6 quantitative traits /V2 intron 17848626 rs7950505 chr11 19566243 A G 6.70E-04 Type 2 diabetes and 6 quantitative traits /V2 intron 17848626 rs874426 chr11 19569563 C A 4.00E-06 Attention deficit hyperactivity disorder (time to onset) /V2 intron 18937294 rs874426 chr11 19569563 C A 2.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) /V2 intron 20877124 rs10500856 chr11 19584502 A G 7.00E-06 Obesity-related traits /V2 intron 23251661 rs10741780 chr11 19599971 T C 6.00E-06 HIV-1 susceptibility /V2 intron 22174851 rs16937030 chr11 19610009 C T 4.40E-04 Multiple complex diseases /V2 intron 17554300 rs7930097 chr11 19619240 G A 1.15E-04 Multiple complex diseases /V2 intron 17554300 rs714585 chr11 19668438 A G 5.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) /V2 intron 23648065 rs744854 chr11 19669475 C T 3.52E-04 Multiple complex diseases /V2 intron 17554300 rs744854 chr11 19669475 C T 2.36E-04 Insulin resistance /V2 intron 21901158 rs16937089 chr11 19682960 T A 1.62E-04 Insulin resistance /V2 intron 21901158 rs7927786 chr11 19701701 A G 4.88E-04 Suicide attempts in bipolar disorder /V2 intron 21423239 rs7113050 chr11 19703368 A G 6.17E-04 Suicide attempts in bipolar disorder /V2 intron 21423239 rs12295525 chr11 19705232 C T 7.44E-08 Multiple complex diseases /V2 intron 17554300 rs1559664 chr11 19749929 G A 0.0000093 Mean arterial pressure /V2 intron 22510845 rs2042600 chr11 19752699 T G 2.28E-05 Migraine /V2 intron 20802479 rs1425227 chr11 19756789 T C 7.15E-05 Lipoproteins /V2 intron pha003079 rs7481639 chr11 19764500 A G 5.29E-05 Multiple complex diseases /V2 intron 17554300 rs1425228 chr11 19765965 T A,G 0.00017 Breast cancer /V2 intron 22228098 rs1425229 chr11 19765978 A G 0.000168 Breast cancer /V2 intron 22228098 rs1425230 chr11 19766264 T C 0.000136 Breast cancer /V2 intron 22228098 rs7126318 chr11 19766712 C T 0.000143 Breast cancer /V2 intron 22228098 rs4757841 chr11 19767614 A G 7.67E-05 Intelligence /V2 intron 21826061 rs4757841 chr11 19767614 A G 0.000042 Breast cancer /V2 intron 22228098 rs12422062 chr11 19768852 A G 0.000104 Breast cancer /V2 intron 22228098 rs4757842 chr11 19771054 C T 6.54E-05 Intelligence /V2 intron 21826061 rs11025239 chr11 19774304 T C 6.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) /V2 intron 20877124 rs2004083 chr11 19790494 T C 4.72E-05 Stroke /V2 intron pha002886 rs7931362 chr11 19811187 T C 1.26E-04 Glycosylated haemoglobin levels /V2 intron 17255346 rs918988 chr11 19817809 T C 3.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) /V2 intron 20877124 rs10833177 chr11 19829331 A C 4.40E-05 Insulin resistance /V2 intron 21901158 rs7933416 chr11 19829789 T C 8.71E-04 Coronary Artery Disease /V2 intron 17634449 rs10766597 chr11 19835031 C T 3.89E-04 Coronary Artery Disease /V2 intron 17634449 rs10766597 chr11 19835031 C T 7.00E-06 Urinary metabolites /V2 intron 21572414 rs11025279 chr11 19853393 T G 8.50E-06 Urinary metabolites /V2 intron 21572414 rs7925366 chr11 19860949 C T 8.84E-04 Body mass index /V2 intron 21701565 rs17531257 chr11 19861308 A C 8.60E-06 Urinary metabolites /V2 intron 21572414 rs12287043 chr11 19871270 G A 6.56E-04 Amyotrophic Lateral Sclerosis /V2 intron 17362836 rs16937206 chr11 19871514 C T 6.62E-04 Telomere length /V2 intron 23900074 rs10833185 chr11 19877561 G A 8.94E-04 Body mass index /V2 intron 21701565 rs11025299 chr11 19885124 A T 0.000219 Breast cancer /V2 intron 22228098 rs11025300 chr11 19886689 G A 1.15E-05 Triglycerides /V2 intron 19074352 rs11025300 chr11 19886689 G A 1.15E-05 Polyunsaturated fatty acid levels,in plasma /V2 intron 19148276 rs2585789 chr11 19891456 G A 6.26E-04 Body mass index /V2 intron 21701565 rs2585753 chr11 19895756 C G 8.54E-04 Type 2 diabetes /V2 intron 17463246 rs2585758 chr11 19902690 T A 6.19E-04 Body mass index /V2 intron 21701565 rs12575413 chr11 19904490 A G 0.000157 Breast cancer /V2 intron 22228098 rs2707096 chr11 19908690 C T 0.000186 Breast cancer /V2 intron 22228098 rs7939327 chr11 19910115 C A 0.000529 Salmonella-induced pyroptosis /V2 intron 22837397 rs2707098 chr11 19911733 G A 6.32E-04 Body mass index /V2 intron 21701565 rs2165798 chr11 19912781 G A 0.000215 Breast cancer /V2 intron 22228098 rs7106863 chr11 19919909 A G 2.06E-04 Sudden cardiac arrest /V2 intron 21658281 rs4757860 chr11 19939214 A G 0.000524 Breast cancer /V2 intron 22228098 rs2099895 chr11 19939764 C T 0.000285 Breast cancer /V2 intron 22228098 rs11025325 chr11 19939841 C T 0.000116 Breast cancer /V2 intron 22228098 rs11025326 chr11 19940506 T C 0.000074 Breast cancer /V2 intron 22228098 rs716172 chr11 19940916 A T 0.000255 Breast cancer /V2 intron 22228098 rs716173 chr11 19940979 G A 0.000069 Breast cancer /V2 intron 22228098 rs10833193 chr11 19941378 A G 0.000074 Breast cancer /V2 intron 22228098 rs10833194 chr11 19942683 G T 0.00007 Breast cancer /V2 intron 22228098 rs10444256 chr11 19943353 T C 0.000081 Breast cancer /V2 intron 22228098 rs4757861 chr11 19944878 C T 0.00026 Breast cancer /V2 intron 22228098 rs7109223 chr11 19945595 G A 0.000255 Breast cancer /V2 intron 22228098 rs10444227 chr11 19945852 A C 0.0000064 Breast cancer /V2 intron 22228098 rs536403196 chr11 19945852 A AC 0.0000064 Breast cancer /V2 intron 22228098 rs7109389 chr11 19945890 C T 0.000186 Breast cancer /V2 intron 22228098 rs920719 chr11 19946239 G A 0.0002 Breast cancer /V2 intron 22228098 rs920720 chr11 19946348 G C 0.000272 Breast cancer /V2 intron 22228098 rs7117201 chr11 19947089 G A 0.000899 Breast cancer /V2 intron 22228098 rs2707081 chr11 19948073 G A 0.000767 Breast cancer /V2 intron 22228098 rs12225529 chr11 19948499 G A 0.000128 Breast cancer /V2 intron 22228098 rs34249590 chr11 19949536 A G 0.000012 Breast cancer /V2 intron 22228098 rs17612287 chr11 19953089 C T 7.38E-05 Cognitive test performance /V2 intron 20125193 rs10833195 chr11 19953442 C T 0.000014 Breast cancer /V2 intron 22228098 rs10833197 chr11 19953492 C A 1.10E-05 Urinary metabolites /V2 intron 21572414 rs10833197 chr11 19953492 C A 9.47E-05 Cognitive impairment induced by topiramate /V2 intron 22091778 rs10833197 chr11 19953492 C A 0.000013 Breast cancer /V2 intron 22228098 rs16937251 chr11 19955194 G C 9.05E-04 Response to taxane treatment (placlitaxel) /V2 missense 23006423 rs11025328 chr11 19956131 A G 8.80E-06 Urinary metabolites /V2 intron 21572414 rs11025328 chr11 19956131 A G 0.000028 Breast cancer /V2 intron 22228098 rs11025329 chr11 19956289 A G 8.80E-06 Urinary metabolites /V2 intron 21572414 rs11025329 chr11 19956289 A G 5.80E-05 Cognitive impairment induced by topiramate /V2 intron 22091778 rs11025329 chr11 19956289 A G 0.000014 Breast cancer /V2 intron 22228098 rs1372990 chr11 19956593 C T 0.000051 Breast cancer /V2 intron 22228098 rs894558 chr11 19956790 C T 5.12E-04 Myocardial Infarction /V2 intron pha002883 rs10833198 chr11 19956948 A G 0.000044 Breast cancer /V2 intron 22228098 rs11025331 chr11 19957675 A G 0.000038 Breast cancer /V2 intron 22228098 rs11025332 chr11 19957715 A G 0.000045 Breast cancer /V2 intron 22228098 rs10833200 chr11 19957779 T A 0.000046 Breast cancer /V2 intron 22228098 rs12807015 chr11 19960147 G T 5.98E-05 Response to cytadine analogues (cytosine arabinoside) /V2 intron 24483146 rs10766606 chr11 19960636 C T 8.40E-06 Urinary metabolites /V2 intron 21572414 rs10833202 chr11 19961663 A G 1.60E-05 Urinary metabolites /V2 intron 21572414 rs2585769 chr11 19962033 C T 9.19E-05 Response to cytadine analogues (cytosine arabinoside) /V2 intron 24483146 rs11025336 chr11 19972603 C T 2.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) /V2 intron 20877124 rs11025336 chr11 19972603 C T 5.22E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) /V2 intron 20877124 rs2585780 chr11 19976319 G T 5.90E-04 Type 2 diabetes /V2 intron 17463246 rs4409798 chr11 19981727 G C 4.96E-04 Multiple complex diseases /V2 intron 17554300 rs2568127 chr11 19990698 T C 3.05E-04 Multiple complex diseases /V2 intron 17554300 rs716667 chr11 19997804 G A 1.31E-04 Parkinson's disease /V2 intron 21248740 rs2625295 chr11 19998919 T C 8.32E-04 Smoking cessation /V2 intron 24665060 rs17614100 chr11 20009445 A G 1.00E-04 Cognitive impairment induced by topiramate /V2 intron 22091778 rs4757023 chr11 20015220 T C 1.28E-04 Parkinson's disease /V2 intron 21248740 rs2625305 chr11 20021253 A T 3.00E-05 Parkinson's disease (age of onset) /V2 intron 19772629 rs4757024 chr11 20038136 A G 7.19E-06 Post-operative nausea and vomiting /V2 intron 21694509 rs920672 chr11 20050143 A G 9.34E-04 Type 2 diabetes /V2 intron 17463246 rs920672 chr11 20050143 A G 5.79E-08 Asthma (childhood onset) /V2 intron 23829686 rs10833224 chr11 20054888 G A 8.83E-04 Type 2 diabetes /V2 intron 22158537 rs6483638 chr11 20091690 G A 7.40E-04 Multiple complex diseases /V2 intron 17554300 rs6483639 chr11 20091724 T C 3.84E-04 Multiple complex diseases /V2 intron 17554300 rs10734289 chr11 20098670 T G 1.34E-05 Coronary heart disease /V2 intron pha003033 rs1867122 chr11 20106884 C G 7.70E-04 Alzheimer's disease /V2 intron 22005930 rs2005163 chr11 20108966 G A 0.000790388 Hypertension (early onset hypertension) /V2 intron 22479346 rs7131316 chr11 20110589 T C 7.99E-04 Alzheimer's disease /V2 intron 22005930 rs2255674 chr11 20115277 C T 0.000535828 Hypertension (early onset hypertension) /V2 intron 22479346 rs10741818 chr11 20120853 A G 1.00E-05 Soluble levels of adhesion molecules /V2 intron pha003072 rs1470253 chr11 20121457 A G 7.10E-05 Soluble levels of adhesion molecules /V2 intron pha003072 rs1470251 chr11 20121592 T C 2.30E-05 Soluble levels of adhesion molecules /V2 intron pha003072 rs144927008 chr11 20139768 T A 0.000011 Prostate cancer (advanced) /V2 missense 23555315 rs1348303 chr11 20154539 C T 0.000518 Breast cancer / / 22228098 rs11025404 chr11 20156114 G A 0.000622 Breast cancer / / 22228098 rs831468 chr11 20156256 G C 0.00043 Breast cancer / / 22228098 rs10833252 chr11 20158838 T G 0.000712 Breast cancer / / 22228098 rs10766631 chr11 20159865 T C 2.09E-04 Smoking quantity / / 24665060 rs6483645 chr11 20171947 G C 4.50E-05 Height / / 19396169 rs11025421 chr11 20199278 C A 7.71E-04 Alcohol dependence / / 24277619 rs11025430 chr11 20213955 A G 5.81E-04 Aortic root size / / 21223598 rs11025430 chr11 20213955 A G 1.40E-06 Urinary metabolites / / 21572414 rs9943568 chr11 20229616 C T 5.80E-06 Urinary metabolites / / 21572414 rs10500872 chr11 20245723 T C 0.00000649 Gains in maximal O2 uptake response / / 21183627 rs1589379 chr11 20252106 C A 8.30E-06 Urinary metabolites / / 21572414 rs1553075 chr11 20261282 T G 1.64E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7114948 chr11 20265327 G C 1.15E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1520896 chr11 20269390 A G 1.08E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1520895 chr11 20275946 G A 2.91E-04 Celiac disease / / 23936387 rs16905904 chr11 20280844 T C 7.77E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7125509 chr11 20285788 G T 1.57E-04 Multiple complex diseases / / 17554300 rs7950594 chr11 20286574 G A 1.72E-04 Celiac disease / / 23936387 rs988659 chr11 20291315 G A 9.83E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1108001 chr11 20298798 G A 4.88E-05 Celiac disease / / 23936387 rs10430897 chr11 20335391 G T 4.42E-05 Waist-Hip Ratio / / pha003029 rs10430897 chr11 20335391 G T 3.40E-05 Cardiovascular disease / / pha003064 rs10430897 chr11 20335391 G T 6.02E-05 HDL cholesterol / / pha003074 rs11025489 chr11 20338952 A C 5.74E-05 Sarcoidosis / / 19165924 rs7930508 chr11 20339381 C T 9.27E-05 Multiple complex diseases / / 17554300 rs10833295 chr11 20348963 C T 4.70E-06 Urinary metabolites / / 21572414 rs7128099 chr11 20356444 G A 3.00E-06 Obesity-related traits / / 23251661 rs952619 chr11 20359771 A C 1.56E-04 Scoliosis / / 21216876 rs11025523 chr11 20378124 G A 2.04E-04 Hearing function / / 17255346 rs11025523 chr11 20378124 G A 7.00E-06 Obesity-related traits / / 23251661 rs10833310 chr11 20378668 A G 0.00011 Breast cancer / / 22228098 rs11025524 chr11 20379276 G A 0.000261 Breast cancer / / 22228098 rs4757940 chr11 20382453 C T 0.000629 Breast cancer / / 22228098 rs12364576 chr11 20382949 T C 0.000536 Breast cancer / / 22228098 rs10766662 chr11 20401007 C T 5.51E-06 Cognitive impairment induced by topiramate HTATIP2 intron 22091778 rs2403590 chr11 20405646 T G 9.50E-05 Multiple complex diseases / / 17554300 rs10500880 chr11 20405807 T C 8.68E-04 Multiple complex diseases / / 17554300 rs7482968 chr11 20431016 C A,G,T 1.63E-04 Response to taxane treatment (placlitaxel) PRMT3 intron 23006423 rs10766671 chr11 20434740 T A 7.61E-05 Multiple complex diseases PRMT3 intron 17554300 rs7127579 chr11 20444106 A G 1.66E-04 Multiple complex diseases PRMT3 intron 17554300 rs10741838 chr11 20447419 T C 8.80E-04 Multiple complex diseases PRMT3 intron 17554300 rs1992567 chr11 20451179 G A 5.88E-09 Triglycerides PRMT3 intron 23063622 rs7933513 chr11 20461625 T C 5.80E-04 Response to taxane treatment (placlitaxel) PRMT3 intron 23006423 rs11025571 chr11 20482801 C G 2.12E-04 Hearing function PRMT3 intron 17255346 rs16906290 chr11 20485430 T G 7.88E-05 Multiple complex diseases PRMT3 intron 17554300 rs10833331 chr11 20490704 A G 1.07E-04 Multiple complex diseases PRMT3 intron 17554300 rs1899483 chr11 20502706 C G 2.40E-05 Urinary metabolites PRMT3 intron 21572414 rs16906340 chr11 20505227 A G 2.36E-11 Triglycerides PRMT3 intron 23063622 rs7934715 chr11 20523657 A G 9.43E-04 Response to taxane treatment (placlitaxel) PRMT3 intron 23006423 rs11025591 chr11 20528960 A G 3.18E-04 Multiple complex diseases PRMT3 intron 17554300 rs1561993 chr11 20531652 C T 6.15E-04 Multiple complex diseases / / 17554300 rs2403601 chr11 20533719 G A 1.34E-04 Multiple complex diseases / / 17554300 rs12787810 chr11 20545926 C T 1.53E-04 Smoking quantity / / 24665060 rs11025602 chr11 20546869 G A 1.96E-04 Smoking quantity / / 24665060 rs16906385 chr11 20552960 C G 6.30E-06 Urinary metabolites / / 21572414 rs16906388 chr11 20553130 G A 7.23E-05 Smoking quantity / / 24665060 rs7112553 chr11 20553689 C T 1.13E-04 Smoking quantity / / 24665060 rs7129522 chr11 20557535 C T 7.51E-04 Multiple complex diseases / / 17554300 rs12288570 chr11 20559027 T A 0.00006547 Sarcoidosis / / 22952805 rs7115359 chr11 20559415 C T 1.77E-04 Smoking quantity / / 24665060 rs12224242 chr11 20560005 G A 0.0000338 Sarcoidosis / / 22952805 rs2120307 chr11 20561143 C T 0.00007201 Sarcoidosis / / 22952805 rs2120308 chr11 20561284 C T 0.00007805 Sarcoidosis / / 22952805 rs2403602 chr11 20561991 C T 2.28E-04 Smoking quantity / / 24665060 rs7128311 chr11 20562519 C T 5.00E-06 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs7924410 chr11 20563041 A G 0.00004621 Sarcoidosis / / 22952805 rs6483705 chr11 20571876 A T 2.50E-05 Urinary metabolites / / 21572414 rs2012543 chr11 20608950 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12791734 chr11 20617011 T A 9.92E-04 Alcohol dependence / / 21314694 rs2241941 chr11 20623023 C T 8.00E-06 Obesity-related traits SLC6A5 cds-synon 23251661 rs1443548 chr11 20623042 T C 9.50E-06 Glaucoma (primary open-angle) SLC6A5 missense 20835238 rs1443551 chr11 20629164 G A 1.70E-04 Age-related macular degeneration SLC6A5 cds-synon 22125219 rs1443551 chr11 20629164 G A 7.13E-04 Amyotrophic lateral sclerosis SLC6A5 cds-synon 23624525 rs3781740 chr11 20630726 G A 7.97E-04 Amyotrophic lateral sclerosis SLC6A5 intron 23624525 rs4922798 chr11 20641022 G A 3.85E-04 QT interval SLC6A5 intron 22726844 rs10833367 chr11 20641508 C T 2.62E-05 Coronary Artery Disease SLC6A5 intron 17634449 rs3740870 chr11 20648364 G C 0.00045 Breast cancer SLC6A5 missense 23555315 rs1805091 chr11 20648380 G A 0.00045 Breast cancer SLC6A5 missense 23555315 rs12283302 chr11 20654585 G T 8.15E-05 IgE levels in asthmatics (D.p. specific) SLC6A5 intron 23967269 rs4923601 chr11 20655239 A C 5.34E-04 Multiple complex diseases SLC6A5 intron 17554300 rs4923602 chr11 20655260 C A 2.73E-04 Multiple complex diseases SLC6A5 intron 17554300 rs2298826 chr11 20659757 G A 1.57E-04 Substance dependence SLC6A5 intron 21818250 rs1617769 chr11 20669971 T C 2.58E-04 Age-related macular degeneration SLC6A5 intron 22125219 rs2276432 chr11 20676253 T C 8.93E-04 Response to cytadine analogues (cytosine arabinoside) SLC6A5 intron 24483146 rs12789398 chr11 20681572 A G 6.78E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2139424 chr11 20684040 G C 7.00E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1792969 chr11 20689486 A G 1.21E-04 Alzheimer's disease / / 22005930 rs1793004 chr11 20698929 C G 3.00E-06 Crohn's disease NELL1 intron 17684544 rs951199 chr11 20700775 C G 8.00E-04 Crohn's disease NELL1 intron 17684544 rs1715282 chr11 20730761 C A 4.26E-04 Response to taxane treatment (placlitaxel) NELL1 intron 23006423 rs1715269 chr11 20738382 G T 9.47E-05 Non-alcoholic fatty liver disease histology (other) NELL1 intron 20708005 rs1401787 chr11 20740930 A G 2.08E-04 Multiple complex diseases NELL1 intron 17554300 rs1996623 chr11 20759416 A G 8.83E-04 Nicotine smoking NELL1 intron 19268276 rs1554368 chr11 20775758 A G 8.35E-04 Nicotine smoking NELL1 intron 19268276 rs327035 chr11 20783835 C T 3.43E-06 Lipid levels NELL1 intron 19016617 rs11025746 chr11 20785239 C T 1.07E-04 Lung function (forced expiratory volume in 1 second) NELL1 intron 24023788 rs11025746 chr11 20785239 C T 3.34E-04 Lung function (forced vital capacity) NELL1 intron 24023788 rs327036 chr11 20785517 A C 1.86E-04 Lung function (forced expiratory volume in 1 second) NELL1 intron 24023788 rs16906777 chr11 20792282 T C 4.16E-04 Lung function (forced vital capacity) NELL1 intron 24023788 rs11825833 chr11 20853246 T C 8.00E-04 Alcohol dependence NELL1 intron 21314694 rs1429778 chr11 20864831 G T 8.48E-05 Coronary heart disease NELL1 intron 21606135 rs12293297 chr11 20876346 G A 9.50E-04 Crohn's disease NELL1 intron 17684544 rs1946513 chr11 20878022 A G 7.78E-04 Smoking initiation NELL1 intron 24665060 rs1017324 chr11 20878176 C A 1.47E-04 Amyotrophic Lateral Sclerosis NELL1 intron 17362836 rs1429794 chr11 20881437 A G 3.59E-05 Antineutrophil cytoplasmic antibody-associated vasculitis NELL1 intron 22808956 rs7109004 chr11 20892763 T C 7.06E-04 Amyotrophic Lateral Sclerosis NELL1 intron 17362836 rs7950875 chr11 20897211 T A 7.02E-08 Metabolite levels NELL1 intron 23281178 rs10766739 chr11 20898390 A G 3.66E-07 Non-small cell lung cancer (survival) NELL1 intron 23704207 rs10741858 chr11 20899330 C T 2.53E-08 Metabolite levels NELL1 intron 23281178 rs1429793 chr11 20926256 G T 1.76E-08 Autism NELL1 intron 22935194 rs7122630 chr11 20957265 C T 8.05E-05 Erythrocyte counts NELL1 intron pha003099 rs12286075 chr11 20958794 T C 2.03E-04 Type 2 diabetes NELL1 intron 17463246 rs11025826 chr11 20963106 T C 2.94E-04 Type 2 diabetes NELL1 intron 17463246 rs7930660 chr11 20966234 A G 6.04E-05 Hemoglobin NELL1 intron pha003098 rs7930660 chr11 20966234 A G 4.99E-05 Erythrocyte counts NELL1 intron pha003099 rs11025829 chr11 20967720 C T 2.49E-04 Type 2 diabetes NELL1 intron 17463246 rs16907131 chr11 20968673 G A 2.38E-04 Type 2 diabetes NELL1 intron 17463246 rs1880084 chr11 20970789 C T 1.43E-04 Alzheimer's disease NELL1 intron 17998437 rs1987307 chr11 20973856 A C 3.14E-04 Parkinson's disease NELL1 intron 17052657 rs61883261 chr11 20984205 A T 9.00E-06 Response to amphetamines NELL1 intron 22952603 rs2003175 chr11 20992263 G A 4.98E-04 Insulin resistance NELL1 intron 21901158 rs11025849 chr11 21003021 G A 6.90E-04 Insulin resistance NELL1 intron 21901158 rs11025849 chr11 21003021 G A 9.07E-07 Odorant perception NELL1 intron 23910658 rs11025862 chr11 21008367 G A 6.88E-04 Multiple complex diseases NELL1 intron 17554300 rs10833429 chr11 21012894 A G 3.82E-04 Coronary heart disease NELL1 intron 21606135 rs10766758 chr11 21014126 C T 9.98E-05 Smoking cessation NELL1 intron 18519826 rs10500885 chr11 21015060 T C 7.76E-04 Alcohol dependence NELL1 intron 20201924 rs1400369 chr11 21016295 A C 6.47E-04 Alcohol dependence NELL1 intron 20201924 rs2896623 chr11 21017397 G A 9.40E-05 Left ventricular hypertrophy NELL1 intron pha003052 rs12791900 chr11 21022007 G A 4.91E-05 Left ventricular hypertrophy NELL1 intron pha003052 rs10500889 chr11 21038020 A G 7.87E-13 Multiple complex diseases NELL1 intron 17554300 rs17298677 chr11 21050925 T C 1.49E-05 Adverse response to lamotrigine and phenytoin NELL1 intron 22379998 rs4569005 chr11 21058731 C T 5.00E-06 Adverse response to lamotrigine and phenytoin NELL1 intron 22379998 rs1516761 chr11 21065744 A G 2.39E-04 Body mass index NELL1 intron 21701565 rs1516761 chr11 21065744 A G 2.52E-05 Body mass index NELL1 intron 21701565 rs10833442 chr11 21068160 A T 2.67E-04 Body mass index NELL1 intron 21701565 rs10833442 chr11 21068160 A T 4.07E-05 Body mass index NELL1 intron 21701565 rs883018 chr11 21069354 G A 1.28E-04 Body mass index NELL1 intron 21701565 rs940199 chr11 21069877 G A 7.11E-04 Body mass index NELL1 intron 21701565 rs10833444 chr11 21072459 G A 1.13E-04 Body mass index NELL1 intron 21701565 rs10833444 chr11 21072459 G A 2.12E-05 Body mass index NELL1 intron 21701565 rs10430837 chr11 21073279 A G 3.17E-04 Body mass index NELL1 intron 21701565 rs10430837 chr11 21073279 A G 7.50E-05 Body mass index NELL1 intron 21701565 rs1516757 chr11 21081277 G A 6.35E-07 Smoking cessation NELL1 intron 18519826 rs1516748 chr11 21090169 C T 4.38E-06 Smoking cessation NELL1 intron 18519826 rs10833455 chr11 21099887 G A 2.22E-05 Response to anti-TNF treatment in rheumatoid arthritis NELL1 intron 23555300 rs10833455 chr11 21099887 G A 3.19E-04 Response to anti-TNF treatment in rheumatoid arthritis NELL1 intron 23555300 rs10833456 chr11 21099935 G A 2.20E-05 Response to anti-TNF treatment in rheumatoid arthritis NELL1 intron 23555300 rs10833456 chr11 21099935 G A 3.19E-04 Response to anti-TNF treatment in rheumatoid arthritis NELL1 intron 23555300 rs7932820 chr11 21100384 C T 2.18E-05 Response to anti-TNF treatment in rheumatoid arthritis NELL1 intron 23555300 rs7932820 chr11 21100384 C T 3.29E-04 Response to anti-TNF treatment in rheumatoid arthritis NELL1 intron 23555300 rs1791842 chr11 21170138 A C 3.70E-05 Body Mass Index NELL1 intron pha003019 rs1791842 chr11 21170138 A C 2.22E-05 Body Mass Index NELL1 intron pha003022 rs12788723 chr11 21171018 A G 6.85E-04 Depression (quantitative trait) NELL1 intron 20800221 rs6483747 chr11 21180977 G A 2.10E-06 Urinary metabolites NELL1 intron 21572414 rs4412753 chr11 21198793 C A 4.40E-06 Urinary metabolites NELL1 intron 21572414 rs1349819 chr11 21210324 T C 0.0009 Breast cancer NELL1 intron 22228098 rs7107350 chr11 21212132 G T 7.20E-04 Lung adenocarcinoma NELL1 intron 21242121 rs7115151 chr11 21217682 T C 8.06E-04 Multiple complex diseases NELL1 intron 17554300 rs16907672 chr11 21227564 G T 9.25E-04 Depression (quantitative trait) NELL1 intron 20800221 rs1670661 chr11 21230670 C T 2.03E-04 Oral cancers (chewing tobacco related) NELL1 intron 22503698 rs10833476 chr11 21233869 C T 0.000817 Breast cancer NELL1 intron 22228098 rs1377741 chr11 21247216 A T 3.86E-04 Type 2 diabetes NELL1 intron 17463246 rs11025987 chr11 21258359 C A 2.91E-04 Lung function (forced expiratory volume in 1 second) NELL1 intron 17255346 rs11025988 chr11 21259095 G A 1.39E-04 Lung function (forced expiratory volume in 1 second) NELL1 intron 17255346 rs1454014 chr11 21259199 C T 0.000493 Breast cancer NELL1 intron 22228098 rs2085028 chr11 21259545 G A 1.06E-04 Lung function (forced expiratory volume in 1 second) NELL1 intron 17255346 rs11025990 chr11 21262032 A G 2.10E-04 Lung function (forced expiratory volume in 1 second) NELL1 intron 17255346 rs1454001 chr11 21262591 T C 9.62E-05 Alzheimer's disease (late onset) NELL1 intron 21379329 rs10766778 chr11 21263171 T G 0.00000974 Transmission distortion NELL1 intron 22377632 rs1670646 chr11 21267418 A G 9.40E-05 Iron levels NELL1 intron 19880490 rs1670646 chr11 21267418 A G 9.40E-05 Iron levels NELL1 intron pha002876 rs1791862 chr11 21268909 T C 2.50E-05 Urinary metabolites NELL1 intron 21572414 rs10833483 chr11 21277762 T C 7.87E-05 Orofacial clefts NELL1 intron 22419666 rs10466386 chr11 21282111 C T 1.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NELL1 intron 20877124 rs4641471 chr11 21283102 C T 1.50E-05 Urinary metabolites NELL1 intron 21572414 rs10833498 chr11 21321305 T C 3.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NELL1 intron 20877124 rs10833498 chr11 21321305 T C 8.40E-05 Orofacial clefts NELL1 intron 22419666 rs4923528 chr11 21343939 A G 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes NELL1 intron 22628534 rs10833507 chr11 21350620 A G 1.46E-04 Celiac disease NELL1 intron 23936387 rs10833509 chr11 21355150 C A 6.29E-05 Lung function (forced vital capacity) NELL1 intron pha003104 rs12421240 chr11 21355784 G A 8.85E-04 Type 2 diabetes NELL1 intron 17463246 rs1010024 chr11 21356815 A T 2.10E-05 Urinary metabolites NELL1 intron 21572414 rs7939346 chr11 21357314 G T 3.80E-07 Urinary metabolites NELL1 intron 21572414 rs7939346 chr11 21357314 G T 7.47E-05 Lung function (forced vital capacity) NELL1 intron pha003104 rs10437584 chr11 21357397 G T 1.14E-04 Celiac disease NELL1 intron 23936387 rs12798947 chr11 21395259 C A 2.03E-04 Birth weight NELL1 intron 17255346 rs10833520 chr11 21396360 T C 2.45E-04 Height NELL1 intron 17255346 rs7105978 chr11 21400116 C T 4.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NELL1 intron 20877124 rs1945448 chr11 21405626 A G 1.00E-04 Multiple complex diseases NELL1 intron 17554300 rs10160599 chr11 21412548 C T 8.36E-05 Erythrocyte counts NELL1 intron pha003101 rs7101928 chr11 21420224 T C 3.98E-05 Serum metabolites NELL1 intron 19043545 rs10833525 chr11 21425763 G A 2.39E-05 Multiple complex diseases NELL1 intron 17554300 rs4531470 chr11 21429888 G T 4.89E-05 Serum albumin level NELL1 intron pha003084 rs4531470 chr11 21429888 G T 3.39E-05 Calcium levels NELL1 intron pha003085 rs11026076 chr11 21436232 T C 2.09E-06 Leukocyte Counts NELL1 intron pha003091 rs7943922 chr11 21437692 T G 3.07E-05 Leukocyte Counts NELL1 intron pha003091 rs12802424 chr11 21441271 G A 1.22E-05 Orofacial clefts NELL1 intron 22419666 rs11026078 chr11 21442142 C T 0.000675 Salmonella-induced pyroptosis NELL1 intron 22837397 rs1945413 chr11 21461874 G A 1.51E-04 Smoking cessation NELL1 intron 18519826 rs368852620 chr11 21461874 GTCAGAGCAAATAAC G 1.51E-04 Smoking cessation NELL1 intron 18519826 rs1945406 chr11 21476559 C T 7.87E-04 Multiple complex diseases NELL1 intron 17554300 rs6483772 chr11 21502994 G C 4.89E-05 Smoking cessation NELL1 intron 18519826 rs73469144 chr11 21504900 A C 6.00E-06 PR interval in Tripanosoma cruzi seropositivity NELL1 intron 24324551 rs12421117 chr11 21515803 G A 1.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NELL1 intron 20877124 rs12421117 chr11 21515803 G A 0.000269 Salmonella-induced pyroptosis NELL1 intron 22837397 rs10219188 chr11 21522529 T G 3.85E-05 Leukocyte Counts NELL1 intron pha003091 rs4279993 chr11 21526443 G A 1.19E-04 Smoking cessation NELL1 intron 18519826 rs12574030 chr11 21529762 G A 1.27E-04 Amyotrophic Lateral Sclerosis NELL1 intron 17827064 rs12574030 chr11 21529762 G A 5.76E-05 Platelet counts NELL1 intron pha003100 rs4923633 chr11 21539845 C T 4.07E-07 Thiazide-induced adverse metabolic effects in hypertensive patients NELL1 intron 23400010 rs4923643 chr11 21562763 C T 1.52E-04 Amyotrophic Lateral Sclerosis NELL1 intron 17827064 rs12279250 chr11 21565079 T C 7.00E-09 Thiazide-induced adverse metabolic effects in hypertensive patients NELL1 intron 23400010 rs7106789 chr11 21569724 T C 4.36E-05 Male fertility NELL1 intron 22633400 rs4319515 chr11 21578367 T C 4.05E-08 Thiazide-induced adverse metabolic effects in hypertensive patients NELL1 intron 23400010 rs1573535 chr11 21620948 A T 4.00E-06 Cannabis use (initiation) / / 22823124 rs7123021 chr11 21631528 T G 1.67E-05 Cognitive impairment induced by topiramate / / 22091778 rs4457740 chr11 21641576 T C 5.16E-04 Type 2 diabetes / / 17463246 rs3958160 chr11 21641954 G A 3.68E-04 Alzheimer's disease / / 17998437 rs1459887 chr11 21646770 T A 8.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs7931276 chr11 21649811 C T 9.76E-05 Cognitive test performance / / 20125193 rs10833583 chr11 21669293 G A 7.00E-06 Obesity-related traits / / 23251661 rs2051457 chr11 21677342 G T 5.00E-06 Obesity-related traits / / 23251661 rs2726125 chr11 21730707 C T 6.00E-06 Multiple myeloma / / 23955597 rs3886894 chr11 21738115 A G 5.00E-06 Multiple myeloma / / 23955597 rs7104861 chr11 21738350 A G 6.00E-06 Multiple myeloma / / 23955597 rs1380517 chr11 21745758 C T 8.31E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs1459873 chr11 21753111 T G 5.00E-06 Multiple myeloma / / 23955597 rs1599196 chr11 21758947 A G 4.00E-06 Multiple myeloma / / 23955597 rs7114439 chr11 21763627 G A 5.00E-06 Multiple myeloma / / 23955597 rs11026213 chr11 21783630 T A 9.97E-04 Multiple complex diseases / / 17554300 rs12225197 chr11 21820406 G A 8.72E-05 LDL lipoproteins / / pha002902 rs11026246 chr11 21822665 A C 5.85E-07 Multiple complex diseases / / 17554300 rs11026274 chr11 21846809 A G 7.36E-04 Multiple complex diseases / / 17554300 rs10766888 chr11 21869349 G C 8.61E-04 Multiple complex diseases / / 17554300 rs901752 chr11 21876018 A T 1.14E-04 Multiple complex diseases / / 17554300 rs11026306 chr11 21884515 T A 7.93E-05 Femoral neck bone geometry / / 22087292 rs2403686 chr11 21891843 T C 5.25E-05 Post-operative nausea and vomiting / / 21694509 rs11026318 chr11 21896880 C T 9.00E-06 Multiple myeloma (hyperdiploidy) / / 23502783 rs9787962 chr11 21915418 T C 5.38E-04 Type 2 diabetes / / 17463246 rs507596 chr11 21942767 G A 6.27E-06 Cognitive test performance / / 20125193 rs12788989 chr11 21946186 C T 4.75E-06 Cognitive test performance / / 20125193 rs16908768 chr11 21948400 A G 9.70E-05 HIV-1 control / / 20041166 rs7930479 chr11 21950093 A G 8.98E-06 Glycemic traits (pregnancy) / / 23903356 rs1487814 chr11 21950485 T C 8.04E-05 Alcohol dependence / / 19581569 rs10833664 chr11 21952556 A G 8.58E-06 Glycemic traits (pregnancy) / / 23903356 rs10833664 chr11 21952556 A G 8.81E-06 Glycemic traits (pregnancy) / / 23903356 rs7117485 chr11 21952721 C G 3.23E-04 Multiple complex diseases / / 17554300 rs7117485 chr11 21952721 C G 9.08E-06 Glycemic traits (pregnancy) / / 23903356 rs7121300 chr11 21953283 G A 4.56E-04 Multiple complex diseases / / 17554300 rs7121300 chr11 21953283 G A 9.10E-06 Glycemic traits (pregnancy) / / 23903356 rs6483813 chr11 21953522 C A 4.85E-04 Multiple complex diseases / / 17554300 rs6483813 chr11 21953522 C A 9.13E-06 Glycemic traits (pregnancy) / / 23903356 rs6483814 chr11 21953557 T G 9.10E-06 Glycemic traits (pregnancy) / / 23903356 rs324175 chr11 21953687 T C 1.98E-04 Multiple complex diseases / / 17554300 rs324175 chr11 21953687 T C 6.03E-07 Cardiovascular disease / / 18179892 rs324258 chr11 21968847 G A 4.75E-06 Cognitive test performance / / 20125193 rs12295951 chr11 21970549 C T 2.04E-05 Neuroblastoma / / pha002895 rs1487837 chr11 21981682 C G 5.97E-04 Multiple complex diseases / / 17554300 rs324228 chr11 21987561 G T 2.14E-05 Cognitive test performance / / 20125193 rs10833684 chr11 21988934 G A 5.37E-06 Glycemic traits (pregnancy) / / 23903356 rs10833684 chr11 21988934 G A 6.56E-06 Glycemic traits (pregnancy) / / 23903356 rs49385 chr11 21997071 G A 7.43E-04 Multiple complex diseases / / 17554300 rs11603377 chr11 21999145 A G 3.51E-04 Cognitive decline / / 23732972 rs324197 chr11 22006963 G A 8.66E-04 Multiple complex diseases / / 17554300 rs12417691 chr11 22015682 A G 3.90E-05 HIV-1 control / / 20041166 rs1157385 chr11 22059879 T C 1.54E-04 Multiple complex diseases / / 17554300 rs10500921 chr11 22067536 G A 5.09E-05 Cognitive test performance / / 20125193 rs16909097 chr11 22078582 T C 3.90E-05 HIV-1 control / / 20041166 rs7924927 chr11 22086159 C T 3.90E-05 HIV-1 control / / 20041166 rs11026407 chr11 22105030 C A 2.00E-08 Thyroid stimulating hormone / / 24722205 rs11026412 chr11 22114093 G A 3.00E-06 Parkinson's disease / / 22451204 rs11026412 chr11 22114093 G A 2.12E-04 Smoking initiation / / 24665060 rs4442550 chr11 22120723 T G 4.93E-04 Smoking initiation / / 24665060 rs7358426 chr11 22123113 A G 9.31E-05 Orofacial clefts / / 22419666 rs4244490 chr11 22178975 A G 8.70E-06 Venous thromboembolism / / 22672568 rs4275631 chr11 22182364 T C 8.70E-06 Venous thromboembolism / / 22672568 rs4478991 chr11 22199265 A G 5.19E-06 Venous thromboembolism / / 22672568 rs10833711 chr11 22200763 G A 3.98E-05 Asthma / / pha003127 rs4581442 chr11 22217395 T C 5.11E-04 Obesity (extreme) ANO5 intron 21935397 rs10741929 chr11 22221784 A C 5.46E-04 Obesity (extreme) ANO5 intron 21935397 rs7481951 chr11 22271870 A T 9.59E-06 Venous thromboembolism ANO5 missense 22672568 rs11827962 chr11 22312566 C T 6.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs1155821 chr11 22358720 A G 6.37E-04 Parkinson's disease / / 17052657 rs1447513 chr11 22363987 G C 6.47E-04 Schizophrenia SLC17A6 intron 21674006 rs2593693 chr11 22368301 T C 3.47E-05 Parkinson's disease SLC17A6 intron 17052657 rs10833748 chr11 22387745 T C 0.0000387 Amyotrophic lateral sclerosis SLC17A6 intron 23587638 rs932084 chr11 22436201 T A 3.50E-06 Urinary metabolites / / 21572414 rs2671120 chr11 22473142 G C 1.10E-05 Urinary metabolites / / 21572414 rs575764 chr11 22485076 A G 0.0000012 Mean arterial pressure / / 22510845 rs17762 chr11 22492454 G A 5.40E-06 Urinary metabolites / / 21572414 rs1399096 chr11 22496095 A G 2.62E-04 Multiple complex diseases / / 17554300 rs340989 chr11 22496218 C G 4.11E-04 Multiple complex diseases / / 17554300 rs186878 chr11 22496259 C T 2.31E-04 Multiple complex diseases / / 17554300 rs11821932 chr11 22499011 G A 3.90E-06 Urinary metabolites / / 21572414 rs10500932 chr11 22501446 G A 2.30E-06 Urinary metabolites / / 21572414 rs7938801 chr11 22524080 A G 3.50E-06 Urinary metabolites / / 21572414 rs1514090 chr11 22526383 C G 8.30E-06 Urinary metabolites / / 21572414 rs10833762 chr11 22526750 T C 3.08E-05 Bipolar disorder / / 19488044 rs1514085 chr11 22530287 T C 3.50E-06 Urinary metabolites / / 21572414 rs7929100 chr11 22530516 T A 2.90E-06 Urinary metabolites / / 21572414 rs7942692 chr11 22530624 G C 3.50E-06 Urinary metabolites / / 21572414 rs10833764 chr11 22533437 A G 5.19E-04 Multiple complex diseases / / 17554300 rs10833764 chr11 22533437 A G 4.45E-05 Bipolar disorder / / 19488044 rs16909583 chr11 22533553 A G 3.50E-06 Urinary metabolites / / 21572414 rs11026697 chr11 22629016 A G 6.55E-04 Body mass index / / 21701565 rs11026697 chr11 22629016 A G 5.63E-04 Smoking cessation / / 24665060 rs10500938 chr11 22644603 G A 4.60E-04 Type 2 diabetes FANCF UTR-3 17846125 rs4447177 chr11 22646025 G A 7.05E-04 Body mass index FANCF UTR-3 21701565 rs10833798 chr11 22686050 A T 6.00E-05 Iris characteristics / / 21835309 rs1628924 chr11 22717120 T C 2.25E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) GAS2 intron 23648065 rs337454 chr11 22729464 A G 2.81E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) GAS2 intron 23648065 rs440991 chr11 22730694 A G 2.82E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) GAS2 intron 23648065 rs12224489 chr11 22737700 A C 6.52E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs11026751 chr11 22745557 C T 6.44E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs11026752 chr11 22745733 A C 6.40E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs11026754 chr11 22748368 T C 6.39E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs11026755 chr11 22749310 G A 6.41E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs10833804 chr11 22752092 G A 3.25E-05 Serum metabolites GAS2 intron 19043545 rs11026758 chr11 22753580 C T 6.13E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs11026759 chr11 22753686 G A 5.37E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs11026761 chr11 22754681 C A 5.39E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs7111726 chr11 22757025 T A 5.38E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs12420811 chr11 22757079 G A 5.38E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs7934119 chr11 22759168 A G 5.38E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs11026763 chr11 22762542 A G 5.41E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs11026764 chr11 22763911 G A 5.36E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs10833806 chr11 22777654 A G 4.83E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs11026771 chr11 22780093 A C 5.94E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs10734321 chr11 22786413 G A 3.59E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs11026778 chr11 22788717 A C 6.28E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs12225923 chr11 22788879 C T 3.46E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs12226338 chr11 22789765 G A 6.04E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs17306216 chr11 22791250 T G 3.55E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs17306223 chr11 22792091 C T 5.79E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs10500941 chr11 22793130 A G 5.75E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs1499242 chr11 22793809 T G 8.12E-04 Endometrial cancer GAS2 intron 24096698 rs17234098 chr11 22797177 A C 6.15E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs17306251 chr11 22803448 A G 6.13E-04 Suicide attempts in bipolar disorder GAS2 intron 21423239 rs7129006 chr11 22803712 G A 4.61E-05 Parkinson's disease GAS2 intron 21812969 rs16910190 chr11 22828606 T G 4.05E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) GAS2 intron 24023788 rs7111546 chr11 22829757 C T 2.00E-06 Dialysis-related mortality GAS2 intron 21546767 rs712022 chr11 22843155 A T 6.00E-06 Dialysis-related mortality / / 21546767 rs712022 chr11 22843155 A T 7.75E-04 Taste perception / / 22132133 rs1019216 chr11 22843220 T C 3.61E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11026805 chr11 22849835 G A 7.36E-04 Multiple complex diseases SVIP intron 17554300 rs4567455 chr11 22863526 G C 8.19E-05 Major depressive disorder (broad) / / 20038947 rs4550218 chr11 22863658 C G 7.10E-05 Major depressive disorder (broad) / / 20038947 rs2302423 chr11 22868937 G A 9.09E-04 Rheumatoid arthritis LOC100500938 UTR-3 21452313 rs1860678 chr11 22881542 A G 5.55E-05 Cognitive impairment induced by topiramate LOC100500938 intron 22091778 rs2429777 chr11 22901323 T C 3.52E-04 Rheumatoid arthritis / / 21452313 rs2429760 chr11 22913191 G A 1.51E-04 Rheumatoid arthritis / / 21452313 rs733295 chr11 22936456 G A 3.05E-06 Lipoproteins / / pha003079 rs10450560 chr11 23013025 A T 9.28E-04 Type 2 diabetes / / 17463246 rs11026888 chr11 23021371 C A 4.22E-04 Multiple complex diseases / / 17554300 rs1426836 chr11 23036063 A G 6.57E-04 Smoking quantity / / 24665060 rs10833905 chr11 23044592 T A 7.00E-07 Sudden cardiac arrest / / 21658281 rs10833942 chr11 23125374 C T 5.60E-05 Coffee consumption / / 21357676 rs17306391 chr11 23191372 A C 5.67E-07 Primary nonsyndromic vesicoureteric reflex / / 19959718 rs16910754 chr11 23192015 C T 2.77E-05 Asthma / / 23181788 rs17306398 chr11 23192235 A C,G,T 1.62E-05 Asthma / / 23181788 rs10500945 chr11 23225638 G A 4.49E-04 Bipolar disorder / / 19259986 rs7942066 chr11 23274937 A G 4.25E-04 Type 2 diabetes / / 17463246 rs12284538 chr11 23429071 C T 8.85E-04 Multiple complex diseases / / 17554300 rs1462559 chr11 23433671 C A 5.24E-05 Post-operative nausea and vomiting / / 21694509 rs7935052 chr11 23477604 T C 9.72E-05 Bone mineral density / / 19181680 rs1462541 chr11 23501214 T C 6.83E-05 Serum metabolites / / 19043545 rs1156202 chr11 23503152 G A 6.55E-05 Serum metabolites / / 19043545 rs1156203 chr11 23503178 T C 7.23E-05 Serum metabolites / / 19043545 rs11027263 chr11 23517187 C T 8.00E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1350948 chr11 23518405 A G 8.65E-04 Response to TNF antagonist treatment / / 21061259 rs1356687 chr11 23519949 G A 6.25E-04 Heart Failure / / pha002884 rs7949875 chr11 23523142 G T 7.20E-04 Heart Failure / / pha002884 rs1381718 chr11 23532600 A G 9.41E-04 Type 2 diabetes / / 17463246 rs1850823 chr11 23533827 G C 4.00E-05 Prostate cancer / / 21743057 rs1850822 chr11 23533902 C T 7.00E-05 Prostate cancer / / 21743057 rs10834124 chr11 23540541 C G 5.24E-04 Smoking initiation / / 24665060 rs11027313 chr11 23577442 T C 7.77E-04 HIV-1 viral setpoint / / 17641165 rs11027318 chr11 23581968 G A 7.58E-04 HIV-1 viral setpoint / / 17641165 rs11027318 chr11 23581968 G A 7.05E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs4359206 chr11 23587874 A G 2.07E-05 Basophils / / pha003087 rs1401613 chr11 23592851 A T 6.64E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10500964 chr11 23596570 C T 1.00E-04 Chronic fatigue syndrome / / 21912186 rs10500965 chr11 23596625 G T 6.00E-05 Chronic fatigue syndrome / / 21912186 rs7109756 chr11 23598642 A G 8.39E-05 Myopia (pathological) / / 21095009 rs2139333 chr11 23609050 G T 8.33E-05 Myopia (pathological) / / 21095009 rs1401618 chr11 23647540 A C 8.30E-05 Myopia (pathological) / / 21095009 rs1401618 chr11 23647540 A C 2.76E-05 Erythrocyte counts / / pha003099 rs12292038 chr11 23679716 G A 5.71E-04 Suicide attempts in bipolar disorder / / 21041247 rs12295501 chr11 23681242 G C 8.57E-04 Suicide attempts in bipolar disorder / / 21041247 rs7122399 chr11 23682890 C G 8.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs11027422 chr11 23685075 G C 8.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs1879036 chr11 23687928 G A 1.86E-04 Multiple complex diseases / / 17554300 rs1879036 chr11 23687928 G A 8.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs1879035 chr11 23687950 C T 8.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs7114872 chr11 23689311 T C 7.57E-04 Suicide attempts in bipolar disorder / / 21041247 rs12294691 chr11 23693314 A G 6.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs12279140 chr11 23697263 C A 6.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs12269913 chr11 23699764 A C 6.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs12269913 chr11 23699764 A C 8.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs11027431 chr11 23705801 T A 6.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs11027431 chr11 23705801 T A 8.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs11027433 chr11 23706483 T C 5.03E-04 Tourette syndrome / / 22889924 rs11027434 chr11 23709180 T C 6.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs11027434 chr11 23709180 T C 8.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs12293501 chr11 23710132 G A 6.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs12293501 chr11 23710132 G A 8.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs11027436 chr11 23710662 C T 6.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs11027436 chr11 23710662 C T 8.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs4922664 chr11 23711813 C T 9.08E-04 Tourette syndrome / / 22889924 rs11027438 chr11 23712608 T A 6.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs11027438 chr11 23712608 T A 8.95E-04 Suicide attempts in bipolar disorder / / 21041247 rs11027440 chr11 23713269 A T 6.35E-04 Suicide attempts in bipolar disorder / / 21041247 rs11027440 chr11 23713269 A T 8.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs12274900 chr11 23714862 C T 6.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs12274900 chr11 23714862 C T 8.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs12283754 chr11 23715702 T A 6.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs12280993 chr11 23719179 T C 6.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs12277987 chr11 23721619 C T 8.82E-04 Suicide attempts in bipolar disorder / / 21041247 rs4317983 chr11 23777459 A G 2.28E-05 HIV-1 viral setpoint / / 22174851 rs11827258 chr11 23779099 C A 1.60E-05 Urinary metabolites / / 21572414 rs7111329 chr11 23820633 G A 3.20E-04 Intelligence (childhood) / / 23358156 rs11027540 chr11 23844975 T G 9.23E-05 Parkinson's disease (motor and cognition) / / 22658654 rs11027540 chr11 23844975 T G 9.23E-05 Immune response to anthrax vaccine / / 22658931 rs4316508 chr11 23915409 C A 4.22E-05 Myopia (pathological) / / 21095009 rs10834232 chr11 23926630 T C 8.94E-04 Intracranial aneurysm / / 20613766 rs10834232 chr11 23926630 T C 1.02E-06 Non-obstructive azoospermia / / 22541561 rs10767138 chr11 23943716 G A 9.94E-06 Myopia (pathological) / / 21095009 rs7106379 chr11 23944659 A G 9.94E-06 Myopia (pathological) / / 21095009 rs11826956 chr11 23949292 G A 5.02E-05 Bipolar disorder and schizophrenia / / 20889312 rs7116456 chr11 23955313 T C 1.00E-07 Systolic blood pressure (alcohol consumption interaction) / / 24376456 rs4604882 chr11 23979808 A C 9.00E-05 Orofacial clefts / / 22419666 rs1879230 chr11 23982573 T C 2.10E-05 Type 2 diabetes / / 17460697 rs199876930 chr11 23990404 T TAC 0.00000994 Bisphosphonate-induced osteonecrosis of the jaw / / 22267851 rs2957789 chr11 23995690 G C 6.93E-04 Multiple complex diseases / / 17554300 rs16911971 chr11 23997478 G A 6.25E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1915067 chr11 24031627 A G 8.14E-04 Response to alcohol consumption (flushing response) / / 24277619 rs7951184 chr11 24046874 T A 7.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs11027665 chr11 24047282 A G 8.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs11027666 chr11 24048206 T C 8.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs6484005 chr11 24051239 C G 6.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs11604992 chr11 24054845 A C 6.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs10834268 chr11 24059452 G T 6.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs1915071 chr11 24060800 A G 6.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs11027680 chr11 24066888 T C 4.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs11603430 chr11 24069488 G A 4.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs11027702 chr11 24086936 A G 4.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs1915063 chr11 24099773 A G 8.88E-04 Obesity (extreme) / / 21935397 rs12791495 chr11 24110315 G A 7.81E-05 Aging (time to event) / / 21782286 rs2955445 chr11 24119133 C G 8.76E-04 Multiple complex diseases / / 17554300 rs1915058 chr11 24125503 C T 3.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs1915061 chr11 24130487 A C 5.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs2947760 chr11 24175181 C G 8.20E-05 Coronary Artery Disease / / 17634449 rs7924473 chr11 24177082 T C 9.58E-04 Type 2 diabetes / / 17463246 rs7924473 chr11 24177082 T C 1.34E-04 Coronary Artery Disease / / 17634449 rs4923161 chr11 24192528 A G 1.90E-04 Blood pressure / / 17255346 rs7129947 chr11 24197954 C T 1.71E-04 Insulin resistance / / 21901158 rs2403888 chr11 24208071 G C 4.18E-05 Response to TNF antagonist treatment / / 21061259 rs6484022 chr11 24209320 C T 6.39E-08 Multiple complex diseases / / 17554300 rs12293729 chr11 24224679 A G 4.18E-05 Response to TNF antagonist treatment / / 21061259 rs16912285 chr11 24252528 A G 7.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs11027786 chr11 24257425 C T 4.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11027786 chr11 24257425 C T 4.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11027791 chr11 24261507 C T 4.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11027791 chr11 24261507 C T 4.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12269768 chr11 24271874 C A 4.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10834309 chr11 24316872 G A 0.0000071 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) / / 23080225 rs10834309 chr11 24316872 G A 3.31E-04 Myocardial Infarction / / pha002873 rs731365 chr11 24334057 G T 4.83E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7950920 chr11 24356464 G A 4.32E-05 Ulcerative colitis / / 19915573 rs1822339 chr11 24359362 A G 5.47E-05 Serum metabolites / / 19043545 rs1822338 chr11 24359477 A C 8.05E-06 Serum metabolites / / 19043545 rs12794505 chr11 24364195 G A 2.98E-05 Kawasaki disease / / 22446961 rs4609598 chr11 24367888 C A 9.42E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs12577327 chr11 24399097 C T 9.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7122189 chr11 24407108 C T 3.44E-04 Insulin resistance / / 21901158 rs11027910 chr11 24458713 C T 7.91E-04 Multiple complex diseases / / 17554300 rs10500978 chr11 24493480 G A 4.60E-04 Multiple complex diseases / / 17554300 rs10500979 chr11 24493876 A G 4.34E-04 Multiple complex diseases / / 17554300 rs10500980 chr11 24494465 A G 4.91E-04 Multiple complex diseases / / 17554300 rs12223724 chr11 24513821 C T 5.04E-04 Insulin resistance / / 21901158 rs7943454 chr11 24521666 T C 8.28E-05 Alzheimer's disease LUZP2 intron 24755620 rs16912642 chr11 24525499 C A 4.24E-05 Sarcoidosis LUZP2 intron 19165924 rs7927293 chr11 24527958 A G 6.29E-04 Alcohol consumption (maxi-drinks) LUZP2 intron 24277619 rs11028019 chr11 24583891 T C 6.97E-04 Nicotine smoking LUZP2 intron 19268276 rs7131395 chr11 24599878 T C 1.58E-05 Schizophrenia LUZP2 intron 21926974 rs1509595 chr11 24610471 A G 4.76E-05 Insulin resistance LUZP2 intron 21901158 rs12361953 chr11 24611130 C G 5.73E-06 Hearing function LUZP2 intron 21493956 rs12361953 chr11 24611130 C G 8.00E-07 Alzheimer's disease (late onset) LUZP2 intron 22881374 rs11028045 chr11 24622149 C T 8.35E-04 Suicide attempts in bipolar disorder LUZP2 intron 21423239 rs11028069 chr11 24640055 G A 4.15E-04 Suicide attempts in bipolar disorder LUZP2 intron 21423239 rs11028081 chr11 24648970 G C 7.58E-04 Suicide attempts in bipolar disorder LUZP2 intron 21423239 rs7941650 chr11 24655271 C T 6.96E-04 Suicide attempts in bipolar disorder LUZP2 intron 21423239 rs12362733 chr11 24671340 A G 2.72E-05 Cognitive decline LUZP2 intron 22054870 rs11028093 chr11 24672424 C T 4.64E-04 Suicide attempts in bipolar disorder LUZP2 intron 21423239 rs11028094 chr11 24673353 T G 5.82E-04 Suicide attempts in bipolar disorder LUZP2 intron 21423239 rs4561213 chr11 24678819 T G 3.00E-07 Magnesium levels LUZP2 intron 20700443 rs3923615 chr11 24681532 G T 1.10E-04 Volumetric brain MRI LUZP2 intron 17903297 rs10834425 chr11 24700012 A G 6.13E-05 Type 2 diabetes LUZP2 intron 17463246 rs2716456 chr11 24733266 A G 0.000536 Salmonella-induced pyroptosis LUZP2 intron 22837397 rs2029191 chr11 24735826 C G 6.53E-04 Type 2 diabetes LUZP2 intron 17463246 rs10834449 chr11 24739804 G A 8.00E-08 Intelligence LUZP2 intron 22449649 rs10834449 chr11 24739804 G A 2.20E-05 Tooth agenesis (third molar) LUZP2 intron 24172245 rs10834449 chr11 24739804 G A 4.30E-05 Tooth agenesis (mandibular third molar) LUZP2 intron 24172245 rs4922692 chr11 24758120 A C 9.85E-05 Monocyte chemoattractant protein-1 LUZP2 intron pha003071 rs11028131 chr11 24760101 G A 5.61E-05 Aging (time to event) LUZP2 intron 21782286 rs11028131 chr11 24760101 G A 2.00E-04 Cognitive impairment induced by topiramate LUZP2 intron 22091778 rs11028138 chr11 24773182 A G 1.00E-04 Cognitive impairment induced by topiramate LUZP2 intron 22091778 rs10834475 chr11 24774037 A G 2.74E-04 Body mass index LUZP2 intron 17255346 rs2716442 chr11 24774153 C A 3.18E-04 Suicide attempts in bipolar disorder LUZP2 intron 21423239 rs10834476 chr11 24774506 T C 4.77E-05 Alcohol withdrawal symptoms LUZP2 intron 22072270 rs12422212 chr11 24778459 C T 2.80E-05 Urinary metabolites LUZP2 intron 21572414 rs2716544 chr11 24802669 T C 1.48E-04 Body mass index LUZP2 intron 17255346 rs1386239 chr11 24817709 C A 2.65E-04 Type 2 diabetes LUZP2 intron 17463246 rs12577365 chr11 24818305 A G 1.42E-04 Multiple complex diseases LUZP2 intron 17554300 rs1906093 chr11 24837039 C T 6.27E-04 Amyotrophic Lateral Sclerosis LUZP2 intron 17362836 rs10834489 chr11 24837801 C T 2.50E-05 Nicotine smoking LUZP2 intron 19268276 rs11028190 chr11 24839058 A G 6.14E-04 Amyotrophic Lateral Sclerosis LUZP2 intron 17362836 rs1486726 chr11 24848560 T G 3.35E-05 ldl cholesterol LUZP2 intron pha003077 rs2631506 chr11 24848824 C T 4.50E-05 ldl cholesterol LUZP2 intron pha003077 rs10500991 chr11 24849566 C T 2.00E-06 Iron status biomarkers LUZP2 intron 19084217 rs2631502 chr11 24849674 G A 8.67E-04 Type 2 diabetes LUZP2 intron 17463246 rs11028199 chr11 24852856 C T 7.94E-05 ldl cholesterol LUZP2 intron pha003077 rs2631461 chr11 24871295 A G 5.56E-04 Type 2 diabetes LUZP2 intron 17463246 rs16913464 chr11 24909408 A T 9.00E-05 Prostate cancer LUZP2 intron 21743057 rs11028255 chr11 24916152 T C 7.85E-06 Stroke (ischemic) LUZP2 intron 21957438 rs7478820 chr11 24934662 G T 1.50E-04 Multiple complex diseases LUZP2 intron 17554300 rs10834564 chr11 25009999 A C 6.30E-04 Multiple complex diseases LUZP2 intron 17554300 rs10742066 chr11 25063237 G C 2.71E-05 Multiple complex diseases LUZP2 intron 17554300 rs11602337 chr11 25113781 C T 0.000719 Salmonella-induced pyroptosis / / 22837397 rs12788764 chr11 25134544 T C 5.00E-06 Age-related nuclear cataracts / / 24951543 rs11604105 chr11 25144879 A G 0.000101 Salmonella-induced pyroptosis / / 22837397 rs12791995 chr11 25145290 C A 0.0000943 Salmonella-induced pyroptosis / / 22837397 rs2404026 chr11 25152481 T C 0.000175 Salmonella-induced pyroptosis / / 22837397 rs11028449 chr11 25157509 G C 2.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11028452 chr11 25160667 C G 0.000183 Salmonella-induced pyroptosis / / 22837397 rs7942081 chr11 25162244 C A 0.000164 Salmonella-induced pyroptosis / / 22837397 rs11028465 chr11 25172085 G A 1.10E-04 Common variable immunodeficiency / / 21497890 rs1584186 chr11 25180965 A G 4.40E-05 Melanoma / / 21983785 rs1596839 chr11 25181448 G T 9.25E-04 Diabetic retinopathy / / 20871662 rs7126778 chr11 25181838 A G 4.01E-04 Multiple complex diseases / / 17554300 rs7931669 chr11 25184503 G A 3.57E-04 Multiple complex diseases / / 17554300 rs7121777 chr11 25187427 C T 4.69E-04 Multiple complex diseases / / 17554300 rs12793062 chr11 25207228 C A 1.70E-05 Urinary metabolites / / 21572414 rs12794435 chr11 25207704 G A 5.00E-06 Ovarian cancer / / 20852632 rs11028502 chr11 25208921 G A 5.00E-05 HIV-1 control / / 20041166 rs145725684 chr11 25214237 A G 6.56E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs112328818 chr11 25215421 A G 7.56E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs79996542 chr11 25215979 T A 7.55E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs11602432 chr11 25219145 C T 2.49E-04 Sudden cardiac arrest / / 21658281 rs12278154 chr11 25219752 C T 0.000403 Salmonella-induced pyroptosis / / 22837397 rs113652043 chr11 25221599 C A 6.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs2114079 chr11 25229290 T C 0.000349 Salmonella-induced pyroptosis / / 22837397 rs11028507 chr11 25229923 A T 0.000267 Salmonella-induced pyroptosis / / 22837397 rs12795872 chr11 25239357 G A 2.60E-05 Urinary metabolites / / 21572414 rs7927031 chr11 25247977 G A 7.98E-05 Lymphocyte counts / / 22286170 rs1834461 chr11 25336459 A G 2.69E-04 Longevity / / 22279548 rs7937230 chr11 25386809 C T 1.82E-04 Fibrinogen / / 17255346 rs7931259 chr11 25389948 G T 7.74E-04 Smoking initiation / / 24665060 rs7932009 chr11 25390794 C T 5.53E-05 Fibrinogen / / 17255346 rs7935930 chr11 25391785 C T 4.30E-06 Fibrinogen / / 17255346 rs2404076 chr11 25396543 A C 2.58E-04 Cholesterol / / 17255346 rs10767370 chr11 25401131 G A 2.94E-04 Cholesterol / / 17255346 rs2404085 chr11 25409020 G A 2.90E-04 Cholesterol / / 17255346 rs2404091 chr11 25415856 G A 2.11E-04 Cholesterol / / 17255346 rs12291405 chr11 25420379 G A 4.40E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4244516 chr11 25426535 T A 1.00E-04 Prostate cancer / / 21743057 rs7941593 chr11 25445635 G A 4.57E-04 Multiple complex diseases / / 17554300 rs2713568 chr11 25464720 T G 6.33E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2618792 chr11 25469690 A G 4.45E-04 Myopia (pathological) / / 21095009 rs10834691 chr11 25490482 G T 4.00E-06 IgG glycosylation / / 23382691 rs17242189 chr11 25499560 C G 8.56E-04 Type 2 diabetes / / 17463246 rs10501009 chr11 25506084 G A 2.26E-04 Fibrinogen / / 17255346 rs10501009 chr11 25506084 G A 3.18E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11028735 chr11 25524191 G A 2.46E-04 Cholesterol / / 17255346 rs10834699 chr11 25528550 T C 1.05E-04 Cholesterol / / 17255346 rs1373020 chr11 25531583 G T 4.71E-05 Cholesterol / / 17255346 rs17242224 chr11 25531839 A G 1.59E-04 Cholesterol / / 17255346 rs11028739 chr11 25533925 G A 1.67E-04 Cholesterol / / 17255346 rs11028743 chr11 25538293 C T 9.29E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11028745 chr11 25543498 T C 1.70E-04 Cholesterol / / 17255346 rs17242293 chr11 25555059 T C 7.66E-05 Cholesterol / / 17255346 rs7933110 chr11 25561426 A C 8.02E-05 Cholesterol / / 17255346 rs10834707 chr11 25564190 T C 9.82E-05 Cholesterol / / 17255346 rs17242363 chr11 25592935 T C 1.09E-04 Fibrinogen / / 17255346 rs10501016 chr11 25625889 G T 1.52E-04 Fibrinogen / / 17255346 rs882257 chr11 25636886 C T 1.71E-04 Fibrinogen / / 17255346 rs1348353 chr11 25645867 G A 1.30E-04 Cholesterol / / 17255346 rs10834725 chr11 25647477 C T 1.25E-04 Cholesterol / / 17255346 rs12791150 chr11 25652338 C G 1.04E-04 Cholesterol / / 17255346 rs7927546 chr11 25681847 T C 2.25E-04 Multiple complex diseases / / 17554300 rs1493664 chr11 25700989 T C 2.25E-05 Urate levels / / 23263486 rs1024022 chr11 25706990 C T 6.31E-05 Post-operative nausea and vomiting / / 21694509 rs10501021 chr11 25755528 A G 1.16E-04 Nonalcoholic fatty liver disease / / 21423719 rs6484176 chr11 25787631 T C 8.84E-07 Nicotine smoking / / 19268276 rs1873962 chr11 25816175 G C 6.74E-23 Narcolepsy / / 19629137 rs4923307 chr11 25817694 T C 2.55E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12418699 chr11 25846889 T C 8.25E-04 Alcohol dependence / / 24277619 rs7110747 chr11 25853822 T A 2.10E-05 Urinary metabolites / / 21572414 rs2033979 chr11 25878681 A G 1.58E-05 Blood pressure / / 24001895 rs10767474 chr11 25889500 G A 7.89E-04 Type 2 diabetes / / 17463246 rs7117670 chr11 25904592 C A 7.04E-05 Serum metabolites / / 19043545 rs7943491 chr11 25905397 G C 3.69E-05 Serum metabolites / / 19043545 rs41526047 chr11 25963235 A C 1.50E-05 Urinary metabolites / / 21572414 rs11029042 chr11 25973647 G A 5.03E-05 Alzheimer's disease (late onset) / / 21379329 rs11029042 chr11 25973647 G A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12273504 chr11 26007640 C T 7.48E-05 Partial epilepsies / / 20522523 rs11029058 chr11 26009705 G A 3.71E-05 Psoriasis / / 20953190 rs16915019 chr11 26016331 A C 3.98E-05 Brain structure / / 22504417 rs10834878 chr11 26034583 C T 1.12E-04 Multiple complex diseases / / 17554300 rs725855 chr11 26056567 T C 9.43E-05 Pulmonary function / / 20010835 rs7114213 chr11 26069128 C T 2.79E-05 Pulmonary function / / 20010835 rs7951445 chr11 26069281 T G 2.92E-05 Pulmonary function / / 20010835 rs4923337 chr11 26069302 C T 3.30E-05 Pulmonary function / / 20010835 rs1979622 chr11 26069353 G A 3.51E-05 Pulmonary function / / 20010835 rs1979623 chr11 26069660 G A 3.51E-05 Pulmonary function / / 20010835 rs1979624 chr11 26069796 G A 3.51E-05 Pulmonary function / / 20010835 rs12803860 chr11 26070031 G A 3.48E-05 Pulmonary function / / 20010835 rs12803371 chr11 26070041 A G 3.50E-05 Pulmonary function / / 20010835 rs12785755 chr11 26070061 T C 3.48E-05 Pulmonary function / / 20010835 rs2349796 chr11 26070326 T C 3.25E-05 Pulmonary function / / 20010835 rs2349798 chr11 26070407 C T 3.22E-05 Pulmonary function / / 20010835 rs2349799 chr11 26070473 T C 3.12E-05 Pulmonary function / / 20010835 rs2349800 chr11 26070505 A G 3.12E-05 Pulmonary function / / 20010835 rs2349801 chr11 26070637 G C 3.16E-05 Pulmonary function / / 20010835 rs10742129 chr11 26071462 T G 3.21E-05 Pulmonary function / / 20010835 rs1387482 chr11 26074380 C G 3.18E-05 Pulmonary function / / 20010835 rs964624 chr11 26075716 A G 3.17E-05 Pulmonary function / / 20010835 rs964625 chr11 26075793 C T 3.23E-05 Pulmonary function / / 20010835 rs2130231 chr11 26076212 A T 3.28E-05 Pulmonary function / / 20010835 rs1489501 chr11 26082951 G C 3.27E-05 Pulmonary function / / 20010835 rs1489502 chr11 26083007 C T 3.24E-05 Pulmonary function / / 20010835 rs1994547 chr11 26083370 T A 3.51E-05 Pulmonary function / / 20010835 rs1994548 chr11 26083430 A G 3.46E-05 Pulmonary function / / 20010835 rs1994549 chr11 26083452 T G 3.39E-05 Pulmonary function / / 20010835 rs10742134 chr11 26084012 T A,G 4.21E-05 Pulmonary function / / 20010835 rs10767507 chr11 26084190 T G 4.22E-05 Pulmonary function / / 20010835 rs10767508 chr11 26084207 G A 4.37E-05 Pulmonary function / / 20010835 rs10834904 chr11 26084504 T C 6.32E-05 Pulmonary function / / 20010835 rs11029158 chr11 26105639 C T 2.70E-07 Primary nonsyndromic vesicoureteric reflex / / 19959718 rs9332433 chr11 26263085 T C 2.47E-04 Osteoarthritis (knee and hip) / / 21177295 rs9332433 chr11 26263085 T C 4.94E-05 Osteoarthritis (knee and hip) / / 21177295 rs2100820 chr11 26298576 G T 7.47E-05 Parkinson's disease / / 17052657 rs11029525 chr11 26355874 A C 3.33E-05 Alcohol consumption ANO3 intron 23743675 rs10834970 chr11 26380169 C A 6.63E-05 HIV-1 viral setpoint ANO3 intron 22174851 rs4285832 chr11 26382290 T G 4.73E-04 Type 2 diabetes ANO3 intron 17463246 rs1381176 chr11 26398690 C A 4.40E-05 Smoking initiation ANO3 intron 24665060 rs10834976 chr11 26446191 G A 4.86E-04 Smoking initiation ANO3 intron 24665060 rs11500182 chr11 26455531 T G 9.71E-06 Stroke (ischemic) ANO3 intron 22941190 rs1493728 chr11 26485520 G A 1.98E-05 Cognitive performance ANO3 intron 19734545 rs1389460 chr11 26508441 G A 2.87E-04 Blood pressure ANO3 intron 17255346 rs294028 chr11 26528789 C T 1.19E-04 Prion diseases ANO3 intron 22210626 rs294027 chr11 26529062 A G 7.62E-05 Cognitive test performance ANO3 intron 20125193 rs294018 chr11 26532286 A C 2.07E-04 Prion diseases ANO3 intron 22210626 rs7945815 chr11 26539736 T G 2.04E-04 Multiple complex diseases ANO3 intron 17554300 rs4923362 chr11 26554127 C T 2.28E-05 Coronary heart disease ANO3 intron pha003030 rs293942 chr11 26555396 G A 1.86E-26 Narcolepsy ANO3 intron 19629137 rs10501051 chr11 26573752 G A 5.90E-04 Type 2 diabetes and 6 quantitative traits ANO3 intron 17848626 rs293983 chr11 26600371 C T 2.80E-05 Schizophrenia ANO3 intron 19571809 rs293983 chr11 26600371 C T 7.79E-05 Schizophrenia ANO3 intron pha002859 rs12793968 chr11 26603926 G T 7.70E-05 Waist Circumference ANO3 intron pha003023 rs12295638 chr11 26605331 T C 4.00E-06 Obesity (extreme) ANO3 intron 19553259 rs7945560 chr11 26608497 C T 0.0008098 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ANO3 intron 23233654 rs7945560 chr11 26608497 C T 8.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) ANO3 intron 23233662 rs10767555 chr11 26611796 A G 1.29E-05 Cholesterol ANO3 intron pha003083 rs4923366 chr11 26619768 G A 6.66E-06 Waist Circumference ANO3 intron pha003023 rs1353142 chr11 26648071 A G 5.60E-04 Response to taxane treatment (placlitaxel) ANO3 intron 23006423 rs12269966 chr11 26651147 T G 1.64E-04 Response to taxane treatment (placlitaxel) ANO3 intron 23006423 rs7127915 chr11 26652962 T A 3.37E-04 Response to taxane treatment (placlitaxel) ANO3 intron 23006423 rs12795885 chr11 26662047 T C 3.92E-04 Alzheimer's disease ANO3 intron 17998437 rs11029661 chr11 26667949 T C 2.97E-04 Multiple complex diseases ANO3 intron 17554300 rs6484236 chr11 26674717 T C 8.27E-04 Type 2 diabetes ANO3 intron 17463246 rs6484236 chr11 26674717 T C 3.23E-04 Alzheimer's disease ANO3 intron 17998437 rs6484237 chr11 26674768 A G 6.98E-04 Alzheimer's disease ANO3 intron 17998437 rs972 chr11 26684763 C T 5.73E-04 Type 2 diabetes ANO3 UTR-3 17463246 rs12575103 chr11 26724778 C T 1.08E-04 Spine bone size SLC5A12 intron 23207799 rs7936032 chr11 26750200 T C 8.40E-06 Urinary metabolites / / 21572414 rs4923383 chr11 26756324 C A 9.86E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10501065 chr11 26763016 T C 2.31E-04 Stroke / / pha002886 rs10501068 chr11 26769636 T G 3.00E-04 Chronic fatigue syndrome / / 21912186 rs10128596 chr11 26770983 G T 8.33E-04 Multiple complex diseases / / 17554300 rs10835065 chr11 26772618 C A,G,T 9.39E-04 Multiple complex diseases / / 17554300 rs10835065 chr11 26772618 C A,G,T 1.87E-05 Major depressive disorder (broad) / / 20038947 rs11029694 chr11 26773651 T C 7.92E-04 Multiple complex diseases / / 17554300 rs10767577 chr11 26798823 T A 1.34E-04 Type 2 diabetes / / 17463246 rs1868656 chr11 26814230 G T 2.50E-04 Response to antidepressants / / 19736353 rs1375974 chr11 26815091 T C 1.01E-05 Odorant perception / / 23910658 rs7936609 chr11 26824627 G A 3.98E-06 Hearing function / / 21493956 rs7926469 chr11 26825003 T C 3.92E-06 Hearing function / / 21493956 rs10767583 chr11 26826710 C T 3.90E-06 Hearing function / / 21493956 rs10767583 chr11 26826710 C T 7.40E-05 Alcohol dependence / / 24277619 rs12363428 chr11 26843292 G A 8.99E-04 Response to alcohol consumption (flushing response) / / 24277619 rs7121319 chr11 26861544 A T 1.40E-05 Urinary metabolites / / 21572414 rs10742161 chr11 26864326 G A 8.08E-04 Multiple complex diseases / / 17554300 rs10742161 chr11 26864326 G A 1.60E-06 Urinary metabolites / / 21572414 rs10742162 chr11 26864773 A G 6.10E-06 Urinary metabolites / / 21572414 rs7112514 chr11 26866366 G A 2.60E-05 Urinary metabolites / / 21572414 rs2060650 chr11 26867987 C T 6.10E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs16916298 chr11 26873100 G A 9.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2122455 chr11 26876180 T C 1.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7102662 chr11 26876833 C T 9.88E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4431984 chr11 26895905 C T 4.62E-05 Asthma / / 11022011 rs17243762 chr11 26921946 C A 4.31E-05 Parkinson's disease (motor and cognition) / / 22658654 rs1445332 chr11 26958009 G A 4.94E-04 Multiple complex diseases / / 17554300 rs1838616 chr11 26980622 T C 9.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs2166259 chr11 26983363 G A 7.79E-04 Intracranial aneurysm / / 20613766 rs11029765 chr11 27005687 T A 2.35E-04 Multiple complex diseases / / 17554300 rs12287195 chr11 27007538 T C 2.79E-04 Multiple complex diseases / / 17554300 rs12419641 chr11 27009348 G A 2.51E-04 Multiple complex diseases / / 17554300 rs10835093 chr11 27020461 C T 2.29E-04 Hemoglobin concentration / / 20534544 rs1445322 chr11 27034998 C T 8.55E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs17309593 chr11 27045200 C T 0.0003751 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17309593 chr11 27045200 C T 3.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10501074 chr11 27052793 A G 9.74E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs10767592 chr11 27062338 C T 6.91E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs16916476 chr11 27062488 T G 1.44E-82 Multiple complex diseases / / 17554300 rs12385796 chr11 27063867 A G 9.03E-04 Alzheimer's disease BBOX1 intron 22005930 rs7107938 chr11 27071118 C T 2.02E-04 Osteoarthritis BBOX1 intron 19508968 rs7107938 chr11 27071118 C T 5.34E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers BBOX1 intron 21775533 rs1445317 chr11 27075087 C A 2.28E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers BBOX1 intron 21775533 rs7942200 chr11 27114538 G A 7.40E-04 Iron levels BBOX1 intron pha002876 rs17309656 chr11 27122322 T A,C,G 5.82E-04 Suicide attempts in bipolar disorder BBOX1 intron 21423239 rs4278476 chr11 27123970 C T 8.72E-04 Suicide attempts in bipolar disorder BBOX1 intron 21423239 rs4532991 chr11 27132531 A G 6.50E-04 Type 2 diabetes BBOX1 intron 17463246 rs4328173 chr11 27133805 T C 7.39E-04 Suicide attempts in bipolar disorder BBOX1 intron 21423239 rs1372902 chr11 27133886 T C 2.30E-05 Fasting plasma glucose BBOX1 intron 19060907 rs17243943 chr11 27137460 A G 2.20E-04 Multiple complex diseases BBOX1 intron 17554300 rs7949619 chr11 27139110 A G 7.06E-04 Suicide attempts in bipolar disorder BBOX1 intron 21423239 rs972904 chr11 27140199 G A 9.90E-04 Suicide attempts in bipolar disorder BBOX1 intron 21423239 rs1044273 chr11 27147270 G A 6.51E-04 Suicide attempts in bipolar disorder BBOX1 cds-synon 21423239 rs10835119 chr11 27162750 G A 8.48E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1545265 chr11 27173896 A G 2.87E-04 Myopia (pathological) / / 21095009 rs1442920 chr11 27175455 A C 8.14E-04 Myopia (pathological) / / 21095009 rs1442920 chr11 27175455 A C 0.000171 Salmonella-induced pyroptosis / / 22837397 rs11029853 chr11 27187360 C T 5.27E-04 Multiple complex diseases / / 17554300 rs4923429 chr11 27213554 T C 1.79E-04 Type 2 diabetes / / 17463246 rs10835148 chr11 27266037 A G 1.30E-08 Bone mineral density (paediatric,skull) / / 24945404 rs7483297 chr11 27272733 T A 8.30E-09 Bone mineral density (paediatric,skull) / / 24945404 rs7948420 chr11 27276450 C T 6.70E-09 Bone mineral density (paediatric,skull) / / 24945404 rs1038099 chr11 27276852 A G 3.20E-10 Bone mineral density (paediatric,skull) / / 24945404 rs1351175 chr11 27280320 C T 2.20E-10 Bone mineral density (paediatric,skull) / / 24945404 rs7950903 chr11 27282268 A G 3.90E-10 Bone mineral density (paediatric,skull) / / 24945404 rs11029901 chr11 27287108 A G 3.90E-10 Bone mineral density (paediatric,skull) / / 24945404 rs11029907 chr11 27295271 G C 9.72E-04 Stroke / / pha002887 rs10835149 chr11 27295678 T C 4.60E-10 Bone mineral density (paediatric,skull) / / 24945404 rs1478690 chr11 27295878 G A 6.30E-10 Bone mineral density (paediatric,skull) / / 24945404 rs7481109 chr11 27298062 A G 6.30E-10 Bone mineral density (paediatric,skull) / / 24945404 rs10835150 chr11 27301061 G C 6.30E-10 Bone mineral density (paediatric,skull) / / 24945404 rs7119628 chr11 27302716 G A 6.30E-10 Bone mineral density (paediatric,skull) / / 24945404 rs7126943 chr11 27303937 C T 5.20E-10 Bone mineral density (paediatric,skull) / / 24945404 rs899303 chr11 27309681 A G 1.70E-09 Bone mineral density (paediatric,skull) / / 24945404 rs10450561 chr11 27309956 T C 1.70E-09 Bone mineral density (paediatric,skull) / / 24945404 rs10767628 chr11 27310871 G C 1.70E-09 Bone mineral density (paediatric,skull) / / 24945404 rs7479309 chr11 27311814 A G 4.22E-06 Opioid sensitivity / / 23183491 rs10835154 chr11 27315356 G A 1.70E-09 Bone mineral density (paediatric,skull) / / 24945404 rs7483162 chr11 27316394 A G 1.40E-09 Bone mineral density (paediatric,skull) / / 24945404 rs7480595 chr11 27316623 T C 1.40E-09 Bone mineral density (paediatric,skull) / / 24945404 rs10835155 chr11 27317812 C T 1.40E-09 Bone mineral density (paediatric,skull) / / 24945404 rs10767632 chr11 27318465 C G 1.20E-09 Bone mineral density (paediatric,skull) / / 24945404 rs10082611 chr11 27320108 C G 9.70E-10 Bone mineral density (paediatric,skull) / / 24945404 rs10082678 chr11 27320448 A G 9.70E-10 Bone mineral density (paediatric,skull) / / 24945404 rs7950335 chr11 27322503 C T 8.10E-10 Bone mineral density (paediatric,skull) / / 24945404 rs10501084 chr11 27323139 T C 6.56E-04 Bipolar disorder / / 19259986 rs10501084 chr11 27323139 T C 5.40E-10 Bone mineral density (paediatric,skull) / / 24945404 rs7107790 chr11 27324730 G A 6.40E-10 Bone mineral density (paediatric,skull) / / 24945404 rs10835156 chr11 27325218 T C 5.40E-10 Bone mineral density (paediatric,skull) / / 24945404 rs11029931 chr11 27325542 T G 3.10E-10 Bone mineral density (paediatric,skull) / / 24945404 rs11029932 chr11 27328254 C T 5.40E-10 Bone mineral density (paediatric,skull) / / 24945404 rs10767633 chr11 27329725 T C 5.40E-10 Bone mineral density (paediatric,skull) / / 24945404 rs7480168 chr11 27330045 A C 5.40E-10 Bone mineral density (paediatric,skull) / / 24945404 rs10835158 chr11 27331770 A G 5.40E-10 Bone mineral density (paediatric,skull) / / 24945404 rs10742174 chr11 27332291 A G 5.40E-10 Bone mineral density (paediatric,skull) / / 24945404 rs10767634 chr11 27332474 C T 5.40E-10 Bone mineral density (paediatric,skull) / / 24945404 rs10160456 chr11 27336704 C T 8.00E-06 Bone mineral density (paediatric,skull) / / 24945404 rs9299997 chr11 27336872 C T 3.50E-10 Bone mineral density (paediatric,skull) / / 24945404 rs10160687 chr11 27337183 T C 3.50E-10 Bone mineral density (paediatric,skull) / / 24945404 rs1478684 chr11 27337345 T G 5.37E-05 Opioid sensitivity / / 23183491 rs7110026 chr11 27337526 A G 3.50E-10 Bone mineral density (paediatric,skull) / / 24945404 rs2045935 chr11 27337843 A G 5.37E-05 Opioid sensitivity / / 23183491 rs9299998 chr11 27338581 T A 6.00E-09 Bone mineral density (paediatric,skull) / / 24945404 rs10835161 chr11 27338689 G T 1.06E-05 Squamous cell carcinoma / / 23341777 rs10835161 chr11 27338689 G T 2.22E-04 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs11029954 chr11 27354449 C T 4.90E-09 Bone mineral density (paediatric,skull) / / 24945404 rs3929244 chr11 27355031 C T 6.00E-09 Bone mineral density (paediatric,skull) / / 24945404 rs10835166 chr11 27355962 C T 5.10E-09 Bone mineral density (paediatric,skull) / / 24945404 rs34804482 chr11 27389739 T C 0.0000698 Body mass index LGR4 missense 23001569 rs2448001 chr11 27393813 G A 4.90E-06 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) LGR4 intron 21221126 rs2472632 chr11 27395875 C A 5.30E-06 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) LGR4 intron 21221126 rs16916969 chr11 27422453 C T 4.75E-04 Multiple complex diseases LGR4 intron 17554300 rs7936621 chr11 27426391 G A 3.30E-08 Bone mineral density (paediatric,skull) LGR4 intron 24945404 rs7927234 chr11 27436356 G C 8.42E-04 Coronary heart disease LGR4 intron 21606135 rs4448642 chr11 27443151 T C 0.0000356 Asthma LGR4 intron 22694930 rs12271278 chr11 27451759 C A 2.10E-05 Urinary metabolites LGR4 intron 21572414 rs5020127 chr11 27461779 T C 2.85E-06 Esophageal cancer (squamous cell) LGR4 intron 22960999 rs4074516 chr11 27465591 T C 6.30E-14 Bone mineral density (paediatric,skull) LGR4 intron 24945404 rs4536164 chr11 27467109 A C 3.00E-04 Pancreatic cancer LGR4 intron 23180869 rs4542364 chr11 27473981 G A 1.00E-13 Bone mineral density (paediatric,skull) LGR4 intron 24945404 rs11030014 chr11 27480827 T C 5.30E-10 Bone mineral density (paediatric,skull) LGR4 intron 24945404 rs11030016 chr11 27487992 C T 4.00E-11 Bone mineral density (paediatric,skull) LGR4 intron 24945404 rs7938467 chr11 27502675 C G 1.10E-12 Bone mineral density (paediatric,skull) / / 24945404 rs10835187 chr11 27505677 C T 8.35E-05 Personality dimensions / / 18957941 rs10835187 chr11 27505677 C T 5.00E-08 Bone mineral density / / 22504420 rs10835187 chr11 27505677 C T 3.00E-04 Pancreatic cancer / / 23180869 rs10835187 chr11 27505677 C T 1.63E-17 Bone mineral density (paediatric,skull) / / 24945404 rs10835187 chr11 27505677 C T 2.00E-17 Bone mineral density (paediatric,skull) / / 24945404 rs10835187 chr11 27505677 C T 3.00E-13 Bone mineral density (paediatric,skull) / / 24945404 rs10835187 chr11 27505677 C T 7.11E-04 Bone mineral density (paediatric,total body less head) / / 24945404 rs11030024 chr11 27508681 C T 9.80E-10 Bone mineral density (paediatric,skull) / / 24945404 rs7104230 chr11 27515109 T C 1.10E-14 Bone mineral density (paediatric,skull) / / 24945404 rs10835188 chr11 27523186 G T 8.00E-04 Pancreatic cancer LIN7C intron 23180869 rs550352232 chr11 27523186 G GTTAAAATTTCAGGCAAAT 8.00E-04 Pancreatic cancer LIN7C intron 23180869 rs3763965 chr11 27528987 A T 1.90E-14 Bone mineral density (paediatric,skull) BDNF-AS1 intron 24945404 rs10835189 chr11 27541995 G T 3.40E-14 Bone mineral density (paediatric,skull) BDNF-AS1 intron 24945404 rs10767646 chr11 27559744 T C 2.56E-04 Bone mineral density BDNF-AS1 intron 24249740 rs988712 chr11 27563382 G T 5.00E-17 Obesity BDNF-AS1 intron 21708048 rs1304101 chr11 27571594 A G 4.90E-14 Bone mineral density (paediatric,skull) BDNF-AS1 intron 24945404 rs1304100 chr11 27571603 A G 4.40E-08 Smoking behavior BDNF-AS1 intron 22832964 rs10835193 chr11 27572337 C T 3.90E-14 Bone mineral density (paediatric,skull) BDNF-AS1 intron 24945404 rs7481311 chr11 27583129 T C 3.00E-06 Weight BDNF-AS1 intron 19079260 rs7481311 chr11 27583129 T C 8.00E-06 Body mass index BDNF-AS1 intron 19079260 rs7481311 chr11 27583129 T C 4.90E-06 Smoking behavior BDNF-AS1 intron 20418888 rs10501086 chr11 27593701 G A 3.84E-04 Smoking initiation BDNF-AS1 intron 24665060 rs10835196 chr11 27601335 G C 8.80E-14 Bone mineral density (paediatric,skull) BDNF-AS1 intron 24945404 rs11030064 chr11 27618016 C T 8.05E-05 Personality dimensions BDNF-AS1 intron 18957941 rs11030064 chr11 27618016 C T 2.30E-13 Bone mineral density (paediatric,skull) BDNF-AS1 intron 24945404 rs7937150 chr11 27620360 C A 2.30E-13 Bone mineral density (paediatric,skull) BDNF-AS1 intron 24945404 rs7937485 chr11 27620473 G A 2.30E-13 Bone mineral density (paediatric,skull) BDNF-AS1 intron 24945404 rs12798439 chr11 27621960 T C 2.30E-13 Bone mineral density (paediatric,skull) BDNF-AS1 intron 24945404 rs7949590 chr11 27623611 C T 1.70E-13 Bone mineral density (paediatric,skull) BDNF-AS1 intron 24945404 rs11030073 chr11 27625942 A G 1.70E-13 Bone mineral density (paediatric,skull) BDNF-AS1 intron 24945404 rs12223664 chr11 27627850 C A 9.40E-13 Bone mineral density (paediatric,skull) BDNF-AS1 intron 24945404 rs10767651 chr11 27628607 G A 3.60E-11 Bone mineral density (paediatric,skull) BDNF-AS1 intron 24945404 rs10767652 chr11 27628826 G A 2.00E-13 Bone mineral density (paediatric,skull) BDNF-AS1 intron 24945404 rs7939810 chr11 27633409 C T 5.63E-04 Myopia (pathological) BDNF-AS1 intron 21095009 rs879048 chr11 27638934 C A 4.90E-08 Smoking behavior BDNF-AS1 intron 22832964 rs4074134 chr11 27647285 C T 1.80E-06 Smoking behavior BDNF-AS1 intron 20418888 rs4074134 chr11 27647285 C T 4.10E-08 Smoking behavior BDNF-AS1 intron 22832964 rs4923457 chr11 27648580 A T 3.30E-08 Smoking behavior BDNF-AS1 intron 22832964 rs4923460 chr11 27656789 G T 4.10E-08 Smoking behavior BDNF-AS1 intron 22832964 rs4923461 chr11 27656910 A G 1.10E-06 Smoking behavior BDNF-AS1 intron 20418888 rs4923461 chr11 27656910 A G 3.10E-04 Menarche (age at onset) BDNF-AS1 intron 21102462 rs11030094 chr11 27659775 G A 4.00E-10 Bone mineral density (paediatric,skull) BDNF-AS1 intron 24945404 rs11030096 chr11 27665543 T C 1.00E-09 Bone mineral density (paediatric,skull) BDNF-AS1 intron 24945404 rs7126752 chr11 27665788 A G 5.09E-04 Acute lung injury BDNF-AS1 intron 22295056 rs7126752 chr11 27665788 A G 0.000212 Height (Pygmy height) BDNF-AS1 intron 22570615 rs7130233 chr11 27666194 A G 5.09E-04 Acute lung injury BDNF-AS1 intron 22295056 rs7130233 chr11 27666194 A G 0.000212 Height (Pygmy height) BDNF-AS1 intron 22570615 rs925946 chr11 27667202 T G 4.00E-09 Weight BDNF-AS1 intron 19079260 rs925946 chr11 27667202 T G 9.00E-10 Body mass index BDNF-AS1 intron 19079260 rs925946 chr11 27667202 T G 8.57E-04 Premature ovarian failure BDNF-AS1 intron 19508998 rs925946 chr11 27667202 T G 2.00E-07 Smoking behavior BDNF-AS1 intron 20418888 rs1519479 chr11 27667531 C T 3.10E-10 Bone mineral density (paediatric,skull) BDNF-AS1 intron 24945404 rs10501087 chr11 27670108 T C 4.20E-06 Smoking behavior BDNF-AS1 intron 20418888 rs10501087 chr11 27670108 T C 3.01E-05 Eating disorders BDNF-AS1 intron 22911880 rs10501087 chr11 27670108 T C 1.69E-05 Esophageal cancer (squamous cell) BDNF-AS1 intron 22960999 rs2203877 chr11 27670910 T C 4.20E-10 Bone mineral density (paediatric,skull) BDNF-AS1 intron 24945404 rs6265 chr11 27679916 C T 2.00E-07 Weight BDNF missense 19079260 rs6265 chr11 27679916 C T 5.00E-10 Body mass index BDNF missense 19079260 rs6265 chr11 27679916 C T 7.20E-06 Smoking behavior BDNF missense 20418888 rs6265 chr11 27679916 C T 2.00E-08 Smoking behavior BDNF missense 20418890 rs6265 chr11 27679916 C T 3.56E-13 Body mass index BDNF missense 22344219 rs6265 chr11 27679916 C T 1.80E-08 Smoking behavior BDNF missense 22832964 rs6265 chr11 27679916 C T 2.33E-05 Eating disorders BDNF missense 22911880 rs6265 chr11 27679916 C T 6.89E-11 Body mass index BDNF missense 23001569 rs11030101 chr11 27680744 A T 7.80E-09 Bone mineral density (paediatric,skull) BDNF UTR-5 24945404 rs11030104 chr11 27684517 A G 2.00E-20 Body mass index BDNF intron 24861553 rs1401635 chr11 27693991 C G 1.25E-08 Body mass index BDNF intron 23001569 rs12291186 chr11 27696318 A C 4.50E-05 HIV-1 control BDNF intron 20041166 rs7103873 chr11 27700317 G C 2.10E-08 Bone mineral density (paediatric,skull) BDNF intron 24945404 rs10835211 chr11 27701365 G A 1.50E-05 Smoking behavior BDNF intron 20418888 rs10835211 chr11 27701365 G A 1.74E-11 Obesity BDNF intron 23563607 rs10835211 chr11 27701365 G A 9.43E-15 Obesity BDNF intron 23563607 rs6484320 chr11 27703188 T A 4.90E-08 Smoking behavior BDNF intron 22832964 rs2049046 chr11 27723775 T A 2.50E-08 Bone mineral density (paediatric,skull) BDNF intron 24945404 rs10767664 chr11 27725986 T A 5.00E-26 Body mass index BDNF intron 20935630 rs10767664 chr11 27725986 T A 0.0000471 Body mass index (males) BDNF intron 23001569 rs10767664 chr11 27725986 T A 0.000313 Body mass index (females) BDNF intron 23001569 rs10767664 chr11 27725986 T A 4.69E-26 Body mass index BDNF intron 23001569 rs2030323 chr11 27728539 A C 4.00E-16 Body mass index BDNF intron 22344221 rs2030323 chr11 27728539 A C 3.00E-22 Obesity BDNF intron 23563607 rs2030323 chr11 27728539 A C 5.00E-17 Obesity BDNF intron 23563607 rs2030323 chr11 27728539 A C 6.00E-10 Body mass index BDNF intron 23563607 rs2030323 chr11 27728539 A C 6.00E-11 Obesity BDNF intron 23563607 rs12273363 chr11 27744859 T C 5.99E-04 Amyotrophic lateral sclerosis (sporadic) BDNF nearGene-5 24529757 rs1008041 chr11 27772997 T C 2.77E-04 HIV-1 viral setpoint / / 17641165 rs11030134 chr11 27786474 T C 8.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10501091 chr11 27787783 T C 7.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11607128 chr11 27804725 C A 1.20E-05 Urinary metabolites / / 21572414 rs11607128 chr11 27804725 C A 6.60E-05 Glaucoma (primary open-angle) / / 22605921 rs1491857 chr11 27845813 C T 7.79E-05 Multiple complex diseases / / 17554300 rs1156562 chr11 27854012 A G 2.60E-05 Urinary metabolites / / 21572414 rs1949876 chr11 27980881 T A 4.62E-06 Glaucoma (primary open-angle) / / 22605921 rs10501093 chr11 27990119 G A 3.00E-05 Breast cancer and prostate cancer / / 17903305 rs11030175 chr11 27992042 C T 9.36E-04 Coronary Artery Disease / / 17634449 rs1568889 chr11 28009463 T C 1.35E-05 Multiple complex diseases / / 17554300 rs1568889 chr11 28009463 T C 2.00E-06 Bipolar disorder / / 21254220 rs141828077 chr11 28057897 G A 0.00029 Breast cancer KIF18A missense 23555315 rs10458896 chr11 28057957 T C 1.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KIF18A missense 20877124 rs12272419 chr11 28110151 T C 1.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KIF18A missense 20877124 rs17310125 chr11 28230627 G T 1.41E-04 Alzheimer's disease METTL15 intron 17998437 rs11601602 chr11 28233768 A G 9.00E-06 Obesity-related traits METTL15 intron 23251661 rs2354426 chr11 28260444 T C 9.88E-05 Lung function (forced vital capacity) METTL15 intron pha003104 rs7940342 chr11 28265598 C A 1.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) METTL15 intron 20877124 rs1564745 chr11 28291555 G A 1.58E-04 Coronary Artery Disease METTL15 intron 17634449 rs1032091 chr11 28292078 A G 8.52E-05 Coronary Artery Disease METTL15 intron 17634449 rs11030292 chr11 28381599 C T 2.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17652117 chr11 28483645 A G 5.04E-04 Multiple complex diseases / / 17554300 rs2585810 chr11 28483787 G A 3.78E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs871004 chr11 28512458 G A 1.31E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10835348 chr11 28518811 C T 4.43E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1596300 chr11 28581430 T C 9.37E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs1596299 chr11 28581557 C T 8.30E-05 Height / / 21998595 rs2585824 chr11 28581801 G T 1.80E-04 Height / / 21998595 rs2585823 chr11 28582062 G A 4.30E-05 Height / / 21998595 rs10767734 chr11 28642381 C T 3.66E-04 Hemoglobin concentration / / 20534544 rs11030393 chr11 28648737 A G 2.78E-05 Hemoglobin concentration / / 20534544 rs7942414 chr11 28669964 T C 7.30E-06 Hemoglobin concentration / / 20534544 rs4923554 chr11 28676838 A G 5.76E-05 Hemoglobin concentration / / 20534544 rs7119404 chr11 28691287 C T 9.78E-06 Hemoglobin concentration / / 20534544 rs939505 chr11 28714139 A C 4.95E-04 Hemoglobin concentration / / 20534544 rs10835395 chr11 28741136 A C 2.90E-04 Hemoglobin concentration / / 20534544 rs2356007 chr11 28751601 C T 8.82E-05 HIV-1 viral setpoint / / 22174851 rs482202 chr11 28785216 G A 1.82E-04 Bipolar disorder,schizoaffective / / 19567891 rs4542397 chr11 28820714 C T 2.51E-04 Bipolar disorder,schizoaffective / / 19567891 rs2883827 chr11 28854208 G T 1.17E-05 Post-operative nausea and vomiting / / 21694509 rs10835415 chr11 28854844 T C 1.58E-04 Bipolar disorder,schizoaffective / / 19567891 rs1589104 chr11 28864299 T C 2.47E-04 Bipolar disorder,schizoaffective / / 19567891 rs10835422 chr11 28867067 C T 3.43E-04 Bipolar disorder,schizoaffective / / 19567891 rs17603351 chr11 28955481 T C 9.75E-05 Orofacial clefts / / 22419666 rs10835482 chr11 29122702 C T 1.90E-04 Schizophrenia (treatment refractory) / / 22479419 rs4923591 chr11 29134515 A G 1.70E-05 Urinary metabolites / / 21572414 rs12366025 chr11 29148890 G A 1.00E-04 Schizophrenia (treatment refractory) / / 22479419 rs1552717 chr11 29158495 A T 5.20E-04 Schizophrenia (treatment refractory) / / 22479419 rs1907605 chr11 29158507 G A 5.60E-04 Schizophrenia (treatment refractory) / / 22479419 rs1602565 chr11 29162136 T C 3.00E-06 Schizophrenia / / 18677311 rs1602565 chr11 29162136 T C 3.20E-04 Schizophrenia (treatment refractory) / / 22479419 rs2172225 chr11 29166202 A G 2.70E-04 Schizophrenia (treatment refractory) / / 22479419 rs2958625 chr11 29167468 C A 3.50E-04 Schizophrenia (treatment refractory) / / 22479419 rs4923593 chr11 29167659 T C 8.02E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs10835491 chr11 29171879 G C 5.10E-04 Schizophrenia (treatment refractory) / / 22479419 rs11030597 chr11 29190528 A G 1.50E-04 Schizophrenia (treatment refractory) / / 22479419 rs1491818 chr11 29195137 A G 8.00E-06 Amyotrophic lateral sclerosis (age of onset) / / 22959728 rs2055014 chr11 29195732 G A 4.95E-05 Pulmonary function / / 20010835 rs11030600 chr11 29196242 T G 6.17E-29 Narcolepsy / / 19629137 rs1463706 chr11 29197113 C G 0.000041 Panic disorder / / 23149450 rs1463706 chr11 29197113 C G 4.10E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs2452144 chr11 29198384 G A 0.00000458 Panic disorder / / 23149450 rs2452144 chr11 29198384 G A 4.58E-06 Serum tamsulosin hydrochloride concentration / / 23151678 rs7938219 chr11 29202440 G A 5.73E-06 Schizophrenia / / 21926974 rs11030606 chr11 29214412 C T 6.80E-04 Schizophrenia (treatment refractory) / / 22479419 rs17513662 chr11 29303887 G T 5.25E-04 Coronary heart disease / / 21971053 rs7106909 chr11 29355351 C T 5.49E-04 Obesity (extreme) / / 21935397 rs2225571 chr11 29470621 A C 5.99E-05 Waist Circumference / / pha003023 rs2667431 chr11 29475619 G T 6.05E-05 Alzheimer's disease / / 22005930 rs10488790 chr11 29478337 A G 7.46E-05 Endometrial cancer / / 24096698 rs10488790 chr11 29478337 A G 8.24E-04 Endometrial cancer / / 24096698 rs2667429 chr11 29479568 T G 2.50E-04 Alzheimer's disease / / 22005930 rs2667428 chr11 29479973 G A 2.66E-04 Alzheimer's disease / / 22005930 rs1533139 chr11 29480419 G C 2.66E-04 Alzheimer's disease / / 22005930 rs584041 chr11 29488271 T C 4.30E-05 Alzheimer's disease / / 22005930 rs546771 chr11 29490531 C A 4.91E-05 Alzheimer's disease / / 22005930 rs1009070 chr11 29527661 T C 5.20E-05 Male-pattern baldness / / 18849994 rs10835533 chr11 29536763 A T 4.04E-04 Fibrinogen / / 17255346 rs10835534 chr11 29541532 G A 1.76E-04 Fibrinogen / / 17255346 rs1231681 chr11 29589269 T C 2.30E-05 Urinary metabolites / / 21572414 rs1231682 chr11 29589341 A G 6.73E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs326765 chr11 29606266 T C 2.11E-04 Fibrinogen / / 17255346 rs326782 chr11 29632786 T C 5.18E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs326789 chr11 29642280 T C 4.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs326790 chr11 29650626 T C 1.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2447045 chr11 29659444 A G 1.80E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2050976 chr11 29668390 A C 6.06E-04 Multiple complex diseases / / 17554300 rs1570337 chr11 29776537 C A 4.84E-04 Multiple complex diseases / / 17554300 rs4408284 chr11 29800878 T C 9.17E-04 Multiple complex diseases / / 17554300 rs1590287 chr11 29806844 C T 9.66E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10501120 chr11 29897097 G A 7.46E-05 Epilepsy / / 22116939 rs12222280 chr11 29938269 T C 1.12E-04 Epilepsy / / 22116939 rs11030877 chr11 29957760 C G 8.99E-04 Multiple complex diseases / / 17554300 rs11030909 chr11 29977241 C A 4.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs637678 chr11 30094814 G C 3.25E-04 Multiple complex diseases / / 17554300 rs585978 chr11 30095169 C G 3.76E-04 Multiple complex diseases / / 17554300 rs1115665 chr11 30141357 T C 1.20E-05 Urinary metabolites / / 21572414 rs1716030 chr11 30143674 C A 3.03E-04 Intracranial aneurysm / / 20613766 rs997081 chr11 30144181 C A 2.50E-05 Urinary metabolites / / 21572414 rs582065 chr11 30162926 A C 7.30E-04 Multiple complex diseases / / 17554300 rs930321 chr11 30165896 T C 4.26E-04 Alcohol dependence / / 20201924 rs2226016 chr11 30175706 C T 2.20E-05 Urinary metabolites / / 21572414 rs11031006 chr11 30226528 G A 2.24E-04 Multiple complex diseases / / 17554300 rs521371 chr11 30231758 C T 0.000577 Salmonella-induced pyroptosis / / 22837397 rs10835647 chr11 30313268 G A 9.34E-04 Multiple complex diseases / / 17554300 rs10835649 chr11 30329175 A G 6.41E-04 Multiple complex diseases / / 17554300 rs1222208 chr11 30361377 A C 4.49E-04 Smoking cessation / / 24665060 rs12363432 chr11 30371615 C T 5.21E-04 Multiple complex diseases / / 17554300 rs1765142 chr11 30378559 C A 4.20E-06 Schizophrenia / / 21791550 rs1765142 chr11 30378559 C A 0.000014 Psychosis / / 23164818 rs12294104 chr11 30382899 C T 1.00E-11 Menopause (age at onset) / / 22267201 rs487336 chr11 30402105 T C 9.39E-06 Dental caries / / 21940522 rs667511 chr11 30425655 G A 6.81E-04 Multiple complex diseases MPPED2 intron 17554300 rs538811 chr11 30427075 C T 0.00000363 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment MPPED2 intron 23392654 rs538811 chr11 30427075 C T 3.63E-06 Thiazide-induced adverse metabolic effects in hypertensive patients MPPED2 intron 23400010 rs12575085 chr11 30428262 G T 8.14E-05 Multiple complex diseases MPPED2 intron 17554300 rs567056 chr11 30435051 G T 4.44E-06 Dental caries MPPED2 intron 21940522 rs10767843 chr11 30436400 G T 4.62E-04 Alzheimer's disease (late onset) MPPED2 intron 21379329 rs11031075 chr11 30448487 C T 2.99E-04 Multiple complex diseases MPPED2 intron 17554300 rs980561 chr11 30456545 C T 4.14E-06 Dental caries MPPED2 intron 21940522 rs980562 chr11 30456817 G A 9.60E-07 Dental caries MPPED2 intron 21940522 rs11031093 chr11 30467500 G A 8.00E-06 Dental caries MPPED2 intron 21940522 rs1026477 chr11 30489027 G A 5.48E-05 Periodontitis (Chronic) MPPED2 intron 25008200 rs1026477 chr11 30489027 G A 6.73E-05 Eosinophil counts MPPED2 intron pha003088 rs473241 chr11 30495405 C T 2.00E-04 Coronary heart disease MPPED2 intron 21606135 rs16920793 chr11 30507095 G A 9.14E-05 Aortic root size MPPED2 intron 21223598 rs545610 chr11 30508108 T C 7.83E-04 Aortic root size MPPED2 intron 21223598 rs545610 chr11 30508108 T C 9.00E-06 Dental caries MPPED2 intron 21940522 rs10835673 chr11 30511665 A C 8.15E-06 Smooth-surface caries MPPED2 intron 24556642 rs16920802 chr11 30512473 C A 9.68E-06 Smooth-surface caries MPPED2 intron 24556642 rs12800941 chr11 30512726 T A 9.07E-06 Smooth-surface caries MPPED2 intron 24556642 rs11031118 chr11 30520163 T C 4.39E-06 Dental caries MPPED2 intron 21940522 rs475183 chr11 30533039 A C 7.00E-04 Heart Failure MPPED2 intron pha002885 rs11031122 chr11 30547438 T C 2.03E-05 Abdominal aortic aneurysm MPPED2 intron 24046328 rs11031125 chr11 30553329 C T 2.84E-05 Abdominal aortic aneurysm MPPED2 intron 24046328 rs559519 chr11 30554476 T C 3.07E-04 Suicide attempts in bipolar disorder MPPED2 intron 21423239 rs7121800 chr11 30564577 T C 6.85E-06 Smooth-surface caries MPPED2 intron 24556642 rs1380018 chr11 30569684 A G 9.90E-04 Type 2 diabetes MPPED2 intron 17463246 rs1374616 chr11 30584613 C A 5.54E-04 Multiple complex diseases MPPED2 intron 17554300 rs566472 chr11 30587583 T C 7.87E-04 Insulin resistance MPPED2 intron 21901158 rs4922556 chr11 30602252 T G 3.12E-04 Multiple complex diseases MPPED2 intron 17554300 rs7119684 chr11 30613825 A G 3.70E-05 Prion diseases / / 22210626 rs294374 chr11 30628538 A G 3.74E-04 Hemoglobin concentration / / 20534544 rs449438 chr11 30651019 A C 5.93E-04 Alcohol dependence / / 21314694 rs294335 chr11 30671304 C T 2.29E-04 Hemoglobin concentration / / 20534544 rs1447265 chr11 30691539 T C 2.15E-05 Body mass index / / 23669352 rs292432 chr11 30735519 C A 3.68E-04 Type 2 diabetes / / 17463246 rs10835705 chr11 30742742 T A 1.40E-04 Smoking initiation / / 24665060 rs963837 chr11 30749090 T C 1.00E-09 Renal function-related traits (eGRFcrea) / / 22797727 rs963837 chr11 30749090 T C 3.00E-09 Renal function-related traits (sCR) / / 22797727 rs618585 chr11 30750391 T C 8.49E-04 Multiple complex diseases / / 17554300 rs2218604 chr11 30752700 C T 8.30E-04 Multiple complex diseases / / 17554300 rs3925584 chr11 30760335 T C 5.00E-16 magnesium levels / / 20700443 rs3925584 chr11 30760335 T C 8.00E-18 Chronic kidney disease / / 22479191 rs584591 chr11 30761964 A C 8.75E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10767873 chr11 30768678 C T 5.00E-16 Renal function-related traits (BUN) / / 22797727 rs617749 chr11 30776679 G A 4.54E-04 Type 2 diabetes / / 17463246 rs682398 chr11 30780863 G A 1.13E-04 Smoking cessation / / 24665060 rs638196 chr11 30780931 C T 7.65E-04 Multiple complex diseases / / 17554300 rs11031208 chr11 30829830 C T 8.22E-04 Myocardial Infarction / / pha002883 rs1448944 chr11 30842913 G C 6.00E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs273575 chr11 30910322 T C 7.37E-04 Body mass index DCDC5 intron 21701565 rs163879 chr11 30951674 C T 2.00E-11 Bone mineral density DCDC5 intron 22504420 rs163856 chr11 30963348 G C 6.38E-04 Multiple complex diseases DCDC5 intron 17554300 rs158584 chr11 30985762 G A 3.90E-04 Multiple complex diseases DCDC5 intron 17554300 rs290075 chr11 31003594 C T 4.90E-04 Multiple complex diseases DCDC5 intron 17554300 rs290740 chr11 31013744 G T 4.83E-05 Cognitive test performance DCDC5 intron 20125193 rs459581 chr11 31027219 T C 1.46E-05 Cognitive test performance / / 20125193 rs98768 chr11 31036069 C T 1.18E-04 Multiple complex diseases LOC100508736 intron 17554300 rs288467 chr11 31061375 G A 9.11E-04 Amyotrophic Lateral Sclerosis LOC100508736 intron 17827064 rs288464 chr11 31062955 C T 8.53E-05 Smoking cessation LOC100508736 intron 18519826 rs566302 chr11 31091232 C T 9.31E-04 Amyotrophic Lateral Sclerosis LOC100508736 intron 17827064 rs208064 chr11 31158395 G A 7.16E-06 Smoking cessation LOC100508736 intron 18519826 rs169623 chr11 31184157 T C 8.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100508736 intron 20877124 rs16921914 chr11 31210771 G A 2.00E-09 Bone mineral density (spine) LOC100508736 intron 19801982 rs158136 chr11 31220712 C T 8.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100508736 intron 20877124 rs1475558 chr11 31263428 T C 6.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs578666 chr11 31404484 G A 7.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) D/JC24 intron 20877124 rs578666 chr11 31404484 G A 7.21E-05 Prion diseases D/JC24 intron 22210626 rs16922146 chr11 31420388 C T 4.76E-04 Multiple complex diseases D/JC24 intron 17554300 rs4922571 chr11 31686449 G A 7.00E-05 Obesity-related traits ELP4 intron 17903300 rs10488689 chr11 31702516 G T 2.22E-04 Body mass index ELP4 intron 17255346 rs1016934 chr11 31720621 A G 2.15E-04 Body mass index ELP4 intron 17255346 rs7948834 chr11 31775396 T C 7.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ELP4 intron 20877124 rs3026411 chr11 31801544 A T 1.40E-05 Word reading ELP4 intron 23738518 rs2177482 chr11 31802357 G A 1.40E-05 Word reading ELP4 intron 23738518 rs3026401 chr11 31807524 C T 4.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PAX6 UTR-3 20877124 rs662702 chr11 31809070 C T 6.36E-05 Myopia (severe) PAX6 UTR-3 23933737 rs2071754 chr11 31812582 C T 2.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PAX6 intron 20877124 rs3026354 chr11 31830657 A G 9.87E-06 Obesity-related traits PAX6 intron 23251661 rs685428 chr11 31867699 G A 7.75E-04 Type 2 diabetes DKFZp686K1684 intron 17463246 rs584762 chr11 31870758 G T 2.00E-04 Suicidal ideation DKFZp686K1684 intron 22030708 rs761453 chr11 31878000 T C 2.00E-04 Suicidal ideation DKFZp686K1684 intron 22030708 rs11031492 chr11 31884919 T G 4.00E-06 Metabolite levels (HVA/5-HIAA ratio) DKFZp686K1684 intron 23319000 rs11031500 chr11 31894252 C T 1.56E-04 Multiple complex diseases DKFZp686K1684 intron 17554300 rs652722 chr11 31905534 C T 8.00E-08 Body mass index DKFZp686K1684 intron 22344219 rs623312 chr11 31907464 G A 1.13E-07 Body mass index / / 22344219 rs2440238 chr11 31907986 T G 1.46E-07 Body mass index / / 22344219 rs597660 chr11 31915214 G T 1.35E-07 Body mass index / / 22344219 rs667156 chr11 31917219 T C 7.49E-08 Body mass index / / 22344219 rs666822 chr11 31917269 A G 3.80E-07 Body mass index / / 22344219 rs673946 chr11 31917599 G A 1.25E-07 Body mass index / / 22344219 rs621420 chr11 31919198 A G 9.42E-08 Body mass index / / 22344219 rs11031526 chr11 31921805 G A 3.68E-04 Multiple complex diseases / / 17554300 rs602907 chr11 31922014 T C 8.72E-08 Body mass index / / 22344219 rs602074 chr11 31922162 C T 1.08E-07 Body mass index / / 22344219 rs683028 chr11 31922575 A G 1.39E-07 Body mass index / / 22344219 rs623102 chr11 31926436 C A 8.53E-08 Body mass index / / 22344219 rs17664001 chr11 31944178 G A 2.28E-04 Self-reported allergy / / 23817569 rs224670 chr11 32019404 T C 5.84E-04 Multiple complex diseases / / 17554300 rs1002229 chr11 32053007 A T 0.00013 Coronary artery calcification / / 23727086 rs224612 chr11 32063229 T C 2.65E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs224618 chr11 32064649 G T 3.88E-04 Multiple complex diseases / / 17554300 rs224619 chr11 32065256 G A 4.65E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2745885 chr11 32070539 A G 7.28E-04 Multiple complex diseases / / 17554300 rs85074 chr11 32076832 G A,T 2.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11828792 chr11 32088100 C T 3.54E-04 Alzheimer's disease (late onset) / / 21379329 rs881183 chr11 32090193 G A 3.47E-04 Alzheimer's disease (late onset) / / 21379329 rs223069 chr11 32119193 T C 8.87E-04 Multiple complex diseases RCN1 intron 17554300 rs2073223 chr11 32122020 T G 5.17E-05 Multiple complex diseases RCN1 intron 17554300 rs10488686 chr11 32129891 G A 9.76E-05 Orofacial clefts / / 22419666 rs223051 chr11 32131303 C T 6.08E-04 Lymphocyte counts / / 22286170 rs2207449 chr11 32132671 A G 6.81E-04 Multiple complex diseases / / 17554300 rs4922579 chr11 32136436 C T 5.55E-04 Multiple complex diseases / / 17554300 rs11031601 chr11 32143623 C A,G,T 4.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7950374 chr11 32168691 A G 2.87E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10835855 chr11 32208950 A G 5.15E-05 Neuroticism / / 23229837 rs2418582 chr11 32250465 G A 6.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs2418583 chr11 32250517 T C 6.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs926968 chr11 32250778 T C 5.57E-04 Suicide attempts in bipolar disorder / / 21041247 rs926967 chr11 32251222 A C,G 5.71E-04 Suicide attempts in bipolar disorder / / 21041247 rs2418584 chr11 32252083 T C 5.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs1998003 chr11 32253286 C A 6.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs7124928 chr11 32255395 C T 5.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs10742273 chr11 32255611 G C 5.37E-04 Suicide attempts in bipolar disorder / / 21041247 rs10742274 chr11 32255641 C T 5.21E-04 Suicide attempts in bipolar disorder / / 21041247 rs12795402 chr11 32255936 T C 4.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs1155856 chr11 32257494 G A 4.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs1155855 chr11 32257842 A G 3.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs12287573 chr11 32258144 T C 3.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs10767925 chr11 32259186 G A 3.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs1884379 chr11 32259460 G T 3.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs1884382 chr11 32259845 G A 2.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs7109202 chr11 32260265 T C 2.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs2207820 chr11 32260731 C A 2.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs10835876 chr11 32262156 A T 2.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs1115704 chr11 32262858 T C 2.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs11031658 chr11 32263818 C T 8.02E-04 Taste perception / / 22132133 rs6484557 chr11 32264051 A C 2.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs2418587 chr11 32264392 C T 2.69E-04 Suicide attempts in bipolar disorder / / 21041247 rs1033627 chr11 32266859 A G 2.71E-04 Suicide attempts in bipolar disorder / / 21041247 rs11031664 chr11 32267393 T C 4.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs11031676 chr11 32286145 C T 3.50E-05 Major depressive disorder / / 19065144 rs11031676 chr11 32286145 C T 5.68E-05 Major depressive disorder / / pha002850 rs7944342 chr11 32287944 T C 6.98E-05 Major depressive disorder / / pha002850 rs764669 chr11 32302799 C T 4.50E-04 Tourette syndrome / / 22889924 rs2224034 chr11 32309707 G C 8.41E-04 Multiple complex diseases / / 17554300 rs1474844 chr11 32309976 T C 8.95E-04 Multiple complex diseases / / 17554300 rs2207550 chr11 32310891 G A 5.70E-04 Tourette syndrome / / 22889924 rs7116279 chr11 32318295 C A 3.72E-04 Tourette syndrome / / 22889924 rs10742276 chr11 32322024 T C 1.31E-04 Multiple complex diseases / / 17554300 rs11031700 chr11 32324260 G A 8.94E-04 Multiple complex diseases / / 17554300 rs11031705 chr11 32330664 A G 2.62E-04 Multiple complex diseases / / 17554300 rs7934939 chr11 32340688 G A 1.62E-04 Multiple complex diseases / / 17554300 rs2038318 chr11 32347237 T C,G 3.50E-04 Multiple complex diseases / / 17554300 rs7116974 chr11 32348789 G A 2.78E-04 Multiple complex diseases / / 17554300 rs7116974 chr11 32348789 G A 6.88E-05 Tuberculosis / / 22306650 rs11031718 chr11 32348953 T G 2.71E-04 Multiple complex diseases / / 17554300 rs7924571 chr11 32350027 C A 3.26E-04 Multiple complex diseases / / 17554300 rs7924866 chr11 32350351 A T 2.80E-04 Multiple complex diseases / / 17554300 rs11031728 chr11 32363616 C G 3.44E-08 Tuberculosis / / 22306650 rs11031728 chr11 32363616 C G 2.86E-06 Tuberculosis / / 24057671 rs2057178 chr11 32364187 G A 3.00E-11 Tuberculosis / / 22306650 rs2057178 chr11 32364187 G A 1.00E-12 Tuberculosis / / 24057671 rs2057178 chr11 32364187 G A 3.00E-06 Tuberculosis / / 24057671 rs11031731 chr11 32365430 G A 1.85E-08 Tuberculosis / / 22306650 rs11031734 chr11 32367735 G A 3.60E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs932503 chr11 32371215 T C 1.29E-04 Coronary Artery Disease / / 17634449 rs932503 chr11 32371215 T C 4.16E-04 Depression (quantitative trait) / / 20800221 rs7103098 chr11 32375437 A T 2.90E-07 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs12285677 chr11 32382167 T C 2.40E-07 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs11822134 chr11 32386448 G T 8.00E-05 Prostate cancer / / 21743057 rs11031758 chr11 32402478 G A 4.92E-04 Multiple complex diseases / / 17554300 rs11031762 chr11 32407854 C G 4.74E-04 Type 2 diabetes / / 17463246 rs5030316 chr11 32410380 T C 3.18E-04 Sudden cardiac arrest WT1 UTR-3 21658281 rs5030310 chr11 32411240 T A 5.21E-04 Type 2 diabetes WT1 intron 17463246 rs5030281 chr11 32416875 G A 6.49E-04 Type 2 diabetes WT1 intron 17463246 rs5030244 chr11 32423752 T C 5.45E-05 Parent of origin effect on language impairment (maternal) WT1 intron 24571439 rs2900740 chr11 32435529 G A 9.60E-04 Celiac disease WT1 intron 23936387 rs12293750 chr11 32446985 C A 1.13E-04 Celiac disease WT1 intron 23936387 rs7110547 chr11 32447347 C G 7.94E-04 Type 2 diabetes WT1 intron 17463246 rs3930513 chr11 32455527 C A 6.60E-06 Urinary metabolites WT1 intron 21572414 rs3809060 chr11 32458807 G T 1.60E-05 Urinary metabolites WT1-AS intron 21572414 rs4275604 chr11 32462576 A G 7.32E-04 Multiple complex diseases / / 17554300 rs10742278 chr11 32465233 C T 3.12E-04 Multiple complex diseases / / 17554300 rs11031791 chr11 32469729 A T 2.26E-04 Multiple complex diseases / / 17554300 rs10835917 chr11 32484265 T C 5.03E-04 Multiple complex diseases / / 17554300 rs2067666 chr11 32498355 T C 9.82E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10767942 chr11 32522007 T C 9.04E-04 Type 2 diabetes / / 17463246 rs10767942 chr11 32522007 T C 8.00E-06 Attention deficit hyperactivity disorder / / 18821565 rs4963214 chr11 32535594 T C 0.000573 Salmonella-induced pyroptosis / / 22837397 rs11031851 chr11 32546869 T C 8.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs12285345 chr11 32549624 A G 8.04E-04 Type 2 diabetes / / 17463246 rs12285345 chr11 32549624 A G 1.70E-05 Urinary metabolites / / 21572414 rs10835941 chr11 32553135 T C 2.50E-07 Urinary metabolites / / 21572414 rs2450411 chr11 32562808 G A 1.32E-04 Breast cancer / / pha002853 rs201835 chr11 32587479 C G 2.20E-05 Urinary metabolites / / 21572414 rs11822904 chr11 32658751 G A 7.43E-04 Obesity (extreme) CCDC73 intron 21935397 rs201845 chr11 32678357 A C 6.86E-05 Alzheimer's disease (age of onset) CCDC73 intron 22005931 rs11031930 chr11 32691569 T C 2.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCDC73 intron 20877124 rs11031930 chr11 32691569 T C 5.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCDC73 intron 20877124 rs11031964 chr11 32775602 C T 7.37E-04 Amyotrophic Lateral Sclerosis CCDC73 intron 17362836 rs17251699 chr11 32821349 G A 5.69E-04 Type 2 diabetes / / 17463246 rs197710 chr11 32838288 A G 4.07E-04 Alcohol dependence / / 21314694 rs11827537 chr11 32841636 G A 1.87E-04 Taste perception / / 22132133 rs12363973 chr11 32851008 A C 1.87E-04 Taste perception / / 22132133 rs956322 chr11 32871485 C T 9.50E-06 Parkinson's disease (age of onset) PRRG4 intron 19772629 rs12364134 chr11 32886090 A C 1.87E-04 Taste perception / / 22132133 rs10767971 chr11 32895664 T C 5.00E-07 Parkinson's disease (age of onset) / / 19772629 rs10767971 chr11 32895664 T C 4.83E-04 Alcohol dependence / / 20201924 rs4756329 chr11 32905094 T A 3.33E-04 Alcohol dependence / / 21314694 rs2297781 chr11 32955122 A G 9.15E-04 Glycosylated haemoglobin levels QSER1 missense 17255346 rs2297781 chr11 32955122 A G 2.18E-06 Height QSER1 missense pha003010 rs2297781 chr11 32955122 A G 9.83E-06 Height QSER1 missense pha003011 rs1033719 chr11 33066525 T G 1.56E-05 Lymphocyte counts TCP11L1 intron 22286170 rs2273549 chr11 33079580 A G 4.26E-06 Taste perception TCP11L1 missense 22132133 rs10742291 chr11 33088727 G A 1.99E-04 Taste perception TCP11L1 intron 22132133 rs9635 chr11 33100852 C T 7.00E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs10836020 chr11 33102251 C T 3.73E-04 QT interval / / 22726844 rs12365818 chr11 33103277 C T 4.63E-06 Taste perception / / 22132133 rs10767987 chr11 33107102 T C 2.05E-04 Taste perception CSTF3 intron 22132133 rs7104129 chr11 33118137 G T 6.31E-04 Taste perception CSTF3 intron 22132133 rs17679635 chr11 33204728 T C 7.31E-04 Type 2 diabetes LOC338739 intron 17463246 rs608568 chr11 33207839 T C 3.78E-04 Multiple complex diseases LOC338739 intron 17554300 rs7131287 chr11 33222902 A G 1.96E-04 Taste perception / / 22132133 rs7931093 chr11 33228155 T A 1.07E-04 Self-reported allergy / / 23817569 rs10768001 chr11 33233486 A G 4.13E-04 Taste perception / / 22132133 rs267442 chr11 33270782 A G 5.94E-04 Taste perception / / 22132133 rs590224 chr11 33288446 A G 3.94E-04 Taste perception HIPK3 intron 22132133 rs10836046 chr11 33291462 G A 8.86E-05 Taste perception HIPK3 intron 22132133 rs4388862 chr11 33310265 C T 5.89E-05 Self-reported allergy HIPK3 intron 23817569 rs16924133 chr11 33325376 A T 2.00E-06 Anger HIPK3 intron 24489884 rs11032230 chr11 33362866 G T 6.42E-05 Taste perception HIPK3 intron 22132133 rs10600 chr11 33378209 A G 1.11E-04 Taste perception / / 22132133 rs2615923 chr11 33394542 C T 7.05E-04 Type 2 diabetes / / 17463246 rs2753412 chr11 33404628 G C 7.20E-06 Urinary metabolites / / 21572414 rs2761210 chr11 33406971 C A 1.10E-05 Urinary metabolites / / 21572414 rs11032251 chr11 33409508 G A 9.98E-04 Acute lung injury / / 22295056 rs11032252 chr11 33412394 A G 9.98E-04 Acute lung injury / / 22295056 rs12291056 chr11 33415151 G A 2.13E-04 Alcohol dependence / / 20201924 rs386752273 chr11 33415151 GGG GTA 2.13E-04 Alcohol dependence / / 20201924 rs11032272 chr11 33456591 T C 3.68E-08 Metabolite levels / / 23281178 rs7951843 chr11 33471306 G A 8.06E-08 Metabolite levels / / 23281178 rs7131170 chr11 33471804 C T 8.06E-08 Metabolite levels / / 23281178 rs7120458 chr11 33472207 T C 8.06E-08 Metabolite levels / / 23281178 rs10836063 chr11 33475831 C T 8.73E-08 Metabolite levels / / 23281178 rs10836063 chr11 33475831 C T 1.10E-04 IgE levels in asthmatics / / 23967269 rs11603947 chr11 33486576 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10836065 chr11 33487251 C T 8.81E-05 Alzheimer's disease (age of onset) / / 22005931 rs2224528 chr11 33508688 A G 1.49E-05 Height / / pha003011 rs2756283 chr11 33511694 A G 1.20E-04 Acute lung injury / / 22295056 rs2756282 chr11 33512192 C A 1.12E-04 Acute lung injury / / 22295056 rs2756281 chr11 33513294 G A 1.37E-04 Acute lung injury / / 22295056 rs2756280 chr11 33515139 A G 7.04E-04 Acute lung injury / / 22295056 rs6484655 chr11 33516164 G C 7.88E-04 Acute lung injury / / 22295056 rs2756278 chr11 33518335 A G 6.30E-04 Acute lung injury / / 22295056 rs2756277 chr11 33518390 T C 6.30E-04 Acute lung injury / / 22295056 rs2615939 chr11 33520628 G A 7.77E-04 Acute lung injury / / 22295056 rs2615938 chr11 33522613 C T 7.34E-04 Acute lung injury / / 22295056 rs2756274 chr11 33527900 C G 7.34E-04 Acute lung injury / / 22295056 rs16924391 chr11 33532767 G A 1.44E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs4755689 chr11 33545255 C T 5.34E-05 Height / / pha003010 rs4755689 chr11 33545255 C T 9.73E-06 Height / / pha003011 rs7119075 chr11 33558430 C G 7.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs7117353 chr11 33562973 G A 4.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs2076624 chr11 33563598 C T 3.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs2076623 chr11 33564123 T C 1.79E-05 Heart Rate C11orf41 cds-synon pha003053 rs17339350 chr11 33570367 T C 2.57E-04 Suicide attempts in bipolar disorder C11orf41 intron 21423239 rs7945032 chr11 33573361 T C 2.35E-04 Multiple complex diseases C11orf41 intron 17554300 rs7949404 chr11 33583840 A G 8.14E-04 Multiple complex diseases C11orf41 intron 17554300 rs11822320 chr11 33585826 A G 3.44E-04 Suicide attempts in bipolar disorder C11orf41 intron 21423239 rs11032297 chr11 33585978 C T 9.54E-04 Suicide attempts in bipolar disorder C11orf41 intron 21423239 rs11032297 chr11 33585978 C T 1.43E-04 Age-related macular degeneration C11orf41 intron 22125219 rs12576953 chr11 33586318 T A 2.06E-04 Suicide attempts in bipolar disorder C11orf41 intron 21423239 rs12576242 chr11 33587649 G A 2.95E-04 Suicide attempts in bipolar disorder C11orf41 intron 21423239 rs10437629 chr11 33588210 A G 4.00E-06 Suicide attempts in bipolar disorder C11orf41 intron 21423239 rs735327 chr11 33600581 A G 2.80E-05 Urinary metabolites C11orf41 intron 21572414 rs4755201 chr11 33601647 C T 7.31E-05 Colorectal cancer C11orf41 intron 19723657 rs4755201 chr11 33601647 C T 4.92E-06 Height C11orf41 intron pha003010 rs4755201 chr11 33601647 C T 3.21E-07 Height C11orf41 intron pha003011 rs4755718 chr11 33602913 G A 7.32E-05 Colorectal cancer C11orf41 intron 19723657 rs4755718 chr11 33602913 G A 3.98E-06 Height C11orf41 intron pha003010 rs4755718 chr11 33602913 G A 2.80E-07 Height C11orf41 intron pha003011 rs761435 chr11 33617771 T C 6.87E-04 Acute lung injury C11orf41 intron 22295056 rs1104742 chr11 33620124 A G 6.87E-04 Acute lung injury C11orf41 intron 22295056 rs2076625 chr11 33628117 A C 6.82E-06 Height C11orf41 intron pha003010 rs2076625 chr11 33628117 A C 4.93E-07 Height C11orf41 intron pha003011 rs4755750 chr11 33630792 A G 3.56E-04 Multiple complex diseases C11orf41 intron 17554300 rs4755750 chr11 33630792 A G 6.25E-04 Acute lung injury C11orf41 intron 22295056 rs10836083 chr11 33642235 A G 1.86E-04 Multiple complex diseases C11orf41 intron 17554300 rs4755765 chr11 33643373 A G 8.08E-04 Multiple complex diseases C11orf41 intron 17554300 rs4755771 chr11 33644514 A G 1.57E-04 Suicide attempts in bipolar disorder C11orf41 intron 21423239 rs7114092 chr11 33645458 G A 1.27E-04 Suicide attempts in bipolar disorder C11orf41 intron 21423239 rs7114092 chr11 33645458 G A 3.72E-04 Acute lung injury C11orf41 intron 22295056 rs4333997 chr11 33653780 T C 4.08E-05 Suicide attempts in bipolar disorder C11orf41 intron 21423239 rs4333997 chr11 33653780 T C 2.94E-04 Acute lung injury C11orf41 intron 22295056 rs7106651 chr11 33661419 C T 1.69E-04 Suicide attempts in bipolar disorder C11orf41 intron 21423239 rs1033543 chr11 33667333 A G 8.49E-05 Creatinine levels C11orf41 cds-synon pha003069 rs10742300 chr11 33668284 C T 7.61E-04 Suicide attempts in bipolar disorder C11orf41 intron 21423239 rs4755237 chr11 33668586 G A 5.69E-04 Multiple complex diseases C11orf41 intron 17554300 rs4755237 chr11 33668586 G A 5.78E-04 Suicide attempts in bipolar disorder C11orf41 intron 21423239 rs4755795 chr11 33670718 G A 3.23E-04 Multiple complex diseases C11orf41 intron 17554300 rs10768015 chr11 33676609 G A 3.66E-04 Suicide attempts in bipolar disorder C11orf41 intron 21423239 rs10836092 chr11 33676946 G C 4.28E-04 Suicide attempts in bipolar disorder C11orf41 intron 21423239 rs7123662 chr11 33695404 A T 1.50E-05 Urinary metabolites C11orf41 UTR-3 21572414 rs10742304 chr11 33696361 T C 3.88E-05 Serum metabolites / / 19043545 rs1009449 chr11 33706166 A G 1.25E-22 Narcolepsy / / 19629137 rs11032341 chr11 33707442 A C 3.97E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10768019 chr11 33707552 G A 8.66E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10768020 chr11 33707690 T C 8.14E-04 Insulin resistance / / 21901158 rs831620 chr11 33709273 A G 3.30E-04 Alcohol dependence / / 20201924 rs831620 chr11 33709273 A G 3.90E-05 Alcohol dependence / / 20201924 rs831620 chr11 33709273 A G 3.87E-05 Alcoholism / / pha002893 rs2746600 chr11 33714641 A G 8.29E-05 Alcoholism / / pha002893 rs831612 chr11 33719850 A G 8.67E-05 Cognitive test performance C11orf91 UTR-3 20125193 rs7117382 chr11 33737733 T C 4.47E-05 Coronary heart disease CD59 intron pha003035 rs10501127 chr11 33741657 C G 1.78E-04 Cardiovascular disease CD59 intron 17903304 rs831628 chr11 33744845 G C 2.60E-04 Schizophrenia CD59 intron 20832056 rs17760694 chr11 33757092 T C 1.50E-05 Urinary metabolites CD59 intron 21572414 rs2273121 chr11 33757770 G A 7.87E-05 Cognitive impairment induced by topiramate CD59 intron 22091778 rs11032362 chr11 33759092 G A 5.12E-05 Multiple complex diseases CD59 nearGene-5 17554300 rs12291756 chr11 33797814 G C 8.51E-06 Coronary artery calcification / / 23870195 rs11825259 chr11 33806822 A G 4.00E-06 Coronary artery calcification / / 23870195 rs953142 chr11 33812034 T C 7.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12576094 chr11 33812828 C T 1.44E-06 Multiple sclerosis (brain glutamate levels) / / 20802204 rs12576094 chr11 33812828 C T 1.93E-05 Monocyte counts / / pha003089 rs1000677 chr11 33814061 A G 1.27E-06 Multiple sclerosis (brain glutamate levels) / / 20802204 rs1000677 chr11 33814061 A G 6.26E-05 Monocyte counts / / pha003089 rs1533801 chr11 33824173 G A 2.41E-04 Age-related macular degeneration / / 22125219 rs4756052 chr11 33852472 G A 8.05E-06 Parkinson's disease / / 17052657 rs11032423 chr11 33868607 T C 8.00E-06 Cognitive performance / / 19734545 rs4756071 chr11 33882716 T C 0.0000146 VLDL cholesterol particle diameter LMO2 intron 23263444 rs3781575 chr11 33885319 T C 5.76E-04 Multiple complex diseases LMO2 intron 17554300 rs2038602 chr11 33886294 A G 9.34E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LMO2 cds-synon 20877124 rs3824848 chr11 33886547 C T 4.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LMO2 intron 20877124 rs11032434 chr11 33906371 A T 1.10E-04 Multiple complex diseases LMO2 intron 17554300 rs4756077 chr11 33907955 T G 8.02E-04 Type 2 diabetes LMO2 intron 17463246 rs7121766 chr11 34002362 T G 4.53E-05 Cognitive test performance / / 20125193 rs7110667 chr11 34028081 A T 7.82E-07 Blood pressure / / 21909110 rs2421459 chr11 34036274 A G 6.64E-04 Multiple complex diseases / / 17554300 rs12418412 chr11 34072011 T C 7.69E-04 Alzheimer's disease / / 17998437 rs17700132 chr11 34120705 A G 7.10E-05 Personality dimensions CAPRIN1 intron 18957941 rs16925182 chr11 34132964 C G 7.70E-05 Personality dimensions /T10 intron 18957941 rs10836156 chr11 34134926 C T 8.75E-04 Multiple complex diseases /T10 intron 17554300 rs12419404 chr11 34153107 G T 7.89E-05 Blood Pressure /T10 intron pha003039 rs8187 chr11 34168153 G A 9.51E-04 Bipolar disorder /T10 UTR-3 19259986 rs745809 chr11 34187847 G A 3.42E-04 Alcohol dependence ABTB2 intron 21314694 rs2957489 chr11 34192092 T C 7.68E-05 Alzheimer's disease ABTB2 intron 17998437 rs2957489 chr11 34192092 T C 6.60E-05 Personality dimensions ABTB2 intron 18957941 rs2955934 chr11 34193578 G A 9.58E-04 Myopia (pathological) ABTB2 intron 21095009 rs7102200 chr11 34195155 T A 7.61E-04 Type 2 diabetes ABTB2 intron 17463246 rs7102200 chr11 34195155 T A 5.13E-05 Bipolar disorder ABTB2 intron 18317468 rs2467383 chr11 34196484 C T 6.72E-04 Myopia (pathological) ABTB2 intron 21095009 rs1883960 chr11 34214501 C T 7.63E-04 Response to cytidine analogues (gemcitabine) ABTB2 intron 24483146 rs2746633 chr11 34228306 G A 3.03E-04 Taste perception ABTB2 intron 22132133 rs10836163 chr11 34257916 C A 6.13E-04 Suicide attempts in bipolar disorder ABTB2 intron 21423239 rs7105914 chr11 34266683 T C 2.33E-04 Alcohol consumption (maxi-drinks) ABTB2 intron 24277619 rs10836174 chr11 34278873 T C 5.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ABTB2 intron 20877124 rs2611145 chr11 34283861 C T 9.31E-06 Liver cancer (hepatocellular carcinoma) in patients with chronic hepatitis B virus infection ABTB2 intron 22174901 rs911500 chr11 34314249 C T 6.79E-05 Erythrocyte counts ABTB2 intron pha003090 rs80286695 chr11 34323765 A G 0.0000727 Nonsyndromic striae distensae (stretch marks) ABTB2 intron 23633020 rs12800573 chr11 34330500 G T 4.74E-04 Type 2 diabetes ABTB2 intron 17463246 rs11032609 chr11 34332090 C T 0.0000938 Nonsyndromic striae distensae (stretch marks) ABTB2 intron 23633020 rs16925419 chr11 34335687 C T 7.79E-04 Multiple complex diseases ABTB2 intron 17554300 rs4755368 chr11 34338342 T C 2.80E-05 Celiac disease ABTB2 intron 23936387 rs2180948 chr11 34354865 C T 6.51E-05 Type 2 diabetes ABTB2 intron 17463246 rs7116915 chr11 34371084 C T 9.41E-05 Calcium levels ABTB2 intron pha003085 rs7934463 chr11 34431654 T C 7.05E-05 Lymphocyte counts / / 22286170 rs11032678 chr11 34438320 T G 8.47E-05 Tunica Media / / pha003038 rs16925514 chr11 34449260 G T 1.50E-04 Multiple complex diseases / / 17554300 rs16925514 chr11 34449260 G T 5.00E-04 Alcohol dependence / / 20201924 rs16925514 chr11 34449260 G T 6.68E-05 Alcohol dependence / / 21703634 rs12295136 chr11 34450461 T C 5.75E-04 Multiple complex diseases / / 17554300 rs12295136 chr11 34450461 T C 8.10E-04 Alcohol dependence / / 20201924 rs12295136 chr11 34450461 T C 9.45E-05 Alcohol dependence / / 21703634 rs1107573 chr11 34456208 C T 3.90E-04 Alcohol dependence / / 20201924 rs1107573 chr11 34456208 C T 6.60E-05 Alcohol dependence / / 21703634 rs10836233 chr11 34457572 G A 0.00039 Coronary artery calcification / / 23727086 rs12272630 chr11 34461665 G C 5.30E-04 Alcohol dependence CAT intron 20201924 rs12272630 chr11 34461665 G C 6.95E-05 Alcohol dependence CAT intron 21703634 rs11032702 chr11 34468123 C T 5.20E-04 Alcohol dependence CAT intron 20201924 rs11032702 chr11 34468123 C T 6.95E-05 Alcohol dependence CAT intron 21703634 rs12269988 chr11 34472774 A G 2.90E-04 Alcohol dependence CAT intron 20201924 rs12269988 chr11 34472774 A G 5.25E-05 Alcohol dependence CAT intron 21703634 rs12273124 chr11 34479711 A G 6.95E-05 Alcohol dependence CAT intron 21703634 rs7949972 chr11 34502042 C T 3.03E-04 Acne (severe) ELF5 intron 24399259 rs7941147 chr11 34503469 T C 2.43E-04 Multiple complex diseases ELF5 intron 17554300 rs7941147 chr11 34503469 T C 9.96E-04 Suicide attempts in bipolar disorder ELF5 intron 21423239 rs12288819 chr11 34505913 C T 6.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ELF5 intron 20877124 rs12293745 chr11 34513560 G C 9.39E-04 Suicide attempts in bipolar disorder ELF5 intron 21423239 rs16930094 chr11 34521649 C T 3.61E-04 Nicotine dependence ELF5 intron 17158188 rs836141 chr11 34537316 G A 2.04E-05 Rheumatoid arthritis ELF5 nearGene-5 19503088 rs836135 chr11 34548906 G A 3.97E-05 Height / / pha003011 rs836132 chr11 34555191 G A 5.00E-08 beta2-Glycoprotein I (beta2-GPI) plasma levels / / 23279374 rs836132 chr11 34555191 G A 3.75E-05 Height / / pha003011 rs836123 chr11 34562939 C T 1.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs5028798 chr11 34605435 T G 3.00E-06 Volumetric brain MRI / / 17903297 rs286938 chr11 34628152 G A 4.05E-04 Multiple complex diseases / / 17554300 rs286930 chr11 34632772 G A 1.90E-04 Multiple complex diseases / / 17554300 rs7113572 chr11 34636464 C T 2.41E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs286913 chr11 34655363 A G 7.00E-08 Response to antipsychotic treatment EHF intron 21107309 rs286913 chr11 34655363 A G 0.00068 Prostate cancer EHF intron 23555315 rs286911 chr11 34657221 C T 1.30E-04 Stroke EHF intron pha002887 rs7936502 chr11 34659807 G T 1.61E-05 Alcohol dependence EHF intron 19581569 rs286905 chr11 34662961 A G 4.00E-06 Obesity-related traits EHF intron 23251661 rs10488739 chr11 34675079 C T 1.90E-05 Urinary metabolites EHF intron 21572414 rs704730 chr11 34686005 G A 2.20E-05 Urinary metabolites / / 21572414 rs704734 chr11 34695389 T C 3.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs704736 chr11 34695895 A G 2.20E-05 Urinary metabolites / / 21572414 rs2123652 chr11 34707542 T C 4.52E-04 Multiple complex diseases / / 17554300 rs1704001 chr11 34741213 A G 2.70E-05 Urinary metabolites / / 21572414 rs16926093 chr11 34753006 A G 5.82E-04 Multiple complex diseases / / 17554300 rs11604069 chr11 34764251 T C 8.49E-05 Cognitive impairment induced by topiramate / / 22091778 rs1355223 chr11 34764479 A G 4.00E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs7937272 chr11 34772427 G A 5.24E-05 Multiple complex diseases / / 17554300 rs11032839 chr11 34777725 A G 4.90E-04 Multiple complex diseases / / 17554300 rs906902 chr11 34780278 G A 3.28E-05 Schizophrenia / / 19197363 rs906902 chr11 34780278 G A 2.10E-07 Systemic lupus erythematosus / / 24871463 rs10466455 chr11 34780936 T C 3.28E-05 Schizophrenia / / 19197363 rs10466455 chr11 34780936 T C 2.00E-07 Systemic lupus erythematosus / / 24871463 rs7929679 chr11 34805849 A G 7.00E-09 Chronic obstructive pulmonary disease-related biomarkers / / 23144326 rs11032873 chr11 34806466 T C 3.08E-05 Pulmonary function in asthmatics / / 23541324 rs12793173 chr11 34834204 T C 1.00E-09 Cystic fibrosis severity / / 21602797 rs967751 chr11 34858084 T G 1.06E-04 Multiple complex diseases / / 17554300 rs2941052 chr11 34890131 T G 8.27E-10 Lymphocyte counts / / 22286170 rs10488801 chr11 34940737 A G 7.67E-04 Multiple complex diseases PDHX intron 17554300 rs2956106 chr11 34940982 G A 8.07E-04 Alzheimer's disease PDHX intron 17998437 rs11032927 chr11 34942836 C G 8.40E-04 Multiple complex diseases PDHX intron 17554300 rs2767038 chr11 35000983 C T 6.86E-04 Alzheimer's disease PDHX intron 17998437 rs2732564 chr11 35015278 G A 8.53E-04 Alzheimer's disease PDHX intron 17998437 rs2767033 chr11 35022908 G A 8.81E-04 Alzheimer's disease / / 17998437 rs7113469 chr11 35055259 A G 9.80E-04 Acute lung injury / / 22295056 rs12420849 chr11 35058208 G A 9.80E-04 Acute lung injury / / 22295056 rs7934858 chr11 35058677 T C 9.80E-04 Acute lung injury / / 22295056 rs737503 chr11 35074000 C T 3.41E-04 Multiple complex diseases / / 17554300 rs737503 chr11 35074000 C T 1.39E-04 Coronary Artery Disease / / 17634449 rs737503 chr11 35074000 C T 5.59E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs2732547 chr11 35088683 T C 2.20E-05 Systemic lupus erythematosus / / 24871463 rs2785197 chr11 35093070 A G 2.00E-07 Systemic lupus erythematosus / / 23273568 rs2785197 chr11 35093070 A G 9.90E-06 Systemic lupus erythematosus / / 24871463 rs1559759 chr11 35123051 C A 9.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs634096 chr11 35131359 C T 1.32E-05 Iron status biomarkers / / 19084217 rs2785178 chr11 35144986 A G 2.00E-04 Information processing speed / / 21130836 rs2785173 chr11 35155732 G A 5.70E-04 Type 2 diabetes LOC100507144 intron 17463246 rs2785173 chr11 35155732 G A 3.00E-06 Response to Vitamin E supplementation LOC100507144 intron 22437554 rs2785171 chr11 35163462 G A 4.23E-05 Lipoprotein A [Lp(a)] levels in plasma CD44 intron 21592478 rs353625 chr11 35168546 C T 0.000112 Gains in maximal O2 uptake response CD44 intron 21183627 rs12275533 chr11 35171027 G A 1.73E-08 Cholesterol,total CD44 intron 23063622 rs187115 chr11 35176159 T C 6.25E-05 Schizophrenia CD44 intron 21674006 rs353616 chr11 35176576 A C 3.75E-11 HDL cholesterol CD44 intron 23063622 rs12283855 chr11 35180253 C T 3.32E-04 Lung function (forced expiratory volume in 1 second) CD44 intron 24023788 rs353648 chr11 35190289 T G 1.20E-04 Thyroid peroxidase antibody positivity CD44 intron 24586183 rs353647 chr11 35191445 C G 0.00037 Coronary artery calcification CD44 intron 23727086 rs112762 chr11 35192629 C T 0.00048 Coronary artery calcification CD44 intron 23727086 rs353645 chr11 35193717 T G 0.00047 Coronary artery calcification CD44 intron 23727086 rs11033013 chr11 35195941 G C 0.00019 Coronary artery calcification CD44 intron 23727086 rs4756196 chr11 35198108 A G 1.12E-04 Stroke CD44 intron pha002887 rs7131335 chr11 35198661 T C 1.34E-08 HDL cholesterol CD44 intron 23063622 rs11033019 chr11 35201810 T C 3.73E-05 Lipoprotein A [Lp(a)] levels in plasma CD44 intron 21592478 rs1071695 chr11 35201842 C T 4.10E-06 Urinary metabolites CD44 cds-synon 21572414 rs3736812 chr11 35208251 A G 0.000081 Coronary artery calcification CD44 intron 23727086 rs11033026 chr11 35223303 G A 1.71E-11 Triglycerides CD44 cds-synon 23063622 rs1467558 chr11 35229673 T C 4.31E-04 Suicide,with and without major depression CD44 missense 22059935 rs1547060 chr11 35236804 C A 7.10E-06 Urinary metabolites CD44 intron 21572414 rs10734436 chr11 35242907 G A 8.51E-04 Multiple complex diseases CD44 intron 17554300 rs10836343 chr11 35244887 T C 8.80E-04 Response to taxane treatment (placlitaxel) CD44 intron 23006423 rs10128586 chr11 35245907 T C 3.56E-04 Response to taxane treatment (placlitaxel) CD44 intron 23006423 rs7105545 chr11 35257588 T A 8.25E-05 Serum metabolites / / 19043545 rs736374 chr11 35266944 G A 4.58E-08 Vitiligo / / 22561518 rs10768122 chr11 35280852 A G 2.00E-09 Vitiligo SLC1A2 UTR-3 22561518 rs7115246 chr11 35286478 A G 1.43E-06 Statin-induced myopathy SLC1A2 intron 21826682 rs4756208 chr11 35320084 A T 6.38E-06 Smoking cessation SLC1A2 intron 18519826 rs3794087 chr11 35329615 G T 1.00E-07 Essential tremor SLC1A2 intron 22764253 rs3847612 chr11 35338200 C T 3.28E-04 Type 2 diabetes SLC1A2 intron 17463246 rs3847613 chr11 35338345 T G 3.36E-04 Type 2 diabetes SLC1A2 intron 17463246 rs11033071 chr11 35347685 C T 2.49E-04 Type 2 diabetes SLC1A2 intron 17463246 rs4083482 chr11 35351639 C T 2.00E-06 Plasma omega-6 polyunsaturated fatty acid levels SLC1A2 intron 24823311 rs12274991 chr11 35353826 G T 2.53E-04 Smoking initiation SLC1A2 intron 24665060 rs4756212 chr11 35362311 G T 5.74E-04 Type 2 diabetes SLC1A2 intron 17463246 rs10768129 chr11 35362489 A G 1.07E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC1A2 intron 20463552 rs7942698 chr11 35363078 G A 7.39E-04 Type 2 diabetes SLC1A2 intron 17463246 rs3847621 chr11 35364435 G A 9.30E-04 Crohn's disease SLC1A2 intron 17684544 rs10836376 chr11 35366551 C A 8.04E-04 Type 2 diabetes SLC1A2 intron 17463246 rs7934047 chr11 35367925 C T 7.63E-04 Type 2 diabetes SLC1A2 intron 17463246 rs7127824 chr11 35373851 T C 1.51E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC1A2 intron 20463552 rs7130967 chr11 35374008 T C 1.51E-04 Response to platinum-based chemotherapy in small-cell lung cancer SLC1A2 intron 20463552 rs4756220 chr11 35376087 G A 3.97E-04 Type 2 diabetes SLC1A2 intron 17463246 rs6484785 chr11 35381907 T A 7.27E-04 Type 2 diabetes SLC1A2 intron 17463246 rs1923298 chr11 35384432 T C 3.86E-04 Schizophrenia SLC1A2 intron 19197363 rs1923298 chr11 35384432 T C 8.39E-04 Suicide attempts in bipolar disorder SLC1A2 intron 21423239 rs7931955 chr11 35385219 G C 7.40E-04 Suicide attempts in bipolar disorder SLC1A2 intron 21423239 rs11033097 chr11 35387697 G A 2.89E-05 Suicide attempts in bipolar disorder SLC1A2 intron 21423239 rs11033098 chr11 35387874 T C 2.61E-05 Suicide attempts in bipolar disorder SLC1A2 intron 21423239 rs11033099 chr11 35388778 C T 3.24E-05 Suicide attempts in bipolar disorder SLC1A2 intron 21423239 rs7104229 chr11 35389661 C T 3.20E-05 Suicide attempts in bipolar disorder SLC1A2 intron 21423239 rs7116961 chr11 35392268 G A 3.21E-05 Suicide attempts in bipolar disorder SLC1A2 intron 21423239 rs9704794 chr11 35394729 G A 2.35E-05 Suicide attempts in bipolar disorder SLC1A2 intron 21423239 rs1923301 chr11 35395977 T C 1.70E-05 Urinary metabolites SLC1A2 intron 21572414 rs7103668 chr11 35396511 A G 5.08E-05 Suicide attempts in bipolar disorder SLC1A2 intron 21423239 rs12294149 chr11 35397515 A G 5.48E-05 Suicide attempts in bipolar disorder SLC1A2 intron 21423239 rs10836384 chr11 35398659 C T 5.33E-05 Suicide attempts in bipolar disorder SLC1A2 intron 21423239 rs911561 chr11 35399110 A G 9.20E-06 Urinary metabolites SLC1A2 intron 21572414 rs2065030 chr11 35399637 T C 5.45E-05 Suicide attempts in bipolar disorder SLC1A2 intron 21423239 rs10836389 chr11 35415971 G A 9.54E-04 Multiple complex diseases SLC1A2 intron 17554300 rs10836389 chr11 35415971 G A 2.55E-04 Smoking cessation SLC1A2 intron 18519826 rs7122811 chr11 35416352 C A 1.77E-05 Height SLC1A2 intron pha003010 rs2145906 chr11 35428375 G A 2.58E-04 Multiple complex diseases SLC1A2 intron 17554300 rs11033114 chr11 35433624 G A 1.69E-06 Phospholipid levels (plasma) SLC1A2 intron 21829377 rs11033115 chr11 35435433 A C 1.71E-06 Phospholipid levels (plasma) SLC1A2 intron 21829377 rs2421897 chr11 35437863 G C 2.28E-06 Phospholipid levels (plasma) SLC1A2 intron 21829377 rs675227 chr11 35456453 G C 6.69E-04 Type 2 diabetes PAMR1 intron 17463246 rs599773 chr11 35459033 T C,G 9.67E-05 Relative hand skill in reading disability PAMR1 intron 24068947 rs1400489 chr11 35461685 A G 9.79E-04 Alzheimer's disease PAMR1 intron 17998437 rs7943168 chr11 35481588 C T 3.31E-07 Cholesterol PAMR1 intron pha003073 rs7943168 chr11 35481588 C T 2.25E-05 ldl cholesterol PAMR1 intron pha003076 rs7943168 chr11 35481588 C T 6.46E-07 Cholesterol PAMR1 intron pha003078 rs7112485 chr11 35486237 G A 6.64E-05 Relative hand skill in reading disability PAMR1 intron 24068947 rs7128765 chr11 35486538 T A 6.78E-05 Relative hand skill in reading disability PAMR1 intron 24068947 rs7112810 chr11 35486755 A T 1.29E-04 Self-reported allergy PAMR1 intron 23817569 rs10501139 chr11 35487046 T C 6.61E-05 Relative hand skill in reading disability PAMR1 intron 24068947 rs10836401 chr11 35487715 T C 1.40E-04 Self-reported allergy PAMR1 intron 23817569 rs11033140 chr11 35494887 C T 4.45E-04 Multiple complex diseases PAMR1 intron 17554300 rs11033140 chr11 35494887 C T 5.54E-05 Relative hand skill in reading disability PAMR1 intron 24068947 rs1996369 chr11 35495441 C G 9.00E-06 Relative hand skill in reading disability PAMR1 intron 24068947 rs16927508 chr11 35495951 C T 2.15E-05 Relative hand skill in reading disability PAMR1 intron 24068947 rs16927509 chr11 35495997 T A 2.10E-05 Relative hand skill in reading disability PAMR1 intron 24068947 rs7478896 chr11 35496605 C T 1.18E-05 Relative hand skill in reading disability PAMR1 intron 24068947 rs1878379 chr11 35496766 A C 1.18E-05 Relative hand skill in reading disability PAMR1 intron 24068947 rs938654 chr11 35496940 C A 9.34E-05 Relative hand skill in reading disability PAMR1 intron 24068947 rs7106288 chr11 35497059 G A 1.43E-05 Relative hand skill in reading disability PAMR1 intron 24068947 rs11033141 chr11 35497733 A G 2.17E-05 Relative hand skill in reading disability PAMR1 intron 24068947 rs938655 chr11 35499434 C T 1.54E-05 Relative hand skill in reading disability PAMR1 intron 24068947 rs7102175 chr11 35499894 C G 2.04E-05 Relative hand skill in reading disability PAMR1 intron 24068947 rs4638283 chr11 35500365 G A 1.28E-05 Relative hand skill in reading disability PAMR1 intron 24068947 rs4456236 chr11 35500592 A C 1.40E-04 Multiple complex diseases PAMR1 intron 17554300 rs4456236 chr11 35500592 A C 4.17E-05 Relative hand skill in reading disability PAMR1 intron 24068947 rs619914 chr11 35504397 T C 0.000442 Salmonella-induced pyroptosis PAMR1 intron 22837397 rs684748 chr11 35504650 C G 0.00033 Salmonella-induced pyroptosis PAMR1 intron 22837397 rs649640 chr11 35508918 A G 0.000549 Salmonella-induced pyroptosis PAMR1 intron 22837397 rs10836406 chr11 35510792 T C 5.18E-04 Suicide attempts in bipolar disorder PAMR1 intron 21423239 rs4142611 chr11 35512220 A G 5.90E-04 Suicide attempts in bipolar disorder PAMR1 intron 21423239 rs635366 chr11 35536622 G T 3.40E-06 Bronchopulmonary dysplasia PAMR1 intron 23897914 rs635366 chr11 35536622 G T 5.47E-05 Waist-Hip Ratio PAMR1 intron pha003029 rs650950 chr11 35539269 T C 2.00E-06 Bronchopulmonary dysplasia PAMR1 intron 23897914 rs1348879 chr11 35593885 G A 4.90E-05 Asthma (bronchodilator response) / / 22792082 rs16927798 chr11 35657763 T C 7.95E-05 Cognitive test performance / / 20125193 rs17297492 chr11 35667533 G A 8.19E-05 Serum metabolites / / 19043545 rs7103188 chr11 35697846 A G 5.41E-05 Cognitive test performance TRIM44 intron 20125193 rs16927845 chr11 35700997 G A 5.85E-04 Multiple complex diseases TRIM44 intron 17554300 rs7928794 chr11 35701236 A C 8.00E-06 Response to antipsychotic therapy (extrapyramidal side effects) TRIM44 intron 19875103 rs12222279 chr11 35747375 A G 2.07E-04 Smoking quantity TRIM44 intron 24665060 rs11033260 chr11 35753511 A G 1.73E-04 Type 2 diabetes TRIM44 intron 17463246 rs11033265 chr11 35775926 G A 1.54E-04 Multiple complex diseases TRIM44 intron 17554300 rs10836443 chr11 35788133 G A 1.42E-04 Type 2 diabetes TRIM44 intron 17463246 rs2147094 chr11 35802040 T C 7.01E-04 Amyotrophic Lateral Sclerosis TRIM44 intron 17827064 rs2938188 chr11 35813921 T G 5.22E-04 Lymphocyte counts TRIM44 intron 22286170 rs671783 chr11 35823818 C T 3.23E-06 Serum metabolites TRIM44 intron 19043545 rs10501143 chr11 35841576 T C 7.54E-05 Vaspin levels / / 22907691 rs10501143 chr11 35841576 T C 0.0000754 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs11033288 chr11 35844930 A G 1.74E-04 Type 2 diabetes / / 17463246 rs636950 chr11 35860568 T C 0.00006302 Sarcoidosis / / 22952805 rs639730 chr11 35861174 C G 0.00005586 Sarcoidosis / / 22952805 rs653641 chr11 35863056 C A 0.00003978 Sarcoidosis / / 22952805 rs676184 chr11 35868300 G T 4.30E-04 HIV-1 viral setpoint / / 17641165 rs12049904 chr11 35868834 A G 1.38E-05 Lung function (forced vital capacity) / / pha003104 rs1752233 chr11 35877603 T A 2.40E-05 Height / / 17255346 rs671068 chr11 35879571 C T 2.67E-05 Height / / 17255346 rs684909 chr11 35886919 T C 3.41E-04 Height / / 17255346 rs684909 chr11 35886919 T C 3.12E-06 Asthma / / 20698975 rs16928007 chr11 35888586 G A 1.62E-04 Multiple complex diseases / / 17554300 rs16928055 chr11 35913571 T C 6.30E-06 Alopecia areata / / 22027810 rs12804535 chr11 35955713 C T 1.30E-04 Cognitive decline / / 23732972 rs11033335 chr11 35957322 C T 1.34E-04 Cognitive decline / / 23732972 rs973942 chr11 35977692 G A 1.75E-04 Multiple complex diseases LDLRAD3 intron 17554300 rs263092 chr11 35978816 A G 8.48E-04 Multiple complex diseases LDLRAD3 intron 17554300 rs11033346 chr11 35983221 T C 2.38E-05 Bipolar disorder LDLRAD3 intron 18317468 rs2984699 chr11 35985584 T C 0.000074 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LDLRAD3 intron 22628534 rs10836477 chr11 35998208 T G 4.12E-06 Crohn's disease and psoriasis LDLRAD3 intron 22482804 rs10836477 chr11 35998208 T G 0.0000974 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LDLRAD3 intron 22628534 rs4755432 chr11 36001396 C A 3.55E-04 Multiple complex diseases LDLRAD3 intron 17554300 rs200117745 chr11 36057654 G C 0.00012 Prostate cancer (advanced) LDLRAD3 missense 23555315 rs7942817 chr11 36074673 T C 8.91E-05 Blood pressure LDLRAD3 intron 17255346 rs4545528 chr11 36092555 C T 3.36E-05 Monocyte chemoattractant protein-1 LDLRAD3 intron pha003071 rs11033401 chr11 36095347 G A 4.21E-04 Alcohol dependence LDLRAD3 intron 21314694 rs10836488 chr11 36104536 G A 5.23E-06 Monocyte chemoattractant protein-1 LDLRAD3 intron pha003071 rs1917899 chr11 36111616 A G 7.27E-05 Type 2 diabetes and other traits LDLRAD3 intron 19734900 rs147309219 chr11 36119939 A G 0.0000038 Breast cancer (ER positive) LDLRAD3 missense 23555315 rs147309219 chr11 36119939 A G 0.00019 Breast cancer LDLRAD3 missense 23555315 rs10768179 chr11 36126838 A G 9.36E-04 Myopia (pathological) LDLRAD3 intron 21095009 rs4756281 chr11 36134670 T C 3.07E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) LDLRAD3 intron 23648065 rs4755436 chr11 36136912 A G 7.98E-04 Type 2 diabetes LDLRAD3 intron 17463246 rs4755436 chr11 36136912 A G 2.80E-05 Urinary metabolites LDLRAD3 intron 21572414 rs10082659 chr11 36143978 G T 6.55E-07 Kawasaki disease LDLRAD3 intron 21221998 rs10768195 chr11 36169869 A G 1.05E-05 Left ventricular hypertrophy LDLRAD3 intron pha003052 rs955249 chr11 36173252 G A 2.09E-06 Left ventricular hypertrophy LDLRAD3 intron pha003052 rs12790641 chr11 36175126 A G 3.05E-04 Type 2 diabetes LDLRAD3 intron 17463246 rs1880709 chr11 36176141 A G 2.38E-04 Insulin resistance LDLRAD3 intron 21901158 rs12576603 chr11 36178090 C T 9.86E-05 Elbow pain LDLRAD3 intron pha003008 rs12576603 chr11 36178090 C T 8.41E-06 Height LDLRAD3 intron pha003010 rs12576603 chr11 36178090 C T 1.19E-05 Height LDLRAD3 intron pha003011 rs7924470 chr11 36178902 C A 7.85E-05 Left ventricular hypertrophy LDLRAD3 intron pha003052 rs2133522 chr11 36179252 A G 5.61E-05 Left ventricular hypertrophy LDLRAD3 intron pha003052 rs4755440 chr11 36202307 G A 9.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) LDLRAD3 intron 23648065 rs12574525 chr11 36215938 G T 4.85E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) LDLRAD3 intron 23648065 rs17740588 chr11 36221091 T G 1.62E-04 Type 2 diabetes LDLRAD3 intron 17463246 rs11601619 chr11 36221890 C T 2.81E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) LDLRAD3 intron 23648065 rs11033492 chr11 36222477 A G 0.0000384 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LDLRAD3 intron 22628534 rs1374376 chr11 36233751 G A 1.36E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) LDLRAD3 intron 23648065 rs12420852 chr11 36235024 C T 4.86E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) LDLRAD3 intron 23648065 rs11033499 chr11 36237317 G C 0.0000071 Sasang constitution (Soyang) LDLRAD3 intron 22394158 rs4485080 chr11 36240949 C T 5.31E-04 Sarcoidosis LDLRAD3 intron 19165924 rs10501147 chr11 36258285 C T 8.32E-04 Smoking cessation / / 24665060 rs921086 chr11 36265190 G C 5.19E-04 Smoking cessation / / 24665060 rs17814201 chr11 36269071 G A 5.65E-04 Smoking cessation / / 24665060 rs7114323 chr11 36273754 T G 2.57E-04 Smoking cessation / / 24665060 rs11033510 chr11 36276739 T C 2.94E-04 Smoking cessation / / 24665060 rs2289989 chr11 36290278 C T 4.00E-05 Prion diseases / / 22210626 rs7104737 chr11 36315189 A G 4.00E-05 Prion diseases / / 22210626 rs11033540 chr11 36320780 C T 7.02E-04 Sarcoidosis PRR5L intron 19165924 rs7127214 chr11 36343693 C G 0.000000019 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) PRR5L intron 23603761 rs12419146 chr11 36353471 C A 1.64E-04 Lung function (forced vital capacity) PRR5L intron 24023788 rs12421046 chr11 36354576 T G 1.64E-04 Lung function (forced vital capacity) PRR5L intron 24023788 rs12418187 chr11 36356242 C T 1.29E-04 Alcohol dependence PRR5L intron 21314694 rs4755450 chr11 36363575 G A 0.000000335 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) PRR5L intron 23603761 rs4755450 chr11 36363575 G A 0.0000638 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis PRR5L intron 23603761 rs4755450 chr11 36363575 G A 0.000475 Oligoarticular juvenile idiopathic arthritis PRR5L intron 23603761 rs2592555 chr11 36371757 T C 7.54E-05 Atopic dermatitis PRR5L intron 23042114 rs10501153 chr11 36386755 C T 7.14E-05 Stroke (ischemic) PRR5L intron 22941190 rs7933726 chr11 36422438 G T 2.00E-04 Cognitive impairment induced by topiramate PRR5L intron 22091778 rs2292648 chr11 36447369 A G 9.30E-05 Alcohol dependence PRR5L intron 20201924 rs2292648 chr11 36447369 A G 9.25E-05 Alcoholism PRR5L intron pha002892 rs7930554 chr11 36460081 T C 6.20E-05 Personality dimensions PRR5L intron 18957941 rs10742373 chr11 36465453 T C 5.98E-05 Blood Pressure PRR5L intron pha003049 rs10501156 chr11 36470815 C A 2.36E-04 Celiac disease PRR5L intron 23936387 rs3740958 chr11 36472800 A G 5.33E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) PRR5L cds-synon 24023788 rs3740958 chr11 36472800 A G 8.01E-06 Creatinine levels PRR5L cds-synon pha003069 rs890258 chr11 36475328 C G 3.39E-04 Multiple complex diseases PRR5L intron 17554300 rs331436 chr11 36486064 G A 6.90E-04 Multiple complex diseases PRR5L UTR-3 17554300 rs11033641 chr11 36487597 C T 1.13E-04 Multiple complex diseases / / 17554300 rs7106522 chr11 36488446 G T 1.09E-04 Multiple complex diseases / / 17554300 rs331463 chr11 36501787 A T 1.00E-07 Rheumatoid arthritis / / 24390342 rs331463 chr11 36501787 A T 3.00E-07 Rheumatoid arthritis / / 24390342 rs1046864 chr11 36510547 G A 6.65E-05 Multiple complex diseases TRAF6 UTR-3 17554300 rs5030445 chr11 36522260 T C 1.44E-05 Multiple complex diseases TRAF6 intron 17554300 rs540386 chr11 36525293 C T 8.20E-05 Multiple complex diseases TRAF6 intron 17554300 rs540386 chr11 36525293 C T 6.71E-11 Rheumatoid arthritis TRAF6 intron 23143596 rs331455 chr11 36540549 C T 0.00048 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines / / 23204130 rs2201845 chr11 36556258 G A 1.95E-04 Multiple complex diseases / / 17554300 rs3740955 chr11 36595600 A G 2.22E-06 Hemoglobin / / pha003096 rs3740955 chr11 36595600 A G 3.05E-05 Hematocrit / / pha003097 rs4151032 chr11 36596427 C T 0.00019 Breast cancer (ER positive) RAG1 missense 23555315 rs1498337 chr11 36632515 G A 5.74E-06 Hemoglobin C11orf74 intron pha003096 rs1498337 chr11 36632515 G A 6.17E-05 Hematocrit C11orf74 intron pha003097 rs12417768 chr11 36635169 C G 2.44E-04 Multiple complex diseases C11orf74 intron 17554300 rs10742376 chr11 36687370 A G 1.01E-05 Hemoglobin / / pha003096 rs10742376 chr11 36687370 A G 5.21E-05 Hematocrit / / pha003097 rs1039205 chr11 36711834 G A 7.37E-05 Hemoglobin / / pha003096 rs12294719 chr11 36728261 T C 3.84E-05 Height / / 22021425 rs11033750 chr11 36728603 A G 4.62E-05 Height / / 22021425 rs1533588 chr11 36730884 A G 2.94E-05 Coronary heart disease / / pha003032 rs2090572 chr11 36732003 C T 8.93E-06 Height / / 22021425 rs10501162 chr11 36746755 C A 1.00E-06 Mathematical ability / / 20039944 rs16929405 chr11 36766362 A G 1.49E-04 Multiple complex diseases / / 17554300 rs4756348 chr11 36777339 T G 4.93E-04 Alcohol dependence / / 21314694 rs1518754 chr11 36827869 G A 7.36E-05 HDL cholesterol / / pha003075 rs1825014 chr11 36985725 G A 8.57E-05 Serum albumin level / / pha003084 rs11604148 chr11 36992048 G A,T 2.58E-04 Smoking initiation / / 24665060 rs391317 chr11 37012537 A T 5.00E-07 Inflammatory biomarkers / / 22228203 rs333805 chr11 37043351 G A 9.10E-04 Type 2 diabetes / / 23209189 rs333785 chr11 37080673 T G 2.10E-05 Urinary metabolites / / 21572414 rs17412140 chr11 37081263 T C 2.00E-05 Urinary metabolites / / 21572414 rs368911 chr11 37089769 G A 2.80E-05 Urinary metabolites / / 21572414 rs12419571 chr11 37118265 T C 2.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs17651845 chr11 37119712 T G 1.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs11033937 chr11 37121295 G T 6.97E-06 Soluble levels of adhesion molecules / / pha003072 rs2614176 chr11 37122836 A G 4.08E-05 Body Mass Index / / pha003020 rs1355617 chr11 37126818 T C 8.40E-04 White matter integrity / / 22425255 rs1381161 chr11 37127070 C A 7.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs4755464 chr11 37127435 T C 5.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs2704917 chr11 37145651 T C 2.60E-05 Parkinson's disease (familial) / / 18985386 rs2614183 chr11 37196336 G C 5.31E-04 Multiple complex diseases / / 17554300 rs1461349 chr11 37200926 G T 9.63E-04 Multiple complex diseases / / 17554300 rs1461347 chr11 37213421 T C 5.09E-31 Narcolepsy / / 19629137 rs11034021 chr11 37222358 T C 2.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs66691212 chr11 37385986 T G 2.52E-04 Cocaine dependence / / 23958962 rs66691212 chr11 37385986 T G 8.50E-04 Cocaine dependence / / 23958962 rs1822933 chr11 37396461 A G 9.49E-05 Pulmonary function in asthmatics / / 23541324 rs6484926 chr11 37427873 G A 6.30E-05 Age-related macular degeneration / / 20385819 rs1822934 chr11 37439348 A G 9.35E-05 Pulmonary function in asthmatics / / 23541324 rs2860762 chr11 37521609 C T 7.98E-04 Alzheimer's disease / / 24755620 rs2077888 chr11 37579480 G A 6.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs7342219 chr11 37579928 C T 6.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs7342222 chr11 37579996 G A 6.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs11034229 chr11 37580012 G T 7.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs987084 chr11 37585468 G A 6.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs1381426 chr11 37587806 G T 4.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs7120892 chr11 37588777 A T 2.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs7121356 chr11 37588895 G A 8.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs1461898 chr11 37590232 G A 7.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs10768274 chr11 37590795 C G 7.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs10768275 chr11 37590972 T C 6.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs7932763 chr11 37591199 A G 5.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs7932889 chr11 37591258 C T 5.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs1350875 chr11 37594681 C G 5.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs2219646 chr11 37594773 C G 6.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs10742392 chr11 37594789 T C 6.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs10742393 chr11 37594803 A G 6.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs7949573 chr11 37595608 G A 6.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs7949424 chr11 37595693 C T 6.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs10836761 chr11 37596450 G T 6.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs11034242 chr11 37596773 A G 6.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs6484938 chr11 37597352 A G 6.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs6484939 chr11 37597706 C T 6.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs10836763 chr11 37597951 G A 7.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs10836764 chr11 37598186 T C 7.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs10742396 chr11 37599496 G A 7.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs11034246 chr11 37599783 T C 6.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs7927460 chr11 37600438 G A 5.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs7930644 chr11 37600933 C T 8.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs7121540 chr11 37604252 G A 8.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs10836771 chr11 37605632 T C 9.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs11034252 chr11 37609010 C T 7.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs10836776 chr11 37609287 C T 7.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs11034257 chr11 37610467 C T 8.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs11034260 chr11 37611149 T C 9.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs11034263 chr11 37611630 G A 1.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs11034268 chr11 37616055 T C 1.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs12293492 chr11 37627724 C T 9.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs7930562 chr11 37631032 A G 7.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs10836812 chr11 37631718 A T 8.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs10836813 chr11 37631735 T A 8.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs10836814 chr11 37632026 T C 8.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs2901770 chr11 37637716 C T 7.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs11034293 chr11 37643771 C A 7.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs10742401 chr11 37645108 C A 7.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs1461891 chr11 37647085 G A 7.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs7932671 chr11 37647731 T C 2.00E-05 Urinary metabolites / / 21572414 rs10768317 chr11 37649535 T C 6.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs1599505 chr11 37651249 C T 8.40E-05 Erythrocyte counts / / pha003101 rs7940338 chr11 37651389 C T 6.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs1599503 chr11 37651777 G A 6.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs7944053 chr11 37652132 C T 7.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs1381420 chr11 37652919 G C 8.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs10768318 chr11 37653393 G T 7.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs10444234 chr11 37654021 G T 9.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs7952120 chr11 37654106 C T 7.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs7938719 chr11 37654158 T C 7.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs7952464 chr11 37654255 G T 7.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs7939194 chr11 37654510 T A 8.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs7952538 chr11 37654573 A C 7.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs7924600 chr11 37654865 C T 7.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs7924610 chr11 37654882 C T 7.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs1461885 chr11 37655619 G A 7.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs11034301 chr11 37656034 T A 7.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs11034302 chr11 37656254 C T 7.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs11034303 chr11 37656356 C T 7.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs11034304 chr11 37656487 A G 5.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs11034306 chr11 37656610 A G 7.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs10836822 chr11 37657679 T C 7.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs1599508 chr11 37659404 C A 7.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs7116309 chr11 37659607 T C 8.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs7116608 chr11 37663058 C A 7.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs10836824 chr11 37663625 T C 8.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs2199420 chr11 37665910 A G,T 6.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs956923 chr11 37667614 T G 4.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs12362125 chr11 37669581 T C 8.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs1515038 chr11 37758393 A G 6.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs16930685 chr11 37870981 T C 2.00E-06 Cutaneous nevi / / 21478494 rs4564309 chr11 37954373 G C 4.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10501188 chr11 37954947 A C,G,T 8.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10501186 chr11 37957613 G T 5.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4313563 chr11 37996978 A G 7.11E-04 Schizophrenia / / 19197363 rs4313563 chr11 37996978 A G 4.53E-04 Stroke / / pha002886 rs7128697 chr11 38264006 T C 0.000000619 Tuberculosis with late age of onset / / 22551897 rs148153660 chr11 38278950 TTAGA T 2.00E-06 Metabolite levels (MHPG) / / 23319000 rs5004866 chr11 38278950 T A 2.00E-06 Metabolite levels (MHPG) / / 23319000 rs10836945 chr11 38285501 T C 7.90E-06 Bronchopulmonary dysplasia / / 23897914 rs10836945 chr11 38285501 T C 8.00E-06 Bronchopulmonary dysplasia / / 23897914 rs11034653 chr11 38288593 C T 2.00E-07 Immune reponse to smallpox (secreted IL-12p40) / / 22610502 rs7942782 chr11 38295966 G T 5.32E-04 Coronary heart disease / / 21606135 rs2045737 chr11 38306585 G T 0.00061 Prostate cancer / / 23555315 rs10501195 chr11 38328784 G A 6.89E-04 Multiple complex diseases / / 17554300 rs10836958 chr11 38346044 C T 7.11E-04 Coronary heart disease / / 21606135 rs1435154 chr11 38349608 C A 3.71E-05 Anxiety in major depressive disorder / / 24047446 rs10501200 chr11 38482784 C T 6.29E-04 Coronary heart disease / / 21606135 rs1030774 chr11 38497601 G A 0.00047 Coronary artery calcification / / 23727086 rs7930841 chr11 38509700 A T 0.0006 Endometrial cancer / / 22426144 rs11034781 chr11 38510453 T G 6.51E-04 Obesity (extreme) / / 21935397 rs12361508 chr11 38527523 C T 9.60E-04 Obesity (extreme) / / 21935397 rs3847638 chr11 38528172 A G 9.45E-04 Obesity (extreme) / / 21935397 rs3898491 chr11 38528628 G C 9.39E-04 Obesity (extreme) / / 21935397 rs7936967 chr11 38544369 T C 5.08E-04 Obesity (extreme) / / 21935397 rs7115870 chr11 38548177 C T 5.04E-04 Obesity (extreme) / / 21935397 rs10837001 chr11 38560367 C T 1.28E-04 Obesity (extreme) / / 21935397 rs1011138 chr11 38561949 G T 1.00E-04 Obesity (extreme) / / 21935397 rs10837002 chr11 38565727 C G 8.95E-04 Obesity (extreme) / / 21935397 rs11606965 chr11 38573394 T C 1.69E-04 Obesity (extreme) / / 21935397 rs11034857 chr11 38589311 C T 1.75E-04 Obesity (extreme) / / 21935397 rs11034860 chr11 38593694 T C 1.77E-04 Obesity (extreme) / / 21935397 rs553741164 chr11 38593694 TGA T 1.77E-04 Obesity (extreme) / / 21935397 rs17623660 chr11 38595345 T G 1.80E-04 Obesity (extreme) / / 21935397 rs2054580 chr11 38595924 T C 1.80E-04 Obesity (extreme) / / 21935397 rs7117710 chr11 38596613 A G 1.81E-04 Obesity (extreme) / / 21935397 rs17623761 chr11 38601224 A G 1.82E-04 Obesity (extreme) / / 21935397 rs7127335 chr11 38603206 A G 1.82E-04 Obesity (extreme) / / 21935397 rs1481294 chr11 38604075 A G 1.90E-04 Obesity (extreme) / / 21935397 rs1481295 chr11 38604158 G A 1.90E-04 Obesity (extreme) / / 21935397 rs11034867 chr11 38604379 A T 1.91E-04 Obesity (extreme) / / 21935397 rs10837017 chr11 38604480 T C 1.92E-04 Obesity (extreme) / / 21935397 rs997192 chr11 38606800 A G 1.92E-04 Obesity (extreme) / / 21935397 rs11034869 chr11 38608228 G A 1.93E-04 Obesity (extreme) / / 21935397 rs10501204 chr11 38641281 A G 3.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs983358 chr11 38648805 G A 7.59E-04 Tourette syndrome / / 22889924 rs12807104 chr11 38663437 G C 2.41E-04 Obesity (extreme) / / 21935397 rs1585961 chr11 38664589 A G 8.87E-04 Tourette syndrome / / 22889924 rs10837029 chr11 38679213 C T 1.39E-04 Obesity (extreme) / / 21935397 rs1354429 chr11 38681306 C T 9.29E-04 Tourette syndrome / / 22889924 rs10742437 chr11 38700909 C G 6.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs325183 chr11 38702667 T C 8.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3817089 chr11 38707653 G A 8.91E-05 Obesity (extreme) / / 21935397 rs12805836 chr11 38714667 C T 6.18E-05 Obesity (extreme) / / 21935397 rs374082 chr11 38726426 T C 2.93E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1504232 chr11 38738683 G A 7.92E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11034944 chr11 38764208 T A 3.91E-05 Obesity (extreme) / / 21935397 rs1867398 chr11 38786252 G T 5.35E-05 Obesity (extreme) / / 21935397 rs11034952 chr11 38788615 T C 5.60E-06 Obesity (extreme) / / 21935397 rs11600794 chr11 38797223 C T 3.38E-05 Obesity (extreme) / / 21935397 rs2655389 chr11 38804214 A C 3.97E-05 Obesity (extreme) / / 21935397 rs1996032 chr11 38805263 A G 2.88E-05 Obesity (extreme) / / 21935397 rs10837042 chr11 38805646 A G 2.88E-05 Obesity (extreme) / / 21935397 rs10837044 chr11 38808049 T C 2.88E-05 Obesity (extreme) / / 21935397 rs10837045 chr11 38808074 A C 2.88E-05 Obesity (extreme) / / 21935397 rs7949686 chr11 38809822 C T 2.88E-05 Obesity (extreme) / / 21935397 rs7924767 chr11 38810398 A G 2.99E-05 Obesity (extreme) / / 21935397 rs7925174 chr11 38810729 A G 3.02E-05 Obesity (extreme) / / 21935397 rs2901919 chr11 38810924 C A 3.14E-05 Obesity (extreme) / / 21935397 rs7114799 chr11 38813463 A T 3.22E-05 Obesity (extreme) / / 21935397 rs12360728 chr11 38817342 T C 2.91E-05 Obesity (extreme) / / 21935397 rs10768414 chr11 38817699 C T 2.94E-05 Obesity (extreme) / / 21935397 rs7951041 chr11 38821947 A G 3.11E-05 Obesity (extreme) / / 21935397 rs7938113 chr11 38831438 A C 3.33E-05 Obesity (extreme) / / 21935397 rs2068461 chr11 38831942 C T 3.43E-05 Obesity (extreme) / / 21935397 rs10768418 chr11 38832622 C T 3.53E-05 Obesity (extreme) / / 21935397 rs1913056 chr11 38837048 T C 3.68E-05 Obesity (extreme) / / 21935397 rs11034968 chr11 38839499 A G 3.78E-05 Obesity (extreme) / / 21935397 rs7928323 chr11 38841059 C A 5.56E-05 Obesity (extreme) / / 21935397 rs10837053 chr11 38841493 T A 3.81E-05 Obesity (extreme) / / 21935397 rs10837055 chr11 38845174 C A 3.68E-05 Obesity (extreme) / / 21935397 rs10837056 chr11 38846515 A C 3.63E-05 Obesity (extreme) / / 21935397 rs10837057 chr11 38846539 A G 3.59E-05 Obesity (extreme) / / 21935397 rs2861328 chr11 38846757 G A 3.57E-05 Obesity (extreme) / / 21935397 rs4612778 chr11 38853186 T C 3.50E-05 Obesity (extreme) / / 21935397 rs2137359 chr11 38854752 T C 3.46E-05 Obesity (extreme) / / 21935397 rs7930395 chr11 38859432 G A 3.44E-05 Obesity (extreme) / / 21935397 rs7930559 chr11 38859716 C T 3.39E-05 Obesity (extreme) / / 21935397 rs11034972 chr11 38860022 T C 3.37E-05 Obesity (extreme) / / 21935397 rs2861329 chr11 38864830 T G 3.34E-05 Obesity (extreme) / / 21935397 rs2861331 chr11 38869367 G T 3.34E-05 Obesity (extreme) / / 21935397 rs1913033 chr11 38869868 T A 1.11E-04 Coronary heart disease / / 21606135 rs1913033 chr11 38869868 T A 5.55E-05 Obesity (extreme) / / 21935397 rs4400783 chr11 39018158 T C 2.73E-05 Serum metabolites / / 19043545 rs11035036 chr11 39018279 G A 3.82E-05 Serum metabolites / / 19043545 rs7951105 chr11 39031793 T G 5.00E-07 Free thyroxine concentration / / 24722205 rs722773 chr11 39058982 G A 8.02E-04 Bipolar disorder / / 19259986 rs7481100 chr11 39079148 G A 2.40E-05 Endometriosis / / 21151130 rs12418031 chr11 39141033 G A 3.70E-05 Endometriosis / / 21151130 rs12420264 chr11 39142741 T C 3.20E-05 Endometriosis / / 21151130 rs7101534 chr11 39178277 G A 3.19E-04 Bipolar disorder / / 19259986 rs12365458 chr11 39214772 G T 5.37E-04 Coronary heart disease / / 21971053 rs729289 chr11 39227651 A C 1.94E-06 Multiple complex diseases / / 17554300 rs4511262 chr11 39290605 T C 9.33E-06 White blood cell count / / 21738479 rs12281307 chr11 39291877 C T 8.71E-06 White blood cell count / / 21738479 rs6485074 chr11 39297842 C T 7.76E-06 White blood cell count / / 21738479 rs7944994 chr11 39322214 A G 2.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12808199 chr11 39327959 G A 9.00E-07 Osteoporosis / / 20548944 rs2101997 chr11 39362837 T C 2.71E-04 Multiple complex diseases / / 17554300 rs994587 chr11 39400626 A G 4.59E-04 Coronary heart disease / / 21606135 rs1391590 chr11 39405761 C A 3.82E-05 C-Reactive Protein / / pha003070 rs12292796 chr11 39426099 A C 3.00E-07 Pulse pressure (alcohol consumption interaction) / / 24376456 rs11035257 chr11 39436698 C T 3.71E-04 Alzheimer's disease / / 17998437 rs6485094 chr11 39442174 G A 5.21E-05 Height / / pha003010 rs6485094 chr11 39442174 G A 1.31E-05 Height / / pha003011 rs6485094 chr11 39442174 G A 9.12E-05 C-Reactive Protein / / pha003070 rs4237674 chr11 39445016 G A 3.32E-05 Height / / pha003011 rs4237674 chr11 39445016 G A 2.51E-05 C-Reactive Protein / / pha003070 rs7944563 chr11 39447041 A C 5.77E-06 Post-operative nausea and vomiting / / 21694509 rs7944563 chr11 39447041 A C 5.08E-05 Height / / pha003011 rs7944563 chr11 39447041 A C 2.49E-05 C-Reactive Protein / / pha003070 rs11035274 chr11 39456990 C T 9.75E-04 Multiple complex diseases / / 17554300 rs2068327 chr11 39487066 T A 8.50E-04 Multiple complex diseases / / 17554300 rs11828347 chr11 39497073 A G 2.34E-05 Vitiligo / / 22951725 rs12273158 chr11 39600839 A C 2.55E-04 Multiple complex diseases / / 17554300 rs4315042 chr11 39606277 C A 4.11E-05 Femoral neck bone geometry / / 22087292 rs10501215 chr11 39611165 G T 7.07E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7932035 chr11 39620131 A G 3.94E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12416853 chr11 39632506 T C 1.87E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1477869 chr11 39633353 G A 9.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10837192 chr11 39643150 C A 1.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10837198 chr11 39652635 A C 1.73E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1676667 chr11 39754051 A C 2.20E-05 Temperament (bipolar disorder) / / 22365631 rs1702585 chr11 39754355 G A 2.70E-05 Temperament (bipolar disorder) / / 22365631 rs1702585 chr11 39754355 G A 9.70E-05 Asthma / / 23181788 rs1676664 chr11 39754514 T C 4.80E-05 Temperament (bipolar disorder) / / 22365631 rs12362542 chr11 39767064 C T 2.86E-05 Prion diseases / / 22210626 rs10768535 chr11 39775097 T C 7.40E-05 Temperament (bipolar disorder) / / 22365631 rs11035468 chr11 39809712 C T 8.60E-05 Temperament (bipolar disorder) / / 22365631 rs1381379 chr11 39817403 C A 8.20E-05 Temperament (bipolar disorder) / / 22365631 rs16933947 chr11 39818697 T A 4.59E-04 Multiple complex diseases / / 17554300 rs1020875 chr11 39829630 G C 3.30E-05 Temperament (bipolar disorder) / / 22365631 rs10768549 chr11 39857064 G T 4.10E-05 Temperament (bipolar disorder) / / 22365631 rs10837288 chr11 39886441 A T 3.00E-05 Temperament (bipolar disorder) / / 22365631 rs10768556 chr11 39902443 C A 4.00E-04 Alcohol dependence / / 20201924 rs11035577 chr11 39908662 T C 5.50E-04 Coronary Artery Disease / / 17634449 rs11035577 chr11 39908662 T C 6.00E-06 Temperament (bipolar disorder) / / 22365631 rs10837301 chr11 39933968 A C 5.20E-04 Alcohol dependence / / 20201924 rs11035610 chr11 39952784 T C 4.71E-05 Coronary Artery Disease / / 17634449 rs12272323 chr11 39954050 G A 8.47E-04 Type 2 diabetes / / 17463246 rs12273784 chr11 39954357 G A 8.68E-04 Type 2 diabetes / / 17463246 rs10837311 chr11 39981948 G A 1.83E-05 Prostate cancer / / 18264096 rs7111117 chr11 39989962 T C 2.00E-04 Alcohol dependence / / 20201924 rs7104248 chr11 39992563 C G 1.37E-04 Coronary Artery Disease / / 17634449 rs6485172 chr11 40041290 A G 8.60E-04 Alcohol dependence / / 20201924 rs6485172 chr11 40041290 A G 1.39E-05 Systemic lupus erythematosus / / pha002867 rs10837325 chr11 40071023 G A 1.73E-05 Systemic lupus erythematosus / / pha002867 rs10768576 chr11 40073820 G A 5.50E-04 Alcohol dependence / / 20201924 rs1462183 chr11 40076546 T C 9.94E-04 Alzheimer's disease / / 24755620 rs16934315 chr11 40092793 T C 1.30E-04 Alcohol dependence / / 20201924 rs7929966 chr11 40093494 G A 5.00E-04 Alzheimer's disease / / 24755620 rs11035693 chr11 40135242 G A 4.74E-05 Meningococcal disease / / 20694013 rs2953310 chr11 40137543 T C 1.75E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LRRC4C cds-synon 20877124 rs7943560 chr11 40142377 G A 3.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LRRC4C intron 20877124 rs7930525 chr11 40142665 T C 7.03E-04 Multiple complex diseases LRRC4C intron 17554300 rs7930525 chr11 40142665 T C 6.86E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LRRC4C intron 20877124 rs968938 chr11 40143759 T C 9.45E-04 Multiple complex diseases LRRC4C intron 17554300 rs1381566 chr11 40149607 T G 3.00E-26 Myopia (Age of onset) LRRC4C intron 23468642 rs7936167 chr11 40156059 T C 4.40E-05 Educational attainment LRRC4C intron 21694764 rs11035724 chr11 40194118 T C 1.48E-05 Magnesium levels LRRC4C intron pha003092 rs533364845 chr11 40194118 TCA T 1.48E-05 Magnesium levels LRRC4C intron pha003092 rs11035727 chr11 40197787 T C 3.04E-06 Magnesium levels LRRC4C intron pha003092 rs4319506 chr11 40205141 C T 7.11E-05 Magnesium levels LRRC4C intron pha003092 rs12362407 chr11 40205191 A G 5.34E-05 Magnesium levels LRRC4C intron pha003092 rs6485187 chr11 40205503 A C 5.51E-05 Insulin Resistance LRRC4C intron pha003062 rs6485187 chr11 40205503 A C 4.61E-05 Insulin-related traits LRRC4C intron pha003063 rs7924805 chr11 40211252 T C 8.48E-05 Cognitive test performance LRRC4C intron 20125193 rs10734479 chr11 40212151 G T 3.66E-05 Asthma LRRC4C intron pha003128 rs7106026 chr11 40221414 A C 1.74E-05 Prion diseases LRRC4C intron 22210626 rs4369393 chr11 40226381 G T 9.37E-04 Alcohol dependence LRRC4C intron 21314694 rs1037412 chr11 40276725 A G 1.01E-04 Epilepsy LRRC4C intron 22116939 rs10501226 chr11 40302006 T C 6.86E-04 Alcohol dependence LRRC4C intron 21314694 rs16934689 chr11 40320791 A G 3.58E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) LRRC4C intron 23648065 rs896618 chr11 40329182 C T 5.43E-04 Coronary Artery Disease LRRC4C intron 17634449 rs896617 chr11 40329199 A G 2.11E-04 Breast cancer LRRC4C intron 21060860 rs896617 chr11 40329199 A G 5.56E-05 Aortic root size LRRC4C intron 21223598 rs1452460 chr11 40330257 A T 1.21E-04 Multiple complex diseases LRRC4C intron 17554300 rs10501228 chr11 40340037 T C 2.47E-05 Lipid levels LRRC4C intron 19016617 rs10501228 chr11 40340037 T C 3.72E-04 Lipid levels LRRC4C intron 19016617 rs1303932 chr11 40376628 C T 3.97E-05 Height LRRC4C intron pha003011 rs1002254 chr11 40414427 C A 3.04E-05 Multiple sclerosis LRRC4C intron 17660530 rs920443 chr11 40423092 A C 8.45E-05 Tunica Media LRRC4C intron pha003037 rs41490153 chr11 40480187 T A 3.13E-04 Type 2 diabetes LRRC4C intron 17463246 rs7940702 chr11 40488331 T C 0.0008219 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LRRC4C intron 23233654 rs7940702 chr11 40488331 T C 8.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) LRRC4C intron 23233662 rs7113061 chr11 40527018 T C 5.55E-04 Response to cytidine analogues (gemcitabine) LRRC4C intron 24483146 rs17406736 chr11 40530245 T C 8.95E-05 Tunica Media LRRC4C intron pha003037 rs967632 chr11 40555598 T G 3.90E-06 Urinary metabolites LRRC4C intron 21572414 rs10837433 chr11 40559715 A G 3.85E-04 Response to cytidine analogues (gemcitabine) LRRC4C intron 24483146 rs1874291 chr11 40565209 C T 8.55E-05 Tunica Media LRRC4C intron pha003037 rs16934933 chr11 40570963 G A 9.40E-06 Urinary metabolites LRRC4C intron 21572414 rs16934935 chr11 40571159 A G 9.40E-06 Urinary metabolites LRRC4C intron 21572414 rs17408566 chr11 40571519 T A 1.00E-05 Urinary metabolites LRRC4C intron 21572414 rs17408751 chr11 40578429 G T 2.20E-05 Urinary metabolites LRRC4C intron 21572414 rs4755553 chr11 40578791 A G 6.86E-04 Response to cytidine analogues (gemcitabine) LRRC4C intron 24483146 rs17487242 chr11 40578833 G T 8.60E-06 Urinary metabolites LRRC4C intron 21572414 rs7945226 chr11 40579505 C T 6.65E-04 Response to cytidine analogues (gemcitabine) LRRC4C intron 24483146 rs7945461 chr11 40579533 G A 7.62E-05 Response to cytidine analogues (gemcitabine) LRRC4C intron 24483146 rs951068 chr11 40580085 C T 2.20E-05 Urinary metabolites LRRC4C intron 21572414 rs1495310 chr11 40581503 G A 3.14E-04 Response to cytidine analogues (gemcitabine) LRRC4C intron 24483146 rs1353354 chr11 40586116 G A 8.00E-04 Multiple complex diseases LRRC4C intron 17554300 rs10837436 chr11 40586402 G T 9.71E-04 Multiple complex diseases LRRC4C intron 17554300 rs12098900 chr11 40590176 A G 2.23E-04 Multiple complex diseases LRRC4C intron 17554300 rs1027388 chr11 40619828 G T 5.29E-04 Multiple complex diseases LRRC4C intron 17554300 rs1027388 chr11 40619828 G T 2.36E-04 Alzheimer's disease LRRC4C intron 24755620 rs1027388 chr11 40619828 G T 5.63E-05 Tunica Media LRRC4C intron pha003037 rs11035962 chr11 40641079 C A 7.97E-06 Tunica Media LRRC4C intron pha003037 rs4523685 chr11 40651655 T C 1.54E-04 Multiple complex diseases LRRC4C intron 17554300 rs3943000 chr11 40653814 C G 9.97E-04 Suicide attempts in bipolar disorder LRRC4C intron 21423239 rs11604865 chr11 40658002 T C 6.26E-08 Narcolepsy LRRC4C intron 19629137 rs11035980 chr11 40659256 C A 8.90E-05 Temperament (bipolar disorder) LRRC4C intron 22365631 rs11035988 chr11 40664763 C G 9.80E-05 Temperament (bipolar disorder) LRRC4C intron 22365631 rs11035996 chr11 40677144 T C 6.62E-06 Tunica Media LRRC4C intron pha003037 rs11603172 chr11 40679479 T G 7.38E-06 Tunica Media LRRC4C intron pha003037 rs2220904 chr11 40680147 T C 8.45E-04 Type 2 diabetes LRRC4C intron 17463246 rs2220904 chr11 40680147 T C 3.42E-05 Serum metabolites LRRC4C intron 19043545 rs10501241 chr11 40696128 C A 7.40E-05 Temperament (bipolar disorder) LRRC4C intron 22365631 rs11036020 chr11 40710758 A C 5.32E-04 Multiple complex diseases LRRC4C intron 17554300 rs11036021 chr11 40711439 G T 2.85E-05 Interstitial lung disease LRRC4C intron 23583980 rs4261274 chr11 40713459 G T 2.03E-05 Fibrinogen LRRC4C intron pha003068 rs11036026 chr11 40716823 A C 5.39E-04 Stroke (pediatric) LRRC4C intron 22990015 rs4132508 chr11 40744768 C T 1.36E-04 Parkinson's disease LRRC4C intron 21248740 rs4285860 chr11 40777007 C T 9.50E-05 Memory performance LRRC4C intron 22105620 rs7106270 chr11 40783051 G A 5.05E-04 Gallstones LRRC4C intron 17632509 rs11036078 chr11 40809311 G C 5.20E-06 Urinary metabolites LRRC4C intron 21572414 rs10837504 chr11 40819106 C A 1.65E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy LRRC4C intron 23834954 rs7112665 chr11 40837529 C T 4.94E-04 Multiple complex diseases LRRC4C intron 17554300 rs4611189 chr11 40837713 G A 6.00E-07 Response to antipsychotic treatment in schizophrenia (reasoning) LRRC4C intron 21107309 rs4427557 chr11 40861756 C T 3.87E-06 Phospholipid levels (plasma) LRRC4C intron 21829377 rs78015633 chr11 40876586 T C 9.00E-06 PR interval in Tripanosoma cruzi seropositivity LRRC4C intron 24324551 rs11036136 chr11 40904848 A G 7.81E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) LRRC4C intron 23648065 rs16935194 chr11 40976602 C T 2.74E-06 Phospholipid levels (plasma) LRRC4C intron 21829377 rs16935201 chr11 40977591 A G 2.06E-06 Phospholipid levels (plasma) LRRC4C intron 21829377 rs16935203 chr11 40978441 G C 2.06E-06 Phospholipid levels (plasma) LRRC4C intron 21829377 rs1462227 chr11 40979321 T C 4.27E-04 Parkinson's disease LRRC4C intron 17052657 rs10501245 chr11 40980449 C T 6.93E-04 Parkinson's disease LRRC4C intron 17052657 rs355230 chr11 40981020 G A 1.85E-04 Amyotrophic lateral sclerosis (sporadic) LRRC4C intron 24529757 rs355232 chr11 40987651 A T 5.92E-04 Alzheimer's disease LRRC4C intron 22005930 rs4756627 chr11 41022602 T A 1.43E-04 Acute lung injury LRRC4C intron 22295056 rs16935255 chr11 41024138 C T 1.36E-04 Acute lung injury LRRC4C intron 22295056 rs16935256 chr11 41024608 A G 1.36E-04 Acute lung injury LRRC4C intron 22295056 rs10837544 chr11 41029732 T C 5.39E-04 Alzheimer's disease LRRC4C intron 22005930 rs16935277 chr11 41035085 A G 2.17E-04 Acute lung injury LRRC4C intron 22295056 rs17506055 chr11 41037313 T A 1.87E-04 Acute lung injury LRRC4C intron 22295056 rs12577965 chr11 41048694 C T 5.15E-04 Alzheimer's disease LRRC4C intron 22005930 rs996263 chr11 41060325 T A 7.86E-04 Suicide attempts in bipolar disorder LRRC4C intron 21041247 rs355220 chr11 41064232 C T 4.70E-05 HIV-1 control LRRC4C intron 20041166 rs355220 chr11 41064232 C T 4.46E-04 Suicide attempts in bipolar disorder LRRC4C intron 21041247 rs12224794 chr11 41068900 C A 6.41E-04 Alzheimer's disease LRRC4C intron 22005930 rs1381577 chr11 41069095 T C 6.53E-04 Alzheimer's disease LRRC4C intron 22005930 rs6485245 chr11 41071513 C T 3.81E-04 Alzheimer's disease LRRC4C intron 22005930 rs11036205 chr11 41072659 A G 7.91E-04 Acute lung injury LRRC4C intron 22295056 rs995986 chr11 41072856 C T 1.96E-04 Alzheimer's disease LRRC4C intron 22005930 rs4147442 chr11 41073602 C T 3.81E-04 Alzheimer's disease LRRC4C intron 22005930 rs4147443 chr11 41073684 G A 3.80E-04 Alzheimer's disease LRRC4C intron 22005930 rs1350917 chr11 41074667 G A 2.54E-04 Alzheimer's disease LRRC4C intron 22005930 rs4488182 chr11 41075561 T G 5.40E-05 Electrocardiographic traits and heart rate variability LRRC4C intron 17903306 rs10837561 chr11 41077568 G A 5.47E-04 Acute lung injury LRRC4C intron 22295056 rs7103962 chr11 41078621 C T 1.93E-04 Alzheimer's disease LRRC4C intron 22005930 rs1462216 chr11 41096261 G A 2.31E-04 Alzheimer's disease LRRC4C intron 22005930 rs12577314 chr11 41097195 T G 1.42E-04 Alzheimer's disease LRRC4C intron 22005930 rs11036221 chr11 41103627 C T 9.24E-04 Acute lung injury LRRC4C intron 22295056 rs11604576 chr11 41127716 G C 3.75E-04 Alzheimer's disease LRRC4C intron 22005930 rs11036236 chr11 41131668 T C 2.86E-04 Alzheimer's disease LRRC4C intron 22005930 rs12273790 chr11 41151356 G A 1.88E-04 Smoking initiation LRRC4C intron 24665060 rs10837579 chr11 41154796 G A 3.72E-05 White matter integrity LRRC4C intron 22425255 rs10837587 chr11 41175597 G A 2.42E-04 Smoking initiation LRRC4C intron 24665060 rs10430986 chr11 41182519 T C 2.63E-06 Intraocular pressure LRRC4C intron 23836780 rs12222492 chr11 41187859 C T 8.68E-06 Intraocular pressure LRRC4C intron 23836780 rs12364931 chr11 41195359 G A 1.51E-05 Cognitive impairment induced by topiramate LRRC4C intron 22091778 rs12364931 chr11 41195359 G A 5.18E-04 White matter integrity LRRC4C intron 22425255 rs12364931 chr11 41195359 G A 0.0008553 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LRRC4C intron 23233654 rs12364931 chr11 41195359 G A 8.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) LRRC4C intron 23233662 rs2171333 chr11 41216468 C T 0.000449 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LRRC4C intron 23233654 rs2171333 chr11 41216468 C T 4.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) LRRC4C intron 23233662 rs12421301 chr11 41219414 A C 0.0006562 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LRRC4C intron 23233654 rs12421301 chr11 41219414 A C 6.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) LRRC4C intron 23233662 rs1487080 chr11 41224281 T C 0.0006567 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LRRC4C intron 23233654 rs1487080 chr11 41224281 T C 6.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) LRRC4C intron 23233662 rs2862035 chr11 41225433 C G 8.00E-06 IgG glycosylation LRRC4C intron 23382691 rs980952 chr11 41225954 T G 5.00E-06 IgG glycosylation LRRC4C intron 23382691 rs11036286 chr11 41226338 A G 0.000765 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LRRC4C intron 23233654 rs11036286 chr11 41226338 A G 7.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) LRRC4C intron 23233662 rs16935437 chr11 41226389 G A 0.0007665 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LRRC4C intron 23233654 rs16935437 chr11 41226389 G A 7.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) LRRC4C intron 23233662 rs7122101 chr11 41228774 G A 7.20E-05 Lung adenocarcinoma LRRC4C intron 22797724 rs1352230 chr11 41257362 G A 1.00E-04 Cognitive impairment induced by topiramate LRRC4C intron 22091778 rs10501252 chr11 41258331 T C 5.14E-04 Multiple complex diseases LRRC4C intron 17554300 rs10501252 chr11 41258331 T C 1.85E-04 Cognitive decline LRRC4C intron 23732972 rs11036306 chr11 41260962 G T 3.50E-04 Smoking initiation LRRC4C intron 24665060 rs12290967 chr11 41261033 G A 8.34E-04 Alzheimer's disease LRRC4C intron 22005930 rs12272916 chr11 41261245 T A 2.46E-04 Alzheimer's disease LRRC4C intron 22005930 rs7101884 chr11 41265966 A C 1.24E-04 Alzheimer's disease LRRC4C intron 22005930 rs11036320 chr11 41278255 C T 1.06E-04 Smoking initiation LRRC4C intron 24665060 rs4756640 chr11 41278649 T C 9.92E-04 Alzheimer's disease LRRC4C intron 22005930 rs16935491 chr11 41279431 G A 1.25E-04 Smoking initiation LRRC4C intron 24665060 rs10501257 chr11 41280710 G A 1.25E-04 Smoking initiation LRRC4C intron 24665060 rs6485261 chr11 41280788 C T 7.70E-04 Alzheimer's disease LRRC4C intron 22005930 rs7930183 chr11 41281620 T C 7.66E-04 Alzheimer's disease LRRC4C intron 22005930 rs11036327 chr11 41282353 T C 6.03E-05 Smoking initiation LRRC4C intron 24665060 rs7925125 chr11 41288897 C T 7.50E-04 Alzheimer's disease LRRC4C intron 22005930 rs4445616 chr11 41289050 G T 7.57E-04 Alzheimer's disease LRRC4C intron 22005930 rs4130500 chr11 41289764 T C 2.12E-04 White matter integrity LRRC4C intron 22425255 rs7111371 chr11 41291478 A G 6.78E-04 Alzheimer's disease LRRC4C intron 22005930 rs10837607 chr11 41294454 G A 3.65E-04 Multiple complex diseases LRRC4C intron 17554300 rs9971441 chr11 41298837 T C 7.33E-04 Alzheimer's disease LRRC4C intron 22005930 rs4625446 chr11 41301051 C T 7.74E-04 Alzheimer's disease LRRC4C intron 22005930 rs7941298 chr11 41303663 G A 9.55E-04 Alzheimer's disease LRRC4C intron 22005930 rs2958856 chr11 41306491 G A 9.01E-04 Alzheimer's disease LRRC4C intron 22005930 rs2922037 chr11 41309275 C T 0.00000822 Social anxiety (ARBQ) in children LRRC4C intron 23565138 rs1447120 chr11 41310794 C T 4.02E-04 Alzheimer's disease LRRC4C intron 22005930 rs2958860 chr11 41316973 A G 2.31E-04 Alzheimer's disease LRRC4C intron 22005930 rs2958861 chr11 41317133 G A 2.30E-04 Alzheimer's disease LRRC4C intron 22005930 rs2958866 chr11 41324413 T C 3.37E-04 Alzheimer's disease LRRC4C intron 22005930 rs2044541 chr11 41343185 C T 3.36E-05 Educational attainment LRRC4C intron 21694764 rs7125162 chr11 41352633 G A 5.50E-05 Smoking initiation LRRC4C intron 24665060 rs11036360 chr11 41355213 G A 3.53E-05 Smoking initiation LRRC4C intron 24665060 rs558177357 chr11 41355213 GC G 3.53E-05 Smoking initiation LRRC4C intron 24665060 rs2922051 chr11 41400090 T C 3.43E-04 Parkinson's disease LRRC4C intron 17052657 rs10501264 chr11 41430830 C T 1.10E-04 Kidney function and endocine traits LRRC4C intron 17903292 rs7105487 chr11 41468936 T C 0.0000806 Nonsyndromic striae distensae (stretch marks) LRRC4C intron 23633020 rs12361464 chr11 41519485 A G 0.0000932 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11823636 chr11 41532026 T C 3.57E-05 Amyotrophic lateral sclerosis / / 20801717 rs10837653 chr11 41534432 T C 0.0000689 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12574095 chr11 41540335 C T 0.0000991 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10768697 chr11 41543093 T C 0.0000996 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs373647976 chr11 41543093 TG TCA,TTG 0.0000996 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10768698 chr11 41543094 G A 0.0000956 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1531219 chr11 41559595 C T 0.000098 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7946270 chr11 41579357 T C 0.0000498 Type 2 diabetes / / 22325160 rs7944293 chr11 41590918 T C 0.00000306 Type 2 diabetes / / 22325160 rs1463075 chr11 41631862 C A 5.39E-04 Diabetic retinopathy / / 20871662 rs2862331 chr11 41647878 C A 3.02E-04 Alzheimer's disease / / 22005930 rs1585615 chr11 41656351 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7125261 chr11 41671450 C T 7.34E-05 Smoking initiation / / 24665060 rs16935830 chr11 41679803 C T 7.09E-04 Alzheimer's disease / / 22005930 rs2045823 chr11 41680191 C G 4.55E-04 Multiple complex diseases / / 17554300 rs2045823 chr11 41680191 C G 7.12E-04 Alzheimer's disease / / 22005930 rs1381944 chr11 41682733 T C 2.76E-04 Alzheimer's disease / / 22005930 rs7123744 chr11 41683364 G A 9.55E-09 LDL cholesterol / / 23063622 rs10742596 chr11 41685519 T C 6.82E-04 Alzheimer's disease / / 22005930 rs1031626 chr11 41686423 A T 3.02E-04 Alzheimer's disease / / 22005930 rs17534803 chr11 41687203 T C 3.04E-04 Alzheimer's disease / / 22005930 rs7126881 chr11 41687702 T A 7.71E-04 Alzheimer's disease / / 22005930 rs10768723 chr11 41702754 A G 7.75E-04 Alzheimer's disease / / 22005930 rs7121305 chr11 41705636 C T 8.26E-04 Alzheimer's disease / / 22005930 rs1381939 chr11 41711851 T C 7.69E-04 Alzheimer's disease / / 22005930 rs1993825 chr11 41718341 A G 8.18E-04 Alzheimer's disease / / 22005930 rs10742598 chr11 41718922 T C 7.57E-04 Alzheimer's disease / / 22005930 rs10742599 chr11 41718998 C T 6.51E-04 Alzheimer's disease / / 22005930 rs4545541 chr11 41720271 T C 7.13E-04 Alzheimer's disease / / 22005930 rs509123 chr11 41722614 C A 9.18E-04 Multiple complex diseases / / 17554300 rs185952 chr11 41736280 G A 9.26E-04 Type 2 diabetes / / 17463246 rs479434 chr11 41742472 C T 2.59E-04 Multiple complex diseases / / 17554300 rs570430 chr11 41743040 A G 4.32E-04 Multiple complex diseases / / 17554300 rs61435922 chr11 41777610 T TC 6.03E-30 Metabolite levels / / 22286219 rs12288214 chr11 41815649 G A 2.50E-05 Type 2 diabetes / / 17463248 rs12284861 chr11 41831300 A G 2.10E-05 Type 2 diabetes / / 17463248 rs11036577 chr11 41835884 C T 2.10E-05 Type 2 diabetes / / 17463248 rs420798 chr11 41836176 C T 9.41E-05 Suicide attempts in bipolar disorder / / 21423239 rs12797436 chr11 41842341 A C 5.40E-05 Type 2 diabetes / / 17463248 rs12274732 chr11 41848925 C T 2.10E-05 Type 2 diabetes / / 17463248 rs1484948 chr11 41852664 T C 2.00E-06 RR interval (heart rate) / / 20031603 rs12275923 chr11 41861950 A C 2.00E-05 Type 2 diabetes / / 17463248 rs12294552 chr11 41864505 G C 5.20E-05 Type 2 diabetes / / 17463248 rs11036600 chr11 41867075 A G 2.00E-05 Type 2 diabetes / / 17463248 rs11600495 chr11 41872033 C A 7.30E-05 Type 2 diabetes / / 17463248 rs10160442 chr11 41877102 T C 2.20E-05 Type 2 diabetes / / 17463248 rs3763827 chr11 41877878 G C 5.90E-05 Type 2 diabetes / / 17463248 rs6485288 chr11 41881338 A G 3.20E-05 Type 2 diabetes / / 17463248 rs12280294 chr11 41881747 G T 2.30E-05 Type 2 diabetes / / 17463248 rs16936027 chr11 41884290 C T 0.00043 Coronary artery calcification / / 23727086 rs12281155 chr11 41887064 C G 2.30E-05 Type 2 diabetes / / 17463248 rs12786634 chr11 41888620 C T 2.30E-05 Type 2 diabetes / / 17463248 rs12277557 chr11 41892576 A T 2.20E-05 Type 2 diabetes / / 17463248 rs12793795 chr11 41898126 G A 8.40E-05 Type 2 diabetes / / 17463248 rs12271525 chr11 41901861 G A 8.10E-05 Type 2 diabetes / / 17463248 rs7928200 chr11 41902533 A G 8.00E-05 Type 2 diabetes / / 17463248 rs12273344 chr11 41902777 G T 6.50E-05 Type 2 diabetes / / 17463248 rs12788548 chr11 41906381 C T 7.90E-05 Type 2 diabetes / / 17463248 rs12288738 chr11 41912299 T C 7.50E-05 Type 2 diabetes / / 17463248 rs1588439 chr11 41914606 G A 7.50E-05 Type 2 diabetes / / 17463248 rs16936067 chr11 41915244 G T 9.50E-05 Type 2 diabetes / / 17463248 rs9300039 chr11 41915366 C A 6.00E-08 Type 2 diabetes / / 17463248 rs9300039 chr11 41915366 C A 1.00E-06 Coronary spasm / / 18075462 rs9300039 chr11 41915366 C A 6.00E-08 Coronary heart disease / / 21347282 rs9300039 chr11 41915366 C A 6.00E-08 Type 2 diabetes / / 21647700 rs11036622 chr11 41916166 C T 6.90E-05 Type 2 diabetes / / 17463248 rs11036624 chr11 41921670 T C 6.80E-05 Type 2 diabetes / / 17463248 rs12797038 chr11 41923877 C T 9.00E-05 Type 2 diabetes / / 17463248 rs12804210 chr11 41924423 T C 5.10E-05 Type 2 diabetes / / 17463248 rs11036627 chr11 41924714 C A 9.20E-08 Type 2 diabetes / / 17463248 rs11036628 chr11 41924776 G A 1.80E-05 Type 2 diabetes / / 17463248 rs7114241 chr11 41925527 T C 5.20E-05 Type 2 diabetes / / 17463248 rs7128743 chr11 41925699 C A 5.20E-05 Type 2 diabetes / / 17463248 rs11500415 chr11 41926727 C T 5.10E-05 Type 2 diabetes / / 17463248 rs12802634 chr11 41929562 T C 5.20E-05 Type 2 diabetes / / 17463248 rs12802862 chr11 41929691 T C 5.20E-05 Type 2 diabetes / / 17463248 rs11608189 chr11 41930811 G T 7.90E-05 Type 2 diabetes / / 17463248 rs11602004 chr11 41944267 G T 7.00E-05 Type 2 diabetes / / 17463248 rs11602127 chr11 41944981 G A 5.60E-05 Type 2 diabetes / / 17463248 rs10501281 chr11 41966359 C T 5.30E-05 Type 2 diabetes / / 17463248 rs11823992 chr11 41970280 A T 4.00E-05 Type 2 diabetes / / 17463248 rs7101809 chr11 41977139 T C 4.10E-05 Type 2 diabetes / / 17463248 rs12287052 chr11 41978568 A G 5.60E-05 Type 2 diabetes / / 17463248 rs11036642 chr11 41984421 T A 3.30E-05 Type 2 diabetes / / 17463248 rs17553408 chr11 41995352 T G 5.80E-05 Type 2 diabetes / / 17463248 rs12293408 chr11 41999756 C T 3.50E-05 Type 2 diabetes / / 17463248 rs16936200 chr11 42006739 A C 3.00E-05 Type 2 diabetes / / 17463248 rs11036649 chr11 42008948 A G 3.10E-05 Type 2 diabetes / / 17463248 rs12576408 chr11 42014627 G T 3.20E-05 Type 2 diabetes / / 17463248 rs11036652 chr11 42014693 T C 3.50E-05 Type 2 diabetes / / 17463248 rs7107246 chr11 42015852 C A 4.00E-05 Type 2 diabetes / / 17463248 rs11604966 chr11 42016160 T C 3.80E-05 Type 2 diabetes / / 17463248 rs4548607 chr11 42021687 A G 0.00029 Coronary artery calcification / / 23727086 rs10837766 chr11 42027801 T C 5.80E-06 Type 2 diabetes / / 17463248 rs17554005 chr11 42032572 A C 3.40E-05 Type 2 diabetes / / 17463248 rs17554054 chr11 42033642 T C 3.60E-05 Type 2 diabetes / / 17463248 rs17554081 chr11 42033704 A G 3.90E-05 Type 2 diabetes / / 17463248 rs2862456 chr11 42034193 C T 4.50E-05 Type 2 diabetes / / 17463248 rs17462952 chr11 42035219 A G 4.60E-05 Type 2 diabetes / / 17463248 rs17462994 chr11 42035313 T C 4.60E-05 Type 2 diabetes / / 17463248 rs11036669 chr11 42060905 G A 0.0001698 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11036669 chr11 42060905 G A 1.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7103236 chr11 42062083 C G 7.59E-05 Alzheimer's disease / / 21098978 rs11036691 chr11 42139303 A C 0.0004068 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11036691 chr11 42139303 A C 4.07E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7939901 chr11 42171214 C A,T 0.00044 Coronary artery calcification / / 23727086 rs4375424 chr11 42185849 A G 5.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11036743 chr11 42191577 G A 5.27E-04 Alzheimer's disease / / 22005930 rs7129158 chr11 42191861 G A 5.27E-04 Alzheimer's disease / / 22005930 rs993432 chr11 42194367 C A 5.31E-04 Alzheimer's disease / / 22005930 rs11036748 chr11 42197353 G T 6.64E-04 Alzheimer's disease / / 22005930 rs992465 chr11 42198171 A G 6.69E-04 Alzheimer's disease / / 22005930 rs992466 chr11 42198433 T C 6.54E-04 Alzheimer's disease / / 22005930 rs727410 chr11 42198884 C A 6.60E-04 Alzheimer's disease / / 22005930 rs2200723 chr11 42198980 G C 5.32E-04 Alzheimer's disease / / 22005930 rs2220423 chr11 42199219 A G 6.65E-04 Alzheimer's disease / / 22005930 rs972373 chr11 42200489 T C 6.68E-04 Alzheimer's disease / / 22005930 rs4756692 chr11 42202069 G T 6.64E-04 Alzheimer's disease / / 22005930 rs1488616 chr11 42202424 T C,G 5.57E-04 Alzheimer's disease / / 22005930 rs16936408 chr11 42206028 G A 6.52E-04 Alzheimer's disease / / 22005930 rs901894 chr11 42209292 T G 1.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16936417 chr11 42211231 A G 1.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100507205 intron 20877124 rs10768787 chr11 42216902 C T 1.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100507205 intron 20877124 rs9300041 chr11 42239022 A G 3.42E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) LOC100507205 intron 24023788 rs7480010 chr11 42246718 G A 1.23E-05 Type 2 diabetes LOC100507205 intron 17293876 rs7480010 chr11 42246718 G A 1.20E-05 Type 2 diabetes LOC100507205 intron 19184112 rs12364934 chr11 42247461 T G 5.60E-04 Alcohol dependence LOC100507205 intron 20201924 rs11827137 chr11 42251768 C T 8.01E-05 Multiple complex diseases LOC100507205 intron 17554300 rs4531450 chr11 42297330 A T 4.80E-04 Multiple complex diseases / / 17554300 rs12366192 chr11 42305063 T C 1.30E-04 Alcohol dependence / / 20201924 rs7394570 chr11 42315886 A G 1.00E-06 Immune response to smallpox vaccine (IL-6) / / 22542470 rs11036844 chr11 42345388 C T 3.98E-05 Brain structure / / 22504417 rs9300042 chr11 42349961 C G 4.09E-05 Brain structure / / 22504417 rs11036848 chr11 42351806 A C 4.14E-05 Brain structure / / 22504417 rs7124781 chr11 42556798 A C 2.00E-07 Volumetric brain MRI / / 17903297 rs4076032 chr11 42599193 A T 3.45E-05 Sudden cardiac arrest / / 21658281 rs7112567 chr11 42599727 A C 8.15E-04 Multiple complex diseases / / 17554300 rs7112567 chr11 42599727 A C 2.93E-04 Body mass index / / 21701565 rs10837883 chr11 42609917 G T 0.000738498 Hypertension (early onset hypertension) / / 22479346 rs10768843 chr11 42644154 T C 7.01E-04 Multiple complex diseases / / 17554300 rs7109600 chr11 42644769 T C 4.77E-04 Multiple complex diseases / / 17554300 rs11604506 chr11 42649538 C T 4.75E-05 Meningococcal disease / / 20694013 rs10734506 chr11 42659451 A G 8.25E-05 Cognitive impairment induced by topiramate / / 22091778 rs7114882 chr11 42663357 T C 8.17E-05 Alcohol consumption / / 23953852 rs4421732 chr11 42699672 A G 2.44E-05 Alcohol consumption / / 23953852 rs11037018 chr11 42722587 C A 3.62E-05 Alcohol consumption / / 23953852 rs142850025 chr11 42738723 A G 6.00E-06 Age-related nuclear cataracts / / 24951543 rs7947641 chr11 42745494 A G 2.91E-04 Smoking initiation / / 24665060 rs4558156 chr11 42772756 A G 1.90E-05 Urinary metabolites / / 21572414 rs7928165 chr11 42795097 A C 1.43E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4408298 chr11 42811366 A G 5.82E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7940302 chr11 42831625 G A 6.30E-04 Smoking initiation / / 24665060 rs4391804 chr11 42837715 T G 3.53E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4755664 chr11 42863763 A G 9.50E-06 Digit length ratio / / 20303062 rs7938181 chr11 42864284 T C 3.83E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs7951701 chr11 42864437 A G 2.16E-04 Coronary Artery Disease / / 17634449 rs4755668 chr11 42868336 A G 2.35E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4237638 chr11 42873011 C A 3.85E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4129601 chr11 42874002 A G 2.36E-04 Type 2 diabetes / / 17463246 rs4129601 chr11 42874002 A G 2.00E-06 Methotrexate phramacokinetics (acute lymphoblastic leukemia) / / 19901119 rs11037107 chr11 42878794 T C 6.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs4132801 chr11 42879186 T C 6.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs4536202 chr11 42879463 C T 6.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs4359198 chr11 42879603 G A 6.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs12283338 chr11 42879811 C T 6.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs12284960 chr11 42880222 G A 6.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs11037109 chr11 42881077 A C 6.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs7128439 chr11 42881687 G A 6.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs10837947 chr11 42882679 C A 5.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs4454701 chr11 42883435 C T 6.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs4384375 chr11 42883827 G C 7.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs10837949 chr11 42884628 A G 7.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs10768894 chr11 42884824 A G 8.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs10768895 chr11 42885153 T C 8.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs4271376 chr11 42886469 A G 9.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs7122883 chr11 42886992 G A 5.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs6485371 chr11 42888407 T C 3.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs10837955 chr11 42893853 A C 4.80E-06 Urinary metabolites / / 21572414 rs4598655 chr11 42904610 G A 7.30E-05 Endometriosis / / 21151130 rs1532096 chr11 42913353 A G 1.61E-05 Major depression (suicidal thoughts and behavior) / / 21750702 rs12366181 chr11 42921770 C T 7.33E-05 Urinary albumin excretion rate in type 1 diabetes / / 24595857 rs964188 chr11 42924732 G A 3.30E-06 Urinary metabolites / / 21572414 rs989357 chr11 42929685 A G 5.30E-05 Endometriosis / / 21151130 rs7124810 chr11 42933187 A G 4.72E-04 Smoking initiation / / 24665060 rs16937119 chr11 42935188 A G 7.60E-06 Urinary metabolites / / 21572414 rs1038673 chr11 42947540 A T 2.40E-05 Urinary metabolites / / 21572414 rs1844279 chr11 42956935 G C 4.90E-07 Urinary metabolites / / 21572414 rs4584564 chr11 42957368 A G 3.90E-05 Endometriosis / / 21151130 rs12576830 chr11 42982475 G T 3.16E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs12576830 chr11 42982475 G T 8.70E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs1489208 chr11 42987523 C T 2.10E-05 Urinary metabolites / / 21572414 rs10501292 chr11 42996387 A G 8.00E-04 Crohn's disease / / 17684544 rs7949008 chr11 43004101 A T 7.26E-04 Insulin resistance / / 21901158 rs10742662 chr11 43005385 T C 6.57E-05 Serum metabolites / / 19043545 rs7114320 chr11 43013621 G C 7.45E-05 Serum metabolites / / 19043545 rs7924326 chr11 43031752 T C 7.25E-05 Serum metabolites / / 19043545 rs720293 chr11 43036313 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7126821 chr11 43046643 C G 9.45E-05 Parkinson's disease (motor and cognition) / / 22658654 rs7126821 chr11 43046643 C G 9.45E-05 Immune response to anthrax vaccine / / 22658931 rs17581519 chr11 43047469 C T 3.47E-04 Multiple complex diseases / / 17554300 rs1425856 chr11 43064452 G A 1.28E-04 Dental caries / / 21940522 rs1425852 chr11 43077155 A C 5.06E-05 Dental caries / / 21940522 rs11037228 chr11 43081654 T C 6.81E-04 Insulin resistance / / 21901158 rs10501293 chr11 43086094 T G 5.00E-06 Cognitive performance / / 19734545 rs1895824 chr11 43099947 G A 1.05E-05 Parkinson's disease / / 21812969 rs7935833 chr11 43101260 C T 2.95E-05 Parkinson's disease / / 21812969 rs17497596 chr11 43102898 C T 7.17E-05 Parkinson's disease (motor and cognition) / / 22658654 rs17497596 chr11 43102898 C T 7.17E-05 Immune response to anthrax vaccine / / 22658931 rs9645617 chr11 43105620 G A 9.84E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs1365084 chr11 43110054 G A 1.05E-05 Parkinson's disease / / 21812969 rs11606803 chr11 43135973 T C 5.62E-04 Insulin resistance / / 21901158 rs12785997 chr11 43141663 G A 6.35E-04 Coronary heart disease / / 21971053 rs2114088 chr11 43181330 C T 7.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2114088 chr11 43181330 C T 3.24E-05 Post-operative nausea and vomiting / / 21694509 rs10838044 chr11 43185513 G A 8.76E-04 Myopia (pathological) / / 21095009 rs1544872 chr11 43196352 A G 6.75E-04 Myopia (pathological) / / 21095009 rs12808373 chr11 43201350 C A 1.37E-04 Coronary heart disease / / 21971053 rs12365397 chr11 43236061 A G 9.00E-06 Migraine / / 23793025 rs16937425 chr11 43284075 G A 2.10E-05 Urinary metabolites / / 21572414 rs11037391 chr11 43285357 C T 2.00E-04 Cognitive impairment induced by topiramate HNRNPKP3 intron 22091778 rs7117651 chr11 43320878 C T 2.07E-04 Cocaine dependence / / 23958962 rs7117651 chr11 43320878 C T 5.59E-05 Cocaine dependence / / 23958962 rs11037421 chr11 43381417 C A 4.49E-04 Lymphocyte counts TTC17 intron 22286170 rs11605997 chr11 43384448 A G 5.06E-04 Multiple complex diseases TTC17 intron 17554300 rs10501298 chr11 43433348 T C 9.85E-05 Cognitive impairment induced by topiramate TTC17 intron 22091778 rs3816766 chr11 43449285 T C 2.49E-04 Alcohol dependence TTC17 intron 21314694 rs17509647 chr11 43473107 T C 6.53E-04 Iron levels TTC17 intron pha002876 rs11602173 chr11 43481949 T C 9.30E-04 Type 2 diabetes TTC17 intron 17463246 rs1115492 chr11 43499555 A G 5.95E-04 Type 2 diabetes TTC17 intron 17463246 rs12224013 chr11 43514710 T G 8.71E-05 Brain lesion load TTC17 intron 19010793 rs7118728 chr11 43528586 G A 8.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs1483129 chr11 43528759 G A 8.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs12421453 chr11 43531010 T G 5.60E-05 Coronary heart disease / / 21971053 rs4755193 chr11 43532023 A G 3.23E-05 Coronary heart disease / / 21971053 rs10838112 chr11 43534929 T C 7.51E-04 Multiple complex diseases / / 17554300 rs11037457 chr11 43535401 A G 9.29E-04 Multiple complex diseases / / 17554300 rs4281471 chr11 43536713 G C 4.49E-04 Multiple complex diseases / / 17554300 rs12279001 chr11 43537091 C G 9.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs16937562 chr11 43551518 C T 5.93E-05 Cognitive test performance / / 20125193 rs11037466 chr11 43553927 A G 2.87E-06 Asthma / / 11022011 rs10400240 chr11 43559991 C A 3.05E-05 Cognitive test performance / / 20125193 rs995034 chr11 43560359 C T 8.70E-05 Cognitive test performance / / 20125193 rs11037472 chr11 43575766 A G 2.10E-05 Urinary metabolites / / 21572414 rs4755726 chr11 43642130 T G 5.61E-05 Serum metabolites / / 19043545 rs4237643 chr11 43648368 T G 4.00E-08 Lung function (forced vital capacity) / / 24929828 rs2862996 chr11 43653833 G T 9.37E-05 Serum metabolites / / 19043545 rs10768970 chr11 43664516 G C 4.80E-04 Blood pressure / / 21228793 rs10768970 chr11 43664516 G C 5.50E-04 Blood pressure / / 21228793 rs4755731 chr11 43685168 A G 3.87E-06 Neuroblastoma / / pha002895 rs7116641 chr11 43696917 T G 0.000101 Coronary artery disease / / 23202125 rs4620711 chr11 43713843 C T 6.31E-06 Neuroblastoma HSD17B12 intron pha002895 rs11037567 chr11 43717275 A G 5.53E-04 Myocardial Infarction HSD17B12 intron pha002883 rs7928523 chr11 43719101 C T 9.37E-05 Serum metabolites HSD17B12 intron 19043545 rs7928523 chr11 43719101 C T 8.36E-04 Suicide attempts in bipolar disorder HSD17B12 intron 21423239 rs11037574 chr11 43726211 G A 6.44E-04 Neuroblastoma (low-risk) HSD17B12 intron 21436895 rs11037575 chr11 43728330 T C 2.77E-09 Neuroblastoma (low-risk) HSD17B12 intron 21436895 rs11037575 chr11 43728330 T C 5.00E-08 Neuroblastoma HSD17B12 intron 22941191 rs11037575 chr11 43728330 T C 3.87E-06 Neuroblastoma HSD17B12 intron pha002895 rs7110523 chr11 43750376 G A 6.12E-05 Heart rate HSD17B12 intron 23583979 rs11037623 chr11 43796734 C A 9.08E-05 Multiple complex diseases HSD17B12 intron 17554300 rs11037641 chr11 43811643 C G 7.86E-04 Multiple complex diseases HSD17B12 intron 17554300 rs4755743 chr11 43813776 T G 9.02E-04 Suicide attempts in bipolar disorder HSD17B12 intron 21423239 rs7118659 chr11 43817125 C T 6.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HSD17B12 intron 20877124 rs1518815 chr11 43825038 C T 6.56E-04 Suicide attempts in bipolar disorder HSD17B12 intron 21423239 rs10768983 chr11 43839935 G A 1.22E-13 Lymphocyte counts HSD17B12 intron 22286170 rs2176598 chr11 43864278 T C 8.84E-04 Suicide attempts in bipolar disorder HSD17B12 intron 21423239 rs10838184 chr11 43869860 C G 7.89E-04 Suicide attempts in bipolar disorder HSD17B12 intron 21423239 rs12364347 chr11 43890633 A G 2.50E-06 Fasting plasma glucose / / 19060907 rs2434478 chr11 43911365 T C 0.00015 Breast cancer / / 23555315 rs2434476 chr11 43954812 T C 7.32E-04 Multiple complex diseases / / 17554300 rs2056248 chr11 43956349 T C 2.50E-05 Urinary metabolites / / 21572414 rs6485477 chr11 43956936 T C 6.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs7126420 chr11 43972609 A G 1.10E-05 Urinary metabolites / / 21572414 rs630211 chr11 43980440 G T 9.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs16937773 chr11 43993199 G A 2.32E-04 Coronary Artery Disease / / 17634449 rs1858976 chr11 43994664 A G 1.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs7119266 chr11 43995745 C T 1.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs2863030 chr11 44003258 G T 1.95E-05 Lipoproteins / / pha003079 rs933301 chr11 44004097 C T 2.14E-04 Coronary Artery Disease / / 17634449 rs10742695 chr11 44009451 G A 2.40E-05 Urinary metabolites / / 21572414 rs16937777 chr11 44014312 G A 6.20E-06 Urinary metabolites / / 21572414 rs16937777 chr11 44014312 G A 1.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11037782 chr11 44015075 G A 1.20E-05 Urinary metabolites / / 21572414 rs11037784 chr11 44015369 C G,T 1.10E-05 Urinary metabolites / / 21572414 rs4595529 chr11 44015866 A C 1.10E-05 Urinary metabolites / / 21572414 rs4595529 chr11 44015866 A C 2.80E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs739568 chr11 44016981 G A 1.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2157993 chr11 44021313 G A 1.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7937428 chr11 44022611 G A 9.24E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11037809 chr11 44041968 A G 9.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs6485492 chr11 44053497 T C 3.01E-04 Type 2 diabetes / / 17463246 rs6485492 chr11 44053497 T C 8.02E-04 Multiple complex diseases / / 17554300 rs10838223 chr11 44055493 C T 7.86E-04 Tourette syndrome / / 22889924 rs10838224 chr11 44055627 T C 8.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs3094395 chr11 44066354 T C 5.16E-04 Multiple complex diseases / / 17554300 rs4237645 chr11 44075714 T C 3.78E-05 Angioedema in response to angiotensin-converting enzyme inhibitor ACCSL intron 23838604 rs7127924 chr11 44085687 C A 1.24E-04 IgA nephropathy / / 22197929 rs7107948 chr11 44133683 C T 3.08E-04 Smoking initiation EXT2 intron 24665060 rs10838236 chr11 44141850 G A 6.58E-05 Multiple complex diseases EXT2 intron 17554300 rs7108467 chr11 44158153 C G 7.15E-05 Multiple complex diseases EXT2 intron 17554300 rs2067787 chr11 44207456 T C 5.97E-05 Hemoglobin EXT2 intron pha003096 rs2067787 chr11 44207456 T C 8.57E-05 Hematocrit EXT2 intron pha003097 rs4755234 chr11 44232435 T C 5.96E-04 Suicide attempts in bipolar disorder EXT2 intron 21041247 rs1532353 chr11 44235253 C T 5.92E-04 Suicide attempts in bipolar disorder EXT2 intron 21041247 rs4755236 chr11 44248826 G C 4.74E-04 Suicide attempts in bipolar disorder EXT2 intron 21041247 rs7941184 chr11 44250281 T C 2.40E-04 Type 2 diabetes EXT2 intron 17463246 rs1113132 chr11 44253403 G C 2.93E-05 Type 2 diabetes EXT2 intron 17293876 rs1113132 chr11 44253403 G C 8.50E-05 Temporomandibular joint disorders EXT2 intron 23746317 rs11037909 chr11 44255614 T C 1.33E-05 Type 2 diabetes EXT2 intron 17293876 rs3740878 chr11 44257802 T C 1.33E-05 Type 2 diabetes EXT2 intron 17293876 rs11037911 chr11 44260804 G A 3.99E-05 Hemoglobin EXT2 intron pha003096 rs11037911 chr11 44260804 G A 4.72E-05 Hematocrit EXT2 intron pha003097 rs4755793 chr11 44267034 G A 0.00035 Coronary artery calcification EXT2 nearGene-3 23727086 rs7126360 chr11 44273442 A G 1.46E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs729287 chr11 44280090 C T 1.30E-05 Type 2 diabetes / / 17293876 rs729287 chr11 44280090 C T 1.30E-05 Type 2 diabetes / / 19184112 rs4755239 chr11 44283297 T C 1.76E-04 Type 2 diabetes ALX4 UTR-3 17463246 rs897005 chr11 44283722 G A 1.54E-05 Erythrocyte counts ALX4 UTR-3 pha003101 rs4755797 chr11 44285887 G A 3.60E-06 Hemoglobin ALX4 UTR-3 pha003096 rs4755797 chr11 44285887 G A 1.48E-06 Hematocrit ALX4 UTR-3 pha003097 rs4755797 chr11 44285887 G A 6.61E-05 Erythrocyte counts ALX4 UTR-3 pha003101 rs11037921 chr11 44287048 G T 8.82E-04 HIV-1 viral setpoint ALX4 intron 17641165 rs7925621 chr11 44287149 C T 5.72E-04 HIV-1 viral setpoint ALX4 intron 17641165 rs7949067 chr11 44291484 A G 1.10E-05 Type 2 diabetes ALX4 intron 17293876 rs7949067 chr11 44291484 A G 1.10E-05 Type 2 diabetes ALX4 intron 19184112 rs12288455 chr11 44292747 G A 7.12E-06 Scoliosis ALX4 intron 21216876 rs10742700 chr11 44299841 G A 6.80E-05 Multiple complex diseases ALX4 intron 17554300 rs2013594 chr11 44302154 T C 4.53E-04 Multiple complex diseases ALX4 intron 17554300 rs4755813 chr11 44363600 C T 5.07E-05 Leukocyte Counts / / pha003091 rs3853291 chr11 44369477 G A 3.36E-04 Cognitive decline / / 23732972 rs11037965 chr11 44378156 C T 2.00E-06 Blood pressure measurement (high sodium intervention) / / 24165912 rs11037965 chr11 44378156 C T 3.00E-07 Blood pressure measurement (high sodium intervention) / / 24165912 rs11037965 chr11 44378156 C T 8.32E-04 Blood pressure measurement (high sodium intervention) / / 24165912 rs10838271 chr11 44384928 T C 1.38E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs898029 chr11 44429719 C T 9.94E-04 Tourette syndrome / / 22889924 rs898029 chr11 44429719 C T 1.79E-05 Smoking initiation / / 24665060 rs7130124 chr11 44432638 G A 7.49E-05 Smoking initiation / / 24665060 rs4755247 chr11 44449519 A G 7.86E-05 Smoking initiation / / 24665060 rs716698 chr11 44450652 G A 1.73E-04 Smoking initiation / / 24665060 rs7926989 chr11 44458019 A G 9.15E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs813632 chr11 44469452 T C 4.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs724411 chr11 44476521 T C 3.20E-07 Urinary metabolites / / 21572414 rs357917 chr11 44492899 A G 1.30E-05 Sickle cell anemia (severity) / / 20029952 rs12801214 chr11 44492917 C T 9.02E-06 Suicide attempts in bipolar disorder / / 21423239 rs7111844 chr11 44495166 G A 4.98E-04 Myocardial Infarction / / pha002883 rs1240751 chr11 44509386 A G 3.88E-05 Bone mineral density / / 19181680 rs1240751 chr11 44509386 A G 4.37E-05 Amyotrophic lateral sclerosis / / 19193627 rs11038030 chr11 44509668 C G 2.70E-05 Urinary metabolites / / 21572414 rs2564447 chr11 44530550 C A 8.96E-07 Brain structure / / 22504417 rs11038044 chr11 44541295 T C 5.59E-04 Tourette syndrome / / 22889924 rs7116194 chr11 44554064 C T 3.78E-04 Myocardial Infarction / / pha002873 rs10501306 chr11 44582865 A G 2.00E-04 Information processing speed / / 21130836 rs730129 chr11 44603328 A G 7.00E-06 Hemostatic factors and hematological phenotypes CD82 intron 22443383 rs1981993 chr11 44607471 G A 9.55E-06 Asthma (childhood onset) CD82 intron 23829686 rs3758815 chr11 44634765 T A 6.30E-05 Coffee consumption CD82 intron 21357676 rs6485553 chr11 44644643 A C 8.14E-05 Multiple complex diseases / / 17554300 rs6485554 chr11 44650927 C T 1.23E-04 Body mass index / / 21701565 rs6485554 chr11 44650927 C T 2.11E-04 Body mass index / / 21701565 rs714679 chr11 44653664 G A 5.71E-05 Vaspin levels / / 22907691 rs714679 chr11 44653664 G A 0.0000571 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs4399316 chr11 44671894 G A 1.25E-05 Body mass index / / 21701565 rs4399316 chr11 44671894 G A 7.40E-05 Body mass index / / 21701565 rs7946216 chr11 44674721 G A 1.78E-05 Body mass index / / 21701565 rs7946216 chr11 44674721 G A 5.97E-05 Body mass index / / 21701565 rs10732499 chr11 44690081 C T 2.99E-04 Type 2 diabetes / / 17463246 rs10732499 chr11 44690081 C T 3.21E-04 Body mass index / / 21701565 rs10732499 chr11 44690081 C T 6.39E-04 Body mass index / / 21701565 rs10732499 chr11 44690081 C T 8.12E-04 Body mass index / / 21701565 rs10732499 chr11 44690081 C T 8.85E-04 Body mass index / / 21701565 rs11038106 chr11 44706160 T C 3.31E-04 Alzheimer's disease (late onset) / / 21379329 rs10838333 chr11 44710825 G A 9.61E-05 Alzheimer's disease (late onset) / / 21379329 rs4755868 chr11 44710934 A G 4.06E-04 Body mass index / / 21701565 rs4755868 chr11 44710934 A G 4.82E-04 Body mass index / / 21701565 rs12420859 chr11 44724527 G A 4.76E-05 Alzheimer's disease (late onset) / / 21379329 rs7950482 chr11 44741349 C T 0.000796 Salmonella-induced pyroptosis / / 22837397 rs4755880 chr11 44749884 G A 8.23E-04 Rheumatoid arthritis / / 21452313 rs7104896 chr11 44784540 G A 4.44E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs16938073 chr11 44784707 C T 2.65E-04 Multiple complex diseases / / 17554300 rs10838353 chr11 44788115 A C 4.80E-05 Celiac disease TSPAN18 intron 17558408 rs10769082 chr11 44800546 A G 8.44E-05 Bipolar disorder TSPAN18 intron 22925353 rs10838354 chr11 44800860 A G 1.61E-04 Body mass index TSPAN18 intron 21701565 rs10838354 chr11 44800860 A G 1.89E-04 Body mass index TSPAN18 intron 21701565 rs10838354 chr11 44800860 A G 5.37E-04 Body mass index TSPAN18 intron 21701565 rs835852 chr11 44818358 T A 4.71E-05 Bipolar disorder TSPAN18 intron 22925353 rs11038167 chr11 44843134 A C 1.00E-11 Schizophrenia TSPAN18 intron 22037552 rs11038172 chr11 44855597 A G 7.21E-10 Schizophrenia TSPAN18 intron 22037552 rs835784 chr11 44863818 A G 2.73E-11 Schizophrenia TSPAN18 intron 22037552 rs12804300 chr11 44870058 A G 6.77E-05 Bipolar disorder and schizophrenia TSPAN18 intron 20889312 rs861354 chr11 44873532 T G 3.98E-04 Alzheimer's disease (late onset) TSPAN18 intron 21379329 rs835807 chr11 44873832 A G 3.64E-04 Alzheimer's disease (late onset) TSPAN18 intron 21379329 rs11038175 chr11 44875939 C T 8.32E-04 Smoking cessation TSPAN18 intron 24665060 rs835751 chr11 44884874 G A 3.79E-04 Intracranial aneurysm TSPAN18 intron 22286173 rs1466199 chr11 44886554 G A 5.93E-05 Post-operative nausea and vomiting TSPAN18 intron 21694509 rs11038182 chr11 44891374 C T 9.67E-05 Glucose levels TSPAN18 intron pha003057 rs11038190 chr11 44919413 T C 1.72E-05 Psoriasis TSPAN18 intron 20953190 rs835997 chr11 44925939 A G 1.19E-04 Multiple complex diseases TSPAN18 intron 17554300 rs11038203 chr11 44931041 G A 5.97E-08 Multiple complex diseases TSPAN18 intron 17554300 rs12576326 chr11 44980383 A G 5.63E-04 Body mass index / / 21701565 rs12291023 chr11 45001370 G T 1.00E-04 Prostate cancer / / 21743057 rs11607247 chr11 45002697 C T 1.00E-04 Prostate cancer / / 21743057 rs4755300 chr11 45013421 A G 2.70E-05 Urinary metabolites / / 21572414 rs2863140 chr11 45027780 T C 1.70E-04 Arthritis (juvenile idiopathic) / / 22354554 rs12361918 chr11 45058482 G T 3.59E-04 Height / / 17255346 rs900859 chr11 45062196 T G 1.95E-04 Type 2 diabetes / / 17463246 rs7395124 chr11 45062251 G A 2.26E-04 Type 2 diabetes / / 17463246 rs7395097 chr11 45062295 A G 1.86E-04 Type 2 diabetes / / 17463246 rs10838407 chr11 45063947 T C 8.15E-04 Coronary heart disease / / 21971053 rs7121790 chr11 45064965 G A,C,T 1.34E-04 Attention deficit hyperactivity disorder / / pha002875 rs7937459 chr11 45068571 C A 5.36E-05 Coronary heart disease / / 21971053 rs10769108 chr11 45071979 A G 5.90E-05 HIV-1 control / / 20041166 rs7951911 chr11 45084531 A G 8.00E-06 IgG glycosylation / / 23382691 rs2863147 chr11 45085525 T G 2.90E-05 Urinary metabolites / / 21572414 rs7126280 chr11 45096369 C T 9.88E-04 Type 2 diabetes / / 17463246 rs875973 chr11 45126783 T C 9.29E-05 Response to metformin PRDM11 intron 21186350 rs7929875 chr11 45152825 T G 3.41E-04 Smoking initiation PRDM11 intron 24665060 rs10838427 chr11 45181682 C T 1.46E-10 Meningococcal disease PRDM11 intron 20694013 rs10838427 chr11 45181682 C T 3.82E-04 Suicide attempts in bipolar disorder PRDM11 intron 21423239 rs72907072 chr11 45181685 G A 2.57E-04 Thyroid stimulating hormone PRDM11 intron 24852370 rs732161 chr11 45185779 C G 2.58E-04 Suicide attempts in bipolar disorder PRDM11 intron 21423239 rs12362992 chr11 45192009 G A 1.11E-04 Suicide attempts in bipolar disorder PRDM11 intron 21423239 rs16938184 chr11 45200619 G C 3.03E-07 Panic disorder PRDM11 intron 19165232 rs17723470 chr11 45227567 C T 3.00E-07 Thyroid hormone levels PRDM11 intron 23408906 rs17723470 chr11 45227567 C T 9.00E-11 Thyroid hormone levels PRDM11 intron 23408906 rs12417962 chr11 45241958 G A 4.36E-04 Common variable immunodeficiency PRDM11 intron 21497890 rs3758722 chr11 45243543 A T 9.96E-04 Multiple complex diseases PRDM11 intron 17554300 rs2863171 chr11 45250732 A C 9.00E-10 Lung function (forced vital capacity) PRDM11 UTR-3 24929828 rs4755943 chr11 45258392 C G 9.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs7109158 chr11 45298223 C T 4.16E-05 Smoking initiation SYT13 intron 24665060 rs7478974 chr11 45343932 C T 7.83E-05 Cognitive impairment induced by topiramate / / 22091778 rs4755969 chr11 45350039 G A,T 7.52E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11038403 chr11 45359713 C A 2.15E-04 Insulin resistance / / 21901158 rs11038408 chr11 45370488 A G 5.47E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4755978 chr11 45380550 C T 5.30E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4755319 chr11 45381346 G T 5.30E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7930779 chr11 45398355 G T 9.82E-05 Response to statin treatment (atorvastatin),change in cholesterol levels FLJ41423 intron 20031582 rs17788257 chr11 45413809 G A 2.50E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs2167377 chr11 45441637 A G 2.50E-05 Urinary metabolites / / 21572414 rs991986 chr11 45466720 G A 2.38E-24 Narcolepsy / / 19629137 rs896337 chr11 45487231 A G 1.11E-04 Multiple complex diseases / / 17554300 rs10838479 chr11 45514565 T C 4.45E-05 Major depressive disorder / / 19107115 rs1488665 chr11 45528116 T G 5.00E-06 Obesity-related traits / / 23251661 rs11038504 chr11 45531345 T A 2.40E-05 Urinary metabolites / / 21572414 rs923374 chr11 45540732 T C 5.18E-05 Multiple complex diseases / / 17554300 rs74329445 chr11 45550368 A G 7.58E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs74360883 chr11 45550753 A G 8.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs17724240 chr11 45566093 G A 7.86E-04 Multiple complex diseases / / 17554300 rs11038540 chr11 45575813 G A 4.83E-04 Smoking initiation / / 24665060 rs2129969 chr11 45586169 G A 7.20E-06 Fasting plasma glucose / / 19060907 rs728516 chr11 45600806 G A 6.27E-04 Type 2 diabetes / / 17846124 rs17786364 chr11 45620673 G A 2.89E-04 Multiple complex diseases / / 17554300 rs11038600 chr11 45662035 G A 4.54E-04 Multiple complex diseases / / 17554300 rs1348965 chr11 45663568 T C 5.00E-04 Alcohol dependence / / 20201924 rs4756007 chr11 45665915 T G 7.47E-05 Multiple complex diseases / / 17554300 rs7121818 chr11 45684557 C T 6.18E-04 Multiple complex diseases CHST1 intron 17554300 rs750398 chr11 45697072 G C 9.30E-06 Odorant perception / / 23910658 rs3926466 chr11 45704923 C T 4.30E-04 Alzheimer's disease (late onset) / / 21379329 rs7929114 chr11 45706162 A G 1.64E-06 Glucose levels / / pha002899 rs724759 chr11 45707560 T C 6.64E-04 Multiple complex diseases / / 17554300 rs895722 chr11 45751600 G A 4.89E-04 Parkinson's disease / / 16252231 rs2666900 chr11 45757401 C T 7.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2593753 chr11 45762996 T G 1.67E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs12285276 chr11 45813581 G C 9.00E-06 Visceral fat / / 22589738 rs3808976 chr11 45827350 A G 7.01E-04 Amyotrophic Lateral Sclerosis SLC35C1 UTR-5 17827064 rs11607883 chr11 45839709 G A 9.36E-26 Fasting blood glucose / / 22885924 rs11605924 chr11 45873091 A C 1.00E-14 Fasting insulin-related traits CRY2 intron 20081858 rs11605924 chr11 45873091 A C 4.00E-15 Fasting glucose-related traits (interaction with BMI) CRY2 intron 22581228 rs11605924 chr11 45873091 A C 1.02E-19 Fasting blood glucose CRY2 intron 22885924 rs11038695 chr11 45878461 G A 9.38E-04 Multiple complex diseases CRY2 intron 17554300 rs1401419 chr11 45879739 T C 7.30E-14 Fasting blood glucose CRY2 intron 22885924 rs2292910 chr11 45903613 A C 2.08E-10 Fasting blood glucose CRY2 UTR-3 22885924 rs1554338 chr11 45906830 A G 2.70E-05 Urinary metabolites CRY2 nearGene-5 21572414 rs4756039 chr11 45912350 A T 9.80E-04 Acute lung injury MAPK8IP1 intron 22295056 rs7114162 chr11 45916781 A G 3.66E-06 Axial length MAPK8IP1 intron 24144296 rs10838529 chr11 45931502 G A 5.12E-06 Axial length PEX16 UTR-3 24144296 rs1132349 chr11 45935384 A C,G,T 5.64E-04 Acute lung injury PEX16 STOP-GAIN 22295056 rs3802758 chr11 45936035 G A 5.64E-04 Acute lung injury PEX16 intron 22295056 rs939108 chr11 45936817 G C 4.09E-04 Acute lung injury PEX16 intron 22295056 rs7115790 chr11 45941844 G C 8.62E-04 Acute lung injury GYLTL1B nearGene-5 22295056 rs10838532 chr11 45947464 G C 2.10E-18 Progranulin levels GYLTL1B intron 21087763 rs10838532 chr11 45947464 G C 2.10E-18 Myocardial infarction GYLTL1B intron 21211798 rs10838532 chr11 45947464 G C 2.00E-06 Axial length GYLTL1B intron 24144296 rs939105 chr11 45949534 C T 5.72E-04 Sleep latency GYLTL1B cds-synon 23728906 rs11038720 chr11 45968661 A T 3.69E-04 Alcohol dependence PHF21A intron 21314694 rs2959103 chr11 45970084 T C 4.34E-06 Cognitive test performance PHF21A intron 20125193 rs2946002 chr11 45987895 A G 4.37E-06 Cognitive test performance PHF21A intron 20125193 rs2959100 chr11 46015138 C G 7.57E-06 Axial length PHF21A intron 24144296 rs16938437 chr11 46052575 C T 4.38E-06 Cognitive test performance PHF21A intron 20125193 rs16938437 chr11 46052575 C T 6.00E-08 Menarche (age at onset) PHF21A intron 21102462 rs12365345 chr11 46089776 T C 5.51E-04 Amyotrophic Lateral Sclerosis PHF21A intron 17362836 rs10501316 chr11 46090550 C T 3.79E-04 Stroke PHF21A intron pha002887 rs2171895 chr11 46113115 T C 6.90E-06 Odorant perception PHF21A intron 23910658 rs7946524 chr11 46144455 C T 5.15E-05 Cognitive test performance / / 20125193 rs7128538 chr11 46180693 G A 2.55E-05 Systemic sclerosis / / 21750679 rs11038804 chr11 46198841 T C 6.45E-05 Waist Circumference / / pha003024 rs10501317 chr11 46202305 T C 7.48E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11038810 chr11 46210773 A G 5.72E-04 Multiple complex diseases / / 17554300 rs2046834 chr11 46218910 A G 6.77E-04 Multiple complex diseases / / 17554300 rs7121257 chr11 46231502 G A 3.15E-05 Waist Circumference / / pha003023 rs7124891 chr11 46245361 A G 3.36E-05 Waist Circumference / / pha003023 rs11038830 chr11 46262022 T C 2.20E-04 Alzheimer's disease / / 17998437 rs11038830 chr11 46262022 T C 1.81E-05 Alzheimer's disease / / pha002879 rs6485671 chr11 46279815 G A 8.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs10437653 chr11 46297631 A C 6.94E-04 Myocardial Infarction / / pha002873 rs4319486 chr11 46320679 C A 3.37E-05 Brain structure CREB3L1 intron 22504417 rs7927724 chr11 46323209 G A 3.81E-05 Brain structure CREB3L1 intron 22504417 rs2303435 chr11 46332504 T C 8.24E-04 Multiple complex diseases CREB3L1 intron 17554300 rs4625425 chr11 46332893 T G 3.19E-04 Multiple complex diseases CREB3L1 intron 17554300 rs11038863 chr11 46348324 G A 1.76E-04 Multiple complex diseases / / 17554300 rs10838599 chr11 46378708 G T 1.91E-08 Thrombin generation potential phenotypes DGKZ intron 24357727 rs11038871 chr11 46379442 T C 2.00E-06 Immunoglobulin A DGKZ intron 20694011 rs20542 chr11 46403649 G A 5.26E-06 Brain structure MDK cds-synon 22504417 rs12574668 chr11 46422686 C A 1.02E-08 Schizophrenia AMBRA1 intron 21747397 rs12283172 chr11 46442526 C T 1.75E-04 Arthritis (juvenile idiopathic) AMBRA1 intron 22354554 rs1472001 chr11 46484685 G A 5.99E-04 Parkinson's disease AMBRA1 intron 17052657 rs7130141 chr11 46499874 C T 6.96E-09 Schizophrenia AMBRA1 intron 21747397 rs7112229 chr11 46513249 C T 7.38E-09 Schizophrenia AMBRA1 intron 21747397 rs12578042 chr11 46515004 C G 7.83E-04 Multiple complex diseases AMBRA1 intron 17554300 rs11819869 chr11 46560680 C T 3.89E-09 Schizophrenia AMBRA1 intron 21747397 rs11038914 chr11 46561301 C T 4.71E-04 Multiple complex diseases AMBRA1 intron 17554300 rs7946801 chr11 46569272 G A 1.26E-04 Multiple complex diseases AMBRA1 intron 17554300 rs28366017 chr11 46616029 G T 3.94E-04 Smoking cessation / / 24665060 rs35619591 chr11 46690413 G A 6.10E-10 Insulin processing and secretion ATG13 missense 23263489 rs7932354 chr11 46722221 T C 4.00E-09 Bone mineral density (hip) / / 19801982 rs7932354 chr11 46722221 T C 5.00E-18 Bone mineral density / / 22504420 rs7932354 chr11 46722221 T C 1.41E-04 Bone mineral density / / 24249740 rs7932354 chr11 46722221 T C 9.51E-04 Bone mineral density / / 24249740 rs10769205 chr11 46723603 G A 5.74E-05 Brain structure ZNF408 intron 22504417 rs12361673 chr11 46723937 G A 4.54E-04 Brain structure ZNF408 intron 22504417 rs2070850 chr11 46741495 C T 0.000000288 HDL cholesterol F2 intron 23063622 rs3136441 chr11 46743247 T C 3.00E-18 HDL cholesterol F2 intron 20686565 rs3136441 chr11 46743247 T C 7.00E-29 HDL cholesterol F2 intron 24097068 rs2070852 chr11 46744925 G C 6.66E-04 Bone mineral density F2 intron 24249740 rs3136455 chr11 46745682 C T 6.52E-04 Multiple complex diseases F2 intron 17554300 rs3136457 chr11 46746258 G C 0.000000175 HDL cholesterol F2 intron 23063622 rs3136478 chr11 46751567 G A 4.77E-04 Multiple complex diseases F2 intron 17554300 rs3136516 chr11 46760756 G A 1.64E-08 Thrombin generation potential phenotypes F2 intron 24357727 rs1799963 chr11 46761055 G A 1.69E-06 Venous thromboembolism F2 UTR-3 22672568 rs11038982 chr11 46762419 C A 3.13E-08 Thrombin generation potential phenotypes / / 24357727 rs6485690 chr11 46798631 A G 6.40E-05 Bone mineral density CKAP5 intron 21927923 rs6485690 chr11 46798631 A G 3.00E-06 Aortic stiffness CKAP5 intron 22068335 rs11038993 chr11 46810916 C A 1.33E-10 End-stage coagulation CKAP5 intron 23381943 rs4506602 chr11 46815633 C T 4.41E-09 End-stage coagulation CKAP5 intron 23381943 rs1007738 chr11 46849360 G A 7.00E-07 Bone mineral density (hip) CKAP5 intron 19079262 rs1007738 chr11 46849360 G A 7.10E-06 Bone mineral density CKAP5 intron 21927923 rs6485700 chr11 46875933 G A 2.96E-04 Multiple complex diseases LOC100507401 intron 17554300 rs2306034 chr11 46878684 C T 0.0000399 Menopause (age at onset) LRP4 UTR-3 23424626 rs2306029 chr11 46893108 T C 8.96E-04 Suicide attempts in bipolar disorder LRP4 missense 21423239 rs2306029 chr11 46893108 T C 3.19E-04 Common variable immunodeficiency LRP4 missense 21497890 rs2306029 chr11 46893108 T C 8.00E-06 D-dimer levels LRP4 missense 21502573 rs2306029 chr11 46893108 T C 2.33E-10 End-stage coagulation LRP4 missense 23381943 rs6485702 chr11 46898771 T C 2.10E-06 Bone mineral density (spine) LRP4 missense 19079262 rs17787912 chr11 46947366 A G 1.63E-11 Thrombin generation potential phenotypes / / 24357727 rs2903517 chr11 46966808 G A 2.17E-05 Alcohol and nictotine co-dependence C11orf49 intron 20158304 rs11039035 chr11 46967415 T G 6.93E-04 Acute lung injury C11orf49 intron 22295056 rs17790204 chr11 46969281 C G 6.93E-04 Acute lung injury C11orf49 intron 22295056 rs6485716 chr11 46981646 A G 7.27E-04 Acute lung injury C11orf49 intron 22295056 rs4494268 chr11 47038220 A G 7.62E-04 Acute lung injury C11orf49 intron 22295056 rs7125807 chr11 47041163 A C 4.67E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs7101470 chr11 47054448 A G 1.20E-10 Fasting blood glucose C11orf49 intron 22885924 rs7479189 chr11 47057009 T A 4.57E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs7103581 chr11 47072805 G T 3.71E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs7127741 chr11 47074479 T C 7.83E-04 Acute lung injury C11orf49 intron 22295056 rs11039074 chr11 47081732 C T 3.12E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs10769234 chr11 47084061 G C 3.14E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs7108902 chr11 47091571 C T 3.20E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs7946709 chr11 47100796 G T 2.70E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs4319472 chr11 47109514 G C 3.14E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs4752957 chr11 47125632 T G 3.08E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs7117404 chr11 47127153 A G 9.00E-06 D-dimer levels C11orf49 intron 21502573 rs11039097 chr11 47131881 A G 6.37E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs12796744 chr11 47132724 A T 7.41E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs4752962 chr11 47141670 C G 6.35E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs6485739 chr11 47145072 G A 6.30E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs10838660 chr11 47152273 G A 9.99E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs11039105 chr11 47157677 T A 6.37E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs4752965 chr11 47159053 G A 7.46E-04 Acute lung injury C11orf49 intron 22295056 rs1872896 chr11 47160623 C T 7.49E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs10466478 chr11 47162604 T G 7.64E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs7121418 chr11 47165106 G A 7.47E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs12574410 chr11 47169228 G C 4.72E-04 Acute lung injury C11orf49 intron 22295056 rs4752967 chr11 47169376 T C 7.22E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs11039112 chr11 47174296 C T 7.47E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs12224096 chr11 47174361 C T 6.38E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs747650 chr11 47176005 C T 5.41E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs747650 chr11 47176005 C T 4.00E-09 Acne (severe) C11orf49 intron 24399259 rs1060573 chr11 47179829 A G 6.55E-04 Suicide attempts in bipolar disorder C11orf49 intron 21423239 rs1060573 chr11 47179829 A G 1.28E-08 Acne (severe) C11orf49 intron 24399259 rs10838663 chr11 47184971 C T 6.17E-04 Acute lung injury C11orf49 intron 22295056 rs1055447 chr11 47186424 C A 1.73E-04 Suicide attempts in bipolar disorder ARFGAP2 UTR-3 21423239 rs11600668 chr11 47193566 G A 5.84E-04 Suicide attempts in bipolar disorder ARFGAP2 intron 21423239 rs74402657 chr11 47194751 C G 0.0000396 Menopause (age at onset) ARFGAP2 intron 23424626 rs11039119 chr11 47201924 G A 5.38E-04 Suicide attempts in bipolar disorder PACSIN3 intron 21423239 rs11039119 chr11 47201924 G A 3.49E-08 Fasting blood glucose PACSIN3 intron 22885924 rs4752971 chr11 47217688 A C 5.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs193030163 chr11 47222804 G C 0.0000557 Menopause (age at onset) / / 23424626 rs7937101 chr11 47226488 A G 4.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs11039130 chr11 47229316 C T 4.60E-10 Fasting blood glucose / / 22885924 rs4567413 chr11 47232184 T C 4.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs2029298 chr11 47234718 C T 4.81E-04 Suicide attempts in bipolar disorder DDB2 nearGene-5 21423239 rs2291120 chr11 47237680 T C 4.00E-04 Progressive supranuclear palsy DDB2 intron 17357082 rs2957873 chr11 47249294 G A 1.00E-04 Lipid levels DDB2 intron 19936222 rs2957873 chr11 47249294 G A 1.60E-04 Lipid levels DDB2 intron 19936222 rs2957873 chr11 47249294 G A 2.90E-04 Lipid levels DDB2 intron 19936222 rs2957873 chr11 47249294 G A 3.80E-04 Lipid levels DDB2 intron 19936222 rs2957873 chr11 47249294 G A 6.90E-06 Lipid levels DDB2 intron 19936222 rs2957873 chr11 47249294 G A 2.04E-05 HDL particle features DDB2 intron pha002900 rs4647731 chr11 47252254 T C 1.54E-04 Multiple complex diseases DDB2 intron 17554300 rs326222 chr11 47259668 T C 2.00E-05 Urinary metabolites DDB2 intron 21572414 rs901746 chr11 47260319 A G 1.00E-04 Progressive supranuclear palsy DDB2 intron 17357082 rs11988 chr11 47261260 G A 5.52E-05 HDL particle features ACP2 UTR-3 pha002900 rs2167079 chr11 47270255 C T 5.13E-08 HDL particle features ACP2 missense pha002900 rs3758671 chr11 47273089 G C 9.00E-04 Progressive supranuclear palsy NR1H3 intron 17357082 rs10838681 chr11 47275064 G A 1.20E-05 Urinary metabolites NR1H3 intron 21572414 rs10838681 chr11 47275064 G A 1.00E-09 Metabolic syndrome NR1H3 intron 22399527 rs181556634 chr11 47277090 C T 0.0000629 Carotid intima media thickness NR1H3 intron 23152477 rs58304713 chr11 47277090 CTT C 0.0000629 Carotid intima media thickness NR1H3 intron 23152477 rs2279238 chr11 47282024 C T 0.000000334 HDL cholesterol NR1H3 cds-synon 23063622 rs7120118 chr11 47286290 T C 4.00E-08 HDL cholesterol NR1H3 intron 19060910 rs7120118 chr11 47286290 T C 4.00E-08 Coronary heart disease NR1H3 intron 21347282 rs7120118 chr11 47286290 T C 0.0006 Allele-specific FAIRE regulation in lymphoblastoid cell lines NR1H3 intron 22916038 rs7120118 chr11 47286290 T C 8.58E-08 HDL cholesterol NR1H3 intron 23063622 rs7120118 chr11 47286290 T C 3.57E-08 HDL particle features NR1H3 intron pha002900 rs7114704 chr11 47293457 C T 6.00E-04 Progressive supranuclear palsy MADD intron 17357082 rs10501320 chr11 47293799 G C 1.00E-04 Progressive supranuclear palsy MADD intron 17357082 rs10501320 chr11 47293799 G C 1.00E-88 Proinsulin levels MADD intron 21873549 rs10501321 chr11 47294626 T C 8.93E-04 Type 2 diabetes MADD intron 17463246 rs10501321 chr11 47294626 T C 4.85E-04 Lymphocyte counts MADD intron 22286170 rs10501321 chr11 47294626 T C 0.00000024 HDL cholesterol MADD intron 23063622 rs4752977 chr11 47300429 T C 9.72E-06 HDL particle features MADD intron pha002900 rs3816725 chr11 47305669 T G 1.47E-11 Fasting blood glucose MADD intron 22885924 rs1051006 chr11 47306585 G A 1.72E-10 Triglycerides MADD missense 19060911 rs1051006 chr11 47306585 G A 0.000000027 Insulin processing and secretion MADD missense 23263489 rs1051006 chr11 47306585 G A 9.51E-06 HDL particle features MADD missense pha002900 rs35233100 chr11 47306630 C T 5.00E-16 Insulin processing and secretion MADD STOP-GAIN 23263489 rs3889096 chr11 47308192 C T 2.00E-04 Multiple complex diseases MADD intron 17554300 rs10838687 chr11 47312892 T G 7.00E-12 Proinsulin levels MADD intron 21873549 rs7124955 chr11 47315274 T A 8.95E-04 Type 2 diabetes MADD intron 17463246 rs7124955 chr11 47315274 T A 0.000000195 HDL cholesterol MADD intron 23063622 rs749067 chr11 47318157 T C 6.12E-15 Fasting blood glucose MADD intron 22885924 rs749067 chr11 47318157 T C 3.01E-05 HDL particle features MADD intron pha002900 rs4752824 chr11 47324666 T A 6.99E-04 Type 2 diabetes MADD intron 17463246 rs1375688 chr11 47327217 G A 0.000000258 HDL cholesterol MADD intron 23063622 rs7944584 chr11 47336320 A T 2.00E-18 Fasting insulin-related traits MADD intron 20081858 rs7944584 chr11 47336320 A T 4.62E-05 Brain structure MADD intron 22504417 rs7944584 chr11 47336320 A T 4.00E-12 Fasting glucose-related traits (interaction with BMI) MADD intron 22581228 rs7944584 chr11 47336320 A T 2.70E-09 Fasting blood glucose MADD intron 22885924 rs7944584 chr11 47336320 A T 8.30E-31 Insulin processing and secretion MADD intron 23263489 rs4752979 chr11 47339180 A G 4.26E-08 Triglycerides MADD intron 19060911 rs4752979 chr11 47339180 A G 1.49E-05 HDL particle features MADD intron pha002900 rs11039182 chr11 47346723 T C 4.82E-22 Fasting blood glucose MADD intron 22885924 rs753992 chr11 47349846 G A 0.00000145 HDL cholesterol MADD intron 23063622 rs753993 chr11 47349969 C A 0.000000779 Fasting blood glucose MADD intron 22885924 rs11570119 chr11 47353311 G T 9.77E-09 Triglycerides MYBPC3 intron 23063622 rs2290146 chr11 47353498 G A 0.000000373 HDL cholesterol MYBPC3 intron 23063622 rs1052373 chr11 47354787 C T 9.45E-04 Type 2 diabetes MYBPC3 cds-synon 17463246 rs11570094 chr11 47359706 C A 3.28E-04 Type 2 diabetes MYBPC3 intron 17463246 rs2697920 chr11 47370607 T C 0.00022 Coronary artery calcification MYBPC3 intron 23727086 rs2856656 chr11 47373425 T C 1.03E-12 Venous thrombosis MYBPC3 intron 22675575 rs2856656 chr11 47373425 T C 5.00E-22 Thrombin generation potential phenotypes MYBPC3 intron 24357727 rs2856656 chr11 47373425 T C 8.29E-11 Thrombin generation potential phenotypes MYBPC3 intron 24357727 rs140541052 chr11 47389771 C G 1.09E-13 Venous thrombosis SPI1 intron 22675575 rs140541052 chr11 47389771 C G 1.10E-09 Thrombin generation potential phenotypes SPI1 intron 24357727 rs140541052 chr11 47389771 C G 1.22E-18 Thrombin generation potential phenotypes SPI1 intron 24357727 rs10769258 chr11 47391039 C T 5.39E-04 Schizophrenia SPI1 intron 19197363 rs11606287 chr11 47407439 C A 7.25E-05 Type 2 diabetes and other traits LOC100507417 intron 19734900 rs10769263 chr11 47417183 A C 6.95E-05 Atopic dermatitis / / 23042114 rs874896 chr11 47418953 C G,T 4.83E-05 Atopic dermatitis / / 23042114 rs1534576 chr11 47419663 G T 7.88E-05 Kawasaki disease / / 22446961 rs1534576 chr11 47419663 G T 4.43E-05 Atopic dermatitis / / 23042114 rs10838703 chr11 47422861 C G 1.43E-06 Kawasaki disease / / 22446961 rs755553 chr11 47432303 G A 3.34E-04 Schizophrenia SLC39A13 intron 19197363 rs2293576 chr11 47434986 G A 2.06E-06 Kawasaki disease SLC39A13 cds-synon 22446961 rs2293579 chr11 47440758 G A 1.00E-07 Serum albumin level PSMC3 intron 23022100 rs2293579 chr11 47440758 G A 8.00E-08 Serum albumin level PSMC3 intron 23022100 rs10838708 chr11 47441513 G A 2.00E-09 Height PSMC3 intron 23563607 rs12292911 chr11 47449072 G A 3.69E-06 Kawasaki disease / / 22446961 rs7105122 chr11 47449544 C T 1.51E-05 Attention deficit hyperactivity disorder / / 22012869 rs11604680 chr11 47457539 A G 2.95E-05 Body mass index / / 24861553 rs7126210 chr11 47460306 A G 8.91E-05 HDL particle features RAPSN cds-synon pha002900 rs3740684 chr11 47468820 C T 8.38E-04 Response to statin treatment (atorvastatin),change in cholesterol levels RAPSN intron 20031582 rs4752843 chr11 47531884 T G 8.50E-05 Immunoglobulin A CELF1 intron 20694011 rs10838725 chr11 47557871 T C 1.00E-08 Alzheimer's disease (late onset) CELF1 intron 24162737 rs77977823 chr11 47565138 T C 5.13E-13 Venous thrombosis CELF1 intron 22675575 rs77977823 chr11 47565138 T C 3.99E-18 Thrombin generation potential phenotypes CELF1 intron 24357727 rs77977823 chr11 47565138 T C 8.66E-10 Thrombin generation potential phenotypes CELF1 intron 24357727 rs60206633 chr11 47574081 C G 5.47E-13 Venous thrombosis CELF1 intron 22675575 rs60206633 chr11 47574081 C G 3.06E-10 Thrombin generation potential phenotypes CELF1 intron 24357727 rs60206633 chr11 47574081 C G 5.99E-18 Thrombin generation potential phenotypes CELF1 intron 24357727 rs60206633 chr11 47574081 C G 8.31E-10 Thrombin generation potential phenotypes CELF1 intron 24357727 rs144915398 chr11 47598481 G A 4.30E-13 Venous thrombosis KBTBD4 intron 22675575 rs144915398 chr11 47598481 G A 1.92E-19 Thrombin generation potential phenotypes KBTBD4 intron 24357727 rs2280231 chr11 47600438 C T 1.67E-13 Fasting blood glucose KBTBD4 UTR-5 22885924 rs908597 chr11 47601741 C T 1.23E-04 Multiple complex diseases NDUFS3 intron 17554300 rs2176403 chr11 47627430 G A,C,T 4.23E-04 Multiple complex diseases / / 17554300 rs4752856 chr11 47648042 G A 4.55E-09 Body mass index MTCH2 intron 19079261 rs4752856 chr11 47648042 G A 4.70E-09 Smoking behavior MTCH2 intron 20418888 rs3817334 chr11 47650993 C T 2.00E-12 Body mass index MTCH2 intron 20935630 rs3817334 chr11 47650993 C T 1.82E-04 Body mass index MTCH2 intron 22344219 rs3817334 chr11 47650993 C T 1.59E-12 Body mass index MTCH2 intron 23001569 rs7118178 chr11 47659135 G A 3.84E-14 Fasting blood glucose MTCH2 intron 22885924 rs7120548 chr11 47662932 T C 7.35E-05 Kawasaki disease MTCH2 intron 22446961 rs10838738 chr11 47663049 A G 5.00E-09 Body mass index MTCH2 intron 19079261 rs10838738 chr11 47663049 A G 4.60E-09 Smoking behavior MTCH2 intron 20418888 rs11039329 chr11 47684908 T C 9.50E-04 Type 2 diabetes AGBL2 intron 17463246 rs12286721 chr11 47701528 C A 6.58E-05 Body Mass Index AGBL2 missense pha002896 rs7941404 chr11 47712213 C T 4.70E-21 Insulin processing and secretion AGBL2 missense 23263489 rs78261087 chr11 47764906 G A 1.08E-12 Venous thrombosis FNBP4 intron 22675575 rs78261087 chr11 47764906 G A 1.69E-09 Thrombin generation potential phenotypes FNBP4 intron 24357727 rs78261087 chr11 47764906 G A 2.35E-18 Thrombin generation potential phenotypes FNBP4 intron 24357727 rs150341456 chr11 47783614 T C 1.11E-12 Venous thrombosis FNBP4 intron 22675575 rs150341456 chr11 47783614 T C 1.26E-18 Thrombin generation potential phenotypes FNBP4 intron 24357727 rs150341456 chr11 47783614 T C 1.74E-09 Thrombin generation potential phenotypes FNBP4 intron 24357727 rs7114011 chr11 47811309 A C 7.36E-04 Multiple complex diseases NUP160 intron 17554300 rs58883118 chr11 47818310 C T 8.22E-13 Venous thrombosis NUP160 intron 22675575 rs58883118 chr11 47818310 C T 1.73E-10 Thrombin generation potential phenotypes NUP160 intron 24357727 rs58883118 chr11 47818310 C T 2.03E-19 Thrombin generation potential phenotypes NUP160 intron 24357727 rs10838771 chr11 47831332 A G 1.00E-04 Prostate cancer NUP160 intron 21743057 rs3816605 chr11 47857253 T A,C,G 8.94E-05 Body Mass Index NUP160 missense pha002896 rs2305983 chr11 47858755 C T 1.00E-04 Prostate cancer NUP160 intron 21743057 rs7942031 chr11 47868474 T C 1.00E-04 Prostate cancer NUP160 intron 21743057 rs6485788 chr11 47873883 A G 1.00E-04 Prostate cancer / / 21743057 rs7924699 chr11 47893120 A T 1.00E-04 Prostate cancer / / 21743057 rs141237278 chr11 47920993 G T 1.13E-11 Venous thrombosis / / 22675575 rs141237278 chr11 47920993 G T 1.37E-10 Thrombin generation potential phenotypes / / 24357727 rs141237278 chr11 47920993 G T 1.64E-20 Thrombin generation potential phenotypes / / 24357727 rs747782 chr11 47940925 T C 1.73E-10 Triglycerides / / 19060911 rs747782 chr11 47940925 T C 2.00E-05 Prostate cancer / / 21743057 rs747782 chr11 47940925 T C 2.75E-05 HDL particle features / / pha002900 rs149327057 chr11 47947894 C T 4.27E-12 Venous thrombosis / / 22675575 rs149327057 chr11 47947894 C T 1.09E-10 Thrombin generation potential phenotypes / / 24357727 rs149327057 chr11 47947894 C T 3.53E-21 Thrombin generation potential phenotypes / / 24357727 rs7936879 chr11 47976882 A G 3.43E-06 Alcohol and nictotine co-dependence / / 20158304 rs7936879 chr11 47976882 A G 5.50E-05 Schizophrenia / / 22037552 rs1228005 chr11 47984281 T C 1.98E-05 Multiple complex diseases / / 17554300 rs1017875 chr11 47999218 C T 3.00E-05 Prostate cancer / / 21743057 rs7946766 chr11 48004369 C T 4.03E-08 Triglycerides PTPRJ intron 19060911 rs7946766 chr11 48004369 C T 1.35E-06 HDL particle features PTPRJ intron pha002900 rs7123436 chr11 48013484 G A 3.00E-05 Prostate cancer PTPRJ intron 21743057 rs4752805 chr11 48018355 A G 1.80E-05 Height PTPRJ intron 21194676 rs4752805 chr11 48018355 A G 7.90E-08 Height PTPRJ intron 21194676 rs7130876 chr11 48050995 A G 1.00E-05 Prostate cancer PTPRJ intron 21743057 rs117784795 chr11 48052066 C T 2.67E-12 Venous thrombosis PTPRJ intron 22675575 rs117784795 chr11 48052066 C T 1.07E-10 Thrombin generation potential phenotypes PTPRJ intron 24357727 rs117784795 chr11 48052066 C T 4.99E-19 Thrombin generation potential phenotypes PTPRJ intron 24357727 rs1113480 chr11 48058313 A C 7.60E-05 Serum metabolites PTPRJ intron 19043545 rs138315285 chr11 48064194 G A 2.94E-12 Venous thrombosis PTPRJ intron 22675575 rs138315285 chr11 48064194 G A 4.71E-20 Thrombin generation potential phenotypes PTPRJ intron 24357727 rs138315285 chr11 48064194 G A 6.00E-11 Thrombin generation potential phenotypes PTPRJ intron 24357727 rs11601310 chr11 48085189 G A 3.62E-05 Oral cancers (chewing tobacco related) PTPRJ intron 22503698 rs10838798 chr11 48091303 T G 7.00E-12 Height PTPRJ intron 23563607 rs10838801 chr11 48098280 G A 4.00E-12 Height PTPRJ intron 20881960 rs7114598 chr11 48101766 A G 1.50E-05 Urinary metabolites PTPRJ intron 21572414 rs10742827 chr11 48102350 T C 1.80E-05 Urinary metabolites PTPRJ intron 21572414 rs6485806 chr11 48102806 C T 9.24E-04 Alcohol dependence PTPRJ intron 24277619 rs7122335 chr11 48106486 G A 1.78E-05 Cognitive impairment induced by topiramate PTPRJ intron 22091778 rs7479361 chr11 48109793 G A 1.63E-05 Serum metabolites PTPRJ intron 19043545 rs2904315 chr11 48109948 A G 5.37E-05 Serum metabolites PTPRJ intron 19043545 rs1910364 chr11 48113232 A G 2.80E-05 Urinary metabolites PTPRJ intron 21572414 rs3942852 chr11 48115089 C T 2.80E-05 Urinary metabolites PTPRJ intron 21572414 rs3942852 chr11 48115089 C T 1.00E-06 Acute lymphoblastic leukemia (childhood) PTPRJ intron 22076464 rs10742829 chr11 48115837 T C 2.30E-05 Urinary metabolites PTPRJ intron 21572414 rs35800856 chr11 48133397 G A 6.13E-09 Thrombin generation potential phenotypes PTPRJ intron 24357727 rs10742833 chr11 48139198 T C 8.95E-04 Suicide attempts in bipolar disorder PTPRJ intron 21423239 rs11039528 chr11 48144345 G A 9.93E-05 Cognitive decline PTPRJ intron 22054870 rs2270993 chr11 48145166 G A 2.00E-05 Prostate cancer PTPRJ cds-synon 21743057 rs1566734 chr11 48145375 A C 8.45E-05 Cognitive decline PTPRJ missense 22054870 rs7129364 chr11 48150576 G A 1.00E-04 Prostate cancer PTPRJ intron 21743057 rs12577284 chr11 48150819 G T 1.13E-05 Cognitive decline PTPRJ intron 22054870 rs11607114 chr11 48151287 C G 4.91E-05 Cognitive decline PTPRJ intron 22054870 rs2270994 chr11 48157869 T C 1.98E-08 Triglycerides PTPRJ intron 19060911 rs2270994 chr11 48157869 T C 5.10E-04 Oral cancers (chewing tobacco related) PTPRJ intron 22503698 rs3741410 chr11 48168664 T G 5.00E-05 Prostate cancer PTPRJ intron 21743057 rs3741410 chr11 48168664 T G 1.56E-05 Attention deficit hyperactivity disorder PTPRJ intron 22012869 rs3741410 chr11 48168664 T G 9.17E-05 HDL particle features PTPRJ intron pha002900 rs17198978 chr11 48172365 C T 2.33E-04 Nicotine smoking PTPRJ intron 19268276 rs17198978 chr11 48172365 C T 5.46E-06 Alcohol and nictotine co-dependence PTPRJ intron 20158304 rs10742837 chr11 48179115 T A,C,G 5.63E-05 Multiple complex diseases PTPRJ intron 17554300 rs17198985 chr11 48183565 T C 1.00E-04 Prostate cancer PTPRJ intron 21743057 rs11039571 chr11 48207259 G A 9.00E-06 D-dimer levels / / 21502573 rs7111194 chr11 48214992 T C 6.74E-06 Rheumatoid arthritis / / 19503088 rs1393794 chr11 48232853 T C 3.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11039588 chr11 48234357 C A,G,T 3.90E-05 Personality dimensions / / 18957941 rs11039588 chr11 48234357 C A,G,T 8.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs11039588 chr11 48234357 C A,G,T 1.16E-05 Major depressive disorder / / 21621269 rs11606506 chr11 48238549 G A 3.50E-04 Alzheimer's disease (late onset) OR4B1 missense 21379329 rs1983071 chr11 48271783 C T 4.36E-04 Alzheimer's disease (late onset) / / 21379329 rs1316604 chr11 48279796 G A 2.38E-05 HDL particle features / / pha002900 rs10838852 chr11 48286256 C T 7.74E-04 Multiple complex diseases OR4X1 missense 17554300 rs10838852 chr11 48286256 C T 5.57E-09 Triglycerides OR4X1 missense 19060911 rs12282928 chr11 48332028 A G 9.00E-06 Migraine - clinic-based / / 23793025 rs1483121 chr11 48333360 G A 2.00E-08 Fasting glucose-related traits (interaction with BMI) / / 22581228 rs1483121 chr11 48333360 G A 1.70E-09 Fasting blood glucose / / 22885924 rs1483121 chr11 48333360 G A 3.80E-14 Insulin processing and secretion / / 23263489 rs11605627 chr11 48337132 C A 7.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs1351696 chr11 48382471 A G 8.00E-06 D-dimer levels / / 21502573 rs10838881 chr11 48387275 T C 1.37E-05 Attention deficit hyperactivity disorder / / 22012869 rs10838881 chr11 48387275 T C 2.26E-05 HDL particle features / / pha002900 rs11039736 chr11 48449477 A G 5.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs9667626 chr11 48485877 T C 9.00E-05 Prostate cancer / / 21743057 rs12420372 chr11 48497603 G T 1.61E-04 Multiple complex diseases / / 17554300 rs12420372 chr11 48497603 G T 5.33E-04 Coronary heart disease / / 21606135 rs7944287 chr11 48516606 T C 1.86E-05 Alcohol and nictotine co-dependence / / 20158304 rs7395662 chr11 48518893 A G 2.22E-04 Multiple complex diseases / / 17554300 rs7395662 chr11 48518893 A G 6.00E-11 HDL cholesterol / / 19060911 rs7395662 chr11 48518893 A G 6.00E-11 Coronary heart disease / / 21347282 rs7395662 chr11 48518893 A G 4.04E-04 Alzheimer's disease (late onset) / / 21379329 rs7395662 chr11 48518893 A G 2.74E-04 Coronary heart disease / / 21606135 rs7942042 chr11 48520270 A G 9.00E-05 Prostate cancer / / 21743057 rs7942284 chr11 48520424 C T 9.00E-05 Prostate cancer / / 21743057 rs10838923 chr11 48534864 G C 8.00E-05 Prostate cancer / / 21743057 rs10838924 chr11 48535205 C T 4.00E-05 Iris characteristics / / 21835309 rs11039798 chr11 48540223 G A 4.00E-06 Axial length / / 24144296 rs6485848 chr11 48541517 G T 9.00E-05 Prostate cancer / / 21743057 rs11039800 chr11 48542579 T C 1.75E-04 Multiple complex diseases / / 17554300 rs12221667 chr11 48548549 G T 4.15E-06 Axial length / / 24144296 rs11039819 chr11 48562181 G T 3.62E-04 Multiple complex diseases / / 17554300 rs11039819 chr11 48562181 G T 2.62E-04 Coronary heart disease / / 21606135 rs11039820 chr11 48562252 A G 2.18E-04 Multiple complex diseases / / 17554300 rs11039820 chr11 48562252 A G 2.81E-04 Coronary heart disease / / 21606135 rs4882017 chr11 48570182 A G 2.58E-04 Multiple complex diseases / / 17554300 rs4882017 chr11 48570182 A G 2.99E-04 Coronary heart disease / / 21606135 rs10838954 chr11 48579323 G A 1.68E-04 Multiple complex diseases / / 17554300 rs10838954 chr11 48579323 G A 2.99E-04 Coronary heart disease / / 21606135 rs6485872 chr11 48579710 T G 2.21E-04 Multiple complex diseases / / 17554300 rs6485872 chr11 48579710 T G 2.88E-04 Coronary heart disease / / 21606135 rs10838956 chr11 48581765 T C 4.04E-04 Alzheimer's disease (late onset) / / 21379329 rs7950737 chr11 48590678 T G 9.00E-05 Prostate cancer / / 21743057 rs6485882 chr11 48592435 C G 1.26E-04 Multiple complex diseases / / 17554300 rs6485882 chr11 48592435 C G 4.61E-04 Coronary heart disease / / 21606135 rs10769383 chr11 48592510 G C 9.00E-05 Prostate cancer / / 21743057 rs4882132 chr11 48593125 C T 1.96E-04 Multiple complex diseases / / 17554300 rs4882132 chr11 48593125 C T 3.44E-04 Coronary heart disease / / 21606135 rs10437592 chr11 48598859 G T 7.00E-05 Prostate cancer / / 21743057 rs10160381 chr11 48599491 A G 3.00E-05 Prostate cancer / / 21743057 rs11039850 chr11 48599789 C A 7.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs7114291 chr11 48608251 A G 4.34E-04 Alzheimer's disease (late onset) / / 21379329 rs11039858 chr11 48611651 G A 9.13E-04 Multiple complex diseases / / 17554300 rs6485891 chr11 48612024 T A 3.00E-05 Prostate cancer / / 21743057 rs12278284 chr11 48612063 G C 3.00E-05 Prostate cancer / / 21743057 rs7129386 chr11 48616694 A G 4.53E-04 Alzheimer's disease (late onset) / / 21379329 rs7129386 chr11 48616694 A G 7.10E-05 Neuroblastoma / / pha002895 rs7108164 chr11 48626363 A C 8.00E-05 Prostate cancer / / 21743057 rs11039871 chr11 48626620 T C 2.39E-04 Multiple complex diseases / / 17554300 rs11039871 chr11 48626620 T C 3.75E-04 Coronary heart disease / / 21606135 rs12365014 chr11 48629434 C T 3.53E-04 Multiple complex diseases / / 17554300 rs11039873 chr11 48630165 T A 3.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs10838987 chr11 48646903 G T 3.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs6485908 chr11 48652198 A G 1.00E-04 Prostate cancer / / 21743057 rs11040016 chr11 48783497 C T 3.72E-04 Multiple complex diseases / / 17554300 rs11040016 chr11 48783497 C T 3.91E-04 Coronary heart disease / / 21606135 rs8188975 chr11 48891877 G A 5.78E-04 Multiple complex diseases / / 17554300 rs8188975 chr11 48891877 G A 7.38E-04 Coronary heart disease / / 21606135 rs1473579 chr11 48901553 A G 4.26E-04 Alzheimer's disease (late onset) / / 21379329 rs7120743 chr11 48922645 C T 5.56E-10 Triglycerides / / 19060911 rs7120743 chr11 48922645 C T 2.77E-04 Alzheimer's disease (late onset) / / 21379329 rs1809986 chr11 48987539 C A 2.92E-10 Triglycerides / / 19060911 rs1809986 chr11 48987539 C A 3.36E-04 Alzheimer's disease (late onset) / / 21379329 rs10839201 chr11 48989417 C T 7.24E-04 Multiple complex diseases / / 17554300 rs7129890 chr11 49042866 G T 2.09E-06 Orofacial clefts / / 22419666 rs10839224 chr11 49146066 T C 7.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs12275064 chr11 49152597 G T 7.54E-04 Multiple complex diseases / / 17554300 rs11040267 chr11 49161683 A G 5.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs10839229 chr11 49162948 C T 4.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs11040270 chr11 49165670 G C 5.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs16906158 chr11 49170774 T C 5.98E-04 Suicide attempts in bipolar disorder FOLH1 intron 21423239 rs16906158 chr11 49170774 T C 0.00000257 Type 2 diabetes FOLH1 intron 22325160 rs2299644 chr11 49189235 G A 7.20E-04 Suicide attempts in bipolar disorder FOLH1 intron 21423239 rs16906173 chr11 49195802 G C 7.90E-05 Personality dimensions FOLH1 intron 18957941 rs16906173 chr11 49195802 G C 5.30E-04 Suicide attempts in bipolar disorder FOLH1 intron 21423239 rs16906190 chr11 49203487 A G 5.35E-04 Suicide attempts in bipolar disorder FOLH1 intron 21423239 rs202676 chr11 49227620 A G 1.50E-07 Height FOLH1 missense 21194676 rs202675 chr11 49228613 C G 2.34E-04 Multiple complex diseases FOLH1 intron 17554300 rs679470 chr11 49242990 G T 9.75E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11040291 chr11 49248150 C T 5.30E-05 Personality dimensions / / 18957941 rs11040291 chr11 49248150 C T 2.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs1164688 chr11 49290604 C G 2.73E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1164663 chr11 49294723 A T 1.02E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7932396 chr11 49299282 A G 8.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs11040313 chr11 49299786 A G 8.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs7939300 chr11 49311134 C A 4.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs7939316 chr11 49311208 A G 5.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs11040318 chr11 49312909 G A 1.50E-05 Personality dimensions / / 18957941 rs11040318 chr11 49312909 G A 5.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs11040329 chr11 49339071 T C 6.36E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs3974686 chr11 49350027 G A 4.10E-05 Suicide attempts in bipolar disorder / / 21423239 rs7929543 chr11 49351026 A C 4.07E-05 Suicide attempts in bipolar disorder / / 21423239 rs10839264 chr11 49356806 C T 4.24E-05 Suicide attempts in bipolar disorder / / 21423239 rs11607791 chr11 49358347 T C 2.53E-05 Suicide attempts in bipolar disorder / / 21423239 rs11040339 chr11 49360688 A G 5.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs2866358 chr11 49364243 T G 4.99E-04 Parkinson's disease / / 17052657 rs11040352 chr11 49395272 A C 8.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs7102702 chr11 49401125 T G 1.35E-07 Peripartum cardiomyopathy / / 21665988 rs7947057 chr11 49403225 A T 4.31E-04 Multiple complex diseases / / 17554300 rs11040353 chr11 49405112 A G 7.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs11040354 chr11 49409798 G A 7.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs11040357 chr11 49434633 A G 9.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs11040359 chr11 49437005 G T 7.10E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11040360 chr11 49441945 G A 9.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs11040390 chr11 49499897 G A 4.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs11040391 chr11 49502848 T C 4.77E-04 Multiple complex diseases / / 17554300 rs11040391 chr11 49502848 T C 4.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs11040396 chr11 49510086 G C 5.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs11040399 chr11 49515913 C A 8.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs7951980 chr11 49520159 G A 5.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs7102641 chr11 49553859 T C 6.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs7117413 chr11 49553984 G C 4.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs1814175 chr11 49559172 T C 2.00E-08 Height / / 20881960 rs3913231 chr11 49560038 A T 5.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs11605639 chr11 49571573 A G 5.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs10431010 chr11 49584821 A T 5.24E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs10431011 chr11 49585195 A G 4.08E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs11040432 chr11 49596079 C T 3.55E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs10839306 chr11 49602501 A G 3.06E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs3862349 chr11 49631521 G A 1.61E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs2133225 chr11 49631658 A G 2.59E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs11040446 chr11 49642177 A C 2.98E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs10839319 chr11 49658331 T C 3.33E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs10839321 chr11 49670562 T C 3.82E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs10769599 chr11 49672943 G A 4.10E-05 Meningococcal disease LOC440040 intron 20694013 rs11040456 chr11 49674346 T C 5.58E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs11040457 chr11 49675593 T G 5.06E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs11040460 chr11 49678005 A G 4.97E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs11605882 chr11 49684925 C T 6.24E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs12364577 chr11 49707361 A C 1.21E-07 Parkinson's disease LOC440040 intron 17052657 rs6416155 chr11 49728161 G A 5.82E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs7937342 chr11 49733184 T G 7.82E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs10734600 chr11 49740634 G A 5.83E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs12224566 chr11 49758856 C A 6.95E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs11040503 chr11 49760350 C A 2.92E-05 Psoriasis LOC440040 intron 20953190 rs7939338 chr11 49768578 T C 9.65E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs7106286 chr11 49770173 A C 5.33E-04 Multiple complex diseases LOC440040 intron 17554300 rs11603859 chr11 49772699 T C 6.78E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs11040509 chr11 49774214 G A 5.29E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs12278889 chr11 49827352 A G 7.22E-04 Suicide attempts in bipolar disorder LOC440040 intron 21423239 rs3960750 chr11 49836271 G T 7.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs11530438 chr11 49836893 T C 7.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs1829948 chr11 49863812 C T 7.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs4570560 chr11 49867885 T C 3.18E-04 Longevity / / 22279548 rs7938734 chr11 49878281 T C 3.20E-05 Blood Phenotypes / / 17903294 rs1965513 chr11 49879466 C T 7.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs11040612 chr11 49898266 C T 7.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs10839422 chr11 49901189 C T 9.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs57131498 chr11 49901189 CT C 9.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs12803675 chr11 49902126 T A 1.80E-04 Weight loss (gastric bypass surgery) / / 23643386 rs10839424 chr11 49903616 A C 7.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs11040625 chr11 49905711 C T 9.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs1623556 chr11 49907856 A G 8.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs847642 chr11 49919238 A G 7.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs11602676 chr11 49925783 T C 7.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs1829949 chr11 49945282 G T 7.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs10839449 chr11 49946069 C T 7.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs1851852 chr11 49953362 C T 4.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs11040668 chr11 49956763 T C 8.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs1916954 chr11 49966096 T G 7.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs11601215 chr11 50002173 C T 6.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs1818894 chr11 50035553 T C 9.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs869195 chr11 50064752 C T 6.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs11245558 chr11 50068171 G A 8.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs12226894 chr11 50068959 G T 8.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs4881702 chr11 50096425 C T 7.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs11245822 chr11 50118787 C T 7.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs11245826 chr11 50119111 A G 6.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs11245858 chr11 50124459 A T 7.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs11245863 chr11 50125634 C A 7.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs11245866 chr11 50125724 A G 7.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs12223607 chr11 50127185 C T 5.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs11606884 chr11 50130676 T G 8.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs1826836 chr11 50140456 G A 7.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs11245912 chr11 50152535 C G 7.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs11606055 chr11 50164027 T A 7.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs1496469 chr11 50165513 C T 7.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs1845865 chr11 50165888 A C 7.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs16906478 chr11 50170337 T C 7.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs11245570 chr11 50193857 G A 9.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs11245571 chr11 50194084 T C 7.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs12360875 chr11 50234122 T C 1.20E-05 Urinary metabolites / / 21572414 rs16906441 chr11 50250131 A G 2.48E-05 Non-small cell lung cancer LOC441601 intron 21866343 rs11245619 chr11 50253541 G A 1.40E-05 Urinary metabolites LOC441601 intron 21572414 rs11245641 chr11 50300221 A G 3.36E-04 Multiple complex diseases / / 17554300 rs11245641 chr11 50300221 A G 6.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs11245642 chr11 50302679 G A 6.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs2200859 chr11 50328661 T C 6.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs474335 chr11 50370223 T A,C,G 8.23E-04 Suicide attempts in bipolar disorder LOC646813 intron 21423239 rs3866801 chr11 50374138 A G 6.60E-05 Response to statin treatment (atorvastatin),change in cholesterol levels LOC646813 intron 20031582 rs492541 chr11 50420195 A G 7.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs11245687 chr11 50450684 T C 1.00E-05 Urinary metabolites / / 21572414 rs8188857 chr11 50467961 A G 2.84E-04 Smoking quantity / / 24665060 rs2313680 chr11 50472171 C A,T 1.50E-05 Urinary metabolites / / 21572414 rs11245714 chr11 50480771 T C 1.50E-05 Urinary metabolites / / 21572414 rs8186177 chr11 50523890 A G 9.20E-06 Urinary metabolites / / 21572414 rs8189213 chr11 50566719 C T 4.64E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs5017948 chr11 51414218 T A 3.00E-08 Height / / 20881960 rs10431196 chr11 51455311 C G 8.79E-04 Alzheimer's disease / / 22005930 rs5009058 chr11 51459057 G A 7.86E-04 Alzheimer's disease / / 22005930 rs12577468 chr11 51461169 G A 1.47E-04 Multiple complex diseases / / 17554300 rs530655 chr11 51469977 T C 2.27E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7112290 chr11 51478072 G A 9.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs7112290 chr11 51478072 G A 9.62E-04 Alzheimer's disease / / 22005930 rs7114240 chr11 51491655 C T 8.22E-04 Alzheimer's disease / / 22005930 rs11246602 chr11 51512090 T C 2.00E-10 HDL cholesterol / / 24097068 rs7944067 chr11 51525878 G T 7.00E-05 Height / / pha003010 rs10902366 chr11 51527010 T G 8.40E-04 Alzheimer's disease / / 22005930 rs11246618 chr11 51527218 A G 8.42E-04 Alzheimer's disease / / 22005930 rs12795435 chr11 55047287 C T 5.23E-05 Multiple complex diseases / / 17554300 rs10792080 chr11 55047415 T A 1.50E-05 Urinary metabolites / / 21572414 rs11229192 chr11 55119267 T A 1.70E-04 Lipid levels / / 18193043 rs7127405 chr11 55132783 A T 8.96E-06 Blood pressure / / 21378095 rs7927370 chr11 55136219 C T 7.00E-06 Systemic lupus erythematosus OR4A15 missense 21408207 rs1364762 chr11 55197913 C T 6.62E-06 Blood pressure / / 21378095 rs17493710 chr11 55204758 T G 3.44E-04 Multiple complex diseases / / 17554300 rs17578661 chr11 55205325 C T 4.14E-06 Blood pressure / / 21378095 rs17494990 chr11 55277761 T C 3.02E-07 Blood pressure / / 21378095 rs17579895 chr11 55278100 G A,T 5.28E-06 Blood pressure / / 21378095 rs17580126 chr11 55289993 C G 3.45E-04 Multiple complex diseases / / 17554300 rs1459104 chr11 55312533 G A 9.87E-05 Multiple complex diseases / / 17554300 rs17581532 chr11 55321823 T A 9.01E-04 Multiple complex diseases OR4C15 missense 17554300 rs17581532 chr11 55321823 T A 4.24E-07 Blood pressure OR4C15 missense 21378095 rs141941152 chr11 55322500 C T 0.0006 Prostate cancer OR4C15 missense 23555315 rs7941750 chr11 55474194 C T 2.17E-04 Multiple complex diseases / / 17554300 rs1504677 chr11 55475356 G A 9.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs12420080 chr11 55514904 A G 3.86E-04 Myocardial Infarction / / pha002883 rs11230864 chr11 55522549 C T 5.00E-05 Schizophrenia / / 19571808 rs11230864 chr11 55522549 C T 3.90E-05 Schizophrenia / / 21791550 rs11230864 chr11 55522549 C T 0.000039 Psychosis / / 23164818 rs75255607 chr11 55563035 A G 0.000047 Breast cancer(er negative) OR5D14 missense 23555315 rs451391 chr11 55584109 T C 8.80E-05 Schizophrenia / / 19571808 rs7951100 chr11 55590296 G T 4.36E-07 Blood pressure / / 21378095 rs12364543 chr11 55591047 A C 8.24E-04 Myocardial Infarction / / pha002883 rs12361036 chr11 55606208 G A 6.30E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs17594092 chr11 55622962 C T 2.76E-06 Blood pressure / / 21378095 rs10897346 chr11 55630825 C T 1 Drug response to Mirtazapine / / 18496129 rs10897346 chr11 55630825 C T 1 Drug response to Venlafaxine / / 18496129 rs12098941 chr11 55666443 T A 7.04E-07 Blood pressure / / 21378095 rs12098903 chr11 55666513 A T 6.78E-07 Blood pressure / / 21378095 rs12098904 chr11 55666553 A T 6.44E-08 Blood pressure / / 21378095 rs17510438 chr11 55670315 G A 7.04E-07 Blood pressure / / 21378095 rs17510445 chr11 55670390 A C 1.76E-06 Blood pressure / / 21378095 rs17511107 chr11 55676025 T C 1.34E-07 Blood pressure / / 21378095 rs17596143 chr11 55678345 T A 7.04E-07 Blood pressure / / 21378095 rs17511601 chr11 55681375 T G 7.04E-07 Blood pressure OR5W2 cds-synon 21378095 rs10501340 chr11 55682795 A G 9.42E-04 Type 2 diabetes / / 17463246 rs17148932 chr11 55686109 G A 4.90E-05 HIV-1 control / / 20041166 rs17597169 chr11 55689110 T C 9.88E-08 Blood pressure / / 21378095 rs17597302 chr11 55689863 C T 7.04E-07 Blood pressure / / 21378095 rs17512592 chr11 55690242 A G 7.04E-07 Blood pressure / / 21378095 rs7936086 chr11 55690859 C T 7.04E-07 Blood pressure / / 21378095 rs9666086 chr11 55703650 A G 1.65E-06 Blood pressure OR5I1 missense 21378095 rs17598045 chr11 55708291 G A 1.65E-07 Blood pressure / / 21378095 rs17598094 chr11 55708815 T C 2.84E-07 Blood pressure / / 21378095 rs17513829 chr11 55715697 C A 3.42E-06 Blood pressure / / 21378095 rs17599023 chr11 55721477 T C 7.36E-06 Blood pressure / / 21378095 rs17599128 chr11 55722033 T A 8.02E-27 Narcolepsy / / 19629137 rs17514414 chr11 55722340 T C 4.12E-06 Blood pressure / / 21378095 rs17599408 chr11 55725650 A G 3.84E-06 Blood pressure / / 21378095 rs17599471 chr11 55726609 G A 4.25E-07 Blood pressure / / 21378095 rs17527788 chr11 55747013 C T 1.23E-07 Blood pressure / / 21378095 rs2512941 chr11 55760239 G A 6.90E-05 Schizophrenia / / 19571808 rs7952321 chr11 55782773 C A 0.0000468 Aging / / 22445811 rs1531762 chr11 55787839 G A 6.05E-04 Type 2 diabetes / / 17846125 rs1384089 chr11 55849016 G C 1.53E-08 Blood pressure / / 21378095 rs17602278 chr11 55849115 T C 7.71E-09 Blood pressure / / 21378095 rs17530228 chr11 55849156 A G 2.91E-08 Blood pressure / / 21378095 rs17530318 chr11 55851022 C A 4.79E-09 Blood pressure / / 21378095 rs7943453 chr11 55859425 G A 1.53E-08 Blood pressure / / 21378095 rs2945816 chr11 55862091 T C 2.00E-08 Phospholipid levels (plasma) / / 22359512 rs7929570 chr11 55877253 T C 4.25E-09 Blood pressure / / 21378095 rs7935728 chr11 55879455 C T 4.55E-09 Blood pressure / / 21378095 rs17603373 chr11 55886219 T C 9.02E-08 Blood pressure / / 21378095 rs17531933 chr11 55895649 T C 3.17E-08 Blood pressure / / 21378095 rs17531954 chr11 55895731 T C 2.91E-08 Blood pressure / / 21378095 rs2220004 chr11 55895745 G T 2.00E-07 Odorant perception / / 23910658 rs17610514 chr11 55895798 A G 3.95E-09 Blood pressure / / 21378095 rs139773791 chr11 55945018 C T 0.00013 Prostate cancer (advanced) OR5J2 missense 23555315 rs2035394 chr11 55967191 C G 2.96E-04 Smoking quantity / / 24665060 rs17150243 chr11 56019925 T G 9.00E-06 Obesity-related traits OR5T3 missense 23251661 rs7108801 chr11 56076600 C T 1.04E-07 Blood pressure / / 21378095 rs1600811 chr11 56080800 T G 5.68E-04 Multiple complex diseases / / 17554300 rs10896271 chr11 56113575 A G 8.41E-05 Orofacial clefts OR8K1 missense 22419666 rs10896272 chr11 56113593 C A 5.17E-05 Orofacial clefts OR8K1 missense 22419666 rs1586004 chr11 56118325 T C 7.77E-04 Multiple complex diseases / / 17554300 rs7940239 chr11 56123922 C T 8.64E-04 Multiple complex diseases / / 17554300 rs3938998 chr11 56156759 A C 6.49E-04 Type 2 diabetes / / 17463246 rs1945222 chr11 56167086 G A 2.50E-05 Orofacial clefts / / 22419666 rs1945213 chr11 56175671 C G,T 2.90E-05 Urinary metabolites / / 21572414 rs1945213 chr11 56175671 C G,T 3.00E-08 Acute lymphoblastic leukemia (childhood) / / 22076464 rs1945213 chr11 56175671 C G,T 4.00E-08 Acute lymphoblastic leukemia (childhood) / / 22076464 rs998544 chr11 56184888 G A 3.47E-05 Orofacial clefts OR5R1 missense 22419666 rs6591324 chr11 56185345 A G 1.57E-05 Orofacial clefts OR5R1 missense 22419666 rs1945205 chr11 56186430 T C 2.33E-05 Orofacial clefts OR5R1 nearGene-5 22419666 rs1945206 chr11 56239881 G A 8.79E-04 Response to statin treatment (atorvastatin),change in cholesterol levels OR5M3 nearGene-5 20031582 rs7939886 chr11 56242261 G T 2.00E-07 Myopia (pathological) / / 23049088 rs668543 chr11 56243891 A G 9.06E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1807254 chr11 56263539 G A 1.76E-06 Blood pressure / / 21378095 rs627933 chr11 56268433 A G 9.40E-05 Schizophrenia / / 19571808 rs12577186 chr11 56269410 T C 4.43E-05 Orofacial clefts / / 22419666 rs679309 chr11 56276235 A G 3.58E-05 Orofacial clefts / / 22419666 rs658845 chr11 56294275 T C 8.00E-05 Schizophrenia / / 19571808 rs10896469 chr11 56309468 G A 4.46E-04 Type 2 diabetes OR5M11 nearGene-3 17463246 rs628524 chr11 56310222 C T 0.0000037 Insulin processing and secretion OR5M11 missense 23263489 rs1876924 chr11 56347636 G A 9.31E-09 Blood pressure / / 21378095 rs7925450 chr11 56351502 G C 1.91E-06 Blood pressure / / 21378095 rs12365860 chr11 56381507 C T 3.10E-06 Schizophrenia OR5M1 nearGene-5 19571808 rs17630698 chr11 56395998 T G 1.76E-06 Blood pressure / / 21378095 rs1397056 chr11 56421197 C T 1.09E-05 Orofacial clefts / / 22419666 rs11228710 chr11 56431216 C T 1.12E-05 Orofacial clefts OR5AR1 STOP-GAIN 22419666 rs11228713 chr11 56438675 G A 2.16E-05 Orofacial clefts / / 22419666 rs11228719 chr11 56440236 C T 4.00E-06 Orofacial clefts / / 22419666 rs1397048 chr11 56466099 C T 7.00E-08 Hemostatic factors and hematological phenotypes OR9G1 nearGene-5 17903294 rs1397048 chr11 56466099 C T 3.03E-05 Orofacial clefts OR9G1 nearGene-5 22419666 rs11228739 chr11 56483227 C A 6.50E-05 Orofacial clefts / / 22419666 rs1912373 chr11 56483865 C T 9.70E-06 Parkinson's disease / / 17052657 rs1397053 chr11 56510694 T C 1.61E-04 Parkinson's disease OR9G4 cds-synon 17052657 rs11228763 chr11 56511160 A G 1.40E-05 Height OR9G4 missense 19396169 rs10501357 chr11 56526100 T C 6.32E-05 Orofacial clefts / / 22419666 rs1943637 chr11 56542757 C T 5.66E-05 Orofacial clefts / / 22419666 rs1943638 chr11 56542818 G A 8.65E-05 Orofacial clefts / / 22419666 rs1015195 chr11 56544017 A G 3.39E-04 Schizophrenia / / 19197363 rs1015195 chr11 56544017 A G 3.10E-05 Schizophrenia / / 19571808 rs17151214 chr11 56574935 T C 1.08E-04 Multiple complex diseases / / 17554300 rs764855 chr11 56610412 G T 1.00E-04 Schizophrenia / / 19197363 rs679124 chr11 56611798 A G 6.59E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7119763 chr11 56626311 G A 2.75E-05 Glucose levels / / pha003057 rs1792500 chr11 56659738 A G 3.85E-04 Parkinson's disease / / 17052657 rs1783453 chr11 56690060 A G 3.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1792461 chr11 56721838 T C 1.71E-04 Multiple complex diseases / / 17554300 rs2853083 chr11 56756664 G A 7.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OR5AK2 missense 20877124 rs602991 chr11 56797089 T G 3.49E-06 Duodenal ulcer / / 22387998 rs527174 chr11 56869386 C T 7.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs527174 chr11 56869386 C T 7.18E-04 Aortic root size / / 21223598 rs10896570 chr11 56879839 C T 8.50E-05 Memory performance / / 22105620 rs3017313 chr11 56905977 T C 8.80E-05 Hypothyroidism / / 22493691 rs3017569 chr11 56925021 G T 6.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs616285 chr11 56929009 G A 3.63E-04 Type 2 diabetes / / 17463246 rs612948 chr11 56930712 G A 6.05E-04 Type 2 diabetes / / 17463246 rs2860508 chr11 56931832 G A 4.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2077190 chr11 56947528 G T 5.36E-06 Coronary heart disease / / pha003032 rs567766 chr11 56951765 A C 6.77E-06 Coronary heart disease LRRC55 intron pha003032 rs717211 chr11 56962559 G A 2.10E-04 Stroke / / 17309882 rs7124474 chr11 56968959 G C 4.82E-04 Multiple complex diseases / / 17554300 rs2156456 chr11 56975099 G A 9.20E-05 Stroke / / 17309882 rs4442567 chr11 56988451 A G 3.54E-06 Coronary heart disease / / pha003032 rs4442567 chr11 56988451 A G 9.17E-05 Coronary heart disease / / pha003033 rs2282624 chr11 57001911 C T 1.20E-04 Stroke APLNR UTR-3 17309882 rs948847 chr11 57004344 G T 4.30E-05 Stroke APLNR cds-synon 17309882 rs948847 chr11 57004344 G T 3.37E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) APLNR cds-synon 20877124 rs948847 chr11 57004344 G T 3.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) APLNR cds-synon 20877124 rs11544374 chr11 57004577 C T 3.50E-04 Stroke APLNR UTR-5 17309882 rs9943582 chr11 57005067 T C 6.60E-05 Stroke / / 17309882 rs10501367 chr11 57005587 T C 3.70E-05 Stroke / / 17309882 rs7119375 chr11 57005964 A G 6.20E-05 Stroke / / 17309882 rs7120078 chr11 57006546 A G 1.93E-15 HDL cholesterol / / 23063622 rs7120078 chr11 57006546 A G 2.68E-09 Cholesterol,total / / 23063622 rs1893675 chr11 57009344 T G 7.90E-05 Stroke / / 17309882 rs499318 chr11 57012322 A G 1.10E-05 Stroke / / 17309882 rs7102963 chr11 57026834 A C 2.90E-05 Stroke / / 17309882 rs1892963 chr11 57037040 G A 2.10E-05 Stroke / / 17309882 rs1892964 chr11 57040720 C A 1.10E-05 Stroke / / 17309882 rs1892964 chr11 57040720 C A 9.71E-06 Meningococcal disease / / 20694013 rs4938861 chr11 57056050 C A 3.00E-05 Stroke / / 17309882 rs12792781 chr11 57060562 T C 5.30E-06 Meningococcal disease / / 20694013 rs6591419 chr11 57064876 T C 7.84E-04 Stroke / / pha002886 rs1939489 chr11 57065496 G T 2.30E-05 Stroke / / 17309882 rs7943907 chr11 57081661 G C 2.60E-04 Stroke TNKS1BP1 intron 17309882 rs879646 chr11 57124196 C T 1.83E-04 Lung function (forced vital capacity) P2RX3 intron 24023788 rs669661 chr11 57148175 A G 7.50E-16 Stroke PRG3 missense 23422753 rs10792093 chr11 57153948 G T 2.95E-04 Multiple complex diseases / / 17554300 rs3741089 chr11 57156438 A G 8.71E-05 Non-alcoholic fatty liver disease histology (other) PRG2 intron 20708005 rs10792094 chr11 57162364 G T 1.69E-05 Alzheimer's disease (late onset) / / 21379329 rs3741085 chr11 57166969 C T 2.85E-05 Alzheimer's disease (late onset) / / 21379329 rs10792095 chr11 57171123 A G 2.15E-05 Alzheimer's disease (late onset) / / 21379329 rs11229030 chr11 57203009 C T 8.00E-09 Crohn's disease / / 22412388 rs2584858 chr11 57207077 A G 5.30E-06 Urinary metabolites / / 21572414 rs2584859 chr11 57207447 C T 2.10E-06 Urinary metabolites / / 21572414 rs2729389 chr11 57211646 A G 1.30E-05 Urinary metabolites / / 21572414 rs2729384 chr11 57258617 T C 7.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC43A1 intron 20877124 rs12364489 chr11 57329466 T C 4.96E-04 Insulin resistance UBE2L6 intron 21901158 rs2649662 chr11 57352562 A C 9.76E-20 Lymphocyte counts / / 22286170 rs28362944 chr11 57365723 T C 9.00E-06 Obesity-related traits SERPING1 UTR-5 23251661 rs11603020 chr11 57374332 T C 2.93E-09 Narcolepsy SERPING1 intron 19629137 rs12294735 chr11 57415394 G A 4.62E-04 Multiple complex diseases YPEL4 intron 17554300 rs1613592 chr11 57424000 G T 2.79E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs147951568 chr11 57428280 T C 0.0000069 Prostate cancer (advanced) CLP1 missense 23555315 rs148451233 chr11 57428771 A G 0.00061 Prostate cancer (non-advanced prostate cancer) CLP1 missense 23555315 rs12801694 chr11 57460224 C T 2.33E-04 Amyotrophic lateral sclerosis (sporadic) ZDHHC5 intron 24529757 rs11570190 chr11 57560452 A C 3.93E-05 Schizophrenia CTNND1 intron 19571811 rs10896644 chr11 57563991 C T 5.51E-04 Amyotrophic lateral sclerosis (sporadic) CTNND1 cds-synon 24529757 rs613152 chr11 57603312 G A 5.38E-04 Multiple complex diseases / / 17554300 rs600488 chr11 57684005 C T 0.000144 Schizophrenia / / 22440650 rs2513724 chr11 57843609 C A 1.00E-04 Information processing speed OR9Q1 intron 21130836 rs2513724 chr11 57843609 C A 9.41E-04 Response to cytidine analogues (gemcitabine) OR9Q1 intron 24483146 rs4939180 chr11 57863416 T C 1.70E-05 Urinary metabolites OR9Q1 intron 21572414 rs1031360 chr11 57871866 C T 2.80E-05 Urinary metabolites OR9Q1 intron 21572414 rs11601841 chr11 57889566 G A 4.54E-04 Amyotrophic lateral sclerosis (sporadic) OR9Q1 intron 24529757 rs921442 chr11 57920869 C T 7.77E-05 Multiple complex diseases OR9Q1 intron 17554300 rs2443426 chr11 57922678 T C 2.82E-05 Serum metabolites OR9Q1 intron 19043545 rs2218868 chr11 57925977 C T 1.90E-06 Endometriosis OR9Q1 intron 21151130 rs2218868 chr11 57925977 C T 3.70E-04 Endometriosis OR9Q1 intron 23104006 rs964720 chr11 57930210 C T 8.53E-05 Smoking quantity OR9Q1 intron 24665060 rs1562861 chr11 57933947 C T 4.03E-05 Serum metabolites OR9Q1 intron 19043545 rs1020538 chr11 57935657 A G 4.90E-07 Urinary metabolites OR9Q1 intron 21572414 rs2514189 chr11 57943328 C T 1.95E-05 Multiple complex diseases OR9Q1 intron 17554300 rs2514189 chr11 57943328 C T 8.40E-06 Urinary metabolites OR9Q1 intron 21572414 rs11229273 chr11 57947264 C G 7.90E-07 Urinary metabolites OR9Q1 cds-synon 21572414 rs10896706 chr11 57951001 G A 1.10E-06 Urinary metabolites / / 21572414 rs143165965 chr11 57958038 C T 0.000064 Breast cancer OR9Q2 missense 23555315 rs1376483 chr11 57967467 T G 5.05E-05 AIDS progression / / 19115949 rs1451316 chr11 57968686 G T 5.28E-04 Smoking quantity / / 24665060 rs1947298 chr11 57972160 C T 1.03E-05 AIDS progression / / 19115949 rs12574405 chr11 57985993 A G 9.06E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11229293 chr11 57986173 G C 0.0007937 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11229293 chr11 57986173 G C 7.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12802604 chr11 57991692 T C 4.85E-05 Type 2 diabetes / / 22158537 rs1031358 chr11 57993924 A G 1.60E-04 Type 2 diabetes / / 22158537 rs11229304 chr11 57998339 C T 1.13E-04 Type 2 diabetes / / 22158537 rs11229307 chr11 58000148 C T 4.91E-05 Type 2 diabetes / / 22158537 rs11229308 chr11 58001841 C T 1.46E-04 Multiple complex diseases / / 17554300 rs17152556 chr11 58002612 C A 0.000847 Salmonella-induced pyroptosis / / 22837397 rs1938659 chr11 58008980 A C 5.74E-05 Type 2 diabetes / / 22158537 rs1938665 chr11 58018594 T C 3.62E-05 Type 2 diabetes / / 22158537 rs11229313 chr11 58018708 G A 1.67E-04 Multiple complex diseases / / 17554300 rs7934043 chr11 58022390 G T 8.80E-05 Type 2 diabetes / / 22158537 rs7935090 chr11 58022622 C T 6.70E-05 Type 2 diabetes / / 22158537 rs1938640 chr11 58023416 C G 6.78E-05 Type 2 diabetes / / 22158537 rs12223901 chr11 58025344 T C 6.87E-05 Type 2 diabetes / / 22158537 rs10750892 chr11 58028409 G T 1.02E-04 Type 2 diabetes / / 22158537 rs7113339 chr11 58030954 A C 5.81E-05 Type 2 diabetes / / 22158537 rs4608102 chr11 58032066 C T 4.80E-05 Type 2 diabetes / / 22158537 rs11229324 chr11 58033688 C T 1.18E-04 Multiple complex diseases / / 17554300 rs4127346 chr11 58042402 A T 5.45E-05 Type 2 diabetes / / 22158537 rs10792159 chr11 58047072 A T 7.75E-05 Type 2 diabetes / / 22158537 rs7101864 chr11 58053188 A G 3.94E-05 Type 2 diabetes / / 22158537 rs12289961 chr11 58060192 C T 1.00E-07 Lymphoma / / 23349640 rs12289961 chr11 58060192 C T 4.00E-08 Lymphoma / / 23349640 rs4459322 chr11 58063166 A G 6.67E-04 Multiple complex diseases / / 17554300 rs11229362 chr11 58090614 T C 5.72E-04 Coronary heart disease / / 21971053 rs4938893 chr11 58095004 G A 8.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1938648 chr11 58111513 T C 8.66E-05 Lung cancer / / 18978787 rs11229371 chr11 58111700 A G 6.81E-04 Multiple complex diseases / / 17554300 rs4363620 chr11 58118614 C T 8.27E-04 Type 2 diabetes / / 17463246 rs7928846 chr11 58150796 C T 8.00E-04 Type 2 diabetes / / 17463246 rs7933631 chr11 58152533 C T 5.85E-04 Type 2 diabetes / / 17463246 rs7951385 chr11 58152587 T C 8.09E-04 Type 2 diabetes / / 17463246 rs11229393 chr11 58152605 C T 7.06E-04 Multiple complex diseases / / 17554300 rs17473544 chr11 58156467 A T 5.16E-04 Multiple complex diseases / / 17554300 rs10896767 chr11 58159176 A G 9.93E-04 Type 2 diabetes / / 17463246 rs11229425 chr11 58178587 A G 8.69E-04 Multiple complex diseases / / 17554300 rs11229439 chr11 58192611 A G 4.97E-04 Coronary heart disease / / 21971053 rs11229440 chr11 58194192 A G 7.54E-04 Coronary heart disease / / 21971053 rs17474904 chr11 58202974 G A 3.30E-04 Type 2 diabetes / / 17463246 rs17474904 chr11 58202974 G A 7.50E-05 Personality dimensions / / 18957941 rs11229485 chr11 58232854 G A 3.74E-04 Coronary heart disease / / 21971053 rs12361887 chr11 58255678 G T 3.42E-04 Coronary heart disease / / 21971053 rs2510866 chr11 58255763 A G 8.53E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2515368 chr11 58264181 G A 9.59E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs11229497 chr11 58265949 T A 9.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2515366 chr11 58274370 T C 2.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7115326 chr11 58278349 C T 2.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7952094 chr11 58287319 C T 2.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7109553 chr11 58309914 C T 2.64E-04 Response to taxane treatment (placlitaxel) LPXN intron 23006423 rs2515359 chr11 58316567 T C 4.48E-04 Response to taxane treatment (placlitaxel) LPXN intron 23006423 rs10896791 chr11 58326795 G C 3.38E-04 Response to taxane treatment (placlitaxel) LPXN intron 23006423 rs2515346 chr11 58327398 C A 8.33E-04 Response to taxane treatment (placlitaxel) LPXN intron 23006423 rs1944054 chr11 58331924 C G 3.01E-04 Response to taxane treatment (placlitaxel) LPXN intron 23006423 rs2509920 chr11 58336544 G C 8.80E-05 Response to taxane treatment (placlitaxel) LPXN intron 23006423 rs10896794 chr11 58339124 T C 7.00E-10 Inflammatory bowel disease LPXN intron 23128233 rs948562 chr11 58347765 A G 3.00E-07 Lymphoma ZFP91 intron 23349640 rs948562 chr11 58347765 A G 6.00E-07 Lymphoma ZFP91 intron 23349640 rs1938596 chr11 58381686 A G 7.58E-04 Response to taxane treatment (placlitaxel) ZFP91 intron 23006423 rs34131586 chr11 58390338 A G 1.64E-12 Cholesterol,total CNTF missense 23063622 rs34131586 chr11 58390338 A G 6.69E-15 LDL cholesterol CNTF missense 23063622 rs1800169 chr11 58391501 G A 1 Drug response to Iloperidone CNTF intron 18303965 rs1800169 chr11 58391501 G A 1.70E-04 HDL particle features CNTF intron 21283740 rs2515362 chr11 58392951 T C 7.58E-04 Response to taxane treatment (placlitaxel) CNTF UTR-3 23006423 rs2154631 chr11 58404733 A C 4.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2509928 chr11 58405458 T C 2.05E-04 Type 2 diabetes / / 17463246 rs2509928 chr11 58405458 T C 4.96E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12798524 chr11 58438655 A G 6.00E-04 Alcohol dependence / / 20201924 rs1014968 chr11 58440720 C T 6.10E-04 Alcohol dependence / / 20201924 rs490871 chr11 58443852 G A 5.32E-04 Aortic root size / / 21223598 rs667933 chr11 58457495 G T 2.30E-05 Urinary metabolites / / 21572414 rs540592 chr11 58472622 C A 5.81E-04 Smoking initiation / / 24665060 rs539567 chr11 58472765 A G 7.88E-10 Multiple complex diseases / / 17554300 rs2507838 chr11 58472799 C A 2.00E-08 Body mass (lean) / / 23108985 rs7939049 chr11 58669421 A G 8.00E-05 Personality dimensions / / 18957941 rs1808064 chr11 58677074 G A 2.63E-05 Magnesium levels / / pha003092 rs10896875 chr11 58678335 A G 2.98E-05 Major depressive disorder / / 19107115 rs10896875 chr11 58678335 A G 7.70E-05 Magnesium levels / / pha003092 rs557678 chr11 58685134 A G 3.83E-04 Multiple complex diseases / / 17554300 rs550864 chr11 58693686 G T 9.79E-04 Alcohol dependence / / 21314694 rs480196 chr11 58701011 T G 9.19E-04 Amyotrophic lateral sclerosis (sporadic) GLYATL1 intron 24529757 rs1938791 chr11 58746238 T C 3.03E-05 Major depressive disorder LOC283194 intron 19107115 rs10501374 chr11 58773573 G C 7.79E-04 Type 2 diabetes LOC283194 intron 17846125 rs1943141 chr11 58800374 G A 5.45E-05 Response to taxane treatment (placlitaxel) LOC283194 intron 23006423 rs7950640 chr11 58864405 G C 1.00E-04 Prostate cancer / / 21743057 rs4409856 chr11 58877909 C T 1.00E-04 Prostate cancer FAM111B intron 21743057 rs11229868 chr11 58953775 C A 1.38E-04 Multiple complex diseases DTX4 intron 17554300 rs10501376 chr11 58971766 C G 3.60E-04 Multiple complex diseases DTX4 intron 17554300 rs10501376 chr11 58971766 C G 5.00E-04 Chronic fatigue syndrome DTX4 intron 21912186 rs3847 chr11 58976711 A G 1.03E-04 Response to taxane treatment (placlitaxel) MPEG1 UTR-3 23006423 rs6591509 chr11 58980549 A G 1.43E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2000875 chr11 58981586 G A 1.56E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1938593 chr11 58984717 G A 1.25E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17153461 chr11 58989046 G A 1.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4939263 chr11 58996396 G A 1.93E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6591515 chr11 59014108 A G 1.92E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7938115 chr11 59014658 G A 1.62E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7931234 chr11 59014749 T G 4.72E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs11229889 chr11 59020419 C A 8.93E-04 Multiple complex diseases / / 17554300 rs12280107 chr11 59025022 C T 5.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11229896 chr11 59027039 T A 7.91E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11229898 chr11 59029485 T C 9.12E-04 Alzheimer's disease / / 22005930 rs11229898 chr11 59029485 T C 7.15E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7929185 chr11 59054448 C T 9.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs10792230 chr11 59059179 C T 3.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs4569028 chr11 59141866 G A 7.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs7925931 chr11 59157250 A G 3.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs6591536 chr11 59211188 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes OR5A1 missense 22628534 rs1453545 chr11 59223388 C T 6.58E-04 Multiple complex diseases / / 17554300 rs7943953 chr11 59224144 T G 1.00E-31 Odorant perception / / 23910658 rs17153810 chr11 59244608 A G 8.13E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12791616 chr11 59256054 C T 6.86E-05 Aging (time to event) / / 21782286 rs17592656 chr11 59276813 A G 9.94E-04 Prostate cancer mortality / / 20978177 rs17153868 chr11 59291932 C A 2.32E-05 Multiple complex diseases / / 17554300 rs11229994 chr11 59303602 A G 1.31E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs567994 chr11 59329313 G A 1.62E-04 Multiple complex diseases / / 17554300 rs567994 chr11 59329313 G A 9.20E-07 Urinary metabolites / / 21572414 rs1299800 chr11 59348398 A T 5.53E-05 Multiple complex diseases OSBP intron 17554300 rs1299800 chr11 59348398 A T 3.60E-06 Urinary metabolites OSBP intron 21572414 rs473490 chr11 59357943 T C 2.73E-04 Multiple complex diseases OSBP intron 17554300 rs488331 chr11 59358576 A G 1.86E-04 Multiple complex diseases OSBP intron 17554300 rs488331 chr11 59358576 A G 6.60E-06 Urinary metabolites OSBP intron 21572414 rs11603417 chr11 59377543 C T 4.92E-04 Lung function (forced vital capacity) OSBP intron 24023788 rs17593682 chr11 59377788 A C 3.60E-06 Urinary metabolites OSBP intron 21572414 rs12289921 chr11 59382306 C A 3.09E-04 Multiple complex diseases OSBP intron 17554300 rs12289921 chr11 59382306 C A 1.60E-06 Urinary metabolites OSBP intron 21572414 rs7112355 chr11 59417171 T G 3.60E-06 Urinary metabolites PATL1 intron 21572414 rs11821465 chr11 59429654 T C 1.61E-04 Multiple complex diseases PATL1 intron 17554300 rs11821465 chr11 59429654 T C 1.70E-06 Urinary metabolites PATL1 intron 21572414 rs7108731 chr11 59485859 C G 2.30E-06 Urinary metabolites / / 21572414 rs477729 chr11 59486481 T C 2.70E-06 Urinary metabolites / / 21572414 rs477577 chr11 59486534 T C 9.06E-04 Multiple complex diseases / / 17554300 rs477577 chr11 59486534 T C 2.80E-06 Urinary metabolites / / 21572414 rs498099 chr11 59495792 G T 2.70E-06 Urinary metabolites / / 21572414 rs1938955 chr11 59504889 C G 1.00E-05 Urinary metabolites / / 21572414 rs552601 chr11 59510155 A G 2.33E-04 Multiple complex diseases / / 17554300 rs536544 chr11 59515532 T A 2.70E-06 Urinary metabolites / / 21572414 rs549086 chr11 59515685 A G 2.70E-06 Urinary metabolites / / 21572414 rs579373 chr11 59515704 C T 4.05E-04 Multiple complex diseases / / 17554300 rs579373 chr11 59515704 C T 1.60E-06 Urinary metabolites / / 21572414 rs2509275 chr11 59519395 T C 1.83E-04 Multiple complex diseases / / 17554300 rs2509275 chr11 59519395 T C 7.50E-06 Urinary metabolites / / 21572414 rs2509274 chr11 59519410 A G 1.65E-04 Multiple complex diseases / / 17554300 rs2509274 chr11 59519410 A G 6.70E-07 Urinary metabolites / / 21572414 rs482355 chr11 59525328 T C 5.44E-04 Multiple complex diseases STX3 intron 17554300 rs482355 chr11 59525328 T C 1.70E-06 Urinary metabolites STX3 intron 21572414 rs529270 chr11 59525741 T G 2.60E-06 Urinary metabolites STX3 intron 21572414 rs529270 chr11 59525741 T G 9.73E-04 Amyotrophic lateral sclerosis (sporadic) STX3 intron 24529757 rs1151064 chr11 59526704 G A 1.70E-06 Urinary metabolites STX3 intron 21572414 rs1151063 chr11 59526767 G C 1.50E-04 Multiple complex diseases STX3 intron 17554300 rs1151063 chr11 59526767 G C 1.70E-06 Urinary metabolites STX3 intron 21572414 rs554848 chr11 59529520 T A,G 6.27E-04 Multiple complex diseases STX3 intron 17554300 rs554848 chr11 59529520 T A,G 2.30E-06 Urinary metabolites STX3 intron 21572414 rs7947514 chr11 59531763 A G 2.40E-04 Multiple complex diseases STX3 intron 17554300 rs7947514 chr11 59531763 A G 1.10E-06 Urinary metabolites STX3 intron 21572414 rs17510841 chr11 59534360 A G 1.00E-05 Urinary metabolites STX3 intron 21572414 rs41384548 chr11 59535902 T C 5.88E-04 Multiple complex diseases STX3 intron 17554300 rs41384548 chr11 59535902 T C 1.70E-06 Urinary metabolites STX3 intron 21572414 rs516912 chr11 59536179 T C 3.40E-04 Multiple complex diseases STX3 intron 17554300 rs516912 chr11 59536179 T C 1.70E-06 Urinary metabolites STX3 intron 21572414 rs17154134 chr11 59543242 T C 2.38E-04 Multiple complex diseases STX3 intron 17554300 rs17154134 chr11 59543242 T C 4.10E-06 Urinary metabolites STX3 intron 21572414 rs17154146 chr11 59544258 A G 3.62E-04 Multiple complex diseases STX3 intron 17554300 rs17154146 chr11 59544258 A G 9.20E-07 Urinary metabolites STX3 intron 21572414 rs17154157 chr11 59550534 T C 4.06E-04 Multiple complex diseases STX3 intron 17554300 rs17154157 chr11 59550534 T C 1.60E-06 Urinary metabolites STX3 intron 21572414 rs17154165 chr11 59550731 A G 1.42E-04 Multiple complex diseases STX3 intron 17554300 rs17154165 chr11 59550731 A G 3.40E-06 Urinary metabolites STX3 intron 21572414 rs12290453 chr11 59558887 C A 1.00E-05 Urinary metabolites STX3 intron 21572414 rs17154180 chr11 59560509 T A 7.22E-04 Multiple complex diseases STX3 intron 17554300 rs17154180 chr11 59560509 T A 1.70E-06 Urinary metabolites STX3 intron 21572414 rs17154200 chr11 59568190 A G 4.40E-04 Multiple complex diseases STX3 intron 17554300 rs17154200 chr11 59568190 A G 1.70E-06 Urinary metabolites STX3 intron 21572414 rs482356 chr11 59570268 C T 4.30E-04 Multiple complex diseases STX3 UTR-3 17554300 rs482356 chr11 59570268 C T 1.70E-06 Urinary metabolites STX3 UTR-3 21572414 rs17154227 chr11 59595071 T A 3.29E-04 Multiple complex diseases / / 17554300 rs17154227 chr11 59595071 T A 7.40E-07 Urinary metabolites / / 21572414 rs7123969 chr11 59595357 C T 5.28E-04 Multiple complex diseases / / 17554300 rs7123969 chr11 59595357 C T 1.50E-06 Urinary metabolites / / 21572414 rs35211634 chr11 59612859 T C 1.17E-05 Amyotrophic lateral sclerosis (sporadic) GIF missense 24529757 rs11230090 chr11 59613646 A G 5.27E-09 Lipid levels GIF nearGene-5 19913121 rs11230090 chr11 59613646 A G 0.00000231 HDL cholesterol GIF nearGene-5 23063622 rs4620739 chr11 59616860 C T 7.00E-05 Prostate cancer / / 21743057 rs526934 chr11 59633493 G A 2.00E-06 Folate pathway vitamin levels TCN1 intron 19303062 rs526934 chr11 59633493 G A 2.00E-10 Folate pathway vitamin levels TCN1 intron 19744961 rs11230099 chr11 59681043 G A 8.92E-05 LDL lipoproteins / / pha002902 rs602041 chr11 59778863 T G 1.28E-05 Personality dimensions / / 18957941 rs602041 chr11 59778863 T G 1.30E-05 Personality dimensions / / 21173776 rs688086 chr11 59797468 G A 8.98E-05 Personality dimensions / / 18957941 rs12364417 chr11 59812644 C T 8.94E-04 Multiple complex diseases PLAC1L intron 17554300 rs1151102 chr11 59815640 A G 4.52E-04 Alzheimer's disease / / 24755620 rs1290429 chr11 59826115 T C 6.48E-04 Response to statin treatment (atorvastatin),change in cholesterol levels MS4A3 intron 20031582 rs1286289 chr11 59826677 T A 1.99E-04 Alzheimer's disease MS4A3 intron 24755620 rs11230135 chr11 59827800 C A 2.06E-05 Body Mass Index MS4A3 intron pha003015 rs1286169 chr11 59832346 T G 1.08E-04 Alzheimer's disease (late onset) MS4A3 intron 21460841 rs501697 chr11 59833123 T A 7.67E-05 Alzheimer's disease (late onset) MS4A3 intron 21460841 rs501697 chr11 59833123 T A 2.96E-04 Alzheimer's disease MS4A3 intron 24755620 rs579721 chr11 59834318 G A 6.42E-05 Alzheimer's disease (late onset) MS4A3 intron 21460841 rs143965382 chr11 59834583 A C 0.00023 Breast cancer MS4A3 missense 23555315 rs528823 chr11 59837097 C T 4.34E-04 Alzheimer's disease (late onset) MS4A3 cds-synon 21379329 rs528823 chr11 59837097 C T 5.23E-05 Alzheimer's disease (late onset) MS4A3 cds-synon 21460841 rs528823 chr11 59837097 C T 1.55E-06 Alzheimer's disease MS4A3 cds-synon 24755620 rs2298585 chr11 59837192 C T 3.00E-15 Vitamin B12 levels MS4A3 intron 22367966 rs10897003 chr11 59837577 T A 0.00075 Salmonella-induced pyroptosis MS4A3 intron 22837397 rs474951 chr11 59838621 T G 5.38E-05 Alzheimer's disease (late onset) / / 21460841 rs474951 chr11 59838621 T G 1.00E-06 Alzheimer's disease / / 24755620 rs539360 chr11 59839682 C A 5.39E-05 Alzheimer's disease (late onset) / / 21460841 rs543695 chr11 59845829 C A 2.19E-05 Alzheimer's disease / / 24755620 rs1151104 chr11 59847805 T A 5.64E-05 Alzheimer's disease (late onset) / / 21460841 rs558788 chr11 59852078 T G 5.89E-05 Alzheimer's disease (late onset) / / 21460841 rs558788 chr11 59852078 T G 2.03E-04 Alzheimer's disease / / 24755620 rs558678 chr11 59852113 T G 6.62E-05 Alzheimer's disease (late onset) / / 21460841 rs558678 chr11 59852113 T G 1.97E-04 Alzheimer's disease / / 24755620 rs12361312 chr11 59852596 C T 9.31E-04 Response to gemcitabine in pancreatic cancer / / 22142827 rs573790 chr11 59855385 T C 5.68E-04 Alzheimer's disease MS4A2 nearGene-5 24755620 rs1441586 chr11 59856028 T C 1.13E-04 Alzheimer's disease MS4A2 nearGene-5 24755620 rs2847663 chr11 59858036 C G 1.04E-04 Alzheimer's disease (late onset) MS4A2 intron 21460841 rs2847663 chr11 59858036 C G 1.24E-05 Alzheimer's disease MS4A2 intron 21627779 rs2847666 chr11 59859576 A G 9.86E-05 Alzheimer's disease (late onset) MS4A2 intron 21460841 rs2847666 chr11 59859576 A G 1.53E-05 Alzheimer's disease MS4A2 intron 21627779 rs2847666 chr11 59859576 A G 1.20E-05 Alzheimer's disease MS4A2 intron 24755620 rs502581 chr11 59860178 G T 2.87E-04 Alzheimer's disease MS4A2 intron 24755620 rs2583471 chr11 59861814 G A 9.69E-05 Alzheimer's disease (late onset) MS4A2 intron 21460841 rs2070970 chr11 59861983 C T 9.75E-05 Alzheimer's disease (late onset) MS4A2 intron 21460841 rs2847668 chr11 59862261 A T 9.62E-05 Alzheimer's disease (late onset) MS4A2 intron 21460841 rs512555 chr11 59863253 C A,G,T 6.62E-05 Lung adenocarcinoma MS4A2 UTR-3 19836008 rs2847655 chr11 59865671 T C 9.68E-05 Alzheimer's disease (late onset) MS4A2 UTR-3 21460841 rs2847655 chr11 59865671 T C 7.57E-05 Alzheimer's disease MS4A2 UTR-3 24755620 rs2855017 chr11 59866309 C T 9.59E-05 Alzheimer's disease (late onset) MS4A2 nearGene-3 21460841 rs17528859 chr11 59867379 T C 9.51E-05 Alzheimer's disease (late onset) / / 21460841 rs580064 chr11 59869119 T C 2.70E-04 Alzheimer's disease / / 24755620 rs562028 chr11 59877850 A C 4.12E-04 Alzheimer's disease / / 24755620 rs4939311 chr11 59877967 C T 1.37E-04 Alzheimer's disease / / 24755620 rs540170 chr11 59880038 C T 5.74E-05 Type 2 diabetes and other traits / / 19734900 rs540170 chr11 59880038 C T 1.59E-05 Alzheimer's disease / / 24755620 rs574695 chr11 59881524 G C 1.27E-04 Alzheimer's disease / / 24755620 rs581133 chr11 59882306 A G 6.18E-05 Type 2 diabetes and other traits / / 19734900 rs581133 chr11 59882306 A G 2.02E-05 Alzheimer's disease / / 24755620 rs1303615 chr11 59885120 C T 1.71E-04 Alzheimer's disease / / 24755620 rs1125357 chr11 59885493 A C 7.34E-05 Alzheimer's disease (late onset) / / 21460841 rs1125357 chr11 59885493 A C 1.40E-05 Alzheimer's disease / / 21627779 rs1303621 chr11 59890674 T C 1.93E-04 Alzheimer's disease / / 24755620 rs4939312 chr11 59900106 C T 4.79E-05 Alzheimer's disease (late onset) / / 21460841 rs4939312 chr11 59900106 C T 1.85E-04 Alzheimer's disease / / 24755620 rs525794 chr11 59903287 A G 2.24E-04 Alzheimer's disease / / 24755620 rs583296 chr11 59914726 T C 2.71E-04 Alzheimer's disease / / 24755620 rs11230160 chr11 59919165 C T 3.78E-05 Alzheimer's disease (late onset) / / 21460841 rs11230161 chr11 59920231 C A 3.55E-05 Alzheimer's disease (late onset) / / 21460841 rs11230161 chr11 59920231 C A 1.06E-05 Alzheimer's disease / / 21627779 rs11230161 chr11 59920231 C A 1.44E-04 Alzheimer's disease / / 24755620 rs34758576 chr11 59920231 CA C 3.55E-05 Alzheimer's disease (late onset) / / 21460841 rs34758576 chr11 59920231 CA C 1.06E-05 Alzheimer's disease / / 21627779 rs34758576 chr11 59920231 CA C 1.44E-04 Alzheimer's disease / / 24755620 rs983392 chr11 59923508 A G 6.00E-16 Alzheimer's disease (late onset) / / 24162737 rs11600716 chr11 59924422 G C 3.18E-05 Alzheimer's disease (late onset) / / 21460841 rs920573 chr11 59924959 G A 2.95E-05 Alzheimer's disease (late onset) / / 21460841 rs17529983 chr11 59927039 G A 2.78E-05 Alzheimer's disease (late onset) / / 21460841 rs17529983 chr11 59927039 G A 9.00E-12 FVII levels / / 21676895 rs11605427 chr11 59928672 G C 1.04E-06 Alzheimer's disease (late onset) / / 21460841 rs11605427 chr11 59928672 G C 1.45E-05 Alzheimer's disease / / 21627779 rs7933202 chr11 59936926 A C 5.53E-07 Alzheimer's disease (late onset) / / 21460841 rs7933202 chr11 59936926 A C 1.37E-05 Alzheimer's disease / / 21627779 rs667897 chr11 59936979 A G 2.47E-05 Type 2 diabetes and other traits / / 19734900 rs667897 chr11 59936979 A G 8.94E-05 Alzheimer's disease (late onset) / / 21460841 rs667897 chr11 59936979 A G 9.12E-05 Alzheimer's disease / / 24755620 rs610932 chr11 59939307 T G 1.43E-06 Type 2 diabetes and other traits MS4A6A UTR-3 19734900 rs610932 chr11 59939307 T G 2.00E-14 Alzheimer's disease MS4A6A UTR-3 21460840 rs610932 chr11 59939307 T G 2.25E-05 Alzheimer's disease (late onset) MS4A6A UTR-3 21460841 rs610932 chr11 59939307 T G 1.80E-14 Prion diseases MS4A6A UTR-3 22210626 rs610932 chr11 59939307 T G 2.41E-05 Alzheimer's disease MS4A6A UTR-3 24755620 rs610932 chr11 59939307 T G 5.21E-05 Magnesium levels MS4A6A UTR-3 pha003092 rs7232 chr11 59940599 T A 4.00E-09 Fibrinogen MS4A6A missense 23969696 rs7232 chr11 59940599 T A 6.46E-07 Alzheimer's disease (late onset) MS4A6A missense 21460841 rs7232 chr11 59940599 T A 4.00E-09 Fibrinogen MS4A6A missense 23969696 rs662196 chr11 59942757 C T 5.15E-06 Type 2 diabetes and other traits MS4A6A intron 19734900 rs662196 chr11 59942757 C T 1.67E-05 Alzheimer's disease (late onset) MS4A6A intron 21460841 rs662196 chr11 59942757 C T 3.90E-05 Alzheimer's disease MS4A6A intron 24755620 rs7935829 chr11 59942815 A G 3.71E-07 Alzheimer's disease (late onset) MS4A6A intron 21460841 rs7935829 chr11 59942815 A G 2.85E-04 Alzheimer's disease MS4A6A intron 24755620 rs2278867 chr11 59943109 A T 3.77E-07 Alzheimer's disease (late onset) MS4A6A intron 21460841 rs2278867 chr11 59943109 A T 9.93E-06 Alzheimer's disease MS4A6A intron 21627779 rs631853 chr11 59944898 T G 1.66E-05 Alzheimer's disease (late onset) MS4A6A intron 21460841 rs624663 chr11 59945065 C T 1.66E-05 Alzheimer's disease (late onset) MS4A6A intron 21460841 rs12453 chr11 59945745 T C 3.94E-07 Alzheimer's disease (late onset) MS4A6A cds-synon 21460841 rs12453 chr11 59945745 T C 4.28E-04 Alzheimer's disease MS4A6A cds-synon 24755620 rs583791 chr11 59947252 C T 5.26E-06 Type 2 diabetes and other traits MS4A6A intron 19734900 rs583791 chr11 59947252 C T 1.67E-05 Alzheimer's disease (late onset) MS4A6A intron 21460841 rs583791 chr11 59947252 C T 1.87E-09 Alzheimer's disease MS4A6A intron 21627779 rs583791 chr11 59947252 C T 6.64E-05 Alzheimer's disease MS4A6A intron 24755620 rs17602572 chr11 59948374 C G 4.19E-07 Alzheimer's disease (late onset) MS4A6A intron 21460841 rs17602572 chr11 59948374 C G 1.15E-05 Alzheimer's disease MS4A6A intron 21627779 rs632185 chr11 59951433 A G 1.69E-05 Alzheimer's disease (late onset) MS4A6A intron 21460841 rs632185 chr11 59951433 A G 7.23E-04 Alzheimer's disease MS4A6A intron 24755620 rs1834550 chr11 59959843 T C 5.40E-07 Alzheimer's disease (late onset) / / 21460841 rs1834550 chr11 59959843 T C 5.35E-06 Alzheimer's disease / / 21627779 rs10897011 chr11 59961427 G A 5.37E-07 Alzheimer's disease (late onset) / / 21460841 rs10897011 chr11 59961427 G A 8.84E-06 Alzheimer's disease / / 21627779 rs11230180 chr11 59961486 G T 1.18E-06 Alzheimer's disease (late onset) / / 21460841 rs11230180 chr11 59961486 G T 6.47E-06 Alzheimer's disease / / 21627779 rs11230180 chr11 59961486 G T 1.49E-04 Alzheimer's disease / / 24755620 rs7926344 chr11 59962166 G A 7.92E-05 Type 2 diabetes and other traits / / 19734900 rs7926344 chr11 59962166 G A 5.64E-07 Alzheimer's disease (late onset) / / 21460841 rs7926344 chr11 59962166 G A 5.48E-06 Alzheimer's disease / / 21627779 rs7926344 chr11 59962166 G A 2.71E-05 Alzheimer's disease / / 24755620 rs11230183 chr11 59965725 C T 5.71E-07 Alzheimer's disease (late onset) / / 21460841 rs11230183 chr11 59965725 C T 8.78E-06 Alzheimer's disease / / 21627779 rs11230183 chr11 59965725 C T 1.43E-04 Alzheimer's disease / / 24755620 rs2123314 chr11 59966295 T C 5.84E-06 Alzheimer's disease / / 21627779 rs2123314 chr11 59966295 T C 1.37E-04 Alzheimer's disease / / 24755620 rs670139 chr11 59971795 G T 1.40E-09 Prion diseases / / 22210626 rs7929589 chr11 59975078 C T 8.29E-05 Type 2 diabetes and other traits / / 19734900 rs7929589 chr11 59975078 C T 1.53E-05 Alzheimer's disease / / 24755620 rs4939320 chr11 59981801 T C 1.40E-07 Alzheimer's disease (late onset) MS4A4E intron 21460841 rs2081547 chr11 59989430 C T 1.34E-07 Alzheimer's disease (late onset) MS4A4E intron 21460841 rs2081547 chr11 59989430 C T 3.08E-05 Alzheimer's disease MS4A4E intron 24755620 rs11601689 chr11 59996266 G C 1.31E-07 Alzheimer's disease (late onset) MS4A4E intron 21460841 rs610352 chr11 59996968 G C 2.38E-07 Alzheimer's disease (late onset) MS4A4E intron 21460841 rs610352 chr11 59996968 G C 3.72E-04 Alzheimer's disease MS4A4E intron 24755620 rs11230201 chr11 59996994 C G 1.31E-07 Alzheimer's disease (late onset) MS4A4E intron 21460841 rs600550 chr11 59997666 C T 2.00E-11 Lipoprotein-associated phospholipase A2 activity and mass / / 23118302 rs2015475 chr11 59998963 A C 1.27E-07 Alzheimer's disease (late onset) / / 21460841 rs1426250 chr11 60001325 A G 1.21E-07 Alzheimer's disease (late onset) / / 21460841 rs676309 chr11 60001573 T C 6.28E-06 Type 2 diabetes and other traits / / 19734900 rs676309 chr11 60001573 T C 6.28E-06 Alzheimer's disease (late onset) / / 21460841 rs718376 chr11 60002935 G A 7.39E-07 Alzheimer's disease (late onset) / / 21460841 rs718376 chr11 60002935 G A 5.37E-05 Alzheimer's disease / / 24755620 rs611267 chr11 60005268 A G 4.33E-07 Alzheimer's disease (late onset) / / 21460841 rs611267 chr11 60005268 A G 4.76E-04 Alzheimer's disease / / 24755620 rs1834554 chr11 60007573 G C 3.30E-05 Alzheimer's disease (late onset) / / 21460841 rs611418 chr11 60011013 C T 1.14E-07 Alzheimer's disease (late onset) / / 21460841 rs603648 chr11 60012673 A T 1.16E-07 Alzheimer's disease (late onset) / / 21460841 rs7127662 chr11 60013117 C T 1.51E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs655231 chr11 60013857 G A 1.16E-07 Alzheimer's disease (late onset) / / 21460841 rs655231 chr11 60013857 G A 2.93E-05 Alzheimer's disease / / 24755620 rs672399 chr11 60020112 T G 1.11E-07 Alzheimer's disease (late onset) / / 21460841 rs1582763 chr11 60021948 G A 7.37E-04 Multiple complex diseases / / 17554300 rs1582763 chr11 60021948 G A 7.26E-08 Alzheimer's disease (late onset) / / 21460841 rs1582763 chr11 60021948 G A 9.55E-05 Femoral neck bone geometry / / 22087292 rs1582763 chr11 60021948 G A 1.18E-05 Alzheimer's disease / / 24755620 rs1562990 chr11 60023087 C A 1.01E-05 Type 2 diabetes and other traits / / 19734900 rs1562990 chr11 60023087 C A 5.22E-08 Alzheimer's disease (late onset) / / 21460841 rs1562990 chr11 60023087 C A 4.00E-11 Alzheimer's disease / / 21627779 rs1562990 chr11 60023087 C A 2.36E-05 Alzheimer's disease / / 24755620 rs6591559 chr11 60025565 A G 7.86E-08 Alzheimer's disease (late onset) / / 21460841 rs6591559 chr11 60025565 A G 1.94E-05 Alzheimer's disease / / 24755620 rs4938931 chr11 60026613 G T 5.26E-08 Alzheimer's disease (late onset) / / 21460841 rs4938931 chr11 60026613 G T 1.14E-05 Alzheimer's disease / / 21627779 rs4938931 chr11 60026613 G T 2.31E-05 Alzheimer's disease / / 24755620 rs7108663 chr11 60028142 C T 5.17E-08 Alzheimer's disease (late onset) / / 21460841 rs7108663 chr11 60028142 C T 1.32E-05 Alzheimer's disease / / 21627779 rs7108663 chr11 60028142 C T 2.15E-05 Alzheimer's disease / / 24755620 rs1530914 chr11 60028940 C T 8.11E-08 Alzheimer's disease (late onset) / / 21460841 rs1530914 chr11 60028940 C T 1.71E-05 Alzheimer's disease / / 24755620 rs1026255 chr11 60029949 G A 7.84E-08 Alzheimer's disease (late onset) / / 21460841 rs1026255 chr11 60029949 G A 1.32E-05 Alzheimer's disease / / 24755620 rs1026254 chr11 60030457 T C 7.70E-08 Alzheimer's disease (late onset) / / 21460841 rs1026254 chr11 60030457 T C 9.63E-06 Alzheimer's disease / / 24755620 rs4938933 chr11 60034429 C T 8.00E-12 Alzheimer's disease (late onset) / / 21460841 rs4938933 chr11 60034429 C T 1.32E-05 Alzheimer's disease / / 21627779 rs4938933 chr11 60034429 C T 1.35E-05 Alzheimer's disease / / 24755620 rs11230221 chr11 60035236 C T 3.92E-05 Post-operative nausea and vomiting / / 21694509 rs7107627 chr11 60041296 T A 5.14E-08 Alzheimer's disease (late onset) / / 21460841 rs7107627 chr11 60041296 T A 1.32E-05 Alzheimer's disease / / 21627779 rs77406754 chr11 60041989 G A 9.00E-07 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs3758866 chr11 60047502 C T 5.57E-05 Alzheimer's disease (late onset) / / 21460841 rs1026250 chr11 60054191 G C 1.20E-04 Diabetic nephropathy MS4A4A intron pha002866 rs10897024 chr11 60055651 C A 1.71E-05 Alzheimer's disease (late onset) MS4A4A intron 21460841 rs2044981 chr11 60060016 T C 4.24E-04 Alzheimer's disease MS4A4A intron 24755620 rs12146430 chr11 60066539 T G 4.54E-04 Obesity (extreme) MS4A4A intron 21935397 rs11230241 chr11 60076588 T C 3.47E-04 Multiple complex diseases / / 17554300 rs11824734 chr11 60076693 G A 3.07E-07 Alzheimer's disease (late onset) / / 21460841 rs11824734 chr11 60076693 G A 9.14E-05 Alzheimer's disease / / 24755620 rs11824773 chr11 60076940 G C 2.82E-07 Alzheimer's disease (late onset) / / 21460841 rs10792263 chr11 60079651 C T 3.17E-04 Alzheimer's disease (late onset) / / 21379329 rs10792263 chr11 60079651 C T 2.97E-07 Alzheimer's disease (late onset) / / 21460841 rs10792263 chr11 60079651 C T 1.88E-05 Alzheimer's disease / / 24755620 rs7125753 chr11 60085713 G A 2.69E-04 Multiple complex diseases / / 17554300 rs4939338 chr11 60099225 T C 3.43E-07 Alzheimer's disease (late onset) / / 21460841 rs11827324 chr11 60099912 A G 3.85E-07 Alzheimer's disease (late onset) / / 21460841 rs11230281 chr11 60107660 A C 1.11E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) MS4A6E intron 24023788 rs4939346 chr11 60122857 G A 2.05E-04 Osteoarthritis / / 19508968 rs7935082 chr11 60155000 T C 6.10E-04 Type 2 diabetes and 6 quantitative traits MS4A7 intron 17848626 rs12793970 chr11 60156484 G A 9.82E-04 Alzheimer's disease MS4A7 intron 22005930 rs2233253 chr11 60157166 C T 4.80E-04 Type 2 diabetes and 6 quantitative traits MS4A7 intron 17848626 rs2241920 chr11 60164204 G A 6.40E-04 Type 2 diabetes and 6 quantitative traits MS4A14 intron 17848626 rs3217518 chr11 60165352 ATT A 0.0000014 Stroke MS4A14 frameshift 23422753 rs12795827 chr11 60172987 T C 2.82E-04 Alzheimer's disease MS4A14 intron 22005930 rs955019 chr11 60174250 C T 7.23E-04 Type 2 diabetes MS4A14 intron 17463246 rs4938943 chr11 60174896 C T 3.20E-05 HIV-1 control MS4A14 intron 20041166 rs7106239 chr11 60178610 T C 4.41E-05 Atopic dermatitis MS4A14 intron 23042114 rs1838092 chr11 60180309 T G 4.48E-05 Monocyte chemoattractant protein-1 MS4A14 intron pha003071 rs12417082 chr11 60182449 C T 4.60E-04 Alzheimer's disease MS4A14 intron 22005930 rs1596313 chr11 60190374 A G 4.01E-05 Atopic dermatitis / / 23042114 rs3763850 chr11 60192915 G A 9.94E-04 Multiple complex diseases / / 17554300 rs3763849 chr11 60193191 C T 1.90E-20 Alzheimer's disease / / 17998437 rs12422164 chr11 60196159 T C 4.71E-04 Alzheimer's disease / / 22005930 rs11820229 chr11 60202598 T C 4.49E-04 Alzheimer's disease MS4A5 intron 22005930 rs3862661 chr11 60209388 A T 4.57E-04 Alzheimer's disease MS4A5 intron 22005930 rs12575876 chr11 60210961 G A 7.99E-04 Smoking initiation MS4A5 intron 24665060 rs10897066 chr11 60216445 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2070769 chr11 60228791 C T 4.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MS4A1 intron 20877124 rs4146870 chr11 60231986 G A 8.54E-04 Multiple complex diseases MS4A1 intron 17554300 rs1941031 chr11 60235683 G T 5.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MS4A1 intron 20877124 rs1941031 chr11 60235683 G T 7.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MS4A1 intron 20877124 rs3802957 chr11 60237410 C T 8.55E-04 Response to cytadine analogues (cytosine arabinoside) MS4A1 UTR-3 24483146 rs4447195 chr11 60249734 C T 7.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4447195 chr11 60249734 C T 8.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2155710 chr11 60269240 T C 4.55E-04 Amyotrophic lateral sclerosis (sporadic) MS4A12 intron 24529757 rs1941027 chr11 60312863 C T 4.00E-06 Metabolite levels (X-11787) / / 23934736 rs12270339 chr11 60352169 C T 5.82E-04 Smoking quantity / / 24665060 rs612342 chr11 60495124 C T 6.51E-04 Amyotrophic lateral sclerosis (sporadic) MS4A18 intron 24529757 rs6591620 chr11 60495821 C T 1.16E-04 Multiple complex diseases MS4A18 intron 17554300 rs7948556 chr11 60517887 A G 2.00E-04 Smoking initiation / / 24665060 rs4939450 chr11 60534901 G C 0.0000458 Panic disorder MS4A15 intron 23149450 rs4939450 chr11 60534901 G C 4.58E-05 Serum tamsulosin hydrochloride concentration MS4A15 intron 23151678 rs11230470 chr11 60539170 C G 5.27E-04 Suicide attempts in bipolar disorder MS4A15 intron 21423239 rs2089343 chr11 60547604 C A 1.40E-04 Psoriasis / / 20953189 rs11230480 chr11 60565244 G C 8.89E-05 Serum metabolites MS4A10 intron 19043545 rs6591625 chr11 60566362 A G 8.65E-04 Sarcoidosis MS4A10 intron 19165924 rs7935803 chr11 60566458 C T 6.38E-05 Serum metabolites MS4A10 intron 19043545 rs595018 chr11 60592276 T C 2.00E-07 Wegener's granulomatosis / / 23740775 rs1940590 chr11 60603298 G A 9.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs539890 chr11 60614010 G C 5.20E-04 Multiple complex diseases CCDC86 intron 17554300 rs530963 chr11 60617834 C A 8.14E-04 Parkinson's disease CCDC86 UTR-3 17052657 rs3888242 chr11 60636227 T C 7.83E-08 Metabolite levels ZP1 intron 23281178 rs566353 chr11 60715712 C T 1.00E-04 Schizophrenia SLC15A3 intron 19197363 rs17824933 chr11 60760612 C A,G 4.00E-09 Multiple sclerosis CD6 intron 19525953 rs17824933 chr11 60760612 C A,G 5.50E-07 Multiple sclerosis CD6 intron 21833088 rs2905516 chr11 60767694 A G 9.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CD6 intron 22566498 rs2237997 chr11 60772090 C T 1.75E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CD6 intron 22566498 rs11230563 chr11 60776209 C T 9.00E-13 Inflammatory bowel disease CD6 missense 23128233 rs2074229 chr11 60783108 C T 3.71E-04 Multiple complex diseases CD6 intron 17554300 rs4939488 chr11 60786474 T C 1.30E-13 Metabolite levels CD6 intron 22286219 rs4939490 chr11 60793651 C G 1.00E-09 Multiple sclerosis / / 21244703 rs12293191 chr11 60806747 C T 6.67E-04 Coronary heart disease / / 21971053 rs175106 chr11 60819421 A G 7.33E-04 Multiple complex diseases / / 17554300 rs175110 chr11 60824609 G T 7.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs175112 chr11 60825022 A T 2.90E-04 Multiple complex diseases / / 17554300 rs175113 chr11 60825070 G T 2.15E-11 Metabolite levels / / 22286219 rs481231 chr11 60825163 C T 2.10E-11 Metabolite levels / / 22286219 rs175114 chr11 60825197 G A 4.90E-13 Metabolite levels / / 22286219 rs175115 chr11 60825214 C T 9.93E-11 Metabolite levels / / 22286219 rs541872 chr11 60825279 G A 1.33E-12 Metabolite levels / / 22286219 rs175116 chr11 60825351 C T 2.04E-11 Metabolite levels / / 22286219 rs175117 chr11 60826076 G T 4.51E-12 Metabolite levels / / 22286219 rs175122 chr11 60830260 C A 3.74E-06 Prostate cancer mortality / / 20978177 rs7925904 chr11 60830567 T C 5.67E-04 Multiple complex diseases / / 17554300 rs650258 chr11 60832282 T C 2.00E-11 Multiple sclerosis / / 21833088 rs650258 chr11 60832282 T C 1.80E-04 Multiple sclerosis / / 24234648 rs175129 chr11 60835322 A G 5.60E-04 Tourette syndrome / / 22889924 rs175131 chr11 60836519 G A 1.37E-04 Celiac disease / / 23936387 rs3016176 chr11 60848143 T C 1.56E-05 Bone mineral density / / 19181680 rs485977 chr11 60853986 A G 3.22E-11 Metabolite levels / / 22286219 rs509936 chr11 60858031 G A 2.50E-13 Metabolite levels / / 22286219 rs477537 chr11 60859624 A C 7.76E-12 Metabolite levels / / 22286219 rs175133 chr11 60859791 C T 1.39E-20 Metabolite levels / / 22286219 rs175133 chr11 60859791 C T 1.38E-07 Metabolite levels (atherosclerosis) / / 22916037 rs612415 chr11 60859886 T A,C,G 1.37E-13 Metabolite levels / / 22286219 rs616340 chr11 60876301 G A 6.03E-11 Metabolite levels CD5 intron 22286219 rs537182 chr11 60876532 A G 5.23E-14 Metabolite levels CD5 intron 22286219 rs572350 chr11 60877211 A G 1.60E-13 Metabolite levels CD5 intron 22286219 rs522073 chr11 60878662 C T 3.58E-11 Metabolite levels CD5 intron 22286219 rs678060 chr11 60880856 A G 4.50E-11 Metabolite levels CD5 intron 22286219 rs671444 chr11 60888001 C T 7.29E-11 Metabolite levels CD5 intron 22286219 rs10792301 chr11 60888519 T C 2.84E-12 Metabolite levels CD5 intron 22286219 rs4245224 chr11 60890563 C T 6.36E-11 Metabolite levels CD5 intron 22286219 rs7925800 chr11 60890869 A G 1.08E-10 Metabolite levels CD5 intron 22286219 rs7106643 chr11 60891310 T C 1.09E-10 Metabolite levels CD5 intron 22286219 rs2229177 chr11 60893235 C T 5.95E-11 Metabolite levels CD5 missense 22286219 rs10897139 chr11 60893631 C G 1.16E-10 Metabolite levels CD5 intron 22286219 rs2186409 chr11 60894492 G T 9.17E-13 Metabolite levels CD5 UTR-3 22286219 rs7105236 chr11 60895526 C T 6.60E-11 Metabolite levels / / 22286219 rs7104333 chr11 60895533 G A 6.61E-11 Metabolite levels / / 22286219 rs10897140 chr11 60896050 C A 9.50E-11 Metabolite levels / / 22286219 rs10792302 chr11 60896165 T C 2.87E-13 Metabolite levels / / 22286219 rs10897141 chr11 60897339 T C 7.42E-11 Metabolite levels / / 22286219 rs754382 chr11 60899767 A G 6.75E-16 Metabolite levels VPS37C missense 22286219 rs2066996 chr11 60900266 C T 8.91E-11 Metabolite levels VPS37C intron 22286219 rs666886 chr11 60901112 C T 2.83E-04 Schizophrenia VPS37C intron 19197363 rs10792303 chr11 60903335 C T 6.01E-11 Metabolite levels VPS37C intron 22286219 rs668323 chr11 60905748 G C,T 3.47E-12 Metabolite levels VPS37C intron 22286219 rs508970 chr11 60906450 A G 2.70E-06 Rheumatoid arthritis VPS37C intron 24390342 rs508970 chr11 60906450 A G 3.00E-06 Rheumatoid arthritis VPS37C intron 24390342 rs595158 chr11 60909581 C A 0.00000556 Rheumatoid arthritis (CCP positive) VPS37C intron 23143596 rs595158 chr11 60909581 C A 3.99E-11 Rheumatoid arthritis VPS37C intron 23143596 rs10792306 chr11 60910740 T A 4.35E-12 Metabolite levels VPS37C intron 22286219 rs6591639 chr11 60911440 A G 7.71E-13 Metabolite levels VPS37C intron 22286219 rs614872 chr11 60911891 C A 4.29E-12 Metabolite levels VPS37C intron 22286219 rs34766626 chr11 60911892 A AG 4.55E-11 Metabolite levels VPS37C intron 22286219 rs614875 chr11 60911892 A G 4.55E-11 Metabolite levels VPS37C intron 22286219 rs507009 chr11 60911922 C T 4.29E-12 Metabolite levels VPS37C intron 22286219 rs478336 chr11 60912700 C T 4.29E-12 Metabolite levels VPS37C intron 22286219 rs612822 chr11 60912840 C T 4.29E-12 Metabolite levels VPS37C intron 22286219 rs614168 chr11 60913148 T C 4.61E-12 Metabolite levels VPS37C intron 22286219 rs615968 chr11 60913556 G C 3.43E-12 Metabolite levels VPS37C intron 22286219 rs616346 chr11 60913600 C T 4.19E-12 Metabolite levels VPS37C intron 22286219 rs663920 chr11 60914533 A G 4.31E-12 Metabolite levels VPS37C intron 22286219 rs530087 chr11 60914535 G A 4.31E-12 Metabolite levels VPS37C intron 22286219 rs677385 chr11 60915234 A T 8.39E-12 Metabolite levels VPS37C intron 22286219 rs678305 chr11 60915438 T C 4.32E-12 Metabolite levels VPS37C intron 22286219 rs657643 chr11 60915967 A G 2.25E-06 Multiple complex diseases VPS37C intron 17554300 rs657643 chr11 60915967 A G 4.14E-12 Metabolite levels VPS37C intron 22286219 rs495377 chr11 60916005 G A 4.43E-12 Metabolite levels VPS37C intron 22286219 rs515855 chr11 60917983 A G 5.24E-12 Metabolite levels VPS37C intron 22286219 rs11437675 chr11 60918029 G GT 2.39E-11 Metabolite levels VPS37C intron 22286219 rs569932213 chr11 60918029 G GT 2.39E-11 Metabolite levels VPS37C intron 22286219 rs687680 chr11 60918029 G T 2.39E-11 Metabolite levels VPS37C intron 22286219 rs688607 chr11 60918223 C T 4.38E-12 Metabolite levels VPS37C intron 22286219 rs948731 chr11 60918344 T C 4.44E-12 Metabolite levels VPS37C intron 22286219 rs948732 chr11 60918376 C T 3.64E-12 Metabolite levels VPS37C intron 22286219 rs593276 chr11 60918735 C T 3.57E-12 Metabolite levels VPS37C intron 22286219 rs628327 chr11 60919145 T C 3.49E-12 Metabolite levels VPS37C intron 22286219 rs578734 chr11 60919229 A G 3.49E-12 Metabolite levels VPS37C intron 22286219 rs519296 chr11 60919754 G A 3.50E-12 Metabolite levels VPS37C intron 22286219 rs639643 chr11 60920746 G A 3.56E-12 Metabolite levels VPS37C intron 22286219 rs98696 chr11 60921094 C T 8.01E-12 Metabolite levels VPS37C intron 22286219 rs642712 chr11 60921448 C T 4.16E-11 Metabolite levels VPS37C intron 22286219 rs655807 chr11 60922055 G A 3.79E-12 Metabolite levels VPS37C intron 22286219 rs672162 chr11 60922110 A G 3.79E-12 Metabolite levels VPS37C intron 22286219 rs656352 chr11 60922226 A G 8.22E-12 Metabolite levels VPS37C intron 22286219 rs1783873 chr11 60922835 G A 4.59E-12 Metabolite levels VPS37C intron 22286219 rs536121 chr11 60923230 A C 4.05E-12 Metabolite levels VPS37C intron 22286219 rs537009 chr11 60923319 C A 1.79E-11 Metabolite levels VPS37C intron 22286219 rs662151 chr11 60923692 C T 4.22E-12 Metabolite levels VPS37C intron 22286219 rs562522 chr11 60923787 A G 6.03E-12 Metabolite levels VPS37C intron 22286219 rs676821 chr11 60924621 C A 7.88E-12 Metabolite levels VPS37C intron 22286219 rs677303 chr11 60924738 T C 8.18E-12 Metabolite levels VPS37C intron 22286219 rs4075302 chr11 61022155 G C 7.29E-04 Multiple complex diseases / / 17554300 rs4939517 chr11 61126858 C T 9.60E-04 Suicidal ideation CYBASC3 intron 22030708 rs1037448 chr11 61134532 T C 9.60E-04 Suicidal ideation TMEM138 intron 22030708 rs17702 chr11 61213920 T C 1.31E-04 Smoking initiation SDHAF2 UTR-3 24665060 rs3741259 chr11 61282350 C T 2.76E-04 Alzheimer's disease (late onset) SYT7 UTR-3 21379329 rs3741259 chr11 61282350 C T 2.12E-13 Metabolite levels SYT7 UTR-3 22286219 rs3741259 chr11 61282350 C T 4.50E-08 Plasma omega-6 polyunsaturated fatty acid levels SYT7 UTR-3 24823311 rs3862736 chr11 61291077 A G 6.45E-05 Multiple complex diseases SYT7 intron 17554300 rs198747 chr11 61338245 G A 3.00E-04 Cognitive impairment induced by topiramate SYT7 intron 22091778 rs2429862 chr11 61379646 C T 2.30E-04 Alcohol dependence / / 20201924 rs2429862 chr11 61379646 C T 8.77E-16 Metabolite levels / / 22286219 rs11230751 chr11 61380904 G A 1.79E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230751 chr11 61380904 G A 7.27E-10 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1495941 chr11 61390368 C T 3.94E-07 Plasma omega-6 polyunsaturated fatty acid levels RPLP0P2 intron 24823311 rs10897169 chr11 61397323 G A 1.52E-08 Plasma omega-6 polyunsaturated fatty acid levels RPLP0P2 intron 24823311 rs10897169 chr11 61397323 G A 6.88E-13 Plasma omega-6 polyunsaturated fatty acid levels RPLP0P2 intron 24823311 rs1692126 chr11 61399489 G C 2.87E-08 Plasma omega-6 polyunsaturated fatty acid levels RPLP0P2 intron 24823311 rs1692126 chr11 61399489 G C 7.15E-12 Plasma omega-6 polyunsaturated fatty acid levels RPLP0P2 intron 24823311 rs12806760 chr11 61399638 G A 1.54E-08 Plasma omega-6 polyunsaturated fatty acid levels RPLP0P2 intron 24823311 rs12806760 chr11 61399638 G A 6.52E-13 Plasma omega-6 polyunsaturated fatty acid levels RPLP0P2 intron 24823311 rs1791786 chr11 61399965 T C 1.08E-14 Metabolite levels RPLP0P2 intron 22286219 rs1791786 chr11 61399965 T C 4.75E-07 Plasma omega-6 polyunsaturated fatty acid levels RPLP0P2 intron 24823311 rs17626916 chr11 61404336 G A 1.44E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs17626916 chr11 61404336 G A 2.74E-13 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs12281961 chr11 61405104 T G 1.66E-13 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs12281961 chr11 61405104 T G 8.50E-09 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230759 chr11 61405853 C A 7.71E-17 Metabolite levels / / 22286219 rs2453710 chr11 61406542 A G 7.50E-07 Phospholipid levels (plasma) / / 21829377 rs2453710 chr11 61406542 A G 1.08E-28 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2453710 chr11 61406542 A G 1.35E-12 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2453710 chr11 61406542 A G 1.61E-09 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2453710 chr11 61406542 A G 9.46E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs962371 chr11 61408285 T G 1.17E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs962371 chr11 61408285 T G 1.98E-13 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1812458 chr11 61408449 T C 1.12E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1812458 chr11 61408449 T C 1.57E-13 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1692116 chr11 61409247 G A 9.17E-22 Metabolite levels / / 22286219 rs1692116 chr11 61409247 G A 2.34E-10 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs12284414 chr11 61409462 G A 1.23E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs12284414 chr11 61409462 G A 2.17E-13 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1791796 chr11 61409958 T C 9.67E-24 Metabolite levels / / 22286219 rs4335555 chr11 61410179 C G 1.08E-13 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4335555 chr11 61410179 C G 9.42E-09 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7946679 chr11 61410345 C T 8.28E-20 Metabolite levels / / 22286219 rs2453712 chr11 61413328 C T 3.82E-19 Metabolite levels / / 22286219 rs2453712 chr11 61413328 C T 7.69E-14 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1692119 chr11 61413722 C T 4.02E-19 Metabolite levels / / 22286219 rs869112 chr11 61416970 A G 3.71E-19 Metabolite levels / / 22286219 rs1692120 chr11 61417472 G A 1.00E-08 Phospholipid levels (plasma) / / 21829377 rs1692120 chr11 61417472 G A 1.12E-14 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1692120 chr11 61417472 G A 1.45E-11 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1692120 chr11 61417472 G A 1.80E-09 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1692120 chr11 61417472 G A 2.26E-35 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs34910943 chr11 61420989 A ACTCTG,ATCTCT 4.44E-32 Metabolite levels / / 22286219 rs3932168 chr11 61420989 A G 4.44E-32 Metabolite levels / / 22286219 rs201608675 chr11 61420990 A ATCTGG 1.58E-42 Metabolite levels / / 22286219 rs3932169 chr11 61420990 A G 1.58E-42 Metabolite levels / / 22286219 rs2132390 chr11 61424995 G T 4.18E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2132390 chr11 61424995 G T 5.78E-14 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230766 chr11 61426582 A T 1.86E-18 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230766 chr11 61426582 A T 2.13E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230766 chr11 61426582 A T 9.91E-11 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230767 chr11 61426932 G A 7.66E-05 Post-operative nausea and vomiting / / 21694509 rs11230767 chr11 61426932 G A 1.59E-06 Phospholipid levels (plasma) / / 21829377 rs11230767 chr11 61426932 G A 1.49E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230767 chr11 61426932 G A 7.59E-11 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230767 chr11 61426932 G A 9.50E-19 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs6591657 chr11 61434532 G T 5.11E-19 Metabolite levels / / 22286219 rs6591657 chr11 61434532 G T 2.37E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs6591657 chr11 61434532 G T 8.04E-15 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7925523 chr11 61442492 G A 4.17E-13 Metabolite levels / / 22286219 rs1791785 chr11 61442813 C T 3.32E-13 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1791785 chr11 61442813 C T 9.24E-16 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs60399071 chr11 61443155 G A 3.35E-13 Metabolite levels / / 22286219 rs59200224 chr11 61450137 A G 5.40E-13 Metabolite levels DAGLA intron 22286219 rs59371352 chr11 61450295 G A 5.41E-13 Metabolite levels DAGLA intron 22286219 rs11230781 chr11 61450330 G A 2.69E-11 Metabolite levels DAGLA intron 22286219 rs4963307 chr11 61454190 A G 2.02E-14 Metabolite levels DAGLA intron 22286219 rs4963308 chr11 61456426 G A 5.35E-13 Metabolite levels DAGLA intron 22286219 rs4963308 chr11 61456426 G A 2.67E-09 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs4963308 chr11 61456426 G A 2.81E-06 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs883724 chr11 61457857 C T 4.01E-13 Metabolite levels DAGLA intron 22286219 rs883724 chr11 61457857 C T 2.43E-09 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs883724 chr11 61457857 C T 2.87E-06 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs11827215 chr11 61458595 G A 5.56E-13 Metabolite levels DAGLA intron 22286219 rs11827215 chr11 61458595 G A 2.54E-09 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs11827215 chr11 61458595 G A 2.68E-06 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs12794220 chr11 61462412 C T 9.30E-06 Urinary metabolites DAGLA intron 21572414 rs12794220 chr11 61462412 C T 5.14E-10 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs12794220 chr11 61462412 C T 8.20E-15 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs3931642 chr11 61462424 C A 2.22E-11 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs3931642 chr11 61462424 C A 9.47E-07 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198456 chr11 61463388 A G 1.41E-09 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198456 chr11 61463388 A G 3.30E-06 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198456 chr11 61463388 A G 5.81E-15 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs60507107 chr11 61463769 C T 2.52E-12 Metabolite levels DAGLA intron 22286219 rs198453 chr11 61464550 C T 1.04E-11 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198453 chr11 61464550 C T 3.67E-12 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs2097853 chr11 61466267 G T 2.31E-13 Metabolite levels DAGLA intron 22286219 rs198452 chr11 61467603 G A 7.88E-05 Serum metabolites DAGLA intron 19043545 rs198452 chr11 61467603 G A 6.61E-13 Metabolite levels DAGLA intron 22286219 rs17827918 chr11 61468165 G A 1.64E-15 Metabolite levels DAGLA intron 22286219 rs17827918 chr11 61468165 G A 1.63E-11 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs17827918 chr11 61468165 G A 3.51E-06 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs58217294 chr11 61469503 T A 1.01E-13 Metabolite levels DAGLA intron 22286219 rs879486 chr11 61475233 T C 2.77E-09 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs879486 chr11 61475233 T C 4.84E-08 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs2003019 chr11 61475467 T G 5.76E-14 Metabolite levels DAGLA intron 22286219 rs12274157 chr11 61477647 A C 5.00E-15 Metabolite levels DAGLA intron 22286219 rs12274157 chr11 61477647 A C 1.14E-06 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs12274157 chr11 61477647 A C 7.11E-11 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198437 chr11 61479322 G A 1.15E-13 Metabolite levels DAGLA intron 22286219 rs731842 chr11 61480191 T C 3.55E-16 Metabolite levels DAGLA intron 22286219 rs198436 chr11 61482046 C T 2.10E-05 Urinary metabolites DAGLA intron 21572414 rs198436 chr11 61482046 C T 2.10E-15 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198436 chr11 61482046 C T 2.73E-06 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198436 chr11 61482046 C T 3.71E-10 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs17156244 chr11 61482395 T G 3.30E-17 Metabolite levels DAGLA intron 22286219 rs198435 chr11 61483324 G C 2.16E-22 Metabolite levels DAGLA intron 22286219 rs198435 chr11 61483324 G C 1.77E-08 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198435 chr11 61483324 G C 3.03E-15 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198432 chr11 61484981 C A 3.87E-05 Prion diseases DAGLA intron 22210626 rs198432 chr11 61484981 C A 3.31E-14 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198432 chr11 61484981 C A 9.70E-14 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198430 chr11 61487690 G A 1.18E-14 Plasma omega-6 polyunsaturated fatty acid levels DAGLA cds-synon 24823311 rs198430 chr11 61487690 G A 8.71E-19 Plasma omega-6 polyunsaturated fatty acid levels DAGLA cds-synon 24823311 rs81658 chr11 61487944 G A 1.01E-14 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs81658 chr11 61487944 G A 3.82E-19 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs2903825 chr11 61488968 C T 2.26E-19 Metabolite levels DAGLA intron 22286219 rs198428 chr11 61489705 A T 4.62E-07 Phospholipid levels (plasma) DAGLA intron 21829377 rs198428 chr11 61489705 A T 1.05E-06 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198428 chr11 61489705 A T 1.11E-19 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198428 chr11 61489705 A T 1.79E-12 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198428 chr11 61489705 A T 3.66E-07 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs17156254 chr11 61490245 G A 2.82E-12 Metabolite levels DAGLA intron 22286219 rs198426 chr11 61490486 C T 3.00E-09 Phospholipid levels (plasma) DAGLA intron 21829377 rs198426 chr11 61490486 C T 1.38E-30 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198426 chr11 61490486 C T 1.87E-10 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198426 chr11 61490486 C T 2.43E-19 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198426 chr11 61490486 C T 4.83E-07 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198426 chr11 61490486 C T 5.29E-06 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs9735635 chr11 61490880 C A 1.16E-19 Metabolite levels DAGLA intron 22286219 rs9735635 chr11 61490880 C A 1.39E-06 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs9735635 chr11 61490880 C A 5.64E-11 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198425 chr11 61491431 A T 1.06E-14 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198425 chr11 61491431 A T 2.80E-19 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs12285167 chr11 61492039 C A 2.31E-11 Metabolite levels DAGLA intron 22286219 rs12285167 chr11 61492039 C A 1.05E-12 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs12285167 chr11 61492039 C A 6.30E-08 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs4963243 chr11 61494327 G A 1.09E-19 Metabolite levels DAGLA intron 22286219 rs4963243 chr11 61494327 G A 2.00E-07 Immune reponse to smallpox (secreted IL-2) DAGLA intron 22610502 rs4963243 chr11 61494327 G A 1.50E-06 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs4963243 chr11 61494327 G A 5.58E-11 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198418 chr11 61496272 A C 1.14E-14 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198418 chr11 61496272 A C 2.01E-19 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198448 chr11 61500487 C T 3.02E-05 Prion diseases DAGLA intron 22210626 rs198448 chr11 61500487 C T 6.31E-11 Metabolite levels DAGLA intron 22286219 rs2013326 chr11 61501276 G A 1.61E-11 Metabolite levels DAGLA intron 22286219 rs198447 chr11 61501592 A G 4.06E-21 Metabolite levels DAGLA intron 22286219 rs34290859 chr11 61501919 C G 4.36E-11 Metabolite levels DAGLA intron 22286219 rs740004 chr11 61502910 C T 4.53E-11 Metabolite levels DAGLA intron 22286219 rs198446 chr11 61503381 G A 1.88E-06 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198446 chr11 61503381 G A 2.64E-15 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198446 chr11 61503381 G A 6.48E-21 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198444 chr11 61505168 G A 1.23E-13 Metabolite levels DAGLA cds-synon 22286219 rs198444 chr11 61505168 G A 2.15E-09 Plasma omega-6 polyunsaturated fatty acid levels DAGLA cds-synon 24823311 rs198444 chr11 61505168 G A 3.04E-06 Plasma omega-6 polyunsaturated fatty acid levels DAGLA cds-synon 24823311 rs2240287 chr11 61505583 G A 3.16E-20 Metabolite levels DAGLA intron 22286219 rs2240287 chr11 61505583 G A 1.02E-06 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs2240287 chr11 61505583 G A 2.30E-11 Plasma omega-6 polyunsaturated fatty acid levels DAGLA intron 24823311 rs198443 chr11 61505696 G T 5.29E-17 Metabolite levels DAGLA intron 22286219 rs61896065 chr11 61506250 C T 3.41E-11 Metabolite levels DAGLA intron 22286219 rs2240286 chr11 61506454 T C 8.05E-33 Metabolite levels DAGLA intron 22286219 rs198442 chr11 61506468 C T 6.83E-19 Metabolite levels DAGLA intron 22286219 rs736121 chr11 61506584 C T 1.13E-11 Metabolite levels DAGLA intron 22286219 rs35571184 chr11 61507569 G C 3.67E-11 Metabolite levels DAGLA intron 22286219 rs4963255 chr11 61507606 G A 3.10E-20 Metabolite levels DAGLA intron 22286219 rs11828739 chr11 61508074 C T 3.78E-11 Metabolite levels DAGLA intron 22286219 rs3741251 chr11 61511133 G A 1.99E-11 Metabolite levels DAGLA cds-synon 22286219 rs3741252 chr11 61511498 C T 1.34E-11 Metabolite levels DAGLA missense 22286219 rs61896067 chr11 61512560 G A 2.25E-11 Metabolite levels DAGLA UTR-3 22286219 rs2014094 chr11 61513952 G A 2.55E-11 Metabolite levels DAGLA UTR-3 22286219 rs4963391 chr11 61514851 C T 2.87E-11 Metabolite levels / / 22286219 rs12282125 chr11 61515405 C T 3.14E-11 Metabolite levels / / 22286219 rs198422 chr11 61515767 T C 3.91E-15 Metabolite levels / / 22286219 rs3825036 chr11 61516476 G A 7.97E-21 Metabolite levels / / 22286219 rs3825036 chr11 61516476 G A 1.81E-11 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs3825036 chr11 61516476 G A 9.82E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs198421 chr11 61518237 G A 1.77E-11 Metabolite levels / / 22286219 rs569258 chr11 61520668 T C 4.37E-10 Phospholipid levels (plasma) C11orf9 intron 21829377 rs569258 chr11 61520668 T C 1.97E-06 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs569258 chr11 61520668 T C 2.49E-10 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs569258 chr11 61520668 T C 3.23E-07 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs569258 chr11 61520668 T C 3.27E-34 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs569258 chr11 61520668 T C 9.01E-21 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198464 chr11 61521621 G A 7.47E-12 Phospholipid levels (plasma) C11orf9 intron 21829377 rs198464 chr11 61521621 G A 2.40E-10 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198464 chr11 61521621 G A 3.48E-16 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198464 chr11 61521621 G A 5.05E-26 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198464 chr11 61521621 G A 5.47E-59 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198464 chr11 61521621 G A 5.72E-12 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs2238003 chr11 61523735 C T 1.46E-07 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs2238003 chr11 61523735 C T 3.78E-11 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198462 chr11 61524119 G A 7.64E-12 Phospholipid levels (plasma) C11orf9 intron 21829377 rs198462 chr11 61524119 G A 1.10E-10 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198462 chr11 61524119 G A 1.16E-60 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198462 chr11 61524119 G A 2.00E-11 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198462 chr11 61524119 G A 2.46E-17 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198462 chr11 61524119 G A 3.97E-26 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs2238001 chr11 61524507 T C 1.32E-08 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198459 chr11 61525020 G A 2.30E-12 Metabolite levels C11orf9 intron 22286219 rs198476 chr11 61525730 G A 8.38E-12 Phospholipid levels (plasma) C11orf9 intron 21829377 rs198476 chr11 61525730 G A 1.35E-11 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198476 chr11 61525730 G A 1.74E-10 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198476 chr11 61525730 G A 1.94E-60 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198476 chr11 61525730 G A 2.94E-26 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198476 chr11 61525730 G A 6.84E-17 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198475 chr11 61526071 T C 6.48E-05 Sphingolipid levels C11orf9 intron 19798445 rs198475 chr11 61526071 T C 1.14E-13 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198475 chr11 61526071 T C 1.23E-08 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198475 chr11 61526071 T C 1.74E-40 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198475 chr11 61526071 T C 2.27E-17 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198473 chr11 61526556 G A 1.10E-08 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198473 chr11 61526556 G A 1.31E-17 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198473 chr11 61526556 G A 8.18E-41 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs198473 chr11 61526556 G A 8.31E-14 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs11230796 chr11 61529267 T G 2.10E-13 Metabolite levels C11orf9 intron 22286219 rs2071212 chr11 61530837 C G 3.50E-07 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs10792318 chr11 61531443 A G 1.65E-16 Metabolite levels C11orf9 intron 22286219 rs55903902 chr11 61531991 A G 1.11E-16 Metabolite levels C11orf9 intron 22286219 rs198467 chr11 61533908 T C 2.14E-13 Metabolite levels C11orf9 intron 22286219 rs2071213 chr11 61534010 C T 1.14E-06 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs547589 chr11 61534872 A C 9.11E-16 Metabolite levels C11orf9 intron 22286219 rs650436 chr11 61536430 C T 1.11E-15 Phospholipid levels (plasma) C11orf9 intron 21829377 rs650436 chr11 61536430 C T 4.56E-17 Metabolite levels C11orf9 intron 22286219 rs650436 chr11 61536430 C T 1.67E-11 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs650436 chr11 61536430 C T 1.75E-57 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs650436 chr11 61536430 C T 4.84E-08 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs650436 chr11 61536430 C T 6.56E-12 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs650436 chr11 61536430 C T 9.68E-29 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs579383 chr11 61536583 G A 1.12E-14 Phospholipid levels (plasma) C11orf9 intron 21829377 rs579383 chr11 61536583 G A 4.99E-17 Metabolite levels C11orf9 intron 22286219 rs579383 chr11 61536583 G A 1.71E-10 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs579383 chr11 61536583 G A 2.15E-07 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs579383 chr11 61536583 G A 2.76E-11 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs579383 chr11 61536583 G A 2.81E-26 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs579383 chr11 61536583 G A 7.42E-52 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs2269928 chr11 61537529 T G 6.19E-41 Phospholipid levels (plasma) C11orf9 intron 21829377 rs2269928 chr11 61537529 T G 5.92E-19 Metabolite levels C11orf9 intron 22286219 rs2269928 chr11 61537529 T G 1.42E-25 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs2269928 chr11 61537529 T G 1.88E-66 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs2269928 chr11 61537529 T G 2.24E-38 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs2269928 chr11 61537529 T G 3.13E-211 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs2269928 chr11 61537529 T G 3.65E-62 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs149804 chr11 61538606 A G 4.98E-12 Metabolite levels C11orf9 intron 22286219 rs149803 chr11 61539020 C G 7.47E-40 Phospholipid levels (plasma) C11orf9 cds-synon 21829377 rs149803 chr11 61539020 C G 5.04E-27 Metabolite levels C11orf9 cds-synon 22286219 rs149803 chr11 61539020 C G 1.15E-41 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 cds-synon 24823311 rs149803 chr11 61539020 C G 1.46E-80 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 cds-synon 24823311 rs149803 chr11 61539020 C G 3.29E-33 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 cds-synon 24823311 rs149803 chr11 61539020 C G 3.73E-22 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 cds-synon 24823311 rs149803 chr11 61539020 C G 4.36E-171 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 cds-synon 24823311 rs628993 chr11 61539691 G A 7.43E-12 Metabolite levels C11orf9 intron 22286219 rs174528 chr11 61543499 T C 8.40E-05 Response to statin therapy C11orf9 intron 20339536 rs174528 chr11 61543499 T C 1.13E-135 Phospholipid levels (plasma) C11orf9 intron 21829377 rs174528 chr11 61543499 T C 3.98E-186 Metabolite levels C11orf9 intron 22286219 rs174528 chr11 61543499 T C 8.26E-17 Metabolite levels C11orf9 intron 23281178 rs174528 chr11 61543499 T C 2.81E-65 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174528 chr11 61543499 T C 3.05E-249 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174528 chr11 61543499 T C 5.54E-134 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174528 chr11 61543499 T C 6.83E-119 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174528 chr11 61543499 T C 3.16E-08 P wave duration C11orf9 intron 24850809 rs174529 chr11 61543961 T C 1.34E-259 Metabolite levels C11orf9 intron 22286219 rs174530 chr11 61546592 A G 1.43E-259 Metabolite levels C11orf9 intron 22286219 rs7943728 chr11 61547068 G A 3.66E-42 Metabolite levels C11orf9 intron 22286219 rs108499 chr11 61547237 C T 2.52E-121 Phospholipid levels (plasma) C11orf9 intron 21829377 rs108499 chr11 61547237 C T 4.20E-181 Metabolite levels C11orf9 intron 22286219 rs108499 chr11 61547237 C T 1.26E-15 Metabolite levels C11orf9 intron 23281178 rs108499 chr11 61547237 C T 1.04E-54 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs108499 chr11 61547237 C T 2.36E-208 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs108499 chr11 61547237 C T 3.68E-135 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs108499 chr11 61547237 C T 7.07E-102 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs509360 chr11 61548559 A G 4.61E-05 Sphingolipid levels C11orf9 intron 19798445 rs509360 chr11 61548559 A G 1.04E-36 Phospholipid levels (plasma) C11orf9 intron 21829377 rs509360 chr11 61548559 A G 9.91E-95 Metabolite levels C11orf9 intron 22286219 rs509360 chr11 61548559 A G 1.07E-42 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs509360 chr11 61548559 A G 6.27E-21 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs509360 chr11 61548559 A G 6.76E-65 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs509360 chr11 61548559 A G 7.08E-251 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs509360 chr11 61548559 A G 9.52E-82 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs61747222 chr11 61548796 G A 7.40E-12 Metabolite levels C11orf9 missense 22286219 rs174532 chr11 61548874 G A 5.19E-51 Phospholipid levels (plasma) C11orf9 intron 21829377 rs174532 chr11 61548874 G A 7.70E-31 Metabolite levels C11orf9 intron 22286219 rs174532 chr11 61548874 G A 1.08E-89 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174532 chr11 61548874 G A 1.23E-184 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174532 chr11 61548874 G A 1.60E-45 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174532 chr11 61548874 G A 2.11E-35 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174532 chr11 61548874 G A 3.53E-25 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174533 chr11 61549025 G A 6.99E-265 Metabolite levels C11orf9 intron 22286219 rs174534 chr11 61549458 A G 7.27E-04 Type 2 diabetes C11orf9 intron 17463246 rs174534 chr11 61549458 A G 5.68E-06 Serum metabolites C11orf9 intron 19043545 rs174534 chr11 61549458 A G 7.68E-07 Lung cancer C11orf9 intron 21725308 rs174534 chr11 61549458 A G 8.26E-122 Phospholipid levels (plasma) C11orf9 intron 21829377 rs174534 chr11 61549458 A G 1.04E-180 Metabolite levels C11orf9 intron 22286219 rs174534 chr11 61549458 A G 5.06E-16 Metabolite levels C11orf9 intron 23281178 rs174534 chr11 61549458 A G 1.34E-54 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174534 chr11 61549458 A G 1.89E-208 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174534 chr11 61549458 A G 7.28E-102 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174534 chr11 61549458 A G 8.89E-135 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174535 chr11 61551356 T A,C,G 1.10E-05 Response to statin therapy C11orf9 cds-synon 20339536 rs174535 chr11 61551356 T A,C,G 1.00E-151 Phospholipid levels (plasma) C11orf9 cds-synon 21829377 rs174535 chr11 61551356 T A,C,G 6.00E-58 Phospholipid levels (plasma) C11orf9 cds-synon 21829377 rs174535 chr11 61551356 T A,C,G 3.66E-265 Metabolite levels C11orf9 cds-synon 22286219 rs174535 chr11 61551356 T A,C,G 1.02E-15 HDL cholesterol C11orf9 cds-synon 23063622 rs174535 chr11 61551356 T A,C,G 5.08E-10 LDL cholesterol C11orf9 cds-synon 23063622 rs174535 chr11 61551356 T A,C,G 5.50E-11 Cholesterol,total C11orf9 cds-synon 23063622 rs174535 chr11 61551356 T A,C,G 8.31E-15 Triglycerides C11orf9 cds-synon 23063622 rs174535 chr11 61551356 T A,C,G 1.48E-18 Metabolite levels C11orf9 cds-synon 23281178 rs174535 chr11 61551356 T A,C,G 2.00E-94 Blood metabolite levels C11orf9 cds-synon 24816252 rs174535 chr11 61551356 T A,C,G 3.00E-36 Blood metabolite levels C11orf9 cds-synon 24816252 rs174535 chr11 61551356 T A,C,G 1.04E-273 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 cds-synon 24823311 rs174535 chr11 61551356 T A,C,G 3.51E-72 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 cds-synon 24823311 rs174535 chr11 61551356 T A,C,G 3.73E-138 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 cds-synon 24823311 rs174535 chr11 61551356 T A,C,G 3.96E-151 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 cds-synon 24823311 rs174536 chr11 61551927 A C 1.10E-05 Response to statin therapy C11orf9 intron 20339536 rs174536 chr11 61551927 A C 1.00E-63 Phospholipid levels (plasma) C11orf9 intron 21829377 rs174536 chr11 61551927 A C 1.79E-266 Metabolite levels C11orf9 intron 22286219 rs174536 chr11 61551927 A C 1.48E-18 Metabolite levels C11orf9 intron 23281178 rs174536 chr11 61551927 A C 1.09E-273 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174536 chr11 61551927 A C 2.12E-151 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174536 chr11 61551927 A C 3.36E-138 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174536 chr11 61551927 A C 3.65E-72 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174537 chr11 61552680 G T 5.95E-46 Triglycerides C11orf9 intron 19074352 rs174537 chr11 61552680 G T 1.04E-14 Polyunsaturated fatty acid levels,in plasma C11orf9 intron 19148276 rs174537 chr11 61552680 G T 2.76E-05 Polyunsaturated fatty acid levels,in plasma C11orf9 intron 19148276 rs174537 chr11 61552680 G T 5.58E-07 Polyunsaturated fatty acid levels,in plasma C11orf9 intron 19148276 rs174537 chr11 61552680 G T 5.95E-46 Polyunsaturated fatty acid levels,in plasma C11orf9 intron 19148276 rs174537 chr11 61552680 G T 6.78E-09 Polyunsaturated fatty acid levels,in plasma C11orf9 intron 19148276 rs174537 chr11 61552680 G T 7.00E-04 Polyunsaturated fatty acid levels,in plasma C11orf9 intron 19148276 rs174537 chr11 61552680 G T 9.04E-12 Sphingolipid levels C11orf9 intron 19798445 rs174537 chr11 61552680 G T 4.50E-09 Lipid levels C11orf9 intron 19936222 rs174537 chr11 61552680 G T 7.57E-14 Lipid levels C11orf9 intron 19936222 rs174537 chr11 61552680 G T 1.40E-05 Response to statin therapy C11orf9 intron 20339536 rs174537 chr11 61552680 G T 4.29E-06 Phospholipid levels (plasma) C11orf9 intron 21829377 rs174537 chr11 61552680 G T 3.51E-264 Metabolite levels C11orf9 intron 22286219 rs174537 chr11 61552680 G T 2.35E-17 Fasting blood glucose C11orf9 intron 22885924 rs174537 chr11 61552680 G T 6.57E-05 Prostate cancer C11orf9 intron 22923026 rs174537 chr11 61552680 G T 1.48E-18 Metabolite levels C11orf9 intron 23281178 rs174537 chr11 61552680 G T 1.02E-71 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174537 chr11 61552680 G T 1.18E-271 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174537 chr11 61552680 G T 5.10E-151 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174537 chr11 61552680 G T 7.71E-138 Plasma omega-6 polyunsaturated fatty acid levels C11orf9 intron 24823311 rs174537 chr11 61552680 G T 9.00E-21 Colorectal cancer C11orf9 intron 24836286 rs174537 chr11 61552680 G T 7.24E-06 LDL lipoproteins C11orf9 intron pha002902 rs17762402 chr11 61553201 G A 1.42E-13 Phospholipid levels (plasma) C11orf9 intron 21829377 rs17762402 chr11 61553201 G A 1.35E-21 Metabolite levels C11orf9 intron 22286219 rs61896141 chr11 61556039 A C 2.11E-14 Metabolite levels / / 22286219 rs102275 chr11 61557803 T C 2.15E-11 Sphingolipid levels C11orf10 intron 19798445 rs102275 chr11 61557803 T C 1.40E-14 Lipid levels C11orf10 intron 19936222 rs102275 chr11 61557803 T C 2.20E-05 Response to statin therapy C11orf10 intron 20339536 rs102275 chr11 61557803 T C 6.00E-07 Metabolic syndrome C11orf10 intron 20694148 rs102275 chr11 61557803 T C 2.00E-11 Crohn's disease C11orf10 intron 21102463 rs102275 chr11 61557803 T C 7.00E-64 Phospholipid levels (plasma) C11orf10 intron 21829377 rs102275 chr11 61557803 T C 8.00E-153 Phospholipid levels (plasma) C11orf10 intron 21829377 rs102275 chr11 61557803 T C 6.66E-268 Metabolite levels C11orf10 intron 22286219 rs102275 chr11 61557803 T C 1.00E-203 Phospholipid levels (plasma) C11orf10 intron 22359512 rs102275 chr11 61557803 T C 4.00E-264 Metabolite levels (atherosclerosis) C11orf10 intron 22916037 rs102275 chr11 61557803 T C 6.15E-05 Prostate cancer C11orf10 intron 22923026 rs102275 chr11 61557803 T C 1.34E-09 LDL cholesterol C11orf10 intron 23063622 rs102275 chr11 61557803 T C 1.95E-15 HDL cholesterol C11orf10 intron 23063622 rs102275 chr11 61557803 T C 5.03E-10 Cholesterol,total C11orf10 intron 23063622 rs102275 chr11 61557803 T C 7.12E-16 Triglycerides C11orf10 intron 23063622 rs102275 chr11 61557803 T C 1.48E-18 Metabolite levels C11orf10 intron 23281178 rs102275 chr11 61557803 T C 1.00E-20 Stearic acid (18:0) plasma levels C11orf10 intron 23362303 rs102275 chr11 61557803 T C 2.00E-32 Oleic acid (18:1n-9) plasma levels C11orf10 intron 23362303 rs102275 chr11 61557803 T C 7.00E-13 Palmitoleic acid (16:1n-7) plasma levels C11orf10 intron 23362303 rs102275 chr11 61557803 T C 1.52E-151 Plasma omega-6 polyunsaturated fatty acid levels C11orf10 intron 24823311 rs102275 chr11 61557803 T C 1.59E-136 Plasma omega-6 polyunsaturated fatty acid levels C11orf10 intron 24823311 rs102275 chr11 61557803 T C 3.01E-271 Plasma omega-6 polyunsaturated fatty acid levels C11orf10 intron 24823311 rs102275 chr11 61557803 T C 4.37E-71 Plasma omega-6 polyunsaturated fatty acid levels C11orf10 intron 24823311 rs102275 chr11 61557803 T C 7.00E-147 Plasma omega-6 polyunsaturated fatty acid levels C11orf10 intron 24823311 rs102275 chr11 61557803 T C 6.51E-06 LDL lipoproteins C11orf10 intron pha002902 rs102275 chr11 61557803 T C 8.28E-05 Left ventricular hypertrophy C11orf10 intron pha003052 rs102274 chr11 61557826 T C 6.55E-268 Metabolite levels C11orf10 intron 22286219 rs740006 chr11 61557868 T C 4.50E-22 Phospholipid levels (plasma) C11orf10 intron 21829377 rs740006 chr11 61557868 T C 3.70E-37 Metabolite levels C11orf10 intron 22286219 rs7102974 chr11 61560035 C T 3.03E-07 Phospholipid levels (plasma) C11orf10 UTR-5 21829377 rs174538 chr11 61560081 G A 1.80E-05 Response to statin therapy C11orf10 UTR-5 20339536 rs174538 chr11 61560081 G A 5.00E-58 Phospholipid levels (plasma) C11orf10 UTR-5 21829377 rs174538 chr11 61560081 G A 1.22E-191 Metabolite levels C11orf10 UTR-5 22286219 rs174538 chr11 61560081 G A 1.72E-15 Metabolite levels C11orf10 UTR-5 23281178 rs174538 chr11 61560081 G A 9.00E-14 Blood metabolite levels C11orf10 UTR-5 24816252 rs174538 chr11 61560081 G A 1.47E-154 Plasma omega-6 polyunsaturated fatty acid levels C11orf10 UTR-5 24823311 rs174538 chr11 61560081 G A 4.21E-228 Plasma omega-6 polyunsaturated fatty acid levels C11orf10 UTR-5 24823311 rs174538 chr11 61560081 G A 4.89E-120 Plasma omega-6 polyunsaturated fatty acid levels C11orf10 UTR-5 24823311 rs174538 chr11 61560081 G A 5.21E-59 Plasma omega-6 polyunsaturated fatty acid levels C11orf10 UTR-5 24823311 rs412334 chr11 61560261 C T 1.40E-26 Phospholipid levels (plasma) FEN1 UTR-5 21829377 rs412334 chr11 61560261 C T 5.25E-17 Metabolite levels FEN1 UTR-5 22286219 rs412334 chr11 61560261 C T 1.11E-18 Plasma omega-6 polyunsaturated fatty acid levels FEN1 UTR-5 24823311 rs412334 chr11 61560261 C T 2.05E-23 Plasma omega-6 polyunsaturated fatty acid levels FEN1 UTR-5 24823311 rs412334 chr11 61560261 C T 2.28E-89 Plasma omega-6 polyunsaturated fatty acid levels FEN1 UTR-5 24823311 rs412334 chr11 61560261 C T 4.06E-11 Plasma omega-6 polyunsaturated fatty acid levels FEN1 UTR-5 24823311 rs412334 chr11 61560261 C T 6.24E-47 Plasma omega-6 polyunsaturated fatty acid levels FEN1 UTR-5 24823311 rs695867 chr11 61561288 A G 1.52E-08 Phospholipid levels (plasma) FEN1 intron 21829377 rs695867 chr11 61561288 A G 2.85E-37 Plasma omega-6 polyunsaturated fatty acid levels FEN1 intron 24823311 rs695867 chr11 61561288 A G 3.11E-08 Plasma omega-6 polyunsaturated fatty acid levels FEN1 intron 24823311 rs695867 chr11 61561288 A G 3.93E-07 Plasma omega-6 polyunsaturated fatty acid levels FEN1 intron 24823311 rs695867 chr11 61561288 A G 5.73E-20 Plasma omega-6 polyunsaturated fatty acid levels FEN1 intron 24823311 rs4246215 chr11 61564299 G T 1.24E-06 Serum metabolites FEN1 UTR-3 19043545 rs4246215 chr11 61564299 G T 2.70E-05 Response to statin therapy FEN1 UTR-3 20339536 rs4246215 chr11 61564299 G T 9.35E-07 Lung cancer FEN1 UTR-3 21725308 rs4246215 chr11 61564299 G T 1.00E-139 Phospholipid levels (plasma) FEN1 UTR-3 21829377 rs4246215 chr11 61564299 G T 6.00E-55 Phospholipid levels (plasma) FEN1 UTR-3 21829377 rs4246215 chr11 61564299 G T 9.00E-60 Phospholipid levels (plasma) FEN1 UTR-3 21829377 rs4246215 chr11 61564299 G T 3.00E-10 Platelet counts FEN1 UTR-3 22139419 rs4246215 chr11 61564299 G T 1.06E-248 Metabolite levels FEN1 UTR-3 22286219 rs4246215 chr11 61564299 G T 2.00E-15 Inflammatory bowel disease FEN1 UTR-3 23128233 rs4246215 chr11 61564299 G T 6.21E-18 Metabolite levels FEN1 UTR-3 23281178 rs4246215 chr11 61564299 G T 1.19E-257 Plasma omega-6 polyunsaturated fatty acid levels FEN1 UTR-3 24823311 rs4246215 chr11 61564299 G T 2.23E-142 Plasma omega-6 polyunsaturated fatty acid levels FEN1 UTR-3 24823311 rs4246215 chr11 61564299 G T 2.95E-124 Plasma omega-6 polyunsaturated fatty acid levels FEN1 UTR-3 24823311 rs4246215 chr11 61564299 G T 4.81E-68 Plasma omega-6 polyunsaturated fatty acid levels FEN1 UTR-3 24823311 rs4246215 chr11 61564299 G T 7.65E-20 Colorectal cancer FEN1 UTR-3 24836286 rs174541 chr11 61565908 T C 2.70E-05 Response to statin therapy / / 20339536 rs174541 chr11 61565908 T C 2.30E-140 Phospholipid levels (plasma) / / 21829377 rs174541 chr11 61565908 T C 1.10E-08 LDL cholesterol / / 21977987 rs174541 chr11 61565908 T C 4.33E-259 Metabolite levels / / 22286219 rs174541 chr11 61565908 T C 1.40E-17 Metabolite levels / / 23281178 rs174541 chr11 61565908 T C 3.00E-09 Metabolite levels (Glycine metabolism) / / 23378610 rs174541 chr11 61565908 T C 1.75E-124 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174541 chr11 61565908 T C 2.20E-68 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174541 chr11 61565908 T C 4.90E-143 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174541 chr11 61565908 T C 4.90E-258 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174544 chr11 61567753 C A 1.25E-243 Metabolite levels FADS1 UTR-3 22286219 rs174545 chr11 61569306 C G 3.90E-06 Response to statin therapy FADS1 UTR-3 20339536 rs174545 chr11 61569306 C G 3.48E-06 Phospholipid levels (plasma) FADS1 UTR-3 21829377 rs174545 chr11 61569306 C G 1.62E-259 Metabolite levels FADS1 UTR-3 22286219 rs174545 chr11 61569306 C G 1.48E-18 Metabolite levels FADS1 UTR-3 23281178 rs174545 chr11 61569306 C G 2.22E-139 Plasma omega-6 polyunsaturated fatty acid levels FADS1 UTR-3 24823311 rs174545 chr11 61569306 C G 2.30E-151 Plasma omega-6 polyunsaturated fatty acid levels FADS1 UTR-3 24823311 rs174545 chr11 61569306 C G 3.49E-72 Plasma omega-6 polyunsaturated fatty acid levels FADS1 UTR-3 24823311 rs174545 chr11 61569306 C G 4.37E-273 Plasma omega-6 polyunsaturated fatty acid levels FADS1 UTR-3 24823311 rs174546 chr11 61569830 C T 1.00E-07 LDL cholesterol FADS1 UTR-3 19060910 rs174546 chr11 61569830 C T 5.49E-15 Triglycerides FADS1 UTR-3 19074352 rs174546 chr11 61569830 C T 1.60E-06 Polyunsaturated fatty acid levels,in plasma FADS1 UTR-3 19148276 rs174546 chr11 61569830 C T 5.49E-15 Polyunsaturated fatty acid levels,in plasma FADS1 UTR-3 19148276 rs174546 chr11 61569830 C T 2.00E-11 Sphingolipid levels FADS1 UTR-3 19798445 rs174546 chr11 61569830 C T 9.77E-11 Lipid levels FADS1 UTR-3 19936222 rs174546 chr11 61569830 C T 3.50E-06 Response to statin therapy FADS1 UTR-3 20339536 rs174546 chr11 61569830 C T 1.00E-21 LDL cholesterol FADS1 UTR-3 20686565 rs174546 chr11 61569830 C T 2.00E-22 HDL cholesterol FADS1 UTR-3 20686565 rs174546 chr11 61569830 C T 5.00E-24 Triglycerides FADS1 UTR-3 20686565 rs174546 chr11 61569830 C T 6.00E-07 Metabolic syndrome FADS1 UTR-3 20694148 rs174546 chr11 61569830 C T 1.00E-07 Coronary heart disease FADS1 UTR-3 21347282 rs174546 chr11 61569830 C T 3.35E-06 Phospholipid levels (plasma) FADS1 UTR-3 21829377 rs174546 chr11 61569830 C T 4.77E-268 Metabolite levels FADS1 UTR-3 22286219 rs174546 chr11 61569830 C T 4.92E-05 Prostate cancer FADS1 UTR-3 22923026 rs174546 chr11 61569830 C T 0.000119 Triglycerides FADS1 UTR-3 23063622 rs174546 chr11 61569830 C T 0.000278 HDL cholesterol FADS1 UTR-3 23063622 rs174546 chr11 61569830 C T 1.48E-18 Metabolite levels FADS1 UTR-3 23281178 rs174546 chr11 61569830 C T 2.00E-39 LDL cholesterol FADS1 UTR-3 24097068 rs174546 chr11 61569830 C T 3.00E-37 Cholesterol,total FADS1 UTR-3 24097068 rs174546 chr11 61569830 C T 7.00E-38 Triglycerides FADS1 UTR-3 24097068 rs174546 chr11 61569830 C T 8.00E-28 HDL cholesterol FADS1 UTR-3 24097068 rs174546 chr11 61569830 C T 1.80E-151 Plasma omega-6 polyunsaturated fatty acid levels FADS1 UTR-3 24823311 rs174546 chr11 61569830 C T 2.13E-273 Plasma omega-6 polyunsaturated fatty acid levels FADS1 UTR-3 24823311 rs174546 chr11 61569830 C T 2.37E-72 Plasma omega-6 polyunsaturated fatty acid levels FADS1 UTR-3 24823311 rs174546 chr11 61569830 C T 2.40E-139 Plasma omega-6 polyunsaturated fatty acid levels FADS1 UTR-3 24823311 rs174546 chr11 61569830 C T 6.38E-06 LDL lipoproteins FADS1 UTR-3 pha002902 rs174547 chr11 61570783 T C 4.43E-04 Type 2 diabetes FADS1 intron 17463246 rs174547 chr11 61570783 T C 7.53E-07 Serum metabolites FADS1 intron 19043545 rs174547 chr11 61570783 T C 2.00E-12 HDL cholesterol FADS1 intron 19060906 rs174547 chr11 61570783 T C 2.00E-14 Triglycerides FADS1 intron 19060906 rs174547 chr11 61570783 T C 7.00E-179 Metabolite levels FADS1 intron 20037589 rs174547 chr11 61570783 T C 3.60E-06 Response to statin therapy FADS1 intron 20339536 rs174547 chr11 61570783 T C 2.00E-09 Resting heart rate FADS1 intron 20639392 rs174547 chr11 61570783 T C 2.00E-12 Coronary heart disease FADS1 intron 21347282 rs174547 chr11 61570783 T C 3.00E-64 Phospholipid levels (plasma) FADS1 intron 21829377 rs174547 chr11 61570783 T C 4.00E-154 Phospholipid levels (plasma) FADS1 intron 21829377 rs174547 chr11 61570783 T C 9.00E-116 Metabolic traits FADS1 intron 21886157 rs174547 chr11 61570783 T C 8.00E-262 Lipid metabolism phenotypes FADS1 intron 22286219 rs174547 chr11 61570783 T C 2.00E-07 Comprehensive strength and appendicular lean mass FADS1 intron 22960237 rs174547 chr11 61570783 T C 1.80E-05 Esophageal cancer (squamous cell) FADS1 intron 22960999 rs174547 chr11 61570783 T C 4.19E-18 Metabolite levels FADS1 intron 23281178 rs174547 chr11 61570783 T C 4.90E-05 Hematology traits FADS1 intron 23303382 rs174547 chr11 61570783 T C 2.00E-72 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174547 chr11 61570783 T C 2.63E-151 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174547 chr11 61570783 T C 3E-971 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174547 chr11 61570783 T C 4.98E-274 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174547 chr11 61570783 T C 6.26E-140 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174548 chr11 61571348 C G 6.07E-05 Type 2 diabetes FADS1 intron 17463246 rs174548 chr11 61571348 C G 1.90E-04 Lipid levels FADS1 intron 18193043 rs174548 chr11 61571348 C G 5.00E-08 Metabolite levels FADS1 intron 19043545 rs174548 chr11 61571348 C G 1.70E-05 Response to statin therapy FADS1 intron 20339536 rs174548 chr11 61571348 C G 1.00E-12 HDL cholesterol FADS1 intron 20864672 rs174548 chr11 61571348 C G 5.00E-14 Triglycerides FADS1 intron 20864672 rs174548 chr11 61571348 C G 1.66E-07 Lung cancer FADS1 intron 21725308 rs174548 chr11 61571348 C G 1.18E-06 Phospholipid levels (plasma) FADS1 intron 21829377 rs174548 chr11 61571348 C G 1.36E-255 Metabolite levels FADS1 intron 22286219 rs174548 chr11 61571348 C G 0.00000347 HDL cholesterol (male) FADS1 intron 23063622 rs174548 chr11 61571348 C G 2.09E-10 HDL cholesterol (female) FADS1 intron 23063622 rs174548 chr11 61571348 C G 6.34E-15 HDL cholesterol FADS1 intron 23063622 rs174548 chr11 61571348 C G 6.63E-08 LDL cholesterol FADS1 intron 23063622 rs174548 chr11 61571348 C G 8.29E-09 Cholesterol,total FADS1 intron 23063622 rs174548 chr11 61571348 C G 8.36E-15 Triglycerides FADS1 intron 23063622 rs174548 chr11 61571348 C G 2.03E-16 Metabolite levels FADS1 intron 23281178 rs174548 chr11 61571348 C G 4.00E-08 Hematology traits FADS1 intron 23303382 rs174548 chr11 61571348 C G 1.00E-84 Blood metabolite levels FADS1 intron 24816252 rs174548 chr11 61571348 C G 2E-361 Blood metabolite ratios FADS1 intron 24816252 rs174548 chr11 61571348 C G 1.01E-61 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174548 chr11 61571348 C G 2.14E-232 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174548 chr11 61571348 C G 3.01E-167 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174548 chr11 61571348 C G 4.66E-128 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174549 chr11 61571382 G A 9.22E-05 Type 2 diabetes FADS1 intron 17463246 rs174549 chr11 61571382 G A 2.20E-07 Serum metabolites FADS1 intron 19043545 rs174549 chr11 61571382 G A 4.98E-04 Response to statin treatment (atorvastatin),change in cholesterol levels FADS1 intron 20031582 rs174549 chr11 61571382 G A 1.50E-05 Response to statin therapy FADS1 intron 20339536 rs174549 chr11 61571382 G A 5.77E-07 Lung cancer FADS1 intron 21725308 rs174549 chr11 61571382 G A 1.27E-06 Phospholipid levels (plasma) FADS1 intron 21829377 rs174549 chr11 61571382 G A 3.99E-256 Metabolite levels FADS1 intron 22286219 rs174549 chr11 61571382 G A 8.00E-07 Comprehensive strength and appendicular lean mass FADS1 intron 22960237 rs174549 chr11 61571382 G A 2.00E-30 Metabolite levels FADS1 intron 23281178 rs174549 chr11 61571382 G A 5.00E-05 Hematology traits FADS1 intron 23303382 rs174549 chr11 61571382 G A 1.00E-22 Heart rate FADS1 intron 23583979 rs174549 chr11 61571382 G A 1.85E-04 QRS duration FADS1 intron 23583979 rs174549 chr11 61571382 G A 4.33E-08 QT duration FADS1 intron 23583979 rs174549 chr11 61571382 G A 4.87E-05 Heart rate FADS1 intron 23583979 rs174549 chr11 61571382 G A 3.88E-232 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174549 chr11 61571382 G A 3.98E-62 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174549 chr11 61571382 G A 4.79E-168 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174549 chr11 61571382 G A 5.94E-128 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174550 chr11 61571478 T C 2.00E-15 Fasting insulin-related traits FADS1 intron 20081858 rs174550 chr11 61571478 T C 5.00E-13 Fasting glucose-related traits FADS1 intron 20081858 rs174550 chr11 61571478 T C 3.90E-06 Response to statin therapy FADS1 intron 20339536 rs174550 chr11 61571478 T C 1.00E-57 Phospholipid levels (plasma) FADS1 intron 21829377 rs174550 chr11 61571478 T C 7.27E-267 Metabolite levels FADS1 intron 22286219 rs174550 chr11 61571478 T C 2.00E-09 Fasting glucose-related traits (interaction with BMI) FADS1 intron 22581228 rs174550 chr11 61571478 T C 1.34E-17 Fasting blood glucose FADS1 intron 22885924 rs174550 chr11 61571478 T C 1.48E-18 Metabolite levels FADS1 intron 23281178 rs174550 chr11 61571478 T C 7.00E-24 Blood metabolite levels FADS1 intron 24816252 rs174550 chr11 61571478 T C 4.00E-140 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174550 chr11 61571478 T C 4.00E-274 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174550 chr11 61571478 T C 5.95E-72 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174550 chr11 61571478 T C 7.44E-152 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174550 chr11 61571478 T C 1.58E-19 Colorectal cancer FADS1 intron 24836286 rs174553 chr11 61575158 A C,G,T 1.55E-267 Metabolite levels FADS1 intron 22286219 rs174554 chr11 61579463 A G 1.87E-266 Metabolite levels FADS1 intron 22286219 rs174555 chr11 61579760 T C 1.70E-05 Response to statin therapy FADS1 intron 20339536 rs174555 chr11 61579760 T C 1.09E-06 Phospholipid levels (plasma) FADS1 intron 21829377 rs174555 chr11 61579760 T C 1.02E-255 Metabolite levels FADS1 intron 22286219 rs174555 chr11 61579760 T C 5.65E-15 Metabolite levels FADS1 intron 23281178 rs174555 chr11 61579760 T C 1.46E-61 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174555 chr11 61579760 T C 1.57E-231 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174555 chr11 61579760 T C 4.62E-128 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174555 chr11 61579760 T C 5.00E-168 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174556 chr11 61580635 C T 1.63E-09 Triglycerides FADS1 intron 19074352 rs174556 chr11 61580635 C T 1.63E-09 Polyunsaturated fatty acid levels,in plasma FADS1 intron 19148276 rs174556 chr11 61580635 C T 3.73E-12 Sphingolipid levels FADS1 intron 19798445 rs174556 chr11 61580635 C T 2.00E-05 Response to statin therapy FADS1 intron 20339536 rs174556 chr11 61580635 C T 1.04E-138 Phospholipid levels (plasma) FADS1 intron 21829377 rs174556 chr11 61580635 C T 3.07E-254 Metabolite levels FADS1 intron 22286219 rs174556 chr11 61580635 C T 7.19E-05 Prostate cancer FADS1 intron 22923026 rs174556 chr11 61580635 C T 5.65E-15 Metabolite levels FADS1 intron 23281178 rs174556 chr11 61580635 C T 2.00E-22 Blood metabolite levels FADS1 intron 24816252 rs174556 chr11 61580635 C T 1.01E-125 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174556 chr11 61580635 C T 2.43E-227 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174556 chr11 61580635 C T 2.71E-61 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174556 chr11 61580635 C T 6.41E-168 Plasma omega-6 polyunsaturated fatty acid levels FADS1 intron 24823311 rs174556 chr11 61580635 C T 4.04E-06 LDL lipoproteins FADS1 intron pha002902 rs174559 chr11 61581656 G A 3.59E-184 Metabolite levels FADS1 intron 22286219 rs174560 chr11 61581764 T C 7.37E-255 Metabolite levels FADS1 intron 22286219 rs174561 chr11 61582708 T C 4.93E-266 Metabolite levels FADS1 intron 22286219 rs174562 chr11 61585144 A G 6.37E-266 Metabolite levels / / 22286219 rs61897792 chr11 61586886 C T 2.37E-11 Metabolite levels / / 22286219 rs174566 chr11 61592362 A G 2.22E-266 Metabolite levels / / 22286219 rs174568 chr11 61593816 C T 1.10E-265 Metabolite levels / / 22286219 rs968567 chr11 61595564 C T 7.50E-07 Rheumatoid arthritis / / 19503088 rs968567 chr11 61595564 C T 6.15E-51 Phospholipid levels (plasma) / / 21829377 rs968567 chr11 61595564 C T 4.83E-13 Metabolite levels / / 22286219 rs968567 chr11 61595564 C T 1.80E-08 Rheumatoid arthritis / / 24390342 rs968567 chr11 61595564 C T 2.00E-08 Rheumatoid arthritis / / 24390342 rs968567 chr11 61595564 C T 2.00E-21 Blood metabolite levels / / 24816252 rs968567 chr11 61595564 C T 3.00E-19 Blood metabolite levels / / 24816252 rs968567 chr11 61595564 C T 1.16E-226 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs968567 chr11 61595564 C T 1.52E-16 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs968567 chr11 61595564 C T 2.02E-161 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs968567 chr11 61595564 C T 2.46E-40 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs968567 chr11 61595564 C T 7.59E-43 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs99780 chr11 61596633 C T 7.64E-265 Metabolite levels FADS2 intron 22286219 rs174570 chr11 61597212 C T 2.47E-05 Lung cancer FADS2 intron 18978787 rs174570 chr11 61597212 C T 2.00E-10 Cholesterol,total FADS2 intron 19060911 rs174570 chr11 61597212 C T 4.00E-06 HDL cholesterol FADS2 intron 19060911 rs174570 chr11 61597212 C T 4.00E-13 LDL cholesterol FADS2 intron 19060911 rs174570 chr11 61597212 C T 9.34E-06 Sphingolipid levels FADS2 intron 19798445 rs174570 chr11 61597212 C T 4.00E-13 Coronary heart disease FADS2 intron 21347282 rs174570 chr11 61597212 C T 8.14E-07 Lung cancer FADS2 intron 21725308 rs174570 chr11 61597212 C T 8.12E-60 Phospholipid levels (plasma) FADS2 intron 21829377 rs174570 chr11 61597212 C T 2.50E-162 Metabolite levels FADS2 intron 22286219 rs174570 chr11 61597212 C T 7.95E-05 Prostate cancer FADS2 intron 22923026 rs174570 chr11 61597212 C T 0.000000285 Triglycerides FADS2 intron 23063622 rs174570 chr11 61597212 C T 0.000000371 Cholesterol,total FADS2 intron 23063622 rs174570 chr11 61597212 C T 2.69E-09 HDL cholesterol FADS2 intron 23063622 rs174570 chr11 61597212 C T 3.86E-10 Metabolite levels FADS2 intron 23281178 rs174570 chr11 61597212 C T 2.00E-07 Glycated hemoglobin levels FADS2 intron 24647736 rs174570 chr11 61597212 C T 1.66E-57 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174570 chr11 61597212 C T 4.37E-10 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174570 chr11 61597212 C T 4.77E-28 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174570 chr11 61597212 C T 9.98E-149 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs1535 chr11 61597972 A G 1.56E-11 Sphingolipid levels FADS2 intron 19798445 rs1535 chr11 61597972 A G 1.00E-08 Lipid levels FADS2 intron 19936222 rs1535 chr11 61597972 A G 1.00E-09 Lipid levels FADS2 intron 19936222 rs1535 chr11 61597972 A G 3.50E-12 Lipid levels FADS2 intron 19936222 rs1535 chr11 61597972 A G 4.35E-08 Lipid levels FADS2 intron 19936222 rs1535 chr11 61597972 A G 7.00E-06 Response to statin therapy FADS2 intron 20339536 rs1535 chr11 61597972 A G 4.00E-07 Metabolic syndrome FADS2 intron 20694148 rs1535 chr11 61597972 A G 3.00E-152 Phospholipid levels (plasma) FADS2 intron 21829377 rs1535 chr11 61597972 A G 3.00E-63 Phospholipid levels (plasma) FADS2 intron 21829377 rs1535 chr11 61597972 A G 9.86E-265 Metabolite levels FADS2 intron 22286219 rs1535 chr11 61597972 A G 0.00000076 HDL cholesterol (female) FADS2 intron 22629316 rs1535 chr11 61597972 A G 0.00068 HDL cholesterol (male) FADS2 intron 22629316 rs1535 chr11 61597972 A G 5.29E-09 HDL cholesterol FADS2 intron 22629316 rs1535 chr11 61597972 A G 3.54E-05 Prostate cancer FADS2 intron 22923026 rs1535 chr11 61597972 A G 1.69E-15 Triglycerides FADS2 intron 23063622 rs1535 chr11 61597972 A G 1.76E-15 HDL cholesterol FADS2 intron 23063622 rs1535 chr11 61597972 A G 1.77E-10 Cholesterol,total FADS2 intron 23063622 rs1535 chr11 61597972 A G 2.13E-10 LDL cholesterol FADS2 intron 23063622 rs1535 chr11 61597972 A G 1.48E-18 Metabolite levels FADS2 intron 23281178 rs1535 chr11 61597972 A G 1.02E-137 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs1535 chr11 61597972 A G 2.01E-152 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs1535 chr11 61597972 A G 3.36E-71 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs1535 chr11 61597972 A G 4.47E-272 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs1535 chr11 61597972 A G 8.21E-20 Colorectal cancer FADS2 intron 24836286 rs1535 chr11 61597972 A G 1.16E-05 LDL lipoproteins FADS2 intron pha002902 rs174572 chr11 61598288 C T 2.67E-59 Metabolite levels FADS2 intron 22286219 rs61897793 chr11 61599347 G A 3.88E-14 Metabolite levels FADS2 intron 22286219 rs174573 chr11 61600327 G A 5.36E-59 Metabolite levels FADS2 intron 22286219 rs174574 chr11 61600342 A C 3.10E-06 Response to statin therapy FADS2 intron 20339536 rs174574 chr11 61600342 A C 4.00E-55 Phospholipid levels (plasma) FADS2 intron 21829377 rs174574 chr11 61600342 A C 6.34E-16 Metabolite levels FADS2 intron 22286219 rs174574 chr11 61600342 A C 1.90E-267 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174574 chr11 61600342 A C 2.33E-135 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174574 chr11 61600342 A C 7.39E-153 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174574 chr11 61600342 A C 9.35E-72 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174574 chr11 61600342 A C 3.40E-08 P wave duration FADS2 intron 24850809 rs2524296 chr11 61601378 C T 1.41E-152 Metabolite levels FADS2 intron 22286219 rs2845574 chr11 61601872 C T 1.19E-152 Metabolite levels FADS2 intron 22286219 rs2845573 chr11 61601908 A G 2.23E-04 Multiple complex diseases FADS2 intron 17554300 rs2845573 chr11 61601908 A G 4.45E-51 Phospholipid levels (plasma) FADS2 intron 21829377 rs2845573 chr11 61601908 A G 1.65E-151 Metabolite levels FADS2 intron 22286219 rs2845573 chr11 61601908 A G 1.12E-306 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2845573 chr11 61601908 A G 1.47E-17 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2845573 chr11 61601908 A G 1.60E-11 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2845573 chr11 61601908 A G 1.92E-116 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2845573 chr11 61601908 A G 2.25E-45 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174575 chr11 61602003 C G 2.17E-84 Phospholipid levels (plasma) FADS2 intron 21829377 rs174575 chr11 61602003 C G 6.53E-59 Metabolite levels FADS2 intron 22286219 rs174575 chr11 61602003 C G 1.58E-134 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174575 chr11 61602003 C G 2.77E-41 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174575 chr11 61602003 C G 3.63E-74 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174575 chr11 61602003 C G 4.07E-114 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs11230805 chr11 61602518 T C 5.04E-32 Metabolite levels FADS2 intron 22286219 rs2727270 chr11 61603237 C T 1.66E-61 Phospholipid levels (plasma) FADS2 intron 21829377 rs2727270 chr11 61603237 C T 2.02E-214 Metabolite levels FADS2 intron 22286219 rs2727270 chr11 61603237 C T 9.88E-10 Metabolite levels FADS2 intron 23281178 rs2727270 chr11 61603237 C T 1.03E-30 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2727270 chr11 61603237 C T 1.77E-13 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2727270 chr11 61603237 C T 3.00E-21 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2727270 chr11 61603237 C T 5.25E-59 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2727271 chr11 61603358 A T 2.29E-61 Phospholipid levels (plasma) FADS2 intron 21829377 rs2727271 chr11 61603358 A T 1.79E-214 Metabolite levels FADS2 intron 22286219 rs2727271 chr11 61603358 A T 6.68E-10 Metabolite levels FADS2 intron 23281178 rs2727271 chr11 61603358 A T 3.00E-11 Blood metabolite levels FADS2 intron 24816252 rs2727271 chr11 61603358 A T 1.08E-30 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2727271 chr11 61603358 A T 1.89E-13 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2727271 chr11 61603358 A T 3.93E-142 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2727271 chr11 61603358 A T 7.15E-59 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174576 chr11 61603510 C A 1.54E-07 Triglycerides FADS2 intron 19074352 rs174576 chr11 61603510 C A 1.54E-07 Polyunsaturated fatty acid levels,in plasma FADS2 intron 19148276 rs174576 chr11 61603510 C A 3.10E-06 Response to statin therapy FADS2 intron 20339536 rs174576 chr11 61603510 C A 3.40E-06 Phospholipid levels (plasma) FADS2 intron 21829377 rs174576 chr11 61603510 C A 6.48E-266 Metabolite levels FADS2 intron 22286219 rs174576 chr11 61603510 C A 1.18E-18 Fasting blood glucose FADS2 intron 22885924 rs174576 chr11 61603510 C A 4.00E-05 Prostate cancer FADS2 intron 22923026 rs174576 chr11 61603510 C A 1.03E-15 Triglycerides FADS2 intron 23063622 rs174576 chr11 61603510 C A 2.54E-10 LDL cholesterol FADS2 intron 23063622 rs174576 chr11 61603510 C A 4.95E-15 HDL cholesterol FADS2 intron 23063622 rs174576 chr11 61603510 C A 5.01E-10 Cholesterol,total FADS2 intron 23063622 rs174576 chr11 61603510 C A 1.83E-18 Metabolite levels FADS2 intron 23281178 rs174576 chr11 61603510 C A 3.05E-134 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174576 chr11 61603510 C A 6.12E-72 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174576 chr11 61603510 C A 6.83E-266 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174576 chr11 61603510 C A 8.34E-153 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174576 chr11 61603510 C A 3.29E-08 P wave duration FADS2 intron 24850809 rs174576 chr11 61603510 C A 9.98E-05 Left ventricular hypertrophy FADS2 intron pha003052 rs2524299 chr11 61604782 A T 9.19E-60 Phospholipid levels (plasma) FADS2 intron 21829377 rs2524299 chr11 61604782 A T 2.82E-215 Metabolite levels FADS2 intron 22286219 rs2524299 chr11 61604782 A T 8.19E-10 Metabolite levels FADS2 intron 23281178 rs2524299 chr11 61604782 A T 1.80E-138 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2524299 chr11 61604782 A T 3.04E-13 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2524299 chr11 61604782 A T 3.53E-30 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2524299 chr11 61604782 A T 7.27E-58 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174577 chr11 61604814 C A 2.80E-06 Response to statin therapy FADS2 intron 20339536 rs174577 chr11 61604814 C A 2.10E-07 Lung cancer FADS2 intron 21725308 rs174577 chr11 61604814 C A 4.40E-06 Phospholipid levels (plasma) FADS2 intron 21829377 rs174577 chr11 61604814 C A 4.20E-267 Metabolite levels FADS2 intron 22286219 rs174577 chr11 61604814 C A 4.70E-10 HDL cholesterol FADS2 intron 23063622 rs174577 chr11 61604814 C A 5.64E-11 Triglycerides FADS2 intron 23063622 rs174577 chr11 61604814 C A 1.83E-18 Metabolite levels FADS2 intron 23281178 rs174577 chr11 61604814 C A 1.11E-71 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174577 chr11 61604814 C A 1.73E-262 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174577 chr11 61604814 C A 3.37E-152 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174577 chr11 61604814 C A 9.13E-134 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174577 chr11 61604814 C A 3.00E-08 P wave duration FADS2 intron 24850809 rs2072113 chr11 61604967 C T 2.54E-215 Metabolite levels FADS2 intron 22286219 rs2072114 chr11 61605215 A G 2.50E-07 Sphingolipid levels FADS2 intron 19798445 rs2072114 chr11 61605215 A G 4.45E-64 Phospholipid levels (plasma) FADS2 intron 21829377 rs2072114 chr11 61605215 A G 3.98E-213 Metabolite levels FADS2 intron 22286219 rs2072114 chr11 61605215 A G 8.19E-10 Metabolite levels FADS2 intron 23281178 rs2072114 chr11 61605215 A G 2.34E-31 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2072114 chr11 61605215 A G 5.95E-15 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2072114 chr11 61605215 A G 6.04E-59 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2072114 chr11 61605215 A G 6.13E-141 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2072114 chr11 61605215 A G 9.58E-05 LDL lipoproteins FADS2 intron pha002902 rs174578 chr11 61605499 T A 2.80E-06 Response to statin therapy FADS2 intron 20339536 rs174578 chr11 61605499 T A 4.51E-06 Phospholipid levels (plasma) FADS2 intron 21829377 rs174578 chr11 61605499 T A 1.96E-267 Metabolite levels FADS2 intron 22286219 rs174578 chr11 61605499 T A 3.00E-24 Blood metabolite levels FADS2 intron 24816252 rs174578 chr11 61605499 T A 6.00E-42 Blood metabolite levels FADS2 intron 24816252 rs174578 chr11 61605499 T A 1.47E-133 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174578 chr11 61605499 T A 2.61E-263 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174578 chr11 61605499 T A 3.18E-72 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174578 chr11 61605499 T A 3.93E-152 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174578 chr11 61605499 T A 2.69E-08 P wave duration FADS2 intron 24850809 rs174579 chr11 61605613 C T 2.02E-05 Triglycerides FADS2 intron 19074352 rs174579 chr11 61605613 C T 2.02E-05 Polyunsaturated fatty acid levels,in plasma FADS2 intron 19148276 rs174579 chr11 61605613 C T 4.08E-63 Phospholipid levels (plasma) FADS2 intron 21829377 rs174579 chr11 61605613 C T 1.83E-20 Metabolite levels FADS2 intron 22286219 rs174579 chr11 61605613 C T 1.23E-127 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174579 chr11 61605613 C T 2.24E-51 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174579 chr11 61605613 C T 3.28E-25 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174579 chr11 61605613 C T 4.34E-72 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174579 chr11 61605613 C T 4.95E-301 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174580 chr11 61606642 A G 5.34E-267 Metabolite levels FADS2 intron 22286219 rs174581 chr11 61606683 G A 3.42E-267 Metabolite levels FADS2 intron 22286219 rs174582 chr11 61607168 A G 4.18E-20 Metabolite levels FADS2 intron 22286219 rs2727265 chr11 61609004 C A 8.85E-156 Metabolite levels FADS2 intron 22286219 rs17156426 chr11 61609323 A C,G,T 5.02E-15 Phospholipid levels (plasma) FADS2 intron 21829377 rs17156426 chr11 61609323 A C,G,T 2.51E-37 Metabolite levels FADS2 intron 22286219 rs17156426 chr11 61609323 A C,G,T 2.45E-17 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs17156426 chr11 61609323 A C,G,T 2.96E-31 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs17156426 chr11 61609323 A C,G,T 7.41E-71 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs17156426 chr11 61609323 A C,G,T 7.43E-19 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174583 chr11 61609750 C T 3.00E-06 Response to statin therapy FADS2 intron 20339536 rs174583 chr11 61609750 C T 2.20E-07 Lung cancer FADS2 intron 21725308 rs174583 chr11 61609750 C T 4.17E-147 Phospholipid levels (plasma) FADS2 intron 21829377 rs174583 chr11 61609750 C T 1.33E-267 Metabolite levels FADS2 intron 22286219 rs174583 chr11 61609750 C T 0.000000057 Fasting blood glucose FADS2 intron 22885924 rs174583 chr11 61609750 C T 1.83E-18 Metabolite levels FADS2 intron 23281178 rs174583 chr11 61609750 C T 0.00033 Prostate cancer FADS2 intron 23555315 rs174583 chr11 61609750 C T 2.63E-263 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174583 chr11 61609750 C T 6.48E-71 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174583 chr11 61609750 C T 9.10E-132 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174583 chr11 61609750 C T 9.96E-149 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174584 chr11 61610750 G A 2.78E-266 Metabolite levels FADS2 intron 22286219 rs174585 chr11 61611694 G A,C,T 3.93E-59 Phospholipid levels (plasma) FADS2 intron 21829377 rs174585 chr11 61611694 G A,C,T 1.74E-13 Metabolite levels FADS2 intron 22286219 rs174585 chr11 61611694 G A,C,T 1.51E-71 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174585 chr11 61611694 G A,C,T 2.71E-122 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174585 chr11 61611694 G A,C,T 2.83E-23 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174585 chr11 61611694 G A,C,T 3.96E-286 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174585 chr11 61611694 G A,C,T 5.26E-48 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174587 chr11 61612830 C T 2.32E-20 Metabolite levels FADS2 intron 22286219 rs93923 chr11 61613745 C T 1.08E-13 Metabolite levels FADS2 intron 22286219 rs12284876 chr11 61613841 A G 9.87E-35 Metabolite levels FADS2 intron 22286219 rs17156442 chr11 61614023 C T 2.09E-11 Phospholipid levels (plasma) FADS2 intron 21829377 rs17156442 chr11 61614023 C T 1.10E-35 Metabolite levels FADS2 intron 22286219 rs17156442 chr11 61614023 C T 1.14E-12 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs17156442 chr11 61614023 C T 1.60E-15 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs17156442 chr11 61614023 C T 1.94E-21 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs17156442 chr11 61614023 C T 7.09E-53 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs7935946 chr11 61615542 C T 4.72E-11 Phospholipid levels (plasma) FADS2 intron 21829377 rs7935946 chr11 61615542 C T 1.19E-36 Metabolite levels FADS2 intron 22286219 rs7935946 chr11 61615542 C T 1.59E-15 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs7935946 chr11 61615542 C T 2.81E-14 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs7935946 chr11 61615542 C T 6.62E-56 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs7935946 chr11 61615542 C T 8.16E-24 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174589 chr11 61615803 C G 6.47E-48 Phospholipid levels (plasma) FADS2 intron 21829377 rs174589 chr11 61615803 C G 1.27E-45 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174589 chr11 61615803 C G 1.76E-69 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174589 chr11 61615803 C G 2.23E-23 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174589 chr11 61615803 C G 2.81E-119 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174589 chr11 61615803 C G 6.13E-281 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2851682 chr11 61616012 A G 1.39E-09 Triglycerides FADS2 intron 19060911 rs2851682 chr11 61616012 A G 8.06E-05 Sphingolipid levels FADS2 intron 19798445 rs2851682 chr11 61616012 A G 1.83E-43 Phospholipid levels (plasma) FADS2 intron 21829377 rs2851682 chr11 61616012 A G 3.65E-155 Metabolite levels FADS2 intron 22286219 rs2851682 chr11 61616012 A G 2.52E-11 Fasting blood glucose FADS2 intron 22885924 rs2851682 chr11 61616012 A G 1.02E-280 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2851682 chr11 61616012 A G 2.12E-11 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2851682 chr11 61616012 A G 2.35E-41 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2851682 chr11 61616012 A G 3.67E-103 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2851682 chr11 61616012 A G 8.93E-17 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174590 chr11 61616977 G C 7.02E-13 Metabolite levels FADS2 intron 22286219 rs174591 chr11 61617676 T A 1.18E-73 Phospholipid levels (plasma) FADS2 intron 21829377 rs174591 chr11 61617676 T A 1.47E-53 Metabolite levels FADS2 intron 22286219 rs174591 chr11 61617676 T A 1.73E-64 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174591 chr11 61617676 T A 2.31E-86 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174591 chr11 61617676 T A 5.06E-36 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174591 chr11 61617676 T A 6.36E-120 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs55896837 chr11 61617753 T C 1.33E-33 Metabolite levels FADS2 intron 22286219 rs61897795 chr11 61618169 A G 3.75E-12 Metabolite levels FADS2 intron 22286219 rs174592 chr11 61618608 A G 1.99E-240 Metabolite levels FADS2 intron 22286219 rs174593 chr11 61618831 T C 7.40E-05 Response to statin therapy FADS2 intron 20339536 rs174593 chr11 61618831 T C 9.40E-57 Phospholipid levels (plasma) FADS2 intron 21829377 rs174593 chr11 61618831 T C 1.78E-45 Metabolite levels FADS2 intron 22286219 rs174593 chr11 61618831 T C 1.41E-23 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174593 chr11 61618831 T C 1.58E-69 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174593 chr11 61618831 T C 2.02E-44 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174593 chr11 61618831 T C 3.48E-104 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174593 chr11 61618831 T C 3.87E-268 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs916924 chr11 61619181 T C 1.19E-09 Phospholipid levels (plasma) FADS2 intron 21829377 rs916924 chr11 61619181 T C 3.80E-33 Metabolite levels FADS2 intron 22286219 rs916925 chr11 61619294 G A 1.11E-33 Metabolite levels FADS2 intron 22286219 rs174594 chr11 61619829 C A 2.62E-15 Metabolite levels FADS2 intron 22286219 rs174597 chr11 61621040 G C 7.70E-05 Response to statin therapy FADS2 intron 20339536 rs174597 chr11 61621040 G C 1.12E-56 Phospholipid levels (plasma) FADS2 intron 21829377 rs174597 chr11 61621040 G C 3.33E-17 Metabolite levels FADS2 intron 22286219 rs174597 chr11 61621040 G C 1.25E-23 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174597 chr11 61621040 G C 1.77E-69 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174597 chr11 61621040 G C 2.15E-44 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174597 chr11 61621040 G C 3.59E-104 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174597 chr11 61621040 G C 5.45E-268 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174598 chr11 61621194 G A 8.63E-189 Metabolite levels FADS2 intron 22286219 rs174599 chr11 61621556 G C 1.25E-253 Metabolite levels FADS2 intron 22286219 rs174600 chr11 61622227 T C 1.30E-191 Metabolite levels FADS2 intron 22286219 rs556656 chr11 61622905 A C,T 2.72E-37 Metabolite levels FADS2 intron 22286219 rs174601 chr11 61623140 C T 8.10E-06 Response to statin therapy FADS2 intron 20339536 rs174601 chr11 61623140 C T 4.30E-06 Phospholipid levels (plasma) FADS2 intron 21829377 rs174601 chr11 61623140 C T 3.00E-09 Liver enzyme levels (alkaline phosphatase) FADS2 intron 22001757 rs174601 chr11 61623140 C T 6.18E-252 Metabolite levels FADS2 intron 22286219 rs174601 chr11 61623140 C T 1.51E-13 HDL cholesterol FADS2 intron 23063622 rs174601 chr11 61623140 C T 1.99E-12 Triglycerides FADS2 intron 23063622 rs174601 chr11 61623140 C T 4.14E-09 LDL cholesterol FADS2 intron 23063622 rs174601 chr11 61623140 C T 6.33E-11 Cholesterol,total FADS2 intron 23063622 rs174601 chr11 61623140 C T 8.00E-16 Blood metabolite levels FADS2 intron 24816252 rs174601 chr11 61623140 C T 1.80E-139 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174601 chr11 61623140 C T 2.82E-253 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174601 chr11 61623140 C T 5.05E-121 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174601 chr11 61623140 C T 6.06E-67 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2526678 chr11 61623793 G A 1.16E-45 Phospholipid levels (plasma) FADS2 intron 21829377 rs2526678 chr11 61623793 G A 5.76E-158 Metabolite levels FADS2 intron 22286219 rs2526678 chr11 61623793 G A 1.40E-10 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2526678 chr11 61623793 G A 2.87E-16 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2526678 chr11 61623793 G A 3.65E-41 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2526678 chr11 61623793 G A 5.29E-280 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs2526678 chr11 61623793 G A 9.18E-106 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs97384 chr11 61624181 T C 2.38E-13 Metabolite levels FADS2 intron 22286219 rs174602 chr11 61624414 T C 5.10E-05 Response to statin therapy FADS2 intron 20339536 rs174602 chr11 61624414 T C 1.46E-56 Phospholipid levels (plasma) FADS2 intron 21829377 rs174602 chr11 61624414 T C 8.31E-64 Metabolite levels FADS2 intron 22286219 rs498793 chr11 61624705 T C 5.84E-16 Phospholipid levels (plasma) FADS2 intron 21829377 rs498793 chr11 61624705 T C 2.27E-40 Metabolite levels FADS2 intron 22286219 rs526126 chr11 61624885 G C 3.42E-40 Phospholipid levels (plasma) FADS2 intron 21829377 rs526126 chr11 61624885 G C 1.16E-11 Metabolite levels FADS2 intron 22286219 rs526126 chr11 61624885 G C 2.47E-207 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs526126 chr11 61624885 G C 2.82E-31 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs526126 chr11 61624885 G C 4.07E-22 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs526126 chr11 61624885 G C 5.34E-55 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs526126 chr11 61624885 G C 5.96E-90 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174605 chr11 61626921 G T 4.78E-06 Serum metabolites FADS2 intron 19043545 rs174605 chr11 61626921 G T 7.48E-47 Phospholipid levels (plasma) FADS2 intron 21829377 rs174605 chr11 61626921 G T 6.82E-64 Metabolite levels FADS2 intron 22286219 rs174605 chr11 61626921 G T 2.07E-86 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174605 chr11 61626921 G T 2.60E-256 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174605 chr11 61626921 G T 4.62E-41 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174605 chr11 61626921 G T 4.64E-76 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174605 chr11 61626921 G T 5.34E-26 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174606 chr11 61626973 G T 3.23E-109 Metabolite levels FADS2 intron 22286219 rs174608 chr11 61627484 A G 3.54E-58 Metabolite levels FADS2 intron 22286219 rs174609 chr11 61627811 T C 2.45E-80 Metabolite levels FADS2 intron 22286219 rs174610 chr11 61627833 A G 9.09E-81 Metabolite levels FADS2 intron 22286219 rs174611 chr11 61627881 T C 2.91E-48 Phospholipid levels (plasma) FADS2 intron 21829377 rs174611 chr11 61627881 T C 1.38E-52 Metabolite levels FADS2 intron 22286219 rs174611 chr11 61627881 T C 1.93E-08 Metabolite levels FADS2 intron 23281178 rs174611 chr11 61627881 T C 1.11E-26 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174611 chr11 61627881 T C 1.31E-264 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174611 chr11 61627881 T C 1.31E-42 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174611 chr11 61627881 T C 1.51E-89 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174611 chr11 61627881 T C 3.12E-75 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174612 chr11 61628266 C G 3.78E-80 Metabolite levels FADS2 intron 22286219 rs174613 chr11 61628492 G A 7.33E-79 Metabolite levels FADS2 intron 22286219 rs174614 chr11 61628915 T C 2.69E-81 Metabolite levels FADS2 intron 22286219 rs174615 chr11 61628964 T A 9.19E-82 Metabolite levels FADS2 intron 22286219 rs174616 chr11 61629122 G A 9.00E-04 Type 2 diabetes FADS2 intron 17463246 rs174616 chr11 61629122 G A 6.34E-50 Phospholipid levels (plasma) FADS2 intron 21829377 rs174616 chr11 61629122 G A 2.88E-108 Metabolite levels FADS2 intron 22286219 rs174616 chr11 61629122 G A 4.30E-09 Metabolite levels FADS2 intron 23281178 rs174616 chr11 61629122 G A 1.24E-79 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174616 chr11 61629122 G A 1.46E-208 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174616 chr11 61629122 G A 1.62E-21 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174616 chr11 61629122 G A 2.09E-53 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174616 chr11 61629122 G A 4.02E-40 Plasma omega-6 polyunsaturated fatty acid levels FADS2 intron 24823311 rs174617 chr11 61629166 A G 1.74E-81 Metabolite levels FADS2 intron 22286219 rs174618 chr11 61629322 T C 3.54E-71 Metabolite levels FADS2 intron 22286219 rs174619 chr11 61629666 A G 2.47E-45 Metabolite levels FADS2 intron 22286219 rs174620 chr11 61629747 A G 5.63E-76 Metabolite levels FADS2 intron 22286219 rs174621 chr11 61630104 G A 9.20E-50 Metabolite levels FADS2 intron 22286219 rs482548 chr11 61633182 C A,G,T 1.97E-11 Metabolite levels FADS2 UTR-3 22286219 rs482548 chr11 61633182 C A,G,T 1.89E-09 Plasma omega-6 polyunsaturated fatty acid levels FADS2 UTR-3 24823311 rs482548 chr11 61633182 C A,G,T 2.53E-26 Plasma omega-6 polyunsaturated fatty acid levels FADS2 UTR-3 24823311 rs482548 chr11 61633182 C A,G,T 3.26E-11 Plasma omega-6 polyunsaturated fatty acid levels FADS2 UTR-3 24823311 rs482548 chr11 61633182 C A,G,T 3.72E-06 Plasma omega-6 polyunsaturated fatty acid levels FADS2 UTR-3 24823311 rs17764288 chr11 61633736 G A 4.97E-13 Metabolite levels FADS2 UTR-3 22286219 rs11539526 chr11 61633770 C T 5.38E-39 Metabolite levels FADS2 UTR-3 22286219 rs17764324 chr11 61635088 G T 1.05E-09 Phospholipid levels (plasma) / / 21829377 rs17764324 chr11 61635088 G T 2.51E-28 Metabolite levels / / 22286219 rs17764324 chr11 61635088 G T 1.22E-10 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs17764324 chr11 61635088 G T 2.83E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs17764324 chr11 61635088 G T 3.09E-58 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs17764324 chr11 61635088 G T 3.83E-32 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs17831757 chr11 61635200 T C 1.16E-09 Phospholipid levels (plasma) / / 21829377 rs17831757 chr11 61635200 T C 2.71E-28 Metabolite levels / / 22286219 rs17831757 chr11 61635200 T C 1.31E-10 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs17831757 chr11 61635200 T C 3.20E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs17831757 chr11 61635200 T C 5.33E-32 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs17831757 chr11 61635200 T C 6.28E-58 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7395424 chr11 61636017 A T 2.66E-22 Metabolite levels / / 22286219 rs11230815 chr11 61636126 G C 1.22E-09 Phospholipid levels (plasma) / / 21829377 rs11230815 chr11 61636126 G C 1.59E-30 Metabolite levels / / 22286219 rs11230815 chr11 61636126 G C 1.01E-57 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230815 chr11 61636126 G C 1.36E-10 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230815 chr11 61636126 G C 3.32E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230815 chr11 61636126 G C 7.03E-32 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230816 chr11 61636253 G C 1.30E-18 Metabolite levels / / 22286219 rs11230817 chr11 61636255 C T 1.30E-18 Metabolite levels / / 22286219 rs174626 chr11 61637057 G A 5.63E-44 Phospholipid levels (plasma) / / 21829377 rs174626 chr11 61637057 G A 3.40E-11 Metabolite levels / / 22286219 rs174626 chr11 61637057 G A 1.81E-37 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174626 chr11 61637057 G A 2.20E-47 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174626 chr11 61637057 G A 5.80E-19 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174626 chr11 61637057 G A 7.59E-71 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174626 chr11 61637057 G A 9.57E-184 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7394459 chr11 61637349 C T 2.62E-39 Metabolite levels / / 22286219 rs174627 chr11 61637466 G A 1.71E-05 Sphingolipid levels / / 19798445 rs174627 chr11 61637466 G A 6.07E-30 Phospholipid levels (plasma) / / 21829377 rs174627 chr11 61637466 G A 2.04E-33 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174627 chr11 61637466 G A 3.04E-127 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174627 chr11 61637466 G A 3.32E-23 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174627 chr11 61637466 G A 5.80E-83 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174627 chr11 61637466 G A 8.69E-13 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174628 chr11 61637587 T C 4.41E-52 Metabolite levels / / 22286219 rs7104849 chr11 61638044 G A 1.42E-09 Phospholipid levels (plasma) / / 21829377 rs7104849 chr11 61638044 G A 3.13E-41 Metabolite levels / / 22286219 rs7104849 chr11 61638044 G A 1.28E-31 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7104849 chr11 61638044 G A 1.48E-10 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7104849 chr11 61638044 G A 3.13E-57 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7104849 chr11 61638044 G A 3.73E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10897181 chr11 61638234 G C 6.36E-39 Metabolite levels / / 22286219 rs472031 chr11 61638420 G A 2.30E-09 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs472031 chr11 61638420 G A 2.34E-27 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs472031 chr11 61638420 G A 2.63E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs472031 chr11 61638420 G A 9.57E-12 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7118175 chr11 61639358 C T 5.34E-29 Metabolite levels / / 22286219 rs422249 chr11 61639488 T C 1.90E-56 Phospholipid levels (plasma) / / 21829377 rs422249 chr11 61639488 T C 7.82E-98 Metabolite levels / / 22286219 rs422249 chr11 61639488 T C 1.27E-51 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs422249 chr11 61639488 T C 1.94E-103 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs422249 chr11 61639488 T C 3.33E-30 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs422249 chr11 61639488 T C 4.87E-74 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs422249 chr11 61639488 T C 9.09E-286 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174448 chr11 61639573 G A 3.00E-60 Phospholipid levels (plasma) / / 21829377 rs174448 chr11 61639573 G A 4.00E-25 Phospholipid levels (plasma) / / 21829377 rs174448 chr11 61639573 G A 7.00E-28 Phospholipid levels (plasma) / / 21829377 rs174448 chr11 61639573 G A 5.29E-73 Metabolite levels / / 22286219 rs174448 chr11 61639573 G A 1.15E-111 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174448 chr11 61639573 G A 1.26E-72 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174448 chr11 61639573 G A 2.03E-292 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174448 chr11 61639573 G A 2.36E-55 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174448 chr11 61639573 G A 6.64E-34 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7481842 chr11 61639705 C T 5.71E-19 Metabolite levels / / 22286219 rs7482316 chr11 61640198 G A 2.63E-09 Phospholipid levels (plasma) / / 21829377 rs7482316 chr11 61640198 G A 5.94E-25 Metabolite levels / / 22286219 rs7482316 chr11 61640198 G A 2.06E-10 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7482316 chr11 61640198 G A 6.41E-30 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7482316 chr11 61640198 G A 7.56E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7482316 chr11 61640198 G A 8.58E-54 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174449 chr11 61640379 G A 1.87E-06 Serum metabolites / / 19043545 rs174449 chr11 61640379 G A 3.00E-11 Sphingolipid levels / / 19798445 rs174449 chr11 61640379 G A 7.58E-60 Phospholipid levels (plasma) / / 21829377 rs174449 chr11 61640379 G A 3.90E-50 Metabolite levels / / 22286219 rs174449 chr11 61640379 G A 7.62E-08 Metabolite levels / / 23281178 rs174449 chr11 61640379 G A 2.24E-04 Smoking cessation / / 24665060 rs174449 chr11 61640379 G A 2.12E-33 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174449 chr11 61640379 G A 2.20E-288 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174449 chr11 61640379 G A 2.72E-72 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174449 chr11 61640379 G A 3.37E-110 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174449 chr11 61640379 G A 7.84E-55 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs6591664 chr11 61640521 G A 2.39E-23 Metabolite levels / / 22286219 rs174450 chr11 61641542 G T 1.33E-05 Sphingolipid levels FADS3 intron 19798445 rs174450 chr11 61641542 G T 6.44E-47 Phospholipid levels (plasma) FADS3 intron 21829377 rs174450 chr11 61641542 G T 3.33E-44 Metabolite levels FADS3 intron 22286219 rs174450 chr11 61641542 G T 1.12E-74 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174450 chr11 61641542 G T 1.58E-186 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174450 chr11 61641542 G T 2.35E-38 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174450 chr11 61641542 G T 2.86E-46 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174450 chr11 61641542 G T 3.85E-20 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174450 chr11 61641542 G T 2.18E-06 LDL lipoproteins FADS3 intron pha002902 rs174451 chr11 61642763 C T 7.56E-64 Metabolite levels FADS3 intron 22286219 rs174453 chr11 61645967 C G 4.24E-31 Metabolite levels FADS3 intron 22286219 rs7942717 chr11 61647288 G A 8.49E-15 Phospholipid levels (plasma) FADS3 intron 21829377 rs7942717 chr11 61647288 G A 4.57E-42 Metabolite levels FADS3 intron 22286219 rs174634 chr11 61647387 G C 6.13E-40 Phospholipid levels (plasma) FADS3 intron 21829377 rs174634 chr11 61647387 G C 2.05E-60 Metabolite levels FADS3 intron 22286219 rs174634 chr11 61647387 G C 2.68E-31 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174634 chr11 61647387 G C 3.57E-61 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174634 chr11 61647387 G C 3.60E-152 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174634 chr11 61647387 G C 3.83E-52 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174634 chr11 61647387 G C 6.99E-21 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174635 chr11 61647427 T G 1.56E-20 Metabolite levels FADS3 intron 22286219 rs174454 chr11 61650747 G A 1.73E-26 Metabolite levels FADS3 intron 22286219 rs7394871 chr11 61652514 A C 3.56E-16 Phospholipid levels (plasma) FADS3 intron 21829377 rs7394871 chr11 61652514 A C 3.96E-23 Metabolite levels FADS3 intron 22286219 rs7394871 chr11 61652514 A C 2.94E-31 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs7394871 chr11 61652514 A C 4.46E-13 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs7394871 chr11 61652514 A C 9.42E-73 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs1000778 chr11 61655305 A G 7.00E-13 Sphingolipid levels FADS3 intron 19798445 rs1000778 chr11 61655305 A G 3.49E-39 Phospholipid levels (plasma) FADS3 intron 21829377 rs1000778 chr11 61655305 A G 1.24E-26 Metabolite levels FADS3 intron 22286219 rs1000778 chr11 61655305 A G 1.33E-148 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs1000778 chr11 61655305 A G 1.82E-30 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs1000778 chr11 61655305 A G 1.86E-20 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs1000778 chr11 61655305 A G 3.10E-50 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs1000778 chr11 61655305 A G 3.81E-60 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174455 chr11 61656117 G A 4.23E-07 Serum metabolites FADS3 intron 19043545 rs174455 chr11 61656117 G A 9.33E-56 Phospholipid levels (plasma) FADS3 intron 21829377 rs174455 chr11 61656117 G A 1.71E-62 Metabolite levels FADS3 intron 22286219 rs174455 chr11 61656117 G A 0.000000686 Triglycerides FADS3 intron 23063622 rs174455 chr11 61656117 G A 1.58E-08 Metabolite levels FADS3 intron 23281178 rs174455 chr11 61656117 G A 1.17E-98 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174455 chr11 61656117 G A 1.44E-45 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174455 chr11 61656117 G A 7.22E-27 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174455 chr11 61656117 G A 7.23E-61 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174455 chr11 61656117 G A 7.51E-255 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174456 chr11 61656182 C A 2.72E-39 Phospholipid levels (plasma) FADS3 intron 21829377 rs174456 chr11 61656182 C A 1.50E-59 Metabolite levels FADS3 intron 22286219 rs174456 chr11 61656182 C A 1.56E-150 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174456 chr11 61656182 C A 2.41E-51 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174456 chr11 61656182 C A 5.83E-60 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174456 chr11 61656182 C A 5.99E-21 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174456 chr11 61656182 C A 8.72E-31 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs1295988 chr11 61656658 A C 2.04E-59 Metabolite levels FADS3 intron 22286219 rs174457 chr11 61656975 T C 3.85E-61 Metabolite levels FADS3 intron 22286219 rs174460 chr11 61657110 C T 5.27E-41 Metabolite levels FADS3 intron 22286219 rs174460 chr11 61657110 C T 0.0000864 Salmonella-induced pyroptosis FADS3 intron 22837397 rs174461 chr11 61657401 A C 1.44E-31 Metabolite levels FADS3 intron 22286219 rs174462 chr11 61657666 G A 4.10E-20 Metabolite levels FADS3 intron 22286219 rs174463 chr11 61657838 G A 1.96E-59 Metabolite levels FADS3 intron 22286219 rs174464 chr11 61657926 A G 1.65E-39 Phospholipid levels (plasma) FADS3 intron 21829377 rs174464 chr11 61657926 A G 9.80E-27 Metabolite levels FADS3 intron 22286219 rs174464 chr11 61657926 A G 2.41E-51 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174464 chr11 61657926 A G 5.80E-152 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174464 chr11 61657926 A G 6.61E-61 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174464 chr11 61657926 A G 8.86E-31 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs174464 chr11 61657926 A G 9.82E-21 Plasma omega-6 polyunsaturated fatty acid levels FADS3 intron 24823311 rs693672 chr11 61658629 T C 1.57E-19 Metabolite levels FADS3 intron 22286219 rs174465 chr11 61658800 C T 1.94E-51 Metabolite levels FADS3 cds-synon 22286219 rs174466 chr11 61659296 A G 2.48E-22 Metabolite levels / / 22286219 rs6591668 chr11 61661113 T C 1.53E-11 Metabolite levels / / 22286219 rs174467 chr11 61662661 T G 5.03E-34 Metabolite levels / / 22286219 rs174468 chr11 61663691 G A 1.00E-12 Phospholipid levels (plasma) / / 21829377 rs174468 chr11 61663691 G A 2.00E-17 Phospholipid levels (plasma) / / 21829377 rs174468 chr11 61663691 G A 3.00E-35 Phospholipid levels (plasma) / / 21829377 rs174468 chr11 61663691 G A 5.80E-34 Metabolite levels / / 22286219 rs174468 chr11 61663691 G A 1.96E-129 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174468 chr11 61663691 G A 2.34E-23 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174468 chr11 61663691 G A 4.40E-28 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174468 chr11 61663691 G A 6.50E-16 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174468 chr11 61663691 G A 9.81E-64 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs17764935 chr11 61664757 G A 1.17E-14 Phospholipid levels (plasma) / / 21829377 rs17764935 chr11 61664757 G A 1.38E-32 Metabolite levels / / 22286219 rs17764935 chr11 61664757 G A 1.23E-31 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs17764935 chr11 61664757 G A 2.22E-70 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs17764935 chr11 61664757 G A 4.03E-13 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs13966 chr11 61664992 T C 2.70E-06 Triglycerides RAB3IL1 UTR-3 19074352 rs13966 chr11 61664992 T C 2.70E-06 Polyunsaturated fatty acid levels,in plasma RAB3IL1 UTR-3 19148276 rs13966 chr11 61664992 T C 9.92E-13 Phospholipid levels (plasma) RAB3IL1 UTR-3 21829377 rs13966 chr11 61664992 T C 1.34E-14 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 UTR-3 24823311 rs13966 chr11 61664992 T C 5.36E-24 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 UTR-3 24823311 rs13966 chr11 61664992 T C 6.35E-12 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 UTR-3 24823311 rs2235093 chr11 61665122 A G 5.36E-13 Phospholipid levels (plasma) RAB3IL1 UTR-3 21829377 rs2235093 chr11 61665122 A G 1.28E-24 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 UTR-3 24823311 rs2235093 chr11 61665122 A G 3.60E-12 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 UTR-3 24823311 rs2235093 chr11 61665122 A G 6.10E-15 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 UTR-3 24823311 rs174469 chr11 61667443 C T 8.14E-26 Phospholipid levels (plasma) RAB3IL1 intron 21829377 rs174471 chr11 61670037 C T 1.86E-30 Metabolite levels RAB3IL1 intron 22286219 rs174472 chr11 61671956 A G 5.74E-14 Phospholipid levels (plasma) RAB3IL1 intron 21829377 rs174472 chr11 61671956 A G 4.89E-12 Metabolite levels RAB3IL1 intron 22286219 rs174472 chr11 61671956 A G 1.48E-28 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs174472 chr11 61671956 A G 2.11E-14 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs174472 chr11 61671956 A G 7.04E-15 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs174475 chr11 61672645 G C 6.72E-17 Metabolite levels RAB3IL1 intron 22286219 rs174476 chr11 61674118 C T 3.35E-33 Phospholipid levels (plasma) / / 21829377 rs174476 chr11 61674118 C T 1.25E-34 Metabolite levels / / 22286219 rs174476 chr11 61674118 C T 1.48E-26 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174476 chr11 61674118 C T 2.34E-60 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174476 chr11 61674118 C T 2.56E-121 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174476 chr11 61674118 C T 3.90E-14 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174476 chr11 61674118 C T 4.30E-21 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs174477 chr11 61675644 T C 1.71E-12 Metabolite levels RAB3IL1 missense 22286219 rs666870 chr11 61677479 G A 3.40E-33 Phospholipid levels (plasma) RAB3IL1 intron 21829377 rs666870 chr11 61677479 G A 1.55E-26 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs666870 chr11 61677479 G A 2.71E-60 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs666870 chr11 61677479 G A 3.11E-121 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs666870 chr11 61677479 G A 4.09E-14 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs666870 chr11 61677479 G A 4.35E-21 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs174478 chr11 61678576 T G 4.06E-33 Phospholipid levels (plasma) RAB3IL1 intron 21829377 rs174478 chr11 61678576 T G 3.97E-76 Metabolite levels RAB3IL1 intron 22286219 rs174478 chr11 61678576 T G 2.78E-26 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs174478 chr11 61678576 T G 2.84E-60 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs174478 chr11 61678576 T G 5.64E-21 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs174478 chr11 61678576 T G 5.89E-14 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs174478 chr11 61678576 T G 7.24E-121 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs174479 chr11 61678754 C G 3.04E-31 Phospholipid levels (plasma) RAB3IL1 intron 21829377 rs174479 chr11 61678754 C G 1.15E-12 Metabolite levels RAB3IL1 intron 22286219 rs174479 chr11 61678754 C G 2.00E-14 Sphingolipid levels RAB3IL1 intron 22359512 rs174479 chr11 61678754 C G 1.10E-65 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs174479 chr11 61678754 C G 3.16E-121 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs174479 chr11 61678754 C G 5.39E-41 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs174479 chr11 61678754 C G 7.16E-21 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs174479 chr11 61678754 C G 7.84E-17 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs540613 chr11 61680870 T C 1.19E-15 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs540613 chr11 61680870 T C 4.35E-09 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs2524287 chr11 61684550 A G 1.05E-06 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs2524287 chr11 61684550 A G 8.49E-10 Plasma omega-6 polyunsaturated fatty acid levels RAB3IL1 intron 24823311 rs2521561 chr11 61685989 T C 5.17E-04 Lymphocyte counts / / 22286170 rs2524290 chr11 61687674 G A 1.91E-04 Blood pressure / / 17255346 rs2524290 chr11 61687674 G A 6.19E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs12420625 chr11 61690405 T G 1.71E-11 Metabolite levels / / 22286219 rs741888 chr11 61690544 C G 1.07E-13 Metabolite levels / / 22286219 rs2521562 chr11 61692019 C A 2.99E-14 Metabolite levels / / 22286219 rs882169 chr11 61692130 T C 2.51E-14 Metabolite levels / / 22286219 rs882169 chr11 61692130 T C 2.69E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs17156580 chr11 61692341 C T 8.52E-04 Alcohol dependence / / 21314694 rs17156580 chr11 61692341 C T 1.46E-14 Metabolite levels / / 22286219 rs2158026 chr11 61694394 C T 2.31E-14 Metabolite levels / / 22286219 rs2524292 chr11 61695146 T G 1.23E-36 Metabolite levels / / 22286219 rs2521564 chr11 61696334 G A 1.78E-14 Metabolite levels / / 22286219 rs2521565 chr11 61696675 A G 1.69E-14 Metabolite levels / / 22286219 rs2521566 chr11 61696885 A G 1.65E-14 Metabolite levels / / 22286219 rs2521567 chr11 61699055 G A 9.22E-04 Depression (quantitative trait) / / 20800221 rs2521567 chr11 61699055 G A 1.07E-17 Metabolite levels / / 22286219 rs2521567 chr11 61699055 G A 1.23E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2736604 chr11 61699827 C A 6.29E-17 Metabolite levels / / 22286219 rs2521568 chr11 61700933 G C 1.10E-07 Phospholipid levels (plasma) / / 21829377 rs2521568 chr11 61700933 G C 1.10E-04 Lymphocyte counts / / 22286170 rs2521568 chr11 61700933 G C 1.15E-23 Metabolite levels / / 22286219 rs2521568 chr11 61700933 G C 1.40E-37 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2521568 chr11 61700933 G C 2.38E-12 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2521568 chr11 61700933 G C 7.39E-17 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2521568 chr11 61700933 G C 7.62E-09 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2521569 chr11 61701418 G A 6.85E-17 Metabolite levels / / 22286219 rs2727273 chr11 61702603 C T 4.10E-12 Metabolite levels / / 22286219 rs2727266 chr11 61704334 A G 8.86E-08 Phospholipid levels (plasma) / / 21829377 rs2727266 chr11 61704334 A G 1.71E-37 Metabolite levels / / 22286219 rs2727266 chr11 61704334 A G 1.20E-37 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2727266 chr11 61704334 A G 2.06E-12 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2727266 chr11 61704334 A G 7.31E-17 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2727266 chr11 61704334 A G 7.42E-09 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2158027 chr11 61705207 G A 4.25E-04 Blood pressure / / 17255346 rs2158027 chr11 61705207 G A 1.43E-04 Depression (quantitative trait) / / 20800221 rs2736603 chr11 61705349 A T 1.16E-15 Metabolite levels / / 22286219 rs2736601 chr11 61705521 C T 2.50E-18 Metabolite levels / / 22286219 rs2736601 chr11 61705521 C T 4.66E-05 Interstitial lung disease / / 23583980 rs2736600 chr11 61706011 T C 1.07E-15 Metabolite levels / / 22286219 rs2727267 chr11 61706116 G A 8.94E-31 Metabolite levels / / 22286219 rs2727267 chr11 61706116 G A 4.21E-05 Interstitial lung disease / / 23583980 rs2736598 chr11 61706135 T C 1.24E-15 Metabolite levels / / 22286219 rs2524293 chr11 61710538 A C 5.02E-14 Metabolite levels / / 22286219 rs2727269 chr11 61710822 A G 1.29E-06 Phospholipid levels (plasma) / / 21829377 rs2727269 chr11 61710822 A G 1.71E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2727269 chr11 61710822 A G 8.27E-10 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2521572 chr11 61711475 T G 4.76E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2521572 chr11 61711475 T G 2.00E-09 Phospholipid levels (plasma) / / 21829377 rs2521572 chr11 61711475 T G 1.24E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2521572 chr11 61711475 T G 2.00E-29 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2521572 chr11 61711475 T G 7.49E-12 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2521572 chr11 61711475 T G 9.65E-11 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2727261 chr11 61712131 T C 8.85E-08 Phospholipid levels (plasma) / / 21829377 rs2727261 chr11 61712131 T C 2.11E-12 Metabolite levels / / 22286219 rs2727261 chr11 61712131 T C 3.00E-06 Estradiol levels / / 22675492 rs2727261 chr11 61712131 T C 1.29E-09 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2727261 chr11 61712131 T C 2.21E-13 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2727261 chr11 61712131 T C 7.88E-28 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1534842 chr11 61713590 A G 4.65E-22 Metabolite levels / / 22286219 rs972355 chr11 61717337 G C 3.56E-08 Plasma omega-6 polyunsaturated fatty acid levels BEST1 nearGene-5 24823311 rs972354 chr11 61717607 C T 2.81E-21 Metabolite levels BEST1 UTR-5 22286219 rs2736596 chr11 61719026 G A 6.39E-18 Metabolite levels BEST1 intron 22286219 rs1800007 chr11 61719387 T C 3.69E-08 Plasma omega-6 polyunsaturated fatty acid levels BEST1 cds-synon 24823311 rs195166 chr11 61721584 T C 1.63E-14 Metabolite levels BEST1 intron 22286219 rs2736594 chr11 61722212 G T 6.70E-15 Metabolite levels BEST1 intron 22286219 rs183176 chr11 61722265 C A 7.83E-15 Metabolite levels BEST1 intron 22286219 rs1109748 chr11 61722645 C A 5.00E-09 Phospholipid levels (plasma) BEST1 cds-synon 21829377 rs1109748 chr11 61722645 C A 1.68E-13 Metabolite levels BEST1 cds-synon 22286219 rs1109748 chr11 61722645 C A 2.98E-09 Plasma omega-6 polyunsaturated fatty acid levels BEST1 cds-synon 24823311 rs1109748 chr11 61722645 C A 6.47E-12 Plasma omega-6 polyunsaturated fatty acid levels BEST1 cds-synon 24823311 rs1109748 chr11 61722645 C A 7.40E-27 Plasma omega-6 polyunsaturated fatty acid levels BEST1 cds-synon 24823311 rs195165 chr11 61722838 T A 5.73E-15 Metabolite levels BEST1 intron 22286219 rs195165 chr11 61722838 T A 3.42E-07 Plasma omega-6 polyunsaturated fatty acid levels BEST1 intron 24823311 rs195165 chr11 61722838 T A 5.74E-13 Plasma omega-6 polyunsaturated fatty acid levels BEST1 intron 24823311 rs195164 chr11 61723556 A G 4.95E-15 Metabolite levels BEST1 intron 22286219 rs168990 chr11 61723859 G C 4.65E-15 Metabolite levels BEST1 intron 22286219 rs195163 chr11 61724003 C T 4.55E-15 Metabolite levels BEST1 intron 22286219 rs760306 chr11 61724292 C T 1.46E-08 Plasma omega-6 polyunsaturated fatty acid levels BEST1 intron 24823311 rs760306 chr11 61724292 C T 2.42E-15 Plasma omega-6 polyunsaturated fatty acid levels BEST1 intron 24823311 rs195162 chr11 61724514 C T 4.27E-15 Metabolite levels BEST1 intron 22286219 rs195162 chr11 61724514 C T 3.14E-07 Plasma omega-6 polyunsaturated fatty acid levels BEST1 intron 24823311 rs195162 chr11 61724514 C T 4.97E-13 Plasma omega-6 polyunsaturated fatty acid levels BEST1 intron 24823311 rs741886 chr11 61724787 G T 1.10E-13 Metabolite levels BEST1 intron 22286219 rs741886 chr11 61724787 G T 1.32E-13 Plasma omega-6 polyunsaturated fatty acid levels BEST1 intron 24823311 rs741886 chr11 61724787 G T 1.68E-07 Plasma omega-6 polyunsaturated fatty acid levels BEST1 intron 24823311 rs741886 chr11 61724787 G T 7.26E-06 Plasma omega-6 polyunsaturated fatty acid levels BEST1 intron 24823311 rs2955684 chr11 61725174 T C 4.14E-15 Metabolite levels BEST1 intron 22286219 rs2955683 chr11 61725175 G A 4.75E-17 Metabolite levels BEST1 intron 22286219 rs2668898 chr11 61725498 A G,T 5.65E-05 Asthma BEST1 intron 11022011 rs2668898 chr11 61725498 A G,T 1.84E-13 Plasma omega-6 polyunsaturated fatty acid levels BEST1 intron 24823311 rs2668898 chr11 61725498 A G,T 2.74E-08 Plasma omega-6 polyunsaturated fatty acid levels BEST1 intron 24823311 rs195160 chr11 61726097 T G 2.10E-15 Metabolite levels BEST1 intron 22286219 rs195160 chr11 61726097 T G 5.92E-12 Plasma omega-6 polyunsaturated fatty acid levels BEST1 intron 24823311 rs195160 chr11 61726097 T G 6.75E-07 Plasma omega-6 polyunsaturated fatty acid levels BEST1 intron 24823311 rs195158 chr11 61726871 G T 7.02E-19 Metabolite levels BEST1 intron 22286219 rs195157 chr11 61727791 G A 1.70E-05 Urinary metabolites BEST1 intron 21572414 rs195157 chr11 61727791 G A 7.74E-19 Metabolite levels BEST1 intron 22286219 rs195157 chr11 61727791 G A 2.34E-11 Plasma omega-6 polyunsaturated fatty acid levels BEST1 intron 24823311 rs195157 chr11 61727791 G A 6.20E-07 Plasma omega-6 polyunsaturated fatty acid levels BEST1 intron 24823311 rs195156 chr11 61729063 C T 8.66E-17 Metabolite levels BEST1 intron 22286219 rs195156 chr11 61729063 C T 1.10E-09 Plasma omega-6 polyunsaturated fatty acid levels BEST1 intron 24823311 rs195156 chr11 61729063 C T 2.13E-06 Plasma omega-6 polyunsaturated fatty acid levels BEST1 intron 24823311 rs1800009 chr11 61730234 T C 1.06E-07 Phospholipid levels (plasma) BEST1 frameshift 21829377 rs1800009 chr11 61730234 T C 1.63E-14 Plasma omega-6 polyunsaturated fatty acid levels BEST1 frameshift 24823311 rs1800009 chr11 61730234 T C 2.86E-32 Plasma omega-6 polyunsaturated fatty acid levels BEST1 frameshift 24823311 rs1800009 chr11 61730234 T C 9.60E-15 Plasma omega-6 polyunsaturated fatty acid levels BEST1 frameshift 24823311 rs17156609 chr11 61731977 G A 3.56E-20 Metabolite levels FTH1 UTR-3 22286219 rs17156609 chr11 61731977 G A 4.09E-08 Plasma omega-6 polyunsaturated fatty acid levels FTH1 UTR-3 24823311 rs17156609 chr11 61731977 G A 4.97E-12 Plasma omega-6 polyunsaturated fatty acid levels FTH1 UTR-3 24823311 rs3758977 chr11 61737244 T G 1.14E-07 Phospholipid levels (plasma) / / 21829377 rs3758977 chr11 61737244 T G 3.56E-32 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs3758977 chr11 61737244 T G 3.81E-14 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs3758977 chr11 61737244 T G 8.42E-14 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs195446 chr11 61742966 C T 1.04E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs195446 chr11 61742966 C T 2.83E-09 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs195445 chr11 61744342 C T 3.13E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs195445 chr11 61744342 C T 5.33E-13 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs17156618 chr11 61744672 A G 9.25E-20 Metabolite levels / / 22286219 rs17156618 chr11 61744672 A G 1.61E-11 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs17156618 chr11 61744672 A G 4.61E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs17633020 chr11 61744881 G A 1.70E-17 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs17633020 chr11 61744881 G A 6.66E-12 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs17185574 chr11 61745694 T C 2.12E-17 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs17185574 chr11 61745694 T C 7.02E-12 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2028062 chr11 61745953 G A 1.35E-07 Phospholipid levels (plasma) / / 21829377 rs2028062 chr11 61745953 G A 1.55E-31 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2028062 chr11 61745953 G A 2.59E-13 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2028062 chr11 61745953 G A 9.27E-14 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10897193 chr11 61746269 T G 4.20E-05 Glucose levels / / pha003061 rs10792320 chr11 61746291 A C 8.00E-08 Phospholipid levels (plasma) / / 21829377 rs10792320 chr11 61746291 A C 1.44E-13 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10792320 chr11 61746291 A C 1.59E-31 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10792320 chr11 61746291 A C 2.88E-13 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7105652 chr11 61749334 G A 1.96E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7105652 chr11 61749334 G A 4.32E-12 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10792322 chr11 61761552 C T 1.87E-05 Cognitive impairment induced by topiramate / / 22091778 rs10736716 chr11 61765133 C G 1.32E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10736716 chr11 61765133 C G 8.59E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4423188 chr11 61766418 A T 1.61E-09 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4423188 chr11 61766418 A T 2.67E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4313591 chr11 61766569 C T 3.83E-13 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4313591 chr11 61766569 C T 6.46E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4963441 chr11 61768639 G C 3.21E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4963441 chr11 61768639 G C 4.01E-13 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4963442 chr11 61768706 C T 3.15E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4963442 chr11 61768706 C T 4.04E-13 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7937198 chr11 61768973 G A 2.95E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7937198 chr11 61768973 G A 4.14E-13 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11605994 chr11 61770839 C T 1.18E-10 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4963444 chr11 61773342 G A 2.76E-07 Phospholipid levels (plasma) / / 21829377 rs4963444 chr11 61773342 G A 1.91E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4963444 chr11 61773342 G A 2.47E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4963444 chr11 61773342 G A 6.31E-10 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10897203 chr11 61778513 A C 1.81E-11 Metabolite levels / / 22286219 rs12789285 chr11 61779988 C G 3.52E-11 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs907634 chr11 61780022 G A 1.62E-04 Type 2 diabetes / / 17463246 rs6591687 chr11 61782648 C T 1.48E-10 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7951604 chr11 61784827 G A 1.14E-10 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10897208 chr11 61791887 A T 2.40E-07 Phospholipid levels (plasma) / / 21829377 rs10897208 chr11 61791887 A T 3.08E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10897208 chr11 61791887 A T 4.58E-09 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10897208 chr11 61791887 A T 9.06E-11 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230874 chr11 61795586 T G 2.00E-08 Phospholipid levels (plasma) / / 21829377 rs11230874 chr11 61795586 T G 1.07E-09 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230874 chr11 61795586 T G 3.85E-12 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230874 chr11 61795586 T G 9.96E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230882 chr11 61800812 G A 1.62E-04 Atopy / / 21625490 rs10897209 chr11 61803540 A G 2.48E-11 Metabolite levels / / 22286219 rs3019619 chr11 61806971 T A 1.34E-11 Metabolite levels / / 22286219 rs3019626 chr11 61808272 T C 1.73E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs259874 chr11 61811441 A G 6.65E-12 Metabolite levels / / 22286219 rs4963452 chr11 61815803 T C 6.00E-07 Phospholipid levels (plasma) / / 21829377 rs4963452 chr11 61815803 T C 5.92E-20 Metabolite levels / / 22286219 rs61896703 chr11 61818461 G A 1.22E-19 Metabolite levels / / 22286219 rs61896704 chr11 61818653 G A 1.17E-19 Metabolite levels / / 22286219 rs259888 chr11 61819450 T A 4.10E-11 Metabolite levels / / 22286219 rs259889 chr11 61820365 T C 6.58E-13 Metabolite levels / / 22286219 rs11533255 chr11 61820565 T C 9.46E-20 Metabolite levels / / 22286219 rs4963453 chr11 61821948 A G 8.92E-20 Metabolite levels / / 22286219 rs11230889 chr11 61823386 A C 9.31E-10 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs12226389 chr11 61823630 T C 2.57E-13 Metabolite levels / / 22286219 rs12224554 chr11 61823723 C T 1.70E-13 Metabolite levels / / 22286219 rs444803 chr11 61824821 G A 4.07E-12 Metabolite levels / / 22286219 rs450402 chr11 61825568 T G 5.60E-13 Metabolite levels / / 22286219 rs442243 chr11 61825696 A G 5.44E-13 Metabolite levels / / 22286219 rs2446738 chr11 61826822 C T 2.32E-11 Metabolite levels / / 22286219 rs2446738 chr11 61826822 C T 2.42E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2446738 chr11 61826822 C T 6.82E-11 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10897213 chr11 61827748 C T 6.10E-13 Metabolite levels / / 22286219 rs10897213 chr11 61827748 C T 1.96E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10897213 chr11 61827748 C T 5.56E-11 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7112985 chr11 61827915 C G 3.27E-13 Metabolite levels / / 22286219 rs7112985 chr11 61827915 C G 1.97E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7112985 chr11 61827915 C G 5.69E-11 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7946441 chr11 61828975 C G 3.03E-13 Metabolite levels / / 22286219 rs7946441 chr11 61828975 C G 1.96E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7946441 chr11 61828975 C G 6.22E-11 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs449397 chr11 61829795 A G 9.25E-13 Metabolite levels / / 22286219 rs449397 chr11 61829795 A G 1.82E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs449397 chr11 61829795 A G 8.09E-11 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs429416 chr11 61829929 T C 3.10E-13 Metabolite levels / / 22286219 rs429416 chr11 61829929 T C 1.78E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs429416 chr11 61829929 T C 8.19E-11 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs387137 chr11 61830169 G C 2.15E-17 Metabolite levels / / 22286219 rs387137 chr11 61830169 G C 8.22E-06 Metabolite levels (atherosclerosis) / / 22916037 rs387137 chr11 61830169 G C 1.66E-14 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs387137 chr11 61830169 G C 6.92E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7944736 chr11 61832031 A C 5.19E-11 Metabolite levels / / 22286219 rs11230896 chr11 61851204 C T 1.04E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230896 chr11 61851204 C T 1.69E-17 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs12365974 chr11 61856767 C T 3.14E-11 Metabolite levels / / 22286219 rs12365974 chr11 61856767 C T 1.00E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs12365974 chr11 61856767 C T 5.71E-10 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11603446 chr11 61869513 T C 4.67E-04 Lung function (forced vital capacity) / / 24023788 rs7934431 chr11 61878515 T C 2.04E-04 Rheumatoid arthritis / / 21452313 rs7945278 chr11 61878569 C A 1.59E-04 Rheumatoid arthritis / / 21452313 rs11230906 chr11 61879689 G A 6.56E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230906 chr11 61879689 G A 9.62E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs3899187 chr11 61883877 A T 3.76E-09 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs3899187 chr11 61883877 A T 4.33E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2264278 chr11 61885073 A C 1.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs3862389 chr11 61889542 G A 9.05E-04 Rheumatoid arthritis / / 21452313 rs17707648 chr11 61890812 G A 9.88E-09 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4144907 chr11 61891350 G C 1.71E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1675127 chr11 61891368 G C 1.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs1628349 chr11 61894482 A G 2.70E-04 Suicide attempts in bipolar disorder INCENP intron 21423239 rs1675131 chr11 61895741 A G 2.33E-04 Aortic root size INCENP cds-synon 21223598 rs1792942 chr11 61898561 G A 3.60E-04 Aortic root size INCENP intron 21223598 rs4963466 chr11 61902126 C G 2.49E-11 Plasma omega-6 polyunsaturated fatty acid levels INCENP intron 24823311 rs4963466 chr11 61902126 C G 6.02E-10 Plasma omega-6 polyunsaturated fatty acid levels INCENP intron 24823311 rs3741250 chr11 61905594 C G 1.77E-06 Plasma omega-6 polyunsaturated fatty acid levels INCENP intron 24823311 rs3781974 chr11 61906864 G A 2.06E-11 Plasma omega-6 polyunsaturated fatty acid levels INCENP intron 24823311 rs3781974 chr11 61906864 G A 6.65E-10 Plasma omega-6 polyunsaturated fatty acid levels INCENP intron 24823311 rs3781973 chr11 61906945 C G 1.09E-06 Plasma omega-6 polyunsaturated fatty acid levels INCENP intron 24823311 rs3781973 chr11 61906945 C G 4.11E-06 Plasma omega-6 polyunsaturated fatty acid levels INCENP intron 24823311 rs12795611 chr11 61907969 C T 3.29E-06 Plasma omega-6 polyunsaturated fatty acid levels INCENP intron 24823311 rs12795611 chr11 61907969 C T 7.48E-07 Plasma omega-6 polyunsaturated fatty acid levels INCENP intron 24823311 rs2277283 chr11 61908440 T A,C,G 0.00074 Prostate cancer INCENP missense 23555315 rs7129085 chr11 61913196 G T 3.42E-07 Plasma omega-6 polyunsaturated fatty acid levels INCENP missense 24823311 rs3781969 chr11 61913611 T G 4.97E-04 Type 2 diabetes INCENP intron 17463246 rs3781969 chr11 61913611 T G 8.24E-07 Plasma omega-6 polyunsaturated fatty acid levels INCENP intron 24823311 rs11230928 chr11 61913805 A G 3.71E-07 Plasma omega-6 polyunsaturated fatty acid levels INCENP intron 24823311 rs2511347 chr11 61914975 T A 6.20E-07 Plasma omega-6 polyunsaturated fatty acid levels INCENP intron 24823311 rs1675108 chr11 61918633 G A 5.97E-07 Plasma omega-6 polyunsaturated fatty acid levels INCENP intron 24823311 rs11230935 chr11 61922848 T C 1.67E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7928360 chr11 61923595 A G 5.52E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230938 chr11 61924705 G A 5.62E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2903922 chr11 61929298 T A 5.70E-12 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2903922 chr11 61929298 T A 9.25E-09 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230941 chr11 61930797 G A 6.33E-12 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230941 chr11 61930797 G A 8.17E-09 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1460027 chr11 61931935 T A 4.50E-09 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1460027 chr11 61931935 T A 7.52E-12 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11603737 chr11 61932940 G T 5.08E-04 Aortic root size / / 21223598 rs11603737 chr11 61932940 G T 7.06E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1675088 chr11 61935741 G C 9.34E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10897221 chr11 61939119 G T 6.15E-10 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10897221 chr11 61939119 G T 7.81E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1675102 chr11 61954009 C T 4.29E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1675102 chr11 61954009 C T 8.25E-10 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2232932 chr11 61957137 G T 4.67E-06 Age-related macular degeneration / / pha000001 rs2298823 chr11 61959819 C G 3.03E-08 Plasma omega-6 polyunsaturated fatty acid levels SCGB1D1 intron 24823311 rs2298823 chr11 61959819 C G 7.55E-11 Plasma omega-6 polyunsaturated fatty acid levels SCGB1D1 intron 24823311 rs1675105 chr11 61963615 A G 1.06E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1675105 chr11 61963615 A G 1.89E-11 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1792876 chr11 61963632 A G 1.00E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1792876 chr11 61963632 A G 1.90E-11 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1729370 chr11 61966021 C G 1.44E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11230982 chr11 61968341 A T 1.56E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1792957 chr11 61968807 C A 1.53E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1729372 chr11 61969011 G A 1.50E-11 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1729372 chr11 61969011 G A 7.46E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1729374 chr11 61969430 A G 1.46E-11 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1729374 chr11 61969430 A G 7.49E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2463838 chr11 61971537 C T 1.45E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs12420642 chr11 61971851 G A 1.27E-11 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs12420642 chr11 61971851 G A 7.01E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1729377 chr11 61974056 T C 1.61E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs3900954 chr11 61975131 G A 1.71E-07 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1792902 chr11 61975755 C G 9.85E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10897237 chr11 61976792 C G 1.35E-07 Plasma omega-6 polyunsaturated fatty acid levels SCGB2A1 intron 24823311 rs3915312 chr11 61990939 C T 9.86E-15 Metabolite levels / / 22286219 rs11602604 chr11 61998537 T C 9.04E-04 Type 2 diabetes / / 17463246 rs11602604 chr11 61998537 T C 0.0004 Personality disorders (PD) - Cluster C / / 22981920 rs12806663 chr11 62001414 C A,T 3.31E-05 Brain lesion load / / 19010793 rs12806663 chr11 62001414 C A,T 2.59E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs12806663 chr11 62001414 C A,T 5.84E-09 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2232946 chr11 62009611 C T 1.75E-14 Metabolite levels / / 22286219 rs2232950 chr11 62010863 C T 1.78E-04 Prion diseases SCGB1D2 missense 22210626 rs17157040 chr11 62015275 A G 4.44E-05 Hypertension / / pha003041 rs7936908 chr11 62016765 C T 8.55E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10897242 chr11 62022442 C A 5.63E-06 Cognitive impairment induced by topiramate / / 22091778 rs10501333 chr11 62023301 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11604814 chr11 62027308 C T 8.77E-05 Cognitive impairment induced by topiramate / / 22091778 rs17157079 chr11 62032990 A G 2.70E-05 Coffee consumption / / 21357676 rs12798472 chr11 62035219 G C 3.83E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs12800927 chr11 62035677 C T 3.83E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7129637 chr11 62038752 T A 1.38E-05 Age-related macular degeneration SCGB2A2 intron pha000001 rs7925016 chr11 62043929 C T 1.40E-09 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10750972 chr11 62053687 A G 0.00028 Salmonella-induced pyroptosis / / 22837397 rs954237 chr11 62064715 T C 1.05E-05 Cocaine dependence SCGB1D4 intron 23958962 rs954237 chr11 62064715 T C 1.38E-04 Cocaine dependence SCGB1D4 intron 23958962 rs17157147 chr11 62068526 G A 6.86E-05 Coronary Artery Disease / / 17634449 rs12282256 chr11 62080857 C T 1.50E-04 Coronary Artery Disease / / 17634449 rs11231029 chr11 62084003 A G 9.00E-05 Coronary Artery Disease / / 17634449 rs10501332 chr11 62101765 G A 5.44E-05 Coronary Artery Disease / / 17634449 rs2463822 chr11 62103420 T C 1.00E-10 Chronic obstructive pulmonary disease-related biomarkers / / 23144326 rs11824690 chr11 62139467 G T 4.92E-04 Hemoglobin concentration ASRGL1 intron 20534544 rs2958531 chr11 62158886 G T 2.40E-04 Lymphocyte counts ASRGL1 intron 22286170 rs2958532 chr11 62158924 C T 6.31E-05 Coronary Artery Disease ASRGL1 intron 17634449 rs11231073 chr11 62161324 G T 4.07E-04 Hemoglobin concentration / / 20534544 rs7119797 chr11 62166235 C T 5.06E-06 Osteoarthritis / / 22763110 rs7119797 chr11 62166235 C T 6.67E-04 Alzheimer's disease / / 24755620 rs17157227 chr11 62169772 C T 3.61E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs3889277 chr11 62178821 G C 3.28E-09 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs10897270 chr11 62183007 C T 6.41E-11 Metabolite levels / / 22286219 rs3741240 chr11 62186542 G A 1.00E-26 Chronic obstructive pulmonary disease-related biomarkers SCGB1A1 UTR-5 23144326 rs2077224 chr11 62197427 C A 2.00E-14 Chronic obstructive pulmonary disease-related biomarkers / / 23144326 rs12788265 chr11 62199766 G C 4.88E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs17157266 chr11 62199817 T C 1.00E-09 Chronic obstructive pulmonary disease-related biomarkers / / 23144326 rs17663676 chr11 62201002 T C 4.52E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs4084164 chr11 62201458 A G 0.0000797 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes AH/K intron 22628534 rs1783180 chr11 62227307 C T 2.25E-05 Alzheimer's disease AH/K intron 24755620 rs2513044 chr11 62237317 A G 5.69E-05 Diabetes (gestational) AH/K intron 22233651 rs11231111 chr11 62260005 C T 5.48E-07 Body mass index AH/K intron 19584900 rs11231111 chr11 62260005 C T 7.39E-05 Body mass index AH/K intron 19584900 rs2509982 chr11 62312318 C T 7.58E-04 Taste perception AH/K intron 22132133 rs7942991 chr11 62337203 C T 7.96E-09 Lymphocyte counts EEF1G intron 22286170 rs146358003 chr11 62381076 C T 0.000026 Breast cancer ROM1 missense 23555315 rs7386 chr11 62430335 G A 0.00000493 Femoral neck bone mineral density (premenopausal) C11orf48 UTR-3 23074152 rs2512561 chr11 62453952 G A 6.96E-05 Cognitive test performance / / 20125193 rs575134 chr11 62461229 A G 6.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) BSCL2 intron 24554482 rs549312 chr11 62479846 T C 4.49E-05 Cognitive test performance HNRNPUL2-BSCL2 intron 20125193 rs584845 chr11 62496519 T C 5.99E-05 Cognitive test performance TTC9C cds-synon 20125193 rs3763851 chr11 62572433 C A 3.27E-04 Alzheimer's disease (late onset) NXF1 intron 21379329 rs489381 chr11 62652063 A G 0.00045 Glomerular filtration rate SLC3A2 intron 22962313 rs2507820 chr11 62661158 A G 5.80E-04 Myocardial Infarction / / pha002883 rs547248 chr11 62663659 C T 8.82E-04 Suicide attempts in bipolar disorder / / 21041247 rs547248 chr11 62663659 C T 3.70E-05 Osteoarthritis (knee and hip) / / 21177295 rs547248 chr11 62663659 C T 9.07E-05 Alzheimer's disease (late onset) / / 21379329 rs2507821 chr11 62666606 T G 2.63E-04 Myocardial Infarction / / pha002883 rs530752 chr11 62671014 G A 6.11E-04 Heart Failure / / pha002885 rs12223849 chr11 62717297 C T 0.0000666 Migraine / / 22678113 rs12223849 chr11 62717297 C T 6.66E-05 Migraine / / 22683712 rs10897307 chr11 62728412 C T 9.03E-04 Stroke / / pha002886 rs736342 chr11 62743055 C T 1.91E-04 Blood pressure / / 17255346 rs11568634 chr11 62746960 C T 1 Drug response to Adefovir Dipivoxil SLC22A6 missense 19940846 rs953894 chr11 62762422 C T 4.53E-04 Bipolar disorder SLC22A8 intron 19259986 rs11568493 chr11 62763607 A C 1 Drug response to Cimetidine SLC22A8 missense 19940846 rs11568493 chr11 62763607 A C 1 Drug response to Conjugated Estrogens SLC22A8 missense 19940846 rs11568496 chr11 62766439 G A 1 Drug response to Cimetidine SLC22A8 STOP-GAIN 19940846 rs11568496 chr11 62766439 G A 1 Drug response to Conjugated Estrogens SLC22A8 STOP-GAIN 19940846 rs45566039 chr11 62767307 G T 1 Drug response to Cimetidine SLC22A8 missense 19940846 rs45566039 chr11 62767307 G T 1 Drug response to Conjugated Estrogens SLC22A8 missense 19940846 rs11231299 chr11 62771388 G A 5.00E-06 Visceral fat SLC22A8 intron 22589738 rs948979 chr11 62783826 T G 0.000592 Salmonella-induced pyroptosis / / 22837397 rs10792369 chr11 62786435 C T 1.72E-04 Vaspin levels / / 22907691 rs10792369 chr11 62786435 C T 0.0001722 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs10897316 chr11 62789763 G A 1.49E-04 Vaspin levels / / 22907691 rs10897316 chr11 62789763 G A 0.0001491 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs1944037 chr11 62803525 G C 5.87E-04 Multiple complex diseases / / 17554300 rs11231328 chr11 62839667 G A 9.07E-05 Tunica Media / / pha003034 rs7926818 chr11 62847562 G T 6.53E-05 Tunica Media SLC22A24 intron pha003034 rs6591751 chr11 62881839 A G 6.74E-04 Multiple complex diseases SLC22A24 intron 17554300 rs948060 chr11 62886319 G C 9.58E-04 Body mass index SLC22A24 intron 17255346 rs11231379 chr11 62904935 C G 4.23E-06 Conotruncal heart defects SLC22A24 intron 24800985 rs7948969 chr11 62907048 A C,G 1.66E-06 Conotruncal heart defects SLC22A24 intron 24800985 rs1939748 chr11 62911079 G C 1.41E-06 Conotruncal heart defects SLC22A24 missense 24800985 rs1939747 chr11 62911658 T C 1.82E-06 Conotruncal heart defects SLC22A24 UTR-5 24800985 rs4393318 chr11 62912785 A C 1.72E-06 Conotruncal heart defects / / 24800985 rs4366490 chr11 62912854 T C 1.00E-06 Conotruncal heart defects / / 24800985 rs12804561 chr11 62916577 A G 1.80E-05 Urinary metabolites / / 21572414 rs10897384 chr11 62949577 A T 9.50E-06 Urinary metabolites SLC22A25 intron 21572414 rs10897399 chr11 63008750 G A 2.80E-06 Urinary metabolites / / 21572414 rs1152240 chr11 63070493 T A 8.48E-04 Substance dependence SLC22A10 intron 21818250 rs1201559 chr11 63072310 C T 8.46E-04 Type 2 diabetes SLC22A10 missense 17463246 rs1193722 chr11 63105017 T G 9.92E-04 Type 2 diabetes / / 17463246 rs7101446 chr11 63173684 T G 3.00E-06 Economic and political preferences SLC22A9 intron 22566634 rs4963412 chr11 63180515 A G 1.06E-04 Hemoglobin concentration / / 20534544 rs12280132 chr11 63231259 T G 7.74E-06 Asthma (childhood onset) HRASLS5 intron 23829686 rs17158380 chr11 63247387 G A 7.21E-04 Multiple complex diseases HRASLS5 intron 17554300 rs1788279 chr11 63288649 G T 9.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs1788279 chr11 63288649 G T 4.74E-05 Basophils / / pha003087 rs948796 chr11 63327186 A G 5.37E-04 Smoking quantity HRASLS2 intron 24665060 rs640908 chr11 63357329 C T 2.39E-05 Serum metabolites PLA2G16 intron 19043545 rs10897449 chr11 63592621 C T 7.00E-06 Electroencephalographic traits in alcoholism C11orf84 intron 22554406 rs928948 chr11 63639881 A G 3.86E-05 Major depressive disorder (broad) MARK2 intron 20038947 rs10897459 chr11 63659778 C T 2.78E-05 Major depressive disorder (broad) MARK2 intron 20038947 rs4980530 chr11 63661512 A C 2.66E-05 Major depressive disorder (broad) MARK2 intron 20038947 rs7105288 chr11 63664306 A G 9.75E-05 Major depressive disorder (broad) MARK2 intron 20038947 rs12099085 chr11 63666944 C T 5.00E-06 Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure) MARK2 intron 21130132 rs4980499 chr11 63707203 G A 2.03E-05 Major depressive disorder (broad) /A40 intron 20038947 rs4980499 chr11 63707203 G A 2.10E-05 Urinary metabolites /A40 intron 21572414 rs3740637 chr11 63713317 G A 2.01E-05 Major depressive disorder (broad) /A40 cds-synon 20038947 rs4980500 chr11 63714319 T C 2.02E-05 Major depressive disorder (broad) /A40 intron 20038947 rs12798491 chr11 63714930 A C 1.90E-06 Stroke (ischemic) /A40 intron 22384361 rs10897466 chr11 63723238 A G 1.40E-06 Stroke (ischemic) /A40 UTR-3 22384361 rs11231662 chr11 63738642 T G 8.44E-05 Major depressive disorder (broad) / / 20038947 rs480211 chr11 63739439 C T 3.87E-06 Blood pressure / / 21909110 rs11231664 chr11 63742553 T G 1.62E-05 Major depressive disorder (broad) COX8A intron 20038947 rs11605797 chr11 63743420 A G 1.50E-05 Major depressive disorder (broad) COX8A intron 20038947 rs12800703 chr11 63746120 A G 3.39E-05 Major depressive disorder (broad) / / 20038947 rs11602700 chr11 63754511 G T 7.61E-05 Multiple complex diseases OTUB1 intron 17554300 rs11602700 chr11 63754511 G T 8.47E-08 White blood cell count OTUB1 intron 21738479 rs11231670 chr11 63759890 G T 1.29E-05 Major depressive disorder (broad) OTUB1 intron 20038947 rs11231671 chr11 63761169 C T 1.28E-05 Major depressive disorder (broad) OTUB1 intron 20038947 rs492357 chr11 63771452 C T 2.05E-05 Major depressive disorder (broad) MACROD1 intron 20038947 rs12291575 chr11 63774487 T C 6.77E-04 Response to statin treatment (atorvastatin),change in cholesterol levels MACROD1 intron 20031582 rs509701 chr11 63774597 T C 2.55E-05 Major depressive disorder (broad) MACROD1 intron 20038947 rs504060 chr11 63775566 T A 2.20E-05 Major depressive disorder (broad) MACROD1 intron 20038947 rs562661 chr11 63810915 A C 4.40E-05 Personality dimensions MACROD1 intron 18957941 rs2622417 chr11 63832142 C A 5.23E-05 Multiple complex diseases MACROD1 intron 17554300 rs12575710 chr11 63849330 G A 1.00E-04 Information processing speed MACROD1 intron 21130836 rs11231693 chr11 63862612 G A 0.000000719 Body mass index MACROD1 intron 22885924 rs641811 chr11 63869596 G A 7.00E-05 Prostate cancer MACROD1 intron 21743057 rs651855 chr11 63870810 T C 7.15E-04 Response to cytidine analogues (gemcitabine) MACROD1 intron 24483146 rs12418845 chr11 63873673 G A 3.09E-08 Urate levels FLRT1 intron 23263486 rs2186643 chr11 63878074 G A 0.000163711 Hypertension (early onset hypertension) FLRT1 intron 22479346 rs3824854 chr11 63885305 C T 6.86E-05 Rheumatoid arthritis (ACPA-negative) FLRT1 cds-synon 24532677 rs2186571 chr11 63915700 G A 2.32E-05 Bipolar disorder,affective MACROD1 intron 20528957 rs1123251 chr11 63917601 G T 0.000172642 Hypertension (early onset hypertension) MACROD1 intron 22479346 rs11607165 chr11 63963947 T G 4.00E-06 Attention deficit hyperactivity disorder STIP1 intron 21784300 rs12575642 chr11 63979643 G T 1.00E-06 Attention deficit hyperactivity disorder FERMT3 intron 21784300 rs75295961 chr11 63987441 C G 0.000024 Breast cancer(er negative) FERMT3 missense 23555315 rs1059440 chr11 63991801 T C 4.00E-06 Attention deficit hyperactivity disorder TRPT1 missense 21784300 rs7943988 chr11 64023971 G A 3.93E-04 Multiple complex diseases PLCB3 cds-synon 17554300 rs2244625 chr11 64026144 G A 0.00000141 HIV-1 infection (natural long-term nonprogression) PLCB3 cds-synon 22238471 rs671976 chr11 64046029 G A 0.00000463 HDL cholesterol BAD intron 23063622 rs477895 chr11 64048912 C T 5.00E-08 Mean platelet volume BAD intron 22423221 rs694739 chr11 64097233 A G 4.00E-07 Alopecia areata / / 20596022 rs694739 chr11 64097233 A G 6.00E-10 Crohn's disease / / 21102463 rs694739 chr11 64097233 A G 1.40E-04 Multiple sclerosis / / 21833088 rs694739 chr11 64097233 A G 0.000285 Primary biliary cirrhosis / / 22936693 rs694739 chr11 64097233 A G 0.000296 Primary biliary cirrhosis (anti-mitochondrial antibody positive) / / 22936693 rs694739 chr11 64097233 A G 0.000000196 Primary biliary cirrhosis / / 22961000 rs694739 chr11 64097233 A G 0.000000825 Primary sclerosing cholangitis / / 23603763 rs479777 chr11 64107477 T C 3.00E-18 Sarcoidosis / / 22837380 rs574835 chr11 64110668 G A 0.000494 Primary biliary cirrhosis CCDC88B cds-synon 22936693 rs685870 chr11 64111928 T C 2.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCDC88B missense 20877124 rs685870 chr11 64111928 T C 3.59E-05 Cognitive impairment induced by topiramate CCDC88B missense 22091778 rs510372 chr11 64115137 C T 1.11E-06 Primary biliary cirrhosis CCDC88B intron 21399635 rs538147 chr11 64129722 G A 2.00E-10 Primary biliary cirrhosis RPS6KA4 intron 21399635 rs538147 chr11 64129722 G A 7.00E-06 Leprosy RPS6KA4 intron 22019778 rs3782101 chr11 64131280 T C 9.25E-04 Type 2 diabetes RPS6KA4 intron 17463246 rs645078 chr11 64135298 A C 0.0000022 Psoriasis RPS6KA4 intron 23143594 rs559928 chr11 64150370 T C 7.44E-06 Crohn's disease / / 18587394 rs559928 chr11 64150370 T C 4.00E-11 Inflammatory bowel disease / / 23128233 rs560800 chr11 64162590 T C 4.95E-04 Multiple complex diseases / / 17554300 rs750832 chr11 64163302 A G 6.51E-04 Type 2 diabetes / / 17463246 rs750832 chr11 64163302 A G 6.90E-06 Urinary metabolites / / 21572414 rs1320628 chr11 64175986 G A 3.20E-06 Urinary metabolites / / 21572414 rs4930175 chr11 64197117 T C 6.70E-06 Urinary metabolites / / 21572414 rs682848 chr11 64200379 C G 4.93E-04 Insulin resistance / / 21901158 rs550840 chr11 64201639 C T 3.06E-04 Insulin resistance / / 21901158 rs606063 chr11 64202729 T C 3.00E-04 Insulin resistance / / 21901158 rs596308 chr11 64210652 G A 8.17E-04 Multiple complex diseases / / 17554300 rs596308 chr11 64210652 G A 3.45E-05 Crohn's disease / / 18587394 rs596308 chr11 64210652 G A 3.53E-05 Personality dimensions / / 18957941 rs596308 chr11 64210652 G A 1.80E-05 Urinary metabolites / / 21572414 rs596308 chr11 64210652 G A 8.08E-04 Insulin resistance / / 21901158 rs10792436 chr11 64219747 G A 8.83E-06 White blood cell count / / 21738479 rs7938871 chr11 64223527 C A 2.07E-08 Urate levels / / 23263486 rs620692 chr11 64224628 G A 3.88E-08 Urate levels / / 23263486 rs488998 chr11 64225239 C T 3.39E-08 Urate levels / / 23263486 rs7936265 chr11 64225632 T C 2.35E-08 Urate levels / / 23263486 rs4247633 chr11 64226279 T C 1.50E-07 Urate levels / / 20884846 rs4247633 chr11 64226279 T C 8.03E-11 Urate levels / / 23263486 rs4247634 chr11 64226488 A G 1.50E-07 Urate levels / / 20884846 rs4247634 chr11 64226488 A G 6.76E-11 Urate levels / / 23263486 rs4247634 chr11 64226488 A G 5.33E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1003697 chr11 64233783 A G 5.90E-08 Urate levels / / 20884846 rs1003697 chr11 64233783 A G 2.29E-11 Urate levels / / 23263486 rs1000662 chr11 64233819 G A 5.90E-08 Urate levels / / 20884846 rs1000662 chr11 64233819 G A 2.34E-11 Urate levels / / 23263486 rs685272 chr11 64237033 G T 5.60E-08 Urate levels / / 20884846 rs685272 chr11 64237033 G T 2.17E-11 Urate levels / / 23263486 rs685272 chr11 64237033 G T 2.96E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs685272 chr11 64237033 G T 3.90E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs547484 chr11 64237121 G A 2.30E-08 Urate levels / / 20884846 rs547484 chr11 64237121 G A 6.82E-12 Urate levels / / 23263486 rs547484 chr11 64237121 G A 5.42E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs490581 chr11 64238796 A G 6.20E-08 Urate levels / / 20884846 rs490581 chr11 64238796 A G 2.37E-11 Urate levels / / 23263486 rs192133 chr11 64240541 A G 2.50E-08 Urate levels / / 20884846 rs192133 chr11 64240541 A G 2.00E-11 Urate levels / / 23263486 rs171284 chr11 64240650 A G 2.50E-08 Urate levels / / 20884846 rs171284 chr11 64240650 A G 1.98E-11 Urate levels / / 23263486 rs240696 chr11 64240751 T C 2.50E-08 Urate levels / / 20884846 rs240696 chr11 64240751 T C 2.40E-11 Urate levels / / 23263486 rs475414 chr11 64241844 G A 3.00E-08 Urate levels / / 20884846 rs475414 chr11 64241844 G A 3.09E-12 Urate levels / / 23263486 rs475414 chr11 64241844 G A 2.41E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs522485 chr11 64244194 C T 1.10E-08 Urate levels / / 20884846 rs522485 chr11 64244194 C T 9.74E-12 Urate levels / / 23263486 rs606496 chr11 64249560 T C 1.10E-08 Urate levels / / 20884846 rs606496 chr11 64249560 T C 6.83E-12 Urate levels / / 23263486 rs525192 chr11 64250465 T C 1.00E-08 Urate levels / / 20884846 rs525192 chr11 64250465 T C 4.70E-12 Urate levels / / 23263486 rs634497 chr11 64251221 C T 9.50E-09 Urate levels / / 20884846 rs634497 chr11 64251221 C T 2.66E-11 Urate levels / / 23263486 rs2845635 chr11 64252970 T C 1.00E-08 Urate levels / / 20884846 rs2845635 chr11 64252970 T C 8.45E-12 Urate levels / / 23263486 rs2845637 chr11 64253620 C T 7.00E-09 Urate levels / / 20884846 rs2845637 chr11 64253620 C T 3.27E-12 Urate levels / / 23263486 rs2845638 chr11 64253704 G T 6.80E-09 Urate levels / / 20884846 rs2845638 chr11 64253704 G T 4.45E-12 Urate levels / / 23263486 rs17299124 chr11 64256859 C A 1.40E-10 Urate levels / / 20884846 rs17299124 chr11 64256859 C A 8.63E-16 Urate levels / / 23263486 rs589852 chr11 64257440 C T 3.30E-09 Urate levels / / 20884846 rs589852 chr11 64257440 C T 4.34E-12 Urate levels / / 23263486 rs604182 chr11 64258282 G T 2.00E-07 Urate levels / / 20884846 rs604182 chr11 64258282 G T 2.26E-11 Urate levels / / 23263486 rs615311 chr11 64258505 T C 6.38E-05 Cognitive test performance / / 20125193 rs615311 chr11 64258505 T C 2.40E-07 Urate levels / / 20884846 rs615311 chr11 64258505 T C 1.68E-10 Urate levels / / 23263486 rs617104 chr11 64258890 G C 1.90E-07 Urate levels / / 20884846 rs617104 chr11 64258890 G C 2.55E-11 Urate levels / / 23263486 rs1210879 chr11 64259806 C T 2.00E-07 Urate levels / / 20884846 rs1210879 chr11 64259806 C T 2.01E-11 Urate levels / / 23263486 rs662228 chr11 64260107 A G 2.00E-07 Urate levels / / 20884846 rs662228 chr11 64260107 A G 1.78E-11 Urate levels / / 23263486 rs661292 chr11 64260478 A C 2.00E-07 Urate levels / / 20884846 rs661292 chr11 64260478 A C 1.30E-11 Urate levels / / 23263486 rs1210877 chr11 64265411 C T 2.10E-07 Urate levels / / 20884846 rs1210877 chr11 64265411 C T 1.25E-09 Urate levels / / 23263486 rs7940108 chr11 64266200 G A 8.67E-05 Cognitive test performance / / 20125193 rs7104498 chr11 64266244 A G 2.10E-07 Urate levels / / 20884846 rs7104498 chr11 64266244 A G 2.09E-11 Urate levels / / 23263486 rs4930402 chr11 64269938 A G 1.70E-07 Urate levels / / 20884846 rs4930402 chr11 64269938 A G 2.71E-11 Urate levels / / 23263486 rs4930402 chr11 64269938 A G 5.93E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7483260 chr11 64273034 C T 1.70E-07 Urate levels / / 20884846 rs7483260 chr11 64273034 C T 3.82E-11 Urate levels / / 23263486 rs7939462 chr11 64299330 G A 1.75E-08 Urate levels / / 23263486 rs12417589 chr11 64301713 G A 2.10E-11 Urate levels / / 20884846 rs12417589 chr11 64301713 G A 5.29E-16 Urate levels / / 23263486 rs11231808 chr11 64302341 G A 2.10E-11 Urate levels / / 20884846 rs11231808 chr11 64302341 G A 1.10E-14 Urate levels / / 23263486 rs10792438 chr11 64302526 G A 4.00E-04 Primary nonsyndromic vesicoureteric reflex / / 19959718 rs10792438 chr11 64302526 G A 4.72E-08 Urate levels / / 23263486 rs1939120 chr11 64304715 G A 1.00E-07 Urate levels / / 20884846 rs1939120 chr11 64304715 G A 7.34E-09 Urate levels / / 23263486 rs7936185 chr11 64305452 C T 4.70E-12 Urate levels / / 20884846 rs7936185 chr11 64305452 C T 2.08E-16 Urate levels / / 23263486 rs4930420 chr11 64307057 G C 1.60E-11 Urate levels / / 20884846 rs4930420 chr11 64307057 G C 1.86E-16 Urate levels / / 23263486 rs7479811 chr11 64308784 C T 7.70E-08 Urate levels / / 20884846 rs7479811 chr11 64308784 C T 7.30E-09 Urate levels / / 23263486 rs6591859 chr11 64311848 A T 4.11E-08 Uric acid levels / / 19503597 rs6591859 chr11 64311848 A T 1.10E-15 Urate levels / / 20884846 rs6591859 chr11 64311848 A T 2.63E-22 Urate levels / / 23263486 rs4930423 chr11 64311897 T G 2.67E-08 Uric acid levels / / 19503597 rs4930423 chr11 64311897 T G 1.10E-15 Urate levels / / 20884846 rs4930423 chr11 64311897 T G 8.12E-22 Urate levels / / 23263486 rs12362644 chr11 64312153 T C 1.10E-15 Urate levels / / 20884846 rs12362644 chr11 64312153 T C 1.45E-21 Urate levels / / 23263486 rs11231816 chr11 64312403 G A 1.20E-15 Urate levels / / 20884846 rs11231816 chr11 64312403 G A 9.78E-22 Urate levels / / 23263486 rs7124676 chr11 64313291 G A 3.21E-12 Uric acid levels / / 19503597 rs7124676 chr11 64313291 G A 4.60E-23 Urate levels / / 20884846 rs7124676 chr11 64313291 G A 3.00E-06 Obesity-related traits / / 23251661 rs7124676 chr11 64313291 G A 1.62E-32 Urate levels / / 23263486 rs4930426 chr11 64315914 C G 1.24E-12 Uric acid levels / / 19503597 rs4930426 chr11 64315914 C G 5.10E-23 Urate levels / / 20884846 rs4930426 chr11 64315914 C G 5.24E-33 Urate levels / / 23263486 rs3759053 chr11 64323080 C T 9.68E-13 Uric acid levels / / 19503597 rs3759053 chr11 64323080 C T 4.10E-23 Urate levels / / 20884846 rs3759053 chr11 64323080 C T 5.31E-06 Obesity-related traits / / 23251661 rs3759053 chr11 64323080 C T 5.15E-33 Urate levels / / 23263486 rs7940321 chr11 64324120 G A 2.04E-12 Uric acid levels SLC22A11 intron 19503597 rs7940321 chr11 64324120 G A 4.30E-23 Urate levels SLC22A11 intron 20884846 rs7940321 chr11 64324120 G A 1.19E-31 Urate levels SLC22A11 intron 23263486 rs693591 chr11 64325069 G C 7.60E-11 Urate levels SLC22A11 intron 20884846 rs693591 chr11 64325069 G C 9.34E-13 Urate levels SLC22A11 intron 23263486 rs3782099 chr11 64327710 T C 1.38E-12 Uric acid levels SLC22A11 intron 19503597 rs3782099 chr11 64327710 T C 2.50E-23 Urate levels SLC22A11 intron 20884846 rs3782099 chr11 64327710 T C 7.87E-34 Urate levels SLC22A11 intron 23263486 rs7943154 chr11 64327844 A G 1.23E-12 Uric acid levels SLC22A11 intron 19503597 rs7943154 chr11 64327844 A G 2.10E-23 Urate levels SLC22A11 intron 20884846 rs7943154 chr11 64327844 A G 3.31E-31 Urate levels SLC22A11 intron 23263486 rs17300741 chr11 64331462 A G 7.00E-14 Uric acid levels SLC22A11 intron 19503597 rs17300741 chr11 64331462 A G 4.69E-04 Alcohol dependence SLC22A11 intron 20201924 rs17300741 chr11 64331462 A G 7.50E-26 Urate levels SLC22A11 intron 20884846 rs17300741 chr11 64331462 A G 1.90E-05 Urate (in serum),gout SLC22A11 intron 21983786 rs17300741 chr11 64331462 A G 7.00E-04 Urate (in serum),gout SLC22A11 intron 21983786 rs17300741 chr11 64331462 A G 4.00E-35 Urate levels SLC22A11 intron 23263486 rs17372915 chr11 64331568 G A 6.52E-13 Uric acid levels SLC22A11 intron 19503597 rs17372915 chr11 64331568 G A 5.50E-26 Urate levels SLC22A11 intron 20884846 rs17372915 chr11 64331568 G A 5.13E-34 Urate levels SLC22A11 intron 23263486 rs1783811 chr11 64333296 A G 3.70E-08 Uric acid levels SLC22A11 intron 19503597 rs1783811 chr11 64333296 A G 1.70E-10 Urate levels SLC22A11 intron 20884846 rs1783811 chr11 64333296 A G 7.75E-14 Urate levels SLC22A11 intron 23263486 rs2078267 chr11 64334114 C T 7.47E-14 Uric acid levels SLC22A11 intron 19503597 rs2078267 chr11 64334114 C T 1.00E-06 Urate levels SLC22A11 intron 20884846 rs2078267 chr11 64334114 C T 2.00E-26 Urate levels SLC22A11 intron 20884846 rs2078267 chr11 64334114 C T 1.10E-05 Urate (in serum),gout SLC22A11 intron 21983786 rs2078267 chr11 64334114 C T 4.80E-04 Urate (in serum),gout SLC22A11 intron 21983786 rs2078267 chr11 64334114 C T 9.00E-38 Urate levels SLC22A11 intron 23263486 rs528211 chr11 64351721 C T 5.49E-09 Uric acid levels / / 19503597 rs528211 chr11 64351721 C T 2.80E-12 Urate levels / / 20884846 rs528211 chr11 64351721 C T 2.52E-28 Urate levels / / 23263486 rs505802 chr11 64357072 T C 2.00E-09 Uric acid levels SLC22A12 nearGene-5 19503597 rs505802 chr11 64357072 T C 1.00E-31 Blood cell counts and other traits SLC22A12 nearGene-5 20139978 rs505802 chr11 64357072 T C 5.10E-12 Urate levels SLC22A12 nearGene-5 20884846 rs505802 chr11 64357072 T C 8.94E-28 Urate levels SLC22A12 nearGene-5 23263486 rs524023 chr11 64358265 C T 1.00E-08 Urate levels SLC22A12 nearGene-5 20884846 rs524023 chr11 64358265 C T 2.37E-25 Urate levels SLC22A12 nearGene-5 23263486 rs9734313 chr11 64358311 C T 1.00E-08 Urate levels SLC22A12 UTR-5 20884846 rs9734313 chr11 64358311 C T 1.35E-25 Urate levels SLC22A12 UTR-5 23263486 rs3825018 chr11 64358809 G A 7.00E-09 Urate levels SLC22A12 UTR-5 20884846 rs3825018 chr11 64358809 G A 2.11E-25 Urate levels SLC22A12 UTR-5 23263486 rs12800450 chr11 64359221 G T 3.00E-16 Urate levels SLC22A12 missense 21768215 rs3825016 chr11 64359286 C T 7.10E-09 Urate levels SLC22A12 cds-synon 20884846 rs3825016 chr11 64359286 C T 2.99E-25 Urate levels SLC22A12 cds-synon 23263486 rs11231825 chr11 64360274 T C 7.30E-09 Urate levels SLC22A12 cds-synon 20884846 rs11231825 chr11 64360274 T C 1.25E-25 Urate levels SLC22A12 cds-synon 23263486 rs10897518 chr11 64360705 C T 5.43E-09 Uric acid levels SLC22A12 intron 19503597 rs10897518 chr11 64360705 C T 3.70E-13 Urate levels SLC22A12 intron 20884846 rs10897518 chr11 64360705 C T 2.00E-04 Gamma gluatamyl transferase levels (interaction with age) SLC22A12 intron 22010049 rs10897518 chr11 64360705 C T 5.62E-30 Urate levels SLC22A12 intron 23263486 rs475688 chr11 64364291 C T 2.40E-07 Urate levels SLC22A12 intron 20884846 rs475688 chr11 64364291 C T 1.35E-17 Urate levels SLC22A12 intron 23263486 rs893006 chr11 64365796 C A 5.40E-11 Urate levels SLC22A12 intron 20884846 rs893006 chr11 64365796 C A 1.05E-24 Urate levels SLC22A12 intron 23263486 rs7932437 chr11 64373504 T C 2.22E-08 Uric acid levels / / 19503597 rs7932437 chr11 64373504 T C 5.40E-11 Urate levels / / 20884846 rs7932437 chr11 64373504 T C 2.32E-24 Urate levels / / 23263486 rs3741399 chr11 64374241 G A 6.70E-05 Response to statin therapy NRXN2 UTR-3 20339536 rs3802947 chr11 64376307 C T 6.10E-05 Response to statin therapy NRXN2 intron 20339536 rs4930556 chr11 64377726 G C 7.20E-11 Urate levels NRXN2 intron 20884846 rs4930556 chr11 64377726 G C 1.89E-24 Urate levels NRXN2 intron 23263486 rs7121121 chr11 64381132 T C 6.68E-15 Urate levels NRXN2 intron 23263486 rs2277311 chr11 64387932 G A 8.00E-11 Urate levels NRXN2 intron 20884846 rs2277311 chr11 64387932 G A 1.96E-24 Urate levels NRXN2 intron 23263486 rs11231842 chr11 64388262 G A 5.50E-05 Response to statin therapy NRXN2 intron 20339536 rs2360873 chr11 64391157 G C 9.30E-11 Urate levels NRXN2 intron 20884846 rs2360873 chr11 64391157 G C 8.48E-08 Urate levels NRXN2 intron 21768215 rs2360873 chr11 64391157 G C 2.82E-24 Urate levels NRXN2 intron 23263486 rs10897521 chr11 64391910 C T 1.17E-14 Urate levels NRXN2 intron 23263486 rs10792443 chr11 64395252 G C 9.90E-11 Urate levels NRXN2 intron 20884846 rs10792443 chr11 64395252 G C 8.34E-08 Urate levels NRXN2 intron 21768215 rs10792443 chr11 64395252 G C 5.40E-24 Urate levels NRXN2 intron 23263486 rs948689 chr11 64400719 A G 1.46E-15 Urate levels NRXN2 intron 23263486 rs1207226 chr11 64402027 T C 1.84E-14 Urate levels NRXN2 intron 23263486 rs11231845 chr11 64407419 G A 1.00E-10 Urate levels NRXN2 intron 20884846 rs11231845 chr11 64407419 G A 8.62E-08 Urate levels NRXN2 intron 21768215 rs11231845 chr11 64407419 G A 6.80E-24 Urate levels NRXN2 intron 23263486 rs2959654 chr11 64412086 G C 1.81E-15 Urate levels NRXN2 intron 23263486 rs1212146 chr11 64412877 A G 1.41E-15 Urate levels NRXN2 intron 23263486 rs11820322 chr11 64412891 C T 9.70E-05 Response to statin therapy NRXN2 intron 20339536 rs7128467 chr11 64415111 C T 1.11E-14 Urate levels NRXN2 intron 23263486 rs3825074 chr11 64415767 G A 8.36E-09 Urate levels NRXN2 cds-synon 23263486 rs3825074 chr11 64415767 G A 4.20E-04 Smoking initiation NRXN2 cds-synon 24665060 rs555456 chr11 64418259 T C 1.20E-10 Urate levels NRXN2 intron 20884846 rs555456 chr11 64418259 T C 8.97E-08 Urate levels NRXN2 intron 21768215 rs555456 chr11 64418259 T C 7.72E-24 Urate levels NRXN2 intron 23263486 rs2285339 chr11 64418305 G A 1.83E-15 Urate levels NRXN2 intron 23263486 rs2269730 chr11 64423831 G A 1.85E-15 Urate levels NRXN2 intron 23263486 rs7117423 chr11 64425120 G T 9.69E-09 Uric acid levels NRXN2 intron 19503597 rs7117423 chr11 64425120 G T 1.33E-15 Urate levels NRXN2 intron 23263486 rs530775 chr11 64426933 A G 1.43E-15 Urate levels NRXN2 intron 23263486 rs544838 chr11 64429059 T C 4.28E-08 Uric acid levels NRXN2 intron 19503597 rs544838 chr11 64429059 T C 1.70E-10 Urate levels NRXN2 intron 20884846 rs544838 chr11 64429059 T C 8.95E-08 Urate levels NRXN2 intron 21768215 rs544838 chr11 64429059 T C 9.72E-24 Urate levels NRXN2 intron 23263486 rs492175 chr11 64433078 G A 1.80E-10 Urate levels NRXN2 intron 20884846 rs492175 chr11 64433078 G A 9.28E-08 Urate levels NRXN2 intron 21768215 rs492175 chr11 64433078 G A 7.73E-24 Urate levels NRXN2 intron 23263486 rs2666559 chr11 64439227 G T 2.00E-10 Urate levels NRXN2 intron 20884846 rs2666559 chr11 64439227 G T 8.80E-08 Urate levels NRXN2 intron 21768215 rs2666559 chr11 64439227 G T 8.04E-24 Urate levels NRXN2 intron 23263486 rs506338 chr11 64440920 T C 2.00E-31 Blood cell counts and other traits NRXN2 intron 20139978 rs506338 chr11 64440920 T C 2.34E-31 Blood cell counts and other traits NRXN2 intron 20139978 rs506338 chr11 64440920 T C 1.50E-10 Urate levels NRXN2 intron 20884846 rs506338 chr11 64440920 T C 9.57E-08 Urate levels NRXN2 intron 21768215 rs506338 chr11 64440920 T C 1.78E-23 Urate levels NRXN2 intron 23263486 rs530252 chr11 64443465 T C 2.75E-14 Urate levels NRXN2 intron 23263486 rs11602411 chr11 64449223 G A 8.30E-09 Urate levels NRXN2 intron 23263486 rs10128590 chr11 64449425 G A 2.17E-15 Urate levels NRXN2 intron 23263486 rs17146216 chr11 64451281 C G 3.65E-15 Urate levels NRXN2 intron 23263486 rs519090 chr11 64456240 G C 2.30E-10 Urate levels NRXN2 intron 20884846 rs519090 chr11 64456240 G C 9.53E-08 Urate levels NRXN2 intron 21768215 rs519090 chr11 64456240 G C 8.46E-24 Urate levels NRXN2 intron 23263486 rs504915 chr11 64464085 T A 2.50E-10 Urate levels NRXN2 intron 20884846 rs504915 chr11 64464085 T A 9.89E-08 Urate levels NRXN2 intron 21768215 rs504915 chr11 64464085 T A 3.00E-63 Renal function-related traits (urea) NRXN2 intron 22797727 rs504915 chr11 64464085 T A 1.63E-23 Urate levels NRXN2 intron 23263486 rs471618 chr11 64465403 T C 2.87E-15 Urate levels NRXN2 intron 23263486 rs490192 chr11 64471369 G A 2.97E-09 Uric acid levels NRXN2 intron 19503597 rs490192 chr11 64471369 G A 9.02E-16 Urate levels NRXN2 intron 23263486 rs551890 chr11 64477999 C T 6.27E-10 Urate levels NRXN2 intron 23263486 rs478607 chr11 64478063 G A 4.00E-11 Urate levels NRXN2 intron 23263486 rs480617 chr11 64478320 C T 3.38E-07 Urate levels NRXN2 intron 21768215 rs480617 chr11 64478320 C T 3.26E-15 Urate levels NRXN2 intron 23263486 rs2666558 chr11 64481579 G A 1.13E-09 Urate levels NRXN2 intron 23263486 rs487662 chr11 64481880 G A 3.32E-07 Urate levels NRXN2 intron 21768215 rs487662 chr11 64481880 G A 1.30E-15 Urate levels NRXN2 intron 23263486 rs500531 chr11 64487019 G T 3.30E-10 Urate levels NRXN2 intron 20884846 rs500531 chr11 64487019 G T 8.82E-08 Urate levels NRXN2 intron 21768215 rs500531 chr11 64487019 G T 7.97E-23 Urate levels NRXN2 intron 23263486 rs534221 chr11 64497161 C T 1.26E-05 Uric acid levels RASGRP2 intron 21294900 rs556356 chr11 64503496 A G 9.86E-06 Uric acid levels RASGRP2 intron 21294900 rs2073798 chr11 64511322 T G 4.22E-04 Multiple complex diseases RASGRP2 intron 17554300 rs2073798 chr11 64511322 T G 1.08E-04 Cognitive function RASGRP2 intron 24684796 rs7126110 chr11 64520255 C G 7.10E-10 Urate levels PYGM intron 23263486 rs589691 chr11 64525216 C T 9.00E-08 Urate levels PYGM intron 21768215 rs489192 chr11 64525644 G T 5.13E-15 Lymphocyte counts PYGM intron 22286170 rs606458 chr11 64546391 C T 6.00E-11 Urate levels SF1 nearGene-5 21768215 rs493573 chr11 64557054 C T 2.00E-17 Urate levels MAP4K2 cds-synon 21768215 rs10897526 chr11 64559898 T C 7.10E-10 Urate levels MAP4K2 intron 20884846 rs10897526 chr11 64559898 T C 4.54E-07 Urate levels MAP4K2 intron 21768215 rs10897526 chr11 64559898 T C 9.41E-14 Urate levels MAP4K2 intron 23263486 rs559566 chr11 64581658 G A 2.71E-09 Urate levels / / 23263486 rs470763 chr11 64584231 G A 5.00E-06 Economic and political preferences (fairness) / / 22566634 rs670358 chr11 64591679 G A 7.71E-06 Leprosy CDC42BPG UTR-3 pha002872 rs670358 chr11 64591679 G A 3.27E-05 Pancreatic cancer CDC42BPG UTR-3 pha002889 rs11606204 chr11 64656069 G A 2.43E-04 Glycosylated haemoglobin levels / / 17255346 rs12293826 chr11 64681360 C T 2.10E-10 Health and aging,CVD and cancer age of onset ATG2A missense 22174011 rs12293826 chr11 64681360 C T 4.40E-12 Health and aging,CVD and cancer age of onset ATG2A missense 22174011 rs527039 chr11 64832496 A G 2.30E-05 Urinary metabolites / / 21572414 rs527039 chr11 64832496 A G 2.51E-05 Odorant perception / / 23910658 rs117304846 chr11 64836385 T C 1.22E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs566908 chr11 64837370 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4930696 chr11 64839414 C T 1.21E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs2282498 chr11 64855986 A G 6.21E-05 Bone mineral density LOC100130348 missense 19181680 rs11227118 chr11 64860655 G A 6.68E-05 Bone mineral density / / 19181680 rs146858807 chr11 64872369 G A 1.48E-06 Serum dimethylarginine levels (symmetric) C11orf2 intron 24159190 rs1129195 chr11 64882789 C T 9.10E-05 Bone mineral density TM7SF2 missense 19181680 rs3825073 chr11 64900270 G T 9.43E-05 Non-alcoholic fatty liver disease histology (other) SYVN1 intron 20708005 rs3825073 chr11 64900270 G T 2.80E-05 Urinary metabolites SYVN1 intron 21572414 rs10895987 chr11 64904908 C T 2.27E-04 Multiple complex diseases / / 17554300 rs1152639 chr11 64915042 A C 0.0000674 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1195958 chr11 64936810 C T 9.06E-05 Cervical cancer / / 24700089 rs144104397 chr11 64942749 C T 7.80E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs149618074 chr11 64968864 C T 1.27E-05 Acne (severe) CAPN1 intron 24927181 rs487989 chr11 65064690 G A 1 Drug response to Gemcitabine POLA2 missense 15224082 rs7114046 chr11 65075173 C T 2.06E-04 Multiple complex diseases / / 17554300 rs629710 chr11 65109233 A C 7.60E-04 Suicide attempts in bipolar disorder DPF2 intron 21423239 rs34400381 chr11 65143892 G A 2.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SLC25A45 missense 24159190 rs34400381 chr11 65143892 G A 2.00E-10 Serum dimethylarginine levels (symmetric) SLC25A45 missense 24159190 rs585210 chr11 65146496 G C 1.52E-05 Alzheimer's disease (age of onset) SLC25A45 intron 22005931 rs681309 chr11 65151449 A G 1.41E-05 Alzheimer's disease (age of onset) / / 22005931 rs652501 chr11 65160145 C T 4.35E-05 Alzheimer's disease (age of onset) FRMD8 intron 22005931 rs2073800 chr11 65161129 C T 4.85E-05 Alzheimer's disease (age of onset) FRMD8 cds-synon 22005931 rs694243 chr11 65172197 C T 1.27E-05 Response to mTOR inhibitor (rapamycin) FRMD8 intron 24009623 rs2904976 chr11 65185387 G A 8.61E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs512715 chr11 65191208 C G 6.88E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs1626021 chr11 65226187 A G 5.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17146964 chr11 65249145 A G 4.00E-09 Vertical cup-disc ratio LOC100507645 intron 20548946 rs113041250 chr11 65260646 A AG 4.00E-06 Bone mineral density LOC100507645 intron 22504420 rs600231 chr11 65260646 A G 4.00E-06 Bone mineral density LOC100507645 intron 22504420 rs3782089 chr11 65336819 C T 4.00E-13 Height / / 20881960 rs2236684 chr11 65338944 T G 5.84E-05 Alzheimer's disease SSSCA1 cds-synon 22832961 rs72939141 chr11 65348347 G A 0.00000021 Myopia (Age of onset) EHBP1L1 intron 23468642 rs6591182 chr11 65349756 T G 9.00E-07 Non-alcoholic fatty liver disease histology (lobular) EHBP1L1 missense 20708005 rs4601790 chr11 65353906 A G 3.00E-07 Blood pressure (age interaction) EHBP1L1 intron 24954895 rs4601790 chr11 65353906 A G 6.00E-07 Blood pressure (age interaction) EHBP1L1 intron 24954895 rs11227234 chr11 65365171 G T 5.96E-04 Multiple complex diseases / / 17554300 rs1151488 chr11 65371604 T C 2.00E-05 Type 2 diabetes and 6 quantitative traits MAP3K11 intron 17848626 rs12801636 chr11 65391317 G A 0.00000113 Coronary artery disease PCNXL3 intron 23202125 rs12801636 chr11 65391317 G A 3.00E-08 HDL cholesterol PCNXL3 intron 24097068 rs1466462 chr11 65419364 G C 8.35E-07 Urate levels / / 21768215 rs1466462 chr11 65419364 G C 7.18E-04 Lymphocyte counts / / 22286170 rs1466462 chr11 65419364 G C 1.42E-12 Urate levels / / 23263486 rs1049728 chr11 65421117 G C 2.70E-16 Soluble ICAM-1 RELA UTR-3 21533024 rs12289836 chr11 65436888 A G 6.14E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12289836 chr11 65436888 A G 8.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12289836 chr11 65436888 A G 6.57E-14 Urate levels / / 23263486 rs7947604 chr11 65442059 G C 1.29E-13 Urate levels / / 23263486 rs7934036 chr11 65451020 G T 8.87E-14 Urate levels / / 23263486 rs1074156 chr11 65458169 G T 1.77E-13 Urate levels / / 23263486 rs1074155 chr11 65458197 T C 4.70E-12 Urate levels / / 23263486 rs7115734 chr11 65458964 G A 1.14E-13 Urate levels / / 23263486 rs10896032 chr11 65459419 C A 1.46E-13 Urate levels / / 23263486 rs6591188 chr11 65467953 T C 5.93E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6591188 chr11 65467953 T C 8.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6591188 chr11 65467953 T C 3.60E-07 Urate levels / / 20884846 rs6591188 chr11 65467953 T C 2.28E-12 Urate levels / / 23263486 rs9666878 chr11 65475816 C A 4.00E-07 Urate levels / / 20884846 rs9666878 chr11 65475816 C A 1.39E-11 Urate levels / / 23263486 rs4645933 chr11 65485120 C T 3.50E-07 Urate levels KAT5 intron 20884846 rs4645933 chr11 65485120 C T 1.09E-10 Urate levels KAT5 intron 23263486 rs478304 chr11 65494260 G T 3.00E-11 Acne (severe) / / 24927181 rs11227279 chr11 65495211 G A 6.42E-10 Urate levels / / 23263486 rs4014195 chr11 65506822 C G 1.00E-07 Chronic kidney disease / / 20383146 rs4014195 chr11 65506822 C G 1.69E-12 Urate levels / / 23263486 rs593982 chr11 65513107 T C 6.00E-07 Atopic dermatitis / / 23042114 rs1193496 chr11 65537556 A G 9.83E-04 Type 2 diabetes / / 17463246 rs489574 chr11 65542739 G A 2.91E-08 Urate levels AP5B1 UTR-3 23263486 rs610037 chr11 65546857 A C 4.04E-11 Acne (severe) AP5B1 cds-synon 24927181 rs11227299 chr11 65549570 C G 8.54E-13 Urate levels / / 23263486 rs479844 chr11 65551957 A G 1.00E-13 Atopic dermatitis / / 22197932 rs479844 chr11 65551957 A G 2.77E-05 Atopic dermatitis / / 23886662 rs642803 chr11 65560620 C T 3.00E-13 Urate levels OVOL1 intron 23263486 rs644740 chr11 65561468 C T 5.81E-04 Multiple complex diseases OVOL1 intron 17554300 rs644740 chr11 65561468 C T 5.91E-14 Urate levels OVOL1 intron 23263486 rs72922786 chr11 65562852 G C 3.39E-08 Acne (severe) OVOL1 UTR-3 24927181 rs44205 chr11 65564786 G A 2.72E-09 Urate levels / / 23263486 rs557675 chr11 65566719 T G 1.57E-13 Urate levels / / 23263486 rs10896050 chr11 65577516 G T 3.14E-04 Multiple complex diseases / / 17554300 rs10896050 chr11 65577516 G T 2.11E-05 Response to TNF antagonist treatment / / 21061259 rs11227306 chr11 65578672 C A 2.09E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs11227306 chr11 65578672 C A 2.00E-07 DNA methylation (variation) / / 23725790 rs10896053 chr11 65579670 G A 1.80E-05 Urinary metabolites / / 21572414 rs1204772 chr11 65581579 C T 1.50E-05 Urinary metabolites / / 21572414 rs7114237 chr11 65581752 G C 2.60E-05 Urinary metabolites / / 21572414 rs7114014 chr11 65581772 C T 2.27E-05 Neuroblastoma / / pha002895 rs3903072 chr11 65583066 G T 9.00E-12 Breast cancer / / 23535729 rs621348 chr11 65586509 T A 1.60E-05 Urinary metabolites / / 21572414 rs7102454 chr11 65594820 T C 1.00E-05 Urinary metabolites / / 21572414 rs11227332 chr11 65623739 A G 3.75E-06 Response to TNF antagonist treatment CFL1 intron 21061259 rs665306 chr11 65624025 T C 2.38E-05 Response to TNF antagonist treatment CFL1 intron 21061259 rs669300 chr11 65624490 A G 0.00002 Mean arterial pressure CFL1 intron 22510845 rs630303 chr11 65631973 G A 1.93E-05 Response to TNF antagonist treatment MUS81 cds-synon 21061259 rs501630 chr11 65637273 A G 2.93E-05 Hypertension (essential hypertension) EFEMP2 intron 22184326 rs116206676 chr11 65647737 G A 0.00017 Breast cancer CTSW missense 23555315 rs114953123 chr11 65649676 G A 0.00027 Prostate cancer (non-advanced prostate cancer) CTSW missense 23555315 rs694994 chr11 65653309 T C 2.44E-04 Multiple complex diseases FIBP intron 17554300 rs694994 chr11 65653309 T C 3.17E-05 Response to TNF antagonist treatment FIBP intron 21061259 rs2231884 chr11 65656564 C T 3.00E-10 Inflammatory bowel disease / / 23128233 rs637571 chr11 65664346 T C 3.22E-04 Smoking initiation FOSL1 cds-synon 24665060 rs1151523 chr11 65665200 C T 5.16E-04 Smoking initiation FOSL1 intron 24665060 rs653914 chr11 65676516 A G 2.69E-04 Atopic dermatitis / / 21666691 rs653914 chr11 65676516 A G 2.93E-04 Smoking initiation / / 24665060 rs617791 chr11 65702523 G C 1.53E-04 Smoking initiation / / 24665060 rs528736 chr11 65705108 A G 1.14E-04 Smoking initiation / / 24665060 rs470192 chr11 65724291 C T 2.49E-04 Smoking initiation TSGA10IP intron 24665060 rs593525 chr11 65727799 T C 3.26E-04 Smoking initiation / / 24665060 rs552130 chr11 65732800 T C 2.32E-04 Smoking initiation SART1 intron 24665060 rs556643 chr11 65733289 G A 4.36E-04 Smoking initiation SART1 intron 24665060 rs688862 chr11 65733393 C T 1.04E-04 Smoking initiation SART1 cds-synon 24665060 rs542332 chr11 65744421 C T 8.31E-05 Smoking initiation SART1 intron 24665060 rs679581 chr11 65746653 A G 8.73E-05 Smoking initiation SART1 UTR-3 24665060 rs503524 chr11 65751764 C T 2.31E-04 Smoking initiation / / 24665060 rs1786175 chr11 65754808 G A 2.24E-04 Smoking initiation / / 24665060 rs538954 chr11 65756808 T C 7.54E-04 Multiple complex diseases / / 17554300 rs538954 chr11 65756808 T C 3.35E-04 Smoking initiation / / 24665060 rs12576969 chr11 65802478 A G 3.82E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs12576969 chr11 65802478 A G 9.71E-04 Alcohol dependence / / 24277619 rs2576 chr11 65808467 C T 2.80E-05 Urinary metabolites GAL3ST3 UTR-3 21572414 rs2452682 chr11 65812609 A G 7.72E-04 Type 2 diabetes GAL3ST3 intron 17463246 rs11227394 chr11 65828995 T C 5.83E-04 Multiple complex diseases SF3B2 intron 17554300 rs564343 chr11 65895166 A G 2.00E-09 Obesity (early onset extreme) PACS1 intron 23563609 rs17147371 chr11 65912524 A C 3.99E-05 Personality dimensions PACS1 intron 18957941 rs801741 chr11 65917084 T C 2.15E-04 Smoking initiation PACS1 intron 24665060 rs512421 chr11 65985168 G A 3.40E-06 Urinary metabolites PACS1 intron 21572414 rs2276036 chr11 66033430 C T 4.46E-04 Schizophrenia(treatment response to risperidone) KLC2 missense 19850283 rs7935572 chr11 66183923 G A 1.99E-04 Alzheimer's disease LOC100505504 intron pha002879 rs1791682 chr11 66222137 C T 1.08E-04 Alzheimer's disease / / pha002879 rs1791687 chr11 66227184 G C 1.16E-05 Lymphocyte counts / / 22286170 rs3892818 chr11 66240191 G A 4.89E-04 Smoking quantity PELI3 intron 24665060 rs2277302 chr11 66240882 T C 4.82E-04 Smoking quantity PELI3 cds-synon 24665060 rs3179961 chr11 66244454 A G 4.01E-04 Smoking quantity PELI3 UTR-3 24665060 rs11821155 chr11 66246337 T C 3.11E-04 Smoking quantity LOC100505554 intron 24665060 rs2511225 chr11 66248431 A C 8.47E-04 Multiple complex diseases DPP3 intron 17554300 rs11550299 chr11 66254085 G T 1.53E-07 Delayed encephalopathy in acute carbon monoxide poisoning DPP3 missense 24265751 rs11550299 chr11 66254085 G T 4.04E-07 Delayed encephalopathy in acute carbon monoxide poisoning DPP3 missense 24265751 rs11550299 chr11 66254085 G T 5.22E-04 Smoking quantity DPP3 missense 24665060 rs4930378 chr11 66255515 T C 6.15E-05 Smoking quantity DPP3 intron 24665060 rs4930379 chr11 66255674 G A 4.26E-04 Smoking quantity DPP3 intron 24665060 rs3867132 chr11 66309269 C T 5.04E-04 Smoking quantity ZDHHC24 intron 24665060 rs10791881 chr11 66319262 G A 1.90E-05 Alcohol dependence ACTN3 intron 20201924 rs10791881 chr11 66319262 G A 6.20E-05 Alcohol dependence ACTN3 intron 20201924 rs10791881 chr11 66319262 G A 6.16E-05 Alcoholism ACTN3 intron pha002892 rs10791881 chr11 66319262 G A 1.93E-05 Alcoholism ACTN3 intron pha002893 rs509556 chr11 66326362 A G 9.92E-04 Multiple complex diseases ACTN3 intron 17554300 rs2275998 chr11 66326581 T C 4.15E-05 Educational attainment ACTN3 intron 21694764 rs572846 chr11 66331458 A G 9.20E-04 Multiple complex diseases CTSF cds-synon 17554300 rs4630309 chr11 66333072 C A 4.43E-04 Gallstones CTSF intron 17632509 rs4630309 chr11 66333072 C A 2.70E-07 Height CTSF intron 21194676 rs4630309 chr11 66333072 C A 2.80E-05 Height CTSF intron 21194676 rs2242663 chr11 66335308 T C 1.00E-06 Bipolar disorder CTSF intron 19416921 rs2242663 chr11 66335308 T C 0.000056 Breast cancer CTSF intron 23555315 rs11550057 chr11 66392880 C T 3.70E-04 Smoking quantity RBM14 cds-synon 24665060 rs15969 chr11 66394387 C T 3.74E-04 Smoking quantity RBM14 UTR-3 24665060 rs580910 chr11 66402333 C T 6.67E-04 Type 2 diabetes RBM14-RBM4 intron 17463246 rs580910 chr11 66402333 C T 2.89E-04 Alzheimer's disease RBM14-RBM4 intron 17998437 rs575797 chr11 66408033 C G 1.00E-05 Urinary metabolites RBM4 intron 21572414 rs10791889 chr11 66493825 C T 1.16E-06 Major depressive disorder / / 22472876 rs376610016 chr11 66493825 C CT 1.16E-06 Major depressive disorder / / 22472876 rs10896135 chr11 66551002 G C 2.00E-07 Bipolar disorder C11orf80 intron 21926972 rs6591222 chr11 66551143 C T 4.57E-05 HIV-1 viral setpoint C11orf80 intron 22174851 rs6591222 chr11 66551143 C T 1.68E-06 Major depressive disorder C11orf80 intron 22472876 rs4930390 chr11 66560023 A G 1.72E-06 Major depressive disorder C11orf80 intron 22472876 rs10750790 chr11 66582210 A G 1.56E-06 Major depressive disorder C11orf80 intron 22472876 rs7930203 chr11 66583759 A G 1.50E-06 Major depressive disorder C11orf80 intron 22472876 rs7948839 chr11 66634397 C T 2.44E-05 HIV-1 viral setpoint PC intron 22174851 rs7948839 chr11 66634397 C T 7.11E-05 Major depressive disorder PC intron 22472876 rs7119426 chr11 66649612 A G 3.26E-05 Hepatocellular carcinoma PC intron 22807686 rs4008953 chr11 66660949 A G 1.28E-05 HIV-1 viral setpoint PC intron 22174851 rs4008953 chr11 66660949 A G 9.45E-05 Major depressive disorder PC intron 22472876 rs7122539 chr11 66662731 G A 8.00E-06 HIV-1 susceptibility PC intron 22174851 rs7122539 chr11 66662731 G A 9.64E-07 Autism PC intron 22843504 rs7122539 chr11 66662731 G A 0.00000419 Cytarabine sensitivity PC intron 23538338 rs10160758 chr11 66673079 T C 3.21E-05 Hepatocellular carcinoma PC intron 22807686 rs896436 chr11 66781263 A G 1.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1253439 chr11 66784715 G A 2.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7112925 chr11 66826160 C T 9.00E-10 Height RHOD intron 20881960 rs2256154 chr11 67090571 C T 7.99E-04 Lymphocyte counts LOC100130987 intron 22286170 rs2256154 chr11 67090571 C T 3.47E-07 Red blood cell traits LOC100130987 intron 23222517 rs1638586 chr11 67174597 G A 7.10E-05 Tooth agenesis (maxillary third molar) TBC1D10C intron 24172245 rs1476792 chr11 67196237 T C 4.84E-04 Type 2 diabetes RPS6KB2 intron 17463246 rs1476792 chr11 67196237 T C 5.46E-08 Red blood cell traits RPS6KB2 intron 23222517 rs917570 chr11 67196544 C G,T 4.08E-04 Type 2 diabetes RPS6KB2 intron 17463246 rs917570 chr11 67196544 C G,T 1.76E-07 Red blood cell traits RPS6KB2 intron 23222517 rs1638588 chr11 67199706 C A 1.67E-08 Red blood cell traits RPS6KB2 intron 23222517 rs1790753 chr11 67201008 C T 6.98E-08 Red blood cell traits RPS6KB2 intron 23222517 rs869736 chr11 67205462 C A 1.65E-08 Red blood cell traits / / 23222517 rs2302264 chr11 67207426 G A 1.04E-08 Red blood cell traits CORO1B intron 23222517 rs1638556 chr11 67213518 T C 1.17E-08 Red blood cell traits / / 23222517 rs949252 chr11 67218909 A G 5.01E-07 Age-related macular degeneration GPR152 cds-synon pha000001 rs1638558 chr11 67219119 C T 1.44E-05 Age-related macular degeneration GPR152 cds-synon pha000001 rs1790761 chr11 67221854 T C 1.97E-08 Red blood cell traits CABP4 nearGene-5 23222517 rs7114510 chr11 67224594 T C 3.17E-08 Red blood cell traits CABP4 intron 23222517 rs11601325 chr11 67227006 G A 9.85E-09 Red blood cell traits CABP4 UTR-3 23222517 rs3741168 chr11 67235351 A G 7.15E-08 Red blood cell traits TMEM134 intron 23222517 rs7124630 chr11 67240611 A G 4.90E-07 Age-related macular degeneration / / pha000001 rs601363 chr11 67256369 G A 1.44E-05 Age-related macular degeneration AIP intron pha000001 rs4084113 chr11 67257037 C T 2.89E-07 Red blood cell traits AIP intron 23222517 rs672432 chr11 67276469 T C 0.0000606 Coronary artery calcification / / 23394302 rs604904 chr11 67283891 G T 0.0000973 Coronary artery calcification / / 23394302 rs2276118 chr11 67288594 C T 1.36E-08 Red blood cell traits CABP2 missense 23222517 rs1871034 chr11 67293234 G A 5.41E-07 Red blood cell traits / / 23222517 rs4930430 chr11 67294198 C T 3.71E-07 Red blood cell traits / / 23222517 rs4930431 chr11 67294308 C T 6.80E-07 Red blood cell traits / / 23222517 rs694616 chr11 67311258 A C 1.35E-05 Bipolar disorder / / 17486107 rs611663 chr11 67312221 C T 9.03E-07 Red blood cell traits / / 23222517 rs684928 chr11 67329742 G A 8.20E-07 Red blood cell traits / / 23222517 rs638140 chr11 67333858 G C 7.51E-07 Red blood cell traits / / 23222517 rs656652 chr11 67343957 C T 1.01E-07 Red blood cell traits / / 23222517 rs625978 chr11 67344664 C T 1.05E-07 Red blood cell traits / / 23222517 rs614080 chr11 67347287 G A 1.43E-07 Red blood cell traits / / 23222517 rs1695 chr11 67352689 A G 1 Drug response to Fluorouracil GSTP1 missense 18540691 rs1695 chr11 67352689 A G 1 Drug response to Cisplatin GSTP1 missense 19786980 rs1695 chr11 67352689 A G 1 Drug response to Cyclophosphamide GSTP1 missense 19786980 rs1138272 chr11 67353579 C T 1 Drug response to Thiotepa GSTP1 missense 19076156 rs1871042 chr11 67353844 C T 9.99E-07 Red blood cell traits GSTP1 intron 23222517 rs947895 chr11 67354406 C A 8.05E-07 Red blood cell traits GSTP1 nearGene-3 23222517 rs596603 chr11 67359603 T G 3.14E-08 Red blood cell traits / / 23222517 rs11603991 chr11 67367922 C T 7.43E-08 Red blood cell traits / / 23222517 rs7103632 chr11 67368443 C A 4.83E-07 Red blood cell traits / / 23222517 rs12790798 chr11 67368641 A G 2.31E-08 Red blood cell traits / / 23222517 rs12793832 chr11 67372593 A C 8.51E-08 Red blood cell traits NDUFV1 nearGene-5 23222517 rs1871043 chr11 67374581 T C 7.01E-07 Red blood cell traits NDUFV1 intron 23222517 rs7948073 chr11 67375184 T G 2.82E-07 Red blood cell traits NDUFV1 intron 23222517 rs4148959 chr11 67381110 A C 3.73E-07 Red blood cell traits DOC2GP intron 23222517 rs4930461 chr11 67394895 C T 3.51E-05 Glycosylated haemoglobin levels / / 17255346 rs4930461 chr11 67394895 C T 7.05E-07 Red blood cell traits / / 23222517 rs7124513 chr11 67395714 C T 9.49E-06 Glycosylated haemoglobin levels NUDT8 cds-synon 17255346 rs1531514 chr11 67398862 A T 8.39E-07 Red blood cell traits TBX10 UTR-3 23222517 rs3765088 chr11 67399970 C T 8.83E-07 Red blood cell traits TBX10 intron 23222517 rs3758938 chr11 67402362 T G 3.34E-05 Glycosylated haemoglobin levels TBX10 missense 17255346 rs2447587 chr11 67411830 T C 4.76E-04 Amyotrophic lateral sclerosis (sporadic) ACY3 intron 24529757 rs12288023 chr11 67421341 T C 9.00E-16 Metabolite levels / / 24625756 rs2054409 chr11 67422063 A G 8.98E-06 White blood cell count / / 21738479 rs1551886 chr11 67430762 T C 4.61E-05 Lung function (forced vital capacity) ALDH3B2 missense 24023788 rs1551888 chr11 67433869 C T 1.30E-04 Lung function (forced vital capacity) ALDH3B2 missense 24023788 rs7127459 chr11 67463537 T C 3.46E-05 Multiple complex diseases / / 17554300 rs2514051 chr11 67464630 A G 7.61E-04 Myopia (pathological) / / 21095009 rs7941000 chr11 67464928 C T 4.03E-04 Smoking initiation / / 24665060 rs10791910 chr11 67467390 C T 0.0002241 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10791910 chr11 67467390 C T 2.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11227888 chr11 67475625 C T 0.0002067 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11227888 chr11 67475625 C T 2.07E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4620727 chr11 67476834 G T 0.0002053 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4620727 chr11 67476834 G T 2.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7933242 chr11 67519047 T A 1.21E-05 Alzheimer's disease / / 17998437 rs10791946 chr11 67588012 A G 1.69E-07 Schizophrenia / / 21926974 rs308309 chr11 67715028 C T 5.00E-06 QRS duration / / 23534349 rs11228120 chr11 67768796 T C 1.24E-04 Gallstones UNC93B1 intron 17632509 rs3794176 chr11 67794643 C T 3.25E-04 Acute lung injury ALDH3B1 intron 22295056 rs886701 chr11 67795066 C T 4.50E-05 Response to Vitamin E supplementation ALDH3B1 intron 22437554 rs3751082 chr11 67795353 G A 5.91E-04 Acute lung injury ALDH3B1 cds-synon 22295056 rs2075626 chr11 67799926 T C 9.52E-05 Lymphocyte counts NDUFS8 intron 22286170 rs2512611 chr11 67842369 C T 6.46E-04 Alzheimer's disease CHKA intron 22005930 rs2457179 chr11 67842821 C G 5.96E-04 Multiple complex diseases CHKA intron 17554300 rs2457179 chr11 67842821 C G 6.11E-04 Alzheimer's disease CHKA intron 22005930 rs2512612 chr11 67844879 C T 4.88E-04 Alzheimer's disease CHKA intron 22005930 rs2511439 chr11 67854035 T C 7.50E-05 Cholesterol CHKA intron 17255346 rs4073551 chr11 67861049 G T 4.92E-04 Alzheimer's disease CHKA intron 22005930 rs10791957 chr11 67867548 C A 5.68E-04 Alzheimer's disease CHKA intron 22005930 rs4930557 chr11 67878157 C T 5.46E-04 Alzheimer's disease CHKA intron 22005930 rs7127090 chr11 67891289 A G 3.01E-04 Cholesterol / / 17255346 rs7944372 chr11 67897483 C T 4.85E-04 Alzheimer's disease / / 22005930 rs10896295 chr11 67898937 G A 3.73E-04 Alzheimer's disease / / 22005930 rs11228139 chr11 67900578 C T 4.98E-04 Alzheimer's disease / / 22005930 rs11228142 chr11 67900727 C T 4.03E-04 Alzheimer's disease / / 22005930 rs6591333 chr11 67902760 G A 4.79E-04 Multiple complex diseases / / 17554300 rs6591333 chr11 67902760 G A 3.66E-04 Alzheimer's disease / / 22005930 rs1540209 chr11 67928520 A C 4.17E-04 Type 2 diabetes SUV420H1 intron 17463246 rs1540209 chr11 67928520 A C 0.000085 Endometrial cancer SUV420H1 intron 22426144 rs4930561 chr11 67931761 G A 1.00E-08 IgG glycosylation SUV420H1 intron 23382691 rs4930561 chr11 67931761 G A 9.00E-10 IgG glycosylation SUV420H1 intron 23382691 rs10896300 chr11 67953772 A G 2.73E-04 Type 2 diabetes SUV420H1 intron 17463246 rs3802746 chr11 68030173 C A 1.00E-04 Body Mass Index C11orf24 missense pha003022 rs3802746 chr11 68030173 C A 9.77E-05 Waist Circumference C11orf24 missense pha003024 rs4988327 chr11 68077666 A G 1.38E-05 Multiple complex diseases / / 17554300 rs7924398 chr11 68093193 C T 2.38E-05 Receptive language ability LRP5 intron 24687471 rs545382 chr11 68171013 T C 5.31E-04 Myocardial Infarction LRP5 cds-synon pha002883 rs2306862 chr11 68177510 C T 2.10E-08 Bone mineral density (paediatric,skull) LRP5 cds-synon 24945404 rs546803 chr11 68186392 C T 8.37E-06 Myocardial Infarction LRP5 intron pha002883 rs599083 chr11 68192346 T G 5.00E-08 Bone mineral density (spine) LRP5 intron 19801982 rs525592 chr11 68195104 C T 3.00E-11 Bone mineral density LRP5 intron 24249740 rs525592 chr11 68195104 C T 9.04E-07 Bone mineral density LRP5 intron 24249740 rs3781586 chr11 68199393 C A 3.30E-08 Bone mineral density (paediatric,skull) LRP5 intron 24945404 rs3736228 chr11 68201295 C T 6.00E-12 Bone mineral density LRP5 missense 18455228 rs3736228 chr11 68201295 C T 1 Drug response to Risedronate LRP5 missense 19148563 rs3736228 chr11 68201295 C T 2.00E-26 Bone mineral density LRP5 missense 22504420 rs3736228 chr11 68201295 C T 2.46E-04 Bone mineral density LRP5 missense 24249740 rs3736228 chr11 68201295 C T 2.24E-04 Bone mineral density (paediatric,total body less head) LRP5 missense 24945404 rs3736228 chr11 68201295 C T 4.63E-07 Bone mineral density (paediatric,skull) LRP5 missense 24945404 rs2242340 chr11 68214119 C T 7.32E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LRP5 intron 22566498 rs632605 chr11 68215954 G A 9.77E-04 Alzheimer's disease LRP5 intron 24755620 rs676318 chr11 68217420 T C 8.36E-05 Schizophrenia / / 21747397 rs676318 chr11 68217420 T C 0.0000141 Schizophrenia / / 23637625 rs676318 chr11 68217420 T C 1.73E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs676318 chr11 68217420 T C 8.52E-05 Alzheimer's disease / / 24755620 rs11228258 chr11 68254328 C A 4.81E-04 Type 2 diabetes PPP6R3 intron 17463246 rs11228258 chr11 68254328 C A 1.10E-08 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs7116994 chr11 68254627 C T 9.80E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs12294029 chr11 68257059 A C 9.80E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs7126340 chr11 68257293 C T 1.20E-08 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs12272917 chr11 68263370 T C 1.00E-10 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs12272917 chr11 68263370 T C 2.00E-10 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs11228262 chr11 68274907 G T 9.80E-10 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs10896334 chr11 68281494 C T 5.40E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs10896337 chr11 68284236 T C 9.80E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs11228269 chr11 68289796 A G 8.40E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs7925275 chr11 68290433 T C 1.20E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs6591340 chr11 68297636 A G 1.40E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs7106259 chr11 68298512 T G 1.20E-08 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs11228271 chr11 68299226 G A 7.90E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) PPP6R3 intron 22566498 rs12281742 chr11 68303629 T C 7.71E-04 Type 2 diabetes PPP6R3 intron 17463246 rs4316515 chr11 68308840 A T 1.77E-04 Type 2 diabetes PPP6R3 intron 17463246 rs4316515 chr11 68308840 A T 1.20E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs7944870 chr11 68309108 C G 4.60E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs948315 chr11 68309140 T C 2.30E-08 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs948316 chr11 68309670 G T 1.20E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs10896341 chr11 68313180 G A 4.00E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs7104345 chr11 68316772 G A 1.20E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs12284933 chr11 68319489 G A 8.90E-10 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs11228284 chr11 68322767 A T 1.20E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs12271290 chr11 68326236 C T 9.12E-04 Type 2 diabetes PPP6R3 intron 17463246 rs12271290 chr11 68326236 C T 6.30E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs7102898 chr11 68328870 G A 1.20E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs2155730 chr11 68329474 T C 1.10E-08 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs7109294 chr11 68332093 T C 3.02E-04 Type 2 diabetes PPP6R3 intron 17463246 rs7109294 chr11 68332093 T C 1.20E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs2282563 chr11 68333200 C T 1.20E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs3740631 chr11 68341722 T G 1.20E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs11228287 chr11 68349754 A G 1.20E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs10896347 chr11 68353127 G A 1.20E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs7118897 chr11 68360680 G A 4.60E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs6591344 chr11 68360873 G A 9.80E-10 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs7123564 chr11 68362164 C T 4.10E-08 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs7127948 chr11 68363062 G A 9.80E-10 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs3758643 chr11 68367193 C T 1.20E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs12283755 chr11 68371658 A G 9.80E-10 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs7104877 chr11 68377602 A C 7.07E-04 Type 2 diabetes PPP6R3 intron 17463246 rs7104877 chr11 68377602 A C 3.80E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs2236708 chr11 68378045 G A 2.20E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs11228292 chr11 68379772 G A 2.98E-04 Type 2 diabetes PPP6R3 intron 17463246 rs11228292 chr11 68379772 G A 2.20E-09 Bone mineral density (paediatric,skull) PPP6R3 intron 24945404 rs4988291 chr11 68381607 G A 2.20E-09 Bone mineral density (paediatric,skull) PPP6R3 UTR-3 24945404 rs1996 chr11 68382591 C T 7.61E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) PPP6R3 UTR-3 22566498 rs11228293 chr11 68384646 T C 1.90E-09 Bone mineral density (paediatric,skull) / / 24945404 rs7102273 chr11 68385579 T C 1.30E-08 Bone mineral density (paediatric,skull) / / 24945404 rs11228295 chr11 68388588 C G 5.23E-04 Body mass index / / 21701565 rs12363572 chr11 68388966 C T 9.01E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11228296 chr11 68391197 G T 9.10E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7123591 chr11 68392358 A G 9.12E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2510389 chr11 68408004 C T 3.40E-05 Personality dimensions / / 18957941 rs2510389 chr11 68408004 C T 7.93E-07 Biliary atresia / / 20460270 rs2156464 chr11 68427244 A G 2.70E-05 Major depressive disorder / / 21042317 rs2156464 chr11 68427244 A G 4.96E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6591348 chr11 68441197 C T 0.0000116 Schizophrenia / / 23637625 rs2510387 chr11 68445902 G A 7.00E-04 Major depressive disorder / / 21042317 rs2513297 chr11 68446144 T C 4.50E-04 Major depressive disorder / / 21042317 rs2187331 chr11 68446424 C T 6.20E-04 Major depressive disorder / / 21042317 rs2187331 chr11 68446424 C T 3.98E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1042577 chr11 68458470 T C 4.96E-04 Myocardial Infarction GAL UTR-3 pha002873 rs6591350 chr11 68468670 A G 2.29E-04 Myocardial Infarction / / pha002873 rs10791993 chr11 68493712 T C 2.92E-04 Myocardial Infarction MTL5 intron pha002873 rs3018712 chr11 68522053 G A 1.30E-04 Major depressive disorder CPT1A nearGene-3 21042317 rs11228346 chr11 68541540 A G 1.97E-05 Alcohol and nictotine co-dependence CPT1A intron 20158304 rs2924683 chr11 68550304 C G 1.92E-04 Lymphocyte counts CPT1A intron 22286170 rs2924679 chr11 68556782 G A 4.00E-06 Obesity-related traits CPT1A intron 23251661 rs75677837 chr11 68560780 C T 5.34E-06 Obesity-related traits CPT1A intron 23251661 rs2229738 chr11 68562328 C A,G,T 8.00E-12 Metabolite levels CPT1A missense 22286219 rs2229738 chr11 68562328 C A,G,T 0.0000748 Triglycerides CPT1A missense 23063622 rs2229738 chr11 68562328 C A,G,T 8.00E-12 Lipid metabolism phenotypes CPT1A missense 22286219 rs11228364 chr11 68583684 C T 3.72E-05 Post-operative nausea and vomiting CPT1A intron 21694509 rs11228364 chr11 68583684 C T 3.75E-05 Tunica Media CPT1A intron pha003037 rs3019607 chr11 68585986 C A 4.60E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CPT1A intron 24023788 rs624420 chr11 68620223 T C 2.24E-04 Parkinson's disease / / 17052657 rs596874 chr11 68630874 T C 1.97E-16 Lymphocyte counts / / 22286170 rs560096 chr11 68678962 T C 4.14E-04 Parkinson's disease IGHMBP2 missense 17052657 rs10896379 chr11 68680577 C T 4.10E-06 Asthma IGHMBP2 intron 21907864 rs646586 chr11 68681653 A G 4.50E-04 Multiple complex diseases IGHMBP2 intron 17554300 rs655915 chr11 68700359 C T 6.16E-04 Parkinson's disease IGHMBP2 intron 17052657 rs645436 chr11 68700701 G C 1.49E-04 Multiple complex diseases IGHMBP2 intron 17554300 rs140221316 chr11 68701997 A G 0.000028 Prostate cancer (advanced) IGHMBP2 missense 23555315 rs2275996 chr11 68705820 G A 1.00E-05 IgA nephropathy IGHMBP2 missense 15599641 rs516510 chr11 68715646 A C 5.79E-04 Parkinson's disease / / 17052657 rs12291142 chr11 68734221 C T 7.26E-04 Multiple complex diseases / / 17554300 rs2846194 chr11 68755043 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11544721 chr11 68777323 T C 0.00072 Prostate cancer MRGPRF missense 23555315 rs2513102 chr11 68779633 T C 9.55E-04 Multiple complex diseases MRGPRF intron 17554300 rs11600377 chr11 68785803 A G 1.80E-05 Urinary metabolites / / 21572414 rs11600377 chr11 68785803 A G 2.00E-05 Prostate cancer / / 21743057 rs11603763 chr11 68789606 G A 3.00E-05 Prostate cancer / / 21743057 rs17399246 chr11 68798901 G A 2.05E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10896396 chr11 68804806 G T 2.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11228461 chr11 68820876 A G 8.20E-04 Multiple complex diseases TPCN2 intron 17554300 rs896978 chr11 68828929 G A 3.80E-08 Skin sensitivity to sun TPCN2 intron 18488028 rs896978 chr11 68828929 G A 2.47E-05 Cholesterol TPCN2 intron pha003083 rs10750839 chr11 68832730 C G 1.31E-04 Multiple complex diseases TPCN2 intron 17554300 rs3750965 chr11 68840160 A G 7.50E-09 Skin sensitivity to sun TPCN2 missense 18488028 rs3750965 chr11 68840160 A G 3.00E-07 Hair color TPCN2 missense 20585627 rs61746574 chr11 68840399 G A 0.00065 Breast cancer TPCN2 missense 23555315 rs10792020 chr11 68842491 G A 1.57E-04 Multiple complex diseases TPCN2 intron 17554300 rs35264875 chr11 68846399 A T 4.00E-30 Blond vs. brown hair color TPCN2 missense 18488028 rs35264875 chr11 68846399 A T 3.80E-04 Hair color TPCN2 missense 23548203 rs731974 chr11 68847156 C T 5.50E-07 Common traits (Other) TPCN2 intron 20585627 rs3829241 chr11 68855363 G A 8.90E-05 Schizophrenia(treatment response to risperidone) TPCN2 missense 19850283 rs3829241 chr11 68855363 G A 4.37E-04 Suicide attempts in bipolar disorder TPCN2 missense 21423239 rs1060435 chr11 68855595 A G 3.24E-05 Coronary Artery Disease TPCN2 UTR-3 17634449 rs1060435 chr11 68855595 A G 6.49E-04 Suicide attempts in bipolar disorder TPCN2 UTR-3 21423239 rs10896422 chr11 68863324 G A 1.31E-04 Multiple complex diseases / / 17554300 rs2305498 chr11 68866914 G A 5.40E-08 Skin sensitivity to sun / / 18488028 rs921670 chr11 68871639 C T 2.40E-05 Urinary metabolites / / 21572414 rs930788 chr11 68886179 C T 6.74E-04 Type 2 diabetes / / 17463246 rs930788 chr11 68886179 C T 9.82E-04 Alzheimer's disease / / 17998437 rs11228530 chr11 68918985 A C 8.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs2290419 chr11 68919649 A G 9.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs7940364 chr11 68932899 G A 6.22E-04 Type 2 diabetes / / 17463246 rs1011176 chr11 68933897 T C 6.70E-10 Skin sensitivity to sun / / 18488028 rs12223972 chr11 68960391 A G 1.20E-05 Urinary metabolites / / 21572414 rs12417971 chr11 68969808 C T 5.90E-07 Stroke (ischemic) / / 22384361 rs12793759 chr11 68974555 G A 7.50E-04 Acute lung injury / / 22295056 rs11228565 chr11 68978580 G A 7.00E-12 Prostate cancer / / 19767754 rs11228565 chr11 68978580 G A 7.00E-12 Nasopharyngeal carcinoma / / 20512145 rs11228565 chr11 68978580 G A 0.0000029 Prostate cancer / / 23555315 rs11228565 chr11 68978580 G A 0.000056 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs7931342 chr11 68994497 T G 2.00E-12 Prostate cancer / / 18264097 rs7931342 chr11 68994497 T G 2.00E-12 Nasopharyngeal carcinoma / / 20512145 rs7931342 chr11 68994497 T G 1.00E-06 Prostate cancer (early onset) / / 24740154 rs10896449 chr11 68994667 A G 2.00E-09 Prostate cancer / / 18264096 rs10896449 chr11 68994667 A G 2.10E-07 Prostate cancer / / 18264097 rs10896449 chr11 68994667 A G 2.00E-09 Nasopharyngeal carcinoma / / 20512145 rs10896449 chr11 68994667 A G 0.00000011 Prostate cancer / / 23555315 rs10896449 chr11 68994667 A G 0.00000026 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs7130881 chr11 68995958 A G 8.00E-13 Prostate cancer / / 19767753 rs7130881 chr11 68995958 A G 8.00E-13 Nasopharyngeal carcinoma / / 20512145 rs7130881 chr11 68995958 A G 9.00E-09 Prostate cancer / / 21743057 rs7130881 chr11 68995958 A G 0.000000094 Prostate cancer / / 23555315 rs7130881 chr11 68995958 A G 0.00000014 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs10896450 chr11 69008114 A G 3.30E-07 Prostate cancer / / 18264097 rs11228583 chr11 69009114 G T 2.00E-07 Prostate cancer (early onset) / / 24740154 rs12799883 chr11 69010651 T G 2.60E-07 Prostate cancer / / 18264097 rs11228589 chr11 69021677 G A 8.63E-05 Schizophrenia(age at onset) / / 21688384 rs7122303 chr11 69025582 T C 3.39E-04 Schizophrenia / / 19197363 rs7122303 chr11 69025582 T C 9.33E-05 Body Mass Index / / pha003007 rs7103126 chr11 69063393 T C 6.46E-11 Longevity,exceptional MYEOV missense 20595579 rs10896464 chr11 69078912 T C 3.55E-04 Hepatocellular carcinoma / / 22807686 rs10896464 chr11 69078912 T C 5.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs7102705 chr11 69143284 A G 5.00E-06 Breast size / / 22747683 rs11263639 chr11 69202603 A G 8.13E-05 Coronary Artery Disease / / 17634449 rs7939454 chr11 69234390 C A 7.46E-05 Type 2 diabetes / / 17463246 rs4980785 chr11 69234494 C T 2.00E-06 Renal cell carcinoma / / 22010048 rs7105934 chr11 69239741 G A 8.00E-14 Renal cell carcinoma / / 21131975 rs7105934 chr11 69239741 G A 7.80E-14 Renal cell carcinoma / / 22010048 rs10796817 chr11 69241032 G A 7.46E-05 Type 2 diabetes LOC100505834 intron 17463246 rs11263429 chr11 69244027 C G 7.32E-05 Type 2 diabetes / / 17463246 rs4980627 chr11 69256899 G A 9.03E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs12575716 chr11 69269216 G A 6.01E-06 Multiple complex diseases / / 17554300 rs11604051 chr11 69275865 G A 1.85E-05 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs612611 chr11 69307463 A G 1.80E-09 Breast cancer / / 20453838 rs537626 chr11 69307695 G C 1.60E-09 Breast cancer / / 20453838 rs537626 chr11 69307695 G C 2.00E-15 Breast cancer (early onset) / / 24493630 rs624797 chr11 69308575 T G 2.10E-07 Breast cancer / / 20453838 rs662169 chr11 69311250 G A 4.60E-08 Breast cancer / / 20453838 rs680618 chr11 69316881 T C 1.90E-06 Breast cancer / / 20453838 rs680618 chr11 69316881 T C 1.04E-10 Breast cancer (early onset) / / 24493630 rs567488 chr11 69318518 G A 2.50E-06 Breast cancer / / 20453838 rs567488 chr11 69318518 G A 3.95E-10 Breast cancer (early onset) / / 24493630 rs587903 chr11 69320873 T G 6.09E-04 Type 2 diabetes / / 17463246 rs567577 chr11 69325111 A G 3.84E-04 Sarcoidosis / / 19165924 rs17136641 chr11 69328512 G A 1.30E-12 Breast cancer / / 20453838 rs614367 chr11 69328764 C T 9.08E-04 Multiple complex diseases / / 17554300 rs614367 chr11 69328764 C T 3.00E-15 Breast cancer / / 20453838 rs614367 chr11 69328764 C T 2.00E-63 Breast cancer / / 23535729 rs614367 chr11 69328764 C T 1.00E-08 Breast cancer (early onset) / / 24493630 rs493786 chr11 69329674 C T 1.23E-08 Breast cancer (early onset) / / 24493630 rs661204 chr11 69330983 G A 4.70E-14 Breast cancer / / 20453838 rs554219 chr11 69331642 C G 4.90E-14 Breast cancer / / 20453838 rs559664 chr11 69332260 A G 1.43E-08 Breast cancer (early onset) / / 24493630 rs657686 chr11 69332670 A G 5.40E-14 Breast cancer / / 20453838 rs510754 chr11 69334307 A G 1.46E-08 Breast cancer (early onset) / / 24493630 rs11604821 chr11 69352137 G A 3.80E-06 Melanoma / / 21983787 rs1485993 chr11 69362414 A G 4.60E-07 Melanoma / / 21983787 rs12422135 chr11 69378736 A G 2.00E-04 Multiple complex diseases / / 17554300 rs11263498 chr11 69382767 T C 1.70E-07 Melanoma / / 21983787 rs1960217 chr11 69383728 C T 5.93E-04 Multiple complex diseases / / 17554300 rs660963 chr11 69386962 A G 3.98E-04 Multiple complex diseases / / 17554300 rs11263501 chr11 69388907 A G 7.44E-04 Multiple complex diseases / / 17554300 rs950747 chr11 69399649 T A 1.00E-05 Urinary metabolites / / 21572414 rs1872569 chr11 69417986 T C 1.51E-04 Multiple complex diseases / / 17554300 rs633485 chr11 69420993 G A 5.47E-05 Type 2 diabetes / / 17463246 rs2450252 chr11 69434272 C T 1.19E-04 Type 2 diabetes / / 17463246 rs11827026 chr11 69446913 C A 8.30E-04 Multiple complex diseases / / 17554300 rs655089 chr11 69448575 T G 4.96E-04 Endometrial cancer / / 24096698 rs1352075 chr11 69457293 C T 2.00E-06 Multiple myeloma (hyperdiploidy) CCND1 intron 23502783 rs9344 chr11 69462910 G A 8.00E-11 Multiple myeloma (IgH translocation) CCND1 cds-synon 23502783 rs948992 chr11 69513338 A G 1.20E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FGF19 UTR-3 24023788 rs11263535 chr11 69533129 A G 8.04E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs7105655 chr11 69553604 C A 1.61E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs4616067 chr11 69556722 A G 4.18E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs9736587 chr11 69569224 T G 5.58E-06 Body Mass Index / / pha003009 rs9736587 chr11 69569224 T G 3.98E-06 Weight / / pha003026 rs9736587 chr11 69569224 T G 3.88E-05 Weight / / pha003027 rs10737157 chr11 69572684 G A 4.55E-05 Body Mass Index / / pha003009 rs3168175 chr11 69586070 A C 4.33E-04 Acute lung injury / / 22295056 rs3740640 chr11 69587583 T C 4.08E-04 Acute lung injury / / 22295056 rs4084127 chr11 69596523 G A 3.00E-06 Type 1 diabetes / / 21980299 rs10796849 chr11 69602412 C G 6.00E-06 IgG glycosylation / / 23382691 rs12361755 chr11 69602646 G A 4.72E-04 Acute lung injury / / 22295056 rs10752567 chr11 69604527 A G 2.00E-05 Immunoglobulin A / / 20694011 rs9666630 chr11 69605286 G A 3.87E-04 Taste perception / / 22132133 rs4631909 chr11 69614847 T C 1.63E-04 Hearing function / / 17255346 rs12577891 chr11 69623641 G T 2.83E-04 Hearing function / / 17255346 rs12287852 chr11 69636490 C T 1.30E-06 Fasting plasma glucose / / 19060907 rs7479857 chr11 69649931 T G 5.13E-05 Myopia (severe) / / 23933737 rs7103884 chr11 69664014 C T 1.50E-06 Primary tooth development (time to first tooth eruption) / / 23704328 rs7103884 chr11 69664014 C T 6.80E-08 Primary tooth development (number of teeth) / / 23704328 rs10898818 chr11 69820567 G A 4.92E-04 Multiple complex diseases / / 17554300 rs733224 chr11 69837751 A G 8.75E-04 Premature ovarian failure LOC100127946 intron 19508998 rs1994776 chr11 69838148 T C 3.42E-04 HIV-1 viral setpoint LOC100127946 intron 17641165 rs4980715 chr11 69845685 G C 2.80E-05 Urinary metabolites LOC100127946 intron 21572414 rs755016 chr11 69952562 G A 7.20E-04 Amyotrophic Lateral Sclerosis ANO1 intron 17362836 rs755016 chr11 69952562 G A 2.20E-05 Alcoholism (heaviness of drinking) ANO1 intron 21529783 rs2509170 chr11 69976047 T C 7.42E-04 Parkinson's disease ANO1 intron 17052657 rs2509175 chr11 69978638 T A 9.80E-05 Eating disorders ANO1 intron 23568457 rs875106 chr11 70005641 G A 2.60E-06 Urinary metabolites ANO1 intron 21572414 rs2186797 chr11 70007770 T C 1.98E-04 Blood pressure ANO1 missense 17255346 rs7127673 chr11 70014478 T C 2.63E-04 Blood pressure ANO1 intron 17255346 rs78972067 chr11 70058419 C T 8.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs644817 chr11 70071927 C A 6.12E-05 Melanoma / / 21926416 rs687660 chr11 70111532 G A 1.30E-05 Urinary metabolites / / 21572414 rs546502 chr11 70118489 G A 6.25E-04 Lung function (forced expiratory volume in 1 second) PPFIA1 missense 17255346 rs546502 chr11 70118489 G A 8.00E-04 Multiple complex diseases PPFIA1 missense 17554300 rs678575 chr11 70138710 T C 3.53E-04 Lung function (forced expiratory volume in 1 second) PPFIA1 intron 17255346 rs674374 chr11 70139665 T G 1.20E-05 Urinary metabolites PPFIA1 intron 21572414 rs561050 chr11 70165223 G C 4.57E-04 Multiple complex diseases PPFIA1 intron 17554300 rs655130 chr11 70179848 T C 1.60E-05 Urinary metabolites PPFIA1 intron 21572414 rs7117443 chr11 70180285 A T 5.66E-04 Multiple complex diseases PPFIA1 intron 17554300 rs531917 chr11 70224599 T A 6.66E-04 Multiple complex diseases PPFIA1 intron 17554300 rs12801756 chr11 70272042 A G 4.29E-04 Stroke CTTN intron pha002886 rs1198236 chr11 70276818 C T 5.04E-04 Multiple complex diseases CTTN intron 17554300 rs579298 chr11 70327305 T G 2.59E-04 Type 2 diabetes SHANK2 intron 17463246 rs579298 chr11 70327305 T G 1.84E-05 Serum metabolites SHANK2 intron 19043545 rs7940864 chr11 70393306 C T 9.33E-04 Suicide attempts in bipolar disorder SHANK2 intron 21423239 rs17336134 chr11 70412972 G C 7.88E-04 Suicide attempts in bipolar disorder SHANK2 intron 21423239 rs948195 chr11 70424306 C T 0.000513188 Hypertension (early onset hypertension) SHANK2 intron 22479346 rs10899208 chr11 70424411 C T 8.74E-06 Blood Pressure SHANK2 intron pha003039 rs10899208 chr11 70424411 C T 8.69E-05 Blood Pressure SHANK2 intron pha003045 rs7945862 chr11 70433687 A G 4.68E-05 Creatinine levels SHANK2 intron pha003069 rs500335 chr11 70496641 A G 6.56E-04 Multiple complex diseases SHANK2 intron 17554300 rs561884 chr11 70502000 G A 2.09E-04 Multiple complex diseases SHANK2 intron 17554300 rs525304 chr11 70506206 G T 3.00E-06 Response to fenofibrate (adiponectin levels) SHANK2 intron 23149075 rs11237165 chr11 70523008 A G 2.60E-05 Urinary metabolites SHANK2 intron 21572414 rs7940843 chr11 70526345 T C 4.10E-05 Alcoholism (heaviness of drinking) SHANK2 intron 21529783 rs947854 chr11 70565076 C T 1.10E-05 Urinary metabolites SHANK2 intron 21572414 rs895197 chr11 70613047 G A 2.40E-05 Urinary metabolites SHANK2 intron 21572414 rs3017493 chr11 70665521 G A 8.16E-04 Suicide attempts in bipolar disorder SHANK2 intron 21423239 rs3017493 chr11 70665521 G A 5.00E-06 Renal transplant outcome SHANK2 intron 23432519 rs11237599 chr11 70666765 C T 3.71E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SHANK2 cds-synon 24023788 rs12295625 chr11 70671860 G A 5.01E-04 Suicide attempts in bipolar disorder SHANK2 intron 21423239 rs1373839 chr11 70696837 A G 3.71E-05 Multiple complex diseases SHANK2 intron 17554300 rs11237722 chr11 70704905 C T 0.000000121 Total IFN-gamma response to smallpox vaccine SHANK2 intron 22661280 rs1207273 chr11 70716035 C T 2.48E-05 Response to statin treatment (atorvastatin),change in cholesterol levels SHANK2 intron 20031582 rs688118 chr11 70730446 T C 6.31E-04 Multiple complex diseases SHANK2 intron 17554300 rs686805 chr11 70730709 T C 3.48E-04 Multiple complex diseases SHANK2 intron 17554300 rs671803 chr11 70731715 T C 7.32E-04 Multiple complex diseases SHANK2 intron 17554300 rs11238042 chr11 70789000 G A 5.20E-05 Alcoholism (heaviness of drinking) SHANK2 intron 21529783 rs7120950 chr11 70807773 C T 6.32E-04 Acute lung injury SHANK2 intron 22295056 rs3924047 chr11 70829858 T C 0.00000877 Alcohol dependence SHANK2 intron 23691058 rs35198051 chr11 70845204 G A 1.00E-06 Obesity-related traits SHANK2 intron 23251661 rs7125114 chr11 70868869 C T 4.36E-05 Body Fat Distribution SHANK2 intron pha003016 rs7125114 chr11 70868869 C T 4.03E-05 Body Fat Distribution SHANK2 intron pha003017 rs7125114 chr11 70868869 C T 3.26E-05 Body Fat Distribution SHANK2 intron pha003018 rs7124728 chr11 70876435 T C 8.18E-09 Glioma SHANK2 intron 19578367 rs4362169 chr11 70915331 A G 1.90E-05 Urinary metabolites SHANK2 intron 21572414 rs7929059 chr11 70925859 A G 7.78E-05 Cognitive test performance SHANK2 intron 20125193 rs1004872 chr11 70948609 C A 6.23E-04 Multiple complex diseases / / 17554300 rs10792581 chr11 70955469 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs879380 chr11 71019412 G A 6.69E-05 Height / / pha003010 rs1660861 chr11 71019766 T C 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2156809 chr11 71027992 G A 5.81E-04 Alzheimer's disease / / 17998437 rs1660832 chr11 71047824 T C 0.000188 Salmonella-induced pyroptosis / / 22837397 rs7120675 chr11 71050681 C T 3.95E-04 Multiple complex diseases / / 17554300 rs10792632 chr11 71051272 C T 5.27E-04 Multiple complex diseases / / 17554300 rs10897995 chr11 71051815 A G 6.41E-04 Multiple complex diseases / / 17554300 rs1660865 chr11 71069298 G A 0.000023 Salmonella-induced pyroptosis / / 22837397 rs1620013 chr11 71089210 C T 1.84E-04 Multiple sclerosis / / 17660530 rs1792254 chr11 71094381 A C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1792254 chr11 71094381 A C 3.57E-05 Myocardial Infarction / / pha002883 rs1790315 chr11 71103143 A G 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1790315 chr11 71103143 A G 5.55E-05 Myocardial Infarction / / pha002883 rs1790313 chr11 71106206 G A 9.10E-05 Serum metabolites / / 19043545 rs12797951 chr11 71143266 T G 3.01E-08 Multiple complex diseases / / 17554300 rs760242 chr11 71146576 C T 2.04E-12 Triglycerides DHCR7 missense 23063622 rs760242 chr11 71146576 C T 2.23E-13 LDL cholesterol DHCR7 missense 23063622 rs760242 chr11 71146576 C T 6.38E-16 HDL cholesterol DHCR7 missense 23063622 rs760242 chr11 71146576 C T 6.79E-26 Cholesterol,total DHCR7 missense 23063622 rs1790324 chr11 71150520 T G 2.36E-05 Attention deficit hyperactivity disorder DHCR7 intron 20732625 rs1790324 chr11 71150520 T G 2.40E-05 Urinary metabolites DHCR7 intron 21572414 rs1630498 chr11 71150785 A C 2.77E-05 Attention deficit hyperactivity disorder DHCR7 intron 20732625 rs736894 chr11 71152258 C T 1.58E-05 Attention deficit hyperactivity disorder DHCR7 intron 20732625 rs11603330 chr11 71153459 C A 2.14E-05 Attention deficit hyperactivity disorder DHCR7 intron 20732625 rs12422045 chr11 71154820 G A 2.03E-05 Attention deficit hyperactivity disorder DHCR7 intron 20732625 rs1790334 chr11 71155153 A G 5.51E-04 Coronary heart disease DHCR7 cds-synon 21971053 rs3750997 chr11 71158841 A C 1.62E-05 Attention deficit hyperactivity disorder DHCR7 intron 20732625 rs7928249 chr11 71161063 A G 2.05E-05 Attention deficit hyperactivity disorder DHCR7 nearGene-5 20732625 rs12785878 chr11 71167449 G T 2.00E-27 Vitamin D insufficiency /DSYN1 intron 20541252 rs12800438 chr11 71171003 G A 2.23E-05 Attention deficit hyperactivity disorder /DSYN1 intron 20732625 rs3829251 chr11 71194559 G A 3.00E-09 Vitamin D levels /DSYN1 intron 20418485 rs10898200 chr11 71199949 G A 0.000000176 Joint damage severity in rheumatoid arthritis /DSYN1 intron 23696630 rs10898201 chr11 71201527 C A 0.00000103 Primary biliary cirrhosis in females /DSYN1 intron 22936693 rs10898201 chr11 71201527 C A 0.00000491 Primary biliary cirrhosis /DSYN1 intron 22936693 rs10898201 chr11 71201527 C A 0.00000843 Primary biliary cirrhosis (anti-mitochondrial antibody positive) /DSYN1 intron 22936693 rs11234027 chr11 71234107 G A 3.00E-09 Vitamin D levels / / 20418485 rs7115118 chr11 71285221 G A 9.21E-04 Alzheimer's disease / / 17998437 rs11234248 chr11 71286539 G C 0.000165198 Primary sclerosing cholangitis / / 23603763 rs12421579 chr11 71291490 T G 0.0000955 Migraine / / 22678113 rs12421579 chr11 71291490 T G 9.55E-05 Migraine / / 22683712 rs10898347 chr11 71294802 T C 0.0001 Migraine / / 22678113 rs3888289 chr11 71339667 A G 8.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4945093 chr11 71347339 A T 6.21E-05 Immune response to anthrax vaccine / / 22658931 rs57480482 chr11 71347339 A AAT 6.21E-05 Immune response to anthrax vaccine / / 22658931 rs71052803 chr11 71347339 A AT 6.21E-05 Immune response to anthrax vaccine / / 22658931 rs4517550 chr11 71521071 G C 2.00E-05 Prostate cancer / / 21743057 rs11235093 chr11 71523318 G A 1.65E-04 Lymphocyte counts / / 22286170 rs10751189 chr11 71670578 G C 8.27E-04 Multiple complex diseases RNF121 intron 17554300 rs7128974 chr11 71677032 C G 7.57E-04 Multiple complex diseases RNF121 intron 17554300 rs6592453 chr11 71683231 G C 4.44E-04 Multiple complex diseases RNF121 intron 17554300 rs6592455 chr11 71689541 A G 4.65E-04 Multiple complex diseases RNF121 intron 17554300 rs5743684 chr11 71714981 G A 6.38E-13 Triglycerides NUMA1 cds-synon 23063622 rs2298456 chr11 71730715 T A 2.38E-04 Multiple complex diseases NUMA1 intron 17554300 rs10898815 chr11 71739423 G A 1.72E-04 Blood pressure (response to calcium channel blocker) NUMA1 intron 24192120 rs4945434 chr11 71759087 C T 2.35E-04 Multiple complex diseases NUMA1 intron 17554300 rs679926 chr11 71769936 C T 4.03E-04 Multiple complex diseases NUMA1 intron 17554300 rs2511079 chr11 71804154 C T 2.12E-04 Multiple complex diseases LRTOMT intron 17554300 rs2250866 chr11 71804513 G A 2.48E-04 Multiple complex diseases LRTOMT intron 17554300 rs11235449 chr11 71851199 G A 5.06E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs623585 chr11 71851567 T C 0.00043 Coronary artery calcification / / 23727086 rs3016432 chr11 71897255 C T 0.00023 Coronary artery calcification / / 23727086 rs2071010 chr11 71900964 G A 1.06E-04 Multiple complex diseases FOLR1 UTR-5 17554300 rs1540087 chr11 71901491 G A 6.40E-30 Narcolepsy FOLR1 intron 19629137 rs651646 chr11 71929526 T A 0.00025 Coronary artery calcification FOLR2 intron 23727086 rs11548491 chr11 71948536 C G 0.00000086 Stroke INPPL1 missense 23422753 rs3900852 chr11 71963129 A C 2.78E-05 Job-related exhaustion / / 23620144 rs506041 chr11 71993202 A T 5.00E-05 Prostate cancer / / 21743057 rs2508201 chr11 71995639 C T 1.11E-05 Job-related exhaustion / / 23620144 rs2508865 chr11 71995656 T G 1.00E-05 Prostate cancer / / 21743057 rs2508865 chr11 71995656 T G 5.78E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs487288 chr11 71996827 G T 5.00E-05 Prostate cancer / / 21743057 rs1783632 chr11 71998325 A C 5.00E-05 Prostate cancer / / 21743057 rs12421674 chr11 72056591 C T 2.96E-05 Lung adenocarcinoma CLPB intron 19836008 rs12418637 chr11 72061218 G A 7.00E-06 Prostate cancer CLPB intron 21743057 rs4944477 chr11 72115610 A C 3.53E-04 Alzheimer's disease CLPB intron 17998437 rs7129167 chr11 72154529 C T 0.00003984 2-hour glucose tolerance test / / 22885924 rs2163125 chr11 72176100 T C 9.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs11235508 chr11 72184591 C T 1.50E-05 Crohn's disease (need for surgery) / / 23665963 rs11235508 chr11 72184591 C T 2.50E-05 Crohn's disease (time to surgery) / / 23665963 rs11235520 chr11 72234970 C A 1.96E-04 Vaspin levels / / 22907691 rs11235520 chr11 72234970 C A 0.0001957 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs10793032 chr11 72249604 C T 7.35E-05 Body Mass Index / / pha003019 rs10793032 chr11 72249604 C T 8.94E-05 Body Mass Index / / pha003022 rs12418204 chr11 72250123 G A 5.00E-06 optic disc size (cup) / / 20395239 rs341076 chr11 72257918 G A 4.80E-05 Diabetic nephropathy / / pha002866 rs193170 chr11 72259140 G A 3.50E-05 Diabetic nephropathy / / pha002866 rs11602155 chr11 72267956 C T 1.27E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs183778342 chr11 72275909 G A 3.00E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs7117518 chr11 72279550 T C 2.40E-05 Height / / pha003010 rs7117518 chr11 72279550 T C 2.60E-05 Height / / pha003011 rs1135029 chr11 72289291 T C 5.90E-04 Response to taxane treatment (placlitaxel) PDE2A cds-synon 23006423 rs458275 chr11 72335500 G A 1.90E-04 Intelligence (childhood) PDE2A intron 23358156 rs3781913 chr11 72373496 T G 6.00E-10 Rheumatoid arthritis PDE2A intron 22446963 rs12289096 chr11 72375326 T G 2.49E-10 HDL cholesterol PDE2A intron 23063622 rs341054 chr11 72389651 T C 1.56E-04 Coronary heart disease / / 21971053 rs11604811 chr11 72389984 G T 1.27E-07 Primary biliary cirrhosis / / 23000144 rs11604811 chr11 72389984 G T 0.000000127 Facial morphology / / 23028347 rs11605042 chr11 72411664 G A 4.90E-05 Rheumatoid arthritis ARAP1 intron 24390342 rs11605042 chr11 72411664 G A 5.50E-04 Rheumatoid arthritis ARAP1 intron 24390342 rs184056970 chr11 72424910 G A 0.0000653 Menopause (age at onset) ARAP1 intron 23424626 rs11603334 chr11 72432985 G A 3.00E-102 Proinsulin levels ARAP1 UTR-5 21873549 rs11603334 chr11 72432985 G A 2.00E-14 Fasting glucose-related traits (interaction with BMI) ARAP1 UTR-5 22581228 rs11603334 chr11 72432985 G A 0.000214 Fasting insulin-related traits ARAP1 UTR-5 22885924 rs11603334 chr11 72432985 G A 5.31E-13 Fasting blood glucose ARAP1 UTR-5 22885924 rs11603334 chr11 72432985 G A 6.10E-45 Insulin processing and secretion ARAP1 UTR-5 23263489 rs11603334 chr11 72432985 G A 8.63E-04 Glycemic traits (pregnancy) ARAP1 UTR-5 23903356 rs1552224 chr11 72433098 A C 1.00E-22 Type 2 diabetes ARAP1 UTR-5 20581827 rs1552224 chr11 72433098 A C 1.00E-22 Type 2 diabetes ARAP1 UTR-5 21647700 rs1552224 chr11 72433098 A C 0.000094 HOMA-B ARAP1 UTR-5 22885922 rs1552224 chr11 72433098 A C 0.00013 Type 2 diabetes (females) ARAP1 UTR-5 22885922 rs1552224 chr11 72433098 A C 0.00017 Fasting insulin-related traits ARAP1 UTR-5 22885922 rs1552224 chr11 72433098 A C 1.50E-11 Fasting blood glucose ARAP1 UTR-5 22885922 rs1552224 chr11 72433098 A C 1.80E-10 Type 2 diabetes ARAP1 UTR-5 22885922 rs1552224 chr11 72433098 A C 8.70E-09 Type 2 diabetes (males) ARAP1 UTR-5 22885922 rs1552224 chr11 72433098 A C 1.00E-07 Type 2 diabetes ARAP1 UTR-5 24509480 rs12099027 chr11 72433920 T C 7.54E-06 Schizophrenia ARAP1 intron 19571811 rs77464186 chr11 72460398 A C 0.00000013 Type 2 diabetes ARAP1 intron 22885922 rs613937 chr11 72474839 A G 0.0000204 Type 2 diabetes STARD10 intron 22325160 rs11235604 chr11 72533536 C T 2.44E-12 Crohn's disease ATG16L2 missense 23850713 rs12805658 chr11 72555300 C A 1.00E-04 Proinsulin levels FCHSD2 intron 21873549 rs11235612 chr11 72613273 A G 2.00E-04 Cognitive impairment induced by topiramate FCHSD2 intron 22091778 rs11235612 chr11 72613273 A G 6.68E-04 White matter integrity FCHSD2 intron 22425255 rs11605166 chr11 72669777 T C 6.07E-04 White matter integrity FCHSD2 intron 22425255 rs72981516 chr11 72670900 T G 4.00E-07 Crohn's disease FCHSD2 intron 23266558 rs10898893 chr11 72676699 T C 0.0000581 Cognitive impairment (no dementia) FCHSD2 intron 23042215 rs7936751 chr11 72720199 T G 9.05E-04 White matter integrity FCHSD2 intron 22425255 rs6592508 chr11 72784673 A G 9.89E-05 Cognitive performance FCHSD2 intron 19734545 rs17131839 chr11 72830496 T C 3.16E-04 Aortic root size FCHSD2 intron 21223598 rs1783598 chr11 72851463 C T 3.18E-04 White matter integrity FCHSD2 intron 22425255 rs1783598 chr11 72851463 C T 1.20E-10 Type 2 diabetes FCHSD2 intron 22885922 rs1783598 chr11 72851463 C T 1.19E-10 Fasting blood glucose FCHSD2 intron 22885924 rs12420406 chr11 72861888 G T 3.42E-04 Aortic root size / / 21223598 rs11235667 chr11 72863697 A G 7.00E-09 Crohn's disease / / 23850713 rs12416851 chr11 72874072 T C 7.45E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1783587 chr11 72887612 T C 2.47E-05 Body Mass Index / / pha003007 rs1783587 chr11 72887612 T C 1.59E-05 Body Mass Index / / pha003015 rs1783587 chr11 72887612 T C 2.09E-05 Waist Circumference / / pha003025 rs1783587 chr11 72887612 T C 1.52E-05 Weight / / pha003027 rs1791049 chr11 72890304 T C 3.46E-05 Body Mass Index / / pha003007 rs1791049 chr11 72890304 T C 6.64E-05 Waist Circumference / / pha003025 rs1791049 chr11 72890304 T C 1.60E-05 Weight / / pha003027 rs11603160 chr11 72894273 C T 2.84E-05 Pulmonary function / / 20010835 rs11603160 chr11 72894273 C T 8.00E-06 Body mass index (asthmatics) / / 23517042 rs1791933 chr11 72894848 T C 8.00E-06 Insomnia (caffeine-induced) / / 22754043 rs498612 chr11 72907686 A C 9.31E-05 Response to hepatitis C treatment / / 19684573 rs12364461 chr11 72934619 T C 0.00012 Coronary artery calcification P2RY2 intron 23727086 rs2510883 chr11 72934914 G A 1.02E-04 Type 2 diabetes P2RY2 intron 17463246 rs7111814 chr11 72935825 C T 7.27E-05 Alcohol dependence P2RY2 intron 21314694 rs1625496 chr11 72937010 G A 7.51E-05 Cytomegalovirus antibody response P2RY2 intron 21993531 rs1625496 chr11 72937010 G A 4.07E-05 Acute lymphoblastic leukemia (childhood) P2RY2 intron 22076464 rs1790080 chr11 72937274 G A 7.36E-05 Cytomegalovirus antibody response P2RY2 intron 21993531 rs1783597 chr11 72937511 C T 7.33E-05 Cytomegalovirus antibody response P2RY2 intron 21993531 rs1790081 chr11 72937540 G A 7.30E-05 Cytomegalovirus antibody response P2RY2 intron 21993531 rs1790082 chr11 72937861 C T 1.45E-08 HDL cholesterol P2RY2 intron 23063622 rs1790083 chr11 72938767 G T 5.34E-05 Cytomegalovirus antibody response P2RY2 intron 21993531 rs1791926 chr11 72944121 C T 2.10E-05 Urinary metabolites P2RY2 intron 21572414 rs1783596 chr11 72946020 C A,G,T 1.50E-05 Urinary metabolites P2RY2 cds-synon 21572414 rs10793057 chr11 72968660 G A 1.00E-05 Insulin response / / 19430760 rs11235706 chr11 72979740 G A 1.99E-04 Coronary Artery Disease P2RY6 intron 17634449 rs11235707 chr11 72982993 C T 6.50E-04 Coronary Artery Disease P2RY6 intron 17634449 rs11235712 chr11 72994199 T C 7.93E-04 Coronary Artery Disease P2RY6 intron 17634449 rs1790063 chr11 72995912 G A 5.24E-04 Alcohol dependence P2RY6 intron 21314694 rs11235714 chr11 72997921 T C 9.00E-06 Memory (short-term) P2RY6 intron 20038948 rs3741152 chr11 73008914 G A 5.67E-08 Red blood cell traits P2RY6 UTR-3 23222517 rs7125949 chr11 73009084 G A 2.06E-09 Red blood cell traits P2RY6 UTR-3 23222517 rs7115806 chr11 73009432 T C 2.62E-09 Red blood cell traits P2RY6 UTR-3 23222517 rs3741149 chr11 73021084 C T 6.47E-07 Red blood cell traits ARHGEF17 cds-synon 23222517 rs2027763 chr11 73035799 T C 4.10E-07 Red blood cell traits ARHGEF17 intron 23222517 rs2027760 chr11 73036481 G A 6.61E-07 Red blood cell traits ARHGEF17 intron 23222517 rs2027760 chr11 73036481 G A 1.00E-06 Pulmonary function (interaction) ARHGEF17 intron 23284291 rs2027760 chr11 73036481 G A 4.00E-07 Pulmonary function (interaction) ARHGEF17 intron 23284291 rs7123298 chr11 73038820 C T 2.98E-04 Multiple complex diseases ARHGEF17 intron 17554300 rs7125978 chr11 73039229 G A 4.63E-07 Red blood cell traits ARHGEF17 intron 23222517 rs625572 chr11 73044243 A G 4.15E-04 Premature ovarian failure ARHGEF17 intron 19508998 rs570111 chr11 73218230 G T 6.55E-05 HIV-1 viral setpoint FAM168A intron 22174851 rs586309 chr11 73303113 C G 6.55E-05 HIV-1 viral setpoint FAM168A intron 22174851 rs10751226 chr11 73312252 C T 3.00E-07 Pulmonary function (interaction) / / 23284291 rs10751226 chr11 73312252 C T 4.00E-07 Pulmonary function (interaction) / / 23284291 rs593927 chr11 73357073 A T 1.38E-05 Age-related macular degeneration / / pha000001 rs640151 chr11 73357179 G A 9.96E-12 Multiple complex diseases / / 17554300 rs642490 chr11 73365615 A G 6.28E-04 Alcohol dependence PLEKHB1 intron 21314694 rs17132260 chr11 73369581 G A 1.57E-04 Multiple complex diseases PLEKHB1 intron 17554300 rs7126049 chr11 73383382 T C 9.49E-05 Intelligence / / 21826061 rs11235864 chr11 73408272 C T 8.89E-04 Type 2 diabetes RAB6A intron 17463246 rs1723838 chr11 73477045 C T 4.00E-06 Obesity-related traits / / 23251661 rs1723845 chr11 73497924 T C 3.76E-06 Obesity-related traits / / 23251661 rs11235911 chr11 73517259 A G 9.50E-05 Creatinine levels MRPL48 intron pha003069 rs7104794 chr11 73538698 T G 5.29E-05 Creatinine levels MRPL48 intron pha003069 rs17132438 chr11 73590503 C T 1.35E-04 Multiple complex diseases PAAF1 intron 17554300 rs935988 chr11 73630929 G T 3.88E-05 Post-operative nausea and vomiting PAAF1 intron 21694509 rs17132534 chr11 73691774 T C 4.28E-04 Insulin resistance UCP2 intron 21901158 rs17132567 chr11 73721225 C T 0.00000172 LDL cholesterol UCP3 nearGene-5 23063622 rs142277857 chr11 73753106 A G 0.00087 Prostate cancer C2CD3 missense 23555315 rs7119710 chr11 73871469 T C 5.46E-04 Multiple complex diseases C2CD3 intron 17554300 rs17132873 chr11 73962447 G A 8.82E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers PPME1 intron 21775533 rs17132911 chr11 73995696 G A 8.51E-08 Lymphocyte counts P4HA3 intron 22286170 rs7951617 chr11 74006925 C T 8.00E-04 Acute lymphoblastic leukemia (childhood) P4HA3 intron 20189245 rs10898976 chr11 74015599 G C 3.06E-04 Multiple complex diseases P4HA3 intron 17554300 rs7120394 chr11 74034473 G T 2.80E-05 Urinary metabolites / / 21572414 rs598869 chr11 74046975 C T 6.36E-04 Multiple complex diseases / / 17554300 rs658976 chr11 74097466 T G 6.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PGM2L1 intron 20877124 rs639228 chr11 74097965 G A 3.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PGM2L1 intron 20877124 rs658126 chr11 74099892 T C 1.51E-05 Alcohol and nictotine co-dependence PGM2L1 intron 20158304 rs639525 chr11 74105105 C T 3.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PGM2L1 intron 20877124 rs633568 chr11 74126023 G T 4.29E-05 Multiple complex diseases / / 17554300 rs11236101 chr11 74129421 C T 1.21E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs612040 chr11 74137551 C A 4.75E-05 Coronary heart disease / / 21606135 rs11236106 chr11 74150424 A G 7.97E-05 Coronary heart disease / / 21606135 rs10793085 chr11 74153008 C T 1.54E-04 Coronary heart disease / / 21606135 rs12800641 chr11 74153240 G A 4.60E-05 Alcohol and nictotine co-dependence / / 20158304 rs2367995 chr11 74163836 C T 9.85E-06 Serum metabolites / / 19043545 rs2887135 chr11 74163855 A G 7.95E-06 Serum metabolites / / 19043545 rs17215437 chr11 74168361 C T 0.00077 Prostate cancer KCNE3 missense 23555315 rs2270676 chr11 74168411 A G 5.00E-06 Corneal astigmatism KCNE3 cds-synon 22144915 rs34604640 chr11 74168493 G C 1.23E-13 LDL cholesterol KCNE3 missense 23063622 rs34604640 chr11 74168493 G C 1.45E-10 Triglycerides KCNE3 missense 23063622 rs34604640 chr11 74168493 G C 9.26E-15 Cholesterol,total KCNE3 missense 23063622 rs601419 chr11 74194650 G A 9.56E-04 Stroke / / pha002887 rs1303475 chr11 74257489 A G 7.36E-04 Multiple complex diseases / / 17554300 rs1655483 chr11 74264777 A G 3.66E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs12798723 chr11 74269061 G C 2.12E-05 Pulmonary function / / 20010835 rs3824999 chr11 74345550 T G 4.00E-10 Colorectal cancer POLD3 intron 22634755 rs3824999 chr11 74345550 T G 3.43E-05 Colorectal cancer POLD3 intron 23266556 rs10793095 chr11 74357364 A C 9.41E-04 Type 2 diabetes / / 17463246 rs10899024 chr11 74358682 A G 6.11E-05 Type 2 diabetes / / 17463246 rs11236187 chr11 74364566 A C 2.28E-04 Type 2 diabetes / / 17463246 rs11236188 chr11 74364730 T G 7.21E-04 Type 2 diabetes / / 17463246 rs9651763 chr11 74365739 T G 9.41E-04 Type 2 diabetes / / 17463246 rs6592579 chr11 74366331 G A 5.98E-04 Type 2 diabetes / / 17463246 rs6592590 chr11 74381029 C T 2.28E-05 Cytomegalovirus antibody response / / 21993531 rs11822234 chr11 74385146 C T 2.48E-05 Cytomegalovirus antibody response / / 21993531 rs7104802 chr11 74386800 G T 3.64E-05 Cytomegalovirus antibody response / / 21993531 rs17244949 chr11 74389781 C T 2.71E-05 Cytomegalovirus antibody response / / 21993531 rs1893361 chr11 74399425 G A 5.00E-05 Lung cancer / / 18978790 rs4944937 chr11 74405348 A G 1.60E-05 Urinary metabolites / / 21572414 rs12576444 chr11 74435861 C T 2.80E-04 Multiple complex diseases CHRDL2 intron 17554300 rs4944947 chr11 74445699 G A 5.60E-04 Multiple complex diseases / / 17554300 rs17133490 chr11 74526117 A G 1.14E-06 Multiple complex diseases RNF169 intron 17554300 rs9943586 chr11 74561248 A T 3.78E-04 Multiple complex diseases XRRA1 intron 17554300 rs7941838 chr11 74757641 A G 1.06E-04 Smoking initiation / / 24665060 rs4335576 chr11 74768733 C T 9.89E-04 Depression (quantitative trait) / / 20800221 rs4531492 chr11 74771478 T C 0.00011 Salmonella-induced pyroptosis / / 22837397 rs4944067 chr11 74778675 A C 0.000499 Salmonella-induced pyroptosis / / 22837397 rs10899068 chr11 74785720 C T 4.96E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11236323 chr11 74798928 C T 7.60E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7122948 chr11 74800829 A G 7.60E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2851085 chr11 74823345 T C 1.28E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2465291 chr11 74827790 T C 9.20E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2712799 chr11 74849219 G A 4.80E-05 Anger / / 24489884 rs2712800 chr11 74852100 T G 2.38E-04 Crohn's disease / / 17435756 rs4100076 chr11 74861416 A C 5.93E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLCO2B1 nearGene-5 22566498 rs12422149 chr11 74883577 G A 3.44E-04 Alzheimer's disease SLCO2B1 missense 17998437 rs12422149 chr11 74883577 G A 1 Drug response to Montelukast SLCO2B1 missense 19151602 rs12422149 chr11 74883577 G A 7.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLCO2B1 missense 20877124 rs12422149 chr11 74883577 G A 0.000053 Breast cancer SLCO2B1 missense 23555315 rs2306168 chr11 74907582 C T 1 Drug response to Montelukast SLCO2B1 missense 19151602 rs17133815 chr11 74913756 G A 9.36E-06 Thiazide-induced adverse metabolic effects in hypertensive patients SLCO2B1 intron 23400010 rs17133858 chr11 74971557 G T 6.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients ARRB1 UTR-3 23400010 rs7952044 chr11 74987683 C T 3.46E-20 LDL cholesterol ARRB1 intron 23063622 rs7952044 chr11 74987683 C T 4.27E-16 Cholesterol,total ARRB1 intron 23063622 rs512797 chr11 74996081 G A 9.93E-04 Alcohol dependence ARRB1 intron 21314694 rs4945005 chr11 75006877 G A,T 2.80E-05 Urinary metabolites ARRB1 intron 21572414 rs737410 chr11 75026082 A G 2.74E-09 Triglycerides ARRB1 intron 23063622 rs737410 chr11 75026082 A G 4.41E-08 LDL cholesterol ARRB1 intron 23063622 rs737410 chr11 75026082 A G 5.26E-16 HDL cholesterol ARRB1 intron 23063622 rs737410 chr11 75026082 A G 9.00E-20 Cholesterol,total ARRB1 intron 23063622 rs17133921 chr11 75034986 G A 1.80E-05 Urinary metabolites ARRB1 intron 21572414 rs643523 chr11 75041207 C T 1.06E-05 Heart Rate ARRB1 intron pha003054 rs676703 chr11 75096063 C T 1.68E-05 Acne (severe teenage) / / 24114350 rs598936 chr11 75100600 C T 5.68E-04 Smoking initiation / / 24665060 rs536538 chr11 75103724 T C 1.02E-04 Smoking initiation / / 24665060 rs3094303 chr11 75114071 A G 5.11E-04 Multiple complex diseases RPS3 intron 17554300 rs3094303 chr11 75114071 A G 9.20E-06 Urinary metabolites RPS3 intron 21572414 rs4348932 chr11 75116959 G A 5.00E-04 Acute lymphoblastic leukemia (childhood) RPS3 UTR-3 20189245 rs2276443 chr11 75153031 T G 9.44E-05 Body mass (lean) GDPD5 intron 19268274 rs482458 chr11 75158449 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) GDPD5 intron 20189245 rs518611 chr11 75160575 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) GDPD5 cds-synon 20189245 rs1790145 chr11 75174197 T C 9.37E-04 Parkinson's disease GDPD5 intron 17052657 rs1790158 chr11 75181249 G A 9.16E-04 Parkinson's disease GDPD5 intron 17052657 rs1793415 chr11 75184885 G C 7.37E-04 Parkinson's disease GDPD5 intron 17052657 rs1557474 chr11 75185648 A G 7.83E-04 Parkinson's disease GDPD5 intron 17052657 rs11236451 chr11 75249479 T A 2.70E-05 Urinary metabolites / / 21572414 rs4945015 chr11 75266967 A G 9.26E-04 HIV-1 viral setpoint / / 17641165 rs590121 chr11 75274150 G T 0.000000762 Coronary artery disease SERPINH1 intron 23202125 rs606452 chr11 75276178 A C 2.00E-09 Height SERPINH1 intron 22021425 rs606452 chr11 75276178 A C 0.00000137 Coronary artery disease SERPINH1 intron 23202125 rs634552 chr11 75282052 T G 4.00E-13 Height SERPINH1 intron 20881960 rs609309 chr11 75287341 A G 2.90E-05 Urinary metabolites / / 21572414 rs599816 chr11 75293982 G A 7.80E-05 Electrocardiographic conduction measures / / 19389651 rs602003 chr11 75324778 A G 2.88E-04 Fibrinogen MAP6 intron 17255346 rs598847 chr11 75335799 C T 8.98E-05 Fibrinogen MAP6 intron 17255346 rs540461 chr11 75400012 G A 3.73E-04 Fibrinogen / / 17255346 rs11236497 chr11 75415940 G A 1.44E-04 Fibrinogen / / 17255346 rs509530 chr11 75422306 C T 3.36E-04 Smoking initiation / / 24665060 rs534299 chr11 75424546 A G 0.000769134 Hypertension (early onset hypertension) / / 22479346 rs141331999 chr11 75439894 A G 0.00000094 Prostate cancer (advanced) MOGAT2 missense 23555315 rs12275093 chr11 75440737 C T 2.00E-04 Cognitive impairment induced by topiramate MOGAT2 intron 22091778 rs11236507 chr11 75444605 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs670345 chr11 75446269 G A 7.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11236511 chr11 75448759 C T 7.67E-05 Cognitive impairment induced by topiramate / / 22091778 rs11236514 chr11 75451343 C A 9.27E-04 Multiple complex diseases / / 17554300 rs11236514 chr11 75451343 C A 2.10E-05 Urinary metabolites / / 21572414 rs11236515 chr11 75451411 A G 9.27E-04 Multiple complex diseases / / 17554300 rs11236515 chr11 75451411 A G 2.40E-05 Urinary metabolites / / 21572414 rs11236516 chr11 75451668 T C 1.40E-05 Urinary metabolites / / 21572414 rs10793124 chr11 75452267 G C 8.48E-04 Multiple complex diseases / / 17554300 rs10793125 chr11 75452364 A G 7.67E-04 Multiple complex diseases / / 17554300 rs11236518 chr11 75453066 C T 9.51E-04 Multiple complex diseases / / 17554300 rs11236518 chr11 75453066 C T 2.70E-05 Urinary metabolites / / 21572414 rs10793126 chr11 75453982 T C 1.70E-05 Urinary metabolites / / 21572414 rs499974 chr11 75455021 C A 1.00E-08 HDL cholesterol / / 24097068 rs499974 chr11 75455021 C A 4.58E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs600626 chr11 75455309 A G 5.00E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11236530 chr11 75489404 C A 1.40E-09 HDL cholesterol DGAT2 intron 23063622 rs7111334 chr11 75637567 C T 1.62E-04 Smoking quantity UVRAG intron 24665060 rs11236588 chr11 75678647 C T 2.78E-04 Smoking initiation UVRAG intron 24665060 rs6592618 chr11 75711897 A G 4.74E-04 Smoking quantity UVRAG intron 24665060 rs6592621 chr11 75733418 G A 7.67E-04 Smoking quantity UVRAG intron 24665060 rs667534 chr11 75805884 A G 9.90E-05 Electrocardiographic conduction measures UVRAG intron 19389651 rs660211 chr11 75819828 G A 8.09E-05 Attention deficit hyperactivity disorder UVRAG intron 22420046 rs660981 chr11 75860179 C A 8.10E-05 Iris characteristics / / 21835309 rs10793139 chr11 75865197 T C 7.05E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4477460 chr11 75866552 G A 3.08E-04 IgE levels / / 17255346 rs12277860 chr11 75896647 C T 6.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs4944092 chr11 75909619 A G 6.24E-04 Type 2 diabetes WNT11 intron 17463246 rs4944092 chr11 75909619 A G 3.00E-08 PR interval WNT11 intron 20062060 rs1402704 chr11 75939600 G A 9.72E-04 Stroke / / pha002887 rs2447947 chr11 75943540 T C 0.000016 Alcohol craving with or without dependence / / 22481050 rs4387369 chr11 75946502 T G 9.30E-05 Pericardial fat / / 22589742 rs1357121 chr11 75949795 G A,C 8.80E-05 Pericardial fat / / 22589742 rs2226615 chr11 75956348 G A 3.36E-04 Alcohol dependence / / 21314694 rs678108 chr11 75966144 T C 2.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10899187 chr11 75966327 T C 0.0000281 Alcohol craving with or without dependence / / 22481050 rs11236663 chr11 75967695 T C 7.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10899188 chr11 75967841 G A 6.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12807555 chr11 75969633 G T 3.77E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11236673 chr11 75977845 A G 4.37E-04 Type 2 diabetes / / 17463246 rs11236673 chr11 75977845 A G 3.52E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2253423 chr11 75981779 A G 6.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs4945061 chr11 75982418 A G 4.59E-04 Heart Failure / / pha002885 rs7117319 chr11 76000086 G A 3.64E-04 Smoking initiation / / 24665060 rs7110007 chr11 76001950 C T 2.93E-05 Telomere length / / 20139977 rs750801 chr11 76033374 T C 5.15E-04 Heart Failure / / pha002884 rs11236724 chr11 76056456 T A 8.99E-04 Multiple complex diseases / / 17554300 rs11236739 chr11 76103233 C A 3.09E-05 Lipoprotein-associated phospholipase A2 activity and mass LOC100506127 intron 20442857 rs12223637 chr11 76104519 T C 8.68E-05 Self-reported allergy LOC100506127 intron 23817569 rs4945083 chr11 76120025 G A 2.30E-04 Heart Failure / / pha002884 rs10160382 chr11 76127214 T C 6.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11236746 chr11 76128490 C T 2.07E-05 Self-reported allergy / / 23817569 rs11236747 chr11 76130040 C T 1.55E-05 Self-reported allergy / / 23817569 rs7929948 chr11 76131069 C T 7.03E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs4945087 chr11 76136482 G A 3.62E-08 Self-reported allergy / / 23817569 rs17134872 chr11 76139846 G A 1.66E-05 Rheumatoid arthritis / / 21452313 rs10793164 chr11 76143019 A T 3.41E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs10793164 chr11 76143019 A T 2.89E-08 Self-reported allergy / / 23817569 rs12278256 chr11 76155555 G T 1.79E-05 Rheumatoid arthritis / / 21452313 rs10793169 chr11 76164012 A G 4.95E-05 Lipoprotein-associated phospholipase A2 activity and mass C11orf30 intron 20442857 rs4625500 chr11 76164959 T G 6.41E-09 Self-reported allergy C11orf30 intron 23817569 rs11606394 chr11 76179116 C T 7.66E-09 Self-reported allergy C11orf30 intron 23817569 rs10899221 chr11 76181631 G A 1.83E-05 Type 2 diabetes and other traits C11orf30 intron 19734900 rs7940390 chr11 76204381 G A 3.84E-09 Self-reported allergy C11orf30 intron 23817569 rs7115331 chr11 76218590 T G 1.27E-04 Self-reported allergy C11orf30 intron 23817569 rs2508740 chr11 76227182 G A 7.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C11orf30 intron 20877124 rs11236774 chr11 76234953 A G 9.43E-06 Rheumatoid arthritis C11orf30 intron 21452313 rs1939469 chr11 76236220 A G 3.58E-04 Alzheimer's disease (late onset) C11orf30 intron 21379329 rs1939469 chr11 76236220 A G 9.49E-05 Vascular dementia C11orf30 intron 22116812 rs2508756 chr11 76243901 G A 3.05E-05 Lipoprotein-associated phospholipase A2 activity and mass C11orf30 intron 20442857 rs2508756 chr11 76243901 G A 7.36E-09 Self-reported allergy C11orf30 intron 23817569 rs2513514 chr11 76244493 G A 4.10E-06 Bilirubin levels,in serum C11orf30 intron 19389676 rs2508755 chr11 76245562 G A 1.54E-09 Self-reported allergy C11orf30 intron 23817569 rs3758715 chr11 76254539 C T 7.79E-05 Self-reported allergy C11orf30 intron 23817569 rs2251075 chr11 76254989 C G 7.70E-09 Self-reported allergy C11orf30 intron 23817569 rs1044265 chr11 76262128 A G 6.49E-09 Self-reported allergy C11orf30 UTR-3 23817569 rs8848 chr11 76262652 G T 9.12E-04 Self-reported allergy / / 23817569 rs2155220 chr11 76266172 C T 3.82E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs2155220 chr11 76266172 C T 6.66E-09 Self-reported allergy / / 23817569 rs7938856 chr11 76267117 A C 5.29E-04 Self-reported allergy / / 23817569 rs7130588 chr11 76270683 A G 2.00E-08 Asthma / / 21907864 rs7130588 chr11 76270683 A G 1.10E-04 Asthma / / 23181788 rs7130588 chr11 76270683 A G 2.16E-12 Self-reported allergy / / 23817569 rs7130588 chr11 76270683 A G 1.71E-04 Atopic dermatitis / / 23886662 rs7130588 chr11 76270683 A G 3.94E-05 Atopic dermatitis / / 23886662 rs7130588 chr11 76270683 A G 4.00E-13 Atopic dermatitis / / 23886662 rs7130588 chr11 76270683 A G 5.81E-07 Atopic dermatitis / / 23886662 rs7130588 chr11 76270683 A G 6.19E-04 Smoking initiation / / 24665060 rs2508746 chr11 76270950 C T 6.54E-04 Rheumatoid arthritis / / 21452313 rs2508746 chr11 76270950 C T 1.21E-07 Self-reported allergy / / 23817569 rs2513517 chr11 76271261 T C 7.02E-10 Self-reported allergy / / 23817569 rs2508747 chr11 76271689 G A 3.71E-04 IgE levels / / 17255346 rs2508747 chr11 76271689 G A 3.53E-04 Multiple complex diseases / / 17554300 rs2508747 chr11 76271689 G A 5.79E-10 Self-reported allergy / / 23817569 rs1892953 chr11 76272542 G A 4.35E-04 IgE levels / / 17255346 rs1892953 chr11 76272542 G A 1.68E-04 Multiple complex diseases / / 17554300 rs1892953 chr11 76272542 G A 4.43E-11 Self-reported allergy / / 23817569 rs2508748 chr11 76273348 T A 1.03E-05 Multiple complex diseases / / 17554300 rs2508748 chr11 76273348 T A 6.68E-11 Self-reported allergy / / 23817569 rs2508751 chr11 76273526 A T 7.07E-11 Self-reported allergy / / 23817569 rs2155226 chr11 76273855 T C 3.32E-05 Multiple complex diseases / / 17554300 rs2155226 chr11 76273855 T C 4.08E-11 Self-reported allergy / / 23817569 rs2513518 chr11 76274234 G C 1.01E-10 Self-reported allergy / / 23817569 rs11606100 chr11 76275578 A T 6.26E-10 Self-reported allergy / / 23817569 rs12789493 chr11 76275703 T C 2.80E-05 Multiple complex diseases / / 17554300 rs12789493 chr11 76275703 T C 6.97E-11 Self-reported allergy / / 23817569 rs7936562 chr11 76278258 T C 4.25E-04 Atopic dermatitis / / 21666691 rs7936562 chr11 76278258 T C 6.07E-11 Self-reported allergy / / 23817569 rs1892959 chr11 76278768 T C 5.25E-11 Self-reported allergy / / 23817569 rs10899232 chr11 76279179 C T 6.46E-11 Self-reported allergy / / 23817569 rs6592646 chr11 76280146 C T 1.70E-11 Self-reported allergy / / 23817569 rs2226612 chr11 76281219 A G 4.18E-11 Self-reported allergy / / 23817569 rs3862807 chr11 76283081 G A 9.15E-05 Multiple complex diseases / / 17554300 rs3862807 chr11 76283081 G A 6.06E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs3862807 chr11 76283081 G A 4.89E-11 Self-reported allergy / / 23817569 rs6592652 chr11 76285579 G A 3.75E-11 Self-reported allergy / / 23817569 rs10899234 chr11 76288937 G A 5.97E-06 Self-reported allergy / / 23817569 rs2155219 chr11 76299194 G T 5.00E-16 Ulcerative colitis / / 21297633 rs2155219 chr11 76299194 G T 1.00E-08 IgE grass sensitization / / 22036096 rs2155219 chr11 76299194 G T 4.00E-08 Allergic rhinitis / / 22036096 rs2155219 chr11 76299194 G T 4.00E-36 Inflammatory bowel disease / / 23128233 rs2155219 chr11 76299194 G T 2.00E-19 Self-reported allergy / / 23817569 rs2155219 chr11 76299194 G T 1.00E-18 Allergic sensitization / / 23817571 rs2155219 chr11 76299194 G T 1.61E-12 Atopic dermatitis / / 23886662 rs2155219 chr11 76299194 G T 5.00E-11 Asthma and hay fever / / 24388013 rs7927894 chr11 76301316 C T 2.77E-04 IgE levels / / 17255346 rs7927894 chr11 76301316 C T 4.01E-04 Multiple complex diseases / / 17554300 rs7927894 chr11 76301316 C T 1.00E-09 Crohn's disease / / 18587394 rs7927894 chr11 76301316 C T 8.00E-10 Atopic dermatitis / / 19349984 rs7927894 chr11 76301316 C T 1.00E-09 Asthma / / 21150878 rs7927894 chr11 76301316 C T 1.32E-09 Multiple sclerosis / / 22190364 rs7927894 chr11 76301316 C T 8.81E-06 Asthma / / 23181788 rs7927894 chr11 76301316 C T 6.25E-16 Self-reported allergy / / 23817569 rs7927894 chr11 76301316 C T 1.73E-06 Atopic dermatitis / / 23886662 rs7927894 chr11 76301316 C T 2.10E-04 Atopic dermatitis / / 23886662 rs7927894 chr11 76301316 C T 9.80E-05 Atopic dermatitis / / 23886662 rs7927997 chr11 76301375 C T 6.00E-13 Crohn's disease / / 21102463 rs7927997 chr11 76301375 C T 7.21E-06 Asthma / / 23181788 rs7927997 chr11 76301375 C T 5.73E-16 Self-reported allergy / / 23817569 rs11827375 chr11 76308272 G A 7.17E-06 Type 2 diabetes and other traits / / 19734900 rs11827375 chr11 76308272 G A 7.17E-06 Alzheimer's disease (late onset) / / 21460841 rs11236806 chr11 76322252 A G 1.19E-04 Blood pressure (response to calcium channel blocker) / / 24192120 rs11236809 chr11 76332210 T G 3.00E-06 Atopic dermatitis / / 23042114 rs11236811 chr11 76339953 G A 7.61E-04 Crohn's disease / / 23266558 rs7931131 chr11 76352908 T G 9.69E-05 Bone mineral density / / 19181680 rs7931131 chr11 76352908 T G 1.33E-06 Heart Rate / / pha003054 rs7931131 chr11 76352908 T G 6.67E-05 Socioeconomic Factors / / pha003067 rs2186674 chr11 76354008 G A 1.40E-06 Heart Rate / / pha003054 rs2186674 chr11 76354008 G A 5.95E-05 Socioeconomic Factors / / pha003067 rs4945096 chr11 76368327 C T 2.22E-06 Self-reported allergy / / 23817569 rs3197153 chr11 76369072 T C 1.34E-06 Self-reported allergy LRRC32 UTR-3 23817569 rs1803627 chr11 76369344 A C 3.45E-04 Taste perception LRRC32 UTR-3 22132133 rs3781701 chr11 76369419 G A 2.01E-06 Self-reported allergy LRRC32 UTR-3 23817569 rs3781700 chr11 76369709 C A 2.42E-06 Self-reported allergy LRRC32 UTR-3 23817569 rs3781699 chr11 76369785 T G 2.69E-06 Self-reported allergy LRRC32 UTR-3 23817569 rs1320644 chr11 76370187 G A 5.51E-06 Self-reported allergy LRRC32 UTR-3 23817569 rs1320644 chr11 76370187 G A 7.00E-05 Asthma and hay fever LRRC32 UTR-3 24388013 rs3740779 chr11 76372052 A G 1.16E-04 Vaspin levels LRRC32 cds-synon 22907691 rs3740779 chr11 76372052 A G 0.0001159 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks LRRC32 cds-synon 22907730 rs7944463 chr11 76373896 T C 6.66E-07 Self-reported allergy LRRC32 intron 23817569 rs7944357 chr11 76374039 A G 3.04E-05 Self-reported allergy LRRC32 intron 23817569 rs6592657 chr11 76377819 G A 1.08E-06 Self-reported allergy LRRC32 intron 23817569 rs10899249 chr11 76380357 C T 8.44E-05 Self-reported allergy LRRC32 intron 23817569 rs731644 chr11 76396289 A G 7.65E-04 Type 2 diabetes GUCY2E intron 17463246 rs731644 chr11 76396289 A G 2.20E-04 Self-reported allergy GUCY2E intron 23817569 rs4945107 chr11 76397110 C T 1.72E-04 Self-reported allergy GUCY2E intron 23817569 rs7950372 chr11 76407114 C T 8.88E-04 Self-reported allergy GUCY2E intron 23817569 rs7127747 chr11 76412663 G A 2.69E-04 Amyotrophic Lateral Sclerosis GUCY2E intron 17362836 rs7127747 chr11 76412663 G A 7.84E-04 Self-reported allergy GUCY2E intron 23817569 rs7127747 chr11 76412663 G A 5.23E-04 Alcohol dependence GUCY2E intron 24277619 rs4483608 chr11 76413086 C T 7.28E-04 Self-reported allergy GUCY2E intron 23817569 rs10128539 chr11 76419992 A T 7.40E-04 Multiple complex diseases GUCY2E intron 17554300 rs6592659 chr11 76421250 G T 1.84E-05 Serum metabolites GUCY2E intron 19043545 rs12295620 chr11 76421899 G C,T 4.41E-04 Self-reported allergy GUCY2E intron 23817569 rs4944120 chr11 76436948 A G 6.97E-05 Male fertility / / 22633400 rs11236909 chr11 76439068 A G 6.11E-05 Male fertility / / 22633400 rs4393347 chr11 76442114 G A 3.91E-05 Orofacial clefts / / 22419666 rs948455 chr11 76442377 C A 3.93E-05 Orofacial clefts / / 22419666 rs12362105 chr11 76450908 G A 8.34E-07 Gallstones / / 17632509 rs873108 chr11 76455618 C T 5.54E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs10899277 chr11 76462811 T A 4.21E-04 Multiple complex diseases / / 17554300 rs147269019 chr11 76465781 G C 9.00E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs180728022 chr11 76466035 C A 9.43E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs7114304 chr11 76466951 T C 1.48E-11 Metabolite levels / / 22286219 rs1149615 chr11 76498133 C T 4.08E-04 Type 2 diabetes TSKU intron 17463246 rs1149616 chr11 76498369 C T 7.40E-04 Type 2 diabetes TSKU intron 17463246 rs7119795 chr11 76543474 T C 1.40E-05 Urinary metabolites / / 21572414 rs1225139 chr11 76553617 G A 3.07E-04 Type 2 diabetes / / 17463246 rs1225139 chr11 76553617 G A 5.51E-04 Smoking initiation / / 24665060 rs618076 chr11 76596504 G T 4.00E-04 Atrial fibrillation ACER3 intron 21846873 rs11236998 chr11 76596620 G A 0.00036 Coronary artery calcification ACER3 intron 23727086 rs2119457 chr11 76622632 G C 8.01E-04 Response to cytadine analogues (cytosine arabinoside) ACER3 intron 24483146 rs12223477 chr11 76630285 T C 7.45E-04 Multiple complex diseases ACER3 intron 17554300 rs6592683 chr11 76632302 G T 6.19E-04 Smoking initiation ACER3 intron 24665060 rs7110532 chr11 76658241 C A 1.07E-04 Smoking initiation ACER3 intron 24665060 rs7118970 chr11 76660780 G A 9.24E-04 Multiple complex diseases ACER3 intron 17554300 rs1589126 chr11 76712615 T G 3.16E-04 Smoking initiation ACER3 intron 24665060 rs3740765 chr11 76731050 A G 1.40E-04 Smoking initiation ACER3 intron 24665060 rs591043 chr11 76732746 T C 3.67E-04 Smoking initiation ACER3 UTR-3 24665060 rs17135325 chr11 76733313 C A 6.84E-04 Aortic root size ACER3 UTR-3 21223598 rs2826 chr11 76733847 C T 6.12E-04 Smoking initiation ACER3 UTR-3 24665060 rs4944137 chr11 76758592 G C 9.19E-04 Type 2 diabetes / / 17463246 rs4944137 chr11 76758592 G C 7.99E-04 Alcohol dependence / / 21314694 rs7949609 chr11 76773510 C T 0.00033 Coronary artery calcification / / 23727086 rs185836777 chr11 76796077 G A 0.00008 Prostate cancer (advanced) CAPN5 missense 23555315 rs4945141 chr11 76805777 A G 4.24E-04 Multiple complex diseases CAPN5 intron 17554300 rs2233547 chr11 76813968 G A 0.00026 Breast cancer OMP missense 23555315 rs2233547 chr11 76813968 G A 0.00035 Breast cancer (ER positive) OMP missense 23555315 rs2233548 chr11 76813991 G A 0.000000548 Cholesterol,total OMP missense 23063622 rs2233548 chr11 76813991 G A 1.46E-11 HDL cholesterol OMP missense 23063622 rs4945143 chr11 76820429 A C 6.20E-05 Cognitive test performance CAPN5 intron 20125193 rs3781684 chr11 76823484 C T 7.00E-06 Cognitive performance CAPN5 intron 19734545 rs4259851 chr11 76831441 A G 1.72E-05 Hirschsprung's disease CAPN5 intron 19196962 rs4517554 chr11 76831622 T C 3.02E-05 Hirschsprung's disease CAPN5 intron 19196962 rs143494790 chr11 76834837 G A 0.00000097 Breast cancer CAPN5 missense 23555315 rs143494790 chr11 76834837 G A 0.00037 Breast cancer (ER positive) CAPN5 missense 23555315 rs1043418 chr11 76836350 T C 4.42E-04 Alzheimer's disease (late onset) CAPN5 UTR-3 21379329 rs1043420 chr11 76836439 A G 4.34E-04 Smoking initiation CAPN5 UTR-3 24665060 rs4945150 chr11 76865617 G A 0.0008959 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MYO7A intron 23233654 rs4945150 chr11 76865617 G A 8.96E-04 Methotrexate clearance (acute lymphoblastic leukemia) MYO7A intron 23233662 rs3737454 chr11 76868278 C A 4.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MYO7A intron 20877124 rs762667 chr11 76868372 T C 5.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MYO7A cds-synon 20877124 rs7943982 chr11 76874992 T G 2.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MYO7A intron 20877124 rs4944147 chr11 76880518 G A 0.0004307 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MYO7A intron 23233654 rs4944147 chr11 76880518 G A 4.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) MYO7A intron 23233662 rs7930391 chr11 76881925 C T 5.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MYO7A intron 20877124 rs11607721 chr11 76881988 C T 0.000243 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MYO7A intron 23233654 rs11607721 chr11 76881988 C T 2.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) MYO7A intron 23233662 rs12418037 chr11 76923352 A G 8.26E-05 Cholesterol MYO7A intron 17255346 rs7104577 chr11 76954898 A G 1.00E-04 Cognitive impairment induced by topiramate GDPD4 intron 22091778 rs7125798 chr11 76959598 A G 9.52E-04 Tourette syndrome GDPD4 intron 22889924 rs1793483 chr11 76975467 T C 4.60E-04 Crohn's disease GDPD4 intron 17684544 rs1377470 chr11 77050714 A C 2.89E-06 Parkinson's disease PAK1 intron 17052657 rs1453342 chr11 77068770 C A 2.85E-05 Vascular dementia PAK1 intron 22116812 rs2602475 chr11 77073359 G A 2.49E-07 Pure-tone audiometry PAK1 intron pha001968 rs618012 chr11 77099817 G C 8.20E-04 Smoking cessation PAK1 intron 24665060 rs10501425 chr11 77142888 T A 2.17E-07 Pure-tone audiometry PAK1 intron pha001968 rs527589 chr11 77154639 C T 3.00E-06 Orofacial clefts PAK1 intron 22419666 rs527589 chr11 77154639 C T 3.82E-05 Height PAK1 intron pha003010 rs10899383 chr11 77211136 A T 6.27E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs7129556 chr11 77300048 C T 4.00E-06 Weight loss (gastric bypass surgery) / / 23643386 rs11237249 chr11 77341135 G A 1.91E-06 Weight loss (gastric bypass surgery) CLNS1A intron 23643386 rs11604207 chr11 77367542 C T 0.00000159 Menopause (age at onset) / / 23424626 rs588217 chr11 77583376 G A 7.00E-05 Weight loss (gastric bypass surgery) C11orf67 UTR-3 23643386 rs17752280 chr11 77613200 G A 2.60E-05 Urinary metabolites INTS4 intron 21572414 rs3018411 chr11 77641161 C T 1.81E-04 Acute lung injury INTS4 intron 22295056 rs12807406 chr11 77680399 G T 6.04E-04 Acute lung injury INTS4 intron 22295056 rs3819256 chr11 77701861 T A 0.0000011 Perception of the odorant galaxolide INTS4 intron 22362865 rs17752458 chr11 77702484 G C 1.83E-04 Multiple complex diseases INTS4 intron 17554300 rs7930865 chr11 77724674 C T 1.92E-05 Waist Circumference / / pha003025 rs7930865 chr11 77724674 C T 7.01E-05 Waist-Hip Ratio / / pha003028 rs3824865 chr11 77727379 T C 4.09E-04 IgE levels KCTD14 UTR-3 17255346 rs2372892 chr11 77730725 G A 9.50E-06 Urinary metabolites KCTD14 intron 21572414 rs2372897 chr11 77742826 A G 2.00E-04 Schizophrenia NDUFC2-KCTD14 intron 19197363 rs2372897 chr11 77742826 A G 6.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NDUFC2-KCTD14 intron 20877124 rs10899433 chr11 77749228 C T 5.20E-04 Type 2 diabetes NDUFC2-KCTD14 intron 17463246 rs10899434 chr11 77761076 G A 8.59E-04 Type 2 diabetes NDUFC2-KCTD14 intron 17463246 rs10899434 chr11 77761076 G A 2.50E-04 Gallstones NDUFC2-KCTD14 intron 17632509 rs589472 chr11 77773715 T C 2.20E-06 Urinary metabolites NDUFC2-KCTD14 intron 21572414 rs606732 chr11 77776911 A G 1.50E-06 Urinary metabolites THRSP intron 21572414 rs584981 chr11 77785939 T C 8.47E-05 Serum metabolites NDUFC2 intron 19043545 rs606164 chr11 77802925 G C 8.99E-04 Type 2 diabetes / / 17463246 rs606164 chr11 77802925 G C 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs10793285 chr11 77811196 G T 6.63E-04 Lymphocyte counts / / 22286170 rs590981 chr11 77821007 G A 5.53E-05 Serum metabolites ALG8 intron 19043545 rs10899440 chr11 77825275 A G 6.30E-05 Endometriosis ALG8 intron 21151130 rs230669 chr11 77875386 A G 4.28E-05 Schizophrenia / / 19197363 rs2510044 chr11 77909014 G A 3.78E-04 Alzheimer's disease USP35 missense 24755620 rs2256464 chr11 77917305 C A 1.35E-05 Alzheimer's disease USP35 intron 21627779 rs2256464 chr11 77917305 C A 3.05E-04 Alzheimer's disease USP35 intron 24755620 rs2510045 chr11 77920563 G T 3.05E-04 Alzheimer's disease USP35 cds-synon 24755620 rs2511178 chr11 77923220 C T 9.28E-06 Alzheimer's disease USP35 intron 21627779 rs2450139 chr11 77924544 G A 8.52E-06 Alzheimer's disease USP35 intron 21627779 rs2450139 chr11 77924544 G A 8.91E-04 Self-reported allergy USP35 intron 23817569 rs2450138 chr11 77924870 C T 2.81E-04 Alzheimer's disease USP35 UTR-3 24755620 rs1055248 chr11 77925573 T C 9.36E-04 Self-reported allergy USP35 UTR-3 23817569 rs2512522 chr11 77925855 G C 1.35E-05 Alzheimer's disease GAB2 nearGene-3 21627779 rs2912 chr11 77926292 G A 2.81E-04 Alzheimer's disease GAB2 nearGene-3 24755620 rs866901 chr11 77926309 C T 2.81E-04 Alzheimer's disease GAB2 nearGene-3 24755620 rs1046780 chr11 77926769 A G 2.56E-04 Alzheimer's disease GAB2 UTR-3 24755620 rs2511162 chr11 77927101 A G 2.56E-04 Alzheimer's disease GAB2 UTR-3 24755620 rs3740677 chr11 77928036 G T 2.94E-04 Alzheimer's disease GAB2 UTR-3 24755620 rs1485483 chr11 77930138 T C 9.28E-06 Alzheimer's disease GAB2 UTR-3 21627779 rs1485483 chr11 77930138 T C 2.94E-04 Alzheimer's disease GAB2 UTR-3 24755620 rs2450122 chr11 77930345 T C 2.83E-04 Alzheimer's disease GAB2 cds-synon 24755620 rs901104 chr11 77930499 G A 4.56E-07 Alzheimer's disease (late onset) GAB2 intron 17553421 rs901104 chr11 77930499 G A 9.07E-06 Alzheimer's disease GAB2 intron 21627779 rs901104 chr11 77930499 G A 2.87E-04 Alzheimer's disease GAB2 intron 24755620 rs2511171 chr11 77930935 G A 8.52E-06 Alzheimer's disease GAB2 intron 21627779 rs1385601 chr11 77936064 A C 2.50E-04 Alzheimer's disease GAB2 intron 24755620 rs1385600 chr11 77936166 A G 2.81E-09 Alzheimer's disease (late onset) GAB2 cds-synon 17553421 rs1385600 chr11 77936166 A G 2.80E-09 Alzheimer's disease (late onset) GAB2 cds-synon 21460841 rs1385600 chr11 77936166 A G 2.44E-04 Alzheimer's disease GAB2 cds-synon 24755620 rs2248407 chr11 77937800 G A 2.80E-06 Alzheimer's disease GAB2 cds-synon 21627779 rs2248407 chr11 77937800 G A 2.38E-04 Alzheimer's disease GAB2 cds-synon 24755620 rs2450128 chr11 77940075 G A 2.80E-06 Alzheimer's disease GAB2 intron 21627779 rs2512549 chr11 77940163 C T 2.38E-04 Alzheimer's disease GAB2 intron 24755620 rs2450129 chr11 77940385 T C 8.29E-05 Alzheimer's disease GAB2 intron 24755620 rs1007837 chr11 77941076 T C 3.97E-07 Alzheimer's disease (late onset) GAB2 intron 17553421 rs1007837 chr11 77941076 T C 4.45E-06 Alzheimer's disease GAB2 intron 21627779 rs1007837 chr11 77941076 T C 3.05E-04 Alzheimer's disease GAB2 intron 24755620 rs2450130 chr11 77943457 T G 9.12E-06 Alzheimer's disease GAB2 intron 21627779 rs2450130 chr11 77943457 T G 2.15E-04 Alzheimer's disease GAB2 intron 24755620 rs2512550 chr11 77943848 C T 1.47E-05 Alzheimer's disease GAB2 intron 21627779 rs2510040 chr11 77944548 T A 1.47E-05 Alzheimer's disease GAB2 intron 21627779 rs2450131 chr11 77944568 A C 1.01E-05 Alzheimer's disease GAB2 intron 21627779 rs2244508 chr11 77948515 T A 1.01E-05 Alzheimer's disease GAB2 intron 21627779 rs2450123 chr11 77952771 T A,C,G 1.47E-05 Alzheimer's disease GAB2 intron 21627779 rs2512546 chr11 77957276 T C 1.47E-05 Alzheimer's disease GAB2 intron 21627779 rs1017907 chr11 77959124 A T 9.44E-06 Alzheimer's disease GAB2 intron 21627779 rs2510038 chr11 77966034 G A 1.19E-05 Alzheimer's disease (late onset) GAB2 intron 17553421 rs2511175 chr11 77975081 A G 9.59E-04 Self-reported allergy GAB2 intron 23817569 rs2511170 chr11 77980582 T C 9.62E-04 Self-reported allergy GAB2 intron 23817569 rs2511187 chr11 77985849 T A 1.47E-05 Alzheimer's disease GAB2 intron 21627779 rs4945261 chr11 77990260 G A 3.06E-08 Alzheimer's disease (late onset) GAB2 intron 17553421 rs4945261 chr11 77990260 G A 3.10E-08 Alzheimer's disease (late onset) GAB2 intron 21460841 rs4945261 chr11 77990260 G A 9.96E-04 Self-reported allergy GAB2 intron 23817569 rs10899451 chr11 77991222 A C 1.47E-05 Alzheimer's disease GAB2 intron 21627779 rs7101429 chr11 77992967 A G 1.06E-06 Alzheimer's disease (late onset) GAB2 intron 17553421 rs9651768 chr11 77996020 C T 9.39E-04 Self-reported allergy GAB2 intron 23817569 rs9651769 chr11 77996166 T C 1.47E-05 Alzheimer's disease GAB2 intron 21627779 rs10793294 chr11 77996403 C A 1.59E-07 Alzheimer's disease (late onset) GAB2 intron 17553421 rs10793294 chr11 77996403 C A 1.60E-07 Alzheimer's disease (late onset) GAB2 intron 21460841 rs10793295 chr11 77996521 G C 5.12E-04 Alzheimer's disease GAB2 intron 24755620 rs7107174 chr11 77997936 C T 3.58E-04 Alzheimer's disease GAB2 intron 24755620 rs10899456 chr11 78000155 C G 5.61E-04 Alzheimer's disease GAB2 intron 24755620 rs4291702 chr11 78001248 C T 5.88E-07 Alzheimer's disease (late onset) GAB2 intron 17553421 rs4291702 chr11 78001248 C T 7.74E-06 Alzheimer's disease GAB2 intron 21627779 rs4291702 chr11 78001248 C T 5.87E-04 Alzheimer's disease GAB2 intron 24755620 rs4944195 chr11 78003499 T C 6.82E-04 Alzheimer's disease GAB2 intron 24755620 rs4944196 chr11 78008731 G A 9.63E-04 Alzheimer's disease GAB2 intron 24755620 rs11602622 chr11 78010830 A G 7.96E-04 Alzheimer's disease GAB2 intron 24755620 rs4417308 chr11 78013492 A C 8.14E-04 Alzheimer's disease GAB2 intron 24755620 rs10899467 chr11 78014057 G T 8.50E-04 Alzheimer's disease GAB2 intron 24755620 rs6592772 chr11 78015563 A C 9.40E-04 Self-reported allergy GAB2 intron 23817569 rs6592772 chr11 78015563 A C 4.19E-04 Alzheimer's disease GAB2 intron 24755620 rs4128206 chr11 78015952 A C 9.79E-04 Self-reported allergy GAB2 intron 23817569 rs10899468 chr11 78016650 C T 9.99E-04 Self-reported allergy GAB2 intron 23817569 rs10899469 chr11 78018313 T C 5.05E-04 Alzheimer's disease GAB2 intron 24755620 rs10793299 chr11 78018954 T A 8.28E-06 Alzheimer's disease GAB2 intron 21627779 rs10899470 chr11 78020052 C T 1.54E-05 Alzheimer's disease GAB2 intron 21627779 rs7941617 chr11 78021146 C T 9.09E-04 Self-reported allergy GAB2 intron 23817569 rs4492844 chr11 78026516 A G 8.74E-04 Alzheimer's disease GAB2 intron 24755620 rs4944198 chr11 78032605 T A 8.64E-04 Self-reported allergy GAB2 intron 23817569 rs7115850 chr11 78045071 G C 2.80E-10 Alzheimer's disease (late onset) GAB2 intron 17553421 rs2373115 chr11 78091150 C A 1.00E-10 Alzheimer's disease (late onset) GAB2 intron 17553421 rs2373115 chr11 78091150 C A 9.70E-11 Alzheimer's disease (late onset) GAB2 intron 21460841 rs10899489 chr11 78095373 C A 8.00E-09 Menarche (age at onset) GAB2 intron 21102462 rs6592775 chr11 78117047 C G 9.41E-04 Self-reported allergy GAB2 intron 23817569 rs12280198 chr11 78161361 C T 6.99E-04 Lymphocyte counts /RS2 intron 22286170 rs7936011 chr11 78275931 G T 2.20E-05 Urinary metabolites /RS2 intron 21572414 rs4309183 chr11 78323351 G A 2.09E-04 Multiple complex diseases / / 17554300 rs7101522 chr11 78325050 G T 3.67E-04 Multiple complex diseases / / 17554300 rs1792134 chr11 78360169 C T 5.97E-05 Cardiovascular disease / / pha003064 rs1790550 chr11 78396039 A C 7.00E-15 Multiple complex diseases ODZ4 intron 17554300 rs1790557 chr11 78443235 C T 3.14E-04 Multiple complex diseases ODZ4 intron 17554300 rs1785812 chr11 78453645 G A 9.87E-04 Myopia (pathological) ODZ4 intron 21095009 rs1785812 chr11 78453645 G A 1.46E-04 Alzheimer's disease (late onset) ODZ4 intron 21379329 rs1783953 chr11 78454125 A G 6.22E-04 Multiple complex diseases ODZ4 intron 17554300 rs1783942 chr11 78455918 T G 1.61E-04 Multiple complex diseases ODZ4 intron 17554300 rs1785820 chr11 78459619 A T 2.39E-04 Multiple complex diseases ODZ4 intron 17554300 rs948396 chr11 78462815 T G 9.67E-04 Myopia (pathological) ODZ4 intron 21095009 rs1540125 chr11 78469723 T C 7.01E-04 Myopia (pathological) ODZ4 intron 21095009 rs1792136 chr11 78470719 A G 7.01E-04 Myopia (pathological) ODZ4 intron 21095009 rs1785814 chr11 78471087 T C 7.01E-04 Myopia (pathological) ODZ4 intron 21095009 rs1790561 chr11 78482589 T A 5.60E-06 Iron levels ODZ4 intron 21208937 rs1970745 chr11 78483823 C T 9.06E-04 Myopia (pathological) ODZ4 intron 21095009 rs1785827 chr11 78487823 G T 9.72E-04 Myopia (pathological) ODZ4 intron 21095009 rs1540124 chr11 78490320 T C 9.19E-04 Myopia (pathological) ODZ4 intron 21095009 rs1941379 chr11 78507790 A G 2.00E-04 Cognitive impairment induced by topiramate ODZ4 intron 22091778 rs648443 chr11 78510519 C T 3.50E-04 Multiple complex diseases ODZ4 intron 17554300 rs10899572 chr11 78530642 G A 1.60E-05 Primary sclerosing cholangitis ODZ4 intron 19944697 rs949365 chr11 78530720 C T 2.30E-05 Primary sclerosing cholangitis ODZ4 intron 19944697 rs7925387 chr11 78531526 G C 9.06E-05 Multiple complex diseases ODZ4 intron 17554300 rs17137210 chr11 78533111 T C 7.78E-04 Multiple complex diseases ODZ4 intron 17554300 rs1945246 chr11 78539115 T G 2.25E-05 Amyotrophic lateral sclerosis (sporadic) ODZ4 intron 24529757 rs547292 chr11 78558239 G T 7.21E-04 Stroke ODZ4 intron pha002887 rs11237644 chr11 78588441 A G 9.24E-06 Longevity ODZ4 intron 21612516 rs870959 chr11 78589149 T C 1.27E-05 Longevity ODZ4 intron 21612516 rs507151 chr11 78595440 G A 3.92E-04 Response to cytadine analogues (cytosine arabinoside) ODZ4 intron 24483146 rs6592810 chr11 78596169 C T 1.10E-05 Longevity ODZ4 intron 21612516 rs548541 chr11 78640980 A G 0.0000551 Nonsyndromic striae distensae (stretch marks) ODZ4 intron 23633020 rs10501432 chr11 78642846 T C 8.76E-04 Multiple complex diseases ODZ4 intron 17554300 rs11826937 chr11 78659145 A T 3.00E-06 Retinopathy in non-diabetics ODZ4 intron 23393555 rs663919 chr11 78661432 C T 7.68E-04 Alzheimer's disease ODZ4 intron 22005930 rs663520 chr11 78661498 G A 1.76E-05 Serum metabolites ODZ4 intron 19043545 rs663520 chr11 78661498 G A 7.68E-04 Alzheimer's disease ODZ4 intron 22005930 rs516783 chr11 78663501 C T 2.99E-04 Alzheimer's disease ODZ4 intron 22005930 rs671290 chr11 78667936 C T 6.10E-04 Alzheimer's disease ODZ4 intron 22005930 rs640555 chr11 78670207 G A 3.30E-04 Alzheimer's disease ODZ4 intron 22005930 rs2852247 chr11 78674045 G T 2.32E-04 Alzheimer's disease ODZ4 intron 22005930 rs681267 chr11 78678682 G A 2.10E-04 Alzheimer's disease ODZ4 intron 22005930 rs620777 chr11 78678857 G A 1.90E-04 Alzheimer's disease ODZ4 intron 22005930 rs21971 chr11 78678911 G A 1.00E-04 Alzheimer's disease ODZ4 intron 22005930 rs673934 chr11 78687012 G A 2.50E-04 Alzheimer's disease ODZ4 intron 22005930 rs1025595 chr11 78690093 G A 1.87E-04 Alzheimer's disease ODZ4 intron 22005930 rs625895 chr11 78695523 G A 2.70E-04 Alzheimer's disease ODZ4 intron 22005930 rs624080 chr11 78695933 C T 4.89E-04 Alzheimer's disease ODZ4 intron 22005930 rs12295080 chr11 78697260 A C 1.79E-06 Multiple complex diseases ODZ4 intron 17554300 rs592257 chr11 78701984 G A 1.79E-04 Alzheimer's disease ODZ4 intron 22005930 rs17827500 chr11 78708275 G C 1.70E-05 Parkinson's disease (motor and cognition) ODZ4 intron 22658654 rs11824887 chr11 78720650 T C 6.48E-05 Body Mass Index ODZ4 intron pha003009 rs17137594 chr11 78723254 A G 7.41E-04 Obesity (extreme) ODZ4 intron 21935397 rs630970 chr11 78724214 A T 7.52E-04 Nicotine smoking ODZ4 intron 19268276 rs11237688 chr11 78728657 G T 2.27E-04 Parkinson's disease ODZ4 intron 16252231 rs10899581 chr11 78750332 A G 9.24E-04 Suicide attempts in bipolar disorder ODZ4 intron 21423239 rs10899582 chr11 78750374 A G 8.14E-04 Suicide attempts in bipolar disorder ODZ4 intron 21423239 rs972139 chr11 78763755 T C 3.44E-04 Self-reported allergy ODZ4 intron 23817569 rs2016337 chr11 78771634 T C 9.34E-04 Type 2 diabetes ODZ4 intron 17463246 rs7105794 chr11 78795359 T C 3.27E-06 Cortisol secretion,in saliva ODZ4 intron 21316860 rs7941097 chr11 78814038 T C 7.14E-05 Body Mass Index ODZ4 intron pha003019 rs7941097 chr11 78814038 T C 1.21E-05 Body Mass Index ODZ4 intron pha003020 rs7935464 chr11 78817097 C T 3.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ODZ4 intron 20877124 rs9667214 chr11 78821945 A G 4.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ODZ4 intron 20877124 rs7938232 chr11 78823701 G A 1.33E-04 Insulin resistance ODZ4 intron 21901158 rs11237730 chr11 78857438 C T 2.34E-04 Height ODZ4 intron 17255346 rs10501434 chr11 78870097 A G 2.87E-04 Multiple complex diseases ODZ4 intron 17554300 rs10501434 chr11 78870097 A G 4.18E-05 Heart Rate ODZ4 intron pha003054 rs533870 chr11 78871902 A C 6.97E-04 Type 2 diabetes ODZ4 intron 17463246 rs10899607 chr11 78911432 C T 1.32E-04 Smoking quantity ODZ4 intron 24665060 rs1938821 chr11 78915775 C T 6.21E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) ODZ4 intron 24236485 rs10501435 chr11 78918314 A G 1.38E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ODZ4 intron 24023788 rs4945334 chr11 78929703 T G 5.70E-04 Response to taxane treatment (placlitaxel) ODZ4 intron 23006423 rs577043 chr11 78933135 G A 0.0000038 Dyslexia ODZ4 intron 23190410 rs616214 chr11 78939166 C T 8.12E-05 Multiple sclerosis ODZ4 intron 17660530 rs500266 chr11 78939405 C A 0.000258682 Hypertension (early onset hypertension) ODZ4 intron 22479346 rs486694 chr11 78951703 C A 4.46E-04 Smoking initiation ODZ4 intron 24665060 rs2007588 chr11 78961828 C A 1.30E-04 Myopia (pathological) ODZ4 intron 21095009 rs509249 chr11 78986758 C A 6.97E-04 Type 2 diabetes ODZ4 intron 17463246 rs1151200 chr11 78992686 T C 4.00E-07 Obesity-related traits ODZ4 intron 23251661 rs499949 chr11 78993207 C T 7.80E-07 Obesity-related traits ODZ4 intron 23251661 rs487345 chr11 79003851 C T 9.60E-06 Creatinine levels ODZ4 intron 20222955 rs7931512 chr11 79020289 A G 7.13E-06 Bipolar disorder ODZ4 intron 19488044 rs7931512 chr11 79020289 A G 3.58E-05 Bipolar disorder and schizophrenia ODZ4 intron 20889312 rs7931512 chr11 79020289 A G 5.78E-04 Suicide attempts in bipolar disorder ODZ4 intron 21423239 rs7931512 chr11 79020289 A G 2.39E-06 Obesity-related traits ODZ4 intron 23251661 rs7931512 chr11 79020289 A G 9.62E-06 Bipolar Disorder ODZ4 intron pha002858 rs7934520 chr11 79020349 T C 5.63E-04 Suicide attempts in bipolar disorder ODZ4 intron 21423239 rs568421 chr11 79036665 C A 9.92E-06 Serum metabolites ODZ4 intron 19043545 rs536215 chr11 79036827 A G 6.08E-06 Body Mass Index ODZ4 intron pha003006 rs536215 chr11 79036827 A G 8.28E-05 Body Mass Index ODZ4 intron pha003015 rs536215 chr11 79036827 A G 2.33E-05 Body Mass Index ODZ4 intron pha003019 rs536215 chr11 79036827 A G 2.91E-06 Body Mass Index ODZ4 intron pha003020 rs536215 chr11 79036827 A G 1.70E-05 Waist Circumference ODZ4 intron pha003024 rs536215 chr11 79036827 A G 4.20E-05 Waist Circumference ODZ4 intron pha003025 rs490195 chr11 79039257 C T 7.35E-06 Serum metabolites ODZ4 intron 19043545 rs483793 chr11 79045170 T C 1.12E-05 Body Mass Index ODZ4 intron pha003006 rs483793 chr11 79045170 T C 5.53E-05 Body Mass Index ODZ4 intron pha003019 rs483793 chr11 79045170 T C 1.48E-05 Body Mass Index ODZ4 intron pha003020 rs483793 chr11 79045170 T C 1.23E-05 Waist Circumference ODZ4 intron pha003024 rs483793 chr11 79045170 T C 8.06E-05 Waist Circumference ODZ4 intron pha003025 rs565758 chr11 79046388 G A 2.16E-05 Serum metabolites ODZ4 intron 19043545 rs10501437 chr11 79047545 A G 6.86E-05 Body Mass Index ODZ4 intron pha003006 rs7932591 chr11 79052860 C G 5.78E-05 Brain derived neurotrophic factor levels,in serum ODZ4 intron 22047184 rs17828949 chr11 79053255 A G 2.68E-06 Glucose levels ODZ4 intron pha003061 rs12577093 chr11 79057097 C T 1.04E-07 Bipolar disorder ODZ4 intron 24618891 rs880762 chr11 79057579 C T 1.49E-04 Alzheimer's disease ODZ4 intron pha002879 rs11237796 chr11 79059444 A G 1.93E-04 Multiple complex diseases ODZ4 intron 17554300 rs11237796 chr11 79059444 A G 1.77E-04 Major depressive disorder ODZ4 intron 22472876 rs11237796 chr11 79059444 A G 8.60E-07 Bipolar disorder ODZ4 intron 24618891 rs954129 chr11 79060796 T A 1.50E-04 Major depressive disorder ODZ4 intron 22472876 rs954129 chr11 79060796 T A 3.31E-07 Bipolar disorder ODZ4 intron 24618891 rs17138171 chr11 79062930 T C 6.36E-07 Bipolar disorder ODZ4 intron 22182935 rs17138171 chr11 79062930 T C 5.23E-05 Major depressive disorder ODZ4 intron 22472876 rs17138171 chr11 79062930 T C 1.37E-08 Bipolar disorder ODZ4 intron 24618891 rs530965 chr11 79065101 C T 4.00E-06 Cognitive test performance ODZ4 intron 17903297 rs11237799 chr11 79067472 A C 5.88E-05 Major depressive disorder ODZ4 intron 22472876 rs11237799 chr11 79067472 A C 2.53E-08 Bipolar disorder ODZ4 intron 24618891 rs12279388 chr11 79067674 A G 1.81E-08 Bipolar disorder ODZ4 intron 24618891 rs7932890 chr11 79068394 A G 1.77E-04 Multiple complex diseases ODZ4 intron 17554300 rs7932890 chr11 79068394 A G 6.03E-05 Major depressive disorder ODZ4 intron 22472876 rs7932890 chr11 79068394 A G 9.35E-09 Bipolar disorder ODZ4 intron 24618891 rs536962 chr11 79068444 A G 3.98E-05 Type 1 diabetes ODZ4 intron 18978792 rs556857 chr11 79068548 T C 3.17E-05 Type 1 diabetes ODZ4 intron 18978792 rs17138230 chr11 79075852 A T 1.07E-04 Major depressive disorder ODZ4 intron 22472876 rs17138230 chr11 79075852 A T 0.0000143 Bipolar disorder ODZ4 intron 23637625 rs17138230 chr11 79075852 A T 5.88E-09 Bipolar disorder ODZ4 intron 24618891 rs12576775 chr11 79077193 A G 4.00E-08 Bipolar disorder ODZ4 intron 21926972 rs12576775 chr11 79077193 A G 1.14E-04 Major depressive disorder ODZ4 intron 22472876 rs12576775 chr11 79077193 A G 6.20E-09 Bipolar disorder ODZ4 intron 23070075 rs12576775 chr11 79077193 A G 4.00E-08 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) ODZ4 intron 23453885 rs12576775 chr11 79077193 A G 4.46E-09 Bipolar disorder ODZ4 intron 24618891 rs7947534 chr11 79077236 A G 7.86E-04 Alzheimer's disease ODZ4 intron 17998437 rs11237805 chr11 79078669 A G 2.96E-08 Bipolar disorder ODZ4 intron 24618891 rs1944449 chr11 79083249 C T 3.60E-05 Bipolar disorder and major depressive disorder (combined) ODZ4 intron 20351715 rs1944449 chr11 79083249 C T 8.76E-07 Bipolar disorder ODZ4 intron 22182935 rs1944449 chr11 79083249 C T 9.85E-05 Major depressive disorder ODZ4 intron 22472876 rs1944449 chr11 79083249 C T 1.43E-09 Bipolar disorder ODZ4 intron 24618891 rs41513944 chr11 79083344 C T 6.27E-04 Alzheimer's disease ODZ4 intron 17998437 rs12290811 chr11 79083620 T A 7.88E-04 Multiple complex diseases ODZ4 intron 17554300 rs12290811 chr11 79083620 T A 4.00E-06 Bipolar disorder ODZ4 intron 18711365 rs12290811 chr11 79083620 T A 2.60E-05 Bipolar disorder and major depressive disorder (combined) ODZ4 intron 20351715 rs12290811 chr11 79083620 T A 1.39E-04 Major depressive disorder ODZ4 intron 22472876 rs12290811 chr11 79083620 T A 1.00E-09 Bipolar disorder ODZ4 intron 24618891 rs10501439 chr11 79085846 A G 3.20E-05 Bipolar disorder and major depressive disorder (combined) ODZ4 intron 20351715 rs10501439 chr11 79085846 A G 7.79E-05 Major depressive disorder ODZ4 intron 22472876 rs10501439 chr11 79085846 A G 2.24E-08 Bipolar disorder ODZ4 intron 24618891 rs473003 chr11 79089204 A T 4.91E-04 Alzheimer's disease ODZ4 intron 17998437 rs472870 chr11 79089255 T C 3.99E-04 Alzheimer's disease ODZ4 intron 17998437 rs11237815 chr11 79090800 A G 7.24E-07 Bipolar disorder ODZ4 intron 24618891 rs489257 chr11 79091227 T C 2.46E-04 Alzheimer's disease ODZ4 intron 17998437 rs489257 chr11 79091227 T C 5.34E-05 Alzheimer's disease ODZ4 intron pha002879 rs12289486 chr11 79092527 C T 8.78E-07 Bipolar disorder ODZ4 intron 24618891 rs12276041 chr11 79092736 G A 9.04E-04 Major depressive disorder ODZ4 intron 22472876 rs12577328 chr11 79093474 C G 8.49E-07 Bipolar disorder ODZ4 intron 24618891 rs572460 chr11 79094154 A G 1.50E-05 Urinary metabolites ODZ4 intron 21572414 rs12277834 chr11 79100156 C T 7.71E-07 Bipolar disorder ODZ4 intron 24618891 rs11237820 chr11 79104665 G A 9.09E-07 Bipolar disorder ODZ4 intron 24618891 rs12275195 chr11 79105799 A C 6.25E-07 Bipolar disorder ODZ4 intron 24618891 rs11237821 chr11 79106804 C T 6.59E-07 Bipolar disorder ODZ4 intron 24618891 rs7108878 chr11 79107807 T G 4.35E-07 Bipolar disorder ODZ4 intron 24618891 rs472186 chr11 79111822 A C 1.10E-04 Alzheimer's disease ODZ4 intron 17998437 rs472186 chr11 79111822 A C 2.71E-05 Alzheimer's disease ODZ4 intron pha002879 rs1511237 chr11 79114684 C T 6.22E-07 Bipolar disorder ODZ4 intron 24618891 rs12286448 chr11 79121342 T G 1.01E-06 Bipolar disorder ODZ4 intron 24618891 rs951932 chr11 79122534 A G 2.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ODZ4 intron 20877124 rs951932 chr11 79122534 A G 4.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ODZ4 intron 20877124 rs2175420 chr11 79123883 C T 2.90E-05 Bipolar disorder ODZ4 intron 21926972 rs2175420 chr11 79123883 C T 6.77E-06 Bipolar disorder ODZ4 intron 24618891 rs1567540 chr11 79124084 A G 1.37E-05 Bipolar disorder ODZ4 intron 24618891 rs12275848 chr11 79127329 G C 7.11E-06 Bipolar disorder ODZ4 intron 24618891 rs11237826 chr11 79128235 T C 1.68E-04 Alzheimer's disease ODZ4 intron pha002879 rs12273727 chr11 79129616 A G 7.54E-06 Bipolar disorder ODZ4 intron 24618891 rs12279943 chr11 79129926 G C 1.35E-05 Bipolar disorder ODZ4 intron 24618891 rs1355423 chr11 79131600 T C 6.34E-04 White matter integrity ODZ4 intron 22425255 rs1355423 chr11 79131600 T C 2.23E-04 Smoking quantity ODZ4 intron 24665060 rs17138318 chr11 79132083 G T 1.65E-05 Bipolar disorder ODZ4 intron 24618891 rs7930347 chr11 79137019 T C 1.52E-04 Blood pressure ODZ4 intron 17255346 rs10501444 chr11 79137378 C G 1.75E-05 Bipolar disorder ODZ4 intron 24618891 rs10899622 chr11 79139709 C G 2.68E-04 Alzheimer's disease ODZ4 intron 17998437 rs17138330 chr11 79143454 T G 2.68E-05 Major depressive disorder (broad) ODZ4 intron 20038947 rs7127580 chr11 79144856 C G 1.53E-07 Bipolar disorder ODZ4 intron 24618891 rs1397726 chr11 79158020 C T 1.10E-05 Urinary metabolites / / 21572414 rs373009262 chr11 79173703 C CAACTTTTTGGAA 5.26E-06 Bipolar disorder / / 24618891 rs4529900 chr11 79173703 C A,G,T 5.26E-06 Bipolar disorder / / 24618891 rs1943849 chr11 79178631 C G 1.49E-05 Bipolar disorder / / 24618891 rs12808922 chr11 79178811 A G 3.48E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2512637 chr11 79191457 A G 2.39E-05 Bipolar disorder / / 24618891 rs35480972 chr11 79191457 A AC 2.39E-05 Bipolar disorder / / 24618891 rs17138435 chr11 79192987 A G 5.08E-26 Narcolepsy / / 19629137 rs7120805 chr11 79213595 G A 9.22E-04 Multiple complex diseases / / 17554300 rs11237884 chr11 79233103 C T 3.02E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs17835313 chr11 79243525 C T 6.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs4586189 chr11 79294675 T C 1.12E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs12222648 chr11 79306924 A C 1.12E-04 Vaspin levels / / 22907691 rs12222648 chr11 79306924 A C 0.0001118 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs10899655 chr11 79316999 C T 1.62E-05 Vaspin levels / / 22907691 rs10899655 chr11 79316999 C T 0.0000162 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs10899655 chr11 79316999 C T 0.0001376 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs4945361 chr11 79329267 T C 1.23E-04 Vaspin levels / / 22907691 rs4945361 chr11 79329267 T C 0.0001233 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs526442 chr11 79349355 T C 4.23E-05 Calcium levels / / pha003085 rs10047496 chr11 79380766 T C 3.42E-05 Acute lung injury / / 22295056 rs6592863 chr11 79381820 A G 9.96E-04 Depression (quantitative trait) / / 20800221 rs7939599 chr11 79385675 G A 9.06E-04 Depression (quantitative trait) / / 20800221 rs11237962 chr11 79387954 C T 6.91E-04 Type 2 diabetes / / 17463246 rs11237962 chr11 79387954 C T 1.03E-04 Depression (quantitative trait) / / 20800221 rs11237964 chr11 79388156 A G 2.99E-04 Depression (quantitative trait) / / 20800221 rs7124492 chr11 79389769 T C 2.32E-04 Depression (quantitative trait) / / 20800221 rs7927582 chr11 79389855 G A 4.74E-04 Depression (quantitative trait) / / 20800221 rs7104818 chr11 79389922 G C 2.21E-04 Depression (quantitative trait) / / 20800221 rs12578029 chr11 79392225 T A 2.32E-04 Depression (quantitative trait) / / 20800221 rs10899665 chr11 79394407 A G 2.38E-04 Depression (quantitative trait) / / 20800221 rs10793391 chr11 79396636 G T 2.91E-04 Type 2 diabetes / / 17463246 rs2186445 chr11 79400408 T C 3.13E-04 Type 2 diabetes / / 17463246 rs2154746 chr11 79401282 G A 4.72E-04 Depression (quantitative trait) / / 20800221 rs10899669 chr11 79408549 C A 9.75E-04 Alzheimer's disease / / 22005930 rs11237978 chr11 79427818 G A 5.13E-04 Acute lung injury / / 22295056 rs2252626 chr11 79430411 T C 8.28E-05 Cognitive impairment induced by topiramate / / 22091778 rs11237982 chr11 79441694 T C 1.79E-07 Primary biliary cirrhosis / / 23000144 rs11237982 chr11 79441694 T C 0.000000179 Facial morphology / / 23028347 rs2257193 chr11 79444242 A G 9.96E-04 Heart Failure / / pha002884 rs17835751 chr11 79448553 A G 4.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs1893912 chr11 79473438 G A 9.49E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12270115 chr11 79485137 G A 5.00E-06 Preschool internalizing problems / / 24839885 rs10501453 chr11 79506098 G A 2.51E-05 Diabetes Mellitus / / pha003060 rs11238009 chr11 79559382 C A 0.00000004 Brain microstructure and intellectual performance / / 22723713 rs283315 chr11 79570988 C T 1.20E-05 Urinary metabolites / / 21572414 rs283315 chr11 79570988 C T 5.29E-05 Lymphocyte counts / / 22286170 rs283312 chr11 79584760 C T 3.10E-06 Urinary metabolites / / 21572414 rs7122784 chr11 79605008 T G 3.70E-05 Schizophrenia / / 19197363 rs601208 chr11 79624615 T C 3.62E-04 Insulin resistance / / 21901158 rs17139078 chr11 79641647 T C 1.19E-04 Cognitive function / / 24684796 rs585832 chr11 79666995 C T 9.40E-05 Cognitive function / / 24684796 rs587677 chr11 79667382 C T 9.40E-05 Cognitive function / / 24684796 rs494336 chr11 79670892 T C 1.05E-04 Cognitive function / / 24684796 rs607301 chr11 79683501 A G 2.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs642770 chr11 79688804 C A 8.40E-05 Immunoglobulin A / / 20694011 rs603876 chr11 79691366 C G 1.31E-04 Cognitive function / / 24684796 rs486935 chr11 79697979 T C 9.35E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs585747 chr11 79700145 A G 1.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs585747 chr11 79700145 A G 3.08E-06 Hearing function / / 21493956 rs6592874 chr11 79704767 A T 5.30E-05 Cognitive function / / 24684796 rs2000518 chr11 79704875 G A 5.30E-05 Cognitive function / / 24684796 rs557207 chr11 79705115 G A 6.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17139230 chr11 79705397 T A 5.30E-05 Cognitive function / / 24684796 rs11238055 chr11 79731180 A G 3.29E-04 Taste perception / / 22132133 rs17548825 chr11 79778099 G A 2.82E-04 Type 2 diabetes / / 17463246 rs11238074 chr11 79781947 T C 8.04E-04 Multiple complex diseases / / 17554300 rs11238074 chr11 79781947 T C 2.40E-06 Stevens-Johnson syndrome / / 20947153 rs12277667 chr11 79808421 C A 9.40E-05 Personality dimensions / / 18957941 rs509876 chr11 79811268 G A 2.29E-05 Obsessive-compulsive disorder / / 24821223 rs10488780 chr11 79812352 C A 4.40E-05 Lipid traits / / 17903299 rs1944487 chr11 79816181 C T 5.90E-05 Personality dimensions / / 18957941 rs10488779 chr11 79817111 A G 3.60E-05 Lipid traits / / 17903299 rs998023 chr11 79817252 A G 8.92E-04 Alcohol dependence / / 20201924 rs998025 chr11 79817365 C T 1.22E-04 Insulin resistance / / 21901158 rs11231950 chr11 79831685 C T 5.12E-04 Smoking initiation / / 24665060 rs1893815 chr11 79858863 G T 6.20E-05 Antisocial behavior / / 20345837 rs688477 chr11 79863593 T C 6.54E-04 Multiple complex diseases / / 17554300 rs1892942 chr11 79863662 A C 7.66E-04 Multiple complex diseases / / 17554300 rs7114833 chr11 79870120 A C 6.40E-04 Multiple complex diseases / / 17554300 rs11231962 chr11 79873531 G T 4.05E-04 Multiple complex diseases / / 17554300 rs11231963 chr11 79873627 A G 4.86E-04 Multiple complex diseases / / 17554300 rs7941538 chr11 79885314 T C 2.32E-04 Multiple complex diseases / / 17554300 rs10792468 chr11 79898818 C T 8.50E-05 Personality dimensions / / 18957941 rs2141418 chr11 79905426 T C 1.28E-04 Multiple complex diseases / / 17554300 rs116530567 chr11 79940259 G T 4.50E-11 Metabolite levels / / 22286219 rs1628460 chr11 79941934 G T 1.62E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs10897568 chr11 79950154 C T 3.47E-04 Smoking initiation / / 24665060 rs11231991 chr11 79962149 A T 4.00E-06 Cognitive decline (age-related) / / 24468470 rs11826437 chr11 80016503 T G 6.90E-04 Alcohol dependence / / 20201924 rs11232073 chr11 80027442 C A 3.13E-04 Lung function (forced vital capacity) / / 24023788 rs10501463 chr11 80033297 A G 4.85E-04 Premature ovarian failure / / 19508998 rs7395555 chr11 80058479 G C 2.00E-07 Response to antipsychotic treatment / / 23241943 rs4945403 chr11 80069506 C T 6.42E-04 Multiple complex diseases / / 17554300 rs11825242 chr11 80069660 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1074543 chr11 80072819 T C 5.94E-04 Depression (quantitative trait) / / 20800221 rs1479290 chr11 80083356 T G 1.40E-06 Bladder cancer / / 19648920 rs2512483 chr11 80094978 T C 3.70E-05 Multiple complex diseases / / 17554300 rs2448273 chr11 80105368 C A 7.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs10792479 chr11 80109899 C T 6.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs2448276 chr11 80110511 C T 5.20E-06 Emphysema-related traits / / 20709820 rs7123160 chr11 80118588 A G 9.78E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs2448281 chr11 80125592 C A 2.40E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs2198254 chr11 80143061 A G 7.22E-05 Cognitive impairment induced by topiramate / / 22091778 rs1037399 chr11 80147284 G A 8.68E-04 Multiple complex diseases / / 17554300 rs1037399 chr11 80147284 G A 2.44E-04 Alzheimer's disease (late onset) / / 21379329 rs1037399 chr11 80147284 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1037399 chr11 80147284 G A 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1037399 chr11 80147284 G A 3.71E-05 Cognitive impairment induced by topiramate / / 22091778 rs2512474 chr11 80147934 A C 2.33E-04 Alzheimer's disease (late onset) / / 21379329 rs2512474 chr11 80147934 A C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2512467 chr11 80149601 C T 6.48E-05 Alzheimer's disease (late onset) / / 21379329 rs2512467 chr11 80149601 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2512467 chr11 80149601 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2512467 chr11 80149601 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2443951 chr11 80152332 T C 8.38E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2198253 chr11 80167948 C T 5.37E-04 Multiple complex diseases / / 17554300 rs2198253 chr11 80167948 C T 1.60E-05 Urinary metabolites / / 21572414 rs2443960 chr11 80169190 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2443961 chr11 80173899 T C 7.98E-04 Multiple complex diseases / / 17554300 rs10501467 chr11 80235789 T C 1.10E-04 Obesity-related traits / / 17903300 rs11232180 chr11 80236788 T C 3.82E-08 Metabolite levels / / 23281178 rs11232183 chr11 80239399 G A,C 7.51E-08 Metabolite levels / / 23281178 rs11232185 chr11 80239863 T C 6.80E-08 Metabolite levels / / 23281178 rs4944253 chr11 80240841 A G 5.73E-08 Metabolite levels / / 23281178 rs4945417 chr11 80241068 G A 5.73E-08 Metabolite levels / / 23281178 rs11232200 chr11 80254982 T C 3.11E-04 Body mass index / / 21701565 rs11232236 chr11 80299004 T C 8.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs11232237 chr11 80299120 G A,C 5.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs1880694 chr11 80299652 G A 6.78E-05 Smoking initiation / / 24665060 rs2140930 chr11 80311671 A G 5.00E-06 IgG glycosylation / / 23382691 rs11232243 chr11 80312863 C T 8.05E-05 Suicide attempts in bipolar disorder / / 21423239 rs17140457 chr11 80330314 T C 6.62E-04 Aortic root size / / 21223598 rs11232250 chr11 80334895 G C 4.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs11232269 chr11 80372241 G A 1.06E-04 Multiple complex diseases / / 17554300 rs17140547 chr11 80377052 C T 8.00E-06 Lentiform nucleus volume / / 22903471 rs7110233 chr11 80381487 A T 9.80E-05 Pericardial fat / / 22589742 rs1970734 chr11 80386324 G A 4.37E-05 Biliary atresia / / 20460270 rs1970732 chr11 80386508 A C 7.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs11603258 chr11 80394562 A G 4.15E-05 Biliary atresia / / 20460270 rs12289502 chr11 80399413 A C 8.92E-05 Biliary atresia / / 20460270 rs7104390 chr11 80399615 G C 8.75E-05 Serum metabolites / / 19043545 rs1917858 chr11 80402387 T A 7.70E-05 Biliary atresia / / 20460270 rs1917857 chr11 80402642 T C 6.77E-05 Biliary atresia / / 20460270 rs7949324 chr11 80413739 A G 4.64E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1945379 chr11 80426497 A G 8.06E-05 Serum metabolites / / 19043545 rs41378346 chr11 80433157 C T 5.10E-04 Multiple complex diseases / / 17554300 rs11232314 chr11 80457481 A G 4.49E-04 Type 2 diabetes / / 17463246 rs1917873 chr11 80462334 T C 1.49E-04 Height / / 17255346 rs12361863 chr11 80499561 G A 7.34E-04 Type 2 diabetes / / 17463246 rs4143640 chr11 80507464 G A 4.90E-04 Type 2 diabetes / / 17463246 rs11232339 chr11 80516495 A C 9.70E-05 Lung adenocarcinoma / / 22797724 rs13377211 chr11 80519406 A G 1.62E-06 Non-obstructive azoospermia / / 22541561 rs1540104 chr11 80524488 A G 4.93E-05 ldl cholesterol / / pha003077 rs1540104 chr11 80524488 A G 8.86E-05 Cholesterol / / pha003083 rs11232346 chr11 80526881 T A 8.50E-04 Type 2 diabetes / / 17463246 rs10501481 chr11 80537336 A G 9.64E-06 Obesity-related traits / / 23251661 rs12273069 chr11 80543606 G A 1.16E-05 Multiple complex diseases / / 17554300 rs4945441 chr11 80558166 C T 1.68E-05 Multiple complex diseases / / 17554300 rs11232369 chr11 80562738 G A 8.00E-06 Cognitive performance / / 20125193 rs4944270 chr11 80610794 A G 1.87E-04 Sarcoidosis / / 19165924 rs10792523 chr11 80612425 T G 4.90E-06 Urinary metabolites / / 21572414 rs4945452 chr11 80614777 A G 9.90E-06 Urinary metabolites / / 21572414 rs4945452 chr11 80614777 A G 0.00041 Prostate cancer / / 23555315 rs4320971 chr11 80615666 T C 4.90E-06 Urinary metabolites / / 21572414 rs17404578 chr11 80649150 C T 3.35E-04 Multiple complex diseases / / 17554300 rs7114324 chr11 80653055 C T 8.35E-04 Multiple complex diseases / / 17554300 rs1498334 chr11 80682191 A G 9.45E-06 Stroke (ischemic) / / 22941190 rs4944276 chr11 80703967 A G 1.08E-04 Type 2 diabetes / / 17463246 rs9919563 chr11 80716264 G A 2.68E-04 Type 2 diabetes / / 17463246 rs10792531 chr11 80718912 A T 1.10E-05 Urinary metabolites / / 21572414 rs17412370 chr11 80726364 T G 1.18E-04 Coronary heart disease / / 21606135 rs10751037 chr11 80736429 C G 9.07E-07 Inflammatory biomarkers / / 22291609 rs12417895 chr11 80736539 T C 7.40E-06 Urinary metabolites / / 21572414 rs10751039 chr11 80743059 T C 3.27E-04 Multiple complex diseases / / 17554300 rs1589574 chr11 80751050 G T 3.74E-04 Multiple complex diseases / / 17554300 rs4944277 chr11 80757902 A G 3.00E-04 Coronary heart disease / / 21606135 rs4945476 chr11 80758126 C G 5.79E-04 Coronary heart disease / / 21606135 rs1533866 chr11 80763143 C T 9.31E-04 Coronary heart disease / / 21606135 rs2373717 chr11 80779416 A T 1.34E-04 Hearing function / / 17255346 rs2373717 chr11 80779416 A T 3.88E-04 Type 2 diabetes / / 17463246 rs12792782 chr11 80782289 A T 1.87E-04 Type 2 diabetes / / 17463246 rs1879900 chr11 80783619 A G 1.79E-04 Coronary heart disease / / 21971053 rs7943711 chr11 80785631 C A 2.09E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1916054 chr11 80790181 G A 9.84E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs1533867 chr11 80790741 A G 6.15E-04 Coronary heart disease / / 21971053 rs11601730 chr11 80828124 G A 3.10E-06 Urinary metabolites / / 21572414 rs17416013 chr11 80833116 A T 3.30E-06 Urinary metabolites / / 21572414 rs2177209 chr11 80840006 A G 1.00E-04 Information processing speed / / 21130836 rs1522659 chr11 80841098 C T 5.93E-06 Amyotrophic lateral sclerosis / / 20801717 rs1522659 chr11 80841098 C T 0.00000403 Amyotrophic lateral sclerosis / / 23587638 rs1522659 chr11 80841098 C T 0.0000041 Amyotrophic lateral sclerosis / / 23587638 rs1522650 chr11 80851608 T C 0.000294 Salmonella-induced pyroptosis / / 22837397 rs1357339 chr11 80854375 C A 5.00E-06 HIV-1 viral setpoint / / 20205591 rs1357339 chr11 80854375 C A 8.70E-05 Information processing speed / / 21130836 rs11232525 chr11 80923036 A G 2.30E-05 Urinary metabolites / / 21572414 rs6591943 chr11 80925241 G T 2.60E-05 Urinary metabolites / / 21572414 rs11232534 chr11 80928471 C T 1.60E-05 Urinary metabolites / / 21572414 rs11232535 chr11 80928809 T C 7.00E-07 Blood trace element (Zn levels) / / 23720494 rs12576623 chr11 80936250 T C 5.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs936368 chr11 80971141 A G 1.10E-07 Platelet aggregation(pre- and post-aspirin) / / 20529293 rs1458072 chr11 80974455 A G 1.80E-07 Platelet aggregation(pre- and post-aspirin) / / 20529293 rs17141842 chr11 80978480 C T 5.14E-05 Suicide attempts in bipolar disorder / / 21041247 rs1894181 chr11 80979923 C T 8.23E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7941624 chr11 80980888 A G 4.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7941624 chr11 80980888 A G 7.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs7941624 chr11 80980888 A G 1.62E-04 Major depression (suicidal thoughts and behavior) / / 21750702 rs2199021 chr11 80982032 A G 4.79E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs17141854 chr11 80984029 A G 7.20E-04 Suicide attempts in bipolar disorder / / 21041247 rs10897779 chr11 80984220 G T 2.57E-04 Major depression (suicidal thoughts and behavior) / / 21750702 rs1458095 chr11 80985548 C T 7.00E-06 Body mass index / / 19851299 rs10501500 chr11 80986806 T C 3.01E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1870277 chr11 80992519 A G 8.46E-04 Body mass index / / 21701565 rs17141868 chr11 80999546 G A 0.000857 Salmonella-induced pyroptosis / / 22837397 rs7934041 chr11 81027804 T C 1.38E-04 Alzheimer's disease (late onset) / / 21460841 rs7129429 chr11 81028121 C T 2.54E-05 Body Mass Index / / pha003006 rs7129429 chr11 81028121 C T 6.65E-05 Waist Circumference / / pha003024 rs7129429 chr11 81028121 C T 4.24E-05 Weight / / pha003026 rs12418411 chr11 81030422 C T 8.80E-05 Cognitive test performance / / 20125193 rs10897794 chr11 81048744 G A 3.32E-05 Type 2 diabetes / / 17463246 rs10897799 chr11 81071843 A G 7.79E-05 Type 2 diabetes / / 17463246 rs721016 chr11 81113797 G T 9.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12798039 chr11 81124233 T C 5.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7928439 chr11 81135730 A C 3.70E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10501511 chr11 81136255 A G 5.00E-05 Warfarin maintenance dose / / 19300499 rs10501511 chr11 81136255 A G 9.30E-05 Hypothyroidism / / 22493691 rs10792563 chr11 81142678 T C 9.80E-05 Hypothyroidism / / 22493691 rs10792563 chr11 81142678 T C 0.000000472 Tuberculosis with early age of onset / / 22551897 rs17382573 chr11 81177040 T C 5.54E-04 Type 2 diabetes / / 17463246 rs12361324 chr11 81179117 T C 7.64E-04 Type 2 diabetes / / 17463246 rs17142280 chr11 81190418 T A 9.47E-04 Type 2 diabetes / / 17463246 rs11232688 chr11 81192956 T C 8.22E-05 Kawasaki disease / / 22446961 rs7928126 chr11 81195405 G A 8.46E-05 Kawasaki disease / / 22446961 rs7928135 chr11 81195418 G A 8.46E-05 Kawasaki disease / / 22446961 rs17384174 chr11 81195540 G T 6.60E-04 Type 2 diabetes / / 17463246 rs1945655 chr11 81223717 C A 4.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2032381 chr11 81235150 G T 4.00E-06 Smooth-surface caries / / 23470693 rs12786388 chr11 81235736 G A 6.50E-05 Response to statin therapy / / 20339536 rs12786273 chr11 81235894 A T 7.40E-05 Response to statin therapy / / 20339536 rs1540173 chr11 81236034 G A 7.50E-05 Response to statin therapy / / 20339536 rs2156837 chr11 81285566 G C 1.10E-07 Urinary metabolites / / 21572414 rs1945714 chr11 81298564 A G 2.70E-08 Urinary metabolites / / 21572414 rs7933268 chr11 81303873 T G 1.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs7950006 chr11 81304188 G A 1.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs1945649 chr11 81308455 C T 2.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs7949287 chr11 81316858 G A 2.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs2097171 chr11 81323471 C T 3.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs10897849 chr11 81327035 G A 4.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs1945662 chr11 81327905 T C 4.21E-04 Suicide attempts in bipolar disorder / / 21041247 rs7946763 chr11 81328181 A C 4.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs10501523 chr11 81339041 C A 2.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1540176 chr11 81354835 T C 7.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs7117338 chr11 81356656 C T 1.93E-04 Glycosylated haemoglobin levels / / 17255346 rs7117338 chr11 81356656 C T 2.90E-05 Urinary metabolites / / 21572414 rs17142733 chr11 81360127 A G 8.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs1945669 chr11 81360397 C T 5.85E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17142739 chr11 81361682 C A 8.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs17142744 chr11 81361756 T G 8.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs17142764 chr11 81376730 C G 8.48E-04 Suicide attempts in bipolar disorder / / 21041247 rs17142769 chr11 81378133 T C 2.61E-04 Scoliosis / / 21216876 rs7938144 chr11 81426835 A G 2.66E-05 Scoliosis / / 21216876 rs4298928 chr11 81470414 A G 1.11E-05 Educational attainment / / 21694764 rs976928 chr11 81479043 A G 9.60E-06 Educational attainment / / 21694764 rs7106258 chr11 81484019 A G 3.71E-07 Educational attainment / / 21694764 rs12273073 chr11 81484996 T A 5.70E-06 Serum metabolites / / 19043545 rs7935680 chr11 81489029 T G 6.39E-06 Serum metabolites / / 19043545 rs7118489 chr11 81492293 C T 6.39E-06 Serum metabolites / / 19043545 rs7940493 chr11 81492348 G A 6.39E-06 Serum metabolites / / 19043545 rs6591999 chr11 81492541 G A 6.89E-06 Serum metabolites / / 19043545 rs7104475 chr11 81492649 T C 2.50E-04 Intelligence (childhood) / / 23358156 rs11232861 chr11 81493085 C T 7.89E-06 Serum metabolites / / 19043545 rs7944887 chr11 81493903 A G 4.91E-06 Serum metabolites / / 19043545 rs7947949 chr11 81493976 C T 1.47E-06 Serum metabolites / / 19043545 rs4606498 chr11 81494513 G T 6.33E-06 Serum metabolites / / 19043545 rs7927911 chr11 81496259 C A 8.37E-07 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs4944357 chr11 81524661 T A 4.76E-05 Serum metabolites / / 19043545 rs11607556 chr11 81526237 C T 2.01E-05 Serum metabolites / / 19043545 rs7931309 chr11 81537674 A T 3.31E-05 Serum metabolites / / 19043545 rs7934819 chr11 81538168 G A 3.03E-05 Serum metabolites / / 19043545 rs4944366 chr11 81577369 T C 1.92E-04 Smoking quantity / / 24665060 rs4943855 chr11 81578584 T G 1.80E-05 Body Mass Index / / pha003022 rs1459952 chr11 81582739 T C 0.000332 Breast cancer early age of onset / / 18463975 rs10897896 chr11 81591244 T G 1.51E-05 Body Mass Index / / pha003022 rs7932645 chr11 81620572 C T 1.35E-05 Multiple complex diseases / / 17554300 rs11232927 chr11 81630984 T C 1.40E-04 Body mass index / / 21701565 rs11232927 chr11 81630984 T C 5.07E-04 Body mass index / / 21701565 rs7951571 chr11 81653514 C T 8.22E-05 Body mass index / / 21701565 rs1955011 chr11 81680388 G A 3.64E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1955011 chr11 81680388 G A 4.23E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs603512 chr11 81698345 G C 8.50E-07 Urinary metabolites / / 21572414 rs603512 chr11 81698345 G C 1.93E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12365882 chr11 81702506 C A,T 2.70E-05 Urinary metabolites / / 21572414 rs516454 chr11 81749990 C T 6.08E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs656948 chr11 81752743 C T 3.70E-05 Alcoholism (heaviness of drinking) / / 21529783 rs656948 chr11 81752743 C T 1.75E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs678021 chr11 81754688 C T 2.95E-05 Asthma / / 11022011 rs2851687 chr11 81775950 T C,G 2.83E-05 Asthma / / 11022011 rs666649 chr11 81782905 T G 7.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs645809 chr11 81792803 G A 7.06E-04 Type 2 diabetes / / 17463246 rs896993 chr11 81793220 G C 8.86E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs2373947 chr11 81799190 C G 8.86E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs575495 chr11 81799369 A G 9.20E-05 Major depressive disorder / / 21042317 rs480213 chr11 81804571 A G 2.69E-05 Asthma / / 11022011 rs7103364 chr11 81807219 G A 9.41E-04 Prostate cancer mortality / / 20978177 rs613683 chr11 81809247 A G 6.00E-07 Urinary metabolites / / 21572414 rs683533 chr11 81886502 G A 9.20E-04 Multiple complex diseases / / 17554300 rs683533 chr11 81886502 G A 6.66E-05 Personality dimensions / / 18957941 rs607558 chr11 81889023 C T 6.80E-05 Personality dimensions / / 18957941 rs652732 chr11 81896531 A C 9.34E-04 Multiple complex diseases / / 17554300 rs652732 chr11 81896531 A C 6.80E-05 Personality dimensions / / 18957941 rs632608 chr11 81902313 C A 6.17E-05 Hypertension / / pha003041 rs649461 chr11 81909788 C T 6.70E-05 Personality dimensions / / 18957941 rs658612 chr11 81928085 T C 9.90E-05 Hypertension / / pha003041 rs590167 chr11 81951251 T C 9.62E-04 Multiple complex diseases / / 17554300 rs666320 chr11 81974862 G A 3.46E-05 Intracerebral hemorrhage / / 24656865 rs597735 chr11 81979077 T C 3.00E-04 Multiple complex diseases / / 17554300 rs597735 chr11 81979077 T C 2.00E-05 Urinary metabolites / / 21572414 rs611530 chr11 81979892 C T 0.00039 Prostate cancer / / 23555315 rs662869 chr11 81982131 A G 1.07E-05 Hypertension / / pha003041 rs11233068 chr11 81996622 C T 3.21E-04 Multiple complex diseases / / 17554300 rs11233069 chr11 81998945 C T 1.81E-04 Multiple complex diseases / / 17554300 rs10488824 chr11 82000639 C G 1.40E-05 Lipid traits / / 17903299 rs3908000 chr11 82027104 A G 1.85E-05 Intracerebral hemorrhage / / 24656865 rs3908000 chr11 82027104 A G 3.91E-05 Intracerebral hemorrhage / / 24656865 rs3907999 chr11 82027114 A G 1.85E-05 Intracerebral hemorrhage / / 24656865 rs3907999 chr11 82027114 A G 3.91E-05 Intracerebral hemorrhage / / 24656865 rs7115314 chr11 82028616 A G 2.73E-05 Intracerebral hemorrhage / / 24656865 rs7115314 chr11 82028616 A G 2.88E-05 Intracerebral hemorrhage / / 24656865 rs12364945 chr11 82031434 A G 3.33E-04 Multiple complex diseases / / 17554300 rs12364945 chr11 82031434 A G 2.53E-05 Intracerebral hemorrhage / / 24656865 rs12364945 chr11 82031434 A G 2.54E-05 Intracerebral hemorrhage / / 24656865 rs11822884 chr11 82032136 C G 4.46E-05 Intracerebral hemorrhage / / 24656865 rs11822884 chr11 82032136 C G 4.82E-05 Intracerebral hemorrhage / / 24656865 rs11233081 chr11 82034725 T C 4.90E-05 Intracerebral hemorrhage / / 24656865 rs12146612 chr11 82037823 G A 1.21E-05 Intracerebral hemorrhage / / 24656865 rs12146612 chr11 82037823 G A 2.72E-05 Intracerebral hemorrhage / / 24656865 rs10897959 chr11 82038385 A G 1.12E-05 Intracerebral hemorrhage / / 24656865 rs10897959 chr11 82038385 A G 3.18E-05 Intracerebral hemorrhage / / 24656865 rs2175961 chr11 82041847 T C 0.00006 Asthma / / 18401594 rs1399358 chr11 82089086 T C 7.38E-04 Multiple complex diseases / / 17554300 rs17143592 chr11 82194775 T C 3.78E-04 Self-reported allergy / / 23817569 rs12577518 chr11 82196595 T C 3.88E-04 Self-reported allergy / / 23817569 rs12577533 chr11 82196908 T C 3.17E-04 Self-reported allergy / / 23817569 rs12294456 chr11 82197666 T C 1.56E-04 Multiple complex diseases / / 17554300 rs17143627 chr11 82199392 G C 3.53E-04 Self-reported allergy / / 23817569 rs4471453 chr11 82224765 A C 3.26E-06 Telomere length / / 23001564 rs10897988 chr11 82265147 T C 5.90E-04 Multiple complex diseases / / 17554300 rs948018 chr11 82312014 C A 7.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs948018 chr11 82312014 C A 0.000250217 Primary sclerosing cholangitis / / 23603763 rs41426651 chr11 82313624 C T 6.50E-05 Multiple complex diseases / / 17554300 rs17143894 chr11 82318227 C T 2.62E-04 Multiple complex diseases / / 17554300 rs1939598 chr11 82321637 T C 2.76E-04 Multiple complex diseases / / 17554300 rs1790707 chr11 82332098 T C 2.90E-04 Multiple complex diseases / / 17554300 rs1629952 chr11 82338131 A G 2.38E-04 Multiple complex diseases / / 17554300 rs1793029 chr11 82342303 G A 8.87E-04 Multiple complex diseases / / 17554300 rs1939627 chr11 82347495 C T 2.17E-04 Multiple complex diseases / / 17554300 rs1497110 chr11 82359448 T C 4.73E-05 Body Mass Index / / pha003019 rs6592078 chr11 82392550 C A 1.05E-04 HIV-1 viral setpoint / / 21490045 rs7940296 chr11 82395784 A G 8.89E-05 HIV-1 viral setpoint / / 21490045 rs7940296 chr11 82395784 A G 9.28E-04 Iron levels / / pha002876 rs12421275 chr11 82410802 G A 4.90E-05 Iron levels / / 21208937 rs1497104 chr11 82411635 T C 5.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11233281 chr11 82414527 C G 5.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs577743 chr11 82421186 T C 8.30E-06 Urinary metabolites / / 21572414 rs515495 chr11 82423340 A G 2.40E-05 Urinary metabolites / / 21572414 rs1811661 chr11 82434877 C T 8.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1353599 chr11 82435414 C T 4.98E-04 Multiple complex diseases / / 17554300 rs1497111 chr11 82437492 T C 5.37E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9666486 chr11 82449606 T C 9.03E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10898028 chr11 82456494 A G 4.61E-04 Alzheimer's disease (late onset) / / 21379329 rs523121 chr11 82465443 G T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs492584 chr11 82501382 T C 2.53E-04 Hearing function / / 17255346 rs2510282 chr11 82522085 A C 7.97E-04 Coronary heart disease / / 21971053 rs10459044 chr11 82552580 G A 7.36E-06 Hearing function PRCP intron 17255346 rs3862769 chr11 82553077 G A 2.19E-06 Hearing function PRCP intron 17255346 rs10898038 chr11 82562486 C T 6.75E-06 Hearing function PRCP intron 17255346 rs7106555 chr11 82563283 A C 1.22E-04 Hearing function PRCP intron 17255346 rs2229437 chr11 82564294 T A,G 1.10E-12 Leukemia(T-cell recognition in patients) PRCP missense 21062987 rs12289095 chr11 82569806 G A 2.07E-28 Narcolepsy PRCP intron 19629137 rs9667326 chr11 82574872 C T 9.71E-05 Hearing function PRCP intron 17255346 rs7104980 chr11 82575195 C G 7.72E-04 Type 2 diabetes PRCP intron 17463246 rs7926170 chr11 82583957 T C 9.73E-04 Type 2 diabetes PRCP intron 17463246 rs6592087 chr11 82595975 T A 1.83E-04 Type 2 diabetes PRCP intron 17463246 rs10792660 chr11 82597704 G C 3.34E-05 Type 2 diabetes PRCP intron 17463246 rs2086298 chr11 82619218 G A 4.55E-04 Type 2 diabetes C11orf82 intron 17463246 rs7947780 chr11 82643760 G T 5.07E-04 Hearing function C11orf82 missense 17255346 rs10792665 chr11 82649768 G T 6.00E-06 Obesity-related traits / / 23251661 rs12293386 chr11 82705431 A C 6.08E-05 Smoking initiation RAB30 intron 24665060 rs12801116 chr11 82723006 C T 1.67E-04 Smoking initiation RAB30 intron 24665060 rs11233413 chr11 82723072 T C 4.00E-07 Economic and political preferences (feminism/equality) RAB30 intron 22566634 rs12280845 chr11 82723424 A T 1.30E-05 Urinary metabolites RAB30 intron 21572414 rs12280845 chr11 82723424 A T 3.15E-04 Smoking initiation RAB30 intron 24665060 rs12808296 chr11 82740116 A C 9.13E-04 Type 2 diabetes RAB30 intron 17463246 rs948182 chr11 82746231 C A,G,T 2.02E-04 Type 2 diabetes RAB30 intron 17463246 rs1079338 chr11 82746365 G A 2.00E-04 Prostate cancer mortality RAB30 intron 20978177 rs1079338 chr11 82746365 G A 3.95E-04 Smoking initiation RAB30 intron 24665060 rs11822105 chr11 82763218 G A 2.00E-04 Prostate cancer mortality RAB30 intron 20978177 rs17144544 chr11 82788439 C T 5.40E-06 Prostate cancer mortality / / 20978177 rs11825381 chr11 82791213 A G 1.78E-05 Prostate cancer mortality / / 20978177 rs11233462 chr11 82813947 C T 2.40E-05 Prostate cancer mortality / / 20978177 rs12279768 chr11 82814094 T A 4.83E-05 Prostate cancer mortality / / 20978177 rs17159801 chr11 82819298 G A 2.34E-06 Osteoarthritis / / 22763110 rs12789328 chr11 82820319 C A 9.56E-04 Coronary heart disease / / 21606135 rs4293143 chr11 82821382 T G 3.09E-05 Personality dimensions / / 22628180 rs4293143 chr11 82821382 T G 8.00E-06 Age-related macular degeneration / / 23326517 rs11604322 chr11 82850052 C A 2.23E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1943345 chr11 82876270 T G 7.00E-06 Obesity-related traits PCF11 intron 23251661 rs12284052 chr11 82880341 G A 1.77E-04 Response to alcohol consumption (flushing response) PCF11 cds-synon 24277619 rs515718 chr11 82939751 C T 1.70E-04 Coronary heart disease ANKRD42 intron 21606135 rs481321 chr11 82957333 T C 8.07E-05 Body Mass Index ANKRD42 intron pha003020 rs506321 chr11 82964288 A G 1.41E-04 Coronary heart disease / / 21606135 rs513438 chr11 82967963 T C 4.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs492710 chr11 82970792 G T 7.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1278402 chr11 82972097 A G 4.22E-04 Coronary heart disease / / 21606135 rs673850 chr11 83012762 G C 6.71E-05 Coronary heart disease / / 21606135 rs17517294 chr11 83048555 T C 6.81E-04 Coronary heart disease / / 21606135 rs6592113 chr11 83065900 A G 2.59E-04 Coronary heart disease / / 21606135 rs7124362 chr11 83065931 T C 5.11E-06 Coronary heart disease / / 21606135 rs2512682 chr11 83122844 T C 3.19E-05 Multiple complex diseases / / 17554300 rs2512674 chr11 83161775 T C 3.82E-05 Coronary heart disease / / 21606135 rs2507847 chr11 83162348 C T 1.17E-04 Coronary heart disease / / 21606135 rs2507848 chr11 83162400 C G 1.04E-04 Coronary heart disease / / 21606135 rs2507850 chr11 83165645 G A 8.98E-06 Coronary heart disease DLG2 nearGene-3 21606135 rs1075719 chr11 83175036 T C 6.30E-04 Coronary heart disease DLG2 intron 21606135 rs891773 chr11 83175779 T C 3.59E-04 Coronary heart disease DLG2 intron 21606135 rs7108874 chr11 83178393 C T 6.68E-05 Coronary heart disease DLG2 intron 21606135 rs17145229 chr11 83184425 T C 5.81E-04 Multiple complex diseases DLG2 intron 17554300 rs2116483 chr11 83256868 C T 8.00E-06 Obesity-related traits DLG2 intron 23251661 rs11233685 chr11 83297092 C A 8.80E-05 Information processing speed DLG2 intron 21130836 rs500571 chr11 83305542 A G 4.15E-04 Multiple complex diseases DLG2 intron 17554300 rs684857 chr11 83308002 C T 3.96E-04 Multiple complex diseases DLG2 intron 17554300 rs478048 chr11 83324320 G A 5.60E-04 Multiple complex diseases DLG2 intron 17554300 rs17145930 chr11 83402806 G T 5.86E-04 Type 2 diabetes DLG2 intron 22238593 rs3885683 chr11 83455707 T C 8.00E-06 Protein quantitative trait loci DLG2 intron 18464913 rs1451392 chr11 83488208 T G 1.20E-04 Multiple complex diseases DLG2 intron 17554300 rs11233743 chr11 83493425 G A 7.61E-04 Smoking initiation DLG2 intron 24665060 rs7479949 chr11 83503404 T C 3.40E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) DLG2 intron 23648065 rs10898155 chr11 83512154 C T 6.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) DLG2 intron 23648065 rs7924552 chr11 83530138 A G 8.76E-05 Brain derived neurotrophic factor levels,in serum DLG2 intron 22047184 rs6592150 chr11 83562296 G T 0.000548999 Hypertension (early onset hypertension) DLG2 intron 22479346 rs7943773 chr11 83563234 C T 4.76E-04 Suicide attempts in bipolar disorder DLG2 intron 21041247 rs2037194 chr11 83574352 G A 4.34E-04 Suicide attempts in bipolar disorder DLG2 intron 21041247 rs1400306 chr11 83578515 C G 7.20E-05 Kidney function and endocine traits DLG2 intron 17903292 rs76809954 chr11 83580306 T C 1.00E-06 QRS duration in Tripanosoma cruzi seropositivity DLG2 intron 24324551 rs938536 chr11 83580576 C T 1.17E-05 stroke (ischemic) DLG2 intron 17434096 rs867033 chr11 83580633 A C 5.90E-04 Type 2 diabetes and 6 quantitative traits DLG2 intron 17848626 rs2138567 chr11 83580958 T C 3.19E-06 stroke (ischemic) DLG2 intron 17434096 rs11820448 chr11 83581307 C T 7.70E-04 Tourette syndrome DLG2 intron 22889924 rs10501550 chr11 83585781 T G 9.89E-04 Type 2 diabetes DLG2 intron 17463246 rs10501550 chr11 83585781 T G 3.86E-04 Multiple complex diseases DLG2 intron 17554300 rs11233774 chr11 83591243 G A 4.44E-05 stroke (ischemic) DLG2 intron 17434096 rs11233774 chr11 83591243 G A 4.34E-05 Cognitive test performance DLG2 intron 20125193 rs12364727 chr11 83602367 T C 6.39E-04 Tourette syndrome DLG2 intron 22889924 rs790356 chr11 83620787 A G 4.00E-15 Wilms tumor DLG2 intron 22544364 rs790363 chr11 83628751 G A 6.23E-04 Multiple complex diseases DLG2 intron 17554300 rs11233811 chr11 83635101 C T 3.46E-04 Multiple complex diseases DLG2 intron 17554300 rs1483403 chr11 83665488 G T 5.08E-05 Cognitive impairment induced by topiramate DLG2 intron 22091778 rs2514149 chr11 83683776 T C 1.70E-06 Urinary metabolites DLG2 intron 21572414 rs4944457 chr11 83736979 C T 7.40E-05 Post-operative nausea and vomiting DLG2 intron 21694509 rs4943885 chr11 83766621 A G 9.69E-04 Alcohol dependence DLG2 intron 21314694 rs17146788 chr11 83806025 C T 5.36E-04 Multiple complex diseases DLG2 intron 17554300 rs2298830 chr11 83817360 T C 9.42E-05 Glucose levels DLG2 intron pha002899 rs12281901 chr11 83839992 G A 2.90E-05 Urinary metabolites DLG2 intron 21572414 rs1377747 chr11 83899440 T C 4.73E-04 Pulmonary function DLG2 intron 20010834 rs1470899 chr11 83986071 G A 7.08E-05 Response to mTOR inhibitor (everolimus) DLG2 intron 24009623 rs1580078 chr11 83993349 G T 1.10E-05 Urinary metabolites DLG2 intron 21572414 rs1567970 chr11 84005844 G A 6.91E-04 Myocardial Infarction DLG2 intron pha002873 rs7121214 chr11 84022936 C A 9.37E-04 Type 2 diabetes DLG2 intron 17463246 rs7121214 chr11 84022936 C A 9.10E-05 Serum metabolites DLG2 intron 19043545 rs7121214 chr11 84022936 C A 6.23E-05 Bipolar disorder DLG2 intron 21771265 rs1559856 chr11 84064182 T G 3.16E-05 Pulmonary function DLG2 intron 20010835 rs1559855 chr11 84064236 G A 5.08E-05 Pulmonary function DLG2 intron 20010835 rs12286690 chr11 84066792 A G 3.33E-05 Pulmonary function DLG2 intron 20010835 rs7928075 chr11 84068267 A G 9.30E-05 Pulmonary function DLG2 intron 20010835 rs10160220 chr11 84080207 T C 8.56E-05 Pulmonary function DLG2 intron 20010835 rs11234001 chr11 84085241 T C 9.03E-05 Pulmonary function DLG2 intron 20010835 rs12277167 chr11 84089412 T C 8.50E-05 Pulmonary function DLG2 intron 20010835 rs9988803 chr11 84090324 G A 8.94E-05 Pulmonary function DLG2 intron 20010835 rs10898230 chr11 84090966 C T 8.90E-05 Pulmonary function DLG2 intron 20010835 rs12808166 chr11 84120020 T C 9.08E-05 Heart Rate DLG2 intron pha003053 rs488925 chr11 84128537 G A 1.07E-05 Podoconiosis DLG2 intron 22455414 rs1365425 chr11 84134019 G A 3.66E-05 Orofacial clefts DLG2 intron 20023658 rs3802894 chr11 84159545 T C 7.55E-04 Stroke DLG2 intron pha002887 rs12274138 chr11 84163419 T C 3.87E-05 Cognitive impairment induced by topiramate DLG2 intron 22091778 rs7952143 chr11 84167835 G A 9.49E-04 Stroke DLG2 intron pha002887 rs1346891 chr11 84204394 C T 9.37E-04 Heart Failure DLG2 intron pha002885 rs10898250 chr11 84222437 T G 9.16E-05 Waist Circumference DLG2 intron pha003025 rs17807611 chr11 84238899 G C 1.58E-05 Major depressive disorder DLG2 intron 22472876 rs17734921 chr11 84245584 T C 2.62E-04 Multiple complex diseases DLG2 intron 17554300 rs10501568 chr11 84247123 A G 3.00E-06 Periodontitis (Chronic) DLG2 intron 25008200 rs11234070 chr11 84248385 G T 5.49E-05 Type 2 diabetes DLG2 intron 17463246 rs4145049 chr11 84254393 G T 1.18E-05 Major depressive disorder DLG2 intron 22472876 rs7937583 chr11 84264056 C T 1.68E-05 Multiple complex diseases DLG2 intron 17554300 rs7937583 chr11 84264056 C T 1.40E-05 Urinary metabolites DLG2 intron 21572414 rs11234073 chr11 84264403 T A 2.40E-06 Urinary metabolites DLG2 intron 21572414 rs7128948 chr11 84267185 G A 3.89E-05 Waist Circumference DLG2 intron pha003025 rs7128948 chr11 84267185 G A 3.37E-05 Weight DLG2 intron pha003027 rs11234076 chr11 84270238 G A 1.40E-06 Urinary metabolites DLG2 intron 21572414 rs7119459 chr11 84298844 T C 9.77E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) DLG2 intron 23648065 rs1807995 chr11 84300326 C A 6.39E-04 Schizophrenia DLG2 intron 19197363 rs11824888 chr11 84318450 G A 0.0005477 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DLG2 intron 23233654 rs11824888 chr11 84318450 G A 5.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) DLG2 intron 23233662 rs11824888 chr11 84318450 G A 4.13E-05 HDL cholesterol DLG2 intron pha003075 rs12294169 chr11 84334329 C T 0.0004974 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DLG2 intron 23233654 rs12294169 chr11 84334329 C T 4.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) DLG2 intron 23233662 rs17735215 chr11 84338284 T C 2.75E-04 Nicotine smoking DLG2 intron 19268276 rs1940071 chr11 84359161 C A,G,T 8.66E-04 Multiple complex diseases DLG2 intron 17554300 rs1940080 chr11 84370674 A G 4.69E-04 Type 2 diabetes DLG2 intron 17463246 rs1940080 chr11 84370674 A G 2.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DLG2 intron 20877124 rs11234129 chr11 84399744 G A 6.98E-04 Suicide attempts in bipolar disorder DLG2 intron 21423239 rs1940094 chr11 84409477 C T 7.70E-04 Alcohol dependence DLG2 intron 20201924 rs10501570 chr11 84417846 T C 7.00E-06 Parkinson's disease DLG2 intron 17052657 rs6592199 chr11 84455359 T G 1.45E-06 Systemic lupus erythematosus DLG2 intron pha002867 rs1943687 chr11 84467936 C A 2.84E-04 Nicotine smoking DLG2 intron 19268276 rs10501571 chr11 84493679 A C 3.90E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) DLG2 intron 17982456 rs1943698 chr11 84494304 A G 9.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) DLG2 intron 17982456 rs12291798 chr11 84521287 A G 1.21E-04 Smoking initiation DLG2 intron 24665060 rs12274130 chr11 84561299 A G 1.90E-05 Urinary metabolites DLG2 intron 21572414 rs10501574 chr11 84566184 T C 2.75E-04 Alzheimer's disease (late onset) DLG2 intron 21379329 rs10501576 chr11 84576644 T C 7.91E-05 Response to mTOR inhibitor (rapamycin) DLG2 intron 24009623 rs4301808 chr11 84597628 G T 3.55E-05 Information processing speed DLG2 intron 21130836 rs10501580 chr11 84599002 T C 8.78E-04 Multiple complex diseases DLG2 intron 17554300 rs1943732 chr11 84599696 A T 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) DLG2 intron 17982456 rs7940089 chr11 84618539 G A 2.65E-05 Multiple complex diseases DLG2 intron 17554300 rs2155413 chr11 84634790 C A 4.70E-10 Myopia (Age of onset) DLG2 intron 23468642 rs6592225 chr11 84665681 C T 3.64E-05 Hemoglobin DLG2 intron pha003098 rs3844141 chr11 84688062 T C 8.70E-05 Hemoglobin DLG2 intron pha003098 rs10792795 chr11 84724809 C A 7.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DLG2 intron 20877124 rs1783749 chr11 84760727 A T 1.40E-05 Urinary metabolites DLG2 intron 21572414 rs472406 chr11 84762691 C T 2.30E-05 Urinary metabolites DLG2 intron 21572414 rs182990 chr11 84783866 C T 8.29E-05 Hemoglobin DLG2 intron pha003098 rs1452928 chr11 84822321 G C 7.00E-07 Hip geometry DLG2 intron 17903296 rs617231 chr11 84837898 C T 3.40E-05 Methamphetamine dependence DLG2 intron 23594818 rs349077 chr11 84838195 A G 1.30E-05 Urinary metabolites DLG2 intron 21572414 rs10898380 chr11 84920320 T C 5.10E-06 Urinary metabolites DLG2 intron 21572414 rs2203702 chr11 84929379 T C 1.40E-05 Urinary metabolites DLG2 intron 21572414 rs1517311 chr11 84930506 T A 2.00E-06 Urinary metabolites DLG2 intron 21572414 rs951729 chr11 84935074 T G 1.00E-04 Cognitive impairment induced by topiramate DLG2 intron 22091778 rs531331 chr11 84990822 A G 1.40E-05 Urinary metabolites DLG2 intron 21572414 rs471786 chr11 84992639 T C 3.50E-06 Urinary metabolites DLG2 intron 21572414 rs17148090 chr11 85017476 A G 4.00E-08 Phospholipid levels (plasma) DLG2 intron 22359512 rs17148090 chr11 85017476 A G 9.64E-05 HDL cholesterol DLG2 intron pha003075 rs12794044 chr11 85060360 C G 7.80E-06 Iron levels DLG2 intron 21208937 rs10898392 chr11 85164751 G T 3.00E-06 Height DLG2 intron 19570815 rs286510 chr11 85227439 A G 1.00E-04 Cognitive impairment induced by topiramate DLG2 intron 22091778 rs77020006 chr11 85406028 A G 0.00006462 Sarcoidosis SYTL2 UTR-3 22952805 rs79422696 chr11 85413699 T C 0.00003904 Sarcoidosis SYTL2 intron 22952805 rs74694063 chr11 85415587 C T 0.00007876 Sarcoidosis SYTL2 intron 22952805 rs185090758 chr11 85500403 A G 0.00009053 Sarcoidosis SYTL2 intron 22952805 rs1893163 chr11 85511808 C T 5.64E-05 Magnesium levels SYTL2 intron pha003092 rs11234416 chr11 85514693 A G 9.35E-04 Multiple complex diseases SYTL2 intron 17554300 rs11607789 chr11 85526151 C T 4.08E-05 Epilepsy / / 22116939 rs17209127 chr11 85532697 G A 3.64E-04 Multiple complex diseases / / 17554300 rs895255 chr11 85534546 C A 0.00019 Erectile dysfunction after radiotherapy for prostate cancer / / 23021708 rs10898417 chr11 85547503 A G 1.17E-06 Alzheimer's disease (late onset) / / 23565137 rs10898417 chr11 85547503 A G 4.51E-06 Alzheimer's disease (late onset) / / 23565137 rs11234450 chr11 85573252 G A 5.52E-04 Multiple complex diseases CCDC83 intron 17554300 rs17744675 chr11 85593906 A G 1.90E-05 Urinary metabolites CCDC83 intron 21572414 rs17817331 chr11 85595338 C T 1.90E-05 Urinary metabolites CCDC83 intron 21572414 rs12363624 chr11 85596572 T C 9.82E-04 Multiple complex diseases CCDC83 intron 17554300 rs10501600 chr11 85609559 C T 2.26E-05 Paget's disease CCDC83 intron 20436471 rs12790645 chr11 85624638 T G 2.40E-06 Alzheimer's disease CCDC83 intron 22832961 rs72947601 chr11 85626157 T C 0.00006848 Sarcoidosis CCDC83 intron 22952805 rs60185300 chr11 85626569 G A 0.00006848 Sarcoidosis CCDC83 intron 22952805 rs12274987 chr11 85626738 T G 2.75E-06 Alzheimer's disease CCDC83 intron 22832961 rs3213934 chr11 85627039 A G 2.66E-06 Alzheimer's disease CCDC83 intron 22832961 rs7927222 chr11 85627108 T C 0.0000783 Sarcoidosis CCDC83 cds-synon 22952805 rs11234474 chr11 85629540 G A 5.54E-04 Smoking cessation CCDC83 intron 24665060 rs11821654 chr11 85630123 C T 9.76E-07 Alzheimer's disease CCDC83 intron 22832961 rs12805520 chr11 85630411 C T 9.82E-07 Alzheimer's disease CCDC83 missense 22832961 rs7118279 chr11 85630837 T A 9.19E-07 Alzheimer's disease CCDC83 UTR-3 22832961 rs579406 chr11 85657759 A C 1.48E-04 Alzheimer's disease / / 22005930 rs12798898 chr11 85659580 A G 3.49E-08 Alzheimer's disease / / 22832961 rs75751 chr11 85664904 G C 7.59E-04 Type 2 diabetes / / 17463246 rs41381550 chr11 85667088 T G 2.80E-05 Urinary metabolites / / 21572414 rs565031 chr11 85671501 A T 1.39E-04 Alzheimer's disease (late onset) PICALM intron 21460841 rs565031 chr11 85671501 A T 3.13E-04 Alzheimer's disease PICALM intron 22005930 rs618679 chr11 85671702 A C 1.18E-05 Type 2 diabetes and other traits PICALM intron 19734900 rs618679 chr11 85671702 A C 2.41E-05 Autism PICALM intron 24189344 rs2077815 chr11 85672383 G A 4.95E-05 Type 2 diabetes and other traits PICALM intron 19734900 rs2077815 chr11 85672383 G A 6.59E-05 Autism PICALM intron 24189344 rs17744938 chr11 85676566 T A,C,G 1.50E-05 Urinary metabolites PICALM intron 21572414 rs17817600 chr11 85677471 A G 2.00E-08 Alzheimer's disease PICALM intron 22832961 rs510566 chr11 85677839 G T 3.79E-04 Tourette syndrome PICALM intron 22889924 rs10501602 chr11 85681389 A G 3.03E-08 Alzheimer's disease PICALM intron 22832961 rs671686 chr11 85681479 C G 1.58E-04 Alzheimer's disease PICALM intron 22005930 rs10501603 chr11 85681916 A G 2.80E-05 Urinary metabolites PICALM intron 21572414 rs17817648 chr11 85685285 T C 2.27E-08 Alzheimer's disease PICALM intron 22832961 rs532470 chr11 85686096 T G 3.36E-05 Alzheimer's disease PICALM intron 22005930 rs475639 chr11 85689785 T C 1.43E-04 Alzheimer's disease PICALM intron 22005930 rs588076 chr11 85691662 G C 8.78E-04 Type 2 diabetes PICALM intron 17463246 rs588076 chr11 85691662 G C 7.41E-05 Blood pressure (response to calcium channel blocker) PICALM intron 24192120 rs645299 chr11 85691810 C A 2.56E-06 Alzheimer's disease (late onset) PICALM intron 21460841 rs645299 chr11 85691810 C A 2.93E-04 Alzheimer's disease PICALM intron 22005930 rs669336 chr11 85698867 G A 1.05E-04 Tourette syndrome PICALM intron 22889924 rs682366 chr11 85701741 T C 9.94E-04 Obesity (extreme) PICALM intron 21935397 rs12787412 chr11 85703093 C T 8.55E-04 Alzheimer's disease PICALM intron 22005930 rs12787412 chr11 85703093 C T 1.67E-07 Alzheimer's disease PICALM intron 22832961 rs12794211 chr11 85703996 G A 7.52E-04 Alzheimer's disease PICALM intron 22005930 rs12794211 chr11 85703996 G A 1.67E-07 Alzheimer's disease PICALM intron 22832961 rs12795381 chr11 85704066 T C 2.34E-04 Alzheimer's disease PICALM intron 22005930 rs12795381 chr11 85704066 T C 6.13E-07 Alzheimer's disease PICALM intron 22832961 rs484154 chr11 85705476 T A 2.12E-05 Alzheimer's disease PICALM intron 22005930 rs12795833 chr11 85713175 G C 4.03E-04 Alzheimer's disease PICALM intron 22005930 rs12795833 chr11 85713175 G C 2.25E-07 Alzheimer's disease PICALM intron 22832961 rs7951988 chr11 85714288 T C 6.35E-04 Obesity (extreme) PICALM intron 21935397 rs527162 chr11 85715736 C T 6.30E-05 Type 2 diabetes and other traits PICALM intron 19734900 rs527162 chr11 85715736 C T 3.30E-05 Autism PICALM intron 24189344 rs680119 chr11 85716032 T C 1.32E-05 Stroke PICALM intron 22306652 rs2508696 chr11 85717923 A C 2.61E-06 Alzheimer's disease (late onset) PICALM intron 21460841 rs602222 chr11 85718231 G T 2.64E-06 Alzheimer's disease (late onset) PICALM intron 21460841 rs17148704 chr11 85721332 T C 1.54E-04 Alzheimer's disease PICALM intron 22005930 rs11234517 chr11 85731576 T C 2.60E-05 Urinary metabolites PICALM intron 21572414 rs676733 chr11 85734010 C T 2.72E-06 Alzheimer's disease (late onset) PICALM intron 21460841 rs676733 chr11 85734010 C T 3.33E-04 Alzheimer's disease PICALM intron 22005930 rs676733 chr11 85734010 C T 8.17E-05 Alzheimer's disease PICALM intron 22832961 rs666682 chr11 85739838 T C 4.59E-05 Alzheimer's disease PICALM intron 22005930 rs609903 chr11 85740409 A G 2.54E-06 Alzheimer's disease (late onset) PICALM intron 21460841 rs609903 chr11 85740409 A G 5.77E-04 Alzheimer's disease PICALM intron 22005930 rs609903 chr11 85740409 A G 8.25E-05 Alzheimer's disease PICALM intron 22832961 rs682928 chr11 85741130 C T 2.51E-06 Alzheimer's disease (late onset) PICALM intron 21460841 rs682928 chr11 85741130 C T 4.47E-04 Alzheimer's disease PICALM intron 22005930 rs682928 chr11 85741130 C T 8.28E-05 Alzheimer's disease PICALM intron 22832961 rs561646 chr11 85746037 C T 2.42E-06 Alzheimer's disease (late onset) PICALM intron 21460841 rs561646 chr11 85746037 C T 4.37E-04 Alzheimer's disease PICALM intron 22005930 rs561646 chr11 85746037 C T 8.42E-05 Alzheimer's disease PICALM intron 22832961 rs2508691 chr11 85750671 A T 2.37E-06 Alzheimer's disease (late onset) PICALM intron 21460841 rs2508691 chr11 85750671 A T 4.25E-04 Alzheimer's disease PICALM intron 22005930 rs2508691 chr11 85750671 A T 8.49E-05 Alzheimer's disease PICALM intron 22832961 rs17817931 chr11 85754814 T C 3.09E-04 Alzheimer's disease PICALM intron 22005930 rs17817931 chr11 85754814 T C 4.67E-07 Alzheimer's disease PICALM intron 22832961 rs12802399 chr11 85756825 T C 2.77E-04 Alzheimer's disease PICALM intron 22005930 rs12802399 chr11 85756825 T C 4.53E-07 Alzheimer's disease PICALM intron 22832961 rs2508692 chr11 85756884 T A 2.50E-05 Alzheimer's disease PICALM intron 22005930 rs1941375 chr11 85757133 T C 5.40E-04 Tourette syndrome PICALM intron 22889924 rs677909 chr11 85757589 C T 1.60E-05 Type 2 diabetes and other traits PICALM intron 19734900 rs677909 chr11 85757589 C T 2.53E-06 Alzheimer's disease (late onset) PICALM intron 21460841 rs677909 chr11 85757589 C T 1.40E-05 Urinary metabolites PICALM intron 21572414 rs677909 chr11 85757589 C T 3.88E-04 Alzheimer's disease PICALM intron 22005930 rs677909 chr11 85757589 C T 7.51E-05 Alzheimer's disease PICALM intron 22832961 rs677909 chr11 85757589 C T 2.49E-04 Alzheimer's disease PICALM intron 24755620 rs694011 chr11 85760028 T C 2.54E-06 Alzheimer's disease (late onset) PICALM intron 21460841 rs694011 chr11 85760028 T C 3.47E-04 Alzheimer's disease PICALM intron 22005930 rs694011 chr11 85760028 T C 7.44E-05 Alzheimer's disease PICALM intron 22832961 rs683494 chr11 85761474 A T 4.09E-05 Alzheimer's disease PICALM intron 22005930 rs545592 chr11 85762118 T C 2.71E-05 Alzheimer's disease PICALM intron 22005930 rs669813 chr11 85762244 C T 1.47E-06 Alzheimer's disease (late onset) PICALM intron 21460841 rs669813 chr11 85762244 C T 5.41E-04 Alzheimer's disease PICALM intron 22005930 rs493254 chr11 85765298 G A 2.73E-06 Alzheimer's disease (late onset) PICALM intron 21460841 rs493254 chr11 85765298 G A 3.02E-04 Alzheimer's disease PICALM intron 22005930 rs493254 chr11 85765298 G A 7.39E-05 Alzheimer's disease PICALM intron 22832961 rs12790526 chr11 85767340 C G 2.19E-04 Alzheimer's disease PICALM intron 22005930 rs12790526 chr11 85767340 C G 4.18E-07 Alzheimer's disease PICALM intron 22832961 rs613222 chr11 85769105 T G 1.59E-04 Alzheimer's disease PICALM intron 22005930 rs3016786 chr11 85774562 T G 2.62E-05 Alzheimer's disease PICALM intron 22005930 rs597446 chr11 85775059 A G 8.22E-05 Blood pressure (response to calcium channel blocker) PICALM intron 24192120 rs867611 chr11 85776544 G A 3.60E-06 Alzheimer's disease (late onset) PICALM intron 21460841 rs867611 chr11 85776544 G A 2.69E-04 Alzheimer's disease PICALM intron 22005930 rs867611 chr11 85776544 G A 7.53E-05 Alzheimer's disease PICALM intron 22832961 rs17817992 chr11 85778751 C T 1.82E-04 Alzheimer's disease PICALM intron 22005930 rs17817992 chr11 85778751 C T 4.94E-07 Alzheimer's disease PICALM intron 22832961 rs2509608 chr11 85779297 T G 9.52E-04 Obesity (extreme) PICALM intron 21935397 rs669556 chr11 85781322 C T 2.39E-05 Autism PICALM nearGene-5 24189344 rs621942 chr11 85783738 C A 9.00E-06 Tourette syndrome / / 22889924 rs638509 chr11 85784979 A C 5.26E-05 Alzheimer's disease / / 22005930 rs536841 chr11 85787824 C T 3.47E-06 Type 2 diabetes and other traits / / 19734900 rs536841 chr11 85787824 C T 3.83E-06 Alzheimer's disease (late onset) / / 21460841 rs536841 chr11 85787824 C T 3.00E-09 Alzheimer's disease / / 21627779 rs536841 chr11 85787824 C T 4.19E-04 Alzheimer's disease / / 22005930 rs536841 chr11 85787824 C T 2.52E-04 Alzheimer's disease / / 24755620 rs541458 chr11 85788351 C T 2.28E-06 Type 2 diabetes and other traits / / 19734900 rs541458 chr11 85788351 C T 3.82E-06 Alzheimer's disease (late onset) / / 21460841 rs541458 chr11 85788351 C T 4.56E-09 Alzheimer's disease / / 21627779 rs541458 chr11 85788351 C T 3.14E-04 Alzheimer's disease / / 22005930 rs541458 chr11 85788351 C T 3.87E-04 Blood pressure (response to calcium channel blocker) / / 24192120 rs541458 chr11 85788351 C T 2.69E-04 Alzheimer's disease / / 24755620 rs604767 chr11 85789983 C G 3.85E-05 Alzheimer's disease / / 22005930 rs561655 chr11 85800279 G A 7.00E-11 Alzheimer's disease (late onset) / / 21460841 rs561655 chr11 85800279 G A 2.23E-04 Alzheimer's disease / / 22005930 rs629343 chr11 85811138 A G 1.45E-04 Alzheimer's disease / / 22005930 rs629343 chr11 85811138 A G 4.55E-05 Intracerebral hemorrhage / / 24656865 rs542126 chr11 85811238 A G 1.13E-05 Alzheimer's disease (late onset) / / 21460841 rs526904 chr11 85811364 T C 9.22E-07 Alzheimer's disease (late onset) / / 21460841 rs526904 chr11 85811364 T C 2.47E-04 Alzheimer's disease / / 22005930 rs497816 chr11 85812210 C T 9.27E-07 Alzheimer's disease (late onset) / / 21460841 rs497816 chr11 85812210 C T 5.31E-04 Alzheimer's disease / / 22005930 rs495942 chr11 85812408 G A 9.18E-04 Tourette syndrome / / 22889924 rs17745409 chr11 85812785 A G 4.10E-05 Alzheimer's disease / / 22832961 rs586274 chr11 85814486 T G 6.78E-07 Alzheimer's disease (late onset) / / 21460841 rs586274 chr11 85814486 T G 3.67E-04 Alzheimer's disease / / 22005930 rs1237999 chr11 85815030 G A 1.14E-06 Type 2 diabetes and other traits / / 19734900 rs1237999 chr11 85815030 G A 1.02E-06 Alzheimer's disease (late onset) / / 21460841 rs1237999 chr11 85815030 G A 6.96E-04 Alzheimer's disease / / 22005930 rs543293 chr11 85820077 A G 6.87E-07 Type 2 diabetes and other traits / / 19734900 rs543293 chr11 85820077 A G 7.66E-07 Alzheimer's disease (late onset) / / 21460841 rs543293 chr11 85820077 A G 6.86E-09 Alzheimer's disease / / 21627779 rs543293 chr11 85820077 A G 4.14E-04 Alzheimer's disease / / 22005930 rs659023 chr11 85824859 A G 3.62E-06 Type 2 diabetes and other traits / / 19734900 rs659023 chr11 85824859 A G 4.02E-06 Alzheimer's disease (late onset) / / 21460841 rs659023 chr11 85824859 A G 7.19E-04 Alzheimer's disease / / 22005930 rs567075 chr11 85830157 T C 3.88E-07 Alzheimer's disease (late onset) / / 21460841 rs567075 chr11 85830157 T C 1.07E-04 Alzheimer's disease / / 22005930 rs573167 chr11 85831246 G A 1.00E-06 Alzheimer's disease (late onset) / / 21460841 rs573167 chr11 85831246 G A 1.46E-04 Alzheimer's disease / / 22005930 rs580887 chr11 85831433 A T 1.33E-05 Alzheimer's disease / / 22005930 rs471470 chr11 85831541 C A 6.02E-07 Alzheimer's disease (late onset) / / 21460841 rs471470 chr11 85831541 C A 3.59E-04 Alzheimer's disease / / 22005930 rs472486 chr11 85831690 A G 1.40E-06 Alzheimer's disease (late onset) / / 21460841 rs472486 chr11 85831690 A G 2.80E-04 Alzheimer's disease / / 22005930 rs519961 chr11 85832424 T C 9.48E-07 Alzheimer's disease (late onset) / / 21460841 rs519961 chr11 85832424 T C 1.63E-04 Alzheimer's disease / / 22005930 rs1898895 chr11 85837669 T C 5.21E-07 Alzheimer's disease (late onset) / / 21460841 rs1898895 chr11 85837669 T C 6.17E-05 Alzheimer's disease / / 22005930 rs11234551 chr11 85838084 G A 8.15E-04 Alzheimer's disease / / 22005930 rs10792830 chr11 85838808 G A 2.15E-05 Cognitive test performance / / 20125193 rs10792830 chr11 85838808 G A 6.00E-06 Alzheimer's disease / / 22005930 rs7114331 chr11 85839719 G A 8.17E-06 Alzheimer's disease / / 22005930 rs7114401 chr11 85839935 C T 9.37E-07 Alzheimer's disease (late onset) / / 21460841 rs7114401 chr11 85839935 C T 4.25E-04 Alzheimer's disease / / 22005930 rs10501610 chr11 85844486 T C 5.13E-05 Alzheimer's disease (late onset) / / 21460841 rs4944560 chr11 85845045 A G 3.13E-05 Alzheimer's disease (late onset) / / 21460841 rs4944560 chr11 85845045 A G 5.81E-05 Alzheimer's disease / / 22005930 rs3844143 chr11 85850243 C T 6.62E-05 Alzheimer's disease (late onset) / / 21460841 rs3844143 chr11 85850243 C T 2.96E-05 Alzheimer's disease / / 22005930 rs10792831 chr11 85852979 G A 4.29E-05 Alzheimer's disease / / 22005930 rs2888903 chr11 85854176 G T 2.08E-04 Alzheimer's disease (late onset) / / 21460841 rs2888903 chr11 85854176 G T 3.36E-05 Alzheimer's disease / / 22005930 rs7110631 chr11 85856187 C G 6.67E-06 Alzheimer's disease (late onset) / / 21460841 rs7110631 chr11 85856187 C G 5.65E-05 Alzheimer's disease / / 22005930 rs7110631 chr11 85856187 C G 5.29E-05 Alzheimer's disease / / 22832961 rs10898438 chr11 85858253 G A 3.30E-05 Type 2 diabetes and other traits / / 19734900 rs10898438 chr11 85858253 G A 9.41E-05 Cognitive test performance / / 20125193 rs10898438 chr11 85858253 G A 4.29E-05 Alzheimer's disease / / 22005930 rs3851178 chr11 85858497 G T 3.64E-05 Alzheimer's disease / / 22005930 rs7941541 chr11 85858538 G A 2.12E-07 Type 2 diabetes and other traits / / 19734900 rs7941541 chr11 85858538 G A 1.05E-05 Alzheimer's disease (late onset) / / 21460841 rs7941541 chr11 85858538 G A 3.33E-05 Alzheimer's disease / / 22005930 rs7941541 chr11 85858538 G A 5.53E-05 Alzheimer's disease / / 22832961 rs10751134 chr11 85858887 G A 1.23E-05 Alzheimer's disease (late onset) / / 21460841 rs10751134 chr11 85858887 G A 5.55E-04 Alzheimer's disease / / 22005930 rs10898439 chr11 85859483 G C 3.49E-05 Alzheimer's disease / / 22005930 rs7480193 chr11 85861419 G A 1.77E-04 Alzheimer's disease (late onset) / / 21460841 rs10792832 chr11 85867875 A G 5.65E-07 Alzheimer's disease (late onset) / / 21460841 rs10792832 chr11 85867875 A G 8.41E-05 Alzheimer's disease / / 22005930 rs10792832 chr11 85867875 A G 9.00E-26 Alzheimer's disease (late onset) / / 24162737 rs3851179 chr11 85868640 T C 1.92E-08 Type 2 diabetes and other traits / / 19734900 rs3851179 chr11 85868640 T C 1.00E-09 Alzheimer's disease / / 19734902 rs3851179 chr11 85868640 T C 6.21E-07 Alzheimer's disease (late onset) / / 21460841 rs3851179 chr11 85868640 T C 7.26E-05 Alzheimer's disease / / 22005930 rs3851179 chr11 85868640 T C 1.90E-08 Prion diseases / / 22210626 rs3851179 chr11 85868640 T C 1.71E-05 Alzheimer's disease (late onset) / / 23565137 rs3851179 chr11 85868640 T C 2.05E-04 Alzheimer's disease / / 24755620 rs7113976 chr11 85869737 C T 4.79E-05 Alzheimer's disease / / 22005930 rs7113976 chr11 85869737 C T 7.66E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs7113976 chr11 85869737 C T 8.14E-04 Alzheimer's disease / / 24755620 rs7129687 chr11 85871184 G C 7.03E-04 Alzheimer's disease / / 22005930 rs10751135 chr11 85885461 A G 1.13E-05 Blood pressure / / 24001895 rs7103707 chr11 85893436 T C 0.0000108 LDL cholesterol particle diameter / / 23263444 rs7123014 chr11 85922442 G A 4.95E-06 Hearing function / / 21493956 rs1874694 chr11 85939947 C T 1.06E-04 Cholesterol / / 17255346 rs991435 chr11 85959364 G C 1.11E-04 Cholesterol EED intron 17255346 rs7951030 chr11 85966665 C G 1.48E-04 Cholesterol EED intron 17255346 rs10792844 chr11 85980828 C A 0.0000494 Ovarian cancer EED intron 22794196 rs11234610 chr11 86026808 A C 3.00E-06 Cognitive performance C11orf73 intron 19734545 rs10792847 chr11 86053419 A G 1.09E-05 Colorectal cancer C11orf73 intron 21242260 rs6592284 chr11 86055901 T C 8.08E-04 Type 2 diabetes C11orf73 intron 17463246 rs6592284 chr11 86055901 T C 2.00E-06 Cognitive performance C11orf73 intron 19734545 rs1955189 chr11 86070096 A C 4.41E-04 Myopia (pathological) / / 21095009 rs7127620 chr11 86071947 A G 9.09E-04 Myopia (pathological) / / 21095009 rs292096 chr11 86078782 C T 2.70E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12804247 chr11 86079342 G T 0.0000145 Menopause (age at onset) / / 23424626 rs292103 chr11 86082980 A G 3.00E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7937090 chr11 86093345 A G 8.10E-05 Temporomandibular joint disorders CCDC81 intron 23746317 rs10792853 chr11 86093568 C T 1.00E-04 Temporomandibular joint disorders CCDC81 intron 23746317 rs7105671 chr11 86101234 G A 2.70E-05 Urinary metabolites CCDC81 intron 21572414 rs10501615 chr11 86103702 A G 2.76E-04 Major depressive disorder CCDC81 missense 22472876 rs10431169 chr11 86108112 T C 3.03E-06 Meningococcal disease CCDC81 intron 20694013 rs12278188 chr11 86114240 A G 2.21E-06 White blood cell count CCDC81 intron 21738479 rs10501617 chr11 86116017 C T 7.52E-05 Cognitive performance CCDC81 intron 19734545 rs4944574 chr11 86121457 G A 5.39E-05 Cognitive performance CCDC81 intron 19734545 rs12269969 chr11 86122104 C T 1.05E-06 White blood cell count CCDC81 intron 21738479 rs1452134 chr11 86133416 T C 9.44E-05 Cognitive performance CCDC81 intron 19734545 rs1458384 chr11 86177055 A G 2.10E-05 Urinary metabolites ME3 intron 21572414 rs1870323 chr11 86188152 A G 2.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule) ME3 intron 24025145 rs634509 chr11 86191420 T G 7.90E-06 Urinary metabolites ME3 intron 21572414 rs2051434 chr11 86211187 C T 7.18E-04 Myopia (pathological) ME3 intron 21095009 rs638492 chr11 86217761 G A 1.50E-05 Urinary metabolites ME3 intron 21572414 rs1542426 chr11 86221300 T C 1.20E-05 Urinary metabolites ME3 intron 21572414 rs7122928 chr11 86230612 C T 6.80E-06 Urinary metabolites ME3 intron 21572414 rs1841066 chr11 86249423 T C 5.00E-06 Urinary metabolites ME3 intron 21572414 rs12797615 chr11 86266683 T C 4.28E-05 Nicotine smoking ME3 intron 19268276 rs7935611 chr11 86288007 G T 5.46E-04 Multiple complex diseases ME3 intron 17554300 rs7935611 chr11 86288007 G T 1.92E-05 Type 1 diabetes ME3 intron 21980299 rs7109270 chr11 86318892 T C 2.61E-04 Tourette syndrome ME3 intron 22889924 rs1894012 chr11 86339871 T C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ME3 intron 22628534 rs7123010 chr11 86341186 G A 4.24E-05 Tourette syndrome ME3 intron 22889924 rs507211 chr11 86376739 G A 2.35E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) ME3 intron 23648065 rs682915 chr11 86383994 T C 1.57E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs594361 chr11 86386784 A G 1.57E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs1938936 chr11 86389000 C A 1.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs642245 chr11 86389536 G A 1.90E-05 Biomarkers / / 17903293 rs642245 chr11 86389536 G A 2.10E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs528948 chr11 86396588 A C 6.16E-04 Schizophrenia / / 19197363 rs17149308 chr11 86412682 C T 2.49E-04 Multiple complex diseases / / 17554300 rs17149311 chr11 86412698 G A 3.39E-04 Multiple complex diseases / / 17554300 rs2512988 chr11 86414027 A G 7.58E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs2512987 chr11 86414282 A G 7.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs17758141 chr11 86427342 T C 1.00E-04 Spine bone size / / 21947420 rs2513008 chr11 86438669 T C 9.17E-05 Orofacial clefts / / 20023658 rs2513009 chr11 86438884 G A 1.60E-05 Urinary metabolites / / 21572414 rs10898527 chr11 86441139 C A 1.89E-06 Phospholipid levels (plasma) / / 21829377 rs2512996 chr11 86446483 G A 2.80E-05 Urinary metabolites / / 21572414 rs2433432 chr11 86448765 A G 3.93E-04 Schizophrenia / / 19197363 rs12365944 chr11 86452020 G A 6.64E-05 Pulmonary function / / 19300500 rs17758195 chr11 86452908 T C 6.57E-05 Pulmonary function / / 19300500 rs2433434 chr11 86453415 G A 4.54E-04 Schizophrenia / / 19197363 rs11602353 chr11 86457164 C T 3.15E-05 Pulmonary function / / 19300500 rs11602353 chr11 86457164 C T 8.96E-05 Pulmonary function / / 20010835 rs3096716 chr11 86457182 C T 6.50E-04 Schizophrenia / / 19197363 rs11234778 chr11 86459103 C T 3.03E-05 Pulmonary function / / 19300500 rs11234778 chr11 86459103 C T 6.94E-05 Pulmonary function / / 20010835 rs4245425 chr11 86461965 T C 1.40E-05 Hemoglobin / / pha003098 rs4245425 chr11 86461965 T C 5.12E-05 Erythrocyte counts / / pha003099 rs4943956 chr11 86462088 G A 1.34E-05 Hemoglobin / / pha003098 rs4943956 chr11 86462088 G A 5.21E-05 Erythrocyte counts / / pha003099 rs12791451 chr11 86475042 C T 2.80E-05 Urinary metabolites / / 21572414 rs12362740 chr11 86476690 A T 6.73E-05 Pulmonary function / / 19300500 rs12362740 chr11 86476690 A T 5.31E-05 Pulmonary function / / 20010835 rs12807796 chr11 86477760 T C 6.32E-05 Pulmonary function / / 20010835 rs11234798 chr11 86478331 G C 5.95E-05 Pulmonary function / / 20010835 rs7128805 chr11 86485390 G C 5.02E-05 Pulmonary function / / 20010835 rs17820139 chr11 86489011 A G 3.73E-05 Pulmonary function / / 20010835 rs17758334 chr11 86489068 A G 3.71E-05 Pulmonary function / / 20010835 rs12802848 chr11 86489148 C T 8.28E-05 Orofacial clefts / / 20023658 rs744293 chr11 86492840 G A 2.74E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs6592315 chr11 86496427 T G 2.19E-05 Orofacial clefts / / 19270707 rs2015747 chr11 86503137 C A 1.32E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs12799567 chr11 86504356 A G 4.93E-05 Orofacial clefts / / 20023658 rs12799567 chr11 86504356 A G 9.40E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs12805405 chr11 86508928 T C 5.74E-05 Orofacial clefts / / 20023658 rs1939110 chr11 86515072 C T 1.11E-05 Orofacial clefts PRSS23 intron 20023658 rs1939105 chr11 86577094 G A 4.07E-05 Coronary heart disease / / 21606135 rs2433447 chr11 86582707 T C 5.91E-04 Type 2 diabetes / / 17846125 rs12801237 chr11 86601428 A T 1.06E-04 Coronary heart disease / / 21606135 rs10898549 chr11 86603490 A G 1.65E-05 Behcet's disease / / 23291587 rs17149491 chr11 86606059 A G 2.95E-05 Type 2 diabetes / / 17463246 rs17149491 chr11 86606059 A G 5.30E-04 Coronary heart disease / / 21606135 rs10128675 chr11 86608002 C T 1.71E-04 Type 2 diabetes / / 17463246 rs17149499 chr11 86612582 A G 9.60E-06 Urinary metabolites / / 21572414 rs10898551 chr11 86612708 A T 3.73E-04 Type 2 diabetes / / 17463246 rs11234870 chr11 86616127 C A 8.65E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7104996 chr11 86618821 T C 9.48E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4944640 chr11 86628005 C T 3.25E-05 Suicide attempts in bipolar disorder / / 21423239 rs7102970 chr11 86632398 C A 1.90E-05 Urinary metabolites / / 21572414 rs4354716 chr11 86634725 C T 3.63E-04 Birth weight / / 17255346 rs1350171 chr11 86644389 C T 7.34E-04 Type 2 diabetes / / 17463246 rs713065 chr11 86657520 A G 9.88E-05 Insulin-related traits FZD4 UTR-3 pha003063 rs2156174 chr11 86689971 C G 6.59E-04 Acute lung injury LOC100506368 intron 22295056 rs12800615 chr11 86708628 T C 9.71E-05 Serum metabolites LOC100506368 intron 19043545 rs7122009 chr11 86710510 T C 9.75E-05 Insulin-related traits LOC100506368 intron pha003063 rs1272073 chr11 86718978 A C 4.20E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs921872 chr11 86724086 C A 1.59E-04 Hearing function / / 17255346 rs2445536 chr11 86767388 A G 5.46E-05 Hearing function TMEM135 intron 17255346 rs17758940 chr11 86786685 T G 6.70E-04 Type 2 diabetes TMEM135 intron 17463246 rs17149719 chr11 86795933 T C 1.10E-05 Alcoholism (heaviness of drinking) TMEM135 intron 21529783 rs17149719 chr11 86795933 T C 3.80E-05 Alcohol dependence TMEM135 intron 21703634 rs2048973 chr11 86839097 G T 8.00E-04 Type 2 diabetes TMEM135 intron 17846125 rs597319 chr11 86853997 A G 3.05E-04 Bone properties (heel) TMEM135 intron 24430505 rs597319 chr11 86853997 A G 5.00E-26 Bone properties (heel) TMEM135 intron 24430505 rs597319 chr11 86853997 A G 8.00E-14 Bone properties (heel) TMEM135 intron 24430505 rs608966 chr11 86854309 G C 5.95E-05 Hearing function TMEM135 intron 17255346 rs611523 chr11 86854857 G T 8.84E-05 Hearing function TMEM135 intron 17255346 rs625554 chr11 86855690 C T 4.99E-05 Hearing function TMEM135 intron 17255346 rs482339 chr11 86857174 C A 8.88E-05 Hearing function TMEM135 intron 17255346 rs606284 chr11 86860244 C T 9.84E-05 Hearing function TMEM135 intron 17255346 rs576582 chr11 86863374 A G 1.00E-04 Hearing function TMEM135 intron 17255346 rs566046 chr11 86864277 A G 7.60E-05 Hearing function TMEM135 intron 17255346 rs580120 chr11 86870848 A T 9.79E-05 Hearing function TMEM135 intron 17255346 rs546229 chr11 86872504 C T 2.86E-04 Hearing function TMEM135 intron 17255346 rs549932 chr11 86872908 T C 6.60E-05 Hearing function TMEM135 intron 17255346 rs604035 chr11 86884825 C G 8.13E-05 Hearing function TMEM135 intron 17255346 rs1948206 chr11 86889284 C T 6.69E-05 Alcohol dependence TMEM135 intron 21703634 rs1948206 chr11 86889284 C T 0.0000377 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes TMEM135 intron 22628534 rs4944672 chr11 86889448 C T 6.42E-05 Alcohol dependence TMEM135 intron 21703634 rs17149800 chr11 86895621 T C 9.25E-05 Alcohol dependence TMEM135 intron 21703634 rs7124448 chr11 86908718 G A 1.70E-05 Urinary metabolites TMEM135 intron 21572414 rs532442 chr11 86912158 G A 5.56E-04 Type 2 diabetes TMEM135 intron 17463246 rs475752 chr11 86918502 G T 5.52E-04 Type 2 diabetes TMEM135 intron 17463246 rs504084 chr11 86918970 G T 7.54E-04 Type 2 diabetes TMEM135 intron 17463246 rs653419 chr11 86919995 C T 7.15E-04 Type 2 diabetes TMEM135 intron 17463246 rs10898619 chr11 86922561 G A 5.00E-06 Urinary metabolites TMEM135 intron 21572414 rs1518385 chr11 86946989 T A 1.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) TMEM135 intron 17982456 rs1518386 chr11 86947024 A G 8.86E-04 Type 2 diabetes TMEM135 intron 17463246 rs12224600 chr11 86947617 T C 2.20E-05 Urinary metabolites TMEM135 intron 21572414 rs1791446 chr11 86961328 A G 9.03E-04 Suicide attempts in bipolar disorder TMEM135 intron 21423239 rs643937 chr11 86961580 T C 9.12E-04 Suicide attempts in bipolar disorder TMEM135 intron 21423239 rs519308 chr11 86961615 G A 9.19E-04 Suicide attempts in bipolar disorder TMEM135 intron 21423239 rs2030234 chr11 86965391 A G 3.87E-05 Fasting insulin (interaction) TMEM135 intron 24204828 rs2030234 chr11 86965391 A G 4.44E-05 Homeostasis model assessment of insulin resistance (interaction) TMEM135 intron 24204828 rs12804243 chr11 86975706 A C 3.48E-04 Suicide attempts in bipolar disorder TMEM135 intron 21423239 rs10898664 chr11 87007030 A G 5.19E-06 Heart Rate TMEM135 intron pha003053 rs4545589 chr11 87018161 A G 1.05E-05 Heart Rate TMEM135 intron pha003053 rs7117070 chr11 87019645 G A 7.42E-04 Smoking cessation TMEM135 intron 24665060 rs7117070 chr11 87019645 G A 1.13E-06 Heart Rate TMEM135 intron pha003053 rs7928637 chr11 87058981 G A 1.59E-06 Heart Rate / / pha003053 rs12417501 chr11 87071233 T G 7.12E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4471448 chr11 87083324 A G 3.80E-06 Longevity and age-related phenotypes / / 17903295 rs11235127 chr11 87088544 G A 5.00E-05 Breast cancer / / 17529967 rs10898685 chr11 87110152 T C 8.79E-04 Multiple complex diseases / / 17554300 rs10501636 chr11 87112319 T C 1.10E-04 Longevity and age-related phenotypes / / 17903295 rs11235135 chr11 87114950 G A 4.20E-04 Body mass index / / 21701565 rs6592362 chr11 87125438 A G 2.00E-08 Inflammatory bowel disease / / 23128233 rs7105817 chr11 87129900 G A 5.16E-05 Paget's disease / / 20436471 rs4944707 chr11 87154097 G A 9.20E-05 HIV-1 control / / 20041166 rs7118472 chr11 87155511 G A 6.20E-06 Type 2 diabetes / / 21647700 rs17150123 chr11 87176854 A G 4.64E-04 Multiple complex diseases / / 17554300 rs7925637 chr11 87204458 G A 1.26E-05 Glucose levels / / pha002899 rs1986778 chr11 87220744 G A 2.04E-05 Cognitive test performance / / 20125193 rs7929583 chr11 87226475 T C 2.89E-05 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs7929583 chr11 87226475 T C 4.08E-05 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs10898723 chr11 87226744 C T 3.69E-05 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs10898723 chr11 87226744 C T 6.12E-05 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs10898723 chr11 87226744 C T 9.25E-05 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs10898723 chr11 87226744 C T 9.56E-05 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs12284047 chr11 87226823 C T 2.70E-05 Urinary metabolites / / 21572414 rs12146626 chr11 87229524 G A 2.72E-05 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs12146626 chr11 87229524 G A 3.51E-05 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs12146626 chr11 87229524 G A 4.83E-05 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs12146626 chr11 87229524 G A 5.26E-05 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs1815083 chr11 87238011 C T 2.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7119134 chr11 87238155 A G 4.77E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4944716 chr11 87249507 T C 1.19E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11235204 chr11 87275855 T G 7.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4512880 chr11 87277924 G A 5.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs5010075 chr11 87284641 T C 9.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3892758 chr11 87285390 A G 7.36E-04 Coronary Artery Disease / / 17634449 rs7121003 chr11 87286604 A C 6.10E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6592387 chr11 87294548 A G 7.21E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7929162 chr11 87295319 G A 7.21E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2097039 chr11 87312781 A G 4.57E-04 Coronary Artery Disease / / 17634449 rs2097039 chr11 87312781 A G 1.83E-04 Body mass index / / 21701565 rs2097039 chr11 87312781 A G 4.29E-04 Body mass index / / 21701565 rs10751174 chr11 87344821 C T 9.93E-04 Type 2 diabetes / / 17463246 rs11235247 chr11 87349407 G A 3.80E-06 Triglycerides / / 19074352 rs11235247 chr11 87349407 G A 3.80E-06 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs17822261 chr11 87375501 C T 9.59E-04 Atopy / / 21625490 rs11235272 chr11 87394150 G C 2.73E-04 Body mass index / / 21701565 rs4556569 chr11 87438597 T C 0.000006 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) / / 23080225 rs2226603 chr11 87449793 A G 4.92E-05 Cognitive test performance / / 20125193 rs7929791 chr11 87478923 C T 8.96E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6592416 chr11 87489404 A G 1.73E-04 Type 2 diabetes / / 17463246 rs1892897 chr11 87514179 A G 0.0000119 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs9326475 chr11 87523904 A G 2.33E-05 Type 2 diabetes / / 17463246 rs2508479 chr11 87548981 G T 1.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1939163 chr11 87569298 G A 1.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2514249 chr11 87571991 T C 1.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs11235340 chr11 87572073 C G 1.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs9666479 chr11 87572490 A G 1.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs12226885 chr11 87574807 C T 3.37E-04 Alzheimer's disease / / 22005930 rs9667306 chr11 87577651 A G 5.95E-04 Multiple complex diseases / / 17554300 rs7121252 chr11 87578468 T C 1.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs1939193 chr11 87582760 C T 3.76E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1939194 chr11 87583124 G T 3.76E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1939194 chr11 87583124 G T 4.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs10898796 chr11 87588521 C T 3.77E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs147578 chr11 87589656 G A 1.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs10501654 chr11 87592256 G A 4.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs661757 chr11 87594490 G T 1.93E-05 Suicide attempts in bipolar disorder / / 21423239 rs11235361 chr11 87610469 G C 5.50E-04 Multiple complex diseases / / 17554300 rs11235365 chr11 87618139 C T 5.58E-05 Parkinson's disease / / 21248740 rs2155105 chr11 87634881 C T 9.47E-04 Multiple complex diseases / / 17554300 rs2226602 chr11 87657063 A T 4.86E-04 Type 2 diabetes / / 17463246 rs2105601 chr11 87666565 T C 2.07E-04 Myocardial Infarction / / pha002873 rs2105601 chr11 87666565 T C 7.77E-05 Stroke / / pha002887 rs7925150 chr11 87674035 T C 1.68E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7945438 chr11 87783280 G A 4.76E-04 Multiple complex diseases / / 17554300 rs534692 chr11 87784344 G A 2.60E-05 Urinary metabolites / / 21572414 rs10501658 chr11 87788892 A C 1.30E-05 Cholesterol / / 17255346 rs16914161 chr11 87790526 T G 4.37E-07 Blood Pressure / / pha003044 rs2220303 chr11 87791436 G C 1.57E-05 Cholesterol / / 17255346 rs627314 chr11 87796131 C T 9.66E-05 Blood Pressure / / pha003044 rs10831205 chr11 87801857 A G 1.57E-05 Cholesterol / / 17255346 rs7936068 chr11 87817583 G A 4.69E-07 Blood Pressure / / pha003044 rs2220304 chr11 87819271 G A 3.65E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs1386330 chr11 87819427 T C 2.00E-06 Multiple sclerosis (age of onset) / / 19010793 rs1386330 chr11 87819427 T C 5.83E-05 Height / / pha003011 rs10831489 chr11 87819562 C T 6.42E-07 Blood Pressure / / pha003044 rs601715 chr11 87821818 T C 8.43E-05 Socioeconomic Factors / / pha003066 rs10734176 chr11 87824321 T C 6.70E-06 Urinary metabolites / / 21572414 rs11827368 chr11 87828768 T G 2.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs501234 chr11 87829246 G A 2.46E-04 Eye color / / 23118974 rs12274561 chr11 87829785 G A 1.40E-05 Diabetic retinopathy / / 21441570 rs675578 chr11 87846803 G A 7.40E-05 Personality dimensions RAB38 UTR-3 18957941 rs12287589 chr11 87853681 T C 9.66E-05 Suicide attempts in bipolar disorder RAB38 intron 21423239 rs11018514 chr11 87853917 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes RAB38 intron 22628534 rs1872739 chr11 87856826 T G 1.37E-06 White blood cell count RAB38 intron 21738479 rs11018531 chr11 87858176 C T 2.92E-04 Suicide attempts in bipolar disorder RAB38 intron 21423239 rs11018533 chr11 87858362 T C 9.87E-05 Suicide attempts in bipolar disorder RAB38 intron 21423239 rs11018537 chr11 87860095 A G 2.43E-06 White blood cell count RAB38 intron 21738479 rs10830242 chr11 87860646 C T 7.90E-05 Pulmonary function RAB38 intron 19300500 rs7395213 chr11 87869579 C A 1.92E-04 Multiple complex diseases RAB38 intron 17554300 rs1386327 chr11 87871538 A G 6.16E-04 Suicide attempts in bipolar disorder RAB38 intron 21423239 rs10128567 chr11 87871776 T C 6.25E-04 Suicide attempts in bipolar disorder RAB38 intron 21423239 rs302668 chr11 87876911 T C 2.00E-07 Frontotemporal dementia RAB38 intron 24943344 rs302666 chr11 87879075 C T 1.15E-04 Multiple complex diseases RAB38 intron 17554300 rs302665 chr11 87879627 A G 5.93E-05 Alcohol dependence RAB38 intron 21703634 rs12278560 chr11 87879800 A G 7.54E-04 Suicide attempts in bipolar disorder RAB38 intron 21423239 rs302662 chr11 87881236 A G 1.27E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) RAB38 intron 24023788 rs12576251 chr11 87882189 T G 6.54E-04 Multiple complex diseases RAB38 intron 17554300 rs302660 chr11 87885448 A G 1.27E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) RAB38 intron 24023788 rs890522 chr11 87895056 C T 2.50E-04 Multiple complex diseases RAB38 intron 17554300 rs890521 chr11 87895371 A G 9.86E-04 Multiple complex diseases RAB38 intron 17554300 rs1426928 chr11 87895890 C T 8.50E-04 Multiple complex diseases RAB38 intron 17554300 rs1426927 chr11 87895936 C T 9.40E-04 Multiple complex diseases RAB38 intron 17554300 rs7111615 chr11 87898429 A G 9.91E-04 Multiple complex diseases RAB38 intron 17554300 rs302645 chr11 87916672 C T 3.12E-04 Multiple complex diseases / / 17554300 rs7943882 chr11 87917670 G A 9.60E-05 Parkinson's disease (age of onset) / / 19772629 rs11825220 chr11 87923183 G A 2.40E-05 Urinary metabolites / / 21572414 rs16913634 chr11 87934068 G A 8.15E-04 Frontotemporal dementia / / 24943344 rs633687 chr11 87936024 G A 6.44E-05 Alcohol dependence / / 21703634 rs16913638 chr11 87936773 C G 3.16E-04 Multiple complex diseases / / 17554300 rs16913652 chr11 87938931 T C 4.57E-04 Body mass index / / 21701565 rs7937882 chr11 87940349 A G 6.33E-04 Body mass index / / 21701565 rs682457 chr11 87949532 T C 1.00E-06 Post-traumatic stress disorder / / 24677629 rs17754282 chr11 87983002 T G 4.97E-05 Attention deficit hyperactivity disorder / / 18980221 rs17754282 chr11 87983002 T G 4.30E-05 Attention deficit hyperactivity disorder / / pha002875 rs217089 chr11 88016576 A C 4.58E-05 Information processing speed / / 21130836 rs217098 chr11 88022988 A G 2.91E-04 Lymphocyte counts / / 22286170 rs217059 chr11 88057255 C G 9.43E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CTSC UTR-3 24578207 rs217059 chr11 88057255 C G 9.43E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CTSC UTR-3 24578207 rs217061 chr11 88060200 C T 5.29E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CTSC intron 24578207 rs217061 chr11 88060200 C T 5.29E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CTSC intron 24578207 rs217070 chr11 88067394 T C 2.54E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CTSC intron 24578207 rs217070 chr11 88067394 T C 2.54E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CTSC intron 24578207 rs11019394 chr11 88069313 A G 4.42E-04 Depression (quantitative trait) CTSC intron 20800221 rs3758832 chr11 88072398 T G 9.61E-05 Elbow pain CTSC nearGene-5 pha003008 rs3758832 chr11 88072398 T G 4.46E-05 Weight CTSC nearGene-5 pha003027 rs10830733 chr11 88086115 A G 5.30E-04 Depression (quantitative trait) / / 20800221 rs7107123 chr11 88087528 A G 5.67E-04 Depression (quantitative trait) / / 20800221 rs10765483 chr11 88089302 G C 6.76E-04 Depression (quantitative trait) / / 20800221 rs1470762 chr11 88097159 C G 7.49E-04 Depression (quantitative trait) / / 20800221 rs16913871 chr11 88101385 G A 4.87E-04 Multiple complex diseases / / 17554300 rs7943537 chr11 88101661 A G 9.47E-04 Depression (quantitative trait) / / 20800221 rs1451613 chr11 88101909 C A 5.75E-04 Multiple complex diseases / / 17554300 rs11019585 chr11 88102482 G A 7.26E-04 Depression (quantitative trait) / / 20800221 rs12807746 chr11 88103181 T C 9.68E-04 Depression (quantitative trait) / / 20800221 rs10501665 chr11 88105220 T C 2.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7930237 chr11 88117962 A G 9.00E-06 Alcohol dependence / / 21956439 rs72968657 chr11 88130249 A G 6.85E-05 Epilepsy (remission after treatment) / / 23962720 rs61901738 chr11 88131339 C T 6.63E-05 Epilepsy (remission after treatment) / / 23962720 rs55633855 chr11 88134563 A G 5.32E-05 Epilepsy (remission after treatment) / / 23962720 rs7939234 chr11 88137113 T G 7.25E-05 Epilepsy (remission after treatment) / / 23962720 rs16924538 chr11 88142353 A G 9.66E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs308764 chr11 88217396 G A 4.13E-05 Cognitive test performance / / 20125193 rs308885 chr11 88243909 G C 0.0000171 Major depressive disorder GRM5 intron 23149448 rs12273907 chr11 88252699 G A 2.31E-26 Narcolepsy GRM5 intron 19629137 rs1024117 chr11 88256603 T C 4.15E-05 Cognitive test performance GRM5 intron 20125193 rs160196 chr11 88266393 G C 1.92E-06 Personality dimensions GRM5 intron 23658558 rs178244 chr11 88269045 G A 1.82E-06 Personality dimensions GRM5 intron 23658558 rs2131068 chr11 88281206 T A 7.09E-04 Nicotine smoking GRM5 intron 19268276 rs10128616 chr11 88286437 G C 6.03E-06 Asthma (childhood onset) GRM5 intron 23829686 rs16914280 chr11 88321724 C T 3.00E-07 HIV-1 control GRM5 intron 20041166 rs10831110 chr11 88323540 A G 7.10E-05 Bladder cancer GRM5 intron 24163127 rs2306153 chr11 88338113 T C 7.43E-09 Multiple complex diseases GRM5 cds-synon 17554300 rs1874946 chr11 88356902 C T 3.66E-04 Stroke GRM5 intron pha002887 rs7481199 chr11 88358544 A G 1.17E-07 Common traits (Other) GRM5 intron 20585627 rs992259 chr11 88378005 A G 1.22E-05 Blood pressure (response to calcium channel blocker) GRM5 intron 24192120 rs10831251 chr11 88398458 T C 6.57E-04 Type 2 diabetes GRM5 intron 17463246 rs1846444 chr11 88402438 G A 5.97E-08 Metabolite levels GRM5 intron 23281178 rs6483362 chr11 88412451 A G 1.60E-04 Alcohol dependence GRM5 intron 21956439 rs16914552 chr11 88422049 G T 6.30E-08 Metabolite levels GRM5 intron 23281178 rs12364596 chr11 88428488 C T 4.84E-04 Obesity (extreme) GRM5 intron 21935397 rs7480936 chr11 88430974 A C 5.26E-05 Multiple complex diseases GRM5 intron 17554300 rs1353802 chr11 88431152 T C 6.30E-08 Metabolite levels GRM5 intron 23281178 rs904463 chr11 88431750 G A 6.30E-08 Metabolite levels GRM5 intron 23281178 rs6483380 chr11 88434287 A G 6.30E-08 Metabolite levels GRM5 intron 23281178 rs7480724 chr11 88434667 G C 6.30E-08 Metabolite levels GRM5 intron 23281178 rs7479186 chr11 88434771 T C 6.30E-08 Metabolite levels GRM5 intron 23281178 rs1353804 chr11 88435580 G T 6.30E-08 Metabolite levels GRM5 intron 23281178 rs1391874 chr11 88435739 G A 3.90E-08 Metabolite levels GRM5 intron 23281178 rs10741500 chr11 88436209 A T 2.80E-08 Metabolite levels GRM5 intron 23281178 rs1846442 chr11 88436996 C G 2.67E-08 Metabolite levels GRM5 intron 23281178 rs1846443 chr11 88437021 C A 2.67E-08 Metabolite levels GRM5 intron 23281178 rs1499035 chr11 88438089 T G 6.30E-08 Metabolite levels GRM5 intron 23281178 rs1353806 chr11 88438526 C G 6.30E-08 Metabolite levels GRM5 intron 23281178 rs1499032 chr11 88438898 C T 6.30E-08 Metabolite levels GRM5 intron 23281178 rs6483387 chr11 88439435 A G 6.30E-08 Metabolite levels GRM5 intron 23281178 rs10501678 chr11 88442102 C T 2.70E-07 HIV-1 control GRM5 intron 20041166 rs1391875 chr11 88447646 G C 6.03E-04 Alcohol dependence GRM5 intron 21314694 rs11021131 chr11 88472034 T C 6.37E-04 Smoking cessation GRM5 intron 24665060 rs10501681 chr11 88477562 A G 9.09E-05 Heart Rate GRM5 intron pha003054 rs1903851 chr11 88480491 T C 2.70E-05 Taste perception GRM5 intron 22132133 rs3893110 chr11 88523685 G T 1.17E-04 IgE levels GRM5 intron 17255346 rs4542417 chr11 88531191 C T 7.18E-04 Response to cytadine analogues (cytosine arabinoside) GRM5 intron 24483146 rs10501688 chr11 88533414 A G 8.62E-05 IgE levels GRM5 intron 17255346 rs10501688 chr11 88533414 A G 8.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRM5 intron 20877124 rs1903841 chr11 88533632 C T 1.98E-04 IgE levels GRM5 intron 17255346 rs993215 chr11 88540359 T C 6.44E-04 Response to cytadine analogues (cytosine arabinoside) GRM5 intron 24483146 rs12795125 chr11 88545014 C T 2.57E-07 Common traits (Other) GRM5 intron 20585627 rs4628675 chr11 88554307 A C,G,T 2.06E-04 IgE levels GRM5 intron 17255346 rs10831496 chr11 88557991 A G 5.00E-09 Tanning GRM5 intron 19340012 rs525214 chr11 88567094 G T 5.03E-04 Response to cytadine analogues (cytosine arabinoside) GRM5 intron 24483146 rs316086 chr11 88584160 A C 1.48E-04 Smoking cessation GRM5 intron 24665060 rs645327 chr11 88588786 C T 1.52E-04 Smoking cessation GRM5 intron 24665060 rs652659 chr11 88599826 A G 3.67E-04 Smoking cessation GRM5 intron 24665060 rs549700 chr11 88638182 C T 7.60E-04 Crohn's disease GRM5 intron 17684544 rs518167 chr11 88668140 A G 2.00E-06 Rheumatoid arthritis (ACPA-negative) GRM5 intron 24532677 rs16915130 chr11 88670423 T C 8.38E-04 Multiple complex diseases GRM5 intron 17554300 rs16915130 chr11 88670423 T C 8.84E-08 Metabolite levels GRM5 intron 23281178 rs655683 chr11 88676854 G T 2.15E-08 Meningococcal disease GRM5 intron 20694013 rs5016282 chr11 88741660 A G 1.00E-06 Attention deficit hyperactivity disorder GRM5 intron 22012869 rs16924543 chr11 88775773 A C 1.08E-04 Vaspin levels GRM5 intron 22907691 rs16924543 chr11 88775773 A C 0.0001078 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks GRM5 intron 22907730 rs1892879 chr11 88791259 A C 2.10E-04 Vaspin levels GRM5 intron 22907691 rs1892879 chr11 88791259 A C 0.0002095 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks GRM5 intron 22907730 rs4121738 chr11 88816538 C T 2.15E-04 Multiple complex diseases / / 17554300 rs16912813 chr11 88871504 T C 4.73E-04 Multiple complex diseases / / 17554300 rs10830228 chr11 88891114 A G 9.00E-06 Age-related macular degeneration / / 23326517 rs7127661 chr11 88896609 T G 2.48E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs10830236 chr11 88900816 C T 2.50E-07 Tanning / / 19340012 rs10830236 chr11 88900816 C T 9.74E-05 Vitiligo / / 20410501 rs10830236 chr11 88900816 C T 2.75E-07 Common traits (Other) / / 20585627 rs949537 chr11 88902830 T C 8.13E-04 Type 2 diabetes / / 17846125 rs1042602 chr11 88911696 C A 2.00E-11 Freckles TYR missense 17952075 rs1042602 chr11 88911696 C A 4.00E-10 Skin pigmentation TYR missense 17999355 rs1042602 chr11 88911696 C A 3.40E-08 Skin sensitivity to sun TYR missense 18488028 rs1042602 chr11 88911696 C A 5.89E-08 Common traits (Other) TYR missense 20585627 rs621313 chr11 88913663 A G 4.00E-06 Age-related macular degeneration TYR intron 23326517 rs7129973 chr11 88915570 A G 3.32E-06 Coronary heart disease TYR intron pha003033 rs12418383 chr11 88922081 A T 7.05E-04 Type 2 diabetes TYR intron 17463246 rs12419341 chr11 88928132 C T 1.60E-04 Type 2 diabetes TYR intron 17463246 rs12417632 chr11 88928835 C T 2.88E-04 Type 2 diabetes TYR intron 17463246 rs11018528 chr11 88930377 A G 2.82E-05 Vitiligo TYR intron 20410501 rs11018528 chr11 88930377 A G 3.31E-11 Common traits (Other) TYR intron 20585627 rs7929991 chr11 88931636 C T 3.97E-04 Smoking initiation TYR intron 24665060 rs7105390 chr11 88934334 T C 4.90E-07 Iron levels TYR intron 21208937 rs7123206 chr11 88951332 C T 2.85E-04 Type 2 diabetes TYR intron 17463246 rs7112373 chr11 88952032 A G 1.19E-04 Type 2 diabetes TYR intron 17463246 rs11018541 chr11 88960147 G A 1.82E-05 Coronary heart disease TYR intron pha003033 rs3793975 chr11 88961188 G A 3.46E-04 Type 2 diabetes TYR intron 17463246 rs3793975 chr11 88961188 G A 7.58E-05 Multiple complex diseases TYR intron 17554300 rs10765198 chr11 88969774 T C 1.64E-05 Vitiligo TYR intron 20410501 rs12295166 chr11 88976157 T C 1.94E-09 Skin pigmentation TYR intron 17999355 rs10741305 chr11 88982718 T C 5.32E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) TYR intron 23648065 rs1847134 chr11 89005253 A C 2.78E-07 Vitiligo TYR intron 20410501 rs1847134 chr11 89005253 A C 1.00E-15 Eye color TYR intron 20585627 rs1393350 chr11 89011046 G A 2.00E-06 Skin sensitivity to sun TYR intron 17952075 rs1393350 chr11 89011046 G A 3.00E-12 Blue vs. green eyes TYR intron 17952075 rs1393350 chr11 89011046 G A 1.20E-10 Skin sensitivity to sun TYR intron 18488028 rs1393350 chr11 89011046 G A 9.38E-05 AIDS progression TYR intron 19115949 rs1393350 chr11 89011046 G A 2.00E-13 Tanning TYR intron 19340012 rs1393350 chr11 89011046 G A 2.00E-14 Melanoma TYR intron 19578364 rs1393350 chr11 89011046 G A 2.00E-18 Vitiligo TYR intron 20410501 rs1393350 chr11 89011046 G A 2.00E-14 Nasopharyngeal carcinoma TYR intron 20512145 rs1393350 chr11 89011046 G A 3.00E-09 Eye color TYR intron 20585627 rs1393350 chr11 89011046 G A 3.24E-13 Vitiligo TYR intron 21326295 rs1393350 chr11 89011046 G A 4.28E-08 Melanoma TYR intron 21706340 rs1393350 chr11 89011046 G A 2.00E-13 Melanoma TYR intron 21983787 rs1393350 chr11 89011046 G A 9.32E-18 Vitiligo TYR intron 22561518 rs1393350 chr11 89011046 G A 6.70E-05 Melanoma TYR intron 24980573 rs1126809 chr11 89017961 G A 2.00E-08 Sunburns TYR missense 23548203 rs1126809 chr11 89017961 G A 5.00E-21 Tanning TYR missense 23548203 rs1126809 chr11 89017961 G A 5.60E-08 Melanoma TYR missense 24980573 rs1827430 chr11 89018440 A G 1.07E-11 Common traits (Other) TYR intron 20585627 rs1806319 chr11 89037936 T C 2.37E-05 Vitiligo / / 20410501 rs1806319 chr11 89037936 T C 4.47E-10 Common traits (Other) / / 20585627 rs1806319 chr11 89037936 T C 2.49E-06 Melanoma / / 21706340 rs1806319 chr11 89037936 T C 5.38E-05 Coronary heart disease / / pha003033 rs3897708 chr11 89062444 C T 1.57E-05 Antineutrophil cytoplasmic antibody-associated vasculitis NOX4 intron 22808956 rs3897708 chr11 89062444 C T 5.26E-04 Smoking initiation NOX4 intron 24665060 rs1847138 chr11 89094606 T C 1.32E-30 Narcolepsy NOX4 intron 19629137 rs7944576 chr11 89099263 C T 1.07E-04 Prostate cancer NOX4 intron 23023329 rs10830264 chr11 89111382 T G 3.50E-05 Cholesterol NOX4 intron 17255346 rs10830265 chr11 89112650 G A 8.00E-06 Obesity-related traits NOX4 intron 23251661 rs317150 chr11 89123768 C T 8.47E-06 Obesity-related traits NOX4 intron 23251661 rs12574346 chr11 89139213 C A 3.89E-05 Cognitive impairment induced by topiramate NOX4 intron 22091778 rs1827432 chr11 89140368 T C 7.94E-05 Cholesterol NOX4 intron 17255346 rs7130284 chr11 89148372 C T 2.00E-20 Homocysteine levels NOX4 intron 23824729 rs317148 chr11 89170515 T C 6.70E-04 Type 2 diabetes and 6 quantitative traits NOX4 intron 17848626 rs2164522 chr11 89190489 G A 6.56E-05 Cholesterol NOX4 intron 17255346 rs11018622 chr11 89197483 C T 2.85E-04 Taste perception NOX4 intron 22132133 rs957140 chr11 89201627 G A 2.00E-08 Homocysteine levels NOX4 intron 23824729 rs11018625 chr11 89202569 G A 7.21E-05 Cholesterol NOX4 intron 17255346 rs11018625 chr11 89202569 G A 6.23E-04 Multiple complex diseases NOX4 intron 17554300 rs11018629 chr11 89206964 G A 4.26E-05 Cholesterol NOX4 intron 17255346 rs11018629 chr11 89206964 G A 2.35E-04 Multiple complex diseases NOX4 intron 17554300 rs10830277 chr11 89208854 T C 3.46E-04 Obesity (extreme) NOX4 intron 21935397 rs2164521 chr11 89209985 G A 2.30E-04 Myocardial infarction NOX4 intron 21107343 rs497279 chr11 89217708 T C 3.42E-05 Type 2 diabetes NOX4 intron 17463246 rs514981 chr11 89221089 C T 9.10E-04 Response to cytadine analogues (cytosine arabinoside) NOX4 intron 24483146 rs11600313 chr11 89237846 T C 5.66E-04 Type 2 diabetes NOX4 intron 17463246 rs319024 chr11 89239875 G A 3.78E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) NOX4 intron 24023788 rs11018639 chr11 89249939 G T 9.45E-05 Serum metabolites NOX4 intron 19043545 rs2917539 chr11 89253253 C G 8.49E-04 Response to cytadine analogues (cytosine arabinoside) NOX4 intron 24483146 rs11018644 chr11 89261530 G T 9.58E-11 Metabolite levels NOX4 intron 22286219 rs3017883 chr11 89275712 C A 4.50E-04 Response to cytidine analogues (gemcitabine) NOX4 intron 24483146 rs3017883 chr11 89275712 C A 5.86E-04 Response to cytadine analogues (cytosine arabinoside) NOX4 intron 24483146 rs12293379 chr11 89276166 T C 4.94E-04 Type 2 diabetes NOX4 intron 17463246 rs2917538 chr11 89281774 G T 6.59E-04 Response to cytidine analogues (gemcitabine) NOX4 intron 24483146 rs3019011 chr11 89296364 A G 6.28E-06 Telomere length NOX4 intron 23001564 rs1488902 chr11 89345025 T C 3.00E-06 Amyotrophic lateral sclerosis / / 20801717 rs10830321 chr11 89380885 T C 3.12E-05 Serum metabolites / / 19043545 rs10047486 chr11 89405190 A G 2.70E-05 Anxiety and major depressive disorder FOLH1B intron 24047446 rs10830352 chr11 89440231 G A 1.21E-05 Anxiety in major depressive disorder / / 24047446 rs7111680 chr11 89444754 G A 5.85E-04 Response to taxane treatment (placlitaxel) TRIM77P intron 23006423 rs10830359 chr11 89455444 T C 3.63E-05 Serum metabolites / / 19043545 rs10830363 chr11 89458468 A G 5.95E-05 Serum metabolites / / 19043545 rs11018751 chr11 89458909 A C 5.95E-05 Serum metabolites / / 19043545 rs11018755 chr11 89461619 G A 5.96E-04 Multiple complex diseases / / 17554300 rs7484001 chr11 89463241 A G 4.45E-05 Non-word repetition / / 23738518 rs17221829 chr11 89466732 C A 2.07E-05 Serum metabolites / / 19043545 rs17221829 chr11 89466732 C A 5.00E-06 Anxiety in major depressive disorder / / 24047446 rs11018756 chr11 89468883 C A 3.71E-05 Non-word repetition / / 23738518 rs2130017 chr11 89502376 C A 8.00E-06 Response to taxane treatment (docetaxel) / / 23006423 rs10734121 chr11 89656239 G A 6.70E-06 Urinary metabolites / / 21572414 rs10830402 chr11 89843151 A C,G,T 9.40E-04 Obesity (extreme) / / 21935397 rs10830403 chr11 89843478 T C 5.14E-05 Multiple complex diseases / / 17554300 rs7951781 chr11 89855889 C A 1.27E-04 Parkinson's disease / / 17052657 rs7124476 chr11 89859994 G A 1.89E-04 Parkinson's disease / / 17052657 rs1892887 chr11 89867872 C T 1.60E-04 Parkinson's disease /ALAD2 UTR-5 17052657 rs7109578 chr11 89868692 G A 1.39E-04 Parkinson's disease /ALAD2 intron 17052657 rs10734123 chr11 89868755 G A 1.39E-04 Parkinson's disease /ALAD2 cds-synon 17052657 rs11018874 chr11 89875437 G A 2.00E-09 White blood cell types /ALAD2 intron 21738478 rs11018874 chr11 89875437 G A 0.00068 Prostate cancer /ALAD2 intron 23555315 rs2186748 chr11 89880469 T C 1.39E-04 Parkinson's disease /ALAD2 intron 17052657 rs4268468 chr11 89886284 G A 6.34E-05 Multiple complex diseases /ALAD2 intron 17554300 rs10830423 chr11 89886954 T G 5.00E-05 Body mass (lean) /ALAD2 intron 19268274 rs3740808 chr11 89892209 A T 1.22E-04 Parkinson's disease /ALAD2 intron 17052657 rs7928477 chr11 89895940 A G 1.82E-04 Parkinson's disease /ALAD2 intron 17052657 rs10734125 chr11 89898841 G T 4.81E-04 Obesity (extreme) /ALAD2 intron 21935397 rs3758755 chr11 89903405 G A 4.38E-04 Obesity (extreme) /ALAD2 intron 21935397 rs2000789 chr11 89913032 T G 1.68E-04 Parkinson's disease /ALAD2 intron 17052657 rs3740814 chr11 89914940 A C 2.06E-04 Parkinson's disease /ALAD2 intron 17052657 rs10765270 chr11 89917262 A G 3.17E-04 Obesity (extreme) /ALAD2 intron 21935397 rs10501713 chr11 89953013 G A 1.66E-04 Stroke CHORDC1 intron pha002887 rs7941284 chr11 89966109 C T 4.69E-05 Obesity (extreme) / / 21935397 rs10830452 chr11 89966202 A G 2.40E-05 Hypertension / / 22384028 rs10830457 chr11 89975099 G C 3.77E-04 Multiple complex diseases / / 17554300 rs7122533 chr11 89980078 T C 3.48E-04 Multiple complex diseases / / 17554300 rs11018938 chr11 89989158 G A 5.83E-04 Multiple complex diseases / / 17554300 rs12417453 chr11 89989487 C T 4.55E-04 Multiple complex diseases / / 17554300 rs1962137 chr11 89990909 T G 8.73E-05 Parkinson's disease / / 17052657 rs1962137 chr11 89990909 T G 2.15E-05 Hepatitis B / / 21750111 rs10765288 chr11 89993602 G A 4.15E-05 Parkinson's disease / / 17052657 rs11018956 chr11 90008163 C A 3.06E-04 Type 2 diabetes / / 17463246 rs12364205 chr11 90018288 A C 8.19E-05 Cognitive test performance / / 20125193 rs12364205 chr11 90018288 A C 5.34E-04 Stroke / / pha002887 rs10765304 chr11 90021786 C T 6.52E-04 Taste perception / / 22132133 rs484213 chr11 90042539 A G 1.22E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs497959 chr11 90050153 T C 1.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1507608 chr11 90070103 C T 5.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs41326848 chr11 90075366 C G 9.43E-04 Multiple complex diseases / / 17554300 rs41326848 chr11 90075366 C G 4.87E-04 Alzheimer's disease / / 17998437 rs10128640 chr11 90086953 A G 4.27E-05 Erythrocyte counts / / pha003090 rs1395895 chr11 90095312 T C 1.84E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs513348 chr11 90149769 G A 4.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs538515 chr11 90152159 C A 6.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs477144 chr11 90164443 A G 5.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs473703 chr11 90174810 G A 1.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs512285 chr11 90204266 T C 9.29E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2510752 chr11 90213472 T C 1.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17835266 chr11 90215938 T A 6.11E-04 Type 2 diabetes / / 17463246 rs476478 chr11 90217059 T G 0.0000555 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs577325 chr11 90219142 A G 1.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7945311 chr11 90255494 G A 2.43E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10501720 chr11 90262683 A T 2.30E-04 Crohn's disease / / 17684544 rs16922188 chr11 90263137 A G 5.59E-04 Multiple complex diseases / / 17554300 rs2155112 chr11 90264682 C T 4.14E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10734129 chr11 90276891 T A 1.40E-05 Urinary metabolites / / 21572414 rs10830545 chr11 90310352 A C 1.90E-05 Urinary metabolites / / 21572414 rs557067 chr11 90342211 C T 1.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs489675 chr11 90347971 T C 3.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs587334 chr11 90350730 T G 8.61E-05 Iron status biomarkers / / 19084217 rs561637 chr11 90352702 G A 2.38E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17257677 chr11 90364187 A G 2.84E-04 Type 2 diabetes / / 17463246 rs17257677 chr11 90364187 A G 1.94E-04 Cognitive decline / / 23732972 rs660753 chr11 90372303 G A 8.49E-04 Stroke / / pha002887 rs10501726 chr11 90375895 T A 4.30E-05 Personality dimensions / / 18957941 rs16923787 chr11 90404668 C G 1.20E-04 Multiple complex diseases / / 17554300 rs7947495 chr11 90406520 T G 4.79E-04 Rheumatoid arthritis / / 21452313 rs12806862 chr11 90425430 A G 5.73E-04 Rheumatoid arthritis / / 21452313 rs10830562 chr11 90453618 G A 5.60E-04 Rheumatoid arthritis / / 21452313 rs16923930 chr11 90469407 G A 9.29E-04 Multiple complex diseases / / 17554300 rs10741362 chr11 90469818 C A 3.13E-04 Rheumatoid arthritis / / 21452313 rs10741363 chr11 90484800 A G 7.88E-04 Rheumatoid arthritis / / 21452313 rs10830568 chr11 90485297 C A 7.79E-04 Rheumatoid arthritis / / 21452313 rs10741367 chr11 90491400 A G 8.90E-04 Alzheimer's disease / / 17998437 rs2511317 chr11 90556357 C T 3.80E-05 Brain lesion load / / 19010793 rs10765392 chr11 90572248 T A 1.90E-06 Urinary metabolites / / 21572414 rs12277729 chr11 90581712 G A 1.62E-04 Multiple complex diseases / / 17554300 rs12274302 chr11 90586900 C T 4.00E-07 HIV-1 control / / 20041166 rs2691829 chr11 90600576 T C 9.38E-06 Osteoarthritis / / 22763110 rs1404527 chr11 90609164 C T 4.72E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11605879 chr11 90641247 T C 2.90E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs6483079 chr11 90652932 G C 5.20E-04 Multiple complex diseases / / 17554300 rs7947321 chr11 90652993 T C 3.85E-04 Multiple complex diseases / / 17554300 rs10765400 chr11 90655274 G T 5.39E-04 Multiple complex diseases / / 17554300 rs1406396 chr11 90761638 A T 2.86E-04 Multiple complex diseases / / 17554300 rs1528753 chr11 90884339 A C 8.00E-08 Aging traits / / 17903295 rs7124339 chr11 90931925 A G 1.89E-04 Tourette syndrome / / 22889924 rs4483549 chr11 90955972 C T 3.58E-05 Alzheimer's disease / / 17998437 rs4483549 chr11 90955972 C T 1.63E-04 Alzheimer's disease / / pha002879 rs4491175 chr11 90956214 T C 8.00E-06 Response to angiotensin II receptor blocker therapy / / 22566498 rs4501949 chr11 90971609 C G 8.03E-05 IgE levels / / 22075330 rs2196517 chr11 90995060 G A 5.66E-05 IgE levels / / 22075330 rs965994 chr11 90997374 A G 5.69E-05 IgE levels / / 22075330 rs6483107 chr11 91002951 G A 3.70E-05 IgE levels / / 22075330 rs4420222 chr11 91005015 C T 1.94E-05 IgE levels / / 22075330 rs1370018 chr11 91016008 C T 9.63E-04 Obesity (extreme) / / 21935397 rs7934873 chr11 91046705 A G 1.51E-04 Multiple complex diseases / / 17554300 rs7934873 chr11 91046705 A G 8.36E-05 Formal thought disorder in schizophrenia / / 22648509 rs10830715 chr11 91061709 T A 7.57E-04 Multiple complex diseases / / 17554300 rs10830716 chr11 91062544 C T 7.51E-04 Multiple complex diseases / / 17554300 rs7929278 chr11 91067077 G A 5.40E-05 Formal thought disorder in schizophrenia / / 22648509 rs11019417 chr11 91089975 C T 1.43E-05 Coronary heart disease / / pha003030 rs11600880 chr11 91132095 A G 6.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs2156846 chr11 91179638 G A 3.98E-05 Cytomegalovirus antibody response / / 21993531 rs7121075 chr11 91198833 G A 4.01E-05 Cytomegalovirus antibody response / / 21993531 rs11019502 chr11 91237099 T A 6.37E-04 Multiple complex diseases / / 17554300 rs10501756 chr11 91255951 A G 8.29E-06 Blood Pressure / / pha003039 rs10501756 chr11 91255951 A G 2.32E-06 Blood Pressure / / pha003045 rs10501756 chr11 91255951 A G 1.29E-05 Blood Pressure / / pha003047 rs2138996 chr11 91273962 G A 3.06E-05 Blood Pressure / / pha003039 rs2138996 chr11 91273962 G A 4.08E-06 Blood Pressure / / pha003045 rs2138996 chr11 91273962 G A 1.41E-05 Blood Pressure / / pha003047 rs11019527 chr11 91294173 T C 8.29E-05 Blood Pressure / / pha003039 rs2514276 chr11 91305952 C T 8.05E-05 Blood Pressure / / pha003039 rs2514277 chr11 91306101 C T 7.85E-05 Blood Pressure / / pha003039 rs11019559 chr11 91321200 G C 3.29E-04 Multiple complex diseases / / 17554300 rs3914694 chr11 91327515 G T 2.41E-04 Multiple complex diseases / / 17554300 rs1728738 chr11 91361983 G A 3.14E-04 Body mass index / / 21701565 rs1728738 chr11 91361983 G A 5.74E-04 Body mass index / / 21701565 rs10501758 chr11 91378958 A C 2.10E-04 Body mass index / / 21701565 rs10501758 chr11 91378958 A C 4.71E-04 Body mass index / / 21701565 rs12291847 chr11 91524321 A G 9.43E-05 Insulin-related traits / / pha002901 rs12787131 chr11 91545471 C T 1.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs12574664 chr11 91573727 T C 9.81E-04 Multiple complex diseases / / 17554300 rs7111565 chr11 91574389 C T 9.82E-04 Multiple complex diseases / / 17554300 rs7115718 chr11 91581283 C T 1.10E-04 Response to alcohol consumption (flushing response) / / 24277619 rs765534 chr11 91590686 T G 2.11E-07 Multiple complex diseases / / 17554300 rs765534 chr11 91590686 T G 5.92E-05 Alzheimer's disease / / 17998437 rs11019662 chr11 91597856 C T 2.28E-04 Response to alcohol consumption (flushing response) / / 24277619 rs16916640 chr11 91613039 A G 8.24E-04 Response to alcohol consumption (flushing response) / / 24277619 rs4753349 chr11 91617460 C T 4.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4753349 chr11 91617460 C T 8.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4753350 chr11 91617547 A G 4.85E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs985598 chr11 91628612 G T 6.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12787480 chr11 91628663 C A 1.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs10501763 chr11 91638725 T C 6.97E-04 Common variable immunodeficiency / / 21497890 rs10501765 chr11 91657276 T C 8.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7107272 chr11 91682680 A G 8.50E-05 Temporomandibular joint disorders / / 23746317 rs1945869 chr11 91702184 A G 8.50E-05 Temporomandibular joint disorders / / 23746317 rs4323826 chr11 91702842 A G 7.73E-04 Type 2 diabetes / / 17846124 rs7940613 chr11 91714466 T G 6.90E-05 Temporomandibular joint disorders / / 23746317 rs10765509 chr11 91732586 G A 1.42E-04 Stroke / / pha002887 rs11019726 chr11 91737371 G T 4.74E-05 Sarcoidosis / / 19165924 rs10765518 chr11 91800709 C G 7.50E-05 Aging (time to event) / / 21782286 rs4753375 chr11 91804305 G A 6.01E-04 Multiple complex diseases / / 17554300 rs7924406 chr11 91815940 G C 1.31E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12793618 chr11 91830717 G A 7.86E-06 Depression (quantitative trait) / / 23290196 rs1027454 chr11 91834246 A C 4.40E-04 Body mass index / / 21701565 rs4753390 chr11 91846180 T C 1.85E-04 Body mass index / / 21701565 rs2125301 chr11 91946830 C A 8.80E-05 Cognitive test performance / / 20125193 rs10830888 chr11 91951447 C T 4.13E-04 Body mass index / / 21701565 rs10830888 chr11 91951447 C T 4.61E-04 Body mass index / / 21701565 rs1350445 chr11 91952154 G A 9.00E-06 Subclinical atherosclerosis / / 17903303 rs10501784 chr11 91952544 A G 1.60E-05 Subclinical atherosclerosis / / 17903303 rs10830892 chr11 91971198 A T 2.77E-04 Schizophrenia / / 20832056 rs11019886 chr11 91980205 A G 0.000106 Salmonella-induced pyroptosis / / 22837397 rs947938 chr11 91988838 T C 8.45E-05 Waist Circumference / / pha003023 rs11019889 chr11 91997261 A G 0.000423 Salmonella-induced pyroptosis / / 22837397 rs1531249 chr11 92009104 G A 2.72E-04 Multiple complex diseases / / 17554300 rs1531249 chr11 92009104 G A 2.60E-05 Urinary metabolites / / 21572414 rs1187158 chr11 92009396 A G 5.40E-06 Urinary metabolites / / 21572414 rs2508586 chr11 92012552 C G 3.57E-05 Multiple complex diseases / / 17554300 rs2508586 chr11 92012552 C G 4.40E-06 Urinary metabolites / / 21572414 rs2212389 chr11 92024786 A G 9.50E-06 Urinary metabolites / / 21572414 rs922006 chr11 92025863 G A 5.20E-06 Urinary metabolites / / 21572414 rs3133370 chr11 92026446 C T 7.90E-07 Urinary metabolites / / 21572414 rs1201352 chr11 92028153 A C 3.60E-06 Urinary metabolites / / 21572414 rs1014646 chr11 92029200 G A 2.80E-05 Urinary metabolites / / 21572414 rs877644 chr11 92035793 T C 1.00E-05 Urinary metabolites / / 21572414 rs2155151 chr11 92068437 C T 1.46E-06 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs11603009 chr11 92071798 A G 2.52E-06 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs4554857 chr11 92090489 T C 2.07E-06 Homeostasis model assessment of beta-cell function (interaction) FAT3 intron 24204828 rs11019927 chr11 92099379 A C 9.23E-06 Telomere length FAT3 intron 23001564 rs7129229 chr11 92100356 A T 1.00E-06 Homeostasis model assessment of beta-cell function (interaction) FAT3 intron 24204828 rs11606920 chr11 92107521 T C 3.43E-06 Homeostasis model assessment of beta-cell function (interaction) FAT3 intron 24204828 rs16912445 chr11 92107704 G A 8.76E-05 Acute lymphoblastic leukemia (childhood) FAT3 intron 22076464 rs7127751 chr11 92115923 G A 4.20E-06 Homeostasis model assessment of beta-cell function (interaction) FAT3 intron 24204828 rs11822486 chr11 92117196 G A 3.16E-06 Homeostasis model assessment of beta-cell function (interaction) FAT3 intron 24204828 rs481643 chr11 92121242 G A 3.25E-06 Homeostasis model assessment of beta-cell function (interaction) FAT3 intron 24204828 rs4753063 chr11 92267129 G A 0.00004228 Sarcoidosis FAT3 intron 22952805 rs1791554 chr11 92301650 C A 3.61E-04 Hemoglobin concentration FAT3 intron 20534544 rs1623581 chr11 92306628 A C 3.82E-04 Response to taxane treatment (placlitaxel) FAT3 intron 23006423 rs17532493 chr11 92327651 C T 4.50E-06 Urinary metabolites FAT3 intron 21572414 rs539194 chr11 92329626 T C 2.57E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) FAT3 intron 25044411 rs512978 chr11 92335162 C A 3.73E-04 Alzheimer's disease (late onset) FAT3 intron 21379329 rs500518 chr11 92347236 C T 2.94E-04 Alzheimer's disease (late onset) FAT3 intron 21379329 rs505423 chr11 92358811 G T 4.19E-04 Alzheimer's disease (late onset) FAT3 intron 21379329 rs6483184 chr11 92388582 G C 2.40E-07 Intraocular pressure FAT3 intron 22570627 rs7935199 chr11 92400798 C G 1.19E-04 Multiple complex diseases FAT3 intron 17554300 rs1458326 chr11 92417312 A G 1.10E-04 Multiple complex diseases FAT3 intron 17554300 rs4122086 chr11 92430846 G A 9.61E-08 Pure-tone audiometry FAT3 intron pha001964 rs10501794 chr11 92442459 C T 1.14E-07 Pure-tone audiometry FAT3 intron pha001964 rs1792361 chr11 92443925 C T 2.42E-04 Multiple complex diseases FAT3 intron 17554300 rs1791552 chr11 92447365 A G 1.29E-04 Multiple complex diseases FAT3 intron 17554300 rs1792367 chr11 92449418 T C 4.16E-04 Multiple complex diseases FAT3 intron 17554300 rs1792369 chr11 92452433 T A 2.53E-04 Multiple complex diseases FAT3 intron 17554300 rs10501796 chr11 92453156 A G 3.16E-07 Multiple complex diseases FAT3 intron 17554300 rs10501796 chr11 92453156 A G 1.14E-07 Pure-tone audiometry FAT3 intron pha001964 rs1791571 chr11 92453759 C T 1.25E-04 Multiple complex diseases FAT3 intron 17554300 rs1791569 chr11 92460320 G A 2.24E-04 Multiple complex diseases FAT3 intron 17554300 rs10501797 chr11 92527970 C G 9.98E-04 Multiple complex diseases FAT3 intron 17554300 rs7949157 chr11 92531356 A G 2.95E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) FAT3 missense 25044411 rs3847535 chr11 92558024 C T 1.79E-05 Multiple complex diseases FAT3 intron 17554300 rs7945975 chr11 92562200 G A 2.45E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) FAT3 intron 25044411 rs2399589 chr11 92603410 T C 8.05E-04 Multiple complex diseases FAT3 intron 17554300 rs1552511 chr11 92605986 T C 6.68E-04 Type 2 diabetes FAT3 intron 17463246 rs7951616 chr11 92610836 C T 3.21E-05 Smoking cessation FAT3 intron 24665060 rs1488859 chr11 92618272 C T 9.21E-04 Suicide attempts in bipolar disorder FAT3 intron 21423239 rs768877 chr11 92618875 G A 4.54E-05 Smoking cessation FAT3 intron 24665060 rs10741450 chr11 92619430 G A 8.18E-04 Suicide attempts in bipolar disorder FAT3 intron 21423239 rs10765571 chr11 92621533 A G 7.61E-04 Multiple complex diseases FAT3 intron 17554300 rs10765571 chr11 92621533 A G 4.08E-05 Smoking cessation FAT3 intron 24665060 rs7950811 chr11 92651002 C A 1.00E-08 Conduct disorder (symptom count) / / 20585324 rs7950811 chr11 92651002 C A 9.00E-07 Conduct disorder (symptom count) / / 20585324 rs737383 chr11 92664875 T C 9.65E-05 Nicotine smoking / / 19268276 rs11020107 chr11 92667730 G C 5.80E-04 Fasting plasma glucose / / 19060907 rs11020107 chr11 92667730 G C 2.90E-07 Fasting glucose-related traits / / 20152958 rs3847554 chr11 92668826 C T 9.03E-05 Chronic obstructive pulmonary disease / / 19300482 rs3847554 chr11 92668826 C T 9.03E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs3847554 chr11 92668826 C T 2.30E-09 Fasting glucose-related traits / / 20152958 rs3847554 chr11 92668826 C T 1.70E-10 Glycemic traits (pregnancy) / / 23903356 rs3847554 chr11 92668826 C T 2.52E-09 Glycemic traits (pregnancy) / / 23903356 rs3847554 chr11 92668826 C T 5.10E-08 Glycemic traits (pregnancy) / / 23903356 rs3847554 chr11 92668826 C T 6.16E-11 Glycemic traits (pregnancy) / / 23903356 rs12792753 chr11 92668975 T C 3.60E-11 Fasting glucose-related traits / / 20152958 rs1387153 chr11 92673828 C T 2.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1387153 chr11 92673828 C T 2.20E-17 Fasting plasma glucose / / 19060907 rs1387153 chr11 92673828 C T 2.00E-36 Fasting plasma glucose / / 19060909 rs1387153 chr11 92673828 C T 8.00E-15 Type 2 diabetes / / 20581827 rs1387153 chr11 92673828 C T 4.00E-11 Glycated Hemoglobin levels / / 20858683 rs1387153 chr11 92673828 C T 2.00E-09 Metabolic syndrome (bivariate traits) / / 21386085 rs1387153 chr11 92673828 C T 8.00E-09 Metabolic syndrome (bivariate traits) / / 21386085 rs1387153 chr11 92673828 C T 8.00E-15 Type 2 diabetes / / 21647700 rs1387153 chr11 92673828 C T 1.60E-11 Type 2 diabetes / / 22885922 rs1387153 chr11 92673828 C T 3.91E-143 Fasting blood glucose / / 22885924 rs1387153 chr11 92673828 C T 3.96E-11 Glycated hemoglobin levels / / 22885924 rs1387153 chr11 92673828 C T 1.91E-06 Obesity-related traits / / 23251661 rs1387153 chr11 92673828 C T 1.00E-06 Type 2 diabetes / / 23300278 rs1387153 chr11 92673828 C T 1.55E-10 Glycemic traits (pregnancy) / / 23903356 rs1387153 chr11 92673828 C T 2.18E-10 Glycemic traits (pregnancy) / / 23903356 rs1387153 chr11 92673828 C T 2.84E-17 Glycemic traits (pregnancy) / / 23903356 rs1387153 chr11 92673828 C T 4.02E-17 Glycemic traits (pregnancy) / / 23903356 rs1387153 chr11 92673828 C T 5.76E-05 Glycemic traits (pregnancy) / / 23903356 rs1387153 chr11 92673828 C T 9.21E-05 Glycemic traits (pregnancy) / / 23903356 rs1387153 chr11 92673828 C T 5.03E-07 Glucose levels / / pha002899 rs11523890 chr11 92679778 C T 1.70E-12 Fasting glucose-related traits / / 20152958 rs11523890 chr11 92679778 C T 1.49E-08 Glycemic traits (pregnancy) / / 23903356 rs11523890 chr11 92679778 C T 1.52E-09 Glycemic traits (pregnancy) / / 23903356 rs11523890 chr11 92679778 C T 7.53E-10 Glycemic traits (pregnancy) / / 23903356 rs11523890 chr11 92679778 C T 8.25E-08 Glycemic traits (pregnancy) / / 23903356 rs10830956 chr11 92681013 C T 5.00E-11 Metabolic syndrome (bivariate traits) / / 21386085 rs10830956 chr11 92681013 C T 1.33E-07 Glycemic traits (pregnancy) / / 23903356 rs10830956 chr11 92681013 C T 1.33E-10 Glycemic traits (pregnancy) / / 23903356 rs10830956 chr11 92681013 C T 1.83E-08 Glycemic traits (pregnancy) / / 23903356 rs10830956 chr11 92681013 C T 3.71E-10 Glycemic traits (pregnancy) / / 23903356 rs7933855 chr11 92684322 G A 1.46E-11 Glycemic traits (pregnancy) / / 23903356 rs7933855 chr11 92684322 G A 1.87E-10 Glycemic traits (pregnancy) / / 23903356 rs7933855 chr11 92684322 G A 8.51E-10 Glycemic traits (pregnancy) / / 23903356 rs7933855 chr11 92684322 G A 8.83E-10 Glycemic traits (pregnancy) / / 23903356 rs7936247 chr11 92690032 G T 2.27E-16 Glycemic traits (pregnancy) / / 23903356 rs7936247 chr11 92690032 G T 3.00E-16 Glycemic traits (pregnancy) / / 23903356 rs7936247 chr11 92690032 G T 4.18E-10 Glycemic traits (pregnancy) / / 23903356 rs11020124 chr11 92690661 T C 7.22E-06 Glycemic traits (pregnancy) / / 23903356 rs11020124 chr11 92690661 T C 9.61E-06 Glycemic traits (pregnancy) / / 23903356 rs2166706 chr11 92691532 T C 2.00E-09 Fasting plasma glucose / / 19651812 rs2166706 chr11 92691532 T C 1.10E-07 Glycemic traits (pregnancy) / / 23903356 rs2166706 chr11 92691532 T C 1.29E-06 Glycemic traits (pregnancy) / / 23903356 rs2166706 chr11 92691532 T C 1.40E-05 Glycemic traits (pregnancy) / / 23903356 rs2166706 chr11 92691532 T C 6.58E-08 Glycemic traits (pregnancy) / / 23903356 rs2166706 chr11 92691532 T C 2.19E-06 Glucose levels / / pha002899 rs10466351 chr11 92697981 C T 5.86E-11 Metabolite levels / / 22286219 rs10830962 chr11 92698427 C G 2.60E-11 Fasting glucose-related traits / / 20152958 rs10830962 chr11 92698427 C G 1.00E-16 Metabolite levels / / 21909109 rs10830962 chr11 92698427 C G 2.00E-13 Diabetes (gestational) / / 22233651 rs10830962 chr11 92698427 C G 5.00E-16 Metabolic syndrome / / 22399527 rs10830962 chr11 92698427 C G 3.00E-12 Glycemic traits / / 23575436 rs10830962 chr11 92698427 C G 5.00E-13 Glycemic traits / / 23575436 rs61739452 chr11 92703085 T C 0.00051 Prostate cancer (non-advanced prostate cancer) MTNR1B missense 23555315 rs7951037 chr11 92706175 G A 9.91E-05 Pulmonary function MTNR1B intron 20010835 rs10765576 chr11 92706944 A G 8.20E-09 Fasting glucose-related traits MTNR1B intron 20152958 rs10830963 chr11 92708710 C G 3.00E-50 Fasting plasma glucose MTNR1B intron 19060907 rs10830963 chr11 92708710 C G 3.00E-43 Fasting glucose-related traits MTNR1B intron 20081858 rs10830963 chr11 92708710 C G 6.00E-175 Fasting insulin-related traits MTNR1B intron 20081858 rs10830963 chr11 92708710 C G 3.30E-19 Fasting glucose-related traits MTNR1B intron 20152958 rs10830963 chr11 92708710 C G 3.00E-11 Metabolite levels MTNR1B intron 22286219 rs10830963 chr11 92708710 C G 1.00E-12 Fasting plasma glucose MTNR1B intron 22508271 rs10830963 chr11 92708710 C G 4.00E-105 Fasting glucose-related traits (interaction with BMI) MTNR1B intron 22581228 rs10830963 chr11 92708710 C G 0.000014 Type 2 diabetes (females) MTNR1B intron 22885922 rs10830963 chr11 92708710 C G 2.70E-10 Type 2 diabetes (males) MTNR1B intron 22885922 rs10830963 chr11 92708710 C G 8.60E-23 HOMA-B MTNR1B intron 22885922 rs10830963 chr11 92708710 C G 0.000000555 2-hour glucose tolerance test MTNR1B intron 22885924 rs10830963 chr11 92708710 C G 1.07E-215 Fasting blood glucose MTNR1B intron 22885924 rs10830963 chr11 92708710 C G 2.99E-09 Glycated hemoglobin levels MTNR1B intron 22885924 rs10830963 chr11 92708710 C G 4.00E-08 Obesity-related traits MTNR1B intron 23251661 rs10830963 chr11 92708710 C G 1.29E-11 Glycemic traits (pregnancy) MTNR1B intron 23903356 rs10830963 chr11 92708710 C G 2.62E-05 Glycemic traits (pregnancy) MTNR1B intron 23903356 rs10830963 chr11 92708710 C G 3.56E-08 Glycemic traits (pregnancy) MTNR1B intron 23903356 rs10830963 chr11 92708710 C G 7.33E-09 Glycemic traits (pregnancy) MTNR1B intron 23903356 rs10830963 chr11 92708710 C G 7.34E-10 Glycemic traits (pregnancy) MTNR1B intron 23903356 rs10830963 chr11 92708710 C G 9.11E-06 Glycemic traits (pregnancy) MTNR1B intron 23903356 rs10830963 chr11 92708710 C G 2.00E-07 Type 2 diabetes MTNR1B intron 24509480 rs1562444 chr11 92715849 G A 1.60E-07 Glycemic traits (pregnancy) MTNR1B UTR-3 23903356 rs1562444 chr11 92715849 G A 1.87E-05 Glycemic traits (pregnancy) MTNR1B UTR-3 23903356 rs1562444 chr11 92715849 G A 6.21E-07 Glycemic traits (pregnancy) MTNR1B UTR-3 23903356 rs4753072 chr11 92717405 C A 1.91E-07 Glycemic traits (pregnancy) / / 23903356 rs4753072 chr11 92717405 C A 7.65E-07 Glycemic traits (pregnancy) / / 23903356 rs4753073 chr11 92717475 G A 2.46E-06 Glycemic traits (pregnancy) / / 23903356 rs4753073 chr11 92717475 G A 6.57E-07 Glycemic traits (pregnancy) / / 23903356 rs1447350 chr11 92718127 G C 2.46E-06 Glycemic traits (pregnancy) / / 23903356 rs1447350 chr11 92718127 G C 7.38E-07 Glycemic traits (pregnancy) / / 23903356 rs1447351 chr11 92718163 A G 2.34E-07 Glycemic traits (pregnancy) / / 23903356 rs1447351 chr11 92718163 A G 7.68E-07 Glycemic traits (pregnancy) / / 23903356 rs4611171 chr11 92719207 T G 1.90E-09 Fasting glucose-related traits / / 20152958 rs4611171 chr11 92719207 T G 2.59E-07 Glycemic traits (pregnancy) / / 23903356 rs4611171 chr11 92719207 T G 8.44E-07 Glycemic traits (pregnancy) / / 23903356 rs10830964 chr11 92719681 C T 5.00E-06 Insomnia (caffeine-induced) / / 22754043 rs1597023 chr11 92721319 G A 1.79E-07 Glycemic traits (pregnancy) / / 23903356 rs1597023 chr11 92721319 G A 2.00E-12 Glycemic traits (pregnancy) / / 23903356 rs1597023 chr11 92721319 G A 2.55E-12 Glycemic traits (pregnancy) / / 23903356 rs1597023 chr11 92721319 G A 8.46E-08 Glycemic traits (pregnancy) / / 23903356 rs4406791 chr11 92721787 A C 2.58E-07 Glycemic traits (pregnancy) / / 23903356 rs4406791 chr11 92721787 A C 8.44E-07 Glycemic traits (pregnancy) / / 23903356 rs1447352 chr11 92722761 G A 6.00E-08 Metabolic traits / / 19060910 rs1447352 chr11 92722761 G A 1.95E-07 Glycemic traits (pregnancy) / / 23903356 rs1447352 chr11 92722761 G A 6.37E-07 Glycemic traits (pregnancy) / / 23903356 rs1447352 chr11 92722761 G A 5.90E-08 Glucose levels / / pha002899 rs7121092 chr11 92724351 T C 1.23E-07 Glucose levels / / pha002899 rs6483213 chr11 92725321 A G 2.42E-07 Glycemic traits (pregnancy) / / 23903356 rs6483213 chr11 92725321 A G 7.93E-07 Glycemic traits (pregnancy) / / 23903356 rs53380 chr11 92749586 C A 8.98E-04 Parkinson's disease / / 17052657 rs621310 chr11 92783339 G A 5.53E-04 Parkinson's disease / / 17052657 rs621310 chr11 92783339 G A 6.24E-05 Cervical cancer / / 24700089 rs7931462 chr11 92784203 G A 2.00E-09 DNA methylation (parent-of-origin) / / 23725790 rs7120482 chr11 92792100 G A 5.00E-08 Adverse response to radiation therapy / / 23719583 rs17630638 chr11 92795212 C T 6.90E-07 Adverse response to radiation therapy / / 23719583 rs1703086 chr11 92807679 A G 3.64E-05 Lymphocyte counts / / pha003094 rs1703086 chr11 92807679 A G 1.71E-05 Neutrophil count / / pha003095 rs1876602 chr11 92809205 G T 6.28E-04 Stroke / / pha002887 rs7947982 chr11 92845646 C T 8.42E-05 Type 2 diabetes / / 17463246 rs12361930 chr11 92859478 T C 4.79E-04 Type 2 diabetes / / 17463246 rs11020175 chr11 92863298 A C 2.00E-05 Urinary metabolites / / 21572414 rs12576495 chr11 92865007 T C 1.00E-06 Crohn's disease / / 17804789 rs10830989 chr11 92886648 C G 8.75E-05 Type 1 diabetes SLC36A4 intron 18978792 rs1508607 chr11 92893654 A T 8.45E-04 Type 2 diabetes SLC36A4 intron 17463246 rs1508608 chr11 92893825 A G 6.45E-04 Oral cancers (chewing tobacco related) SLC36A4 intron 22503698 rs4753436 chr11 92898342 G A 9.66E-04 Oral cancers (chewing tobacco related) SLC36A4 intron 22503698 rs12296063 chr11 92920402 C T 2.00E-06 Obesity-related traits SLC36A4 intron 23251661 rs12419806 chr11 93000480 A C 7.83E-04 Multiple complex diseases / / 17554300 rs12419806 chr11 93000480 A C 5.93E-06 Non-obstructive azoospermia / / 22541561 rs8181486 chr11 93015765 T C 5.00E-05 Prostate cancer / / 21743057 rs7130117 chr11 93072893 T C 4.00E-05 Prostate cancer CCDC67 intron 21743057 rs12098946 chr11 93093137 C T 4.00E-06 Obesity-related traits CCDC67 intron 23251661 rs12292451 chr11 93132328 G T 2.70E-05 Urinary metabolites CCDC67 intron 21572414 rs12287849 chr11 93139551 G A 2.90E-05 Urinary metabolites CCDC67 intron 21572414 rs11020318 chr11 93149258 C G 6.97E-05 Cytomegalovirus antibody response CCDC67 intron 21993531 rs2658782 chr11 93166731 T G 4.00E-06 Pulmonary function decline CCDC67 intron 22424883 rs2085334 chr11 93181050 C T 7.18E-04 Alzheimer's disease / / 22005930 rs7127240 chr11 93184892 T A 9.38E-04 Alzheimer's disease / / 22005930 rs6483244 chr11 93197935 A G 8.93E-04 Alzheimer's disease / / 22005930 rs16918969 chr11 93206273 G C 3.57E-04 Multiple complex diseases / / 17554300 rs2605593 chr11 93206897 C G 1 Drug response to Etoposide / / 17537913 rs2658801 chr11 93216751 G A 1.19E-05 Orofacial clefts C11orf75 intron 22419666 rs11020388 chr11 93240847 G T 0.00023 Salmonella-induced pyroptosis C11orf75 intron 22837397 rs7928401 chr11 93244823 T C 0.000111 Salmonella-induced pyroptosis C11orf75 intron 22837397 rs2605627 chr11 93259515 A G 0.000000085 Fasting blood glucose C11orf75 intron 22885924 rs12419851 chr11 93265505 T C 4.10E-04 Rheumatoid arthritis C11orf75 intron 21452313 rs7126188 chr11 93277266 C T 4.59E-04 Alcohol dependence / / 20201924 rs4753475 chr11 93295861 A G 6.17E-04 Type 2 diabetes / / 17463246 rs7124828 chr11 93299743 G T 5.56E-09 Sickle cell anemia (severity) / / 20029952 rs6483253 chr11 93306682 G A 3.72E-04 Type 2 diabetes / / 17463246 rs6483253 chr11 93306682 G A 7.53E-04 Alzheimer's disease / / 17998437 rs4753480 chr11 93309040 A G 8.05E-04 Iron levels / / pha002876 rs4237559 chr11 93309447 A G 6.84E-04 Iron levels / / pha002876 rs11020442 chr11 93332485 C A 9.74E-04 Iron levels / / pha002876 rs1939563 chr11 93338641 C T 5.02E-04 Alzheimer's disease / / 17998437 rs4612756 chr11 93358154 A G 8.97E-04 Iron levels / / pha002876 rs948016 chr11 93369305 C A 6.27E-04 Iron levels / / pha002876 rs1939565 chr11 93379359 T C 8.57E-04 Heart Failure / / pha002885 rs10501805 chr11 93391954 T C 1.08E-160 Multiple complex diseases / / 17554300 rs7939460 chr11 93393196 C G 0.00067 Salmonella-induced pyroptosis / / 22837397 rs10765620 chr11 93401193 A G 0.000033 Salmonella-induced pyroptosis KIAA1731 intron 22837397 rs11020484 chr11 93415840 A T 0.000548 Salmonella-induced pyroptosis KIAA1731 intron 22837397 rs7939577 chr11 93417460 C T 2.26E-04 Alzheimer's disease (late onset) KIAA1731 intron 21379329 rs10831093 chr11 93421782 G A 9.68E-04 Type 2 diabetes KIAA1731 intron 17463246 rs10831093 chr11 93421782 G A 0.000796 Salmonella-induced pyroptosis KIAA1731 intron 22837397 rs10160552 chr11 93422613 G A 9.94E-04 Type 2 diabetes KIAA1731 intron 17463246 rs10160552 chr11 93422613 G A 0.000306 Salmonella-induced pyroptosis KIAA1731 intron 22837397 rs34591613 chr11 93469892 G C 0.00053 Breast cancer TAF1D missense 23555315 rs7105804 chr11 93472964 C T 0.00033 Salmonella-induced pyroptosis TAF1D intron 22837397 rs670871 chr11 93491020 T C 0.000853 Salmonella-induced pyroptosis C11orf54 intron 22837397 rs1284108 chr11 93498833 G T 8.20E-04 Lymphocyte counts / / 22286170 rs675441 chr11 93505490 A C 0.000209 Salmonella-induced pyroptosis / / 22837397 rs625249 chr11 93510141 A G 6.28E-04 Coronary heart disease / / 21971053 rs584324 chr11 93514237 G A 2.99E-04 Type 2 diabetes / / 17463246 rs606087 chr11 93522642 A G 4.60E-05 Amyotrophic lateral sclerosis MED17 intron 20801717 rs655699 chr11 93534990 G A 0.000016 Salmonella-induced pyroptosis MED17 intron 22837397 rs669565 chr11 93535839 A G 0.0000433 Amyotrophic lateral sclerosis MED17 intron 23587638 rs11020522 chr11 93539050 A G 0.000011 Salmonella-induced pyroptosis MED17 intron 22837397 rs592526 chr11 93539520 G A 3.25E-04 Multiple complex diseases MED17 intron 17554300 rs673869 chr11 93540001 G A 0.000013 Salmonella-induced pyroptosis MED17 intron 22837397 rs644009 chr11 93550568 A G 0.000012 Salmonella-induced pyroptosis / / 22837397 rs585768 chr11 93552855 C T 2.93E-04 Type 2 diabetes / / 17463246 rs16919416 chr11 93566937 C T 8.37E-04 Multiple complex diseases VSTM5 intron 17554300 rs7103466 chr11 93572910 G A 9.70E-04 Alzheimer's disease VSTM5 intron 22005930 rs142523125 chr11 93626148 C T 0.0000916 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7117597 chr11 93655091 A G 9.47E-04 Major depressive disorder / / 22472876 rs10765647 chr11 93662459 T C 7.20E-04 Major depressive disorder / / 22472876 rs10501809 chr11 93666263 G C 7.16E-04 Major depressive disorder / / 22472876 rs1518555 chr11 93691008 A C 2.70E-05 Malaria / / 19465909 rs11825709 chr11 93704049 A G 4.00E-06 Obesity-related traits / / 23251661 rs4753115 chr11 93767116 G A 4.10E-04 Iris characteristics HEPHL1 intron 21835309 rs2949861 chr11 93812039 T C 5.79E-05 Post-operative nausea and vomiting HEPHL1 intron 21694509 rs4073612 chr11 93865651 G T 8.30E-04 Endometriosis PANX1 intron 21151130 rs11607757 chr11 93866147 T G 8.54E-04 Amyotrophic lateral sclerosis (sporadic) PANX1 intron 24529757 rs11020672 chr11 93906538 A C 3.77E-04 Insulin resistance PANX1 intron 21901158 rs1070 chr11 93914956 A G 2.46E-05 Glucose levels PANX1 UTR-3 pha003058 rs1792624 chr11 93921810 G A 9.64E-266 Meningococcal disease / / 20694013 rs1792624 chr11 93921810 G A 8.45E-05 Glucose levels / / pha003058 rs1792634 chr11 93929510 G T 2.44E-05 Glucose levels / / pha003058 rs1541300 chr11 93944545 G T 4.00E-05 Glucose levels / / pha003058 rs504207 chr11 94060402 G A 8.24E-04 Multiple complex diseases / / 17554300 rs11602404 chr11 94062135 C T 5.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs598645 chr11 94071745 A T 8.30E-06 Urinary metabolites / / 21572414 rs11600240 chr11 94098333 T C 4.72E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7950328 chr11 94099615 A G 8.01E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7950328 chr11 94099615 A G 4.72E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4753597 chr11 94100258 C T 4.72E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7933112 chr11 94101704 T A 2.50E-05 Urinary metabolites / / 21572414 rs3758785 chr11 94132139 A G 2.00E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GPR83 intron 22566498 rs3758786 chr11 94132284 C T 1.44E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GPR83 intron 22566498 rs3758789 chr11 94133124 T A 1.50E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GPR83 intron 22566498 rs12270338 chr11 94147464 C A 1.10E-05 Urinary metabolites / / 21572414 rs12270338 chr11 94147464 C A 2.65E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11020780 chr11 94158034 C T 3.25E-04 Type 2 diabetes MRE11A intron 17463246 rs13447720 chr11 94165326 T C 9.75E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MRE11A intron 22566498 rs13447595 chr11 94222690 A G 1.00E-05 Urinary metabolites MRE11A intron 21572414 rs16924603 chr11 94255259 T C 3.70E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LOC643037 intron 22566498 rs16924599 chr11 94256431 A C 9.71E-07 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LOC643037 intron 22566498 rs589546 chr11 94256640 A T 1.79E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LOC643037 intron 22566498 rs7936320 chr11 94260957 T C 3.68E-04 Response to taxane treatment (placlitaxel) LOC643037 intron 23006423 rs566917 chr11 94262084 G C 1.75E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LOC643037 intron 22566498 rs12286498 chr11 94263023 T G 9.66E-07 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LOC643037 intron 22566498 rs7934178 chr11 94264473 C T 9.68E-07 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LOC643037 intron 22566498 rs16924610 chr11 94264656 T C 9.70E-07 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LOC643037 intron 22566498 rs12294732 chr11 94264882 G A 9.90E-07 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LOC643037 intron 22566498 rs11020812 chr11 94267117 T C 9.93E-07 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs16912567 chr11 94270005 A G 1.17E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11020821 chr11 94271663 C A 4.00E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11020821 chr11 94271663 C A 9.00E-07 Response to angiotensin II receptor blocker therapy / / 22566498 rs2230274 chr11 94278713 C T 3.52E-05 Bipolar disorder and schizophrenia FUT4 cds-synon 20889312 rs6483346 chr11 94288651 G C 4.30E-06 Urinary metabolites / / 21572414 rs7946385 chr11 94290449 C A 4.70E-06 Urinary metabolites / / 21572414 rs1815826 chr11 94307285 C T 6.27E-05 Lupus nephritis in systemic lupus erythematosus PIWIL4 intron 24925725 rs2212361 chr11 94312323 T C 9.00E-07 Attention deficit hyperactivity disorder symptoms (interaction) PIWIL4 intron 18846501 rs11020839 chr11 94313230 A G 5.08E-05 Bipolar disorder and schizophrenia PIWIL4 intron 20889312 rs1105465 chr11 94313757 A G 8.91E-05 Bipolar disorder and schizophrenia PIWIL4 intron 20889312 rs7342170 chr11 94314477 A T 9.73E-04 Multiple complex diseases PIWIL4 intron 17554300 rs10831244 chr11 94315307 C A 1.84E-05 Lupus nephritis in systemic lupus erythematosus PIWIL4 intron 24925725 rs7110167 chr11 94320237 T C 1.77E-05 Lupus nephritis in systemic lupus erythematosus PIWIL4 cds-synon 24925725 rs2186623 chr11 94320708 C T 7.26E-05 Bipolar disorder and schizophrenia PIWIL4 intron 20889312 rs2155100 chr11 94321398 C T 1.77E-05 Lupus nephritis in systemic lupus erythematosus PIWIL4 intron 24925725 rs2155099 chr11 94321986 T C 1.73E-05 Lupus nephritis in systemic lupus erythematosus PIWIL4 intron 24925725 rs10831246 chr11 94322695 T C 1.77E-05 Lupus nephritis in systemic lupus erythematosus PIWIL4 intron 24925725 rs7107559 chr11 94323674 C T 8.70E-07 Urinary metabolites PIWIL4 intron 21572414 rs7126782 chr11 94323840 T G 1.40E-06 Urinary metabolites PIWIL4 intron 21572414 rs515115 chr11 94328339 A T 5.11E-06 Type 2 diabetes PIWIL4 intron 21573907 rs476209 chr11 94332731 G T 7.17E-04 Amyotrophic Lateral Sclerosis PIWIL4 intron 17827064 rs649973 chr11 94333874 G A 2.55E-05 Lupus nephritis in systemic lupus erythematosus PIWIL4 intron 24925725 rs649944 chr11 94367296 T C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs561886 chr11 94397663 T C 8.63E-04 Coronary heart disease / / 21971053 rs555600 chr11 94398327 T A,C 3.15E-04 Smoking initiation / / 24665060 rs7931634 chr11 94399446 C T 2.53E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs643797 chr11 94404440 G A 2.70E-06 Odorant perception / / 23910658 rs2510950 chr11 94414398 C G 2.80E-05 Urinary metabolites / / 21572414 rs10741493 chr11 94438461 C T 2.40E-05 Urinary metabolites / / 21572414 rs4753145 chr11 94440853 C A 2.25E-11 Metabolite levels / / 22286219 rs4753146 chr11 94441066 G C 1.50E-05 Urinary metabolites / / 21572414 rs4475878 chr11 94453903 A G 1.50E-05 Urinary metabolites / / 21572414 rs1815907 chr11 94455919 G A 2.70E-05 Urinary metabolites / / 21572414 rs949161 chr11 94461297 C T 1.50E-05 Urinary metabolites / / 21572414 rs6483359 chr11 94462311 C T 8.70E-06 Urinary metabolites / / 21572414 rs2851584 chr11 94463156 T G 1.50E-05 Urinary metabolites / / 21572414 rs1430860 chr11 94471927 G A 5.64E-05 Osteoarthritis / / 19508968 rs12418045 chr11 94513070 T C 8.79E-09 Schizophrenia AMOTL1 intron 22440650 rs11020946 chr11 94538849 G A 7.69E-04 Multiple complex diseases AMOTL1 intron 17554300 rs2033367 chr11 94555708 G A 7.88E-04 Multiple complex diseases AMOTL1 intron 17554300 rs1486219 chr11 94570209 C G 9.90E-04 Multiple complex diseases AMOTL1 intron 17554300 rs1785863 chr11 94635095 C T 9.03E-81 Multiple complex diseases / / 17554300 rs689843 chr11 94657150 C T 6.18E-04 Multiple complex diseases / / 17554300 rs10831284 chr11 94667964 G A 2.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs7112323 chr11 94691391 T A 7.76E-06 White blood cell count / / 21738479 rs7937776 chr11 94697142 C T 2.42E-05 Breast cancer CWC15 intron 21060860 rs7937776 chr11 94697142 C T 7.00E-04 Alzheimer's disease (late onset) CWC15 intron 21460841 rs7103675 chr11 94702868 A G 7.41E-06 White blood cell count CWC15 intron 21738479 rs7930127 chr11 94703428 A G 5.13E-06 White blood cell count CWC15 intron 21738479 rs12804868 chr11 94712845 T G 8.49E-04 Tourette syndrome KDM4D intron 22889924 rs10501819 chr11 94722715 G A 2.80E-05 Lymphocyte counts KDM4D intron 22286170 rs1054532 chr11 94732407 G A 0.0006728 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KDM4D UTR-3 23233654 rs1054532 chr11 94732407 G A 6.73E-04 Methotrexate clearance (acute lymphoblastic leukemia) KDM4D UTR-3 23233662 rs2048174 chr11 94739144 G T 0.0006737 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2048174 chr11 94739144 G T 6.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11021009 chr11 94749970 C T 1.52E-04 Multiple complex diseases / / 17554300 rs2895576 chr11 94757600 C G 0.0005986 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2895576 chr11 94757600 C G 5.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10741501 chr11 94761019 T G 0.0005947 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10741501 chr11 94761019 T G 5.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7926605 chr11 94764892 G A 0.0005709 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7926605 chr11 94764892 G A 5.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs609921 chr11 94820472 T C 1.41E-04 Telomere length / / 21573004 rs4611172 chr11 94834270 G T 6.18E-05 Orofacial clefts ENDOD1 intron 22419666 rs654499 chr11 94843507 C A 5.80E-06 Alcohol and nictotine co-dependence ENDOD1 intron 22488850 rs3740862 chr11 94862288 G A 4.20E-04 Obesity (extreme) ENDOD1 missense 21935397 rs3740861 chr11 94862577 G T 4.39E-04 Amyotrophic Lateral Sclerosis ENDOD1 missense 17362836 rs586421 chr11 94865334 T C 9.76E-05 Lipoproteins ENDOD1 UTR-3 pha003079 rs10501821 chr11 94878090 A G 3.11E-05 Socioeconomic Factors / / pha003066 rs10831311 chr11 94882279 A C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11601341 chr11 94887947 G A 4.82E-04 Body mass index / / 21701565 rs12574604 chr11 94888163 G A 4.69E-04 Alzheimer's disease (late onset) / / 21379329 rs11021059 chr11 94894963 C A 2.22E-05 Multiple complex diseases / / 17554300 rs646667 chr11 94915978 T C 3.38E-04 Alcohol consumption (maxi-drinks) SESN3 intron 24277619 rs629508 chr11 94922399 T C 9.20E-04 Multiple complex diseases SESN3 intron 17554300 rs564954 chr11 94927115 T C 5.99E-04 Suicide attempts in bipolar disorder SESN3 intron 21423239 rs722531 chr11 94939234 A G 1.87E-04 Suicide attempts in bipolar disorder SESN3 intron 21423239 rs11021077 chr11 94944159 G T 2.47E-04 Suicide attempts in bipolar disorder SESN3 intron 21423239 rs10831320 chr11 94960017 A T 1.09E-04 Suicide attempts in bipolar disorder SESN3 intron 21423239 rs10765718 chr11 94978395 T C 4.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs1466327 chr11 94980027 C T 1.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs9888201 chr11 94981323 A G 1.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs9667295 chr11 94984115 T C 8.80E-07 Urinary metabolites / / 21572414 rs10458853 chr11 94984917 A G 6.54E-05 Suicide attempts in bipolar disorder / / 21423239 rs11021111 chr11 95003263 C G 7.98E-07 Asthma (childhood onset) / / 23829686 rs12283509 chr11 95037134 A G 1.87E-05 Cognitive test performance / / 20125193 rs12275549 chr11 95039414 G T 1.73E-05 Cognitive test performance / / 20125193 rs11021127 chr11 95053298 G A 9.78E-04 Type 2 diabetes / / 17463246 rs560489 chr11 95061176 C T 1.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10765731 chr11 95061245 A G 7.38E-04 Type 2 diabetes / / 17463246 rs486829 chr11 95062882 C T 6.86E-04 Type 2 diabetes / / 17463246 rs10831338 chr11 95064726 A G 7.41E-04 Type 2 diabetes / / 17463246 rs7125428 chr11 95068954 C T 6.59E-04 Type 2 diabetes / / 17463246 rs4082252 chr11 95071214 T C 4.62E-04 Type 2 diabetes / / 17463246 rs4753663 chr11 95073031 G A 6.98E-04 Type 2 diabetes / / 17463246 rs10831341 chr11 95090090 C G 6.47E-04 Type 2 diabetes / / 17463246 rs569612 chr11 95114053 C A 6.13E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs547531 chr11 95132416 C T 1.76E-04 Multiple complex diseases / / 17554300 rs4121869 chr11 95146203 G C 1.85E-04 Type 2 diabetes / / 17463246 rs4753674 chr11 95149268 C T 3.17E-04 Type 2 diabetes / / 17463246 rs541821 chr11 95161575 G A 4.24E-05 HIV-1 progression to AIDS and death / / 21811574 rs2510580 chr11 95167861 G A 3.24E-05 Iron status biomarkers / / 19084217 rs11821606 chr11 95197220 T C 5.66E-04 Type 2 diabetes / / 17463246 rs11821606 chr11 95197220 T C 8.38E-05 Magnesium levels / / pha003092 rs2156469 chr11 95229401 G A 1.20E-04 Alzheimer's disease (late onset) / / 21379329 rs6483426 chr11 95233592 A G 2.14E-04 Alzheimer's disease (late onset) / / 21379329 rs6483427 chr11 95234466 A C 2.07E-04 Alzheimer's disease (late onset) / / 21379329 rs10501828 chr11 95244209 G A 1.00E-04 Type 2 diabetes / / 17903298 rs4753686 chr11 95253056 C T 3.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4121809 chr11 95270802 T C 2.27E-05 Left ventricular hypertrophy / / pha003052 rs11606101 chr11 95290521 T C 5.29E-04 Nicotine dependence / / 17158188 rs4753176 chr11 95290854 G T 8.50E-17 Mean platelet volume / / 22423221 rs16922192 chr11 95291295 T C 5.94E-04 Multiple complex diseases / / 17554300 rs16922195 chr11 95292457 A G 3.81E-04 Nicotine dependence / / 17158188 rs7113885 chr11 95295377 A C,T 1.37E-04 Nicotine dependence / / 17158188 rs4409785 chr11 95311422 T C 6.00E-07 Multiple sclerosis / / 21833088 rs4409785 chr11 95311422 T C 2.00E-13 Vitiligo / / 22561518 rs4409785 chr11 95311422 T C 0.00000537 Graves' disease / / 22922229 rs4409785 chr11 95311422 T C 0.000354 Hashimoto's thyroiditis / / 22922229 rs4409785 chr11 95311422 T C 7.69E-08 Graves' disease and Hashimoto's thyroiditis / / 22922229 rs4409785 chr11 95311422 T C 1.00E-11 Rheumatoid arthritis / / 24390342 rs4409785 chr11 95311422 T C 4.00E-09 Rheumatoid arthritis / / 24390342 rs4409785 chr11 95311422 T C 4.30E-04 Rheumatoid arthritis / / 24390342 rs1255538 chr11 95319253 A G 5.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs11021232 chr11 95320808 T C 1.37E-08 Vitiligo / / 22561518 rs11021233 chr11 95320986 G A 2.67E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2254634 chr11 95327130 T C 8.27E-05 Erythrocyte counts / / pha003101 rs10831387 chr11 95350518 C A 6.30E-04 Type 2 diabetes / / 17463246 rs12365735 chr11 95368454 T A 2.95E-04 Type 2 diabetes / / 17463246 rs10831389 chr11 95371352 C A 5.56E-04 Type 2 diabetes / / 17463246 rs998939 chr11 95414613 C T 6.61E-05 Caffeine consumption / / 21490707 rs4237575 chr11 95417293 A C 1.75E-04 Type 2 diabetes / / 17463246 rs4237575 chr11 95417293 A C 8.32E-05 Multiple complex diseases / / 17554300 rs16922394 chr11 95419046 C T 6.66E-04 Multiple complex diseases / / 17554300 rs16922406 chr11 95421518 C T 4.50E-04 Multiple complex diseases / / 17554300 rs1939875 chr11 95422867 A G 3.00E-06 Eosinophilic esophagitis (pediatric) / / 20208534 rs1939875 chr11 95422867 A G 7.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2049621 chr11 95428288 G C 9.00E-04 Breast cancer / / 17529967 rs948075 chr11 95437738 A G 1.00E-06 Urinary metabolites / / 21572414 rs948075 chr11 95437738 A G 4.41E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1789300 chr11 95463632 G C 8.80E-04 Multiple complex diseases / / 17554300 rs1255182 chr11 95472391 C T 1.50E-04 Hypertension / / 21082022 rs1727164 chr11 95489184 G A 2.40E-05 Urinary metabolites / / 21572414 rs3748256 chr11 95521953 A G 1.36E-04 Hypertension FAM76B intron 21082022 rs1784135 chr11 95531748 G A 1.97E-04 Hypertension CEP57 intron 21082022 rs546809 chr11 95579938 A G 7.10E-05 Bone mass and geometry MTMR2 intron 17903296 rs693364 chr11 95621926 A G 6.71E-05 Hypertension MTMR2 intron 21082022 rs41496451 chr11 95635241 G C 5.12E-04 Type 2 diabetes MTMR2 intron 17463246 rs11021348 chr11 95655481 G A 3.30E-05 Response to statin therapy MTMR2 intron 20339536 rs10765777 chr11 95656385 A C 7.84E-05 Hypertension MTMR2 intron 21082022 rs3808977 chr11 95657761 A G 1.08E-04 Hypertension MTMR2 nearGene-5 21082022 rs1940163 chr11 95707042 C A 7.53E-04 Heart Failure / / pha002884 rs11021362 chr11 95707213 G A 4.11E-04 Blood pressure / / 17255346 rs62028 chr11 95733239 A C 1.28E-05 Lung function (forced expiratory volume in 1 second) MAML2 intron pha003102 rs62028 chr11 95733239 A C 8.92E-05 Lung function (forced vital capacity) MAML2 intron pha003104 rs561981 chr11 95737387 A G 1.04E-05 Lung function (forced expiratory volume in 1 second) MAML2 intron pha003102 rs561981 chr11 95737387 A G 7.27E-05 Lung function (forced vital capacity) MAML2 intron pha003104 rs607395 chr11 95756412 G A 3.18E-04 Alcohol dependence MAML2 intron 21314694 rs600873 chr11 95762965 A G 4.29E-04 Type 2 diabetes MAML2 intron 17463246 rs7934164 chr11 95778278 T C 2.79E-05 Hypertension (early onset hypertension) MAML2 intron 22479346 rs11021404 chr11 95783686 C T 2.20E-05 Urinary metabolites MAML2 intron 21572414 rs7941059 chr11 95785245 T G 8.70E-04 Major depressive disorder MAML2 intron 21042317 rs1939485 chr11 95808391 C T 3.05E-04 Parkinson's disease MAML2 intron 16252231 rs10501843 chr11 95840120 G A 1.80E-04 Crohn's disease MAML2 intron 17684544 rs1074742 chr11 95840436 A G 1.20E-04 Crohn's disease MAML2 intron 17684544 rs2155227 chr11 95841812 T C 6.12E-04 Suicide attempts in bipolar disorder MAML2 intron 21423239 rs12281661 chr11 95850908 C T 1.80E-04 Insulin resistance MAML2 intron 21901158 rs10765791 chr11 95854094 C T 6.60E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) MAML2 intron 23648065 rs7930909 chr11 95865884 A G 6.76E-05 Response to cholinesterase inhibitors in Alzheimer's disease MAML2 intron 23374588 rs10765792 chr11 95866700 G C 8.00E-13 Sudden cardiac arrest MAML2 intron 21658281 rs10501844 chr11 95870218 T C 8.50E-04 Type 2 diabetes and 6 quantitative traits MAML2 intron 17848626 rs488303 chr11 95884157 T C 8.68E-04 Multiple complex diseases MAML2 intron 17554300 rs515200 chr11 95884567 A T 9.53E-04 Multiple complex diseases MAML2 intron 17554300 rs531686 chr11 95897852 C A 1.60E-05 Urinary metabolites MAML2 intron 21572414 rs12281547 chr11 95902117 A G 1.55E-04 Smoking cessation MAML2 intron 24665060 rs523519 chr11 95929945 C A 3.93E-10 Matrix metalloproteinase levels MAML2 intron 20031604 rs11021469 chr11 95937792 G A 9.14E-04 Multiple complex diseases MAML2 intron 17554300 rs16923264 chr11 95938418 A C 6.33E-04 Suicide attempts in bipolar disorder MAML2 intron 21423239 rs10501846 chr11 95952664 T G 5.28E-08 Matrix metalloproteinase levels MAML2 intron 20031604 rs16923343 chr11 95953493 G A 2.80E-05 Malaria MAML2 intron 19465909 rs12417347 chr11 95957204 A G 8.88E-08 Matrix metalloproteinase levels MAML2 intron 20031604 rs12417347 chr11 95957204 A G 7.45E-04 Alcohol dependence MAML2 intron 20201924 rs693182 chr11 95970204 A C 8.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAML2 intron 20877124 rs527077 chr11 95972510 C T 6.97E-04 Depression (quantitative trait) MAML2 intron 20800221 rs573191 chr11 95975117 C G 6.18E-04 Depression (quantitative trait) MAML2 intron 20800221 rs544656 chr11 95975925 G T 5.97E-05 Glaucoma (primary open-angle) MAML2 intron 22605921 rs566607 chr11 95986160 G T 8.31E-04 Amyotrophic lateral sclerosis (sporadic) MAML2 intron 24529757 rs11021499 chr11 95992129 G A 2.00E-06 Waist-to-hip circumference ratio (interaction) MAML2 intron 23192594 rs11021504 chr11 95995448 T A 8.00E-09 Height MAML2 intron 23456168 rs7115578 chr11 96000100 G A 8.00E-06 Response to treatment for acute lymphoblastic leukemia MAML2 intron 19176441 rs4598633 chr11 96011351 T C 6.43E-04 Multiple complex diseases MAML2 intron 17554300 rs485842 chr11 96023214 C T 2.00E-06 Corneal astigmatism MAML2 intron 23322567 rs483905 chr11 96023427 G A 1.00E-08 Ulcerative colitis MAML2 intron 23128233 rs16923522 chr11 96035344 A G 9.98E-04 Insulin resistance MAML2 intron 21901158 rs575698 chr11 96035952 G A 3.29E-04 Myocardial Infarction MAML2 intron pha002873 rs559477 chr11 96041692 C A 2.21E-05 Psoriasis MAML2 intron 20953190 rs559477 chr11 96041692 C A 1.03E-06 Type 2 diabetes MAML2 intron 21799836 rs494901 chr11 96049343 T C 7.79E-05 Cognitive impairment induced by topiramate MAML2 intron 22091778 rs11606555 chr11 96052081 T C 2.51E-04 Multiple complex diseases MAML2 intron 17554300 rs4753195 chr11 96058245 C T 4.47E-08 Urate (in serum),gout MAML2 intron 21818773 rs4753196 chr11 96061468 C A 6.26E-05 Cognitive impairment induced by topiramate MAML2 intron 22091778 rs10831508 chr11 96064480 T C 3.97E-05 Multiple complex diseases MAML2 intron 17554300 rs16923548 chr11 96088967 A C 1.62E-04 Depression (quantitative trait) CCDC82 intron 20800221 rs549010 chr11 96096973 A G 7.29E-05 Relative hand skill in reading disability CCDC82 intron 24068947 rs7118648 chr11 96108428 T C 2.00E-07 Parkinson's disease CCDC82 intron 23793441 rs7118648 chr11 96108428 T C 6.44E-05 Smoking initiation CCDC82 intron 24665060 rs2043965 chr11 96155649 G A 4.06E-05 Telomere length / / 23001564 rs12803308 chr11 96180609 T A 4.20E-04 Multiple complex diseases / / 17554300 rs1159169 chr11 96203545 C A 2.89E-04 Alzheimer's disease / / 17998437 rs34717128 chr11 96233803 T A 1.17E-04 Cocaine dependence / / 23958962 rs34717128 chr11 96233803 T A 4.73E-05 Cocaine dependence / / 23958962 rs10501855 chr11 96243189 G A 5.50E-04 Diabetic retinopathy / / 20871662 rs10501856 chr11 96243337 G T 2.16E-05 Schizophrenia / / 20185149 rs10501856 chr11 96243337 G T 3.77E-05 Bipolar disorder / / 20451256 rs3019791 chr11 96267523 A G 2.86E-04 White matter integrity / / 22425255 rs11212360 chr11 96467331 C T 4.07E-09 Matrix metalloproteinase levels / / 20031604 rs4320978 chr11 96472454 A G 3.27E-09 Matrix metalloproteinase levels / / 20031604 rs7104014 chr11 96520378 A C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs11225538 chr11 96521055 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1371352 chr11 96528019 A G 9.63E-05 Meningococcal disease / / 20694013 rs11212819 chr11 96579677 C T 9.65E-04 Multiple complex diseases / / 17554300 rs3019723 chr11 96581502 T C 3.04E-09 Matrix metalloproteinase levels / / 20031604 rs3019692 chr11 96601256 C A 3.33E-09 Matrix metalloproteinase levels / / 20031604 rs1439528 chr11 96610573 G A 5.82E-09 Matrix metalloproteinase levels / / 20031604 rs11215374 chr11 96641718 C T 6.50E-05 Personality dimensions / / 18957941 rs7946451 chr11 96651973 C G 1.85E-04 Type 2 diabetes / / 17463246 rs11216411 chr11 96664995 T C 4.57E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10501864 chr11 96666580 A C 5.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs1155410 chr11 96667409 A G 2.20E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7928356 chr11 96747342 C T 2.88E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17129669 chr11 96752463 A G 6.32E-04 Multiple complex diseases / / 17554300 rs17129671 chr11 96757238 T C 5.90E-04 Multiple complex diseases / / 17554300 rs17129673 chr11 96757271 A G 6.62E-04 Multiple complex diseases / / 17554300 rs17129675 chr11 96758011 G T 7.19E-04 Multiple complex diseases / / 17554300 rs17129677 chr11 96758216 C G 3.54E-04 Multiple complex diseases / / 17554300 rs1944794 chr11 96765069 G A 6.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10501865 chr11 96774339 C T 3.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2198343 chr11 96778370 T C 4.26E-04 Multiple complex diseases / / 17554300 rs1944796 chr11 96798130 A G 6.16E-04 Multiple complex diseases / / 17554300 rs596117 chr11 96804619 G A 3.89E-04 Type 2 diabetes / / 17463246 rs1944782 chr11 96809030 A G 3.41E-05 Pancreatic cancer / / 23180869 rs10894523 chr11 96812443 A G 8.24E-05 Information processing speed / / 21130836 rs1944788 chr11 96818703 T C 1.88E-05 Pancreatic cancer / / 23180869 rs587952 chr11 96823387 T C 2.30E-04 Type 2 diabetes / / 17463246 rs475420 chr11 96829897 C T 1.00E-05 Iron levels / / 21208937 rs4753975 chr11 96832383 G A 8.01E-05 Information processing speed / / 21130836 rs17275283 chr11 96841814 T C 4.68E-06 Rheumatoid arthritis / / 19503088 rs17275283 chr11 96841814 T C 2.30E-05 Asthma / / 20159242 rs17275283 chr11 96841814 T C 1.30E-05 Pancreatic cancer / / 23180869 rs11224253 chr11 96845364 C T 1.00E-04 Information processing speed / / 21130836 rs12420935 chr11 96853065 A G 3.94E-05 Formal thought disorder in schizophrenia / / 22648509 rs11224280 chr11 96853779 T G 3.10E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7124287 chr11 96870233 G A 8.85E-04 Nicotine dependence / / 17158188 rs4754011 chr11 96942393 G A 4.09E-05 LDL lipoproteins / / pha002902 rs11224899 chr11 96959525 G A 2.00E-06 Formal thought disorder in schizophrenia / / 22648509 rs1793393 chr11 96965058 T A 1.99E-04 Insulin resistance / / 21901158 rs11224938 chr11 96965192 C G 2.61E-05 Formal thought disorder in schizophrenia / / 22648509 rs2511481 chr11 96974220 G C 1.38E-04 Insulin resistance / / 21901158 rs17129847 chr11 96993848 A G 4.57E-04 Multiple complex diseases / / 17554300 rs7943518 chr11 96997312 C T 6.86E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1793368 chr11 97015874 G A 1.73E-04 Smoking initiation / / 24665060 rs1793370 chr11 97017572 G A 1.94E-04 Smoking initiation / / 24665060 rs1494035 chr11 97019713 G A 1.14E-04 Smoking initiation / / 24665060 rs1690596 chr11 97039583 A G 1.81E-04 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs1793372 chr11 97040910 A C 1.81E-04 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs4754859 chr11 97058949 T C 2.01E-04 Multiple complex diseases / / 17554300 rs7932634 chr11 97084310 C T 1.36E-04 Multiple complex diseases / / 17554300 rs6590995 chr11 97084405 T C 4.75E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs12285889 chr11 97162056 A G 9.04E-08 Breast cancer / / 20852631 rs1834639 chr11 97162589 C A 4.00E-05 Prostate cancer / / 21743057 rs1426651 chr11 97176319 T C 0.00000229 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs1426651 chr11 97176319 T C 0.00000313 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs1426631 chr11 97177669 G C 1.50E-05 Urinary metabolites / / 21572414 rs17130037 chr11 97209178 G A 2.30E-05 Urinary metabolites / / 21572414 rs10501872 chr11 97214831 G A 4.03E-04 Bone mass and geometry / / 17903296 rs7946324 chr11 97234412 A G 3.33E-05 Aging (time to event) / / 21782286 rs10160323 chr11 97280822 A G 3.89E-04 Multiple complex diseases / / 17554300 rs11226595 chr11 97301408 C T 2.00E-04 Acute lung injury / / 22295056 rs921562 chr11 97301729 T C 3.48E-04 Acute lung injury / / 22295056 rs4426160 chr11 97302684 T A 3.16E-04 Acute lung injury / / 22295056 rs2060877 chr11 97305601 G T 6.30E-05 Response to statin therapy / / 20339536 rs1840056 chr11 97306044 C G 5.77E-04 Acute lung injury / / 22295056 rs17285355 chr11 97306158 G A 1.83E-04 White matter integrity / / 22425255 rs4303261 chr11 97308755 G T 4.45E-04 Acute lung injury / / 22295056 rs4533067 chr11 97312382 G A 4.66E-04 Acute lung injury / / 22295056 rs11226636 chr11 97313035 A C,T 6.45E-04 Acute lung injury / / 22295056 rs11226646 chr11 97314378 A G 4.29E-04 Acute lung injury / / 22295056 rs1869208 chr11 97316670 G T 4.30E-04 White matter integrity / / 22425255 rs1869208 chr11 97316670 G T 7.55E-05 Epilepsy (remission after treatment) / / 23962720 rs4598702 chr11 97316840 G A 5.71E-04 Acute lung injury / / 22295056 rs12361829 chr11 97316883 A T 5.58E-04 Acute lung injury / / 22295056 rs2198326 chr11 97321326 T C 2.75E-04 Acute lung injury / / 22295056 rs1452669 chr11 97321493 T C 5.03E-04 Acute lung injury / / 22295056 rs12362067 chr11 97351349 G T 3.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs11226865 chr11 97382880 G A 4.64E-10 Matrix metalloproteinase levels / / 20031604 rs12049798 chr11 97388680 G A 8.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2601669 chr11 97407844 G A 6.46E-04 Body mass index / / 21701565 rs1381981 chr11 97469005 A G 3.75E-04 White matter integrity / / 22425255 rs1477627 chr11 97499847 C G 1.41E-06 Bilirubin levels,in serum / / 19389676 rs11820294 chr11 97501053 T C 5.84E-05 Pulmonary function / / 19300500 rs11212364 chr11 97574984 A G 3.00E-06 Information processing speed / / 21130836 rs12030343 chr11 97608050 C T 0.0000764 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12274023 chr11 97608622 A G 7.54E-04 Multiple complex diseases / / 17554300 rs12275494 chr11 97608704 T C 8.68E-04 Type 2 diabetes / / 17463246 rs12275494 chr11 97608704 T C 5.36E-04 Multiple complex diseases / / 17554300 rs10890824 chr11 97614840 T C 4.86E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs925425 chr11 97620700 G T 2.14E-04 Height / / 17255346 rs925425 chr11 97620700 G T 7.63E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2897122 chr11 97624171 A G 7.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2897122 chr11 97624171 A G 4.07E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1039951 chr11 97624373 G A 5.00E-06 Asthma / / 21790008 rs10501874 chr11 97631874 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1960997 chr11 97643824 T C 6.38E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs12577978 chr11 97667822 G A 8.43E-04 Type 2 diabetes / / 17463246 rs2405657 chr11 97682564 A G 3.00E-06 Amyotrophic lateral sclerosis / / 19734901 rs2851619 chr11 97707396 A G 6.17E-05 Coronary restenosis / / 21878436 rs2851619 chr11 97707396 A G 4.40E-05 Coronary heart disease / / pha003035 rs2851623 chr11 97709396 A C 5.94E-05 Coronary restenosis / / 21878436 rs2246397 chr11 97723251 T C 4.88E-06 Bipolar disorder / / 20451256 rs2443008 chr11 97724930 T C 4.41E-05 Coronary restenosis / / 21878436 rs949175 chr11 97737007 G T 9.70E-06 Sleep and circadian phenotypes / / 17903308 rs10890990 chr11 97737457 T C 0.0008597 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10890990 chr11 97737457 T C 8.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2851649 chr11 97749744 A C 2.80E-05 Urinary metabolites / / 21572414 rs1815913 chr11 97852498 C T 6.14E-09 Matrix metalloproteinase levels / / 20031604 rs4326759 chr11 97862555 A C 2.70E-05 Information processing speed / / 21130836 rs11213519 chr11 97863145 T A 9.85E-04 Multiple complex diseases / / 17554300 rs4590838 chr11 97867665 T C 4.03E-05 Cardiovascular disease / / 17903304 rs10789792 chr11 97870079 T C 6.90E-05 Serum metabolites / / 19043545 rs10891169 chr11 97871998 G T 9.99E-05 Serum metabolites / / 19043545 rs3016276 chr11 97879764 A T 7.97E-05 Serum metabolites / / 19043545 rs593860 chr11 97895628 C T 3.92E-06 Triglycerides / / 19074352 rs593860 chr11 97895628 C T 3.92E-06 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs1941852 chr11 97900222 C T 3.76E-05 Multiple complex diseases / / 17554300 rs1941852 chr11 97900222 C T 0.00000791 Transmission distortion / / 22377632 rs11213776 chr11 97917823 T C 2.78E-04 Taste perception / / 22132133 rs11213924 chr11 97945697 G A 1.71E-12 Matrix metalloproteinase levels / / 20031604 rs17130463 chr11 97958577 A G 2.08E-04 Multiple complex diseases / / 17554300 rs3018249 chr11 98035433 T G 2.61E-11 Matrix metalloproteinase levels / / 20031604 rs2252684 chr11 98047380 C T 1.74E-05 QT interval / / 22726844 rs11214383 chr11 98080379 T C 4.58E-06 Bipolar disorder and schizophrenia / / 20889312 rs2155907 chr11 98094673 C T 2.02E-07 Bipolar disorder and schizophrenia / / 20889312 rs2155907 chr11 98094673 C T 4.02E-05 Schizophrenia / / pha002857 rs2848520 chr11 98098071 A G 1.01E-06 Bipolar disorder and schizophrenia / / 20889312 rs1941776 chr11 98104605 T C 1.74E-06 Bipolar disorder and schizophrenia / / 20889312 rs12275115 chr11 98105040 T C 7.66E-04 Taste perception / / 22132133 rs2848519 chr11 98113179 C G,T 1.72E-06 Bipolar disorder and schizophrenia / / 20889312 rs2848547 chr11 98123504 T C 3.52E-06 Bipolar disorder and schizophrenia / / 20889312 rs2848546 chr11 98124120 G A 1.59E-05 Bipolar disorder and schizophrenia / / 20889312 rs2509843 chr11 98125404 A G 6.42E-04 Multiple complex diseases / / 17554300 rs2509843 chr11 98125404 A G 2.00E-07 Bipolar disorder and schizophrenia / / 20889312 rs2509843 chr11 98125404 A G 1.10E-06 Schizophrenia / / 21926974 rs2509843 chr11 98125404 A G 4.70E-05 Schizophrenia / / pha002857 rs7939072 chr11 98130056 C T 6.31E-13 Matrix metalloproteinase levels / / 20031604 rs11214631 chr11 98148444 C G 1.23E-05 Schizophrenia(age at onset) / / 21688384 rs2852044 chr11 98148532 A G 2.70E-05 Urinary metabolites / / 21572414 rs2848538 chr11 98148962 A G 1.00E-05 Urinary metabolites / / 21572414 rs2155908 chr11 98151662 C T 2.77E-04 Multiple complex diseases / / 17554300 rs10891572 chr11 98153408 A G 2.40E-04 Multiple complex diseases / / 17554300 rs2155910 chr11 98156718 G T 9.57E-05 Personality dimensions / / 18957941 rs12224719 chr11 98176280 C T 8.37E-04 Multiple complex diseases / / 17554300 rs2155912 chr11 98179489 A G 9.34E-08 Matrix metalloproteinase levels / / 20031604 rs10891713 chr11 98256358 A G 4.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs11215078 chr11 98256475 T C,G 3.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs12418117 chr11 98257308 A C 7.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs1156412 chr11 98259014 G C 3.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs982159 chr11 98260573 G A 4.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs7926001 chr11 98262121 C T 8.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs7929155 chr11 98263094 G A 3.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs1482235 chr11 98264664 A G 3.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs11215167 chr11 98269359 G A 4.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs10891732 chr11 98269429 T G 2.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs1941758 chr11 98270813 A G 2.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs7122788 chr11 98271679 C A 7.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs1482230 chr11 98275861 A G 1.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs2007479 chr11 98276249 C G 1.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs10891756 chr11 98277303 C A 1.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs12787881 chr11 98282311 C G 1.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs11822227 chr11 98287360 A G 5.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs10790053 chr11 98289956 A G 7.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs4754509 chr11 98290805 G A 6.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs1586036 chr11 98297755 G A 8.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs7483729 chr11 98298601 T C 7.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs1482236 chr11 98298980 G A 6.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs1905105 chr11 98302199 A T 6.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs10790062 chr11 98302817 C T 6.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs10790062 chr11 98302817 C T 6.28E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs2062111 chr11 98303732 T A 6.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs12418504 chr11 98318463 A G 6.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs4603275 chr11 98320413 G A 1.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs2406083 chr11 98328998 C G 6.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs10891845 chr11 98338008 G T 1.80E-05 Urinary metabolites / / 21572414 rs11215567 chr11 98343357 G A 2.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs7937906 chr11 98370464 G A 3.73E-05 Odorant perception / / 23910658 rs2128235 chr11 98377248 T C 6.39E-04 Acute lung injury / / 22295056 rs7113171 chr11 98424151 C G 2.29E-04 Smoking quantity / / 24665060 rs17132191 chr11 98430156 C G 3.08E-04 Multiple complex diseases / / 17554300 rs10790140 chr11 98432196 G A 7.35E-08 Matrix metalloproteinase levels / / 20031604 rs7127964 chr11 98445530 C T 5.50E-06 Urinary metabolites / / 21572414 rs4342998 chr11 98448486 A C 1.89E-08 Matrix metalloproteinase levels / / 20031604 rs11216033 chr11 98457484 T C 5.30E-05 Major depressive disorder / / 21042317 rs4237591 chr11 98466268 T C 2.00E-06 Non-alcoholic fatty liver disease histology (lobular) / / 20708005 rs10892026 chr11 98474723 G A 9.83E-05 Pulmonary function in asthmatics / / 23541324 rs11216155 chr11 98481393 A G 8.76E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7102022 chr11 98483202 A G 3.29E-05 Pulmonary function in asthmatics / / 23541324 rs1348515 chr11 98495905 G A 9.34E-04 Multiple complex diseases / / 17554300 rs3018592 chr11 98503193 C T 8.26E-04 Multiple complex diseases / / 17554300 rs7927687 chr11 98505749 G A 6.30E-04 Multiple complex diseases / / 17554300 rs17340054 chr11 98509312 T G 1.70E-05 Urinary metabolites / / 21572414 rs3018579 chr11 98522540 G A 6.20E-04 Multiple complex diseases / / 17554300 rs7944933 chr11 98540929 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10892118 chr11 98543218 G A 4.31E-04 Multiple complex diseases / / 17554300 rs2435563 chr11 98553932 G T 9.35E-05 Hypertension / / pha003041 rs11216529 chr11 98573005 G A 9.34E-05 Relative hand skill in reading disability / / 24068947 rs1430468 chr11 98582099 G T 5.67E-05 Relative hand skill in reading disability / / 24068947 rs11216640 chr11 98591309 C T 9.04E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11216640 chr11 98591309 C T 6.80E-05 Relative hand skill in reading disability / / 24068947 rs3858427 chr11 98596131 C T 6.02E-15 Gallbladder disease / / pha001404 rs2897423 chr11 98596988 G A 9.63E-05 Relative hand skill in reading disability / / 24068947 rs12577421 chr11 98599094 C G 0.0000699 Panic disorder / / 23149450 rs12577421 chr11 98599094 C G 6.99E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs11216681 chr11 98599280 A G 5.62E-05 Relative hand skill in reading disability / / 24068947 rs963069 chr11 98605131 T C 4.45E-04 Schizophrenia / / 20832056 rs1548014 chr11 98614136 A G 8.76E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4754540 chr11 98625050 C T 9.62E-05 Epilepsy (remission after treatment) / / 23962720 rs6589662 chr11 98630194 A G 8.58E-05 Epilepsy (remission after treatment) / / 23962720 rs11217082 chr11 98687504 T A 4.55E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11217223 chr11 98723216 A G 1.00E-06 Obesity-related traits / / 23251661 rs11217223 chr11 98723216 A G 6.00E-06 Obesity-related traits / / 23251661 rs4754552 chr11 98733632 G A 4.29E-04 Iron levels / / pha002876 rs11217332 chr11 98756238 T C 8.09E-08 Matrix metalloproteinase levels / / 20031604 rs1601690 chr11 98761743 T C 8.84E-08 Matrix metalloproteinase levels / / 20031604 rs11217456 chr11 98772583 C T 2.80E-08 Matrix metalloproteinase levels / / 20031604 rs7944622 chr11 98774134 G A 6.59E-08 Matrix metalloproteinase levels / / 20031604 rs7947532 chr11 98774163 G C 2.80E-08 Matrix metalloproteinase levels / / 20031604 rs1021272 chr11 98811260 C T 1.58E-04 Bipolar disorder / / 18317468 rs3990898 chr11 98836091 C T 2.57E-05 Biliary atresia / / 20460270 rs35852551 chr11 98842306 G A 2.29E-04 Alzheimer's disease (late onset) / / 21379329 rs11217901 chr11 98849957 C T 9.06E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11217902 chr11 98849990 C T 7.74E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs901541 chr11 98850459 A G 1.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs901541 chr11 98850459 A G 5.22E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs901541 chr11 98850459 A G 2.16E-05 Chronic Hepatitis C infection / / 21725309 rs11604871 chr11 98879110 G A 1.12E-04 Insulin resistance / / 21901158 rs6589849 chr11 98886331 C A 2.39E-05 Post-operative nausea and vomiting / / 21694509 rs6589849 chr11 98886331 C A 0.0001 Migraine / / 22678113 rs17132819 chr11 98894449 A T 8.32E-04 Multiple complex diseases CNTN5 intron 17554300 rs7948049 chr11 98897805 C A 3.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CNTN5 intron 20877124 rs7948049 chr11 98897805 C A 7.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CNTN5 intron 20877124 rs10501897 chr11 98907603 G T 1.30E-05 Urinary metabolites CNTN5 intron 21572414 rs10501898 chr11 98907905 G A 2.77E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CNTN5 intron 20877124 rs10501898 chr11 98907905 G A 1.40E-05 Urinary metabolites CNTN5 intron 21572414 rs11218223 chr11 98921797 G A 1.50E-05 Urinary metabolites CNTN5 intron 21572414 rs10892719 chr11 98927114 C T 2.40E-05 Urinary metabolites CNTN5 intron 21572414 rs10790433 chr11 98927719 A T 1.60E-05 Urinary metabolites CNTN5 intron 21572414 rs4271353 chr11 98930223 C G 1.40E-05 Urinary metabolites CNTN5 intron 21572414 rs10750186 chr11 98933163 A G 2.30E-05 Urinary metabolites CNTN5 intron 21572414 rs7115136 chr11 98935203 A G 9.03E-05 Multiple complex diseases CNTN5 intron 17554300 rs12276707 chr11 98935946 C G 1.06E-04 Multiple complex diseases CNTN5 intron 17554300 rs10892755 chr11 98952517 A G 3.35E-04 Multiple complex diseases CNTN5 intron 17554300 rs17133035 chr11 98983412 C A 2.19E-04 Rheumatoid arthritis CNTN5 intron 21452313 rs4753939 chr11 98988308 A G 1.05E-05 Male fertility CNTN5 intron 22633400 rs11218459 chr11 98990381 G A 5.34E-10 Multiple complex diseases CNTN5 intron 17554300 rs7109365 chr11 98995954 C T 2.96E-06 Parent of origin effect on language impairment (child trend) CNTN5 intron 24571439 rs7105720 chr11 99013080 G C 0.00000946 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment CNTN5 intron 23392654 rs7105720 chr11 99013080 G C 9.46E-06 Thiazide-induced adverse metabolic effects in hypertensive patients CNTN5 intron 23400010 rs1940505 chr11 99013167 A C 0.00000874 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment CNTN5 intron 23392654 rs1940505 chr11 99013167 A C 8.74E-06 Thiazide-induced adverse metabolic effects in hypertensive patients CNTN5 intron 23400010 rs1940504 chr11 99013221 C T 0.00000827 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment CNTN5 intron 23392654 rs1940504 chr11 99013221 C T 8.27E-06 Thiazide-induced adverse metabolic effects in hypertensive patients CNTN5 intron 23400010 rs1940503 chr11 99013312 T C 0.00000922 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment CNTN5 intron 23392654 rs1940503 chr11 99013312 T C 9.22E-06 Thiazide-induced adverse metabolic effects in hypertensive patients CNTN5 intron 23400010 rs7933061 chr11 99013895 C T 0.00000806 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment CNTN5 intron 23392654 rs7933061 chr11 99013895 C T 8.06E-06 Thiazide-induced adverse metabolic effects in hypertensive patients CNTN5 intron 23400010 rs6589911 chr11 99014189 T A 2.20E-05 Urinary metabolites CNTN5 intron 21572414 rs12789966 chr11 99041999 A G 9.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) CNTN5 intron 23648065 rs7114546 chr11 99044554 C A 9.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) CNTN5 intron 23648065 rs2100832 chr11 99060807 G A 3.28E-05 Intracerebral hemorrhage CNTN5 intron 24656865 rs898777 chr11 99089028 C T 2.68E-05 Tunica Media CNTN5 intron pha003036 rs4754595 chr11 99090508 A G 4.90E-05 Chronic obstructive pulmonary disease CNTN5 intron 19300482 rs1461687 chr11 99093769 G A 2.45E-05 Response to tocilizumab in rheumatoid arthritis CNTN5 intron 22491018 rs1461684 chr11 99096479 A G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CNTN5 intron 22628534 rs7947162 chr11 99101320 A G 3.50E-04 Myasthenia gravis CNTN5 intron 23055271 rs11607090 chr11 99115770 T A 8.09E-08 Matrix metalloproteinase levels CNTN5 intron 20031604 rs17659971 chr11 99122404 C G 4.52E-04 Type 2 diabetes CNTN5 intron 17463246 rs6589988 chr11 99126016 A G 5.45E-04 Parkinson's disease CNTN5 intron 17052657 rs12421122 chr11 99154402 C T 3.52E-05 Chronic obstructive pulmonary disease CNTN5 intron 19300482 rs12577504 chr11 99165666 C T 8.16E-05 Chronic obstructive pulmonary disease CNTN5 intron 19300482 rs10501905 chr11 99184602 C T 8.55E-04 Obesity (extreme) CNTN5 intron 21935397 rs7937128 chr11 99185423 G T 7.91E-04 Multiple complex diseases CNTN5 intron 17554300 rs12576370 chr11 99191617 C T 7.59E-05 Chronic obstructive pulmonary disease CNTN5 intron 19300482 rs10893131 chr11 99201317 G T 4.52E-04 Tourette syndrome CNTN5 intron 22889924 rs1381330 chr11 99203450 A G 3.07E-05 Hypertension CNTN5 intron 22384028 rs9645670 chr11 99224406 A G 4.32E-05 Heart Rate CNTN5 intron pha003051 rs12273886 chr11 99225174 T A 5.82E-04 Response to cytadine analogues (cytosine arabinoside) CNTN5 intron 24483146 rs2102272 chr11 99241675 G T 6.38E-04 Tourette syndrome CNTN5 intron 22889924 rs12574856 chr11 99241865 C T 1.00E-04 Information processing speed CNTN5 intron 21130836 rs12792538 chr11 99243087 A G 2.93E-06 Heart Rate CNTN5 intron pha003051 rs4754610 chr11 99244104 C A 3.17E-05 Heart Rate CNTN5 intron pha003051 rs1504731 chr11 99255306 A C 3.17E-05 Heart Rate CNTN5 intron pha003051 rs11219732 chr11 99257825 C T 4.47E-06 Chronic obstructive pulmonary disease CNTN5 intron 19300482 rs11219741 chr11 99262251 C T 7.10E-04 Tourette syndrome CNTN5 intron 22889924 rs2466907 chr11 99290400 A T 5.76E-04 Smoking cessation CNTN5 intron 24665060 rs7131217 chr11 99309008 A G 2.00E-04 Cognitive impairment induced by topiramate CNTN5 intron 22091778 rs2656172 chr11 99321743 T C 1.00E-04 Cognitive impairment induced by topiramate CNTN5 intron 22091778 rs2656172 chr11 99321743 T C 5.75E-06 Cognitive impairment induced by topiramate CNTN5 intron 22091778 rs2726399 chr11 99322698 C T 5.32E-05 Cognitive impairment induced by topiramate CNTN5 intron 22091778 rs2726399 chr11 99322698 C T 6.56E-05 Cognitive impairment induced by topiramate CNTN5 intron 22091778 rs2726396 chr11 99324035 G A 4.44E-05 Cognitive impairment induced by topiramate CNTN5 intron 22091778 rs2726396 chr11 99324035 G A 4.68E-05 Cognitive impairment induced by topiramate CNTN5 intron 22091778 rs2726363 chr11 99347724 T A 6.62E-05 Attention deficit hyperactivity disorder CNTN5 intron pha002875 rs2726417 chr11 99377407 T C 9.86E-04 Response to taxane treatment (placlitaxel) CNTN5 intron 23006423 rs7950260 chr11 99378256 A C 9.70E-04 Alzheimer's disease CNTN5 intron 24755620 rs17133656 chr11 99379174 T C 3.61E-04 Multiple complex diseases CNTN5 intron 17554300 rs2466912 chr11 99386817 G A 1.06E-12 Matrix metalloproteinase levels CNTN5 intron 20031604 rs10501915 chr11 99392516 C T 4.78E-04 Type 2 diabetes CNTN5 intron 17846125 rs10750313 chr11 99398320 T C 1.64E-08 Matrix metalloproteinase levels CNTN5 intron 20031604 rs11220314 chr11 99399190 A G 2.50E-05 Urinary metabolites CNTN5 intron 21572414 rs11220314 chr11 99399190 A G 5.75E-04 Response to taxane treatment (placlitaxel) CNTN5 intron 23006423 rs2726355 chr11 99455061 G A 9.75E-05 Amyotrophic lateral sclerosis CNTN5 intron 20801717 rs2726355 chr11 99455061 G A 1.68E-04 Stroke CNTN5 intron pha002887 rs7117574 chr11 99462465 G A 9.79E-05 Amyotrophic lateral sclerosis CNTN5 intron 20801717 rs10501918 chr11 99466202 C G 2.40E-05 Cardiovascular disease CNTN5 intron 17903304 rs2019576 chr11 99482918 G A 5.55E-04 Intracranial aneurysm CNTN5 intron 20613766 rs12276555 chr11 99485849 T C 5.60E-04 Type 2 diabetes CNTN5 intron 17463246 rs11220658 chr11 99489014 G A 2.37E-09 Matrix metalloproteinase levels CNTN5 intron 20031604 rs12807920 chr11 99491537 C T 6.50E-05 Obesity,menopause CNTN5 intron 21424828 rs10501920 chr11 99493173 C G 9.00E-06 Atrial fibrillation CNTN5 intron 17903304 rs7103504 chr11 99501264 C T 0.0000439 Aging CNTN5 intron 22445811 rs673798 chr11 99507058 A G 7.64E-04 Type 2 diabetes CNTN5 intron 17463246 rs10893634 chr11 99509199 G A 8.90E-05 Response to alcohol consumption (flushing response) CNTN5 intron 24277619 rs665801 chr11 99516815 C T 3.69E-04 Smoking initiation CNTN5 intron 24665060 rs599197 chr11 99521055 G T 1.09E-04 Smoking initiation CNTN5 intron 24665060 rs639187 chr11 99544152 A T 4.47E-04 Smoking initiation CNTN5 intron 24665060 rs12419474 chr11 99565102 T A 8.14E-04 Multiple complex diseases CNTN5 intron 17554300 rs666825 chr11 99574689 T C 2.40E-15 Matrix metalloproteinase levels CNTN5 intron 20031604 rs614096 chr11 99577390 C G 2.15E-04 Multiple complex diseases CNTN5 intron 17554300 rs952700 chr11 99585736 G A 6.00E-06 Volumetric brain MRI CNTN5 intron 17903297 rs605559 chr11 99587080 T C 1.90E-05 Urinary metabolites CNTN5 intron 21572414 rs605521 chr11 99587113 A G 6.60E-09 Matrix metalloproteinase levels CNTN5 intron 20031604 rs1606273 chr11 99590049 G A 4.34E-05 Height CNTN5 intron pha003010 rs4323834 chr11 99592885 T C 0.000381 Salmonella-induced pyroptosis CNTN5 intron 22837397 rs2063536 chr11 99593538 A C 3.27E-04 Alzheimer's disease (late onset) CNTN5 intron 21379329 rs7935705 chr11 99594162 T C 4.89E-04 Alzheimer's disease (late onset) CNTN5 intron 21379329 rs2439598 chr11 99625758 T G 2.16E-06 Carotenoid and tocopherol levels CNTN5 intron 19185284 rs1231086 chr11 99627353 T C 8.44E-05 Height CNTN5 intron pha003011 rs10893843 chr11 99628972 T C 6.98E-04 Suicide attempts in bipolar disorder CNTN5 intron 21423239 rs1219050 chr11 99629201 G A 0.000079 post-traumatic stress disorder CNTN5 intron 22869035 rs1219050 chr11 99629201 G A 7.90E-05 Schizophrenia CNTN5 intron 22883433 rs10750395 chr11 99630378 G A 8.65E-04 Suicide attempts in bipolar disorder CNTN5 intron 21423239 rs973407 chr11 99642607 A C 7.07E-04 Suicide attempts in bipolar disorder CNTN5 intron 21423239 rs12574195 chr11 99649561 A G 6.72E-04 Suicide attempts in bipolar disorder CNTN5 intron 21423239 rs10893895 chr11 99658637 A G 7.01E-04 Multiple complex diseases CNTN5 intron 17554300 rs1074477 chr11 99674131 G T 7.66E-04 Suicide attempts in bipolar disorder CNTN5 intron 21423239 rs11221580 chr11 99713219 G A 3.73E-04 Multiple complex diseases CNTN5 intron 17554300 rs10501924 chr11 99722295 C T 8.39E-04 Multiple complex diseases CNTN5 intron 17554300 rs10894036 chr11 99740292 C T 3.80E-04 Type 2 diabetes CNTN5 intron 17463246 rs10894037 chr11 99740317 C T 5.68E-04 Type 2 diabetes CNTN5 intron 17463246 rs7931411 chr11 99754345 A G 2.52E-04 Heart Failure CNTN5 intron pha002885 rs10501927 chr11 99757729 T G 1.99E-06 Type 2 diabetes and other traits CNTN5 intron 19734900 rs10501927 chr11 99757729 T G 1.99E-06 Alzheimer's disease (late onset) CNTN5 intron 21460841 rs11221803 chr11 99766045 T C 6.01E-04 Multiple complex diseases CNTN5 intron 17554300 rs7926941 chr11 99786533 A G 1.37E-04 Suicide attempts in bipolar disorder CNTN5 intron 21423239 rs1992535 chr11 99788739 T C 2.52E-04 Suicide attempts in bipolar disorder CNTN5 intron 21423239 rs10791059 chr11 99796576 T C 3.07E-04 Suicide attempts in bipolar disorder CNTN5 intron 21423239 rs10791060 chr11 99796756 C A 4.04E-04 Suicide attempts in bipolar disorder CNTN5 intron 21423239 rs11221929 chr11 99798080 A T 6.43E-04 Suicide attempts in bipolar disorder CNTN5 intron 21423239 rs12364835 chr11 99802137 G T 6.88E-04 Suicide attempts in bipolar disorder CNTN5 intron 21423239 rs11222039 chr11 99828023 C T 7.74E-05 Relative hand skill in reading disability CNTN5 intron 24068947 rs1349785 chr11 99856690 C G 8.42E-05 Relative hand skill in reading disability CNTN5 intron 24068947 rs7933349 chr11 99858032 T G 1.11E-05 Type 2 diabetes and other traits CNTN5 intron 19734900 rs12273744 chr11 99861275 A G 1 Drug response to Etoposide CNTN5 intron 17537913 rs11222247 chr11 99861726 C G 1.01E-04 Autism spectrum disorders (language delay) CNTN5 intron 21519539 rs12277155 chr11 99862406 T C 1 Drug response to Etoposide CNTN5 intron 17537913 rs2407309 chr11 99862625 G T 1 Drug response to Etoposide CNTN5 intron 17537913 rs888597 chr11 99862785 A G 1 Drug response to Etoposide CNTN5 intron 17537913 rs737583 chr11 99863183 G A 1 Drug response to Etoposide CNTN5 intron 17537913 rs737582 chr11 99863401 G A 1 Drug response to Etoposide CNTN5 intron 17537913 rs6590489 chr11 99863775 T C 1 Drug response to Etoposide CNTN5 intron 17537913 rs4258342 chr11 99865248 A G 1 Drug response to Etoposide CNTN5 intron 17537913 rs4269885 chr11 99865549 G A 1 Drug response to Etoposide CNTN5 intron 17537913 rs7125241 chr11 99865706 G A 1 Drug response to Etoposide CNTN5 intron 17537913 rs7125266 chr11 99865752 G A 1 Drug response to Etoposide CNTN5 intron 17537913 rs7114978 chr11 99865921 T A 1 Drug response to Etoposide CNTN5 intron 17537913 rs1377580 chr11 99866163 T C 1 Drug response to Etoposide CNTN5 intron 17537913 rs1035339 chr11 99866660 C T 1 Drug response to Etoposide CNTN5 intron 17537913 rs6590495 chr11 99866998 T C 1 Drug response to Etoposide CNTN5 intron 17537913 rs12282593 chr11 99871361 A G 1 Drug response to Etoposide CNTN5 intron 17537913 rs1833489 chr11 99872172 T C 1 Drug response to Etoposide CNTN5 intron 17537913 rs11222291 chr11 99873546 T C 1 Drug response to Etoposide CNTN5 intron 17537913 rs12287931 chr11 99876222 G A 1 Drug response to Etoposide CNTN5 intron 17537913 rs3909276 chr11 99878216 A G 1 Drug response to Etoposide CNTN5 intron 17537913 rs12289401 chr11 99880224 A G 1 Drug response to Etoposide CNTN5 intron 17537913 rs808828 chr11 99884527 C T 2.20E-05 Urinary metabolites CNTN5 intron 21572414 rs770577 chr11 99884736 A G 1.00E-04 Prostate cancer CNTN5 intron 21743057 rs11222505 chr11 99915396 T A,C,G 9.90E-04 Multiple complex diseases CNTN5 intron 17554300 rs12291466 chr11 99935629 T C 2.45E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CNTN5 intron 24023788 rs10501943 chr11 99946999 T C 5.45E-04 Diabetic retinopathy CNTN5 intron 20871662 rs10791161 chr11 99963969 A G 5.54E-04 Stroke CNTN5 intron pha002887 rs17094347 chr11 99967284 C T 3.28E-08 Matrix metalloproteinase levels CNTN5 intron 20031604 rs11222749 chr11 99968814 G A 7.26E-04 Myocardial Infarction CNTN5 intron pha002873 rs10894483 chr11 99997054 T A 8.64E-04 Multiple complex diseases CNTN5 intron 17554300 rs17624571 chr11 100005547 C G 1.90E-05 Urinary metabolites CNTN5 intron 21572414 rs17624571 chr11 100005547 C G 2.96E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CNTN5 intron 25044411 rs1813443 chr11 100011011 G C 0.00008677 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CNTN5 intron 23233654 rs1813443 chr11 100011011 G C 3.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) CNTN5 intron 23233662 rs11222969 chr11 100017048 C T 2.50E-05 Urinary metabolites CNTN5 intron 21572414 rs11222969 chr11 100017048 C T 1.66E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CNTN5 intron 25044411 rs2044984 chr11 100036365 A G 9.22E-04 Type 2 diabetes CNTN5 intron 22158537 rs7941829 chr11 100038669 A G 8.16E-04 Type 2 diabetes CNTN5 intron 22158537 rs12803066 chr11 100043420 A G 4.00E-06 Myopia (pathological) CNTN5 intron 23049088 rs7119230 chr11 100045242 A G 0.000322 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CNTN5 intron 23233654 rs7119230 chr11 100045242 A G 3.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) CNTN5 intron 23233662 rs17094497 chr11 100045424 T G 2.50E-05 Urinary metabolites CNTN5 intron 21572414 rs1947362 chr11 100047322 A T 0.0006759 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CNTN5 intron 23233654 rs1947362 chr11 100047322 A T 6.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) CNTN5 intron 23233662 rs10894576 chr11 100052952 G A 1.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CNTN5 intron 20877124 rs7130695 chr11 100052977 T C 1.30E-05 Urinary metabolites CNTN5 intron 21572414 rs7934785 chr11 100055523 T C 6.15E-06 Myopia (pathological) CNTN5 intron 23049088 rs1452575 chr11 100063425 T G 3.38E-05 Lung adenocarcinoma CNTN5 intron 19836008 rs1939694 chr11 100079723 G A 5.44E-04 Smoking initiation CNTN5 intron 24665060 rs10501954 chr11 100081313 T C 9.83E-05 Multiple complex diseases CNTN5 intron 17554300 rs11223269 chr11 100087315 A C 0.00020977 Hypertension (early onset hypertension) CNTN5 intron 22479346 rs11223274 chr11 100088335 A G 2.93E-05 Lipoproteins CNTN5 intron pha003079 rs1939697 chr11 100091693 T G 3.97E-07 Primary biliary cirrhosis CNTN5 intron 23000144 rs1939697 chr11 100091693 T G 0.000000397 Facial morphology CNTN5 intron 23028347 rs1939707 chr11 100102098 C T 4.65E-07 Primary biliary cirrhosis CNTN5 intron 23000144 rs1939707 chr11 100102098 C T 0.000000465 Facial morphology CNTN5 intron 23028347 rs544633 chr11 100110095 T C 1.73E-05 Lung adenocarcinoma CNTN5 intron 19836008 rs1348271 chr11 100137346 T G 6.43E-05 Colorectal cancer CNTN5 intron 19723657 rs1348271 chr11 100137346 T G 4.14E-04 Thyroid stimulating hormone CNTN5 intron 24852370 rs11223581 chr11 100173537 A G 9.00E-09 Immune reponse to smallpox (secreted IL-2) CNTN5 intron 22610502 rs569376 chr11 100183385 A T 2.90E-05 Urinary metabolites CNTN5 intron 21572414 rs1216190 chr11 100200417 A G 5.67E-04 Suicide attempts in bipolar disorder CNTN5 intron 21423239 rs1216189 chr11 100200615 G A 5.43E-04 Suicide attempts in bipolar disorder CNTN5 intron 21423239 rs539487 chr11 100205844 A G 5.51E-04 Suicide attempts in bipolar disorder CNTN5 intron 21423239 rs1216192 chr11 100207500 C T 7.50E-05 Major depressive disorder CNTN5 intron 19107115 rs492107 chr11 100210203 C A 1.01E-05 Major depressive disorder CNTN5 intron 19107115 rs540267 chr11 100210323 G A,C 7.79E-04 Suicide attempts in bipolar disorder CNTN5 intron 21423239 rs1216162 chr11 100213654 A C 6.65E-04 Suicide attempts in bipolar disorder CNTN5 intron 21423239 rs1216162 chr11 100213654 A C 6.02E-05 Calcium levels CNTN5 intron pha003085 rs482851 chr11 100216491 T A 8.22E-04 Suicide attempts in bipolar disorder CNTN5 intron 21423239 rs501892 chr11 100223636 A G 7.05E-05 Major depressive disorder CNTN5 intron 19107115 rs1301784 chr11 100243478 G A 8.20E-04 Multiple complex diseases / / 17554300 rs1301784 chr11 100243478 G A 1.87E-09 Matrix metalloproteinase levels / / 20031604 rs1301783 chr11 100244908 G A 8.60E-04 Multiple complex diseases / / 17554300 rs1301783 chr11 100244908 G A 6.58E-11 Matrix metalloproteinase levels / / 20031604 rs537783 chr11 100248321 C A 6.41E-08 Metabolite levels / / 23281178 rs1145412 chr11 100248773 T C 6.41E-08 Metabolite levels / / 23281178 rs10894847 chr11 100255775 G T 4.03E-08 Metabolite levels / / 23281178 rs7930146 chr11 100330608 T C 2.39E-11 Matrix metalloproteinase levels / / 20031604 rs17095079 chr11 100344204 T C 7.36E-06 Multiple complex diseases / / 17554300 rs12289202 chr11 100386275 T C 5.25E-09 Matrix metalloproteinase levels / / 20031604 rs1216472 chr11 100405406 T C 7.99E-04 Myocardial Infarction / / pha002883 rs12800752 chr11 100406640 T C 3.00E-06 Menarche (age at onset) / / 23667675 rs1216476 chr11 100410346 A G 3.87E-06 Alopecia areata / / 22027810 rs17095168 chr11 100428969 G T 2.53E-04 Type 2 diabetes / / 17463246 rs11224282 chr11 100435676 G A 0.0000133 Polycystic ovary syndrome / / 22951595 rs11224282 chr11 100435676 G A 1.33E-05 Intracranial aneurysm / / 22961961 rs11224282 chr11 100435676 G A 4.37E-04 Smoking initiation / / 24665060 rs650297 chr11 100449142 T G 2.07E-04 Type 2 diabetes / / 22238593 rs11224294 chr11 100449162 T C 2.17E-07 Alopecia areata / / 22027810 rs11224294 chr11 100449162 T C 4.17E-04 Smoking initiation / / 24665060 rs17095212 chr11 100455993 A G 6.02E-04 Smoking quantity / / 24665060 rs7125960 chr11 100468735 T C 6.09E-08 Matrix metalloproteinase levels / / 20031604 rs1783689 chr11 100481651 A C 1.59E-04 Hemoglobin concentration / / 20534544 rs17710616 chr11 100496675 C T 5.29E-12 Matrix metalloproteinase levels / / 20031604 rs10894993 chr11 100498729 T G 5.64E-07 Panic disorder / / 19165232 rs10894993 chr11 100498729 T G 8.62E-24 Narcolepsy / / 19629137 rs947866 chr11 100509529 C T 4.72E-04 Multiple complex diseases / / 17554300 rs1032779 chr11 100513913 A C 4.88E-05 Telomere length / / 20139977 rs11224367 chr11 100534980 C G 1.63E-04 Type 2 diabetes / / 17463246 rs10431107 chr11 100544292 T C 5.46E-04 Multiple complex diseases / / 17554300 rs10895007 chr11 100550446 T C 4.71E-04 Multiple complex diseases / / 17554300 rs1021794 chr11 100554299 T A 1.46E-04 Multiple complex diseases / / 17554300 rs11224401 chr11 100576983 C T 0.00000113 Menopause (age at onset) ARHGAP42 intron 23424626 rs633185 chr11 100593538 G C 7.00E-10 Blood pressure ARHGAP42 intron 21909110 rs633185 chr11 100593538 G C 1.00E-17 Systolic blood pressure ARHGAP42 intron 21909115 rs633185 chr11 100593538 G C 2.00E-15 Diastolic blood pressure ARHGAP42 intron 21909115 rs633185 chr11 100593538 G C 5.00E-11 Hypertension ARHGAP42 intron 21909115 rs7946913 chr11 100603314 G A 7.45E-04 Multiple complex diseases ARHGAP42 intron 17554300 rs7946913 chr11 100603314 G A 9.66E-10 Matrix metalloproteinase levels ARHGAP42 intron 20031604 rs604723 chr11 100610546 T C 2.30E-09 Blood pressure ARHGAP42 intron 21909110 rs7947761 chr11 100624599 A G 2.65E-08 Matrix metalloproteinase levels ARHGAP42 intron 20031604 rs17713163 chr11 100638414 C G,T 3.42E-04 Type 2 diabetes ARHGAP42 intron 17463246 rs17095426 chr11 100638603 G A 3.55E-04 Multiple complex diseases ARHGAP42 intron 17554300 rs17095426 chr11 100638603 G A 1.03E-08 Matrix metalloproteinase levels ARHGAP42 intron 20031604 rs17095426 chr11 100638603 G A 1.50E-05 Urinary metabolites ARHGAP42 intron 21572414 rs17095429 chr11 100639302 C A 3.30E-04 Multiple complex diseases ARHGAP42 intron 17554300 rs17095429 chr11 100639302 C A 5.04E-09 Matrix metalloproteinase levels ARHGAP42 intron 20031604 rs11224447 chr11 100659839 G T 0.0000611 Menopause (age at onset) ARHGAP42 intron 23424626 rs10895016 chr11 100670925 G A 2.38E-06 Retinopathy in non-diabetics ARHGAP42 intron 23393555 rs11605920 chr11 100694310 T C 9.23E-06 Retinopathy in non-diabetics ARHGAP42 intron 23393555 rs10895018 chr11 100696117 A C 9.09E-06 Retinopathy in non-diabetics ARHGAP42 intron 23393555 rs3758697 chr11 100709894 G A 3.43E-04 Type 2 diabetes ARHGAP42 intron 17846124 rs655175 chr11 100710202 A G 6.55E-04 Multiple complex diseases ARHGAP42 intron 17554300 rs637127 chr11 100718626 G T 3.64E-05 Amyotrophic lateral sclerosis (sporadic) ARHGAP42 intron 24529757 rs619191 chr11 100722138 A C 1.50E-05 Urinary metabolites ARHGAP42 intron 21572414 rs662501 chr11 100729841 G A 6.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARHGAP42 intron 20877124 rs661237 chr11 100730087 G A 6.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARHGAP42 intron 20877124 rs12274135 chr11 100734010 G A 6.86E-05 Coronary heart disease ARHGAP42 intron pha003031 rs10488786 chr11 100740194 G A 1.80E-05 Urinary metabolites ARHGAP42 intron 21572414 rs10488786 chr11 100740194 G A 8.70E-05 Male fertility ARHGAP42 intron 22633400 rs626596 chr11 100777290 G A 6.72E-04 Type 2 diabetes ARHGAP42 intron 17463246 rs626596 chr11 100777290 G A 1.37E-08 Matrix metalloproteinase levels ARHGAP42 intron 20031604 rs11224514 chr11 100793689 A C 1.71E-05 Glucose levels ARHGAP42 intron pha003061 rs10791432 chr11 100802521 C T 7.44E-04 Type 2 diabetes ARHGAP42 intron 17463246 rs10791432 chr11 100802521 C T 1.29E-10 Matrix metalloproteinase levels ARHGAP42 intron 20031604 rs576472 chr11 100806469 A G 9.69E-05 Serum metabolites ARHGAP42 intron 19043545 rs11604594 chr11 100807770 C T 3.51E-04 Lung function (forced vital capacity) ARHGAP42 intron 24023788 rs543146 chr11 100814570 A G 3.91E-09 Matrix metalloproteinase levels ARHGAP42 cds-synon 20031604 rs618155 chr11 100814609 G T 5.48E-04 Type 2 diabetes ARHGAP42 intron 17463246 rs524416 chr11 100817655 C T 9.67E-04 Type 2 diabetes ARHGAP42 intron 17463246 rs17647207 chr11 100820663 G A 0.000378 Salmonella-induced pyroptosis ARHGAP42 missense 22837397 rs7939782 chr11 100822315 T C 6.58E-04 Type 2 diabetes ARHGAP42 intron 17463246 rs7939782 chr11 100822315 T C 7.41E-09 Matrix metalloproteinase levels ARHGAP42 intron 20031604 rs10895033 chr11 100823814 T C 1.29E-10 Matrix metalloproteinase levels ARHGAP42 intron 20031604 rs539204 chr11 100826629 A T 2.92E-04 Type 2 diabetes ARHGAP42 intron 17463246 rs1944432 chr11 100829520 T C 4.87E-17 Matrix metalloproteinase levels ARHGAP42 intron 20031604 rs17726715 chr11 100835255 T G 1.64E-04 Coronary Artery Disease ARHGAP42 intron 17634449 rs10895036 chr11 100837586 T C 1.18E-10 Matrix metalloproteinase levels ARHGAP42 intron 20031604 rs1893069 chr11 100847343 T A 6.03E-04 Type 2 diabetes ARHGAP42 intron 17463246 rs1893069 chr11 100847343 T A 5.33E-10 Matrix metalloproteinase levels ARHGAP42 intron 20031604 rs581468 chr11 100852596 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) ARHGAP42 intron 20708005 rs551632 chr11 100856955 C T 2.70E-05 Urinary metabolites ARHGAP42 intron 21572414 rs12788818 chr11 100868646 A G 7.72E-05 Glucose levels / / pha003061 rs523332 chr11 100874319 T G 1.25E-10 Matrix metalloproteinase levels / / 20031604 rs11224546 chr11 100890993 A G 3.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1046982 chr11 100900716 T C 3.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PGR UTR-3 20877124 rs11224571 chr11 100918673 C A 1.16E-12 Cholesterol,total PGR intron 23063622 rs11224571 chr11 100918673 C A 8.06E-10 LDL cholesterol PGR intron 23063622 rs635984 chr11 100923166 C G 3.20E-05 Endometriosis PGR intron 21151130 rs660541 chr11 100934367 G A 7.80E-04 Endometriosis PGR intron 23104006 rs495997 chr11 100935780 A G 8.89E-05 Abdominal aortic aneurysm PGR intron 24046328 rs1145465 chr11 100982994 A C 1.65E-08 Matrix metalloproteinase levels PGR intron 20031604 rs565186 chr11 100983629 T C 2.44E-08 Matrix metalloproteinase levels PGR intron 20031604 rs486992 chr11 100984844 G A 4.94E-05 Brain structure PGR intron 22504417 rs7928851 chr11 100987891 C A 1.27E-10 LDL cholesterol PGR intron 23063622 rs7928851 chr11 100987891 C A 1.47E-13 Cholesterol,total PGR intron 23063622 rs562894 chr11 100991685 T C 7.36E-08 Matrix metalloproteinase levels PGR intron 20031604 rs11571151 chr11 100998217 C G 1.18E-20 HDL cholesterol PGR missense 23063622 rs11571151 chr11 100998217 C G 3.48E-32 Cholesterol,total PGR missense 23063622 rs11571151 chr11 100998217 C G 3.83E-11 Triglycerides PGR missense 23063622 rs11571151 chr11 100998217 C G 9.55E-16 LDL cholesterol PGR missense 23063622 rs12417627 chr11 101048332 A G 3.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs538343 chr11 101056339 G A 3.09E-08 Matrix metalloproteinase levels / / 20031604 rs11224685 chr11 101143272 T C 6.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs10895087 chr11 101145350 C A 3.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1943761 chr11 101161919 A G 0.000304 Salmonella-induced pyroptosis / / 22837397 rs1938994 chr11 101208278 T C 2.23E-04 Alzheimer's disease (late onset) / / 21379329 rs6590849 chr11 101218094 T C 3.35E-04 Alzheimer's disease (late onset) / / 21379329 rs4754010 chr11 101218192 C T 1.00E-04 Prostate cancer / / 21743057 rs1938980 chr11 101218544 T A 1.00E-04 Prostate cancer / / 21743057 rs12223715 chr11 101219339 G C 1.00E-04 Prostate cancer / / 21743057 rs12226605 chr11 101219495 C T 1.00E-04 Prostate cancer / / 21743057 rs1892883 chr11 101223389 T A 1.00E-04 Prostate cancer / / 21743057 rs12795332 chr11 101224362 T C 1.67E-04 Alzheimer's disease (late onset) / / 21379329 rs12795332 chr11 101224362 T C 1.00E-04 Prostate cancer / / 21743057 rs4754752 chr11 101225730 T C 2.45E-04 Cognition,early reading ability / / 17684495 rs4754752 chr11 101225730 T C 1.00E-04 Prostate cancer / / 21743057 rs11224728 chr11 101227985 A T 1.00E-04 Prostate cancer / / 21743057 rs11224729 chr11 101228512 G T 1.00E-04 Prostate cancer / / 21743057 rs11224733 chr11 101235197 T A 3.50E-09 Matrix metalloproteinase levels / / 20031604 rs7945321 chr11 101243533 A G 8.05E-05 Body mass index / / 24827717 rs7948518 chr11 101243644 T C 1.48E-04 Alzheimer's disease (late onset) / / 21379329 rs2508358 chr11 101255789 T C 2.05E-04 Alzheimer's disease (late onset) / / 21379329 rs1938988 chr11 101262425 G C 4.85E-09 Matrix metalloproteinase levels / / 20031604 rs2508375 chr11 101264879 A C 1.00E-04 Prostate cancer / / 21743057 rs2508371 chr11 101268447 G A 3.57E-04 Alzheimer's disease (late onset) / / 21379329 rs11224760 chr11 101300187 G T 2.00E-04 Coronary Artery Disease / / 17634449 rs7948940 chr11 101311359 G A,C,T 6.91E-05 Bipolar disorder / / 17486107 rs11224780 chr11 101343629 A G 2.20E-05 Urinary metabolites TRPC6 intron 21572414 rs11224781 chr11 101347908 G T 1.41E-05 Bipolar disorder TRPC6 intron 17486107 rs7942339 chr11 101355126 T G 9.58E-05 Insulin resistance TRPC6 intron 21901158 rs7934021 chr11 101356606 A C 3.36E-04 Alzheimer's disease (late onset) TRPC6 intron 21379329 rs4129255 chr11 101365203 G A 1.78E-04 Alzheimer's disease (late onset) TRPC6 intron 21379329 rs4403777 chr11 101367719 G A 1.10E-04 Alzheimer's disease (late onset) TRPC6 intron 21379329 rs6590870 chr11 101371503 A G 6.00E-05 Bipolar disorder TRPC6 intron 22925353 rs10501981 chr11 101375615 C G 1.10E-05 Biomarkers TRPC6 intron 17903293 rs7932871 chr11 101376063 A G 1.33E-04 Alzheimer's disease (late onset) TRPC6 intron 21379329 rs7931676 chr11 101405218 A G 7.23E-05 Cognitive impairment induced by topiramate TRPC6 intron 22091778 rs7925662 chr11 101408306 T C 6.25E-05 Cognitive impairment induced by topiramate TRPC6 intron 22091778 rs4457714 chr11 101409786 G T 4.30E-06 Urinary metabolites TRPC6 intron 21572414 rs10791507 chr11 101474731 T C 5.84E-05 Cognitive performance / / 19734545 rs17676029 chr11 101483577 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2186580 chr11 101524873 C A 4.69E-05 Parkinson's disease / / 21812969 rs1938831 chr11 101536336 T C 4.63E-06 Alcohol dependence / / 23089632 rs11601702 chr11 101538691 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11601702 chr11 101538691 A G 4.33E-04 Longevity / / 22279548 rs10895174 chr11 101541224 T C 9.72E-05 Parkinson's disease / / 21812969 rs1938859 chr11 101547723 T A,C,G 8.75E-11 Matrix metalloproteinase levels / / 20031604 rs11224953 chr11 101556057 C G 9.33E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10501987 chr11 101585664 A G 1.69E-04 Glycosylated haemoglobin levels / / 17255346 rs17744964 chr11 101588673 G A 6.09E-08 Matrix metalloproteinase levels / / 20031604 rs4754019 chr11 101590923 G A 2.95E-13 Matrix metalloproteinase levels / / 20031604 rs59969433 chr11 101590923 G GA 2.95E-13 Matrix metalloproteinase levels / / 20031604 rs10895184 chr11 101593061 C T 6.45E-05 Insulin-related traits / / pha002901 rs17097072 chr11 101602137 T C 9.90E-06 Pulmonary function / / 20010835 rs1939052 chr11 101626575 T C 1.14E-14 Matrix metalloproteinase levels / / 20031604 rs10895193 chr11 101631933 G A 6.36E-11 Matrix metalloproteinase levels / / 20031604 rs17097133 chr11 101634662 G C 8.40E-05 Pulmonary function / / 20010835 rs731593 chr11 101636730 G A 7.61E-05 Pulmonary function / / 20010835 rs17097156 chr11 101640924 A C 7.42E-05 Pulmonary function / / 20010835 rs17097163 chr11 101646261 A G 7.34E-05 Pulmonary function / / 20010835 rs10501990 chr11 101667158 T C 6.42E-08 Matrix metalloproteinase levels / / 20031604 rs4754800 chr11 101667330 A G 4.45E-08 Matrix metalloproteinase levels / / 20031604 rs10791523 chr11 101668820 A G 6.15E-08 Matrix metalloproteinase levels / / 20031604 rs10791524 chr11 101668885 C T 6.25E-08 Matrix metalloproteinase levels / / 20031604 rs7101850 chr11 101671345 C T 6.38E-08 Matrix metalloproteinase levels / / 20031604 rs7949648 chr11 101688347 G A 6.36E-04 Multiple complex diseases / / 17554300 rs17097252 chr11 101733543 T C 7.83E-04 Type 2 diabetes / / 17463246 rs10791539 chr11 101741939 G A 9.52E-09 Matrix metalloproteinase levels / / 20031604 rs17097290 chr11 101760892 C T 1.55E-06 Common variable immunodeficiency / / 21497890 rs12804060 chr11 101770360 C T 3.37E-05 Serum metabolites ANGPTL5 intron 19043545 rs11225055 chr11 101771433 T C 1.00E-06 Response to methotrexate in juvenile idiopathic arthritis ANGPTL5 intron 24709693 rs56249024 chr11 101777238 T C 0.0002914 Sarcoidosis ANGPTL5 intron 22952805 rs7942191 chr11 101860024 T C 2.20E-05 Urinary metabolites KIAA1377 intron 21572414 rs1661412 chr11 101870458 A G 2.20E-05 Urinary metabolites KIAA1377 UTR-3 21572414 rs1470196 chr11 101880373 G A 4.99E-04 Longevity / / 22279548 rs7930416 chr11 101927044 G A 1.52E-09 Matrix metalloproteinase levels C11orf70 intron 20031604 rs10791555 chr11 101928225 T C 2.43E-09 Matrix metalloproteinase levels C11orf70 intron 20031604 rs17097403 chr11 101934867 A G 1.70E-05 Urinary metabolites C11orf70 intron 21572414 rs10895257 chr11 101986644 G A 1.19E-12 Matrix metalloproteinase levels YAP1 intron 20031604 rs11225148 chr11 102009280 A G 2.00E-06 Pubertal anthropometrics YAP1 intron 23449627 rs11602707 chr11 102045643 C T 6.52E-15 Matrix metalloproteinase levels YAP1 intron 20031604 rs17689778 chr11 102063437 G A 1.63E-04 Multiple complex diseases YAP1 intron 17554300 rs10501995 chr11 102070361 A G 8.15E-06 Hearing function YAP1 intron 17255346 rs11225161 chr11 102070494 C T 2.20E-06 Hearing function YAP1 intron 17255346 rs1894116 chr11 102070639 A G 8.15E-06 Hearing function YAP1 intron 17255346 rs1894116 chr11 102070639 A G 1.00E-22 Polycystic ovary syndrome YAP1 intron 22885925 rs7131529 chr11 102086761 A T 9.56E-04 Multiple complex diseases YAP1 intron 17554300 rs10791569 chr11 102088335 A C 4.92E-09 Matrix metalloproteinase levels YAP1 intron 20031604 rs11225166 chr11 102090467 G C 1.34E-05 Hearing function YAP1 intron 17255346 rs2846836 chr11 102105673 A G 2.05E-09 Matrix metalloproteinase levels / / 20031604 rs2124216 chr11 102138903 G A 7.02E-05 Cognitive impairment induced by topiramate / / 22091778 rs2852894 chr11 102155474 A G 1.00E-06 MRI atrophy measures / / 21116278 rs11601671 chr11 102250065 C T 1.23E-05 Cognitive test performance / / 20125193 rs7952037 chr11 102250384 C T 1.56E-08 LDL cholesterol / / 23063622 rs7952037 chr11 102250384 C T 3.56E-08 Cholesterol,total / / 23063622 rs11225247 chr11 102280751 A C 3.60E-04 Taste perception TMEM123 intron 22132133 rs3758843 chr11 102338396 T C 6.43E-04 Coronary Artery Disease / / 17634449 rs480846 chr11 102345234 A G 1.19E-08 Matrix metalloproteinase levels / / 20031604 rs480950 chr11 102345274 A C 2.69E-11 Matrix metalloproteinase levels / / 20031604 rs11225266 chr11 102346586 A C 1.15E-05 Clubfoot / / 24667120 rs10750642 chr11 102357279 C T 3.80E-05 Body mass index / / 20818722 rs3990027 chr11 102359665 C A,G,T 1.30E-05 Urinary metabolites / / 21572414 rs651853 chr11 102365970 A G 1.19E-08 Matrix metalloproteinase levels / / 20031604 rs2509689 chr11 102368719 G A 4.70E-05 Attention deficit hyperactivity disorder / / 22012869 rs2509689 chr11 102368719 G A 2.52E-04 Taste perception / / 22132133 rs520100 chr11 102377269 G A 1.62E-09 Matrix metalloproteinase levels / / 20031604 rs520100 chr11 102377269 G A 1.10E-06 Urinary metabolites / / 21572414 rs2510488 chr11 102377428 T A 6.21E-10 Matrix metalloproteinase levels / / 20031604 rs2510488 chr11 102377428 T A 1.20E-06 Urinary metabolites / / 21572414 rs598693 chr11 102384322 G A 2.42E-04 Multiple complex diseases / / 17554300 rs598693 chr11 102384322 G A 1.10E-05 Urinary metabolites / / 21572414 rs7945819 chr11 102389487 C A 4.85E-04 Tourette syndrome / / 22889924 rs11225308 chr11 102399478 T G 1.00E-04 Mathematical ability MMP7 intron 20039944 rs11225308 chr11 102399478 T G 2.00E-04 Mathematical ability MMP7 intron 20039944 rs11568818 chr11 102401661 T C 2.00E-11 Prostate cancer / / 23535732 rs7110424 chr11 102423666 G T 8.62E-04 Alcohol dependence / / 20201924 rs12785255 chr11 102424802 G A 5.24E-04 Insulin resistance / / 21901158 rs9651711 chr11 102428713 G A 1.36E-11 Matrix metalloproteinase levels / / 20031604 rs4754857 chr11 102432478 T C 8.16E-04 Insulin resistance / / 21901158 rs17098593 chr11 102449212 G A 1.70E-04 Coronary heart disease MMP20 intron 21966275 rs10502004 chr11 102449931 T C 1.19E-05 Bipolar disorder MMP20 intron 20451256 rs1940054 chr11 102449951 A C 1.24E-12 Matrix metalloproteinase levels MMP20 intron 20031604 rs2245803 chr11 102495998 T G 5.24E-05 Osteoarthritis (knee and hip) MMP20 missense 21177295 rs2245803 chr11 102495998 T G 8.91E-05 Osteoarthritis (knee and hip) MMP20 missense 21177295 rs7129777 chr11 102512086 T C 2.19E-05 Serum metabolites / / 19043545 rs7129790 chr11 102512114 T G 2.84E-05 Serum metabolites / / 19043545 rs12270184 chr11 102530431 C T 9.71E-26 Narcolepsy / / 19629137 rs12575154 chr11 102534875 C T 7.57E-04 Acute lung injury / / 22295056 rs17099394 chr11 102564576 G T 1.69E-04 Common variable immunodeficiency MMP27 intron 21497890 rs1940461 chr11 102580408 G C 3.89E-06 White blood cell count / / 21738479 rs3765620 chr11 102595492 G A 3.35E-06 Hearing function MMP8 missense 21493956 rs6590986 chr11 102598859 C T 1.44E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs7924357 chr11 102628052 G A 1.00E-06 Multiple sclerosis / / 23412934 rs470171 chr11 102641452 G C 7.15E-04 Multiple complex diseases MMP10 UTR-3 17554300 rs7938449 chr11 102648898 C T 0.00000186 LDL cholesterol MMP10 intron 23063622 rs7938449 chr11 102648898 C T 5.19E-08 Cholesterol,total MMP10 intron 23063622 rs1939008 chr11 102656423 G A 3.04E-11 Matrix metalloproteinase levels LOC100288077 intron 20031604 rs2075847 chr11 102669824 A G 1.35E-08 Triglycerides LOC100288077 intron 23063622 rs2075847 chr11 102669824 A G 9.32E-09 HDL cholesterol LOC100288077 intron 23063622 rs12289128 chr11 102679966 G C 5.99E-05 Multiple complex diseases LOC100288077 intron 17554300 rs603050 chr11 102680229 C T 1.15E-33 Matrix metalloproteinase levels LOC100288077 intron 20031604 rs470530 chr11 102680949 A G 3.60E-04 Multiple complex diseases LOC100288077 intron 17554300 rs11225434 chr11 102691482 T C 9.00E-29 Matrix metalloproteinase levels LOC100288077 intron 20031604 rs499459 chr11 102693186 A G 4.80E-04 Multiple complex diseases LOC100288077 intron 17554300 rs495366 chr11 102695108 G A 6.00E-34 Matrix metalloproteinase levels LOC100288077 intron 20031604 rs7926920 chr11 102698724 G A 1.03E-26 Matrix metalloproteinase levels LOC100288077 intron 20031604 rs473238 chr11 102700360 T C 3.20E-04 Multiple complex diseases LOC100288077 intron 17554300 rs650108 chr11 102708787 G A 9.44E-31 Matrix metalloproteinase levels MMP3 intron 20031604 rs3025063 chr11 102711440 C T 0.00000192 Triglycerides MMP3 intron 23063622 rs3025063 chr11 102711440 C T 1.47E-08 HDL cholesterol MMP3 intron 23063622 rs610950 chr11 102719730 T C 1.08E-10 Matrix metalloproteinase levels / / 20031604 rs610950 chr11 102719730 T C 1.61E-05 Diabetic nephropathy / / pha002864 rs17361668 chr11 102720344 T A 2.02E-04 Multiple complex diseases / / 17554300 rs613804 chr11 102720421 G A 1.91E-12 Matrix metalloproteinase levels / / 20031604 rs613804 chr11 102720421 G A 3.38E-05 Diabetic nephropathy / / pha002864 rs626750 chr11 102720945 G A 3.00E-09 Chronic obstructive pulmonary disease (severe) / / 24621683 rs12808148 chr11 102733163 T C 1.00E-06 Alzheimer's disease / / 22832961 rs17368814 chr11 102748695 A G 2.75E-04 Multiple complex diseases / / 17554300 rs11225458 chr11 102765408 T C 8.98E-19 Matrix metalloproteinase levels / / 20031604 rs11225464 chr11 102770998 C T 3.37E-04 Multiple complex diseases / / 17554300 rs948399 chr11 102771140 C T 4.78E-19 Matrix metalloproteinase levels / / 20031604 rs2096767 chr11 102791399 C G 3.10E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs4754052 chr11 102800914 T C 9.74E-05 Bipolar disorder and schizophrenia / / 20889312 rs4754052 chr11 102800914 T C 9.00E-05 Prostate cancer / / 21743057 rs12792912 chr11 102801303 T G 4.60E-05 Response to statin therapy / / 20339536 rs12788925 chr11 102801847 A G 5.80E-05 Response to statin therapy / / 20339536 rs7115014 chr11 102804933 A G 3.99E-19 Matrix metalloproteinase levels / / 20031604 rs7115014 chr11 102804933 A G 9.59E-05 Alzheimer's disease (late onset) / / 21379329 rs10502008 chr11 102805602 T C 3.63E-12 Matrix metalloproteinase levels / / 20031604 rs11828157 chr11 102818124 G A 3.20E-11 Triglycerides MMP13 intron 23063622 rs11828157 chr11 102818124 G A 3.83E-11 LDL cholesterol MMP13 intron 23063622 rs11828157 chr11 102818124 G A 6.99E-15 HDL cholesterol MMP13 intron 23063622 rs11824953 chr11 102819968 C G 0.000000015 Triglycerides MMP13 intron 23063622 rs11824953 chr11 102819968 C G 5.99E-10 HDL cholesterol MMP13 intron 23063622 rs3819089 chr11 102822733 C T 1.07E-13 Matrix metalloproteinase levels MMP13 intron 20031604 rs3819089 chr11 102822733 C T 2.80E-05 Urinary metabolites MMP13 intron 21572414 rs671188 chr11 102829455 G A 2.00E-08 Matrix metalloproteinase levels / / 20031604 rs675504 chr11 102829731 A G 1.84E-12 Triglycerides / / 23063622 rs675504 chr11 102829731 A G 2.08E-09 LDL cholesterol / / 23063622 rs675504 chr11 102829731 A G 2.78E-10 HDL cholesterol / / 23063622 rs659383 chr11 102831091 G A 5.38E-09 Matrix metalloproteinase levels / / 20031604 rs687558 chr11 102833618 A G 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs579627 chr11 102835419 G A 6.20E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12222856 chr11 102872108 A G 1.86E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11225514 chr11 102877513 A G 5.85E-06 Glycemic traits (pregnancy) / / 23903356 rs514835 chr11 102906516 T C,G 1.60E-05 Urinary metabolites / / 21572414 rs7105967 chr11 102929443 C T 3.51E-06 Tuberculosis DCUN1D5 UTR-3 24057671 rs7947821 chr11 102947465 T C 2.00E-06 Tuberculosis DCUN1D5 intron 24057671 rs11225543 chr11 102952538 A T 2.67E-04 Acute lung injury DCUN1D5 intron 22295056 rs11225545 chr11 102954119 G A 2.59E-04 Acute lung injury DCUN1D5 intron 22295056 rs11225547 chr11 102967852 A C 4.20E-08 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs11225547 chr11 102967852 A C 2.46E-04 Acute lung injury / / 22295056 rs17301028 chr11 102980324 C T 4.89E-04 Alzheimer's disease DYNC2H1 cds-synon 17998437 rs12283022 chr11 102980594 A G 2.00E-06 Tuberculosis DYNC2H1 intron 24057671 rs2513998 chr11 102983568 G C 1.88E-16 Matrix metalloproteinase levels DYNC2H1 intron 20031604 rs12146667 chr11 102988090 G A 8.79E-04 Acute lung injury DYNC2H1 intron 22295056 rs12146610 chr11 102988504 A T 8.79E-04 Acute lung injury DYNC2H1 missense 22295056 rs11225553 chr11 102989206 A G 8.79E-04 Acute lung injury DYNC2H1 intron 22295056 rs11225555 chr11 102996242 G A 8.79E-04 Acute lung injury DYNC2H1 intron 22295056 rs12365335 chr11 103014604 T C 4.02E-04 Acute lung injury DYNC2H1 intron 22295056 rs11225569 chr11 103016193 G A 4.02E-04 Acute lung injury DYNC2H1 intron 22295056 rs11225570 chr11 103018826 A G 4.02E-04 Acute lung injury DYNC2H1 intron 22295056 rs11225573 chr11 103024489 G T 5.83E-05 Acute lung injury DYNC2H1 intron 22295056 rs626330 chr11 103035791 A C 2.27E-04 Multiple complex diseases DYNC2H1 intron 17554300 rs12361541 chr11 103040144 C T 1.14E-04 Acute lung injury DYNC2H1 intron 22295056 rs12365377 chr11 103051106 A G 1.12E-04 Acute lung injury DYNC2H1 intron 22295056 rs17374436 chr11 103056680 T C 8.20E-04 Alcohol dependence DYNC2H1 intron 20201924 rs11225592 chr11 103064610 A G 1.49E-04 Acute lung injury DYNC2H1 intron 22295056 rs11225593 chr11 103064688 A G 7.80E-05 Acute lung injury DYNC2H1 intron 22295056 rs11225594 chr11 103065171 A G 8.04E-05 Acute lung injury DYNC2H1 intron 22295056 rs641823 chr11 103066027 G A 8.51E-04 Suicide attempts in bipolar disorder DYNC2H1 intron 21423239 rs685395 chr11 103067460 T C 3.22E-17 Matrix metalloproteinase levels DYNC2H1 intron 20031604 rs685395 chr11 103067460 T C 5.85E-04 Suicide attempts in bipolar disorder DYNC2H1 intron 21423239 rs11225600 chr11 103068941 G A 6.33E-05 Acute lung injury DYNC2H1 intron 22295056 rs12360974 chr11 103078629 C T 6.27E-05 Acute lung injury DYNC2H1 intron 22295056 rs11225604 chr11 103079673 C T 6.55E-05 Acute lung injury DYNC2H1 intron 22295056 rs664310 chr11 103084838 T C 3.78E-09 Matrix metalloproteinase levels DYNC2H1 intron 20031604 rs680071 chr11 103088414 T C 6.46E-04 Suicide attempts in bipolar disorder DYNC2H1 intron 21423239 rs11225615 chr11 103108510 C T 8.85E-05 Acute lung injury DYNC2H1 intron 22295056 rs11225621 chr11 103110863 C G 9.64E-05 Acute lung injury DYNC2H1 intron 22295056 rs11225624 chr11 103112456 C T 5.76E-04 Multiple complex diseases DYNC2H1 intron 17554300 rs665317 chr11 103116366 C T 9.31E-04 HIV-1 viral setpoint DYNC2H1 intron 17641165 rs11225625 chr11 103117512 A G 2.30E-05 Urinary metabolites DYNC2H1 intron 21572414 rs11225625 chr11 103117512 A G 9.75E-05 Acute lung injury DYNC2H1 intron 22295056 rs11225628 chr11 103120428 C T 9.75E-05 Acute lung injury DYNC2H1 intron 22295056 rs3912622 chr11 103121473 A C 4.80E-04 Schizophrenia DYNC2H1 intron 19197363 rs11225632 chr11 103122147 A G 9.99E-05 Acute lung injury DYNC2H1 intron 22295056 rs12294076 chr11 103127065 T C 1.00E-07 Tuberculosis DYNC2H1 intron 24057671 rs11225640 chr11 103139930 T C 3.54E-05 Acute lung injury DYNC2H1 intron 22295056 rs11225641 chr11 103141894 G A 9.26E-05 Acute lung injury DYNC2H1 intron 22295056 rs11225649 chr11 103151516 C A 5.30E-12 Matrix metalloproteinase levels DYNC2H1 intron 20031604 rs11225649 chr11 103151516 C A 2.50E-05 Urinary metabolites DYNC2H1 intron 21572414 rs12275164 chr11 103168414 G A 3.64E-04 Alzheimer's disease DYNC2H1 intron 17998437 rs7102731 chr11 103169889 C G 3.41E-04 Alzheimer's disease DYNC2H1 intron 17998437 rs4754901 chr11 103170312 A G 3.50E-04 Alzheimer's disease DYNC2H1 intron 17998437 rs7118046 chr11 103185564 C T 3.60E-04 Alzheimer's disease DYNC2H1 intron 17998437 rs11225703 chr11 103185959 C T 5.55E-05 Serum metabolites DYNC2H1 intron 19043545 rs12282979 chr11 103186255 A G 4.33E-04 Alzheimer's disease DYNC2H1 intron 17998437 rs12292276 chr11 103191268 A G 3.59E-04 Alzheimer's disease DYNC2H1 intron 17998437 rs313408 chr11 103191330 T C 8.49E-05 Serum metabolites DYNC2H1 intron 19043545 rs313408 chr11 103191330 T C 2.20E-05 Urinary metabolites DYNC2H1 intron 21572414 rs313396 chr11 103193087 C A 6.10E-05 HIV-1 control DYNC2H1 intron 20041166 rs11225721 chr11 103205311 T C 3.20E-16 Matrix metalloproteinase levels DYNC2H1 intron 20031604 rs10895399 chr11 103210115 G A 3.91E-15 Matrix metalloproteinase levels DYNC2H1 intron 20031604 rs10895400 chr11 103210214 C T 1.33E-15 Matrix metalloproteinase levels DYNC2H1 intron 20031604 rs11225730 chr11 103211316 T G 4.49E-04 Acute lung injury DYNC2H1 intron 22295056 rs7118092 chr11 103215748 C T 4.78E-16 Matrix metalloproteinase levels DYNC2H1 intron 20031604 rs3847582 chr11 103216252 G A 2.86E-05 Menopause (age at onset) DYNC2H1 intron 19448619 rs7107436 chr11 103218918 G A 3.32E-04 Acute lung injury DYNC2H1 intron 22295056 rs7941666 chr11 103221537 G A 4.07E-15 Matrix metalloproteinase levels DYNC2H1 intron 20031604 rs7941666 chr11 103221537 G A 4.43E-04 Acute lung injury DYNC2H1 intron 22295056 rs7935444 chr11 103222286 T G 5.18E-04 Acute lung injury DYNC2H1 intron 22295056 rs7945242 chr11 103225913 A C 5.22E-04 Acute lung injury DYNC2H1 intron 22295056 rs7941781 chr11 103226865 C A,G 5.30E-04 Acute lung injury DYNC2H1 intron 22295056 rs3910095 chr11 103249629 A G 3.65E-15 Matrix metalloproteinase levels DYNC2H1 intron 20031604 rs3910095 chr11 103249629 A G 6.57E-04 Acute lung injury DYNC2H1 intron 22295056 rs11225755 chr11 103250088 A G 9.17E-14 Matrix metalloproteinase levels DYNC2H1 intron 20031604 rs11225755 chr11 103250088 A G 6.57E-04 Acute lung injury DYNC2H1 intron 22295056 rs12420792 chr11 103253696 C T 5.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DYNC2H1 intron 20877124 rs11225765 chr11 103266986 T G 7.71E-05 Alzheimer's disease DYNC2H1 intron 17998437 rs11225768 chr11 103273098 G A 5.81E-04 Acute lung injury DYNC2H1 intron 22295056 rs10895423 chr11 103279762 A C 7.36E-04 Acute lung injury DYNC2H1 intron 22295056 rs11225778 chr11 103281559 T G 7.36E-04 Acute lung injury DYNC2H1 intron 22295056 rs7129349 chr11 103281943 G A 4.07E-15 Matrix metalloproteinase levels DYNC2H1 intron 20031604 rs7129349 chr11 103281943 G A 7.36E-04 Acute lung injury DYNC2H1 intron 22295056 rs17308149 chr11 103297966 C T 9.06E-07 White blood cell count DYNC2H1 intron 21738479 rs11225796 chr11 103306072 A T 7.87E-04 Acute lung injury DYNC2H1 intron 22295056 rs1384079 chr11 103307544 A G 7.91E-04 Acute lung injury DYNC2H1 intron 22295056 rs10895428 chr11 103310299 A T 9.38E-04 Acute lung injury DYNC2H1 intron 22295056 rs17100918 chr11 103317879 G A 3.90E-04 Smoking quantity DYNC2H1 intron 24665060 rs581977 chr11 103318329 A G 7.86E-05 Schizophrenia DYNC2H1 intron 24253340 rs10895429 chr11 103319469 T A 3.62E-04 Smoking quantity DYNC2H1 intron 24665060 rs17100943 chr11 103323596 A G 4.71E-04 Smoking quantity DYNC2H1 intron 24665060 rs313862 chr11 103334643 T C 3.80E-04 HIV-1 viral setpoint DYNC2H1 intron 17641165 rs313862 chr11 103334643 T C 6.06E-05 Schizophrenia DYNC2H1 intron 24253340 rs12418302 chr11 103338877 A G 4.02E-04 Smoking quantity DYNC2H1 intron 24665060 rs3740942 chr11 103339246 G A 1.83E-04 Smoking quantity DYNC2H1 intron 24665060 rs12419850 chr11 103342939 A G 2.62E-04 Smoking quantity DYNC2H1 intron 24665060 rs11225822 chr11 103345030 A C 2.55E-15 Matrix metalloproteinase levels DYNC2H1 intron 20031604 rs11225822 chr11 103345030 A C 1.20E-06 Left ventricular hypertrophy DYNC2H1 intron 21828061 rs10895437 chr11 103358091 A G 2.22E-05 Attention deficit hyperactivity disorder / / 20732627 rs1481964 chr11 103393839 G A 2.49E-05 Attention deficit hyperactivity disorder / / 20732627 rs1481963 chr11 103393927 G A 1.78E-05 Attention deficit hyperactivity disorder / / 20732627 rs1481961 chr11 103394962 C A 3.36E-05 Attention deficit hyperactivity disorder / / 20732627 rs11826048 chr11 103398297 C T 9.70E-07 Cardiovascular disease / / 18179892 rs10895454 chr11 103399692 C A,G,T 3.61E-05 Attention deficit hyperactivity disorder / / 20732627 rs7105630 chr11 103403862 T C 2.04E-05 Attention deficit hyperactivity disorder / / 20732627 rs7105630 chr11 103403862 T C 1.25E-05 Cognitive impairment induced by topiramate / / 22091778 rs7117196 chr11 103403911 C T 1.64E-05 Attention deficit hyperactivity disorder / / 20732627 rs1481954 chr11 103406150 G A 2.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs716273 chr11 103417868 T C 8.98E-06 Attention deficit hyperactivity disorder / / 20732627 rs10895458 chr11 103418084 A C 2.81E-05 Attention deficit hyperactivity disorder / / 20732627 rs10895458 chr11 103418084 A C 2.36E-04 Alzheimer's disease (late onset) / / 21379329 rs716274 chr11 103418158 A G 8.67E-06 Attention deficit hyperactivity disorder / / 20732627 rs716274 chr11 103418158 A G 9.00E-08 Small-cell lung cancer / / 21118971 rs1481996 chr11 103421935 A G 1.28E-04 Alzheimer's disease (late onset) / / 21379329 rs10895465 chr11 103434914 G T 9.61E-05 Multiple complex diseases / / 17554300 rs4754974 chr11 103509801 A C 3.96E-10 Matrix metalloproteinase levels / / 20031604 rs10791634 chr11 103524012 G A 3.96E-10 Matrix metalloproteinase levels / / 20031604 rs11225952 chr11 103524114 T G 3.96E-10 Matrix metalloproteinase levels / / 20031604 rs7118412 chr11 103525754 A G 9.00E-06 Disc degeneration (lumbar) / / 22993228 rs7103004 chr11 103526024 C T 9.00E-06 Disc degeneration (lumbar) / / 22993228 rs2060752 chr11 103527489 T C 1.33E-09 Matrix metalloproteinase levels / / 20031604 rs12805875 chr11 103529632 A G 9.00E-06 Disc degeneration (lumbar) / / 22993228 rs4554859 chr11 103530366 G T 9.00E-06 Disc degeneration (lumbar) / / 22993228 rs10488753 chr11 103530707 T C 6.73E-09 Matrix metalloproteinase levels / / 20031604 rs7120812 chr11 103531128 T C 3.02E-10 Matrix metalloproteinase levels / / 20031604 rs7106605 chr11 103540542 A G 1.72E-05 Bipolar disorder,affective / / 20528957 rs10488749 chr11 103540781 G C 6.64E-09 Matrix metalloproteinase levels / / 20031604 rs7130910 chr11 103545238 T C 2.37E-05 Bipolar disorder,affective / / 20528957 rs10895514 chr11 103579840 C G 1.72E-05 Bipolar disorder,affective / / 20528957 rs10895514 chr11 103579840 C G 8.60E-05 Cognitive function / / 24684796 rs1917445 chr11 103589094 C T 6.00E-07 Neutrophil count / / 21507922 rs6591048 chr11 103640047 C T 1.18E-04 Multiple complex diseases / / 17554300 rs974819 chr11 103660567 T C 2.00E-09 Coronary heart disease / / 21378988 rs974819 chr11 103660567 T C 1.89E-08 Coronary artery disease (CAD) age >50 / / 23202125 rs974819 chr11 103660567 T C 1.89E-11 Coronary artery disease / / 23202125 rs974819 chr11 103660567 T C 3.44E-09 Coronary artery disease (CAD) age <=50 / / 23202125 rs974819 chr11 103660567 T C 5.41E-10 Coronary artery disease (CAD) (males) / / 23202125 rs974819 chr11 103660567 T C 6.99E-09 Coronary artery disease with myocardial infarction / / 23202125 rs974819 chr11 103660567 T C 7.00E-04 Coronary artery disease / / 24262325 rs11226015 chr11 103664059 A G 3.39E-05 Glycosylated haemoglobin levels / / 17255346 rs900517 chr11 103669806 G A 9.86E-06 Glycosylated haemoglobin levels / / 17255346 rs11226019 chr11 103673960 A G 1.02E-05 Glycosylated haemoglobin levels / / 17255346 rs10791643 chr11 103674339 A G 2.08E-05 Glycosylated haemoglobin levels / / 17255346 rs10791643 chr11 103674339 A G 9.32E-11 Matrix metalloproteinase levels / / 20031604 rs10502019 chr11 103713532 T C 8.23E-08 Matrix metalloproteinase levels / / 20031604 rs721346 chr11 103737457 T G 2.70E-05 Type 2 diabetes / / 17903298 rs11601578 chr11 103761009 T C 5.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs1053861 chr11 103778154 C T 2.55E-04 Taste perception PDGFD UTR-3 22132133 rs10895534 chr11 103779793 T C 6.14E-04 Taste perception PDGFD UTR-3 22132133 rs11226078 chr11 103792018 C T 1.17E-04 Multiple complex diseases PDGFD intron 17554300 rs10895547 chr11 103808152 C T 3.00E-06 Coronary heart disease PDGFD intron 21347282 rs12274248 chr11 103825110 C T 3.49E-08 HDL cholesterol PDGFD intron 23063622 rs10502023 chr11 103838408 A G 7.18E-04 Type 2 diabetes PDGFD intron 17463246 rs260823 chr11 103845007 C T 4.50E-04 Type 2 diabetes PDGFD intron 17463246 rs2129741 chr11 103867975 G C 2.40E-04 Coronary heart disease PDGFD intron 21966275 rs722355 chr11 103884797 A C 4.95E-04 Premature ovarian failure PDGFD intron 19508998 rs7128670 chr11 103904556 A C,G,T 5.07E-04 Response to taxane treatment (placlitaxel) PDGFD intron 23006423 rs1052313 chr11 103908735 G A 3.35E-08 Matrix metalloproteinase levels DDI1 cds-synon 20031604 rs260818 chr11 103920105 C A 9.71E-04 Myopia (pathological) PDGFD intron 21095009 rs260818 chr11 103920105 C A 1.47E-05 Post-operative nausea and vomiting PDGFD intron 21694509 rs260818 chr11 103920105 C A 3.60E-05 Elbow pain PDGFD intron pha003008 rs2515081 chr11 103968476 T A 9.77E-05 Alzheimer's disease PDGFD intron 17998437 rs2515081 chr11 103968476 T A 8.48E-12 Matrix metalloproteinase levels PDGFD intron 20031604 rs11226165 chr11 103980615 C T 5.22E-04 Obesity (extreme) PDGFD intron 21935397 rs168636 chr11 103981833 A G 2.99E-10 Matrix metalloproteinase levels PDGFD intron 20031604 rs668285 chr11 104003545 C T 8.76E-09 Matrix metalloproteinase levels PDGFD intron 20031604 rs2170719 chr11 104012767 G A 8.54E-04 Multiple complex diseases PDGFD intron 17554300 rs12226700 chr11 104013263 A T 8.32E-11 Matrix metalloproteinase levels PDGFD intron 20031604 rs12274835 chr11 104013460 G A 8.32E-11 Matrix metalloproteinase levels PDGFD intron 20031604 rs8181543 chr11 104017037 G A 6.14E-04 Rheumatoid arthritis PDGFD intron 21452313 rs7943401 chr11 104018088 G A 4.84E-04 Rheumatoid arthritis PDGFD intron 21452313 rs10895595 chr11 104031450 C T 7.98E-06 Post-operative nausea and vomiting PDGFD intron 21694509 rs10895595 chr11 104031450 C T 2.90E-05 Kawasaki disease PDGFD intron 22446962 rs10895597 chr11 104037060 G A 8.73E-16 Matrix metalloproteinase levels / / 20031604 rs10502032 chr11 104170706 C A 9.04E-04 Myocardial Infarction / / pha002873 rs1002248 chr11 104211022 C G 7.95E-05 Serum metabolites / / 19043545 rs12365754 chr11 104249002 A G 1.36E-05 Acne (severe teenage) / / 24114350 rs11226367 chr11 104321634 T C 5.02E-18 Matrix metalloproteinase levels / / 20031604 rs11226373 chr11 104334239 A G 2.46E-04 Type 2 diabetes / / 17463246 rs11226373 chr11 104334239 A G 2.00E-18 Matrix metalloproteinase levels / / 20031604 rs10895692 chr11 104341165 C T 8.30E-05 Personality dimensions / / 18957941 rs1487694 chr11 104356169 A G 3.48E-04 Type 2 diabetes / / 17463246 rs1487694 chr11 104356169 A G 9.05E-15 Matrix metalloproteinase levels / / 20031604 rs2046652 chr11 104360654 G A 3.13E-04 Type 2 diabetes / / 17463246 rs2046652 chr11 104360654 G A 1.11E-14 Matrix metalloproteinase levels / / 20031604 rs7114728 chr11 104369761 G T 3.95E-04 Type 2 diabetes / / 17463246 rs7114728 chr11 104369761 G T 4.67E-15 Matrix metalloproteinase levels / / 20031604 rs4558140 chr11 104372156 A T 3.13E-04 Type 2 diabetes / / 17463246 rs4558140 chr11 104372156 A T 9.05E-15 Matrix metalloproteinase levels / / 20031604 rs17102576 chr11 104373588 G C 4.79E-04 Multiple complex diseases / / 17554300 rs2408942 chr11 104383714 G C 4.05E-04 Type 2 diabetes / / 17463246 rs2408942 chr11 104383714 G C 1.72E-14 Matrix metalloproteinase levels / / 20031604 rs7930608 chr11 104383926 A T 3.13E-04 Type 2 diabetes / / 17463246 rs7930608 chr11 104383926 A T 9.05E-15 Matrix metalloproteinase levels / / 20031604 rs11226402 chr11 104385371 G A 2.33E-04 Type 2 diabetes / / 17463246 rs11226402 chr11 104385371 G A 9.05E-15 Matrix metalloproteinase levels / / 20031604 rs11226403 chr11 104385628 G A 4.41E-04 Type 2 diabetes / / 17463246 rs11226403 chr11 104385628 G A 9.05E-15 Matrix metalloproteinase levels / / 20031604 rs1565130 chr11 104388020 T G 8.80E-04 Type 2 diabetes / / 17463246 rs1565130 chr11 104388020 T G 9.05E-15 Matrix metalloproteinase levels / / 20031604 rs1565131 chr11 104388262 A G 6.78E-04 Type 2 diabetes / / 17463246 rs1565131 chr11 104388262 A G 9.05E-15 Matrix metalloproteinase levels / / 20031604 rs1565132 chr11 104388329 A G 3.67E-04 Type 2 diabetes / / 17463246 rs1565132 chr11 104388329 A G 9.05E-15 Matrix metalloproteinase levels / / 20031604 rs1487683 chr11 104388714 T G 3.13E-04 Type 2 diabetes / / 17463246 rs1487683 chr11 104388714 T G 9.05E-15 Matrix metalloproteinase levels / / 20031604 rs11226407 chr11 104388759 T A 5.63E-04 Type 2 diabetes / / 17463246 rs11226407 chr11 104388759 T A 1.87E-14 Matrix metalloproteinase levels / / 20031604 rs10502035 chr11 104403209 A G 2.71E-04 Type 2 diabetes / / 17463246 rs10502035 chr11 104403209 A G 6.84E-15 Matrix metalloproteinase levels / / 20031604 rs2220349 chr11 104412288 G A 5.52E-12 Matrix metalloproteinase levels / / 20031604 rs17102636 chr11 104417374 C T 3.30E-04 Type 2 diabetes / / 17463246 rs17102636 chr11 104417374 C T 8.64E-15 Matrix metalloproteinase levels / / 20031604 rs2029285 chr11 104418194 C T 8.35E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs722354 chr11 104423008 C T 6.08E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1942510 chr11 104497607 T C 7.20E-05 Tunica Media / / pha003038 rs1942518 chr11 104540289 C A 4.03E-21 Matrix metalloproteinase levels / / 20031604 rs1942517 chr11 104541863 G A 1.96E-15 Matrix metalloproteinase levels / / 20031604 rs1893462 chr11 104558798 G A 2.08E-15 Matrix metalloproteinase levels / / 20031604 rs6591093 chr11 104563568 A T 1.96E-15 Matrix metalloproteinase levels / / 20031604 rs883505 chr11 104564526 T A 1.49E-20 Matrix metalloproteinase levels / / 20031604 rs17102902 chr11 104573604 T C 9.05E-08 Matrix metalloproteinase levels / / 20031604 rs2155161 chr11 104573828 T C 4.29E-15 Matrix metalloproteinase levels / / 20031604 rs7122441 chr11 104598374 A T 4.26E-14 Matrix metalloproteinase levels / / 20031604 rs1147027 chr11 104604262 C A 2.23E-15 Matrix metalloproteinase levels / / 20031604 rs2052752 chr11 104618572 A G 3.01E-04 White matter integrity / / 22425255 rs1834631 chr11 104620211 G A 3.22E-04 White matter integrity / / 22425255 rs1200649 chr11 104632721 C T 4.78E-04 White matter integrity / / 22425255 rs1147049 chr11 104659536 T C 2.01E-15 Matrix metalloproteinase levels / / 20031604 rs12804529 chr11 104666801 G A 1.03E-04 Smoking cessation / / 24665060 rs1147055 chr11 104681248 A T 6.90E-04 Multiple complex diseases / / 17554300 rs1529337 chr11 104681690 G A 2.06E-09 Matrix metalloproteinase levels / / 20031604 rs6591099 chr11 104690993 G A 2.84E-08 Matrix metalloproteinase levels / / 20031604 rs1030395 chr11 104696057 C T 2.06E-09 Matrix metalloproteinase levels / / 20031604 rs10736643 chr11 104696204 A T 2.06E-09 Matrix metalloproteinase levels / / 20031604 rs520977 chr11 104696225 A G 6.89E-04 Multiple complex diseases / / 17554300 rs1559839 chr11 104696726 G A 1.04E-09 Matrix metalloproteinase levels / / 20031604 rs11226540 chr11 104745330 C T 6.99E-05 Lung function (forced vital capacity) / / 24023788 rs11226540 chr11 104745330 C T 9.02E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs573894 chr11 104771486 A G 3.78E-10 Matrix metalloproteinase levels / / 20031604 rs551312 chr11 104786973 G A 0.00000064 Mean arterial pressure LOC643733 intron 22510845 rs1944908 chr11 104788962 A C 2.50E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs488928 chr11 104789221 A G 5.77E-04 Type 2 diabetes / / 17463246 rs488928 chr11 104789221 A G 5.43E-08 Matrix metalloproteinase levels / / 20031604 rs674467 chr11 104812647 C T 2.38E-06 Asthma (childhood onset) / / 23829686 rs579408 chr11 104828306 A T 9.00E-05 Type 2 diabetes CASP4 intron 17463246 rs540819 chr11 104866461 A T 7.44E-04 Type 2 diabetes CASP5 intron 17463246 rs3181174 chr11 104876724 T A 1.38E-09 Matrix metalloproteinase levels CASP5 intron 20031604 rs45585331 chr11 104878019 A C 0.0000013 Breast cancer CASP5 missense 23555315 rs3181320 chr11 104879628 G C 5.74E-04 Multiple complex diseases CASP5 missense 17554300 rs17375681 chr11 104913560 A G 8.61E-04 Multiple complex diseases CARD16 intron 17554300 rs17375681 chr11 104913560 A G 1.41E-05 Smoking initiation CARD16 intron 24665060 rs562704 chr11 104922670 T G 3.34E-04 Multiple complex diseases / / 17554300 rs508760 chr11 104923951 G T 5.87E-05 Depression (quantitative trait) / / 23290196 rs562441 chr11 104924786 C T 3.08E-04 Parkinson's disease / / 16252231 rs529809 chr11 104933442 A C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1792754 chr11 104936842 C G 3.38E-04 Multiple complex diseases / / 17554300 rs11226608 chr11 104937371 G T 3.64E-05 Multiple complex diseases / / 17554300 rs11226609 chr11 104937459 T C 9.58E-04 Multiple complex diseases / / 17554300 rs538943 chr11 104939029 C T 5.50E-06 Urinary metabolites / / 21572414 rs1785869 chr11 104939776 T C 4.24E-04 Multiple complex diseases / / 17554300 rs530009 chr11 104941257 G A 4.51E-04 Type 2 diabetes / / 17463246 rs481926 chr11 104950495 A G 1.32E-04 Type 2 diabetes / / 17463246 rs1699095 chr11 104952022 A G 9.99E-04 Parkinson's disease / / 16252231 rs1699081 chr11 104958571 G A 3.62E-04 Type 2 diabetes / / 17463246 rs11226613 chr11 104972518 T A 5.00E-06 Bronchopulmonary dysplasia / / 23897914 rs1847293 chr11 104979669 G A 5.85E-04 Type 2 diabetes / / 17463246 rs12420524 chr11 104979973 C T 1.08E-04 Type 2 diabetes / / 17463246 rs2062806 chr11 104980898 G C 2.73E-04 Parkinson's disease / / 16252231 rs1847298 chr11 104993409 G A 2.95E-04 Type 2 diabetes / / 17463246 rs7934633 chr11 105006750 G C 2.66E-04 Type 2 diabetes / / 17463246 rs7117758 chr11 105007755 C G 7.77E-05 Type 2 diabetes / / 17463246 rs7117758 chr11 105007755 C G 8.20E-06 Urinary metabolites / / 21572414 rs7107383 chr11 105008884 A T 1.91E-05 Depression (quantitative trait) CARD18 intron 23290196 rs2291269 chr11 105010191 A G 2.43E-04 Type 2 diabetes CARD18 intron 17463246 rs10895779 chr11 105018100 G C 2.54E-04 Type 2 diabetes / / 17463246 rs7948428 chr11 105018459 A C 2.38E-04 Type 2 diabetes / / 17463246 rs17103836 chr11 105018953 G A 1.47E-04 Type 2 diabetes / / 17463246 rs17103836 chr11 105018953 G A 7.20E-06 Urinary metabolites / / 21572414 rs17103858 chr11 105024039 C A 7.09E-04 Type 2 diabetes / / 17463246 rs17103873 chr11 105026841 G A 1.02E-04 Type 2 diabetes / / 17463246 rs17103873 chr11 105026841 G A 1.20E-05 Urinary metabolites / / 21572414 rs1566770 chr11 105028875 G A 2.49E-04 Type 2 diabetes / / 17463246 rs12421544 chr11 105038968 A G 9.70E-06 Urinary metabolites / / 21572414 rs10895781 chr11 105038988 T G 2.15E-04 Type 2 diabetes / / 17463246 rs1503389 chr11 105041958 C T 6.80E-04 Type 2 diabetes / / 17463246 rs1503389 chr11 105041958 C T 1.06E-05 Depression (quantitative trait) / / 23290196 rs17103951 chr11 105049892 A G 1.07E-04 Type 2 diabetes / / 17463246 rs4754128 chr11 105058220 G A 4.97E-04 Type 2 diabetes / / 17463246 rs4754128 chr11 105058220 G A 1.44E-04 Multiple complex diseases / / 17554300 rs4754128 chr11 105058220 G A 1.86E-05 Depression (quantitative trait) / / 23290196 rs2409064 chr11 105058837 G A 1.30E-05 Depression (quantitative trait) / / 23290196 rs4755095 chr11 105059791 G A 1.48E-04 Type 2 diabetes / / 17463246 rs7118394 chr11 105081273 A T 0.0001172 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7118394 chr11 105081273 A T 1.17E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17103984 chr11 105085734 G A 0.0001116 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17103984 chr11 105085734 G A 1.12E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13377527 chr11 105086933 C T 0.0001398 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13377527 chr11 105086933 C T 1.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7940032 chr11 105090711 G C 0.0001747 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7940032 chr11 105090711 G C 1.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9888195 chr11 105091333 A C 0.0001757 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9888195 chr11 105091333 A C 1.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9888157 chr11 105091538 C T 0.000176 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9888157 chr11 105091538 C T 1.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7101358 chr11 105093476 C A 0.0001855 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7101358 chr11 105093476 C A 1.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11226667 chr11 105096976 G T 7.80E-05 Type 2 diabetes / / 17463246 rs11226667 chr11 105096976 G T 0.0002032 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11226667 chr11 105096976 G T 2.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1449045 chr11 105098107 C T 4.37E-05 Serum metabolites / / 19043545 rs1449045 chr11 105098107 C T 7.12E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs7926945 chr11 105217173 C T 7.42E-05 Multiple complex diseases / / 17554300 rs11823542 chr11 105276553 C T 2.47E-12 Multiple complex diseases / / 17554300 rs2513265 chr11 105423795 T A 4.20E-05 Effectiveness of iloperidone treatment in schizophrenia / / 18521090 rs2510177 chr11 105441060 A G 8.65E-08 Matrix metalloproteinase levels / / 20031604 rs11226774 chr11 105441422 G A 3.21E-04 Multiple complex diseases / / 17554300 rs11226791 chr11 105460042 T C 3.31E-08 Matrix metalloproteinase levels / / 20031604 rs1445604 chr11 105498095 G T 1.22E-05 Nephrolithiasis GRIA4 intron 22396660 rs4754133 chr11 105503658 T C 5.29E-04 Epilepsy GRIA4 intron 22116939 rs10895846 chr11 105507515 A C 3.58E-06 Ejection fraction in Tripanosoma cruzi seropositivity GRIA4 intron 24324551 rs6591137 chr11 105507517 C T 5.95E-06 Ejection fraction in Tripanosoma cruzi seropositivity GRIA4 intron 24324551 rs11226814 chr11 105507866 T C 3.12E-06 Ejection fraction in Tripanosoma cruzi seropositivity GRIA4 intron 24324551 rs56034429 chr11 105507928 T G 3.12E-06 Ejection fraction in Tripanosoma cruzi seropositivity GRIA4 intron 24324551 rs10895847 chr11 105508690 A G 7.29E-06 Ejection fraction in Tripanosoma cruzi seropositivity GRIA4 intron 24324551 rs4261254 chr11 105508772 T C 3.80E-06 Ejection fraction in Tripanosoma cruzi seropositivity GRIA4 intron 24324551 rs10895849 chr11 105510193 C T 3.87E-06 Ejection fraction in Tripanosoma cruzi seropositivity GRIA4 intron 24324551 rs2409574 chr11 105511383 C G 4.71E-06 Ejection fraction in Tripanosoma cruzi seropositivity GRIA4 intron 24324551 rs4301761 chr11 105511471 G C 7.05E-06 Ejection fraction in Tripanosoma cruzi seropositivity GRIA4 intron 24324551 rs4754134 chr11 105512824 C T 5.58E-06 Ejection fraction in Tripanosoma cruzi seropositivity GRIA4 intron 24324551 rs3170 chr11 105513061 A T 3.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity GRIA4 intron 24324551 rs10895857 chr11 105554203 C T 6.49E-04 Parkinson's disease GRIA4 intron 16252231 rs11601239 chr11 105556598 C G 6.00E-09 Refractive error GRIA4 intron 23396134 rs1822993 chr11 105566602 A C 6.08E-04 Parkinson's disease GRIA4 intron 16252231 rs638099 chr11 105577200 C T 6.14E-04 Parkinson's disease GRIA4 intron 16252231 rs499945 chr11 105585683 G T 6.06E-04 Parkinson's disease GRIA4 intron 16252231 rs12808612 chr11 105588070 A G 6.64E-05 Post-operative nausea and vomiting GRIA4 intron 21694509 rs12808612 chr11 105588070 A G 9.92E-04 Epilepsy GRIA4 intron 22116939 rs2186598 chr11 105614894 T G 8.64E-05 Serum albumin level GRIA4 intron pha003084 rs10502062 chr11 105621257 T G 1.83E-08 Matrix metalloproteinase levels GRIA4 intron 20031604 rs10502063 chr11 105621281 T C 2.06E-08 Matrix metalloproteinase levels GRIA4 intron 20031604 rs10791773 chr11 105631278 C A 6.77E-04 Parkinson's disease GRIA4 intron 16252231 rs10791774 chr11 105645648 A G 6.81E-05 Serum albumin level GRIA4 intron pha003084 rs610160 chr11 105696895 T C 7.05E-06 Telomere length GRIA4 intron 20139977 rs41375749 chr11 105702316 T A 1.54E-05 Telomere length GRIA4 intron 20139977 rs1940964 chr11 105709856 T C 5.13E-04 Cognitive impairment induced by topiramate GRIA4 intron 22091778 rs2277279 chr11 105732731 C T 8.94E-04 HIV-1 viral setpoint GRIA4 intron 17641165 rs515803 chr11 105735110 C T 1.50E-05 Response to statin therapy GRIA4 intron 20339536 rs680109 chr11 105750709 C A 0.0000252 Aging GRIA4 intron 22445811 rs1939153 chr11 105751726 C T 5.29E-05 Alzheimer's disease (late onset) GRIA4 intron 20885792 rs2508467 chr11 105758104 G A 6.62E-04 Response to taxane treatment (placlitaxel) GRIA4 intron 23006423 rs585464 chr11 105762601 G A 2.36E-04 Glycosylated haemoglobin levels GRIA4 intron 17255346 rs589104 chr11 105807772 T G 0.000812 Salmonella-induced pyroptosis GRIA4 intron 22837397 rs17391295 chr11 105807886 C T 4.63E-04 HIV-1 viral setpoint GRIA4 intron 17641165 rs17104835 chr11 105842083 A G 1.47E-07 Lymphocyte counts GRIA4 intron 22286170 rs551893 chr11 105842111 A G 3.99E-09 Multiple complex diseases GRIA4 intron 17554300 rs609665 chr11 105844065 C T 7.40E-04 Alcohol dependence GRIA4 intron 20201924 rs609665 chr11 105844065 C T 0.000372 Salmonella-induced pyroptosis GRIA4 intron 22837397 rs11821382 chr11 105847468 C T 0.000167 Salmonella-induced pyroptosis GRIA4 intron 22837397 rs7110414 chr11 105861507 G A 0.000332 Salmonella-induced pyroptosis / / 22837397 rs10895889 chr11 105865432 T C 0.000221 Salmonella-induced pyroptosis / / 22837397 rs10895889 chr11 105865432 T C 7.40E-05 Diabetic nephropathy / / pha002864 rs11226891 chr11 105871930 T C 0.000239 Salmonella-induced pyroptosis / / 22837397 rs10895895 chr11 105907226 C T 4.62E-05 Post-operative nausea and vomiting / / 21694509 rs10791779 chr11 105918592 T A 9.92E-05 Lymphocyte counts / / 22286170 rs3737347 chr11 105923564 C T 1.38E-04 Amyotrophic lateral sclerosis (sporadic) KBTBD3 UTR-3 24529757 rs2155340 chr11 105959082 A T 5.68E-04 Type 2 diabetes AASDHPPT intron 17463246 rs7554 chr11 105969101 A G 7.56E-04 Multiple complex diseases AASDHPPT UTR-3 17554300 rs10791780 chr11 105971474 G C 7.61E-04 Multiple complex diseases / / 17554300 rs754562 chr11 106005901 G A 5.07E-04 Type 2 diabetes / / 17463246 rs10895910 chr11 106018470 G A 2.30E-04 Type 2 diabetes / / 17463246 rs7947817 chr11 106018679 G C 5.23E-04 Type 2 diabetes / / 17463246 rs12286785 chr11 106026300 A G 6.20E-04 Multiple complex diseases / / 17554300 rs11226939 chr11 106026427 G A 3.27E-04 Type 2 diabetes / / 17463246 rs4505037 chr11 106047102 T G 8.17E-04 Type 2 diabetes / / 17463246 rs1940763 chr11 106050169 T A 8.60E-04 Multiple complex diseases / / 17554300 rs1940767 chr11 106058917 A G 8.31E-04 Type 2 diabetes / / 17463246 rs4755139 chr11 106062504 C G 2.26E-04 Multiple complex diseases / / 17554300 rs10895932 chr11 106067671 A G 7.20E-04 Type 2 diabetes / / 17463246 rs1940777 chr11 106067720 C T 8.10E-04 Type 2 diabetes / / 17463246 rs1893854 chr11 106069348 C T 9.15E-04 Type 2 diabetes / / 17463246 rs1940778 chr11 106069517 T C 6.46E-04 Type 2 diabetes / / 17463246 rs565672 chr11 106085501 T C 9.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs584618 chr11 106091658 A G 5.98E-04 Multiple complex diseases / / 17554300 rs4755142 chr11 106092299 G A 5.88E-04 Type 2 diabetes / / 17463246 rs1115160 chr11 106095211 G A 9.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs580071 chr11 106098428 A G 9.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12225407 chr11 106102065 C T 5.87E-04 Type 2 diabetes / / 17463246 rs10895935 chr11 106102188 A T 9.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1396152 chr11 106102773 T C 9.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs657786 chr11 106109861 A G 9.73E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs574225 chr11 106171015 T A 8.14E-04 Multiple complex diseases / / 17554300 rs613928 chr11 106192955 G A 0.0006853 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs613928 chr11 106192955 G A 6.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10750754 chr11 106216510 G A 2.64E-04 Type 2 diabetes / / 17463246 rs7952658 chr11 106223869 A G 6.51E-04 Type 2 diabetes / / 17463246 rs563816 chr11 106231144 C T 7.17E-06 Alcohol and nictotine co-dependence / / 20158304 rs618453 chr11 106233094 A G 5.46E-04 Type 2 diabetes / / 17463246 rs618453 chr11 106233094 A G 2.11E-05 Alcohol and nictotine co-dependence / / 20158304 rs520345 chr11 106235011 A T 2.06E-04 Type 2 diabetes / / 17463246 rs638266 chr11 106245491 A T 7.23E-04 Type 2 diabetes / / 17463246 rs617689 chr11 106262357 A G 4.80E-04 Type 2 diabetes / / 17463246 rs567992 chr11 106262397 C T 3.29E-04 Heart Failure / / pha002884 rs9326355 chr11 106265116 C G 5.95E-04 Type 2 diabetes / / 17463246 rs10895950 chr11 106265361 A G 8.04E-08 Matrix metalloproteinase levels / / 20031604 rs10895951 chr11 106265530 A G 9.57E-08 Matrix metalloproteinase levels / / 20031604 rs11227029 chr11 106276534 G A 9.25E-05 Post-operative nausea and vomiting / / 21694509 rs17552029 chr11 106285669 C T 7.31E-04 Iron levels / / pha002876 rs4755154 chr11 106311608 T C 6.66E-04 Alzheimer's disease / / 17998437 rs907647 chr11 106318515 A G 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10895959 chr11 106330162 G A 3.00E-06 Inattentive symptoms / / 18821565 rs2469483 chr11 106334777 A G 3.49E-05 Personality dimensions / / 22628180 rs12385797 chr11 106336289 C A 6.70E-07 Fasting plasma glucose / / 19060907 rs10895961 chr11 106336311 A G 8.06E-05 Multiple complex diseases / / 17554300 rs11227059 chr11 106337122 G T 3.25E-04 Type 2 diabetes / / 17463246 rs11227059 chr11 106337122 G T 2.34E-09 Matrix metalloproteinase levels / / 20031604 rs10502070 chr11 106339209 G A 1.70E-04 Type 2 diabetes / / 17463246 rs10502070 chr11 106339209 G A 4.00E-10 Matrix metalloproteinase levels / / 20031604 rs12276765 chr11 106341204 A G 1.87E-04 Multiple complex diseases / / 17554300 rs10502072 chr11 106349874 T C 2.70E-09 Matrix metalloproteinase levels / / 20031604 rs12290638 chr11 106363983 T G 7.14E-08 Matrix metalloproteinase levels / / 20031604 rs12805072 chr11 106368793 C T 2.94E-11 Matrix metalloproteinase levels / / 20031604 rs12274945 chr11 106375299 A C 9.38E-04 Multiple complex diseases / / 17554300 rs12274945 chr11 106375299 A C 8.14E-06 Rheumatoid arthritis / / 19503088 rs12274945 chr11 106375299 A C 3.02E-08 Matrix metalloproteinase levels / / 20031604 rs1945076 chr11 106382378 C T 1.06E-04 Multiple complex diseases / / 17554300 rs10895974 chr11 106390596 C T 1.74E-04 Multiple complex diseases / / 17554300 rs12284877 chr11 106390653 T C 3.97E-04 Type 2 diabetes / / 17463246 rs17105807 chr11 106391036 T A 4.07E-04 Type 2 diabetes / / 17463246 rs12285411 chr11 106391907 A G 3.97E-04 Type 2 diabetes / / 17463246 rs1791463 chr11 106416708 G A 3.82E-05 Brain structure / / 22504417 rs11821466 chr11 106474261 A G 6.57E-04 Stroke / / pha002887 rs17105869 chr11 106477091 G A 3.83E-04 Stroke / / pha002887 rs1791581 chr11 106496038 G A 8.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs12364992 chr11 106523224 A G 6.00E-06 Obesity-related traits / / 23251661 rs1793079 chr11 106528717 G T 8.50E-07 Urinary metabolites / / 21572414 rs1783135 chr11 106531675 G T 2.40E-07 Urinary metabolites / / 21572414 rs11211846 chr11 106538523 G A 0.000629 Salmonella-induced pyroptosis / / 22837397 rs17105932 chr11 106543465 T A 1.67E-04 Multiple complex diseases / / 17554300 rs17105932 chr11 106543465 T A 0.000827 Salmonella-induced pyroptosis / / 22837397 rs10502074 chr11 106559413 C G 7.56E-05 Response to taxane treatment (placlitaxel) GUCY1A2 intron 23006423 rs631214 chr11 106574720 A G 9.57E-04 Suicide attempts in bipolar disorder GUCY1A2 intron 21423239 rs617358 chr11 106575512 C G 2.27E-04 Suicide attempts in bipolar disorder GUCY1A2 intron 21423239 rs10890568 chr11 106581197 C T 6.33E-05 Intelligence GUCY1A2 intron 21826061 rs4553343 chr11 106583901 C A 7.03E-05 Erythrocyte counts GUCY1A2 intron pha003099 rs11211884 chr11 106597231 G A 8.70E-06 Urinary metabolites GUCY1A2 intron 21572414 rs4121677 chr11 106615180 A G 2.84E-04 Myocardial Infarction GUCY1A2 intron pha002883 rs11608184 chr11 106620010 G A 7.48E-05 Progressive supranuclear palsy GUCY1A2 intron 21685912 rs12798695 chr11 106630756 C T 1.07E-04 Progressive supranuclear palsy GUCY1A2 intron 21685912 rs879929 chr11 106654359 T A 1.88E-10 Matrix metalloproteinase levels GUCY1A2 intron 20031604 rs901779 chr11 106656863 A G 1.77E-05 Colorectal cancer GUCY1A2 intron 21242260 rs10890590 chr11 106666059 G A 4.60E-04 Suicide attempts in bipolar disorder GUCY1A2 intron 21041247 rs10890590 chr11 106666059 G A 1.46E-04 Major depression (suicidal thoughts and behavior) GUCY1A2 intron 21750702 rs10890597 chr11 106675310 A G 9.31E-04 Alcohol dependence GUCY1A2 intron 21314694 rs17106108 chr11 106683102 G A 3.01E-04 Parkinson's disease GUCY1A2 intron 16252231 rs1487892 chr11 106692416 G A 5.49E-04 Suicide attempts in bipolar disorder GUCY1A2 intron 21041247 rs10890604 chr11 106705322 G A 8.90E-04 Suicide attempts in bipolar disorder GUCY1A2 intron 21041247 rs10890608 chr11 106711984 T A 4.36E-04 Suicide attempts in bipolar disorder GUCY1A2 intron 21041247 rs7943998 chr11 106715879 A C 4.60E-05 Weight loss (gastric bypass surgery) GUCY1A2 intron 23633212 rs7943998 chr11 106715879 A C 5.23E-05 Fibrinogen GUCY1A2 intron pha003068 rs7944123 chr11 106715970 A G 8.17E-04 Suicide attempts in bipolar disorder GUCY1A2 intron 21041247 rs1954864 chr11 106717518 T G 8.94E-04 Suicide attempts in bipolar disorder GUCY1A2 intron 21041247 rs10890611 chr11 106721959 T C 8.53E-04 Suicide attempts in bipolar disorder GUCY1A2 intron 21041247 rs7950959 chr11 106722884 C T 3.22E-04 Weight loss (gastric bypass surgery) GUCY1A2 intron 23633212 rs11211945 chr11 106722896 A C 7.46E-04 Smoking initiation GUCY1A2 intron 24665060 rs1944195 chr11 106750095 A G 1.47E-04 Cholesterol GUCY1A2 intron 17255346 rs2187036 chr11 106760002 G A 7.02E-05 Schizophrenia (cytomegalovirus infection interaction) GUCY1A2 intron 23358160 rs7125424 chr11 106779309 G T 1.31E-11 Matrix metalloproteinase levels GUCY1A2 intron 20031604 rs7103285 chr11 106781292 C A 6.51E-05 Schizophrenia (cytomegalovirus infection interaction) GUCY1A2 intron 23358160 rs12364403 chr11 106831656 T C 7.45E-04 Suicide attempts in bipolar disorder GUCY1A2 intron 21041247 rs11211996 chr11 106858675 T C 4.29E-07 Autism GUCY1A2 intron 22843504 rs17106280 chr11 106859670 C T 2.67E-04 Multiple complex diseases GUCY1A2 intron 17554300 rs17106280 chr11 106859670 C T 1.23E-06 Body mass index GUCY1A2 intron 19584900 rs17106280 chr11 106859670 C T 3.38E-06 Body mass index GUCY1A2 intron 19584900 rs4754176 chr11 106863758 G A 4.38E-05 Cognitive impairment induced by topiramate GUCY1A2 intron 22091778 rs11211999 chr11 106867274 C A 4.18E-05 Multiple complex diseases GUCY1A2 intron 17554300 rs10502081 chr11 106871106 T G 2.09E-11 Matrix metalloproteinase levels GUCY1A2 intron 20031604 rs11212007 chr11 106884012 C A 7.70E-04 Suicide attempts in bipolar disorder GUCY1A2 intron 21041247 rs1455593 chr11 106936689 C T 4.00E-05 Type 2 diabetes / / 17460697 rs11212024 chr11 106947600 G A 2.00E-10 Matrix metalloproteinase levels / / 20031604 rs1895729 chr11 106983728 G A 1.32E-07 Autism / / 22843504 rs17106456 chr11 106999460 A C 7.99E-09 Matrix metalloproteinase levels / / 20031604 rs10749886 chr11 107000535 G A 4.05E-07 Autism / / 22843504 rs879295 chr11 107010273 G A 1.47E-06 Erythrocyte counts / / pha003101 rs4754188 chr11 107047996 C T 4.47E-04 Multiple complex diseases / / 17554300 rs12222308 chr11 107053856 C T 0.000087 Polycystic ovary syndrome / / 22951595 rs12222308 chr11 107053856 C T 8.70E-05 Intracranial aneurysm / / 22961961 rs1490936 chr11 107067987 C A 1.11E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10502084 chr11 107068687 C T 2.82E-04 Multiple complex diseases / / 17554300 rs10502084 chr11 107068687 C T 7.09E-05 Hypertension / / 19609347 rs17106596 chr11 107069657 A G 4.16E-04 Multiple complex diseases / / 17554300 rs2017912 chr11 107073420 C T 3.71E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2017912 chr11 107073420 C T 6.83E-05 Amyotrophic lateral sclerosis / / 20801717 rs2017912 chr11 107073420 C T 7.37E-05 HIV-1 viral setpoint / / 21490045 rs4754193 chr11 107090112 A G 2.26E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10890667 chr11 107114222 T C 3.78E-08 Matrix metalloproteinase levels / / 20031604 rs962379 chr11 107118721 T C 3.96E-04 Multiple complex diseases / / 17554300 rs7938897 chr11 107138678 C T 7.33E-04 Multiple complex diseases / / 17554300 rs7946787 chr11 107140547 C A 4.19E-08 Matrix metalloproteinase levels / / 20031604 rs7930061 chr11 107184123 A G 1.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10789607 chr11 107184854 C T 6.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs661889 chr11 107257389 T C 9.20E-08 Matrix metalloproteinase levels CWF19L2 intron 20031604 rs11212198 chr11 107263130 T C 5.92E-05 Alzheimer's disease (late onset) CWF19L2 intron 21379329 rs524764 chr11 107295294 T G 7.75E-06 Insulin resistance CWF19L2 intron 21901158 rs654272 chr11 107315311 C G 4.77E-06 Insulin resistance CWF19L2 intron 21901158 rs11212242 chr11 107316499 C T 1.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CWF19L2 intron 20877124 rs476028 chr11 107324276 C T 9.61E-04 Insulin resistance CWF19L2 intron 21901158 rs7926163 chr11 107330997 G T 4.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12291601 chr11 107340783 T C 1.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11212260 chr11 107347277 T C 5.00E-06 IgG glycosylation / / 23382691 rs11212260 chr11 107347277 T C 7.00E-06 IgG glycosylation / / 23382691 rs11212260 chr11 107347277 T C 9.00E-06 IgG glycosylation / / 23382691 rs7937106 chr11 107354312 T C 6.00E-08 Large artery stroke / / 24262325 rs489243 chr11 107362693 C T 2.99E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1728909 chr11 107363459 G A 9.90E-05 Hypertension / / pha003041 rs1789158 chr11 107372065 A C 7.15E-04 Coronary heart disease / / 21606135 rs1789163 chr11 107377010 C G 6.22E-04 Multiple complex diseases ALKBH8 intron 17554300 rs515555 chr11 107391023 G A 3.31E-08 Narcolepsy ALKBH8 intron 19629137 rs533757 chr11 107397587 T C 6.89E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ALKBH8 intron 22566498 rs4754230 chr11 107410527 G A 6.54E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) ALKBH8 intron 17982456 rs502318 chr11 107416994 T C 6.66E-09 Matrix metalloproteinase levels ALKBH8 intron 20031604 rs116578571 chr11 107427713 T C 0.00007 Breast cancer (ER positive) ALKBH8 missense 23555315 rs116578571 chr11 107427713 T C 0.00027 Breast cancer ALKBH8 missense 23555315 rs10502094 chr11 107430054 A G 7.95E-05 Response to treatment for acute lymphoblastic leukemia ALKBH8 intron 19176441 rs1528494 chr11 107433835 G A 8.49E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ALKBH8 intron 22566498 rs7123473 chr11 107481451 G A 6.51E-04 Multiple complex diseases ELMOD1 intron 17554300 rs10431058 chr11 107481518 C T 8.00E-07 Common traits (Other) ELMOD1 intron 20585627 rs1531751 chr11 107518966 G C 6.09E-10 Matrix metalloproteinase levels ELMOD1 intron 20031604 rs524611 chr11 107531320 C T 7.80E-04 Multiple complex diseases ELMOD1 intron 17554300 rs494957 chr11 107531759 C T 5.38E-04 Type 2 diabetes ELMOD1 intron 17463246 rs509613 chr11 107540937 A G 4.63E-05 Stroke / / pha002887 rs684901 chr11 107546689 T C 7.32E-04 Type 2 diabetes / / 17463246 rs10890750 chr11 107549519 G A 7.68E-05 Alcohol dependence / / 21314694 rs1790137 chr11 107551922 C A 8.07E-04 Stroke / / pha002887 rs597872 chr11 107566585 T C 3.08E-05 Asthma / / 22561531 rs10789636 chr11 107571389 T A 9.49E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs683266 chr11 107571850 G A 9.66E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs649974 chr11 107580985 G A 4.10E-06 Urinary metabolites SLN intron 21572414 rs4378354 chr11 107582554 T C 0.00000114 Cholesterol,total SLN intron 23063622 rs7946553 chr11 107585728 T C 7.06E-04 Type 2 diabetes / / 17463246 rs7946553 chr11 107585728 T C 2.38E-04 Multiple complex diseases / / 17554300 rs7931539 chr11 107585821 A G 2.02E-04 Multiple complex diseases / / 17554300 rs11212337 chr11 107586241 G A 6.95E-04 Type 2 diabetes / / 17463246 rs11212337 chr11 107586241 G A 5.53E-04 Multiple complex diseases / / 17554300 rs11212337 chr11 107586241 G A 2.60E-05 Urinary metabolites / / 21572414 rs535346 chr11 107587316 C A 2.01E-04 Multiple complex diseases / / 17554300 rs561202 chr11 107590335 C T 3.32E-04 Multiple complex diseases / / 17554300 rs2128114 chr11 107600282 T A 1.50E-05 Urinary metabolites / / 21572414 rs2128114 chr11 107600282 T A 1.00E-04 Prostate cancer / / 21743057 rs10890758 chr11 107615247 C T 1.42E-04 Type 2 diabetes / / 17463246 rs10890758 chr11 107615247 C T 1.63E-04 Multiple complex diseases / / 17554300 rs621334 chr11 107651095 G A 5.58E-04 Smoking initiation / / 24665060 rs184602466 chr11 107675467 C T 0.00079 Breast cancer SLC35F2 missense 23555315 rs498851 chr11 107710976 G C 4.92E-04 Alzheimer's disease SLC35F2 intron 17998437 rs542931 chr11 107711836 C A,G,T 1.16E-05 Cortisol secretion,in saliva SLC35F2 intron 21316860 rs7941501 chr11 107747025 C T 3.97E-05 Lymphocyte counts / / 22286170 rs2186903 chr11 107756551 G A 1.30E-05 Urinary metabolites / / 21572414 rs2186903 chr11 107756551 G A 4.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs2186903 chr11 107756551 G A 7.15E-05 Coronary heart disease / / pha003031 rs10890773 chr11 107760002 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10890773 chr11 107760002 G A 4.84E-05 Cognitive impairment induced by topiramate / / 22091778 rs12800508 chr11 107762623 A G 9.31E-07 Stroke / / pha002887 rs10890784 chr11 107825239 G A 1.84E-05 Asthma RAB39A intron 11022011 rs12574049 chr11 107858027 G C 2.40E-05 Urinary metabolites / / 21572414 rs4028260 chr11 107869216 T C 1.88E-04 Multiple complex diseases / / 17554300 rs11212484 chr11 107884390 C A 8.20E-04 Prostate cancer mortality CUL5 intron 20978177 rs11212484 chr11 107884390 C A 2.50E-05 Urinary metabolites CUL5 intron 21572414 rs12277368 chr11 107887274 T C 6.97E-04 Lymphocyte counts CUL5 intron 22286170 rs10890798 chr11 107902017 G A 2.43E-05 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia CUL5 intron 24039173 rs10890800 chr11 107904646 C T 8.75E-04 Rheumatoid arthritis CUL5 intron 21452313 rs17107685 chr11 107914869 T G 1.93E-04 Multiple complex diseases CUL5 intron 17554300 rs17107685 chr11 107914869 T G 2.00E-05 Urinary metabolites CUL5 intron 21572414 rs17617000 chr11 107924104 A G 8.27E-04 Lymphocyte counts CUL5 intron 22286170 rs4550189 chr11 107986344 G A 1.20E-05 Urinary metabolites / / 21572414 rs10890819 chr11 108014799 C T 7.19E-04 Stroke ACAT1 intron pha002886 rs12787445 chr11 108034124 A G 8.81E-07 Response to metformin NPAT intron 21186350 rs6589007 chr11 108040104 A G 2.69E-07 Response to metformin NPAT intron 21186350 rs659584 chr11 108061379 C T 2.17E-05 Telomere length NPAT intron 23001564 rs2083707 chr11 108066130 A T 1.80E-06 Response to metformin NPAT intron 21186350 rs609557 chr11 108084513 G T 2.47E-07 Response to metformin NPAT intron 21186350 rs228606 chr11 108087847 G T 5.07E-05 Response to metformin NPAT intron 21186350 rs183460 chr11 108090710 A C 2.98E-07 Response to metformin NPAT intron 21186350 rs4987876 chr11 108092637 G T 1.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) NPAT intron 17982456 rs228591 chr11 108097333 A G 2.65E-07 Response to metformin ATM intron 21186350 rs4987897 chr11 108098142 C T 3.02E-11 HDL cholesterol ATM intron 23063622 rs3218688 chr11 108139322 C T 1.27E-09 LDL cholesterol ATM missense 23063622 rs3218688 chr11 108139322 C T 1.80E-12 HDL cholesterol ATM missense 23063622 rs618499 chr11 108148839 A G 1.49E-06 Response to metformin ATM intron 21186350 rs624366 chr11 108154097 G C 1.69E-07 Response to metformin ATM intron 21186350 rs645485 chr11 108168863 A G 2.37E-07 Response to metformin ATM intron 21186350 rs1801516 chr11 108175462 G A 3.00E-09 Melanoma ATM missense 21983787 rs673281 chr11 108182069 G A 1.95E-06 Response to metformin ATM intron 21186350 rs56009889 chr11 108196896 C T 0.00041 Breast cancer ATM missense 23555315 rs227073 chr11 108212692 G C 4.06E-07 Response to metformin ATM intron 21186350 rs227075 chr11 108218196 T C 1.73E-06 Response to metformin ATM intron 21186350 rs373759 chr11 108220657 C T 7.50E-04 Lymphocyte counts ATM intron 22286170 rs419716 chr11 108221099 A C 2.85E-07 Response to metformin ATM intron 21186350 rs227041 chr11 108222801 C A 2.85E-07 Response to metformin ATM intron 21186350 rs664143 chr11 108225661 A G 1.73E-06 Response to metformin ATM intron 21186350 rs652541 chr11 108226025 A G 1.23E-06 Response to metformin ATM intron 21186350 rs573890 chr11 108251363 C G 3.90E-07 Response to metformin / / 21186350 rs227077 chr11 108253252 C T 3.35E-07 Response to metformin / / 21186350 rs7931930 chr11 108268286 G T 2.78E-07 Response to metformin C11orf65 intron 21186350 rs11212617 chr11 108283161 C A 3.00E-09 Response to metformin C11orf65 intron 21186350 rs11212617 chr11 108283161 C A 3.00E-09 Response to metformin C11orf65 intron 21845381 rs3765632 chr11 108353018 C A 5.50E-06 Response to metformin KDELC2 intron 21186350 rs11212676 chr11 108361578 G A 6.66E-05 Response to metformin KDELC2 intron 21186350 rs893279 chr11 108365182 C T 9.68E-05 Response to metformin KDELC2 intron 21186350 rs2846412 chr11 108384207 C T 5.65E-05 Orofacial clefts EXPH5 missense 22419666 rs12146448 chr11 108384661 C A 8.50E-04 Alcohol dependence EXPH5 missense 20201924 rs7943820 chr11 108389285 C T 8.24E-05 Orofacial clefts EXPH5 intron 22419666 rs2256372 chr11 108432753 T C 1.76E-04 Rheumatoid arthritis EXPH5 intron 21452313 rs2846419 chr11 108475820 A G 9.89E-05 Autism spectrum disorders (language delay) / / 21519539 rs2846419 chr11 108475820 A G 2.40E-05 Urinary metabolites / / 21572414 rs7122442 chr11 108478140 A G 5.72E-04 Multiple complex diseases / / 17554300 rs11212733 chr11 108478823 T A 9.76E-06 Autism spectrum disorders (language delay) / / 21519539 rs4539291 chr11 108482112 A G 5.00E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2852205 chr11 108482273 A G 7.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs7125479 chr11 108485402 A C 7.63E-04 Suicide attempts in bipolar disorder / / 21041247 rs7125479 chr11 108485402 A C 1.48E-04 Autism spectrum disorders (language delay) / / 21519539 rs7934388 chr11 108486117 T A 7.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs7934388 chr11 108486117 T A 1.48E-04 Autism spectrum disorders (language delay) / / 21519539 rs7925656 chr11 108492651 A G 2.81E-05 Bipolar disorder and schizophrenia / / 20889312 rs7925656 chr11 108492651 A G 2.61E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs990253 chr11 108494855 G A 8.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2306118 chr11 108535792 C T 7.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7109110 chr11 108657507 G C 5.59E-04 Response to taxane treatment (placlitaxel) DDX10 intron 23006423 rs7342253 chr11 108703297 C T 7.09E-04 Response to taxane treatment (placlitaxel) DDX10 intron 23006423 rs1365048 chr11 108735192 G A 1.32E-04 Alzheimer's disease DDX10 intron 22005930 rs1365047 chr11 108735625 T A 1.31E-04 Alzheimer's disease DDX10 intron 22005930 rs2726910 chr11 108735923 T G 1.85E-04 Alzheimer's disease DDX10 intron 22005930 rs2726911 chr11 108736884 T G 1.85E-04 Alzheimer's disease DDX10 intron 22005930 rs2726913 chr11 108739776 G A 2.07E-04 Alzheimer's disease DDX10 intron 22005930 rs2726914 chr11 108739909 A G 1.34E-04 Alzheimer's disease DDX10 intron 22005930 rs2726915 chr11 108740282 C T 1.31E-04 Alzheimer's disease DDX10 intron 22005930 rs2726916 chr11 108740947 A G 9.96E-05 Alzheimer's disease DDX10 intron 22005930 rs2553757 chr11 108744305 A G 9.42E-05 Alzheimer's disease DDX10 intron 22005930 rs2726919 chr11 108745652 T G 1.26E-04 Alzheimer's disease DDX10 intron 22005930 rs2726920 chr11 108747224 A G 4.20E-05 Electrocardiographic traits and heart rate variability DDX10 intron 17903306 rs2726920 chr11 108747224 A G 1.94E-04 Alzheimer's disease DDX10 intron 22005930 rs2553758 chr11 108748786 A C 1.09E-04 Alzheimer's disease DDX10 intron 22005930 rs2553760 chr11 108753316 A G 7.79E-05 Alzheimer's disease DDX10 intron 22005930 rs2553761 chr11 108754443 A G 8.30E-05 Alzheimer's disease DDX10 intron 22005930 rs41422546 chr11 108767993 T C 1.50E-04 Insulin resistance DDX10 intron 21901158 rs7933931 chr11 108825907 A G 1.88E-04 Cocaine dependence / / 23958962 rs7933931 chr11 108825907 A G 5.70E-05 Cocaine dependence / / 23958962 rs4630256 chr11 108831875 T C 6.07E-05 Body Mass Index / / pha003009 rs10890917 chr11 108859584 C G 1.42E-07 Stroke (ischemic) / / 22941190 rs10890920 chr11 108873119 G A 3.00E-06 QT interval (interaction) / / 23459443 rs17705117 chr11 108890720 C T 9.93E-04 Type 2 diabetes / / 17463246 rs4754373 chr11 108892846 C T 9.50E-07 Adiposity / / 19461586 rs7101378 chr11 108893367 G A 7.00E-06 IgG glycosylation / / 23382691 rs1509729 chr11 108927483 C T 1.50E-05 Adiposity / / 19461586 rs11212913 chr11 108947644 G A 6.50E-06 Adiposity / / 19461586 rs17706299 chr11 108980817 C G 6.51E-05 Nicotine dependence / / 17158188 rs17706334 chr11 108980864 A G 6.38E-05 Nicotine dependence / / 17158188 rs17633211 chr11 108985505 T C 9.33E-05 Nicotine dependence / / 17158188 rs17633258 chr11 108985874 C G 7.31E-05 Nicotine dependence / / 17158188 rs17706512 chr11 108990406 G A 5.38E-04 Multiple complex diseases / / 17554300 rs989595 chr11 108995326 A G 7.68E-04 Premature ovarian failure / / 19508998 rs989595 chr11 108995326 A G 2.26E-04 Myocardial Infarction / / pha002883 rs1482047 chr11 109156782 T C 1.57E-04 IgE levels / / 17255346 rs655799 chr11 109176791 G A 9.34E-05 Insulin Resistance / / pha003062 rs655763 chr11 109176817 C T 4.91E-05 Multiple sclerosis / / 19525953 rs2884215 chr11 109183092 A G 4.65E-04 Type 2 diabetes / / 17463246 rs2884215 chr11 109183092 A G 8.44E-04 Multiple complex diseases / / 17554300 rs10890985 chr11 109228405 A G 5.02E-04 Longevity / / 22279548 rs17708753 chr11 109281268 C G 8.31E-04 Acute lung injury / / 22295056 rs7936391 chr11 109416276 G A 8.98E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7129310 chr11 109417401 C T 9.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs11213125 chr11 109473911 T C 6.88E-05 Bipolar disorder and schizophrenia / / 20889312 rs7117804 chr11 109496208 T A 8.71E-04 Multiple complex diseases / / 17554300 rs6589076 chr11 109505577 G A 1.05E-04 Diabetic nephropathy / / pha002866 rs1386718 chr11 109508311 T C 6.22E-04 Myopia (pathological) / / 21095009 rs1352306 chr11 109561625 C A 3.42E-04 Myopia (pathological) / / 21095009 rs1790928 chr11 109576994 A G 2.21E-04 Myopia (pathological) / / 21095009 rs1685397 chr11 109578991 T G 4.38E-04 Myopia (pathological) / / 21095009 rs2716045 chr11 109595644 A G 2.47E-04 Stroke / / pha002887 rs4754402 chr11 109608010 G T 4.99E-04 Myopia (pathological) / / 21095009 rs875430 chr11 109615658 C T 4.40E-05 Diabetic nephropathy / / pha002866 rs2099378 chr11 109622154 T C 2.97E-04 Stroke / / pha002887 rs2716040 chr11 109623269 T A 6.90E-05 Diabetic nephropathy / / pha002866 rs2253536 chr11 109637777 T C 4.53E-04 Myopia (pathological) / / 21095009 rs989695 chr11 109640972 C T 5.68E-04 Type 2 diabetes / / 17463246 rs7944886 chr11 109669699 G C 3.24E-04 Type 2 diabetes / / 17463246 rs1955024 chr11 109673821 G A 4.72E-04 Multiple complex diseases / / 17554300 rs2851174 chr11 109700369 T C 6.68E-04 Multiple complex diseases / / 17554300 rs11213174 chr11 109700964 T A 5.83E-04 Multiple complex diseases / / 17554300 rs2852136 chr11 109703305 G A 1.80E-04 Multiple complex diseases / / 17554300 rs11213210 chr11 109817830 T C 1.22E-04 Type 2 diabetes / / 17463246 rs10891041 chr11 109839996 C T 1.25E-04 Type 2 diabetes / / 17463246 rs10891041 chr11 109839996 C T 7.09E-04 Body mass index / / 21701565 rs11213219 chr11 109854283 C A 3.75E-04 Multiple complex diseases / / 17554300 rs7947141 chr11 109865559 C T 3.04E-04 Osteoarthritis / / 19508968 rs1789395 chr11 109869253 C T 1.62E-04 Multiple complex diseases / / 17554300 rs4753878 chr11 109870083 C T 6.13E-04 Multiple complex diseases / / 17554300 rs1648148 chr11 109888752 T C 7.40E-04 Heart Failure / / pha002884 rs1648148 chr11 109888752 T C 2.85E-05 Triglycerides / / pha003081 rs10789746 chr11 109903196 C T 4.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs7111498 chr11 109904780 C T 6.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17110679 chr11 109932069 T A 8.00E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs1648131 chr11 109936027 G A 8.84E-04 Myocardial Infarction / / pha002883 rs7930843 chr11 109951407 G A 1.01E-04 Parkinson's disease / / 17052657 rs7115956 chr11 109956346 C T 5.54E-06 Psoriasis / / 20953190 rs4561177 chr11 109962432 A G 7.70E-13 Psoriasis / / 23143594 rs1789369 chr11 109995287 C T 9.40E-05 Psoriasis ZC3H12C intron 20953190 rs746463 chr11 109995944 C T 5.00E-06 Exercise treadmill test traits ZC3H12C intron 17903301 rs689183 chr11 110012143 G T 3.41E-04 Cognitive decline ZC3H12C intron 23732972 rs653992 chr11 110018931 C T 1.71E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs694974 chr11 110019352 T C 1.67E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs10891068 chr11 110019706 G A 9.77E-05 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs10891069 chr11 110019791 C T 9.13E-05 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs602189 chr11 110020530 A G 2.40E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs600421 chr11 110020882 G T 1.72E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs683593 chr11 110020933 C A 9.13E-04 Type 2 diabetes ZC3H12C intron 17463246 rs683593 chr11 110020933 C A 1.72E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs12362273 chr11 110022157 A C 9.89E-05 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs581464 chr11 110022382 T G 1.76E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs2846615 chr11 110022591 T C 1.79E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs1675981 chr11 110022668 T G 1.81E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs667625 chr11 110023060 T G 1.86E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs622822 chr11 110023164 G T 1.90E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs665013 chr11 110023628 C T 1.97E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs649847 chr11 110024627 C G 2.06E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs633410 chr11 110024686 C T 2.13E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs585334 chr11 110025637 A G 2.17E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs584008 chr11 110025926 T C 2.36E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs679264 chr11 110026460 G A 2.26E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs678835 chr11 110026577 C T 2.32E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs17110877 chr11 110027186 A G 2.35E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs3017769 chr11 110028037 A G 2.49E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs622192 chr11 110033237 A T 2.56E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs633505 chr11 110033291 C A 8.31E-04 Parkinson's disease ZC3H12C intron 17052657 rs621672 chr11 110033646 T C 2.50E-04 Suicide attempts in bipolar disorder ZC3H12C intron 21041247 rs1026608 chr11 110035262 A G 2.15E-04 Suicide attempts in bipolar disorder ZC3H12C cds-synon 21041247 rs1026607 chr11 110035301 A G 2.15E-04 Suicide attempts in bipolar disorder ZC3H12C cds-synon 21041247 rs10891073 chr11 110056971 C G 7.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs11213299 chr11 110058600 C T 7.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs11525418 chr11 110059838 T C 6.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs747943 chr11 110064366 A G 6.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs2077595 chr11 110140876 T A 9.12E-04 Suicide attempts in bipolar disorder RDX intron 21423239 rs10891078 chr11 110144023 A G 7.06E-04 Suicide attempts in bipolar disorder RDX intron 21423239 rs10891079 chr11 110160323 T C 6.24E-04 Suicide attempts in bipolar disorder RDX intron 21423239 rs3858406 chr11 110162058 G A 5.17E-04 Suicide attempts in bipolar disorder RDX intron 21423239 rs1676536 chr11 110162430 T C 7.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) RDX intron 23648065 rs11213340 chr11 110163314 C T 4.01E-04 Suicide attempts in bipolar disorder RDX intron 21423239 rs11213342 chr11 110165840 G A 5.37E-04 Suicide attempts in bipolar disorder RDX intron 21423239 rs11823096 chr11 110201724 T A 4.30E-06 Urinary metabolites / / 21572414 rs12420766 chr11 110203900 A C 4.40E-06 Urinary metabolites / / 21572414 rs2724409 chr11 110237299 A G 7.01E-04 Alzheimer's disease / / 17998437 rs2051466 chr11 110241999 C A 6.28E-04 Myocardial Infarction / / pha002883 rs2051466 chr11 110241999 C A 3.66E-05 Coronary heart disease / / pha003033 rs7945071 chr11 110243922 G T 7.00E-06 Cognitive function / / 24684796 rs1443120 chr11 110244228 C G 3.79E-04 Multiple complex diseases / / 17554300 rs7931910 chr11 110244245 T C 9.94E-04 Tourette syndrome / / 22889924 rs7931910 chr11 110244245 T C 7.86E-06 Cognitive function / / 24684796 rs7931910 chr11 110244245 T C 2.10E-05 Myocardial Infarction / / pha002883 rs2724421 chr11 110278508 A G 9.39E-04 Multiple complex diseases / / 17554300 rs2724432 chr11 110284193 C T 4.50E-04 Nicotine dependence / / 17158188 rs2724432 chr11 110284193 C T 7.34E-05 Bipolar disorder / / 17486107 rs2724432 chr11 110284193 C T 7.04E-05 Tourette syndrome / / 22889924 rs2724432 chr11 110284193 C T 1.89E-07 Liver disease in chronic hepatitis B virus infection / / 24065354 rs2853001 chr11 110286562 C A 1.94E-04 Tourette syndrome / / 22889924 rs12575797 chr11 110287537 G A 3.48E-08 Metabolite levels / / 23281178 rs11213393 chr11 110293177 C T 5.00E-04 Multiple complex diseases / / 17554300 rs4753891 chr11 110298547 G A 3.44E-05 Smoking cessation / / 18519826 rs935135 chr11 110329895 A G 1.46E-04 Smoking cessation FDX1 intron 18519826 rs935135 chr11 110329895 A G 3.36E-05 Insulin-related traits FDX1 intron pha003063 rs17111262 chr11 110340699 C G 1.22E-05 Lymphocyte counts / / 22286170 rs10891124 chr11 110357002 T C 7.09E-05 Multiple complex diseases / / 17554300 rs2136361 chr11 110357133 C T 3.28E-05 Coronary heart disease / / pha003033 rs11213434 chr11 110357423 C T 6.82E-04 Multiple complex diseases / / 17554300 rs12575639 chr11 110364300 A G 5.27E-05 Coronary heart disease / / pha003033 rs10891130 chr11 110364319 G A 5.00E-06 Primary sclerosing cholangitis / / 21151127 rs328287 chr11 110378558 A G 8.95E-04 Multiple complex diseases / / 17554300 rs328281 chr11 110391916 T C 3.94E-04 Multiple complex diseases / / 17554300 rs882535 chr11 110391978 G A 5.08E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs12294479 chr11 110395207 C T 1.45E-04 Multiple complex diseases / / 17554300 rs12294479 chr11 110395207 C T 7.00E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs4486596 chr11 110395534 G A 7.36E-04 Multiple complex diseases / / 17554300 rs12785341 chr11 110395858 A C 8.00E-06 Renal sinus fat / / 22044751 rs328286 chr11 110396769 C T 3.89E-04 Parkinson's disease / / 17052657 rs328262 chr11 110402394 T G 5.45E-04 Multiple complex diseases / / 17554300 rs10749963 chr11 110439241 G T 3.66E-04 Multiple complex diseases / / 17554300 rs17111435 chr11 110445651 A G 8.57E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs10749964 chr11 110452830 C T 1.62E-04 Lung function (forced vital capacity) ARHGAP20 intron 24023788 rs10488767 chr11 110458835 G A 9.00E-04 Chronic fatigue syndrome ARHGAP20 intron 21912186 rs10488768 chr11 110459060 C T 1.05E-04 Multiple complex diseases ARHGAP20 intron 17554300 rs4388918 chr11 110472030 T C 6.63E-05 Multiple complex diseases ARHGAP20 intron 17554300 rs17111539 chr11 110484551 C A 4.27E-05 Coronary heart disease ARHGAP20 intron pha003033 rs326946 chr11 110499253 A C 7.00E-07 Alzheimer's disease (cognitive decline) ARHGAP20 intron 23535033 rs4938148 chr11 110505012 G A 6.60E-06 Urinary metabolites ARHGAP20 intron 21572414 rs326949 chr11 110505721 G A 3.64E-04 Multiple complex diseases ARHGAP20 intron 17554300 rs4583006 chr11 110511048 C G 8.55E-04 Multiple complex diseases ARHGAP20 intron 17554300 rs12223844 chr11 110530935 G A 6.30E-06 Urinary metabolites ARHGAP20 intron 21572414 rs11213578 chr11 110625742 C G 1.80E-04 Corneal structure / / 23291589 rs10160342 chr11 110648985 T C 6.38E-04 Multiple complex diseases / / 17554300 rs1848044 chr11 110649270 T C 9.35E-05 Multiple complex diseases / / 17554300 rs6589176 chr11 110651468 A C 3.32E-04 Multiple complex diseases / / 17554300 rs11819842 chr11 110684462 G C 6.48E-04 Major depressive disorder / / 22472876 rs2432700 chr11 110685226 G A 6.19E-04 Multiple complex diseases / / 17554300 rs226150 chr11 110690406 A G 3.78E-05 Type 2 diabetes / / 17463246 rs170487 chr11 110693706 C A 4.84E-04 Sarcoidosis / / 19165924 rs5005886 chr11 110696247 C A 4.58E-04 Glaucoma (primary open-angle) / / 22419738 rs226129 chr11 110703667 T C 9.52E-05 Celiac disease / / 23936387 rs7123425 chr11 110721187 G A 2.20E-04 Type 2 diabetes / / 17463246 rs10891181 chr11 110723177 G T 5.15E-05 Schizophrenia(age at onset) / / 21688384 rs10488720 chr11 110731482 G C 5.29E-05 Multiple complex diseases / / 17554300 rs11213629 chr11 110739392 T C 4.47E-04 Type 2 diabetes / / 17463246 rs11213630 chr11 110739555 A G 3.03E-07 Malaria / / 23717212 rs1469170 chr11 110741014 A G 9.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs1469170 chr11 110741014 A G 8.00E-08 Malaria / / 23717212 rs10488719 chr11 110748070 G A 6.50E-04 Alcohol dependence / / 20201924 rs10488719 chr11 110748070 G A 5.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs918841 chr11 110748882 A G 7.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs763302 chr11 110756816 G T 7.80E-05 Personality dimensions / / 18957941 rs10488717 chr11 110757862 T C 3.54E-04 Type 2 diabetes / / 17463246 rs17505526 chr11 110776646 C A 6.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs17414419 chr11 110776750 A C 7.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs17414468 chr11 110777154 T C 7.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs11213646 chr11 110782978 T C 5.76E-04 Multiple complex diseases / / 17554300 rs1486907 chr11 110824960 T C 3.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs1486908 chr11 110825314 G A 8.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs365231 chr11 110867986 G T 4.02E-04 Parkinson's disease / / 17052657 rs17729728 chr11 110877746 T G 6.32E-05 Serum metabolites / / 19043545 rs17730056 chr11 110882350 C T 5.65E-05 Type 2 diabetes / / 17463246 rs978769 chr11 110888484 C T 2.87E-04 Alzheimer's disease / / 21059989 rs978769 chr11 110888484 C T 2.90E-06 Alzheimer's disease / / 21059989 rs978770 chr11 110888592 C T 1.49E-06 Alzheimer's disease / / 21059989 rs978770 chr11 110888592 C T 2.23E-04 Alzheimer's disease / / 21059989 rs11213703 chr11 110889940 T C 2.35E-06 Alzheimer's disease / / 21059989 rs11213703 chr11 110889940 T C 2.87E-04 Alzheimer's disease / / 21059989 rs4638339 chr11 110897937 G A 2.17E-04 Type 2 diabetes / / 17463246 rs4638339 chr11 110897937 G A 6.00E-04 Alzheimer's disease / / 17998437 rs17534559 chr11 110910329 G T 1.38E-04 Type 2 diabetes / / 17463246 rs4938174 chr11 110913240 G A 4.00E-09 Corneal structure / / 23291589 rs17456109 chr11 110913368 C G 1.38E-04 Type 2 diabetes / / 17463246 rs17456109 chr11 110913368 C G 5.97E-04 Multiple complex diseases / / 17554300 rs17535075 chr11 110919219 A G 5.52E-05 Type 2 diabetes / / 17463246 rs321344 chr11 110943136 T G 2.27E-04 Multiple complex diseases / / 17554300 rs7950087 chr11 110953260 A G 2.43E-04 Alzheimer's disease / / 17998437 rs6589210 chr11 110959132 A C 7.10E-04 Alzheimer's disease / / 17998437 rs7110930 chr11 110959280 C T 5.15E-04 Alzheimer's disease / / 17998437 rs7111445 chr11 110976511 C T 7.80E-04 Alzheimer's disease / / 17998437 rs17458235 chr11 110976838 A G 7.80E-04 Alzheimer's disease / / 17998437 rs17112394 chr11 111068648 T A 5.76E-04 Multiple complex diseases / / 17554300 rs17552796 chr11 111073786 A G 3.48E-04 Type 2 diabetes / / 17463246 rs17112408 chr11 111077824 A C 3.64E-05 Multiple complex diseases / / 17554300 rs7940533 chr11 111078415 G T 2.29E-04 Type 2 diabetes / / 17463246 rs7119658 chr11 111109258 G A 5.00E-05 Prostate cancer / / 21743057 rs7952641 chr11 111111729 C A 5.00E-05 Prostate cancer / / 21743057 rs949280 chr11 111111747 A G 8.44E-05 Height / / pha003011 rs1986684 chr11 111124487 T C 6.22E-04 Multiple complex diseases / / 17554300 rs11213809 chr11 111135745 A G 2.40E-12 Colorectal cancer C11orf53 intron 19011631 rs12296076 chr11 111166504 G A 1.80E-06 Colorectal cancer / / 20610541 rs3802842 chr11 111171709 C A 6.00E-10 Colorectal cancer C11orf93 intron 18372901 rs3802842 chr11 111171709 C A 5.20E-13 Colorectal cancer C11orf93 intron 19011631 rs3802842 chr11 111171709 C A 6.00E-10 Nasopharyngeal carcinoma C11orf93 intron 20512145 rs3802842 chr11 111171709 C A 4.00E-07 Colorectal cancer C11orf93 intron 21761138 rs3802842 chr11 111171709 C A 4.00E-07 Colorectal cancer C11orf93 intron 23266556 rs3802842 chr11 111171709 C A 3.00E-07 Colorectal cancer C11orf93 intron 24836286 rs5020096 chr11 111182812 G C 1.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs4617622 chr11 111183157 A G 6.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs10749971 chr11 111189158 A G 8.00E-07 Colorectal cancer / / 19011631 rs7104791 chr11 111196858 T C 7.90E-05 Celiac disease / / 17558408 rs7104791 chr11 111196858 T C 1.90E-11 Celiac disease / / 22057235 rs7104791 chr11 111196858 T C 0.000896265 Hypertension (early onset hypertension) / / 22479346 rs7109448 chr11 111201308 A C 8.09E-04 Obesity (extreme) / / 21935397 rs1893989 chr11 111202478 A G 7.66E-04 Obesity (extreme) / / 21935397 rs10502141 chr11 111221554 C A 7.44E-04 Obesity (extreme) / / 21935397 rs10502142 chr11 111221806 T C 7.40E-04 Obesity (extreme) / / 21935397 rs7118200 chr11 111233450 C T 3.67E-04 Heart Failure POU2AF1 intron pha002884 rs4938509 chr11 111246611 G T 2.30E-05 Urinary metabolites POU2AF1 intron 21572414 rs6589224 chr11 111246832 T A 1.09E-04 Self-reported allergy POU2AF1 intron 23817569 rs4489781 chr11 111248177 A G 1.10E-04 Self-reported allergy POU2AF1 intron 23817569 rs6589226 chr11 111249226 T C 8.69E-05 Self-reported allergy POU2AF1 intron 23817569 rs4356268 chr11 111250650 A G 5.84E-04 Alcohol dependence / / 20201924 rs4356268 chr11 111250650 A G 9.67E-05 Self-reported allergy / / 23817569 rs17577003 chr11 111272400 C T 0.000557834 Hypertension (early onset hypertension) / / 22479346 rs4938534 chr11 111275133 G A 2.00E-08 Primary biliary cirrhosis / / 23000144 rs4938535 chr11 111275250 T C 0.000859919 Hypertension (early onset hypertension) / / 22479346 rs4938579 chr11 111294580 C T 1.04E-04 Multiple complex diseases / / 17554300 rs949126 chr11 111310559 A G 0.0000874 Coronary artery calcification LOC644277 intron 23394302 rs9783376 chr11 111330986 A G 0.00011 Salmonella-induced pyroptosis / / 22837397 rs1944118 chr11 111352032 G A 0.0000127 Oxaliplatin induced neuropathy in response to colorectal cancer treatment BTG4 intron 22310351 rs1113851 chr11 111354161 G A 1.90E-04 Tourette syndrome BTG4 intron 22889924 rs11213927 chr11 111363161 C T 0.0000137 LDL cholesterol particle diameter BTG4 intron 23263444 rs10891277 chr11 111373103 A G 2.87E-04 Tourette syndrome BTG4 intron 22889924 rs11213935 chr11 111411608 G A 4.00E-06 Obesity-related traits LAYN missense 23251661 rs4938784 chr11 111413465 C T 3.76E-04 Tourette syndrome LAYN intron 22889924 rs7130440 chr11 111417779 A G 3.84E-04 Self-reported allergy LAYN intron 23817569 rs4938792 chr11 111420936 T C 2.88E-04 Self-reported allergy LAYN intron 23817569 rs663763 chr11 111422217 C T 6.03E-04 Self-reported allergy LAYN intron 23817569 rs679032 chr11 111423286 G T 6.56E-04 Self-reported allergy LAYN intron 23817569 rs518294 chr11 111424716 A T 7.33E-04 Self-reported allergy LAYN intron 23817569 rs682239 chr11 111425105 C T 7.35E-04 Self-reported allergy LAYN intron 23817569 rs587010 chr11 111425658 C A 6.41E-04 Self-reported allergy LAYN intron 23817569 rs542275 chr11 111431614 C T 8.25E-04 Self-reported allergy LAYN UTR-3 23817569 rs539693 chr11 111477387 A G 1.04E-04 Self-reported allergy SIK2 intron 23817569 rs1784784 chr11 111483185 G A 7.12E-05 Self-reported allergy SIK2 intron 23817569 rs552387 chr11 111490047 T G 5.84E-05 Self-reported allergy SIK2 intron 23817569 rs11828343 chr11 111491322 A G 6.56E-05 Self-reported allergy SIK2 intron 23817569 rs493810 chr11 111491888 G T 1.02E-04 Self-reported allergy SIK2 intron 23817569 rs10749984 chr11 111492861 T C 9.90E-05 Self-reported allergy SIK2 intron 23817569 rs491937 chr11 111494947 A T 5.46E-05 Self-reported allergy SIK2 intron 23817569 rs1784782 chr11 111525764 A C 3.32E-04 Type 2 diabetes SIK2 intron 17846124 rs7130060 chr11 111543217 G C 7.33E-04 Multiple complex diseases SIK2 intron 17554300 rs10891288 chr11 111552053 A C 7.24E-05 Serum metabolites SIK2 intron 19043545 rs10502147 chr11 111569931 G A 1.41E-04 Type 2 diabetes SIK2 intron 17846124 rs7937682 chr11 111579939 G C 3.17E-09 Primary sclerosing cholangitis SIK2 intron 23603763 rs17565975 chr11 111586950 G A 7.89E-06 IgE levels SIK2 intron 22075330 rs17565975 chr11 111586950 G A 2.79E-05 Coronary heart disease SIK2 intron pha003055 rs10891290 chr11 111605215 T C 3.13E-05 IgE levels PPP2R1B intron 22075330 rs669778 chr11 111606412 C T 7.82E-05 Post-operative nausea and vomiting PPP2R1B intron 21694509 rs3737445 chr11 111625566 T C 2.75E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PPP2R1B intron 20877124 rs10502148 chr11 111647998 C T 3.09E-05 IgE levels / / 22075330 rs11214003 chr11 111662564 C A 6.62E-05 Heart rate ALG9 intron 23583979 rs582465 chr11 111668585 C T 9.70E-05 Celiac disease ALG9 intron 17558408 rs582465 chr11 111668585 C T 4.37E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ALG9 intron 20877124 rs1633471 chr11 111690331 A G 4.53E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ALG9 intron 20877124 rs645411 chr11 111694490 T C 5.11E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ALG9 intron 20877124 rs11214015 chr11 111719417 T A 1.14E-05 Serum metabolites ALG9 intron 19043545 rs11214029 chr11 111761230 C T 7.06E-06 Serum metabolites / / 19043545 rs14133 chr11 111782697 G C 1.14E-05 Serum metabolites CRYAB nearGene-5 19043545 rs14133 chr11 111782697 G C 6.12E-04 Lymphocyte counts CRYAB nearGene-5 22286170 rs14133 chr11 111782697 G C 2.10E-04 Heart rate CRYAB nearGene-5 23583979 rs360726 chr11 111989592 T C 1.69E-04 Menopause (age at onset) / / 22267201 rs11214093 chr11 111992592 C T 2.31E-05 Cholesterol / / 17255346 rs11214093 chr11 111992592 C T 1.22E-07 Interleukin-18 levels / / 20150558 rs11214093 chr11 111992592 C T 7.08E-04 Myocardial Infarction / / pha002883 rs578784 chr11 112000303 G A 6.70E-05 Memory performance / / 22105620 rs243908 chr11 112005939 A G 2.95E-04 Prostate cancer mortality / / 20978177 rs243908 chr11 112005939 A G 6.10E-06 Urinary metabolites / / 21572414 rs5744276 chr11 112016871 C G 2.58E-06 Interleukin-18 levels IL18 intron 20150558 rs360729 chr11 112016921 A T 2.05E-04 Prostate cancer mortality IL18 intron 20978177 rs360729 chr11 112016921 A T 8.80E-06 Urinary metabolites IL18 intron 21572414 rs5744258 chr11 112021767 C G 2.05E-06 Interleukin-18 levels IL18 intron 20150558 rs5744256 chr11 112022848 A G 2.02E-06 Interleukin-18 levels IL18 intron 20150558 rs5744256 chr11 112022848 A G 5.40E-28 Inflammatory biomarkers IL18 intron 24182552 rs1834481 chr11 112023827 C G 1.00E-08 Interleukin-18 levels IL18 intron 20150558 rs1834481 chr11 112023827 C G 5.30E-28 Inflammatory biomarkers IL18 intron 24182552 rs2043055 chr11 112031624 A G 1.47E-06 Interleukin-18 levels IL18 intron 20150558 rs5744222 chr11 112037014 G T 1.22E-06 Interleukin-18 levels TEX12 nearGene-5 20150558 rs5744222 chr11 112037014 G T 8.60E-28 Inflammatory biomarkers TEX12 nearGene-5 24182552 rs7131094 chr11 112044917 C T 2.11E-06 Interleukin-18 levels / / 20150558 rs7131094 chr11 112044917 C T 1.00E-27 Inflammatory biomarkers / / 24182552 rs7121554 chr11 112048051 C T 1.26E-06 Interleukin-18 levels BCO2 intron 20150558 rs12796114 chr11 112049140 A C 1.50E-06 Interleukin-18 levels BCO2 intron 20150558 rs12797880 chr11 112049191 T C 1.49E-06 Interleukin-18 levels BCO2 intron 20150558 rs2115763 chr11 112051169 A T 4.00E-09 Interleukin-18 levels BCO2 intron 20150558 rs10891334 chr11 112057100 G A 2.38E-06 Interleukin-18 levels BCO2 intron 20150558 rs10891337 chr11 112063254 C T 6.50E-06 Urinary metabolites BCO2 intron 21572414 rs7105056 chr11 112064431 T C 1.00E-08 Immune reponse to smallpox (secreted IL-12p40) BCO2 intron 22610502 rs7123686 chr11 112065483 A C 4.43E-06 Interleukin-18 levels BCO2 intron 20150558 rs11214127 chr11 112068593 G A 3.80E-06 Urinary metabolites BCO2 intron 21572414 rs4937176 chr11 112068973 G A 4.39E-06 Interleukin-18 levels BCO2 intron 20150558 rs10789863 chr11 112077378 A T 5.68E-06 Interleukin-18 levels BCO2 intron 20150558 rs1972421 chr11 112078120 C T 6.44E-06 Interleukin-18 levels BCO2 intron 20150558 rs10891343 chr11 112080384 T C 3.63E-07 Interleukin-18 levels BCO2 intron 20150558 rs10891343 chr11 112080384 T C 4.80E-32 Inflammatory biomarkers BCO2 intron 24182552 rs2250417 chr11 112085316 T C 7.00E-13 Protein quantitative trait loci BCO2 intron 18464913 rs2250417 chr11 112085316 T C 4.75E-07 Interleukin-18 levels BCO2 intron 20150558 rs2250417 chr11 112085316 T C 2.94E-14 Interleukin-18 (IL-18) BCO2 intron 23696881 rs2250417 chr11 112085316 T C 2.00E-32 Inflammatory biomarkers BCO2 intron 24182552 rs1367038 chr11 112091299 G T 8.60E-06 Urinary metabolites / / 21572414 rs2676375 chr11 112095619 G A 2.10E-05 Urinary metabolites PTS nearGene-5 21572414 rs3819331 chr11 112099410 T C 1.20E-05 Urinary metabolites PTS intron 21572414 rs2564873 chr11 112121117 T C 2.10E-05 Urinary metabolites C11orf34 intron 21572414 rs2564883 chr11 112135760 T C 2.50E-05 Urinary metabolites / / 21572414 rs2518365 chr11 112135797 A G 2.50E-05 Urinary metabolites / / 21572414 rs1946522 chr11 112139224 G T 1.90E-05 Urinary metabolites / / 21572414 rs2518385 chr11 112142255 G T 1.80E-05 Urinary metabolites / / 21572414 rs2518387 chr11 112142799 C T 1.90E-05 Urinary metabolites / / 21572414 rs2518390 chr11 112142996 G A 1.80E-05 Urinary metabolites / / 21572414 rs2853126 chr11 112163817 A G 6.62E-05 Multiple complex diseases / / 17554300 rs10502155 chr11 112205471 G A 2.92E-04 Obesity (extreme) / / 21935397 rs940751 chr11 112208568 T G 6.93E-04 Multiple complex diseases / / 17554300 rs7120198 chr11 112213130 C G 2.48E-04 Obesity (extreme) / / 21935397 rs12801998 chr11 112216648 G C 8.38E-04 Obesity (extreme) / / 21935397 rs1554684 chr11 112230165 G A 3.05E-05 Multiple complex diseases / / 17554300 rs7109070 chr11 112263176 C T 4.40E-06 Iron levels / / 21208937 rs11214188 chr11 112264291 G C 0.0001082 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11214188 chr11 112264291 G C 1.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11214189 chr11 112264401 C T 0.0001108 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11214189 chr11 112264401 C T 1.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4638337 chr11 112272189 A C 0.0001642 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4638337 chr11 112272189 A C 1.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11214194 chr11 112272255 G A 0.0001636 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11214194 chr11 112272255 G A 1.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12802170 chr11 112272753 T C 0.0001632 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12802170 chr11 112272753 T C 1.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11607669 chr11 112272997 T C 0.0001628 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11607669 chr11 112272997 T C 1.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11601282 chr11 112273107 A G 0.0001626 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11601282 chr11 112273107 A G 1.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7102352 chr11 112273708 A C 0.0001624 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7102352 chr11 112273708 A C 1.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7102908 chr11 112273843 G A 0.0001623 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7102908 chr11 112273843 G A 1.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2222606 chr11 112276032 G C 0.0001625 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2222606 chr11 112276032 G C 1.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7931891 chr11 112280439 A G 0.0001629 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7931891 chr11 112280439 A G 1.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10891364 chr11 112280582 G T 0.0001633 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10891364 chr11 112280582 G T 1.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7932795 chr11 112281226 A G 0.0001637 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7932795 chr11 112281226 A G 1.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10891365 chr11 112281727 A G 0.0001635 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10891365 chr11 112281727 A G 1.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10789880 chr11 112281905 A G 0.0001792 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10789880 chr11 112281905 A G 1.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs953045 chr11 112284778 T A 0.0002025 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs953045 chr11 112284778 T A 2.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs953046 chr11 112284836 A G 0.000198 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs953046 chr11 112284836 A G 1.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2222608 chr11 112285877 A G 0.0001987 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2222608 chr11 112285877 A G 1.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1357931 chr11 112287801 G A 0.0001942 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1357931 chr11 112287801 G A 1.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12418084 chr11 112312955 T C 6.47E-04 Insulin resistance / / 21901158 rs951432 chr11 112349439 G A 9.00E-04 Type 2 diabetes / / 17846124 rs951432 chr11 112349439 G A 6.60E-04 Coronary heart disease / / 21971053 rs7105881 chr11 112456221 T C 9.93E-04 Type 2 diabetes / / 17463246 rs7105881 chr11 112456221 T C 3.00E-07 Response to antipsychotic treatment / / 20195266 rs7940211 chr11 112458951 G A 1.00E-05 Smoking behavior / / 20418888 rs994781 chr11 112510051 T C 2.60E-05 Cognitive impairment induced by topiramate / / 22091778 rs1459665 chr11 112517412 A G 1.68E-05 Cognitive impairment induced by topiramate / / 22091778 rs2360063 chr11 112535094 A G 6.99E-05 Cognitive impairment induced by topiramate / / 22091778 rs7113799 chr11 112546305 T C 0.0000138 Asthma / / 22694930 rs473990 chr11 112580577 T C 4.36E-04 HIV-1 viral setpoint / / 17641165 rs748631 chr11 112605041 A G 3.56E-04 Parkinson's disease / / 16252231 rs11214342 chr11 112614635 A G 4.14E-04 Parkinson's disease / / 16252231 rs12418173 chr11 112628269 A G 1.33E-04 Multiple complex diseases / / 17554300 rs11214357 chr11 112638785 C T 3.50E-04 Parkinson's disease / / 16252231 rs161130 chr11 112654974 A G 2.79E-05 Fibrinogen / / pha003068 rs321117 chr11 112656595 G A 2.75E-05 Fibrinogen / / pha003068 rs161133 chr11 112663596 G A 1.88E-04 Alzheimer's disease / / 17998437 rs73567082 chr11 112671220 T C 0.00004676 Sarcoidosis / / 22952805 rs11826217 chr11 112674641 A G 0.00004676 Sarcoidosis / / 22952805 rs73568917 chr11 112678092 A C 0.00004676 Sarcoidosis / / 22952805 rs73568921 chr11 112678187 T C 0.00004676 Sarcoidosis / / 22952805 rs1447477 chr11 112678865 G A,C 0.00004676 Sarcoidosis / / 22952805 rs11823835 chr11 112679937 T A 0.00004676 Sarcoidosis / / 22952805 rs1531325 chr11 112680008 G C 6.88E-04 Type 2 diabetes / / 17463246 rs11821416 chr11 112680041 C A 0.00004676 Sarcoidosis / / 22952805 rs17114417 chr11 112682421 C T 0.00004676 Sarcoidosis / / 22952805 rs73568946 chr11 112683259 C T 0.00004676 Sarcoidosis / / 22952805 rs73568952 chr11 112684806 C T 0.00004413 Sarcoidosis / / 22952805 rs12419606 chr11 112684906 G A 0.00004413 Sarcoidosis / / 22952805 rs56837403 chr11 112687690 A G 0.00007658 Sarcoidosis / / 22952805 rs73568967 chr11 112687919 G A 0.00004413 Sarcoidosis / / 22952805 rs75144197 chr11 112688535 C T 0.00004413 Sarcoidosis / / 22952805 rs73568977 chr11 112690600 G A 0.00004453 Sarcoidosis / / 22952805 rs73568979 chr11 112690882 T C 0.00004453 Sarcoidosis / / 22952805 rs73568984 chr11 112691370 C A,T 0.00004453 Sarcoidosis / / 22952805 rs1348940 chr11 112696746 A G 1.12E-04 Height / / 17255346 rs10789916 chr11 112700325 T C 6.69E-05 Height / / 17255346 rs1374695 chr11 112722829 T C 7.83E-05 Height / / 17255346 rs7941724 chr11 112778206 A C 7.13E-04 Alzheimer's disease / / 17998437 rs4937833 chr11 112782064 A G 8.51E-04 Alzheimer's disease / / 17998437 rs7929711 chr11 112782162 G C 8.34E-04 Alzheimer's disease / / 17998437 rs720024 chr11 112838512 T C 7.46E-04 Multiple complex diseases NCAM1 intron 17554300 rs2155287 chr11 112847206 G A 5.28E-18 Metabolite levels NCAM1 intron 22286219 rs6589354 chr11 112878547 T A 1.40E-04 Smoking cessation NCAM1 intron 18519826 rs1940700 chr11 112903555 A T 9.88E-08 HDL cholesterol NCAM1 intron 23063622 rs1436108 chr11 112927742 C A,G,T 9.29E-05 Orofacial clefts NCAM1 intron 22419666 rs2853191 chr11 112929357 A C 2.90E-05 Urinary metabolites NCAM1 intron 21572414 rs12794745 chr11 112951709 G T 2.81E-05 Smoking cessation NCAM1 intron 18519826 rs11214501 chr11 112985477 T A 5.11E-05 Smoking cessation NCAM1 intron 18519826 rs1436109 chr11 112991618 G T 3.00E-07 Left ventricular mass NCAM1 intron 21212386 rs1436109 chr11 112991618 G T 4.00E-09 Left ventricular mass NCAM1 intron 21212386 rs1436109 chr11 112991618 G T 9.00E-07 Left ventricular mass NCAM1 intron 21212386 rs1273044 chr11 112993848 T C 8.43E-05 Schizophrenia NCAM1 intron 19571809 rs4937993 chr11 113004662 A G 1.23E-04 Smoking cessation NCAM1 intron 18519826 rs10891510 chr11 113008160 T G 4.31E-05 Smoking cessation NCAM1 intron 18519826 rs1245133 chr11 113011721 A G 1.65E-05 Schizophrenia NCAM1 intron 19571809 rs28463004 chr11 113026758 A G 8.49E-05 Cocaine dependence NCAM1 intron 23958962 rs1245124 chr11 113029314 A T 3.00E-04 Heroin addiction NCAM1 intron 20520587 rs11214521 chr11 113031696 A G 4.54E-06 Stroke (ischemic) NCAM1 intron 22941190 rs965560 chr11 113072605 G A 9.83E-05 Non-alcoholic fatty liver disease histology (other) NCAM1 intron 20708005 rs4646981 chr11 113090805 C T 9.21E-04 Suicide attempts in bipolar disorder NCAM1 intron 21423239 rs12279261 chr11 113106455 A G 9.00E-06 Entorhinal cortical thickness NCAM1 intron 21116278 rs643830 chr11 113106548 A C 0.000000028 HDL cholesterol NCAM1 intron 23063622 rs61902539 chr11 113113152 G T 5.00E-06 QRS duration in Tripanosoma cruzi seropositivity NCAM1 intron 24324551 rs591042 chr11 113115748 A G 8.41E-04 Suicide attempts in bipolar disorder NCAM1 intron 21423239 rs3781878 chr11 113120212 G A 2.00E-06 Suicide attempts in depression or bipolar disorder NCAM1 intron 24964207 rs2288158 chr11 113133676 T G 0.0000898 Nicotine dependence (smoking) NCAM1 UTR-3 22377092 rs598026 chr11 113139250 A G 1.92E-04 IgE levels NCAM1 intron 17255346 rs668204 chr11 113149642 T C 2.43E-04 Myocardial Infarction NCAM1 nearGene-3 pha002883 rs10891527 chr11 113151790 C T 4.68E-05 Cleft lip / / 20436469 rs688011 chr11 113154170 G A 0.0000108 Nicotine dependence (smoking) / / 22377092 rs12279103 chr11 113177189 A G 1.80E-05 Urinary metabolites / / 21572414 rs2236709 chr11 113186776 G A 2.67E-06 Phospholipid levels (plasma) TTC12 intron 21829377 rs6589371 chr11 113192797 C T 2.00E-05 Urinary metabolites TTC12 intron 21572414 rs635358 chr11 113197243 T A 3.05E-04 Suicide attempts in bipolar disorder TTC12 intron 21423239 rs10502172 chr11 113199146 C T 2.10E-04 Alcohol dependence TTC12 intron 20201924 rs10502172 chr11 113199146 C T 7.00E-04 Alcohol dependence TTC12 intron 20201924 rs10502172 chr11 113199146 C T 2.86E-04 Suicide attempts in bipolar disorder TTC12 intron 21423239 rs10891535 chr11 113201280 C G 2.77E-04 Suicide attempts in bipolar disorder TTC12 intron 21423239 rs11214577 chr11 113204266 C T 4.72E-04 Suicide attempts in bipolar disorder TTC12 intron 21423239 rs1893695 chr11 113206085 A C 2.40E-04 Suicide attempts in bipolar disorder TTC12 intron 21423239 rs2155462 chr11 113206799 A C 2.38E-04 Suicide attempts in bipolar disorder TTC12 intron 21423239 rs10891536 chr11 113209428 C G 3.10E-04 Suicide attempts in bipolar disorder TTC12 intron 21423239 rs10891537 chr11 113211370 T G 3.00E-04 Alcohol dependence TTC12 intron 20201924 rs10891537 chr11 113211370 T G 7.50E-04 Alcohol dependence TTC12 intron 20201924 rs10891537 chr11 113211370 T G 2.14E-04 Suicide attempts in bipolar disorder TTC12 intron 21423239 rs11214582 chr11 113218050 C T 3.44E-04 Suicide attempts in bipolar disorder TTC12 intron 21423239 rs11493880 chr11 113225144 C T 4.38E-04 Suicide attempts in bipolar disorder TTC12 intron 21423239 rs7939992 chr11 113229665 T C 3.90E-04 Suicide attempts in bipolar disorder TTC12 intron 21423239 rs4438071 chr11 113231614 C T 4.69E-04 Suicide attempts in bipolar disorder TTC12 intron 21423239 rs4438071 chr11 113231614 C T 7.44E-05 Diabetes Mellitus TTC12 intron pha003060 rs4370966 chr11 113231691 G A 4.71E-04 Suicide attempts in bipolar disorder TTC12 intron 21423239 rs11214587 chr11 113232422 T G 4.70E-04 Suicide attempts in bipolar disorder TTC12 intron 21423239 rs719802 chr11 113234679 T C 7.72E-04 Endometrial cancer TTC12 intron 24096698 rs10789942 chr11 113236199 A G 2.92E-04 Suicide attempts in bipolar disorder TTC12 intron 21423239 rs10891539 chr11 113236492 G C 3.42E-04 Suicide attempts in bipolar disorder TTC12 intron 21423239 rs10891540 chr11 113239082 G A 2.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs12804573 chr11 113241726 G A 3.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs12805699 chr11 113241810 T A 3.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs1078 chr11 113241877 C T 3.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs2186799 chr11 113242533 G T 3.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs2186800 chr11 113242860 G A 4.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs754672 chr11 113249136 C T 8.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs754672 chr11 113249136 C T 5.72E-04 Endometrial cancer / / 24096698 rs754672 chr11 113249136 C T 6.50E-04 Endometrial cancer / / 24096698 rs754672 chr11 113249136 C T 8.35E-05 Coronary heart disease / / pha003031 rs7107223 chr11 113255574 A T 5.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs10891544 chr11 113256152 C A 6.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs877137 chr11 113256330 C T 6.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs1800497 chr11 113270828 G A 1 Drug response to Bupropion ANKK1 missense 18058343 rs1800497 chr11 113270828 G A 1 Drug response to Risperidone ANKK1 missense 18855532 rs1800497 chr11 113270828 G A 1 Drug response to Postoperative Nausea and Vomiting ANKK1 missense 19011779 rs1800497 chr11 113270828 G A 1 Drug response to Risperidone ANKK1 missense 19339912 rs6275 chr11 113283477 A G 1 Drug response to Methadone DRD2 cds-synon 19373123 rs1076560 chr11 113283688 C A 1 Drug response to Ethanol DRD2 intron 17196743 rs2440390 chr11 113286878 T C 5.00E-04 Atrial fibrillation DRD2 intron 21846873 rs1079596 chr11 113296619 C T 3.00E-06 Select biomarker traits DRD2 intron 17903293 rs12364051 chr11 113305314 A G 5.66E-05 Longevity DRD2 intron 20304771 rs4436578 chr11 113306765 C T 0.00044 Coronary artery calcification DRD2 intron 23727086 rs4586205 chr11 113307129 G T 4.50E-05 Atrial fibrillation DRD2 intron 21846873 rs11214606 chr11 113309869 C T 5.00E-07 Response to antipsychotic treatment in schizophrenia (working memory) DRD2 intron 21107309 rs7125415 chr11 113310681 C T 9.44E-05 Stroke (ischemic) DRD2 intron 22941190 rs12574471 chr11 113316236 C T 3.00E-04 Atrial fibrillation DRD2 intron 21846873 rs17529477 chr11 113317067 G A 1.93E-05 Systolic blood pressure in sickle cell anemia DRD2 intron 24058526 rs4245147 chr11 113318007 C T 8.51E-05 Lymphocyte counts DRD2 intron 22286170 rs4274224 chr11 113319452 G A 5.00E-05 Immunoglobulin A DRD2 intron 20694011 rs4581480 chr11 113324474 C T 1.80E-05 Urinary metabolites DRD2 intron 21572414 rs4936274 chr11 113330451 A G 2.80E-05 Urinary metabolites DRD2 intron 21572414 rs11601054 chr11 113336172 G A 7.85E-04 Response to taxane treatment (placlitaxel) DRD2 intron 23006423 rs1799978 chr11 113346351 T C 1 Drug response to Risperidone DRD2 nearGene-5 18855532 rs1799978 chr11 113346351 T C 1 Drug response to Risperidone DRD2 nearGene-5 19339912 rs6589377 chr11 113355736 G A 2.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4245150 chr11 113364647 G T 2.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4938021 chr11 113364803 C T 2.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4936275 chr11 113365084 C T 3.14E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4938025 chr11 113383282 T C 5.13E-04 Iron levels / / pha002876 rs4245154 chr11 113388674 A G 9.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11214647 chr11 113407492 A C 6.20E-06 Urinary metabolites / / 21572414 rs17115673 chr11 113410114 A G 8.50E-06 Urinary metabolites / / 21572414 rs7952106 chr11 113424558 G T 9.00E-07 Systolic blood pressure in sickle cell anemia / / 24058526 rs7125215 chr11 113435819 A C 8.88E-05 Serum metabolites / / 19043545 rs6589386 chr11 113443753 C T 2.70E-07 Schizophrenia / / 21791550 rs6589386 chr11 113443753 C T 0.00000036 Psychosis / / 23164818 rs4488232 chr11 113457673 C T 4.98E-04 Multiple complex diseases / / 17554300 rs11607834 chr11 113461680 C A 5.08E-05 Longevity / / 20304771 rs11607852 chr11 113461717 C G 5.02E-05 Longevity / / 20304771 rs3923972 chr11 113462012 G A 4.98E-05 Longevity / / 20304771 rs17603387 chr11 113477587 T C 5.37E-05 Longevity / / 20304771 rs1039832 chr11 113478201 A G 7.51E-05 Blood Pressure / / pha003043 rs10789952 chr11 113488088 G C 4.04E-04 Alzheimer's disease / / 22005930 rs11601692 chr11 113500821 C T 8.18E-05 Longevity / / 20304771 rs3914059 chr11 113503954 C T 1.23E-05 Personality dimensions / / 22628180 rs11605737 chr11 113504136 T C 6.09E-05 Longevity / / 20304771 rs1509513 chr11 113504913 A G 1.29E-05 Personality dimensions / / 22628180 rs17531898 chr11 113507087 T C 5.44E-05 Longevity / / 20304771 rs1022084 chr11 113508425 A G 1.27E-05 Personality dimensions / / 22628180 rs11601402 chr11 113512522 A T 2.57E-05 Longevity / / 20304771 rs17610557 chr11 113513499 A T 2.32E-05 Longevity / / 20304771 rs17532157 chr11 113516770 G T 4.03E-05 Longevity / / 20304771 rs17532254 chr11 113518935 A G 2.23E-05 Longevity / / 20304771 rs11602504 chr11 113520122 A G 2.10E-05 Longevity / / 20304771 rs17532375 chr11 113521607 G A 2.12E-05 Longevity / / 20304771 rs17610915 chr11 113522590 T C 2.12E-05 Longevity / / 20304771 rs17532479 chr11 113522981 T C 2.15E-05 Longevity / / 20304771 rs11600717 chr11 113523862 G A 2.17E-05 Longevity / / 20304771 rs11602934 chr11 113524147 T C 2.30E-05 Longevity / / 20304771 rs11601890 chr11 113526148 C T 5.27E-05 Longevity / / 20304771 rs11607594 chr11 113526551 C T 2.56E-05 Longevity / / 20304771 rs11607622 chr11 113526665 C T 3.31E-05 Longevity / / 20304771 rs11607747 chr11 113527201 G A 2.39E-05 Longevity / / 20304771 rs11602134 chr11 113536910 G A,T 2.11E-05 Longevity / / 20304771 rs11606746 chr11 113537310 A G 2.39E-05 Longevity / / 20304771 rs1355202 chr11 113541021 C T 2.28E-05 Longevity / / 20304771 rs11605078 chr11 113541994 C T 2.19E-05 Longevity / / 20304771 rs11605096 chr11 113542110 C A 1.94E-05 Longevity / / 20304771 rs11600908 chr11 113542171 A G 1.96E-05 Longevity / / 20304771 rs11606211 chr11 113543533 C A 2.10E-05 Longevity / / 20304771 rs11606336 chr11 113544156 G A 2.04E-05 Longevity / / 20304771 rs11607704 chr11 113548049 T C 2.36E-05 Longevity / / 20304771 rs17611093 chr11 113548309 T C 2.37E-05 Longevity / / 20304771 rs17611127 chr11 113548674 T C 2.36E-05 Longevity / / 20304771 rs11604194 chr11 113553049 A C 2.20E-05 Longevity / / 20304771 rs17532884 chr11 113553617 C T 2.23E-05 Longevity / / 20304771 rs11607690 chr11 113561727 G A 7.41E-05 Longevity TMPRSS5 intron 20304771 rs11600570 chr11 113564012 G A 7.80E-05 Longevity TMPRSS5 intron 20304771 rs11601425 chr11 113570385 C T 8.48E-05 Longevity TMPRSS5 missense 20304771 rs2363549 chr11 113574363 C T 2.10E-05 Urinary metabolites TMPRSS5 intron 21572414 rs10891588 chr11 113579598 C T 1.10E-05 Urinary metabolites / / 21572414 rs4936281 chr11 113582590 C A 1.58E-05 Multiple complex diseases / / 17554300 rs4936281 chr11 113582590 C A 7.00E-04 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs10502177 chr11 113585911 C G 5.44E-05 Longevity / / 20304771 rs17612378 chr11 113590197 C A 5.15E-05 Longevity / / 20304771 rs7932415 chr11 113590575 C A 1.41E-04 Age-related macular degeneration / / 22125219 rs11607718 chr11 113592008 G A 4.91E-05 Longevity / / 20304771 rs2885987 chr11 113602555 T G 1.74E-05 Blood Pressure / / pha003043 rs11604887 chr11 113602809 T C 5.18E-05 Longevity / / 20304771 rs41468448 chr11 113604332 C T 3.52E-04 Multiple complex diseases ZW10 UTR-3 17554300 rs17541000 chr11 113611738 A G 5.59E-05 Longevity ZW10 intron 20304771 rs17115920 chr11 113613869 G A 6.62E-04 Body mass index ZW10 intron 21701565 rs17541153 chr11 113615622 G C 5.01E-05 Longevity ZW10 intron 20304771 rs7105512 chr11 113619339 G T 1.74E-04 Age-related macular degeneration ZW10 intron 22125219 rs10891592 chr11 113620632 T C 2.04E-04 Age-related macular degeneration ZW10 intron 22125219 rs142759842 chr11 113629371 G A 0.000067 Prostate cancer (advanced) ZW10 missense 23555315 rs17614161 chr11 113647332 C T 6.86E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs2465647 chr11 113679119 C T 2.90E-04 Age-related macular degeneration USP28 cds-synon 22125219 rs2519200 chr11 113684809 A G 1.80E-05 Cognitive function USP28 intron 24684796 rs7111825 chr11 113696653 C T 2.10E-04 Age-related macular degeneration USP28 intron 22125219 rs7111825 chr11 113696653 C T 9.01E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) USP28 intron 23648065 rs7112957 chr11 113712526 T C 4.11E-04 Age-related macular degeneration USP28 intron 22125219 rs12270070 chr11 113799047 G C 1.39E-04 Response to cytadine analogues (cytosine arabinoside) HTR3B intron 24483146 rs17116117 chr11 113801591 A G 2.64E-11 Multiple complex diseases HTR3B intron 17554300 rs2276307 chr11 113803887 A G 1 Drug response to Atorvastatin HTR3B intron 17600820 rs2276307 chr11 113803887 A G 1 Drug response to Pravastatin HTR3B intron 17600820 rs2276307 chr11 113803887 A G 1 Drug response to Simvastatin HTR3B intron 17600820 rs2276307 chr11 113803887 A G 8.15E-04 Response to cytadine analogues (cytosine arabinoside) HTR3B intron 24483146 rs2276308 chr11 113803976 C G 6.32E-04 Response to cytadine analogues (cytosine arabinoside) HTR3B intron 24483146 rs4936285 chr11 113817579 T C 6.26E-04 Response to cytadine analogues (cytosine arabinoside) HTR3B nearGene-3 24483146 rs1185027 chr11 113817656 T A 5.45E-05 Serum metabolites HTR3B nearGene-3 19043545 rs11607692 chr11 113818783 T C 9.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17116178 chr11 113827326 G T 9.05E-06 Blood Pressure / / pha003043 rs1150229 chr11 113833152 A G 1.09E-04 Intracranial aneurysm / / 20613766 rs897685 chr11 113864109 C T 1.60E-04 Response to antidepressants / / 19736353 rs897685 chr11 113864109 C T 4.32E-04 Renal cell carcinoma / / 22010048 rs897685 chr11 113864109 C T 5.42E-05 IgA nephropathy / / 22197929 rs2846626 chr11 113923311 T C 4.92E-04 Insulin resistance / / 21901158 rs3018331 chr11 113940469 C A 7.84E-04 Type 2 diabetes ZBTB16 intron 17463246 rs1672692 chr11 113945609 G A 3.52E-05 Lung adenocarcinoma ZBTB16 intron 19836008 rs1784692 chr11 113949232 T C 6.43E-05 Lung adenocarcinoma ZBTB16 intron 19836008 rs2606724 chr11 113957880 G A 2.00E-04 Cognitive impairment induced by topiramate ZBTB16 intron 22091778 rs17116334 chr11 113961762 C T 9.00E-06 Conduct disorder (interaction) ZBTB16 intron 18846501 rs10488697 chr11 113969669 A G 2.20E-05 Homocysteine levels,in plasma ZBTB16 intron 19525478 rs10488697 chr11 113969669 A G 6.51E-06 Blood Pressure ZBTB16 intron pha003039 rs238924 chr11 113975446 A G 2.68E-04 Response to cytadine analogues (cytosine arabinoside) ZBTB16 intron 24483146 rs17116384 chr11 113981241 A G 1.77E-04 Sudden cardiac arrest ZBTB16 intron 21658281 rs238913 chr11 113984489 A G 1.25E-05 Type 2 diabetes ZBTB16 intron 17463246 rs238913 chr11 113984489 A G 8.05E-05 Sudden cardiac arrest ZBTB16 intron 21658281 rs2073844 chr11 113984975 A G 8.08E-04 Suicide attempts in bipolar disorder ZBTB16 intron 21423239 rs2073844 chr11 113984975 A G 5.19E-05 Potassium levels ZBTB16 intron pha003086 rs238910 chr11 113986879 A G 3.66E-05 Type 2 diabetes ZBTB16 intron 17463246 rs238899 chr11 113990717 T C 7.83E-04 Type 2 diabetes ZBTB16 intron 17463246 rs238898 chr11 113994044 C G 1.52E-04 Type 2 diabetes ZBTB16 intron 17463246 rs238898 chr11 113994044 C G 5.75E-04 Multiple complex diseases ZBTB16 intron 17554300 rs238897 chr11 113994374 A G 5.29E-04 Type 2 diabetes ZBTB16 intron 17463246 rs238896 chr11 113994505 G A 6.48E-04 Type 2 diabetes ZBTB16 intron 17463246 rs2735207 chr11 113997675 C T 1.15E-04 Type 2 diabetes ZBTB16 intron 17463246 rs238889 chr11 113997994 T C 6.40E-05 Type 2 diabetes ZBTB16 intron 17463246 rs238887 chr11 113998602 C G 8.66E-05 Type 2 diabetes ZBTB16 intron 17463246 rs926075 chr11 114000727 C T 7.34E-04 Type 2 diabetes ZBTB16 intron 17463246 rs10488696 chr11 114003347 G A 8.46E-04 Suicide attempts in bipolar disorder ZBTB16 intron 21041247 rs12278218 chr11 114004128 C T 8.70E-04 Suicide attempts in bipolar disorder ZBTB16 intron 21041247 rs717676 chr11 114007713 G T 2.45E-04 Bicuspid aortic valve ZBTB16 intron 20098615 rs12293744 chr11 114023016 C T 5.23E-05 Cognitive impairment induced by topiramate ZBTB16 intron 22091778 rs12293744 chr11 114023016 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ZBTB16 intron 22628534 rs485550 chr11 114023864 C T 9.84E-04 Alzheimer's disease ZBTB16 intron 22005930 rs11214881 chr11 114023946 T C 7.66E-06 Cognitive impairment induced by topiramate ZBTB16 intron 22091778 rs11214881 chr11 114023946 T C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ZBTB16 intron 22628534 rs622200 chr11 114028774 T C 2.31E-04 Schizophrenia ZBTB16 intron 19197363 rs1184748 chr11 114037061 A G 2.91E-04 Suicide attempts in bipolar disorder ZBTB16 intron 21423239 rs513039 chr11 114037158 G A 9.02E-04 Suicide attempts in bipolar disorder ZBTB16 intron 21423239 rs672849 chr11 114038866 C T 8.47E-04 Type 2 diabetes ZBTB16 intron 17846124 rs672849 chr11 114038866 C T 1.49E-05 Type 2 diabetes ZBTB16 intron 17846125 rs686989 chr11 114039225 G A 9.09E-04 Type 2 diabetes ZBTB16 intron 17846124 rs686989 chr11 114039225 G A 2.68E-06 Type 2 diabetes ZBTB16 intron 17846125 rs500629 chr11 114045560 C A 3.62E-05 Male-pattern baldness ZBTB16 intron 18849994 rs2073848 chr11 114051904 T C 2.00E-04 Schizophrenia ZBTB16 intron 19197363 rs3782007 chr11 114066438 G A 6.89E-04 Schizophrenia ZBTB16 intron 19197363 rs3782000 chr11 114072875 C T 1.84E-07 Autism ZBTB16 intron 22843504 rs583647 chr11 114074681 G A 4.70E-05 Lung function (forced expiratory volume in 1 second) ZBTB16 intron 24023788 rs583200 chr11 114074756 C T 3.09E-04 Lung function (forced expiratory volume in 1 second) ZBTB16 intron 24023788 rs12273315 chr11 114076935 G A 3.08E-04 Tourette syndrome ZBTB16 intron 22889924 rs405388 chr11 114081271 G A 4.07E-05 Glucose levels ZBTB16 intron pha003058 rs549427 chr11 114084859 G A 3.88E-04 Nicotine smoking ZBTB16 intron 19268276 rs397461 chr11 114087467 C T 2.42E-04 Response to taxane treatment (placlitaxel) ZBTB16 intron 23006423 rs424337 chr11 114087577 C G 7.27E-04 Suicide attempts in bipolar disorder ZBTB16 intron 21423239 rs375620 chr11 114089435 T A 2.58E-04 Type 2 diabetes ZBTB16 intron 17463246 rs573264 chr11 114092582 A G 4.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZBTB16 intron 20877124 rs3781990 chr11 114093055 C T 7.80E-06 Crohn's disease ZBTB16 intron 20570966 rs382312 chr11 114103913 C T 3.61E-05 Coronary heart disease ZBTB16 intron pha003031 rs387301 chr11 114112013 G A 2.16E-04 Multiple complex diseases ZBTB16 intron 17554300 rs11600671 chr11 114125324 G A 0.000828108 Hypertension (early onset hypertension) / / 22479346 rs4938087 chr11 114154765 G A 5.13E-05 Cognitive performance / / 19734545 rs2604294 chr11 114156318 T C 2.50E-04 Longevity / / 22279548 rs2847476 chr11 114191016 A G 3.00E-06 Volumetric brain MRI / / 17903297 rs144262762 chr11 114192132 CAGCTGTG C 7.30E-04 Acute lung injury / / 22295056 rs375444016 chr11 114192132 CAGCTGTG C 7.30E-04 Acute lung injury / / 22295056 rs7929497 chr11 114192132 C G 7.30E-04 Acute lung injury / / 22295056 rs2604299 chr11 114199213 A G 7.44E-04 Acute lung injury / / 22295056 rs2847473 chr11 114199240 T A 7.44E-04 Acute lung injury / / 22295056 rs2852444 chr11 114199803 T C 7.44E-04 Acute lung injury / / 22295056 rs2604300 chr11 114199958 A C 7.44E-04 Acute lung injury / / 22295056 rs3133235 chr11 114200359 G A 7.44E-04 Acute lung injury / / 22295056 rs2852429 chr11 114200953 C T 7.44E-04 Acute lung injury / / 22295056 rs2852438 chr11 114214702 A G 7.78E-05 Parkinson's disease / / 17052657 rs2365880 chr11 114217981 T A 6.63E-04 Acute lung injury / / 22295056 rs11214966 chr11 114231255 T C 6.00E-07 Asthma / / 21804549 rs7951645 chr11 114232733 A C 4.71E-04 Acute lung injury / / 22295056 rs2852448 chr11 114235288 C T 6.93E-04 Acute lung injury / / 22295056 rs1941395 chr11 114235304 A G 6.01E-04 Acute lung injury / / 22295056 rs2604296 chr11 114259653 C T 1.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs536179 chr11 114275073 A G 7.08E-04 Coronary heart disease RBM7 intron 21971053 rs3863298 chr11 114275756 T C 4.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBM7 intron 20877124 rs11214985 chr11 114292014 G A 3.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs528747 chr11 114302800 A G 2.04E-05 Type 2 diabetes / / 17463246 rs542941 chr11 114305805 T C 1.98E-04 Type 2 diabetes / / 17463246 rs2271716 chr11 114314972 C T 3.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) REXO2 intron 20877124 rs527717 chr11 114326834 A G 9.61E-04 Type 2 diabetes / / 17463246 rs619689 chr11 114326954 C G 9.61E-04 Type 2 diabetes / / 17463246 rs112750 chr11 114328285 A G 8.76E-04 Type 2 diabetes / / 17463246 rs112750 chr11 114328285 A G 8.59E-04 Coronary heart disease / / 21971053 rs112750 chr11 114328285 A G 8.02E-04 Myocardial Infarction / / pha002873 rs479707 chr11 114333923 A G 9.88E-04 Type 2 diabetes / / 17463246 rs479707 chr11 114333923 A G 7.32E-04 Coronary heart disease / / 21971053 rs479707 chr11 114333923 A G 8.04E-04 Myocardial Infarction / / pha002873 rs12797627 chr11 114349787 G A 5.37E-06 Insulin resistance / / 21901158 rs581015 chr11 114349840 C T 4.38E-04 Coronary heart disease / / 21971053 rs581015 chr11 114349840 C T 3.88E-04 Myocardial Infarction / / pha002873 rs1671819 chr11 114381448 G A 7.26E-04 Type 2 diabetes / / 17463246 rs561722 chr11 114386830 C T 5.00E-17 Ulcerative colitis / / 23128233 rs4466877 chr11 114387102 G A 9.00E-07 IgG glycosylation / / 23382691 rs9326244 chr11 114390106 C T 5.00E-07 IgG glycosylation / / 23382691 rs10891692 chr11 114393652 C T 5.98E-04 Coronary heart disease FAM55A missense 21971053 rs11215037 chr11 114403674 G A 6.25E-04 Coronary heart disease FAM55A intron 21971053 rs531824 chr11 114423320 A G 6.58E-04 Myocardial Infarction FAM55A intron pha002873 rs678170 chr11 114431956 A G 5.00E-14 Ulcerative colitis / / 21297633 rs550897 chr11 114442103 A G 8.97E-04 Myocardial Infarction FAM55D missense pha002873 rs623426 chr11 114456084 T C 1.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM55D intron 20877124 rs10790026 chr11 114467897 T G 4.43E-05 Hemoglobin / / pha003096 rs1631759 chr11 114494998 C T 3.62E-04 Blood pressure / / 17255346 rs1517688 chr11 114541075 T C 3.60E-04 Smoking initiation / / 24665060 rs11215158 chr11 114568942 T C 4.73E-04 Smoking initiation FAM55B missense 24665060 rs1517697 chr11 114602435 G A 9.00E-05 Personality dimensions / / 18957941 rs11215175 chr11 114604149 T G 9.64E-05 Personality dimensions / / 18957941 rs17117373 chr11 114609136 T C 7.57E-05 Personality dimensions / / 18957941 rs12270926 chr11 114619805 G A 8.67E-06 Waist-Hip Ratio / / pha003013 rs12270926 chr11 114619805 G A 2.46E-05 Waist-Hip Ratio / / pha003028 rs1712790 chr11 114621469 T C 2.00E-06 Urinary albumin excretion / / 17903292 rs10502192 chr11 114622352 C T 3.60E-05 Kidney function and endocine traits / / 17903292 rs7113782 chr11 114642623 A C 2.90E-04 Alcohol dependence / / 20201924 rs17117491 chr11 114654506 T C 7.90E-06 Urinary metabolites / / 21572414 rs12287008 chr11 114661466 A G 1.90E-05 Triglycerides / / 19074352 rs17117506 chr11 114664299 G A 6.90E-04 Multiple complex diseases / / 17554300 rs10502193 chr11 114664651 A G 6.72E-04 Multiple complex diseases / / 17554300 rs10502194 chr11 114664994 C G 5.09E-04 Multiple complex diseases / / 17554300 rs7949181 chr11 114665112 T C 9.18E-05 Insulin-related traits / / pha002901 rs1980306 chr11 114666495 A T 6.68E-05 Cervical cancer / / 24700089 rs2366583 chr11 114668076 G T 6.16E-04 Multiple complex diseases / / 17554300 rs17117553 chr11 114695496 T C 7.70E-04 Type 2 diabetes / / 22158537 rs11215223 chr11 114702663 A G 1.97E-04 Multiple complex diseases / / 17554300 rs4938144 chr11 114718070 T C 6.78E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1916792 chr11 114726012 T A 5.81E-04 Schizophrenia / / 21674006 rs1398365 chr11 114727155 T C 4.97E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12225903 chr11 114741577 G A 4.13E-04 Aortic root size / / 21223598 rs10790059 chr11 114818174 G A 3.45E-05 Post-operative nausea and vomiting / / 21694509 rs4542446 chr11 114878065 C T 4.56E-04 Type 2 diabetes / / 17463246 rs4146886 chr11 114917927 A G 1.98E-04 Osteoarthritis / / 19508968 rs978187 chr11 114934127 A C 2.00E-04 Information processing speed / / 21130836 rs2427671 chr11 114939294 T C 1.00E-04 Acute lung injury / / 22295056 rs2514373 chr11 114947468 G A 1.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10891797 chr11 114967902 T G 1.30E-05 Urinary metabolites / / 21572414 rs9971533 chr11 114996408 A G 1.46E-05 Blood Pressure / / pha003046 rs2513676 chr11 114999873 A G 2.30E-06 Crohn's disease / / 20570966 rs2187986 chr11 115001410 G A 2.20E-05 Urinary metabolites / / 21572414 rs2507904 chr11 115001610 T C 1.10E-05 Urinary metabolites / / 21572414 rs11215371 chr11 115007698 A G 5.92E-04 Multiple complex diseases / / 17554300 rs2008801 chr11 115008175 G T 5.42E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2008801 chr11 115008175 G T 5.93E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2507905 chr11 115008605 G A 5.42E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2507905 chr11 115008605 G A 5.93E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2507909 chr11 115010867 A G 5.60E-07 Urinary metabolites / / 21572414 rs12421648 chr11 115013447 G A 1.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7122402 chr11 115016307 G A 5.42E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12787954 chr11 115020328 T C 2.43E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12286929 chr11 115022404 A G 1.10E-05 Urinary metabolites / / 21572414 rs4938179 chr11 115033425 G T 2.56E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4938180 chr11 115041012 C T 2.16E-05 Longevity / / 21612516 rs4938182 chr11 115043036 G C 3.09E-05 Bipolar disorder / / 22925353 rs17564430 chr11 115043574 T G 1.74E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11215406 chr11 115065082 T C 1.92E-05 Response to cytadine analogues (cytosine arabinoside) CADM1 intron 24483146 rs11215406 chr11 115065082 T C 6.73E-04 Response to cytidine analogues (gemcitabine) CADM1 intron 24483146 rs10128746 chr11 115075436 T C 5.89E-04 Obesity (extreme) CADM1 intron 21935397 rs10891809 chr11 115076572 A G 2.28E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CADM1 intron 21844884 rs11215416 chr11 115077327 A G 9.57E-06 Response to cytadine analogues (cytosine arabinoside) CADM1 intron 24483146 rs11215417 chr11 115077381 C A 5.58E-04 Obesity (extreme) CADM1 intron 21935397 rs3802858 chr11 115078492 T C 0.00000428 Body mass index CADM1 intron 23001569 rs11215418 chr11 115079894 A T 5.36E-04 Obesity (extreme) CADM1 intron 21935397 rs1124848 chr11 115085948 T C 1.01E-05 Smoking cessation CADM1 intron 18519826 rs1124848 chr11 115085948 T C 1.51E-04 Smoking cessation CADM1 intron 18519826 rs4936323 chr11 115091119 T G 1.20E-04 Response to cytidine analogues (gemcitabine) CADM1 intron 24483146 rs4936323 chr11 115091119 T G 4.00E-06 Response to cytadine analogues (cytosine arabinoside) CADM1 intron 24483146 rs11215427 chr11 115093438 G C 1.20E-04 Response to cytidine analogues (gemcitabine) CADM1 intron 24483146 rs11215427 chr11 115093438 G C 4.48E-06 Response to cytadine analogues (cytosine arabinoside) CADM1 intron 24483146 rs12417740 chr11 115098436 G A 3.83E-04 Coronary Artery Disease CADM1 intron 17634449 rs10891813 chr11 115102283 A C 6.92E-04 Insulin resistance CADM1 intron 21901158 rs7123503 chr11 115122033 A C 4.00E-05 Prostate cancer CADM1 intron 21743057 rs10891817 chr11 115136714 A G 9.00E-04 Type 2 diabetes CADM1 intron 17463246 rs7950069 chr11 115140553 G A 5.00E-06 Orofacial clefts CADM1 intron 22863734 rs10891820 chr11 115144454 T C 3.68E-05 Kawasaki disease CADM1 intron 22446961 rs11215464 chr11 115156236 A T 3.24E-04 Smoking cessation CADM1 intron 18519826 rs11215464 chr11 115156236 A T 3.97E-05 Smoking cessation CADM1 intron 18519826 rs10891823 chr11 115158234 G A 3.12E-07 Smoking cessation CADM1 intron 18519826 rs17118230 chr11 115182330 T C 6.33E-04 Insulin resistance CADM1 intron 21901158 rs10891829 chr11 115198696 C G 5.10E-06 Urinary metabolites CADM1 intron 21572414 rs10488710 chr11 115207176 C G 3.05E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CADM1 intron 24578207 rs10488710 chr11 115207176 C G 3.05E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CADM1 intron 24578207 rs7105871 chr11 115212725 C T 0.0000066 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 CADM1 intron 21873659 rs1013416 chr11 115220254 T G 7.73E-04 Multiple complex diseases CADM1 intron 17554300 rs7107573 chr11 115231041 A T 6.07E-04 Multiple complex diseases CADM1 intron 17554300 rs10891841 chr11 115231740 T G 0.000000697 HDL cholesterol CADM1 intron 23063622 rs11215545 chr11 115286750 C T 2.22E-04 Multiple complex diseases CADM1 intron 17554300 rs7943417 chr11 115300499 T C 4.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CADM1 intron 20877124 rs220836 chr11 115301871 C T 6.00E-06 Obesity-related traits CADM1 intron 23251661 rs7122693 chr11 115304363 A G 6.10E-05 Triglycerides CADM1 intron 19074352 rs220840 chr11 115320963 A G 2.50E-05 Lipid traits CADM1 intron 17903299 rs314474 chr11 115321133 T C 1.80E-05 Lipid traits CADM1 intron 17903299 rs17118345 chr11 115322548 C T 5.62E-10 Triglycerides CADM1 intron 23063622 rs7101558 chr11 115387449 A G 9.85E-05 Cognitive impairment induced by topiramate / / 22091778 rs11215584 chr11 115395297 G A 7.99E-04 Multiple complex diseases / / 17554300 rs7483296 chr11 115398746 A T 5.00E-07 Metabolite levels (HVA/MHPG ratio) / / 23319000 rs7483296 chr11 115398746 A T 8.00E-07 Metabolite levels (5-HIAA/ MHPG Ratio) / / 23319000 rs12286126 chr11 115405695 G A 2.09E-04 Insulin resistance / / 21901158 rs718484 chr11 115416852 G A 1.42E-05 Bilirubin levels,in serum / / 19389676 rs7119152 chr11 115421617 G A 2.38E-05 Bilirubin levels,in serum / / 19389676 rs2513645 chr11 115423876 A G 7.06E-04 Type 2 diabetes / / 17463246 rs12284008 chr11 115427308 A G 3.00E-05 Insulin resistance / / 21901158 rs1870675 chr11 115432255 A G 9.46E-04 Type 2 diabetes / / 17463246 rs2513630 chr11 115443955 G T 2.95E-05 Alcohol consumption / / 23953852 rs2846895 chr11 115487740 C T 2.93E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs2613468 chr11 115487952 G A 3.39E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs10891873 chr11 115495353 C G 2.23E-04 Hearing function / / 17255346 rs11823854 chr11 115496912 C T 2.44E-04 Aortic root size / / 21223598 rs2155633 chr11 115498833 C T 2.91E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs2155631 chr11 115501794 A C 4.89E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs1785016 chr11 115515326 C T 7.20E-04 Alzheimer's disease / / 17998437 rs1785016 chr11 115515326 C T 3.64E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs1618710 chr11 115515974 T A 7.25E-04 Alzheimer's disease / / 17998437 rs1698193 chr11 115519503 C A 6.04E-04 Type 2 diabetes / / 17463246 rs1698157 chr11 115521706 C A 1.30E-04 IgE levels in asthmatics / / 23967269 rs1698157 chr11 115521706 C A 4.49E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs2515314 chr11 115524651 C T 6.57E-04 Type 2 diabetes / / 17463246 rs1784992 chr11 115541768 G A 1.25E-05 Type 2 diabetes / / 17463246 rs1612635 chr11 115545356 C T 2.85E-05 Type 2 diabetes / / 17463246 rs867272 chr11 115548530 T C 2.25E-05 Type 2 diabetes / / 17463246 rs1625168 chr11 115551904 A G 1.55E-04 Type 2 diabetes / / 17463246 rs1784975 chr11 115553972 G A 3.20E-05 Type 2 diabetes / / 17463246 rs1393273 chr11 115560184 G A 1.42E-05 Type 2 diabetes / / 17463246 rs1784964 chr11 115563555 A G 8.31E-05 Waist-Hip Ratio / / pha003029 rs11826326 chr11 115570349 G A 5.24E-05 Schizophrenia(age at onset) / / 21688384 rs12291717 chr11 115599070 T C 7.99E-05 Triglycerides / / pha003080 rs12291717 chr11 115599070 T C 9.71E-05 Triglycerides / / pha003081 rs17118726 chr11 115601699 A T 4.00E-04 Insulin resistance / / 21901158 rs11215672 chr11 115605955 C A 6.29E-05 Triglycerides / / pha003080 rs2285253 chr11 115616372 T C 9.42E-05 Pulmonary function / / 20010835 rs6589497 chr11 115622993 T C 2.69E-06 Parkinson's disease / / 21738487 rs11215675 chr11 115627217 G A 9.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs11215714 chr11 115761567 T C 7.26E-04 Multiple complex diseases / / 17554300 rs638882 chr11 115764045 C T 4.00E-06 Hip geometry / / 17903296 rs7129139 chr11 115771144 A G 8.95E-04 Multiple complex diseases / / 17554300 rs11215722 chr11 115775755 A C 9.60E-05 Cholesterol / / pha003078 rs6589517 chr11 115788173 A C 5.89E-05 Cholesterol / / pha003073 rs6589517 chr11 115788173 A C 2.87E-05 ldl cholesterol / / pha003076 rs6589517 chr11 115788173 A C 2.60E-05 Cholesterol / / pha003078 rs1320650 chr11 115788307 T A 2.26E-04 Multiple complex diseases / / 17554300 rs1320654 chr11 115788427 C A 6.58E-04 Multiple complex diseases / / 17554300 rs374729 chr11 115792775 G A 6.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs369845 chr11 115803202 T C 1.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs427875 chr11 115803926 C A 7.42E-05 Suicide attempts in bipolar disorder / / 21041247 rs1145180 chr11 115812171 A G 7.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs11215750 chr11 115867672 G T 1.30E-04 IgE levels / / 17255346 rs11215756 chr11 115889941 G T 2.50E-04 IgE levels / / 17255346 rs373027767 chr11 115889941 GGT G 2.50E-04 IgE levels / / 17255346 rs71066457 chr11 115889941 GGTGTGTGT G 2.50E-04 IgE levels / / 17255346 rs379625 chr11 115906705 T G 2.54E-04 Multiple complex diseases / / 17554300 rs1791915 chr11 115916092 T G 3.62E-05 IgE levels / / 17255346 rs930005 chr11 115917338 C T 2.87E-04 Multiple complex diseases / / 17554300 rs1632799 chr11 115918301 C G 7.12E-05 Multiple complex diseases / / 17554300 rs10891914 chr11 115930633 G T 1.42E-04 Type 2 diabetes / / 17463246 rs720036 chr11 115941731 A G 7.09E-05 Parkinson's disease / / 17052657 rs1426391 chr11 115943253 A C 7.00E-06 Hypertriglyceridemia / / 23505323 rs1648364 chr11 115948410 C T 2.50E-04 Type 2 diabetes / / 17846124 rs573713 chr11 115989597 A G 4.69E-05 Socioeconomic Factors / / pha003066 rs1894063 chr11 115999794 C A 8.53E-05 Sudden cardiac arrest / / 21658281 rs563272 chr11 116007539 T C 4.36E-05 Schizophrenia / / 21747397 rs11215811 chr11 116009138 G A 3.85E-04 Multiple complex diseases / / 17554300 rs1783219 chr11 116030500 G A 2.90E-05 Urinary metabolites / / 21572414 rs77576197 chr11 116034074 C G 8.81E-05 Tuberculosis / / 22306650 rs2251835 chr11 116053284 G A 5.28E-04 Stroke / / pha002887 rs1009746 chr11 116118912 T G 1.80E-05 Alcohol dependence / / 20201924 rs1009746 chr11 116118912 T G 4.00E-05 Alcohol dependence / / 20201924 rs1009746 chr11 116118912 T G 4.03E-05 Alcoholism / / pha002892 rs1009746 chr11 116118912 T G 1.83E-05 Alcoholism / / pha002893 rs10891936 chr11 116126460 G A 3.30E-04 Alcohol dependence / / 20201924 rs10891936 chr11 116126460 G A 4.80E-04 Alcohol dependence / / 20201924 rs10891937 chr11 116126804 G A 1.60E-04 Alcohol dependence / / 20201924 rs10891937 chr11 116126804 G A 8.60E-04 Alcohol dependence / / 20201924 rs17473320 chr11 116129017 C T 3.30E-04 Alcohol dependence / / 20201924 rs17473320 chr11 116129017 C T 8.80E-05 Alcohol dependence / / 20201924 rs17473320 chr11 116129017 C T 8.79E-05 Alcoholism / / pha002893 rs7128824 chr11 116131952 A C 1.50E-04 Alcohol dependence / / 20201924 rs7128824 chr11 116131952 A C 2.10E-04 Alcohol dependence / / 20201924 rs10790119 chr11 116134341 A C 5.76E-04 Multiple complex diseases / / 17554300 rs4938246 chr11 116139119 G A 1.10E-04 Alcohol dependence / / 20201924 rs4938246 chr11 116139119 G A 7.30E-04 Alcohol dependence / / 20201924 rs12420498 chr11 116168614 T A 5.20E-05 Panic disorder / / 19165232 rs10502218 chr11 116181859 G A 3.78E-04 Fibrinogen / / 17255346 rs10502218 chr11 116181859 G A 4.94E-06 Statin-induced myopathy / / 21826682 rs11601506 chr11 116215109 G T 4.40E-04 Smoking initiation / / 24665060 rs567681 chr11 116216713 A C 3.51E-04 Smoking initiation / / 24665060 rs552104 chr11 116219158 T G 4.13E-04 Smoking initiation / / 24665060 rs554865 chr11 116219458 C T 5.01E-04 Smoking initiation / / 24665060 rs2512160 chr11 116222809 A G 3.58E-04 Smoking initiation / / 24665060 rs17119506 chr11 116227500 G A 7.43E-04 Multiple complex diseases / / 17554300 rs531852 chr11 116228699 A C 4.17E-04 Smoking initiation / / 24665060 rs491111 chr11 116238034 G A 4.80E-04 Multiple sclerosis / / 21833088 rs531860 chr11 116261676 G A 2.18E-05 Bipolar disorder and schizophrenia / / 20889312 rs532227 chr11 116271094 A G 3.62E-04 Type 2 diabetes / / 17463246 rs4938268 chr11 116272339 A G 6.92E-06 Schizophrenia / / 19571811 rs505128 chr11 116273511 T C 5.36E-04 Smoking initiation / / 24665060 rs508994 chr11 116280252 A C 8.58E-04 Multiple complex diseases / / 17554300 rs536484 chr11 116280965 C G 5.59E-04 Multiple complex diseases / / 17554300 rs563990 chr11 116285538 G A 9.15E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs693603 chr11 116296243 A G 6.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs693603 chr11 116296243 A G 2.10E-05 Urinary metabolites / / 21572414 rs490592 chr11 116298367 A C 1.00E-06 Brain structure / / 20171287 rs490592 chr11 116298367 A C 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10047413 chr11 116304429 T A 7.55E-05 Serum metabolites / / 19043545 rs2174880 chr11 116304983 G A 6.23E-05 Serum metabolites / / 19043545 rs11215936 chr11 116313516 G A 6.76E-04 Multiple complex diseases / / 17554300 rs11215936 chr11 116313516 G A 2.63E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs489164 chr11 116316777 T C 9.97E-04 Stroke / / pha002887 rs12418858 chr11 116328380 G A 5.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs17119713 chr11 116338675 T G 2.83E-04 Multiple complex diseases / / 17554300 rs1354975 chr11 116352339 C T 9.61E-04 Type 2 diabetes / / 17463246 rs573554 chr11 116355860 T C 2.58E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2367873 chr11 116376840 A G 9.38E-04 Type 2 diabetes / / 17463246 rs12421717 chr11 116377625 T A 6.56E-05 Orofacial clefts / / 22419666 rs1039755 chr11 116384126 C T 3.60E-06 Dietary macronutrient intake / / 23372041 rs7952521 chr11 116385354 G A 8.00E-04 Polycystic ovary syndrome / / 22178785 rs4938276 chr11 116393980 C T 3.47E-04 Taste perception / / 22132133 rs1944156 chr11 116396613 A C 5.83E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4936353 chr11 116397649 A G 4.98E-04 Taste perception / / 22132133 rs7941534 chr11 116400382 A G 8.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs7925845 chr11 116403905 A G 3.16E-05 Cognitive impairment induced by topiramate / / 22091778 rs11215990 chr11 116407583 C T 5.95E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11215990 chr11 116407583 C T 8.80E-05 Cognitive function / / 24684796 rs951839 chr11 116409788 C A 4.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10790147 chr11 116411836 C T 5.32E-04 Multiple complex diseases / / 17554300 rs10891987 chr11 116417181 G C 4.30E-04 Multiple complex diseases / / 17554300 rs4938280 chr11 116419442 T C 1.69E-04 Multiple complex diseases / / 17554300 rs12362410 chr11 116422860 G A 2.46E-05 Multiple complex diseases / / 17554300 rs7930491 chr11 116427932 G A 5.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17119815 chr11 116429563 T G 2.66E-04 Multiple complex diseases / / 17554300 rs10431079 chr11 116440678 A G 4.45E-04 Multiple complex diseases / / 17554300 rs7122363 chr11 116449283 C T 4.98E-04 Alzheimer's disease / / 17998437 rs11216031 chr11 116466289 A C 4.23E-04 Taste perception / / 22132133 rs1145185 chr11 116514699 G A 4.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs1240769 chr11 116517591 T G 2.19E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs499790 chr11 116519739 C T 3.24E-05 Type 2 diabetes / / 17463246 rs499790 chr11 116519739 C T 3.24E-07 Lipid levels / / 19913121 rs499790 chr11 116519739 C T 6.01E-05 Lipid levels / / 19913121 rs499790 chr11 116519739 C T 0.000000133 Cholesterol,total / / 23063622 rs499790 chr11 116519739 C T 1.01E-10 HDL cholesterol / / 23063622 rs499790 chr11 116519739 C T 2.16E-34 Triglycerides / / 23063622 rs1240773 chr11 116520527 G T 8.00E-06 HIV-1 susceptibility / / 21160409 rs480878 chr11 116522854 G A 7.99E-09 Triglycerides / / 19060911 rs480823 chr11 116525730 T C 1.00E-04 Lipid levels / / 19913121 rs480823 chr11 116525730 T C 1.07E-08 Lipid levels / / 19913121 rs480823 chr11 116525730 T C 8.06E-04 Lipid levels / / 19913121 rs480823 chr11 116525730 T C 2.25E-08 HDL cholesterol / / 23063622 rs480823 chr11 116525730 T C 2.44E-34 Triglycerides / / 23063622 rs480823 chr11 116525730 T C 2.87E-09 Cholesterol,total / / 23063622 rs481843 chr11 116525867 C T 2.08E-05 Type 2 diabetes / / 17463246 rs481843 chr11 116525867 C T 2.79E-04 Alzheimer's disease / / 17998437 rs481843 chr11 116525867 C T 1.48E-08 Lipid levels / / 19913121 rs481843 chr11 116525867 C T 1.83E-04 Lipid levels / / 19913121 rs481843 chr11 116525867 C T 1.06E-09 Cholesterol,total / / 23063622 rs481843 chr11 116525867 C T 1.35E-47 Triglycerides / / 23063622 rs481843 chr11 116525867 C T 7.50E-12 HDL cholesterol / / 23063622 rs486394 chr11 116526322 A C 2.19E-04 Multiple sclerosis / / 17660530 rs486394 chr11 116526322 A C 7.40E-06 Lipid levels / / 18193043 rs486394 chr11 116526322 A C 2.36E-09 HDL cholesterol / / 23063622 rs486394 chr11 116526322 A C 2.56E-26 Triglycerides / / 23063622 rs3016353 chr11 116527282 C T 1.30E-07 Response to statin therapy / / 20339536 rs579674 chr11 116528224 T G 9.50E-05 Response to statin therapy / / 20339536 rs579674 chr11 116528224 T G 1.34E-10 Metabolite levels / / 22286219 rs496958 chr11 116528876 T C 9.40E-05 Response to statin therapy / / 20339536 rs524467 chr11 116529641 T G 8.50E-05 Response to statin therapy / / 20339536 rs528806 chr11 116529914 C T 9.20E-05 Response to statin therapy / / 20339536 rs17119878 chr11 116531479 T A 3.40E-05 Response to statin therapy / / 20339536 rs509728 chr11 116533167 G C 1.10E-13 Metabolite levels / / 22286219 rs1240776 chr11 116536281 T C 9.10E-06 Urinary metabolites / / 21572414 rs7952043 chr11 116552562 C T 2.40E-05 Response to statin therapy / / 20339536 rs12806224 chr11 116552815 T C 5.81E-11 Metabolite levels / / 22286219 rs12805061 chr11 116553025 A G 1.90E-10 Lipid levels / / 19802338 rs12805061 chr11 116553025 A G 2.20E-07 Response to statin therapy / / 20339536 rs12805061 chr11 116553025 A G 9.70E-07 Response to Vitamin E supplementation / / 22437554 rs12805061 chr11 116553025 A G 2.07E-05 Triglycerides / / pha002904 rs11826999 chr11 116553778 G A 1.70E-07 Response to statin therapy / / 20339536 rs12225622 chr11 116553924 C T 5.43E-05 Hypertension (early onset hypertension) / / 22479346 rs1145212 chr11 116556865 G A 3.00E-04 Celiac disease / / 23936387 rs2156120 chr11 116557155 A G 4.56E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs17092642 chr11 116557248 T C 1.80E-07 Response to statin therapy / / 20339536 rs12799766 chr11 116558427 G A 1.20E-07 Response to statin therapy / / 20339536 rs12799766 chr11 116558427 G A 3.74E-04 Sudden cardiac arrest / / 21658281 rs1145210 chr11 116559002 C T 9.42E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs57984552 chr11 116566672 A C,T 1.61E-11 Metabolite levels / / 22286219 rs4938300 chr11 116567619 C T 5.20E-05 Response to statin therapy / / 20339536 rs10892017 chr11 116567881 G C 2.90E-05 Response to statin therapy / / 20339536 rs11601584 chr11 116571284 T C 8.50E-06 Response to statin therapy / / 20339536 rs1892948 chr11 116572089 C A,G,T 1.35E-06 Carotenoid and tocopherol levels / / 19185284 rs1892948 chr11 116572089 C A,G,T 3.10E-05 Response to statin therapy / / 20339536 rs11216103 chr11 116574488 G A 2.80E-05 Response to statin therapy / / 20339536 rs12802944 chr11 116576400 T C 2.50E-05 Response to statin therapy / / 20339536 rs11216107 chr11 116579663 T C 3.06E-12 Metabolite levels / / 22286219 rs11216109 chr11 116580815 C G 2.40E-05 Response to statin therapy / / 20339536 rs11216109 chr11 116580815 C G 2.37E-08 Iron status biomarkers / / 21149283 rs2367970 chr11 116581641 G A 2.40E-05 Response to statin therapy / / 20339536 rs2367970 chr11 116581641 G A 1.60E-08 Iron status biomarkers / / 21149283 rs6589562 chr11 116583439 A G 2.40E-05 Response to statin therapy / / 20339536 rs6589562 chr11 116583439 A G 9.23E-09 Iron status biomarkers / / 21149283 rs4938302 chr11 116584504 C T 7.02E-12 Metabolite levels / / 22286219 rs4938303 chr11 116584987 C T 1.81E-04 Lipid levels / / 19913121 rs4938303 chr11 116584987 C T 3.47E-06 Lipid levels / / 19913121 rs4938303 chr11 116584987 C T 1.80E-10 Response to statin therapy / / 20339536 rs4938303 chr11 116584987 C T 4.00E-21 Triglycerides / / 20864672 rs4938303 chr11 116584987 C T 4.09E-09 Iron status biomarkers / / 21149283 rs4938303 chr11 116584987 C T 3.16E-11 Metabolite levels / / 22286219 rs4938303 chr11 116584987 C T 4.44E-08 Cholesterol,total / / 23063622 rs4938303 chr11 116584987 C T 4.72E-78 Triglycerides / / 23063622 rs4938303 chr11 116584987 C T 7.21E-21 HDL cholesterol / / 23063622 rs4938303 chr11 116584987 C T 0.0000165 Interleukin-6 (IL-6) levels / / 23505291 rs2000571 chr11 116585533 A G 5.70E-08 Lipid levels / / 18193043 rs2000571 chr11 116585533 A G 1.42E-05 Triglycerides / / 19074352 rs2000571 chr11 116585533 A G 1.42E-05 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs2000571 chr11 116585533 A G 1.10E-09 Lipid levels / / 19802338 rs2000571 chr11 116585533 A G 1.00E-05 Response to statin therapy / / 20339536 rs2000571 chr11 116585533 A G 4.23E-09 Iron status biomarkers / / 21149283 rs2000571 chr11 116585533 A G 3.20E-06 Response to Vitamin E supplementation / / 22437554 rs2000571 chr11 116585533 A G 1.43E-32 Triglycerides / / 23063622 rs2000571 chr11 116585533 A G 2.43E-10 HDL cholesterol / / 23063622 rs7350481 chr11 116586283 T C 1.43E-49 Blood cell counts and other traits / / 20139978 rs7350481 chr11 116586283 T C 8.79E-10 Blood cell counts and other traits / / 20139978 rs7350481 chr11 116586283 T C 9.00E-10 Blood cell counts and other traits / / 20139978 rs7350481 chr11 116586283 T C 3.70E-05 Response to statin therapy / / 20339536 rs7350481 chr11 116586283 T C 7.83E-12 Iron status biomarkers / / 21149283 rs7350481 chr11 116586283 T C 5.80E-14 Metabolite levels / / 22286219 rs7350481 chr11 116586283 T C 2.80E-06 Response to Vitamin E supplementation / / 22437554 rs10892020 chr11 116589652 G C 3.80E-05 Response to statin therapy / / 20339536 rs10892020 chr11 116589652 G C 2.57E-09 Iron status biomarkers / / 21149283 rs6589563 chr11 116590787 G A 2.30E-08 Response to statin therapy / / 20339536 rs180360 chr11 116598988 A G 3.18E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs180360 chr11 116598988 A G 7.47E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs180358 chr11 116599392 C T 6.00E-06 Multiple sclerosis (severity) / / 19010793 rs180358 chr11 116599392 C T 6.80E-08 Lipid levels / / 19802338 rs7123583 chr11 116600021 T C 2.63E-09 Iron status biomarkers / / 21149283 rs12279373 chr11 116600400 A C,G,T 1.20E-07 Response to statin therapy / / 20339536 rs12279373 chr11 116600400 A C,G,T 7.95E-09 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs2008915 chr11 116603134 C G 2.44E-09 Iron status biomarkers / / 21149283 rs12272004 chr11 116603724 C A 5.00E-13 Triglycerides / / 19060911 rs12272004 chr11 116603724 C A 7.00E-07 Cholesterol,total / / 19060911 rs12272004 chr11 116603724 C A 8.00E-10 Carotenoid and tocopherol levels / / 19185284 rs12272004 chr11 116603724 C A 7.60E-11 Lipid levels / / 19802338 rs12272004 chr11 116603724 C A 4.30E-07 Response to statin therapy / / 20339536 rs12272004 chr11 116603724 C A 5.00E-13 Coronary heart disease / / 21347282 rs12272004 chr11 116603724 C A 3.28E-09 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs12272004 chr11 116603724 C A 2.20E-06 Response to Vitamin E supplementation / / 22437554 rs12272004 chr11 116603724 C A 5.37E-13 Triglycerides / / 23063622 rs190060931 chr11 116605932 T G 0.0000221 Menopause (age at onset) / / 23424626 rs1558860 chr11 116607368 A C 7.93E-18 Metabolite levels / / 22286219 rs1558861 chr11 116607437 C T 2.00E-26 Triglycerides / / 18193046 rs1558861 chr11 116607437 C T 2.00E-06 LDL cholesterol / / 20864672 rs1558861 chr11 116607437 C T 2.43E-17 Metabolite levels / / 22286219 rs1558861 chr11 116607437 C T 0.000000113 Cholesterol,total / / 23063622 rs1558861 chr11 116607437 C T 2.14E-13 Triglycerides / / 23063622 rs10466588 chr11 116610249 A G 1.40E-08 Response to statin therapy / / 20339536 rs10466588 chr11 116610249 A G 2.09E-10 Triglycerides / / 23063622 rs9326246 chr11 116611733 C G 1.90E-07 Response to statin therapy / / 20339536 rs9326246 chr11 116611733 C G 4.52E-13 Iron status biomarkers / / 21149283 rs9326246 chr11 116611733 C G 1.42E-14 Metabolite levels / / 22286219 rs9326246 chr11 116611733 C G 0.000000151 Coronary artery disease / / 23202125 rs9326246 chr11 116611733 C G 0.000169 Coronary artery disease with myocardial infarction / / 23202125 rs9326246 chr11 116611733 C G 0.000192 Coronary artery disease (CAD) (males) / / 23202125 rs9326246 chr11 116611733 C G 0.000227 Coronary artery disease (CAD) age >50 / / 23202125 rs9326246 chr11 116611733 C G 1.79E-19 HDL cholesterol / / 23202125 rs9326246 chr11 116611733 C G 4.70E-124 Triglycerides / / 23202125 rs9326246 chr11 116611733 C G 7.09E-32 Cholesterol,total / / 23202125 rs9326246 chr11 116611733 C G 9.99E-15 LDL cholesterol / / 23202125 rs9326246 chr11 116611733 C G 3.00E-07 Coronary artery disease / / 24262325 rs180349 chr11 116611827 A T 2.43E-05 Calcium intake levels and metabolic syndrome / / 22170361 rs10466589 chr11 116611985 G A 6.60E-08 Response to statin therapy / / 20339536 rs10466589 chr11 116611985 G A 6.12E-09 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs12280724 chr11 116613423 G T 3.90E-08 Response to statin therapy / / 20339536 rs12280724 chr11 116613423 G T 5.71E-09 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs12280753 chr11 116613660 C T 5.90E-09 Response to statin therapy / / 20339536 rs12280753 chr11 116613660 C T 8.00E-06 Cardiovascular disease risk factors / / 20838585 rs12280753 chr11 116613660 C T 5.75E-09 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs11216126 chr11 116617240 A C 3.00E-34 HDL cholesterol / / 21909109 rs11216126 chr11 116617240 A C 1.80E-05 Calcium intake levels and metabolic syndrome / / 22170361 rs28927680 chr11 116619073 C G 6.06E-05 Type 2 diabetes BUD13 UTR-3 17463246 rs28927680 chr11 116619073 C G 2.00E-17 Triglycerides BUD13 UTR-3 18193044 rs28927680 chr11 116619073 C G 3.86E-09 Triglycerides BUD13 UTR-3 19060911 rs28927680 chr11 116619073 C G 2.09E-05 Lipid levels BUD13 UTR-3 19913121 rs28927680 chr11 116619073 C G 4.09E-04 Lipid levels BUD13 UTR-3 19913121 rs28927680 chr11 116619073 C G 4.24E-09 Lipid levels BUD13 UTR-3 19913121 rs28927680 chr11 116619073 C G 4.70E-07 Lipoprotein-associated phospholipase A2 activity and mass BUD13 UTR-3 20442857 rs28927680 chr11 116619073 C G 2.39E-83 Triglycerides BUD13 UTR-3 23063622 rs28927680 chr11 116619073 C G 3.44E-21 HDL cholesterol BUD13 UTR-3 23063622 rs28927680 chr11 116619073 C G 5.91E-08 Cholesterol,total BUD13 UTR-3 23063622 rs28927680 chr11 116619073 C G 3.00E-07 Lipid traits BUD13 UTR-3 24023261 rs11216129 chr11 116620256 C A 8.71E-04 Response to cytidine analogues (gemcitabine) BUD13 intron 24483146 rs17440396 chr11 116621770 G A 3.20E-06 Urinary metabolites BUD13 intron 21572414 rs12292921 chr11 116621963 T G 9.06E-13 Triglycerides BUD13 intron 19060911 rs12292921 chr11 116621963 T G 2.78E-06 Carotenoid and tocopherol levels BUD13 intron 19185284 rs12292921 chr11 116621963 T G 2.10E-10 Lipid levels BUD13 intron 19802338 rs12292921 chr11 116621963 T G 1.80E-08 Response to statin therapy BUD13 intron 20339536 rs12292921 chr11 116621963 T G 1.93E-09 Lipoprotein-associated phospholipase A2 activity and mass BUD13 intron 22003152 rs12292921 chr11 116621963 T G 2.00E-07 Response to Vitamin E supplementation BUD13 intron 22437554 rs180327 chr11 116623659 C T 3.09E-12 Lipid levels BUD13 intron 19913121 rs180327 chr11 116623659 C T 3.81E-06 Lipid levels BUD13 intron 19913121 rs180327 chr11 116623659 C T 7.70E-07 Lipid levels BUD13 intron 19913121 rs180327 chr11 116623659 C T 6.54E-11 Metabolite levels BUD13 intron 22286219 rs180327 chr11 116623659 C T 3.44E-23 Triglycerides BUD13 intron 22629316 rs180327 chr11 116623659 C T 1.77E-45 Triglycerides BUD13 intron 23063622 rs180327 chr11 116623659 C T 2.13E-09 Cholesterol,total BUD13 intron 23063622 rs180327 chr11 116623659 C T 3.26E-11 HDL cholesterol BUD13 intron 23063622 rs6589564 chr11 116624153 C G 6.60E-07 Response to statin therapy BUD13 intron 20339536 rs6589564 chr11 116624153 C G 4.17E-12 Iron status biomarkers BUD13 intron 21149283 rs6589564 chr11 116624153 C G 1.64E-18 Metabolite levels BUD13 intron 22286219 rs7930786 chr11 116624727 C G 6.90E-07 Response to statin therapy BUD13 intron 20339536 rs7930786 chr11 116624727 C G 6.71E-13 Iron status biomarkers BUD13 intron 21149283 rs7930786 chr11 116624727 C G 5.20E-18 Metabolite levels BUD13 intron 22286219 rs11825181 chr11 116626258 G A 5.80E-09 Response to statin therapy BUD13 intron 20339536 rs11825181 chr11 116626258 G A 3.00E-09 Triglycerides-Blood Pressure (TG-BP) BUD13 intron 21386085 rs11825181 chr11 116626258 G A 3.29E-09 Lipoprotein-associated phospholipase A2 activity and mass BUD13 intron 22003152 rs11825181 chr11 116626258 G A 3.00E-11 Blood metabolite levels BUD13 intron 24816252 rs2075295 chr11 116628401 T C 2.49E-08 Triglycerides BUD13 intron 23063622 rs4938310 chr11 116629949 C T 1.88E-19 Triglycerides BUD13 intron 23063622 rs918143 chr11 116630600 C T 7.79E-05 Triglycerides BUD13 intron pha002904 rs3741300 chr11 116631690 G A 1.28E-16 Triglycerides BUD13 intron 23063622 rs3741300 chr11 116631690 G A 0.0000979 Interleukin-6 (IL-6) levels BUD13 intron 23505291 rs3825041 chr11 116631707 T C 5.30E-08 Response to statin therapy BUD13 intron 20339536 rs3825041 chr11 116631707 T C 9.18E-13 Iron status biomarkers BUD13 intron 21149283 rs3825041 chr11 116631707 T C 3.96E-18 Metabolite levels BUD13 intron 22286219 rs10488699 chr11 116632500 C T 6.00E-08 Response to statin therapy BUD13 intron 20339536 rs10488699 chr11 116632500 C T 3.80E-09 Lipoprotein-associated phospholipase A2 activity and mass BUD13 intron 22003152 rs11820589 chr11 116633862 G A 1.50E-10 Lipid levels BUD13 missense 19802338 rs11820589 chr11 116633862 G A 1.47E-04 Lipid levels BUD13 missense 19913121 rs11820589 chr11 116633862 G A 1.54E-06 Lipid levels BUD13 missense 19913121 rs11820589 chr11 116633862 G A 2.58E-09 Lipid levels BUD13 missense 19913121 rs11820589 chr11 116633862 G A 4.30E-08 Response to statin therapy BUD13 missense 20339536 rs11820589 chr11 116633862 G A 1.37E-07 Lipoprotein-associated phospholipase A2 activity and mass BUD13 missense 20442857 rs11820589 chr11 116633862 G A 6.00E-09 Metabolic syndrome (bivariate traits) BUD13 missense 21386085 rs11820589 chr11 116633862 G A 4.09E-09 Lipoprotein-associated phospholipase A2 activity and mass BUD13 missense 22003152 rs11820589 chr11 116633862 G A 1.50E-43 Triglycerides in males BUD13 missense 23063622 rs11820589 chr11 116633862 G A 2.04E-33 Triglycerides in females BUD13 missense 23063622 rs11820589 chr11 116633862 G A 2.74E-08 Cholesterol,total BUD13 missense 23063622 rs11820589 chr11 116633862 G A 4.83E-84 Triglycerides BUD13 missense 23063622 rs11820589 chr11 116633862 G A 9.55E-22 HDL cholesterol BUD13 missense 23063622 rs10488698 chr11 116633947 G A 2.90E-05 Response to statin therapy BUD13 missense 20339536 rs2187126 chr11 116635784 A G 6.20E-05 Response to statin therapy BUD13 intron 20339536 rs12294259 chr11 116637146 C T 6.30E-08 Response to statin therapy BUD13 intron 20339536 rs12294259 chr11 116637146 C T 7.84E-09 Lipoprotein-associated phospholipase A2 activity and mass BUD13 intron 22003152 rs10790162 chr11 116639104 A G 1.50E-07 Response to statin therapy BUD13 intron 20339536 rs10790162 chr11 116639104 A G 1.89E-13 Iron status biomarkers BUD13 intron 21149283 rs10790162 chr11 116639104 A G 3.00E-15 HDL Cholesterol - Triglycerides (HDLC-TG) BUD13 intron 21386085 rs10790162 chr11 116639104 A G 5.00E-09 Metabolic syndrome BUD13 intron 21386085 rs10790162 chr11 116639104 A G 7.00E-16 Waist Circumference - Triglycerides (WC-TG) BUD13 intron 21386085 rs10790162 chr11 116639104 A G 6.50E-07 FVII levels BUD13 intron 21676895 rs10790162 chr11 116639104 A G 9.65E-19 Metabolite levels BUD13 intron 22286219 rs6589565 chr11 116640237 A G 2.01E-10 Lipid levels BUD13 intron 19913121 rs6589565 chr11 116640237 A G 3.33E-06 Lipid levels BUD13 intron 19913121 rs6589565 chr11 116640237 A G 4.40E-07 Lipid levels BUD13 intron 19913121 rs6589565 chr11 116640237 A G 4.49E-20 Lipid levels BUD13 intron 19913121 rs6589565 chr11 116640237 A G 4.20E-07 Response to statin therapy BUD13 intron 20339536 rs6589565 chr11 116640237 A G 1.37E-11 Iron status biomarkers BUD13 intron 21149283 rs6589565 chr11 116640237 A G 1.30E-18 Metabolite levels BUD13 intron 22286219 rs6589565 chr11 116640237 A G 2.63E-22 HDL cholesterol BUD13 intron 23063622 rs6589565 chr11 116640237 A G 3.03E-19 Cholesterol,total BUD13 intron 23063622 rs6589565 chr11 116640237 A G 5.11E-97 Triglycerides BUD13 intron 23063622 rs6589565 chr11 116640237 A G 0.000000151 Triglycerides BUD13 intron 23236364 rs623908 chr11 116640368 A G 1.53E-04 Smoking initiation BUD13 intron 24665060 rs664059 chr11 116642137 C T 7.40E-05 Response to statin therapy BUD13 intron 20339536 rs2160669 chr11 116647607 C T 3.00E-07 Response to statin therapy / / 20339536 rs2160669 chr11 116647607 C T 1.13E-13 Iron status biomarkers / / 21149283 rs2160669 chr11 116647607 C T 9.42E-19 Metabolite levels / / 22286219 rs2160669 chr11 116647607 C T 9.00E-06 Obesity-related traits / / 23251661 rs2160669 chr11 116647607 C T 3.00E-128 Triglycerides / / 24097068 rs964184 chr11 116648917 G C 1.50E-16 Lipid levels / / 18193043 rs964184 chr11 116648917 G C 1.00E-12 HDL cholesterol / / 19060906 rs964184 chr11 116648917 G C 4.00E-62 Triglycerides / / 19060906 rs964184 chr11 116648917 G C 1.67E-49 Blood cell counts and other traits / / 20139978 rs964184 chr11 116648917 G C 2.41E-07 Blood cell counts and other traits / / 20139978 rs964184 chr11 116648917 G C 1.90E-14 Response to statin therapy / / 20339536 rs964184 chr11 116648917 G C 5.00E-24 Hypertriglyceridemia / / 20657596 rs964184 chr11 116648917 G C 1.00E-26 LDL cholesterol / / 20686565 rs964184 chr11 116648917 G C 5.00E-47 HDL cholesterol / / 20686565 rs964184 chr11 116648917 G C 6.00E-57 Cholesterol,total / / 20686565 rs964184 chr11 116648917 G C 7.00E-240 Triglycerides / / 20686565 rs964184 chr11 116648917 G C 2.00E-11 HDL cholesterol / / 20864672 rs964184 chr11 116648917 G C 2.94E-11 Iron status biomarkers / / 21149283 rs964184 chr11 116648917 G C 1.00E-12 Coronary heart disease / / 21347282 rs964184 chr11 116648917 G C 1.00E-17 Coronary heart disease / / 21378990 rs964184 chr11 116648917 G C 1.06E-05 HDL cholesterol / / 21589926 rs964184 chr11 116648917 G C 8.37E-07 HDL cholesterol / / 21589926 rs964184 chr11 116648917 G C 8.00E-12 Vitamin E levels / / 21729881 rs964184 chr11 116648917 G C 1.92E-17 Cardiovascular disease risk factors / / 21943158 rs964184 chr11 116648917 G C 8.00E-11 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs964184 chr11 116648917 G C 1.20E-10 Metabolic syndrome phenotype / / 22022282 rs964184 chr11 116648917 G C 1.80E-12 Metabolic syndrome phenotype / / 22022282 rs964184 chr11 116648917 G C 5.50E-22 Metabolic syndrome phenotype / / 22022282 rs964184 chr11 116648917 G C 6.10E-15 Triglycerides / / 22171074 rs964184 chr11 116648917 G C 2.00E-10 Phospholipid levels (plasma) / / 22359512 rs964184 chr11 116648917 G C 3.00E-31 Metabolic syndrome / / 22399527 rs964184 chr11 116648917 G C 3.00E-12 Response to Vitamin E supplementation / / 22437554 rs964184 chr11 116648917 G C 4.00E-07 Response to Vitamin E supplementation / / 22437554 rs964184 chr11 116648917 G C 1.02E-17 Pericardial fat / / 22589742 rs964184 chr11 116648917 G C 8.00E-20 Metabolite levels (atherosclerosis) / / 22916037 rs964184 chr11 116648917 G C 3.48E-09 Triglycerides / / 23063622 rs964184 chr11 116648917 G C 5.00E-35 Hypertriglyceridemia / / 23505323 rs964184 chr11 116648917 G C 6.66E-09 Vitamin E alpha tocopherol / / 23696881 rs964184 chr11 116648917 G C 9.03E-09 Triglycerides / / 23696881 rs964184 chr11 116648917 G C 3.00E-12 HDL cholesterol / / 23726366 rs964184 chr11 116648917 G C 4.00E-33 Triglycerides / / 23726366 rs964184 chr11 116648917 G C 2.00E-26 LDL cholesterol / / 24097068 rs964184 chr11 116648917 G C 3.00E-55 Cholesterol,total / / 24097068 rs964184 chr11 116648917 G C 6.00E-48 HDL cholesterol / / 24097068 rs964184 chr11 116648917 G C 7.00E-224 Triglycerides / / 24097068 rs964184 chr11 116648917 G C 2.00E-05 Coronary artery disease or ischemic stroke / / 24262325 rs964184 chr11 116648917 G C 9.00E-10 Coronary artery disease or large artery stroke / / 24262325 rs964184 chr11 116648917 G C 7.18E-16 Lipid traits / / 24386095 rs964184 chr11 116648917 G C 8.00E-15 Blood metabolite levels / / 24816252 rs964184 chr11 116648917 G C 6.08E-33 Triglycerides / / 24886709 rs11823543 chr11 116649135 G A 8.30E-08 Response to statin therapy / / 20339536 rs11823543 chr11 116649135 G A 3.00E-09 Triglycerides-Blood Pressure (TG-BP) / / 21386085 rs11823543 chr11 116649135 G A 1.08E-08 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs11823543 chr11 116649135 G A 1.05E-10 Metabolite levels / / 22286219 rs17120029 chr11 116650118 C T 1.90E-12 Lipid levels ZNF259 intron 18193043 rs17120029 chr11 116650118 C T 8.40E-08 Response to statin therapy ZNF259 intron 20339536 rs17120029 chr11 116650118 C T 7.14E-09 Lipoprotein-associated phospholipase A2 activity and mass ZNF259 intron 22003152 rs17120029 chr11 116650118 C T 1.12E-10 Metabolite levels ZNF259 intron 22286219 rs11604424 chr11 116651115 C T 6.18E-15 Metabolite levels ZNF259 intron 22286219 rs1942478 chr11 116651463 T G 7.24E-04 Response to cytidine analogues (gemcitabine) ZNF259 intron 24483146 rs12286037 chr11 116652207 C T 2.03E-04 Type 2 diabetes ZNF259 intron 17463246 rs12286037 chr11 116652207 C T 1.00E-26 Triglycerides ZNF259 intron 18193043 rs12286037 chr11 116652207 C T 1.01E-12 Lipid levels ZNF259 intron 19913121 rs12286037 chr11 116652207 C T 2.29E-05 Lipid levels ZNF259 intron 19913121 rs12286037 chr11 116652207 C T 8.51E-04 Lipid levels ZNF259 intron 19913121 rs12286037 chr11 116652207 C T 1.60E-04 Primary sclerosing cholangitis ZNF259 intron 19944697 rs12286037 chr11 116652207 C T 7.80E-08 Response to statin therapy ZNF259 intron 20339536 rs12286037 chr11 116652207 C T 4.00E-08 Lipoprotein-associated phospholipase A2 activity and mass ZNF259 intron 20442857 rs12286037 chr11 116652207 C T 1.00E-08 Metabolic syndrome (bivariate traits) ZNF259 intron 21386085 rs12286037 chr11 116652207 C T 6.95E-09 Lipoprotein-associated phospholipase A2 activity and mass ZNF259 intron 22003152 rs12286037 chr11 116652207 C T 1.12E-10 Metabolite levels ZNF259 intron 22286219 rs12286037 chr11 116652207 C T 1.20E-19 HDL cholesterol ZNF259 intron 23063622 rs12286037 chr11 116652207 C T 2.97E-83 Triglycerides ZNF259 intron 23063622 rs12286037 chr11 116652207 C T 3.84E-10 Cholesterol,total ZNF259 intron 23063622 rs12286037 chr11 116652207 C T 1.14E-06 Lipid traits ZNF259 intron 24023261 rs4417316 chr11 116652301 C T 0.000000306 Triglycerides ZNF259 intron 23063622 rs4417316 chr11 116652301 C T 0.00000193 Cholesterol,total ZNF259 intron 23063622 rs4417316 chr11 116652301 C T 5.84E-04 Response to cytidine analogues (gemcitabine) ZNF259 intron 24483146 rs6589566 chr11 116652423 G A 1.72E-04 Type 2 diabetes ZNF259 intron 17463246 rs6589566 chr11 116652423 G A 3.00E-11 LDL cholesterol ZNF259 intron 18179892 rs6589566 chr11 116652423 G A 2.10E-07 Response to statin therapy ZNF259 intron 20339536 rs6589566 chr11 116652423 G A 1.72E-13 Iron status biomarkers ZNF259 intron 21149283 rs6589566 chr11 116652423 G A 3.00E-11 Coronary heart disease ZNF259 intron 21347282 rs6589566 chr11 116652423 G A 2.82E-07 FVII levels ZNF259 intron 21676895 rs6589566 chr11 116652423 G A 3.35E-09 Cardiovascular disease risk factors ZNF259 intron 21943158 rs6589566 chr11 116652423 G A 9.28E-05 Calcium intake levels and metabolic syndrome ZNF259 intron 22170361 rs6589566 chr11 116652423 G A 2.55E-19 Metabolite levels ZNF259 intron 22286219 rs6589566 chr11 116652423 G A 1.38E-10 Triglycerides ZNF259 intron 23063622 rs6589566 chr11 116652423 G A 3.92E-08 Cholesterol,total ZNF259 intron 23063622 rs6589566 chr11 116652423 G A 5.00E-14 Triglycerides ZNF259 intron 23726366 rs2075290 chr11 116653296 C T 4.24E-07 Lipid levels ZNF259 intron 19913121 rs2075290 chr11 116653296 C T 4.73E-10 Lipid levels ZNF259 intron 19913121 rs2075290 chr11 116653296 C T 6.05E-06 Lipid levels ZNF259 intron 19913121 rs2075290 chr11 116653296 C T 6.55E-20 Lipid levels ZNF259 intron 19913121 rs2075290 chr11 116653296 C T 2.10E-07 Response to statin therapy ZNF259 intron 20339536 rs2075290 chr11 116653296 C T 1.71E-13 Iron status biomarkers ZNF259 intron 21149283 rs2075290 chr11 116653296 C T 1.00E-16 Waist Circumference - Triglycerides (WC-TG) ZNF259 intron 21386085 rs2075290 chr11 116653296 C T 2.00E-09 Metabolic syndrome ZNF259 intron 21386085 rs2075290 chr11 116653296 C T 2.00E-14 HDL Cholesterol - Triglycerides (HDLC-TG) ZNF259 intron 21386085 rs2075290 chr11 116653296 C T 3.35E-09 Cardiovascular disease risk factors ZNF259 intron 21943158 rs2075290 chr11 116653296 C T 1.02E-18 Metabolite levels ZNF259 intron 22286219 rs2075290 chr11 116653296 C T 1.75E-33 Triglycerides (males) ZNF259 intron 22629316 rs2075290 chr11 116653296 C T 6.07E-25 Triglycerides (females) ZNF259 intron 22629316 rs2075290 chr11 116653296 C T 8.13E-51 Triglycerides ZNF259 intron 22629316 rs2075290 chr11 116653296 C T 1.80E-92 Triglycerides ZNF259 intron 23063622 rs2075290 chr11 116653296 C T 2.43E-18 Cholesterol,total ZNF259 intron 23063622 rs2075290 chr11 116653296 C T 7.32E-20 HDL cholesterol ZNF259 intron 23063622 rs7926960 chr11 116654086 A C 0.00000011 Triglycerides ZNF259 intron 23236364 rs618923 chr11 116654159 A G 2.40E-12 Lipid levels ZNF259 intron 19936222 rs618923 chr11 116654159 A G 3.70E-09 Lipid levels ZNF259 intron 19936222 rs618923 chr11 116654159 A G 1.59E-17 Triglycerides ZNF259 intron 23063622 rs603446 chr11 116654435 C T 8.78E-06 Lipid levels ZNF259 intron 19913121 rs603446 chr11 116654435 C T 2.00E-86 Triglycerides ZNF259 intron 21909109 rs603446 chr11 116654435 C T 0.00000105 Cholesterol,total ZNF259 intron 23063622 rs603446 chr11 116654435 C T 4.11E-19 Triglycerides ZNF259 intron 23063622 rs35120633 chr11 116655600 G A 2.29E-10 Triglycerides ZNF259 missense 19060911 rs35120633 chr11 116655600 G A 1.07E-13 Triglycerides ZNF259 missense 23063622 rs10750096 chr11 116656788 C A 1.04E-18 Metabolite levels ZNF259 intron 22286219 rs3741298 chr11 116657561 C T 5.67E-19 Metabolite levels ZNF259 intron 22286219 rs3741298 chr11 116657561 C T 0.00000143 Cholesterol,total ZNF259 intron 23063622 rs3741298 chr11 116657561 C T 7.92E-15 Triglycerides ZNF259 intron 23063622 rs3741298 chr11 116657561 C T 3.00E-08 Obesity-related traits ZNF259 intron 23251661 rs3741297 chr11 116657667 C T 3.20E-12 Lipid traits ZNF259 intron 24023260 rs12285095 chr11 116658031 T G 1.92E-05 Lipid levels ZNF259 intron 19913121 rs12285095 chr11 116658031 T G 7.29E-09 Lipid levels ZNF259 intron 19913121 rs12285095 chr11 116658031 T G 8.40E-08 Response to statin therapy ZNF259 intron 20339536 rs12285095 chr11 116658031 T G 1.95E-87 Triglycerides ZNF259 intron 23063622 rs12285095 chr11 116658031 T G 8.56E-21 HDL cholesterol ZNF259 intron 23063622 rs12285095 chr11 116658031 T G 9.80E-11 Cholesterol,total ZNF259 intron 23063622 rs2266788 chr11 116660686 G A 1.16E-19 Lipid levels APOA5 UTR-3 19913121 rs2266788 chr11 116660686 G A 3.42E-10 Lipid levels APOA5 UTR-3 19913121 rs2266788 chr11 116660686 G A 4.82E-07 Lipid levels APOA5 UTR-3 19913121 rs2266788 chr11 116660686 G A 5.43E-06 Lipid levels APOA5 UTR-3 19913121 rs2266788 chr11 116660686 G A 2.10E-07 Response to statin therapy APOA5 UTR-3 20339536 rs2266788 chr11 116660686 G A 5.93E-14 Iron status biomarkers APOA5 UTR-3 21149283 rs2266788 chr11 116660686 G A 2.00E-09 Metabolic syndrome APOA5 UTR-3 21386085 rs2266788 chr11 116660686 G A 2.00E-16 Waist Circumference - Triglycerides (WC-TG) APOA5 UTR-3 21386085 rs2266788 chr11 116660686 G A 4.00E-08 Triglycerides-Blood Pressure (TG-BP) APOA5 UTR-3 21386085 rs2266788 chr11 116660686 G A 5.00E-13 HDL Cholesterol - Triglycerides (HDLC-TG) APOA5 UTR-3 21386085 rs2266788 chr11 116660686 G A 4.00E-09 FVII levels APOA5 UTR-3 21676895 rs2266788 chr11 116660686 G A 3.34E-09 Cardiovascular disease risk factors APOA5 UTR-3 21943158 rs2266788 chr11 116660686 G A 3.55E-19 Metabolite levels APOA5 UTR-3 22286219 rs2266788 chr11 116660686 G A 2.10E-95 Triglycerides APOA5 UTR-3 23063622 rs2266788 chr11 116660686 G A 2.12E-18 Cholesterol,total APOA5 UTR-3 23063622 rs2266788 chr11 116660686 G A 4.18E-21 HDL cholesterol APOA5 UTR-3 23063622 rs2266788 chr11 116660686 G A 8.92E-06 Obesity-related traits APOA5 UTR-3 23251661 rs619054 chr11 116660813 G A 6.25E-16 Triglycerides APOA5 UTR-3 23063622 rs2075291 chr11 116661392 C A 0.00000241 HDL cholesterol APOA5 missense 23236364 rs3135507 chr11 116661488 C T 0.000000116 Triglycerides APOA5 missense 23063622 rs3135507 chr11 116661488 C T 0.000000245 Triglycerides APOA5 missense 23063622 rs2072560 chr11 116661826 T C 1.40E-12 Lipid levels APOA5 intron 19913121 rs2072560 chr11 116661826 T C 1.92E-20 Lipid levels APOA5 intron 19913121 rs2072560 chr11 116661826 T C 2.36E-07 Lipid levels APOA5 intron 19913121 rs2072560 chr11 116661826 T C 7.39E-08 Lipid levels APOA5 intron 19913121 rs2072560 chr11 116661826 T C 1.87E-20 Metabolite levels APOA5 intron 22286219 rs2072560 chr11 116661826 T C 1.03E-19 Cholesterol,total APOA5 intron 23063622 rs2072560 chr11 116661826 T C 2.85E-93 Triglycerides APOA5 intron 23063622 rs2072560 chr11 116661826 T C 8.09E-20 HDL cholesterol APOA5 intron 23063622 rs12287066 chr11 116662331 G T 3.13E-09 Lipid levels APOA5 cds-synon 19913121 rs12287066 chr11 116662331 G T 4.72E-05 Lipid levels APOA5 cds-synon 19913121 rs12287066 chr11 116662331 G T 8.84E-04 Lipid levels APOA5 cds-synon 19913121 rs12287066 chr11 116662331 G T 3.54E-34 Triglycerides APOA5 cds-synon 22629316 rs12287066 chr11 116662331 G T 1.18E-11 Cholesterol,total APOA5 cds-synon 23063622 rs12287066 chr11 116662331 G T 3.39E-21 HDL cholesterol APOA5 cds-synon 23063622 rs12287066 chr11 116662331 G T 3.71E-89 Triglycerides APOA5 cds-synon 23063622 rs34282181 chr11 116662352 G T 0.00000103 HDL cholesterol APOA5 missense 23063622 rs3135506 chr11 116662407 G C 7.44E-10 Triglycerides APOA5 missense 19060911 rs3135506 chr11 116662407 G C 5.50E-12 Lipid levels APOA5 missense 19802338 rs3135506 chr11 116662407 G C 8.40E-08 Lipid levels APOA5 missense 19802338 rs3135506 chr11 116662407 G C 1.10E-12 Lipid levels APOA5 missense 19936222 rs3135506 chr11 116662407 G C 1.10E-20 Lipid levels APOA5 missense 19936222 rs3135506 chr11 116662407 G C 1.15E-18 Lipid levels APOA5 missense 19936222 rs3135506 chr11 116662407 G C 1.20E-33 Lipid levels APOA5 missense 19936222 rs3135506 chr11 116662407 G C 1.38E-15 Lipid levels APOA5 missense 19936222 rs3135506 chr11 116662407 G C 1.80E-13 Lipid levels APOA5 missense 19936222 rs3135506 chr11 116662407 G C 2.28E-22 Lipid levels APOA5 missense 19936222 rs3135506 chr11 116662407 G C 2.86E-31 Lipid levels APOA5 missense 19936222 rs3135506 chr11 116662407 G C 3.55E-19 Lipid levels APOA5 missense 19936222 rs3135506 chr11 116662407 G C 4.00E-36 Lipid levels APOA5 missense 19936222 rs3135506 chr11 116662407 G C 5.06E-46 Lipid levels APOA5 missense 19936222 rs3135506 chr11 116662407 G C 5.60E-16 Lipid levels APOA5 missense 19936222 rs3135506 chr11 116662407 G C 5.66E-23 Lipid levels APOA5 missense 19936222 rs3135506 chr11 116662407 G C 7.00E-43 Lipid levels APOA5 missense 19936222 rs3135506 chr11 116662407 G C 7.16E-12 Lipid levels APOA5 missense 19936222 rs3135506 chr11 116662407 G C 7.36E-16 Lipid levels APOA5 missense 19936222 rs3135506 chr11 116662407 G C 7.77E-42 Lipid levels APOA5 missense 19936222 rs3135506 chr11 116662407 G C 8.26E-12 Lipid levels APOA5 missense 19936222 rs3135506 chr11 116662407 G C 9.20E-29 Lipid levels APOA5 missense 19936222 rs3135506 chr11 116662407 G C 7.47E-14 Triglycerides APOA5 missense 23063622 rs651821 chr11 116662579 C T 1.03E-07 Lipid levels / / 19913121 rs651821 chr11 116662579 C T 3.55E-12 Lipid levels / / 19913121 rs651821 chr11 116662579 C T 6.90E-07 Lipid levels / / 19913121 rs651821 chr11 116662579 C T 8.89E-21 Lipid levels / / 19913121 rs651821 chr11 116662579 C T 2.20E-07 Response to statin therapy / / 20339536 rs651821 chr11 116662579 C T 4.10E-05 Major depressive disorder / / 21042317 rs651821 chr11 116662579 C T 1.17E-11 Iron status biomarkers / / 21149283 rs651821 chr11 116662579 C T 9.00E-26 Triglycerides / / 22171074 rs651821 chr11 116662579 C T 8.00E-20 Lipid metabolism phenotypes / / 22286219 rs651821 chr11 116662579 C T 1.54E-91 Triglycerides / / 23063622 rs651821 chr11 116662579 C T 5.52E-19 Cholesterol,total / / 23063622 rs651821 chr11 116662579 C T 9.85E-19 HDL cholesterol / / 23063622 rs651821 chr11 116662579 C T 5.30E-07 Obesity-related traits / / 23251661 rs651821 chr11 116662579 C T 2.00E-59 Lipid traits / / 24386095 rs34003087 chr11 116663596 C T 1.65E-11 HDL cholesterol APOA5 nearGene-5 23063622 rs34003087 chr11 116663596 C T 2.11E-08 Triglycerides APOA5 nearGene-5 23063622 rs662799 chr11 116663707 G A 2.40E-15 Lipid levels APOA5 nearGene-5 18193043 rs662799 chr11 116663707 G A 2.90E-15 Lipid levels APOA5 nearGene-5 19802338 rs662799 chr11 116663707 G A 3.50E-07 Lipid levels APOA5 nearGene-5 19802338 rs662799 chr11 116663707 G A 1.07E-08 Lipid levels APOA5 nearGene-5 19913121 rs662799 chr11 116663707 G A 2.91E-20 Lipid levels APOA5 nearGene-5 19913121 rs662799 chr11 116663707 G A 5.18E-12 Lipid levels APOA5 nearGene-5 19913121 rs662799 chr11 116663707 G A 7.19E-07 Lipid levels APOA5 nearGene-5 19913121 rs662799 chr11 116663707 G A 3.50E-27 Lipid levels APOA5 nearGene-5 19936222 rs662799 chr11 116663707 G A 8.40E-07 Response to statin therapy APOA5 nearGene-5 20339536 rs662799 chr11 116663707 G A 2.90E-14 Iron status biomarkers APOA5 nearGene-5 21149283 rs662799 chr11 116663707 G A 6.22E-20 Metabolite levels APOA5 nearGene-5 22286219 rs662799 chr11 116663707 G A 1.37E-19 HDL cholesterol APOA5 nearGene-5 23063622 rs662799 chr11 116663707 G A 4.75E-94 Triglycerides APOA5 nearGene-5 23063622 rs662799 chr11 116663707 G A 8.38E-19 Cholesterol,total APOA5 nearGene-5 23063622 rs662799 chr11 116663707 G A 0.000000891 HDL cholesterol APOA5 nearGene-5 23236364 rs662799 chr11 116663707 G A 1.57E-13 Triglycerides APOA5 nearGene-5 23236364 rs662799 chr11 116663707 G A 5.43E-07 Obesity-related traits APOA5 nearGene-5 23251661 rs662799 chr11 116663707 G A 6.00E-24 Lipid traits APOA5 nearGene-5 24023260 rs7103224 chr11 116663966 G A 1.24E-04 Lipid levels APOA5 nearGene-5 19913121 rs7103224 chr11 116663966 G A 2.73E-04 Lipid levels APOA5 nearGene-5 19913121 rs7103224 chr11 116663966 G A 7.82E-06 Lipid levels APOA5 nearGene-5 19913121 rs7103224 chr11 116663966 G A 0.000000115 Triglycerides APOA5 nearGene-5 23063622 rs7103224 chr11 116663966 G A 3.52E-08 Cholesterol,total APOA5 nearGene-5 23063622 rs10750097 chr11 116664040 G A 1.26E-10 Lipid levels APOA5 nearGene-5 19913121 rs10750097 chr11 116664040 G A 1.33E-07 Lipid levels APOA5 nearGene-5 19913121 rs10750097 chr11 116664040 G A 2.54E-17 Metabolite levels APOA5 nearGene-5 22286219 rs10750097 chr11 116664040 G A 2.76E-18 HDL cholesterol APOA5 nearGene-5 22629316 rs10750097 chr11 116664040 G A 3.17E-09 HDL cholesterol (female) APOA5 nearGene-5 22629316 rs10750097 chr11 116664040 G A 5.13E-12 HDL cholesterol (male) APOA5 nearGene-5 22629316 rs10750097 chr11 116664040 G A 2.12E-95 Triglycerides APOA5 nearGene-5 23063622 rs10750097 chr11 116664040 G A 3.19E-08 Cholesterol,total APOA5 nearGene-5 23063622 rs10750097 chr11 116664040 G A 9.15E-30 HDL cholesterol APOA5 nearGene-5 23063622 rs10750097 chr11 116664040 G A 3.75E-13 Triglycerides APOA5 nearGene-5 23236364 rs10750097 chr11 116664040 G A 0.0000155 C-reactive protein APOA5 nearGene-5 23505291 rs10750097 chr11 116664040 G A 0.000247 Interleukin-6 (IL-6) levels APOA5 nearGene-5 23505291 rs9804646 chr11 116665079 C T 1.25E-06 Lipid levels APOA5 nearGene-5 19913121 rs9804646 chr11 116665079 C T 2.95E-04 Lipid levels APOA5 nearGene-5 19913121 rs9804646 chr11 116665079 C T 3.45E-05 Lipid levels APOA5 nearGene-5 19913121 rs9804646 chr11 116665079 C T 0.000000481 Triglycerides APOA5 nearGene-5 22629316 rs9804646 chr11 116665079 C T 0.000221 Triglycerides (males) APOA5 nearGene-5 22629316 rs9804646 chr11 116665079 C T 0.000231 Triglycerides (females) APOA5 nearGene-5 22629316 rs9804646 chr11 116665079 C T 3.02E-08 Triglycerides APOA5 nearGene-5 23063622 rs9804646 chr11 116665079 C T 8.88E-09 Cholesterol,total APOA5 nearGene-5 23063622 rs9804646 chr11 116665079 C T 0.00000255 Triglycerides APOA5 nearGene-5 23236364 rs601634 chr11 116668511 C T 1.50E-15 Triglycerides / / 23063622 rs11600380 chr11 116670182 T C 1.14E-04 Lipid levels / / 19913121 rs11600380 chr11 116670182 T C 1.34E-04 Lipid levels / / 19913121 rs11600380 chr11 116670182 T C 5.19E-06 Lipid levels / / 19913121 rs11600380 chr11 116670182 T C 1.99E-10 Cholesterol,total / / 23063622 rs11600380 chr11 116670182 T C 2.53E-09 Triglycerides / / 23063622 rs11600380 chr11 116670182 T C 3.80E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6589567 chr11 116670676 A C 7.76E-07 Cardiovascular disease / / 18179892 rs6589567 chr11 116670676 A C 1.55E-08 Iron status biomarkers / / 21149283 rs6589567 chr11 116670676 A C 6.82E-05 Triglycerides / / pha003081 rs6589567 chr11 116670676 A C 9.16E-05 Lipid levels / / pha003082 rs6589568 chr11 116670738 G A 0.0000291 HDL cholesterol / / 23063622 rs6589568 chr11 116670738 G A 2.86E-19 Triglycerides / / 23063622 rs4938313 chr11 116671005 A G 4.87E-11 Metabolite levels / / 22286219 rs6589569 chr11 116671476 T C 3.33E-12 Metabolite levels / / 22286219 rs9667814 chr11 116671823 C G 1.70E-11 Metabolite levels / / 22286219 rs9666150 chr11 116671824 T C 1.78E-11 Metabolite levels / / 22286219 rs11216140 chr11 116672013 T C 3.29E-12 Metabolite levels / / 22286219 rs1263173 chr11 116681008 G A 6.80E-15 Iron status biomarkers / / 21149283 rs1263173 chr11 116681008 G A 2.00E-07 Coronary heart disease / / 21347282 rs1263173 chr11 116681008 G A 0.000000164 Triglycerides / / 23063622 rs7396835 chr11 116684028 T C 4.06E-04 Birth weight / / 17255346 rs7396835 chr11 116684028 T C 1.00E-09 Quantitative traits / / 19197348 rs7396835 chr11 116684028 T C 1.38E-08 Lipid levels / / 19913121 rs7396835 chr11 116684028 T C 8.94E-05 Lipid levels / / 19913121 rs7396835 chr11 116684028 T C 2.55E-12 Cholesterol,total / / 23063622 rs7396835 chr11 116684028 T C 3.01E-26 Triglycerides / / 23063622 rs7396851 chr11 116684164 T C 4.06E-04 Birth weight / / 17255346 rs7396851 chr11 116684164 T C 4.66E-09 Lipid levels / / 19913121 rs7396851 chr11 116684164 T C 9.77E-05 Lipid levels / / 19913121 rs7396851 chr11 116684164 T C 2.55E-26 Triglycerides / / 23063622 rs7396851 chr11 116684164 T C 2.68E-12 Cholesterol,total / / 23063622 rs5110 chr11 116691634 C A 5.13E-13 Iron status biomarkers APOA4 missense 21149283 rs675 chr11 116691675 T A,C 7.64E-15 Triglycerides APOA4 missense 23063622 rs2849174 chr11 116697066 G A 0.00000159 Triglycerides / / 23063622 rs2854117 chr11 116700142 T C 1 Drug response to Ritonavir APOC3 nearGene-5 15809899 rs2854117 chr11 116700142 T C 1 Drug response to Ritonavir APOC3 nearGene-5 16417409 rs2854117 chr11 116700142 T C 1 Drug response to Ritonavir APOC3 nearGene-5 17700365 rs2854116 chr11 116700169 C T 1 Drug response to Ritonavir APOC3 nearGene-5 15809899 rs2854116 chr11 116700169 C T 1 Drug response to Ritonavir APOC3 nearGene-5 16417409 rs2854116 chr11 116700169 C T 1 Drug response to Ritonavir APOC3 nearGene-5 17700364 rs11827682 chr11 116700785 C T 0.00000172 HDL cholesterol APOC3 intron 23063622 rs5142 chr11 116701850 T C 1.26E-08 Lipid levels APOC3 intron 19913121 rs5142 chr11 116701850 T C 0.00000505 HDL cholesterol APOC3 intron 23063622 rs5142 chr11 116701850 T C 1.04E-45 Triglycerides APOC3 intron 23063622 rs5142 chr11 116701850 T C 3.52E-13 Cholesterol,total APOC3 intron 23063622 rs5142 chr11 116701850 T C 4.34E-47 Triglycerides APOC3 intron 23063622 rs5128 chr11 116703640 G C 1 Drug response to Ritonavir APOC3 UTR-3 15809899 rs5128 chr11 116703640 G C 1 Drug response to Ritonavir APOC3 UTR-3 16417409 rs5128 chr11 116703640 G C 1 Drug response to Ritonavir APOC3 UTR-3 17700366 rs5128 chr11 116703640 G C 5.14E-14 Metabolite levels APOC3 UTR-3 22286219 rs12721025 chr11 116706047 G A 2.00E-10 Infantile hypertrophic pyloric stenosis APOA1 nearGene-3 23989729 rs5072 chr11 116707583 A G 1.74E-07 Lipid levels APOA1 intron 19913121 rs5072 chr11 116707583 A G 5.19E-04 Lipid levels APOA1 intron 19913121 rs5072 chr11 116707583 A G 9.50E-14 Metabolite levels APOA1 intron 22286219 rs5072 chr11 116707583 A G 1.81E-08 Cholesterol,total APOA1 intron 23063622 rs5072 chr11 116707583 A G 6.78E-40 Triglycerides APOA1 intron 23063622 rs2070665 chr11 116707684 A G 2.30E-12 Lipid levels APOA1 intron 19802338 rs2070665 chr11 116707684 A G 7.57E-13 Metabolite levels APOA1 intron 22286219 rs2727786 chr11 116708523 C G 1 Drug response to Fenofibrate APOA1 nearGene-5 19207029 rs579163 chr11 116713630 C G 4.89E-05 Response to Vitamin E supplementation / / 22437554 rs579163 chr11 116713630 C G 7.67E-06 LDL lipoproteins / / pha002902 rs10047459 chr11 116721826 C T 6.17E-27 Iron status biomarkers SIK3 intron 21149283 rs10047459 chr11 116721826 C T 4.31E-11 Triglycerides SIK3 intron 23063622 rs10047462 chr11 116722041 G T 4.00E-25 Iron status biomarkers SIK3 intron 21149283 rs10047462 chr11 116722041 G T 5.43E-09 Cholesterol,total SIK3 intron 23063622 rs10047462 chr11 116722041 G T 7.94E-27 Triglycerides SIK3 intron 23063622 rs689243 chr11 116722693 G C 6.11E-10 Iron status biomarkers SIK3 intron 21149283 rs689243 chr11 116722693 G C 1.38E-25 Triglycerides SIK3 intron 23063622 rs689243 chr11 116722693 G C 8.37E-10 Cholesterol,total SIK3 intron 23063622 rs888245 chr11 116723737 C G 0.0000183 Triglycerides in females SIK3 intron 23063622 rs888245 chr11 116723737 C G 3.94E-10 Triglycerides in males SIK3 intron 23063622 rs888245 chr11 116723737 C G 8.40E-14 Triglycerides SIK3 intron 23063622 rs888246 chr11 116724232 C T 5.53E-17 Triglycerides SIK3 intron 23063622 rs640411 chr11 116725303 G C 4.07E-04 Type 2 diabetes SIK3 intron 17463246 rs12099358 chr11 116726048 C A 2.14E-10 Triglycerides SIK3 intron 23063622 rs1035237 chr11 116727850 G C 2.19E-24 Iron status biomarkers SIK3 intron 21149283 rs625145 chr11 116727936 A T 2.26E-08 Triglycerides SIK3 intron 23063622 rs11216162 chr11 116728277 G A 0.000000327 Triglycerides SIK3 intron 23063622 rs11216162 chr11 116728277 G A 0.000000626 HDL cholesterol SIK3 intron 23063622 rs12225230 chr11 116728630 G C 4.00E-09 Lipid levels SIK3 missense 19802338 rs12225230 chr11 116728630 G C 5.30E-05 Lipid levels SIK3 missense 19802338 rs12225230 chr11 116728630 G C 1.30E-11 Lipid levels SIK3 missense 19936222 rs12225230 chr11 116728630 G C 1.87E-17 Lipid levels SIK3 missense 19936222 rs12225230 chr11 116728630 G C 6.40E-23 Lipid levels SIK3 missense 19936222 rs12225230 chr11 116728630 G C 8.95E-15 Lipid levels SIK3 missense 19936222 rs12225230 chr11 116728630 G C 0.000000317 Triglycerides SIK3 missense 23063622 rs12225230 chr11 116728630 G C 0.00000045 HDL cholesterol SIK3 missense 23063622 rs6589574 chr11 116730638 A G 8.90E-26 Iron status biomarkers SIK3 intron 21149283 rs4938315 chr11 116731205 G A 1.86E-25 Iron status biomarkers SIK3 intron 21149283 rs4938315 chr11 116731205 G A 1.16E-25 Triglycerides SIK3 intron 23063622 rs4938315 chr11 116731205 G A 3.35E-08 Cholesterol,total SIK3 intron 23063622 rs2075292 chr11 116732512 G T 5.00E-08 Triglycerides SIK3 intron 18193046 rs2075292 chr11 116732512 G T 5.68E-12 Triglycerides SIK3 intron 19060911 rs2075292 chr11 116732512 G T 3.30E-08 Lipid levels SIK3 intron 19802338 rs2075292 chr11 116732512 G T 2.60E-23 Iron status biomarkers SIK3 intron 21149283 rs718847 chr11 116734146 C T 2.72E-23 Iron status biomarkers SIK3 intron 21149283 rs573549 chr11 116736679 A G 3.35E-09 Iron status biomarkers SIK3 intron 21149283 rs548638 chr11 116737093 T G 5.91E-14 Triglycerides SIK3 intron 23063622 rs599320 chr11 116740659 G C 4.07E-04 Type 2 diabetes SIK3 intron 17463246 rs533556 chr11 116741572 A C 6.80E-09 Iron status biomarkers SIK3 intron 21149283 rs9919599 chr11 116745484 C G 1.89E-23 Iron status biomarkers SIK3 intron 21149283 rs681524 chr11 116748314 T C 1.10E-05 Triglycerides SIK3 intron 19074352 rs6589577 chr11 116749977 C T 1.04E-23 Iron status biomarkers SIK3 intron 21149283 rs482371 chr11 116752163 T C 5.61E-09 Iron status biomarkers SIK3 intron 21149283 rs482371 chr11 116752163 T C 7.82E-05 LDL lipoproteins SIK3 intron pha002902 rs7124741 chr11 116752219 A T 8.60E-07 Triglycerides SIK3 intron 18193046 rs7124741 chr11 116752219 A T 3.50E-25 Iron status biomarkers SIK3 intron 21149283 rs17174502 chr11 116759655 G A 1.46E-25 Iron status biomarkers SIK3 intron 21149283 rs660443 chr11 116760693 T C 9.57E-09 Iron status biomarkers SIK3 intron 21149283 rs499910 chr11 116763034 G A 3.23E-15 Iron status biomarkers SIK3 intron 21149283 rs672058 chr11 116764021 C T 5.13E-16 Iron status biomarkers SIK3 intron 21149283 rs77349713 chr11 116765476 T C 1.20E-09 Infantile hypertrophic pyloric stenosis SIK3 intron 23989729 rs609177 chr11 116770517 A G 2.50E-09 Iron status biomarkers SIK3 intron 21149283 rs1076485 chr11 116772441 C T 3.82E-16 Iron status biomarkers SIK3 intron 21149283 rs518181 chr11 116772787 C A 1.48E-28 Lipid levels SIK3 intron 19936222 rs518181 chr11 116772787 C A 3.88E-21 Lipid levels SIK3 intron 19936222 rs518181 chr11 116772787 C A 6.80E-21 Lipid levels SIK3 intron 19936222 rs518181 chr11 116772787 C A 8.10E-16 Lipid levels SIK3 intron 19936222 rs518181 chr11 116772787 C A 4.02E-09 Iron status biomarkers SIK3 intron 21149283 rs518181 chr11 116772787 C A 2.49E-05 LDL lipoproteins SIK3 intron pha002902 rs17120139 chr11 116774201 G A 6.20E-08 Triglycerides SIK3 intron 18193046 rs17120139 chr11 116774201 G A 2.95E-25 Iron status biomarkers SIK3 intron 21149283 rs11216185 chr11 116782974 T G 1.00E-07 Infantile hypertrophic pyloric stenosis SIK3 intron 22306654 rs6589579 chr11 116789635 C A 6.93E-05 Type 2 diabetes SIK3 intron 17463246 rs7121898 chr11 116796846 A T 5.90E-10 Iron status biomarkers SIK3 intron 21149283 rs579890 chr11 116798963 A G 1.67E-24 Iron status biomarkers SIK3 intron 21149283 rs139961185 chr11 116807343 G A 1.15E-12 Triglycerides SIK3 intron 24886709 rs473172 chr11 116807970 A G 3.57E-22 Iron status biomarkers SIK3 intron 21149283 rs511676 chr11 116824884 T G 4.06E-24 Iron status biomarkers SIK3 intron 21149283 rs10502221 chr11 116826870 C T 7.51E-04 Type 2 diabetes SIK3 intron 17463246 rs10502221 chr11 116826870 C T 6.95E-05 Alcohol consumption SIK3 intron pha001399 rs6589582 chr11 116829200 A C 3.79E-10 Iron status biomarkers SIK3 intron 21149283 rs7120173 chr11 116829653 T G 5.00E-06 Visceral adipose tissue adjusted for BMI SIK3 intron 22589738 rs7120706 chr11 116830087 T C 1.57E-10 Iron status biomarkers SIK3 intron 21149283 rs7120963 chr11 116830261 T C 1.57E-10 Iron status biomarkers SIK3 intron 21149283 rs10502222 chr11 116833730 C T 1.60E-10 Iron status biomarkers SIK3 intron 21149283 rs10892052 chr11 116834313 G A 9.98E-05 Waist-Hip Ratio SIK3 intron pha003029 rs2513092 chr11 116844279 T C 7.09E-05 Type 2 diabetes SIK3 intron 17463246 rs588918 chr11 116856642 T C 1.01E-04 Birth weight SIK3 intron 17255346 rs588918 chr11 116856642 T C 4.92E-08 Triglycerides SIK3 intron 19060911 rs588918 chr11 116856642 T C 1.30E-08 Lipid levels SIK3 intron 19802338 rs588918 chr11 116856642 T C 1.39E-23 Iron status biomarkers SIK3 intron 21149283 rs10892053 chr11 116857003 C T 4.11E-10 Iron status biomarkers SIK3 intron 21149283 rs638392 chr11 116860456 T A 4.50E-04 Type 2 diabetes SIK3 intron 17463246 rs11216230 chr11 116884789 G A 3.00E-10 HDL cholesterol SIK3 intron 24886709 rs10892063 chr11 116896155 A C 1.24E-13 Iron status biomarkers SIK3 intron 21149283 rs10892063 chr11 116896155 A C 9.98E-05 Waist-Hip Ratio SIK3 intron pha003029 rs10892064 chr11 116896553 G C 1.47E-09 Iron status biomarkers SIK3 intron 21149283 rs7950364 chr11 116898886 C G 2.19E-23 Iron status biomarkers SIK3 intron 21149283 rs10732856 chr11 116907113 T C 2.73E-04 Birth weight SIK3 intron 17255346 rs10732856 chr11 116907113 T C 4.94E-23 Iron status biomarkers SIK3 intron 21149283 rs7115242 chr11 116908283 A G 1.64E-04 Birth weight SIK3 intron 17255346 rs7115242 chr11 116908283 A G 5.75E-24 Iron status biomarkers SIK3 intron 21149283 rs2155583 chr11 116915217 A G 2.00E-23 Iron status biomarkers SIK3 intron 21149283 rs2000614 chr11 116915742 C T 2.00E-23 Iron status biomarkers SIK3 intron 21149283 rs2000615 chr11 116915819 C T 1.99E-23 Iron status biomarkers SIK3 intron 21149283 rs2000616 chr11 116916529 C T 3.34E-23 Iron status biomarkers SIK3 intron 21149283 rs10750100 chr11 116917244 T C 3.32E-23 Iron status biomarkers SIK3 intron 21149283 rs4938332 chr11 116930798 A G 7.44E-10 Iron status biomarkers SIK3 intron 21149283 rs6589589 chr11 116932428 T C 3.06E-23 Iron status biomarkers SIK3 intron 21149283 rs11216257 chr11 116932561 C T 6.88E-26 Iron status biomarkers SIK3 intron 21149283 rs6589590 chr11 116936081 A C 1.75E-09 Iron status biomarkers SIK3 intron 21149283 rs1351452 chr11 116943354 A C 1.63E-04 Birth weight SIK3 intron 17255346 rs1351452 chr11 116943354 A C 7.41E-10 Triglycerides SIK3 intron 19060911 rs1351452 chr11 116943354 A C 5.90E-09 Lipid levels SIK3 intron 19802338 rs1351452 chr11 116943354 A C 2.86E-23 Iron status biomarkers SIK3 intron 21149283 rs10736487 chr11 116950232 A G 3.06E-24 Iron status biomarkers SIK3 intron 21149283 rs11216267 chr11 116952392 C T 5.07E-09 Iron status biomarkers SIK3 intron 21149283 rs11216267 chr11 116952392 C T 3.91E-05 LDL lipoproteins SIK3 intron pha002902 rs11216267 chr11 116952392 C T 9.98E-05 Waist-Hip Ratio SIK3 intron pha003029 rs1871756 chr11 116953645 G A 9.34E-05 HDL cholesterol SIK3 intron pha003074 rs10892072 chr11 116960313 G A 2.25E-09 Iron status biomarkers SIK3 intron 21149283 rs900012 chr11 116966435 G A 4.28E-25 Iron status biomarkers SIK3 intron 21149283 rs1320668 chr11 116967666 C T 3.73E-25 Iron status biomarkers SIK3 intron 21149283 rs4938338 chr11 116972894 C A 4.10E-06 Response to Vitamin E supplementation / / 22437554 rs12269901 chr11 116973929 G C 2.00E-06 Coronary heart disease / / 21347282 rs55703909 chr11 116984866 G A 2.78E-11 Metabolite levels / / 22286219 rs10892076 chr11 116988936 G A 1.57E-10 Iron status biomarkers / / 21149283 rs7120515 chr11 116991926 A G 5.10E-06 Lipid levels / / 18193043 rs7120515 chr11 116991926 A G 1.55E-10 Iron status biomarkers / / 21149283 rs6589597 chr11 116997798 C T 1.83E-04 Birth weight / / 17255346 rs6589597 chr11 116997798 C T 8.63E-26 Iron status biomarkers / / 21149283 rs12420200 chr11 116998306 G A,T 1.37E-04 Aortic root size / / 21223598 rs12420200 chr11 116998306 G A,T 2.00E-05 Urinary metabolites / / 21572414 rs9326248 chr11 116999225 T G 1.24E-15 Iron status biomarkers / / 21149283 rs6589598 chr11 117002403 A G 7.25E-24 Iron status biomarkers / / 21149283 rs4938343 chr11 117003528 G C 6.67E-15 Iron status biomarkers / / 21149283 rs4938344 chr11 117003749 G A 9.01E-16 Iron status biomarkers / / 21149283 rs4938347 chr11 117021759 T A 5.37E-13 Iron status biomarkers PAFAH1B2 intron 21149283 rs4938349 chr11 117021923 C T 2.35E-15 Iron status biomarkers PAFAH1B2 intron 21149283 rs7940310 chr11 117024481 T C 1.21E-25 Iron status biomarkers PAFAH1B2 intron 21149283 rs7940310 chr11 117024481 T C 0.00000159 Cholesterol,total PAFAH1B2 intron 23063622 rs7940310 chr11 117024481 T C 7.75E-21 Triglycerides PAFAH1B2 intron 23063622 rs7940310 chr11 117024481 T C 5.66E-09 Soluble transferrin receptor PAFAH1B2 intron 23696881 rs2127905 chr11 117026374 A C 1.22E-25 Iron status biomarkers PAFAH1B2 intron 21149283 rs1871757 chr11 117030581 T A 9.02E-13 Iron status biomarkers PAFAH1B2 intron 21149283 rs3736120 chr11 117032125 G T 2.26E-15 Iron status biomarkers PAFAH1B2 intron 21149283 rs7122944 chr11 117034619 G T 1.70E-08 Lipid levels PAFAH1B2 intron 19802338 rs7122944 chr11 117034619 G T 1.32E-25 Iron status biomarkers PAFAH1B2 intron 21149283 rs7122944 chr11 117034619 G T 0.00000152 Cholesterol,total PAFAH1B2 intron 23063622 rs7122944 chr11 117034619 G T 1.64E-20 Triglycerides PAFAH1B2 intron 23063622 rs10790175 chr11 117034729 T C 1.36E-16 Iron status biomarkers PAFAH1B2 intron 21149283 rs6589602 chr11 117037065 T C 4.00E-11 Iron status biomarkers PAFAH1B2 intron 21149283 rs6589602 chr11 117037065 T C 1.50E-13 Triglycerides PAFAH1B2 intron 23063622 rs7112513 chr11 117037361 A G 6.00E-09 Protein quantitative trait loci PAFAH1B2 intron 18464913 rs7112513 chr11 117037361 A G 1.26E-25 Iron status biomarkers PAFAH1B2 intron 21149283 rs10892082 chr11 117039325 T G 1.08E-04 Birth weight PAFAH1B2 UTR-3 17255346 rs10892082 chr11 117039325 T G 3.00E-25 Iron status biomarkers PAFAH1B2 UTR-3 21149283 rs4936367 chr11 117042377 G A 2.97E-25 Iron status biomarkers PAFAH1B2 missense 21149283 rs4938353 chr11 117046197 G A 1.95E-12 Iron status biomarkers PAFAH1B2 UTR-3 21149283 rs10790177 chr11 117048417 A G 2.13E-15 Iron status biomarkers / / 21149283 rs4938354 chr11 117051165 A G 2.13E-15 Iron status biomarkers SIDT2 intron 21149283 rs7946257 chr11 117053165 A G 7.21E-11 Iron status biomarkers SIDT2 intron 21149283 rs7107152 chr11 117056080 A G 2.65E-16 Iron status biomarkers SIDT2 intron 21149283 rs90192 chr11 117059347 C T 1.40E-08 Lipid levels SIDT2 intron 19802338 rs90192 chr11 117059347 C T 7.96E-16 Iron status biomarkers SIDT2 intron 21149283 rs474339 chr11 117059552 G A 3.41E-15 Iron status biomarkers SIDT2 intron 21149283 rs1242229 chr11 117062370 T C 2.43E-04 Birth weight SIDT2 intron 17255346 rs1242229 chr11 117062370 T C 3.43E-24 Iron status biomarkers SIDT2 intron 21149283 rs1242229 chr11 117062370 T C 0.00000112 Triglycerides in females SIDT2 intron 23063622 rs1242229 chr11 117062370 T C 2.78E-11 Triglycerides in males SIDT2 intron 23063622 rs1242229 chr11 117062370 T C 3.13E-20 Triglycerides SIDT2 intron 23063622 rs1242229 chr11 117062370 T C 6.55E-09 Soluble transferrin receptor SIDT2 intron 23696881 rs521171 chr11 117064693 C G 1.32E-15 Iron status biomarkers SIDT2 intron 21149283 rs1784042 chr11 117065476 G A 3.52E-04 Body mass index SIDT2 intron 21701565 rs8521 chr11 117067699 C T 5.92E-11 Iron status biomarkers SIDT2 UTR-3 21149283 rs664971 chr11 117070857 G A 8.47E-17 Iron status biomarkers TAGLN intron 21149283 rs641620 chr11 117074229 T C 9.84E-15 Iron status biomarkers TAGLN intron 21149283 rs641620 chr11 117074229 T C 5.90E-09 Triglycerides TAGLN intron 23063622 rs508487 chr11 117075566 C T 3.03E-20 Iron status biomarkers / / 21149283 rs508487 chr11 117075566 C T 2.00E-10 Cardiovascular disease risk factors / / 21943158 rs17120434 chr11 117075685 A G 0.000000165 LDL cholesterol / / 23063622 rs17120434 chr11 117075685 A G 9.03E-11 Triglycerides / / 23063622 rs1263499 chr11 117081709 A G 3.45E-04 Type 2 diabetes PCSK7 intron 17463246 rs1263499 chr11 117081709 A G 5.06E-04 Smoking initiation PCSK7 intron 24665060 rs236911 chr11 117085270 A C 5.07E-24 Iron status biomarkers PCSK7 intron 21149283 rs150758276 chr11 117085874 G C 1.40E-07 Infantile hypertrophic pyloric stenosis PCSK7 intron 23989729 rs2238005 chr11 117088082 C T 2.10E-12 Infantile hypertrophic pyloric stenosis PCSK7 intron 22306654 rs236915 chr11 117088450 A C,G,T 2.41E-12 Iron status biomarkers PCSK7 intron 21149283 rs236916 chr11 117089628 G A 1.15E-15 Iron status biomarkers PCSK7 intron 21149283 rs236918 chr11 117091609 G C 1.00E-27 Iron status biomarkers PCSK7 intron 21149283 rs236919 chr11 117095361 C T 6.25E-12 Iron status biomarkers PCSK7 intron 21149283 rs236919 chr11 117095361 C T 1.13E-04 Body mass index PCSK7 intron 21701565 rs236919 chr11 117095361 C T 4.36E-04 Body mass index PCSK7 intron 21701565 rs236919 chr11 117095361 C T 2.33E-05 HDL cholesterol PCSK7 intron pha003074 rs2306473 chr11 117097952 C T 6.47E-09 Triglycerides PCSK7 cds-synon 23063622 rs500389 chr11 117100594 A G 1.21E-10 Iron status biomarkers PCSK7 intron 21149283 rs500389 chr11 117100594 A G 1.81E-05 HDL cholesterol PCSK7 intron pha003074 rs1047964 chr11 117156893 G A,C,T 8.00E-07 Cardiovascular disease risk factors BACE1 UTR-3 21779381 rs676134 chr11 117179891 C T 4.45E-04 Body mass index BACE1 intron 21701565 rs593245 chr11 117183650 C T 6.90E-04 Body mass index BACE1 intron 21701565 rs593245 chr11 117183650 C T 8.22E-04 Body mass index BACE1 intron 21701565 rs1261791 chr11 117200638 T A 3.10E-04 Volumetric brain MRI CEP164 intron 17903297 rs948181 chr11 117208949 C T 3.54E-04 Smoking initiation CEP164 intron 24665060 rs493516 chr11 117213160 G A 9.09E-04 Insulin resistance CEP164 intron 21901158 rs580119 chr11 117216213 T G 6.13E-04 Insulin resistance CEP164 intron 21901158 rs490262 chr11 117222592 G A 6.87E-05 Stroke (pediatric) CEP164 missense 22990015 rs537323 chr11 117226849 C T 2.72E-04 Smoking initiation CEP164 intron 24665060 rs2305825 chr11 117232492 C T 6.71E-04 Smoking initiation CEP164 intron 24665060 rs10790180 chr11 117246150 T C 5.22E-05 Tunica Media CEP164 intron pha003037 rs523159 chr11 117260504 G A 4.37E-04 Multiple complex diseases CEP164 intron 17554300 rs8258 chr11 117283676 T C 9.90E-06 Obesity,menopause CEP164 UTR-3 21424828 rs9163 chr11 117283808 C T 6.45E-04 Smoking initiation CEP164 UTR-3 24665060 rs3863310 chr11 117293929 C T 6.34E-04 Acute lung injury / / 22295056 rs3889570 chr11 117300040 T C 7.62E-05 Alzheimer's disease (late onset) DSCAML1 intron 21379329 rs11216386 chr11 117309989 C T 1.90E-05 Urinary metabolites DSCAML1 cds-synon 21572414 rs11216396 chr11 117319720 A G 7.14E-05 Orofacial clefts DSCAML1 intron 22419666 rs500713 chr11 117320976 C T 8.56E-04 Obesity (extreme) DSCAML1 intron 21935397 rs10892117 chr11 117325478 T C 1.63E-04 Coronary heart disease DSCAML1 intron 21606135 rs7103239 chr11 117325898 G A 9.15E-04 Response to cytadine analogues (cytosine arabinoside) DSCAML1 intron 24483146 rs665406 chr11 117347058 T C 3.50E-05 Cognitive function DSCAML1 intron 24684796 rs587443 chr11 117347400 C T 3.90E-05 Cognitive function DSCAML1 intron 24684796 rs1574433 chr11 117347947 C T 1.43E-04 Endometrial cancer DSCAML1 intron 24096698 rs1574433 chr11 117347947 C T 8.15E-05 Endometrial cancer DSCAML1 intron 24096698 rs7929976 chr11 117349817 A G 1.37E-04 Type 2 diabetes DSCAML1 intron 17463246 rs3741278 chr11 117352949 G A 3.17E-06 Carotenoid and tocopherol levels DSCAML1 intron 19185284 rs549289 chr11 117358220 A C 2.86E-04 Coronary Artery Disease DSCAML1 intron 17634449 rs4938390 chr11 117358313 C T 3.72E-05 Multiple complex diseases DSCAML1 intron 17554300 rs12222915 chr11 117359244 G A 9.81E-04 Response to cytadine analogues (cytosine arabinoside) DSCAML1 intron 24483146 rs597686 chr11 117361861 C T 5.47E-05 Scoliosis DSCAML1 intron 21216876 rs11216435 chr11 117388932 C T 7.36E-04 Gallbladder cancer DSCAML1 intron 22318345 rs11216435 chr11 117388932 C T 3.00E-06 Menarche (age at onset) DSCAML1 intron 23599027 rs41326347 chr11 117398154 C A 4.09E-04 Multiple complex diseases DSCAML1 intron 17554300 rs12806865 chr11 117404769 A G 5.13E-05 Bipolar disorder DSCAML1 intron 20451256 rs650535 chr11 117414385 C T 6.67E-04 Response to cytidine analogues (gemcitabine) DSCAML1 intron 24483146 rs3802879 chr11 117414714 G T 9.02E-04 Response to cytadine analogues (cytosine arabinoside) DSCAML1 intron 24483146 rs7111299 chr11 117415385 C A 9.02E-04 Response to cytadine analogues (cytosine arabinoside) DSCAML1 intron 24483146 rs17509752 chr11 117432779 C T 7.35E-05 Male fertility DSCAML1 intron 22633400 rs755791 chr11 117433686 C A 1.53E-05 Postoperative ventricular dysfunction DSCAML1 intron 21980348 rs2010473 chr11 117433739 C T 1.47E-05 Postoperative ventricular dysfunction DSCAML1 intron 21980348 rs1893899 chr11 117436936 G T 5.42E-05 Male fertility DSCAML1 intron 22633400 rs681046 chr11 117452212 C T 2.91E-04 Multiple complex diseases DSCAML1 intron 17554300 rs6589615 chr11 117455699 G C 1.72E-04 Multiple complex diseases DSCAML1 intron 17554300 rs553637 chr11 117461602 C T 2.00E-06 Alcohol dependence DSCAML1 intron 23089632 rs680730 chr11 117475233 C T 2.45E-05 Male fertility DSCAML1 intron 22633400 rs4936393 chr11 117503394 G A 1.50E-05 Urinary metabolites DSCAML1 intron 21572414 rs480801 chr11 117512831 C T 8.47E-05 Blood Pressure DSCAML1 intron pha002903 rs7949670 chr11 117530935 C A 4.60E-06 Triglycerides DSCAML1 intron 19074352 rs10892151 chr11 117531731 C T 3.00E-29 Triglycerides DSCAML1 intron 19074352 rs11216492 chr11 117536758 A G 1.30E-06 Urinary metabolites DSCAML1 intron 21572414 rs11216515 chr11 117593119 T C 8.02E-05 Multiple sclerosis DSCAML1 intron 17660530 rs11216517 chr11 117595511 C T 8.98E-04 Parkinson's disease DSCAML1 intron 17052657 rs11216517 chr11 117595511 C T 1.09E-04 Coronary heart disease DSCAML1 intron 21971053 rs11216517 chr11 117595511 C T 5.45E-06 Stroke DSCAML1 intron pha002887 rs1942931 chr11 117610854 G A 1.65E-04 Glycosylated haemoglobin levels DSCAML1 intron 17255346 rs7950743 chr11 117613781 A G 5.03E-04 Alzheimer's disease DSCAML1 intron 17998437 rs4936406 chr11 117618437 C T 1.27E-04 Obesity (early onset extreme) DSCAML1 intron 23563609 rs12291974 chr11 117661447 C T 1.76E-05 Smoking initiation DSCAML1 intron 24665060 rs12795949 chr11 117662138 G A 0.000304643 Hypertension (early onset hypertension) DSCAML1 intron 22479346 rs528431 chr11 117662909 C A 0.0002 Migraine DSCAML1 intron 22678113 rs12281156 chr11 117677039 T A 4.09E-04 Alzheimer's disease / / 22005930 rs10892178 chr11 117685343 C T 0.0000902 Migraine / / 22678113 rs10892178 chr11 117685343 C T 9.02E-05 Migraine / / 22683712 rs4597100 chr11 117686456 C A 7.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs10892179 chr11 117692121 A G 1.11E-04 Response to cytadine analogues (cytosine arabinoside) FXYD2 intron 24483146 rs4938440 chr11 117693971 G A 4.09E-05 Cognitive impairment induced by topiramate FXYD2 intron 22091778 rs11216577 chr11 117710150 C T 6.57E-04 Multiple complex diseases FXYD6 intron 17554300 rs12098917 chr11 117716151 T C 7.62E-04 Coronary heart disease FXYD6 intron 21606135 rs1145223 chr11 117716453 T C 2.08E-04 Response to taxane treatment (placlitaxel) FXYD6 intron 23006423 rs2845712 chr11 117774291 A C 3.40E-04 Amyotrophic Lateral Sclerosis TMPRSS13 intron 17362836 rs11216645 chr11 117819863 G A 6.19E-04 Insulin resistance / / 21901158 rs7103514 chr11 117820561 A G 4.62E-04 Smoking initiation / / 24665060 rs2512159 chr11 117826191 C G 0.00007569 Sarcoidosis / / 22952805 rs3020913 chr11 117831809 A G 5.87E-07 Coronary heart disease / / pha003056 rs58603829 chr11 117851052 C T 6.00E-06 Obesity-related traits / / 23251661 rs11216665 chr11 117851174 G T 1.20E-05 Urinary metabolites / / 21572414 rs4936414 chr11 117853613 C T 9.30E-06 Urinary metabolites / / 21572414 rs2508450 chr11 117863829 T C 0.0001 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 IL10RA intron 21873659 rs2256111 chr11 117864047 A G 3.74E-04 Smoking cessation IL10RA cds-synon 24665060 rs4252273 chr11 117864811 G A 3.22E-18 HDL cholesterol IL10RA missense 23063622 rs2229115 chr11 117869591 C T 6.09E-06 Obesity-related traits IL10RA cds-synon 23251661 rs2512147 chr11 117872734 T C 5.40E-06 Urinary metabolites / / 21572414 rs947889 chr11 117874531 C T 4.31E-05 Tunica Media / / pha003037 rs2512152 chr11 117887757 C T 9.99E-04 Suicide attempts in bipolar disorder LOC100526771 intron 21423239 rs2512153 chr11 117889224 A G 4.62E-04 Suicide attempts in bipolar disorder LOC100526771 intron 21423239 rs675929 chr11 117892050 G A 6.65E-04 Suicide attempts in bipolar disorder LOC100526771 intron 21423239 rs685308 chr11 117897098 C G 9.92E-04 Suicide attempts in bipolar disorder LOC100526771 intron 21423239 rs3016863 chr11 117908328 A G 5.11E-04 Alcohol dependence LOC100526771 intron 21314694 rs11216720 chr11 117909101 C T 6.38E-04 Type 2 diabetes LOC100526771 intron 17463246 rs12576767 chr11 117915055 C T 2.62E-05 Height LOC100526771 intron pha003011 rs11216730 chr11 117918702 C T 7.67E-04 Type 2 diabetes LOC100526771 intron 17463246 rs625267 chr11 117932630 T C 4.78E-04 Schizophrenia LOC100526771 intron 19197363 rs12279572 chr11 117952960 A G 1.92E-05 Postoperative ventricular dysfunction TMPRSS4 intron 21980348 rs602445 chr11 117958148 T C 2.04E-04 Endometrial cancer TMPRSS4 intron 24096698 rs602445 chr11 117958148 T C 5.71E-04 Endometrial cancer TMPRSS4 intron 24096698 rs2276435 chr11 117959372 G A 0.0000974 Panic disorder TMPRSS4 intron 23149450 rs2276435 chr11 117959372 G A 9.74E-05 Serum tamsulosin hydrochloride concentration TMPRSS4 intron 23151678 rs11216740 chr11 117963766 G A 6.93E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) TMPRSS4 intron 23648065 rs11216747 chr11 117970326 A G 2.87E-05 Bipolar disorder TMPRSS4 intron 21771265 rs10502229 chr11 117979970 G T 1.55E-06 Myocardial Infarction TMPRSS4 intron pha002883 rs1941637 chr11 117999443 C A 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10790239 chr11 118001445 C T 2.70E-05 Urinary metabolites / / 21572414 rs7934994 chr11 118005780 G A 7.29E-05 HIV-1 control SCN4B UTR-3 20041166 rs11607985 chr11 118029798 C G 8.90E-07 Triglycerides / / 19074352 rs11608072 chr11 118030086 G C 8.40E-08 Triglycerides / / 19074352 rs11600901 chr11 118031986 G A 2.70E-05 Triglycerides / / 19074352 rs11600901 chr11 118031986 G A 9.00E-06 Preeclampsia / / 23551011 rs608176 chr11 118033789 C G 6.19E-04 Multiple complex diseases SCN2B UTR-3 17554300 rs679327 chr11 118042974 A G 4.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SCN2B intron 20877124 rs679327 chr11 118042974 A G 1.73E-04 Cognitive impairment induced by topiramate SCN2B intron 22091778 rs679327 chr11 118042974 A G 2.00E-04 Cognitive impairment induced by topiramate SCN2B intron 22091778 rs11216799 chr11 118046570 G A 8.11E-07 Glycosylated haemoglobin levels SCN2B intron 17255346 rs7944321 chr11 118055801 G A 4.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs619250 chr11 118064582 A C,T 6.26E-04 Multiple complex diseases AMICA1 UTR-3 17554300 rs17121871 chr11 118073344 T C 8.76E-04 Multiple complex diseases AMICA1 intron 17554300 rs11216816 chr11 118075152 C A 0.00000045 Secreted IFN-gamma response to smallpox vaccine AMICA1 intron 22661280 rs1805 chr11 118076069 T G 3.26E-05 Lung adenocarcinoma AMICA1 intron 19836008 rs17121893 chr11 118083044 G A 1.13E-04 Multiple complex diseases AMICA1 intron 17554300 rs17121901 chr11 118086461 T A 5.40E-04 Multiple complex diseases AMICA1 intron 17554300 rs12361791 chr11 118100176 T G 4.30E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs11216831 chr11 118117018 G A 4.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients MPZL3 intron 23400010 rs1624780 chr11 118134785 T G 3.46E-05 Bipolar disorder MPZL2 intron 21771265 rs3759001 chr11 118135745 T C 5.78E-05 Bipolar disorder / / 21771265 rs7940554 chr11 118142930 C T 6.03E-04 Multiple complex diseases / / 17554300 rs17122021 chr11 118145686 C T 7.00E-07 Pain / / 19207018 rs2277289 chr11 118182660 T C 3.32E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CD3E intron 24023788 rs2277289 chr11 118182660 T C 9.82E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CD3E intron 24023788 rs2277289 chr11 118182660 T C 1.66E-04 Heart Failure CD3E intron pha002884 rs3782042 chr11 118185919 A G 2.11E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CD3E intron 20031582 rs2276418 chr11 118230264 A T 8.05E-04 Alzheimer's disease / / 17998437 rs11216858 chr11 118237405 C G 7.67E-04 Type 2 diabetes UBE4A intron 17463246 rs11216860 chr11 118240332 T C 5.86E-04 Type 2 diabetes UBE4A intron 17463246 rs502514 chr11 118241995 T C 2.20E-06 Subcutaneous adipose tissue volume in HIV-infected men UBE4A intron 21897333 rs12274926 chr11 118295117 T C 4.34E-05 Heart rate / / 23583979 rs7948661 chr11 118341649 T C 5.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) MLL intron 23453885 rs572126 chr11 118359161 G A 0.000651617 Primary sclerosing cholangitis MLL intron 23603763 rs570809 chr11 118435365 T C 1.43E-04 Insulin resistance IFT46 intron 21901158 rs498872 chr11 118477367 A G 1.00E-08 Glioma PHLDB1 UTR-5 19578367 rs498872 chr11 118477367 A G 1.00E-08 Nasopharyngeal carcinoma PHLDB1 UTR-5 20512145 rs498872 chr11 118477367 A G 5.00E-11 Glioma PHLDB1 UTR-5 21531791 rs11603023 chr11 118486067 T C 1.45E-10 Glioma PHLDB1 intron 21531791 rs11603023 chr11 118486067 T C 1.00E-08 Cholesterol,total PHLDB1 intron 24097068 rs11216930 chr11 118488782 A C 1.62E-09 Glioma PHLDB1 intron 21531791 rs633683 chr11 118504742 T C 7.03E-04 Suicide attempts in bipolar disorder PHLDB1 intron 21041247 rs633683 chr11 118504742 T C 0.00000029 Primary sclerosing cholangitis PHLDB1 intron 23603763 rs625287 chr11 118506751 G A 6.58E-04 Multiple complex diseases PHLDB1 intron 17554300 rs4245184 chr11 118510562 G A 2.74E-04 Type 2 diabetes PHLDB1 intron 22158537 rs494560 chr11 118521549 G A 8.38E-11 Glioma PHLDB1 intron 21531791 rs17748 chr11 118528424 C T 2.14E-07 Glioma PHLDB1 UTR-3 19578367 rs17748 chr11 118528424 C T 8.02E-10 Glioma PHLDB1 UTR-3 21531791 rs200440695 chr11 118531367 A G 0.00058 Prostate cancer (non-advanced prostate cancer) TREH missense 23555315 rs507080 chr11 118549582 G A 3.00E-30 Metabolite levels TREH intron 24625756 rs11216943 chr11 118556398 G A 3.91E-08 Glioma / / 21531791 rs573905 chr11 118572267 A G 3.59E-08 Glioma / / 21531791 rs4639966 chr11 118573519 T C 1.00E-16 Systemic lupus erythematosus / / 19838193 rs4639966 chr11 118573519 T C 4.80E-05 Systemic lupus erythematosus / / 23273568 rs494459 chr11 118574675 C T 2.00E-08 Height / / 20881960 rs494459 chr11 118574675 C T 1.60E-05 Self-reported allergy / / 23817569 rs626645 chr11 118575180 T C 1.60E-05 Self-reported allergy / / 23817569 rs625735 chr11 118575419 G A 1.66E-05 Self-reported allergy / / 23817569 rs10892258 chr11 118579865 G A 4.06E-07 Celiac disease and Rheumatoid arthritis / / 21383967 rs10892258 chr11 118579865 G A 1.73E-07 Glioma / / 21531791 rs10892258 chr11 118579865 G A 1.70E-11 Celiac disease / / 22057235 rs10892258 chr11 118579865 G A 1.70E-11 Celiac disease / / 23143596 rs10892279 chr11 118611781 G A 1.00E-12 Celiac disease and Rheumatoid arthritis / / 21383967 rs10892279 chr11 118611781 G A 1.34E-10 Rheumatoid arthritis (CCP positive) / / 23143596 rs10892279 chr11 118611781 G A 2.95E-08 Rheumatoid arthritis / / 23143596 rs2155433 chr11 118612921 G A 3.11E-07 Celiac disease and Rheumatoid arthritis / / 21383967 rs632124 chr11 118613235 T A 1.71E-05 Self-reported allergy / / 23817569 rs607125 chr11 118617299 T C 1.80E-05 Self-reported allergy / / 23817569 rs488219 chr11 118620697 T C 1.64E-05 Self-reported allergy DDX6 UTR-3 23817569 rs581045 chr11 118632522 C T 1.63E-05 Self-reported allergy DDX6 intron 23817569 rs614554 chr11 118635151 T C 1.79E-05 Self-reported allergy DDX6 intron 23817569 rs10892286 chr11 118642085 A C 2.82E-07 Celiac disease and Rheumatoid arthritis DDX6 intron 21383967 rs10892287 chr11 118642999 T C 4.60E-05 Triglycerides DDX6 intron 19074352 rs555649 chr11 118651809 T C 1.69E-05 Self-reported allergy DDX6 intron 23817569 rs57494551 chr11 118661398 C T 4.64E-14 Primary biliary cirrhosis DDX6 intron 22961000 rs10892294 chr11 118667357 G C 5.61E-10 Primary biliary cirrhosis / / 21399635 rs1784300 chr11 118679629 A T 2.60E-09 Alcohol and nictotine co-dependence / / 20158304 rs1784300 chr11 118679629 A T 6.28E-07 Alcohol and nictotine co-dependence / / 20158304 rs1784300 chr11 118679629 A T 1.97E-05 Self-reported allergy / / 23817569 rs10607450 chr11 118682767 T C 7.20E-16 Primary biliary cirrhosis / / 22961000 rs715412 chr11 118684610 G A 5.09E-07 Celiac disease and Rheumatoid arthritis / / 21383967 rs715412 chr11 118684610 G A 2.26E-15 Primary biliary cirrhosis / / 22961000 rs638893 chr11 118698537 G A 2.00E-09 Vitiligo / / 22951725 rs4938561 chr11 118718485 C T 0.0000929 Gains in maximal O2 uptake response / / 21183627 rs17122462 chr11 118725584 C T 8.87E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs17122462 chr11 118725584 C T 9.45E-04 Insulin resistance / / 21901158 rs10790268 chr11 118729391 A G 1.00E-15 Rheumatoid arthritis / / 24390342 rs10790268 chr11 118729391 A G 1.00E-17 Rheumatoid arthritis / / 24390342 rs7933007 chr11 118730669 C T 0.0000735 Gains in maximal O2 uptake response / / 21183627 rs10892301 chr11 118735476 G A 0.000672224 Hypertension (early onset hypertension) / / 22479346 rs7119044 chr11 118738298 G C 3.64E-09 Primary biliary cirrhosis / / 22936693 rs4936443 chr11 118740864 C T 5.13E-14 Primary biliary cirrhosis / / 22961000 rs4938572 chr11 118740931 C T 2.83E-14 Primary biliary cirrhosis / / 22961000 rs7117261 chr11 118741157 T C 1.16E-09 Primary biliary cirrhosis in females / / 22936693 rs7117261 chr11 118741157 T C 2.68E-10 Primary biliary cirrhosis (anti-mitochondrial antibody positive) / / 22936693 rs7117261 chr11 118741157 T C 3.18E-10 Primary biliary cirrhosis / / 22936693 rs7117261 chr11 118741157 T C 3.48E-14 Primary biliary cirrhosis / / 22961000 rs4938573 chr11 118741842 C T 6.59E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs4938573 chr11 118741842 C T 5.02E-10 Primary biliary cirrhosis / / 21399635 rs4938573 chr11 118741842 C T 3.07E-14 Primary biliary cirrhosis / / 22961000 rs4938573 chr11 118741842 C T 0.000000484 Rheumatoid arthritis (CCP positive) / / 23143596 rs4938573 chr11 118741842 C T 0.00000053 Rheumatoid arthritis / / 23143596 rs12365699 chr11 118743286 G A 5.72E-05 Self-reported allergy / / 23817569 rs4936444 chr11 118743338 T C 2.25E-13 Primary biliary cirrhosis / / 22961000 rs6421571 chr11 118743772 T A,C 4.88E-07 Celiac disease and Rheumatoid arthritis / / 21383967 rs6421571 chr11 118743772 T A,C 3.00E-12 Primary biliary cirrhosis / / 21399635 rs6421571 chr11 118743772 T A,C 1.80E-05 Rheumatoid arthritis / / 24449572 rs10892306 chr11 118751326 A T 6.12E-04 Type 2 diabetes / / 17463246 rs10892306 chr11 118751326 A T 6.60E-05 Triglycerides / / 19074352 rs630923 chr11 118754353 C A 3.00E-07 Multiple sclerosis / / 21833088 rs630923 chr11 118754353 C A 7.00E-09 Inflammatory bowel disease / / 23128233 rs630923 chr11 118754353 C A 2.33E-04 Self-reported allergy / / 23817569 rs1790192 chr11 118757191 G A 2.34E-04 Self-reported allergy CXCR5 intron 23817569 rs665648 chr11 118765283 G A 6.80E-04 Alcohol dependence CXCR5 missense 20201924 rs12270280 chr11 118791150 C T 0.00007674 Sarcoidosis / / 22952805 rs11217091 chr11 118793613 T C 4.89E-04 Epilepsy / / 22116939 rs602716 chr11 118801235 G A 5.76E-04 Taste perception / / 22132133 rs602716 chr11 118801235 G A 5.20E-04 Heart Failure / / pha002885 rs602716 chr11 118801235 G A 3.50E-04 Stroke / / pha002887 rs11217099 chr11 118809882 C A 2.96E-04 Depression (quantitative trait) / / 20800221 rs11606199 chr11 118811641 G A 1.43E-04 Depression (quantitative trait) / / 20800221 rs587263 chr11 118816156 T C 1.35E-05 Diabetes Mellitus / / pha003060 rs4442562 chr11 118845813 G A 8.89E-05 Cognitive test performance FOXR1 intron 20125193 rs4938604 chr11 118846574 T C 1.60E-05 Urinary metabolites FOXR1 intron 21572414 rs4938606 chr11 118852081 A G 2.80E-05 Urinary metabolites / / 21572414 rs9645664 chr11 118873987 T C 1.92E-07 Lymphocyte counts CCDC84 intron 22286170 rs7931970 chr11 118918537 G A 3.24E-09 HDL cholesterol HYOU1 intron 23063622 rs4531480 chr11 118943599 T C 3.91E-04 Alcohol dependence VPS11 intron 21314694 rs7122226 chr11 118951724 A G 4.61E-10 HDL cholesterol VPS11 intron 23063622 rs1144041 chr11 118959280 T C 3.80E-13 HDL cholesterol HMBS intron 23063622 rs10790282 chr11 118973133 G A 7.46E-04 Multiple complex diseases DPAGT1 nearGene-5 17554300 rs617948 chr11 118981025 A G 3.56E-04 Multiple complex diseases C2CD2L intron 17554300 rs35060365 chr11 119027711 C T 4.73E-18 HDL cholesterol ABCG4 missense 23063622 rs4938638 chr11 119075429 G A 3.78E-04 Multiple complex diseases CBL nearGene-5 17554300 rs4938638 chr11 119075429 G A 8.59E-05 Personality dimensions CBL nearGene-5 18957941 rs12786104 chr11 119096785 T G 5.10E-06 Urinary metabolites CBL intron 21572414 rs4938642 chr11 119099906 G C 8.00E-11 Platelet counts CBL intron 22139419 rs4938642 chr11 119099906 G C 1.00E-05 Platelet counts CBL intron 24026423 rs7113047 chr11 119108112 A G 4.30E-05 Personality dimensions CBL intron 18957941 rs2276083 chr11 119145274 A G 4.90E-06 Urinary metabolites CBL intron 21572414 rs1047417 chr11 119172536 A G 3.86E-05 Inflammation CBL UTR-3 pha002897 rs2511847 chr11 119203359 G A 4.54E-04 Obesity (extreme) / / 21935397 rs11824001 chr11 119203505 C T 3.37E-05 Personality dimensions / / 22628180 rs2511841 chr11 119206375 G A 4.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RNF26 cds-synon 20877124 rs2248863 chr11 119207341 G A 4.11E-04 Obesity (extreme) RNF26 UTR-3 21935397 rs2248853 chr11 119207446 C T 3.39E-04 Obesity (extreme) RNF26 UTR-3 21935397 rs2509656 chr11 119208576 G A 3.90E-04 Obesity (extreme) / / 21935397 rs9640 chr11 119209979 T A 3.89E-04 Obesity (extreme) MFRP UTR-3 21935397 rs2195525 chr11 119235404 C T 2.00E-06 Urate levels USP2 intron 23263486 rs514808 chr11 119241120 A G 5.28E-04 Suicide attempts in bipolar disorder USP2 intron 21423239 rs576945 chr11 119246896 G A 8.83E-06 Blood Pressure USP2 intron pha003043 rs576945 chr11 119246896 G A 9.44E-05 Blood Pressure USP2 intron pha003044 rs565296 chr11 119252151 C T 1.02E-05 Blood Pressure USP2 intron pha003043 rs565296 chr11 119252151 C T 6.70E-05 Blood Pressure USP2 intron pha003044 rs667775 chr11 119256775 T C 5.65E-04 Multiple complex diseases LOC100499227 intron 17554300 rs7926015 chr11 119261867 T G 2.07E-04 Suicide attempts in bipolar disorder LOC100499227 intron 21423239 rs3751026 chr11 119291688 A G 1.74E-04 Suicide attempts in bipolar disorder THY1 intron 21423239 rs3910017 chr11 119295082 A G 1.76E-04 Suicide attempts in bipolar disorder LOC100499227 intron 21423239 rs10790293 chr11 119304090 A C 1.78E-04 Suicide attempts in bipolar disorder LOC100499227 intron 21423239 rs4938653 chr11 119305611 C T 1.93E-04 Suicide attempts in bipolar disorder LOC100499227 intron 21423239 rs4938653 chr11 119305611 C T 5.15E-05 Blood Pressure LOC100499227 intron pha003043 rs10736497 chr11 119309664 C T 1.61E-04 Suicide attempts in bipolar disorder LOC100499227 intron 21423239 rs12291488 chr11 119310558 T C 3.24E-04 Multiple complex diseases LOC100499227 intron 17554300 rs7130716 chr11 119318306 A G 1.38E-04 Suicide attempts in bipolar disorder LOC100499227 intron 21423239 rs582973 chr11 119320333 T C 1.27E-04 Suicide attempts in bipolar disorder LOC100499227 intron 21423239 rs7112232 chr11 119320444 A G 1.28E-04 Suicide attempts in bipolar disorder LOC100499227 intron 21423239 rs10750140 chr11 119323284 T C 2.21E-04 Suicide attempts in bipolar disorder LOC100499227 intron 21423239 rs10750140 chr11 119323284 T C 9.78E-05 Blood Pressure LOC100499227 intron pha003043 rs482002 chr11 119330588 A T 1.52E-04 Suicide attempts in bipolar disorder LOC100499227 intron 21423239 rs611719 chr11 119349454 G A 9.06E-04 Amyotrophic lateral sclerosis (sporadic) LOC100499227 intron 24529757 rs592525 chr11 119383853 G A 2.09E-04 Type 2 diabetes / / 17463246 rs4366498 chr11 119395257 A C 8.40E-05 Cognitive impairment induced by topiramate / / 22091778 rs4622279 chr11 119446118 A G 8.94E-04 Insulin resistance / / 21901158 rs4582984 chr11 119499014 C A 5.11E-04 Stroke / / pha002886 rs1567375 chr11 119502477 A C 1.31E-05 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs11217371 chr11 119517449 C T 0.000398 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PVRL1 intron 23233654 rs11217371 chr11 119517449 C T 3.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) PVRL1 intron 23233662 rs7103685 chr11 119523181 T C 1.66E-04 Birth weight PVRL1 intron 17255346 rs10892448 chr11 119624823 A C 8.70E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10892449 chr11 119628238 C G 8.00E-04 Type 2 diabetes / / 17463246 rs11217470 chr11 119629249 T C 7.53E-04 Type 2 diabetes / / 17463246 rs9633947 chr11 119644360 G A 5.00E-04 Type 2 diabetes / / 17463246 rs6589774 chr11 119646732 G A 3.00E-04 Polycystic ovary syndrome / / 22178785 rs10892471 chr11 119679283 G A 9.16E-04 Type 2 diabetes / / 17463246 rs2166658 chr11 119682874 T C 9.85E-04 Multiple complex diseases / / 17554300 rs2121575 chr11 119683218 C G 7.73E-04 Multiple complex diseases / / 17554300 rs895647 chr11 119684145 T G 2.94E-04 Multiple complex diseases / / 17554300 rs1447149 chr11 119691069 G A 2.98E-04 Type 2 diabetes / / 17463246 rs11217524 chr11 119692871 T C 7.42E-04 Type 2 diabetes / / 17463246 rs7395971 chr11 119693573 C T 9.92E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11217527 chr11 119697584 G A 6.06E-04 Type 2 diabetes / / 17463246 rs1007369 chr11 119700031 C A 2.66E-06 Hirschsprung's disease / / 19196962 rs10892480 chr11 119737648 G A 6.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs895649 chr11 119751585 A G 5.45E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs503175 chr11 119753926 C T 4.97E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs607824 chr11 119754895 G A 4.47E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2044545 chr11 119765318 C T 4.85E-04 Type 2 diabetes / / 17463246 rs518932 chr11 119771843 C T 2.51E-04 Type 2 diabetes / / 17463246 rs525588 chr11 119774225 C G 8.00E-04 Type 2 diabetes / / 17463246 rs508479 chr11 119775811 A C 9.30E-05 Type 2 diabetes / / 17463246 rs10502232 chr11 119790068 A G 2.11E-05 Blood Pressure / / pha002903 rs17123485 chr11 119792173 T C 1.64E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs504542 chr11 119802591 G T 8.10E-06 Urinary metabolites / / 21572414 rs692775 chr11 119804518 C T 4.34E-17 Multiple complex diseases / / 17554300 rs12273820 chr11 119805016 T C 2.80E-05 Urinary metabolites / / 21572414 rs668781 chr11 119816512 T C 3.93E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs657317 chr11 119816766 A C 3.80E-05 Multiple complex diseases / / 17554300 rs17245340 chr11 119822015 T C 5.75E-04 Acute lung injury / / 22295056 rs626466 chr11 119837112 C T 7.62E-04 Rheumatoid arthritis / / 21452313 rs10790361 chr11 119844041 C T 2.53E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11600793 chr11 119858507 G C 3.08E-04 Acute lung injury / / 22295056 rs10892512 chr11 119878901 G A 4.26E-05 Cognitive test performance / / 20125193 rs4936507 chr11 119934563 G A 8.14E-04 Body mass index / / 21701565 rs1551238 chr11 119948132 A C 2.90E-05 Urinary metabolites / / 21572414 rs4938769 chr11 119948566 C T 9.95E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs20494 chr11 119957453 G A 9.19E-04 Multiple complex diseases / / 17554300 rs20494 chr11 119957453 G A 5.46E-05 Potassium levels / / pha003086 rs3915715 chr11 119960260 G A 4.29E-05 Personality dimensions / / 18957941 rs3895896 chr11 119961536 T A 2.70E-04 Aortic root size / / 21223598 rs617320 chr11 119961694 G T 7.64E-05 Cleft lip / / 20436469 rs617320 chr11 119961694 G T 1.54E-05 Orofacial clefts / / 22863734 rs4938780 chr11 119976805 T C 4.07E-04 Multiple sclerosis / / 17660530 rs11217695 chr11 119977625 C T 8.50E-06 Triglycerides / / 19074352 rs530291 chr11 119989569 T C 8.48E-04 Coronary heart disease TRIM29 intron 21606135 rs666432 chr11 120003533 C T 2.50E-05 Adiposity TRIM29 intron 19461586 rs470411 chr11 120012390 G C 7.50E-04 Iris characteristics / / 21835309 rs470370 chr11 120013984 T C 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs470373 chr11 120026271 C T 5.90E-07 Corneal curvature / / 22969067 rs2084898 chr11 120026748 G A 4.00E-06 Stroke (pediatric) / / 22990015 rs2084898 chr11 120026748 G A 4.00E-07 Stroke (pediatric) / / 22990015 rs470606 chr11 120028202 T G 5.66E-07 Corneal curvature / / 22969067 rs2444240 chr11 120040442 T G 0.000076 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC729173 intron 22628534 rs2444240 chr11 120040442 T G 4.00E-07 Corneal curvature LOC729173 intron 22969067 rs4936509 chr11 120041444 C T 2.82E-06 Corneal curvature / / 22969067 rs494965 chr11 120053650 C T 4.50E-07 Corneal curvature / / 22969067 rs692804 chr11 120099368 T C 2.70E-06 Psoriasis OAF intron 19169255 rs947906 chr11 120106086 G T 3.33E-06 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs882856 chr11 120107411 G A 9.51E-04 Parkinson's disease POU2F3 missense 17052657 rs4938793 chr11 120146360 G T 7.03E-05 Multiple complex diseases POU2F3 intron 17554300 rs4938793 chr11 120146360 G T 1.40E-05 Temperament (bipolar disorder) POU2F3 intron 22365631 rs948404 chr11 120150533 G A 4.50E-05 Temperament (bipolar disorder) POU2F3 intron 22365631 rs11217785 chr11 120152591 C T 2.82E-07 HDL cholesterol POU2F3 intron 23726366 rs4936513 chr11 120157168 T A 9.04E-04 Multiple complex diseases POU2F3 intron 17554300 rs6589804 chr11 120161641 G A 8.07E-06 Multiple sclerosis POU2F3 intron 17660530 rs6589804 chr11 120161641 G A 3.60E-05 Triglycerides POU2F3 intron 19074352 rs11603757 chr11 120164658 G T 5.24E-04 Nicotine smoking POU2F3 intron 19268276 rs4142654 chr11 120167057 A G 5.14E-05 Multiple sclerosis POU2F3 intron 17660530 rs4142654 chr11 120167057 A G 5.76E-04 Alcohol dependence POU2F3 intron 21314694 rs11217806 chr11 120169962 T C 5.05E-04 Hemoglobin concentration POU2F3 intron 20534544 rs11217806 chr11 120169962 T C 0.0002 Migraine POU2F3 intron 22678113 rs17245504 chr11 120178753 T G 1.30E-05 Nicotine smoking POU2F3 intron 19268276 rs17123851 chr11 120231618 T G 8.42E-04 Multiple complex diseases ARHGEF12 intron 17554300 rs632137 chr11 120247033 C T 7.39E-04 Type 2 diabetes ARHGEF12 intron 17463246 rs11217854 chr11 120267537 A G 4.20E-04 Multiple complex diseases ARHGEF12 intron 17554300 rs4373935 chr11 120273301 A G 4.30E-05 Multiple sclerosis ARHGEF12 intron 17660530 rs3901366 chr11 120408071 G A 6.83E-04 Type 2 diabetes / / 17463246 rs3901366 chr11 120408071 G A 1.21E-05 Chronic obstructive pulmonary disease / / 19300482 rs3901366 chr11 120408071 G A 1.21E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2253023 chr11 120412169 C T 2.46E-05 Chronic obstructive pulmonary disease / / 19300482 rs2253023 chr11 120412169 C T 2.46E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2248558 chr11 120426508 C T 5.66E-04 Multiple complex diseases / / 17554300 rs2248540 chr11 120426966 T C 6.99E-06 Chronic obstructive pulmonary disease / / 19300482 rs2248540 chr11 120426966 T C 6.99E-06 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12796185 chr11 120446830 T C 1.79E-05 Chronic obstructive pulmonary disease / / 19300482 rs12796185 chr11 120446830 T C 1.79E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7105963 chr11 120468752 C T 9.90E-05 Chronic obstructive pulmonary disease / / 19300482 rs7105963 chr11 120468752 C T 9.90E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12278532 chr11 120481773 C T 5.50E-05 Triglycerides / / 19074352 rs11603831 chr11 120483858 C T 5.24E-04 Type 2 diabetes / / 17463246 rs11603831 chr11 120483858 C T 2.83E-06 Chronic obstructive pulmonary disease / / 19300482 rs11603831 chr11 120483858 C T 2.83E-06 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7949316 chr11 120495204 T C 3.50E-05 HIV-1 viral setpoint / / 22174851 rs4935744 chr11 120496704 T G 1.67E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12292151 chr11 120499500 C A 2.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs12577725 chr11 120500339 C T 6.89E-05 Major depressive disorder (broad) / / 20038947 rs1317514 chr11 120513914 C T 4.51E-04 Rheumatoid arthritis / / 21452313 rs4245040 chr11 120520629 T C 7.00E-06 Attention deficit hyperactivity disorder / / 23728934 rs4935750 chr11 120521066 C T 1.89E-05 Attention deficit hyperactivity disorder / / 23728934 rs10892592 chr11 120522003 T C 3.78E-05 Attention deficit hyperactivity disorder / / 23728934 rs4570590 chr11 120523139 C G 1.89E-05 Attention deficit hyperactivity disorder / / 23728934 rs4936537 chr11 120526365 G A 3.20E-05 Attention deficit hyperactivity disorder / / 23728934 rs11217956 chr11 120540795 C T 7.06E-04 Multiple complex diseases GRIK4 intron 17554300 rs10892596 chr11 120541873 C T 6.93E-04 Multiple complex diseases GRIK4 intron 17554300 rs12360673 chr11 120544237 A G 2.33E-04 Celiac disease GRIK4 intron 23936387 rs2000869 chr11 120544871 A G 2.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRIK4 intron 20877124 rs10892604 chr11 120546223 C T 3.93E-04 Type 2 diabetes GRIK4 intron 17463246 rs10892604 chr11 120546223 C T 8.88E-04 Multiple complex diseases GRIK4 intron 17554300 rs10502240 chr11 120547912 C T 7.00E-04 Heroin addiction GRIK4 intron 20520587 rs10790394 chr11 120548076 G C 8.35E-04 Multiple complex diseases GRIK4 intron 17554300 rs11607732 chr11 120548318 A G 3.67E-04 Type 2 diabetes GRIK4 intron 17463246 rs11607732 chr11 120548318 A G 6.50E-04 Multiple complex diseases GRIK4 intron 17554300 rs11603586 chr11 120548353 C T 5.09E-04 Multiple complex diseases GRIK4 intron 17554300 rs10892608 chr11 120549745 G A 7.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRIK4 intron 20877124 rs10892609 chr11 120551100 T C 8.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRIK4 intron 20877124 rs10790395 chr11 120551419 C A 5.01E-04 Multiple complex diseases GRIK4 intron 17554300 rs10892612 chr11 120553182 G A 3.85E-04 Multiple complex diseases GRIK4 intron 17554300 rs4445646 chr11 120556341 T C 0.0008 Change in depression severity with antidepressants (NRI or SRI) GRIK4 intron 23091423 rs12284730 chr11 120560459 C T 4.03E-06 Sarcoidosis GRIK4 intron 19165924 rs11217974 chr11 120562489 A G 5.56E-04 Nicotine smoking GRIK4 intron 19268276 rs7925270 chr11 120563298 C T 2.00E-05 Triglycerides GRIK4 intron 19074352 rs4567478 chr11 120577423 T C 2.33E-05 Cognitive impairment induced by topiramate GRIK4 intron 22091778 rs4567478 chr11 120577423 T C 5.23E-05 Cognitive impairment induced by topiramate GRIK4 intron 22091778 rs4567478 chr11 120577423 T C 9.27E-04 Stroke GRIK4 intron pha002887 rs7103228 chr11 120580767 G A 7.75E-04 Nicotine smoking GRIK4 intron 19268276 rs7103228 chr11 120580767 G A 2.33E-05 Cognitive impairment induced by topiramate GRIK4 intron 22091778 rs7103228 chr11 120580767 G A 5.23E-05 Cognitive impairment induced by topiramate GRIK4 intron 22091778 rs11217989 chr11 120583983 T C 1.30E-05 Triglycerides GRIK4 intron 19074352 rs11217989 chr11 120583983 T C 2.05E-04 Sarcoidosis GRIK4 intron 19165924 rs3133226 chr11 120592036 C T 2.05E-05 Waist Circumference GRIK4 intron pha003023 rs3133224 chr11 120614787 C T 7.94E-05 Multiple sclerosis (age of onset) GRIK4 intron 19010793 rs3133864 chr11 120628012 C T 5.63E-04 Amyotrophic Lateral Sclerosis GRIK4 intron 17827064 rs7934092 chr11 120643090 C A 4.20E-04 Smoking initiation GRIK4 intron 24665060 rs3133861 chr11 120659485 T G 0.000162 Salmonella-induced pyroptosis GRIK4 intron 22837397 rs1954787 chr11 120663363 T C 1 Drug response to Citalopram GRIK4 intron 17671280 rs948034 chr11 120677398 T C 8.09E-04 Oral cancers (chewing tobacco related) GRIK4 intron 22503698 rs11218016 chr11 120694754 T C 2.87E-04 Type 2 diabetes GRIK4 intron 17463246 rs7114795 chr11 120697544 T C 1.98E-05 Multiple complex diseases GRIK4 intron 17554300 rs6589847 chr11 120715884 A G 6.04E-07 Multiple complex diseases GRIK4 intron 17554300 rs11218029 chr11 120718086 T A 1.07E-05 Type 2 diabetes GRIK4 intron 17463246 rs6589848 chr11 120724018 T C 9.36E-06 Osteoarthritis GRIK4 intron 22763110 rs7104543 chr11 120724121 A G 6.78E-04 Type 2 diabetes GRIK4 intron 17463246 rs4414232 chr11 120730638 T C 8.98E-04 Type 2 diabetes GRIK4 intron 17463246 rs3824978 chr11 120732508 C T 4.53E-04 Type 2 diabetes GRIK4 intron 17463246 rs3901285 chr11 120733435 C T 1.34E-05 Type 2 diabetes GRIK4 intron 17463246 rs10892631 chr11 120734139 G A 1.52E-05 Type 2 diabetes GRIK4 intron 17463246 rs11218035 chr11 120736087 C T 7.92E-05 Cognitive impairment induced by topiramate GRIK4 intron 22091778 rs11218035 chr11 120736087 C T 8.52E-04 Cognitive impairment induced by topiramate GRIK4 intron 22091778 rs3802912 chr11 120738397 G A 4.70E-05 Tooth agenesis (mandibular third molar) GRIK4 intron 24172245 rs4936562 chr11 120741937 T C 4.90E-05 Tooth agenesis (mandibular third molar) GRIK4 intron 24172245 rs12577638 chr11 120755655 G A 6.67E-04 Common variable immunodeficiency GRIK4 intron 21497890 rs10892635 chr11 120759130 G A 3.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRIK4 intron 20877124 rs17124538 chr11 120783369 A G 6.59E-05 Cognitive performance GRIK4 intron 19734545 rs10892643 chr11 120790963 C T 2.20E-05 Urinary metabolites GRIK4 intron 21572414 rs2850808 chr11 120797604 A G 4.63E-04 Multiple complex diseases GRIK4 intron 17554300 rs12797755 chr11 120809460 T G 8.00E-06 Cognitive performance GRIK4 intron 20125193 rs684913 chr11 120819562 T C 5.95E-04 Smoking initiation GRIK4 intron 24665060 rs10750178 chr11 120823528 A G 3.64E-04 Smoking initiation GRIK4 intron 24665060 rs11218078 chr11 120824692 T G 1.68E-04 Multiple complex diseases GRIK4 intron 17554300 rs655824 chr11 120834480 C T 2.35E-04 Attention deficit hyperactivity disorder GRIK4 intron 22012869 rs7128009 chr11 120835281 A G 1.47E-04 Multiple complex diseases GRIK4 intron 17554300 rs645156 chr11 120853259 C T 1.87E-05 Cognitive impairment induced by topiramate GRIK4 intron 22091778 rs646543 chr11 120853577 C T 9.63E-04 Multiple complex diseases GRIK4 intron 17554300 rs540787 chr11 120854479 C T 3.22E-04 Alzheimer's disease GRIK4 intron 17998437 rs10750179 chr11 120864593 A G 1.65E-04 Multiple complex diseases / / 17554300 rs1944522 chr11 120864922 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2000526 chr11 120905771 T C 9.63E-04 Multiple complex diseases TBCEL intron 17554300 rs12225989 chr11 120930947 C A 1.93E-04 Multiple complex diseases TBCEL intron 17554300 rs12795310 chr11 120931054 T C 0.0002 Migraine TBCEL intron 22678113 rs4643089 chr11 120941583 A G 0.0001 Migraine TBCEL intron 22678113 rs584329 chr11 120994638 T C 1.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TECTA intron 20877124 rs10502247 chr11 120998942 C T 3.35E-04 Multiple complex diseases TECTA cds-synon 17554300 rs10892674 chr11 121002972 G A 3.20E-04 Multiple complex diseases TECTA intron 17554300 rs7105712 chr11 121003358 T C 1.95E-04 Multiple complex diseases TECTA intron 17554300 rs612804 chr11 121077373 T C 4.44E-04 Multiple complex diseases / / 17554300 rs745517 chr11 121092052 C T 5.37E-04 Glaucoma (primary open-angle) / / 22419738 rs6589865 chr11 121115206 C T 9.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1893248 chr11 121120755 C T 6.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7928669 chr11 121121448 T C 4.49E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7942167 chr11 121121501 G A 6.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17125022 chr11 121126968 C T 1.48E-04 Multiple complex diseases / / 17554300 rs4423192 chr11 121128543 T C 1.63E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10892705 chr11 121135286 A T 0.0006854 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10892705 chr11 121135286 A T 6.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10790424 chr11 121137520 C T 3.31E-04 Coronary heart disease / / 21606135 rs12363999 chr11 121144114 T C 5.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10892723 chr11 121194946 A G 1.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6589877 chr11 121195951 G T 5.93E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs4936613 chr11 121204601 A G 6.00E-06 Response to taxane treatment (placlitaxel) / / 23006423 rs2060009 chr11 121206354 G A 1.00E-04 Asthma and hay fever / / 24388013 rs116875324 chr11 121206449 C T 9.00E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs891436 chr11 121208310 A G 8.55E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs716066 chr11 121216567 G A 3.82E-04 Alzheimer's disease / / 22005930 rs17125182 chr11 121223636 A G 3.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs4936618 chr11 121223996 A C 6.17E-06 Major depressive disorder / / 19107115 rs4936618 chr11 121223996 A C 8.79E-04 Alcohol dependence / / 20201924 rs10790443 chr11 121234131 C A 3.38E-04 Coronary heart disease / / 21606135 rs297530 chr11 121243291 T C 7.37E-05 Basophils / / pha003087 rs72991 chr11 121243716 C T 2.82E-04 Coronary heart disease / / 21606135 rs72991 chr11 121243716 C T 5.00E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs2370386 chr11 121258418 G C 9.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs297503 chr11 121264426 C T 8.00E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs7105326 chr11 121266057 C T 6.52E-04 Response to alcohol consumption (flushing response) / / 24277619 rs297509 chr11 121271440 T C 1.64E-04 Response to alcohol consumption (flushing response) / / 24277619 rs297517 chr11 121294360 G T 1.90E-05 Urinary metabolites / / 21572414 rs668053 chr11 121308525 G A 5.05E-04 Stroke / / pha002887 rs17125349 chr11 121324207 T C 0.000000861 Triglycerides SORL1 intron 23063622 rs985421 chr11 121362316 G A 1.23E-04 Coronary heart disease SORL1 intron 21606135 rs4598682 chr11 121375951 A G 2.25E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs4598682 chr11 121375951 A G 3.03E-06 Alzheimer's disease (late onset) SORL1 intron 23565137 rs4598682 chr11 121375951 A G 9.50E-06 Alzheimer's disease (late onset) SORL1 intron 23565137 rs4598682 chr11 121375951 A G 9.51E-06 Alzheimer's disease (late onset) SORL1 intron 23565137 rs6589884 chr11 121382172 A T 2.58E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs6589884 chr11 121382172 A T 2.86E-06 Alzheimer's disease (late onset) SORL1 intron 23565137 rs12285364 chr11 121393226 C T 4.60E-07 Fasting plasma glucose SORL1 intron 19060907 rs2276345 chr11 121414456 A C 1.51E-04 Alzheimer's disease (late onset) SORL1 intron 23565137 rs2276345 chr11 121414456 A C 9.34E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs2276345 chr11 121414456 A C 2.04E-04 Smoking initiation SORL1 intron 24665060 rs10502262 chr11 121415312 C T 7.85E-05 Monocyte chemoattractant protein-1 SORL1 intron pha003071 rs11604897 chr11 121423552 C T 2.01E-04 Alzheimer's disease (late onset) SORL1 intron 23565137 rs11604897 chr11 121423552 C T 6.60E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs11605969 chr11 121430872 C T 8.37E-04 Suicide attempts in bipolar disorder SORL1 intron 21423239 rs11218343 chr11 121435587 T C 6.61E-04 Multiple complex diseases SORL1 intron 17554300 rs11218343 chr11 121435587 T C 2.00E-09 Alzheimer's disease (late onset) SORL1 intron 23565137 rs11218343 chr11 121435587 T C 3.80E-04 Alzheimer's disease (late onset) SORL1 intron 23565137 rs11218343 chr11 121435587 T C 1.00E-14 Alzheimer's disease (late onset) SORL1 intron 24162737 rs3781831 chr11 121436004 G A 1.63E-04 Alzheimer's disease (late onset) SORL1 intron 23565137 rs3781831 chr11 121436004 G A 4.86E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs11218346 chr11 121439181 G A 1.38E-04 Multiple complex diseases SORL1 intron 17554300 rs1699105 chr11 121442619 A G 2.06E-05 Cognitive test performance SORL1 intron 20125193 rs924746 chr11 121443037 G A 8.65E-04 Suicide attempts in bipolar disorder SORL1 intron 21423239 rs1792125 chr11 121443663 C T 9.85E-04 Suicide attempts in bipolar disorder SORL1 intron 21423239 rs17125473 chr11 121444811 G C 1.51E-04 Alzheimer's disease (late onset) SORL1 intron 23565137 rs17125473 chr11 121444811 G C 4.18E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs3781834 chr11 121445940 A G 8.70E-05 Hypothyroidism SORL1 intron 22493691 rs3781834 chr11 121445940 A G 1.58E-04 Alzheimer's disease (late onset) SORL1 intron 23565137 rs3781834 chr11 121445940 A G 4.27E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs3781834 chr11 121445940 A G 7.30E-07 Alzheimer's disease (late onset) SORL1 intron 23565137 rs3781834 chr11 121445940 A G 7.33E-07 Alzheimer's disease (late onset) SORL1 intron 23565137 rs4936637 chr11 121447188 T C 7.35E-04 Tourette syndrome SORL1 intron 22889924 rs4936637 chr11 121447188 T C 3.68E-05 Blood Pressure SORL1 intron pha003043 rs2070045 chr11 121448090 T G 4.36E-05 Blood Pressure SORL1 cds-synon pha003043 rs3781837 chr11 121448972 T C 1.53E-04 Alzheimer's disease (late onset) SORL1 intron 23565137 rs3781837 chr11 121448972 T C 4.45E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs59260691 chr11 121450332 G A 1.52E-04 Alzheimer's disease (late onset) SORL1 intron 23565137 rs59260691 chr11 121450332 G A 4.42E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs7120354 chr11 121452354 G A 1.68E-04 Alzheimer's disease (late onset) SORL1 intron 23565137 rs7120354 chr11 121452354 G A 4.94E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs11218350 chr11 121452651 T A 1.79E-04 Colorectal cancer SORL1 intron 24978480 rs11218351 chr11 121453707 C T 9.35E-04 Coronary heart disease SORL1 intron 21606135 rs58698151 chr11 121453779 A T 1.55E-04 Alzheimer's disease (late onset) SORL1 intron 23565137 rs58698151 chr11 121453779 A T 4.45E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs2282647 chr11 121461593 G C 1.52E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs2282647 chr11 121461593 G C 6.12E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs10892759 chr11 121464088 G A 6.05E-05 Bipolar disorder SORL1 intron 19488044 rs10892759 chr11 121464088 G A 4.49E-05 Bipolar Disorder SORL1 intron pha002863 rs12274536 chr11 121470620 C G 1.98E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs12274536 chr11 121470620 C G 7.36E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs12274541 chr11 121470646 C T 1.14E-04 Alzheimer's disease (late onset) SORL1 intron 23565137 rs12274541 chr11 121470646 C T 2.16E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs1620003 chr11 121472993 G A 7.02E-05 Bipolar disorder SORL1 intron 19488044 rs1620003 chr11 121472993 G A 9.91E-05 Bipolar Disorder SORL1 intron pha002863 rs11218360 chr11 121473391 T C 2.20E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs11218360 chr11 121473391 T C 9.05E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs12287339 chr11 121474025 T C 2.19E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs12287339 chr11 121474025 T C 8.93E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs17125523 chr11 121474239 A G 2.20E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs17125523 chr11 121474239 A G 5.50E-06 Alzheimer's disease (late onset) SORL1 intron 23565137 rs17125523 chr11 121474239 A G 5.51E-06 Alzheimer's disease (late onset) SORL1 intron 23565137 rs17125523 chr11 121474239 A G 9.05E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs3737529 chr11 121477816 C T 1.51E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs3737529 chr11 121477816 C T 4.10E-06 Alzheimer's disease (late onset) SORL1 intron 23565137 rs3737529 chr11 121477816 C T 4.14E-06 Alzheimer's disease (late onset) SORL1 intron 23565137 rs3737529 chr11 121477816 C T 6.30E-05 Alzheimer's disease (late onset) SORL1 intron 23565137 rs726601 chr11 121481407 C T 8.20E-04 Volumetric brain MRI SORL1 intron 17903297 rs62622819 chr11 121485599 T A 0.00061 Prostate cancer (non-advanced prostate cancer) SORL1 missense 23555315 rs9633951 chr11 121495141 T C 8.30E-04 Coronary heart disease SORL1 intron 21966275 rs1131497 chr11 121502745 C G 3.20E-06 Volumetric brain MRI SORL1 UTR-3 17903297 rs647905 chr11 121534938 C T 1.67E-04 Bipolar disorder / / 18317468 rs17337279 chr11 121568116 C T 5.61E-04 Alcohol dependence / / 21314694 rs2887763 chr11 121568179 A G 5.04E-04 Alzheimer's disease / / 24755620 rs1074086 chr11 121575095 G A 3.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs662333 chr11 121578945 G A 8.31E-27 Narcolepsy / / 19629137 rs10502259 chr11 121584083 G A 3.37E-04 Diabetic retinopathy / / 20871662 rs664424 chr11 121588031 A G 2.56E-04 Smoking initiation / / 24665060 rs7937934 chr11 121635211 C T 7.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7936807 chr11 121640236 C A 7.44E-04 Smoking initiation / / 24665060 rs1944683 chr11 121641496 C T 7.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1944679 chr11 121643646 T G 8.03E-04 Smoking initiation / / 24665060 rs7109992 chr11 121646113 C T 7.14E-04 Smoking initiation / / 24665060 rs17125849 chr11 121664415 T C 2.02E-04 Multiple complex diseases / / 17554300 rs1448127 chr11 121702960 C T 1.14E-04 Type 2 diabetes / / 17463246 rs472074 chr11 121707866 G A 6.09E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs17125867 chr11 121712103 C T 2.58E-06 Phospholipid levels (plasma) / / 21829377 rs7480288 chr11 121725106 T G 1.93E-06 Phospholipid levels (plasma) / / 21829377 rs12792401 chr11 121738662 C T 2.57E-06 Phospholipid levels (plasma) / / 21829377 rs17125870 chr11 121740944 T C 3.03E-06 Phospholipid levels (plasma) / / 21829377 rs7946844 chr11 121742667 A C 3.15E-06 Phospholipid levels (plasma) / / 21829377 rs7947574 chr11 121743220 C T 3.42E-06 Phospholipid levels (plasma) / / 21829377 rs1219400 chr11 121754288 C A 3.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1219396 chr11 121760604 A G 6.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1078402 chr11 121779467 T C 5.22E-04 Substance dependence / / 21818250 rs747915 chr11 121779664 T C 3.21E-04 Alcohol dependence / / 24277619 rs1219414 chr11 121797897 G A 5.00E-58 Rheumatoid arthritis / / 21156761 rs1219446 chr11 121804892 A C 9.95E-04 Alzheimer's disease / / 24755620 rs1789839 chr11 121814696 A G 9.67E-04 Alzheimer's disease / / 24755620 rs1448130 chr11 121815423 G A 7.90E-04 Alcohol dependence / / 20201924 rs11218490 chr11 121862691 A G 1.53E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7117776 chr11 121894025 C T 9.10E-04 Type 2 diabetes / / 17463246 rs7949079 chr11 121913925 G T 3.63E-04 Type 2 diabetes / / 17463246 rs12295607 chr11 121917083 A T 7.94E-04 Type 2 diabetes / / 17463246 rs7937427 chr11 121928419 C G 2.16E-04 Type 2 diabetes / / 17463246 rs11218513 chr11 121930860 G A 2.40E-06 Triglycerides / / 19074352 rs621153 chr11 121939228 C T 3.98E-04 Multiple complex diseases LOC100507145 intron 17554300 rs11218519 chr11 121939553 A G 1.68E-04 Type 2 diabetes LOC100507145 intron 17463246 rs7121446 chr11 121954657 G A 3.00E-06 Cardiovascular disease risk factors LOC100507145 intron 20838585 rs512932 chr11 121973541 A G 2.71E-05 Suicide attempts in bipolar disorder MIR100HG intron 21423239 rs512932 chr11 121973541 A G 8.90E-06 Urinary metabolites MIR100HG intron 21572414 rs10790486 chr11 121977751 G C 5.77E-04 Suicide attempts in bipolar disorder MIR100HG intron 21423239 rs4121975 chr11 121977902 G A 5.70E-04 Suicide attempts in bipolar disorder MIR100HG intron 21423239 rs630852 chr11 121985367 A G 1.12E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) MIR100HG intron 23648065 rs492085 chr11 121994700 G T 4.40E-05 Triglycerides MIR100HG intron 19074352 rs492085 chr11 121994700 G T 1.71E-05 Alcohol consumption MIR100HG intron 23953852 rs687928 chr11 121996261 T C 3.50E-05 Triglycerides MIR100HG intron 19074352 rs678586 chr11 122002604 C T 3.20E-05 Triglycerides MIR100HG intron 19074352 rs594358 chr11 122005125 A T 4.20E-05 Triglycerides MIR100HG intron 19074352 rs560279 chr11 122023511 A G 6.25E-05 HIV-1 control MIR100HG intron 20041166 rs577948 chr11 122030190 A G 2.00E-07 Myopia (pathological) MIR100HG intron 19779542 rs577948 chr11 122030190 A G 7.91E-04 Acute lung injury MIR100HG intron 22295056 rs7114614 chr11 122036041 A G 3.57E-04 Acute lung injury MIR100HG intron 22295056 rs17126243 chr11 122049675 G A 0.0000129 Schizophrenia MIR100HG intron 23637625 rs516415 chr11 122051699 G A 5.01E-05 Type 2 diabetes MIR100HG intron 17846125 rs6589912 chr11 122054261 C T 6.68E-04 Response to statin treatment (atorvastatin),change in cholesterol levels MIR100HG intron 20031582 rs11218557 chr11 122099839 T C 0.000145133 Hypertension (early onset hypertension) / / 22479346 rs640786 chr11 122101556 G A 9.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4936679 chr11 122102623 T C 2.64E-06 Brain structure / / 22504417 rs3867241 chr11 122105565 A G 1.60E-06 Urinary metabolites / / 21572414 rs10790490 chr11 122110188 T C 2.75E-06 Brain structure / / 22504417 rs502553 chr11 122115386 T C 2.60E-06 Brain structure / / 22504417 rs622166 chr11 122121081 G A 3.60E-06 Brain structure / / 22504417 rs489877 chr11 122128526 A C 1.11E-05 Brain structure / / 22504417 rs11218566 chr11 122138371 C T 2.29E-04 Smoking quantity / / 24665060 rs4144299 chr11 122143033 G C 1.30E-05 Urinary metabolites / / 21572414 rs537119 chr11 122143668 C G 2.72E-05 Brain structure / / 22504417 rs10892825 chr11 122144113 T C 2.50E-05 Urinary metabolites / / 21572414 rs11218568 chr11 122144811 G T 4.12E-04 Smoking quantity / / 24665060 rs497879 chr11 122148259 G A 2.00E-05 Brain structure / / 22504417 rs526977 chr11 122155670 T C 3.57E-05 Brain structure / / 22504417 rs482449 chr11 122180828 T C 6.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs482449 chr11 122180828 T C 7.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs535905 chr11 122180904 T C 5.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs535905 chr11 122180904 T C 7.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs565229 chr11 122189465 G A 4.00E-06 Hemostatic factors and hematological phenotypes / / 17903294 rs561201 chr11 122197275 C T 4.62E-06 Odorant perception / / 23910658 rs2078216 chr11 122204076 C A 6.89E-04 Insulin resistance / / 21901158 rs7931235 chr11 122213550 T C 7.96E-04 Multiple complex diseases / / 17554300 rs689100 chr11 122239261 T C 9.88E-04 Type 2 diabetes / / 17463246 rs17337773 chr11 122239702 T C 1.93E-05 Parkinson's disease (motor and cognition) / / 22658654 rs10892831 chr11 122258356 T C 5.15E-05 HIV-1 viral setpoint / / 22174851 rs475199 chr11 122281001 C G 9.66E-04 Type 2 diabetes / / 17463246 rs559453 chr11 122289272 A G 1.32E-04 Cardiovascular disease / / 17903304 rs580069 chr11 122289345 T C 1.24E-04 Cardiovascular disease / / 17903304 rs11218624 chr11 122317946 G A 7.79E-04 Multiple complex diseases / / 17554300 rs1216554 chr11 122317996 G T 4.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs2084637 chr11 122391187 T C 5.15E-04 Stroke / / pha002887 rs10502250 chr11 122403463 A G 3.63E-06 Nephrolithiasis / / 22396660 rs7925049 chr11 122452193 A G 4.40E-05 Parkinson's disease (familial) / / 18985386 rs7925049 chr11 122452193 A G 3.00E-05 Alcoholism (heaviness of drinking) / / 21529783 rs4565904 chr11 122460079 G A 2.70E-05 Parkinson's disease (familial) / / 18985386 rs7103823 chr11 122462813 C T 6.03E-05 Brain lesion load / / 19010793 rs12419313 chr11 122466121 G A 5.98E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12420917 chr11 122477025 T C 8.02E-04 Coronary heart disease / / 21971053 rs7944144 chr11 122477706 A G 9.67E-05 Coronary heart disease / / 21971053 rs4936715 chr11 122489043 A G 1.94E-04 Multiple complex diseases / / 17554300 rs11218714 chr11 122495631 A G 0.000032 Primary sclerosing cholangitis / / 22521342 rs6589937 chr11 122501162 T G 2.50E-06 Triglycerides / / 19074352 rs7941030 chr11 122522375 T C 2.00E-10 Cholesterol,total / / 20686565 rs7941030 chr11 122522375 T C 3.00E-08 HDL cholesterol / / 20686565 rs7941030 chr11 122522375 T C 1.60E-05 Multiple sclerosis / / 21833088 rs7941030 chr11 122522375 T C 1.00E-14 HDL cholesterol / / 24097068 rs7941030 chr11 122522375 T C 2.00E-14 Cholesterol,total / / 24097068 rs11218755 chr11 122557750 A G 2.91E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines UBASH3B intron 21844884 rs17126767 chr11 122579404 C T 4.31E-05 Response to taxane treatment (placlitaxel) UBASH3B intron 23006423 rs7104341 chr11 122580938 G T 2.60E-05 Tuberculosis UBASH3B intron 24057671 rs7930792 chr11 122581725 C G 1.56E-04 Smoking cessation UBASH3B intron 18519826 rs11218769 chr11 122587608 C A 1.37E-04 Smoking cessation UBASH3B intron 18519826 rs10736526 chr11 122589092 T C 8.40E-05 Response to gemcitabine in pancreatic cancer UBASH3B intron 22142827 rs7932902 chr11 122591233 T C 7.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) UBASH3B intron 20877124 rs41507249 chr11 122607364 A G 8.25E-04 Type 2 diabetes UBASH3B intron 17463246 rs7126299 chr11 122609280 C T 4.85E-04 Multiple complex diseases UBASH3B intron 17554300 rs4936737 chr11 122622531 T C 2.30E-06 Urinary metabolites UBASH3B intron 21572414 rs4936742 chr11 122641086 T C 1.72E-04 Smoking cessation UBASH3B intron 18519826 rs4936742 chr11 122641086 T C 3.80E-04 Smoking cessation UBASH3B intron 18519826 rs4936742 chr11 122641086 T C 7.60E-04 Behcet's disease UBASH3B intron 19442274 rs4936742 chr11 122641086 T C 8.00E-04 Behcet's disease UBASH3B intron 19442274 rs12797324 chr11 122654588 T G 5.52E-05 Monocyte chemoattractant protein-1 UBASH3B intron pha003071 rs2370779 chr11 122659691 T C 3.19E-04 Response to cytadine analogues (cytosine arabinoside) UBASH3B intron 24483146 rs955051 chr11 122659918 T G 8.03E-04 Stroke UBASH3B cds-synon pha002887 rs4936746 chr11 122666790 C T 1.81E-05 Waist Circumference UBASH3B intron pha003023 rs12576789 chr11 122675109 G A 5.91E-05 Waist Circumference UBASH3B intron pha003023 rs3819248 chr11 122677047 T C 8.25E-04 Response to cytadine analogues (cytosine arabinoside) UBASH3B intron 24483146 rs12793476 chr11 122678728 A G 7.14E-04 Type 2 diabetes UBASH3B intron 17463246 rs2276408 chr11 122678911 C T 4.33E-04 Response to cytadine analogues (cytosine arabinoside) UBASH3B intron 24483146 rs1945394 chr11 122684597 T C 7.50E-05 Parkinson's disease (familial) UBASH3B UTR-3 18985386 rs7936539 chr11 122689018 C G 9.53E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11218856 chr11 122707889 T C 2.40E-04 Birth weight / / 17255346 rs17338032 chr11 122733603 G T 3.19E-07 Malignant mesothelioma CRTAM intron 23827383 rs7126620 chr11 122742428 T G 9.75E-04 Coronary heart disease CRTAM UTR-3 21606135 rs12808527 chr11 122750044 C G 7.82E-04 Multiple complex diseases / / 17554300 rs4936758 chr11 122757120 C T 4.89E-04 Multiple complex diseases C11orf63 intron 17554300 rs12098906 chr11 122760987 C T 2.60E-06 Coffee consumption C11orf63 intron 21357676 rs3107622 chr11 122768693 T C 0.000267 Salmonella-induced pyroptosis C11orf63 intron 22837397 rs3107635 chr11 122781556 G A 3.39E-04 Coronary heart disease C11orf63 intron 21606135 rs7129125 chr11 122797916 G A 8.74E-04 Type 2 diabetes C11orf63 intron 17463246 rs4293127 chr11 122804263 G C 6.42E-04 Suicide attempts in bipolar disorder C11orf63 intron 21423239 rs7123283 chr11 122809055 C T 9.35E-04 Suicide attempts in bipolar disorder C11orf63 intron 21423239 rs4259833 chr11 122809205 G A 7.33E-04 Suicide attempts in bipolar disorder C11orf63 intron 21423239 rs1461499 chr11 122843987 C A 3.80E-04 Menarche (age at onset) / / 23599027 rs1870761 chr11 122851563 C A 6.79E-05 Sensory disturbances after bilateral sagittal split ramus osteotomy BSX intron 23834954 rs6589964 chr11 122870683 A C 2.00E-12 Menarche (age at onset) / / 21102462 rs2126200 chr11 122873076 C G 7.00E-06 IgG glycosylation / / 23382691 rs11605702 chr11 122911091 G T 5.05E-04 Hemoglobin concentration / / 20534544 rs7111590 chr11 122926127 C G 4.00E-04 Adverse response to radiation therapy / / 23719583 rs7111598 chr11 122926146 C T 2.00E-04 Adverse response to radiation therapy / / 23719583 rs1461495 chr11 122926844 T C 6.11E-04 Multiple complex diseases / / 17554300 rs4936770 chr11 122928875 C T 1.37E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses HSPA8 intron 17903301 rs10892958 chr11 122932123 C G 4.40E-04 Iris characteristics HSPA8 intron 21835309 rs7944075 chr11 122933677 C T 1.60E-04 HDL particle features LOC100652787 intron 21283740 rs3763896 chr11 122940813 T C 1.10E-05 Cognitive impairment induced by topiramate LOC100652787 intron 22091778 rs11605822 chr11 122986326 G A 7.89E-04 Multiple complex diseases CLMP intron 17554300 rs2169355 chr11 122995279 A G 1.80E-05 Urinary metabolites CLMP intron 21572414 rs4936778 chr11 123010654 G T 6.07E-04 Alzheimer's disease CLMP intron 24755620 rs6589969 chr11 123013271 T C 5.00E-06 Urinary metabolites CLMP intron 21572414 rs12280662 chr11 123019450 A G 9.30E-04 Multiple complex diseases CLMP intron 17554300 rs9943547 chr11 123026014 G A 2.43E-04 Gallstones CLMP intron 17632509 rs12281746 chr11 123029038 T C 1.50E-04 Lung function (forced expiratory volume in 1 second) CLMP intron 24023788 rs12281746 chr11 123029038 T C 2.88E-04 Lung function (forced vital capacity) CLMP intron 24023788 rs10790558 chr11 123038840 A G 9.15E-05 Leukocyte Counts CLMP intron pha003091 rs485345 chr11 123074915 G A 8.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs577432 chr11 123078194 A C 7.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10892983 chr11 123092243 C T 1.30E-05 Urinary metabolites / / 21572414 rs4245047 chr11 123094797 T C 1.96E-04 Insulin resistance / / 21901158 rs550113 chr11 123096869 C T 1.00E-05 Urinary metabolites / / 21572414 rs550113 chr11 123096869 C T 7.62E-05 Insulin resistance / / 21901158 rs559254 chr11 123096933 A G 1.50E-05 Urinary metabolites / / 21572414 rs525854 chr11 123098651 A G 2.30E-05 Urinary metabolites / / 21572414 rs11219092 chr11 123130751 C T 6.79E-04 Type 2 diabetes / / 17463246 rs7115792 chr11 123132645 G A 4.87E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs7949765 chr11 123135684 G A 1.76E-08 Coronary heart disease / / pha003030 rs7949765 chr11 123135684 G A 3.59E-08 Coronary heart disease / / pha003031 rs883410 chr11 123138144 G A 1.43E-04 Type 2 diabetes / / 17463246 rs7927484 chr11 123138960 T C 4.53E-05 Coronary heart disease / / pha003030 rs7941914 chr11 123147698 T C 8.18E-07 Coronary heart disease / / pha003030 rs7941914 chr11 123147698 T C 1.14E-05 Coronary heart disease / / pha003031 rs7934887 chr11 123149582 G T 3.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17127226 chr11 123152748 G T 4.48E-04 Response to TNF antagonist treatment / / 21061259 rs6589986 chr11 123153275 C T 9.34E-04 Response to TNF antagonist treatment / / 21061259 rs6589994 chr11 123167298 T A 6.00E-04 Asthma (childhood onset) / / 21359210 rs11602677 chr11 123176516 G A 3.30E-04 Thyroid peroxidase antibody positivity / / 24586183 rs9888300 chr11 123179064 A C 0.00000053 LDL cholesterol response after 40mg daily simvastatin treatment / / 23100282 rs9888300 chr11 123179064 A C 0.000034 Apolipoprotein B levels response after 40mg daily simvastatin treatment / / 23100282 rs9888204 chr11 123179123 C A 6.09E-07 Glycosylated haemoglobin levels / / 17255346 rs13377457 chr11 123181129 G A 9.23E-07 Glycosylated haemoglobin levels / / 17255346 rs13377457 chr11 123181129 G A 4.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13377457 chr11 123181129 G A 3.51E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10893006 chr11 123183969 C T 0.0000099 LDL cholesterol response after 40mg daily simvastatin treatment / / 23100282 rs10893006 chr11 123183969 C T 0.00045 Apolipoprotein B levels response after 40mg daily simvastatin treatment / / 23100282 rs7101668 chr11 123190744 T C 1.69E-04 Multiple complex diseases / / 17554300 rs11219114 chr11 123194520 A C 1.00E-04 Multiple complex diseases / / 17554300 rs17127253 chr11 123195602 G T 7.60E-06 Urinary metabolites / / 21572414 rs7107396 chr11 123196208 A G 5.65E-05 Progressive supranuclear palsy / / 21685912 rs7119209 chr11 123196916 C T 9.36E-05 Multiple complex diseases / / 17554300 rs11219115 chr11 123199567 G A 9.64E-07 Glycosylated haemoglobin levels / / 17255346 rs10893019 chr11 123217828 A G 3.82E-04 Multiple complex diseases / / 17554300 rs10893025 chr11 123232801 T C 6.09E-05 Multiple complex diseases / / 17554300 rs11822822 chr11 123243942 A G 6.19E-04 Smoking initiation / / 24665060 rs12574231 chr11 123252802 C T 8.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs7927064 chr11 123261385 T C 4.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs7106228 chr11 123265949 G A 4.73E-05 Parkinson's disease (motor and cognition) / / 22658654 rs17127340 chr11 123275452 G C 8.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs2282561 chr11 123280309 C T 1.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs7950886 chr11 123282195 G A 1.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs17127350 chr11 123282814 C T 9.17E-05 Suicide attempts in bipolar disorder / / 21423239 rs17127353 chr11 123282952 A G 1.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs2714059 chr11 123283922 T C 8.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12575737 chr11 123285639 A G 1.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs2156443 chr11 123289851 G A 8.92E-04 Multiple complex diseases / / 17554300 rs2156443 chr11 123289851 G A 8.93E-04 Type 2 diabetes / / 17846125 rs3016380 chr11 123304650 T C 6.93E-05 Waist Circumference LOC100128242 intron pha003024 rs2846293 chr11 123307262 A G 7.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2846293 chr11 123307262 A G 5.37E-04 Tourette syndrome / / 22889924 rs2846062 chr11 123318063 G A 2.28E-04 Glycosylated haemoglobin levels / / 17255346 rs735665 chr11 123361397 G A 4.00E-12 Chronic lymphocytic leukemia / / 18758461 rs735665 chr11 123361397 G A 5.32E-04 Bipolar disorder,schizoaffective / / 19567891 rs735665 chr11 123361397 G A 4.00E-12 Nasopharyngeal carcinoma / / 20512145 rs735665 chr11 123361397 G A 4.00E-09 Follicular lymphoma / / 20639881 rs735665 chr11 123361397 G A 3.00E-12 Chronic lymphocytic leukemia / / 22700719 rs735665 chr11 123361397 G A 3.36E-12 Erectile dysfunction / / 22704111 rs735665 chr11 123361397 G A 4.00E-39 Chronic lymphocytic leukemia / / 23770605 rs735665 chr11 123361397 G A 4.00E-24 Chronic lymphocytic leukemia / / 24292274 rs3016471 chr11 123364917 T C 4.62E-05 Rheumatoid arthritis / / 17804836 rs2714078 chr11 123370239 T C 1.57E-05 Rheumatoid arthritis / / 17804836 rs11219172 chr11 123370460 C A 5.56E-05 Bipolar Disorder / / pha002858 rs3016473 chr11 123370595 G A 4.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17092996 chr11 123374587 A G 7.67E-05 Bipolar disorder / / 18317468 rs4936819 chr11 123391051 C A 2.23E-06 Bipolar disorder / / 19488044 rs4936819 chr11 123391051 C A 1.24E-06 Bipolar Disorder / / pha002858 rs17127435 chr11 123395348 A G 1.83E-05 Coronary heart disease / / pha003035 rs17672997 chr11 123399395 C T 7.81E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GRAMD1B intron 20031582 rs2714068 chr11 123399541 A G 2.40E-05 Ankylosing spondylitis GRAMD1B intron 20062062 rs2714068 chr11 123399541 A G 6.31E-05 Alzheimer's disease (late onset) GRAMD1B intron 20885792 rs2714066 chr11 123400468 G A 9.60E-04 Alzheimer's disease GRAMD1B intron 22005930 rs2846308 chr11 123402092 G A 9.48E-04 Alzheimer's disease GRAMD1B intron 22005930 rs2714065 chr11 123403209 C T 6.87E-04 Alzheimer's disease GRAMD1B intron 22005930 rs2714063 chr11 123403522 A G 3.99E-04 Type 2 diabetes GRAMD1B intron 17463246 rs3016475 chr11 123403572 A G 7.97E-04 Alzheimer's disease GRAMD1B intron 22005930 rs17673113 chr11 123405152 A G 2.69E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GRAMD1B intron 20031582 rs3016477 chr11 123408170 G C 9.42E-04 Alzheimer's disease GRAMD1B intron 22005930 rs7951407 chr11 123408473 T C 9.26E-04 Acute lung injury GRAMD1B intron 22295056 rs4936824 chr11 123408945 T C 8.94E-04 Acute lung injury GRAMD1B intron 22295056 rs4936825 chr11 123409791 G C 8.49E-04 Acute lung injury GRAMD1B intron 22295056 rs2846311 chr11 123409885 A G 7.86E-04 Alzheimer's disease GRAMD1B intron 22005930 rs2846312 chr11 123410006 G C 8.40E-04 Alzheimer's disease GRAMD1B intron 22005930 rs1029278 chr11 123421402 A G 4.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRAMD1B intron 20877124 rs863731 chr11 123424329 G T 7.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRAMD1B intron 20877124 rs11219196 chr11 123424434 C T 1.73E-04 Response to cytadine analogues (cytosine arabinoside) GRAMD1B intron 24483146 rs11219196 chr11 123424434 C T 4.45E-05 Response to cytidine analogues (gemcitabine) GRAMD1B intron 24483146 rs11219198 chr11 123427805 A G 2.34E-04 Response to cytadine analogues (cytosine arabinoside) GRAMD1B intron 24483146 rs743631 chr11 123429425 T C 2.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRAMD1B intron 20877124 rs2852732 chr11 123447713 G A 3.67E-04 Hearing function GRAMD1B intron 17255346 rs17127472 chr11 123448588 G A 1.75E-05 Glycosylated haemoglobin levels GRAMD1B intron 17255346 rs1274214 chr11 123474531 T C 8.87E-06 Aging (time to event) GRAMD1B intron 21782286 rs1274213 chr11 123475615 G A 1.86E-04 Type 2 diabetes GRAMD1B intron 17463246 rs11219210 chr11 123495005 T C 4.28E-05 Height / / pha003011 rs3741118 chr11 123496902 T C 4.46E-04 Multiple complex diseases / / 17554300 rs1275085 chr11 123513161 G A,T 1.89E-05 HDL cholesterol SCN3B cds-synon pha003074 rs1275085 chr11 123513161 G A,T 1.95E-05 Triglycerides SCN3B cds-synon pha003080 rs11219218 chr11 123528616 A G 2.00E-04 Personality dimensions / / 23903073 rs12577878 chr11 123539375 C G 4.18E-04 Insulin resistance / / 21901158 rs10750238 chr11 123545743 C T 2.90E-04 Cholesterol / / 17255346 rs10790586 chr11 123548719 C T 7.56E-04 Multiple complex diseases / / 17554300 rs1841876 chr11 123549724 C T 2.05E-05 Multiple complex diseases / / 17554300 rs2298809 chr11 123554086 T C 1.98E-05 AIDS progression / / 19115949 rs4430519 chr11 123568321 G T 2.37E-04 Multiple complex diseases / / 17554300 rs12419599 chr11 123568404 G T 6.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs4406833 chr11 123568464 A T 6.01E-04 Multiple complex diseases / / 17554300 rs4406833 chr11 123568464 A T 6.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs10893076 chr11 123569986 C T 5.02E-04 Multiple complex diseases / / 17554300 rs1275055 chr11 123571731 T A 7.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs552820 chr11 123578628 C T 1.72E-04 Smoking cessation / / 24665060 rs655756 chr11 123585960 G A 2.09E-05 Smoking cessation / / 24665060 rs625888 chr11 123587947 T A 1.59E-04 Smoking cessation / / 24665060 rs597530 chr11 123593222 T C 4.17E-05 Smoking cessation / / 24665060 rs481168 chr11 123594240 C A 8.30E-05 Hepatocellular carcinoma / / 22807686 rs2126709 chr11 123595927 C T 4.00E-07 Response to antipsychotic therapy (extrapyramidal side effects) ZNF202 UTR-3 19875103 rs1144507 chr11 123600475 A C,G,T 2.60E-05 Iron levels ZNF202 missense 21208937 rs2282642 chr11 123601916 G A 1.58E-04 Multiple complex diseases ZNF202 intron 17554300 rs1144505 chr11 123602199 T A 1.83E-04 Multiple complex diseases ZNF202 intron 17554300 rs1880058 chr11 123602945 T C 1.32E-04 Multiple complex diseases ZNF202 intron 17554300 rs9326264 chr11 123605937 C T 2.82E-04 Multiple complex diseases ZNF202 intron 17554300 rs9326264 chr11 123605937 C T 6.90E-05 Diabetic nephropathy ZNF202 intron pha002864 rs10893079 chr11 123608274 T C 2.10E-04 Multiple complex diseases ZNF202 intron 17554300 rs1940185 chr11 123608581 G A 1.78E-04 Multiple complex diseases ZNF202 intron 17554300 rs10893085 chr11 123618477 C T 9.84E-05 Diabetic nephropathy / / pha002864 rs11219274 chr11 123622086 T C 8.17E-05 Diabetic nephropathy / / pha002864 rs12364099 chr11 123624658 G T 1.21E-04 Stroke OR6X1 missense pha002887 rs7103374 chr11 123631872 A G 1.38E-04 Multiple complex diseases / / 17554300 rs17744026 chr11 123648333 T G 3.00E-06 IgE levels in asthmatics (D.p. specific) / / 23967269 rs4345979 chr11 123683274 G A 0.000004 Salmonella-induced pyroptosis / / 22837397 rs11219307 chr11 123686185 G T 1.90E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs2186744 chr11 123687130 G A 0.0000556 Salmonella-induced pyroptosis / / 22837397 rs2155362 chr11 123687286 G A 1.90E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs17120 chr11 123694039 G A 0.000512 Salmonella-induced pyroptosis / / 22837397 rs10502272 chr11 123710711 T C 3.05E-04 Type 2 diabetes / / 17463246 rs10502274 chr11 123715541 A G 6.95E-04 Myopia (pathological) / / 21095009 rs1939915 chr11 123716249 T C 8.80E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs2155363 chr11 123717248 T C 8.80E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs2186745 chr11 123717398 G A 0.000119 Salmonella-induced pyroptosis / / 22837397 rs7937848 chr11 123722392 A G 3.36E-04 Type 2 diabetes / / 17463246 rs12283877 chr11 123723946 C T 3.88E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs948159 chr11 123733108 G A 0.000103 Salmonella-induced pyroptosis / / 22837397 rs7951825 chr11 123734583 T C 8.90E-04 Alzheimer's disease / / 17998437 rs7951825 chr11 123734583 T C 2.10E-09 Triglycerides / / 19074352 rs4936856 chr11 123742298 C A 0.0000947 Salmonella-induced pyroptosis / / 22837397 rs4936856 chr11 123742298 C A 4.99E-04 Tourette syndrome / / 22889924 rs12273131 chr11 123742913 C T 3.14E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs7124726 chr11 123747350 A T 3.33E-04 Type 2 diabetes / / 17463246 rs2015232 chr11 123747593 G A 0.000000055 Mean arterial pressure / / 22510845 rs11219333 chr11 123747790 A T 3.47E-04 Type 2 diabetes / / 17463246 rs12280105 chr11 123751828 G A 3.00E-06 Oleic acid (18:1n-9) plasma levels / / 23362303 rs10502283 chr11 123753265 T C 0.0000985 Salmonella-induced pyroptosis / / 22837397 rs728177 chr11 123755719 G T 3.00E-05 Iron levels TMEM225 intron 21208937 rs10502281 chr11 123756623 C A 2.39E-04 Multiple complex diseases / / 17554300 rs7941883 chr11 123756885 C G 3.00E-05 Obesity-related traits / / 17903300 rs7131308 chr11 123762718 T G 7.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7131308 chr11 123762718 T G 0.000038 Salmonella-induced pyroptosis / / 22837397 rs7114772 chr11 123768313 A T 1.00E-05 Urinary metabolites / / 21572414 rs2315027 chr11 123770186 A G 1.02E-06 Nephrolithiasis / / 22396660 rs7925715 chr11 123780926 T A 9.57E-04 Multiple complex diseases / / 17554300 rs10893105 chr11 123792642 T A 7.08E-04 Alzheimer's disease / / 22005930 rs10893106 chr11 123794954 A G 7.04E-04 Alzheimer's disease / / 22005930 rs17684986 chr11 123797120 T A 6.74E-04 Alzheimer's disease / / 22005930 rs12099152 chr11 123798908 C G 6.50E-04 Alzheimer's disease / / 22005930 rs1377606 chr11 123802845 T C 9.42E-04 Type 2 diabetes / / 17463246 rs4936859 chr11 123814489 A G 5.20E-05 Iron levels OR6T1 cds-synon 21208937 rs4936859 chr11 123814489 A G 6.18E-04 Alzheimer's disease OR6T1 cds-synon 22005930 rs4936863 chr11 123826565 T A 6.50E-04 Alzheimer's disease / / 22005930 rs7114486 chr11 123828187 C A 6.55E-04 Alzheimer's disease / / 22005930 rs7943298 chr11 123833301 T C 7.12E-04 Alzheimer's disease / / 22005930 rs763640 chr11 123846833 C G 5.66E-04 Type 2 diabetes / / 17463246 rs10893117 chr11 123847392 G C 7.19E-04 Alzheimer's disease / / 22005930 rs10893118 chr11 123848982 A C 4.85E-04 Alzheimer's disease / / 22005930 rs10893119 chr11 123849258 A T 5.91E-04 Alzheimer's disease / / 22005930 rs11219389 chr11 123852381 C T 1.64E-04 Alzheimer's disease / / 22005930 rs11530582 chr11 123853970 G A 5.95E-04 Alzheimer's disease / / 22005930 rs10893123 chr11 123861875 C G 6.95E-04 Alzheimer's disease / / 22005930 rs10790620 chr11 123863989 C T 8.56E-04 Alzheimer's disease / / 22005930 rs1453654 chr11 123864216 T C 0.000000141 Secreted IFN-gamma response to smallpox vaccine / / 22661280 rs10790622 chr11 123865305 G A 9.35E-04 Alzheimer's disease / / 22005930 rs17687161 chr11 123874283 G A 4.60E-06 Urinary metabolites / / 21572414 rs17128126 chr11 123880596 C T 2.90E-06 Urinary metabolites / / 21572414 rs6590033 chr11 123882818 G A 1.30E-05 Urinary metabolites / / 21572414 rs10893128 chr11 123890745 C T 7.96E-04 Alzheimer's disease / / 22005930 rs2076941 chr11 123893286 C T 5.91E-04 Alzheimer's disease / / 22005930 rs11219413 chr11 123894234 A G 8.59E-04 Alzheimer's disease OR10G9 missense 22005930 rs4936891 chr11 123920645 G C 8.62E-06 Male fertility / / 22633400 rs589600 chr11 123939207 G T 1.37E-04 Coronary heart disease / / 21971053 rs11219435 chr11 123941586 T C 4.96E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs651739 chr11 123942501 A G 5.62E-04 Coronary heart disease / / 21971053 rs3741110 chr11 123947587 A G 8.79E-04 Coronary heart disease / / 21971053 rs488582 chr11 123955625 T C 5.69E-04 Nicotine dependence / / 17158188 rs638299 chr11 123956395 A C 1.85E-04 Nicotine dependence / / 17158188 rs1893767 chr11 123956466 A G 4.00E-06 Obesity-related traits / / 23251661 rs1893767 chr11 123956466 A G 9.00E-06 Obesity-related traits / / 23251661 rs526257 chr11 123962800 G A 4.98E-04 Nicotine dependence / / 17158188 rs540370 chr11 123965631 G A 6.70E-05 HIV-1 control / / 20041166 rs565947 chr11 123966117 A G 9.00E-05 HIV-1 control / / 20041166 rs569689 chr11 123966514 T C 3.72E-04 Coronary heart disease / / 21971053 rs58908941 chr11 123976067 T G 1.33E-04 Acne (severe) / / 24927181 rs1939847 chr11 123983579 T C 3.74E-05 Cholesterol / / pha003073 rs1939847 chr11 123983579 T C 6.17E-05 Cholesterol / / pha003078 rs10790633 chr11 123984040 G A 7.50E-04 Multiple complex diseases / / 17554300 rs880321 chr11 123994008 T C 6.40E-04 Parkinson's disease VWA5A intron 17052657 rs2276051 chr11 124012631 A G 3.36E-04 Alzheimer's disease (late onset) VWA5A intron 21379329 rs4936894 chr11 124017493 G A 2.00E-06 Aging (time to death) VWA5A UTR-3 21782286 rs11440 chr11 124017563 C G 4.90E-05 Lipid traits VWA5A UTR-3 24386095 rs12417948 chr11 124060875 C T 8.30E-05 HIV-1 control / / 20041166 rs12417948 chr11 124060875 C T 3.50E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4935872 chr11 124075995 A G 1.86E-04 Smoking cessation / / 18519826 rs4936911 chr11 124076220 G C 1.38E-05 Smoking cessation / / 18519826 rs10893162 chr11 124076269 G A 9.02E-07 Smoking cessation / / 18519826 rs10893168 chr11 124079739 A C,T 6.11E-05 Smoking cessation / / 18519826 rs2508888 chr11 124082810 T G 4.26E-05 Height / / 22021425 rs2508889 chr11 124085046 T G 6.31E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2512284 chr11 124086422 G A 9.33E-05 Smoking cessation / / 18519826 rs2512284 chr11 124086422 G A 8.53E-04 Coronary heart disease / / 21606135 rs2466616 chr11 124094817 A G 2.97E-04 Alzheimer's disease (late onset) / / 21379329 rs2466605 chr11 124100246 C T 1.41E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2512167 chr11 124135438 G A 1.85E-04 Amyotrophic Lateral Sclerosis OR8G5 missense 17362836 rs2466627 chr11 124155409 G T 4.68E-05 Height / / 22021425 rs2466625 chr11 124164891 A T 2.35E-05 Height / / 22021425 rs11602188 chr11 124167145 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs10893205 chr11 124172565 C T 3.08E-06 Smoking cessation / / 18519826 rs10893206 chr11 124174874 C T 1.98E-04 Smoking cessation / / 18519826 rs7107539 chr11 124180282 A C 2.35E-04 Smoking cessation OR8D1 missense 18519826 rs539802 chr11 124199865 C T 6.69E-05 Prion diseases / / 22210626 rs666135 chr11 124208977 A G 6.20E-05 Prion diseases / / 22210626 rs613207 chr11 124225191 G A 6.09E-05 Prion diseases / / 22210626 rs2428301 chr11 124229916 T G 9.50E-05 Prion diseases / / 22210626 rs546658 chr11 124234228 A C 5.69E-05 Prion diseases / / 22210626 rs617909 chr11 124245050 G A 2.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs538032 chr11 124247361 C T 2.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3867247 chr11 124278130 G A 2.00E-05 Height / / pha003010 rs1893705 chr11 124295382 C T 8.57E-05 Height / / pha003010 rs2298509 chr11 124341985 A G 9.05E-04 Heart Failure / / pha002884 rs4296050 chr11 124386472 A G 4.58E-05 Serum metabolites / / 19043545 rs1942668 chr11 124400611 C T 9.99E-05 Body Mass Index / / pha003009 rs948725 chr11 124409935 G A 1.17E-04 Osteoarthritis / / 19508968 rs948725 chr11 124409935 G A 2.04E-04 Breast cancer / / pha002853 rs7111254 chr11 124416606 A C 3.89E-05 Cognitive performance / / 19734545 rs2187149 chr11 124432323 A G 2.57E-04 Osteoarthritis / / 19508968 rs12792184 chr11 124440617 C T 5.94E-05 Osteoarthritis OR8A1 missense 19508968 rs12792184 chr11 124440617 C T 8.30E-05 Information processing speed OR8A1 missense 21130836 rs12792184 chr11 124440617 C T 7.08E-05 Breast cancer OR8A1 missense pha002853 rs2187151 chr11 124446801 G T 8.40E-05 Information processing speed / / 21130836 rs7926263 chr11 124452268 G C 5.63E-04 Alzheimer's disease / / 17998437 rs10893276 chr11 124452329 C T 1.10E-05 Urinary metabolites / / 21572414 rs7127399 chr11 124461274 G A 2.24E-05 Sickle cell anemia (severity) / / 20029952 rs11219743 chr11 124522720 T C 6.11E-04 Aortic root size SIAE intron 21223598 rs7124585 chr11 124532440 G A 1.00E-04 Cognitive impairment induced by topiramate SIAE intron 22091778 rs544368 chr11 124537995 T C 2.49E-05 Multiple complex diseases SIAE intron 17554300 rs544368 chr11 124537995 T C 6.00E-06 Bipolar disorder SIAE intron 18711365 rs544368 chr11 124537995 T C 3.90E-05 Bipolar disorder and major depressive disorder (combined) SIAE intron 20351715 rs12282107 chr11 124539273 T C 5.00E-14 Metabolite levels SIAE missense 24625756 rs1784539 chr11 124574228 T C 9.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs1784539 chr11 124574228 T C 1.25E-06 Common variable immunodeficiency / / 21497890 rs1784531 chr11 124588798 T A 4.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs671371 chr11 124590079 G T 3.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs570375 chr11 124592879 A G 3.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs12807809 chr11 124606285 T C 2.00E-09 Schizophrenia / / 19571808 rs12807809 chr11 124606285 T C 2.80E-09 Schizophrenia / / 21791550 rs12807809 chr11 124606285 T C 2.40E-09 Schizophrenia (treatment refractory) / / 22479419 rs12807809 chr11 124606285 T C 0.00034 Schizophrenia / / 23164818 rs12807809 chr11 124606285 T C 3.50E-11 Psychosis / / 23164818 rs2075713 chr11 124617939 A C 0.000698 Salmonella-induced pyroptosis VSIG2 intron 22837397 rs11219769 chr11 124620147 G T 2.10E-04 Systemic lupus erythematosus(serologic and cytokine profiles in serum) VSIG2 intron 20659327 rs485469 chr11 124657183 T C 5.58E-06 Basophils MSANTD2 intron pha003087 rs653403 chr11 124696291 T A 8.50E-04 Multiple complex diseases / / 17554300 rs610104 chr11 124708698 A G 5.08E-06 Cognitive impairment induced by topiramate / / 22091778 rs610104 chr11 124708698 A G 7.13E-05 Cognitive impairment induced by topiramate / / 22091778 rs11604758 chr11 124721003 G A 7.82E-04 Multiple complex diseases / / 17554300 rs4606490 chr11 124742731 C T 7.62E-05 Amyotrophic lateral sclerosis ROBO3 intron 23624525 rs144055440 chr11 124742934 C A,T 0.00018 Breast cancer ROBO3 missense 23555315 rs4245058 chr11 124759342 T C 6.41E-05 Cognitive impairment induced by topiramate ROBO4 intron 22091778 rs11219831 chr11 124762769 A G 2.45E-04 Blood pressure ROBO4 intron 17255346 rs12421354 chr11 124765168 C T 9.86E-05 Prostate cancer ROBO4 intron pha002878 rs10790716 chr11 124793716 G A 4.07E-04 Aortic root size HEPACAM cds-synon 21223598 rs10893305 chr11 124796696 A G 4.31E-05 Type 2 diabetes HEPACAM intron 17463246 rs7130442 chr11 124798250 G T 1.19E-05 Type 2 diabetes HEPACAM intron 17463246 rs4254088 chr11 124805619 T C 5.14E-05 Cognitive impairment induced by topiramate HEPACAM intron 22091778 rs7937347 chr11 124814152 C T 4.46E-05 Cognitive impairment induced by topiramate / / 22091778 rs4408325 chr11 124821575 T A 1.00E-07 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs4575285 chr11 124822169 C G 4.90E-06 Triglycerides / / 19074352 rs4936963 chr11 124823305 A C 1.57E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs4612816 chr11 124874382 G A 1.85E-04 Amyotrophic lateral sclerosis (sporadic) CCDC15 intron 24529757 rs7103312 chr11 124916597 C T 2.60E-05 Urinary metabolites / / 21572414 rs3802806 chr11 124923107 C T 2.40E-05 Urinary metabolites / / 21572414 rs7938776 chr11 124950159 C G 3.52E-04 Suicide attempts in bipolar disorder SLC37A2 intron 21423239 rs6590126 chr11 124957465 T C 1.33E-04 Multiple complex diseases SLC37A2 intron 17554300 rs608393 chr11 124988516 G A 3.15E-05 Lung adenocarcinoma / / 19836008 rs10893331 chr11 124993187 A G 7.26E-05 Lung adenocarcinoma / / 19836008 rs10893331 chr11 124993187 A G 3.34E-05 Height / / 22021425 rs10893332 chr11 124995104 C T 5.29E-05 Lung adenocarcinoma / / 19836008 rs10893332 chr11 124995104 C T 6.70E-04 Alcohol dependence / / 20201924 rs597900 chr11 124997521 C T 3.30E-05 Lung adenocarcinoma / / 19836008 rs597900 chr11 124997521 C T 2.80E-04 Alcohol dependence / / 20201924 rs585977 chr11 125001843 G A 1.47E-05 Lung adenocarcinoma / / 19836008 rs585977 chr11 125001843 G A 6.20E-05 Alcohol dependence / / 20201924 rs585977 chr11 125001843 G A 6.15E-05 Alcoholism / / pha002892 rs601813 chr11 125006353 A G 3.20E-04 Alcohol dependence / / 20201924 rs7929346 chr11 125024925 G A 1.32E-08 Multiple complex diseases / / 17554300 rs590211 chr11 125053634 A G 1.31E-04 Longevity PKNOX2 intron 22279548 rs631953 chr11 125069793 G A 8.48E-04 Multiple complex diseases PKNOX2 intron 17554300 rs685664 chr11 125071672 T C 9.78E-04 Multiple complex diseases PKNOX2 intron 17554300 rs10893349 chr11 125075915 G T 8.99E-06 Hearing function PKNOX2 intron 21493956 rs10790728 chr11 125078011 T C 8.91E-06 Hearing function PKNOX2 intron 21493956 rs11219971 chr11 125079282 T C 5.35E-06 Hearing function PKNOX2 intron 21493956 rs658641 chr11 125079694 G C 4.46E-04 Multiple complex diseases PKNOX2 intron 17554300 rs10790729 chr11 125100122 T C 5.96E-07 Hearing function PKNOX2 intron 21493956 rs11219981 chr11 125109627 G A 2.86E-07 Hearing function PKNOX2 intron 21493956 rs10893354 chr11 125113503 G A 4.11E-04 Multiple complex diseases PKNOX2 intron 17554300 rs10893356 chr11 125117108 G C 4.23E-04 Multiple complex diseases PKNOX2 intron 17554300 rs12577901 chr11 125123425 T C 2.85E-04 Lung function (forced expiratory volume in 1 second) PKNOX2 intron 17255346 rs12274979 chr11 125124001 A G 3.97E-04 Multiple complex diseases PKNOX2 intron 17554300 rs12288391 chr11 125124082 G A 2.70E-04 Multiple complex diseases PKNOX2 intron 17554300 rs10893363 chr11 125165779 A G 7.16E-05 Male fertility PKNOX2 intron 22633400 rs1426153 chr11 125170639 A G 1.01E-05 Alcohol dependence PKNOX2 intron 21703634 rs1426153 chr11 125170639 A G 2.00E-06 Alcohol and nictotine co-dependence PKNOX2 intron 22488850 rs11220015 chr11 125171374 G A 3.66E-05 Alcohol dependence PKNOX2 intron 21703634 rs11602925 chr11 125171431 A G 2.31E-05 Alcohol dependence PKNOX2 intron 21703634 rs750338 chr11 125172593 A G 2.39E-06 Alcohol dependence PKNOX2 intron 20202923 rs750338 chr11 125172593 A G 1.00E-06 Alcohol dependence PKNOX2 intron 21703634 rs750338 chr11 125172593 A G 7.50E-06 Alcohol dependence PKNOX2 intron 21956439 rs750338 chr11 125172593 A G 1.60E-07 Alcohol and nictotine co-dependence PKNOX2 intron 22488850 rs2005404 chr11 125173980 G A 6.35E-04 Multiple complex diseases PKNOX2 intron 17554300 rs12792626 chr11 125174570 C T 0.00088 Endometrial cancer PKNOX2 intron 22426144 rs10893365 chr11 125176437 T C 9.55E-06 Alcohol dependence PKNOX2 intron 21703634 rs10893365 chr11 125176437 T C 3.60E-05 Alcohol dependence PKNOX2 intron 21956439 rs10893366 chr11 125178403 C T 1.61E-05 Alcohol dependence PKNOX2 intron 21703634 rs10893366 chr11 125178403 C T 8.00E-06 Alcohol dependence PKNOX2 intron 21956439 rs10893366 chr11 125178403 C T 4.20E-06 Alcohol and nictotine co-dependence PKNOX2 intron 22488850 rs12284594 chr11 125179853 A G 8.12E-06 Alcohol dependence PKNOX2 intron 20202923 rs12284594 chr11 125179853 A G 7.00E-08 Substance dependence PKNOX2 intron 21298047 rs12284594 chr11 125179853 A G 6.53E-06 Alcohol dependence PKNOX2 intron 21703634 rs12284594 chr11 125179853 A G 9.70E-04 Alcohol dependence PKNOX2 intron 21956439 rs11220020 chr11 125183480 G A 4.00E-04 Multiple complex diseases PKNOX2 intron 17554300 rs1035791 chr11 125192281 C T 1.56E-04 Multiple complex diseases PKNOX2 intron 17554300 rs4935918 chr11 125200247 A G 6.17E-04 Multiple complex diseases PKNOX2 intron 17554300 rs12360927 chr11 125204253 G A 1.70E-06 Urinary metabolites PKNOX2 intron 21572414 rs12273350 chr11 125241046 G A 2.00E-06 Creutzfeldt-Jakob disease (variant) PKNOX2 intron 22137330 rs11220043 chr11 125257848 G A 2.22E-04 Cholesterol PKNOX2 intron 17255346 rs3740898 chr11 125275857 G T 4.52E-05 HIV-1 viral setpoint PKNOX2 intron 22174851 rs7112365 chr11 125277494 C T 7.50E-05 Response to lithium treatment in bipolar disorder PKNOX2 intron 19448189 rs7112365 chr11 125277494 C T 2.00E-06 Obesity-related traits PKNOX2 intron 23251661 rs597432 chr11 125291160 A G 8.43E-04 Type 2 diabetes PKNOX2 intron 17463246 rs1783925 chr11 125304009 A G 4.00E-07 Formal thought disorder in schizophrenia / / 22648509 rs1615640 chr11 125308076 G C 1.08E-06 Formal thought disorder in schizophrenia / / 22648509 rs614910 chr11 125311492 T A 2.15E-04 Multiple complex diseases / / 17554300 rs7930295 chr11 125313599 A G 3.00E-06 Schizophrenia / / 23894747 rs11220082 chr11 125323965 C T 2.57E-07 Schizophrenia FEZ1 intron 21926974 rs11220082 chr11 125323965 C T 7.00E-07 Schizophrenia FEZ1 intron 22688191 rs4344501 chr11 125383747 G A 1.42E-04 Multiple complex diseases / / 17554300 rs11501211 chr11 125425773 C T 4.55E-04 Insulin resistance / / 21901158 rs1002777 chr11 125444604 C T 6.50E-05 Triglycerides EI24 intron 19074352 rs548181 chr11 125461709 A G 1.00E-06 Schizophrenia / / 21926974 rs548181 chr11 125461709 A G 9.00E-07 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs12280233 chr11 125469264 T G 9.54E-04 Insulin resistance STT3A intron 21901158 rs12289897 chr11 125483885 G A 2.68E-05 Type 2 diabetes STT3A intron 17463246 rs3731399 chr11 125497247 T C 9.64E-05 Schizophrenia CHEK1 intron 20832056 rs3731440 chr11 125511917 G A 8.25E-04 Type 2 diabetes CHEK1 intron 17463246 rs11220184 chr11 125551608 G T 9.07E-05 Cognitive performance / / 19734545 rs519413 chr11 125569646 G A 3.35E-04 Type 2 diabetes / / 17463246 rs7924417 chr11 125588691 A C 7.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1365080 chr11 125603535 A C 2.90E-05 HIV-1 control / / 20041166 rs1056417 chr11 125619578 G T 9.10E-05 HIV-1 control PATE1 UTR-3 20041166 rs519297 chr11 125635411 G C 9.70E-05 Triglycerides / / 19074352 rs1425839 chr11 125640858 G C 4.70E-06 Urinary metabolites / / 21572414 rs10893425 chr11 125645229 T C 2.40E-05 Urinary metabolites / / 21572414 rs7950427 chr11 125661622 T C 6.98E-04 Obesity (extreme) / / 21935397 rs7929262 chr11 125678171 A T 4.37E-04 Suicide attempts in bipolar disorder / / 21041247 rs540225 chr11 125753360 T C 3.89E-04 Suicide attempts in bipolar disorder HYLS1 nearGene-5 21041247 rs516482 chr11 125788985 G A 1.10E-09 Multiple complex diseases DDX25 intron 17554300 rs12281146 chr11 125795859 T C 4.00E-04 Insulin resistance / / 21901158 rs2471480 chr11 125809627 T C 1.90E-05 Urinary metabolites / / 21572414 rs10893450 chr11 125818754 C G 9.90E-06 Triglycerides LOC338667 intron 19074352 rs4937076 chr11 125826702 G A 3.10E-05 Primary tooth development (number of teeth) LOC338667 cds-synon 23704328 rs4937076 chr11 125826702 G A 4.00E-08 Primary tooth development (time to first tooth eruption) LOC338667 cds-synon 23704328 rs11220301 chr11 125852273 C T 4.90E-05 Triglycerides CDON intron 19074352 rs7925077 chr11 125860161 G T 7.78E-04 Smoking quantity CDON intron 24665060 rs2298477 chr11 125864537 C T 2.87E-04 Smoking quantity CDON intron 24665060 rs7104745 chr11 125873102 G A 6.00E-06 Breast size CDON intron 22747683 rs472926 chr11 125905258 C T 3.00E-06 Alzheimer's disease (late onset) CDON intron 22881374 rs2043438 chr11 125930405 T C 2.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDON intron 20877124 rs564327 chr11 125937383 T C 9.29E-05 Post-operative nausea and vomiting / / 21694509 rs472559 chr11 125949919 T C 8.23E-04 Multiple complex diseases / / 17554300 rs472559 chr11 125949919 T C 6.55E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs17135097 chr11 125970366 G A 1.83E-05 Heart Rate / / pha003051 rs17135097 chr11 125970366 G A 4.53E-07 Heart Rate / / pha003054 rs545830 chr11 125974071 C T 3.44E-04 Multiple complex diseases / / 17554300 rs681223 chr11 125975854 G A 8.64E-05 Heart Rate / / pha003051 rs681223 chr11 125975854 G A 3.30E-06 Heart Rate / / pha003054 rs684407 chr11 125976526 C T 6.32E-05 Heart Rate / / pha003054 rs533239 chr11 125984426 A G 4.83E-04 Myopia (pathological) / / 21095009 rs17460223 chr11 125991298 G A 2.55E-04 Type 2 diabetes / / 17463246 rs556645 chr11 126009142 T C 6.57E-05 HDL cholesterol / / pha003075 rs556645 chr11 126009142 T C 6.60E-05 Lipid levels / / pha003082 rs541601 chr11 126009500 T C 1.10E-05 Urinary metabolites / / 21572414 rs541601 chr11 126009500 T C 8.95E-05 HDL cholesterol / / pha003075 rs7129706 chr11 126023487 T C 1.50E-05 Urinary metabolites / / 21572414 rs4937107 chr11 126024533 A G 8.50E-06 Urinary metabolites / / 21572414 rs7126503 chr11 126026304 G C 9.23E-13 Metabolite levels / / 22286219 rs3133084 chr11 126027473 A G 3.53E-05 Lipid levels / / pha003082 rs563519 chr11 126028717 T C 3.00E-06 Heart failure / / 20445134 rs10501858 chr11 126030615 G A 1.00E-06 Estradiol plasma levels (breast cancer) / / 23518928 rs732431 chr11 126032739 G A 4.35E-04 Multiple complex diseases / / 17554300 rs547991 chr11 126052497 A G 2.45E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs562731 chr11 126057344 A G 4.52E-05 Bipolar disorder / / 20451256 rs686646 chr11 126059422 A C 5.18E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs681664 chr11 126060838 C T 5.18E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9326282 chr11 126066224 G A 3.42E-04 Depression (quantitative trait) / / 20800221 rs547862 chr11 126082661 C T 7.73E-04 Coronary heart disease FAM118B intron 21971053 rs512577 chr11 126091941 C T 4.27E-06 Longevity,exceptional FAM118B intron 20595579 rs2298452 chr11 126142764 C T 1.85E-05 Lymphocyte counts FOXRED1 intron 22286170 rs655540 chr11 126151242 T C 4.34E-05 adolescent idiopathic scoliosis TIRAP nearGene-5 24023777 rs8177358 chr11 126155724 C T 3.61E-22 Triglycerides TIRAP intron 23063622 rs8177358 chr11 126155724 C T 4.59E-09 HDL cholesterol TIRAP intron 23063622 rs7932976 chr11 126162893 G A 8.98E-09 LDL cholesterol TIRAP missense 23063622 rs684687 chr11 126183594 A T 4.00E-05 Response to statin therapy DCPS intron 20339536 rs683800 chr11 126183756 T C 4.00E-05 Response to statin therapy DCPS intron 20339536 rs683800 chr11 126183756 T C 0.000146 Coronary artery disease DCPS intron 23202125 rs685903 chr11 126187837 T C 1.40E-05 Response to statin therapy DCPS intron 20339536 rs651922 chr11 126201290 A G 4.75E-05 Longevity DCPS intron 22279548 rs646358 chr11 126204161 C T 4.85E-04 Type 2 diabetes DCPS intron 17463246 rs646358 chr11 126204161 C T 4.65E-06 Lymphocyte counts DCPS intron 22286170 rs77137587 chr11 126228258 A T 4.00E-04 Polycystic ovary syndrome ST3GAL4 intron 22178785 rs77685025 chr11 126230844 G A 5.00E-04 Polycystic ovary syndrome ST3GAL4 intron 22178785 rs78287793 chr11 126240911 A G 5.00E-04 Polycystic ovary syndrome ST3GAL4 intron 22178785 rs11220462 chr11 126243952 G A 1.00E-15 LDL cholesterol ST3GAL4 intron 20686565 rs11220462 chr11 126243952 G A 2.00E-11 Cholesterol,total ST3GAL4 intron 20686565 rs11220462 chr11 126243952 G A 6.00E-15 Cholesterol,total ST3GAL4 intron 24097068 rs11220462 chr11 126243952 G A 7.00E-21 LDL cholesterol ST3GAL4 intron 24097068 rs77951192 chr11 126263947 A C 5.00E-04 Polycystic ovary syndrome ST3GAL4 intron 22178785 rs11220477 chr11 126275402 C T 4.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ST3GAL4 intron 20877124 rs4937126 chr11 126281897 G A 5.00E-06 Coronary heart disease ST3GAL4 intron 21378990 rs2236653 chr11 126283785 C T 2.00E-09 Liver enzyme levels (alkaline phosphatase) ST3GAL4 intron 22001757 rs948054 chr11 126293188 G T 2.02E-04 Self-reported allergy KIRREL3 nearGene-3 23817569 rs752805 chr11 126293285 A T 1.60E-06 Chronic kidney disease KIRREL3 nearGene-3 22479191 rs7113465 chr11 126294088 C T 1.49E-04 HIV-1 viral setpoint KIRREL3 UTR-3 17641165 rs4935969 chr11 126296589 C T 4.00E-07 Hair color KIRREL3 intron 20585627 rs4935969 chr11 126296589 C T 1.89E-04 Attention deficit hyperactivity disorder KIRREL3 intron pha002875 rs11605349 chr11 126305755 T C 4.29E-04 Multiple complex diseases KIRREL3 intron 17554300 rs3802821 chr11 126315213 A G 6.85E-04 Taste perception KIRREL3 intron 22132133 rs4294574 chr11 126315727 T C 8.67E-04 Multiple complex diseases KIRREL3 intron 17554300 rs12801239 chr11 126323328 T C 3.20E-05 Bladder cancer KIRREL3 intron 19648920 rs12801239 chr11 126323328 T C 4.19E-06 Magnesium levels KIRREL3 intron pha003092 rs12577641 chr11 126323337 C G 7.59E-04 Obesity (extreme) KIRREL3 intron 21935397 rs11220503 chr11 126332878 C T 4.57E-04 Obesity (extreme) KIRREL3 intron 21935397 rs11220504 chr11 126334745 T C 3.10E-04 Obesity (extreme) KIRREL3 intron 21935397 rs11220506 chr11 126335329 G A 4.07E-04 Obesity (extreme) KIRREL3 intron 21935397 rs10893512 chr11 126337291 T C 4.63E-05 Epilepsy (remission after treatment) KIRREL3 intron 23962720 rs11220516 chr11 126349968 C T 7.88E-05 Body Mass Index KIRREL3 intron pha003009 rs11220520 chr11 126357908 C T 6.58E-04 Multiple complex diseases KIRREL3 intron 17554300 rs10893525 chr11 126359805 C T 8.07E-05 HDL cholesterol KIRREL3 intron pha003075 rs1000255 chr11 126360525 G A 2.00E-04 Cognitive impairment induced by topiramate KIRREL3 intron 22091778 rs7127176 chr11 126369168 T C 2.00E-04 Cognitive impairment induced by topiramate KIRREL3 intron 22091778 rs7941193 chr11 126370843 G A 3.26E-07 Osteoarthritis KIRREL3 intron 22763110 rs10128646 chr11 126371892 A G 4.50E-07 Urinary metabolites KIRREL3 intron 21572414 rs4519108 chr11 126383237 C T 8.66E-05 Serum metabolites KIRREL3 intron 19043545 rs1784230 chr11 126401845 G A 3.95E-05 Type 2 diabetes KIRREL3 intron 17463246 rs1784232 chr11 126408381 T A 1.40E-04 Type 2 diabetes KIRREL3 intron 17463246 rs599561 chr11 126408604 A C 1.56E-04 Type 2 diabetes KIRREL3 intron 17463246 rs10893538 chr11 126422370 G A 4.28E-05 Caffeine consumption KIRREL3 intron 21490707 rs11824491 chr11 126430913 A G 1.07E-04 Smoking initiation KIRREL3 intron 24665060 rs12574555 chr11 126458263 T G 9.90E-06 Urinary metabolites KIRREL3 intron 21572414 rs541969 chr11 126459999 T C 2.10E-05 Urinary metabolites KIRREL3 intron 21572414 rs10893545 chr11 126466129 T C 1.70E-05 Urinary metabolites KIRREL3 intron 21572414 rs12575184 chr11 126469802 C T 1.20E-05 Urinary metabolites KIRREL3 intron 21572414 rs10893546 chr11 126473234 C T 9.20E-06 Urinary metabolites KIRREL3 intron 21572414 rs483027 chr11 126474428 C A 1.72E-04 Acute lung injury KIRREL3 intron 22295056 rs493725 chr11 126480356 C T 2.79E-05 Gallbladder cancer KIRREL3 intron 22318345 rs693253 chr11 126527765 A G 3.58E-05 Serum metabolites KIRREL3 intron 19043545 rs7950175 chr11 126528035 C T 1.90E-06 Type 2 diabetes KIRREL3 intron 17293876 rs7950175 chr11 126528035 C T 1.90E-06 Type 2 diabetes KIRREL3 intron 19184112 rs2874773 chr11 126553649 A T 9.66E-04 Alzheimer's disease KIRREL3 intron 17998437 rs11220583 chr11 126560619 C T 8.22E-05 Serum metabolites KIRREL3 intron 19043545 rs10790822 chr11 126583997 A G 9.03E-04 Type 2 diabetes KIRREL3 intron 17463246 rs7946234 chr11 126591869 G C 4.30E-05 White matter hyperintensity burden KIRREL3 intron 21681796 rs7933188 chr11 126592268 T C 1.17E-04 Type 2 diabetes KIRREL3 intron 17463246 rs7929968 chr11 126594924 G A 5.40E-05 White matter hyperintensity burden KIRREL3 intron 21681796 rs4356239 chr11 126596730 A T 7.00E-05 White matter hyperintensity burden KIRREL3 intron 21681796 rs11220594 chr11 126601132 C T 0.0002 Migraine KIRREL3 intron 22678113 rs3862642 chr11 126605034 T C 4.97E-06 Menarche (age at onset) KIRREL3 intron 23667675 rs7114000 chr11 126607580 A G 2.00E-06 Menarche (age at onset) KIRREL3 intron 23667675 rs3862645 chr11 126608446 G A 2.07E-06 Menarche (age at onset) KIRREL3 intron 23667675 rs3889461 chr11 126608705 T C 5.98E-06 Menarche (age at onset) KIRREL3 intron 23667675 rs1106420 chr11 126609067 A T 4.39E-05 Depression (quantitative trait) KIRREL3 intron 23290196 rs1106419 chr11 126609087 G A 3.12E-06 Menarche (age at onset) KIRREL3 intron 23667675 rs7131312 chr11 126611548 G A 0.00000226 HDL cholesterol particle diameter KIRREL3 intron 23263444 rs13377256 chr11 126618378 T C 0.00000614 HDL cholesterol particle diameter KIRREL3 intron 23263444 rs1557488 chr11 126619190 T C 5.00E-06 Attention deficit hyperactivity disorder and conduct disorder KIRREL3 intron 18951430 rs1557488 chr11 126619190 T C 7.69E-04 Heart Failure KIRREL3 intron pha002884 rs7350493 chr11 126619671 A G 0.000006 HDL cholesterol particle diameter KIRREL3 intron 23263444 rs12361044 chr11 126621535 G A 0.00000594 HDL cholesterol particle diameter KIRREL3 intron 23263444 rs11220599 chr11 126622933 A G 0.0000134 HDL cholesterol particle diameter KIRREL3 intron 23263444 rs10893564 chr11 126626689 A G 0.0000116 HDL cholesterol particle diameter KIRREL3 intron 23263444 rs10790835 chr11 126676389 G C 3.94E-04 Type 2 diabetes KIRREL3 intron 17463246 rs1106805 chr11 126689554 G T 3.34E-04 Type 2 diabetes KIRREL3 intron 17463246 rs1946065 chr11 126695147 C A 8.51E-04 Heart Failure KIRREL3 intron pha002884 rs7129447 chr11 126711088 G A 8.52E-04 Heart Failure KIRREL3 intron pha002884 rs9888281 chr11 126731851 A C 6.39E-04 Type 2 diabetes KIRREL3 intron 17463246 rs4936001 chr11 126735963 G A 3.79E-04 Heart Failure KIRREL3 intron pha002884 rs1540252 chr11 126752932 C T 9.31E-04 Type 2 diabetes KIRREL3 intron 17463246 rs4936003 chr11 126753631 T C 4.20E-05 Atopy KIRREL3 intron 21094521 rs4936003 chr11 126753631 T C 7.33E-04 Atopy KIRREL3 intron 21094521 rs4937216 chr11 126768090 G A 8.70E-05 Type 2 diabetes KIRREL3 intron 17463246 rs1940001 chr11 126771801 C T 2.40E-05 Type 2 diabetes KIRREL3 intron 17463246 rs1793660 chr11 126788587 A G 3.60E-06 Primary sclerosing cholangitis KIRREL3 intron 21151127 rs1793675 chr11 126808123 A G 2.50E-06 Urinary metabolites KIRREL3 intron 21572414 rs1939992 chr11 126809705 T C 1.00E-06 Protein quantitative trait loci KIRREL3 intron 18464913 rs1784327 chr11 126812820 G A 1.20E-06 Urinary metabolites KIRREL3 intron 21572414 rs1784330 chr11 126815725 C A 5.60E-07 Urinary metabolites KIRREL3 intron 21572414 rs1784331 chr11 126816941 A C 6.00E-07 Urinary metabolites KIRREL3 intron 21572414 rs1793671 chr11 126823541 C A 6.00E-07 Urinary metabolites KIRREL3 intron 21572414 rs606845 chr11 126835640 C T 8.20E-07 Urinary metabolites KIRREL3 intron 21572414 rs1939995 chr11 126850849 G C 7.30E-05 Hypothyroidism KIRREL3 intron 22493691 rs646236 chr11 126851452 G A 6.26E-04 Type 2 diabetes KIRREL3 intron 17463246 rs669765 chr11 126858161 T C 9.00E-04 Multiple complex diseases KIRREL3 intron 17554300 rs669765 chr11 126858161 T C 4.69E-04 Response to statin treatment (atorvastatin),change in cholesterol levels KIRREL3 intron 20031582 rs620875 chr11 126859157 A C 5.74E-04 Type 2 diabetes KIRREL3 intron 17463246 rs620875 chr11 126859157 A C 3.00E-06 Response to antipsychotic treatment KIRREL3 intron 20195266 rs488054 chr11 126864394 G A,C,T 1.59E-04 Type 2 diabetes KIRREL3 intron 17463246 rs11220704 chr11 126880301 G C 9.50E-04 Acute lymphoblastic leukemia (childhood) / / 22076464 rs1287146 chr11 126884015 T C 6.00E-05 Prostate cancer / / 21743057 rs11220727 chr11 126900993 C T 1.30E-05 Urinary metabolites / / 21572414 rs715364 chr11 126953493 C T 6.06E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11220802 chr11 127013810 T C 8.40E-04 Multiple complex diseases / / 17554300 rs11220804 chr11 127013891 T A 6.26E-04 Multiple complex diseases / / 17554300 rs1944837 chr11 127031672 G C 1.00E-04 Personality dimensions / / 23903073 rs2510711 chr11 127031766 T A 7.90E-06 Urinary metabolites / / 21572414 rs2513427 chr11 127031820 T C 0.000107 Salmonella-induced pyroptosis / / 22837397 rs7926407 chr11 127043296 C T 6.27E-04 Multiple complex diseases / / 17554300 rs12799000 chr11 127044915 G A 1.40E-05 Urinary metabolites / / 21572414 rs2513444 chr11 127053249 G A 7.05E-04 Smoking quantity / / 24665060 rs10893649 chr11 127054686 T C 4.85E-05 Body Mass Index / / pha003014 rs7924850 chr11 127055116 G A 3.94E-05 Body Mass Index / / pha003014 rs949095 chr11 127058233 T G 4.53E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7121129 chr11 127058947 T C 5.25E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4529888 chr11 127081591 G A 5.00E-06 Amyotrophic lateral sclerosis / / 22959728 rs11220834 chr11 127087965 C T 4.92E-04 Myopia (pathological) / / 21095009 rs2514890 chr11 127088392 C T 5.09E-06 Multiple complex diseases / / 17554300 rs7943239 chr11 127089440 T C 9.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12575322 chr11 127089819 A T 9.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2441683 chr11 127091524 A G 6.97E-06 Multiple complex diseases / / 17554300 rs2514897 chr11 127091963 T C 0.0000105 Alpha-2-adrenoceptor-mediated vasoconstriction / / 23337848 rs11220835 chr11 127093556 T C 4.47E-05 Body Mass Index / / pha003022 rs10790871 chr11 127095382 C T 0.0008495 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10790871 chr11 127095382 C T 8.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11220838 chr11 127097977 G A 0.0008575 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11220838 chr11 127097977 G A 8.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10893654 chr11 127100266 C G 0.0008609 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10893654 chr11 127100266 C G 8.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2441686 chr11 127102481 A G 1.33E-05 Multiple complex diseases / / 17554300 rs2464870 chr11 127105446 T G 2.00E-04 Multiple complex diseases / / 17554300 rs10431093 chr11 127105912 A G 0.0005972 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10431093 chr11 127105912 A G 5.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2441692 chr11 127109105 T G 2.81E-04 Depression (quantitative trait) / / 20800221 rs2514895 chr11 127110183 C T 2.00E-06 IgG glycosylation / / 23382691 rs2513432 chr11 127111563 A G 3.07E-05 Body Mass Index / / pha003022 rs10893655 chr11 127113172 G A 2.46E-04 Depression (quantitative trait) / / 20800221 rs2322662 chr11 127114387 C T 7.63E-04 Depression (quantitative trait) / / 20800221 rs1105957 chr11 127116693 G A 5.72E-05 Body Mass Index / / pha003022 rs2322732 chr11 127156732 A G 6.07E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs7104000 chr11 127159334 A G 8.21E-05 Coronary heart disease / / pha003032 rs2259330 chr11 127178679 G A 0.000018 Mean arterial pressure / / 22510845 rs10893666 chr11 127196756 A G 7.60E-04 Multiple complex diseases / / 17554300 rs10893666 chr11 127196756 A G 7.68E-05 Type 1 diabetes / / 18978792 rs10893668 chr11 127197608 G T 7.01E-04 Multiple complex diseases / / 17554300 rs10893670 chr11 127206270 T A 8.92E-05 Serum metabolites / / 19043545 rs10893670 chr11 127206270 T A 0.00002887 Sarcoidosis / / 22952805 rs12364837 chr11 127209645 T C 0.00006248 Sarcoidosis / / 22952805 rs4937230 chr11 127241251 C A 3.17E-05 Bladder cancer / / 19648920 rs7104644 chr11 127268499 T G 8.22E-04 Multiple complex diseases / / 17554300 rs10893678 chr11 127276840 C T 0.0000316 Colorectal adenoma (excluding hyperplasic) / / 23677573 rs10893678 chr11 127276840 C T 0.0000316 Colorectal adenoma (including hyperplasic) / / 23677573 rs1600223 chr11 127293049 C T 3.40E-06 Urinary metabolites / / 21572414 rs954838 chr11 127329350 G T 9.70E-04 Coronary heart disease / / 21606135 rs1881470 chr11 127333840 G C 5.00E-04 Chronic fatigue syndrome / / 21912186 rs1358557 chr11 127340512 T C 2.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs356233 chr11 127422804 A G 0.000714677 Hypertension (early onset hypertension) / / 22479346 rs168554 chr11 127448532 G A 8.98E-04 Amyotrophic lateral sclerosis / / 23624525 rs7109626 chr11 127451064 G A 7.22E-06 Smooth-surface caries / / 24556642 rs11822667 chr11 127460571 G A 4.12E-06 Smooth-surface caries / / 24556642 rs1431571 chr11 127469702 C T 4.17E-04 Multiple complex diseases / / 17554300 rs1431573 chr11 127476759 C T 4.43E-04 Multiple complex diseases / / 17554300 rs12295483 chr11 127480765 C T 6.87E-06 Smooth-surface caries / / 24556642 rs356242 chr11 127484644 G A 2.73E-04 Multiple complex diseases / / 17554300 rs17136789 chr11 127491305 A T 5.70E-05 Triglycerides / / 19074352 rs17136822 chr11 127545470 C T 1.97E-05 Multiple complex diseases / / 17554300 rs12420554 chr11 127589360 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12420554 chr11 127589360 A G 6.49E-05 Cognitive impairment induced by topiramate / / 22091778 rs371808590 chr11 127659737 GCA G 3.72E-04 Renal cell carcinoma / / 22010048 rs6590279 chr11 127659737 G A 3.72E-04 Renal cell carcinoma / / 22010048 rs1863254 chr11 127683994 T G 9.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11221064 chr11 127687313 G C 3.89E-05 Attention deficit hyperactivity disorder / / 18980221 rs11221064 chr11 127687313 G C 1.60E-05 Attention deficit hyperactivity disorder / / pha002875 rs7130878 chr11 127690475 A C 1.66E-05 Attention deficit hyperactivity disorder / / pha002875 rs11221067 chr11 127693694 C T 3.19E-27 Narcolepsy / / 19629137 rs1559660 chr11 127713173 T C 2.06E-04 Type 2 diabetes / / 17463246 rs890132 chr11 127715426 C T 3.50E-04 Type 2 diabetes / / 17463246 rs2322978 chr11 127716140 A G 8.00E-07 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12792932 chr11 127721562 G A 5.20E-05 Type 2 diabetes / / 17463248 rs12806859 chr11 127729169 T G 5.20E-05 Type 2 diabetes / / 17463248 rs10790928 chr11 127731619 T C 9.95E-05 Erythrocyte counts / / pha003101 rs10750376 chr11 127737929 C T 2.24E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7927044 chr11 127761666 G A 7.00E-09 Asthma (childhood onset) / / 22560479 rs2009865 chr11 127779825 T C 4.80E-130 Butyrylcholinesterase levels / / 21862451 rs4937277 chr11 127796350 C A 2.32E-05 Erythrocyte counts / / pha003101 rs12799032 chr11 127823199 G A 8.30E-05 Type 2 diabetes / / 17463248 rs12792749 chr11 127830982 G A 8.60E-05 Type 2 diabetes / / 17463248 rs12797631 chr11 127836398 T G 8.70E-05 Type 2 diabetes / / 17463248 rs12796900 chr11 127836714 C A 8.80E-05 Type 2 diabetes / / 17463248 rs12793901 chr11 127839975 G A 8.60E-05 Type 2 diabetes / / 17463248 rs1785039 chr11 127900579 A G 6.10E-05 Alcoholism (heaviness of drinking) / / 21529783 rs2162174 chr11 127940816 C T 5.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs6590307 chr11 128028490 G A 1.33E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10893829 chr11 128042575 T C 6.26E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1977997 chr11 128045869 T C 8.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs1648178 chr11 128047538 C T 7.53E-06 Body Mass Index / / pha003006 rs1648178 chr11 128047538 C T 9.66E-05 Body Mass Index / / pha003014 rs1648178 chr11 128047538 C T 4.10E-05 Waist Circumference / / pha003024 rs9787850 chr11 128076596 G A 2.33E-05 Body Mass Index / / pha003009 rs4936041 chr11 128083424 G A,T 8.27E-05 Orofacial clefts / / 22419666 rs1783921 chr11 128094803 T C 5.20E-05 Personality dimensions / / 18957941 rs7101922 chr11 128104117 G C 9.21E-05 Multiple complex diseases / / 17554300 rs722345 chr11 128149065 G A 2.51E-05 Self-reported allergy / / 23817569 rs4936044 chr11 128150039 A C 2.61E-05 Self-reported allergy / / 23817569 rs4937310 chr11 128150147 T C 2.29E-05 Self-reported allergy / / 23817569 rs12795702 chr11 128156314 A G 2.56E-04 Glaucoma (primary open-angle) / / 22419738 rs500207 chr11 128157643 A G 4.28E-06 Self-reported allergy / / 23817569 rs12786743 chr11 128159029 A G 1.77E-05 Self-reported allergy / / 23817569 rs12419147 chr11 128165127 G A 2.58E-06 Self-reported allergy / / 23817569 rs12291771 chr11 128168452 A C 1.32E-05 Self-reported allergy / / 23817569 rs12806750 chr11 128170323 A C 1.36E-05 Self-reported allergy / / 23817569 rs1522435 chr11 128179467 G A 1.13E-05 Self-reported allergy / / 23817569 rs10893845 chr11 128186882 T G 6.00E-07 Self-reported allergy / / 23817569 rs10893845 chr11 128186882 T G 4.05E-04 Smoking initiation / / 24665060 rs7127307 chr11 128187383 T C 8.16E-07 Self-reported allergy / / 23817569 rs970924 chr11 128187902 A G 6.58E-07 Self-reported allergy / / 23817569 rs4937314 chr11 128189101 A G 4.20E-05 Psoriasis / / 20953189 rs4937314 chr11 128189101 A G 7.00E-06 Alzheimer's disease (late onset) / / 22881374 rs12291789 chr11 128198603 A T 1.20E-05 Urinary metabolites / / 21572414 rs4936046 chr11 128199706 C T 1.50E-05 Response to statin therapy / / 20339536 rs11221251 chr11 128200225 G A 1.30E-05 Response to statin therapy / / 20339536 rs10893850 chr11 128201793 G A 1.30E-05 Response to statin therapy / / 20339536 rs6590322 chr11 128206410 C T 9.00E-06 Hippocampal atrophy / / 19668339 rs1557477 chr11 128231995 T C 5.34E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs7939722 chr11 128266238 A C 4.70E-04 Myasthenia gravis / / 23055271 rs7934171 chr11 128269844 C A 2.00E-04 Myasthenia gravis / / 23055271 rs9943540 chr11 128275692 A G 5.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs11221288 chr11 128282153 A G 5.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs1946007 chr11 128283445 G T 8.66E-05 Schizophrenia(age at onset) / / 21688384 rs6590329 chr11 128284772 T C 2.84E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7936180 chr11 128288400 C T 3.77E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6590330 chr11 128311059 G A 2.00E-25 Systemic lupus erythematosus / / 19838193 rs6590330 chr11 128311059 G A 1.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6590330 chr11 128311059 G A 3.00E-08 Systemic lupus erythematosus / / 23273568 rs10893872 chr11 128325553 T C 1.80E-06 Systemic lupus erythematosus / / 23273568 rs1128334 chr11 128328959 C T 2.00E-11 Systemic lupus erythematosus ETS1 UTR-3 20169177 rs12146687 chr11 128333215 T C 7.43E-04 Response to taxane treatment (placlitaxel) ETS1 intron 23006423 rs12146687 chr11 128333215 T C 4.70E-05 Magnesium levels ETS1 intron pha003092 rs11221332 chr11 128380974 C T 5.00E-16 Celiac disease ETS1 intron 20190752 rs11221332 chr11 128380974 C T 5.00E-16 Asthma ETS1 intron 21150878 rs11221332 chr11 128380974 C T 5.28E-16 Celiac disease and Rheumatoid arthritis ETS1 intron 21383967 rs11221332 chr11 128380974 C T 5.28E-16 Multiple sclerosis ETS1 intron 22190364 rs11819995 chr11 128389391 C T 2.08E-06 Type 2 diabetes ETS1 intron 23945395 rs61907765 chr11 128391937 C A,G,T 3.40E-13 Celiac disease ETS1 UTR-5 22057235 rs3802826 chr11 128406438 A G 9.50E-10 Psoriasis ETS1 intron 23143594 rs2156696 chr11 128434157 G A 9.77E-05 Multiple sclerosis (age of onset) ETS1 intron 19010793 rs1944850 chr11 128435103 A G 4.47E-05 Multiple sclerosis (age of onset) ETS1 intron 19010793 rs7117932 chr11 128436953 C T 8.00E-06 Obesity-related traits ETS1 intron 23251661 rs11221362 chr11 128450219 C A 9.27E-04 Coronary heart disease ETS1 intron 21606135 rs7125213 chr11 128451280 A G 4.71E-04 Multiple complex diseases ETS1 intron 17554300 rs2213018 chr11 128466849 A G 2.76E-05 Anxiety in major depressive disorder / / 24047446 rs11221390 chr11 128477169 C T 4.41E-05 Hypertension / / 21082022 rs1893864 chr11 128479404 C T 5.65E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7115037 chr11 128480513 T C 5.58E-04 Rheumatoid arthritis / / 21452313 rs1002476 chr11 128488029 G C 9.91E-06 Metabolite levels (X-11787) / / 23934736 rs4937362 chr11 128492739 T C 8.00E-07 Rheumatoid arthritis / / 22446963 rs4937362 chr11 128492739 T C 0.0000491 Follicular lymphoma / / 23025665 rs73013527 chr11 128496952 C T 1.00E-06 Rheumatoid arthritis / / 24390342 rs73013527 chr11 128496952 C T 1.00E-10 Rheumatoid arthritis / / 24390342 rs73013527 chr11 128496952 C T 4.00E-06 Rheumatoid arthritis / / 24390342 rs6590343 chr11 128500215 A G 5.11E-05 Rheumatoid arthritis / / 21452313 rs4936059 chr11 128502496 A G 1.10E-04 Rheumatoid arthritis / / 21452313 rs4936059 chr11 128502496 A G 0.000060799 Hypertension (early onset hypertension) / / 22479346 rs7128819 chr11 128575132 G A,C 3.06E-04 Myopia (pathological) FLI1 intron 21095009 rs665440 chr11 128582557 T C 2.00E-08 Myopia (pathological) FLI1 intron 23049088 rs609017 chr11 128582944 C T 8.89E-05 Type 1 diabetes FLI1 intron 18978792 rs609017 chr11 128582944 C T 5.39E-05 Height FLI1 intron pha003011 rs654723 chr11 128586155 C A 4.00E-11 Height FLI1 intron 20881960 rs587862 chr11 128595173 A G 2.84E-04 Multiple complex diseases FLI1 intron 17554300 rs587862 chr11 128595173 A G 3.63E-05 Type 1 diabetes FLI1 intron 18978792 rs1939236 chr11 128602827 A G 9.45E-04 Multiple complex diseases FLI1 intron 17554300 rs1939236 chr11 128602827 A G 5.27E-05 Type 1 diabetes FLI1 intron 18978792 rs613587 chr11 128633309 A G 6.15E-05 Multiple complex diseases FLI1 intron 17554300 rs7124123 chr11 128634156 C A,G 9.73E-04 Multiple complex diseases FLI1 intron 17554300 rs674946 chr11 128639830 C T 1.30E-05 Urinary metabolites FLI1 intron 21572414 rs3819826 chr11 128650166 G T 5.00E-06 Urinary metabolites FLI1 intron 21572414 rs2246290 chr11 128651219 A G 7.70E-06 Urinary metabolites FLI1 intron 21572414 rs2246291 chr11 128651272 G C 1.10E-05 Urinary metabolites FLI1 intron 21572414 rs2847376 chr11 128651528 A G 3.80E-06 Urinary metabolites FLI1 intron 21572414 rs7110998 chr11 128665901 A C 2.60E-05 Urinary metabolites FLI1 intron 21572414 rs2268610 chr11 128668000 A G 2.80E-05 Urinary metabolites FLI1 intron 21572414 rs2268611 chr11 128668092 T C 1.30E-07 Urinary metabolites FLI1 intron 21572414 rs2284788 chr11 128670115 C T 1.30E-07 Urinary metabolites FLI1 intron 21572414 rs2284789 chr11 128670190 A T 2.60E-05 Urinary metabolites FLI1 intron 21572414 rs500081 chr11 128687305 G T 4.48E-04 Prostate cancer mortality / / 20978177 rs504760 chr11 128687835 A G 4.48E-04 Prostate cancer mortality / / 20978177 rs651213 chr11 128688420 T A 9.69E-04 Prostate cancer mortality / / 20978177 rs2155549 chr11 128690596 T C 3.96E-04 Prostate cancer mortality / / 20978177 rs588407 chr11 128696597 C T 3.26E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs677035 chr11 128697063 C T 2.61E-06 Personality dimensions / / 21173776 rs664451 chr11 128700576 G A 9.64E-06 Personality dimensions / / 21173776 rs1148058 chr11 128712781 G A 6.50E-06 Urinary metabolites KCNJ1 intron 21572414 rs1148059 chr11 128713844 C A 8.50E-06 Urinary metabolites KCNJ1 intron 21572414 rs3758766 chr11 128715972 A G 8.10E-06 Urinary metabolites KCNJ1 intron 21572414 rs7925428 chr11 128724209 A G 2.09E-05 Blood Pressure KCNJ1 intron pha003048 rs7925428 chr11 128724209 A G 1.45E-05 Blood Pressure KCNJ1 intron pha003050 rs11601659 chr11 128728887 A C 2.27E-08 Metabolite levels KCNJ1 intron 23281178 rs12795437 chr11 128730876 G C 1.38E-08 Metabolite levels KCNJ1 intron 23281178 rs11600347 chr11 128733314 C A 1.78E-08 Metabolite levels KCNJ1 intron 23281178 rs6590354 chr11 128739363 C T 7.20E-04 Multiple complex diseases / / 17554300 rs4937378 chr11 128743018 T C 4.73E-05 Height / / pha003011 rs7111082 chr11 128756014 G A 8.87E-05 Hemoglobin / / pha003096 rs7111082 chr11 128756014 G A 3.36E-05 Hematocrit / / pha003097 rs11221503 chr11 128772452 C T 5.67E-04 Type 2 diabetes C11orf45 cds-synon 17463246 rs11221504 chr11 128772614 G A 1.38E-04 Multiple complex diseases KCNJ5 intron 17554300 rs6590357 chr11 128781339 T C 8.64E-04 Alzheimer's disease KCNJ5 cds-synon 24755620 rs7118824 chr11 128781978 T G 8.64E-04 Alzheimer's disease KCNJ5 cds-synon 24755620 rs11221512 chr11 128785641 G A 9.96E-04 Alzheimer's disease KCNJ5 intron 17998437 rs10790977 chr11 128785742 G A 8.84E-04 Alzheimer's disease KCNJ5 intron 24755620 rs2604194 chr11 128791079 T C 7.30E-05 Bipolar disorder / / 17486107 rs2604230 chr11 128798654 A C 6.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2846685 chr11 128815361 G T 4.71E-06 Suicidal ideation / / 20877300 rs11221522 chr11 128816221 G A 5.00E-07 Metabolite levels (5-HIAA) / / 23319000 rs11820420 chr11 128822203 A G 6.31E-04 Acute lung injury / / 22295056 rs6590360 chr11 128822629 C T 1.69E-04 Multiple complex diseases / / 17554300 rs4616048 chr11 129143231 T C 1.08E-04 Type 2 diabetes / / 17463246 rs4937409 chr11 129156530 G A 7.16E-04 Response to TNF antagonist treatment / / 21061259 rs4644651 chr11 129160763 G A 7.94E-04 Type 2 diabetes / / 17463246 rs7928467 chr11 129206881 A T 4.97E-05 Bipolar disorder and schizophrenia / / 20889312 rs7952135 chr11 129218345 G A 8.89E-05 Bipolar disorder and schizophrenia / / 20889312 rs7103242 chr11 129231248 G T 9.01E-05 Bipolar disorder and schizophrenia / / 20889312 rs10894032 chr11 129239784 T C 2.81E-04 Stroke / / pha002887 rs1540666 chr11 129251227 A C 8.69E-04 Schizophrenia BARX2 intron 19197363 rs10894034 chr11 129255618 C T 5.65E-04 Alzheimer's disease BARX2 intron 24755620 rs10791006 chr11 129263154 T C 2.45E-05 IgE levels in asthmatics (D.p. specific) BARX2 intron 23967269 rs752450 chr11 129267481 G A 2.70E-04 Myasthenia gravis BARX2 intron 23055271 rs12577139 chr11 129301284 C T 9.14E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BARX2 intron 20877124 rs11600554 chr11 129305905 G A 8.40E-06 Urinary metabolites BARX2 intron 21572414 rs7126004 chr11 129308742 T C 8.03E-05 HIV-1 viral setpoint BARX2 intron 22174851 rs6590386 chr11 129309424 A G 9.45E-04 Multiple complex diseases BARX2 intron 17554300 rs6590386 chr11 129309424 A G 6.68E-05 HIV-1 viral setpoint BARX2 intron 22174851 rs2307127 chr11 129312072 A C 1.50E-05 Urinary metabolites BARX2 intron 21572414 rs3019793 chr11 129315586 A G 3.97E-11 Narcolepsy BARX2 intron 19629137 rs3019793 chr11 129315586 A G 8.06E-04 Response to taxane treatment (placlitaxel) BARX2 intron 23006423 rs984176 chr11 129327691 A G 0.0000028 Asthma / / 23040885 rs10791012 chr11 129330769 G A 2.51E-04 Smoking cessation / / 24665060 rs10894041 chr11 129351006 A T 2.97E-04 Multiple complex diseases / / 17554300 rs3019805 chr11 129376495 C T 2.75E-04 Multiple complex diseases / / 17554300 rs1493270 chr11 129392269 G A 7.49E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1353071 chr11 129414580 G A 1.07E-04 Multiple complex diseases / / 17554300 rs1021451 chr11 129414967 A G 3.08E-04 Multiple complex diseases / / 17554300 rs923811 chr11 129415217 T G 2.83E-04 Multiple complex diseases / / 17554300 rs923811 chr11 129415217 T G 6.95E-05 Orofacial clefts / / 22863734 rs2954146 chr11 129423614 T A 2.71E-04 Multiple complex diseases / / 17554300 rs2933891 chr11 129429381 G A 2.27E-04 Multiple complex diseases / / 17554300 rs2220757 chr11 129430058 G T 1.99E-04 Multiple complex diseases / / 17554300 rs2220757 chr11 129430058 G T 4.80E-05 Personality dimensions / / 18957941 rs2087889 chr11 129456444 A T 9.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12787230 chr11 129459840 T G 6.55E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs11822830 chr11 129461016 A G 3.52E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs11820646 chr11 129461171 T C 8.79E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs11820646 chr11 129461171 T C 1.00E-09 Breast cancer / / 23535729 rs11820646 chr11 129461171 T C 2.30E-04 Breast cancer / / 23535733 rs745382 chr11 129462233 A G 7.90E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs7107217 chr11 129473690 A C 1.06E-05 Diabetic nephropathy / / 21150874 rs7107217 chr11 129473690 A C 3.00E-07 Type 2 diabetes / / 22238593 rs7107217 chr11 129473690 A C 5.00E-07 Breast cancer / / 22383897 rs1493266 chr11 129477363 A G 4.53E-04 Alzheimer's disease / / 24755620 rs1873873 chr11 129479175 C T 1.10E-04 Bone mineral density (BMD),in women / / 20164292 rs10750416 chr11 129480797 C T 9.41E-05 Cholesterol / / 17255346 rs10791037 chr11 129593169 A T 6.57E-04 Smoking initiation / / 24665060 rs691766 chr11 129593870 A G 6.80E-04 Alzheimer's disease / / 17998437 rs504990 chr11 129594021 G A 8.19E-04 Alzheimer's disease / / 17998437 rs691035 chr11 129605170 G C 8.20E-06 Urinary metabolites / / 21572414 rs7128882 chr11 129619479 C T 6.23E-05 Schizophrenia / / 19571811 rs1784454 chr11 129627748 C T 2.40E-05 Urinary metabolites / / 21572414 rs2178579 chr11 129631062 C T 6.25E-04 Myopia (pathological) / / 21095009 rs2178579 chr11 129631062 C T 6.03E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1940108 chr11 129650451 T C 1.94E-05 Asthma / / 23181788 rs10791048 chr11 129657216 C A 4.36E-04 White matter integrity / / 22425255 rs10791048 chr11 129657216 C A 7.03E-05 Asthma / / 23181788 rs4937460 chr11 129657981 T C 7.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10750422 chr11 129692580 G A 1.65E-04 Multiple complex diseases TMEM45B intron 17554300 rs10894147 chr11 129698856 C T 9.11E-04 Multiple complex diseases TMEM45B intron 17554300 rs10894147 chr11 129698856 C T 7.00E-06 Obesity-related traits TMEM45B intron 23251661 rs10894155 chr11 129717235 C A 6.24E-04 Type 2 diabetes TMEM45B intron 17463246 rs7114881 chr11 129723725 G A 3.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM45B intron 20877124 rs3087920 chr11 129728867 C G 6.79E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) TMEM45B UTR-3 22566498 rs200010268 chr11 129739816 G A 0.00008 Prostate cancer NFRKB missense 23555315 rs1030467 chr11 129744252 T C 2.58E-05 Cleft lip NFRKB intron 20436469 rs1016364 chr11 129744872 A G 5.56E-05 Cleft lip NFRKB intron 20436469 rs1733448 chr11 129748737 T C 9.80E-04 Multiple complex diseases NFRKB intron 17554300 rs2303663 chr11 129753900 T C 3.43E-05 Paget's disease NFRKB intron 20436471 rs1650820 chr11 129762407 G A 8.92E-04 Multiple complex diseases NFRKB intron 17554300 rs1650820 chr11 129762407 G A 4.54E-08 Narcolepsy NFRKB intron 19629137 rs1783919 chr11 129764526 C T 6.98E-04 Multiple complex diseases NFRKB intron 17554300 rs3734078 chr11 129772013 C T 3.01E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) PRDM10 UTR-3 22566498 rs1650817 chr11 129773524 C A 2.69E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) PRDM10 intron 22566498 rs3734075 chr11 129781796 C T 2.92E-05 Hodgkin's lymphoma PRDM10 intron 24149102 rs2241572 chr11 129793448 C G 5.84E-94 Multiple complex diseases PRDM10 intron 17554300 rs2241571 chr11 129794950 T C 7.91E-04 Myopia (pathological) PRDM10 missense 21095009 rs12276033 chr11 129803181 C A 6.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PRDM10 intron 20877124 rs7948010 chr11 129804813 T C 6.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PRDM10 intron 20877124 rs12793517 chr11 129865592 G A 5.32E-04 Celiac disease PRDM10 intron 23936387 rs3808986 chr11 129910584 C A 1.38E-05 Anorexia nervosa / / 21079607 rs12278451 chr11 130004759 G A 6.15E-05 Cytomegalovirus antibody response APLP2 intron 21993531 rs7950184 chr11 130038487 A C 8.78E-04 Myopia (pathological) ST14 intron 21095009 rs7123795 chr11 130043978 A G 5.26E-04 Multiple complex diseases ST14 intron 17554300 rs577740 chr11 130062701 G A 4.52E-08 Metabolite levels ST14 intron 23281178 rs2324002 chr11 130066957 C T 2.56E-04 Multiple complex diseases ST14 intron 17554300 rs2324003 chr11 130067069 G C 2.47E-04 Multiple complex diseases ST14 intron 17554300 rs7938567 chr11 130070544 G A 5.94E-04 Multiple complex diseases ST14 intron 17554300 rs1102478 chr11 130089380 G A 8.12E-04 Multiple complex diseases / / 17554300 rs4936094 chr11 130094199 G A 0.000755 Antisocial behavior / / 23077488 rs858723 chr11 130094626 C T 4.26E-04 Nicotine smoking / / 19268276 rs7933236 chr11 130111728 G C 6.71E-04 Nicotine smoking ZBTB44 intron 19268276 rs12364607 chr11 130115746 G A 8.83E-05 Cognitive performance ZBTB44 intron 19734545 rs17139164 chr11 130128324 A C 6.73E-04 Multiple complex diseases ZBTB44 intron 17554300 rs7102988 chr11 130134441 G T 3.34E-04 Multiple complex diseases ZBTB44 intron 17554300 rs17605375 chr11 130134510 T C 7.07E-05 Body Mass Index ZBTB44 intron pha003015 rs17139249 chr11 130155706 C G 4.53E-04 Multiple complex diseases ZBTB44 intron 17554300 rs10488778 chr11 130156997 A T 2.25E-04 Multiple complex diseases ZBTB44 intron 17554300 rs858719 chr11 130160456 T C 2.87E-05 Multiple complex diseases ZBTB44 intron 17554300 rs7950772 chr11 130161698 A G 5.79E-04 Multiple complex diseases ZBTB44 intron 17554300 rs17139300 chr11 130164836 C T 4.39E-04 Multiple complex diseases ZBTB44 intron 17554300 rs2324055 chr11 130185378 A C 4.83E-04 Smoking initiation / / 24665060 rs923076 chr11 130218583 G A 1.97E-05 Coronary heart disease / / pha003030 rs12291222 chr11 130253207 G A 9.25E-05 Multiple complex diseases / / 17554300 rs3740890 chr11 130255113 T C 1.27E-05 Coronary heart disease / / pha003031 rs11222084 chr11 130273230 A T 2.00E-11 Blood pressure / / 21909110 rs2291347 chr11 130286766 G A 2.29E-04 Multiple complex diseases ADAMTS8 intron 17554300 rs12576846 chr11 130288150 T C 3.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADAMTS8 intron 20877124 rs765386 chr11 130289608 T C 3.54E-05 Non-word repetition ADAMTS8 intron 23738518 rs3758822 chr11 130299985 G A 6.27E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4936101 chr11 130305605 A G 3.51E-05 Cognitive impairment induced by topiramate / / 22091778 rs923075 chr11 130311545 C T 7.18E-06 Cognitive impairment induced by topiramate / / 22091778 rs10894203 chr11 130327882 A G 1.00E-04 Cognitive impairment induced by topiramate ADAMTS15 intron 22091778 rs10894203 chr11 130327882 A G 8.81E-05 Body Fat Distribution ADAMTS15 intron pha003017 rs731446 chr11 130339312 T C 2.50E-05 Major depressive disorder ADAMTS15 cds-synon 21042317 rs10750437 chr11 130395314 T C 0.0003787 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10750437 chr11 130395314 T C 3.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7116902 chr11 130395764 C T 0.0003797 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7116902 chr11 130395764 C T 3.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11222149 chr11 130399488 C T 6.21E-04 Smoking quantity / / 24665060 rs7358347 chr11 130399649 C T 0.0001151 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7358347 chr11 130399649 C T 1.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4245088 chr11 130416206 T C 3.96E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2703752 chr11 130416832 T G 1.27E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2172491 chr11 130423305 C T 6.42E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11222164 chr11 130424826 A G 9.26E-05 Pancreatic cancer / / pha002874 rs1389241 chr11 130425426 C T 6.99E-05 Bipolar disorder and schizophrenia / / 20889312 rs1021452 chr11 130431482 T C 1.51E-05 Lung adenocarcinoma / / 19836008 rs7125089 chr11 130479001 A G 5.74E-04 Multiple complex diseases / / 17554300 rs11222221 chr11 130488369 A T 2.67E-04 Multiple complex diseases / / 17554300 rs11222238 chr11 130500152 A T 8.79E-04 Multiple complex diseases / / 17554300 rs7105145 chr11 130506526 C A 6.80E-04 Multiple complex diseases / / 17554300 rs12792526 chr11 130529219 A G 3.00E-06 Periodontitis (Mean PAL) / / 24024966 rs12792526 chr11 130529219 A G 4.00E-06 Periodontitis (Mean PAL) / / 24024966 rs2951955 chr11 130544872 T G 7.03E-05 Left ventricular hypertrophy C11orf44 intron pha003052 rs10894239 chr11 130629122 C A 6.00E-06 Obesity-related traits / / 23251661 rs948084 chr11 130631608 A C 2.63E-04 Age-related macular degeneration / / 22125219 rs7116050 chr11 130637654 G C 1.09E-05 Breast cancer / / 21060860 rs7127732 chr11 130639957 C T 2.02E-05 Breast cancer / / 21060860 rs9285790 chr11 130659981 T G 6.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs4245095 chr11 130665384 A G 4.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs7128694 chr11 130666444 T C 4.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs4937569 chr11 130666858 G A 4.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs9666096 chr11 130668165 G A 6.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs1939906 chr11 130668520 A G 3.43E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10791094 chr11 130673321 T G 2.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs10894254 chr11 130673727 T G 3.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs4937571 chr11 130674669 T C 9.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs12806925 chr11 130675805 G T 0.0000697 Sarcoidosis / / 22952805 rs948999 chr11 130698539 C T 6.95E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs4937577 chr11 130702221 C T 6.67E-04 Alzheimer's disease / / 17998437 rs4936118 chr11 130702454 C T 7.76E-05 HDL cholesterol / / pha003074 rs12419710 chr11 130708331 G A 5.21E-05 Serum metabolites / / 19043545 rs7943936 chr11 130709067 C T 3.10E-05 Schizophrenia / / 19197363 rs7943757 chr11 130716157 C T 3.64E-05 Schizophrenia LOC100507431 intron 19197363 rs7943757 chr11 130716157 C T 5.59E-05 Height LOC100507431 intron pha003010 rs10791098 chr11 130718711 T G 3.32E-05 Height LOC100507431 intron pha003010 rs10791098 chr11 130718711 T G 7.56E-05 Height LOC100507431 intron pha003011 rs7119425 chr11 130733185 C T 4.03E-05 Schizophrenia / / 19197363 rs10791100 chr11 130738946 T A 5.49E-04 Obesity (extreme) / / 21935397 rs2236711 chr11 130739284 G A 2.00E-04 Schizophrenia / / 19197363 rs2236711 chr11 130739284 G A 5.34E-04 Obesity (extreme) / / 21935397 rs4936123 chr11 130740967 G A 5.17E-04 Obesity (extreme) / / 21935397 rs10894273 chr11 130742155 G T 5.02E-04 Obesity (extreme) / / 21935397 rs1054869 chr11 130742630 G A 6.34E-05 Schizophrenia / / 19197363 rs1054869 chr11 130742630 G A 4.96E-04 Obesity (extreme) / / 21935397 rs10160281 chr11 130742788 T C 5.10E-04 Obesity (extreme) / / 21935397 rs12363140 chr11 130744268 A C 5.25E-04 Obesity (extreme) / / 21935397 rs11222369 chr11 130744670 A G 5.90E-04 Obesity (extreme) / / 21935397 rs1050071 chr11 130747231 C G 6.44E-04 Obesity (extreme) SNX19 UTR-3 21935397 rs6590520 chr11 130747386 C G 6.33E-04 Obesity (extreme) SNX19 UTR-3 21935397 rs3190331 chr11 130748131 A G 6.21E-04 Obesity (extreme) SNX19 UTR-3 21935397 rs12365680 chr11 130749059 G A 8.65E-05 Schizophrenia SNX19 intron 19197363 rs7942621 chr11 130751308 C G 6.04E-04 Obesity (extreme) SNX19 intron 21935397 rs876641 chr11 130752040 A C 6.04E-04 Obesity (extreme) SNX19 intron 21935397 rs2155751 chr11 130755240 G A 6.25E-04 Obesity (extreme) SNX19 intron 21935397 rs4457753 chr11 130755575 A G 6.27E-04 Obesity (extreme) SNX19 intron 21935397 rs4436551 chr11 130755739 G A 6.29E-04 Obesity (extreme) SNX19 intron 21935397 rs4264159 chr11 130755784 G T 6.38E-04 Obesity (extreme) SNX19 intron 21935397 rs4456262 chr11 130755813 T C 6.39E-04 Obesity (extreme) SNX19 intron 21935397 rs2155752 chr11 130755998 C T 6.42E-04 Obesity (extreme) SNX19 intron 21935397 rs4459316 chr11 130756176 T C 6.42E-04 Obesity (extreme) SNX19 intron 21935397 rs1893017 chr11 130756253 C T 7.81E-04 Obesity (extreme) SNX19 intron 21935397 rs1893018 chr11 130756632 T C 6.46E-04 Obesity (extreme) SNX19 intron 21935397 rs1893019 chr11 130756664 C G 6.52E-04 Obesity (extreme) SNX19 intron 21935397 rs10791103 chr11 130757161 G A 6.54E-04 Obesity (extreme) SNX19 intron 21935397 rs7106973 chr11 130758113 G A 6.36E-04 Obesity (extreme) SNX19 intron 21935397 rs7107595 chr11 130758556 G A 7.08E-04 Obesity (extreme) SNX19 intron 21935397 rs185989409 chr11 130784838 G A 0.00057 Prostate cancer SNX19 missense 23555315 rs11222391 chr11 130792048 G A 6.80E-04 Obesity (extreme) / / 21935397 rs11222395 chr11 130794355 A C 0.000136 Schizophrenia / / 23637625 rs7106928 chr11 130809259 T G 6.64E-04 Obesity (extreme) / / 21935397 rs7940866 chr11 130817579 T A 2.00E-09 Schizophrenia / / 23974872 rs10894294 chr11 130830748 C A 3.00E-06 Schizophrenia / / 21926974 rs10894294 chr11 130830748 C A 3.00E-07 Schizophrenia / / 22688191 rs10791109 chr11 130850377 T G 6.54E-05 Bipolar disorder and schizophrenia / / 20889312 rs10791115 chr11 130894699 G A 4.85E-04 Multiple complex diseases / / 17554300 rs1655495 chr11 130899633 C A 3.23E-05 Serum metabolites / / 19043545 rs1647956 chr11 130909809 A G 2.54E-04 Alzheimer's disease (late onset) / / 21379329 rs4937598 chr11 130934617 G A 2.12E-04 Alcohol dependence / / 20201924 rs11222448 chr11 130935142 G A 3.78E-04 Multiple complex diseases / / 17554300 rs1647965 chr11 130942735 T C 4.11E-05 Cognitive test performance / / 20125193 rs1647967 chr11 130943681 G A 1.40E-05 Suicidal ideation / / 20877300 rs2298836 chr11 130956627 T C 0.000843908 Hypertension (early onset hypertension) / / 22479346 rs2298837 chr11 130956677 T C 4.86E-05 Cognitive test performance / / 20125193 rs10750462 chr11 130959664 G A 4.86E-05 Cognitive test performance / / 20125193 rs1105526 chr11 130970543 T C 2.57E-05 Cognitive test performance / / 20125193 rs2276437 chr11 130971744 C T 5.35E-06 Rheumatoid arthritis / / 19503088 rs6590549 chr11 130980153 G A 8.50E-05 Femoral neck bone geometry / / 22087292 rs2187560 chr11 130987535 T C 2.37E-05 Cognitive test performance / / 20125193 rs11222475 chr11 130989300 A G 3.60E-05 Multiple complex diseases / / 17554300 rs1945935 chr11 131000885 C A 2.40E-05 Urinary metabolites / / 21572414 rs4145055 chr11 131001053 C G 5.55E-04 Multiple complex diseases / / 17554300 rs11222479 chr11 131001534 G A 9.36E-05 Aging (time to event) / / 21782286 rs10750464 chr11 131002938 C T 4.25E-05 Insulin Resistance / / pha003062 rs10750464 chr11 131002938 C T 2.46E-05 Insulin-related traits / / pha003063 rs1793823 chr11 131018917 C T 2.65E-04 Type 2 diabetes / / 17846124 rs1793602 chr11 131033190 A C 5.38E-05 Cholesterol / / pha003073 rs1793602 chr11 131033190 A C 3.67E-05 Cholesterol / / pha003078 rs11222509 chr11 131053786 T G 3.05E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10791130 chr11 131085110 G C 5.64E-04 Multiple complex diseases / / 17554300 rs10791130 chr11 131085110 G C 2.40E-05 Urinary metabolites / / 21572414 rs10791130 chr11 131085110 G C 7.22E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1630972 chr11 131085891 C T 1.00E-05 Serum metabolites / / 19043545 rs10894348 chr11 131096604 C T 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1628402 chr11 131099798 G A 8.79E-05 Orofacial clefts / / 19270707 rs1793791 chr11 131111013 A G 3.61E-05 Educational attainment / / 21694764 rs11222539 chr11 131116997 A C 1.88E-04 Multiple complex diseases / / 17554300 rs10894360 chr11 131138723 T C 7.92E-04 Multiple complex diseases / / 17554300 rs1110256 chr11 131157945 A T 5.99E-04 Multiple complex diseases / / 17554300 rs1894218 chr11 131158533 C A 4.49E-04 Multiple complex diseases / / 17554300 rs4937616 chr11 131159007 A G 3.14E-04 Multiple complex diseases / / 17554300 rs7106592 chr11 131159692 G A 5.03E-04 Multiple complex diseases / / 17554300 rs1793783 chr11 131192383 A C,G,T 8.22E-04 Type 2 diabetes / / 17846124 rs1793553 chr11 131193742 G T 5.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1540231 chr11 131194688 A G 3.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2511506 chr11 131197551 G A 5.46E-05 Tardive dyskinesia / / 20939080 rs2511506 chr11 131197551 G A 5.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7947194 chr11 131206462 A G 5.97E-05 Blood Pressure / / pha003046 rs4414226 chr11 131236611 C T 5.40E-04 Type 2 diabetes / / 17463246 rs7108536 chr11 131290041 G A 9.48E-05 Serum metabolites NTM intron 19043545 rs7108536 chr11 131290041 G A 0.00001 Central corneal thickness in patients with an IOP <= 21mmHg and no history of IOP>= 21mmHg NTM intron 22661486 rs7108536 chr11 131290041 G A 1.00E-05 Testosterone levels NTM intron 22675492 rs7481514 chr11 131291963 A G 0.0000103 Central corneal thickness in patients with an IOP <= 21mmHg and no history of IOP>= 21mmHg NTM intron 22661486 rs7481514 chr11 131291963 A G 1.03E-05 Testosterone levels NTM intron 22675492 rs1448354 chr11 131296565 A G 9.43E-05 Non-alcoholic fatty liver disease histology (other) NTM intron 20708005 rs2512648 chr11 131301517 C T 5.00E-04 Smoking initiation NTM intron 24665060 rs1550976 chr11 131320070 T C 2.00E-06 Asperger disorder NTM intron 21182207 rs1550976 chr11 131320070 T C 3.00E-06 Asperger disorder NTM intron 21182207 rs1550976 chr11 131320070 T C 5.59E-06 Glucose levels NTM intron pha002899 rs1448363 chr11 131320190 T C 2.30E-06 Asperger disorder NTM intron 21182207 rs2034382 chr11 131322977 T C 3.70E-04 Smoking initiation NTM intron 24665060 rs7950545 chr11 131324796 C T 3.52E-04 Smoking initiation NTM intron 24665060 rs11603690 chr11 131325169 T C 9.20E-06 Obesity-related traits NTM intron 23251661 rs11601906 chr11 131325246 C T 2.00E-06 Obesity-related traits NTM intron 23251661 rs10791146 chr11 131326181 A G 6.39E-05 Smoking initiation NTM intron 24665060 rs11222631 chr11 131326368 A T 8.78E-07 Multiple complex diseases NTM intron 17554300 rs11222632 chr11 131327074 T A 6.42E-07 Multiple complex diseases NTM intron 17554300 rs2034387 chr11 131331019 T C 4.22E-05 Smoking initiation NTM intron 24665060 rs11222647 chr11 131331487 G A 4.06E-06 Multiple complex diseases NTM intron 17554300 rs7107326 chr11 131332567 C T 4.63E-07 Multiple complex diseases NTM intron 17554300 rs11222652 chr11 131333162 C T 1.22E-06 Multiple complex diseases NTM intron 17554300 rs11222653 chr11 131333598 A G 1.23E-06 Multiple complex diseases NTM intron 17554300 rs11222657 chr11 131335576 G A 4.38E-07 Multiple complex diseases NTM intron 17554300 rs992564 chr11 131336074 G T 4.00E-06 Bipolar disorder and schizophrenia NTM intron 20889312 rs992564 chr11 131336074 G T 7.46E-05 Post-operative nausea and vomiting NTM intron 21694509 rs1533339 chr11 131336773 G A 4.39E-07 Multiple complex diseases NTM intron 17554300 rs11222662 chr11 131343517 C T 1.40E-06 Multiple complex diseases NTM intron 17554300 rs12421680 chr11 131350968 G A 6.00E-06 Sunburns NTM intron 23548203 rs956993 chr11 131354471 T G 3.40E-04 Breast cancer NTM intron 19330027 rs318966 chr11 131366138 G A 1.17E-05 Celiac disease NTM intron 23936387 rs433406 chr11 131371019 A G 3.36E-06 Male fertility NTM intron 22633400 rs433443 chr11 131371202 G A 2.87E-05 Male fertility NTM intron 22633400 rs1543120 chr11 131398334 A G 8.92E-04 Response to statin treatment (atorvastatin),change in cholesterol levels NTM intron 20031582 rs318950 chr11 131436564 C T 4.29E-04 Multiple complex diseases NTM intron 17554300 rs2512874 chr11 131461292 T C 1.13E-04 Multiple complex diseases NTM intron 17554300 rs2512885 chr11 131467794 T C 1.70E-05 Urinary metabolites NTM intron 21572414 rs2512885 chr11 131467794 T C 6.05E-04 Response to cytadine analogues (cytosine arabinoside) NTM intron 24483146 rs2512884 chr11 131467856 C A 6.05E-04 Response to cytadine analogues (cytosine arabinoside) NTM intron 24483146 rs2324509 chr11 131469511 C T 6.13E-04 Response to cytadine analogues (cytosine arabinoside) NTM intron 24483146 rs4936140 chr11 131472834 A C 4.78E-04 Response to cytadine analogues (cytosine arabinoside) NTM intron 24483146 rs10791154 chr11 131473175 C G 2.80E-05 Urinary metabolites NTM intron 21572414 rs2324520 chr11 131475035 A G 5.89E-04 Response to cytadine analogues (cytosine arabinoside) NTM intron 24483146 rs7121221 chr11 131476599 G A 9.32E-04 Response to cytadine analogues (cytosine arabinoside) NTM intron 24483146 rs906167 chr11 131485710 C A 6.26E-04 Response to cytadine analogues (cytosine arabinoside) NTM intron 24483146 rs7110535 chr11 131486334 C T 8.27E-04 Alzheimer's disease NTM intron 17998437 rs11222720 chr11 131492764 A C 2.20E-05 Urinary metabolites NTM intron 21572414 rs11600229 chr11 131493271 A G 2.29E-06 Alopecia areata NTM intron 22027810 rs1857922 chr11 131520368 T C 4.00E-05 Asthma (bronchodilator response) NTM intron 22792082 rs873801 chr11 131543391 C T 9.00E-05 Prostate cancer NTM intron 21743057 rs2063024 chr11 131613622 G A 2.26E-05 Osteoarthritis (knee and hip) NTM intron 21177295 rs2063024 chr11 131613622 G A 6.56E-04 Osteoarthritis (knee and hip) NTM intron 21177295 rs4254085 chr11 131644529 C T 8.99E-04 Type 2 diabetes NTM intron 17463246 rs10736601 chr11 131644588 G C 9.65E-04 Type 2 diabetes NTM intron 17463246 rs11222788 chr11 131649367 C G 9.79E-04 Suicide attempts in bipolar disorder NTM intron 21423239 rs11222791 chr11 131652336 C A 6.02E-04 Suicide attempts in bipolar disorder NTM intron 21423239 rs10750489 chr11 131656339 C G 1.98E-07 Schizophrenia NTM intron 21926974 rs10894446 chr11 131656518 A G 6.08E-04 Suicide attempts in bipolar disorder NTM intron 21423239 rs7945105 chr11 131657770 G A 0.0000493 Uterine leiomyomata NTM intron 23040493 rs7945105 chr11 131657770 G A 2.98E-04 Stroke NTM intron pha002886 rs7116261 chr11 131681049 A G 5.51E-04 Suicide attempts in bipolar disorder NTM intron 21423239 rs483097 chr11 131690566 T C 5.80E-05 Creatinine levels NTM intron 20222955 rs10894462 chr11 131725127 C T 4.79E-04 Smoking initiation NTM intron 24665060 rs11222819 chr11 131728057 C T 1.28E-04 Type 2 diabetes NTM intron 17463246 rs920139 chr11 131793993 G A 2.87E-04 Multiple complex diseases NTM intron 17554300 rs920139 chr11 131793993 G A 1.30E-06 Urinary metabolites NTM intron 21572414 rs695127 chr11 131795139 A G 3.12E-04 Multiple complex diseases NTM intron 17554300 rs516431 chr11 131795999 T C 8.25E-05 Tunica Media NTM intron pha003036 rs516431 chr11 131795999 T C 7.30E-05 Triglycerides NTM intron pha003081 rs516431 chr11 131795999 T C 3.09E-05 Lipid levels NTM intron pha003082 rs667007 chr11 131803434 T C 4.47E-04 Multiple complex diseases NTM intron 17554300 rs667007 chr11 131803434 T C 7.85E-04 Aortic root size NTM intron 21223598 rs12098973 chr11 131807171 A G 1.00E-06 Cardiac Troponin-T levels NTM intron 23247143 rs501981 chr11 131809462 G A 2.35E-05 Tunica Media NTM intron pha003036 rs501050 chr11 131809571 C T 1.16E-04 Nicotine smoking NTM intron 19268276 rs574322 chr11 131821000 G A 9.86E-04 Stroke NTM intron pha002887 rs574322 chr11 131821000 G A 8.21E-05 Monocyte counts NTM intron pha003089 rs471677 chr11 131827706 A C 4.34E-04 Alzheimer's disease (late onset) NTM intron 21379329 rs471677 chr11 131827706 A C 6.45E-04 Alcohol consumption (maxi-drinks) NTM intron 24277619 rs525721 chr11 131829753 C T 8.00E-06 Urinary metabolites NTM intron 21572414 rs2105606 chr11 131832204 A G 9.79E-05 Lipoproteins NTM intron pha003079 rs1940028 chr11 131842743 C G 5.99E-05 Attention deficit hyperactivity disorder NTM intron 23728934 rs10894478 chr11 131843403 A G 2.08E-04 Multiple complex diseases NTM intron 17554300 rs585904 chr11 131854850 T G 4.57E-16 Gallbladder disease NTM intron pha001404 rs12419881 chr11 131870763 G A 8.70E-07 Urinary metabolites NTM intron 21572414 rs503915 chr11 131873116 G A 5.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NTM intron 20877124 rs2517996 chr11 131878375 G A 4.69E-04 Alzheimer's disease NTM intron 22005930 rs2518016 chr11 131884441 T G 1.11E-04 Response to taxane treatment (placlitaxel) NTM intron 23006423 rs11525415 chr11 131888483 G A 6.65E-04 Alzheimer's disease NTM intron 22005930 rs10894486 chr11 131891514 T C 4.59E-04 Alzheimer's disease NTM intron 22005930 rs566390 chr11 131894864 C T 1.13E-04 Response to taxane treatment (placlitaxel) NTM intron 23006423 rs1940585 chr11 131896413 G A 8.32E-04 Alzheimer's disease NTM intron 22005930 rs4936152 chr11 131899407 C T 2.09E-04 Response to taxane treatment (placlitaxel) NTM intron 23006423 rs1939717 chr11 131900736 T C 3.16E-05 Response to taxane treatment (placlitaxel) NTM intron 23006423 rs11222869 chr11 131901748 A G 1 Drug response to Etoposide NTM intron 17537913 rs11222869 chr11 131901748 A G 2.16E-05 Response to taxane treatment (placlitaxel) NTM intron 23006423 rs948039 chr11 131901805 A G 1.81E-04 Response to taxane treatment (placlitaxel) NTM intron 23006423 rs2018361 chr11 131902177 C A 7.85E-05 Response to taxane treatment (placlitaxel) NTM intron 23006423 rs527745 chr11 131908888 C T 7.53E-04 Suicide attempts in bipolar disorder NTM intron 21423239 rs579984 chr11 131912523 G A 1.28E-04 Response to taxane treatment (placlitaxel) NTM intron 23006423 rs484096 chr11 131912780 A C 2.54E-04 Response to taxane treatment (placlitaxel) NTM intron 23006423 rs505595 chr11 131915611 G A 3.99E-04 Heart Failure NTM intron pha002885 rs11222888 chr11 131920851 T G 1.77E-05 Smoking cessation NTM intron 18519826 rs1793640 chr11 131921698 T G 4.95E-05 Response to taxane treatment (placlitaxel) NTM intron 23006423 rs542216 chr11 131922651 G A 7.44E-04 Tourette syndrome NTM intron 22889924 rs1793630 chr11 131926198 T C 5.94E-04 Response to taxane treatment (placlitaxel) NTM intron 23006423 rs1015055 chr11 131933341 C T 3.50E-04 Response to taxane treatment (placlitaxel) NTM intron 23006423 rs1790171 chr11 131935236 T C 3.86E-04 Response to taxane treatment (placlitaxel) NTM intron 23006423 rs7110697 chr11 131935336 C A 1.57E-05 Lipoprotein-associated phospholipase A2 activity and mass NTM intron 20442857 rs7110697 chr11 131935336 C A 2.50E-04 Alzheimer's disease NTM intron 22005930 rs1626583 chr11 131935628 C T 6.99E-04 Response to taxane treatment (placlitaxel) NTM intron 23006423 rs7937152 chr11 131936494 C T 7.47E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy NTM intron 24578207 rs7937152 chr11 131936494 C T 7.47E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy NTM intron 24578207 rs11222903 chr11 131947173 T A 3.68E-04 Alzheimer's disease NTM intron 22005930 rs11222906 chr11 131950240 G T 3.47E-04 Alzheimer's disease NTM intron 22005930 rs1790181 chr11 131954147 A C 4.13E-04 Response to taxane treatment (placlitaxel) NTM intron 23006423 rs11222916 chr11 131965039 T C 2.00E-05 Urinary metabolites NTM intron 21572414 rs11605616 chr11 131977847 C G 1.74E-04 Suicide attempts in bipolar disorder NTM intron 21041247 rs10894502 chr11 131981852 G T 1.00E-04 Prostate cancer NTM intron 21743057 rs9667087 chr11 131984142 A G 3.88E-05 Smoking cessation NTM intron 18519826 rs12223742 chr11 131984267 T C 4.53E-04 Suicide attempts in bipolar disorder NTM intron 21041247 rs10894503 chr11 131984553 C T 1.61E-04 Smoking cessation NTM intron 18519826 rs3925045 chr11 131989637 C G 4.33E-04 Suicide attempts in bipolar disorder NTM intron 21041247 rs3925045 chr11 131989637 C G 5.47E-04 Alzheimer's disease NTM intron 22005930 rs3925046 chr11 131989896 G A 3.46E-04 Type 2 diabetes NTM intron 17846124 rs10791209 chr11 132008380 G A 1.92E-04 Smoking cessation NTM intron 18519826 rs4468361 chr11 132010117 T C 8.00E-06 Chronic obstructive pulmonary disease-related biomarkers NTM intron 23144326 rs7937519 chr11 132017367 C T 1.40E-05 Height NTM intron pha003010 rs7119760 chr11 132025395 G A 8.83E-04 Alzheimer's disease NTM intron 22005930 rs7943322 chr11 132027609 T G 4.65E-04 Type 2 diabetes NTM intron 17463246 rs11222958 chr11 132027797 C T 4.77E-04 Type 2 diabetes NTM intron 17463246 rs4937677 chr11 132033531 T C 2.86E-04 Stroke (pediatric) NTM intron 22990015 rs10791217 chr11 132052335 C T 3.09E-04 Amyotrophic lateral sclerosis (sporadic) NTM intron 24529757 rs3824870 chr11 132081873 G A 4.16E-04 Depression (quantitative trait) NTM intron 20800221 rs11222977 chr11 132086128 C T 7.27E-04 Acute lung injury NTM intron 22295056 rs1868534 chr11 132094466 T G 5.29E-04 Nicotine smoking NTM intron 19268276 rs6590631 chr11 132094965 C A 5.08E-04 Acute lung injury NTM intron 22295056 rs6590632 chr11 132095250 T C 6.05E-04 Acute lung injury NTM intron 22295056 rs7103588 chr11 132097084 A G 6.02E-04 Acute lung injury NTM intron 22295056 rs921271 chr11 132098428 G T 6.46E-04 Acute lung injury NTM intron 22295056 rs4937683 chr11 132099465 T A 6.46E-04 Acute lung injury NTM intron 22295056 rs11222978 chr11 132102938 C T 4.02E-04 Acute lung injury NTM intron 22295056 rs11222981 chr11 132103389 G A 5.03E-04 Acute lung injury NTM intron 22295056 rs7108494 chr11 132119423 T C 7.16E-04 Acute lung injury NTM intron 22295056 rs3099797 chr11 132121386 C T 4.60E-05 Type 2 diabetes NTM intron 21647700 rs4937687 chr11 132135481 G A 5.57E-08 Elbow pain NTM intron pha003008 rs4937688 chr11 132135496 T C 5.57E-08 Elbow pain NTM intron pha003008 rs10894526 chr11 132136885 C T 6.51E-04 Response to taxane treatment (placlitaxel) NTM intron 23006423 rs10894532 chr11 132160813 G A 8.34E-07 Elbow pain NTM intron pha003008 rs3099773 chr11 132176500 T C 5.99E-04 HIV-1 viral setpoint NTM intron 17641165 rs3099773 chr11 132176500 T C 2.40E-05 Urinary metabolites NTM intron 21572414 rs11223007 chr11 132182003 C T 3.60E-05 Cognitive decline NTM intron 22054870 rs520420 chr11 132207239 T C 9.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs577640 chr11 132208428 A G 6.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs617423 chr11 132209953 G A 8.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs11223020 chr11 132219179 C A 2.08E-04 Multiple complex diseases / / 17554300 rs620813 chr11 132223685 C T 9.80E-05 Fibrinogen / / 17255346 rs882584 chr11 132229070 G T 8.03E-05 Multiple complex diseases / / 17554300 rs1968652 chr11 132233390 A C 1.87E-04 Depression (quantitative trait) / / 20800221 rs6590634 chr11 132237417 T G 5.83E-04 Depression (quantitative trait) / / 20800221 rs10894539 chr11 132239365 A C 7.94E-04 Depression (quantitative trait) / / 20800221 rs10894540 chr11 132239708 C T 7.11E-04 Depression (quantitative trait) / / 20800221 rs10791229 chr11 132265728 T A 4.35E-04 Multiple complex diseases / / 17554300 rs7120180 chr11 132266425 G C 4.27E-04 Multiple complex diseases / / 17554300 rs7105078 chr11 132267922 A G 3.86E-04 Multiple complex diseases / / 17554300 rs12284699 chr11 132271740 G A 5.72E-04 Multiple complex diseases / / 17554300 rs10791230 chr11 132272991 G C 3.77E-04 Multiple complex diseases / / 17554300 rs1065 chr11 132273416 T A 1.37E-04 Multiple complex diseases / / 17554300 rs10894554 chr11 132277720 C T 7.78E-05 Multiple complex diseases / / 17554300 rs1940013 chr11 132281651 C T 6.00E-06 Sleep-related phenotypes / / 17903308 rs1940013 chr11 132281651 C T 6.10E-06 Sleep and circadian phenotypes / / 17903308 rs3824898 chr11 132285443 G A 3.95E-04 Multiple complex diseases OPCML UTR-3 17554300 rs4937700 chr11 132287328 C T 2.66E-04 Multiple complex diseases OPCML UTR-3 17554300 rs4937700 chr11 132287328 C T 8.88E-05 Type 1 diabetes OPCML UTR-3 18978792 rs12417610 chr11 132291036 G A 4.64E-04 Type 2 diabetes OPCML intron 17463246 rs12417610 chr11 132291036 G A 1.24E-04 Multiple complex diseases OPCML intron 17554300 rs12417610 chr11 132291036 G A 2.82E-05 Type 1 diabetes OPCML intron 18978792 rs12221543 chr11 132296204 A G 7.22E-04 Type 2 diabetes OPCML intron 17463246 rs4936168 chr11 132314776 T C 1.77E-04 Multiple complex diseases OPCML intron 17554300 rs4936168 chr11 132314776 T C 2.96E-05 Type 1 diabetes OPCML intron 18978792 rs11223077 chr11 132319543 G A 5.50E-04 Multiple complex diseases OPCML intron 17554300 rs948208 chr11 132327820 G A 3.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OPCML intron 20877124 rs607810 chr11 132337904 G A 1.00E-04 Information processing speed OPCML intron 21130836 rs2508982 chr11 132358166 C A 9.17E-05 Smoking initiation OPCML intron 24665060 rs1893041 chr11 132368053 G A 4.53E-05 Fibrinogen OPCML intron 17255346 rs2508936 chr11 132375815 T C 3.36E-04 Lung function (forced expiratory volume in 1 second) OPCML intron 24023788 rs2508936 chr11 132375815 T C 5.15E-05 Lung function (forced vital capacity) OPCML intron 24023788 rs12361323 chr11 132385359 C T 2.00E-05 Urinary metabolites OPCML intron 21572414 rs494050 chr11 132387220 T C 5.02E-05 Cholesterol OPCML intron pha003083 rs1940400 chr11 132389627 G A 7.50E-04 Schizophrenia OPCML intron 21795503 rs2212487 chr11 132398054 C T 1.18E-04 Amyotrophic Lateral Sclerosis OPCML intron 17362836 rs2277271 chr11 132399272 A G 9.93E-04 Amyotrophic Lateral Sclerosis OPCML intron 17362836 rs7117914 chr11 132401703 G A 9.96E-04 Type 2 diabetes OPCML intron 17463246 rs7125438 chr11 132402910 G A 2.32E-05 Schizophrenia OPCML intron 19571809 rs7125438 chr11 132402910 G A 2.08E-05 Schizophrenia OPCML intron pha002859 rs11223108 chr11 132415909 C T 8.70E-04 Type 2 diabetes OPCML intron 17463246 rs7947822 chr11 132420784 C A 1.04E-05 Osteoarthritis (knee and hip) OPCML intron 21177295 rs7947822 chr11 132420784 C A 1.10E-05 Osteoarthritis (knee and hip) OPCML intron 21177295 rs11223123 chr11 132433033 A C 9.04E-05 Heart Rate OPCML intron pha003053 rs2437831 chr11 132461616 C T 1.86E-04 Alzheimer's disease OPCML intron 17998437 rs2437825 chr11 132469865 A G 5.48E-05 Chronic Hepatitis C infection OPCML intron 21725309 rs10791240 chr11 132486995 G A 9.67E-05 Heart Rate OPCML intron pha003053 rs4936173 chr11 132492426 C T 3.73E-04 Alcohol dependence OPCML intron 21314694 rs4936173 chr11 132492426 C T 2.33E-05 Chronic Hepatitis C infection OPCML intron 21725309 rs1894193 chr11 132527512 C T 3.23E-05 Odorant perception OPCML intron 23910658 rs1784176 chr11 132539474 C A 2.91E-04 Lung function (forced vital capacity) OPCML intron 24023788 rs3018406 chr11 132553580 A T 6.83E-04 Multiple complex diseases OPCML intron 17554300 rs3019859 chr11 132569416 G C 1.66E-04 Multiple complex diseases OPCML intron 17554300 rs3016384 chr11 132573390 C T 6.18E-04 Multiple complex diseases OPCML intron 17554300 rs1620329 chr11 132577443 G A 2.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OPCML intron 20877124 rs1784522 chr11 132578834 A G 3.72E-04 Oral cancers (chewing tobacco related) OPCML intron 22503698 rs1784522 chr11 132578834 A G 8.62E-05 Waist-Hip Ratio OPCML intron pha003029 rs1784520 chr11 132581348 A G 5.53E-04 Multiple complex diseases OPCML intron 17554300 rs3016500 chr11 132581927 T C 5.50E-05 Chronic Hepatitis C infection OPCML intron 21725309 rs1793257 chr11 132584119 C T 4.60E-04 Non-substance related behavioral disinhibition OPCML intron 23942779 rs1793257 chr11 132584119 C T 7.00E-06 Alcohol dependence OPCML intron 23942779 rs11822374 chr11 132637429 T C 8.12E-05 Brain derived neurotrophic factor levels,in serum OPCML intron 22047184 rs10894604 chr11 132641746 T G 4.00E-07 Waist-hip ratio OPCML intron 23966867 rs2001903 chr11 132645373 C A 3.29E-04 Depression (quantitative trait) OPCML intron 20800221 rs10894606 chr11 132671611 C A 0.00000002 Brain microstructure and intellectual performance OPCML intron 22723713 rs12285031 chr11 132685984 G A 1.89E-05 Cognitive performance OPCML intron 19734545 rs4287347 chr11 132686007 T C 3.90E-04 Type 2 diabetes OPCML intron 21874001 rs11223224 chr11 132689635 C G 1.40E-06 Urinary metabolites OPCML intron 21572414 rs10160341 chr11 132710240 G A 2.01E-04 Depression (quantitative trait) OPCML intron 20800221 rs1506877 chr11 132717062 C T 1.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OPCML intron 20877124 rs1506876 chr11 132717613 C T 5.22E-05 Amyotrophic lateral sclerosis OPCML intron 23624525 rs2725438 chr11 132718196 A G 9.36E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OPCML intron 20877124 rs2725438 chr11 132718196 A G 8.35E-05 Amyotrophic lateral sclerosis OPCML intron 23624525 rs11223249 chr11 132724717 G A 3.52E-05 Personality dimensions OPCML intron 18957941 rs1395504 chr11 132729167 T G 6.59E-04 Coronary heart disease OPCML intron 21606135 rs11824635 chr11 132746594 T G 0.0000246 Tuberculosis with early age of onset OPCML intron 22551897 rs2063071 chr11 132755278 G A 2.30E-04 Osteoarthritis OPCML intron 19508968 rs11223273 chr11 132774841 C T 9.91E-05 Systemic sclerosis OPCML intron 21750679 rs2725466 chr11 132779393 A G 6.19E-06 Systemic sclerosis OPCML intron 21750679 rs2725466 chr11 132779393 A G 9.69E-05 Creatinine levels OPCML intron pha003069 rs2725437 chr11 132781823 T C 2.52E-05 Systemic sclerosis OPCML intron 21750679 rs10894623 chr11 132795569 G T 7.75E-05 Systemic sclerosis OPCML intron 21750679 rs7130483 chr11 132811203 A G 4.46E-05 Serum metabolites OPCML intron 19043545 rs1567127 chr11 132829862 A G 1.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio OPCML intron 22589738 rs7935421 chr11 132872052 C T 7.90E-05 Hypothyroidism OPCML intron 22493691 rs11223321 chr11 132882997 A C 4.17E-04 Alcohol dependence OPCML intron 21314694 rs4399339 chr11 132893871 G A 1.32E-05 Alzheimer's disease (late onset) OPCML intron 21379329 rs12796515 chr11 132897222 G C 7.60E-06 Urinary metabolites OPCML intron 21572414 rs11223335 chr11 132906064 C T 7.89E-04 Suicide attempts in bipolar disorder OPCML intron 21423239 rs4387353 chr11 132909293 A G 2.92E-04 Alzheimer's disease (late onset) OPCML intron 21379329 rs11223336 chr11 132911101 A G 8.30E-05 Malaria OPCML intron 19465909 rs11223337 chr11 132912844 G A 8.08E-04 Multiple complex diseases OPCML intron 17554300 rs11223339 chr11 132918464 G T 6.24E-06 Alopecia areata OPCML intron 22027810 rs10791273 chr11 132920785 G A 8.71E-06 Calcium levels OPCML intron pha003085 rs7126587 chr11 132928435 A G 8.31E-04 Schizophrenia OPCML intron 19197363 rs7126587 chr11 132928435 A G 1.15E-04 Age-related macular degeneration OPCML intron 21909106 rs7126587 chr11 132928435 A G 1.44E-05 Calcium levels OPCML intron pha003085 rs12362615 chr11 132934391 T C 2.77E-05 Calcium levels OPCML intron pha003085 rs2060123 chr11 132938574 C T 6.60E-05 Angioedema in response to angiotensin-converting enzyme inhibitor OPCML intron 23838604 rs1007018 chr11 132949473 T C 2.58E-04 Height OPCML intron 17255346 rs1346977 chr11 132962859 A G 3.71E-04 Alzheimer's disease OPCML intron 17998437 rs1431780 chr11 132981446 G A 1.98E-04 Alzheimer's disease OPCML intron 17998437 rs7101401 chr11 132981753 C G 1.30E-04 Alzheimer's disease OPCML intron 17998437 rs7101444 chr11 132981833 C T 2.77E-04 Alzheimer's disease OPCML intron 17998437 rs4319525 chr11 132982603 C T 2.08E-04 Alzheimer's disease OPCML intron 17998437 rs4548631 chr11 132983408 A G 0.0005391 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) OPCML intron 23233654 rs4548631 chr11 132983408 A G 5.39E-04 Methotrexate clearance (acute lymphoblastic leukemia) OPCML intron 23233662 rs4405324 chr11 132983506 T G 0.0005218 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) OPCML intron 23233654 rs4405324 chr11 132983506 T G 5.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) OPCML intron 23233662 rs4536228 chr11 132983679 A C 0.0006109 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) OPCML intron 23233654 rs4536228 chr11 132983679 A C 6.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) OPCML intron 23233662 rs11223367 chr11 132989139 T G 0.0007196 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) OPCML intron 23233654 rs11223367 chr11 132989139 T G 7.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) OPCML intron 23233662 rs11223373 chr11 133014138 G A 4.96E-05 Height OPCML intron 22021425 rs12787504 chr11 133017890 G A 9.51E-05 Alzheimer's disease (age of onset) OPCML intron 22005931 rs2163561 chr11 133026354 C T 3.82E-05 Cognitive impairment induced by topiramate OPCML intron 22091778 rs728341 chr11 133037027 G T 9.41E-05 Tunica Media OPCML intron pha003038 rs475056 chr11 133043258 A G 5.39E-04 Response to statin treatment (atorvastatin),change in cholesterol levels OPCML intron 20031582 rs11606197 chr11 133051091 T C 7.13E-05 Information processing speed OPCML intron 21130836 rs517218 chr11 133087325 C T 8.20E-05 Response to cytadine analogues (cytosine arabinoside) OPCML intron 24483146 rs12577796 chr11 133102683 C A 6.16E-05 Sleep latency OPCML intron 23728906 rs2078454 chr11 133120937 C A 6.00E-06 Smooth-surface caries OPCML intron 23470693 rs722449 chr11 133150936 G A 0.0000088 Primary sclerosing cholangitis OPCML intron 22521342 rs1941220 chr11 133154441 A G 6.55E-04 Alcohol consumption (maxi-drinks) OPCML intron 24277619 rs7128156 chr11 133164312 A G 7.54E-04 Type 2 diabetes OPCML intron 17463246 rs7128156 chr11 133164312 A G 2.41E-04 Multiple complex diseases OPCML intron 17554300 rs7122854 chr11 133168523 A G 8.08E-07 Osteoarthritis OPCML intron 22763110 rs2212517 chr11 133169430 T C 9.06E-05 Type 1 diabetes OPCML intron 21980299 rs4379857 chr11 133183604 G A 9.74E-05 Nicotine smoking OPCML intron 19268276 rs948205 chr11 133190796 C A 0.0008252 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) OPCML intron 23233654 rs948205 chr11 133190796 C A 8.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) OPCML intron 23233662 rs11223437 chr11 133193153 A G 3.53E-04 Type 2 diabetes OPCML intron 17463246 rs7101547 chr11 133194915 C T 0.0008338 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) OPCML intron 23233654 rs7101547 chr11 133194915 C T 8.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) OPCML intron 23233662 rs7104890 chr11 133201036 G A 1.73E-34 Metabolite levels OPCML intron 22286219 rs10894669 chr11 133206940 C A 1.00E-04 Cognitive impairment induced by topiramate OPCML intron 22091778 rs10894669 chr11 133206940 C A 7.97E-04 Alcohol consumption (maxi-drinks) OPCML intron 24277619 rs10894671 chr11 133224978 C A 8.35E-04 Sleep depth OPCML intron 23728906 rs4643088 chr11 133245713 G T 6.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OPCML intron 20877124 rs4073610 chr11 133247675 A T 2.81E-04 Multiple complex diseases OPCML intron 17554300 rs4391826 chr11 133255029 C T 4.20E-05 Cognitive function OPCML intron 24684796 rs7105814 chr11 133259745 A G 8.87E-04 Suicide attempts in bipolar disorder OPCML intron 21423239 rs7935477 chr11 133260924 A T 8.03E-04 Suicide attempts in bipolar disorder OPCML intron 21423239 rs57110167 chr11 133287107 G A 0.00009011 Sarcoidosis OPCML intron 22952805 rs1941212 chr11 133288335 T C 9.29E-04 Multiple complex diseases OPCML intron 17554300 rs2155777 chr11 133290007 C T 8.87E-05 Multiple complex diseases OPCML intron 17554300 rs6590695 chr11 133292376 C T 3.70E-04 Multiple complex diseases OPCML intron 17554300 rs7942722 chr11 133296327 T C 0.00005897 Sarcoidosis OPCML intron 22952805 rs34280483 chr11 133302517 T C 0.0001203 Sarcoidosis OPCML intron 22952805 rs10894683 chr11 133320967 C T 7.22E-06 Carotenoid and tocopherol levels OPCML intron 19185284 rs7481883 chr11 133322722 G T 3.70E-05 Body mass (lean) OPCML intron 19268274 rs7927989 chr11 133356488 G A 7.89E-06 Diabetes Mellitus OPCML intron pha003060 rs4937788 chr11 133376068 C T 8.50E-05 Hypothyroidism OPCML intron 22493691 rs7117082 chr11 133392294 G T 8.00E-09 Amyotrophic lateral sclerosis (sporadic) OPCML intron 24529757 rs7117082 chr11 133392294 G T 1.37E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) OPCML intron 25044411 rs4403819 chr11 133401871 A C 0.000754 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) OPCML intron 23233654 rs4403819 chr11 133401871 A C 7.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) OPCML intron 23233662 rs11223511 chr11 133434425 A G 4.39E-04 Multiple complex diseases / / 17554300 rs6590719 chr11 133456095 A G 6.42E-04 Multiple complex diseases / / 17554300 rs12290536 chr11 133459873 G A 8.27E-05 Cervical cancer / / 24700089 rs11606737 chr11 133472324 A G 9.30E-05 Serum metabolites / / 19043545 rs7952524 chr11 133479904 T A 9.53E-05 Serum metabolites / / 19043545 rs4245120 chr11 133489916 C A 1.37E-04 Progressive supranuclear palsy / / 21685912 rs10791298 chr11 133490944 G T 1.48E-04 Progressive supranuclear palsy / / 21685912 rs11822149 chr11 133492755 T C 1.87E-05 Bipolar disorder and schizophrenia / / 20889312 rs2279694 chr11 133520207 T C 7.51E-05 Cervical cancer / / 24700089 rs4937808 chr11 133524393 C A 7.37E-05 Serum metabolites / / 19043545 rs4397868 chr11 133566985 C T 3.00E-07 Menopause (age at onset) / / 19448619 rs4397868 chr11 133566985 C T 6.10E-05 Receptive language ability / / 24687471 rs7927483 chr11 133590335 G A 4.26E-04 Breast cancer / / 20852631 rs12279437 chr11 133603494 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12279437 chr11 133603494 C T 0.000343 fMRI brain tests in schizophrenia / / 22440650 rs12279437 chr11 133603494 C T 8.71E-05 ldl cholesterol / / pha003076 rs1603389 chr11 133640611 T C 9.27E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4379863 chr11 133660717 T C 4.29E-04 Type 2 diabetes / / 17463246 rs9667033 chr11 133664606 A C 2.56E-04 Type 2 diabetes / / 17463246 rs9667066 chr11 133687923 G A 0.000110508 Hypertension (early onset hypertension) / / 22479346 rs2723589 chr11 133688009 G A 6.06E-04 Multiple complex diseases / / 17554300 rs1485197 chr11 133756187 A G 3.43E-04 Multiple complex diseases / / 17554300 rs329674 chr11 133776948 A G 5.80E-04 Tourette syndrome / / 22889924 rs329674 chr11 133776948 A G 3.60E-05 Creatinine levels / / pha003069 rs1682859 chr11 133800219 C A 1.00E-06 Obesity-related traits IGSF9B intron 23251661 rs561561 chr11 133829706 A T 6.68E-04 Type 2 diabetes / / 17463246 rs561561 chr11 133829706 A T 7.22E-04 Multiple complex diseases / / 17554300 rs493888 chr11 133832473 C T 6.06E-04 Type 2 diabetes / / 17463246 rs493888 chr11 133832473 C T 2.23E-04 Multiple complex diseases / / 17554300 rs7106715 chr11 133838905 C T 0.0000652 Schizophrenia / / 23637625 rs329680 chr11 133842480 T C 9.89E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs901036 chr11 133858766 G C 1.55E-04 Multiple complex diseases / / 17554300 rs12364540 chr11 133860039 C T 5.46E-05 Hepatocellular carcinoma / / 22807686 rs2019649 chr11 133862976 A G 5.02E-05 Height / / 17255346 rs682386 chr11 133896873 A G 9.49E-04 Multiple complex diseases / / 17554300 rs724095 chr11 133897382 A G 0.00034 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines / / 23204130 rs608838 chr11 133901854 A G 1.95E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1784391 chr11 133926704 G A 8.89E-05 Cognitive test performance / / 20125193 rs661820 chr11 133932652 T C 8.87E-05 Cognitive test performance / / 20125193 rs661820 chr11 133932652 T C 2.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1784394 chr11 133963216 T C 3.57E-16 Cleft lip JAM3 intron 20436469 rs11604455 chr11 133982866 C T 1.05E-04 Multiple complex diseases JAM3 intron 17554300 rs12287552 chr11 133990164 C T 9.21E-05 Waist-Hip Ratio JAM3 intron pha003029 rs11223704 chr11 133997052 T A 1.49E-04 Multiple complex diseases JAM3 intron 17554300 rs11606866 chr11 134039963 A C 2.30E-05 Multiple complex diseases NCAPD3 intron 17554300 rs11606866 chr11 134039963 A C 2.64E-05 Cognitive performance NCAPD3 intron 19734545 rs12573858 chr11 134064675 G T 1.63E-05 Cognitive performance NCAPD3 intron 19734545 rs12276543 chr11 134073460 C A 7.39E-05 Body Mass Index NCAPD3 intron pha003022 rs1031381 chr11 134088682 G A 4.95E-04 Multiple complex diseases NCAPD3 intron 17554300 rs1031381 chr11 134088682 G A 6.00E-06 Cognitive test performance NCAPD3 intron 17903297 rs12808353 chr11 134115936 G T 2.40E-06 Primary sclerosing cholangitis VPS26B UTR-3 21151127 rs492761 chr11 134117015 T C 3.90E-05 Tooth agenesis (third molar) / / 24172245 rs570113 chr11 134122250 C T 5.35E-05 Response to tocilizumab in rheumatoid arthritis THYN1 intron 22491018 rs200170162 chr11 134128968 A G 0.000032 Prostate cancer ACAD8 missense 23555315 rs478881 chr11 134139780 A G 7.00E-06 Obesity-related traits / / 23251661 rs1144223 chr11 134162866 G A 9.33E-04 Type 2 diabetes GLB1L3 intron 22158537 rs1144219 chr11 134172031 G T 5.57E-05 Asthma GLB1L3 intron 23181788 rs2509062 chr11 134182375 G A 1.40E-14 Health and aging,CVD and cancer age of onset GLB1L3 missense 22174011 rs2509062 chr11 134182375 G A 1.80E-07 Health and aging,CVD and cancer age of onset GLB1L3 missense 22174011 rs2509062 chr11 134182375 G A 2.90E-13 Health and aging,CVD and cancer age of onset GLB1L3 missense 22174011 rs513412 chr11 134194937 G A 6.82E-04 Multiple complex diseases / / 17554300 rs513412 chr11 134194937 G A 2.58E-04 Alzheimer's disease (late onset) / / 21379329 rs7928758 chr11 134265967 T G 1.66E-08 N-glycan levels,in plasma B3GAT1 intron 21908519 rs7928758 chr11 134265967 T G 3.00E-06 Alcohol consumption (maxi-drinks) B3GAT1 intron 24277619 rs10894810 chr11 134273559 C T 1.20E-05 Urinary metabolites B3GAT1 intron 21572414 rs1866769 chr11 134274676 A G 8.83E-04 Response to taxane treatment (placlitaxel) B3GAT1 intron 23006423 rs4937883 chr11 134293443 A G 9.00E-04 Coronary heart disease / / 21606135 rs10791360 chr11 134301899 C A 4.54E-06 Alopecia areata / / 22027810 rs10894818 chr11 134316222 G A 4.77E-04 Gallstones LOC283177 intron 17632509 rs10791373 chr11 134347974 C T 1.81E-04 Sudden cardiac arrest LOC283177 intron 21658281 rs11223858 chr11 134350107 C T 4.71E-04 Response to taxane treatment (placlitaxel) LOC283177 intron 23006423 rs11606721 chr11 134352896 G C 5.41E-04 Smoking cessation LOC283177 intron 24665060 rs7111077 chr11 134353827 A G 8.18E-04 Smoking cessation LOC283177 intron 24665060 rs11602971 chr11 134356705 C T 8.02E-04 Smoking cessation LOC283177 intron 24665060 rs11605721 chr11 134373881 A C 5.84E-04 Smoking cessation LOC283177 intron 24665060 rs11223888 chr11 134403389 C T 6.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6590745 chr11 134408935 C T 9.09E-04 Tourette syndrome / / 22889924 rs11223899 chr11 134423252 C T 4.34E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11223899 chr11 134423252 C T 4.03E-04 Alzheimer's disease (late onset) / / 21379329 rs10894845 chr11 134448470 C T 1.00E-05 Triglycerides / / 19074352 rs9919607 chr11 134449247 G A 2.87E-04 Hemoglobin concentration / / 20534544 rs4937918 chr11 134455371 A C 4.93E-04 Multiple complex diseases / / 17554300 rs4937920 chr11 134465744 C T 7.76E-04 Multiple complex diseases / / 17554300 rs4315093 chr11 134475682 C T 3.53E-04 Multiple complex diseases / / 17554300 rs7106815 chr11 134476412 C T 2.63E-04 Multiple complex diseases / / 17554300 rs1944866 chr11 134482466 T C 2.00E-06 Myopia (pathological) / / 23049088 rs1944866 chr11 134482466 T C 3.01E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs3019643 chr11 134503242 A G 3.75E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs3017963 chr11 134508438 A G 2.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs3018015 chr11 134510309 T C 2.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs11223936 chr11 134548813 G A 2.36E-04 Multiple complex diseases / / 17554300 rs11223956 chr11 134568942 T C 2.98E-04 Multiple complex diseases / / 17554300 rs11825685 chr11 134573810 C T 9.00E-06 IgG glycosylation / / 23382691 rs11604608 chr11 134602946 G A 1.25E-04 Sudden cardiac arrest / / 21658281 rs11601707 chr11 134619154 T C 2.30E-05 Urinary metabolites LOC729305 intron 21572414 rs11600687 chr11 134621010 G A 4.11E-05 Cervical cancer LOC729305 intron 24700089 rs6590763 chr11 134622399 C G 1.41E-04 Multiple complex diseases LOC729305 intron 17554300 rs11223996 chr11 134626887 T C 7.00E-07 Myopia (pathological) LOC729305 intron 23049088 rs750965 chr11 134635242 C T 1.57E-05 Parkinson's disease / / 21738487 rs11826391 chr11 134676420 T C 5.07E-05 Receptive language ability / / 24687471 rs12806059 chr11 134676970 T G 1.20E-06 Urinary metabolites / / 21572414 rs11826539 chr11 134680285 G A 4.16E-05 Receptive language ability / / 24687471 rs12786906 chr11 134684914 C A 7.60E-05 Tooth agenesis (mandibular third molar) / / 24172245 rs7127211 chr11 134692092 G A 3.03E-04 Hemoglobin concentration / / 20534544 rs2846186 chr11 134698376 T C 2.85E-04 Hemoglobin concentration / / 20534544 rs2186713 chr11 134706069 C T 3.87E-04 Sarcoidosis / / 19165924 rs2846154 chr11 134714635 C T 8.45E-05 Hemoglobin concentration / / 20534544 rs1892987 chr11 134715777 T C 8.45E-05 Hemoglobin concentration / / 20534544 rs2846142 chr11 134718095 G A 8.45E-05 Hemoglobin concentration / / 20534544 rs2661969 chr11 134718217 T C 8.45E-05 Hemoglobin concentration / / 20534544 rs11224040 chr11 134727848 T C 1.09E-05 Alcohol dependence / / 23089632 rs906628 chr11 134738270 A C 8.00E-06 Tooth agenesis (mandibular third molar) / / 24172245 rs11224060 chr11 134748523 A T 0.0007359 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11224060 chr11 134748523 A T 7.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4290245 chr11 134763958 G A 3.08E-05 Non-word repetition / / 23738518 rs1478747 chr11 134769426 G A 1.81E-04 Celiac disease / / 23936387 rs476135 chr11 134776970 A G 1.39E-05 Alzheimer's disease (late onset) / / 21379329 rs11224103 chr11 134821370 C T 8.61E-04 Body mass index / / 21701565 rs11224189 chr11 134895823 C T 5.84E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12575381 chr11 134903460 G A 9.97E-07 Chronic kidney disease / / 21931561 rs10774263 chr12 192220 G A 6.39E-04 Type 2 diabetes IQSEC3 intron 17463246 rs10774263 chr12 192220 G A 7.57E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) IQSEC3 intron 22566498 rs4980929 chr12 193818 C T 4.14E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) IQSEC3 intron 22566498 rs12426587 chr12 202094 T C 4.88E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) IQSEC3 intron 22566498 rs3741970 chr12 216039 T C 1.74E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) IQSEC3 intron 22566498 rs3741970 chr12 216039 T C 9.46E-04 Heart Failure IQSEC3 intron pha002885 rs7974165 chr12 216234 G A 3.03E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) IQSEC3 intron 22566498 rs7132589 chr12 218024 G T 3.08E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) IQSEC3 intron 22566498 rs2011738 chr12 219988 A G 6.00E-06 Response to angiotensin II receptor blocker therapy IQSEC3 intron 22566498 rs7135126 chr12 221203 A G 7.93E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) IQSEC3 intron 22566498 rs4980976 chr12 232704 C T 2.55E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer IQSEC3 intron 22872573 rs10744731 chr12 237521 G A 2.75E-04 Smoking cessation IQSEC3 intron 24665060 rs7974784 chr12 245335 T C 1.84E-04 Lung function (forced vital capacity) IQSEC3 intron 24023788 rs2291928 chr12 250239 A G 1.70E-05 Response to mTOR inhibitor (rapamycin) IQSEC3 intron 24009623 rs9651889 chr12 257060 C T 1.27E-05 Height IQSEC3 intron 22021425 rs2270797 chr12 257987 C T 5.50E-06 Alopecia areata IQSEC3 intron 22027810 rs2368785 chr12 260682 T C 4.07E-04 Hemoglobin concentration IQSEC3 intron 20534544 rs4980804 chr12 261929 T C 3.22E-05 Height IQSEC3 intron 22021425 rs7955668 chr12 263839 T C 1.40E-04 Hemoglobin concentration IQSEC3 intron 20534544 rs628121 chr12 288149 A C 2.03E-04 Hemoglobin concentration / / 20534544 rs499368 chr12 320920 T A,C 2.00E-10 Metabolite levels (Glycine metabolism) SLC6A12 intron 23378610 rs499368 chr12 320920 T A,C 8.00E-13 Blood metabolite levels SLC6A12 intron 24816252 rs16928441 chr12 321353 G A 5.74E-04 Type 2 diabetes SLC6A12 intron 17463246 rs2289954 chr12 332362 C T 2.85E-05 Celiac disease SLC6A13 cds-synon 23936387 rs555044 chr12 335922 C A 1.00E-12 Metabolite levels SLC6A13 intron 24625756 rs7303797 chr12 342911 G A 3.77E-05 Insulin-related traits SLC6A13 intron 19902172 rs10774021 chr12 349298 C T 1.00E-09 Chronic kidney disease SLC6A13 intron 20383146 rs10774021 chr12 349298 C T 4.67E-07 Chronic kidney disease SLC6A13 intron 22479191 rs11613331 chr12 351467 G A 2.00E-25 Blood metabolite levels SLC6A13 intron 24816252 rs7969761 chr12 355842 C T 1.00E-27 Blood metabolite ratios SLC6A13 intron 24816252 rs3782858 chr12 362369 C A,G,T 7.85E-05 Prion diseases SLC6A13 intron 22210626 rs576159 chr12 382876 T C 3.10E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs525381 chr12 384792 G A 8.27E-04 Alcohol dependence / / 20201924 rs956231 chr12 385092 G A 8.06E-06 Cognitive impairment induced by topiramate / / 22091778 rs1207324 chr12 387464 G A 8.54E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11062357 chr12 421394 T C 2.02E-04 Tourette syndrome KDM5A intron 22889924 rs11062385 chr12 427575 A G 3.68E-04 Amyotrophic Lateral Sclerosis KDM5A missense 17362836 rs1860360 chr12 493900 C T 9.45E-04 Amyotrophic Lateral Sclerosis KDM5A intron 17362836 rs4980819 chr12 544095 A G 1.45E-04 Smoking initiation CCDC77 intron 24665060 rs1048466 chr12 551550 G A 8.00E-08 Obesity (early onset extreme) CCDC77 UTR-3 23563609 rs12372234 chr12 558423 C T 2.40E-05 Alcohol dependence / / 24277619 rs4980915 chr12 564185 A G 6.10E-05 Response to alcohol consumption (flushing response) / / 24277619 rs7311655 chr12 585827 T G 1.00E-04 Spine bone size B4GALNT3 intron 21947420 rs10744648 chr12 586407 A G 0.000693418 Primary sclerosing cholangitis B4GALNT3 intron 23603763 rs7294326 chr12 594174 G T 3.40E-06 Urinary metabolites B4GALNT3 intron 21572414 rs2286782 chr12 628236 C A 9.50E-05 Type 2 diabetes B4GALNT3 intron 17463246 rs2075033 chr12 644337 G A 9.07E-04 Alcohol consumption (maxi-drinks) B4GALNT3 missense 24277619 rs12582126 chr12 644726 G A 9.85E-05 Lung function (forced expiratory volume in 1 second) B4GALNT3 intron 24023788 rs7298766 chr12 661656 A G 3.05E-05 Serum metabolites B4GALNT3 missense 19043545 rs148059237 chr12 662873 C T 0.000046 Prostate cancer B4GALNT3 missense 23555315 rs1860613 chr12 671670 C T 1.41E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2245918 chr12 673515 T C 6.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NINJ2 UTR-3 20877124 rs2245906 chr12 673788 A G 6.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NINJ2 UTR-3 20877124 rs1468624 chr12 673854 A G 3.64E-04 Intracranial aneurysm NINJ2 intron 20613766 rs11063757 chr12 698043 G C 8.78E-04 Type 2 diabetes NINJ2 intron 17463246 rs2535436 chr12 698634 A G 9.93E-05 Schizophrenia NINJ2 intron pha002859 rs11063838 chr12 714576 T G 3.82E-04 Response to cytidine analogues (gemcitabine) NINJ2 intron 24483146 rs722097 chr12 714842 A G 1.78E-05 Orofacial clefts NINJ2 intron 22863734 rs3809263 chr12 773456 C T 6.08E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11616050 chr12 783350 A G 9.26E-04 Response to alcohol consumption (flushing response) / / 24277619 rs12425791 chr12 783484 G A 1.00E-09 Stroke / / 19369658 rs11064190 chr12 785642 G A 2.06E-04 Acute lung injury / / 22295056 rs1870199 chr12 786238 A G 6.06E-04 Multiple complex diseases / / 17554300 rs11064204 chr12 787923 T C 2.18E-04 Acute lung injury / / 22295056 rs11064294 chr12 805451 C T 6.54E-05 HDL cholesterol / / pha003074 rs11064294 chr12 805451 C T 1.27E-05 HDL cholesterol / / pha003075 rs10774464 chr12 922408 C T 5.50E-04 Alcohol dependence WNK1 intron 20201924 rs7963376 chr12 926248 T C 5.50E-04 Alcohol dependence WNK1 intron 20201924 rs11611246 chr12 939480 G T 0.00000797 Body mass index WNK1 intron 23001569 rs6489756 chr12 964506 G A 4.86E-04 Type 2 diabetes WNK1 intron 17463246 rs12309274 chr12 975948 T G 4.57E-05 Lung adenocarcinoma WNK1 intron 19836008 rs12309274 chr12 975948 T G 3.00E-06 Colorectal cancer WNK1 intron 24836286 rs16931965 chr12 976487 C T 8.65E-04 Type 2 diabetes WNK1 intron 17463246 rs17800834 chr12 981994 G C 9.28E-04 Obesity (extreme) WNK1 intron 21935397 rs150532648 chr12 992587 A G 0.00025 Breast cancer WNK1 missense 23555315 rs72650721 chr12 992653 G A 2.27E-12 Metabolite levels WNK1 cds-synon 22286219 rs7955371 chr12 994487 G C 2.38E-10 Triglycerides WNK1 missense 23063622 rs12828016 chr12 998365 G T 1.10E-16 Leukemia(T-cell recognition in patients) WNK1 missense 21062987 rs17755373 chr12 999638 C T 0.0000162 Triglycerides WNK1 missense 23063622 rs7972490 chr12 1009056 G A 7.64E-04 Coronary Artery Disease WNK1 intron 17634449 rs11571475 chr12 1022352 A G 8.52E-04 Obesity (extreme) RAD52 UTR-3 21935397 rs6413436 chr12 1022679 A G 4.90E-04 Alcohol dependence RAD52 intron 20201924 rs6413436 chr12 1022679 A G 9.00E-06 Alcohol dependence RAD52 intron 20201924 rs6413436 chr12 1022679 A G 8.95E-06 Alcoholism RAD52 intron pha002892 rs7311151 chr12 1050254 G A 7.95E-05 Angioedema in response to angiotensin-converting enzyme inhibitor RAD52 intron 23838604 rs10849605 chr12 1064438 T C 9.13E-06 Lung adenocarcinoma / / 19836008 rs10849605 chr12 1064438 T C 6.00E-07 Lung cancer / / 22899653 rs6489769 chr12 1072965 C T 2.85E-05 Lung adenocarcinoma / / 19836008 rs2107643 chr12 1121571 A G 5.94E-04 Lymphocyte counts ERC1 intron 22286170 rs7974686 chr12 1125475 A G 8.27E-05 Blood Pressure ERC1 intron pha003049 rs12316126 chr12 1210884 A G 2.50E-04 Gallbladder cancer ERC1 intron 22318345 rs10848438 chr12 1211576 G A 9.20E-05 Primary sclerosing cholangitis ERC1 intron 19944697 rs4766143 chr12 1245218 C G,T 7.40E-04 Type 2 diabetes ERC1 intron 17463246 rs2906115 chr12 1248068 G A 3.63E-04 Multiple complex diseases ERC1 intron 17554300 rs2369701 chr12 1259831 G C 5.20E-04 Primary sclerosing cholangitis ERC1 intron 19944697 rs17800852 chr12 1262829 A G 7.72E-04 Type 2 diabetes ERC1 intron 17463246 rs11061655 chr12 1277463 G C 7.22E-05 Multiple complex diseases ERC1 intron 17554300 rs12426509 chr12 1357650 T G 7.17E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) ERC1 intron 24236485 rs1544426 chr12 1366511 A G 7.65E-06 Body Mass Index ERC1 intron pha003015 rs2286036 chr12 1371828 G A,C,T 1.83E-05 Body Mass Index ERC1 intron pha003009 rs2286036 chr12 1371828 G A,C,T 3.14E-05 Waist Circumference ERC1 intron pha003025 rs2286036 chr12 1371828 G A,C,T 2.48E-05 Weight ERC1 intron pha003026 rs2286036 chr12 1371828 G A,C,T 1.32E-05 Weight ERC1 intron pha003027 rs16928347 chr12 1416592 C T 2.42E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) ERC1 intron 23648065 rs12298813 chr12 1458885 G C 4.50E-04 Primary sclerosing cholangitis ERC1 intron 19944697 rs12320293 chr12 1486636 G A 3.60E-04 Primary sclerosing cholangitis ERC1 intron 19944697 rs10773943 chr12 1510505 A G 4.70E-05 Amyotrophic lateral sclerosis ERC1 intron 19193627 rs12302187 chr12 1524144 A G 7.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ERC1 intron 20877124 rs3741977 chr12 1601561 G A 5.55E-04 Amyotrophic lateral sclerosis (sporadic) ERC1 UTR-3 24529757 rs3741976 chr12 1601896 C T 8.80E-05 Schizophrenia ERC1 UTR-3 21791550 rs3741976 chr12 1601896 C T 0.000088 Psychosis ERC1 UTR-3 23164818 rs2887571 chr12 1638171 A G 6.00E-12 Bone mineral density / / 22504420 rs7976606 chr12 1654877 A C 2.20E-05 Urinary metabolites / / 21572414 rs7316135 chr12 1718074 G A 5.93E-04 Coronary Artery Disease / / 17634449 rs4766396 chr12 1726411 A G 0.000527 Height (Pygmy height) WNT5B intron 22570615 rs4765834 chr12 1729635 T G 6.67E-04 Multiple complex diseases WNT5B intron 17554300 rs4765834 chr12 1729635 T G 4.69E-04 Lymphocyte counts WNT5B intron 22286170 rs4766399 chr12 1734560 G T 1.70E-05 Urinary metabolites WNT5B intron 21572414 rs10773971 chr12 1740171 C G 0.00008581 Sarcoidosis WNT5B intron 22952805 rs2270031 chr12 1742509 C G 0.00006487 Sarcoidosis WNT5B intron 22952805 rs2270034 chr12 1743524 T G 0.00003229 Sarcoidosis WNT5B intron 22952805 rs11061889 chr12 1747946 A G 0.00008812 Sarcoidosis WNT5B intron 22952805 rs28384807 chr12 1749473 C A 0.00009654 Sarcoidosis WNT5B intron 22952805 rs2270037 chr12 1749841 T C 3.92E-04 Multiple complex diseases WNT5B intron 17554300 rs2058032 chr12 1774149 T C 9.90E-06 Urinary metabolites / / 21572414 rs10491959 chr12 1788033 C G 3.94E-04 Multiple complex diseases / / 17554300 rs10773979 chr12 1788864 A C 1.57E-04 Coronary heart disease / / 21606135 rs2058033 chr12 1804880 T G 6.07E-06 Schizophrenia ADIPOR2 intron 19571809 rs11061935 chr12 1813774 A G 4.06E-06 Schizophrenia ADIPOR2 intron 19571809 rs12230440 chr12 1856953 T G 3.00E-06 Adverse response to lamotrigine and phenytoin ADIPOR2 intron 22379998 rs7134070 chr12 1867401 T C 0.000000789 Triglycerides ADIPOR2 intron 23063622 rs7134070 chr12 1867401 T C 0.00013 Coronary artery calcification ADIPOR2 intron 23727086 rs12821401 chr12 1878392 C A 3.46E-05 Schizophrenia ADIPOR2 intron 19571809 rs10161408 chr12 1888673 T C 1.80E-04 Alcohol dependence ADIPOR2 intron 21314694 rs4140993 chr12 1889282 T G 3.55E-08 Triglycerides ADIPOR2 intron 23063622 rs2286382 chr12 1896779 G A 4.50E-06 Coffee consumption ADIPOR2 UTR-3 21357676 rs62621429 chr12 1910786 C T 0.00029 Breast cancer CAC/2D4 missense 23555315 rs7315298 chr12 1912880 C T 5.61E-05 Cognitive performance CAC/2D4 intron 19734545 rs3741974 chr12 1914273 T C 1.19E-05 Cognitive performance CAC/2D4 intron 19734545 rs11611260 chr12 1916838 C T 3.78E-04 Amyotrophic Lateral Sclerosis CAC/2D4 intron 17362836 rs4765845 chr12 1929958 G A 2.59E-04 Iron levels LRTM2 UTR-5 pha002876 rs2887631 chr12 1934581 G A 1.09E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D4 intron 20877124 rs2887631 chr12 1934581 G A 4.00E-06 Behavioural disinhibition (generation interaction) CAC/2D4 intron 23942779 rs10491960 chr12 1934920 T G 2.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/2D4 intron 20877124 rs11061995 chr12 1945042 G A 2.45E-04 Alzheimer's disease (late onset) LRTM2 UTR-3 20885792 rs886942 chr12 1964885 C T 5.48E-05 Type 2 diabetes CAC/2D4 intron 17463246 rs758160 chr12 1983782 C T 4.85E-06 Coronary arterial lesions in patients with Kawasaki disease CAC/2D4 cds-synon 23677057 rs7297190 chr12 1987044 T C 5.02E-06 QRS duration in Tripanosoma cruzi seropositivity CAC/2D4 intron 24324551 rs7308134 chr12 1987245 G A 3.00E-06 QRS duration in Tripanosoma cruzi seropositivity CAC/2D4 intron 24324551 rs58041839 chr12 1988524 G A 7.57E-06 QRS duration in Tripanosoma cruzi seropositivity CAC/2D4 intron 24324551 rs60945277 chr12 1989018 T C 7.86E-06 QRS duration in Tripanosoma cruzi seropositivity CAC/2D4 cds-synon 24324551 rs61085710 chr12 1989197 A G 8.28E-06 QRS duration in Tripanosoma cruzi seropositivity CAC/2D4 intron 24324551 rs11838338 chr12 1989355 G A 2.90E-05 Orofacial clefts CAC/2D4 intron 22419666 rs11838338 chr12 1989355 G A 7.73E-06 QRS duration in Tripanosoma cruzi seropositivity CAC/2D4 intron 24324551 rs11829061 chr12 1989584 G C 7.77E-06 QRS duration in Tripanosoma cruzi seropositivity CAC/2D4 intron 24324551 rs4765855 chr12 1997181 C T 1.04E-05 Orofacial clefts CAC/2D4 intron 22419666 rs4765864 chr12 2021395 T C 1.75E-05 Bipolar disorder CAC/2D4 intron 19488044 rs4765864 chr12 2021395 T C 1.24E-05 Bipolar Disorder CAC/2D4 intron pha002858 rs10848593 chr12 2021700 T A 1.51E-04 Type 2 diabetes CAC/2D4 intron 17463246 rs16928921 chr12 2023486 C G 9.51E-04 Type 2 diabetes CAC/2D4 intron 17463246 rs10505725 chr12 2056363 C T 8.00E-06 Obesity-related traits DCP1B intron 23251661 rs11613469 chr12 2074022 G T 2.42E-04 Parkinson's disease DCP1B intron 17052657 rs10848600 chr12 2083928 G A 1.32E-04 Parkinson's disease DCP1B intron 17052657 rs11062038 chr12 2089230 T C 2.08E-04 Vaspin levels DCP1B intron 22907691 rs11062038 chr12 2089230 T C 0.0002079 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks DCP1B intron 22907730 rs11062040 chr12 2091257 C T 8.00E-06 Response to gemcitabine in pancreatic cancer DCP1B intron 22142827 rs4141130 chr12 2097716 T C 1.51E-05 Nicotine smoking DCP1B intron 19268276 rs6489341 chr12 2104468 A T 1.06E-04 Parkinson's disease DCP1B intron 17052657 rs16929017 chr12 2129773 A G 4.96E-04 Multiple complex diseases / / 17554300 rs11062078 chr12 2135487 C T 8.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11062078 chr12 2135487 C T 4.62E-04 Taste perception / / 22132133 rs7972947 chr12 2170433 C A 1.76E-04 Parkinson's disease CAC/1C intron 17052657 rs7972947 chr12 2170433 C A 7.77E-07 Schizophrenia CAC/1C intron 21926974 rs7972947 chr12 2170433 C A 0.000000532 Schizophrenia CAC/1C intron 23637625 rs2238017 chr12 2178545 A G 3.37E-05 Heart rate CAC/1C intron 23583979 rs4765663 chr12 2178760 G C 7.89E-04 Response to cytadine analogues (cytosine arabinoside) CAC/1C intron 24483146 rs2283272 chr12 2182486 C T 1.18E-04 Type 2 diabetes CAC/1C intron 17463246 rs2283275 chr12 2184560 C T 2.00E-05 Type 2 diabetes CAC/1C intron 17463246 rs2283276 chr12 2184847 C T 1.86E-05 Type 2 diabetes CAC/1C intron 17463246 rs7298821 chr12 2205886 T C 1.30E-04 IgE levels in asthmatics CAC/1C intron 23967269 rs2283283 chr12 2211145 C T 8.54E-04 Aortic root size CAC/1C intron 21223598 rs7297252 chr12 2225069 T C 2.39E-05 Tunica Media CAC/1C intron pha003038 rs7302743 chr12 2269588 C T 1.80E-05 Urinary metabolites CAC/1C intron 21572414 rs2238043 chr12 2275663 G A 3.97E-04 Nicotine smoking CAC/1C intron 19268276 rs2238043 chr12 2275663 G A 0.00007299 Sarcoidosis CAC/1C intron 22952805 rs3794299 chr12 2285984 A G 3.14E-05 Blood pressure (response to angiotensin II receptor blocker) CAC/1C intron 24192120 rs3922315 chr12 2289899 G C 5.48E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CAC/1C intron 21844884 rs758171 chr12 2294263 A G 1.10E-05 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs11062145 chr12 2297353 C T 6.40E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs10744559 chr12 2298298 C T 6.40E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs2283287 chr12 2298724 T C 6.30E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs2283288 chr12 2299048 C T 6.20E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs2238046 chr12 2299998 A C 3.90E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs2238048 chr12 2300207 A G 3.80E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs2239018 chr12 2304357 C T 2.70E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs2238049 chr12 2306128 A G 4.40E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs2238050 chr12 2306707 G A 2.60E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs2238052 chr12 2307296 G A 4.00E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs10459125 chr12 2309864 C T 3.60E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs2239019 chr12 2310310 G T 2.00E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs2239023 chr12 2310616 A G 4.00E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs10848627 chr12 2312408 A G 1.80E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs10848628 chr12 2312489 T C 1.09E-04 Multiple complex diseases CAC/1C intron 17554300 rs10848628 chr12 2312489 T C 1.80E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs12422554 chr12 2312620 A C 1.85E-04 Multiple complex diseases CAC/1C intron 17554300 rs12422554 chr12 2312620 A C 2.00E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs10848629 chr12 2312897 C T 2.00E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs4765902 chr12 2312965 G A 1.18E-04 Multiple complex diseases CAC/1C intron 17554300 rs4765902 chr12 2312965 G A 3.80E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs4765670 chr12 2313126 A G 3.60E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs10774033 chr12 2314426 C T 3.10E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs758173 chr12 2315228 G A 1.90E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs758174 chr12 2315706 T C 2.70E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs10848632 chr12 2315993 C T 1.82E-04 Multiple complex diseases CAC/1C intron 17554300 rs10848632 chr12 2315993 C T 2.10E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs10848633 chr12 2316019 A G 1.17E-04 Multiple complex diseases CAC/1C intron 17554300 rs10848633 chr12 2316019 A G 3.20E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs10848634 chr12 2316127 T C 9.96E-05 Multiple complex diseases CAC/1C intron 17554300 rs10848634 chr12 2316127 T C 3.20E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs10848635 chr12 2316195 T A 1.98E-04 Multiple complex diseases CAC/1C intron 17554300 rs10848635 chr12 2316195 T A 1.10E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs10848636 chr12 2316493 G T 8.67E-05 Multiple complex diseases CAC/1C intron 17554300 rs10848636 chr12 2316493 G T 2.00E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs11062155 chr12 2316617 T C 8.55E-04 Multiple complex diseases CAC/1C intron 17554300 rs2238053 chr12 2317096 T C 2.60E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs11062156 chr12 2317523 G A 1.32E-04 Multiple complex diseases CAC/1C intron 17554300 rs11062156 chr12 2317523 G A 8.63E-05 Serum metabolites CAC/1C intron 19043545 rs11062156 chr12 2317523 G A 3.10E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs2238054 chr12 2317644 T C 7.38E-05 Multiple complex diseases CAC/1C intron 17554300 rs2238054 chr12 2317644 T C 7.55E-05 Serum metabolites CAC/1C intron 19043545 rs2238054 chr12 2317644 T C 7.10E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs12424245 chr12 2322513 A G 6.00E-07 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs7957545 chr12 2324042 T C 2.70E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs11062158 chr12 2325978 T C 7.91E-04 Suicide attempts in bipolar disorder CAC/1C intron 21041247 rs10848640 chr12 2326169 C G 7.92E-04 Suicide attempts in bipolar disorder CAC/1C intron 21041247 rs10848641 chr12 2326181 T C 7.93E-04 Suicide attempts in bipolar disorder CAC/1C intron 21041247 rs11062159 chr12 2326224 G A 2.40E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs2238056 chr12 2327944 T C 8.95E-04 Multiple complex diseases CAC/1C intron 17554300 rs2238056 chr12 2327944 T C 6.58E-04 Coronary Artery Disease CAC/1C intron 17634449 rs11062161 chr12 2329970 T C 2.79E-04 Coronary Artery Disease CAC/1C intron 17634449 rs11062161 chr12 2329970 T C 7.20E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs10774034 chr12 2330458 C T 6.60E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs12228890 chr12 2330997 C A 8.28E-04 Suicide attempts in bipolar disorder CAC/1C intron 21041247 rs10848642 chr12 2331572 A G 2.70E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs10848642 chr12 2331572 A G 2.80E-07 Bipolar disorder CAC/1C intron 22182935 rs11062162 chr12 2332104 A G 6.60E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs2239028 chr12 2332210 C T 4.40E-04 Smoking quantity CAC/1C intron 24665060 rs4765904 chr12 2332393 A C 8.00E-07 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs1108221 chr12 2332795 A T 1.10E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs1108222 chr12 2332856 C A 2.50E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs1108074 chr12 2333484 C T 1.10E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs1108073 chr12 2333638 T C 6.70E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs11062164 chr12 2333652 C A 5.61E-05 Vascular dementia CAC/1C intron 22116812 rs7135319 chr12 2342417 A G 7.68E-04 Suicide attempts in bipolar disorder CAC/1C intron 21041247 rs7305301 chr12 2342636 C G 7.99E-04 Suicide attempts in bipolar disorder CAC/1C intron 21041247 rs769087 chr12 2344644 G A 7.80E-08 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs2007044 chr12 2344960 A G 5.20E-08 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs1006737 chr12 2345295 G A 1.60E-04 Multiple complex diseases CAC/1C intron 17554300 rs1006737 chr12 2345295 G A 3.15E-06 Bipolar disorder CAC/1C intron 18317468 rs1006737 chr12 2345295 G A 7.00E-08 Bipolar disorder CAC/1C intron 18711365 rs1006737 chr12 2345295 G A 3.00E-08 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs1006737 chr12 2345295 G A 0.000000216 Bipolar disorder CAC/1C intron 23070075 rs1006737 chr12 2345295 G A 5.00E-09 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) CAC/1C intron 23453885 rs1006737 chr12 2345295 G A 0.0000352 Schizophrenia CAC/1C intron 23637625 rs1006737 chr12 2345295 G A 5.00E-12 Schizophrenia CAC/1C intron 23974872 rs1006737 chr12 2345295 G A 2.00E-06 Bipolar disorder and schizophrenia CAC/1C intron 24280982 rs1006737 chr12 2345295 G A 6.00E-13 Bipolar disorder and schizophrenia CAC/1C intron 24280982 rs1006737 chr12 2345295 G A 7.00E-08 Bipolar disorder and schizophrenia CAC/1C intron 24280982 rs2159100 chr12 2346393 C T 8.00E-08 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs12315711 chr12 2346830 T A 8.00E-08 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs11062170 chr12 2348844 G C 7.90E-08 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs4765905 chr12 2349584 G C 2.05E-04 Multiple complex diseases CAC/1C intron 17554300 rs4765905 chr12 2349584 G C 1.40E-07 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs4765905 chr12 2349584 G C 2.00E-06 Schizophrenia CAC/1C intron 21926974 rs4765905 chr12 2349584 G C 1.00E-07 Schizophrenia CAC/1C intron 22688191 rs4765905 chr12 2349584 G C 2.00E-07 Schizophrenia CAC/1C intron 22688191 rs882194 chr12 2350452 A G 0.0000553 Bipolar disorder CAC/1C intron 23070075 rs2370413 chr12 2354870 T C 5.22E-04 Multiple complex diseases CAC/1C intron 17554300 rs2370413 chr12 2354870 T C 6.10E-07 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs7297582 chr12 2355806 C T 3.40E-08 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs758170 chr12 2361460 C T 7.00E-08 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs2239037 chr12 2363716 A G 4.25E-04 Depression (quantitative trait) CAC/1C intron 20800221 rs10774035 chr12 2368674 C T 7.00E-08 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs2239038 chr12 2374130 G A 1.80E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs2238057 chr12 2384005 T G 7.20E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs10774036 chr12 2386948 C T 1.20E-07 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs10744560 chr12 2387099 C T 1.48E-04 Multiple complex diseases CAC/1C intron 17554300 rs10744560 chr12 2387099 C T 1.20E-07 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs10744560 chr12 2387099 C T 4.71E-05 Bipolar disorder and schizophrenia CAC/1C intron 20889312 rs4298967 chr12 2408194 A G 1.00E-07 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs1860002 chr12 2413803 C T 9.80E-07 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs4765913 chr12 2419896 A T 1.30E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs4765913 chr12 2419896 A T 2.00E-08 Bipolar disorder CAC/1C intron 21926972 rs4765913 chr12 2419896 A T 9.78E-10 Bipolar disorder CAC/1C intron 23070075 rs4765914 chr12 2420377 T C 4.41E-06 Type 2 diabetes CAC/1C intron 17463246 rs4765914 chr12 2420377 T C 3.61E-04 Multiple complex diseases CAC/1C intron 17554300 rs4765914 chr12 2420377 T C 1.99E-05 HIV-1 control CAC/1C intron 20041166 rs4765914 chr12 2420377 T C 4.20E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs4765914 chr12 2420377 T C 3.05E-07 Major depressive disorder CAC/1C intron 22472876 rs10774037 chr12 2420526 G A 8.63E-06 Type 2 diabetes CAC/1C intron 17463246 rs10774037 chr12 2420526 G A 3.88E-04 Multiple complex diseases CAC/1C intron 17554300 rs10774037 chr12 2420526 G A 4.00E-06 Bipolar disorder and major depressive disorder (combined) CAC/1C intron 20351715 rs10774037 chr12 2420526 G A 9.88E-08 Major depressive disorder CAC/1C intron 22472876 rs10774037 chr12 2420526 G A 0.000000242 Bipolar disorder CAC/1C intron 23637625 rs3819526 chr12 2436522 C T 1.80E-06 Blood pressure CAC/1C intron 22100073 rs3819526 chr12 2436522 C T 2.31E-04 Blood pressure CAC/1C intron 22100073 rs3819526 chr12 2436522 C T 4.85E-06 Blood pressure CAC/1C intron 22100073 rs3819526 chr12 2436522 C T 5.07E-05 Blood pressure CAC/1C intron 22100073 rs7304986 chr12 2438105 T C 1.38E-06 Sleep latency CAC/1C intron 23728906 rs2239051 chr12 2452192 A G 0.000000302 Triglycerides CAC/1C intron 23063622 rs2239051 chr12 2452192 A G 1.29E-10 HDL cholesterol CAC/1C intron 23063622 rs2239051 chr12 2452192 A G 3.65E-15 Cholesterol,total CAC/1C intron 23063622 rs61907782 chr12 2453853 C T 0.00007941 Sarcoidosis CAC/1C intron 22952805 rs2238069 chr12 2456062 C T 8.38E-04 Multiple complex diseases CAC/1C intron 17554300 rs7132154 chr12 2461223 G A 3.09E-04 Sudden cardiac arrest CAC/1C intron 21658281 rs740419 chr12 2465364 A G 5.71E-04 Suicide attempts in bipolar disorder CAC/1C intron 21423239 rs12425203 chr12 2474661 C T 3.49E-07 Red blood cell traits CAC/1C intron 23222517 rs886898 chr12 2481936 T C 1.93E-05 Crohn's disease CAC/1C intron 17435756 rs2238082 chr12 2486711 G A 2.16E-06 Body mass index CAC/1C intron 19584900 rs2238082 chr12 2486711 G A 2.37E-06 Body mass index CAC/1C intron 19584900 rs10491964 chr12 2500431 G A 4.89E-07 Red blood cell traits CAC/1C intron 23222517 rs2239061 chr12 2502512 T C 1.40E-04 Blood pressure CAC/1C intron 17255346 rs733782 chr12 2511311 T A 6.80E-04 Type 2 diabetes and 6 quantitative traits CAC/1C intron 17848626 rs2239063 chr12 2511831 A C 5.81E-08 Red blood cell traits CAC/1C intron 23222517 rs4765929 chr12 2518352 T C 1.43E-07 Red blood cell traits CAC/1C intron 23222517 rs7312105 chr12 2523355 A G 3.00E-09 Red blood cell traits CAC/1C intron 23222517 rs7312107 chr12 2523370 A G 6.77E-07 Red blood cell traits CAC/1C intron 23222517 rs2239074 chr12 2538549 C T 1.02E-04 Multiple complex diseases CAC/1C intron 17554300 rs2239074 chr12 2538549 C T 3.09E-04 Aortic root size CAC/1C intron 21223598 rs1860097 chr12 2541008 T C 5.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/1C intron 20877124 rs4765930 chr12 2544245 G T 7.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/1C intron 20877124 rs16927947 chr12 2546766 C A 7.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/1C intron 20877124 rs4765679 chr12 2549018 G C 6.26E-04 Body mass index CAC/1C intron 21701565 rs2239079 chr12 2550818 G A 3.37E-05 Serum metabolites CAC/1C intron 19043545 rs1076344 chr12 2553988 A G 1.52E-05 Serum metabolites CAC/1C intron 19043545 rs4765680 chr12 2557099 G A 2.14E-05 Serum metabolites CAC/1C intron 19043545 rs1544514 chr12 2558186 G A 9.20E-04 Stroke CAC/1C cds-synon pha002886 rs4765687 chr12 2560116 A G 0.000832 Salmonella-induced pyroptosis CAC/1C intron 22837397 rs4765687 chr12 2560116 A G 2.01E-05 Creatinine levels CAC/1C intron pha003069 rs2283310 chr12 2569458 C T 7.51E-04 Alzheimer's disease CAC/1C intron 24755620 rs4765937 chr12 2570535 T C 0.0000321 LDL cholesterol CAC/1C intron 23063622 rs16929447 chr12 2574045 C T 1.53E-04 Alzheimer's disease CAC/1C intron 24755620 rs2283314 chr12 2585572 G A 1.50E-04 Coronary Artery Disease CAC/1C intron 17634449 rs16929460 chr12 2597759 G A 2.57E-05 Aortic root size CAC/1C intron 21223598 rs16929460 chr12 2597759 G A 0.000000766 Cholesterol,total CAC/1C intron 23063622 rs16929486 chr12 2606283 A G 6.69E-05 Type 2 diabetes CAC/1C intron 20818381 rs10848665 chr12 2609084 T C 9.69E-05 Tunica Media CAC/1C intron pha003036 rs2239104 chr12 2623543 T G 2.01E-05 Response to mTOR inhibitor (rapamycin) CAC/1C intron 24009623 rs2239105 chr12 2623665 C G 1.68E-05 Response to mTOR inhibitor (rapamycin) CAC/1C intron 24009623 rs2239109 chr12 2628811 T G 3.97E-05 Response to mTOR inhibitor (rapamycin) CAC/1C intron 24009623 rs12231350 chr12 2635190 A G 7.61E-05 Response to mTOR inhibitor (rapamycin) CAC/1C intron 24009623 rs12227580 chr12 2641677 G A 3.77E-05 Response to mTOR inhibitor (rapamycin) CAC/1C intron 24009623 rs11062260 chr12 2646783 G A 5.11E-05 Response to mTOR inhibitor (rapamycin) CAC/1C intron 24009623 rs4394887 chr12 2649980 A G 1.10E-05 Response to mTOR inhibitor (rapamycin) CAC/1C intron 24009623 rs12322010 chr12 2651887 A G 5.97E-17 Triglycerides CAC/1C intron 23063622 rs10848675 chr12 2659848 T C 1.60E-05 Response to mTOR inhibitor (rapamycin) CAC/1C intron 24009623 rs4765961 chr12 2668472 T C 1.21E-07 Common variable immunodeficiency CAC/1C intron 21497890 rs12316536 chr12 2673222 T A 3.32E-04 Insulin resistance CAC/1C intron 21901158 rs2238090 chr12 2683332 A G 8.58E-05 Schizophrenia CAC/1C intron 19571811 rs215996 chr12 2719297 G C 3.60E-05 Anger CAC/1C intron 24489884 rs2238091 chr12 2722264 G A 3.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAC/1C intron 20877124 rs216013 chr12 2729632 A G 9.00E-07 Warfarin maintenance dose CAC/1C intron 18535201 rs216026 chr12 2749127 T G 1.43E-04 Fractional exhaled nitric oxide (childhood) CAC/1C intron 24315451 rs216026 chr12 2749127 T G 8.00E-06 Fractional exhaled nitric oxide (childhood) CAC/1C intron 24315451 rs216027 chr12 2749836 G T 8.60E-04 Multiple complex diseases CAC/1C intron 17554300 rs11062296 chr12 2766253 A G 9.90E-05 Diabetic retinopathy CAC/1C intron 21441570 rs12228141 chr12 2766984 A G 8.70E-05 Diabetic retinopathy CAC/1C intron 21441570 rs4765702 chr12 2773862 T G 1.60E-05 Diabetic retinopathy CAC/1C intron 21441570 rs2302727 chr12 2774601 C A 1.70E-05 Diabetic retinopathy CAC/1C intron 21441570 rs7295250 chr12 2776943 T C 1.71E-05 Hemoglobin CAC/1C intron pha003096 rs7295250 chr12 2776943 T C 4.55E-05 Hematocrit CAC/1C intron pha003097 rs7306298 chr12 2777311 G A 1.10E-05 Diabetic retinopathy CAC/1C intron 21441570 rs7295775 chr12 2777405 T C 4.10E-05 HDL particle features CAC/1C intron 21283740 rs6489375 chr12 2777768 A G 1.10E-05 Diabetic retinopathy CAC/1C intron 21441570 rs16929874 chr12 2778700 G T 5.96E-04 Multiple complex diseases CAC/1C intron 17554300 rs7138079 chr12 2781304 G A 1.70E-05 Diabetic retinopathy CAC/1C intron 21441570 rs4765967 chr12 2783037 T C 2.26E-04 Multiple complex diseases CAC/1C intron 17554300 rs2302729 chr12 2783972 T C 5.40E-05 Diabetic retinopathy CAC/1C intron 21441570 rs2302729 chr12 2783972 T C 4.00E-06 Sleep quality CAC/1C intron 23728906 rs4765968 chr12 2787850 T C 3.23E-04 Multiple complex diseases CAC/1C intron 17554300 rs1051375 chr12 2788879 G A 1 Drug response to Atenolol CAC/1C cds-synon 20031608 rs1051375 chr12 2788879 G A 1 Drug response to Verapamil CAC/1C cds-synon 20031608 rs3794288 chr12 2789221 A G 9.60E-04 Suicide attempts in bipolar disorder CAC/1C intron 21423239 rs10848683 chr12 2791130 C T 2.20E-05 Diabetic retinopathy CAC/1C missense 21441570 rs2098425 chr12 2828334 G A 1.10E-04 HIV-1 viral setpoint / / 17641165 rs12310349 chr12 2830907 A G 1.10E-04 HIV-1 viral setpoint / / 17641165 rs7296848 chr12 2873537 A C 3.42E-05 Multiple complex diseases LOC283440 intron 17554300 rs10848704 chr12 2882544 C T 2.00E-06 Quantitative traits / / 19197348 rs10848704 chr12 2882544 C T 2.50E-05 Urinary metabolites / / 21572414 rs4765709 chr12 2883637 C T 4.93E-04 Serum selenium levels / / 23698163 rs4073984 chr12 2885780 G A 3.09E-04 Serum selenium levels / / 23698163 rs2968909 chr12 2897864 C G 5.80E-04 Coronary Artery Disease / / 17634449 rs1981655 chr12 2907726 A T 7.70E-04 Suicide attempts in bipolar disorder FKBP4 intron 21041247 rs3021522 chr12 2909145 C G 7.57E-04 Suicide attempts in bipolar disorder FKBP4 intron 21041247 rs4765999 chr12 2945970 C T 7.87E-04 Smoking cessation / / 24665060 rs4766000 chr12 2950504 C T 3.35E-05 Coronary heart disease LOC100507424 intron pha003030 rs4766000 chr12 2950504 C T 9.87E-05 Hemoglobin LOC100507424 intron pha003096 rs11062386 chr12 2964684 C T 4.14E-06 Lung adenocarcinoma LOC100507424 intron 19836008 rs192385949 chr12 3039437 G A,C 0.00036 Prostate cancer TULP3 missense 23555315 rs998814 chr12 3049698 T C 1.90E-04 Parkinson's disease TULP3 missense 17052657 rs2159415 chr12 3054457 T C 2.87E-04 Parkinson's disease / / 17052657 rs2335331 chr12 3117015 C T 1.18E-04 Alzheimer's disease (late onset) TEAD4 intron 21379329 rs12580779 chr12 3140979 C T 5.55E-04 Coronary heart disease TEAD4 intron 21971053 rs10848765 chr12 3141495 C T 4.76E-04 Coronary heart disease TEAD4 intron 21971053 rs10848768 chr12 3142646 A C 6.36E-04 Smoking initiation TEAD4 intron 24665060 rs7139125 chr12 3148726 T C 4.02E-04 Coronary heart disease TEAD4 intron 21971053 rs7139125 chr12 3148726 T C 7.69E-04 Smoking initiation TEAD4 intron 24665060 rs3782834 chr12 3148864 T G 7.49E-04 Smoking initiation TEAD4 intron 24665060 rs4766030 chr12 3150174 G A 3.61E-04 Coronary heart disease TEAD4 nearGene-3 21971053 rs4766030 chr12 3150174 G A 7.63E-04 Smoking initiation TEAD4 nearGene-3 24665060 rs7316728 chr12 3163547 C T 7.78E-04 Smoking initiation / / 24665060 rs12425451 chr12 3164923 C T 2.00E-07 Narcolepsy with cataplexy / / 23496005 rs10744590 chr12 3170680 T C 6.58E-06 Post-operative nausea and vomiting / / 21694509 rs7963198 chr12 3171429 C T 2.75E-05 Post-operative nausea and vomiting / / 21694509 rs10744591 chr12 3207758 T C 2.80E-05 Urinary metabolites TSPAN9 intron 21572414 rs12810695 chr12 3211189 A G 2.80E-05 Urinary metabolites TSPAN9 intron 21572414 rs6489438 chr12 3226930 A G 1.14E-04 Arthritis (juvenile idiopathic) TSPAN9 intron 22354554 rs7980328 chr12 3244552 A C 2.00E-04 Cognitive impairment induced by topiramate TSPAN9 intron 22091778 rs7980339 chr12 3244580 A G 2.00E-04 Cognitive impairment induced by topiramate TSPAN9 intron 22091778 rs533137 chr12 3251191 G A 1.43E-04 Type 2 diabetes TSPAN9 intron 17463246 rs17835270 chr12 3258267 C T 1.10E-05 Urinary metabolites TSPAN9 intron 21572414 rs878962 chr12 3287279 G T 8.00E-06 Temporomandibular joint disorders TSPAN9 intron 23746317 rs879188 chr12 3288309 G A 2.33E-04 Response to platinum-based chemotherapy in small-cell lung cancer TSPAN9 intron 20463552 rs2335817 chr12 3294236 A C 4.36E-04 Type 2 diabetes TSPAN9 intron 17463246 rs2335817 chr12 3294236 A C 1.20E-05 Temporomandibular joint disorders TSPAN9 intron 23746317 rs3741947 chr12 3325665 C T 1.00E-04 Cognitive impairment induced by topiramate TSPAN9 intron 22091778 rs11062578 chr12 3327167 G A 3.00E-06 Amyotrophic lateral sclerosis (sporadic) TSPAN9 intron 24529757 rs2011973 chr12 3333578 C T 1.40E-16 Progranulin levels TSPAN9 intron 21087763 rs2011973 chr12 3333578 C T 1.40E-16 Myocardial infarction TSPAN9 intron 21211798 rs3782814 chr12 3335125 A G 4.75E-05 Aging (time to event) TSPAN9 intron 21782286 rs17779114 chr12 3349894 T G 1.41E-04 Substance dependence TSPAN9 intron 21818250 rs4765723 chr12 3352543 T G 6.01E-05 Partial epilepsies TSPAN9 intron 20522523 rs3782788 chr12 3357992 T G 8.47E-04 Multiple complex diseases TSPAN9 intron 17554300 rs12371422 chr12 3360946 G A,C,T 9.54E-04 Response to taxane treatment (placlitaxel) TSPAN9 intron 23006423 rs7296705 chr12 3374675 T C 6.20E-05 Epilepsy TSPAN9 intron 22116939 rs3782772 chr12 3375632 A G 1.60E-04 Hearing function TSPAN9 intron 17255346 rs519474 chr12 3385647 C T 8.69E-04 Tourette syndrome TSPAN9 intron 22889924 rs635332 chr12 3386273 G A 5.25E-04 Multiple complex diseases TSPAN9 intron 17554300 rs16930370 chr12 3387697 T C 8.12E-05 Cervical cancer TSPAN9 cds-synon 24700089 rs998374 chr12 3435530 C T 8.46E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1860394 chr12 3439051 C A 4.40E-04 Myasthenia gravis / / 23055271 rs10848856 chr12 3451273 A G 2.70E-04 Myasthenia gravis / / 23055271 rs7964814 chr12 3460390 C T 1.67E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4238009 chr12 3477594 G A 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4766119 chr12 3548756 G A 2.65E-06 Type 2 diabetes PRMT8 intron 21647700 rs6489469 chr12 3556350 G A 1.31E-05 Sickle cell anemia (severity) PRMT8 intron 20029952 rs6489469 chr12 3556350 G A 5.35E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) PRMT8 intron 23648065 rs11615941 chr12 3556799 C T 7.31E-05 Socioeconomic Factors PRMT8 intron pha003066 rs12826471 chr12 3584942 G A 1.29E-05 Melanoma PRMT8 intron 21926416 rs7972248 chr12 3625097 T C 2.60E-05 Soluble levels of adhesion molecules PRMT8 intron pha003072 rs11062697 chr12 3631368 C A 8.50E-06 Stroke (ischemic) PRMT8 intron 22384361 rs10848873 chr12 3640748 A G 2.25E-04 Lung function (forced vital capacity) PRMT8 intron 24023788 rs10848873 chr12 3640748 A G 3.37E-04 Lung function (forced expiratory volume in 1 second) PRMT8 intron 24023788 rs3741939 chr12 3647531 C T 1.98E-04 Multiple complex diseases PRMT8 intron 17554300 rs10774156 chr12 3664704 C A 7.31E-04 Response to cytadine analogues (cytosine arabinoside) PRMT8 intron 24483146 rs3782751 chr12 3673499 C T 7.54E-04 Response to cytadine analogues (cytosine arabinoside) PRMT8 intron 24483146 rs17769793 chr12 3678251 A G 1.12E-04 Alzheimer's disease (late onset) PRMT8 intron 21379329 rs3741935 chr12 3701390 C T 3.83E-05 Response to Vitamin E supplementation PRMT8 intron 22437554 rs4765746 chr12 3729883 A G 4.57E-05 Cognitive test performance EFCAB4B intron 20125193 rs4765747 chr12 3735620 T A 6.55E-04 Multiple complex diseases EFCAB4B intron 17554300 rs10848895 chr12 3749312 G A 1.50E-05 Urinary metabolites EFCAB4B intron 21572414 rs11062747 chr12 3750109 A T 1.50E-05 Urinary metabolites EFCAB4B intron 21572414 rs4766152 chr12 3750128 T C 5.00E-06 Cytomegalovirus antibody response EFCAB4B intron 21993531 rs10848899 chr12 3757267 G A 1.50E-05 Urinary metabolites EFCAB4B UTR-3 21572414 rs887304 chr12 3757548 T C 8.00E-07 Non-alcoholic fatty liver disease histology (lobular) EFCAB4B UTR-3 20708005 rs758530 chr12 3757923 A G 1.00E-06 Angioedema in response to angiotensin-converting enzyme inhibitor EFCAB4B intron 23838604 rs10848906 chr12 3768705 C A 1.83E-05 Smoking cessation EFCAB4B intron 18519826 rs10848906 chr12 3768705 C A 8.39E-05 Smoking cessation EFCAB4B intron 18519826 rs1015762 chr12 3772977 T C 5.18E-06 Angioedema in response to angiotensin-converting enzyme inhibitor EFCAB4B intron 23838604 rs242033 chr12 3786073 A C 4.42E-05 Parkinson's disease EFCAB4B intron 17052657 rs242028 chr12 3786715 G A 9.68E-06 Smoking cessation EFCAB4B intron 18519826 rs17770663 chr12 3791143 T C 2.10E-05 Urinary metabolites EFCAB4B intron 21572414 rs10848911 chr12 3814238 G A 4.00E-06 Male infertility EFCAB4B intron 19478329 rs4766163 chr12 3820258 C A 1.05E-04 Smoking cessation EFCAB4B intron 18519826 rs241964 chr12 3841695 C T 4.28E-06 Common variable immunodeficiency EFCAB4B intron 21497890 rs10774168 chr12 3846299 T C 2.00E-05 Urinary metabolites EFCAB4B intron 21572414 rs16930742 chr12 3848518 A G 4.95E-05 Multiple complex diseases EFCAB4B intron 17554300 rs575980366 chr12 3848518 AT A 4.95E-05 Multiple complex diseases EFCAB4B intron 17554300 rs16930743 chr12 3848672 C T 8.45E-05 Multiple complex diseases EFCAB4B intron 17554300 rs16930744 chr12 3848767 G A 8.39E-05 Multiple complex diseases EFCAB4B intron 17554300 rs16930752 chr12 3850495 C A 4.03E-05 Multiple complex diseases EFCAB4B intron 17554300 rs16930761 chr12 3851577 T C 6.79E-05 Multiple complex diseases EFCAB4B intron 17554300 rs10848917 chr12 3853196 T A 9.11E-04 Alzheimer's disease EFCAB4B intron 17998437 rs11062784 chr12 3854467 A G 6.28E-04 Nicotine smoking EFCAB4B intron 19268276 rs11062784 chr12 3854467 A G 1.00E-05 Parkinson's disease (age of onset) EFCAB4B intron 19772629 rs11062784 chr12 3854467 A G 6.15E-04 Myocardial Infarction EFCAB4B intron pha002873 rs7976397 chr12 3857650 C T 1.70E-05 Urinary metabolites EFCAB4B intron 21572414 rs10848921 chr12 3861144 C T 1.00E-05 Urinary metabolites EFCAB4B intron 21572414 rs10744625 chr12 3868168 C T 5.50E-05 Primary sclerosing cholangitis / / 19944697 rs10744625 chr12 3868168 C T 8.00E-06 Fasting insulin (interaction) / / 24204828 rs10744625 chr12 3868168 C T 9.00E-06 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs11062805 chr12 3872359 C T 7.35E-04 Obesity (extreme) / / 21935397 rs7977865 chr12 3900555 G A 6.62E-05 Cognitive test performance / / 20125193 rs2058350 chr12 3913427 C T 8.00E-06 Cognitive performance / / 20125193 rs10848943 chr12 3944022 G A 8.72E-05 Cognitive test performance PARP11 intron 20125193 rs7300043 chr12 3958713 A G 6.60E-05 Cognitive test performance PARP11 intron 20125193 rs11062884 chr12 3977712 C T 2.09E-05 Cognitive test performance PARP11 intron 20125193 rs10774178 chr12 3983235 C A 1.06E-05 Cognitive test performance LOC100507492 intron 20125193 rs7973859 chr12 3985224 A G 8.02E-04 Response to taxane treatment (placlitaxel) LOC100507492 intron 23006423 rs2109112 chr12 3987473 T C 5.58E-04 Response to taxane treatment (placlitaxel) LOC100507492 intron 23006423 rs7954694 chr12 3989667 C T 7.80E-05 Memory performance LOC100507492 intron 22105620 rs10774180 chr12 3992311 C A 1.48E-05 Cognitive test performance LOC100507492 intron 20125193 rs11062901 chr12 3998061 C T 4.74E-05 Cognitive test performance LOC100507492 intron 20125193 rs11062907 chr12 4004939 T C 3.49E-04 Multiple complex diseases LOC100507492 intron 17554300 rs10774183 chr12 4005023 C T 4.05E-04 Type 2 diabetes LOC100507492 intron 17463246 rs2907511 chr12 4027103 A G 1.52E-04 Age-related macular degeneration / / 22125219 rs654397 chr12 4028747 C T 8.58E-05 ldl cholesterol / / pha003077 rs10848958 chr12 4031104 C T 3.81E-04 Alcohol dependence / / 21314694 rs10848958 chr12 4031104 C T 1.73E-04 Myocardial Infarction / / pha002873 rs11062924 chr12 4042363 G T 3.05E-04 Myocardial Infarction / / pha002873 rs2907512 chr12 4051757 C A 3.00E-05 Waist circumference / / 23966867 rs17836464 chr12 4066928 G A 3.59E-04 Multiple complex diseases / / 17554300 rs624304 chr12 4070800 C T 2.09E-04 Celiac disease / / 23936387 rs17836475 chr12 4073544 G C 1.40E-05 Diabetic retinopathy / / 21441570 rs7963108 chr12 4073872 C T 7.10E-05 Diabetic retinopathy / / 21441570 rs672304 chr12 4074906 A C 2.00E-05 Prostate cancer / / 21743057 rs672303 chr12 4074907 A C 2.00E-05 Prostate cancer / / 21743057 rs631750 chr12 4075855 T C 2.00E-05 Prostate cancer / / 21743057 rs631750 chr12 4075855 T C 3.92E-04 Stroke / / pha002886 rs629690 chr12 4076265 C T 2.00E-05 Prostate cancer / / 21743057 rs4491324 chr12 4082865 T C 2.93E-06 Waist-Hip Ratio / / pha003029 rs4766193 chr12 4108513 T C 4.28E-05 Cognitive impairment induced by topiramate / / 22091778 rs4238010 chr12 4118317 G A 6.00E-06 Major depressive disorder / / 19107115 rs4766196 chr12 4123085 C T 2.50E-04 Aortic root size / / 21223598 rs7300338 chr12 4139900 C T 9.05E-04 Multiple complex diseases / / 17554300 rs7300338 chr12 4139900 C T 1.61E-05 Serum alpha1-antitrypsin levels / / 23990791 rs10492325 chr12 4158184 A C 3.45E-04 Alzheimer's disease (late onset) / / 21379329 rs2724240 chr12 4164716 G A 4.76E-04 Multiple complex diseases / / 17554300 rs2532562 chr12 4164815 T G 7.76E-04 Multiple complex diseases / / 17554300 rs763417 chr12 4165311 G C 2.90E-05 Urinary metabolites / / 21572414 rs7315461 chr12 4206768 C T 1.90E-04 Coronary Artery Disease / / 17634449 rs11063009 chr12 4239492 G A 6.42E-05 HIV-1 viral setpoint / / 22174851 rs11063009 chr12 4239492 G A 3.00E-04 Longevity / / 22279548 rs6489520 chr12 4262862 A G 1.86E-05 Bipolar disorder and schizophrenia / / 20889312 rs2080268 chr12 4265274 T C 6.44E-05 HIV-1 viral setpoint / / 22174851 rs10848990 chr12 4269841 C T 2.70E-04 Aortic root size / / 21223598 rs10848995 chr12 4278090 G C 8.44E-04 Multiple complex diseases / / 17554300 rs2041731 chr12 4304800 T G 2.01E-04 Scoliosis / / 21216876 rs12827476 chr12 4305883 T C 9.00E-06 Obesity-related traits / / 23251661 rs2540126 chr12 4311734 G A 4.33E-05 Multiple complex diseases / / 17554300 rs1544631 chr12 4315651 C T 7.97E-04 Parkinson's disease / / 17052657 rs7307707 chr12 4325316 G A,C,T 1.50E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs4573764 chr12 4330215 C T 2.37E-09 Red blood cell traits / / 23222517 rs12320749 chr12 4331647 C G 4.54E-09 Red blood cell traits / / 23222517 rs10849020 chr12 4332009 C G 3.57E-09 Red blood cell traits / / 23222517 rs10849023 chr12 4332478 C T 8.00E-12 Red blood cell traits / / 23222517 rs11611647 chr12 4333919 T C 6.00E-09 Blood cell counts and other traits / / 20139978 rs11611647 chr12 4333919 T C 6.44E-09 Blood cell counts and other traits / / 20139978 rs11611647 chr12 4333919 T C 9.67E-12 Red blood cell traits / / 23222517 rs7309743 chr12 4334295 A G 9.36E-09 Red blood cell traits / / 23222517 rs7138216 chr12 4334308 G C 4.90E-08 Red blood cell traits / / 23222517 rs41404648 chr12 4341431 C A 4.40E-04 Multiple complex diseases / / 17554300 rs12426043 chr12 4341538 G C 4.38E-07 Red blood cell traits / / 23222517 rs10744636 chr12 4343848 C T 0.000469 Salmonella-induced pyroptosis / / 22837397 rs10774214 chr12 4368352 T C 1.60E-05 Non-small cell lung cancer / / 21866343 rs10774214 chr12 4368352 T C 3.00E-08 Colorectal cancer / / 23263487 rs10774214 chr12 4368352 T C 5.00E-10 Colorectal cancer / / 23263487 rs10774214 chr12 4368352 T C 1.00E-10 Colorectal cancer / / 24836286 rs4631962 chr12 4373132 A G 2.32E-06 Non-small cell lung cancer / / 21866343 rs7954777 chr12 4373320 C T 2.32E-06 Non-small cell lung cancer / / 21866343 rs11063069 chr12 4374373 A G 1.10E-09 Type 2 diabetes (males) / / 22885922 rs11063069 chr12 4374373 A G 9.80E-10 Type 2 diabetes / / 22885922 rs11063069 chr12 4374373 A G 7.50E-04 Type 2 diabetes / / 24509480 rs3217795 chr12 4386064 A G 5.88E-05 Blood pressure CCND2 intron 17255346 rs3217810 chr12 4388271 C T 6.00E-08 Colorectal cancer CCND2 intron 23266556 rs3217827 chr12 4392391 C A 2.50E-07 Colorectal cancer CCND2 intron 23266556 rs3217869 chr12 4399970 G A 4.00E-06 QT interval (interaction) CCND2 intron 23459443 rs3217875 chr12 4401201 T C 8.89E-05 Parent of origin effect on language impairment (maternal) CCND2 intron 24571439 rs3217881 chr12 4402688 A G 3.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCND2 intron 20877124 rs3217881 chr12 4402688 A G 3.79E-05 Colorectal cancer CCND2 intron 23266556 rs3217882 chr12 4402817 A G 3.29E-05 Colorectal cancer CCND2 intron 23266556 rs3217891 chr12 4403850 C G 6.40E-04 Insulin resistance CCND2 intron 21901158 rs3217896 chr12 4404158 G A 3.47E-04 Alzheimer's disease CCND2 intron 22005930 rs3217898 chr12 4404376 A G 1.27E-04 Alzheimer's disease CCND2 intron 22005930 rs3217901 chr12 4405389 A G 3.00E-07 Colorectal cancer CCND2 intron 23266556 rs3217907 chr12 4406836 C A 6.45E-04 Alzheimer's disease CCND2 intron 22005930 rs3217926 chr12 4411683 T C 3.37E-04 Alzheimer's disease CCND2 UTR-3 22005930 rs1049612 chr12 4412762 A G 3.35E-04 Alzheimer's disease CCND2 UTR-3 22005930 rs4625554 chr12 4416304 A G 9.00E-06 Major depressive disorder / / 23377640 rs10849033 chr12 4425122 G A 9.00E-06 Acute lymphoblastic leukemia (childhood) / / 19684603 rs10849033 chr12 4425122 G A 9.00E-06 Nasopharyngeal carcinoma / / 20512145 rs11063081 chr12 4436080 A G 7.29E-04 Smoking quantity C12orf5 intron 24665060 rs7133330 chr12 4461485 G A 5.22E-04 Smoking quantity C12orf5 cds-synon 24665060 rs61909234 chr12 4467086 A G 0.0000674 Sarcoidosis C12orf5 UTR-3 22952805 rs2075317 chr12 4492315 T C 3.22E-05 Cognitive performance / / 19734545 rs12820100 chr12 4500711 T C 6.74E-05 Cognitive performance / / 19734545 rs10849061 chr12 4523456 C T 1.00E-06 Migraine - clinic-based / / 23793025 rs10849061 chr12 4523456 C T 2.00E-06 Migraine without aura / / 23793025 rs10849061 chr12 4523456 C T 2.00E-07 Migraine / / 23793025 rs10849061 chr12 4523456 C T 2.83E-04 Migraine with aura / / 23793025 rs888468 chr12 4533379 C T 5.00E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs888466 chr12 4533605 T C 9.86E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs888465 chr12 4533676 G A 6.81E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7295812 chr12 4536096 T G 1.41E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2970806 chr12 4537658 G A 5.20E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2270438 chr12 4549019 C A,G,T 2.69E-04 HIV-1 viral setpoint FGF6 intron 17641165 rs2270437 chr12 4549255 G A 2.69E-04 HIV-1 viral setpoint FGF6 intron 17641165 rs2970828 chr12 4553669 T C 1.00E-04 Prostate cancer FGF6 intron 21743057 rs2970809 chr12 4564613 C T 0.0000483 Amyotrophic lateral sclerosis / / 23587638 rs2970818 chr12 4606168 T A 4.00E-09 Phosphorus levels C12orf4 intron 20558539 rs7308641 chr12 4667910 A C 5.16E-04 Multiple complex diseases RAD51AP1 intron 17554300 rs7298545 chr12 4671926 T C 9.51E-05 Amyotrophic lateral sclerosis / / 20801717 rs10774241 chr12 4683466 A G 2.73E-08 Multiple complex diseases / / 17554300 rs4766257 chr12 4689013 T C 4.64E-05 Cognitive test performance / / 20125193 rs4766258 chr12 4691682 A G 4.88E-05 Cognitive test performance / / 20125193 rs2240764 chr12 4701303 A G 4.98E-04 Multiple complex diseases DYRK4 intron 17554300 rs17774188 chr12 4714035 G A 8.02E-04 Alzheimer's disease DYRK4 intron 24755620 rs141858181 chr12 4737736 G A 0.00028 Prostate cancer (non-advanced prostate cancer) AKAP3 missense 23555315 rs1860342 chr12 4744248 G A 2.16E-04 Lymphocyte counts AKAP3 intron 22286170 rs10774255 chr12 4751798 C T 9.16E-05 Bipolar disorder AKAP3 intron 17486107 rs4766288 chr12 4872989 C T 3.72E-04 HIV-1 viral setpoint GALNT8 intron 17641165 rs766504 chr12 4875255 T G 2.00E-05 Urinary metabolites GALNT8 intron 21572414 rs1860345 chr12 4910812 T C 1.85E-05 Colorectal cancer / / 19723657 rs2239503 chr12 4921228 T C 7.07E-04 HIV-1 viral setpoint KC/6 UTR-3 17641165 rs965185 chr12 4924301 A G 1.97E-04 Multiple complex diseases KC/6 intron 17554300 rs17702448 chr12 4929787 C T 5.17E-04 Smoking cessation KC/6 intron 24665060 rs12423234 chr12 4930360 G A 4.12E-04 HIV-1 viral setpoint KC/6 intron 17641165 rs7296238 chr12 4932367 T C 4.57E-04 Multiple complex diseases KC/6 intron 17554300 rs972884 chr12 4937575 G T 5.15E-04 Smoking cessation KC/6 intron 24665060 rs12582063 chr12 4967533 T C 1.90E-04 Smoking initiation / / 24665060 rs10849165 chr12 4984866 C T 8.65E-04 Type 2 diabetes / / 17463246 rs9804895 chr12 4987262 T C 5.04E-04 Type 2 diabetes / / 17463246 rs17775527 chr12 4989915 G C 6.84E-04 Type 2 diabetes / / 17463246 rs7309273 chr12 5015381 C T 4.73E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4766312 chr12 5031590 T C 9.72E-05 Orofacial clefts / / 22419666 rs17784422 chr12 5032532 G A,C 6.19E-04 Type 2 diabetes / / 17463246 rs10492065 chr12 5048861 G T 6.70E-04 Heroin addiction / / 20520587 rs4766314 chr12 5054623 T G 2.62E-04 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs10849182 chr12 5074338 G A 9.33E-04 Alcohol dependence / / 21314694 rs1157754 chr12 5097021 C A 4.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs2013301 chr12 5097054 A G 4.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs11063447 chr12 5099901 A G 7.80E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1558278 chr12 5105597 T C 1.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs7963902 chr12 5118677 C T 8.76E-04 Cognition,early reading ability / / 17684495 rs7963902 chr12 5118677 C T 1.90E-04 Pulmonary function / / 23932459 rs12425784 chr12 5125458 C G 9.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs16932616 chr12 5128359 C T 4.48E-04 Aortic root size / / 21223598 rs1860421 chr12 5131138 A C 1.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16932667 chr12 5131553 T G 8.00E-06 Intelligence (childhood) / / 23358156 rs11063467 chr12 5133940 A C 1.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100507560 intron 20877124 rs4766328 chr12 5134164 C G 0.0007729 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100507560 intron 23233654 rs4766328 chr12 5134164 C G 7.73E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100507560 intron 23233662 rs6489598 chr12 5136101 T C 0.0005474 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6489598 chr12 5136101 T C 5.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17776352 chr12 5137513 T G 1.38E-04 Parkinson's disease / / 21044948 rs17776352 chr12 5137513 T G 0.0005516 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17776352 chr12 5137513 T G 5.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10849195 chr12 5139269 C T 2.78E-04 Type 2 diabetes / / 17463246 rs9919707 chr12 5139494 A G 0.0007926 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9919707 chr12 5139494 A G 7.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6489600 chr12 5140060 T A 0.0007979 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6489600 chr12 5140060 T A 7.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12302829 chr12 5140484 A G 8.00E-06 Conduct disorder (symptom count) / / 20585324 rs6489601 chr12 5140530 T C 0.0008152 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6489601 chr12 5140530 T C 8.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10849197 chr12 5140718 C G 7.89E-04 Type 2 diabetes / / 17463246 rs6489602 chr12 5140968 C T 0.0008445 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6489602 chr12 5140968 C T 8.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11063476 chr12 5140982 A G 1.12E-04 Type 2 diabetes / / 17463246 rs7963105 chr12 5142865 G C 2.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10744675 chr12 5145122 G A 4.93E-04 Parkinson's disease / / 21044948 rs2016141 chr12 5146003 G A 6.99E-04 Parkinson's disease / / 21044948 rs7961013 chr12 5149184 A G 2.00E-04 Atrial fibrillation / / 21846873 rs7961013 chr12 5149184 A G 0.0007779 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7961013 chr12 5149184 A G 7.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs887354 chr12 5149533 T A 0.0007035 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs887354 chr12 5149533 T A 7.04E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3759356 chr12 5150362 G A 9.11E-04 Type 2 diabetes / / 17463246 rs3759356 chr12 5150362 G A 7.60E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11615552 chr12 5152576 T C 0.0006899 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KC/5 nearGene-5 23233654 rs11615552 chr12 5152576 T C 6.90E-04 Methotrexate clearance (acute lymphoblastic leukemia) KC/5 nearGene-5 23233662 rs10744676 chr12 5152949 C T 0.0005542 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KC/5 nearGene-5 23233654 rs10744676 chr12 5152949 C T 5.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) KC/5 nearGene-5 23233662 rs3741930 chr12 5153147 C T 6.77E-04 Taste perception KC/5 UTR-5 22132133 rs1056468 chr12 5155663 A T 5.94E-04 Taste perception KC/5 UTR-3 22132133 rs1860420 chr12 5156275 A G 2.25E-04 Taste perception KC/5 nearGene-3 22132133 rs11063482 chr12 5159686 T C 1.82E-04 Taste perception / / 22132133 rs11063482 chr12 5159686 T C 0.0001033 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11063482 chr12 5159686 T C 1.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4765800 chr12 5160276 A G 2.10E-05 Information processing speed / / 21130836 rs12820914 chr12 5161555 A G 6.66E-04 Type 2 diabetes / / 17463246 rs4765803 chr12 5190001 G A 8.24E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs17777010 chr12 5208993 G A 3.66E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11063498 chr12 5209048 G T 2.60E-05 Coronary heart disease / / pha003033 rs1076395 chr12 5212642 G C 1.60E-05 Urinary metabolites / / 21572414 rs554447 chr12 5212927 C T 6.10E-06 Urinary metabolites / / 21572414 rs7964832 chr12 5213837 G A 1.60E-05 Urinary metabolites / / 21572414 rs667472 chr12 5214153 T A 3.30E-06 Urinary metabolites / / 21572414 rs667472 chr12 5214153 T A 0.000313 Prostate cancer / / 22532847 rs17720767 chr12 5220816 T C 2.60E-05 Urinary metabolites / / 21572414 rs11063524 chr12 5240972 G A 4.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs646707 chr12 5244783 A G 6.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs546299 chr12 5250109 T C 4.05E-05 Glucose levels / / pha003058 rs546299 chr12 5250109 T C 8.83E-06 Glucose levels / / pha003061 rs7953864 chr12 5299505 G A 7.82E-04 Multiple complex diseases / / 17554300 rs7953864 chr12 5299505 G A 6.68E-04 Body mass index / / 21701565 rs7953869 chr12 5299519 G A 7.49E-04 Multiple complex diseases / / 17554300 rs635445 chr12 5315980 C T 6.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11063567 chr12 5322551 A G 5.70E-06 Urinary metabolites / / 21572414 rs10774302 chr12 5327103 A G 2.10E-05 Urinary metabolites / / 21572414 rs7312458 chr12 5334836 G C 4.75E-04 Type 2 diabetes / / 17463246 rs1558386 chr12 5335604 C T 4.75E-04 Type 2 diabetes / / 17463246 rs7302032 chr12 5355373 G A 4.99E-05 Asthma / / 11022011 rs4766348 chr12 5358594 G A 7.21E-04 Type 2 diabetes / / 17463246 rs974991 chr12 5365683 C T 5.65E-06 Odorant perception / / 23910658 rs1420403 chr12 5377209 G A 3.80E-05 Personality dimensions / / 18957941 rs11063590 chr12 5383432 C T 6.86E-05 Multiple complex diseases / / 17554300 rs10849223 chr12 5384521 T C 9.11E-05 Eosinophil counts / / pha003088 rs10492090 chr12 5391393 G A 2.03E-06 Neuropathic pain in type 2 diabetes / / 24974787 rs11615866 chr12 5393329 C T 1.00E-06 Neuropathic pain in type 2 diabetes / / 24974787 rs16933383 chr12 5400620 C T 3.03E-06 Neuropathic pain in type 2 diabetes / / 24974787 rs16933389 chr12 5401196 A G 3.02E-06 Neuropathic pain in type 2 diabetes / / 24974787 rs7979058 chr12 5401450 T G 3.18E-06 Neuropathic pain in type 2 diabetes / / 24974787 rs7137245 chr12 5402869 T C 3.04E-06 Neuropathic pain in type 2 diabetes / / 24974787 rs11063602 chr12 5405457 C T 2.94E-06 Neuropathic pain in type 2 diabetes / / 24974787 rs1159978 chr12 5408789 G A 8.51E-04 Tourette syndrome / / 22889924 rs10849241 chr12 5448511 A G 4.04E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs10774318 chr12 5460707 T G 9.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs1002101 chr12 5492460 G A 5.98E-06 Narcolepsy / / 20711174 rs2359895 chr12 5499690 G A 6.29E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11063667 chr12 5533134 C T 1.30E-05 Urinary metabolites / / 21572414 rs10849266 chr12 5533547 G A 4.29E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1861835 chr12 5538112 G A 1.80E-05 Urinary metabolites / / 21572414 rs11063674 chr12 5539134 G A 8.24E-05 Post-operative nausea and vomiting / / 21694509 rs7980566 chr12 5544994 A G 4.99E-05 Cognitive performance NTF3 intron 19734545 rs11063679 chr12 5552126 A C 1.00E-04 Cognitive impairment induced by topiramate NTF3 intron 22091778 rs11063679 chr12 5552126 A C 4.56E-04 Response to cytadine analogues (cytosine arabinoside) NTF3 intron 24483146 rs10744682 chr12 5555040 G A 2.58E-05 Serum metabolites NTF3 intron 19043545 rs10849271 chr12 5555120 G A 8.90E-05 Myasthenia gravis NTF3 intron 23055271 rs7297212 chr12 5563509 A G 9.89E-05 Parkinson's disease NTF3 intron 21738487 rs11063686 chr12 5564541 G T 7.10E-04 Type 2 diabetes NTF3 intron 17463246 rs11063691 chr12 5571448 T G 2.03E-04 Type 2 diabetes NTF3 intron 17463246 rs2052355 chr12 5576943 G A 1.80E-04 Blood pressure NTF3 intron 17255346 rs11063703 chr12 5589409 A G 5.97E-04 Major depressive disorder NTF3 intron 22472876 rs4074967 chr12 5600466 T G 5.60E-05 Alcoholism (heaviness of drinking) NTF3 intron 21529783 rs6489633 chr12 5641664 A G 2.26E-04 Multiple complex diseases / / 17554300 rs11063732 chr12 5642112 C T 4.68E-05 Prostate cancer / / 22923026 rs10849295 chr12 5673427 G A 3.06E-05 Prostate cancer ANO2 intron 22923026 rs10849295 chr12 5673427 G A 0.00000769 Amyotrophic lateral sclerosis ANO2 intron 23587638 rs10849295 chr12 5673427 G A 0.0000118 Amyotrophic lateral sclerosis ANO2 intron 23587638 rs12426185 chr12 5709635 G C 2.45E-05 Tuberculosis ANO2 intron 24057671 rs4930766 chr12 5712164 T C 7.78E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) ANO2 intron 23648065 rs2110166 chr12 5751342 C T 5.00E-06 IgG glycosylation ANO2 intron 23382691 rs2110166 chr12 5751342 C T 6.00E-06 IgG glycosylation ANO2 intron 23382691 rs2215738 chr12 5784874 C T 6.03E-05 Brain lesion load ANO2 intron 19010793 rs387896 chr12 5795451 T A 1.30E-05 Multiple complex diseases ANO2 intron 17554300 rs3782631 chr12 5795743 C T 8.95E-05 Body Mass Index ANO2 intron pha002896 rs12579350 chr12 5797101 G A 7.58E-04 Multiple complex diseases ANO2 intron 17554300 rs12579350 chr12 5797101 G A 4.00E-09 Panic disorder ANO2 intron 19165232 rs11836388 chr12 5813402 A C 6.31E-04 Response to TNF antagonist treatment ANO2 intron 21061259 rs1544608 chr12 5813534 C A 8.25E-04 Schizophrenia ANO2 intron 19197363 rs1544608 chr12 5813534 C A 3.40E-04 Alzheimer's disease (late onset) ANO2 intron 21379329 rs7308694 chr12 5816681 G C 6.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) ANO2 intron 17982456 rs10774369 chr12 5820678 C T 6.94E-04 Type 2 diabetes ANO2 intron 17463246 rs3782637 chr12 5833530 A C,G 1.33E-05 Glucose levels ANO2 intron pha003061 rs11559856 chr12 5850904 A C,G,T 3.14E-04 Alzheimer's disease (late onset) ANO2 intron 21379329 rs2159952 chr12 5885320 C T 1.20E-05 Urinary metabolites ANO2 intron 21572414 rs2192191 chr12 5903406 G A 2.80E-05 Sodium levels ANO2 intron pha003093 rs6489665 chr12 5968018 T C 9.36E-05 Pulmonary function ANO2 intron 19300500 rs11063895 chr12 5981007 C T 8.82E-05 Pulmonary function ANO2 intron 19300500 rs7307889 chr12 5981353 C T 8.80E-05 Pulmonary function ANO2 intron 19300500 rs7307889 chr12 5981353 C T 3.00E-06 Obesity-related traits ANO2 intron 23251661 rs7306990 chr12 5981405 G C 8.20E-05 Pulmonary function ANO2 intron 19300500 rs17786382 chr12 6025054 T G 5.28E-04 Multiple complex diseases ANO2 intron 17554300 rs17724494 chr12 6027292 C T 6.76E-04 Multiple complex diseases ANO2 intron 17554300 rs11613774 chr12 6039623 G A 3.44E-06 Psoriasis ANO2 intron 20953190 rs3809241 chr12 6056450 G T 7.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs933408 chr12 6058736 T G 9.19E-04 Response to taxane treatment (placlitaxel) VWF intron 23006423 rs3759320 chr12 6062853 C T 5.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) VWF intron 23648065 rs3759321 chr12 6062878 G A 9.96E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) VWF intron 23648065 rs2363309 chr12 6070839 G A 8.03E-04 Myocardial Infarction VWF intron pha002883 rs12369177 chr12 6073520 T G 0.000513591 Hypertension (early onset hypertension) VWF intron 22479346 rs917857 chr12 6081824 G A 2.12E-04 Cocaine dependence VWF intron 23958962 rs2058473 chr12 6093926 A G 4.56E-04 Alzheimer's disease VWF intron 22005930 rs216903 chr12 6105499 T C 9.50E-04 Volumetric brain MRI VWF intron 17903297 rs216904 chr12 6106018 T C 1.36E-04 Type 2 diabetes VWF intron 17463246 rs216905 chr12 6106255 C T 4.61E-05 Squamous cell carcinoma VWF intron 23341777 rs216801 chr12 6108513 G A 4.53E-04 Type 2 diabetes VWF intron 17463246 rs9645765 chr12 6116457 A G 7.60E-04 Diabetic nephropathy VWF intron 20347642 rs9634155 chr12 6123777 T C 5.85E-08 Triglycerides VWF intron 23063622 rs1800385 chr12 6127891 C A 8.39E-04 Alcohol dependence VWF missense 21314694 rs141211612 chr12 6128454 G A 0.000016 Breast cancer(er negative) VWF missense 23555315 rs11063998 chr12 6136435 A G 1.92E-08 vWF levels,in plasma VWF intron 21534939 rs11608550 chr12 6137266 C T 1.98E-08 vWF levels,in plasma VWF intron 21534939 rs11610629 chr12 6137456 A C 9.16E-04 Prostate cancer mortality VWF intron 20978177 rs216318 chr12 6139261 A C 3.23E-04 Alcohol dependence VWF intron 21314694 rs216318 chr12 6139261 A C 1.60E-07 Metabolic syndrome phenotype VWF intron 22022282 rs216318 chr12 6139261 A C 1.90E-10 Metabolic syndrome phenotype VWF intron 22022282 rs11609728 chr12 6139692 C A 3.60E-08 vWF levels,in plasma VWF intron 21534939 rs216320 chr12 6143356 T C 1.67E-16 vWF levels,in plasma VWF intron 21534939 rs216321 chr12 6143984 T C 7.21E-16 vWF levels,in plasma / / 21534939 rs12810426 chr12 6144138 G A 7.61E-07 vWF levels,in plasma VWF intron 21534939 rs216334 chr12 6147611 C T 2.55E-05 Height VWF intron pha003011 rs17419697 chr12 6147786 T C 1.60E-05 Urinary metabolites VWF intron 21572414 rs11614912 chr12 6148555 A G 8.85E-08 vWF levels,in plasma VWF intron 21534939 rs10849378 chr12 6148674 G A 1.84E-10 vWF levels,in plasma VWF intron 21534939 rs216340 chr12 6149799 G A 7.76E-05 Body Mass Index VWF intron pha003022 rs216290 chr12 6151597 G A 4.18E-07 vWF levels,in plasma VWF intron 21534939 rs2239162 chr12 6151670 C G 1.82E-14 vWF levels,in plasma VWF intron 21534939 rs1063857 chr12 6153514 A G 6.58E-20 vWF levels,in plasma VWF cds-synon 21534939 rs1063857 chr12 6153514 A G 6.00E-07 Coagulation factor levels VWF cds-synon 23267103 rs1063856 chr12 6153534 T C,G 2.31E-20 vWF levels,in plasma VWF missense 21534939 rs1063856 chr12 6153534 T C,G 1.80E-04 Metabolic syndrome phenotype VWF missense 22022282 rs1063856 chr12 6153534 T C,G 5.70E-08 Metabolic syndrome phenotype VWF missense 22022282 rs1063856 chr12 6153534 T C,G 5.00E-16 Coagulation factor levels VWF missense 23267103 rs201818069 chr12 6153659 G GAT 4.56E-05 vWF levels,in plasma VWF intron 21534939 rs216293 chr12 6153659 G T 4.56E-05 vWF levels,in plasma VWF intron 21534939 rs216295 chr12 6154206 T C 5.13E-15 vWF levels,in plasma VWF intron 21534939 rs216296 chr12 6154670 A G 5.59E-14 vWF levels,in plasma VWF intron 21534939 rs216298 chr12 6156477 C T 4.75E-15 vWF levels,in plasma VWF intron 21534939 rs2239161 chr12 6162661 G A 9.39E-11 vWF levels,in plasma VWF intron 21534939 rs2239160 chr12 6162754 A G 8.74E-11 vWF levels,in plasma VWF intron 21534939 rs2283333 chr12 6162852 T C 2.17E-10 vWF levels,in plasma VWF intron 21534939 rs12319392 chr12 6170486 G T 1.20E-04 Multiple complex diseases VWF intron 17554300 rs12319392 chr12 6170486 G T 6.23E-04 Antineutrophil cytoplasmic antibody-associated vasculitis VWF intron 22808956 rs1800378 chr12 6172202 T C 9.37E-04 Obesity (extreme) VWF missense 21935397 rs2283332 chr12 6174729 G A 3.76E-05 vWF levels,in plasma VWF intron 21534939 rs7955850 chr12 6175579 T G 9.48E-06 vWF levels,in plasma VWF intron 21534939 rs2239157 chr12 6179467 C T 2.03E-05 vWF levels,in plasma VWF intron 21534939 rs3782711 chr12 6183181 T C 3.44E-05 vWF levels,in plasma VWF intron 21534939 rs12310690 chr12 6185029 G C 5.17E-05 vWF levels,in plasma VWF intron 21534939 rs12310690 chr12 6185029 G C 0.0000637 Primary sclerosing cholangitis VWF intron 23603763 rs7135976 chr12 6186116 T C 8.34E-05 Pulmonary function VWF intron 19300500 rs2238104 chr12 6187665 G T 8.34E-05 Pulmonary function VWF intron 19300500 rs11064024 chr12 6202049 G A 6.10E-04 Coronary heart disease VWF intron 21966275 rs12307072 chr12 6226547 T A 2.30E-06 Urinary metabolites VWF intron 21572414 rs10849385 chr12 6227919 G A 1.20E-06 Urinary metabolites VWF intron 21572414 rs10849387 chr12 6238479 C T 4.00E-06 Urinary metabolites / / 21572414 rs10774394 chr12 6238593 C T 2.20E-06 Urinary metabolites / / 21572414 rs11064059 chr12 6263980 G C 2.60E-06 Urinary metabolites / / 21572414 rs12367163 chr12 6267238 C G 7.10E-06 Urinary metabolites / / 21572414 rs12369484 chr12 6271973 C T 6.50E-06 Urinary metabolites / / 21572414 rs1860363 chr12 6276533 T C 6.50E-06 Urinary metabolites / / 21572414 rs10774403 chr12 6277311 C T 5.90E-06 Urinary metabolites / / 21572414 rs1558324 chr12 6289219 G A 2.00E-21 Mean platelet volume / / 22139419 rs1558324 chr12 6289219 G A 1.00E-05 Mean platelet volume / / 24026423 rs7342306 chr12 6291093 G A 4.00E-11 Platelet counts / / 22139419 rs797773 chr12 6307566 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs3181157 chr12 6308523 C T 4.00E-06 Paclitaxel-induced neuropathy / / 23776197 rs10849421 chr12 6327008 A G 4.15E-05 Response to acetaminophen (hepatotoxicity) CD9 intron 21177773 rs4764486 chr12 6327989 T C 5.27E-05 Response to acetaminophen (hepatotoxicity) CD9 intron 21177773 rs740839 chr12 6338637 C T 7.32E-05 Cognitive test performance CD9 intron 20125193 rs3181291 chr12 6341499 G A 6.95E-04 Parkinson's disease CD9 intron 16252231 rs3181295 chr12 6344174 A G 7.93E-04 Obesity (extreme) CD9 intron 21935397 rs3181295 chr12 6344174 A G 3.10E-04 Allergic sensitization CD9 intron 23817571 rs3181298 chr12 6344825 C A 8.81E-05 Amyotrophic lateral sclerosis (sporadic) CD9 intron 24529757 rs10849432 chr12 6385727 C T 6.00E-10 Colorectal cancer / / 24836286 rs1990385 chr12 6394635 T C 6.56E-04 Smoking cessation / / 24665060 rs16932505 chr12 6402273 T G 8.23E-04 Smoking cessation / / 24665060 rs7315020 chr12 6409770 T C 3.11E-05 Waist-Hip Ratio / / pha003013 rs7315020 chr12 6409770 T C 5.40E-05 Waist-Hip Ratio / / pha003028 rs1003563 chr12 6424577 A G 5.05E-04 Amyotrophic Lateral Sclerosis PLEKHG6 intron 17362836 rs10849441 chr12 6435571 A G 9.00E-06 Obesity-related traits PLEKHG6 intron 23251661 rs1800693 chr12 6440009 T C 2.00E-11 Multiple sclerosis TNFRSF1A intron 19525953 rs1800693 chr12 6440009 T C 2.80E-05 Ankylosing spondylitis TNFRSF1A intron 20062062 rs1800693 chr12 6440009 T C 2.00E-09 Primary biliary cirrhosis TNFRSF1A intron 21399635 rs1800693 chr12 6440009 T C 4.00E-14 Multiple sclerosis TNFRSF1A intron 21833088 rs1800693 chr12 6440009 T C 7.92E-05 Multiple sclerosis TNFRSF1A intron 22190364 rs1800693 chr12 6440009 T C 1.18E-14 Primary biliary cirrhosis TNFRSF1A intron 22961000 rs4149639 chr12 6442001 T C 3.00E-07 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) TNFRSF1A intron 23648065 rs4149639 chr12 6442001 T C 7.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) TNFRSF1A intron 23648065 rs4149584 chr12 6442643 C A,G,T 5.00E-06 Multiple sclerosis TNFRSF1A missense 19525953 rs1860545 chr12 6446777 G A 0.0000527 Primary biliary cirrhosis TNFRSF1A intron 22936693 rs1860545 chr12 6446777 G A 0.000348 Primary biliary cirrhosis (anti-mitochondrial antibody positive) TNFRSF1A intron 22936693 rs1860545 chr12 6446777 G A 2.18E-13 Primary biliary cirrhosis TNFRSF1A intron 22961000 rs1860545 chr12 6446777 G A 8.42E-04 Sleep duration TNFRSF1A intron 23728906 rs4149581 chr12 6446985 T C 8.27E-07 Primary biliary cirrhosis TNFRSF1A intron 21399635 rs4149581 chr12 6446985 T C 3.55E-13 Primary biliary cirrhosis TNFRSF1A intron 22961000 rs4149580 chr12 6446990 G A 6.82E-13 Primary biliary cirrhosis TNFRSF1A intron 22961000 rs4149576 chr12 6449115 C T 1.03E-08 Multiple sclerosis TNFRSF1A intron 19525953 rs767455 chr12 6450945 T C 2.71E-11 Primary biliary cirrhosis TNFRSF1A cds-synon 22961000 rs4149621 chr12 6451561 T C 6.59E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) TNFRSF1A nearGene-5 23648065 rs4149621 chr12 6451561 T C 5.17E-04 Amyotrophic lateral sclerosis (sporadic) TNFRSF1A nearGene-5 24529757 rs4149570 chr12 6451590 A C 3.51E-04 Bicuspid aortic valve TNFRSF1A nearGene-5 20098615 rs4149570 chr12 6451590 A C 6.82E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) TNFRSF1A nearGene-5 23648065 rs4149617 chr12 6452612 G A 0.000000681 Cholesterol,total TNFRSF1A nearGene-5 23063622 rs7297961 chr12 6454297 A G 3.96E-04 Alzheimer's disease (late onset) / / 21379329 rs11064145 chr12 6455098 T G 2.37E-06 Primary biliary cirrhosis / / 21399635 rs2228576 chr12 6457062 T C 8.60E-05 Sensory disturbances after bilateral sagittal split ramus osteotomy SCNN1A missense 23834954 rs3782724 chr12 6466081 A G 3.00E-07 Obesity (early onset extreme) SCNN1A intron 23563609 rs6489711 chr12 6468303 T C 3.84E-05 Gaucher disease severity SCNN1A intron 22388998 rs10849446 chr12 6479292 A C 3.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SCNN1A intron 20877124 rs10849446 chr12 6479292 A C 6.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SCNN1A intron 20877124 rs10849446 chr12 6479292 A C 3.66E-05 Parkinson's disease SCNN1A intron pha002868 rs11064153 chr12 6488450 T C 5.39E-05 Asthma SCNN1A nearGene-5 11022011 rs10849448 chr12 6493351 A G 4.54E-09 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs2364480 chr12 6495275 C A 0.000000051 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs2364480 chr12 6495275 C A 0.00000887 Oligoarticular juvenile idiopathic arthritis / / 23603761 rs2364480 chr12 6495275 C A 0.000414 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis / / 23603761 rs12354 chr12 6500105 T G 0.000114 Primary biliary cirrhosis / / 22936693 rs4301834 chr12 6500843 G A 2.23E-04 Self-reported allergy / / 23817569 rs11616188 chr12 6502742 G A 1.50E-05 Type 2 diabetes / / 17463248 rs11616188 chr12 6502742 G A 4.00E-12 Ankylosing spondylitis / / 21743469 rs9669611 chr12 6503786 T C 1.53E-04 Self-reported allergy / / 23817569 rs9668139 chr12 6504098 G A 2.08E-04 Self-reported allergy / / 23817569 rs2364484 chr12 6511996 C A 1.78E-04 Self-reported allergy / / 23817569 rs7313533 chr12 6515855 A G 9.80E-05 Type 2 diabetes / / 17463248 rs4764589 chr12 6532282 G A 0.00088 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs7958488 chr12 6546166 A T 7.95E-06 Malignant mesothelioma / / 23827383 rs11569361 chr12 6553806 G A 4.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC678655 intron 20877124 rs25680 chr12 6554628 G A 1.07E-04 Amyotrophic lateral sclerosis (sporadic) CD27 missense 24529757 rs2244083 chr12 6570539 A T 2.71E-09 Lymphocyte counts TAPBPL intron 22286170 rs10492096 chr12 6580582 A G 3.00E-06 Hip geometry / / 17903296 rs11064237 chr12 6614156 T C 1.35E-08 Lymphocyte counts NCAPD2 intron 22286170 rs2072374 chr12 6637845 T C 0.00041 Breast cancer NCAPD2 cds-synon 23555315 rs2270177 chr12 6651681 T A 8.07E-05 Serum metabolites IFFO1 intron 19043545 rs1057510 chr12 6683287 G A 6.00E-06 Myopia (pathological) CHD4 intron 23049088 rs7316626 chr12 6691452 G A 1.10E-05 HIV-1 control CHD4 intron 20041166 rs12310569 chr12 6697353 G A 8.70E-05 Interstitial lung disease CHD4 intron 23583980 rs11539542 chr12 6709059 G A 3.30E-05 HIV-1 control CHD4 cds-synon 20041166 rs12099908 chr12 6713636 C A 1.10E-05 HIV-1 control CHD4 intron 20041166 rs1639123 chr12 6714668 T C 2.10E-05 HIV-1 control CHD4 intron 20041166 rs10849492 chr12 6720795 A G 8.70E-05 HIV-1 control / / 20041166 rs2886271 chr12 6734313 C T 3.31E-04 Iron levels LPAR5 intron pha002876 rs3759343 chr12 6833104 T C 0.000337742 Hypertension (early onset hypertension) / / 22479346 rs12578573 chr12 6842959 T C 2.48E-05 Lymphocyte counts / / 22286170 rs7305330 chr12 6849879 A G 3.26E-04 Smoking initiation / / 24665060 rs2302371 chr12 6858126 G A 3.40E-05 Brain structure MLF2 cds-synon 22504417 rs7970575 chr12 6858971 C T 1.25E-05 Brain structure MLF2 intron 22504417 rs7316251 chr12 6870549 A G 6.70E-06 Urinary metabolites / / 21572414 rs2091781 chr12 6872512 G A 1.00E-05 Urinary metabolites / / 21572414 rs2301333 chr12 6880996 G A 2.43E-05 Cognitive performance / / 19734545 rs28917504 chr12 6924122 A G 0.000000105 Triglycerides CD4 missense 23063622 rs28917504 chr12 6924122 A G 1.32E-15 Cholesterol,total CD4 missense 23063622 rs28917504 chr12 6924122 A G 8.78E-14 LDL cholesterol CD4 missense 23063622 rs3741920 chr12 6938872 C T 4.00E-06 Response to Vitamin E supplementation LEPREL2 intron 22437554 rs10744716 chr12 6939850 A G 8.57E-05 HIV-1 viral setpoint LEPREL2 missense 22174851 rs1047771 chr12 6941021 G A 6.83E-04 Acute lung injury LEPREL2 cds-synon 22295056 rs10849527 chr12 6946360 C T 4.27E-04 Acute lung injury LEPREL2 intron 22295056 rs5440 chr12 6948899 A G 4.10E-05 Response to Vitamin E supplementation LEPREL2 UTR-3 22437554 rs2301339 chr12 6954624 G A 6.30E-05 Diabetic retinopathy GNB3 intron 21441570 rs5443 chr12 6954875 C T 1 Drug response to Sildenafil (Viagra) GNB3 cds-synon 12576843 rs5443 chr12 6954875 C T 1 Drug response to Almotriptan GNB3 cds-synon 17361120 rs5443 chr12 6954875 C T 1 Drug response to Eletriptan GNB3 cds-synon 17361120 rs5443 chr12 6954875 C T 1 Drug response to Naratriptan GNB3 cds-synon 17361120 rs5443 chr12 6954875 C T 1 Drug response to Rizatriptan GNB3 cds-synon 17361120 rs5443 chr12 6954875 C T 1 Drug response to Sumatriptan GNB3 cds-synon 17361120 rs5443 chr12 6954875 C T 1 Drug response to Zolmitriptan GNB3 cds-synon 17361120 rs5443 chr12 6954875 C T 1 Drug response to Atorvastatin GNB3 cds-synon 18551043 rs5443 chr12 6954875 C T 1 Drug response to Fluvastatin GNB3 cds-synon 18551043 rs5443 chr12 6954875 C T 1 Drug response to Lovastatin GNB3 cds-synon 18551043 rs5443 chr12 6954875 C T 1 Drug response to Pravastatin GNB3 cds-synon 18551043 rs5443 chr12 6954875 C T 1 Drug response to Rosuvastatin GNB3 cds-synon 18551043 rs5443 chr12 6954875 C T 1 Drug response to Simvastatin GNB3 cds-synon 18551043 rs5443 chr12 6954875 C T 1 Drug response to Olanzapine GNB3 cds-synon 19193342 rs5446 chr12 6956462 C T 1.40E-05 Diabetic retinopathy GNB3 UTR-3 21441570 rs11064429 chr12 6959088 T C 8.43E-04 Multiple complex diseases CDCA3 intron 17554300 rs2071058 chr12 6960893 A T 1.80E-05 Diabetic retinopathy / / 21441570 rs2226955 chr12 6965194 A G 1.90E-05 Diabetic retinopathy USP5 cds-synon 21441570 rs2238114 chr12 6965740 C A 1.70E-05 Diabetic retinopathy USP5 intron 21441570 rs2071059 chr12 6969731 A G 1.40E-05 Diabetic retinopathy USP5 intron 21441570 rs2001004 chr12 6977359 A G 1.90E-05 Diabetic retinopathy TPI1 UTR-5 21441570 rs7955412 chr12 6998371 G C 2.50E-05 Diabetic retinopathy / / 21441570 rs7138526 chr12 6999264 G A 2.40E-05 Diabetic retinopathy / / 21441570 rs2040352 chr12 7007004 C A 2.40E-05 Diabetic retinopathy / / 21441570 rs2040352 chr12 7007004 C A 0.000577673 Hypertension (early onset hypertension) / / 22479346 rs2187611 chr12 7009602 G T 2.50E-05 Diabetic retinopathy / / 21441570 rs3759349 chr12 7011825 G C 2.60E-05 Diabetic retinopathy / / 21441570 rs3759350 chr12 7011947 G T 2.70E-05 Diabetic retinopathy / / 21441570 rs3759352 chr12 7012055 T G 2.70E-05 Diabetic retinopathy / / 21441570 rs2239163 chr12 7014076 C G 2.80E-05 Diabetic retinopathy LRRC23 UTR-5 21441570 rs1007923 chr12 7014107 T A 5.60E-05 Diabetic retinopathy LRRC23 UTR-5 21441570 rs10849538 chr12 7014607 A G 3.60E-05 Diabetic retinopathy LRRC23 intron 21441570 rs10849538 chr12 7014607 A G 3.72E-06 Lymphocyte counts LRRC23 intron 22286170 rs1007924 chr12 7015915 A G 6.50E-05 Diabetic retinopathy LRRC23 intron 21441570 rs2301137 chr12 7018949 C T 6.60E-05 Diabetic retinopathy LRRC23 intron 21441570 rs2301137 chr12 7018949 C T 0.000472803 Hypertension (early onset hypertension) LRRC23 intron 22479346 rs1057077 chr12 7022085 T A 7.40E-05 Diabetic retinopathy LRRC23 missense 21441570 rs710415 chr12 7023123 A G 7.90E-05 Diabetic retinopathy LRRC23 missense 21441570 rs11064464 chr12 7028394 T C 3.31E-04 Multiple complex diseases ENO2 intron 17554300 rs729751 chr12 7054350 T A,C,G 9.72E-05 Type 2 diabetes C12orf57 intron 17463246 rs759052 chr12 7069620 T C 9.56E-04 Suicide attempts in bipolar disorder PTPN6 intron 21423239 rs11064477 chr12 7074365 G A 0.000000516 Bisphosphonate-induced osteonecrosis of the jaw / / 22267851 rs16928105 chr12 7114196 C T 5.60E-06 Urinary metabolites LPCAT3 intron 21572414 rs3919533 chr12 7162801 C T 6.99E-05 Major depressive disorder (broad) / / 20038947 rs3919533 chr12 7162801 C T 2.76E-04 Alzheimer's disease / / 22005930 rs7311672 chr12 7165114 A G 6.58E-05 Major depressive disorder (broad) / / 20038947 rs7311672 chr12 7165114 A G 2.50E-04 Alzheimer's disease / / 22005930 rs12146727 chr12 7170336 G A 3.63E-05 Sudden cardiac arrest C1S missense 21658281 rs2192137 chr12 7174770 A G 9.72E-05 Type 2 diabetes C1S intron 17463246 rs2192137 chr12 7174770 A G 5.24E-05 Major depressive disorder (broad) C1S intron 20038947 rs1143664 chr12 7175047 A C,G,T 8.33E-05 Orofacial clefts C1S cds-synon 22419666 rs10744062 chr12 7313760 C T 2.75E-04 Multiple complex diseases / / 17554300 rs7958865 chr12 7316029 A G 4.29E-04 Smoking initiation / / 24665060 rs7973719 chr12 7334813 C T 4.00E-08 IgG glycosylation / / 23382691 rs12828421 chr12 7335217 T C 9.00E-07 IgG glycosylation / / 23382691 rs12312641 chr12 7340994 G A 1.21E-04 Atopy PEX5 nearGene-5 21625490 rs1551097 chr12 7376654 A G 1.40E-04 Lung function (forced vital capacity) / / 24023788 rs1551097 chr12 7376654 A G 4.68E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs11045415 chr12 7377419 G A 3.52E-04 Lymphocyte counts / / 22286170 rs11045894 chr12 7382544 C T 5.71E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7962099 chr12 7383187 G A 5.90E-06 Substance dependence phenotypes / / 24832863 rs7962099 chr12 7383187 G A 8.26E-04 Substance dependence phenotypes / / 24832863 rs10770826 chr12 7385493 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4883177 chr12 7412351 C T 6.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4883177 chr12 7412351 C T 2.40E-05 Hypothyroidism / / 22493691 rs11612407 chr12 7435250 A C 9.50E-05 Hypothyroidism / / 22493691 rs7137120 chr12 7455597 A G 6.07E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7294678 chr12 7465941 G A 5.14E-04 Response to taxane treatment (placlitaxel) ACSM4 intron 23006423 rs12815715 chr12 7489353 G C 5.03E-06 Lipid traits / / 21777205 rs7308628 chr12 7512026 A C 2.66E-05 Hypertension CD163L1 intron 21082022 rs10845007 chr12 7525795 C T 1.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CD163L1 intron 20877124 rs150856487 chr12 7528404 C T 0.000038 Breast cancer(er negative) CD163L1 missense 23555315 rs11053534 chr12 7529700 T C 1.24E-05 Hepatocellular carcinoma CD163L1 intron 22807686 rs11053562 chr12 7535354 G A 1.06E-04 Multiple complex diseases CD163L1 intron 17554300 rs4075106 chr12 7550186 G A 1.41E-05 Personality dimensions CD163L1 intron 22628180 rs7489145 chr12 7551222 G C 1.47E-05 Personality dimensions CD163L1 intron 22628180 rs7487128 chr12 7551307 A G 1.48E-05 Personality dimensions CD163L1 intron 22628180 rs12312491 chr12 7552855 A G 1.52E-05 Personality dimensions CD163L1 intron 22628180 rs12305920 chr12 7553051 G T 1.53E-05 Personality dimensions CD163L1 intron 22628180 rs12306216 chr12 7553625 G C 1.57E-05 Personality dimensions CD163L1 intron 22628180 rs11053748 chr12 7564740 G A 9.66E-04 Type 2 diabetes CD163L1 intron 17463246 rs12309292 chr12 7582113 C T 2.00E-05 Personality dimensions CD163L1 intron 22628180 rs10431296 chr12 7587534 T C 3.98E-05 Hypertension CD163L1 intron 21082022 rs12368910 chr12 7600674 C T 2.66E-05 Graves' disease / / 21841780 rs6488338 chr12 7632143 T C 3.13E-04 Myocardial Infarction CD163 intron pha002873 rs11054180 chr12 7647187 A G 8.63E-05 Cognitive impairment induced by topiramate CD163 intron 22091778 rs7136716 chr12 7691134 A G 2.54E-26 Blood cell counts and other traits / / 20139978 rs7136716 chr12 7691134 A G 3.00E-26 Blood cell counts and other traits / / 20139978 rs11054623 chr12 7735319 G T 3.52E-05 Blood Pressure / / pha003043 rs41384747 chr12 7794774 T G 3.39E-05 Multiple complex diseases / / 17554300 rs7962216 chr12 7832148 G A 2.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs11832968 chr12 7834612 T C 2.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs7297638 chr12 7834950 T C 5.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs10845708 chr12 7849144 A G 4.83E-05 Prostate cancer GDF3 nearGene-5 22923026 rs10772625 chr12 7849465 T C 4.14E-04 Smoking initiation GDF3 nearGene-5 24665060 rs17789655 chr12 7849986 G A 8.30E-07 Thiazide-induced adverse metabolic effects in hypertensive patients GDF3 nearGene-5 23400010 rs7299581 chr12 7850215 G A 6.97E-06 Thiazide-induced adverse metabolic effects in hypertensive patients GDF3 nearGene-5 23400010 rs7132821 chr12 7850431 A G 3.78E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs11055277 chr12 7852052 G A 3.77E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs11055283 chr12 7853512 G A 3.82E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs12307997 chr12 7855271 G A 6.00E-07 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs12582518 chr12 7856726 T C 2.54E-05 Prostate cancer / / 22923026 rs6488610 chr12 7887010 T C 2.10E-05 Urinary metabolites CLEC4C intron 21572414 rs7959924 chr12 7949230 G T 2.39E-05 Blood Pressure / / pha003048 rs2098247 chr12 7957777 G A 6.30E-06 Urinary metabolites / / 21572414 rs10846018 chr12 7985318 C A 4.40E-05 Pericardial fat SLC2A14 cds-synon 22589742 rs2889545 chr12 7993316 A C 1.82E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SLC2A14 intron 24023788 rs2889545 chr12 7993316 A C 6.70E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SLC2A14 intron 24023788 rs11056079 chr12 7996890 C T 6.60E-04 Alcohol dependence SLC2A14 intron 20201924 rs11056079 chr12 7996890 C T 7.10E-04 Alcohol dependence SLC2A14 intron 20201924 rs7965203 chr12 8000336 T G 3.70E-04 Alcohol dependence SLC2A14 intron 20201924 rs7965203 chr12 8000336 T G 4.50E-04 Alcohol dependence SLC2A14 intron 20201924 rs1894829 chr12 8014041 A G 6.20E-05 Alcohol dependence SLC2A14 intron 20201924 rs1894829 chr12 8014041 A G 8.00E-05 Alcohol dependence SLC2A14 intron 20201924 rs1894829 chr12 8014041 A G 8.02E-05 Alcoholism SLC2A14 intron pha002892 rs1894829 chr12 8014041 A G 6.24E-05 Alcoholism SLC2A14 intron pha002893 rs11612319 chr12 8016925 G A 4.40E-05 Alcohol dependence SLC2A14 intron 20201924 rs11612319 chr12 8016925 G A 6.60E-05 Alcohol dependence SLC2A14 intron 20201924 rs11612319 chr12 8016925 G A 6.55E-05 Alcoholism SLC2A14 intron pha002892 rs11612319 chr12 8016925 G A 4.41E-05 Alcoholism SLC2A14 intron pha002893 rs10047605 chr12 8023276 G T 1.60E-04 Alcohol dependence SLC2A14 intron 20201924 rs10047605 chr12 8023276 G T 2.60E-05 Alcohol dependence SLC2A14 intron 20201924 rs10047605 chr12 8023276 G T 2.60E-05 Alcoholism SLC2A14 intron pha002893 rs11502980 chr12 8044997 C A 7.99E-05 Height / / pha003011 rs6488767 chr12 8057859 G T 3.60E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7975101 chr12 8068227 C A 3.65E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7975829 chr12 8068881 C T 3.20E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12315382 chr12 8080330 A G 9.40E-05 Multiple complex diseases SLC2A3 intron 17554300 rs7309332 chr12 8090839 T C 8.34E-05 Serum albumin level / / pha003084 rs4883463 chr12 8117069 T A 8.63E-04 Multiple complex diseases / / 17554300 rs4628755 chr12 8143466 T C 8.77E-04 Multiple complex diseases / / 17554300 rs10732571 chr12 8146689 C T 2.65E-04 Type 2 diabetes / / 17463246 rs35297839 chr12 8185853 A C 7.85E-04 Response to cytadine analogues (cytosine arabinoside) FOXJ2 UTR-5 24483146 rs3782679 chr12 8190206 C A 9.39E-04 Multiple complex diseases FOXJ2 intron 17554300 rs3782683 chr12 8191911 C A 4.70E-04 Alcohol consumption (maxi-drinks) FOXJ2 intron 24277619 rs16916733 chr12 8195968 C T 5.22E-09 LDL cholesterol FOXJ2 intron 23063622 rs16916733 chr12 8195968 C T 6.07E-10 Cholesterol,total FOXJ2 intron 23063622 rs2889626 chr12 8240017 A G 9.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) NECAP1 intron 23233662 rs2241025 chr12 8244972 A G 0.0007978 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NECAP1 intron 23233654 rs2241025 chr12 8244972 A G 7.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) NECAP1 intron 23233662 rs11043394 chr12 8262572 T G 2.79E-04 Tourette syndrome / / 22889924 rs2024304 chr12 8267225 G A 1.92E-04 Tourette syndrome / / 22889924 rs2110067 chr12 8268997 C T 1.08E-04 Tourette syndrome / / 22889924 rs4883071 chr12 8271102 A G 9.78E-05 Alcohol dependence / / 21314694 rs2889630 chr12 8280755 C A 5.46E-04 Tourette syndrome CLEC4A intron 22889924 rs17728930 chr12 8281418 T G 9.22E-05 Kawasaki disease CLEC4A intron 22446961 rs17728942 chr12 8288403 G A 7.87E-05 Response to TNF antagonist treatment CLEC4A intron 21061259 rs11043661 chr12 8309400 A G 1.00E-05 Urinary metabolites / / 21572414 rs7307734 chr12 8309433 G A 7.87E-04 Type 2 diabetes / / 17463246 rs11044062 chr12 8371320 A G 7.79E-06 Type 2 diabetes / / 17463246 rs2719019 chr12 8410893 C T 7.20E-04 Multiple complex diseases / / 17554300 rs9668636 chr12 8488085 C T 1.40E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12830720 chr12 8510463 T C 7.92E-05 Major depressive disorder LOC389634 intron 21621269 rs12830720 chr12 8510463 T C 6.93E-05 Major depressive disorder LOC389634 intron pha002850 rs4459385 chr12 8609795 C T 2.01E-04 Type 2 diabetes CLEC6A intron 17463246 rs10770847 chr12 8698471 C T 7.00E-04 Alzheimer's disease / / 17998437 rs2028373 chr12 8757481 G A 3.39E-04 Insulin resistance AICDA cds-synon 21901158 rs14541 chr12 8800566 A G 6.40E-05 Insulin resistance MFAP5 UTR-3 21901158 rs10505737 chr12 8804572 C A 4.59E-04 Alcohol dependence MFAP5 intron 21314694 rs2969097 chr12 8891527 A G 3.19E-04 Type 2 diabetes RIMKLB intron 17463246 rs2969097 chr12 8891527 A G 2.91E-04 Schizophrenia RIMKLB intron 19197363 rs11047080 chr12 8907196 T C 5.75E-04 Multiple complex diseases RIMKLB intron 17554300 rs9783460 chr12 8927520 C A 5.84E-04 Multiple complex diseases RIMKLB UTR-3 17554300 rs10161484 chr12 8969005 T C 7.00E-05 Primary sclerosing cholangitis / / 19944697 rs1344454 chr12 8995211 C T 2.08E-06 Stroke (ischemic) A2ML1 intron 21957438 rs17729753 chr12 9019477 C T 7.20E-06 White blood cell count A2ML1 intron 21738479 rs7311897 chr12 9020328 T C 5.67E-05 Multiple sclerosis A2ML1 intron 19525953 rs7311897 chr12 9020328 T C 1.78E-06 White blood cell count A2ML1 intron 21738479 rs144876785 chr12 9020509 C G 0.00022 Breast cancer A2ML1 missense 23555315 rs200176373 chr12 9020859 A C,G 0.00026 Breast cancer A2ML1 missense 23555315 rs7313300 chr12 9023877 G A 3.07E-06 White blood cell count A2ML1 intron 21738479 rs7316141 chr12 9027429 A G 2.30E-04 Response to antidepressants A2ML1 intron 19736353 rs1894815 chr12 9038572 T C 5.92E-04 Coronary Artery Disease / / 17634449 rs10771179 chr12 9049198 A C 8.58E-04 Multiple complex diseases / / 17554300 rs11611106 chr12 9060204 C A 7.03E-04 Multiple complex diseases / / 17554300 rs3809218 chr12 9066613 C T 1.28E-05 Amyotrophic lateral sclerosis / / 23624525 rs1805740 chr12 9075014 G T 4.20E-05 Serum metabolites PHC1 intron 19043545 rs11048060 chr12 9079625 G A 6.01E-06 Amyotrophic lateral sclerosis PHC1 intron 23624525 rs4883201 chr12 9082581 A G 2.00E-09 Cholesterol,total PHC1 intron 24097068 rs887783 chr12 9085099 G A 6.65E-05 Lung adenocarcinoma PHC1 intron 19836008 rs1805733 chr12 9089272 A C 2.31E-06 Lung adenocarcinoma PHC1 intron 19836008 rs1476911 chr12 9090859 G A 2.31E-04 Multiple complex diseases PHC1 intron 17554300 rs1805732 chr12 9090892 C T 1.99E-04 Multiple complex diseases PHC1 intron 17554300 rs1805727 chr12 9097398 G T 2.50E-05 Urinary metabolites M6PR intron 21572414 rs1805762 chr12 9097902 C G 3.00E-04 Hypertension M6PR intron 18003638 rs1805761 chr12 9099533 T C 2.00E-05 Tanning M6PR intron 19340012 rs1805761 chr12 9099533 T C 2.27E-06 Lung adenocarcinoma M6PR intron 19836008 rs1805755 chr12 9102412 A G 4.89E-14 Multiple sclerosis / / 17660530 rs12821842 chr12 9108984 G A 1.32E-06 Lung adenocarcinoma / / 19836008 rs2377674 chr12 9112761 A G 1.28E-06 Lung adenocarcinoma / / 19836008 rs12423746 chr12 9113002 G T 1.61E-04 Multiple complex diseases / / 17554300 rs11048264 chr12 9113581 A G 1.32E-04 Multiple complex diseases / / 17554300 rs11048338 chr12 9121362 C G 1.28E-04 Multiple complex diseases / / 17554300 rs2110192 chr12 9136351 T A 1.11E-04 Multiple complex diseases / / 17554300 rs7296295 chr12 9139282 G A 2.24E-04 Alcohol dependence / / 24277619 rs1805723 chr12 9142297 T C 9.59E-06 Lung adenocarcinoma KLRG1 cds-synon 19836008 rs1805721 chr12 9147569 G A 7.86E-05 Multiple complex diseases KLRG1 intron 17554300 rs1805721 chr12 9147569 G A 9.89E-06 Lung adenocarcinoma KLRG1 intron 19836008 rs16917975 chr12 9226984 C T 4.38E-04 Multiple complex diseases A2M intron 17554300 rs2889717 chr12 9286801 T C 9.30E-05 Volumetric brain MRI / / 17903297 rs3741851 chr12 9303440 A G 7.76E-04 Iron levels PZP intron pha002876 rs10771407 chr12 9345273 A G 1.93E-05 Stroke (ischemic) PZP cds-synon 22941190 rs1017301 chr12 9362931 C A 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1017301 chr12 9362931 C A 2.24E-05 Bone mineral traits,in men / / 21427758 rs6487679 chr12 9371332 C T 1.00E-06 Non-alcoholic fatty liver disease histology (AST) / / 20708005 rs7305336 chr12 9375089 C A 5.42E-04 Alzheimer's disease / / 22005930 rs10771431 chr12 9380859 G A 2.00E-06 Breast size / / 22747683 rs34362 chr12 9385425 C T 5.42E-04 Alzheimer's disease A2MP1 intron 22005930 rs11049781 chr12 9399888 C T 0.00005065 Sarcoidosis / / 22952805 rs12369816 chr12 9407282 T C 0.00001401 Sarcoidosis / / 22952805 rs11049830 chr12 9411142 G T 0.00006993 Sarcoidosis / / 22952805 rs11049845 chr12 9413442 C T 0.0000111 Sarcoidosis / / 22952805 rs11049846 chr12 9413607 A G 0.00001057 Sarcoidosis / / 22952805 rs34337 chr12 9424308 G A 0.00004623 Sarcoidosis / / 22952805 rs6487734 chr12 9427520 C G 0.00003301 Sarcoidosis / / 22952805 rs6487748 chr12 9435768 A G 0.00000099 Myopia (Age of onset) / / 23468642 rs2429893 chr12 9453571 C T 2.00E-05 Urinary metabolites LOC642846 intron 21572414 rs10771515 chr12 9463806 T C 9.00E-06 Obesity-related traits / / 23251661 rs10843422 chr12 9477252 G T 0.00002202 Sarcoidosis / / 22952805 rs7302181 chr12 9478137 A G 4.92E-04 Multiple complex diseases / / 17554300 rs741623 chr12 9490426 G T 4.25E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7397814 chr12 9546962 T C 4.00E-06 IgG glycosylation / / 23382691 rs11050701 chr12 9549072 T C 1.68E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10771901 chr12 9735686 C T 8.30E-04 Multiple sclerosis / / 17660530 rs2109903 chr12 9739449 A G 3.84E-04 Multiple complex diseases / / 17554300 rs7137213 chr12 9740839 G A 3.36E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4763655 chr12 9755578 G A 6.85E-04 Multiple sclerosis KLRB1 intron 17660530 rs10844160 chr12 9757154 C T 2.63E-04 Multiple complex diseases KLRB1 intron 17554300 rs11051879 chr12 9758119 C A 1.33E-04 Multiple complex diseases KLRB1 intron 17554300 rs6488079 chr12 9804215 T C 5.85E-04 Multiple complex diseases LOC374443 intron 17554300 rs10844372 chr12 9815902 G C 2.41E-08 Lymphocyte counts / / 22286170 rs2114870 chr12 9823140 G A 1.84E-05 Multiple complex diseases CLEC2D intron 17554300 rs11052372 chr12 9831959 C G 1.41E-07 Multiple complex diseases CLEC2D intron 17554300 rs3764021 chr12 9833628 C T 5.00E-08 Type 1 diabetes CLEC2D cds-synon 17554300 rs11052384 chr12 9834481 A C 4.98E-05 Response to tocilizumab in rheumatoid arthritis CLEC2D intron 22491018 rs11052423 chr12 9840038 C T 1.39E-07 Multiple complex diseases CLEC2D intron 17554300 rs7310460 chr12 9840773 T A 5.35E-06 Multiple complex diseases CLEC2D intron 17554300 rs11052552 chr12 9855958 T G 7.00E-07 Type 1 diabetes / / 17554300 rs741199 chr12 9873365 G A 6.41E-04 Tourette syndrome CLECL1 intron 22889924 rs2192439 chr12 9874226 G A 1.77E-04 Attention deficit hyperactivity disorder CLECL1 intron 22420046 rs10772079 chr12 9874394 T A 4.14E-08 Multiple complex diseases CLECL1 intron 17554300 rs10466829 chr12 9876091 G A 1.00E-08 Multiple sclerosis CLECL1 intron 21833088 rs10466829 chr12 9876091 G A 2.10E-05 Hypothyroidism CLECL1 intron 22493691 rs10466829 chr12 9876091 G A 9.00E-04 Multiple sclerosis CLECL1 intron 24234648 rs10492166 chr12 9885999 G A 6.04E-09 Type 1 diabetes / / 21980299 rs10844673 chr12 9897565 G A 1.36E-04 Multiple complex diseases / / 17554300 rs10844682 chr12 9899624 T C 3.56E-06 Multiple complex diseases / / 17554300 rs6416258 chr12 9909997 C T 3.64E-06 Lymphocyte counts CD69 intron 22286170 rs4763879 chr12 9910164 G A 2.67E-05 Multiple complex diseases CD69 intron 17554300 rs4763879 chr12 9910164 G A 2.00E-11 Type 1 diabetes CD69 intron 19430480 rs4763879 chr12 9910164 G A 1.90E-11 Multiple sclerosis CD69 intron 22190364 rs3136560 chr12 9916546 G A 1.48E-04 Orofacial clefts / / 22863734 rs10772132 chr12 9924912 G T 4.23E-04 Multiple complex diseases / / 17554300 rs10772132 chr12 9924912 G T 5.60E-04 Prostate cancer mortality / / 20978177 rs10772137 chr12 9927654 C T 6.41E-04 Multiple complex diseases / / 17554300 rs6488204 chr12 9943910 C T 4.69E-04 Alzheimer's disease / / 17998437 rs7955679 chr12 9959149 A G 0.000213 fMRI brain tests in schizophrenia / / 22440650 rs7299885 chr12 9971982 T C 5.24E-05 Lung function (forced vital capacity) / / pha003104 rs11610670 chr12 9973552 G A 0.000646 Salmonella-induced pyroptosis / / 22837397 rs2110447 chr12 9974110 T C 8.47E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs33871 chr12 10007897 C T 6.80E-04 Type 2 diabetes and 6 quantitative traits CLEC2B intron 17848626 rs3829318 chr12 10008230 T A 7.51E-09 Multiple complex diseases CLEC2B intron 17554300 rs10219684 chr12 10026944 C T 8.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs7313246 chr12 10029514 T A 7.21E-04 Suicide attempts in bipolar disorder / / 21041247 rs935537 chr12 10032270 G C 4.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs577575 chr12 10045919 G A 8.90E-05 Height KLRF2 intron pha003010 rs576601 chr12 10046052 C A 4.77E-04 Suicide attempts in bipolar disorder KLRF2 missense 21041247 rs7312799 chr12 10054895 C G 2.60E-05 Urinary metabolites / / 21572414 rs17204888 chr12 10075181 G A 9.23E-04 Suicide attempts in bipolar disorder CLEC2A intron 21423239 rs11053515 chr12 10083738 C T 4.95E-04 Amyotrophic Lateral Sclerosis CLEC2A intron 17362836 rs11610998 chr12 10086811 C T 8.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs11612095 chr12 10088346 C A,G 7.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs7967565 chr12 10089593 G C 5.47E-04 Suicide attempts in bipolar disorder LOC100506159 intron 21423239 rs7968634 chr12 10089806 C A 5.85E-04 Suicide attempts in bipolar disorder LOC100506159 intron 21423239 rs7971846 chr12 10090095 C T 3.41E-04 Suicide attempts in bipolar disorder LOC100506159 intron 21423239 rs7972089 chr12 10090281 C T 6.16E-04 Suicide attempts in bipolar disorder LOC100506159 intron 21423239 rs11612832 chr12 10091256 A T 6.79E-04 Suicide attempts in bipolar disorder LOC100506159 intron 21423239 rs619039 chr12 10091815 C T 1.02E-04 Multiple complex diseases LOC100506159 intron 17554300 rs7957464 chr12 10104289 C T 4.93E-04 Multiple complex diseases CLEC12A intron 17554300 rs1447877 chr12 10109162 A C 7.92E-04 Multiple complex diseases CLEC12A intron 17554300 rs479624 chr12 10121347 A G 3.47E-04 Multiple complex diseases CLEC12A intron 17554300 rs478829 chr12 10121411 T C 3.55E-04 Multiple complex diseases CLEC12A intron 17554300 rs607567 chr12 10131684 T G 2.97E-04 Multiple complex diseases CLEC12A intron 17554300 rs608418 chr12 10131865 T C 0.000014 Primary sclerosing cholangitis CLEC12A intron 22521342 rs7313235 chr12 10132283 C T 7.46E-04 Multiple complex diseases CLEC12A intron 17554300 rs479499 chr12 10137557 A C 5.05E-04 Multiple complex diseases CLEC12A missense 17554300 rs679982 chr12 10142897 G A 1.10E-04 Multiple complex diseases / / 17554300 rs1447888 chr12 10155706 T A 5.96E-05 Multiple complex diseases / / 17554300 rs7305054 chr12 10156646 A G 9.79E-04 White matter integrity / / 22425255 rs1054611 chr12 10170161 G T 6.00E-06 Sensory disturbances after bilateral sagittal split ramus osteotomy CLEC12B UTR-3 23834954 rs11053548 chr12 10170727 A G 5.00E-06 Systolic blood pressure in sickle cell anemia CLEC12B intron 24058526 rs11053550 chr12 10172353 T C 4.80E-16 Metabolite levels / / 22286219 rs11053555 chr12 10175993 G A 3.71E-04 Rheumatoid arthritis / / 21452313 rs10505745 chr12 10176144 C T 3.19E-04 Rheumatoid arthritis / / 21452313 rs10505748 chr12 10199357 G A 2.33E-04 Multiple complex diseases CLEC9A intron 17554300 rs10505751 chr12 10209711 A G 5.50E-04 Type 2 diabetes and 6 quantitative traits CLEC9A intron 17848626 rs7297177 chr12 10211041 C A 8.85E-04 Multiple complex diseases CLEC9A intron 17554300 rs952545 chr12 10247053 G A 8.60E-04 Type 2 diabetes and 6 quantitative traits CLEC1A intron 17848626 rs11053603 chr12 10274029 G A 2.10E-05 Urinary metabolites CLEC7A intron 21572414 rs11053608 chr12 10275684 T G 6.71E-04 Multiple complex diseases CLEC7A intron 17554300 rs59819090 chr12 10277906 G A 0.000042 Breast cancer(er negative) CLEC7A missense 23555315 rs11053623 chr12 10282736 T C 3.83E-04 Tourette syndrome CLEC7A UTR-5 22889924 rs2742115 chr12 10322182 T C 0.00041 Coronary artery calcification OLR1 intron 23727086 rs4764299 chr12 10329751 C T 9.29E-04 Coronary heart disease / / 21971053 rs10505752 chr12 10333347 G A 1.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C12orf59 intron 20877124 rs6488270 chr12 10350587 G A 1.31E-04 Parkinson's disease / / 16252231 rs6488270 chr12 10350587 G A 4.76E-04 Alzheimer's disease (late onset) / / 21379329 rs10845067 chr12 10356973 C G 3.42E-04 Cognitive decline / / 23732972 rs4764321 chr12 10359086 G A 3.05E-04 Lung function (forced vital capacity) / / 24023788 rs4764321 chr12 10359086 G A 7.20E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs4764326 chr12 10364337 G C 7.81E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4326886 chr12 10367886 C T 2.32E-05 Bipolar disorder and schizophrenia GABARAPL1 intron 20889312 rs2900384 chr12 10373881 G A 9.46E-05 Cognitive test performance GABARAPL1 intron 20125193 rs7248 chr12 10375302 C A 6.23E-05 Aortic root size GABARAPL1 UTR-3 21223598 rs4764331 chr12 10380682 A C 6.16E-05 Aortic root size / / 21223598 rs7957898 chr12 10414360 A G 3.31E-06 Retinopathy in non-diabetics / / 23393555 rs11053720 chr12 10418405 A G 6.07E-04 Multiple sclerosis / / 17660530 rs10845099 chr12 10420802 G C 8.36E-04 Aortic root size / / 21223598 rs2537782 chr12 10453915 T C 4.59E-05 Response to methylphenidate treatment / / 21130132 rs3912117 chr12 10454556 G A 3.59E-04 Body mass index / / 17255346 rs12303914 chr12 10471050 A G 6.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs4102739 chr12 10480508 A G 3.00E-04 Alcohol dependence / / 21314694 rs2537763 chr12 10482311 G A 3.47E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4764422 chr12 10507378 T C 7.44E-05 Multiple sclerosis / / 17660530 rs11053772 chr12 10514359 G A 1.31E-04 Multiple complex diseases / / 17554300 rs10743889 chr12 10521389 G T 6.00E-06 Obesity-related traits / / 23251661 rs2617150 chr12 10529034 T C 1.20E-05 Behcet's disease KLRK1 intron 23291587 rs2617170 chr12 10560957 T C 1.00E-09 Behcet's disease KLRC4 missense 23291587 rs2734562 chr12 10564329 T C 1.22E-05 Intelligence / / 21826061 rs12824474 chr12 10602925 T C 9.67E-05 Non-alcoholic fatty liver disease histology (other) KLRC1 intron 20708005 rs1967432 chr12 10604945 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) KLRC1 intron 20708005 rs2900421 chr12 10622047 G A 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6488297 chr12 10666025 A C 7.26E-04 Taste perception / / 22132133 rs11053831 chr12 10672377 A T 4.83E-16 Metabolite levels / / 22286219 rs12819066 chr12 10675930 T C 2.93E-05 Hypertension / / 19609347 rs2417903 chr12 10704691 A T 0.000000976 Ovarian follicle number and menopause / / 22696150 rs7305642 chr12 10705382 T C 0.000000976 Ovarian follicle number and menopause / / 22696150 rs7978850 chr12 10722585 C T 2.50E-05 Urinary metabolites / / 21572414 rs2125093 chr12 10731380 A G 9.26E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs4763527 chr12 10737277 T C 2.88E-05 Hypertension / / 19609347 rs2168749 chr12 10748314 C T 6.00E-04 End-stage renal disease / / 19929986 rs1078437 chr12 10775195 T C 1.51E-04 Alzheimer's disease STYK1 intron 17998437 rs10845187 chr12 10785012 C G 9.03E-05 Schizophrenia STYK1 intron 19571809 rs2252664 chr12 10786797 C T 1.97E-05 Eosinophil counts STYK1 intron pha003088 rs2277410 chr12 10789855 T G 9.61E-06 Eosinophil counts STYK1 intron pha003088 rs2418087 chr12 10806285 T C 7.55E-04 Alzheimer's disease STYK1 intron 17998437 rs1073305 chr12 10809949 G T 5.99E-04 Alzheimer's disease STYK1 intron 17998437 rs7968284 chr12 10817860 T C 3.77E-04 Prostate cancer mortality STYK1 intron 20978177 rs17809746 chr12 10817943 G A 1.31E-04 Lung function (forced expiratory volume in 1 second) STYK1 intron 17255346 rs7297205 chr12 10820840 C T 7.44E-04 Suicide attempts in bipolar disorder STYK1 intron 21041247 rs797165 chr12 10833873 A G 6.28E-04 Type 2 diabetes / / 17463246 rs2305849 chr12 10854537 C T 2.26E-05 Partial epilepsies CSDA intron 20522523 rs2418103 chr12 10856255 A G 1.42E-05 Partial epilepsies CSDA intron 20522523 rs11053915 chr12 10876805 G C 4.83E-16 Metabolite levels / / 22286219 rs2607901 chr12 10880356 G A 1.00E-04 Prostate cancer / / 21743057 rs813321 chr12 10883422 G A 1.00E-04 Prostate cancer / / 21743057 rs11053936 chr12 10914097 C T 2.76E-04 Type 2 diabetes LOC100506226 intron 17463246 rs11053937 chr12 10915359 G T 2.03E-04 Type 2 diabetes LOC100506226 intron 17463246 rs11053937 chr12 10915359 G T 5.83E-04 Multiple complex diseases LOC100506226 intron 17554300 rs12231432 chr12 10915547 T A 2.65E-04 Type 2 diabetes LOC100506226 intron 17463246 rs11053938 chr12 10915566 G A 1.17E-04 Type 2 diabetes LOC100506226 intron 17463246 rs11053939 chr12 10915597 G T 2.75E-04 Type 2 diabetes LOC100506226 intron 17463246 rs7294470 chr12 10925795 C T 1.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100506226 intron 20877124 rs11053972 chr12 10926233 T C 2.75E-04 Type 2 diabetes LOC100506226 intron 17463246 rs10845212 chr12 10926357 C T 6.94E-04 Alcohol dependence LOC100506226 intron 21314694 rs11053973 chr12 10926489 C A 2.75E-04 Type 2 diabetes LOC100506226 intron 17463246 rs6488326 chr12 10928179 G T 1.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100506226 intron 20877124 rs1444211 chr12 10928951 A G 3.26E-04 Response to taxane treatment (placlitaxel) LOC100506226 intron 23006423 rs11053986 chr12 10930264 G A 5.24E-04 Type 2 diabetes / / 17463246 rs11054000 chr12 10931970 G A,C 1.31E-04 Type 2 diabetes / / 17463246 rs7964393 chr12 10942033 G C 2.91E-04 Type 2 diabetes / / 17463246 rs2588350 chr12 10953057 T C 9.84E-04 Alzheimer's disease / / 24755620 rs1838346 chr12 10961017 G A 1.15E-04 Body mass index TAS2R8 nearGene-5 21701565 rs1838346 chr12 10961017 G A 3.45E-04 Body mass index TAS2R8 nearGene-5 21701565 rs7978242 chr12 10970645 G A 3.77E-05 Body mass index / / 21701565 rs7978242 chr12 10970645 G A 4.69E-04 Body mass index / / 21701565 rs10845219 chr12 10977654 T C 2.28E-04 Body mass index TAS2R10 nearGene-3 21701565 rs10845219 chr12 10977654 T C 7.26E-04 Body mass index TAS2R10 nearGene-3 21701565 rs12826445 chr12 10996316 G A 9.00E-05 Pericardial fat / / 22589742 rs11054083 chr12 11108281 A C 2.00E-04 Cognitive impairment induced by topiramate PRH1-PRR4 intron 22091778 rs7301545 chr12 11151030 T C 3.00E-05 Parkinson's disease (age of onset) PRH1-PRR4 intron 19772629 rs4298989 chr12 11160740 C T 6.62E-05 Vitiligo PRH1-PRR4 intron 22951725 rs7310849 chr12 11166968 A G 1.59E-04 Multiple complex diseases PRH1-PRR4 intron 17554300 rs10743937 chr12 11173455 C T 9.81E-05 Bitter taste perception PRH1-PRR4 intron 23966204 rs10772420 chr12 11174276 G A 4.89E-05 Bitter taste perception TAS2R19 missense 23966204 rs1868769 chr12 11174753 G A 4.58E-05 Formal thought disorder in schizophrenia TAS2R19 cds-synon 22648509 rs4763235 chr12 11175414 C G 3.26E-08 Lymphocyte counts PRH1-PRR4 intron 22286170 rs7297949 chr12 11188140 A G 4.32E-05 Bitter taste perception PRH1-PRR4 intron 23966204 rs2708377 chr12 11216315 C T 3.00E-08 Bitter taste perception PRH1-PRR4 intron 23966204 rs10845301 chr12 11222368 G A 8.94E-05 Multiple complex diseases PRH1-PRR4 intron 17554300 rs2597972 chr12 11253373 A G 1.78E-05 Bitter taste perception PRH1-PRR4 intron 23966204 rs2597963 chr12 11258011 C T 3.80E-05 Bitter taste perception PRH1-PRR4 intron 23966204 rs1031391 chr12 11279092 C G 2.00E-19 Bitter taste perception PRH1-PRR4 intron 23966204 rs7132674 chr12 11344304 A G 1.40E-05 Vitiligo / / 22951725 rs11835196 chr12 11411923 C T 8.99E-04 Alcohol dependence / / 20201924 rs10017381 chr12 11487923 G A 2.05E-04 Multiple complex diseases / / 17554300 rs2059764 chr12 11503205 A G 9.39E-04 Parkinson's disease / / 16252231 rs2900149 chr12 11519428 G A 2.91E-04 Multiple complex diseases / / 17554300 rs2900174 chr12 11547532 A G 1.00E-06 Response to gemcitabine in pancreatic cancer PRB2 intron 22142827 rs71455379 chr12 11558877 C G 9.00E-06 Periodontitis (CDC/AAP) / / 24024966 rs1921333 chr12 11593336 C T 2.00E-04 Information processing speed / / 21130836 rs2908835 chr12 11648418 C T 7.00E-06 Information processing speed / / 21130836 rs2908835 chr12 11648418 C T 4.38E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11054328 chr12 11663755 C T 5.90E-05 Endometriosis / / 21151130 rs2908828 chr12 11665814 G C 4.30E-04 Multiple complex diseases / / 17554300 rs7979294 chr12 11731773 G A 2.90E-04 Multiple complex diseases / / 17554300 rs11054362 chr12 11750137 C T 8.43E-05 Stroke (ischemic) / / 22941190 rs11054385 chr12 11776232 A G 2.47E-04 Alzheimer's disease / / 17998437 rs10491984 chr12 11787989 C A 1.00E-05 Cognitive function / / 24684796 rs10772497 chr12 11801125 C T 5.43E-05 Parkinson's disease ETV6 nearGene-5 17052657 rs2724631 chr12 11810846 C T 1.36E-04 Multiple complex diseases ETV6 intron 17554300 rs2111049 chr12 11827629 G A 1.83E-04 Multiple complex diseases ETV6 intron 17554300 rs2541119 chr12 11829309 A G 9.82E-04 Depression (quantitative trait) ETV6 intron 20800221 rs2724625 chr12 11830518 G C 9.82E-04 Depression (quantitative trait) ETV6 intron 20800221 rs205534 chr12 11841117 A G 3.39E-04 Parkinson's disease ETV6 intron 17052657 rs205534 chr12 11841117 A G 5.90E-04 Alcohol dependence ETV6 intron 20201924 rs205536 chr12 11842904 A G 9.38E-05 Cognitive test performance ETV6 intron 20125193 rs7959282 chr12 11846948 T C 5.19E-04 Multiple complex diseases ETV6 intron 17554300 rs2187642 chr12 11855624 A C 2.00E-06 Height ETV6 intron 18391951 rs2856321 chr12 11855773 G A 5.00E-15 Height ETV6 intron 20881960 rs2856321 chr12 11855773 G A 3.00E-11 Height ETV6 intron 23563607 rs11054425 chr12 11864281 G A 3.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ETV6 intron 20877124 rs972798 chr12 11874695 A G 6.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ETV6 intron 20877124 rs972798 chr12 11874695 A G 2.06E-04 Age-related macular degeneration ETV6 intron 22125219 rs2900208 chr12 11878464 C A 1.20E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses ETV6 intron 17903301 rs2051525 chr12 11888423 A G 6.01E-05 Angioedema in response to angiotensin-converting enzyme inhibitor ETV6 intron 23838604 rs2724635 chr12 11899973 G A 3.50E-04 Age-related macular degeneration ETV6 intron 22125219 rs2724635 chr12 11899973 G A 2.73E-05 Angioedema in response to angiotensin-converting enzyme inhibitor ETV6 intron 23838604 rs2051526 chr12 11907128 C T 3.42E-05 Oral cancers (chewing tobacco related) ETV6 intron 22503698 rs10772505 chr12 11907756 C T 5.80E-06 Urinary metabolites ETV6 intron 21572414 rs2710288 chr12 11911214 G A 1.06E-04 Multiple complex diseases ETV6 intron 17554300 rs7961094 chr12 11912367 T C 5.45E-05 Hypertension ETV6 intron 21082022 rs7963499 chr12 11917397 C T 3.86E-05 Oral cancers (chewing tobacco related) ETV6 intron 22503698 rs3802993 chr12 11927531 A G 8.20E-05 Hypertension ETV6 intron 19609347 rs10491990 chr12 11939528 G A 3.38E-04 Oral cancers (chewing tobacco related) ETV6 intron 22503698 rs2856329 chr12 11942720 C T 4.55E-04 Lung function (forced vital capacity) ETV6 intron 24023788 rs2856329 chr12 11942720 C T 6.00E-06 Lung function (forced expiratory volume in 1 second) ETV6 intron 24023788 rs2856329 chr12 11942720 C T 8.14E-05 Socioeconomic Factors ETV6 intron pha003066 rs762721 chr12 11952424 A C 4.42E-05 Schizophrenia ETV6 intron 19571811 rs2856336 chr12 11955998 A C 7.69E-06 Parkinson's disease ETV6 intron pha002868 rs7314811 chr12 11962573 T C 4.00E-06 IgG glycosylation ETV6 intron 23382691 rs12827379 chr12 11971623 C G 8.54E-05 Progressive supranuclear palsy ETV6 intron 21685912 rs2710287 chr12 11975532 T C 8.51E-04 Response to taxane treatment (placlitaxel) ETV6 intron 23006423 rs10505762 chr12 11990610 C T 1.72E-05 Parkinson's disease ETV6 intron pha002868 rs34976161 chr12 12008864 G GT 5.89E-05 Cognitive impairment induced by topiramate ETV6 intron 22091778 rs743613 chr12 12008864 G A 5.89E-05 Cognitive impairment induced by topiramate ETV6 intron 22091778 rs10772508 chr12 12009529 A G 6.69E-04 Type 2 diabetes ETV6 intron 17463246 rs10772508 chr12 12009529 A G 6.30E-05 Cognitive impairment induced by topiramate ETV6 intron 22091778 rs928936 chr12 12016183 G T 9.85E-06 Multiple sclerosis (brain glutamate levels) ETV6 intron 20802204 rs11054481 chr12 12035282 C G 6.80E-04 Response to taxane treatment (placlitaxel) ETV6 intron 23006423 rs2071163 chr12 12037081 G A 3.07E-04 Response to taxane treatment (placlitaxel) ETV6 intron 23006423 rs2239175 chr12 12042459 T G 5.97E-04 Myopia (pathological) ETV6 intron 21095009 rs2239175 chr12 12042459 T G 2.32E-05 Hypertension ETV6 intron pha003041 rs2239177 chr12 12042866 T C 3.87E-05 AIDS progression ETV6 intron 19115949 rs2954930 chr12 12052702 G A 2.66E-05 F-cell distribution / / 21326311 rs2710301 chr12 12056702 T G 2.37E-04 Multiple complex diseases / / 17554300 rs2710301 chr12 12056702 T G 4.23E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4262801 chr12 12058411 C A 0.000774147 Hypertension (early onset hypertension) / / 22479346 rs11054515 chr12 12077976 A G 9.15E-05 Stroke / / pha002887 rs2961557 chr12 12109505 A C 8.70E-04 Alcohol dependence / / 20201924 rs11054568 chr12 12127785 A G 0.000756161 Hypertension (early onset hypertension) / / 22479346 rs10743972 chr12 12133803 G A 4.00E-06 Urinary metabolites / / 21572414 rs10743973 chr12 12134784 T C 2.79E-04 Multiple complex diseases / / 17554300 rs7976590 chr12 12134980 T G 9.76E-04 Type 2 diabetes / / 17463246 rs7976590 chr12 12134980 T G 7.22E-04 Multiple complex diseases / / 17554300 rs7972254 chr12 12140933 T C 3.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10845443 chr12 12145080 G A 7.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12582693 chr12 12145941 G T 4.60E-05 Alcohol and nictotine co-dependence / / 20158304 rs7315674 chr12 12146359 A G 4.80E-06 Urinary metabolites / / 21572414 rs12367002 chr12 12148040 G T 4.20E-06 Urinary metabolites / / 21572414 rs7305426 chr12 12156322 A C 9.84E-04 Multiple complex diseases / / 17554300 rs7971136 chr12 12160475 G A 8.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs6488484 chr12 12160730 A T 5.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs728189 chr12 12161541 C A 7.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs728188 chr12 12161755 C A 8.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs1797657 chr12 12188622 C G 5.27E-05 Personality dimensions / / 18957941 rs2016891 chr12 12221430 A G 5.21E-05 Post-operative nausea and vomiting / / 21694509 rs10845474 chr12 12238317 T C 5.29E-05 Cognitive test performance BCL2L14 intron 20125193 rs10492119 chr12 12239494 C A,G,T 5.63E-04 Telomere length BCL2L14 intron 23900074 rs2448047 chr12 12249699 T G 4.41E-04 Smoking quantity BCL2L14 intron 24665060 rs12313200 chr12 12284590 G A 9.70E-04 Multiple complex diseases LRP6 intron 17554300 rs11054710 chr12 12302884 A G 6.07E-04 Type 2 diabetes LRP6 intron 17463246 rs11054713 chr12 12310960 A T 4.54E-04 Type 2 diabetes LRP6 intron 17463246 rs11054713 chr12 12310960 A T 6.23E-04 Multiple complex diseases LRP6 intron 17554300 rs2300231 chr12 12315880 T G 0.00027 Coronary artery calcification LRP6 intron 23727086 rs12316043 chr12 12318490 T C 3.78E-04 Type 2 diabetes LRP6 intron 17463246 rs12316043 chr12 12318490 T C 9.09E-04 Multiple complex diseases LRP6 intron 17554300 rs7973718 chr12 12342821 G A 1.30E-04 Type 2 diabetes LRP6 intron 17463246 rs12307111 chr12 12358524 C A 4.25E-04 Alcohol dependence LRP6 intron 21314694 rs11054731 chr12 12376465 A G 6.00E-06 Coronary artery calcification LRP6 intron 23870195 rs12425946 chr12 12410964 G A 2.90E-04 Multiple complex diseases LRP6 intron 17554300 rs10743980 chr12 12412795 T C 1.16E-04 IgE levels LRP6 intron 17255346 rs10431302 chr12 12429651 C T 4.62E-04 IgE levels / / 17255346 rs11054761 chr12 12430036 T C 6.69E-05 Calcium levels / / pha003085 rs4763795 chr12 12437482 T G 9.27E-05 IgE levels / / 17255346 rs1317893 chr12 12472918 T C 9.58E-05 Cognitive test performance / / 20125193 rs17375215 chr12 12483764 C T 9.25E-04 Body mass index MANSC1 missense 17255346 rs11054854 chr12 12521332 T G 8.37E-05 Celiac disease LOH12CR1 intron 23936387 rs11054901 chr12 12577950 C T 5.94E-04 Suicide attempts in bipolar disorder LOH12CR1 intron 21423239 rs1861674 chr12 12589705 G A 7.38E-05 Elbow pain LOH12CR1 intron pha003008 rs11836180 chr12 12599582 C A 5.56E-04 Aortic root size LOH12CR1 intron 21223598 rs10845551 chr12 12614495 A G 2.50E-05 Urinary metabolites LOH12CR1 intron 21572414 rs7132512 chr12 12617337 C A 7.27E-05 Magnesium levels LOH12CR1 intron pha003092 rs3751261 chr12 12618427 C T 9.59E-05 Magnesium levels LOH12CR1 intron pha003092 rs3751262 chr12 12618690 G A 2.78E-04 Multiple complex diseases LOH12CR1 missense 17554300 rs17312055 chr12 12621567 T G 8.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs736107 chr12 12627410 G A 3.37E-06 Alzheimer's disease DUSP16 UTR-3 21098978 rs16908146 chr12 12634131 A G 2.58E-04 Multiple complex diseases DUSP16 intron 17554300 rs11054927 chr12 12641369 C T 4.72E-04 Type 2 diabetes DUSP16 intron 17463246 rs11054931 chr12 12643587 C T 9.09E-04 Type 2 diabetes DUSP16 intron 17463246 rs12819116 chr12 12646521 G A 8.66E-04 Multiple complex diseases DUSP16 intron 17554300 rs12819116 chr12 12646521 G A 7.90E-05 Type 1 diabetes DUSP16 intron 18978792 rs16908167 chr12 12647216 T C 4.87E-04 Multiple complex diseases DUSP16 intron 17554300 rs17312912 chr12 12647608 A G 2.00E-04 Cognitive impairment induced by topiramate DUSP16 intron 22091778 rs16908171 chr12 12650225 T C 9.51E-04 Multiple complex diseases DUSP16 intron 17554300 rs2417191 chr12 12651256 G C 8.37E-05 Type 1 diabetes DUSP16 intron 18978792 rs11054938 chr12 12655145 C T 8.90E-04 Type 2 diabetes DUSP16 intron 17463246 rs16908188 chr12 12656820 A G 9.48E-05 Multiple complex diseases DUSP16 intron 17554300 rs11612508 chr12 12657513 A G 1.00E-08 Inflammatory bowel disease DUSP16 intron 23128233 rs16908204 chr12 12675854 T G 4.60E-04 Multiple complex diseases DUSP16 intron 17554300 rs17313592 chr12 12679491 A G 5.80E-05 Telomere length DUSP16 intron 21573004 rs4763845 chr12 12728803 T C 7.13E-04 Type 2 diabetes / / 17463246 rs12302103 chr12 12729316 G A 4.00E-06 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs12582396 chr12 12736119 C T 9.03E-04 Multiple complex diseases / / 17554300 rs881612 chr12 12738443 A T 8.03E-04 Multiple complex diseases / / 17554300 rs759745 chr12 12739197 C A 8.33E-04 Type 2 diabetes / / 17463246 rs17819128 chr12 12761659 G C 3.02E-06 Personality dimensions / / 18957941 rs17819128 chr12 12761659 G C 3.00E-06 Personality dimensions / / 21173776 rs12822507 chr12 12773521 A G 2.00E-08 Systemic lupus erythematosus CREBL2 intron 23273568 rs35527447 chr12 12790427 C T 5.93E-04 Multiple complex diseases CREBL2 intron 17554300 rs41276680 chr12 12815037 C T 0.000019 Breast cancer(er negative) GPR19 missense 23555315 rs10845606 chr12 12834894 C A 5.48E-04 Type 2 diabetes GPR19 intron 17463246 rs10845606 chr12 12834894 C A 4.00E-17 Systemic lupus erythematosus GPR19 intron 23273568 rs16908341 chr12 12844233 G A 2.50E-04 Multiple complex diseases GPR19 intron 17554300 rs10734854 chr12 12860157 A G 2.28E-04 Multiple complex diseases / / 17554300 rs7311556 chr12 12862280 G A 5.37E-08 HDL cholesterol / / 23063622 rs10845615 chr12 12863470 G A 1.10E-04 Type 2 diabetes / / 17463246 rs12229100 chr12 12865836 C T 6.09E-04 Type 2 diabetes / / 17463246 rs34330 chr12 12870695 T C 5.00E-12 Systemic lupus erythematosus CDKN1B UTR-5 23273568 rs7330 chr12 12874917 C A 0.0000084 Type 2 diabetes CDKN1B UTR-3 22325160 rs10845623 chr12 12898699 T C 5.90E-05 Tooth agenesis (maxillary third molar) APOLD1 intron 24172245 rs10505768 chr12 12899030 C G,T 4.30E-04 Type 2 diabetes and 6 quantitative traits APOLD1 intron 17848626 rs4763870 chr12 12902011 T G 3.58E-05 Serum metabolites APOLD1 intron 19043545 rs12318822 chr12 12902272 T G 0.000036 Asthma APOLD1 intron 22694930 rs11055041 chr12 12903582 T A 3.37E-05 Serum metabolites APOLD1 intron 19043545 rs11055041 chr12 12903582 T A 4.41E-04 Alcohol dependence APOLD1 intron 21314694 rs1473168 chr12 12912804 G T 4.93E-05 Glucose levels APOLD1 intron pha003058 rs2417232 chr12 12924960 C T 2.90E-04 Type 2 diabetes and 6 quantitative traits APOLD1 intron 17848626 rs7956578 chr12 12932281 T C 2.79E-05 Post-operative nausea and vomiting APOLD1 intron 21694509 rs2110597 chr12 12941013 G A 2.88E-06 Post-operative nausea and vomiting APOLD1 UTR-3 21694509 rs2110597 chr12 12941013 G A 2.35E-06 Alopecia areata APOLD1 UTR-3 22027810 rs7301360 chr12 12942533 C A 3.11E-05 Post-operative nausea and vomiting APOLD1 UTR-3 21694509 rs117734680 chr12 12952560 A G 0.00006531 Sarcoidosis / / 22952805 rs11834394 chr12 12963945 T A 2.08E-04 Mammographic density / / 22532574 rs1010878 chr12 12977400 G A 3.52E-06 Mammographic density DDX47 intron 22532574 rs16908465 chr12 13026606 A G 1.34E-04 Multiple complex diseases / / 17554300 rs11055126 chr12 13031889 T C 1.50E-04 Mammographic density / / 22532574 rs1056927 chr12 13070752 A G 7.24E-05 Neuroblastoma / / pha002895 rs7134402 chr12 13097327 T C 6.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GPRC5D intron 20877124 rs149059133 chr12 13102576 G A 0.00071 Breast cancer GPRC5D missense 23555315 rs1291371 chr12 13106510 C T 5.09E-04 Multiple complex diseases / / 17554300 rs1291370 chr12 13108561 C T 2.29E-04 Multiple complex diseases / / 17554300 rs17819589 chr12 13116380 T C 3.79E-07 Lymphocyte counts / / 22286170 rs1642197 chr12 13119048 C T 4.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1486329 chr12 13120851 C T 8.10E-07 Sickle cell anemia (severity) / / 20029952 rs12812470 chr12 13150905 G A 8.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HEBP1 intron 20877124 rs10744011 chr12 13168834 G T 1.10E-06 Urinary metabolites / / 21572414 rs11055197 chr12 13169694 G A 9.74E-04 Multiple complex diseases / / 17554300 rs11055198 chr12 13169780 T C 3.47E-04 Multiple complex diseases / / 17554300 rs12827915 chr12 13179236 G A 3.48E-04 Multiple complex diseases / / 17554300 rs10845697 chr12 13184886 G A 1.40E-05 Urinary metabolites / / 21572414 rs11055209 chr12 13187985 T C 3.36E-05 Post-operative nausea and vomiting / / 21694509 rs7294646 chr12 13202019 C G 1.71E-04 Multiple complex diseases KIAA1467 intron 17554300 rs17820032 chr12 13248157 C T 8.02E-05 Bladder cancer GSG1 intron 19648920 rs10772620 chr12 13256353 A G 3.67E-04 Alzheimer's disease (late onset) GSG1 intron 21379329 rs10772620 chr12 13256353 A G 2.00E-04 Cognitive impairment induced by topiramate GSG1 intron 22091778 rs11055258 chr12 13322867 C T 2.10E-04 Smoking initiation / / 24665060 rs7967865 chr12 13324295 T C 4.92E-05 Cholesterol / / pha003078 rs10772627 chr12 13335140 T C 6.26E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4763326 chr12 13336367 G A 1.40E-05 Urinary metabolites / / 21572414 rs4485187 chr12 13338113 A G 3.09E-04 IgA nephropathy / / 22197929 rs7971350 chr12 13345231 G T 1.14E-05 Cognitive test performance / / 20125193 rs2291060 chr12 13365054 A G 7.86E-04 Suicide attempts in bipolar disorder EMP1 intron 21041247 rs2069086 chr12 13368322 T A,C,G 6.13E-04 Suicide attempts in bipolar disorder EMP1 UTR-3 21041247 rs3191064 chr12 13369574 A G 6.04E-04 Suicide attempts in bipolar disorder EMP1 UTR-3 21041247 rs10505772 chr12 13371511 G T 4.14E-05 Cognitive test performance / / 20125193 rs16908783 chr12 13375486 G A 1.85E-04 Multiple complex diseases / / 17554300 rs11055289 chr12 13375896 C G 6.27E-04 Obesity (extreme) / / 21935397 rs7962943 chr12 13376727 A G 6.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs7966096 chr12 13376911 T C 6.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs17395410 chr12 13376964 G A 6.28E-04 Obesity (extreme) / / 21935397 rs10845718 chr12 13378975 A G 6.33E-04 Obesity (extreme) / / 21935397 rs11614016 chr12 13379640 T A 8.69E-04 Obesity (extreme) / / 21935397 rs10772635 chr12 13380486 C A 6.60E-04 Obesity (extreme) / / 21935397 rs12316815 chr12 13385707 T C 1.12E-05 Serum metabolites / / 19043545 rs1351227 chr12 13386985 T A 4.63E-04 Response to TNF antagonist treatment / / 21061259 rs11055303 chr12 13395155 G C 0.0003881 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11055303 chr12 13395155 G C 3.88E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1600285 chr12 13398792 A G 1.50E-06 Urinary metabolites / / 21572414 rs2417263 chr12 13403367 G A 0.0003987 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2417263 chr12 13403367 G A 3.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2061868 chr12 13421837 A G 9.53E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2061868 chr12 13421837 A G 8.82E-04 Response to TNF antagonist treatment / / 21061259 rs4578488 chr12 13424929 C T 5.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs899437 chr12 13428022 T C 1.95E-04 Response to TNF antagonist treatment / / 21061259 rs9634127 chr12 13441476 G A 1.00E-05 Urinary metabolites / / 21572414 rs899435 chr12 13452780 C A 9.00E-06 Coronary artery calcification / / 23870195 rs10845746 chr12 13467727 T C 1.69E-04 Multiple complex diseases / / 17554300 rs9651864 chr12 13485340 G A 3.36E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7314446 chr12 13491237 A G 2.69E-04 Myocardial Infarction / / pha002883 rs11055387 chr12 13519996 G C 8.00E-06 Major depressive disorder / / 23377640 rs7315922 chr12 13520028 G A 4.48E-04 Multiple complex diseases / / 17554300 rs2060301 chr12 13522627 G C,T 2.00E-04 Multiple complex diseases / / 17554300 rs2060301 chr12 13522627 G C,T 9.49E-04 Myopia (pathological) / / 21095009 rs7301842 chr12 13525907 A G 7.34E-04 Insulin resistance / / 21901158 rs12579519 chr12 13529105 A C 1.63E-04 Suicide attempts in bipolar disorder C12orf36 intron 21423239 rs11055391 chr12 13530450 C T 2.30E-05 Urinary metabolites / / 21572414 rs4763340 chr12 13530493 T C 1.51E-05 Smoking cessation / / 18519826 rs12579926 chr12 13530606 A G 2.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs1993508 chr12 13532331 G C 1 Drug response to Etoposide / / 17537913 rs1993508 chr12 13532331 G C 3.39E-05 Smoking cessation / / 18519826 rs970063 chr12 13533249 G A 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs892267 chr12 13540222 T C 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs892267 chr12 13540222 T C 7.45E-04 Myocardial Infarction / / pha002883 rs877972 chr12 13540262 C T 5.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs877971 chr12 13540282 A G 4.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs1457623 chr12 13541424 C G 5.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs12580476 chr12 13544063 G A 0.000108 Gains in maximal O2 uptake response / / 21183627 rs12580476 chr12 13544063 G A 8.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs741661 chr12 13584297 A G 9.67E-04 Type 2 diabetes / / 17463246 rs1457627 chr12 13584308 G T 9.67E-04 Multiple complex diseases / / 17554300 rs11055430 chr12 13591156 A T 8.76E-04 Type 2 diabetes / / 17463246 rs1457608 chr12 13616362 A G 1.40E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs10772682 chr12 13625450 G A 7.21E-04 Heart Failure / / pha002884 rs1477105 chr12 13627565 A G 5.94E-08 Metabolite levels / / 23281178 rs1531228 chr12 13629381 C T 9.00E-06 Barrett's esophagus / / 22961001 rs1531228 chr12 13629381 C T 9.00E-06 Body mass index / / 22982992 rs17820480 chr12 13638977 T C 7.92E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1457614 chr12 13641706 C A 7.65E-04 Tourette syndrome / / 22889924 rs1457614 chr12 13641706 C A 8.00E-06 Major depressive disorder / / 23377640 rs17219978 chr12 13650663 A G 7.26E-05 Blood Pressure / / pha003043 rs17822096 chr12 13651081 A G 5.66E-04 Multiple complex diseases / / 17554300 rs12423978 chr12 13709852 C T 7.09E-05 Alcohol consumption / / 23953852 rs1805495 chr12 13710010 T G 2.20E-05 Height / / 21998595 rs764525 chr12 13711987 T C 1.70E-05 Height / / 21998595 rs16909222 chr12 13722705 A G 7.46E-05 Glucose levels GRIN2B intron pha003061 rs7970177 chr12 13738988 T C 9.80E-04 Bipolar disorder GRIN2B intron 19259986 rs1805490 chr12 13741071 G A 2.80E-05 Urinary metabolites GRIN2B intron 21572414 rs1805474 chr12 13742150 T G 6.08E-04 Bipolar disorder GRIN2B intron 19259986 rs2160519 chr12 13787846 T C 2.00E-06 Cognitive performance GRIN2B intron 19734545 rs2284405 chr12 13804560 C T 3.04E-04 Bipolar disorder GRIN2B intron 19259986 rs17760889 chr12 13820414 A G 3.70E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GRIN2B intron 22566498 rs7313149 chr12 13828287 T C 6.73E-05 Nicotine smoking GRIN2B intron 19268276 rs11831620 chr12 13834996 T C 7.38E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GRIN2B intron 22566498 rs4764026 chr12 13835420 A C 7.29E-04 Alzheimer's disease GRIN2B intron 24755620 rs2300245 chr12 13841295 G T 1.00E-05 Urinary metabolites GRIN2B intron 21572414 rs10772701 chr12 13849836 C T 9.90E-06 Urinary metabolites GRIN2B intron 21572414 rs10845826 chr12 13858822 A C 5.15E-04 Type 2 diabetes GRIN2B intron 17463246 rs17220663 chr12 13859584 G A 9.30E-05 Asthma GRIN2B intron pha003127 rs2268118 chr12 13872044 G T 1.00E-08 Immune reponse to smallpox (secreted IL-2) GRIN2B intron 22610502 rs4763358 chr12 13873691 G C 1.39E-04 Nicotine smoking GRIN2B intron 19268276 rs7307315 chr12 13912682 G A 2.69E-05 Body mass index GRIN2B intron 17255346 rs11055608 chr12 13913426 T G 1.34E-04 Body mass index GRIN2B intron 17255346 rs12369725 chr12 13914407 A G 1.40E-05 Tooth agenesis (third molar) GRIN2B intron 24172245 rs12369725 chr12 13914407 A G 2.40E-05 Tooth agenesis (maxillary third molar) GRIN2B intron 24172245 rs2284415 chr12 13918091 A G 3.83E-04 Body mass index GRIN2B intron 17255346 rs1075010 chr12 13918341 T C 2.10E-05 Tooth agenesis (third molar) GRIN2B intron 24172245 rs1075010 chr12 13918341 T C 2.60E-05 Tooth agenesis (maxillary third molar) GRIN2B intron 24172245 rs11055612 chr12 13923328 C T 2.81E-06 Temporal lobe volumes GRIN2B intron 20197096 rs11055612 chr12 13923328 C T 7.85E-04 Alzheimer's disease GRIN2B intron 22005930 rs6488619 chr12 13927896 C T 9.00E-07 Ovarian reserve GRIN2B intron 22116950 rs10845840 chr12 13930857 T C 1.26E-07 Temporal lobe volumes GRIN2B intron 20197096 rs10845840 chr12 13930857 T C 6.27E-04 Alzheimer's disease GRIN2B intron 22005930 rs220549 chr12 13937320 T C 1.05E-05 Neuroticism GRIN2B intron 23229837 rs11055619 chr12 13942092 A C 0.000638 Salmonella-induced pyroptosis GRIN2B intron 22837397 rs2300267 chr12 13951931 T C 4.00E-05 Prostate cancer GRIN2B intron 21743057 rs10744039 chr12 13952707 T C 4.00E-05 Prostate cancer GRIN2B intron 21743057 rs2058878 chr12 13953118 T A 6.00E-05 Prostate cancer GRIN2B intron 21743057 rs17833961 chr12 13954130 A T 8.20E-06 Urinary metabolites GRIN2B intron 21572414 rs220567 chr12 13954403 C G 1.98E-04 Multiple complex diseases GRIN2B intron 17554300 rs2300272 chr12 13956579 G A 7.57E-04 Alzheimer's disease GRIN2B intron 22005930 rs220587 chr12 13962270 G C 5.70E-04 Alzheimer's disease GRIN2B intron 22005930 rs220590 chr12 13964967 G A 6.59E-04 Smoking initiation GRIN2B intron 24665060 rs220597 chr12 13968186 A G 3.01E-04 Body mass index GRIN2B intron 17255346 rs11612353 chr12 13984598 A G 5.07E-04 Response to taxane treatment (placlitaxel) GRIN2B intron 23006423 rs2284425 chr12 13989019 G T 0.0000821 fMRI brain tests in schizophrenia GRIN2B intron 22440650 rs2193509 chr12 13996273 T C 8.49E-04 Alzheimer's disease GRIN2B intron 22005930 rs4764036 chr12 13996606 A G 7.95E-04 Alzheimer's disease GRIN2B intron 22005930 rs12305339 chr12 13998342 G A 3.71E-04 Heart Failure GRIN2B intron pha002884 rs11832404 chr12 14006305 T C 3.94E-06 Venous thromboembolism GRIN2B intron 22672568 rs11833339 chr12 14008727 A G 3.95E-06 Venous thromboembolism GRIN2B intron 22672568 rs11835020 chr12 14016610 A C 6.65E-06 Venous thromboembolism GRIN2B intron 22672568 rs10772714 chr12 14025015 C T 4.44E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GRIN2B intron 20031582 rs11830268 chr12 14025316 G A 6.35E-06 Venous thromboembolism GRIN2B intron 22672568 rs7311764 chr12 14031100 C T 0.00082 Salmonella-induced pyroptosis GRIN2B intron 22837397 rs10492142 chr12 14045266 T C 1.00E-05 Urinary metabolites GRIN2B intron 21572414 rs10845858 chr12 14045718 G A 6.20E-06 Urinary metabolites GRIN2B intron 21572414 rs11055670 chr12 14051237 T A 6.80E-06 Urinary metabolites GRIN2B intron 21572414 rs11055681 chr12 14061569 G T 0.00055845 Hypertension (early onset hypertension) GRIN2B intron 22479346 rs9971835 chr12 14061867 A T 2.31E-04 Smoking cessation GRIN2B intron 18519826 rs4764039 chr12 14064461 C T 3.00E-06 Total ventricular volume GRIN2B intron 21116278 rs4764039 chr12 14064461 C T 7.16E-04 Suicide attempts in bipolar disorder GRIN2B intron 21423239 rs10772719 chr12 14068697 G A 3.00E-05 Smoking cessation GRIN2B intron 18519826 rs2160729 chr12 14071844 C T 6.56E-04 Multiple complex diseases GRIN2B intron 17554300 rs11055687 chr12 14072223 T C 4.81E-04 Suicide attempts in bipolar disorder GRIN2B intron 21423239 rs172677 chr12 14097470 A G 9.54E-05 Soluble levels of adhesion molecules GRIN2B intron pha003072 rs219920 chr12 14101311 T C 1.61E-04 Smoking cessation GRIN2B intron 18519826 rs4764043 chr12 14115482 C T 6.00E-06 Aging (time to event) GRIN2B intron 21782286 rs10505778 chr12 14125564 A G 2.00E-04 Chronic fatigue syndrome GRIN2B intron 21912186 rs1421106 chr12 14125734 G T 2.97E-04 Response to taxane treatment (placlitaxel) GRIN2B intron 23006423 rs3764030 chr12 14133332 C T 3.12E-04 Amyotrophic Lateral Sclerosis GRIN2B nearGene-5 17362836 rs7304327 chr12 14147348 G A 5.98E-06 Retinopathy in non-diabetics / / 23393555 rs7302724 chr12 14164721 C T 5.72E-04 Multiple complex diseases / / 17554300 rs10772724 chr12 14177113 C A 9.69E-05 Soluble levels of adhesion molecules / / pha003072 rs1592668 chr12 14229229 C T 5.51E-05 Coronary heart disease / / pha003031 rs4616128 chr12 14261515 G A 2.30E-05 Urinary metabolites / / 21572414 rs7975440 chr12 14262889 T C 9.60E-06 Urinary metabolites / / 21572414 rs17399790 chr12 14263954 C T 4.85E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs10845883 chr12 14266144 T G 3.50E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs10772729 chr12 14282375 A C 9.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs10845892 chr12 14299145 T C 6.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs4617674 chr12 14299572 G T 6.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs16909749 chr12 14321324 A C 7.32E-04 Multiple complex diseases / / 17554300 rs17834211 chr12 14402358 T G 3.60E-05 Kawasaki disease / / 22446962 rs12300043 chr12 14409528 G A 2.91E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12300043 chr12 14409528 G A 3.35E-05 Creatinine levels / / pha003069 rs17221259 chr12 14410485 T C 7.00E-06 Breast cancer / / 24143190 rs12422552 chr12 14413931 G C 4.00E-08 Breast cancer / / 23535729 rs16909808 chr12 14426092 G T 4.21E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10083074 chr12 14436248 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10845943 chr12 14437186 G C 9.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7302221 chr12 14465976 C G 9.88E-04 Type 2 diabetes / / 17463246 rs11055930 chr12 14477187 T C 1.54E-05 Cortisol secretion,in saliva / / 21316860 rs6488674 chr12 14488914 T G 2.70E-06 Prostate-specific antigen levels / / 23359319 rs6488679 chr12 14521376 G T 9.73E-07 Prostate-specific antigen levels ATF7IP intron 23359319 rs7308681 chr12 14523674 A G 3.25E-05 Height ATF7IP intron 22021425 rs7137532 chr12 14523972 G T 1.02E-06 Prostate-specific antigen levels ATF7IP intron 23359319 rs7312042 chr12 14533490 G A 9.38E-07 Prostate-specific antigen levels ATF7IP intron 23359319 rs11055956 chr12 14534426 G A 5.72E-07 Prostate-specific antigen levels ATF7IP intron 23359319 rs11055960 chr12 14536666 T G 1.93E-06 Prostate-specific antigen levels ATF7IP intron 23359319 rs10734875 chr12 14542541 A G 6.29E-07 Prostate-specific antigen levels ATF7IP intron 23359319 rs11055962 chr12 14547892 G A 2.00E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ATF7IP intron 24023788 rs7954210 chr12 14548314 A C 1.80E-07 Prostate-specific antigen levels ATF7IP intron 23359319 rs7966054 chr12 14551025 T C 1.12E-06 Prostate-specific antigen levels ATF7IP intron 23359319 rs7970587 chr12 14575459 A G 2.05E-07 Prostate-specific antigen levels ATF7IP intron 23359319 rs2417349 chr12 14581449 C T 1.06E-07 Prostate-specific antigen levels ATF7IP intron 23359319 rs3213764 chr12 14587301 A G 2.00E-09 Prostate-specific antigen levels ATF7IP missense 23359319 rs10772782 chr12 14592843 A G 3.96E-07 Prostate-specific antigen levels ATF7IP intron 23359319 rs7310929 chr12 14593902 T C 1.69E-07 Prostate-specific antigen levels ATF7IP intron 23359319 rs7964899 chr12 14595756 G A 1.47E-06 Prostate-specific antigen levels ATF7IP intron 23359319 rs7298685 chr12 14607721 C A 4.09E-06 Prostate-specific antigen levels ATF7IP intron 23359319 rs12366507 chr12 14608799 G A 6.31E-06 Prostate-specific antigen levels ATF7IP intron 23359319 rs962504 chr12 14610439 A G 1.03E-06 Prostate-specific antigen levels ATF7IP intron 23359319 rs11055980 chr12 14611522 C T 4.52E-07 Prostate-specific antigen levels ATF7IP intron 23359319 rs4764090 chr12 14612323 A G 4.38E-07 Prostate-specific antigen levels ATF7IP intron 23359319 rs4237951 chr12 14624574 A C 2.15E-07 Prostate-specific antigen levels ATF7IP intron 23359319 rs4346018 chr12 14628069 A G 3.20E-19 Testicular germ cell cancer ATF7IP intron 20543847 rs2900333 chr12 14653867 C T 6.00E-10 Testicular germ cell cancer / / 20543847 rs2900333 chr12 14653867 C T 6.51E-08 Prostate-specific antigen levels / / 23359319 rs2900333 chr12 14653867 C T 1.00E-13 Testicular germ cell tumor / / 23666240 rs3827886 chr12 14660184 T C 7.00E-06 Response to amphetamines PLBD1 intron 22952603 rs2287539 chr12 14694234 C T 6.66E-05 Alzheimer's disease PLBD1 intron 21098978 rs1862013 chr12 14694877 T C 6.68E-05 Alzheimer's disease PLBD1 intron 21098978 rs10846021 chr12 14705533 T C 1.42E-04 Alzheimer's disease PLBD1 intron 17998437 rs7296684 chr12 14707128 C T 6.40E-05 Alzheimer's disease PLBD1 intron 21098978 rs7296684 chr12 14707128 C T 3.43E-04 Response to taxane treatment (placlitaxel) PLBD1 intron 23006423 rs2032762 chr12 14707773 C G 6.30E-05 Alzheimer's disease PLBD1 intron 21098978 rs12425606 chr12 14715793 C T 1.15E-04 Nicotine dependence PLBD1 intron 17158188 rs3811174 chr12 14721203 T G 7.22E-04 Alzheimer's disease / / 17998437 rs11831626 chr12 14760028 T C 0.0000095 Asthma (exacerbation) / / 23706709 rs2287538 chr12 14775214 T C 1.80E-04 Lymphocyte counts GUCY2C intron 22286170 rs11836172 chr12 14775260 G A 0.0000095 Asthma (exacerbation) GUCY2C intron 23706709 rs10846059 chr12 14919862 T C 6.43E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs4764124 chr12 14966604 C T 8.00E-07 Pubertal anthropometrics C12orf60 intron 23449627 rs11610238 chr12 14975721 C T 4.21E-05 Lymphocyte counts C12orf60 intron 22286170 rs11276 chr12 14993439 C T 0.00044 Breast cancer ART4 missense 23555315 rs4236 chr12 15035081 T C 0.00046 Breast cancer MGP missense 23555315 rs918121 chr12 15071242 G A 6.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ERP27 intron 20877124 rs918121 chr12 15071242 G A 6.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ERP27 intron 20877124 rs10047541 chr12 15075202 C T 3.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ERP27 intron 20877124 rs10047541 chr12 15075202 C T 4.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ERP27 intron 20877124 rs4703 chr12 15095558 C G 5.50E-16 Leukemia(T-cell recognition in patients) ARHGDIB cds-synon 21062987 rs10772825 chr12 15101478 G A 7.91E-05 Cognitive test performance ARHGDIB intron 20125193 rs4763407 chr12 15105560 A T 4.41E-04 Multiple complex diseases ARHGDIB intron 17554300 rs4763407 chr12 15105560 A T 1.30E-05 Urinary metabolites ARHGDIB intron 21572414 rs10492147 chr12 15105703 C T 2.00E-05 Urinary metabolites ARHGDIB intron 21572414 rs10492145 chr12 15109056 A G 1.10E-05 Urinary metabolites ARHGDIB intron 21572414 rs10492145 chr12 15109056 A G 7.10E-04 Insulin resistance ARHGDIB intron 21901158 rs918124 chr12 15109571 T C 1.67E-04 Multiple complex diseases ARHGDIB intron 17554300 rs2445433 chr12 15110207 T C 6.80E-04 Myopia (pathological) ARHGDIB intron 21095009 rs7978415 chr12 15123468 G A 3.16E-04 Aortic root size / / 21223598 rs3983696 chr12 15123872 C T 2.89E-04 Aortic root size / / 21223598 rs12305014 chr12 15127339 T C 8.76E-05 Cognitive test performance PDE6H intron 20125193 rs11056267 chr12 15129668 C T 1.69E-05 Cognitive test performance PDE6H intron 20125193 rs10744079 chr12 15133720 C T 7.01E-04 Insulin resistance PDE6H intron 21901158 rs12422325 chr12 15155575 G A 4.09E-05 Cognitive test performance / / 20125193 rs10846109 chr12 15159686 A C 3.60E-05 Major depressive disorder / / 21042317 rs7969715 chr12 15161833 G A 3.10E-05 Major depressive disorder / / 21042317 rs2445421 chr12 15165841 G A 1.39E-05 Cognitive test performance / / 20125193 rs1558789 chr12 15168791 C A 0.000106 Schizophrenia / / 22440650 rs10846115 chr12 15175698 T C 3.40E-05 Major depressive disorder / / 21042317 rs2058784 chr12 15235173 C T 9.92E-06 Tuberculosis / / 22306650 rs7308621 chr12 15245164 G T 4.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7308621 chr12 15245164 G T 7.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1544671 chr12 15252140 C T 2.48E-04 Aortic root size / / 21223598 rs16910630 chr12 15267916 T C 6.50E-05 HIV-1 viral setpoint RERG intron 22174851 rs3748303 chr12 15305161 T C 2.78E-04 Response to cytadine analogues (cytosine arabinoside) RERG intron 24483146 rs2193173 chr12 15308353 A T 6.64E-04 Response to cytadine analogues (cytosine arabinoside) RERG intron 24483146 rs4763421 chr12 15313601 T C 6.31E-05 Major depressive disorder RERG intron 21621269 rs17762368 chr12 15333860 G A 3.93E-04 Type 2 diabetes RERG intron 17463246 rs11056399 chr12 15365510 C T 1.29E-05 Urate levels RERG intron 23263486 rs7955309 chr12 15368198 T C 4.73E-04 Alcohol dependence RERG intron 20201924 rs7965695 chr12 15368644 G A 8.80E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines RERG intron 21844884 rs767201 chr12 15370878 G A 3.39E-04 Alcohol dependence RERG intron 20201924 rs767201 chr12 15370878 G A 2.00E-04 Cognitive impairment induced by topiramate RERG intron 22091778 rs767201 chr12 15370878 G A 2.00E-04 Cognitive impairment induced by topiramate RERG intron 22091778 rs767201 chr12 15370878 G A 5.41E-05 Cognitive impairment induced by topiramate RERG intron 22091778 rs767201 chr12 15370878 G A 7.50E-06 Behavioural disinhibition (generation interaction) RERG intron 23942779 rs12320285 chr12 15372062 G T 7.30E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines RERG intron 21844884 rs6488766 chr12 15374630 T C 9.51E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11056410 chr12 15382815 T C 9.15E-05 Cognitive impairment induced by topiramate / / 22091778 rs11056410 chr12 15382815 T C 9.73E-05 Cognitive impairment induced by topiramate / / 22091778 rs11056410 chr12 15382815 T C 5.85E-04 Taste perception / / 22132133 rs11056410 chr12 15382815 T C 5.50E-06 Behavioural disinhibition (generation interaction) / / 23942779 rs12311304 chr12 15389637 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12311304 chr12 15389637 T C 7.05E-05 Cognitive impairment induced by topiramate / / 22091778 rs12311304 chr12 15389637 T C 7.41E-05 Cognitive impairment induced by topiramate / / 22091778 rs12311304 chr12 15389637 T C 4.00E-06 Behavioural disinhibition (generation interaction) / / 23942779 rs12307681 chr12 15402932 C T 6.58E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7954918 chr12 15420197 C T 7.77E-04 Aortic root size / / 21223598 rs7972872 chr12 15420446 T C 5.61E-04 Aortic root size / / 21223598 rs1117152 chr12 15438032 T G 5.20E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6488769 chr12 15463296 C T 6.85E-04 Alcohol dependence / / 20201924 rs11056473 chr12 15577729 T C 1.55E-04 Multiple complex diseases PTPRO intron 17554300 rs253810 chr12 15616544 A G 1.74E-09 Pure-tone audiometry PTPRO intron pha001964 rs253813 chr12 15619681 G A 1.04E-10 Multiple complex diseases PTPRO intron 17554300 rs2111173 chr12 15666517 C T 5.22E-05 Longevity PTPRO intron 21612516 rs2041898 chr12 15666967 C G 1.47E-04 Lymphocyte counts PTPRO intron 22286170 rs3748299 chr12 15733669 G A 7.13E-04 Major depressive disorder PTPRO cds-synon 22472876 rs144347297 chr12 15734702 C A,T 0.0000003 Breast cancer(er negative) PTPRO missense 23555315 rs144347297 chr12 15734702 C A,T 0.000029 Breast cancer PTPRO missense 23555315 rs2300290 chr12 15735442 G A 1.00E-08 Cognitive function PTPRO intron 22126837 rs16910957 chr12 15735870 A G 3.63E-04 Multiple complex diseases PTPRO intron 17554300 rs10846216 chr12 15740294 C A 4.15E-05 Response to mTOR inhibitor (rapamycin) PTPRO intron 24009623 rs4644683 chr12 15780763 T C 5.60E-04 Type 2 diabetes EPS8 intron 17463246 rs4417353 chr12 15812575 C T 8.12E-04 Type 2 diabetes EPS8 intron 17463246 rs10772868 chr12 15820408 G A 5.26E-05 Multiple complex diseases EPS8 intron 17554300 rs7956378 chr12 15885361 G A 5.69E-04 Multiple complex diseases EPS8 intron 17554300 rs17415853 chr12 15930805 T C 7.00E-07 Protein quantitative trait loci EPS8 intron 18464913 rs7311565 chr12 15991165 T C 6.55E-05 Multiple complex diseases / / 17554300 rs16911328 chr12 16002622 T C 9.58E-04 Multiple complex diseases / / 17554300 rs7310070 chr12 16074407 A G 2.41E-04 Multiple complex diseases DERA intron 17554300 rs2306181 chr12 16109673 T G 1.96E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines DERA intron 21844884 rs7969174 chr12 16159897 G T 4.62E-05 Body mass index DERA intron 21701565 rs7969174 chr12 16159897 G T 7.39E-04 Body mass index DERA intron 21701565 rs12228816 chr12 16165214 A G 1.00E-05 Urinary metabolites DERA intron 21572414 rs10846274 chr12 16202190 G C 9.20E-06 Urinary metabolites / / 21572414 rs10505790 chr12 16226152 A T 4.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7967061 chr12 16243248 A G 6.17E-04 Type 2 diabetes / / 17463246 rs10846287 chr12 16255614 T C 6.04E-04 Type 2 diabetes / / 17463246 rs10846290 chr12 16258907 C T 4.52E-04 Type 2 diabetes / / 17463246 rs1526993 chr12 16322667 C T 5.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs1671497 chr12 16323539 A G 6.92E-05 Dengue shock syndrome / / 22001756 rs11056813 chr12 16327746 G T 6.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs12812739 chr12 16328237 C G 7.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs11056825 chr12 16364884 A G 8.47E-04 Response to taxane treatment (placlitaxel) SLC15A5 intron 23006423 rs10772915 chr12 16406690 G A 5.00E-06 Visceral fat SLC15A5 intron 22589738 rs7305495 chr12 16466171 G A 1.70E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4149198 chr12 16513190 T C 6.95E-05 Cognitive performance MGST1 intron 19734545 rs7135371 chr12 16517926 G T 9.52E-04 Lymphocyte counts / / 22286170 rs2160512 chr12 16519020 A G 1.45E-05 QT interval / / 16648850 rs2160512 chr12 16519020 A G 1.45E-04 Progressive supranuclear palsy / / 21685912 rs9332958 chr12 16519263 A G 5.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs12313805 chr12 16523922 A G 6.68E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2900377 chr12 16541511 T C 2.50E-05 Urinary metabolites / / 21572414 rs7964142 chr12 16568101 A T 1.90E-05 Urinary metabolites / / 21572414 rs7314403 chr12 16568804 C T 1.20E-05 Urinary metabolites / / 21572414 rs10772935 chr12 16571448 A G 1.40E-05 Urinary metabolites / / 21572414 rs34725238 chr12 16578597 A G 8.77E-05 Response to methylphenidate treatment / / 21130132 rs34725238 chr12 16578597 A G 8.30E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10772939 chr12 16609038 T C 5.00E-06 Economic and political preferences / / 22566634 rs6488848 chr12 16641512 G C 2.02E-06 Multiple sclerosis / / 17660530 rs992690 chr12 16650161 G T 5.05E-04 Schizophrenia / / 19197363 rs11056970 chr12 16667164 C A 3.90E-04 White blood cell types / / 21738478 rs11832997 chr12 16694800 C T 6.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs989231 chr12 16741500 T C 2.67E-04 Lung function (forced expiratory volume in 1 second) LMO3 intron 24023788 rs989231 chr12 16741500 T C 2.79E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LMO3 intron 24023788 rs11057006 chr12 16750931 A G 5.92E-05 Bipolar disorder LMO3 intron 20451256 rs9651873 chr12 16755372 A C 9.43E-05 Bipolar disorder LMO3 intron 20451256 rs2160514 chr12 16756508 A C 5.19E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LMO3 intron 24023788 rs16912067 chr12 16773372 C A 0.00000786 Lumbar spine bone mineral density (premenopausal) / / 23074152 rs431899 chr12 16855241 C T 6.96E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10161409 chr12 16893077 G C 1.36E-04 Multiple complex diseases / / 17554300 rs10772963 chr12 16896212 T G 7.05E-05 Body Fat Distribution / / pha003018 rs7296019 chr12 16916169 A C 6.75E-04 Smoking cessation / / 24665060 rs11057069 chr12 16928510 T G 5.87E-04 Obesity (extreme) / / 21935397 rs7963143 chr12 16934292 A G 5.73E-04 Smoking cessation / / 24665060 rs10082759 chr12 16936820 A G 5.93E-04 Smoking cessation / / 24665060 rs7296745 chr12 16940641 T G 5.39E-04 Smoking cessation / / 24665060 rs2077833 chr12 16941511 C T 5.69E-04 Smoking cessation / / 24665060 rs2129818 chr12 16942935 G T 4.28E-05 Serum alpha1-antitrypsin levels / / 23990791 rs2129818 chr12 16942935 G T 6.05E-04 Smoking cessation / / 24665060 rs1386819 chr12 16956601 A G 4.72E-05 Serum alpha1-antitrypsin levels / / 23990791 rs12370426 chr12 16968038 C T 1.40E-05 Urinary metabolites / / 21572414 rs10846440 chr12 16969359 G A 8.75E-05 Body Fat Distribution / / pha003018 rs17673772 chr12 17014207 G A 2.50E-05 Urinary metabolites / / 21572414 rs10772976 chr12 17019788 A C 4.19E-04 Smoking cessation / / 24665060 rs11519533 chr12 17088421 T C 1.50E-05 Urinary metabolites / / 21572414 rs16912313 chr12 17103760 G T 0.000697 Height (Pygmy height) / / 22570615 rs10772983 chr12 17141582 C T 8.41E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7955617 chr12 17182120 C T 5.92E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2044049 chr12 17184753 T C 5.80E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7305646 chr12 17264337 T C 9.16E-04 Response to TNF antagonist treatment / / 21061259 rs11043347 chr12 17325026 T G 5.50E-05 Major depressive disorder / / 21042317 rs1513049 chr12 17362816 G C 7.00E-06 Word reading / / 23738518 rs9971637 chr12 17373739 G A 2.00E-06 Amyotrophic lateral sclerosis / / 19734901 rs17380361 chr12 17376115 G C 6.20E-04 Multiple complex diseases / / 17554300 rs17439723 chr12 17376306 T C 5.25E-04 Multiple complex diseases / / 17554300 rs17440157 chr12 17386127 C T 6.88E-04 Multiple complex diseases / / 17554300 rs932062 chr12 17392055 T A 1.49E-04 Multiple complex diseases / / 17554300 rs11043375 chr12 17401796 G A 6.16E-04 Smoking initiation / / 24665060 rs2942582 chr12 17406796 A G 9.44E-04 Response to alcohol consumption (flushing response) / / 24277619 rs7314782 chr12 17423964 C T 9.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11614632 chr12 17425468 C T 3.96E-04 Smoking initiation / / 24665060 rs16912594 chr12 17431575 G A 1.15E-05 Body Mass Index / / pha003006 rs16912594 chr12 17431575 G A 6.05E-05 Body Mass Index / / pha003019 rs2942578 chr12 17450756 C T 6.60E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16912667 chr12 17502660 A G 3.83E-05 Body Mass Index / / pha003019 rs16912667 chr12 17502660 A G 7.96E-05 Body Mass Index / / pha003020 rs2971177 chr12 17505513 C T 4.87E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1532521 chr12 17508277 T G 4.63E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2936206 chr12 17520113 A G 4.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs1163983 chr12 17555289 G T 9.98E-04 Alzheimer's disease / / 24755620 rs635910 chr12 17557828 G A 4.57E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1305295 chr12 17572242 G A 2.20E-04 Alcohol dependence / / 20201924 rs1305295 chr12 17572242 G A 6.55E-05 Cholesterol / / pha003073 rs11043460 chr12 17595624 G A 2.00E-05 Urinary metabolites / / 21572414 rs1163929 chr12 17602872 A C 5.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs1163913 chr12 17605775 A G 6.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs653966 chr12 17608215 G A 7.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs1728196 chr12 17609866 C A 7.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs665016 chr12 17610500 A T 7.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs1163903 chr12 17611613 G A 6.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs1163900 chr12 17612617 G A 3.30E-05 Aging (time to event) / / 21782286 rs1728200 chr12 17615669 G A 6.74E-04 Alzheimer's disease / / 24755620 rs1694747 chr12 17617111 C A 8.57E-04 Alzheimer's disease / / 24755620 rs1163895 chr12 17625605 A C,G,T 8.90E-06 Urinary metabolites / / 21572414 rs1163895 chr12 17625605 A C,G,T 6.87E-04 Alzheimer's disease / / 24755620 rs642578 chr12 17634341 G A 6.79E-04 Alzheimer's disease / / 24755620 rs10840726 chr12 17634357 G A 7.56E-04 Multiple complex diseases / / 17554300 rs10840728 chr12 17638662 T C 9.16E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs10219728 chr12 17639821 A G 4.30E-04 Alcohol dependence / / 20201924 rs10219728 chr12 17639821 A G 6.46E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs10219673 chr12 17639951 T A 6.00E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs1706605 chr12 17644613 G T 9.96E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs904401 chr12 17650271 C T 4.54E-04 Alzheimer's disease / / 24755620 rs1553115 chr12 17650712 T G 3.42E-04 White matter integrity / / 22425255 rs1553115 chr12 17650712 T G 5.17E-04 Alzheimer's disease / / 24755620 rs10840729 chr12 17653834 G A 8.40E-04 Alcohol dependence / / 20201924 rs1706631 chr12 17662235 A T 6.00E-06 Major depressive disorder / / 23377640 rs1694773 chr12 17667606 A G 7.20E-06 Parkinson's disease (familial) / / 18985386 rs1631596 chr12 17667916 G A 7.63E-04 Alzheimer's disease / / 24755620 rs1912884 chr12 17669498 C A 2.30E-05 Parkinson's disease (familial) / / 18985386 rs2250838 chr12 17670461 A G 1.30E-05 Parkinson's disease (familial) / / 18985386 rs7488750 chr12 17676797 A G 7.79E-04 Smoking initiation / / 24665060 rs1912879 chr12 17683517 C T 1.47E-06 Serum metabolites / / 19043545 rs1912879 chr12 17683517 C T 8.20E-06 Urinary metabolites / / 21572414 rs11043491 chr12 17684675 T G 2.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs1912886 chr12 17704712 A G 8.19E-05 Coronary heart disease / / pha003030 rs1186300 chr12 17728991 C A,G,T 9.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs1163784 chr12 17740910 A G 1.70E-04 Statin-induced myopathy / / 21826682 rs2467123 chr12 17749603 T G 4.17E-04 Smoking initiation / / 24665060 rs10505808 chr12 17788564 G A 2.84E-04 Obesity (extreme) / / 21935397 rs1437082 chr12 17810471 T A 6.70E-04 Multiple complex diseases / / 17554300 rs1437082 chr12 17810471 T A 3.17E-04 Alzheimer's disease / / 17998437 rs2437970 chr12 17829626 A G 0.000043 Tuberculosis with early age of onset / / 22551897 rs10743216 chr12 17845593 G A 6.33E-04 Acute lung injury / / 22295056 rs10770244 chr12 17848331 A G 7.24E-04 Acute lung injury / / 22295056 rs4346021 chr12 17860715 G A 8.78E-04 Acute lung injury / / 22295056 rs7973547 chr12 17881386 C A 0.0000711 Panic disorder / / 23149450 rs7973547 chr12 17881386 C A 7.11E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs7974149 chr12 17881713 G A 9.87E-04 Acute lung injury / / 22295056 rs7974041 chr12 17881755 C T 9.87E-04 Acute lung injury / / 22295056 rs7136879 chr12 17884529 G T 2.42E-04 Acute lung injury / / 22295056 rs12813320 chr12 17884776 C T 7.76E-04 Acute lung injury / / 22295056 rs11043626 chr12 17884993 A G 8.26E-04 Acute lung injury / / 22295056 rs11043627 chr12 17885289 C T 8.26E-04 Acute lung injury / / 22295056 rs11043628 chr12 17885661 C T 7.89E-05 Serum metabolites / / 19043545 rs11043628 chr12 17885661 C T 8.77E-04 Acute lung injury / / 22295056 rs11043629 chr12 17885719 C T 8.77E-04 Acute lung injury / / 22295056 rs7299334 chr12 17886099 A T 8.70E-04 Acute lung injury / / 22295056 rs6486834 chr12 17887870 A T 3.54E-05 Serum metabolites / / 19043545 rs4323926 chr12 17888069 T C 3.35E-05 Serum metabolites / / 19043545 rs7973206 chr12 17888184 G A 3.65E-04 Multiple complex diseases / / 17554300 rs6486835 chr12 17888264 A G 3.54E-05 Serum metabolites / / 19043545 rs4477487 chr12 17892560 C T 2.52E-04 Acute lung injury / / 22295056 rs10840845 chr12 17902658 A C 4.08E-04 Multiple complex diseases / / 17554300 rs6486842 chr12 17911002 T C 6.84E-04 Acute lung injury / / 22295056 rs7307377 chr12 17914383 T C 7.30E-04 Acute lung injury / / 22295056 rs7959742 chr12 17927368 C T 4.60E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs11043662 chr12 17928813 A G 0.000814 Salmonella-induced pyroptosis / / 22837397 rs11043664 chr12 17944624 T C 4.24E-04 Multiple complex diseases / / 17554300 rs11611975 chr12 17962680 G A 5.41E-05 Longevity / / 20304771 rs10840887 chr12 17989049 A T 9.58E-04 Multiple complex diseases / / 17554300 rs11043688 chr12 17993007 A C 5.45E-04 Acute lung injury / / 22295056 rs7137477 chr12 17994017 T C 5.45E-04 Acute lung injury / / 22295056 rs7309968 chr12 17994311 A G 5.27E-04 Acute lung injury / / 22295056 rs7954736 chr12 17996528 C T 4.61E-04 Acute lung injury / / 22295056 rs7957241 chr12 18000383 T G 5.56E-04 Acute lung injury / / 22295056 rs4128332 chr12 18002714 A G 5.56E-04 Acute lung injury / / 22295056 rs11836491 chr12 18027034 G A 2.61E-04 Multiple complex diseases / / 17554300 rs11043723 chr12 18040964 A C 9.85E-04 Acute lung injury / / 22295056 rs10840919 chr12 18074703 C T 2.95E-04 Alzheimer's disease (late onset) / / 21379329 rs7970960 chr12 18102310 T C 2.59E-04 Osteoarthritis / / 19508968 rs1609001 chr12 18104732 C T 4.10E-06 Urinary metabolites / / 21572414 rs2417686 chr12 18114417 T C 8.13E-05 Multiple sclerosis (age of onset) / / 19010793 rs2417686 chr12 18114417 T C 3.84E-04 Alzheimer's disease (late onset) / / 21379329 rs11043754 chr12 18117926 A C 9.40E-07 Urinary metabolites / / 21572414 rs12305001 chr12 18140559 G A 7.80E-06 Urinary metabolites / / 21572414 rs12301968 chr12 18145249 T A 9.40E-07 Urinary metabolites / / 21572414 rs11043845 chr12 18241252 T G 9.07E-04 Obesity (extreme) RERGL intron 21935397 rs17469935 chr12 18242858 C G 8.10E-04 Alzheimer's disease RERGL intron 17998437 rs7973657 chr12 18247969 G A 6.11E-05 Serum metabolites / / 19043545 rs4764373 chr12 18252060 A C 2.97E-04 Alzheimer's disease / / 17998437 rs11043876 chr12 18277377 T A 9.29E-04 Obesity (extreme) / / 21935397 rs16913855 chr12 18287616 A C 9.14E-04 Obesity (extreme) / / 21935397 rs11043885 chr12 18287994 C G 7.25E-04 Multiple complex diseases / / 17554300 rs12579910 chr12 18290643 T C 9.05E-04 Obesity (extreme) / / 21935397 rs4309203 chr12 18298785 C A 9.20E-04 Obesity (extreme) / / 21935397 rs16913870 chr12 18299091 C G 8.41E-04 Obesity (extreme) / / 21935397 rs17471532 chr12 18300504 G A 9.91E-04 Obesity (extreme) / / 21935397 rs7307876 chr12 18307287 G A 4.82E-05 Hemoglobin / / pha003096 rs7307876 chr12 18307287 G A 8.37E-05 Hematocrit / / pha003097 rs11559740 chr12 18325335 C T 7.93E-05 Bipolar disorder and schizophrenia / / 20889312 rs11043936 chr12 18361643 C T 9.58E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs10505816 chr12 18375680 G A 8.00E-05 Response to statin therapy / / 20339536 rs7970341 chr12 18382373 G A 6.84E-05 Biliary atresia / / 20460270 rs11043979 chr12 18400036 C T 4.10E-05 Response to statin therapy / / 20339536 rs10770334 chr12 18404274 T C 4.90E-05 Response to statin therapy / / 20339536 rs4369463 chr12 18409894 A G 3.97E-04 Lung function (forced vital capacity) / / 24023788 rs9300118 chr12 18465237 G A 1.35E-04 Multiple complex diseases PIK3C2G intron 17554300 rs11044026 chr12 18473729 T C 5.45E-06 Gray matter volume (schizophrenia interaction) PIK3C2G intron 24086445 rs12580062 chr12 18488064 A G 4.71E-06 Gray matter volume (schizophrenia interaction) PIK3C2G intron 24086445 rs11044045 chr12 18508252 C T 3.00E-06 Gray matter volume (schizophrenia interaction) PIK3C2G intron 24086445 rs11044045 chr12 18508252 C T 5.15E-06 Gray matter volume (schizophrenia interaction) PIK3C2G intron 24086445 rs10841019 chr12 18515117 G A 1.95E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIK3C2G intron 20877124 rs4595599 chr12 18533041 A G 2.55E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIK3C2G intron 20877124 rs11044058 chr12 18540574 A G 9.75E-04 Multiple complex diseases PIK3C2G intron 17554300 rs11044058 chr12 18540574 A G 3.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIK3C2G intron 20877124 rs11044084 chr12 18565063 A C 7.02E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIK3C2G intron 20877124 rs10770359 chr12 18572602 A G 6.50E-06 Gray matter volume (schizophrenia interaction) PIK3C2G intron 24086445 rs10770359 chr12 18572602 A G 9.02E-06 Gray matter volume (schizophrenia interaction) PIK3C2G intron 24086445 rs12581163 chr12 18575554 T C 6.07E-05 Multiple complex diseases PIK3C2G intron 17554300 rs12581163 chr12 18575554 T C 2.70E-06 Gray matter volume (schizophrenia interaction) PIK3C2G intron 24086445 rs12581163 chr12 18575554 T C 5.56E-06 Gray matter volume (schizophrenia interaction) PIK3C2G intron 24086445 rs11044097 chr12 18575804 G A 1.59E-04 Multiple complex diseases PIK3C2G intron 17554300 rs11044100 chr12 18577377 T C 1.15E-04 Multiple complex diseases PIK3C2G intron 17554300 rs7308613 chr12 18578825 C G 3.22E-04 Multiple complex diseases PIK3C2G intron 17554300 rs11044106 chr12 18584676 T G 4.36E-06 Gray matter volume (schizophrenia interaction) PIK3C2G intron 24086445 rs11044106 chr12 18584676 T G 9.39E-06 Gray matter volume (schizophrenia interaction) PIK3C2G intron 24086445 rs12427286 chr12 18589718 C T 1.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIK3C2G intron 20877124 rs4275678 chr12 18592080 T G 0.0000353 Primary sclerosing cholangitis PIK3C2G intron 23603763 rs12371624 chr12 18613946 T C 4.48E-04 Multiple complex diseases PIK3C2G intron 17554300 rs1447410 chr12 18642537 A C 2.26E-05 Sleep duration PIK3C2G intron 22105623 rs1447411 chr12 18642620 C T 2.27E-05 Sleep duration PIK3C2G intron 22105623 rs60685745 chr12 18668253 A T 6.42E-06 Intracerebral hemorrhage PIK3C2G intron 24656865 rs10505824 chr12 18680745 G T 3.28E-04 Type 2 diabetes PIK3C2G intron 17846125 rs10505824 chr12 18680745 G T 8.12E-04 Alzheimer's disease PIK3C2G intron 22005930 rs1375156 chr12 18681767 G A 6.27E-04 Type 2 diabetes PIK3C2G intron 17463246 rs1375156 chr12 18681767 G A 5.30E-05 Multiple complex diseases PIK3C2G intron 17554300 rs1375156 chr12 18681767 G A 1.11E-05 Taste perception PIK3C2G intron 22132133 rs1375156 chr12 18681767 G A 3.45E-08 Metabolite levels PIK3C2G intron 23281178 rs7301316 chr12 18682599 C T 4.88E-09 Metabolite levels PIK3C2G intron 23281178 rs7978424 chr12 18685441 A G 9.42E-04 Type 2 diabetes PIK3C2G intron 17463246 rs7978424 chr12 18685441 A G 7.39E-05 Multiple complex diseases PIK3C2G intron 17554300 rs7978424 chr12 18685441 A G 6.37E-08 Metabolite levels PIK3C2G intron 23281178 rs11044165 chr12 18685521 T C 3.32E-04 White matter integrity PIK3C2G intron 22425255 rs7969452 chr12 18686733 T C 8.37E-04 Type 2 diabetes PIK3C2G intron 17463246 rs7969452 chr12 18686733 T C 1.87E-05 Multiple complex diseases PIK3C2G intron 17554300 rs7969452 chr12 18686733 T C 9.10E-06 Taste perception PIK3C2G intron 22132133 rs12301772 chr12 18698876 C T 8.31E-04 Alzheimer's disease PIK3C2G intron 22005930 rs11829471 chr12 18701427 C G 9.76E-04 Alzheimer's disease PIK3C2G intron 22005930 rs10770370 chr12 18701924 T A 7.29E-04 Alzheimer's disease PIK3C2G intron 22005930 rs10841041 chr12 18726705 G A 3.38E-04 Body mass index PIK3C2G intron 17255346 rs12581078 chr12 18739138 G A 7.03E-04 Alzheimer's disease PIK3C2G intron 22005930 rs12832281 chr12 18744595 G C 7.72E-04 Alzheimer's disease PIK3C2G intron 22005930 rs17419409 chr12 18744797 T C 6.28E-05 Body mass index PIK3C2G intron 17255346 rs7305694 chr12 18748350 G T 3.93E-04 Type 2 diabetes PIK3C2G intron 17463246 rs7305694 chr12 18748350 G T 9.76E-06 Multiple complex diseases PIK3C2G intron 17554300 rs12818409 chr12 18749214 T C 9.42E-04 Alzheimer's disease PIK3C2G intron 22005930 rs7316758 chr12 18752939 T A 7.47E-04 Alzheimer's disease PIK3C2G intron 22005930 rs12371247 chr12 18753076 T G 7.43E-04 Alzheimer's disease PIK3C2G intron 22005930 rs12809738 chr12 18762113 G A 3.85E-04 Multiple complex diseases PIK3C2G intron 17554300 rs7964182 chr12 18764558 G A 6.72E-04 Multiple complex diseases PIK3C2G intron 17554300 rs11831892 chr12 18766488 T A 9.39E-04 Alzheimer's disease PIK3C2G intron 22005930 rs11829511 chr12 18766698 C T 8.85E-04 Alzheimer's disease PIK3C2G intron 22005930 rs12811846 chr12 18771033 T G 4.90E-04 Alzheimer's disease PIK3C2G intron 22005930 rs11044232 chr12 18797296 A G 4.56E-04 Lung function (forced vital capacity) PIK3C2G intron 24023788 rs578947 chr12 18807331 C T 2.06E-04 Lung function (forced vital capacity) / / 24023788 rs10841066 chr12 18839235 C T 1.80E-04 Body mass index PLCZ1 intron 17255346 rs11044248 chr12 18840128 G A 0.00000104 HDL cholesterol PLCZ1 intron 23063622 rs1487070 chr12 18848131 T C 7.95E-04 Suicide attempts in bipolar disorder PLCZ1 intron 21423239 rs4764417 chr12 18850289 G A 7.66E-04 Suicide attempts in bipolar disorder PLCZ1 intron 21423239 rs901528 chr12 18856824 C A 1.89E-04 Body mass index PLCZ1 intron 17255346 rs10841075 chr12 18863652 A G 3.14E-04 Body mass index PLCZ1 intron 17255346 rs17488409 chr12 18899969 A G 1.01E-04 Smoking quantity / / 24665060 rs17488451 chr12 18900373 C T 3.38E-05 Intracerebral hemorrhage / / 24656865 rs1388090 chr12 19012463 T C 9.75E-05 Type 2 diabetes / / 17846125 rs1388090 chr12 19012463 T C 3.16E-05 Blood Pressure / / pha002898 rs1532054 chr12 19012908 T A 1.59E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs1532054 chr12 19012908 T A 2.10E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs7964992 chr12 19016296 T A 2.65E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs7964992 chr12 19016296 T A 7.41E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs10437758 chr12 19018632 C T 2.84E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs10437758 chr12 19018632 C T 7.47E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs1490734 chr12 19019467 T A 5.79E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs1490734 chr12 19019467 T A 6.24E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs12313606 chr12 19021912 G A 3.46E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs1844687 chr12 19023236 G A 2.28E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs12319113 chr12 19024558 G A,C 1.00E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs12319113 chr12 19024558 G A,C 5.00E-07 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs1873386 chr12 19052180 A G 8.00E-06 Personality dimensions / / 23903073 rs1490713 chr12 19067068 T C 1.58E-04 Type 2 diabetes / / 17463246 rs974872 chr12 19091177 G A 1.91E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs974872 chr12 19091177 G A 6.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4763513 chr12 19096208 C T 4.75E-05 Pulmonary function / / 19300500 rs4763514 chr12 19096567 T A 4.83E-05 Pulmonary function / / 19300500 rs1027077 chr12 19096972 G T 7.86E-06 Intracerebral hemorrhage / / 24656865 rs1027076 chr12 19097205 A G 5.07E-06 Intracerebral hemorrhage / / 24656865 rs1027075 chr12 19097281 G A 8.36E-06 Intracerebral hemorrhage / / 24656865 rs7975626 chr12 19098035 G A 1.03E-05 Intracerebral hemorrhage / / 24656865 rs7976015 chr12 19098569 C T 7.06E-06 Intracerebral hemorrhage / / 24656865 rs76885577 chr12 19098603 T G 7.05E-06 Intracerebral hemorrhage / / 24656865 rs16914899 chr12 19098892 T G 7.71E-04 Type 2 diabetes / / 17463246 rs16914899 chr12 19098892 T G 3.62E-06 Intracerebral hemorrhage / / 24656865 rs17493333 chr12 19098939 T C 3.46E-06 Intracerebral hemorrhage / / 24656865 rs74779214 chr12 19099084 A T 3.56E-06 Intracerebral hemorrhage / / 24656865 rs17493417 chr12 19099613 G A 2.84E-06 Intracerebral hemorrhage / / 24656865 rs12308333 chr12 19099838 T G 1.54E-05 Intracerebral hemorrhage / / 24656865 rs16914904 chr12 19100102 T C 2.18E-05 Intracerebral hemorrhage / / 24656865 rs12303068 chr12 19100761 C A 2.87E-05 Intracerebral hemorrhage / / 24656865 rs74560932 chr12 19102596 A G 2.07E-05 Intracerebral hemorrhage / / 24656865 rs12298536 chr12 19103160 G T 2.55E-05 Intracerebral hemorrhage / / 24656865 rs4143503 chr12 19103225 T C 6.15E-05 Pulmonary function / / 19300500 rs16914908 chr12 19104435 A G 8.86E-04 Type 2 diabetes / / 17463246 rs16914908 chr12 19104435 A G 2.01E-06 Intracerebral hemorrhage / / 24656865 rs7973505 chr12 19164304 T C 9.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs7973505 chr12 19164304 T C 5.13E-06 Stroke (ischemic) / / 21957438 rs11044389 chr12 19168581 G T 2.50E-06 Stroke (ischemic) / / 21957438 rs7979074 chr12 19169528 G C 9.31E-06 Stroke (ischemic) / / 21957438 rs55825297 chr12 19170353 G A 3.37E-07 Stroke (ischemic) / / 21957438 rs56031230 chr12 19171407 T G 3.01E-07 Stroke (ischemic) / / 21957438 rs146997533 chr12 19182287 GAT G 7.98E-06 Stroke (ischemic) / / 21957438 rs397781177 chr12 19182287 GAT G 7.98E-06 Stroke (ischemic) / / 21957438 rs66648408 chr12 19182287 GAT G 7.98E-06 Stroke (ischemic) / / 21957438 rs78429556 chr12 19182287 G T 7.98E-06 Stroke (ischemic) / / 21957438 rs1018298 chr12 19182772 A G 6.64E-06 Stroke (ischemic) / / 21957438 rs11044400 chr12 19186047 C T 1.57E-07 Stroke (ischemic) / / 21957438 rs16915000 chr12 19193673 A G 1.16E-04 Multiple complex diseases / / 17554300 rs1514839 chr12 19205651 C T 9.47E-04 Multiple complex diseases / / 17554300 rs1399473 chr12 19222955 G A 6.58E-04 Multiple complex diseases / / 17554300 rs12815398 chr12 19224185 T G 9.77E-04 Multiple complex diseases / / 17554300 rs883529 chr12 19241393 G A 7.15E-04 Heart Failure / / pha002885 rs3829827 chr12 19242092 G A 2.02E-04 Multiple complex diseases / / 17554300 rs2970839 chr12 19254829 G A 2.18E-04 Multiple complex diseases / / 17554300 rs1514831 chr12 19303772 T C 1.35E-04 Smoking cessation PLEKHA5 intron 18519826 rs10841162 chr12 19317082 T C 4.27E-05 Smoking cessation PLEKHA5 intron 18519826 rs11044441 chr12 19322754 G A 2.60E-05 Urinary metabolites PLEKHA5 intron 21572414 rs11044446 chr12 19343580 A T 9.84E-04 Type 2 diabetes PLEKHA5 intron 17463246 rs16915248 chr12 19384213 G A 5.93E-05 Smoking cessation PLEKHA5 intron 18519826 rs12427026 chr12 19414900 C G 5.25E-04 Suicide attempts in bipolar disorder PLEKHA5 intron 21423239 rs7956106 chr12 19419496 A G 6.54E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) PLEKHA5 intron 24192120 rs7965006 chr12 19439080 C T 1.94E-05 Cognitive test performance PLEKHA5 intron 20125193 rs7297169 chr12 19466956 G T 3.80E-06 Urinary metabolites PLEKHA5 intron 21572414 rs10770476 chr12 19493103 G A 0.000733824 Primary sclerosing cholangitis PLEKHA5 intron 23603763 rs11616166 chr12 19599001 A G 0.0000142 Prostate cancer AEBP2 intron 22532847 rs10841243 chr12 19653752 A G 8.19E-04 Multiple complex diseases AEBP2 intron 17554300 rs3903219 chr12 19698168 G A 6.73E-04 Type 2 diabetes / / 17463246 rs11044668 chr12 19702516 C T 6.21E-05 Blood Pressure / / pha003049 rs10841268 chr12 19727977 C T 7.35E-05 Serum metabolites / / 19043545 rs11044702 chr12 19738434 T G 5.81E-05 Serum metabolites / / 19043545 rs11044702 chr12 19738434 T G 4.89E-05 Formal thought disorder in schizophrenia / / 22648509 rs6486975 chr12 19742183 A G 2.08E-05 Serum metabolites / / 19043545 rs7312615 chr12 19746587 A G 5.62E-06 Body Mass Index / / pha003019 rs7312615 chr12 19746587 A G 9.06E-05 Body Mass Index / / pha003020 rs7312615 chr12 19746587 A G 3.98E-05 Body Mass Index / / pha003022 rs10841282 chr12 19758872 T C 5.50E-05 Serum metabolites / / 19043545 rs12314956 chr12 19777491 C T 9.37E-04 Multiple complex diseases / / 17554300 rs12314956 chr12 19777491 C T 6.96E-04 Alzheimer's disease / / 17998437 rs10841287 chr12 19779793 T C 2.00E-06 Obesity-related traits / / 23251661 rs10841289 chr12 19783721 G T 4.00E-05 White matter hyperintensity burden / / 21681796 rs10770509 chr12 19785990 G A 6.01E-04 White matter integrity / / 22425255 rs6416209 chr12 19787481 T C 2.18E-04 White matter integrity / / 22425255 rs7488635 chr12 19797520 T C 7.95E-04 Insulin resistance / / 21901158 rs7960308 chr12 19800103 T C 5.42E-04 Type 2 diabetes / / 17463246 rs6486986 chr12 19801595 G T 8.00E-06 Cognitive performance / / 19734545 rs6486986 chr12 19801595 G T 0.000895757 Hypertension (early onset hypertension) / / 22479346 rs7303587 chr12 19804415 A C,G,T 2.45E-04 Type 2 diabetes / / 17463246 rs7303587 chr12 19804415 A C,G,T 4.61E-04 Multiple complex diseases / / 17554300 rs6486990 chr12 19806842 A G 4.42E-04 Type 2 diabetes / / 17463246 rs6486990 chr12 19806842 A G 5.30E-04 Multiple complex diseases / / 17554300 rs10161342 chr12 19807145 C T 2.58E-04 Type 2 diabetes / / 17463246 rs10161342 chr12 19807145 C T 3.21E-04 Multiple complex diseases / / 17554300 rs7489213 chr12 19807162 A G 6.09E-04 Type 2 diabetes / / 17463246 rs7489213 chr12 19807162 A G 5.38E-04 Multiple complex diseases / / 17554300 rs7306423 chr12 19817473 A G 2.13E-04 Multiple complex diseases / / 17554300 rs10770516 chr12 19818502 T C 5.04E-04 Type 2 diabetes / / 17463246 rs10841306 chr12 19819977 T C 4.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10841306 chr12 19819977 T C 6.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7131725 chr12 19828656 T C 1.72E-05 HIV-1 viral setpoint / / 22174851 rs12581840 chr12 19834151 T C 6.48E-04 Type 2 diabetes / / 17463246 rs12581840 chr12 19834151 T C 9.70E-05 Insulin resistance / / 21901158 rs4511354 chr12 19845238 A G 3.15E-04 Body mass index / / 17255346 rs10770522 chr12 19852696 G A 3.18E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs4564400 chr12 19859178 C T 3.18E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs4762767 chr12 19866129 A G 8.00E-06 Pulmonary function / / 21946350 rs7139246 chr12 19872765 A C,T 8.12E-05 Bipolar disorder and schizophrenia / / 20889312 rs10431210 chr12 19873951 C G 8.95E-04 Type 2 diabetes / / 17463246 rs10431210 chr12 19873951 C G 2.81E-04 Multiple complex diseases / / 17554300 rs10770535 chr12 19876746 A C 9.45E-05 Serum metabolites / / 19043545 rs4762943 chr12 19892979 G T 6.22E-04 Multiple complex diseases / / 17554300 rs10505854 chr12 19893674 T C 2.19E-04 Multiple complex diseases / / 17554300 rs7294556 chr12 19893946 T C 1.88E-05 Serum metabolites / / 19043545 rs4281541 chr12 19907176 T C 2.16E-05 Blood Pressure / / pha003043 rs7959819 chr12 19909935 A G 9.39E-04 Alzheimer's disease / / 22005930 rs10505849 chr12 19911529 T C 8.97E-04 Alzheimer's disease / / 22005930 rs10841340 chr12 19917405 G C 7.35E-04 Alzheimer's disease / / 22005930 rs4351887 chr12 19919127 A G 7.23E-04 Alzheimer's disease / / 22005930 rs1405609 chr12 19924041 T A 7.65E-04 Type 2 diabetes / / 17463246 rs16921936 chr12 19924660 T G 9.24E-04 Multiple complex diseases / / 17554300 rs10505848 chr12 19947908 A G 1.45E-05 Tunica Media / / pha003034 rs1465089 chr12 19948851 G A 1.67E-05 Tunica Media / / pha003034 rs1994738 chr12 19956655 C T 6.67E-06 Kawasaki disease / / 21221998 rs11044887 chr12 19973815 G C 1.47E-04 Type 2 diabetes / / 17463246 rs10841371 chr12 19974645 G A 1.69E-04 Type 2 diabetes / / 17463246 rs10841372 chr12 19974796 A G 2.44E-04 Type 2 diabetes / / 17463246 rs10841376 chr12 19979881 C G 7.40E-04 Type 2 diabetes / / 17463246 rs10841376 chr12 19979881 C G 1.58E-06 Blood pressure / / 21909110 rs11044902 chr12 20009482 T G 5.00E-06 Urinary metabolites / / 21572414 rs7959247 chr12 20018222 T C 2.24E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs941223 chr12 20021125 G A 2.24E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs16915343 chr12 20036289 C A 3.79E-05 Bipolar disorder and schizophrenia / / 20889312 rs17288199 chr12 20037610 G C 1.26E-08 Metabolite levels / / 23281178 rs7957570 chr12 20042583 G A 1.09E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1586840 chr12 20062497 G A 6.45E-08 Breast cancer / / 20852631 rs10841397 chr12 20063968 T C 9.00E-06 Response to amphetamines / / 22952603 rs7303830 chr12 20135242 G A 2.35E-05 Cognitive test performance / / 20125193 rs2728632 chr12 20146527 C A 6.85E-04 Multiple complex diseases / / 17554300 rs4762911 chr12 20160746 G A 0.0000638 Coronary artery disease / / 23202125 rs10505843 chr12 20168087 T C 2.02E-04 Bone mass and geometry LOC100506393 intron 17903296 rs2579206 chr12 20182733 T A 6.21E-04 Response to taxane treatment (placlitaxel) LOC100506393 intron 23006423 rs2248385 chr12 20186390 A G 8.11E-04 Response to taxane treatment (placlitaxel) LOC100506393 intron 23006423 rs2728553 chr12 20217448 T G 3.85E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) LOC100506393 intron 24023788 rs10770612 chr12 20230639 A G 2.00E-08 Aortic root size LOC100506393 intron 19584346 rs2728547 chr12 20238545 A G 2.90E-06 Urinary metabolites LOC100506393 intron 21572414 rs2579260 chr12 20238866 T C 7.74E-04 Type 2 diabetes LOC100506393 intron 17463246 rs2417849 chr12 20276513 C T 3.36E-04 Depression (quantitative trait) / / 20800221 rs7964046 chr12 20278266 T C 9.39E-04 Depression (quantitative trait) / / 20800221 rs2303658 chr12 20278430 G A 2.46E-04 Depression (quantitative trait) / / 20800221 rs11609944 chr12 20279290 G A 4.79E-04 Depression (quantitative trait) / / 20800221 rs17373317 chr12 20279517 A G 5.79E-04 Depression (quantitative trait) / / 20800221 rs16922688 chr12 20290761 T G 3.44E-04 Schizophrenia / / 19197363 rs10841452 chr12 20295742 A G 7.60E-06 Urinary metabolites / / 21572414 rs1427988 chr12 20313437 A C 0.0000292 Asthma / / 22694930 rs11045107 chr12 20329378 G T 1.54E-04 Type 2 diabetes / / 17463246 rs7131815 chr12 20332220 A G 1.52E-04 Type 2 diabetes / / 17463246 rs7953761 chr12 20332669 G A 1.52E-04 Type 2 diabetes / / 17463246 rs4528416 chr12 20333198 G A 1.52E-04 Type 2 diabetes / / 17463246 rs6487064 chr12 20335697 A C 1.90E-05 Urinary metabolites / / 21572414 rs1030460 chr12 20358213 T C 8.48E-05 Response to hepatitis C treatment / / 19684573 rs10770631 chr12 20368816 A G 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4335623 chr12 20371195 C T 1.68E-05 Multiple complex diseases / / 17554300 rs7976912 chr12 20371594 G A 6.71E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6487068 chr12 20378156 G T 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs16922781 chr12 20418731 C G 7.30E-05 Primary sclerosing cholangitis / / 19944697 rs11045134 chr12 20421735 T C 9.68E-04 Alzheimer's disease / / 22005930 rs10841479 chr12 20425618 C A 8.60E-05 Primary sclerosing cholangitis / / 19944697 rs1593849 chr12 20428407 A G 7.30E-05 Primary sclerosing cholangitis / / 19944697 rs1373571 chr12 20461693 T C 8.38E-04 Type 2 diabetes / / 17463246 rs7134375 chr12 20473758 C A 4.00E-08 HDL cholesterol / / 20686565 rs7134375 chr12 20473758 C A 1.00E-08 HDL cholesterol / / 24097068 rs12812995 chr12 20477874 G C 8.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs10770641 chr12 20480992 C G,T 3.01E-05 Suicide attempts in bipolar disorder / / 21423239 rs10505866 chr12 20496053 C T 4.51E-04 Type 2 diabetes / / 17463246 rs7955516 chr12 20498036 A C 4.00E-08 Adiponectin levels / / 22479202 rs2120757 chr12 20502000 C T 4.16E-04 Smoking initiation / / 24665060 rs12815593 chr12 20504638 C T 2.17E-04 Smoking initiation / / 24665060 rs3943606 chr12 20508037 C T 6.74E-04 Smoking initiation / / 24665060 rs10841495 chr12 20518025 T G 7.07E-04 Smoking initiation / / 24665060 rs10841496 chr12 20521654 C A 5.00E-07 Male infertility PDE3A nearGene-5 19478329 rs10841497 chr12 20524202 G T 1.48E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PDE3A intron 21844884 rs8181710 chr12 20525082 G A 0.0000002 Triglycerides PDE3A intron 23063622 rs11045195 chr12 20526501 C T 4.86E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines PDE3A intron 21844884 rs10743366 chr12 20526626 G A 5.50E-04 Coronary heart disease PDE3A intron 21966275 rs10841498 chr12 20526654 A G 5.31E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PDE3A intron 21844884 rs7306380 chr12 20528692 T C 8.33E-04 Suicide attempts in bipolar disorder PDE3A intron 21423239 rs1899908 chr12 20530097 A G 1.08E-04 Suicide attempts in bipolar disorder PDE3A intron 21423239 rs1348581 chr12 20531641 T C 3.48E-05 Suicide attempts in bipolar disorder PDE3A intron 21423239 rs1348582 chr12 20531756 T C 1.00E-06 QT interval PDE3A intron 20031603 rs1348582 chr12 20531756 T C 5.62E-05 Suicide attempts in bipolar disorder PDE3A intron 21423239 rs10841500 chr12 20533246 A G 1.26E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PDE3A intron 21844884 rs1530446 chr12 20534430 G A 6.86E-05 Suicide attempts in bipolar disorder PDE3A intron 21423239 rs12300264 chr12 20535916 T G 6.56E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines PDE3A intron 21844884 rs4326884 chr12 20536371 G A 7.95E-07 Cisplatin and carboplatin cytotoxicity,in blood cell lines PDE3A intron 21844884 rs4326884 chr12 20536371 G A 8.31E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PDE3A intron 21844884 rs10770645 chr12 20537935 C T 1.10E-05 Suicide attempts in bipolar disorder PDE3A intron 21423239 rs1899909 chr12 20544707 C T 1.74E-05 Suicide attempts in bipolar disorder PDE3A intron 21423239 rs1444642 chr12 20548751 A G 7.88E-06 Suicide attempts in bipolar disorder PDE3A intron 21423239 rs10770648 chr12 20550520 A G 1.49E-05 Suicide attempts in bipolar disorder PDE3A intron 21423239 rs10841506 chr12 20552783 G C 4.28E-06 Suicide attempts in bipolar disorder PDE3A intron 21423239 rs10505865 chr12 20562594 A G 1.40E-04 Volumetric brain MRI PDE3A intron 17903297 rs1444629 chr12 20562907 A G 2.70E-04 Volumetric brain MRI PDE3A intron 17903297 rs1444644 chr12 20565960 T C 8.80E-05 Volumetric brain MRI PDE3A intron 17903297 rs1444645 chr12 20565997 T C 1.80E-04 Volumetric brain MRI PDE3A intron 17903297 rs10770652 chr12 20568884 T A 6.19E-05 Multiple complex diseases PDE3A intron 17554300 rs1444646 chr12 20568949 C T 6.67E-04 Type 2 diabetes PDE3A intron 17463246 rs5014033 chr12 20569438 G A 5.36E-04 Type 2 diabetes PDE3A intron 17463246 rs5014035 chr12 20569511 G A 5.49E-04 Type 2 diabetes PDE3A intron 17463246 rs6487083 chr12 20570099 C A,G 3.92E-04 Type 2 diabetes PDE3A intron 17463246 rs12369443 chr12 20582651 A G 0.000013 Triglycerides PDE3A intron 23063622 rs12426222 chr12 20586640 A T 8.37E-05 Diabetic nephropathy PDE3A intron 21150874 rs12426222 chr12 20586640 A T 2.69E-04 Type 2 diabetes PDE3A intron 22238593 rs10841523 chr12 20588575 G A 4.70E-05 Information processing speed PDE3A intron 21130836 rs10841528 chr12 20597486 A G 1.93E-05 Triglycerides PDE3A intron 19074352 rs10841528 chr12 20597486 A G 1.93E-05 Polyunsaturated fatty acid levels,in plasma PDE3A intron 19148276 rs10841528 chr12 20597486 A G 2.30E-05 Urinary metabolites PDE3A intron 21572414 rs10841530 chr12 20599112 A G 6.00E-07 Systolic blood pressure (alcohol consumption interaction) PDE3A intron 24376456 rs10047560 chr12 20605216 A G 1.35E-07 Diabetic nephropathy PDE3A intron 21150874 rs7304649 chr12 20607266 G A 6.54E-04 Multiple complex diseases PDE3A intron 17554300 rs12311557 chr12 20608723 A G 6.46E-04 HIV-1 viral setpoint PDE3A intron 17641165 rs4762758 chr12 20614659 G A 0.000255825 Hypertension (early onset hypertension) PDE3A intron 22479346 rs11045279 chr12 20636382 A G 2.50E-05 Urinary metabolites PDE3A intron 21572414 rs9971916 chr12 20688641 A T 5.39E-11 HDL cholesterol PDE3A intron 23063622 rs7953797 chr12 20719629 T C 7.69E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PDE3A intron 20031582 rs11045313 chr12 20729965 A G 2.40E-05 Urinary metabolites PDE3A intron 21572414 rs7313422 chr12 20746037 T C 5.34E-11 HDL cholesterol PDE3A intron 23063622 rs11611208 chr12 20758613 G A 2.00E-06 Height PDE3A intron 18391951 rs10770687 chr12 20810511 C T 2.30E-05 Anger PDE3A intron 24489884 rs7137534 chr12 20831777 T C 3.50E-04 Height PDE3A intron 21194676 rs7137534 chr12 20831777 T C 4.30E-07 Height PDE3A intron 21194676 rs7137534 chr12 20831777 T C 5.00E-04 Height PDE3A intron 21194676 rs7137534 chr12 20831777 T C 7.10E-04 Coronary heart disease PDE3A intron 21966275 rs11045392 chr12 20840839 T C 2.00E-06 Response to TNF-alpha inhibitors in rheumatoid arthritis / / 22569225 rs12578492 chr12 20842041 A G 8.77E-04 Coronary Artery Disease / / 17634449 rs10770705 chr12 20857467 A C 8.00E-18 Height SLCO1C1 intron 20881960 rs3794271 chr12 20860093 G A 4.00E-06 Response to TNF-alpha inhibitors in rheumatoid arthritis SLCO1C1 intron 22569225 rs1515777 chr12 20863573 A G 2.23E-04 Height SLCO1C1 intron 17255346 rs1515777 chr12 20863573 A G 5.69E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SLCO1C1 intron 24023788 rs10770712 chr12 20870700 G A 9.12E-05 Multiple complex diseases SLCO1C1 intron 17554300 rs4531518 chr12 20899320 A G 1.54E-05 Serum metabolites SLCO1C1 intron 19043545 rs12371796 chr12 20902288 T C 3.28E-05 Serum metabolites SLCO1C1 intron 19043545 rs972505 chr12 20903235 C A 9.60E-04 Coronary Artery Disease SLCO1C1 intron 17634449 rs972505 chr12 20903235 C A 8.00E-05 Serum metabolites SLCO1C1 intron 19043545 rs972507 chr12 20903520 T C 3.60E-05 Bilirubin levels SLCO1C1 intron 19414484 rs10841614 chr12 20908165 A G 2.80E-06 Bilirubin levels / / 19414484 rs10505869 chr12 20911587 G T 3.00E-06 Bilirubin levels / / 19414484 rs2417859 chr12 20919162 T C 3.20E-06 Bilirubin levels / / 19414484 rs11045455 chr12 20920104 G C 3.20E-06 Bilirubin levels / / 19414484 rs4762781 chr12 20928472 T C 2.80E-06 Bilirubin levels / / 19414484 rs1588918 chr12 20928803 G T 3.10E-06 Bilirubin levels / / 19414484 rs1399936 chr12 20942465 T G 3.30E-05 Bilirubin levels / / 19414484 rs2099368 chr12 20943318 G A 3.10E-05 Bilirubin levels / / 19414484 rs12823467 chr12 20943576 T C 8.30E-07 Bilirubin levels / / 19414484 rs12313384 chr12 20943761 G T 8.00E-07 Bilirubin levels / / 19414484 rs10841642 chr12 20944674 C T 7.30E-07 Bilirubin levels / / 19414484 rs4762785 chr12 20945273 T G 6.70E-07 Bilirubin levels / / 19414484 rs10841644 chr12 20946762 A C 3.80E-06 Bilirubin levels / / 19414484 rs7965380 chr12 20947996 C A 3.40E-06 Bilirubin levels / / 19414484 rs7968656 chr12 20948305 G C 1.00E-04 Multiple complex diseases / / 17554300 rs10841645 chr12 20948734 A C 6.20E-07 Bilirubin levels / / 19414484 rs11045503 chr12 20948776 C T 2.50E-05 Bilirubin levels / / 19414484 rs11045505 chr12 20949446 C T 6.10E-07 Bilirubin levels / / 19414484 rs7309696 chr12 20951307 T C 3.10E-06 Bilirubin levels / / 19414484 rs4141475 chr12 20951861 A C 2.90E-06 Bilirubin levels / / 19414484 rs1002441 chr12 20953580 T G 2.20E-05 Bilirubin levels / / 19414484 rs10841648 chr12 20954557 C A 4.30E-07 Bilirubin levels / / 19414484 rs1588917 chr12 20993935 G A 5.80E-14 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs10841669 chr12 20994327 G C 5.86E-14 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs1515768 chr12 20994485 C A 5.38E-14 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs1829004 chr12 20996156 T C 3.25E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs1399935 chr12 20996213 T C 2.93E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs10770750 chr12 20996305 T A 2.70E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs7305921 chr12 20996932 G T 3.38E-14 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs17674290 chr12 20998109 T G 1.20E-06 Bilirubin levels SLCO1B3 intron 19414484 rs4509820 chr12 20998166 T C 3.38E-14 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs4562873 chr12 20998402 G C 3.38E-14 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs975653 chr12 20998860 C T 5.71E-14 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs975655 chr12 20999068 C T 3.38E-14 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs2033513 chr12 20999635 G C 3.17E-14 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs1304608 chr12 21000586 G A 3.38E-14 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs4762796 chr12 21002349 G A 3.38E-14 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs11494550 chr12 21004952 T C 3.38E-14 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs7303743 chr12 21008498 G T 4.08E-14 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs2900474 chr12 21010048 C T 3.38E-14 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs4149117 chr12 21011480 T G 1 Drug response to Mycophenolate Mofetil SLCO1B3 missense 19890249 rs4149117 chr12 21011480 T G 1 Drug response to Mycophenolic Acid SLCO1B3 missense 19890249 rs4149117 chr12 21011480 T G 1 Drug response to Sirolimus SLCO1B3 missense 19890249 rs4149117 chr12 21011480 T G 1 Drug response to Tacrolimus SLCO1B3 missense 19890249 rs4149117 chr12 21011480 T G 3.38E-14 Bilirubin levels,in serum SLCO1B3 missense 20639394 rs12582527 chr12 21012137 G T 8.68E-05 Cognitive impairment induced by topiramate SLCO1B3 intron 22091778 rs12829162 chr12 21013422 C A 1.10E-06 Bilirubin levels SLCO1B3 intron 19414484 rs1966648 chr12 21013429 G A 3.38E-14 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs3764009 chr12 21013948 C T 3.81E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs3764008 chr12 21014139 C G 3.00E-04 Crohn's disease SLCO1B3 intron 17684544 rs3764007 chr12 21014163 T A 5.10E-04 Crohn's disease SLCO1B3 intron 17684544 rs7306033 chr12 21014178 A G 1.10E-06 Bilirubin levels SLCO1B3 intron 19414484 rs1036261 chr12 21015610 A G 3.25E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs7311358 chr12 21015760 G A 1 Drug response to Cyclosporine SLCO1B3 missense 19890249 rs7311358 chr12 21015760 G A 1 Drug response to Mycophenolate Mofetil SLCO1B3 missense 19890249 rs7311358 chr12 21015760 G A 1 Drug response to Sirolimus SLCO1B3 missense 19890249 rs7311358 chr12 21015760 G A 1 Drug response to Tacrolimus SLCO1B3 missense 19890249 rs17680137 chr12 21015906 C G 1.20E-06 Bilirubin levels SLCO1B3 intron 19414484 rs2417941 chr12 21017796 A G 2.52E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs2417940 chr12 21017875 T C 1.67E-18 Height SLCO1B3 intron 20400458 rs2417940 chr12 21017875 T C 1.67E-18 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs2417940 chr12 21017875 T C 2.00E-16 Bilirubin levels SLCO1B3 intron 23371916 rs2417940 chr12 21017875 T C 5.00E-13 Bilirubin levels SLCO1B3 intron 23371916 rs2417940 chr12 21017875 T C 7.00E-19 Bilirubin levels SLCO1B3 intron 23371916 rs1991849 chr12 21018131 G A 3.54E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs4762686 chr12 21020440 A T 3.91E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs2196028 chr12 21020906 G A 1.42E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs10841684 chr12 21024839 A T 2.35E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs2417939 chr12 21025866 A G 1.79E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs6487171 chr12 21026416 C G 3.57E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs10841686 chr12 21027348 T C 3.14E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs10492339 chr12 21027459 G A 3.37E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs4149132 chr12 21030202 T C 2.51E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs2417938 chr12 21031020 A G 3.96E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs2053095 chr12 21036102 A G 3.37E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs1549967 chr12 21036949 A T 3.61E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs1549968 chr12 21037553 A G 3.37E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs7299670 chr12 21037895 G A 3.10E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs11045580 chr12 21039149 A G 4.85E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs11045581 chr12 21039225 G T 3.37E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs11045582 chr12 21039336 A G 2.05E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs11045583 chr12 21039398 G A 2.69E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs7959792 chr12 21039974 T G 6.82E-13 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs11045585 chr12 21045694 A G 1 Drug response to Docetaxel SLCO1B3 intron 18294295 rs2417886 chr12 21049997 C T 1.10E-06 Bilirubin levels SLCO1B3 intron 19414484 rs7973653 chr12 21051769 T A 1.10E-06 Bilirubin levels SLCO1B3 intron 19414484 rs7970514 chr12 21054664 C T 1.10E-05 Bilirubin levels SLCO1B3 intron 19414484 rs11045595 chr12 21064348 A G 1.34E-15 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs2117031 chr12 21068182 G A 1.34E-15 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs1549970 chr12 21068337 G A 1.34E-15 Bilirubin levels,in serum SLCO1B3 intron 20639394 rs10841707 chr12 21070137 T A 9.75E-04 Alcohol dependence SLCO1B3 nearGene-3 21314694 rs919840 chr12 21070922 G C 4.32E-15 Bilirubin levels,in serum / / 20639394 rs11045598 chr12 21071213 A G 3.20E-07 Bilirubin levels / / 19414484 rs1865159 chr12 21071259 G A 1.34E-15 Bilirubin levels,in serum / / 20639394 rs2117032 chr12 21074122 C T 1.30E-06 Bilirubin levels / / 19414484 rs2117032 chr12 21074122 C T 3.00E-14 Bilirubin levels / / 19419973 rs2117032 chr12 21074122 C T 2.76E-05 Bilirubin levels,in serum / / 20639394 rs2196019 chr12 21076145 G T 1.25E-15 Bilirubin levels,in serum / / 20639394 rs12366506 chr12 21079595 C T 3.40E-07 Bilirubin levels / / 19414484 rs6487177 chr12 21079811 G A 1.34E-15 Bilirubin levels,in serum / / 20639394 rs11045603 chr12 21083394 A G 1.00E-06 Bilirubin levels / / 19414484 rs10841712 chr12 21086383 A G 9.80E-07 Bilirubin levels / / 19414484 rs7137186 chr12 21088345 G A 1.34E-15 Bilirubin levels,in serum / / 20639394 rs11045611 chr12 21099272 A C 2.80E-07 Bilirubin levels / / 19414484 rs987869 chr12 21116055 A T 3.00E-15 Bilirubin levels,in serum / / 20639394 rs4762691 chr12 21116367 A G 1.17E-15 Bilirubin levels,in serum / / 20639394 rs7488975 chr12 21117001 G A 3.00E-15 Bilirubin levels,in serum / / 20639394 rs1910196 chr12 21117213 G A 1.00E-06 Bilirubin levels / / 19414484 rs4762810 chr12 21117696 C G 1.34E-15 Bilirubin levels,in serum / / 20639394 rs10770763 chr12 21118456 T C 1.10E-06 Bilirubin levels / / 19414484 rs11045626 chr12 21118897 A G 3.20E-07 Bilirubin levels / / 19414484 rs11045627 chr12 21119063 C G 3.20E-07 Bilirubin levels / / 19414484 rs7956656 chr12 21123577 A C 7.73E-16 Bilirubin levels,in serum / / 20639394 rs7136226 chr12 21123892 C T 7.73E-16 Bilirubin levels,in serum / / 20639394 rs7294718 chr12 21124197 G A 7.73E-16 Bilirubin levels,in serum / / 20639394 rs7964690 chr12 21125423 G T 7.73E-16 Bilirubin levels,in serum / / 20639394 rs11045630 chr12 21125521 T C 6.00E-07 Bilirubin levels / / 19414484 rs12825142 chr12 21125672 C G 3.70E-07 Bilirubin levels / / 19414484 rs2007379 chr12 21126230 G A 7.73E-16 Bilirubin levels,in serum / / 20639394 rs2900475 chr12 21126482 A T 7.73E-16 Bilirubin levels,in serum / / 20639394 rs11835320 chr12 21134504 C T 7.73E-16 Bilirubin levels,in serum / / 20639394 rs11837932 chr12 21134883 T C 7.73E-16 Bilirubin levels,in serum / / 20639394 rs7976250 chr12 21161868 A G 8.92E-17 Bilirubin levels,in serum / / 20639394 rs6487202 chr12 21165221 A G 1.54E-10 Bilirubin levels,in serum / / 20639394 rs2417873 chr12 21166323 G A 1.50E-09 Bilirubin levels / / 19414484 rs10505870 chr12 21171896 G A 6.21E-05 Rheumatoid arthritis SLCO1B7 intron 17804836 rs7980084 chr12 21222880 A G 6.89E-04 Alcohol dependence SLCO1B7 intron 20201924 rs11045726 chr12 21231767 T C 4.20E-04 Gallstones SLCO1B7 intron 17632509 rs11045752 chr12 21253270 C T 3.70E-05 Bilirubin levels / / 19414484 rs10841750 chr12 21268913 T C 6.99E-04 Type 2 diabetes / / 17463246 rs10841750 chr12 21268913 T C 4.26E-05 Hirschsprung's disease / / 19196962 rs327543 chr12 21275451 A C 4.30E-05 Bilirubin levels / / 19414484 rs852549 chr12 21281889 T G 5.88E-04 Insulin resistance / / 21901158 rs4149014 chr12 21282953 T G 1.73E-05 Multiple complex diseases SLCO1B1 nearGene-5 17554300 rs4149015 chr12 21283322 G A 1 Drug response to Pravastatin SLCO1B1 nearGene-5 15226675 rs4149018 chr12 21291561 T G 1.00E-07 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity SLCO1B1 intron 24324551 rs3829310 chr12 21292056 G A 4.60E-05 Bilirubin levels SLCO1B1 intron 19414484 rs3829306 chr12 21292280 C T 2.00E-04 Cognitive impairment induced by topiramate SLCO1B1 intron 22091778 rs3829306 chr12 21292280 C T 2.84E-05 Paclitaxel-induced neuropathy SLCO1B1 intron 23776197 rs2010668 chr12 21294293 T G 4.70E-05 Bilirubin levels SLCO1B1 intron 19414484 rs10743408 chr12 21296707 C G 4.90E-05 Bilirubin levels SLCO1B1 intron 19414484 rs12582717 chr12 21296806 C G 2.31E-07 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity SLCO1B1 intron 24324551 rs2061903 chr12 21298702 A G 4.90E-05 Bilirubin levels SLCO1B1 intron 19414484 rs11045807 chr12 21317038 A G 7.27E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs10444413 chr12 21317668 T C 3.64E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs4149033 chr12 21317810 A G 6.40E-06 Bilirubin levels SLCO1B1 intron 19414484 rs4149034 chr12 21317922 G A 2.93E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SLCO1B1 intron 24023788 rs11045808 chr12 21318689 G C 2.32E-04 Multiple complex diseases SLCO1B1 intron 17554300 rs10841753 chr12 21321370 T C 7.00E-06 Methotrexate phramacokinetics (acute lymphoblastic leukemia) SLCO1B1 intron 19901119 rs10841753 chr12 21321370 T C 1.89E-06 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045813 chr12 21322056 G A 2.85E-07 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045814 chr12 21322212 T A 3.24E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLCO1B1 intron 22566498 rs12313639 chr12 21322972 G C 3.22E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLCO1B1 intron 22566498 rs11045816 chr12 21323272 A G 2.21E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs2417957 chr12 21323611 C T 3.21E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLCO1B1 intron 22566498 rs2291074 chr12 21325949 A G 3.19E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLCO1B1 intron 22566498 rs4149037 chr12 21328211 A G 3.18E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLCO1B1 intron 22566498 rs4149040 chr12 21328424 G C 1.24E-12 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs17329885 chr12 21328565 T C 6.05E-06 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs4149041 chr12 21328839 G T 3.16E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLCO1B1 intron 22566498 rs2306283 chr12 21329738 A G 1 Drug response to Pravastatin SLCO1B1 missense 11477075 rs2306283 chr12 21329738 A G 1 Drug response to Pravastatin SLCO1B1 missense 15116054 rs2306283 chr12 21329738 A G 1 Drug response to Nateglinide SLCO1B1 missense 18854776 rs2306283 chr12 21329738 A G 1 Drug response to Repaglinide SLCO1B1 missense 18854776 rs2306283 chr12 21329738 A G 1 Drug response to Pravastatin SLCO1B1 missense 19387419 rs2306283 chr12 21329738 A G 1 Drug response to Mycophenolate Mofetil SLCO1B1 missense 19890249 rs2306283 chr12 21329738 A G 1 Drug response to Mycophenolic Acid SLCO1B1 missense 19890249 rs2306283 chr12 21329738 A G 1 Drug response to Sirolimus SLCO1B1 missense 19890249 rs2306283 chr12 21329738 A G 1 Drug response to Tacrolimus SLCO1B1 missense 19890249 rs2306283 chr12 21329738 A G 3.97E-11 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 missense 23233662 rs11045818 chr12 21329761 G A 7.00E-07 Methotrexate phramacokinetics (acute lymphoblastic leukemia) SLCO1B1 cds-synon 19901119 rs11045818 chr12 21329761 G A 2.63E-07 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 cds-synon 23233662 rs11045819 chr12 21329813 C A 1 Drug response to Fluvastatin SLCO1B1 missense 18781850 rs11045819 chr12 21329813 C A 0.000024 LDL cholesterol response after 40mg daily simvastatin treatment SLCO1B1 missense 23100282 rs11045819 chr12 21329813 C A 0.00043 Apolipoprotein B levels response after 40mg daily simvastatin treatment SLCO1B1 missense 23100282 rs11045819 chr12 21329813 C A 3.90E-05 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) SLCO1B1 missense 23103227 rs11045819 chr12 21329813 C A 1.21E-09 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 missense 23233662 rs11045819 chr12 21329813 C A 1.21E-09 Response to antipsychotic treatment SLCO1B1 missense 23241943 rs11045820 chr12 21329991 C T 3.02E-06 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs4149050 chr12 21330988 T C 7.70E-06 Bilirubin levels SLCO1B1 intron 19414484 rs4149050 chr12 21330988 T C 5.52E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs4149051 chr12 21331057 A C,G 6.02E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs4149052 chr12 21331059 A C,G 6.02E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs4149054 chr12 21331179 G A 7.40E-06 Bilirubin levels SLCO1B1 intron 19414484 rs4149056 chr12 21331549 T C 1 Drug response to Statins SLCO1B1 missense 12672737 rs4149056 chr12 21331549 T C 1 Drug response to Pravastatin SLCO1B1 missense 12811365 rs4149056 chr12 21331549 T C 1 Drug response to Simvastatin SLCO1B1 missense 15681900 rs4149056 chr12 21331549 T C 1 Drug response to Pravastatin SLCO1B1 missense 17177112 rs4149056 chr12 21331549 T C 1 Drug response to Nateglinide SLCO1B1 missense 18187595 rs4149056 chr12 21331549 T C 1 Drug response to Repaglinide SLCO1B1 missense 18187595 rs4149056 chr12 21331549 T C 2.00E-09 Response to statin therapy SLCO1B1 missense 18650507 rs4149056 chr12 21331549 T C 1 Drug response to Simvastatin SLCO1B1 missense 18650508 rs4149056 chr12 21331549 T C 1 Drug response to Atorvastatin SLCO1B1 missense 18794729 rs4149056 chr12 21331549 T C 1 Drug response to Fluvastatin SLCO1B1 missense 18794729 rs4149056 chr12 21331549 T C 1 Drug response to Pravastatin SLCO1B1 missense 18794729 rs4149056 chr12 21331549 T C 1 Drug response to Rosuvastatin SLCO1B1 missense 18794729 rs4149056 chr12 21331549 T C 1 Drug response to Simvastatin SLCO1B1 missense 18794729 rs4149056 chr12 21331549 T C 1 Drug response to Simvastatin SLCO1B1 missense 18988647 rs4149056 chr12 21331549 T C 1 Drug response to Atorvastatin SLCO1B1 missense 19374892 rs4149056 chr12 21331549 T C 7.00E-13 Bilirubin levels SLCO1B1 missense 19414484 rs4149056 chr12 21331549 T C 1 Drug response to Statins SLCO1B1 missense 19528564 rs4149056 chr12 21331549 T C 1 Drug response to Atorvastatin SLCO1B1 missense 19833260 rs4149056 chr12 21331549 T C 1 Drug response to Pravastatin SLCO1B1 missense 19833260 rs4149056 chr12 21331549 T C 1 Drug response to Simvastatin SLCO1B1 missense 19833260 rs4149056 chr12 21331549 T C 1 Drug response to Mycophenolate Mofetil SLCO1B1 missense 19890249 rs4149056 chr12 21331549 T C 1 Drug response to Mycophenolic Acid SLCO1B1 missense 19890249 rs4149056 chr12 21331549 T C 1 Drug response to Sirolimus SLCO1B1 missense 19890249 rs4149056 chr12 21331549 T C 1 Drug response to Tacrolimus SLCO1B1 missense 19890249 rs4149056 chr12 21331549 T C 1 Drug response to Simvastatin SLCO1B1 missense 19920157 rs4149056 chr12 21331549 T C 2.00E-08 Sex hormone-binding globulin levels SLCO1B1 missense 22829776 rs4149056 chr12 21331549 T C 0.00000005 LDL cholesterol response after 40mg daily simvastatin treatment SLCO1B1 missense 23100282 rs4149056 chr12 21331549 T C 0.0000001 Apolipoprotein B levels response after 40mg daily simvastatin treatment SLCO1B1 missense 23100282 rs4149056 chr12 21331549 T C 5.00E-08 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) SLCO1B1 missense 23103227 rs4149056 chr12 21331549 T C 4.90E-10 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 missense 23233662 rs4149056 chr12 21331549 T C 4.90E-10 Response to antipsychotic treatment SLCO1B1 missense 23241943 rs4149056 chr12 21331549 T C 0.0000507 Primary sclerosing cholangitis SLCO1B1 missense 23603763 rs4149056 chr12 21331549 T C 1.00E-18 Blood metabolite levels SLCO1B1 missense 24816252 rs4149056 chr12 21331549 T C 1.00E-73 Blood metabolite levels SLCO1B1 missense 24816252 rs4149056 chr12 21331549 T C 3.00E-18 Blood metabolite levels SLCO1B1 missense 24816252 rs4149056 chr12 21331549 T C 3.00E-32 Blood metabolite levels SLCO1B1 missense 24816252 rs4149056 chr12 21331549 T C 6E-315 Blood metabolite levels SLCO1B1 missense 24816252 rs4149056 chr12 21331549 T C 6E-328 Blood metabolite ratios SLCO1B1 missense 24816252 rs4149056 chr12 21331549 T C 9.00E-44 Blood metabolite levels SLCO1B1 missense 24816252 rs4149057 chr12 21331599 T C 1.60E-05 Bilirubin levels SLCO1B1 cds-synon 19414484 rs2291075 chr12 21331625 C T 1.76E-09 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 cds-synon 23233662 rs11045821 chr12 21332423 G A 2.44E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs4149058 chr12 21333214 A G 6.40E-06 Bilirubin levels SLCO1B1 intron 19414484 rs2169970 chr12 21333340 G A 2.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs1000691 chr12 21333426 G A 3.18E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLCO1B1 intron 22566498 rs1000691 chr12 21333426 G A 8.11E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SLCO1B1 intron 24023788 rs11045823 chr12 21333745 G A 1.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045824 chr12 21333912 G T 1.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045825 chr12 21334010 T C 8.79E-04 Multiple complex diseases SLCO1B1 intron 17554300 rs11045825 chr12 21334010 T C 1.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs4149059 chr12 21334227 C T 3.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs12819994 chr12 21334369 G C 1.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs12821068 chr12 21334387 T C 1.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs12821228 chr12 21334461 T A 1.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs56148886 chr12 21334570 T C 3.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045826 chr12 21334599 T C 1.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs4381410 chr12 21334970 C T 1.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs1564369 chr12 21335290 T G 6.84E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs1564367 chr12 21335392 A C 6.84E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs2169969 chr12 21335454 T C 6.84E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs1564366 chr12 21335749 G C 3.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs74544495 chr12 21335883 T C 7.01E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs2417961 chr12 21335949 A G 1.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs2900476 chr12 21336063 C T 4.70E-06 Bilirubin levels SLCO1B1 intron 19414484 rs79304409 chr12 21336085 C G 6.84E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs80349167 chr12 21336144 A G 4.68E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs2417965 chr12 21336157 C T 3.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs80125989 chr12 21336181 G A 6.84E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs71446755 chr12 21336447 G A 6.84E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs12368356 chr12 21337171 C A 6.84E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs7485550 chr12 21337611 C A 6.84E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs1002552 chr12 21337981 A T 1.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs35406304 chr12 21338284 T C 2.28E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs76835577 chr12 21339258 G A 4.54E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs1120964 chr12 21339690 C T 2.96E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLCO1B1 intron 22566498 rs35236625 chr12 21339823 G A 4.54E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045831 chr12 21340398 T C 4.73E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045833 chr12 21340507 G A 1.48E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs35157563 chr12 21340856 G A 4.54E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs35928112 chr12 21340863 T C 6.72E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs34888642 chr12 21341006 A G 6.72E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs73079476 chr12 21343833 A C 1.50E-09 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs67981690 chr12 21343886 A G 1.50E-09 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045842 chr12 21346140 C A,T 6.65E-06 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045843 chr12 21346141 G T 1.48E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs12367888 chr12 21347021 G A,T 1.08E-07 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs12371570 chr12 21347351 A C 1.48E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs1871395 chr12 21352315 A G 1.90E-12 Bilirubin levels SLCO1B1 intron 19414484 rs1871395 chr12 21352315 A G 4.86E-10 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs1871395 chr12 21352315 A G 1.00E-89 Blood metabolite levels SLCO1B1 intron 24816252 rs1871395 chr12 21352315 A G 2.00E-52 Blood metabolite levels SLCO1B1 intron 24816252 rs1871395 chr12 21352315 A G 4.00E-31 Blood metabolite levels SLCO1B1 intron 24816252 rs12317268 chr12 21352541 A G 1.90E-12 Bilirubin levels SLCO1B1 intron 19414484 rs12317268 chr12 21352541 A G 2.43E-09 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs12317268 chr12 21352541 A G 2.00E-45 Blood metabolite levels SLCO1B1 intron 24816252 rs12317268 chr12 21352541 A G 2.00E-67 Blood metabolite levels SLCO1B1 intron 24816252 rs12317268 chr12 21352541 A G 4.00E-60 Blood metabolite levels SLCO1B1 intron 24816252 rs11045858 chr12 21352671 A G 1.39E-04 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs4149067 chr12 21353911 C G 1.63E-09 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs58310495 chr12 21357711 C T 8.15E-10 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs56165099 chr12 21357731 C T 1.21E-08 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs55695203 chr12 21357753 G C 1.74E-10 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs12427008 chr12 21357948 T C 2.35E-04 Insulin resistance SLCO1B1 intron 21901158 rs2417967 chr12 21360735 G A 3.14E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLCO1B1 intron 22566498 rs77289848 chr12 21360761 G A 7.87E-11 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs73063122 chr12 21361213 A C 3.96E-11 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045862 chr12 21361584 A G 1.45E-06 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045863 chr12 21361868 C T 2.78E-07 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs58258204 chr12 21368015 C T 3.62E-11 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs4363657 chr12 21368722 T C 8.60E-13 Bilirubin levels SLCO1B1 intron 19414484 rs4363657 chr12 21368722 T C 5.00E-08 Bilirubin levels SLCO1B1 intron 21646302 rs4363657 chr12 21368722 T C 1.65E-10 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs2900478 chr12 21368797 T A 8.50E-13 Bilirubin levels SLCO1B1 intron 19414484 rs2900478 chr12 21368797 T A 9.64E-10 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs71446760 chr12 21369560 C T 1.45E-06 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045870 chr12 21371075 G A 8.94E-07 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045871 chr12 21372224 A G 1.89E-07 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045872 chr12 21372344 A G 1.36E-06 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs10841761 chr12 21374219 G C 1.89E-07 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs71446761 chr12 21374464 C T 1.45E-06 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs74690297 chr12 21374603 C G 1.89E-07 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs987839 chr12 21374838 A G 4.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLCO1B1 intron 20877124 rs987839 chr12 21374838 A G 0.00000319 Aging SLCO1B1 intron 22445811 rs11045873 chr12 21375061 T A 7.13E-06 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045874 chr12 21375063 G C 9.03E-06 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs12814646 chr12 21377497 C A 1.89E-07 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs4149080 chr12 21377559 G C 6.00E-21 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs4149081 chr12 21378021 G A 5.29E-04 Multiple complex diseases SLCO1B1 intron 17554300 rs4149081 chr12 21378021 G A 7.60E-13 Bilirubin levels SLCO1B1 intron 19414484 rs4149081 chr12 21378021 G A 3.00E-22 Metabolic traits SLCO1B1 intron 21886157 rs4149081 chr12 21378021 G A 1.05E-09 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs7966613 chr12 21379632 A G 9.00E-06 Bilirubin levels SLCO1B1 intron 19414484 rs78252685 chr12 21379910 A G 1.45E-06 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs75355229 chr12 21379930 C A 1.45E-06 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs58487503 chr12 21379980 G A 1.31E-10 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs4149083 chr12 21380630 A T 8.65E-10 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs12369359 chr12 21381191 T G 1.33E-09 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs80267902 chr12 21381270 A G 1.45E-06 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045878 chr12 21382222 A G 8.60E-06 Bilirubin levels SLCO1B1 intron 19414484 rs10841763 chr12 21382342 T C 1.00E-05 Bilirubin levels SLCO1B1 intron 19414484 rs11045879 chr12 21382619 T C 3.29E-04 Multiple complex diseases SLCO1B1 intron 17554300 rs11045879 chr12 21382619 T C 7.80E-13 Bilirubin levels SLCO1B1 intron 19414484 rs11045879 chr12 21382619 T C 8.00E-11 Methotrexate phramacokinetics (acute lymphoblastic leukemia) SLCO1B1 intron 19901119 rs11045879 chr12 21382619 T C 6.23E-11 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045879 chr12 21382619 T C 5.00E-15 Metabolite levels SLCO1B1 intron 23281178 rs717958 chr12 21382730 T G 3.58E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLCO1B1 intron 22566498 rs7137060 chr12 21382830 C T 4.98E-07 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045884 chr12 21384382 G C 1.89E-07 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs10841766 chr12 21385248 G A 1.89E-07 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs7969341 chr12 21385604 A G 2.60E-12 Bilirubin levels SLCO1B1 intron 19414484 rs7969341 chr12 21385604 A G 1.37E-10 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045885 chr12 21386018 A G 2.60E-12 Bilirubin levels SLCO1B1 intron 19414484 rs11045885 chr12 21386018 A G 6.35E-11 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs10841767 chr12 21386061 A G 1.89E-07 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs10841768 chr12 21386096 A C 1.89E-07 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045886 chr12 21386493 A C 2.92E-10 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs11045887 chr12 21387478 C G 4.43E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs12829704 chr12 21388621 G A 9.00E-21 Blood metabolite levels SLCO1B1 intron 24816252 rs73067080 chr12 21388829 T C 1.31E-10 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 intron 23233662 rs12371604 chr12 21391336 T C 2.20E-09 Bilirubin levels SLCO1B1 intron 19414484 rs12371604 chr12 21391336 T C 3.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLCO1B1 intron 20877124 rs12369881 chr12 21391352 G A 4.40E-11 Bilirubin levels SLCO1B1 intron 19414484 rs12366582 chr12 21391608 A G 4.40E-11 Bilirubin levels SLCO1B1 intron 19414484 rs11045892 chr12 21392794 A G 3.76E-07 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1B1 nearGene-3 23233662 rs12372157 chr12 21393018 T G 3.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLCO1B1 nearGene-3 20877124 rs9804732 chr12 21404321 G T 7.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7975087 chr12 21404832 A C 6.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2417970 chr12 21412734 T C 3.68E-05 Bilirubin levels,in serum / / 19389676 rs2199680 chr12 21415496 A T 7.70E-11 Bilirubin levels / / 19414484 rs10841780 chr12 21418143 C T 1.86E-05 Cognitive impairment induced by topiramate SLCO1A2 UTR-3 22091778 rs4149000 chr12 21447997 C T 2.70E-08 Bilirubin levels SLCO1A2 intron 19414484 rs4149000 chr12 21447997 C T 1.78E-05 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1A2 intron 23233662 rs16923647 chr12 21451395 C T 4.10E-08 Bilirubin levels SLCO1A2 intron 19414484 rs16923647 chr12 21451395 C T 2.00E-06 Methotrexate phramacokinetics (acute lymphoblastic leukemia) SLCO1A2 intron 19901119 rs16923647 chr12 21451395 C T 1.09E-06 Methotrexate clearance (acute lymphoblastic leukemia) SLCO1A2 intron 23233662 rs11568563 chr12 21457434 T G 1 Drug response to Conjugated Estrogens SLCO1A2 missense 19940846 rs11568563 chr12 21457434 T G 1 Drug response to Methotrexate SLCO1A2 missense 19940846 rs11568563 chr12 21457434 T G 7.00E-08 Progressive supranuclear palsy SLCO1A2 missense 21685912 rs11568564 chr12 21457448 G A 1 Drug response to Conjugated Estrogens SLCO1A2 missense 19940846 rs11568564 chr12 21457448 G A 1 Drug response to Methotrexate SLCO1A2 missense 19940846 rs10770803 chr12 21513827 C T 0.0000277 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SLCO1A2 intron 23233654 rs12824228 chr12 21514616 G A 2.25E-04 Acute lung injury SLCO1A2 intron 22295056 rs11046043 chr12 21588168 T C 1.90E-04 Obesity (extreme) / / 21935397 rs11046048 chr12 21592200 A C 1.90E-04 Obesity (extreme) PYROXD1 intron 21935397 rs7309377 chr12 21592893 A G 1.89E-04 Obesity (extreme) PYROXD1 intron 21935397 rs10841813 chr12 21597866 G A 1.80E-04 Obesity (extreme) PYROXD1 intron 21935397 rs11046061 chr12 21600952 C T 1.76E-04 Obesity (extreme) PYROXD1 intron 21935397 rs10841814 chr12 21603429 C A 1.73E-04 Obesity (extreme) PYROXD1 intron 21935397 rs11046075 chr12 21621419 C A 2.33E-04 Obesity (extreme) PYROXD1 intron 21935397 rs1029931 chr12 21629313 T C 4.56E-05 Hodgkin's lymphoma RECQL intron 24149102 rs2192170 chr12 21633036 C T 6.83E-04 Obesity (extreme) RECQL intron 21935397 rs7307064 chr12 21634394 A C 5.90E-04 Suicidal ideation RECQL intron 22030708 rs11046081 chr12 21641177 T A 5.47E-04 Obesity (extreme) RECQL intron 21935397 rs4762703 chr12 21644822 G A 5.55E-04 Obesity (extreme) RECQL intron 21935397 rs1061627 chr12 21654407 G A 7.24E-04 Response to taxane treatment (placlitaxel) RECQL UTR-5 23006423 rs1060126 chr12 21654831 G T 5.53E-04 Response to taxane treatment (placlitaxel) GOLT1B UTR-5 23006423 rs2417995 chr12 21690377 A C 0.000076 Polycystic ovary syndrome GYS2 intron 22951595 rs10841842 chr12 21690774 A T 0.000076 Polycystic ovary syndrome GYS2 intron 22951595 rs10841843 chr12 21691891 T C 0.0000802 Polycystic ovary syndrome GYS2 intron 22951595 rs10841843 chr12 21691891 T C 8.02E-05 Intracranial aneurysm GYS2 intron 22961961 rs10492118 chr12 21691958 C T 6.08E-04 Lymphocyte counts GYS2 intron 22286170 rs10492118 chr12 21691958 C T 0.0000971 Polycystic ovary syndrome GYS2 intron 22951595 rs1871130 chr12 21692949 A G 0.0000932 Polycystic ovary syndrome GYS2 intron 22951595 rs1871129 chr12 21693243 A T 0.0000932 Polycystic ovary syndrome GYS2 intron 22951595 rs200581306 chr12 21693243 AT A 0.0000932 Polycystic ovary syndrome GYS2 intron 22951595 rs1871128 chr12 21693244 T A 0.0000932 Polycystic ovary syndrome GYS2 intron 22951595 rs1904121 chr12 21699508 T C 0.0000308 Polycystic ovary syndrome GYS2 intron 22951595 rs6487236 chr12 21699916 G A 0.0000697 Polycystic ovary syndrome GYS2 intron 22951595 rs6487237 chr12 21699928 C A 4.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GYS2 intron 20877124 rs6487237 chr12 21699928 C A 0.0000814 Polycystic ovary syndrome GYS2 intron 22951595 rs6487238 chr12 21699939 G A 4.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GYS2 intron 20877124 rs6487238 chr12 21699939 G A 0.0000697 Polycystic ovary syndrome GYS2 intron 22951595 rs7962754 chr12 21700495 T G 0.0000697 Polycystic ovary syndrome GYS2 intron 22951595 rs1580300 chr12 21701150 T A 0.0000697 Polycystic ovary syndrome GYS2 intron 22951595 rs2126885 chr12 21701437 C T 0.0000697 Polycystic ovary syndrome GYS2 intron 22951595 rs7485509 chr12 21702005 C T 0.0000697 Polycystic ovary syndrome GYS2 intron 22951595 rs7485489 chr12 21702020 A T 0.0000697 Polycystic ovary syndrome GYS2 intron 22951595 rs2169745 chr12 21702503 G C 0.0000697 Polycystic ovary syndrome GYS2 intron 22951595 rs10505873 chr12 21728345 T C 7.19E-04 Response to taxane treatment (placlitaxel) GYS2 intron 23006423 rs11046127 chr12 21731522 C T 1.02E-04 Asthma GYS2 intron 23181788 rs192210 chr12 21767975 G A 8.44E-04 Rheumatoid arthritis / / 21452313 rs852816 chr12 21849348 T C 2.20E-05 Urinary metabolites / / 21572414 rs11046166 chr12 21853012 G A 9.90E-05 Response to statin therapy / / 20339536 rs11046170 chr12 21857409 G T 9.90E-05 Response to statin therapy / / 20339536 rs860447 chr12 21858180 C T 8.70E-05 Response to statin therapy / / 20339536 rs852815 chr12 21864067 T C 4.90E-05 Response to statin therapy / / 20339536 rs10841886 chr12 21864377 T C 5.00E-05 Response to statin therapy / / 20339536 rs10841887 chr12 21869015 T C 4.80E-05 Response to statin therapy / / 20339536 rs10841888 chr12 21869178 A G 4.90E-05 Response to statin therapy / / 20339536 rs1586844 chr12 21869672 A G 4.90E-05 Response to statin therapy / / 20339536 rs12816929 chr12 21870169 T C 5.00E-05 Response to statin therapy / / 20339536 rs11046171 chr12 21870385 T C 5.20E-05 Response to statin therapy / / 20339536 rs11046171 chr12 21870385 T C 5.04E-04 Rheumatoid arthritis / / 21452313 rs11046172 chr12 21870424 C G 5.20E-05 Response to statin therapy / / 20339536 rs11046173 chr12 21871046 A G 5.50E-05 Response to statin therapy / / 20339536 rs10841889 chr12 21871510 T A 5.70E-05 Response to statin therapy / / 20339536 rs11046174 chr12 21873492 T G 6.20E-05 Response to statin therapy / / 20339536 rs10841891 chr12 21878493 T G 6.40E-05 Response to statin therapy / / 20339536 rs704169 chr12 21889725 G A 4.10E-05 Response to statin therapy / / 20339536 rs10841892 chr12 21894542 C G 6.10E-05 Response to statin therapy / / 20339536 rs11046181 chr12 21897616 A G 6.50E-05 Response to statin therapy / / 20339536 rs10841893 chr12 21910795 C G 8.70E-05 Response to statin therapy / / 20339536 rs10770860 chr12 21936383 A G 6.22E-04 Type 2 diabetes / / 17463246 rs10770860 chr12 21936383 A G 0.0007423 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10770860 chr12 21936383 A G 7.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11046186 chr12 21938544 G T 0.0007435 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11046186 chr12 21938544 G T 7.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs829064 chr12 21940508 T C 8.20E-05 Response to statin therapy / / 20339536 rs829060 chr12 21958399 G C 3.80E-04 Type 2 diabetes ABCC9 intron 17463246 rs4148679 chr12 21966701 T C 7.50E-05 Response to statin therapy ABCC9 intron 20339536 rs9668454 chr12 21969436 T C 6.30E-05 Response to statin therapy ABCC9 intron 20339536 rs2638441 chr12 21970019 C T 8.30E-05 Response to statin therapy ABCC9 intron 20339536 rs7309274 chr12 21972305 T C 5.80E-05 Response to statin therapy ABCC9 intron 20339536 rs2726120 chr12 21975420 G C 6.10E-05 Response to statin therapy ABCC9 intron 20339536 rs4148677 chr12 21976428 C T 2.26E-05 Ulcerative colitis ABCC9 intron 24837172 rs12369421 chr12 21992297 G A 1.55E-05 Sleep duration ABCC9 intron 22105623 rs12371172 chr12 21992315 T A 1.48E-05 Sleep duration ABCC9 intron 22105623 rs11046205 chr12 21992326 G A 2.78E-09 Sleep duration ABCC9 intron 22105623 rs704178 chr12 21993478 G C 1.00E-09 Hippocampal sclerosis of aging ABCC9 intron 24770881 rs11046206 chr12 21993532 G A 1.38E-05 Sleep duration ABCC9 intron 22105623 rs11046207 chr12 21996045 T C 1.43E-05 Sleep duration ABCC9 intron 22105623 rs11046207 chr12 21996045 T C 5.00E-06 Obesity-related traits ABCC9 intron 23251661 rs11046209 chr12 21996966 A T 1.42E-05 Sleep duration ABCC9 intron 22105623 rs2307026 chr12 21997121 G C 1.36E-05 Sleep duration ABCC9 intron 22105623 rs829080 chr12 21999863 C T 6.13E-04 Tourette syndrome ABCC9 intron 22889924 rs11046211 chr12 22003722 C T 9.90E-06 Sleep duration ABCC9 intron 22105623 rs2161063 chr12 22008941 A G 8.60E-06 Recombination rate ABCC9 intron 21698098 rs4148665 chr12 22035247 A G 8.80E-06 Parkinson's disease (familial) ABCC9 intron 18985386 rs7137730 chr12 22039180 G T 1.50E-05 Urinary metabolites ABCC9 intron 21572414 rs7138546 chr12 22039987 C T 1.50E-05 Urinary metabolites ABCC9 intron 21572414 rs704209 chr12 22042560 C A 3.63E-05 Blood pressure (response to angiotensin II receptor blocker) ABCC9 intron 24192120 rs2131136 chr12 22042621 G T 1.20E-05 Urinary metabolites ABCC9 intron 21572414 rs1283807 chr12 22042740 A G 3.63E-05 Blood pressure (response to angiotensin II receptor blocker) ABCC9 intron 24192120 rs1914361 chr12 22045853 A G 7.13E-05 Cognitive impairment induced by topiramate ABCC9 intron 22091778 rs704217 chr12 22047174 C T 1.50E-05 Urinary metabolites ABCC9 intron 21572414 rs10841907 chr12 22051296 T G 1.10E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy ABCC9 intron 23834954 rs4148654 chr12 22063971 A G 2.80E-06 Systemic lupus erythematosus and Systemic sclerosis ABCC9 intron 23740937 rs11046238 chr12 22092921 A G 4.00E-04 Dilated cardiomyopathy / / 20975947 rs2138722 chr12 22097831 G T 3.47E-04 Multiple complex diseases / / 17554300 rs10743428 chr12 22105568 T C 4.72E-04 Alcohol dependence / / 21314694 rs10743428 chr12 22105568 T C 2.90E-05 Urinary metabolites / / 21572414 rs10743430 chr12 22151573 C T 6.00E-07 Entorhinal cortical thickness / / 21116278 rs2955503 chr12 22198865 G A 0.0000334 Asthma / / 22694930 rs11046274 chr12 22200916 A G 1.06E-04 Aortic root size CMAS intron 21223598 rs7135160 chr12 22239298 G A 4.08E-04 Alzheimer's disease (late onset) / / 21379329 rs17644034 chr12 22239819 T C 4.46E-04 Acute lung injury / / 22295056 rs11046298 chr12 22244188 A C 7.29E-04 Alzheimer's disease / / 24755620 rs7962600 chr12 22244599 C G 7.41E-04 Alzheimer's disease / / 24755620 rs7962880 chr12 22244635 G A 7.41E-04 Alzheimer's disease / / 24755620 rs7962622 chr12 22244696 A G 6.98E-04 Alzheimer's disease / / 24755620 rs2909075 chr12 22263219 C T 6.84E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6487283 chr12 22263613 T G 1.42E-04 Multiple complex diseases / / 17554300 rs7955550 chr12 22267297 G T 4.04E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7968893 chr12 22281269 C A 8.48E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1861710 chr12 22284919 G A 9.36E-05 Serum metabolites / / 19043545 rs11046324 chr12 22309411 A G 6.47E-04 Multiple complex diseases / / 17554300 rs10841963 chr12 22310865 A G 8.25E-04 Multiple complex diseases / / 17554300 rs11046327 chr12 22318014 G A 6.95E-04 Insulin resistance / / 21901158 rs2216228 chr12 22365835 T C 4.00E-06 Non-alcoholic fatty liver disease histology (lobular) ST8SIA1 intron 20708005 rs722248 chr12 22367073 G A 3.06E-05 Lactate dehydrogenase levels ST8SIA1 intron 20981236 rs7310117 chr12 22386556 T A 1.10E-05 Urinary metabolites ST8SIA1 intron 21572414 rs2900501 chr12 22387507 C T 6.00E-06 Urinary metabolites ST8SIA1 intron 21572414 rs4762894 chr12 22387764 A G 3.71E-04 Multiple complex diseases ST8SIA1 intron 17554300 rs1558793 chr12 22388543 T C 1.10E-05 Urinary metabolites ST8SIA1 intron 21572414 rs2268861 chr12 22389474 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) ST8SIA1 intron 20708005 rs2216231 chr12 22453936 C T 4.10E-05 Response to statin therapy ST8SIA1 intron 20339536 rs11830582 chr12 22454567 A G 3.80E-05 Response to statin therapy ST8SIA1 intron 20339536 rs11046362 chr12 22460338 G A 4.20E-05 Response to statin therapy ST8SIA1 intron 20339536 rs2900502 chr12 22471047 C T 2.36E-05 Personality dimensions ST8SIA1 intron 22628180 rs2728822 chr12 22472695 A C 2.01E-05 Personality dimensions ST8SIA1 intron 22628180 rs2541300 chr12 22474960 G T 1.69E-04 Attention deficit hyperactivity disorder ST8SIA1 intron 22420046 rs2728827 chr12 22476044 G A 4.20E-05 Body Composition ST8SIA1 intron pha003012 rs2728827 chr12 22476044 G A 7.72E-05 Body Mass Index ST8SIA1 intron pha003021 rs12228077 chr12 22543499 G T 3.76E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs11046430 chr12 22566429 C T 4.00E-06 Coronary artery calcification / / 23870195 rs16924949 chr12 22569681 A G 2.88E-05 Type 2 diabetes / / 17463246 rs12320963 chr12 22618605 G T 2.02E-04 Lung function (forced vital capacity) KIAA0528 intron 24023788 rs7296372 chr12 22626071 T C 0.0000336 Carotid intima media thickness KIAA0528 intron 23152477 rs10505879 chr12 22647856 G T 3.06E-05 Cardiovascular disease KIAA0528 intron 17903304 rs10505881 chr12 22674870 C G 6.09E-04 Bipolar disorder KIAA0528 intron 19259986 rs7297546 chr12 22788773 G T 1.53E-19 Multiple complex diseases ETNK1 intron 17554300 rs2271097 chr12 22837282 A G 2.10E-05 Urinary metabolites ETNK1 intron 21572414 rs2271097 chr12 22837282 A G 5.81E-04 Alzheimer's disease ETNK1 intron 24755620 rs901625 chr12 22856575 G T 2.20E-05 Urinary metabolites / / 21572414 rs7307976 chr12 22866944 A C 6.88E-04 Alzheimer's disease / / 17998437 rs7311822 chr12 22867619 C T 4.57E-05 Alzheimer's disease / / 17998437 rs7979865 chr12 22868165 C T 2.31E-04 Alzheimer's disease / / 17998437 rs7980208 chr12 22868305 G A 3.62E-04 Alzheimer's disease / / 17998437 rs1542684 chr12 22883930 T C 8.42E-05 Lipid levels / / pha003082 rs17350791 chr12 22884476 T C 4.87E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs12816749 chr12 22884721 G A 7.63E-04 Type 2 diabetes / / 17463246 rs4533092 chr12 22887438 G C 3.11E-04 Multiple complex diseases / / 17554300 rs4533092 chr12 22887438 G C 7.80E-05 Hematology traits / / 23303382 rs2726336 chr12 22892059 C T 7.91E-05 Cognitive impairment induced by topiramate / / 22091778 rs2171392 chr12 22906325 C T 7.94E-05 Type 2 diabetes / / 17463246 rs11046592 chr12 22915342 C T 9.41E-04 Type 2 diabetes / / 17463246 rs11046592 chr12 22915342 C T 1.40E-05 Urinary metabolites / / 21572414 rs10770927 chr12 22915363 G A 7.75E-05 Type 2 diabetes / / 17463246 rs10505888 chr12 22945808 G A 2.89E-04 Lung function (forced vital capacity) / / 24023788 rs2418082 chr12 22960127 C T 0.000284522 Hypertension (early onset hypertension) / / 22479346 rs12581238 chr12 22976813 T C 3.85E-05 Leukocyte Counts / / pha003091 rs17175003 chr12 22985151 C T 2.28E-04 Multiple complex diseases / / 17554300 rs17175038 chr12 22988106 G T 1.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs2466966 chr12 22988849 T C 3.88E-04 Smoking initiation / / 24665060 rs2466887 chr12 22989382 C T 6.14E-05 Smoking initiation / / 24665060 rs1365703 chr12 22994150 T C 3.95E-04 Smoking initiation / / 24665060 rs2433632 chr12 22994828 T G 3.76E-05 Blood pressure / / 17255346 rs16925469 chr12 22997986 A G 8.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs11046650 chr12 23000207 A G 3.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs1863657 chr12 23000966 T C 2.15E-04 Coronary heart disease / / 21606135 rs1863656 chr12 23001016 A G 3.35E-05 Lung adenocarcinoma / / 19836008 rs1863656 chr12 23001016 A G 6.29E-04 Smoking quantity / / 24665060 rs2467458 chr12 23004397 G A 6.66E-05 Lung adenocarcinoma / / 19836008 rs10842083 chr12 23014998 A G 1.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs10842083 chr12 23014998 A G 2.68E-04 Smoking initiation / / 24665060 rs11046688 chr12 23075354 G A 4.39E-05 Diabetic nephropathy / / pha002864 rs12815688 chr12 23088867 C T 4.91E-06 Personality dimensions / / 21173776 rs4964061 chr12 23091991 C T 9.29E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs12809316 chr12 23117397 T G 8.68E-06 Personality dimensions / / 21173776 rs11046719 chr12 23141333 C T 7.81E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4964062 chr12 23148062 A C 3.87E-04 Smoking quantity / / 24665060 rs3913142 chr12 23150568 C A 4.30E-04 Smoking quantity / / 24665060 rs7970197 chr12 23154869 A G 2.83E-04 Smoking quantity / / 24665060 rs12816878 chr12 23155705 C T 4.55E-04 Smoking quantity / / 24665060 rs3847894 chr12 23156102 G T 5.76E-04 Smoking quantity / / 24665060 rs3847899 chr12 23172273 G A 9.83E-05 Coronary heart disease / / pha003035 rs11046743 chr12 23182965 A G 8.15E-05 Coronary heart disease / / pha003035 rs3913141 chr12 23193102 G A 9.73E-05 Alcohol dependence / / 19581569 rs10770944 chr12 23206406 A G 4.84E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10842120 chr12 23258003 G A 4.44E-04 Multiple complex diseases / / 17554300 rs10842120 chr12 23258003 G A 7.21E-05 Serum metabolites / / 19043545 rs17459026 chr12 23259999 T C 2.70E-04 Multiple complex diseases / / 17554300 rs17459026 chr12 23259999 T C 6.26E-05 Serum metabolites / / 19043545 rs17361720 chr12 23261612 T C 2.50E-04 Multiple complex diseases / / 17554300 rs17361720 chr12 23261612 T C 3.13E-05 Serum metabolites / / 19043545 rs17361776 chr12 23261653 T G 8.62E-05 Multiple complex diseases / / 17554300 rs17361776 chr12 23261653 T G 1.04E-05 Serum metabolites / / 19043545 rs11046795 chr12 23262095 C G 7.75E-05 Multiple complex diseases / / 17554300 rs11046795 chr12 23262095 C G 1.29E-05 Serum metabolites / / 19043545 rs10842122 chr12 23265863 T C 2.27E-04 Multiple complex diseases / / 17554300 rs10842122 chr12 23265863 T C 8.64E-04 Alzheimer's disease / / 17998437 rs10842122 chr12 23265863 T C 9.42E-06 Serum metabolites / / 19043545 rs10466798 chr12 23271777 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11046841 chr12 23328320 G A 2.00E-04 Information processing speed / / 21130836 rs17365493 chr12 23381488 T C 9.54E-05 Elbow pain / / pha003008 rs2218451 chr12 23548797 A C 0.000295 Salmonella-induced pyroptosis / / 22837397 rs2218451 chr12 23548797 A C 5.21E-05 Height / / pha003011 rs12422695 chr12 23553422 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2120771 chr12 23639917 A G 3.00E-06 Economic and political preferences (feminism/equality) / / 22566634 rs10770998 chr12 23665984 A T 3.63E-06 Stroke (ischemic) / / 22941190 rs10842176 chr12 23674257 G A 4.91E-06 Alcohol dependence / / 23089632 rs10842176 chr12 23674257 G A 4.81E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1899919 chr12 23676440 G A 3.55E-06 Stroke (ischemic) / / 22941190 rs10505892 chr12 23678552 G A 2.87E-04 Body mass index / / 17255346 rs9737974 chr12 23679273 T C 4.70E-06 Stroke (ischemic) / / 22941190 rs11612157 chr12 23698236 C T 8.40E-04 Myopia (pathological) SOX5 intron 21095009 rs4246217 chr12 23698352 C T 4.68E-05 Multiple complex diseases SOX5 intron 17554300 rs4246218 chr12 23698387 C G 1.92E-04 Multiple complex diseases SOX5 intron 17554300 rs4559766 chr12 23714022 T C 8.28E-04 HIV-1 viral setpoint SOX5 intron 17641165 rs4559766 chr12 23714022 T C 2.34E-05 Orofacial clefts SOX5 intron 20023658 rs7972005 chr12 23725705 T G 1.56E-05 Platelet counts SOX5 intron pha003100 rs10842183 chr12 23733442 G A 6.05E-08 Corneal structure SOX5 intron 22003120 rs12231481 chr12 23739437 C T 5.95E-04 Myopia (pathological) SOX5 intron 21095009 rs10771005 chr12 23744650 G A 3.91E-04 Suicide attempts in bipolar disorder SOX5 intron 21423239 rs6487350 chr12 23746430 G A 3.52E-05 Hematocrit SOX5 intron pha003097 rs16926452 chr12 23764620 G A 7.26E-04 Multiple complex diseases SOX5 intron 17554300 rs10505896 chr12 23770330 T C 6.51E-04 Multiple complex diseases SOX5 intron 17554300 rs10505899 chr12 23793205 G A 4.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) SOX5 intron 17982456 rs973588 chr12 23828139 T C 8.85E-04 Type 2 diabetes SOX5 intron 17463246 rs1382826 chr12 23859015 A G 5.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SOX5 intron 20877124 rs10771021 chr12 23875372 T C 3.64E-04 Oral cancers (chewing tobacco related) SOX5 intron 22503698 rs7295342 chr12 23879554 A G 8.83E-04 Oral cancers (chewing tobacco related) SOX5 intron 22503698 rs7295342 chr12 23879554 A G 1.94E-05 Amyotrophic lateral sclerosis (sporadic) SOX5 intron 24529757 rs10505904 chr12 23884513 G A 7.53E-05 Body Mass Index SOX5 intron pha003021 rs4432100 chr12 23936823 C T 1.58E-04 Multiple complex diseases SOX5 intron 17554300 rs4362223 chr12 23937856 A G 9.69E-05 Adipocyte fatty acid-binding protein concentration,in serum SOX5 intron 21863005 rs11047102 chr12 23946146 C T 1.38E-04 Type 2 diabetes SOX5 intron 17463246 rs11047102 chr12 23946146 C T 1.00E-07 Systemic sclerosis SOX5 intron 21779181 rs11047102 chr12 23946146 C T 5.00E-06 Systemic sclerosis SOX5 intron 21779181 rs11047102 chr12 23946146 C T 0.000036 Breast cancer SOX5 intron 23555315 rs16926727 chr12 23952345 A G 4.72E-04 Lung function (forced expiratory volume in 1 second) SOX5 intron 24023788 rs9804956 chr12 23981788 C T 3.12E-05 Asthma SOX5 intron 23181788 rs10505911 chr12 24022160 C A 0.000556724 Hypertension (early onset hypertension) SOX5 intron 22479346 rs7136898 chr12 24054572 G T 1.32E-05 Multiple complex diseases SOX5 intron 17554300 rs4581551 chr12 24057198 C T 0.000288347 Hypertension (early onset hypertension) SOX5 intron 22479346 rs3925064 chr12 24093764 T C 4.20E-04 Pulmonary function SOX5 intron 23932459 rs11047179 chr12 24122931 C T 4.24E-04 Alcohol dependence SOX5 intron 24277619 rs11830218 chr12 24124745 G A 0.000173 Trunk whole body fat mass SOX5 intron 23436924 rs4480631 chr12 24125775 T C 6.80E-04 Obesity (extreme) SOX5 intron 21935397 rs12229376 chr12 24129436 G T 9.35E-04 Alcohol dependence SOX5 intron 24277619 rs11047188 chr12 24134126 T C 8.59E-04 Obesity (extreme) SOX5 intron 21935397 rs17401403 chr12 24135271 A G 5.00E-05 Prostate cancer SOX5 intron 21743057 rs11047189 chr12 24138764 G T 5.88E-04 Obesity (extreme) SOX5 intron 21935397 rs10505921 chr12 24139829 A G 5.72E-04 Obesity (extreme) SOX5 intron 21935397 rs1391781 chr12 24140100 C T 8.96E-04 Obesity (extreme) SOX5 intron 21935397 rs1498869 chr12 24166453 T C 4.06E-04 Alzheimer's disease SOX5 intron 22005930 rs6487369 chr12 24170019 G A 1.00E-04 Cognitive impairment induced by topiramate SOX5 intron 22091778 rs4963737 chr12 24172215 T C 1.43E-05 Lupus nephritis in systemic lupus erythematosus SOX5 intron 24925725 rs17481181 chr12 24172546 T G 1.20E-07 Urinary metabolites SOX5 intron 21572414 rs17481181 chr12 24172546 T G 1.43E-05 Lupus nephritis in systemic lupus erythematosus SOX5 intron 24925725 rs7973213 chr12 24176297 C T 1.37E-05 Lupus nephritis in systemic lupus erythematosus SOX5 intron 24925725 rs12823336 chr12 24177194 T C 1.38E-05 Lupus nephritis in systemic lupus erythematosus SOX5 intron 24925725 rs17403340 chr12 24177880 T C 1.41E-05 Lupus nephritis in systemic lupus erythematosus SOX5 intron 24925725 rs10505927 chr12 24179673 G A 1.67E-05 Lupus nephritis in systemic lupus erythematosus SOX5 intron 24925725 rs7307316 chr12 24181408 A G 1.40E-05 Lupus nephritis in systemic lupus erythematosus SOX5 intron 24925725 rs1909351 chr12 24182848 C T 8.89E-08 Non-obstructive azoospermia SOX5 intron 22197933 rs10842262 chr12 24184544 G C 2.00E-09 Non-obstructive azoospermia SOX5 intron 22197933 rs1039229 chr12 24185520 T C 2.72E-08 Non-obstructive azoospermia SOX5 intron 22197933 rs4963738 chr12 24190602 T C 1.30E-06 Urinary metabolites SOX5 intron 21572414 rs1353793 chr12 24190988 T G 7.20E-05 stroke (ischemic) SOX5 intron 17434096 rs11047222 chr12 24192044 A G 7.14E-04 Alzheimer's disease SOX5 intron 22005930 rs10505931 chr12 24194795 T C 6.29E-04 Parkinson's disease SOX5 intron 17052657 rs11047225 chr12 24195587 C T 3.53E-04 Alzheimer's disease SOX5 intron 22005930 rs7966115 chr12 24199202 C T 2.84E-04 Alzheimer's disease SOX5 intron 22005930 rs7966115 chr12 24199202 C T 7.36E-04 Response to taxane treatment (placlitaxel) SOX5 intron 23006423 rs11047240 chr12 24208478 A G 1.35E-04 Multiple complex diseases SOX5 intron 17554300 rs7958678 chr12 24211259 T C 1.00E-04 Cognitive impairment induced by topiramate SOX5 intron 22091778 rs4963564 chr12 24214050 C T 4.56E-05 Lupus nephritis in systemic lupus erythematosus SOX5 intron 24925725 rs4963565 chr12 24214258 A G 2.60E-07 Urinary metabolites SOX5 intron 21572414 rs4963565 chr12 24214258 A G 4.51E-05 Lupus nephritis in systemic lupus erythematosus SOX5 intron 24925725 rs12810574 chr12 24214665 C T 4.52E-05 Lupus nephritis in systemic lupus erythematosus SOX5 intron 24925725 rs17485232 chr12 24215026 T C 4.47E-05 Lupus nephritis in systemic lupus erythematosus SOX5 intron 24925725 rs10505932 chr12 24237747 T G 6.61E-05 QT interval SOX5 intron 16648850 rs17407659 chr12 24238010 C T 2.50E-05 Lupus nephritis in systemic lupus erythematosus SOX5 intron 24925725 rs10505936 chr12 24273423 G A 4.93E-04 White matter integrity SOX5 intron 22425255 rs7139049 chr12 24273754 G T 3.88E-04 Taste perception SOX5 intron 22132133 rs2030130 chr12 24274071 C T 4.00E-06 Response to statin therapy SOX5 intron 20339536 rs2030129 chr12 24275387 C G 2.50E-06 Response to statin therapy SOX5 intron 20339536 rs7979575 chr12 24278821 C G,T 2.00E-06 Response to statin therapy SOX5 intron 20339536 rs10842277 chr12 24280870 T A 6.54E-04 Multiple complex diseases SOX5 intron 17554300 rs11047279 chr12 24293302 C T 7.00E-05 Alcohol and nictotine co-dependence SOX5 intron 20158304 rs11047279 chr12 24293302 C T 7.06E-04 Myopia (pathological) SOX5 intron 21095009 rs10734733 chr12 24294258 T C 4.91E-04 Myopia (pathological) SOX5 intron 21095009 rs10082842 chr12 24300902 T C 3.01E-05 Amyotrophic lateral sclerosis SOX5 intron 20801718 rs16927285 chr12 24326382 A G 9.38E-04 Multiple complex diseases SOX5 intron 17554300 rs10842292 chr12 24348317 C A 2.70E-05 Urinary metabolites SOX5 intron 21572414 rs12581837 chr12 24358253 T C 3.27E-04 Blood pressure SOX5 intron 17255346 rs3922562 chr12 24358865 C T 5.92E-05 Body Mass Index SOX5 intron pha003020 rs1357251 chr12 24375601 T C 7.65E-04 Alcohol dependence SOX5 intron 20201924 rs11047323 chr12 24384154 A G 8.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SOX5 intron 20877124 rs1464502 chr12 24388089 A G 5.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SOX5 intron 20877124 rs1464500 chr12 24389660 G T 1.00E-07 Response to antipsychotic treatment SOX5 intron 20195266 rs884440 chr12 24392816 G A 1.77E-05 Psoriasis SOX5 intron 18364390 rs1522232 chr12 24394372 T C 2.00E-06 AIDS SOX5 intron 19754311 rs2686331 chr12 24403997 A C 3.15E-04 Systemic lupus erythematosus and Systemic sclerosis SOX5 intron 23740937 rs10505939 chr12 24447034 T C 1.22E-04 Smoking initiation SOX5 intron 24665060 rs1522228 chr12 24453707 C T 5.65E-04 HIV-1 viral setpoint SOX5 intron 17641165 rs11047359 chr12 24457216 G A 4.95E-04 Multiple complex diseases SOX5 intron 17554300 rs7978406 chr12 24466704 C G 6.44E-04 Insulin resistance SOX5 intron 21901158 rs11616084 chr12 24467149 T C 3.48E-04 Insulin resistance SOX5 intron 21901158 rs579556 chr12 24471760 C T 4.00E-04 Multiple complex diseases SOX5 intron 17554300 rs953334 chr12 24471815 C T 9.30E-04 Multiple complex diseases SOX5 intron 17554300 rs953334 chr12 24471815 C T 1.01E-04 Insulin resistance SOX5 intron 21901158 rs7980156 chr12 24475862 T G 1.54E-04 Insulin resistance SOX5 intron 21901158 rs563776 chr12 24479206 C A 5.29E-04 Multiple complex diseases SOX5 intron 17554300 rs472100 chr12 24479494 C T 2.09E-05 Anxiety and major depressive disorder SOX5 intron 24047446 rs2055731 chr12 24482034 C T 0.000522459 Hypertension (early onset hypertension) SOX5 intron 22479346 rs550338 chr12 24512037 G A 2.20E-04 Alcohol dependence SOX5 intron 20201924 rs550338 chr12 24512037 G A 8.90E-05 Alcohol dependence SOX5 intron 20201924 rs550338 chr12 24512037 G A 8.88E-05 Alcoholism SOX5 intron pha002893 rs7968811 chr12 24536837 C T 2.80E-04 Pulmonary function SOX5 intron 23932459 rs7966399 chr12 24551705 A G 9.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) SOX5 intron 23233662 rs4963756 chr12 24553387 G A 9.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) SOX5 intron 23233662 rs11047417 chr12 24555441 T C 5.86E-04 Oral cancers (chewing tobacco related) SOX5 intron 22503698 rs17417768 chr12 24558745 T C 1.15E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SOX5 intron 25044411 rs10743498 chr12 24559370 T C 1.73E-04 Type 2 diabetes SOX5 intron 17463246 rs10743498 chr12 24559370 T C 0.0005609 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SOX5 intron 23233654 rs10743498 chr12 24559370 T C 5.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) SOX5 intron 23233662 rs7309268 chr12 24560244 G T 9.64E-04 Alcohol dependence SOX5 intron 21314694 rs11047424 chr12 24560842 G A 7.44E-05 Serum metabolites SOX5 intron 19043545 rs11047425 chr12 24560894 C G 0.00003261 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SOX5 intron 23233654 rs11047425 chr12 24560894 C G 9.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) SOX5 intron 23233662 rs17509005 chr12 24576205 T C 3.96E-04 Multiple complex diseases SOX5 intron 17554300 rs11047431 chr12 24578520 A G 0.000872 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SOX5 intron 23233654 rs11047431 chr12 24578520 A G 8.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) SOX5 intron 23233662 rs10505940 chr12 24581756 T C 1.08E-05 Body Mass Index SOX5 intron pha003014 rs1396200 chr12 24613747 C T 1.13E-05 Calcium levels SOX5 intron pha003085 rs11047458 chr12 24614105 A G 0.0007523 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SOX5 intron 23233654 rs11047458 chr12 24614105 A G 7.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) SOX5 intron 23233662 rs11047461 chr12 24618042 C T 6.32E-05 Body Mass Index SOX5 intron pha003014 rs7969711 chr12 24619507 C T 2.77E-05 Body Mass Index SOX5 intron pha003014 rs10842357 chr12 24628433 T G 6.52E-04 Multiple complex diseases SOX5 intron 17554300 rs4963767 chr12 24653672 C T 6.21E-05 Response to cytadine analogues (cytosine arabinoside) SOX5 intron 24483146 rs4963768 chr12 24654276 G A 7.12E-05 Response to cytadine analogues (cytosine arabinoside) SOX5 intron 24483146 rs4963768 chr12 24654276 G A 3.44E-05 Left ventricular hypertrophy SOX5 intron pha003052 rs17284897 chr12 24672026 C T 5.77E-05 Lipid levels SOX5 intron pha003082 rs7295669 chr12 24701792 T C 2.30E-04 Multiple complex diseases SOX5 intron 17554300 rs16927697 chr12 24704498 A G 3.65E-04 Smoking quantity SOX5 intron 24665060 rs7306415 chr12 24725497 A C 1.70E-05 Diabetic retinopathy LINC00477 intron 21441570 rs12312504 chr12 24726630 G A 1.50E-05 Diabetic retinopathy LINC00477 intron 21441570 rs6487399 chr12 24727774 G T 1.48E-04 Smoking quantity LINC00477 intron 24665060 rs6487400 chr12 24727926 T C 2.30E-05 Diabetic retinopathy LINC00477 intron 21441570 rs721094 chr12 24728831 G A 2.30E-05 Diabetic retinopathy LINC00477 intron 21441570 rs7299236 chr12 24732386 T C 2.52E-04 Smoking quantity LINC00477 intron 24665060 rs201772636 chr12 24737062 C CAA 3.60E-04 Smoking quantity / / 24665060 rs7969292 chr12 24737062 C A 3.60E-04 Smoking quantity / / 24665060 rs10771099 chr12 24740304 C G 3.92E-04 Smoking quantity / / 24665060 rs7956401 chr12 24744105 A G 3.40E-04 Smoking quantity / / 24665060 rs7976009 chr12 24745537 T C 2.60E-04 Smoking quantity / / 24665060 rs7969117 chr12 24747780 A G 3.70E-05 Diabetic retinopathy / / 21441570 rs7298579 chr12 24749874 T C 3.60E-05 Diabetic retinopathy / / 21441570 rs17287293 chr12 24770878 A G 2.00E-10 Resting heart rate / / 20639392 rs17287293 chr12 24770878 A G 2.38E-07 Atrial fibrillation / / 23583979 rs17287293 chr12 24770878 A G 3.00E-20 Heart rate / / 23583979 rs17287293 chr12 24770878 A G 4.91E-13 PR duration / / 23583979 rs10842383 chr12 24771967 C T 1.40E-04 Type 2 diabetes / / 17463246 rs4246224 chr12 24784139 G A 6.60E-04 Alcohol dependence / / 20201924 rs11047543 chr12 24788339 G A 3.00E-13 PR interval / / 20062060 rs11047543 chr12 24788339 G A 3.50E-07 Atrial fibrillation / / 22544366 rs10842390 chr12 24814274 G A 0.0002 Migraine / / 22678113 rs1976130 chr12 24818342 C T 1.94E-04 Lung function (forced vital capacity) / / 24023788 rs7302752 chr12 24819861 G A 5.03E-05 Suicide attempts in bipolar disorder / / 21423239 rs2087200 chr12 24821986 C T 5.01E-05 Suicide attempts in bipolar disorder / / 21423239 rs9668920 chr12 24853374 A G 4.24E-05 Body Mass Index / / pha003014 rs11047579 chr12 24854171 C A 1.90E-05 Odorant perception / / 23910658 rs2354029 chr12 24906822 G A 3.40E-07 Urinary metabolites / / 21572414 rs2354029 chr12 24906822 G A 1.36E-04 Cognitive function / / 24684796 rs12322149 chr12 24907715 C T 3.40E-07 Urinary metabolites / / 21572414 rs12828456 chr12 24912241 T C 1.70E-05 Urinary metabolites / / 21572414 rs7973533 chr12 24917962 T G 0.0000084 Paclitaxel-induced sensory peripheral neuropathy / / 22843789 rs11047615 chr12 24920047 T C 3.40E-07 Urinary metabolites / / 21572414 rs7305157 chr12 24920581 C A 9.30E-07 Urinary metabolites / / 21572414 rs10505947 chr12 24920666 C A 1.36E-04 Cognitive function / / 24684796 rs1872639 chr12 24944999 C T 4.46E-04 Multiple complex diseases / / 17554300 rs11486 chr12 24964567 T C 2.20E-04 Prion diseases BCAT1 UTR-3 22210626 rs1872645 chr12 24967212 C T 4.07E-06 Esophageal cancer (squamous cell) BCAT1 UTR-3 22960999 rs7305794 chr12 24969627 T C 8.26E-06 Osteoarthritis BCAT1 UTR-3 22763110 rs10505952 chr12 24974646 G A 3.51E-04 Bipolar disorder BCAT1 intron 19259986 rs7961152 chr12 24981611 A C 7.39E-06 Multiple complex diseases BCAT1 intron 17554300 rs12424348 chr12 24989145 G A 9.15E-05 Multiple complex diseases BCAT1 intron 17554300 rs11613673 chr12 24998509 C T 6.47E-05 Multiple complex diseases BCAT1 intron 17554300 rs16928111 chr12 25000019 A G 5.83E-04 Multiple complex diseases BCAT1 intron 17554300 rs11047681 chr12 25009856 G A 0.0000511 Polycystic ovary syndrome BCAT1 intron 22951595 rs11047681 chr12 25009856 G A 5.11E-05 Intracranial aneurysm BCAT1 intron 22961961 rs4522264 chr12 25036332 C T 1.55E-04 Multiple complex diseases BCAT1 intron 17554300 rs11047689 chr12 25041904 T C 2.20E-06 Coronary heart disease BCAT1 intron 21966275 rs16928173 chr12 25051265 G T 7.72E-04 Taste perception BCAT1 intron 22132133 rs10842424 chr12 25051916 T C 9.67E-05 Non-alcoholic fatty liver disease histology (other) BCAT1 intron 20708005 rs12579934 chr12 25064418 G A 2.45E-05 HIV(mother-to-child transmission) BCAT1 intron 20487506 rs12579934 chr12 25064418 G A 7.54E-06 HIV(mother-to-child transmission) BCAT1 intron 20487506 rs7964239 chr12 25073685 T C 0.00026 Coronary artery calcification BCAT1 intron 23727086 rs12321766 chr12 25090086 A G 7.70E-05 Insulin Resistance BCAT1 intron pha003062 rs10505955 chr12 25094221 T C 4.33E-04 Stroke BCAT1 intron pha002886 rs7296881 chr12 25094536 C A 3.32E-04 Multiple complex diseases BCAT1 intron 17554300 rs1105937 chr12 25096090 A G 2.00E-04 Suicide attempts in bipolar disorder BCAT1 intron 21423239 rs3950612 chr12 25096564 T C 8.89E-05 Insulin Resistance BCAT1 intron pha003062 rs3950612 chr12 25096564 T C 1.81E-05 Insulin-related traits BCAT1 intron pha003063 rs11047723 chr12 25101572 C G 1.06E-04 Arthritis (juvenile idiopathic) BCAT1 intron 22354554 rs11047735 chr12 25129588 C T 5.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs10842444 chr12 25138016 G A 4.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs16928315 chr12 25147192 A T 7.86E-04 Multiple complex diseases C12orf77 UTR-3 17554300 rs699030 chr12 25147300 G C 7.30E-04 Multiple complex diseases C12orf77 intron 17554300 rs860876 chr12 25158319 G T 1.27E-05 Lymphocyte counts LOC645177 intron 22286170 rs11047768 chr12 25180058 G A 6.65E-04 Alcohol dependence LOC645177 intron 24277619 rs10771158 chr12 25182403 G A 3.39E-05 Brain lesion load LOC645177 intron 19010793 rs1012980 chr12 25184008 A G 6.03E-05 Brain lesion load LOC645177 intron 19010793 rs699053 chr12 25187170 T C 1.93E-04 Myocardial Infarction LOC645177 intron pha002873 rs41347844 chr12 25188629 T C 6.59E-04 Multiple complex diseases LOC645177 missense 17554300 rs962656 chr12 25204353 C T 4.90E-05 Endometriosis / / 21151130 rs1497259 chr12 25207653 A G 7.76E-04 Myocardial Infarction LRMP intron pha002873 rs11047806 chr12 25221574 G A 8.00E-05 Parkinson's disease (age of onset) LRMP intron 19772629 rs1683163 chr12 25233618 G A 1.00E-04 Cognitive impairment induced by topiramate LRMP intron 22091778 rs11047820 chr12 25237576 T C 6.43E-05 ldl cholesterol LRMP intron pha003077 rs1693359 chr12 25239422 C T 8.70E-04 HIV-1 viral setpoint LRMP intron 17641165 rs859157 chr12 25240480 A G 2.56E-06 ldl cholesterol LRMP intron pha003077 rs859157 chr12 25240480 A G 7.08E-05 Cholesterol LRMP intron pha003083 rs859153 chr12 25241297 C T 9.74E-06 ldl cholesterol LRMP intron pha003077 rs1979522 chr12 25243893 C T 4.38E-05 Alcohol and nictotine co-dependence LRMP intron 20158304 rs7977670 chr12 25244383 A G 4.79E-04 Type 2 diabetes LRMP intron 17463246 rs7960092 chr12 25252178 C A 8.39E-04 Type 2 diabetes LRMP intron 17463246 rs7134616 chr12 25263890 G C 9.25E-04 Parkinson's disease CASC1 intron 16252231 rs7297103 chr12 25265295 C T 5.84E-05 Serum metabolites CASC1 intron 19043545 rs7971288 chr12 25297907 C G 5.33E-04 Type 2 diabetes CASC1 intron 17463246 rs7979296 chr12 25348514 T G 8.97E-05 Lymphocyte counts LYRM5 intron 22286170 rs6487465 chr12 25410283 T C 3.68E-05 Lung adenocarcinoma / / 19836008 rs10743555 chr12 25429768 A C 9.88E-04 Alzheimer's disease / / 24755620 rs10505978 chr12 25445122 G A 9.90E-04 Alzheimer's disease / / 24755620 rs4963606 chr12 25471480 C A 4.28E-04 Multiple complex diseases / / 17554300 rs4963607 chr12 25471712 A G 4.92E-04 Multiple complex diseases / / 17554300 rs7953994 chr12 25472568 T A 2.20E-05 Urinary metabolites / / 21572414 rs7954242 chr12 25472779 T A 6.74E-04 Multiple complex diseases / / 17554300 rs10505975 chr12 25476219 G A 1.20E-05 Urinary metabolites / / 21572414 rs10505975 chr12 25476219 G A 1.43E-05 Neuroblastoma / / pha002895 rs7965364 chr12 25484193 C T 6.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1489907 chr12 25556704 G C 9.36E-04 Multiple complex diseases / / 17554300 rs11048014 chr12 25568169 C G 7.97E-04 Multiple complex diseases / / 17554300 rs2340376 chr12 25573086 C A 8.55E-05 Heart Failure / / pha002884 rs7310380 chr12 25622197 G A 2.62E-04 Multiple complex diseases / / 17554300 rs11048057 chr12 25623972 C T 4.87E-05 Body Mass Index / / pha003020 rs16928923 chr12 25627171 T C 8.82E-05 Alzheimer's disease (late onset) / / 21379329 rs7973188 chr12 25634138 A C 8.67E-05 Body Mass Index IFLTD1 intron pha003020 rs3863354 chr12 25644657 G A 3.74E-04 Multiple complex diseases IFLTD1 intron 17554300 rs10505968 chr12 25645817 T C 2.36E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) IFLTD1 intron 17982456 rs6487494 chr12 25646583 C T 2.26E-05 Cognitive impairment induced by topiramate IFLTD1 intron 22091778 rs10505967 chr12 25655522 C T 1.77E-05 Body Mass Index IFLTD1 intron pha003020 rs10771224 chr12 25659672 T C 5.00E-04 Alcohol dependence IFLTD1 intron 21314694 rs10743565 chr12 25660579 A G 0.0000164 Preeclampsia IFLTD1 intron 22748001 rs10743565 chr12 25660579 A G 6.77E-06 Preeclampsia IFLTD1 intron 23551011 rs10842572 chr12 25665027 G A 8.03E-05 Cognitive impairment induced by topiramate IFLTD1 intron 22091778 rs279011 chr12 25682031 T C 2.34E-06 Body Mass Index IFLTD1 intron pha003019 rs279011 chr12 25682031 T C 4.92E-07 Body Mass Index IFLTD1 intron pha003020 rs278998 chr12 25767170 C G 1.18E-05 Recombination rate IFLTD1 intron 21698098 rs7139066 chr12 25771895 A G 5.48E-04 Heart Failure IFLTD1 intron pha002885 rs4963626 chr12 25777167 C A 5.10E-05 Response to lithium treatment in bipolar disorder IFLTD1 intron 19448189 rs11048130 chr12 25777324 C A 2.93E-04 Type 2 diabetes IFLTD1 intron 17463246 rs6487505 chr12 25807636 G A 9.85E-04 Type 2 diabetes / / 17463246 rs7977844 chr12 25811125 G A 7.49E-05 Multiple complex diseases / / 17554300 rs11048155 chr12 25811585 A G 8.99E-04 Type 2 diabetes / / 17463246 rs10771232 chr12 25834871 A G 1.58E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs11048174 chr12 25835245 C T 8.13E-04 Multiple complex diseases / / 17554300 rs4963910 chr12 25844865 C T 8.37E-06 Leprosy / / pha002872 rs4963630 chr12 25865336 A T 5.77E-04 Insulin resistance / / 21901158 rs7956393 chr12 25883105 G A 3.42E-05 Heart Rate / / pha003051 rs1381804 chr12 25947984 T C 3.08E-05 Heart Rate / / pha003051 rs10466805 chr12 25949006 C T 3.12E-05 Heart Rate / / pha003051 rs16929496 chr12 25993804 T C 2.60E-07 Asthma / / 21804549 rs17428721 chr12 25995388 G A 4.31E-04 Type 2 diabetes / / 17463246 rs11048311 chr12 26022138 A C 4.70E-07 Asthma / / 21804549 rs11048317 chr12 26028407 T G 3.32E-07 Asthma / / 21804549 rs1488827 chr12 26043419 T C 1.37E-04 Sudden cardiac arrest / / 21658281 rs1495651 chr12 26071745 T G 1.90E-05 Urinary metabolites / / 21572414 rs1167632 chr12 26074458 G A 7.93E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs706521 chr12 26114019 G A 9.88E-05 Left ventricular hypertrophy RASSF8 intron pha003052 rs1149806 chr12 26115117 A C,G,T 3.85E-04 Multiple complex diseases RASSF8 intron 17554300 rs829986 chr12 26118517 C G 1.09E-05 Multiple complex diseases RASSF8 intron 17554300 rs10842643 chr12 26119253 A G 7.97E-05 Multiple complex diseases RASSF8 intron 17554300 rs706529 chr12 26123345 A G 7.80E-05 Left ventricular hypertrophy RASSF8 intron pha003052 rs2729662 chr12 26162429 A G 9.94E-04 Multiple complex diseases RASSF8 intron 17554300 rs956627 chr12 26213720 C T 9.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) RASSF8 intron 17982456 rs11048398 chr12 26221269 G A 4.65E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) RASSF8 intron 24023788 rs11048399 chr12 26222732 G A 9.52E-04 Acute lung injury RASSF8 UTR-3 22295056 rs2271480 chr12 26223438 G A 4.04E-04 Multiple complex diseases RASSF8 UTR-3 17554300 rs2669565 chr12 26227859 G C 3.59E-04 Multiple complex diseases RASSF8 intron 17554300 rs11048402 chr12 26227881 G A 4.40E-07 Urinary metabolites RASSF8 intron 21572414 rs2669566 chr12 26228070 C T 2.59E-04 Multiple complex diseases RASSF8 intron 17554300 rs2729626 chr12 26228819 G C 5.03E-04 Multiple complex diseases RASSF8 intron 17554300 rs10505992 chr12 26258289 T C 8.65E-04 Insulin resistance / / 21901158 rs2343072 chr12 26269047 A T 0.0004 Coronary artery calcification / / 23727086 rs7358598 chr12 26285545 G A 1.45E-04 Acne (severe) / / 24927181 rs78579876 chr12 26285974 A C 6.65E-05 Acne (severe) / / 24927181 rs748775 chr12 26297832 C T 3.50E-04 Atrial fibrillation / / 21846873 rs10771263 chr12 26299270 C G 4.20E-05 Bipolar disorder / / 19488044 rs10842682 chr12 26306222 T C 4.60E-05 Bipolar disorder / / 19488044 rs4963968 chr12 26314978 T A 1.64E-04 Multiple complex diseases / / 17554300 rs2343866 chr12 26315082 C T 5.16E-04 Multiple complex diseases / / 17554300 rs7300697 chr12 26317170 C T 4.47E-04 Multiple complex diseases / / 17554300 rs10505993 chr12 26317799 C T 4.17E-04 Multiple complex diseases / / 17554300 rs10842686 chr12 26325379 C T 3.28E-04 Multiple complex diseases / / 17554300 rs768347 chr12 26331146 C T 5.12E-05 Type 2 diabetes / / 17463246 rs10842688 chr12 26338294 A C 2.01E-04 Multiple complex diseases / / 17554300 rs10842689 chr12 26338365 T C 2.65E-04 Multiple complex diseases / / 17554300 rs10771265 chr12 26349311 G A 9.28E-05 Serum metabolites SSPN intron 19043545 rs7959761 chr12 26389242 T C 9.56E-05 Longevity / / 22279548 rs1480043 chr12 26389769 T C 8.16E-05 Erythrocyte counts / / pha003090 rs12424263 chr12 26390319 T C 9.77E-04 Depression (quantitative trait) / / 20800221 rs1480039 chr12 26422648 G T 1.35E-04 Bipolar disorder,schizoaffective / / 19567891 rs1355735 chr12 26425894 G A 2.64E-04 Alzheimer's disease (late onset) / / 21379329 rs6487547 chr12 26444373 G A 7.21E-04 Parkinson's disease / / 17052657 rs11048450 chr12 26450150 T C 1.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs718314 chr12 26453283 A G 2.00E-17 Waist-hip ratio / / 20935629 rs718314 chr12 26453283 A G 9.00E-10 Renal cell carcinoma / / 22010048 rs718314 chr12 26453283 A G 3.62E-04 Sexual dimorphism in anthropometric traits / / 23754948 rs11048452 chr12 26453917 T C 2.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs11048459 chr12 26469427 T C 2.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs11048467 chr12 26476668 G A 7.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs1049380 chr12 26489544 G T 6.07E-09 Renal cell carcinoma ITPR2 UTR-3 22010048 rs2570 chr12 26491838 G A 2.73E-04 Smoking initiation ITPR2 UTR-3 24665060 rs901838 chr12 26494346 C T 0.00000147 Triglycerides ITPR2 intron 23063622 rs11048476 chr12 26502312 A G 4.20E-05 Smoking cessation ITPR2 intron 18519826 rs11048476 chr12 26502312 A G 3.68E-05 Serum metabolites ITPR2 intron 19043545 rs2171520 chr12 26504337 G A 2.70E-05 Smoking cessation ITPR2 intron 18519826 rs10505997 chr12 26529242 T C 3.71E-04 Hemoglobin concentration ITPR2 intron 20534544 rs10771279 chr12 26530543 T C 7.60E-05 Renal cell carcinoma ITPR2 intron 24220910 rs11614384 chr12 26536761 T C 3.20E-04 Alcohol dependence ITPR2 intron 20201924 rs3782291 chr12 26555558 C T 2.80E-05 Urinary metabolites ITPR2 intron 21572414 rs3782291 chr12 26555558 C T 2.69E-05 Brain structure ITPR2 intron 22504417 rs12826091 chr12 26563399 A G 3.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ITPR2 intron 20877124 rs7968229 chr12 26567440 T G 2.11E-04 Suicide attempts in bipolar disorder ITPR2 intron 21423239 rs1021296 chr12 26569724 A C 3.19E-04 Suicide attempts in bipolar disorder ITPR2 intron 21423239 rs12424389 chr12 26570140 C G 3.55E-04 Suicide attempts in bipolar disorder ITPR2 intron 21423239 rs11048506 chr12 26572512 G C 0.00023 Coronary artery calcification ITPR2 intron 23727086 rs2055468 chr12 26576321 T G 2.54E-04 Suicide attempts in bipolar disorder ITPR2 intron 21423239 rs11048510 chr12 26576334 G C 4.10E-05 Waist-hip ratio ITPR2 intron 23966867 rs6487552 chr12 26579817 A C 1.34E-04 Depression (quantitative trait) ITPR2 intron 20800221 rs12426143 chr12 26580124 C T 7.28E-05 Depression (quantitative trait) ITPR2 intron 20800221 rs12426143 chr12 26580124 C T 1.48E-05 Heart Rate ITPR2 intron pha003053 rs7955200 chr12 26585829 C T 8.38E-05 Depression (quantitative trait) ITPR2 intron 20800221 rs4146368 chr12 26590428 A G 0.00001 Coronary artery calcification ITPR2 intron 23727086 rs10743585 chr12 26594948 C T 6.30E-05 Cognitive test performance ITPR2 intron 20125193 rs1532067 chr12 26602433 A T 9.10E-04 Multiple complex diseases ITPR2 intron 17554300 rs1532067 chr12 26602433 A T 2.61E-05 Smoking cessation ITPR2 intron 18519826 rs7975290 chr12 26613918 A G 6.19E-05 Postoperative ventricular dysfunction ITPR2 intron 21980348 rs11048538 chr12 26618259 T C 9.05E-05 Response to mTOR inhibitor (rapamycin) ITPR2 intron 24009623 rs1565190 chr12 26622942 T C 0.000000835 Joint damage severity in rheumatoid arthritis ITPR2 intron 23696630 rs11048543 chr12 26626638 T C 1.73E-05 Response to mTOR inhibitor (everolimus) ITPR2 intron 24009623 rs11048543 chr12 26626638 T C 2.32E-05 Response to mTOR inhibitor (rapamycin) ITPR2 intron 24009623 rs2306677 chr12 26636386 A G 3.00E-06 Amyotrophic lateral sclerosis ITPR2 intron 17827064 rs2306677 chr12 26636386 A G 2.16E-05 Information processing speed ITPR2 intron 21130836 rs905298 chr12 26641933 G T 4.71E-04 Amyotrophic Lateral Sclerosis ITPR2 intron 17827064 rs905298 chr12 26641933 G T 3.09E-05 Information processing speed ITPR2 intron 21130836 rs10743586 chr12 26642577 C T 1.00E-04 Information processing speed ITPR2 intron 21130836 rs1393413 chr12 26658168 A G 4.86E-05 Insulin-related traits ITPR2 intron pha003063 rs16930908 chr12 26660180 T C 2.52E-04 Type 2 diabetes ITPR2 intron 17463246 rs10842744 chr12 26664625 C T 1.00E-04 Information processing speed ITPR2 intron 21130836 rs1843224 chr12 26681313 T C 9.11E-05 Information processing speed ITPR2 intron 21130836 rs7312147 chr12 26687654 T C 7.08E-05 Insulin-related traits ITPR2 intron pha003063 rs11048567 chr12 26689621 A G 3.38E-05 Coronary heart disease ITPR2 intron 24778558 rs10842750 chr12 26690565 A C 3.39E-10 Esophageal cancer ITPR2 intron 21642993 rs16931019 chr12 26729490 C A 7.32E-04 Smoking initiation ITPR2 intron 24665060 rs16931036 chr12 26749137 T C 1.41E-04 Smoking cessation ITPR2 intron 24665060 rs11048606 chr12 26756606 C G,T 3.29E-06 Lipid traits ITPR2 intron 21777205 rs11048606 chr12 26756606 C G,T 9.30E-04 Alzheimer's disease ITPR2 intron 22005930 rs11048611 chr12 26761513 T G 1.07E-10 Metabolite levels ITPR2 intron 22286219 rs12303865 chr12 26774401 G C 2.90E-05 Urinary metabolites ITPR2 intron 21572414 rs17399103 chr12 26781745 G A 5.27E-04 Type 2 diabetes ITPR2 intron 17463246 rs7972342 chr12 26790518 G A 0.00000233 Apnea hypopnea index ITPR2 intron 23155414 rs4964010 chr12 26798389 G T 3.41E-06 Bipolar disorder ITPR2 intron 19488044 rs4964010 chr12 26798389 G T 1.56E-05 Serum selenium levels ITPR2 intron 23698163 rs4964010 chr12 26798389 G T 4.67E-06 Bipolar Disorder ITPR2 intron pha002858 rs2291263 chr12 26810816 T G 1.30E-05 Iron levels ITPR2 cds-synon 21208937 rs1375656 chr12 26816496 T C 3.21E-04 Coronary Artery Disease ITPR2 intron 17634449 rs7968535 chr12 26833655 T C 7.11E-04 Alzheimer's disease ITPR2 intron 17998437 rs7316723 chr12 26836895 T C 7.31E-04 Alzheimer's disease ITPR2 intron 17998437 rs12424645 chr12 26843626 T C 6.13E-04 Alzheimer's disease ITPR2 intron 17998437 rs3782309 chr12 26859396 G T 5.53E-05 Attention deficit hyperactivity disorder ITPR2 intron 18980221 rs3782309 chr12 26859396 G T 1.01E-05 Attention deficit hyperactivity disorder ITPR2 intron pha002875 rs12814812 chr12 26862439 T C 3.24E-05 Acute lymphoblastic leukemia (childhood) ITPR2 intron 19684603 rs2230383 chr12 26868289 C T 6.48E-04 Taste perception ITPR2 cds-synon 22132133 rs753568 chr12 26876355 A C 6.40E-05 Response to statin therapy ITPR2 intron 20339536 rs2035440 chr12 26883825 A G 5.90E-05 Response to statin therapy ITPR2 intron 20339536 rs1031301 chr12 26887731 A G 5.40E-05 Response to statin therapy ITPR2 intron 20339536 rs10743593 chr12 26891687 C T 5.30E-05 Response to statin therapy ITPR2 intron 20339536 rs10771296 chr12 26892560 G A 5.20E-05 Response to statin therapy ITPR2 intron 20339536 rs16931325 chr12 26896516 G T 5.10E-05 Response to statin therapy ITPR2 intron 20339536 rs10771297 chr12 26898486 T C 6.10E-05 Response to statin therapy ITPR2 intron 20339536 rs12582348 chr12 26905974 A G 7.91E-05 Acute lymphoblastic leukemia (childhood) ITPR2 intron 19684603 rs2122267 chr12 26906476 A G 7.30E-05 Response to statin therapy ITPR2 intron 20339536 rs4436638 chr12 26911289 C T 4.97E-05 Acute lymphoblastic leukemia (childhood) ITPR2 intron 19684603 rs1449568 chr12 26911705 T C 7.36E-05 Acute lymphoblastic leukemia (childhood) ITPR2 intron 19684603 rs11048674 chr12 26912719 G A 3.00E-06 Smoking initiation ITPR2 intron 24665060 rs1375657 chr12 26917108 A G 6.20E-05 Response to statin therapy ITPR2 intron 20339536 rs11048717 chr12 26994391 C T 0.000591845 Hypertension (early onset hypertension) / / 22479346 rs7138744 chr12 27005960 A G 3.00E-06 Smooth-surface caries / / 24556642 rs12372288 chr12 27015543 T C 3.75E-04 Premature ovarian failure / / 19508998 rs10842809 chr12 27022872 G A 5.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10506012 chr12 27027201 G A 6.47E-06 Alopecia areata / / 22027810 rs1488051 chr12 27059422 T C 2.39E-05 F-cell distribution ASUN intron 21326311 rs149436455 chr12 27125371 C T 0.0000907 Nonsyndromic striae distensae (stretch marks) TM7SF3 UTR-3 23633020 rs10771314 chr12 27143508 G A 2.30E-05 Endometriosis TM7SF3 missense 21151130 rs11048801 chr12 27144880 C T 3.14E-04 Fibrinogen TM7SF3 intron 17255346 rs12227386 chr12 27150110 A G 2.67E-04 Fibrinogen TM7SF3 intron 17255346 rs9651825 chr12 27159784 A G 3.07E-04 Type 2 diabetes TM7SF3 intron 17463246 rs7978167 chr12 27161129 G A 1.40E-04 Endometriosis TM7SF3 intron 21151130 rs1484086 chr12 27163343 T C 3.71E-04 Fibrinogen TM7SF3 intron 17255346 rs6487586 chr12 27168878 A G 5.77E-05 Magnesium levels / / pha003092 rs7968850 chr12 27231573 G C 9.88E-04 Type 2 diabetes / / 17463246 rs7303320 chr12 27343183 G C 2.60E-05 Urinary metabolites / / 21572414 rs7301331 chr12 27355213 A G 1.82E-06 Cholesterol / / pha003073 rs7301331 chr12 27355213 A G 3.11E-05 ldl cholesterol / / pha003076 rs7301331 chr12 27355213 A G 1.93E-05 Cholesterol / / pha003078 rs6487598 chr12 27451600 A T 4.41E-05 Brain structure STK38L intron 22504417 rs2242185 chr12 27470682 C T 2.90E-05 Cardiovascular disease adverse events in renal patients treated with calcineurin inhibitors STK38L intron 16155738 rs2100840 chr12 27492738 G A 7.70E-05 Cognitive impairment induced by topiramate ARNTL2 intron 22091778 rs17497606 chr12 27494449 C T 2.05E-05 Prion diseases ARNTL2 intron 22210626 rs2968758 chr12 27502955 G T 5.86E-04 Multiple complex diseases ARNTL2 intron 17554300 rs1443857 chr12 27545360 C T 2.30E-08 Metabolite levels ARNTL2 intron 23281178 rs3794273 chr12 27551249 T A 1.33E-08 Metabolite levels ARNTL2 intron 23281178 rs1037922 chr12 27553107 A T 7.75E-09 Metabolite levels ARNTL2 intron 23281178 rs1037920 chr12 27553741 A C 5.90E-09 Metabolite levels ARNTL2 intron 23281178 rs1037919 chr12 27553869 C T 5.90E-09 Metabolite levels ARNTL2 intron 23281178 rs16931954 chr12 27555090 A G 5.90E-09 Metabolite levels ARNTL2 intron 23281178 rs7957971 chr12 27578572 G A 4.81E-04 Multiple complex diseases ARNTL2 UTR-3 17554300 rs1150934 chr12 27602123 A G 2.80E-05 Urinary metabolites / / 21572414 rs11049014 chr12 27602813 G A 4.47E-04 Multiple complex diseases / / 17554300 rs2280430 chr12 27605988 A G 2.52E-04 Type 2 diabetes / / 17463246 rs2280431 chr12 27606039 C T 5.19E-04 Type 2 diabetes / / 17463246 rs16931982 chr12 27610447 C G 1.14E-05 Type 2 diabetes / / 17463246 rs411816 chr12 27627805 G A 1.80E-06 Urinary metabolites C12orf70 cds-synon 21572414 rs976914 chr12 27657161 G A 1.75E-04 Multiple complex diseases / / 17554300 rs306657 chr12 27693851 A T 3.09E-04 Schizophrenia(treatment response to risperidone) PPFIBP1 intron 19850283 rs10506025 chr12 27726370 G A 1.00E-04 Chronic fatigue syndrome PPFIBP1 intron 21912186 rs1975920 chr12 27735986 G T 1.00E-10 Pancreatic cancer PPFIBP1 intron 21849791 rs16932216 chr12 27738978 T C 9.27E-04 Multiple complex diseases PPFIBP1 intron 17554300 rs142897702 chr12 27739570 C G 9.57E-06 PR interval in Tripanosoma cruzi seropositivity PPFIBP1 intron 24324551 rs4409879 chr12 27739993 G A 3.36E-05 Telomere length PPFIBP1 intron 24795349 rs2162028 chr12 27756488 C T 8.91E-04 Response to cytidine analogues (gemcitabine) PPFIBP1 intron 24483146 rs7965657 chr12 27786415 A G 4.14E-04 Multiple complex diseases PPFIBP1 intron 17554300 rs2075377 chr12 27787635 C T 6.51E-04 Alzheimer's disease PPFIBP1 intron 17998437 rs7295096 chr12 27797905 A G 5.74E-05 Bipolar disorder and schizophrenia PPFIBP1 intron 20889312 rs7295096 chr12 27797905 A G 6.16E-04 Insulin resistance PPFIBP1 intron 21901158 rs7959164 chr12 27800446 T C 3.94E-05 Serum metabolites PPFIBP1 intron 19043545 rs7973582 chr12 27811224 A G 1.17E-04 Alzheimer's disease (late onset) PPFIBP1 intron 21379329 rs1010094 chr12 27843923 A G 4.04E-04 Response to taxane treatment (placlitaxel) PPFIBP1 intron 23006423 rs10734762 chr12 27845174 C G 3.88E-04 Response to taxane treatment (placlitaxel) PPFIBP1 intron 23006423 rs10842972 chr12 27897424 T C 6.65E-04 Amyotrophic lateral sclerosis (sporadic) MRPS35 intron 24529757 rs7316898 chr12 27904564 T C 7.36E-09 Type 2 diabetes MRPS35 intron 23945395 rs4931412 chr12 27922954 A G 1.10E-05 Urinary metabolites MANSC4 intron 21572414 rs2288232 chr12 27944858 G A 3.90E-06 Type 2 diabetes KLHDC5 intron 21647700 rs3751235 chr12 27949283 C T 0.000028 Type 2 diabetes KLHDC5 intron 22885922 rs7311374 chr12 27959905 C T 3.90E-04 Alcohol dependence / / 20201924 rs12578595 chr12 27964996 C T 0.000004 Type 2 diabetes / / 22885922 rs10842994 chr12 27965150 C T 0.000000032 Type 2 diabetes (males) / / 22885922 rs10842994 chr12 27965150 C T 0.00053 Type 2 diabetes (females) / / 22885922 rs10842994 chr12 27965150 C T 0.0009 Fasting blood glucose / / 22885922 rs10842994 chr12 27965150 C T 6.10E-10 Type 2 diabetes / / 22885922 rs10842994 chr12 27965150 C T 8.00E-06 Type 2 diabetes / / 24509480 rs4420311 chr12 27984190 G A 1.00E-07 Bone mineral density (paediatric,lower limb) / / 24945404 rs4420311 chr12 27984190 G A 3.00E-08 Bone mineral density (paediatric,lower limb) / / 24945404 rs4420311 chr12 27984190 G A 4.00E-07 Bone mineral density (paediatric,total body less head) / / 24945404 rs4420311 chr12 27984190 G A 4.00E-08 Bone mineral density (paediatric,total body less head) / / 24945404 rs7304170 chr12 28005841 C T 9.15E-05 Aging (time to event) / / 21782286 rs258401 chr12 28008769 T G 6.00E-06 Retinopathy in non-diabetics / / 23393555 rs10492367 chr12 28014970 G T 7.00E-07 Osteoarthritis / / 22763110 rs7953528 chr12 28017159 T A 2.00E-12 Bone mineral density / / 22504420 rs7953528 chr12 28017159 T A 1.07E-04 Bone mineral density / / 24249740 rs7953528 chr12 28017159 T A 7.09E-05 Bone mineral density / / 24249740 rs258415 chr12 28017522 A C 6.95E-04 Type 2 diabetes / / 17463246 rs258415 chr12 28017522 A C 7.92E-19 Peripartum cardiomyopathy / / 21665988 rs258415 chr12 28017522 A C 8.00E-10 White matter microstructure (global fractional anisotropy) / / 24736177 rs10843015 chr12 28029554 C T 9.17E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12301526 chr12 28031526 C T 5.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs7132107 chr12 28031963 C A 9.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs11049210 chr12 28037987 C T 9.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs4013943 chr12 28040392 C A 3.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs10771385 chr12 28047377 C T 6.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10771385 chr12 28047377 C T 9.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs956679 chr12 28052194 G A 6.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs956679 chr12 28052194 G A 8.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs7978444 chr12 28060631 C T 8.59E-05 Height / / pha003010 rs7965247 chr12 28060801 T C 8.52E-05 Height / / pha003010 rs10492366 chr12 28071369 G C 8.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs7313833 chr12 28083196 G A 6.00E-06 Breast cancer / / 17529967 rs7137085 chr12 28085129 G A 8.68E-05 Hypertension / / 19609347 rs7137085 chr12 28085129 G A 3.40E-05 Alcohol dependence / / 20201924 rs7137085 chr12 28085129 G A 3.70E-04 Alcohol dependence / / 20201924 rs7137085 chr12 28085129 G A 3.38E-05 Alcoholism / / pha002893 rs7137085 chr12 28085129 G A 8.44E-05 Glucose levels / / pha003058 rs10771395 chr12 28089202 A G 4.81E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12300399 chr12 28090871 C A 2.22E-05 Intelligence / / 21826061 rs2347590 chr12 28093217 T C 2.13E-05 Intelligence / / 21826061 rs11609312 chr12 28095425 G A 1.89E-05 Intelligence / / 21826061 rs1981790 chr12 28096339 A G 2.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1861911 chr12 28099396 G T 7.67E-05 Intelligence / / 21826061 rs3906888 chr12 28104655 A C 3.03E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs997200 chr12 28119561 C T 7.44E-04 Heart Failure PTHLH intron pha002884 rs1268693 chr12 28126939 A G 8.31E-05 Waist-Hip Ratio / / pha003013 rs10843049 chr12 28134344 C T 2.74E-05 Longevity / / 20304771 rs11049255 chr12 28135989 T C 2.80E-05 Longevity / / 20304771 rs11049256 chr12 28137473 G A 2.95E-05 Longevity / / 20304771 rs42294 chr12 28137869 G T 4.38E-05 Longevity / / 20304771 rs33083 chr12 28139312 A G 6.45E-05 Longevity / / 20304771 rs805510 chr12 28139846 T C 0.00034 Coronary artery calcification / / 23727086 rs10771399 chr12 28155080 A G 8.00E-31 Breast cancer / / 23535729 rs10771399 chr12 28155080 A G 2.00E-12 Breast cancer / / 23535733 rs10771399 chr12 28155080 A G 8.00E-06 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs10771399 chr12 28155080 A G 2.00E-08 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) / / 24325915 rs12371778 chr12 28156081 C G 1.00E-08 Breast size / / 22747683 rs2619434 chr12 28165457 G A 1.00E-05 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) / / 24325915 rs7964407 chr12 28192989 G A 6.00E-06 IgG glycosylation / / 23382691 rs11049300 chr12 28195125 A G 3.00E-07 Asthma and hay fever / / 24388013 rs1554985 chr12 28214138 T C 2.25E-04 Heart Failure / / pha002885 rs522958 chr12 28228567 G A 1.00E-06 Attention deficit hyperactivity disorder / / 18821565 rs522958 chr12 28228567 G A 8.00E-07 Hyperactive-impulsive symptoms / / 18821565 rs10459086 chr12 28268444 G A 8.14E-04 Taste perception / / 22132133 rs10843104 chr12 28276626 T C 4.43E-07 Primary biliary cirrhosis / / 23000144 rs10843104 chr12 28276626 T C 0.000000443 Facial morphology / / 23028347 rs11049407 chr12 28334364 A G 1.48E-04 Multiple complex diseases / / 17554300 rs11049407 chr12 28334364 A G 4.10E-06 Height / / 18391952 rs6487673 chr12 28438407 T C 2.54E-10 Alcohol consumption CCDC91 intron pha001398 rs2169755 chr12 28491157 C G 6.45E-05 Crohn's disease and Celiac disease CCDC91 intron 21298027 rs10506030 chr12 28515881 A T 5.42E-04 Alcohol dependence CCDC91 intron 21314694 rs1586868 chr12 28521109 C T 7.36E-05 Crohn's disease and Celiac disease CCDC91 intron 21298027 rs2638953 chr12 28534415 G C 7.00E-17 Height CCDC91 intron 20881960 rs1257741 chr12 28534569 G C 5.62E-05 Crohn's disease and Celiac disease CCDC91 intron 21298027 rs10843164 chr12 28569714 T C 6.00E-12 Height CCDC91 intron 23563607 rs10771427 chr12 28605426 G A 5.72E-05 Crohn's disease and Celiac disease CCDC91 missense 21298027 rs10843178 chr12 28613434 G C 5.93E-04 Multiple complex diseases CCDC91 intron 17554300 rs11049634 chr12 28614229 G A 6.46E-04 Multiple complex diseases CCDC91 intron 17554300 rs3926041 chr12 28614709 A G 7.33E-04 Multiple complex diseases CCDC91 intron 17554300 rs2141203 chr12 28614861 A G 7.02E-04 Multiple complex diseases CCDC91 intron 17554300 rs10843179 chr12 28615058 G A 8.21E-04 Multiple complex diseases CCDC91 intron 17554300 rs10843180 chr12 28615154 A C 4.97E-04 Multiple complex diseases CCDC91 intron 17554300 rs1355473 chr12 28616565 A G 4.93E-04 Multiple complex diseases CCDC91 intron 17554300 rs11049635 chr12 28617226 T C 6.15E-04 Multiple complex diseases CCDC91 intron 17554300 rs11049656 chr12 28634638 C T 7.25E-04 Multiple complex diseases CCDC91 intron 17554300 rs11049658 chr12 28634863 T C 8.51E-04 Multiple complex diseases CCDC91 intron 17554300 rs6487684 chr12 28643213 T C 7.35E-06 Osteoarthritis CCDC91 intron 22763110 rs10506036 chr12 28650565 C T 7.44E-04 Multiple complex diseases CCDC91 intron 17554300 rs11049669 chr12 28651915 T C 6.79E-04 Multiple complex diseases CCDC91 intron 17554300 rs11049677 chr12 28658039 G C 7.37E-04 Multiple complex diseases CCDC91 intron 17554300 rs11049678 chr12 28658479 A G 8.81E-04 Multiple complex diseases CCDC91 intron 17554300 rs10506038 chr12 28659172 A G 7.35E-04 Multiple complex diseases CCDC91 intron 17554300 rs10843189 chr12 28659918 G A 6.39E-04 Multiple complex diseases CCDC91 intron 17554300 rs10843191 chr12 28660527 T G 6.42E-04 Multiple complex diseases CCDC91 intron 17554300 rs11049679 chr12 28661094 C G 7.66E-04 Multiple complex diseases CCDC91 intron 17554300 rs11049680 chr12 28661369 T C 3.15E-04 Multiple complex diseases CCDC91 intron 17554300 rs11049682 chr12 28661995 G A 5.36E-04 Multiple complex diseases CCDC91 intron 17554300 rs11049713 chr12 28711545 A G 9.05E-04 Multiple complex diseases / / 17554300 rs11049715 chr12 28714453 A G 6.55E-04 Multiple complex diseases / / 17554300 rs2175464 chr12 28717111 C A 4.75E-04 Gallstones / / 17632509 rs10843208 chr12 28725104 G A 3.52E-04 Multiple complex diseases / / 17554300 rs12314459 chr12 28728265 C T 1.43E-05 Adverse response to lamotrigine and phenytoin / / 22379998 rs7315906 chr12 28728545 A C 7.86E-04 Type 2 diabetes / / 17463246 rs11049723 chr12 28728836 G T 6.46E-04 Multiple complex diseases / / 17554300 rs7134807 chr12 28729250 G A 6.18E-04 Type 2 diabetes / / 17463246 rs10843211 chr12 28730650 C G 4.29E-04 Multiple complex diseases / / 17554300 rs4931087 chr12 28735091 G T 4.12E-04 Type 2 diabetes / / 17463246 rs10843215 chr12 28744641 C T 8.00E-06 Obesity-related traits / / 23251661 rs10843215 chr12 28744641 C T 1.52E-04 Attention deficit hyperactivity disorder / / pha002875 rs1398377 chr12 28752354 T C 4.93E-04 Alzheimer's disease / / 24755620 rs1996042 chr12 28755517 C T 4.86E-04 Alzheimer's disease / / 24755620 rs1512568 chr12 28758275 C A 4.32E-04 Alzheimer's disease / / 24755620 rs1996041 chr12 28758634 A G 5.28E-06 Colorectal cancer / / 21242260 rs1996041 chr12 28758634 A G 4.45E-04 Alzheimer's disease / / 24755620 rs7133546 chr12 28760126 T A 4.45E-04 Alzheimer's disease / / 24755620 rs17530372 chr12 28790240 A G 9.53E-04 Alzheimer's disease / / 24755620 rs12317868 chr12 28793329 A T 3.33E-04 Insulin resistance / / 21901158 rs10450689 chr12 28794063 C T 2.29E-05 Colorectal cancer / / 21242260 rs973687 chr12 28811318 C T 4.12E-04 Insulin resistance / / 21901158 rs1606355 chr12 28815792 G A 2.00E-06 Metabolite levels (Pyroglutamine) / / 23934736 rs10161071 chr12 28818038 C A 7.03E-04 Insulin resistance / / 21901158 rs1398373 chr12 28819034 C T 1.47E-05 Bilirubin levels,in serum / / 19389676 rs7136560 chr12 28870501 A G 4.55E-05 Triglycerides / / pha003080 rs17531637 chr12 28891374 A G 8.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs7307357 chr12 28900236 T C 1.60E-05 Cognitive test performance / / 20125193 rs1480632 chr12 28906620 A G 3.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs12370182 chr12 28950121 A T 0.000252 Salmonella-induced pyroptosis / / 22837397 rs723036 chr12 28951138 A G 0.0000984 Salmonella-induced pyroptosis / / 22837397 rs11049850 chr12 28980438 C T 2.69E-13 Metabolite levels / / 22286219 rs2086102 chr12 28981545 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs16933406 chr12 29001088 T G 3.87E-04 Multiple complex diseases / / 17554300 rs16933408 chr12 29001174 T C 4.82E-04 Multiple complex diseases / / 17554300 rs16933414 chr12 29001962 A G 9.95E-04 Multiple complex diseases / / 17554300 rs16933419 chr12 29002086 A G 6.67E-04 Multiple complex diseases / / 17554300 rs16933429 chr12 29003504 C G 6.90E-04 Multiple complex diseases / / 17554300 rs10506043 chr12 29003597 G A 8.37E-04 Type 2 diabetes / / 17463246 rs4931109 chr12 29005992 T C 9.00E-04 Chronic fatigue syndrome / / 21912186 rs16933443 chr12 29019363 A C 9.49E-05 Coronary heart disease / / pha003032 rs11049890 chr12 29024755 C T 4.88E-05 Coronary heart disease / / pha003035 rs11838106 chr12 29026123 A G 5.54E-04 Multiple complex diseases / / 17554300 rs16933533 chr12 29041042 C T 7.00E-06 Hypertension / / 22384028 rs11049899 chr12 29042933 C T 5.21E-12 Metabolite levels / / 22286219 rs7973181 chr12 29080104 A G 4.74E-05 Magnesium levels / / pha003092 rs16933618 chr12 29081823 T A 1.41E-05 Bipolar disorder and schizophrenia / / 20889312 rs16933618 chr12 29081823 T A 3.44E-05 Schizophrenia / / pha002857 rs12581564 chr12 29087463 A G 4.30E-04 Multiple complex diseases / / 17554300 rs1387243 chr12 29093524 T C 1.94E-04 Type 2 diabetes / / 17463246 rs17544148 chr12 29110669 A G 1.30E-06 Urinary metabolites / / 21572414 rs11049953 chr12 29111480 T C 2.60E-06 Urinary metabolites / / 21572414 rs10437765 chr12 29154310 T G 2.51E-04 Bipolar disorder / / 18317468 rs4931129 chr12 29167983 G A 1.90E-04 Bipolar disorder / / 18317468 rs10843294 chr12 29168178 G A 6.15E-04 Multiple complex diseases / / 17554300 rs10843294 chr12 29168178 G A 8.26E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2060568 chr12 29177603 G A 2.17E-04 Bipolar disorder / / 18317468 rs2060567 chr12 29177720 G A 2.08E-04 Bipolar disorder / / 18317468 rs2099530 chr12 29179523 G A 2.35E-05 Bipolar disorder / / 18317468 rs6487749 chr12 29189337 G A 1.64E-05 Bipolar disorder / / 18317468 rs4931135 chr12 29190261 A G 1.65E-05 Bipolar disorder / / 18317468 rs11049997 chr12 29190385 A G 4.39E-06 Left ventricular mass / / 21212386 rs10771467 chr12 29192282 C T 1.62E-05 Bipolar disorder / / 18317468 rs11049998 chr12 29194445 T C 2.95E-05 Bipolar disorder / / 18317468 rs4931148 chr12 29233852 G A 2.80E-05 Urinary metabolites / / 21572414 rs11050037 chr12 29258269 A C 1.59E-05 Bipolar disorder / / 18317468 rs11050038 chr12 29258327 A G 1.47E-05 Bipolar disorder / / 18317468 rs7970149 chr12 29273302 A C 2.06E-05 Bipolar disorder / / 18317468 rs4081964 chr12 29273524 G A 2.18E-05 Bipolar disorder / / 18317468 rs11050048 chr12 29273595 A G 1.23E-10 Metabolite levels / / 22286219 rs7310157 chr12 29274701 C T 1.85E-05 Bipolar disorder / / 18317468 rs7302742 chr12 29297562 G A 7.73E-04 Type 2 diabetes / / 17463246 rs7315584 chr12 29330843 A G 4.06E-04 Lung function (forced vital capacity) / / 24023788 rs10771498 chr12 29372629 G T 1.35E-05 Aging (time to event) / / 21782286 rs11610910 chr12 29404715 T C 9.88E-04 Type 2 diabetes FAR2 intron 17463246 rs11610910 chr12 29404715 T C 5.00E-04 Acute lymphoblastic leukemia (childhood) FAR2 intron 20189245 rs2015599 chr12 29435480 G A 6.00E-16 Mean platelet volume FAR2 intron 22139419 rs2015599 chr12 29435480 G A 6.00E-04 Mean platelet volume FAR2 intron 24026423 rs12814180 chr12 29460278 G A 4.00E-04 Acute lymphoblastic leukemia (childhood) FAR2 intron 20189245 rs10843389 chr12 29486229 T C 3.69E-04 Smoking quantity FAR2 intron 24665060 rs3782514 chr12 29530464 A G 8.59E-04 HIV-1 viral setpoint ERGIC2 intron 17641165 rs7296963 chr12 29579646 A G 1.30E-05 Urinary metabolites / / 21572414 rs7965795 chr12 29585932 C T 2.57E-04 Amyotrophic lateral sclerosis (sporadic) OVCH1 intron 24529757 rs10492375 chr12 29641032 C A 5.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OVCH1 intron 20877124 rs967181 chr12 29642573 A C 5.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OVCH1 missense 20877124 rs10492374 chr12 29648191 T G 8.80E-04 Parkinson's disease OVCH1 intron 17052657 rs10492374 chr12 29648191 T G 8.05E-05 Bipolar disorder and schizophrenia OVCH1 intron 20889312 rs10771544 chr12 29650361 A C 1.24E-04 Type 2 diabetes OVCH1 intron 17463246 rs10771544 chr12 29650361 A C 4.33E-05 Cognitive impairment induced by topiramate OVCH1 intron 22091778 rs10492308 chr12 29660777 T C 8.25E-04 Tourette syndrome TMTC1 intron 22889924 rs12823875 chr12 29810125 T C 9.59E-04 Multiple complex diseases TMTC1 intron 17554300 rs16934692 chr12 29811471 G A 4.02E-05 Body Mass Index TMTC1 intron pha003006 rs16934692 chr12 29811471 G A 7.31E-05 Weight TMTC1 intron pha003026 rs10843492 chr12 29851719 T C 3.24E-06 Systemic lupus erythematosus and Systemic sclerosis TMTC1 intron 23740937 rs2216979 chr12 29856414 C T 9.93E-05 Height TMTC1 intron pha003011 rs12809562 chr12 29871289 T G 9.80E-05 Monocyte chemoattractant protein-1 TMTC1 intron pha003071 rs16934812 chr12 29872318 T G 7.00E-06 Schizophrenia TMTC1 intron 22885689 rs302385 chr12 29872623 C T 6.69E-05 Smoking quantity TMTC1 intron 24665060 rs61803 chr12 29879550 T C 7.99E-04 Amyotrophic Lateral Sclerosis TMTC1 intron 17362836 rs302371 chr12 29888386 T C 1.05E-04 Myopia (pathological) TMTC1 intron 21095009 rs302334 chr12 29903912 T C 3.28E-05 Cognitive test performance TMTC1 intron 20125193 rs7977334 chr12 29910378 T C 2.18E-04 Hepatocellular carcinoma TMTC1 intron 22807686 rs12231167 chr12 29918319 T C 5.52E-05 Atopic dermatitis TMTC1 intron 23042114 rs4931215 chr12 29919461 A G 5.43E-05 Atopic dermatitis TMTC1 intron 23042114 rs11609828 chr12 29920088 A G 5.40E-05 Atopic dermatitis TMTC1 intron 23042114 rs10843501 chr12 29920111 T C 4.70E-05 Atopic dermatitis TMTC1 intron 23042114 rs10843502 chr12 29920117 T C 5.99E-05 Atopic dermatitis TMTC1 intron 23042114 rs10843503 chr12 29920318 T C 5.34E-05 Atopic dermatitis TMTC1 intron 23042114 rs10771579 chr12 29920420 G C 5.32E-05 Atopic dermatitis TMTC1 intron 23042114 rs10743672 chr12 29920565 G A 5.29E-05 Atopic dermatitis TMTC1 intron 23042114 rs10743673 chr12 29920569 G T 5.28E-05 Atopic dermatitis TMTC1 intron 23042114 rs4931216 chr12 29921735 A G 5.22E-05 Atopic dermatitis TMTC1 intron 23042114 rs7967779 chr12 29922051 G C 4.40E-05 Atopic dermatitis TMTC1 intron 23042114 rs4931217 chr12 29922821 A T 4.39E-05 Atopic dermatitis TMTC1 intron 23042114 rs4931218 chr12 29923853 G C 5.09E-05 Atopic dermatitis TMTC1 intron 23042114 rs4931219 chr12 29923876 T A 5.06E-05 Atopic dermatitis TMTC1 intron 23042114 rs4931220 chr12 29925233 C A 4.96E-05 Atopic dermatitis TMTC1 intron 23042114 rs4244848 chr12 29925273 A G 4.94E-05 Atopic dermatitis TMTC1 intron 23042114 rs4244849 chr12 29925484 T A 4.89E-05 Atopic dermatitis TMTC1 intron 23042114 rs10843504 chr12 29926132 G A 4.87E-05 Atopic dermatitis TMTC1 intron 23042114 rs2882467 chr12 29926776 A G 9.99E-05 Serum metabolites TMTC1 intron 19043545 rs2882467 chr12 29926776 A G 4.85E-05 Atopic dermatitis TMTC1 intron 23042114 rs11050428 chr12 29931784 G A 5.15E-05 Serum metabolites TMTC1 intron 19043545 rs11050428 chr12 29931784 G A 2.20E-04 Pulmonary function TMTC1 intron 23932459 rs302310 chr12 29970473 T C 7.28E-04 Smoking quantity / / 24665060 rs7972685 chr12 29981706 C T 1.98E-04 Multiple complex diseases / / 17554300 rs7972685 chr12 29981706 C T 3.60E-06 Urinary metabolites / / 21572414 rs12822092 chr12 30021696 C T 5.16E-05 Multiple complex diseases / / 17554300 rs11050512 chr12 30022328 C T 4.64E-05 Multiple complex diseases / / 17554300 rs11050515 chr12 30026488 A G 5.73E-05 Multiple complex diseases / / 17554300 rs2062295 chr12 30028120 T G 1.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12302114 chr12 30039024 G A 3.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11050546 chr12 30073334 C T 1.27E-04 Multiple complex diseases / / 17554300 rs7958129 chr12 30097843 G T 1.80E-05 Asthma (bronchodilator response) / / 22792082 rs2046383 chr12 30104142 T G 3.00E-06 Heart failure / / 20445134 rs2046383 chr12 30104142 T G 1.97E-04 Heart Failure / / pha002885 rs1463604 chr12 30113768 A G 6.98E-04 Cognition,early reading ability / / 17684495 rs1463605 chr12 30113883 C G 6.78E-04 Multiple complex diseases / / 17554300 rs1463605 chr12 30113883 C G 7.00E-08 Aging traits / / 17903295 rs2046384 chr12 30131243 A T 5.76E-04 Multiple complex diseases / / 17554300 rs7313472 chr12 30153329 C T 5.23E-04 Alzheimer's disease / / 24755620 rs1909149 chr12 30161627 T C 7.34E-04 Taste perception / / 22132133 rs7299394 chr12 30162624 G A 6.92E-04 Alzheimer's disease / / 24755620 rs16935257 chr12 30167493 G C 4.05E-04 Multiple complex diseases / / 17554300 rs4032492 chr12 30170897 A G 2.76E-04 Multiple complex diseases / / 17554300 rs12822379 chr12 30174496 G A 5.35E-04 Multiple complex diseases / / 17554300 rs12829697 chr12 30175956 A G 7.00E-06 Parkinson's disease (age of onset) / / 19772629 rs4931243 chr12 30181387 G C 3.28E-04 Type 2 diabetes / / 17463246 rs11609984 chr12 30184418 C G 7.00E-05 Multiple complex diseases / / 17554300 rs11610584 chr12 30185513 G A 8.06E-06 Multiple complex diseases / / 17554300 rs17547650 chr12 30186995 G A 1.31E-05 Multiple complex diseases / / 17554300 rs10771622 chr12 30215615 T C 6.84E-04 Type 2 diabetes / / 17463246 rs4931251 chr12 30220676 C T 1.12E-24 Narcolepsy / / 19629137 rs11561211 chr12 30221172 A G 9.00E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6487878 chr12 30247772 T C 5.57E-04 Alzheimer's disease / / 24755620 rs11050665 chr12 30277220 T C 2.60E-05 Cognitive performance / / 19734545 rs11050668 chr12 30281846 A G 3.16E-05 Cognitive performance / / 19734545 rs17549779 chr12 30282288 T G 2.46E-05 Cognitive performance / / 19734545 rs17549779 chr12 30282288 T G 1.43E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs17549779 chr12 30282288 T G 4.07E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs7311139 chr12 30313505 G T 6.50E-05 Triglycerides / / 19074352 rs1948032 chr12 30329034 T C 3.60E-05 Triglycerides / / 19074352 rs1879423 chr12 30335322 A G 9.00E-05 Triglycerides / / 19074352 rs10843648 chr12 30344432 G T 1.38E-04 Sarcoidosis / / 19165924 rs17459648 chr12 30356215 A G 1.07E-04 Multiple complex diseases / / 17554300 rs17459648 chr12 30356215 A G 5.80E-06 Urinary metabolites / / 21572414 rs10843660 chr12 30368457 T C 3.25E-67 Multiple complex diseases / / 17554300 rs11050722 chr12 30370825 G T 7.06E-04 Type 2 diabetes / / 17463246 rs2564577 chr12 30399425 C T 7.22E-04 Smoking quantity / / 24665060 rs2564567 chr12 30402461 G A 1.94E-04 Multiple complex diseases / / 17554300 rs12230378 chr12 30409810 G A 2.40E-04 Multiple complex diseases / / 17554300 rs11050764 chr12 30413152 A C 1.09E-10 Metabolite levels / / 22286219 rs17522293 chr12 30422235 C A 5.99E-04 Multiple complex diseases / / 17554300 rs4930919 chr12 30422705 C T 3.26E-04 White matter integrity / / 22425255 rs1965728 chr12 30436187 A G 7.79E-05 White matter integrity / / 22425255 rs10843708 chr12 30441330 C T 1.13E-04 White matter integrity / / 22425255 rs10843712 chr12 30448261 C T 1.13E-04 White matter integrity / / 22425255 rs10506065 chr12 30451040 C A 5.00E-06 Volumetric brain MRI / / 17903297 rs1731494 chr12 30458263 G A 7.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16906208 chr12 30488831 C T 2.58E-04 Multiple complex diseases / / 17554300 rs7975892 chr12 30496619 G A 2.19E-04 Multiple complex diseases / / 17554300 rs10843724 chr12 30497129 G C 8.03E-04 Multiple complex diseases / / 17554300 rs11050836 chr12 30497495 T A 9.44E-04 Multiple complex diseases / / 17554300 rs10506067 chr12 30498018 C T 9.52E-04 Multiple complex diseases / / 17554300 rs11050844 chr12 30498892 T C 8.21E-04 Multiple complex diseases / / 17554300 rs11050846 chr12 30499387 C G 8.37E-04 Multiple complex diseases / / 17554300 rs7139306 chr12 30499871 G A 9.16E-04 Multiple complex diseases / / 17554300 rs12579259 chr12 30503935 C A 0.0000467 Carotid intima media thickness / / 23152477 rs17481416 chr12 30538230 T G 5.72E-05 Type 2 diabetes / / 17463246 rs1506382 chr12 30549163 C T 5.01E-05 Rheumatoid arthritis / / 19503088 rs7308605 chr12 30562405 T C 2.85E-04 Multiple complex diseases / / 17554300 rs7968815 chr12 30568259 T C 3.80E-06 Urinary metabolites / / 21572414 rs4931328 chr12 30568646 T C 4.30E-06 Urinary metabolites / / 21572414 rs1580964 chr12 30576824 T C 2.30E-05 Urinary metabolites / / 21572414 rs1354713 chr12 30580612 G A 7.00E-06 Urinary metabolites / / 21572414 rs10771719 chr12 30590175 C T 1.30E-05 Urinary metabolites / / 21572414 rs10843753 chr12 30590426 C T 1.30E-05 Urinary metabolites / / 21572414 rs4931337 chr12 30599082 G A 2.70E-05 Urinary metabolites / / 21572414 rs10506068 chr12 30630673 G A 7.90E-06 Urinary metabolites / / 21572414 rs1506392 chr12 30632198 C T 1.40E-05 Urinary metabolites / / 21572414 rs11050937 chr12 30668771 G A 1.09E-10 Metabolite levels / / 22286219 rs17484785 chr12 30669753 T A 1.30E-05 Urinary metabolites / / 21572414 rs1385344 chr12 30687243 C T 2.20E-06 Urinary metabolites / / 21572414 rs1905675 chr12 30691807 G A 4.82E-07 Common variable immunodeficiency / / 21497890 rs11050953 chr12 30711970 T G 4.30E-06 Urinary metabolites / / 21572414 rs794161 chr12 30734402 C T 2.99E-05 Tunica Media / / pha003034 rs794161 chr12 30734402 C T 9.11E-05 Tunica Media / / pha003036 rs1258276 chr12 30753417 C A 8.78E-05 Elbow pain / / pha003008 rs33270 chr12 30785759 G A 2.41E-05 Bone mineral density IPO8 intron 19181680 rs33270 chr12 30785759 G A 9.91E-05 HDL cholesterol IPO8 intron pha003075 rs3910561 chr12 30800040 G C 8.45E-42 Lymphocyte counts IPO8 intron 22286170 rs7974489 chr12 30809492 G A 8.98E-04 Type 2 diabetes IPO8 intron 17463246 rs12809335 chr12 30848675 C T 4.76E-05 HIV-1 viral setpoint IPO8 UTR-5 22174851 rs7134692 chr12 30857391 C T 3.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs33132 chr12 30889293 T C 1.06E-04 Parkinson's disease CAPRIN2 intron 16252231 rs17688567 chr12 30906358 G A 0.00039 Breast cancer CAPRIN2 missense 23555315 rs11051070 chr12 30925894 T C 4.24E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs11051070 chr12 30925894 T C 4.24E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs1116163 chr12 30927650 A G 2.85E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs1116163 chr12 30927650 A G 2.85E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs2434121 chr12 30967208 T G 4.44E-04 Body mass index / / 21701565 rs2114904 chr12 30968662 A G 5.49E-04 Alcohol dependence / / 24277619 rs33149 chr12 30977355 A C 2.84E-05 Coronary heart disease / / pha003056 rs33151 chr12 30981978 G A 2.80E-05 Response to statin therapy / / 20339536 rs33153 chr12 30983838 A C 1.28E-04 Parkinson's disease / / 17052657 rs33153 chr12 30983838 A C 1.40E-05 Response to statin therapy / / 20339536 rs33153 chr12 30983838 A C 6.50E-05 Alcoholism (heaviness of drinking) / / 21529783 rs33157 chr12 30987977 A T 5.96E-04 Coronary Artery Disease / / 17634449 rs11612603 chr12 31009557 C T 7.46E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs11051119 chr12 31017481 T C 2.77E-04 Multiple complex diseases / / 17554300 rs11051126 chr12 31028087 C T 7.77E-04 Multiple complex diseases / / 17554300 rs11051137 chr12 31037881 G A 4.63E-04 Type 2 diabetes / / 17463246 rs1485348 chr12 31039752 G A 1.57E-05 Intelligence / / 21826061 rs39638 chr12 31040987 C T 8.62E-06 Intelligence / / 21826061 rs33249 chr12 31044197 T C 5.93E-06 Intelligence / / 21826061 rs10843853 chr12 31050186 G A 4.67E-05 Coronary heart disease / / pha003031 rs11051145 chr12 31050201 C T 6.27E-05 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs10843855 chr12 31055179 C G 5.96E-05 Type 2 diabetes / / 17463246 rs7307884 chr12 31058824 T C 6.83E-05 Attention deficit hyperactivity disorder / / 22420046 rs7975877 chr12 31068197 G T 3.63E-04 Obesity (extreme) / / 21935397 rs2075367 chr12 31092504 T G 8.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TSPAN11 intron 20877124 rs11051174 chr12 31092897 G A 2.20E-05 Parkinson's disease (familial) TSPAN11 intron 18985386 rs7315783 chr12 31099340 G A 7.63E-05 Multiple complex diseases TSPAN11 intron 17554300 rs7971358 chr12 31127160 A G 6.74E-04 Response to taxane treatment (placlitaxel) TSPAN11 intron 23006423 rs4931395 chr12 31128016 G A 3.65E-04 Response to taxane treatment (placlitaxel) TSPAN11 intron 23006423 rs11051196 chr12 31133065 C T 5.25E-07 Esophageal cancer (squamous cell) TSPAN11 intron 22960999 rs35083 chr12 31139301 T C 3.00E-04 Cognitive impairment induced by topiramate TSPAN11 intron 22091778 rs35075 chr12 31145029 A G 0.00008741 Sarcoidosis TSPAN11 UTR-3 22952805 rs3741869 chr12 31148187 G A 3.19E-05 Systemic lupus erythematosus TSPAN11 UTR-3 pha002867 rs35065 chr12 31149663 T C 9.13E-05 Waist Circumference / / pha003024 rs35065 chr12 31149663 T C 5.79E-06 Weight / / pha003026 rs35047 chr12 31163186 T G 5.90E-06 Elbow pain / / pha003008 rs10492245 chr12 31171028 C G 1.70E-06 Urinary metabolites / / 21572414 rs11051218 chr12 31201717 A G 6.60E-06 Urinary metabolites LOC100506660 intron 21572414 rs11051219 chr12 31201922 C A 7.10E-06 Urinary metabolites LOC100506660 intron 21572414 rs11051219 chr12 31201922 C A 3.19E-04 Substance dependence LOC100506660 intron 21818250 rs244496 chr12 31210114 C T 1.25E-06 Post-operative nausea and vomiting LOC100506660 intron 21694509 rs4356315 chr12 31213735 C T 1.03E-11 Lymphocyte counts LOC100506660 intron 22286170 rs6487980 chr12 31310808 T C 5.50E-04 Alcohol dependence OVOS2 intron 20201924 rs6487980 chr12 31310808 T C 9.00E-04 Alcohol dependence OVOS2 intron 20201924 rs7953222 chr12 31311075 C T 5.70E-04 Alcohol dependence OVOS2 intron 20201924 rs11051303 chr12 31334803 C T 5.07E-05 Height OVOS2 intron pha003010 rs41441848 chr12 31356049 A G 2.48E-04 Multiple complex diseases OVOS2 intron 17554300 rs4931462 chr12 31377942 T G 4.30E-07 Osteoarthritis / / 22566624 rs12826616 chr12 31379463 C T 3.90E-05 Memory performance / / 22105620 rs12818297 chr12 31383443 G C 7.30E-05 Memory performance / / 22105620 rs12825461 chr12 31384709 G A 2.90E-05 Memory performance / / 22105620 rs6487983 chr12 31387953 A C 0.0000044 Endometrial cancer / / 22426144 rs12819069 chr12 31390550 T C 6.76E-06 Common variable immunodeficiency / / 21497890 rs639449 chr12 31410821 G A 2.10E-05 Odorant perception / / 23910658 rs4931477 chr12 31454991 A G 7.52E-05 Blood Pressure FAM60A intron pha003049 rs4930974 chr12 31456888 C T 2.20E-05 Urinary metabolites FAM60A intron 21572414 rs4931478 chr12 31464663 G A 7.52E-05 Blood Pressure FAM60A intron pha003049 rs9971825 chr12 31499671 C A 2.85E-05 Elbow pain / / pha003008 rs2090772 chr12 31513999 G A 5.41E-05 Orofacial clefts / / 22419666 rs2090772 chr12 31513999 G A 9.59E-05 Blood Pressure / / pha003045 rs792871 chr12 31517960 C T 1.58E-05 Self-reported allergy / / 23817569 rs793191 chr12 31523856 A G 4.00E-05 Self-reported allergy / / 23817569 rs793161 chr12 31549334 C T 6.99E-05 Self-reported allergy DENND5B intron 23817569 rs7313889 chr12 31572227 T C 8.34E-04 Type 2 diabetes DENND5B intron 17463246 rs7314404 chr12 31579919 T G 6.20E-04 Type 2 diabetes DENND5B intron 17463246 rs793148 chr12 31587970 C T 1.00E-04 Information processing speed DENND5B intron 21130836 rs793186 chr12 31606463 T C 1.00E-04 Information processing speed DENND5B intron 21130836 rs2617191 chr12 31612627 C T 2.48E-05 Self-reported allergy DENND5B intron 23817569 rs4930977 chr12 31612905 G A 4.70E-05 Response to lithium treatment in bipolar disorder DENND5B intron 19448189 rs1259236 chr12 31624800 C A 1.60E-05 Response to lithium treatment in bipolar disorder DENND5B intron 19448189 rs1259235 chr12 31626732 A T 8.84E-05 Self-reported allergy DENND5B intron 23817569 rs1012154 chr12 31627584 C T 2.35E-05 Self-reported allergy DENND5B intron 23817569 rs793171 chr12 31637244 A G 8.54E-05 Self-reported allergy DENND5B intron 23817569 rs793177 chr12 31641826 C T 2.50E-05 Self-reported allergy DENND5B intron 23817569 rs1150942 chr12 31643951 T C 2.22E-05 Self-reported allergy DENND5B intron 23817569 rs4930979 chr12 31648826 C T 7.09E-04 Type 2 diabetes DENND5B missense 17463246 rs1716216 chr12 31664259 G A 9.22E-05 Self-reported allergy DENND5B intron 23817569 rs1259430 chr12 31673875 C T 8.72E-05 Self-reported allergy DENND5B intron 23817569 rs4931512 chr12 31675185 G A 6.20E-04 Type 2 diabetes DENND5B intron 17463246 rs4931513 chr12 31675229 G A 6.20E-04 Type 2 diabetes DENND5B intron 17463246 rs1150953 chr12 31677258 A C 9.99E-05 Self-reported allergy DENND5B intron 23817569 rs560239 chr12 31771689 G A 2.02E-04 Stroke / / pha002886 rs11051507 chr12 31795364 C A 2.07E-05 Alcohol and nictotine co-dependence / / 20158304 rs900609 chr12 31816767 G A 8.68E-04 Multiple complex diseases METTL20 intron 17554300 rs12818390 chr12 31832544 C T 5.45E-04 Response to cytidine analogues (gemcitabine) AMN1 intron 24483146 rs12818390 chr12 31832544 C T 7.37E-04 Response to cytadine analogues (cytosine arabinoside) AMN1 intron 24483146 rs11051544 chr12 31866833 T A,C,G 2.38E-14 Metabolite levels AMN1 intron 22286219 rs11051544 chr12 31866833 T A,C,G 7.83E-04 Response to cytadine analogues (cytosine arabinoside) AMN1 intron 24483146 rs11051548 chr12 31877289 G A 3.92E-04 Multiple complex diseases AMN1 intron 17554300 rs10506080 chr12 31935769 A G 0.0000963 Transmission distortion / / 22377632 rs4931558 chr12 31957496 T C 6.65E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs11051642 chr12 32025600 T C 0.0000495 Amyotrophic lateral sclerosis / / 23587638 rs11051645 chr12 32031114 G T 7.39E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1666224 chr12 32034552 C T 1.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7297402 chr12 32061753 C T 6.10E-06 Urinary metabolites / / 21572414 rs1151008 chr12 32097360 G T 1.00E-06 Corneal astigmatism / / 23761726 rs10771895 chr12 32139418 T G 9.14E-04 Multiple complex diseases C12orf35 intron 17554300 rs10771895 chr12 32139418 T G 1.89E-04 Lymphocyte counts C12orf35 intron 22286170 rs4931005 chr12 32145000 A G 2.36E-04 Multiple complex diseases C12orf35 intron 17554300 rs4931594 chr12 32150243 A C 5.00E-06 Obesity-related traits / / 23251661 rs1033306 chr12 32158726 T C 2.80E-06 Urinary metabolites / / 21572414 rs7316376 chr12 32178900 G A 5.00E-05 Asperger disorder / / 21182207 rs7316376 chr12 32178900 G A 2.48E-05 Dental caries / / 21940522 rs61926348 chr12 32188292 C T 0.0000545 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs61926351 chr12 32188696 T A,G 0.0000718 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2630564 chr12 32189664 A G 0.0000892 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2594033 chr12 32192156 T C 0.0000863 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2594034 chr12 32194375 C T 1.02E-04 Dental caries / / 21940522 rs7136780 chr12 32197877 G T 4.00E-05 Asperger disorder / / 21182207 rs1684119 chr12 32211642 C T 2.86E-04 Self-reported allergy / / 23817569 rs11051765 chr12 32215071 A T 1.60E-04 Multiple complex diseases / / 17554300 rs1260712 chr12 32222347 G A 4.86E-04 Multiple complex diseases / / 17554300 rs10844108 chr12 32222646 C T 4.18E-04 Multiple complex diseases / / 17554300 rs11051774 chr12 32226051 T A 6.18E-04 Multiple complex diseases / / 17554300 rs375895651 chr12 32228558 T TC 6.89E-05 Fibrinogen / / pha003068 rs6488029 chr12 32228558 T C 6.89E-05 Fibrinogen / / pha003068 rs2652007 chr12 32244773 G A 4.05E-04 Coronary heart disease / / 21971053 rs2652007 chr12 32244773 G A 5.00E-04 Schizophrenia / / 22037552 rs1144713 chr12 32261239 A G 7.00E-06 Obesity-related traits BICD1 intron 23251661 rs1798255 chr12 32287259 C T 5.70E-06 Urinary metabolites BICD1 intron 21572414 rs10506083 chr12 32323357 A G 2.07E-04 Suicide attempts in bipolar disorder BICD1 intron 21041247 rs792853 chr12 32378417 G A 1.50E-04 Epilepsy BICD1 intron 22116939 rs10844154 chr12 32380501 A C 4.00E-06 Weight BICD1 intron 19851299 rs10844154 chr12 32380501 A C 6.00E-07 Emphysema-related traits BICD1 intron 20709820 rs326633 chr12 32394104 C T 1.10E-06 Emphysema-related traits BICD1 intron 20709820 rs11051873 chr12 32398913 G A 4.02E-16 Metabolite levels BICD1 intron 22286219 rs161981 chr12 32418251 T C 6.10E-07 Emphysema-related traits BICD1 intron 20709820 rs261869 chr12 32422835 A G 8.10E-06 Emphysema-related traits BICD1 intron 20709820 rs2129590 chr12 32426389 A G 4.80E-06 Emphysema-related traits BICD1 intron 20709820 rs792859 chr12 32428826 G A 3.58E-04 Acute lung injury BICD1 intron 22295056 rs708224 chr12 32436409 A G 3.00E-07 Pancreatic cancer BICD1 intron 20686608 rs2593998 chr12 32442253 T C 2.14E-04 Acute lung injury BICD1 intron 22295056 rs261900 chr12 32463015 T G 9.76E-09 Electroencephalogram traits,in brain BICD1 intron 20421487 rs261902 chr12 32476727 A G 4.00E-06 Normalized brain volume BICD1 intron 19010793 rs16919787 chr12 32506874 G A 6.16E-04 Multiple complex diseases BICD1 intron 17554300 rs10771940 chr12 32513888 A T 4.37E-04 Smoking quantity BICD1 intron 24665060 rs325429 chr12 32514115 A G 4.37E-04 Smoking quantity BICD1 intron 24665060 rs16919819 chr12 32531539 T G 5.52E-04 Multiple complex diseases / / 17554300 rs11051970 chr12 32537488 G T 1.00E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs118143741 chr12 32546270 C G 0.0000226 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs111704698 chr12 32546551 G A 0.0000224 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35926650 chr12 32550835 A G 3.30E-04 Smoking initiation / / 24665060 rs4931622 chr12 32560781 C G 6.84E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10771951 chr12 32622097 C T 6.75E-04 Smoking initiation / / 24665060 rs10506085 chr12 32630503 G A 1.31E-04 Alzheimer's disease (late onset) / / 21379329 rs7961107 chr12 32635183 A G 4.64E-04 Depression (quantitative trait) / / 20800221 rs7961107 chr12 32635183 A G 2.91E-04 Smoking initiation / / 24665060 rs1032725 chr12 32641200 A G 3.30E-04 Smoking initiation / / 24665060 rs10506086 chr12 32642659 C T 1.53E-04 Alzheimer's disease (late onset) / / 21379329 rs10844220 chr12 32645059 A C 1.81E-04 Smoking initiation / / 24665060 rs2088809 chr12 32648257 C T 1.90E-05 Bipolar disorder and schizophrenia / / 20889312 rs16919947 chr12 32650582 G A 5.18E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs10844222 chr12 32651232 C T 6.06E-04 White matter integrity / / 22425255 rs1875311 chr12 32651839 T C 3.58E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs2133943 chr12 32654210 A G 4.04E-04 White matter integrity FGD4 nearGene-5 22425255 rs10844223 chr12 32657276 G A 4.88E-04 White matter integrity FGD4 intron 22425255 rs10844223 chr12 32657276 G A 6.61E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) FGD4 intron 23648065 rs7963397 chr12 32658637 C T 2.95E-04 White matter integrity FGD4 intron 22425255 rs17536908 chr12 32661218 A C 9.67E-04 Alzheimer's disease FGD4 intron 17998437 rs10506092 chr12 32667330 G T 3.71E-04 Parkinson's disease FGD4 intron 17052657 rs17609576 chr12 32674645 G T 4.62E-04 Type 2 diabetes FGD4 intron 17463246 rs17609576 chr12 32674645 G T 5.30E-06 Urinary metabolites FGD4 intron 21572414 rs11052055 chr12 32684909 A G 3.07E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FGD4 intron 24023788 rs7315682 chr12 32685957 C T 9.30E-04 Type 2 diabetes and 6 quantitative traits FGD4 intron 17848626 rs7315682 chr12 32685957 C T 2.10E-05 Kidney function and endocine traits FGD4 intron 17903292 rs17537634 chr12 32687352 A G 7.62E-05 Hearing function FGD4 intron 17255346 rs4931016 chr12 32690746 T C 8.93E-04 Stroke FGD4 intron pha002886 rs17538032 chr12 32702469 A G 2.82E-05 Cognitive performance FGD4 intron 19734545 rs7298165 chr12 32702740 T C 5.17E-05 Cognitive performance FGD4 intron 19734545 rs1875059 chr12 32702900 C T 2.66E-04 Insulin resistance FGD4 intron 21901158 rs10129043 chr12 32753008 G C 2.29E-06 Serum metabolites FGD4 intron 19043545 rs10844251 chr12 32753219 C T 4.07E-06 Serum metabolites FGD4 intron 19043545 rs999840 chr12 32762492 C T 6.84E-05 Alzheimer's disease FGD4 intron 24755620 rs10844253 chr12 32764184 G A 6.39E-05 Alzheimer's disease FGD4 cds-synon 24755620 rs10844259 chr12 32771912 G A 1.25E-04 Alzheimer's disease FGD4 intron 24755620 rs11052110 chr12 32777362 G A 6.35E-05 Alzheimer's disease FGD4 cds-synon 24755620 rs7970584 chr12 32778039 A G 1.42E-04 Alzheimer's disease FGD4 intron 24755620 rs10844260 chr12 32780496 T C 1.50E-04 Alzheimer's disease FGD4 intron 24755620 rs11052117 chr12 32783057 C T 7.40E-05 Alzheimer's disease FGD4 intron 24755620 rs10771969 chr12 32788131 A T 7.40E-05 Alzheimer's disease FGD4 intron 24755620 rs10771973 chr12 32792974 G A 2.28E-04 Breast cancer FGD4 intron 20852631 rs10771973 chr12 32792974 G A 2.77E-06 Paclitaxel-induced neuropathy FGD4 intron 23776197 rs10771973 chr12 32792974 G A 6.87E-05 Alzheimer's disease FGD4 intron 24755620 rs10844268 chr12 32794600 A C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FGD4 UTR-3 22628534 rs10844268 chr12 32794600 A C 1.17E-05 Alzheimer's disease FGD4 UTR-3 24755620 rs10506095 chr12 32800127 C T 1.36E-20 Parkinson's disease / / 24842889 rs6488076 chr12 32824887 A C 5.80E-05 Amyotrophic lateral sclerosis / / 19193627 rs9971875 chr12 32829864 G A 1.93E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7954206 chr12 32844706 A G 2.95E-05 Amyotrophic lateral sclerosis DNM1L intron 19193627 rs11052187 chr12 32851364 G A 6.30E-04 Alzheimer's disease DNM1L intron 24755620 rs10771984 chr12 32851417 T C 3.27E-05 Amyotrophic lateral sclerosis DNM1L intron 19193627 rs10844309 chr12 32859757 C T 3.32E-05 Amyotrophic lateral sclerosis DNM1L intron 19193627 rs2293341 chr12 32889911 C T 3.62E-04 Alzheimer's disease (late onset) DNM1L intron 21379329 rs3600 chr12 32896944 C T 3.87E-05 Bipolar disorder and schizophrenia DNM1L UTR-3 20889312 rs3789978 chr12 32947193 A G 6.70E-06 Urinary metabolites PKP2 intron 21572414 rs11052236 chr12 32948216 C T 0.0000341 Nonsyndromic striae distensae (stretch marks) PKP2 intron 23633020 rs11052249 chr12 32956901 C G 0.0000874 Nonsyndromic striae distensae (stretch marks) PKP2 intron 23633020 rs11052251 chr12 32957377 A G 2.40E-05 Urinary metabolites PKP2 intron 21572414 rs11533495 chr12 32962822 G A 0.0000311 Nonsyndromic striae distensae (stretch marks) PKP2 intron 23633020 rs141070704 chr12 32965581 C T 0.0000393 Nonsyndromic striae distensae (stretch marks) PKP2 intron 23633020 rs11052261 chr12 32968923 T G 5.20E-06 Urinary metabolites PKP2 intron 21572414 rs10844367 chr12 32973881 C T 0.0000506 Nonsyndromic striae distensae (stretch marks) PKP2 intron 23633020 rs7967264 chr12 32974218 T C 1.78E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) PKP2 intron 24023788 rs2389109 chr12 32980382 A C 0.0000747 Nonsyndromic striae distensae (stretch marks) PKP2 intron 23633020 rs16920304 chr12 32992139 C T 4.51E-04 Alzheimer's disease (late onset) PKP2 intron 21379329 rs1454933 chr12 33017043 A C 3.00E-06 Obesity-related traits PKP2 intron 23251661 rs1454933 chr12 33017043 A C 9.00E-06 Obesity-related traits PKP2 intron 23251661 rs11052286 chr12 33039426 T C 2.00E-05 Urinary metabolites PKP2 intron 21572414 rs11052286 chr12 33039426 T C 7.98E-04 Body mass index PKP2 intron 21701565 rs16920321 chr12 33055494 G A 1.43E-04 Body mass index / / 21701565 rs16920325 chr12 33055910 G A 4.35E-04 Body mass index / / 21701565 rs7132311 chr12 33060986 T G 1.70E-05 Urinary metabolites / / 21572414 rs4627165 chr12 33064966 C G 2.10E-05 Urinary metabolites / / 21572414 rs16920395 chr12 33066705 C T 2.60E-04 Body mass index / / 21701565 rs12425072 chr12 33072947 C A 4.76E-05 Coronary heart disease / / pha003035 rs10844390 chr12 33085198 C T 4.02E-04 Body mass index / / 21701565 rs10844390 chr12 33085198 C T 7.10E-04 Body mass index / / 21701565 rs10772019 chr12 33085304 A G 3.22E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs10844392 chr12 33085573 A G 3.85E-04 Alzheimer's disease (late onset) / / 21379329 rs10844393 chr12 33085583 C T 4.77E-04 Alzheimer's disease (late onset) / / 21379329 rs12370505 chr12 33089955 T C 1.41E-04 Alzheimer's disease (late onset) / / 21379329 rs11052322 chr12 33091018 C T 2.42E-04 Body mass index / / 21701565 rs11052322 chr12 33091018 C T 5.78E-04 Body mass index / / 21701565 rs7980576 chr12 33092156 A G 3.92E-04 Alzheimer's disease (late onset) / / 21379329 rs7980576 chr12 33092156 A G 6.90E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs11830829 chr12 33099129 A G 3.71E-05 Neuroblastoma / / pha002895 rs4128506 chr12 33102575 A C 5.83E-04 White matter integrity / / 22425255 rs11052333 chr12 33103270 C T 5.83E-04 White matter integrity / / 22425255 rs11052348 chr12 33117235 C T 5.83E-04 White matter integrity / / 22425255 rs16920456 chr12 33122213 G C 8.53E-32 Narcolepsy / / 19629137 rs17623138 chr12 33123890 G A 2.52E-04 Type 2 diabetes / / 17463246 rs10506099 chr12 33126965 A C 9.15E-05 Lung adenocarcinoma / / 19836008 rs10506099 chr12 33126965 A C 5.44E-04 White matter integrity / / 22425255 rs2133676 chr12 33130836 T G 2.66E-04 Alzheimer's disease (late onset) / / 21379329 rs983579 chr12 33144798 G A 1.35E-05 Nicotine smoking / / 19268276 rs1500071 chr12 33150520 C T 9.23E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2389118 chr12 33161568 C G 1.11E-04 Type 2 diabetes / / 17463246 rs2221160 chr12 33174272 C G 0.000843 Salmonella-induced pyroptosis / / 22837397 rs16920533 chr12 33180151 G A 5.54E-05 Type 2 diabetes / / 17463246 rs17624271 chr12 33207242 A G 5.59E-04 Multiple complex diseases / / 17554300 rs17554288 chr12 33244993 G T 2.40E-05 Urinary metabolites / / 21572414 rs1392331 chr12 33249832 A G 9.29E-05 White matter integrity / / 22425255 rs1500054 chr12 33263720 G A 2.59E-05 Sleep duration / / 22105623 rs10844469 chr12 33265244 C G 2.57E-05 Sleep duration / / 22105623 rs12305595 chr12 33265578 A G 2.57E-05 Sleep duration / / 22105623 rs4931057 chr12 33265703 T C 2.55E-05 Sleep duration / / 22105623 rs7976558 chr12 33265725 T C 1.89E-05 Sleep duration / / 22105623 rs10772033 chr12 33266612 A G 2.60E-05 Sleep duration / / 22105623 rs10506103 chr12 33266943 C T 1.15E-06 Sleep duration / / 22105623 rs10772036 chr12 33267018 T A 1.84E-05 Sleep duration / / 22105623 rs1846629 chr12 33267681 A G 2.41E-05 Sleep duration / / 22105623 rs1846630 chr12 33268089 T G 2.32E-05 Sleep duration / / 22105623 rs7308643 chr12 33268599 A T 2.48E-05 Sleep duration / / 22105623 rs10506104 chr12 33278996 T C 9.29E-05 White matter integrity / / 22425255 rs11052483 chr12 33308928 T C 9.29E-05 White matter integrity / / 22425255 rs10047666 chr12 33332749 C T 9.29E-05 White matter integrity / / 22425255 rs1379534 chr12 33333067 A G 2.50E-04 Type 2 diabetes / / 17463246 rs1902776 chr12 33355636 G A 2.79E-04 Taste perception / / 22132133 rs1457682 chr12 33359231 A G 1.17E-04 Taste perception / / 22132133 rs7958802 chr12 33368505 T C 9.29E-05 White matter integrity / / 22425255 rs4931708 chr12 33369682 C T 4.83E-05 Taste perception / / 22132133 rs11832405 chr12 33404713 T C 3.00E-04 Alzheimer's disease (late onset) / / 21379329 rs7296488 chr12 33408219 C T 0.0000458 Major depressive disorder / / 23149448 rs12307589 chr12 33414473 G A 5.72E-05 Multiple complex diseases / / 17554300 rs7294500 chr12 33425682 G A 1.21E-04 Multiple complex diseases / / 17554300 rs11052584 chr12 33427701 G T 1.24E-05 Multiple complex diseases / / 17554300 rs1007709 chr12 33438081 T G 1.32E-04 Alzheimer's disease (late onset) / / 21379329 rs1905421 chr12 33482212 T C 4.40E-05 Type 2 diabetes / / 17460697 rs11052670 chr12 33538179 C T 9.43E-04 Multiple complex diseases SYT10 cds-synon 17554300 rs1994169 chr12 33545516 T G 9.55E-06 Pulmonary function SYT10 intron 17903307 rs7980799 chr12 33576990 A C 6.00E-24 Heart rate SYT10 intron 23583979 rs6488163 chr12 33599127 C T 1.90E-05 Urinary metabolites / / 21572414 rs11052734 chr12 33663573 T C 4.32E-05 Brain structure / / 22504417 rs9300212 chr12 33701166 T C 8.00E-06 Cognitive test performance / / 17903297 rs10743827 chr12 33765194 T C 8.28E-04 Type 2 diabetes / / 17463246 rs7969103 chr12 33774077 A G 6.75E-04 Type 2 diabetes / / 17463246 rs7953801 chr12 33807712 G A 2.51E-04 Type 2 diabetes / / 17463246 rs16921293 chr12 33940823 A G 7.30E-04 Multiple complex diseases / / 17554300 rs12582885 chr12 33974535 G A 6.54E-05 Attention deficit hyperactivity disorder / / 23728934 rs1486885 chr12 34027419 C T 0.0005093 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1486885 chr12 34027419 C T 5.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4384452 chr12 34030026 T C 0.0004512 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4384452 chr12 34030026 T C 4.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10732555 chr12 34052364 A G 0.0004025 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10732555 chr12 34052364 A G 4.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs369316 chr12 34076290 T C 0.0003891 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs369316 chr12 34076290 T C 3.89E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs694088 chr12 34078575 C A 8.25E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs694088 chr12 34078575 C A 0.000172 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs694088 chr12 34078575 C A 1.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs694088 chr12 34078575 C A 1.72E-04 Response to antipsychotic treatment / / 23241943 rs3898966 chr12 34081127 A G 0.0003867 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs3898966 chr12 34081127 A G 3.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10844745 chr12 34083981 T G 0.0003824 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10844745 chr12 34083981 T G 3.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7962789 chr12 34089209 T G 0.0003758 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7962789 chr12 34089209 T G 3.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs412066 chr12 34091025 G A 0.0005705 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs412066 chr12 34091025 G A 5.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1844523 chr12 34091538 T C 0.0003092 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1844523 chr12 34091538 T C 3.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2636088 chr12 34097324 G A 0.0008019 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2636088 chr12 34097324 G A 8.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7303358 chr12 34108390 T C 0.0002991 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7303358 chr12 34108390 T C 2.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7976763 chr12 34110660 T C 0.0002974 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7976763 chr12 34110660 T C 2.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6488200 chr12 34111118 C A 0.0002711 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6488200 chr12 34111118 C A 2.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12306542 chr12 34112388 T C 0.0002688 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12306542 chr12 34112388 T C 2.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10844753 chr12 34113381 A G 0.0002681 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10844753 chr12 34113381 A G 2.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10844754 chr12 34113665 G A 0.0002672 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10844754 chr12 34113665 G A 2.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11053024 chr12 34119925 G A 0.0006617 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11053024 chr12 34119925 G A 6.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1826145 chr12 34127016 G A 0.000262 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1826145 chr12 34127016 G A 2.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11053027 chr12 34127731 G A 0.0002578 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11053027 chr12 34127731 G A 2.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10844762 chr12 34131161 T C 0.000257 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10844762 chr12 34131161 T C 2.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10844763 chr12 34132517 C G 0.0002556 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10844763 chr12 34132517 C G 2.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11053031 chr12 34135810 A C 0.0006144 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11053031 chr12 34135810 A C 6.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1627770 chr12 34149433 G T 1.52E-07 Response to statin therapy / / 22368281 rs1627770 chr12 34149433 G T 0.0004072 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1627770 chr12 34149433 G T 4.07E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs863626 chr12 34150869 C T 1.34E-07 Response to statin therapy / / 22368281 rs863626 chr12 34150869 C T 0.0004064 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs863626 chr12 34150869 C T 4.06E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11053045 chr12 34158221 A T 1.30E-07 Response to statin therapy / / 22368281 rs11053045 chr12 34158221 A T 0.0003946 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11053045 chr12 34158221 A T 3.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs814652 chr12 34167670 T G 0.0003802 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs814652 chr12 34167670 T G 3.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10844775 chr12 34170425 A G 0.0003658 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10844775 chr12 34170425 A G 3.66E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1619785 chr12 34170605 C A 1.26E-07 Response to statin therapy / / 22368281 rs1619785 chr12 34170605 C A 0.0003575 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1619785 chr12 34170605 C A 3.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs366873 chr12 34177847 T C 0.0008138 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ALG10 intron 23233654 rs366873 chr12 34177847 T C 8.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) ALG10 intron 23233662 rs10844779 chr12 34186008 G A 1.38E-07 Response to statin therapy / / 22368281 rs10844779 chr12 34186008 G A 0.0003575 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10844779 chr12 34186008 G A 3.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11053068 chr12 34194210 T C 1.38E-07 Response to statin therapy / / 22368281 rs11053068 chr12 34194210 T C 0.0003529 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11053068 chr12 34194210 T C 3.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs5004272 chr12 34245756 A G 2.87E-07 Response to statin therapy / / 22368281 rs5004272 chr12 34245756 A G 0.0004014 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs5004272 chr12 34245756 A G 4.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10844823 chr12 34266867 G C 2.90E-07 Response to statin therapy / / 22368281 rs10844823 chr12 34266867 G C 0.0003835 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10844823 chr12 34266867 G C 3.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11614489 chr12 34285581 C T 2.50E-05 Fasting plasma glucose / / 19060907 rs11614489 chr12 34285581 C T 4.18E-05 Glucose levels / / pha002899 rs7977995 chr12 34362752 T C 2.10E-05 Urinary metabolites / / 21572414 rs10772153 chr12 34369926 C T 3.55E-04 Type 2 diabetes / / 17463246 rs10844842 chr12 34375830 C A 7.98E-04 Type 2 diabetes / / 17463246 rs10844844 chr12 34380350 C A 1.40E-05 Urinary metabolites / / 21572414 rs10743844 chr12 34383570 G T 2.00E-05 Urinary metabolites / / 21572414 rs10506121 chr12 34399035 G C 2.50E-05 Urinary metabolites / / 21572414 rs10844849 chr12 34415617 G A 7.98E-04 Type 2 diabetes / / 17463246 rs11053184 chr12 34427785 C G 2.50E-05 Urinary metabolites / / 21572414 rs11053185 chr12 34428857 A G 1.90E-05 Urinary metabolites / / 21572414 rs11053199 chr12 34450534 A G 2.10E-05 Urinary metabolites / / 21572414 rs11053208 chr12 34460029 A G 2.60E-05 Urinary metabolites / / 21572414 rs6488219 chr12 34460562 T C 1.70E-05 Urinary metabolites / / 21572414 rs11834063 chr12 34468525 T G 5.71E-05 Multiple complex diseases / / 17554300 rs11053218 chr12 34474792 G A,C,T 2.30E-05 Urinary metabolites / / 21572414 rs7306435 chr12 34482933 C T 2.50E-05 Urinary metabolites / / 21572414 rs7309532 chr12 34483140 A T 2.00E-05 Urinary metabolites / / 21572414 rs11053249 chr12 34518834 T A 1.40E-05 Urinary metabolites / / 21572414 rs11053262 chr12 34532722 G A 5.45E-04 Smoking cessation / / 24665060 rs7309421 chr12 34553795 G A 1.40E-05 Urinary metabolites / / 21572414 rs10844932 chr12 34673444 G A 0.00000002 Brain microstructure and intellectual performance / / 22723713 rs11829528 chr12 34778715 A G 0.000000002 Brain microstructure and intellectual performance / / 22723713 rs11053463 chr12 34835837 A G 2.00E-05 Urinary metabolites / / 21572414 rs7294316 chr12 38195942 A T 8.40E-04 Type 2 diabetes / / 17463246 rs11179774 chr12 38219559 A C 8.40E-04 Type 2 diabetes / / 17463246 rs11514342 chr12 38236710 T A 8.40E-04 Type 2 diabetes / / 17463246 rs11495369 chr12 38238673 T C 8.40E-04 Type 2 diabetes / / 17463246 rs8189467 chr12 38241956 T C 8.40E-04 Type 2 diabetes / / 17463246 rs8189549 chr12 38245752 A G 8.40E-04 Type 2 diabetes / / 17463246 rs2320522 chr12 38251438 C T 8.40E-04 Type 2 diabetes / / 17463246 rs61177382 chr12 38361925 C T 3.76E-19 Metabolite levels / / 22286219 rs2204008 chr12 38439203 C T 3.00E-15 Bladder cancer / / 24163127 rs12227938 chr12 38633860 A T 3.58E-07 Multiple complex diseases / / 17554300 rs12424762 chr12 38643486 A G 5.27E-05 Alzheimer's disease / / 21098978 rs1973293 chr12 38679575 C T 3.31E-06 Drug-induced liver injury (flucloxacillin) / / 19483685 rs12425010 chr12 38684007 A G 4.17E-05 Alzheimer's disease / / 21098978 rs1825806 chr12 38692547 G A 4.71E-06 Drug-induced liver injury (flucloxacillin) / / 19483685 rs6582576 chr12 38701230 T C 4.71E-06 Drug-induced liver injury (flucloxacillin) / / 19483685 rs11183233 chr12 38701336 T C 7.33E-05 Multiple complex diseases / / 17554300 rs1843876 chr12 38708549 C T 4.71E-06 Drug-induced liver injury (flucloxacillin) / / 19483685 rs4882284 chr12 38710459 A G 4.71E-06 Drug-induced liver injury (flucloxacillin) / / 19483685 rs6582607 chr12 38717678 T C 3.48E-06 Drug-induced liver injury (flucloxacillin) ALG10B UTR-3 19483685 rs10880934 chr12 38730455 C T 2.74E-06 Drug-induced liver injury (flucloxacillin) / / 19483685 rs6582630 chr12 38743508 G A 1.00E-06 Drug-induced liver injury (flucloxacillin) / / 19483685 rs12422226 chr12 38755773 A G 3.50E-05 Alzheimer's disease / / 21098978 rs7310514 chr12 38767144 G A 3.39E-05 Alzheimer's disease / / 21098978 rs7968322 chr12 38792348 T C 4.08E-06 Drug-induced liver injury (flucloxacillin) / / 19483685 rs4073360 chr12 38875152 A G 0.00000692 Cytarabine sensitivity / / 23538338 rs7980932 chr12 38921583 G T 4.66E-06 Drug-induced liver injury (flucloxacillin) / / 19483685 rs12423659 chr12 38979640 A G 2.60E-05 Alzheimer's disease / / 21098978 rs11168782 chr12 39001014 A G 7.39E-04 Type 2 diabetes / / 17463246 rs2653762 chr12 39039258 T C 9.76E-04 Multiple complex diseases / / 17554300 rs826886 chr12 39095797 G A 2.17E-04 Type 2 diabetes CPNE8 intron 17463246 rs826838 chr12 39106731 C T 3.31E-04 Type 2 diabetes CPNE8 intron 17463246 rs826838 chr12 39106731 C T 4.00E-09 Heart rate CPNE8 intron 23583979 rs1095575 chr12 39110284 G C 3.28E-04 Type 2 diabetes CPNE8 intron 17463246 rs864324 chr12 39122853 G A 6.20E-05 Eating disorders (purging via substances) CPNE8 intron 23568457 rs12822721 chr12 39128923 C T 7.62E-04 Suicide attempts in bipolar disorder CPNE8 intron 21423239 rs1352122 chr12 39130885 G A 9.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) CPNE8 intron 23648065 rs1021257 chr12 39139518 A C 9.49E-06 Alzheimer's disease CPNE8 intron 21098978 rs12230422 chr12 39161047 A G 8.84E-05 Alzheimer's disease CPNE8 intron 21098978 rs10876062 chr12 39168186 T C 4.23E-05 Alzheimer's disease CPNE8 intron 21098978 rs826837 chr12 39184525 T C 6.01E-05 Alzheimer's disease CPNE8 intron 21098978 rs826836 chr12 39185406 A G 5.96E-05 Alzheimer's disease CPNE8 intron 21098978 rs2388059 chr12 39187660 C G 9.44E-04 Type 2 diabetes CPNE8 intron 17846124 rs7309194 chr12 39207946 G A 5.05E-05 Alzheimer's disease CPNE8 intron 21098978 rs12424244 chr12 39215652 C G 3.47E-05 Alzheimer's disease CPNE8 intron 21098978 rs17126713 chr12 39219018 G A 3.32E-05 Alzheimer's disease CPNE8 intron 21098978 rs10876149 chr12 39228083 C G 5.01E-04 Type 2 diabetes CPNE8 intron 17463246 rs9943730 chr12 39243193 C G 3.01E-05 Alzheimer's disease CPNE8 intron 21098978 rs12425783 chr12 39250684 T C 2.88E-05 Alzheimer's disease CPNE8 intron 21098978 rs11169838 chr12 39253108 C T 2.00E-06 IgG glycosylation CPNE8 intron 23382691 rs11169838 chr12 39253108 C T 8.00E-06 IgG glycosylation CPNE8 intron 23382691 rs12422883 chr12 39256950 C A 2.93E-05 Alzheimer's disease CPNE8 intron 21098978 rs10876185 chr12 39258649 A G 2.90E-05 Alzheimer's disease CPNE8 intron 21098978 rs11169878 chr12 39264960 T C 7.86E-05 Alzheimer's disease CPNE8 intron 21098978 rs7311812 chr12 39282318 A G 6.35E-05 Alzheimer's disease CPNE8 intron 21098978 rs7308580 chr12 39284958 C T 1.42E-05 Alzheimer's disease CPNE8 intron 21098978 rs7307936 chr12 39285106 G A 1.42E-05 Alzheimer's disease CPNE8 intron 21098978 rs1516555 chr12 39297028 T C 1.45E-05 Alzheimer's disease CPNE8 intron 21098978 rs908511 chr12 39300741 T C 1.31E-05 Cognitive test performance / / 20125193 rs12423647 chr12 39306767 G A 2.16E-05 Alzheimer's disease / / 21098978 rs1878224 chr12 39309714 T C 2.34E-05 Alzheimer's disease / / 21098978 rs7968397 chr12 39310591 A T 3.70E-05 Alzheimer's disease / / 21098978 rs7971601 chr12 39310651 T C 3.77E-05 Alzheimer's disease / / 21098978 rs7974510 chr12 39310730 T C 3.83E-05 Alzheimer's disease / / 21098978 rs1878223 chr12 39313135 C T 4.30E-05 Alzheimer's disease / / 21098978 rs5017082 chr12 39314564 C A 9.68E-04 Type 2 diabetes / / 17463246 rs7298320 chr12 39317837 C G 6.67E-05 Alzheimer's disease / / 21098978 rs12424948 chr12 39318952 A G 4.68E-05 Alzheimer's disease / / 21098978 rs7308161 chr12 39363459 T C 0.000633 Salmonella-induced pyroptosis / / 22837397 rs6580889 chr12 39369742 T C 0.000457 Salmonella-induced pyroptosis / / 22837397 rs12578384 chr12 39372149 A G 0.000009 Salmonella-induced pyroptosis / / 22837397 rs3858554 chr12 39381460 G A 4.04E-04 Type 2 diabetes / / 17463246 rs11170489 chr12 39433977 T C 1.00E-06 Urinary metabolites / / 21572414 rs11170554 chr12 39453361 G A 7.37E-05 Serum metabolites / / 19043545 rs1349255 chr12 39473093 T C 0.00004312 Sarcoidosis / / 22952805 rs4768553 chr12 39482640 T C 0.00008131 Sarcoidosis / / 22952805 rs4768554 chr12 39482756 T C 2.90E-05 Urinary metabolites / / 21572414 rs4768554 chr12 39482756 T C 0.000053 Sarcoidosis / / 22952805 rs10876499 chr12 39490066 A G 0.00005738 Sarcoidosis / / 22952805 rs11170764 chr12 39502455 A G 5.29E-05 Serum metabolites / / 19043545 rs12231816 chr12 39525136 T A 4.14E-04 Sudden cardiac arrest / / 21658281 rs11613448 chr12 39525149 C G 5.77E-05 Serum metabolites / / 19043545 rs10876547 chr12 39536022 G A 4.33E-05 Serum metabolites / / 19043545 rs7978480 chr12 39565735 A G 4.39E-05 Attention deficit hyperactivity disorder / / 23728934 rs4445677 chr12 39565846 T G 7.17E-05 Attention deficit hyperactivity disorder / / 23728934 rs17483228 chr12 39570573 T C 3.38E-04 Obesity (extreme) / / 21935397 rs7956733 chr12 39594506 C T 3.60E-05 Waist-Hip Ratio / / pha003028 rs7135625 chr12 39617223 C G 5.90E-06 Urinary metabolites / / 21572414 rs17126995 chr12 39666198 A G 3.32E-04 Multiple complex diseases / / 17554300 rs11172263 chr12 39870640 C A 1.39E-04 Multiple complex diseases / / 17554300 rs11172502 chr12 39932451 A T 9.68E-04 Depression (quantitative trait) / / 20800221 rs11172566 chr12 39947325 T C 9.54E-04 Depression (quantitative trait) ABCD2 UTR-3 20800221 rs11172696 chr12 39980523 T C 9.96E-04 Depression (quantitative trait) ABCD2 intron 20800221 rs11836770 chr12 40034699 G A 3.53E-06 Body mass (lean) C12orf40 intron 19268274 rs11173546 chr12 40174871 A G 6.20E-06 Urinary metabolites SLC2A13 intron 21572414 rs4539398 chr12 40244001 G A 9.53E-04 Multiple complex diseases SLC2A13 intron 17554300 rs7135349 chr12 40284554 C T 5.94E-05 Nicotine smoking SLC2A13 intron 19268276 rs884864 chr12 40284666 T C 6.17E-05 Height SLC2A13 intron pha003011 rs17127259 chr12 40303631 G A 1.63E-05 Progressive supranuclear palsy SLC2A13 intron 21685912 rs11174338 chr12 40323641 G T 7.91E-06 Cardiovascular disease SLC2A13 intron 18179892 rs11174359 chr12 40327411 G A 1.99E-05 Height SLC2A13 intron pha003010 rs11174359 chr12 40327411 G A 7.62E-06 Height SLC2A13 intron pha003011 rs953824 chr12 40331774 T C 1.00E-05 Urinary metabolites SLC2A13 intron 21572414 rs953824 chr12 40331774 T C 4.55E-06 Height SLC2A13 intron pha003010 rs953824 chr12 40331774 T C 1.65E-06 Height SLC2A13 intron pha003011 rs953824 chr12 40331774 T C 3.56E-05 Lung function (forced vital capacity) SLC2A13 intron pha003104 rs1005956 chr12 40341085 T C 3.00E-06 Sleep quality SLC2A13 intron 23728906 rs2896824 chr12 40350925 C T 1.79E-05 Height SLC2A13 intron pha003010 rs2896824 chr12 40350925 C T 5.67E-06 Height SLC2A13 intron pha003011 rs28370608 chr12 40351869 G A 7.83E-04 Obesity (extreme) SLC2A13 intron 21935397 rs10877840 chr12 40352996 T C 1.00E-06 Parkinson's disease SLC2A13 intron 22451204 rs11174478 chr12 40354244 G A 2.00E-06 Insomnia SLC2A13 intron 23728906 rs7311756 chr12 40370173 C A 1.30E-04 Body mass index SLC2A13 intron 17255346 rs2200085 chr12 40378333 A G 0.000182225 Primary sclerosing cholangitis SLC2A13 intron 23603763 rs814228 chr12 40383902 C G 6.45E-04 Multiple complex diseases SLC2A13 intron 17554300 rs11174631 chr12 40385118 C T 9.64E-05 Parkinson's disease SLC2A13 intron 21738487 rs2242367 chr12 40413698 G A 1.82E-04 Amyotrophic Lateral Sclerosis SLC2A13 intron 17827064 rs1542594 chr12 40418628 A G 2.23E-04 Amyotrophic Lateral Sclerosis SLC2A13 intron 17827064 rs483163 chr12 40424953 T C 1.65E-04 Amyotrophic Lateral Sclerosis SLC2A13 intron 17827064 rs1994090 chr12 40428561 G T 3.00E-08 Parkinson's disease SLC2A13 intron 19915576 rs1994090 chr12 40428561 G T 2.72E-08 Prion diseases SLC2A13 intron 22210626 rs1994090 chr12 40428561 G T 6.31E-10 Parkinson's disease SLC2A13 intron 22438815 rs1994090 chr12 40428561 G T 3.20E-54 Parkinson's disease SLC2A13 intron 24842889 rs4611275 chr12 40433169 A G 8.33E-04 Suicide attempts in bipolar disorder SLC2A13 intron 21423239 rs2404347 chr12 40433275 T C 7.70E-04 Suicide attempts in bipolar disorder SLC2A13 intron 21423239 rs11564162 chr12 40442892 A G 9.52E-05 Parkinson's disease SLC2A13 intron 19915575 rs10784359 chr12 40445750 C T 2.01E-05 Parkinson's disease SLC2A13 intron pha002868 rs11564279 chr12 40445759 G A 2.73E-04 Amyotrophic Lateral Sclerosis SLC2A13 intron 17827064 rs7974495 chr12 40460938 A G 8.84E-04 Suicide attempts in bipolar disorder SLC2A13 intron 21423239 rs11175024 chr12 40463950 A G 2.72E-04 Multiple complex diseases SLC2A13 intron 17554300 rs7304279 chr12 40465942 T C 1.13E-10 Parkinson's disease SLC2A13 intron 22438815 rs7304279 chr12 40465942 T C 3.62E-54 Parkinson's disease SLC2A13 intron 24842889 rs4768212 chr12 40474147 C T 6.18E-07 Parkinson's disease SLC2A13 intron 22438815 rs4768212 chr12 40474147 C T 3.62E-54 Parkinson's disease SLC2A13 intron 24842889 rs1586038 chr12 40475482 A C 4.49E-04 Multiple complex diseases SLC2A13 intron 17554300 rs2708453 chr12 40478652 G T 4.83E-07 Parkinson's disease SLC2A13 intron 22438815 rs2708453 chr12 40478652 G T 3.62E-54 Parkinson's disease SLC2A13 intron 24842889 rs11564216 chr12 40480027 G T 1.43E-04 Multiple complex diseases SLC2A13 intron 17554300 rs10878089 chr12 40486605 A G 3.51E-04 Multiple complex diseases SLC2A13 intron 17554300 rs17458459 chr12 40492437 G A 6.74E-04 Obesity (extreme) SLC2A13 intron 21935397 rs2896905 chr12 40493416 G A 5.03E-06 Parkinson's disease SLC2A13 intron pha002868 rs11564122 chr12 40547750 G A 7.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7959787 chr12 40551073 C T 2.21E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1873613 chr12 40552417 T C 5.10E-05 Leprosy / / 20018961 rs2249017 chr12 40561220 A G 5.50E-04 Volumetric brain MRI / / 17903297 rs1388587 chr12 40561535 C G 8.10E-05 Serum metabolites / / 19043545 rs11564116 chr12 40569777 C T 7.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2046932 chr12 40580440 G A 1.11E-06 Parkinson's disease / / 22438815 rs2046932 chr12 40580440 G A 1.63E-41 Parkinson's disease / / 24842889 rs7975693 chr12 40588678 C T 8.10E-05 Volumetric brain MRI / / 17903297 rs1491923 chr12 40591117 A G 1.55E-05 Parkinson's disease / / 19915575 rs1491923 chr12 40591117 A G 2.46E-04 Parkinson's disease / / 22438815 rs11564273 chr12 40598152 T G 6.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs11564273 chr12 40598152 T G 6.72E-11 Parkinson's disease / / 22438815 rs11175593 chr12 40601940 C T 3.00E-10 Crohn's disease / / 18587394 rs11175593 chr12 40601940 C T 3.00E-10 Asthma / / 21150878 rs11175593 chr12 40601940 C T 3.08E-10 Multiple sclerosis / / 22190364 rs1491932 chr12 40602224 T G 9.12E-06 Parkinson's disease / / 21738487 rs6581593 chr12 40602765 C T 4.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs2638230 chr12 40604075 T G 1.34E-05 Parkinson's disease / / 21738487 rs17519419 chr12 40606702 C T 5.68E-04 Taste perception / / 22132133 rs17465681 chr12 40606992 G A 7.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs7970326 chr12 40607891 A C 7.47E-06 Parkinson's disease / / 21738487 rs10878220 chr12 40608880 C T 7.24E-05 Multiple sclerosis (age of onset) / / 19010793 rs2708437 chr12 40614779 C T 4.57E-06 Multiple complex diseases / / 17554300 rs1388598 chr12 40616166 G A 7.83E-04 Taste perception / / 22132133 rs28365207 chr12 40616414 A G 8.02E-04 Taste perception / / 22132133 rs7294619 chr12 40617202 T C 5.19E-05 Parkinson's disease LRRK2 nearGene-5 21738487 rs7294619 chr12 40617202 T C 4.85E-04 Taste perception LRRK2 nearGene-5 22132133 rs10878226 chr12 40617692 G C 4.85E-04 Taste perception LRRK2 nearGene-5 22132133 rs1491942 chr12 40620808 C G 6.00E-14 Parkinson's disease LRRK2 intron 21292315 rs1491942 chr12 40620808 C G 6.00E-15 Parkinson's disease LRRK2 intron 22438815 rs1491942 chr12 40620808 C G 3.23E-08 Parkinson's disease LRRK2 intron 22451204 rs1491942 chr12 40620808 C G 6.00E-04 Parkinson's disease LRRK2 intron 24511991 rs1491942 chr12 40620808 C G 6.00E-04 Parkinson's disease LRRK2 intron 24511991 rs1491942 chr12 40620808 C G 1.71E-41 Parkinson's disease LRRK2 intron 24842889 rs1491941 chr12 40620815 G A 1.53E-05 Parkinson's disease LRRK2 intron 21738487 rs11175655 chr12 40623727 G A 5.20E-04 Taste perception LRRK2 intron 22132133 rs11175658 chr12 40624310 A G 4.85E-04 Taste perception LRRK2 intron 22132133 rs1352877 chr12 40626378 A T 9.88E-05 Multiple complex diseases LRRK2 intron 17554300 rs10878244 chr12 40631608 G A 8.24E-06 Parkinson's disease LRRK2 intron 21738487 rs10878245 chr12 40631791 T C 1.51E-04 Coronary Artery Disease LRRK2 cds-synon 17634449 rs10878245 chr12 40631791 T C 1.05E-04 Taste perception LRRK2 cds-synon 22132133 rs10878246 chr12 40632099 T G 2.79E-06 Parkinson's disease LRRK2 intron 21738487 rs954884 chr12 40632958 G T 5.00E-05 Taste perception LRRK2 intron 22132133 rs10878249 chr12 40633314 T C 1.70E-04 Tourette syndrome LRRK2 intron 22889924 rs2404580 chr12 40639561 A G 3.40E-04 Taste perception LRRK2 intron 22132133 rs1491938 chr12 40645630 G A 1.64E-04 Taste perception LRRK2 intron 22132133 rs1491938 chr12 40645630 G A 6.48E-04 Tourette syndrome LRRK2 intron 22889924 rs1907633 chr12 40650351 C T 8.86E-05 Parkinson's disease LRRK2 intron 21738487 rs1907632 chr12 40650502 G A 9.33E-05 Parkinson's disease LRRK2 intron 21738487 rs28903073 chr12 40653510 G A 2.72E-12 Parkinson's disease LRRK2 intron 21738487 rs11175769 chr12 40656179 A G 1.60E-05 Urinary metabolites LRRK2 intron 21572414 rs4293189 chr12 40657225 G A 1.10E-05 Urinary metabolites LRRK2 intron 21572414 rs10506151 chr12 40670998 C A 1.60E-04 Volumetric brain MRI LRRK2 intron 17903297 rs10878307 chr12 40671989 A G 3.04E-04 Lung function (forced vital capacity) LRRK2 missense 24023788 rs10878307 chr12 40671989 A G 4.16E-04 Lung function (forced expiratory volume in 1 second) LRRK2 missense 24023788 rs10784498 chr12 40697434 G A 4.37E-04 Epilepsy LRRK2 intron 22116939 rs7133914 chr12 40702911 G A 7.03E-05 Parkinson's disease LRRK2 missense 21738487 rs721709 chr12 40709413 T A 1.36E-04 Progressive supranuclear palsy LRRK2 intron 21685912 rs11564148 chr12 40713901 T A 5.33E-05 Parkinson's disease LRRK2 missense 22438815 rs11564205 chr12 40714009 A G 9.23E-05 Parkinson's disease LRRK2 intron 21738487 rs10878368 chr12 40714785 A T 1.40E-05 Urinary metabolites LRRK2 intron 21572414 rs12370996 chr12 40723171 C T 3.74E-04 Body mass index LRRK2 intron 17255346 rs10878386 chr12 40725928 A G 6.95E-05 Parkinson's disease LRRK2 intron 21738487 rs1427271 chr12 40732394 T C 1.10E-04 Myasthenia gravis LRRK2 intron 23055271 rs1427271 chr12 40732394 T C 9.83E-05 Neutrophil count LRRK2 intron pha003095 rs34637584 chr12 40734202 G A 2.00E-28 Parkinson's disease LRRK2 missense 21738487 rs34637584 chr12 40734202 G A 4.46E-41 Parkinson's disease LRRK2 missense 24842889 rs11176195 chr12 40756207 T C 3.99E-04 Aortic root size LRRK2 intron 21223598 rs34778348 chr12 40757328 G A 3.00E-21 Parkinson's disease LRRK2 missense 22438815 rs10467147 chr12 40767362 G A 5.00E-06 Obesity-related traits / / 23251661 rs4768239 chr12 40768582 G A 1.30E-04 Epilepsy / / 22116939 rs11564259 chr12 40792197 G C 9.16E-04 Multiple complex diseases / / 17554300 rs11564172 chr12 40792224 C A 7.98E-05 Epilepsy / / 22116939 rs11564258 chr12 40792300 G A 6.00E-21 Crohn's disease / / 21102463 rs11564258 chr12 40792300 G A 6.00E-29 Inflammatory bowel disease / / 23128233 rs971616 chr12 40792856 T G 6.66E-04 Multiple complex diseases / / 17554300 rs11564252 chr12 40813733 T C 2.83E-05 Parkinson's disease / / 21738487 rs11564144 chr12 40817995 A C 4.25E-04 Multiple complex diseases / / 17554300 rs11564251 chr12 40818046 T C 1.20E-04 Multiple complex diseases / / 17554300 rs11564247 chr12 40821478 T C 6.15E-04 Multiple complex diseases / / 17554300 rs2114567 chr12 40825487 G A 4.82E-05 Parkinson's disease / / 21738487 rs11564168 chr12 40830583 T C 6.49E-05 Schizophrenia / / 19197363 rs7972511 chr12 40843090 G A 1.17E-04 Multiple complex diseases / / 17554300 rs2588400 chr12 40873251 C T 5.38E-04 Multiple complex diseases / / 17554300 rs1444216 chr12 40892518 A T 3.46E-04 Multiple complex diseases / / 17554300 rs4767978 chr12 40893496 C G 1.90E-05 Urinary metabolites / / 21572414 rs7133943 chr12 40938944 C T 0.000734217 Hypertension (early onset hypertension) / / 22479346 rs11177226 chr12 40954046 A T 4.90E-05 Multiple complex diseases / / 17554300 rs4768293 chr12 40958672 T C 6.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs2046968 chr12 40972095 T C 3.55E-04 Multiple complex diseases / / 17554300 rs10506170 chr12 40978902 C T 6.26E-04 Myopia (pathological) / / 21095009 rs1918942 chr12 40995961 T C 5.97E-05 Serum metabolites / / 19043545 rs1918943 chr12 40996013 T C 8.87E-05 Serum metabolites / / 19043545 rs4768301 chr12 41023399 T C 3.50E-05 Information processing speed / / 21130836 rs17128554 chr12 41023760 G A,C,T 1.80E-05 Information processing speed / / 21130836 rs11177623 chr12 41047351 T C 3.60E-05 Cytomegalovirus antibody response / / 21993531 rs1348511 chr12 41072291 G A 4.57E-05 Fibrinogen / / 17255346 rs10784789 chr12 41074388 T C 2.70E-04 Fibrinogen / / 17255346 rs17128788 chr12 41171754 C T 2.32E-04 Multiple complex diseases CNTN1 intron 17554300 rs7300813 chr12 41195135 C T 3.02E-04 Tourette syndrome CNTN1 intron 22889924 rs1119059 chr12 41198904 G A 7.94E-04 Insulin resistance CNTN1 intron 21901158 rs1596516 chr12 41203928 A G 5.84E-06 Bilirubin levels,in serum CNTN1 intron 19389676 rs4767991 chr12 41219126 T C 5.20E-05 Diabetic retinopathy CNTN1 intron 21441570 rs7970381 chr12 41219224 C A 8.48E-04 Response to cytadine analogues (cytosine arabinoside) CNTN1 intron 24483146 rs12581257 chr12 41236705 T C 2.20E-06 Urinary metabolites CNTN1 intron 21572414 rs1928560 chr12 41241645 C T 9.90E-05 Diabetic retinopathy CNTN1 intron 21441570 rs312274 chr12 41246280 T A 4.00E-06 Metabolite levels (X-11787) CNTN1 intron 23934736 rs312273 chr12 41247742 G A 9.00E-06 Bipolar disorder CNTN1 intron 22925353 rs312272 chr12 41247933 T C 3.73E-05 Coronary heart disease CNTN1 intron pha003032 rs312272 chr12 41247933 T C 8.11E-05 Creatinine levels CNTN1 intron pha003069 rs312270 chr12 41248950 T C 6.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CNTN1 intron 20877124 rs312270 chr12 41248950 T C 5.64E-05 Coronary heart disease CNTN1 intron pha003032 rs10506176 chr12 41274800 G T 8.80E-04 Volumetric brain MRI CNTN1 intron 17903297 rs11178884 chr12 41277268 T C 4.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CNTN1 intron 20877124 rs11178884 chr12 41277268 T C 8.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CNTN1 intron 20877124 rs11178884 chr12 41277268 T C 2.54E-05 Coronary heart disease CNTN1 intron pha003032 rs12316203 chr12 41283671 C T 6.06E-05 Parkinson's disease CNTN1 intron 21738487 rs12372413 chr12 41291402 C T 3.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CNTN1 intron 20877124 rs12372413 chr12 41291402 C T 9.03E-05 Coronary heart disease CNTN1 intron pha003032 rs10506177 chr12 41292469 T C 2.75E-05 Coronary heart disease CNTN1 intron pha003032 rs2044091 chr12 41293374 T C 2.99E-05 Coronary heart disease CNTN1 intron pha003032 rs11178961 chr12 41295539 C T 5.14E-05 Parkinson's disease CNTN1 intron 21738487 rs4768319 chr12 41299039 A C 4.25E-05 Creatinine levels CNTN1 intron pha003069 rs17621741 chr12 41300290 A C 3.59E-05 Bipolar disorder CNTN1 intron 22925353 rs11178982 chr12 41301332 T C 3.59E-05 Bipolar disorder CNTN1 intron 22925353 rs11179042 chr12 41311466 C T 7.67E-05 Creatinine levels CNTN1 intron pha003069 rs1372542 chr12 41324876 C T 8.06E-05 Creatinine levels CNTN1 intron pha003069 rs2289522 chr12 41330531 T C 7.22E-05 Creatinine levels CNTN1 intron pha003069 rs10879417 chr12 41347940 T C 4.56E-05 Creatinine levels CNTN1 intron pha003069 rs13328933 chr12 41353749 C T 8.58E-06 Parkinson's disease CNTN1 intron 21738487 rs13328933 chr12 41353749 C T 5.00E-06 IgG glycosylation CNTN1 intron 23382691 rs13328933 chr12 41353749 C T 8.80E-04 Myocardial Infarction CNTN1 intron pha002873 rs1442190 chr12 41365640 G A 2.00E-27 Parkinson's disease CNTN1 UTR-3 24842889 rs935104 chr12 41372690 G A 3.48E-05 Coronary heart disease CNTN1 intron pha003032 rs11613035 chr12 41376449 C T 1.26E-05 Coronary heart disease CNTN1 intron pha003032 rs278917 chr12 41380488 A C 7.73E-05 Coronary heart disease CNTN1 intron pha003032 rs11179347 chr12 41385793 G T 1.64E-05 Coronary heart disease CNTN1 intron pha003032 rs278901 chr12 41402278 G A 1.17E-06 Parkinson's disease CNTN1 intron 21738487 rs17624000 chr12 41412212 G A 8.68E-05 Coronary heart disease CNTN1 intron pha003032 rs278909 chr12 41424072 T C 1.63E-06 Parkinson's disease CNTN1 intron 21738487 rs691564 chr12 41454138 T C 1.40E-05 Urinary metabolites CNTN1 intron 21572414 rs12816667 chr12 41468894 A G 3.05E-05 Parkinson's disease / / 21738487 rs4768331 chr12 41486448 C T 5.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1546081 chr12 41515090 A G 1.53E-04 Body mass index / / 17255346 rs11179951 chr12 41526287 C T 1.74E-04 Body mass index / / 17255346 rs281838 chr12 41545195 C T 5.80E-04 Multiple complex diseases / / 17554300 rs2567034 chr12 41545725 A G 0.000271 Breast cancer early age of onset / / 18463975 rs281840 chr12 41546220 C T 0.000204 Breast cancer early age of onset / / 18463975 rs6582240 chr12 41580177 A T 0.000204 Breast cancer early age of onset / / 18463975 rs2043134 chr12 41602355 A G 0.000118 Breast cancer early age of onset PDZRN4 intron 18463975 rs12367762 chr12 41614599 G T 4.00E-06 Urinary metabolites PDZRN4 intron 21572414 rs12367762 chr12 41614599 G T 8.94E-05 Bipolar disorder PDZRN4 intron 22925353 rs12367762 chr12 41614599 G T 6.38E-05 Response to taxane treatment (placlitaxel) PDZRN4 intron 23006423 rs1880889 chr12 41721235 A C 1.96E-08 Alkaline phosphatase (ALP) PDZRN4 intron 23696881 rs1880887 chr12 41721430 C T 1.00E-10 Protein quantitative trait loci PDZRN4 intron 18464913 rs1880887 chr12 41721430 C T 8.69E-05 Cognitive impairment induced by topiramate PDZRN4 intron 22091778 rs11180828 chr12 41723120 A G 7.88E-05 Panic disorder PDZRN4 intron 19165232 rs11180828 chr12 41723120 A G 2.50E-05 Urinary metabolites PDZRN4 intron 21572414 rs11180828 chr12 41723120 A G 0.0000442 Panic disorder PDZRN4 intron 23149450 rs11180828 chr12 41723120 A G 4.42E-05 Serum tamsulosin hydrochloride concentration PDZRN4 intron 23151678 rs1405553 chr12 41726649 T C 5.09E-04 Myopia (pathological) PDZRN4 intron 21095009 rs1000147 chr12 41727678 A C 8.26E-06 Bone mineral density PDZRN4 intron 19181680 rs10785246 chr12 41747428 C T 4.67E-05 Alcohol and nictotine co-dependence PDZRN4 intron 20158304 rs10506189 chr12 41755479 T C 1.59E-05 Bone mineral density PDZRN4 intron 19181680 rs10880063 chr12 41760767 T C 5.41E-05 Lung function (forced vital capacity) PDZRN4 intron 24023788 rs11180863 chr12 41766492 G T 5.62E-05 Lung function (forced vital capacity) PDZRN4 intron 24023788 rs10880067 chr12 41768111 G A 5.41E-05 Lung function (forced vital capacity) PDZRN4 intron 24023788 rs12305552 chr12 41797386 G A 2.01E-04 Multiple complex diseases PDZRN4 intron 17554300 rs987823 chr12 41816002 T C 5.20E-04 Multiple complex diseases PDZRN4 intron 17554300 rs1350430 chr12 41819215 T C 3.96E-04 Myopia (pathological) PDZRN4 intron 21095009 rs1458165 chr12 41822199 G A 2.38E-04 Myopia (pathological) PDZRN4 intron 21095009 rs2730828 chr12 41833162 A G 3.96E-04 Myopia (pathological) PDZRN4 intron 21095009 rs1870286 chr12 41848356 C A 6.09E-04 Myopia (pathological) PDZRN4 intron 21095009 rs17129414 chr12 41893994 A G 1.57E-06 Asthma (childhood onset) PDZRN4 intron 23829686 rs12423463 chr12 41903274 G A 5.38E-04 Stroke PDZRN4 intron pha002886 rs725527 chr12 41932438 C T 8.78E-05 Cognitive performance PDZRN4 intron 19734545 rs11180989 chr12 41935609 C A 9.95E-05 Cognitive performance PDZRN4 intron 19734545 rs157972 chr12 41952824 G A 7.42E-04 Type 2 diabetes PDZRN4 intron 17463246 rs157972 chr12 41952824 G A 8.27E-05 Femoral neck bone geometry PDZRN4 intron 22087292 rs1458175 chr12 41965861 A C 2.00E-06 Multiple sclerosis PDZRN4 intron 19010793 rs287028 chr12 41986968 G T 9.25E-05 Cognitive test performance / / 20125193 rs1390373 chr12 41996155 C T 3.32E-06 Creatinine levels / / pha003069 rs4378453 chr12 41997375 C A 6.35E-06 Creatinine levels / / pha003069 rs4514489 chr12 41997687 G A 4.68E-06 Menarche (age at onset) / / 19282985 rs287003 chr12 42026766 G A 2.00E-05 Urinary metabolites / / 21572414 rs287070 chr12 42038171 T C 5.93E-04 Multiple complex diseases / / 17554300 rs287071 chr12 42038441 A G 6.36E-04 Type 2 diabetes / / 17463246 rs2218863 chr12 42080348 G A 2.30E-05 Urinary metabolites / / 21572414 rs7967618 chr12 42100594 A C 9.74E-04 Type 2 diabetes / / 17463246 rs11181126 chr12 42118642 G A 1.60E-05 Urinary metabolites / / 21572414 rs2220999 chr12 42135768 A G 1.30E-05 Amyotrophic Lateral Sclerosis / / 17362836 rs11181141 chr12 42156899 G A 9.97E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs871392 chr12 42171982 C T 3.00E-06 Biochemical measures / / 19260141 rs10880160 chr12 42174431 C T 9.97E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs904075 chr12 42189095 T C 1.36E-04 Stroke / / pha002887 rs10785296 chr12 42192408 C T 1.92E-04 Multiple complex diseases / / 17554300 rs1817957 chr12 42203837 C T 5.58E-04 Stroke / / pha002887 rs11532502 chr12 42205329 C T 3.99E-05 Bipolar disorder / / 19488044 rs11532502 chr12 42205329 C T 1.30E-05 Bipolar Disorder / / pha002858 rs7316176 chr12 42232875 T C 9.68E-05 Major depressive disorder (broad) / / 20038947 rs1497176 chr12 42233282 C T 3.07E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12813155 chr12 42239175 T C 4.67E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4768376 chr12 42252056 C T 2.69E-05 Cognitive impairment induced by topiramate / / 22091778 rs1391006 chr12 42253186 G A 3.01E-04 Type 2 diabetes / / 17463246 rs1391005 chr12 42253319 C T 4.18E-05 Cognitive impairment induced by topiramate / / 22091778 rs12049977 chr12 42254234 T C 7.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10491996 chr12 42256797 G A 2.38E-04 Stroke / / pha002887 rs1472402 chr12 42263030 T A 1.44E-05 Parkinson's disease / / 16252231 rs978797 chr12 42272542 G A 1.03E-04 Parkinson's disease / / 16252231 rs10785308 chr12 42274805 T C 3.34E-04 Type 2 diabetes / / 17463246 rs1391003 chr12 42281777 T G 9.52E-04 Parkinson's disease / / 16252231 rs1860604 chr12 42298132 C T 4.60E-06 Urinary metabolites / / 21572414 rs10491997 chr12 42298730 G A 4.40E-06 Urinary metabolites / / 21572414 rs10880189 chr12 42304688 A T 2.00E-06 Urinary metabolites / / 21572414 rs11181240 chr12 42304789 T C 4.40E-06 Urinary metabolites / / 21572414 rs722216 chr12 42305357 A G 4.60E-06 Urinary metabolites / / 21572414 rs2215456 chr12 42309909 T C 1.30E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs7301238 chr12 42312703 A G 6.24E-04 Parkinson's disease / / 16252231 rs11181253 chr12 42323774 T C 7.22E-04 Multiple complex diseases / / 17554300 rs1234028 chr12 42348282 C A 3.45E-04 Rheumatoid arthritis / / 21452313 rs7314728 chr12 42348480 G C 7.69E-04 Coronary Artery Disease / / 17634449 rs1234032 chr12 42354629 T C 6.49E-04 Multiple complex diseases / / 17554300 rs2012636 chr12 42356400 G A 1.15E-04 IgE levels / / 17255346 rs1920699 chr12 42361106 C T 2.11E-04 Multiple complex diseases / / 17554300 rs11181284 chr12 42376551 A G 1.26E-04 Multiple complex diseases / / 17554300 rs7958582 chr12 42377944 G A 3.81E-05 IgE levels / / 17255346 rs10880221 chr12 42384589 C A 4.23E-05 Cognitive test performance / / 20125193 rs10492000 chr12 42394365 G A 1.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10748324 chr12 42420621 A C 1.33E-04 IgE levels / / 17255346 rs6582378 chr12 42471200 C A 6.53E-04 Multiple complex diseases / / 17554300 rs17801478 chr12 42481545 T C 7.04E-04 Type 2 diabetes GXYLT1 UTR-3 17463246 rs17801478 chr12 42481545 T C 5.73E-04 Multiple complex diseases GXYLT1 UTR-3 17554300 rs7972986 chr12 42481732 G A 0.00014 Breast cancer GXYLT1 cds-synon 23555315 rs7964383 chr12 42482978 A G 2.67E-04 Multiple complex diseases GXYLT1 intron 17554300 rs7959852 chr12 42490951 G A 1.26E-04 Multiple complex diseases GXYLT1 intron 17554300 rs865420 chr12 42498400 A G 5.45E-04 Multiple complex diseases GXYLT1 intron 17554300 rs1226303 chr12 42514260 T C 2.39E-04 IgE levels GXYLT1 intron 17255346 rs7971943 chr12 42529472 C T 3.21E-04 Multiple complex diseases GXYLT1 intron 17554300 rs10785332 chr12 42561468 A G 9.34E-05 Lymphocyte counts YAF2 intron 22286170 rs12371615 chr12 42563989 G C 1.50E-04 Multiple complex diseases YAF2 intron 17554300 rs12371615 chr12 42563989 G C 8.73E-05 Smoking cessation YAF2 intron 18519826 rs1683195 chr12 42573868 G C 2.49E-05 Multiple complex diseases YAF2 intron 17554300 rs1683195 chr12 42573868 G C 1.40E-05 Urinary metabolites YAF2 intron 21572414 rs1238290 chr12 42585939 T A 3.40E-05 Multiple complex diseases YAF2 intron 17554300 rs1238290 chr12 42585939 T A 8.50E-06 Urinary metabolites YAF2 intron 21572414 rs10785333 chr12 42586470 G A 2.27E-04 Multiple complex diseases YAF2 intron 17554300 rs10880264 chr12 42586535 T C 2.18E-04 Multiple complex diseases YAF2 intron 17554300 rs10880264 chr12 42586535 T C 4.12E-05 Smoking cessation YAF2 intron 18519826 rs10785334 chr12 42620377 G A 1.70E-04 Multiple complex diseases YAF2 intron 17554300 rs10785334 chr12 42620377 G A 7.05E-05 Smoking cessation YAF2 intron 18519826 rs7956016 chr12 42620578 C T 6.10E-06 Urinary metabolites YAF2 intron 21572414 rs6582392 chr12 42640396 G A 6.44E-05 Multiple complex diseases / / 17554300 rs6582392 chr12 42640396 G A 5.30E-06 Urinary metabolites / / 21572414 rs10880279 chr12 42664105 C T 4.30E-06 Urinary metabolites / / 21572414 rs11181399 chr12 42666412 G A 7.01E-05 Rheumatoid arthritis / / 24449572 rs2061192 chr12 42675269 C A 6.90E-06 Urinary metabolites / / 21572414 rs12422970 chr12 42697092 C G 1.36E-04 Multiple complex diseases / / 17554300 rs12422970 chr12 42697092 C G 9.50E-06 Urinary metabolites / / 21572414 rs10880285 chr12 42712550 G A 2.80E-05 Urinary metabolites ZCRB1 intron 21572414 rs3810788 chr12 42720773 G A 2.60E-05 Urinary metabolites PPHLN1 intron 21572414 rs116975820 chr12 42722908 T G 5.00E-06 PR interval in Tripanosoma cruzi seropositivity PPHLN1 intron 24324551 rs10880289 chr12 42735898 C T 2.50E-05 Urinary metabolites PPHLN1 intron 21572414 rs4768401 chr12 42749849 C T 1.00E-06 Urinary metabolites PPHLN1 intron 21572414 rs11181459 chr12 42756516 C G 2.60E-05 Urinary metabolites PPHLN1 intron 21572414 rs11181461 chr12 42758931 T C 3.78E-04 Multiple complex diseases PPHLN1 intron 17554300 rs754012 chr12 42763748 G C 2.72E-05 Multiple complex diseases PPHLN1 intron 17554300 rs1669909 chr12 42772471 T G 6.63E-05 Rheumatoid arthritis PPHLN1 intron 17804836 rs17091141 chr12 42776155 A G 9.90E-04 Response to cytadine analogues (cytosine arabinoside) PPHLN1 intron 24483146 rs2243465 chr12 42781178 A T 9.40E-07 Urinary metabolites PPHLN1 intron 21572414 rs1796360 chr12 42805030 T C 1.60E-06 Urinary metabolites PPHLN1 intron 21572414 rs1796374 chr12 42809282 C T 2.70E-06 Urinary metabolites PPHLN1 intron 21572414 rs1796357 chr12 42815553 T C 9.20E-07 Urinary metabolites PPHLN1 intron 21572414 rs1796398 chr12 42828323 G C 2.62E-04 Multiple complex diseases PPHLN1 intron 17554300 rs1796398 chr12 42828323 G C 9.70E-07 Urinary metabolites PPHLN1 intron 21572414 rs1796381 chr12 42842475 A G 1.36E-04 Multiple complex diseases / / 17554300 rs10880301 chr12 42847999 G A 2.80E-05 Urinary metabolites / / 21572414 rs4768411 chr12 42855390 A G 6.57E-05 Multiple complex diseases PRICKLE1 intron 17554300 rs11832772 chr12 42859588 C T 3.92E-04 Multiple complex diseases PRICKLE1 intron 17554300 rs11832772 chr12 42859588 C T 3.21E-05 Orofacial clefts PRICKLE1 intron 20023658 rs11832772 chr12 42859588 C T 5.40E-06 Urinary metabolites PRICKLE1 intron 21572414 rs11832772 chr12 42859588 C T 6.35E-05 Kawasaki disease PRICKLE1 intron 22081228 rs34837068 chr12 42863262 A G 0.00028 Breast cancer PRICKLE1 missense 23555315 rs3213989 chr12 42863801 G A 6.64E-08 Primary biliary cirrhosis PRICKLE1 intron 21399635 rs4768412 chr12 42869140 C T 3.70E-08 Primary biliary cirrhosis PRICKLE1 intron 21399635 rs4768412 chr12 42869140 C T 0.00000033 Graves' disease PRICKLE1 intron 22922229 rs4768412 chr12 42869140 C T 0.00000356 Graves' disease and Hashimoto's thyroiditis PRICKLE1 intron 22922229 rs1796361 chr12 42873402 C T 8.95E-04 Multiple complex diseases PRICKLE1 intron 17554300 rs1796361 chr12 42873402 C T 5.90E-05 Temperament (bipolar disorder) PRICKLE1 intron 22365631 rs2708070 chr12 42878328 T C 8.62E-04 Multiple complex diseases PRICKLE1 intron 17554300 rs1796390 chr12 42878604 T C 8.99E-04 Multiple complex diseases PRICKLE1 intron 17554300 rs1796390 chr12 42878604 T C 3.90E-05 Temperament (bipolar disorder) PRICKLE1 intron 22365631 rs896559 chr12 42879126 G C 9.20E-04 Multiple complex diseases PRICKLE1 intron 17554300 rs1796391 chr12 42882153 G A 4.70E-05 Temperament (bipolar disorder) PRICKLE1 intron 22365631 rs1796339 chr12 42884003 A G 4.30E-05 Multiple complex diseases PRICKLE1 intron 17554300 rs1669925 chr12 42886217 A G 2.19E-04 Multiple complex diseases PRICKLE1 intron 17554300 rs1669925 chr12 42886217 A G 1.35E-06 Rheumatoid arthritis PRICKLE1 intron 19503088 rs11181527 chr12 42892740 C T 7.87E-04 Depression (quantitative trait) PRICKLE1 intron 20800221 rs11181528 chr12 42893132 A G 5.44E-04 Depression (quantitative trait) PRICKLE1 intron 20800221 rs11181528 chr12 42893132 A G 4.40E-05 Temperament (bipolar disorder) PRICKLE1 intron 22365631 rs11181528 chr12 42893132 A G 5.03E-04 Self-reported allergy PRICKLE1 intron 23817569 rs11181528 chr12 42893132 A G 9.52E-05 Cardiovascular disease PRICKLE1 intron pha003064 rs2708064 chr12 42893203 A C 5.00E-05 Temperament (bipolar disorder) PRICKLE1 intron 22365631 rs10785342 chr12 42895401 A G 6.11E-04 Depression (quantitative trait) PRICKLE1 intron 20800221 rs2406683 chr12 42898233 C T 3.95E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PRICKLE1 intron 20031582 rs2019557 chr12 42901635 G A 3.44E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PRICKLE1 intron 21844884 rs1008040 chr12 42901825 C T 4.27E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PRICKLE1 intron 21844884 rs2708079 chr12 42916073 T C 8.06E-04 Depression (quantitative trait) PRICKLE1 intron 20800221 rs1376930 chr12 42917248 T G 1.74E-04 Depression (quantitative trait) PRICKLE1 intron 20800221 rs10880312 chr12 42925175 A G 6.82E-04 Depression (quantitative trait) PRICKLE1 intron 20800221 rs1669943 chr12 42927331 G A 4.49E-05 Depression (quantitative trait) PRICKLE1 intron 20800221 rs2034614 chr12 42929397 G A 1.73E-04 Vaspin levels PRICKLE1 intron 22907691 rs2034614 chr12 42929397 G A 0.0001726 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks PRICKLE1 intron 22907730 rs1452106 chr12 42934707 A G 1.24E-04 Depression (quantitative trait) PRICKLE1 intron 20800221 rs12370911 chr12 42990645 A G 4.47E-05 HDL particle features / / pha002900 rs10785350 chr12 42991138 C T 6.99E-04 Depression (quantitative trait) / / 20800221 rs10785350 chr12 42991138 C T 8.60E-06 HDL particle features / / pha002900 rs6582406 chr12 43002428 G A 5.74E-04 Alzheimer's disease / / 17998437 rs6582406 chr12 43002428 G A 1.21E-04 Alzheimer's disease / / pha002879 rs11610557 chr12 43033004 T A 1.70E-06 Urinary metabolites / / 21572414 rs11181609 chr12 43039497 T C 1.20E-06 Urinary metabolites / / 21572414 rs17091568 chr12 43043583 C T 1.00E-05 Urinary metabolites / / 21572414 rs4429125 chr12 43063536 T A 2.40E-05 Urinary metabolites / / 21572414 rs1554255 chr12 43077486 T C 1.62E-05 Orofacial clefts / / 22863734 rs7304375 chr12 43090701 T C 1.27E-05 Orofacial clefts LOC100506684 intron 22863734 rs10506214 chr12 43111690 T C 5.80E-04 Volumetric brain MRI / / 17903297 rs10506217 chr12 43131208 T C 7.19E-05 Insulin-related traits / / pha002901 rs1356422 chr12 43142996 T C 1.01E-04 Alzheimer's disease / / 17998437 rs1356421 chr12 43143042 C T 1.19E-04 Alzheimer's disease / / 17998437 rs11181674 chr12 43149010 A T 8.71E-06 Crohn's disease / / 17804789 rs11181676 chr12 43150251 G A 8.15E-05 Alzheimer's disease / / 17998437 rs11181677 chr12 43150285 C G 5.31E-05 Alzheimer's disease / / 17998437 rs870114 chr12 43151303 C T 6.72E-05 Insulin-related traits / / pha002901 rs12316797 chr12 43160744 T G 1.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs2731006 chr12 43160825 C T 4.00E-06 Panic disorder / / 19165232 rs1878578 chr12 43164112 G A 1.30E-04 Alzheimer's disease / / 17998437 rs2138861 chr12 43166458 A T 3.96E-06 Mathematical ability / / 24801482 rs2731000 chr12 43181274 C T 4.81E-05 Panic disorder / / 19165232 rs2468330 chr12 43198722 G A,C 7.78E-05 Cognitive test performance / / 20125193 rs12227600 chr12 43206476 C T 2.63E-05 Panic disorder / / 19165232 rs11181702 chr12 43213948 G A 6.16E-05 Bone mineral density / / 19181680 rs1914490 chr12 43214484 G A 3.81E-05 Bone mineral density / / 19181680 rs10880370 chr12 43236170 G T 5.02E-05 Bone mineral density / / 19181680 rs1520832 chr12 43253415 T G 1.00E-06 Heart failure / / 20445134 rs11181735 chr12 43262480 C T 2.56E-04 Multiple complex diseases / / 17554300 rs7962560 chr12 43287688 C T 5.16E-04 Hemoglobin concentration / / 20534544 rs7966133 chr12 43303486 T A 8.66E-05 Bipolar disorder and schizophrenia / / 20889312 rs10785395 chr12 43304759 C A 4.13E-04 Hemoglobin concentration / / 20534544 rs17505252 chr12 43309514 T C 2.80E-04 Multiple complex diseases / / 17554300 rs17092413 chr12 43324048 T A 3.45E-06 Multiple complex diseases / / 17554300 rs10880412 chr12 43417877 A G 1.70E-05 Urinary metabolites / / 21572414 rs10880415 chr12 43428855 C T 2.60E-05 Urinary metabolites / / 21572414 rs1167125 chr12 43434282 C A 5.00E-06 Obesity-related traits / / 23251661 rs1828859 chr12 43511015 C T 5.84E-16 Multiple complex diseases / / 17554300 rs7315835 chr12 43565729 A G 8.46E-04 Aortic root size / / 21223598 rs7311395 chr12 43574178 G A 4.49E-04 Smoking quantity / / 24665060 rs1949281 chr12 43585475 C T 0.000361 Salmonella-induced pyroptosis / / 22837397 rs2138010 chr12 43611585 G T 5.51E-05 AIDS / / 19754311 rs1808120 chr12 43615881 A G 7.18E-05 Male fertility / / 22633400 rs7310342 chr12 43616645 G A 3.21E-05 Pancreatic cancer / / pha002874 rs1514673 chr12 43644153 C T 7.18E-05 Male fertility / / 22633400 rs12049958 chr12 43648823 T G 4.88E-05 Male fertility / / 22633400 rs7956756 chr12 43681783 G C 2.30E-04 Type 2 diabetes / / 17463246 rs7962163 chr12 43683251 C T 2.30E-04 Type 2 diabetes / / 17463246 rs17521729 chr12 43703981 C T 9.67E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs905080 chr12 43708928 C G 7.00E-04 Amyotrophic lateral sclerosis / / 17671248 rs1027615 chr12 43712289 G A 4.00E-04 Amyotrophic lateral sclerosis / / 17671248 rs2134066 chr12 43714537 A G 8.30E-04 Crohn's disease / / 17684544 rs11182015 chr12 43716919 C G 1.40E-05 Urinary metabolites / / 21572414 rs11182028 chr12 43735478 G A 0.0005851 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11182028 chr12 43735478 G A 5.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11182038 chr12 43756274 T C 8.60E-06 Urinary metabolites ADAMTS20 intron 21572414 rs2201465 chr12 43825415 G T 5.66E-04 Response to taxane treatment (placlitaxel) ADAMTS20 intron 23006423 rs17615699 chr12 43887603 C T 3.50E-06 Urinary metabolites ADAMTS20 intron 21572414 rs17615723 chr12 43887626 A C 9.84E-04 Type 2 diabetes ADAMTS20 intron 17463246 rs12099675 chr12 43893000 G C 1.50E-05 Urinary metabolites ADAMTS20 intron 21572414 rs1510521 chr12 43907206 G A 4.94E-04 Amyotrophic Lateral Sclerosis ADAMTS20 intron 17362836 rs275371 chr12 43916216 G A 9.12E-04 Aortic root size ADAMTS20 intron 21223598 rs10785439 chr12 43916617 T C 6.14E-04 Amyotrophic Lateral Sclerosis ADAMTS20 intron 17362836 rs1510526 chr12 43924296 G A 5.40E-06 Urinary metabolites ADAMTS20 intron 21572414 rs7960952 chr12 43926132 C T 8.94E-04 Amyotrophic Lateral Sclerosis ADAMTS20 intron 17362836 rs275380 chr12 43929996 A C 1.00E-06 Adverse response to lamotrigine and phenytoin ADAMTS20 intron 22379998 rs166700 chr12 43936795 A G 4.55E-06 Adverse response to lamotrigine and phenytoin ADAMTS20 intron 22379998 rs7295246 chr12 43967677 T G 3.00E-07 Alzheimer's disease (late onset) / / 24162737 rs405615 chr12 43980459 G A 1.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs277206 chr12 44034672 G A 3.26E-05 Schizophrenia / / 20185149 rs116948464 chr12 44130330 G A 0.00013 Breast cancer PUS7L missense 23555315 rs9783418 chr12 44144643 G A 2.53E-04 Lymphocyte counts PUS7L intron 22286170 rs4251424 chr12 44153826 C T 2.00E-08 Immune reponse to smallpox (secreted TNF-alpha) IRAK4 intron 22610502 rs4251583 chr12 44177508 A G 0.000000406 Cholesterol,total IRAK4 missense 23063622 rs4251583 chr12 44177508 A G 3.20E-21 Triglycerides IRAK4 missense 23063622 rs4251583 chr12 44177508 A G 3.42E-13 LDL cholesterol IRAK4 missense 23063622 rs4251583 chr12 44177508 A G 3.87E-14 HDL cholesterol IRAK4 missense 23063622 rs11182268 chr12 44194910 A G 6.92E-05 Suicide attempts in bipolar disorder TWF1 intron 21423239 rs17537237 chr12 44205887 A G 1.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs12830662 chr12 44206417 T A 6.92E-05 Suicide attempts in bipolar disorder / / 21423239 rs1731448 chr12 44244270 A G 6.93E-05 Multiple complex diseases TMEM117 intron 17554300 rs1621279 chr12 44249011 C T 1.75E-04 Multiple complex diseases TMEM117 intron 17554300 rs1731434 chr12 44272915 A G 2.44E-04 Multiple complex diseases TMEM117 intron 17554300 rs2614394 chr12 44282166 A G 1.21E-04 Multiple complex diseases TMEM117 intron 17554300 rs1675789 chr12 44290545 A G 8.34E-05 Multiple complex diseases TMEM117 intron 17554300 rs1675787 chr12 44290928 T G 9.93E-05 Multiple complex diseases TMEM117 intron 17554300 rs7955615 chr12 44295861 C T 1.39E-04 Multiple complex diseases TMEM117 intron 17554300 rs10785462 chr12 44299067 A G 7.14E-05 Multiple complex diseases TMEM117 intron 17554300 rs5019975 chr12 44299370 G A 1.60E-04 Multiple complex diseases TMEM117 intron 17554300 rs1609549 chr12 44306994 A G 6.05E-05 Multiple complex diseases TMEM117 intron 17554300 rs4363674 chr12 44307404 C G 6.84E-05 Multiple complex diseases TMEM117 intron 17554300 rs7136340 chr12 44307577 G A 2.24E-04 Multiple complex diseases TMEM117 intron 17554300 rs7294490 chr12 44307742 G A 3.16E-04 Multiple complex diseases TMEM117 intron 17554300 rs11182325 chr12 44307930 G C 9.29E-05 Multiple complex diseases TMEM117 intron 17554300 rs4768053 chr12 44309069 C G 1.21E-04 Multiple complex diseases TMEM117 intron 17554300 rs7969372 chr12 44309996 C T 5.20E-06 Urinary metabolites TMEM117 intron 21572414 rs10880587 chr12 44311477 T G 9.91E-04 Multiple complex diseases TMEM117 intron 17554300 rs7311847 chr12 44315590 A G 3.09E-04 Multiple complex diseases TMEM117 intron 17554300 rs7965873 chr12 44354797 A G 5.47E-04 Multiple complex diseases TMEM117 intron 17554300 rs12306662 chr12 44378314 A G 4.57E-05 Personality dimensions TMEM117 intron 22628180 rs1701083 chr12 44417904 G A 2.72E-04 Type 2 diabetes TMEM117 intron 17463246 rs12296857 chr12 44419592 G A 8.59E-04 Type 2 diabetes TMEM117 intron 17463246 rs11182402 chr12 44444897 T C 5.17E-04 Type 2 diabetes TMEM117 intron 17463246 rs866839 chr12 44446985 A G 8.48E-05 Cognitive test performance TMEM117 intron 20125193 rs11182405 chr12 44447849 A C 3.60E-04 Type 2 diabetes TMEM117 intron 17463246 rs842199 chr12 44457572 A T 3.90E-04 Type 2 diabetes TMEM117 intron 17463246 rs11613902 chr12 44497238 C A 1.44E-05 Multiple complex diseases TMEM117 intron 17554300 rs17094119 chr12 44512431 A G 3.66E-05 Cognitive performance TMEM117 intron 19734545 rs1907688 chr12 44527496 G A 6.85E-04 Suicide attempts in bipolar disorder TMEM117 intron 21423239 rs1492310 chr12 44549435 G A 2.77E-05 Cognitive test performance TMEM117 intron 20125193 rs1492310 chr12 44549435 G A 1.90E-06 Biliary atresia TMEM117 intron 20460270 rs1492310 chr12 44549435 G A 6.93E-04 Suicide attempts in bipolar disorder TMEM117 intron 21423239 rs11182427 chr12 44549602 G T 4.94E-04 Multiple complex diseases TMEM117 intron 17554300 rs842209 chr12 44583825 T A 8.21E-04 Suicide attempts in bipolar disorder TMEM117 intron 21423239 rs10880627 chr12 44599081 C T 5.68E-04 Suicide attempts in bipolar disorder TMEM117 intron 21423239 rs7961974 chr12 44604028 G A 3.94E-04 Suicide attempts in bipolar disorder TMEM117 intron 21423239 rs10506241 chr12 44604107 A G 8.38E-04 Suicide attempts in bipolar disorder TMEM117 intron 21423239 rs860867 chr12 44675396 C T 0.000026 LDL cholesterol TMEM117 intron 23063622 rs841068 chr12 44678267 C T 1.94E-04 Suicide attempts in bipolar disorder TMEM117 intron 21423239 rs1726874 chr12 44678817 A G 3.90E-04 Suicide attempts in bipolar disorder TMEM117 intron 21423239 rs1798027 chr12 44680713 G A 3.54E-04 Suicide attempts in bipolar disorder TMEM117 intron 21423239 rs1644009 chr12 44682825 T A 6.54E-04 Suicide attempts in bipolar disorder TMEM117 intron 21423239 rs1726890 chr12 44687671 G T 3.95E-04 Suicide attempts in bipolar disorder TMEM117 intron 21423239 rs1644007 chr12 44689702 C A 4.44E-04 Suicide attempts in bipolar disorder TMEM117 intron 21423239 rs1643432 chr12 44693945 A G 0.0003637 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMEM117 intron 23233654 rs1643432 chr12 44693945 A G 3.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMEM117 intron 23233662 rs840766 chr12 44698441 G C 9.39E-04 Suicide attempts in bipolar disorder TMEM117 intron 21423239 rs1798023 chr12 44706814 A G 5.75E-04 Suicide attempts in bipolar disorder TMEM117 intron 21423239 rs1098498 chr12 44707667 C T 2.25E-04 Suicide attempts in bipolar disorder TMEM117 intron 21423239 rs1625442 chr12 44711555 C T 5.53E-04 Suicide attempts in bipolar disorder TMEM117 intron 21423239 rs840763 chr12 44716628 A G 5.72E-23 Triglycerides TMEM117 intron 23063622 rs840763 chr12 44716628 A G 7.98E-13 HDL cholesterol TMEM117 intron 23063622 rs7957859 chr12 44720874 G A 3.27E-04 Suicide attempts in bipolar disorder TMEM117 intron 21423239 rs1726886 chr12 44722776 G A 2.79E-04 Suicide attempts in bipolar disorder TMEM117 intron 21423239 rs840772 chr12 44734268 C A 0.0005671 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TMEM117 intron 23233654 rs840772 chr12 44734268 C A 5.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) TMEM117 intron 23233662 rs17094516 chr12 44749170 T A 2.45E-10 Triglycerides TMEM117 intron 23063622 rs1493758 chr12 44791617 A G 0.0006987 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1493758 chr12 44791617 A G 6.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10880632 chr12 44793224 A G 0.0006999 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10880632 chr12 44793224 A G 7.00E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17121322 chr12 44819162 A G 9.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17094634 chr12 44819569 G A 9.04E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1353143 chr12 44820597 G A 0.000884 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1353143 chr12 44820597 G A 8.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12318553 chr12 44820855 A T 0.000896 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12318553 chr12 44820855 A T 8.96E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12297907 chr12 44820992 G A 9.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11182500 chr12 44842114 C T 5.86E-04 Prostate cancer mortality / / 20978177 rs7980297 chr12 44920565 C T 8.64E-04 Suicide attempts in bipolar disorder NELL2 intron 21423239 rs4768555 chr12 44927340 A G 7.48E-04 Alcohol dependence NELL2 intron 20201924 rs1552859 chr12 44930901 G T 7.40E-04 Alcohol dependence NELL2 intron 24277619 rs11182536 chr12 44944711 C T 1.27E-04 Multiple complex diseases NELL2 intron 17554300 rs10785513 chr12 44992730 C T 1.80E-05 Intelligence (childhood) NELL2 intron 23358156 rs7305652 chr12 45025396 C T 3.66E-04 Osteoarthritis NELL2 intron 19508968 rs10506257 chr12 45158289 C T 3.07E-05 Osteoarthritis NELL2 intron 19508968 rs2408050 chr12 45159930 T C 3.80E-04 Lung function (forced expiratory volume in 1 second) NELL2 intron 17255346 rs1901147 chr12 45160864 C T 5.92E-04 Premature ovarian failure NELL2 intron 19508998 rs7295947 chr12 45168910 G A 5.92E-04 Premature ovarian failure NELL2 intron 19508998 rs1122351 chr12 45173884 G A 4.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NELL2 intron 20877124 rs10880717 chr12 45357804 T C 0.0000181 Panic disorder / / 23149450 rs10880717 chr12 45357804 T C 1.81E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs17095280 chr12 45367674 C A 9.28E-04 Depression (quantitative trait) / / 20800221 rs1395395 chr12 45374324 G A 9.29E-04 Depression (quantitative trait) / / 20800221 rs12310696 chr12 45374799 C T 9.29E-04 Depression (quantitative trait) / / 20800221 rs6582526 chr12 45383372 C T 9.28E-04 Depression (quantitative trait) / / 20800221 rs4768582 chr12 45388817 A G 5.29E-04 Depression (quantitative trait) / / 20800221 rs4768584 chr12 45389301 T G 5.58E-04 Depression (quantitative trait) / / 20800221 rs13328953 chr12 45394369 A G 5.50E-04 Depression (quantitative trait) / / 20800221 rs7315173 chr12 45394863 A G 5.55E-04 Depression (quantitative trait) / / 20800221 rs7299805 chr12 45395168 C G 5.60E-04 Depression (quantitative trait) / / 20800221 rs10880724 chr12 45396231 A G 5.68E-04 Depression (quantitative trait) / / 20800221 rs7315747 chr12 45396892 C G 5.69E-04 Depression (quantitative trait) / / 20800221 rs12819320 chr12 45397762 T G 5.83E-04 Depression (quantitative trait) / / 20800221 rs12579631 chr12 45398438 A C 5.88E-04 Depression (quantitative trait) / / 20800221 rs10880726 chr12 45399428 C T 6.06E-04 Depression (quantitative trait) / / 20800221 rs11182788 chr12 45400523 G A 4.83E-04 Multiple complex diseases / / 17554300 rs2731038 chr12 45417666 T C 6.24E-04 Fibrinogen DBX2 missense 17255346 rs2042100 chr12 45496537 T C 1.60E-04 Multiple complex diseases / / 17554300 rs7303573 chr12 45519555 C A 2.80E-04 Hemoglobin concentration / / 20534544 rs1903937 chr12 45521487 C T 4.21E-07 Bilirubin levels,in serum / / 19389676 rs9787988 chr12 45543754 A G 6.10E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs1896024 chr12 45560192 G C 1.30E-05 Urinary metabolites / / 21572414 rs10880755 chr12 45572174 C A 2.80E-05 Urinary metabolites PLEKHA8P1 intron 21572414 rs1025090 chr12 45573620 T G 8.93E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) PLEKHA8P1 intron 23648065 rs10880758 chr12 45584810 T C 9.96E-05 Cognitive performance PLEKHA8P1 intron 19734545 rs12231753 chr12 45597540 C T 6.96E-05 Alcohol dependence PLEKHA8P1 intron 19581569 rs2052603 chr12 45646266 G T 2.23E-05 Alcohol dependence ANO6 intron 19581569 rs11182954 chr12 45656502 C T 7.07E-05 Cognitive performance ANO6 intron 19734545 rs12815577 chr12 45656984 G A 1.70E-05 Urinary metabolites ANO6 intron 21572414 rs7138247 chr12 45669753 G A 7.21E-06 Alcohol dependence ANO6 intron 19581569 rs7304389 chr12 45690593 G A 1.27E-04 Multiple complex diseases ANO6 intron 17554300 rs7965430 chr12 45710230 A G 2.02E-05 Alcohol dependence ANO6 intron 19581569 rs965125 chr12 45722222 T C 2.53E-04 Suicide attempts in bipolar disorder ANO6 intron 21423239 rs12579771 chr12 45733422 C T 2.20E-05 Major depressive disorder ANO6 intron 19065144 rs12579771 chr12 45733422 C T 1.20E-05 Major depressive disorder ANO6 intron 21621269 rs12579771 chr12 45733422 C T 2.29E-05 Major depressive disorder ANO6 intron pha002850 rs11182988 chr12 45737956 T C 2.22E-05 stroke (ischemic) ANO6 intron 17434096 rs1913696 chr12 45740280 A C 9.59E-05 Hemoglobin ANO6 intron pha003098 rs1863549 chr12 45763069 A G 2.22E-05 stroke (ischemic) ANO6 intron 17434096 rs17095830 chr12 45774908 A G 2.00E-08 Ankylosing spondylitis ANO6 intron 22138694 rs7307549 chr12 45838714 G T 9.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10880792 chr12 45867365 A G 9.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs10748424 chr12 45870318 T C 8.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs10748425 chr12 45871023 C T 4.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs10880795 chr12 45881423 C G 5.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs7484690 chr12 45882430 G A 9.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs7972208 chr12 45887757 A T 4.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs6582555 chr12 45889818 C T 3.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs12830362 chr12 45890331 G A 6.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4576884 chr12 45892993 G A 3.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs7964616 chr12 45893296 A G 9.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs11183067 chr12 45894373 A G 6.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11183068 chr12 45895019 T C 6.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2408273 chr12 45897099 C T 5.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs4408369 chr12 45898888 T C 8.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs10880801 chr12 45899396 T C 6.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs11183094 chr12 45924015 T C 7.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs7132173 chr12 45924409 G T 2.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs10880810 chr12 45924964 T C 7.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs7960483 chr12 45925755 G T 1.00E-07 Hypertension / / 21626137 rs11183098 chr12 45926120 T C 8.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs4606536 chr12 45928887 T C 8.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs11183099 chr12 45930141 T C 9.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs10785581 chr12 45930973 C G 1.00E-07 Hypertension / / 21626137 rs4768636 chr12 45940334 A C 6.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs11183105 chr12 45942027 C T 4.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs2408267 chr12 45944322 A G 6.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs1862019 chr12 45991000 C T 1.64E-05 Bipolar disorder / / 21771265 rs4768654 chr12 46039883 C T 1.70E-05 Urinary metabolites / / 21572414 rs11183154 chr12 46043181 C T 1.40E-05 Urinary metabolites / / 21572414 rs10492248 chr12 46043613 T C 9.60E-04 Crohn's disease / / 17684544 rs11183159 chr12 46053609 T C 1.60E-05 Urinary metabolites / / 21572414 rs7980781 chr12 46082651 G A 7.53E-04 Multiple complex diseases / / 17554300 rs7138683 chr12 46083717 G T 9.59E-04 Multiple complex diseases / / 17554300 rs7299538 chr12 46085330 C T 9.46E-04 Multiple complex diseases / / 17554300 rs7299538 chr12 46085330 C T 9.08E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs7979398 chr12 46086708 C T 5.09E-06 Lung adenocarcinoma / / 19836008 rs7136397 chr12 46091467 T C 9.66E-04 Multiple complex diseases / / 17554300 rs7303119 chr12 46254995 A G 7.03E-04 Smoking initiation ARID2 intron 24665060 rs10880880 chr12 46375306 A G 9.15E-05 Lung adenocarcinoma SCAF11 intron 19836008 rs10161306 chr12 46392736 T A 5.41E-04 Type 2 diabetes / / 17463246 rs11183287 chr12 46410133 T A 1.55E-04 Type 2 diabetes / / 17463246 rs2408461 chr12 46416831 C T 8.86E-06 Multiple complex diseases / / 17554300 rs7309577 chr12 46436825 T C 0.000169 Salmonella-induced pyroptosis / / 22837397 rs11183312 chr12 46454411 A G 5.79E-04 Type 2 diabetes / / 17463246 rs10880908 chr12 46479056 T C 1.28E-04 Arthritis (juvenile idiopathic) / / 22354554 rs7304591 chr12 46483354 T G 3.14E-04 Multiple complex diseases / / 17554300 rs1373549 chr12 46485838 A G 8.00E-06 Hippocampal atrophy / / 19668339 rs1373549 chr12 46485838 A G 8.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs7304593 chr12 46493047 G A 7.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs11183341 chr12 46493582 A T 9.51E-04 Depression (quantitative trait) / / 20800221 rs7970663 chr12 46537488 A G 2.70E-05 Urinary metabolites / / 21572414 rs9325217 chr12 46539044 T C 5.50E-07 Urinary metabolites / / 21572414 rs12300905 chr12 46545783 C T 5.03E-06 Uric acid levels / / 21294900 rs12423604 chr12 46548273 T C 2.33E-04 Alzheimer's disease (late onset) / / 21379329 rs11183370 chr12 46550063 T C 3.85E-05 Basophils / / pha003087 rs12309226 chr12 46551998 A G 6.90E-06 Uric acid levels / / 21294900 rs3497 chr12 46579388 A G 3.89E-04 Amyotrophic Lateral Sclerosis SLC38A1 UTR-3 17827064 rs17096738 chr12 46579641 C T 8.82E-05 Attention deficit hyperactivity disorder SLC38A1 UTR-3 23728934 rs3742060 chr12 46581309 T G 1.98E-04 Parkinson's disease SLC38A1 UTR-3 17052657 rs963326 chr12 46605959 G A 4.12E-04 Suicide attempts in bipolar disorder SLC38A1 intron 21423239 rs962683 chr12 46607280 C T 1.02E-04 Suicide attempts in bipolar disorder SLC38A1 intron 21423239 rs4768106 chr12 46608080 G C 8.70E-05 Suicide attempts in bipolar disorder SLC38A1 intron 21423239 rs4768107 chr12 46608163 G T 8.68E-05 Suicide attempts in bipolar disorder SLC38A1 intron 21423239 rs960117 chr12 46613819 C T 1.92E-04 Suicide attempts in bipolar disorder SLC38A1 intron 21423239 rs10880939 chr12 46614641 C G,T 8.71E-04 Tourette syndrome SLC38A1 intron 22889924 rs10880942 chr12 46619130 T C 0.00000044 Antithrombin SLC38A1 intron 23705025 rs2125645 chr12 46623807 G A 5.00E-04 Amyotrophic lateral sclerosis (sporadic) SLC38A1 intron 24529757 rs11836863 chr12 46624012 G A 4.10E-05 Height SLC38A1 intron 21998595 rs12303214 chr12 46649528 A G 9.50E-04 Suicide attempts in bipolar disorder SLC38A1 intron 21423239 rs2279560 chr12 46661279 A G 9.67E-05 Suicide attempts in bipolar disorder SLC38A1 intron 21423239 rs1060735 chr12 46661387 A G 6.86E-05 Suicide attempts in bipolar disorder SLC38A1 intron 21423239 rs2242355 chr12 46662485 G C 7.78E-04 Suicide attempts in bipolar disorder SLC38A1 UTR-5 21423239 rs7310869 chr12 46665386 G C 8.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs2172398 chr12 46672571 A G 6.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs7316127 chr12 46674249 T G 7.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs11504511 chr12 46677044 T G 8.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs7315493 chr12 46689427 G A 8.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs1492892 chr12 46691487 C A 9.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs7967669 chr12 46692991 C T 8.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs12310125 chr12 46693154 A G 9.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs6582625 chr12 46698317 G A 8.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs7135897 chr12 46698902 A G 8.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs11183467 chr12 46802461 T C 6.58E-04 Multiple complex diseases LOC100288798 intron 17554300 rs17096928 chr12 46803990 G C 4.01E-04 Type 2 diabetes LOC100288798 intron 17463246 rs4768124 chr12 46865137 A G 0.000701 Salmonella-induced pyroptosis LOC100288798 intron 22837397 rs4073925 chr12 46920163 C T 3.81E-04 Age-related macular degeneration LOC100288798 intron 21909106 rs4768735 chr12 46944134 T G 4.84E-04 Suicide attempts in bipolar disorder LOC100288798 intron 21423239 rs11183527 chr12 46946363 A G 2.91E-04 Suicide attempts in bipolar disorder LOC100288798 intron 21423239 rs7315480 chr12 47005736 A T 3.25E-04 Suicide attempts in bipolar disorder LOC100288798 intron 21423239 rs12306495 chr12 47018846 C T 0.000393 Salmonella-induced pyroptosis LOC100288798 intron 22837397 rs12229299 chr12 47084893 C G 8.36E-04 Alcohol dependence LOC100288798 intron 21314694 rs10880987 chr12 47091841 A G 8.81E-06 Glycemic traits (pregnancy) LOC100288798 intron 23903356 rs12303703 chr12 47095263 G C 1.30E-05 Urinary metabolites LOC100288798 intron 21572414 rs12297321 chr12 47109387 C T 2.00E-05 Urinary metabolites LOC100288798 intron 21572414 rs4140782 chr12 47118844 C T 6.14E-06 Glycemic traits (pregnancy) LOC100288798 intron 23903356 rs10880996 chr12 47119820 G C 9.48E-06 Glycemic traits (pregnancy) LOC100288798 intron 23903356 rs12426014 chr12 47145441 A C 8.10E-06 Glycemic traits (pregnancy) LOC100288798 intron 23903356 rs180433 chr12 47179557 T C 2.31E-04 Response to taxane treatment (placlitaxel) SLC38A4 intron 23006423 rs180434 chr12 47179574 C T 7.43E-05 Response to taxane treatment (placlitaxel) SLC38A4 intron 23006423 rs2109125 chr12 47189295 C T 5.87E-05 Coronary heart disease SLC38A4 intron pha003032 rs11183621 chr12 47216189 T C 3.50E-05 Response to statin therapy SLC38A4 intron 20339536 rs10881014 chr12 47336133 G A 6.60E-05 Suicide attempts in bipolar disorder / / 21423239 rs2465223 chr12 47336910 C T 3.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2465625 chr12 47350747 G T 0.00000032 Mean arterial pressure / / 22510845 rs12307532 chr12 47357228 A C 2.58E-04 Myocardial Infarction / / pha002883 rs7965705 chr12 47358286 G A 9.91E-05 Multiple complex diseases / / 17554300 rs12302640 chr12 47358490 C T 1.32E-04 Multiple complex diseases / / 17554300 rs10881016 chr12 47362876 C T 6.02E-05 Glucose levels / / pha003057 rs10881016 chr12 47362876 C T 5.20E-05 Diabetes Mellitus / / pha003060 rs2711721 chr12 47372270 C T 2.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs2711721 chr12 47372270 C T 6.48E-05 Glucose levels / / pha003057 rs2711721 chr12 47372270 C T 2.07E-05 Glucose levels / / pha003058 rs12306599 chr12 47384810 C T 8.26E-04 Type 2 diabetes / / 17463246 rs17097496 chr12 47420131 C T 3.11E-05 Gaucher disease severity / / 22388998 rs10881029 chr12 47443537 G A 6.19E-05 Parkinson's disease / / 21812969 rs2158133 chr12 47450430 G A 6.19E-05 Parkinson's disease / / 21812969 rs17097570 chr12 47461183 C T 9.56E-04 Type 2 diabetes / / 17463246 rs2269828 chr12 47471439 G A 1.30E-04 Suicide attempts in bipolar disorder AMIGO2 cds-synon 21041247 rs2269828 chr12 47471439 G A 6.13E-04 Suicide attempts in bipolar disorder AMIGO2 cds-synon 21041247 rs2269828 chr12 47471439 G A 8.07E-04 Suicide attempts in bipolar disorder AMIGO2 cds-synon 21423239 rs2106928 chr12 47474845 C G 7.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs2898002 chr12 47476227 C G 4.65E-07 Schizophrenia / / 21926974 rs7979008 chr12 47479528 C A 4.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs739706 chr12 47482666 T C 9.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs11183725 chr12 47486147 T C 9.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs7960745 chr12 47486814 C A 9.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs10785655 chr12 47493483 A G 7.52E-04 Multiple complex diseases / / 17554300 rs2040673 chr12 47495946 T A 3.32E-05 Multiple complex diseases / / 17554300 rs17222290 chr12 47548864 A G 0.0007315 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17222290 chr12 47548864 A G 7.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12368600 chr12 47550388 C A 0.0007263 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12368600 chr12 47550388 C A 7.26E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4768142 chr12 47568721 C T 0.0005443 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4768142 chr12 47568721 C T 5.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12370192 chr12 47568930 C T 0.000542 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12370192 chr12 47568930 C T 5.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11183777 chr12 47575860 G C 0.0004914 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11183777 chr12 47575860 G C 4.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs832729 chr12 47577979 T C 0.0006285 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs832729 chr12 47577979 T C 6.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11183779 chr12 47579248 C T 0.0005013 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11183779 chr12 47579248 C T 5.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11183783 chr12 47580138 G C 0.0006918 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11183783 chr12 47580138 G C 6.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10881072 chr12 47585115 G A 1.80E-05 Urinary metabolites / / 21572414 rs11610206 chr12 47639526 T C 3.00E-07 Alzheimer's disease / / 19118814 rs11610206 chr12 47639526 T C 3.50E-07 Alzheimer's disease (late onset) / / 20885792 rs11610206 chr12 47639526 T C 3.50E-07 Alzheimer's disease (late onset) / / 21460841 rs12315929 chr12 47659666 G T 4.13E-04 Tourette syndrome / / 22889924 rs214679 chr12 47677388 G T 9.40E-05 Waist-hip ratio / / 23966867 rs855137 chr12 47718183 T C 2.19E-04 Longevity / / 22279548 rs855137 chr12 47718183 T C 4.42E-05 ldl cholesterol / / pha003076 rs1730454 chr12 47735500 A G 5.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2074193 chr12 47771429 T G 5.00E-07 Migraine with aura / / 23793025 rs11183932 chr12 47786575 T A 9.27E-04 Multiple complex diseases / / 17554300 rs4329752 chr12 47807984 G A 6.05E-04 Multiple complex diseases / / 17554300 rs2698791 chr12 47810959 C G 6.97E-04 Obesity (extreme) / / 21935397 rs916809 chr12 47814851 G A 4.41E-05 Blood Pressure / / pha003040 rs916809 chr12 47814851 G A 1.48E-05 Blood Pressure / / pha003049 rs1881744 chr12 47814972 G A 2.00E-06 Metabolite levels (HVA/5-HIAA ratio) / / 23319000 rs6582709 chr12 47817901 G A 8.92E-04 Response to TNF antagonist treatment / / 21061259 rs7955374 chr12 47880149 C T 8.26E-05 Schizophrenia / / 19571811 rs7307902 chr12 47923016 T C 1.00E-06 Obesity-related traits / / 23251661 rs7971524 chr12 47935320 T C 3.01E-05 Osteoarthritis (knee and hip) / / 21177295 rs7971524 chr12 47935320 T C 3.72E-05 Osteoarthritis (knee and hip) / / 21177295 rs12304191 chr12 47949145 G A 1.81E-04 Breast cancer / / 21060860 rs7309928 chr12 47950691 C G 1.40E-05 Lipid levels / / 18193043 rs1476581 chr12 47961999 A G 9.90E-06 Lymphocyte counts / / 22286170 rs757357 chr12 47971577 T A 5.84E-04 Multiple complex diseases / / 17554300 rs7971093 chr12 47971864 A C 1.10E-05 Serum metabolites / / 19043545 rs653136 chr12 47996550 C T 4.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs622098 chr12 48007475 C A 4.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7136561 chr12 48081637 C T 4.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPAP3 intron 20877124 rs11834770 chr12 48117365 A T 5.08E-04 Type 2 diabetes ENDOU intron 17463246 rs2239187 chr12 48117707 T C 1.23E-04 Multiple complex diseases ENDOU intron 17554300 rs11168228 chr12 48150951 A G 6.51E-04 Multiple complex diseases RAPGEF3 intron 17554300 rs11168228 chr12 48150951 A G 2.63E-04 Sudden cardiac arrest RAPGEF3 intron 21658281 rs4760636 chr12 48173352 T C 6.00E-06 Urate levels SLC48A1 intron 23263486 rs75365750 chr12 48187254 A G 5.00E-06 Obesity-related traits HDAC7 missense 23251661 rs2525051 chr12 48195939 G C 2.50E-04 Obesity,menopause HDAC7 intron 21424828 rs11168249 chr12 48208368 T C 1.00E-06 Primary sclerosing cholangitis HDAC7 intron 21151127 rs11168249 chr12 48208368 T C 8.00E-09 Inflammatory bowel disease HDAC7 intron 23128233 rs11168249 chr12 48208368 T C 5.49E-09 Primary sclerosing cholangitis HDAC7 intron 23603763 rs11574121 chr12 48237928 G A 0.000000221 LDL cholesterol VDR UTR-3 23063622 rs731236 chr12 48238757 A G 1 Drug response to Clodronate VDR cds-synon 19020788 rs886441 chr12 48262964 G A 0.000000863 HDL cholesterol particle diameter VDR intron 23263444 rs2189480 chr12 48263828 G T 9.28E-05 Blood Pressure VDR intron pha003048 rs3819545 chr12 48265006 A G 4.07E-05 Blood Pressure VDR intron pha003048 rs11574049 chr12 48272515 A G 1.19E-22 Narcolepsy VDR intron 19629137 rs7979360 chr12 48297792 A G 2.51E-08 LDL cholesterol VDR intron 23063622 rs11168326 chr12 48345666 T C 5.84E-05 Bone mineral density / / 19181680 rs1541408 chr12 48348352 C G 4.12E-04 Lymphocyte counts / / 22286170 rs2286024 chr12 48360620 A G 1.00E-04 Information processing speed TMEM106C intron 21130836 rs4760608 chr12 48368989 A C 2.68E-05 Cognitive decline COL2A1 intron 22054870 rs1793949 chr12 48371595 G A 5.00E-05 Body mass index COL2A1 intron 22446040 rs1793949 chr12 48371595 G A 3.14E-05 Parkinson's disease COL2A1 intron pha002868 rs1635544 chr12 48380031 A G 9.93E-04 Parkinson's disease COL2A1 intron 17052657 rs1034762 chr12 48389643 A C 4.36E-07 Osteoarthritis COL2A1 intron 22763110 rs7971880 chr12 48391055 G A 7.12E-05 Bipolar disorder COL2A1 intron 19488044 rs7971880 chr12 48391055 G A 1.58E-05 Bipolar disorder and schizophrenia COL2A1 intron 20889312 rs11168351 chr12 48403765 G A 8.24E-05 Bipolar disorder / / 19488044 rs11168351 chr12 48403765 G A 9.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs11168353 chr12 48408212 C A,G,T 1.08E-05 Glycosylated haemoglobin levels / / 17255346 rs11168363 chr12 48420713 A G 4.23E-05 Glycosylated haemoglobin levels / / 17255346 rs11168364 chr12 48421363 G T 3.77E-05 Glycosylated haemoglobin levels / / 17255346 rs1859441 chr12 48423233 C T 1.70E-04 Type 2 diabetes / / 17846125 rs2240306 chr12 48434507 G A 1.70E-08 Graves' disease / / 21900946 rs11168371 chr12 48437686 G A 1.50E-05 Urinary metabolites SENP1 UTR-3 21572414 rs2408955 chr12 48499131 G T 1.31E-07 Red blood cell traits SENP1 intron 23222517 rs10875746 chr12 48518264 A C 1.80E-05 Urinary metabolites PFKM intron 21572414 rs11168421 chr12 48518333 C A 5.68E-04 Recombination rate PFKM intron 21698098 rs41291971 chr12 48538908 G A 0.00073 Prostate cancer PFKM missense 23555315 rs10783231 chr12 48578325 A C 1.48E-05 Job-related exhaustion C12orf68 missense 23620144 rs7487682 chr12 48579665 G T 4.07E-04 Myopia (pathological) C12orf68 UTR-3 21095009 rs10875770 chr12 48600520 A G 8.69E-05 Schizophrenia / / 19571809 rs10875779 chr12 48629869 G A 1.64E-08 Red blood cell traits / / 23222517 rs146000937 chr12 48635177 TAAAC T 4.07E-04 Myopia (pathological) / / 21095009 rs1542707 chr12 48635177 T C 4.07E-04 Myopia (pathological) / / 21095009 rs716553 chr12 48641403 T C 2.02E-04 Coronary Artery Disease / / 17634449 rs7297298 chr12 48672306 C G 5.12E-05 Body mass (lean) / / 19268274 rs901964 chr12 48676038 T G 1.20E-05 Job-related exhaustion / / 23620144 rs1489111 chr12 48679615 T C 1.20E-05 Job-related exhaustion / / 23620144 rs2054903 chr12 48724493 G A 3.74E-04 Multiple complex diseases / / 17554300 rs2634685 chr12 48768555 G A 1.21E-05 Job-related exhaustion / / 23620144 rs11168562 chr12 48808492 G A 0.0006517 Sarcoidosis / / 22952805 rs4489787 chr12 48811100 T C 1.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs10875813 chr12 48827658 G A 0.0002514 Sarcoidosis / / 22952805 rs79202456 chr12 48831854 C A 0.000214 Sarcoidosis / / 22952805 rs4760707 chr12 48848640 A G 5.46E-04 Multiple complex diseases / / 17554300 rs2956467 chr12 48853239 G C 5.46E-14 Lung cancer / / 21725308 rs11168599 chr12 48879951 T G 7.30E-04 Multiple complex diseases C12orf54 intron 17554300 rs11615184 chr12 48911217 A G 2.36E-05 Schizophrenia / / 20185149 rs10506281 chr12 48923774 G A 2.97E-04 Multiple complex diseases / / 17554300 rs4237859 chr12 48924675 T C 5.82E-04 Multiple complex diseases / / 17554300 rs4523733 chr12 48927514 A G 3.48E-04 Multiple complex diseases / / 17554300 rs4409884 chr12 48927541 A G 3.19E-04 Multiple complex diseases / / 17554300 rs11168618 chr12 48933233 C T 1.00E-07 Adiponectin levels / / 24105470 rs7974371 chr12 48935730 C G 1.37E-04 Multiple complex diseases / / 17554300 rs11168658 chr12 49023163 C G 7.76E-04 Multiple complex diseases / / 17554300 rs12426435 chr12 49052795 C G 9.55E-04 Multiple complex diseases KANSL2 intron 17554300 rs7315319 chr12 49066940 T C 5.84E-05 Alcohol dependence KANSL2 intron 20201924 rs7315319 chr12 49066940 T C 5.84E-05 Alcoholism KANSL2 intron pha002891 rs2898086 chr12 49069636 T C 1.34E-04 Alcohol dependence KANSL2 intron 20201924 rs7297499 chr12 49099850 T C 5.97E-05 Alcohol dependence CCNT1 intron 20201924 rs7297499 chr12 49099850 T C 5.97E-05 Alcoholism CCNT1 intron pha002891 rs10783282 chr12 49146947 G A 0.000000617 Change in depression severity with antidepressants (NRI or SRI) LOC255411 intron 23091423 rs10783282 chr12 49146947 G A 0.00000116 Change in depression severity with Serotonin reuptake inhibitors (SRI) LOC255411 intron 23091423 rs3729980 chr12 49167202 A C 0.0002 Coronary artery calcification ADCY6 intron 23727086 rs6580695 chr12 49201207 C G 1.46E-04 Lymphocyte counts / / 22286170 rs2070615 chr12 49218171 A G 1.00E-06 Bipolar disorder CACNB3 intron 21926972 rs2070615 chr12 49218171 A G 2.19E-04 Smoking initiation CACNB3 intron 24665060 rs11168751 chr12 49219138 C G 1.80E-05 Bipolar disorder CACNB3 intron 21926972 rs2446971 chr12 49262393 T G 2.50E-05 Urinary metabolites / / 21572414 rs903570 chr12 49268519 G A 3.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs872313 chr12 49269099 T C 3.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs2446981 chr12 49270969 G C,T 4.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs2446982 chr12 49271097 G A 4.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs7954041 chr12 49271997 G A 1.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs17175174 chr12 49285634 G A 7.97E-05 Blood Pressure / / pha003040 rs10783289 chr12 49299195 T C 0.000485 Salmonella-induced pyroptosis CCDC65 intron 22837397 rs2293448 chr12 49317852 T C 4.40E-06 Lung adenocarcinoma FKBP11 intron 22797724 rs7311091 chr12 49383207 C T 4.01E-04 Major depressive disorder / / 22472876 rs10875906 chr12 49385679 C T 2.16E-04 Bone mineral density / / 24249740 rs10783299 chr12 49390677 T C 1.09E-05 Major depressive disorder DDN missense 22472876 rs2293445 chr12 49398862 G A 1.01E-05 Major depressive disorder PRKAG1 intron 22472876 rs10875912 chr12 49416944 T C 7.14E-06 Major depressive disorder MLL2 intron 22472876 rs11168827 chr12 49419677 G C 8.75E-06 Major depressive disorder MLL2 intron 22472876 rs10875914 chr12 49422094 A G 1.40E-06 Major depressive disorder MLL2 intron 22472876 rs11168830 chr12 49424534 G A 7.86E-05 Hepatocellular carcinoma MLL2 cds-synon 22807686 rs11614738 chr12 49424616 G A 5.05E-06 Major depressive disorder MLL2 intron 22472876 rs12580349 chr12 49436724 A G 2.81E-04 Multiple complex diseases MLL2 intron 17554300 rs12580349 chr12 49436724 A G 2.70E-05 Urinary metabolites MLL2 intron 21572414 rs12580349 chr12 49436724 A G 4.44E-06 Major depressive disorder MLL2 intron 22472876 rs2304275 chr12 49442813 T C 1.78E-04 Major depressive disorder MLL2 intron 22472876 rs2241726 chr12 49444545 G A 3.71E-06 Major depressive disorder MLL2 cds-synon 22472876 rs11168839 chr12 49457635 G A 8.67E-05 Multiple complex diseases / / 17554300 rs7969091 chr12 49464449 A G 1.26E-06 Major depressive disorder / / 22472876 rs12821008 chr12 49474605 C T 1.95E-06 Major depressive disorder / / 22472876 rs12821008 chr12 49474605 C T 1.00E-15 Bone mineral density / / 22504420 rs12821008 chr12 49474605 C T 0.0000756 Lumbar spine bone mineral density (premenopausal) / / 23074152 rs12821008 chr12 49474605 C T 3.56E-04 Bone mineral density / / 24249740 rs12821008 chr12 49474605 C T 9.89E-04 Bone mineral density / / 24249740 rs12821008 chr12 49474605 C T 9.89E-04 Bone mineral density / / 24249740 rs6580698 chr12 49478658 T C 9.13E-07 Major depressive disorder / / 22472876 rs6580699 chr12 49478812 T G 1.09E-06 Major depressive disorder / / 22472876 rs7296288 chr12 49479968 A C 1.52E-04 Multiple complex diseases / / 17554300 rs7296288 chr12 49479968 A C 8.39E-08 Bipolar disorder / / 21926972 rs7296288 chr12 49479968 A C 1.33E-07 Major depressive disorder / / 22472876 rs7296288 chr12 49479968 A C 8.97E-09 Bipolar disorder / / 23070075 rs7296288 chr12 49479968 A C 0.0000288 Bipolar disorder / / 23637625 rs2117028 chr12 49480948 G A 3.64E-06 Major depressive disorder / / 22472876 rs10783302 chr12 49498130 G T 2.14E-06 Major depressive disorder LMBR1L intron 22472876 rs1274726 chr12 49501398 C T 1.13E-05 Major depressive disorder LMBR1L intron 22472876 rs1274726 chr12 49501398 C T 0.00000148 Bipolar disorder LMBR1L intron 23070075 rs12321116 chr12 49568067 T C 6.69E-04 Multiple complex diseases / / 17554300 rs10875934 chr12 49602205 A G 1.86E-05 HDL particle features / / pha002900 rs10875943 chr12 49676010 T C 7.00E-12 Prostate cancer / / 21743467 rs10875943 chr12 49676010 T C 6.77E-05 Lipoproteins / / pha003079 rs3847764 chr12 49678212 A G 0.000809 fMRI brain tests in schizophrenia / / 22440650 rs4898519 chr12 49714103 A G 8.70E-04 Alcohol dependence / / 20201924 rs7974420 chr12 49767756 T A,C 8.10E-07 Urinary metabolites SPATS2 intron 21572414 rs7962951 chr12 49832618 T C 2.60E-05 Urinary metabolites SPATS2 intron 21572414 rs7294648 chr12 49881343 C G 2.40E-05 Urinary metabolites SPATS2 intron 21572414 rs7975712 chr12 49905713 T C 1.68E-05 Anorexia nervosa SPATS2 intron 21079607 rs12320612 chr12 49915127 G T 1.78E-04 Multiple complex diseases SPATS2 intron 17554300 rs11169058 chr12 49924637 C T 1.44E-05 Anorexia nervosa / / 21079607 rs12296440 chr12 49927148 G A 1.24E-05 Anorexia nervosa / / 21079607 rs11169063 chr12 49931585 T C 1.92E-05 Anorexia nervosa / / 21079607 rs17123764 chr12 49947952 C T 8.10E-06 Elbow pain KCNH3 intron pha003008 rs12299505 chr12 50019894 T C 3.71E-05 Elbow pain PRPF40B intron pha003008 rs7956181 chr12 50056339 T C 5.06E-05 Elbow pain FMNL3 intron pha003008 rs7963954 chr12 50064928 A G 1.39E-05 Anorexia nervosa FMNL3 intron 21079607 rs17123865 chr12 50066047 G A 8.27E-06 Elbow pain FMNL3 intron pha003008 rs17123865 chr12 50066047 G A 9.22E-05 Height FMNL3 intron pha003010 rs17123927 chr12 50149347 A G 3.81E-06 Elbow pain TMBIM6 intron pha003008 rs12316284 chr12 50158866 G A 7.26E-05 Elbow pain / / pha003008 rs2720295 chr12 50171714 A C 2.22E-04 Obesity (extreme) / / 21935397 rs2720293 chr12 50175380 A G 1.65E-05 Obesity (extreme) / / 21935397 rs11836282 chr12 50177324 A T 1.22E-05 Obesity (extreme) / / 21935397 rs2603107 chr12 50183874 T G 9.17E-04 Obesity (extreme) / / 21935397 rs1470909 chr12 50183966 T C 9.41E-04 Obesity (extreme) / / 21935397 rs2603105 chr12 50188434 T A 5.97E-05 Obesity (extreme) NCKAP5L intron 21935397 rs3741554 chr12 50190667 A T 0.00061 Prostate cancer NCKAP5L missense 23555315 rs1075366 chr12 50192009 T C 9.68E-04 Obesity (extreme) NCKAP5L intron 21935397 rs2603112 chr12 50199949 A G 3.02E-04 Obesity (extreme) NCKAP5L intron 21935397 rs7313563 chr12 50204337 C A 3.02E-04 Obesity (extreme) NCKAP5L intron 21935397 rs11169162 chr12 50207126 T C 2.92E-04 Obesity (extreme) NCKAP5L intron 21935397 rs11169163 chr12 50208343 A G 1.94E-04 Obesity (extreme) NCKAP5L intron 21935397 rs4075681 chr12 50214637 C T 4.26E-05 Obesity (extreme) NCKAP5L intron 21935397 rs11169167 chr12 50216801 T C 1.67E-04 Obesity (extreme) NCKAP5L intron 21935397 rs1031477 chr12 50218644 C T 6.76E-04 Myopia (pathological) NCKAP5L intron 21095009 rs1031477 chr12 50218644 C T 3.61E-05 Obesity (extreme) NCKAP5L intron 21935397 rs11169170 chr12 50223013 C T 1.18E-05 Obesity (extreme) LOC100286844 intron 21935397 rs4391887 chr12 50225250 A G 1.52E-04 Obesity (extreme) LOC100286844 intron 21935397 rs10875976 chr12 50226467 G A 1.08E-05 Obesity (extreme) LOC100286844 intron 21935397 rs10875976 chr12 50226467 G A 2.00E-10 Obesity LOC100286844 intron 23563607 rs4898534 chr12 50231025 A G 1.08E-05 Obesity (extreme) BCDIN3D UTR-3 21935397 rs7973894 chr12 50233256 G A 1.09E-05 Obesity (extreme) BCDIN3D intron 21935397 rs4898536 chr12 50240150 C T 4.67E-04 Obesity (extreme) / / 21935397 rs11169176 chr12 50241013 G A 4.93E-06 Body mass index / / 19557197 rs11169176 chr12 50241013 G A 3.10E-06 Obesity (extreme) / / 21935397 rs4898537 chr12 50243342 C G 4.75E-04 Obesity (extreme) / / 21935397 rs10875980 chr12 50244767 A T 2.74E-06 Obesity (extreme) / / 21935397 rs10875982 chr12 50245706 A G 8.17E-06 Body mass index / / 19557197 rs10875982 chr12 50245706 A G 2.81E-06 Obesity (extreme) / / 21935397 rs7138803 chr12 50247468 G A 1.00E-07 Body mass index / / 19079260 rs7138803 chr12 50247468 G A 2.00E-07 Weight / / 19079260 rs7138803 chr12 50247468 G A 8.00E-07 Waist circumference / / 19557197 rs7138803 chr12 50247468 G A 9.60E-07 Smoking behavior / / 20418888 rs7138803 chr12 50247468 G A 2.00E-17 Body mass index / / 20935630 rs7138803 chr12 50247468 G A 1.70E-06 Menarche (age at onset) / / 21102462 rs7138803 chr12 50247468 G A 6.36E-08 Obesity (extreme) / / 21935397 rs7138803 chr12 50247468 G A 2.09E-10 Obesity / / 22484627 rs7138803 chr12 50247468 G A 1.82E-17 Body mass index / / 23001569 rs7138803 chr12 50247468 G A 1.00E-16 Obesity / / 23563607 rs7138803 chr12 50247468 G A 1.00E-20 Obesity / / 23563607 rs7138803 chr12 50247468 G A 2.00E-09 Body mass index / / 23563607 rs10783321 chr12 50249603 C T 6.04E-04 Obesity (extreme) / / 21935397 rs4898539 chr12 50251910 G T 6.02E-04 Obesity (extreme) / / 21935397 rs1975732 chr12 50257946 C T 5.97E-04 Obesity (extreme) / / 21935397 rs3741557 chr12 50258325 T G 4.18E-04 Obesity (extreme) / / 21935397 rs9805137 chr12 50259062 T A 4.87E-04 Obesity (extreme) / / 21935397 rs2271688 chr12 50259529 A C 2.62E-04 Obesity (extreme) / / 21935397 rs7132908 chr12 50263148 G A 2.18E-06 Body mass index FAIM2 UTR-3 19557197 rs7132908 chr12 50263148 G A 6.07E-09 Obesity (extreme) FAIM2 UTR-3 21935397 rs706798 chr12 50266164 G A 1.28E-04 Obesity (extreme) FAIM2 intron 21935397 rs897057 chr12 50266279 T C 1.29E-04 Obesity (extreme) FAIM2 intron 21935397 rs897057 chr12 50266279 T C 2.24E-05 Body mass index FAIM2 intron 24861553 rs706797 chr12 50266858 C G 5.77E-04 Obesity (extreme) FAIM2 intron 21935397 rs836964 chr12 50269895 A G 2.20E-06 Smoking behavior FAIM2 intron 20418888 rs1248263 chr12 50271372 G T 1.86E-04 Obesity (extreme) FAIM2 intron 21935397 rs836959 chr12 50275137 A C 1.85E-04 Obesity (extreme) FAIM2 intron 21935397 rs383307 chr12 50277129 T G 2.37E-04 Obesity (extreme) FAIM2 intron 21935397 rs423934 chr12 50277412 T C 1.71E-04 Obesity (extreme) FAIM2 intron 21935397 rs297924 chr12 50285061 T C 9.21E-06 Body mass index FAIM2 intron 19557197 rs297924 chr12 50285061 T C 7.97E-06 Obesity (extreme) FAIM2 intron 21935397 rs17201502 chr12 50285562 C T 1.94E-06 Body mass index FAIM2 intron 19557197 rs17201502 chr12 50285562 C T 1.11E-05 Obesity (extreme) FAIM2 intron 21935397 rs17201502 chr12 50285562 C T 2.43E-04 Obesity (early onset extreme) FAIM2 intron 23563609 rs11836450 chr12 50289797 G C 4.89E-04 Multiple complex diseases FAIM2 intron 17554300 rs6580724 chr12 50300424 C T 9.40E-04 Multiple complex diseases / / 17554300 rs584105 chr12 50306148 A G 2.00E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs584105 chr12 50306148 A G 3.62E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs836961 chr12 50314617 T C 9.80E-04 Acute lung injury / / 22295056 rs297907 chr12 50316818 A G 3.16E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs297943 chr12 50318450 T C 7.30E-04 Acute lung injury / / 22295056 rs297941 chr12 50319086 A G 5.00E-07 Obsessive-compulsive disorder / / 22889921 rs296741 chr12 50332070 G A 5.42E-08 Metabolite levels / / 23281178 rs296742 chr12 50335086 T C 7.88E-04 Parkinson's disease / / 17052657 rs296742 chr12 50335086 T C 8.92E-05 Leukocyte Counts / / pha003091 rs7305290 chr12 50341465 T C 9.58E-06 Obesity-related traits / / 23251661 rs2849266 chr12 50366300 G A 1.67E-04 Multiple complex diseases / / 17554300 rs10875990 chr12 50372026 C T 6.33E-04 Multiple complex diseases / / 17554300 rs1105203 chr12 50433234 C T 4.53E-04 Schizophrenia / / 19197363 rs1108923 chr12 50458096 G T 4.59E-04 Suicide attempts in bipolar disorder ASIC1 intron 21423239 rs3782323 chr12 50482921 G A 0.0000283 Alcohol craving with or without dependence SMARCD1 intron 22481050 rs7136570 chr12 50529936 A G 1.61E-14 Lymphocyte counts CERS5 intron 22286170 rs34245511 chr12 50573433 G C 3.00E-08 Colorectal cancer LIMA1 intron 24737748 rs12817211 chr12 50579398 C T 8.32E-04 Suicide attempts in bipolar disorder LIMA1 intron 21423239 rs6580742 chr12 50727811 C T 4.00E-06 Smoking behavior FAM186A missense 20418888 rs4348979 chr12 50763415 G T 9.07E-05 Serum metabolites FAM186A intron 19043545 rs7136702 chr12 50880216 T C 5.83E-05 Colorectal cancer / / 23266556 rs10506296 chr12 51087857 C G 9.60E-04 Crohn's disease DIP2B intron 17684544 rs3825402 chr12 51127738 T C 1.17E-06 Esophageal cancer (squamous cell) DIP2B intron 22960999 rs7968440 chr12 51134741 A G 3.00E-08 Fibrinogen DIP2B intron 23969696 rs12301118 chr12 51145877 G A,C 4.78E-04 Multiple complex diseases / / 17554300 rs11169552 chr12 51155663 C T 2.00E-10 Colorectal cancer / / 20972440 rs11169561 chr12 51185950 C T 1.40E-06 Esophageal cancer (squamous cell) ATF1 intron 22960999 rs11169561 chr12 51185950 C T 1.40E-04 Smoking initiation ATF1 intron 24665060 rs1344958 chr12 51197717 C T 4.18E-04 Smoking initiation ATF1 intron 24665060 rs10876097 chr12 51209636 A G 5.18E-04 Smoking initiation ATF1 intron 24665060 rs17291650 chr12 51213433 A G 3.00E-07 Sudden cardiac arrest ATF1 cds-synon 21658281 rs4768925 chr12 51218323 C G 3.29E-04 Smoking initiation / / 24665060 rs17125088 chr12 51326702 T C 4.90E-05 Multiple complex diseases / / 17554300 rs12305170 chr12 51345265 T C 2.49E-06 Monocyte counts / / pha003089 rs319936 chr12 51350285 C T 2.50E-05 Urinary metabolites HIGD1C intron 21572414 rs4768942 chr12 51355701 C T 3.97E-06 Monocyte counts HIGD1C intron pha003089 rs12304921 chr12 51357542 A G 7.00E-06 Type 2 diabetes HIGD1C intron 17554300 rs12304921 chr12 51357542 A G 7.00E-06 Coronary heart disease HIGD1C intron 21347282 rs12304921 chr12 51357542 A G 7.00E-06 Type 2 diabetes HIGD1C intron 21647700 rs319931 chr12 51357918 C A 2.10E-05 Urinary metabolites HIGD1C intron 21572414 rs12821444 chr12 51361498 T C 3.61E-04 Lymphocyte counts HIGD1C intron 22286170 rs853235 chr12 51375969 C T 1.90E-05 Urinary metabolites SLC11A2 intron 21572414 rs11169654 chr12 51380835 C T 2.08E-04 Smoking quantity SLC11A2 UTR-3 24665060 rs4768959 chr12 51445661 T C 1.22E-04 Common variable immunodeficiency LETMD1 intron 21497890 rs142643949 chr12 51457921 T C 0.00002 Breast cancer(er negative) CSRNP2 missense 23555315 rs6580784 chr12 51468311 G A 3.58E-04 Smoking quantity CSRNP2 intron 24665060 rs2018022 chr12 51475353 T C 1.35E-04 Multiple complex diseases CSRNP2 intron 17554300 rs2018022 chr12 51475353 T C 7.89E-04 Lymphocyte counts CSRNP2 intron 22286170 rs4768967 chr12 51506328 T C 2.53E-06 Kawasaki disease TFCP2 intron 21221998 rs3751275 chr12 51518787 C G 5.60E-04 Multiple complex diseases TFCP2 intron 17554300 rs2730648 chr12 51537196 C T 4.53E-04 Smoking quantity TFCP2 intron 24665060 rs7399214 chr12 51544304 C T 9.29E-04 Aortic root size TFCP2 intron 21223598 rs2640525 chr12 51544817 C T 7.57E-04 Aortic root size TFCP2 intron 21223598 rs2029686 chr12 51564802 T A 1.20E-05 Urinary metabolites TFCP2 intron 21572414 rs11169748 chr12 51579171 A G 8.50E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs11169761 chr12 51595505 G A 2.38E-04 Prostate cancer mortality POU6F1 intron 20978177 rs6580809 chr12 51609600 C T 4.65E-04 Suicide attempts in bipolar disorder POU6F1 intron 21041247 rs10747608 chr12 51616582 A G 8.51E-04 Alcohol dependence / / 21314694 rs10783424 chr12 51621910 A G 3.53E-05 Serum metabolites / / 19043545 rs7305016 chr12 51642543 A G 6.72E-04 Prostate cancer mortality SMAGP intron 20978177 rs4761998 chr12 51682159 G A 2.44E-05 Bladder cancer BIN2 intron 19648920 rs1362963 chr12 51686984 T C 4.55E-05 Gallstones BIN2 intron 17632509 rs766903 chr12 51703834 A G 2.00E-06 Aging (time to death) BIN2 intron 21782286 rs10876162 chr12 51724286 T C 2.98E-05 Bladder cancer CELA1 intron 19648920 rs3951439 chr12 51727596 C T 6.00E-06 Obesity-related traits CELA1 intron 23251661 rs11169806 chr12 51730991 C A 8.33E-06 Height CELA1 intron 20400458 rs3847862 chr12 51732500 G A 2.84E-05 Bladder cancer CELA1 intron 19648920 rs10783433 chr12 51755293 G A 8.44E-05 Blood pressure GALNT6 intron 17255346 rs10876172 chr12 51795857 G A 2.40E-07 Urinary metabolites SLC4A8 intron 21572414 rs147845115 chr12 51878760 G A 3.00E-07 Alzheimer's disease (cognitive decline) SLC4A8 intron 23535033 rs10783455 chr12 51931939 G A 1.57E-05 Serum metabolites / / 19043545 rs1905248 chr12 52007003 A G 9.10E-07 Amyotrophic Lateral Sclerosis SCN8A intron 17362836 rs4512905 chr12 52051130 T C 3.85E-05 Response to lithium treatment in bipolar disorder SCN8A intron 21961650 rs10876203 chr12 52084866 C T 7.96E-04 Cognitive impairment induced by topiramate SCN8A intron 22091778 rs167337 chr12 52182052 A G 9.00E-04 Chronic fatigue syndrome SCN8A intron 21912186 rs9943809 chr12 52182545 A G 1.30E-04 Multiple complex diseases SCN8A intron 17554300 rs303816 chr12 52183485 C T 6.10E-04 Volumetric brain MRI SCN8A intron 17903297 rs7306698 chr12 52189753 C T 0.0007157 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SCN8A intron 23233654 rs7306698 chr12 52189753 C T 7.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) SCN8A intron 23233662 rs633370 chr12 52225638 T A 5.05E-04 Suicide attempts in bipolar disorder FIGNL2 UTR-5 21423239 rs7976059 chr12 52251272 G T 8.90E-07 Amyotrophic Lateral Sclerosis / / 17362836 rs7976059 chr12 52251272 G T 2.00E-09 Urate levels / / 23263486 rs7295382 chr12 52260783 T G 7.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs12306470 chr12 52261003 G C 4.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs17126180 chr12 52263956 C G 9.00E-07 Response to antipsychotic treatment in schizophrenia (reasoning) / / 21107309 rs17126180 chr12 52263956 C G 0.0004393 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17126180 chr12 52263956 C G 4.39E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1566869 chr12 52266348 G A 2.12E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs1566869 chr12 52266348 G A 9.05E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs150919589 chr12 52282460 C T 0.00012 Prostate cancer (advanced) ANKRD33 missense 23555315 rs697636 chr12 52282873 A T 0.000095 Stroke ANKRD33 missense 23422753 rs4343071 chr12 52286776 T G 4.72E-05 Cholesterol / / pha003073 rs4343071 chr12 52286776 T G 3.52E-05 Cholesterol / / pha003078 rs3759178 chr12 52299259 G T 3.34E-05 Cholesterol ACVRL1 nearGene-5 pha003073 rs3759178 chr12 52299259 G T 3.83E-05 Cholesterol ACVRL1 nearGene-5 pha003078 rs2277383 chr12 52314388 T G 2.32E-04 Smoking quantity ACVRL1 intron 24665060 rs7962469 chr12 52348259 A G 3.62E-04 Multiple complex diseases ACVR1B intron 17554300 rs771997 chr12 52358168 G A 6.13E-05 Hemoglobin concentration ACVR1B intron 20534544 rs771998 chr12 52358195 T C 8.12E-04 Multiple complex diseases ACVR1B intron 17554300 rs2641530 chr12 52384811 C T 6.13E-05 Hemoglobin concentration ACVR1B intron 20534544 rs877869 chr12 52392200 G A 1.13E-04 Hemoglobin concentration / / 20534544 rs2701113 chr12 52424606 G A 1.50E-05 Urinary metabolites NR4A1 intron 21572414 rs2701113 chr12 52424606 G A 0.00022 Coronary artery calcification NR4A1 intron 23727086 rs2603751 chr12 52453282 T C 9.83E-04 Acute lung injury NR4A1 UTR-3 22295056 rs11521 chr12 52471159 C T 4.37E-04 Smoking initiation C12orf44 UTR-3 24665060 rs2360644 chr12 52504038 G A 5.77E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11503938 chr12 52506299 T C 5.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs11503940 chr12 52506647 C T 4.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs12424533 chr12 52568501 C T 4.45E-05 Caffeine consumption KRT80 intron 21490707 rs12424533 chr12 52568501 C T 3.57E-04 Coronary heart disease KRT80 intron 21971053 rs17653722 chr12 52587518 G T 7.00E-06 Telomere length KRT80 nearGene-5 24465473 rs17126450 chr12 52608712 C T 9.03E-04 HIV-1 viral setpoint LOC283404 intron 17641165 rs10876248 chr12 52611660 C T 8.01E-04 HIV-1 viral setpoint LOC283404 intron 17641165 rs7970654 chr12 52611900 T C 3.74E-04 Amyotrophic Lateral Sclerosis LOC283404 intron 17362836 rs6580868 chr12 52612993 T C 9.29E-04 HIV-1 viral setpoint LOC283404 intron 17641165 rs12578642 chr12 52618050 G A 3.48E-04 Type 2 diabetes / / 17463246 rs7300317 chr12 52632573 A G 3.27E-05 HIV-1 viral setpoint KRT7 intron 17641165 rs2852453 chr12 52651010 C T 1.28E-04 Vaspin levels / / 22907691 rs2852453 chr12 52651010 C T 0.0001276 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs1902764 chr12 52657399 T C 1.18E-05 Bipolar disorder / / 18317468 rs1902764 chr12 52657399 T C 0.000759 Salmonella-induced pyroptosis / / 22837397 rs1902763 chr12 52657665 T C 0.000685 Salmonella-induced pyroptosis / / 22837397 rs1902763 chr12 52657665 T C 5.62E-05 Vaspin levels / / 22907691 rs1902763 chr12 52657665 T C 0.0000346 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs1902763 chr12 52657665 T C 0.0000562 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs2852474 chr12 52660812 G A 3.80E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs916162 chr12 52661714 G A 0.0001 Migraine / / 22678113 rs916162 chr12 52661714 G A 2.54E-05 Coronary heart disease / / pha003031 rs1945300 chr12 52666920 A G 6.80E-05 Vaspin levels / / 22907691 rs1945300 chr12 52666920 A G 0.0000328 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs1945300 chr12 52666920 A G 0.000068 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs2608017 chr12 52675917 G A 6.81E-05 Vaspin levels / / 22907691 rs2608017 chr12 52675917 G A 0.0000681 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs2608017 chr12 52675917 G A 0.0001261 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs6580873 chr12 52681925 A C,T 1.51E-04 Vaspin levels KRT81 missense 22907691 rs6580873 chr12 52681925 A C,T 0.0000461 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit KRT81 missense 22907730 rs6580873 chr12 52681925 A C,T 0.0001514 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit KRT81 missense 22907730 rs7953684 chr12 52687070 G A 1.04E-04 Weight loss (gastric bypass surgery) KRT81 nearGene-5 23643386 rs17655565 chr12 52691958 T C 2.00E-06 Plasma amyloid beta peptide concentrations (ABx-42) / / 24535457 rs11611330 chr12 52710037 A G 1.64E-04 Stroke KRT83 intron pha002886 rs2277384 chr12 52711375 G C 0.000366 Salmonella-induced pyroptosis KRT83 intron 22837397 rs2857663 chr12 52713088 G A 1.53E-04 Multiple complex diseases KRT83 missense 17554300 rs2857663 chr12 52713088 G A 2.20E-06 Urinary metabolites KRT83 missense 21572414 rs1573514 chr12 52719253 C A 4.48E-05 Stroke / / pha002886 rs2226907 chr12 52726792 C T 8.21E-04 Schizophrenia / / 19197363 rs2226907 chr12 52726792 C T 7.52E-05 Stroke / / pha002886 rs1732310 chr12 52741091 C T 5.26E-05 Multiple complex diseases / / 17554300 rs1732323 chr12 52749738 C A 1.45E-04 Stroke / / pha002886 rs1791625 chr12 52761679 T C 3.11E-04 Stroke KRT85 nearGene-5 pha002886 rs1732281 chr12 52771206 G A 5.14E-04 Smoking cessation KRT84 nearGene-3 24665060 rs2271084 chr12 52775431 A G 2.47E-05 Body mass (lean) KRT84 intron 19268274 rs1732297 chr12 52776679 A G 1.80E-05 Urinary metabolites KRT84 intron 21572414 rs11170109 chr12 52786026 G A 1.31E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11170112 chr12 52788039 A G 8.28E-06 Body mass (lean) KRT82 UTR-3 19268274 rs2658658 chr12 52788928 G A 5.33E-04 Response to cytadine analogues (cytosine arabinoside) KRT82 missense 24483146 rs2658658 chr12 52788928 G A 1.14E-04 Stroke KRT82 missense pha002886 rs10876286 chr12 52790194 C A 8.46E-06 Hearing function KRT82 intron 21493956 rs2249384 chr12 52790940 C T 9.19E-05 Stroke KRT82 intron pha002886 rs17125077 chr12 52823214 A G 4.97E-04 Aortic root size KRT75 intron 21223598 rs17097973 chr12 52832465 G C 5.19E-04 Aortic root size / / 21223598 rs421007 chr12 52850845 G T 3.70E-06 Primary tooth development (time to first tooth eruption) / / 23704328 rs11549950 chr12 52908917 T C 0.000019 Stroke KRT5 missense 23422753 rs11170164 chr12 52913668 C T 3.00E-06 Basal cell carcinoma KRT5 missense 24403052 rs609704 chr12 52935247 C T 8.96E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs2292506 chr12 52938320 C T 1.03E-04 Attention deficit hyperactivity disorder KRT71 missense 22420046 rs2292506 chr12 52938320 C T 0.000033 Breast cancer KRT71 missense 23555315 rs2292507 chr12 52938364 T C 3.97E-05 Insulin-related traits KRT71 cds-synon pha002901 rs622446 chr12 52942362 G A 3.16E-04 Schizophrenia KRT71 intron 19197363 rs640014 chr12 52962914 T G 8.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KRT74 intron 20877124 rs640014 chr12 52962914 T G 1.10E-05 Diabetic retinopathy KRT74 intron 21441570 rs670741 chr12 52965173 T G 6.93E-04 Smoking initiation KRT74 missense 24665060 rs11612661 chr12 52971564 A G 2.41E-04 Heart Failure / / pha002885 rs670142 chr12 53000987 A C 7.09E-04 Cocaine dependence KRT73 nearGene-3 23958962 rs591636 chr12 53002956 T C 3.43E-05 Scoliosis KRT73 intron 21216876 rs597520 chr12 53010585 G T 1.49E-04 Scoliosis KRT73 intron 21216876 rs7953708 chr12 53013042 C A 1.70E-05 Urinary metabolites KRT73 nearGene-5 21572414 rs17117322 chr12 53029003 G T 1.34E-04 Multiple complex diseases / / 17554300 rs11170211 chr12 53033440 C A 1.90E-05 Urinary metabolites / / 21572414 rs685190 chr12 53035460 C T 1.46E-04 Alzheimer's disease (late onset) / / 21379329 rs2232560 chr12 53039537 C T 5.23E-05 Multiple complex diseases KRT2 intron 17554300 rs2232559 chr12 53040411 T C 1.24E-04 Diabetic nephropathy KRT2 intron pha002866 rs10506310 chr12 53054269 C T 1.25E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10783526 chr12 53054557 G A 7.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1873063 chr12 53059645 A G 1.40E-05 Urinary metabolites / / 21572414 rs8181747 chr12 53064393 G A 4.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs646526 chr12 53065258 T C 9.14E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1402588 chr12 53066805 C A 9.77E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11170231 chr12 53068633 G A 2.09E-07 Post-operative nausea and vomiting KRT1 UTR-3 21694509 rs14024 chr12 53069014 T C 2.90E-05 Alcohol dependence KRT1 missense 20201924 rs14024 chr12 53069014 T C 4.90E-04 Alcohol dependence KRT1 missense 20201924 rs14024 chr12 53069014 T C 2.86E-05 Alcoholism KRT1 missense pha002893 rs2741158 chr12 53071560 A G 8.71E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KRT1 intron 20877124 rs3759191 chr12 53075660 T C 8.71E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KRT1 nearGene-5 20877124 rs684471 chr12 53111327 G A 3.94E-05 Serum metabolites / / 19043545 rs4761944 chr12 53125184 A G 3.16E-04 Myopia (pathological) / / 21095009 rs4761958 chr12 53144736 C T 1.80E-05 Urinary metabolites / / 21572414 rs1818763 chr12 53155345 T C 1.57E-04 Multiple complex diseases / / 17554300 rs4499050 chr12 53156064 G T 3.22E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17118856 chr12 53157968 T C 4.52E-04 Lymphocyte counts / / 22286170 rs1521341 chr12 53161420 C T 5.74E-05 Body Fat Distribution / / pha003017 rs1521341 chr12 53161420 C T 8.72E-05 Body Fat Distribution / / pha003018 rs2280480 chr12 53162528 G A 2.24E-05 Amyotrophic lateral sclerosis (sporadic) KRT76 missense 24529757 rs2280479 chr12 53162638 G A 7.17E-04 Alzheimer's disease KRT76 cds-synon 17998437 rs12308045 chr12 53165178 A G 3.98E-05 Body Fat Distribution KRT76 intron pha003017 rs12308045 chr12 53165178 A G 5.56E-05 Body Fat Distribution KRT76 intron pha003018 rs7397684 chr12 53173073 A G 2.10E-05 Alcohol dependence KRT76 nearGene-5 20201924 rs7397684 chr12 53173073 A G 4.90E-04 Alcohol dependence KRT76 nearGene-5 20201924 rs7397684 chr12 53173073 A G 2.09E-05 Alcoholism KRT76 nearGene-5 pha002893 rs4919706 chr12 53177573 T C 6.55E-05 Body Fat Distribution / / pha003017 rs12312467 chr12 53184725 G A 1.30E-06 Alcohol and nictotine co-dependence KRT3 intron 20158304 rs923722 chr12 53196303 C T 9.96E-05 Soluble levels of adhesion molecules / / pha003072 rs10876351 chr12 53196699 A G 5.24E-05 Soluble levels of adhesion molecules / / pha003072 rs7965628 chr12 53197448 G A 4.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1994755 chr12 53199883 G A 7.45E-04 Amyotrophic Lateral Sclerosis KRT4 nearGene-3 17362836 rs3103736 chr12 53200180 T C 0.000529 Salmonella-induced pyroptosis KRT4 nearGene-3 22837397 rs3134665 chr12 53206039 G A 9.44E-04 Tourette syndrome KRT4 intron 22889924 rs2638525 chr12 53207628 G A 4.68E-04 Coronary heart disease KRT4 missense 21971053 rs902774 chr12 53273904 G A 2.00E-07 Prostate cancer / / 18264097 rs902774 chr12 53273904 G A 5.00E-09 Prostate cancer / / 21743057 rs17746685 chr12 53280673 T C 1.69E-05 Multiple complex diseases / / 17554300 rs12422322 chr12 53284167 A G 1.50E-05 Urinary metabolites / / 21572414 rs11613918 chr12 53321998 C G 6.80E-06 Urinary metabolites KRT8 intron 21572414 rs7308151 chr12 53346848 G C 3.61E-04 Multiple complex diseases KRT18 nearGene-3 17554300 rs6580921 chr12 53353508 C A 1.52E-05 Cognitive test performance / / 20125193 rs727266 chr12 53356411 C T 1.52E-05 Cognitive test performance / / 20125193 rs727266 chr12 53356411 C T 9.82E-05 Orofacial clefts / / 22863734 rs17121291 chr12 53365540 T C 4.94E-04 Multiple complex diseases / / 17554300 rs10506315 chr12 53416251 C T 4.30E-05 Cognitive test performance EIF4B intron 20125193 rs4919697 chr12 53421507 G A 1.44E-04 Multiple complex diseases EIF4B intron 17554300 rs10747658 chr12 53445282 G A 5.02E-04 Suicide attempts in bipolar disorder TENC1 intron 21041247 rs2364153 chr12 53449735 T C 4.58E-04 Suicide attempts in bipolar disorder TENC1 intron 21041247 rs17123210 chr12 53497927 C G 5.71E-04 Multiple complex diseases SOAT2 intron 17554300 rs10876407 chr12 53502438 T A 6.20E-08 Health and aging,CVD and cancer age of onset SOAT2 intron 22174011 rs822682 chr12 53512444 T C 0.0000394 Body mass index SOAT2 intron 23001569 rs2280697 chr12 53517820 A C 8.90E-05 Magnesium levels SOAT2 intron pha003092 rs12581102 chr12 53521658 C T 8.90E-05 Magnesium levels / / pha003092 rs2272306 chr12 53554283 G A 2.00E-06 Obesity-related traits CSAD intron 23251661 rs11574546 chr12 53584871 A G 1.63E-06 Obesity-related traits / / 23251661 rs7314769 chr12 53637466 C T 5.51E-04 Alzheimer's disease / / 17998437 rs7314769 chr12 53637466 C T 8.80E-05 Bone mineral density / / 21927923 rs7954360 chr12 53645198 G A 4.20E-04 Alzheimer's disease / / 17998437 rs1976938 chr12 53661925 C T 8.81E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6580942 chr12 53662624 C A 4.67E-04 Bone mineral density ESPL1 missense 19181680 rs4759086 chr12 53666713 A G 1.96E-04 Response to cytadine analogues (cytosine arabinoside) ESPL1 intron 24483146 rs7313752 chr12 53675663 T C 3.83E-05 Type 2 diabetes ESPL1 intron 17463246 rs4759021 chr12 53714868 G A 9.76E-04 Bone mineral density AAAS intron 19181680 rs2016266 chr12 53727955 G A 4.60E-06 Bone mineral density (spine) SP7 intron 19079262 rs2016266 chr12 53727955 G A 3.73E-04 Bone mineral density SP7 intron 19181680 rs2016266 chr12 53727955 G A 1.00E-08 Bone mineral density (spine) SP7 intron 19801982 rs2016266 chr12 53727955 G A 0.000161171 Hypertension (early onset hypertension) SP7 intron 22479346 rs2016266 chr12 53727955 G A 3.00E-20 Bone mineral density SP7 intron 22504420 rs2016266 chr12 53727955 G A 6.18E-05 Bone mineral density SP7 intron 24249740 rs2016266 chr12 53727955 G A 3.70E-04 Bone mineral density (paediatric,total body less head) SP7 intron 24945404 rs2016266 chr12 53727955 G A 4.23E-05 Bone mineral density (paediatric,upper limb) SP7 intron 24945404 rs10876432 chr12 53731891 G A 1.00E-07 Bone mineral density (spine) SP7 nearGene-5 19079262 rs10876432 chr12 53731891 G A 6.45E-04 Bone mineral density SP7 nearGene-5 19181680 rs10876432 chr12 53731891 G A 5.42E-04 Schizophrenia SP7 nearGene-5 19197363 rs10876432 chr12 53731891 G A 1.00E-06 Bone mineral density SP7 nearGene-5 21927923 rs4759082 chr12 53734506 C T 7.27E-04 Schizophrenia / / 19197363 rs34656641 chr12 53797236 A C 3.51E-05 Bone mineral density SP1 intron 24249740 rs34656641 chr12 53797236 A C 9.06E-04 Bone mineral density SP1 intron 24249740 rs35822762 chr12 53900640 A G 1.29E-11 Triglycerides NPFF missense 23063622 rs12321906 chr12 53916715 T C 5.00E-06 Height ATF7 intron 21998595 rs784562 chr12 53919700 A C 9.29E-04 Response to cytadine analogues (cytosine arabinoside) ATF7 intron 24483146 rs784568 chr12 53927554 C A 5.17E-04 Schizophrenia ATF7 intron 19197363 rs784568 chr12 53927554 C A 8.45E-04 Response to cytadine analogues (cytosine arabinoside) ATF7 intron 24483146 rs1247956 chr12 53963814 G T 6.40E-04 Response to cytadine analogues (cytosine arabinoside) ATF7 intron 24483146 rs1247955 chr12 53964133 G T 5.77E-04 Schizophrenia ATF7 intron 19197363 rs1247955 chr12 53964133 G T 6.40E-04 Response to cytadine analogues (cytosine arabinoside) ATF7 intron 24483146 rs1153134 chr12 53991321 C T 6.40E-04 Response to cytadine analogues (cytosine arabinoside) ATF7 intron 24483146 rs1485395 chr12 53995077 T C 1.60E-04 Migraine - clinic-based ATF7 intron 23793025 rs1485395 chr12 53995077 T C 7.00E-06 Migraine without aura ATF7 intron 23793025 rs1485395 chr12 53995077 T C 9.66E-05 Migraine ATF7 intron 23793025 rs7970141 chr12 54001237 G A 7.02E-05 Schizophrenia ATF7 intron 19197363 rs11170631 chr12 54041192 T C 9.00E-07 Height / / 20189936 rs7976793 chr12 54073069 G T 8.40E-05 Schizophrenia / / 24253340 rs10747678 chr12 54077687 C A 3.27E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7975862 chr12 54078427 C A 6.81E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs941184 chr12 54114158 C T 3.00E-07 Panic disorder CALCOCO1 intron 19165232 rs17102261 chr12 54126732 T G 2.90E-05 Urinary metabolites / / 21572414 rs12423655 chr12 54131094 C T 9.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7969151 chr12 54159277 G A 2.00E-06 Tanning / / 19340012 rs6580960 chr12 54159380 A C 9.86E-04 Heart Failure / / pha002885 rs1316636 chr12 54179028 G A 0.0004889 Sarcoidosis / / 22952805 rs17102916 chr12 54181171 G T 2.77E-04 Multiple complex diseases / / 17554300 rs10506318 chr12 54188182 T G 1.94E-07 Pure-tone audiometry / / pha001966 rs3910926 chr12 54212591 G A,C 1.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs7303149 chr12 54256094 C T 5.63E-04 Multiple complex diseases / / 17554300 rs796720 chr12 54259609 A G 1.38E-04 Multiple complex diseases / / 17554300 rs7306498 chr12 54259701 G A 3.87E-05 Biliary atresia / / 20460270 rs10506325 chr12 54261760 C T 1.74E-06 Lipid levels / / 19016617 rs2120991 chr12 54270228 C A 9.00E-06 Biliary atresia / / 20460270 rs182713 chr12 54274624 T C 5.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2120992 chr12 54275125 T A 3.82E-04 Multiple complex diseases / / 17554300 rs1596370 chr12 54275266 G A 7.97E-04 Type 2 diabetes / / 17463246 rs2577864 chr12 54287161 C T 3.36E-05 Biliary atresia / / 20460270 rs2577865 chr12 54287178 T C 3.67E-04 Multiple complex diseases / / 17554300 rs2590712 chr12 54287445 C G 3.13E-05 Biliary atresia / / 20460270 rs1947021 chr12 54300785 A G 8.53E-05 Hemoglobin concentration / / 20534544 rs1470321 chr12 54301044 G A 1.47E-04 Multiple complex diseases / / 17554300 rs7312914 chr12 54309622 A G 3.27E-04 Multiple complex diseases / / 17554300 rs1443504 chr12 54316307 G T 6.76E-05 Multiple complex diseases / / 17554300 rs10735853 chr12 54318146 T C 1.97E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs894734 chr12 54319727 A G 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs979013 chr12 54320805 C A 8.22E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs2366144 chr12 54324069 C A 6.05E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs1975473 chr12 54334625 G A 5.94E-04 Multiple complex diseases HOXC13 intron 17554300 rs17105382 chr12 54339104 G A 4.54E-04 Multiple complex diseases HOXC13 UTR-3 17554300 rs1443512 chr12 54342684 A C 6.00E-16 Waist-hip ratio / / 20935629 rs1443512 chr12 54342684 A C 4.10E-04 Sexual dimorphism in anthropometric traits / / 23754948 rs2120295 chr12 54352836 A G 2.92E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2366150 chr12 54353523 A G 5.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2366151 chr12 54355708 G A 6.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17840857 chr12 54357757 G A,C,T 3.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs736825 chr12 54417576 C G 8.00E-16 Bone mineral density HOXC4 intron 22504420 rs11170792 chr12 54450876 G A 7.00E-04 Alcohol dependence / / 20201924 rs11170826 chr12 54531952 T C 8.17E-04 Response to TNF antagonist treatment / / 21061259 rs3136397 chr12 54574213 T C 1.03E-04 Multiple complex diseases SMUG1 UTR-3 17554300 rs2029166 chr12 54590099 C T 7.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1317996 chr12 54600543 G C 0.0000178 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17109475 chr12 54624374 T C 3.50E-06 Urinary metabolites / / 21572414 rs1049688 chr12 54685927 G A 6.00E-04 Kidney function and endocine traits NFE2 UTR-3 17903292 rs10506328 chr12 54687232 A C 5.00E-07 Mean platelet volume NFE2 intron 19820697 rs10506328 chr12 54687232 A C 2.00E-09 Mean platelet volume NFE2 intron 24026423 rs10876550 chr12 54712308 G A 2.25E-04 Type 2 diabetes / / 17463246 rs10876550 chr12 54712308 G A 1.60E-06 Blood cell counts and traits,in red and white blood cells / / 21153663 rs10876550 chr12 54712308 G A 2.00E-14 Mean platelet volume / / 22139419 rs10876550 chr12 54712308 G A 1.60E-06 Mean platelet volume / / 22423221 rs10876550 chr12 54712308 G A 4.00E-08 Mean platelet volume / / 24026423 rs4326844 chr12 54736470 A G 5.00E-08 Platelet counts COPZ1 intron 23263863 rs2141587 chr12 54737701 A G 6.50E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) COPZ1 intron 23648065 rs2141587 chr12 54737701 A G 7.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) COPZ1 intron 23648065 rs4758960 chr12 54748626 G A 1.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs4758960 chr12 54748626 G A 2.28E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs9653 chr12 54789156 T G 5.34E-04 Smoking initiation ITGA5 UTR-3 24665060 rs11170895 chr12 54811708 C T 2.40E-04 Gallstones ITGA5 intron 17632509 rs11170895 chr12 54811708 C T 6.94E-05 Height ITGA5 intron pha003011 rs12318758 chr12 54827568 C T 6.68E-06 Height / / pha003011 rs11170917 chr12 54865988 C T 9.82E-05 Response to mTOR inhibitor (rapamycin) GTSF1 intron 24009623 rs7135745 chr12 54867251 T A 4.80E-05 Response to mTOR inhibitor (rapamycin) GTSF1 intron 24009623 rs2458409 chr12 54905815 C G 9.92E-04 Suicide attempts in bipolar disorder NCKAP1L cds-synon 21423239 rs1629826 chr12 54909144 G A 3.00E-06 Obesity-related traits NCKAP1L intron 23251661 rs12821748 chr12 54923034 C T 3.32E-05 Mammographic density NCKAP1L intron 22532574 rs4759088 chr12 54924504 C T 3.33E-05 Mammographic density NCKAP1L intron 22532574 rs4759088 chr12 54924504 C T 1.50E-06 Cystic fibrosis-related diabetes NCKAP1L intron 23670970 rs17113238 chr12 54926329 G A 3.51E-05 Mammographic density NCKAP1L intron 22532574 rs2036068 chr12 54930531 A G 1.40E-05 Urinary metabolites NCKAP1L intron 21572414 rs2036067 chr12 54930914 A G 1.40E-05 Urinary metabolites NCKAP1L intron 21572414 rs1153138 chr12 54963907 T C 6.83E-06 Response to tamoxifen in breast cancer PDE1B intron 22180457 rs2280426 chr12 54966757 G A 1.73E-04 Alzheimer's disease PDE1B intron 22005930 rs3782411 chr12 54967901 C T 9.51E-05 Rheumatoid arthritis PDE1B intron 17804836 rs11170980 chr12 54976112 C T 4.06E-05 Telomere length PPP1R1A intron 23001564 rs1157485 chr12 54997372 T C 8.38E-05 Multiple complex diseases / / 17554300 rs2643615 chr12 55014152 A G 4.64E-04 Tourette syndrome / / 22889924 rs924070 chr12 55034908 G A 2.74E-04 Multiple complex diseases / / 17554300 rs10876575 chr12 55043233 T G 1.53E-05 Cognitive impairment induced by topiramate / / 22091778 rs11171005 chr12 55047126 G A 1.98E-05 Calcium levels / / pha003085 rs6580988 chr12 55047189 T C 4.53E-04 Age-related macular degeneration / / 21909106 rs1495927 chr12 55050763 C T 2.14E-05 Cognitive impairment induced by topiramate / / 22091778 rs10876579 chr12 55051647 T C 2.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11171007 chr12 55053543 C T 8.97E-04 Aortic root size / / 21223598 rs903767 chr12 55077159 C T 1.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17115699 chr12 55079182 C T 5.85E-05 Multiple complex diseases / / 17554300 rs17115699 chr12 55079182 C T 9.84E-06 Calcium levels / / pha003085 rs884499 chr12 55087216 A G 2.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1692108 chr12 55095662 G A 7.88E-05 Endometrial cancer / / 24096698 rs1692108 chr12 55095662 G A 8.34E-05 Endometrial cancer / / 24096698 rs1692108 chr12 55095662 G A 9.53E-05 Endometrial cancer / / 24096698 rs1153188 chr12 55098996 T A 2.00E-07 Type 2 diabetes / / 18372903 rs1153188 chr12 55098996 T A 2.00E-07 Coronary heart disease / / 21347282 rs1153188 chr12 55098996 T A 2.00E-07 Type 2 diabetes / / 21647700 rs2198600 chr12 55140402 C T 4.14E-07 Breast cancer / / 20852631 rs1542363 chr12 55213678 A G 1.31E-04 Multiple complex diseases / / 17554300 rs1542364 chr12 55213701 A G 1.19E-04 Multiple complex diseases / / 17554300 rs7298952 chr12 55216415 C T 1.65E-04 Multiple complex diseases / / 17554300 rs10735855 chr12 55216698 A G 1.44E-04 Multiple complex diseases / / 17554300 rs921723 chr12 55221359 G T 3.40E-04 Multiple complex diseases / / 17554300 rs7296324 chr12 55261053 G A 6.54E-04 Multiple complex diseases / / 17554300 rs2887909 chr12 55272184 A C 6.40E-05 Parkinson's disease / / 17052657 rs9943768 chr12 55287990 A G 6.79E-05 Serum metabolites / / 19043545 rs11171174 chr12 55329575 C T 3.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs2252795 chr12 55343628 A G 1.41E-04 Birth weight / / 17255346 rs2252795 chr12 55343628 A G 8.32E-04 Alcohol dependence / / 21314694 rs997173 chr12 55355033 C T 9.69E-05 Prion diseases KIAA0748 missense 22210626 rs997173 chr12 55355033 C T 7.03E-04 Stroke KIAA0748 missense pha002887 rs998401 chr12 55355233 G A 4.14E-04 Lymphocyte counts KIAA0748 intron 22286170 rs10876682 chr12 55389667 G A 7.41E-04 Multiple complex diseases / / 17554300 rs11171216 chr12 55396339 G A 5.38E-04 Multiple complex diseases / / 17554300 rs1488047 chr12 55403194 C A 3.31E-05 Prion diseases / / 22210626 rs7297842 chr12 55404523 A G 3.96E-05 Prion diseases / / 22210626 rs10506337 chr12 55405829 T C 7.84E-04 Multiple complex diseases / / 17554300 rs4758996 chr12 55413004 G A 8.30E-07 Urinary metabolites / / 21572414 rs1386809 chr12 55424916 A C 7.00E-06 IgG glycosylation / / 23382691 rs6581016 chr12 55458430 C A 3.99E-07 White blood cell count / / 21738479 rs7966464 chr12 55498520 C A 9.56E-04 Depression (quantitative trait) / / 20800221 rs11171301 chr12 55518567 A G 7.86E-04 Depression (quantitative trait) / / 20800221 rs11171338 chr12 55553675 G A 7.86E-04 Depression (quantitative trait) / / 20800221 rs2169856 chr12 55572652 C G 2.92E-06 White blood cell count / / 21738479 rs11504009 chr12 55598126 C T 9.25E-04 Depression (quantitative trait) / / 20800221 rs1478732 chr12 55618069 G T 9.21E-04 Depression (quantitative trait) / / 20800221 rs1382489 chr12 55620711 G A 9.15E-04 Depression (quantitative trait) / / 20800221 rs999131 chr12 55621746 G A 9.10E-04 Depression (quantitative trait) / / 20800221 rs12311227 chr12 55633142 G A 7.14E-04 Depression (quantitative trait) / / 20800221 rs7968976 chr12 55636519 G T 9.38E-04 Depression (quantitative trait) / / 20800221 rs7301102 chr12 55637349 T G 7.12E-04 Depression (quantitative trait) / / 20800221 rs7315945 chr12 55637505 G A 6.35E-04 Depression (quantitative trait) / / 20800221 rs11612625 chr12 55638275 G A 6.26E-04 Depression (quantitative trait) / / 20800221 rs11608600 chr12 55638384 A G 6.23E-04 Depression (quantitative trait) / / 20800221 rs7137816 chr12 55638709 A G 6.20E-04 Depression (quantitative trait) / / 20800221 rs7309099 chr12 55638811 T A 6.13E-04 Depression (quantitative trait) / / 20800221 rs7138444 chr12 55639107 C T 6.09E-04 Depression (quantitative trait) / / 20800221 rs7138584 chr12 55639304 A G 6.05E-04 Depression (quantitative trait) / / 20800221 rs7301705 chr12 55641075 A G 5.91E-04 Depression (quantitative trait) OR6C74 missense 20800221 rs4522268 chr12 55641255 C T 5.81E-04 Depression (quantitative trait) OR6C74 STOP-GAIN 20800221 rs4388990 chr12 55641295 A G 4.46E-04 Depression (quantitative trait) OR6C74 missense 20800221 rs6581025 chr12 55641328 G A 4.37E-04 Depression (quantitative trait) OR6C74 missense 20800221 rs79165229 chr12 55641811 C T 0.00089 Breast cancer OR6C74 missense 23555315 rs7294935 chr12 55662006 C G 9.60E-04 Multiple complex diseases / / 17554300 rs10876736 chr12 55665948 G A 3.63E-04 Depression (quantitative trait) / / 20800221 rs12303191 chr12 55669474 C T 3.40E-04 Depression (quantitative trait) / / 20800221 rs12310560 chr12 55673008 C T 4.19E-04 Depression (quantitative trait) / / 20800221 rs12308170 chr12 55677023 G A 4.06E-04 Depression (quantitative trait) / / 20800221 rs10876740 chr12 55716364 A G 4.85E-05 Alcohol consumption / / 23953852 rs10783724 chr12 55746910 G A 9.65E-04 Depression (quantitative trait) / / 20800221 rs6581045 chr12 55809968 G T 3.49E-06 Diabetic nephropathy / / 21150874 rs7487750 chr12 55818508 A G 9.37E-04 Depression (quantitative trait) / / 20800221 rs11171535 chr12 55914635 C A 4.81E-06 Contrast sensitivity / / 24152035 rs12230513 chr12 55916780 A G 5.00E-06 Contrast sensitivity / / 24152035 rs77755732 chr12 55924293 C T 6.17E-06 Contrast sensitivity / / 24152035 rs183973202 chr12 55935021 C A 7.75E-06 Contrast sensitivity / / 24152035 rs4324500 chr12 55935029 G A 7.74E-06 Contrast sensitivity / / 24152035 rs76179834 chr12 55936746 A T 5.06E-06 Contrast sensitivity / / 24152035 rs76783572 chr12 55936752 G A 5.06E-06 Contrast sensitivity / / 24152035 rs76126658 chr12 55942458 C A 6.18E-06 Contrast sensitivity / / 24152035 rs11171556 chr12 55949852 G A 6.49E-06 Contrast sensitivity / / 24152035 rs11532447 chr12 55957772 A T 8.04E-06 Contrast sensitivity / / 24152035 rs146073724 chr12 55958414 T A 9.27E-06 Contrast sensitivity / / 24152035 rs11171580 chr12 55975171 T G 4.03E-04 Alzheimer's disease / / 24755620 rs11171619 chr12 56015919 G A 2.05E-04 Blood pressure / / 17255346 rs7978340 chr12 56032766 G A 3.00E-04 Iris characteristics / / 21835309 rs7133243 chr12 56034204 A G 1.00E-04 Prostate cancer / / 21743057 rs7302443 chr12 56047707 G T 9.62E-04 Alzheimer's disease / / 24755620 rs10876844 chr12 56050706 C A 0.0000478 5-fluorouracil induced diarrhoea in response to colorectal cancer treatment / / 22310351 rs57862109 chr12 56065070 A T 1.01E-06 Response to amphetamines / / 22952603 rs12313602 chr12 56069138 C T 6.54E-07 Response to amphetamines / / 22952603 rs4533076 chr12 56069231 C A 2.76E-04 Type 2 diabetes / / 17463246 rs55874825 chr12 56070668 C T 3.00E-07 Response to amphetamines / / 22952603 rs55927117 chr12 56070774 G A 8.06E-07 Response to amphetamines / / 22952603 rs7135552 chr12 56071331 T G 1.64E-06 Response to amphetamines / / 22952603 rs4759187 chr12 56075263 C T 3.70E-07 Response to amphetamines / / 22952603 rs3138144 chr12 56114769 G C 4.00E-12 Refractive error RDH5 intron 23396134 rs3138142 chr12 56115585 C T 1.80E-20 Myopia (Age of onset) RDH5 cds-synon 23468642 rs12304296 chr12 56148726 G A 9.56E-05 Smoking initiation SARNP intron 24665060 rs1463591 chr12 56170893 A G 1.71E-05 Bone mineral density SARNP intron 19181680 rs11171681 chr12 56193233 A C 2.94E-04 Smoking initiation SARNP intron 24665060 rs1463592 chr12 56257292 C A 8.96E-04 White matter integrity / / 22425255 rs772464 chr12 56308562 G T 4.96E-04 Multiple complex diseases WIBG intron 17554300 rs1052165 chr12 56351346 G A 1.03E-04 White matter integrity PMEL cds-synon 22425255 rs2069408 chr12 56364321 A G 6.53E-05 Multiple complex diseases CDK2 intron 17554300 rs2069408 chr12 56364321 A G 1.00E-10 Asthma CDK2 intron 21804548 rs2069408 chr12 56364321 A G 4.92E-04 White matter integrity CDK2 intron 22425255 rs2069408 chr12 56364321 A G 3.73E-17 Polycystic ovary syndrome CDK2 intron 22885925 rs2069415 chr12 56365979 G A 8.07E-05 Asthma CDK2 UTR-3 21804548 rs1045435 chr12 56366160 G C 9.67E-06 Pulmonary function CDK2 UTR-3 20010835 rs773107 chr12 56369506 A G 8.45E-04 White matter integrity RAB5B intron 22425255 rs773108 chr12 56369911 A G 4.25E-05 Alzheimer's disease (age of onset) RAB5B intron 22005931 rs773109 chr12 56374695 G A 2.56E-05 Asthma RAB5B intron 21804548 rs773109 chr12 56374695 G A 4.09E-05 Alzheimer's disease (age of onset) RAB5B intron 22005931 rs11171713 chr12 56374803 G A 4.90E-06 Pulmonary function RAB5B intron 20010835 rs11171713 chr12 56374803 G A 8.34E-04 Acute lung injury RAB5B intron 22295056 rs17118206 chr12 56379298 C T 9.85E-06 Pulmonary function RAB5B intron 20010835 rs1873914 chr12 56379427 G C 1.08E-09 Multiple complex diseases RAB5B intron 17554300 rs17118208 chr12 56381301 G A 9.63E-06 Pulmonary function RAB5B intron 20010835 rs705698 chr12 56384687 T C 7.47E-09 Multiple complex diseases RAB5B intron 17554300 rs705698 chr12 56384687 T C 2.85E-05 Alzheimer's disease (age of onset) RAB5B intron 22005931 rs705702 chr12 56390636 A G 5.82E-09 Multiple complex diseases / / 17554300 rs705702 chr12 56390636 A G 4.25E-05 Alzheimer's disease (age of onset) / / 22005931 rs705702 chr12 56390636 A G 9.00E-26 Polycystic ovary syndrome / / 22885925 rs773125 chr12 56394954 A G 1.00E-10 Rheumatoid arthritis SUOX intron 24390342 rs773125 chr12 56394954 A G 2.00E-08 Rheumatoid arthritis SUOX intron 24390342 rs773115 chr12 56398454 G C,T 1.07E-05 Pulmonary function SUOX cds-synon 20010835 rs10876864 chr12 56401085 G A 2.70E-06 Asthma / / 21804548 rs10876864 chr12 56401085 G A 2.19E-05 White matter integrity / / 22425255 rs10876864 chr12 56401085 G A 4.40E-04 Rheumatoid arthritis / / 22446963 rs10876864 chr12 56401085 G A 8.00E-12 Vitiligo / / 22951725 rs1701706 chr12 56402204 A G 1.12E-05 Pulmonary function / / 20010835 rs772923 chr12 56404566 A C 1.37E-05 Pulmonary function / / 20010835 rs12815387 chr12 56410889 T C 1.41E-05 Pulmonary function / / 20010835 rs1701704 chr12 56412487 T G 9.00E-10 Type 1 diabetes / / 18198356 rs1701704 chr12 56412487 T G 3.00E-08 Alopecia areata / / 20596022 rs1701704 chr12 56412487 T G 2.00E-13 Asthma / / 21804548 rs1701704 chr12 56412487 T G 5.00E-18 Type 1 diabetes autoantibodies / / 21829393 rs1701704 chr12 56412487 T G 4.63E-04 White matter integrity / / 22425255 rs1701704 chr12 56412487 T G 8.30E-08 Vitiligo / / 22561518 rs2456973 chr12 56416928 A C 3.00E-14 Vitiligo IKZF4 intron 22561518 rs2658479 chr12 56417403 T C 1.40E-05 Pulmonary function IKZF4 intron 20010835 rs705704 chr12 56435412 G A 4.31E-31 Type 1 diabetes RPS26 nearGene-5 21980299 rs12580100 chr12 56439209 A G 8.10E-04 Parkinson's disease / / 17052657 rs12580100 chr12 56439209 A G 9.00E-04 Systemic lupus erythematosus / / 18204446 rs12580100 chr12 56439209 A G 1.00E-06 Psoriasis / / 20953189 rs12580100 chr12 56439209 A G 6.18E-07 Crohn's disease and psoriasis / / 22482804 rs12580100 chr12 56439209 A G 2.83E-05 Hemoglobin / / pha003098 rs12580100 chr12 56439209 A G 7.79E-05 Erythrocyte counts / / pha003099 rs2456972 chr12 56442728 C G 1.73E-05 Pulmonary function / / 20010835 rs12099979 chr12 56454989 T C 2.06E-05 Pulmonary function / / 20010835 rs12831884 chr12 56466128 T G 2.23E-05 Pulmonary function / / 20010835 rs1689511 chr12 56467385 G A 2.45E-05 Pulmonary function / / 20010835 rs7312770 chr12 56467587 C T 1.80E-05 Urinary metabolites / / 21572414 rs11171739 chr12 56470625 C T 1.00E-11 Type 1 diabetes / / 17554300 rs11171739 chr12 56470625 C T 2.09E-18 Lymphocyte counts / / 22286170 rs34379766 chr12 56474143 C A 5.00E-07 Obesity-related traits ERBB3 missense 23251661 rs7971751 chr12 56478658 A C 3.29E-06 Asthma ERBB3 intron 21804548 rs877636 chr12 56480583 G A 3.90E-20 Polycystic ovary syndrome ERBB3 intron 22885925 rs2292239 chr12 56482180 T G 2.00E-20 Type 1 diabetes ERBB3 intron 17554260 rs2292239 chr12 56482180 T G 5.78E-13 Multiple complex diseases ERBB3 intron 17554300 rs2292239 chr12 56482180 T G 3.00E-16 Type 1 diabetes ERBB3 intron 18978792 rs2292239 chr12 56482180 T G 2.00E-25 Type 1 diabetes ERBB3 intron 19430480 rs2292239 chr12 56482180 T G 3.00E-27 Type 1 diabetes autoantibodies ERBB3 intron 21829393 rs2292239 chr12 56482180 T G 2.00E-20 Multiple sclerosis ERBB3 intron 22190364 rs2292239 chr12 56482180 T G 2.72E-22 Polycystic ovary syndrome ERBB3 intron 22885925 rs10783779 chr12 56491880 T G 0.0000158 Tuberculosis with late age of onset ERBB3 intron 22551897 rs1689512 chr12 56510637 A G 5.56E-04 Type 2 diabetes RPL41 intron 17463246 rs11171747 chr12 56518408 T G 6.00E-08 Systemic sclerosis / / 21779181 rs2271192 chr12 56531154 T C 8.64E-04 Type 2 diabetes ESYT1 cds-synon 17463246 rs1274298 chr12 56555022 A C 5.72E-04 Type 2 diabetes MYL6 intron 17463246 rs10747763 chr12 56603066 C G 9.56E-04 Acute lung injury RNF41 intron 22295056 rs808919 chr12 56647911 G C 7.03E-05 Multiple complex diseases ANKRD52 cds-synon 17554300 rs744051 chr12 56667298 T C 3.24E-06 Corneal structure CS intron 22003120 rs17118439 chr12 56667604 T C 6.98E-04 Multiple complex diseases CS intron 17554300 rs872103 chr12 56668174 A G 8.01E-04 Type 2 diabetes CS intron 17463246 rs3816804 chr12 56680745 C T 8.38E-04 Prostate cancer mortality CS intron 20978177 rs3816804 chr12 56680745 C T 3.00E-09 Height CS intron 23456168 rs10783780 chr12 56704152 A G 0.00000003 Joint damage severity in rheumatoid arthritis / / 23696630 rs3809129 chr12 56711371 C T 0.00000001 Joint damage severity in rheumatoid arthritis PAN2 UTR-3 23696630 rs2291361 chr12 56717805 G A 1.07E-05 Corneal structure PAN2 intron 22003120 rs2066808 chr12 56737973 A G 1.00E-09 Psoriasis STAT2 intron 19169254 rs2066808 chr12 56737973 A G 1.00E-09 Psoriasis STAT2 intron 20953187 rs2066808 chr12 56737973 A G 2.00E-07 Psoriasis STAT2 intron 20953190 rs2066808 chr12 56737973 A G 1.00E-09 Multiple sclerosis STAT2 intron 22190364 rs2066807 chr12 56740682 C G 1.00E-13 Height STAT2 missense 20881960 rs12422499 chr12 56741698 G C 0.00000003 Joint damage severity in rheumatoid arthritis STAT2 intron 23696630 rs2066819 chr12 56750204 C T 5.40E-17 Psoriasis STAT2 intron 23143594 rs11575221 chr12 56754137 T G 5.71E-07 Age-related macular degeneration / / pha000001 rs7979812 chr12 56781444 C A 6.67E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2047229 chr12 56783240 C T 4.22E-06 Axial length / / 24144296 rs11171824 chr12 56785655 G A 4.10E-06 Axial length / / 24144296 rs4759205 chr12 56804310 C T 7.03E-11 Metabolite levels / / 22286219 rs2101646 chr12 56804909 G C,T 6.58E-11 Metabolite levels / / 22286219 rs2131096 chr12 56807188 T C 5.29E-11 Metabolite levels / / 22286219 rs2643628 chr12 56810008 G C 4.82E-11 Metabolite levels / / 22286219 rs7134031 chr12 56812271 A T 4.73E-11 Metabolite levels TIMELESS intron 22286219 rs2638286 chr12 56813539 T C 4.67E-11 Metabolite levels TIMELESS intron 22286219 rs812279 chr12 56814570 T G 2.65E-06 Axial length TIMELESS intron 24144296 rs2291739 chr12 56814653 G A 3.12E-06 Axial length TIMELESS missense 24144296 rs2291738 chr12 56815281 T C 4.00E-07 Axial length TIMELESS intron 24144296 rs774047 chr12 56815922 C T 1.14E-06 Axial length TIMELESS missense 24144296 rs774048 chr12 56816814 C A 1.61E-11 Metabolite levels TIMELESS intron 22286219 rs774049 chr12 56816978 C T 9.72E-12 Metabolite levels TIMELESS intron 22286219 rs774050 chr12 56818922 C T 1.62E-11 Metabolite levels TIMELESS cds-synon 22286219 rs774027 chr12 56822378 T A 1.07E-06 Axial length TIMELESS missense 24144296 rs774029 chr12 56823317 A G 5.08E-11 Metabolite levels TIMELESS intron 22286219 rs703829 chr12 56823622 C T 1.26E-06 Axial length TIMELESS intron 24144296 rs774033 chr12 56825311 C T 1.11E-06 Axial length TIMELESS cds-synon 24144296 rs774034 chr12 56825737 T C 1.05E-06 Axial length TIMELESS intron 24144296 rs774035 chr12 56825749 A G 1.05E-06 Axial length TIMELESS intron 24144296 rs774036 chr12 56825779 G A 1.05E-06 Axial length TIMELESS intron 24144296 rs774039 chr12 56825981 A G 1.17E-06 Axial length TIMELESS intron 24144296 rs2279665 chr12 56827694 C G 9.57E-07 Axial length TIMELESS cds-synon 24144296 rs11171846 chr12 56828056 C T 7.80E-05 Coronary heart disease TIMELESS intron 21966275 rs11171846 chr12 56828056 C T 6.00E-10 Immune reponse to smallpox (secreted IFN-alpha) TIMELESS intron 22610502 rs6581094 chr12 56828235 A G 5.13E-06 Axial length TIMELESS intron 24144296 rs7312888 chr12 56828548 G C 5.63E-07 Axial length TIMELESS intron 24144296 rs200343594 chr12 56828620 GC G 9.57E-07 Axial length TIMELESS intron 24144296 rs7977477 chr12 56828620 G T 9.57E-07 Axial length TIMELESS intron 24144296 rs11833581 chr12 56828818 G T 9.69E-07 Axial length TIMELESS intron 24144296 rs7302060 chr12 56829092 T C 1.04E-06 Axial length TIMELESS intron 24144296 rs10876889 chr12 56829151 A G 1.01E-06 Axial length TIMELESS intron 24144296 rs71446553 chr12 56829151 AA AAA,AG 1.01E-06 Axial length TIMELESS intron 24144296 rs11171850 chr12 56831105 T C 8.90E-07 Axial length TIMELESS intron 24144296 rs12299614 chr12 56831182 A G 8.90E-07 Axial length TIMELESS intron 24144296 rs7964902 chr12 56832409 G A 4.90E-11 Metabolite levels TIMELESS intron 22286219 rs11171852 chr12 56833224 C T 7.80E-07 Axial length TIMELESS intron 24144296 rs10876890 chr12 56833751 A T 7.66E-07 Axial length TIMELESS intron 24144296 rs11610921 chr12 56833873 A G 7.27E-07 Axial length TIMELESS intron 24144296 rs774042 chr12 56834983 T A 1.17E-10 Metabolite levels TIMELESS intron 22286219 rs774044 chr12 56837979 C T 5.62E-11 Metabolite levels TIMELESS intron 22286219 rs774045 chr12 56838745 G A 6.96E-11 Metabolite levels TIMELESS intron 22286219 rs11171856 chr12 56841819 C T 8.03E-07 Axial length TIMELESS intron 24144296 rs2371455 chr12 56843893 G T 2.41E-06 Axial length MIP UTR-3 24144296 rs3809125 chr12 56844349 C T 2.46E-06 Axial length MIP UTR-3 24144296 rs799187 chr12 56845843 T A 2.99E-11 Metabolite levels MIP intron 22286219 rs1082214 chr12 56846490 C T 1.00E-04 Cognitive impairment induced by topiramate MIP intron 22091778 rs1082214 chr12 56846490 C T 3.25E-11 Metabolite levels MIP intron 22286219 rs7313455 chr12 56853231 C A 1.84E-04 Endometrial cancer / / 24096698 rs7313455 chr12 56853231 C A 5.09E-04 Endometrial cancer / / 24096698 rs7313455 chr12 56853231 C A 5.01E-06 Axial length / / 24144296 rs12313841 chr12 56856618 C T 8.97E-11 Metabolite levels / / 22286219 rs2638319 chr12 56857057 C T 1.56E-11 Metabolite levels / / 22286219 rs2638318 chr12 56857422 C T 1.25E-12 Metabolite levels / / 22286219 rs34287864 chr12 56858317 G A 6.87E-12 Metabolite levels / / 22286219 rs7302925 chr12 56861458 A G 3.85E-33 Metabolite levels / / 22286219 rs7302925 chr12 56861458 A G 2.90E-05 Systemic lupus erythematosus / / 22291604 rs7302925 chr12 56861458 A G 0.00000342 Inter-adventitial common carotid artery diameter / / 23246012 rs2657880 chr12 56863770 G C 2.26E-11 Lymphocyte counts SPRYD4 UTR-3 22286170 rs2657880 chr12 56863770 G C 2.28E-31 Metabolite levels SPRYD4 UTR-3 22286219 rs2657880 chr12 56863770 G C 7.00E-30 Metabolite levels (atherosclerosis) SPRYD4 UTR-3 22916037 rs1043011 chr12 56865040 G T 2.12E-04 Type 2 diabetes GLS2 UTR-3 17463246 rs1043011 chr12 56865040 G T 4.98E-33 Metabolite levels GLS2 UTR-3 22286219 rs2638315 chr12 56865056 G C 2.12E-04 Type 2 diabetes GLS2 UTR-3 17463246 rs2638315 chr12 56865056 G C 2.00E-35 Metabolite levels GLS2 UTR-3 22286219 rs2657879 chr12 56865338 A G 2.06E-04 Type 2 diabetes GLS2 missense 17463246 rs2657879 chr12 56865338 A G 3.00E-17 Metabolic traits GLS2 missense 21886157 rs2657879 chr12 56865338 A G 4.61E-33 Metabolite levels GLS2 missense 22286219 rs2657879 chr12 56865338 A G 0.000000039 Fasting blood glucose GLS2 missense 22885924 rs2657879 chr12 56865338 A G 6.00E-18 Blood metabolite levels GLS2 missense 24816252 rs2657879 chr12 56865338 A G 6.00E-19 Blood metabolite levels GLS2 missense 24816252 rs2638314 chr12 56866334 T A 5.56E-36 Metabolite levels GLS2 intron 22286219 rs11171862 chr12 56871314 G A 4.99E-11 Metabolite levels GLS2 intron 22286219 rs12304519 chr12 56874522 C A 9.57E-12 Metabolite levels GLS2 intron 22286219 rs7314242 chr12 56876372 C A 8.12E-13 Metabolite levels GLS2 intron 22286219 rs6581096 chr12 56878120 G A 2.73E-04 Amyotrophic Lateral Sclerosis GLS2 intron 17362836 rs6581096 chr12 56878120 G A 3.75E-11 Metabolite levels GLS2 intron 22286219 rs11171863 chr12 56879548 C T 4.03E-12 Metabolite levels GLS2 intron 22286219 rs2638335 chr12 56880672 A G 9.49E-13 Metabolite levels GLS2 intron 22286219 rs2638334 chr12 56882528 A C 6.91E-13 Metabolite levels / / 22286219 rs3809122 chr12 56882710 A T 4.09E-14 Metabolite levels / / 22286219 rs12316930 chr12 56885816 C G 8.72E-13 Metabolite levels / / 22286219 rs11171865 chr12 56885861 C T 4.37E-13 Metabolite levels / / 22286219 rs2638285 chr12 56886361 A G 9.21E-13 Metabolite levels / / 22286219 rs2657910 chr12 56891649 G A 1.20E-20 Metabolite levels / / 22286219 rs2657909 chr12 56895503 T C 2.65E-14 Metabolite levels / / 22286219 rs11171880 chr12 56903379 C A 8.78E-13 Metabolite levels / / 22286219 rs2657908 chr12 56907446 G A 6.02E-04 Aortic root size / / 21223598 rs2694917 chr12 56912864 T C 1.01E-29 Metabolite levels / / 22286219 rs2694917 chr12 56912864 T C 2.00E-29 Blood metabolite ratios / / 24816252 rs2694919 chr12 56917390 C T 1.28E-31 Metabolite levels RBMS2 intron 22286219 rs774211 chr12 56920939 T C 5.78E-32 Metabolite levels RBMS2 intron 22286219 rs813497 chr12 56924116 G A 6.26E-32 Metabolite levels RBMS2 intron 22286219 rs799261 chr12 56924389 C G 6.35E-30 Metabolite levels RBMS2 intron 22286219 rs2638301 chr12 56928814 A G 1.97E-30 Metabolite levels RBMS2 intron 22286219 rs2657896 chr12 56929694 C T 6.21E-32 Metabolite levels RBMS2 intron 22286219 rs2933234 chr12 56930349 T C 5.66E-16 Metabolite levels RBMS2 intron 22286219 rs36073309 chr12 56930992 G A 6.01E-17 Metabolite levels RBMS2 intron 22286219 rs2657897 chr12 56931228 A G 2.10E-12 Metabolite levels RBMS2 intron 22286219 rs2657898 chr12 56931234 T C 3.00E-17 Metabolite levels RBMS2 intron 22286219 rs2657899 chr12 56931403 G A 4.91E-17 Metabolite levels RBMS2 intron 22286219 rs2657900 chr12 56931428 T C 5.64E-17 Metabolite levels RBMS2 intron 22286219 rs10735864 chr12 56932303 A G 3.23E-18 Metabolite levels RBMS2 intron 22286219 rs2939312 chr12 56932554 G A 9.92E-18 Metabolite levels RBMS2 intron 22286219 rs7300877 chr12 56933233 C A 1.52E-16 Metabolite levels RBMS2 intron 22286219 rs7301093 chr12 56933244 G T 4.99E-12 Metabolite levels RBMS2 intron 22286219 rs2657901 chr12 56933416 A G 3.86E-17 Metabolite levels RBMS2 intron 22286219 rs2657902 chr12 56933651 G A 1.37E-17 Metabolite levels RBMS2 intron 22286219 rs2657903 chr12 56933722 G A 1.26E-17 Metabolite levels RBMS2 intron 22286219 rs2694909 chr12 56934928 T C 1.35E-17 Metabolite levels RBMS2 intron 22286219 rs2657905 chr12 56935402 T A 1.99E-17 Metabolite levels RBMS2 intron 22286219 rs7309685 chr12 56935413 A G 3.77E-17 Metabolite levels RBMS2 intron 22286219 rs7310284 chr12 56935652 G A 4.78E-17 Metabolite levels RBMS2 intron 22286219 rs2657888 chr12 56938383 T G 1.91E-04 Amyotrophic Lateral Sclerosis RBMS2 intron 17362836 rs2657888 chr12 56938383 T G 2.09E-04 Lymphocyte counts RBMS2 intron 22286170 rs2657888 chr12 56938383 T G 1.82E-17 Metabolite levels RBMS2 intron 22286219 rs2657888 chr12 56938383 T G 8.00E-06 Adiponectin levels RBMS2 intron 22479202 rs2657890 chr12 56938577 C T 1.94E-17 Metabolite levels RBMS2 intron 22286219 rs28697089 chr12 56938703 A G 1.94E-17 Metabolite levels RBMS2 intron 22286219 rs7312441 chr12 56941146 C A 2.61E-16 Metabolite levels RBMS2 intron 22286219 rs17540509 chr12 56943840 T C 4.41E-17 Metabolite levels RBMS2 intron 22286219 rs116287412 chr12 56946015 T C 3.92E-13 Metabolite levels RBMS2 intron 22286219 rs11171894 chr12 56951219 G A 1.92E-12 Metabolite levels RBMS2 intron 22286219 rs3759091 chr12 56956213 T C 8.97E-29 Metabolite levels RBMS2 cds-synon 22286219 rs7304944 chr12 56958447 T C 2.27E-28 Metabolite levels RBMS2 intron 22286219 rs12232026 chr12 56960766 T A 1.11E-21 Metabolite levels RBMS2 intron 22286219 rs7305370 chr12 56961932 C T 1.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBMS2 intron 20877124 rs7305370 chr12 56961932 C T 1.43E-19 Metabolite levels RBMS2 intron 22286219 rs10783793 chr12 56964730 C A 5.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBMS2 intron 20877124 rs10783793 chr12 56964730 C A 1.92E-11 Metabolite levels RBMS2 intron 22286219 rs7977500 chr12 56969281 C G 3.06E-13 Metabolite levels RBMS2 intron 22286219 rs7299189 chr12 56972856 C A 3.30E-12 Metabolite levels RBMS2 intron 22286219 rs2950391 chr12 56973143 G A 4.58E-14 Metabolite levels RBMS2 intron 22286219 rs7307755 chr12 56974785 A G 6.65E-12 Metabolite levels RBMS2 intron 22286219 rs4759253 chr12 56978171 G A 9.55E-11 Metabolite levels RBMS2 intron 22286219 rs201075316 chr12 56998559 C T 0.0000071 Breast cancer BAZ2A missense 23555315 rs941207 chr12 57023284 C G 2.00E-10 Platelet counts BAZ2A intron 22139419 rs941207 chr12 57023284 C G 8.00E-04 Platelet counts BAZ2A intron 24026423 rs2950390 chr12 57055291 C T 9.90E-06 Urinary metabolites LOC100506732 intron 21572414 rs2950390 chr12 57055291 C T 7.00E-14 Mean platelet volume LOC100506732 intron 22139419 rs2958155 chr12 57064545 T G 9.80E-07 Urinary metabolites PTGES3 intron 21572414 rs2958154 chr12 57065713 C T 2.00E-06 Age-related macular degeneration PTGES3 intron 20385819 rs2958154 chr12 57065713 C T 3.00E-06 Urinary metabolites PTGES3 intron 21572414 rs2926743 chr12 57114100 A G 2.83E-04 Heart rate /CA missense 23583979 rs2958127 chr12 57114307 A T 2.90E-06 Urinary metabolites /CA missense 21572414 rs1466382 chr12 57116834 G A 4.50E-07 Urinary metabolites /CA intron 21572414 rs1131514 chr12 57133140 T G 4.60E-06 Urinary metabolites PRIM1 cds-synon 21572414 rs1026565 chr12 57137828 T A 9.20E-07 Urinary metabolites PRIM1 intron 21572414 rs2277339 chr12 57146069 T G 2.00E-19 Menopause (age at onset) PRIM1 missense 22267201 rs898611 chr12 57163316 C T 5.40E-06 Urinary metabolites HSD17B6 intron 21572414 rs12229899 chr12 57172341 A G 0.0000691 Nonsyndromic striae distensae (stretch marks) HSD17B6 intron 23633020 rs6581105 chr12 57185968 T C 0.0000995 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11171979 chr12 57195983 C G 2.40E-05 Urinary metabolites / / 21572414 rs12367822 chr12 57204160 G T 1.00E-06 Platelet aggregation / / 20526338 rs1903370 chr12 57206684 C T 1.60E-05 Urinary metabolites / / 21572414 rs7954692 chr12 57259162 C T 1.70E-04 Type 2 diabetes / / 17463246 rs10783807 chr12 57266313 C T 5.13E-04 Type 2 diabetes / / 17463246 rs10876956 chr12 57318731 A C 4.27E-04 Type 2 diabetes SDR9C7 intron 17463246 rs11172067 chr12 57320618 T C 9.32E-06 Duodenal ulcer SDR9C7 intron 22387998 rs7296999 chr12 57321212 C T 1.45E-05 Duodenal ulcer SDR9C7 intron 22387998 rs7296999 chr12 57321212 C T 1.63E-07 Glaucoma (primary open-angle) SDR9C7 intron 22605921 rs11172068 chr12 57322853 G A 1.46E-05 Duodenal ulcer SDR9C7 intron 22387998 rs747275 chr12 57328282 G A 6.19E-05 IgE levels / / 22075330 rs10506348 chr12 57331370 A G 9.40E-06 IgE levels / / 22075330 rs725957 chr12 57331741 G A 8.19E-05 Colorectal cancer / / 24836286 rs725956 chr12 57331936 A G 8.11E-06 IgE levels / / 22075330 rs901069 chr12 57346379 G A 1.00E-04 Cognitive impairment induced by topiramate RDH16 intron 22091778 rs3782331 chr12 57347290 C T 3.23E-05 Kawasaki disease RDH16 intron 22081228 rs4759042 chr12 57377347 C T 3.00E-06 Migraine / / 23793025 rs4759042 chr12 57377347 C T 5.69E-04 Migraine without aura / / 23793025 rs3741578 chr12 57394635 G C 8.30E-07 IgE levels ZBTB39 UTR-3 22075330 rs11172086 chr12 57449206 C T 5.22E-07 IgE levels / / 22075330 rs1059513 chr12 57489709 T C 2.00E-12 IgE levels STAT6 UTR-3 22075330 rs1059513 chr12 57489709 T C 1.00E-14 Allergic sensitization STAT6 UTR-3 23817571 rs1059513 chr12 57489709 T C 7.00E-06 Sensory disturbances after bilateral sagittal split ramus osteotomy STAT6 UTR-3 23834954 rs703817 chr12 57489828 C T 4.74E-05 Brain structure STAT6 UTR-3 22504417 rs841718 chr12 57492996 G A 3.99E-05 Brain structure STAT6 intron 22504417 rs3024971 chr12 57493727 T G 2.88E-08 IgE levels STAT6 intron 22075330 rs324011 chr12 57502182 C T 5.82E-06 IgE levels STAT6 intron 22075330 rs167769 chr12 57503775 C T 2.00E-06 Eosinophilic esophagitis (pediatric) STAT6 intron 20208534 rs167769 chr12 57503775 C T 5.18E-06 IgE levels STAT6 intron 22075330 rs17119482 chr12 57509766 C A,T 3.55E-04 Multiple complex diseases / / 17554300 rs12368672 chr12 57512470 C G 2.57E-04 Type 2 diabetes / / 17463246 rs12368672 chr12 57512470 C G 3.21E-06 IgE levels / / 22075330 rs11172106 chr12 57512875 C G 1.65E-06 IgE levels / / 22075330 rs12309413 chr12 57513879 C G 5.31E-07 IgE levels / / 22075330 rs12298170 chr12 57515363 A G 5.30E-07 IgE levels / / 22075330 rs34660894 chr12 57522894 G A 1.84E-14 HDL cholesterol LRP1 intron 23063622 rs34660894 chr12 57522894 G A 3.78E-23 Cholesterol,total LRP1 intron 23063622 rs34660894 chr12 57522894 G A 9.12E-13 LDL cholesterol LRP1 intron 23063622 rs4759275 chr12 57525756 G A 6.53E-07 IgE levels LRP1 intron 22075330 rs11172113 chr12 57527283 T C 4.00E-09 Migraine LRP1 intron 21666692 rs11172113 chr12 57527283 T C 1.00E-08 Pulmonary function LRP1 intron 21946350 rs11172113 chr12 57527283 T C 3.53E-05 IgE levels LRP1 intron 22075330 rs11172113 chr12 57527283 T C 3.00E-08 Migraine LRP1 intron 22683712 rs11172113 chr12 57527283 T C 8.00E-06 Pulmonary function (interaction) LRP1 intron 23284291 rs11172113 chr12 57527283 T C 1.00E-06 Migraine - clinic-based LRP1 intron 23793025 rs11172113 chr12 57527283 T C 1.00E-10 Migraine without aura LRP1 intron 23793025 rs11172113 chr12 57527283 T C 1.11E-05 Migraine with aura LRP1 intron 23793025 rs11172113 chr12 57527283 T C 1.15E-06 Migraine - clinic-based LRP1 intron 23793025 rs11172113 chr12 57527283 T C 3.94E-19 Migraine LRP1 intron 23793025 rs11172113 chr12 57527283 T C 4.00E-19 Migraine LRP1 intron 23793025 rs11172113 chr12 57527283 T C 9.96E-11 Migraine without aura LRP1 intron 23793025 rs4759044 chr12 57530670 T C 1.67E-05 Brain structure LRP1 intron 22504417 rs4759044 chr12 57530670 T C 5.40E-05 Abdominal aortic aneurysm LRP1 intron 24046328 rs4367982 chr12 57531632 A G 1.10E-05 Brain structure LRP1 intron 22504417 rs1385526 chr12 57532749 G C 2.35E-05 IgE levels LRP1 intron 22075330 rs4759277 chr12 57533690 C A 2.38E-05 IgE levels LRP1 intron 22075330 rs4759277 chr12 57533690 C A 4.27E-05 Brain structure LRP1 intron 22504417 rs1466535 chr12 57534470 G A 5.00E-10 Abdominal aortic aneurysm LRP1 intron 22055160 rs1466535 chr12 57534470 G A 2.41E-05 IgE levels LRP1 intron 22075330 rs1466535 chr12 57534470 G A 1.45E-05 Brain structure LRP1 intron 22504417 rs1466535 chr12 57534470 G A 2.12E-05 Abdominal aortic aneurysm LRP1 intron 24046328 rs2306692 chr12 57541265 C T 7.66E-05 Endometrial cancer LRP1 intron 24096698 rs2306692 chr12 57541265 C T 8.95E-05 Endometrial cancer LRP1 intron 24096698 rs10876966 chr12 57543572 C T 4.30E-06 Urinary metabolites LRP1 intron 21572414 rs34574998 chr12 57548364 T C 1.22E-09 Triglycerides LRP1 cds-synon 23063622 rs35253246 chr12 57548860 T G 1.08E-11 Triglycerides LRP1 intron 23063622 rs34614287 chr12 57549135 C G 2.86E-29 Triglycerides LRP1 intron 23063622 rs34614287 chr12 57549135 C G 4.48E-27 LDL cholesterol LRP1 intron 23063622 rs34614287 chr12 57549135 C G 9.71E-24 Cholesterol,total LRP1 intron 23063622 rs35599705 chr12 57568827 G A 5.56E-11 Triglycerides LRP1 intron 23063622 rs35161844 chr12 57577840 C T 5.47E-12 Triglycerides LRP1 intron 23063622 rs7488264 chr12 57588049 A G 0.000000102 Cholesterol,total LRP1 intron 23063622 rs7488264 chr12 57588049 A G 0.00000179 LDL cholesterol LRP1 intron 23063622 rs34576916 chr12 57603071 C G 1.77E-08 Cholesterol,total LRP1 intron 23063622 rs34630693 chr12 57606255 C A,T 2.22E-22 Cholesterol,total LRP1 missense 23063622 rs34630693 chr12 57606255 C A,T 4.16E-36 Triglycerides LRP1 missense 23063622 rs34630693 chr12 57606255 C A,T 7.15E-14 LDL cholesterol LRP1 missense 23063622 rs7485577 chr12 57616061 G A 2.55E-08 Urate levels NXPH4 intron 23263486 rs7301155 chr12 57622821 G A 9.45E-09 Urate levels SHMT2 nearGene-5 23263486 rs3204635 chr12 57637593 G A 0.00000763 HDL cholesterol STAC3 UTR-3 23063622 rs11172134 chr12 57645789 T A 4.40E-10 Urate levels / / 20884846 rs11172134 chr12 57645789 T A 1.81E-17 Urate levels / / 23263486 rs11172147 chr12 57696677 G A 4.10E-11 Urate levels R3HDM2 intron 20884846 rs11172147 chr12 57696677 G A 8.28E-21 Urate levels R3HDM2 intron 23263486 rs4760355 chr12 57725197 G A 4.70E-11 Urate levels / / 20884846 rs4760355 chr12 57725197 G A 2.37E-19 Urate levels / / 23263486 rs11830804 chr12 57734892 C A 5.17E-04 Menopause (age at onset) / / 22267201 rs11609805 chr12 57735045 G A 4.60E-11 Urate levels / / 20884846 rs11609805 chr12 57735045 G A 2.20E-19 Urate levels / / 23263486 rs4760254 chr12 57766392 G C 3.10E-11 Urate levels / / 20884846 rs4760254 chr12 57766392 G C 5.58E-21 Urate levels / / 23263486 rs4760278 chr12 57771153 C A 3.00E-11 Urate levels / / 20884846 rs4760278 chr12 57771153 C A 2.52E-20 Urate levels / / 23263486 rs11613352 chr12 57792580 C T 2.00E-08 HDL cholesterol / / 20686565 rs11613352 chr12 57792580 C T 4.00E-10 Triglycerides / / 20686565 rs11613352 chr12 57792580 C T 3.90E-11 Urate levels / / 20884846 rs11613352 chr12 57792580 C T 5.28E-18 Urate levels / / 23263486 rs11613352 chr12 57792580 C T 2.00E-13 HDL cholesterol / / 24097068 rs11613352 chr12 57792580 C T 9.00E-14 Triglycerides / / 24097068 rs1106766 chr12 57809456 C T 2.00E-11 Urate levels / / 20884846 rs1106766 chr12 57809456 C T 8.40E-04 Urate (in serum),gout / / 21983786 rs1106766 chr12 57809456 C T 4.60E-16 Urate levels / / 23263486 rs538548 chr12 57810104 T C 8.26E-04 Multiple complex diseases / / 17554300 rs11614506 chr12 57815675 T C 3.80E-11 Urate levels / / 20884846 rs11614506 chr12 57815675 T C 1.92E-19 Urate levels / / 23263486 rs7964492 chr12 57823585 A C 4.20E-11 Urate levels / / 20884846 rs7964492 chr12 57823585 A C 3.15E-20 Urate levels / / 23263486 rs776037 chr12 57843014 C T 1.38E-05 Age-related macular degeneration INHBC intron pha000001 rs3741414 chr12 57844049 C T 3.40E-10 Urate levels INHBC UTR-3 20884846 rs3741414 chr12 57844049 C T 0.00000022 Glomerular filtration rate INHBC UTR-3 22962313 rs3741414 chr12 57844049 C T 2.00E-25 Urate levels INHBC UTR-3 23263486 rs3809114 chr12 57848639 G A 3.36E-12 Urate levels / / 23263486 rs2242578 chr12 57853153 G C 1.40E-05 Personality dimensions GLI1 nearGene-5 22628180 rs1148556 chr12 57917525 C T 2.80E-04 Alcohol dependence MBD6 intron 20201924 rs1148555 chr12 57918634 A G 0.0000657 Primary sclerosing cholangitis MBD6 intron 23603763 rs775238 chr12 57938081 C T 5.90E-04 Alcohol dependence DCTN2 intron 20201924 rs703841 chr12 57942305 T G 1.80E-04 Alcohol dependence KIF5A nearGene-5 20201924 rs1148552 chr12 57942972 C T 4.90E-04 Alcohol dependence KIF5A nearGene-5 20201924 rs1148551 chr12 57945860 G A 7.40E-04 Alcohol dependence KIF5A intron 20201924 rs6581146 chr12 57946477 C T 3.60E-04 Alcohol dependence KIF5A intron 20201924 rs2600003 chr12 57953244 A C 1.80E-04 Alcohol dependence KIF5A intron 20201924 rs1678542 chr12 57968715 C G 3.51E-05 Multiple complex diseases KIF5A intron 17554300 rs1678542 chr12 57968715 C G 9.00E-08 Rheumatoid arthritis KIF5A intron 18794853 rs1678542 chr12 57968715 C G 1.70E-08 Celiac disease and Rheumatoid arthritis KIF5A intron 21383967 rs1678542 chr12 57968715 C G 0.0002 Rheumatoid arthritis KIF5A intron 23143596 rs1678542 chr12 57968715 C G 1.00E-07 Rheumatoid arthritis KIF5A intron 24449572 rs775251 chr12 57978740 C T 3.44E-06 Multiple complex diseases KIF5A nearGene-3 17554300 rs775251 chr12 57978740 C T 3.48E-05 Bipolar disorder and schizophrenia KIF5A nearGene-3 20889312 rs10747780 chr12 57980541 T C 6.41E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1545783 chr12 57982254 T G 5.73E-04 Body mass index / / 21701565 rs2277324 chr12 58013175 G A 2.65E-08 Triglycerides / / 19074352 rs2277324 chr12 58013175 G A 2.65E-08 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs2277324 chr12 58013175 G A 2.65E-09 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs113207856 chr12 58017860 G A 0.00027 Prostate cancer SLC26A10 STOP-GAIN 23555315 rs10083154 chr12 58020933 G A 9.32E-05 Myopia (severe) B4GALNT1 intron 23933737 rs7314281 chr12 58034040 G T 9.88E-05 HIV-1 viral setpoint / / 22174851 rs1689595 chr12 58056763 C T 3.55E-05 Multiple complex diseases / / 17554300 rs10876993 chr12 58062667 C T 4.00E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs10876994 chr12 58064737 A C 2.70E-10 Multiple sclerosis / / 19525955 rs10683701 chr12 58092088 C CACTT 0.000023 Rheumatoid arthritis OS9 intron 23143596 rs397806999 chr12 58092088 C CACTT 0.000023 Rheumatoid arthritis OS9 intron 23143596 rs1633360 chr12 58108052 C T 1.00E-07 Rheumatoid arthritis OS9 intron 24390342 rs1633360 chr12 58108052 C T 7.00E-08 Rheumatoid arthritis OS9 intron 24390342 rs12368653 chr12 58133256 G A 1.00E-07 Multiple sclerosis AGAP2 intron 19525955 rs12368653 chr12 58133256 G A 2.00E-09 Multiple sclerosis AGAP2 intron 21833088 rs2069501 chr12 58144781 T C 1.48E-05 HIV-1 viral setpoint CDK4 cds-synon 22174851 rs703842 chr12 58162739 A G 3.44E-04 Multiple complex diseases METTL1 UTR-3 17554300 rs703842 chr12 58162739 A G 5.00E-11 Multiple sclerosis METTL1 UTR-3 19525955 rs703842 chr12 58162739 A G 6.00E-06 Multiple sclerosis METTL1 UTR-3 21833088 rs703842 chr12 58162739 A G 1.72E-05 Multiple sclerosis METTL1 UTR-3 22190364 rs703842 chr12 58162739 A G 0.00002701 Sarcoidosis METTL1 UTR-3 22952805 rs10877013 chr12 58165085 C T 0.000006368 Sarcoidosis METTL1 intron 22952805 rs10877014 chr12 58167661 A G 0.000004239 Sarcoidosis METTL21B intron 22952805 rs10877015 chr12 58167788 A G 4.60E-04 Alcohol dependence METTL21B intron 24277619 rs10877017 chr12 58169361 T C 0.000003163 Sarcoidosis METTL21B intron 22952805 rs11172333 chr12 58170335 A G 8.42E-04 Multiple complex diseases METTL21B intron 17554300 rs11172333 chr12 58170335 A G 1.88E-07 Lymphocyte counts METTL21B intron 22286170 rs9652011 chr12 58170556 T C 0.00001702 Sarcoidosis METTL21B intron 22952805 rs10877018 chr12 58171726 T C 0.000002773 Sarcoidosis METTL21B intron 22952805 rs10877019 chr12 58172929 C T 7.07E-04 Multiple complex diseases METTL21B intron 17554300 rs923829 chr12 58174306 T C 0.00009088 Sarcoidosis METTL21B cds-synon 22952805 rs6581155 chr12 58178162 A C,G 0.00003643 Sarcoidosis TSFM intron 22952805 rs10431505 chr12 58178589 A G 0.00007595 Sarcoidosis TSFM intron 22952805 rs7965287 chr12 58188696 G C 0.00001624 Sarcoidosis TSFM intron 22952805 rs111935385 chr12 58192181 G A 0.0000679 Sarcoidosis TSFM intron 22952805 rs11172344 chr12 58193448 T C 0.00009586 Sarcoidosis TSFM intron 22952805 rs10783847 chr12 58196447 G A 0.00009138 Sarcoidosis TSFM UTR-3 22952805 rs11172350 chr12 58213272 A G 0.00001979 Sarcoidosis / / 22952805 rs141052380 chr12 58233370 G A 0.00007134 Sarcoidosis CTDSP2 intron 22952805 rs10877028 chr12 58241028 T G 0.00000145 Sarcoidosis / / 22952805 rs1599750 chr12 58242545 T G 0.00002686 Sarcoidosis / / 22952805 rs1599751 chr12 58242849 T C 0.00002611 Sarcoidosis / / 22952805 rs11172361 chr12 58244746 A C 0.00002061 Sarcoidosis / / 22952805 rs10877029 chr12 58256010 T C 7.15E-04 Multiple complex diseases / / 17554300 rs10747787 chr12 58260657 T C 9.87E-04 Multiple complex diseases / / 17554300 rs4760341 chr12 58281495 T A 5.82E-04 Type 1 diabetes / / 21980299 rs11172377 chr12 58296498 A C 6.18E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2372309 chr12 58329820 G A 9.88E-04 Multiple complex diseases / / 17554300 rs951901 chr12 58398365 C A 5.77E-04 Sarcoidosis / / 21540310 rs2221541 chr12 58402465 G C 3.55E-04 Multiple complex diseases / / 17554300 rs7135063 chr12 58402912 T C 3.91E-04 Multiple complex diseases / / 17554300 rs7304755 chr12 58403250 C G 9.98E-04 Multiple complex diseases / / 17554300 rs1911260 chr12 58410756 T C 9.59E-04 Multiple complex diseases / / 17554300 rs11172427 chr12 58421053 G A 6.85E-04 Multiple complex diseases / / 17554300 rs970249 chr12 58421132 C T 4.39E-04 Multiple complex diseases / / 17554300 rs12422977 chr12 58421729 T C 3.22E-07 Red blood cell traits / / 23222517 rs4435045 chr12 58423203 T C 2.46E-04 Multiple complex diseases / / 17554300 rs11172457 chr12 58466617 G A 2.00E-04 Amyotrophic lateral sclerosis / / 17671248 rs4354731 chr12 58478598 G T 7.23E-05 Multiple complex diseases / / 17554300 rs12368412 chr12 58574428 C T 7.10E-04 Multiple complex diseases / / 17554300 rs17120482 chr12 58595535 A G 1.58E-04 Multiple complex diseases / / 17554300 rs2888284 chr12 58627837 C A 2.90E-06 Urinary metabolites / / 21572414 rs1174651 chr12 58632584 A C 3.40E-06 Urinary metabolites / / 21572414 rs1148549 chr12 58637140 G C 2.80E-06 Urinary metabolites / / 21572414 rs1502807 chr12 58647067 G A 1.90E-05 Cognitive test performance / / 20125193 rs1502807 chr12 58647067 G A 7.49E-04 Myopia (pathological) / / 21095009 rs1174387 chr12 58682665 C T 2.30E-05 Urinary metabolites / / 21572414 rs2047171 chr12 58709649 G T 7.20E-05 Tunica Media / / pha003037 rs10877101 chr12 58730897 T C 4.54E-07 Tunica Media / / pha003037 rs1174600 chr12 58735712 G A 4.99E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2698250 chr12 58737269 T C 5.43E-05 Bipolar disorder and schizophrenia / / 20889312 rs1795704 chr12 58739693 C A 2.70E-05 Urinary metabolites / / 21572414 rs1795708 chr12 58750680 T C 4.00E-06 Obesity-related traits / / 23251661 rs1729790 chr12 58750741 C G 6.82E-05 Bipolar disorder and schizophrenia / / 20889312 rs12424547 chr12 58787122 G T 2.52E-05 Bipolar disorder and schizophrenia / / 20889312 rs4093823 chr12 58791489 G A 7.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11829757 chr12 58801523 C T 7.11E-05 Lung adenocarcinoma / / 19836008 rs11172591 chr12 58802241 C G 2.83E-05 Progressive supranuclear palsy / / 21685912 rs782099 chr12 58813930 G C 9.62E-05 Bipolar disorder and schizophrenia / / 20889312 rs3907505 chr12 58856156 T C 8.38E-05 Glucose levels / / pha003061 rs2883575 chr12 58863107 A G 8.31E-05 Glucose levels / / pha003061 rs11172627 chr12 58872671 G A 9.94E-04 Obesity (extreme) / / 21935397 rs10783899 chr12 58872899 T C 0.0000982 Panic disorder / / 23149450 rs10783899 chr12 58872899 T C 9.82E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs11172630 chr12 58874881 C T 0.0000751 Panic disorder / / 23149450 rs11172630 chr12 58874881 C T 7.51E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs6581191 chr12 58875698 A G 1.23E-05 Educational attainment / / 21694764 rs6581196 chr12 58876062 A C 0.0000888 Panic disorder / / 23149450 rs6581196 chr12 58876062 A C 8.88E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs10506374 chr12 58889616 G A,C,T 8.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs3847728 chr12 58894819 A G 5.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10506373 chr12 58922272 G A 2.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs11615907 chr12 58924726 A G 9.91E-04 Type 2 diabetes / / 17463246 rs17121007 chr12 58929444 A G 5.00E-04 Multiple complex diseases / / 17554300 rs2354997 chr12 58942426 G A 2.60E-05 Urinary metabolites / / 21572414 rs3913063 chr12 58948751 C T 2.38E-05 Multiple complex diseases / / 17554300 rs4418850 chr12 58950645 T C 3.40E-04 Alzheimer's disease (late onset) / / 21379329 rs10877149 chr12 58989050 A C 7.28E-04 Type 2 diabetes LOC100506869 intron 17463246 rs7305641 chr12 58993364 A C 7.27E-04 Type 2 diabetes LOC100506869 intron 17463246 rs3847697 chr12 58995990 T C 2.19E-05 Self-employment LOC100506869 intron 23593239 rs7310852 chr12 59041821 G A 2.00E-05 Multiple complex diseases LOC100506869 intron 17554300 rs17121276 chr12 59056503 A G 1.59E-06 Plasma omega-6 polyunsaturated fatty acid levels LOC100506869 intron 24823311 rs7968324 chr12 59066580 T G 8.00E-07 Plasma omega-6 polyunsaturated fatty acid levels LOC100506869 intron 24823311 rs7302361 chr12 59159601 T C 6.24E-04 Body mass index LOC100506869 intron 21701565 rs11172719 chr12 59171210 G A 6.10E-05 Type 2 diabetes LOC100506869 intron 17463246 rs12371471 chr12 59181068 C G,T 9.15E-04 Suicide attempts in bipolar disorder LOC100506869 intron 21423239 rs12371471 chr12 59181068 C G,T 2.70E-05 Urinary metabolites LOC100506869 intron 21572414 rs12308086 chr12 59191729 T C 5.03E-04 Multiple complex diseases LOC100506869 intron 17554300 rs12308086 chr12 59191729 T C 5.37E-04 Body mass index LOC100506869 intron 21701565 rs7303938 chr12 59210932 C T 9.49E-04 Multiple complex diseases / / 17554300 rs7303938 chr12 59210932 C T 4.41E-04 Body mass index / / 21701565 rs1587254 chr12 59222720 T C 1.90E-05 Urinary metabolites / / 21572414 rs11172758 chr12 59238386 A G 2.00E-05 Urinary metabolites / / 21572414 rs11172782 chr12 59259628 A G 7.00E-08 Heart failure / / 20445134 rs11172823 chr12 59312113 T C 6.92E-04 Alzheimer's disease LRIG3 intron 17998437 rs11833888 chr12 59350153 A G 5.74E-04 Multiple complex diseases / / 17554300 rs17121856 chr12 59414864 T C 3.88E-04 Multiple complex diseases / / 17554300 rs17121856 chr12 59414864 T C 3.40E-05 Temperament (bipolar disorder) / / 22365631 rs12367126 chr12 59418658 T G 3.56E-04 Alzheimer's disease / / 17998437 rs17121868 chr12 59418718 G A 1.90E-05 Temperament (bipolar disorder) / / 22365631 rs17121873 chr12 59420065 C T 1.90E-05 Temperament (bipolar disorder) / / 22365631 rs11611527 chr12 59431285 C G 1.20E-05 Temperament (bipolar disorder) / / 22365631 rs1878871 chr12 59435030 T C 6.30E-05 Temperament (bipolar disorder) / / 22365631 rs12370707 chr12 59440071 G A 5.60E-04 Alzheimer's disease / / 17998437 rs17121944 chr12 59440232 T C 4.00E-06 Temperament (bipolar disorder) / / 22365631 rs6581227 chr12 59440659 T G 6.10E-05 Temperament (bipolar disorder) / / 22365631 rs7303996 chr12 59444966 T C 5.80E-05 Temperament (bipolar disorder) / / 22365631 rs1373355 chr12 59451121 T C 8.14E-10 Multiple complex diseases / / 17554300 rs10506354 chr12 59472767 G C 2.20E-05 Lipid traits / / 17903299 rs2371978 chr12 59472972 T C 2.40E-05 Lipid traits / / 17903299 rs12367511 chr12 59484069 T C 8.05E-04 Taste perception / / 22132133 rs12367511 chr12 59484069 T C 1.80E-06 Height / / pha003010 rs12367511 chr12 59484069 T C 7.93E-06 Height / / pha003011 rs7952875 chr12 59507893 A G 6.45E-06 Height / / pha003010 rs7952875 chr12 59507893 A G 1.61E-05 Height / / pha003011 rs908394 chr12 59512781 T C 5.28E-05 Height / / pha003010 rs1392313 chr12 59537339 G A 4.36E-05 Height / / pha003010 rs1392313 chr12 59537339 G A 9.45E-05 Height / / pha003011 rs10877221 chr12 59563122 A G 9.55E-04 Multiple complex diseases / / 17554300 rs10877258 chr12 59675368 G T 2.78E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1392312 chr12 59699697 C T 5.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10747833 chr12 59707258 G A 9.68E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1996199 chr12 59773458 A G 3.97E-05 Crohn's disease / / 18587394 rs11173018 chr12 59774030 A G 1.99E-05 Tuberculosis / / 20694014 rs10877268 chr12 59776063 A C 8.54E-05 Tuberculosis / / 20694014 rs276056 chr12 59800932 A T 3.82E-04 Multiple complex diseases / / 17554300 rs398984 chr12 59829829 C T 1.82E-04 Alzheimer's disease / / 17998437 rs276067 chr12 59842203 A G 1.20E-04 Lung function (forced vital capacity) / / 24023788 rs276000 chr12 59849677 T C 7.00E-07 Methotrexate phramacokinetics (acute lymphoblastic leukemia) / / 19901119 rs12815102 chr12 59889555 A T 9.85E-04 Acute lung injury / / 22295056 rs276086 chr12 59910672 T C 4.69E-04 Depression (quantitative trait) / / 20800221 rs10877301 chr12 59913026 T A 2.58E-05 Tuberculosis / / 20694014 rs11173067 chr12 59916822 A G 3.32E-05 Tuberculosis / / 20694014 rs12369542 chr12 59918266 T C 2.58E-05 Tuberculosis / / 20694014 rs2175950 chr12 59920382 G A 1.79E-05 Tuberculosis / / 20694014 rs275982 chr12 59927570 A C 1.10E-04 Smoking behavior / / 20418888 rs11173071 chr12 59935026 C T 4.16E-07 Multiple complex diseases / / 17554300 rs276014 chr12 59935109 G A 7.99E-04 Depression (quantitative trait) / / 20800221 rs12818777 chr12 59990069 C G 3.94E-04 Acute lung injury / / 22295056 rs17122678 chr12 59992844 C T 5.03E-04 Multiple complex diseases / / 17554300 rs17122718 chr12 60013887 C A 8.73E-04 Type 2 diabetes / / 17463246 rs982322 chr12 60037770 T G 3.99E-05 Periodontitis (Chronic) / / 25008200 rs17122830 chr12 60073240 A G 2.61E-04 Multiple complex diseases / / 17554300 rs17122837 chr12 60073907 C T 4.77E-04 Type 2 diabetes / / 17463246 rs1497473 chr12 60075383 A T 7.88E-04 Multiple complex diseases / / 17554300 rs7976838 chr12 60086206 A G 5.98E-05 Multiple complex diseases SLC16A7 intron 17554300 rs7976838 chr12 60086206 A G 4.40E-05 Cognitive performance SLC16A7 intron 19734545 rs11173119 chr12 60106513 C T 0.00000458 HDL cholesterol particle diameter SLC16A7 intron 23263444 rs10877330 chr12 60111653 A G 2.90E-04 Smoking initiation SLC16A7 intron 24665060 rs1795893 chr12 60113910 A G 9.42E-04 Type 2 diabetes SLC16A7 intron 17463246 rs1795893 chr12 60113910 A G 5.12E-05 Multiple complex diseases SLC16A7 intron 17554300 rs1693603 chr12 60114150 C T 1.12E-05 Multiple complex diseases SLC16A7 intron 17554300 rs1693598 chr12 60117186 G T 9.95E-04 Type 2 diabetes SLC16A7 intron 17463246 rs1693598 chr12 60117186 G T 6.59E-05 Multiple complex diseases SLC16A7 intron 17554300 rs1693597 chr12 60117251 T C 9.82E-04 Type 2 diabetes SLC16A7 intron 17463246 rs1693597 chr12 60117251 T C 1.61E-04 Multiple complex diseases SLC16A7 intron 17554300 rs1619563 chr12 60117546 T C 6.69E-04 Type 2 diabetes SLC16A7 intron 17463246 rs1619563 chr12 60117546 T C 1.36E-04 Multiple complex diseases SLC16A7 intron 17554300 rs1795883 chr12 60119190 C T 1.41E-04 Multiple complex diseases SLC16A7 intron 17554300 rs2711679 chr12 60125706 T G 3.10E-04 Multiple complex diseases SLC16A7 intron 17554300 rs2711669 chr12 60128972 G A 7.06E-04 Type 2 diabetes SLC16A7 intron 17463246 rs2711667 chr12 60129405 G A 1.25E-04 Type 2 diabetes SLC16A7 intron 17463246 rs2711667 chr12 60129405 G A 1.18E-04 Multiple complex diseases SLC16A7 intron 17554300 rs2706307 chr12 60129493 T C 2.28E-04 Multiple complex diseases SLC16A7 intron 17554300 rs12824600 chr12 60130044 G C 9.67E-04 Type 2 diabetes SLC16A7 intron 17463246 rs12824600 chr12 60130044 G C 2.35E-04 Multiple complex diseases SLC16A7 intron 17554300 rs2178671 chr12 60130188 G A 1.33E-04 Multiple complex diseases SLC16A7 intron 17554300 rs2178671 chr12 60130188 G A 5.13E-05 Cognitive performance SLC16A7 intron 19734545 rs7303876 chr12 60135212 T C 4.87E-07 Alzheimer's disease (late onset) SLC16A7 intron 20885792 rs2706300 chr12 60135504 G A 5.59E-04 Type 2 diabetes SLC16A7 intron 17463246 rs2706300 chr12 60135504 G A 2.47E-05 Multiple complex diseases SLC16A7 intron 17554300 rs2706292 chr12 60136308 G A 6.14E-05 Multiple complex diseases SLC16A7 intron 17554300 rs2711664 chr12 60136384 T A 5.42E-05 Multiple complex diseases SLC16A7 intron 17554300 rs2711654 chr12 60139558 G A 7.53E-04 Type 2 diabetes SLC16A7 intron 17463246 rs2711654 chr12 60139558 G A 9.75E-05 Multiple complex diseases SLC16A7 intron 17554300 rs2711652 chr12 60139581 G A 8.95E-04 Type 2 diabetes SLC16A7 intron 17463246 rs2711652 chr12 60139581 G A 5.97E-05 Multiple complex diseases SLC16A7 intron 17554300 rs12826493 chr12 60167204 C T 8.27E-04 Type 2 diabetes SLC16A7 intron 17463246 rs12826493 chr12 60167204 C T 1.03E-04 Multiple complex diseases SLC16A7 intron 17554300 rs17122978 chr12 60167835 C A 9.46E-04 Type 2 diabetes SLC16A7 intron 17463246 rs17122978 chr12 60167835 C A 7.19E-05 Multiple complex diseases SLC16A7 intron 17554300 rs3763979 chr12 60173406 C T 7.66E-04 Type 2 diabetes SLC16A7 cds-synon 17463246 rs3763979 chr12 60173406 C T 6.29E-05 Multiple complex diseases SLC16A7 cds-synon 17554300 rs7137002 chr12 60184770 T C 8.93E-04 Type 2 diabetes / / 17463246 rs7137002 chr12 60184770 T C 3.16E-05 Multiple complex diseases / / 17554300 rs17120243 chr12 60206636 A G 1.07E-04 Multiple complex diseases / / 17554300 rs11173190 chr12 60240935 T C 3.73E-08 Metabolite levels / / 23281178 rs12582540 chr12 60246089 A G 3.73E-08 Metabolite levels / / 23281178 rs12231727 chr12 60252000 A G 3.03E-08 Metabolite levels / / 23281178 rs7303705 chr12 60252997 T C 1.27E-04 Multiple complex diseases / / 17554300 rs12230605 chr12 60255892 C T 8.74E-05 Serum metabolites / / 19043545 rs10784006 chr12 60256542 T A 4.20E-08 Metabolite levels / / 23281178 rs12228679 chr12 60257517 T C 4.20E-08 Metabolite levels / / 23281178 rs11173203 chr12 60258448 C A 1.19E-08 Metabolite levels / / 23281178 rs12229058 chr12 60258530 T A 2.72E-08 Metabolite levels / / 23281178 rs12227882 chr12 60258712 C A 1.02E-08 Metabolite levels / / 23281178 rs11173212 chr12 60274570 T G 7.42E-04 Multiple complex diseases / / 17554300 rs12297974 chr12 60294217 A G 0.0000041 HDL cholesterol particle diameter / / 23263444 rs10784015 chr12 60302823 A G 7.76E-04 Multiple complex diseases / / 17554300 rs11173245 chr12 60321483 T C 0.00000414 HDL cholesterol particle diameter / / 23263444 rs11173246 chr12 60324496 A T 0.00000414 HDL cholesterol particle diameter / / 23263444 rs12313195 chr12 60324927 G C 0.00000414 HDL cholesterol particle diameter / / 23263444 rs2068673 chr12 60333403 C G 0.0000125 HDL cholesterol particle diameter / / 23263444 rs4534617 chr12 60334109 G A 2.04E-04 Multiple complex diseases / / 17554300 rs12321932 chr12 60334724 C T 0.00000413 HDL cholesterol particle diameter / / 23263444 rs10082957 chr12 60336376 A T 0.00000566 VLDL cholesterol particle diameter / / 23263444 rs11173254 chr12 60353261 G A 0.00006773 Sarcoidosis / / 22952805 rs7135268 chr12 60357338 C A 0.0000039 HDL cholesterol particle diameter / / 23263444 rs4363643 chr12 60372362 T C 0.00005354 Sarcoidosis / / 22952805 rs9325169 chr12 60383069 C A 5.40E-05 Triglycerides / / pha003080 rs11173268 chr12 60383712 A G 0.0000581 Sarcoidosis / / 22952805 rs7303843 chr12 60384829 G A 0.00002112 Sarcoidosis / / 22952805 rs7954965 chr12 60393735 A T 0.00003942 Sarcoidosis / / 22952805 rs11173276 chr12 60399059 C T 0.00004818 Sarcoidosis / / 22952805 rs4519124 chr12 60399691 T C 1.20E-04 Multiple complex diseases / / 17554300 rs12422272 chr12 60402484 T A 0.00005961 Sarcoidosis / / 22952805 rs7965070 chr12 60405191 T A 0.00005073 Sarcoidosis / / 22952805 rs11173287 chr12 60411170 T C 0.00005137 Sarcoidosis / / 22952805 rs4492856 chr12 60433578 A C 0.00004954 Sarcoidosis / / 22952805 rs1602835 chr12 60439156 T C 7.95E-04 Multiple complex diseases / / 17554300 rs11173305 chr12 60446201 T C 2.74E-04 Parkinson's disease / / 17052657 rs1154719 chr12 60504229 A C 5.70E-04 Multiple complex diseases / / 17554300 rs3847663 chr12 60542054 G A 6.67E-04 Smoking initiation / / 24665060 rs73111657 chr12 60548705 C A 0.0008703 Sarcoidosis / / 22952805 rs12580188 chr12 60549171 T C 0.0008381 Sarcoidosis / / 22952805 rs35468534 chr12 60549171 T TC 0.0008381 Sarcoidosis / / 22952805 rs7301616 chr12 60608389 C T 9.21E-07 Panic disorder / / 19165232 rs7298350 chr12 60659990 C T 9.63E-04 Multiple complex diseases / / 17554300 rs1995516 chr12 60719734 C G 0.0000126 HDL cholesterol particle diameter / / 23263444 rs1857728 chr12 60725389 T G 9.71E-34 Narcolepsy / / 19629137 rs7974425 chr12 60735173 C T 6.00E-06 Obesity-related traits / / 23251661 rs7974425 chr12 60735173 C T 9.00E-06 Obesity-related traits / / 23251661 rs1847514 chr12 60784433 G C 1.60E-05 Multiple complex diseases / / 17554300 rs2731461 chr12 60788062 T A 0.00000871 HDL cholesterol particle diameter / / 23263444 rs2655872 chr12 60788564 C T 0.00000851 HDL cholesterol particle diameter / / 23263444 rs2731462 chr12 60788585 A G 0.00000832 HDL cholesterol particle diameter / / 23263444 rs35274006 chr12 60788585 A AG 0.00000832 HDL cholesterol particle diameter / / 23263444 rs2731464 chr12 60788996 T A 0.00000819 HDL cholesterol particle diameter / / 23263444 rs1504445 chr12 60789138 G T 0.00000807 HDL cholesterol particle diameter / / 23263444 rs1504447 chr12 60789454 A G 0.00000785 HDL cholesterol particle diameter / / 23263444 rs2047909 chr12 60789586 T C 0.00000774 HDL cholesterol particle diameter / / 23263444 rs2655874 chr12 60789708 A G 0.00000695 HDL cholesterol particle diameter / / 23263444 rs2047910 chr12 60789885 T C 0.00000675 HDL cholesterol particle diameter / / 23263444 rs1504448 chr12 60790025 G T 0.00000656 HDL cholesterol particle diameter / / 23263444 rs1472738 chr12 60790215 G A 0.00000612 HDL cholesterol particle diameter / / 23263444 rs2731466 chr12 60791214 C G 0.00000453 HDL cholesterol particle diameter / / 23263444 rs2655876 chr12 60791225 G A 0.00000434 HDL cholesterol particle diameter / / 23263444 rs1394325 chr12 60791387 T C 0.00000389 HDL cholesterol particle diameter / / 23263444 rs2047911 chr12 60791727 T C 0.00000382 HDL cholesterol particle diameter / / 23263444 rs2655877 chr12 60792616 A C 0.00000371 HDL cholesterol particle diameter / / 23263444 rs1983091 chr12 60793755 A G 0.00000366 HDL cholesterol particle diameter / / 23263444 rs2655879 chr12 60794991 C T 8.76E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2731468 chr12 60797083 T C 3.92E-04 White matter integrity / / 22425255 rs10506410 chr12 60797703 A T 2.00E-06 Cardiac hypertrophy / / 21348951 rs2655898 chr12 60810652 T C 8.00E-06 Obesity-related traits / / 23251661 rs11173452 chr12 60819044 T G 7.15E-04 White matter integrity / / 22425255 rs4451769 chr12 60829905 G A 8.84E-05 White matter integrity / / 22425255 rs10877431 chr12 60846199 A G 1.46E-04 Parkinson's disease / / 17052657 rs10747874 chr12 60858680 T G 1.46E-04 Parkinson's disease / / 17052657 rs11173482 chr12 60863550 A G 8.60E-06 Urinary metabolites / / 21572414 rs17608369 chr12 60864444 T C 3.19E-06 Stroke (ischemic) / / 21957438 rs10128952 chr12 60876090 T C 3.06E-04 Blood pressure / / 17255346 rs7975412 chr12 60876219 G A 6.41E-04 Bipolar disorder,schizoaffective / / 19567891 rs12309129 chr12 60895252 A G 6.04E-04 Multiple complex diseases / / 17554300 rs4147491 chr12 60897603 A G 1.90E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11173521 chr12 60951398 G T 6.40E-06 Urinary metabolites / / 21572414 rs905559 chr12 60989194 A T 1.10E-05 Urinary metabolites / / 21572414 rs2654664 chr12 60994020 A C 2.60E-05 Urinary metabolites / / 21572414 rs1503583 chr12 61003196 T C 8.00E-06 Urinary metabolites / / 21572414 rs2733656 chr12 61009426 T C 6.60E-06 Urinary metabolites / / 21572414 rs1587740 chr12 61019462 G A 5.30E-06 Urinary metabolites / / 21572414 rs2723724 chr12 61021245 G A 4.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs2654663 chr12 61021586 A G 5.80E-07 Urinary metabolites / / 21572414 rs1393984 chr12 61022987 A G 2.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs1566788 chr12 61027135 G A 6.72E-04 Parkinson's disease / / 17052657 rs2654656 chr12 61049683 G A 1.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs273790 chr12 61079478 A G 8.60E-07 Urinary metabolites / / 21572414 rs17124060 chr12 61080039 T G 1.47E-04 Prostate cancer / / 23023329 rs273820 chr12 61091275 A T 3.50E-07 Urinary metabolites / / 21572414 rs1498463 chr12 61154009 T C 2.31E-04 Blood pressure / / 17255346 rs11173607 chr12 61175053 T C 1.90E-06 Urinary metabolites / / 21572414 rs12320242 chr12 61191039 T A 4.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs1353733 chr12 61196087 G A 2.81E-04 Blood pressure / / 17255346 rs17618290 chr12 61261399 C T 1.84E-04 Blood pressure / / 17255346 rs4758762 chr12 61295914 G A 1.60E-05 Urinary metabolites / / 21572414 rs1480177 chr12 61300873 G A 2.80E-05 Urinary metabolites / / 21572414 rs4758764 chr12 61314276 T C 0.0008424 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4758764 chr12 61314276 T C 8.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1383190 chr12 61314423 C T 0.0008409 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1383190 chr12 61314423 C T 8.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10877483 chr12 61315588 A C 0.0008351 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10877483 chr12 61315588 A C 8.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10506416 chr12 61316609 G A 2.10E-05 Urinary metabolites / / 21572414 rs1383185 chr12 61322180 C A 0.0006503 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1383185 chr12 61322180 C A 6.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1383183 chr12 61324728 A G 0.0006831 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1383183 chr12 61324728 A G 6.83E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1600544 chr12 61326791 A G 0.0006383 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2362794 chr12 61327832 A T 9.31E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7136522 chr12 61329639 T C 0.0006308 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7136522 chr12 61329639 T C 6.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12422928 chr12 61330042 T A 0.0006275 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12422928 chr12 61330042 T A 6.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6581355 chr12 61331222 C T 0.0006017 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6581355 chr12 61331222 C T 6.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1542572 chr12 61335415 G T 0.0005543 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1542572 chr12 61335415 G T 5.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7971956 chr12 61338456 T G 0.0005429 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7971956 chr12 61338456 T G 5.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1021015 chr12 61339092 T C 0.0005364 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1021015 chr12 61339092 T C 5.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10877486 chr12 61340142 A C 0.0005321 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10877486 chr12 61340142 A C 5.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7312598 chr12 61343384 G A 0.0005266 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7312598 chr12 61343384 G A 5.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10747885 chr12 61344443 T A 0.0005058 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10747885 chr12 61344443 T A 5.06E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7971423 chr12 61347134 C T 0.000503 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7971423 chr12 61347134 C T 5.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10877487 chr12 61351816 A G 0.0006645 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10877487 chr12 61351816 A G 6.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10877489 chr12 61354459 A G 0.000467 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10877489 chr12 61354459 A G 4.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10877489 chr12 61354459 A G 3.56E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs795397 chr12 61359644 C T 0.0006516 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs795397 chr12 61359644 C T 6.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs795390 chr12 61364515 A G 0.0004666 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs795390 chr12 61364515 A G 4.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2620868 chr12 61370770 T C 0.000495 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2620868 chr12 61370770 T C 4.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2620868 chr12 61370770 T C 8.72E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs795398 chr12 61379319 G C 0.000485 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs795398 chr12 61379319 G C 4.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11173690 chr12 61385570 G C 7.50E-06 Primary tooth development (number of teeth) / / 23704328 rs795405 chr12 61393338 T C 0.0008586 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs795405 chr12 61393338 T C 8.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10784083 chr12 61403078 T C 2.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10784083 chr12 61403078 T C 6.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10877495 chr12 61412507 C A 2.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10784091 chr12 61437048 A G 3.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10784091 chr12 61437048 A G 8.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7974374 chr12 61448177 G C 9.00E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11173758 chr12 61498796 G T 8.69E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1608610 chr12 61507621 T C 8.69E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs795324 chr12 61509855 G A 5.40E-04 Multiple complex diseases / / 17554300 rs10784138 chr12 61510828 A G 9.62E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10747911 chr12 61516112 A G 6.12E-04 Type 2 diabetes / / 17463246 rs10747911 chr12 61516112 A G 7.76E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs906263 chr12 61522533 C T 8.69E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7971987 chr12 61530512 C T 6.71E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10877556 chr12 61531533 C T 6.01E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs951614 chr12 61538726 A G 2.12E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10747922 chr12 61539128 C T 6.49E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17124610 chr12 61549081 C T 8.00E-06 IgG glycosylation / / 23382691 rs7976897 chr12 61556218 G C 8.80E-04 Type 2 diabetes / / 17463246 rs7979976 chr12 61559984 G A 9.79E-04 Type 2 diabetes / / 17463246 rs10784173 chr12 61561407 G T 0.00000028 Lumbar spine bone mineral density (premenopausal) / / 23074152 rs4237791 chr12 61643164 C T 5.20E-04 Type 2 diabetes / / 17463246 rs7963956 chr12 61672165 T G 4.00E-05 Asthma (aspirin-intolerant) / / 21072201 rs10784209 chr12 61756650 T C 4.38E-04 Blood pressure / / 17255346 rs11173910 chr12 61756789 T C 3.02E-04 Blood pressure / / 17255346 rs2674887 chr12 61788767 A G 2.95E-25 Narcolepsy / / 19629137 rs2009164 chr12 61854732 T C 1.10E-05 Urinary metabolites / / 21572414 rs10877673 chr12 61879699 G A 6.94E-05 Triglycerides / / pha003080 rs11174055 chr12 61909374 A C 6.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7296490 chr12 61957419 A G 9.71E-04 Iron levels / / pha002876 rs2048078 chr12 61962973 C T 7.24E-04 Iron levels / / pha002876 rs2360616 chr12 61964134 T C 9.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs1531000 chr12 61964264 C T 9.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs7958718 chr12 61980912 C A 5.88E-04 Multiple complex diseases / / 17554300 rs1506843 chr12 62059096 T C 1.46E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1506843 chr12 62059096 T C 2.90E-04 Lung function (forced vital capacity) / / 24023788 rs6581420 chr12 62115165 T C 0.000777432 Hypertension (early onset hypertension) FAM19A2 intron 22479346 rs11174151 chr12 62138901 T C 3.07E-05 Multiple complex diseases FAM19A2 intron 17554300 rs11174152 chr12 62141882 C A 1.40E-04 Multiple complex diseases FAM19A2 intron 17554300 rs7484947 chr12 62171973 T C 6.41E-04 Multiple complex diseases FAM19A2 intron 17554300 rs7304109 chr12 62198475 T C 0.000262113 Hypertension (early onset hypertension) FAM19A2 intron 22479346 rs7304109 chr12 62198475 T C 1.26E-06 Obesity-related traits FAM19A2 intron 23251661 rs7304109 chr12 62198475 T C 1.97E-04 Iron levels FAM19A2 intron pha002876 rs12581923 chr12 62210660 T C 7.05E-05 Body Mass Index FAM19A2 intron pha003009 rs1869890 chr12 62213401 G A 1.04E-06 Obesity-related traits FAM19A2 intron 23251661 rs12424350 chr12 62216308 A C 4.85E-04 Multiple complex diseases FAM19A2 intron 17554300 rs717271 chr12 62221297 G A 9.90E-04 Multiple complex diseases FAM19A2 intron 17554300 rs724986 chr12 62224811 T C 9.82E-04 Multiple complex diseases FAM19A2 intron 17554300 rs11174192 chr12 62228464 C T 9.20E-04 Type 2 diabetes FAM19A2 intron 17463246 rs12814204 chr12 62232356 G A 9.59E-04 Multiple complex diseases FAM19A2 intron 17554300 rs2198776 chr12 62234833 C T 5.00E-06 Obesity-related traits FAM19A2 intron 23251661 rs2198776 chr12 62234833 C T 5.00E-07 Obesity-related traits FAM19A2 intron 23251661 rs2198773 chr12 62238260 A C 3.89E-05 Body Mass Index FAM19A2 intron pha003009 rs7136585 chr12 62249990 T C 5.28E-04 Type 2 diabetes FAM19A2 intron 17463246 rs17605016 chr12 62250420 T G 2.00E-06 Asthma and hay fever FAM19A2 intron 24388013 rs12578673 chr12 62254446 G C 7.39E-04 Multiple complex diseases FAM19A2 intron 17554300 rs10877756 chr12 62271383 C T 1.29E-04 Iron levels FAM19A2 intron pha002876 rs349882 chr12 62309587 A G 7.18E-04 Multiple complex diseases FAM19A2 intron 17554300 rs851903 chr12 62325370 C T 5.53E-04 Response to taxane treatment (placlitaxel) FAM19A2 intron 23006423 rs349874 chr12 62341787 G T 1.60E-05 Urinary metabolites FAM19A2 intron 21572414 rs11174250 chr12 62345143 G A 6.73E-04 Type 2 diabetes FAM19A2 intron 17463246 rs11174250 chr12 62345143 G A 1.30E-05 Urinary metabolites FAM19A2 intron 21572414 rs7981014 chr12 62363197 G A 7.40E-06 Urinary metabolites FAM19A2 intron 21572414 rs11174267 chr12 62386600 A G 8.00E-07 Chronic obstructive pulmonary disease (moderate to severe) FAM19A2 intron 24621683 rs7963802 chr12 62395774 A G 2.03E-04 Vaspin levels FAM19A2 intron 22907691 rs7963802 chr12 62395774 A G 0.0002031 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks FAM19A2 intron 22907730 rs11174274 chr12 62395934 A C 1.90E-05 Urinary metabolites FAM19A2 intron 21572414 rs980891 chr12 62403101 C T 7.55E-04 Suicide attempts in bipolar disorder FAM19A2 intron 21041247 rs1732362 chr12 62406171 A G 5.22E-05 Nephrolithiasis FAM19A2 intron 22396660 rs348696 chr12 62418622 C T 7.66E-04 Suicide attempts in bipolar disorder FAM19A2 intron 21041247 rs17125683 chr12 62420959 A T 2.70E-05 Urinary metabolites FAM19A2 intron 21572414 rs10506434 chr12 62439782 A G 2.30E-05 Urinary metabolites FAM19A2 intron 21572414 rs2951468 chr12 62445289 C A 7.56E-04 Suicide attempts in bipolar disorder FAM19A2 intron 21041247 rs11174296 chr12 62471458 C G 9.63E-04 Type 2 diabetes FAM19A2 intron 17463246 rs348670 chr12 62472436 T C 2.50E-05 Urinary metabolites FAM19A2 intron 21572414 rs9738798 chr12 62481190 C T 1.77E-05 Insulin-related traits FAM19A2 intron pha003063 rs11174305 chr12 62485243 T C 5.78E-04 Multiple complex diseases FAM19A2 intron 17554300 rs11174316 chr12 62494349 A T 2.82E-04 Multiple complex diseases FAM19A2 intron 17554300 rs9738227 chr12 62520507 A G 6.72E-05 Insulin Resistance FAM19A2 intron pha003062 rs9738227 chr12 62520507 A G 3.20E-06 Insulin-related traits FAM19A2 intron pha003063 rs11832462 chr12 62525039 T C 6.65E-06 Insulin-related traits FAM19A2 intron pha003063 rs1245443 chr12 62530153 A G 9.61E-04 Alzheimer's disease FAM19A2 intron 24755620 rs10877800 chr12 62536274 A T 2.92E-04 Coronary Artery Disease FAM19A2 intron 17634449 rs4348998 chr12 62538148 G A,C,T 9.20E-06 Urinary metabolites FAM19A2 intron 21572414 rs11174347 chr12 62538854 A G 2.70E-04 Coronary Artery Disease FAM19A2 intron 17634449 rs10784285 chr12 62558314 C T 4.41E-04 White matter integrity FAM19A2 intron 22425255 rs10784285 chr12 62558314 C T 9.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy) FAM19A2 intron 24554482 rs1881957 chr12 62567676 C T 9.24E-04 Multiple complex diseases FAM19A2 intron 17554300 rs1881959 chr12 62568371 A G 2.85E-04 White matter integrity FAM19A2 intron 22425255 rs17715440 chr12 62579779 C T 2.39E-04 Heart rate FAM19A2 intron 23583979 rs11174365 chr12 62581977 T C 9.80E-06 Urinary metabolites FAM19A2 intron 21572414 rs10877809 chr12 62587572 G A 2.70E-06 Primary tooth development (time to first tooth eruption) / / 23704328 rs10877810 chr12 62593726 T C 1.80E-05 Urinary metabolites / / 21572414 rs1245652 chr12 62600764 C T 4.54E-04 Multiple complex diseases / / 17554300 rs11615916 chr12 62610860 A G 7.00E-06 Pulmonary function decline / / 22424883 rs7313479 chr12 62623097 A C 3.35E-06 Parkinson's disease / / 17052657 rs7965326 chr12 62660483 C T 1.48E-06 Serum metabolites USP15 intron 19043545 rs7965326 chr12 62660483 C T 5.30E-06 Urinary metabolites USP15 intron 21572414 rs11174412 chr12 62674866 C T 6.88E-06 Serum metabolites USP15 intron 19043545 rs11174412 chr12 62674866 C T 5.40E-06 Urinary metabolites USP15 intron 21572414 rs7976058 chr12 62675647 C T 2.98E-06 Serum metabolites USP15 intron 19043545 rs7976058 chr12 62675647 C T 5.00E-06 Urinary metabolites USP15 intron 21572414 rs10506440 chr12 62707586 G T 4.18E-05 Blood Pressure and Arterial Stiffness USP15 intron 17903302 rs7953967 chr12 62712070 G T 7.51E-06 Serum metabolites USP15 intron 19043545 rs7953967 chr12 62712070 G T 7.90E-06 Urinary metabolites USP15 intron 21572414 rs12310616 chr12 62757863 C T 7.51E-06 Serum metabolites USP15 intron 19043545 rs12310616 chr12 62757863 C T 4.70E-06 Urinary metabolites USP15 intron 21572414 rs10877839 chr12 62818481 T C 9.00E-06 IgG glycosylation / / 23382691 rs7136205 chr12 62843620 C T 6.37E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1874523 chr12 62845324 A T 6.34E-05 Serum metabolites / / 19043545 rs1874523 chr12 62845324 A T 2.50E-06 Urinary metabolites / / 21572414 rs2029939 chr12 62846107 T C 1.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7968937 chr12 62846672 A G 4.90E-06 Urinary metabolites / / 21572414 rs10877849 chr12 62846785 T C 8.60E-07 Urinary metabolites / / 21572414 rs11174500 chr12 62871827 T A 2.49E-04 Coronary Artery Disease MON2 intron 17634449 rs4763171 chr12 62875910 T A 3.00E-06 Urinary metabolites MON2 intron 21572414 rs2173086 chr12 62878970 T C 5.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MON2 intron 20877124 rs10784301 chr12 62884552 A G 3.59E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MON2 intron 20877124 rs10784301 chr12 62884552 A G 6.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MON2 intron 20877124 rs7301016 chr12 62886123 A G 8.00E-06 IgG glycosylation MON2 intron 23382691 rs4763023 chr12 62916144 G T 2.57E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MON2 intron 20877124 rs4763023 chr12 62916144 G T 6.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MON2 intron 20877124 rs7953380 chr12 62916430 T C 4.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MON2 intron 20877124 rs7302017 chr12 63004583 G A 5.00E-06 Waist circumference / / 20966902 rs4763181 chr12 63007102 G C 3.26E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4763181 chr12 63007102 G C 5.00E-06 Urinary metabolites / / 21572414 rs2359381 chr12 63016659 T C 8.30E-06 Urinary metabolites / / 21572414 rs17732182 chr12 63026131 C T 9.00E-08 Primary tooth development (number of teeth) / / 23704328 rs12317552 chr12 63040610 C T 9.14E-06 Attention deficit hyperactivity disorder PPM1H UTR-3 20732627 rs10506445 chr12 63045255 A G 1.44E-05 Attention deficit hyperactivity disorder PPM1H intron 20732627 rs342169 chr12 63086591 A G 2.14E-05 Bipolar disorder PPM1H intron 19259986 rs17733777 chr12 63098281 A C 0.000899 Salmonella-induced pyroptosis PPM1H intron 22837397 rs3843661 chr12 63108904 G A 4.57E-04 Multiple complex diseases PPM1H intron 17554300 rs2663963 chr12 63112082 A G 2.38E-04 Insulin resistance PPM1H intron 21901158 rs342170 chr12 63113828 T C 7.51E-05 Heart Rate PPM1H intron pha003054 rs342171 chr12 63114510 T C 4.09E-04 Alcohol dependence PPM1H intron 21314694 rs12581737 chr12 63125469 T G 7.10E-05 Recombination rate PPM1H intron 21698098 rs11174626 chr12 63128158 G T 9.86E-04 Parkinson's disease PPM1H intron 16252231 rs342161 chr12 63131654 A G 3.37E-05 Post-operative nausea and vomiting PPM1H intron 21694509 rs342142 chr12 63155138 C A 6.70E-05 White matter hyperintensity burden PPM1H intron 21681796 rs12303266 chr12 63167945 C T 7.49E-05 Alcohol dependence PPM1H intron 21703634 rs17098314 chr12 63173558 G T 4.21E-05 Taste perception PPM1H intron 22132133 rs549433 chr12 63180816 T C 4.00E-06 Obesity-related traits PPM1H intron 23251661 rs10506448 chr12 63209623 G A 3.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) PPM1H intron 17982456 rs10506449 chr12 63209788 T G 1.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) PPM1H intron 17982456 rs10506450 chr12 63223443 A G 1.00E-07 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) PPM1H intron 17982456 rs668562 chr12 63238592 C A 7.37E-05 Type 2 diabetes PPM1H intron 17463246 rs3847906 chr12 63249773 A G 0.000000186 Secreted IFN-gamma response to smallpox vaccine PPM1H intron 22661280 rs7299978 chr12 63252359 A G 5.05E-04 Type 2 diabetes PPM1H intron 17463246 rs11174698 chr12 63254389 C T 2.30E-06 Urinary metabolites PPM1H intron 21572414 rs10506452 chr12 63254991 G A 8.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PPM1H intron 20877124 rs1088467 chr12 63279663 A C 2.49E-04 Glycemic traits (pregnancy) PPM1H intron 23903356 rs10784318 chr12 63281446 G C 3.60E-05 Systemic lupus erythematosus(serologic and cytokine profiles in serum) PPM1H intron 20659327 rs654228 chr12 63282342 A G 4.38E-06 Glycemic traits (pregnancy) PPM1H intron 23903356 rs7962536 chr12 63304021 C T 2.53E-05 Body Mass Index PPM1H intron pha003009 rs7967481 chr12 63305683 G T 2.42E-04 Alcohol dependence PPM1H intron 21314694 rs699585 chr12 63306132 T G 8.19E-04 Bipolar disorder PPM1H intron 19259986 rs699586 chr12 63306382 T C 8.19E-04 Bipolar disorder PPM1H intron 19259986 rs7296020 chr12 63309327 A C 6.34E-05 Body Mass Index PPM1H intron pha003009 rs3842944 chr12 63311967 G A 0.0000169 Tuberculosis with late age of onset PPM1H intron 22551897 rs11829891 chr12 63315485 G A 1.32E-04 Glycosylated haemoglobin levels PPM1H intron 17255346 rs10506469 chr12 63318123 G A 2.00E-04 Glycosylated haemoglobin levels PPM1H intron 17255346 rs11174720 chr12 63319509 T C 3.56E-05 Glycosylated haemoglobin levels PPM1H intron 17255346 rs1146090 chr12 63319878 T A 5.36E-05 Glycosylated haemoglobin levels PPM1H intron 17255346 rs3858673 chr12 63320335 C A 3.10E-05 Glycosylated haemoglobin levels PPM1H intron 17255346 rs1695022 chr12 63338172 C T 1.27E-05 Multiple complex diseases / / 17554300 rs10877932 chr12 63342921 C A 6.37E-05 Diabetes Mellitus / / pha003060 rs1081780 chr12 63344993 C T 5.19E-05 Serum metabolites / / 19043545 rs1081780 chr12 63344993 C T 2.48E-04 Depression (quantitative trait) / / 20800221 rs699619 chr12 63379516 C T 9.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs771976 chr12 63388856 G C 3.51E-04 Fibrinogen / / 17255346 rs12826619 chr12 63392391 G C 1.05E-05 Asthma / / 23181788 rs771961 chr12 63400709 G T 8.57E-06 stroke (ischemic) / / 17434096 rs1463821 chr12 63402875 G C 3.50E-04 Multiple complex diseases / / 17554300 rs1273109 chr12 63411765 A G 8.57E-06 stroke (ischemic) / / 17434096 rs10506458 chr12 63445092 G A 5.00E-06 Hemostatic factors and hematological phenotypes / / 17903294 rs10877945 chr12 63445962 G A 7.00E-06 Obesity-related traits / / 23251661 rs10877950 chr12 63474964 C T 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4547160 chr12 63503650 T G 2.24E-04 Type 2 diabetes / / 17463246 rs4547160 chr12 63503650 T G 2.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs10877958 chr12 63503952 A C 9.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs11174782 chr12 63517050 C T 6.41E-04 Smoking initiation / / 24665060 rs11174783 chr12 63517395 C T 3.14E-04 Smoking initiation / / 24665060 rs1587097 chr12 63530245 C T 6.18E-05 Major depressive disorder / / 19107115 rs7972829 chr12 63530607 A G 9.31E-05 Lung adenocarcinoma / / 19836008 rs10747983 chr12 63538458 G A 7.48E-05 Lung adenocarcinoma / / 19836008 rs2738250 chr12 63549593 G C 9.98E-04 Insulin resistance / / 21901158 rs1390033 chr12 63603528 G A 6.80E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10878007 chr12 63613005 A C 5.80E-04 Type 2 diabetes / / 17463246 rs17099183 chr12 63626692 C T 3.75E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs7962346 chr12 63666496 T C 3.85E-04 Sarcoidosis / / 21540310 rs1909327 chr12 63673968 C T 7.40E-05 Glaucoma (primary open-angle) / / 20835238 rs1146110 chr12 63699092 G A 6.62E-05 Tuberculosis / / 20694014 rs7295507 chr12 63789475 T G 8.07E-05 Erythrocyte counts / / pha003099 rs11175040 chr12 63947694 C T 4.36E-05 Insulin-related traits / / pha002901 rs12811912 chr12 64051877 T C 3.72E-05 Waist-Hip Ratio DPY19L2 intron pha003029 rs11175120 chr12 64084267 T C 8.51E-04 Multiple complex diseases / / 17554300 rs11175121 chr12 64084334 A G 4.52E-04 Multiple complex diseases / / 17554300 rs11175122 chr12 64084447 G A 2.41E-04 Multiple complex diseases / / 17554300 rs949956 chr12 64188450 T C 2.48E-04 Blood pressure TMEM5 intron 17255346 rs10506464 chr12 64209976 C T 5.84E-04 Multiple complex diseases / / 17554300 rs10506464 chr12 64209976 C T 8.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10506464 chr12 64209976 C T 1.90E-05 Urinary metabolites / / 21572414 rs10506464 chr12 64209976 C T 1.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs10506463 chr12 64210316 A G 4.09E-04 Insulin resistance / / 21901158 rs12578452 chr12 64210746 G A 2.06E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs4497499 chr12 64213103 T C 5.02E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs4497499 chr12 64213103 T C 8.14E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs7136130 chr12 64232082 T C 1.90E-05 Urinary metabolites / / 21572414 rs17099873 chr12 64240002 A G 1.00E-04 Prostate cancer SRGAP1 intron 21743057 rs17099873 chr12 64240002 A G 2.46E-05 Glucose levels SRGAP1 intron pha003061 rs11837218 chr12 64253778 T A 1.00E-04 Prostate cancer SRGAP1 intron 21743057 rs17099879 chr12 64257969 T C 1.00E-04 Prostate cancer SRGAP1 intron 21743057 rs17099886 chr12 64281052 T C 3.40E-05 Response to mTOR inhibitor (rapamycin) SRGAP1 intron 24009623 rs17099889 chr12 64281973 T C 2.89E-05 Glucose levels SRGAP1 intron pha003061 rs4346062 chr12 64284283 A G 1.63E-06 Glucose levels SRGAP1 intron pha003061 rs1989584 chr12 64333212 G T 9.64E-06 Systolic blood pressure in sickle cell anemia SRGAP1 intron 24058526 rs17099949 chr12 64336805 C T 2.37E-05 Blood Pressure SRGAP1 intron pha003039 rs17099949 chr12 64336805 C T 5.87E-05 HDL cholesterol SRGAP1 intron pha003074 rs1947504 chr12 64361462 T C 6.41E-04 Insulin resistance SRGAP1 intron 21901158 rs11175219 chr12 64362719 C T 1.06E-05 Attention deficit hyperactivity disorder SRGAP1 intron 22420046 rs6581515 chr12 64379443 A G 6.05E-04 Insulin resistance SRGAP1 intron 21901158 rs1162789 chr12 64449908 C T 4.76E-05 Body Mass Index SRGAP1 intron pha003014 rs1827073 chr12 64458201 A C 5.12E-04 Smoking initiation SRGAP1 intron 24665060 rs2279740 chr12 64586309 G A 4.71E-05 Blood Pressure / / pha003043 rs12581277 chr12 64597327 T C 8.51E-04 Alcohol dependence C12orf66 intron 21314694 rs790007 chr12 64604793 T C 1.77E-05 Response to cytidine analogues (gemcitabine) C12orf66 intron 24483146 rs790007 chr12 64604793 T C 6.42E-04 Response to cytadine analogues (cytosine arabinoside) C12orf66 intron 24483146 rs790006 chr12 64606439 C T 5.01E-04 Response to cytadine analogues (cytosine arabinoside) C12orf66 intron 24483146 rs790006 chr12 64606439 C T 8.00E-06 Response to cytidine analogues (gemcitabine) C12orf66 intron 24483146 rs812590 chr12 64607482 C A 1.16E-05 Response to cytidine analogues (gemcitabine) C12orf66 intron 24483146 rs812590 chr12 64607482 C A 3.24E-04 Response to cytadine analogues (cytosine arabinoside) C12orf66 intron 24483146 rs10878126 chr12 64644711 G T 5.96E-04 Myopia (pathological) / / 21095009 rs4628780 chr12 64652610 G A 3.54E-05 Cardiovascular disease / / pha003065 rs7133188 chr12 64711766 C T 0.000016 Major depressive disorder C12orf56 intron 22915352 rs1865801 chr12 64717742 T C 0.000000135 Major depressive disorder age at onset<25 C12orf56 intron 22915352 rs1865801 chr12 64717742 T C 0.00000149 Major depressive disorder age at onset<20 C12orf56 intron 22915352 rs1865801 chr12 64717742 T C 0.0000929 Major depressive disorder C12orf56 intron 22915352 rs7487873 chr12 64727456 A C 5.00E-06 Antibody status in Tripanosoma cruzi seropositivity C12orf56 intron 24324551 rs10878150 chr12 64728921 G C 9.77E-06 Antibody status in Tripanosoma cruzi seropositivity C12orf56 intron 24324551 rs6581543 chr12 64729745 A G 8.60E-06 Antibody status in Tripanosoma cruzi seropositivity C12orf56 intron 24324551 rs10878151 chr12 64730398 G A 9.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) C12orf56 intron 23233662 rs10784404 chr12 64730506 A G 4.74E-04 Type 2 diabetes C12orf56 intron 17463246 rs10784404 chr12 64730506 A G 8.87E-05 Multiple complex diseases C12orf56 intron 17554300 rs7398603 chr12 64739642 G A 1.90E-05 Urinary metabolites C12orf56 intron 21572414 rs11175353 chr12 64747936 C A 5.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C12orf56 intron 20877124 rs10878167 chr12 64788087 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11175379 chr12 64797093 A G 7.10E-05 Personality dimensions / / 18957941 rs7961632 chr12 64797923 T C 2.30E-05 Urinary metabolites / / 21572414 rs7962498 chr12 64801863 C T 2.47E-06 Cognitive impairment induced by topiramate XPOT intron 22091778 rs6581563 chr12 64830566 C G 2.20E-05 Urinary metabolites XPOT intron 21572414 rs11837890 chr12 64863983 G T 3.75E-05 Major depressive disorder (broad) TBK1 intron 20038947 rs11829120 chr12 64870510 C A 3.97E-05 Major depressive disorder (broad) TBK1 intron 20038947 rs7303577 chr12 64874102 A C 6.37E-05 Major depressive disorder (broad) TBK1 intron 20038947 rs4075094 chr12 64877053 T A 4.24E-05 Major depressive disorder (broad) TBK1 intron 20038947 rs11175431 chr12 64928957 C T 9.55E-04 Type 2 diabetes / / 17463246 rs11175431 chr12 64928957 C T 3.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs4964110 chr12 64930823 C T 9.83E-05 Coronary heart disease / / pha003031 rs4964111 chr12 64931507 C G 2.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs11175436 chr12 64933627 C T 2.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs4964090 chr12 64944069 A G 4.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs11175457 chr12 64970096 C A 3.99E-04 Type 2 diabetes / / 17463246 rs7313765 chr12 65011980 G A 6.22E-05 Coronary heart disease RASSF3 intron pha003055 rs1245168 chr12 65017844 G T 1.79E-05 Coronary heart disease RASSF3 intron pha003055 rs2682714 chr12 65018192 T C 1.79E-05 Coronary heart disease RASSF3 intron pha003055 rs1147105 chr12 65026115 G A 1.92E-05 Coronary heart disease RASSF3 intron pha003055 rs1147107 chr12 65026342 A G 1.97E-05 Coronary heart disease RASSF3 intron pha003055 rs2682724 chr12 65034859 C T 7.36E-05 Serum metabolites RASSF3 intron 19043545 rs17100505 chr12 65038155 C T 5.99E-04 Multiple complex diseases RASSF3 intron 17554300 rs1797688 chr12 65044814 G T 7.93E-05 Coronary heart disease RASSF3 intron pha003055 rs1797679 chr12 65049191 A G 5.18E-05 Coronary heart disease RASSF3 intron pha003055 rs1270837 chr12 65054758 A C 7.93E-05 Coronary heart disease RASSF3 intron pha003055 rs150781447 chr12 65224220 C T 1.30E-16 Insulin processing and secretion TBC1D30 missense 23263489 rs17100705 chr12 65224711 C T 3.53E-05 Multiple complex diseases TBC1D30 intron 17554300 rs939876 chr12 65252118 A G 2.00E-06 Cognitive performance TBC1D30 intron 20125193 rs939875 chr12 65269047 G A 4.11E-04 Smoking quantity TBC1D30 missense 24665060 rs1144424 chr12 65280719 C T 6.38E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) FLJ41278 intron 23648065 rs1445442 chr12 65291294 G A 9.69E-04 Response to taxane treatment (placlitaxel) FLJ41278 intron 23006423 rs1144418 chr12 65293514 T G 4.00E-04 Chronic fatigue syndrome FLJ41278 intron 21912186 rs155951 chr12 65310076 G C 2.40E-05 Urinary metabolites FLJ41278 intron 21572414 rs155950 chr12 65310612 G A 6.28E-05 Glycosylated haemoglobin levels FLJ41278 intron 17255346 rs464817 chr12 65315297 T C 5.32E-05 Glycosylated haemoglobin levels FLJ41278 intron 17255346 rs10878218 chr12 65325448 G A 2.30E-05 Urinary metabolites FLJ41278 intron 21572414 rs22124 chr12 65328241 A G 8.78E-06 Glycosylated haemoglobin levels FLJ41278 intron 17255346 rs462135 chr12 65329760 G T 7.61E-06 Glycosylated haemoglobin levels FLJ41278 intron 17255346 rs465530 chr12 65330766 G T 2.07E-05 Glycosylated haemoglobin levels FLJ41278 intron 17255346 rs465530 chr12 65330766 G T 5.75E-04 Alzheimer's disease FLJ41278 intron 17998437 rs478380 chr12 65332054 C T 7.72E-06 Glycosylated haemoglobin levels FLJ41278 intron 17255346 rs478380 chr12 65332054 C T 6.48E-04 Alzheimer's disease FLJ41278 intron 17998437 rs457919 chr12 65332322 A G 7.72E-06 Glycosylated haemoglobin levels FLJ41278 intron 17255346 rs457919 chr12 65332322 A G 6.34E-04 Alzheimer's disease FLJ41278 intron 17998437 rs461829 chr12 65335717 A G 2.72E-05 Glycosylated haemoglobin levels FLJ41278 intron 17255346 rs432586 chr12 65337076 T C 2.77E-05 Glycosylated haemoglobin levels FLJ41278 intron 17255346 rs432586 chr12 65337076 T C 6.34E-04 Alzheimer's disease FLJ41278 intron 17998437 rs458890 chr12 65337237 C T 7.72E-06 Glycosylated haemoglobin levels FLJ41278 intron 17255346 rs458890 chr12 65337237 C T 6.34E-04 Alzheimer's disease FLJ41278 intron 17998437 rs462010 chr12 65338145 G A 6.39E-06 Glycosylated haemoglobin levels FLJ41278 intron 17255346 rs11175613 chr12 65378107 G T 1.36E-04 Multiple complex diseases / / 17554300 rs11175632 chr12 65433083 C T 1.50E-04 Multiple complex diseases / / 17554300 rs1446526 chr12 65446935 G A 5.01E-05 Serum metabolites WIF1 intron 19043545 rs1446527 chr12 65447037 T G 2.66E-05 Serum metabolites WIF1 intron 19043545 rs1446528 chr12 65463647 A G 2.40E-07 Hippocampal volume WIF1 intron 22504421 rs2034262 chr12 65465614 T C 2.30E-07 Hippocampal volume WIF1 intron 22504421 rs969028 chr12 65467577 G C 2.30E-07 Hippocampal volume WIF1 intron 22504421 rs1979034 chr12 65480038 G A 2.20E-07 Hippocampal volume WIF1 intron 22504421 rs1979035 chr12 65480359 A G 2.20E-07 Hippocampal volume WIF1 intron 22504421 rs11610885 chr12 65481947 C T 2.20E-07 Hippocampal volume WIF1 intron 22504421 rs17765135 chr12 65503747 C G 1.70E-07 Hippocampal volume WIF1 intron 22504421 rs4762126 chr12 65504924 T C 1.60E-07 Hippocampal volume WIF1 intron 22504421 rs10878230 chr12 65508788 T G 1.90E-07 Hippocampal volume WIF1 intron 22504421 rs7301320 chr12 65514266 T C 1.80E-07 Hippocampal volume WIF1 cds-synon 22504421 rs1155722 chr12 65523157 T C 3.50E-08 Hippocampal volume / / 22504421 rs10748016 chr12 65532745 A T 4.57E-13 Lymphocyte counts / / 22286170 rs6581612 chr12 65534624 C A 7.00E-11 Hippocampal volume / / 22504421 rs10784440 chr12 65536607 C T 4.80E-08 Hippocampal volume / / 22504421 rs1498792 chr12 65537670 T C 4.60E-08 Hippocampal volume / / 22504421 rs2047485 chr12 65538011 G A 4.60E-08 Hippocampal volume / / 22504421 rs1498793 chr12 65539422 A G 4.60E-08 Hippocampal volume / / 22504421 rs7302095 chr12 65540794 C A 4.60E-08 Hippocampal volume / / 22504421 rs7307410 chr12 65542578 C G 4.60E-08 Hippocampal volume / / 22504421 rs7138233 chr12 65542654 T C 4.60E-08 Hippocampal volume / / 22504421 rs7309669 chr12 65547821 G T 4.60E-08 Hippocampal volume / / 22504421 rs6581613 chr12 65549131 A G 5.00E-08 Hippocampal volume / / 22504421 rs7308958 chr12 65551527 T C 4.90E-08 Hippocampal volume / / 22504421 rs17177768 chr12 65552794 C T 7.10E-08 Hippocampal volume / / 22504421 rs7300703 chr12 65552861 G A 7.20E-08 Hippocampal volume / / 22504421 rs6581615 chr12 65556179 A G 7.80E-08 Hippocampal volume / / 22504421 rs7975999 chr12 65592023 T G 3.76E-05 Monocyte chemoattractant protein-1 LEMD3 intron pha003071 rs1344945 chr12 65675628 T C 1.10E-05 Hippocampal volume MSRB3 intron 22504421 rs9668269 chr12 65680026 C T 4.30E-05 Hippocampal volume MSRB3 intron 22504421 rs7306938 chr12 65687878 A G 1.20E-05 Urinary metabolites MSRB3 intron 21572414 rs11612273 chr12 65707858 A C 2.90E-05 Hippocampal volume MSRB3 intron 22504421 rs17178006 chr12 65718299 T G 5.00E-11 Hippocampal volume MSRB3 intron 22504421 rs1370938 chr12 65754242 C A 1.60E-07 Hippocampal volume MSRB3 intron 22504421 rs1370938 chr12 65754242 C A 3.14E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) MSRB3 intron 24023788 rs10878264 chr12 65759522 A G 9.59E-04 Multiple complex diseases MSRB3 intron 17554300 rs12229918 chr12 65762058 G C 2.00E-09 Primary tooth development (number of teeth) MSRB3 intron 23704328 rs12229918 chr12 65762058 G C 7.00E-14 Primary tooth development (time to first tooth eruption) MSRB3 intron 23704328 rs17824714 chr12 65764277 G A 1.30E-04 Multiple complex diseases MSRB3 intron 17554300 rs17178139 chr12 65765944 G A 1.50E-07 Hippocampal volume MSRB3 intron 22504421 rs11611334 chr12 65766282 A G 1.50E-07 Hippocampal volume MSRB3 intron 22504421 rs17765551 chr12 65776840 G A 2.54E-05 Serum metabolites MSRB3 intron 19043545 rs17765551 chr12 65776840 G A 1.00E-07 Hippocampal volume MSRB3 intron 22504421 rs10506525 chr12 65783378 T C 6.00E-09 Primary tooth development (time to first tooth eruption) MSRB3 intron 20195514 rs10506525 chr12 65783378 T C 9.00E-07 Primary tooth development (number of teeth) MSRB3 intron 20195514 rs7316273 chr12 65808126 G C 9.79E-06 Glycosylated haemoglobin levels MSRB3 intron 17255346 rs1494505 chr12 65810174 T C 1.38E-04 Glycosylated haemoglobin levels MSRB3 intron 17255346 rs1494505 chr12 65810174 T C 0.00071 Breast cancer MSRB3 intron 23555315 rs4762096 chr12 65827996 T C 1.50E-04 Glycosylated haemoglobin levels MSRB3 intron 17255346 rs3858644 chr12 65838529 C G 1.75E-05 Glycosylated haemoglobin levels MSRB3 intron 17255346 rs4762098 chr12 65839407 C T 9.91E-06 Glycosylated haemoglobin levels MSRB3 intron 17255346 rs10878279 chr12 65839958 G A 1.07E-04 Multiple complex diseases MSRB3 intron 17554300 rs10878279 chr12 65839958 G A 8.87E-05 Bipolar disorder MSRB3 intron 20451256 rs1494508 chr12 65842258 A G 1.66E-04 Glycosylated haemoglobin levels MSRB3 intron 17255346 rs1494508 chr12 65842258 A G 2.00E-06 Temperament MSRB3 intron 22832960 rs6581637 chr12 65852924 A G 1.51E-04 Multiple complex diseases MSRB3 intron 17554300 rs10784460 chr12 65863584 G A 1.30E-05 Bipolar disorder / / 19488044 rs10784460 chr12 65863584 G A 2.18E-05 Bipolar Disorder / / pha002858 rs11175790 chr12 65901393 G A 2.99E-04 Smoking quantity LOC100507065 intron 24665060 rs11175790 chr12 65901393 G A 5.69E-04 Smoking initiation LOC100507065 intron 24665060 rs11175792 chr12 65905668 T C 2.50E-04 Response to taxane treatment (placlitaxel) LOC100507065 intron 23006423 rs7300729 chr12 65912521 A C 4.86E-04 Response to taxane treatment (placlitaxel) LOC100507065 intron 23006423 rs10878294 chr12 65913907 T C 8.99E-05 Smoking initiation LOC100507065 intron 24665060 rs1532326 chr12 65917188 A G 3.21E-05 Response to taxane treatment (placlitaxel) LOC100507065 intron 23006423 rs11175799 chr12 65917502 T C 3.23E-04 Smoking initiation LOC100507065 intron 24665060 rs4417335 chr12 65961018 A G 7.10E-05 Cognitive impairment induced by topiramate LOC100507065 intron 22091778 rs4237904 chr12 65967187 T G 1.16E-07 Non-small cell lung cancer (survival) LOC100507065 intron 23704207 rs3943015 chr12 65998561 T C 6.42E-04 Body mass index LOC100507065 intron 21701565 rs7976914 chr12 66015567 C A 1.79E-07 Non-small cell lung cancer (survival) LOC100507065 intron 23704207 rs11175885 chr12 66114630 A G 3.66E-04 Diabetic nephropathy / / 21150874 rs12372185 chr12 66115224 G T 4.78E-04 Multiple complex diseases / / 17554300 rs2358944 chr12 66117558 G A 4.00E-06 Type 2 diabetes nephropathy / / 21150874 rs2358944 chr12 66117558 G A 9.48E-04 Type 2 diabetes / / 22238593 rs11612733 chr12 66156098 T C 8.40E-06 Urinary metabolites RPSAP52 intron 21572414 rs10784496 chr12 66160971 A G 3.00E-07 AB1-42 levels RPSAP52 intron 20932310 rs10878333 chr12 66167085 A G 3.65E-05 Glaucoma (primary open-angle) RPSAP52 intron 22605921 rs7134682 chr12 66168151 G T 0.0000015 Type 2 diabetes RPSAP52 intron 22885922 rs1531343 chr12 66174894 G C 4.00E-09 Type 2 diabetes RPSAP52 intron 20581827 rs1531343 chr12 66174894 G C 4.00E-09 Type 2 diabetes RPSAP52 intron 21647700 rs1531343 chr12 66174894 G C 0.00000049 Type 2 diabetes RPSAP52 intron 22885922 rs2612035 chr12 66192667 A G 0.000000003 Type 2 diabetes RPSAP52 intron 22885922 rs1870566 chr12 66212017 T C 7.00E-04 Prostate cancer RPSAP52 intron 18073375 rs1870566 chr12 66212017 T C 3.76E-04 Suicide attempts in bipolar disorder RPSAP52 intron 21423239 rs2261181 chr12 66212318 C T 0.00000011 Type 2 diabetes (males) RPSAP52 intron 22885922 rs2261181 chr12 66212318 C T 0.00013 Type 2 diabetes (females) RPSAP52 intron 22885922 rs2261181 chr12 66212318 C T 1.20E-09 Type 2 diabetes RPSAP52 intron 22885922 rs2261181 chr12 66212318 C T 4.00E-08 Type 2 diabetes RPSAP52 intron 24509480 rs2272046 chr12 66224461 A C 2.00E-21 Polycystic ovary syndrome HMGA2 intron 22885925 rs7979673 chr12 66227257 C T 7.00E-10 Height HMGA2 intron 21998595 rs11175936 chr12 66228059 A C 0.0000521 Polycystic ovary syndrome HMGA2 intron 22951595 rs11175936 chr12 66228059 A C 5.21E-05 Intracranial aneurysm HMGA2 intron 22961961 rs9668162 chr12 66268782 C G 0.000000241 Type 2 diabetes HMGA2 intron 22325160 rs17179453 chr12 66283600 T C 0.000373 Type 2 diabetes HMGA2 intron 22325160 rs12423095 chr12 66291232 T C 7.50E-04 Coronary heart disease HMGA2 intron 21966275 rs12298541 chr12 66306441 A C 3.20E-09 Height HMGA2 intron 21998595 rs12298541 chr12 66306441 A C 5.18E-06 Brain structure HMGA2 intron 22504417 rs7487625 chr12 66319996 A C 1.32E-04 Brain structure HMGA2 intron 22504417 rs10878346 chr12 66320873 G A 1.40E-05 Urinary metabolites HMGA2 intron 21572414 rs1480474 chr12 66326943 A G 9.01E-06 Brain structure HMGA2 intron 22504417 rs1156095 chr12 66327254 A G 4.49E-04 Coronary Artery Disease HMGA2 intron 17634449 rs17101923 chr12 66338202 G T 1.00E-10 Primary tooth development (number of teeth) HMGA2 intron 23704328 rs17101923 chr12 66338202 G T 6.00E-11 Primary tooth development (time to first tooth eruption) HMGA2 intron 23704328 rs10784502 chr12 66343810 C T 1.00E-12 Brain structure HMGA2 intron 22504417 rs1979440 chr12 66346624 T C 1.10E-07 Height HMGA2 intron 21998595 rs1979440 chr12 66346624 T C 8.49E-05 Brain structure HMGA2 intron 22504417 rs1351394 chr12 66351826 T C 2.00E-65 Height HMGA2 intron 20881960 rs1351394 chr12 66351826 T C 8.19E-06 Permanent tooth development HMGA2 intron 21931568 rs1351394 chr12 66351826 T C 1.60E-04 Height HMGA2 intron 22216288 rs1351394 chr12 66351826 T C 9.26E-07 Brain structure HMGA2 intron 22504417 rs1351394 chr12 66351826 T C 7.00E-32 Height HMGA2 intron 23563607 rs867633 chr12 66354911 G A 1.10E-19 Height HMGA2 intron 21194676 rs867633 chr12 66354911 G A 2.60E-13 Height HMGA2 intron 21194676 rs867633 chr12 66354911 G A 5.60E-31 Height HMGA2 intron 21194676 rs867633 chr12 66354911 G A 4.90E-08 Height HMGA2 intron 21998595 rs1042725 chr12 66358347 C T 4.46E-05 Height HMGA2 UTR-3 17255346 rs1042725 chr12 66358347 C T 1.71E-04 Type 2 diabetes HMGA2 UTR-3 17463246 rs1042725 chr12 66358347 C T 6.00E-16 Height HMGA2 UTR-3 17767157 rs1042725 chr12 66358347 C T 3.00E-20 Height HMGA2 UTR-3 18391950 rs1042725 chr12 66358347 C T 3.00E-18 Height HMGA2 UTR-3 18391952 rs1042725 chr12 66358347 C T 6.28E-05 Height HMGA2 UTR-3 19570815 rs1042725 chr12 66358347 C T 5.21E-05 Height HMGA2 UTR-3 22216288 rs1042725 chr12 66358347 C T 2.70E-06 Brain structure HMGA2 UTR-3 22504417 rs1042725 chr12 66358347 C T 3.00E-10 Head circumference (infant) HMGA2 UTR-3 22504419 rs1042725 chr12 66358347 C T 1.00E-19 Birth weight HMGA2 UTR-3 23202124 rs8756 chr12 66359752 C A 2.00E-16 Height HMGA2 UTR-3 18391951 rs8756 chr12 66359752 C A 5.00E-14 Height HMGA2 UTR-3 19343178 rs8756 chr12 66359752 C A 6.00E-05 Height HMGA2 UTR-3 19570815 rs8756 chr12 66359752 C A 4.00E-07 Height HMGA2 UTR-3 20397748 rs8756 chr12 66359752 C A 7.22E-07 Brain structure HMGA2 UTR-3 22504417 rs7970350 chr12 66360164 C T 2.22E-07 Adiposity HMGA2 nearGene-3 19557161 rs7968902 chr12 66363070 T G 2.75E-05 Brain structure / / 22504417 rs12422370 chr12 66363539 C G 1.70E-05 Urinary metabolites / / 21572414 rs12422370 chr12 66363539 C G 7.26E-04 Brain structure / / 22504417 rs12424086 chr12 66364509 T C 4.00E-06 Primary tooth development (number of teeth) / / 20195514 rs12424086 chr12 66364509 T C 8.00E-06 Primary tooth development (time to first tooth eruption) / / 20195514 rs12424086 chr12 66364509 T C 2.00E-12 Permanent tooth development / / 21931568 rs12424086 chr12 66364509 T C 8.95E-04 Brain structure / / 22504417 rs7968682 chr12 66371880 G T 1.29E-04 Height / / 17255346 rs7968682 chr12 66371880 G T 8.73E-04 Type 2 diabetes / / 17463246 rs7968682 chr12 66371880 G T 7.00E-08 Height / / 17767157 rs7968682 chr12 66371880 G T 4.00E-10 Height / / 22021425 rs7968682 chr12 66371880 G T 3.96E-06 Brain structure / / 22504417 rs7966895 chr12 66383843 A G 2.54E-05 Brain structure / / 22504417 rs10400419 chr12 66389968 T C 4.61E-05 Height / / 17255346 rs10400419 chr12 66389968 T C 9.81E-07 Brain structure / / 22504417 rs10400419 chr12 66389968 T C 2.00E-07 Axial length / / 24144296 rs1993997 chr12 66393817 T C 9.62E-05 Postoperative ventricular dysfunction / / 21980348 rs4026608 chr12 66394664 C T 2.00E-09 Aortic root size / / 19584346 rs922628 chr12 66394835 A G 3.61E-05 Postoperative ventricular dysfunction / / 21980348 rs12230818 chr12 66437493 A G 8.13E-05 IgE levels / / 22075330 rs11176015 chr12 66441684 C T 8.54E-05 IgE levels / / 22075330 rs11176016 chr12 66442261 C T 7.40E-05 IgE levels / / 22075330 rs7975189 chr12 66446108 C G 7.24E-05 IgE levels / / 22075330 rs11836463 chr12 66449972 C A 6.48E-05 IgE levels / / 22075330 rs11176057 chr12 66537283 C A 2.30E-05 Response to Vitamin E supplementation TMBIM4 intron 22437554 rs1168745 chr12 66556960 G A 6.21E-05 IgE levels in asthmatics TMBIM4 intron 23967269 rs1732887 chr12 66581616 G A 1.00E-04 Prostate cancer IRAK3 nearGene-5 21743057 rs4762088 chr12 66591582 G C 4.05E-04 Type 2 diabetes IRAK3 intron 17463246 rs17767298 chr12 66593241 A G 1.80E-04 Type 2 diabetes IRAK3 intron 17463246 rs1168757 chr12 66594116 T C 1.10E-05 Urinary metabolites IRAK3 intron 21572414 rs1168758 chr12 66594134 C G 4.00E-06 Urinary metabolites IRAK3 intron 21572414 rs1152888 chr12 66605228 A G 1.27E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IRAK3 missense 20877124 rs1152888 chr12 66605228 A G 5.20E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IRAK3 missense 20877124 rs17854945 chr12 66605228 A AA,AG 1.27E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IRAK3 missense 20877124 rs17854945 chr12 66605228 A AA,AG 5.20E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IRAK3 missense 20877124 rs1821777 chr12 66606228 C T 6.55E-04 Oral cancers (chewing tobacco related) IRAK3 intron 22503698 rs17826057 chr12 66633164 G A 6.00E-04 Amyotrophic lateral sclerosis (sporadic) IRAK3 intron 24529757 rs17826057 chr12 66633164 G A 3.00E-07 Smooth-surface caries IRAK3 intron 24556642 rs17826057 chr12 66633164 G A 3.45E-07 Smooth-surface caries IRAK3 intron 24556642 rs1152912 chr12 66633908 A G 5.05E-04 Amyotrophic Lateral Sclerosis IRAK3 intron 17827064 rs7135413 chr12 66641975 A G 1.42E-06 Lipid levels IRAK3 UTR-3 19913121 rs11541076 chr12 66648328 A T 5.80E-04 Smoking quantity IRAK3 UTR-3 24665060 rs11176107 chr12 66654437 C T 2.94E-04 Alzheimer's disease / / 24755620 rs12307857 chr12 66655839 T C 3.61E-04 Alzheimer's disease / / 24755620 rs289068 chr12 66662003 C T 5.06E-04 Menopause (age at onset) / / 22267201 rs11176137 chr12 66701001 A G 8.52E-04 Suicide attempts in bipolar disorder HELB intron 21423239 rs11176138 chr12 66701577 G T 7.49E-04 Suicide attempts in bipolar disorder HELB intron 21423239 rs7315366 chr12 66701882 T G 9.44E-04 Suicide attempts in bipolar disorder HELB intron 21423239 rs7964860 chr12 66702158 A T 9.48E-04 Suicide attempts in bipolar disorder HELB intron 21423239 rs10784524 chr12 66704816 G A 8.27E-04 Suicide attempts in bipolar disorder HELB intron 21423239 rs7316880 chr12 66706026 G A 9.25E-04 Suicide attempts in bipolar disorder HELB intron 21423239 rs7978354 chr12 66706748 T G 8.62E-04 Suicide attempts in bipolar disorder HELB intron 21423239 rs7133479 chr12 66708138 T A 8.38E-04 Suicide attempts in bipolar disorder HELB intron 21423239 rs10748038 chr12 66709353 T C 8.08E-04 Suicide attempts in bipolar disorder HELB intron 21423239 rs1168357 chr12 66749879 T C 2.40E-07 Chronic kidney disease GRIP1 intron 22479191 rs1168330 chr12 66763167 A G 1.50E-04 Type 2 diabetes and 6 quantitative traits GRIP1 intron 17848626 rs1472314 chr12 66788838 C G 6.20E-06 Urinary metabolites GRIP1 intron 21572414 rs10748045 chr12 66816139 A G 1.21E-05 Suicidal ideation GRIP1 intron 20877300 rs10748045 chr12 66816139 A G 1.00E-06 Suicidal ideation in depression or bipolar disorder GRIP1 intron 24964207 rs1038923 chr12 66849408 T C 5.98E-05 Response to hepatitis C treatment GRIP1 intron 19684573 rs952562 chr12 66851444 G A 3.31E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GRIP1 intron 20877124 rs7952846 chr12 66854354 C T 2.36E-05 Response to hepatitis C treatment GRIP1 intron 19684573 rs1565730 chr12 66857210 T C 6.46E-04 Amyotrophic Lateral Sclerosis GRIP1 intron 17827064 rs4913307 chr12 66864291 T C 9.44E-05 Response to hepatitis C treatment GRIP1 intron 19684573 rs7487758 chr12 66879842 C T 7.19E-05 Response to hepatitis C treatment GRIP1 intron 19684573 rs12312548 chr12 66889555 A G 1.09E-05 Cognitive impairment induced by topiramate GRIP1 intron 22091778 rs12312548 chr12 66889555 A G 7.03E-05 Platelet counts GRIP1 intron pha003100 rs17102580 chr12 66902873 A G 2.93E-04 Smoking initiation GRIP1 intron 24665060 rs7316113 chr12 66903072 T C 5.36E-04 Type 2 diabetes GRIP1 intron 17463246 rs7316113 chr12 66903072 T C 3.28E-05 Smoking initiation GRIP1 intron 24665060 rs7956611 chr12 66904523 T C 2.00E-06 Smoking initiation GRIP1 intron 24665060 rs7973560 chr12 66905383 A G 5.07E-05 Smoking initiation GRIP1 intron 24665060 rs7973654 chr12 66905405 A T 2.90E-04 Type 2 diabetes GRIP1 intron 17463246 rs7973654 chr12 66905405 A T 6.22E-05 Smoking initiation GRIP1 intron 24665060 rs12316942 chr12 66909389 C T 4.35E-05 Smoking initiation GRIP1 intron 24665060 rs6581701 chr12 66910539 C T 2.26E-04 Smoking initiation GRIP1 intron 24665060 rs11838180 chr12 66911771 G T 1.53E-04 Smoking initiation GRIP1 intron 24665060 rs7138741 chr12 66913729 C A 3.98E-05 Smoking initiation GRIP1 intron 24665060 rs35912619 chr12 66921777 A C 5.21E-04 Smoking initiation GRIP1 intron 24665060 rs10878443 chr12 66926459 G T 6.63E-05 Smoking initiation GRIP1 intron 24665060 rs11833142 chr12 66929469 C T 3.02E-04 Type 2 diabetes GRIP1 intron 17463246 rs11833142 chr12 66929469 C T 2.84E-05 Smoking initiation GRIP1 intron 24665060 rs7131852 chr12 66929800 C T 2.40E-04 Smoking initiation GRIP1 intron 24665060 rs903088 chr12 66935080 G A 6.74E-05 Smoking initiation GRIP1 intron 24665060 rs903087 chr12 66935120 G C 5.94E-05 Smoking initiation GRIP1 intron 24665060 rs10748052 chr12 66938636 T C 1.37E-04 Smoking initiation GRIP1 intron 24665060 rs10748052 chr12 66938636 T C 3.75E-04 Myocardial Infarction GRIP1 intron pha002883 rs7971899 chr12 66940047 A C 5.04E-04 Smoking initiation GRIP1 intron 24665060 rs10748053 chr12 66944945 G A 8.18E-04 Substance dependence GRIP1 intron 21818250 rs10878457 chr12 66982091 G A 1.80E-04 Birth weight GRIP1 intron 17255346 rs12314237 chr12 66985226 A G 2.57E-04 Birth weight GRIP1 intron 17255346 rs7968118 chr12 66995054 T C 6.43E-05 Serum metabolites GRIP1 intron 19043545 rs7953305 chr12 66995156 C G 6.18E-05 Serum metabolites GRIP1 intron 19043545 rs4486703 chr12 67017230 T C 8.37E-05 Height GRIP1 intron pha003010 rs4486703 chr12 67017230 T C 3.59E-05 Height GRIP1 intron pha003011 rs10878473 chr12 67021637 C A 9.81E-04 Alzheimer's disease GRIP1 intron 22005930 rs6581709 chr12 67040543 T G 4.38E-04 Myocardial Infarction GRIP1 intron pha002873 rs11176385 chr12 67091550 G A 5.46E-05 Height / / pha003011 rs11176397 chr12 67110966 C G 6.08E-04 Type 2 diabetes / / 17463246 rs2127535 chr12 67134174 C G 2.13E-04 Acne (severe) / / 24927181 rs2870913 chr12 67135759 A G 3.53E-05 Acne (severe) / / 24927181 rs7961471 chr12 67136166 T C 4.96E-07 Amyotrophic lateral sclerosis / / 23624525 rs10784582 chr12 67149443 C T 5.35E-04 Parkinson's disease / / 16252231 rs10878506 chr12 67161779 G A 1.83E-06 Amyotrophic lateral sclerosis / / 23624525 rs10878506 chr12 67161779 G A 2.58E-05 Coronary heart disease / / pha003030 rs2046065 chr12 67172213 G A 8.46E-05 Cognitive test performance / / 20125193 rs2046065 chr12 67172213 G A 3.54E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs4913499 chr12 67187320 G A 5.62E-04 Type 2 diabetes / / 17463246 rs7957244 chr12 67207630 G A 5.72E-04 Tourette syndrome / / 22889924 rs1480011 chr12 67213725 A G 7.19E-09 Metabolite levels / / 23281178 rs1351329 chr12 67215122 C T 6.57E-04 Response to alcohol consumption (flushing response) / / 24277619 rs11176436 chr12 67215697 T C 1.19E-04 Multiple complex diseases / / 17554300 rs11176439 chr12 67219478 G T 6.57E-04 Response to alcohol consumption (flushing response) / / 24277619 rs11176443 chr12 67233434 A G 1.13E-04 Multiple complex diseases / / 17554300 rs11176449 chr12 67241653 T C 7.48E-05 Multiple complex diseases / / 17554300 rs905697 chr12 67245090 C T 2.64E-05 Neutrophil count / / pha003095 rs7960495 chr12 67256696 T A 1.50E-05 Urinary metabolites / / 21572414 rs12319870 chr12 67257435 G A 6.55E-06 Neutrophil count / / pha003095 rs11176466 chr12 67261845 T A 1.98E-04 Multiple complex diseases / / 17554300 rs12820694 chr12 67264001 G A 5.18E-04 Type 2 diabetes / / 17463246 rs12827976 chr12 67273785 G T 7.02E-05 Diabetic nephropathy / / 21150874 rs17103027 chr12 67276862 T C 5.97E-04 Multiple complex diseases / / 17554300 rs2464269 chr12 67279004 C T 2.20E-04 Multiple complex diseases / / 17554300 rs1504316 chr12 67288719 G A 5.49E-05 Multiple complex diseases / / 17554300 rs983665 chr12 67289743 T C 1.21E-05 Cortisol secretion,in saliva / / 21316860 rs3924008 chr12 67291485 C T 7.96E-04 Multiple complex diseases / / 17554300 rs1001408 chr12 67292288 T C 2.01E-04 Multiple complex diseases / / 17554300 rs924822 chr12 67294461 G T 1.82E-05 Cortisol secretion,in saliva / / 21316860 rs2904532 chr12 67296044 A G 4.13E-04 Diabetic nephropathy / / 21150874 rs2904532 chr12 67296044 A G 7.21E-05 Femoral neck bone geometry / / 22087292 rs2904532 chr12 67296044 A G 8.17E-04 Type 2 diabetes / / 22238593 rs11176482 chr12 67296547 T C 4.79E-05 Diabetic nephropathy / / 21150874 rs11176482 chr12 67296547 T C 6.89E-05 Femoral neck bone geometry / / 22087292 rs11176482 chr12 67296547 T C 7.08E-04 Type 2 diabetes / / 22238593 rs10506514 chr12 67296924 A G 6.51E-05 Femoral neck bone geometry / / 22087292 rs1875831 chr12 67299064 T C 1.86E-04 Type 2 diabetes / / 22238593 rs1566827 chr12 67302012 A G 5.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs6581722 chr12 67302758 A C 7.75E-05 Hemoglobin / / pha003098 rs6581722 chr12 67302758 A C 7.51E-05 Erythrocyte counts / / pha003099 rs17836565 chr12 67303411 A T 1.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs7486333 chr12 67304136 A G 2.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs12227383 chr12 67306526 T G 5.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs17836569 chr12 67308955 A T 2.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs12422377 chr12 67313966 C T 1.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs12581024 chr12 67320618 A C 4.60E-05 Femoral neck bone geometry / / 22087292 rs12230530 chr12 67325495 T C 1.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs1316645 chr12 67328430 T C 5.89E-05 Femoral neck bone geometry / / 22087292 rs10784600 chr12 67336812 G A 6.75E-05 Cognitive test performance / / 20125193 rs10784600 chr12 67336812 G A 4.85E-04 Hemoglobin concentration / / 20534544 rs969845 chr12 67381287 A G 7.22E-05 Longevity / / 21612516 rs11176527 chr12 67396219 G A 3.75E-04 Suicide attempts in bipolar disorder / / 21041247 rs11176528 chr12 67397789 T C 4.24E-05 Cognitive performance / / 19734545 rs11176528 chr12 67397789 T C 2.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs17103154 chr12 67398938 A G 4.06E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11176534 chr12 67405493 C T 2.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs992738 chr12 67406626 C T 2.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs10506540 chr12 67413097 G A,C,T 2.20E-05 Blood Phenotypes / / 17903294 rs12369132 chr12 67413187 A G 2.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs7953084 chr12 67413793 C A 2.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs905699 chr12 67418307 C T 3.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs905699 chr12 67418307 C T 2.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs17103210 chr12 67419396 T A 2.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs6581729 chr12 67419781 G A 2.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs11176539 chr12 67420332 G C 2.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs11176540 chr12 67422181 T G 2.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs11176545 chr12 67423297 T A 2.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs7955793 chr12 67432656 G A 2.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs774380 chr12 67439199 C T 7.54E-04 Type 2 diabetes / / 17463246 rs774380 chr12 67439199 C T 4.38E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs774381 chr12 67440088 G A 1.60E-05 Urinary metabolites / / 21572414 rs17781082 chr12 67476327 C T 5.52E-06 Paclitaxel-induced neuropathy / / 23776197 rs17781082 chr12 67476327 C T 9.31E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs12315969 chr12 67498530 A G 7.42E-06 Lung adenocarcinoma / / 19836008 rs4913526 chr12 67501987 C T 2.27E-05 Lung adenocarcinoma / / 19836008 rs10878563 chr12 67510419 G A 1.10E-05 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia / / 24039173 rs10878566 chr12 67518301 A G 8.07E-05 Lung adenocarcinoma / / 19836008 rs11176588 chr12 67521658 T C 4.80E-04 Multiple complex diseases / / 17554300 rs10878569 chr12 67523344 C T 8.09E-04 Aortic root size / / 21223598 rs10748069 chr12 67527018 C A 5.04E-05 Waist-Hip Ratio / / pha003029 rs4603385 chr12 67530664 C A,T 4.17E-05 Waist-Hip Ratio / / pha003029 rs4913530 chr12 67531212 T C 5.15E-05 Multiple complex diseases / / 17554300 rs2917849 chr12 67599863 A G 0.00000479 Antisocial behavior / / 23077488 rs11176629 chr12 67601182 G T 0.00000477 Antisocial behavior / / 23077488 rs1657978 chr12 67603681 C T 0.00000478 Antisocial behavior / / 23077488 rs775313 chr12 67612129 G A 0.00000479 Antisocial behavior / / 23077488 rs1082714 chr12 67628831 C T 5.00E-06 Hippocampal atrophy / / 19668339 rs17781645 chr12 67672870 A G 3.25E-04 Suicide attempts in bipolar disorder CAND1 intron 21423239 rs11176678 chr12 67705187 A G 8.30E-05 Non-alcoholic fatty liver disease histology (other) CAND1 intron 20708005 rs1066387 chr12 67715505 A G 8.30E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs17781793 chr12 67739929 A G 9.41E-04 Endometrial cancer / / 24096698 rs983630 chr12 67740254 A G 8.30E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10506545 chr12 67764836 C T 8.30E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs17103748 chr12 67778823 G A 8.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs10506546 chr12 67780305 T G 5.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs17103758 chr12 67781280 T C 4.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs11176716 chr12 67786770 G A 5.13E-04 Multiple complex diseases / / 17554300 rs4913322 chr12 67796170 G A 9.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs12300012 chr12 67810570 A G 0.000409 Salmonella-induced pyroptosis / / 22837397 rs11176729 chr12 67811807 C T 7.40E-05 Parkinson's disease (age of onset) / / 19772629 rs10878616 chr12 67834137 C T 9.70E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1152881 chr12 67835533 A G 7.78E-05 Suicide attempts in bipolar disorder / / 21423239 rs1161108 chr12 67839839 A G 1.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs1161107 chr12 67840329 C A 9.84E-05 Suicide attempts in bipolar disorder / / 21423239 rs10506549 chr12 67844999 C T 7.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs1882282 chr12 67846129 T A 6.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs1161098 chr12 67847460 G A 1.90E-05 Urinary metabolites / / 21572414 rs17103902 chr12 67904497 G A 2.35E-05 Multiple complex diseases / / 17554300 rs17103906 chr12 67904963 G A 3.80E-05 Cognitive performance / / 19734545 rs10506554 chr12 67908999 G A 5.43E-05 Alzheimer's disease (late onset) / / 21379329 rs4913250 chr12 67928224 C T 6.84E-05 Parkinson's disease LOC100507175 intron 21812969 rs7133043 chr12 67940645 A G 2.67E-04 Multiple complex diseases LOC100507175 intron 17554300 rs7133043 chr12 67940645 A G 1.83E-05 Telomere length LOC100507175 intron 20139977 rs11176782 chr12 67951266 G A 5.98E-04 Multiple complex diseases LOC100507175 intron 17554300 rs2700559 chr12 67954197 C T 8.28E-05 Body Fat Distribution LOC100507175 intron pha003017 rs10878630 chr12 67958700 G A 1.10E-05 Osteoarthritis (hip) LOC100507175 intron 23989986 rs2700143 chr12 67987187 G T 4.55E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2127547 chr12 67989318 C T 2.30E-05 Urinary metabolites / / 21572414 rs2127546 chr12 67989361 C T 2.70E-05 Urinary metabolites / / 21572414 rs2700131 chr12 67991944 A T 9.60E-04 Alzheimer's disease / / 17998437 rs1731549 chr12 67993565 A G 2.40E-05 Urinary metabolites / / 21572414 rs17801826 chr12 67996644 C T 1.93E-04 Spine bone size / / 23207799 rs2700104 chr12 68005058 T G 2.55E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1480065 chr12 68009487 G A 3.43E-05 Tunica Media / / pha003036 rs6581768 chr12 68077188 A G 3.00E-07 Chronic kidney disease / / 21931561 rs1993974 chr12 68104481 G A 2.12E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs17104382 chr12 68183273 C T 1.44E-04 HIV-1 viral setpoint / / 17641165 rs10878660 chr12 68189227 C T 8.59E-05 Post-operative nausea and vomiting / / 21694509 rs12425479 chr12 68194869 C T 2.10E-05 Urinary metabolites / / 21572414 rs2870793 chr12 68198358 C T 2.10E-05 Urinary metabolites / / 21572414 rs6581778 chr12 68228170 A T 4.36E-04 Alzheimer's disease / / 17998437 rs17625725 chr12 68235299 T A 8.94E-05 Smoking quantity / / 24665060 rs7974355 chr12 68274112 G A 6.64E-04 Response to alcohol consumption (flushing response) / / 24277619 rs4103248 chr12 68275317 A G 4.68E-04 Response to alcohol consumption (flushing response) / / 24277619 rs11176927 chr12 68287318 C T 5.57E-04 Multiple complex diseases / / 17554300 rs7959346 chr12 68287907 C T 7.42E-04 Multiple complex diseases / / 17554300 rs7139230 chr12 68288578 A T 8.37E-04 Multiple complex diseases / / 17554300 rs7301138 chr12 68293351 T C 9.30E-04 Multiple complex diseases / / 17554300 rs7965673 chr12 68301869 C G 5.51E-04 Smoking cessation / / 24665060 rs2908764 chr12 68312016 A G 2.79E-05 Hypertension (essential hypertension) / / 22184326 rs2930120 chr12 68313812 A G 2.03E-05 Hypertension (essential hypertension) / / 22184326 rs11176946 chr12 68314021 C T 7.98E-04 Multiple complex diseases / / 17554300 rs1351768 chr12 68315559 T C 1.80E-05 Urinary metabolites / / 21572414 rs2160243 chr12 68315996 G A 3.00E-05 Hypertension (essential hypertension) / / 22184326 rs4913372 chr12 68324859 C T 6.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10878698 chr12 68328689 G A 7.94E-04 Tourette syndrome / / 22889924 rs2870807 chr12 68335802 C T 1.09E-04 Type 2 diabetes / / 17846124 rs7312407 chr12 68340257 C T 1.03E-04 Type 2 diabetes / / 17846124 rs7980416 chr12 68340822 C T 6.37E-05 Neuroblastoma / / pha002895 rs10492202 chr12 68341738 G A 3.48E-05 Type 2 diabetes / / 17846124 rs10492202 chr12 68341738 G A 3.50E-05 Type 2 diabetes / / 21647700 rs10784663 chr12 68376539 A T 4.00E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs2906853 chr12 68386012 G T 8.07E-04 Multiple complex diseases / / 17554300 rs10878723 chr12 68399273 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12422954 chr12 68401391 A T 9.26E-05 Bipolar disorder / / 22925353 rs7952790 chr12 68406452 C T 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs721793 chr12 68434014 C T 0.0000228 Alcohol craving with or without dependence / / 22481050 rs10748094 chr12 68435316 T C 5.25E-04 Multiple complex diseases / / 17554300 rs988606 chr12 68481411 A G 4.08E-04 Type 2 diabetes / / 17463246 rs10735944 chr12 68489993 T C 2.83E-04 Type 2 diabetes / / 17463246 rs2160439 chr12 68491457 A C 2.88E-04 Type 2 diabetes / / 17463246 rs2111056 chr12 68491597 T A 7.88E-04 Type 2 diabetes / / 17463246 rs2111056 chr12 68491597 T A 4.48E-04 Multiple complex diseases / / 17554300 rs7134599 chr12 68500075 G A 1.00E-16 Ulcerative colitis / / 21297633 rs7134599 chr12 68500075 G A 0.000088 Height (Pygmy height) / / 22570615 rs7134599 chr12 68500075 G A 9.00E-32 Inflammatory bowel disease / / 23128233 rs1558744 chr12 68504592 G A 3.00E-12 Ulcerative colitis / / 19122664 rs1558744 chr12 68504592 G A 4.00E-12 Ulcerative colitis / / 20228799 rs1558744 chr12 68504592 G A 9.03E-05 Ulcerative colitis,refractory / / 20848476 rs1558744 chr12 68504592 G A 4.20E-12 Multiple sclerosis / / 22190364 rs10784677 chr12 68508990 G A 7.10E-05 Response to statin therapy / / 20339536 rs10784678 chr12 68509094 T C 1.60E-05 Response to statin therapy / / 20339536 rs12321565 chr12 68532077 T C 5.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs12308338 chr12 68569191 G C 5.17E-05 Bipolar disorder and schizophrenia / / 20889312 rs10784688 chr12 68580569 T C 0.000697 Height (Pygmy height) / / 22570615 rs12309496 chr12 68582271 A T 6.16E-05 Bipolar disorder and schizophrenia / / 20889312 rs2870950 chr12 68584706 G A 1.20E-04 Obesity-related traits / / 17903300 rs10492197 chr12 68585607 G A 1.00E-04 Obesity-related traits / / 17903300 rs971545 chr12 68591685 A G 6.25E-04 Tourette syndrome / / 22889924 rs2870946 chr12 68596661 T C 5.00E-07 Ulcerative colitis IL26 intron 19122664 rs11177102 chr12 68598482 G A 0.0000379 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) IL26 intron 23233654 rs11177102 chr12 68598482 G A 3.79E-05 Methotrexate clearance (acute lymphoblastic leukemia) IL26 intron 23233662 rs2068016 chr12 68620241 C T 4.07E-05 Body Mass Index / / pha003015 rs10878795 chr12 68624858 T A 2.21E-04 Multiple complex diseases / / 17554300 rs734871 chr12 68630788 G A 4.16E-04 Type 2 diabetes / / 17463246 rs4913281 chr12 68636667 T C 2.02E-05 Body Mass Index / / pha003007 rs4913281 chr12 68636667 T C 5.67E-06 Body Mass Index / / pha003015 rs1026785 chr12 68651834 G T 4.66E-05 Body Mass Index / / pha003015 rs5029846 chr12 68652441 G A 5.92E-06 Blood Pressure / / pha003049 rs7954576 chr12 68654780 A G 8.52E-05 Body Mass Index / / pha003015 rs4913287 chr12 68658270 C T 1.84E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs10506557 chr12 68667462 A C 3.34E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs11832463 chr12 68668533 C T 6.81E-04 Aortic root size / / 21223598 rs11177152 chr12 68670718 A G 5.68E-04 Multiple complex diseases / / 17554300 rs4913289 chr12 68673594 A G 5.50E-06 Urinary metabolites / / 21572414 rs7138823 chr12 68676905 A G 5.10E-06 Urinary metabolites / / 21572414 rs1038164 chr12 68698086 A G 8.23E-05 Fibrinogen MDM1 intron 17255346 rs2306393 chr12 68708761 C T 3.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) MDM1 missense 21239504 rs2870812 chr12 68719216 G A 4.10E-06 Urinary metabolites MDM1 UTR-3 21572414 rs962976 chr12 68720627 G A 1.60E-05 Biomarkers MDM1 missense 17903293 rs962976 chr12 68720627 G A 3.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) MDM1 missense 21239504 rs7966516 chr12 68721462 A G 3.80E-06 Urinary metabolites MDM1 intron 21572414 rs3741808 chr12 68724951 G T 4.10E-06 Urinary metabolites MDM1 cds-synon 21572414 rs7302909 chr12 68730295 T A 1.90E-05 Urinary metabolites LOC100507195 intron 21572414 rs4913437 chr12 68733314 C T 5.80E-06 Urinary metabolites LOC100507195 intron 21572414 rs10878810 chr12 68736103 C T 9.97E-05 Body Mass Index LOC100507195 intron pha002896 rs1383118 chr12 68738674 T C 3.60E-06 Urinary metabolites LOC100507195 intron 21572414 rs12810375 chr12 68754727 G A 7.65E-05 Coronary heart disease LOC100507195 intron pha003056 rs11177192 chr12 68764325 C T 8.69E-04 Type 2 diabetes LOC100507195 intron 17463246 rs11177192 chr12 68764325 C T 2.84E-04 Multiple complex diseases LOC100507195 intron 17554300 rs5011574 chr12 68767127 G T 2.43E-05 Response to mTOR inhibitor (everolimus) LOC100507195 intron 24009623 rs5011574 chr12 68767127 G T 9.65E-05 Schizophrenia LOC100507195 intron 24253340 rs416350 chr12 68779413 G A 4.00E-08 Temperament (bipolar disorder) LOC100507195 intron 22365631 rs10878819 chr12 68794723 T G 3.51E-04 Multiple complex diseases LOC100507195 intron 17554300 rs1154818 chr12 68841276 G A 5.26E-04 Multiple complex diseases / / 17554300 rs1154818 chr12 68841276 G A 7.37E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10492304 chr12 68841676 C G 1.68E-04 Attention deficit hyperactivity disorder / / pha002875 rs1861933 chr12 68842405 A G 4.00E-05 Prostate cancer / / 21743057 rs1861933 chr12 68842405 A G 2.18E-04 Taste perception / / 22132133 rs11177242 chr12 68852933 A G 1.00E-04 Prostate cancer / / 21743057 rs12309411 chr12 68855234 C T 7.49E-05 Diabetes Mellitus / / pha003060 rs10878837 chr12 68873130 A G 6.69E-04 Smoking initiation / / 24665060 rs2160891 chr12 68877237 A C 3.06E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2160891 chr12 68877237 A C 8.38E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1861932 chr12 68886533 T C 5.68E-04 Coronary heart disease / / 21606135 rs1861932 chr12 68886533 T C 3.09E-04 White matter integrity / / 22425255 rs7305123 chr12 68926640 T C 1.70E-04 Endometriosis / / 21151130 rs2468406 chr12 68950671 G A 9.87E-04 Nicotine dependence / / 17158188 rs150516896 chr12 68955572 A G 4.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs114588203 chr12 68956185 C T 3.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs116075389 chr12 68957164 C T 3.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs12313946 chr12 68961584 C A 2.85E-08 Blood cell counts and other traits / / 20139978 rs12313946 chr12 68961584 C A 3.00E-08 Blood cell counts and other traits / / 20139978 rs2468411 chr12 68974606 T C 6.72E-05 Amyotrophic lateral sclerosis / / 20801717 rs12306094 chr12 68987155 G A 0.000000654 Cholesterol,total / / 23063622 rs11177321 chr12 69031913 G A 4.94E-05 Anxiety in major depressive disorder RAP1B intron 24047446 rs2920022 chr12 69040055 G A 1.90E-04 Response to antidepressants RAP1B intron 19736353 rs2920022 chr12 69040055 G A 1.00E-04 Information processing speed RAP1B intron 21130836 rs11177325 chr12 69064978 C T 3.86E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs142470451 chr12 69113390 T C 0.000046 Breast cancer NUP107 missense 23555315 rs11177355 chr12 69148522 C T 8.95E-05 Parkinson's disease SLC35E3 intron 21248740 rs12321570 chr12 69162243 T C 8.60E-04 Alcohol dependence / / 20201924 rs11177371 chr12 69177690 A T 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2088578 chr12 69198112 G A 2.48E-04 Multiple complex diseases / / 17554300 rs7315435 chr12 69284330 G A 3.99E-05 Post-operative nausea and vomiting CPM intron 21694509 rs2029774 chr12 69301287 T C 1.09E-04 Celiac disease CPM intron 23936387 rs1152937 chr12 69305458 T C 4.45E-05 IgE levels in asthmatics CPM intron 23967269 rs1565862 chr12 69311053 C T 1.32E-05 Heart Failure CPM intron pha002885 rs1195816 chr12 69331714 A G 5.30E-06 Urinary metabolites CPM intron 21572414 rs1144962 chr12 69334985 A G 1.60E-04 Alcohol dependence CPM intron 20201924 rs1144962 chr12 69334985 A G 9.00E-04 Alcohol dependence CPM intron 20201924 rs1144963 chr12 69335625 C T 2.67E-05 Blood Pressure CPM intron pha003047 rs1195812 chr12 69341025 A G 5.30E-04 Alcohol dependence CPM intron 20201924 rs10878879 chr12 69343225 A G 7.20E-06 Urinary metabolites CPM intron 21572414 rs4913477 chr12 69349868 C T 5.85E-04 Multiple complex diseases CPM intron 17554300 rs2870830 chr12 69351390 G T 4.20E-06 Urinary metabolites CPM intron 21572414 rs7313212 chr12 69356027 G A 7.09E-04 Smoking cessation CPM intron 24665060 rs9943849 chr12 69370756 C T 3.00E-06 Major depressive disorder / / 20673876 rs10878883 chr12 69375536 C T 4.99E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1908676 chr12 69394080 G A 5.70E-05 Fibrinogen / / pha003068 rs10784744 chr12 69395011 T C 1.60E-05 Glucose levels / / pha003058 rs11177448 chr12 69405820 A C 9.38E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs7970405 chr12 69412629 C G,T 9.64E-04 Multiple complex diseases / / 17554300 rs10784749 chr12 69422029 C G 0.000117 5-fluorouracil induced diarrhoea in response to colorectal cancer treatment / / 22310351 rs3925053 chr12 69432620 A G,T 4.10E-04 Alcohol dependence / / 20201924 rs3925053 chr12 69432620 A G,T 8.80E-04 Alcohol dependence / / 20201924 rs10878908 chr12 69470327 G A 1.20E-06 Thyroid function / / 20826269 rs10878908 chr12 69470327 G A 3.52E-05 Diabetes Mellitus / / pha003060 rs1908679 chr12 69478038 G C 8.00E-07 Thyroid function / / 20826269 rs7961809 chr12 69497995 A G 2.70E-05 Urinary metabolites / / 21572414 rs12830473 chr12 69498860 A T 4.66E-04 Obesity (extreme) / / 21935397 rs12302316 chr12 69506416 C T 6.01E-04 Smoking initiation / / 24665060 rs12309456 chr12 69506466 T C 8.21E-04 Smoking initiation / / 24665060 rs10878920 chr12 69522188 G A 8.47E-05 Body Mass Index / / pha003009 rs10784762 chr12 69523923 C T 3.30E-06 Urinary metabolites / / 21572414 rs10784762 chr12 69523923 C T 6.00E-06 QRS duration / / 23534349 rs4075026 chr12 69526932 T C 5.49E-04 Body mass index / / 21701565 rs12425617 chr12 69527778 C T 3.12E-04 Body mass index / / 21701565 rs7304995 chr12 69530154 C T 8.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs7296069 chr12 69535054 G A 7.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs7956654 chr12 69546501 C T 2.58E-04 Taste perception / / 22132133 rs10878930 chr12 69567211 G A 7.73E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs7972058 chr12 69574568 T G 7.70E-05 Cognitive performance / / 19734545 rs12367448 chr12 69581222 C A 6.00E-06 IgG glycosylation / / 23382691 rs12367448 chr12 69581222 C A 1.48E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10878938 chr12 69586439 C T 2.80E-05 Urinary metabolites / / 21572414 rs3905279 chr12 69595944 C T 4.55E-04 Type 2 diabetes / / 17463246 rs7485097 chr12 69597645 A G 2.70E-05 Urinary metabolites / / 21572414 rs11177571 chr12 69648246 A G 7.34E-05 Personality dimensions CPSF6 intron 18957941 rs10878951 chr12 69663047 C T 6.32E-04 Depression (quantitative trait) CPSF6 intron 20800221 rs10878956 chr12 69687325 G T 7.59E-05 Personality dimensions / / 18957941 rs11177587 chr12 69697366 C T 7.63E-05 Multiple complex diseases / / 17554300 rs11177594 chr12 69714813 C T 3.82E-05 Personality dimensions / / 18957941 rs10878964 chr12 69720691 T G 9.63E-05 Cognitive performance / / 19734545 rs317689 chr12 69727190 G A 3.00E-07 Response to diuretic therapy / / 18591461 rs1800973 chr12 69744014 C A 9.46E-07 Alcohol dependence LYZ missense 19581569 rs2306204 chr12 69753530 C A 6.20E-05 Cognitive performance / / 19734545 rs315129 chr12 69760861 T C 4.39E-04 Multiple complex diseases YEATS4 intron 17554300 rs315135 chr12 69762987 A G 6.00E-06 Response to diuretic therapy YEATS4 intron 18591461 rs315122 chr12 69771073 G T 1.00E-09 Venous thromboembolism (gene x gene interaction) YEATS4 intron 23509962 rs2603088 chr12 69776299 A G 3.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) YEATS4 intron 20877124 rs2603088 chr12 69776299 A G 2.41E-04 Alzheimer's disease YEATS4 intron 24755620 rs10878977 chr12 69799690 T C 1.04E-04 Coronary heart disease / / 21606135 rs11177653 chr12 69802927 G A 4.08E-05 Cytomegalovirus antibody response / / 21993531 rs17225223 chr12 69810208 C T 3.78E-05 Cytomegalovirus antibody response / / 21993531 rs7295234 chr12 69811369 A C 5.82E-05 Serum metabolites / / 19043545 rs7295234 chr12 69811369 A C 4.50E-05 Hemoglobin / / pha003096 rs7979527 chr12 69811993 T A 4.37E-05 Serum metabolites / / 19043545 rs12368608 chr12 69814447 C G 3.76E-05 Cytomegalovirus antibody response / / 21993531 rs9645827 chr12 69814495 G A 3.76E-05 Cytomegalovirus antibody response / / 21993531 rs732214 chr12 69815826 T C 3.12E-05 Hemoglobin / / pha003096 rs732214 chr12 69815826 T C 8.19E-05 Hematocrit / / pha003097 rs7963983 chr12 69817516 A T 6.50E-05 Cytomegalovirus antibody response / / 21993531 rs11177662 chr12 69818480 C T 2.65E-05 Cytomegalovirus antibody response / / 21993531 rs11177664 chr12 69819297 T C 2.53E-05 Cytomegalovirus antibody response / / 21993531 rs17813371 chr12 69821414 A G 4.85E-05 Cytomegalovirus antibody response / / 21993531 rs17106576 chr12 69823491 T G 3.63E-07 Hemoglobin / / pha003096 rs17106576 chr12 69823491 T G 1.04E-06 Hematocrit / / pha003097 rs7297610 chr12 69824024 C T 6.00E-06 Response to diuretic therapy / / 18591461 rs11177666 chr12 69825111 A G 5.28E-04 Coronary heart disease / / 21606135 rs11177666 chr12 69825111 A G 2.26E-05 Cytomegalovirus antibody response / / 21993531 rs10748128 chr12 69827658 G T 2.00E-20 Height / / 20881960 rs10748128 chr12 69827658 G T 7.00E-15 Height / / 23563607 rs11177669 chr12 69828681 G A 3.00E-06 Height / / 18391951 rs41415548 chr12 69831635 A G 5.79E-04 Insulin resistance / / 21901158 rs10878988 chr12 69832469 A G 0.00000249 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs10878988 chr12 69832469 A G 0.00000342 Internal carotid artery thickness (far walls) / / 23487405 rs7312976 chr12 69836625 T C 1.44E-05 Cocaine dependence / / 23958962 rs7312976 chr12 69836625 T C 5.77E-05 Cocaine dependence / / 23958962 rs11177680 chr12 69850258 G A 2.69E-04 Type 2 diabetes / / 17463246 rs11177680 chr12 69850258 G A 7.73E-04 Multiple complex diseases / / 17554300 rs7967509 chr12 69855550 A C 1.75E-05 Personality dimensions / / 22628180 rs221066 chr12 69858279 T C 2.06E-05 Personality dimensions / / 22628180 rs221067 chr12 69858563 T C 1.93E-05 Personality dimensions / / 22628180 rs502736 chr12 69922738 A G 4.50E-04 Amyotrophic Lateral Sclerosis FRS2 intron 17362836 rs532669 chr12 69953596 C T 1.30E-05 Personality dimensions FRS2 intron 22628180 rs516391 chr12 69958202 G T 1.79E-05 Personality dimensions FRS2 intron 22628180 rs484319 chr12 69980141 G C 7.40E-21 Progranulin levels CCT2 intron 21087763 rs484319 chr12 69980141 G C 7.40E-21 Myocardial infarction CCT2 intron 21211798 rs3858594 chr12 69985452 T A 7.21E-04 Type 2 diabetes CCT2 intron 17463246 rs7200 chr12 69995273 T C 3.63E-04 Type 2 diabetes CCT2 UTR-3 17463246 rs727948 chr12 70000518 A G 4.97E-04 Type 2 diabetes / / 17463246 rs11177752 chr12 70005534 T G 9.18E-04 Type 2 diabetes / / 17463246 rs35638 chr12 70011856 C T 9.22E-04 Multiple complex diseases / / 17554300 rs776413 chr12 70020685 C T 0.000354 Salmonella-induced pyroptosis / / 22837397 rs710745 chr12 70024023 T C 4.80E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs1867445 chr12 70041122 C T 2.54E-04 Parkinson's disease / / 17052657 rs1867445 chr12 70041122 C T 1.22E-05 Orofacial clefts / / 22863734 rs11177766 chr12 70043603 G C 2.11E-06 Glycemic traits (pregnancy) / / 23903356 rs11177766 chr12 70043603 G C 3.91E-06 Glycemic traits (pregnancy) / / 23903356 rs10906 chr12 70047498 C T 2.42E-06 Glycemic traits (pregnancy) BEST3 UTR-3 23903356 rs10906 chr12 70047498 C T 4.21E-06 Glycemic traits (pregnancy) BEST3 UTR-3 23903356 rs11177775 chr12 70049760 C T 2.61E-06 Glycemic traits (pregnancy) BEST3 intron 23903356 rs11177775 chr12 70049760 C T 4.83E-06 Glycemic traits (pregnancy) BEST3 intron 23903356 rs11177777 chr12 70050410 A T 2.18E-06 Glycemic traits (pregnancy) BEST3 intron 23903356 rs11177777 chr12 70050410 A T 4.00E-06 Glycemic traits (pregnancy) BEST3 intron 23903356 rs11177779 chr12 70050658 G A 2.55E-06 Glycemic traits (pregnancy) BEST3 intron 23903356 rs11177779 chr12 70050658 G A 5.11E-06 Glycemic traits (pregnancy) BEST3 intron 23903356 rs11177780 chr12 70052768 G A 3.39E-06 Glycemic traits (pregnancy) BEST3 intron 23903356 rs11177780 chr12 70052768 G A 6.32E-06 Glycemic traits (pregnancy) BEST3 intron 23903356 rs1373453 chr12 70054910 A G 3.26E-04 Parkinson's disease BEST3 intron 17052657 rs1373453 chr12 70054910 A G 2.00E-06 Orofacial clefts BEST3 intron 22863734 rs11177781 chr12 70055117 C G 1.53E-06 Glycemic traits (pregnancy) BEST3 intron 23903356 rs11177781 chr12 70055117 C G 3.32E-06 Glycemic traits (pregnancy) BEST3 intron 23903356 rs11177783 chr12 70055978 T C 1.72E-06 Glycemic traits (pregnancy) BEST3 intron 23903356 rs11177783 chr12 70055978 T C 3.50E-06 Glycemic traits (pregnancy) BEST3 intron 23903356 rs12367331 chr12 70057822 A T 2.19E-04 Glycemic traits (pregnancy) BEST3 intron 23903356 rs12367331 chr12 70057822 A T 3.47E-04 Glycemic traits (pregnancy) BEST3 intron 23903356 rs17106910 chr12 70057874 G T 3.48E-04 Sarcoidosis BEST3 intron 19165924 rs17106937 chr12 70066280 A G 1.60E-05 Orofacial clefts BEST3 intron 22863734 rs710722 chr12 70067766 G A 7.49E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) BEST3 intron 23648065 rs17225496 chr12 70069471 C T 1.80E-06 Glycemic traits (pregnancy) BEST3 intron 23903356 rs17225496 chr12 70069471 C T 6.20E-07 Glycemic traits (pregnancy) BEST3 intron 23903356 rs775490 chr12 70072916 G T 1.78E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) BEST3 intron 23648065 rs11177789 chr12 70073218 A C 2.67E-06 Glycemic traits (pregnancy) BEST3 intron 23903356 rs11177789 chr12 70073218 A C 8.92E-06 Glycemic traits (pregnancy) BEST3 intron 23903356 rs775484 chr12 70074492 A G 4.99E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) BEST3 intron 23648065 rs12322558 chr12 70080153 A G 7.84E-05 Orofacial clefts BEST3 intron 22863734 rs7298838 chr12 70083214 G A,C,T 9.83E-04 Type 2 diabetes BEST3 intron 17463246 rs3937886 chr12 70086939 T G 2.51E-04 Parkinson's disease BEST3 intron 17052657 rs1025016 chr12 70091452 A G 5.71E-05 Tunica Media BEST3 missense pha003036 rs775455 chr12 70106879 C T 2.10E-05 Urinary metabolites / / 21572414 rs775451 chr12 70112707 A G 5.85E-04 Insulin resistance / / 21901158 rs11177823 chr12 70139673 T G 2.19E-04 Type 2 diabetes RAB3IP intron 17463246 rs1586983 chr12 70156051 G A 1.70E-05 Urinary metabolites RAB3IP intron 21572414 rs4512898 chr12 70181427 G A 2.70E-05 Urinary metabolites RAB3IP intron 21572414 rs11177849 chr12 70182473 A G 2.80E-07 Urinary metabolites RAB3IP intron 21572414 rs1599745 chr12 70186029 C T 2.60E-07 Urinary metabolites RAB3IP intron 21572414 rs1240255 chr12 70228658 T A 2.10E-05 Urinary metabolites / / 21572414 rs17107156 chr12 70234066 C T 1.80E-07 Urinary metabolites / / 21572414 rs7295793 chr12 70273985 T G 2.03E-04 Multiple complex diseases LOC100652962 missense 17554300 rs1240271 chr12 70289546 A G 8.36E-04 Multiple complex diseases LOC100652962 intron 17554300 rs11177955 chr12 70301719 C T 7.00E-05 Multiple complex diseases LOC100652962 intron 17554300 rs1152972 chr12 70312890 G A 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC100652962 intron 22628534 rs1152965 chr12 70320126 C T 1.87E-05 Platelet counts LOC100652962 intron 21507922 rs789560 chr12 70331827 G T 7.00E-06 Attention deficit hyperactivity disorder and conduct disorder C12orf28 intron 18951430 rs7972006 chr12 70341955 T C 8.20E-04 Bipolar disorder C12orf28 intron 19259986 rs1882191 chr12 70385323 C T 7.52E-05 Behcet's disease / / pha002888 rs7134411 chr12 70387446 C T 4.57E-04 Suicide attempts in bipolar disorder / / 21041247 rs17107510 chr12 70389055 C T 1.89E-04 Alzheimer's disease (late onset) / / 21379329 rs1152948 chr12 70392585 C T 3.13E-05 Serum metabolites / / 19043545 rs1152948 chr12 70392585 C T 1.24E-05 Male fertility / / 22633400 rs1152947 chr12 70392711 C T 3.13E-05 Serum metabolites / / 19043545 rs11178026 chr12 70394281 T C 4.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs1565723 chr12 70397028 T C 4.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs1565724 chr12 70397568 C A 4.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs1565725 chr12 70397590 C T 4.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs1239930 chr12 70401149 A C 1.23E-04 Heart Failure / / pha002884 rs1239925 chr12 70403306 C T 2.33E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1239925 chr12 70403306 C T 2.97E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1239925 chr12 70403306 C T 7.61E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1092161 chr12 70419336 G A 4.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1239904 chr12 70440646 G T 3.00E-08 Glaucoma (primary open-angle) / / 22428042 rs1239915 chr12 70444888 C T 9.55E-05 Serum metabolites / / 19043545 rs7310352 chr12 70509873 G A 8.60E-06 Urinary metabolites / / 21572414 rs10879110 chr12 70600684 A G 9.28E-05 Aging (time to event) / / 21782286 rs11610554 chr12 70608694 C T 1.98E-04 Longevity / / 22279548 rs7960641 chr12 70610137 T C 2.19E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6581928 chr12 70612235 G A 9.03E-04 Heart Failure / / pha002884 rs12831626 chr12 70624006 G A 8.13E-05 Cognitive test performance / / 20125193 rs7306865 chr12 70627319 G T 8.66E-05 Cognitive test performance / / 20125193 rs10506584 chr12 70645392 C T 3.03E-05 Heart Failure CNOT2 intron pha002884 rs10784835 chr12 70668054 A G 1.84E-04 Height CNOT2 intron 17255346 rs12230432 chr12 70681604 T C 0.0000322 Panic disorder CNOT2 intron 23149450 rs12230432 chr12 70681604 T C 3.22E-05 Serum tamsulosin hydrochloride concentration CNOT2 intron 23151678 rs2904524 chr12 70690085 G A 5.00E-06 Amyotrophic lateral sclerosis (age of onset) CNOT2 intron 22959728 rs11178177 chr12 70691305 C T 8.42E-04 Alcohol dependence CNOT2 intron 21314694 rs7136214 chr12 70713655 G A 2.51E-04 Height CNOT2 intron 17255346 rs720653 chr12 70718437 C T 2.80E-04 Height CNOT2 intron 17255346 rs3817487 chr12 70740194 G A 2.38E-04 Height CNOT2 intron 17255346 rs7967279 chr12 70751275 G A 5.02E-04 Multiple complex diseases / / 17554300 rs7133677 chr12 70755167 C T 9.85E-05 Cognitive test performance / / 20125193 rs1495345 chr12 70776876 A C 3.80E-04 Height KCNMB4 intron 17255346 rs12423152 chr12 70785046 A G 3.84E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) KCNMB4 intron 24023788 rs787940 chr12 70786819 C T 2.36E-04 Height KCNMB4 intron 17255346 rs710650 chr12 70794570 T C 8.95E-04 Premature ovarian failure KCNMB4 intron 19508998 rs10879135 chr12 70806551 A G 2.46E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) KCNMB4 intron 24023788 rs11178236 chr12 70822198 T C 0.000017 HDL cholesterol particle diameter KCNMB4 intron 23263444 rs3825188 chr12 70823988 T C 3.21E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) KCNMB4 intron 24023788 rs12299876 chr12 70832568 C G 1.20E-05 Urinary metabolites / / 21572414 rs635461 chr12 70832580 G C 0.0000154 HDL cholesterol particle diameter / / 23263444 rs412528 chr12 70833868 A G 0.00000287 HDL cholesterol particle diameter / / 23263444 rs381485 chr12 70833998 G T 0.00000287 HDL cholesterol particle diameter / / 23263444 rs402325 chr12 70834031 T G 0.00000279 HDL cholesterol particle diameter / / 23263444 rs1603228 chr12 70884496 G A 3.86E-04 Type 2 diabetes / / 17846124 rs10506595 chr12 70905354 G A 3.40E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs17226367 chr12 70925864 C G 1.77E-04 Suicide attempts in bipolar disorder PTPRB missense 21423239 rs2278345 chr12 70934961 C T 8.32E-04 Schizophrenia PTPRB intron 19197363 rs3782377 chr12 70943954 C T 5.00E-04 Bipolar disorder PTPRB intron 17486107 rs2567134 chr12 70947539 G C 9.86E-04 Type 2 diabetes PTPRB intron 17463246 rs61758735 chr12 70949014 G A 0.00054 Prostate cancer PTPRB missense 23555315 rs2116209 chr12 70949248 T C 9.24E-04 Response to cytidine analogues (gemcitabine) PTPRB intron 24483146 rs17108344 chr12 70954464 C T 3.00E-08 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) PTPRB cds-synon 24554482 rs149998223 chr12 70965009 G A 0.00087 Prostate cancer PTPRB missense 23555315 rs2165627 chr12 70983895 A C 8.50E-05 Calcium levels PTPRB missense pha003085 rs1465934 chr12 70984019 C T 8.50E-05 Calcium levels PTPRB intron pha003085 rs2717426 chr12 70987472 C T 0.00000419 HDL cholesterol particle diameter PTPRB intron 23263444 rs11178315 chr12 70988719 T C 2.09E-04 Type 2 diabetes PTPRB intron 17463246 rs11178315 chr12 70988719 T C 2.10E-05 Urinary metabolites PTPRB intron 21572414 rs2717434 chr12 71008547 T G 1.35E-04 Alzheimer's disease PTPRB intron 17998437 rs2439732 chr12 71015131 A G 2.38E-04 Multiple complex diseases PTPRB intron 17554300 rs2465810 chr12 71015280 A G 5.03E-04 Nicotine smoking PTPRB intron 19268276 rs10506598 chr12 71015939 T C 4.30E-04 Type 2 diabetes and 6 quantitative traits PTPRB intron 17848626 rs7978668 chr12 71039176 T C 2.46E-05 Post-operative nausea and vomiting PTPRR intron 21694509 rs1372560 chr12 71040392 G A 6.62E-04 Multiple complex diseases PTPRR intron 17554300 rs10879175 chr12 71043254 G A 5.83E-06 Post-operative nausea and vomiting PTPRR intron 21694509 rs12581294 chr12 71054163 T C 4.90E-04 Multiple complex diseases PTPRR intron 17554300 rs11178377 chr12 71111607 A G 7.51E-04 Smoking quantity PTPRR intron 24665060 rs4760933 chr12 71143758 A G 1.39E-05 Major depressive disorder PTPRR intron 19107115 rs7313937 chr12 71167582 T C 4.50E-06 Urinary metabolites PTPRR intron 21572414 rs1567747 chr12 71183695 C T 1.55E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PTPRR intron 20031582 rs7980133 chr12 71196302 C T 2.96E-04 Parkinson's disease PTPRR intron 17052657 rs7980133 chr12 71196302 C T 2.92E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PTPRR intron 20031582 rs1022242 chr12 71206355 G A 1.10E-04 Parkinson's disease PTPRR intron 17052657 rs2458440 chr12 71219976 A G 3.46E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PTPRR intron 20031582 rs12580754 chr12 71223606 T A 8.28E-04 Insulin resistance PTPRR intron 21901158 rs2470378 chr12 71226480 A G 3.46E-05 Parkinson's disease PTPRR intron 17052657 rs12229663 chr12 71249996 A G 5.00E-09 Refractive error PTPRR intron 23396134 rs12229663 chr12 71249996 A G 4.29E-04 Alcohol dependence PTPRR intron 24277619 rs4294640 chr12 71255025 T G 9.00E-05 IgE levels in asthmatics (D.p. specific) PTPRR intron 23967269 rs4294640 chr12 71255025 T G 4.41E-05 Waist-Hip Ratio PTPRR intron pha003013 rs4294640 chr12 71255025 T G 7.92E-05 Waist-Hip Ratio PTPRR intron pha003028 rs7975082 chr12 71265577 A G 5.33E-04 Multiple complex diseases PTPRR intron 17554300 rs12305560 chr12 71269754 C T 1.45E-04 Amyotrophic lateral sclerosis (sporadic) PTPRR intron 24529757 rs17108998 chr12 71282714 C A 2.84E-04 Multiple complex diseases PTPRR intron 17554300 rs6581971 chr12 71289408 C T 4.74E-06 Waist-Hip Ratio PTPRR intron pha003013 rs6581971 chr12 71289408 C T 9.34E-06 Waist-Hip Ratio PTPRR intron pha003028 rs4760854 chr12 71289556 G A 9.00E-06 IgG glycosylation PTPRR intron 23382691 rs4638407 chr12 71301276 C T 1.30E-05 Urinary metabolites PTPRR intron 21572414 rs6581974 chr12 71303058 C G 5.96E-04 Insulin resistance PTPRR intron 21901158 rs12816176 chr12 71308403 T C 6.62E-05 Lung function (forced expiratory volume in 1 second) PTPRR intron 24023788 rs10879218 chr12 71311770 A G 5.39E-04 Insulin resistance PTPRR intron 21901158 rs11178489 chr12 71316301 G A 4.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10879220 chr12 71322921 C A 6.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs4550310 chr12 71324275 T C 6.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs12582861 chr12 71326688 A G 6.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs10879222 chr12 71329535 T G 6.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs12321332 chr12 71331651 A G 6.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs11178497 chr12 71334472 A C 6.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs11178499 chr12 71342270 G A 4.35E-04 Type 2 diabetes / / 17463246 rs11178499 chr12 71342270 G A 8.33E-05 Multiple complex diseases / / 17554300 rs12304555 chr12 71347418 A G 5.86E-04 Type 2 diabetes / / 17463246 rs1877529 chr12 71347970 G A 1.69E-04 Multiple complex diseases / / 17554300 rs1118539 chr12 71352544 A G 6.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs1512979 chr12 71353876 T C 7.72E-04 Type 2 diabetes / / 17463246 rs1028035 chr12 71355847 T C 6.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs12321435 chr12 71355944 A C 8.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12321435 chr12 71355944 A C 1.90E-05 Urinary metabolites / / 21572414 rs1012226 chr12 71357539 T C 5.86E-04 Type 2 diabetes / / 17463246 rs7308897 chr12 71358136 A C 5.77E-04 Type 2 diabetes / / 17463246 rs12718003 chr12 71358147 G A 4.92E-04 Type 2 diabetes / / 17463246 rs12303957 chr12 71364392 C T 5.93E-04 Type 2 diabetes / / 17463246 rs1996080 chr12 71371447 T G 5.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs10879232 chr12 71377563 G A 7.50E-05 Tooth agenesis (third molar) / / 24172245 rs1877530 chr12 71378297 A C 1.52E-04 Multiple complex diseases / / 17554300 rs11178521 chr12 71378466 A G 1.60E-05 Urinary metabolites / / 21572414 rs4492904 chr12 71381548 C A 1.83E-07 Glaucoma (primary open-angle) / / 22605921 rs10506619 chr12 71381918 T C 4.39E-05 Multiple complex diseases / / 17554300 rs10784885 chr12 71387093 T C 6.20E-05 Multiple complex diseases / / 17554300 rs983168 chr12 71402356 C T 1.63E-04 Multiple complex diseases / / 17554300 rs11178531 chr12 71408690 A G 1.00E-05 Type 2 diabetes / / 17463249 rs11178531 chr12 71408690 A G 1.01E-05 Multiple complex diseases / / 17554300 rs11178531 chr12 71408690 A G 2.00E-05 Urinary metabolites / / 21572414 rs11178531 chr12 71408690 A G 5.10E-04 Age-related macular degeneration (extreme sampling) / / 23577725 rs7132840 chr12 71411561 T G 1.93E-08 Multiple complex diseases / / 17554300 rs7132840 chr12 71411561 T G 2.10E-05 Urinary metabolites / / 21572414 rs7132840 chr12 71411561 T G 4.18E-05 Creutzfeldt-Jakob disease (variant) / / 22137330 rs7298255 chr12 71428069 A T 9.99E-08 Multiple complex diseases / / 17554300 rs6581986 chr12 71431294 T C 1.63E-04 Common variable immunodeficiency / / 21497890 rs7955901 chr12 71433293 C T 6.50E-09 Type 2 diabetes / / 22885922 rs7138300 chr12 71439589 C T 1.70E-05 Urinary metabolites / / 21572414 rs7138300 chr12 71439589 C T 0.0000018 Type 2 diabetes (males) / / 22885922 rs7138300 chr12 71439589 C T 0.00001 Type 2 diabetes (females) / / 22885922 rs1913201 chr12 71439825 G A 1.60E-05 Urinary metabolites / / 21572414 rs4760786 chr12 71446789 T C 6.87E-04 Multiple complex diseases / / 17554300 rs7316843 chr12 71449811 C T 2.52E-04 Smoking quantity / / 24665060 rs11178577 chr12 71454972 A T 3.45E-04 Multiple complex diseases / / 17554300 rs1512988 chr12 71454999 T A 1.10E-06 Multiple complex diseases / / 17554300 rs715776 chr12 71459064 C T 2.46E-04 Scoliosis / / 21216876 rs11178602 chr12 71491505 C T 5.20E-07 Multiple complex diseases / / 17554300 rs1580713 chr12 71500166 C T 1.81E-05 Multiple complex diseases / / 17554300 rs1353360 chr12 71507561 T C 8.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7311994 chr12 71510255 T G 9.88E-07 Multiple complex diseases / / 17554300 rs10506625 chr12 71522397 G C 7.20E-05 Type 2 diabetes TSPAN8 intron 17463249 rs10506625 chr12 71522397 G C 7.16E-05 Multiple complex diseases TSPAN8 intron 17554300 rs10506626 chr12 71529491 G A 4.01E-07 Multiple complex diseases TSPAN8 intron 17554300 rs2270584 chr12 71532099 G A 5.88E-07 Multiple complex diseases TSPAN8 intron 17554300 rs11178648 chr12 71533210 C T 9.48E-07 Multiple complex diseases TSPAN8 intron 17554300 rs1705236 chr12 71545558 T A 6.11E-07 Bipolar disorder TSPAN8 intron 18317468 rs17226863 chr12 71558448 G C 9.53E-06 Multiple complex diseases / / 17554300 rs17226863 chr12 71558448 G C 1.02E-05 Creutzfeldt-Jakob disease (variant) / / 22137330 rs7972188 chr12 71566754 T C 9.80E-06 Type 2 diabetes / / 17463249 rs7972188 chr12 71566754 T C 9.83E-06 Multiple complex diseases / / 17554300 rs7972188 chr12 71566754 T C 1.83E-05 Creutzfeldt-Jakob disease (variant) / / 22137330 rs1510937 chr12 71566956 T C 3.32E-06 Multiple complex diseases / / 17554300 rs1510937 chr12 71566956 T C 2.28E-05 Creutzfeldt-Jakob disease (variant) / / 22137330 rs1397552 chr12 71567331 C T 9.25E-04 Multiple complex diseases / / 17554300 rs1495377 chr12 71577101 G C 1.30E-06 Type 2 diabetes / / 17463249 rs1495377 chr12 71577101 G C 7.00E-06 Type 2 diabetes / / 17554300 rs1495377 chr12 71577101 G C 7.00E-06 Coronary heart disease / / 21347282 rs1495377 chr12 71577101 G C 7.00E-06 Type 2 diabetes / / 21647700 rs1495377 chr12 71577101 G C 2.00E-06 Creutzfeldt-Jakob disease (variant) / / 22137330 rs1705244 chr12 71589246 G A 1.80E-05 Urinary metabolites / / 21572414 rs1798076 chr12 71589671 G A 9.50E-06 Urinary metabolites / / 21572414 rs4760915 chr12 71634112 T C 0.000011 Type 2 diabetes / / 22885922 rs4760790 chr12 71634794 A G 4.00E-06 Type 2 diabetes / / 20581827 rs4760790 chr12 71634794 A G 0.000008 Type 2 diabetes / / 22885922 rs7961581 chr12 71663102 C T 3.60E-06 Type 2 diabetes / / 17463249 rs7961581 chr12 71663102 C T 1.23E-06 Multiple complex diseases / / 17554300 rs7961581 chr12 71663102 C T 1.00E-09 Type 2 diabetes / / 18372903 rs7961581 chr12 71663102 C T 1.00E-09 Coronary heart disease / / 21347282 rs7961581 chr12 71663102 C T 2.40E-05 Urinary metabolites / / 21572414 rs7961581 chr12 71663102 C T 1.10E-09 Type 2 diabetes / / 23300278 rs1397571 chr12 71663435 C T 1.70E-05 Urinary metabolites / / 21572414 rs12307112 chr12 71671808 G A 5.58E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7980195 chr12 71672779 G A 5.47E-05 Age-related macular degeneration / / pha002890 rs6582000 chr12 71673148 G T 4.48E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7486365 chr12 71699269 C T 1.87E-04 Hearing function / / 17255346 rs7972483 chr12 71701115 G A 2.15E-04 Hearing function / / 17255346 rs4760792 chr12 71702986 A T 1.48E-04 Hearing function / / 17255346 rs4760924 chr12 71707221 C T 1.81E-04 Hearing function / / 17255346 rs10879278 chr12 71713517 C G 1.05E-04 Hearing function / / 17255346 rs6582010 chr12 71736740 A G 2.26E-04 Hearing function / / 17255346 rs7485363 chr12 71740040 G A 2.70E-04 Hearing function / / 17255346 rs941197 chr12 71937646 A G 3.00E-04 Atrial fibrillation LGR5 intron 21846873 rs2304274 chr12 71950749 G A 2.59E-05 Coronary heart disease LGR5 intron pha003031 rs1280596 chr12 72023759 C T 8.71E-05 Lipoproteins ZFC3H1 intron pha003079 rs1149006 chr12 72030252 T C 8.99E-05 Lipoproteins ZFC3H1 intron pha003079 rs3741691 chr12 72058416 G T 8.46E-05 Coronary heart disease THAP2 intron pha003031 rs10748180 chr12 72071045 A G 5.00E-06 Economic and political preferences (time) THAP2 UTR-3 22566634 rs327779 chr12 72113592 T C 9.50E-05 Parkinson's disease (age of onset) / / 19772629 rs11178918 chr12 72125285 A G 8.00E-06 Economic and political preferences (time) / / 22566634 rs4146372 chr12 72131620 C G 7.00E-05 Breast cancer and prostate cancer / / 17903305 rs328744 chr12 72181905 G A 3.06E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs328761 chr12 72232292 A G 9.76E-05 Major depressive disorder (broad) / / 20038947 rs328764 chr12 72233949 G A 6.56E-05 Bipolar disorder TBC1D15 intron 19488044 rs328764 chr12 72233949 G A 3.07E-05 Bipolar disorder and schizophrenia TBC1D15 intron 20889312 rs328764 chr12 72233949 G A 7.52E-05 Bipolar Disorder TBC1D15 intron pha002858 rs6582059 chr12 72248742 T G 1.80E-05 Urinary metabolites TBC1D15 intron 21572414 rs1035778 chr12 72264234 G T 9.31E-05 Glucose levels TBC1D15 intron pha003058 rs2052732 chr12 72275209 G A 2.79E-04 Body mass index TBC1D15 intron 17255346 rs41375846 chr12 72288762 A G 2.01E-18 Multiple complex diseases TBC1D15 intron 17554300 rs3759171 chr12 72307616 A G 6.40E-05 Glucose levels TBC1D15 cds-synon pha003058 rs11178985 chr12 72312268 G A 6.50E-05 Lymphocyte counts TBC1D15 cds-synon 22286170 rs4131348 chr12 72324479 T C 3.51E-05 Soluble levels of adhesion molecules / / pha003072 rs10879345 chr12 72346800 C G 5.68E-04 Multiple complex diseases TPH2 intron 17554300 rs1843809 chr12 72348698 G T 1.60E-05 Urinary metabolites TPH2 intron 21572414 rs1386489 chr12 72349290 G A 2.40E-05 Urinary metabolites TPH2 intron 21572414 rs10784944 chr12 72359418 C G 2.10E-05 Urinary metabolites TPH2 intron 21572414 rs2171363 chr12 72360264 A G 3.29E-05 Waist Circumference TPH2 intron pha003023 rs7978482 chr12 72365973 T C 6.20E-06 Urinary metabolites TPH2 intron 21572414 rs17110563 chr12 72366306 C T 1.42E-08 Cholesterol,total TPH2 missense 23063622 rs1843812 chr12 72367655 A G 2.10E-05 Urinary metabolites TPH2 intron 21572414 rs7305115 chr12 72372862 A G 1.36E-05 Waist Circumference TPH2 cds-synon pha003023 rs4760751 chr12 72377918 A G 2.60E-05 Urinary metabolites TPH2 intron 21572414 rs1386498 chr12 72398143 A G 6.42E-06 Waist Circumference TPH2 intron pha003023 rs1487278 chr12 72400851 T C 1 Drug response to Mirtazapine TPH2 intron 18496129 rs1487278 chr12 72400851 T C 1 Drug response to Venlafaxine TPH2 intron 18496129 rs11179039 chr12 72402186 T C 3.61E-06 Waist Circumference TPH2 intron pha003023 rs9325202 chr12 72407477 A G 7.82E-06 Waist Circumference TPH2 intron pha003023 rs17110690 chr12 72407997 G A 5.75E-04 Type 2 diabetes TPH2 intron 17463246 rs17110690 chr12 72407997 G A 2.00E-04 Body mass index TPH2 intron 24827717 rs12231341 chr12 72409436 C T 2.72E-04 Rheumatoid arthritis TPH2 intron 21452313 rs10879354 chr12 72409782 C T 6.98E-06 Waist Circumference TPH2 intron pha003023 rs111390076 chr12 72409782 C CT 6.98E-06 Waist Circumference TPH2 intron pha003023 rs11179050 chr12 72410079 G A 3.88E-06 Waist Circumference TPH2 intron pha003023 rs1487275 chr12 72410292 C A 2.00E-04 Cognitive impairment induced by topiramate TPH2 intron 22091778 rs1487275 chr12 72410292 C A 3.72E-07 Waist Circumference TPH2 intron pha003023 rs1386485 chr12 72412367 G T 7.30E-04 Type 2 diabetes and 6 quantitative traits TPH2 intron 17848626 rs1386485 chr12 72412367 G T 6.54E-04 Body mass index TPH2 intron 21701565 rs1386483 chr12 72412494 T C 8.78E-04 Body mass index TPH2 intron 21701565 rs1386483 chr12 72412494 T C 3.57E-06 Waist Circumference TPH2 intron pha003023 rs10879355 chr12 72413009 T C 5.06E-04 Body mass index TPH2 intron 21701565 rs10879357 chr12 72414563 A G 3.00E-06 Colorectal cancer TPH2 intron 23300701 rs10879357 chr12 72414563 A G 8.55E-05 Waist Circumference TPH2 intron pha003023 rs1872824 chr12 72430314 A G 1.99E-05 Waist Circumference / / pha003023 rs1879914 chr12 72485949 A G 9.58E-04 Obesity (extreme) / / 21935397 rs10784950 chr12 72490294 A G 9.56E-04 Obesity (extreme) / / 21935397 rs2367897 chr12 72492104 G A 9.55E-04 Obesity (extreme) / / 21935397 rs7133520 chr12 72494407 A G 9.61E-04 Obesity (extreme) / / 21935397 rs7977245 chr12 72497868 G A 9.64E-04 Obesity (extreme) / / 21935397 rs6582086 chr12 72498191 A G 9.66E-04 Obesity (extreme) / / 21935397 rs1484834 chr12 72500764 A G 9.96E-04 Obesity (extreme) / / 21935397 rs985207 chr12 72501356 A G 9.74E-04 Obesity (extreme) / / 21935397 rs1484833 chr12 72501986 T A,G 9.85E-04 Obesity (extreme) / / 21935397 rs2730666 chr12 72569746 G T 4.79E-04 Celiac disease / / 23936387 rs17110927 chr12 72602045 T C 1.74E-05 Vascular dementia / / 22116812 rs11179124 chr12 72632018 G A 3.26E-04 Multiple complex diseases / / 17554300 rs4584622 chr12 72672823 C T 2.00E-04 Response to antidepressant treatment (citalopram) TRHDE intron 23726668 rs4237862 chr12 72694691 T C 2.73E-04 Parkinson's disease TRHDE intron 16252231 rs7488259 chr12 72705175 G A 9.81E-04 Type 2 diabetes TRHDE intron 17463246 rs12321257 chr12 72711388 C T 6.79E-04 Type 2 diabetes TRHDE intron 17463246 rs12321315 chr12 72711489 C T 6.26E-04 Type 2 diabetes TRHDE intron 17463246 rs7971962 chr12 72713053 T C 9.34E-04 Rheumatoid arthritis TRHDE intron 21452313 rs7957269 chr12 72713372 A G 8.13E-04 Type 2 diabetes TRHDE intron 17463246 rs12312745 chr12 72719069 A G 9.34E-04 Rheumatoid arthritis TRHDE intron 21452313 rs17783131 chr12 72719792 A C 6.08E-04 Substance dependence TRHDE intron 21818250 rs12831974 chr12 72724034 T C 6.00E-06 Rheumatoid arthritis TRHDE intron 21452313 rs7970417 chr12 72734174 C T 9.98E-05 Rheumatoid arthritis TRHDE intron 21452313 rs11179163 chr12 72738061 A G 9.76E-05 Rheumatoid arthritis TRHDE intron 21452313 rs148340537 chr12 72762998 C G 2.92E-04 Acne (severe) TRHDE intron 24927181 rs17111252 chr12 72889122 A T 2.17E-04 Multiple complex diseases TRHDE intron 17554300 rs954147 chr12 72903301 G A 2.04E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) TRHDE intron 23648065 rs7295506 chr12 72914831 C T 7.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) TRHDE intron 23648065 rs997590 chr12 72924295 C T 4.50E-04 Type 2 diabetes and 6 quantitative traits TRHDE intron 17848626 rs997590 chr12 72924295 C T 4.51E-05 Hemoglobin TRHDE intron pha003098 rs11179242 chr12 72939127 G A 1.25E-04 Smoking initiation TRHDE intron 24665060 rs10506659 chr12 72990194 C T 7.67E-05 Hemoglobin TRHDE intron pha003098 rs10879468 chr12 73016564 G A 3.36E-04 Multiple complex diseases TRHDE intron 17554300 rs11179317 chr12 73069563 T C 4.46E-04 Multiple complex diseases / / 17554300 rs2887021 chr12 73074432 C T 6.42E-05 Multiple complex diseases / / 17554300 rs11834071 chr12 73075352 T C 4.53E-04 Multiple complex diseases / / 17554300 rs7137407 chr12 73090374 C A 1.71E-04 Multiple complex diseases / / 17554300 rs10879490 chr12 73163151 T A 9.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) / / 23934736 rs10879508 chr12 73242116 T G 5.07E-05 Serum metabolites / / 19043545 rs7313919 chr12 73243456 C T 1.21E-04 Colorectal cancer / / 24448986 rs7486406 chr12 73280037 A T 8.96E-04 Alzheimer's disease / / 22005930 rs13377628 chr12 73285510 A T 8.51E-04 Alzheimer's disease / / 22005930 rs12299906 chr12 73286532 A G 8.54E-04 Alzheimer's disease / / 22005930 rs6421237 chr12 73287610 G T 8.57E-04 Alzheimer's disease / / 22005930 rs7976032 chr12 73288458 C A 8.43E-04 Alzheimer's disease / / 22005930 rs7134277 chr12 73290092 C T 8.51E-04 Alzheimer's disease / / 22005930 rs12425415 chr12 73290999 G A 9.84E-04 Alzheimer's disease / / 22005930 rs12300890 chr12 73291884 A G 8.50E-04 Alzheimer's disease / / 22005930 rs17111781 chr12 73292952 C T 8.49E-04 Alzheimer's disease / / 22005930 rs17799756 chr12 73293779 C T 8.52E-04 Alzheimer's disease / / 22005930 rs7311140 chr12 73295206 G T 8.90E-04 Alzheimer's disease / / 22005930 rs1516277 chr12 73296140 T C 9.16E-04 Alzheimer's disease / / 22005930 rs17799895 chr12 73296609 A G 9.29E-04 Alzheimer's disease / / 22005930 rs1400143 chr12 73303228 C T 7.19E-05 Serum metabolites / / 19043545 rs10879517 chr12 73307582 A G 4.00E-06 Cognitive performance / / 20125193 rs961511 chr12 73308563 G A 7.12E-04 Multiple complex diseases / / 17554300 rs12424659 chr12 73319007 G A 2.45E-05 Cognitive test performance / / 20125193 rs1516275 chr12 73385096 A G 5.47E-05 Monocyte chemoattractant protein-1 / / pha003071 rs1356222 chr12 73415114 A G 9.38E-05 Cognitive test performance / / 20125193 rs7960235 chr12 73439648 G A 1.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1878149 chr12 73442039 G A 7.71E-04 Type 2 diabetes / / 17463246 rs1400142 chr12 73442495 C T 1.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11179527 chr12 73444590 A G 6.87E-04 Body mass index / / 21701565 rs28727366 chr12 73444812 C A 4.42E-05 Intracerebral hemorrhage / / 24656865 rs34997848 chr12 73455475 T C 1.63E-05 Intracerebral hemorrhage / / 24656865 rs1878150 chr12 73458219 A T 2.05E-05 Intracerebral hemorrhage / / 24656865 rs9668887 chr12 73459976 C A 1.18E-05 Intracerebral hemorrhage / / 24656865 rs2090315 chr12 73461400 T C 3.89E-05 Intracerebral hemorrhage / / 24656865 rs2090315 chr12 73461400 T C 5.55E-06 Intracerebral hemorrhage / / 24656865 rs10879543 chr12 73461910 C T 1.69E-05 Intracerebral hemorrhage / / 24656865 rs12319470 chr12 73482915 A G 1.78E-05 Intracerebral hemorrhage / / 24656865 rs1400059 chr12 73486199 C T 9.14E-06 Intracerebral hemorrhage / / 24656865 rs1474010 chr12 73494161 T C 7.15E-06 Intracerebral hemorrhage / / 24656865 rs1516063 chr12 73495456 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs11179546 chr12 73496604 C G 4.99E-06 Intracerebral hemorrhage / / 24656865 rs11179547 chr12 73496626 C T 3.33E-06 Intracerebral hemorrhage / / 24656865 rs11179548 chr12 73497059 A C 2.31E-06 Intracerebral hemorrhage / / 24656865 rs11179548 chr12 73497059 A C 3.28E-05 Intracerebral hemorrhage / / 24656865 rs10785006 chr12 73497131 A G 4.96E-06 Intracerebral hemorrhage / / 24656865 rs10879547 chr12 73497463 C T 4.93E-06 Intracerebral hemorrhage / / 24656865 rs1878120 chr12 73497640 T C 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1878121 chr12 73497747 C T 7.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10879548 chr12 73501855 A G 3.92E-06 Intracerebral hemorrhage / / 24656865 rs7301921 chr12 73506025 A C 3.16E-06 Intracerebral hemorrhage / / 24656865 rs11179552 chr12 73506220 T C 2.82E-06 Intracerebral hemorrhage / / 24656865 rs11179552 chr12 73506220 T C 4.95E-05 Intracerebral hemorrhage / / 24656865 rs12308109 chr12 73507117 A G 3.20E-06 Intracerebral hemorrhage / / 24656865 rs12308109 chr12 73507117 A G 4.95E-05 Intracerebral hemorrhage / / 24656865 rs12321835 chr12 73507288 G T 2.24E-06 Intracerebral hemorrhage / / 24656865 rs12321835 chr12 73507288 G T 2.57E-05 Intracerebral hemorrhage / / 24656865 rs11179553 chr12 73507345 A T 3.22E-06 Intracerebral hemorrhage / / 24656865 rs11179553 chr12 73507345 A T 4.96E-05 Intracerebral hemorrhage / / 24656865 rs10879554 chr12 73511933 C T 5.38E-06 Intracerebral hemorrhage / / 24656865 rs10879555 chr12 73512998 T A 4.70E-06 Intracerebral hemorrhage / / 24656865 rs10879556 chr12 73513001 T A 4.70E-06 Intracerebral hemorrhage / / 24656865 rs12230898 chr12 73516804 A T 3.83E-06 Intracerebral hemorrhage / / 24656865 rs12230898 chr12 73516804 A T 4.47E-05 Intracerebral hemorrhage / / 24656865 rs10879559 chr12 73519415 A G 3.74E-06 Intracerebral hemorrhage / / 24656865 rs12311315 chr12 73521180 C T 5.53E-05 Serum metabolites / / 19043545 rs12311315 chr12 73521180 C T 8.67E-04 Prostate cancer mortality / / 20978177 rs7300179 chr12 73523691 G T 8.00E-06 Intracerebral hemorrhage LOC100507363 intron 24656865 rs11179559 chr12 73525625 C A 7.05E-05 Serum metabolites LOC100507363 intron 19043545 rs11179560 chr12 73527424 T A 1.48E-06 Intracerebral hemorrhage LOC100507363 intron 24656865 rs11179560 chr12 73527424 T A 2.25E-05 Intracerebral hemorrhage LOC100507363 intron 24656865 rs7967256 chr12 73528954 C T 1.50E-06 Intracerebral hemorrhage LOC100507363 intron 24656865 rs7967256 chr12 73528954 C T 1.77E-05 Intracerebral hemorrhage LOC100507363 intron 24656865 rs10161441 chr12 73530269 C T 1.62E-05 Intracerebral hemorrhage LOC100507363 intron 24656865 rs10161441 chr12 73530269 C T 9.58E-07 Intracerebral hemorrhage LOC100507363 intron 24656865 rs1516058 chr12 73531669 T C 1.42E-05 Intracerebral hemorrhage LOC100507363 intron 24656865 rs1516058 chr12 73531669 T C 9.72E-07 Intracerebral hemorrhage LOC100507363 intron 24656865 rs10879561 chr12 73533327 A T 1.12E-05 Intracerebral hemorrhage LOC100507363 intron 24656865 rs10879561 chr12 73533327 A T 6.30E-07 Intracerebral hemorrhage LOC100507363 intron 24656865 rs10879563 chr12 73536503 G A 1.56E-06 Intracerebral hemorrhage LOC100507363 intron 24656865 rs10879563 chr12 73536503 G A 1.66E-05 Intracerebral hemorrhage LOC100507363 intron 24656865 rs11179569 chr12 73547054 G C 1.20E-05 Intracerebral hemorrhage / / 24656865 rs11179569 chr12 73547054 G C 5.84E-07 Intracerebral hemorrhage / / 24656865 rs34661740 chr12 73547492 C T 1.25E-05 Intracerebral hemorrhage / / 24656865 rs34661740 chr12 73547492 C T 8.97E-07 Intracerebral hemorrhage / / 24656865 rs34144381 chr12 73547558 A T 1.25E-05 Intracerebral hemorrhage / / 24656865 rs34144381 chr12 73547558 A T 8.97E-07 Intracerebral hemorrhage / / 24656865 rs7311904 chr12 73548743 C T 1.24E-05 Intracerebral hemorrhage / / 24656865 rs7311904 chr12 73548743 C T 8.93E-07 Intracerebral hemorrhage / / 24656865 rs7312029 chr12 73548826 C T 1.37E-05 Intracerebral hemorrhage / / 24656865 rs7312029 chr12 73548826 C T 6.58E-07 Intracerebral hemorrhage / / 24656865 rs10879567 chr12 73550092 G C 1.22E-05 Intracerebral hemorrhage / / 24656865 rs10879567 chr12 73550092 G C 6.67E-07 Intracerebral hemorrhage / / 24656865 rs10879568 chr12 73550277 C T 1.17E-05 Intracerebral hemorrhage / / 24656865 rs10879568 chr12 73550277 C T 7.44E-07 Intracerebral hemorrhage / / 24656865 rs10879569 chr12 73550881 A G 1.18E-05 Intracerebral hemorrhage / / 24656865 rs10879569 chr12 73550881 A G 6.07E-07 Intracerebral hemorrhage / / 24656865 rs10785010 chr12 73551267 T C 4.27E-07 Intracerebral hemorrhage / / 24656865 rs10785010 chr12 73551267 T C 8.52E-06 Intracerebral hemorrhage / / 24656865 rs10879572 chr12 73551571 C T 4.28E-07 Intracerebral hemorrhage / / 24656865 rs10879572 chr12 73551571 C T 8.52E-06 Intracerebral hemorrhage / / 24656865 rs1878126 chr12 73551731 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7960698 chr12 73552114 C G 6.75E-07 Intracerebral hemorrhage / / 24656865 rs7960698 chr12 73552114 C G 9.23E-06 Intracerebral hemorrhage / / 24656865 rs1976729 chr12 73553089 G A 1.02E-05 Intracerebral hemorrhage / / 24656865 rs1976729 chr12 73553089 G A 4.95E-07 Intracerebral hemorrhage / / 24656865 rs1976730 chr12 73553182 A G 4.26E-07 Intracerebral hemorrhage / / 24656865 rs1976730 chr12 73553182 A G 8.49E-06 Intracerebral hemorrhage / / 24656865 rs2176205 chr12 73553218 C T 4.27E-07 Intracerebral hemorrhage / / 24656865 rs2176205 chr12 73553218 C T 8.49E-06 Intracerebral hemorrhage / / 24656865 rs7299264 chr12 73553337 A C 3.91E-07 Intracerebral hemorrhage / / 24656865 rs7299264 chr12 73553337 A C 7.66E-06 Intracerebral hemorrhage / / 24656865 rs12811378 chr12 73553914 C G 4.21E-07 Intracerebral hemorrhage / / 24656865 rs12811378 chr12 73553914 C G 8.44E-06 Intracerebral hemorrhage / / 24656865 rs12813018 chr12 73553998 T A 5.94E-07 Intracerebral hemorrhage / / 24656865 rs12813018 chr12 73553998 T A 8.06E-06 Intracerebral hemorrhage / / 24656865 rs12826112 chr12 73555900 T C 3.50E-07 Intracerebral hemorrhage / / 24656865 rs12826112 chr12 73555900 T C 6.91E-06 Intracerebral hemorrhage / / 24656865 rs7302852 chr12 73557168 C A 3.12E-07 Intracerebral hemorrhage / / 24656865 rs7302852 chr12 73557168 C A 6.09E-06 Intracerebral hemorrhage / / 24656865 rs7968144 chr12 73557400 A C 2.40E-05 Urinary metabolites / / 21572414 rs6582131 chr12 73567449 A C 1.50E-05 Urinary metabolites / / 21572414 rs1022331 chr12 73569295 A T 2.27E-06 Intracerebral hemorrhage / / 24656865 rs1022331 chr12 73569295 A T 4.07E-05 Intracerebral hemorrhage / / 24656865 rs11179580 chr12 73586579 C T 5.42E-07 Intracerebral hemorrhage / / 24656865 rs11179580 chr12 73586579 C T 7.01E-08 Intracerebral hemorrhage / / 24656865 rs11615274 chr12 73601132 C T 9.00E-08 Body mass index and cholesterol (psychopharmacological treatment) / / 22417934 rs11179583 chr12 73603758 C T 1.32E-04 Multiple complex diseases / / 17554300 rs1606958 chr12 73659931 C A 1.10E-07 Intracerebral hemorrhage / / 24656865 rs1606958 chr12 73659931 C A 2.06E-06 Intracerebral hemorrhage / / 24656865 rs2063860 chr12 73673738 A G 3.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7315770 chr12 73685326 C T 3.01E-05 Post-operative nausea and vomiting / / 21694509 rs1915280 chr12 73756135 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7295470 chr12 73776884 T C 3.75E-05 Depression (quantitative trait) / / 23290196 rs6582148 chr12 73779132 C G 2.11E-04 Type 2 diabetes / / 17463246 rs10785027 chr12 73782526 A T 2.30E-05 Depression (quantitative trait) / / 23290196 rs1520550 chr12 73783120 G A 2.57E-04 Type 2 diabetes / / 17463246 rs1520550 chr12 73783120 G A 7.40E-04 Multiple complex diseases / / 17554300 rs1520550 chr12 73783120 G A 2.23E-05 Depression (quantitative trait) / / 23290196 rs2139680 chr12 73784155 A T 3.18E-04 Type 2 diabetes / / 17463246 rs2139680 chr12 73784155 A T 5.85E-04 Multiple complex diseases / / 17554300 rs2139680 chr12 73784155 A T 1.59E-05 Depression (quantitative trait) / / 23290196 rs7485858 chr12 73784488 T C 1.37E-05 Depression (quantitative trait) / / 23290196 rs7978337 chr12 73785077 A T 2.37E-04 Type 2 diabetes / / 17463246 rs7978337 chr12 73785077 A T 4.85E-04 Multiple complex diseases / / 17554300 rs7978337 chr12 73785077 A T 1.50E-05 Depression (quantitative trait) / / 23290196 rs7308693 chr12 73796472 C T 3.33E-05 Depression (quantitative trait) / / 23290196 rs10785028 chr12 73797508 G T 3.38E-05 Depression (quantitative trait) / / 23290196 rs7137885 chr12 73801249 T C 3.42E-05 Depression (quantitative trait) / / 23290196 rs10748226 chr12 73805442 G T 4.60E-05 Depression (quantitative trait) / / 23290196 rs7975033 chr12 73807517 A T 5.94E-05 Depression (quantitative trait) / / 23290196 rs1915293 chr12 73811639 C T 6.24E-05 Depression (quantitative trait) / / 23290196 rs6582151 chr12 73813659 T C 4.91E-05 Depression (quantitative trait) / / 23290196 rs6582152 chr12 73814053 C G 8.11E-05 Depression (quantitative trait) / / 23290196 rs7954465 chr12 73816593 A G 5.16E-05 Coronary heart disease / / pha003031 rs7964705 chr12 73816760 C T 2.34E-04 Type 2 diabetes / / 17463246 rs7964705 chr12 73816760 C T 3.42E-04 Multiple complex diseases / / 17554300 rs7964705 chr12 73816760 C T 6.17E-05 Depression (quantitative trait) / / 23290196 rs4760780 chr12 73818611 C T 4.60E-05 Depression (quantitative trait) / / 23290196 rs2203976 chr12 73820610 C T 4.87E-05 Depression (quantitative trait) / / 23290196 rs7953276 chr12 73821580 A C 4.43E-05 Depression (quantitative trait) / / 23290196 rs2363065 chr12 73827434 C T 5.37E-05 Depression (quantitative trait) / / 23290196 rs7963521 chr12 73828956 C T 9.00E-06 Chemerin levels / / 20237162 rs1356893 chr12 73830392 C T 2.85E-05 Depression (quantitative trait) / / 23290196 rs2139675 chr12 73831656 G T 4.93E-05 Depression (quantitative trait) / / 23290196 rs988542 chr12 73838741 G A 4.39E-05 Depression (quantitative trait) / / 23290196 rs10879604 chr12 73870560 A T 5.38E-04 Type 2 diabetes / / 17463246 rs10879604 chr12 73870560 A T 3.26E-05 Depression (quantitative trait) / / 23290196 rs10879605 chr12 73870866 T C 4.13E-05 Depression (quantitative trait) / / 23290196 rs6421241 chr12 73879749 C T 4.69E-04 Type 2 diabetes / / 17463246 rs6421241 chr12 73879749 C T 7.99E-04 Multiple complex diseases / / 17554300 rs6421241 chr12 73879749 C T 7.65E-05 Depression (quantitative trait) / / 23290196 rs11609631 chr12 73884941 T C 7.08E-05 Alzheimer's disease (late onset) / / 21379329 rs11609631 chr12 73884941 T C 8.69E-05 Coronary heart disease / / pha003032 rs11179670 chr12 73889769 A G 8.21E-04 Type 2 diabetes / / 17463246 rs7976937 chr12 73899480 T C 5.38E-05 Depression (quantitative trait) / / 23290196 rs12368237 chr12 73901385 G A 7.61E-05 Depression (quantitative trait) / / 23290196 rs1545292 chr12 73901869 A G 7.83E-05 Depression (quantitative trait) / / 23290196 rs7974278 chr12 73902551 G C 7.87E-05 Depression (quantitative trait) / / 23290196 rs11179680 chr12 73907497 G A 5.64E-05 Depression (quantitative trait) / / 23290196 rs11611073 chr12 73907547 G A 5.86E-05 Depression (quantitative trait) / / 23290196 rs11179681 chr12 73907688 A G 7.14E-05 Depression (quantitative trait) / / 23290196 rs12824659 chr12 73907923 G A 5.79E-05 Depression (quantitative trait) / / 23290196 rs1443742 chr12 73908486 T C 7.66E-05 Depression (quantitative trait) / / 23290196 rs1443738 chr12 73914088 T G 7.18E-05 Depression (quantitative trait) / / 23290196 rs1443737 chr12 73914791 T A 6.70E-05 Depression (quantitative trait) / / 23290196 rs12367407 chr12 73917539 A T 6.27E-05 Depression (quantitative trait) / / 23290196 rs11179688 chr12 73918395 G T 9.70E-05 Depression (quantitative trait) / / 23290196 rs11179690 chr12 73919717 G A 9.75E-05 Depression (quantitative trait) / / 23290196 rs11179697 chr12 73925841 G A 6.74E-05 Depression (quantitative trait) / / 23290196 rs2730495 chr12 73928727 G T 7.46E-04 Multiple complex diseases / / 17554300 rs7316126 chr12 73930019 T A 9.88E-05 Depression (quantitative trait) / / 23290196 rs10785052 chr12 73963383 T C 3.00E-05 Parkinson's disease (age of onset) / / 19772629 rs1154865 chr12 73989837 C G 7.00E-07 Breast cancer / / 17903305 rs1154865 chr12 73989837 C G 7.00E-07 Nasopharyngeal carcinoma / / 20512145 rs17814881 chr12 74023249 G A 4.40E-06 Urinary metabolites / / 21572414 rs2730517 chr12 74038120 C T 4.27E-04 Type 2 diabetes / / 17463246 rs2730519 chr12 74051131 T C 9.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2730520 chr12 74051635 G A 9.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2730523 chr12 74054808 C T 5.83E-04 Type 2 diabetes / / 17463246 rs2586939 chr12 74056763 C T 0.0007901 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2586939 chr12 74056763 C T 7.90E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2730525 chr12 74057467 A G 0.0007981 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2730525 chr12 74057467 A G 7.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1867333 chr12 74064547 G A 9.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1867331 chr12 74064889 G A 0.0007848 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1867331 chr12 74064889 G A 7.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7970034 chr12 74077317 A G 1.93E-05 Prion diseases / / 22210626 rs7970034 chr12 74077317 A G 5.81E-06 Obesity-related traits / / 23251661 rs7970735 chr12 74077615 G C 9.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs7970541 chr12 74077691 C G 9.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs7973710 chr12 74077969 C T 9.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs1595790 chr12 74082978 A G 4.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs10879654 chr12 74083283 C G 9.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs7964120 chr12 74087808 C T 5.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs7964120 chr12 74087808 C T 5.00E-06 Obesity-related traits / / 23251661 rs10879657 chr12 74088110 T C 5.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs10879658 chr12 74089878 T C 7.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs4883490 chr12 74094569 A G 5.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs10785065 chr12 74106579 A G 5.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs11179754 chr12 74107434 A G 6.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs1009993 chr12 74110880 G A 6.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs7133665 chr12 74118822 T C 7.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs7308038 chr12 74120477 C A 9.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs10785070 chr12 74121018 A T 8.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs10785072 chr12 74122742 T C 7.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs7135111 chr12 74122955 G A 7.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs7302750 chr12 74125818 G C 9.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs2165207 chr12 74132268 A C 1.10E-05 Sleep and circadian phenotypes / / 17903308 rs2886365 chr12 74394040 G A 0.0000017 HDL cholesterol particle diameter / / 23263444 rs1829127 chr12 74429110 G A 4.79E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs7305291 chr12 74445607 C T 1.80E-05 Asthma (bronchodilator response) / / 22792082 rs12824038 chr12 74462370 G A 5.50E-06 Asthma (bronchodilator response) / / 22792082 rs11179902 chr12 74465532 C A 5.50E-06 Asthma (bronchodilator response) / / 22792082 rs11179922 chr12 74505531 T C 2.10E-05 Asthma (bronchodilator response) / / 22792082 rs11179926 chr12 74514953 T C 3.59E-04 Type 2 diabetes / / 17463246 rs12306576 chr12 74522056 A G 1.30E-05 Asthma (bronchodilator response) / / 22792082 rs11179933 chr12 74528830 C T 2.50E-05 Asthma (bronchodilator response) LOC100507377 intron 22792082 rs17768585 chr12 74545304 T G 1.52E-04 Tourette syndrome LOC100507377 intron 22889924 rs4883504 chr12 74546211 A T 4.03E-04 Acute lung injury LOC100507377 intron 22295056 rs12426662 chr12 74546400 G T 4.03E-04 Acute lung injury LOC100507377 intron 22295056 rs17113127 chr12 74556615 T A 4.03E-04 Acute lung injury LOC100507377 intron 22295056 rs9788180 chr12 74565985 A C 8.94E-04 Acute lung injury LOC100507377 intron 22295056 rs9788023 chr12 74565997 C T 8.94E-04 Acute lung injury LOC100507377 intron 22295056 rs12424820 chr12 74576497 G A 8.94E-04 Acute lung injury LOC100507377 intron 22295056 rs10506701 chr12 74586210 T G 1.00E-06 Bone mineral density LOC100507377 intron 17903296 rs17113229 chr12 74638630 C T 1.88E-30 Narcolepsy LOC100507377 intron 19629137 rs11180023 chr12 74717465 C G 4.61E-05 Pulmonary function / / 20010835 rs12424603 chr12 74728764 A G 5.22E-05 Pulmonary function / / 20010835 rs11180032 chr12 74734460 T G 5.12E-05 Pulmonary function / / 20010835 rs12423438 chr12 74738165 C T 4.96E-05 Pulmonary function / / 20010835 rs7961201 chr12 74749476 G A 5.04E-05 Pulmonary function / / 20010835 rs10879761 chr12 74777951 G T 4.05E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs10879763 chr12 74778481 C A 7.34E-06 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2169288 chr12 74782677 A C 7.53E-05 Pulmonary function / / 20010835 rs10785114 chr12 74794344 G T 4.81E-05 Pulmonary function / / 20010835 rs10785115 chr12 74794360 C T 4.93E-05 Pulmonary function / / 20010835 rs980784 chr12 74806774 A G 5.46E-05 Pulmonary function / / 20010835 rs10785117 chr12 74807555 C T 5.59E-05 Pulmonary function / / 20010835 rs10879770 chr12 74812328 C G 5.64E-04 Multiple complex diseases / / 17554300 rs10879771 chr12 74817329 C A 8.80E-05 Schizophrenia / / 19571808 rs11180063 chr12 74818098 C G 2.50E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2169292 chr12 74818827 A C 2.86E-05 Pulmonary function / / 20010835 rs2169293 chr12 74818841 G A 6.04E-05 Pulmonary function / / 20010835 rs41504747 chr12 74820891 A G 5.44E-21 Multiple complex diseases / / 17554300 rs1903421 chr12 74835107 C T 3.68E-04 Multiple complex diseases / / 17554300 rs17176910 chr12 74835662 G A 4.04E-04 Multiple complex diseases / / 17554300 rs7963889 chr12 74850683 A G 6.48E-05 Coronary heart disease / / pha003030 rs10785122 chr12 74874472 A G 6.16E-05 Crohn's disease / / 20570966 rs17113542 chr12 74880668 A G 4.53E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1389488 chr12 74934162 C T 4.55E-04 Longevity ATXN7L3B UTR-3 22279548 rs2061579 chr12 74938255 A G 1.40E-04 Sleep and circadian phenotypes / / 17903308 rs10506697 chr12 74955474 A G 3.61E-07 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs2047103 chr12 74984110 A C 9.83E-09 Metabolite levels / / 23281178 rs7299181 chr12 75045728 G T 8.40E-04 Multiple complex diseases / / 17554300 rs7311660 chr12 75054593 A G 4.00E-06 Obesity-related traits / / 23251661 rs11180138 chr12 75056986 T A 5.31E-05 Multiple complex diseases / / 17554300 rs11836636 chr12 75063110 A G 2.36E-04 Celiac disease / / 23936387 rs11180157 chr12 75077344 T C 2.77E-04 Celiac disease / / 23936387 rs7314330 chr12 75095164 A G 9.67E-06 Type 2 diabetes / / 17463246 rs7314793 chr12 75095249 G A 9.67E-06 Type 2 diabetes / / 17463246 rs7138969 chr12 75107893 A C 1.16E-04 Type 2 diabetes / / 17463246 rs11180178 chr12 75108308 G A 3.87E-04 Type 2 diabetes / / 17463246 rs7967572 chr12 75109801 A C 2.10E-04 Type 2 diabetes / / 17463246 rs7316173 chr12 75113419 A G 3.22E-06 Type 2 diabetes / / 17463246 rs7316173 chr12 75113419 A G 3.00E-06 Height / / 17767157 rs4882653 chr12 75118838 A G 6.73E-05 Hemoglobin / / pha003096 rs4882653 chr12 75118838 A G 5.48E-05 Hematocrit / / pha003097 rs12424873 chr12 75131333 G T 9.04E-05 Coronary restenosis / / 21878436 rs1027849 chr12 75141215 T C 9.04E-05 Coronary restenosis / / 21878436 rs12320234 chr12 75141699 C T 9.04E-05 Coronary restenosis / / 21878436 rs1508283 chr12 75155034 A C 3.82E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1508282 chr12 75158824 G A 9.37E-05 Serum metabolites / / 19043545 rs17114195 chr12 75162314 A G 3.90E-06 Multiple complex diseases / / 17554300 rs1911723 chr12 75163097 G A 5.86E-05 Hematocrit / / pha003097 rs7955494 chr12 75168411 T A 1.65E-04 Multiple complex diseases / / 17554300 rs4427626 chr12 75205104 T C 2.00E-05 Response to alcohol consumption (flushing response) / / 24277619 rs1508274 chr12 75228825 C T 5.82E-04 Multiple complex diseases / / 17554300 rs4882660 chr12 75231982 A G 1.08E-04 Response to alcohol consumption (flushing response) / / 24277619 rs10879852 chr12 75259268 A G 7.50E-05 Response to alcohol consumption (flushing response) / / 24277619 rs10506684 chr12 75289669 A G 1.78E-04 Response to alcohol consumption (flushing response) / / 24277619 rs17114354 chr12 75291946 A G 1.77E-04 Response to alcohol consumption (flushing response) / / 24277619 rs7302339 chr12 75298553 C T 7.06E-05 Height / / pha003011 rs1396226 chr12 75299845 A G 5.58E-05 Height / / pha003010 rs1396226 chr12 75299845 A G 2.00E-05 Height / / pha003011 rs7300859 chr12 75301504 T C 2.29E-04 Multiple complex diseases / / 17554300 rs4131955 chr12 75311335 A G 7.67E-05 Height / / pha003010 rs4131955 chr12 75311335 A G 2.97E-05 Height / / pha003011 rs4131954 chr12 75311408 G A 0.0000688 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity / / 22945461 rs4131954 chr12 75311408 G A 6.52E-05 Height / / pha003011 rs1358213 chr12 75335027 A G 6.70E-05 Height / / pha003011 rs12315638 chr12 75340402 C T 8.85E-05 Height / / pha003011 rs7314533 chr12 75352005 T C 5.67E-05 Height / / pha003011 rs10161414 chr12 75372667 T C 8.18E-05 Height / / pha003011 rs1526805 chr12 75384637 T C 2.18E-07 Multiple complex diseases / / 17554300 rs10785164 chr12 75395025 A G 6.20E-04 Smoking initiation / / 24665060 rs11180333 chr12 75401890 T C 3.66E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs10506678 chr12 75422205 G T 6.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) LOC100652893 intron 23648065 rs1589968 chr12 75425891 A G 2.40E-04 Primary sclerosing cholangitis LOC100652893 intron 19944697 rs10785168 chr12 75437253 A C 0.000412 Salmonella-induced pyroptosis KCNC2 intron 22837397 rs10785169 chr12 75443288 C T 0.000444 Salmonella-induced pyroptosis KCNC2 intron 22837397 rs17114532 chr12 75451378 A G 3.70E-04 Sudden cardiac arrest KCNC2 intron 21658281 rs17114678 chr12 75518079 T C 2.00E-04 Cognitive impairment induced by topiramate KCNC2 intron 22091778 rs1379953 chr12 75569444 T C 9.62E-05 Multiple complex diseases KCNC2 intron 17554300 rs17803126 chr12 75576866 T C 2.08E-05 Alcohol and nictotine co-dependence KCNC2 intron 20158304 rs7296952 chr12 75692755 A T 5.24E-04 Multiple complex diseases CAPS2 intron 17554300 rs7301532 chr12 75693751 G A 4.69E-04 Suicide attempts in bipolar disorder CAPS2 intron 21423239 rs11837697 chr12 75707396 A G 5.43E-04 Tourette syndrome CAPS2 intron 22889924 rs12318506 chr12 75718423 G T 8.00E-06 Coronary artery calcification CAPS2 intron 23870195 rs17217158 chr12 75871264 A G 3.56E-04 Alzheimer's disease / / 17998437 rs15513 chr12 75888251 G A 3.70E-05 Monocyte chemoattractant protein-1 GLIPR1 intron pha003071 rs2279244 chr12 75896664 C T 1.45E-04 Alzheimer's disease KRR1 intron 17998437 rs3741495 chr12 75897488 G A 5.03E-05 Monocyte chemoattractant protein-1 KRR1 intron pha003071 rs1275475 chr12 75919693 T C 1.60E-05 Schizophrenia / / 19571808 rs1275475 chr12 75919693 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11610328 chr12 75925402 A G 9.48E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs2700521 chr12 75969345 A G 2.58E-04 Alzheimer's disease / / 17998437 rs2700521 chr12 75969345 A G 9.48E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs1383098 chr12 75981887 C T 9.70E-05 Schizophrenia / / 21791550 rs1383098 chr12 75981887 C T 0.000097 Psychosis / / 23164818 rs2054517 chr12 75991446 C A 9.48E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs1026783 chr12 75997547 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1383102 chr12 76016961 T C 5.40E-05 Schizophrenia / / 19571808 rs7958760 chr12 76023401 G A 1.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4882602 chr12 76026511 C T 5.40E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11180619 chr12 76048838 A C 5.01E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10879957 chr12 76064345 C T 1.07E-04 Parkinson's disease / / 17052657 rs12582659 chr12 76064528 T C 3.00E-06 Blood trace element (Cu levels) / / 23720494 rs11180649 chr12 76110751 A G 8.49E-05 Cognitive impairment induced by topiramate / / 22091778 rs12315478 chr12 76116463 T C 9.01E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7488278 chr12 76129356 T C 7.05E-05 Coronary heart disease / / pha003031 rs17115602 chr12 76135669 T C 6.84E-05 Taste perception / / 22132133 rs10467182 chr12 76174053 T C 8.56E-04 Taste perception / / 22132133 rs11180676 chr12 76174818 T C 3.87E-04 Taste perception / / 22132133 rs1275559 chr12 76217954 C T 5.84E-04 Multiple complex diseases / / 17554300 rs11180700 chr12 76219996 A G 4.16E-05 Multiple complex diseases / / 17554300 rs7307780 chr12 76220618 C T 5.00E-15 Sudden cardiac arrest / / 21658281 rs12822358 chr12 76242070 C G 2.00E-05 Urinary metabolites / / 21572414 rs1623319 chr12 76270756 G A 9.30E-05 Alcoholism (heaviness of drinking) / / 21529783 rs1623319 chr12 76270756 G A 7.57E-05 Attention deficit hyperactivity disorder / / 22012869 rs10879997 chr12 76273506 C A 4.55E-04 Obesity (extreme) / / 21935397 rs1795669 chr12 76273692 G A 4.55E-04 Obesity (extreme) / / 21935397 rs7314267 chr12 76291888 G A 4.10E-05 Alcoholism (heaviness of drinking) / / 21529783 rs2367440 chr12 76312828 T C 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1921484 chr12 76322991 C A 5.46E-04 Taste perception / / 22132133 rs1921484 chr12 76322991 C A 1.98E-04 Lymphocyte counts / / 22286170 rs10735990 chr12 76323196 G A 1.00E-05 Urinary metabolites / / 21572414 rs12809711 chr12 76326273 T C 5.48E-05 Major depressive disorder / / 21621269 rs11180766 chr12 76351647 G A 4.23E-04 Multiple complex diseases / / 17554300 rs3860052 chr12 76352699 T G 9.59E-04 Alcohol dependence / / 21314694 rs17115989 chr12 76357686 A C 1.54E-05 Response to citalopram treatment / / 19846067 rs10450802 chr12 76387761 G A 1.25E-04 Cholesterol / / 17255346 rs10450802 chr12 76387761 G A 2.40E-05 Urinary metabolites / / 21572414 rs4831965 chr12 76388307 A G 1.26E-04 Cholesterol / / 17255346 rs4831965 chr12 76388307 A G 2.50E-05 Urinary metabolites / / 21572414 rs1967986 chr12 76390848 C T 1.54E-04 Cholesterol / / 17255346 rs9739178 chr12 76391166 T A 1.39E-04 Cholesterol / / 17255346 rs4831962 chr12 76391749 G T 1.26E-04 Cholesterol / / 17255346 rs10785219 chr12 76391825 C T 1.26E-04 Cholesterol / / 17255346 rs2367446 chr12 76398733 T C 6.28E-05 Parkinson's disease (motor and cognition) / / 22658654 rs2367446 chr12 76398733 T C 6.28E-05 Immune response to anthrax vaccine / / 22658931 rs17835106 chr12 76405801 T C 1.70E-05 Urinary metabolites / / 21572414 rs7297654 chr12 76413494 G A 5.09E-05 Alcohol and nictotine co-dependence / / 20158304 rs4831914 chr12 76444510 G A 2.90E-05 Urinary metabolites /P1L1 intron 21572414 rs7976730 chr12 76448584 T A 2.00E-05 Urinary metabolites /P1L1 intron 21572414 rs7136330 chr12 76454448 A G 8.13E-04 Type 2 diabetes /P1L1 intron 17463246 rs10880034 chr12 76462612 T C 7.85E-04 Type 2 diabetes /P1L1 intron 17463246 rs10880034 chr12 76462612 T C 2.80E-05 Urinary metabolites /P1L1 intron 21572414 rs1433363 chr12 76464607 T C 3.46E-04 Obesity (extreme) /P1L1 intron 21935397 rs7294592 chr12 76465245 G C 5.73E-05 Alzheimer's disease /P1L1 intron 21098978 rs4831940 chr12 76466230 G A 7.90E-04 Type 2 diabetes /P1L1 intron 17463246 rs1368578 chr12 76476956 A G 1.00E-06 Obesity-related traits /P1L1 intron 23251661 rs11180823 chr12 76477941 A C 5.42E-05 Alzheimer's disease /P1L1 intron 21098978 rs7978060 chr12 76480290 G A 1.70E-06 Obesity-related traits / / 23251661 rs34699916 chr12 76493055 A G 9.97E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11115016 chr12 76574377 G A 9.91E-06 Axial length / / 24144296 rs7311560 chr12 76604910 C T 2.00E-04 Osteoarthritis / / 19508968 rs7971281 chr12 76724809 T G 1.86E-05 B cell non-Hodgkin lymphoma / / 23749188 rs4761423 chr12 76786349 G A 8.20E-04 Multiple complex diseases OSBPL8 intron 17554300 rs7954730 chr12 76822034 A G 9.26E-04 Multiple complex diseases OSBPL8 intron 17554300 rs17197538 chr12 76822661 C T 7.44E-04 Multiple complex diseases OSBPL8 intron 17554300 rs2140489 chr12 76825826 C T 6.50E-04 Multiple complex diseases OSBPL8 intron 17554300 rs10506718 chr12 76875461 C T 1.10E-05 Volumetric brain MRI OSBPL8 intron 17903297 rs2175605 chr12 76885875 G T 7.89E-04 Multiple complex diseases OSBPL8 intron 17554300 rs17042320 chr12 76891199 A G 1.97E-05 Multiple complex diseases OSBPL8 intron 17554300 rs1553944 chr12 76891785 A G 5.99E-04 Multiple complex diseases OSBPL8 intron 17554300 rs4482071 chr12 76911886 G A 1.33E-04 Intracranial aneurysm OSBPL8 intron 20613766 rs73385569 chr12 76931246 C T 1.64E-04 Acne (severe) OSBPL8 intron 24927181 rs7303892 chr12 76953042 G A 9.71E-05 B cell non-Hodgkin lymphoma OSBPL8 intron 23749188 rs10862167 chr12 76960747 A C 7.00E-04 Bone mineral density / / 21927923 rs2632208 chr12 77000851 T C 2.30E-05 Bone mineral density / / 21927923 rs2669010 chr12 77009060 A G 5.00E-06 Systemic lupus erythematosus / / 21408207 rs2632214 chr12 77032629 T C 6.95E-06 B cell non-Hodgkin lymphoma / / 23749188 rs2632212 chr12 77043891 A T 3.05E-05 Multiple complex diseases / / 17554300 rs10746191 chr12 77057949 T G 2.50E-05 Urinary metabolites / / 21572414 rs10506720 chr12 77059559 C T 1.29E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10862334 chr12 77069205 A G 3.64E-04 Type 2 diabetes / / 17463246 rs17259942 chr12 77072077 A G 1.81E-08 Lipid levels / / 20370913 rs17200717 chr12 77077098 T C 3.98E-04 Alcohol dependence / / 21314694 rs10778829 chr12 77079677 C T 7.83E-05 Cognitive performance / / 19734545 rs10862354 chr12 77082287 A G 2.60E-05 Urinary metabolites / / 21572414 rs6539583 chr12 77088881 A G 8.45E-05 Alzheimer's disease (late onset) / / 21379329 rs4258422 chr12 77112010 T G 5.68E-04 Alzheimer's disease / / 24755620 rs7974465 chr12 77122733 C T 1.00E-04 Prostate cancer / / 21743057 rs7956544 chr12 77140628 T C 6.82E-04 Multiple complex diseases / / 17554300 rs11115281 chr12 77152232 C T 2.40E-05 HIV-1 control / / 20041166 rs12369907 chr12 77159952 C T 2.40E-05 HIV-1 control ZDHHC17 intron 20041166 rs11115312 chr12 77165609 C T 2.40E-05 HIV-1 control ZDHHC17 intron 20041166 rs11115453 chr12 77188745 T C 2.40E-05 HIV-1 control ZDHHC17 intron 20041166 rs11115513 chr12 77205235 T C 2.40E-05 HIV-1 control ZDHHC17 intron 20041166 rs10862558 chr12 77207884 A G 3.09E-04 Multiple complex diseases ZDHHC17 intron 17554300 rs1477745 chr12 77212915 G A 2.80E-05 Hypothyroidism ZDHHC17 intron 22493691 rs12368947 chr12 77252971 C T 2.40E-05 HIV-1 control CSRP2 intron 20041166 rs12316906 chr12 77266718 G C 3.45E-04 Alzheimer's disease CSRP2 intron 17998437 rs10862707 chr12 77270548 C A 9.63E-04 Alzheimer's disease CSRP2 intron 17998437 rs1037232 chr12 77341906 G A 8.90E-06 Carotid intima media thickness / / 21909108 rs11836178 chr12 77368984 C G 4.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs12817199 chr12 77372157 A C 4.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs11832533 chr12 77376577 A G 5.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs7976098 chr12 77379179 G C 8.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs7976452 chr12 77381447 T C 9.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs6539856 chr12 77381531 G A 2.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs11832777 chr12 77383787 C A 9.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs12816431 chr12 77384824 G A 5.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs12827341 chr12 77385179 T C 2.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs11116614 chr12 77388231 A G 7.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs310882 chr12 77389165 G A 9.76E-05 Hypertension / / 19609347 rs12810304 chr12 77392678 A G 6.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs12423410 chr12 77421087 C T 2.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) E2F7 intron 20877124 rs2369464 chr12 77434688 A C 8.65E-04 Type 2 diabetes E2F7 intron 17463246 rs310786 chr12 77436148 C T 0.000051 Tamoxifen sensitivity E2F7 intron 23508821 rs310786 chr12 77436148 C T 0.00005 Endoxifen sentivity (10 uM) E2F7 intron 23508821 rs431951 chr12 77437234 A C 5.18E-04 Parkinson's disease E2F7 intron 17052657 rs310802 chr12 77442004 C T 7.01E-04 Multiple complex diseases E2F7 intron 17554300 rs10506725 chr12 77449514 T C 9.24E-04 Alcohol dependence E2F7 intron 21314694 rs12831350 chr12 77470119 T C 5.07E-05 Erythrocyte counts / / pha003090 rs310806 chr12 77501365 G A 7.40E-05 Bone mineral density / / 19181680 rs11117132 chr12 77501909 T C 4.61E-04 Multiple complex diseases / / 17554300 rs4761350 chr12 77511309 G T 2.61E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs7304401 chr12 77543819 T A 3.68E-04 Birth weight / / 17255346 rs771655 chr12 77545429 A G 5.81E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7298190 chr12 77546841 C A 2.55E-04 Gallstones / / 17632509 rs771631 chr12 77554197 C T 7.81E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17043026 chr12 77554617 T C 4.13E-04 Multiple complex diseases / / 17554300 rs10858504 chr12 77591416 T G 6.04E-05 Alcohol withdrawal symptoms / / 22072270 rs4280044 chr12 77593238 G A 6.90E-06 Bone mineral density / / 21124946 rs2369599 chr12 77593579 C T 6.99E-06 Bone mineral density / / 21124946 rs884220 chr12 77593794 T A 7.09E-06 Bone mineral density / / 21124946 rs6538057 chr12 77597063 G A 7.29E-06 Bone mineral density / / 21124946 rs10777010 chr12 77597771 C T 5.73E-04 Smoking cessation / / 24665060 rs7305776 chr12 77598108 A G 7.27E-04 Smoking cessation / / 24665060 rs1520799 chr12 77607223 T C 3.08E-05 Age-related macular degeneration / / pha000002 rs2460728 chr12 77644034 A G 8.45E-05 Body Mass Index / / pha003020 rs1798751 chr12 77647377 G A 1.84E-04 Alzheimer's disease / / 17998437 rs1716525 chr12 77659576 C T 5.24E-04 Alzheimer's disease / / 17998437 rs7296969 chr12 77670502 G C 6.75E-04 Multiple complex diseases / / 17554300 rs7296969 chr12 77670502 G C 7.80E-06 Urinary metabolites / / 21572414 rs10506738 chr12 77680091 T G 2.00E-04 Response to interferon beta in multiple sclerosis / / 18195134 rs2222329 chr12 77686828 A G 9.95E-05 Body Mass Index / / pha003020 rs2222329 chr12 77686828 A G 8.91E-05 Body Mass Index / / pha003021 rs1798747 chr12 77687514 T C 4.37E-04 Alzheimer's disease / / 17998437 rs11104627 chr12 77687546 T C 5.58E-04 White matter integrity / / 22425255 rs11829193 chr12 77687579 C T 2.29E-04 Multiple complex diseases / / 17554300 rs1798746 chr12 77687760 A G 2.31E-04 Alzheimer's disease / / 17998437 rs7974990 chr12 77694415 A G 6.45E-04 Alzheimer's disease / / 17998437 rs10858665 chr12 77697923 C A 1.80E-05 Urinary metabolites / / 21572414 rs7969707 chr12 77705657 A C 5.00E-06 Urinary metabolites / / 21572414 rs7969707 chr12 77705657 A C 1.63E-04 Smoking initiation / / 24665060 rs1402279 chr12 77729385 C T 5.00E-06 Smoking behavior / / 19247474 rs7313980 chr12 77735744 A G 5.10E-04 Smoking initiation / / 24665060 rs6538140 chr12 77738005 G A 4.00E-06 Tuberculosis / / 24057671 rs7958647 chr12 77747825 A G 7.43E-04 Multiple complex diseases / / 17554300 rs4761371 chr12 77749549 C T 6.53E-04 Taste perception / / 22132133 rs4761371 chr12 77749549 C T 3.91E-07 Autism / / 22843504 rs1527047 chr12 77773549 A G 2.54E-05 Iron levels / / 19880490 rs1527047 chr12 77773549 A G 2.54E-05 Iron levels / / pha002876 rs1405539 chr12 77783360 G A 3.75E-05 Iron levels / / 19880490 rs1405539 chr12 77783360 G A 3.75E-05 Iron levels / / pha002876 rs1465070 chr12 77790549 G A 7.18E-04 Iron levels / / pha002876 rs4761378 chr12 77806686 T C 3.30E-05 Alcoholism (heaviness of drinking) / / 21529783 rs798396 chr12 77814373 A G 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs17043588 chr12 77824326 G T 6.58E-04 Smoking initiation / / 24665060 rs4761383 chr12 77888292 A C 4.17E-04 Type 2 diabetes / / 17463246 rs17043686 chr12 77889697 C G 7.80E-04 Type 2 diabetes / / 17463246 rs17788937 chr12 77899510 G A 4.00E-15 Myopia (pathological) / / 23049088 rs1388214 chr12 77901810 A G 0.0002 Migraine / / 22678113 rs711076 chr12 77905207 T C 0.0002 Migraine / / 22678113 rs10506752 chr12 77927190 A G 1.67E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs7307304 chr12 77951894 A G 1.90E-05 Urinary metabolites / / 21572414 rs10858981 chr12 77952294 T C 1.30E-05 Urinary metabolites / / 21572414 rs711098 chr12 77976559 A C 1.00E-05 Urinary metabolites / / 21572414 rs711100 chr12 77982621 C T 1.00E-05 Urinary metabolites / / 21572414 rs711110 chr12 77991049 G C 2.90E-05 Urinary metabolites / / 21572414 rs11105881 chr12 78000729 A G 2.50E-05 Urinary metabolites / / 21572414 rs12827908 chr12 78032818 G T 2.88E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs711124 chr12 78039074 G T 2.35E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1727855 chr12 78063874 G T 2.67E-04 Smoking initiation / / 24665060 rs10161149 chr12 78075142 C T 2.11E-04 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs2251630 chr12 78097425 A G 3.02E-05 Multiple complex diseases / / 17554300 rs12302041 chr12 78130225 G A 1.87E-04 Diabetic nephropathy / / 21150874 rs12302041 chr12 78130225 G A 3.09E-04 Type 2 diabetes / / 22238593 rs1949593 chr12 78161874 C T 4.80E-04 Smoking cessation / / 24665060 rs1569029 chr12 78164406 G T 2.15E-04 Multiple complex diseases / / 17554300 rs11106877 chr12 78221535 A G 8.19E-05 Response to hepatitis C treatment / / 19684573 rs7307970 chr12 78247085 T C 1.63E-04 Smoking cessation /V3 intron 24665060 rs770163 chr12 78256673 G A 6.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) /V3 intron 20877124 rs770155 chr12 78263692 C T 7.50E-06 Urinary metabolites /V3 intron 21572414 rs1677923 chr12 78269151 C G 6.60E-06 Urinary metabolites /V3 intron 21572414 rs1725964 chr12 78269297 C T 5.20E-06 Urinary metabolites /V3 intron 21572414 rs1677915 chr12 78274268 G A 8.10E-06 Urinary metabolites /V3 intron 21572414 rs1677914 chr12 78274425 T C 1.80E-05 Urinary metabolites /V3 intron 21572414 rs936560 chr12 78275379 G T 1.90E-05 Urinary metabolites /V3 intron 21572414 rs1731754 chr12 78275963 A G 3.89E-04 Multiple complex diseases /V3 intron 17554300 rs1731754 chr12 78275963 A G 1.10E-05 Urinary metabolites /V3 intron 21572414 rs1242298 chr12 78279844 A C 1.40E-05 Urinary metabolites /V3 intron 21572414 rs2045989 chr12 78288587 C T 8.39E-04 Type 2 diabetes /V3 intron 17463246 rs7976374 chr12 78293575 G A 9.57E-04 Type 2 diabetes /V3 intron 17463246 rs1920428 chr12 78315081 G A 9.70E-04 Type 2 diabetes /V3 intron 17463246 rs1479027 chr12 78315707 A C 2.70E-05 Urinary metabolites /V3 intron 21572414 rs11107411 chr12 78317934 T G 8.86E-04 Type 2 diabetes /V3 intron 17463246 rs1564303 chr12 78330807 C A 1.75E-04 Type 2 diabetes /V3 intron 17463246 rs1564303 chr12 78330807 C A 2.14E-05 Recombination rate /V3 intron 21698098 rs1677893 chr12 78338386 A T 4.73E-04 Type 2 diabetes /V3 intron 17463246 rs7295890 chr12 78338798 A C 2.36E-04 Type 2 diabetes /V3 intron 17463246 rs1479018 chr12 78340697 T C 6.23E-05 Type 2 diabetes /V3 intron 17463246 rs17044607 chr12 78353984 A C 6.42E-04 Smoking cessation /V3 intron 24665060 rs11107562 chr12 78355782 A C,G,T 9.59E-04 Response to cytidine analogues (gemcitabine) /V3 intron 24483146 rs2731423 chr12 78357509 G T 6.99E-04 Myocardial Infarction /V3 intron pha002873 rs1628326 chr12 78360876 C A 7.94E-04 Myocardial Infarction /V3 intron pha002873 rs11107616 chr12 78364780 T G 7.09E-04 Myocardial Infarction /V3 intron pha002873 rs10859738 chr12 78367551 T A 3.74E-05 Type 2 diabetes /V3 intron 17463246 rs11107763 chr12 78391958 A C 4.69E-04 Response to cytidine analogues (gemcitabine) /V3 intron 24483146 rs10859789 chr12 78395973 G A 5.45E-04 Response to cytidine analogues (gemcitabine) /V3 intron 24483146 rs10506765 chr12 78396276 A C 4.67E-04 Type 2 diabetes /V3 intron 17463246 rs11107957 chr12 78432055 A C 7.19E-07 Osteoarthritis /V3 intron 22763110 rs11108014 chr12 78441806 C T 6.59E-05 Suicide attempts in bipolar disorder /V3 intron 21423239 rs11108015 chr12 78441860 C T 6.98E-05 Suicide attempts in bipolar disorder /V3 intron 21423239 rs3912148 chr12 78445653 T G 3.91E-04 Suicide attempts in bipolar disorder /V3 intron 21423239 rs770108 chr12 78446057 C T 3.38E-05 Suicide attempts in bipolar disorder /V3 intron 21423239 rs11108037 chr12 78448492 A G 4.07E-05 Myocardial Infarction /V3 intron pha002873 rs10506769 chr12 78450734 T C 9.12E-04 Suicide attempts in bipolar disorder /V3 intron 21423239 rs1448753 chr12 78455040 T C 9.22E-04 Suicide attempts in bipolar disorder /V3 intron 21423239 rs300412 chr12 78457671 T C 5.88E-05 Magnesium levels /V3 intron pha003092 rs300476 chr12 78475583 A G 4.47E-04 Parkinson's disease /V3 intron 17052657 rs300483 chr12 78480593 A G 1.05E-04 Myocardial Infarction /V3 intron pha002873 rs300486 chr12 78484121 A G 1.71E-04 Myocardial Infarction /V3 intron pha002873 rs300489 chr12 78485994 G A 5.00E-06 Self-rated health /V3 intron 20707712 rs895860 chr12 78510072 G C 8.03E-04 Smoking quantity /V3 intron 24665060 rs300446 chr12 78517266 T C 1.41E-04 Smoking quantity /V3 intron 24665060 rs300447 chr12 78517410 C T 7.30E-04 Smoking quantity /V3 intron 24665060 rs2694667 chr12 78517968 A C 4.43E-04 Smoking quantity /V3 intron 24665060 rs2694835 chr12 78522136 G A 2.48E-05 Smoking quantity /V3 intron 24665060 rs1852464 chr12 78530979 G A 2.50E-04 Smoking quantity /V3 cds-synon 24665060 rs2290103 chr12 78531156 A G 4.30E-05 Smoking quantity /V3 intron 24665060 rs300462 chr12 78531207 T C 2.42E-04 Smoking quantity /V3 intron 24665060 rs300463 chr12 78532013 C T 1.67E-04 Smoking quantity /V3 intron 24665060 rs300464 chr12 78532030 G C 2.93E-04 Smoking quantity /V3 intron 24665060 rs167274 chr12 78532312 C A 2.50E-04 Smoking quantity /V3 intron 24665060 rs167275 chr12 78532692 A G 2.87E-04 Myocardial Infarction /V3 intron pha002873 rs1726427 chr12 78534233 A G 6.70E-05 Type 2 diabetes /V3 intron 19184112 rs418934 chr12 78538168 T C 6.64E-04 Smoking quantity /V3 intron 24665060 rs1527101 chr12 78539321 G A 7.70E-04 Parkinson's disease /V3 intron 17052657 rs392773 chr12 78546806 G A 7.18E-04 Smoking initiation /V3 intron 24665060 rs1020461 chr12 78571186 T C 7.64E-04 Amyotrophic Lateral Sclerosis /V3 intron 17362836 rs2442133 chr12 78589053 C A 9.28E-04 Response to cytadine analogues (cytosine arabinoside) /V3 intron 24483146 rs300493 chr12 78601785 G A 8.12E-04 Myocardial Infarction /V3 intron pha002873 rs3803039 chr12 78605628 C T 3.70E-04 Smoking initiation /V3 UTR-3 24665060 rs795950 chr12 78632036 A G 6.78E-05 Cholesterol / / pha003083 rs795955 chr12 78636050 T C 8.26E-05 Smoking initiation / / 24665060 rs7312612 chr12 78640351 G T 2.80E-05 Urinary metabolites / / 21572414 rs10506777 chr12 78681923 C A 6.76E-05 stroke (ischemic) / / 17434096 rs1510886 chr12 78700495 A G 3.47E-05 Multiple complex diseases / / 17554300 rs589680 chr12 78729008 T A 4.15E-05 Response to statin treatment (atorvastatin),change in cholesterol levels LOC100507498 intron 20031582 rs7132140 chr12 78736797 G A 6.50E-05 Insulin resistance LOC100507498 intron 21901158 rs12581061 chr12 78755758 G T 1.01E-04 Insulin resistance / / 21901158 rs11109504 chr12 78755911 G A 2.89E-05 Nicotine smoking / / 19268276 rs10777960 chr12 78818865 A G 8.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1031297 chr12 78843915 G C 8.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs12300279 chr12 78844001 G C 7.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs12300279 chr12 78844001 G C 1.10E-05 Urinary metabolites / / 21572414 rs4761417 chr12 78849587 G A 1.98E-05 IgE levels / / 22075330 rs10506786 chr12 78851869 G A 1.95E-05 IgE levels / / 22075330 rs10506786 chr12 78851869 G A 5.59E-05 Asthma / / pha003127 rs9308307 chr12 78852008 C T 6.50E-05 Lipid levels / / 19016617 rs9308307 chr12 78852008 C T 6.94E-06 Lipid levels / / 19016617 rs9308307 chr12 78852008 C T 1.45E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2887745 chr12 78853236 G T 9.29E-04 Type 2 diabetes / / 17463246 rs12579704 chr12 78854747 T A 2.14E-05 IgE levels / / 22075330 rs11109877 chr12 78855602 A G 2.21E-05 IgE levels / / 22075330 rs11109950 chr12 78867586 T G 2.26E-05 IgE levels / / 22075330 rs12315707 chr12 78880444 C T 2.51E-05 IgE levels / / 22075330 rs12309054 chr12 78887565 A T 4.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs1795977 chr12 78887700 G C 2.40E-04 Alzheimer's disease / / 17998437 rs12099529 chr12 78888020 A G 6.43E-05 Alzheimer's disease / / 17998437 rs1581375 chr12 78889751 C T 2.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs12310700 chr12 78890377 G A 3.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs1922395 chr12 78895436 A G 2.05E-04 Schizophrenia / / 21674006 rs2710922 chr12 78899351 T C 3.32E-04 Alzheimer's disease / / 17998437 rs2707126 chr12 78909652 C T 8.51E-04 Coronary heart disease / / 21606135 rs1357096 chr12 78958896 G A 8.18E-04 Alcohol dependence / / 20201924 rs1402608 chr12 78970699 G A 8.92E-06 Mammographic density / / 22532574 rs1717396 chr12 78978563 G C 5.02E-04 Type 2 diabetes / / 17463246 rs1402607 chr12 78990230 G T 2.25E-05 Multiple complex diseases / / 17554300 rs1717379 chr12 78990482 A G 7.34E-05 Mammographic density / / 22532574 rs1609977 chr12 78990847 C T 9.64E-05 Mammographic density / / 22532574 rs487651 chr12 79093237 T G 2.47E-04 Alcohol dependence / / 24277619 rs10219720 chr12 79109021 A T 9.10E-06 Asthma (childhood onset) / / 23829686 rs12298722 chr12 79144329 G A 1.15E-04 Multiple complex diseases / / 17554300 rs1585604 chr12 79208506 T A 4.69E-04 Multiple complex diseases / / 17554300 rs4842415 chr12 79218238 G C 6.35E-04 Multiple complex diseases / / 17554300 rs11111692 chr12 79269121 A G 2.90E-05 Urinary metabolites SYT1 intron 21572414 rs1551847 chr12 79291372 A C 0.0000022 Asthma (exacerbation) SYT1 intron 23706709 rs17045900 chr12 79295601 T C 8.80E-06 Urinary metabolites SYT1 intron 21572414 rs17046032 chr12 79316376 C G 2.00E-06 Insulin-related traits SYT1 intron 22791750 rs17046064 chr12 79329749 A G 2.30E-05 Urinary metabolites SYT1 intron 21572414 rs17046148 chr12 79361757 C T 4.95E-04 Type 2 diabetes SYT1 intron 17463246 rs17046168 chr12 79387804 C T 4.81E-04 Response to taxane treatment (placlitaxel) SYT1 intron 23006423 rs11833585 chr12 79394379 A G 1.64E-04 Type 2 diabetes SYT1 intron 17463246 rs10506803 chr12 79407988 A T 1.39E-06 Type 2 diabetes SYT1 intron 17463246 rs7963579 chr12 79411579 C G,T 7.46E-04 Multiple complex diseases SYT1 intron 17554300 rs12312807 chr12 79433205 G A 5.68E-05 Type 2 diabetes SYT1 intron 17463246 rs1527119 chr12 79440014 T G 1.26E-04 Type 2 diabetes SYT1 intron 17463246 rs1033196 chr12 79442837 G A 8.75E-05 Type 2 diabetes SYT1 intron 17463246 rs1356022 chr12 79450402 A G 1.02E-04 Type 2 diabetes SYT1 intron 17463246 rs10506806 chr12 79454982 C T 3.00E-04 Type 2 diabetes and 6 quantitative traits SYT1 intron 17848626 rs11610381 chr12 79455787 T C 7.45E-05 Type 2 diabetes SYT1 intron 17463246 rs7971081 chr12 79455920 T C 2.59E-05 Type 2 diabetes SYT1 intron 17463246 rs11112562 chr12 79456455 T A 6.77E-04 Depression (quantitative trait) SYT1 intron 20800221 rs17273464 chr12 79460072 G A 5.31E-05 Creutzfeldt-Jakob disease (variant) SYT1 intron 22137330 rs10506807 chr12 79481297 T C 7.00E-05 Creatinine levels SYT1 intron 20222955 rs12300068 chr12 79481371 G A 5.70E-05 Creatinine levels SYT1 intron 20222955 rs11112829 chr12 79505136 T C 7.60E-05 Creatinine levels SYT1 intron 20222955 rs17005224 chr12 79506862 G A 4.65E-04 Celiac disease SYT1 intron 23936387 rs1245771 chr12 79721313 C T 9.86E-04 Aortic root size SYT1 intron 21223598 rs1002491 chr12 79737843 C T 4.48E-05 Anxiety and major depressive disorder SYT1 intron 24047446 rs11114027 chr12 79775248 G T 3.00E-06 Obesity-related traits SYT1 intron 23251661 rs7308297 chr12 79777844 C T 4.63E-04 Type 2 diabetes SYT1 intron 17463246 rs7966962 chr12 79779417 T G 3.97E-04 Type 2 diabetes SYT1 intron 17463246 rs10506815 chr12 79793312 G A 7.30E-06 Urinary metabolites SYT1 intron 21572414 rs1405493 chr12 79793964 A G 2.00E-05 Urinary metabolites SYT1 intron 21572414 rs10861975 chr12 79794590 T C 3.10E-04 Type 2 diabetes SYT1 intron 17463246 rs17005588 chr12 79809256 C T 1.10E-05 Urinary metabolites SYT1 intron 21572414 rs11114112 chr12 79812829 A G 6.51E-06 Obesity-related traits SYT1 intron 23251661 rs11114112 chr12 79812829 A G 2.91E-04 Lung function (forced expiratory volume in 1 second) SYT1 intron 24023788 rs1245665 chr12 79814063 T C 3.00E-09 Electroencephalogram traits,in brain SYT1 intron 20421487 rs11114120 chr12 79837325 G A 2.54E-04 Multiple complex diseases SYT1 intron 17554300 rs7138252 chr12 79922319 C T 1.70E-05 Urinary metabolites / / 21572414 rs11114162 chr12 79931485 A G 3.93E-04 Type 2 diabetes / / 17463246 rs7971769 chr12 79964192 A C 7.12E-04 Type 2 diabetes / / 17463246 rs2307220 chr12 79985874 A C 8.32E-04 Type 2 diabetes PAWR UTR-3 17463246 rs7297018 chr12 80062230 A G 4.00E-06 Attention deficit hyperactivity disorder and conduct disorder PAWR intron 18951430 rs2463107 chr12 80093317 A C 7.30E-05 Alcoholism (heaviness of drinking) / / 21529783 rs12833727 chr12 80167361 C G 8.98E-04 Suicide attempts in bipolar disorder PPP1R12A UTR-3 21041247 rs7961195 chr12 80186065 T C 8.67E-04 Suicide attempts in bipolar disorder PPP1R12A intron 21041247 rs3789989 chr12 80225987 A G 6.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PPP1R12A intron 20877124 rs11114260 chr12 80241493 G A 6.19E-04 Multiple complex diseases PPP1R12A intron 17554300 rs10746146 chr12 80242416 C T 7.45E-04 Type 2 diabetes PPP1R12A intron 17463246 rs1823461 chr12 80278464 T A 8.74E-04 Type 2 diabetes PPP1R12A intron 17463246 rs10506820 chr12 80294654 G T 8.40E-04 Type 2 diabetes PPP1R12A intron 17463246 rs1463228 chr12 80304810 C A 7.14E-04 Type 2 diabetes PPP1R12A intron 17463246 rs7294440 chr12 80309122 T A 3.98E-04 Type 2 diabetes PPP1R12A intron 17463246 rs10746147 chr12 80316758 A G 7.45E-04 Type 2 diabetes PPP1R12A intron 17463246 rs1245077 chr12 80411972 T C 4.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1245077 chr12 80411972 T C 0.000829875 Hypertension (early onset hypertension) / / 22479346 rs1245073 chr12 80414184 T C 6.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1245073 chr12 80414184 T C 0.000898167 Hypertension (early onset hypertension) / / 22479346 rs11114297 chr12 80421199 C T 2.77E-04 Lung function (forced vital capacity) / / 24023788 rs11114297 chr12 80421199 C T 4.50E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs11114299 chr12 80425398 A G 7.68E-05 Multiple complex diseases / / 17554300 rs10862034 chr12 80428105 A G 3.63E-28 Metabolite levels / / 22286219 rs2698271 chr12 80428342 A G 6.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2698271 chr12 80428342 A G 0.000876148 Hypertension (early onset hypertension) / / 22479346 rs1406553 chr12 80429665 A G 1.02E-04 Multiple complex diseases / / 17554300 rs1919579 chr12 80430288 G A 6.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1919579 chr12 80430288 G A 0.000815773 Hypertension (early onset hypertension) / / 22479346 rs10778699 chr12 80463084 G A 4.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs7961750 chr12 80487405 T C 6.41E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs10506821 chr12 80496923 C G 2.00E-07 Hip geometry / / 17903296 rs1113540 chr12 80533199 C T 8.17E-05 Gallstones / / 17632509 rs7976086 chr12 80546693 C G 8.58E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs11114340 chr12 80559764 T C 5.81E-04 Multiple complex diseases / / 17554300 rs11114340 chr12 80559764 T C 4.98E-04 Body mass index / / 21701565 rs6539494 chr12 80569980 T C 5.24E-04 Multiple complex diseases / / 17554300 rs1245016 chr12 80572969 G A 6.60E-04 Body mass index / / 21701565 rs1245016 chr12 80572969 G A 2.42E-05 Tuberculosis / / 24057671 rs12311409 chr12 80574389 T C 5.41E-04 Multiple complex diseases / / 17554300 rs12311409 chr12 80574389 T C 6.60E-04 Body mass index / / 21701565 rs12423804 chr12 80580111 C T 7.79E-04 Multiple complex diseases / / 17554300 rs17006491 chr12 80602463 T C 6.08E-04 Multiple complex diseases / / 17554300 rs12313692 chr12 80608564 G A 3.95E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) OTOGL intron 24023788 rs12313692 chr12 80608564 G A 7.79E-05 Lung function (forced expiratory volume in 1 second) OTOGL intron 24023788 rs12831548 chr12 80608770 T A 7.66E-04 Body mass index OTOGL intron 21701565 rs11114359 chr12 80632556 A G 6.43E-04 Multiple complex diseases OTOGL intron 17554300 rs17307832 chr12 80649989 C G 8.11E-04 Multiple complex diseases OTOGL intron 17554300 rs10862084 chr12 80672533 C A 0.000495 Common carotid artery thickness (average of near and far wall measures) OTOGL intron 23487405 rs10506825 chr12 80689417 G A 5.65E-04 Diabetic retinopathy OTOGL intron 20871662 rs10778724 chr12 80711932 C T 6.80E-05 Bone mineral density (BMD),in women OTOGL intron 20164292 rs6539502 chr12 80763410 C G 3.90E-05 Body mass (lean) OTOGL intron 19268274 rs12313713 chr12 80775817 T C 1.50E-05 Body mass (lean) / / 19268274 rs7311270 chr12 80840771 G A 2.50E-04 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs10862121 chr12 80849580 A G 1.20E-05 Urinary metabolites / / 21572414 rs10862123 chr12 80849794 C T 1.20E-05 Urinary metabolites / / 21572414 rs7300248 chr12 80850127 G A 2.70E-05 Urinary metabolites / / 21572414 rs10862124 chr12 80850522 A T 2.44E-04 Body mass index / / 21701565 rs4489813 chr12 80853265 T C 1.72E-04 Smoking initiation / / 24665060 rs11837911 chr12 80853649 G A 4.13E-04 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs7308740 chr12 80939816 G A 2.55E-05 Bipolar disorder / / 19488044 rs7308740 chr12 80939816 G A 3.72E-05 Bipolar Disorder / / pha002863 rs7309612 chr12 80947082 C T 9.38E-05 Body mass index / / 21701565 rs1163039 chr12 81031541 A C 2.20E-05 Endometriosis / / 21151130 rs1185873 chr12 81101398 G A 1.21E-04 Multiple complex diseases MYF6 nearGene-5 17554300 rs3759084 chr12 81110156 A C 2.02E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1603218 chr12 81141782 A G 5.59E-05 Stroke / / pha002887 rs1305261 chr12 81141819 A G 5.67E-04 Multiple complex diseases / / 17554300 rs12423492 chr12 81142308 A G 6.85E-04 Multiple complex diseases / / 17554300 rs3782169 chr12 81205690 A G 4.24E-04 Response to cytidine analogues (gemcitabine) LIN7A intron 24483146 rs9788209 chr12 81211311 G T 3.17E-04 Multiple complex diseases LIN7A intron 17554300 rs1532370 chr12 81213635 C T 4.20E-04 Response to cytidine analogues (gemcitabine) LIN7A intron 24483146 rs1874302 chr12 81221696 A G 8.29E-04 Response to cytidine analogues (gemcitabine) LIN7A intron 24483146 rs1874302 chr12 81221696 A G 9.34E-04 Response to cytadine analogues (cytosine arabinoside) LIN7A intron 24483146 rs10506836 chr12 81221764 A G 5.46E-04 Multiple complex diseases LIN7A intron 17554300 rs17007444 chr12 81233648 T G 1.66E-04 Multiple complex diseases LIN7A intron 17554300 rs1882169 chr12 81256898 T C 9.85E-05 Left ventricular hypertrophy LIN7A intron pha003052 rs1184776 chr12 81274065 A G 1.12E-04 Non-small cell lung cancer,hypertriglyceridemia with bexarotene treatment of LIN7A intron 21737656 rs11114653 chr12 81310769 G A 2.47E-04 Multiple complex diseases LIN7A intron 17554300 rs7487519 chr12 81315248 T C 1.49E-04 Celiac disease LIN7A intron 23936387 rs2037407 chr12 81321376 A G 4.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LIN7A intron 20877124 rs1163656 chr12 81337458 T A,C,G 2.90E-05 Urinary metabolites / / 21572414 rs1163656 chr12 81337458 T A,C,G 9.00E-06 Dental caries / / 23259602 rs10161012 chr12 81348409 A C 1.70E-04 Multiple complex diseases / / 17554300 rs12310028 chr12 81351839 A G 1.20E-05 Waist Circumference / / pha003023 rs11114666 chr12 81359863 T C 3.51E-04 Multiple complex diseases / / 17554300 rs11114666 chr12 81359863 T C 1.20E-05 Waist Circumference / / pha003023 rs11114668 chr12 81366066 A G 3.70E-05 Waist Circumference / / pha003023 rs11114670 chr12 81368298 G A 3.24E-05 Waist Circumference / / pha003023 rs12819209 chr12 81370848 C T 9.21E-05 Cervical cancer / / 24700089 rs2400862 chr12 81408196 A G 4.38E-04 Multiple complex diseases / / 17554300 rs4842376 chr12 81437253 T C 1.63E-04 Multiple complex diseases / / 17554300 rs7138951 chr12 81475633 G A 5.00E-06 Plasma amyloid beta peptide concentrations (ABx-42) ACSS3 intron 24535457 rs4077193 chr12 81477961 G A 6.80E-04 Amyotrophic lateral sclerosis (sporadic) ACSS3 intron 24529757 rs12296937 chr12 81494252 T G 2.00E-04 Information processing speed ACSS3 intron 21130836 rs5027920 chr12 81512758 C T 2.17E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ACSS3 intron 24023788 rs4240725 chr12 81515046 G A 3.65E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ACSS3 intron 24023788 rs10778791 chr12 81516527 A G 9.99E-05 Information processing speed ACSS3 intron 21130836 rs10778791 chr12 81516527 A G 2.69E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ACSS3 intron 24023788 rs2574740 chr12 81522025 C T 2.37E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ACSS3 intron 24023788 rs61745251 chr12 81528625 C T 0.00087 Prostate cancer ACSS3 missense 23555315 rs2574730 chr12 81530779 A C,G,T 9.99E-05 Information processing speed ACSS3 intron 21130836 rs769056 chr12 81537653 C T 8.91E-05 Information processing speed ACSS3 intron 21130836 rs1435964 chr12 81542215 T C 6.77E-06 Response to antidepressant treatment (citalopram) ACSS3 intron 23726668 rs10492002 chr12 81544536 C T 4.00E-06 Response to antidepressant treatment (citalopram) ACSS3 intron 23726668 rs7132119 chr12 81549675 C A 1.05E-05 Response to antidepressant treatment (citalopram) ACSS3 intron 23726668 rs10778797 chr12 81565373 T C 0.000741 Salmonella-induced pyroptosis ACSS3 intron 22837397 rs12425311 chr12 81575695 C T 0.0003014 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ACSS3 intron 23233654 rs12425311 chr12 81575695 C T 3.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) ACSS3 intron 23233662 rs7972054 chr12 81605153 A C 1.12E-04 Birth weight ACSS3 intron 17255346 rs1921059 chr12 81608567 T A,G 4.79E-05 Cognitive test performance ACSS3 intron 20125193 rs11614103 chr12 81619132 A T 1.53E-04 Acute lung injury ACSS3 intron 22295056 rs1921072 chr12 81621882 C T 1.37E-04 Insulin resistance ACSS3 intron 21901158 rs1950100 chr12 81624720 T A 2.52E-04 Acute lung injury ACSS3 intron 22295056 rs1921057 chr12 81645855 T C 2.20E-05 Urinary metabolites ACSS3 intron 21572414 rs7954123 chr12 81687226 G A 9.15E-04 Insulin resistance PPFIA2 intron 21901158 rs1921049 chr12 81706686 G A 2.52E-04 Multiple complex diseases PPFIA2 intron 17554300 rs1882182 chr12 81723387 C T 2.18E-04 Body mass index PPFIA2 intron 17255346 rs12424630 chr12 81743937 C A 6.51E-04 Multiple complex diseases PPFIA2 intron 17554300 rs10862303 chr12 81792692 C T 2.73E-04 Body mass index PPFIA2 intron 17255346 rs1357264 chr12 81806696 C T 2.68E-04 Body mass index PPFIA2 intron 17255346 rs12578559 chr12 81823972 T C 2.96E-04 Blood pressure PPFIA2 intron 17255346 rs12426725 chr12 81843128 G A 4.00E-06 Schizophrenia PPFIA2 intron 22885689 rs12582634 chr12 81861791 C T 3.06E-04 Body mass index PPFIA2 intron 17255346 rs10746190 chr12 81901318 C A 4.35E-05 Major depressive disorder (broad) PPFIA2 intron 20038947 rs1879800 chr12 81904122 C T 4.40E-05 Major depressive disorder (broad) PPFIA2 intron 20038947 rs1829717 chr12 81909093 G C 7.80E-05 Pulmonary function PPFIA2 intron 23932459 rs7306960 chr12 81918056 C T 9.19E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) PPFIA2 intron 23648065 rs1851386 chr12 81931767 T G 8.93E-05 Birth weight PPFIA2 intron 17255346 rs1851386 chr12 81931767 T G 5.82E-05 Type 2 diabetes PPFIA2 intron 17463246 rs2400954 chr12 81932981 C T 9.39E-05 Major depressive disorder (broad) PPFIA2 intron 20038947 rs2400955 chr12 81933208 T C 5.65E-05 Major depressive disorder (broad) PPFIA2 intron 20038947 rs2400955 chr12 81933208 T C 1.63E-04 Common variable immunodeficiency PPFIA2 intron 21497890 rs11114908 chr12 81933948 T C 1.26E-04 Birth weight PPFIA2 intron 17255346 rs11114908 chr12 81933948 T C 1.86E-04 Type 2 diabetes PPFIA2 intron 17463246 rs2178683 chr12 81941458 C T 1.07E-04 Type 2 diabetes PPFIA2 intron 17463246 rs4842300 chr12 81951301 C T 1.49E-04 Birth weight PPFIA2 intron 17255346 rs1955383 chr12 82003495 A C 6.40E-04 Primary sclerosing cholangitis PPFIA2 intron 19944697 rs2895889 chr12 82003917 C T 1.76E-04 Birth weight PPFIA2 intron 17255346 rs2895889 chr12 82003917 C T 1.13E-04 Type 2 diabetes PPFIA2 intron 17463246 rs2141876 chr12 82016098 T C 1.56E-04 Birth weight PPFIA2 intron 17255346 rs10862339 chr12 82076089 A C 1.90E-05 Major depressive disorder PPFIA2 intron 21042317 rs1344016 chr12 82081470 T C 2.30E-05 Major depressive disorder PPFIA2 intron 21042317 rs10778827 chr12 82105383 T C 6.30E-05 Major depressive disorder PPFIA2 intron 21042317 rs10778828 chr12 82117216 C A 3.83E-04 Obesity (extreme) PPFIA2 intron 21935397 rs1343933 chr12 82123301 A C 4.12E-04 Obesity (extreme) PPFIA2 intron 21935397 rs11615729 chr12 82128318 T A 4.27E-04 Obesity (extreme) PPFIA2 intron 21935397 rs17691177 chr12 82130365 T G 4.25E-04 Coronary heart disease PPFIA2 intron 21606135 rs2244802 chr12 82153749 C G 7.06E-04 Obesity (extreme) / / 21935397 rs10862355 chr12 82162698 C T 5.97E-04 Obesity (extreme) / / 21935397 rs10506852 chr12 82162939 G A 4.93E-04 Coronary heart disease / / 21606135 rs10506852 chr12 82162939 G A 4.72E-07 Post-operative nausea and vomiting / / 21694509 rs12579530 chr12 82163930 A C 5.04E-04 Obesity (extreme) / / 21935397 rs12579544 chr12 82164043 A C 5.04E-04 Obesity (extreme) / / 21935397 rs11115007 chr12 82164673 T A 5.04E-04 Obesity (extreme) / / 21935397 rs11115008 chr12 82164859 G A 5.04E-04 Obesity (extreme) / / 21935397 rs11115009 chr12 82165409 A C 5.04E-04 Obesity (extreme) / / 21935397 rs11115010 chr12 82165895 G T 5.04E-04 Obesity (extreme) / / 21935397 rs7300900 chr12 82166821 G T 7.01E-04 Obesity (extreme) / / 21935397 rs17748942 chr12 82170478 G A 8.73E-04 Obesity (extreme) / / 21935397 rs17692407 chr12 82171369 G C 8.81E-04 Obesity (extreme) / / 21935397 rs17692461 chr12 82171755 C G 8.85E-04 Obesity (extreme) / / 21935397 rs11613196 chr12 82173251 T A 8.87E-04 Obesity (extreme) / / 21935397 rs7956826 chr12 82173365 A G 8.87E-04 Obesity (extreme) / / 21935397 rs11115015 chr12 82174543 T C 8.86E-04 Obesity (extreme) / / 21935397 rs10862356 chr12 82175599 T C 7.61E-04 Multiple complex diseases / / 17554300 rs10862356 chr12 82175599 T C 5.26E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7306395 chr12 82175867 T C 8.85E-04 Obesity (extreme) / / 21935397 rs11115017 chr12 82176914 C A 8.84E-04 Obesity (extreme) / / 21935397 rs17749243 chr12 82178079 A C 8.84E-04 Obesity (extreme) / / 21935397 rs17749267 chr12 82178308 G A 8.84E-04 Obesity (extreme) / / 21935397 rs7965168 chr12 82184467 C A 9.64E-04 Obesity (extreme) / / 21935397 rs11115028 chr12 82200211 A G 4.35E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1922558 chr12 82202002 T C 3.84E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11610365 chr12 82218108 C T 8.12E-04 Obesity (extreme) / / 21935397 rs11115041 chr12 82221714 G A 8.85E-05 Serum metabolites / / 19043545 rs11115041 chr12 82221714 G A 5.99E-04 Alzheimer's disease / / 22005930 rs12307959 chr12 82233424 G A 4.08E-04 Coronary heart disease / / 21606135 rs12580477 chr12 82236527 T C 9.16E-05 Serum metabolites / / 19043545 rs4240731 chr12 82262731 A G 2.60E-06 Prostate cancer / / 22923026 rs6419401 chr12 82283129 T C 3.49E-05 Serum metabolites / / 19043545 rs11115091 chr12 82313681 G A 1.10E-04 Multiple complex diseases / / 17554300 rs6539603 chr12 82325768 T C 3.51E-05 Asthma / / pha003127 rs11115113 chr12 82343529 A G 4.00E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9783478 chr12 82344954 A G 4.90E-05 Personality dimensions / / 18957941 rs9783478 chr12 82344954 A G 3.45E-05 Serum metabolites / / 19043545 rs11115117 chr12 82345329 T C 4.76E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1821320 chr12 82363696 C T 8.82E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10778845 chr12 82365988 G T 4.48E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10862411 chr12 82377165 T C 8.82E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10506855 chr12 82381180 G T 5.70E-04 Type 2 diabetes / / 17846125 rs12814695 chr12 82385896 A C 6.83E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11115146 chr12 82387729 A G 2.26E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10746214 chr12 82388202 A C 5.20E-05 Personality dimensions / / 18957941 rs10746214 chr12 82388202 A C 3.67E-05 Serum metabolites / / 19043545 rs11115148 chr12 82389124 T G 2.05E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1347222 chr12 82394154 T C 3.27E-05 Pulmonary function / / 17903307 rs1347222 chr12 82394154 T C 3.40E-05 Alcoholism (heaviness of drinking) / / 21529783 rs1529757 chr12 82400181 C T 0.0000451 Asthma / / 22694930 rs7961308 chr12 82404500 T C 4.10E-05 Alcoholism (heaviness of drinking) / / 21529783 rs2053093 chr12 82427176 A G 5.70E-04 Alzheimer's disease / / 22005930 rs2256660 chr12 82437609 A T 5.59E-04 Alzheimer's disease / / 22005930 rs12423616 chr12 82439108 T C 5.67E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2256907 chr12 82439672 C T 5.18E-04 Alzheimer's disease / / 22005930 rs11615777 chr12 82446348 G A 8.10E-04 Alzheimer's disease / / 17998437 rs2246421 chr12 82446420 T C 2.30E-04 Alzheimer's disease / / 22005930 rs2246428 chr12 82446605 C T 8.52E-05 Serum metabolites / / 19043545 rs6539608 chr12 82452204 G A 9.26E-04 Alzheimer's disease / / 22005930 rs12425256 chr12 82453709 C G 1.55E-04 Alzheimer's disease / / 22005930 rs10862430 chr12 82455464 A G 4.79E-04 Alzheimer's disease / / 22005930 rs4567545 chr12 82457868 C G 1.23E-04 Alzheimer's disease / / 22005930 rs4076170 chr12 82458325 T C 5.39E-04 Alzheimer's disease / / 22005930 rs4075795 chr12 82458364 C G 5.35E-04 Alzheimer's disease / / 22005930 rs4842417 chr12 82458584 G A 3.50E-04 Alzheimer's disease / / 22005930 rs4842418 chr12 82458718 G A 1.18E-04 Alzheimer's disease / / 22005930 rs12298933 chr12 82458915 G C 1.17E-04 Alzheimer's disease / / 22005930 rs17009197 chr12 82458999 C A 3.65E-04 Alzheimer's disease / / 22005930 rs10160919 chr12 82459556 G A 1.12E-04 Alzheimer's disease / / 22005930 rs10160841 chr12 82459833 T C 1.21E-04 Alzheimer's disease / / 22005930 rs10160959 chr12 82460010 G C 1.10E-04 Alzheimer's disease / / 22005930 rs12314735 chr12 82460141 C T 1.09E-04 Alzheimer's disease / / 22005930 rs12296282 chr12 82460151 T C 1.08E-04 Alzheimer's disease / / 22005930 rs12296487 chr12 82460512 T A 3.05E-04 Alzheimer's disease / / 22005930 rs7953811 chr12 82460654 T C 9.93E-04 Alzheimer's disease / / 22005930 rs7133780 chr12 82461672 A G 1.10E-04 Alzheimer's disease / / 22005930 rs7307137 chr12 82462129 C T 1.11E-04 Alzheimer's disease / / 22005930 rs7137515 chr12 82462226 A G 1.50E-04 Alzheimer's disease / / 22005930 rs7137515 chr12 82462226 A G 6.00E-06 IgG glycosylation / / 23382691 rs7310210 chr12 82462977 G T 1.13E-04 Alzheimer's disease / / 22005930 rs4442614 chr12 82464467 G C 1.16E-04 Alzheimer's disease / / 22005930 rs4500554 chr12 82464504 C A 5.15E-04 Alzheimer's disease / / 22005930 rs10778859 chr12 82464980 G C 1.17E-04 Alzheimer's disease / / 22005930 rs12581457 chr12 82467176 G T 6.75E-05 Diabetes Mellitus / / pha003060 rs4584653 chr12 82468012 A G 3.31E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6539613 chr12 82476853 T C 7.38E-04 Alzheimer's disease / / 22005930 rs11115189 chr12 82488294 G A 8.03E-05 Cognitive test performance / / 20125193 rs11115195 chr12 82500587 A G 0.000627752 Hypertension (early onset hypertension) / / 22479346 rs10082920 chr12 82534465 C T 5.00E-04 Alzheimer's disease / / 17998437 rs12320680 chr12 82537451 A G 8.36E-04 Alzheimer's disease / / 17998437 rs17708720 chr12 82544397 A G 8.24E-04 Multiple complex diseases / / 17554300 rs7309071 chr12 82614676 A G 5.16E-05 Triglycerides / / pha003080 rs4495950 chr12 82744187 A G 7.68E-05 Sodium levels / / pha003093 rs2401035 chr12 82751167 T C 7.68E-05 Sodium levels CCDC59 intron pha003093 rs2401027 chr12 82773899 T C 1.48E-07 Height C12orf26 intron 20400458 rs10506873 chr12 82792942 A G 9.36E-05 Sodium levels C12orf26 cds-synon pha003093 rs17712868 chr12 82796011 A G 6.22E-04 Alzheimer's disease C12orf26 intron 17998437 rs17719063 chr12 82831845 T C 9.36E-05 Sodium levels C12orf26 intron pha003093 rs10506874 chr12 82927005 G A 3.51E-05 Orofacial clefts / / 22419666 rs11832758 chr12 82957844 G A 6.40E-05 Orofacial clefts / / 22419666 rs17720596 chr12 82967011 A C 9.20E-05 Orofacial clefts / / 22419666 rs12425131 chr12 82984879 G A 2.00E-06 Immune response to smallpox vaccine (IL-6) / / 22542470 rs10506876 chr12 83007619 A G 4.67E-05 Blood Pressure / / pha003048 rs11115322 chr12 83019188 T C 3.00E-06 Immune response to smallpox vaccine (IL-6) / / 22542470 rs12822754 chr12 83040610 A G 6.40E-04 Alcohol dependence / / 21314694 rs17840860 chr12 83043909 A G 8.82E-05 Bipolar disorder and schizophrenia / / 20889312 rs17778686 chr12 83059070 T A 9.20E-05 Bipolar disorder and schizophrenia / / 20889312 rs4254133 chr12 83071648 C T 4.90E-04 Alcohol dependence / / 20201924 rs12579483 chr12 83089431 T C 1.86E-06 Alcohol dependence TMTC2 intron 23089632 rs10862496 chr12 83089957 A C 8.90E-04 Parkinson's disease TMTC2 intron 17052657 rs10862496 chr12 83089957 A C 2.51E-04 Amyotrophic Lateral Sclerosis TMTC2 intron 17362836 rs7961953 chr12 83091836 G A 2.27E-04 Lung function (forced expiratory volume in 1 second) TMTC2 intron 17255346 rs7961953 chr12 83091836 G A 4.23E-04 Alzheimer's disease TMTC2 intron 17998437 rs7961953 chr12 83091836 G A 7.00E-05 Glaucoma (primary open-angle) TMTC2 intron 19625618 rs4620789 chr12 83108395 G T 9.63E-06 Alcohol dependence TMTC2 intron 23089632 rs11115386 chr12 83160190 G T 9.07E-05 Parent of origin effect on language impairment (child trend) TMTC2 intron 24571439 rs12317459 chr12 83164556 G A 4.00E-06 Prostate cancer (gene x gene interaction) TMTC2 intron 22219177 rs7953496 chr12 83190546 G T 6.31E-04 Response to cytadine analogues (cytosine arabinoside) TMTC2 intron 24483146 rs7307968 chr12 83191337 A T 5.19E-04 Response to cytadine analogues (cytosine arabinoside) TMTC2 intron 24483146 rs7132287 chr12 83197611 G A 2.08E-04 Type 2 diabetes TMTC2 intron 17463246 rs7132287 chr12 83197611 G A 7.11E-04 Response to cytadine analogues (cytosine arabinoside) TMTC2 intron 24483146 rs7132287 chr12 83197611 G A 8.73E-04 Response to cytidine analogues (gemcitabine) TMTC2 intron 24483146 rs10862511 chr12 83201596 G A 2.76E-04 Response to cytadine analogues (cytosine arabinoside) TMTC2 intron 24483146 rs10862511 chr12 83201596 G A 9.19E-04 Response to cytidine analogues (gemcitabine) TMTC2 intron 24483146 rs10778912 chr12 83201615 A G 2.84E-04 Response to cytadine analogues (cytosine arabinoside) TMTC2 intron 24483146 rs10778912 chr12 83201615 A G 9.12E-04 Response to cytidine analogues (gemcitabine) TMTC2 intron 24483146 rs10506882 chr12 83205152 T C 1.22E-04 Response to cytadine analogues (cytosine arabinoside) TMTC2 intron 24483146 rs10506882 chr12 83205152 T C 6.51E-04 Response to cytidine analogues (gemcitabine) TMTC2 intron 24483146 rs11115447 chr12 83218911 A G 2.10E-05 Urinary metabolites TMTC2 intron 21572414 rs11115448 chr12 83219128 G A 2.30E-05 Urinary metabolites TMTC2 intron 21572414 rs12316012 chr12 83266589 T G 0.000754 Salmonella-induced pyroptosis TMTC2 intron 22837397 rs1796209 chr12 83304031 C T 1.07E-04 Alzheimer's disease (late onset) TMTC2 intron 21379329 rs17010268 chr12 83355139 A T 1.23E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) TMTC2 intron 24192120 rs10862530 chr12 83355980 G A 5.33E-04 Type 2 diabetes TMTC2 intron 17463246 rs10862530 chr12 83355980 G A 1.23E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) TMTC2 intron 24192120 rs7965643 chr12 83413894 T C 1.74E-07 Facial morphology TMTC2 intron 22341974 rs17796608 chr12 83414151 T C 3.52E-07 Facial morphology TMTC2 intron 22341974 rs10862545 chr12 83415230 T A 1.63E-07 Facial morphology TMTC2 intron 22341974 rs10862548 chr12 83415719 G C 1.73E-07 Facial morphology TMTC2 intron 22341974 rs892540 chr12 83417475 T C 3.19E-04 Multiple complex diseases TMTC2 intron 17554300 rs892540 chr12 83417475 T C 5.43E-08 Facial morphology TMTC2 intron 22341974 rs12312967 chr12 83417655 G A 0.0000446 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes TMTC2 intron 22628534 rs2020370 chr12 83417894 G A 6.02E-08 Facial morphology TMTC2 intron 22341974 rs11115542 chr12 83419259 A G 1.95E-07 Facial morphology TMTC2 intron 22341974 rs11115544 chr12 83419504 A G 1.84E-07 Facial morphology TMTC2 intron 22341974 rs11115545 chr12 83419600 A G 1.84E-07 Facial morphology TMTC2 intron 22341974 rs10862560 chr12 83419668 T C 1.81E-07 Facial morphology TMTC2 intron 22341974 rs10746265 chr12 83420448 C G 4.76E-08 Facial morphology TMTC2 intron 22341974 rs4374000 chr12 83421339 A C 1.57E-07 Facial morphology TMTC2 intron 22341974 rs10862566 chr12 83422304 T C 1.56E-07 Facial morphology TMTC2 intron 22341974 rs10862567 chr12 83422352 T A 4.43E-08 Facial morphology TMTC2 intron 22341974 rs11115550 chr12 83422486 T C 1.50E-07 Facial morphology TMTC2 intron 22341974 rs10862568 chr12 83422524 A G 1.22E-07 Facial morphology TMTC2 intron 22341974 rs10862569 chr12 83423108 A T 9.68E-08 Facial morphology TMTC2 intron 22341974 rs17740709 chr12 83423340 A G 1.75E-07 Facial morphology TMTC2 intron 22341974 rs11115563 chr12 83448632 C T 2.50E-05 Urinary metabolites TMTC2 intron 21572414 rs1850531 chr12 83467588 T C 1.20E-04 Amyotrophic lateral sclerosis TMTC2 intron 20801718 rs11836568 chr12 83479442 A T 0.00005362 Sarcoidosis TMTC2 intron 22952805 rs3958102 chr12 83481871 C T 9.72E-04 Response to alcohol consumption (flushing response) TMTC2 intron 24277619 rs75224184 chr12 83482823 C T 0.00002334 Sarcoidosis TMTC2 intron 22952805 rs57910634 chr12 83484407 A G 0.00001981 Sarcoidosis TMTC2 intron 22952805 rs59938885 chr12 83484523 C T 0.00002005 Sarcoidosis TMTC2 intron 22952805 rs56775467 chr12 83485405 G A 0.00004661 Sarcoidosis TMTC2 intron 22952805 rs59976494 chr12 83485465 T G 0.00004661 Sarcoidosis TMTC2 intron 22952805 rs59795570 chr12 83486043 C G 0.00004583 Sarcoidosis TMTC2 intron 22952805 rs79396144 chr12 83487067 T G 0.00008361 Sarcoidosis TMTC2 intron 22952805 rs77787774 chr12 83488607 T C 0.00004099 Sarcoidosis TMTC2 intron 22952805 rs11832362 chr12 83492629 A G 0.00007175 Sarcoidosis TMTC2 intron 22952805 rs79499102 chr12 83495366 T C 0.00007175 Sarcoidosis TMTC2 intron 22952805 rs77312101 chr12 83496474 G A 0.00009894 Sarcoidosis TMTC2 intron 22952805 rs11115597 chr12 83509143 T G 8.39E-04 Multiple complex diseases TMTC2 intron 17554300 rs12826890 chr12 83524765 T C 8.87E-04 Multiple complex diseases TMTC2 intron 17554300 rs2056218 chr12 83532540 C A 4.50E-04 Pulmonary function / / 23932459 rs12820610 chr12 83533676 G C 2.84E-04 Multiple complex diseases / / 17554300 rs1400878 chr12 83609398 A C 9.05E-04 Depression (quantitative trait) / / 20800221 rs11833219 chr12 83610880 T G 9.08E-04 Depression (quantitative trait) / / 20800221 rs7487120 chr12 83728829 G A 3.30E-04 Type 2 diabetes / / 17463246 rs7956512 chr12 83745554 C A,G,T 1.89E-04 Type 2 diabetes / / 17463246 rs7959848 chr12 83746006 C T 3.67E-04 Type 2 diabetes / / 17463246 rs4882448 chr12 83746599 T C 3.90E-04 Type 2 diabetes / / 17463246 rs7136505 chr12 83784502 A G 1.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs6539747 chr12 83813669 A C 4.07E-05 Hypertension / / 21082022 rs17010837 chr12 83847541 G A 2.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs7964484 chr12 83849475 A G 2.30E-05 Hypertension / / 21082022 rs3112112 chr12 83857594 C T 5.00E-04 Myocardial Infarction / / pha002873 rs9651972 chr12 83861845 A G 1.27E-06 Cognitive decline / / 23207651 rs10862691 chr12 83941693 C T 1.96E-04 Multiple complex diseases / / 17554300 rs11115912 chr12 83951676 A G 1.76E-04 Multiple complex diseases / / 17554300 rs9634235 chr12 83962099 C T 3.44E-04 Multiple complex diseases / / 17554300 rs389844 chr12 83977425 A G 5.69E-05 Cognitive test performance / / 20125193 rs2403106 chr12 84008275 A G 3.00E-06 Neonatal lupus / / 20662065 rs10779022 chr12 84070493 A G 2.37E-04 Multiple complex diseases / / 17554300 rs7305888 chr12 84092928 T G 9.62E-05 Multiple complex diseases / / 17554300 rs7305888 chr12 84092928 T G 9.92E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11115997 chr12 84113309 C T 2.35E-04 Multiple complex diseases / / 17554300 rs10779033 chr12 84121474 G T 1.14E-04 Multiple complex diseases / / 17554300 rs717996 chr12 84133820 C T 2.38E-04 Sarcoidosis / / 21540310 rs11116026 chr12 84165587 C T 6.16E-04 Multiple complex diseases / / 17554300 rs11116045 chr12 84196529 A G 2.00E-07 Obesity-related traits / / 23251661 rs17813210 chr12 84206503 T G 5.95E-05 Height / / pha003010 rs7960073 chr12 84216310 A G 1.20E-05 Urinary metabolites / / 21572414 rs1599259 chr12 84220337 A C 1.30E-05 Urinary metabolites / / 21572414 rs17011461 chr12 84231625 A G 8.50E-04 Tourette syndrome / / 22889924 rs1841337 chr12 84251041 T C 5.59E-04 Type 2 diabetes / / 17463246 rs12826181 chr12 84257465 A G 2.00E-05 Urinary metabolites / / 21572414 rs11116093 chr12 84272168 G A 2.20E-05 Urinary metabolites / / 21572414 rs10779058 chr12 84301084 T G 3.22E-06 Coronary heart disease / / 22319020 rs7315661 chr12 84301834 A G 9.30E-04 Type 2 diabetes / / 17463246 rs10862802 chr12 84343247 A C 9.33E-05 Cognitive impairment induced by topiramate / / 22091778 rs7309603 chr12 84392473 C T 7.69E-05 Height / / pha003010 rs12426820 chr12 84465510 T C 3.24E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs10746307 chr12 84477383 A C 4.88E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs17815728 chr12 84508840 T G 4.59E-05 Height / / pha003010 rs1482426 chr12 84521271 A G 0.0000017 Pancreatic cancer and survival / / 22665904 rs10862826 chr12 84534026 G C 1.30E-06 Urinary metabolites / / 21572414 rs1545843 chr12 84564068 G A 1.00E-09 Major depressive disorder / / 21521612 rs12301261 chr12 84578162 C T 5.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs558875487 chr12 84578162 CG C 5.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs12305026 chr12 84580225 C T 8.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs11503588 chr12 84586775 C T 7.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs11116247 chr12 84596635 C A 1.95E-05 Height / / pha003010 rs11116247 chr12 84596635 C A 2.70E-05 Height / / pha003011 rs2929814 chr12 84600256 T C 9.87E-06 Height / / pha003010 rs2929814 chr12 84600256 T C 1.96E-05 Height / / pha003011 rs12099631 chr12 84636620 A G 2.61E-06 Height / / pha003010 rs12099631 chr12 84636620 A G 5.23E-06 Height / / pha003011 rs12313061 chr12 84650489 T A 9.17E-04 Multiple complex diseases / / 17554300 rs7957248 chr12 84657619 A T 5.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs728084 chr12 84668342 G A 5.64E-05 Height / / pha003010 rs2947121 chr12 84681525 G A 2.48E-06 Height / / pha003010 rs2947121 chr12 84681525 G A 2.31E-06 Height / / pha003011 rs2947126 chr12 84687359 T C 2.48E-06 Height / / pha003010 rs2947126 chr12 84687359 T C 2.31E-06 Height / / pha003011 rs1564606 chr12 84697133 A C 2.97E-06 Height / / pha003010 rs1564606 chr12 84697133 A C 3.31E-06 Height / / pha003011 rs2947117 chr12 84705307 A G 7.50E-05 Hypothyroidism / / 22493691 rs4882504 chr12 84733417 A G 7.10E-04 Multiple complex diseases / / 17554300 rs7955818 chr12 84750245 A G 1.83E-05 Aging (time to event) / / 21782286 rs10735471 chr12 84760219 T A 9.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs9668635 chr12 84821550 C T 8.30E-04 Multiple complex diseases / / 17554300 rs4237879 chr12 84824067 A G 5.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs10746321 chr12 84835712 A C 8.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs12229834 chr12 84837414 G A 9.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs10746322 chr12 84838402 G A 9.99E-04 Multiple complex diseases / / 17554300 rs2468286 chr12 84890246 A G 8.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs11116427 chr12 84891650 A G 1.56E-04 Multiple complex diseases / / 17554300 rs982021 chr12 84904357 T C 7.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs2468292 chr12 84906449 A C 8.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs2926474 chr12 84907220 G A 8.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs2446660 chr12 84915416 C T 9.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs2468304 chr12 84919733 A G 9.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs2125716 chr12 84941429 A G 1.13E-05 Systemic lupus erythematosus / / pha002867 rs1471239 chr12 84999922 A G 8.29E-04 Prostate cancer mortality / / 20978177 rs11116503 chr12 85017182 A G 8.70E-04 Nonalcoholic fatty liver disease / / 21423719 rs7960353 chr12 85025936 G A 9.05E-05 Multiple sclerosis / / 17660530 rs10779116 chr12 85034596 T C 5.40E-06 Urinary metabolites / / 21572414 rs1459618 chr12 85036178 C T 4.56E-04 Taste perception / / 22132133 rs9943759 chr12 85048219 T G 3.50E-06 Urinary metabolites / / 21572414 rs12425180 chr12 85076189 A G 8.81E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11116552 chr12 85113168 G A 4.33E-06 Diabetes Mellitus / / pha003059 rs3922762 chr12 85139080 A G 3.23E-04 Stroke / / pha002887 rs10862927 chr12 85141236 C G 4.80E-04 Multiple complex diseases / / 17554300 rs11116586 chr12 85148344 T C 5.34E-04 Multiple complex diseases / / 17554300 rs11116589 chr12 85152301 G A 9.13E-04 Stroke / / pha002887 rs10779128 chr12 85153171 A G 4.46E-04 Type 2 diabetes / / 17463246 rs10779128 chr12 85153171 A G 5.54E-04 Multiple complex diseases / / 17554300 rs10779128 chr12 85153171 A G 2.28E-05 Lung Function (Forced Expiratory Volume in 1 second) / / 25044411 rs11116595 chr12 85165879 T C 2.30E-06 Behavioural disinhibition (generation interaction) / / 23942779 rs11116595 chr12 85165879 T C 5.90E-05 Behavioural disinhibition (generation interaction) / / 23942779 rs1452243 chr12 85171056 T G 7.69E-05 Diabetes Mellitus / / pha003059 rs7300456 chr12 85175559 C T 1.16E-05 Multiple complex diseases / / 17554300 rs6539857 chr12 85177419 C G 1.23E-05 Multiple complex diseases / / 17554300 rs12580834 chr12 85178759 G C 1.27E-05 Bipolar disorder and schizophrenia / / 20889312 rs1452237 chr12 85180128 G A 2.10E-05 Multiple complex diseases / / 17554300 rs1670003 chr12 85185474 G T 1.16E-04 Multiple complex diseases / / 17554300 rs4761097 chr12 85187511 G A 2.00E-06 Behavioural disinhibition (generation interaction) / / 23942779 rs4761097 chr12 85187511 G A 4.80E-05 Behavioural disinhibition (generation interaction) / / 23942779 rs1376985 chr12 85195930 A T 1.69E-05 Multiple complex diseases / / 17554300 rs7976801 chr12 85201306 G A 5.91E-05 Diabetes Mellitus / / pha003059 rs10746333 chr12 85203403 C T 4.39E-05 Diabetes Mellitus / / pha003059 rs1452234 chr12 85203829 T A 2.24E-04 Multiple complex diseases / / 17554300 rs1452228 chr12 85208437 G T 4.96E-05 Multiple complex diseases / / 17554300 rs10779137 chr12 85216724 T C 4.86E-05 Multiple complex diseases / / 17554300 rs4761100 chr12 85218850 T C 1.83E-05 Multiple complex diseases / / 17554300 rs4761102 chr12 85219181 C T 2.12E-05 Multiple complex diseases / / 17554300 rs7968335 chr12 85224141 T C 1.90E-04 Behavioural disinhibition (generation interaction) / / 23942779 rs7968335 chr12 85224141 T C 6.50E-04 Behavioural disinhibition (generation interaction) / / 23942779 rs7968335 chr12 85224141 T C 7.30E-06 Behavioural disinhibition (generation interaction) / / 23942779 rs6539870 chr12 85243681 A C,G 1 Drug response to Etoposide / / 17537913 rs7968722 chr12 85246672 C T 1 Drug response to Etoposide / / 17537913 rs1525544 chr12 85292360 T C 4.31E-04 Multiple complex diseases SLC6A15 intron 17554300 rs7295913 chr12 85313602 A G 1.34E-04 Multiple complex diseases / / 17554300 rs7297073 chr12 85345642 G C 1 Drug response to Etoposide / / 17537913 rs1404866 chr12 85364479 G T 3.04E-07 Osteoarthritis / / 22763110 rs1581563 chr12 85397604 A G 2.73E-05 Bone mineral traits,in men / / 21427758 rs1581563 chr12 85397604 A G 4.31E-05 Bone mineral traits,in men / / 21427758 rs1581563 chr12 85397604 A G 8.36E-05 Bone mineral traits,in men / / 21427758 rs13377881 chr12 85428374 A T 7.56E-04 Alzheimer's disease TSPAN19 intron 22005930 rs17249909 chr12 85437542 A G 5.63E-04 Alzheimer's disease LRRIQ1 intron 22005930 rs11116692 chr12 85448488 G A 7.25E-04 Alzheimer's disease LRRIQ1 intron 22005930 rs7974418 chr12 85449465 T A 6.22E-05 Bipolar disorder and schizophrenia LRRIQ1 cds-synon 20889312 rs7133817 chr12 85452250 A C 8.97E-05 Serum metabolites LRRIQ1 intron 19043545 rs718551 chr12 85465932 T G 5.90E-04 Alzheimer's disease LRRIQ1 intron 22005930 rs3847769 chr12 85471016 T C 4.91E-04 Alzheimer's disease LRRIQ1 intron 22005930 rs11615246 chr12 85486884 A G 6.26E-04 Alzheimer's disease LRRIQ1 intron 22005930 rs7977507 chr12 85509906 T A 5.46E-04 Alzheimer's disease LRRIQ1 intron 22005930 rs11612337 chr12 85511005 T C 4.54E-04 Alzheimer's disease LRRIQ1 intron 22005930 rs7309648 chr12 85532045 T C 5.05E-04 Alzheimer's disease LRRIQ1 intron 22005930 rs11116725 chr12 85532958 A T 3.69E-04 Alzheimer's disease LRRIQ1 intron 22005930 rs11833251 chr12 85533296 T C 5.01E-04 Alzheimer's disease LRRIQ1 intron 22005930 rs7961956 chr12 85551659 G A 3.27E-04 Alzheimer's disease LRRIQ1 intron 22005930 rs201636197 chr12 85552028 A AG 4.42E-04 Alzheimer's disease LRRIQ1 intron 22005930 rs7980616 chr12 85552028 A G 4.42E-04 Alzheimer's disease LRRIQ1 intron 22005930 rs7971976 chr12 85556602 T C 4.35E-04 Alzheimer's disease LRRIQ1 intron 22005930 rs7969025 chr12 85573405 T C 5.21E-04 Alzheimer's disease LRRIQ1 intron 22005930 rs2660454 chr12 85578064 G A 3.23E-05 Bipolar disorder and schizophrenia LRRIQ1 intron 20889312 rs2708499 chr12 85579027 A T 4.23E-04 Alzheimer's disease LRRIQ1 intron 22005930 rs1395676 chr12 85623348 C A 0.00028 Prostate cancer LRRIQ1 cds-synon 23555315 rs1395676 chr12 85623348 C A 0.00055 Prostate cancer (non-advanced prostate cancer) LRRIQ1 cds-synon 23555315 rs7295242 chr12 85698817 G A 5.79E-05 HDL particle features / / pha002900 rs17252053 chr12 85727948 G A 1.09E-07 Primary biliary cirrhosis / / 23000144 rs17252053 chr12 85727948 G A 0.000000109 Facial morphology / / 23028347 rs1913134 chr12 85755859 T C 2.46E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs4761080 chr12 85801359 T C 8.88E-04 Multiple complex diseases / / 17554300 rs1849384 chr12 85833160 A C 0.00034 Prostate cancer / / 23555315 rs6539899 chr12 85972124 A G 1.02E-06 White blood cell count / / 21738479 rs2061689 chr12 86000783 C T 6.17E-06 White blood cell count / / 21738479 rs4897839 chr12 86084899 A G 7.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4897839 chr12 86084899 A G 4.98E-04 Tourette syndrome / / 22889924 rs4897835 chr12 86106960 A G 7.36E-04 Multiple complex diseases / / 17554300 rs11117003 chr12 86115212 G T 6.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10746352 chr12 86120810 G A 6.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10746352 chr12 86120810 G A 6.20E-04 Tourette syndrome / / 22889924 rs2126590 chr12 86139905 A G 4.93E-08 Metabolite levels / / 23281178 rs2126590 chr12 86139905 A G 6.07E-05 Schizophrenia / / 24253340 rs7298458 chr12 86141163 C T 1.26E-08 Metabolite levels / / 23281178 rs7297627 chr12 86141207 G T 1.26E-08 Metabolite levels / / 23281178 rs7314668 chr12 86141471 A G 1.59E-08 Metabolite levels / / 23281178 rs11117016 chr12 86141602 T C 1.26E-08 Metabolite levels / / 23281178 rs11117017 chr12 86141840 G A 1.26E-08 Metabolite levels / / 23281178 rs4341613 chr12 86142152 A T 1.26E-08 Metabolite levels / / 23281178 rs11117020 chr12 86142237 C T 1.26E-08 Metabolite levels / / 23281178 rs2405615 chr12 86143525 C A 1.26E-08 Metabolite levels / / 23281178 rs11117021 chr12 86143624 C T 1.26E-08 Metabolite levels / / 23281178 rs10779201 chr12 86143872 A G 1.26E-08 Metabolite levels / / 23281178 rs974818 chr12 86144307 T C 1.69E-08 Metabolite levels / / 23281178 rs974816 chr12 86144552 A G 1.69E-08 Metabolite levels / / 23281178 rs10863071 chr12 86145813 A G 1.10E-08 Metabolite levels / / 23281178 rs7955135 chr12 86146350 G A 1.10E-08 Metabolite levels / / 23281178 rs4469976 chr12 86146723 T C 1.10E-08 Metabolite levels / / 23281178 rs4492889 chr12 86146735 C A 1.10E-08 Metabolite levels / / 23281178 rs1993807 chr12 86146833 A G 1.10E-08 Metabolite levels / / 23281178 rs1993806 chr12 86147151 T C 1.10E-08 Metabolite levels / / 23281178 rs7139088 chr12 86147878 T C 1.10E-08 Metabolite levels / / 23281178 rs2405616 chr12 86148042 A G 1.10E-08 Metabolite levels / / 23281178 rs7305443 chr12 86148491 G A 1.10E-08 Metabolite levels / / 23281178 rs7137041 chr12 86148726 A C 2.94E-08 Metabolite levels / / 23281178 rs2405621 chr12 86149336 A C,T 2.94E-08 Metabolite levels / / 23281178 rs4559760 chr12 86149414 G A 2.94E-08 Metabolite levels / / 23281178 rs4462416 chr12 86150966 T C 2.94E-08 Metabolite levels / / 23281178 rs4278581 chr12 86151054 A G 2.94E-08 Metabolite levels / / 23281178 rs7307617 chr12 86151317 T C 2.94E-08 Metabolite levels / / 23281178 rs7307626 chr12 86151337 T C 2.94E-08 Metabolite levels / / 23281178 rs10506923 chr12 86152595 C T 2.94E-08 Metabolite levels / / 23281178 rs2405623 chr12 86153466 G A 2.14E-08 Metabolite levels / / 23281178 rs7959372 chr12 86160680 T C 2.94E-08 Metabolite levels / / 23281178 rs4897823 chr12 86161484 C T 2.94E-08 Metabolite levels / / 23281178 rs17344834 chr12 86162226 T A 2.94E-08 Metabolite levels / / 23281178 rs17279133 chr12 86162353 G A 2.94E-08 Metabolite levels / / 23281178 rs17279240 chr12 86162550 A T 2.94E-08 Metabolite levels / / 23281178 rs17279261 chr12 86162714 C T 2.94E-08 Metabolite levels / / 23281178 rs17279289 chr12 86162792 T G 2.94E-08 Metabolite levels / / 23281178 rs17279338 chr12 86162874 G A 2.94E-08 Metabolite levels / / 23281178 rs11613070 chr12 86167544 T A 5.51E-08 Metabolite levels / / 23281178 rs11612432 chr12 86172052 A T 7.44E-04 Multiple complex diseases / / 17554300 rs1448099 chr12 86235433 C T 8.59E-04 Multiple complex diseases / / 17554300 rs7297996 chr12 86235899 C T 3.64E-04 Smoking initiation / / 24665060 rs7137596 chr12 86239884 C G 6.38E-08 Multiple sclerosis / / 17660530 rs12314274 chr12 86249196 T C 7.85E-08 Gallstones / / 17632509 rs3764040 chr12 86266125 A G 4.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs2121889 chr12 86281157 C T 4.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs2121889 chr12 86281157 C T 2.77E-08 Metabolite levels / / 23281178 rs2121889 chr12 86281157 C T 8.00E-05 Celiac disease / / 23936387 rs4143239 chr12 86291728 T A 5.47E-04 Multiple complex diseases / / 17554300 rs11117096 chr12 86302962 C G 1.54E-04 Multiple complex diseases / / 17554300 rs7303256 chr12 86333217 T C 7.99E-04 Multiple complex diseases / / 17554300 rs17354637 chr12 86347752 A G 5.74E-05 IgE levels / / 22075330 rs10506928 chr12 86501376 G A 1.62E-05 Blood Pressure and Arterial Stiffness MGAT4C intron 17903302 rs17013781 chr12 86597346 A G 5.84E-05 Cognitive test performance MGAT4C intron 20125193 rs7302169 chr12 86628268 C T 7.64E-05 Diabetes Mellitus MGAT4C intron pha003060 rs17013833 chr12 86633366 T A 2.57E-04 Multiple complex diseases MGAT4C intron 17554300 rs2897277 chr12 86725799 A G 2.73E-05 Cognitive impairment induced by topiramate MGAT4C intron 22091778 rs2897275 chr12 86726128 C G 3.12E-04 Multiple complex diseases MGAT4C intron 17554300 rs17040806 chr12 86874591 T C 1.00E-04 Cognitive impairment induced by topiramate MGAT4C intron 22091778 rs7134480 chr12 86963546 C G 3.00E-06 Parkinson's disease (interaction with coffee consumption) MGAT4C intron 21876681 rs11836240 chr12 87136991 G T 7.15E-06 QRS duration in Tripanosoma cruzi seropositivity MGAT4C intron 24324551 rs11104067 chr12 87141799 T A 6.92E-06 QRS duration in Tripanosoma cruzi seropositivity MGAT4C intron 24324551 rs2195233 chr12 87142419 A C 6.86E-06 QRS duration in Tripanosoma cruzi seropositivity MGAT4C intron 24324551 rs201316074 chr12 87145223 AAAG A 5.00E-06 QRS duration in Tripanosoma cruzi seropositivity MGAT4C intron 24324551 rs2217235 chr12 87145223 A G 5.00E-06 QRS duration in Tripanosoma cruzi seropositivity MGAT4C intron 24324551 rs4583046 chr12 87177972 T G 8.72E-05 Cytomegalovirus antibody response MGAT4C intron 21993531 rs11104117 chr12 87225050 G A 2.03E-04 Multiple complex diseases MGAT4C intron 17554300 rs4509845 chr12 87242122 A G 6.87E-04 Alcohol dependence / / 21314694 rs1387404 chr12 87242638 A G 0.000549 Salmonella-induced pyroptosis / / 22837397 rs1489347 chr12 87254962 A G 3.26E-04 Multiple complex diseases / / 17554300 rs1489347 chr12 87254962 A G 0.000561 Salmonella-induced pyroptosis / / 22837397 rs1489346 chr12 87255339 C T 1.49E-04 Multiple complex diseases / / 17554300 rs17014258 chr12 87255414 A C 1.60E-05 Urinary metabolites / / 21572414 rs7975775 chr12 87292337 G T 7.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs12322935 chr12 87302254 T A 6.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs10858535 chr12 87339195 A G 2.45E-05 Cytomegalovirus antibody response / / 21993531 rs10777014 chr12 87342209 C A 2.50E-05 Urinary metabolites / / 21572414 rs12311381 chr12 87435308 C A 8.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11104251 chr12 87442480 A C 5.29E-04 Multiple complex diseases / / 17554300 rs1344791 chr12 87464274 C T 3.40E-05 Alcoholism (heaviness of drinking) / / 21529783 rs11104342 chr12 87604084 G T 8.93E-04 Type 2 diabetes / / 17463246 rs11104342 chr12 87604084 G T 5.84E-04 Prostate cancer mortality / / 20978177 rs11612582 chr12 87612844 C A 6.35E-04 Intracranial aneurysm / / 20613766 rs11104365 chr12 87640519 T C 1.09E-04 Celiac disease / / 23936387 rs17605650 chr12 87668025 C T 8.98E-15 Metabolite levels / / 22286219 rs7968238 chr12 87674351 G A 9.22E-05 Orofacial clefts / / 22419666 rs4842553 chr12 87722701 A G 6.72E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3990897 chr12 87727594 C T 1.22E-04 Celiac disease / / 23936387 rs7968395 chr12 87762575 A G 3.84E-04 Alzheimer's disease (late onset) / / 21379329 rs4491334 chr12 87763438 G A 9.86E-05 Multiple complex diseases / / 17554300 rs10777039 chr12 87794714 T C 6.63E-05 Multiple complex diseases / / 17554300 rs10777039 chr12 87794714 T C 1.20E-05 Urinary metabolites / / 21572414 rs12424060 chr12 87801947 T C 2.36E-04 Alzheimer's disease (late onset) / / 21379329 rs9783446 chr12 87806152 G A 1.71E-04 Multiple complex diseases / / 17554300 rs11104481 chr12 87829601 G A 4.43E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs17014865 chr12 87838096 T C 3.91E-07 Multiple complex diseases / / 17554300 rs11832191 chr12 87841866 T C 1.91E-04 Multiple complex diseases / / 17554300 rs1603406 chr12 87887139 G A 9.05E-05 Body Fat Distribution / / pha003016 rs11104524 chr12 87894921 C G 2.50E-05 Urinary metabolites / / 21572414 rs4842577 chr12 87897105 G A 5.21E-05 Lipoproteins / / pha003079 rs12424042 chr12 87905878 G A 8.81E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10858625 chr12 87993243 A G 1.35E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs790443 chr12 88007337 G T 1.83E-04 Multiple complex diseases / / 17554300 rs2698746 chr12 88062014 G A 9.54E-06 Glycemic traits (pregnancy) / / 23903356 rs17329620 chr12 88150777 A C 0.000000552 Stroke / / 23422753 rs1461282 chr12 88186449 C A 4.02E-04 Multiple complex diseases / / 17554300 rs7974491 chr12 88228515 A G 5.67E-04 Multiple complex diseases / / 17554300 rs11104638 chr12 88234604 C A 7.56E-04 Multiple complex diseases / / 17554300 rs7964664 chr12 88238270 A G 9.42E-05 Type 2 diabetes / / 22158537 rs1461294 chr12 88242955 C A 1.93E-04 Blood pressure / / 17255346 rs7311568 chr12 88244801 T C 1.98E-05 Multiple complex diseases / / 17554300 rs1026576 chr12 88249353 C T 1.57E-04 Blood pressure / / 17255346 rs10858652 chr12 88251484 A G 2.99E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2085866 chr12 88266612 A T 2.80E-05 Urinary metabolites / / 21572414 rs2061593 chr12 88279797 A G 2.80E-05 Urinary metabolites / / 21572414 rs11104658 chr12 88294795 G C 2.14E-04 Type 2 diabetes / / 17463246 rs10735266 chr12 88295662 A G 2.80E-05 Urinary metabolites / / 21572414 rs10745469 chr12 88347200 G C 6.59E-04 Multiple complex diseases / / 17554300 rs10777084 chr12 88380094 T C 2.43E-05 Coronary heart disease C12orf50 missense pha003030 rs10858677 chr12 88385522 T C 9.01E-05 Coronary heart disease C12orf50 intron pha003030 rs2731639 chr12 88423374 C G 6.92E-07 Multiple complex diseases / / 17554300 rs2731639 chr12 88423374 C G 1.90E-05 Urinary metabolites / / 21572414 rs10506950 chr12 88438631 A G 1.46E-04 Suicide attempts in bipolar disorder C12orf29 intron 21423239 rs2471513 chr12 88453171 C T 1.63E-04 Multiple complex diseases CEP290 intron 17554300 rs2471503 chr12 88463451 T C 7.05E-04 Alcohol dependence CEP290 intron 21314694 rs2471533 chr12 88495906 C A 2.90E-05 Urinary metabolites CEP290 intron 21572414 rs17335506 chr12 88519346 T C 4.23E-04 Suicide attempts in bipolar disorder CEP290 intron 21423239 rs17335562 chr12 88519610 T C 3.51E-04 Suicide attempts in bipolar disorder CEP290 intron 21423239 rs2471515 chr12 88562221 T A 3.08E-04 Multiple complex diseases TMTC3 intron 17554300 rs11104772 chr12 88624902 A C 1.90E-04 Multiple complex diseases / / 17554300 rs11104778 chr12 88643302 C G 6.21E-04 Alcohol dependence / / 21314694 rs17422027 chr12 88704290 T G 4.26E-04 Multiple complex diseases / / 17554300 rs2041859 chr12 88724929 C T 4.94E-07 Red blood cell traits / / 23222517 rs4842602 chr12 88732585 C T 9.43E-07 Testicular germ cell cancer / / 20543847 rs2111041 chr12 88739435 C T 1.50E-05 Urinary metabolites / / 21572414 rs7965472 chr12 88740127 G A 1.50E-05 Urinary metabolites / / 21572414 rs2193027 chr12 88751845 C T 5.10E-07 Red blood cell traits / / 23222517 rs12423928 chr12 88754155 A G 5.96E-04 Multiple complex diseases / / 17554300 rs10777108 chr12 88760269 A C 3.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs10777111 chr12 88776646 C A 7.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs7300108 chr12 88777621 C T 8.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs2407708 chr12 88779194 A G 5.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs759483 chr12 88783374 A G 5.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs10777112 chr12 88785576 G A 5.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs10858724 chr12 88786335 C G 5.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs7955421 chr12 88787112 C T 5.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs10745480 chr12 88787395 T C 4.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs2080413 chr12 88788720 A T 4.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs2216151 chr12 88788901 A T 4.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs6538147 chr12 88789888 T C 3.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs7358738 chr12 88790025 A G 4.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs4842608 chr12 88790974 G A 7.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs1468827 chr12 88794587 C T 3.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs1024823 chr12 88795465 C T 8.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs1468829 chr12 88800676 G C 5.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs2019997 chr12 88801020 G T 5.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs4529971 chr12 88801794 C A 7.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs7308721 chr12 88802460 C T 6.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs10777114 chr12 88805632 C T 5.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs2193023 chr12 88806424 A C 4.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs7488371 chr12 88808007 A C 4.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs7488412 chr12 88808147 A G 4.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs11104858 chr12 88808208 T C 4.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs4842609 chr12 88811188 T C 7.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs4842610 chr12 88811689 C T 8.23E-10 Testicular germ cell cancer / / 20543847 rs4842610 chr12 88811689 C T 1.99E-07 Red blood cell traits / / 23222517 rs4842611 chr12 88811799 C T 5.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs4130353 chr12 88812525 C G 4.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs4842612 chr12 88816232 A G 3.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs6538148 chr12 88818479 C G 2.55E-08 Red blood cell traits / / 23222517 rs7296587 chr12 88821852 A G 4.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs11104866 chr12 88826959 C G 4.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs10858730 chr12 88827890 G C 4.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs11104868 chr12 88828442 G A 8.65E-04 Multiple complex diseases / / 17554300 rs11104870 chr12 88829294 C T 6.00E-11 Red blood cell traits / / 23222517 rs7487416 chr12 88829519 C G 5.97E-04 Multiple complex diseases / / 17554300 rs7486184 chr12 88847001 A G 4.56E-07 Testicular cancer / / 19483682 rs7486184 chr12 88847001 A G 3.95E-07 Testicular cancer / / 21551455 rs7974506 chr12 88848006 A G 7.18E-08 Testicular germ cell cancer / / 20543847 rs11104896 chr12 88865241 T C 6.88E-07 Testicular germ cell cancer / / 20543847 rs11104901 chr12 88874179 G T 2.31E-13 Testicular germ cell cancer / / 20543847 rs995030 chr12 88890671 A G 1.00E-31 Testicular germ cell tumor KITLG UTR-3 19483681 rs995030 chr12 88890671 A G 3.00E-30 Testicular germ cell tumor KITLG UTR-3 19483681 rs995030 chr12 88890671 A G 7.47E-09 Testicular cancer KITLG UTR-3 19483682 rs995030 chr12 88890671 A G 1.00E-31 Nasopharyngeal carcinoma KITLG UTR-3 20512145 rs995030 chr12 88890671 A G 2.65E-12 Testicular germ cell cancer KITLG UTR-3 20543847 rs995030 chr12 88890671 A G 5.78E-10 Testicular cancer KITLG UTR-3 21551455 rs995030 chr12 88890671 A G 3.00E-13 Testicular germ cell tumor KITLG UTR-3 23666239 rs995030 chr12 88890671 A G 2.00E-50 Testicular germ cell tumor KITLG UTR-3 23666240 rs11104911 chr12 88904764 C T 8.85E-25 Testicular germ cell cancer KITLG intron 20543847 rs11104913 chr12 88911022 G C 9.21E-04 Multiple complex diseases KITLG intron 17554300 rs10777125 chr12 88915835 G A 6.66E-13 Testicular germ cell cancer KITLG intron 20543847 rs1022034 chr12 88918743 T G 4.13E-11 Testicular germ cell cancer KITLG intron 20543847 rs1492347 chr12 88925973 T C 2.29E-24 Testicular germ cell cancer KITLG intron 20543847 rs4842632 chr12 88931532 T C 8.99E-04 Multiple complex diseases KITLG intron 17554300 rs10506956 chr12 88932035 C A 8.84E-04 Multiple complex diseases KITLG intron 17554300 rs10506956 chr12 88932035 C A 1.24E-10 Testicular germ cell cancer KITLG intron 20543847 rs11104939 chr12 88932364 T C 1.63E-04 Multiple complex diseases KITLG intron 17554300 rs11104941 chr12 88933341 G A 8.20E-04 Multiple complex diseases KITLG intron 17554300 rs1492348 chr12 88936648 G A 3.07E-04 Suicide attempts in bipolar disorder KITLG intron 21041247 rs3782176 chr12 88939133 A G 1.29E-12 Testicular germ cell cancer KITLG intron 20543847 rs2407206 chr12 88943323 G A 7.44E-04 Multiple complex diseases KITLG intron 17554300 rs1472899 chr12 88951485 C T 3.63E-04 Multiple complex diseases KITLG intron 17554300 rs1472899 chr12 88951485 C T 3.09E-09 Testicular cancer KITLG intron 19483682 rs1472899 chr12 88951485 C T 4.08E-10 Testicular cancer KITLG intron 21551455 rs3782179 chr12 88953326 C T 3.78E-04 Multiple complex diseases KITLG intron 17554300 rs3782179 chr12 88953326 C T 1.35E-09 Testicular cancer KITLG intron 19483682 rs3782179 chr12 88953326 C T 1.82E-10 Testicular cancer KITLG intron 21551455 rs3782180 chr12 88953399 C A 5.57E-04 Multiple complex diseases KITLG intron 17554300 rs3782181 chr12 88953561 C A 2.63E-04 Multiple complex diseases KITLG intron 17554300 rs3782181 chr12 88953561 C A 8.38E-10 Testicular cancer KITLG intron 19483682 rs3782181 chr12 88953561 C A 2.00E-26 Testicular germ cell cancer KITLG intron 20543847 rs3782181 chr12 88953561 C A 1.11E-10 Testicular cancer KITLG intron 21551455 rs4474514 chr12 88953959 G A 5.77E-04 Multiple complex diseases KITLG intron 17554300 rs4474514 chr12 88953959 G A 6.00E-15 Testicular cancer KITLG intron 19483682 rs4474514 chr12 88953959 G A 6.00E-15 Nasopharyngeal carcinoma KITLG intron 20512145 rs4474514 chr12 88953959 G A 7.08E-11 Testicular cancer KITLG intron 21551455 rs11104952 chr12 88956400 T G 8.36E-04 Multiple complex diseases KITLG intron 17554300 rs11104952 chr12 88956400 T G 1.90E-09 Testicular cancer KITLG intron 19483682 rs11104952 chr12 88956400 T G 3.58E-10 Testicular cancer KITLG intron 21551455 rs1352947 chr12 88960727 C T 4.24E-09 Testicular cancer KITLG intron 19483682 rs1352947 chr12 88960727 C T 1.01E-09 Testicular cancer KITLG intron 21551455 rs1508595 chr12 88986016 G A 3.00E-30 Nasopharyngeal carcinoma / / 20512145 rs1508595 chr12 88986016 G A 1.81E-26 Testicular germ cell cancer / / 20543847 rs1508595 chr12 88986016 G A 1.29E-10 Testicular germ cell tumor / / 23666239 rs1508595 chr12 88986016 G A 4.91E-46 Testicular germ cell tumor / / 23666240 rs2639101 chr12 89012852 A C 1.37E-06 Testicular cancer / / 21551455 rs7131923 chr12 89017335 C A 3.98E-04 Type 2 diabetes / / 17463246 rs10858765 chr12 89028441 G A 1.66E-04 Type 2 diabetes / / 17463246 rs7953625 chr12 89045399 G T 7.02E-04 Type 2 diabetes / / 17463246 rs17016022 chr12 89150244 G A 3.82E-04 Schizophrenia / / 20832056 rs10732643 chr12 89162115 T G 6.61E-05 Brain lesion load / / 19010793 rs10732643 chr12 89162115 T G 8.30E-06 Stroke (ischemic) / / 22384361 rs11105050 chr12 89175535 T C 1.18E-04 Telomere length / / 21573004 rs198639 chr12 89313894 G A 1.76E-04 Multiple complex diseases / / 17554300 rs12821256 chr12 89328335 T C 4.00E-30 Blond vs. brown hair color / / 17952075 rs12821256 chr12 89328335 T C 8.40E-18 Skin sensitivity to sun / / 18488028 rs12821256 chr12 89328335 T C 1.80E-05 Urinary metabolites / / 21572414 rs12821256 chr12 89328335 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12821256 chr12 89328335 T C 7.00E-19 Hair color / / 23548203 rs10161354 chr12 89345489 T G 2.34E-05 Myopia (severe) / / 23933737 rs764833 chr12 89349970 G T 3.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs10858809 chr12 89365305 A G 6.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs11608458 chr12 89369806 C T 8.54E-05 stroke (ischemic) / / 17434096 rs735390 chr12 89375407 G A 5.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10858818 chr12 89426732 A C 5.12E-04 Multiple complex diseases / / 17554300 rs12311684 chr12 89435177 A G 2.58E-04 Multiple complex diseases / / 17554300 rs7312905 chr12 89462845 C G 5.78E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12820818 chr12 89470891 C T 5.15E-04 Multiple complex diseases / / 17554300 rs7960664 chr12 89471235 G A 5.21E-05 Major depressive disorder / / 21621269 rs7960664 chr12 89471235 G A 9.96E-05 Major depressive disorder / / pha002850 rs11105168 chr12 89473626 A C 1.23E-06 Schizophrenia / / 24253340 rs11105171 chr12 89475779 A G 2.59E-04 Multiple complex diseases / / 17554300 rs11834560 chr12 89488629 G T 4.29E-04 Aortic root size / / 21223598 rs10745494 chr12 89499293 G A 2.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10745494 chr12 89499293 G A 2.55E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3926062 chr12 89504012 G A 4.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17016437 chr12 89535970 T C 2.95E-04 Multiple complex diseases / / 17554300 rs1356773 chr12 89555278 T C 4.16E-05 Recombination rate / / 21698098 rs17016472 chr12 89573825 A G 5.55E-04 Multiple complex diseases / / 17554300 rs17016528 chr12 89611275 C T 3.20E-04 Self-reported allergy / / 23817569 rs2046950 chr12 89618130 G A 1.57E-04 Self-reported allergy / / 23817569 rs963921 chr12 89624279 C T 1.58E-04 Self-reported allergy / / 23817569 rs10506967 chr12 89624599 A G 5.75E-05 Alzheimer's disease / / 17998437 rs17016542 chr12 89627079 C G 1.48E-04 Self-reported allergy / / 23817569 rs1091646 chr12 89635823 G A 7.37E-04 Substance dependence / / 21818250 rs10858841 chr12 89662733 C A 3.58E-04 Multiple complex diseases / / 17554300 rs2638463 chr12 89669785 G A 2.90E-06 Major depressive disorder / / 21042317 rs2085997 chr12 89674579 C T 4.53E-04 Body mass index / / 17255346 rs2085997 chr12 89674579 C T 6.60E-06 Urinary metabolites / / 21572414 rs2638470 chr12 89675376 G A 3.60E-06 Major depressive disorder / / 21042317 rs2638470 chr12 89675376 G A 9.87E-06 Blood Pressure / / pha003040 rs12302525 chr12 89726425 C G 4.10E-05 Nicotine smoking / / 19268276 rs1688549 chr12 89752321 A T 8.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs10506971 chr12 89757937 G A 3.92E-04 Type 2 diabetes / / 17463246 rs1427828 chr12 89762499 C G 4.58E-05 Cardiovascular disease / / 17903304 rs770083 chr12 89776284 T C 3.10E-04 Type 2 diabetes / / 17463246 rs770082 chr12 89776485 G A 9.43E-04 Type 2 diabetes / / 17463246 rs770377 chr12 89816443 T A 3.76E-04 Type 2 diabetes POC1B intron 17463246 rs770374 chr12 89818022 T G 5.30E-05 Pancreatic cancer POC1B intron pha002889 rs17016868 chr12 89824309 G A 3.20E-06 Urinary metabolites POC1B intron 21572414 rs6538188 chr12 89857138 G A 3.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) POC1B intron 20877124 rs3958726 chr12 89857423 A C 3.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) POC1B intron 20877124 rs3958726 chr12 89857423 A C 6.40E-171 Blood pressure POC1B intron 22100073 rs11105298 chr12 89876143 T C 7.70E-04 Coronary Artery Disease POC1B intron 17634449 rs10777177 chr12 89899103 A C 2.80E-04 Lung function (forced expiratory volume in 1 second) POC1B intron 24023788 rs10777181 chr12 89908627 T C 3.94E-08 Lymphocyte counts POC1B intron 22286170 rs4842666 chr12 89941549 T C 2.00E-07 Blood pressure / / 24954895 rs4842666 chr12 89941549 T C 4.00E-08 Blood pressure / / 24954895 rs11105329 chr12 89951345 T G 2.08E-04 Type 2 diabetes / / 17463246 rs11610818 chr12 89963672 G A 9.92E-05 Type 2 diabetes / / 17463246 rs1224263 chr12 89975703 G A 2.83E-04 Type 2 diabetes / / 17463246 rs10506975 chr12 89986523 T C 5.13E-04 Suicide attempts in bipolar disorder ATP2B1 intron 21423239 rs1401982 chr12 89989599 G A 0.000051 Coronary artery calcification ATP2B1 intron 23727086 rs2681479 chr12 89995732 A G 3.99E-04 Type 2 diabetes ATP2B1 intron 17463246 rs17017109 chr12 90004107 T G 1.99E-04 Suicide attempts in bipolar disorder ATP2B1 intron 21423239 rs2681472 chr12 90008959 A G 1.00E-09 Diastolic blood pressure ATP2B1 intron 19430479 rs2681472 chr12 90008959 A G 2.00E-11 Hypertension ATP2B1 intron 19430479 rs2681472 chr12 90008959 A G 2.00E-11 Coronary heart disease ATP2B1 intron 21347282 rs2681472 chr12 90008959 A G 5.07E-09 Blood pressure ATP2B1 intron 21909110 rs2681472 chr12 90008959 A G 2.30E-11 Blood pressure ATP2B1 intron 22100073 rs2681472 chr12 90008959 A G 0.000123 Coronary artery disease ATP2B1 intron 23202125 rs2681492 chr12 90013089 T C 4.00E-11 Systolic blood pressure ATP2B1 intron 19430479 rs2681492 chr12 90013089 T C 4.00E-11 Coronary heart disease ATP2B1 intron 21347282 rs2681492 chr12 90013089 T C 9.91E-09 Blood pressure ATP2B1 intron 21909110 rs2681492 chr12 90013089 T C 3.39E-07 Blood pressure ATP2B1 intron 24001895 rs11105354 chr12 90026523 A G 1.10E-10 Blood pressure ATP2B1 intron 22100073 rs11105354 chr12 90026523 A G 3.25E-09 Blood pressure ATP2B1 intron 22100073 rs11105354 chr12 90026523 A G 3.95E-08 Blood pressure ATP2B1 intron 22100073 rs11105354 chr12 90026523 A G 4.43E-09 Blood pressure ATP2B1 intron 22100073 rs11105354 chr12 90026523 A G 7.86E-05 Blood pressure ATP2B1 intron 22100073 rs11105354 chr12 90026523 A G 0.000028 Coronary artery calcification ATP2B1 intron 23727086 rs4842669 chr12 90036710 C T 3.93E-04 Type 2 diabetes ATP2B1 intron 17463246 rs4842670 chr12 90037342 C T 3.80E-04 Type 2 diabetes ATP2B1 intron 17463246 rs10858915 chr12 90051547 G A 0.000043 Coronary artery calcification ATP2B1 nearGene-5 23727086 rs17249754 chr12 90060586 G A 1.00E-07 Biomedical quantitative traits / / 19396169 rs17249754 chr12 90060586 G A 3.00E-06 Biomedical quantitative traits / / 19396169 rs17249754 chr12 90060586 G A 2.00E-13 Blood pressure / / 21572416 rs17249754 chr12 90060586 G A 8.00E-20 Blood pressure / / 21572416 rs17249754 chr12 90060586 G A 1.00E-17 Blood pressure / / 21909110 rs17249754 chr12 90060586 G A 6.00E-10 Blood pressure / / 21909110 rs17249754 chr12 90060586 G A 1.82E-18 Systolic blood pressure / / 21909115 rs17249754 chr12 90060586 G A 1.21E-05 Blood pressure / / 24001895 rs17249754 chr12 90060586 G A 7.00E-15 Blood pressure / / 24001895 rs17249754 chr12 90060586 G A 7.48E-15 Blood pressure / / 24001895 rs6538196 chr12 90064604 T G 4.79E-04 Type 2 diabetes / / 17463246 rs4842673 chr12 90072015 G A 4.66E-04 Type 2 diabetes / / 17463246 rs1880979 chr12 90078050 T G 5.19E-04 Type 2 diabetes / / 17463246 rs10745509 chr12 90080220 C A 8.05E-04 Type 2 diabetes / / 17463246 rs7136259 chr12 90081188 T C 6.00E-10 Coronary heart disease / / 22751097 rs7136259 chr12 90081188 T C 0.00014 Coronary artery calcification / / 23727086 rs10858918 chr12 90096345 T C 4.74E-05 Hypertension (essential hypertension) / / 22184326 rs4842499 chr12 90109321 T G 5.70E-06 Urinary metabolites / / 21572414 rs17782943 chr12 90182790 G T 5.03E-09 Bilirubin levels,in serum / / 20639394 rs12424558 chr12 90266133 C G 4.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs11105447 chr12 90270430 G C 2.36E-05 Type 1 diabetes / / 21980299 rs12321194 chr12 90301455 A G 1.52E-04 Acute lung injury / / 22295056 rs141875161 chr12 90305779 ATGTGTGTG A 1.00E-16 magnesium levels / / 20700443 rs34105374 chr12 90305779 ATG A 1.00E-16 magnesium levels / / 20700443 rs398044634 chr12 90305779 ATG A 1.00E-16 magnesium levels / / 20700443 rs567888741 chr12 90305779 ATGTGTG A 1.00E-16 magnesium levels / / 20700443 rs569428430 chr12 90305779 ATGTG A 1.00E-16 magnesium levels / / 20700443 rs57648028 chr12 90305779 ATG A 1.00E-16 magnesium levels / / 20700443 rs7965584 chr12 90305779 A G 1.00E-16 magnesium levels / / 20700443 rs7307097 chr12 90340007 A G 9.08E-05 Epilepsy (remission after treatment) / / 23962720 rs4433629 chr12 90341455 G A 1.34E-07 Primary biliary cirrhosis / / 23000144 rs4433629 chr12 90341455 G A 0.000000134 Facial morphology / / 23028347 rs10745519 chr12 90341628 G T 9.10E-05 Epilepsy (remission after treatment) / / 23962720 rs4471496 chr12 90349061 C T 4.49E-05 Epilepsy (remission after treatment) / / 23962720 rs7132526 chr12 90351237 T G 5.56E-04 Smoking initiation / / 24665060 rs4842700 chr12 90351662 A G 4.39E-05 Epilepsy (remission after treatment) / / 23962720 rs7306228 chr12 90352436 C T 1.78E-04 Smoking initiation / / 24665060 rs4129656 chr12 90354375 G A 4.71E-05 Epilepsy (remission after treatment) / / 23962720 rs10745520 chr12 90360063 A G 1.63E-04 Smoking initiation / / 24665060 rs4584633 chr12 90360461 C T 8.25E-05 Epilepsy (remission after treatment) / / 23962720 rs4466894 chr12 90362052 A G 6.94E-04 Smoking initiation / / 24665060 rs4842702 chr12 90368079 C T 7.26E-05 Epilepsy (remission after treatment) / / 23962720 rs4842703 chr12 90368149 G T 7.27E-05 Epilepsy (remission after treatment) / / 23962720 rs7303123 chr12 90369351 A G 2.19E-04 Smoking initiation / / 24665060 rs7134374 chr12 90369627 T C 7.61E-05 Epilepsy (remission after treatment) / / 23962720 rs7972170 chr12 90370231 C G 4.52E-04 Acute lung injury / / 22295056 rs4370985 chr12 90384591 C T 6.31E-04 Acute lung injury / / 22295056 rs7964216 chr12 90396480 T C 2.40E-04 Multiple complex diseases / / 17554300 rs10777218 chr12 90398262 T C 1.24E-04 Multiple complex diseases / / 17554300 rs10858942 chr12 90412549 T C 4.88E-04 Smoking initiation / / 24665060 rs4842708 chr12 90428447 C T 3.50E-05 Information processing speed / / 21130836 rs10858945 chr12 90443482 A G 6.00E-06 optic disc size (cup) / / 20395239 rs10858945 chr12 90443482 A G 4.28E-04 Smoking initiation / / 24665060 rs10858946 chr12 90444042 A C 6.00E-06 Optic nerve measurement (cup-to-disc ratio) / / 20395239 rs10777222 chr12 90444741 A G 7.05E-04 Smoking initiation / / 24665060 rs7303035 chr12 90455180 T C 8.20E-05 Smoking initiation / / 24665060 rs6538223 chr12 90466043 A G 7.59E-05 Smoking initiation / / 24665060 rs7485419 chr12 90474475 G A 5.19E-04 Smoking initiation / / 24665060 rs7962435 chr12 90474946 G A 1.28E-04 Smoking initiation / / 24665060 rs7316395 chr12 90481378 T C 6.83E-04 Smoking initiation / / 24665060 rs17017492 chr12 90560907 A G 8.90E-04 Multiple complex diseases / / 17554300 rs2731235 chr12 90566700 T C 5.65E-04 Insulin resistance / / 21901158 rs1347851 chr12 90566978 C T 0.0000423 Oxaliplatin induced diarrhea in response to colorectal cancer treatment / / 22310351 rs11105537 chr12 90589322 A G 4.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs12368069 chr12 90600424 A G 4.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs10745527 chr12 90609017 G T 5.00E-06 vWF and FVIII levels / / 21810271 rs11105548 chr12 90633214 A C 9.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs7299003 chr12 90633995 G C 5.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs7139199 chr12 90638639 A G 8.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs12306556 chr12 90641917 A G 7.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs10777237 chr12 90643524 T C 5.41E-04 Response to TNF antagonist treatment / / 21061259 rs11105550 chr12 90643836 A G 5.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs11105553 chr12 90652982 T A 3.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs10506983 chr12 90653284 C A 8.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs2196785 chr12 90658241 G A 9.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs1347847 chr12 90660239 T C 5.71E-05 Suicide attempts in bipolar disorder / / 21423239 rs1347846 chr12 90660341 G A 3.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs7956251 chr12 90661988 C T 3.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs7956258 chr12 90662045 A G 3.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs2165038 chr12 90666272 G A 3.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs7976181 chr12 90666950 C T 3.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs7976231 chr12 90667106 A T 3.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs722459 chr12 90667674 G C 2.50E-05 Urinary metabolites / / 21572414 rs10777240 chr12 90668825 G A,T 2.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs7963806 chr12 90669701 A T 3.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs1344963 chr12 90671979 G T 0.000014 Pancreatic cancer and survival / / 22665904 rs1438991 chr12 90674600 C A 4.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs1948689 chr12 90676997 T C 7.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs2731260 chr12 90677210 T C 4.21E-04 Coronary Artery Disease / / 17634449 rs2731260 chr12 90677210 T C 7.54E-04 Response to TNF antagonist treatment / / 21061259 rs11105560 chr12 90683201 G T 6.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs1438989 chr12 90684221 C G 4.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs1438988 chr12 90684470 G C 6.11E-04 Response to TNF antagonist treatment / / 21061259 rs7968415 chr12 90688101 C A 4.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs11105563 chr12 90693103 G A 4.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs10506984 chr12 90693265 G C 5.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs1238172 chr12 90693444 A G 3.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs11105565 chr12 90694622 T C 3.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs1095404 chr12 90694931 T C 3.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs1696071 chr12 90694976 G T 3.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs825977 chr12 90696945 G A 2.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs2056700 chr12 90697347 C T 2.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs825978 chr12 90698101 A G 3.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs11105567 chr12 90700285 A C 3.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs1587440 chr12 90700331 G A 3.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs825964 chr12 90700739 A G 3.65E-04 Type 2 diabetes / / 17463246 rs12817029 chr12 90701807 A G 5.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs17836993 chr12 90705400 G A 3.81E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs1222610 chr12 90709355 A G 1.77E-04 Smoking initiation / / 24665060 rs10506986 chr12 90712508 C T 5.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs10506986 chr12 90712508 C T 2.79E-04 Age-related macular degeneration / / 22125219 rs704091 chr12 90719225 G T 3.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs825959 chr12 90724475 T C 1.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs1384603 chr12 90793269 C T 1.70E-05 Urinary metabolites / / 21572414 rs2408114 chr12 90844064 C T 2.10E-05 Urinary metabolites / / 21572414 rs12299857 chr12 90867381 T C 9.33E-07 White blood cell count / / 21738479 rs2051713 chr12 90977131 C T 1.70E-04 Schizophrenia / / 19197363 rs2051713 chr12 90977131 C T 4.18E-05 Orofacial clefts / / 22419666 rs2723902 chr12 90977734 T G 1.40E-04 Schizophrenia / / 19197363 rs1847461 chr12 91077508 G A 8.00E-06 Smoking behavior / / 19247474 rs4842732 chr12 91203618 C T 4.36E-04 Type 2 diabetes / / 17463246 rs11105838 chr12 91236097 A C 1.73E-04 Type 2 diabetes / / 17463246 rs11105842 chr12 91243910 G A 8.91E-04 Type 2 diabetes / / 17463246 rs10859064 chr12 91247202 G T 7.64E-04 Type 2 diabetes / / 17463246 rs7305621 chr12 91247947 G A 5.83E-04 Type 2 diabetes / / 17463246 rs10745532 chr12 91252492 G C 9.48E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6538249 chr12 91261605 C T 9.75E-05 HIV-1 viral setpoint / / 22174851 rs10745535 chr12 91263550 G A 2.04E-05 Type 2 diabetes / / 17463246 rs10777264 chr12 91263588 G A 2.79E-04 Type 2 diabetes / / 17463246 rs4586243 chr12 91266920 G C 3.49E-04 Type 2 diabetes / / 17463246 rs12423763 chr12 91290766 C T 2.50E-05 Urinary metabolites / / 21572414 rs6538254 chr12 91344988 C A 5.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4842744 chr12 91352360 G A 1.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs10745543 chr12 91352710 G A 9.40E-05 Suicide attempts in bipolar disorder / / 21423239 rs1920738 chr12 91354305 A G 6.70E-05 Suicide attempts in bipolar disorder / / 21423239 rs1920737 chr12 91354499 A C 8.70E-05 Suicide attempts in bipolar disorder / / 21423239 rs1920736 chr12 91354611 G A 8.72E-05 Suicide attempts in bipolar disorder / / 21423239 rs4335611 chr12 91354681 T A 8.68E-05 Suicide attempts in bipolar disorder / / 21423239 rs11105885 chr12 91354721 T C 8.72E-05 Suicide attempts in bipolar disorder / / 21423239 rs7968423 chr12 91354830 A G 8.45E-05 Suicide attempts in bipolar disorder / / 21423239 rs7968912 chr12 91355132 C T 1.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs2141677 chr12 91355639 A T 1.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs11613174 chr12 91356023 T C 1.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs12820238 chr12 91356040 T G 9.90E-05 Suicide attempts in bipolar disorder / / 21423239 rs7964309 chr12 91359594 C A 1.84E-04 Suicide attempts in bipolar disorder EPYC intron 21423239 rs7954350 chr12 91360010 T C 2.24E-04 Suicide attempts in bipolar disorder EPYC intron 21423239 rs10859081 chr12 91360104 C T 1.14E-04 Suicide attempts in bipolar disorder EPYC intron 21423239 rs2178459 chr12 91361447 T C 1.60E-04 Suicide attempts in bipolar disorder EPYC intron 21423239 rs7959357 chr12 91364957 C A 1.37E-04 Suicide attempts in bipolar disorder EPYC intron 21423239 rs10492233 chr12 91414286 A G 1.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs7968370 chr12 91425754 A T 2.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs2408422 chr12 91428098 G A 1.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs10859101 chr12 91444445 C A 9.63E-04 Response to taxane treatment (placlitaxel) KERA UTR-3 23006423 rs1920735 chr12 91458219 G A 7.20E-05 Pericardial fat / / 22589742 rs12229563 chr12 91460424 T C 8.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12578934 chr12 91466496 A G 8.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12578934 chr12 91466496 A G 8.70E-05 Pericardial fat / / 22589742 rs10492232 chr12 91468396 T C 9.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs10777288 chr12 91473798 G A 5.00E-07 Pulmonary function (interaction) / / 23284291 rs991427 chr12 91474422 C T 2.00E-07 Systolic blood pressure (alcohol consumption interaction) / / 24376456 rs4494364 chr12 91477114 G A 2.00E-07 Systolic blood pressure (alcohol consumption interaction) / / 24376456 rs11105996 chr12 91503633 A C 7.01E-04 Type 2 diabetes LUM intron 17463246 rs3759223 chr12 91506783 A G 7.01E-04 Type 2 diabetes / / 17463246 rs9971900 chr12 91532325 G T 9.49E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1803343 chr12 91539784 T C 6.11E-04 Celiac disease DCN UTR-3 23936387 rs3138288 chr12 91540103 T A,C 9.59E-04 Response to taxane treatment (placlitaxel) DCN intron 23006423 rs3138262 chr12 91547030 A G 9.59E-04 Response to taxane treatment (placlitaxel) DCN intron 23006423 rs3138191 chr12 91565343 G A 3.82E-04 Response to taxane treatment (placlitaxel) DCN intron 23006423 rs3138191 chr12 91565343 G A 0.00000157 HDL cholesterol DCN intron 23063622 rs544968 chr12 91587923 T C 1.22E-07 Adiponectin levels / / 20887962 rs1522412 chr12 91608201 A T 9.40E-04 Coronary Artery Disease / / 17634449 rs1403121 chr12 91616922 A C 2.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs10777293 chr12 91617454 C G 2.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs7298323 chr12 91621655 T C 9.74E-04 HIV-1 viral setpoint / / 17641165 rs1522430 chr12 91630155 G A 9.74E-04 HIV-1 viral setpoint / / 17641165 rs826765 chr12 91649755 C T 5.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs826766 chr12 91650185 G A 3.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs861158 chr12 91653296 A C 9.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs1718527 chr12 91659804 A G 5.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs826757 chr12 91667188 A G 4.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs866119 chr12 91669505 G C 7.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs826762 chr12 91669932 C T 7.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs826776 chr12 91672302 T A 7.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs11106125 chr12 91776944 C T 1.60E-05 Urinary metabolites / / 21572414 rs12820095 chr12 91833310 T C 6.51E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2408514 chr12 91853696 G C 1.84E-04 Multiple complex diseases / / 17554300 rs11106167 chr12 91866303 T C 7.40E-04 Multiple complex diseases / / 17554300 rs10745558 chr12 91910183 T C 2.05E-04 Multiple complex diseases / / 17554300 rs1598943 chr12 91912198 C T 2.95E-04 Multiple complex diseases / / 17554300 rs7980717 chr12 91916437 T C 3.84E-04 Multiple complex diseases / / 17554300 rs989525 chr12 91918513 C G 2.47E-04 Multiple complex diseases / / 17554300 rs4842776 chr12 91938831 G A 2.50E-04 Multiple complex diseases / / 17554300 rs10777317 chr12 91980374 T C 5.00E-06 Sudden cardiac arrest / / 21658281 rs1565351 chr12 91984257 T G 3.93E-05 Cytomegalovirus antibody response / / 21993531 rs768804 chr12 91994098 A G 3.63E-05 Cytomegalovirus antibody response / / 21993531 rs17193733 chr12 91999816 C G 3.68E-05 Cytomegalovirus antibody response / / 21993531 rs3943102 chr12 92016754 T C 3.63E-04 Depression (quantitative trait) / / 20800221 rs11106222 chr12 92029403 G A 9.47E-04 Depression (quantitative trait) / / 20800221 rs11106224 chr12 92031586 T G 3.75E-04 Depression (quantitative trait) / / 20800221 rs7980683 chr12 92041027 C T 3.27E-04 Depression (quantitative trait) / / 20800221 rs10777319 chr12 92045625 G A 3.78E-04 Depression (quantitative trait) / / 20800221 rs6538287 chr12 92046691 T C 3.29E-04 Depression (quantitative trait) / / 20800221 rs10859174 chr12 92050477 A T 3.39E-04 Depression (quantitative trait) / / 20800221 rs1352642 chr12 92050768 G A 3.41E-04 Depression (quantitative trait) / / 20800221 rs2172595 chr12 92087937 G A 6.23E-04 Multiple complex diseases / / 17554300 rs1493759 chr12 92090932 A G 8.36E-04 Multiple complex diseases / / 17554300 rs1387763 chr12 92107613 C T 8.95E-04 Multiple complex diseases / / 17554300 rs4581488 chr12 92116974 A G 7.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs1873984 chr12 92117261 A G 8.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs2382683 chr12 92129944 G C 9.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs7131944 chr12 92159557 A T 7.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs10777331 chr12 92161384 T C 8.94E-06 Narcolepsy / / 20711174 rs10777332 chr12 92164302 C T 5.00E-06 Biochemical measures / / 19260141 rs11106293 chr12 92206482 A C 8.19E-04 Taste perception / / 22132133 rs4240748 chr12 92246786 C G 4.70E-06 Urinary metabolites / / 21572414 rs7294593 chr12 92248851 A G 9.00E-06 Hypertension / / 22384028 rs7964689 chr12 92250108 C T 9.00E-06 Hypertension / / 22384028 rs17019652 chr12 92256025 T C 1.98E-04 Multiple complex diseases / / 17554300 rs10777342 chr12 92257133 T C 3.50E-06 Urinary metabolites / / 21572414 rs11106310 chr12 92257509 G A 2.60E-05 Urinary metabolites / / 21572414 rs10507004 chr12 92274855 A G 2.50E-05 Cardiovascular disease / / pha003064 rs11106325 chr12 92284301 C T 1.82E-04 Alzheimer's disease / / pha002879 rs10859227 chr12 92300761 A C 2.21E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10859228 chr12 92302987 A G 1.67E-05 Blood pressure / / 24001895 rs17019682 chr12 92305270 A T 2.00E-06 Heart failure / / 20445134 rs4503583 chr12 92308227 T C 1.54E-04 IgE levels / / 17255346 rs4356270 chr12 92319215 G A 3.60E-04 Alcohol dependence / / 20201924 rs4356270 chr12 92319215 G A 4.40E-05 Alcohol dependence / / 20201924 rs4356270 chr12 92319215 G A 0.00000842 Alcohol dependence / / 23691058 rs4356270 chr12 92319215 G A 4.44E-05 Alcoholism / / pha002892 rs4499040 chr12 92322558 G A 4.00E-04 Alcohol dependence / / 20201924 rs4499040 chr12 92322558 G A 6.60E-05 Alcohol dependence / / 20201924 rs4499040 chr12 92322558 G A 6.57E-05 Alcoholism / / pha002892 rs12427267 chr12 92323972 A G 2.40E-04 Alcohol dependence / / 20201924 rs12427267 chr12 92323972 A G 0.0000006 Alcohol dependence / / 23691058 rs4842798 chr12 92325420 T C 4.00E-04 Alcohol dependence / / 20201924 rs11106345 chr12 92326500 T C 3.70E-04 Alcohol dependence / / 20201924 rs11106345 chr12 92326500 T C 6.00E-05 Alcohol dependence / / 20201924 rs11106345 chr12 92326500 T C 0.00000722 Alcohol dependence / / 23691058 rs11106345 chr12 92326500 T C 6.02E-05 Alcoholism / / pha002892 rs10745574 chr12 92331588 A G 4.90E-04 Alcohol dependence / / 20201924 rs10777357 chr12 92336694 A G 4.70E-04 Alcohol dependence / / 20201924 rs4542452 chr12 92338833 C A 5.10E-04 Alcohol dependence / / 20201924 rs10777365 chr12 92353719 C T 2.10E-05 Urinary metabolites / / 21572414 rs10777366 chr12 92353751 C A 9.00E-04 Alcohol dependence / / 20201924 rs7132890 chr12 92359839 G A 6.00E-04 Alcohol dependence / / 20201924 rs11106374 chr12 92368093 T C 4.10E-04 Alcohol dependence / / 20201924 rs10859259 chr12 92370206 C T 5.30E-04 Alcohol dependence / / 20201924 rs10859259 chr12 92370206 C T 2.40E-05 Urinary metabolites / / 21572414 rs12146838 chr12 92375595 A T 4.00E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs11106382 chr12 92377981 C G 7.96E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs11106385 chr12 92388461 C T 4.20E-05 Body Mass Index LOC256021 intron pha003022 rs7959206 chr12 92419799 C T 8.90E-04 Tourette syndrome LOC256021 intron 22889924 rs7962316 chr12 92419955 G A 5.09E-04 Response to TNF antagonist treatment LOC256021 intron 21061259 rs17019941 chr12 92421472 C T 1.17E-32 Narcolepsy LOC256021 intron 19629137 rs2279577 chr12 92501843 G A 7.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC256021 intron 20877124 rs17251453 chr12 92502080 A G 2.69E-04 Cholesterol LOC256021 intron 17255346 rs790575 chr12 92531608 T G 2.03E-05 Vaspin levels LOC256021 intron 22907691 rs790575 chr12 92531608 T G 0.0000203 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks LOC256021 intron 22907730 rs35666 chr12 92534370 G T 1.50E-06 Type 2 diabetes BTG1 UTR-3 17293876 rs35666 chr12 92534370 G T 1.50E-06 Type 2 diabetes BTG1 UTR-3 19184112 rs35666 chr12 92534370 G T 1.16E-04 Vaspin levels BTG1 UTR-3 22907691 rs35666 chr12 92534370 G T 0.0001161 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks BTG1 UTR-3 22907730 rs709229 chr12 92552934 A G 1.31E-04 Type 2 diabetes / / 17463246 rs17251474 chr12 92565318 C G 1.07E-04 Adiponectin levels / / 20887962 rs813164 chr12 92587757 A G 4.73E-04 Myocardial Infarction / / pha002883 rs1629563 chr12 92599393 C G 5.51E-04 Lymphocyte counts / / 22286170 rs17020113 chr12 92615618 C T 2.28E-04 Vaspin levels / / 22907691 rs17020113 chr12 92615618 C T 0.0002277 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs790450 chr12 92617103 A G 1.42E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs790450 chr12 92617103 A G 7.06E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs1347750 chr12 92630354 G A 2.74E-05 Urinary albumin excretion rate in type 1 diabetes / / 24595857 rs7300328 chr12 92634415 C T 5.03E-04 Insulin resistance / / 21901158 rs872969 chr12 92646000 C T 5.10E-05 Arthritis (juvenile idiopathic) / / 22354554 rs7132776 chr12 92652482 T C 9.10E-05 HIV-1 control / / 20041166 rs1469984 chr12 92658330 A G 8.87E-04 Multiple complex diseases / / 17554300 rs7980688 chr12 92664512 T C 7.17E-05 Vaspin levels / / 22907691 rs7980688 chr12 92664512 T C 0.0000717 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs3955402 chr12 92682936 G A 7.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs337656 chr12 92684351 C T 6.03E-05 Longevity,exceptional / / 20595579 rs337656 chr12 92684351 C T 5.74E-05 Longevity / / 22279548 rs337647 chr12 92698209 T G 7.03E-04 Stroke / / pha002886 rs337650 chr12 92702906 A G 5.98E-06 Acute lung injury / / 22295056 rs337661 chr12 92704736 T C 4.39E-05 Acute lung injury / / 22295056 rs337662 chr12 92704907 T A 9.19E-06 Acute lung injury / / 22295056 rs337663 chr12 92705204 A G 6.27E-05 Acute lung injury / / 22295056 rs454217 chr12 92718558 C T 2.00E-06 Smoking quantity / / 24665060 rs7978613 chr12 92718772 C A 2.50E-04 Acute lung injury / / 22295056 rs427600 chr12 92720662 T C 5.74E-05 Acute lung injury / / 22295056 rs427600 chr12 92720662 T C 1.22E-04 Stroke / / pha002886 rs418571 chr12 92724156 G A 5.74E-05 Acute lung injury / / 22295056 rs11106513 chr12 92727056 G A 2.38E-04 Type 2 diabetes / / 17463246 rs428699 chr12 92728598 T C 5.74E-05 Acute lung injury / / 22295056 rs381966 chr12 92729689 C T 6.77E-05 Acute lung injury / / 22295056 rs11106515 chr12 92730670 T C 8.67E-04 Acute lung injury / / 22295056 rs1948656 chr12 92731284 T C 5.54E-05 Acute lung injury / / 22295056 rs402436 chr12 92736111 C T 1.98E-05 Age-related macular degeneration / / pha000002 rs430102 chr12 92750421 C G 2.14E-04 Self-reported allergy / / 23817569 rs421323 chr12 92751149 G T 2.03E-04 Self-reported allergy / / 23817569 rs525810 chr12 92755395 G A 2.72E-04 Self-reported allergy / / 23817569 rs17837135 chr12 92790233 G A 3.12E-04 Type 2 diabetes / / 17463246 rs7304710 chr12 92804394 T G 1.40E-05 Urinary metabolites / / 21572414 rs10859313 chr12 92805433 C T 1.52E-07 Dilated cardiomyopathy / / 23853074 rs4760440 chr12 92806197 A G 2.88E-05 Major depressive disorder / / 22472876 rs1515569 chr12 92813646 A G 3.72E-05 Major depressive disorder / / 22472876 rs1515565 chr12 92818786 A G 2.54E-05 Major depressive disorder CLLU1 cds-synon 22472876 rs1515563 chr12 92819139 A C 2.59E-05 Major depressive disorder CLLU1 UTR-3 22472876 rs17251627 chr12 92824404 A G 7.30E-04 Type 2 diabetes CLLU1 UTR-3 17463246 rs6538329 chr12 92824593 T G 2.05E-05 Major depressive disorder CLLU1 UTR-3 22472876 rs7308198 chr12 92824698 C A 1.10E-05 Urinary metabolites CLLU1 UTR-3 21572414 rs7314040 chr12 92834618 T C 1.63E-04 Multiple complex diseases / / 17554300 rs814231 chr12 92859911 C T 7.49E-05 Body Mass Index / / pha003009 rs2277364 chr12 92860542 C T 2.55E-04 Alzheimer's disease / / 24755620 rs552398 chr12 92860563 A G 5.00E-04 Major depressive disorder / / 22472876 rs2385087 chr12 92863296 T C 3.43E-06 Lymphocyte counts LOC100507616 intron 22286170 rs10859319 chr12 92871244 C G 9.54E-04 Type 2 diabetes LOC100507616 intron 17463246 rs10219495 chr12 92890520 T C 5.00E-06 Sudden cardiac arrest / / 21658281 rs11106601 chr12 92903958 C T 2.38E-05 Prostate cancer / / pha002878 rs11829373 chr12 92987208 G C 7.00E-06 Periodontitis (Mean PAL) / / 24024966 rs4760467 chr12 93016481 C G 5.86E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10859349 chr12 93021626 G A 7.24E-05 Serum metabolites / / 19043545 rs10859354 chr12 93049689 T C 6.64E-04 Alcohol dependence / / 20201924 rs1504907 chr12 93155535 G A 4.00E-05 Type 2 diabetes and 6 quantitative traits PLEKHG7 cds-synon 17848626 rs17194416 chr12 93167435 G C 7.32E-05 Major depressive disorder EEA1 UTR-3 21621269 rs7970286 chr12 93202801 C T 7.97E-05 Cognitive performance EEA1 cds-synon 19734545 rs1995169 chr12 93245476 A G 9.88E-04 Alzheimer's disease EEA1 intron 22005930 rs12368715 chr12 93349126 C A 5.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6538367 chr12 93352786 C A 2.05E-05 HDL cholesterol / / pha003075 rs17020854 chr12 93355884 A C 2.05E-05 HDL cholesterol / / pha003075 rs10507022 chr12 93381268 T A 2.77E-04 Type 2 diabetes / / 17463246 rs10859402 chr12 93409843 G A 3.76E-05 Insulin-related traits LOC643339 intron 19902172 rs11106822 chr12 93436119 A C 1.20E-05 Urinary metabolites LOC643339 intron 21572414 rs10777465 chr12 93436202 T G 6.50E-06 Urinary metabolites LOC643339 intron 21572414 rs10777466 chr12 93436253 A G 5.60E-06 Urinary metabolites LOC643339 intron 21572414 rs10859418 chr12 93447320 G A 5.22E-04 Multiple complex diseases LOC643339 intron 17554300 rs10859419 chr12 93452175 G A 1.80E-05 Urinary metabolites LOC643339 intron 21572414 rs4584620 chr12 93454823 C T 1.79E-04 Coronary heart disease LOC643339 intron 21971053 rs4570623 chr12 93464532 T C 1.80E-05 Urinary metabolites LOC643339 intron 21572414 rs11608500 chr12 93469749 C T 4.24E-05 Duodenal ulcer LOC643339 intron 22387998 rs11608500 chr12 93469749 C T 8.30E-05 Blood Pressure LOC643339 intron pha003047 rs7313939 chr12 93496444 T C 1.10E-05 Urinary metabolites LOC643339 intron 21572414 rs6538386 chr12 93507311 T C 4.45E-05 Height LOC643339 intron pha003011 rs1836127 chr12 93550301 G T 3.00E-06 Non-alcoholic fatty liver disease histology (other) LOC643339 intron 20708005 rs10777483 chr12 93602000 A G 5.97E-06 Hemoglobin LOC643339 intron pha003096 rs10777483 chr12 93602000 A G 4.60E-06 Hematocrit LOC643339 intron pha003097 rs10859463 chr12 93675874 C T 2.81E-05 Erythrocyte counts LOC643339 intron pha003090 rs7486291 chr12 93681302 T A 2.50E-06 Glaucoma (primary open-angle) LOC643339 intron 20835238 rs10745641 chr12 93686810 A G 1.13E-06 Erythrocyte counts LOC643339 intron pha003090 rs10777502 chr12 93687055 G A 1.50E-06 Erythrocyte counts LOC643339 intron pha003090 rs4761659 chr12 93687084 T C 3.00E-07 Amyotrophic lateral sclerosis (sporadic) LOC643339 intron 24529757 rs7398015 chr12 93690748 C T 1.64E-05 Erythrocyte counts LOC643339 intron pha003090 rs6538407 chr12 93693515 A C 2.95E-04 Type 2 diabetes LOC643339 intron 17463246 rs4761708 chr12 93752086 C T 6.40E-04 Psychosis LOC643339 intron 23871474 rs11107025 chr12 93824397 C A 3.48E-04 Acute lung injury UBE2N intron 22295056 rs1483003 chr12 93834379 C T 8.49E-05 Insulin Resistance UBE2N intron pha003062 rs10777522 chr12 93921620 A G 9.44E-04 Acute lung injury / / 22295056 rs11107070 chr12 93922017 G A 9.96E-04 Acute lung injury / / 22295056 rs11107070 chr12 93922017 G A 3.90E-06 Stroke (ischemic) / / 22384361 rs11107101 chr12 93949565 C T 5.75E-04 Smoking initiation / / 24665060 rs3782415 chr12 93967755 T C 1.20E-12 Height SOCS2 intron 21194676 rs3782415 chr12 93967755 T C 1.20E-16 Height SOCS2 intron 21194676 rs3782415 chr12 93967755 T C 4.80E-06 Height SOCS2 intron 21194676 rs3782415 chr12 93967755 T C 2.85E-04 Longevity SOCS2 intron 22279548 rs3816997 chr12 93970786 A C 0.000423607 Hypertension (early onset hypertension) / / 22479346 rs17021323 chr12 93972870 A G 8.54E-04 Alcohol dependence / / 21314694 rs3825199 chr12 93976954 A G 2.00E-07 Height / / 18391951 rs3825199 chr12 93976954 A G 0.0000805 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs3825198 chr12 93977465 T A 0.0001 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11107116 chr12 93978504 G T 6.00E-10 Height / / 18391952 rs11107116 chr12 93978504 G T 1.00E-34 Height / / 20881960 rs10492321 chr12 93980088 T A 7.00E-11 Height / / 23563607 rs7953508 chr12 93983554 C T 4.00E-06 Pubertal anthropometrics / / 23449627 rs7953508 chr12 93983554 C T 0.00000873 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7971647 chr12 93983854 T C 0.00000943 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11107124 chr12 93988283 G C 0.0000236 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10777531 chr12 93988384 G A 0.0000192 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6538437 chr12 93989735 A T 0.0000186 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12230050 chr12 93990553 A G 0.00000791 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9634212 chr12 93993266 C A 0.0000675 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2364232 chr12 93994827 A C 0.0000145 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1498706 chr12 93996980 G A 0.0000254 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1498707 chr12 93997128 G A 0.0000283 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12312736 chr12 93997264 C G 0.0000253 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11107126 chr12 93997373 A T 0.0000283 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs998616 chr12 93998000 T G 0.0000456 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7957632 chr12 93998321 T C 0.0000496 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11107127 chr12 94006434 T C 1.16E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9668896 chr12 94071012 C T 2.79E-06 Alcohol and nictotine co-dependence CRADD nearGene-5 20158304 rs9668896 chr12 94071012 C T 5.62E-07 Alcohol and nictotine co-dependence CRADD nearGene-5 20158304 rs10859563 chr12 94120339 C G 3.00E-12 Height CRADD intron 20881960 rs11107181 chr12 94180692 G A 1.30E-05 Urinary metabolites CRADD intron 21572414 rs12302839 chr12 94180702 A G 3.23E-04 Multiple complex diseases CRADD intron 17554300 rs3847788 chr12 94207729 G A 5.80E-04 Myocardial Infarction CRADD intron pha002883 rs7306174 chr12 94211465 C G 1.98E-04 Suicide attempts in bipolar disorder CRADD intron 21423239 rs7974729 chr12 94212090 G T 5.41E-04 Suicide attempts in bipolar disorder CRADD intron 21423239 rs7295931 chr12 94218860 G T 9.66E-04 Suicide attempts in bipolar disorder CRADD intron 21423239 rs11107204 chr12 94221183 T A 6.53E-04 Suicide attempts in bipolar disorder CRADD intron 21423239 rs61144803 chr12 94235165 A G 5.00E-08 Alzheimer's disease (cognitive decline) CRADD intron 23535033 rs12297002 chr12 94242230 A G 5.78E-04 Alzheimer's disease CRADD intron 17998437 rs11107219 chr12 94246356 A G 9.81E-06 Osteoarthritis / / 22763110 rs4275668 chr12 94258196 T C 7.54E-05 Bipolar disorder / / 17486107 rs4275668 chr12 94258196 T C 6.42E-05 Serum metabolites / / 19043545 rs511925 chr12 94319228 G A 9.39E-04 Multiple complex diseases / / 17554300 rs511925 chr12 94319228 G A 8.39E-04 Body mass index / / 21701565 rs270870 chr12 94331698 G A 3.21E-04 Body mass index / / 21701565 rs270869 chr12 94336323 T C 6.84E-04 Alzheimer's disease (late onset) / / 21460841 rs270864 chr12 94342695 G A 5.06E-04 Alzheimer's disease (late onset) / / 21460841 rs11519591 chr12 94345345 G A 2.90E-04 Alzheimer's disease (late onset) / / 21379329 rs11107295 chr12 94345434 C T 2.64E-04 Alzheimer's disease (late onset) / / 21379329 rs10444517 chr12 94350823 C T 1.24E-04 Height / / 22216288 rs4146626 chr12 94361527 G A 9.60E-05 Asthma (bronchodilator response) / / 22792082 rs270883 chr12 94372811 A C 3.74E-05 Height / / pha003011 rs6538465 chr12 94372857 A G 7.05E-04 Multiple complex diseases / / 17554300 rs270882 chr12 94374591 G A 3.74E-05 Height / / pha003011 rs2971589 chr12 94385712 G A 1.50E-08 Platelet aggregation(pre- and post-aspirin) / / 20529293 rs1434709 chr12 94416209 G A 4.40E-04 Myocardial Infarction / / pha002883 rs879703 chr12 94421992 T A 2.40E-04 Pulmonary function / / 23932459 rs1036360 chr12 94453329 A G 7.32E-06 Nicotine smoking / / 19268276 rs10777572 chr12 94453809 A T 2.73E-05 Sudden cardiac arrest / / 21658281 rs10777576 chr12 94473122 A G 8.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4761567 chr12 94481350 G A 2.67E-04 Multiple complex diseases / / 17554300 rs12227011 chr12 94485033 C T 2.59E-04 Multiple complex diseases / / 17554300 rs11107390 chr12 94488977 T C 4.74E-04 Multiple complex diseases / / 17554300 rs10859671 chr12 94497229 T C 6.18E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7308292 chr12 94500590 G A 4.67E-05 Pulmonary function in asthmatics / / 23541324 rs17231818 chr12 94502584 T C 3.94E-05 Pulmonary function in asthmatics / / 23541324 rs1808748 chr12 94506816 C T 6.84E-06 Multiple complex diseases / / 17554300 rs17232161 chr12 94512683 C T 7.73E-05 Multiple complex diseases / / 17554300 rs3847794 chr12 94528825 A G 7.00E-06 Behavioural disinhibition (generation interaction) / / 23942779 rs11613298 chr12 94532765 G A 5.00E-06 Breast cancer / / 23468962 rs17298648 chr12 94549550 C T 2.30E-05 Urinary metabolites PLXNC1 intron 21572414 rs11107420 chr12 94554813 A G 6.80E-05 Aging (time to event) PLXNC1 intron 21782286 rs3843641 chr12 94559247 G A 1.20E-05 Urinary metabolites PLXNC1 intron 21572414 rs3847810 chr12 94579025 T C 7.52E-04 Parkinson's disease PLXNC1 intron 17052657 rs3847810 chr12 94579025 T C 8.78E-05 Cholesterol PLXNC1 intron 17255346 rs17022166 chr12 94587405 A C 1.08E-04 Cholesterol PLXNC1 intron 17255346 rs10507031 chr12 94592992 T C 3.30E-04 Type 2 diabetes and 6 quantitative traits PLXNC1 intron 17848626 rs2291333 chr12 94621058 T C 6.61E-05 Angioedema in response to angiotensin-converting enzyme inhibitor PLXNC1 intron 23838604 rs870034 chr12 94640095 T C 1.07E-04 AIDS progression PLXNC1 intron 19115949 rs2291326 chr12 94648945 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes PLXNC1 intron 22628534 rs865569 chr12 94649103 T C 3.67E-05 Parkinson's disease PLXNC1 intron 17052657 rs2242499 chr12 94650325 A G 3.01E-04 Iron levels PLXNC1 intron pha002876 rs12579612 chr12 94665793 A G 0.0000875 Uterine leiomyomata PLXNC1 intron 23040493 rs4761601 chr12 94672002 G A 4.05E-05 Alcohol dependence PLXNC1 intron 19581569 rs4761470 chr12 94683204 G A 6.00E-07 Estradiol plasma levels (breast cancer) PLXNC1 intron 23518928 rs575315089 chr12 94683204 G GT 6.00E-07 Estradiol plasma levels (breast cancer) PLXNC1 intron 23518928 rs17302436 chr12 94693251 T C 2.37E-05 Smoking initiation PLXNC1 intron 24665060 rs17243215 chr12 94698095 T G 1.22E-04 Smoking initiation PLXNC1 intron 24665060 rs4761605 chr12 94729577 C T 1.64E-05 Alcohol dependence CCDC41 intron 19581569 rs17022408 chr12 94732594 A G 3.07E-05 Smoking initiation CCDC41 intron 24665060 rs7138291 chr12 94741706 T C 5.70E-05 Alcohol dependence CCDC41 intron 19581569 rs17022417 chr12 94765496 A G 9.16E-05 Smoking initiation CCDC41 intron 24665060 rs17302889 chr12 94765721 T C 5.23E-05 Smoking initiation CCDC41 intron 24665060 rs10507037 chr12 94769945 A G 5.19E-05 Smoking initiation CCDC41 intron 24665060 rs2271979 chr12 94772742 C T 1.40E-05 Urinary metabolites CCDC41 missense 21572414 rs11107531 chr12 94801321 C T 8.31E-07 Estradiol plasma levels (breast cancer) CCDC41 intron 23518928 rs11107531 chr12 94801321 C T 3.98E-04 Smoking initiation CCDC41 intron 24665060 rs11833200 chr12 94815375 C T 9.46E-05 Smoking initiation CCDC41 intron 24665060 rs1520724 chr12 94865477 C T 9.00E-06 Obesity-related traits / / 23251661 rs10777592 chr12 94870643 C T 3.33E-05 Schizophrenia / / 24253340 rs7968386 chr12 94888615 G A 8.43E-04 Multiple complex diseases / / 17554300 rs17022501 chr12 94901687 A G 4.86E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17022501 chr12 94901687 A G 4.55E-04 White matter integrity / / 22425255 rs7966574 chr12 94907717 C T 6.21E-04 Smoking initiation / / 24665060 rs11107581 chr12 94934162 T C 8.29E-06 Intracerebral hemorrhage / / 24656865 rs17022644 chr12 94943904 G A 8.72E-04 Obesity (extreme) / / 21935397 rs2170771 chr12 94948657 C T 9.52E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7955502 chr12 94949997 C A 5.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs6538508 chr12 94950329 T C 4.38E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10859730 chr12 94953200 C T 2.19E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10859731 chr12 94953413 G A 2.19E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17022738 chr12 94953487 G A 7.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1316366 chr12 94957027 A G 6.69E-05 Cognitive test performance / / 20125193 rs10507040 chr12 94963476 T C 7.31E-05 Iron status biomarkers TMCC3 UTR-3 19084217 rs6538516 chr12 94979046 C A 2.80E-06 Response to lithium treatment in bipolar disorder TMCC3 intron 19448189 rs1553295 chr12 94983042 T C 8.02E-04 Multiple complex diseases TMCC3 intron 17554300 rs7301498 chr12 94988487 C A 2.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMCC3 intron 20877124 rs2651959 chr12 95000896 C T 0.000415 Salmonella-induced pyroptosis TMCC3 intron 22837397 rs2625933 chr12 95001778 A G 1.35E-04 Telomere length TMCC3 intron 21573004 rs10859739 chr12 95016969 T A 7.48E-04 Multiple complex diseases TMCC3 intron 17554300 rs2625937 chr12 95019091 T C 5.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMCC3 intron 20877124 rs6538524 chr12 95029281 T C 1.10E-05 Urinary metabolites TMCC3 intron 21572414 rs10735322 chr12 95065630 T C 1.36E-05 Erythrocyte counts / / pha003101 rs7304470 chr12 95066388 G A 3.07E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs17309820 chr12 95070591 T C 8.71E-05 Multiple complex diseases / / 17554300 rs7966485 chr12 95083342 C T 7.61E-04 Coronary Artery Disease / / 17634449 rs7966506 chr12 95083374 C T 8.75E-04 Coronary Artery Disease / / 17634449 rs7302717 chr12 95119816 T C 5.72E-06 Post-traumatic stress disorder / / 24080187 rs7963894 chr12 95135023 G A 2.45E-04 Multiple complex diseases / / 17554300 rs7963894 chr12 95135023 G A 7.69E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs7134051 chr12 95138334 G A 1.33E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11609420 chr12 95151944 G A 6.55E-04 Smoking initiation / / 24665060 rs6538534 chr12 95154502 T C 1.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs7953189 chr12 95157454 C T 5.52E-05 Suicide attempts in bipolar disorder / / 21423239 rs2008023 chr12 95160155 A G 1.13E-04 Osteoarthritis (knee and hip) / / 21177295 rs2008023 chr12 95160155 A G 1.24E-05 Osteoarthritis (knee and hip) / / 21177295 rs2008023 chr12 95160155 A G 4.49E-04 Osteoarthritis (knee and hip) / / 21177295 rs2008023 chr12 95160155 A G 5.48E-04 Osteoarthritis (knee and hip) / / 21177295 rs2366796 chr12 95162360 T C 1.32E-04 Heart Failure / / pha002885 rs7134586 chr12 95163133 A T 2.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs7138595 chr12 95163879 C T 1.95E-04 Multiple complex diseases / / 17554300 rs7959196 chr12 95167773 T C 1.25E-04 Alzheimer's disease (late onset) / / 21379329 rs6538538 chr12 95168197 A G 1.72E-04 Alzheimer's disease (late onset) / / 21379329 rs4761664 chr12 95178080 C G 3.22E-04 Alzheimer's disease / / 17998437 rs892497 chr12 95191771 T G 8.74E-05 Hypertension / / pha003041 rs10507044 chr12 95249995 C T 7.25E-06 Ankle-brachial index / / 22199011 rs2886766 chr12 95273562 A G 1.55E-04 Multiple complex diseases / / 17554300 rs1434239 chr12 95289731 T C 4.30E-05 Myasthenia gravis / / 23055271 rs7304048 chr12 95292948 T C 1.74E-05 Brain lesion load / / 19010793 rs6538566 chr12 95296558 A C 1.20E-04 Myasthenia gravis / / 23055271 rs7961470 chr12 95307795 A G 7.20E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4761514 chr12 95313113 T A 7.01E-04 Lymphocyte counts / / 22286170 rs11107789 chr12 95313261 T C 4.84E-05 Brain structure / / 22504417 rs11107802 chr12 95319773 G T 0.00007505 Sarcoidosis / / 22952805 rs249153 chr12 95324389 T C 1.18E-04 Atopy / / 21625490 rs249153 chr12 95324389 T C 4.00E-07 Alzheimer's disease / / 24755620 rs249155 chr12 95324882 A G 2.56E-05 Alzheimer's disease / / 24755620 rs7974531 chr12 95325819 G A 1.66E-04 Alzheimer's disease / / 24755620 rs249166 chr12 95328473 G T 6.91E-07 Alzheimer's disease / / 24755620 rs249167 chr12 95330273 T A 6.91E-07 Alzheimer's disease / / 24755620 rs10128879 chr12 95331124 C T 5.87E-04 Alzheimer's disease / / 24755620 rs10128881 chr12 95331185 C T 2.52E-04 Alzheimer's disease / / 24755620 rs12814712 chr12 95360709 G A 6.72E-04 Obesity (extreme) / / 21935397 rs10859805 chr12 95361464 A T 6.04E-04 Alzheimer's disease / / 17998437 rs7133992 chr12 95381702 A G 4.26E-04 Nicotine smoking NDUFA12 intron 19268276 rs11107851 chr12 95388843 T C 3.76E-04 Nicotine smoking NDUFA12 intron 19268276 rs10859824 chr12 95429432 G A 5.78E-05 Pulmonary function NR2C1 intron 19300500 rs17023586 chr12 95433360 T C 7.34E-04 Multiple complex diseases NR2C1 intron 17554300 rs12579299 chr12 95442242 A G 4.73E-04 Coronary Artery Disease NR2C1 intron 17634449 rs7971079 chr12 95443489 A G 9.83E-05 Pulmonary function NR2C1 intron 19300500 rs11107877 chr12 95446761 T C 9.83E-05 Pulmonary function NR2C1 intron 19300500 rs12310399 chr12 95490248 T C 2.00E-07 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) FGD6 intron 23648065 rs4762311 chr12 95493336 T C 2.65E-07 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) FGD6 intron 23648065 rs6538592 chr12 95502747 G A 5.05E-07 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) FGD6 intron 23648065 rs7484333 chr12 95510913 G A 3.24E-06 Lymphocyte counts FGD6 intron 22286170 rs7308154 chr12 95558142 T C 4.75E-04 Smoking initiation FGD6 intron 24665060 rs11107921 chr12 95567034 G A 7.84E-05 Parkinson's disease (motor and cognition) FGD6 intron 22658654 rs11107921 chr12 95567034 G A 7.84E-05 Immune response to anthrax vaccine FGD6 intron 22658931 rs7956452 chr12 95570167 C T 8.83E-05 Coronary heart disease FGD6 intron pha003030 rs10777670 chr12 95574831 G A 1.60E-07 Endometriosis FGD6 intron 23104006 rs1488643 chr12 95616085 G T 5.54E-05 Cognitive performance VEZT intron 19734545 rs10859856 chr12 95631276 T C 4.80E-07 Endometriosis VEZT intron 23104006 rs3596 chr12 95696420 A G 2.00E-06 Endometriosis VEZT UTR-3 23472165 rs11107973 chr12 95702385 T C 2.10E-06 Endometriosis / / 23104006 rs10859871 chr12 95711876 A C 2.90E-06 Endometriosis / / 21151130 rs10859871 chr12 95711876 A C 5.00E-13 Endometriosis / / 23104006 rs11107993 chr12 95729493 C T 8.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17346064 chr12 95737208 G T 8.74E-04 Multiple complex diseases / / 17554300 rs2727663 chr12 95771236 T C 5.78E-06 Response to TNF antagonist treatment / / 21061259 rs2252812 chr12 95776258 T C 1.21E-05 Response to TNF antagonist treatment / / 21061259 rs7973262 chr12 95780613 C G 3.48E-04 Alzheimer's disease / / 22005930 rs2658736 chr12 95785062 G C 2.82E-04 Response to TNF antagonist treatment / / 21061259 rs1120107 chr12 95787532 G T 4.79E-04 Alzheimer's disease / / 17998437 rs17024165 chr12 95802955 G A 2.63E-04 Lymphocyte counts / / 22286170 rs2658728 chr12 95803483 G A 1.60E-08 Multiple complex diseases / / 17554300 rs2456549 chr12 95804191 A C 7.00E-05 Cholesterol / / pha003073 rs2456549 chr12 95804191 A C 4.91E-05 Cholesterol / / pha003078 rs12814743 chr12 95804671 C T 7.00E-05 Cholesterol / / pha003073 rs12814743 chr12 95804671 C T 4.91E-05 Cholesterol / / pha003078 rs7973687 chr12 95804956 G A 2.53E-06 ldl cholesterol / / pha003076 rs2769436 chr12 95805052 A G 7.00E-05 Cholesterol / / pha003073 rs2769436 chr12 95805052 A G 4.91E-05 Cholesterol / / pha003078 rs7973747 chr12 95805205 C T 2.47E-06 ldl cholesterol / / pha003076 rs7973850 chr12 95805247 C T 1.73E-06 ldl cholesterol / / pha003076 rs11833183 chr12 95806380 G A 1.64E-06 ldl cholesterol / / pha003076 rs12809883 chr12 95806843 G A 3.81E-06 ldl cholesterol / / pha003076 rs11833759 chr12 95807035 C T 2.47E-06 ldl cholesterol / / pha003076 rs12828313 chr12 95808099 A G 2.79E-06 ldl cholesterol / / pha003076 rs2658717 chr12 95864641 C A 7.37E-04 Type 2 diabetes / / 17463246 rs4762519 chr12 95885590 T C 6.92E-04 Multiple complex diseases METAP2 intron 17554300 rs2596741 chr12 95903543 C T 7.83E-05 Serum metabolites METAP2 intron 19043545 rs10777699 chr12 95921261 G C 3.05E-04 Coronary heart disease USP44 intron 21606135 rs2197973 chr12 95928560 C T 5.30E-04 Iris characteristics USP44 intron 21835309 rs7975322 chr12 95946139 A C 8.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs10859895 chr12 95948094 G A 8.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs7304617 chr12 95953639 T C 9.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs7304640 chr12 95953692 T A 9.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs7304754 chr12 95953758 T C 7.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs7136572 chr12 95959788 A G 3.00E-07 Response to antidepressant treatment / / 22041458 rs6538657 chr12 95965690 T C 5.61E-05 Bipolar disorder and schizophrenia / / 20889312 rs7968140 chr12 95965797 T A 4.95E-05 Bipolar disorder and schizophrenia / / 20889312 rs4237910 chr12 95967457 A G 8.51E-05 Taste perception / / 22132133 rs10160954 chr12 95969099 T C 1.30E-05 Urinary metabolites / / 21572414 rs10859907 chr12 95995906 T C 2.10E-04 Vaspin levels / / 22907691 rs10859907 chr12 95995906 T C 0.00021 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs17284282 chr12 96015637 T C 3.20E-05 Cognitive impairment induced by topiramate / / 22091778 rs17356907 chr12 96027759 A G 1.00E-06 Breast size / / 22747683 rs17356907 chr12 96027759 A G 2.00E-22 Breast cancer / / 23535729 rs17356907 chr12 96027759 A G 9.00E-06 Breast cancer / / 23535733 rs2367563 chr12 96057184 A G 4.00E-06 Allergic dermatitis (nickel) NTN4 intron 23921680 rs2367559 chr12 96063266 A C 2.81E-05 Serum metabolites NTN4 intron 19043545 rs12423171 chr12 96091058 A G 6.07E-04 Suicide attempts in bipolar disorder NTN4 intron 21041247 rs17286390 chr12 96091353 A T 6.09E-04 Suicide attempts in bipolar disorder NTN4 intron 21041247 rs11108202 chr12 96100250 G A 6.40E-04 Suicide attempts in bipolar disorder NTN4 intron 21041247 rs11108203 chr12 96100594 C T 3.78E-05 Cardiovascular disease NTN4 intron pha003065 rs12824729 chr12 96103229 G A 6.39E-04 Suicide attempts in bipolar disorder NTN4 intron 21041247 rs10507059 chr12 96105834 C T 7.46E-04 Suicide attempts in bipolar disorder NTN4 intron 21041247 rs4129599 chr12 96106943 T A,C,G 4.71E-04 Schizophrenia NTN4 intron 21674006 rs4077227 chr12 96108212 C T 8.04E-04 Suicide attempts in bipolar disorder NTN4 intron 21041247 rs17287370 chr12 96111118 A G 8.13E-04 Suicide attempts in bipolar disorder NTN4 intron 21041247 rs11108225 chr12 96130713 T C 8.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NTN4 intron 20877124 rs4341610 chr12 96149288 A C 1.86E-05 Type 2 diabetes NTN4 intron 17463246 rs11108242 chr12 96156668 T A 7.89E-04 Multiple complex diseases NTN4 intron 17554300 rs11612530 chr12 96159659 C T 1.02E-05 Antineutrophil cytoplasmic antibody-associated vasculitis NTN4 intron 22808956 rs4237913 chr12 96162288 C T 1.84E-05 Job-related exhaustion NTN4 intron 23620144 rs12582105 chr12 96198627 G A 5.71E-04 Suicide attempts in bipolar disorder LOC100505645 intron 21041247 rs1561092 chr12 96204253 T C 6.46E-05 Response to taxane treatment (placlitaxel) LOC100505645 intron 23006423 rs10859956 chr12 96204979 T C 5.68E-04 Suicide attempts in bipolar disorder LOC100505645 intron 21041247 rs4762626 chr12 96205161 T C 6.33E-06 Pulmonary function LOC100505645 intron 20010835 rs7307769 chr12 96205888 G A 5.66E-04 Suicide attempts in bipolar disorder LOC100505645 intron 21041247 rs7134181 chr12 96214200 C T 5.61E-04 Suicide attempts in bipolar disorder LOC100505645 intron 21041247 rs12366571 chr12 96214566 A C 2.89E-04 Suicide attempts in bipolar disorder LOC100505645 intron 21041247 rs2060546 chr12 96215456 G A 3.68E-04 Tourette syndrome LOC100505645 intron 22889924 rs10859959 chr12 96216680 T C 5.57E-04 Suicide attempts in bipolar disorder LOC100505645 intron 21041247 rs10777742 chr12 96217159 C T 5.57E-04 Suicide attempts in bipolar disorder / / 21041247 rs10859960 chr12 96218158 G A 5.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs1436120 chr12 96220650 T C 5.33E-06 Pulmonary function / / 20010835 rs11612901 chr12 96221318 T C 2.80E-06 Cognitive decline / / 23207651 rs7310140 chr12 96222187 G A 4.89E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7299632 chr12 96232154 C A 4.88E-06 Pulmonary function / / 20010835 rs7307510 chr12 96237570 T C 4.26E-06 Pulmonary function / / 20010835 rs1865736 chr12 96247829 A G 5.24E-06 Pulmonary function / / 20010835 rs2887026 chr12 96248491 C A 6.08E-06 Pulmonary function / / 20010835 rs4762631 chr12 96249476 A C 9.37E-06 Pulmonary function / / 20010835 rs2367583 chr12 96250360 T C 5.86E-06 Pulmonary function / / 20010835 rs4762633 chr12 96254073 C T 1.08E-05 Pulmonary function SNRPF intron 20010835 rs7957346 chr12 96260474 C A 2.20E-08 Pulmonary emphysema / / 24383474 rs6538678 chr12 96261568 A G 2.63E-05 Pulmonary function CCDC38 intron 20010835 rs6538678 chr12 96261568 A G 2.00E-06 Lupus nephritis in systemic lupus erythematosus CCDC38 intron 24925725 rs10777747 chr12 96263970 G A 9.64E-05 Pulmonary function CCDC38 intron 20010835 rs7308921 chr12 96264535 G A 9.54E-05 Pulmonary function CCDC38 intron 20010835 rs10507063 chr12 96267298 G C 1.19E-05 Crohn's disease CCDC38 intron 17684544 rs1036429 chr12 96271428 T C 2.63E-06 Pulmonary function CCDC38 intron 20010835 rs1036429 chr12 96271428 T C 2.00E-11 Pulmonary function CCDC38 intron 21946350 rs1036429 chr12 96271428 T C 1.00E-07 Pulmonary function (interaction) CCDC38 intron 23284291 rs2196457 chr12 96274690 A G 5.07E-06 Orofacial clefts CCDC38 intron 22419666 rs4762637 chr12 96282655 G A 1.14E-05 Pulmonary function CCDC38 intron 20010835 rs1436124 chr12 96283432 T G 1.16E-05 Pulmonary function CCDC38 intron 20010835 rs10859981 chr12 96307651 C T 7.79E-05 Gallstones CCDC38 intron 17632509 rs4762639 chr12 96315487 C T 2.50E-04 Height CCDC38 intron 17255346 rs7311009 chr12 96335003 C G 8.94E-06 Ankle-brachial index CCDC38 intron 22199011 rs7487781 chr12 96355376 T G 4.29E-04 Multiple complex diseases AMDHD1 intron 17554300 rs10507068 chr12 96360473 C T 2.79E-04 Height AMDHD1 intron 17255346 rs1059845 chr12 96366698 G A 3.30E-06 Urinary metabolites HAL UTR-3 21572414 rs2068662 chr12 96368255 A G 4.67E-06 Narcolepsy HAL intron 20711174 rs17676451 chr12 96375785 G A 4.08E-06 Coronary artery calcification HAL intron 22144573 rs2540500 chr12 96398828 T C 5.09E-08 Metabolite levels LTA4H intron 23281178 rs10492226 chr12 96403989 T A 6.70E-04 Volumetric brain MRI LTA4H intron 17903297 rs10492226 chr12 96403989 T A 2.50E-19 Varicose Veins LTA4H intron pha001416 rs2660896 chr12 96423782 T C 0.0000794 Ankle-brachial index LTA4H intron 22361517 rs7971150 chr12 96434746 A G 6.46E-05 Lupus nephritis in systemic lupus erythematosus LTA4H intron 24925725 rs2540482 chr12 96434880 C T 9.48E-06 Lung cancer LTA4H intron 19654303 rs2887104 chr12 96435443 A G 7.57E-05 Lupus nephritis in systemic lupus erythematosus LTA4H intron 24925725 rs2540477 chr12 96437554 G A 3.48E-04 Prostate cancer mortality / / 20978177 rs2660844 chr12 96438319 A C 5.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2660845 chr12 96438553 G A 1 Drug response to Montelukast / / 16293801 rs7966098 chr12 96438641 G T 5.25E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs2660848 chr12 96440613 A C 2.94E-04 Smoking initiation / / 24665060 rs41392450 chr12 96444554 G A 2.79E-04 Smoking initiation / / 24665060 rs2660851 chr12 96444697 T G 4.73E-04 Multiple complex diseases / / 17554300 rs2660888 chr12 96451687 A G 6.60E-05 Longevity / / 22279548 rs759394 chr12 96459342 C A 3.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2540457 chr12 96471864 T G 2.37E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2660869 chr12 96479267 G C 3.00E-06 Height / / 20966902 rs2540513 chr12 96492448 A G 7.19E-05 Serum metabolites / / 19043545 rs256177 chr12 96546049 G C 2.75E-04 Type 2 diabetes / / 17463246 rs256177 chr12 96546049 G C 1.17E-04 Insulin resistance / / 21901158 rs10492224 chr12 96561741 A G 1.28E-04 Amyotrophic lateral sclerosis / / 23624525 rs12424513 chr12 96563954 T C 2.25E-04 Blood pressure / / 17255346 rs12424513 chr12 96563954 T C 3.66E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2075362 chr12 96606889 G A 2.26E-05 Stroke ELK3 intron pha002887 rs11835157 chr12 96634205 A G 6.00E-06 Response to inhaled corticosteroid treatment in asthma (percentage change of FEV1) ELK3 intron 24792382 rs2268500 chr12 96657491 G A 0.00005567 Sarcoidosis ELK3 intron 22952805 rs2302901 chr12 96661014 G A 5.64E-04 Rheumatoid arthritis ELK3 UTR-3 21452313 rs2302901 chr12 96661014 G A 0.000161415 Hypertension (early onset hypertension) ELK3 UTR-3 22479346 rs11108454 chr12 96683173 G A 7.27E-04 Coronary heart disease CDK17 intron 21971053 rs11108457 chr12 96695875 C T 1.76E-05 Coronary heart disease CDK17 intron 21971053 rs2887150 chr12 96705508 G A 5.10E-05 Coronary heart disease CDK17 intron 21971053 rs11108483 chr12 96768898 A G 5.87E-04 Coronary heart disease CDK17 intron 21971053 rs11108495 chr12 96807917 T C 4.00E-06 Weight / / 20966902 rs2028385 chr12 96817422 A G 9.00E-09 Venous thromboembolism (gene x gene interaction) / / 23509962 rs7312607 chr12 96826170 C A 9.34E-05 Parkinson's disease / / pha002865 rs11108507 chr12 96836030 T G 6.28E-05 Serum metabolites / / 19043545 rs17025418 chr12 96836126 T C 1.57E-12 Metabolite levels / / 22286219 rs12423247 chr12 96858362 A T 3.00E-08 Phospholipid levels (plasma) / / 22359512 rs3858655 chr12 96880242 C A 1.47E-04 Colorectal cancer / / 24978480 rs3858655 chr12 96880242 C A 1.12E-05 Fibrinogen / / pha003068 rs7315210 chr12 96882865 T G 5.99E-04 Smoking cessation / / 24665060 rs7308077 chr12 96907972 C T 6.05E-07 Breast cancer C12orf55 intron 20852631 rs7297965 chr12 96916254 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes C12orf55 intron 22628534 rs17375557 chr12 96918529 C T 1.75E-04 Colorectal cancer C12orf55 intron 24978480 rs7314750 chr12 96923355 T G 9.93E-06 Substance dependence phenotypes C12orf55 intron 24832863 rs10777800 chr12 96942299 G A 1.20E-05 Urinary metabolites C12orf55 intron 21572414 rs10860052 chr12 96942366 G A 6.69E-04 Multiple complex diseases C12orf55 intron 17554300 rs2052293 chr12 96986190 G A 7.33E-05 Lymphocyte counts C12orf55 intron pha003094 rs4012 chr12 97021110 A G 7.72E-05 Lymphocyte counts C12orf55 intron pha003094 rs11108625 chr12 97053902 T C 4.91E-04 Iron levels C12orf55 intron pha002876 rs2371229 chr12 97104104 G A 5.69E-04 Parkinson's disease / / 17052657 rs7963861 chr12 97127091 T G 7.53E-05 Diabetes Mellitus C12orf63 intron pha003059 rs7139219 chr12 97135273 C A 2.70E-05 Urinary metabolites C12orf63 intron 21572414 rs11108693 chr12 97172138 T G 3.59E-04 Smoking cessation C12orf63 intron 24665060 rs34450 chr12 97210829 C A 7.98E-04 Smoking cessation C12orf63 intron 24665060 rs970332 chr12 97278178 T G 4.14E-04 Smoking cessation / / 24665060 rs252170 chr12 97291848 A G 8.95E-05 Progressive supranuclear palsy / / 21685912 rs2024490 chr12 97299364 A G 3.06E-05 Hemoglobin / / pha003096 rs2024490 chr12 97299364 A G 4.62E-05 Hematocrit / / pha003097 rs2024490 chr12 97299364 A G 9.85E-05 Erythrocyte counts / / pha003101 rs1548947 chr12 97304464 A G 6.27E-05 Smoking cessation NEDD1 intron 24665060 rs10860105 chr12 97311821 C T 6.20E-05 Smoking cessation NEDD1 intron 24665060 rs249571 chr12 97321211 C T 7.68E-04 Alcohol dependence NEDD1 intron 20201924 rs2371356 chr12 97404972 T G 4.77E-04 Bipolar disorder / / 19259986 rs6538761 chr12 97434220 A C 2.00E-06 Autism / / 24189344 rs1548968 chr12 97463592 T G 9.68E-04 Multiple complex diseases / / 17554300 rs759572 chr12 97483035 C T 7.12E-04 Multiple complex diseases / / 17554300 rs7314295 chr12 97489810 T C 6.99E-04 Alzheimer's disease / / 22005930 rs7308394 chr12 97509945 C T 2.20E-05 Urinary metabolites / / 21572414 rs6538780 chr12 97509968 T A 4.13E-06 Schizophrenia / / 19571811 rs7953959 chr12 97528140 C T 8.00E-06 IgG glycosylation / / 23382691 rs11108836 chr12 97529985 G A 3.68E-05 Nephrolithiasis / / 22396660 rs12427050 chr12 97546392 G A 8.69E-04 Multiple complex diseases / / 17554300 rs12427050 chr12 97546392 G A 0.0005 Bipolar disorder / / 23637625 rs4762367 chr12 97551024 C T 6.98E-05 Calcium levels / / pha003085 rs11108857 chr12 97553106 T C 5.97E-05 Nephrolithiasis / / 22396660 rs7486084 chr12 97577947 A G 2.49E-04 Multiple complex diseases / / 17554300 rs4762371 chr12 97584966 C A 4.91E-04 Multiple complex diseases / / 17554300 rs2160427 chr12 97588017 C T 2.21E-05 Nephrolithiasis / / 22396660 rs11108881 chr12 97604787 A G 9.28E-04 Type 2 diabetes / / 17463246 rs12424340 chr12 97606222 A G 6.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11108890 chr12 97613399 C A 4.00E-04 Epithelial ovarian cancer / / 24190013 rs41468746 chr12 97648569 C T 1.05E-04 Multiple complex diseases / / 17554300 rs12423819 chr12 97657487 G A 4.64E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11609353 chr12 97660291 C T 3.29E-04 Obesity (extreme) / / 21935397 rs7967235 chr12 97674118 G A 9.44E-05 Hepatocellular carcinoma / / 22807686 rs6538797 chr12 97674468 C T 8.51E-05 Hepatocellular carcinoma / / 22807686 rs1558726 chr12 97676235 G A 1.02E-05 Asthma (corticosteroid response) / / 24486069 rs2111027 chr12 97685057 G A 2.96E-05 Cholesterol / / pha003073 rs2111027 chr12 97685057 G A 5.15E-05 Cholesterol / / pha003078 rs11611637 chr12 97685364 T C 8.78E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs10777845 chr12 97689768 C T 4.51E-04 Multiple complex diseases / / 17554300 rs10777845 chr12 97689768 C T 5.00E-06 Sudden cardiac arrest / / 21658281 rs257964 chr12 97710446 G T 1.37E-04 Multiple complex diseases / / 17554300 rs1558729 chr12 97718018 A C 9.59E-05 Serum metabolites / / 19043545 rs11108974 chr12 97722178 G A 3.50E-05 Coronary heart disease / / pha003031 rs10860180 chr12 97722393 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17026787 chr12 97729032 G A 3.80E-06 Urinary metabolites / / 21572414 rs10777852 chr12 97729691 G A 3.39E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs874389 chr12 97732266 A C 3.57E-04 Type 2 diabetes / / 17463246 rs10860191 chr12 97733010 T C 8.08E-05 Serum metabolites / / 19043545 rs10860192 chr12 97736162 A G 8.03E-05 Serum metabolites / / 19043545 rs11108995 chr12 97758782 C T 1.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7298683 chr12 97785855 G T 1.93E-05 Glucose levels / / pha002899 rs10777859 chr12 97792787 A G 8.80E-05 Coronary heart disease / / pha003056 rs7977936 chr12 97800076 C T 1.20E-05 Urinary metabolites / / 21572414 rs17026920 chr12 97800239 C T 3.47E-04 Blood pressure / / 17255346 rs12579296 chr12 97823526 T C 0.000769769 Hypertension (early onset hypertension) / / 22479346 rs1579198 chr12 97827162 C G 7.87E-04 Alzheimer's disease / / 17998437 rs1965020 chr12 97827578 A C 3.89E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1579244 chr12 97846542 A C 9.78E-04 Multiple complex diseases / / 17554300 rs11109051 chr12 97870501 G T 1.18E-04 Multiple complex diseases RMST intron 17554300 rs10507088 chr12 97879744 G A 5.12E-04 Breast cancer RMST intron 20852631 rs7309372 chr12 97894261 C T 8.77E-04 Acute lung injury RMST intron 22295056 rs11109072 chr12 97901270 C A 4.00E-09 Obesity (early onset extreme) RMST intron 23563609 rs7962117 chr12 97919052 A G 8.31E-04 Response to taxane treatment (placlitaxel) RMST intron 23006423 rs2371722 chr12 97920694 A G 5.19E-04 Suicide attempts in bipolar disorder RMST intron 21423239 rs11109097 chr12 97928437 C T 9.92E-05 Waist-Hip Ratio / / pha003028 rs57508337 chr12 97935508 G GA 6.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs7977469 chr12 97935508 G A 6.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs10860219 chr12 97959792 A G 2.08E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1868813 chr12 97969111 T C 5.94E-05 Smoking initiation / / 24665060 rs11109114 chr12 97970138 A G 9.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7966342 chr12 98017607 G A 8.90E-05 Immunoglobulin A / / 20694011 rs11109141 chr12 98025622 G A 1.63E-05 Hypertension / / pha003042 rs11109142 chr12 98027691 C G 4.00E-06 Social communication problems / / 24564958 rs1450997 chr12 98029100 T C 9.31E-07 Nephrolithiasis / / 22396660 rs6538815 chr12 98032566 G A 3.59E-05 Nephrolithiasis / / 22396660 rs34552 chr12 98038863 A G 2.01E-06 Nephrolithiasis / / 22396660 rs10735355 chr12 98054607 G A 2.19E-05 Nephrolithiasis / / 22396660 rs248812 chr12 98061146 C A 9.38E-06 Nephrolithiasis / / 22396660 rs1420396 chr12 98061885 A G 6.69E-04 Alzheimer's disease / / 22005930 rs248820 chr12 98084420 G A 8.64E-04 Myocardial Infarction / / pha002883 rs1362498 chr12 98152671 G C 7.29E-04 Multiple complex diseases / / 17554300 rs10777884 chr12 98154299 A G 3.74E-04 Coronary Artery Disease / / 17634449 rs34546 chr12 98177630 T C 0.0000199 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7139232 chr12 98207612 T C 8.98E-04 Alzheimer's disease / / 17998437 rs7139232 chr12 98207612 T C 7.47E-05 Serum metabolites / / 19043545 rs11109229 chr12 98208150 G T 4.30E-05 Epilepsy / / 22116939 rs6538823 chr12 98213483 C T 3.77E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11109232 chr12 98214576 A G 2.20E-04 White matter integrity / / 22425255 rs12370281 chr12 98249633 C G 7.50E-05 Cognitive function / / 24684796 rs6538829 chr12 98256144 G T 1.50E-04 Multiple complex diseases / / 17554300 rs11109258 chr12 98259565 T C 1.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs10745813 chr12 98265464 G A 9.48E-04 Multiple complex diseases / / 17554300 rs1450064 chr12 98310924 T C 3.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10492267 chr12 98349338 G A 5.35E-41 Multiple complex diseases / / 17554300 rs4612863 chr12 98359862 G C 3.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs7301409 chr12 98369314 C T 1.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs11109315 chr12 98378706 G A 5.40E-04 Aortic root size / / 21223598 rs17605914 chr12 98391616 A C 7.41E-05 Cognitive performance / / 19734545 rs2192796 chr12 98424869 G A 3.20E-07 Urinary metabolites / / 21572414 rs9669668 chr12 98442118 A G 1.10E-05 Urinary metabolites / / 21572414 rs2003580 chr12 98457661 T C 2.96E-05 Cognitive performance / / 19734545 rs2216017 chr12 98467194 G A 4.80E-06 Urinary metabolites / / 21572414 rs7968996 chr12 98469903 G A 7.30E-06 Urinary metabolites / / 21572414 rs2160245 chr12 98475103 C T 8.30E-06 Urinary metabolites / / 21572414 rs3887322 chr12 98485451 A G 5.57E-11 Metabolite levels / / 22286219 rs10777903 chr12 98509589 C T 3.30E-06 Urinary metabolites / / 21572414 rs7952745 chr12 98531463 G T 3.61E-04 Smoking initiation / / 24665060 rs7960848 chr12 98533477 G A 5.90E-04 Obesity (extreme) / / 21935397 rs7960881 chr12 98533658 C T 5.93E-04 Obesity (extreme) / / 21935397 rs12315137 chr12 98534489 G A 5.95E-04 Obesity (extreme) / / 21935397 rs905749 chr12 98534797 T G 1.20E-05 Urinary metabolites / / 21572414 rs11109356 chr12 98535518 C T 6.01E-04 Obesity (extreme) / / 21935397 rs7138340 chr12 98538276 A G 2.00E-04 Alzheimer's disease (late onset) / / 21379329 rs1383131 chr12 98546812 C T 0.00006718 Sarcoidosis / / 22952805 rs11109362 chr12 98547621 T C 0.00006262 Sarcoidosis / / 22952805 rs1394376 chr12 98548762 C G 0.00005537 Sarcoidosis / / 22952805 rs7136740 chr12 98550134 C T 0.0000424 Sarcoidosis / / 22952805 rs10860299 chr12 98551559 G A 8.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs1480069 chr12 98558489 C A 2.10E-05 Urinary metabolites / / 21572414 rs978341 chr12 98559474 A T 5.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs11109370 chr12 98563249 C A 5.58E-05 ldl cholesterol / / pha003076 rs11109371 chr12 98567138 T C 3.17E-04 Alzheimer's disease / / 24755620 rs1480073 chr12 98568330 G A 7.55E-04 Alzheimer's disease / / 24755620 rs1504558 chr12 98568966 C G 4.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs1847534 chr12 98570133 C A 7.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs1354486 chr12 98570328 G A 8.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs10860303 chr12 98573602 C T 1.94E-04 Alzheimer's disease (late onset) / / 21379329 rs10860303 chr12 98573602 C T 1.33E-04 Alzheimer's disease / / 24755620 rs10467001 chr12 98574428 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7966704 chr12 98577304 C T 6.62E-04 Alzheimer's disease / / 24755620 rs7980332 chr12 98591211 A C 7.75E-04 Suicide attempts in bipolar disorder / / 21041247 rs10777913 chr12 98618474 A G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2372176 chr12 98734177 T C 4.61E-05 Post-operative nausea and vomiting / / 21694509 rs1420449 chr12 98760031 T G 5.38E-05 Post-operative nausea and vomiting / / 21694509 rs7954125 chr12 98762487 G T 1.15E-05 Post-operative nausea and vomiting / / 21694509 rs7957890 chr12 98763498 A T 2.22E-04 Multiple complex diseases / / 17554300 rs6538867 chr12 98782210 A G 2.09E-05 Job-related exhaustion / / 23620144 rs7137207 chr12 98793414 G A 4.51E-05 Paget's disease / / 20436471 rs12819710 chr12 98811405 G A 9.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs249851 chr12 98864971 G A 1.20E-04 Pancreatic cancer / / pha002874 rs249820 chr12 98897473 A G 1.05E-04 Glycosylated haemoglobin levels LOC643770 intron 17255346 rs249820 chr12 98897473 A G 2.82E-06 Rheumatoid arthritis LOC643770 intron 19503088 rs249821 chr12 98897811 T C 9.44E-05 Glycosylated haemoglobin levels / / 17255346 rs249821 chr12 98897811 T C 1.82E-05 Rheumatoid arthritis / / 19503088 rs249821 chr12 98897811 T C 6.59E-04 Smoking initiation / / 24665060 rs3213900 chr12 98925865 C A 7.05E-06 Glycemic traits (pregnancy) TMPO intron 23903356 rs4762495 chr12 98934105 C T 5.00E-04 End-stage renal disease TMPO intron 19929986 rs3847874 chr12 99027045 T A 9.06E-04 Coronary Artery Disease IKBIP intron 17634449 rs7303112 chr12 99071892 C T 4.46E-12 Triglycerides APAF1 intron 23063622 rs7313090 chr12 99074772 G A 4.38E-04 Suicide attempts in bipolar disorder APAF1 intron 21423239 rs919699 chr12 99084326 A G 4.90E-04 Suicide attempts in bipolar disorder APAF1 intron 21423239 rs11831003 chr12 99101457 A G 1.08E-04 Multiple complex diseases APAF1 intron 17554300 rs11109583 chr12 99119355 T C 5.48E-04 Response to cytidine analogues (gemcitabine) APAF1 intron 24483146 rs1866477 chr12 99119833 T G 6.12E-04 Suicide attempts in bipolar disorder APAF1 intron 21423239 rs17028658 chr12 99132112 T C 9.63E-04 Multiple complex diseases ANKS1B intron 17554300 rs4762507 chr12 99135638 C T 1.27E-05 Leukocyte Counts ANKS1B intron pha003091 rs17815383 chr12 99148442 A C 9.45E-04 Multiple complex diseases ANKS1B intron 17554300 rs10860363 chr12 99148667 T C 1.00E-04 Prostate cancer ANKS1B intron 21743057 rs11109596 chr12 99164614 A G 7.62E-04 Multiple complex diseases ANKS1B intron 17554300 rs11109604 chr12 99177369 T C 1.36E-04 Vaspin levels ANKS1B intron 22907691 rs11109604 chr12 99177369 T C 0.0001359 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks ANKS1B intron 22907730 rs2036225 chr12 99190372 C T 8.00E-06 Amyotrophic lateral sclerosis (age of onset) ANKS1B intron 22959728 rs17028701 chr12 99200282 T C 1.90E-05 Iron levels ANKS1B intron 21208937 rs936208 chr12 99205713 C T 3.33E-04 Amyotrophic lateral sclerosis ANKS1B intron 23624525 rs169302 chr12 99240835 A G 9.47E-04 Multiple complex diseases ANKS1B intron 17554300 rs201369 chr12 99241320 A G 5.17E-04 Type 2 diabetes ANKS1B intron 17463246 rs201369 chr12 99241320 A G 1.80E-05 Urinary metabolites ANKS1B intron 21572414 rs201363 chr12 99244826 T C 2.39E-04 Type 2 diabetes ANKS1B intron 17463246 rs201371 chr12 99262677 C G 2.06E-05 Vaspin levels ANKS1B intron 22907691 rs201418 chr12 99277908 A G 8.94E-04 Suicide attempts in bipolar disorder ANKS1B intron 21423239 rs201410 chr12 99300340 A G 4.75E-04 Suicide attempts in bipolar disorder ANKS1B intron 21423239 rs201408 chr12 99304404 T G 5.06E-04 Suicide attempts in bipolar disorder ANKS1B intron 21423239 rs201407 chr12 99305987 T C 3.91E-04 Suicide attempts in bipolar disorder ANKS1B intron 21423239 rs200791 chr12 99308282 A G 3.50E-04 Type 2 diabetes and 6 quantitative traits ANKS1B intron 17848626 rs7301791 chr12 99324868 A C 8.62E-04 HIV-1 viral setpoint ANKS1B intron 17641165 rs483610 chr12 99334529 C T 7.00E-06 Obesity-related traits ANKS1B intron 23251661 rs4536282 chr12 99349828 G A 4.35E-05 Response to methotrexate in juvenile idiopathic arthritis ANKS1B intron 24709693 rs869032 chr12 99398017 C T 7.39E-04 Multiple complex diseases ANKS1B intron 17554300 rs7487923 chr12 99404503 A G 3.53E-04 Multiple complex diseases ANKS1B intron 17554300 rs11109705 chr12 99423811 C A 6.22E-04 Multiple complex diseases ANKS1B intron 17554300 rs4762546 chr12 99430469 G C 4.00E-04 Major depressive disorder ANKS1B intron 21042317 rs7974917 chr12 99457672 G A 1.50E-05 Urinary metabolites ANKS1B intron 21572414 rs2372644 chr12 99490760 T G 6.80E-04 Alcohol dependence ANKS1B intron 24277619 rs10860392 chr12 99498187 C T 2.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) ANKS1B intron 23453885 rs7965982 chr12 99515353 A G 2.00E-05 Urinary metabolites ANKS1B intron 21572414 rs17367186 chr12 99520594 T G 5.20E-04 Alcohol dependence ANKS1B intron 20201924 rs2712665 chr12 99594947 C T 3.00E-05 Asthma and hay fever ANKS1B intron 24388013 rs7137220 chr12 99659691 C G 8.57E-04 Multiple complex diseases ANKS1B intron 17554300 rs11109794 chr12 99676996 G A 9.16E-04 Alcohol dependence ANKS1B intron 21314694 rs10735366 chr12 99766206 G A 8.46E-04 Nicotine smoking ANKS1B intron 19268276 rs10860434 chr12 99809041 C A 6.90E-06 Urinary metabolites ANKS1B intron 21572414 rs10777982 chr12 99811021 T C 1.50E-05 Urinary metabolites ANKS1B intron 21572414 rs10860438 chr12 99816442 G A 1.14E-05 Cognitive performance ANKS1B intron 19734545 rs10860438 chr12 99816442 G A 2.53E-04 Lung function (forced vital capacity) ANKS1B intron 24023788 rs7968606 chr12 99816842 C T 3.00E-07 Response to antipsychotic treatment ANKS1B intron 19721433 rs1511961 chr12 99830822 G A 6.97E-04 Smoking cessation ANKS1B intron 24665060 rs2175523 chr12 99883532 G C 2.46E-08 Metabolite levels ANKS1B intron 23281178 rs7398357 chr12 99887674 G A 6.85E-08 Metabolite levels ANKS1B intron 23281178 rs10860447 chr12 99890240 C T 2.90E-04 Multiple complex diseases ANKS1B intron 17554300 rs924507 chr12 99895336 A C 4.78E-04 Multiple complex diseases ANKS1B intron 17554300 rs2202037 chr12 99901776 C T 8.58E-04 Multiple complex diseases ANKS1B intron 17554300 rs11109882 chr12 99903546 T G 1.21E-04 Multiple complex diseases ANKS1B intron 17554300 rs1961649 chr12 99904540 A T 3.00E-06 Metabolite levels (HVA/5-HIAA ratio) ANKS1B intron 23319000 rs2373013 chr12 99923770 G A 2.85E-05 ldl cholesterol ANKS1B intron pha003076 rs17393423 chr12 99927811 T C 8.81E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ANKS1B intron 21844884 rs2133898 chr12 99938670 G A 2.10E-04 Multiple complex diseases ANKS1B intron 17554300 rs2373011 chr12 99961349 C G 4.01E-05 Multiple complex diseases ANKS1B intron 17554300 rs2373011 chr12 99961349 C G 2.00E-06 Waist circumference ANKS1B intron 20966902 rs2373011 chr12 99961349 C G 9.00E-06 Body mass index ANKS1B intron 20966902 rs11109953 chr12 100019917 C A 7.68E-04 Suicide attempts in bipolar disorder ANKS1B intron 21423239 rs1500656 chr12 100022372 A C 6.42E-04 Myopia (pathological) ANKS1B intron 21095009 rs1587504 chr12 100025158 T C 0.0000634 Major depressive disorder ANKS1B intron 23149448 rs10467010 chr12 100039156 T C 5.32E-04 Myocardial Infarction ANKS1B intron pha002883 rs11109968 chr12 100042040 C G 0.00011 Breast cancer FAM71C missense 23555315 rs11109969 chr12 100042163 A G 0.00026 Breast cancer FAM71C missense 23555315 rs10778007 chr12 100093083 A G 9.03E-04 Obesity (extreme) ANKS1B intron 21935397 rs10860494 chr12 100093423 C A 8.94E-04 Obesity (extreme) ANKS1B intron 21935397 rs1500660 chr12 100094779 T G 8.86E-04 Obesity (extreme) ANKS1B intron 21935397 rs7955548 chr12 100096840 C T 9.99E-04 Obesity (extreme) ANKS1B intron 21935397 rs4986685 chr12 100097300 G A 8.92E-04 Obesity (extreme) ANKS1B intron 21935397 rs4986687 chr12 100098748 C T 8.95E-04 Obesity (extreme) ANKS1B intron 21935397 rs6538945 chr12 100152136 C T 9.07E-04 Obesity (extreme) ANKS1B intron 21935397 rs11110031 chr12 100164367 A T 5.57E-04 Obesity (extreme) ANKS1B intron 21935397 rs7979049 chr12 100166239 A G 8.41E-04 Obesity (extreme) ANKS1B intron 21935397 rs10860519 chr12 100169836 C T 4.26E-04 Obesity (extreme) ANKS1B intron 21935397 rs10507115 chr12 100227984 A C 8.20E-05 Amyotrophic lateral sclerosis (sporadic) ANKS1B intron 24529757 rs732718 chr12 100230985 G T 9.66E-05 Non-alcoholic fatty liver disease histology (other) ANKS1B intron 20708005 rs17029835 chr12 100232213 T C 3.27E-04 Multiple complex diseases ANKS1B intron 17554300 rs4764735 chr12 100255257 G A 5.71E-05 Magnesium levels ANKS1B intron pha003092 rs17029838 chr12 100258995 A G 6.83E-04 Aortic root size ANKS1B intron 21223598 rs827795 chr12 100260994 C T 2.17E-05 Post-operative nausea and vomiting ANKS1B intron 21694509 rs11110077 chr12 100266113 C G 4.00E-07 Response to antipsychotic treatment in schizophrenia (working memory) ANKS1B intron 21107309 rs17029861 chr12 100309128 A G 1.10E-07 Platelet aggregation(pre- and post-aspirin) ANKS1B intron 20529293 rs2373201 chr12 100332815 C T 2.10E-07 Platelet aggregation(pre- and post-aspirin) ANKS1B intron 20529293 rs11614483 chr12 100415419 T G 6.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs17029981 chr12 100491551 G A 2.30E-05 Urinary metabolites UHRF1BP1L intron 21572414 rs7960152 chr12 100575773 A C 1.77E-05 Post-operative nausea and vomiting / / 21694509 rs7960152 chr12 100575773 A C 0.000761 Schizophrenia / / 22440650 rs10778044 chr12 100578633 C T 1.19E-08 Brain activation patterns in response to human facial expressions-for the negative faces task / / 22828495 rs10778044 chr12 100578633 C T 1.19E-08 Airflow obstruction / / 22837378 rs3887427 chr12 100643450 G A 2.80E-05 Urinary metabolites / / 21572414 rs11110337 chr12 100708054 C T 9.79E-04 Alzheimer's disease SCYL2 intron 22005930 rs828933 chr12 100745653 T C 8.39E-06 Rheumatoid arthritis / / 19503088 rs7311096 chr12 100775956 T C 0.00086 Prostate cancer SLC17A8 intron 23555315 rs7485480 chr12 100780919 A G 9.29E-04 Alzheimer's disease SLC17A8 intron 22005930 rs17030132 chr12 100782614 G A 5.46E-04 Smoking initiation SLC17A8 intron 24665060 rs943402 chr12 100792979 T C 3.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC17A8 intron 20877124 rs7966317 chr12 100795311 A G 4.36E-07 Primary biliary cirrhosis SLC17A8 intron 23000144 rs7966317 chr12 100795311 A G 0.000000435 Facial morphology SLC17A8 intron 23028347 rs1887276 chr12 100797485 A G 3.87E-05 Intelligence SLC17A8 intron 21826061 rs1887276 chr12 100797485 A G 3.84E-07 Primary biliary cirrhosis SLC17A8 intron 23000144 rs1887276 chr12 100797485 A G 0.000000384 Facial morphology SLC17A8 intron 23028347 rs7965082 chr12 100800193 C T 2.65E-07 Primary biliary cirrhosis SLC17A8 intron 23000144 rs7965082 chr12 100800193 C T 0.000000265 Facial morphology SLC17A8 intron 23028347 rs11615115 chr12 100802452 A G 9.03E-06 Intelligence SLC17A8 intron 21826061 rs11615115 chr12 100802452 A G 0.0000402 Migraine SLC17A8 intron 22678113 rs11615115 chr12 100802452 A G 4.02E-05 Migraine SLC17A8 intron 22683712 rs17030141 chr12 100802824 A G 6.46E-05 Squamous cell carcinoma SLC17A8 intron 23341777 rs11110370 chr12 100804733 C T 8.63E-04 Myopia (pathological) SLC17A8 intron 21095009 rs11568535 chr12 100806715 G T 7.43E-05 Squamous cell carcinoma SLC17A8 intron 23341777 rs10860590 chr12 100816758 G A 6.98E-05 Intelligence / / 21826061 rs7311059 chr12 100818801 A G 7.06E-04 Myopia (pathological) / / 21095009 rs12296850 chr12 100820085 A G 5.03E-04 Body mass index / / 21701565 rs12296850 chr12 100820085 A G 1.00E-10 Squamous cell carcinoma / / 23341777 rs11110385 chr12 100852705 C T 8.34E-04 Schizophrenia / / 19197363 rs17030285 chr12 100930213 C G 3.42E-04 Alzheimer's disease NR1H4 intron 17998437 rs35724 chr12 100955378 C G 3.39E-04 Parkinson's disease NR1H4 intron 17052657 rs10778056 chr12 101023579 T C 3.10E-04 Obesity,menopause / / 21424828 rs10778070 chr12 101151475 C A 5.88E-04 Migraine with aura / / 23793025 rs10778070 chr12 101151475 C A 9.84E-06 Migraine - clinic-based / / 23793025 rs1514797 chr12 101180962 A G 4.51E-05 Heart Failure / / pha002884 rs11110532 chr12 101203535 G A 4.05E-04 Heart Failure ANO4 intron pha002884 rs7967096 chr12 101214789 A G 6.41E-04 Acute lung injury ANO4 intron 22295056 rs6538973 chr12 101214823 C T 4.98E-04 Acute lung injury ANO4 intron 22295056 rs7136752 chr12 101215477 T C 6.67E-04 Tourette syndrome ANO4 intron 22889924 rs1399439 chr12 101221239 A G 4.00E-07 Alzheimer's disease (cognitive decline) ANO4 intron 23535033 rs1913595 chr12 101223225 A G 1.80E-04 Prion diseases ANO4 intron 22210626 rs11110540 chr12 101223660 T C 2.15E-05 Schizophrenia ANO4 intron 20185149 rs10860641 chr12 101224010 A G 0.0000192 Tuberculosis with early age of onset ANO4 intron 22551897 rs10860643 chr12 101226276 T A 1.25E-04 Multiple complex diseases ANO4 intron 17554300 rs2222001 chr12 101227030 A G 1.38E-04 Multiple complex diseases ANO4 intron 17554300 rs10860644 chr12 101234265 T A 6.40E-04 Acute lung injury ANO4 intron 22295056 rs11110549 chr12 101235684 T C 3.38E-05 Multiple complex diseases ANO4 intron 17554300 rs11110549 chr12 101235684 T C 6.40E-04 Acute lung injury ANO4 intron 22295056 rs10778080 chr12 101236329 A G 1.34E-04 Multiple complex diseases ANO4 intron 17554300 rs2138045 chr12 101236914 G A 6.40E-04 Acute lung injury ANO4 intron 22295056 rs2138045 chr12 101236914 G A 0.0000408 Tuberculosis with early age of onset ANO4 intron 22551897 rs17403347 chr12 101238028 A G 5.85E-06 Schizophrenia ANO4 intron 20185149 rs11110555 chr12 101245023 G A 6.90E-04 Acute lung injury ANO4 intron 22295056 rs11110556 chr12 101245544 C T 7.22E-04 Acute lung injury ANO4 intron 22295056 rs4764762 chr12 101246871 C G 6.34E-04 Acute lung injury ANO4 intron 22295056 rs11110560 chr12 101249555 C G 1.46E-04 Multiple complex diseases ANO4 intron 17554300 rs11110560 chr12 101249555 C G 8.53E-04 Acute lung injury ANO4 intron 22295056 rs925713 chr12 101250141 A G 8.32E-04 Acute lung injury ANO4 intron 22295056 rs10507121 chr12 101251554 G T 3.19E-05 Prion diseases ANO4 intron 22210626 rs1514788 chr12 101257749 G A 9.18E-04 Acute lung injury ANO4 intron 22295056 rs11110564 chr12 101258396 C T 9.18E-04 Acute lung injury ANO4 intron 22295056 rs10437889 chr12 101261857 C T 6.90E-06 Urinary metabolites ANO4 intron 21572414 rs1399447 chr12 101263905 G A 1.80E-04 Prion diseases ANO4 intron 22210626 rs10860652 chr12 101276216 C T 9.87E-04 Depression (quantitative trait) ANO4 intron 20800221 rs10860652 chr12 101276216 C T 2.29E-04 Acute lung injury ANO4 intron 22295056 rs2672502 chr12 101290384 T C 6.94E-05 Multiple complex diseases ANO4 intron 17554300 rs2653448 chr12 101291490 G C 6.03E-04 Multiple complex diseases ANO4 intron 17554300 rs2653448 chr12 101291490 G C 3.78E-05 Serum metabolites ANO4 intron 19043545 rs1964079 chr12 101293789 T C 7.07E-06 Serum metabolites ANO4 intron 19043545 rs4764630 chr12 101321060 G A 6.31E-05 Information processing speed ANO4 intron 21130836 rs676527 chr12 101332113 C T 4.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ANO4 intron 20877124 rs654379 chr12 101350622 C T 4.76E-05 Serum metabolites ANO4 intron 19043545 rs12830193 chr12 101354493 T C 1.09E-04 Multiple complex diseases ANO4 intron 17554300 rs7974164 chr12 101358282 T C 8.61E-05 Multiple complex diseases ANO4 intron 17554300 rs3803140 chr12 101381132 A C 2.98E-04 Suicide attempts in bipolar disorder ANO4 intron 21423239 rs66861122 chr12 101383958 T G 5.00E-06 Response to methotrexate in juvenile idiopathic arthritis ANO4 intron 24709693 rs17485225 chr12 101400699 G A 9.53E-04 Suicide attempts in bipolar disorder ANO4 intron 21423239 rs7956620 chr12 101447641 A G 1.40E-05 Multiple complex diseases ANO4 intron 17554300 rs583825 chr12 101467863 A G 4.39E-04 Multiple complex diseases ANO4 intron 17554300 rs606569 chr12 101470052 A G 2.40E-05 Cognitive impairment induced by topiramate ANO4 intron 22091778 rs1606865 chr12 101489750 C G 9.29E-05 Personality dimensions ANO4 intron 18957941 rs4764780 chr12 101510951 T C 4.20E-04 Multiple complex diseases ANO4 intron 17554300 rs3847935 chr12 101513740 C T 5.34E-04 Multiple complex diseases ANO4 intron 17554300 rs10860680 chr12 101514633 G A 4.71E-05 Personality dimensions ANO4 intron 18957941 rs10860680 chr12 101514633 G A 4.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ANO4 intron 20877124 rs3902307 chr12 101521520 A G 8.01E-04 Multiple complex diseases ANO4 intron 17554300 rs1849710 chr12 101522078 C G 2.29E-05 Personality dimensions ANO4 UTR-3 18957941 rs1849710 chr12 101522078 C G 7.97E-04 Depression (quantitative trait) ANO4 UTR-3 20800221 rs1849710 chr12 101522078 C G 2.30E-05 Personality dimensions ANO4 UTR-3 21173776 rs3914433 chr12 101525373 C T 9.54E-05 Depression (quantitative trait) / / 20800221 rs7300078 chr12 101525562 G T 2.31E-04 Depression (quantitative trait) / / 20800221 rs11110670 chr12 101526064 T C 3.10E-04 Depression (quantitative trait) / / 20800221 rs905610 chr12 101528318 C G 8.26E-05 Bipolar disorder,schizoaffective / / 19567891 rs905610 chr12 101528318 C G 2.09E-04 Depression (quantitative trait) / / 20800221 rs905611 chr12 101528576 T C 2.10E-04 Depression (quantitative trait) / / 20800221 rs4764639 chr12 101529494 G T 6.70E-05 Bipolar disorder,schizoaffective / / 19567891 rs4764639 chr12 101529494 G T 2.20E-04 Depression (quantitative trait) / / 20800221 rs823559 chr12 101530109 A G 4.80E-05 Crohn's disease (time to surgery) / / 23665963 rs6538976 chr12 101530391 C A 4.17E-04 Depression (quantitative trait) / / 20800221 rs7298531 chr12 101530566 C T 8.68E-05 Bipolar disorder,schizoaffective / / 19567891 rs7298531 chr12 101530566 C T 2.30E-04 Depression (quantitative trait) / / 20800221 rs9804950 chr12 101531938 T C 2.38E-04 Depression (quantitative trait) / / 20800221 rs12313926 chr12 101533066 T C 4.32E-04 Depression (quantitative trait) / / 20800221 rs11110674 chr12 101533421 A C 2.37E-04 Depression (quantitative trait) / / 20800221 rs12370713 chr12 101533459 T C 1.91E-04 Depression (quantitative trait) / / 20800221 rs2137889 chr12 101534166 A C 3.33E-04 Depression (quantitative trait) / / 20800221 rs2137890 chr12 101534218 A G 2.39E-04 Depression (quantitative trait) / / 20800221 rs10860685 chr12 101535175 T C 4.29E-04 Depression (quantitative trait) / / 20800221 rs10860686 chr12 101535644 C T 2.90E-04 Depression (quantitative trait) / / 20800221 rs10860687 chr12 101535704 A G 9.74E-04 Multiple complex diseases / / 17554300 rs11110675 chr12 101536053 G A 3.14E-04 Depression (quantitative trait) / / 20800221 rs11110676 chr12 101536192 T A 2.14E-04 Depression (quantitative trait) / / 20800221 rs11110677 chr12 101536561 A G 2.14E-04 Depression (quantitative trait) / / 20800221 rs11110678 chr12 101537699 C T 2.15E-04 Depression (quantitative trait) / / 20800221 rs2279834 chr12 101550176 T C 2.14E-04 Depression (quantitative trait) SLC5A8 UTR-3 20800221 rs7138043 chr12 101565885 C T 1.83E-04 Depression (quantitative trait) SLC5A8 intron 20800221 rs1399236 chr12 101604222 T C 8.99E-04 Alzheimer's disease SLC5A8 nearGene-5 22005930 rs7313582 chr12 101633887 C T 4.70E-05 Response to statin therapy / / 20339536 rs17031187 chr12 101640894 T C 4.00E-05 Response to statin therapy / / 20339536 rs2037053 chr12 101646796 C G 1.20E-05 Response to statin therapy / / 20339536 rs10467013 chr12 101647847 A C 1.20E-05 Urinary metabolites / / 21572414 rs703717 chr12 101666017 A G 6.70E-06 Alcohol dependence (age at onset) / / 24962325 rs703719 chr12 101667550 C T 5.07E-05 Pulmonary function / / 19300500 rs703720 chr12 101667827 G T 7.49E-06 Alcohol dependence (age at onset) / / 24962325 rs2651251 chr12 101669016 C T 7.49E-06 Alcohol dependence (age at onset) / / 24962325 rs824310 chr12 101670656 T A 7.49E-06 Alcohol dependence (age at onset) / / 24962325 rs824313 chr12 101671577 C T 9.09E-05 Pulmonary function / / 19300500 rs703711 chr12 101674285 G C 8.41E-06 Alcohol dependence (age at onset) UTP20 intron 24962325 rs844030 chr12 101685422 G A 7.68E-06 Alcohol dependence (age at onset) UTP20 intron 24962325 rs2290720 chr12 101687043 C T 9.07E-05 Pulmonary function UTP20 intron 19300500 rs2290720 chr12 101687043 C T 2.84E-06 Temporal lobe volumes UTP20 intron 20197096 rs11608415 chr12 101688045 C T 5.93E-06 Alcohol dependence (age at onset) UTP20 intron 24962325 rs7296572 chr12 101690217 C T 6.35E-06 Alcohol dependence (age at onset) UTP20 intron 24962325 rs10778110 chr12 101690678 T C 7.17E-04 Multiple complex diseases UTP20 intron 17554300 rs7312071 chr12 101698982 A G 9.41E-05 Pulmonary function UTP20 intron 19300500 rs1472556 chr12 101705178 C A 6.35E-06 Alcohol dependence (age at onset) UTP20 intron 24962325 rs55721648 chr12 101715202 C A 7.23E-06 Alcohol dependence (age at onset) UTP20 intron 24962325 rs7973083 chr12 101724081 T A 3.80E-05 Response to statin therapy UTP20 intron 20339536 rs7973083 chr12 101724081 T A 5.53E-08 Alcohol dependence (age at onset) UTP20 intron 24962325 rs2002895 chr12 101728166 A G 3.80E-05 Response to statin therapy UTP20 intron 20339536 rs1814577 chr12 101729282 A G 5.21E-08 Alcohol dependence (age at onset) UTP20 intron 24962325 rs56265469 chr12 101732655 C T 1.25E-07 Alcohol dependence (age at onset) UTP20 cds-synon 24962325 rs7963896 chr12 101734277 T C 3.90E-05 Response to statin therapy UTP20 intron 20339536 rs7977587 chr12 101734684 A G 1.66E-07 Alcohol dependence (age at onset) UTP20 intron 24962325 rs2270861 chr12 101736381 A G 2.00E-05 Subclinical atherosclerosis UTP20 intron 17903303 rs2270861 chr12 101736381 A G 3.70E-05 Response to statin therapy UTP20 intron 20339536 rs2270861 chr12 101736381 A G 9.88E-04 Suicide attempts in bipolar disorder UTP20 intron 21423239 rs2270861 chr12 101736381 A G 6.79E-08 Alcohol dependence (age at onset) UTP20 intron 24962325 rs6538985 chr12 101738184 T A 5.33E-04 Suicide attempts in bipolar disorder UTP20 intron 21423239 rs117417637 chr12 101738482 G A 0.00032 Breast cancer UTP20 missense 23555315 rs3782848 chr12 101739860 G A 6.31E-06 Alcohol dependence (age at onset) UTP20 intron 24962325 rs57083693 chr12 101742180 T C 4.00E-08 Alcohol dependence (age at onset) UTP20 intron 24962325 rs2242138 chr12 101748904 A C 4.03E-04 Smoking quantity UTP20 intron 24665060 rs10507130 chr12 101753954 G A 7.00E-06 Coronary artery calcification UTP20 intron 17903303 rs10507130 chr12 101753954 G A 9.64E-05 Pulmonary function UTP20 intron 19300500 rs10507130 chr12 101753954 G A 6.60E-05 Response to statin therapy UTP20 intron 20339536 rs10507130 chr12 101753954 G A 1.20E-07 Alcohol dependence (age at onset) UTP20 intron 24962325 rs11609516 chr12 101754920 C G 9.54E-05 Pulmonary function UTP20 intron 19300500 rs11609516 chr12 101754920 C G 6.80E-05 Response to statin therapy UTP20 intron 20339536 rs11609516 chr12 101754920 C G 7.77E-04 Suicide attempts in bipolar disorder UTP20 intron 21423239 rs11609516 chr12 101754920 C G 1.20E-07 Alcohol dependence (age at onset) UTP20 intron 24962325 rs7313312 chr12 101755683 T C 6.90E-05 Response to statin therapy UTP20 intron 20339536 rs7313312 chr12 101755683 T C 1.03E-05 Alcohol dependence UTP20 intron 23089632 rs7313312 chr12 101755683 T C 1.20E-07 Alcohol dependence (age at onset) UTP20 intron 24962325 rs2305862 chr12 101757530 G A 7.49E-04 Suicide attempts in bipolar disorder UTP20 intron 21423239 rs11616031 chr12 101800507 A G 9.82E-04 Suicide attempts in bipolar disorder ARL1 intron 21423239 rs1554137 chr12 101828923 A G 5.99E-05 Femoral neck bone geometry / / 22087292 rs59420447 chr12 101842391 G C 3.56E-05 Response to methotrexate in juvenile idiopathic arthritis / / 24709693 rs2373455 chr12 101892921 T C 8.20E-04 Coronary heart disease / / 21606135 rs733328 chr12 101893159 C A 5.39E-04 Coronary heart disease / / 21606135 rs733327 chr12 101893315 A G 4.59E-04 Coronary heart disease / / 21606135 rs11614937 chr12 101893726 A G 6.49E-04 Coronary heart disease / / 21606135 rs2202078 chr12 101905587 C T 3.95E-05 White matter integrity / / 22425255 rs7967941 chr12 101941157 T C 4.20E-05 Immunoglobulin A / / 20694011 rs7299475 chr12 101944178 A G 7.47E-04 Alcohol dependence / / 21314694 rs825038 chr12 101964081 C A 9.77E-04 Multiple complex diseases / / 17554300 rs11110867 chr12 101975140 A C 3.05E-05 Femoral neck bone geometry / / 22087292 rs11110868 chr12 101975297 T C 7.38E-05 Femoral neck bone geometry / / 22087292 rs952061 chr12 101978225 C T 7.34E-05 Blood Pressure / / pha002898 rs6538998 chr12 101993580 C T 1.26E-06 Lung function (forced expiratory volume in 1 second) MYBPC1 intron 24023788 rs6538998 chr12 101993580 C T 3.42E-04 Lung function (forced vital capacity) MYBPC1 intron 24023788 rs11110880 chr12 101993940 C T 1.46E-05 Lung function (forced expiratory volume in 1 second) MYBPC1 intron 24023788 rs11110880 chr12 101993940 C T 4.01E-04 Lung function (forced vital capacity) MYBPC1 intron 24023788 rs12146808 chr12 101996607 G A 4.46E-06 Lung function (forced expiratory volume in 1 second) MYBPC1 intron 24023788 rs4321010 chr12 102000977 A G 3.82E-05 Lung function (forced expiratory volume in 1 second) MYBPC1 intron 24023788 rs7308665 chr12 102006501 G A 1.48E-06 Lung function (forced expiratory volume in 1 second) MYBPC1 intron 24023788 rs7308665 chr12 102006501 G A 2.12E-04 Lung function (forced vital capacity) MYBPC1 intron 24023788 rs825088 chr12 102010815 T C 1.52E-04 Multiple complex diseases MYBPC1 intron 17554300 rs825089 chr12 102012267 A T 1.15E-04 Multiple complex diseases MYBPC1 intron 17554300 rs825092 chr12 102014779 G A 2.40E-04 Multiple complex diseases MYBPC1 intron 17554300 rs825064 chr12 102017570 T C 2.31E-04 Multiple complex diseases MYBPC1 intron 17554300 rs10860757 chr12 102020446 T C 1.46E-04 Lung function (forced vital capacity) MYBPC1 intron 24023788 rs10860757 chr12 102020446 T C 7.00E-07 Lung function (forced expiratory volume in 1 second) MYBPC1 intron 24023788 rs17031719 chr12 102022264 A G 2.97E-05 Attention deficit hyperactivity disorder MYBPC1 intron 22012869 rs1727091 chr12 102028792 G A 2.21E-05 Multiple complex diseases MYBPC1 intron 17554300 rs10507134 chr12 102034120 T G 2.13E-04 Lung function (forced expiratory volume in 1 second) MYBPC1 intron 24023788 rs17031746 chr12 102041757 A G 1.01E-04 Lung function (forced expiratory volume in 1 second) MYBPC1 intron 24023788 rs11110912 chr12 102042213 C G 9.18E-06 Multiple complex diseases MYBPC1 intron 17554300 rs10778135 chr12 102054812 C T 7.14E-04 Type 2 diabetes MYBPC1 intron 17463246 rs10778135 chr12 102054812 C T 2.80E-05 Urinary metabolites MYBPC1 intron 21572414 rs1263786 chr12 102069264 G C 2.30E-05 Urinary metabolites MYBPC1 intron 21572414 rs4597119 chr12 102081450 G A 1.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs2695298 chr12 102082589 G A 6.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs10778139 chr12 102083202 A G 8.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs2114918 chr12 102084518 C T 4.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs2695290 chr12 102087844 G A 4.34E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2695289 chr12 102087937 G T 7.84E-05 Suicide attempts in bipolar disorder / / 21423239 rs2695284 chr12 102089318 G A 7.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs2695282 chr12 102089502 G A 6.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs2695281 chr12 102089999 G A 6.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs2559855 chr12 102090080 C T 7.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs2559853 chr12 102090363 A T 9.99E-05 Suicide attempts in bipolar disorder / / 21423239 rs3809260 chr12 102091017 G T 9.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs1124605 chr12 102093754 G A 5.70E-04 Type 2 diabetes and 6 quantitative traits CHPT1 intron 17848626 rs1124605 chr12 102093754 G A 2.08E-04 Suicide attempts in bipolar disorder CHPT1 intron 21423239 rs2288379 chr12 102123919 G T 9.16E-04 Suicide attempts in bipolar disorder SYCP3 intron 21423239 rs11110986 chr12 102125090 G A 8.76E-04 Suicide attempts in bipolar disorder SYCP3 intron 21423239 rs10431453 chr12 102133391 G A 8.57E-04 Suicide attempts in bipolar disorder SYCP3 nearGene-5 21423239 rs10492085 chr12 102162325 G A 1.50E-04 Iris characteristics GNPTAB intron 21835309 rs17725026 chr12 102165424 A G 3.64E-04 Smoking initiation GNPTAB intron 24665060 rs919214 chr12 102170777 C T 7.02E-05 HIV-1 viral setpoint GNPTAB intron 17641165 rs10860784 chr12 102173033 A G 1.91E-04 Response to alcohol consumption (flushing response) GNPTAB intron 24277619 rs741645 chr12 102178307 A G 3.61E-04 HIV-1 viral setpoint GNPTAB intron 17641165 rs6539012 chr12 102180228 C T 3.61E-06 Post-operative nausea and vomiting GNPTAB intron 21694509 rs6539012 chr12 102180228 C T 8.42E-06 Lymphocyte counts GNPTAB intron 22286170 rs11111029 chr12 102194140 T C 3.52E-04 Suicide attempts in bipolar disorder GNPTAB intron 21423239 rs10860790 chr12 102197729 T G 3.07E-04 Suicide attempts in bipolar disorder GNPTAB intron 21423239 rs10860791 chr12 102210221 A T 3.75E-04 Suicide attempts in bipolar disorder GNPTAB intron 21423239 rs10128858 chr12 102221366 A G 1.85E-04 Bipolar disorder GNPTAB intron 18317468 rs7966207 chr12 102229631 T C 3.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs11111055 chr12 102238129 T C 1.63E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs12371710 chr12 102248565 T C 1.86E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10778155 chr12 102277049 A G 2.64E-06 Post-operative nausea and vomiting DRAM1 intron 21694509 rs2176092 chr12 102287370 T C 4.49E-04 Multiple complex diseases DRAM1 intron 17554300 rs10860812 chr12 102288370 G A 9.81E-05 Multiple complex diseases DRAM1 intron 17554300 rs7975309 chr12 102288481 G A 5.58E-04 Multiple complex diseases DRAM1 intron 17554300 rs7306175 chr12 102294618 C A 3.33E-04 Multiple complex diseases DRAM1 intron 17554300 rs17032046 chr12 102300819 C G 6.69E-04 Smoking initiation DRAM1 intron 24665060 rs201711328 chr12 102300819 C CA 6.69E-04 Smoking initiation DRAM1 intron 24665060 rs12298720 chr12 102318856 A G 6.15E-04 Spine bone size / / 23207799 rs4622329 chr12 102321935 G A 9.00E-12 Systemic lupus erythematosus / / 23273568 rs2373558 chr12 102337262 C G 2.78E-05 Multiple complex diseases / / 17554300 rs2373558 chr12 102337262 C G 6.10E-06 Urinary metabolites / / 21572414 rs10507136 chr12 102352028 C T 2.38E-04 Parkinson's disease / / 17052657 rs4764854 chr12 102355342 T G 7.40E-05 Parkinson's disease (age of onset) / / 19772629 rs7971536 chr12 102373788 T A 8.00E-14 Height / / 20881960 rs2373560 chr12 102379673 C A 6.26E-04 Type 2 diabetes / / 17463246 rs11111121 chr12 102397730 A G 2.20E-04 Multiple complex diseases / / 17554300 rs11111146 chr12 102452264 C A 0.00000221 Ovarian follicle number and menopause CCDC53 intron 22696150 rs12425639 chr12 102480423 C T 5.82E-09 Narcolepsy NUP37 intron 19629137 rs2292303 chr12 102513531 G C 8.60E-05 Height / / 19396169 rs2292303 chr12 102513531 G C 8.00E-06 Height / / 19893584 rs7313075 chr12 102630679 C A 7.19E-04 Bipolar disorder / / 21302346 rs12426318 chr12 102635521 C A 3.94E-05 Bipolar disorder / / 21302346 rs12316898 chr12 102657973 A G 2.90E-06 Urinary metabolites / / 21572414 rs17439974 chr12 102668833 T A 5.30E-05 Response to statin therapy / / 20339536 rs7969401 chr12 102713073 A C 8.80E-05 Response to statin therapy / / 20339536 rs7978057 chr12 102715235 G A 6.22E-06 Diabetes Mellitus / / pha003060 rs1520223 chr12 102726338 T C 9.00E-07 Height / / 19893584 rs10860859 chr12 102753327 A G 1.64E-04 Heart rate / / 23583979 rs4764876 chr12 102758702 G C 0.00013 Fasting insulin-related traits / / 22885924 rs1980236 chr12 102767892 G A 9.30E-04 Volumetric brain MRI / / 17903297 rs10860861 chr12 102785569 C T 8.67E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs5742692 chr12 102799598 A G 4.00E-08 Height IGF1 intron 20189936 rs2072592 chr12 102813632 C T 8.39E-04 Bipolar disorder IGF1 intron 21302346 rs5742683 chr12 102813717 A G 2.02E-10 Triglycerides IGF1 intron 23063622 rs5742667 chr12 102823478 A G 5.66E-06 Glycemic traits (pregnancy) IGF1 intron 23903356 rs5742663 chr12 102823990 T G 1.74E-11 Triglycerides IGF1 intron 23063622 rs7300373 chr12 102831786 T G 6.96E-12 Triglycerides IGF1 intron 23063622 rs5742632 chr12 102856474 A G 1.70E-05 Response to statin therapy IGF1 intron 20339536 rs2195240 chr12 102856647 A G 1.80E-05 Response to statin therapy IGF1 intron 20339536 rs2195239 chr12 102856702 C G 1.80E-05 Response to statin therapy IGF1 intron 20339536 rs5742629 chr12 102857263 T C 5.40E-05 Response to statin therapy IGF1 intron 20339536 rs5742629 chr12 102857263 T C 7.00E-05 Alcohol consumption IGF1 intron 23953852 rs5742626 chr12 102857909 T C 4.10E-10 HDL cholesterol IGF1 intron 23063622 rs5742626 chr12 102857909 T C 7.27E-08 Triglycerides IGF1 intron 23063622 rs7956547 chr12 102858816 T C 6.70E-05 Response to statin therapy IGF1 intron 20339536 rs12423791 chr12 102858828 G C 2.61E-04 Bipolar disorder IGF1 intron 21302346 rs4764698 chr12 102860060 C G 2.55E-04 Bipolar disorder IGF1 intron 21302346 rs10778176 chr12 102862979 C T 4.40E-05 Response to statin therapy IGF1 intron 20339536 rs10778176 chr12 102862979 C T 8.60E-05 Alcohol consumption IGF1 intron 23953852 rs1019731 chr12 102864425 C A 4.71E-04 Type 2 diabetes IGF1 intron 17463246 rs1019731 chr12 102864425 C A 7.10E-04 Height IGF1 intron 21194676 rs10860869 chr12 102865052 A T 9.52E-04 Type 2 diabetes IGF1 intron 17463246 rs10860869 chr12 102865052 A T 4.90E-05 Response to statin therapy IGF1 intron 20339536 rs17796225 chr12 102866638 T C 4.70E-05 Response to statin therapy IGF1 intron 20339536 rs5742617 chr12 102869905 C T 7.46E-12 Triglycerides IGF1 intron 23063622 rs5742615 chr12 102870801 G A,C,T 3.73E-05 Bipolar disorder IGF1 intron 18317468 rs5742615 chr12 102870801 G A,C,T 3.73E-05 Bipolar disorder IGF1 intron 21302346 rs35767 chr12 102875569 A G 2.00E-09 Fasting insulin-related traits IGF1 nearGene-5 20081858 rs35767 chr12 102875569 A G 3.00E-08 Fasting insulin-related traits IGF1 nearGene-5 20081858 rs35767 chr12 102875569 A G 7.27E-08 Fasting insulin-related traits IGF1 nearGene-5 22885924 rs860598 chr12 102898446 G A 1.46E-08 Fasting insulin-related traits / / 22885924 rs17797047 chr12 102905712 T G 3.40E-05 Response to statin therapy / / 20339536 rs35747 chr12 102912558 G A 1.00E-09 Fasting insulin-related traits (interaction with BMI) / / 22581228 rs7964748 chr12 102965329 A G 3.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs7955640 chr12 102968299 C T 7.23E-04 Body mass index / / 21701565 rs7955640 chr12 102968299 C T 3.02E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1350356 chr12 102978525 T C 7.65E-05 Information processing speed / / 21130836 rs1350356 chr12 102978525 T C 4.62E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1840958 chr12 102979219 A G 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10745943 chr12 102980756 A C 6.10E-06 Urinary metabolites / / 21572414 rs1391677 chr12 102982868 A G 2.00E-04 Information processing speed / / 21130836 rs10860887 chr12 102985384 G A 4.74E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1463446 chr12 102985749 A G 5.30E-04 Crohn's disease / / 17684544 rs1457594 chr12 102987638 C T 7.97E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs17032884 chr12 102995192 A G 7.56E-04 Body mass index / / 21701565 rs11111326 chr12 103023887 A C 0.000771 Salmonella-induced pyroptosis / / 22837397 rs833718 chr12 103071086 G A 1.94E-04 Height / / 22216288 rs863854 chr12 103074012 C T 2.48E-05 Information processing speed / / 21130836 rs2172873 chr12 103125690 G A 2.00E-06 Uterine fibroids / / 21460842 rs41499552 chr12 103139721 T C 6.98E-05 Multiple complex diseases / / 17554300 rs1404288 chr12 103151018 C T 6.69E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs2270729 chr12 103240452 A C 6.89E-05 Cognitive impairment induced by topiramate PAH intron 22091778 rs1498694 chr12 103257876 A G 7.00E-11 Blood metabolite levels PAH intron 24816252 rs7955991 chr12 103325244 T C 3.65E-04 Alzheimer's disease (late onset) / / 21379329 rs2133294 chr12 103377389 G T 9.77E-04 Multiple complex diseases / / 17554300 rs2133294 chr12 103377389 G T 7.41E-06 Serum metabolites / / 19043545 rs4764936 chr12 103474068 C T 3.49E-05 Caffeine consumption / / 21490707 rs10745954 chr12 103483094 A G 2.00E-11 C-reactive protein / / 21300955 rs10778213 chr12 103495151 T C 1.00E-10 C-reactive protein / / 18439548 rs10778213 chr12 103495151 T C 1.76E-08 Lipid levels / / 19936222 rs10778213 chr12 103495151 T C 7.60E-09 Lipid levels / / 19936222 rs10778213 chr12 103495151 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12318722 chr12 103509590 C G 3.88E-04 Multiple complex diseases / / 17554300 rs1818702 chr12 103523555 C T 2.70E-10 Lipid levels / / 19936222 rs7976027 chr12 103563024 A G 3.54E-04 Multiple complex diseases / / 17554300 rs17033545 chr12 103567683 G A 5.97E-06 Liver disease in chronic hepatitis B virus infection / / 24065354 rs10860955 chr12 103581985 A G 3.38E-04 Multiple complex diseases / / 17554300 rs4433630 chr12 103650031 T C 4.11E-04 Alzheimer's disease (late onset) / / 21379329 rs4764949 chr12 103658096 A G 7.26E-04 Type 2 diabetes / / 17463246 rs11111512 chr12 103666272 A G 2.90E-05 Urinary metabolites / / 21572414 rs7961837 chr12 103702603 A G 5.18E-04 Tourette syndrome C12orf42 intron 22889924 rs10778237 chr12 103742661 A G 4.80E-04 Type 2 diabetes C12orf42 intron 17463246 rs2374053 chr12 103747178 T C 2.57E-05 Femoral neck bone geometry C12orf42 intron 22087292 rs11111539 chr12 103761292 G A 0.00079 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines C12orf42 intron 23204130 rs10860990 chr12 103765744 T C 9.38E-04 Type 2 diabetes C12orf42 intron 17463246 rs7306825 chr12 103771416 T G 0.00072 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines C12orf42 intron 23204130 rs1317015 chr12 103777467 T C 3.68E-04 Myopia (pathological) C12orf42 intron 21095009 rs17568045 chr12 103783314 T C 0.0000811 Menopause (age at onset) C12orf42 intron 23424626 rs17033840 chr12 103794782 G A 4.10E-04 Lung function (forced expiratory volume in 1 second) C12orf42 intron 17255346 rs10467022 chr12 103813706 C T 3.60E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) C12orf42 intron 23648065 rs10467022 chr12 103813706 C T 5.40E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) C12orf42 intron 23648065 rs10745966 chr12 103817326 C T 1.61E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) C12orf42 intron 23648065 rs10860999 chr12 103818049 A G 3.57E-04 Lung function (forced expiratory volume in 1 second) C12orf42 intron 17255346 rs2374076 chr12 103849908 A C 3.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) C12orf42 intron 23648065 rs4506750 chr12 103864665 A G 1.49E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) C12orf42 intron 23648065 rs2888731 chr12 103866354 T G 1.61E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) C12orf42 intron 23648065 rs2374068 chr12 103866808 C A 3.00E-04 Lung function (forced expiratory volume in 1 second) C12orf42 intron 17255346 rs10861032 chr12 103912506 T C 1.00E-07 Coronary restenosis / / 21878436 rs9804922 chr12 103913442 C T 1.03E-06 Coronary restenosis / / 21878436 rs17034050 chr12 103914945 T C 6.58E-04 Multiple complex diseases / / 17554300 rs11111689 chr12 104029462 C T 6.09E-05 Calcium levels STAB2 intron pha003085 rs1650123 chr12 104034319 C T 1.00E-06 IgG glycosylation STAB2 intron 23382691 rs1650123 chr12 104034319 C T 6.00E-06 IgG glycosylation STAB2 intron 23382691 rs831427 chr12 104054434 C T 8.68E-04 Body mass index STAB2 intron 21701565 rs703642 chr12 104066321 G C 2.70E-05 Urinary metabolites STAB2 intron 21572414 rs703643 chr12 104067016 C A 7.79E-04 Type 2 diabetes STAB2 intron 17463246 rs6539095 chr12 104092085 G A 2.30E-05 Urinary metabolites STAB2 intron 21572414 rs4981042 chr12 104124061 A G 1.57E-07 Cognitive test performance STAB2 intron 20125193 rs10778284 chr12 104130510 A G 1.04E-05 Coronary heart disease STAB2 intron pha003056 rs1370785 chr12 104132365 G A 5.12E-04 Response to cytidine analogues (gemcitabine) STAB2 intron 24483146 rs7306642 chr12 104139034 C A 3.00E-06 vWF and FVIII levels STAB2 missense 21810271 rs17505851 chr12 104144835 G A 1.76E-04 Amyotrophic lateral sclerosis (sporadic) STAB2 intron 24529757 rs11111748 chr12 104149022 G A 9.28E-04 Suicide attempts in bipolar disorder STAB2 intron 21423239 rs9142 chr12 104167404 A G 2.31E-04 Hemoglobin concentration NT5DC3 UTR-3 20534544 rs10861099 chr12 104175575 A G 2.31E-04 Hemoglobin concentration NT5DC3 intron 20534544 rs7296900 chr12 104177668 T C 2.31E-04 Hemoglobin concentration NT5DC3 intron 20534544 rs934845 chr12 104185257 T G 3.86E-05 Amyotrophic lateral sclerosis (sporadic) NT5DC3 intron 24529757 rs4964805 chr12 104192824 C G 5.00E-06 Attention deficit hyperactivity disorder NT5DC3 intron 18839057 rs4964571 chr12 104227273 G A 5.47E-04 Response to alcohol consumption (flushing response) NT5DC3 intron 24277619 rs1370413 chr12 104244434 C T 5.69E-04 Bipolar disorder GNN intron 19259986 rs11111814 chr12 104248696 T C 9.24E-10 Brain activation patterns in response to human facial expressions-for the negative faces task GNN intron 22828495 rs11111814 chr12 104248696 T C 9.24E-10 Airflow obstruction GNN intron 22837378 rs9669708 chr12 104262070 T G 0.0000119 Central corneal thickness GNN intron 22661486 rs9669708 chr12 104262070 T G 1.19E-05 Testosterone levels GNN intron 22675492 rs728165 chr12 104267143 G A 7.66E-04 Multiple complex diseases GNN intron 17554300 rs1595339 chr12 104268179 G C 5.03E-04 Multiple complex diseases GNN intron 17554300 rs2576961 chr12 104273533 G A 9.07E-04 Multiple complex diseases GNN intron 17554300 rs2583245 chr12 104273934 A G 8.19E-04 Multiple complex diseases GNN intron 17554300 rs2583237 chr12 104277572 C T 8.36E-05 Type 2 diabetes / / 17463246 rs2243680 chr12 104291595 G A 3.85E-05 Type 2 diabetes GNN intron 17463246 rs2243680 chr12 104291595 G A 0.000294 Breast cancer early age of onset GNN intron 18463975 rs11111839 chr12 104310723 C A 2.51E-07 Cardiovascular disease GNN intron 18179892 rs1165668 chr12 104317996 G A 3.00E-09 Coronary heart disease GNN intron 21626137 rs1165669 chr12 104318172 A G 3.00E-09 Coronary heart disease GNN intron 21626137 rs17797090 chr12 104324266 G A 1.64E-05 Lung adenocarcinoma HSP90B1 UTR-5 19836008 rs1882019 chr12 104337667 G A 5.70E-04 Response to statin treatment (atorvastatin),change in cholesterol levels HSP90B1 intron 20031582 rs2629768 chr12 104361176 C T 0.000679 Salmonella-induced pyroptosis TDG intron 22837397 rs2629771 chr12 104366480 A G 0.000328 Salmonella-induced pyroptosis TDG intron 22837397 rs4135067 chr12 104366545 T G 4.49E-04 Multiple complex diseases TDG intron 17554300 rs2723876 chr12 104368931 T C,G 0.000672 Salmonella-induced pyroptosis TDG intron 22837397 rs11553765 chr12 104413436 C T 8.23E-04 Alzheimer's disease GLT8D2 UTR-5 17998437 rs2629751 chr12 104421808 A G 1.00E-07 Hepatitis C induced liver fibrosis GLT8D2 intron 22841784 rs17035146 chr12 104442938 G A 2.34E-04 Amyotrophic Lateral Sclerosis GLT8D2 intron 17362836 rs1564892 chr12 104445742 A G 2.00E-10 Corneal structure / / 23291589 rs2722171 chr12 104449487 T G 1.76E-05 Magnesium levels / / pha003092 rs11111888 chr12 104475630 C T 1.60E-06 Urinary metabolites HCFC2 intron 21572414 rs78717299 chr12 104476255 G C 4.38E-05 Intracerebral hemorrhage HCFC2 intron 24656865 rs73177977 chr12 104489662 C G 4.51E-05 Intracerebral hemorrhage HCFC2 intron 24656865 rs2629755 chr12 104492003 A G 4.25E-04 Heart Failure HCFC2 intron pha002884 rs1485591 chr12 104500906 T G 1.70E-06 Urinary metabolites / / 21572414 rs10861159 chr12 104506318 G A 4.49E-04 Graves' disease / / 21841780 rs12317467 chr12 104577494 G A 8.12E-06 White blood cell count / / 21738479 rs4614534 chr12 104597917 A G 8.27E-04 Alzheimer's disease / / 17998437 rs4545635 chr12 104636844 A C 5.66E-04 Alzheimer's disease TXNRD1 intron 22005930 rs4964735 chr12 104656126 G A 6.38E-04 Type 2 diabetes TXNRD1 intron 17463246 rs10861184 chr12 104664093 A G 9.18E-05 Alcohol dependence TXNRD1 intron 19581569 rs10735392 chr12 104674198 G A 2.30E-05 Urinary metabolites TXNRD1 intron 21572414 rs10861197 chr12 104706031 T C 4.71E-05 Glucose levels TXNRD1 intron pha003057 rs7978310 chr12 104748620 A G 1.09E-04 Multiple complex diseases / / 17554300 rs77724872 chr12 104754500 C T 7.00E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs4129848 chr12 104755243 T A 8.60E-06 Urinary metabolites / / 21572414 rs11608280 chr12 104756080 C G 5.70E-06 Urinary metabolites / / 21572414 rs11112012 chr12 104757442 C T 9.80E-06 Urinary metabolites / / 21572414 rs11112046 chr12 104818192 C T 3.00E-06 Obesity-related traits / / 23251661 rs11112057 chr12 104834662 A G 5.26E-05 Cognitive impairment induced by topiramate / / 22091778 rs10778332 chr12 104836544 A G 1.20E-05 Urinary metabolites / / 21572414 rs11112058 chr12 104838060 A T 1.20E-05 Urinary metabolites / / 21572414 rs3751322 chr12 104853787 T C 6.09E-07 Diabetes Mellitus CHST11 intron pha003060 rs1922261 chr12 104854011 G A 1.08E-05 Diabetes Mellitus CHST11 intron pha003060 rs10861220 chr12 104863417 G A 3.55E-04 Suicide attempts in bipolar disorder CHST11 intron 21423239 rs11112069 chr12 104867018 T A 7.35E-21 Multiple complex diseases CHST11 intron 17554300 rs7976717 chr12 104876567 T G 9.52E-04 Type 2 diabetes CHST11 intron 17463246 rs11112082 chr12 104891397 G T 7.53E-04 Nicotine smoking CHST11 intron 19268276 rs10778338 chr12 104894402 A G 3.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CHST11 intron 20877124 rs2141857 chr12 104902190 C A 6.60E-05 Malaria CHST11 intron 19465909 rs10861229 chr12 104906745 G T 1.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CHST11 intron 20877124 rs4964815 chr12 104907444 G T 1.05E-04 Suicide attempts in bipolar disorder CHST11 intron 21423239 rs1795850 chr12 104910801 A G 2.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CHST11 intron 20877124 rs1704907 chr12 104910844 C T 2.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CHST11 intron 20877124 rs1795873 chr12 104918621 T C 2.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CHST11 intron 20877124 rs17812021 chr12 104928663 C G 8.01E-08 Metabolite levels CHST11 intron 23281178 rs1795856 chr12 104930273 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) CHST11 intron 20708005 rs1704904 chr12 104942386 C T 8.37E-04 Nicotine smoking CHST11 intron 19268276 rs7980528 chr12 104944297 C T 0.000343374 Hypertension (early onset hypertension) CHST11 intron 22479346 rs313315 chr12 104965584 C A 3.21E-05 Response to methotrexate in juvenile idiopathic arthritis CHST11 intron 24709693 rs313327 chr12 104974021 C T 8.17E-08 Schizophrenia CHST11 intron 21926974 rs167510 chr12 104975209 G A 8.22E-05 Height CHST11 intron pha003011 rs7309946 chr12 104975826 T C 0.0001393 Hypertension (early onset hypertension) CHST11 intron 22479346 rs1650141 chr12 104978758 T C 7.15E-04 Multiple complex diseases CHST11 intron 17554300 rs1626044 chr12 104979879 G A 0.000398 Breast cancer early age of onset CHST11 intron 18463975 rs1650137 chr12 104980310 G A 0.000398 Breast cancer early age of onset CHST11 intron 18463975 rs1650137 chr12 104980310 G A 4.01E-04 Tourette syndrome CHST11 intron 22889924 rs313322 chr12 104985695 A G 3.92E-04 Multiple complex diseases CHST11 intron 17554300 rs313321 chr12 104986901 A C 4.30E-04 Multiple complex diseases CHST11 intron 17554300 rs3812796 chr12 104995459 T C 6.21E-05 Major depressive disorder CHST11 intron 19107115 rs6539163 chr12 104996237 A G 6.26E-04 Multiple complex diseases CHST11 intron 17554300 rs6539164 chr12 104997370 A C 9.66E-04 Multiple complex diseases CHST11 intron 17554300 rs2162661 chr12 104997626 G A 6.92E-04 Multiple complex diseases CHST11 intron 17554300 rs10746004 chr12 105001822 G C 2.93E-04 Multiple complex diseases CHST11 intron 17554300 rs10507177 chr12 105008908 C T 2.72E-05 Response to methotrexate in juvenile idiopathic arthritis CHST11 intron 24709693 rs12811699 chr12 105017164 C T 8.00E-06 Cannabis dependence CHST11 intron 21668797 rs10507180 chr12 105024405 C T 7.18E-04 Bone mass and geometry CHST11 intron 17903296 rs10861259 chr12 105024690 C T 9.47E-05 Non-alcoholic fatty liver disease histology (other) CHST11 intron 20708005 rs7971034 chr12 105032939 T G 0.000249 Salmonella-induced pyroptosis CHST11 intron 22837397 rs1164856 chr12 105035423 A C 1.77E-05 Major depressive disorder CHST11 intron 19107115 rs2694418 chr12 105038670 G T 9.61E-05 Major depressive disorder CHST11 intron 19107115 rs11112146 chr12 105051769 C T 4.60E-04 Suicide attempts in bipolar disorder CHST11 intron 21423239 rs7965164 chr12 105052813 A G 3.67E-04 Suicide attempts in bipolar disorder CHST11 intron 21423239 rs117476504 chr12 105054827 G A 0.000024 Nonsyndromic striae distensae (stretch marks) CHST11 intron 23633020 rs835487 chr12 105060767 A G 3.26E-06 Osteoarthritis CHST11 intron 22763110 rs703672 chr12 105068918 A G 9.53E-08 Tumor biomarkers CHST11 intron 23300138 rs703678 chr12 105070513 C T 6.46E-08 Tumor biomarkers CHST11 intron 23300138 rs12579373 chr12 105071415 G C 5.09E-08 Tumor biomarkers CHST11 intron 23300138 rs312145 chr12 105087152 C A 7.79E-05 Height CHST11 intron 17255346 rs312145 chr12 105087152 C A 5.66E-05 Prion diseases CHST11 intron 22210626 rs312141 chr12 105092213 G A 1.76E-04 Prostate cancer mortality CHST11 intron 20978177 rs11112173 chr12 105095232 C T 1.64E-04 Alzheimer's disease (late onset) CHST11 intron 21379329 rs2730291 chr12 105149126 T C 3.00E-05 Prostate cancer CHST11 intron 21743057 rs12321404 chr12 105157975 T G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1038968 chr12 105161854 C T 0.000044 Endometrial cancer / / 22426144 rs2468083 chr12 105180145 A G 2.62E-05 Schizophrenia / / 19571811 rs2731031 chr12 105226122 A C 8.44E-04 Multiple complex diseases SLC41A2 intron 17554300 rs17036429 chr12 105230719 C T 4.52E-04 Smoking initiation SLC41A2 intron 24665060 rs17036433 chr12 105250242 A G 3.98E-04 Smoking initiation SLC41A2 intron 24665060 rs1565813 chr12 105253927 A G 7.17E-04 Multiple complex diseases SLC41A2 intron 17554300 rs12230637 chr12 105258876 G A 7.99E-05 Cognitive impairment induced by topiramate SLC41A2 intron 22091778 rs17036489 chr12 105292284 C G 3.98E-04 Smoking initiation SLC41A2 intron 24665060 rs4964116 chr12 105335884 T C 6.24E-04 Alzheimer's disease / / 17998437 rs12579129 chr12 105396602 G A 1.93E-04 Smoking initiation / / 24665060 rs11608294 chr12 105410885 A G 5.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs7304326 chr12 105418294 G A 6.72E-07 Lymphocyte counts ALDH1L2 intron 22286170 rs17036606 chr12 105422567 G A 1.23E-04 Smoking initiation ALDH1L2 intron 24665060 rs4964316 chr12 105433077 T C 4.58E-04 Suicide attempts in bipolar disorder ALDH1L2 intron 21423239 rs4964120 chr12 105433463 C T 3.99E-04 Suicide attempts in bipolar disorder ALDH1L2 intron 21423239 rs2228699 chr12 105435490 T C 4.59E-04 Suicide attempts in bipolar disorder ALDH1L2 intron 21423239 rs2228700 chr12 105435567 C T 3.87E-04 Suicide attempts in bipolar disorder ALDH1L2 intron 21423239 rs7301527 chr12 105436828 C A 4.31E-04 Suicide attempts in bipolar disorder ALDH1L2 intron 21423239 rs4964325 chr12 105438812 C T 7.64E-04 Suicide attempts in bipolar disorder ALDH1L2 intron 21423239 rs10861319 chr12 105439378 C G 4.88E-04 Suicide attempts in bipolar disorder ALDH1L2 intron 21423239 rs10861325 chr12 105441501 T C 6.50E-04 Suicide attempts in bipolar disorder ALDH1L2 intron 21423239 rs10746009 chr12 105442186 T C 5.46E-04 Suicide attempts in bipolar disorder ALDH1L2 intron 21423239 rs10861337 chr12 105452442 G A 2.00E-07 IgG glycosylation ALDH1L2 intron 23382691 rs10861342 chr12 105458797 T C 2.00E-06 IgG glycosylation ALDH1L2 intron 23382691 rs1196845 chr12 105499040 G A 2.10E-05 Obesity-related traits / / 17658951 rs1663563 chr12 105549209 G A 9.14E-05 Bipolar Disorder KIAA1033 intron pha002863 rs10861359 chr12 105561991 C A 7.67E-04 Alcohol dependence KIAA1033 UTR-3 21314694 rs752471 chr12 105606670 C T 6.67E-05 Serum metabolites APPL2 intron 19043545 rs2440695 chr12 105618862 C T 7.46E-04 Type 2 diabetes APPL2 intron 17463246 rs10861369 chr12 105670337 C T 9.39E-05 Chronic obstructive pulmonary disease / / 19300482 rs10861369 chr12 105670337 C T 9.39E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1469664 chr12 105711368 G T 0.0000132 fMRI brain tests in schizophrenia / / 22440650 rs1469662 chr12 105713218 T C 0.00015 fMRI brain tests in schizophrenia / / 22440650 rs2888846 chr12 105742674 A G 0.000897 Common carotid artery thickness (average of near and far wall measures) C12orf75 intron 23487405 rs7302174 chr12 105761662 G C 8.08E-04 Type 2 diabetes C12orf75 intron 17463246 rs11112499 chr12 105772249 A G 0.000394 Common carotid artery thickness (average of near and far wall measures) / / 23487405 rs11112502 chr12 105774697 C T 0.000394 Common carotid artery thickness (average of near and far wall measures) / / 23487405 rs1368254 chr12 105785482 C G 7.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4964364 chr12 105786753 A G 6.02E-04 Smoking initiation / / 24665060 rs10746025 chr12 105797436 C T 8.95E-05 Serum metabolites / / 19043545 rs11112519 chr12 105811779 G T 1.01E-04 Multiple complex diseases / / 17554300 rs11112522 chr12 105821448 A G 4.20E-06 Urinary metabolites / / 21572414 rs10746034 chr12 105827413 C T 2.20E-04 Alcohol dependence / / 20201924 rs10746034 chr12 105827413 C T 6.40E-04 Alcohol dependence / / 20201924 rs2082371 chr12 105833967 A G 1.70E-04 Alcohol dependence / / 20201924 rs2082371 chr12 105833967 A G 2.90E-04 Alcohol dependence / / 20201924 rs7314620 chr12 105903316 T G 2.80E-05 Urinary metabolites / / 21572414 rs1526852 chr12 105917765 C T 4.37E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1358221 chr12 105926455 T C 9.13E-04 Depression (quantitative trait) / / 20800221 rs1358221 chr12 105926455 T C 7.40E-04 Alzheimer's disease / / 22005930 rs7975357 chr12 105930395 T G 5.60E-04 Alzheimer's disease / / 22005930 rs11112592 chr12 105951702 A G 8.54E-04 Multiple complex diseases / / 17554300 rs3915229 chr12 105966343 G T 6.48E-04 Multiple complex diseases / / 17554300 rs1983480 chr12 105983355 A G 2.70E-06 Urinary metabolites / / 21572414 rs10861465 chr12 106048142 G A 4.88E-05 Waist Circumference / / pha003023 rs11112639 chr12 106048984 A G 7.78E-04 Taste perception / / 22132133 rs4145262 chr12 106053310 C A 0.000000324 Panic disorder / / 23149450 rs4145262 chr12 106053310 C A 3.24E-07 Serum tamsulosin hydrochloride concentration / / 23151678 rs2888865 chr12 106083042 G A 4.71E-04 Schizophrenia / / 19197363 rs4964400 chr12 106083736 G A 3.15E-04 Spine bone size / / 23207799 rs11833072 chr12 106100211 C T 4.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs1962255 chr12 106100432 A C 7.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs3863381 chr12 106103568 A G 5.93E-05 Self-reported allergy / / 23817569 rs4590982 chr12 106104823 G A 4.24E-05 Alcohol and nictotine co-dependence / / 20158304 rs10861485 chr12 106107149 A G 7.50E-05 Diabetic retinopathy / / 21441570 rs10219670 chr12 106108719 C A 4.00E-06 Alzheimer's disease biomarkers / / 23419831 rs4130169 chr12 106122964 G A 1.27E-04 Tuberculosis / / 22239941 rs4964404 chr12 106124877 C G 7.61E-04 Type 2 diabetes / / 17463246 rs1862041 chr12 106219192 T C 4.94E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs12321813 chr12 106271016 A C 4.64E-04 Multiple complex diseases / / 17554300 rs4964169 chr12 106275015 G A 9.43E-05 Hematocrit / / pha003097 rs10161316 chr12 106316253 A G 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11112803 chr12 106332204 T C 1.30E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11112803 chr12 106332204 T C 3.99E-05 Glucose levels / / pha002899 rs9630290 chr12 106332850 T C 2.56E-04 Smoking initiation / / 24665060 rs7976523 chr12 106344131 T C 4.62E-04 Smoking initiation / / 24665060 rs7976523 chr12 106344131 T C 6.54E-04 Smoking initiation / / 24665060 rs7300069 chr12 106345139 A G 3.52E-04 Smoking initiation / / 24665060 rs1362980 chr12 106346664 A T 1.64E-04 Smoking initiation / / 24665060 rs7973846 chr12 106347228 G C 2.89E-04 Smoking initiation / / 24665060 rs7139318 chr12 106356170 A G 9.28E-06 Carotenoid and tocopherol levels / / 19185284 rs2569980 chr12 106366983 G T 1.07E-04 Hearing function / / 17255346 rs2544115 chr12 106367904 A G 1.07E-04 Hearing function / / 17255346 rs996295 chr12 106368729 G A 1.93E-04 Hearing function / / 17255346 rs2730484 chr12 106369403 A G 1.18E-04 Hearing function / / 17255346 rs2544121 chr12 106372688 C T 1.76E-04 Hearing function / / 17255346 rs1895108 chr12 106373338 T C 2.74E-04 Hearing function / / 17255346 rs1895108 chr12 106373338 T C 3.49E-05 Type 2 diabetes / / 17463246 rs7965384 chr12 106374948 G A 8.00E-04 Multiple complex diseases / / 17554300 rs2569974 chr12 106376742 A G 2.05E-04 Hearing function / / 17255346 rs2569974 chr12 106376742 A G 4.42E-05 Type 2 diabetes / / 17463246 rs1862032 chr12 106377448 T C 1.77E-05 Type 2 diabetes / / 17463246 rs2196011 chr12 106381796 C T 2.76E-04 Hearing function / / 17255346 rs2196011 chr12 106381796 C T 2.34E-05 Type 2 diabetes / / 17463246 rs2436614 chr12 106383173 G C 2.87E-04 Hearing function / / 17255346 rs2436614 chr12 106383173 G C 2.36E-05 Type 2 diabetes / / 17463246 rs2436618 chr12 106385731 G A 2.40E-04 Hearing function / / 17255346 rs2436618 chr12 106385731 G A 3.41E-05 Type 2 diabetes / / 17463246 rs2569977 chr12 106388379 A G 3.29E-05 Type 2 diabetes / / 17463246 rs2730477 chr12 106390234 T C 4.47E-05 Type 2 diabetes / / 17463246 rs17038024 chr12 106423918 T C 2.10E-04 Multiple complex diseases / / 17554300 rs10861554 chr12 106470169 A C 1.56E-04 Attention deficit hyperactivity disorder NUAK1 intron pha002875 rs17038085 chr12 106472201 C T 4.64E-04 Body mass index NUAK1 intron 21701565 rs17038091 chr12 106476402 T C 4.30E-04 Body mass index NUAK1 intron 21701565 rs892270 chr12 106478826 T G 2.16E-05 Reading disability and language impairment NUAK1 intron 24024963 rs1427792 chr12 106479091 G A 7.34E-04 Body mass index NUAK1 intron 21701565 rs2251027 chr12 106480450 A G 8.35E-05 Attention deficit hyperactivity disorder NUAK1 intron pha002875 rs1366041 chr12 106484512 C T 2.91E-04 Celiac disease NUAK1 intron 23936387 rs1560000 chr12 106493147 C G 1.80E-05 Urinary metabolites NUAK1 intron 21572414 rs11112867 chr12 106496846 G T 2.68E-04 Coronary heart disease NUAK1 intron 21606135 rs11112867 chr12 106496846 G T 9.85E-06 QT interval NUAK1 intron 23166209 rs1427785 chr12 106500408 T C 2.00E-05 Urinary metabolites NUAK1 intron 21572414 rs2936703 chr12 106585445 G A 2.78E-04 Bipolar disorder / / 19259986 rs2936703 chr12 106585445 G A 1.80E-05 Urinary metabolites / / 21572414 rs1965 chr12 106587950 G C 1.00E-05 Urinary metabolites / / 21572414 rs2556506 chr12 106589282 C T 5.90E-06 Urinary metabolites / / 21572414 rs2649712 chr12 106589658 C G 1.60E-05 Urinary metabolites / / 21572414 rs2173595 chr12 106593949 C T 1.50E-05 Urinary metabolites / / 21572414 rs2173595 chr12 106593949 C T 2.23E-04 Vaspin levels / / 22907691 rs2173595 chr12 106593949 C T 0.0002226 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs1148417 chr12 106625732 T C 4.47E-11 Statin-induced myopathy / / 21826682 rs10507209 chr12 106629105 A C 1.65E-08 Statin-induced myopathy / / 21826682 rs35227737 chr12 106629105 A ACC 1.65E-08 Statin-induced myopathy / / 21826682 rs1237262 chr12 106629989 A G 2.13E-08 Statin-induced myopathy / / 21826682 rs2936702 chr12 106650351 A G 3.75E-04 Smoking initiation / / 24665060 rs4964457 chr12 106666830 C T 3.30E-04 Tourette syndrome / / 22889924 rs6539264 chr12 106691577 A G 3.33E-06 Orofacial clefts / / 22863734 rs1532586 chr12 106700584 G A 2.25E-05 Orofacial clefts TCP11L2 intron 22863734 rs1532587 chr12 106700709 A G 8.28E-04 Alzheimer's disease TCP11L2 intron 17998437 rs4964174 chr12 106701422 G A 5.98E-05 Insulin resistance TCP11L2 intron 21901158 rs2250441 chr12 106713257 C T 3.80E-04 Type 2 diabetes TCP11L2 intron 17463246 rs2250441 chr12 106713257 C T 5.76E-05 Lymphocyte counts TCP11L2 intron 22286170 rs6539267 chr12 106785554 T C 6.00E-06 Tourette syndrome POLR3B intron 22889924 rs11112992 chr12 106829279 T C 3.08E-09 Coronary heart disease POLR3B intron 23364394 rs12581936 chr12 106854071 A G 7.40E-05 Cognitive impairment induced by topiramate POLR3B intron 22091778 rs4625578 chr12 106880726 A G 9.08E-04 Multiple complex diseases POLR3B intron 17554300 rs11113032 chr12 106936623 G A 9.57E-05 Post-operative nausea and vomiting LOC100287944 intron 21694509 rs4964469 chr12 106949987 G A 2.00E-07 Parkinson's disease LOC100287944 intron 21084426 rs3891355 chr12 106950695 T C 3.00E-06 Cognitive test performance LOC100287944 intron 17903297 rs10861633 chr12 106962360 A G 4.42E-05 Hearing function LOC100287944 intron 17255346 rs7296145 chr12 106965482 C T 5.65E-05 Hearing function LOC100287944 intron 17255346 rs7980743 chr12 106968327 C T 3.98E-05 Hearing function LOC100287944 intron 17255346 rs1991297 chr12 106969216 C T 7.18E-05 Hearing function LOC100287944 intron 17255346 rs12230895 chr12 106972402 C T 3.90E-04 Hearing function LOC100287944 intron 17255346 rs7310098 chr12 107009047 A G 2.00E-04 Cognitive impairment induced by topiramate RFX4 intron 22091778 rs1230211 chr12 107051840 C T 5.09E-04 Multiple complex diseases RFX4 intron 17554300 rs1922435 chr12 107082455 A G 4.34E-04 Multiple complex diseases RFX4 intron 17554300 rs7973906 chr12 107107472 T C 1.50E-05 Urinary metabolites RFX4 intron 21572414 rs10746065 chr12 107110075 G A 4.78E-04 Multiple complex diseases RFX4 intron 17554300 rs2067615 chr12 107149422 A T 2.00E-09 Heart rate RFX4 intron 23583979 rs3910853 chr12 107165637 C T 3.20E-06 Urinary metabolites LOC100287944 intron 21572414 rs12369214 chr12 107198611 G A 1.26E-08 Primary sclerosing cholangitis RIC8B intron 23603763 rs4964491 chr12 107222515 G A 5.79E-06 Social autistic-like traits RIC8B intron 24133439 rs7959026 chr12 107223052 A G 7.10E-06 Urinary metabolites RIC8B intron 21572414 rs10778511 chr12 107225331 A T 3.80E-06 Social autistic-like traits RIC8B intron 24133439 rs10444533 chr12 107229705 C T 4.00E-06 Social autistic-like traits RIC8B intron 24133439 rs12308186 chr12 107254557 T C 9.66E-05 Post-operative nausea and vomiting RIC8B intron 21694509 rs34748 chr12 107272448 G A 6.89E-04 Multiple complex diseases RIC8B intron 17554300 rs7961366 chr12 107296041 C T 2.53E-05 Bone mineral density / / 24249740 rs2024519 chr12 107296830 G A 1.00E-04 Prostate cancer / / 21743057 rs1053051 chr12 107367225 T C 1.00E-09 Bone mineral density C12orf23 UTR-3 22504420 rs3759317 chr12 107370252 T C 2.27E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12315175 chr12 107499272 T C 4.01E-05 Orofacial clefts / / 22419666 rs2374674 chr12 107504730 A T 5.82E-04 Multiple complex diseases / / 17554300 rs10507217 chr12 107552904 A G 3.28E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4964527 chr12 107563247 T C 0.00033 Prostate cancer / / 23555315 rs2111330 chr12 107630378 G A 4.31E-04 Response to TNF antagonist treatment / / 21061259 rs7976575 chr12 107634542 G A 4.30E-04 Response to TNF antagonist treatment / / 21061259 rs11113250 chr12 107671866 A G 3.00E-05 Glycemic traits (pregnancy) / / 23903356 rs11113250 chr12 107671866 A G 3.78E-05 Glycemic traits (pregnancy) / / 23903356 rs2193353 chr12 107672895 A T 2.47E-05 Glycemic traits (pregnancy) / / 23903356 rs2193353 chr12 107672895 A T 3.05E-05 Glycemic traits (pregnancy) / / 23903356 rs2374688 chr12 107673202 T G 9.10E-05 Kidney function and endocine traits / / 17903292 rs2374688 chr12 107673202 T G 3.23E-05 Glycemic traits (pregnancy) / / 23903356 rs2374688 chr12 107673202 T G 3.95E-05 Glycemic traits (pregnancy) / / 23903356 rs2374689 chr12 107674370 A G 2.80E-06 Glycemic traits (pregnancy) / / 23903356 rs2374689 chr12 107674370 A G 5.09E-06 Glycemic traits (pregnancy) / / 23903356 rs1861691 chr12 107677546 A C 3.59E-05 Glycemic traits (pregnancy) / / 23903356 rs1861691 chr12 107677546 A C 4.58E-05 Glycemic traits (pregnancy) / / 23903356 rs7310294 chr12 107690351 T C 6.74E-05 Orofacial clefts / / 22419666 rs876662 chr12 107696626 T A 9.81E-04 Prostate cancer mortality / / 20978177 rs2374690 chr12 107704114 A G 9.10E-04 Prostate cancer mortality / / 20978177 rs1820460 chr12 107704705 C A 8.00E-06 Cognitive performance / / 19734545 rs11609982 chr12 107709150 G A 1.46E-04 Type 2 diabetes / / 17463246 rs10861724 chr12 107723717 G A 7.09E-04 Multiple complex diseases BTBD11 intron 17554300 rs759564 chr12 107728676 G A 9.97E-04 Alzheimer's disease BTBD11 intron 17998437 rs7953431 chr12 107732227 T G 6.46E-05 Major depressive disorder BTBD11 intron 21621269 rs1863538 chr12 107743775 A C 3.32E-05 Major depressive disorder BTBD11 intron 21621269 rs4964213 chr12 107750777 T C 1.30E-05 Amyotrophic Lateral Sclerosis BTBD11 intron 17362836 rs4964569 chr12 107751511 G A 6.38E-05 Smoking cessation BTBD11 intron 18519826 rs11113292 chr12 107767730 G A 5.39E-05 Major depressive disorder BTBD11 intron 21621269 rs7968306 chr12 107771447 T C 5.53E-04 Multiple complex diseases BTBD11 intron 17554300 rs1426467 chr12 107772248 C G 6.49E-05 Smoking cessation BTBD11 intron 18519826 rs10861732 chr12 107772542 G A 6.96E-04 Amyotrophic Lateral Sclerosis BTBD11 intron 17362836 rs1426466 chr12 107772567 T C 9.49E-05 Multiple complex diseases BTBD11 intron 17554300 rs10861733 chr12 107776025 A G 8.96E-04 Alzheimer's disease BTBD11 intron 17998437 rs7302236 chr12 107779889 A G 4.12E-04 Amyotrophic Lateral Sclerosis BTBD11 intron 17362836 rs1895990 chr12 107785498 T C 8.26E-06 Serum metabolites BTBD11 intron 19043545 rs10128899 chr12 107788365 G A 3.02E-04 Rheumatoid arthritis BTBD11 intron 21452313 rs10778554 chr12 107790783 A C 3.09E-04 Rheumatoid arthritis BTBD11 intron 21452313 rs749137 chr12 107801897 A G 8.68E-05 Multiple complex diseases BTBD11 intron 17554300 rs11113318 chr12 107814757 A G 5.00E-04 Multiple complex diseases BTBD11 intron 17554300 rs7957618 chr12 107830356 C T 1.72E-04 Smoking cessation BTBD11 intron 18519826 rs17039297 chr12 107842863 C T 7.32E-04 Multiple complex diseases BTBD11 intron 17554300 rs10861740 chr12 107847588 G C 8.40E-04 Response to cytidine analogues (gemcitabine) BTBD11 intron 24483146 rs10778561 chr12 107861624 T C 1.91E-05 Smoking cessation BTBD11 intron 18519826 rs10778561 chr12 107861624 T C 1.48E-05 Parent of origin effect on language impairment (maternal) BTBD11 intron 24571439 rs11113349 chr12 107879066 C T 1.16E-05 Response to methotrexate in juvenile idiopathic arthritis BTBD11 intron 24709693 rs11113379 chr12 107922099 G A 9.61E-04 Multiple complex diseases BTBD11 intron 17554300 rs17756735 chr12 107942604 G A 3.64E-06 C-reactive protein BTBD11 intron 22492993 rs182722816 chr12 107956249 G T 7.00E-07 Asthma BTBD11 intron 24406073 rs11832945 chr12 107979573 T A 4.06E-04 Multiple complex diseases BTBD11 intron 17554300 rs957626 chr12 107979941 C A 9.20E-05 Response to lithium treatment in bipolar disorder BTBD11 intron 19448189 rs4528429 chr12 107987966 G A 6.22E-05 Multiple complex diseases BTBD11 intron 17554300 rs7309802 chr12 108040682 G T 7.05E-04 Obesity (extreme) BTBD11 intron 21935397 rs2241187 chr12 108045139 T G 3.96E-04 Suicide attempts in bipolar disorder BTBD11 intron 21423239 rs2241187 chr12 108045139 T G 5.45E-05 Obesity (extreme) BTBD11 intron 21935397 rs10492157 chr12 108059193 T C 2.09E-04 IgE levels / / 17255346 rs4964604 chr12 108061806 C T 9.59E-05 Vaspin levels / / 22907691 rs4964604 chr12 108061806 C T 0.0000959 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs11113431 chr12 108064952 G A 5.83E-04 Myocardial Infarction / / pha002883 rs1802937 chr12 108106058 T C 7.98E-04 Multiple complex diseases PWP1 UTR-3 17554300 rs2160591 chr12 108137525 C T 6.13E-05 Aging (time to event) PRDM4 intron 21782286 rs11113470 chr12 108164550 C T 6.60E-04 Blood pressure / / 21228793 rs57043169 chr12 108167002 A C,G 0.0000708 post-traumatic stress disorder / / 22869035 rs57043169 chr12 108167002 A C,G 7.08E-05 Schizophrenia / / 22883433 rs7134063 chr12 108199331 T C 4.40E-05 Pulmonary function / / 23932459 rs10507218 chr12 108207233 C T 1.25E-04 Type 2 diabetes / / 17463246 rs10507218 chr12 108207233 C T 3.70E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs9919721 chr12 108221560 G C 4.67E-04 Type 2 diabetes / / 17463246 rs9919721 chr12 108221560 G C 3.19E-04 Multiple complex diseases / / 17554300 rs10861811 chr12 108224240 A T 3.75E-04 Multiple complex diseases / / 17554300 rs11113528 chr12 108224894 A G 4.25E-04 Type 2 diabetes / / 17463246 rs11113528 chr12 108224894 A G 2.91E-04 Multiple complex diseases / / 17554300 rs6539369 chr12 108228298 A G 2.92E-05 Major depressive disorder (broad) / / 20038947 rs6539370 chr12 108229828 A G 5.15E-04 Type 2 diabetes / / 17463246 rs6539370 chr12 108229828 A G 2.55E-04 Multiple complex diseases / / 17554300 rs6539371 chr12 108232723 T A 3.06E-04 Type 2 diabetes / / 17463246 rs6539371 chr12 108232723 T A 7.03E-04 Multiple complex diseases / / 17554300 rs1895943 chr12 108240832 C A 8.70E-06 Major depressive disorder (broad) / / 20038947 rs6539377 chr12 108242007 C T 2.37E-05 Major depressive disorder (broad) / / 20038947 rs11113550 chr12 108247815 A G 2.71E-05 Major depressive disorder (broad) / / 20038947 rs11113585 chr12 108318994 T C 9.07E-05 Multiple complex diseases / / 17554300 rs11835862 chr12 108346718 A G 0.0000207 Tuberculosis with late age of onset / / 22551897 rs11835862 chr12 108346718 A G 6.43E-04 Tourette syndrome / / 22889924 rs933864 chr12 108349783 G C 2.70E-05 Urinary metabolites / / 21572414 rs11113611 chr12 108358333 G A 3.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17039960 chr12 108363446 T G 3.72E-04 Multiple complex diseases / / 17554300 rs7974135 chr12 108371313 G A 1.90E-07 Asthma (childhood onset) / / 23829686 rs3910755 chr12 108372340 C T 5.72E-04 Type 2 diabetes / / 17463246 rs1895959 chr12 108374808 G A 2.40E-04 Multiple complex diseases / / 17554300 rs7296362 chr12 108375618 C T 3.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12316047 chr12 108393845 G A 6.32E-04 Type 2 diabetes / / 17463246 rs11610152 chr12 108393998 A G 0.00000251 VLDL cholesterol particle diameter / / 23263444 rs7295909 chr12 108397985 G A 4.50E-04 Type 2 diabetes / / 17463246 rs7295909 chr12 108397985 G A 0.00000225 VLDL cholesterol particle diameter / / 23263444 rs11616130 chr12 108408079 G A 0.00000194 VLDL cholesterol particle diameter / / 23263444 rs2077857 chr12 108418307 C T 4.08E-05 Bipolar disorder / / 21771265 rs7962481 chr12 108424705 T G 6.66E-04 Type 2 diabetes / / 17463246 rs1896088 chr12 108425627 A G 7.85E-04 Type 2 diabetes / / 17463246 rs2081594 chr12 108425851 A G 1.00E-04 Multiple complex diseases / / 17554300 rs11113677 chr12 108430257 C T 4.97E-04 Multiple complex diseases / / 17554300 rs933890 chr12 108438922 T C 6.60E-04 Subclinical atherosclerosis / / 17903303 rs933890 chr12 108438922 T C 0.00000307 VLDL cholesterol particle diameter / / 23263444 rs881512 chr12 108446077 G C 5.86E-04 Type 2 diabetes / / 17463246 rs11113703 chr12 108452596 T C 6.32E-04 Type 2 diabetes / / 17463246 rs17318085 chr12 108458820 A G 0.00000639 VLDL cholesterol particle diameter / / 23263444 rs11608785 chr12 108474631 C T 9.32E-04 Type 2 diabetes / / 17463246 rs11608785 chr12 108474631 C T 0.0000157 VLDL cholesterol particle diameter / / 23263444 rs11608789 chr12 108474692 C T 0.0000182 VLDL cholesterol particle diameter / / 23263444 rs1896091 chr12 108475002 C A 6.39E-04 Insulin resistance / / 21901158 rs17318454 chr12 108476137 G A 4.54E-04 Type 2 diabetes / / 17463246 rs7969681 chr12 108488110 C G 7.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs1896054 chr12 108496508 C T 5.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs8181767 chr12 108497577 G C 5.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs1896056 chr12 108499471 G A 1.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs338171 chr12 108521159 C A 5.25E-05 Diabetes Mellitus / / pha003060 rs181947843 chr12 108547387 G A 5.00E-06 Acne (severe) WSCD2 intron 24927181 rs11113768 chr12 108558344 A G 1.70E-05 Urinary metabolites WSCD2 intron 21572414 rs11113771 chr12 108590669 A G 1.20E-08 Multiple complex diseases WSCD2 intron 17554300 rs4964656 chr12 108594069 G C 5.78E-05 Bipolar disorder and schizophrenia WSCD2 intron 20889312 rs4964656 chr12 108594069 G C 2.50E-06 Urinary metabolites WSCD2 intron 21572414 rs3794260 chr12 108598274 G A 1.00E-04 Hypertension WSCD2 intron 18003638 rs7313402 chr12 108602970 C A 8.00E-06 Temperament (bipolar disorder) WSCD2 intron 22365631 rs3764002 chr12 108618630 C T 6.34E-05 Osteoarthritis (knee and hip) WSCD2 missense 21177295 rs3764002 chr12 108618630 C T 8.80E-05 Osteoarthritis (knee and hip) WSCD2 missense 21177295 rs41466446 chr12 108627179 C T 4.38E-04 Multiple complex diseases WSCD2 intron 17554300 rs4964665 chr12 108628067 T C 2.70E-05 Temperament (bipolar disorder) WSCD2 intron 22365631 rs11113789 chr12 108651620 A G 5.22E-05 Multiple complex diseases / / 17554300 rs12315949 chr12 108658034 G A 7.82E-05 Multiple complex diseases / / 17554300 rs12308347 chr12 108661689 A G 2.64E-05 Multiple complex diseases / / 17554300 rs11113808 chr12 108696850 C T 4.00E-04 Response to taxane treatment (placlitaxel) CMKLR1 intron 23006423 rs4964243 chr12 108697894 T C 9.11E-04 Response to taxane treatment (placlitaxel) CMKLR1 intron 23006423 rs1878022 chr12 108699032 C T 5.00E-07 Response to platinum-based chemotherapy in non-small-cell lung cancer CMKLR1 intron 21483023 rs11113818 chr12 108717929 C T 4.00E-06 Response to methotrexate in juvenile idiopathic arthritis CMKLR1 intron 24709693 rs4373981 chr12 108734689 G C 9.26E-04 Multiple complex diseases / / 17554300 rs17322627 chr12 108737031 T C 4.57E-06 Hearing function / / 21493956 rs4964679 chr12 108739318 A G 4.62E-06 Hearing function / / 21493956 rs17040430 chr12 108742820 G T 9.00E-07 Bipolar disorder / / 22688191 rs11113842 chr12 108765463 T G 9.11E-04 Prostate cancer mortality / / 20978177 rs10861905 chr12 108767333 C A 8.00E-07 Erectile dysfunction and prostate cancer treatment / / 20932654 rs720051 chr12 108778192 C T 5.78E-04 Multiple complex diseases / / 17554300 rs41489249 chr12 108790577 A G 4.10E-05 Tuberculosis / / 24057671 rs10861912 chr12 108793318 C G 9.63E-04 Multiple complex diseases / / 17554300 rs11113857 chr12 108798873 T C 2.80E-04 Alcohol dependence / / 20201924 rs17040470 chr12 108803755 G A 1.55E-04 Alcohol dependence / / 20201924 rs17040470 chr12 108803755 G A 4.82E-04 Prostate cancer mortality / / 20978177 rs2673743 chr12 108805152 G A 1.77E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10492255 chr12 108823747 T G 9.34E-05 Elbow pain / / pha003008 rs986292 chr12 108838841 A G 6.35E-06 Obesity-related traits / / 23251661 rs11113894 chr12 108841863 G A 2.00E-06 Obesity-related traits / / 23251661 rs12311469 chr12 108851079 G T 8.50E-04 Obesity (extreme) / / 21935397 rs10861927 chr12 108851561 G A 8.53E-04 Obesity (extreme) / / 21935397 rs2111949 chr12 108861534 A C 8.43E-04 Multiple complex diseases / / 17554300 rs10778641 chr12 108874961 G T 9.41E-04 Myocardial Infarction / / pha002873 rs7958130 chr12 108876280 A T 5.94E-06 Lipid traits / / 21777205 rs918304 chr12 108877541 C T 8.00E-06 IgG glycosylation / / 23382691 rs918304 chr12 108877541 C T 9.00E-06 IgG glycosylation / / 23382691 rs2160974 chr12 108883621 T C 8.37E-04 Type 2 diabetes / / 17463246 rs888554 chr12 108885112 A G 2.94E-04 Type 2 diabetes / / 17463246 rs1072577 chr12 108900020 A T 1.67E-05 Malignant pleural mesothelioma / / 23626673 rs2287552 chr12 108937242 C T 4.64E-04 Suicide attempts in bipolar disorder SART3 intron 21423239 rs2287553 chr12 108943296 T A 4.79E-04 Suicide attempts in bipolar disorder SART3 intron 21423239 rs4964266 chr12 108949660 C G 4.83E-04 Suicide attempts in bipolar disorder SART3 intron 21423239 rs741543 chr12 108964102 C T 9.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs8179116 chr12 109025427 C T 3.00E-06 Conduct disorder (symptom count) SELPLG intron 20585324 rs8179106 chr12 109028341 A G 3.00E-05 Prostate cancer / / 21743057 rs10778652 chr12 109044723 G C 2.18E-05 Aging (time to event) CORO1C intron 21782286 rs750134 chr12 109061106 G T 2.18E-04 Alzheimer's disease CORO1C intron 24755620 rs1362614 chr12 109063958 A G 2.21E-04 Alzheimer's disease CORO1C intron 24755620 rs10507231 chr12 109073338 C T 2.80E-04 Alzheimer's disease CORO1C intron 24755620 rs17040860 chr12 109080030 C T 2.26E-04 Alzheimer's disease CORO1C intron 24755620 rs12581386 chr12 109082999 C A 7.60E-05 Type 2 diabetes CORO1C intron 17463248 rs10746129 chr12 109091089 T C 1.60E-04 Myasthenia gravis CORO1C intron 23055271 rs17040895 chr12 109093713 C T 2.80E-04 Alzheimer's disease CORO1C intron 24755620 rs3825253 chr12 109109281 A G 3.60E-05 Type 2 diabetes CORO1C intron 17463248 rs3825253 chr12 109109281 A G 8.86E-05 Cognitive impairment induced by topiramate CORO1C intron 22091778 rs12423733 chr12 109117989 C T 2.44E-04 Alzheimer's disease CORO1C intron 24755620 rs10778656 chr12 109133588 C T 2.29E-05 Heart Rate / / pha003053 rs3741781 chr12 109178003 C A 6.03E-05 Cognitive impairment induced by topiramate SSH1 UTR-3 22091778 rs1549087 chr12 109201326 T C 3.37E-04 Alzheimer's disease SSH1 intron 24755620 rs12424287 chr12 109226950 A G 3.56E-04 Alzheimer's disease SSH1 intron 24755620 rs11114068 chr12 109237959 C G 4.69E-04 Type 2 diabetes SSH1 intron 17463246 rs11114068 chr12 109237959 C G 3.73E-04 Alzheimer's disease SSH1 intron 24755620 rs3825251 chr12 109287984 A G 4.98E-05 Hemoglobin DAO intron pha003098 rs3825251 chr12 109287984 A G 5.01E-06 Erythrocyte counts DAO intron pha003099 rs7294679 chr12 109304690 T A 8.73E-04 Type 2 diabetes / / 17463246 rs7294679 chr12 109304690 T A 3.96E-04 Lymphocyte counts / / 22286170 rs10778660 chr12 109305521 T C 1.24E-04 Age-related macular degeneration / / 22125219 rs11114094 chr12 109306627 A G 4.29E-05 Coronary heart disease / / pha003031 rs10861980 chr12 109310854 G A 1.10E-05 Urinary metabolites / / 21572414 rs12425421 chr12 109323647 G A 2.62E-05 Aging (time to event) / / 21782286 rs4964286 chr12 109325020 T C 1.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11114106 chr12 109329118 C T 3.02E-04 Multiple complex diseases / / 17554300 rs11114106 chr12 109329118 C T 2.10E-05 Age-related macular degeneration / / 20861866 rs7980554 chr12 109330196 T G 3.06E-04 Multiple complex diseases / / 17554300 rs1865147 chr12 109432616 G T 8.52E-05 Epilepsy / / 22116939 rs16939972 chr12 109568797 T C 6.93E-04 Response to taxane treatment (placlitaxel) LOC100506415 intron 23006423 rs2300459 chr12 109586479 A G 2.47E-04 Multiple complex diseases ACACB intron 17554300 rs6606692 chr12 109591369 T G 7.91E-04 Multiple complex diseases ACACB intron 17554300 rs7966218 chr12 109600214 A G 3.67E-04 Suicide attempts in bipolar disorder ACACB intron 21423239 rs4766583 chr12 109663100 C T 5.52E-04 Multiple complex diseases ACACB intron 17554300 rs4766584 chr12 109663581 A G 2.59E-04 Multiple complex diseases ACACB intron 17554300 rs10849968 chr12 109694320 C A 5.59E-05 Glucose levels ACACB intron pha003058 rs882355 chr12 109708389 G A 8.07E-05 Glucose levels / / pha003058 rs7976088 chr12 109722703 G A 0.0000511 Nonsyndromic striae distensae (stretch marks) FOXN4 intron 23633020 rs7959782 chr12 109725688 G A 0.0000548 Nonsyndromic striae distensae (stretch marks) FOXN4 cds-synon 23633020 rs11066130 chr12 109728175 G A 0.0000697 Nonsyndromic striae distensae (stretch marks) FOXN4 intron 23633020 rs7971706 chr12 109728687 G A 0.0000642 Nonsyndromic striae distensae (stretch marks) FOXN4 intron 23633020 rs11066170 chr12 109737079 T C 0.0000545 Nonsyndromic striae distensae (stretch marks) FOXN4 intron 23633020 rs7967204 chr12 109738070 G A 9.97E-04 Coronary heart disease FOXN4 intron 21971053 rs11066182 chr12 109740442 G A 9.93E-04 Alzheimer's disease FOXN4 intron 22005930 rs10850017 chr12 109748806 T C 9.85E-04 Alzheimer's disease / / 22005930 rs12316209 chr12 109750363 G T 0.000056 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11066213 chr12 109751246 G A 0.0000627 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10850022 chr12 109752535 C T 0.0000646 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10850029 chr12 109757921 C A 0.0000793 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10850030 chr12 109758835 G A 0.0000678 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11066262 chr12 109759792 G A 0.0000929 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12319869 chr12 109777677 A G 4.66E-04 Smoking quantity / / 24665060 rs12231342 chr12 109782656 A G 2.51E-04 Smoking quantity / / 24665060 rs11066357 chr12 109785206 A C 1.43E-04 Smoking quantity / / 24665060 rs10850065 chr12 109787936 G A 6.80E-04 Drinking behavior / / 21372407 rs10850110 chr12 109824726 G A 5.20E-04 Drinking behavior / / 21372407 rs9943753 chr12 109840940 A G 3.00E-06 HDL cholesterol MYO1H intron 20864672 rs7954301 chr12 109857093 C T 3.89E-04 Alzheimer's disease (late onset) MYO1H intron 21379329 rs2075440 chr12 109859100 A G 0.000000678 HDL cholesterol MYO1H intron 22629316 rs2075440 chr12 109859100 A G 0.0000512 HDL cholesterol (male) MYO1H intron 22629316 rs2075440 chr12 109859100 A G 0.000889 HDL cholesterol (female) MYO1H intron 22629316 rs11611370 chr12 109870291 G A 7.41E-04 Type 2 diabetes MYO1H intron 17463246 rs7308864 chr12 109871179 A G 4.77E-04 Aortic root size MYO1H intron 21223598 rs2075432 chr12 109874230 A G 2.50E-04 Drinking behavior MYO1H intron 21372407 rs10850141 chr12 109876128 C T 3.50E-04 Drinking behavior MYO1H intron 21372407 rs7956194 chr12 109877825 G A 2.00E-04 Blood Phenotypes MYO1H intron 17903294 rs7969719 chr12 109883577 C T 4.30E-04 Type 2 diabetes MYO1H intron 17463246 rs1477117 chr12 109888779 G A 3.23E-04 Scoliosis KCTD10 UTR-3 21216876 rs1477117 chr12 109888779 G A 2.20E-05 Urinary metabolites KCTD10 UTR-3 21572414 rs1477117 chr12 109888779 G A 3.70E-04 Atrial fibrillation KCTD10 UTR-3 21846873 rs4766601 chr12 109890080 G C 9.83E-04 Type 2 diabetes KCTD10 intron 17463246 rs4766601 chr12 109890080 G C 5.51E-26 Lymphocyte counts KCTD10 intron 22286170 rs9943689 chr12 109890339 G A 5.87E-05 Body Composition KCTD10 intron pha003012 rs10774708 chr12 109893156 A G 9.20E-08 Lipid levels KCTD10 intron 18193043 rs2338104 chr12 109895168 C G 3.00E-08 HDL cholesterol KCTD10 intron 18193043 rs2338104 chr12 109895168 C G 1.00E-10 HDL cholesterol KCTD10 intron 19060906 rs2338104 chr12 109895168 C G 1.00E-10 Coronary heart disease KCTD10 intron 21347282 rs10850201 chr12 109903062 C G 4.88E-04 Body mass index KCTD10 intron 21701565 rs918107 chr12 109904198 T C 1.00E-05 Urinary metabolites KCTD10 intron 21572414 rs11066737 chr12 109904792 G A 4.49E-04 Type 2 diabetes KCTD10 intron 17463246 rs11066737 chr12 109904792 G A 1.00E-05 Urinary metabolites KCTD10 intron 21572414 rs2058804 chr12 109909011 A G 2.40E-05 Lipid levels KCTD10 intron 19936222 rs2058804 chr12 109909011 A G 5.50E-05 Lipid levels KCTD10 intron 19936222 rs2058804 chr12 109909011 A G 5.80E-06 Lipid levels KCTD10 intron 19936222 rs2058804 chr12 109909011 A G 4.07E-04 Alzheimer's disease (late onset) KCTD10 intron 21379329 rs2058804 chr12 109909011 A G 6.08E-05 Neuroblastoma KCTD10 intron pha002895 rs11066856 chr12 109923138 C G 2.10E-04 Type 2 diabetes UBE3B intron 17463246 rs7311488 chr12 109930905 C G 4.54E-04 Type 2 diabetes UBE3B intron 17463246 rs7311488 chr12 109930905 C G 2.50E-05 Urinary metabolites UBE3B intron 21572414 rs2287192 chr12 109931594 G A 3.84E-04 Type 2 diabetes UBE3B intron 17463246 rs2287192 chr12 109931594 G A 8.30E-06 Urinary metabolites UBE3B intron 21572414 rs7298565 chr12 109937534 G A 3.39E-04 Alzheimer's disease (late onset) UBE3B missense 21379329 rs7298565 chr12 109937534 G A 0.00000198 Cholesterol,total UBE3B missense 23063622 rs7298565 chr12 109937534 G A 0.00028 Breast cancer UBE3B missense 23555315 rs7298565 chr12 109937534 G A 6.93E-05 Neuroblastoma UBE3B missense pha002895 rs11067030 chr12 109955317 C T 3.94E-04 Type 2 diabetes UBE3B intron 17463246 rs11067030 chr12 109955317 C T 6.70E-06 Urinary metabolites UBE3B intron 21572414 rs11609871 chr12 109965006 C G 4.12E-04 Type 2 diabetes UBE3B intron 17463246 rs2241206 chr12 109968848 T C 3.00E-04 Lipid levels UBE3B intron 19802338 rs1078424 chr12 109970105 G A 7.46E-45 Triglycerides UBE3B intron 23063622 rs7979816 chr12 109977386 G A 4.81E-04 Type 2 diabetes / / 17463246 rs7979816 chr12 109977386 G A 4.90E-06 Urinary metabolites / / 21572414 rs12831657 chr12 109979267 T C 2.70E-06 Urinary metabolites / / 21572414 rs7486178 chr12 109980266 G A 3.90E-06 Neuroblastoma / / pha002895 rs729784 chr12 109981264 G T 3.72E-04 Type 2 diabetes / / 17463246 rs729784 chr12 109981264 G T 6.90E-06 Urinary metabolites / / 21572414 rs2241201 chr12 109992132 C G 0.0000152 Cholesterol,total MMAB UTR-3 23063622 rs9593 chr12 109994870 A T 0.000049 Breast cancer(er negative) MMAB missense 23555315 rs9593 chr12 109994870 A T 0.00015 Breast cancer MMAB missense 23555315 rs7134594 chr12 110000193 C T 7.00E-15 HDL cholesterol MMAB intron 20686565 rs7134594 chr12 110000193 C T 2.50E-04 Alzheimer's disease (late onset) MMAB intron 21379329 rs7134594 chr12 110000193 C T 0.000069 Breast cancer(er negative) MMAB intron 23555315 rs7134594 chr12 110000193 C T 0.00013 Breast cancer MMAB intron 23555315 rs7134594 chr12 110000193 C T 2.00E-13 HDL cholesterol MMAB intron 24097068 rs7134594 chr12 110000193 C T 6.48E-05 Neuroblastoma MMAB intron pha002895 rs59227481 chr12 110007993 A G 6.00E-07 Age-related nuclear cataracts MMAB intron 24951543 rs3759387 chr12 110012467 G T 9.45E-05 Neuroblastoma MVK intron pha002895 rs7957619 chr12 110013879 G A 1.84E-04 Prion diseases MVK missense 22210626 rs4766613 chr12 110016559 G A 2.79E-04 Type 2 diabetes MVK intron 17463246 rs4766613 chr12 110016559 G A 6.90E-06 Urinary metabolites MVK intron 21572414 rs11615637 chr12 110023689 G A 2.27E-04 Type 2 diabetes MVK intron 17463246 rs11615637 chr12 110023689 G A 7.60E-06 Urinary metabolites MVK intron 21572414 rs11067376 chr12 110027795 A G 2.60E-04 Lipid levels MVK intron 19936222 rs17183465 chr12 110029750 T A 2.73E-04 Type 2 diabetes MVK intron 17463246 rs17183465 chr12 110029750 T A 6.30E-06 Urinary metabolites MVK intron 21572414 rs10850435 chr12 110033270 G C 1.80E-05 Lipid levels MVK intron 19936222 rs10161126 chr12 110042348 A G 1.24E-04 Alzheimer's disease (late onset) / / 21379329 rs10161126 chr12 110042348 A G 0.000414 HDL cholesterol / / 23063622 rs1861679 chr12 110055044 C T 0.0000445 Cholesterol,total / / 23063622 rs7960944 chr12 110076938 C T 6.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1344542 chr12 110082154 G A 3.30E-04 Drinking behavior / / 21372407 rs11614658 chr12 110082320 T C 6.16E-04 Type 2 diabetes / / 17463246 rs16940455 chr12 110105271 G A,C 8.13E-06 Odorant perception / / 23910658 rs11067936 chr12 110144932 C T 3.05E-04 Type 2 diabetes / / 17463246 rs7971523 chr12 110188155 G C 5.68E-04 Depression (quantitative trait) C12orf34 intron 20800221 rs10774883 chr12 110195100 G A 4.47E-04 Depression (quantitative trait) C12orf34 intron 20800221 rs10850708 chr12 110201605 T C 3.43E-05 Depression (quantitative trait) C12orf34 intron 20800221 rs10735104 chr12 110227965 C T 2.06E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) TRPV4 intron 23648065 rs12579553 chr12 110235632 A G 5.26E-05 Platelet counts TRPV4 intron pha003100 rs10850800 chr12 110248089 A G 7.80E-04 Drinking behavior TRPV4 intron 21372407 rs7971845 chr12 110260702 C G 5.40E-05 Serum metabolites TRPV4 intron 19043545 rs4766635 chr12 110276914 C T 5.37E-04 Insulin resistance / / 21901158 rs4525299 chr12 110285646 A G 3.69E-04 Smoking initiation / / 24665060 rs7966820 chr12 110302270 C T 7.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GLTP intron 20877124 rs10850913 chr12 110312232 A G 6.51E-04 Body mass index GLTP intron 21701565 rs10774978 chr12 110341933 A G 8.99E-04 Suicide attempts in bipolar disorder TCHP missense 21423239 rs74416240 chr12 110342598 G A 2.15E-25 Alcohol (ever vs. never) TCHP cds-synon 23555315 rs16940688 chr12 110360321 G A 4.83E-08 Alcohol consumption (maxi-drinks) / / 24277619 rs16940688 chr12 110360321 G A 5.90E-09 Response to alcohol consumption (flushing response) / / 24277619 rs2292354 chr12 110368201 G A 7.00E-06 Metabolic syndrome GIT2 UTR-3 20694148 rs2292354 chr12 110368201 G A 1.90E-05 Urinary metabolites GIT2 UTR-3 21572414 rs3742010 chr12 110369872 G A 6.99E-04 Insulin resistance GIT2 UTR-3 21901158 rs16940707 chr12 110374782 G A 1.34E-04 Multiple complex diseases GIT2 intron 17554300 rs925368 chr12 110390979 T C 1.30E-26 Alcohol (ever vs. never) GIT2 missense 23555315 rs925368 chr12 110390979 T C 1.49E-08 Response to alcohol consumption (flushing response) GIT2 missense 24277619 rs925368 chr12 110390979 T C 5.31E-08 Alcohol consumption (maxi-drinks) GIT2 missense 24277619 rs4766646 chr12 110398145 T A 4.00E-07 Metabolite levels (MHPG) GIT2 intron 23319000 rs12829374 chr12 110521368 G T 4.16E-04 Insulin resistance / / 21901158 rs1547975 chr12 110547162 A C 2.00E-04 Polycystic ovary syndrome / / 22178785 rs7300045 chr12 110620661 C T 2.00E-04 Polycystic ovary syndrome IFT81 intron 22178785 rs17619763 chr12 110645829 G A 3.20E-04 Response to taxane treatment (placlitaxel) IFT81 intron 23006423 rs11065611 chr12 110704487 C T 1.00E-07 Protein quantitative trait loci / / 18464913 rs6606683 chr12 110712212 T G 4.35E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3026465 chr12 110757585 A G 3.00E-04 Polycystic ovary syndrome ATP2A2 intron 22178785 rs17187412 chr12 110766767 A G 3.20E-04 Response to taxane treatment (placlitaxel) ATP2A2 intron 23006423 rs3026470 chr12 110768227 G C 0.000000468 Triglycerides ATP2A2 intron 23063622 rs11065633 chr12 110786250 C T 0.00000022 HDL cholesterol ATP2A2 UTR-3 23063622 rs6606684 chr12 110800166 T C 1.90E-05 Heart rate / / 23583979 rs12369492 chr12 110908254 A C 7.00E-04 Polycystic ovary syndrome FAM216A intron 22178785 rs17188964 chr12 110925718 A G 2.10E-17 Health and aging,CVD and cancer age of onset FAM216A missense 22174011 rs17188964 chr12 110925718 A G 3.00E-07 Health and aging,CVD and cancer age of onset FAM216A missense 22174011 rs17188964 chr12 110925718 A G 9.00E-19 Health and aging,CVD and cancer age of onset FAM216A missense 22174011 rs4766492 chr12 110929261 C T 4.19E-04 Sarcoidosis / / 19165924 rs61942603 chr12 110944299 G C 7.00E-04 Polycystic ovary syndrome RAD9B intron 22178785 rs4766500 chr12 110993791 G A 7.87E-05 Cognitive impairment induced by topiramate PPTC7 intron 22091778 rs16940902 chr12 111016630 T G 8.60E-06 Sarcoidosis PPTC7 intron 19165924 rs11065688 chr12 111082142 C T 6.51E-04 Insulin resistance TCTN1 intron 21901158 rs17625767 chr12 111102627 T G 4.50E-04 Response to taxane treatment (placlitaxel) HVCN1 intron 23006423 rs11065706 chr12 111155531 T C 6.00E-07 Heart rate / / 23583979 rs7960552 chr12 111164237 T C 1.00E-04 Cognitive impairment induced by topiramate PPP1CC intron 22091778 rs850511 chr12 111239821 T C 5.52E-04 Multiple complex diseases / / 17554300 rs850509 chr12 111242361 C T 2.80E-05 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs7974845 chr12 111246640 G A 4.96E-04 Multiple complex diseases / / 17554300 rs11065724 chr12 111248624 C T 3.40E-07 Urinary metabolites / / 21572414 rs7960825 chr12 111255027 C T 3.42E-04 Multiple complex diseases / / 17554300 rs2188399 chr12 111272553 A G 2.65E-04 Multiple complex diseases / / 17554300 rs11065733 chr12 111294520 A G 4.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCDC63 intron 20877124 rs11065733 chr12 111294520 A G 3.20E-07 Drinking behavior CCDC63 intron 21372407 rs2283351 chr12 111300010 G A 2.40E-04 Drinking behavior CCDC63 intron 21372407 rs2238149 chr12 111311929 T C 1.30E-08 Esophageal cancer (squamous cell) CCDC63 intron 20833657 rs2238149 chr12 111311929 T C 3.50E-04 Myocardial infarction CCDC63 intron 21107343 rs2238149 chr12 111311929 T C 5.82E-19 Drinking behavior CCDC63 intron 23364009 rs2238149 chr12 111311929 T C 1.06E-06 Alcohol consumption (maxi-drinks) CCDC63 intron 24277619 rs2238149 chr12 111311929 T C 1.95E-08 Response to alcohol consumption (flushing response) CCDC63 intron 24277619 rs2238149 chr12 111311929 T C 5.47E-04 Response to cytadine analogues (cytosine arabinoside) CCDC63 intron 24483146 rs11612727 chr12 111314289 T C 4.23E-08 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCDC63 intron 20877124 rs11612727 chr12 111314289 T C 2.50E-15 Drinking behavior CCDC63 intron 21372407 rs11612727 chr12 111314289 T C 7.60E-06 Coronary heart disease CCDC63 intron 21971053 rs11612727 chr12 111314289 T C 8.44E-04 Response to cytadine analogues (cytosine arabinoside) CCDC63 intron 24483146 rs10492013 chr12 111319724 A T 8.90E-04 Myocardial infarction CCDC63 intron 21107343 rs11065750 chr12 111331016 G A 2.96E-10 Alcohol consumption (maxi-drinks) CCDC63 intron 24277619 rs11065750 chr12 111331016 G A 3.00E-05 Alcohol dependence CCDC63 intron 24277619 rs11065750 chr12 111331016 G A 9.68E-15 Response to alcohol consumption (flushing response) CCDC63 intron 24277619 rs10849915 chr12 111333622 T C 1.00E-23 Alcohol consumption CCDC63 intron 21270382 rs10849915 chr12 111333622 T C 5.58E-22 Drinking behavior CCDC63 intron 23364009 rs1858881 chr12 111334117 T C 1.67E-09 Alcohol consumption (maxi-drinks) CCDC63 intron 24277619 rs1858881 chr12 111334117 T C 1.80E-05 Alcohol dependence CCDC63 intron 24277619 rs1858881 chr12 111334117 T C 7.48E-15 Response to alcohol consumption (flushing response) CCDC63 intron 24277619 rs11065756 chr12 111338794 C T 7.10E-12 Esophageal cancer (squamous cell) CCDC63 intron 20833657 rs11065756 chr12 111338794 C T 1.11E-23 Drinking behavior CCDC63 intron 23364009 rs10774610 chr12 111340243 T C 2.03E-13 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCDC63 intron 20877124 rs10774610 chr12 111340243 T C 9.00E-120 Drinking behavior CCDC63 intron 21372407 rs10774610 chr12 111340243 T C 1.43E-05 Coronary heart disease CCDC63 intron 21971053 rs10774610 chr12 111340243 T C 1.67E-09 Alcohol consumption (maxi-drinks) CCDC63 intron 24277619 rs10774610 chr12 111340243 T C 1.80E-05 Alcohol dependence CCDC63 intron 24277619 rs10774610 chr12 111340243 T C 7.48E-15 Response to alcohol consumption (flushing response) CCDC63 intron 24277619 rs3782889 chr12 111350655 A G 4.18E-14 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MYL2 intron 20877124 rs3782889 chr12 111350655 A G 9.40E-18 Drinking behavior MYL2 intron 21372407 rs3782889 chr12 111350655 A G 5.86E-06 Coronary heart disease MYL2 intron 21971053 rs3782889 chr12 111350655 A G 1.31E-23 Drinking behavior MYL2 intron 23364009 rs3782889 chr12 111350655 A G 4.00E-14 Coronary heart disease MYL2 intron 23364394 rs3825389 chr12 111350771 C T 2.15E-14 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MYL2 intron 20877124 rs3825389 chr12 111350771 C T 4.20E-19 Drinking behavior MYL2 intron 21372407 rs3825389 chr12 111350771 C T 6.22E-06 Coronary heart disease MYL2 intron 21971053 rs2071629 chr12 111351186 C T 4.70E-04 Myocardial infarction MYL2 intron 21107343 rs933296 chr12 111352848 A C 4.10E-04 Blood Pressure and Arterial Stiffness MYL2 intron 17903302 rs933296 chr12 111352848 A C 5.60E-05 Drinking behavior MYL2 intron 21372407 rs11065774 chr12 111355326 G A 1.66E-14 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MYL2 intron 20877124 rs11065774 chr12 111355326 G A 1.50E-19 Drinking behavior MYL2 intron 21372407 rs11065774 chr12 111355326 G A 9.67E-05 Coronary heart disease MYL2 intron 21971053 rs10849917 chr12 111357074 T A 3.21E-08 Coronary heart disease MYL2 intron 23364394 rs4766517 chr12 111359712 G C 5.27E-07 Multiple complex diseases MYL2 nearGene-5 17554300 rs4766517 chr12 111359712 G C 9.64E-05 Sarcoidosis MYL2 nearGene-5 19165924 rs4766517 chr12 111359712 G C 2.81E-05 Bipolar disorder MYL2 nearGene-5 20451256 rs6489834 chr12 111363243 T C 9.73E-04 Response to alcohol consumption (flushing response) / / 24277619 rs886125 chr12 111365324 A G 5.42E-07 Multiple complex diseases / / 17554300 rs886125 chr12 111365324 A G 1.50E-08 Type 1 diabetes / / 18978792 rs886125 chr12 111365324 A G 2.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs886125 chr12 111365324 A G 1.60E-06 Drinking behavior / / 21372407 rs12227162 chr12 111367244 C T 6.27E-10 Coronary heart disease / / 23364394 rs7979656 chr12 111376637 C T 6.27E-06 Multiple complex diseases / / 17554300 rs10849918 chr12 111376921 T C 2.37E-07 Multiple complex diseases / / 17554300 rs6489844 chr12 111385296 A G 8.64E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6489844 chr12 111385296 A G 4.10E-08 Drinking behavior / / 21372407 rs2188380 chr12 111386127 T C 1.40E-04 White blood cell types / / 21738478 rs4766521 chr12 111386961 T C 6.93E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4766521 chr12 111386961 T C 5.50E-08 Drinking behavior / / 21372407 rs3919447 chr12 111391799 C T 7.37E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3919447 chr12 111391799 C T 5.50E-08 Drinking behavior / / 21372407 rs4766522 chr12 111393519 T G 7.37E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4766522 chr12 111393519 T G 5.60E-08 Drinking behavior / / 21372407 rs2106407 chr12 111394327 T C 2.63E-07 Multiple complex diseases / / 17554300 rs2106406 chr12 111394384 G A 1.17E-07 Multiple complex diseases / / 17554300 rs12425190 chr12 111394929 C A 9.42E-07 Multiple complex diseases / / 17554300 rs11065783 chr12 111396249 A G 3.10E-08 Esophageal cancer (squamous cell) / / 20833657 rs11065783 chr12 111396249 A G 1.01E-04 Drinking behavior / / 23364009 rs2339706 chr12 111396419 G A 2.07E-07 Multiple complex diseases / / 17554300 rs4509829 chr12 111396613 C T 2.13E-07 Multiple complex diseases / / 17554300 rs4509829 chr12 111396613 C T 7.37E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4509829 chr12 111396613 C T 4.90E-08 Drinking behavior / / 21372407 rs7961663 chr12 111399771 G A 3.07E-07 Multiple complex diseases / / 17554300 rs4766526 chr12 111401316 G T 6.02E-06 Multiple complex diseases / / 17554300 rs4766526 chr12 111401316 G T 7.37E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4766526 chr12 111401316 G T 4.80E-08 Drinking behavior / / 21372407 rs4766442 chr12 111401693 G A 1.04E-07 Multiple complex diseases / / 17554300 rs4766442 chr12 111401693 G A 3.29E-05 Sarcoidosis / / 19165924 rs12815195 chr12 111402363 T C 1.72E-07 Multiple complex diseases / / 17554300 rs4766527 chr12 111405470 T G 7.81E-04 Response to alcohol consumption (flushing response) / / 24277619 rs991817 chr12 111410537 A G 7.07E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs991817 chr12 111410537 A G 5.10E-08 Drinking behavior / / 21372407 rs991817 chr12 111410537 A G 6.93E-04 Response to alcohol consumption (flushing response) / / 24277619 rs12229654 chr12 111414461 T G 3.30E-18 Esophageal cancer (squamous cell) / / 20833657 rs12229654 chr12 111414461 T G 4.00E-35 Alcohol consumption / / 21270382 rs12229654 chr12 111414461 T G 4.07E-09 Esophageal cancer / / 21642993 rs12229654 chr12 111414461 T G 3.00E-23 HDL cholesterol / / 21909109 rs12229654 chr12 111414461 T G 9.00E-58 Gamma glutamyl transpeptidase / / 21909109 rs12229654 chr12 111414461 T G 1.08E-10 Drinking behavior / / 23364009 rs12229654 chr12 111414461 T G 0.00000136 Alcohol consumption / / 23555315 rs12229654 chr12 111414461 T G 3.09E-53 Alcohol (ever vs. never) / / 23555315 rs12229654 chr12 111414461 T G 9.00E-13 Glycemic traits / / 23575436 rs12229654 chr12 111414461 T G 5.00E-09 Body mass index / / 24861553 rs7304705 chr12 111438001 A G 1.22E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7314285 chr12 111522026 T G 1.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CUX2 intron 20877124 rs7314285 chr12 111522026 T G 9.50E-06 D-dimer levels CUX2 intron 21502573 rs1001484 chr12 111536822 A G 4.47E-04 Atopy CUX2 intron 21625490 rs10774613 chr12 111546165 T C 3.57E-08 Multiple complex diseases CUX2 intron 17554300 rs4766542 chr12 111590492 T C 1.96E-08 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CUX2 intron 20877124 rs4766542 chr12 111590492 T C 2.30E-07 Drinking behavior CUX2 intron 21372407 rs4766542 chr12 111590492 T C 8.14E-05 Coronary heart disease CUX2 intron 21971053 rs2157876 chr12 111592380 G T 1.90E-04 Response to ximelagatran treatment CUX2 intron 17505501 rs2157876 chr12 111592380 G T 4.09E-10 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CUX2 intron 20877124 rs2157876 chr12 111592380 G T 5.20E-05 Myocardial infarction CUX2 intron 21107343 rs2157876 chr12 111592380 G T 3.30E-07 Drinking behavior CUX2 intron 21372407 rs2157876 chr12 111592380 G T 9.26E-05 Coronary heart disease CUX2 intron 21971053 rs2157876 chr12 111592380 G T 2.95E-04 Response to alcohol consumption (flushing response) CUX2 intron 24277619 rs16941284 chr12 111610723 T A 3.04E-05 Multiple complex diseases CUX2 intron 17554300 rs4766549 chr12 111618332 T G 1.46E-08 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CUX2 intron 20877124 rs4766549 chr12 111618332 T G 2.00E-07 Drinking behavior CUX2 intron 21372407 rs4766549 chr12 111618332 T G 4.15E-05 Coronary heart disease CUX2 intron 21971053 rs12578742 chr12 111622980 A G 1.80E-04 Drinking behavior CUX2 intron 21372407 rs7959625 chr12 111623138 A G 2.80E-07 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CUX2 intron 20877124 rs7959625 chr12 111623138 A G 5.20E-07 Drinking behavior CUX2 intron 21372407 rs7959625 chr12 111623138 A G 9.07E-05 Coronary heart disease CUX2 intron 21971053 rs4766553 chr12 111634281 T G 8.44E-04 Multiple complex diseases CUX2 intron 17554300 rs4766553 chr12 111634281 T G 5.78E-05 Type 1 diabetes CUX2 intron 18978792 rs4766553 chr12 111634281 T G 5.21E-09 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CUX2 intron 20877124 rs4766553 chr12 111634281 T G 9.00E-07 Drinking behavior CUX2 intron 21372407 rs4766553 chr12 111634281 T G 1.90E-06 Coronary heart disease CUX2 intron 21971053 rs9783423 chr12 111639456 G C 1.56E-04 Multiple complex diseases CUX2 intron 17554300 rs3809291 chr12 111645043 A G 1.30E-04 Drinking behavior CUX2 intron 21372407 rs3809291 chr12 111645043 A G 3.94E-05 Coronary heart disease CUX2 intron 21971053 rs3809290 chr12 111647453 C T 7.40E-06 Drinking behavior CUX2 intron 21372407 rs3809290 chr12 111647453 C T 2.43E-05 Coronary heart disease CUX2 intron 21971053 rs1034603 chr12 111649344 A G 6.50E-06 Drinking behavior CUX2 intron 21372407 rs1034603 chr12 111649344 A G 3.00E-05 Coronary heart disease CUX2 intron 21971053 rs1034603 chr12 111649344 A G 2.87E-08 Response to alcohol consumption (flushing response) CUX2 intron 24277619 rs3809288 chr12 111652522 G A 3.40E-04 Drinking behavior CUX2 intron 21372407 rs3809288 chr12 111652522 G A 2.10E-05 Coronary heart disease CUX2 intron 21971053 rs7962233 chr12 111655513 C T 4.51E-05 Type 1 diabetes CUX2 intron 18978792 rs4766556 chr12 111659074 T C 1.20E-04 Drinking behavior CUX2 intron 21372407 rs4766556 chr12 111659074 T C 2.88E-05 Coronary heart disease CUX2 intron 21971053 rs7971185 chr12 111660599 G T 2.09E-08 Response to alcohol consumption (flushing response) CUX2 intron 24277619 rs4766558 chr12 111664061 T G 1.30E-04 Drinking behavior CUX2 intron 21372407 rs4766558 chr12 111664061 T G 1.76E-04 Coronary heart disease CUX2 intron 21971053 rs4766559 chr12 111666984 C T 7.20E-08 Drinking behavior CUX2 intron 21372407 rs4766559 chr12 111666984 C T 1.49E-06 Coronary heart disease CUX2 intron 21971053 rs4766451 chr12 111670682 G T 5.28E-04 Multiple complex diseases CUX2 intron 17554300 rs4766451 chr12 111670682 G T 8.49E-06 Response to alcohol consumption (flushing response) CUX2 intron 24277619 rs886126 chr12 111679214 C T 3.82E-04 Multiple complex diseases CUX2 intron 17554300 rs886126 chr12 111679214 C T 1.00E-06 Coronary heart disease CUX2 intron 23364394 rs2078851 chr12 111690579 T C 3.91E-05 Multiple complex diseases CUX2 intron 17554300 rs2078851 chr12 111690579 T C 5.01E-06 Type 1 diabetes CUX2 intron 18978792 rs4766453 chr12 111692124 C T 8.79E-09 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CUX2 intron 20877124 rs4766453 chr12 111692124 C T 1.50E-05 Drinking behavior CUX2 intron 21372407 rs4766453 chr12 111692124 C T 1.39E-06 Alcohol dependence CUX2 intron 24277619 rs4766453 chr12 111692124 C T 2.90E-05 Alcohol consumption (maxi-drinks) CUX2 intron 24277619 rs4766453 chr12 111692124 C T 6.20E-05 Response to alcohol consumption (flushing response) CUX2 intron 24277619 rs6490029 chr12 111698457 G A 4.76E-14 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CUX2 intron 20877124 rs6490029 chr12 111698457 G A 6.40E-13 Drinking behavior CUX2 intron 21372407 rs6490029 chr12 111698457 G A 1.82E-05 Coronary heart disease CUX2 intron 21971053 rs6490029 chr12 111698457 G A 1.33E-04 Alcohol dependence CUX2 intron 24277619 rs6490029 chr12 111698457 G A 6.84E-10 Alcohol consumption (maxi-drinks) CUX2 intron 24277619 rs6490029 chr12 111698457 G A 9.83E-14 Response to alcohol consumption (flushing response) CUX2 intron 24277619 rs4766566 chr12 111706877 C T 3.38E-14 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CUX2 intron 20877124 rs4766566 chr12 111706877 C T 8.40E-16 Drinking behavior CUX2 intron 21372407 rs4766566 chr12 111706877 C T 6.06E-07 Coronary heart disease CUX2 intron 21971053 rs4766566 chr12 111706877 C T 2.60E-05 Alcohol dependence CUX2 intron 24277619 rs4766566 chr12 111706877 C T 7.21E-15 Response to alcohol consumption (flushing response) CUX2 intron 24277619 rs4766566 chr12 111706877 C T 8.75E-12 Alcohol consumption (maxi-drinks) CUX2 intron 24277619 rs4766567 chr12 111707556 G A 1.25E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CUX2 intron 20877124 rs4766567 chr12 111707556 G A 5.20E-07 Drinking behavior CUX2 intron 21372407 rs3809282 chr12 111707797 C T 1.13E-04 Coronary heart disease CUX2 intron 21971053 rs1265564 chr12 111708458 A C 1.00E-16 Type 1 diabetes CUX2 intron 22293688 rs1265566 chr12 111716376 C T 5.86E-08 Multiple complex diseases CUX2 intron 17554300 rs1265566 chr12 111716376 C T 1.00E-04 Drinking behavior CUX2 intron 21372407 rs1265566 chr12 111716376 C T 1.73E-07 Red blood cell traits CUX2 intron 23222517 rs3809278 chr12 111725185 C A 5.60E-04 Drinking behavior CUX2 intron 21372407 rs2301658 chr12 111733274 C T 4.21E-04 Multiple complex diseases CUX2 intron 17554300 rs7300082 chr12 111737115 T C 2.60E-06 Urinary metabolites CUX2 intron 21572414 rs10849930 chr12 111739236 T C 2.10E-04 Drinking behavior CUX2 intron 21372407 rs3809277 chr12 111743047 G T 3.10E-05 Drinking behavior CUX2 intron 21372407 rs2879559 chr12 111750629 G A 3.75E-04 Response to alcohol consumption (flushing response) CUX2 intron 24277619 rs7300860 chr12 111754597 T C 1.72E-04 Multiple complex diseases CUX2 intron 17554300 rs7300860 chr12 111754597 T C 9.61E-06 Type 1 diabetes CUX2 intron 18978792 rs7970490 chr12 111756438 A G 7.53E-05 Fibrinogen CUX2 intron pha003068 rs3847953 chr12 111765464 C T 5.17E-05 Magnesium levels CUX2 intron pha003092 rs61507607 chr12 111767994 A G 0.0000585 Menopause (age at onset) CUX2 intron 23424626 rs7398833 chr12 111786892 T C 4.60E-07 Multiple complex diseases CUX2 UTR-3 17554300 rs10219736 chr12 111788402 C T 1.10E-04 Drinking behavior CUX2 nearGene-3 21372407 rs10219736 chr12 111788402 C T 7.73E-05 Coronary heart disease CUX2 nearGene-3 21971053 rs11065884 chr12 111818701 A G 2.55E-09 Red blood cell traits / / 23222517 rs10849944 chr12 111825389 T C 2.35E-09 Red blood cell traits / / 23222517 rs7302763 chr12 111827569 C T 7.88E-09 Red blood cell traits / / 23222517 rs10849946 chr12 111830485 G C 2.17E-07 Multiple complex diseases / / 17554300 rs10849946 chr12 111830485 G C 2.19E-09 Red blood cell traits / / 23222517 rs4766573 chr12 111830809 C A 6.19E-09 Red blood cell traits / / 23222517 rs10774623 chr12 111833589 A G 9.50E-04 Iris characteristics / / 21835309 rs10774623 chr12 111833589 A G 2.87E-05 Attention deficit hyperactivity disorder / / 22420046 rs10774623 chr12 111833589 A G 9.91E-09 Red blood cell traits / / 23222517 rs10774624 chr12 111833788 G A 6.80E-09 Rheumatoid arthritis / / 24390342 rs10774624 chr12 111833788 G A 7.00E-09 Rheumatoid arthritis / / 24390342 rs12580300 chr12 111849271 G A 3.72E-08 Red blood cell traits SH2B3 intron 23222517 rs7309325 chr12 111849515 G T 0.0000254 Primary biliary cirrhosis SH2B3 intron 22936693 rs7309325 chr12 111849515 G T 0.0000427 Primary biliary cirrhosis (anti-mitochondrial antibody positive) SH2B3 intron 22936693 rs2078863 chr12 111857487 T C 6.50E-05 Response to alcohol consumption (flushing response) SH2B3 intron 24277619 rs11065898 chr12 111862575 C T 1.41E-05 Multiple complex diseases SH2B3 intron 17554300 rs11065898 chr12 111862575 C T 1.96E-08 Red blood cell traits SH2B3 intron 23222517 rs2283358 chr12 111865565 C T 4.10E-08 Red blood cell traits SH2B3 intron 23222517 rs7296313 chr12 111878526 T C 2.74E-08 Red blood cell traits SH2B3 intron 23222517 rs2239195 chr12 111881309 G T 5.95E-08 Red blood cell traits SH2B3 intron 23222517 rs2238154 chr12 111882485 C A 5.54E-08 Red blood cell traits SH2B3 intron 23222517 rs3184504 chr12 111884608 T C 7.00E-19 Eosinophil counts SH2B3 missense 19198610 rs3184504 chr12 111884608 T C 3.00E-14 Diastolic blood pressure SH2B3 missense 19430479 rs3184504 chr12 111884608 T C 5.00E-09 Systolic blood pressure SH2B3 missense 19430479 rs3184504 chr12 111884608 T C 3.00E-27 Type 1 diabetes SH2B3 missense 19430480 rs3184504 chr12 111884608 T C 3.67E-09 Other erythrocyte phenotypes SH2B3 missense 19862010 rs3184504 chr12 111884608 T C 2.17E-06 Lipid levels SH2B3 missense 19913121 rs3184504 chr12 111884608 T C 6.00E-06 Rheumatoid arthritis SH2B3 missense 20453842 rs3184504 chr12 111884608 T C 1.50E-06 Blood cell counts and traits,in red and white blood cells SH2B3 missense 21153663 rs3184504 chr12 111884608 T C 3.20E-07 Blood cell counts and traits,in red and white blood cells SH2B3 missense 21153663 rs3184504 chr12 111884608 T C 3.00E-14 Coronary heart disease SH2B3 missense 21347282 rs3184504 chr12 111884608 T C 6.00E-06 Coronary heart disease SH2B3 missense 21378990 rs3184504 chr12 111884608 T C 1.40E-11 Celiac disease and Rheumatoid arthritis SH2B3 missense 21383967 rs3184504 chr12 111884608 T C 2.90E-17 Soluble ICAM-1 SH2B3 missense 21533024 rs3184504 chr12 111884608 T C 2.00E-38 Type 1 diabetes autoantibodies SH2B3 missense 21829393 rs3184504 chr12 111884608 T C 3.64E-18 Blood pressure SH2B3 missense 21909110 rs3184504 chr12 111884608 T C 4.00E-25 Diastolic blood pressure SH2B3 missense 21909115 rs3184504 chr12 111884608 T C 1.77E-21 Type 1 diabetes SH2B3 missense 21980299 rs3184504 chr12 111884608 T C 5.40E-21 Celiac disease SH2B3 missense 22057235 rs3184504 chr12 111884608 T C 1.00E-26 Platelet counts SH2B3 missense 22139419 rs3184504 chr12 111884608 T C 3.00E-12 Hypothyroidism SH2B3 missense 22493691 rs3184504 chr12 111884608 T C 0.00046 Primary sclerosing cholangitis SH2B3 missense 22521342 rs3184504 chr12 111884608 T C 4.12E-06 Vitiligo SH2B3 missense 22561518 rs3184504 chr12 111884608 T C 6.35E-06 Pericardial fat SH2B3 missense 22589742 rs3184504 chr12 111884608 T C 1.11E-08 Primary biliary cirrhosis SH2B3 missense 22961000 rs3184504 chr12 111884608 T C 1.30E-11 LDL cholesterol SH2B3 missense 23063622 rs3184504 chr12 111884608 T C 2.14E-11 Cholesterol,total SH2B3 missense 23063622 rs3184504 chr12 111884608 T C 0.00000323 Coronary artery disease (CAD) (males) SH2B3 missense 23202125 rs3184504 chr12 111884608 T C 0.00000497 HDL cholesterol SH2B3 missense 23202125 rs3184504 chr12 111884608 T C 0.0000811 Coronary artery disease (CAD) (females) SH2B3 missense 23202125 rs3184504 chr12 111884608 T C 0.00013 Body mass index SH2B3 missense 23202125 rs3184504 chr12 111884608 T C 1.58E-10 Coronary artery disease (CAD) age >50 SH2B3 missense 23202125 rs3184504 chr12 111884608 T C 1.69E-09 Systolic blood pressure SH2B3 missense 23202125 rs3184504 chr12 111884608 T C 1.73E-09 LDL cholesterol SH2B3 missense 23202125 rs3184504 chr12 111884608 T C 1.74E-11 Coronary artery disease SH2B3 missense 23202125 rs3184504 chr12 111884608 T C 2.33E-14 Diastolic blood pressure SH2B3 missense 23202125 rs3184504 chr12 111884608 T C 2.69E-11 Cholesterol,total SH2B3 missense 23202125 rs3184504 chr12 111884608 T C 4.00E-19 Red blood cell traits SH2B3 missense 23222517 rs3184504 chr12 111884608 T C 2.60E-10 Urate levels SH2B3 missense 23263486 rs3184504 chr12 111884608 T C 1.48E-07 Tetralogy of Fallot SH2B3 missense 23297363 rs3184504 chr12 111884608 T C 3.00E-08 Beta-2 microglubulin plasma levels SH2B3 missense 23417110 rs3184504 chr12 111884608 T C 0.000000396 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis SH2B3 missense 23603761 rs3184504 chr12 111884608 T C 0.0000711 Oligoarticular juvenile idiopathic arthritis SH2B3 missense 23603761 rs3184504 chr12 111884608 T C 2.60E-09 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) SH2B3 missense 23603761 rs3184504 chr12 111884608 T C 5.91E-11 Primary sclerosing cholangitis SH2B3 missense 23603763 rs3184504 chr12 111884608 T C 5.82E-05 Self-reported allergy SH2B3 missense 23817569 rs3184504 chr12 111884608 T C 5.00E-11 Platelet counts SH2B3 missense 24026423 rs3184504 chr12 111884608 T C 1.01E-06 Stroke (ischemic) SH2B3 missense 24262325 rs3184504 chr12 111884608 T C 1.50E-04 Large artery stroke SH2B3 missense 24262325 rs3184504 chr12 111884608 T C 9.00E-07 Coronary artery disease SH2B3 missense 24262325 rs3184504 chr12 111884608 T C 8.00E-08 Autoimmune hepatitis type-1 SH2B3 missense 24768677 rs3184504 chr12 111884608 T C 6.00E-18 Blood metabolite levels SH2B3 missense 24816252 rs739496 chr12 111887659 A G 1.67E-06 Multiple complex diseases SH2B3 UTR-3 17554300 rs739496 chr12 111887659 A G 4.75E-19 Blood cell counts and other traits SH2B3 UTR-3 20139978 rs739496 chr12 111887659 A G 5.00E-19 Blood cell counts and other traits SH2B3 UTR-3 20139978 rs739496 chr12 111887659 A G 1.20E-05 Urinary metabolites SH2B3 UTR-3 21572414 rs739496 chr12 111887659 A G 4.75E-19 Hepatitis B SH2B3 UTR-3 21750111 rs739496 chr12 111887659 A G 8.92E-06 Attention deficit hyperactivity disorder SH2B3 UTR-3 22420046 rs739496 chr12 111887659 A G 4.75E-19 Mean platelet volume SH2B3 UTR-3 22423221 rs739496 chr12 111887659 A G 3.59E-08 Red blood cell traits SH2B3 UTR-3 23222517 rs10849949 chr12 111893537 A G 9.70E-06 Urinary metabolites ATXN2 intron 21572414 rs10849949 chr12 111893537 A G 8.62E-08 Red blood cell traits ATXN2 intron 23222517 rs2073950 chr12 111894072 C T 1.60E-05 Urinary metabolites ATXN2 intron 21572414 rs2073950 chr12 111894072 C T 7.27E-08 Red blood cell traits ATXN2 intron 23222517 rs2073950 chr12 111894072 C T 4.44E-04 Response to alcohol consumption (flushing response) ATXN2 intron 24277619 rs2301622 chr12 111895203 C G 9.22E-08 Red blood cell traits ATXN2 intron 23222517 rs2301621 chr12 111895272 C T 1.31E-05 Attention deficit hyperactivity disorder ATXN2 intron 22420046 rs2301621 chr12 111895272 C T 6.88E-08 Red blood cell traits ATXN2 intron 23222517 rs4766578 chr12 111904371 T A 5.30E-10 Other erythrocyte phenotypes ATXN2 intron 19862010 rs4766578 chr12 111904371 T A 4.00E-18 Vitiligo ATXN2 intron 22561518 rs4766578 chr12 111904371 T A 5.25E-18 Red blood cell traits ATXN2 intron 23222517 rs4766578 chr12 111904371 T A 1.68E-08 Urate levels ATXN2 intron 23263486 rs4766578 chr12 111904371 T A 8.91E-05 Self-reported allergy ATXN2 intron 23817569 rs10774625 chr12 111910219 A G 4.88E-10 Other erythrocyte phenotypes ATXN2 intron 19862010 rs10774625 chr12 111910219 A G 2.00E-13 Retinal vascular caliber ATXN2 intron 21060863 rs10774625 chr12 111910219 A G 8.57E-18 Red blood cell traits ATXN2 intron 23222517 rs10774625 chr12 111910219 A G 1.14E-09 Urate levels ATXN2 intron 23263486 rs10774625 chr12 111910219 A G 9.79E-05 Self-reported allergy ATXN2 intron 23817569 rs10849952 chr12 111911285 T C 8.10E-05 Response to alcohol consumption (flushing response) ATXN2 intron 24277619 rs2339816 chr12 111912188 T C 1.41E-07 Red blood cell traits ATXN2 intron 23222517 rs2285518 chr12 111923417 A G 4.70E-05 Response to alcohol consumption (flushing response) ATXN2 intron 24277619 rs1029388 chr12 111926901 T C 7.30E-06 Urinary metabolites ATXN2 intron 21572414 rs1029388 chr12 111926901 T C 3.44E-07 Red blood cell traits ATXN2 intron 23222517 rs7137828 chr12 111932800 C T 1.61E-09 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) ATXN2 intron 23603761 rs2238153 chr12 111939547 G A 4.59E-04 Multiple complex diseases ATXN2 intron 17554300 rs6490162 chr12 111941120 T C 1.40E-05 Attention deficit hyperactivity disorder ATXN2 intron 22420046 rs6490162 chr12 111941120 T C 2.41E-07 Red blood cell traits ATXN2 intron 23222517 rs6490162 chr12 111941120 T C 6.65E-04 Response to alcohol consumption (flushing response) ATXN2 intron 24277619 rs628825 chr12 111951850 C T 1.81E-07 Red blood cell traits ATXN2 intron 23222517 rs630512 chr12 111952167 C T 2.34E-05 Attention deficit hyperactivity disorder ATXN2 intron 22420046 rs630512 chr12 111952167 C T 1.97E-07 Red blood cell traits ATXN2 intron 23222517 rs688812 chr12 111962581 C T 1.62E-07 Red blood cell traits ATXN2 intron 23222517 rs657197 chr12 111965658 C A 1.90E-07 Red blood cell traits ATXN2 intron 23222517 rs607316 chr12 111969448 C T 1.63E-05 Attention deficit hyperactivity disorder ATXN2 intron 22420046 rs607316 chr12 111969448 C T 2.39E-07 Red blood cell traits ATXN2 intron 23222517 rs616668 chr12 111974280 T G 8.62E-06 Attention deficit hyperactivity disorder ATXN2 intron 22420046 rs616668 chr12 111974280 T G 2.37E-07 Red blood cell traits ATXN2 intron 23222517 rs648997 chr12 111976776 C T 1.42E-08 Red blood cell traits ATXN2 intron 23222517 rs625093 chr12 111988432 A G 1.78E-07 Red blood cell traits ATXN2 intron 23222517 rs638791 chr12 111989236 A G 1.74E-07 Red blood cell traits ATXN2 intron 23222517 rs638791 chr12 111989236 A G 7.63E-04 Response to alcohol consumption (flushing response) ATXN2 intron 24277619 rs7969300 chr12 111993712 C T 1.64E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ATXN2 missense 20877124 rs7969300 chr12 111993712 C T 2.20E-04 Drinking behavior ATXN2 missense 21372407 rs7969300 chr12 111993712 C T 2.73E-19 Alcohol (ever vs. never) ATXN2 missense 23555315 rs593226 chr12 111993886 A G 1.58E-08 Red blood cell traits ATXN2 intron 23222517 rs616559 chr12 112003350 T C 3.53E-06 Multiple complex diseases ATXN2 intron 17554300 rs616559 chr12 112003350 T C 9.70E-06 Urinary metabolites ATXN2 intron 21572414 rs616559 chr12 112003350 T C 4.28E-07 Red blood cell traits ATXN2 intron 23222517 rs616513 chr12 112003383 G T 4.18E-07 Red blood cell traits ATXN2 intron 23222517 rs653178 chr12 112007756 C T 8.00E-08 Celiac disease ATXN2 intron 18311140 rs653178 chr12 112007756 C T 3.00E-18 Diastolic blood pressure ATXN2 intron 19430483 rs653178 chr12 112007756 C T 2.23E-09 Other erythrocyte phenotypes ATXN2 intron 19862010 rs653178 chr12 112007756 C T 7.00E-21 Celiac disease ATXN2 intron 20190752 rs653178 chr12 112007756 C T 4.00E-11 Chronic kidney disease ATXN2 intron 20383146 rs653178 chr12 112007756 C T 7.00E-21 Asthma ATXN2 intron 21150878 rs653178 chr12 112007756 C T 3.00E-18 Coronary heart disease ATXN2 intron 21347282 rs653178 chr12 112007756 C T 3.00E-18 Blood pressure ATXN2 intron 21378095 rs653178 chr12 112007756 C T 3.00E-19 Celiac disease and Rheumatoid arthritis ATXN2 intron 21383967 rs653178 chr12 112007756 C T 3.20E-17 Soluble ICAM-1 ATXN2 intron 21533024 rs653178 chr12 112007756 C T 7.00E-20 Blood pressure ATXN2 intron 21909110 rs653178 chr12 112007756 C T 7.15E-21 Multiple sclerosis ATXN2 intron 22190364 rs653178 chr12 112007756 C T 7.63E-05 Attention deficit hyperactivity disorder ATXN2 intron 22420046 rs653178 chr12 112007756 C T 5.00E-12 Hypothyroidism ATXN2 intron 22493691 rs653178 chr12 112007756 C T 1.41E-17 Red blood cell traits ATXN2 intron 23222517 rs653178 chr12 112007756 C T 7.00E-12 Urate levels ATXN2 intron 23263486 rs653178 chr12 112007756 C T 1.08E-07 Tetralogy of Fallot ATXN2 intron 23297363 rs653178 chr12 112007756 C T 8.20E-10 Glomerular filtration rate ATXN2 intron 23535967 rs653178 chr12 112007756 C T 9.85E-05 Self-reported allergy ATXN2 intron 23817569 rs653178 chr12 112007756 C T 1.00E-07 Thyroid peroxidase antibody levels ATXN2 intron 24586183 rs653178 chr12 112007756 C T 1.00E-09 Thyroid peroxidase antibody positivity ATXN2 intron 24586183 rs653178 chr12 112007756 C T 6.00E-07 Peripheral artery disease ATXN2 intron 25009551 rs12369009 chr12 112019799 G T 7.47E-07 Red blood cell traits ATXN2 intron 23222517 rs695871 chr12 112037000 G C 4.90E-07 Red blood cell traits ATXN2 missense 23222517 rs3809274 chr12 112044333 G C 0.000000514 Coronary artery disease / / 23202125 rs3809274 chr12 112044333 G C 2.08E-07 Red blood cell traits / / 23222517 rs11065979 chr12 112059557 C T 2.87E-09 Primary biliary cirrhosis / / 22961000 rs1544396 chr12 112062875 T C 1.45E-06 Multiple complex diseases / / 17554300 rs1544396 chr12 112062875 T C 4.60E-04 Iris characteristics / / 21835309 rs9300319 chr12 112064897 T C 2.60E-07 Red blood cell traits / / 23222517 rs10849964 chr12 112068438 A G 4.81E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs10849964 chr12 112068438 A G 8.00E-05 Response to alcohol consumption (flushing response) / / 24277619 rs11065987 chr12 112072424 A G 1.00E-11 Hemoglobin / / 19862010 rs11065987 chr12 112072424 A G 1.00E-12 Hematocrit / / 19862010 rs11065987 chr12 112072424 A G 2.00E-09 LDL cholesterol / / 20686565 rs11065987 chr12 112072424 A G 7.00E-12 Cholesterol,total / / 20686565 rs11065987 chr12 112072424 A G 2.20E-04 Metabolic syndrome phenotype / / 22022282 rs11065987 chr12 112072424 A G 2.90E-10 Metabolic syndrome phenotype / / 22022282 rs11065987 chr12 112072424 A G 2.20E-13 Mean platelet volume / / 22423221 rs11065987 chr12 112072424 A G 1.70E-10 Hypothyroidism / / 22493691 rs11065987 chr12 112072424 A G 1.73E-13 Red blood cell traits / / 23222517 rs11065987 chr12 112072424 A G 2.58E-08 Urate levels / / 23263486 rs11065987 chr12 112072424 A G 8.00E-11 Tetralogy of Fallot / / 23297363 rs11065987 chr12 112072424 A G 3.69E-05 Self-reported allergy / / 23817569 rs11065987 chr12 112072424 A G 1.00E-11 LDL cholesterol / / 24097068 rs11065987 chr12 112072424 A G 2.00E-16 Cholesterol,total / / 24097068 rs11065987 chr12 112072424 A G 3.00E-10 Coronary artery disease or large artery stroke / / 24262325 rs11065987 chr12 112072424 A G 4.00E-14 Coronary artery disease or ischemic stroke / / 24262325 rs3809276 chr12 112073916 A G 2.49E-07 Red blood cell traits / / 23222517 rs10744773 chr12 112086810 C A 1.49E-07 Red blood cell traits BRAP intron 23222517 rs7977828 chr12 112094766 A G 3.14E-07 Red blood cell traits BRAP intron 23222517 rs3742001 chr12 112103148 C T 1.70E-07 Red blood cell traits BRAP intron 23222517 rs3782886 chr12 112110489 T C 5.00E-09 Blood cell counts and other traits BRAP cds-synon 20139978 rs3782886 chr12 112110489 T C 5.49E-09 Blood cell counts and other traits BRAP cds-synon 20139978 rs3782886 chr12 112110489 T C 6.96E-19 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BRAP cds-synon 20877124 rs3782886 chr12 112110489 T C 7.60E-10 Myocardial infarction BRAP cds-synon 21107343 rs3782886 chr12 112110489 T C 2.20E-25 Drinking behavior BRAP cds-synon 21372407 rs3782886 chr12 112110489 T C 9.03E-12 Esophageal cancer BRAP cds-synon 21642993 rs3782886 chr12 112110489 T C 5.49E-09 Hepatitis B BRAP cds-synon 21750111 rs3782886 chr12 112110489 T C 7.34E-11 Coronary heart disease BRAP cds-synon 21971053 rs3782886 chr12 112110489 T C 2.62E-05 Schizophrenia BRAP cds-synon 22037552 rs3782886 chr12 112110489 T C 4.42E-33 Drinking behavior BRAP cds-synon 23364009 rs3782886 chr12 112110489 T C 7.83E-11 Coronary heart disease BRAP cds-synon 23364394 rs3782886 chr12 112110489 T C 2.17E-09 Alcohol consumption BRAP cds-synon 23555315 rs3782886 chr12 112110489 T C 4.48E-77 Alcohol (ever vs. never) BRAP cds-synon 23555315 rs3782886 chr12 112110489 T C 1.95E-16 Alcohol consumption (maxi-drinks) BRAP cds-synon 24277619 rs3782886 chr12 112110489 T C 4.55E-08 Alcohol dependence BRAP cds-synon 24277619 rs3782886 chr12 112110489 T C 9.31E-26 Response to alcohol consumption (flushing response) BRAP cds-synon 24277619 rs3782886 chr12 112110489 T C 1.00E-14 Myocardial infarction BRAP cds-synon 24916648 rs3782886 chr12 112110489 T C 1.14E-14 Myocardial infarction BRAP cds-synon 24916648 rs7136874 chr12 112113658 C T 9.38E-07 Multiple complex diseases BRAP intron 17554300 rs7136874 chr12 112113658 C T 4.12E-07 Red blood cell traits BRAP intron 23222517 rs847895 chr12 112118576 T C 2.54E-07 Red blood cell traits BRAP intron 23222517 rs11066001 chr12 112119171 T C 5.92E-12 Esophageal cancer BRAP intron 21642993 rs11066001 chr12 112119171 T C 1.07E-15 Coronary heart disease BRAP intron 21971053 rs11066001 chr12 112119171 T C 7.83E-11 Coronary heart disease BRAP intron 23364394 rs601663 chr12 112123284 A G 2.20E-06 Multiple complex diseases BRAP intron 17554300 rs601663 chr12 112123284 A G 8.10E-06 Urinary metabolites BRAP intron 21572414 rs649406 chr12 112126065 T C 1.49E-07 Red blood cell traits ACAD10 intron 23222517 rs659964 chr12 112130199 G C 3.27E-07 Multiple complex diseases ACAD10 intron 17554300 rs659964 chr12 112130199 G C 9.80E-07 Red blood cell traits ACAD10 intron 23222517 rs617044 chr12 112132875 T C 3.03E-07 Red blood cell traits ACAD10 intron 23222517 rs11066008 chr12 112140669 A G 3.92E-11 Esophageal cancer ACAD10 intron 21642993 rs642898 chr12 112141233 A G 6.43E-07 Red blood cell traits ACAD10 intron 23222517 rs627308 chr12 112146555 C A 5.27E-05 Multiple complex diseases ACAD10 intron 17554300 rs609230 chr12 112146911 C T 1.77E-06 Multiple complex diseases ACAD10 intron 17554300 rs609230 chr12 112146911 C T 3.34E-07 Red blood cell traits ACAD10 intron 23222517 rs608848 chr12 112146964 C T 1.01E-06 Multiple complex diseases ACAD10 intron 17554300 rs608848 chr12 112146964 C T 4.90E-06 Urinary metabolites ACAD10 intron 21572414 rs608848 chr12 112146964 C T 8.13E-07 Red blood cell traits ACAD10 intron 23222517 rs630616 chr12 112158966 T C 4.07E-07 Red blood cell traits ACAD10 intron 23222517 rs847898 chr12 112163646 T C 2.21E-06 Multiple complex diseases ACAD10 intron 17554300 rs847898 chr12 112163646 T C 8.84E-05 Bipolar disorder ACAD10 intron 20451256 rs634389 chr12 112164715 C G 6.20E-06 Multiple complex diseases ACAD10 intron 17554300 rs634389 chr12 112164715 C G 9.69E-05 Bipolar disorder ACAD10 intron 20451256 rs634389 chr12 112164715 C G 2.33E-07 Red blood cell traits ACAD10 intron 23222517 rs11066015 chr12 112168009 G A 7.00E-21 Esophageal cancer ACAD10 intron 21642993 rs11066015 chr12 112168009 G A 5.00E-11 Coronary heart disease ACAD10 intron 23364394 rs11066015 chr12 112168009 G A 1.73E-85 Alcohol (ever vs. never) ACAD10 intron 23555315 rs11066015 chr12 112168009 G A 4.28E-09 Alcohol consumption ACAD10 intron 23555315 rs640783 chr12 112168050 A G 2.13E-06 Multiple complex diseases ACAD10 intron 17554300 rs640783 chr12 112168050 A G 1.92E-07 Red blood cell traits ACAD10 intron 23222517 rs7962138 chr12 112180177 A G 4.30E-07 Red blood cell traits ACAD10 intron 23222517 rs11066019 chr12 112183887 A G 2.10E-05 Response to alcohol consumption (flushing response) ACAD10 intron 24277619 rs11066019 chr12 112183887 A G 5.31E-04 Alcohol consumption (maxi-drinks) ACAD10 intron 24277619 rs6490294 chr12 112190438 C A 5.17E-06 Multiple complex diseases ACAD10 intron 17554300 rs6490294 chr12 112190438 C A 5.00E-09 Mean platelet volume ACAD10 intron 22423221 rs10849969 chr12 112199080 C T 4.14E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs371486573 chr12 112199080 CGA C 4.14E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4767944 chr12 112209341 C T 4.14E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ALDH2 intron 20877124 rs2238151 chr12 112211833 T C 1.00E-06 Stroke (ischemic) ALDH2 intron 23041239 rs4648328 chr12 112222788 C T 3.19E-07 Red blood cell traits ALDH2 intron 23222517 rs440 chr12 112228714 T C 1.40E-04 Iris characteristics ALDH2 intron 21835309 rs4646776 chr12 112230019 G C 9.08E-11 Esophageal cancer ALDH2 intron 21642993 rs4646776 chr12 112230019 G C 5.17E-35 Drinking behavior ALDH2 intron 23364009 rs10744777 chr12 112233018 T C 3.61E-07 Multiple complex diseases ALDH2 intron 17554300 rs10744777 chr12 112233018 T C 2.70E-05 Urinary metabolites ALDH2 intron 21572414 rs10744777 chr12 112233018 T C 2.00E-05 Coronary heart disease ALDH2 intron 21966275 rs4646778 chr12 112235783 C A 5.39E-04 Response to alcohol consumption (flushing response) ALDH2 intron 24277619 rs4767035 chr12 112239141 A C 2.60E-05 Response to alcohol consumption (flushing response) ALDH2 intron 24277619 rs671 chr12 112241766 G A 1 Drug response to Ethanol ALDH2 missense 11375898 rs671 chr12 112241766 G A 1 Drug response to Ethanol ALDH2 missense 12213289 rs671 chr12 112241766 G A 1 Drug response to Ethanol ALDH2 missense 12419833 rs671 chr12 112241766 G A 1 Drug response to Ethanol ALDH2 missense 16054979 rs671 chr12 112241766 G A 1 Drug response to Ethanol ALDH2 missense 18033686 rs671 chr12 112241766 G A 1 Drug response to Ethanol ALDH2 missense 18322963 rs671 chr12 112241766 G A 1 Drug response to Ethanol ALDH2 missense 19452585 rs671 chr12 112241766 G A 3.00E-24 Esophageal cancer ALDH2 missense 19698717 rs671 chr12 112241766 G A 4.50E-09 Blood cell counts and other traits ALDH2 missense 20139978 rs671 chr12 112241766 G A 5.00E-09 Blood cell counts and other traits ALDH2 missense 20139978 rs671 chr12 112241766 G A 7.25E-10 Blood cell counts and other traits ALDH2 missense 20139978 rs671 chr12 112241766 G A 3.00E-24 Nasopharyngeal carcinoma ALDH2 missense 20512145 rs671 chr12 112241766 G A 5.50E-62 Esophageal cancer (squamous cell) ALDH2 missense 20833657 rs671 chr12 112241766 G A 2.24E-68 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ALDH2 missense 20877124 rs671 chr12 112241766 G A 3.80E-27 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ALDH2 missense 20877124 rs671 chr12 112241766 G A 4.37E-50 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ALDH2 missense 20877124 rs671 chr12 112241766 G A 5.40E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ALDH2 missense 20877124 rs671 chr12 112241766 G A 7.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ALDH2 missense 20877124 rs671 chr12 112241766 G A 4.00E-211 Drinking behavior ALDH2 missense 21372407 rs671 chr12 112241766 G A 2.15E-08 Esophageal cancer ALDH2 missense 21642993 rs671 chr12 112241766 G A 4.50E-09 Hepatitis B ALDH2 missense 21750111 rs671 chr12 112241766 G A 2.00E-34 Coronary heart disease ALDH2 missense 21971053 rs671 chr12 112241766 G A 2.00E-06 Triglycerides ALDH2 missense 22171074 rs671 chr12 112241766 G A 3.00E-06 Intracranial aneurysm ALDH2 missense 22286173 rs671 chr12 112241766 G A 3.00E-10 Renal function-related traits (sCR) ALDH2 missense 22797727 rs671 chr12 112241766 G A 5.17E-35 Drinking behavior ALDH2 missense 23364009 rs671 chr12 112241766 G A 2.77E-09 Alcohol consumption ALDH2 missense 23555315 rs671 chr12 112241766 G A 6.32E-86 Alcohol (ever vs. never) ALDH2 missense 23555315 rs671 chr12 112241766 G A 1.00E-16 Alcohol consumption (maxi-drinks) ALDH2 missense 24277619 rs671 chr12 112241766 G A 5.00E-08 Alcohol dependence ALDH2 missense 24277619 rs671 chr12 112241766 G A 5.00E-26 Response to alcohol consumption (flushing response) ALDH2 missense 24277619 rs671 chr12 112241766 G A 3.00E-11 Body mass index ALDH2 missense 24861553 rs11066028 chr12 112245170 A C 2.71E-07 Red blood cell traits ALDH2 intron 23222517 rs16941669 chr12 112245637 T G 7.23E-05 Amyotrophic lateral sclerosis (sporadic) ALDH2 intron 24529757 rs7296651 chr12 112246954 C G 7.63E-06 Multiple complex diseases ALDH2 intron 17554300 rs7296651 chr12 112246954 C G 1.10E-05 Urinary metabolites ALDH2 intron 21572414 rs7296651 chr12 112246954 C G 3.80E-04 Iris characteristics ALDH2 intron 21835309 rs10849971 chr12 112251197 A G 1.78E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs10849971 chr12 112251197 A G 7.96E-06 Response to alcohol consumption (flushing response) / / 24277619 rs11066038 chr12 112258304 G A 2.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs736534 chr12 112264800 G A 7.25E-06 Response to alcohol consumption (flushing response) / / 24277619 rs736534 chr12 112264800 G A 8.58E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs3177647 chr12 112277576 C T 2.41E-06 Multiple complex diseases / / 17554300 rs3177647 chr12 112277576 C T 2.49E-04 Response to alcohol consumption (flushing response) / / 24277619 rs3213628 chr12 112280773 G T 2.49E-04 Response to alcohol consumption (flushing response) MAPKAPK5 intron 24277619 rs4767068 chr12 112281013 A G 2.30E-06 Multiple complex diseases MAPKAPK5 intron 17554300 rs4767068 chr12 112281013 A G 2.70E-05 Urinary metabolites MAPKAPK5 intron 21572414 rs4346023 chr12 112285542 T C 3.20E-06 Urinary metabolites MAPKAPK5 intron 21572414 rs11066053 chr12 112304353 G A 7.25E-06 Response to alcohol consumption (flushing response) MAPKAPK5 intron 24277619 rs11066053 chr12 112304353 G A 8.58E-04 Alcohol consumption (maxi-drinks) MAPKAPK5 intron 24277619 rs12423041 chr12 112324846 T C 2.54E-06 Multiple complex diseases MAPKAPK5 intron 17554300 rs12423041 chr12 112324846 T C 2.49E-04 Response to alcohol consumption (flushing response) MAPKAPK5 intron 24277619 rs16941724 chr12 112327057 T G 3.59E-04 Multiple complex diseases MAPKAPK5 intron 17554300 rs150495619 chr12 112330774 G A 0.00062 Prostate cancer (non-advanced prostate cancer) MAPKAPK5 missense 23555315 rs9971746 chr12 112337362 C T 8.56E-08 Multiple complex diseases / / 17554300 rs9971746 chr12 112337362 C T 2.49E-04 Response to alcohol consumption (flushing response) / / 24277619 rs3742000 chr12 112338539 T C 2.85E-06 Multiple complex diseases / / 17554300 rs12321677 chr12 112339015 G A 1.63E-06 Multiple complex diseases / / 17554300 rs16941759 chr12 112367921 G A 2.28E-06 Multiple complex diseases / / 17554300 rs1016078 chr12 112410077 C A 1.53E-06 Multiple complex diseases TMEM116 intron 17554300 rs1016078 chr12 112410077 C A 8.39E-07 Red blood cell traits TMEM116 intron 23222517 rs1016079 chr12 112410186 T G 5.37E-07 Multiple complex diseases TMEM116 intron 17554300 rs11066119 chr12 112434504 A G 8.80E-05 Multiple complex diseases TMEM116 intron 17554300 rs7307862 chr12 112437514 C T 3.74E-04 Multiple complex diseases TMEM116 intron 17554300 rs7310545 chr12 112443960 G A 2.49E-04 Response to alcohol consumption (flushing response) TMEM116 intron 24277619 rs7135514 chr12 112448485 T C 9.78E-05 Multiple complex diseases TMEM116 intron 17554300 rs11066128 chr12 112450754 T C 2.49E-04 Response to alcohol consumption (flushing response) TMEM116 intron 24277619 rs7114 chr12 112460749 A G 1.46E-04 Multiple complex diseases ERP29 UTR-3 17554300 rs4767293 chr12 112463296 A G 1.63E-07 Multiple complex diseases / / 17554300 rs4767293 chr12 112463296 A G 8.60E-06 Urinary metabolites / / 21572414 rs4767293 chr12 112463296 A G 4.58E-07 Red blood cell traits / / 23222517 rs11066132 chr12 112468206 C T 4.13E-18 Coronary heart disease /A25 intron 21971053 rs3825388 chr12 112485951 G A 1.00E-05 Response to alcohol consumption (flushing response) /A25 intron 24277619 rs3825388 chr12 112485951 G A 8.11E-04 Alcohol consumption (maxi-drinks) /A25 intron 24277619 rs17696736 chr12 112486818 A G 2.00E-16 Type 1 diabetes /A25 intron 17554260 rs17696736 chr12 112486818 A G 2.00E-14 Type 1 diabetes /A25 intron 17554300 rs17696736 chr12 112486818 A G 6.00E-18 Type 1 diabetes /A25 intron 18978792 rs17696736 chr12 112486818 A G 1.77E-09 Other erythrocyte phenotypes /A25 intron 19862010 rs17696736 chr12 112486818 A G 7.00E-06 Coronary heart disease /A25 intron 21966275 rs17696736 chr12 112486818 A G 2.00E-16 Multiple sclerosis /A25 intron 22190364 rs17696736 chr12 112486818 A G 2.80E-10 Hypothyroidism /A25 intron 22493691 rs17696736 chr12 112486818 A G 5.64E-08 LDL cholesterol /A25 intron 23063622 rs17696736 chr12 112486818 A G 8.57E-09 Cholesterol,total /A25 intron 23063622 rs17696736 chr12 112486818 A G 2.44E-11 Red blood cell traits /A25 intron 23222517 rs17696736 chr12 112486818 A G 1.44E-08 Tetralogy of Fallot /A25 intron 23297363 rs17696736 chr12 112486818 A G 6.00E-08 Stroke (ischemic) /A25 intron 24262325 rs17696736 chr12 112486818 A G 6.56E-08 Coronary artery disease /A25 intron 24262325 rs2339941 chr12 112490764 G A,C,T 2.80E-04 Iris characteristics /A25 intron 21835309 rs7959011 chr12 112501237 G A 2.49E-04 Response to alcohol consumption (flushing response) /A25 intron 24277619 rs1980364 chr12 112517642 T C 2.68E-04 Multiple complex diseases /A25 intron 17554300 rs1980364 chr12 112517642 T C 1.16E-06 Type 1 diabetes /A25 intron 18978792 rs2339973 chr12 112520883 C T 2.60E-06 Urinary metabolites /A25 intron 21572414 rs4767364 chr12 112521448 G A 2.00E-08 Upper aerodigestive tract cancers /A25 intron 21437268 rs11066173 chr12 112554667 A G 7.25E-06 Response to alcohol consumption (flushing response) / / 24277619 rs11066173 chr12 112554667 A G 8.58E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs7309841 chr12 112565053 A G 3.53E-04 Response to alcohol consumption (flushing response) TRAFD1 intron 24277619 rs7299227 chr12 112568643 T A 4.47E-04 Blood pressure TRAFD1 intron 17255346 rs7299227 chr12 112568643 T A 9.19E-06 Type 2 diabetes TRAFD1 intron 17463246 rs10850003 chr12 112571169 G A 3.64E-06 Multiple complex diseases TRAFD1 intron 17554300 rs10850003 chr12 112571169 G A 1.60E-05 Urinary metabolites TRAFD1 intron 21572414 rs12231737 chr12 112574616 C T 5.75E-12 Esophageal cancer TRAFD1 intron 21642993 rs12231737 chr12 112574616 C T 5.14E-09 Coronary heart disease TRAFD1 intron 23364394 rs882919 chr12 112586362 G T 2.60E-05 Response to alcohol consumption (flushing response) TRAFD1 intron 24277619 rs17630235 chr12 112591686 G A 5.70E-10 Other erythrocyte phenotypes / / 19862010 rs17630235 chr12 112591686 G A 5.20E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17630235 chr12 112591686 G A 4.44E-09 Coronary artery disease / / 23202125 rs17630235 chr12 112591686 G A 2.57E-12 Red blood cell traits / / 23222517 rs17630235 chr12 112591686 G A 2.03E-04 Self-reported allergy / / 23817569 rs3519 chr12 112598321 G A 7.00E-04 Multiple complex diseases C12orf51 UTR-3 17554300 rs3519 chr12 112598321 G A 9.36E-06 Type 1 diabetes C12orf51 UTR-3 18978792 rs2242496 chr12 112605611 T C 2.60E-05 Response to alcohol consumption (flushing response) C12orf51 intron 24277619 rs11066188 chr12 112610714 G A 6.24E-10 Other erythrocyte phenotypes C12orf51 intron 19862010 rs11066188 chr12 112610714 G A 3.19E-06 Primary biliary cirrhosis C12orf51 intron 21399635 rs11066188 chr12 112610714 G A 4.30E-12 Soluble ICAM-1 C12orf51 intron 21533024 rs11066188 chr12 112610714 G A 4.10E-10 Hypothyroidism C12orf51 intron 22493691 rs11066188 chr12 112610714 G A 9.35E-10 Red blood cell traits C12orf51 intron 23222517 rs11066188 chr12 112610714 G A 2.86E-09 Tetralogy of Fallot C12orf51 intron 23297363 rs11066188 chr12 112610714 G A 2.12E-04 Self-reported allergy C12orf51 intron 23817569 rs3741993 chr12 112621886 C T 3.61E-04 Response to alcohol consumption (flushing response) C12orf51 intron 24277619 rs2074356 chr12 112645401 G A 8.00E-12 Biomedical quantitative traits C12orf51 intron 19396169 rs2074356 chr12 112645401 G A 3.90E-21 Esophageal cancer (squamous cell) C12orf51 intron 20833657 rs2074356 chr12 112645401 G A 9.00E-59 Alcohol consumption C12orf51 intron 21270382 rs2074356 chr12 112645401 G A 2.00E-31 Esophageal cancer C12orf51 intron 21642993 rs2074356 chr12 112645401 G A 3.00E-126 Gamma glutamyl transpeptidase C12orf51 intron 21909109 rs2074356 chr12 112645401 G A 7.00E-37 HDL cholesterol C12orf51 intron 21909109 rs2074356 chr12 112645401 G A 1.49E-13 Coronary heart disease C12orf51 intron 21971053 rs2074356 chr12 112645401 G A 2.00E-09 Renal function-related traits (BUN) C12orf51 intron 22797727 rs2074356 chr12 112645401 G A 7.66E-40 Drinking behavior C12orf51 intron 23364009 rs2074356 chr12 112645401 G A 6.73E-11 Coronary heart disease C12orf51 intron 23364394 rs2074356 chr12 112645401 G A 6.73E-11 Major depressive disorder C12orf51 intron 23377640 rs2074356 chr12 112645401 G A 1.19E-75 Alcohol (ever vs. never) C12orf51 intron 23555315 rs2074356 chr12 112645401 G A 6.42E-08 Alcohol consumption C12orf51 intron 23555315 rs2074356 chr12 112645401 G A 1.00E-16 Glycemic traits C12orf51 intron 23575436 rs2074356 chr12 112645401 G A 6.00E-09 Glycemic traits C12orf51 intron 23575436 rs2074356 chr12 112645401 G A 6.00E-14 Glycemic traits C12orf51 intron 23575436 rs11066193 chr12 112647744 A C 2.60E-05 Response to alcohol consumption (flushing response) C12orf51 intron 24277619 rs10850016 chr12 112652523 T C 1.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C12orf51 intron 20877124 rs10850016 chr12 112652523 T C 2.60E-05 Response to alcohol consumption (flushing response) C12orf51 intron 24277619 rs1005902 chr12 112667675 T G 1.62E-06 Multiple complex diseases C12orf51 cds-synon 17554300 rs11066209 chr12 112677279 A G 1.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C12orf51 intron 20877124 rs4767530 chr12 112679176 C T 2.60E-05 Response to alcohol consumption (flushing response) C12orf51 intron 24277619 rs2301757 chr12 112703732 A C 1.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C12orf51 cds-synon 20877124 rs2301757 chr12 112703732 A C 2.60E-05 Response to alcohol consumption (flushing response) C12orf51 cds-synon 24277619 rs11066226 chr12 112707398 T C 1.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C12orf51 intron 20877124 rs2285809 chr12 112708426 T C 2.19E-04 Multiple complex diseases C12orf51 intron 17554300 rs2285809 chr12 112708426 T C 6.80E-07 Type 1 diabetes C12orf51 intron 18978792 rs12228104 chr12 112710206 T G 3.40E-05 Response to alcohol consumption (flushing response) C12orf51 intron 24277619 rs11066245 chr12 112735492 A G 2.20E-05 Response to alcohol consumption (flushing response) C12orf51 intron 24277619 rs77768175 chr12 112736118 A G 3.16E-09 Coronary heart disease C12orf51 intron 23364394 rs1859246 chr12 112740315 G A 3.62E-04 Multiple complex diseases C12orf51 intron 17554300 rs4357753 chr12 112740709 T C 3.61E-04 Response to alcohol consumption (flushing response) C12orf51 intron 24277619 rs11066247 chr12 112741811 G A 2.60E-05 Response to alcohol consumption (flushing response) C12orf51 intron 24277619 rs12229891 chr12 112747662 G A 2.60E-05 Response to alcohol consumption (flushing response) C12orf51 intron 24277619 rs7965261 chr12 112754449 G A 3.53E-04 Response to alcohol consumption (flushing response) C12orf51 intron 24277619 rs1468251 chr12 112777433 T C 7.96E-04 Multiple complex diseases C12orf51 intron 17554300 rs1468251 chr12 112777433 T C 3.84E-06 Type 1 diabetes C12orf51 intron 18978792 rs4766898 chr12 112781844 C T 3.80E-05 Response to alcohol consumption (flushing response) C12orf51 intron 24277619 rs1362036 chr12 112812282 C T 3.18E-04 Blood pressure C12orf51 intron 17255346 rs11066280 chr12 112817783 T A 2.50E-21 Esophageal cancer (squamous cell) C12orf51 intron 20833657 rs11066280 chr12 112817783 T A 1.00E-35 Blood pressure C12orf51 intron 21572416 rs11066280 chr12 112817783 T A 8.00E-31 Blood pressure C12orf51 intron 21572416 rs11066280 chr12 112817783 T A 2.00E-15 Esophageal cancer C12orf51 intron 21642993 rs11066280 chr12 112817783 T A 3.00E-63 Metabolite levels C12orf51 intron 21909109 rs11066280 chr12 112817783 T A 8.00E-22 Metabolite levels C12orf51 intron 21909109 rs11066280 chr12 112817783 T A 6.84E-17 Coronary heart disease C12orf51 intron 21971053 rs11066280 chr12 112817783 T A 2.00E-11 Coronary heart disease C12orf51 intron 22751097 rs11066280 chr12 112817783 T A 3.00E-215 Drinking behavior C12orf51 intron 23364009 rs11066280 chr12 112817783 T A 1.44E-08 Coronary heart disease C12orf51 intron 23364394 rs11066280 chr12 112817783 T A 1.44E-08 Major depressive disorder C12orf51 intron 23377640 rs11066280 chr12 112817783 T A 2.76E-09 Alcohol consumption C12orf51 intron 23555315 rs11066280 chr12 112817783 T A 2.94E-76 Alcohol (ever vs. never) C12orf51 intron 23555315 rs7311681 chr12 112817847 T G 8.60E-06 Urinary metabolites C12orf51 intron 21572414 rs16942036 chr12 112824473 C T 3.70E-05 Response to alcohol consumption (flushing response) / / 24277619 rs2233861 chr12 112843998 A T 6.22E-07 Red blood cell traits RPL6 intron 23222517 rs11066286 chr12 112844857 A G 4.17E-06 Blood pressure RPL6 intron 17255346 rs11066286 chr12 112844857 A G 9.13E-06 Type 2 diabetes RPL6 intron 17463246 rs11066301 chr12 112871372 A G 8.00E-12 Hematological parameters PTPN11 intron 19820697 rs11066301 chr12 112871372 A G 1.29E-09 Other erythrocyte phenotypes PTPN11 intron 19862010 rs11066301 chr12 112871372 A G 7.70E-12 Mean platelet volume PTPN11 intron 22423221 rs11066301 chr12 112871372 A G 3.81E-12 Red blood cell traits PTPN11 intron 23222517 rs11066308 chr12 112881996 A G 2.77E-04 Response to alcohol consumption (flushing response) PTPN11 intron 24277619 rs7976467 chr12 112887941 G C 4.47E-04 Blood pressure PTPN11 intron 17255346 rs7976467 chr12 112887941 G C 2.81E-05 Type 2 diabetes PTPN11 intron 17463246 rs11066320 chr12 112906415 A G 3.40E-08 Other erythrocyte phenotypes PTPN11 intron 19862010 rs11066320 chr12 112906415 A G 3.90E-10 Soluble ICAM-1 PTPN11 intron 21533024 rs11066320 chr12 112906415 A G 3.50E-09 Hypothyroidism PTPN11 intron 22493691 rs11066320 chr12 112906415 A G 9.96E-13 Red blood cell traits PTPN11 intron 23222517 rs11066320 chr12 112906415 A G 2.90E-08 Tetralogy of Fallot PTPN11 intron 23297363 rs12423190 chr12 112909340 T C 2.77E-04 Response to alcohol consumption (flushing response) PTPN11 intron 24277619 rs7132778 chr12 112941354 C A 3.10E-05 Response to alcohol consumption (flushing response) PTPN11 intron 24277619 rs7953150 chr12 112941571 G A 3.61E-06 Multiple complex diseases PTPN11 intron 17554300 rs7953150 chr12 112941571 G A 9.70E-06 Urinary metabolites PTPN11 intron 21572414 rs10774654 chr12 112963560 A G 4.56E-04 Multiple complex diseases / / 17554300 rs10774654 chr12 112963560 A G 8.74E-07 Type 1 diabetes / / 18978792 rs4767879 chr12 112964070 T G 5.68E-04 Multiple complex diseases / / 17554300 rs4767879 chr12 112964070 T G 2.99E-06 Type 1 diabetes / / 18978792 rs4767880 chr12 112964168 T G 7.16E-04 Multiple complex diseases / / 17554300 rs4767880 chr12 112964168 T G 2.37E-05 Type 1 diabetes / / 18978792 rs2384000 chr12 112965142 A G 6.23E-04 Multiple complex diseases / / 17554300 rs2384000 chr12 112965142 A G 1.17E-06 Type 1 diabetes / / 18978792 rs10850053 chr12 112977777 T C 2.70E-04 Multiple complex diseases / / 17554300 rs10850053 chr12 112977777 T C 3.42E-07 Type 1 diabetes / / 18978792 rs10850053 chr12 112977777 T C 4.40E-05 Cognitive function / / 24684796 rs10850061 chr12 113016553 C T 8.16E-04 Multiple complex diseases / / 17554300 rs10850061 chr12 113016553 C T 8.59E-05 Type 1 diabetes / / 18978792 rs11614063 chr12 113025661 G A 8.41E-05 Cervical cancer / / 24700089 rs11614063 chr12 113025661 G A 9.92E-05 Attention deficit hyperactivity disorder / / pha002875 rs233722 chr12 113031474 G A 7.83E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs233722 chr12 113031474 G A 1.20E-05 Drinking behavior / / 21372407 rs233722 chr12 113031474 G A 1.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs233722 chr12 113031474 G A 1.75E-09 Tetralogy of Fallot / / 23297363 rs233721 chr12 113031543 T A 8.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs233721 chr12 113031543 T A 1.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs233716 chr12 113039943 C T 1.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs233716 chr12 113039943 C T 5.40E-05 Drinking behavior / / 21372407 rs233716 chr12 113039943 C T 2.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs233716 chr12 113039943 C T 8.43E-09 Tetralogy of Fallot / / 23297363 rs1419616 chr12 113054560 G T 1.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1419616 chr12 113054560 G T 1.20E-04 Drinking behavior / / 21372407 rs41361349 chr12 113074557 C A 9.51E-04 Insulin resistance / / 21901158 rs17824620 chr12 113100994 C A 1.00E-08 Platelet counts / / 22139419 rs17824620 chr12 113100994 C A 2.00E-04 Platelet counts / / 24026423 rs232924 chr12 113104903 T C 1.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs232925 chr12 113109378 C T 8.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs4766648 chr12 113119813 G A 1.71E-05 Multiple complex diseases / / 17554300 rs1344358 chr12 113124577 A T 2.74E-05 Multiple complex diseases / / 17554300 rs1015249 chr12 113125311 G T 2.24E-05 Multiple complex diseases / / 17554300 rs2891403 chr12 113137572 A G 1.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs2891403 chr12 113137572 A G 0.000000451 Coronary artery disease / / 23202125 rs17825483 chr12 113147563 G A 2.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12314124 chr12 113157771 T C 7.43E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7312122 chr12 113158838 G A 9.00E-06 Methotrexate phramacokinetics (acute lymphoblastic leukemia) / / 19901119 rs10850071 chr12 113165852 C G 1.39E-04 Multiple complex diseases / / 17554300 rs10850071 chr12 113165852 C G 7.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs10744782 chr12 113166569 A G 8.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs3803064 chr12 113173494 G A 7.00E-06 Platelet counts / / 21507922 rs10850075 chr12 113182298 G A 7.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs739742 chr12 113184739 C A 5.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs739743 chr12 113185030 T C 5.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs1024467 chr12 113187354 C T 9.61E-04 Multiple complex diseases / / 17554300 rs1024467 chr12 113187354 C T 3.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs1011966 chr12 113190029 G T 9.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs7315519 chr12 113192927 A G 5.35E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2384032 chr12 113195605 A G 9.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs11614295 chr12 113196733 G A 5.50E-04 Myocardial infarction / / 21107343 rs3803063 chr12 113196915 C T 1.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs3803062 chr12 113196920 A G 2.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs886349 chr12 113202553 T C 8.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs11610836 chr12 113202967 C T 3.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11610836 chr12 113202967 C T 8.99E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1156817 chr12 113238728 A G 2.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPH3A intron 20877124 rs1156817 chr12 113238728 A G 9.98E-05 Neutrophil count RPH3A intron pha003095 rs10492024 chr12 113269412 A G 5.80E-07 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPH3A intron 20877124 rs10492024 chr12 113269412 A G 3.70E-05 Drinking behavior RPH3A intron 21372407 rs10492024 chr12 113269412 A G 6.95E-06 Coronary heart disease RPH3A intron 21971053 rs10492025 chr12 113273050 C T 1.10E-04 Kidney function and endocine traits RPH3A intron 17903292 rs2384068 chr12 113273531 T C 1.61E-08 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPH3A intron 20877124 rs2384068 chr12 113273531 T C 3.40E-05 Drinking behavior RPH3A intron 21372407 rs2384068 chr12 113273531 T C 2.81E-04 Coronary heart disease RPH3A intron 21971053 rs3825202 chr12 113281621 A G 4.64E-08 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPH3A intron 20877124 rs3825202 chr12 113281621 A G 9.90E-06 Drinking behavior RPH3A intron 21372407 rs3825202 chr12 113281621 A G 1.35E-06 Coronary heart disease RPH3A intron 21971053 rs3825202 chr12 113281621 A G 5.38E-04 Smoking quantity RPH3A intron 24665060 rs1029484 chr12 113285073 G A 1.88E-07 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPH3A intron 20877124 rs1029484 chr12 113285073 G A 2.10E-05 Drinking behavior RPH3A intron 21372407 rs1029484 chr12 113285073 G A 1.59E-05 Coronary heart disease RPH3A intron 21971053 rs4767019 chr12 113289070 G A 1.42E-07 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPH3A intron 20877124 rs4767019 chr12 113289070 G A 4.20E-05 Drinking behavior RPH3A intron 21372407 rs4767019 chr12 113289070 G A 1.56E-05 Coronary heart disease RPH3A intron 21971053 rs4141252 chr12 113294547 T C 1.83E-07 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPH3A intron 20877124 rs4141252 chr12 113294547 T C 3.90E-06 Drinking behavior RPH3A intron 21372407 rs4141252 chr12 113294547 T C 1.14E-04 Coronary heart disease RPH3A intron 21971053 rs2269872 chr12 113302685 G A 1.69E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPH3A intron 20877124 rs2269872 chr12 113302685 G A 3.60E-05 Drinking behavior RPH3A intron 21372407 rs3782871 chr12 113315750 A G 5.76E-04 Smoking quantity RPH3A intron 24665060 rs757399 chr12 113318053 G T 6.74E-04 Smoking quantity RPH3A intron 24665060 rs886479 chr12 113319105 A C 7.57E-04 Smoking quantity RPH3A intron 24665060 rs886476 chr12 113319471 G A 3.32E-08 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPH3A intron 20877124 rs886476 chr12 113319471 G A 5.60E-05 Drinking behavior RPH3A intron 21372407 rs886476 chr12 113319471 G A 8.40E-07 Coronary heart disease RPH3A intron 21971053 rs11609969 chr12 113322580 A G 1.24E-05 Response to cytadine analogues (cytosine arabinoside) RPH3A intron 24483146 rs11609969 chr12 113322580 A G 6.39E-05 ldl cholesterol RPH3A intron pha003076 rs10850089 chr12 113323067 C T 3.71E-08 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPH3A intron 20877124 rs10850089 chr12 113323067 C T 1.30E-04 Drinking behavior RPH3A intron 21372407 rs10850089 chr12 113323067 C T 2.38E-06 Coronary heart disease RPH3A intron 21971053 rs7958347 chr12 113325061 C T 2.62E-08 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPH3A intron 20877124 rs7958347 chr12 113325061 C T 8.70E-04 Drinking behavior RPH3A intron 21372407 rs7958347 chr12 113325061 C T 8.57E-06 Coronary heart disease RPH3A intron 21971053 rs4141253 chr12 113325629 T C 0.00026 Prostate cancer (non-advanced prostate cancer) RPH3A cds-synon 23555315 rs12177 chr12 113335425 A G 3.59E-07 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPH3A UTR-3 20877124 rs12177 chr12 113335425 A G 6.30E-04 Drinking behavior RPH3A UTR-3 21372407 rs12177 chr12 113335425 A G 7.56E-06 Coronary heart disease RPH3A UTR-3 21971053 rs2240193 chr12 113335661 C A 2.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPH3A UTR-3 20877124 rs2240193 chr12 113335661 C A 5.85E-08 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPH3A UTR-3 20877124 rs2240193 chr12 113335661 C A 1.30E-05 Drinking behavior RPH3A UTR-3 21372407 rs2240193 chr12 113335661 C A 3.04E-05 Coronary heart disease RPH3A UTR-3 21971053 rs2240192 chr12 113335687 G A 1.03E-08 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPH3A UTR-3 20877124 rs2240192 chr12 113335687 G A 4.90E-05 Drinking behavior RPH3A UTR-3 21372407 rs2240192 chr12 113335687 G A 1.01E-05 Coronary heart disease RPH3A UTR-3 21971053 rs2240191 chr12 113335731 G T 3.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPH3A UTR-3 20877124 rs2158390 chr12 113343375 C G 3.64E-04 Smoking initiation OAS1 nearGene-5 24665060 rs2660 chr12 113357442 G A 2.80E-04 Multiple complex diseases OAS1 missense 17554300 rs4767030 chr12 113359577 C T 4.58E-04 Multiple complex diseases / / 17554300 rs10850094 chr12 113360563 T C 1.16E-04 Multiple complex diseases / / 17554300 rs10774674 chr12 113361174 T C 1.96E-04 Multiple complex diseases / / 17554300 rs10850098 chr12 113362058 G C 2.99E-04 Multiple complex diseases / / 17554300 rs10774676 chr12 113362407 A G 1.60E-04 Multiple complex diseases / / 17554300 rs4766663 chr12 113362974 A G 2.09E-04 Multiple complex diseases / / 17554300 rs6489868 chr12 113363692 G C 2.06E-04 Multiple complex diseases / / 17554300 rs4766673 chr12 113365161 A G 1.41E-04 Multiple complex diseases / / 17554300 rs4766674 chr12 113365201 G T 2.32E-04 Multiple complex diseases / / 17554300 rs4766674 chr12 113365201 G T 7.03E-07 Smoking cessation / / 18519826 rs4766674 chr12 113365201 G T 8.83E-04 Smoking cessation / / 18519826 rs4766675 chr12 113365453 A T 1.48E-04 Multiple complex diseases / / 17554300 rs4766676 chr12 113365581 C T 1.99E-04 Multiple complex diseases / / 17554300 rs4766676 chr12 113365581 C T 6.43E-13 Lymphocyte counts / / 22286170 rs11066453 chr12 113365621 A G 6.00E-44 Gamma glutamyl transpeptidase / / 21909109 rs11066453 chr12 113365621 A G 5.00E-09 Glycemic traits / / 23575436 rs7315441 chr12 113365687 G T 2.17E-04 Multiple complex diseases / / 17554300 rs7134391 chr12 113366691 G A 5.92E-05 Multiple complex diseases / / 17554300 rs1859336 chr12 113367309 C T 1.27E-04 Multiple complex diseases / / 17554300 rs7132404 chr12 113368605 T C 1.62E-04 Multiple complex diseases / / 17554300 rs3803057 chr12 113368734 G A 8.89E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3803057 chr12 113368734 G A 1.20E-04 Myocardial infarction / / 21107343 rs7966314 chr12 113372539 A G 2.49E-04 Multiple complex diseases / / 17554300 rs4767040 chr12 113374017 G C 3.65E-04 Multiple complex diseases / / 17554300 rs10774679 chr12 113374748 C T 1.93E-04 Multiple complex diseases / / 17554300 rs10774679 chr12 113374748 C T 1.19E-04 Smoking cessation / / 18519826 rs10735079 chr12 113380008 G A 1.65E-04 Multiple complex diseases OAS3 intron 17554300 rs2285932 chr12 113386950 T C 7.00E-04 Multiple complex diseases / / 17554300 rs4766678 chr12 113397691 G A 9.91E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OAS3 intron 20877124 rs2072135 chr12 113399179 C T 8.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OAS3 intron 20877124 rs11066461 chr12 113402297 C T 6.80E-05 Myocardial infarction OAS3 intron 21107343 rs2072134 chr12 113409176 G A 6.00E-17 Alcohol consumption OAS3 UTR-3 21270382 rs2072134 chr12 113409176 G A 6.00E-06 HDL cholesterol OAS3 UTR-3 21909109 rs2072134 chr12 113409176 G A 1.70E-37 Alcohol (ever vs. never) OAS3 UTR-3 23555315 rs2072133 chr12 113409260 T C 5.19E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OAS3 UTR-3 20877124 rs2072133 chr12 113409260 T C 3.86E-05 Coronary heart disease OAS3 UTR-3 21971053 rs10744791 chr12 113410316 G A 8.65E-04 Multiple complex diseases OAS3 UTR-3 17554300 rs1293770 chr12 113421869 A G 8.57E-04 Coronary heart disease OAS2 intron 21971053 rs12821546 chr12 113421977 A C 3.66E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OAS2 intron 20877124 rs12821546 chr12 113421977 A C 2.90E-04 Drinking behavior OAS2 intron 21372407 rs12821546 chr12 113421977 A C 7.53E-05 Coronary heart disease OAS2 intron 21971053 rs1293756 chr12 113435293 C A 8.75E-04 Multiple complex diseases OAS2 intron 17554300 rs2239193 chr12 113436823 A G 3.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OAS2 intron 20877124 rs2239193 chr12 113436823 A G 1.39E-04 Coronary heart disease OAS2 intron 21971053 rs1293748 chr12 113444024 T C 8.99E-04 Multiple complex diseases OAS2 intron 17554300 rs13311 chr12 113448652 C A 9.22E-04 Type 2 diabetes OAS2 UTR-3 17463246 rs2525846 chr12 113453553 C T 8.11E-05 Smoking cessation / / 18519826 rs10744793 chr12 113453863 G A 6.24E-04 Type 2 diabetes / / 17463246 rs1635136 chr12 113454743 A G 4.13E-04 Insulin resistance / / 21901158 rs1732778 chr12 113456925 G A 1.03E-05 Smoking cessation / / 18519826 rs11066476 chr12 113465367 T C 3.87E-04 Multiple complex diseases / / 17554300 rs1293778 chr12 113467127 T C 4.54E-06 Smoking cessation / / 18519826 rs1293778 chr12 113467127 T C 4.57E-04 Smoking cessation / / 18519826 rs2001298 chr12 113478072 A C 2.24E-04 Schizophrenia / / 19197363 rs11613438 chr12 113480510 G A 2.36E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11613438 chr12 113480510 G A 8.13E-05 Amyotrophic lateral sclerosis / / 20801717 rs7956193 chr12 113491784 C T 1.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs1732803 chr12 113519816 T G 2.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DTX1 intron 20877124 rs2701623 chr12 113522774 T C 6.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DTX1 intron 20877124 rs2701623 chr12 113522774 T C 3.50E-05 Drinking behavior DTX1 intron 21372407 rs1732771 chr12 113543828 G A 4.34E-05 Cognitive test performance RASAL1 intron 20125193 rs7978582 chr12 113551392 A G 8.92E-04 Schizophrenia RASAL1 intron 19197363 rs7964202 chr12 113551525 C T 1.15E-05 Lymphocyte counts RASAL1 intron 22286170 rs146551951 chr12 113565637 G A 0.000022 Prostate cancer (advanced) RASAL1 missense 23555315 rs35080925 chr12 113603678 G A 0.00032 Breast cancer (ER positive) DDX54 missense 23555315 rs4767064 chr12 113606389 G A 6.82E-04 Response to statin treatment (atorvastatin),change in cholesterol levels DDX54 intron 20031582 rs2384207 chr12 113607502 T C 5.00E-08 Response to fenofibrate (adiponectin levels) DDX54 intron 23149075 rs1458366 chr12 113672577 T C 4.05E-04 White matter integrity TPCN1 intron 22425255 rs2241544 chr12 113724945 A G 3.98E-04 White matter integrity TPCN1 intron 22425255 rs2232515 chr12 113734413 G A 2.36E-04 White matter integrity TPCN1 UTR-3 22425255 rs2241543 chr12 113737574 G T 5.86E-05 Prostate cancer SLC24A6 UTR-3 22923026 rs7953252 chr12 113740442 A G 2.35E-04 White matter integrity SLC24A6 intron 22425255 rs10507238 chr12 113749780 G A 1.00E-04 Cognitive impairment induced by topiramate SLC24A6 intron 22091778 rs16942745 chr12 113758166 G A 5.79E-05 Prostate cancer SLC24A6 missense 22923026 rs16942754 chr12 113766291 T C 2.00E-04 Cognitive impairment induced by topiramate SLC24A6 intron 22091778 rs16942754 chr12 113766291 T C 2.46E-04 White matter integrity SLC24A6 intron 22425255 rs76573623 chr12 113788501 A G 5.69E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs16934262 chr12 113878391 T G 8.81E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs10850140 chr12 113936372 A G 9.31E-04 Multiple complex diseases / / 17554300 rs76270203 chr12 113936996 A C 9.00E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs75753760 chr12 113939698 C T 3.28E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs10774698 chr12 113964164 A G 9.84E-05 Bipolar disorder / / 20451256 rs4586216 chr12 113965309 A T 5.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs12368882 chr12 113966364 G C 6.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs12368882 chr12 113966364 G C 2.70E-05 Urinary metabolites / / 21572414 rs11066587 chr12 113979656 C G 5.00E-06 Quantitative traits / / 19197348 rs933877 chr12 113982356 C T 1.00E-04 Information processing speed / / 21130836 rs933877 chr12 113982356 C T 4.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs933877 chr12 113982356 C T 8.15E-05 Triglycerides / / pha003081 rs11066595 chr12 113982522 C G 6.42E-04 Alcohol dependence / / 21314694 rs12579595 chr12 114005404 G T 6.75E-04 Response to alcohol consumption (flushing response) / / 24277619 rs7313883 chr12 114040847 A G 6.03E-05 Hepatocellular carcinoma / / 22807686 rs11066637 chr12 114047074 A G 8.59E-05 Diabetes Mellitus / / pha003060 rs11066660 chr12 114076654 G A 4.59E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs168719 chr12 114083614 A G 7.06E-05 Insulin resistance / / 21901158 rs41334252 chr12 114134157 C T 7.20E-04 Multiple complex diseases / / 17554300 rs1993397 chr12 114169390 A C 4.59E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7316874 chr12 114173558 C T 5.11E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs336259 chr12 114182800 T C 6.77E-04 Multiple complex diseases / / 17554300 rs2042726 chr12 114182892 G A 9.32E-04 Response to alcohol consumption (flushing response) / / 24277619 rs7305258 chr12 114202846 C T 0.00000053 Joint damage severity in rheumatoid arthritis LOC100506465 intron 23696630 rs11066738 chr12 114225208 A C 5.97E-05 Monocyte chemoattractant protein-1 / / pha003071 rs11066740 chr12 114232348 G A 1.56E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs11066758 chr12 114240419 G A 7.08E-05 Serum metabolites / / 19043545 rs11066765 chr12 114248168 G A 2.06E-04 Response to alcohol consumption (flushing response) / / 24277619 rs12816806 chr12 114248191 T C 8.63E-06 Alzheimer's disease (age of onset) / / 22005931 rs16943292 chr12 114281363 G A 6.01E-04 Multiple complex diseases RBM19 intron 17554300 rs16943292 chr12 114281363 G A 8.71E-05 Smoking quantity RBM19 intron 24665060 rs890414 chr12 114285113 T C 8.86E-04 Response to alcohol consumption (flushing response) RBM19 intron 24277619 rs890414 chr12 114285113 T C 6.99E-05 Smoking quantity RBM19 intron 24665060 rs3782432 chr12 114287300 G A 6.99E-05 Smoking quantity RBM19 intron 24665060 rs3782433 chr12 114287352 C T 1.47E-04 Multiple complex diseases RBM19 intron 17554300 rs3782433 chr12 114287352 C T 7.12E-05 Smoking quantity RBM19 intron 24665060 rs3825208 chr12 114287448 A G 6.78E-04 Multiple complex diseases RBM19 intron 17554300 rs3825208 chr12 114287448 A G 5.39E-05 Smoking quantity RBM19 intron 24665060 rs759904 chr12 114290058 G T 6.47E-04 Multiple complex diseases RBM19 intron 17554300 rs16943317 chr12 114290903 C T 6.49E-05 Smoking quantity RBM19 intron 24665060 rs2075385 chr12 114296587 C T 2.89E-04 Multiple complex diseases RBM19 intron 17554300 rs2075385 chr12 114296587 C T 3.68E-05 Smoking quantity RBM19 intron 24665060 rs11613793 chr12 114304756 C G 7.57E-04 Type 2 diabetes RBM19 intron 17463246 rs736640 chr12 114316080 G A 2.75E-05 Smoking quantity RBM19 intron 24665060 rs1014942 chr12 114326583 C A 5.92E-04 Myopia (pathological) RBM19 intron 21095009 rs1005444 chr12 114328548 T C 6.06E-04 Myopia (pathological) RBM19 intron 21095009 rs4767161 chr12 114351555 T C 3.20E-04 Type 2 diabetes and 6 quantitative traits RBM19 intron 17848626 rs3782455 chr12 114359265 G T 6.00E-06 Amyotrophic lateral sclerosis (sporadic) RBM19 intron 24529757 rs1017711 chr12 114390643 C T 5.84E-04 Multiple complex diseases RBM19 intron 17554300 rs12425509 chr12 114399157 C T 4.93E-04 Multiple complex diseases RBM19 intron 17554300 rs12426674 chr12 114433636 A G 4.00E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12426674 chr12 114433636 A G 2.62E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs898078 chr12 114463587 G A 2.50E-05 Alcoholism (heaviness of drinking) / / 21529783 rs7958635 chr12 114488668 C T 5.31E-05 Colorectal cancer / / 19723657 rs11066949 chr12 114555558 C T 6.26E-05 Gallstones / / 17632509 rs7973040 chr12 114562389 C T 4.07E-04 Multiple complex diseases / / 17554300 rs4766720 chr12 114574608 T C 7.89E-04 Multiple complex diseases / / 17554300 rs10492333 chr12 114575477 T C 2.88E-05 Alcohol consumption / / pha001397 rs1920584 chr12 114576723 T G 6.64E-04 Multiple complex diseases / / 17554300 rs741636 chr12 114583198 A G 6.03E-04 Multiple complex diseases / / 17554300 rs741637 chr12 114583442 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7298436 chr12 114595539 C T 1.28E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10492338 chr12 114596678 A G 1.37E-04 Smoking quantity / / 24665060 rs7971457 chr12 114615807 T C 7.17E-04 Alcohol dependence / / 24277619 rs7294372 chr12 114637423 T C 3.00E-06 Visceral fat / / 22589738 rs4767234 chr12 114637848 A C 6.00E-07 Airflow obstruction / / 22837378 rs11066989 chr12 114646834 C T 5.60E-05 Bipolar disorder and schizophrenia / / 20889312 rs12229813 chr12 114646859 C T 5.60E-05 Bipolar disorder and schizophrenia / / 20889312 rs7301162 chr12 114657494 A C 5.11E-05 Coronary heart disease / / pha003031 rs1920561 chr12 114659110 C T 6.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs1920562 chr12 114660658 T C 1.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2701108 chr12 114674261 T C 3.38E-05 Waist Circumference / / pha003023 rs1270884 chr12 114685571 A G 7.00E-11 Prostate cancer / / 23535732 rs17660176 chr12 114692626 G A 3.39E-05 Schizophrenia / / 20832056 rs1920597 chr12 114704092 G A 1.02E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs1920592 chr12 114705586 C T 1.00E-06 Schizophrenia / / 23212062 rs7973374 chr12 114710682 C T 5.99E-07 Obesity-related traits / / 23251661 rs10744816 chr12 114714266 T C 6.00E-07 Obesity-related traits / / 23251661 rs2114326 chr12 114743644 C A 0.0000497 Panic disorder / / 23149450 rs2114326 chr12 114743644 C A 4.97E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs725086 chr12 114745739 C T 1.34E-06 Obesity-related traits / / 23251661 rs11067036 chr12 114746907 T C 6.87E-04 Insulin resistance / / 21901158 rs11067037 chr12 114746957 T C 7.39E-06 Obesity-related traits / / 23251661 rs883079 chr12 114793240 C T 1.00E-10 Ventricular conduction TBX5 UTR-3 21076409 rs883079 chr12 114793240 C T 3.97E-04 Brugada syndrome TBX5 UTR-3 23872634 rs3825214 chr12 114795443 G A 1.00E-07 Electrocardiographic traits TBX5 intron 20062063 rs3825214 chr12 114795443 G A 3.00E-12 Electrocardiographic traits TBX5 intron 20062063 rs3825214 chr12 114795443 G A 3.00E-13 Electrocardiographic traits TBX5 intron 20062063 rs3825214 chr12 114795443 G A 4.10E-07 Atrial fibrillation TBX5 intron 22544366 rs7312625 chr12 114799974 G A 6.91E-09 PR interval TBX5 intron 21347284 rs7312625 chr12 114799974 G A 5.46E-04 Brugada syndrome TBX5 intron 23872634 rs4767237 chr12 114800813 A G 2.37E-08 PR interval TBX5 intron 21347284 rs1895585 chr12 114802138 A G 1.73E-08 PR interval TBX5 intron 21347284 rs1895585 chr12 114802138 A G 1.00E-19 PR interval TBX5 intron 23139255 rs1946295 chr12 114802361 A G 4.40E-04 Myasthenia gravis TBX5 intron 23055271 rs3825215 chr12 114804898 G C 1.89E-08 PR interval TBX5 intron 21347284 rs1895582 chr12 114807035 G A 1.83E-08 PR interval TBX5 intron 21347284 rs10850331 chr12 114807388 G A 1.39E-04 Insulin resistance TBX5 intron 21901158 rs10850335 chr12 114813108 T C 5.47E-04 Calcium intake levels and metabolic syndrome TBX5 intron 22170361 rs12319868 chr12 114845013 G A,T 1.95E-08 Triglycerides TBX5 intron 23063622 rs1248068 chr12 114849195 G A 1.20E-05 Mammographic density / / 22532574 rs1996821 chr12 114849237 G A 6.90E-04 Schizophrenia / / 19197363 rs2948167 chr12 114850094 C T 3.60E-06 Mammographic density / / 22532574 rs1248052 chr12 114852008 C A 2.80E-06 Mammographic density / / 22532574 rs1248047 chr12 114857179 A T 4.97E-04 Mammographic density / / 22532574 rs2551390 chr12 114857358 A G 2.46E-06 Mammographic density / / 22532574 rs2551389 chr12 114857726 A G 2.67E-08 Mammographic density / / 22532574 rs2551388 chr12 114858247 G A 5.79E-06 Mammographic density / / 22532574 rs1248067 chr12 114859194 A G 3.20E-04 Mammographic density / / 22532574 rs1248066 chr12 114859214 G A 5.64E-06 Mammographic density / / 22532574 rs933743 chr12 114860057 T C 3.96E-06 Mammographic density / / 22532574 rs1248065 chr12 114860808 A T 3.10E-04 Mammographic density / / 22532574 rs1248064 chr12 114860900 A G 2.93E-04 Mammographic density / / 22532574 rs933741 chr12 114861719 G A 2.51E-04 Mammographic density / / 22532574 rs1248063 chr12 114862921 C A 4.81E-05 Mammographic density / / 22532574 rs933740 chr12 114863208 T C 1.88E-05 Mammographic density / / 22532574 rs939868 chr12 114863646 A G 3.14E-04 Mammographic density / / 22532574 rs1248060 chr12 114864252 C T 5.90E-06 Mammographic density / / 22532574 rs1248059 chr12 114864650 C G 3.26E-04 Mammographic density / / 22532574 rs1265508 chr12 114867127 A T 7.01E-06 Mammographic density / / 22532574 rs1265507 chr12 114868138 A G 1.00E-08 Mammographic density / / 22532574 rs1248056 chr12 114869143 C T 1.24E-05 Mammographic density / / 22532574 rs2076966 chr12 114869775 T C 1.14E-05 Mammographic density / / 22532574 rs2551382 chr12 114870889 T C 1.28E-05 Mammographic density / / 22532574 rs1862908 chr12 114871981 A C 1.31E-05 Mammographic density / / 22532574 rs2686569 chr12 114872300 A G 1.32E-05 Mammographic density / / 22532574 rs2551380 chr12 114872408 G A 1.35E-05 Mammographic density / / 22532574 rs2686571 chr12 114874686 A T 1.35E-05 Mammographic density / / 22532574 rs2551379 chr12 114874818 T C 1.35E-05 Mammographic density / / 22532574 rs2551378 chr12 114874902 T C 9.23E-06 Mammographic density / / 22532574 rs2161792 chr12 114875198 C T 1.34E-05 Mammographic density / / 22532574 rs1949692 chr12 114875855 G A 1.30E-05 Mammographic density / / 22532574 rs933739 chr12 114876609 T C 1.31E-05 Mammographic density / / 22532574 rs2686572 chr12 114878114 C G 1.29E-05 Mammographic density / / 22532574 rs7966636 chr12 114879451 C G 2.13E-04 Response to TNF antagonist treatment / / 21061259 rs2686573 chr12 114879553 A G 7.41E-07 Mammographic density / / 22532574 rs2859670 chr12 114879632 C T 1.53E-05 Mammographic density / / 22532574 rs1248032 chr12 114880709 T C 6.74E-07 Mammographic density / / 22532574 rs1248033 chr12 114881294 G A 5.69E-05 Pulmonary function / / 20010835 rs1248033 chr12 114881294 G A 3.50E-06 Mammographic density / / 22532574 rs1248034 chr12 114881406 A G 7.21E-06 Mammographic density / / 22532574 rs1248037 chr12 114882379 C T 1.81E-04 Mammographic density / / 22532574 rs7303913 chr12 114885632 G A 3.15E-04 Depression (quantitative trait) / / 20800221 rs16944310 chr12 114887730 T C 5.77E-04 Depression (quantitative trait) / / 20800221 rs6489959 chr12 114892458 T G 4.92E-04 Insulin resistance / / 21901158 rs12229163 chr12 114900429 T C 9.27E-04 Depression (quantitative trait) / / 20800221 rs12229163 chr12 114900429 T C 0.0000243 Transmission distortion / / 22377632 rs12229163 chr12 114900429 T C 6.25E-04 Heart Failure / / pha002885 rs5025219 chr12 114910700 T A 9.93E-04 Depression (quantitative trait) / / 20800221 rs16944360 chr12 114910883 G A 4.35E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs3914952 chr12 114913891 T C 6.43E-05 Depression (quantitative trait) / / 20800221 rs3858618 chr12 114915022 T A 5.59E-05 Depression (quantitative trait) / / 20800221 rs3914951 chr12 114916300 G A 1.83E-04 Multiple complex diseases / / 17554300 rs838327 chr12 114939288 A G 6.76E-05 Coronary heart disease / / pha003032 rs11067148 chr12 114942504 C T 2.07E-04 Depression (quantitative trait) / / 20800221 rs1522367 chr12 114947741 G A 6.68E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs10507251 chr12 114987794 G C 2.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs838334 chr12 115000120 T C 2.59E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs838338 chr12 115002962 G A 5.85E-04 Insulin resistance / / 21901158 rs2249944 chr12 115005463 T C 2.46E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1718377 chr12 115024237 A G 5.83E-05 Iron levels / / 19880490 rs1718377 chr12 115024237 A G 5.83E-05 Iron levels / / pha002876 rs7964041 chr12 115049923 G A 6.41E-08 Schizophrenia / / 21926974 rs7311627 chr12 115060246 T C 4.31E-04 Heart Failure / / pha002884 rs7310879 chr12 115065669 T C 9.26E-04 Type 2 diabetes / / 17463246 rs7313392 chr12 115088212 G A 2.21E-04 Birth weight / / 17255346 rs11067228 chr12 115094260 A G 2.00E-11 Prostate-specific antigen levels / / 21160077 rs11067228 chr12 115094260 A G 6.72E-05 Colorectal cancer / / 23266556 rs551510 chr12 115114036 C T 9.42E-07 Colorectal cancer TBX3 intron 23266556 rs59336 chr12 115116352 T A 4.00E-07 Colorectal cancer TBX3 intron 23266556 rs515746 chr12 115118997 G A 9.61E-07 Colorectal cancer TBX3 intron 23266556 rs545076 chr12 115119903 G A 6.73E-06 Colorectal cancer TBX3 intron 23266556 rs1910047 chr12 115128655 A T 0.000037 Rate of forced expiratory volume in 1 second (FEV1) decline (young adult women) / / 23527081 rs12304649 chr12 115144453 C T 7.69E-04 Alzheimer's disease / / 17998437 rs12320582 chr12 115154436 A G 2.76E-04 Alzheimer's disease / / 17998437 rs16944593 chr12 115156879 C A 3.90E-04 Tourette syndrome / / 22889924 rs10850369 chr12 115157609 T G 2.86E-08 PR segment / / 24850809 rs10850373 chr12 115169479 A G 5.96E-05 Femoral neck bone geometry / / 22087292 rs11067270 chr12 115172175 C T 4.19E-05 Multiple complex diseases / / 17554300 rs2062713 chr12 115176552 C T 7.33E-06 Femoral neck bone geometry / / 22087292 rs2062715 chr12 115176627 G A 1.33E-05 Femoral neck bone geometry / / 22087292 rs11067276 chr12 115181490 G T 2.15E-04 Multiple complex diseases / / 17554300 rs11067278 chr12 115184053 G C 3.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs4767252 chr12 115187724 A C 3.26E-04 Type 2 diabetes / / 17463246 rs10850375 chr12 115190655 T C 2.70E-05 Urinary metabolites / / 21572414 rs11067283 chr12 115195891 T A 6.28E-07 Pulmonary function / / 20010834 rs1566643 chr12 115206320 A G 4.16E-05 Leukocyte Counts / / pha003091 rs16944632 chr12 115224251 C T 1.50E-04 Endometriosis / / 21151130 rs7966479 chr12 115229953 A G 2.80E-05 Urinary metabolites / / 21572414 rs11067311 chr12 115281893 G A 3.78E-05 Multiple complex diseases / / 17554300 rs7967062 chr12 115334968 T G 1.08E-04 Taste perception / / 22132133 rs7963771 chr12 115343492 C T 8.30E-04 Alzheimer's disease / / 17998437 rs4625524 chr12 115344085 G A 7.28E-09 PR segment / / 24850809 rs1955105 chr12 115344782 T G 2.61E-09 PR segment / / 24850809 rs1896312 chr12 115346424 C T 3.00E-17 PR interval / / 20062060 rs1896312 chr12 115346424 C T 1.17E-09 PR segment / / 24850809 rs1124477 chr12 115349497 T C 5.83E-10 PR segment / / 24850809 rs2384550 chr12 115352731 G A 4.00E-08 Diastolic blood pressure / / 19430479 rs2384550 chr12 115352731 G A 4.00E-08 Coronary heart disease / / 21347282 rs2384550 chr12 115352731 G A 4.00E-06 Blood pressure / / 21909110 rs6489992 chr12 115352769 G A 5.75E-04 Insulin resistance / / 21901158 rs10744835 chr12 115353849 G A 3.37E-05 Brain structure / / 22504417 rs4766748 chr12 115354179 C T 1.14E-09 PR segment / / 24850809 rs1896330 chr12 115357003 G A 5.98E-10 PR segment / / 24850809 rs1896329 chr12 115357432 C T 6.57E-10 PR segment / / 24850809 rs2384552 chr12 115357928 A G 5.49E-10 PR segment / / 24850809 rs2891537 chr12 115358952 T G 5.51E-10 PR segment / / 24850809 rs7967168 chr12 115359206 T A 2.32E-10 PR segment / / 24850809 rs7132580 chr12 115360824 G A 7.82E-10 PR segment / / 24850809 rs7132593 chr12 115360866 G A 7.13E-10 PR segment / / 24850809 rs6416327 chr12 115361364 T G 1.23E-10 PR segment / / 24850809 rs2384554 chr12 115362278 T G 1.61E-09 PR segment / / 24850809 rs7979724 chr12 115362584 T C 1.93E-09 PR segment / / 24850809 rs7977151 chr12 115362972 A G 6.64E-11 PR segment / / 24850809 rs7980361 chr12 115363111 T C 7.65E-10 PR segment / / 24850809 rs11067327 chr12 115363443 C T 6.01E-11 PR segment / / 24850809 rs3914956 chr12 115363751 T A 9.15E-10 PR segment / / 24850809 rs7966951 chr12 115365211 A G 9.80E-12 PR segment / / 24850809 rs7311039 chr12 115371208 G C 1.74E-09 PR segment / / 24850809 rs10744836 chr12 115371742 T G 5.40E-09 PR segment / / 24850809 rs7966651 chr12 115371958 T C 1.56E-09 PR segment / / 24850809 rs10850408 chr12 115380393 C T 9.00E-07 Alzheimer's disease / / 22159054 rs10850408 chr12 115380393 C T 2.00E-05 Brain structure / / 22504417 rs7132327 chr12 115381071 T C 7.98E-13 PR segment / / 24850809 rs10850409 chr12 115381740 G A 3.00E-10 Ventricular conduction / / 21076409 rs10850409 chr12 115381740 G A 8.00E-13 PR segment / / 24850809 rs4994122 chr12 115383743 G C 2.59E-10 PR segment / / 24850809 rs11611538 chr12 115387033 C A 1.83E-08 PR segment / / 24850809 rs10850411 chr12 115387796 T C 4.44E-06 Blood pressure / / 21909110 rs10850411 chr12 115387796 T C 5.43E-10 Systolic blood pressure / / 21909115 rs10850412 chr12 115387968 T C 2.34E-08 PR segment / / 24850809 rs10744840 chr12 115389126 G A 1.32E-08 PR segment / / 24850809 rs11067338 chr12 115393235 C T 5.14E-07 Red blood cell traits / / 23222517 rs10850414 chr12 115394076 C A 8.60E-04 Multiple complex diseases / / 17554300 rs10850414 chr12 115394076 C A 3.91E-08 PR segment / / 24850809 rs11067343 chr12 115399620 A G 3.84E-05 Alzheimer's disease / / 17998437 rs11067344 chr12 115399935 C T 4.70E-05 Alzheimer's disease / / 17998437 rs11611866 chr12 115413953 A G 7.09E-09 PR segment / / 24850809 rs17689762 chr12 115414845 T C 4.50E-05 Alzheimer's disease / / 17998437 rs10850421 chr12 115423129 A G 8.43E-09 PR segment / / 24850809 rs10850424 chr12 115426858 C T 5.15E-07 Multiple complex diseases / / 17554300 rs2384506 chr12 115429353 T C 1.74E-09 Gallstones / / 17632509 rs12579024 chr12 115435016 A C 1.57E-05 Rheumatoid arthritis / / 21452313 rs11067362 chr12 115438082 T C 6.00E-06 Upper aerodigestive tract cancers / / 21437268 rs10744845 chr12 115445788 G A 8.99E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10850428 chr12 115453154 C T 8.19E-05 Leukocyte Counts / / pha003091 rs10492258 chr12 115453937 C G 6.91E-05 Schizophrenia / / pha002859 rs16944877 chr12 115459615 T C 0.0000218 Polycystic ovary syndrome / / 22951595 rs16944877 chr12 115459615 T C 2.18E-05 Intracranial aneurysm / / 22961961 rs35516 chr12 115476753 G T 6.52E-05 Glycosylated haemoglobin levels / / 17255346 rs10850434 chr12 115495279 G A 2.80E-05 Glycosylated haemoglobin levels / / 17255346 rs1848864 chr12 115500103 A G 8.00E-05 Personality dimensions / / 18957941 rs2194980 chr12 115502718 A G 3.00E-07 Metabolite levels / / 19043545 rs35503 chr12 115504520 A G 3.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs35461 chr12 115533823 C T 2.20E-04 Premature ovarian failure / / 19508998 rs11610871 chr12 115551934 G A 5.40E-05 Response to statin therapy / / 20339536 rs35444 chr12 115552437 A G 1.00E-10 Blood pressure / / 21572416 rs35444 chr12 115552437 A G 8.00E-07 Blood pressure / / 21572416 rs35444 chr12 115552437 A G 7.12E-04 Stroke / / pha002887 rs10850440 chr12 115554889 C T 6.60E-05 Response to statin therapy / / 20339536 rs3858646 chr12 115575693 A T 7.70E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs1828384 chr12 115575730 C T 7.04E-05 Age-related macular degeneration / / 22125219 rs254689 chr12 115586441 C T 5.20E-05 Eosinophil counts / / pha003088 rs254694 chr12 115589524 T C 5.63E-04 Insulin resistance / / 21901158 rs16945105 chr12 115616315 C T 1.79E-05 F-cell distribution / / 21326311 rs7299221 chr12 115630361 A G 2.80E-05 Personality dimensions / / 22628180 rs2114314 chr12 115651997 G T 2.52E-05 Biliary atresia / / 20460270 rs1426435 chr12 115661498 T C 1.54E-05 Aging (time to event) / / 21782286 rs11067490 chr12 115675843 T C 3.72E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11067491 chr12 115679329 T C 5.63E-04 Type 2 diabetes / / 17463246 rs10507257 chr12 115688402 A G 1.41E-04 Type 2 diabetes / / 17463246 rs10507257 chr12 115688402 A G 3.63E-05 Multiple sclerosis / / 20598377 rs1634141 chr12 115718410 G T 4.13E-04 Smoking initiation / / 24665060 rs1920955 chr12 115729848 C T 7.40E-07 Urinary metabolites / / 21572414 rs10507258 chr12 115744758 A G 1.00E-04 Information processing speed / / 21130836 rs11615848 chr12 115772088 G T 8.01E-05 Bladder cancer / / 19648920 rs1463833 chr12 115816442 A G 8.95E-07 Height / / 20400458 rs1498759 chr12 115824082 C T 1.70E-07 Height / / 20400458 rs2133317 chr12 115834946 C G 7.36E-04 Type 2 diabetes / / 17463246 rs1292011 chr12 115836522 A G 8.00E-04 Parkinson's disease / / 17052657 rs1292011 chr12 115836522 A G 3.96E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1292011 chr12 115836522 A G 9.00E-22 Breast cancer / / 23535729 rs768860 chr12 115851419 G T 8.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs7964025 chr12 115852309 G A 8.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs11067584 chr12 115852757 C T 9.15E-04 Multiple complex diseases / / 17554300 rs11067584 chr12 115852757 C T 8.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs11067585 chr12 115853437 G C 5.37E-04 Aortic root size / / 21223598 rs7295176 chr12 115859196 T C 1.13E-04 Alzheimer's disease / / 17998437 rs10774811 chr12 115864642 T C 9.36E-05 Multiple complex diseases / / 17554300 rs10774811 chr12 115864642 T C 2.40E-05 Type 2 diabetes / / 24509480 rs10161338 chr12 115865303 T C 9.00E-04 Alzheimer's disease (late onset) / / 21460841 rs7133159 chr12 115867269 C T 2.22E-04 Multiple complex diseases / / 17554300 rs4767318 chr12 115874054 G A 1.58E-04 Multiple complex diseases / / 17554300 rs11067600 chr12 115877777 T C 5.56E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs7315438 chr12 115891403 C T 6.00E-06 Colorectal cancer / / 21761138 rs16945668 chr12 115934730 T C 2.49E-04 Multiple complex diseases / / 17554300 rs11067627 chr12 115940650 T C 3.80E-04 Type 2 diabetes / / 17463246 rs1874902 chr12 115950699 A G 6.48E-04 Multiple complex diseases / / 17554300 rs2384616 chr12 115951160 T G 2.03E-05 Height / / pha003011 rs1874898 chr12 115951238 C A 3.00E-04 Multiple complex diseases / / 17554300 rs1463829 chr12 115960409 A G 9.12E-04 Multiple complex diseases / / 17554300 rs1463829 chr12 115960409 A G 2.94E-05 Height / / pha003011 rs1463828 chr12 115960430 A T 6.60E-04 Multiple complex diseases / / 17554300 rs12580480 chr12 115963873 A T 3.71E-06 Retinopathy in non-diabetics / / 23393555 rs4767335 chr12 115971396 T C 2.10E-05 Height / / pha003010 rs4767335 chr12 115971396 T C 8.06E-07 Height / / pha003011 rs6490024 chr12 115980907 G A 6.69E-04 Multiple complex diseases / / 17554300 rs2195003 chr12 116035167 A G 6.11E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs11835096 chr12 116041955 A G 2.04E-05 Colorectal cancer / / 21242260 rs11067676 chr12 116048740 C T 6.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs5004600 chr12 116051199 C T 7.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs12369896 chr12 116062039 G A 9.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs7953665 chr12 116062983 C G 1.39E-04 Multiple complex diseases / / 17554300 rs7953665 chr12 116062983 C G 9.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs7953110 chr12 116063191 T G 4.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs7310317 chr12 116069843 A G 5.41E-05 Suicide attempts in bipolar disorder / / 21423239 rs10850546 chr12 116075435 C T 5.90E-05 Suicide attempts in bipolar disorder / / 21423239 rs11067693 chr12 116075722 G A 6.12E-05 Suicide attempts in bipolar disorder / / 21423239 rs2279403 chr12 116077151 T C 1.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs12230231 chr12 116085810 C T 7.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2384671 chr12 116089614 G A 3.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs16946023 chr12 116109223 T G 3.25E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10744860 chr12 116113438 A G 0.00000705 HDL cholesterol particle diameter / / 23263444 rs1549338 chr12 116162616 G A 7.22E-04 Parkinson's disease / / 17052657 rs17774603 chr12 116176053 A C 3.97E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs16946143 chr12 116176575 C T 2.02E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs868451 chr12 116179237 C A 4.59E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs11610288 chr12 116180354 A C 4.56E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1084062 chr12 116183484 A C 9.63E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs2891576 chr12 116187506 A G 3.33E-04 Hearing function / / 17255346 rs780876 chr12 116188095 T C 2.00E-05 Myasthenia gravis / / 23055271 rs11067762 chr12 116198214 G A 9.50E-06 Urinary metabolites / / 21572414 rs11067763 chr12 116198341 A G 3.00E-06 Urinary metabolites / / 21572414 rs17719045 chr12 116199324 T C 8.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs780886 chr12 116200160 G A 3.49E-04 Cognitive decline / / 23732972 rs17719439 chr12 116211863 G A 1.00E-06 IgG glycosylation / / 23382691 rs4584625 chr12 116214850 C A 5.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs17719558 chr12 116215578 A G 0.0002551 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17719558 chr12 116215578 A G 2.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3906005 chr12 116220550 C T 1.00E-04 Information processing speed / / 21130836 rs3906005 chr12 116220550 C T 7.28E-05 Major depressive disorder / / 21621269 rs3906005 chr12 116220550 C T 3.98E-05 Intelligence / / 21826061 rs1715583 chr12 116225839 A G 6.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs1647103 chr12 116227378 T C 6.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs12307483 chr12 116228016 T C 0.0001476 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12307483 chr12 116228016 T C 1.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1647106 chr12 116228374 G A 1.53E-04 IgE levels / / 17255346 rs1647110 chr12 116233010 T C 6.69E-05 IgE levels / / 17255346 rs708812 chr12 116239834 C T 3.29E-05 IgE levels / / 17255346 rs11067788 chr12 116247605 A G 2.87E-04 Multiple complex diseases / / 17554300 rs11067789 chr12 116248016 T C 9.01E-04 Type 2 diabetes / / 17463246 rs708820 chr12 116250699 T A 3.34E-05 Lymphocyte counts / / 22286170 rs1424610 chr12 116252835 G A 1.41E-06 Multiple complex diseases / / 17554300 rs1424611 chr12 116252862 G A 6.00E-05 Prostate cancer / / 21743057 rs1424612 chr12 116252945 C T 6.00E-05 Prostate cancer / / 21743057 rs12320046 chr12 116254605 C T 2.00E-05 Prostate cancer / / 21743057 rs16946346 chr12 116269163 A G,T 1.05E-04 Multiple complex diseases / / 17554300 rs16946402 chr12 116288910 G A 4.52E-04 Multiple complex diseases / / 17554300 rs802144 chr12 116293395 C T 5.48E-04 Multiple complex diseases / / 17554300 rs9300329 chr12 116301494 A G 1.84E-05 Cytomegalovirus antibody response / / 21993531 rs1647141 chr12 116311335 T A 3.28E-05 Cytomegalovirus antibody response / / 21993531 rs2542703 chr12 116312828 C T 3.53E-05 Cytomegalovirus antibody response / / 21993531 rs7964653 chr12 116313426 A G 2.68E-09 Coronary heart disease / / 23364394 rs7967915 chr12 116313715 T C 2.50E-09 Coronary heart disease / / 23364394 rs11067815 chr12 116314268 A T 1.94E-09 Coronary heart disease / / 23364394 rs697887 chr12 116314776 A G 5.89E-05 Cytomegalovirus antibody response / / 21993531 rs697887 chr12 116314776 A G 1.33E-04 Longevity / / 22279548 rs4767382 chr12 116321990 A G 5.83E-10 Coronary heart disease / / 23364394 rs12305904 chr12 116325091 G A 7.64E-04 Aortic root size / / 21223598 rs1344862 chr12 116331817 G A 2.27E-05 Type 2 diabetes / / 17463246 rs12308119 chr12 116350780 G A 4.54E-04 Type 2 diabetes / / 17463246 rs10850577 chr12 116356475 A G 4.87E-06 Type 2 diabetes / / 17463246 rs7952741 chr12 116356707 C A 1.91E-05 Type 2 diabetes / / 17463246 rs7970731 chr12 116356999 T C 3.01E-05 Type 2 diabetes / / 17463246 rs10850578 chr12 116360864 C T 6.79E-06 Type 2 diabetes / / 17463246 rs10850580 chr12 116370210 A C 6.18E-04 Acute lung injury / / 22295056 rs12304536 chr12 116371320 C T 4.81E-04 Multiple complex diseases / / 17554300 rs1436357 chr12 116371567 A T 8.84E-04 Multiple complex diseases / / 17554300 rs3847863 chr12 116378024 G T 5.28E-05 Hypertension (early onset hypertension) / / 22479346 rs11067855 chr12 116378716 C G 8.01E-04 Multiple complex diseases / / 17554300 rs6490045 chr12 116387630 A G 3.57E-05 Schizophrenia / / 19571809 rs10507266 chr12 116452575 T C 2.25E-06 Lipid levels MED13L intron 19016617 rs11611238 chr12 116457804 T G 6.15E-05 Neuroblastoma MED13L intron pha002895 rs2551753 chr12 116523880 A C 2.14E-05 Cognitive decline MED13L intron 22054870 rs17580303 chr12 116539384 G C 4.32E-04 Multiple complex diseases MED13L intron 17554300 rs11067914 chr12 116563447 G A 8.00E-06 Urinary metabolites MED13L intron 21572414 rs4145166 chr12 116621185 G T 9.61E-04 Alzheimer's disease MED13L intron 17998437 rs17580584 chr12 116636258 G A 5.55E-04 Multiple complex diseases MED13L intron 17554300 rs16946541 chr12 116658162 A G 0.00000008 Brain microstructure and intellectual performance MED13L intron 22723713 rs17614815 chr12 116734479 G T 7.62E-04 Smoking initiation / / 24665060 rs12829280 chr12 116739837 A G 1.52E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10850601 chr12 116745690 T C 2.22E-04 White matter integrity / / 22425255 rs10850601 chr12 116745690 T C 3.70E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7978789 chr12 116747687 T G 8.18E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10850603 chr12 116749737 T C 3.52E-04 Alzheimer's disease / / 22005930 rs10850603 chr12 116749737 T C 0.00000189 Asthma / / 22694930 rs7977246 chr12 116751727 C T 1.06E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7972837 chr12 116773970 G A 7.28E-04 Type 2 diabetes / / 17463246 rs4767397 chr12 116780545 T C 3.49E-05 Heart Failure / / pha002884 rs1796016 chr12 116784611 T C 8.83E-04 Rheumatoid arthritis / / 21452313 rs952417 chr12 116785387 T G 8.82E-04 Rheumatoid arthritis / / 21452313 rs2393042 chr12 116806443 T C 6.38E-04 Smoking initiation / / 24665060 rs6490059 chr12 116809145 T C 7.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs2254705 chr12 116831388 T C 5.89E-05 Coronary Artery Disease / / 17634449 rs10850625 chr12 116840200 T G 2.39E-05 Intracerebral hemorrhage / / 24656865 rs17581242 chr12 116844438 T G 3.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs4767404 chr12 116869085 T C 4.00E-04 Multiple complex diseases / / 17554300 rs1566929 chr12 116883813 G A 3.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1566929 chr12 116883813 G A 9.64E-04 Iron levels / / pha002876 rs10774863 chr12 116891156 T C 5.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1241226 chr12 116916404 T C 2.34E-04 Multiple complex diseases / / 17554300 rs7306112 chr12 116958827 T C 4.66E-04 Insulin resistance / / 21901158 rs7300418 chr12 116985064 C G 1.00E-04 Prostate cancer / / 21743057 rs2089222 chr12 117002658 G A 8.00E-08 Acute lymphoblastic leukemia (childhood) MAP1LC3B2 intron 19684603 rs2089222 chr12 117002658 G A 8.00E-08 Nasopharyngeal carcinoma MAP1LC3B2 intron 20512145 rs12227287 chr12 117013401 T C 6.06E-04 Type 2 diabetes MAP1LC3B2 intron 17463246 rs10850677 chr12 117027499 T C 9.79E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2393074 chr12 117030428 C A 3.83E-05 Waist-Hip Ratio / / pha003013 rs2393074 chr12 117030428 C A 6.68E-05 Waist Circumference / / pha003025 rs2393074 chr12 117030428 C A 7.45E-05 Waist-Hip Ratio / / pha003028 rs7304254 chr12 117050611 C A 3.35E-04 Major depressive disorder / / 22472876 rs17615758 chr12 117051036 C T 1.34E-04 Major depressive disorder / / 22472876 rs1011493 chr12 117082846 A G 8.30E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1009981 chr12 117103935 G A 3.03E-04 Body mass index / / 17255346 rs1009981 chr12 117103935 G A 0.00000002 Brain microstructure and intellectual performance / / 22723713 rs2029852 chr12 117175266 G C 7.15E-04 Obesity (extreme) C12orf49 intron 21935397 rs7312638 chr12 117184484 A G 1.65E-04 Smoking quantity RNFT2 intron 24665060 rs7300541 chr12 117185647 G A 4.36E-04 Smoking quantity RNFT2 intron 24665060 rs12322695 chr12 117199414 G T 7.00E-06 Obesity-related traits RNFT2 intron 23251661 rs17500871 chr12 117217212 A C 1.67E-05 Alzheimer's disease (age of onset) RNFT2 intron 22005931 rs7134617 chr12 117243827 T G 1.21E-05 Alzheimer's disease (age of onset) RNFT2 intron 22005931 rs10735098 chr12 117250688 G A 6.20E-05 Obesity,menopause RNFT2 intron 21424828 rs924078 chr12 117253871 T A 2.06E-04 Type 2 diabetes RNFT2 intron 17463246 rs6490095 chr12 117285879 T C 7.58E-04 Alzheimer's disease RNFT2 intron 17998437 rs903771 chr12 117291591 C A 3.38E-04 Type 2 diabetes / / 17463246 rs17429217 chr12 117295333 A G 3.00E-06 Alzheimer's disease (age of onset) / / 22005931 rs11068218 chr12 117307117 A G 6.51E-04 Multiple complex diseases HRK intron 17554300 rs7132910 chr12 117320658 T C 3.52E-05 Brain structure / / 22504417 rs7315280 chr12 117320938 A G 2.85E-05 Brain structure / / 22504417 rs4767469 chr12 117326854 C T 9.44E-04 Brain structure / / 22504417 rs7294919 chr12 117327592 T C 7.00E-16 Brain structure / / 22504417 rs7294919 chr12 117327592 T C 3.00E-11 Hippocampal volume / / 22504421 rs7312900 chr12 117332370 A T 3.80E-08 Hippocampal volume / / 22504421 rs12310299 chr12 117335487 C G 3.70E-08 Hippocampal volume / / 22504421 rs7132339 chr12 117335912 G A 4.87E-06 Brain structure / / 22504417 rs7132339 chr12 117335912 G A 3.80E-08 Hippocampal volume / / 22504421 rs7133290 chr12 117335944 C T 3.70E-08 Hippocampal volume / / 22504421 rs7980519 chr12 117342165 G A 4.08E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11068277 chr12 117424506 T A 3.07E-08 Lymphocyte counts FBXW8 intron 22286170 rs4767492 chr12 117436861 C T 9.49E-04 Brain structure FBXW8 intron 22504417 rs4767492 chr12 117436861 C T 3.50E-07 Hippocampal volume FBXW8 intron 22504421 rs1875144 chr12 117475178 T C 9.37E-05 Alcohol dependence / / 21703634 rs1875144 chr12 117475178 T C 7.00E-04 Tourette syndrome / / 22889924 rs11068326 chr12 117527314 T C 2.03E-05 Brain structure TESC intron 22504417 rs17617052 chr12 117552553 C G 3.23E-04 Type 2 diabetes / / 17463246 rs6490111 chr12 117565281 G T 5.80E-04 Alcohol dependence / / 20201924 rs10850795 chr12 117618952 G A 2.21E-05 Post-operative nausea and vomiting FBXO21 intron 21694509 rs7314778 chr12 117623651 G A 4.42E-04 Insulin resistance FBXO21 intron 21901158 rs9658498 chr12 117668525 A G 1.87E-04 Smoking cessation NOS1 intron 18519826 rs3741476 chr12 117672135 T C 1.66E-04 Smoking cessation NOS1 intron 18519826 rs7960451 chr12 117673242 C T 9.39E-09 LDL cholesterol NOS1 intron 23063622 rs816353 chr12 117684780 G T 7.92E-05 Cognitive performance NOS1 intron 19734545 rs9658465 chr12 117684898 T G 6.39E-12 LDL cholesterol NOS1 intron 23063622 rs9658465 chr12 117684898 T G 9.44E-12 Triglycerides NOS1 intron 23063622 rs2291909 chr12 117684917 T G 0.000000451 LDL cholesterol NOS1 intron 23063622 rs9658449 chr12 117690132 A G 0.000000444 LDL cholesterol NOS1 intron 23063622 rs2293050 chr12 117718822 C T 8.70E-05 Alcoholism (heaviness of drinking) NOS1 intron 21529783 rs884847 chr12 117723613 A G 4.99E-05 Post-operative nausea and vomiting NOS1 intron 21694509 rs532967 chr12 117732339 A G 8.05E-07 Post-operative nausea and vomiting NOS1 intron 21694509 rs532967 chr12 117732339 A G 4.35E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) NOS1 intron 24023788 rs733334 chr12 117732689 T C 1.14E-05 Smoking cessation NOS1 intron 18519826 rs11068438 chr12 117737545 T A 7.27E-06 Personality dimensions NOS1 intron 22628180 rs7961147 chr12 117738879 C T 7.32E-06 Personality dimensions NOS1 intron 22628180 rs12810591 chr12 117739450 T C 7.07E-06 Personality dimensions NOS1 intron 22628180 rs12811583 chr12 117739942 T C 7.40E-06 Personality dimensions NOS1 intron 22628180 rs3825103 chr12 117740509 T C 7.28E-06 Personality dimensions NOS1 intron 22628180 rs12811676 chr12 117741229 G A 7.29E-06 Personality dimensions NOS1 intron 22628180 rs7139134 chr12 117743766 C T 1.63E-05 Personality dimensions NOS1 intron 22628180 rs11068444 chr12 117744743 A G 7.87E-06 Personality dimensions NOS1 intron 22628180 rs11068445 chr12 117744929 G A 7.87E-06 Personality dimensions NOS1 intron 22628180 rs7298903 chr12 117747210 T C 5.39E-06 Personality dimensions NOS1 UTR-5 22628180 rs7310618 chr12 117747306 C G 8.45E-06 Personality dimensions NOS1 intron 22628180 rs7299154 chr12 117747395 T G 9.13E-06 Personality dimensions NOS1 intron 22628180 rs10850809 chr12 117747441 G C 2.19E-05 Personality dimensions NOS1 intron 22628180 rs10850810 chr12 117747487 C T 1.04E-05 Personality dimensions NOS1 intron 22628180 rs11068446 chr12 117747614 C T 1.04E-05 Personality dimensions NOS1 intron 22628180 rs11068447 chr12 117747687 C T 1.03E-05 Personality dimensions NOS1 intron 22628180 rs12824048 chr12 117748042 C T 1.03E-05 Personality dimensions NOS1 intron 22628180 rs9658309 chr12 117748304 A T 1.09E-05 Personality dimensions NOS1 intron 22628180 rs9658308 chr12 117748410 A G 1.17E-05 Personality dimensions NOS1 intron 22628180 rs478597 chr12 117751425 G A 8.00E-06 Inattentive symptoms NOS1 intron 18821565 rs16947443 chr12 117752023 A G 9.88E-04 Type 2 diabetes NOS1 intron 17463246 rs9658292 chr12 117756785 G C 1.03E-09 HDL cholesterol NOS1 intron 23063622 rs9658292 chr12 117756785 G C 4.62E-12 Triglycerides NOS1 intron 23063622 rs9658292 chr12 117756785 G C 8.37E-08 LDL cholesterol NOS1 intron 23063622 rs3782213 chr12 117756798 G C 0.00000204 Triglycerides NOS1 intron 23063622 rs471871 chr12 117765518 T A 9.08E-04 Type 2 diabetes NOS1 intron 17463246 rs12424669 chr12 117778956 C T 4.50E-04 Body mass index NOS1 intron 21701565 rs17509231 chr12 117794323 C T 1.12E-04 Smoking cessation NOS1 intron 18519826 rs9658253 chr12 117800626 C T 8.95E-04 Body mass index NOS1 nearGene-5 21701565 rs11068458 chr12 117802742 A G 9.45E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10850824 chr12 117865061 A G 2.10E-05 Urinary metabolites / / 21572414 rs1580855 chr12 117914894 G T 5.62E-06 Waist Circumference KSR2 intron pha003023 rs1104831 chr12 117924562 G A 1.35E-04 Multiple complex diseases KSR2 intron 17554300 rs1093309 chr12 117925208 T C 4.81E-04 Myopia (pathological) KSR2 intron 21095009 rs12828172 chr12 117928182 C T 1 Drug response to Etoposide KSR2 intron 17537913 rs11068516 chr12 117931367 C A 8.27E-14 Metabolite levels KSR2 intron 22286219 rs1846644 chr12 117938380 T C 1 Drug response to Etoposide KSR2 intron 17537913 rs1604079 chr12 117938519 C T 1 Drug response to Etoposide KSR2 intron 17537913 rs11068519 chr12 117940996 C A 9.71E-04 Alzheimer's disease KSR2 intron 24755620 rs11068520 chr12 117942320 C T 9.14E-04 Alzheimer's disease KSR2 intron 24755620 rs4767551 chr12 117954060 C T 1 Drug response to Etoposide KSR2 intron 17537913 rs10774929 chr12 117955027 G A,T 1 Drug response to Etoposide KSR2 intron 17537913 rs1111599 chr12 117956032 T C 1 Drug response to Etoposide KSR2 intron 17537913 rs2134143 chr12 117956422 C T 1 Drug response to Etoposide KSR2 intron 17537913 rs2134142 chr12 117956508 T G 1 Drug response to Etoposide KSR2 intron 17537913 rs7974925 chr12 117960736 G A 1 Drug response to Etoposide KSR2 intron 17537913 rs4766856 chr12 117975279 C T 3.85E-05 Obesity (early onset extreme) KSR2 intron 23563609 rs7977174 chr12 117986709 T C 3.92E-05 B cell non-Hodgkin lymphoma KSR2 intron 23749188 rs816189 chr12 117991734 T C 5.42E-04 Response to platinum-based chemotherapy in non-small-cell lung cancer KSR2 intron 21483023 rs1004361 chr12 117991894 G A 1.20E-05 Urinary metabolites KSR2 intron 21572414 rs816182 chr12 118001881 T G 4.17E-04 Alzheimer's disease KSR2 intron 24755620 rs10850842 chr12 118005342 A C 1.32E-04 Schizophrenia KSR2 intron 21747397 rs845753 chr12 118011133 T C 7.05E-04 Multiple complex diseases KSR2 intron 17554300 rs816202 chr12 118011284 T G 5.00E-04 Multiple complex diseases KSR2 intron 17554300 rs10507281 chr12 118011769 A G 3.03E-04 Multiple complex diseases KSR2 intron 17554300 rs10850845 chr12 118017851 G A 7.50E-05 HIV-1 control KSR2 intron 20041166 rs1400589 chr12 118026401 C T 3.34E-04 Alzheimer's disease KSR2 intron 22005930 rs6490130 chr12 118028661 A G 1.18E-05 Multiple complex diseases KSR2 intron 17554300 rs6490131 chr12 118028810 T G 1.00E-04 Multiple complex diseases KSR2 intron 17554300 rs11068568 chr12 118042672 T C 7.98E-04 Multiple complex diseases KSR2 intron 17554300 rs1400593 chr12 118051578 T C 1.28E-04 Multiple complex diseases KSR2 intron 17554300 rs11068578 chr12 118058785 C T 9.19E-05 Insulin resistance KSR2 intron 21901158 rs1568158 chr12 118060457 G T 1.50E-05 Urinary metabolites KSR2 intron 21572414 rs17585413 chr12 118060777 A G 3.67E-04 Alzheimer's disease KSR2 intron 17998437 rs1517204 chr12 118060980 C T 4.34E-04 Multiple complex diseases KSR2 intron 17554300 rs4767581 chr12 118062365 C T 2.47E-04 Multiple complex diseases KSR2 intron 17554300 rs7131858 chr12 118067649 C G 5.10E-05 Serum metabolites KSR2 intron 19043545 rs10850862 chr12 118070951 G T 4.18E-04 Insulin resistance KSR2 intron 21901158 rs11068590 chr12 118072155 A G 3.05E-05 Insulin resistance KSR2 intron 21901158 rs10850872 chr12 118077971 T C 1.20E-06 Urinary metabolites KSR2 intron 21572414 rs10850872 chr12 118077971 T C 8.77E-05 Insulin resistance KSR2 intron 21901158 rs1568154 chr12 118078626 T G 1.03E-04 Multiple complex diseases KSR2 intron 17554300 rs7979936 chr12 118079776 C T 4.36E-04 Schizophrenia KSR2 intron 20832056 rs10850878 chr12 118081994 G A 3.11E-04 Type 2 diabetes KSR2 intron 17463246 rs10850879 chr12 118082145 C T 3.20E-04 Type 2 diabetes KSR2 intron 17463246 rs4766866 chr12 118083390 G T 9.70E-04 Type 2 diabetes KSR2 intron 17463246 rs7965602 chr12 118094067 C T 5.50E-06 Longevity,exceptional KSR2 intron 20595579 rs16947853 chr12 118101685 C T 2.05E-05 Schizophrenia KSR2 intron 20832056 rs10431397 chr12 118106194 C T 7.00E-06 Endometriosis KSR2 intron 23472165 rs481745 chr12 118109371 C T 1.52E-04 Attention deficit hyperactivity disorder KSR2 intron pha002875 rs17618923 chr12 118120923 T C 4.24E-04 Smoking initiation KSR2 intron 24665060 rs7303368 chr12 118134939 C T 7.10E-04 Alcohol dependence KSR2 intron 20201924 rs605265 chr12 118135896 G A 6.40E-06 Urinary metabolites KSR2 intron 21572414 rs604356 chr12 118136088 C T 3.15E-04 Type 2 diabetes KSR2 intron 17463246 rs754219 chr12 118139624 G A 5.05E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) KSR2 intron 24023788 rs637368 chr12 118139812 C T 3.65E-04 Obesity (extreme) KSR2 intron 21935397 rs637307 chr12 118139859 T C 7.19E-04 Type 2 diabetes KSR2 intron 17463246 rs7956318 chr12 118156646 G A 1.80E-05 Urinary metabolites KSR2 intron 21572414 rs11068648 chr12 118158805 C T 2.87E-04 Amyotrophic Lateral Sclerosis KSR2 intron 17362836 rs4304868 chr12 118169909 C A 8.00E-06 Visceral adipose tissue adjusted for BMI KSR2 intron 22589738 rs603863 chr12 118191949 C T 4.84E-05 Cardiovascular disease KSR2 intron pha003064 rs631531 chr12 118200112 C T 1.78E-04 Body mass index KSR2 intron 17255346 rs631531 chr12 118200112 C T 6.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KSR2 intron 20877124 rs4767620 chr12 118226761 G A 3.60E-06 Urinary metabolites KSR2 intron 21572414 rs4767621 chr12 118228441 G A 4.28E-05 Multiple sclerosis KSR2 intron 17660530 rs2062906 chr12 118248066 T A 3.09E-04 Coronary heart disease KSR2 intron 21606135 rs4767629 chr12 118255077 G T 3.60E-04 Coronary heart disease KSR2 intron 21606135 rs16947978 chr12 118257106 A G 1.40E-06 Urinary metabolites KSR2 intron 21572414 rs479143 chr12 118257673 G A 0.0001944 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KSR2 intron 23233654 rs479143 chr12 118257673 G A 1.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) KSR2 intron 23233662 rs2723279 chr12 118272871 C A 5.00E-06 Migraine KSR2 intron 23793025 rs2723279 chr12 118272871 C A 9.60E-05 Migraine with aura KSR2 intron 23793025 rs2592296 chr12 118284819 G A 8.73E-04 Parkinson's disease KSR2 intron 17052657 rs11611577 chr12 118289948 C T 7.49E-04 Taste perception KSR2 intron 22132133 rs12317638 chr12 118291145 T C 2.00E-05 Urinary metabolites KSR2 intron 21572414 rs2592286 chr12 118292418 C A 2.96E-04 Taste perception KSR2 intron 22132133 rs1547496 chr12 118302133 A G 0.000816605 Hypertension (early onset hypertension) KSR2 intron 22479346 rs4767631 chr12 118311743 G A 6.00E-07 Biochemical measures KSR2 intron 19260141 rs12306561 chr12 118342427 G A 4.00E-04 Response to alcohol consumption (flushing response) KSR2 intron 24277619 rs11068738 chr12 118348833 C T 8.04E-05 Cognitive performance KSR2 intron 19734545 rs11068738 chr12 118348833 C T 3.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KSR2 intron 20877124 rs12424290 chr12 118349501 C T 1.10E-05 Urinary metabolites KSR2 intron 21572414 rs12424290 chr12 118349501 C T 1.36E-05 Erythrocyte counts KSR2 intron pha003090 rs10444502 chr12 118353871 A C 6.00E-06 Biochemical measures KSR2 intron 19260141 rs11068744 chr12 118364178 C T 6.66E-04 Multiple complex diseases KSR2 intron 17554300 rs11068744 chr12 118364178 C T 8.47E-05 Lipoprotein-associated phospholipase A2 activity and mass KSR2 intron 20442857 rs11616110 chr12 118400017 A C 1.20E-05 Urinary metabolites KSR2 intron 21572414 rs7957610 chr12 118409106 A T 7.10E-06 Urinary metabolites / / 21572414 rs10850942 chr12 118413484 A G 3.70E-06 Urinary metabolites / / 21572414 rs7316408 chr12 118417779 A G 2.60E-05 Job-related exhaustion / / 23620144 rs7295696 chr12 118431327 T C 2.21E-05 Behcet's disease / / 23291587 rs7295696 chr12 118431327 T C 1.77E-05 Behcet's disease / / pha002888 rs5745796 chr12 118454669 G A 5.00E-06 Obesity-related traits RFC5 missense 23251661 rs5745807 chr12 118456285 G A 3.47E-04 Multiple complex diseases RFC5 intron 17554300 rs11068777 chr12 118462095 A G 2.08E-11 Metabolite levels RFC5 intron 22286219 rs5745879 chr12 118467645 C T 2.49E-04 Alcohol dependence RFC5 intron 21314694 rs5745895 chr12 118469875 A G 4.70E-05 Job-related exhaustion RFC5 UTR-3 23620144 rs9788041 chr12 118473054 T C 3.38E-04 Multiple complex diseases WSB2 cds-synon 17554300 rs11068780 chr12 118476079 C T 9.75E-06 Cognitive performance WSB2 intron 19734545 rs4128858 chr12 118501598 G A 2.10E-05 HIV-1 control VSIG10 UTR-3 20041166 rs10850953 chr12 118506607 T G 8.50E-05 Personality dimensions VSIG10 intron 18957941 rs11068807 chr12 118515230 A C 2.06E-05 Cognitive test performance VSIG10 intron 20125193 rs7957463 chr12 118518306 T C 4.20E-05 Type 2 diabetes VSIG10 intron 17463248 rs7957463 chr12 118518306 T C 6.30E-05 Cognitive function VSIG10 intron 24684796 rs7957463 chr12 118518306 T C 6.90E-05 Cognitive function VSIG10 intron 24684796 rs10850956 chr12 118518357 A G 4.09E-04 Type 2 diabetes VSIG10 intron 17463246 rs7958110 chr12 118518759 T C 4.40E-05 Type 2 diabetes VSIG10 intron 17463248 rs4767658 chr12 118519441 T C 4.10E-05 Type 2 diabetes VSIG10 intron 17463248 rs4767658 chr12 118519441 T C 4.09E-04 Schizophrenia VSIG10 intron 19197363 rs4767658 chr12 118519441 T C 4.30E-05 Schizophrenia VSIG10 intron 19571808 rs7488309 chr12 118520170 G A 4.30E-05 Type 2 diabetes VSIG10 cds-synon 17463248 rs7488514 chr12 118520426 C T 9.90E-05 Schizophrenia VSIG10 intron 19571808 rs7957470 chr12 118524426 A G 8.00E-06 Obesity-related traits VSIG10 intron 23251661 rs7974375 chr12 118585698 G T 0.0000439 Ovarian cancer / / 22794196 rs795484 chr12 118589862 T C 3.00E-07 Morphine dose requirement in tonsillectomy and adenoidectomy surgery TAOK3 intron 24909733 rs2280711 chr12 118649954 C T 2.11E-04 Fibrinogen TAOK3 intron 17255346 rs16948225 chr12 118706415 C T 5.83E-04 Multiple complex diseases TAOK3 intron 17554300 rs9943819 chr12 118736722 G A 8.42E-05 Fibrinogen TAOK3 intron 17255346 rs575121 chr12 118768428 A G 2.20E-04 Blood Pressure and Arterial Stiffness TAOK3 intron 17903302 rs12579764 chr12 118873429 C T 1.10E-05 Urinary metabolites / / 21572414 rs17625759 chr12 118879677 T C 7.17E-04 Alzheimer's disease / / 17998437 rs11068953 chr12 118889559 G A 5.66E-05 Obesity (extreme) / / 21935397 rs11613092 chr12 118893248 C T 6.00E-06 Hemostatic factors and hematological phenotypes / / 22443383 rs7132650 chr12 118893434 C T 1.59E-04 Type 2 diabetes / / 17463246 rs7132650 chr12 118893434 C T 7.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7316050 chr12 118896470 A T 4.78E-05 Alcohol dependence / / 21314694 rs12826003 chr12 118909907 C T 2.18E-05 Elbow pain / / pha003008 rs11612886 chr12 118929937 G C 3.38E-04 Insulin resistance / / 21901158 rs7965011 chr12 118954402 G T 1.60E-05 Urinary metabolites / / 21572414 rs11068980 chr12 118956709 T C 2.70E-05 Urinary metabolites / / 21572414 rs11068981 chr12 118956751 T C 3.30E-06 Urinary metabolites / / 21572414 rs12299767 chr12 118965661 C T 2.70E-05 Urinary metabolites / / 21572414 rs10850993 chr12 118984905 A G 0.000847 Salmonella-induced pyroptosis / / 22837397 rs1520782 chr12 119004368 C A 4.57E-04 Alzheimer's disease (late onset) / / 21379329 rs2730589 chr12 119016318 A C 7.46E-04 Multiple complex diseases / / 17554300 rs1879405 chr12 119022869 C G 4.72E-05 Telomere length / / 20139977 rs11610823 chr12 119031926 G A 7.07E-04 Alzheimer's disease / / 22005930 rs956866 chr12 119037599 C T 6.32E-04 Alzheimer's disease / / 22005930 rs1520780 chr12 119039725 G A 5.57E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2682738 chr12 119054828 A G 9.70E-04 Alzheimer's disease / / 22005930 rs4387413 chr12 119062216 G C 4.95E-04 Multiple complex diseases / / 17554300 rs1520777 chr12 119076869 C T 3.44E-05 Cognitive impairment induced by topiramate / / 22091778 rs1846598 chr12 119148705 A C 4.95E-06 Obesity-related traits / / 23251661 rs2730756 chr12 119153614 T C 9.74E-05 Cognitive impairment induced by topiramate / / 22091778 rs2682733 chr12 119157263 A G 8.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1499908 chr12 119161071 C T 5.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1499908 chr12 119161071 C T 9.74E-05 Cognitive impairment induced by topiramate / / 22091778 rs1829565 chr12 119161558 G A 4.63E-04 Alzheimer's disease (late onset) / / 21379329 rs11069062 chr12 119163079 G A 3.00E-06 Obesity-related traits / / 23251661 rs1827175 chr12 119172763 T C 4.96E-04 Aortic root size / / 21223598 rs2698054 chr12 119189725 T C 4.06E-05 Cognitive impairment induced by topiramate / / 22091778 rs2698079 chr12 119312046 A G 0.00009735 Sarcoidosis / / 22952805 rs2730442 chr12 119313572 A G 0.000176096 Primary sclerosing cholangitis / / 23603763 rs11069155 chr12 119334779 C T 4.71E-05 Elbow pain / / pha003008 rs11069178 chr12 119367827 A C 8.67E-04 Tourette syndrome / / 22889924 rs4575336 chr12 119382394 G A 2.91E-06 Elbow pain / / pha003008 rs4575336 chr12 119382394 G A 5.07E-05 Height / / pha003010 rs4575336 chr12 119382394 G A 5.62E-05 Height / / pha003011 rs1997111 chr12 119387918 A C 1.00E-08 T-tau levels / / 20932310 rs1997111 chr12 119387918 A C 6.79E-04 Tourette syndrome / / 22889924 rs12298021 chr12 119389239 G A 1.54E-05 Elbow pain / / pha003008 rs12228387 chr12 119402543 G A 2.26E-06 Alopecia areata / / 22027810 rs1405050 chr12 119443713 C T 0.0000177 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SRRM4 intron 22628534 rs12309091 chr12 119444197 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SRRM4 intron 22628534 rs7138083 chr12 119454647 C G 2.00E-04 Response to antidepressant treatment (citalopram) SRRM4 intron 23726668 rs11064652 chr12 119510544 C T 4.00E-04 Multiple complex diseases SRRM4 intron 17554300 rs11609302 chr12 119529695 C T 4.70E-04 Response to taxane treatment (placlitaxel) SRRM4 intron 23006423 rs7314453 chr12 119532430 T C 7.49E-04 Response to taxane treatment (placlitaxel) SRRM4 intron 23006423 rs11609210 chr12 119535001 G A 8.95E-05 Partial epilepsies SRRM4 intron 20522523 rs11611821 chr12 119535709 T C 7.26E-05 Partial epilepsies SRRM4 intron 20522523 rs4767783 chr12 119554349 G A 8.88E-04 Self-reported allergy SRRM4 intron 23817569 rs11064669 chr12 119558565 C T 2.15E-04 Multiple complex diseases SRRM4 intron 17554300 rs11064675 chr12 119568721 T C 5.88E-04 Amyotrophic Lateral Sclerosis SRRM4 intron 17362836 rs7301936 chr12 119569596 G A 2.29E-04 Multiple complex diseases SRRM4 intron 17554300 rs6490241 chr12 119569839 T C 5.68E-05 Acute lymphoblastic leukemia (childhood) SRRM4 intron 19684603 rs4075946 chr12 119570064 G T 6.12E-04 Multiple complex diseases SRRM4 intron 17554300 rs7134341 chr12 119581131 T G 2.84E-10 Coronary heart disease SRRM4 intron 23364394 rs2555275 chr12 119587953 T A 1.07E-04 Multiple complex diseases SRRM4 intron 17554300 rs78852656 chr12 119619997 G A 4.00E-08 PR interval in Tripanosoma cruzi seropositivity HSPB8 intron 24324551 rs11064699 chr12 119623666 A G 9.23E-04 Multiple complex diseases HSPB8 intron 17554300 rs1346227 chr12 119659857 C T 2.50E-05 Urinary metabolites / / 21572414 rs11064722 chr12 119673183 C T 6.16E-06 Osteoarthritis / / 22763110 rs12146774 chr12 119673503 C T 3.64E-05 Bone mineral density / / 19181680 rs12146774 chr12 119673503 C T 7.47E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs10849635 chr12 119674146 G A 7.47E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11064724 chr12 119676607 A G 4.27E-05 Multiple complex diseases / / 17554300 rs11064724 chr12 119676607 A G 7.48E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11064727 chr12 119678986 G A 7.48E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2467021 chr12 119679056 A G 6.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs721874 chr12 119679868 A G 6.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2727675 chr12 119684829 C T 8.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4576883 chr12 119689459 A G 9.77E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2393507 chr12 119701821 G T 9.38E-04 Insulin resistance / / 21901158 rs7303593 chr12 119715653 C T 6.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs7303593 chr12 119715653 C T 3.23E-04 Stroke / / pha002886 rs7295657 chr12 119716164 T A 8.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs7314688 chr12 119723294 C T 2.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs7974646 chr12 119729967 G A 7.71E-04 Suicide attempts in bipolar disorder LOC144742 intron 21423239 rs4767805 chr12 119731530 C T 5.18E-04 Alzheimer's disease LOC144742 intron 24755620 rs2727733 chr12 119733874 G A 1.12E-04 Myopia (pathological) LOC144742 intron 21095009 rs11064768 chr12 119818509 A G 1.00E-06 Schizophrenia CCDC60 intron 18332876 rs12371047 chr12 119842473 A G 8.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCDC60 intron 20877124 rs12320164 chr12 119853392 T C 1.90E-05 Urinary metabolites CCDC60 intron 21572414 rs7485706 chr12 119856515 G A 2.00E-05 Urinary metabolites CCDC60 intron 21572414 rs1716466 chr12 119863860 A G 7.73E-04 White matter integrity CCDC60 intron 22425255 rs2293495 chr12 119871266 C T 5.96E-05 Coronary heart disease CCDC60 intron pha003031 rs2711747 chr12 119898233 G T 4.90E-05 Type 2 diabetes CCDC60 intron 17463248 rs708881 chr12 119948032 G A 3.33E-05 Cognitive test performance CCDC60 intron 20125193 rs708891 chr12 119981577 T C 4.70E-04 Volumetric brain MRI / / 17903297 rs7137869 chr12 119989646 A G 6.00E-07 Aging traits / / 17903295 rs7972859 chr12 119990045 C T 2.50E-05 Longevity and age-related phenotypes / / 17903295 rs1918416 chr12 120000413 C T 4.90E-05 Type 2 diabetes / / 17463248 rs804628 chr12 120005738 G C 4.40E-05 Type 2 diabetes / / 17463248 rs7315003 chr12 120015591 A G 1.80E-04 Alzheimer's disease (late onset) / / 21379329 rs7315003 chr12 120015591 A G 8.58E-04 Response to alcohol consumption (flushing response) / / 24277619 rs9634174 chr12 120030381 T C 8.97E-04 Response to alcohol consumption (flushing response) / / 24277619 rs10849673 chr12 120033999 A G 9.77E-05 Coronary heart disease TMEM233 intron pha003031 rs7301592 chr12 120036209 T C 5.97E-05 Bipolar disorder TMEM233 intron 18317468 rs7312321 chr12 120036235 G A 5.45E-05 Bipolar disorder TMEM233 intron 18317468 rs7304294 chr12 120041889 G A 6.42E-05 Bipolar disorder TMEM233 intron 18317468 rs4767833 chr12 120050970 A G 4.91E-05 Bipolar disorder TMEM233 intron 18317468 rs2893796 chr12 120051269 A G 4.89E-05 Bipolar disorder TMEM233 intron 18317468 rs2893796 chr12 120051269 A G 2.05E-04 Alzheimer's disease (late onset) TMEM233 intron 21379329 rs11064845 chr12 120051929 G C 2.38E-05 Bipolar disorder TMEM233 intron 18317468 rs11064845 chr12 120051929 G C 3.05E-06 Coronary arterial lesions in patients with Kawasaki disease TMEM233 intron 23677057 rs7310536 chr12 120054073 G C 2.60E-05 Bipolar disorder TMEM233 intron 18317468 rs7310536 chr12 120054073 G C 2.77E-06 Coronary arterial lesions in patients with Kawasaki disease TMEM233 intron 23677057 rs11064853 chr12 120060108 G A 1.17E-05 Systolic blood pressure in sickle cell anemia TMEM233 intron 24058526 rs10849682 chr12 120060130 T C 2.96E-05 Bipolar disorder TMEM233 intron 18317468 rs7973772 chr12 120086737 A G 2.73E-05 Bipolar disorder / / 18317468 rs7310266 chr12 120098409 T C 2.58E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7310266 chr12 120098409 T C 5.81E-05 Behcet's disease / / pha002888 rs1978107 chr12 120101714 G A 5.37E-04 Multiple complex diseases / / 17554300 rs6490267 chr12 120106376 G T 1.58E-06 Coronary arterial lesions in patients with Kawasaki disease PRKAB1 intron 23677057 rs278145 chr12 120112099 C T 8.10E-05 White matter hyperintensity burden PRKAB1 intron 21681796 rs278151 chr12 120116494 A G 1.97E-05 Bipolar disorder PRKAB1 intron 18317468 rs278151 chr12 120116494 A G 2.77E-06 Coronary arterial lesions in patients with Kawasaki disease PRKAB1 intron 23677057 rs4213 chr12 120119183 T G 2.77E-06 Coronary arterial lesions in patients with Kawasaki disease PRKAB1 UTR-3 23677057 rs7312866 chr12 120131740 G A 3.47E-04 Multiple complex diseases CIT intron 17554300 rs7133714 chr12 120141547 A G 8.48E-04 Alzheimer's disease CIT intron 17998437 rs11064881 chr12 120146925 G A 0.000389078 Primary sclerosing cholangitis CIT intron 23603763 rs2936830 chr12 120167155 C T 2.01E-06 Alzheimer's disease (late onset) CIT intron 21379329 rs2952444 chr12 120175791 C T 8.96E-06 Alzheimer's disease (late onset) CIT intron 21379329 rs1318272 chr12 120189688 A G 8.07E-06 Alzheimer's disease (late onset) CIT intron 21379329 rs203327 chr12 120205095 T G 1.22E-05 Lymphocyte counts CIT intron 22286170 rs203366 chr12 120215864 G A 6.96E-06 Alzheimer's disease (late onset) CIT intron 21379329 rs385930 chr12 120219064 G A 1.90E-05 Alzheimer's disease (late onset) CIT intron 21379329 rs433091 chr12 120228792 T C 1.58E-05 Alzheimer's disease (late onset) CIT intron 21379329 rs203351 chr12 120232646 A G 1.33E-05 Multiple complex diseases CIT intron 17554300 rs203343 chr12 120233601 T C 2.17E-04 Alzheimer's disease (late onset) CIT intron 21379329 rs203339 chr12 120236754 T C 3.20E-04 Alzheimer's disease (late onset) CIT intron 21379329 rs203339 chr12 120236754 T C 8.20E-05 Alcoholism (heaviness of drinking) CIT intron 21529783 rs10774514 chr12 120242845 A G 7.91E-04 Type 2 diabetes CIT intron 17463246 rs450902 chr12 120261041 A G 5.30E-05 Height CIT intron 18391952 rs7309586 chr12 120274323 T C 1.73E-04 Alzheimer's disease (late onset) CIT intron 21379329 rs4766950 chr12 120278241 T C 4.73E-04 Alzheimer's disease (late onset) CIT intron 21379329 rs10774518 chr12 120291463 C A 4.37E-04 Alzheimer's disease (late onset) CIT intron 21379329 rs7304029 chr12 120295225 G A 2.15E-04 Multiple complex diseases CIT intron 17554300 rs7304029 chr12 120295225 G A 6.62E-04 Smoking cessation CIT intron 24665060 rs4767858 chr12 120347677 T C 3.38E-04 IgE levels / / 17255346 rs12582427 chr12 120363678 G A 5.26E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs3847964 chr12 120368330 G T 6.12E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs10774538 chr12 120403797 C T 0.000792 Autism / / 22935194 rs16949870 chr12 120449610 A G 4.83E-04 Type 2 diabetes CCDC64 intron 17463246 rs11064994 chr12 120455764 A G 6.00E-06 Cognitive performance CCDC64 intron 19734545 rs5028648 chr12 120488636 G A 6.34E-04 Suicide attempts in bipolar disorder CCDC64 intron 21041247 rs5028648 chr12 120488636 G A 7.67E-04 Response to taxane treatment (placlitaxel) CCDC64 intron 23006423 rs3852585 chr12 120513625 T C 6.72E-04 Suicide attempts in bipolar disorder CCDC64 intron 21041247 rs3852585 chr12 120513625 T C 3.84E-04 Response to taxane treatment (placlitaxel) CCDC64 intron 23006423 rs3852587 chr12 120540290 A C 7.23E-04 Suicide attempts in bipolar disorder RAB35 intron 21041247 rs3852587 chr12 120540290 A C 8.07E-04 Response to taxane treatment (placlitaxel) RAB35 intron 23006423 rs3936255 chr12 120546927 T G 7.34E-04 Suicide attempts in bipolar disorder RAB35 intron 21041247 rs10744748 chr12 120561836 C T 6.15E-06 Obesity-related traits / / 23251661 rs10744749 chr12 120561882 C T 6.15E-06 Obesity-related traits / / 23251661 rs11065028 chr12 120562974 C T 4.00E-06 Obesity-related traits / / 23251661 rs2422 chr12 120565188 G A 7.16E-06 Obesity-related traits GCN1L1 UTR-3 23251661 rs7296380 chr12 120609325 T G 5.25E-05 Height GCN1L1 intron pha003011 rs16950047 chr12 120729498 A C 3.91E-04 Heart rate / / 23583979 rs2522129 chr12 120747913 G T 7.60E-07 Post-operative nausea and vomiting SIRT4 intron 21694509 rs5637 chr12 120762765 C T 2.53E-04 Parkinson's disease PLA2G1B cds-synon 16252231 rs2701632 chr12 120769657 G A 2.78E-04 Multiple complex diseases / / 17554300 rs2701632 chr12 120769657 G A 7.28E-05 Personality dimensions / / 18957941 rs2701632 chr12 120769657 G A 1.15E-06 Post-operative nausea and vomiting / / 21694509 rs2701632 chr12 120769657 G A 3.72E-04 Lymphocyte counts / / 22286170 rs2522136 chr12 120771157 A G 3.25E-04 Multiple complex diseases / / 17554300 rs2522136 chr12 120771157 A G 5.19E-05 Personality dimensions / / 18957941 rs12423303 chr12 120785685 A G 5.74E-04 Heart rate MSI1 intron 23583979 rs1179434 chr12 120786083 C A 1.19E-04 Multiple complex diseases MSI1 intron 17554300 rs206952 chr12 120823722 C G 1.00E-04 Body mass index / / 24827717 rs17431357 chr12 120880434 C T 1.00E-06 Insulin resistance / / 21901158 rs2235218 chr12 120888619 A C 2.15E-04 Cholesterol GATC intron 17255346 rs7137953 chr12 120894685 C T 2.19E-05 Multiple sclerosis GATC intron 19525953 rs614226 chr12 120974510 C T 2.00E-06 Type 1 diabetes nephropathy RNF10 intron 23028342 rs1167715 chr12 120981471 T C 6.03E-04 Lymphocyte counts RNF10 intron 22286170 rs3213565 chr12 120992401 C T 1.92E-04 Cholesterol RNF10 intron 17255346 rs7299238 chr12 121061750 G A 7.57E-04 Coronary heart disease / / 21606135 rs10744753 chr12 121066038 G T 2.20E-05 Intelligence (childhood) / / 23358156 rs4766974 chr12 121069115 G A 1.41E-04 Obesity (extreme) / / 21935397 rs12370780 chr12 121070973 C T 1.45E-04 Obesity (extreme) / / 21935397 rs10774564 chr12 121085940 G A 2.81E-04 Alzheimer's disease (late onset) CABP1 intron 21379329 rs11065202 chr12 121112429 T C 8.87E-08 Red blood cell traits / / 23222517 rs3829290 chr12 121126438 T C 9.24E-09 Red blood cell traits MLEC intron 23222517 rs2005455 chr12 121128699 A G 2.24E-07 Red blood cell traits MLEC intron 23222517 rs10431385 chr12 121128882 T C 9.36E-08 Red blood cell traits MLEC intron 23222517 rs10431386 chr12 121128926 C T 8.07E-08 Metabolite levels MLEC intron 23281178 rs7306541 chr12 121130046 A G 2.93E-09 Metabolite levels MLEC intron 23281178 rs7976497 chr12 121135467 T C 9.31E-09 Red blood cell traits / / 23222517 rs17847 chr12 121149475 A G 3.67E-07 Red blood cell traits UNC119B intron 23222517 rs556001 chr12 121152967 A G 8.74E-07 Red blood cell traits UNC119B intron 23222517 rs696337 chr12 121159380 T C 8.13E-08 Red blood cell traits UNC119B UTR-3 23222517 rs2066938 chr12 121160615 A G 4.00E-305 Metabolic traits UNC119B UTR-3 21886157 rs2066938 chr12 121160615 A G 1.04E-08 Metabolite levels UNC119B UTR-3 23281178 rs2066938 chr12 121160615 A G 3E-630 Blood metabolite levels UNC119B UTR-3 24816252 rs2239760 chr12 121163518 C A 1.19E-08 Red blood cell traits ACADS nearGene-5 23222517 rs3999408 chr12 121167387 C T 1.65E-08 Metabolite levels ACADS intron 23281178 rs3794215 chr12 121168083 T C 5.57E-07 Red blood cell traits ACADS intron 23222517 rs3794214 chr12 121168245 T C 3.33E-07 Red blood cell traits ACADS intron 23222517 rs3914 chr12 121174899 T C 1.51E-08 Red blood cell traits ACADS cds-synon 23222517 rs2014355 chr12 121175524 T C 5.00E-96 Metabolite levels ACADS intron 20037589 rs2014355 chr12 121175524 T C 2.40E-08 Metabolite levels ACADS intron 23281178 rs28940872 chr12 121177159 C T 0.0000071 Breast cancer ACADS missense 23555315 rs35233375 chr12 121177160 G A 2.66E-12 HDL cholesterol ACADS missense 23063622 rs35233375 chr12 121177160 G A 5.92E-12 Cholesterol,total ACADS missense 23063622 rs3916 chr12 121177272 G C 1.12E-08 Metabolite levels ACADS UTR-3 23281178 rs3916 chr12 121177272 G C 2.00E-22 Urinary metabolites (H-NMR features) ACADS UTR-3 24586186 rs9204 chr12 121177778 A G 2.03E-07 Red blood cell traits ACADS UTR-3 23222517 rs10849788 chr12 121211841 G A 3.50E-14 Parkinson's disease (familial) SPPL3 intron 18985386 rs4767935 chr12 121216531 T C 1.52E-08 Metabolite levels SPPL3 intron 23281178 rs574141958 chr12 121216531 TTTTACTAACTAACTTGACA T 1.52E-08 Metabolite levels SPPL3 intron 23281178 rs12824150 chr12 121220031 G C 1.52E-08 Metabolite levels SPPL3 intron 23281178 rs3213568 chr12 121222496 C T 8.59E-04 Tourette syndrome SPPL3 intron 22889924 rs1039302 chr12 121236258 C T 5.00E-06 Quantitative traits SPPL3 intron 19197348 rs2047568 chr12 121243790 G A 9.45E-05 Multiple complex diseases SPPL3 intron 17554300 rs674021 chr12 121248584 G A 1.02E-04 Lipid levels SPPL3 intron 19016617 rs674021 chr12 121248584 G A 6.94E-06 Lipid levels SPPL3 intron 19016617 rs2062507 chr12 121259051 C T 1.52E-08 Metabolite levels SPPL3 intron 23281178 rs3809313 chr12 121329967 T C 4.72E-09 Metabolite levels SPPL3 intron 23281178 rs6489785 chr12 121363724 T C 1.00E-06 Longevity / / 20834067 rs868795 chr12 121371233 C T 1.80E-06 Urinary metabolites / / 21572414 rs868795 chr12 121371233 C T 9.44E-05 Waist Circumference / / pha003025 rs2649999 chr12 121380544 T C 1.00E-08 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs2649999 chr12 121380544 T C 1.83E-11 C-reactive protein / / 23844046 rs2650000 chr12 121388962 A C 2.00E-08 LDL cholesterol / / 19060906 rs2650000 chr12 121388962 A C 3.00E-11 Metabolic traits / / 19060910 rs2650000 chr12 121388962 A C 6.17E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2650000 chr12 121388962 A C 2.00E-08 Coronary heart disease / / 21347282 rs2650000 chr12 121388962 A C 2.80E-07 C-reactive protein / / 21647738 rs2650000 chr12 121388962 A C 2.24E-08 N-glycan levels,in plasma / / 21908519 rs2650000 chr12 121388962 A C 9.26E-09 N-glycan levels,in plasma / / 21908519 rs2650000 chr12 121388962 A C 9.27E-10 N-glycan levels,in plasma / / 21908519 rs2650000 chr12 121388962 A C 9.41E-10 Cardiovascular disease risk factors / / 21943158 rs2650000 chr12 121388962 A C 3.40E-10 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs2650000 chr12 121388962 A C 0.00070031 Hypertension (early onset hypertension) / / 22479346 rs2650000 chr12 121388962 A C 0.000344426 2-hour glucose tolerance test / / 22885924 rs2650000 chr12 121388962 A C 5.00E-10 Insulin processing and secretion / / 23263489 rs2650000 chr12 121388962 A C 3.12E-11 C-reactive protein / / 23844046 rs2650000 chr12 121388962 A C 2.71E-11 Inflammation / / pha002897 rs11065374 chr12 121400205 T C 2.69E-06 Inflammation / / pha002897 rs7305618 chr12 121402932 C T 3.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7305618 chr12 121402932 C T 2.00E-08 Type 2 diabetes / / 21573907 rs7305618 chr12 121402932 C T 1.00E-08 C-reactive protein / / 21647738 rs7305618 chr12 121402932 C T 4.70E-08 C-reactive protein / / 23844046 rs7305618 chr12 121402932 C T 8.79E-08 C-reactive protein / / 24763700 rs7953249 chr12 121403724 G A 3.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7953249 chr12 121403724 G A 2.00E-08 N-glycan levels / / 21203500 rs7953249 chr12 121403724 G A 3.30E-08 C-reactive protein / / 21647738 rs7953249 chr12 121403724 G A 2.22E-11 N-glycan levels,in plasma / / 21908519 rs7953249 chr12 121403724 G A 3.15E-11 N-glycan levels,in plasma / / 21908519 rs7953249 chr12 121403724 G A 6.91E-10 N-glycan levels,in plasma / / 21908519 rs7953249 chr12 121403724 G A 3.30E-08 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs7953249 chr12 121403724 G A 1.00E-06 Chronic obstructive pulmonary disease-related biomarkers / / 23144326 rs7953249 chr12 121403724 G A 6.39E-10 C-reactive protein / / 23844046 rs7953249 chr12 121403724 G A 1.27E-07 C-reactive protein / / 24763700 rs7953249 chr12 121403724 G A 1.44E-09 Inflammation / / pha002897 rs7303401 chr12 121404056 T A 1.48E-04 Alcohol dependence / / 21314694 rs1920792 chr12 121404584 T C 8.12E-08 C-reactive protein / / 24763700 rs2251468 chr12 121405126 C A 7.60E-08 C-reactive protein / / 21647738 rs2251468 chr12 121405126 C A 3.40E-10 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs2251468 chr12 121405126 C A 1.00E-12 Homocysteine levels / / 23824729 rs2251468 chr12 121405126 C A 3.76E-11 C-reactive protein / / 23844046 rs10774579 chr12 121405210 T C 1.60E-08 C-reactive protein / / 21647738 rs10774579 chr12 121405210 T C 4.90E-07 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs10774579 chr12 121405210 T C 8.73E-05 Self-reported allergy / / 23817569 rs10774579 chr12 121405210 T C 8.50E-09 C-reactive protein / / 23844046 rs12815613 chr12 121407256 A G 1.05E-04 Self-reported allergy / / 23817569 rs1169288 chr12 121416650 A C 1.00E-14 Cholesterol,total HNF1A missense 20686565 rs1169288 chr12 121416650 A C 1.00E-15 LDL cholesterol HNF1A missense 20686565 rs1169288 chr12 121416650 A C 1.50E-07 C-reactive protein HNF1A missense 21647738 rs1169288 chr12 121416650 A C 3.08E-11 Cardiovascular disease risk factors HNF1A missense 21943158 rs1169288 chr12 121416650 A C 2.00E-18 Gamma gluatamyl transferase levels HNF1A missense 22010049 rs1169288 chr12 121416650 A C 0.000024 Type 2 diabetes HNF1A missense 22885922 rs1169288 chr12 121416650 A C 0.000273 Cholesterol,total HNF1A missense 23063622 rs1169288 chr12 121416650 A C 2.02E-05 Relative hand skill in reading disability HNF1A missense 24068947 rs1169288 chr12 121416650 A C 4.00E-17 Cholesterol,total HNF1A missense 24097068 rs1169288 chr12 121416650 A C 6.00E-21 LDL cholesterol HNF1A missense 24097068 rs1800574 chr12 121416864 C T 3.57E-08 Type 2 diabetes HNF1A missense 22325160 rs2244608 chr12 121416988 A G 4.70E-07 C-reactive protein HNF1A intron 21647738 rs2244608 chr12 121416988 A G 4.80E-13 Gamma gluatamyl transferase levels (interaction with age) HNF1A intron 22010049 rs2244608 chr12 121416988 A G 1.09E-09 Cholesterol,total HNF1A intron 23063622 rs2244608 chr12 121416988 A G 2.13E-08 Total cholesterol in females HNF1A intron 23063622 rs2244608 chr12 121416988 A G 8.00E-08 Urate levels HNF1A intron 23263486 rs2244608 chr12 121416988 A G 3.18E-18 C-reactive protein HNF1A intron 23505291 rs2244608 chr12 121416988 A G 7.61E-12 C-reactive protein HNF1A intron 23844046 rs1169286 chr12 121419056 T C 4.90E-07 C-reactive protein HNF1A intron 21647738 rs1169286 chr12 121419056 T C 3.30E-10 Gamma gluatamyl transferase levels (interaction with age) HNF1A intron 22010049 rs1169286 chr12 121419056 T C 1.52E-08 C-reactive protein HNF1A intron 23844046 rs7979473 chr12 121420260 A C,G 1.70E-10 Gamma gluatamyl transferase levels (interaction with age) HNF1A intron 22010049 rs7979473 chr12 121420260 A C,G 1.10E-09 Metabolic syndrome phenotype HNF1A intron 22022282 rs7979473 chr12 121420260 A C,G 2.60E-08 Metabolic syndrome phenotype HNF1A intron 22022282 rs7979473 chr12 121420260 A C,G 1.00E-10 C-reactive protein HNF1A intron 22939635 rs7979473 chr12 121420260 A C,G 6.91E-10 C-reactive protein HNF1A intron 23844046 rs7979478 chr12 121420263 A G 2.40E-10 Gamma gluatamyl transferase levels (interaction with age) HNF1A intron 22010049 rs7979478 chr12 121420263 A G 7.07E-10 C-reactive protein HNF1A intron 23844046 rs1183910 chr12 121420807 G A 1.00E-30 C-reactive protein HNF1A intron 19567438 rs1183910 chr12 121420807 G A 2.00E-124 C-reactive protein HNF1A intron 21300955 rs1183910 chr12 121420807 G A 5.90E-07 C-reactive protein HNF1A intron 21647738 rs1183910 chr12 121420807 G A 1.18E-11 Cardiovascular disease risk factors HNF1A intron 21943158 rs1183910 chr12 121420807 G A 1.10E-12 Gamma gluatamyl transferase levels (interaction with age) HNF1A intron 22010049 rs1183910 chr12 121420807 G A 4.00E-12 C-reactive protein HNF1A intron 23844046 rs11065385 chr12 121423386 A G 5.60E-07 C-reactive protein HNF1A intron 21647738 rs11065385 chr12 121423386 A G 1.30E-12 Gamma gluatamyl transferase levels (interaction with age) HNF1A intron 22010049 rs11065385 chr12 121423386 A G 2.49E-11 C-reactive protein HNF1A intron 23844046 rs2393791 chr12 121423956 C T 7.00E-30 Gamma glutamyl transpeptidase HNF1A intron 21909109 rs2393791 chr12 121423956 C T 2.20E-10 Gamma gluatamyl transferase levels (interaction with age) HNF1A intron 22010049 rs2393791 chr12 121423956 C T 3.00E-09 C-reactive protein and white blood cell count HNF1A intron 22788528 rs2393791 chr12 121423956 C T 1.23E-11 C-reactive protein HNF1A intron 23844046 rs2393791 chr12 121423956 C T 3.00E-10 C-reactive protein HNF1A intron 24763700 rs2393775 chr12 121424574 G A 4.60E-11 Gamma gluatamyl transferase levels (interaction with age) HNF1A intron 22010049 rs2393775 chr12 121424574 G A 1.82E-11 C-reactive protein HNF1A intron 23844046 rs2393775 chr12 121424574 G A 7.51E-10 C-reactive protein HNF1A intron 24763700 rs7310409 chr12 121424861 A G 7.00E-17 C-reactive protein HNF1A intron 18439548 rs7310409 chr12 121424861 A G 3.00E-08 C-reactive protein HNF1A intron 21196492 rs7310409 chr12 121424861 A G 2.44E-08 Cardiovascular disease risk factors HNF1A intron 21943158 rs7310409 chr12 121424861 A G 7.00E-45 Liver enzyme levels (gamma-glutamyl transferase) HNF1A intron 22001757 rs7310409 chr12 121424861 A G 3.20E-11 Gamma gluatamyl transferase levels (interaction with age) HNF1A intron 22010049 rs7310409 chr12 121424861 A G 2.85E-11 C-reactive protein HNF1A intron 23844046 rs7310409 chr12 121424861 A G 4.35E-10 C-reactive protein HNF1A intron 24763700 rs7310409 chr12 121424861 A G 4.36E-05 Pancreatic cancer HNF1A intron pha002874 rs7310409 chr12 121424861 A G 8.56E-06 Pancreatic cancer HNF1A intron pha002889 rs12427353 chr12 121426901 G C 0.000476 Type 2 diabetes HNF1A intron 22325160 rs12427353 chr12 121426901 G C 0.000000065 Type 2 diabetes HNF1A intron 22885922 rs12427353 chr12 121426901 G C 0.000025 Type 2 diabetes (females) HNF1A intron 22885922 rs12427353 chr12 121426901 G C 0.000035 Type 2 diabetes (males) HNF1A intron 22885922 rs12427353 chr12 121426901 G C 8.45E-08 C-reactive protein HNF1A intron 23505291 rs12427353 chr12 121426901 G C 4.00E-06 Type 2 diabetes HNF1A intron 24509480 rs1169300 chr12 121431225 G A 1.40E-09 Lipid levels HNF1A intron 19936222 rs1169300 chr12 121431225 G A 1.23E-10 N-glycan levels,in plasma HNF1A intron 21908519 rs1169300 chr12 121431225 G A 2.29E-08 N-glycan levels,in plasma HNF1A intron 21908519 rs1169300 chr12 121431225 G A 2.87E-08 N-glycan levels,in plasma HNF1A intron 21908519 rs1169300 chr12 121431225 G A 4.66E-09 N-glycan levels,in plasma HNF1A intron 21908519 rs1169300 chr12 121431225 G A 6.00E-14 Gamma gluatamyl transferase levels (interaction with age) HNF1A intron 22010049 rs1169300 chr12 121431225 G A 4.56E-09 C-reactive protein HNF1A intron 23844046 rs1169300 chr12 121431225 G A 2.01E-09 Inflammation HNF1A intron pha002897 rs1169302 chr12 121432302 T G 6.20E-08 Gamma gluatamyl transferase levels (interaction with age) HNF1A intron 22010049 rs1169302 chr12 121432302 T G 0.000000577 Cholesterol,total HNF1A intron 23063622 rs1169302 chr12 121432302 T G 0.00000173 C-reactive protein HNF1A intron 23505291 rs1169302 chr12 121432302 T G 1.20E-07 Inflammation HNF1A intron pha002897 rs2259820 chr12 121435342 C T 5.50E-14 Gamma gluatamyl transferase levels (interaction with age) HNF1A cds-synon 22010049 rs2259820 chr12 121435342 C T 1.32E-09 C-reactive protein HNF1A cds-synon 23844046 rs2259820 chr12 121435342 C T 5.13E-09 C-reactive protein HNF1A cds-synon 24763700 rs2464196 chr12 121435427 G A 2.22E-10 N-glycan levels,in plasma HNF1A missense 21908519 rs2464196 chr12 121435427 G A 2.26E-09 N-glycan levels,in plasma HNF1A missense 21908519 rs2464196 chr12 121435427 G A 2.93E-08 N-glycan levels,in plasma HNF1A missense 21908519 rs2464196 chr12 121435427 G A 4.69E-08 N-glycan levels,in plasma HNF1A missense 21908519 rs2464196 chr12 121435427 G A 5.50E-14 Gamma gluatamyl transferase levels (interaction with age) HNF1A missense 22010049 rs2464196 chr12 121435427 G A 0.000000433 Cholesterol,total HNF1A missense 23063622 rs2464196 chr12 121435427 G A 1.40E-15 C-reactive protein HNF1A missense 23505291 rs2464196 chr12 121435427 G A 6.13E-09 C-reactive protein HNF1A missense 23844046 rs2464196 chr12 121435427 G A 5.13E-09 C-reactive protein HNF1A missense 24763700 rs2464196 chr12 121435427 G A 4.78E-09 Inflammation HNF1A missense pha002897 rs2464195 chr12 121435475 G A 4.20E-12 Gamma gluatamyl transferase levels (interaction with age) HNF1A intron 22010049 rs2464195 chr12 121435475 G A 3.08E-09 C-reactive protein HNF1A intron 23844046 rs2464195 chr12 121435475 G A 2.09E-09 C-reactive protein HNF1A intron 24763700 rs2259816 chr12 121435587 G T 5.00E-07 Coronary heart disease HNF1A intron 19198612 rs2259816 chr12 121435587 G T 5.00E-07 Coronary heart disease HNF1A intron 21347282 rs2259816 chr12 121435587 G T 2.42E-10 Cardiovascular disease risk factors HNF1A intron 21943158 rs2259816 chr12 121435587 G T 4.20E-12 Gamma gluatamyl transferase levels (interaction with age) HNF1A intron 22010049 rs2259816 chr12 121435587 G T 3.00E-10 C-reactive protein HNF1A intron 22939635 rs2259816 chr12 121435587 G T 2.59E-09 C-reactive protein HNF1A intron 23844046 rs2259816 chr12 121435587 G T 2.45E-09 C-reactive protein HNF1A intron 24763700 rs1169303 chr12 121436376 A C 4.00E-07 Gamma gluatamyl transferase levels (interaction with age) HNF1A intron 22010049 rs1169303 chr12 121436376 A C 1.56E-09 C-reactive protein HNF1A intron 23505291 rs1169303 chr12 121436376 A C 1.04E-06 C-reactive protein HNF1A intron 24763700 rs1169306 chr12 121438311 C T 3.80E-12 Gamma gluatamyl transferase levels (interaction with age) HNF1A intron 22010049 rs1169306 chr12 121438311 C T 2.40E-09 C-reactive protein HNF1A intron 23844046 rs1169306 chr12 121438311 C T 1.84E-09 C-reactive protein HNF1A intron 24763700 rs1169307 chr12 121438382 T C 2.00E-06 Gamma gluatamyl transferase levels (interaction with age) HNF1A intron 22010049 rs1169307 chr12 121438382 T C 2.76E-05 Inflammation HNF1A intron pha002897 rs735396 chr12 121438844 T C 4.00E-08 N-glycan levels HNF1A intron 21203500 rs735396 chr12 121438844 T C 1.67E-10 N-glycan levels,in plasma HNF1A intron 21908519 rs735396 chr12 121438844 T C 3.76E-10 N-glycan levels,in plasma HNF1A intron 21908519 rs735396 chr12 121438844 T C 4.19E-09 N-glycan levels,in plasma HNF1A intron 21908519 rs735396 chr12 121438844 T C 4.31E-08 N-glycan levels,in plasma HNF1A intron 21908519 rs735396 chr12 121438844 T C 4.95E-10 N-glycan levels,in plasma HNF1A intron 21908519 rs735396 chr12 121438844 T C 7.81E-12 N-glycan levels,in plasma HNF1A intron 21908519 rs735396 chr12 121438844 T C 4.20E-12 Gamma gluatamyl transferase levels (interaction with age) HNF1A intron 22010049 rs735396 chr12 121438844 T C 1.21E-08 C-reactive protein HNF1A intron 23844046 rs735396 chr12 121438844 T C 1.91E-09 C-reactive protein HNF1A intron 24763700 rs735396 chr12 121438844 T C 2.13E-07 Inflammation HNF1A intron pha002897 rs1169310 chr12 121439433 G A 2.00E-08 C-reactive protein HNF1A UTR-3 18439552 rs1169310 chr12 121439433 G A 2.42E-10 Cardiovascular disease risk factors HNF1A UTR-3 21943158 rs1169310 chr12 121439433 G A 4.20E-12 Gamma gluatamyl transferase levels (interaction with age) HNF1A UTR-3 22010049 rs1169310 chr12 121439433 G A 2.61E-09 C-reactive protein HNF1A UTR-3 23844046 rs1169310 chr12 121439433 G A 1.75E-09 C-reactive protein HNF1A UTR-3 24763700 rs1169312 chr12 121441461 G T 4.20E-12 Gamma gluatamyl transferase levels (interaction with age) C12orf43 UTR-3 22010049 rs1169312 chr12 121441461 G T 1.27E-09 C-reactive protein C12orf43 UTR-3 23844046 rs3751151 chr12 121442199 T A 2.74E-04 Alcohol dependence / / 21314694 rs1169313 chr12 121442670 T A,C 2.00E-10 Liver enzyme levels C12orf43 intron 18940312 rs1169313 chr12 121442670 T A,C 2.42E-10 Cardiovascular disease risk factors C12orf43 intron 21943158 rs1169313 chr12 121442670 T A,C 4.20E-12 Gamma gluatamyl transferase levels (interaction with age) C12orf43 intron 22010049 rs1169313 chr12 121442670 T A,C 1.58E-09 C-reactive protein C12orf43 intron 23844046 rs1169313 chr12 121442670 T A,C 1.72E-09 C-reactive protein C12orf43 intron 24763700 rs2257764 chr12 121446446 T A 5.50E-14 Gamma gluatamyl transferase levels (interaction with age) C12orf43 intron 22010049 rs3751149 chr12 121453962 C A 2.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C12orf43 intron 20877124 rs2258287 chr12 121454313 C A 4.30E-11 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs1182933 chr12 121454622 C T 6.80E-14 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs1182933 chr12 121454622 C T 2.61E-10 C-reactive protein / / 23844046 rs1182933 chr12 121454622 C T 3.44E-08 C-reactive protein / / 24763700 rs2259693 chr12 121457995 G A 4.40E-09 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs7957197 chr12 121460686 T A 2.00E-08 Type 2 diabetes OASL intron 20581827 rs7957197 chr12 121460686 T A 2.00E-08 Type 2 diabetes OASL intron 21647700 rs7957197 chr12 121460686 T A 0.00000033 Type 2 diabetes OASL intron 22885922 rs7957197 chr12 121460686 T A 2.00E-08 Type 2 diabetes OASL intron 23300278 rs7957197 chr12 121460686 T A 5.44E-05 Glycemic traits (pregnancy) OASL intron 23903356 rs7957197 chr12 121460686 T A 6.18E-05 Glycemic traits (pregnancy) OASL intron 23903356 rs2259883 chr12 121462139 G C 8.30E-07 Gamma gluatamyl transferase levels (interaction with age) OASL intron 22010049 rs2260399 chr12 121469653 C T 3.70E-09 Gamma gluatamyl transferase levels (interaction with age) OASL intron 22010049 rs10849829 chr12 121470256 G A 3.60E-09 Gamma gluatamyl transferase levels (interaction with age) OASL intron 22010049 rs3213545 chr12 121471337 G A 4.00E-15 Cardiovascular disease risk factors OASL cds-synon 21943158 rs3213545 chr12 121471337 G A 1.50E-12 Gamma gluatamyl transferase levels (interaction with age) OASL cds-synon 22010049 rs3213545 chr12 121471337 G A 3.22E-10 C-reactive protein OASL cds-synon 23844046 rs10774580 chr12 121476423 A G 5.53E-10 C-reactive protein OASL intron 23844046 rs10774580 chr12 121476423 A G 4.97E-07 Inflammation OASL intron pha002897 rs2708104 chr12 121483949 T G 9.32E-11 C-reactive protein / / 23844046 rs2708104 chr12 121483949 T G 3.30E-06 Inflammation / / pha002897 rs2708101 chr12 121487632 C T 1.03E-07 C-reactive protein / / 24763700 rs2258844 chr12 121488372 G C 1.19E-08 C-reactive protein / / 23844046 rs10849835 chr12 121489377 C T 9.99E-04 Multiple complex diseases / / 17554300 rs11065406 chr12 121490520 C T 6.57E-05 Relative hand skill in reading disability / / 24068947 rs2708092 chr12 121525886 G A 7.77E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1796412 chr12 121541712 C T 3.38E-04 Longevity / / 22279548 rs669547 chr12 121577284 T C 4.53E-04 Smoking initiation P2RX7 intron 24665060 rs535557 chr12 121578387 T C 8.18E-04 Multiple complex diseases P2RX7 intron 17554300 rs535557 chr12 121578387 T C 1.14E-04 Smoking initiation P2RX7 intron 24665060 rs568531 chr12 121579673 C T 2.77E-04 Smoking initiation P2RX7 intron 24665060 rs607094 chr12 121580464 T C 2.46E-04 Smoking initiation P2RX7 intron 24665060 rs208288 chr12 121588088 G C 4.92E-04 Smoking initiation P2RX7 intron 24665060 rs17525809 chr12 121592689 T C 0.00073 Breast cancer P2RX7 missense 23555315 rs1718125 chr12 121593019 C T 4.38E-05 Heart Rate P2RX7 intron pha003054 rs1653583 chr12 121598652 G A 2.06E-04 Smoking initiation P2RX7 intron 24665060 rs208296 chr12 121600953 G A 8.52E-04 Multiple complex diseases P2RX7 intron 17554300 rs208296 chr12 121600953 G A 1.54E-05 Lymphocyte counts P2RX7 intron 22286170 rs208296 chr12 121600953 G A 4.19E-04 Smoking cessation P2RX7 intron 24665060 rs208297 chr12 121602027 C T 0.00022 Type 2 diabetes P2RX7 intron 22325160 rs12829218 chr12 121618391 A G 7.18E-05 IgE levels P2RX7 intron 17255346 rs3751143 chr12 121622304 A C 4.00E-06 Chronic obstructive pulmonary disease-related biomarkers P2RX7 missense 23144326 rs1169722 chr12 121641625 G A 2.06E-05 Multiple complex diseases / / 17554300 rs11065483 chr12 121643856 C T 7.18E-04 Type 2 diabetes / / 17463246 rs10774588 chr12 121652541 G A 7.60E-05 Tooth agenesis (mandibular third molar) P2RX4 intron 24172245 rs55780768 chr12 121656404 G A 9.60E-04 Urinary metabolites P2RX4 intron 21572414 rs55837222 chr12 121656561 A G 9.60E-04 Urinary metabolites P2RX4 intron 21572414 rs11065494 chr12 121661614 A C 8.80E-04 Urinary metabolites P2RX4 intron 21572414 rs11065495 chr12 121661688 C T 8.80E-04 Urinary metabolites P2RX4 intron 21572414 rs11065496 chr12 121662182 G A 8.80E-04 Urinary metabolites P2RX4 intron 21572414 rs11065497 chr12 121662370 A C 8.80E-04 Urinary metabolites P2RX4 intron 21572414 rs2567992 chr12 121665853 A G 9.30E-04 Urinary metabolites P2RX4 intron 21572414 rs25644 chr12 121666646 A G 7.60E-05 Tooth agenesis (mandibular third molar) P2RX4 missense 24172245 rs10849859 chr12 121667427 C T 8.02E-04 Multiple complex diseases P2RX4 intron 17554300 rs10849859 chr12 121667427 C T 7.50E-04 Coronary heart disease P2RX4 intron 21966275 rs2668252 chr12 121668474 A C 2.45E-04 Type 2 diabetes P2RX4 intron 17463246 rs1169717 chr12 121668684 C T 9.90E-05 Tooth agenesis (mandibular third molar) P2RX4 intron 24172245 rs1140886 chr12 121681536 C T 0.000163331 Hypertension (early onset hypertension) CAMKK2 UTR-3 22479346 rs1063843 chr12 121681687 T C 3.42E-06 Inflammation CAMKK2 UTR-3 pha002897 rs2695148 chr12 121794777 T C 1.57E-05 Alzheimer's disease (late onset) / / 21379329 rs1647253 chr12 121801098 T C 4.32E-05 Alzheimer's disease (late onset) / / 21379329 rs10849873 chr12 121827474 T A 6.42E-05 Type 2 diabetes / / 17463246 rs7961855 chr12 121829943 C T 3.37E-04 Type 2 diabetes / / 17463246 rs10849877 chr12 121842268 G A 6.42E-05 Type 2 diabetes RNF34 intron 17463246 rs10774594 chr12 121842720 A G 2.90E-05 Urinary metabolites RNF34 intron 21572414 rs10849878 chr12 121844292 G A 6.42E-05 Type 2 diabetes RNF34 intron 17463246 rs7296507 chr12 121847135 A G 2.20E-05 Gamma gluatamyl transferase levels (interaction with age) RNF34 intron 22010049 rs4081775 chr12 121847579 A G 6.42E-05 Type 2 diabetes RNF34 intron 17463246 rs10849880 chr12 121859844 A C 6.42E-05 Type 2 diabetes RNF34 intron 17463246 rs951498 chr12 121865865 C T 6.42E-05 Type 2 diabetes / / 17463246 rs7316497 chr12 121870066 C T 0.000163 Salmonella-induced pyroptosis KDM2B intron 22837397 rs12427382 chr12 121870922 G A 6.42E-05 Type 2 diabetes KDM2B intron 17463246 rs11065575 chr12 121871006 A C 6.42E-05 Type 2 diabetes KDM2B intron 17463246 rs9634167 chr12 121874019 C T 7.44E-05 Type 2 diabetes KDM2B intron 17463246 rs10444489 chr12 121876257 G T 7.44E-05 Type 2 diabetes KDM2B intron 17463246 rs11065576 chr12 121877487 G A 7.44E-05 Type 2 diabetes KDM2B intron 17463246 rs1064951 chr12 121878659 C T 7.44E-05 Type 2 diabetes KDM2B cds-synon 17463246 rs2288154 chr12 121879111 G C 7.44E-05 Type 2 diabetes KDM2B intron 17463246 rs11065577 chr12 121879592 C T 7.44E-05 Type 2 diabetes KDM2B intron 17463246 rs11065578 chr12 121879685 C G 7.44E-05 Type 2 diabetes KDM2B intron 17463246 rs11065579 chr12 121879702 C A 7.44E-05 Type 2 diabetes KDM2B intron 17463246 rs3751131 chr12 121880520 G A 7.44E-05 Type 2 diabetes KDM2B cds-synon 17463246 rs3817549 chr12 121882471 G C 7.44E-05 Type 2 diabetes KDM2B intron 17463246 rs3817544 chr12 121882819 T C 7.44E-05 Type 2 diabetes KDM2B intron 17463246 rs10849888 chr12 121892786 A G 3.46E-04 Type 2 diabetes KDM2B intron 17463246 rs10744764 chr12 121893020 G A 7.44E-05 Type 2 diabetes KDM2B intron 17463246 rs10849889 chr12 121897098 C T 7.44E-05 Type 2 diabetes KDM2B intron 17463246 rs3817543 chr12 121900000 T C 7.44E-05 Type 2 diabetes KDM2B intron 17463246 rs11065585 chr12 121903971 G C 7.44E-05 Type 2 diabetes KDM2B intron 17463246 rs10774598 chr12 121908509 A G 7.44E-05 Type 2 diabetes KDM2B intron 17463246 rs10849891 chr12 121911602 T G 7.44E-05 Type 2 diabetes KDM2B intron 17463246 rs7316418 chr12 121927603 G A 8.46E-05 Parkinson's disease KDM2B intron 21738487 rs11065598 chr12 121933663 C T 2.66E-05 Parkinson's disease KDM2B intron 21738487 rs10849893 chr12 121938185 C G 2.00E-06 Fasting glucose-related traits (interaction with BMI) KDM2B intron 22581228 rs28468612 chr12 122013607 G A 7.65E-04 Response to cytidine analogues (gemcitabine) KDM2B intron 24483146 rs11833075 chr12 122114593 T C 2.73E-04 Multiple complex diseases / / 17554300 rs2669161 chr12 122200419 C G 6.30E-05 Type 2 diabetes TMEM120B intron 17463248 rs10840615 chr12 122203680 C T 8.10E-04 Urinary metabolites TMEM120B intron 21572414 rs2707069 chr12 122204084 C T 6.40E-05 Type 2 diabetes TMEM120B intron 17463248 rs11043196 chr12 122212659 C T 2.20E-06 Urinary metabolites TMEM120B intron 21572414 rs11043196 chr12 122212659 C T 3.85E-05 HDL cholesterol TMEM120B intron pha003074 rs1064169 chr12 122215520 T C 2.13E-05 HDL cholesterol TMEM120B UTR-3 pha003074 rs568533359 chr12 122219787 T TG 9.41E-05 Erythrocyte counts TMEM120B UTR-3 pha003090 rs9165 chr12 122219787 T C 9.41E-05 Erythrocyte counts TMEM120B UTR-3 pha003090 rs11043198 chr12 122222466 G A 2.10E-04 Urinary metabolites RHOF intron 21572414 rs1168667 chr12 122226529 A G 2.10E-05 Urinary metabolites RHOF intron 21572414 rs3741593 chr12 122261456 G A 1.10E-05 Urinary metabolites SETD1B cds-synon 21572414 rs1678960 chr12 122264635 T C 5.50E-10 Urinary metabolites SETD1B intron 21572414 rs1678960 chr12 122264635 T C 4.67E-04 Obesity (extreme) SETD1B intron 21935397 rs7138525 chr12 122264647 C T 8.60E-06 Urinary metabolites SETD1B intron 21572414 rs2242259 chr12 122265106 T C 6.70E-06 Urinary metabolites SETD1B intron 21572414 rs2242260 chr12 122265163 A G 5.40E-06 Urinary metabolites SETD1B intron 21572414 rs11614326 chr12 122269182 G A 7.80E-04 Urinary metabolites SETD1B UTR-3 21572414 rs4298948 chr12 122276255 C G 6.37E-05 Serum metabolites / / 19043545 rs4298948 chr12 122276255 C G 3.00E-06 Obesity-related traits / / 23251661 rs2515729 chr12 122279333 T A 3.70E-06 Urinary metabolites HPD intron 21572414 rs1795963 chr12 122281575 A G 8.60E-07 Urinary metabolites HPD intron 21572414 rs12310752 chr12 122282117 A G 6.70E-09 Urinary metabolites HPD intron 21572414 rs1610041 chr12 122283781 T C 3.97E-05 Erythrocyte counts HPD intron pha003101 rs2247291 chr12 122284715 T C 2.80E-13 Urinary metabolites HPD intron 21572414 rs2707056 chr12 122287290 T A 4.50E-13 Urinary metabolites HPD intron 21572414 rs1449562 chr12 122287885 G A 2.00E-08 Urinary metabolites HPD intron 21572414 rs2707070 chr12 122290439 G A 1.70E-08 Urinary metabolites HPD intron 21572414 rs4760105 chr12 122290930 G A 2.10E-08 Urinary metabolites HPD intron 21572414 rs2620340 chr12 122291261 G A 6.30E-13 Urinary metabolites HPD intron 21572414 rs4760103 chr12 122291714 C G 1.90E-08 Urinary metabolites HPD intron 21572414 rs11043214 chr12 122291860 A T 1.50E-08 Urinary metabolites HPD intron 21572414 rs2596140 chr12 122292962 T G 1.80E-08 Urinary metabolites HPD intron 21572414 rs2620334 chr12 122293639 G A 1.80E-08 Urinary metabolites HPD intron 21572414 rs34943778 chr12 122294005 G A 1.80E-08 Urinary metabolites HPD intron 21572414 rs1154510 chr12 122295335 T C 7.80E-14 Urinary metabolites / / 21572414 rs2707075 chr12 122296084 C T 2.20E-08 Urinary metabolites HPD intron 21572414 rs3741591 chr12 122296784 C T 8.10E-07 Urinary metabolites HPD intron 21572414 rs2596144 chr12 122297738 T C 7.50E-14 Urinary metabolites HPD intron 21572414 rs11043222 chr12 122301275 C T 8.10E-14 Urinary metabolites HPD intron 21572414 rs10840624 chr12 122301299 A G 4.93E-05 Erythrocyte counts HPD intron pha003101 rs7342332 chr12 122303499 G A 4.60E-08 Urinary metabolites HPD intron 21572414 rs2928283 chr12 122303755 C T 2.40E-08 Urinary metabolites HPD intron 21572414 rs9668191 chr12 122305295 A G 4.60E-14 Urinary metabolites HPD intron 21572414 rs1947826 chr12 122305970 T C 4.30E-14 Urinary metabolites HPD intron 21572414 rs2101017 chr12 122306857 C T 3.80E-14 Urinary metabolites HPD intron 21572414 rs11043226 chr12 122307286 G A 4.10E-13 Urinary metabolites HPD intron 21572414 rs10840627 chr12 122307580 A G 7.30E-14 Urinary metabolites HPD intron 21572414 rs12817002 chr12 122309113 A C 1.30E-06 Urinary metabolites HPD intron 21572414 rs7969647 chr12 122313351 A G 1.40E-06 Urinary metabolites HPD intron 21572414 rs4991095 chr12 122316304 G C 7.10E-09 Urinary metabolites HPD intron 21572414 rs4760099 chr12 122318723 A G 8.70E-15 Urinary metabolites HPD intron 21572414 rs895959 chr12 122320352 C T 1.10E-14 Urinary metabolites HPD intron 21572414 rs7309105 chr12 122321699 A G 4.50E-04 Urinary metabolites HPD intron 21572414 rs7309105 chr12 122321699 A G 3.16E-04 Obesity (extreme) HPD intron 21935397 rs2230681 chr12 122326812 T C 1.36E-05 Alcohol and nictotine co-dependence PSMD9 missense 20158304 rs2230681 chr12 122326812 T C 7.10E-15 Urinary metabolites PSMD9 missense 21572414 rs59517025 chr12 122330708 G A 6.70E-04 Urinary metabolites PSMD9 intron 21572414 rs483416 chr12 122338113 G A 6.70E-04 Urinary metabolites PSMD9 intron 21572414 rs483416 chr12 122338113 G A 3.34E-04 Obesity (extreme) PSMD9 intron 21935397 rs482421 chr12 122338233 A G 7.40E-04 Urinary metabolites PSMD9 intron 21572414 rs1168658 chr12 122338566 C T 6.40E-04 Urinary metabolites PSMD9 intron 21572414 rs1168658 chr12 122338566 C T 3.35E-04 Obesity (extreme) PSMD9 intron 21935397 rs56177852 chr12 122339335 A G 7.50E-04 Urinary metabolites PSMD9 intron 21572414 rs3825172 chr12 122340475 C T 7.50E-04 Urinary metabolites PSMD9 intron 21572414 rs3825172 chr12 122340475 C T 1.64E-04 Obesity (extreme) PSMD9 intron 21935397 rs58379261 chr12 122341560 A G 7.40E-04 Urinary metabolites PSMD9 intron 21572414 rs7314056 chr12 122342964 T C 5.00E-14 Urinary metabolites PSMD9 intron 21572414 rs7314056 chr12 122342964 T C 4.00E-16 Urinary metabolites (H-NMR features) PSMD9 intron 24586186 rs1795967 chr12 122344302 A G 2.10E-15 Urinary metabolites PSMD9 intron 21572414 rs895960 chr12 122346052 A G 5.40E-09 Urinary metabolites PSMD9 intron 21572414 rs1720035 chr12 122347612 T G 5.40E-09 Urinary metabolites PSMD9 intron 21572414 rs4069666 chr12 122348746 A G 6.60E-04 Urinary metabolites PSMD9 intron 21572414 rs2688412 chr12 122349058 A G 1.60E-14 Urinary metabolites PSMD9 intron 21572414 rs14259 chr12 122353796 A G 5.30E-04 Urinary metabolites PSMD9 missense 21572414 rs14259 chr12 122353796 A G 5.48E-04 Obesity (extreme) PSMD9 missense 21935397 rs876934 chr12 122354848 C T 7.00E-04 Urinary metabolites PSMD9 UTR-3 21572414 rs876935 chr12 122355716 C T 3.10E-07 Urinary metabolites / / 21572414 rs2272135 chr12 122356157 C T 6.00E-04 Urinary metabolites / / 21572414 rs2272135 chr12 122356157 C T 4.51E-04 Obesity (extreme) / / 21935397 rs200386901 chr12 122359396 G GTC 3.20E-04 Urinary metabolites WDR66 missense 21572414 rs58415126 chr12 122359396 G A 3.20E-04 Urinary metabolites WDR66 missense 21572414 rs12824001 chr12 122359408 G A 2.20E-05 Urinary metabolites WDR66 missense 21572414 rs1720068 chr12 122363695 C T 3.50E-04 Urinary metabolites WDR66 intron 21572414 rs1720068 chr12 122363695 C T 3.60E-04 Obesity (extreme) WDR66 intron 21935397 rs7961894 chr12 122365583 C T 7.00E-48 Mean platelet volume WDR66 intron 19110211 rs7961894 chr12 122365583 C T 3.00E-44 Mean platelet volume WDR66 intron 19820697 rs7961894 chr12 122365583 C T 1.00E-103 Mean platelet volume WDR66 intron 22139419 rs7961894 chr12 122365583 C T 1.00E-10 Platelet counts WDR66 intron 22139419 rs7961894 chr12 122365583 C T 7.24E-44 Mean platelet volume WDR66 intron 22423221 rs7961894 chr12 122365583 C T 6.00E-38 Mean platelet volume WDR66 intron 24026423 rs7314989 chr12 122365795 G C 3.89E-04 Multiple complex diseases WDR66 intron 17554300 rs12578258 chr12 122369153 A G 5.60E-04 Urinary metabolites WDR66 intron 21572414 rs12578258 chr12 122369153 A G 7.15E-04 Obesity (extreme) WDR66 intron 21935397 rs7313748 chr12 122369762 C T 5.60E-04 Urinary metabolites WDR66 cds-synon 21572414 rs7313748 chr12 122369762 C T 7.23E-04 Obesity (extreme) WDR66 cds-synon 21935397 rs1667583 chr12 122370206 T C 5.20E-16 Urinary metabolites WDR66 intron 21572414 rs1678969 chr12 122371474 T C 9.50E-16 Urinary metabolites WDR66 intron 21572414 rs35252940 chr12 122374513 C G 7.50E-04 Urinary metabolites WDR66 intron 21572414 rs1667580 chr12 122377088 G A 2.00E-15 Urinary metabolites WDR66 intron 21572414 rs895958 chr12 122378206 G A 6.00E-16 Urinary metabolites WDR66 intron 21572414 rs2247139 chr12 122380274 A G 9.00E-16 Urinary metabolites WDR66 intron 21572414 rs1667586 chr12 122382179 A G 1.10E-07 Urinary metabolites WDR66 intron 21572414 rs529736 chr12 122384457 A C 3.00E-11 Urinary metabolites WDR66 intron 21572414 rs1720030 chr12 122384959 T C 3.30E-08 Urinary metabolites WDR66 intron 21572414 rs1678952 chr12 122385151 C A 5.10E-08 Urinary metabolites WDR66 intron 21572414 rs1678953 chr12 122385213 G A 6.80E-08 Urinary metabolites WDR66 intron 21572414 rs1375655 chr12 122385690 C T 5.60E-08 Urinary metabolites WDR66 intron 21572414 rs1375654 chr12 122385711 C T 5.10E-08 Urinary metabolites WDR66 intron 21572414 rs686220 chr12 122386515 A G 5.10E-08 Urinary metabolites WDR66 intron 21572414 rs1630699 chr12 122386758 G C 5.10E-08 Urinary metabolites WDR66 intron 21572414 rs1630694 chr12 122386765 G C 5.50E-15 Urinary metabolites WDR66 intron 21572414 rs12579389 chr12 122387337 G T 6.80E-04 Urinary metabolites WDR66 intron 21572414 rs693277 chr12 122387737 A G 9.20E-16 Urinary metabolites WDR66 intron 21572414 rs1375653 chr12 122388314 A G 4.80E-08 Urinary metabolites WDR66 intron 21572414 rs1667584 chr12 122388396 A G 4.20E-16 Urinary metabolites WDR66 intron 21572414 rs1177588 chr12 122389167 A G 2.70E-08 Urinary metabolites WDR66 intron 21572414 rs1185260 chr12 122389248 A G 1.00E-15 Urinary metabolites WDR66 intron 21572414 rs11324705 chr12 122390326 TA T 5.10E-08 Urinary metabolites WDR66 intron 21572414 rs2948666 chr12 122390326 T A 5.10E-08 Urinary metabolites WDR66 intron 21572414 rs1154513 chr12 122391963 A G 1.10E-15 Urinary metabolites WDR66 intron 21572414 rs830124 chr12 122395777 A G 1.00E-46 Urinary metabolites WDR66 intron 21572414 rs17852561 chr12 122396395 C T 6.90E-04 Urinary metabolites WDR66 missense 21572414 rs493519 chr12 122397476 T C 1.70E-15 Urinary metabolites WDR66 intron 21572414 rs493519 chr12 122397476 T C 1.00E-18 Blood metabolite levels WDR66 intron 24816252 rs10840636 chr12 122397855 C A 4.30E-09 Urinary metabolites WDR66 intron 21572414 rs369287246 chr12 122397855 CA CCC 4.30E-09 Urinary metabolites WDR66 intron 21572414 rs853759 chr12 122397856 A C 2.40E-10 Urinary metabolites WDR66 intron 21572414 rs830126 chr12 122398123 A G 1.70E-10 Urinary metabolites WDR66 intron 21572414 rs2309275 chr12 122400813 C T 7.10E-04 Urinary metabolites WDR66 intron 21572414 rs2309275 chr12 122400813 C T 9.26E-04 Obesity (extreme) WDR66 intron 21935397 rs1184893 chr12 122403811 G A 8.10E-08 Urinary metabolites WDR66 intron 21572414 rs1177589 chr12 122403933 A G 1.50E-10 Urinary metabolites WDR66 intron 21572414 rs1169081 chr12 122405912 G T 7.90E-06 Urinary metabolites WDR66 missense 21572414 rs1169081 chr12 122405912 G T 8.20E-04 Obesity (extreme) WDR66 missense 21935397 rs11043276 chr12 122406752 G A 6.57E-04 Multiple complex diseases WDR66 intron 17554300 rs853758 chr12 122408855 T A 3.40E-15 Urinary metabolites WDR66 intron 21572414 rs658957 chr12 122409664 T C 1.50E-10 Urinary metabolites WDR66 UTR-3 21572414 rs1169080 chr12 122410870 G T 2.70E-14 Urinary metabolites WDR66 intron 21572414 rs830116 chr12 122412832 A G 4.80E-15 Urinary metabolites WDR66 intron 21572414 rs830115 chr12 122414103 C T 8.90E-04 Urinary metabolites WDR66 intron 21572414 rs1971955 chr12 122420437 A G 2.50E-11 Urinary metabolites WDR66 intron 21572414 rs1169077 chr12 122425012 A G 2.20E-13 Urinary metabolites WDR66 intron 21572414 rs830123 chr12 122426217 A G 5.80E-11 Urinary metabolites WDR66 intron 21572414 rs830122 chr12 122426236 C T 7.00E-15 Urinary metabolites WDR66 intron 21572414 rs830121 chr12 122427161 C A 7.30E-04 Urinary metabolites WDR66 intron 21572414 rs830121 chr12 122427161 C A 6.77E-04 Obesity (extreme) WDR66 intron 21935397 rs830120 chr12 122427654 T A,C,G 1.70E-10 Urinary metabolites WDR66 intron 21572414 rs1169076 chr12 122429484 G A 8.80E-08 Urinary metabolites WDR66 intron 21572414 rs1169076 chr12 122429484 G A 7.56E-05 Hemoglobin WDR66 intron pha003096 rs1182927 chr12 122439369 T C 1.10E-14 Urinary metabolites WDR66 intron 21572414 rs1179947 chr12 122442444 G A 9.30E-08 Urinary metabolites / / 21572414 rs200801125 chr12 122442444 G GTAA 9.30E-08 Urinary metabolites / / 21572414 rs1169085 chr12 122445233 T C 1.10E-14 Urinary metabolites / / 21572414 rs1169084 chr12 122447128 C T 6.00E-04 Urinary metabolites / / 21572414 rs1169083 chr12 122448979 A G 6.00E-04 Urinary metabolites / / 21572414 rs1169087 chr12 122453740 G C 4.60E-04 Urinary metabolites / / 21572414 rs745327 chr12 122456524 T C 2.50E-04 Urinary metabolites / / 21572414 rs2009257 chr12 122456987 C T 5.90E-04 Urinary metabolites / / 21572414 rs1720041 chr12 122457579 G T 1.60E-14 Urinary metabolites / / 21572414 rs1916333 chr12 122458637 C G 1.10E-14 Urinary metabolites / / 21572414 rs1169091 chr12 122462486 C T 7.00E-07 Urinary metabolites BCL7A intron 21572414 rs1169093 chr12 122464920 T C 1.60E-14 Urinary metabolites BCL7A intron 21572414 rs1169094 chr12 122465535 A G 2.60E-04 Urinary metabolites BCL7A intron 21572414 rs1169095 chr12 122465738 G A 2.60E-04 Urinary metabolites BCL7A intron 21572414 rs1169096 chr12 122465836 G C 2.60E-04 Urinary metabolites BCL7A intron 21572414 rs2272133 chr12 122468273 C T 8.80E-04 Urinary metabolites BCL7A intron 21572414 rs7957207 chr12 122469395 T C 2.00E-13 Urinary metabolites BCL7A intron 21572414 rs6486794 chr12 122469878 G C 2.00E-13 Urinary metabolites BCL7A intron 21572414 rs6486794 chr12 122469878 G C 4.81E-04 Smoking initiation BCL7A intron 24665060 rs7961103 chr12 122470324 T C 2.80E-13 Urinary metabolites BCL7A intron 21572414 rs10840643 chr12 122478854 C T 2.10E-08 Urinary metabolites BCL7A intron 21572414 rs7953704 chr12 122625992 A G 3.00E-08 Urate levels / / 23263486 rs1043763 chr12 122630909 G A 7.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs925460 chr12 122634003 T C 1.30E-04 Smoking behavior / / 20418888 rs10846916 chr12 122639910 T A 2.00E-04 Urinary metabolites / / 21572414 rs556531601 chr12 122639910 T TA 2.00E-04 Urinary metabolites / / 21572414 rs11611988 chr12 122646735 C T 2.93E-05 Coronary restenosis / / 21878436 rs11058789 chr12 122651418 C T 1.42E-04 Multiple complex diseases / / 17554300 rs7972979 chr12 122662856 C T 5.85E-05 Coronary restenosis LRRC43 intron 21878436 rs11059505 chr12 122665285 C G 4.99E-04 Aortic root size LRRC43 intron 21223598 rs4758677 chr12 122675081 G A 4.08E-04 Multiple complex diseases LRRC43 intron 17554300 rs11060167 chr12 122676013 A C 4.00E-05 Asthma (aspirin-intolerant) LRRC43 cds-synon 21072201 rs11060333 chr12 122678607 T C 7.98E-05 Coronary restenosis LRRC43 intron 21878436 rs3809116 chr12 122715535 C T 8.61E-05 Serum metabolites / / 19043545 rs12423987 chr12 122785412 A C 6.63E-05 Serum metabolites CLIP1 intron 19043545 rs11057421 chr12 122789696 C T 2.34E-05 Tunica Media CLIP1 intron pha003036 rs7956480 chr12 122817507 A G 2.90E-05 Amyotrophic lateral sclerosis (sporadic) CLIP1 intron 24529757 rs882969 chr12 122823408 G C 5.60E-04 Acute lung injury CLIP1 intron 22295056 rs10846664 chr12 122823777 A G 5.31E-04 Coronary Artery Disease CLIP1 intron 17634449 rs3817012 chr12 122839909 C T 1.68E-04 Acute lung injury CLIP1 intron 22295056 rs8181750 chr12 122858273 A G 1.33E-04 Acute lung injury CLIP1 intron 22295056 rs11057787 chr12 122859841 C T 1.33E-04 Acute lung injury CLIP1 intron 22295056 rs11058001 chr12 122888594 G A 1.33E-04 Acute lung injury CLIP1 intron 22295056 rs11058062 chr12 122903468 A C 1.33E-04 Acute lung injury CLIP1 intron 22295056 rs7959550 chr12 122915054 C T 4.56E-05 Coronary Artery Disease / / 17634449 rs10846896 chr12 122932472 T C 7.84E-05 Acute lung injury / / 22295056 rs2173581 chr12 122937725 C T 7.84E-05 Acute lung injury / / 22295056 rs10846921 chr12 122943376 A C 7.41E-05 Coronary Artery Disease / / 17634449 rs11058480 chr12 122991279 C T 1.27E-04 Multiple complex diseases RSRC2 intron 17554300 rs9988963 chr12 122991478 C G 4.53E-04 Multiple complex diseases RSRC2 intron 17554300 rs6489157 chr12 123101673 G C 5.00E-04 Multiple complex diseases KNTC1 intron 17554300 rs6489157 chr12 123101673 G C 5.83E-04 Coronary Artery Disease KNTC1 intron 17634449 rs7954006 chr12 123131824 C A 1.20E-05 Parkinson's disease (age of onset) / / 19772629 rs11059258 chr12 123141687 G A 9.60E-05 Parkinson's disease (familial) / / 18985386 rs6489190 chr12 123153825 C T 5.91E-04 Multiple complex diseases / / 17554300 rs601339 chr12 123174743 A G 4.00E-06 Adiponectin levels / / 22479202 rs4759361 chr12 123178280 T A 2.50E-12 HDL cholesterol / / 23063622 rs3922628 chr12 123209295 T A 3.78E-09 HDL cholesterol / / 23063622 rs11060112 chr12 123292503 A C 3.71E-05 Cognitive test performance CCDC62 intron 20125193 rs12817488 chr12 123296294 G A 3.00E-13 Parkinson's disease CCDC62 intron 21292315 rs12817488 chr12 123296294 G A 9.06E-07 Prion diseases CCDC62 intron 22210626 rs12817488 chr12 123296294 G A 2.83E-05 Parkinson's disease CCDC62 intron 22438815 rs12817488 chr12 123296294 G A 4.43E-09 Parkinson's disease CCDC62 intron 22451204 rs11060180 chr12 123303586 A G 5.55E-05 Cognitive test performance CCDC62 intron 20125193 rs10847864 chr12 123326598 G T 1.29E-17 Parkinson's disease HIP1R intron 22438815 rs10847980 chr12 123387922 T G 7.00E-06 Adiponectin levels / / 24105470 rs2270788 chr12 123414349 T C 7.00E-06 IgG glycosylation ABCB9 UTR-3 23382691 rs12311043 chr12 123440612 A G 5.03E-04 Multiple complex diseases ABCB9 intron 17554300 rs4275659 chr12 123447928 T C 9.50E-09 Type 2 diabetes ABCB9 intron 24509480 rs7296418 chr12 123457619 C T 2.00E-06 Platelet counts ABCB9 intron 21507922 rs1727307 chr12 123575742 A G 3.00E-06 Platelet counts PITPNM2 intron 21507922 rs949143 chr12 123595163 G A 5.80E-04 Multiple sclerosis / / 21833088 rs1106240 chr12 123626982 C T 2.69E-05 Multiple sclerosis / / 17660530 rs1569068 chr12 123632276 G A 8.53E-06 Multiple sclerosis / / 17660530 rs1727302 chr12 123632930 G A 4.88E-06 Brachial circumference / / 22479309 rs1727315 chr12 123638930 G A 9.41E-06 Multiple sclerosis / / 17660530 rs1727313 chr12 123640853 C G 5.78E-05 Multiple sclerosis / / 17660530 rs1727313 chr12 123640853 C G 1.00E-08 Type 2 diabetes / / 24509480 rs1051431 chr12 123645803 G A 3.90E-04 Height MPHOSPH9 cds-synon 21194676 rs1051431 chr12 123645803 G A 5.10E-04 Height MPHOSPH9 cds-synon 21194676 rs1051431 chr12 123645803 G A 6.90E-07 Height MPHOSPH9 cds-synon 21194676 rs1716167 chr12 123651162 A G 1.88E-05 Multiple sclerosis MPHOSPH9 intron 17660530 rs1716168 chr12 123651966 G C 1.11E-05 Multiple sclerosis MPHOSPH9 intron 17660530 rs1790100 chr12 123656725 G T 7.00E-07 Multiple sclerosis MPHOSPH9 intron 19525953 rs1790100 chr12 123656725 G T 6.61E-04 Multiple sclerosis MPHOSPH9 intron 22190364 rs2049114 chr12 123657338 T C 1.15E-06 Multiple sclerosis MPHOSPH9 intron 19525953 rs2695478 chr12 123689521 C T 6.82E-05 Multiple sclerosis MPHOSPH9 intron 17660530 rs11532322 chr12 123731423 A G 2.00E-08 Schizophrenia C12orf65 intron 23974872 rs6633 chr12 123745809 G T 0.000225475 Primary sclerosing cholangitis CDK2AP1 UTR-3 23603763 rs3825141 chr12 123794104 G T 7.01E-04 Type 2 diabetes SBNO1 cds-synon 17463246 rs4759375 chr12 123796238 C T 8.00E-09 HDL cholesterol SBNO1 intron 20686565 rs4759375 chr12 123796238 C T 3.00E-08 HDL cholesterol SBNO1 intron 24097068 rs7980687 chr12 123822711 G A 8.00E-09 Head circumference (infant) SBNO1 intron 22504419 rs11830103 chr12 123823546 A G 4.00E-15 Height SBNO1 intron 20881960 rs4310694 chr12 124050760 A G 3.30E-06 Blood Pressure / / pha003050 rs11057298 chr12 124057112 C A 5.15E-04 Taste perception / / 22132133 rs786425 chr12 124085502 G A 3.00E-06 Pubertal anthropometrics LOC100652786 intron 23449627 rs80215100 chr12 124092004 C T 0.00022 Breast cancer DDX55 missense 23555315 rs10846531 chr12 124098612 C G 2.94E-04 Coronary heart disease DDX55 intron 21606135 rs3748269 chr12 124099925 T C 0.0000769 HDL cholesterol DDX55 intron 23063622 rs15587 chr12 124104049 A G 7.00E-05 Response to statin therapy DDX55 cds-synon 20339536 rs3204541 chr12 124104686 G A 7.20E-05 Response to statin therapy DDX55 cds-synon 20339536 rs1050448 chr12 124105925 G A 3.04E-04 Suicide attempts in bipolar disorder EIF2B1 UTR-3 21423239 rs908373 chr12 124113319 C G 0.0000896 HDL cholesterol EIF2B1 intron 23063622 rs12830927 chr12 124120991 C T 0.00000157 HDL cholesterol GTF2H3 intron 23063622 rs4930737 chr12 124139597 A G 5.52E-04 Suicide attempts in bipolar disorder GTF2H3 intron 21423239 rs7958693 chr12 124162750 G A 1.46E-04 Progressive supranuclear palsy TCTN2 intron 21685912 rs7313032 chr12 124172731 G A 1.26E-04 Progressive supranuclear palsy TCTN2 intron 21685912 rs7966867 chr12 124179417 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) TCTN2 cds-synon 20708005 rs6488898 chr12 124203832 G A 3.00E-10 Adiponectin levels ATP6V0A2 intron 22479202 rs11057353 chr12 124265687 T C 6.14E-06 Non-obstructive azoospermia D/H10 missense 22541561 rs7978454 chr12 124316876 A G 7.00E-06 IgG glycosylation D/H10 intron 23382691 rs7965847 chr12 124316915 G A 5.42E-04 Alzheimer's disease D/H10 intron 17998437 rs10773043 chr12 124350704 T C 1.14E-05 Waist Circumference D/H10 intron pha003023 rs11057383 chr12 124369421 T C 2.12E-05 Waist Circumference D/H10 intron pha003023 rs10773046 chr12 124375210 A G 2.00E-06 Osteoarthritis (hip) D/H10 intron 23989986 rs1316952 chr12 124399550 T C 1.00E-07 Visceral adipose tissue/subcutaneous adipose tissue ratio D/H10 intron 22589738 rs1316952 chr12 124399550 T C 5.00E-06 Visceral adipose tissue adjusted for BMI D/H10 intron 22589738 rs1316952 chr12 124399550 T C 9.00E-07 Visceral adipose tissue/subcutaneous adipose tissue ratio D/H10 intron 22589738 rs1316952 chr12 124399550 T C 2.23E-04 Sexual dimorphism in anthropometric traits D/H10 intron 23754948 rs11057401 chr12 124427306 T A 1.65E-05 Type 2 diabetes CCDC92 missense 17463246 rs4765219 chr12 124440110 C A 9.17E-05 Type 2 diabetes CCDC92 intron 17463246 rs7305864 chr12 124441880 C G 3.14E-04 Type 2 diabetes CCDC92 intron 17463246 rs6488914 chr12 124447841 G C 9.23E-06 Type 2 diabetes CCDC92 intron 17463246 rs7973683 chr12 124449223 C A 0.000000699 Body mass index CCDC92 intron 22885924 rs4765127 chr12 124460167 G T 1.31E-04 Type 2 diabetes ZNF664 intron 17463246 rs4765127 chr12 124460167 G T 1.00E-08 Triglycerides ZNF664 intron 20686565 rs4765127 chr12 124460167 G T 3.00E-10 HDL cholesterol ZNF664 intron 20686565 rs4765127 chr12 124460167 G T 2.00E-08 Triglycerides ZNF664 intron 24097068 rs4765127 chr12 124460167 G T 8.00E-10 HDL cholesterol ZNF664 intron 24097068 rs12311114 chr12 124460703 C A 1.96E-05 Type 2 diabetes ZNF664 intron 17463246 rs4765528 chr12 124462254 T A 2.31E-05 Type 2 diabetes ZNF664 intron 17463246 rs4765528 chr12 124462254 T A 8.49E-04 Coronary Artery Disease ZNF664 intron 17634449 rs11057408 chr12 124464836 G T 9.43E-05 Type 2 diabetes ZNF664 intron 17463246 rs7311969 chr12 124470333 T C 7.57E-05 Type 2 diabetes ZNF664 intron 17463246 rs7307277 chr12 124475156 A G 1.00E-08 Lipid levels ZNF664 intron 19936222 rs7307277 chr12 124475156 A G 1.10E-11 Lipid levels ZNF664 intron 19936222 rs7307277 chr12 124475156 A G 1.20E-12 Lipid levels ZNF664 intron 19936222 rs7307277 chr12 124475156 A G 1.40E-09 Lipid levels ZNF664 intron 19936222 rs7307277 chr12 124475156 A G 1.50E-12 Lipid levels ZNF664 intron 19936222 rs7307277 chr12 124475156 A G 2.90E-10 Lipid levels ZNF664 intron 19936222 rs7307277 chr12 124475156 A G 5.00E-10 Lipid levels ZNF664 intron 19936222 rs7307277 chr12 124475156 A G 5.50E-08 Lipid levels ZNF664 intron 19936222 rs7307277 chr12 124475156 A G 6.10E-10 Lipid levels ZNF664 intron 19936222 rs7307277 chr12 124475156 A G 6.70E-11 Lipid levels ZNF664 intron 19936222 rs7307277 chr12 124475156 A G 9.00E-13 Lipid levels ZNF664 intron 19936222 rs7311233 chr12 124475940 A G 3.60E-05 Type 2 diabetes ZNF664 intron 17463246 rs7311233 chr12 124475940 A G 7.54E-04 Coronary Artery Disease ZNF664 intron 17634449 rs4765148 chr12 124478637 G T 5.76E-05 Type 2 diabetes ZNF664 intron 17463246 rs11057409 chr12 124479331 C T 1.94E-04 Type 2 diabetes ZNF664 intron 17463246 rs11057409 chr12 124479331 C T 7.33E-04 Coronary Artery Disease ZNF664 intron 17634449 rs7975482 chr12 124481690 A G 3.30E-04 Type 2 diabetes ZNF664 intron 17463246 rs1187415 chr12 124491529 G C 8.94E-05 Type 2 diabetes ZNF664 intron 17463246 rs1187415 chr12 124491529 G C 2.00E-07 Adiponectin levels ZNF664 intron 24105470 rs7307053 chr12 124494540 C T 1.86E-05 Type 2 diabetes ZNF664 intron 17463246 rs7307053 chr12 124494540 C T 5.01E-04 Coronary Artery Disease ZNF664 intron 17634449 rs1048497 chr12 124499542 G A 7.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio ZNF664 UTR-3 22589738 rs1048497 chr12 124499542 G A 9.00E-06 Visceral adipose tissue adjusted for BMI ZNF664 UTR-3 22589738 rs3768 chr12 124499839 C T 2.80E-06 Waist-hip ratio ZNF664 UTR-3 20935629 rs825508 chr12 124504283 T C 8.18E-04 Coronary heart disease ZNF664-FAM101A intron 21971053 rs863750 chr12 124505444 C T 6.83E-04 Coronary heart disease ZNF664-FAM101A intron 21971053 rs1716403 chr12 124519846 T C 2.00E-06 Response to fenofibrate (adiponectin levels) ZNF664-FAM101A intron 23149075 rs825497 chr12 124525443 A C 9.27E-05 Multiple complex diseases ZNF664-FAM101A intron 17554300 rs10846585 chr12 124528178 G A 2.50E-04 Coronary heart disease ZNF664-FAM101A intron 21971053 rs825456 chr12 124537575 G A 4.46E-04 Coronary heart disease ZNF664-FAM101A intron 21971053 rs902169 chr12 124583446 G A 9.90E-06 Crohn's disease ZNF664-FAM101A intron 20570966 rs902169 chr12 124583446 G A 6.83E-06 Height ZNF664-FAM101A intron pha003010 rs902169 chr12 124583446 G A 9.52E-06 Height ZNF664-FAM101A intron pha003011 rs12824096 chr12 124595327 C T 5.10E-04 Alzheimer's disease ZNF664-FAM101A intron 22005930 rs10773057 chr12 124598267 T G 6.40E-04 Alzheimer's disease ZNF664-FAM101A intron 22005930 rs446580 chr12 124602503 G A 6.28E-04 Aortic root size ZNF664-FAM101A intron 21223598 rs372201 chr12 124602598 C T 3.60E-04 Multiple complex diseases ZNF664-FAM101A intron 17554300 rs7969148 chr12 124614538 T C 2.00E-07 Clubfoot ZNF664-FAM101A intron 24667120 rs400521 chr12 124624602 A G 1.66E-04 Multiple complex diseases ZNF664-FAM101A intron 17554300 rs4765078 chr12 124646827 T C 3.50E-05 Major depressive disorder ZNF664-FAM101A intron 19065144 rs4765078 chr12 124646827 T C 3.34E-05 Major depressive disorder ZNF664-FAM101A intron 21621269 rs4765078 chr12 124646827 T C 1.67E-05 Major depressive disorder ZNF664-FAM101A intron pha002850 rs10846616 chr12 124660939 A C 8.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZNF664-FAM101A intron 20877124 rs10846616 chr12 124660939 A C 6.58E-04 Alcohol consumption (maxi-drinks) ZNF664-FAM101A intron 24277619 rs11057500 chr12 124676823 C T 5.56E-05 Major depressive disorder (broad) ZNF664-FAM101A intron 20038947 rs10846630 chr12 124683205 C T 6.54E-05 Major depressive disorder (broad) ZNF664-FAM101A intron 20038947 rs11057513 chr12 124688501 G C 6.08E-04 Obesity (extreme) ZNF664-FAM101A intron 21935397 rs10773069 chr12 124700826 G T 7.62E-04 Multiple complex diseases ZNF664-FAM101A intron 17554300 rs11057526 chr12 124710996 G A 4.26E-04 Multiple complex diseases ZNF664-FAM101A intron 17554300 rs4765477 chr12 124721270 T C 3.87E-04 Myocardial Infarction ZNF664-FAM101A intron pha002873 rs7972182 chr12 124743155 G A 1.01E-04 Common variable immunodeficiency ZNF664-FAM101A intron 21497890 rs10846637 chr12 124745586 C T 0.0000274 Tuberculosis with early age of onset ZNF664-FAM101A intron 22551897 rs10846641 chr12 124749683 G A 4.39E-04 Lung function (forced expiratory volume in 1 second) ZNF664-FAM101A intron 24023788 rs10161506 chr12 124749869 T C 5.59E-05 Multiple complex diseases ZNF664-FAM101A intron 17554300 rs7297291 chr12 124753264 G C 2.00E-05 Urinary metabolites ZNF664-FAM101A intron 21572414 rs11610586 chr12 124798413 G A 4.94E-05 Blood Pressure FAM101A intron pha003048 rs1809889 chr12 124801226 T C 1.90E-09 Height / / 20881960 rs199762590 chr12 124810911 C T 0.00025 Prostate cancer (non-advanced prostate cancer) NCOR2 missense 23555315 rs1268892 chr12 124845413 T G 8.81E-04 Obesity (extreme) NCOR2 intron 21935397 rs1244068 chr12 124845913 G A 8.44E-04 Obesity (extreme) NCOR2 intron 21935397 rs906302 chr12 124850457 C G 7.04E-04 Obesity (extreme) NCOR2 intron 21935397 rs3782257 chr12 124854903 G A 9.30E-21 Progranulin levels NCOR2 intron 21087763 rs3782257 chr12 124854903 G A 9.30E-21 Myocardial infarction NCOR2 intron 21211798 rs1244050 chr12 124862697 G A 5.65E-04 Obesity (extreme) NCOR2 intron 21935397 rs1268891 chr12 124867996 G T 7.86E-04 Suicide attempts in bipolar disorder NCOR2 intron 21423239 rs12582168 chr12 124894184 T C 9.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) NCOR2 intron 23648065 rs1244096 chr12 124915091 T C 1.92E-05 Alzheimer's disease (late onset) NCOR2 intron 20885792 rs906304 chr12 124926143 G A 6.70E-05 Breast cancer and prostate cancer NCOR2 intron 17903305 rs7980125 chr12 124927970 G A 6.88E-05 Height NCOR2 intron pha003011 rs1794942 chr12 124957153 C T 7.28E-04 Iron levels NCOR2 intron pha002876 rs11057637 chr12 124975312 C T 7.16E-04 Multiple complex diseases NCOR2 intron 17554300 rs11608551 chr12 124995394 G A 2.45E-05 Height NCOR2 intron pha003011 rs150954431 chr12 125002323 C T 5.00E-07 Cocaine dependence NCOR2 intron 23958962 rs701038 chr12 125005128 T C 1.08E-05 Height NCOR2 intron pha003011 rs837466 chr12 125010447 T C 2.60E-05 HIV-1 control NCOR2 intron 20041166 rs12423712 chr12 125033933 G A 7.00E-06 Cognitive performance NCOR2 intron 19734545 rs12423712 chr12 125033933 G A 1.27E-05 Orofacial clefts NCOR2 intron 22419666 rs12423712 chr12 125033933 G A 2.38E-07 Red blood cell traits NCOR2 intron 23222517 rs6488934 chr12 125054769 T A 1.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs837467 chr12 125059927 T C 5.29E-04 Acute lung injury / / 22295056 rs837473 chr12 125067249 A G 1.80E-04 Acute lung injury / / 22295056 rs1726263 chr12 125071643 C T 4.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs837494 chr12 125076210 G A 6.75E-04 Aortic root size / / 21223598 rs11057697 chr12 125085767 C G 3.88E-04 Type 2 diabetes / / 17463246 rs10846690 chr12 125086417 T C 6.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs4765583 chr12 125088084 G A 3.67E-04 Multiple complex diseases / / 17554300 rs11057700 chr12 125088516 C G 6.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs4765158 chr12 125092296 A C 7.63E-04 Obesity (extreme) / / 21935397 rs56303253 chr12 125093422 G A 3.00E-04 Urinary metabolites / / 21572414 rs4765161 chr12 125101700 C A 2.30E-04 Urinary metabolites / / 21572414 rs4765587 chr12 125101850 A T 2.30E-04 Urinary metabolites / / 21572414 rs2950367 chr12 125112666 T C 0.0000732 Sarcoidosis / / 22952805 rs11057712 chr12 125113491 C A 7.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs643167 chr12 125120081 A G 4.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs732954 chr12 125123562 C A 5.07E-04 Aortic root size / / 21223598 rs4765594 chr12 125123792 G A 3.43E-04 Alzheimer's disease / / 17998437 rs11057723 chr12 125125398 C T 2.27E-04 Alzheimer's disease / / 17998437 rs7956328 chr12 125125465 T A 6.36E-06 Diabetic nephropathy / / pha002852 rs7956328 chr12 125125465 T A 8.55E-06 Diabetic nephropathy / / pha002864 rs7132377 chr12 125151994 G A 3.80E-04 Smoking quantity / / 24665060 rs11057750 chr12 125158762 A G 7.59E-04 Alcohol dependence / / 24277619 rs860791 chr12 125161443 C T 5.10E-04 Urinary metabolites / / 21572414 rs701089 chr12 125169957 T C 7.64E-05 Height / / pha003011 rs10846721 chr12 125204141 G A 1.94E-05 Insulin resistance / / 21901158 rs1726353 chr12 125227320 G A 9.25E-04 Obesity (extreme) / / 21935397 rs1726353 chr12 125227320 G A 9.57E-05 Socioeconomic Factors / / pha003067 rs838918 chr12 125238811 C T 9.30E-05 Socioeconomic Factors / / pha003067 rs701099 chr12 125240995 C G 8.36E-05 Serum metabolites / / 19043545 rs838878 chr12 125260645 A G 5.05E-05 Lipid levels / / 19913121 rs838878 chr12 125260645 A G 0.000000661 HDL cholesterol / / 23063622 rs838880 chr12 125261593 C T 3.00E-14 HDL cholesterol / / 20686565 rs838880 chr12 125261593 C T 6.00E-32 HDL cholesterol / / 24097068 rs12580323 chr12 125279661 C T 8.12E-09 HDL cholesterol SCARB1 intron 23063622 rs12819677 chr12 125283521 C T 6.31E-09 HDL cholesterol SCARB1 intron 23063622 rs10773105 chr12 125283766 C T 1.22E-09 HDL cholesterol SCARB1 intron 23063622 rs865716 chr12 125290856 A T 7.45E-11 HDL cholesterol SCARB1 intron 23063622 rs5889 chr12 125298877 G A 9.15E-04 Insulin resistance SCARB1 cds-synon 21901158 rs4765615 chr12 125299830 C T 0.0000635 HDL cholesterol SCARB1 intron 23063622 rs7958037 chr12 125306248 G A 0.00000108 HDL cholesterol SCARB1 intron 23063622 rs7137923 chr12 125306848 G T 0.000000826 HDL cholesterol SCARB1 intron 23063622 rs11057830 chr12 125307053 G A 8.00E-09 Vitamin E levels SCARB1 intron 21729881 rs11057830 chr12 125307053 G A 2.01E-08 Lipoprotein-associated phospholipase A2 activity and mass SCARB1 intron 22003152 rs10846743 chr12 125310305 G A 1.19E-04 Type 2 diabetes SCARB1 intron 17463246 rs10846743 chr12 125310305 G A 0.0000001 HDL cholesterol SCARB1 intron 23063622 rs10846744 chr12 125312425 G C 1.00E-08 Lipoprotein-associated phospholipase A2 activity and mass SCARB1 intron 20442857 rs10846744 chr12 125312425 G C 6.07E-09 Lipoprotein-associated phospholipase A2 activity and mass SCARB1 intron 22003152 rs11608336 chr12 125313426 C T 5.40E-06 Urinary metabolites SCARB1 intron 21572414 rs11057841 chr12 125316743 C T 1.39E-08 Lipoprotein-associated phospholipase A2 activity and mass SCARB1 intron 22003152 rs11057841 chr12 125316743 C T 6.00E-14 Lipoprotein-associated phospholipase A2 activity and mass SCARB1 intron 23118302 rs11057841 chr12 125316743 C T 0.000000156 Coronary artery disease SCARB1 intron 23202125 rs7967521 chr12 125316770 T C 2.00E-05 Urinary metabolites SCARB1 intron 21572414 rs7967521 chr12 125316770 T C 1.40E-04 IgE levels in asthmatics SCARB1 intron 23967269 rs7967521 chr12 125316770 T C 3.85E-05 Response to mTOR inhibitor (everolimus) SCARB1 intron 24009623 rs12581963 chr12 125317125 G A 4.25E-08 Lipoprotein-associated phospholipase A2 activity and mass SCARB1 intron 22003152 rs12580803 chr12 125317247 A G 7.40E-05 Lipid levels SCARB1 intron 19913121 rs12580803 chr12 125317247 A G 3.70E-07 Urinary metabolites SCARB1 intron 21572414 rs4765623 chr12 125320850 C T 3.00E-08 Renal cell carcinoma SCARB1 intron 21131975 rs3924313 chr12 125328375 G A 7.19E-05 Lipoprotein-associated phospholipase A2 activity and mass SCARB1 intron 20442857 rs10773112 chr12 125338529 C T 0.00000876 HDL cholesterol (female) SCARB1 intron 23063622 rs10773112 chr12 125338529 C T 4.36E-10 HDL cholesterol SCARB1 intron 23063622 rs4238001 chr12 125348263 C T 1 Drug response to Fenofibrate SCARB1 missense 18542840 rs6488950 chr12 125354103 C T 6.67E-04 Alzheimer's disease / / 22005930 rs7295752 chr12 125363433 A G 6.46E-04 Lymphocyte counts / / 22286170 rs2070628 chr12 125398517 G A 0.000000623 HDL cholesterol UBC intron 23063622 rs10846771 chr12 125412006 C T 0.00000943 Menopause (age at onset) / / 23424626 rs11057913 chr12 125412075 T C 5.55E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9988954 chr12 125413422 A C 5.61E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10773123 chr12 125427751 T C 6.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10773124 chr12 125428528 C T 6.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10082832 chr12 125429725 G A 2.70E-05 Psoriasis / / 19169255 rs10744185 chr12 125430760 C T 5.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3803143 chr12 125431990 C T 5.76E-04 Depression (quantitative trait) DHX37 UTR-3 20800221 rs10744187 chr12 125437591 G A 1.44E-04 Multiple complex diseases DHX37 intron 17554300 rs4765195 chr12 125456505 C T 2.94E-04 Coronary heart disease DHX37 intron 21606135 rs7310934 chr12 125458859 C T 7.60E-06 Urinary metabolites DHX37 intron 21572414 rs4580006 chr12 125460667 T A 2.86E-04 Alcohol dependence DHX37 intron 21314694 rs11057970 chr12 125486750 C T 2.35E-04 Multiple complex diseases BRI3BP intron 17554300 rs10846806 chr12 125496759 T C 3.64E-04 Response to TNF antagonist treatment BRI3BP intron 21061259 rs3751184 chr12 125497055 G A 1.71E-04 Multiple complex diseases BRI3BP intron 17554300 rs7316480 chr12 125500077 G T 7.07E-05 Cognitive performance BRI3BP intron 19734545 rs11613364 chr12 125503753 C T 9.18E-04 Suicide attempts in bipolar disorder BRI3BP intron 21423239 rs12300899 chr12 125546575 C T 5.00E-07 Bipolar disorder (body mass index interaction) / / 24322204 rs201585816 chr12 125546575 C CT 5.00E-07 Bipolar disorder (body mass index interaction) / / 24322204 rs879993 chr12 125555462 G A 1.91E-09 Multiple complex diseases AACS intron 17554300 rs7970937 chr12 125590417 T C 2.13E-04 Substance dependence AACS intron 21818250 rs10773145 chr12 125625603 T C 4.86E-05 Multiple sclerosis AACS intron 17660530 rs4412800 chr12 125674742 T C 1.09E-05 Multiple sclerosis / / 17660530 rs12578774 chr12 125681761 C T 8.05E-06 Multiple sclerosis / / 17660530 rs4765232 chr12 125704554 T C 1.72E-05 Serum metabolites / / 19043545 rs4442602 chr12 125710951 T C 2.58E-05 Serum metabolites / / 19043545 rs12818316 chr12 125737328 C T 3.79E-05 Elbow pain / / pha003008 rs4765237 chr12 125749239 A G 9.86E-04 Alzheimer's disease / / 17998437 rs11058115 chr12 125759099 A G 3.08E-06 Cholesterol / / 17255346 rs10846855 chr12 125762980 T C 1.47E-04 Cholesterol / / 17255346 rs11058118 chr12 125763431 C T 2.04E-04 Cholesterol / / 17255346 rs11058119 chr12 125763481 C G 1.47E-04 Cholesterol / / 17255346 rs12369591 chr12 125764947 T C 3.33E-06 Cholesterol / / 17255346 rs11058123 chr12 125765296 G A 1.78E-04 Cholesterol / / 17255346 rs4765036 chr12 125775474 T C 2.65E-04 Cholesterol / / 17255346 rs7306356 chr12 125776130 C T 1.07E-05 Major depressive disorder / / 20516156 rs12146745 chr12 125778841 G T 1.34E-05 Cholesterol / / 17255346 rs12146745 chr12 125778841 G T 8.15E-04 Epilepsy / / 22116939 rs7972260 chr12 125785134 A C 2.00E-06 Urinary metabolites / / 21572414 rs12425883 chr12 125789999 G C 1.90E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs2088707 chr12 125791463 G A 4.78E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs3843671 chr12 125807035 G A 7.93E-04 Schizophrenia / / 19197363 rs7134868 chr12 125825114 G A 1.12E-04 Breast cancer TMEM132B intron pha002853 rs7971264 chr12 125833964 C T 7.13E-05 Cognitive test performance TMEM132B intron 20125193 rs7135679 chr12 125846380 A G 1.32E-04 Type 2 diabetes TMEM132B intron 17463246 rs7960063 chr12 125861637 C T 5.00E-06 Urinary metabolites TMEM132B intron 21572414 rs12306023 chr12 125873274 C T 2.10E-05 Urinary metabolites TMEM132B intron 21572414 rs1147246 chr12 125875466 T G 2.00E-06 Amyotrophic lateral sclerosis (sporadic) TMEM132B intron 24529757 rs161716 chr12 125889344 T C 1.45E-04 Multiple complex diseases TMEM132B intron 17554300 rs12422793 chr12 125892835 G A 6.10E-04 Body mass index TMEM132B intron 21701565 rs10846883 chr12 125897951 C T 4.61E-04 Smoking initiation TMEM132B intron 24665060 rs7312043 chr12 125931715 T G 8.71E-04 Multiple complex diseases TMEM132B intron 17554300 rs11058197 chr12 125968344 G A 2.00E-04 Asperger disorder TMEM132B intron 21182207 rs4765045 chr12 125991984 A G 2.06E-06 Asthma TMEM132B intron 23181788 rs849347 chr12 126005997 T G 4.59E-04 Smoking initiation TMEM132B intron 24665060 rs865379 chr12 126006605 G A 8.89E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TMEM132B intron 24023788 rs11058220 chr12 126008058 C A 2.13E-05 Lupus nephritis in systemic lupus erythematosus TMEM132B intron 24925725 rs11058222 chr12 126008354 A G 4.76E-05 Lupus nephritis in systemic lupus erythematosus TMEM132B intron 24925725 rs12814129 chr12 126010198 T C 2.64E-05 Lupus nephritis in systemic lupus erythematosus TMEM132B intron 24925725 rs12832769 chr12 126010335 C T 2.06E-05 Lupus nephritis in systemic lupus erythematosus TMEM132B intron 24925725 rs11058227 chr12 126018404 T G 8.16E-05 Cognitive performance TMEM132B intron 19734545 rs10459109 chr12 126019726 A G 8.34E-05 Attention deficit hyperactivity disorder TMEM132B intron 23728934 rs10846917 chr12 126043123 C T 3.92E-04 Multiple complex diseases TMEM132B intron 17554300 rs7956979 chr12 126052404 A G 1.22E-08 Narcolepsy TMEM132B intron 19629137 rs10492032 chr12 126077244 T G 9.66E-05 Non-alcoholic fatty liver disease histology (other) TMEM132B intron 20708005 rs11058260 chr12 126082041 G T 3.24E-05 Height TMEM132B intron 22021425 rs16919315 chr12 126084363 C T 5.12E-08 Autism TMEM132B intron 22843504 rs11610341 chr12 126107480 C T 1.84E-05 Panic disorder TMEM132B intron 19165232 rs1043607 chr12 126143346 G A 4.00E-06 Bipolar disorder (body mass index interaction) TMEM132B UTR-3 24322204 rs2214959 chr12 126149641 T G 1.50E-05 Subclinical atherosclerosis / / 17903303 rs16919388 chr12 126159566 G A 3.92E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs12305273 chr12 126163943 T A 4.80E-04 Multiple complex diseases / / 17554300 rs2345773 chr12 126209166 G A 6.82E-04 Type 2 diabetes / / 17463246 rs11058304 chr12 126210754 A G 1.33E-05 Type 2 diabetes / / 17463246 rs10846960 chr12 126211294 G A 1.65E-05 Type 2 diabetes / / 17463246 rs12318567 chr12 126217834 A G 2.23E-05 Type 2 diabetes / / 17463246 rs4765066 chr12 126238948 G A 6.56E-09 Multiple complex diseases / / 17554300 rs1558062 chr12 126253507 G A 6.74E-04 Alcohol dependence / / 20201924 rs2190480 chr12 126256876 C T 9.39E-04 Type 2 diabetes / / 17463246 rs4765299 chr12 126280837 C T 6.20E-04 Multiple complex diseases / / 17554300 rs4765299 chr12 126280837 C T 2.22E-06 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines / / 21483694 rs2079548 chr12 126290697 G A 4.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6489016 chr12 126296091 G T 4.17E-04 Alzheimer's disease / / 17998437 rs6489020 chr12 126301003 C T 4.30E-04 Graves' disease / / 21841780 rs10846982 chr12 126303338 G A 4.75E-04 Graves' disease / / 21841780 rs2345779 chr12 126317824 G T 8.64E-04 Graves' disease / / 21841780 rs2190679 chr12 126319949 A G 6.60E-05 Homocysteine levels,in plasma / / 19525478 rs1859943 chr12 126326568 A G 6.40E-05 Homocysteine levels,in plasma / / 19525478 rs1859943 chr12 126326568 A G 8.73E-04 Graves' disease / / 21841780 rs11058371 chr12 126328809 G A 3.48E-04 Type 2 diabetes / / 17463246 rs34080861 chr12 126332890 G A,C 1.23E-04 Type 2 diabetes / / 17463246 rs2108521 chr12 126335464 T C 9.96E-05 Parkinson's disease / / pha002865 rs733361 chr12 126345752 T G 6.96E-07 Graves' disease / / 21841780 rs929423 chr12 126347014 T C 5.42E-07 Graves' disease / / 21841780 rs10847009 chr12 126368528 G A 1.00E-04 Information processing speed / / 21130836 rs7980248 chr12 126381317 T C 0.0000147 Panic disorder / / 23149450 rs7980248 chr12 126381317 T C 1.47E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs11058396 chr12 126406271 T A 0.0000196 Panic disorder / / 23149450 rs11058396 chr12 126406271 T A 1.96E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs225518 chr12 126415017 G A 0.0000689 Panic disorder / / 23149450 rs225518 chr12 126415017 G A 6.89E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs225556 chr12 126436539 T C 4.29E-04 Multiple complex diseases / / 17554300 rs16919816 chr12 126436953 T C 3.88E-04 Multiple complex diseases / / 17554300 rs225559 chr12 126438878 C T 3.81E-04 Multiple complex diseases / / 17554300 rs10847023 chr12 126444520 T C 2.30E-04 Alcohol dependence LOC400084 intron 20201924 rs10847023 chr12 126444520 T C 8.40E-05 Alcohol dependence LOC400084 intron 20201924 rs10847023 chr12 126444520 T C 8.38E-05 Alcoholism LOC400084 intron pha002893 rs10847028 chr12 126476292 G A 4.97E-04 Type 2 diabetes / / 17463246 rs764553 chr12 126481108 G A 4.46E-04 Type 2 diabetes / / 17463246 rs7302674 chr12 126490070 G T 6.36E-04 Type 2 diabetes / / 17463246 rs11058441 chr12 126497390 C T 7.16E-04 Type 2 diabetes / / 17463246 rs7956291 chr12 126497455 C T 6.66E-04 Type 2 diabetes / / 17463246 rs7955812 chr12 126497766 G C 8.71E-04 Type 2 diabetes / / 17463246 rs225495 chr12 126501464 A C 1.61E-04 Blood pressure / / 17255346 rs224778 chr12 126521240 T C 3.88E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs224780 chr12 126523626 T G 2.31E-04 Type 2 diabetes / / 17463246 rs4765318 chr12 126528730 C T 2.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10847046 chr12 126534862 G A 2.73E-05 Hepatitis B / / 21750111 rs10773227 chr12 126537580 G A 3.11E-05 Hepatitis B / / 21750111 rs7954887 chr12 126539615 C T 6.65E-04 Smoking initiation / / 24665060 rs7312063 chr12 126543165 G A 2.38E-05 Hepatitis B / / 21750111 rs10847054 chr12 126550167 T C 5.02E-05 Type 2 diabetes / / 17463246 rs10847056 chr12 126554519 A C 2.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs17548327 chr12 126555279 C T 5.30E-05 Cognitive function / / 24684796 rs2109130 chr12 126559271 C T 3.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs11612464 chr12 126560089 G A 3.89E-04 Type 2 diabetes / / 17463246 rs7316146 chr12 126564383 T C 4.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs929484 chr12 126564421 A C 9.11E-04 Bipolar disorder / / 19259986 rs7297382 chr12 126564513 C T 5.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs7973147 chr12 126572749 G C 1.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs7963351 chr12 126572762 T C 1.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs10847072 chr12 126576633 T C 1.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs10847075 chr12 126577699 C T 1.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs10492040 chr12 126583323 A G 1.32E-05 Bipolar disorder / / 19259986 rs7304433 chr12 126586344 T C 6.75E-05 Suicide attempts in bipolar disorder / / 21423239 rs7970693 chr12 126587642 A G 6.71E-05 Suicide attempts in bipolar disorder / / 21423239 rs10847084 chr12 126590523 T C 1.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs7960175 chr12 126624164 T C 2.27E-05 Height / / pha003011 rs7295877 chr12 126629052 G T 3.32E-05 Height / / pha003011 rs11613501 chr12 126654881 C T 7.38E-05 Aging (time to event) / / 21782286 rs7977375 chr12 126661071 C T 4.00E-06 Emphysema-related traits / / 20709820 rs10773257 chr12 126726530 G A 2.60E-05 Urinary metabolites / / 21572414 rs10847119 chr12 126731343 T C 1.90E-05 Urinary metabolites / / 21572414 rs7309523 chr12 126738140 G A 2.40E-05 Urinary metabolites / / 21572414 rs11058598 chr12 126762767 C T 9.02E-11 Metabolite levels / / 22286219 rs7138309 chr12 126799141 C T 4.03E-04 Multiple complex diseases / / 17554300 rs7958738 chr12 126820127 A G 9.24E-05 Lung function (forced vital capacity) / / pha003104 rs10773263 chr12 126823845 A G 2.43E-04 Multiple complex diseases / / 17554300 rs2192902 chr12 126824356 C A 1.86E-04 Multiple complex diseases / / 17554300 rs4765083 chr12 126837365 A T 1.03E-04 Multiple complex diseases / / 17554300 rs12311815 chr12 126855058 G A 2.67E-05 Cognitive impairment induced by topiramate / / 22091778 rs12307155 chr12 126855226 T C 2.67E-05 Cognitive impairment induced by topiramate / / 22091778 rs7953497 chr12 126863718 G T 7.13E-04 Multiple complex diseases / / 17554300 rs11058637 chr12 126895488 T C 2.83E-05 Orofacial clefts / / 22419666 rs1014153 chr12 126900016 G T 4.97E-05 Psoriasis / / 18364390 rs16920636 chr12 126910898 G A 5.83E-04 Multiple complex diseases / / 17554300 rs2109148 chr12 126939798 A C 6.89E-04 Parkinson's disease LOC100128554 intron 17052657 rs11058659 chr12 126940768 C T 0.00052 Breast cancer LOC100128554 intron 23555315 rs4765391 chr12 126944404 T C 7.17E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) LOC100128554 intron 23648065 rs10847163 chr12 126945623 C A 5.80E-04 Amyotrophic Lateral Sclerosis LOC100128554 intron 17362836 rs7313490 chr12 126965095 T A 7.86E-04 Multiple complex diseases / / 17554300 rs10734928 chr12 126983701 T C 5.32E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16920745 chr12 126998184 C A 3.03E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1981670 chr12 127010704 C G 2.77E-15 Multiple complex diseases / / 17554300 rs16920791 chr12 127044990 C G 9.64E-05 IgE levels / / 22075330 rs16920797 chr12 127054170 A G 2.30E-05 Urinary metabolites / / 21572414 rs8181751 chr12 127062791 C T 2.26E-04 Multiple complex diseases / / 17554300 rs6489102 chr12 127084637 C T 3.22E-05 Gaucher disease severity / / 22388998 rs11058749 chr12 127096227 C G 5.80E-11 Metabolite levels / / 22286219 rs7135161 chr12 127137839 T C 1.28E-09 Coronary heart disease / / 23364394 rs1194029 chr12 127230195 G A 8.15E-04 Type 2 diabetes LOC387895 intron 17463246 rs1194032 chr12 127231394 G C 5.38E-04 Type 2 diabetes LOC387895 intron 17463246 rs1194032 chr12 127231394 G C 2.70E-05 Urinary metabolites LOC387895 intron 21572414 rs4765451 chr12 127237464 C T 6.89E-04 Heart Failure LOC387895 intron pha002884 rs1798816 chr12 127239259 T C 7.97E-04 Smoking initiation LOC387895 intron 24665060 rs4765457 chr12 127264577 T G 9.39E-04 Multiple complex diseases / / 17554300 rs4765458 chr12 127264886 C T 9.73E-04 Multiple complex diseases / / 17554300 rs4765114 chr12 127271669 C T 4.61E-05 Pancreatic cancer / / pha002889 rs11058806 chr12 127276834 A G 4.87E-04 Alzheimer's disease / / 17998437 rs4765461 chr12 127276861 C A 9.11E-04 Alzheimer's disease / / 17998437 rs6489129 chr12 127282975 G T 5.90E-04 Alzheimer's disease / / 17998437 rs950795 chr12 127292003 G A 8.00E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs12304971 chr12 127292957 G T 1.90E-05 Urinary metabolites / / 21572414 rs12827056 chr12 127310621 C T 6.00E-06 Upper aerodigestive tract cancers / / 21437268 rs12817093 chr12 127329113 T G 7.69E-04 Type 2 diabetes / / 17463246 rs1166229 chr12 127353820 G A 1.33E-05 Cognitive performance / / 19734545 rs7315778 chr12 127379621 T C 1.40E-05 Urinary metabolites / / 21572414 rs1166245 chr12 127380354 T C 9.56E-04 Multiple complex diseases / / 17554300 rs7952769 chr12 127389524 C G 2.27E-04 Multiple complex diseases / / 17554300 rs7952781 chr12 127389568 C T 3.73E-04 Lung function (forced vital capacity) / / 24023788 rs10773338 chr12 127404403 G A 3.00E-05 Psoriasis / / 19169255 rs1732449 chr12 127412915 C T 2.40E-04 Multiple complex diseases / / 17554300 rs1166427 chr12 127423958 T C 5.24E-04 Multiple complex diseases / / 17554300 rs12426396 chr12 127429898 G A 1.35E-05 Multiple complex diseases / / 17554300 rs7307729 chr12 127435781 T C 7.47E-05 Relative hand skill / / 24068947 rs1627684 chr12 127438507 T A,C 6.65E-04 Parkinson's disease / / 17052657 rs7138792 chr12 127484300 C T 6.48E-05 Body Fat Distribution / / pha003016 rs7138792 chr12 127484300 C T 7.14E-05 Weight / / pha003026 rs7138792 chr12 127484300 C T 6.25E-05 Weight / / pha003027 rs2541995 chr12 127488436 C T 2.76E-05 Body Fat Distribution / / pha003016 rs2541995 chr12 127488436 C T 3.29E-05 Weight / / pha003026 rs2541995 chr12 127488436 C T 2.56E-05 Weight / / pha003027 rs2701248 chr12 127490054 T C 2.76E-05 Body Fat Distribution / / pha003016 rs2701248 chr12 127490054 T C 3.29E-05 Weight / / pha003026 rs2701248 chr12 127490054 T C 2.56E-05 Weight / / pha003027 rs2732494 chr12 127490326 A C 9.74E-06 Body Mass Index / / pha003006 rs2732494 chr12 127490326 A C 6.17E-06 Body Mass Index / / pha003007 rs2732494 chr12 127490326 A C 1.02E-05 Body Mass Index / / pha003015 rs2732494 chr12 127490326 A C 1.99E-06 Body Fat Distribution / / pha003016 rs2732494 chr12 127490326 A C 9.78E-06 Body Fat Distribution / / pha003017 rs2732494 chr12 127490326 A C 2.35E-05 Body Fat Distribution / / pha003018 rs2732494 chr12 127490326 A C 6.83E-05 Waist Circumference / / pha003024 rs2732494 chr12 127490326 A C 8.12E-06 Waist Circumference / / pha003025 rs2732494 chr12 127490326 A C 6.38E-06 Weight / / pha003026 rs2732494 chr12 127490326 A C 1.06E-05 Weight / / pha003027 rs2541993 chr12 127490572 G A 2.76E-05 Body Fat Distribution / / pha003016 rs2541993 chr12 127490572 G A 3.29E-05 Weight / / pha003026 rs2541993 chr12 127490572 G A 2.56E-05 Weight / / pha003027 rs11058910 chr12 127493679 C A 1.50E-06 Urinary metabolites / / 21572414 rs10847255 chr12 127496488 T C 9.92E-06 Obesity-related traits / / 23251661 rs11058914 chr12 127500351 A G 2.90E-07 Urinary metabolites / / 21572414 rs7132616 chr12 127500406 G A 1.80E-07 Urinary metabolites / / 21572414 rs12314127 chr12 127512658 A G 0.0000547 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12314127 chr12 127512658 A G 5.47E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1978360 chr12 127512752 C T 0.0000545 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1978360 chr12 127512752 C T 5.45E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12296715 chr12 127513917 G A 0.000054 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12296715 chr12 127513917 G A 5.40E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7955903 chr12 127518456 C T 0.0006937 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7955903 chr12 127518456 C T 6.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11058936 chr12 127522968 C A 2.80E-06 Urinary metabolites / / 21572414 rs11058946 chr12 127527070 T G 5.92E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs10773359 chr12 127537905 C T 7.86E-04 Multiple complex diseases / / 17554300 rs2347910 chr12 127553272 C T 7.60E-05 Lung adenocarcinoma / / 22797724 rs7296444 chr12 127555734 G A 3.01E-05 Fasting insulin (interaction) / / 24204828 rs7296444 chr12 127555734 G A 5.09E-05 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs1396566 chr12 127621521 G A 8.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs10847282 chr12 127629984 C T 1.40E-05 Alcohol dependence / / 20201924 rs10847282 chr12 127629984 C T 1.39E-05 Alcoholism / / pha002892 rs2712553 chr12 127639922 G A 7.73E-05 Suicide attempts in bipolar disorder / / 21423239 rs2712557 chr12 127644386 T C 7.84E-05 Pulmonary function / / 19300500 rs10773370 chr12 127656553 C T 8.26E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs906724 chr12 127677897 G T 8.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs10431315 chr12 127725881 G C 6.81E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2712542 chr12 127730787 T C 8.60E-07 Urinary metabolites / / 21572414 rs1848532 chr12 127731714 G C 9.70E-07 Urinary metabolites / / 21572414 rs1868017 chr12 127756570 C T 5.34E-05 Sodium levels / / pha003093 rs7974564 chr12 127782628 G T 6.98E-04 Type 2 diabetes / / 17463246 rs1823172 chr12 127792614 C T 5.00E-07 Sudden cardiac arrest / / 21658281 rs1447090 chr12 127793437 G A 6.75E-04 Alzheimer's disease / / 17998437 rs2656825 chr12 127813229 A T 7.24E-04 Depression (quantitative trait) / / 20800221 rs2695952 chr12 127813442 C T 4.02E-04 Depression (quantitative trait) / / 20800221 rs10744304 chr12 127813741 G A 9.00E-06 Depression (quantitative trait) / / 20800221 rs10744304 chr12 127813741 G A 8.70E-06 Depression (quantitative trait) / / 23290196 rs2656824 chr12 127815086 C T 2.07E-04 Depression (quantitative trait) / / 20800221 rs2593270 chr12 127815178 G A 4.45E-04 Depression (quantitative trait) / / 20800221 rs2656823 chr12 127815260 A G 2.07E-04 Depression (quantitative trait) / / 20800221 rs2656822 chr12 127815488 C T 2.06E-04 Depression (quantitative trait) / / 20800221 rs2593272 chr12 127815644 A G 2.06E-04 Depression (quantitative trait) / / 20800221 rs2593273 chr12 127816124 C T 5.84E-04 Depression (quantitative trait) / / 20800221 rs4765531 chr12 127816203 C A 4.13E-04 Depression (quantitative trait) / / 20800221 rs2921983 chr12 127816280 T C 4.38E-04 Depression (quantitative trait) / / 20800221 rs1700400 chr12 127816720 C T 1.09E-04 Depression (quantitative trait) / / 20800221 rs7979980 chr12 127826818 T C 2.46E-04 Depression (quantitative trait) / / 20800221 rs7980475 chr12 127844150 T A 4.00E-07 Urinary metabolites / / 21572414 rs1684227 chr12 127846842 T G 6.22E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs1385993 chr12 127851007 A G 1.38E-04 Aortic root size / / 21223598 rs1684196 chr12 127851079 T G 6.96E-04 Type 2 diabetes / / 17463246 rs1684196 chr12 127851079 T G 3.88E-04 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs1354560 chr12 127851380 C T 6.09E-04 Type 2 diabetes / / 17463246 rs11059101 chr12 127874250 T C 2.31E-04 Celiac disease / / 23936387 rs1875952 chr12 127875923 G A 9.57E-05 Monocyte chemoattractant protein-1 / / pha003071 rs7977962 chr12 127909548 A G 1.16E-04 Multiple complex diseases / / 17554300 rs1879390 chr12 127918132 C A 6.93E-06 Suicidal ideation / / 20877300 rs11059124 chr12 127922595 A G 5.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs11059127 chr12 127922837 G T 4.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs10847348 chr12 127924342 C T 3.75E-04 Suicide attempts in bipolar disorder / / 21041247 rs4761007 chr12 127924890 T C 4.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs10847351 chr12 127943220 T C 7.50E-06 Urinary metabolites / / 21572414 rs901235 chr12 127944690 G A 1.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs1463752 chr12 127958609 C T 1.23E-04 Multiple complex diseases / / 17554300 rs1463752 chr12 127958609 C T 2.40E-06 Urinary metabolites / / 21572414 rs4426172 chr12 127958733 C T 1.30E-04 Type 2 diabetes / / 17463249 rs4426172 chr12 127958733 C T 1.31E-04 Multiple complex diseases / / 17554300 rs4426172 chr12 127958733 C T 2.70E-06 Urinary metabolites / / 21572414 rs11059151 chr12 127959459 T A 1.98E-04 Multiple complex diseases / / 17554300 rs11059151 chr12 127959459 T A 4.10E-06 Urinary metabolites / / 21572414 rs971599 chr12 127978708 A G 5.97E-04 Type 2 diabetes / / 17463246 rs839947 chr12 127986790 T C 6.40E-05 Cognitive impairment induced by topiramate / / 22091778 rs7295355 chr12 127992426 T C 4.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2171115 chr12 127993192 G T 1.51E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7972200 chr12 128000966 A G 6.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs10847401 chr12 128029218 A C 8.74E-04 Acute lung injury / / 22295056 rs345643 chr12 128035306 G A 3.91E-04 Insulin resistance / / 21901158 rs11059265 chr12 128052533 C G 1.70E-05 Urinary metabolites / / 21572414 rs345673 chr12 128054641 T G 2.57E-06 Monocyte chemoattractant protein-1 / / pha003071 rs1967060 chr12 128071611 G A 9.40E-04 Multiple complex diseases / / 17554300 rs1960136 chr12 128079420 C T 1.26E-06 Phospholipid levels (plasma) / / 21829377 rs7955165 chr12 128090927 T G 2.28E-06 Phospholipid levels (plasma) / / 21829377 rs10847417 chr12 128092257 T C 2.38E-06 Phospholipid levels (plasma) / / 21829377 rs2134485 chr12 128095470 G A 3.56E-06 Phospholipid levels (plasma) / / 21829377 rs4760949 chr12 128111939 T A 3.13E-06 Phospholipid levels (plasma) / / 21829377 rs4760993 chr12 128112077 A G 2.87E-06 Phospholipid levels (plasma) / / 21829377 rs10847423 chr12 128129249 C T 2.51E-06 Phospholipid levels (plasma) / / 21829377 rs2242455 chr12 128133284 C T 4.10E-06 Phospholipid levels (plasma) / / 21829377 rs11059295 chr12 128134169 A G 4.77E-06 Phospholipid levels (plasma) / / 21829377 rs10847425 chr12 128134474 A G 1.01E-06 Phospholipid levels (plasma) / / 21829377 rs2047054 chr12 128154473 A T 1.87E-04 Multiple complex diseases / / 17554300 rs7308245 chr12 128160378 G A 1.92E-05 Hearing impairment / / 19047183 rs10847434 chr12 128160793 C T 1.70E-06 Urinary metabolites / / 21572414 rs10847434 chr12 128160793 C T 6.81E-15 Coronary heart disease / / 23364394 rs12322559 chr12 128212135 A C 2.90E-05 Urinary metabolites / / 21572414 rs2348938 chr12 128228764 C T 0.000239 Salmonella-induced pyroptosis / / 22837397 rs714634 chr12 128230496 G A 9.77E-04 Type 2 diabetes / / 17463246 rs4761014 chr12 128230639 A G 9.33E-04 Type 2 diabetes / / 17463246 rs4761014 chr12 128230639 A G 7.38E-06 Serum metabolites / / 19043545 rs2099269 chr12 128259580 G T 7.42E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs10773432 chr12 128274870 T G 1.00E-04 Prostate cancer / / 21743057 rs11059374 chr12 128304418 C T 2.00E-06 Response to amphetamines / / 22952603 rs11059385 chr12 128332050 A G 7.39E-05 Cognitive test performance / / 20125193 rs857654 chr12 128338195 G A 1.72E-04 Type 2 diabetes / / 17463246 rs10847469 chr12 128339548 C T 7.70E-06 Urinary metabolites / / 21572414 rs2043202 chr12 128358772 T C 4.61E-05 Cognitive test performance / / 20125193 rs2633462 chr12 128371453 C A 3.28E-04 Coronary Artery Disease FLJ37505 intron 17634449 rs2699095 chr12 128382982 A G 2.60E-04 Insulin resistance / / 21901158 rs4761031 chr12 128403474 C T 7.82E-05 Coronary Artery Disease LINC00507 intron 17634449 rs2699089 chr12 128404203 T C 4.44E-05 Body Mass Index LINC00507 intron pha003019 rs2699089 chr12 128404203 T C 6.43E-05 Body Mass Index LINC00507 intron pha003022 rs2699061 chr12 128406319 T A 1.80E-05 Urinary metabolites LINC00507 intron 21572414 rs2701822 chr12 128406647 C T 1.40E-05 Urinary metabolites LINC00507 intron 21572414 rs2633467 chr12 128421906 T G 3.09E-04 Depression (quantitative trait) LINC00507 intron 20800221 rs2699060 chr12 128464046 C T 0.000366 Salmonella-induced pyroptosis / / 22837397 rs4761051 chr12 128494033 G A 2.68E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs4627127 chr12 128505768 T G 1.40E-05 Urinary metabolites / / 21572414 rs4761053 chr12 128506201 C T 2.80E-05 Urinary metabolites / / 21572414 rs10847502 chr12 128535161 C A 2.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs11059460 chr12 128538213 A G 6.13E-09 Multiple complex diseases / / 17554300 rs7300686 chr12 128547209 C T 5.72E-07 Glioma / / 19578367 rs12306801 chr12 128548533 T C 2.00E-04 Alzheimer's disease (late onset) / / 21379329 rs6489232 chr12 128549207 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11059474 chr12 128550905 G A 1.08E-04 Alzheimer's disease (late onset) / / 21379329 rs10847508 chr12 128550974 T C 2.09E-04 Alzheimer's disease (late onset) / / 21379329 rs12424326 chr12 128551441 G A 7.60E-04 Alzheimer's disease / / 24755620 rs11613043 chr12 128566031 C T 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10847525 chr12 128571048 G A 7.17E-04 Alzheimer's disease / / 24755620 rs997269 chr12 128638074 G A 1.78E-06 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines / / 21483694 rs6486550 chr12 128641379 G A 1.38E-04 Coronary Artery Disease / / 17634449 rs12829757 chr12 128661291 G C 1.57E-17 Coronary heart disease / / 23364394 rs11059562 chr12 128663933 G A 2.28E-05 Arthritis (juvenile idiopathic) / / 22354554 rs1554080 chr12 128667558 C T 7.72E-05 Tourette syndrome / / 22889924 rs10431335 chr12 128679068 C T 4.50E-10 Coronary heart disease / / 23364394 rs867509 chr12 128716321 C T 7.95E-04 Alzheimer's disease / / 17998437 rs7316647 chr12 128717289 T G 9.31E-04 Alzheimer's disease / / 17998437 rs11612995 chr12 128719362 C T 0.0000005 Asthma (exacerbation) / / 23706709 rs7970358 chr12 128729838 A G 0.0000033 Asthma (exacerbation) / / 23706709 rs7970449 chr12 128729866 A G 2.27E-05 Bipolar disorder / / 20451256 rs7974042 chr12 128729912 T A 1.59E-05 Bipolar disorder / / 20451256 rs10773511 chr12 128730045 T C 2.27E-05 Bipolar disorder / / 20451256 rs4533103 chr12 128730071 C T 1.73E-05 Bipolar disorder / / 20451256 rs10734958 chr12 128730468 A G 3.01E-05 Bipolar disorder / / 20451256 rs2398395 chr12 128730902 C T 5.78E-05 Bipolar disorder / / 20451256 rs12372191 chr12 128734010 C T 8.00E-05 Height / / pha003010 rs12372191 chr12 128734010 C T 2.02E-05 Coronary heart disease / / pha003030 rs10744373 chr12 128734938 A T 5.05E-04 Multiple complex diseases / / 17554300 rs12297524 chr12 128736522 C T 6.16E-05 Alzheimer's disease / / 21098978 rs12297524 chr12 128736522 C T 5.00E-06 Palmitic acid (16:0) plasma levels / / 23362303 rs11059603 chr12 128737017 T C 6.04E-05 Alzheimer's disease / / 21098978 rs12299465 chr12 128737550 C T 7.50E-05 Alzheimer's disease / / 21098978 rs11609257 chr12 128737746 C T 5.74E-05 Alzheimer's disease / / 21098978 rs12825406 chr12 128738199 G A 5.68E-05 Alzheimer's disease / / 21098978 rs1514898 chr12 128738255 G A 5.62E-05 Alzheimer's disease / / 21098978 rs10847586 chr12 128744212 A G 0.0006201 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10847586 chr12 128744212 A G 6.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1193373 chr12 128745755 A G 2.86E-05 Alzheimer's disease / / 21098978 rs1193376 chr12 128746115 T C 2.86E-05 Alzheimer's disease / / 21098978 rs11059618 chr12 128758519 T C 1.18E-06 Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel) TMEM132C intron 24025145 rs12302898 chr12 128762741 G A 4.75E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) TMEM132C intron 23648065 rs10773519 chr12 128767084 A G 8.41E-06 Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel) TMEM132C intron 24025145 rs11059635 chr12 128782022 C T 2.00E-07 Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel) TMEM132C intron 24025145 rs4882730 chr12 128792381 C A 1.73E-04 Osteoarthritis TMEM132C intron 19508968 rs1193390 chr12 128814339 T C 1.00E-04 Cognitive impairment induced by topiramate TMEM132C intron 22091778 rs1193389 chr12 128814703 C G 8.87E-05 Blood pressure TMEM132C intron 17255346 rs1709707 chr12 128823144 G A 1.55E-04 Blood pressure TMEM132C intron 17255346 rs1713623 chr12 128826190 A G 3.92E-04 Blood pressure TMEM132C intron 17255346 rs952093 chr12 128844571 T C 8.73E-04 Suicide attempts in bipolar disorder TMEM132C intron 21423239 rs10847607 chr12 128871874 C T 4.93E-05 Amyotrophic lateral sclerosis (sporadic) TMEM132C intron 24529757 rs1683695 chr12 128873468 A T 9.11E-04 Multiple complex diseases TMEM132C intron 17554300 rs1401098 chr12 128884559 G A 4.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM132C intron 20877124 rs10773542 chr12 128916550 G T 5.62E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) TMEM132C intron 23648065 rs4882764 chr12 128923597 G A 1.30E-04 Amyotrophic Lateral Sclerosis TMEM132C intron 17362836 rs10773543 chr12 128923726 A G 1.60E-05 Amyotrophic Lateral Sclerosis TMEM132C intron 17362836 rs6486693 chr12 128985502 T C 0.0000903 Skin naphthyl-keratin adduct (NKA) levels in workers exposed to naphthalene TMEM132C intron 22391508 rs11059755 chr12 129025149 T C 6.65E-04 Coronary Artery Disease TMEM132C intron 17634449 rs7301968 chr12 129030333 A G 2.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM132C intron 20877124 rs1379782 chr12 129058869 T C 9.17E-04 Multiple complex diseases TMEM132C intron 17554300 rs1379782 chr12 129058869 T C 6.10E-06 Urinary metabolites TMEM132C intron 21572414 rs7963766 chr12 129083981 A G 2.79E-04 Suicide attempts in bipolar disorder TMEM132C intron 21423239 rs12833839 chr12 129094535 A G 3.29E-05 Suicide attempts in bipolar disorder TMEM132C intron 21423239 rs7296262 chr12 129095072 T C 1.00E-06 Suicide attempts in bipolar disorder TMEM132C intron 21423239 rs7136901 chr12 129113745 C A 5.60E-05 Alzheimer's disease (late onset) TMEM132C intron 21379329 rs11059821 chr12 129157292 C T 0.000552948 Hypertension (early onset hypertension) TMEM132C intron 22479346 rs955452 chr12 129157873 G A 0.000612266 Hypertension (early onset hypertension) TMEM132C intron 22479346 rs7960753 chr12 129158367 A C 1.30E-04 Alcohol dependence TMEM132C intron 20201924 rs7960753 chr12 129158367 A C 4.40E-04 Alcohol dependence TMEM132C intron 20201924 rs11608979 chr12 129161625 G A 1.50E-04 Alcohol dependence TMEM132C intron 20201924 rs11608979 chr12 129161625 G A 1.70E-04 Alcohol dependence TMEM132C intron 20201924 rs10773566 chr12 129163648 G T 1.70E-05 Alcohol dependence TMEM132C intron 20201924 rs10773566 chr12 129163648 G T 7.50E-05 Alcohol dependence TMEM132C intron 20201924 rs10773566 chr12 129163648 G T 7.52E-05 Alcoholism TMEM132C intron pha002892 rs10773566 chr12 129163648 G T 1.68E-05 Alcoholism TMEM132C intron pha002893 rs1489430 chr12 129166145 T C 1.90E-04 Alcohol dependence TMEM132C intron 20201924 rs1489430 chr12 129166145 T C 5.10E-05 Alcohol dependence TMEM132C intron 20201924 rs1489430 chr12 129166145 T C 5.09E-05 Alcoholism TMEM132C intron pha002893 rs6486717 chr12 129167872 T G 2.40E-04 Alcohol dependence TMEM132C intron 20201924 rs6486717 chr12 129167872 T G 6.90E-05 Alcohol dependence TMEM132C intron 20201924 rs6486717 chr12 129167872 T G 6.89E-05 Alcoholism TMEM132C intron pha002893 rs2101506 chr12 129172689 G A 7.71E-05 Cognitive test performance TMEM132C intron 20125193 rs7979107 chr12 129174675 T C 1.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM132C intron 20877124 rs7979107 chr12 129174675 T C 5.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM132C intron 20877124 rs10773568 chr12 129186190 G A 3.00E-06 Height TMEM132C intron 23456168 rs7959567 chr12 129189850 C T 2.10E-06 Iron levels TMEM132C cds-synon 21208937 rs7959567 chr12 129189850 C T 8.96E-10 Corneal structure TMEM132C cds-synon 22003120 rs7302166 chr12 129202591 A C 3.61E-04 Alzheimer's disease / / 17998437 rs7484360 chr12 129208448 G A 3.09E-05 Cognitive test performance / / 20125193 rs4760557 chr12 129228730 G T 5.62E-04 Multiple complex diseases / / 17554300 rs7967621 chr12 129230513 A G 4.38E-05 Diabetes Mellitus / / pha003060 rs11059876 chr12 129238618 T C 6.67E-04 Type 2 diabetes / / 17463246 rs12228506 chr12 129243705 A G 6.74E-04 Aortic root size / / 21223598 rs6486726 chr12 129249817 C T 9.48E-05 Taste perception / / 22132133 rs12299194 chr12 129264838 T C 3.22E-04 Multiple complex diseases / / 17554300 rs4760583 chr12 129271508 T C 8.99E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs3825181 chr12 129279264 G A 8.99E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC15A4 intron 20877124 rs7311875 chr12 129293267 A G 2.40E-05 Urinary metabolites SLC15A4 intron 21572414 rs4760533 chr12 129297651 C T 7.97E-04 Multiple complex diseases SLC15A4 intron 17554300 rs10847697 chr12 129299385 G A 2.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC15A4 cds-synon 20877124 rs10847697 chr12 129299385 G A 4.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC15A4 cds-synon 20877124 rs10847697 chr12 129299385 G A 1.10E-07 Systemic lupus erythematosus SLC15A4 cds-synon 23273568 rs1385374 chr12 129300694 C T 2.00E-11 Systemic lupus erythematosus SLC15A4 intron 19838193 rs1385374 chr12 129300694 C T 2.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC15A4 intron 20877124 rs1385374 chr12 129300694 C T 4.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC15A4 intron 20877124 rs1385374 chr12 129300694 C T 8.00E-08 Systemic lupus erythematosus SLC15A4 intron 23273568 rs10773581 chr12 129313150 A C 1.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs2398438 chr12 129323800 A G 4.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs10744391 chr12 129324938 G A 1.00E-06 Renal sinus fat / / 22044751 rs11059974 chr12 129334854 A G 7.67E-04 Suicide attempts in bipolar disorder LOC100128276 intron 21423239 rs1798914 chr12 129344110 T C 4.38E-04 Suicide attempts in bipolar disorder GLT1D1 intron 21423239 rs11059987 chr12 129349117 C T 4.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GLT1D1 intron 20877124 rs11059987 chr12 129349117 C T 4.75E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GLT1D1 intron 20877124 rs470444 chr12 129377354 A C 1.30E-05 Multiple complex diseases GLT1D1 intron 17554300 rs7310927 chr12 129380423 A G 3.96E-05 Telomere length GLT1D1 intron 23001564 rs683262 chr12 129385106 G A 2.71E-04 Type 2 diabetes GLT1D1 intron 17463246 rs12579680 chr12 129400328 G A 8.87E-04 Myocardial Infarction GLT1D1 intron pha002883 rs627431 chr12 129413128 G A 1.00E-04 Information processing speed GLT1D1 intron 21130836 rs6486738 chr12 129432715 C G 4.25E-04 Multiple complex diseases GLT1D1 intron 17554300 rs11060036 chr12 129432789 G A 6.29E-04 Multiple complex diseases GLT1D1 intron 17554300 rs6486740 chr12 129442675 A G 1.56E-16 Coronary heart disease GLT1D1 intron 23364394 rs1616468 chr12 129442937 T C 6.71E-06 Multiple complex diseases GLT1D1 intron 17554300 rs470379 chr12 129458743 G A 9.23E-05 Monocyte counts GLT1D1 intron pha003089 rs643473 chr12 129475939 A G 9.00E-06 Aging / / 22773346 rs470609 chr12 129481599 T G 9.54E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs470663 chr12 129494388 A T 7.94E-04 Alzheimer's disease / / 17998437 rs470617 chr12 129494415 A G 7.62E-04 Alzheimer's disease / / 17998437 rs519579 chr12 129498317 A G 1.65E-05 Orofacial clefts / / 22419666 rs543533 chr12 129500630 G A 0.00000767 Attention deficit-hyperactivity disorder (ADHD) DSM-IV scale,preschool edition / / 23049896 rs479605 chr12 129507348 A C 4.29E-04 Alzheimer's disease / / 17998437 rs555891 chr12 129517157 G A 1.85E-04 Type 2 diabetes / / 17463246 rs10773591 chr12 129528907 A G 3.27E-05 Serum metabolites / / 19043545 rs12368790 chr12 129539156 T C 6.73E-05 Alzheimer's disease / / 17998437 rs10773593 chr12 129539501 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11060108 chr12 129550791 G T 2.69E-05 Hypertension / / 19609347 rs11060130 chr12 129581856 T G 1.90E-04 Myopia (pathological) TMEM132D intron 21095009 rs11060130 chr12 129581856 T G 9.96E-05 Vascular dementia TMEM132D intron 22116812 rs10847765 chr12 129585113 G A 2.68E-05 Bipolar disorder and schizophrenia TMEM132D intron 20889312 rs12580388 chr12 129591144 T C 1.03E-04 Multiple complex diseases TMEM132D intron 17554300 rs7310361 chr12 129595289 C G,T 1.46E-06 Retinopathy in non-diabetics TMEM132D intron 23393555 rs10847773 chr12 129597700 A G 6.52E-04 Multiple complex diseases TMEM132D intron 17554300 rs10847773 chr12 129597700 A G 8.76E-05 Non-alcoholic fatty liver disease histology (other) TMEM132D intron 20708005 rs12824981 chr12 129637348 C T 9.00E-06 Heart rate TMEM132D intron 23534349 rs12580240 chr12 129646572 A G 2.00E-06 IgG glycosylation TMEM132D intron 23382691 rs12580533 chr12 129646601 T C 8.00E-06 IgG glycosylation TMEM132D intron 23382691 rs12580490 chr12 129652391 A C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes TMEM132D intron 22628534 rs1386216 chr12 129652771 T G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes TMEM132D intron 22628534 rs12422767 chr12 129675423 C T 0.0000865 Asthma TMEM132D intron 22694930 rs1013741 chr12 129696131 G T 6.93E-05 Amyotrophic lateral sclerosis TMEM132D intron 20801718 rs1825720 chr12 129700505 G A 1.80E-06 Urinary metabolites TMEM132D intron 21572414 rs10773613 chr12 129700697 A G 1.80E-06 Urinary metabolites TMEM132D intron 21572414 rs7300009 chr12 129701205 A T 5.47E-04 Alzheimer's disease TMEM132D intron 17998437 rs10847806 chr12 129707483 T G 1.04E-04 Amyotrophic Lateral Sclerosis TMEM132D intron 17362836 rs4411334 chr12 129707719 C T 4.56E-04 Amyotrophic Lateral Sclerosis TMEM132D intron 17362836 rs4411335 chr12 129707854 C T 1.22E-04 Amyotrophic Lateral Sclerosis TMEM132D intron 17362836 rs4411335 chr12 129707854 C T 6.09E-04 Schizophrenia TMEM132D intron 19197363 rs1482294 chr12 129710791 G A 2.00E-04 Schizophrenia TMEM132D intron 19197363 rs12371373 chr12 129711446 G A 7.18E-05 Asthma TMEM132D intron 11022011 rs2306517 chr12 129715575 T C 9.99E-05 B cell non-Hodgkin lymphoma TMEM132D intron 23749188 rs10847807 chr12 129722628 T G 0.0001 Migraine TMEM132D intron 22678113 rs4759808 chr12 129722961 T C 0.0001 Migraine TMEM132D intron 22678113 rs4436610 chr12 129736393 G T 2.07E-06 Glucose levels TMEM132D intron pha003058 rs11060225 chr12 129739046 A G 7.26E-08 Schizophrenia TMEM132D intron 21926974 rs12315751 chr12 129773186 T C 8.17E-04 Response to taxane treatment (placlitaxel) TMEM132D intron 23006423 rs10773632 chr12 129781378 G A 9.91E-04 Depression (quantitative trait) TMEM132D intron 20800221 rs10744409 chr12 129783438 G A 6.46E-05 Response to taxane treatment (placlitaxel) TMEM132D intron 23006423 rs900256 chr12 129786584 C T 1.40E-06 Anxiety spectrum disorders TMEM132D intron 20368705 rs900256 chr12 129786584 C T 3.00E-04 Anxiety spectrum disorders TMEM132D intron 20368705 rs879560 chr12 129791496 C T 5.00E-07 Anxiety spectrum disorders TMEM132D intron 20368705 rs879560 chr12 129791496 C T 6.00E-04 Anxiety spectrum disorders TMEM132D intron 20368705 rs11060247 chr12 129804154 C T 7.50E-04 Alcohol dependence TMEM132D intron 20201924 rs1842737 chr12 129806980 T C 2.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM132D intron 20877124 rs2128281 chr12 129807019 G A 2.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM132D intron 20877124 rs3850002 chr12 129808362 G A 7.81E-04 Type 2 diabetes TMEM132D intron 17463246 rs3850002 chr12 129808362 G A 4.59E-04 Multiple complex diseases TMEM132D intron 17554300 rs7967817 chr12 129810763 C T 8.39E-04 Alzheimer's disease TMEM132D intron 17998437 rs3861080 chr12 129811613 G A 9.00E-05 Prostate cancer TMEM132D intron 21743057 rs10847832 chr12 129812096 A G 7.00E-04 Anxiety spectrum disorders TMEM132D intron 20368705 rs997442 chr12 129839544 A C 5.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM132D intron 20877124 rs10847836 chr12 129842590 G T 7.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM132D intron 20877124 rs7304215 chr12 129847634 A G 9.18E-04 Myopia (pathological) TMEM132D intron 21095009 rs12319171 chr12 129851734 A G 2.24E-04 Body mass index TMEM132D intron 21701565 rs12319171 chr12 129851734 A G 6.79E-04 Body mass index TMEM132D intron 21701565 rs10847838 chr12 129852015 G A 1.00E-05 Urinary metabolites TMEM132D intron 21572414 rs11060283 chr12 129853660 C T 8.21E-04 Renal cell carcinoma TMEM132D intron 22010048 rs11060284 chr12 129856724 G A 4.70E-06 Urinary metabolites TMEM132D intron 21572414 rs3929573 chr12 129858233 C T 1.43E-05 Parent of origin effect on language impairment (paternal) TMEM132D intron 24571439 rs11060288 chr12 129859528 G A 1.56E-05 Parent of origin effect on language impairment (paternal) TMEM132D intron 24571439 rs1915485 chr12 129885628 A G 1.50E-04 Body mass index TMEM132D intron 21701565 rs1976829 chr12 129894506 A G 2.78E-04 Multiple complex diseases TMEM132D intron 17554300 rs2030436 chr12 129894564 A G 0.00000032 Chronic obstructive pulmonary disease (moderate to severe) TMEM132D intron 22986903 rs12230577 chr12 129910889 G A 8.96E-05 Cognitive impairment induced by topiramate TMEM132D intron 22091778 rs4759938 chr12 129926006 C T 6.27E-04 Multiple complex diseases TMEM132D intron 17554300 rs7488953 chr12 129932796 A G 8.61E-05 Tunica Media TMEM132D intron pha003037 rs6486470 chr12 129934003 C T 7.92E-05 Tunica Media TMEM132D intron pha003037 rs11614267 chr12 129936569 G C 6.56E-05 Cognitive decline TMEM132D intron 22054870 rs10847879 chr12 129937144 T C 5.85E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM132D intron 20877124 rs4759572 chr12 129937204 T C 1.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM132D intron 20877124 rs11060355 chr12 129938262 T C 1.92E-04 Response to cytadine analogues (cytosine arabinoside) TMEM132D intron 24483146 rs4759943 chr12 129939109 G A 9.88E-04 Response to cytidine analogues (gemcitabine) TMEM132D intron 24483146 rs7487808 chr12 129942716 T C 2.38E-04 Hemoglobin concentration TMEM132D intron 20534544 rs7309727 chr12 129955359 T C 4.87E-08 Anxiety spectrum disorders TMEM132D intron 20368705 rs11060369 chr12 129960197 A C 7.63E-06 Anxiety spectrum disorders TMEM132D intron 20368705 rs7953756 chr12 129963107 T C 6.18E-04 Myocardial Infarction TMEM132D intron pha002883 rs12317773 chr12 129967036 G A 4.06E-04 Response to cytidine analogues (gemcitabine) TMEM132D intron 24483146 rs11060375 chr12 129970616 G A 4.43E-04 Response to cytidine analogues (gemcitabine) TMEM132D intron 24483146 rs6486477 chr12 129977454 G A 2.01E-04 Response to cytidine analogues (gemcitabine) TMEM132D intron 24483146 rs7132165 chr12 129977609 C T 2.07E-04 Response to cytidine analogues (gemcitabine) TMEM132D intron 24483146 rs902891 chr12 129978517 T C 4.92E-05 Serum metabolites TMEM132D intron 19043545 rs902891 chr12 129978517 T C 6.10E-04 Response to cytidine analogues (gemcitabine) TMEM132D intron 24483146 rs10847890 chr12 129985815 G A 4.86E-04 Response to cytidine analogues (gemcitabine) TMEM132D intron 24483146 rs4759955 chr12 130004698 G T 5.90E-04 Amyotrophic Lateral Sclerosis TMEM132D intron 17362836 rs11060391 chr12 130007356 A G 6.52E-04 Parkinson's disease TMEM132D intron 17052657 rs11060391 chr12 130007356 A G 1.50E-04 Myopia (pathological) TMEM132D intron 21095009 rs10744425 chr12 130029607 C T 2.07E-06 Serum metabolites TMEM132D intron 19043545 rs4759966 chr12 130038858 C A,G 3.10E-05 Asthma TMEM132D intron 11022011 rs1873726 chr12 130050521 G A 4.38E-04 Multiple complex diseases TMEM132D intron 17554300 rs269157 chr12 130062232 C T 3.40E-05 Alzheimer's disease (late onset) TMEM132D intron 21379329 rs11060451 chr12 130069919 T C 3.06E-05 Multiple complex diseases TMEM132D intron 17554300 rs1610177 chr12 130072736 C T 7.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMEM132D intron 20877124 rs10744426 chr12 130080551 A C 1.24E-05 Serum metabolites TMEM132D intron 19043545 rs265625 chr12 130109564 C T 8.30E-04 Myopia (pathological) TMEM132D intron 21095009 rs12297578 chr12 130124424 T C 3.90E-05 Postoperative ventricular dysfunction TMEM132D intron 21980348 rs11060480 chr12 130126515 G A 7.24E-05 Postoperative ventricular dysfunction TMEM132D intron 21980348 rs11060480 chr12 130126515 G A 9.87E-04 Response to cytidine analogues (gemcitabine) TMEM132D intron 24483146 rs265603 chr12 130135990 T G 1.18E-05 Triglycerides TMEM132D intron 19074352 rs265603 chr12 130135990 T G 1.18E-05 Polyunsaturated fatty acid levels,in plasma TMEM132D intron 19148276 rs585618 chr12 130145407 A C 6.73E-05 Postoperative ventricular dysfunction TMEM132D intron 21980348 rs585618 chr12 130145407 A C 6.44E-04 Response to cytidine analogues (gemcitabine) TMEM132D intron 24483146 rs605142 chr12 130145758 T C 2.49E-05 Postoperative ventricular dysfunction TMEM132D intron 21980348 rs605142 chr12 130145758 T C 4.60E-04 Response to cytidine analogues (gemcitabine) TMEM132D intron 24483146 rs264501 chr12 130159705 G T 2.57E-04 Cholesterol TMEM132D intron 17255346 rs264501 chr12 130159705 G T 2.72E-04 Alzheimer's disease (late onset) TMEM132D intron 21379329 rs264501 chr12 130159705 G T 2.17E-05 Major depressive disorder TMEM132D intron 22472876 rs264515 chr12 130168280 T C 3.87E-04 Coronary Artery Disease TMEM132D intron 17634449 rs1397504 chr12 130187283 T C 9.58E-04 Multiple complex diseases TMEM132D intron 17554300 rs7962650 chr12 130188504 T A 5.50E-04 Multiple complex diseases TMEM132D intron 17554300 rs925381 chr12 130192315 C T 5.96E-04 Multiple complex diseases TMEM132D intron 17554300 rs4759997 chr12 130193038 C T 5.53E-04 Multiple complex diseases TMEM132D intron 17554300 rs7962736 chr12 130205544 G C 9.24E-04 Suicide attempts in bipolar disorder TMEM132D intron 21423239 rs2218917 chr12 130224189 A C 1.48E-04 Amyotrophic lateral sclerosis (sporadic) TMEM132D intron 24529757 rs7979367 chr12 130230407 G T 2.00E-06 Illicit drug use TMEM132D intron 23942779 rs7979367 chr12 130230407 G T 6.00E-06 Behavioural disinhibition (generation interaction) TMEM132D intron 23942779 rs11831917 chr12 130243171 C T 5.00E-04 Type 2 diabetes TMEM132D intron 17463246 rs4641522 chr12 130248522 A G 2.06E-04 Multiple complex diseases TMEM132D intron 17554300 rs12580073 chr12 130269577 C T 8.33E-05 Blood Pressure TMEM132D intron pha003040 rs12580073 chr12 130269577 C T 8.78E-05 Glucose levels TMEM132D intron pha003061 rs12314724 chr12 130274359 T C 3.06E-05 Glucose levels TMEM132D intron pha003061 rs2398485 chr12 130277195 G A 3.06E-04 Multiple complex diseases TMEM132D intron 17554300 rs2398486 chr12 130278402 T C 5.48E-05 Multiple complex diseases TMEM132D intron 17554300 rs1031400 chr12 130279326 G A 7.51E-04 Suicide attempts in bipolar disorder TMEM132D intron 21041247 rs1376795 chr12 130280270 C T 8.51E-04 Multiple complex diseases TMEM132D intron 17554300 rs1376795 chr12 130280270 C T 7.30E-04 Suicide attempts in bipolar disorder TMEM132D intron 21041247 rs1376796 chr12 130280358 T G 7.50E-04 Suicide attempts in bipolar disorder TMEM132D intron 21041247 rs2167512 chr12 130281195 G A 3.59E-05 Multiple complex diseases TMEM132D intron 17554300 rs10773708 chr12 130281212 G A 7.61E-04 Suicide attempts in bipolar disorder TMEM132D intron 21041247 rs4759984 chr12 130281773 T C 2.52E-04 Multiple complex diseases TMEM132D intron 17554300 rs1376797 chr12 130284595 C T 6.20E-05 Suicide attempts in bipolar disorder TMEM132D intron 21041247 rs11060565 chr12 130291700 C T 3.87E-05 Suicide attempts in bipolar disorder TMEM132D intron 21041247 rs11060567 chr12 130298708 G A 6.09E-04 Alzheimer's disease TMEM132D intron 24755620 rs10773715 chr12 130339043 G C 5.42E-04 Type 2 diabetes TMEM132D intron 17463246 rs12297883 chr12 130395730 T A 2.78E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12317807 chr12 130395910 C T 7.89E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs825879 chr12 130425950 A T 7.39E-05 Serum metabolites / / 19043545 rs4760022 chr12 130426025 C T 4.36E-05 Serum metabolites / / 19043545 rs667393 chr12 130456236 A G 4.43E-05 Cognitive test performance / / 20125193 rs10744442 chr12 130461603 C A 7.59E-05 Cognitive test performance / / 20125193 rs1499928 chr12 130465932 C T 5.25E-05 Sudden cardiac arrest / / 21658281 rs708356 chr12 130473914 T C 1.50E-05 Blood Phenotypes / / 17903294 rs1993757 chr12 130474465 C T 8.01E-23 Alcohol consumption / / pha001400 rs1993757 chr12 130474465 C T 2.02E-19 Alcohol consumption / / pha001402 rs6486512 chr12 130486501 T C 2.40E-05 Urinary metabolites / / 21572414 rs708345 chr12 130486603 T C 2.72E-05 Bipolar disorder / / 21771265 rs10847975 chr12 130489049 C T 7.97E-05 Cognitive test performance / / 20125193 rs1696432 chr12 130496976 T C 1.17E-06 Obesity-related traits / / 23251661 rs1624802 chr12 130497472 A G 5.00E-07 Obesity-related traits / / 23251661 rs3852545 chr12 130502705 A T 4.14E-04 Multiple complex diseases / / 17554300 rs607248 chr12 130520307 C T 2.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs619302 chr12 130520674 C T 8.74E-04 Coronary heart disease / / 21606135 rs826715 chr12 130534578 G A 7.21E-04 Smoking initiation / / 24665060 rs826917 chr12 130567562 A G 1.65E-05 Job-related exhaustion / / 23620144 rs1696422 chr12 130568190 G A 1.05E-05 Job-related exhaustion / / 23620144 rs11060702 chr12 130591803 C T 5.80E-04 Rheumatoid arthritis / / 21452313 rs10848012 chr12 130615741 T C 9.62E-04 Type 2 diabetes / / 17463246 rs11060730 chr12 130626963 T C 1.76E-04 Bipolar disorder / / 18317468 rs11060736 chr12 130630935 T C 4.00E-06 Gambling / / 22780124 rs4760084 chr12 130643486 T C 6.10E-05 Insulin resistance FLJ31485 intron 21901158 rs7966482 chr12 130653572 G C 8.22E-04 Multiple complex diseases / / 17554300 rs2055347 chr12 130662745 G A 1.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12815249 chr12 130677247 T C 9.66E-04 Multiple complex diseases / / 17554300 rs12822055 chr12 130678432 T C 4.72E-04 Rheumatoid arthritis / / 21452313 rs937642 chr12 130680437 C T 3.64E-05 Serum metabolites / / 19043545 rs10848034 chr12 130689311 C G 3.22E-05 Serum metabolites / / 19043545 rs7135366 chr12 130689349 T C 8.47E-04 Multiple complex diseases / / 17554300 rs12580487 chr12 130704950 C T 8.67E-06 Esophageal cancer (squamous cell) / / 20729853 rs11060784 chr12 130707007 A G 5.77E-04 Type 2 diabetes / / 17463246 rs2133640 chr12 130751608 T A 3.18E-04 Insulin resistance / / 21901158 rs4759643 chr12 130762234 T G 3.27E-04 Insulin resistance / / 21901158 rs7960284 chr12 130770170 C T 4.58E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs10848066 chr12 130773863 G A 3.26E-04 Heart Failure / / pha002884 rs4759647 chr12 130780226 C T 4.50E-04 Schizophrenia(age at onset) / / 21688384 rs4759647 chr12 130780226 C T 3.16E-05 Post-operative nausea and vomiting / / 21694509 rs10744459 chr12 130814262 T C 6.00E-06 Urinary metabolites / / 21572414 rs1874521 chr12 130839645 A C 3.46E-05 Brain structure PIWIL1 intron 22504417 rs10848088 chr12 130849993 A G 6.53E-06 Brain structure PIWIL1 intron 22504417 rs10773770 chr12 130855027 A G 7.42E-05 Parent of origin effect on language impairment (maternal) PIWIL1 intron 24571439 rs10773776 chr12 130888094 T C 9.56E-04 Multiple complex diseases RIMBP2 intron 17554300 rs7304899 chr12 130893588 A G 8.85E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) RIMBP2 intron 23648065 rs11609204 chr12 130895518 C T 6.26E-05 Brain derived neurotrophic factor levels,in serum RIMBP2 intron 22047184 rs10848096 chr12 130895719 T G 3.95E-05 Brain derived neurotrophic factor levels,in serum RIMBP2 intron 22047184 rs11060869 chr12 130897323 C T 0.00064 Prostate cancer (non-advanced prostate cancer) RIMBP2 missense 23555315 rs11060870 chr12 130897752 C T 9.76E-05 Brain derived neurotrophic factor levels,in serum RIMBP2 intron 22047184 rs11060872 chr12 130898414 C T 2.89E-04 Multiple complex diseases RIMBP2 intron 17554300 rs7295851 chr12 130900815 G A 8.55E-05 Multiple complex diseases RIMBP2 intron 17554300 rs11060883 chr12 130904400 A G 8.03E-04 Nicotine smoking RIMBP2 intron 19268276 rs11060883 chr12 130904400 A G 2.45E-04 Lung function (forced vital capacity) RIMBP2 intron 24023788 rs2292664 chr12 130921664 G C 1.40E-37 Health and aging,CVD and cancer age of onset RIMBP2 missense 22174011 rs2292664 chr12 130921664 G C 1.70E-07 Health and aging,CVD and cancer age of onset RIMBP2 missense 22174011 rs2292664 chr12 130921664 G C 2.00E-25 Health and aging,CVD and cancer age of onset RIMBP2 missense 22174011 rs2292664 chr12 130921664 G C 3.30E-19 Health and aging,CVD and cancer age of onset RIMBP2 missense 22174011 rs2292664 chr12 130921664 G C 3.80E-13 Health and aging,CVD and cancer age of onset RIMBP2 missense 22174011 rs2292664 chr12 130921664 G C 6.00E-11 Health and aging,CVD and cancer age of onset RIMBP2 missense 22174011 rs2292664 chr12 130921664 G C 6.80E-14 Health and aging,CVD and cancer age of onset RIMBP2 missense 22174011 rs11060895 chr12 130937122 A G 1.10E-06 Urinary metabolites RIMBP2 intron 21572414 rs7298078 chr12 130937649 A G 1.20E-05 Urinary metabolites RIMBP2 intron 21572414 rs11060898 chr12 130939564 G T 1.20E-05 Urinary metabolites RIMBP2 intron 21572414 rs2048777 chr12 130939908 G A 5.43E-05 Acute lymphoblastic leukemia (childhood) RIMBP2 intron 19684603 rs6486542 chr12 130952209 C T 7.73E-04 Amyotrophic Lateral Sclerosis RIMBP2 intron 17362836 rs10161112 chr12 130952454 G T 4.05E-05 Duodenal ulcer RIMBP2 intron 22387998 rs884255 chr12 130962191 C A 9.65E-04 Type 2 diabetes RIMBP2 intron 17463246 rs10848114 chr12 130979355 C T 4.75E-06 Hearing function RIMBP2 intron 21493956 rs2048779 chr12 130981617 A C 4.05E-05 Alcohol consumption RIMBP2 intron 23953852 rs12425226 chr12 130995411 G C 2.21E-04 Multiple complex diseases RIMBP2 intron 17554300 rs12822943 chr12 131008739 C T 2.61E-04 Tourette syndrome / / 22889924 rs1464108 chr12 131022010 A C 8.00E-06 Alzheimer's disease / / 22005930 rs12231658 chr12 131030163 G A 1.69E-04 Vaspin levels / / 22907691 rs12231658 chr12 131030163 G A 0.0001691 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs12320988 chr12 131030239 G A 2.82E-04 Smoking quantity / / 24665060 rs12809631 chr12 131045190 C A 7.74E-05 Vaspin levels / / 22907691 rs12809631 chr12 131045190 C A 0.0000333 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs12809631 chr12 131045190 C A 0.0000774 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs8181764 chr12 131062900 C A 6.84E-04 IgA nephropathy / / 22197929 rs8181764 chr12 131062900 C A 1.80E-04 Cognitive decline / / 23732972 rs11061008 chr12 131066584 C T 3.50E-04 Alzheimer's disease / / 24755620 rs7969337 chr12 131078425 G A 2.74E-05 F-cell distribution / / 21326311 rs2129663 chr12 131088522 T G 7.53E-06 F-cell distribution / / 21326311 rs1532026 chr12 131103887 T C 2.30E-05 Urinary metabolites / / 21572414 rs4376942 chr12 131104082 G A 1.03E-04 Multiple complex diseases / / 17554300 rs10848164 chr12 131121133 A G 2.00E-04 Tetralogy of Fallot / / 23297363 rs10848180 chr12 131157748 T C 4.58E-06 Tuberculosis / / 22306650 rs7958924 chr12 131162180 A C 1.40E-05 Cocaine dependence / / 23958962 rs4759753 chr12 131164633 A G 2.16E-07 Hirschsprung's disease / / 19196962 rs1011347 chr12 131164897 G T 8.25E-05 Response to hepatitis C treatment / / 19684573 rs7977673 chr12 131165965 T C 6.36E-04 Multiple complex diseases / / 17554300 rs12425018 chr12 131167181 C T 6.03E-05 Response to hepatitis C treatment / / 19684573 rs10848190 chr12 131202035 C T 0.00000543 Alcohol dependence / / 23691058 rs4759771 chr12 131224803 T C 8.40E-04 Myopia (pathological) / / 21095009 rs4759511 chr12 131225119 C T 6.66E-07 Schizophrenia / / 21926974 rs10848194 chr12 131225337 A C 9.54E-04 Type 2 diabetes / / 17463246 rs74780504 chr12 131255067 A G 0.00002829 Sarcoidosis / / 22952805 rs1881064 chr12 131262041 G C 3.09E-05 Alzheimer's disease / / 17998437 rs1881064 chr12 131262041 G C 3.40E-05 Age-related macular degeneration / / 20861866 rs11061149 chr12 131281159 C T 3.54E-06 Alzheimer's disease STX2 intron 17998437 rs7301826 chr12 131291101 C T 1.00E-09 Plasma plasminogen activator levels STX2 intron 24578379 rs1106369 chr12 131300095 C A 6.86E-04 Intracranial aneurysm STX2 intron 20613766 rs4619189 chr12 131313797 T C 7.82E-04 Multiple complex diseases STX2 intron 17554300 rs4420312 chr12 131330173 T C 5.57E-05 Vascular dementia / / 22116812 rs10848218 chr12 131332064 C T 9.24E-04 Multiple complex diseases / / 17554300 rs10773829 chr12 131332099 G A 4.41E-05 Panic disorder / / 19165232 rs10848219 chr12 131332128 G A 2.20E-04 Alzheimer's disease / / 17998437 rs55999298 chr12 131342537 A G 4.50E-06 Response to amphetamines / / 22952603 rs9788176 chr12 131344585 C T 8.43E-06 Response to amphetamines / / 22952603 rs112288406 chr12 131345615 T G 8.41E-06 Response to amphetamines / / 22952603 rs113473376 chr12 131346554 T C 7.67E-06 Response to amphetamines / / 22952603 rs56988338 chr12 131348464 C T 7.65E-06 Response to amphetamines / / 22952603 rs113186822 chr12 131348620 A G 5.07E-06 Response to amphetamines / / 22952603 rs60409697 chr12 131348930 A C 4.55E-06 Response to amphetamines / / 22952603 rs111432356 chr12 131350140 G A 7.61E-06 Response to amphetamines / / 22952603 rs111390894 chr12 131350228 G A 5.09E-06 Response to amphetamines / / 22952603 rs77207911 chr12 131350864 T A 4.26E-06 Response to amphetamines / / 22952603 rs112286807 chr12 131351150 G A 6.88E-06 Response to amphetamines / / 22952603 rs113855039 chr12 131351794 G A 4.64E-06 Response to amphetamines / / 22952603 rs7304057 chr12 131352562 A G 4.00E-06 Response to amphetamines / / 22952603 rs7304201 chr12 131352681 A G 5.08E-06 Response to amphetamines / / 22952603 rs74532503 chr12 131353095 G A 4.45E-06 Response to amphetamines / / 22952603 rs10773832 chr12 131368436 T C 1.70E-05 Urinary metabolites / / 21572414 rs10773833 chr12 131368639 C G 1.10E-05 Urinary metabolites / / 21572414 rs11061222 chr12 131374052 T C 7.40E-04 Multiple complex diseases / / 17554300 rs11061222 chr12 131374052 T C 1.50E-05 Urinary metabolites / / 21572414 rs10848243 chr12 131379314 T C 1.80E-05 Urinary metabolites / / 21572414 rs7299940 chr12 131390754 C G 7.00E-06 Panic disorder / / 19165232 rs7299940 chr12 131390754 C G 4.26E-04 Coronary heart disease / / 21606135 rs1405904 chr12 131405553 C T 5.02E-05 Calcium levels / / pha003085 rs4759802 chr12 131407177 A G 7.44E-05 Nicotine smoking / / 19268276 rs819120 chr12 131443536 A G 7.06E-05 Cognitive test performance GPR133 intron 20125193 rs843899 chr12 131444428 C T 8.60E-04 Type 2 diabetes GPR133 intron 17463246 rs1195747 chr12 131445695 A G 2.96E-04 Multiple complex diseases GPR133 intron 17554300 rs4759814 chr12 131455221 T G 9.60E-06 Alcohol dependence GPR133 intron 23942779 rs11061269 chr12 131456449 G A 8.00E-10 Amyotrophic lateral sclerosis (sporadic) GPR133 intron 24529757 rs11061274 chr12 131478239 A G 4.38E-05 Response to cytadine analogues (cytosine arabinoside) GPR133 intron 24483146 rs7135850 chr12 131483990 G A 1.86E-04 Response to cytadine analogues (cytosine arabinoside) GPR133 intron 24483146 rs7975441 chr12 131484433 A G 5.02E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GPR133 intron 22566498 rs7305093 chr12 131488041 T C 7.49E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GPR133 intron 22566498 rs13377643 chr12 131517793 T G 3.47E-04 Response to taxane treatment (placlitaxel) GPR133 intron 23006423 rs11061302 chr12 131524747 G A 0.000899 Salmonella-induced pyroptosis GPR133 intron 22837397 rs3847687 chr12 131525053 C T 1.00E-06 Longevity GPR133 intron 20834067 rs11833801 chr12 131561394 G A 0.000000278 HDL cholesterol GPR133 missense 23063622 rs11061318 chr12 131569105 C T 5.17E-04 Cholesterol GPR133 missense 17255346 rs11061318 chr12 131569105 C T 0.00000446 Ankle-brachial index GPR133 missense 22361517 rs1467348 chr12 131574641 G C 5.90E-05 Pericardial fat GPR133 intron 22589742 rs1569019 chr12 131576191 C A 5.00E-08 Height GPR133 intron 19729412 rs1976930 chr12 131576445 C T 3.37E-07 Height GPR133 intron 19729412 rs12372170 chr12 131610065 A G 6.90E-07 Post-operative nausea and vomiting GPR133 intron 21694509 rs7958151 chr12 131617635 C A 9.60E-08 Dietary macronutrient intake GPR133 intron 23372041 rs885389 chr12 131621762 A G 4.00E-08 RR interval (heart rate) GPR133 intron 20031603 rs7485210 chr12 131638853 A C 3.33E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs12822389 chr12 131640896 T C 1.80E-05 Pericardial fat / / 22589742 rs10773855 chr12 131661333 T A 1.62E-04 Multiple complex diseases LOC116437 intron 17554300 rs11061376 chr12 131687762 G A 4.34E-05 Alzheimer's disease (late onset) LOC116437 intron 21460841 rs7980440 chr12 131689072 G C 3.95E-05 Alzheimer's disease (late onset) LOC116437 intron 21460841 rs10848307 chr12 131691694 G A 3.31E-04 Alzheimer's disease (late onset) LOC116437 intron 21460841 rs4759865 chr12 131697146 A C 5.22E-04 Alzheimer's disease (late onset) / / 21460841 rs7966420 chr12 131697746 G A 3.95E-04 Alzheimer's disease (late onset) / / 21460841 rs4335625 chr12 131700412 G T 3.50E-11 Health and aging,CVD and cancer age of onset / / 22174011 rs10848319 chr12 131717006 C A 1.91E-05 Cognitive test performance / / 20125193 rs4759882 chr12 131734621 A C 5.72E-05 Magnesium levels / / pha003092 rs12818967 chr12 131797608 T G 0.0002 Migraine / / 22678113 rs11061473 chr12 131840307 G C 1.46E-04 Multiple complex diseases / / 17554300 rs11061476 chr12 131849823 G A 7.40E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs7965445 chr12 131862903 G A 2.00E-06 Heart failure / / 20400778 rs883673 chr12 131933350 C G 0.0000655 Major depressive disorder / / 23149448 rs10466868 chr12 131939920 G T 1.00E-06 Protein quantitative trait loci / / 18464913 rs10466868 chr12 131939920 G T 6.39E-05 Pulmonary function in asthmatics / / 23541324 rs10466868 chr12 131939920 G T 1.48E-04 Endometrial cancer / / 24096698 rs10466868 chr12 131939920 G T 2.28E-04 Endometrial cancer / / 24096698 rs7301811 chr12 131945176 C G 3.18E-04 Smoking initiation / / 24665060 rs11061558 chr12 131970306 A G 0.0000326 Major depressive disorder / / 23149448 rs11061560 chr12 131971504 C T 8.63E-04 Coronary heart disease / / 21606135 rs7956521 chr12 131975369 T C 8.27E-05 Rheumatoid arthritis / / 17804836 rs7956521 chr12 131975369 T C 1.47E-05 Myopia (severe) / / 23933737 rs11061563 chr12 131976552 G A 0.0001313 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11061563 chr12 131976552 G A 1.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs941152 chr12 131991337 T G 7.65E-06 Rheumatoid arthritis / / 17804836 rs7976920 chr12 131995718 C A 0.0006759 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7976920 chr12 131995718 C A 6.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10773916 chr12 132005925 C T 0.0001729 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10773916 chr12 132005925 C T 1.73E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10773917 chr12 132006831 T G 5.70E-05 Parkinson's disease (age of onset) / / 19772629 rs11061596 chr12 132009176 C T 0.000172 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11061596 chr12 132009176 C T 1.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1918210 chr12 132011337 G A 0.0001743 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1918210 chr12 132011337 G A 1.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11610538 chr12 132012266 G A 0.000104 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11610538 chr12 132012266 G A 1.04E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10773920 chr12 132014206 A C 8.00E-06 Obesity-related traits / / 23251661 rs10848425 chr12 132018701 C T 9.16E-05 Elbow pain / / pha003008 rs4133254 chr12 132042958 A G 9.63E-04 Obesity (extreme) / / 21935397 rs7398258 chr12 132045682 T C 1.88E-04 Obesity (extreme) / / 21935397 rs7488571 chr12 132046004 C T 9.32E-04 Obesity (extreme) / / 21935397 rs7398686 chr12 132047807 G A 1.43E-06 Left ventricular mass / / 21212386 rs7398686 chr12 132047807 G A 6.37E-04 Alzheimer's disease / / 24755620 rs10902443 chr12 132050690 G A 0.00000927 Nicotine dependence (smoking) / / 23643383 rs11614599 chr12 132054781 A C 8.68E-04 Obesity (extreme) / / 21935397 rs11246833 chr12 132057720 G C 4.10E-05 Height / / 19396169 rs11246833 chr12 132057720 G C 1.43E-06 Left ventricular mass / / 21212386 rs11246833 chr12 132057720 G C 4.36E-04 Alzheimer's disease / / 24755620 rs1006028 chr12 132077820 A C 7.43E-04 Alzheimer's disease / / 24755620 rs10082970 chr12 132078182 T C 2.70E-05 Urinary metabolites / / 21572414 rs10736914 chr12 132078197 T A 2.14E-05 Serum metabolites / / 19043545 rs7966790 chr12 132078847 A G 2.19E-05 Serum metabolites / / 19043545 rs7315621 chr12 132085196 G A 1.00E-06 Longevity / / 20834067 rs11609565 chr12 132093024 G A 4.40E-06 Urinary metabolites / / 21572414 rs930860 chr12 132101139 G A 3.20E-04 Myopia (pathological) / / 21095009 rs7294672 chr12 132101949 T C 2.91E-04 Obesity (extreme) / / 21935397 rs12832187 chr12 132154193 C T 2.94E-04 Alcohol dependence / / 21314694 rs7485834 chr12 132182209 G A 7.37E-05 Height / / pha003010 rs7134297 chr12 132184314 C T 1.60E-04 Obesity (extreme) / / 21935397 rs4964984 chr12 132190958 G T 3.42E-04 Obesity (extreme) / / 21935397 rs10444602 chr12 132192836 T G 5.92E-07 Blood pressure / / 21996601 rs10794423 chr12 132200162 C T 6.32E-05 Systemic sclerosis SFSWAP intron 21750679 rs10794423 chr12 132200162 C T 6.14E-04 Heart Failure SFSWAP intron pha002884 rs4964985 chr12 132202662 A G 2.98E-04 Obesity (extreme) SFSWAP intron 21935397 rs4964986 chr12 132207169 C A 2.93E-04 Obesity (extreme) SFSWAP intron 21935397 rs11612305 chr12 132212523 A G 1.10E-04 Heart Failure SFSWAP intron pha002884 rs10902438 chr12 132213573 C T 2.77E-04 Obesity (extreme) SFSWAP intron 21935397 rs11246780 chr12 132214574 A G 7.60E-05 Self-reported allergy SFSWAP intron 23817569 rs12370005 chr12 132217987 G A 3.22E-04 Obesity (extreme) SFSWAP intron 21935397 rs7980865 chr12 132219427 A G 3.27E-05 Obesity (extreme) SFSWAP intron 21935397 rs10902439 chr12 132219807 T G 3.26E-04 Obesity (extreme) SFSWAP intron 21935397 rs10902440 chr12 132220347 T C 3.28E-04 Obesity (extreme) SFSWAP intron 21935397 rs737434 chr12 132221059 C T 3.31E-04 Obesity (extreme) SFSWAP intron 21935397 rs12312632 chr12 132223880 G C 3.27E-04 Obesity (extreme) SFSWAP intron 21935397 rs12314207 chr12 132224280 G C 3.48E-04 Obesity (extreme) SFSWAP intron 21935397 rs11246796 chr12 132233607 A C 2.84E-04 Obesity (extreme) SFSWAP intron 21935397 rs10902444 chr12 132235859 C T 3.29E-05 Self-reported allergy SFSWAP intron 23817569 rs3741526 chr12 132240341 C T 4.16E-04 Suicide attempts in bipolar disorder SFSWAP intron 21041247 rs10751692 chr12 132243928 T C 8.78E-04 Multiple complex diseases SFSWAP intron 17554300 rs10751692 chr12 132243928 T C 4.15E-04 Suicide attempts in bipolar disorder SFSWAP intron 21041247 rs6598153 chr12 132249488 T C 4.89E-04 Suicide attempts in bipolar disorder SFSWAP intron 21041247 rs10751693 chr12 132273316 A G 4.81E-04 Suicide attempts in bipolar disorder SFSWAP intron 21041247 rs12319878 chr12 132289989 C T 8.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs11246824 chr12 132292347 T C 5.30E-04 Alzheimer's disease / / 17998437 rs12813376 chr12 132302324 C T 7.82E-05 Cognitive test performance / / 20125193 rs4964926 chr12 132316224 G C 3.97E-05 Obesity (extreme) MMP17 intron 21935397 rs7134349 chr12 132317829 G C 5.63E-04 Body mass index MMP17 intron 21701565 rs7134349 chr12 132317829 G C 3.98E-05 Obesity (extreme) MMP17 intron 21935397 rs11246838 chr12 132317991 A G 6.17E-04 Body mass index MMP17 intron 21701565 rs11246838 chr12 132317991 A G 4.02E-05 Obesity (extreme) MMP17 intron 21935397 rs143543400 chr12 132322812 C A 0.000011 Breast cancer(er negative) MMP17 missense 23555315 rs6598163 chr12 132325239 G A 5.00E-07 Migraine MMP17 missense 22683712 rs10902456 chr12 132330531 G T 0.00000696 Cholesterol,total MMP17 intron 23236364 rs11613757 chr12 132332237 C T 1.97E-04 Obesity (extreme) MMP17 intron 21935397 rs4964933 chr12 132339957 T C 9.67E-04 Celiac disease / / 23936387 rs10902482 chr12 132424944 T C 3.67E-04 Body mass index PUS1 intron 21701565 rs7313415 chr12 132489946 A G 8.17E-04 Body mass index EP400 intron 21701565 rs11835531 chr12 132521581 A G 8.78E-04 Body mass index EP400 intron 21701565 rs6598192 chr12 132529649 T C 5.20E-06 Dietary macronutrient intake EP400 intron 23372041 rs7979734 chr12 132587687 G A 2.86E-05 Multiple complex diseases EP400NL intron 17554300 rs12422267 chr12 132601596 A G 2.00E-06 Plasma amyloid beta peptide concentrations (ABx-40) EP400NL intron 24535457 rs7131729 chr12 132663423 G A 2.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs10902505 chr12 132677905 C G 0.00005397 Sarcoidosis / / 22952805 rs11246983 chr12 132682189 A G 0.0001259 Sarcoidosis GALNT9 intron 22952805 rs12308155 chr12 132682481 T G 0.000127 Sarcoidosis GALNT9 cds-synon 22952805 rs12306514 chr12 132682484 A G 0.00002514 Sarcoidosis GALNT9 cds-synon 22952805 rs12579310 chr12 133021393 C T 2.24E-05 C-Reactive Protein / / pha003070 rs11146962 chr12 133022983 A G 8.89E-05 Vaspin levels / / 22907691 rs11146962 chr12 133022983 A G 0.0000889 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs10747083 chr12 133041618 G A 7.55E-09 Fasting blood glucose / / 22885924 rs10781655 chr12 133044914 C T 7.57E-04 Alzheimer's disease / / 24755620 rs4883520 chr12 133115405 T C 3.10E-04 Multiple complex diseases FBRSL1 intron 17554300 rs4883543 chr12 133202004 C T 5.21E-04 Oral cancers (chewing tobacco related) POLE intron 22503698 rs5744934 chr12 133220526 T C 8.50E-05 Response to statin treatment (atorvastatin),change in cholesterol levels POLE missense 20031582 rs5744903 chr12 133225713 C T 1.47E-05 Amyotrophic lateral sclerosis (sporadic) POLE intron 24529757 rs5744750 chr12 133254083 T C 7.02E-04 Oral cancers (chewing tobacco related) POLE intron 22503698 rs11147021 chr12 133303035 T C 3.82E-05 Multiple complex diseases ANKLE2 UTR-3 17554300 rs11147040 chr12 133318406 G T 7.31E-09 Metabolite levels ANKLE2 intron 23281178 rs11613456 chr12 133318989 T C 1.98E-04 Suicide attempts in bipolar disorder ANKLE2 intron 21423239 rs4075751 chr12 133324693 A G 5.26E-04 Multiple complex diseases ANKLE2 intron 17554300 rs11147045 chr12 133325639 G A 3.41E-05 Suicide attempts in bipolar disorder ANKLE2 intron 21423239 rs7304425 chr12 133327470 A T 9.28E-04 Suicide attempts in bipolar disorder ANKLE2 intron 21423239 rs11147046 chr12 133327808 C T 2.87E-04 Suicide attempts in bipolar disorder ANKLE2 intron 21423239 rs11147047 chr12 133329783 C T 2.52E-04 Suicide attempts in bipolar disorder ANKLE2 intron 21423239 rs1132375 chr12 133331537 G A 1.58E-04 Suicide attempts in bipolar disorder ANKLE2 missense 21423239 rs4758927 chr12 133341070 G A 1.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs11147067 chr12 133343554 C A 7.69E-05 Suicide attempts in bipolar disorder / / 21423239 rs12282 chr12 133345809 C T 3.00E-07 Immune response to smallpox vaccine (IL-6) GOLGA3 UTR-3 22542470 rs900443 chr12 133354453 C T 4.87E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GOLGA3 intron 20031582 rs2291260 chr12 133357412 T C 1.19E-06 Suicide attempts in bipolar disorder GOLGA3 missense 21423239 rs1009320 chr12 133360964 G A 3.01E-04 Suicide attempts in bipolar disorder GOLGA3 intron 21423239 rs10870511 chr12 133361843 G A 3.74E-04 Suicide attempts in bipolar disorder GOLGA3 intron 21423239 rs2242294 chr12 133363264 C T 3.62E-04 Suicide attempts in bipolar disorder GOLGA3 intron 21423239 rs34172546 chr12 133372395 A AG 1.17E-04 Suicide attempts in bipolar disorder GOLGA3 intron 21423239 rs4758905 chr12 133372395 A C,G,T 1.17E-04 Suicide attempts in bipolar disorder GOLGA3 intron 21423239 rs2242291 chr12 133373504 G A 1.19E-04 Suicide attempts in bipolar disorder GOLGA3 intron 21423239 rs2291258 chr12 133378440 C T 4.74E-04 Suicide attempts in bipolar disorder GOLGA3 cds-synon 21423239 rs3741488 chr12 133385188 A T 5.84E-04 Suicide attempts in bipolar disorder GOLGA3 intron 21423239 rs11147095 chr12 133398020 G C 1.86E-04 Suicide attempts in bipolar disorder GOLGA3 intron 21423239 rs12303977 chr12 133401184 C A 1.80E-04 Suicide attempts in bipolar disorder GOLGA3 intron 21423239 rs8021 chr12 133417285 T C 3.33E-04 Suicide attempts in bipolar disorder CHFR UTR-3 21423239 rs3741489 chr12 133417802 T C 2.00E-06 Cognitive function CHFR UTR-3 24684796 rs3741490 chr12 133417908 C T 4.87E-04 Suicide attempts in bipolar disorder CHFR UTR-3 21423239 rs2306541 chr12 133428242 G A 2.60E-04 Suicide attempts in bipolar disorder CHFR missense 21423239 rs7297261 chr12 133432653 A T 5.69E-04 Suicide attempts in bipolar disorder CHFR intron 21423239 rs2062162 chr12 133432744 C T 1.66E-06 Cognitive function CHFR intron 24684796 rs2062163 chr12 133433173 T C 9.63E-05 Multiple complex diseases / / 17554300 rs4758954 chr12 133434553 C T 7.59E-04 Rheumatoid arthritis CHFR intron 21452313 rs7969859 chr12 133437240 G A 4.53E-04 Suicide attempts in bipolar disorder CHFR intron 21423239 rs2291254 chr12 133448815 G A 1.32E-04 Suicide attempts in bipolar disorder CHFR intron 21423239 rs12811327 chr12 133449177 G A 4.51E-04 Suicide attempts in bipolar disorder CHFR intron 21423239 rs12815354 chr12 133476501 G A 8.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs12815207 chr12 133476559 C T 8.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs4758915 chr12 133477147 A G 7.97E-04 Type 2 diabetes / / 17463246 rs13273 chr12 133498344 G A 7.34E-05 Psoriasis ZNF605 UTR-3 18364390 rs11147178 chr12 133531127 G T 2.04E-04 Alzheimer's disease ZNF605 intron 24755620 rs115858642 chr12 133563254 T C 6.03E-05 Hypertension (essential hypertension) ZNF26 UTR-5 22184326 rs4758930 chr12 133578159 A G 7.28E-05 Hypertension (essential hypertension) ZNF26 intron 22184326 rs116647663 chr12 133595631 C T 7.27E-05 Hypertension (essential hypertension) / / 22184326 rs116087477 chr12 133599116 T C 8.84E-05 Hypertension (essential hypertension) / / 22184326 rs116465927 chr12 133633459 A G 6.62E-05 Hypertension (essential hypertension) ZNF84 intron 22184326 rs202097614 chr12 133633536 A G 9.24E-05 Lung function (forced expiratory volume in 1 second) ZNF84 intron 24023788 rs115172135 chr12 133634450 A C 7.12E-05 Hypertension (essential hypertension) ZNF84 cds-synon 22184326 rs114972238 chr12 133635613 T C 6.62E-05 Hypertension (essential hypertension) / / 22184326 rs12322454 chr12 133696373 A T 3.81E-04 Multiple complex diseases / / 17554300 rs11147244 chr12 133704501 A G 6.83E-05 Hypertension (essential hypertension) ZNF891 intron 22184326 rs2292029 chr12 133734113 C T 1.97E-05 Lymphocyte counts ZNF10 UTR-3 22286170 rs10747098 chr12 133766801 T A 7.06E-04 Type 2 diabetes ZNF268 intron 17463246 rs9509399 chr13 19260565 G C,T 3.76E-04 Body mass index / / 21701565 rs9509399 chr13 19260565 G C,T 6.45E-04 Body mass index / / 21701565 rs9509474 chr13 19273251 G A 6.70E-04 Smoking quantity / / 24665060 rs9552416 chr13 19311241 C T 3.00E-24 Fasting insulin-related traits (interaction with BMI) / / 22581228 rs1838127 chr13 19450806 C G 9.54E-04 Type 2 diabetes / / 17463246 rs1443351 chr13 19450957 G C 9.32E-04 Type 2 diabetes / / 17463246 rs1822374 chr13 19496928 T C 3.32E-04 Type 2 diabetes LOC100652856 intron 17463246 rs9551000 chr13 19543915 G A 8.05E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9578637 chr13 19548826 T C 2.83E-04 Taste perception / / 22132133 rs7997564 chr13 19549527 T G 5.47E-04 Aortic root size / / 21223598 rs6490840 chr13 19564715 G T 8.13E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs9510969 chr13 19569428 G A 8.12E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7992041 chr13 19571844 T C 3.88E-04 Aortic root size / / 21223598 rs7992041 chr13 19571844 T C 8.13E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4091742 chr13 19590984 C T 8.20E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9511095 chr13 19591386 T C 9.19E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7982646 chr13 19623713 A G 4.00E-06 Multiple myeloma PHF2P1 intron 23955597 rs4770720 chr13 19639078 T G 8.74E-06 Non-obstructive azoospermia PHF2P1 intron 22541561 rs9581191 chr13 19658933 C T 0.0000213 Asthma PHF2P1 intron 22694930 rs7984141 chr13 19660641 C T 4.68E-04 Smoking initiation PHF2P1 intron 24665060 rs12584206 chr13 19668871 C G,T 7.69E-08 Metabolite levels PHF2P1 intron 23281178 rs4770762 chr13 19670142 A G 8.71E-08 Metabolite levels PHF2P1 intron 23281178 rs7328859 chr13 19675536 T C 2.61E-05 Attention deficit hyperactivity disorder PHF2P1 intron 22420046 rs4238186 chr13 19690836 G A 1.11E-05 Attention deficit hyperactivity disorder PHF2P1 intron 22420046 rs2006655 chr13 19746610 C T 3.03E-04 Type 2 diabetes / / 17463246 rs10492523 chr13 19747750 C T 5.20E-06 Calcium levels / / pha003085 rs9507572 chr13 19752291 A G 6.12E-06 Calcium levels TUBA3C intron pha003085 rs2765209 chr13 19798532 C T 3.69E-05 Asthma / / pha003128 rs590897 chr13 19834619 T G 8.17E-05 Multiple complex diseases / / 17554300 rs2785568 chr13 19894041 G A 8.57E-05 Multiple complex diseases ANKRD26P3 intron 17554300 rs7990527 chr13 19894163 A G 3.91E-05 Cognitive impairment induced by topiramate ANKRD26P3 intron 22091778 rs1330730 chr13 19895384 G A 3.08E-05 Multiple sclerosis ANKRD26P3 intron 17660530 rs2812746 chr13 19906655 C T 6.41E-04 Multiple complex diseases ANKRD26P3 intron 17554300 rs2812746 chr13 19906655 C T 7.89E-05 Multiple sclerosis ANKRD26P3 intron 17660530 rs4771142 chr13 19933372 G A 3.48E-05 Height / / pha003010 rs4771142 chr13 19933372 G A 1.49E-05 Height / / pha003011 rs4771175 chr13 19957848 C T 4.61E-05 Cognitive impairment induced by topiramate / / 22091778 rs1856021 chr13 19984413 T C 3.50E-06 Urinary metabolites / / 21572414 rs2999200 chr13 19989941 T C 6.06E-15 Gender / / 22362730 rs2497073 chr13 20023016 G C 7.94E-04 Multiple complex diseases TPTE2 intron 17554300 rs3002104 chr13 20060963 C T 5.50E-04 Multiple complex diseases TPTE2 intron 17554300 rs3123288 chr13 20085213 T C 8.88E-04 Multiple complex diseases TPTE2 intron 17554300 rs2451078 chr13 20098289 G C 1.94E-10 Parkinson's disease TPTE2 intron 21812969 rs2451078 chr13 20098289 G C 8.56E-25 Gender TPTE2 intron 22362730 rs2451078 chr13 20098289 G C 5.40E-04 Oral cancers (chewing tobacco related) TPTE2 intron 22503698 rs2880301 chr13 20100534 C T 1.05E-16 Coronary Artery Disease TPTE2 intron 17634449 rs2880301 chr13 20100534 C T 1.36E-25 Gender TPTE2 intron 22362730 rs2880301 chr13 20100534 C T 1.51E-32 HDL cholesterol particle diameter TPTE2 intron 23263444 rs2880301 chr13 20100534 C T 5.85E-25 LDL cholesterol particle diameter TPTE2 intron 23263444 rs3002099 chr13 20101964 T A 2.08E-05 Multiple complex diseases TPTE2 intron 17554300 rs3933766 chr13 20110195 A G 6.03E-04 Multiple complex diseases TPTE2 intron 17554300 rs9508455 chr13 20119614 A T 1.70E-05 Urinary metabolites / / 21572414 rs4769756 chr13 20127358 G A 1.80E-05 Urinary metabolites / / 21572414 rs9551718 chr13 20143975 T C 8.50E-06 Urinary metabolites / / 21572414 rs7994632 chr13 20146417 A G 4.90E-06 Urinary metabolites / / 21572414 rs2446464 chr13 20163413 C G 1.30E-05 Urinary metabolites / / 21572414 rs2446462 chr13 20169564 T C 2.90E-05 Urinary metabolites / / 21572414 rs4769042 chr13 20236385 C T 2.30E-05 Urinary metabolites MPHOSPH8 intron 21572414 rs9579701 chr13 20393811 C T 7.28E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11838644 chr13 20397058 T C 2.98E-08 Lymphocyte counts / / 22286170 rs9579703 chr13 20397124 T C 7.07E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9578222 chr13 20401310 C T 7.25E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ZMYM5 intron 22566498 rs11840619 chr13 20410571 G A 7.51E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ZMYM5 intron 22566498 rs11839389 chr13 20410910 A T 7.56E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ZMYM5 intron 22566498 rs10220121 chr13 20419475 T C 7.83E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ZMYM5 intron 22566498 rs9578225 chr13 20420137 C T 7.88E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ZMYM5 intron 22566498 rs10219966 chr13 20424260 C T 9.41E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ZMYM5 intron 22566498 rs9579717 chr13 20425911 C A,G,T 9.47E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ZMYM5 missense 22566498 rs9579719 chr13 20427358 G A 9.53E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ZMYM5 intron 22566498 rs7327207 chr13 20494558 A G 1.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7983972 chr13 20509959 G A 4.70E-05 Cognitive decline / / 22054870 rs17074797 chr13 20570396 T C 7.47E-04 Multiple complex diseases ZMYM2 intron 17554300 rs6490506 chr13 20574373 A G 5.19E-08 Multiple complex diseases ZMYM2 intron 17554300 rs7324021 chr13 20637140 T G 1.76E-05 Cognitive decline ZMYM2 intron 22054870 rs7321929 chr13 20642012 T C 9.30E-05 Cognitive decline ZMYM2 intron 22054870 rs9550612 chr13 20678227 A G 0.00004137 Sarcoidosis / / 22952805 rs17076520 chr13 20678513 T C 5.81E-04 Multiple complex diseases / / 17554300 rs17076534 chr13 20678731 G A 4.56E-06 Cognitive decline / / 22054870 rs7988137 chr13 20682079 A G 4.49E-05 Multiple complex diseases / / 17554300 rs9509040 chr13 20686272 C T 5.21E-04 Multiple complex diseases / / 17554300 rs6490525 chr13 20736216 C G 4.00E-06 Capecitabine sensitivity GJA3 nearGene-5 22864933 rs2313474 chr13 20749167 T C 2.90E-04 Type 2 diabetes / / 17463246 rs2313476 chr13 20751019 A G 2.80E-05 Urinary metabolites / / 21572414 rs3751385 chr13 20762956 A G 2.20E-11 Psoriasis GJB2 UTR-3 20953187 rs3751385 chr13 20762956 A G 4.40E-08 Psoriasis GJB2 UTR-3 20953187 rs3751385 chr13 20762956 A G 4.30E-04 Myocardial Infarction GJB2 UTR-3 pha002873 rs870729 chr13 20781879 A G 2.85E-04 Myocardial Infarction / / pha002873 rs877098 chr13 20798240 A G 9.56E-04 Multiple complex diseases GJB6 intron 17554300 rs877098 chr13 20798240 A G 5.91E-04 Alcohol dependence GJB6 intron 21314694 rs10492508 chr13 20829582 T C 3.61E-05 Response to hepatitis C treatment / / 19684573 rs9509124 chr13 20841770 G A 8.53E-04 Coronary Artery Disease / / 17634449 rs9550626 chr13 20861153 C G 1.15E-05 Multiple complex diseases / / 17554300 rs876165 chr13 20891653 G A 5.00E-04 Heart Failure / / pha002884 rs7337231 chr13 20896618 T C 4.60E-05 Psoriasis / / 19169255 rs7320913 chr13 20897841 T G 8.20E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7320913 chr13 20897841 T G 4.73E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs9509161 chr13 20903919 G A 9.03E-04 Multiple complex diseases / / 17554300 rs17475847 chr13 20908370 C T 9.88E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17475847 chr13 20908370 C T 2.24E-05 Orofacial clefts / / 22863734 rs12868032 chr13 20910048 T C 7.80E-05 Psoriasis / / 19169255 rs17080439 chr13 20912067 A G 1.15E-04 Celiac disease / / 23936387 rs9550637 chr13 20912527 A G 6.58E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9550637 chr13 20912527 A G 5.90E-06 Multiple sclerosis / / 21833088 rs9550637 chr13 20912527 A G 3.91E-04 Lung function (forced vital capacity) / / 24023788 rs7995321 chr13 20924535 C T 4.56E-04 Multiple complex diseases / / 17554300 rs4483706 chr13 20939064 A G 1.30E-04 Alzheimer's disease / / 17998437 rs1105267 chr13 20939236 G A 5.12E-10 Crohn's disease / / 17068223 rs4770010 chr13 20942037 A C 1.79E-04 Multiple complex diseases / / 17554300 rs9552162 chr13 20942224 C A 9.56E-05 Multiple complex diseases / / 17554300 rs9550642 chr13 20950092 G A 8.44E-06 Multiple complex diseases / / 17554300 rs7321107 chr13 20956208 C T 3.86E-04 Multiple complex diseases / / 17554300 rs7998484 chr13 20958747 C T 5.03E-05 Alzheimer's disease (age of onset) / / 22005931 rs1122662 chr13 20975671 C T 2.66E-04 Multiple complex diseases / / 17554300 rs17081647 chr13 20977507 T C 2.01E-04 Smoking cessation / / 18519826 rs6490564 chr13 20979104 G A 6.20E-04 Type 2 diabetes CRYL1 intron 22158537 rs7330265 chr13 20996798 A G 2.27E-04 Type 2 diabetes CRYL1 intron 22158537 rs9552183 chr13 21015215 C T 2.96E-05 Information processing speed CRYL1 intron 21130836 rs12866627 chr13 21018715 G A 9.03E-04 Suicide attempts in bipolar disorder CRYL1 intron 21423239 rs11618713 chr13 21020918 T G 6.71E-04 Suicide attempts in bipolar disorder CRYL1 intron 21423239 rs9315607 chr13 21041654 A T 1.27E-04 Smoking cessation CRYL1 intron 18519826 rs4573790 chr13 21043086 G A 6.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) CRYL1 intron 23648065 rs9506494 chr13 21047858 C T 7.17E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) CRYL1 intron 23648065 rs9552195 chr13 21048924 G A 4.41E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) CRYL1 intron 23648065 rs7989332 chr13 21050575 A C 5.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) CRYL1 intron 23648065 rs9552196 chr13 21057250 C T 6.12E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) CRYL1 intron 23648065 rs9509246 chr13 21065555 T C 2.03E-04 Alzheimer's disease (late onset) CRYL1 intron 21379329 rs9552210 chr13 21067941 G A 1.61E-04 Alzheimer's disease (late onset) CRYL1 intron 21379329 rs9579876 chr13 21068591 G A 9.12E-04 Suicide attempts in bipolar disorder CRYL1 intron 21423239 rs9550656 chr13 21069259 A G 8.34E-04 Suicide attempts in bipolar disorder CRYL1 intron 21423239 rs12146943 chr13 21076875 G A 1.82E-05 Height CRYL1 intron pha003011 rs9315648 chr13 21081593 T C 9.47E-05 Height CRYL1 intron pha003011 rs4381447 chr13 21085644 A G 9.15E-05 Non-alcoholic fatty liver disease histology (other) CRYL1 intron 20708005 rs2314232 chr13 21087335 T C 9.06E-04 Oral cancers (chewing tobacco related) CRYL1 intron 22503698 rs4770049 chr13 21093604 C T 5.00E-06 Obesity-related traits CRYL1 intron 23251661 rs9552230 chr13 21120804 G T 0.0000013 Mean arterial pressure / / 22510845 rs9506514 chr13 21131211 C A 5.00E-06 Coronary artery calcification / / 23870195 rs9506528 chr13 21188339 G A 7.63E-04 Alcohol dependence IFT88 intron 20201924 rs17054778 chr13 21207148 T G 4.95E-04 Multiple complex diseases IFT88 intron 17554300 rs7326068 chr13 21209512 G A 3.00E-06 Schizophrenia,bipolar disorder and depression (combined) IFT88 intron 20713499 rs7981691 chr13 21241147 G A 5.81E-04 Multiple complex diseases IFT88 intron 17554300 rs735539 chr13 21280034 A G 4.00E-06 Dental caries IL17D intron 23064961 rs2253017 chr13 21300909 C T 2.00E-08 PR segment / / 24850809 rs3936081 chr13 21348279 A C,G 2.77E-08 PR segment / / 24850809 rs4770073 chr13 21382117 A G 5.81E-07 Neuroblastoma XPO4 intron pha002895 rs1822365 chr13 21406858 A G 4.35E-05 Monocyte counts XPO4 intron pha003089 rs499577 chr13 21424404 G A 7.92E-05 Monocyte counts XPO4 intron pha003089 rs9579975 chr13 21495509 G C 6.16E-05 Bipolar disorder / / 19488044 rs9579975 chr13 21495509 G C 6.22E-05 Bipolar Disorder / / pha002863 rs3858744 chr13 21496144 G A 9.11E-05 Hemoglobin / / pha003096 rs9509441 chr13 21499444 G A 1.99E-05 Hemoglobin / / pha003096 rs9509441 chr13 21499444 G A 1.86E-05 Hematocrit / / pha003097 rs483624 chr13 21534752 G A 3.25E-04 White matter integrity / / 22425255 rs551714 chr13 21538464 C T 4.69E-06 Multiple complex diseases / / 17554300 rs507186 chr13 21548026 A G 9.84E-04 Suicide attempts in bipolar disorder LATS2 UTR-3 21423239 rs555919 chr13 21550138 C T 7.71E-04 Suicide attempts in bipolar disorder LATS2 intron 21423239 rs7990975 chr13 21552462 C T 1.60E-04 Major depressive disorder LATS2 intron 21042317 rs688663 chr13 21554217 A T 1.50E-05 Urinary metabolites LATS2 intron 21572414 rs7317623 chr13 21563642 G C 8.23E-04 Suicide attempts in bipolar disorder LATS2 intron 21423239 rs1199735 chr13 21570202 G C 7.71E-04 Multiple complex diseases LATS2 intron 17554300 rs9552323 chr13 21575298 C T 5.02E-04 Multiple complex diseases LATS2 intron 17554300 rs11841745 chr13 21583572 A G 2.60E-05 Major depressive disorder LATS2 intron 21042317 rs572224 chr13 21586044 T G 2.90E-05 Urinary metabolites LATS2 intron 21572414 rs7139662 chr13 21628007 G A 2.77E-04 Bipolar disorder,schizoaffective LATS2 intron 19567891 rs4769152 chr13 21689630 G A 2.51E-05 Coronary heart disease / / pha003032 rs9578341 chr13 21691101 A G 3.56E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs9580025 chr13 21798497 C T 5.70E-06 Urinary metabolites / / 21572414 rs1970208 chr13 21807752 T C 4.10E-05 Iron levels / / 21208937 rs2184533 chr13 21813551 C G 3.30E-05 Iron levels / / 21208937 rs17064136 chr13 21815869 G A 4.00E-06 Obesity-related traits / / 23251661 rs261381 chr13 21820213 A G 9.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs9580033 chr13 21820242 G A 9.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs7989583 chr13 21829170 T C 7.99E-05 Multiple complex diseases / / 17554300 rs7320553 chr13 21861226 G A 4.07E-05 Cognitive test performance / / 20125193 rs261375 chr13 21871882 C T 4.79E-04 Type 2 diabetes / / 17463246 rs9788333 chr13 21876096 C G 4.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients MIPEPP3 intron 23400010 rs7328482 chr13 21877418 T G 1.80E-05 Multiple complex diseases MIPEPP3 intron 17554300 rs7328482 chr13 21877418 T G 8.12E-04 Myopia (pathological) MIPEPP3 intron 21095009 rs7335922 chr13 21878779 T C 1.68E-04 Myopia (pathological) MIPEPP3 intron 21095009 rs7335922 chr13 21878779 T C 4.55E-04 Alzheimer's disease MIPEPP3 intron 22005930 rs10161851 chr13 21898168 A T 5.77E-04 Type 2 diabetes MIPEPP3 intron 17463246 rs9580087 chr13 21913662 C T 2.65E-04 Alzheimer's disease MIPEPP3 intron 22005930 rs7996457 chr13 21914031 C T 7.82E-04 Alzheimer's disease MIPEPP3 intron 22005930 rs4770139 chr13 21914549 C T 6.27E-04 Alzheimer's disease MIPEPP3 intron 22005930 rs17356983 chr13 21915114 A G 2.00E-06 Obesity-related traits MIPEPP3 intron 23251661 rs17356983 chr13 21915114 A G 8.41E-06 Blood Pressure MIPEPP3 intron pha003040 rs17065406 chr13 21916420 G A 6.21E-04 Alzheimer's disease MIPEPP3 intron 22005930 rs9509656 chr13 21917780 A G 4.90E-04 Alzheimer's disease MIPEPP3 intron 22005930 rs9509657 chr13 21917902 C T 4.72E-04 Alzheimer's disease MIPEPP3 intron 22005930 rs7336525 chr13 21918844 G A 7.39E-05 Alzheimer's disease MIPEPP3 intron 22005930 rs12864885 chr13 21944935 T A 1.50E-05 Urinary metabolites MIPEPP3 intron 21572414 rs2315545 chr13 22076491 C T 2.62E-09 PR segment EFHA1 intron 24850809 rs718426 chr13 22085659 A G 2.84E-09 PR segment EFHA1 intron 24850809 rs1044090 chr13 22090066 A C 2.08E-09 PR segment EFHA1 intron 24850809 rs12861578 chr13 22092762 T G 1.75E-09 PR segment EFHA1 intron 24850809 rs4770170 chr13 22092961 T C 1.84E-09 PR segment EFHA1 intron 24850809 rs1359190 chr13 22096611 T G 2.03E-09 PR segment EFHA1 intron 24850809 rs10492455 chr13 22102976 A G 1.06E-09 PR segment EFHA1 intron 24850809 rs12869776 chr13 22103294 A G 1.05E-09 PR segment EFHA1 intron 24850809 rs2798264 chr13 22106134 A T 2.31E-09 PR segment EFHA1 intron 24850809 rs11841562 chr13 22111521 C A 1.71E-09 PR segment EFHA1 intron 24850809 rs2798280 chr13 22112853 T C 1.96E-09 PR segment EFHA1 intron 24850809 rs11616720 chr13 22115822 A G 7.82E-10 PR segment EFHA1 intron 24850809 rs2761909 chr13 22116804 T C 2.82E-09 PR segment EFHA1 intron 24850809 rs1539562 chr13 22117071 A G 8.90E-10 PR segment EFHA1 intron 24850809 rs12584577 chr13 22120666 C T 4.08E-10 PR segment EFHA1 intron 24850809 rs17679426 chr13 22122477 A T 4.05E-10 PR segment EFHA1 intron 24850809 rs4770172 chr13 22123676 A G 3.40E-10 PR segment EFHA1 intron 24850809 rs12877509 chr13 22124028 G C 1.25E-09 PR segment EFHA1 intron 24850809 rs1200046 chr13 22131160 C A 1.18E-09 PR segment EFHA1 intron 24850809 rs2761911 chr13 22131801 T G 1.23E-09 PR segment EFHA1 intron 24850809 rs2798269 chr13 22131897 C T 3.00E-10 PR segment EFHA1 intron 24850809 rs2761912 chr13 22134037 C T 4.58E-10 PR segment EFHA1 intron 24850809 rs2761913 chr13 22135042 C T 7.91E-04 Multiple complex diseases EFHA1 intron 17554300 rs2761913 chr13 22135042 C T 4.40E-05 Serum metabolites EFHA1 intron 19043545 rs2761913 chr13 22135042 C T 4.58E-10 PR segment EFHA1 intron 24850809 rs2798272 chr13 22136766 C G 3.84E-10 PR segment EFHA1 intron 24850809 rs2761914 chr13 22137130 T A 1.44E-09 PR segment EFHA1 intron 24850809 rs2476639 chr13 22137266 T G 1.46E-09 PR segment EFHA1 intron 24850809 rs11148157 chr13 22137608 A T 4.40E-10 PR segment EFHA1 intron 24850809 rs11148158 chr13 22137743 C T 4.54E-10 PR segment EFHA1 intron 24850809 rs2093804 chr13 22138384 T G 1.61E-09 PR segment EFHA1 intron 24850809 rs4770174 chr13 22138691 T C 1.70E-09 PR segment EFHA1 intron 24850809 rs11148159 chr13 22141526 T A 2.11E-09 PR segment EFHA1 intron 24850809 rs2249901 chr13 22141587 C G 2.63E-09 PR segment EFHA1 intron 24850809 rs2040059 chr13 22143100 C G 8.34E-04 Multiple complex diseases EFHA1 intron 17554300 rs2040059 chr13 22143100 C G 2.41E-05 Serum metabolites EFHA1 intron 19043545 rs2040059 chr13 22143100 C G 4.08E-10 PR segment EFHA1 intron 24850809 rs12429479 chr13 22145941 C T 4.21E-10 PR segment EFHA1 intron 24850809 rs12430739 chr13 22146413 A T 5.61E-10 PR segment EFHA1 intron 24850809 rs10870842 chr13 22150209 A C 4.40E-10 PR segment EFHA1 intron 24850809 rs2798277 chr13 22155781 G C 3.89E-09 PR segment EFHA1 intron 24850809 rs2798275 chr13 22159035 T A 3.45E-09 PR segment EFHA1 intron 24850809 rs1200032 chr13 22161805 T C 3.28E-05 Information processing speed EFHA1 intron 21130836 rs1200034 chr13 22165262 T C 4.11E-09 PR segment EFHA1 intron 24850809 rs11148172 chr13 22170275 C T 4.34E-10 PR segment EFHA1 intron 24850809 rs4770182 chr13 22179186 T G 1.15E-04 Multiple complex diseases / / 17554300 rs4770182 chr13 22179186 T G 1.68E-08 PR segment / / 24850809 rs11617488 chr13 22193962 A G 0.000000347 Child behavior checklist/1.5-5 total problems / / 23049896 rs7350671 chr13 22205442 T C 3.63E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7350671 chr13 22205442 T C 4.33E-04 Lung function (forced vital capacity) / / 24023788 rs263930 chr13 22238662 C G 4.33E-05 Nicotine smoking / / 19268276 rs9580184 chr13 22238972 C T 2.30E-06 Urinary metabolites / / 21572414 rs6490667 chr13 22263950 T C 6.28E-04 Type 2 diabetes FGF9 intron 17463246 rs678603 chr13 22279516 G A 2.86E-04 Myopia (pathological) / / 21095009 rs642197 chr13 22290189 G A 6.39E-04 Myopia (pathological) / / 21095009 rs670821 chr13 22304216 C T 9.00E-05 Alcoholism (heaviness of drinking) / / 21529783 rs518590 chr13 22305099 C T 2.00E-07 Response to antipsychotic treatment / / 20195266 rs596837 chr13 22315063 C T 1.80E-05 Sickle cell anemia (severity) / / 20029952 rs7317531 chr13 22320178 G T 8.59E-05 Depression (quantitative trait) / / 23290196 rs495459 chr13 22323765 A G 4.72E-04 Multiple complex diseases / / 17554300 rs535367 chr13 22328631 T C 1.00E-04 B cell non-Hodgkin lymphoma / / 23749188 rs2320340 chr13 22341466 C T 1.53E-04 Type 2 diabetes / / 17463246 rs2320340 chr13 22341466 C T 4.27E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs17680062 chr13 22348173 T C 6.47E-04 Type 2 diabetes / / 17463246 rs749170 chr13 22350875 C T 2.28E-04 Vaspin levels / / 22907691 rs749170 chr13 22350875 C T 0.0002281 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs625875 chr13 22361907 C T 1.29E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs9580203 chr13 22379480 T G 3.10E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs9316567 chr13 22385730 T C 6.58E-05 Major depressive disorder / / pha002850 rs4769172 chr13 22402927 T G 9.88E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs6490675 chr13 22413807 T C 8.30E-05 Coronary restenosis / / 21878436 rs11840027 chr13 22443633 C T 2.74E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10507297 chr13 22450233 G C 5.58E-04 Type 2 diabetes / / 17846124 rs17072974 chr13 22453926 C T 8.22E-04 Smoking initiation / / 24665060 rs17073002 chr13 22455045 T A 5.70E-04 Smoking initiation / / 24665060 rs11838565 chr13 22455862 A G 1.91E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7323166 chr13 22460343 G A 0.0000285 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs17368525 chr13 22467989 G A 3.90E-05 Kawasaki disease / / 22446962 rs9316596 chr13 22469240 G A 2.70E-05 Kawasaki disease / / 22446962 rs17369571 chr13 22487625 G A 1.00E-07 Protein quantitative trait loci / / 18464913 rs2761375 chr13 22504972 G A 4.57E-05 Alzheimer's disease (age of onset) / / 22005931 rs17073722 chr13 22512817 T C 5.33E-04 Alzheimer's disease / / 17998437 rs3117963 chr13 22534122 C A 9.50E-06 Urinary metabolites / / 21572414 rs3117969 chr13 22539167 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs3129678 chr13 22547878 A G 7.72E-06 Personality dimensions / / 22628180 rs9506765 chr13 22550857 A G 4.35E-04 Taste perception / / 22132133 rs9316663 chr13 22554991 G A 1.82E-05 Socioeconomic Factors / / pha003066 rs10507300 chr13 22555778 A G 1.82E-05 Socioeconomic Factors / / pha003066 rs3129595 chr13 22560282 T C 8.31E-05 Hepatocellular carcinoma / / 22807686 rs3129596 chr13 22561178 C T 1.19E-04 Multiple complex diseases / / 17554300 rs4769185 chr13 22561282 G A 4.96E-04 Multiple complex diseases / / 17554300 rs9509957 chr13 22561684 G A 4.15E-04 Alzheimer's disease (late onset) / / 21379329 rs3129599 chr13 22562842 A G 6.81E-05 Alzheimer's disease (late onset) / / 21379329 rs3129601 chr13 22562993 A G 3.37E-04 Schizophrenia / / 20832056 rs9550805 chr13 22603401 A C 7.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7999075 chr13 22620207 C A 1.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9509986 chr13 22630930 T G 3.34E-04 Taste perception / / 22132133 rs1323172 chr13 22652247 C T 7.48E-06 Multiple complex diseases / / 17554300 rs17075874 chr13 22671341 G A 8.00E-07 Urinary metabolites / / 21572414 rs9552595 chr13 22675890 C T 4.02E-05 Cognitive impairment induced by topiramate / / 22091778 rs1885900 chr13 22676940 C G 2.96E-04 Multiple complex diseases / / 17554300 rs7333294 chr13 22677359 T C 1.80E-06 Urinary metabolites / / 21572414 rs4770244 chr13 22682650 T C 2.91E-04 Alzheimer's disease (late onset) / / 21379329 rs7318731 chr13 22709670 A C 1.00E-06 RR interval (heart rate) / / 20031603 rs7982293 chr13 22717681 T C 8.68E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9580300 chr13 22720398 C T 6.93E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9578440 chr13 22734648 A C 9.83E-05 Gallbladder cancer / / 22318345 rs6490701 chr13 22735957 C G 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2025302 chr13 22739748 G T 1.49E-04 Gallbladder cancer / / 22318345 rs9578443 chr13 22743154 C T 2.86E-04 Multiple complex diseases / / 17554300 rs9510015 chr13 22753687 T C 9.29E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs9580312 chr13 22754093 A G 8.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs2224722 chr13 22758748 G T 2.06E-04 Alzheimer's disease (late onset) / / 21379329 rs9510029 chr13 22762222 A G 6.47E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs9510030 chr13 22763097 C A 2.10E-05 Urinary metabolites / / 21572414 rs10781825 chr13 22770518 A C 2.33E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs12716699 chr13 22779237 T C 7.66E-04 Coronary heart disease / / 21606135 rs2320968 chr13 22792974 A G 1.11E-06 Serum albumin level LINC00540 intron pha003084 rs2503334 chr13 22798237 C T 5.00E-05 Prostate cancer LINC00540 intron 21743057 rs9510051 chr13 22799661 T C 7.04E-04 Type 2 diabetes LINC00540 intron 17463246 rs9510051 chr13 22799661 T C 3.63E-04 Smoking cessation LINC00540 intron 24665060 rs7331722 chr13 22799808 C T 9.28E-04 Multiple complex diseases LINC00540 intron 17554300 rs7331722 chr13 22799808 C T 4.56E-04 Aortic root size LINC00540 intron 21223598 rs4770250 chr13 22800214 C T 7.90E-04 Smoking cessation LINC00540 intron 24665060 rs4770252 chr13 22801475 G A 1.32E-04 Smoking cessation LINC00540 intron 24665060 rs912325 chr13 22806995 G T 5.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00540 intron 20877124 rs7998010 chr13 22810615 A G 1.90E-05 Urinary metabolites LINC00540 intron 21572414 rs7995696 chr13 22817713 G C 3.46E-05 Femoral neck bone geometry LINC00540 intron 22087292 rs951904 chr13 22820528 A G 5.43E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00540 intron 20877124 rs951904 chr13 22820528 A G 4.35E-05 Femoral neck bone geometry LINC00540 intron 22087292 rs9550830 chr13 22835073 G T 3.10E-06 Urinary metabolites LINC00540 intron 21572414 rs9510082 chr13 22859174 G A 8.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs2038711 chr13 22859408 C T 4.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs2038712 chr13 22859616 C T 4.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs555000786 chr13 22859616 CCATT C 4.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs9510084 chr13 22859893 C A 4.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs9510085 chr13 22859961 G T 5.63E-04 Suicide attempts in bipolar disorder / / 21041247 rs9550833 chr13 22860087 A C 5.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs9506819 chr13 22860269 G T 5.81E-04 Suicide attempts in bipolar disorder / / 21041247 rs9506820 chr13 22860453 T C 5.47E-04 Type 2 diabetes / / 17463246 rs4770264 chr13 22860866 G A 5.81E-04 Suicide attempts in bipolar disorder / / 21041247 rs9506821 chr13 22861295 A G 3.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs9316871 chr13 22861921 A G 6.85E-04 Type 2 diabetes / / 17463246 rs9316871 chr13 22861921 A G 9.40E-05 Schizophrenia / / 19571808 rs7989744 chr13 22865503 C T 2.32E-04 Blood pressure / / 17255346 rs1360783 chr13 22866524 G A 2.17E-04 Type 2 diabetes / / 17463246 rs1999671 chr13 22868533 T A 6.46E-04 Type 2 diabetes / / 17463246 rs9580339 chr13 22868685 T C 2.68E-04 Type 2 diabetes / / 17463246 rs10870911 chr13 22869266 C T 1.83E-04 Blood pressure / / 17255346 rs17076551 chr13 22869583 G A 7.17E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs9506827 chr13 22869986 T C 3.70E-04 Multiple complex diseases / / 17554300 rs2202731 chr13 22871630 T C 3.52E-04 Type 2 diabetes / / 17463246 rs465174 chr13 22891393 G A 8.85E-04 Alzheimer's disease / / 24755620 rs7989263 chr13 22895358 C A 1.29E-06 Hearing function / / 21493956 rs1556644 chr13 22896816 G A 6.57E-04 Type 2 diabetes / / 17463246 rs7326236 chr13 22903551 T C 5.29E-07 Hearing function / / 21493956 rs289962 chr13 22933087 A G 6.48E-05 Glycemic traits (pregnancy) / / 23903356 rs2992022 chr13 23021819 T C 4.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs292476 chr13 23033120 A G 2.11E-05 Alcohol consumption / / 23953852 rs17422614 chr13 23056758 G C 1.00E-04 Prostate cancer / / 21743057 rs41334648 chr13 23200009 G A 8.24E-06 Asthma (childhood onset) / / 23829686 rs2334946 chr13 23228060 T C 5.30E-06 Central corneal thickness / / 20485516 rs1034200 chr13 23228691 C A 1.60E-06 Central corneal thickness / / 20485516 rs1034200 chr13 23228691 C A 4.00E-09 Central corneal thickness / / 20719862 rs1034200 chr13 23228691 C A 4.00E-09 Corneal structure / / 23291589 rs9552679 chr13 23231920 T C 3.02E-05 Asthma (bronchodilator response) / / 23508266 rs17077429 chr13 23241969 T C 2.37E-04 Type 2 diabetes / / 17463246 rs2114225 chr13 23269969 T A 8.16E-04 Multiple complex diseases / / 17554300 rs7333215 chr13 23279834 T C 2.18E-04 Parkinson's disease / / 16252231 rs373767 chr13 23294033 C T 3.00E-10 Myopia (pathological) / / 22685421 rs561877428 chr13 23294033 C CAGAT 3.00E-10 Myopia (pathological) / / 22685421 rs58680938 chr13 23294033 C CAGAT,CAGATAGAT 3.00E-10 Myopia (pathological) / / 22685421 rs9510315 chr13 23320655 G T 3.90E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs9506918 chr13 23329062 A G 5.40E-04 Type 2 diabetes / / 17463246 rs9506918 chr13 23329062 A G 7.79E-04 Alzheimer's disease / / 17998437 rs8002402 chr13 23339687 G A 6.95E-04 Alzheimer's disease / / 17998437 rs35595341 chr13 23341126 GA G 3.16E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs9317196 chr13 23341126 G A 3.16E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4770301 chr13 23346768 T C 3.30E-05 Malaria / / 19465909 rs12428099 chr13 23350341 G C 9.76E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9552709 chr13 23350586 T C 5.57E-04 Multiple complex diseases / / 17554300 rs7999435 chr13 23374178 G A 4.60E-04 Smoking initiation / / 24665060 rs7990570 chr13 23388777 A G 9.60E-05 Body mass index / / 20818722 rs7986449 chr13 23449055 A C 1.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7986449 chr13 23449055 A C 0.0001011 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7986449 chr13 23449055 A C 1.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2182617 chr13 23562914 A G 2.40E-06 Urinary metabolites / / 21572414 rs6490765 chr13 23575968 G A 6.82E-06 Uric acid levels / / 21294900 rs754115 chr13 23580378 A G 1.04E-04 HIV-1 viral setpoint / / 17641165 rs12430946 chr13 23596330 G A 4.61E-04 Schizophrenia / / 19197363 rs9552800 chr13 23599673 G A 0.000190239 Hypertension (early onset hypertension) / / 22479346 rs1170698 chr13 23612645 G A 9.86E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2311185 chr13 23616490 A G 7.81E-05 Celiac disease / / 23936387 rs9634385 chr13 23638279 G A 8.17E-05 Multiple complex diseases / / 17554300 rs9634385 chr13 23638279 G A 8.36E-05 Bipolar disorder and schizophrenia / / 20889312 rs9552824 chr13 23673219 G A 3.52E-04 Type 2 diabetes / / 17463246 rs9552824 chr13 23673219 G A 9.52E-05 Heart Rate / / pha003054 rs872273 chr13 23675103 C G 3.05E-04 Multiple complex diseases / / 17554300 rs7318219 chr13 23678799 T G 8.95E-04 Multiple complex diseases / / 17554300 rs9550908 chr13 23685594 G A 3.87E-04 Multiple complex diseases / / 17554300 rs7987749 chr13 23689158 G C 9.89E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4770393 chr13 23692789 T C 1.27E-04 Multiple complex diseases / / 17554300 rs4770394 chr13 23692978 G A 1.20E-05 Multiple complex diseases / / 17554300 rs4770394 chr13 23692978 G A 9.00E-06 Bipolar disorder / / 21738484 rs7322449 chr13 23693091 T C 1.30E-04 Multiple complex diseases / / 17554300 rs9507025 chr13 23693377 C T 8.17E-05 Multiple complex diseases / / 17554300 rs10507325 chr13 23717653 G T 5.49E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs9507041 chr13 23744379 C T 8.00E-06 Cannabis dependence / / 21668797 rs7327420 chr13 23747532 A G 8.77E-04 Major depressive disorder / / 22472876 rs597425 chr13 23751313 T C 2.24E-04 Multiple complex diseases / / 17554300 rs597425 chr13 23751313 T C 4.03E-05 Coronary heart disease / / pha003031 rs597425 chr13 23751313 T C 1.05E-05 Hypertension / / pha003041 rs574662 chr13 23752396 A C 3.76E-05 ldl cholesterol / / pha003077 rs574662 chr13 23752396 A C 5.90E-05 Cholesterol / / pha003083 rs4770403 chr13 23755127 G A 6.00E-06 Alcohol dependence SGCG UTR-5 22004471 rs9317535 chr13 23755892 G A 4.41E-04 Taste perception SGCG intron 22132133 rs9552871 chr13 23766862 T C 2.20E-05 Urinary metabolites SGCG intron 21572414 rs648991 chr13 23767814 G T 1.20E-05 Urinary metabolites SGCG intron 21572414 rs9317547 chr13 23769670 G C 8.60E-04 Type 2 diabetes and 6 quantitative traits SGCG intron 17848626 rs9507049 chr13 23770245 C T 5.97E-04 Acute lung injury SGCG intron 22295056 rs9507050 chr13 23770361 C A 7.76E-04 Acute lung injury SGCG intron 22295056 rs3794364 chr13 23771196 T C 3.80E-04 Type 2 diabetes and 6 quantitative traits SGCG intron 17848626 rs685017 chr13 23791027 C T 6.04E-05 Coronary heart disease SGCG intron pha003056 rs1410515 chr13 23795093 A G 7.31E-04 Smoking quantity SGCG intron 24665060 rs1410518 chr13 23795767 C T 6.82E-05 Coronary heart disease SGCG intron pha003056 rs11148693 chr13 23796239 T C 4.48E-05 Blood Pressure SGCG intron pha003047 rs4769246 chr13 23808914 A C 2.43E-05 Femoral neck bone geometry SGCG intron 22087292 rs4536325 chr13 23814442 T G 2.95E-05 Femoral neck bone geometry SGCG intron 22087292 rs2018051 chr13 23819919 A G 2.67E-04 Multiple complex diseases SGCG intron 17554300 rs2018273 chr13 23820510 G T 6.42E-04 Multiple complex diseases SGCG intron 17554300 rs2002748 chr13 23820684 C G 5.18E-04 Multiple complex diseases SGCG intron 17554300 rs4550321 chr13 23823888 A G 1.91E-04 Multiple complex diseases SGCG intron 17554300 rs1800351 chr13 23824783 T G 1.20E-06 Urinary metabolites SGCG cds-synon 21572414 rs7995077 chr13 23827815 G A 6.14E-05 Leukocyte Counts SGCG intron pha003091 rs9507064 chr13 23850905 G T 3.26E-05 Multiple complex diseases SGCG intron 17554300 rs17374863 chr13 23852802 G A 7.93E-04 Type 2 diabetes SGCG intron 17463246 rs11617228 chr13 23855056 T C 5.42E-05 Leukocyte Counts SGCG intron pha003091 rs1887756 chr13 23864250 G T 1.95E-05 Leukocyte Counts SGCG intron pha003091 rs9552911 chr13 23864657 G A 2.00E-08 Type 2 diabetes SGCG intron 23300278 rs1753097 chr13 23878686 G A 1.96E-05 Paclitaxel-induced neuropathy SGCG intron 23776197 rs9510702 chr13 23899627 A G 5.62E-04 Suicide attempts in bipolar disorder SGCG nearGene-3 21423239 rs4770433 chr13 23903791 A G 4.00E-06 Protein quantitative trait loci SACS UTR-3 18464913 rs41360252 chr13 23922462 A G 7.60E-05 Cognitive function SACS intron 24684796 rs17078678 chr13 23957514 C A 1.01E-04 Alcohol dependence SACS intron 20201924 rs17078682 chr13 23963253 A C 1.48E-04 Suicide attempts in bipolar disorder SACS intron 21423239 rs17078687 chr13 23963439 T A 1.67E-04 Suicide attempts in bipolar disorder SACS intron 21423239 rs17078690 chr13 23963714 A T 1.71E-04 Suicide attempts in bipolar disorder SACS intron 21423239 rs7339176 chr13 23964095 G A 7.01E-06 Depression (quantitative trait) SACS intron 23290196 rs1008812 chr13 23966145 A G 5.80E-06 Depression (quantitative trait) SACS intron 23290196 rs1008813 chr13 23966252 G A 5.77E-06 Depression (quantitative trait) SACS intron 23290196 rs1008814 chr13 23966395 T A 6.16E-06 Depression (quantitative trait) SACS intron 23290196 rs8000066 chr13 23967078 C T 6.60E-06 Depression (quantitative trait) SACS intron 23290196 rs8001909 chr13 23967690 A G 7.90E-05 Suicide attempts in bipolar disorder SACS intron 21423239 rs9510717 chr13 23968485 T C 4.52E-05 Cognitive impairment induced by topiramate SACS intron 22091778 rs7990558 chr13 23969866 G C 2.03E-04 Suicide attempts in bipolar disorder SACS intron 21423239 rs9634390 chr13 23970631 A G 2.81E-04 Suicide attempts in bipolar disorder SACS intron 21423239 rs9634391 chr13 23970639 T C 2.35E-04 Suicide attempts in bipolar disorder SACS intron 21423239 rs9634392 chr13 23970653 G T 2.37E-04 Suicide attempts in bipolar disorder SACS intron 21423239 rs9552943 chr13 23970817 A G 2.37E-04 Suicide attempts in bipolar disorder SACS intron 21423239 rs9552944 chr13 23970859 A C 1.84E-04 Suicide attempts in bipolar disorder SACS intron 21423239 rs11618590 chr13 23970877 T C 7.81E-05 Depression (quantitative trait) SACS intron 23290196 rs9552946 chr13 23971188 A T 1.90E-04 Suicide attempts in bipolar disorder SACS intron 21423239 rs9550966 chr13 23971287 C G 1.87E-04 Suicide attempts in bipolar disorder SACS intron 21423239 rs1359668 chr13 23971390 C A 2.35E-04 Suicide attempts in bipolar disorder SACS intron 21423239 rs4391906 chr13 23972835 C T 6.48E-04 Suicide attempts in bipolar disorder SACS intron 21423239 rs9507089 chr13 23978938 T C 4.26E-04 Suicide attempts in bipolar disorder SACS intron 21423239 rs9578592 chr13 23982485 G A 7.40E-04 Multiple complex diseases SACS intron 17554300 rs17078717 chr13 23984431 A G 5.55E-04 Alcohol dependence SACS intron 20201924 rs17078717 chr13 23984431 A G 7.01E-04 Suicide attempts in bipolar disorder SACS intron 21423239 rs17078720 chr13 23985391 T C 7.89E-04 Suicide attempts in bipolar disorder SACS UTR-5 21423239 rs10507330 chr13 23996765 A G 3.14E-04 Premature ovarian failure SACS intron 19508998 rs10161585 chr13 23999136 C T 8.53E-04 Suicide attempts in bipolar disorder SACS intron 21423239 rs4083575 chr13 24001362 T C 7.54E-05 Blood Pressure SACS intron pha003047 rs2225621 chr13 24028215 G T 6.74E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10162002 chr13 24042510 G A 5.00E-06 Hypothyroidism / / 22493691 rs3764070 chr13 24043069 G A 4.07E-12 Hirschsprung's disease / / 19196962 rs17390122 chr13 24071322 A G 2.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7325483 chr13 24108468 A G 2.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs1889180 chr13 24115747 C T 1.23E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1572069 chr13 24124492 A C 5.98E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1572072 chr13 24127210 G T 1.00E-08 Nasopharyngeal carcinoma / / 20512145 rs17078934 chr13 24128199 C T 7.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9510775 chr13 24129102 C G 8.27E-04 Type 2 diabetes / / 17463246 rs7995083 chr13 24145162 T C 4.63E-05 Melanoma TNFRSF19 intron 21926416 rs1928112 chr13 24180202 G A 6.51E-04 Multiple complex diseases TNFRSF19 intron 17554300 rs9510787 chr13 24205195 A G 2.00E-09 Nasopharyngeal carcinoma TNFRSF19 intron 20512145 rs9510793 chr13 24213120 T C 2.11E-05 Nasopharyngeal carcinoma TNFRSF19 intron 23209447 rs4769281 chr13 24255790 A G 6.11E-04 Alcohol dependence / / 21314694 rs7322450 chr13 24280497 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12876652 chr13 24280832 C T 7.19E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2861539 chr13 24289783 A G 5.70E-05 Lung cancer / / 21725308 rs12867512 chr13 24289849 G A 5.20E-05 Lung cancer / / 21725308 rs11617518 chr13 24290267 C T 4.60E-05 Lung cancer / / 21725308 rs9580741 chr13 24290621 T C 4.00E-05 Lung cancer / / 21725308 rs745068 chr13 24291878 T G 4.00E-05 Lung cancer / / 21725308 rs745069 chr13 24291972 T C 1.90E-05 Lung cancer / / 21725308 rs2840252 chr13 24292701 A T 8.10E-05 Lung cancer / / 21725308 rs9553037 chr13 24293053 T C 2.60E-05 Lung cancer / / 21725308 rs753955 chr13 24293859 A G 2.00E-12 Lung cancer / / 21725308 rs753954 chr13 24294105 G A 3.00E-05 Lung cancer / / 21725308 rs9507148 chr13 24296345 G T 0.000088 Panic disorder / / 23149450 rs9507148 chr13 24296345 G T 8.80E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs7324557 chr13 24296862 A G 8.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs7324557 chr13 24296862 A G 0.0000355 Panic disorder / / 23149450 rs7324557 chr13 24296862 A G 7.14E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs4238171 chr13 24301897 T C 6.58E-05 Multiple complex diseases / / 17554300 rs4769283 chr13 24301943 A G 1.70E-05 Multiple complex diseases / / 17554300 rs1536299 chr13 24318963 A C 6.10E-04 Crohn's disease MIPEP intron 17684544 rs9318025 chr13 24324497 C T 5.87E-04 Multiple complex diseases MIPEP intron 17554300 rs41388845 chr13 24345846 C T 1.48E-04 Multiple complex diseases MIPEP intron 17554300 rs11839873 chr13 24350993 T C 5.74E-05 Multiple complex diseases MIPEP intron 17554300 rs7322274 chr13 24353245 T C 2.61E-04 Multiple complex diseases MIPEP intron 17554300 rs9670422 chr13 24424039 C T 4.97E-04 Multiple complex diseases MIPEP intron 17554300 rs9318086 chr13 24432467 A G 2.00E-16 Myopia (pathological) MIPEP intron 21640322 rs1886970 chr13 24440498 T C 1.03E-04 Myopia (pathological) MIPEP intron 21640322 rs1977381 chr13 24470554 G A 3.60E-04 Myopia (pathological) C1QTNF9B intron 21640322 rs716608 chr13 24476045 G A 1.47E-04 Myopia (pathological) / / 21640322 rs2077709 chr13 24476073 G A 1.79E-04 Myopia (pathological) / / 21640322 rs1409281 chr13 24488126 A G 0.000765943 Hypertension (early onset hypertension) / / 22479346 rs1325670 chr13 24490921 G T 0.000515351 Hypertension (early onset hypertension) / / 22479346 rs2810709 chr13 24501583 G C 5.51E-04 Type 2 diabetes / / 17463246 rs2765086 chr13 24504955 C T 6.00E-06 Weight / / 19851299 rs2182227 chr13 24523768 G C 6.04E-04 Type 2 diabetes / / 17463246 rs1570885 chr13 24524626 A G 5.60E-06 Weight / / 19851299 rs2147995 chr13 24525604 A C 3.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs35747503 chr13 24525604 A AG 3.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs2765122 chr13 24531398 G A 3.80E-05 Crohn's disease (time to surgery) / / 23665963 rs2147987 chr13 24534112 C T 7.15E-05 Multiple complex diseases / / 17554300 rs1886797 chr13 24535988 T C 2.18E-05 Anorexia nervosa / / 24514567 rs9510982 chr13 24553861 G A 3.10E-05 Amyotrophic Lateral Sclerosis / / 17362836 rs942880 chr13 24560360 T C 1.34E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs942880 chr13 24560360 T C 4.42E-05 Rheumatoid arthritis / / 21452313 rs9553136 chr13 24576555 C T 8.10E-06 Urinary metabolites / / 21572414 rs4770545 chr13 24580203 T C 1.95E-04 Alzheimer's disease / / 22005930 rs882554 chr13 24585843 G A 6.85E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9510997 chr13 24592857 G T 5.67E-05 Parkinson's disease / / 17052657 rs4770552 chr13 24594430 C T 2.40E-06 Urinary metabolites / / 21572414 rs4769307 chr13 24597985 G A 8.09E-04 Multiple complex diseases / / 17554300 rs17079773 chr13 24598384 C T 5.00E-06 Inattentive symptoms / / 18821565 rs17079773 chr13 24598384 C T 2.20E-05 Urinary metabolites / / 21572414 rs5021764 chr13 24598757 C T 7.18E-06 Type 2 diabetes / / 21799836 rs9553145 chr13 24602061 G C 4.90E-06 Urinary metabolites / / 21572414 rs4770557 chr13 24604963 G A 1.26E-05 Type 2 diabetes / / 21799836 rs1570889 chr13 24624469 C T 7.83E-04 Multiple complex diseases / / 17554300 rs9511023 chr13 24631796 A G 4.86E-05 Nephrolithiasis / / 22396660 rs7334243 chr13 24639175 C G 3.42E-04 Type 2 diabetes / / 17463246 rs9507235 chr13 24639595 G A 3.43E-04 Type 2 diabetes / / 17463246 rs6416353 chr13 24639693 G C 2.68E-04 Type 2 diabetes / / 17463246 rs6490865 chr13 24639731 A G 3.60E-04 Type 2 diabetes / / 17463246 rs4470013 chr13 24639823 T C 5.37E-04 Type 2 diabetes / / 17463246 rs942110 chr13 24640043 T C 3.46E-04 Type 2 diabetes / / 17463246 rs976418 chr13 24647986 A C 3.65E-04 Type 2 diabetes / / 17463246 rs4770569 chr13 24648443 A G 3.42E-04 Type 2 diabetes / / 17463246 rs9553161 chr13 24652171 G A 2.62E-04 Multiple complex diseases / / 17554300 rs9553161 chr13 24652171 G A 7.70E-04 Alzheimer's disease / / 17998437 rs912151 chr13 24652549 C T 3.08E-04 Multiple complex diseases / / 17554300 rs912151 chr13 24652549 C T 8.66E-04 Alzheimer's disease / / 17998437 rs912150 chr13 24652886 C T 4.77E-04 Multiple complex diseases / / 17554300 rs17079928 chr13 24654228 G A 6.00E-06 Orofacial clefts / / 22419666 rs9805786 chr13 24658356 G T 4.50E-04 Alcohol dependence / / 20201924 rs9805786 chr13 24658356 G T 8.60E-04 Alcohol dependence / / 20201924 rs9805786 chr13 24658356 G T 7.00E-06 Depression and alcohol dependence / / 22064162 rs9805786 chr13 24658356 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs736081 chr13 24659726 T C 1.10E-04 Alcohol dependence / / 20201924 rs736081 chr13 24659726 T C 2.90E-04 Alcohol dependence / / 20201924 rs8002029 chr13 24666535 A G 4.65E-05 Serum alpha1-antitrypsin levels / / 23990791 rs7984719 chr13 24666571 T C 4.73E-05 Serum alpha1-antitrypsin levels / / 23990791 rs9511045 chr13 24666937 G A 1.44E-05 Serum alpha1-antitrypsin levels / / 23990791 rs756025 chr13 24668520 G A 9.88E-04 Multiple complex diseases / / 17554300 rs756025 chr13 24668520 G A 8.31E-05 Blood Pressure / / pha003039 rs1983870 chr13 24670163 C T 3.04E-05 Serum alpha1-antitrypsin levels / / 23990791 rs9511057 chr13 24678732 T G 3.36E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7317204 chr13 24705705 A G 4.52E-04 Multiple complex diseases / / 17554300 rs1033848 chr13 24714679 C A 1.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs1033849 chr13 24714767 A G 2.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs1033850 chr13 24714845 C T 2.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs7982678 chr13 24718406 G A 4.80E-04 Alcohol dependence / / 20201924 rs9511089 chr13 24724716 A G 7.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs4770606 chr13 24725796 T C 4.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs9507262 chr13 24727026 T G 2.50E-05 Urinary metabolites / / 21572414 rs4769329 chr13 24727901 C T 1.60E-05 Urinary metabolites / / 21572414 rs7336618 chr13 24736246 A C 5.07E-04 Alzheimer's disease SPATA13 intron 24755620 rs9511097 chr13 24737951 T C 2.85E-04 Alzheimer's disease SPATA13 intron 24755620 rs2264962 chr13 24746691 C G 8.00E-04 Acute lymphoblastic leukemia (childhood) SPATA13 intron 20189245 rs2861545 chr13 24782729 C T 3.38E-04 Blood pressure SPATA13 intron 17255346 rs17462267 chr13 24787025 A C 5.65E-04 Type 2 diabetes SPATA13 intron 17463246 rs1220605 chr13 24789809 G A 8.65E-05 Height SPATA13 intron pha003011 rs715921 chr13 24795489 G A 8.00E-07 Airflow obstruction SPATA13 intron 22837378 rs927553 chr13 24808704 C G 0.000305 5-fluorouracil induced mucositis in response to colorectal cancer treatment SPATA13 intron 22310351 rs2252068 chr13 24825353 A G 2.04E-05 Word reading SPATA13 intron 23738518 rs2793491 chr13 24826051 C T 6.72E-04 Type 2 diabetes SPATA13 intron 17463246 rs912144 chr13 24828660 C T 8.56E-04 Multiple complex diseases SPATA13 intron 17554300 rs17367047 chr13 24833041 G A 5.69E-04 Multiple complex diseases SPATA13 intron 17554300 rs3803218 chr13 24878466 A G 2.11E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) SPATA13 UTR-3 23648065 rs17077825 chr13 24931981 C T 4.86E-04 Alzheimer's disease (late onset) / / 21379329 rs8181826 chr13 24970708 A T 2.05E-04 Multiple complex diseases / / 17554300 rs1816752 chr13 24980949 A G 2.00E-06 Obesity-related traits / / 23251661 rs4770666 chr13 24989029 T C 2.15E-06 Obesity-related traits / / 23251661 rs1050112 chr13 25009297 G T 3.43E-06 Obesity-related traits PARP4 missense 23251661 rs200523290 chr13 25013297 T TAAC 4.00E-06 Obesity-related traits PARP4 intron 23251661 rs7995909 chr13 25013297 T C 4.00E-06 Obesity-related traits PARP4 intron 23251661 rs9581043 chr13 25023936 C T 2.33E-04 Type 2 diabetes PARP4 missense 17463246 rs3818938 chr13 25029083 G A 9.06E-04 Type 2 diabetes PARP4 intron 17463246 rs7140044 chr13 25029295 C T 1.20E-04 Type 2 diabetes PARP4 missense 17463246 rs7317188 chr13 25029401 C G 2.93E-04 Type 2 diabetes PARP4 intron 17463246 rs1807111 chr13 25045158 G A 8.73E-05 Type 2 diabetes PARP4 intron 17463246 rs1807110 chr13 25045198 A G 8.06E-05 Type 2 diabetes PARP4 intron 17463246 rs9581073 chr13 25064654 C A 1.47E-04 Type 2 diabetes PARP4 intron 17463246 rs9581079 chr13 25070871 C T 4.55E-05 Type 2 diabetes PARP4 intron 17463246 rs1965154 chr13 25072200 T A,C 7.35E-04 Schizophrenia PARP4 intron 19197363 rs9581094 chr13 25082630 T C 7.00E-07 Sudden cardiac arrest PARP4 intron 21658281 rs6490943 chr13 25087810 C G 9.37E-04 Multiple complex diseases / / 17554300 rs2862909 chr13 25101167 G T 7.75E-07 Parkinson's disease / / 17052657 rs9551113 chr13 25120453 A G 5.96E-05 Major depressive disorder (broad) / / 20038947 rs7987245 chr13 25139893 C T 5.00E-05 Response to statin therapy / / 20339536 rs4770710 chr13 25139931 A G 4.90E-05 Response to statin therapy / / 20339536 rs4770714 chr13 25155781 A G 4.80E-05 Response to statin therapy / / 20339536 rs9511364 chr13 25166099 C G 4.80E-05 Response to statin therapy TPTE2P6 intron 20339536 rs9553363 chr13 25166946 G A 4.80E-05 Response to statin therapy TPTE2P6 intron 20339536 rs943049 chr13 25180151 C T 4.60E-05 Response to statin therapy / / 20339536 rs943048 chr13 25180246 A G 5.10E-06 Urinary metabolites / / 21572414 rs4769376 chr13 25194771 G T 2.91E-05 Orofacial clefts / / 22863734 rs7993583 chr13 25217481 T G 7.12E-05 Serum metabolites / / 19043545 rs7331491 chr13 25237504 A G 6.32E-05 HIV-1 control / / 20041166 rs9511403 chr13 25239699 C T 1.52E-04 Multiple complex diseases / / 17554300 rs9511403 chr13 25239699 C T 4.24E-04 Alzheimer's disease / / 17998437 rs9511411 chr13 25246838 T C 7.54E-06 Narcolepsy / / 20711174 rs1530530 chr13 25247286 A G 6.00E-07 Obesity-related traits / / 23251661 rs2277422 chr13 25259223 C T 1.30E-04 Multiple complex diseases ATP12A intron 17554300 rs17081002 chr13 25262286 A G 4.86E-04 Type 2 diabetes ATP12A intron 17463246 rs6490973 chr13 25262342 C G 6.66E-04 Multiple complex diseases ATP12A intron 17554300 rs7988856 chr13 25263004 G A 8.84E-05 Cognitive impairment induced by topiramate ATP12A intron 22091778 rs735772 chr13 25264037 A G 1.00E-04 Cognitive impairment induced by topiramate ATP12A intron 22091778 rs12872010 chr13 25265271 C T 6.24E-06 Obesity-related traits ATP12A cds-synon 23251661 rs9318740 chr13 25291876 T C 7.17E-05 Bipolar disorder and schizophrenia / / 20889312 rs80107111 chr13 25311694 G A 7.35E-06 Stroke (ischemic) / / 21957438 rs7335910 chr13 25322725 A G 2.69E-06 Diabetic nephropathy / / pha002866 rs921048 chr13 25326179 G C 2.20E-05 Obesity,menopause / / 21424828 rs9511436 chr13 25328680 A G 4.26E-05 Pulmonary function / / 19300500 rs3803217 chr13 25331027 A C 5.26E-04 Parkinson's disease / / 17052657 rs3803217 chr13 25331027 A C 8.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs8000984 chr13 25335068 C A 2.10E-05 Urinary metabolites / / 21572414 rs9511451 chr13 25378476 A G 6.90E-05 Diabetic nephropathy RNF17 missense pha002866 rs17081254 chr13 25407960 C T 3.10E-06 Urinary metabolites RNF17 intron 21572414 rs9511479 chr13 25432215 C T 8.90E-05 Diabetic nephropathy RNF17 intron pha002866 rs9553461 chr13 25453116 T C 7.95E-04 Amyotrophic Lateral Sclerosis RNF17 intron 17362836 rs11149256 chr13 25477001 G A 7.89E-04 Parkinson's disease CENPJ intron 17052657 rs2290277 chr13 25486374 C T 7.89E-04 Parkinson's disease CENPJ intron 17052657 rs1029114 chr13 25490436 A G 7.70E-06 Urinary metabolites CENPJ intron 21572414 rs9578798 chr13 25503836 C A 1.30E-06 Urinary metabolites / / 21572414 rs17081408 chr13 25509384 G T 2.80E-06 Urinary metabolites TPTE2P1 intron 21572414 rs7322671 chr13 25509612 G C 3.51E-04 Multiple complex diseases TPTE2P1 intron 17554300 rs2002297 chr13 25514503 A G 6.70E-06 Multiple complex diseases TPTE2P1 intron 17554300 rs75426593 chr13 25516775 C T 8.61E-06 Stroke (ischemic) TPTE2P1 intron 21957438 rs2483374 chr13 25533831 A C 5.00E-06 Obesity-related traits TPTE2P1 intron 23251661 rs2483397 chr13 25559548 A C 6.59E-05 Waist Circumference / / pha003023 rs9511575 chr13 25566804 C T 4.38E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4238183 chr13 25599695 A G 6.74E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs9511601 chr13 25629820 C T 9.69E-05 Left ventricular hypertrophy / / pha003052 rs3002179 chr13 25636802 T C 2.53E-05 Waist Circumference / / pha003023 rs9507460 chr13 25646078 T C 1.50E-05 Urinary metabolites / / 21572414 rs2185611 chr13 25651891 C T 9.40E-05 Personality dimensions / / 18957941 rs9805312 chr13 25662387 C A 1.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9511628 chr13 25666239 G A 6.30E-05 Response to statin therapy / / 20339536 rs6491016 chr13 25680690 T C 7.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2487596 chr13 25689163 C A 7.16E-04 Lymphocyte counts / / 22286170 rs9511647 chr13 25694482 C A 8.80E-05 Response to statin therapy / / 20339536 rs7325122 chr13 25709467 T A 2.80E-05 Urinary metabolites / / 21572414 rs875911 chr13 25711096 C A 2.10E-05 Urinary metabolites / / 21572414 rs10507344 chr13 25725069 C T 4.10E-05 Kidney function and endocine traits / / 17903292 rs9578831 chr13 25754557 C T 7.60E-05 Pericardial fat / / 22589742 rs9581297 chr13 25784082 G T 4.33E-05 Blood pressure / / 17255346 rs9581297 chr13 25784082 G T 2.08E-04 Alcohol dependence / / 21314694 rs9551187 chr13 25786848 C T 4.58E-04 Smoking cessation / / 24665060 rs4769414 chr13 25788586 T C 2.93E-04 Parkinson's disease / / 17052657 rs4769414 chr13 25788586 T C 2.30E-04 Heart Failure / / pha002884 rs4769414 chr13 25788586 T C 9.34E-05 Neuroblastoma / / pha002895 rs9553561 chr13 25792173 A G 4.71E-04 Parkinson's disease / / 17052657 rs9551188 chr13 25808286 A C 1.02E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs9319209 chr13 25810823 T A 1.30E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs17082017 chr13 25816715 C T 4.56E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs12431317 chr13 25818110 T C 2.45E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs9553567 chr13 25820101 T C 1.05E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs8262 chr13 25821603 A G 2.14E-06 Brain derived neurotrophic factor levels,in serum MTMR6 UTR-3 22047184 rs7999040 chr13 25823207 T A 2.95E-06 Brain derived neurotrophic factor levels,in serum MTMR6 UTR-3 22047184 rs9553568 chr13 25823919 C T 2.50E-06 Brain derived neurotrophic factor levels,in serum MTMR6 intron 22047184 rs9553570 chr13 25824906 G A 3.49E-06 Brain derived neurotrophic factor levels,in serum MTMR6 intron 22047184 rs12431141 chr13 25825574 G A 1.24E-05 Brain derived neurotrophic factor levels,in serum MTMR6 intron 22047184 rs4312169 chr13 25825889 T C 8.84E-06 Brain derived neurotrophic factor levels,in serum MTMR6 cds-synon 22047184 rs7995033 chr13 25831888 T C 1.23E-05 Brain derived neurotrophic factor levels,in serum MTMR6 missense 22047184 rs9553572 chr13 25837097 C T 5.94E-04 Parkinson's disease MTMR6 intron 17052657 rs9553572 chr13 25837097 C T 5.90E-05 Response to antidepressants MTMR6 intron 19736353 rs9553572 chr13 25837097 C T 4.88E-06 Brain derived neurotrophic factor levels,in serum MTMR6 intron 22047184 rs12427761 chr13 25840828 T C 2.37E-05 Brain derived neurotrophic factor levels,in serum MTMR6 intron 22047184 rs4594103 chr13 25841842 T A 7.08E-06 Brain derived neurotrophic factor levels,in serum MTMR6 intron 22047184 rs17082070 chr13 25842806 C T 5.34E-05 Brain derived neurotrophic factor levels,in serum MTMR6 intron 22047184 rs4468451 chr13 25845860 G C 1.05E-05 Brain derived neurotrophic factor levels,in serum MTMR6 intron 22047184 rs9645860 chr13 25846200 T C 3.32E-06 Brain derived neurotrophic factor levels,in serum MTMR6 intron 22047184 rs9581311 chr13 25846645 T C 7.83E-06 Brain derived neurotrophic factor levels,in serum MTMR6 intron 22047184 rs12430251 chr13 25849146 T G 2.55E-05 Brain derived neurotrophic factor levels,in serum MTMR6 intron 22047184 rs7995484 chr13 25853989 A G 6.03E-05 Brain derived neurotrophic factor levels,in serum MTMR6 intron 22047184 rs9511740 chr13 25860031 C G 3.29E-05 Brain derived neurotrophic factor levels,in serum MTMR6 intron 22047184 rs7982860 chr13 25860273 A C 1.51E-05 Brain derived neurotrophic factor levels,in serum MTMR6 intron 22047184 rs12431091 chr13 25860926 G C 1.58E-05 Brain derived neurotrophic factor levels,in serum MTMR6 intron 22047184 rs3809335 chr13 25861577 A G 5.40E-05 Pulmonary function in asthmatics MTMR6 UTR-5 23541324 rs11556093 chr13 25876011 G A 9.01E-05 Osteoarthritis NUPL1 missense 19508968 rs9511762 chr13 25919624 C T 1.00E-04 Prostate cancer / / 21743057 rs1555721 chr13 25933438 A G 7.16E-05 Pulmonary function / / 20010835 rs9511784 chr13 25968976 G A 2.89E-04 Response to cytidine analogues (gemcitabine) ATP8A2 intron 24483146 rs1924775 chr13 25972811 A G 5.80E-06 Urinary metabolites ATP8A2 intron 21572414 rs1924774 chr13 25972882 C T 1.94E-05 Serum metabolites ATP8A2 intron 19043545 rs9511790 chr13 25989752 C T 1.20E-04 Bone mineral density (BMD),in women ATP8A2 intron 20164292 rs17725018 chr13 25993791 A C 8.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ATP8A2 intron 20877124 rs67017808 chr13 25993791 A AC 8.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ATP8A2 intron 20877124 rs13378890 chr13 25996690 C T 9.90E-04 Alcohol dependence ATP8A2 intron 21314694 rs1748588 chr13 26000772 T C 9.97E-04 Multiple complex diseases ATP8A2 intron 17554300 rs7322916 chr13 26007977 G A 8.00E-07 Eating disorders ATP8A2 intron 23568457 rs4770836 chr13 26037909 T C 4.68E-06 Bipolar disorder and schizophrenia ATP8A2 intron 20889312 rs4770837 chr13 26037960 C G 5.00E-06 Bipolar disorder and schizophrenia ATP8A2 intron 20889312 rs7337541 chr13 26076998 C T 1.70E-06 Urinary metabolites ATP8A2 intron 21572414 rs7320702 chr13 26077538 A G 2.20E-05 Urinary metabolites ATP8A2 intron 21572414 rs17082396 chr13 26102151 T C 4.93E-04 Multiple complex diseases ATP8A2 intron 17554300 rs9581389 chr13 26125731 T C 5.80E-04 Obesity (extreme) ATP8A2 intron 21935397 rs12862551 chr13 26133009 C T 2.20E-06 Urinary metabolites ATP8A2 intron 21572414 rs7331349 chr13 26141876 T C 4.53E-04 Multiple complex diseases ATP8A2 intron 17554300 rs9581395 chr13 26142342 C T 9.33E-04 Multiple complex diseases ATP8A2 intron 17554300 rs6491069 chr13 26152039 G A 4.10E-05 Parkinson's disease (age of onset) ATP8A2 intron 19772629 rs4075982 chr13 26159067 A G 8.00E-05 Type 2 diabetes and 6 quantitative traits ATP8A2 intron 17848626 rs4442642 chr13 26192118 T G 1.00E-04 Cognitive impairment induced by topiramate ATP8A2 intron 22091778 rs17082600 chr13 26228314 C T 5.16E-04 Multiple complex diseases ATP8A2 intron 17554300 rs17685787 chr13 26262180 A G 7.25E-04 Alcohol dependence ATP8A2 intron 21314694 rs10492428 chr13 26281281 G A 4.90E-04 Type 2 diabetes and 6 quantitative traits ATP8A2 intron 17848626 rs1475183 chr13 26287826 A C 1.86E-04 Birth weight ATP8A2 intron 17255346 rs3117861 chr13 26291745 C T 7.60E-04 Type 2 diabetes and 6 quantitative traits ATP8A2 intron 17848626 rs11618222 chr13 26299649 C T 6.79E-04 Acute lung injury ATP8A2 intron 22295056 rs536569857 chr13 26299649 CA C 6.79E-04 Acute lung injury ATP8A2 intron 22295056 rs9634421 chr13 26309248 G A 9.95E-04 Alcohol consumption (maxi-drinks) ATP8A2 intron 24277619 rs9634423 chr13 26310566 C T 6.25E-05 Bone mineral density ATP8A2 intron 19181680 rs4770875 chr13 26319727 A G 1.61E-04 Nicotine smoking ATP8A2 intron 19268276 rs4770877 chr13 26335570 A G 1 Drug response to Etoposide ATP8A2 intron 17537913 rs2765751 chr13 26350861 T C 1.53E-04 Alzheimer's disease ATP8A2 intron 17998437 rs9507577 chr13 26363076 G T 1 Drug response to Etoposide ATP8A2 intron 17537913 rs9507577 chr13 26363076 G T 9.93E-05 Lung adenocarcinoma ATP8A2 intron 19836008 rs9581464 chr13 26422818 G A 0.000005813 Sarcoidosis ATP8A2 intron 22952805 rs9581465 chr13 26423082 A C 5.53E-07 Sarcoidosis ATP8A2 intron 22952805 rs9319247 chr13 26423097 T G 5.53E-07 Sarcoidosis ATP8A2 intron 22952805 rs9319248 chr13 26423168 C A 5.53E-07 Sarcoidosis ATP8A2 intron 22952805 rs10162249 chr13 26423657 T C 6.41E-07 Sarcoidosis ATP8A2 intron 22952805 rs9511937 chr13 26423898 G A 6.30E-07 Sarcoidosis ATP8A2 intron 22952805 rs9511938 chr13 26423912 A G 6.30E-07 Sarcoidosis ATP8A2 intron 22952805 rs9581466 chr13 26424284 G A 0.00001548 Sarcoidosis ATP8A2 intron 22952805 rs9581467 chr13 26424369 C T 3.54E-07 Sarcoidosis ATP8A2 intron 22952805 rs9511939 chr13 26424656 T G 3.52E-07 Sarcoidosis ATP8A2 intron 22952805 rs9511941 chr13 26424830 A G 3.08E-07 Sarcoidosis ATP8A2 intron 22952805 rs9511942 chr13 26424840 G A 3.08E-07 Sarcoidosis ATP8A2 intron 22952805 rs9511943 chr13 26425059 A T 3.08E-07 Sarcoidosis ATP8A2 intron 22952805 rs9511944 chr13 26425063 T A 3.08E-07 Sarcoidosis ATP8A2 intron 22952805 rs9511945 chr13 26425194 C G 3.08E-07 Sarcoidosis ATP8A2 intron 22952805 rs9511946 chr13 26425268 A G 3.08E-07 Sarcoidosis ATP8A2 intron 22952805 rs9511947 chr13 26425377 G A 3.08E-07 Sarcoidosis ATP8A2 intron 22952805 rs9511949 chr13 26425614 G A 3.08E-07 Sarcoidosis ATP8A2 intron 22952805 rs12020004 chr13 26425651 G A 3.08E-07 Sarcoidosis ATP8A2 intron 22952805 rs9511950 chr13 26425652 C A 3.08E-07 Sarcoidosis ATP8A2 intron 22952805 rs9511952 chr13 26425668 C T 3.08E-07 Sarcoidosis ATP8A2 intron 22952805 rs9511955 chr13 26426053 T C 3.37E-07 Sarcoidosis ATP8A2 intron 22952805 rs9507586 chr13 26426294 A T 3.49E-07 Sarcoidosis ATP8A2 intron 22952805 rs9507587 chr13 26426500 G A 3.27E-07 Sarcoidosis ATP8A2 intron 22952805 rs9511957 chr13 26426801 C T 3.42E-07 Sarcoidosis ATP8A2 intron 22952805 rs9507588 chr13 26426836 C T 2.69E-07 Sarcoidosis ATP8A2 intron 22952805 rs9507589 chr13 26426973 T C 2.36E-07 Sarcoidosis ATP8A2 intron 22952805 rs9511958 chr13 26427763 C T 2.20E-07 Sarcoidosis ATP8A2 intron 22952805 rs9319249 chr13 26428189 T C 2.26E-07 Sarcoidosis ATP8A2 intron 22952805 rs10467674 chr13 26428238 T A 2.26E-07 Sarcoidosis ATP8A2 intron 22952805 rs9319250 chr13 26428607 T C 0.000000208 Sarcoidosis ATP8A2 intron 22952805 rs61949368 chr13 26429117 G A 5.96E-07 Sarcoidosis ATP8A2 intron 22952805 rs112198380 chr13 26429376 A G 0.000000274 Sarcoidosis ATP8A2 intron 22952805 rs9507591 chr13 26431045 G A 0.00000459 Sarcoidosis ATP8A2 intron 22952805 rs661347 chr13 26441025 C T 8.56E-05 Lung adenocarcinoma ATP8A2 intron 19836008 rs641267 chr13 26442696 A G 2.77E-05 Personality dimensions ATP8A2 intron 22628180 rs641730 chr13 26442829 A G 2.78E-05 Personality dimensions ATP8A2 intron 22628180 rs306395 chr13 26450564 A G 2.95E-05 Personality dimensions ATP8A2 intron 22628180 rs306420 chr13 26466549 G A 2.16E-05 Personality dimensions ATP8A2 intron 22628180 rs12877019 chr13 26479030 C T 5.36E-04 Alzheimer's disease ATP8A2 intron 17998437 rs4141777 chr13 26493312 A G 2.72E-05 Personality dimensions ATP8A2 intron 22628180 rs1748104 chr13 26501020 C T 1.50E-05 Urinary metabolites ATP8A2 intron 21572414 rs184249 chr13 26510069 G A 8.72E-04 Alcohol dependence ATP8A2 intron 24277619 rs1324408 chr13 26516460 A G 2.46E-04 Alcohol dependence ATP8A2 intron 24277619 rs754100 chr13 26538455 T C 2.55E-04 Type 2 diabetes ATP8A2 intron 17463246 rs912514 chr13 26544369 C T 5.44E-04 Premature ovarian failure ATP8A2 intron 19508998 rs3783142 chr13 26555548 G A 1.60E-05 Urinary metabolites ATP8A2 intron 21572414 rs2031351 chr13 26559034 C T 4.83E-04 Response to taxane treatment (placlitaxel) ATP8A2 intron 23006423 rs873770 chr13 26614208 T C 5.82E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1960061 chr13 26670374 C T 6.23E-05 Bipolar disorder / / 22925353 rs17083306 chr13 26704154 A T 5.84E-04 Multiple complex diseases / / 17554300 rs17511627 chr13 26724328 A C 5.00E-06 Alzheimer's disease / / 22159054 rs7990711 chr13 26743956 A G 9.47E-04 Type 2 diabetes / / 17463246 rs9512144 chr13 26759079 C T 6.15E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs9578975 chr13 26763542 C A 2.46E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs9578975 chr13 26763542 C A 7.84E-06 Serum metabolites / / 19043545 rs17526316 chr13 26763802 G T 1.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4770949 chr13 26765096 C T 8.51E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4770949 chr13 26765096 C T 1.70E-05 Serum metabolites / / 19043545 rs3891621 chr13 26774905 G A 3.18E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs3891621 chr13 26774905 G A 5.19E-06 Serum metabolites / / 19043545 rs9581587 chr13 26777083 A C 8.01E-06 White blood cell count / / 21738479 rs9319280 chr13 26778961 T G 6.48E-06 White blood cell count / / 21738479 rs12873948 chr13 26779776 A G 1.01E-04 Gallstones / / 17632509 rs10507349 chr13 26781528 G A 2.00E-07 Type 2 diabetes / / 24509480 rs586915 chr13 26783070 A G 3.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8002226 chr13 26827054 T A 1.08E-04 Multiple complex diseases / / 17554300 rs682181 chr13 26840163 G T 9.42E-05 Post-operative nausea and vomiting CDK8 intron 21694509 rs711214 chr13 26881568 A G 1.24E-22 Narcolepsy CDK8 intron 19629137 rs873342 chr13 26902132 C A 9.70E-05 Body Fat Distribution CDK8 intron pha003017 rs17083838 chr13 26911112 G A 8.47E-04 Multiple complex diseases CDK8 intron 17554300 rs2901064 chr13 26914040 A G 3.79E-05 Body Fat Distribution CDK8 intron pha003017 rs1541038 chr13 26923073 G A 5.51E-05 Body Fat Distribution CDK8 intron pha003017 rs3736995 chr13 26923565 T G 3.00E-07 Immune response to measles-mumps-rubella vaccine CDK8 intron 24811271 rs4770971 chr13 26925864 A G 5.57E-05 Body Fat Distribution CDK8 intron pha003017 rs17083956 chr13 26949454 C G 2.84E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CDK8 intron 21844884 rs6491121 chr13 26972222 G T 3.90E-04 Smoking quantity CDK8 intron 24665060 rs1410280 chr13 26986735 T C 2.35E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9507713 chr13 27016436 A G 8.75E-05 Height / / pha003011 rs475300 chr13 27034050 T G 2.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs475300 chr13 27034050 T G 2.98E-04 Alzheimer's disease / / 24755620 rs12864131 chr13 27045939 G A 7.37E-04 Multiple complex diseases / / 17554300 rs9553839 chr13 27063546 T C 1.00E-07 Urinary metabolites / / 21572414 rs530991 chr13 27063586 T C 7.90E-07 Urinary metabolites / / 21572414 rs545865 chr13 27077454 C G 2.00E-06 Urinary metabolites / / 21572414 rs501244 chr13 27083865 C T 3.90E-06 Urinary metabolites / / 21572414 rs17543112 chr13 27089539 G A 8.96E-04 Alzheimer's disease / / 22005930 rs17543181 chr13 27089634 G A 7.80E-04 Alzheimer's disease / / 22005930 rs944696 chr13 27091051 A T 9.70E-04 Alzheimer's disease / / 22005930 rs9512236 chr13 27092269 G C 9.35E-04 Alzheimer's disease / / 22005930 rs793627 chr13 27102741 A C 1.93E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1571938 chr13 27113247 G A 9.27E-04 Alzheimer's disease / / 22005930 rs1123267 chr13 27113849 T G 9.27E-04 Alzheimer's disease / / 22005930 rs647163 chr13 27118023 C T 9.71E-04 Alzheimer's disease / / 22005930 rs574593 chr13 27118279 T C 9.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9581708 chr13 27156057 A G 9.70E-05 White matter hyperintensity burden WASF3 intron 21681796 rs494000 chr13 27164786 A G 8.56E-04 Multiple complex diseases WASF3 intron 17554300 rs523671 chr13 27164848 T C 7.58E-04 Multiple complex diseases WASF3 intron 17554300 rs793638 chr13 27180947 G A 6.67E-04 Multiple complex diseases WASF3 intron 17554300 rs7986966 chr13 27201109 G A 9.05E-05 Information processing speed WASF3 intron 21130836 rs1018123 chr13 27214914 T C 9.14E-05 Information processing speed WASF3 intron 21130836 rs9319312 chr13 27219117 T G 5.41E-04 HIV-1 viral setpoint WASF3 intron 17641165 rs9512317 chr13 27238475 T C 1.00E-05 Urinary metabolites WASF3 intron 21572414 rs977351 chr13 27239161 A G 6.80E-06 Urinary metabolites WASF3 intron 21572414 rs1078632 chr13 27256067 C T 7.40E-05 Multiple complex diseases WASF3 intron 17554300 rs1078630 chr13 27256102 A G 1.00E-05 Urinary metabolites WASF3 intron 21572414 rs9512333 chr13 27263750 G C 9.60E-06 Urinary metabolites / / 21572414 rs61465187 chr13 27267972 A AG 1.20E-05 Urinary metabolites / / 21572414 rs9512334 chr13 27267972 A G 1.20E-05 Urinary metabolites / / 21572414 rs11149447 chr13 27268330 G A 8.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1887596 chr13 27271370 G A 8.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2094499 chr13 27272502 C T 3.80E-05 Parkinson's disease (age of onset) / / 19772629 rs4771006 chr13 27282684 G A 7.30E-06 Parkinson's disease (age of onset) / / 19772629 rs1632215 chr13 27311246 G A 3.73E-04 Myocardial Infarction / / pha002873 rs1752653 chr13 27322777 T C 6.29E-06 Alcohol consumption / / 23953852 rs10507372 chr13 27323607 C A 9.74E-05 Blood Pressure / / pha003044 rs2479505 chr13 27330953 T G 1.22E-05 Alcohol consumption GPR12 UTR-3 23953852 rs9512379 chr13 27366674 C T 1.06E-04 Glycemic traits (pregnancy) / / 23903356 rs9512379 chr13 27366674 C T 7.18E-04 Glycemic traits (pregnancy) / / 23903356 rs4421848 chr13 27369683 T C 7.92E-04 Glycemic traits (pregnancy) / / 23903356 rs7329984 chr13 27376741 G A 3.94E-05 Multiple complex diseases / / 17554300 rs4769524 chr13 27377221 C T 0.00000278 Ovarian follicle number and menopause / / 22696150 rs9553897 chr13 27386655 G A 2.15E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs943719 chr13 27405427 C T 8.30E-04 Multiple complex diseases / / 17554300 rs7995334 chr13 27409049 T C 8.43E-05 Alzheimer's disease (age of onset) / / 22005931 rs1927508 chr13 27411091 T A 9.36E-05 Alzheimer's disease (age of onset) / / 22005931 rs17084756 chr13 27415285 C T 9.90E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9319321 chr13 27415673 A T 3.00E-06 Asthma (toluene diisocyanate-induced) / / 19187332 rs9553915 chr13 27442889 A G 7.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs17084854 chr13 27467432 T C 5.94E-04 Coronary Artery Disease / / 17634449 rs17084857 chr13 27469768 T C 7.67E-05 Asthma / / 11022011 rs9581776 chr13 27472564 G A 7.54E-04 Alzheimer's disease / / 17998437 rs4771040 chr13 27474856 C T 6.89E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9319327 chr13 27489315 T C 2.00E-05 Urinary metabolites / / 21572414 rs9319328 chr13 27489773 C T 9.50E-04 Myopia (pathological) / / 21095009 rs4771046 chr13 27497264 A G 3.83E-04 Depression (quantitative trait) / / 20800221 rs9512446 chr13 27497653 G A 1.13E-04 Depression (quantitative trait) / / 20800221 rs9512447 chr13 27497791 G A 9.35E-05 Depression (quantitative trait) / / 20800221 rs880809 chr13 27498549 T C 8.34E-04 Heart Failure / / pha002885 rs17084983 chr13 27528301 A G 0.000312432 Primary sclerosing cholangitis / / 23603763 rs12863583 chr13 27528322 T C 2.68E-04 Alzheimer's disease / / 24755620 rs17085007 chr13 27531267 T C 7.00E-08 Ulcerative colitis / / 19915573 rs17085007 chr13 27531267 T C 1.00E-16 Ulcerative colitis / / 21297633 rs17085007 chr13 27531267 T C 3.00E-19 Inflammatory bowel disease / / 23128233 rs17085007 chr13 27531267 T C 3.00E-07 Ulcerative colitis / / 23511034 rs17085007 chr13 27531267 T C 8.00E-06 Ulcerative colitis / / 23511034 rs9553939 chr13 27533642 G A 2.70E-05 Serum metabolites / / 19043545 rs9553939 chr13 27533642 G A 4.60E-05 Ulcerative colitis / / 19915573 rs9553939 chr13 27533642 G A 2.00E-04 Dietary macronutrient intake / / 23636237 rs9579054 chr13 27534715 G A 6.24E-05 Serum metabolites / / 19043545 rs6491170 chr13 27537873 T C 8.11E-06 Ulcerative colitis / / 19915573 rs7987059 chr13 27541625 T C 2.34E-04 Alzheimer's disease (late onset) / / 21379329 rs3897233 chr13 27542276 C A 1.20E-06 Ulcerative colitis / / 19915572 rs6650264 chr13 27543757 C T 4.00E-05 Ulcerative colitis / / 19915573 rs2039062 chr13 27565562 G A 3.79E-04 Multiple complex diseases / / 17554300 rs10507375 chr13 27573612 G T 4.83E-04 Multiple complex diseases / / 17554300 rs10161639 chr13 27581662 T C 6.00E-06 Urinary metabolites / / 21572414 rs10161645 chr13 27581778 T C 6.00E-06 Urinary metabolites / / 21572414 rs9512491 chr13 27586873 G C 5.00E-06 Alcohol dependence / / 21314694 rs9512491 chr13 27586873 G C 5.00E-06 Alcohol dependence / / 21314694 rs7329290 chr13 27589418 G C 4.06E-05 IgE levels / / 22075330 rs9512492 chr13 27590400 C T 1.48E-05 IgE levels / / 22075330 rs9512492 chr13 27590400 C T 0.00000264 HDL cholesterol particle diameter / / 23263444 rs4769538 chr13 27607377 T A 0.00000987 HDL cholesterol particle diameter / / 23263444 rs143134312 chr13 27680564 A AC 7.30E-06 Type 2 diabetes USP12 intron 17460697 rs565707 chr13 27680564 A C 7.30E-06 Type 2 diabetes USP12 intron 17460697 rs7337844 chr13 27720562 C T 2.08E-04 Schizophrenia USP12 intron 20832056 rs7984685 chr13 27737031 C T 2.20E-05 Type 2 diabetes USP12 intron 17460697 rs7998347 chr13 27739643 C T 2.40E-05 Type 2 diabetes USP12 intron 17460697 rs7336237 chr13 27748294 A G 6.96E-04 Alcohol dependence / / 20201924 rs10507380 chr13 27879526 A G 8.00E-06 Electrocardiographic traits / / 17903306 rs1333347 chr13 27900204 C T 4.80E-05 Diabetic retinopathy / / 21441570 rs1333348 chr13 27900534 G A 7.80E-05 Diabetic retinopathy / / 21441570 rs1537438 chr13 27908973 T G 3.90E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1537438 chr13 27908973 T G 0.0000253 Aging / / 22445811 rs2094497 chr13 27910122 T C 1.10E-05 Alcoholism (heaviness of drinking) / / 21529783 rs9512637 chr13 27920611 T C 1.00E-07 Alcoholism (heaviness of drinking) / / 21529783 rs17085484 chr13 27930039 T C 2.30E-04 Glycosylated haemoglobin levels / / 17255346 rs6491207 chr13 27930900 G A 0.0000463 Aging / / 22445811 rs9507881 chr13 27934706 A G 7.12E-05 Cognitive performance / / 19734545 rs7997379 chr13 27936117 A G 1.97E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7997379 chr13 27936117 A G 5.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1537432 chr13 27943696 T C 2.30E-05 Urinary metabolites / / 21572414 rs8000509 chr13 27949088 C T 9.25E-04 Type 2 diabetes / / 17463246 rs718617 chr13 27967841 G A 3.99E-04 Acute lung injury / / 22295056 rs2760902 chr13 27978642 G A 1.12E-05 Hepatitis B vaccine response / / 21764829 rs9581847 chr13 27995497 G A 4.31E-06 Job-related exhaustion / / 23620144 rs7323 chr13 28009031 G C 2.99E-04 Type 2 diabetes GTF3A missense 17463246 rs4771122 chr13 28020180 G A 9.00E-10 Body mass index MTIF3 intron 20935630 rs4771122 chr13 28020180 G A 9.48E-10 Body mass index MTIF3 intron 23001569 rs1885990 chr13 28040502 C T 5.60E-04 Schizophrenia / / 21747397 rs9319372 chr13 28042796 T C 8.13E-04 Multiple complex diseases / / 17554300 rs9319373 chr13 28042835 A G 7.90E-04 Multiple complex diseases / / 17554300 rs9507904 chr13 28049506 C T 9.40E-04 Type 2 diabetes / / 17463246 rs7336332 chr13 28058404 A G 1.00E-06 Weight / / 19079260 rs7336332 chr13 28058404 A G 6.30E-06 Smoking behavior / / 20418888 rs7336332 chr13 28058404 A G 3.85E-05 Lung function (forced vital capacity) / / pha003104 rs9554051 chr13 28059853 C T 0.0000797 Tuberculosis with late age of onset / / 22551897 rs927578 chr13 28075022 G T 5.26E-05 Lung function (forced vital capacity) / / pha003104 rs9512730 chr13 28077144 G C 5.00E-06 Schizophrenia / / 18347602 rs1218897 chr13 28079774 T C 2.49E-05 Neuroblastoma / / pha002895 rs7334690 chr13 28081535 G A 3.99E-05 Height / / pha003010 rs7334690 chr13 28081535 G A 7.46E-05 Height / / pha003011 rs9579096 chr13 28084069 T C 4.19E-05 Lung function (forced vital capacity) / / pha003104 rs1218887 chr13 28097567 T C 6.49E-05 Serum metabolites / / 19043545 rs1218885 chr13 28097996 C T 4.54E-05 Neuroblastoma / / pha002895 rs9581881 chr13 28106637 T C 2.11E-05 Lung function (forced vital capacity) / / pha003104 rs1235848 chr13 28111559 C A 7.93E-04 Multiple complex diseases / / 17554300 rs1235848 chr13 28111559 C A 7.77E-04 Lymphocyte counts / / 22286170 rs9512745 chr13 28121315 G A 6.52E-06 Response to cytadine analogues (cytosine arabinoside) LNX2 UTR-3 24483146 rs17085753 chr13 28123590 C A 1.40E-05 Response to lithium treatment in bipolar disorder LNX2 intron 19448189 rs11619599 chr13 28126745 T C 9.51E-04 Suicide attempts in bipolar disorder LNX2 intron 21423239 rs11619599 chr13 28126745 T C 1.94E-04 Smoking cessation LNX2 intron 24665060 rs2181774 chr13 28130723 T C 6.68E-04 Multiple complex diseases LNX2 intron 17554300 rs11617897 chr13 28155920 C G 8.98E-04 Suicide attempts in bipolar disorder LNX2 UTR-5 21423239 rs9512755 chr13 28158229 C T 4.00E-06 Response to cytadine analogues (cytosine arabinoside) LNX2 intron 24483146 rs17811793 chr13 28164859 G C 4.02E-06 Response to cytadine analogues (cytosine arabinoside) LNX2 intron 24483146 rs9512757 chr13 28165233 G A 4.29E-06 Response to cytadine analogues (cytosine arabinoside) LNX2 intron 24483146 rs625437 chr13 28176427 A T 2.80E-05 Urinary metabolites LNX2 intron 21572414 rs510342 chr13 28178525 T C 2.59E-04 Myocardial Infarction LNX2 intron pha002883 rs7097 chr13 28197436 C T 7.00E-06 Large B-cell lymphoma POLR1D UTR-3 21471979 rs880214 chr13 28198414 G A 5.10E-04 Spine bone size POLR1D intron 23207799 rs10492487 chr13 28199368 T A 6.70E-05 Lymphocyte counts POLR1D intron 22286170 rs1218953 chr13 28206469 T C 8.38E-05 Response to cytadine analogues (cytosine arabinoside) POLR1D intron 24483146 rs616662 chr13 28208423 G A 9.70E-06 Smoking cessation POLR1D intron 24665060 rs507217 chr13 28208517 C A 8.32E-05 Smoking cessation POLR1D intron 24665060 rs535534 chr13 28209323 A G 9.50E-05 Smoking cessation POLR1D intron 24665060 rs12584838 chr13 28211308 G C 1.30E-05 Obesity,menopause POLR1D intron 21424828 rs12870355 chr13 28218157 T C 1.45E-05 Bipolar disorder,affective POLR1D intron 20528957 rs7337722 chr13 28219158 G C 3.86E-05 Response to cytadine analogues (cytosine arabinoside) POLR1D intron 24483146 rs9512776 chr13 28221687 A G 2.90E-04 Response to cytadine analogues (cytosine arabinoside) POLR1D intron 24483146 rs9512776 chr13 28221687 A G 1.74E-04 Smoking cessation POLR1D intron 24665060 rs1218951 chr13 28224258 G A 3.35E-05 Smoking cessation POLR1D intron 24665060 rs7336858 chr13 28225919 A G 1.68E-05 Smoking cessation POLR1D intron 24665060 rs10492484 chr13 28232706 A G 1.39E-04 Smoking cessation POLR1D intron 24665060 rs12050009 chr13 28235239 G A 4.00E-06 Response to lithium treatment in bipolar disorder POLR1D intron 19448189 rs4769562 chr13 28238069 C T 9.56E-04 Amyotrophic lateral sclerosis (sporadic) POLR1D intron 24529757 rs17085862 chr13 28240277 G A 2.64E-05 Smoking cessation POLR1D UTR-3 24665060 rs17085866 chr13 28240417 C G 2.43E-05 Smoking cessation POLR1D UTR-3 24665060 rs9512781 chr13 28241123 A G 3.24E-04 Response to cytadine analogues (cytosine arabinoside) POLR1D UTR-3 24483146 rs9554088 chr13 28242221 A G 4.64E-05 Cognitive performance / / 19734545 rs969702 chr13 28245365 G A 4.46E-04 Bipolar disorder,affective / / 20528957 rs9579104 chr13 28249504 A G 1.73E-05 Bipolar disorder,affective / / 20528957 rs9634346 chr13 28251912 T G 3.07E-04 Bipolar disorder,affective / / 20528957 rs1117381 chr13 28260120 G A 4.81E-04 Bipolar disorder,affective / / 20528957 rs9512808 chr13 28280337 C A 5.24E-05 Bipolar disorder,affective / / 20528957 rs9512814 chr13 28282256 G A 1.02E-04 Bipolar disorder,affective / / 20528957 rs9512815 chr13 28282567 T C 3.35E-04 Bipolar disorder,affective / / 20528957 rs9512816 chr13 28284808 A G 0.00001969 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9512816 chr13 28284808 A G 1.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9512817 chr13 28284941 T C 0.0001636 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9512817 chr13 28284941 T C 1.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4771157 chr13 28286748 C T 0.0008746 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4771157 chr13 28286748 C T 8.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9512824 chr13 28291913 G C 0.0004327 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9512824 chr13 28291913 G C 4.33E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9512825 chr13 28292515 T C 0.0001514 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9512825 chr13 28292515 T C 1.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9512826 chr13 28293086 A G 0.0003792 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9512826 chr13 28293086 A G 3.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2093619 chr13 28295181 C T 0.0005614 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2093619 chr13 28295181 C T 5.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9554145 chr13 28296108 T C 0.0005616 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9554145 chr13 28296108 T C 5.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1923837 chr13 28296671 C T 0.0005617 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1923837 chr13 28296671 C T 5.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9512828 chr13 28298329 C G 0.0005627 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9512828 chr13 28298329 C G 5.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7985274 chr13 28299780 G A 0.0002948 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7985274 chr13 28299780 G A 2.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9512830 chr13 28300007 G A 0.0005652 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9512830 chr13 28300007 G A 5.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4769565 chr13 28300201 T C 5.66E-04 Multiple complex diseases / / 17554300 rs4769565 chr13 28300201 T C 0.0002955 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4769565 chr13 28300201 T C 2.96E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9507935 chr13 28300298 C T 0.0004209 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9507935 chr13 28300298 C T 4.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9507936 chr13 28301143 C T 0.0002953 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9507936 chr13 28301143 C T 2.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9512833 chr13 28301230 T C 0.0002949 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9512833 chr13 28301230 T C 2.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs34841496 chr13 28301642 A AG 0.000295 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs34841496 chr13 28301642 A AG 2.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9512837 chr13 28301642 A G 0.000295 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9512837 chr13 28301642 A G 2.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4442644 chr13 28302159 G C 0.0002951 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4442644 chr13 28302159 G C 2.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9512843 chr13 28311966 G A 0.0006186 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9512843 chr13 28311966 G A 6.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7984969 chr13 28312712 T C 0.0002829 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7984969 chr13 28312712 T C 2.83E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2031137 chr13 28314330 C A 0.0002829 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2031137 chr13 28314330 C A 2.83E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9512847 chr13 28314694 G A 0.0002838 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9512847 chr13 28314694 G A 2.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2027576 chr13 28315618 T C 0.0006181 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2027576 chr13 28315618 T C 6.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2027577 chr13 28315830 A T 0.000617 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2027577 chr13 28315830 A T 6.17E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9512850 chr13 28316163 A G 0.0002318 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9512850 chr13 28316163 A G 2.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs745980 chr13 28316531 T A 0.0002712 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs745980 chr13 28316531 T A 2.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1079001 chr13 28317567 T A 0.000606 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1079001 chr13 28317567 T A 6.06E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs874873 chr13 28346302 C T 5.42E-04 Type 2 diabetes / / 17463246 rs1231044 chr13 28346594 T C 1.42E-05 Telomere length / / 20139977 rs9579113 chr13 28348879 G A 9.07E-04 Insulin resistance / / 21901158 rs1326384 chr13 28356322 T C 3.41E-05 Bipolar disorder / / 22925353 rs1923834 chr13 28360487 C T 5.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs927848 chr13 28377139 A G 7.30E-04 Alcohol dependence / / 20201924 rs1231064 chr13 28379709 A G 5.66E-05 Lung adenocarcinoma / / 19836008 rs17752257 chr13 28401578 C A 1.22E-04 Multiple complex diseases / / 17554300 rs4769574 chr13 28411817 G A 9.81E-04 Multiple complex diseases / / 17554300 rs9551406 chr13 28426156 A G 9.83E-05 Monocyte chemoattractant protein-1 / / pha003071 rs2387100 chr13 28426759 A G 3.80E-05 Alzheimer's disease (late onset) / / 20885792 rs2387100 chr13 28426759 A G 3.80E-05 Alzheimer's disease (late onset) / / 21460841 rs9512900 chr13 28429738 T C 9.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs1778797 chr13 28452129 T A 6.98E-06 Liver disease in chronic hepatitis B virus infection / / 24065354 rs9554196 chr13 28476640 C G 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs7989117 chr13 28479260 C T 2.73E-05 Waist-Hip Ratio / / pha003013 rs7989117 chr13 28479260 C T 4.33E-05 Waist-Hip Ratio / / pha003028 rs9319399 chr13 28479980 T C 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs9551419 chr13 28480356 C T 3.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs9581941 chr13 28482654 T C 2.33E-05 Waist-Hip Ratio / / pha003013 rs9581941 chr13 28482654 T C 3.79E-05 Waist-Hip Ratio / / pha003028 rs11619319 chr13 28487599 A G 1.30E-15 Fasting blood glucose / / 22885924 rs2293941 chr13 28491198 G A 5.00E-10 Fasting glucose-related traits (interaction with BMI) / / 22581228 rs7993724 chr13 28493276 T C 1.03E-20 LDL cholesterol PDX1 nearGene-5 23063622 rs7993724 chr13 28493276 T C 1.23E-30 HDL cholesterol PDX1 nearGene-5 23063622 rs7993724 chr13 28493276 T C 2.90E-11 Triglycerides PDX1 nearGene-5 23063622 rs7993724 chr13 28493276 T C 7.75E-45 Cholesterol,total PDX1 nearGene-5 23063622 rs4769581 chr13 28506003 T C 3.30E-04 Iris characteristics / / 21835309 rs9512928 chr13 28513301 T C 1.90E-08 Corneal structure / / 22003120 rs6491241 chr13 28514849 T C 1.87E-04 Body mass index / / 21701565 rs6491241 chr13 28514849 T C 3.36E-04 Body mass index / / 21701565 rs6491241 chr13 28514849 T C 7.58E-04 B cell non-Hodgkin lymphoma / / 23749188 rs2504220 chr13 28519354 A C 8.33E-04 Type 2 diabetes / / 17463246 rs2504220 chr13 28519354 A C 2.94E-04 Multiple complex diseases / / 17554300 rs4769585 chr13 28550578 C T 7.85E-04 Insulin resistance / / 21901158 rs2481971 chr13 28568456 C G 1.25E-04 Multiple complex diseases / / 17554300 rs11616427 chr13 28572348 T C 4.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs1999364 chr13 28577035 T C,G 8.55E-04 Multiple complex diseases FLT3 nearGene-3 17554300 rs3829382 chr13 28577688 G T 4.73E-04 Alzheimer's disease FLT3 UTR-3 22005930 rs17086213 chr13 28584744 T C 9.06E-04 Alcohol dependence FLT3 intron 21314694 rs7317159 chr13 28586220 T C 1.62E-04 Alcohol dependence FLT3 intron 21314694 rs4771206 chr13 28621431 C T 1.73E-06 Multiple complex diseases FLT3 intron 17554300 rs9513000 chr13 28621937 C G 9.31E-04 Multiple complex diseases FLT3 intron 17554300 rs2153000 chr13 28622356 G A 2.85E-04 Multiple complex diseases FLT3 intron 17554300 rs7998462 chr13 28674026 A G 2.94E-05 Lung cancer FLT3 intron 18978787 rs4366576 chr13 28678488 G T 9.86E-06 Post-operative nausea and vomiting / / 21694509 rs9551447 chr13 28717392 G T 2.41E-04 Multiple complex diseases PAN3 intron 17554300 rs9554277 chr13 28728026 G A 3.05E-04 Multiple complex diseases PAN3 intron 17554300 rs7327508 chr13 28730023 T G 2.80E-04 Multiple complex diseases PAN3 intron 17554300 rs7982828 chr13 28758037 G A 5.66E-04 Multiple complex diseases PAN3 intron 17554300 rs9508005 chr13 28789794 T G 4.40E-04 Stroke PAN3 intron pha002887 rs9551449 chr13 28812308 A G 1.18E-04 Multiple complex diseases PAN3 intron 17554300 rs7330759 chr13 28826983 A G 4.25E-04 Multiple complex diseases PAN3 intron 17554300 rs4343125 chr13 28828893 A G 3.83E-04 Type 2 diabetes PAN3 intron 17463246 rs9582029 chr13 28829992 G A 7.52E-04 Acute lung injury PAN3 intron 22295056 rs1830792 chr13 28873907 T C 3.57E-04 Stroke / / pha002887 rs720661 chr13 28878544 C T 0.00000124 HDL cholesterol FLT1 intron 23063622 rs9554316 chr13 28881335 T G 8.62E-04 Type 2 diabetes FLT1 intron 17463246 rs3794396 chr13 28892653 G C 0.00000162 Triglycerides FLT1 intron 23063622 rs2296189 chr13 28893642 A G 6.64E-05 Calcium intake levels and metabolic syndrome FLT1 cds-synon 22170361 rs7981680 chr13 28893870 C G 9.64E-13 Alcohol consumption FLT1 intron pha001400 rs2296192 chr13 28919462 T C 1.00E-04 Cognitive impairment induced by topiramate FLT1 intron 22091778 rs1324057 chr13 28925435 T C 7.55E-05 Bone mineral density FLT1 intron 19181680 rs17086609 chr13 28929711 A G 5.00E-06 Cognitive performance FLT1 intron 19734545 rs9319428 chr13 28973621 G A 0.000000179 Coronary artery disease (CAD) (males) FLT1 intron 23202125 rs9319428 chr13 28973621 G A 0.000000674 Coronary artery disease (CAD) age >50 FLT1 intron 23202125 rs9319428 chr13 28973621 G A 0.0000416 Coronary artery disease with myocardial infarction FLT1 intron 23202125 rs9319428 chr13 28973621 G A 0.000449 Coronary artery disease (CAD) age <=50 FLT1 intron 23202125 rs9319428 chr13 28973621 G A 7.32E-11 Coronary artery disease FLT1 intron 23202125 rs9319428 chr13 28973621 G A 4.47E-05 Coronary artery disease FLT1 intron 24262325 rs9508025 chr13 28984063 C G 6.00E-07 Coronary heart disease FLT1 intron 23364394 rs1013418 chr13 28991597 C T 0.000026 Mean arterial pressure FLT1 intron 22510845 rs9513106 chr13 28993669 A C 9.15E-04 Acute lung injury FLT1 intron 22295056 rs10507385 chr13 28996960 T C 9.84E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) FLT1 intron 24236485 rs722503 chr13 28997052 C T 5.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FLT1 intron 20877124 rs722503 chr13 28997052 C T 9.75E-07 Retinal arteriolar caliber FLT1 intron 23776548 rs2281827 chr13 29001721 C T 1.40E-05 Retinal arteriolar caliber FLT1 intron 23776548 rs10507386 chr13 29028554 C T 0.00042 Coronary artery calcification FLT1 intron 23727086 rs679791 chr13 29061777 A C 1.82E-05 Serum metabolites FLT1 intron 19043545 rs600640 chr13 29063969 G A 4.90E-05 Kawasaki disease FLT1 intron 22446962 rs8000288 chr13 29072477 T C 7.72E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs113537842 chr13 29085004 A AC 2.87E-04 White matter integrity / / 22425255 rs4462445 chr13 29085004 A C 2.87E-04 White matter integrity / / 22425255 rs17086772 chr13 29097397 T C 5.17E-109 Multiple complex diseases / / 17554300 rs9550377 chr13 29101681 C T 7.72E-04 Alcohol dependence / / 21314694 rs3812868 chr13 29149341 C G 7.90E-05 Multiple complex diseases / / 17554300 rs10507387 chr13 29150318 T C 1.95E-04 Cholesterol / / 17255346 rs9508066 chr13 29152505 G A 6.43E-04 Alcohol dependence / / 21314694 rs7989324 chr13 29153177 T C 1.21E-04 Height / / 17255346 rs7989324 chr13 29153177 T C 4.93E-04 Aortic root size / / 21223598 rs974288 chr13 29161437 A G 2.12E-04 Cholesterol / / 17255346 rs9578047 chr13 29164731 T C 7.90E-06 Breast cancer (menopausal hormone therapy interaction) / / 24080446 rs9579199 chr13 29164783 G A 8.00E-06 Breast cancer (menopausal hormone therapy interaction) / / 24080446 rs17086849 chr13 29166399 G A 1.00E-05 Urinary metabolites / / 21572414 rs9314912 chr13 29171985 A G 8.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9551502 chr13 29182290 G A 3.21E-04 Lung function (forced vital capacity) / / 24023788 rs17086894 chr13 29187679 T G 2.51E-04 Multiple complex diseases / / 17554300 rs4573787 chr13 29193434 A G 1.96E-04 Lung function (forced vital capacity) / / 24023788 rs1417482 chr13 29194611 G A 7.51E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9508098 chr13 29207352 T C 7.12E-05 Alzheimer's disease / / 17998437 rs9551515 chr13 29228569 T C 6.68E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1771200 chr13 29237055 A G 4.52E-04 Multiple complex diseases POMP intron 17554300 rs2487345 chr13 29238352 G A 3.85E-04 Multiple complex diseases POMP intron 17554300 rs1305088 chr13 29278450 T C 9.00E-06 Non-alcoholic fatty liver disease histology (other) SLC46A3 intron 20708005 rs8181891 chr13 29289043 A G 3.60E-04 Multiple complex diseases SLC46A3 intron 17554300 rs17640857 chr13 29325508 C T 5.00E-06 Urinary metabolites / / 21572414 rs9508133 chr13 29334217 A G 1.80E-05 Urinary metabolites / / 21572414 rs9578061 chr13 29352227 C T 3.68E-04 Multiple complex diseases / / 17554300 rs1792023 chr13 29368502 G A 5.67E-06 Obesity-related traits / / 23251661 rs954108 chr13 29368706 C T 1.00E-06 Obesity-related traits / / 23251661 rs715705 chr13 29369467 T C 5.15E-06 Obesity-related traits / / 23251661 rs947248 chr13 29369553 G T 9.49E-05 Erythrocyte counts / / pha003099 rs947247 chr13 29369685 T G 8.66E-06 Obesity-related traits / / 23251661 rs9508154 chr13 29370726 A G 8.27E-06 Obesity-related traits / / 23251661 rs6490331 chr13 29386700 T A,C,G 8.12E-06 Obesity-related traits / / 23251661 rs1341329 chr13 29396100 C T 8.08E-06 Obesity-related traits / / 23251661 rs2105300 chr13 29398616 G A 9.57E-06 Obesity-related traits / / 23251661 rs7322214 chr13 29401271 A C 9.42E-06 Obesity-related traits / / 23251661 rs2153666 chr13 29411518 A G 6.40E-06 Obesity-related traits / / 23251661 rs1161463 chr13 29431338 A G 2.00E-06 Attention deficit hyperactivity disorder symptoms (interaction) / / 18846501 rs327118 chr13 29506175 C T 8.48E-05 Sudden cardiac arrest / / 21658281 rs189009 chr13 29515875 A C 5.85E-04 Myopia (pathological) / / 21095009 rs327127 chr13 29518900 C G 2.28E-05 Nicotine smoking / / 19268276 rs327130 chr13 29521831 T C 6.24E-04 Myopia (pathological) / / 21095009 rs1998360 chr13 29546733 T G 3.56E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1322379 chr13 29554256 C T 5.76E-04 Type 2 diabetes / / 17463246 rs1322379 chr13 29554256 C T 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs9508207 chr13 29558694 C T 6.79E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs1570309 chr13 29560146 G A 5.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs7140033 chr13 29562065 A C 8.84E-04 Alzheimer's disease / / 22005930 rs1407435 chr13 29562491 C T 8.49E-04 Alzheimer's disease / / 22005930 rs9506065 chr13 29566341 G C 7.89E-04 Alzheimer's disease / / 22005930 rs1040913 chr13 29566949 G C 3.70E-04 Alzheimer's disease / / 22005930 rs4575377 chr13 29577019 A G 7.88E-04 Alzheimer's disease / / 22005930 rs9314926 chr13 29577387 A G 1.97E-04 Multiple complex diseases / / 17554300 rs3899582 chr13 29577996 T G 8.82E-24 Narcolepsy / / 19629137 rs3892746 chr13 29578309 A G 8.19E-04 Alzheimer's disease / / 22005930 rs3858734 chr13 29579059 A G 7.58E-04 Alzheimer's disease / / 22005930 rs3886761 chr13 29579265 C T 7.54E-04 Alzheimer's disease / / 22005930 rs4110543 chr13 29579660 C T 7.52E-04 Alzheimer's disease / / 22005930 rs4445745 chr13 29580358 G A 7.67E-04 Alzheimer's disease / / 22005930 rs2479768 chr13 29620654 A G 6.00E-06 Methotrexate phramacokinetics (acute lymphoblastic leukemia) MTUS2 intron 19901119 rs226909 chr13 29636113 T C 3.00E-04 Type 2 diabetes MTUS2 intron 17463246 rs9579284 chr13 29670007 G A 4.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MTUS2 intron 20877124 rs1887752 chr13 29670346 T C 7.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MTUS2 intron 20877124 rs9506102 chr13 29670483 C T 6.93E-04 Multiple complex diseases MTUS2 intron 17554300 rs9314932 chr13 29673614 A G 6.85E-04 Smoking cessation MTUS2 intron 24665060 rs9551602 chr13 29675891 G A 6.03E-04 Smoking cessation MTUS2 intron 24665060 rs9579290 chr13 29680887 C A 3.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MTUS2 intron 20877124 rs35665418 chr13 29682268 G GT 2.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MTUS2 intron 20877124 rs7994251 chr13 29682268 G T 2.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MTUS2 intron 20877124 rs9634353 chr13 29685954 G C 8.04E-04 Smoking cessation MTUS2 intron 24665060 rs7332351 chr13 29698143 T C 1.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MTUS2 intron 20877124 rs1927837 chr13 29712753 T C 3.80E-04 Heart Failure MTUS2 intron pha002885 rs1927845 chr13 29720732 T C 1.40E-04 Heart Failure MTUS2 intron pha002885 rs9508300 chr13 29728058 T C 7.46E-04 Tourette syndrome MTUS2 intron 22889924 rs3930809 chr13 29738328 C T 7.72E-04 Heart Failure MTUS2 intron pha002884 rs6490370 chr13 29786977 A G 2.34E-05 Paget's disease MTUS2 intron 20436471 rs1999716 chr13 29813633 T G 6.04E-05 Asthma MTUS2 intron pha003128 rs9506126 chr13 29829386 G A 4.34E-05 Serum metabolites MTUS2 intron 19043545 rs9508327 chr13 29841357 G A 2.63E-04 Lung function (forced expiratory volume in 1 second) MTUS2 intron 17255346 rs1023166 chr13 29845810 C T 2.40E-05 Urinary metabolites MTUS2 intron 21572414 rs1543660 chr13 29855650 T C 3.62E-05 Alcohol withdrawal symptoms MTUS2 intron 22072270 rs4341627 chr13 29857421 A G 2.69E-04 Multiple complex diseases MTUS2 intron 17554300 rs7996177 chr13 29865678 T C 1.10E-06 Urinary metabolites MTUS2 intron 21572414 rs7334097 chr13 29869240 G A 8.87E-04 Multiple complex diseases MTUS2 intron 17554300 rs7334097 chr13 29869240 G A 6.00E-04 Acute lymphoblastic leukemia (childhood) MTUS2 intron 20189245 rs1544309 chr13 29872965 G A 8.00E-04 Acute lymphoblastic leukemia (childhood) MTUS2 intron 20189245 rs4769010 chr13 29875238 A C 1.60E-04 Multiple complex diseases MTUS2 intron 17554300 rs9551642 chr13 29877699 A T 1.17E-04 Multiple complex diseases MTUS2 intron 17554300 rs7326604 chr13 29898086 C T 6.36E-04 Response to taxane treatment (placlitaxel) MTUS2 intron 23006423 rs61999321 chr13 29898783 C T 8.00E-06 Obesity-related traits MTUS2 missense 23251661 rs2388089 chr13 29940827 T C 6.85E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MTUS2 intron 21844884 rs3125704 chr13 29951387 T C 1.30E-04 Primary sclerosing cholangitis MTUS2 intron 19944697 rs3125708 chr13 29952002 A G 1.30E-04 Primary sclerosing cholangitis MTUS2 intron 19944697 rs2388082 chr13 29961332 C G 4.00E-06 Insomnia (caffeine-induced) MTUS2 intron 22754043 rs9508434 chr13 29962368 C T 5.80E-04 Primary sclerosing cholangitis MTUS2 intron 19944697 rs12585116 chr13 29968548 A G 0.000395 Salmonella-induced pyroptosis MTUS2 intron 22837397 rs9578097 chr13 29973381 A G 9.72E-04 Alzheimer's disease MTUS2 intron 22005930 rs9551682 chr13 30015805 T C 3.22E-04 Myopia (pathological) MTUS2 intron 21095009 rs4272876 chr13 30023198 C T 6.31E-04 Amyotrophic Lateral Sclerosis MTUS2 intron 17362836 rs7999813 chr13 30028110 A C 3.84E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MTUS2 intron 22566498 rs2388084 chr13 30047005 A G 3.30E-04 Multiple complex diseases MTUS2 intron 17554300 rs2388084 chr13 30047005 A G 4.10E-06 Urinary metabolites MTUS2 intron 21572414 rs17601608 chr13 30067933 T C 6.30E-04 Multiple complex diseases MTUS2 intron 17554300 rs2258198 chr13 30071310 G T 6.06E-04 Coronary heart disease MTUS2 intron 21971053 rs1571784 chr13 30084952 G A 4.63E-04 Body mass index SLC7A1 UTR-3 21701565 rs883055 chr13 30092675 G A 7.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC7A1 intron 20877124 rs17073593 chr13 30095301 C T 6.39E-04 Insulin resistance SLC7A1 intron 21901158 rs9508490 chr13 30119500 C A,G,T 1.00E-04 Cognitive impairment induced by topiramate SLC7A1 intron 22091778 rs9579401 chr13 30125811 C T 4.90E-06 Hearing function SLC7A1 intron 17255346 rs819388 chr13 30130140 C T 1.57E-05 Hearing function SLC7A1 intron 17255346 rs478085 chr13 30135331 C A,G,T 1.12E-05 Hearing function SLC7A1 intron 17255346 rs555913 chr13 30136969 T C 1.48E-05 Hearing function SLC7A1 intron 17255346 rs7338758 chr13 30137828 T C 1.24E-04 Multiple complex diseases SLC7A1 intron 17554300 rs6490411 chr13 30140981 A G 2.00E-07 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) SLC7A1 intron 17982456 rs9579410 chr13 30152140 A T 3.93E-06 Hearing function SLC7A1 intron 17255346 rs9579410 chr13 30152140 A T 7.57E-05 Multiple complex diseases SLC7A1 intron 17554300 rs9579422 chr13 30176650 C T 7.00E-05 Response to alcohol consumption (flushing response) / / 24277619 rs2036975 chr13 30181117 G C 4.30E-05 Multiple complex diseases / / 17554300 rs1010154 chr13 30290260 C T 2.07E-05 Lactate dehydrogenase levels / / 20981236 rs7321919 chr13 30295287 T C 9.94E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12584812 chr13 30303509 G A 2.60E-04 Height / / 17255346 rs17502383 chr13 30306277 A G 7.51E-05 Socioeconomic Factors / / pha003067 rs9579477 chr13 30308054 T C 2.33E-05 Sudden cardiac arrest / / 21658281 rs10454559 chr13 30309999 G A 1.94E-04 Height / / 17255346 rs6490428 chr13 30337216 C A 1.90E-05 Multiple complex diseases / / 17554300 rs9551740 chr13 30344936 G C 5.10E-08 Health and aging,CVD and cancer age of onset UBL3 intron 22174011 rs2892463 chr13 30347835 G T 8.00E-06 Non-word repetition UBL3 intron 23738518 rs9508555 chr13 30372036 C G 1.18E-05 Non-word repetition UBL3 intron 23738518 rs719199 chr13 30389252 C G 4.78E-04 Multiple complex diseases UBL3 intron 17554300 rs278050 chr13 30436968 C A 3.46E-04 Bipolar disorder,schizoaffective / / 19567891 rs7321345 chr13 30439397 T C 1.37E-04 Multiple complex diseases / / 17554300 rs9551757 chr13 30448063 C T 3.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9551757 chr13 30448063 C T 6.35E-05 Lymphocyte counts / / pha003094 rs9551757 chr13 30448063 C T 1.65E-05 Neutrophil count / / pha003095 rs17631397 chr13 30453522 A G 8.47E-05 Lymphocyte counts / / pha003094 rs17631397 chr13 30453522 A G 2.67E-05 Neutrophil count / / pha003095 rs9805864 chr13 30455345 C T 1.00E-05 Urinary metabolites / / 21572414 rs1590501 chr13 30456307 C T 2.74E-05 Biliary atresia / / 20460270 rs9314986 chr13 30458737 G T 2.00E-06 Biliary atresia / / 20460270 rs278040 chr13 30459712 T C 5.06E-06 Non-obstructive azoospermia / / 22541561 rs4769778 chr13 30475850 C G 7.78E-04 Type 2 diabetes / / 17463246 rs874266 chr13 30475887 G A 6.72E-04 Multiple complex diseases / / 17554300 rs41449847 chr13 30484765 A G 5.00E-04 Multiple complex diseases / / 17554300 rs11617065 chr13 30488370 G A 9.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2031491 chr13 30490882 T C 7.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2039951 chr13 30494759 C G 7.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7323424 chr13 30496565 C T 8.09E-04 Multiple complex diseases / / 17554300 rs17503263 chr13 30496598 C T 1.44E-05 Psoriasis / / 20953190 rs74042894 chr13 30502229 T C 0.0000282 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs113912429 chr13 30502859 C T 0.0000452 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs3847988 chr13 30503277 C A 3.22E-04 Multiple complex diseases / / 17554300 rs17587770 chr13 30509009 T C 3.11E-05 Tuberculosis / / 24057671 rs7996122 chr13 30515128 T C 9.92E-05 Epilepsy (remission after treatment) LOC440131 intron 23962720 rs491138 chr13 30515349 A T 9.86E-05 Epilepsy (remission after treatment) LOC440131 intron 23962720 rs647794 chr13 30515408 C T 9.88E-05 Epilepsy (remission after treatment) LOC440131 intron 23962720 rs646983 chr13 30515553 A G 1.20E-05 Longevity and age-related phenotypes LOC440131 intron 17903295 rs646983 chr13 30515553 A G 8.28E-05 Epilepsy (remission after treatment) LOC440131 intron 23962720 rs573132 chr13 30516123 G A 8.65E-05 Epilepsy (remission after treatment) LOC440131 intron 23962720 rs572055 chr13 30516268 A G 8.38E-05 Epilepsy (remission after treatment) LOC440131 intron 23962720 rs571307 chr13 30516310 C T 8.35E-05 Epilepsy (remission after treatment) LOC440131 intron 23962720 rs633496 chr13 30516338 A C 8.28E-05 Epilepsy (remission after treatment) LOC440131 intron 23962720 rs7338743 chr13 30516527 A G 8.31E-05 Epilepsy (remission after treatment) LOC440131 intron 23962720 rs632258 chr13 30516563 C T 8.31E-05 Epilepsy (remission after treatment) LOC440131 intron 23962720 rs632214 chr13 30516598 C A 8.35E-05 Epilepsy (remission after treatment) LOC440131 intron 23962720 rs912785 chr13 30516728 G C 8.35E-05 Epilepsy (remission after treatment) LOC440131 intron 23962720 rs17503526 chr13 30517041 G T 2.15E-05 Tuberculosis LOC440131 intron 24057671 rs619367 chr13 30517172 G A 8.47E-05 Epilepsy (remission after treatment) LOC440131 intron 23962720 rs605478 chr13 30517989 T C 8.48E-05 Epilepsy (remission after treatment) LOC440131 intron 23962720 rs605464 chr13 30517994 C T 8.48E-05 Epilepsy (remission after treatment) LOC440131 intron 23962720 rs602388 chr13 30518658 T C 8.80E-05 Epilepsy (remission after treatment) LOC440131 intron 23962720 rs12429187 chr13 30537297 G A 4.47E-04 Insulin resistance / / 21901158 rs75404762 chr13 30562130 T A,C,G 7.04E-06 Prostate cancer / / 24185611 rs4769800 chr13 30588484 C G 1.20E-05 Urinary metabolites / / 21572414 rs9551801 chr13 30602582 C T 8.69E-04 Insulin resistance / / 21901158 rs663528 chr13 30607076 T A,C,G 1.20E-06 Bilirubin levels / / 23371916 rs604205 chr13 30609779 A T 1.13E-06 Bilirubin levels / / 23371916 rs593261 chr13 30617750 A G 2.79E-06 Bilirubin levels / / 23371916 rs687242 chr13 30618557 A G 2.52E-06 Bilirubin levels / / 23371916 rs684587 chr13 30619171 T A 3.88E-06 Bilirubin levels / / 23371916 rs928456 chr13 30634917 A G 3.48E-04 Alzheimer's disease (late onset) / / 21379329 rs9314995 chr13 30644418 G T 5.05E-05 Alcohol and nictotine co-dependence / / 20158304 rs17504394 chr13 30646520 C A 1.37E-04 Glycosylated haemoglobin levels / / 17255346 rs9550520 chr13 30649751 A G 4.63E-04 Multiple complex diseases / / 17554300 rs486253 chr13 30653802 G C 6.27E-04 Multiple complex diseases / / 17554300 rs636519 chr13 30655181 A T 9.40E-04 Multiple complex diseases / / 17554300 rs478410 chr13 30656081 G A 8.84E-04 Multiple complex diseases / / 17554300 rs478410 chr13 30656081 G A 1.30E-05 Parkinson's disease (age of onset) / / 19772629 rs676495 chr13 30663754 T C 9.10E-06 Parkinson's disease (age of onset) / / 19772629 rs515620 chr13 30668935 A G 4.45E-04 Multiple complex diseases / / 17554300 rs17504553 chr13 30668989 G T 1.97E-04 Multiple complex diseases / / 17554300 rs571845 chr13 30670264 A G 6.77E-04 Multiple complex diseases / / 17554300 rs490290 chr13 30685388 A T 3.18E-04 Alzheimer's disease / / 17998437 rs589064 chr13 30691808 G C 8.30E-06 Dietary macronutrient intake / / 23372041 rs913908 chr13 30725876 G A 9.20E-04 Multiple complex diseases / / 17554300 rs913908 chr13 30725876 G A 2.20E-05 Urinary metabolites / / 21572414 rs2183350 chr13 30739158 C A 2.93E-04 Multiple complex diseases / / 17554300 rs9508667 chr13 30747950 G A 2.10E-05 Parkinson's disease (age of onset) / / 19772629 rs4385994 chr13 30775537 C A 1.34E-04 Multiple complex diseases / / 17554300 rs10478 chr13 30777202 T C 5.96E-05 Cognitive performance KAT/L1 UTR-3 19734545 rs2277450 chr13 30805815 T C 4.32E-04 Suicide attempts in bipolar disorder KAT/L1 intron 21423239 rs846489 chr13 30842355 A C 7.84E-04 Alzheimer's disease KAT/L1 intron 17998437 rs185694 chr13 30885223 A G 4.00E-06 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs12429252 chr13 30916263 A G 4.00E-06 Fractional exhaled nitric oxide (childhood) LINC00426 intron 24315451 rs7983230 chr13 30942955 G A 9.30E-05 Serum metabolites LINC00426 intron 19043545 rs1275189 chr13 30946291 T C 2.27E-05 Serum metabolites LINC00426 intron 19043545 rs7335631 chr13 30957688 C A 2.60E-06 Subcutaneous adipose tissue volume in HIV-infected men / / 21897333 rs7335631 chr13 30957688 C A 3.24E-04 Stroke / / pha002886 rs6490455 chr13 30961468 G C 9.00E-07 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs2892545 chr13 30971421 C T 2.40E-04 Multiple complex diseases / / 17554300 rs2388540 chr13 30971582 A C 2.91E-05 Multiple complex diseases / / 17554300 rs6490460 chr13 30972664 C G 5.14E-04 Multiple complex diseases / / 17554300 rs6490461 chr13 30976845 C A 6.69E-05 Taste perception / / 22132133 rs9506307 chr13 30978056 T G 2.93E-04 Multiple complex diseases / / 17554300 rs9550565 chr13 30985522 T C 8.59E-05 Lung adenocarcinoma / / 19836008 rs1360485 chr13 31031884 C T 8.77E-05 Lymphocyte counts / / pha003094 rs1360485 chr13 31031884 C T 1.16E-05 Neutrophil count / / pha003095 rs1045411 chr13 31033232 C T 4.22E-05 Smoking initiation HMGB1 UTR-3 24665060 rs9550568 chr13 31056281 T C 2.60E-05 White blood cell types / / 21738478 rs9551929 chr13 31080015 A G 0.0000225 Polycystic ovary syndrome / / 22951595 rs9551929 chr13 31080015 A G 2.25E-05 Intracranial aneurysm / / 22961961 rs17074678 chr13 31081685 G T 5.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs17074691 chr13 31091988 C A 4.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs7983751 chr13 31094021 T A 3.37E-05 HIV-1 progression / / 20064070 rs7316941 chr13 31097316 T C 4.76E-04 Type 2 diabetes / / 17463246 rs4769841 chr13 31108727 T C 2.40E-05 Urinary metabolites / / 21572414 rs11618202 chr13 31113379 T G 7.00E-06 MRI atrophy measures / / 21116278 rs11618202 chr13 31113379 T G 8.67E-05 HDL cholesterol / / pha003075 rs11618202 chr13 31113379 T G 3.16E-05 Lipid levels / / pha003082 rs17074712 chr13 31127975 C T 3.54E-05 Multiple complex diseases / / 17554300 rs1331697 chr13 31133133 C T 1.52E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs1556428 chr13 31134432 G A 5.86E-05 Multiple complex diseases / / 17554300 rs4769041 chr13 31168109 G A 3.31E-04 Aortic root size / / 21223598 rs10507390 chr13 31259072 G A 7.43E-05 Cervical cancer / / 24700089 rs4769045 chr13 31259630 C T 3.55E-05 Cervical cancer / / 24700089 rs9743363 chr13 31263697 C T 2.50E-04 Multiple complex diseases / / 17554300 rs9743363 chr13 31263697 C T 1.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9550371 chr13 31264917 G A 5.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6490478 chr13 31276728 G T 2.56E-07 Testicular cancer / / 21551455 rs9551954 chr13 31278440 T C 1.69E-04 Multiple complex diseases / / 17554300 rs7995384 chr13 31279259 C T 1.00E-04 Prion diseases / / 22210626 rs17074937 chr13 31310225 A T 6.85E-10 Multiple complex diseases ALOX5AP intron 17554300 rs4075131 chr13 31310919 A G 4.62E-04 Iron levels ALOX5AP intron pha002876 rs17239074 chr13 31313225 C G 3.53E-08 HDL cholesterol ALOX5AP intron 23063622 rs3885907 chr13 31314455 C A 1.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU) ALOX5AP intron 24025145 rs3922435 chr13 31314680 T C 7.00E-06 Non-word repetition ALOX5AP intron 23738518 rs10162089 chr13 31316738 G A 2.66E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU) ALOX5AP intron 24025145 rs4238137 chr13 31319741 T C 4.63E-05 Non-word repetition ALOX5AP intron 23738518 rs4075692 chr13 31323342 A G 7.48E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU) ALOX5AP intron 24025145 rs9671124 chr13 31324253 T C 7.48E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU) ALOX5AP intron 24025145 rs9508835 chr13 31334698 C A 1.52E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU) ALOX5AP intron 24025145 rs9550577 chr13 31340375 G A 7.70E-07 Urinary metabolites / / 21572414 rs12872037 chr13 31371737 G A 3.47E-05 Bipolar disorder and schizophrenia / / 20889312 rs9506356 chr13 31403677 A G 6.23E-04 Depression (quantitative trait) / / 20800221 rs9508846 chr13 31408076 G A 3.95E-04 Depression (quantitative trait) / / 20800221 rs7328020 chr13 31412128 C A 4.12E-04 Depression (quantitative trait) / / 20800221 rs1125434 chr13 31427259 G A 2.46E-04 Depression (quantitative trait) / / 20800221 rs9569027 chr13 31427866 C T 2.43E-04 Depression (quantitative trait) / / 20800221 rs213587 chr13 31429657 G A 2.45E-04 Depression (quantitative trait) / / 20800221 rs1831549 chr13 31430486 T C 2.92E-04 Depression (quantitative trait) / / 20800221 rs213584 chr13 31431275 G C 2.48E-04 Depression (quantitative trait) / / 20800221 rs1999420 chr13 31431984 A G 2.55E-04 Depression (quantitative trait) / / 20800221 rs8001778 chr13 31433110 T C 2.07E-04 Myopia (pathological) / / 21095009 rs2313742 chr13 31435150 C T 6.70E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9535536 chr13 31445613 G A 5.88E-04 Amyotrophic Lateral Sclerosis LINC00545 intron 17362836 rs1331849 chr13 31484608 G T 7.01E-05 Serum metabolites C13orf33 intron 19043545 rs17600802 chr13 31512154 T C 1.40E-04 Alcohol dependence TEX26 intron 20201924 rs9535050 chr13 31603057 A G 1.72E-05 Depression (quantitative trait) / / 23290196 rs4942783 chr13 31604816 G C 1.85E-05 Depression (quantitative trait) / / 23290196 rs2312972 chr13 31605117 C T 2.18E-05 Depression (quantitative trait) / / 23290196 rs2312971 chr13 31605269 G C 1.76E-05 Depression (quantitative trait) / / 23290196 rs11147450 chr13 31606120 C T 3.18E-05 Depression (quantitative trait) / / 23290196 rs9535127 chr13 31606961 T C 4.59E-05 Depression (quantitative trait) / / 23290196 rs9596054 chr13 31607186 A G 3.04E-05 Depression (quantitative trait) / / 23290196 rs7999330 chr13 31609094 C T 5.61E-04 Myopia (pathological) / / 21095009 rs12872133 chr13 31621172 A G 9.30E-04 Rheumatoid arthritis / / 21452313 rs4142337 chr13 31623993 C G 4.29E-04 Multiple complex diseases / / 17554300 rs1571187 chr13 31642155 G A 8.37E-04 Response to TNF antagonist treatment / / 21061259 rs7996548 chr13 31642481 A T 6.67E-04 Response to TNF antagonist treatment / / 21061259 rs9591599 chr13 31661825 T C 6.90E-06 Urinary metabolites / / 21572414 rs2031725 chr13 31662077 G A 2.69E-05 Serum metabolites / / 19043545 rs17075390 chr13 31675624 G T 1.86E-04 Multiple complex diseases / / 17554300 rs9527749 chr13 31696931 A G 5.74E-04 Body mass index / / 21701565 rs7982141 chr13 31710355 C T 1.86E-14 Esophageal cancer / / 21642993 rs4943157 chr13 31726178 T C 6.56E-04 Alcohol dependence HSPH1 intron 21314694 rs11618433 chr13 31765139 C A 3.90E-06 Urinary metabolites / / 21572414 rs4941787 chr13 31767035 C T 7.16E-05 Serum metabolites / / 19043545 rs2274190 chr13 31797455 C T 5.11E-05 Alzheimer's disease B3GALTL intron 17998437 rs9542236 chr13 31819325 T C 2.00E-08 Age-related macular degeneration B3GALTL intron 23455636 rs9315120 chr13 31823589 G A 6.90E-05 Age-related macular degeneration B3GALTL intron pha002890 rs9543234 chr13 31848383 A G 2.30E-05 Urinary metabolites B3GALTL intron 21572414 rs200771119 chr13 31854617 G GC 3.59E-04 IgE levels B3GALTL intron 17255346 rs4143851 chr13 31854617 G C 3.59E-04 IgE levels B3GALTL intron 17255346 rs7327458 chr13 31854744 G A 4.33E-04 Multiple complex diseases B3GALTL intron 17554300 rs9543606 chr13 31860769 G C 1.50E-05 Urinary metabolites B3GALTL intron 21572414 rs7998271 chr13 31862334 C A 2.50E-05 Urinary metabolites B3GALTL intron 21572414 rs1995969 chr13 31874444 C T 2.70E-05 Urinary metabolites B3GALTL intron 21572414 rs9315123 chr13 31893030 T C 1.60E-05 Urinary metabolites B3GALTL intron 21572414 rs912603 chr13 31905641 G A 1.30E-06 Urinary metabolites B3GALTL UTR-3 21572414 rs2056443 chr13 31905942 T C 3.40E-06 Urinary metabolites B3GALTL UTR-3 21572414 rs13080 chr13 31906141 A C 3.90E-06 Urinary metabolites B3GALTL UTR-3 21572414 rs9545125 chr13 31911822 C T 1.90E-05 Urinary metabolites / / 21572414 rs1326308 chr13 31935616 G C 5.30E-06 Urinary metabolites / / 21572414 rs1121122 chr13 31941210 A G 5.40E-06 Urinary metabolites / / 21572414 rs9546285 chr13 31947325 T A,C,G 5.38E-05 Cytomegalovirus antibody response / / 21993531 rs7318776 chr13 31953689 G A 2.10E-05 Urinary metabolites / / 21572414 rs1571029 chr13 31958011 G A 1.74E-04 Epilepsy / / 22116939 rs1359634 chr13 31981675 T C 5.92E-06 Height / / 20400458 rs11841788 chr13 31990519 A G 3.14E-05 Major depression (suicidal thoughts and behavior) / / 21750702 rs17076005 chr13 31993213 A G 9.18E-06 Age-related macular degeneration / / 22125219 rs12584266 chr13 31994485 G A 2.80E-05 Age-related macular degeneration / / 22125219 rs1410811 chr13 32012454 T C 8.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1410811 chr13 32012454 T C 6.96E-05 Coronary heart disease / / pha003031 rs9315129 chr13 32013006 C A 6.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9547656 chr13 32013781 G A 2.90E-05 Urinary metabolites / / 21572414 rs1328949 chr13 32016433 A G 6.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17076133 chr13 32020058 A G 5.59E-04 Body mass index / / 21701565 rs489621 chr13 32027563 T C 6.10E-04 Body mass index / / 21701565 rs548399 chr13 32032045 G A 2.99E-04 Body mass index / / 21701565 rs548399 chr13 32032045 G A 8.56E-04 Body mass index / / 21701565 rs578301 chr13 32044914 A G 5.25E-04 Body mass index / / 21701565 rs17076208 chr13 32062345 G T 5.94E-05 Osteoarthritis (knee and hip) / / 21177295 rs17076208 chr13 32062345 G T 6.50E-05 Osteoarthritis (knee and hip) / / 21177295 rs2605159 chr13 32063355 G T 9.06E-05 Serum metabolites / / 19043545 rs1613660 chr13 32066605 T C 9.28E-04 HIV-1 viral setpoint / / 17641165 rs485591 chr13 32077013 T C 9.28E-04 HIV-1 viral setpoint / / 17641165 rs1119911 chr13 32081769 G A 1.09E-04 HIV-1 viral setpoint / / 17641165 rs9532094 chr13 32105873 A T 6.56E-06 Metabolite levels (MHPG) / / 23319000 rs1902272 chr13 32125315 T C 1.00E-06 Metabolite levels (HVA/MHPG ratio) / / 23319000 rs7998013 chr13 32171381 G A 5.75E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs1671970 chr13 32190263 A C 1.19E-04 Multiple complex diseases / / 17554300 rs9603395 chr13 32202333 C A 4.95E-04 Lung function (forced vital capacity) / / 24023788 rs4142296 chr13 32284393 T C 6.03E-04 Type 2 diabetes / / 17463246 rs3904063 chr13 32291079 C A 4.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs3904063 chr13 32291079 C A 3.29E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4359320 chr13 32305370 G A 6.21E-05 Lung adenocarcinoma / / 19836008 rs17076574 chr13 32326602 A G 2.13E-05 Femoral neck bone geometry RXFP2 intron 22087292 rs9548957 chr13 32327091 A G 5.72E-05 Multiple complex diseases RXFP2 intron 17554300 rs9576911 chr13 32329118 C T 2.39E-04 Multiple complex diseases RXFP2 intron 17554300 rs9549059 chr13 32351162 A C 2.73E-04 Multiple complex diseases RXFP2 intron 17554300 rs4943777 chr13 32380317 G A 2.10E-05 Urinary metabolites / / 21572414 rs17076673 chr13 32381039 G A 4.15E-04 Coronary heart disease / / 21606135 rs10492606 chr13 32383225 T C 5.28E-04 Coronary heart disease / / 21606135 rs623441 chr13 32442015 G A 5.71E-04 Multiple complex diseases EEF1DP3 intron 17554300 rs622702 chr13 32442347 A G 1.39E-04 Multiple complex diseases EEF1DP3 intron 17554300 rs12871982 chr13 32445065 A G 2.85E-04 Multiple complex diseases EEF1DP3 intron 17554300 rs4 chr13 32447222 A G 2.95E-04 Multiple complex diseases EEF1DP3 intron 17554300 rs348 chr13 32449504 G C 2.57E-04 Multiple complex diseases EEF1DP3 intron 17554300 rs362 chr13 32477206 T G 1.49E-04 Multiple complex diseases EEF1DP3 intron 17554300 rs364 chr13 32479297 T G 6.14E-04 Multiple complex diseases EEF1DP3 intron 17554300 rs370 chr13 32482344 T C 2.27E-23 Parkinson's disease EEF1DP3 intron 22438815 rs372 chr13 32485542 A G 5.28E-05 Osteoporosis EEF1DP3 intron 20548944 rs7986448 chr13 32521086 C A 1.53E-06 stroke (ischemic) EEF1DP3 intron 17434096 rs799524 chr13 32523928 T C 7.53E-04 Multiple complex diseases EEF1DP3 intron 17554300 rs439716 chr13 32571088 A C 1.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11617881 chr13 32580110 T C 6.09E-04 Alzheimer's disease / / 22005930 rs1411481 chr13 32586408 A T 9.81E-04 Alzheimer's disease / / 22005930 rs12856583 chr13 32589490 G A 8.04E-04 Alzheimer's disease / / 22005930 rs460366 chr13 32590165 A G 9.88E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs456705 chr13 32618005 T G 3.02E-04 Schizophrenia FRY intron 19197363 rs456705 chr13 32618005 T G 1.56E-04 Vaspin levels FRY intron 22907691 rs456705 chr13 32618005 T G 0.0001556 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks FRY intron 22907730 rs456053 chr13 32635763 G A 4.68E-04 Alcohol dependence FRY intron 21314694 rs9315155 chr13 32648311 C T 1.18E-05 Body Fat Distribution FRY intron pha003017 rs9315155 chr13 32648311 C T 4.21E-05 Body Fat Distribution FRY intron pha003018 rs17591593 chr13 32665969 G C 8.73E-04 Suicide attempts in bipolar disorder FRY intron 21041247 rs396150 chr13 32683609 G A 3.05E-05 Fibrinogen FRY intron pha003068 rs7331540 chr13 32710520 G C 5.00E-06 IgG glycosylation FRY intron 23382691 rs13313317 chr13 32718750 C T 2.04E-05 B cell non-Hodgkin lymphoma FRY intron 23749188 rs9315157 chr13 32744352 C T 7.77E-05 Prostate cancer FRY intron 22923026 rs798957 chr13 32764327 G A 2.61E-09 Narcolepsy FRY intron 19629137 rs9533913 chr13 32796996 C T 2.30E-05 Urinary metabolites FRY intron 21572414 rs205013 chr13 32807586 T A 2.10E-05 Urinary metabolites FRY intron 21572414 rs17635503 chr13 32849959 G C 1.60E-05 Urinary metabolites FRY intron 21572414 rs11617975 chr13 32855018 C T 8.46E-05 Schizophrenia FRY intron 24253340 rs2078326 chr13 32859674 A C 3.19E-04 Multiple complex diseases FRY intron 17554300 rs17514707 chr13 32867667 A G 6.03E-06 Multiple complex diseases FRY intron 17554300 rs17514707 chr13 32867667 A G 2.15E-05 Bipolar disorder FRY intron 18317468 rs56084662 chr13 32869864 G A 1.88E-15 Lung cancer FRY UTR-3 24880342 rs56084662 chr13 32869864 G A 4.12E-17 Lung cancer FRY UTR-3 24880342 rs9534093 chr13 32870906 G T 5.75E-06 Cortisol secretion,in saliva / / 21316860 rs206131 chr13 32875763 C T 1.10E-04 Lipid levels / / 18193043 rs1799944 chr13 32911463 A G 2.19E-04 Insulin resistance BRCA2 missense 21901158 rs206081 chr13 32922136 C T 8.45E-04 Type 2 diabetes BRCA2 intron 17463246 rs11571686 chr13 32922331 A C 2.20E-05 Urinary metabolites BRCA2 intron 21572414 rs9534275 chr13 32940345 C A 0.000000539 Cholesterol,total BRCA2 intron 23063622 rs9534275 chr13 32940345 C A 5.67E-09 LDL cholesterol BRCA2 intron 23063622 rs4942486 chr13 32953388 T C 2.00E-11 LDL cholesterol BRCA2 intron 24097068 rs11571801 chr13 32963529 C G 7.09E-04 Depression (quantitative trait) BRCA2 intron 20800221 rs11571833 chr13 32972626 A T 5.00E-08 Breast cancer BRCA2 STOP-GAIN 23535729 rs11571833 chr13 32972626 A T 6.00E-06 Breast cancer BRCA2 STOP-GAIN 23535733 rs11571833 chr13 32972626 A T 2.00E-19 Lung cancer BRCA2 STOP-GAIN 24880342 rs11571833 chr13 32972626 A T 4.66E-04 Lung cancer BRCA2 STOP-GAIN 24880342 rs11571833 chr13 32972626 A T 5.00E-20 Lung cancer BRCA2 STOP-GAIN 24880342 rs798273 chr13 33046284 A T 1.15E-04 Multiple complex diseases N4BP2L2 intron 17554300 rs9315167 chr13 33069188 C T 4.76E-05 Brain structure N4BP2L2 intron 22504417 rs2010997 chr13 33070506 G A 5.60E-04 Depression (quantitative trait) N4BP2L2 intron 20800221 rs743760 chr13 33071127 G C 1.84E-05 Brain structure N4BP2L2 intron 22504417 rs718444 chr13 33147052 C T 2.00E-10 Height / / 23563607 rs7332115 chr13 33147548 T G 6.00E-10 Height / / 20881960 rs208418 chr13 33154022 C T 3.42E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs208418 chr13 33154022 C T 1.12E-04 Multiple complex diseases / / 17554300 rs7331393 chr13 33221202 C T 3.40E-04 Multiple complex diseases PDS5B intron 17554300 rs687416 chr13 33256987 C T 9.44E-05 Multiple complex diseases PDS5B intron 17554300 rs597860 chr13 33277626 C T 1.80E-05 Multiple complex diseases PDS5B intron 17554300 rs4942925 chr13 33381244 T C 5.71E-05 Neuroblastoma / / pha002895 rs990324 chr13 33387246 A G 5.00E-06 Total ventricular volume / / 21116278 rs990324 chr13 33387246 A G 2.00E-05 Alcoholism (heaviness of drinking) / / 21529783 rs2320611 chr13 33395373 G A 1.74E-04 Alzheimer's disease (late onset) / / 21379329 rs17077917 chr13 33412453 T G 1.77E-05 Multiple complex diseases / / 17554300 rs9535576 chr13 33449863 C T 2.60E-05 Urinary metabolites / / 21572414 rs2147356 chr13 33474475 G T 3.45E-05 Insulin-related traits / / pha003063 rs2320761 chr13 33483294 C T 6.29E-04 Diabetic retinopathy / / 20871662 rs9535698 chr13 33490553 C T 9.35E-04 Multiple complex diseases / / 17554300 rs211230 chr13 33511498 A G 4.42E-05 Personality dimensions / / 22628180 rs9568660 chr13 33511789 A T 1.10E-05 Iron levels / / 21208937 rs9568680 chr13 33536199 C T 9.49E-04 Multiple complex diseases / / 17554300 rs378609 chr13 33553549 A C 9.07E-04 White matter integrity / / 22425255 rs576674 chr13 33554302 G A 5.14E-10 Fasting blood glucose / / 22885924 rs518306 chr13 33555320 T C 5.18E-04 Response to alcohol consumption (flushing response) / / 24277619 rs527337 chr13 33561520 G A 3.20E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs495392 chr13 33592193 C A 5.02E-04 Amyotrophic Lateral Sclerosis KL intron 17362836 rs575536 chr13 33592777 T C 1.36E-04 Breast cancer KL intron 21060860 rs480780 chr13 33607319 G T 0.0000463 LDL cholesterol KL intron 23063622 rs480780 chr13 33607319 G T 0.000053 Cholesterol,total KL intron 23063622 rs472875 chr13 33614046 A G 2.42E-13 Cholesterol,total KL intron 23063622 rs472875 chr13 33614046 A G 2.62E-15 LDL cholesterol KL intron 23063622 rs649964 chr13 33635835 T C 4.72E-14 LDL cholesterol KL cds-synon 23063622 rs649964 chr13 33635835 T C 6.15E-11 Cholesterol,total KL cds-synon 23063622 rs9536357 chr13 33651505 G A 5.10E-05 Schizophrenia / / 19571809 rs9536357 chr13 33651505 G A 3.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs523086 chr13 33666174 A G 8.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs521247 chr13 33666380 A G 9.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs642899 chr13 33680854 T G 3.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) STARD13 intron 20877124 rs642899 chr13 33680854 T G 8.00E-06 Behavioural disinhibition (generation interaction) STARD13 intron 23942779 rs9315204 chr13 33693837 C T 3.00E-09 Intracranial aneurysm STARD13 intron 20364137 rs17596576 chr13 33699982 C T 9.65E-05 Cognitive test performance STARD13 intron 20125193 rs1980781 chr13 33700374 T G 2.60E-09 Intracranial aneurysm STARD13 cds-synon 20364137 rs1980781 chr13 33700374 T G 9.52E-05 Intracranial aneurysm STARD13 cds-synon 22286173 rs3742321 chr13 33704065 T C 6.10E-09 Intracranial aneurysm STARD13 missense 20364137 rs2764615 chr13 33706354 C T 1.80E-04 HDL particle features STARD13 intron 21283740 rs523656 chr13 33720840 G A 7.08E-04 Body mass index STARD13 intron 21701565 rs2858809 chr13 33720890 C T 6.97E-04 Body mass index STARD13 intron 21701565 rs12863103 chr13 33723244 C T 8.26E-04 Body mass index STARD13 intron 21701565 rs9536548 chr13 33723786 C T 8.71E-04 Body mass index STARD13 intron 21701565 rs7329549 chr13 33745358 A G 3.40E-04 Suicide attempts in bipolar disorder STARD13 intron 21423239 rs12874557 chr13 33746529 T C 6.39E-04 Body mass index STARD13 intron 21701565 rs2555607 chr13 33754516 C T 3.48E-04 Suicide attempts in bipolar disorder STARD13 intron 21423239 rs9527178 chr13 33755260 C T 5.40E-04 Suicide attempts in bipolar disorder STARD13 intron 21423239 rs2555616 chr13 33756472 A G 5.08E-04 Suicide attempts in bipolar disorder STARD13 intron 21423239 rs797212 chr13 33756612 C T 4.38E-04 Body mass index STARD13 intron 21701565 rs2764629 chr13 33756837 G C 5.79E-04 Suicide attempts in bipolar disorder STARD13 intron 21423239 rs2858124 chr13 33756859 T C 7.39E-04 Suicide attempts in bipolar disorder STARD13 intron 21423239 rs797199 chr13 33768347 C T 6.83E-04 Myopia (pathological) STARD13 intron 21095009 rs7332950 chr13 33772323 A T 3.58E-04 Suicide attempts in bipolar disorder STARD13 intron 21423239 rs797195 chr13 33772511 A C,G,T 6.79E-04 Suicide attempts in bipolar disorder STARD13 intron 21423239 rs2555592 chr13 33776903 T G 9.45E-10 HDL cholesterol STARD13 intron 23063622 rs2764627 chr13 33777078 C T 1.17E-08 HDL cholesterol STARD13 intron 23063622 rs2555603 chr13 33798262 A C 3.00E-06 Body mass index (asthmatics) STARD13 intron 23517042 rs2555595 chr13 33825641 T C 1.30E-05 Body mass index (asthmatics) STARD13 intron 23517042 rs17597497 chr13 33826644 T C 5.06E-05 Post-operative nausea and vomiting STARD13 intron 21694509 rs7328838 chr13 33832867 A G 5.15E-04 Alzheimer's disease STARD13 intron 17998437 rs2555605 chr13 33833810 C T 3.49E-04 Parkinson's disease STARD13 intron 17052657 rs9527307 chr13 33842296 A G 4.16E-05 Serum metabolites STARD13 intron 19043545 rs4943086 chr13 33843317 G A 3.91E-05 Serum metabolites STARD13 intron 19043545 rs6561812 chr13 33843642 G T 3.69E-05 Serum metabolites STARD13 intron 19043545 rs2321168 chr13 33853491 G A 0.00000044 Cholesterol,total STARD13 intron 23063622 rs2321168 chr13 33853491 G A 0.000000906 Triglycerides STARD13 intron 23063622 rs2321168 chr13 33853491 G A 6.97E-09 LDL cholesterol STARD13 intron 23063622 rs6561821 chr13 33861185 A T 0.000001 Triglycerides STARD13 intron 23063622 rs2321162 chr13 33887121 G A 2.09E-04 Multiple complex diseases STARD13 intron 17554300 rs7992367 chr13 33893065 A G 5.65E-04 Multiple complex diseases STARD13 intron 17554300 rs7323268 chr13 33909738 C T 9.57E-06 Post-operative nausea and vomiting STARD13 intron 21694509 rs9537312 chr13 33942308 T C 4.41E-05 Post-operative nausea and vomiting STARD13 intron 21694509 rs570336 chr13 33945349 G A 4.98E-05 Waist-Hip Ratio STARD13 intron pha003013 rs570336 chr13 33945349 G A 5.93E-05 Waist-Hip Ratio STARD13 intron pha003028 rs9597332 chr13 33947222 T C 6.44E-07 Post-operative nausea and vomiting STARD13 intron 21694509 rs500813 chr13 33948936 G A 9.59E-05 Waist-Hip Ratio STARD13 intron pha003028 rs9597353 chr13 33956690 C T 2.56E-05 Post-operative nausea and vomiting STARD13 intron 21694509 rs525633 chr13 33957317 G T 2.37E-05 Waist-Hip Ratio STARD13 intron pha003013 rs525633 chr13 33957317 G T 1.62E-05 Waist-Hip Ratio STARD13 intron pha003028 rs7334982 chr13 33973109 A C 9.15E-06 Alopecia areata STARD13 intron 22027810 rs9527554 chr13 34025577 A G 1.15E-04 Schizophrenia STARD13 intron 20832056 rs9527555 chr13 34025997 G C 1.03E-04 Schizophrenia STARD13 intron 20832056 rs9315215 chr13 34043750 C T 1.41E-04 Schizophrenia STARD13 intron 20832056 rs12858634 chr13 34084052 C T 5.00E-04 Schizophrenia STARD13 intron 20832056 rs10507408 chr13 34088583 A G 5.39E-05 Bipolar disorder STARD13 intron 21771265 rs9597687 chr13 34157288 A C 7.99E-05 C-Reactive Protein STARD13 intron pha003070 rs7333539 chr13 34216530 T C 6.17E-05 Potassium levels STARD13 intron pha003086 rs8001893 chr13 34222261 C A 7.00E-06 Plasma amyloid beta peptide concentrations (ABx-40) STARD13 intron 24535457 rs4943130 chr13 34236716 C T 2.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) STARD13 intron 20877124 rs9570045 chr13 34250002 G T 2.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) STARD13 intron 20877124 rs7999869 chr13 34262060 C T 6.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9538443 chr13 34291462 C A 9.66E-04 Rheumatoid arthritis / / 21452313 rs12429186 chr13 34292278 T C 5.21E-09 Non-obstructive azoospermia / / 22197933 rs2182058 chr13 34293117 T A 5.26E-06 Personality dimensions / / 22628180 rs9315242 chr13 34297026 T C 4.36E-06 Personality dimensions / / 22628180 rs9598025 chr13 34297290 G C 4.36E-06 Personality dimensions / / 22628180 rs9598026 chr13 34297324 T C 4.10E-06 Personality dimensions / / 22628180 rs9598027 chr13 34297478 C A 4.09E-06 Personality dimensions / / 22628180 rs9598029 chr13 34297679 A C 4.13E-06 Personality dimensions / / 22628180 rs9592004 chr13 34297704 A G 4.10E-06 Personality dimensions / / 22628180 rs10507414 chr13 34297843 C G 4.20E-06 Personality dimensions / / 22628180 rs7318085 chr13 34298055 C T 4.25E-06 Personality dimensions / / 22628180 rs7319180 chr13 34298295 A G 4.25E-06 Personality dimensions / / 22628180 rs17079650 chr13 34298499 T C 4.20E-06 Personality dimensions / / 22628180 rs9592005 chr13 34302574 G A 4.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs4943142 chr13 34315815 T C 9.20E-05 Cognitive performance / / 19734545 rs12870296 chr13 34316191 T C 5.83E-04 Body mass index / / 21701565 rs9598051 chr13 34318946 A C 2.69E-04 Endometrial cancer / / 24096698 rs2321482 chr13 34319615 T C 8.52E-04 Body mass index / / 21701565 rs1925093 chr13 34319806 C A 8.64E-04 Body mass index / / 21701565 rs9598060 chr13 34325075 C T 6.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs4491372 chr13 34326329 T A 1.00E-05 Urinary metabolites / / 21572414 rs9315248 chr13 34347961 C T 0.0000431 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1543551 chr13 34362526 G A 6.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1543551 chr13 34362526 G A 0.0000461 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1158807 chr13 34394716 C T 3.30E-05 Immunoglobulin A RFC3 intron 20694011 rs9315265 chr13 34465685 A G 3.34E-04 Suicide attempts in bipolar disorder RFC3 intron 21423239 rs7990589 chr13 34509069 A G 5.50E-06 Iron levels RFC3 intron 21208937 rs2321744 chr13 34606186 A G 1.00E-09 Venous thromboembolism (gene x gene interaction) / / 23509962 rs12857276 chr13 34622773 C A 2.32E-04 Insulin resistance / / 21901158 rs692423 chr13 34645141 T C 1.21E-05 Sarcoidosis / / 19165924 rs690705 chr13 34654918 A G 6.00E-07 Alzheimer's Disease / / 20061627 rs581738 chr13 34688581 A C 3.33E-05 Hypertension (early onset hypertension) / / 22479346 rs9539828 chr13 34703592 G T 6.48E-04 Multiple complex diseases / / 17554300 rs7335534 chr13 34710780 A G 9.70E-05 Systemic sclerosis / / 21750679 rs11147544 chr13 34716493 A G 8.26E-05 Systemic sclerosis / / 21750679 rs4559793 chr13 34720412 G A 1.66E-04 Hearing function / / 17255346 rs8002785 chr13 34723850 A T 0.00000961 LDL cholesterol particle diameter / / 23263444 rs12876644 chr13 34725977 T C 0.0000151 LDL cholesterol particle diameter / / 23263444 rs4142811 chr13 34726266 G A 0.0000137 LDL cholesterol particle diameter / / 23263444 rs8181839 chr13 34728853 C T 0.0000105 LDL cholesterol particle diameter / / 23263444 rs9528685 chr13 34731033 T C 3.42E-05 Left ventricular hypertrophy / / pha003052 rs1538005 chr13 34760437 C T 3.55E-04 Sudden cardiac arrest / / 21658281 rs12871148 chr13 34818128 A G 1.40E-05 Urinary metabolites / / 21572414 rs9528836 chr13 34826872 G T 2.30E-05 Urinary metabolites / / 21572414 rs9528836 chr13 34826872 G T 4.54E-05 Coronary heart disease / / pha003055 rs9528837 chr13 34827563 G A 4.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs1337953 chr13 34830822 G A 3.08E-05 Caffeine consumption / / 21490707 rs9540308 chr13 34840523 A C 5.64E-04 Multiple complex diseases / / 17554300 rs7998020 chr13 34842610 G A 1.64E-04 Multiple complex diseases / / 17554300 rs7998435 chr13 34842840 G A 1.39E-04 Coronary Artery Disease / / 17634449 rs12584484 chr13 34843895 C T 6.13E-04 Multiple complex diseases / / 17554300 rs1415838 chr13 34862570 T A 9.06E-04 Multiple complex diseases / / 17554300 rs9540467 chr13 34893493 A G 6.79E-04 Smoking initiation / / 24665060 rs492452 chr13 34894789 A G 7.00E-06 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs571411 chr13 34903092 G A 3.00E-06 Obesity-related traits / / 23251661 rs627871 chr13 34906055 C A 3.00E-06 Obesity-related traits / / 23251661 rs2787087 chr13 34908957 G A 9.19E-05 Caffeine consumption / / 21490707 rs683203 chr13 34927803 T C 4.50E-06 Obesity-related traits / / 23251661 rs17798800 chr13 34950527 C T 7.00E-06 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs12184559 chr13 34958770 C T 8.66E-04 Stroke / / pha002886 rs7996007 chr13 35023246 T G 8.41E-20 Multiple complex diseases / / 17554300 rs11147551 chr13 35028367 T C 1.13E-04 Cholesterol / / 17255346 rs11147551 chr13 35028367 T C 1.22E-04 Type 2 diabetes / / 17463246 rs17744902 chr13 35045552 C T 1.30E-05 Urinary metabolites / / 21572414 rs17744902 chr13 35045552 C T 1.09E-08 Metabolite levels / / 23281178 rs9315301 chr13 35078238 A G 1.60E-04 Prion diseases / / 22210626 rs9541148 chr13 35095884 C T 9.59E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs9541148 chr13 35095884 C T 6.73E-05 Obsessive-compulsive disorder / / 24821223 rs9541148 chr13 35095884 C T 6.73E-05 Obsessive-compulsive disorder / / 24821223 rs9541193 chr13 35104243 T C 1.54E-04 Cholesterol / / 17255346 rs1410950 chr13 35127983 C T 7.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7325039 chr13 35168608 G A 7.36E-04 Type 2 diabetes / / 17463246 rs9541338 chr13 35177997 C T 6.21E-08 QT interval / / 19587794 rs9592551 chr13 35179080 T A 6.19E-08 QT interval / / 19587794 rs9541373 chr13 35186415 C T 1.50E-07 QT interval / / 19587794 rs885170 chr13 35197789 A G 1.83E-08 QT interval / / 19587794 rs7337690 chr13 35204094 A G 4.42E-05 Orofacial clefts / / 22419666 rs9529408 chr13 35209520 G A 1.10E-07 QT interval / / 19587794 rs12583395 chr13 35219778 A G 9.50E-04 Suicidal ideation / / 22030708 rs12583395 chr13 35219778 A G 7.30E-05 Coronary heart disease / / pha003031 rs1396311 chr13 35268730 G T 4.20E-05 Multiple complex diseases / / 17554300 rs1876582 chr13 35283075 A G 6.28E-04 Multiple complex diseases / / 17554300 rs1876582 chr13 35283075 A G 9.00E-06 Urinary metabolites / / 21572414 rs17081694 chr13 35296729 T C 2.10E-05 Urinary metabolites / / 21572414 rs9541976 chr13 35297304 T C 5.24E-05 HIV-1 control / / 20041166 rs9564594 chr13 35313501 C T 2.52E-04 Stroke / / pha002887 rs4943253 chr13 35347598 G A 3.00E-05 Rheumatoid arthritis / / 22446963 rs10492728 chr13 35362120 T G 3.61E-04 Multiple complex diseases / / 17554300 rs7999583 chr13 35371071 C A 1.30E-05 Urinary metabolites / / 21572414 rs3858858 chr13 35371738 G A 1.20E-05 Urinary metabolites / / 21572414 rs2322384 chr13 35412895 C T 2.64E-06 Nasopharyngeal carcinoma / / 23209447 rs4943278 chr13 35426782 T C 1.85E-06 Nasopharyngeal carcinoma / / 23209447 rs7321462 chr13 35448362 C T 9.20E-05 HIV-1 control / / 20041166 rs9572720 chr13 35473956 G A 3.26E-05 Bipolar disorder / / 18317468 rs9572720 chr13 35473956 G A 7.44E-04 Obesity (extreme) / / 21935397 rs17051776 chr13 35540656 A G 2.99E-05 Cardiovascular disease NBEA intron 22029572 rs7332133 chr13 35573743 T A 7.73E-04 Obesity (extreme) NBEA intron 21935397 rs79498400 chr13 35573743 T TA 7.73E-04 Obesity (extreme) NBEA intron 21935397 rs7996851 chr13 35584132 G A 9.99E-05 Cognitive impairment induced by topiramate NBEA intron 22091778 rs9543028 chr13 35603879 A G 6.60E-05 Hemoglobin NBEA intron pha003098 rs17051917 chr13 35768789 C T 9.00E-06 Migraine with aura NBEA intron 23793025 rs9600364 chr13 35808182 T C 7.00E-05 Body mass index NBEA intron 22446040 rs10129134 chr13 35811439 C T 2.96E-05 Body mass index NBEA intron 22446040 rs2247674 chr13 35875125 T A 4.80E-05 Cognitive function NBEA intron 24684796 rs1197850 chr13 35930744 T G 4.57E-05 Blood Pressure and Arterial Stiffness NBEA intron 17903302 rs486056 chr13 35937802 C G 4.27E-04 Multiple complex diseases NBEA intron 17554300 rs1197852 chr13 35950999 G A 5.61E-04 Multiple complex diseases NBEA intron 17554300 rs9544180 chr13 35953882 G A 9.75E-04 Obesity (extreme) NBEA intron 21935397 rs1461968 chr13 35970655 T C 9.81E-04 Obesity (extreme) NBEA intron 21935397 rs12100100 chr13 36026484 A G 1.35E-04 Multiple complex diseases NBEA intron 17554300 rs9544427 chr13 36054972 C T 7.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NBEA intron 20877124 rs7332116 chr13 36078427 C A 1.98E-05 Alcohol and nictotine co-dependence NBEA intron 20158304 rs7333310 chr13 36080957 T C 0.0007177 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBEA intron 23233654 rs7333310 chr13 36080957 T C 7.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBEA intron 23233662 rs4500591 chr13 36081260 G A 1.97E-04 Suicide attempts in bipolar disorder NBEA intron 21423239 rs9530648 chr13 36081432 C T 9.45E-04 Multiple complex diseases NBEA intron 17554300 rs9530648 chr13 36081432 C T 5.00E-06 Parkinson's disease (familial) NBEA intron 18985386 rs9530649 chr13 36081750 A G 9.61E-04 Iron levels NBEA intron pha002876 rs9600885 chr13 36082762 G A 3.66E-04 Suicide attempts in bipolar disorder NBEA intron 21423239 rs17052316 chr13 36087703 G A 8.43E-05 Prostate cancer NBEA intron 22923026 rs981386 chr13 36089537 A G 7.95E-04 Iron levels NBEA intron pha002876 rs12871823 chr13 36089568 G C 4.14E-04 Suicide attempts in bipolar disorder NBEA intron 21423239 rs1381479 chr13 36090680 T C 6.44E-04 Multiple complex diseases NBEA intron 17554300 rs1381479 chr13 36090680 T C 3.87E-04 Suicide attempts in bipolar disorder NBEA intron 21423239 rs7337804 chr13 36102523 T C 4.88E-05 Prostate cancer NBEA intron 22923026 rs4143549 chr13 36108184 T C 5.80E-04 Type 2 diabetes NBEA intron 17463246 rs7999690 chr13 36109202 G A 3.40E-04 Suicide attempts in bipolar disorder NBEA intron 21423239 rs9574135 chr13 36144078 A C 0.0001058 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBEA intron 23233654 rs9574135 chr13 36144078 A C 1.06E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBEA intron 23233662 rs9574151 chr13 36150959 C A 0.0002581 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBEA intron 23233654 rs9574151 chr13 36150959 C A 2.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBEA intron 23233662 rs9574161 chr13 36153969 G T 0.0001914 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBEA intron 23233654 rs9574161 chr13 36153969 G T 1.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBEA intron 23233662 rs1777670 chr13 36154966 A G 4.31E-04 Stroke NBEA intron pha002887 rs9565383 chr13 36155684 G A 0.0001924 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBEA intron 23233654 rs9565383 chr13 36155684 G A 1.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBEA intron 23233662 rs9574172 chr13 36156587 C G 0.0001936 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBEA intron 23233654 rs9574172 chr13 36156587 C G 1.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBEA intron 23233662 rs9565388 chr13 36157004 C G 0.0001946 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBEA intron 23233654 rs9565388 chr13 36157004 C G 1.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBEA intron 23233662 rs9565391 chr13 36159159 T G 0.0001965 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBEA intron 23233654 rs9565391 chr13 36159159 T G 1.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBEA intron 23233662 rs9565392 chr13 36159265 C T 0.0001972 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBEA intron 23233654 rs9565392 chr13 36159265 C T 1.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBEA intron 23233662 rs9574203 chr13 36164985 G A 0.0002077 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBEA intron 23233654 rs9574203 chr13 36164985 G A 2.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) NBEA intron 23233662 rs17052477 chr13 36165618 A G 6.05E-04 Multiple complex diseases NBEA intron 17554300 rs2798337 chr13 36172282 A G 0.0000778 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NBEA intron 23233654 rs2798337 chr13 36172282 A G 7.78E-05 Methotrexate clearance (acute lymphoblastic leukemia) NBEA intron 23233662 rs1777672 chr13 36177819 G A 4.00E-07 HIV-1 control NBEA intron 20041166 rs9574250 chr13 36188957 C T 9.68E-04 Multiple complex diseases NBEA intron 17554300 rs3794392 chr13 36224934 T C 4.15E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) NBEA intron 24023788 rs17769531 chr13 36229300 A G 3.98E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) NBEA intron 24023788 rs445435 chr13 36279556 G A 1.36E-05 Lipoproteins / / pha003079 rs9530931 chr13 36292676 C T 4.34E-04 Multiple complex diseases / / 17554300 rs9530931 chr13 36292676 C T 0.00006657 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9530931 chr13 36292676 C T 8.73E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9545131 chr13 36292809 C T 4.88E-04 Type 2 diabetes / / 17463246 rs4635204 chr13 36310309 A C 7.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs12429464 chr13 36314627 C T 4.27E-07 Hearing function / / 21493956 rs9574464 chr13 36314793 A G 3.18E-07 Hearing function / / 21493956 rs9574471 chr13 36316940 T C 9.96E-07 Hearing function / / 21493956 rs9574474 chr13 36317379 T C 1.00E-06 Hearing function / / 21493956 rs9574476 chr13 36317647 T C 9.88E-07 Hearing function / / 21493956 rs7317552 chr13 36318804 C T 1.70E-05 Urinary metabolites / / 21572414 rs6563133 chr13 36318869 G A 5.38E-06 Hearing function / / 21493956 rs9574482 chr13 36319556 G A 2.22E-06 Hearing function / / 21493956 rs9574483 chr13 36319579 C T 1.02E-06 Hearing function / / 21493956 rs7328278 chr13 36351766 A C 3.00E-06 Asthma (childhood onset) DCLK1 intron 22560479 rs2182486 chr13 36367082 T C 2.90E-05 Urinary metabolites DCLK1 intron 21572414 rs12855118 chr13 36372410 C T 8.34E-04 Alzheimer's disease DCLK1 intron 22005930 rs10507430 chr13 36377977 A G 4.13E-04 Multiple complex diseases DCLK1 intron 17554300 rs9545532 chr13 36408524 T C 3.31E-04 Multiple complex diseases DCLK1 intron 17554300 rs10507433 chr13 36424698 C T 1.47E-04 Schizophrenia DCLK1 UTR-3 19197363 rs10507433 chr13 36424698 C T 3.09E-04 Stroke DCLK1 UTR-3 22306652 rs12427459 chr13 36437371 C T 8.07E-05 Cognitive test performance DCLK1 intron 20125193 rs10507434 chr13 36440404 G C 2.30E-05 Urinary metabolites DCLK1 intron 21572414 rs10507435 chr13 36440996 A G 9.69E-04 Stroke DCLK1 intron pha002887 rs12428086 chr13 36441099 T C 5.00E-06 Obesity-related traits DCLK1 intron 23251661 rs11838747 chr13 36443674 G T 4.62E-06 Obesity-related traits DCLK1 intron 23251661 rs17786591 chr13 36444633 A C 2.97E-05 Personality dimensions DCLK1 intron 18957941 rs1539549 chr13 36451881 C T 2.88E-05 Attention deficit hyperactivity disorder DCLK1 intron 18980221 rs1539549 chr13 36451881 C T 2.28E-05 Attention deficit hyperactivity disorder DCLK1 intron pha002875 rs1750921 chr13 36452069 A G 1.00E-04 Information processing speed DCLK1 intron 21130836 rs4941822 chr13 36453613 C A 1.82E-05 Acute lung injury DCLK1 intron 22295056 rs4943350 chr13 36453860 C T 1.82E-05 Acute lung injury DCLK1 intron 22295056 rs4941823 chr13 36453926 A G 4.13E-05 Acute lung injury DCLK1 intron 22295056 rs2051090 chr13 36454193 G A 2.73E-05 Information processing speed DCLK1 intron 21130836 rs2051090 chr13 36454193 G A 1.82E-05 Acute lung injury DCLK1 intron 22295056 rs2051090 chr13 36454193 G A 7.00E-06 Non-alcoholic fatty liver disease DCLK1 intron 23535911 rs1936002 chr13 36456084 C T 2.73E-05 Information processing speed DCLK1 intron 21130836 rs1936002 chr13 36456084 C T 2.12E-05 Acute lung injury DCLK1 intron 22295056 rs9545602 chr13 36456503 T C 2.11E-05 Acute lung injury DCLK1 intron 22295056 rs9545604 chr13 36456942 C T 2.11E-05 Acute lung injury DCLK1 intron 22295056 rs9531159 chr13 36470336 T A 3.01E-05 Personality dimensions DCLK1 intron 22628180 rs9531159 chr13 36470336 T A 0.0000193 LDL cholesterol particle diameter DCLK1 intron 23263444 rs9315372 chr13 36471289 A G 5.80E-05 Height DCLK1 intron 21998595 rs7327576 chr13 36473631 G A 9.63E-04 Acute lung injury DCLK1 intron 22295056 rs6563210 chr13 36476447 A G 7.00E-07 Height DCLK1 intron 21998595 rs17053131 chr13 36479998 C T 8.15E-04 Acute lung injury DCLK1 intron 22295056 rs6563212 chr13 36482415 A G 7.30E-04 Biomarkers DCLK1 intron 17903293 rs1539542 chr13 36484253 A T 1.30E-05 Height DCLK1 intron 21998595 rs2182487 chr13 36484951 C G 4.10E-06 Height DCLK1 intron 21998595 rs1171057 chr13 36497808 C A 6.60E-06 Urinary metabolites DCLK1 intron 21572414 rs1891670 chr13 36523209 C T 3.73E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) DCLK1 intron 24023788 rs34065801 chr13 36531548 T C 6.00E-06 Breast size DCLK1 intron 22747683 rs9545925 chr13 36535192 G T 3.43E-04 Alcohol dependence DCLK1 intron 20201924 rs1547838 chr13 36538197 A G 7.01E-04 Multiple complex diseases DCLK1 intron 17554300 rs9531273 chr13 36539003 A G 4.86E-04 Multiple complex diseases DCLK1 intron 17554300 rs913071 chr13 36553105 C T 5.17E-05 Amyotrophic lateral sclerosis (sporadic) DCLK1 intron 24529757 rs4275732 chr13 36554724 G C 1.30E-06 Urinary metabolites DCLK1 intron 21572414 rs9546021 chr13 36560485 T G 1.40E-06 Urinary metabolites DCLK1 intron 21572414 rs9546063 chr13 36574007 G A 8.00E-04 Intelligence (childhood) DCLK1 intron 23358156 rs9575140 chr13 36597522 C T 5.00E-05 Prostate cancer DCLK1 intron 21743057 rs1171004 chr13 36607771 A G 3.77E-04 Response to cytadine analogues (cytosine arabinoside) DCLK1 intron 24483146 rs1750719 chr13 36615408 G T 9.30E-05 Malaria DCLK1 intron 19465909 rs1750719 chr13 36615408 G T 9.13E-04 Response to cytadine analogues (cytosine arabinoside) DCLK1 intron 24483146 rs7982504 chr13 36642023 T A 6.57E-04 Nicotine smoking DCLK1 intron 19268276 rs7323428 chr13 36643601 G T 6.02E-04 Response to cytadine analogues (cytosine arabinoside) DCLK1 intron 24483146 rs1926318 chr13 36644142 C T 7.53E-04 Response to cytadine analogues (cytosine arabinoside) DCLK1 intron 24483146 rs7330329 chr13 36644724 G T 9.62E-04 Response to cytadine analogues (cytosine arabinoside) DCLK1 intron 24483146 rs1159388 chr13 36646706 G T 6.61E-05 Response to cytadine analogues (cytosine arabinoside) DCLK1 intron 24483146 rs1157599 chr13 36651792 G C 2.05E-04 Response to cytadine analogues (cytosine arabinoside) DCLK1 intron 24483146 rs1926320 chr13 36652617 T C 1.00E-08 Vertical cup-disc ratio DCLK1 intron 20548946 rs7331892 chr13 36653923 G T 3.99E-04 Response to cytadine analogues (cytosine arabinoside) DCLK1 intron 24483146 rs9575257 chr13 36659784 G A 2.53E-04 Response to cytadine analogues (cytosine arabinoside) DCLK1 intron 24483146 rs9315385 chr13 36663302 T G 8.00E-06 Heart rate variability traits DCLK1 intron 17903306 rs9315385 chr13 36663302 T G 3.98E-05 Longevity DCLK1 intron 21612516 rs7989154 chr13 36667442 G T 6.70E-04 Response to cytadine analogues (cytosine arabinoside) DCLK1 intron 24483146 rs9531436 chr13 36674859 C T 9.34E-04 Amyotrophic Lateral Sclerosis DCLK1 intron 17362836 rs7994174 chr13 36675018 G A 6.66E-04 Response to cytidine analogues (gemcitabine) DCLK1 intron 24483146 rs7984436 chr13 36696255 A T 3.76E-04 Response to cytadine analogues (cytosine arabinoside) DCLK1 intron 24483146 rs6563354 chr13 36696494 C T 3.92E-04 Alcohol dependence DCLK1 intron 20201924 rs1328652 chr13 36709527 C T 9.42E-04 Multiple complex diseases / / 17554300 rs1328650 chr13 36712330 G T 1.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs1328650 chr13 36712330 G T 7.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1410642 chr13 36712717 G A 7.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs9531504 chr13 36712972 A G 5.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs1328649 chr13 36713251 C G 3.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs7336271 chr13 36719923 G A 9.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs1887829 chr13 36721724 A G 8.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs9565886 chr13 36724777 A T 3.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs9575416 chr13 36724919 C T 4.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs1928018 chr13 36729694 G C 2.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs9315391 chr13 36731309 C A 1.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs7322400 chr13 36736825 G C 1.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs1410637 chr13 36736992 A G 6.08E-05 Suicide attempts in bipolar disorder / / 21423239 rs12861843 chr13 36740422 T C 1.29E-05 Cognitive test performance / / 20125193 rs943896 chr13 36741698 G T 2.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs9546567 chr13 36742906 T C 2.32E-04 Suicide attempts in bipolar disorder SOHLH2 UTR-3 21423239 rs9546567 chr13 36742906 T C 2.06E-04 Insulin resistance SOHLH2 UTR-3 21901158 rs9602362 chr13 36743638 C T 2.56E-04 Suicide attempts in bipolar disorder SOHLH2 intron 21423239 rs1556059 chr13 36743924 C T 2.57E-04 Suicide attempts in bipolar disorder SOHLH2 intron 21423239 rs9602371 chr13 36747240 A G 2.15E-04 Suicide attempts in bipolar disorder SOHLH2 intron 21423239 rs9602375 chr13 36749756 G A 2.39E-04 Suicide attempts in bipolar disorder SOHLH2 intron 21423239 rs7331697 chr13 36763345 G A 1.39E-04 Suicide attempts in bipolar disorder SOHLH2 intron 21423239 rs7327064 chr13 36771017 C T 1.47E-04 Suicide attempts in bipolar disorder SOHLH2 intron 21423239 rs7327064 chr13 36771017 C T 6.00E-06 Economic and political preferences SOHLH2 intron 22566634 rs9546652 chr13 36773131 C A 1.70E-04 Suicide attempts in bipolar disorder SOHLH2 intron 21423239 rs6563389 chr13 36777536 A G 2.11E-04 Suicide attempts in bipolar disorder SOHLH2 intron 21423239 rs7317820 chr13 36781831 C T 2.45E-04 Suicide attempts in bipolar disorder SOHLH2 intron 21423239 rs9546679 chr13 36783233 A T 1.96E-04 Suicide attempts in bipolar disorder SOHLH2 intron 21423239 rs11617600 chr13 36783312 C T 9.32E-05 Blood Pressure SOHLH2 intron pha003044 rs1328655 chr13 36783569 A G 1.77E-04 Suicide attempts in bipolar disorder SOHLH2 intron 21423239 rs7994245 chr13 36783888 C T 1.32E-04 Suicide attempts in bipolar disorder SOHLH2 intron 21423239 rs13378730 chr13 36784800 T C 2.40E-04 Suicide attempts in bipolar disorder SOHLH2 intron 21423239 rs1170932 chr13 36813522 C A 7.09E-04 Multiple complex diseases CCDC169 intron 17554300 rs11842927 chr13 36823731 A G 5.82E-04 Multiple complex diseases CCDC169 intron 17554300 rs11147600 chr13 36830371 C T 6.44E-04 Multiple complex diseases CCDC169 intron 17554300 rs11620284 chr13 36837987 C A 1.45E-06 Waist Circumference CCDC169 intron pha003023 rs9575700 chr13 36837999 C T 6.45E-04 Response to cytadine analogues (cytosine arabinoside) CCDC169 intron 24483146 rs912927 chr13 36848187 T C 8.20E-06 Crohn's disease CCDC169 intron 20570966 rs7334585 chr13 36875496 T G 1.36E-05 Cognitive test performance SPG20 nearGene-3 20125193 rs2025647 chr13 36937156 T A 3.47E-04 Suicide attempts in bipolar disorder SPG20 intron 21423239 rs78022293 chr13 36937156 T TA 3.47E-04 Suicide attempts in bipolar disorder SPG20 intron 21423239 rs9547461 chr13 36937681 A G 3.24E-05 Waist Circumference SPG20 intron pha003023 rs10514840 chr13 37031396 G T 9.91E-04 Type 2 diabetes / / 17463246 rs9315420 chr13 37033415 A G 9.49E-05 Tunica Media / / pha003036 rs9315422 chr13 37055511 T G 1.20E-05 Urinary metabolites / / 21572414 rs9315425 chr13 37082608 C T 6.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2094501 chr13 37092068 A T 9.78E-04 Multiple complex diseases / / 17554300 rs7318972 chr13 37097377 A G 7.82E-04 Multiple complex diseases / / 17554300 rs1517894 chr13 37102267 A G 8.99E-04 Type 2 diabetes / / 17463246 rs1517881 chr13 37129895 G A 5.40E-05 Cognitive test performance / / 20125193 rs1474085 chr13 37147906 T C 2.42E-05 Multiple complex diseases / / 17554300 rs7317651 chr13 37161497 T G 9.17E-04 Multiple complex diseases / / 17554300 rs1517884 chr13 37162918 A G 0.000887103 Hypertension (early onset hypertension) / / 22479346 rs4943398 chr13 37185064 T A 8.45E-06 Adiponectin levels / / 20887962 rs7399673 chr13 37301640 C T 8.09E-04 Obesity (extreme) / / 21935397 rs7999411 chr13 37339651 T A 2.33E-04 Type 2 diabetes / / 17463246 rs3897230 chr13 37347977 C T 7.10E-04 Alcohol dependence / / 20201924 rs7322307 chr13 37350679 A G 7.90E-04 Alcohol dependence / / 20201924 rs4633574 chr13 37351756 T C 7.95E-04 Multiple complex diseases / / 17554300 rs7997612 chr13 37358108 A G 4.96E-05 Orofacial clefts / / 22419666 rs7320732 chr13 37363086 A T 2.18E-04 Alzheimer's disease / / 22005930 rs9566163 chr13 37363484 T C 2.11E-04 Alzheimer's disease / / 22005930 rs9566164 chr13 37363659 G A 3.42E-04 Alzheimer's disease / / 22005930 rs9566164 chr13 37363659 G A 5.22E-05 Orofacial clefts / / 22419666 rs3934269 chr13 37369136 A T 2.24E-04 Alzheimer's disease / / 22005930 rs2031812 chr13 37369314 C T 3.97E-04 Alzheimer's disease / / 22005930 rs9547678 chr13 37386100 G A 0.000654 fMRI brain tests in schizophrenia / / 22440650 rs4943418 chr13 37389234 A G 4.60E-05 Cognitive function / / 24684796 rs609418 chr13 37417427 A C 9.46E-04 Stroke / / pha002886 rs683558 chr13 37430341 G A 1.66E-04 Myopia (pathological) SMAD9 intron 21095009 rs12858120 chr13 37430403 G A 3.70E-05 Circulating vasoactive peptide levels SMAD9 intron 23381795 rs17054640 chr13 37439327 G T 1.99E-05 Multiple complex diseases SMAD9 intron 17554300 rs576434 chr13 37458139 T C 6.10E-04 Alcohol dependence SMAD9 intron 20201924 rs574770 chr13 37458280 C G 6.29E-05 Personality dimensions SMAD9 intron 18957941 rs17054676 chr13 37460550 G A 7.19E-05 Multiple complex diseases SMAD9 intron 17554300 rs1571317 chr13 37484693 T C 1.60E-05 Personality dimensions SMAD9 intron 18957941 rs9315454 chr13 37493054 C A 9.09E-05 Personality dimensions SMAD9 intron 18957941 rs594679 chr13 37502102 C G 6.44E-04 Coronary heart disease / / 21606135 rs8000946 chr13 37547260 A T 1.90E-05 Schizophrenia ALG5 intron 19571811 rs8001724 chr13 37549928 T G 5.50E-07 Interleukin levels (IL10,IL1Ra,IL6),in plasma ALG5 intron 22205395 rs8000672 chr13 37554345 A G 4.27E-07 Interleukin levels (IL10,IL1Ra,IL6),in plasma ALG5 intron 22205395 rs7989205 chr13 37570182 C T 4.50E-07 Interleukin levels (IL10,IL1Ra,IL6),in plasma ALG5 intron 22205395 rs17054796 chr13 37570731 T C 2.00E-07 Interleukin levels (IL10,IL1Ra,IL6),in plasma ALG5 intron 22205395 rs7995985 chr13 37609991 C G 1.60E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma FAM48A intron 22205395 rs1211337 chr13 37617299 G A 1.30E-07 Interleukin levels (IL10,IL1Ra,IL6),in plasma FAM48A intron 22205395 rs17054831 chr13 37619600 A G 3.80E-07 Interleukin levels (IL10,IL1Ra,IL6),in plasma FAM48A intron 22205395 rs9285111 chr13 37622950 T A 1.10E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma FAM48A intron 22205395 rs1199964 chr13 37632651 G A 1.30E-07 Interleukin levels (IL10,IL1Ra,IL6),in plasma FAM48A intron 22205395 rs12585998 chr13 37688157 G A 2.73E-05 Tunica Media / / pha003034 rs9566187 chr13 37714435 T C 6.34E-05 Tunica Media / / pha003034 rs17054986 chr13 37723675 A G 3.05E-04 Multiple complex diseases / / 17554300 rs2323397 chr13 37762637 A T 3.00E-06 Palmitoleic acid (16:1n-7) plasma levels / / 23362303 rs9603150 chr13 37795584 C T 5.17E-05 Alzheimer's disease / / 21098978 rs9315475 chr13 37798434 T G 5.02E-05 Alzheimer's disease / / 21098978 rs1324034 chr13 37807331 T C 1.28E-04 Myocardial Infarction / / pha002873 rs10219784 chr13 37812511 C T 7.30E-05 Alzheimer's disease / / 21098978 rs1980733 chr13 37816086 A G 7.88E-05 Alzheimer's disease / / 21098978 rs1980732 chr13 37816223 G A 7.46E-05 Alzheimer's disease / / 21098978 rs1324020 chr13 37822869 A G 7.48E-05 Alzheimer's disease / / 21098978 rs17226415 chr13 37849502 C G 5.81E-05 Alzheimer's disease / / 17998437 rs9576235 chr13 37850706 G A 6.46E-04 Alzheimer's disease / / 17998437 rs7985720 chr13 37865145 A G 3.11E-04 Alzheimer's disease / / 17998437 rs1324038 chr13 37879168 C T 6.86E-04 Prostate cancer mortality / / 20978177 rs1324038 chr13 37879168 C T 2.34E-04 Alzheimer's disease / / pha002879 rs9547786 chr13 37881471 A G 8.88E-04 Acute lung injury / / 22295056 rs7320867 chr13 37912629 G A 3.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs9315483 chr13 37920192 C T 5.11E-05 Coronary heart disease / / pha003056 rs9566214 chr13 37943776 C T 8.25E-04 Multiple complex diseases / / 17554300 rs9566214 chr13 37943776 C T 3.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs9566215 chr13 37943825 C T 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1324023 chr13 37944928 A G 8.08E-04 Myopia (pathological) / / 21095009 rs1359208 chr13 37949846 C T 2.29E-05 Cognitive test performance / / 20125193 rs7491873 chr13 37951949 G A 9.60E-05 Triglycerides / / 19074352 rs7985376 chr13 37953121 C T 8.12E-05 Cognitive test performance / / 20125193 rs9547829 chr13 37954091 A G 2.68E-04 Myopia (pathological) / / 21095009 rs7318591 chr13 37957009 T C 1.36E-04 Myopia (pathological) / / 21095009 rs1407613 chr13 37960524 T C 2.23E-04 Myopia (pathological) / / 21095009 rs9603175 chr13 37960839 C T 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs6563533 chr13 37965814 G T 2.29E-05 Cognitive test performance / / 20125193 rs2323476 chr13 37966084 G A 4.16E-04 Myopia (pathological) / / 21095009 rs9576261 chr13 37967290 G A 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs9547846 chr13 37978338 C G 6.66E-04 Multiple complex diseases / / 17554300 rs9532047 chr13 37978531 A T 6.55E-04 Multiple complex diseases / / 17554300 rs9532047 chr13 37978531 A T 1.48E-04 Gallstones / / 17632509 rs9315490 chr13 37978657 T C 6.19E-04 Multiple complex diseases / / 17554300 rs9547847 chr13 37979154 T C 7.91E-04 Multiple complex diseases / / 17554300 rs4943508 chr13 37984354 C T 1.43E-04 Multiple complex diseases / / 17554300 rs1407612 chr13 37989578 G A 2.27E-04 Multiple complex diseases / / 17554300 rs7992122 chr13 38002110 G A 3.10E-04 Smoking initiation / / 24665060 rs9547858 chr13 38002795 A G 8.06E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs9547878 chr13 38017741 C A 8.06E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs17055644 chr13 38020672 A G 5.80E-04 Multiple complex diseases / / 17554300 rs7319671 chr13 38025224 A G 3.60E-05 Blood Phenotypes / / 17903294 rs1590305 chr13 38035189 C T 3.00E-06 Hip geometry / / 17903296 rs9547893 chr13 38039962 T A 5.45E-04 Multiple complex diseases / / 17554300 rs9603201 chr13 38040495 G C 1.90E-05 Urinary metabolites / / 21572414 rs12867234 chr13 38049733 G C 1.75E-04 Multiple complex diseases / / 17554300 rs7324216 chr13 38059218 C T 6.50E-04 Addiction / / 17099884 rs17055893 chr13 38063628 A C 2.06E-04 Taste perception / / 22132133 rs9646096 chr13 38065446 A C 6.00E-06 Age-related macular degeneration / / 23326517 rs17055932 chr13 38067143 T C 7.36E-05 HIV-1 control / / 20041166 rs9547912 chr13 38071135 C T 4.60E-06 Serum metabolites / / 19043545 rs7335400 chr13 38103152 A C 1.58E-07 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs10467365 chr13 38112413 A C,T 6.50E-04 Addiction LINC00547 intron 17099884 rs7995907 chr13 38135780 C T 3.37E-05 Smoking cessation / / 18519826 rs9547964 chr13 38151202 T G 1.59E-06 Esophageal cancer (squamous cell) POSTN intron 22960999 rs117103342 chr13 38156538 C T 0.00066 Prostate cancer POSTN missense 23555315 rs9576309 chr13 38161563 G A 5.31E-05 Smoking cessation POSTN intron 18519826 rs17257154 chr13 38173383 C T 9.87E-04 Multiple complex diseases / / 17554300 rs1924299 chr13 38184054 C G 9.39E-04 Multiple complex diseases / / 17554300 rs1924293 chr13 38204632 A G 2.18E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9547991 chr13 38217415 T C 8.09E-07 Esophageal cancer (squamous cell) TRPC4 intron 22960999 rs9547994 chr13 38219448 A C 1.91E-04 Amyotrophic lateral sclerosis (sporadic) TRPC4 intron 24529757 rs7321872 chr13 38246607 A G 9.98E-04 Tourette syndrome TRPC4 intron 22889924 rs10507457 chr13 38269676 C T 6.83E-05 Height TRPC4 intron pha003011 rs1333363 chr13 38275877 A C 8.41E-04 Multiple complex diseases TRPC4 intron 17554300 rs7319926 chr13 38280430 A G 1.98E-04 Multiple complex diseases TRPC4 intron 17554300 rs2991010 chr13 38291011 G A 1.67E-04 Stroke TRPC4 intron pha002887 rs1333364 chr13 38295580 T C 2.09E-04 Multiple complex diseases TRPC4 intron 17554300 rs1570607 chr13 38305325 G A 1.98E-04 Multiple complex diseases TRPC4 intron 17554300 rs17203407 chr13 38315086 C T 6.47E-04 Multiple complex diseases TRPC4 intron 17554300 rs12586046 chr13 38336234 A G 2.56E-04 Multiple complex diseases TRPC4 intron 17554300 rs9548050 chr13 38363450 A G 2.00E-06 Urinary metabolites TRPC4 intron 21572414 rs9548050 chr13 38363450 A G 9.00E-06 Obesity-related traits TRPC4 intron 23251661 rs9566255 chr13 38378364 T C 3.82E-04 Alzheimer's disease (late onset) TRPC4 intron 21379329 rs9566256 chr13 38378546 C T 3.59E-04 Alzheimer's disease (late onset) TRPC4 intron 21379329 rs861005 chr13 38424084 A G 3.80E-04 Alzheimer's disease (late onset) TRPC4 intron 21379329 rs10507461 chr13 38441848 C G 3.67E-07 Pure-tone audiometry TRPC4 intron pha001966 rs1538145 chr13 38445304 A T 0.000374 Salmonella-induced pyroptosis TRPC4 nearGene-5 22837397 rs17056817 chr13 38479710 C T 8.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs817737 chr13 38484529 C T 0.0003 Asthma / / 18401594 rs817737 chr13 38484529 C T 1.66E-05 Elbow pain / / pha003008 rs846414 chr13 38486045 C T 2.83E-05 Elbow pain / / pha003008 rs1337604 chr13 38511215 C T 0.00028 Asthma / / 18401594 rs9548113 chr13 38512532 T C 2.20E-04 Alcohol dependence / / 21314694 rs9548115 chr13 38520144 C T 1.77E-06 Elbow pain / / pha003008 rs9548115 chr13 38520144 C T 3.72E-05 Body Mass Index / / pha003009 rs17210569 chr13 38523096 A T 3.59E-10 Lipoprotein a [lp(a)] levels in plasma / / pha002870 rs9548119 chr13 38531581 T A 9.00E-06 Self-rated health / / 20707712 rs2225872 chr13 38541196 A G 8.58E-05 IgE levels / / 22075330 rs2265458 chr13 38542152 C G 9.46E-05 IgE levels / / 22075330 rs1337647 chr13 38542845 C T 9.51E-05 IgE levels / / 22075330 rs2485488 chr13 38543039 A G 9.51E-05 IgE levels / / 22075330 rs9576408 chr13 38549502 A G 7.60E-07 Elbow pain / / pha003008 rs2485492 chr13 38550242 G A 9.58E-05 IgE levels / / 22075330 rs2255148 chr13 38551635 G A 9.60E-05 IgE levels / / 22075330 rs2243570 chr13 38557085 A G 9.76E-05 IgE levels / / 22075330 rs1890121 chr13 38586285 T C 7.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12429115 chr13 38596233 G A 2.98E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9315538 chr13 38610936 G T 6.71E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs9548166 chr13 38619750 G A 6.19E-06 Malignant mesothelioma / / 23827383 rs1360922 chr13 38627010 A G 9.61E-06 Elbow pain / / pha003008 rs9315543 chr13 38632578 A C 3.35E-05 Elbow pain / / pha003008 rs7334221 chr13 38632798 G A 8.00E-06 Elbow pain / / pha003008 rs7336735 chr13 38632923 A G 9.88E-06 Elbow pain / / pha003008 rs12050013 chr13 38654219 T C 3.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1577779 chr13 38655046 T C 2.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4941887 chr13 38692585 A C 5.09E-04 Multiple complex diseases / / 17554300 rs9548213 chr13 38694917 T C 1.00E-04 Information processing speed / / 21130836 rs9548217 chr13 38718535 G T 7.91E-05 IgE levels / / 22075330 rs3920586 chr13 38727020 G T 9.27E-04 Multiple complex diseases / / 17554300 rs9548221 chr13 38730542 C T 6.24E-04 Multiple complex diseases / / 17554300 rs683479 chr13 38753676 T C 2.68E-05 Tuberculosis / / 24057671 rs1924181 chr13 38768892 A G 6.31E-04 Multiple complex diseases / / 17554300 rs9576471 chr13 38769793 A G 7.01E-05 Body Mass Index / / pha003009 rs9548241 chr13 38792982 C T 3.47E-05 Body Mass Index / / pha003009 rs610642 chr13 38826809 A C 8.79E-05 Multiple complex diseases / / 17554300 rs6563594 chr13 38830980 C T 7.70E-05 Blood Pressure / / pha003044 rs473755 chr13 38836680 G A 7.27E-05 Blood Pressure / / pha003044 rs7318940 chr13 38838950 T C 9.77E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2455415 chr13 38860697 C T 1.44E-05 Major depressive disorder / / 21621269 rs606702 chr13 38877678 C T 5.31E-05 Waist Circumference / / pha003023 rs514830 chr13 38881428 A G 3.14E-06 Multiple complex diseases / / 17554300 rs2150468 chr13 38927888 T G 0.00009 Asthma UFM1 intron 18401594 rs9888482 chr13 38928976 A C 3.19E-04 Response to taxane treatment (placlitaxel) UFM1 intron 23006423 rs4943583 chr13 38948851 G A 2.25E-06 Common variable immunodeficiency / / 21497890 rs17057943 chr13 38963392 T C 1.35E-04 Multiple complex diseases / / 17554300 rs17233698 chr13 38975892 G A 1.72E-04 Multiple complex diseases / / 17554300 rs17299897 chr13 39002924 T C 7.31E-05 Bipolar disorder and schizophrenia / / 20889312 rs6563618 chr13 39021562 G A 4.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7328507 chr13 39022191 T C 2.43E-05 Alcohol and nictotine co-dependence / / 20158304 rs9532233 chr13 39033484 T C 3.50E-04 Multiple complex diseases / / 17554300 rs2875194 chr13 39069439 G T 9.26E-04 Multiple complex diseases / / 17554300 rs9548374 chr13 39077255 T C 7.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2323930 chr13 39081413 A G 7.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7333117 chr13 39115304 C T 6.80E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17058178 chr13 39116394 A G 3.38E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7320842 chr13 39141336 C G 7.75E-04 Insulin resistance / / 21901158 rs7983501 chr13 39141385 G A 4.63E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17058262 chr13 39160728 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17058266 chr13 39160908 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9548413 chr13 39171034 T C 2.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10507476 chr13 39189009 G C 7.23E-04 Smoking initiation / / 24665060 rs2805090 chr13 39192428 A G 9.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs11841753 chr13 39200826 C T 6.54E-05 Multiple sclerosis / / 17660530 rs17058379 chr13 39219859 C G 9.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs17058383 chr13 39224353 G A 8.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs895898 chr13 39227547 T G 6.85E-04 Taste perception / / 22132133 rs2122208 chr13 39242025 T A 4.58E-04 Smoking initiation / / 24665060 rs2218722 chr13 39273153 A C 3.17E-04 Hemoglobin concentration FREM2 intron 20534544 rs2442360 chr13 39298845 G C 6.24E-08 Narcolepsy FREM2 intron 19629137 rs2442357 chr13 39313967 T C 9.29E-04 Type 2 diabetes FREM2 intron 17463246 rs2442356 chr13 39317053 G A 8.01E-04 Type 2 diabetes FREM2 intron 17463246 rs7329184 chr13 39323535 A G 3.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FREM2 intron 20877124 rs9548446 chr13 39324093 T C 8.37E-04 Amyotrophic lateral sclerosis (sporadic) FREM2 intron 24529757 rs7318271 chr13 39328541 A G 4.67E-04 Type 2 diabetes FREM2 intron 17463246 rs1037253 chr13 39329692 A G 1.10E-04 Multiple complex diseases FREM2 intron 17554300 rs9603421 chr13 39340661 A G 9.95E-04 Type 2 diabetes FREM2 intron 17463246 rs9594293 chr13 39370595 G A 7.00E-06 Cytomegalovirus antibody response FREM2 intron 21993531 rs9576614 chr13 39379038 A G 5.29E-04 Body mass index FREM2 intron 21701565 rs9603433 chr13 39379365 C A 9.00E-04 Multiple complex diseases FREM2 intron 17554300 rs9548502 chr13 39420663 T C 1.50E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FREM2 intron 24023788 rs9548505 chr13 39422624 C T 1.29E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FREM2 missense 24023788 rs9548517 chr13 39445743 G A 3.00E-05 Crohn's disease (time to surgery) FREM2 intron 23665963 rs2156810 chr13 39467391 C T 6.25E-05 HDL cholesterol / / pha003075 rs7317127 chr13 39470642 T C 3.19E-04 Insulin resistance / / 21901158 rs1413102 chr13 39498265 C A 6.46E-04 Heart Failure / / pha002885 rs9315632 chr13 39516627 G T 3.00E-06 Metabolic syndrome / / 20694148 rs4439630 chr13 39545127 G A 2.71E-05 Coronary heart disease STOML3 intron pha003032 rs9576711 chr13 39623621 G T 0.000023 Primary sclerosing cholangitis NHLRC3 UTR-3 22521342 rs1012243 chr13 39628344 C T 7.14E-04 Multiple complex diseases / / 17554300 rs7320516 chr13 39643400 G A 7.27E-05 Parkinson's disease / / 21738487 rs2209631 chr13 39675022 G A 7.28E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs1536343 chr13 39675421 T C 7.28E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs2324129 chr13 39682032 A G 6.36E-04 Multiple complex diseases / / 17554300 rs6563675 chr13 39699260 C T 1.13E-06 Multiple complex diseases / / 17554300 rs7984252 chr13 39703461 G A 3.45E-04 Alzheimer's disease / / 22005930 rs7998548 chr13 39706329 T C 1.02E-04 Telomere length / / 21573004 rs1413040 chr13 39707939 A G 0.000098 Primary sclerosing cholangitis / / 22521342 rs7994616 chr13 39709095 T C 3.84E-04 Alzheimer's disease / / 22005930 rs11616610 chr13 39714209 C T 8.01E-04 Alzheimer's disease / / 22005930 rs7328319 chr13 39741322 G A 6.83E-06 Serum metabolites / / 19043545 rs1333441 chr13 39751273 A G 6.86E-04 Type 2 diabetes / / 17846126 rs4277226 chr13 39759268 G T 8.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs7330452 chr13 39779861 A C 8.60E-05 Malaria / / 19465909 rs9532354 chr13 39786449 G A 9.93E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs17590107 chr13 39787335 G A 3.19E-04 Alzheimer's disease / / 24755620 rs7324440 chr13 39787406 T C 6.56E-04 Multiple complex diseases / / 17554300 rs4643180 chr13 39793468 T C 5.70E-04 Alzheimer's disease / / 24755620 rs7335044 chr13 39801283 T C 4.52E-04 Alzheimer's disease / / 24755620 rs9576762 chr13 39806412 G A 4.66E-04 Alzheimer's disease / / 24755620 rs17059545 chr13 39807768 C T 6.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs7993897 chr13 39818752 C T 4.22E-04 Alzheimer's disease / / 24755620 rs9576766 chr13 39827173 A G 4.02E-04 Alzheimer's disease / / 24755620 rs7323831 chr13 39891818 G A 4.53E-05 Body Fat Distribution / / pha003017 rs8000853 chr13 39892986 T C 5.84E-05 Body Fat Distribution / / pha003017 rs6563695 chr13 39903243 G T 5.00E-06 Preeclampsia / / 23551011 rs2025411 chr13 39911735 T C 2.80E-05 Urinary metabolites / / 21572414 rs1887474 chr13 39943576 T C 1.12E-04 Tuberculosis LHFP intron 22306650 rs9315679 chr13 39943962 C T 1.00E-05 Urinary metabolites LHFP intron 21572414 rs7336133 chr13 39947574 A G 2.71E-04 Acute lymphoblastic leukemia (childhood) LHFP intron 22076464 rs9594331 chr13 39961128 G A 3.76E-06 Lymphocyte counts LHFP intron 22286170 rs10467465 chr13 39963291 G A 4.79E-04 Multiple complex diseases LHFP intron 17554300 rs17059785 chr13 39966885 G A 5.08E-05 Insulin resistance LHFP intron 21901158 rs4941926 chr13 39978207 T A 1.60E-05 Urinary metabolites LHFP intron 21572414 rs9548754 chr13 39987245 A C 3.00E-05 Diabetic retinopathy LHFP intron 21441570 rs9548755 chr13 39987481 A G 1.70E-05 Diabetic retinopathy LHFP intron 21441570 rs7335330 chr13 40007199 T C 3.12E-05 Waist Circumference LHFP intron pha003023 rs9594332 chr13 40008960 G A 6.07E-05 Alcohol consumption LHFP intron 23743675 rs7317775 chr13 40014918 T A 5.60E-05 Alcohol consumption LHFP intron 23743675 rs12873765 chr13 40039652 C T 9.66E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) LHFP intron 24236485 rs10492737 chr13 40039812 C T 6.65E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) LHFP intron 24236485 rs10492736 chr13 40039932 A G 6.65E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) LHFP intron 24236485 rs10492735 chr13 40040036 A G 6.65E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) LHFP intron 24236485 rs10492734 chr13 40040314 C T 6.65E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) LHFP intron 24236485 rs9576827 chr13 40080381 A G 2.29E-11 Longevity,exceptional LHFP intron 20595579 rs1927207 chr13 40090806 T C 7.57E-04 Rheumatoid arthritis LHFP intron 21452313 rs9576829 chr13 40091136 A G 4.01E-04 Multiple complex diseases LHFP intron 17554300 rs9548791 chr13 40092691 A G 6.57E-04 Rheumatoid arthritis LHFP intron 21452313 rs9548798 chr13 40097853 A C 5.89E-04 Suicide attempts in bipolar disorder LHFP intron 21423239 rs6563719 chr13 40097904 C T 2.80E-04 Rheumatoid arthritis LHFP intron 21452313 rs9532392 chr13 40100591 C T 8.86E-05 Alzheimer's disease LHFP intron 21098978 rs1040961 chr13 40108008 G A 3.79E-04 Rheumatoid arthritis LHFP intron 21452313 rs1040961 chr13 40108008 G A 1.44E-05 Coronary heart disease LHFP intron pha003030 rs9566456 chr13 40117691 T C 8.33E-04 Multiple complex diseases LHFP intron 17554300 rs9315702 chr13 40118068 C A 7.79E-04 Multiple complex diseases LHFP intron 17554300 rs9315702 chr13 40118068 C A 2.88E-04 Response to platinum-based chemotherapy in small-cell lung cancer LHFP intron 20463552 rs9315702 chr13 40118068 C A 2.00E-08 Hippocampal atrophy LHFP intron 22745009 rs9576849 chr13 40122096 A G 6.29E-04 Multiple complex diseases LHFP intron 17554300 rs7982917 chr13 40132277 G A 2.47E-04 Response to platinum-based chemotherapy in small-cell lung cancer LHFP intron 20463552 rs7996238 chr13 40135976 G A 8.59E-05 Attention deficit hyperactivity disorder LHFP intron 22420046 rs9315704 chr13 40140215 A G 2.08E-05 Multiple complex diseases LHFP intron 17554300 rs7318072 chr13 40146225 G A 5.65E-05 Attention deficit hyperactivity disorder LHFP intron 22420046 rs9315715 chr13 40187075 A G 3.21E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4254189 chr13 40212417 G A 9.44E-05 Coronary heart disease / / pha003031 rs11840965 chr13 40224981 C T 7.68E-05 Hypertension / / pha003041 rs11840965 chr13 40224981 C T 9.02E-05 Hypertension / / pha003042 rs3812882 chr13 40229891 G A 3.13E-04 Tourette syndrome COG6 missense 22889924 rs3812888 chr13 40230294 T C 1.71E-04 Tourette syndrome COG6 intron 22889924 rs4941939 chr13 40252190 C T 1.69E-04 Arthritis (juvenile idiopathic) COG6 intron 22354554 rs4133063 chr13 40307119 T C 7.48E-04 Tourette syndrome COG6 intron 22889924 rs7325068 chr13 40311300 G A 8.02E-04 Multiple complex diseases COG6 intron 17554300 rs7998641 chr13 40327895 C T 6.65E-04 Multiple complex diseases COG6 intron 17554300 rs7998641 chr13 40327895 C T 6.64E-05 Serum metabolites COG6 intron 19043545 rs4943694 chr13 40329032 C T 8.11E-04 Multiple complex diseases COG6 intron 17554300 rs4943694 chr13 40329032 C T 1.17E-04 Tourette syndrome COG6 intron 22889924 rs4409964 chr13 40342741 G A 1.58E-04 Tourette syndrome COG6 intron 22889924 rs7993214 chr13 40350912 T C 2.00E-06 Psoriasis COG6 intron 18369459 rs7993214 chr13 40350912 T C 0.00000455 Rheumatoid arthritis (CCP positive) COG6 intron 23143596 rs7993214 chr13 40350912 T C 0.000102 Rheumatoid arthritis COG6 intron 23143596 rs7993214 chr13 40350912 T C 0.000000161 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) COG6 intron 23603761 rs7993214 chr13 40350912 T C 0.00000826 Oligoarticular juvenile idiopathic arthritis COG6 intron 23603761 rs9532434 chr13 40355913 T C 4.52E-08 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) COG6 intron 23603761 rs4303351 chr13 40360754 A C 5.29E-04 Type 2 diabetes COG6 intron 17463246 rs9603616 chr13 40368069 C T 2.00E-12 Rheumatoid arthritis / / 24390342 rs9603616 chr13 40368069 C T 3.00E-11 Rheumatoid arthritis / / 24390342 rs8181861 chr13 40370177 C T 9.30E-05 Tourette syndrome / / 22889924 rs17060619 chr13 40408255 T C 8.60E-04 Coronary Artery Disease / / 17634449 rs12862721 chr13 40440805 C A 8.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs2224846 chr13 40473525 G A 6.77E-05 Major depressive disorder (broad) / / 20038947 rs9548967 chr13 40473991 T C 6.49E-05 Major depressive disorder (broad) / / 20038947 rs9548968 chr13 40476109 G A 7.17E-05 Major depressive disorder (broad) / / 20038947 rs9566483 chr13 40478401 T C 6.32E-05 Major depressive disorder (broad) / / 20038947 rs9548970 chr13 40478755 A G 6.45E-05 Major depressive disorder (broad) / / 20038947 rs9548971 chr13 40479576 C T 6.41E-05 Major depressive disorder (broad) / / 20038947 rs9576916 chr13 40480447 A G 6.14E-05 Major depressive disorder (broad) / / 20038947 rs9548973 chr13 40483478 C T 8.76E-05 Major depressive disorder (broad) / / 20038947 rs9576917 chr13 40484556 A G 6.54E-05 Major depressive disorder (broad) / / 20038947 rs7140080 chr13 40485863 G T 5.74E-05 Major depressive disorder (broad) / / 20038947 rs9532454 chr13 40487456 G A 5.42E-05 Major depressive disorder (broad) / / 20038947 rs9548974 chr13 40490129 T C 6.63E-05 Major depressive disorder (broad) / / 20038947 rs9548975 chr13 40490173 A G 6.48E-05 Major depressive disorder (broad) / / 20038947 rs4943713 chr13 40491103 A G 6.08E-05 Major depressive disorder (broad) / / 20038947 rs7317907 chr13 40492588 A C 5.76E-05 Major depressive disorder (broad) / / 20038947 rs9548978 chr13 40493659 T C 5.24E-05 Major depressive disorder (broad) / / 20038947 rs9566485 chr13 40493988 G A 5.06E-05 Major depressive disorder (broad) / / 20038947 rs9532457 chr13 40494969 T G 4.89E-05 Major depressive disorder (broad) / / 20038947 rs2209239 chr13 40496029 C T 4.65E-05 Major depressive disorder (broad) / / 20038947 rs2209240 chr13 40496045 G A 4.36E-05 Major depressive disorder (broad) / / 20038947 rs12019497 chr13 40498629 C A 4.31E-05 Major depressive disorder (broad) / / 20038947 rs9548982 chr13 40499917 G T 3.93E-05 Major depressive disorder (broad) / / 20038947 rs2146368 chr13 40500414 C T 3.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2146368 chr13 40500414 C T 2.80E-06 Urinary metabolites / / 21572414 rs9548988 chr13 40505510 C T 3.00E-07 Ulcerative colitis / / 19915572 rs7338145 chr13 40545193 A G 2.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs7322623 chr13 40556803 C A 2.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs276429 chr13 40556859 G A 7.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs276429 chr13 40556859 G A 5.64E-05 Cognitive decline / / 22054870 rs276422 chr13 40567395 T G 6.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs7339164 chr13 40572053 G A 1.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs7339164 chr13 40572053 G A 1.54E-05 Major depression (suicidal thoughts and behavior) / / 21750702 rs276420 chr13 40572070 T G 4.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs276420 chr13 40572070 T G 2.96E-05 Major depression (suicidal thoughts and behavior) / / 21750702 rs276420 chr13 40572070 T G 3.25E-05 Cognitive decline / / 22054870 rs12873354 chr13 40576064 C T 1.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs276407 chr13 40581629 G A 4.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs276402 chr13 40585845 C A 4.48E-04 Suicide attempts in bipolar disorder / / 21041247 rs9603660 chr13 40595139 C T 7.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs4943722 chr13 40595988 G A 8.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs9603665 chr13 40602347 C T 1.29E-04 Major depression (suicidal thoughts and behavior) / / 21750702 rs366300 chr13 40602866 T C 5.71E-04 Suicide attempts in bipolar disorder / / 21041247 rs415484 chr13 40619078 C A 4.09E-04 Hemoglobin concentration / / 20534544 rs1547347 chr13 40644540 T G 0.000564717 Hypertension (early onset hypertension) / / 22479346 rs369655 chr13 40646156 T C 0.000742072 Hypertension (early onset hypertension) / / 22479346 rs953341 chr13 40658658 C T 7.67E-05 Blood Pressure / / pha003046 rs7990993 chr13 40674372 G T 6.18E-04 Body mass index / / 21701565 rs1889935 chr13 40677486 G A 1.50E-05 Urinary metabolites / / 21572414 rs9549067 chr13 40702657 G A 2.99E-05 Major depressive disorder / / 20516156 rs9315761 chr13 40733856 A G 3.89E-05 Blood Pressure / / pha003049 rs6563798 chr13 40736262 G A 6.86E-05 Blood Pressure / / pha003049 rs9603692 chr13 40738316 G T 3.75E-04 Sudden cardiac arrest / / 21658281 rs2039623 chr13 40739964 A G 2.07E-05 Blood Pressure / / pha003049 rs9315762 chr13 40741907 C T 7.00E-06 Presence of antiphospholipid antibodies / / 23509613 rs17591848 chr13 40744051 A G 6.00E-05 Blood Pressure / / pha003049 rs9549096 chr13 40757910 A C 1.43E-05 Cognitive impairment induced by topiramate / / 22091778 rs10507483 chr13 40759773 T C 2.60E-05 Urinary metabolites / / 21572414 rs17060974 chr13 40765013 T G 2.10E-05 Urinary metabolites / / 21572414 rs6563808 chr13 40766662 T C 3.94E-04 Type 2 diabetes / / 17463246 rs6563808 chr13 40766662 T C 3.44E-04 Multiple complex diseases / / 17554300 rs9566497 chr13 40773110 T C 6.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00548 intron 20877124 rs9566497 chr13 40773110 T C 3.83E-04 Obesity (extreme) LINC00548 intron 21935397 rs9566498 chr13 40773652 T C 3.83E-04 Obesity (extreme) LINC00548 intron 21935397 rs4943740 chr13 40776938 G A 8.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00548 intron 20877124 rs9549111 chr13 40789482 T C 3.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00548 intron 20877124 rs12161861 chr13 40794113 T C 6.08E-04 Obesity (extreme) LINC00548 intron 21935397 rs9603703 chr13 40799522 T C 1.90E-05 Urinary metabolites / / 21572414 rs9549123 chr13 40804332 G T 6.20E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10492681 chr13 40807483 G C 1.66E-04 Multiple complex diseases / / 17554300 rs10492681 chr13 40807483 G C 2.00E-06 Select biomarker traits / / 17903293 rs4943746 chr13 40815153 C T 4.26E-04 Type 2 diabetes / / 17463246 rs4943746 chr13 40815153 C T 1.11E-04 Multiple complex diseases / / 17554300 rs7325568 chr13 40818284 C T 0.0000661 5-fluorouracil and oxaliplatin combined induced haematologic in response to colorectal cancer treatment / / 22310351 rs7325568 chr13 40818284 C T 0.0000661 Oxaliplatin induced haematologic in response to colorectal cancer treatment / / 22310351 rs17061055 chr13 40835400 T G 9.58E-04 Type 2 diabetes / / 17463246 rs34793731 chr13 40835400 T TG 9.58E-04 Type 2 diabetes / / 17463246 rs7321617 chr13 40878755 C G 9.11E-04 Alzheimer's disease / / 22005930 rs9549168 chr13 40886355 T C 4.70E-05 Coronary heart disease / / 21606135 rs9549172 chr13 40894002 C T 2.36E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11618523 chr13 40917459 C T 3.28E-04 Lung function (forced vital capacity) / / 24023788 rs9549185 chr13 40930271 T C 1.10E-04 Gallstones TTL intron 17632509 rs1041211 chr13 40940659 C A 6.18E-04 Iron levels TTL intron pha002876 rs1028850 chr13 40941480 T C 2.14E-09 Multiple complex diseases TTL intron 17554300 rs1782806 chr13 40945790 G T 0.000093 Sarcoidosis TTL intron 22952805 rs913246 chr13 40948151 C T 7.00E-06 Bipolar disorder and schizophrenia TTL intron 20889312 rs1782786 chr13 40954490 T G 7.80E-04 Multiple complex diseases TTL intron 17554300 rs1751852 chr13 40978966 G C 5.07E-04 Multiple complex diseases TTL intron 17554300 rs11617562 chr13 41009283 G T 7.90E-05 Cognitive test performance TTL intron 20125193 rs941823 chr13 41013977 T C 4.00E-12 Ulcerative colitis TTL intron 21297633 rs941823 chr13 41013977 T C 5.92E-05 Orofacial clefts TTL intron 22863734 rs941823 chr13 41013977 T C 2.00E-14 Inflammatory bowel disease TTL intron 23128233 rs1998281 chr13 41068593 T C 5.06E-04 Smoking initiation / / 24665060 rs2721043 chr13 41078668 C A 4.30E-06 Central corneal thickness / / 20485516 rs2721043 chr13 41078668 C A 1.01E-11 Corneal structure / / 23291589 rs17199729 chr13 41081310 A G 6.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17592094 chr13 41091489 G A 5.45E-06 Central corneal thickness / / 20719862 rs2721052 chr13 41109040 C T 7.76E-04 Coronary heart disease / / 21971053 rs2755237 chr13 41109429 A C 2.50E-08 Central corneal thickness / / 20485516 rs2755237 chr13 41109429 A C 1.00E-08 Central corneal thickness / / 20719862 rs2755237 chr13 41109429 A C 1.76E-11 Corneal structure / / 23291589 rs2755238 chr13 41110270 T C 2.86E-14 Corneal structure / / 23291589 rs2721051 chr13 41110884 C T 5.00E-10 Central corneal thickness / / 20485516 rs2721051 chr13 41110884 C T 4.00E-14 Corneal structure / / 23291589 rs11616662 chr13 41119466 G A 3.70E-04 Insulin resistance / / 21901158 rs11616662 chr13 41119466 G A 1.96E-13 Corneal structure / / 23291589 rs2701858 chr13 41138389 C T 9.00E-04 Atrial fibrillation FOXO1 intron 21846873 rs2701859 chr13 41141232 T C 6.51E-04 Myopia (pathological) FOXO1 intron 21095009 rs9549236 chr13 41147158 T C 6.25E-04 Multiple complex diseases FOXO1 intron 17554300 rs2951787 chr13 41161770 G A 1.00E-06 Urinary metabolites FOXO1 intron 21572414 rs4943794 chr13 41173408 G C 2.80E-04 Longevity and age-related phenotypes FOXO1 intron 17903295 rs7986407 chr13 41179798 A G 6.35E-04 Myopia (pathological) FOXO1 intron 21095009 rs10507486 chr13 41186501 G A 1.30E-04 Longevity and age-related phenotypes FOXO1 intron 17903295 rs9549244 chr13 41218685 G A 9.44E-06 Rheumatoid arthritis FOXO1 intron 19503088 rs9549244 chr13 41218685 G A 7.01E-04 Myopia (pathological) FOXO1 intron 21095009 rs4943804 chr13 41269994 A G 6.11E-06 Rheumatoid arthritis / / 19503088 rs4245402 chr13 41287540 C T 4.65E-06 Rheumatoid arthritis / / 19503088 rs12184871 chr13 41291928 C A 6.75E-06 Rheumatoid arthritis / / 19503088 rs7322754 chr13 41322977 G T 4.77E-06 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines MRPS31 intron 21483694 rs9549281 chr13 41330171 T G 4.85E-06 Rheumatoid arthritis MRPS31 intron 19503088 rs3783165 chr13 41380130 A G 7.70E-05 Multiple complex diseases SLC25A15 intron 17554300 rs7992208 chr13 41416221 T C 1.09E-04 Crohn's disease LOC100616668 intron 23266558 rs9525397 chr13 41425711 G C 4.02E-04 Obesity (extreme) LOC100616668 intron 21935397 rs59597769 chr13 41427029 T C 1.66E-05 Crohn's disease LOC100616668 intron 23266558 rs77419885 chr13 41427506 C T 2.00E-05 Crohn's disease LOC100616668 intron 23266558 rs4941999 chr13 41434062 C T 7.74E-05 Blood Pressure LOC100616668 intron pha003040 rs7333274 chr13 41436667 T C 9.24E-04 Obesity (extreme) LOC100616668 intron 21935397 rs7339089 chr13 41437926 C T 1.62E-05 Crohn's disease LOC100616668 intron 23266558 rs79487860 chr13 41438217 G A 2.71E-05 Crohn's disease LOC100616668 intron 23266558 rs4942005 chr13 41445772 A G 7.74E-05 Blood Pressure LOC100616668 intron pha003040 rs4254182 chr13 41453256 T C 4.79E-04 Obesity (extreme) LOC100616668 intron 21935397 rs9532645 chr13 41455034 G A 2.14E-04 Birth weight LOC100616668 intron 17255346 rs7320344 chr13 41459638 A G 4.05E-04 Obesity (extreme) LOC100616668 intron 21935397 rs7329474 chr13 41470342 C T 3.32E-05 Crohn's disease LOC100616668 intron 23266558 rs1989252 chr13 41485668 T C 7.43E-07 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines LOC100616668 intron 21483694 rs1989252 chr13 41485668 T C 3.08E-04 Obesity (extreme) LOC100616668 intron 21935397 rs57088152 chr13 41487686 T C 1.75E-05 Crohn's disease SUGT1P3 intron 23266558 rs7333447 chr13 41491722 A T 3.13E-04 Obesity (extreme) SUGT1P3 intron 21935397 rs9594460 chr13 41501643 C A 3.32E-04 Crohn's disease / / 23266558 rs9532670 chr13 41501827 T C 9.92E-04 Obesity (extreme) / / 21935397 rs77419017 chr13 41510339 G A 1.39E-04 Crohn's disease ELF1 intron 23266558 rs75719223 chr13 41522272 T G 1.51E-04 Crohn's disease ELF1 intron 23266558 rs3736953 chr13 41525586 A G 1.94E-04 Obesity (extreme) ELF1 intron 21935397 rs60129138 chr13 41526350 C T 1.96E-04 Crohn's disease ELF1 intron 23266558 rs9532689 chr13 41532126 T C 1.47E-04 Obesity (extreme) ELF1 intron 21935397 rs7799 chr13 41533052 T C 1.46E-04 Obesity (extreme) ELF1 missense 21935397 rs9562254 chr13 41535038 G A 1.51E-04 Obesity (extreme) ELF1 intron 21935397 rs7329302 chr13 41536532 A G 1.52E-04 Obesity (extreme) ELF1 intron 21935397 rs9525438 chr13 41538259 A G 7.98E-04 Alzheimer's disease ELF1 intron 17998437 rs9525438 chr13 41538259 A G 1.53E-04 Obesity (extreme) ELF1 intron 21935397 rs17630801 chr13 41539817 A C 1.59E-04 Crohn's disease ELF1 intron 23266558 rs4942014 chr13 41540502 A T 1.53E-04 Obesity (extreme) ELF1 intron 21935397 rs9532690 chr13 41542790 T C 1.55E-04 Obesity (extreme) ELF1 intron 21935397 rs9532691 chr13 41543494 T C 1.55E-04 Obesity (extreme) ELF1 intron 21935397 rs77553977 chr13 41547143 T C 5.93E-05 Crohn's disease ELF1 intron 23266558 rs9532692 chr13 41552738 G A 2.63E-05 Crohn's disease ELF1 intron 23266558 rs78076494 chr13 41555724 G A 1.48E-05 Crohn's disease ELF1 intron 23266558 rs57668933 chr13 41557118 T C 2.75E-05 Crohn's disease ELF1 intron 23266558 rs7329174 chr13 41558110 A G 1.00E-08 Systemic lupus erythematosus ELF1 intron 21044949 rs7329174 chr13 41558110 A G 8.00E-09 Crohn's disease ELF1 intron 23266558 rs7329174 chr13 41558110 A G 6.00E-06 Systemic lupus erythematosus ELF1 intron 23273568 rs12585650 chr13 41562860 C A 1.56E-05 Crohn's disease ELF1 intron 23266558 rs2324748 chr13 41563588 T C 1.73E-04 Obesity (extreme) ELF1 intron 21935397 rs78053745 chr13 41563902 T C 2.86E-05 Crohn's disease ELF1 intron 23266558 rs59691646 chr13 41564287 A C 2.53E-05 Crohn's disease ELF1 intron 23266558 rs9525439 chr13 41566781 G A 1.75E-04 Obesity (extreme) ELF1 intron 21935397 rs80022860 chr13 41568872 G A 2.17E-05 Crohn's disease ELF1 intron 23266558 rs1543589 chr13 41573200 C T 1.76E-04 Obesity (extreme) ELF1 intron 21935397 rs74674762 chr13 41575804 T C 2.86E-05 Crohn's disease ELF1 intron 23266558 rs7335629 chr13 41579868 T C 8.39E-05 Crohn's disease ELF1 intron 23266558 rs12584853 chr13 41583941 C T 6.96E-05 Crohn's disease ELF1 intron 23266558 rs74757048 chr13 41585055 T C 1.81E-05 Crohn's disease ELF1 intron 23266558 rs4264266 chr13 41588832 G T 1.03E-04 Crohn's disease ELF1 intron 23266558 rs61300271 chr13 41602462 T C 4.81E-05 Crohn's disease / / 23266558 rs2031662 chr13 41610561 C T 4.30E-06 Asthma (childhood onset) / / 23829686 rs4942023 chr13 41675611 G A 8.15E-05 Caffeine consumption / / 21490707 rs7334971 chr13 41683827 A C 5.46E-04 Type 2 diabetes / / 17463246 rs484124 chr13 41722830 T C 2.49E-04 Insulin resistance / / 21901158 rs693856 chr13 41729632 G A 6.61E-04 Insulin resistance / / 21901158 rs9566712 chr13 41761499 C G 7.93E-04 Insulin resistance / / 21901158 rs1591127 chr13 41842561 C T 7.26E-05 Relative hand skill / / 24068947 rs9562287 chr13 41898147 T G 8.27E-04 Depression (quantitative trait) /A16 intron 20800221 rs9566743 chr13 41898405 A G 8.26E-04 Depression (quantitative trait) /A16 intron 20800221 rs11620416 chr13 41907826 A G 4.56E-04 Depression (quantitative trait) /A16 intron 20800221 rs9562289 chr13 41912190 T G 4.14E-04 Depression (quantitative trait) /A16 intron 20800221 rs4346095 chr13 41912340 T C 2.85E-04 Hearing function /A16 intron 17255346 rs7989372 chr13 41921933 G A 6.19E-04 Parkinson's disease /A16 intron 17052657 rs7321509 chr13 41928314 A G 3.79E-04 Depression (quantitative trait) /A16 intron 20800221 rs9562292 chr13 41928593 T A 3.80E-04 Depression (quantitative trait) /A16 intron 20800221 rs9566753 chr13 41933464 T C 3.78E-04 Depression (quantitative trait) /A16 intron 20800221 rs9566754 chr13 41933637 A G 3.78E-04 Depression (quantitative trait) /A16 intron 20800221 rs3829396 chr13 41935250 C A,G,T 4.60E-04 Depression (quantitative trait) /A16 intron 20800221 rs9562293 chr13 41937790 T C 4.59E-04 Depression (quantitative trait) /A16 intron 20800221 rs9562294 chr13 41938284 T C 4.59E-04 Depression (quantitative trait) /A16 intron 20800221 rs9566755 chr13 41940597 A G 4.58E-04 Depression (quantitative trait) /A16 intron 20800221 rs9562295 chr13 41943052 A T 4.58E-04 Depression (quantitative trait) /A16 intron 20800221 rs9566757 chr13 41948125 A G 4.57E-04 Depression (quantitative trait) /A16 intron 20800221 rs4558307 chr13 41958476 G A 2.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11620020 chr13 41960630 T G 8.54E-04 Depression (quantitative trait) / / 20800221 rs9562297 chr13 41961175 T A 6.05E-04 Depression (quantitative trait) / / 20800221 rs3923988 chr13 41962997 A G 5.95E-04 Depression (quantitative trait) / / 20800221 rs11616683 chr13 41985154 A G 3.14E-04 Depression (quantitative trait) / / 20800221 rs7489810 chr13 41987767 G A 7.45E-04 Obesity (extreme) / / 21935397 rs4427698 chr13 41988053 C A 7.51E-04 Obesity (extreme) / / 21935397 rs9594542 chr13 41993091 T C 7.64E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9532824 chr13 42037920 T C 9.58E-04 Alzheimer's disease RGCC intron 24755620 rs7326471 chr13 42037935 C T 8.31E-04 Schizophrenia RGCC intron 19197363 rs9562311 chr13 42071866 G A 4.04E-04 Alzheimer's disease / / 24755620 rs1105145 chr13 42073812 C T 0.000172 Asthma / / 22502797 rs348254 chr13 42076415 T A 2.67E-04 Depression (quantitative trait) / / 20800221 rs1179957 chr13 42077774 T G 7.56E-04 Depression (quantitative trait) / / 20800221 rs2770043 chr13 42079410 T C 4.21E-04 Multiple complex diseases / / 17554300 rs1473789 chr13 42104869 G A 6.43E-04 Multiple complex diseases / / 17554300 rs4941403 chr13 42105710 A G 1.75E-05 Suicidal ideation / / 20877300 rs9532889 chr13 42115117 G A 5.13E-04 Multiple complex diseases / / 17554300 rs375557 chr13 42131866 G A 4.36E-04 Self-reported allergy / / 23817569 rs376255 chr13 42131899 A C 3.13E-04 Self-reported allergy / / 23817569 rs17594362 chr13 42139245 C T 4.00E-06 Multiple sclerosis / / 21833088 rs1023243 chr13 42151623 G A 0.00000288 Major depressive disorder KIAA0564 intron 22915352 rs7326977 chr13 42156006 G A 2.06E-04 Self-reported allergy KIAA0564 intron 23817569 rs17637352 chr13 42160976 A T 9.61E-04 Suicide attempts in bipolar disorder KIAA0564 intron 21423239 rs2025969 chr13 42173001 T C 5.65E-04 Alzheimer's disease KIAA0564 intron 24755620 rs9566806 chr13 42174792 C T 3.28E-06 Bipolar disorder,affective KIAA0564 intron 20528957 rs9566806 chr13 42174792 C T 8.03E-05 Alzheimer's disease KIAA0564 intron 24755620 rs9566808 chr13 42180806 T C 1.18E-07 Bipolar disorder,affective KIAA0564 intron 20528957 rs9566808 chr13 42180806 T C 1.89E-04 Alzheimer's disease KIAA0564 intron 24755620 rs9566809 chr13 42182377 C A 6.47E-06 Bipolar disorder,affective KIAA0564 intron 20528957 rs9566809 chr13 42182377 C A 6.62E-05 Alzheimer's disease KIAA0564 intron 24755620 rs7981912 chr13 42196943 G A 4.86E-04 Alcohol dependence KIAA0564 intron 21314694 rs7981912 chr13 42196943 G A 1.65E-04 Alzheimer's disease KIAA0564 intron 24755620 rs9315855 chr13 42240425 G T 7.19E-04 Alzheimer's disease KIAA0564 intron 24755620 rs17637547 chr13 42257921 T C 9.61E-05 Alzheimer's disease KIAA0564 intron 24755620 rs78161810 chr13 42259195 T G 0.00084 Prostate cancer KIAA0564 missense 23555315 rs7140090 chr13 42266889 T C 3.70E-05 Alzheimer's disease KIAA0564 intron 24755620 rs9562336 chr13 42274240 G A 0.000606038 Hypertension (early onset hypertension) KIAA0564 intron 22479346 rs17449722 chr13 42285381 A C 5.74E-04 Tourette syndrome KIAA0564 intron 22889924 rs932879 chr13 42294156 A T 6.50E-05 Diabetic retinopathy KIAA0564 intron 21441570 rs10507495 chr13 42294397 T C 3.09E-05 Bipolar disorder,affective KIAA0564 intron 20528957 rs11620206 chr13 42299437 T C 1.54E-04 Body mass index KIAA0564 intron 17255346 rs9590630 chr13 42299559 C T 7.48E-04 Multiple complex diseases KIAA0564 intron 17554300 rs9590631 chr13 42299653 G C 4.33E-04 Multiple complex diseases KIAA0564 intron 17554300 rs9594618 chr13 42300108 C G 7.41E-04 Multiple complex diseases KIAA0564 intron 17554300 rs7337310 chr13 42300323 T C 9.64E-04 Multiple complex diseases KIAA0564 intron 17554300 rs928038 chr13 42307687 C T 8.93E-05 Body mass index KIAA0564 intron 17255346 rs1475482 chr13 42308768 G A 9.41E-05 Body mass index KIAA0564 intron 17255346 rs9566836 chr13 42309732 C T 7.00E-05 Diabetic retinopathy KIAA0564 intron 21441570 rs2039281 chr13 42314903 C T 7.91E-04 Multiple complex diseases KIAA0564 intron 17554300 rs2039281 chr13 42314903 C T 7.00E-05 Diabetic retinopathy KIAA0564 intron 21441570 rs9566845 chr13 42336080 G A 7.70E-08 Bipolar disorder,affective KIAA0564 intron 20528957 rs9566845 chr13 42336080 G A 3.12E-05 Alzheimer's disease KIAA0564 intron 24755620 rs11619225 chr13 42336617 T G 1.44E-04 Body mass index KIAA0564 intron 17255346 rs11619225 chr13 42336617 T G 6.30E-04 Multiple complex diseases KIAA0564 intron 17554300 rs7319641 chr13 42337621 C T 1.30E-04 Suicide attempts in bipolar disorder KIAA0564 intron 21423239 rs4942078 chr13 42338938 A G 1.38E-04 Suicide attempts in bipolar disorder KIAA0564 intron 21423239 rs9566846 chr13 42340198 C T 1.99E-07 Bipolar disorder,affective KIAA0564 intron 20528957 rs9566846 chr13 42340198 C T 9.08E-05 Alzheimer's disease KIAA0564 intron 24755620 rs9590642 chr13 42343084 C G 4.47E-04 Suicide attempts in bipolar disorder KIAA0564 intron 21423239 rs9562353 chr13 42385446 T C 4.10E-05 Alzheimer's disease KIAA0564 missense 24755620 rs9594635 chr13 42389208 C A 7.08E-05 Bipolar disorder,affective KIAA0564 intron 20528957 rs9594635 chr13 42389208 C A 5.30E-04 Alzheimer's disease KIAA0564 intron 24755620 rs17595042 chr13 42393885 A T 1.57E-07 Bipolar disorder,affective KIAA0564 intron 20528957 rs17595042 chr13 42393885 A T 4.25E-05 Alzheimer's disease KIAA0564 intron 24755620 rs9562355 chr13 42398275 G A 4.64E-05 Alzheimer's disease KIAA0564 intron 24755620 rs9532931 chr13 42400079 T C 3.54E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) KIAA0564 intron 24023788 rs7990886 chr13 42423706 A G 8.12E-04 Alzheimer's disease KIAA0564 intron 24755620 rs9566867 chr13 42428899 G A 8.27E-08 Bipolar disorder,affective KIAA0564 intron 20528957 rs9566867 chr13 42428899 G A 4.89E-05 Alzheimer's disease KIAA0564 intron 24755620 rs7993467 chr13 42431100 T C 4.89E-05 Alzheimer's disease KIAA0564 intron 24755620 rs3904327 chr13 42440981 C G 8.88E-05 Bipolar disorder,affective KIAA0564 intron 20528957 rs7334298 chr13 42461622 C T 1.95E-04 Multiple complex diseases KIAA0564 intron 17554300 rs10507501 chr13 42463833 C T 1.25E-07 Bipolar disorder,affective KIAA0564 intron 20528957 rs10507501 chr13 42463833 C T 3.98E-05 Alzheimer's disease KIAA0564 intron 24755620 rs9525553 chr13 42489501 C T 3.92E-05 Tuberculosis KIAA0564 intron 24057671 rs9566878 chr13 42490566 A G 6.90E-05 Bipolar disorder,affective KIAA0564 intron 20528957 rs11838643 chr13 42491984 C G 1.71E-04 Multiple complex diseases KIAA0564 intron 17554300 rs7318638 chr13 42501654 C T 9.73E-06 Tuberculosis KIAA0564 intron 24057671 rs1900442 chr13 42505674 T C 5.00E-06 Tuberculosis KIAA0564 intron 24057671 rs9525555 chr13 42510305 C T 2.71E-04 Multiple complex diseases KIAA0564 intron 17554300 rs17535055 chr13 42512412 T C 5.10E-05 HIV-1 control KIAA0564 intron 20041166 rs7318112 chr13 42525876 T C 2.87E-05 Tuberculosis KIAA0564 intron 24057671 rs9532960 chr13 42545676 G T 3.19E-04 Multiple complex diseases LOC100507240 intron 17554300 rs7336933 chr13 42559076 G A 9.00E-10 Calcium levels / / 24068962 rs11620406 chr13 42560772 C T 7.90E-05 Alcoholism (heaviness of drinking) / / 21529783 rs11618198 chr13 42560832 A G 5.60E-04 Multiple complex diseases / / 17554300 rs2324845 chr13 42569528 T C 4.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs7997862 chr13 42571136 G A 7.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs17062712 chr13 42580370 C T 5.52E-04 Acute lung injury / / 22295056 rs7328840 chr13 42587661 C T 4.65E-04 Acute lung injury / / 22295056 rs17062718 chr13 42589041 G A 4.65E-04 Acute lung injury / / 22295056 rs9562369 chr13 42590075 C T 2.78E-06 Nephrolithiasis / / 22396660 rs9532969 chr13 42591839 C T 3.00E-06 Metabolite levels (X-11787) / / 23934736 rs17062732 chr13 42597284 A G 5.90E-06 Colorectal cancer / / 19723657 rs8000933 chr13 42598291 C T 9.23E-04 Acute lung injury / / 22295056 rs737439 chr13 42601979 A T 8.15E-04 Acute lung injury / / 22295056 rs1900447 chr13 42604294 C A 8.73E-04 Acute lung injury / / 22295056 rs9525562 chr13 42611667 C A 9.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs17062754 chr13 42630501 C A 2.44E-04 Acute lung injury DGKH intron 22295056 rs6561030 chr13 42631719 C A 7.00E-06 Height DGKH intron 20189936 rs17062758 chr13 42631759 C T 8.05E-04 Acute lung injury DGKH intron 22295056 rs9566906 chr13 42642546 G A 1.18E-05 Nephrolithiasis DGKH intron 22396660 rs9566906 chr13 42642546 G A 0.000101187 Hypertension (early onset hypertension) DGKH intron 22479346 rs9315885 chr13 42642810 C T 1.00E-04 Bipolar disorder DGKH intron 17486107 rs1170183 chr13 42650733 C A 7.61E-04 Smoking initiation DGKH intron 24665060 rs9566910 chr13 42651002 G A 2.08E-05 Nephrolithiasis DGKH intron 22396660 rs9566910 chr13 42651002 G A 2.81E-07 Esophageal cancer (squamous cell) DGKH intron 22960999 rs1033951 chr13 42652637 T C 3.86E-05 Body Composition DGKH intron pha003012 rs1012053 chr13 42653437 C A 2.00E-08 Bipolar disorder DGKH intron 17486107 rs9532991 chr13 42654189 G A 0.000813361 Hypertension (early onset hypertension) DGKH intron 22479346 rs2253650 chr13 42656841 C T 7.16E-05 Nephrolithiasis DGKH intron 22396660 rs1750009 chr13 42657094 A G 9.85E-04 Multiple complex diseases DGKH intron 17554300 rs4994103 chr13 42657148 C T 9.42E-04 Acute lung injury DGKH intron 22295056 rs4994103 chr13 42657148 C T 1.17E-05 Nephrolithiasis DGKH intron 22396660 rs9562373 chr13 42659480 G A 1.22E-05 Nephrolithiasis DGKH intron 22396660 rs1900413 chr13 42660006 A G 1.22E-05 Nephrolithiasis DGKH intron 22396660 rs9525568 chr13 42663251 A G 5.78E-06 Nephrolithiasis DGKH intron 22396660 rs1115398 chr13 42669119 G T 6.12E-05 Amyotrophic lateral sclerosis (sporadic) DGKH intron 24529757 rs1170191 chr13 42675493 A G 3.70E-06 Bipolar disorder DGKH intron 17486107 rs1170191 chr13 42675493 A G 1.16E-05 Nephrolithiasis DGKH intron 22396660 rs912875 chr13 42677238 A C 4.09E-07 Nephrolithiasis DGKH intron 22396660 rs7984523 chr13 42678357 C T 5.48E-06 Nephrolithiasis DGKH intron 22396660 rs1170188 chr13 42678971 A G 1.13E-05 Nephrolithiasis DGKH intron 22396660 rs1170187 chr13 42679835 G A 1.13E-05 Nephrolithiasis DGKH intron 22396660 rs9562377 chr13 42685379 A G 4.22E-06 Nephrolithiasis DGKH intron 22396660 rs9566921 chr13 42687004 A G 4.22E-06 Nephrolithiasis DGKH intron 22396660 rs585206 chr13 42689853 A G 1.75E-06 Nephrolithiasis DGKH intron 22396660 rs7981733 chr13 42690060 C T 7.73E-06 Pancreatic cancer DGKH intron 22158540 rs7981733 chr13 42690060 C T 4.08E-07 Nephrolithiasis DGKH intron 22396660 rs1177637 chr13 42692823 G A 1.40E-05 Nephrolithiasis DGKH intron 22396660 rs1170169 chr13 42697807 G C 1.42E-06 Nephrolithiasis DGKH intron 22396660 rs9315891 chr13 42699079 C T 4.12E-07 Nephrolithiasis DGKH intron 22396660 rs9315891 chr13 42699079 C T 0.000639459 Hypertension (early onset hypertension) DGKH intron 22479346 rs9566924 chr13 42699907 T C 2.12E-05 Nephrolithiasis DGKH intron 22396660 rs670676 chr13 42701739 A T 5.17E-06 Nephrolithiasis DGKH intron 22396660 rs1170158 chr13 42701941 G T 6.25E-06 Nephrolithiasis DGKH intron 22396660 rs1170155 chr13 42702711 C T 1.15E-05 Nephrolithiasis DGKH intron 22396660 rs3742261 chr13 42703682 T C 8.05E-04 Alzheimer's disease DGKH intron 17998437 rs1750017 chr13 42704451 G A 2.13E-05 Nephrolithiasis DGKH intron 22396660 rs1170178 chr13 42705808 T C 1.60E-05 Nephrolithiasis DGKH intron 22396660 rs9566928 chr13 42708389 A G 1.44E-05 Nephrolithiasis DGKH intron 22396660 rs682573 chr13 42708655 G T 1.97E-05 Nephrolithiasis DGKH intron 22396660 rs9533007 chr13 42710235 A G 1.94E-05 Nephrolithiasis DGKH intron 22396660 rs12585075 chr13 42711224 C T 1.97E-05 Nephrolithiasis DGKH intron 22396660 rs12876965 chr13 42712741 A T 1.65E-05 Nephrolithiasis DGKH intron 22396660 rs1886811 chr13 42722064 A G 1.76E-04 Alzheimer's disease DGKH intron 17998437 rs1886811 chr13 42722064 A G 2.38E-04 Alzheimer's disease DGKH intron pha002879 rs17701966 chr13 42748558 T A 1.38E-05 Nephrolithiasis DGKH intron 22396660 rs9533023 chr13 42750593 T G 6.28E-04 Smoking initiation DGKH intron 24665060 rs4142110 chr13 42754522 T C 5.00E-09 Nephrolithiasis DGKH intron 22396660 rs12585267 chr13 42759971 A C 1.93E-05 Nephrolithiasis DGKH intron 22396660 rs4598803 chr13 42762871 A G 1.89E-05 Nephrolithiasis DGKH intron 22396660 rs2122247 chr13 42763140 G A 1.90E-05 Nephrolithiasis DGKH intron 22396660 rs9566935 chr13 42767185 T G 1.29E-05 Nephrolithiasis DGKH intron 22396660 rs10492438 chr13 42767706 C A 1.90E-05 Nephrolithiasis DGKH intron 22396660 rs12584544 chr13 42768720 G A 1.90E-05 Nephrolithiasis DGKH intron 22396660 rs11617266 chr13 42770696 G A 8.52E-05 Major depressive disorder DGKH intron 21621269 rs17598799 chr13 42772222 C G 4.00E-05 Nephrolithiasis DGKH intron 22396660 rs9566937 chr13 42773061 G A 4.08E-05 Major depressive disorder DGKH intron 21621269 rs1170102 chr13 42776117 G A 1.67E-05 Nephrolithiasis DGKH intron 22396660 rs1170103 chr13 42777027 G C 1.86E-05 Nephrolithiasis DGKH intron 22396660 rs1170109 chr13 42779694 G T 2.50E-05 Nephrolithiasis DGKH intron 22396660 rs9562385 chr13 42780628 C A 2.21E-05 Nephrolithiasis DGKH intron 22396660 rs9566939 chr13 42782887 C A 9.21E-06 Nephrolithiasis DGKH intron 22396660 rs347413 chr13 42787040 G A 2.61E-05 Nephrolithiasis DGKH intron 22396660 rs347420 chr13 42788348 A C 2.81E-04 Smoking initiation DGKH intron 24665060 rs347403 chr13 42789366 A G 1.10E-05 Nephrolithiasis DGKH intron 22396660 rs9315899 chr13 42793298 G T 6.38E-05 Monocyte counts DGKH intron pha003089 rs347387 chr13 42796369 G A 8.95E-04 Cognition,early reading ability DGKH intron 17684495 rs9590678 chr13 42811550 T A 5.58E-05 Major depressive disorder / / 21621269 rs9533044 chr13 42812356 A G 6.99E-05 Major depressive disorder / / 21621269 rs17646249 chr13 42826661 G A 4.70E-05 Intelligence (childhood) / / 23358156 rs10492434 chr13 42838864 C T 3.37E-05 Height / / pha003011 rs10492433 chr13 42838908 T G 6.76E-04 Multiple complex diseases / / 17554300 rs746447 chr13 42841176 G A 4.51E-04 Multiple complex diseases / / 17554300 rs875006 chr13 42843054 T C 2.70E-05 Diabetic retinopathy / / 21441570 rs34149529 chr13 42855604 C A 9.42E-04 Multiple complex diseases AKAP11 intron 17554300 rs17063155 chr13 42865197 C G 9.80E-06 Diabetic retinopathy AKAP11 intron 21441570 rs9315908 chr13 42890109 G T 6.76E-04 Multiple complex diseases AKAP11 intron 17554300 rs9525607 chr13 42890378 C T 8.47E-04 Multiple complex diseases AKAP11 intron 17554300 rs12861586 chr13 42910464 C A,T 4.30E-10 Bone mineral density (spine) / / 19801982 rs7995240 chr13 42913933 G A 3.30E-11 Bone mineral density (spine) / / 19801982 rs238250 chr13 42914646 G T 7.70E-06 Diabetic retinopathy / / 21441570 rs238252 chr13 42915654 C G 2.40E-08 Bone mineral density (spine) / / 19801982 rs238252 chr13 42915654 C G 6.30E-06 Diabetic retinopathy / / 21441570 rs17063206 chr13 42917459 C T 1.90E-08 Bone mineral density (spine) / / 19801982 rs17063206 chr13 42917459 C T 1.00E-05 Diabetic retinopathy / / 21441570 rs9525613 chr13 42918648 C T 9.07E-06 Bone mineral density / / 21124946 rs7994338 chr13 42919417 G A 1.80E-08 Bone mineral density (spine) / / 19801982 rs7994338 chr13 42919417 G A 1.80E-05 Diabetic retinopathy / / 21441570 rs430586 chr13 42920160 G A 3.07E-04 Insulin resistance / / 21901158 rs417768 chr13 42920398 A G 4.30E-10 Bone mineral density (spine) / / 19801982 rs11842146 chr13 42922506 C T 4.40E-10 Bone mineral density (spine) / / 19801982 rs238255 chr13 42923361 G A 4.60E-10 Bone mineral density (spine) / / 19801982 rs7998154 chr13 42923391 T C 1.60E-08 Bone mineral density (spine) / / 19801982 rs238256 chr13 42923675 A G 1.30E-05 Bone mineral density (spine) / / 19079262 rs238256 chr13 42923675 A G 4.20E-10 Bone mineral density (spine) / / 19801982 rs238257 chr13 42924883 C G 1.20E-13 Bone mineral density (spine) / / 19801982 rs238270 chr13 42932925 G A 5.60E-10 Bone mineral density (spine) / / 19801982 rs238271 chr13 42933354 T C 7.37E-05 Type 1 diabetes / / 18978792 rs238271 chr13 42933354 T C 1.90E-08 Bone mineral density (spine) / / 19801982 rs238271 chr13 42933354 T C 2.60E-05 Diabetic retinopathy / / 21441570 rs180851 chr13 42934040 C G 1.70E-12 Bone mineral density (spine) / / 19801982 rs7338012 chr13 42934126 A C 3.90E-09 Bone mineral density (spine) / / 19801982 rs238280 chr13 42938474 T C 8.50E-09 Bone mineral density (spine) / / 19801982 rs238280 chr13 42938474 T C 3.10E-05 Diabetic retinopathy / / 21441570 rs2875462 chr13 42945261 T C 2.00E-09 Bone mineral density (spine) / / 19801982 rs7992970 chr13 42945463 A G 3.00E-09 Bone mineral density (spine) / / 19079262 rs7992970 chr13 42945463 A G 2.70E-09 Bone mineral density (spine) / / 19801982 rs7988075 chr13 42945572 T C 4.00E-09 Bone mineral density (spine) / / 19801982 rs9533089 chr13 42951012 T A 1 Drug response to Etoposide / / 17537913 rs9533089 chr13 42951012 T A 5.70E-16 Bone mineral density (spine) / / 19801982 rs9533090 chr13 42951449 C T 1 Drug response to Etoposide / / 17537913 rs9533090 chr13 42951449 C T 5.00E-25 Bone mineral density (spine) / / 19801982 rs9533090 chr13 42951449 C T 5.00E-68 Bone mineral density / / 22504420 rs9533090 chr13 42951449 C T 0.000867 Lumbar spine bone mineral density (premenopausal) / / 23074152 rs9533090 chr13 42951449 C T 8.00E-14 Bone mineral density / / 23437003 rs9533090 chr13 42951449 C T 3.00E-07 Bone mineral density / / 24249740 rs9533090 chr13 42951449 C T 5.76E-04 Bone mineral density / / 24249740 rs9533090 chr13 42951449 C T 1.40E-05 Bone properties (heel) / / 24430505 rs9594738 chr13 42952145 C T 1 Drug response to Etoposide / / 17537913 rs9594738 chr13 42952145 C T 2.00E-08 Bone mineral density (hip) / / 18445777 rs9594738 chr13 42952145 C T 1.50E-24 Bone mineral density (spine) / / 19801982 rs9594738 chr13 42952145 C T 6.86E-06 Primary biliary cirrhosis / / 21399635 rs9594738 chr13 42952145 C T 4.00E-06 Bone mineral density / / 21533022 rs1475249 chr13 42954505 A G 1.00E-10 Bone mineral density (spine) / / 19801982 rs11840862 chr13 42956463 A G 1.20E-16 Bone mineral density (spine) / / 19801982 rs17638544 chr13 42956621 C T 1.70E-10 Bone mineral density (spine) / / 19801982 rs17638544 chr13 42956621 C T 5.00E-06 Bone mineral density / / 23437003 rs7317323 chr13 42957489 T C 1.90E-10 Bone mineral density (spine) / / 19801982 rs7317323 chr13 42957489 T C 4.63E-04 Self-reported allergy / / 23817569 rs9533093 chr13 42961597 T C 5.40E-11 Bone mineral density (spine) / / 19079262 rs17457561 chr13 42964203 G A 4.20E-13 Bone mineral density (spine) / / 19801982 rs8001611 chr13 42965694 C T 2.00E-12 Bone mineral density / / 23644456 rs7987211 chr13 42966734 T C 1.90E-10 Bone mineral density (spine) / / 19801982 rs7987728 chr13 42967012 T A 1.90E-10 Bone mineral density (spine) / / 19801982 rs7994209 chr13 42968129 T C 2.20E-10 Bone mineral density (spine) / / 19801982 rs7993166 chr13 42968163 G A 2.20E-10 Bone mineral density (spine) / / 19801982 rs7994236 chr13 42968178 T C 2.30E-10 Bone mineral density (spine) / / 19801982 rs7992844 chr13 42968250 A T 2.20E-10 Bone mineral density (spine) / / 19801982 rs7994609 chr13 42968325 T G 2.20E-10 Bone mineral density (spine) / / 19801982 rs12873631 chr13 42968396 T C 2.20E-10 Bone mineral density (spine) / / 19801982 rs9533095 chr13 42969049 G T 2.00E-15 Bone mineral density / / 24249740 rs9533095 chr13 42969049 G T 8.32E-08 Bone mineral density / / 24249740 rs10507507 chr13 42969646 T C 1.50E-06 Bone mineral density (spine) / / 19079262 rs10507508 chr13 42969782 A G 6.50E-09 Bone mineral density (spine) / / 19801982 rs12874234 chr13 42970723 A G 2.10E-10 Bone mineral density (spine) / / 19801982 rs7989519 chr13 42971214 A G 2.10E-10 Bone mineral density (spine) / / 19801982 rs10507509 chr13 42973090 C T 2.10E-10 Bone mineral density (spine) / / 19801982 rs4454853 chr13 42973297 G A 2.10E-10 Bone mineral density (spine) / / 19801982 rs2875470 chr13 42973595 C G 2.30E-10 Bone mineral density (spine) / / 19801982 rs7992415 chr13 42975297 A C 2.30E-10 Bone mineral density (spine) / / 19801982 rs1324003 chr13 42976126 C T 2.50E-10 Bone mineral density (spine) / / 19801982 rs7994531 chr13 42977439 C T 9.56E-04 Coronary Artery Disease / / 17634449 rs7994531 chr13 42977439 C T 1.00E-04 Chronic fatigue syndrome / / 21912186 rs7326472 chr13 42979951 A G 5.44E-05 Cholesterol / / 17255346 rs7326472 chr13 42979951 A G 1.20E-10 Bone mineral density (spine) / / 19801982 rs7326472 chr13 42979951 A G 7.23E-04 Self-reported allergy / / 23817569 rs12854504 chr13 42983701 T G 1.20E-10 Bone mineral density (spine) / / 19801982 rs7328203 chr13 42988546 T G 6.20E-12 Bone mineral density (spine) / / 19801982 rs7327510 chr13 42988924 A G 6.30E-12 Bone mineral density (spine) / / 19801982 rs9594746 chr13 42989660 T C 1.60E-11 Bone mineral density (spine) / / 19801982 rs9525619 chr13 42992135 C T 6.30E-11 Bone mineral density (spine) / / 19801982 rs9590697 chr13 42994481 C G 4.07E-05 Femoral neck bone geometry / / 22087292 rs727243 chr13 42995262 G A 9.06E-05 Femoral neck bone geometry / / 22087292 rs9533100 chr13 42996548 G T 6.40E-11 Bone mineral density (spine) / / 19801982 rs12864265 chr13 43014464 G A 3.24E-05 Femoral neck bone geometry / / 22087292 rs7316953 chr13 43017470 T C 2.93E-05 Femoral neck bone geometry / / 22087292 rs1324005 chr13 43017500 G C 2.08E-05 Femoral neck bone geometry / / 22087292 rs9533104 chr13 43017895 G C 9.30E-11 Bone mineral density (spine) / / 19801982 rs9525625 chr13 43018030 T C 9.30E-11 Bone mineral density (spine) / / 19801982 rs720824 chr13 43018177 A T 6.23E-05 Femoral neck bone geometry / / 22087292 rs9533108 chr13 43024710 C T 4.71E-05 Hypertension / / 21082022 rs9533108 chr13 43024710 C T 2.97E-06 Primary biliary cirrhosis / / 21399635 rs9315919 chr13 43029068 T A 1.73E-05 Femoral neck bone geometry / / 22087292 rs12430303 chr13 43032027 T C 7.40E-11 Bone mineral density (spine) / / 19801982 rs12429224 chr13 43032053 G T 3.50E-10 Bone mineral density (spine) / / 19801982 rs9594759 chr13 43032593 C T 2.00E-21 Bone mineral density (spine) / / 18445777 rs9594759 chr13 43032593 C T 2.00E-17 Bone mineral density (spine) / / 19079262 rs9594759 chr13 43032593 C T 7.30E-11 Bone mineral density (spine) / / 19801982 rs1853573 chr13 43034968 G C 7.30E-11 Bone mineral density (spine) / / 19801982 rs17536002 chr13 43035209 T C 3.62E-05 Femoral neck bone geometry / / 22087292 rs9594766 chr13 43040043 G A 7.40E-11 Bone mineral density (spine) / / 19801982 rs927623 chr13 43046054 T C 2.27E-05 Femoral neck bone geometry / / 22087292 rs7322806 chr13 43046397 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs912423 chr13 43051804 T A 9.32E-05 Femoral neck bone geometry / / 22087292 rs2062305 chr13 43052880 G A 1.90E-11 Bone mineral density (spine) / / 19801982 rs2062305 chr13 43052880 G A 5.00E-10 Crohn's disease / / 21102463 rs34132030 chr13 43056036 C T 0.000000177 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs34132030 chr13 43056036 C T 0.0000168 Oligoarticular juvenile idiopathic arthritis / / 23603761 rs34132030 chr13 43056036 C T 0.000612 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis / / 23603761 rs8000640 chr13 43057060 T A 0.0000305 Primary biliary cirrhosis / / 22936693 rs12876545 chr13 43057478 A G 1.16E-04 Self-reported allergy / / 23817569 rs9594770 chr13 43058031 A G 2.62E-05 Self-reported allergy / / 23817569 rs4942131 chr13 43058974 A G 2.47E-05 Self-reported allergy / / 23817569 rs6561054 chr13 43059882 A G 2.48E-05 Self-reported allergy / / 23817569 rs17536071 chr13 43060407 C T 2.80E-05 Urinary metabolites / / 21572414 rs17536071 chr13 43060407 C T 1.84E-05 Femoral neck bone geometry / / 22087292 rs9533127 chr13 43060658 T C 2.58E-05 Self-reported allergy / / 23817569 rs9525630 chr13 43060784 G T 2.58E-05 Self-reported allergy / / 23817569 rs2324919 chr13 43061784 C T 3.30E-05 Self-reported allergy / / 23817569 rs6561055 chr13 43062379 G A 2.60E-10 Bone mineral density (spine) / / 19801982 rs12868231 chr13 43064910 C T 2.80E-05 Urinary metabolites / / 21572414 rs12868231 chr13 43064910 C T 1.66E-05 Femoral neck bone geometry / / 22087292 rs9533129 chr13 43066117 C T 3.54E-05 Self-reported allergy / / 23817569 rs9533130 chr13 43066523 T A 3.44E-05 Self-reported allergy / / 23817569 rs4942133 chr13 43070050 A G 1.60E-05 Diabetic retinopathy / / 21441570 rs4942133 chr13 43070050 A G 1.23E-05 Self-reported allergy / / 23817569 rs4942134 chr13 43070217 C G 1.50E-05 Diabetic retinopathy / / 21441570 rs4942134 chr13 43070217 C G 1.09E-05 Self-reported allergy / / 23817569 rs9315921 chr13 43070771 G T 1.50E-05 Diabetic retinopathy / / 21441570 rs9315921 chr13 43070771 G T 1.20E-05 Self-reported allergy / / 23817569 rs9315922 chr13 43070780 G A 1.60E-05 Diabetic retinopathy / / 21441570 rs9315922 chr13 43070780 G A 1.19E-05 Self-reported allergy / / 23817569 rs10507510 chr13 43073157 A T 1.40E-05 Diabetic retinopathy / / 21441570 rs346593 chr13 43078346 C T 1.30E-05 Diabetic retinopathy / / 21441570 rs346593 chr13 43078346 C T 1.89E-05 Self-reported allergy / / 23817569 rs6561056 chr13 43082400 T C 1.20E-05 Diabetic retinopathy / / 21441570 rs6561056 chr13 43082400 T C 1.38E-05 Self-reported allergy / / 23817569 rs346599 chr13 43084305 G T 1.30E-05 Diabetic retinopathy / / 21441570 rs346599 chr13 43084305 G T 1.15E-05 Self-reported allergy / / 23817569 rs7336228 chr13 43085216 T G 1.20E-05 Diabetic retinopathy / / 21441570 rs7336228 chr13 43085216 T G 1.47E-05 Self-reported allergy / / 23817569 rs4941430 chr13 43086351 A G 1.20E-05 Diabetic retinopathy / / 21441570 rs4941430 chr13 43086351 A G 1.91E-05 Self-reported allergy / / 23817569 rs376999 chr13 43086646 A G 1.20E-05 Diabetic retinopathy / / 21441570 rs376999 chr13 43086646 A G 1.49E-05 Self-reported allergy / / 23817569 rs3862738 chr13 43086907 G A 6.83E-05 Femoral neck bone geometry / / 22087292 rs3862738 chr13 43086907 G A 2.18E-08 Primary biliary cirrhosis / / 22936693 rs3862738 chr13 43086907 G A 4.93E-08 Primary biliary cirrhosis (anti-mitochondrial antibody positive) / / 22936693 rs3862738 chr13 43086907 G A 9.63E-09 Primary biliary cirrhosis in females / / 22936693 rs17639156 chr13 43088407 T G 4.60E-10 Bone mineral density (spine) / / 19801982 rs665657 chr13 43089378 C T 3.33E-05 Hypertension / / 21082022 rs665657 chr13 43089378 C T 1.20E-05 Diabetic retinopathy / / 21441570 rs665657 chr13 43089378 C T 1.56E-05 Self-reported allergy / / 23817569 rs9315924 chr13 43097466 A G 1.10E-05 Diabetic retinopathy / / 21441570 rs9315924 chr13 43097466 A G 1.23E-05 Self-reported allergy / / 23817569 rs2025650 chr13 43098125 T A 9.30E-06 Diabetic retinopathy / / 21441570 rs2025650 chr13 43098125 T A 1.25E-05 Self-reported allergy / / 23817569 rs4942139 chr13 43098328 A G 8.70E-06 Diabetic retinopathy / / 21441570 rs4942139 chr13 43098328 A G 1.13E-05 Self-reported allergy / / 23817569 rs4941432 chr13 43098347 A G 7.90E-06 Diabetic retinopathy / / 21441570 rs4941432 chr13 43098347 A G 1.17E-05 Self-reported allergy / / 23817569 rs749934 chr13 43108245 G A 1.02E-06 Bone mineral density / / 21124946 rs749934 chr13 43108245 G A 3.20E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs7491228 chr13 43111120 C T 4.35E-04 Musician's dystonia / / 24375517 rs17458078 chr13 43111354 A C,T 9.74E-07 Bone mineral density / / 21124946 rs17458078 chr13 43111354 A C,T 5.46E-04 Smoking quantity / / 24665060 rs17458078 chr13 43111354 A C,T 2.70E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs17458078 chr13 43111354 A C,T 3.10E-08 Bone mineral density (paediatric,total body less head) / / 24945404 rs9533143 chr13 43111405 G C 9.11E-07 Bone mineral density / / 21124946 rs9533143 chr13 43111405 G C 2.50E-08 Bone mineral density (paediatric,total body less head) / / 24945404 rs9533143 chr13 43111405 G C 2.70E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs1021188 chr13 43116133 C T 2.00E-14 Bone mineral density / / 21124946 rs1021188 chr13 43116133 C T 4.00E-14 Bone mineral density / / 23437003 rs1021189 chr13 43116211 T C 8.75E-07 Bone mineral density / / 21124946 rs1021189 chr13 43116211 T C 1.90E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs1021189 chr13 43116211 T C 4.30E-08 Bone mineral density (paediatric,total body less head) / / 24945404 rs17596685 chr13 43117201 C T 5.36E-11 Bone mineral density / / 21124946 rs17596685 chr13 43117201 C T 4.00E-06 C-reactive protein / / 24763700 rs1853856 chr13 43117771 T G 3.79E-07 Bone mineral density / / 21124946 rs9533146 chr13 43117900 G A 3.77E-07 Bone mineral density / / 21124946 rs9594780 chr13 43121473 A G 1.88E-04 Musician's dystonia / / 24375517 rs168312 chr13 43121760 A G 7.07E-11 Bone mineral density / / 21124946 rs9533147 chr13 43123925 C T 6.53E-07 Bone mineral density / / 21124946 rs6561058 chr13 43126173 C T 7.44E-11 Bone mineral density / / 21124946 rs9525638 chr13 43128577 T C 5.62E-07 Bone mineral density / / 21124946 rs9525638 chr13 43128577 T C 4.00E-09 Cortical thickness / / 22792071 rs9525638 chr13 43128577 T C 1.30E-08 Bone mineral density (paediatric,total body less head) / / 24945404 rs9525638 chr13 43128577 T C 2.00E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs9525638 chr13 43128577 T C 3.00E-09 Bone mineral density (paediatric,upper limb) / / 24945404 rs9525639 chr13 43132879 C A 7.60E-11 Bone mineral density / / 21124946 rs4531631 chr13 43135131 A G 7.60E-11 Bone mineral density TNFSF11 nearGene-5 21124946 rs7999416 chr13 43136346 G A 2.63E-10 Bone mineral density TNFSF11 nearGene-5 21124946 rs7324282 chr13 43137704 A C 7.38E-11 Bone mineral density TNFSF11 intron 21124946 rs1325798 chr13 43139049 C T 5.47E-07 Bone mineral density TNFSF11 intron 21124946 rs1325798 chr13 43139049 C T 1.10E-08 Bone mineral density (paediatric,total body less head) TNFSF11 intron 24945404 rs1325798 chr13 43139049 C T 2.50E-09 Bone mineral density (paediatric,upper limb) TNFSF11 intron 24945404 rs7996068 chr13 43139390 G A 9.72E-11 Bone mineral density TNFSF11 intron 21124946 rs8000846 chr13 43139586 G C 6.85E-11 Bone mineral density TNFSF11 intron 21124946 rs9533154 chr13 43140102 C T 5.27E-07 Bone mineral density TNFSF11 intron 21124946 rs9533154 chr13 43140102 C T 1.90E-08 Bone mineral density (paediatric,total body less head) TNFSF11 intron 24945404 rs9533154 chr13 43140102 C T 4.30E-09 Bone mineral density (paediatric,upper limb) TNFSF11 intron 24945404 rs12585014 chr13 43140559 G A 8.58E-11 Bone mineral density TNFSF11 intron 21124946 rs9943924 chr13 43142684 G A 9.60E-12 HDL cholesterol TNFSF11 intron 23063622 rs17536328 chr13 43143029 C T 7.11E-07 Bone mineral density TNFSF11 intron 21124946 rs17536328 chr13 43143029 C T 1.17E-04 Lymphocyte counts TNFSF11 intron 22286170 rs17536328 chr13 43143029 C T 2.51E-04 Smoking quantity TNFSF11 intron 24665060 rs17536328 chr13 43143029 C T 3.00E-07 Bone mineral density (paediatric,total body less head) TNFSF11 intron 24945404 rs17536328 chr13 43143029 C T 3.10E-09 Bone mineral density (paediatric,upper limb) TNFSF11 intron 24945404 rs17536328 chr13 43143029 C T 8.00E-09 Bone mineral density (paediatric,total body less head) TNFSF11 intron 24945404 rs7988338 chr13 43144842 G A 1.11E-10 Bone mineral density TNFSF11 intron 21124946 rs7325635 chr13 43145319 G A 7.07E-07 Bone mineral density TNFSF11 intron 21124946 rs7325635 chr13 43145319 G A 1.30E-08 Bone mineral density (paediatric,total body less head) TNFSF11 intron 24945404 rs7325635 chr13 43145319 G A 5.40E-09 Bone mineral density (paediatric,upper limb) TNFSF11 intron 24945404 rs9533156 chr13 43147671 T C 3.07E-07 Bone mineral density TNFSF11 intron 21124946 rs9533156 chr13 43147671 T C 8.40E-09 Bone mineral density (paediatric,upper limb) TNFSF11 intron 24945404 rs9525641 chr13 43148024 T C 2.83E-07 Bone mineral density TNFSF11 intron 21124946 rs9525641 chr13 43148024 T C 7.00E-09 Bone mineral density (paediatric,upper limb) TNFSF11 intron 24945404 rs4942143 chr13 43154806 G A 9.92E-11 Bone mineral density TNFSF11 intron 21124946 rs2277439 chr13 43155443 G A 9.85E-11 Bone mineral density TNFSF11 intron 21124946 rs1022926 chr13 43158734 C G 9.80E-11 Bone mineral density TNFSF11 intron 21124946 rs4941433 chr13 43159135 G T 9.80E-11 Bone mineral density TNFSF11 intron 21124946 rs9525643 chr13 43159516 T C 6.75E-07 Bone mineral density TNFSF11 intron 21124946 rs9525643 chr13 43159516 T C 1.10E-08 Bone mineral density (paediatric,total body less head) TNFSF11 intron 24945404 rs9525643 chr13 43159516 T C 4.60E-09 Bone mineral density (paediatric,upper limb) TNFSF11 intron 24945404 rs9525644 chr13 43159804 G A 2.87E-07 Bone mineral density TNFSF11 intron 21124946 rs9525644 chr13 43159804 G A 3.00E-08 Bone mineral density (paediatric,total body less head) TNFSF11 intron 24945404 rs9525644 chr13 43159804 G A 8.40E-09 Bone mineral density (paediatric,upper limb) TNFSF11 intron 24945404 rs2324851 chr13 43160930 A G 9.08E-11 Bone mineral density TNFSF11 intron 21124946 rs2324851 chr13 43160930 A G 8.63E-05 Major depressive disorder TNFSF11 intron 21621269 rs2148072 chr13 43162063 G A 2.00E-06 Bone mineral density (paediatric,upper limb) TNFSF11 intron 24945404 rs2148073 chr13 43163799 G C 1.40E-10 Bone mineral density TNFSF11 intron 21124946 rs4356365 chr13 43164171 T C 1.40E-10 Bone mineral density TNFSF11 intron 21124946 rs8002449 chr13 43164541 G A 1.41E-10 Bone mineral density TNFSF11 intron 21124946 rs346588 chr13 43165468 A G 1.43E-10 Bone mineral density TNFSF11 intron 21124946 rs346589 chr13 43166284 G A 1.49E-10 Bone mineral density TNFSF11 intron 21124946 rs346590 chr13 43166295 A G 1.47E-10 Bone mineral density TNFSF11 intron 21124946 rs1038434 chr13 43167333 T C 1.45E-10 Bone mineral density TNFSF11 intron 21124946 rs346591 chr13 43167474 A T 1.45E-10 Bone mineral density TNFSF11 intron 21124946 rs346592 chr13 43167513 A G 9.33E-11 Bone mineral density TNFSF11 intron 21124946 rs931273 chr13 43178583 C T 2.00E-04 Information processing speed TNFSF11 intron 21130836 rs1054016 chr13 43182002 G T 1.08E-06 Bone mineral density TNFSF11 UTR-3 21124946 rs1054016 chr13 43182002 G T 1.60E-08 Bone mineral density (paediatric,upper limb) TNFSF11 UTR-3 24945404 rs1054016 chr13 43182002 G T 3.70E-08 Bone mineral density (paediatric,total body less head) TNFSF11 UTR-3 24945404 rs4338693 chr13 43183683 T C 2.39E-06 Bone mineral density / / 21124946 rs9533171 chr13 43185106 G T 2.81E-05 Major depressive disorder / / 21621269 rs9533172 chr13 43185132 G C 1.55E-10 Bone mineral density / / 21124946 rs17596972 chr13 43186005 G A 2.56E-06 Bone mineral density / / 21124946 rs9533173 chr13 43186976 C T 1.41E-06 Bone mineral density / / 21124946 rs9525647 chr13 43189121 C T 3.62E-06 Bone mineral density / / 21124946 rs9533177 chr13 43189225 G T 3.30E-06 Bone mineral density / / 21124946 rs4942146 chr13 43199755 G T 6.03E-04 Type 2 diabetes / / 17463246 rs7984986 chr13 43200764 G A 6.03E-04 Type 2 diabetes / / 17463246 rs1325803 chr13 43205269 C T 1.57E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs1325804 chr13 43205517 T A 1.14E-06 Bone mineral density / / 21124946 rs9533186 chr13 43206107 A T 5.28E-04 Type 2 diabetes / / 17463246 rs7320593 chr13 43206484 G A 4.05E-04 Type 2 diabetes / / 17463246 rs7994396 chr13 43211344 T C 1.36E-04 Height / / 17255346 rs9567011 chr13 43219467 G A 2.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10507514 chr13 43234814 A G 1.28E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs9590707 chr13 43290930 A T 7.53E-04 Acute lung injury / / 22295056 rs9594795 chr13 43291922 G A 7.53E-04 Acute lung injury / / 22295056 rs17597366 chr13 43292681 A G 1.86E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs9590709 chr13 43293177 G A 8.05E-04 Acute lung injury / / 22295056 rs9315938 chr13 43293347 C T 8.05E-04 Acute lung injury / / 22295056 rs7331929 chr13 43294489 A G 3.10E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2296112 chr13 43295173 C T 7.55E-04 HIV-1 viral setpoint / / 17641165 rs9315939 chr13 43295589 G A 9.61E-04 Acute lung injury / / 22295056 rs9594797 chr13 43296058 A T 9.32E-04 Acute lung injury / / 22295056 rs9594799 chr13 43297882 T C 8.50E-04 Acute lung injury / / 22295056 rs10507515 chr13 43298637 G A 8.42E-04 Acute lung injury / / 22295056 rs9533234 chr13 43322777 A G 3.11E-04 Alzheimer's disease / / 22005930 rs9525676 chr13 43332753 G A 3.86E-04 Alzheimer's disease / / 22005930 rs9533236 chr13 43339346 A G 3.70E-04 Alzheimer's disease / / 22005930 rs10507516 chr13 43342108 G A 3.36E-04 Alzheimer's disease / / 22005930 rs10507516 chr13 43342108 G A 1.11E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs9525680 chr13 43352995 G A 3.68E-04 Alzheimer's disease / / 22005930 rs9525681 chr13 43355238 T A 3.84E-04 Alzheimer's disease / / 22005930 rs2875496 chr13 43359981 C T 2.54E-04 Alzheimer's disease FAM216B intron 22005930 rs9533245 chr13 43361269 G T 2.39E-04 Alzheimer's disease FAM216B intron 22005930 rs9525683 chr13 43362254 C A 2.41E-04 Alzheimer's disease FAM216B intron 22005930 rs9525684 chr13 43362523 C T 2.46E-04 Alzheimer's disease FAM216B intron 22005930 rs2296244 chr13 43364820 G A 1.96E-04 Alzheimer's disease FAM216B UTR-3 22005930 rs9533249 chr13 43367660 C G 3.82E-04 Alzheimer's disease / / 22005930 rs1323608 chr13 43368536 A G 8.85E-05 Bipolar disorder,schizoaffective / / 19567891 rs1535902 chr13 43371359 C A,G,T 1.75E-04 Bipolar disorder,schizoaffective / / 19567891 rs9562431 chr13 43379500 G A 1.52E-04 Bipolar disorder,schizoaffective / / 19567891 rs9567041 chr13 43379674 C T 1.53E-04 Bipolar disorder,schizoaffective / / 19567891 rs1535905 chr13 43388544 T C 1.37E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7329763 chr13 43394456 A G 8.01E-04 Alzheimer's disease / / 22005930 rs7990962 chr13 43399245 A G 5.61E-06 Bipolar disorder,schizoaffective / / 19567891 rs9533253 chr13 43402433 G A 9.37E-04 Alzheimer's disease / / 22005930 rs9525690 chr13 43403879 T C 6.98E-04 Alzheimer's disease / / 22005930 rs10507517 chr13 43404546 A G 2.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs9533256 chr13 43404854 C T 4.91E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs3918568 chr13 43454448 A G 9.50E-04 Type 2 diabetes / / 17463246 rs1535900 chr13 43480001 G A 3.76E-05 Male fertility EPSTI1 intron 22633400 rs12870438 chr13 43480205 G A 2.07E-05 Male fertility EPSTI1 intron 22633400 rs9567068 chr13 43492349 C A 1.83E-04 Height EPSTI1 intron 17255346 rs9533329 chr13 43549782 G A 9.86E-04 Response to cytadine analogues (cytosine arabinoside) EPSTI1 intron 24483146 rs9315977 chr13 43555534 A G 4.07E-04 Alzheimer's disease EPSTI1 intron 22005930 rs9533333 chr13 43555837 C T 3.59E-04 Alzheimer's disease EPSTI1 intron 22005930 rs9562447 chr13 43556058 C T 3.58E-04 Alzheimer's disease EPSTI1 intron 22005930 rs9315979 chr13 43556885 A G 3.52E-04 Alzheimer's disease EPSTI1 intron 22005930 rs4942185 chr13 43558846 T C 3.82E-04 Alzheimer's disease EPSTI1 intron 22005930 rs4245318 chr13 43559199 A C 3.87E-04 Alzheimer's disease EPSTI1 intron 22005930 rs9567087 chr13 43559454 A G 7.33E-04 Alzheimer's disease EPSTI1 intron 22005930 rs1886153 chr13 43559804 G A 4.87E-04 Alzheimer's disease EPSTI1 intron 22005930 rs2104316 chr13 43560431 C T 8.66E-04 Alzheimer's disease EPSTI1 intron 22005930 rs1011949 chr13 43562028 C G 5.19E-04 Alzheimer's disease EPSTI1 intron 22005930 rs7321249 chr13 43568914 A G 3.35E-04 Alzheimer's disease / / 22005930 rs17064002 chr13 43570801 C T 7.00E-07 Obesity-related traits / / 23251661 rs7998368 chr13 43571086 G T 3.60E-04 Alzheimer's disease (late onset) / / 21379329 rs4142312 chr13 43574986 G A 3.61E-04 Alzheimer's disease (late onset) / / 21379329 rs7339297 chr13 43575098 T C 4.34E-06 Lymphocyte counts / / 22286170 rs9315981 chr13 43587084 C T 4.06E-04 Alzheimer's disease / / 22005930 rs9525720 chr13 43588576 G A 2.87E-04 Alzheimer's disease / / 22005930 rs9567096 chr13 43592189 T C 2.55E-04 Alzheimer's disease / / 22005930 rs9525722 chr13 43602105 T C 9.67E-04 Alzheimer's disease D/JC15 intron 22005930 rs1323862 chr13 43603871 C T 8.60E-05 Insulin-related traits D/JC15 intron pha002901 rs9533356 chr13 43616658 G C 6.56E-04 Alzheimer's disease D/JC15 intron 17998437 rs6561104 chr13 43618530 T C 3.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) D/JC15 intron 20877124 rs9533357 chr13 43619651 G A 8.44E-04 Alzheimer's disease D/JC15 intron 22005930 rs9525726 chr13 43621021 C T 8.64E-04 Alzheimer's disease D/JC15 intron 22005930 rs9533360 chr13 43622356 C A 8.79E-04 Alzheimer's disease D/JC15 intron 22005930 rs9533361 chr13 43623587 C T 8.87E-04 Alzheimer's disease D/JC15 intron 22005930 rs9533364 chr13 43626924 G A 9.66E-04 Alzheimer's disease D/JC15 intron 22005930 rs11617605 chr13 43632094 G A 9.02E-04 Alzheimer's disease D/JC15 intron 22005930 rs9533371 chr13 43635885 G A 9.90E-04 Alzheimer's disease D/JC15 intron 22005930 rs1028734 chr13 43637997 T G 9.89E-04 Alzheimer's disease D/JC15 intron 22005930 rs9533373 chr13 43638230 G A 9.89E-04 Alzheimer's disease D/JC15 intron 22005930 rs9567106 chr13 43638464 A G 4.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) D/JC15 intron 20877124 rs9533374 chr13 43639015 G A 9.84E-04 Alzheimer's disease D/JC15 intron 22005930 rs9533377 chr13 43644493 A G 9.90E-04 Alzheimer's disease D/JC15 intron 22005930 rs9525732 chr13 43645337 C A 9.91E-04 Alzheimer's disease D/JC15 intron 22005930 rs9533378 chr13 43646516 G A 9.98E-04 Alzheimer's disease D/JC15 intron 22005930 rs7321162 chr13 43656663 C T 5.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) D/JC15 intron 20877124 rs9525734 chr13 43661213 T C 9.77E-04 Alzheimer's disease D/JC15 intron 22005930 rs9533382 chr13 43663537 A T 9.90E-04 Alzheimer's disease D/JC15 intron 22005930 rs9525744 chr13 43684498 C T 1.12E-15 Lymphocyte counts / / 22286170 rs11618074 chr13 43688916 G A 4.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7325480 chr13 43691291 G T 5.65E-05 Glucose levels / / pha003058 rs9567111 chr13 43693919 A C 7.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17537900 chr13 43695449 T C 7.29E-06 Waist circumference / / 19557197 rs9567115 chr13 43696902 G A 4.04E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1324015 chr13 43727849 A G 9.00E-06 Cognitive performance / / 19734545 rs2589315 chr13 43743464 T C 1.40E-04 Multiple complex diseases / / 17554300 rs12857230 chr13 43756650 T G 1.76E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7323280 chr13 43761349 A G 7.87E-07 Coronary heart disease / / pha003032 rs9533423 chr13 43767963 C T 9.48E-04 Multiple complex diseases / / 17554300 rs9533425 chr13 43770474 G C 2.00E-09 End-stage coagulation / / 23381943 rs1037022 chr13 43787647 C T 2.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1037022 chr13 43787647 C T 5.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs703206 chr13 43788036 T G 6.62E-04 Smoking cessation ENOX1 UTR-3 24665060 rs2289774 chr13 43798348 T C 4.60E-04 Alcohol dependence ENOX1 intron 20201924 rs2289774 chr13 43798348 T C 6.45E-04 Major depressive disorder ENOX1 intron 22472876 rs1037023 chr13 43798406 C T 6.18E-04 Major depressive disorder ENOX1 intron 22472876 rs9285151 chr13 43814236 G A 1.70E-05 Subclinical atherosclerosis ENOX1 intron 17903303 rs10507519 chr13 43815123 C T 3.90E-04 Alcohol dependence ENOX1 intron 20201924 rs7319813 chr13 43824441 C T 3.92E-04 Longevity ENOX1 intron 22279548 rs9567136 chr13 43828746 A T 2.90E-04 Multiple complex diseases ENOX1 intron 17554300 rs17538444 chr13 43834270 C T 2.86E-04 Suicide attempts in bipolar disorder ENOX1 intron 21423239 rs17538444 chr13 43834270 C T 4.00E-07 Major depressive disorder ENOX1 intron 23377640 rs1867514 chr13 43835218 T A 9.29E-05 Serum metabolites ENOX1 intron 19043545 rs7995026 chr13 43853550 A C 6.90E-05 Subclinical atherosclerosis ENOX1 intron 17903303 rs12874803 chr13 43859324 T C 1.00E-04 Alcohol dependence ENOX1 intron 20201924 rs7338766 chr13 43859983 T C 5.73E-04 Depression (quantitative trait) ENOX1 intron 20800221 rs4942197 chr13 43861926 G C 6.30E-04 Depression (quantitative trait) ENOX1 intron 20800221 rs1117942 chr13 43863718 C A 6.42E-04 Depression (quantitative trait) ENOX1 intron 20800221 rs9590754 chr13 43865812 A T 9.20E-06 Uric acid levels ENOX1 intron 21294900 rs9533443 chr13 43867740 G C 2.48E-04 Nicotine smoking ENOX1 intron 19268276 rs12857536 chr13 43883604 G T 2.10E-04 Alcohol dependence ENOX1 intron 20201924 rs10492572 chr13 43890376 G A 7.17E-04 Myopia (pathological) ENOX1 intron 21095009 rs9590755 chr13 43898426 C T 2.31E-04 Multiple complex diseases ENOX1 intron 17554300 rs2093873 chr13 43899096 A T 6.27E-04 Suicide attempts in bipolar disorder ENOX1 intron 21423239 rs7318601 chr13 43917465 G A 5.09E-04 Longevity ENOX1 intron 22279548 rs1570681 chr13 43920876 C T 4.02E-04 Smoking initiation ENOX1 intron 24665060 rs9316014 chr13 43921761 A T 9.74E-05 Multiple complex diseases ENOX1 intron 17554300 rs9567174 chr13 43972664 T C 4.25E-04 Multiple complex diseases ENOX1 intron 17554300 rs2296041 chr13 43986771 G A 5.16E-04 Diabetic retinopathy ENOX1 intron 20871662 rs9567177 chr13 43988843 T G 2.95E-04 Insulin resistance ENOX1 intron 21901158 rs9533481 chr13 43989185 T C 1.46E-07 Diabetic nephropathy ENOX1 intron 21150874 rs9533481 chr13 43989185 T C 9.94E-05 Type 2 diabetes ENOX1 intron 22238593 rs1323161 chr13 44000631 G A 6.70E-05 Alcohol dependence ENOX1 intron 24277619 rs7338233 chr13 44002538 A G 1.45E-04 Multiple complex diseases ENOX1 intron 17554300 rs7320651 chr13 44024779 A G 7.49E-04 Type 2 diabetes ENOX1 intron 17463246 rs3884613 chr13 44085945 T C 7.95E-04 Alcohol dependence ENOX1 intron 20201924 rs9533521 chr13 44119458 A T 6.76E-04 Body mass index ENOX1 intron 21701565 rs9533533 chr13 44152148 G T 1.60E-05 Urinary metabolites ENOX1 intron 21572414 rs12585807 chr13 44170749 C T 5.94E-05 Serum metabolites ENOX1 intron 19043545 rs1329285 chr13 44170982 T C 2.80E-05 Urinary metabolites ENOX1 intron 21572414 rs17460665 chr13 44171453 C T 3.12E-05 Serum metabolites ENOX1 intron 19043545 rs17460665 chr13 44171453 C T 2.60E-05 Urinary metabolites ENOX1 intron 21572414 rs4941466 chr13 44173317 C T 2.90E-05 Urinary metabolites ENOX1 intron 21572414 rs2172926 chr13 44197999 G A 1.50E-05 Non-word repetition ENOX1 intron 23738518 rs9525812 chr13 44200099 T C 6.30E-05 Response to tocilizumab in rheumatoid arthritis ENOX1 intron 22491018 rs9562501 chr13 44205683 A G 2.20E-07 Response to tocilizumab in rheumatoid arthritis ENOX1 intron 22491018 rs1472330 chr13 44209628 A G 8.10E-05 Response to tocilizumab in rheumatoid arthritis ENOX1 intron 22491018 rs1390371 chr13 44211727 A G 1.40E-05 Response to tocilizumab in rheumatoid arthritis ENOX1 intron 22491018 rs4942242 chr13 44217064 T C 2.00E-07 Response to tocilizumab in rheumatoid arthritis ENOX1 intron 22491018 rs7319346 chr13 44218201 T C 4.50E-05 Response to tocilizumab in rheumatoid arthritis ENOX1 intron 22491018 rs9525816 chr13 44223898 A G 3.80E-05 Response to tocilizumab in rheumatoid arthritis ENOX1 intron 22491018 rs9533567 chr13 44225066 G A 8.91E-04 Body mass index ENOX1 intron 21701565 rs9525817 chr13 44225189 T C 3.70E-05 Response to tocilizumab in rheumatoid arthritis ENOX1 intron 22491018 rs1105856 chr13 44227067 G T 2.50E-07 Response to tocilizumab in rheumatoid arthritis ENOX1 intron 22491018 rs9594986 chr13 44229595 A G 7.15E-05 Serum metabolites ENOX1 intron 19043545 rs17538959 chr13 44229911 T G 5.50E-05 Response to tocilizumab in rheumatoid arthritis ENOX1 intron 22491018 rs7331003 chr13 44230253 T C 2.50E-07 Response to tocilizumab in rheumatoid arthritis ENOX1 intron 22491018 rs9594987 chr13 44230994 T C 3.66E-04 White matter integrity ENOX1 intron 22425255 rs9594987 chr13 44230994 T C 6.20E-07 Response to tocilizumab in rheumatoid arthritis ENOX1 intron 22491018 rs1105586 chr13 44232633 T C 2.70E-07 Response to tocilizumab in rheumatoid arthritis ENOX1 intron 22491018 rs9533573 chr13 44235707 C G 6.81E-04 Body mass index ENOX1 intron 21701565 rs883877 chr13 44239557 T C 6.57E-04 Multiple complex diseases ENOX1 intron 17554300 rs9525821 chr13 44239706 T C 7.21E-04 Multiple complex diseases ENOX1 intron 17554300 rs9567243 chr13 44239768 T C 7.80E-04 Multiple complex diseases ENOX1 intron 17554300 rs1032520 chr13 44241773 C T 0.000016 Major depressive disorder ENOX1 intron 22915352 rs1032521 chr13 44242578 A T 9.78E-05 Bipolar disorder ENOX1 intron 22925353 rs299347 chr13 44260783 C G 5.01E-04 Multiple complex diseases ENOX1 intron 17554300 rs299344 chr13 44263589 C A 6.67E-04 Multiple complex diseases ENOX1 intron 17554300 rs393632 chr13 44274730 A G 8.72E-05 Bipolar disorder ENOX1 intron 22925353 rs12864863 chr13 44294500 G A 1.79E-04 Multiple complex diseases ENOX1 intron 17554300 rs9525830 chr13 44304458 A C 7.89E-05 Multiple complex diseases ENOX1 intron 17554300 rs9567256 chr13 44307013 G C 1.48E-04 Multiple complex diseases ENOX1 intron 17554300 rs11619756 chr13 44329004 G A 7.93E-04 Multiple complex diseases ENOX1 intron 17554300 rs9533608 chr13 44329066 C A 9.73E-04 Multiple complex diseases ENOX1 intron 17554300 rs12427698 chr13 44373886 G A 7.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs9590793 chr13 44379896 T C 0.00000079 Joint damage severity in rheumatoid arthritis / / 23696630 rs9567265 chr13 44386266 C T 4.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs9533634 chr13 44397815 T C 4.77E-12 Leprosy / / 20018961 rs3088362 chr13 44433630 C A 1.36E-31 Leprosy CCDC122 intron 20018961 rs3088362 chr13 44433630 C A 3.84E-13 Leprosy CCDC122 intron 22019778 rs3088362 chr13 44433630 C A 1.37E-09 Leprosy CCDC122 intron pha002872 rs3088362 chr13 44433630 C A 2.28E-05 Body Mass Index CCDC122 intron pha003009 rs9567289 chr13 44437104 C T 0.00000313 Inter-adventitial common carotid artery diameter CCDC122 intron 23246012 rs10507521 chr13 44441834 G C 6.52E-04 Multiple complex diseases CCDC122 intron 17554300 rs17065161 chr13 44443723 A T 8.76E-04 Multiple complex diseases CCDC122 intron 17554300 rs2325089 chr13 44450222 G C 7.49E-04 Type 2 diabetes CCDC122 intron 17846124 rs3764147 chr13 44457925 A G 3.97E-05 Multiple complex diseases LACC1 missense 17554300 rs3764147 chr13 44457925 A G 2.00E-13 Crohn's disease LACC1 missense 18587394 rs3764147 chr13 44457925 A G 4.00E-54 Leprosy LACC1 missense 20018961 rs3764147 chr13 44457925 A G 1.00E-10 Crohn's disease LACC1 missense 21102463 rs3764147 chr13 44457925 A G 2.00E-13 Asthma LACC1 missense 21150878 rs3764147 chr13 44457925 A G 3.83E-18 Leprosy LACC1 missense 22019778 rs3764147 chr13 44457925 A G 2.08E-13 Multiple sclerosis LACC1 missense 22190364 rs3764147 chr13 44457925 A G 2.00E-21 Crohn's disease LACC1 missense 23128233 rs3764147 chr13 44457925 A G 8.55E-06 Behcet's disease LACC1 missense 23291587 rs3764147 chr13 44457925 A G 1.21E-10 Leprosy LACC1 missense pha002872 rs3764147 chr13 44457925 A G 7.36E-06 Behcet's disease LACC1 missense pha002888 rs2121037 chr13 44471317 C T 4.56E-05 Behcet's disease / / pha002888 rs1373904 chr13 44475398 A G 7.78E-06 Behcet's disease / / 23291587 rs10507522 chr13 44479000 A G 4.64E-24 Leprosy / / 20018961 rs10507522 chr13 44479000 A G 1.33E-08 Leprosy / / pha002872 rs687582 chr13 44507689 T C 6.19E-06 Leprosy / / pha002872 rs17600693 chr13 44509519 C G 7.43E-04 Type 2 diabetes / / 17463246 rs17600726 chr13 44514431 A G 1.45E-04 Cholesterol / / 17255346 rs17572130 chr13 44519281 C G 5.29E-04 Multiple complex diseases / / 17554300 rs2028809 chr13 44523136 G A 6.48E-04 Heart Failure / / pha002885 rs9562532 chr13 44599789 G A 1.44E-07 Crohn's disease LINC00284 intron 18587394 rs17065323 chr13 44627788 C T 4.00E-06 Uric acid levels / / 18759275 rs9567349 chr13 44637405 A G 4.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs9567354 chr13 44640995 T C 2.99E-06 White blood cell count / / 21738479 rs4941481 chr13 44666744 A G 8.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4406961 chr13 44669168 T C 8.80E-04 Type 2 diabetes / / 17463246 rs4406961 chr13 44669168 T C 8.83E-06 Squamous cell carcinoma / / 23341777 rs4942278 chr13 44681950 C A 2.50E-05 Lung adenocarcinoma / / 22797724 rs4270067 chr13 44682724 A G 2.74E-04 Coronary Artery Disease / / 17634449 rs9525916 chr13 44702869 T A 5.00E-06 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs9525916 chr13 44702869 T A 7.00E-06 Fasting insulin (interaction) / / 24204828 rs9595066 chr13 44706268 T C 2.72E-05 Bipolar disorder and schizophrenia / / 20889312 rs9595066 chr13 44706268 T C 8.09E-05 Femoral neck bone geometry / / 22087292 rs9533777 chr13 44708720 G A 3.86E-05 Bipolar disorder and schizophrenia / / 20889312 rs9533777 chr13 44708720 G A 9.15E-05 Femoral neck bone geometry / / 22087292 rs9525917 chr13 44710561 A G 3.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs9567377 chr13 44720217 G T 2.71E-04 Alzheimer's disease (late onset) C13orf44-AS1 intron 21379329 rs4941484 chr13 44739329 A G 6.56E-04 Alzheimer's disease / / 17998437 rs7317055 chr13 44742426 T C 8.21E-04 Alzheimer's disease / / 17998437 rs9533783 chr13 44751925 G A 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4391951 chr13 44755071 T C 2.75E-05 Femoral neck bone geometry / / 22087292 rs9567389 chr13 44763883 G A 8.54E-05 Femoral neck bone geometry / / 22087292 rs9316073 chr13 44793122 G A 2.75E-04 Alzheimer's disease (late onset) / / 21379329 rs9316073 chr13 44793122 G A 4.18E-04 Alzheimer's disease / / 24755620 rs2843389 chr13 44798525 A T 1.58E-04 Multiple complex diseases / / 17554300 rs9533799 chr13 44808174 C A 4.69E-05 Amyotrophic lateral sclerosis / / 20801717 rs9533799 chr13 44808174 C A 4.00E-06 Amyotrophic lateral sclerosis / / 22959728 rs9285153 chr13 44812570 G A 6.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9595087 chr13 44813700 G A 1.40E-05 Urinary metabolites / / 21572414 rs2256363 chr13 44818006 T C 3.17E-05 Amyotrophic lateral sclerosis / / 20801717 rs2246122 chr13 44826508 T C 2.27E-04 Multiple complex diseases / / 17554300 rs2246129 chr13 44826634 C T 9.39E-04 Multiple complex diseases / / 17554300 rs9525927 chr13 44842503 G A 2.15E-04 Vaspin levels / / 22907691 rs9525927 chr13 44842503 G A 0.0002153 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs6561169 chr13 44844238 C T 2.09E-05 Multiple sclerosis (age of onset) / / 19010793 rs1330102 chr13 44845243 T C 7.40E-06 Urinary metabolites / / 21572414 rs9595095 chr13 44850295 C T 4.42E-05 Non-word repetition / / 23738518 rs11839128 chr13 44851278 G A 4.42E-05 Non-word repetition / / 23738518 rs10400629 chr13 44852020 C T 4.42E-05 Non-word repetition / / 23738518 rs1536944 chr13 44852696 G A 4.42E-05 Non-word repetition / / 23738518 rs1536945 chr13 44852858 G A 4.42E-05 Non-word repetition / / 23738518 rs1536946 chr13 44853226 A C 4.42E-05 Non-word repetition / / 23738518 rs12100284 chr13 44858122 G A 5.94E-04 Aortic root size / / 21223598 rs2031996 chr13 44875173 C T 1.80E-05 Urinary metabolites / / 21572414 rs2093939 chr13 44876701 T C 1.10E-05 Urinary metabolites / / 21572414 rs2773271 chr13 44879271 A G 4.25E-04 Alzheimer's disease (late onset) / / 21379329 rs1033902 chr13 44882626 T C 1.50E-05 Urinary metabolites / / 21572414 rs1033901 chr13 44882689 G C 1.30E-05 Urinary metabolites / / 21572414 rs4942315 chr13 44886966 G T 5.12E-04 Multiple complex diseases / / 17554300 rs721735 chr13 44892338 C T 3.16E-05 Cognitive performance / / 19734545 rs1175191 chr13 44899028 T C 3.03E-04 Acute lung injury / / 22295056 rs1013092 chr13 44904741 C T 1.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs4942319 chr13 44907415 C G 1.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs582369 chr13 44907594 G A 5.22E-05 Suicide attempts in bipolar disorder / / 21423239 rs1571561 chr13 44907942 T G 1.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs9567414 chr13 44908211 A G 1.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs9567415 chr13 44908572 G A 1.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs9567416 chr13 44908741 T C 1.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs4942321 chr13 44910022 A G 6.33E-05 Suicide attempts in bipolar disorder / / 21423239 rs9567417 chr13 44910736 G A 1.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs1175196 chr13 44911116 C A 1.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs7983067 chr13 44911556 C T 8.13E-05 Suicide attempts in bipolar disorder / / 21423239 rs7326226 chr13 44912736 G C 1.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs13378575 chr13 44927384 C T 2.02E-04 Coronary heart disease / / 21606135 rs9525954 chr13 44978167 C A 4.46E-04 Type 2 diabetes / / 17463246 rs2325129 chr13 44999258 T C 1.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs2875552 chr13 45004494 C T 5.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs12583155 chr13 45024370 T C 6.00E-04 Suicide attempts in bipolar disorder TSC22D1 intron 21041247 rs11619041 chr13 45029733 A G 3.17E-04 Suicide attempts in bipolar disorder TSC22D1 intron 21041247 rs4942331 chr13 45030799 C T 5.96E-04 Suicide attempts in bipolar disorder TSC22D1 intron 21041247 rs9533862 chr13 45034814 G C 3.46E-04 Suicide attempts in bipolar disorder TSC22D1 intron 21041247 rs9595128 chr13 45036565 A G 5.89E-04 Suicide attempts in bipolar disorder TSC22D1 intron 21041247 rs9595132 chr13 45048832 A G 5.85E-04 Suicide attempts in bipolar disorder TSC22D1 intron 21041247 rs17065868 chr13 45055091 T C 3.00E-06 Antineutrophil cytoplasmic antibody-associated vasculitis TSC22D1 intron 22808956 rs9533877 chr13 45072674 G A 3.98E-04 Suicide attempts in bipolar disorder TSC22D1 intron 21041247 rs9533885 chr13 45089160 A G 4.15E-04 Suicide attempts in bipolar disorder TSC22D1 intron 21041247 rs1041711 chr13 45106018 T C 4.42E-04 Coronary heart disease TSC22D1 intron 21606135 rs12184729 chr13 45193665 A G 3.24E-04 Multiple complex diseases / / 17554300 rs9567450 chr13 45208744 C T 3.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs9567458 chr13 45243639 A C 9.90E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs928709 chr13 45247391 G A 5.88E-04 Multiple complex diseases / / 17554300 rs9526000 chr13 45333690 T C 0.00007171 Sarcoidosis / / 22952805 rs139450281 chr13 45335142 G A 0.00004846 Sarcoidosis / / 22952805 rs7333314 chr13 45335782 T C 9.99E-05 Cognitive performance / / 19734545 rs2325151 chr13 45336693 C T 0.00001368 Sarcoidosis / / 22952805 rs3904808 chr13 45337632 A G 0.00001506 Sarcoidosis / / 22952805 rs3904807 chr13 45337663 G A 0.00001506 Sarcoidosis / / 22952805 rs2050638 chr13 45341834 G A 0.00008021 Sarcoidosis / / 22952805 rs1361100 chr13 45342436 A G 0.00004876 Sarcoidosis / / 22952805 rs9567474 chr13 45344685 A G 0.00001999 Sarcoidosis / / 22952805 rs9567475 chr13 45344755 C T 0.00001999 Sarcoidosis / / 22952805 rs73175379 chr13 45347187 T C 0.0000184 Sarcoidosis / / 22952805 rs7400172 chr13 45348375 G C 0.00002009 Sarcoidosis / / 22952805 rs139778809 chr13 45349521 T C 0.00003035 Sarcoidosis / / 22952805 rs144239110 chr13 45350691 G A 0.00003035 Sarcoidosis / / 22952805 rs56213590 chr13 45352734 G A 0.00002009 Sarcoidosis / / 22952805 rs150179043 chr13 45353462 C T 0.00002009 Sarcoidosis / / 22952805 rs9567477 chr13 45354566 C A 0.00002009 Sarcoidosis / / 22952805 rs9567478 chr13 45356685 A G 0.000023 Sarcoidosis / / 22952805 rs9567479 chr13 45358131 A C 0.00003832 Sarcoidosis / / 22952805 rs9567479 chr13 45358131 A C 1.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4941512 chr13 45358525 T C 0.00003075 Sarcoidosis / / 22952805 rs9595206 chr13 45360761 T C 0.00002431 Sarcoidosis / / 22952805 rs9590855 chr13 45361097 T C 0.00006984 Sarcoidosis / / 22952805 rs9567480 chr13 45364304 C T 0.00007578 Sarcoidosis / / 22952805 rs7323985 chr13 45368289 T A 6.24E-04 Self-reported allergy / / 23817569 rs2760386 chr13 45379502 T G 2.70E-05 Urinary metabolites LINC00330 intron 21572414 rs2146700 chr13 45381526 C T 1.94E-05 Mammographic density LINC00330 intron 22532574 rs1175311 chr13 45395677 A G 8.30E-05 Mammographic density / / 22532574 rs6561189 chr13 45449014 C G 5.26E-05 Multiple complex diseases / / 17554300 rs10492743 chr13 45463147 T A 7.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17648246 chr13 45493881 A G 1.00E-06 Oleic acid (18:1n-9) plasma levels / / 23362303 rs17066364 chr13 45515989 G C 4.44E-06 Bone mineral density NUFIP1 intron 21124946 rs17066368 chr13 45524443 T A 4.56E-06 Bone mineral density NUFIP1 intron 21124946 rs11620113 chr13 45550796 A G 4.73E-06 Bone mineral density NUFIP1 intron 21124946 rs17066376 chr13 45555062 C T 4.72E-06 Bone mineral density NUFIP1 intron 21124946 rs11616867 chr13 45566816 G A 4.72E-06 Bone mineral density KIAA1704 intron 21124946 rs17334045 chr13 45569862 A G 1.23E-04 Multiple complex diseases KIAA1704 intron 17554300 rs17334045 chr13 45569862 A G 7.28E-06 Bone mineral density KIAA1704 intron 21124946 rs11619825 chr13 45574057 A G 4.69E-06 Bone mineral density KIAA1704 intron 21124946 rs3783149 chr13 45582765 G A 4.70E-06 Bone mineral density KIAA1704 intron 21124946 rs11620104 chr13 45587765 G A 4.69E-06 Bone mineral density KIAA1704 intron 21124946 rs11147961 chr13 45589515 A G 4.69E-06 Bone mineral density KIAA1704 intron 21124946 rs3783148 chr13 45589854 G A 7.15E-06 Bone mineral density KIAA1704 intron 21124946 rs11618756 chr13 45595975 A G 4.73E-06 Bone mineral density KIAA1704 intron 21124946 rs7995712 chr13 45596683 G C 7.11E-06 Bone mineral density KIAA1704 intron 21124946 rs7995392 chr13 45596725 A T 4.75E-06 Bone mineral density KIAA1704 intron 21124946 rs7335692 chr13 45600715 G C 4.77E-06 Bone mineral density KIAA1704 intron 21124946 rs11618657 chr13 45600908 A T 4.78E-06 Bone mineral density KIAA1704 intron 21124946 rs11841716 chr13 45604491 T G 4.83E-06 Bone mineral density / / 21124946 rs3949337 chr13 45604889 T C 4.82E-06 Bone mineral density / / 21124946 rs11840919 chr13 45611646 C G 4.86E-06 Bone mineral density / / 21124946 rs7332969 chr13 45612903 A G 5.33E-06 Bone mineral density / / 21124946 rs7986584 chr13 45614775 C G 5.33E-06 Bone mineral density / / 21124946 rs7324584 chr13 45616911 A G 5.11E-06 Bone mineral density / / 21124946 rs1747103 chr13 45620169 G A 4.90E-04 Stroke / / pha002886 rs17066406 chr13 45624623 C T 2.95E-04 Multiple complex diseases / / 17554300 rs17066406 chr13 45624623 C T 2.80E-05 Urinary metabolites / / 21572414 rs11618616 chr13 45635321 A G 1.23E-04 Aortic root size / / 21223598 rs7323288 chr13 45657195 A G 8.90E-05 Major depressive disorder / / 21042317 rs7323288 chr13 45657195 A G 3.04E-04 Smoking initiation / / 24665060 rs7336303 chr13 45658934 C A 7.84E-05 Bipolar Disorder / / pha002858 rs17066439 chr13 45674773 C T 6.00E-05 Major depressive disorder / / 21042317 rs17066439 chr13 45674773 C T 6.76E-04 Smoking initiation / / 24665060 rs4483759 chr13 45676009 C G 7.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs2025418 chr13 45685847 T C 8.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs10507534 chr13 45826220 G A 1.05E-05 Blood Pressure and Arterial Stiffness GTF2F2 intron 17903302 rs7323755 chr13 45900267 G A 2.00E-13 Myopia (pathological) / / 23049088 rs9534145 chr13 46010469 A C 7.55E-04 Coronary heart disease / / 21606135 rs12866473 chr13 46037501 C T 2.20E-06 Urinary metabolites / / 21572414 rs3794331 chr13 46053544 T G 2.70E-05 Migraine COG3 intron 20802479 rs9316144 chr13 46106071 A G 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes COG3 intron 22628534 rs3014904 chr13 46112492 G A 3.12E-05 Celiac disease / / 23936387 rs3014917 chr13 46137837 T C 5.32E-04 Myopia (pathological) FAM194B intron 21095009 rs17066914 chr13 46139444 G T 6.55E-04 Type 2 diabetes FAM194B intron 17463246 rs2985941 chr13 46153600 C G 9.49E-04 Type 2 diabetes FAM194B intron 17463246 rs1925757 chr13 46186976 T C 9.40E-04 Amyotrophic Lateral Sclerosis FAM194B intron 17827064 rs1925757 chr13 46186976 T C 3.40E-05 HIV-1 control FAM194B intron 20041166 rs6561237 chr13 46197823 T C 7.50E-05 HIV-1 control / / 20041166 rs1123242 chr13 46208065 A G 8.10E-05 HIV-1 control / / 20041166 rs7991424 chr13 46233325 G A 9.00E-04 Stroke / / pha002887 rs17067018 chr13 46249013 T C 7.50E-04 Insulin resistance / / 21901158 rs1536182 chr13 46275415 G A 7.40E-06 Urinary metabolites / / 21572414 rs17068928 chr13 46276766 C T 6.70E-06 Urinary metabolites SPERT intron 21572414 rs9562611 chr13 46282275 A G 0.000775 Salmonella-induced pyroptosis SPERT intron 22837397 rs7317245 chr13 46288145 A G 7.89E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) SPERT missense 23648065 rs9316155 chr13 46290082 T C 1.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs9534199 chr13 46291526 T C 1.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs942869 chr13 46303952 C T 0.0002 Endometrial cancer / / 22426144 rs9567569 chr13 46308522 G T 4.95E-04 Lung function (forced vital capacity) / / 24023788 rs9316160 chr13 46312725 C T 2.58E-05 Cognitive test performance / / 20125193 rs7988311 chr13 46313781 A G 4.67E-05 Body Mass Index / / pha003014 rs7989399 chr13 46314231 C T 1.38E-05 Cognitive test performance / / 20125193 rs9526106 chr13 46324433 G T 4.83E-05 Cognitive test performance / / 20125193 rs1325643 chr13 46335170 T C 6.05E-05 Blood Pressure / / pha003043 rs7324600 chr13 46347354 A G 1.24E-04 Coronary heart disease / / 21606135 rs7993363 chr13 46347782 A T 6.02E-05 Multiple complex diseases / / 17554300 rs2896913 chr13 46348754 T C 3.73E-04 Multiple complex diseases / / 17554300 rs4942434 chr13 46353786 A G 8.86E-05 Multiple complex diseases / / 17554300 rs7988287 chr13 46363053 A C 4.69E-05 Chronic obstructive pulmonary disease SIAH3 intron 19300482 rs7988287 chr13 46363053 A C 4.69E-05 Response to statin treatment (atorvastatin),change in cholesterol levels SIAH3 intron 20031582 rs7988287 chr13 46363053 A C 1.20E-05 Urinary metabolites SIAH3 intron 21572414 rs1536184 chr13 46364642 A G 1.00E-05 Urinary metabolites SIAH3 intron 21572414 rs9316161 chr13 46371975 A C 4.20E-06 Urinary metabolites SIAH3 intron 21572414 rs7986581 chr13 46374573 T C 2.80E-05 Urinary metabolites SIAH3 intron 21572414 rs7985729 chr13 46374646 G A 2.99E-04 Multiple complex diseases SIAH3 intron 17554300 rs9590930 chr13 46380938 T C 3.47E-04 Multiple complex diseases SIAH3 intron 17554300 rs9526111 chr13 46381688 A G 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SIAH3 intron 22628534 rs1529880 chr13 46384672 T C 1.10E-04 Multiple complex diseases SIAH3 intron 17554300 rs959475 chr13 46389539 T C 6.40E-06 Urinary metabolites SIAH3 intron 21572414 rs9534226 chr13 46389795 C T 1.20E-05 Urinary metabolites SIAH3 intron 21572414 rs9534241 chr13 46433501 T G 1.05E-05 Cognitive performance / / 19734545 rs9534241 chr13 46433501 T G 7.75E-05 Orofacial clefts / / 22419666 rs9534241 chr13 46433501 T G 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4941534 chr13 46441539 T A 1.09E-05 Suicide attempts in bipolar disorder / / 21041247 rs4941534 chr13 46441539 T A 6.44E-06 Suicide attempts in bipolar disorder / / 21041247 rs4942456 chr13 46441589 G A 1.09E-05 Suicide attempts in bipolar disorder / / 21041247 rs4942456 chr13 46441589 G A 2.24E-05 Suicide attempts in bipolar disorder / / 21041247 rs17067329 chr13 46443520 T A 1.09E-05 Suicide attempts in bipolar disorder / / 21041247 rs17067329 chr13 46443520 T A 3.07E-05 Suicide attempts in bipolar disorder / / 21041247 rs7998666 chr13 46443887 G T 1.09E-05 Suicide attempts in bipolar disorder / / 21041247 rs7998666 chr13 46443887 G T 3.21E-05 Suicide attempts in bipolar disorder / / 21041247 rs11841875 chr13 46444922 C T 5.76E-04 Prostate cancer mortality / / 20978177 rs7982931 chr13 46445012 C T 1.09E-05 Suicide attempts in bipolar disorder / / 21041247 rs7982931 chr13 46445012 C T 3.87E-05 Suicide attempts in bipolar disorder / / 21041247 rs7983269 chr13 46445084 G A 1.19E-05 Suicide attempts in bipolar disorder / / 21041247 rs7983269 chr13 46445084 G A 9.72E-05 Suicide attempts in bipolar disorder / / 21041247 rs17067344 chr13 46446450 T C 1.01E-05 Suicide attempts in bipolar disorder / / 21041247 rs17067344 chr13 46446450 T C 6.70E-05 Suicide attempts in bipolar disorder / / 21041247 rs2573294 chr13 46455864 A G 7.99E-04 Iron levels / / pha002876 rs17067412 chr13 46468754 G T 1.10E-06 Urinary metabolites / / 21572414 rs2573286 chr13 46484940 T C 3.96E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2573260 chr13 46511517 G A 3.28E-04 Blood pressure / / 17255346 rs1080107 chr13 46516959 C A 9.43E-04 White matter integrity / / 22425255 rs2806922 chr13 46518059 C T 9.45E-05 Multiple complex diseases / / 17554300 rs12585823 chr13 46536291 A G 2.55E-05 Orofacial clefts / / 22419666 rs1041167 chr13 46620135 A T 2.55E-05 Behcet's disease ZC3H13 intron 23291587 rs4942472 chr13 46645115 C T 2.52E-05 Multiple complex diseases CPB2 intron 17554300 rs3818477 chr13 46656412 T G 5.76E-06 Intelligence CPB2 intron 21826061 rs11574980 chr13 46679312 T C 1.04E-26 HDL cholesterol / / 23063622 rs11574980 chr13 46679312 T C 8.56E-11 LDL cholesterol / / 23063622 rs7334509 chr13 46692411 G A 3.35E-04 Non-small cell lung cancer,hypertriglyceridemia with bexarotene treatment of / / 21737656 rs7324845 chr13 46703142 G A 3.00E-06 Non-alcoholic fatty liver disease histology (other) LCP1 intron 23213074 rs7337306 chr13 46719156 G A 8.87E-05 Bipolar disorder,affective LCP1 intron 20528957 rs7321994 chr13 46742539 G A 1.50E-04 Cholesterol LCP1 intron 17255346 rs7330090 chr13 46745531 G A 2.19E-04 Cholesterol LCP1 intron 17255346 rs2209092 chr13 46747184 A G 3.62E-05 Cognitive test performance LCP1 intron 20125193 rs17647647 chr13 46749087 T C 9.20E-05 HIV-1 control LCP1 intron 20041166 rs2209090 chr13 46750002 A G 2.67E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) LCP1 intron 23648065 rs372540087 chr13 46754734 TAGA T 1.93E-04 Alcohol dependence LCP1 intron 20201924 rs9567638 chr13 46754734 T C 1.93E-04 Alcohol dependence LCP1 intron 20201924 rs1230477 chr13 46772628 A T 1.28E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs912784 chr13 46785521 C A 3.16E-04 Alcohol dependence / / 20201924 rs6561303 chr13 46802177 A G 9.64E-05 Cognitive impairment induced by topiramate LRRC63 missense 22091778 rs958546 chr13 46833717 G C 5.00E-06 Atrial fibrillation LRRC63 intron 17903304 rs10507539 chr13 46834706 G A 1.05E-05 Cardiovascular disease LRRC63 intron 17903304 rs259730 chr13 46845976 T C 1.52E-05 Anxiety in major depressive disorder LRRC63 intron 24047446 rs17067945 chr13 46861059 T C 6.63E-04 Multiple complex diseases / / 17554300 rs597059 chr13 46868013 G A 5.85E-04 Type 2 diabetes / / 17463246 rs729074 chr13 46871754 G A 1.76E-04 Multiple complex diseases / / 17554300 rs1216717 chr13 46871964 C T 4.46E-04 Type 2 diabetes / / 17463246 rs675170 chr13 46873020 A G 4.60E-04 Type 2 diabetes / / 17463246 rs2764585 chr13 46880235 A G 1.97E-04 Type 2 diabetes / / 17463246 rs1216707 chr13 46887593 G A 1.02E-04 Type 2 diabetes / / 17463246 rs9595462 chr13 46920645 C T 9.35E-04 Multiple complex diseases KIAA0226L intron 17554300 rs1408184 chr13 46946157 C T 6.33E-04 Premature ovarian failure KIAA0226L missense 19508998 rs7333428 chr13 46975365 T C 8.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs9534415 chr13 47088878 T C 1.27E-05 Bipolar disorder / / 21771265 rs7329974 chr13 47133122 C A 4.28E-04 Insulin resistance LRCH1 intron 21901158 rs7337999 chr13 47143284 C T 6.30E-05 Erythrocyte counts LRCH1 intron pha003090 rs6561321 chr13 47161560 C A 7.60E-05 Myopia (pathological) LRCH1 intron 21640322 rs6561323 chr13 47185601 A G 3.41E-05 Myopia (pathological) LRCH1 intron 21640322 rs12429886 chr13 47194685 G T 5.53E-06 Stroke (ischemic) LRCH1 intron 22941190 rs7983635 chr13 47195267 A G 5.17E-06 Stroke (ischemic) LRCH1 intron 22941190 rs12427953 chr13 47203895 T C 3.64E-06 Stroke (ischemic) LRCH1 intron 22941190 rs9316222 chr13 47214690 T C 8.12E-05 Myopia (pathological) LRCH1 intron 21640322 rs17068501 chr13 47215907 A G 8.74E-05 Coronary heart disease LRCH1 intron 21606135 rs9534458 chr13 47237952 G A 3.00E-08 PR segment LRCH1 intron 24850809 rs9590974 chr13 47238717 C A 2.00E-08 PR segment LRCH1 intron 24850809 rs9534459 chr13 47238950 T A 2.13E-08 PR segment LRCH1 intron 24850809 rs8001925 chr13 47239853 G A 2.67E-08 PR segment LRCH1 intron 24850809 rs12430990 chr13 47240177 T C 5.72E-06 Stroke (ischemic) LRCH1 intron 22941190 rs12429970 chr13 47240326 C G 2.41E-06 Stroke (ischemic) LRCH1 intron 22941190 rs6561324 chr13 47244404 G A 3.27E-04 Coronary heart disease LRCH1 intron 21606135 rs5013916 chr13 47244479 A G 6.91E-06 Stroke (ischemic) LRCH1 intron 22941190 rs9645940 chr13 47245991 T C 5.64E-04 Coronary heart disease LRCH1 intron 21606135 rs17068595 chr13 47246504 G T 7.05E-04 Coronary heart disease LRCH1 intron 21606135 rs17068595 chr13 47246504 G T 0.000695 Salmonella-induced pyroptosis LRCH1 intron 22837397 rs842368 chr13 47251712 G A 9.10E-06 Urinary metabolites LRCH1 intron 21572414 rs842392 chr13 47277099 A T 1.61E-04 Schizophrenia LRCH1 intron 21674006 rs9534470 chr13 47283874 C T 9.87E-05 Serum albumin level LRCH1 intron pha003084 rs17347740 chr13 47284766 G A 9.87E-05 Serum albumin level LRCH1 intron pha003084 rs2762130 chr13 47286938 C G 2.71E-04 Prostate cancer mortality LRCH1 intron 20978177 rs9534476 chr13 47294221 A G 6.49E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LRCH1 intron 22566498 rs9567721 chr13 47297094 C T 7.18E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LRCH1 intron 22566498 rs1539177 chr13 47300055 G A 7.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LRCH1 intron 22566498 rs8192892 chr13 47348229 T C 8.92E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) ESD intron 24192120 rs2794658 chr13 47350482 G A 8.92E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) ESD intron 24192120 rs2794658 chr13 47350482 G A 3.02E-04 Iron levels ESD intron pha002876 rs1216968 chr13 47371389 C A 3.10E-04 Multiple complex diseases / / 17554300 rs9567731 chr13 47400686 A G 8.20E-05 Aging (time to event) / / 21782286 rs6314 chr13 47409034 G A 1 Drug response to Fluoxetine HTR2A missense 11311507 rs6314 chr13 47409034 G A 1 Drug response to Paroxetine HTR2A missense 11311507 rs6314 chr13 47409034 G A 1 Drug response to Fluoxetine HTR2A missense 15052272 rs6314 chr13 47409034 G A 1 Drug response to Paroxetine HTR2A missense 15052272 rs6314 chr13 47409034 G A 1 Drug response to Fluoxetine HTR2A missense 18253134 rs6314 chr13 47409034 G A 1 Drug response to Paroxetine HTR2A missense 18253134 rs6308 chr13 47409048 G A 9.71E-05 Response to statin treatment (atorvastatin),change in cholesterol levels HTR2A missense 20031582 rs7997012 chr13 47411985 A G 1 Drug response to Citalopram HTR2A intron 16642436 rs7997012 chr13 47411985 A G 1 Drug response to Olanzapine HTR2A intron 19636338 rs7330636 chr13 47423592 C T 2.81E-04 Height HTR2A intron 17255346 rs6561334 chr13 47424124 G A 0.000000172 Cholesterol,total HTR2A intron 23063622 rs6561334 chr13 47424124 G A 0.000000819 LDL cholesterol HTR2A intron 23063622 rs6561334 chr13 47424124 G A 2.84E-08 Triglycerides HTR2A intron 23063622 rs9316233 chr13 47433355 C G 1 Drug response to Escitalopram HTR2A intron 19365399 rs1928042 chr13 47437216 G T 7.64E-04 Amyotrophic Lateral Sclerosis HTR2A intron 17362836 rs9316235 chr13 47445703 G A 4.01E-05 Cognitive performance HTR2A intron 19734545 rs582854 chr13 47445877 C A 3.13E-04 Multiple complex diseases HTR2A intron 17554300 rs2770298 chr13 47446847 C T 2.87E-05 Cognitive performance HTR2A intron 19734545 rs927544 chr13 47456051 G A 4.18E-05 Cognitive performance HTR2A intron 19734545 rs1328683 chr13 47458874 C T 8.80E-07 Serum metabolites HTR2A intron 19043545 rs6313 chr13 47469940 G A 1 Drug response to Olanzapine HTR2A cds-synon 19193342 rs6313 chr13 47469940 G A 1 Drug response to Olanzapine HTR2A cds-synon 19494443 rs6313 chr13 47469940 G A 1 Drug response to Risperidone HTR2A cds-synon 19494443 rs6311 chr13 47471478 C T 1 Drug response to Antidepressant Response HTR2A nearGene-5 16710319 rs6311 chr13 47471478 C T 1 Drug response to Risperidone HTR2A nearGene-5 19997080 rs4142900 chr13 47473550 T G 3.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2149434 chr13 47478344 A C 2.94E-06 Blood Pressure / / pha003043 rs10507546 chr13 47483074 G A 1.86E-04 Alzheimer's disease (late onset) / / 21460841 rs2026690 chr13 47483177 G T 3.12E-05 Blood Pressure / / pha003043 rs17289695 chr13 47484378 T A 1.93E-04 Alzheimer's disease (late onset) / / 21460841 rs17289854 chr13 47486937 C T 1.77E-04 Alzheimer's disease (late onset) / / 21460841 rs17289889 chr13 47487758 A T 2.35E-04 Alzheimer's disease (late onset) / / 21460841 rs7990072 chr13 47526995 A G 2.15E-04 Alzheimer's disease (late onset) / / 21460841 rs2026692 chr13 47528545 T C 3.63E-05 Meningococcal disease / / 20694013 rs4942592 chr13 47532438 C T 5.69E-04 Type 2 diabetes / / 17463246 rs9316245 chr13 47546456 A G 2.12E-04 Type 2 diabetes / / 17463246 rs4941581 chr13 47547968 G A 1.95E-04 Type 2 diabetes / / 17463246 rs12583882 chr13 47573616 A G 6.00E-06 Subcutaneous adipose tissue / / 22589738 rs17069282 chr13 47574726 T C 9.41E-04 Obesity (extreme) / / 21935397 rs17310690 chr13 47577521 C T 2.71E-04 Obesity (extreme) / / 21935397 rs754325 chr13 47588943 T C 6.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs4942603 chr13 47589582 A G 2.87E-05 Bone mineral density / / 19181680 rs1019883 chr13 47591924 T C 1.21E-04 Alzheimer's disease (late onset) / / 21460841 rs1157078 chr13 47596020 T C 1.26E-04 Alzheimer's disease (late onset) / / 21460841 rs11619704 chr13 47598306 C T 8.67E-04 Obesity (extreme) / / 21935397 rs1864704 chr13 47600322 C T 1.49E-04 Alzheimer's disease (late onset) / / 21460841 rs2082292 chr13 47600907 G C 8.58E-04 Obesity (extreme) / / 21935397 rs12860002 chr13 47603960 A G 6.40E-06 Urinary metabolites / / 21572414 rs11616518 chr13 47607957 G A 1.30E-05 Urinary metabolites / / 21572414 rs1328673 chr13 47615594 C T 7.13E-05 Response to metformin / / 21186350 rs2039095 chr13 47618634 C T 9.83E-05 Response to metformin / / 21186350 rs2039095 chr13 47618634 C T 1.80E-05 Urinary metabolites / / 21572414 rs11620080 chr13 47620477 G A 2.20E-05 Urinary metabolites / / 21572414 rs9562700 chr13 47620956 A G 4.98E-05 Response to metformin / / 21186350 rs9595589 chr13 47640810 A G 4.11E-05 Response to metformin / / 21186350 rs1469595 chr13 47640886 A C 4.11E-05 Response to metformin / / 21186350 rs9595590 chr13 47642196 A T 4.11E-05 Response to metformin / / 21186350 rs1431772 chr13 47643062 G A 1.18E-04 Multiple complex diseases / / 17554300 rs7994733 chr13 47643594 G C 8.40E-05 Response to metformin / / 21186350 rs9595600 chr13 47654068 C T 2.23E-04 HIV-1 viral setpoint / / 17641165 rs6561351 chr13 47666228 G C 5.76E-04 Multiple complex diseases / / 17554300 rs1431768 chr13 47669350 G A 8.37E-05 Response to metformin / / 21186350 rs2802397 chr13 47675070 G A 6.53E-04 Smoking quantity / / 24665060 rs7332165 chr13 47682803 A C 1.16E-04 Glycosylated haemoglobin levels / / 17255346 rs12372818 chr13 47683125 G A 1.93E-13 Gender / / 22362730 rs17069577 chr13 47710680 C G 8.30E-06 Iron levels / / 21208937 rs971379 chr13 47714474 A G 9.28E-04 Parkinson's disease / / 16252231 rs973908 chr13 47716018 A G 1.10E-04 Blood pressure (response to calcium channel blocker) / / 24192120 rs9526282 chr13 47747520 A G 6.33E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9534563 chr13 47758236 T C 7.40E-05 Smoking quantity / / 24665060 rs10507551 chr13 47761883 G A 4.80E-05 Sleep and circadian phenotypes / / 17903308 rs7331274 chr13 47767498 G A 4.60E-04 Smoking quantity / / 24665060 rs9526286 chr13 47777286 G C 8.23E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7987410 chr13 47787020 T C 6.21E-04 Coronary Artery Disease / / 17634449 rs12184711 chr13 47806831 A G 3.28E-04 Multiple complex diseases / / 17554300 rs9595629 chr13 47823735 A G 5.30E-05 Personality dimensions / / 18957941 rs6561362 chr13 47826159 C T 2.64E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7985155 chr13 47827489 A G 3.31E-06 Asthma or chronic obstructive pulmonary disease / / 24993907 rs7998555 chr13 47829134 T A 3.16E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4391953 chr13 47830990 T C 7.80E-06 Asthma or chronic obstructive pulmonary disease / / 24993907 rs9316274 chr13 47834109 A T 4.10E-05 Birth weight / / 17255346 rs17069785 chr13 47839338 A G 1.95E-05 Asthma or chronic obstructive pulmonary disease / / 24993907 rs17069787 chr13 47840024 G A 1.79E-06 Asthma or chronic obstructive pulmonary disease / / 24993907 rs7994542 chr13 47841000 C T 2.77E-06 Asthma or chronic obstructive pulmonary disease / / 24993907 rs9534576 chr13 47841995 T C 1.16E-04 Birth weight / / 17255346 rs9534578 chr13 47843377 C A 2.00E-07 Asthma or chronic obstructive pulmonary disease / / 24993907 rs17069859 chr13 47863170 C T 1.27E-04 Alzheimer's disease / / 17998437 rs1417205 chr13 47898879 A G 8.00E-07 Cannabis use (initiation) / / 22823124 rs564425 chr13 47899095 A G 1.03E-05 Pulmonary function / / 17903307 rs1578303 chr13 47963146 C T 7.24E-04 Heart Failure / / pha002885 rs17069948 chr13 47983014 G A 3.09E-05 Waist-Hip Ratio / / pha003029 rs7338889 chr13 47984571 C T 3.64E-04 Body mass index / / 17255346 rs7338889 chr13 47984571 C T 7.53E-04 Coronary Artery Disease / / 17634449 rs9567854 chr13 47992111 G A 3.42E-04 Multiple complex diseases / / 17554300 rs9591046 chr13 48004741 C T 2.42E-05 Multiple complex diseases / / 17554300 rs9591064 chr13 48051528 G C 9.28E-04 Response to TNF antagonist treatment / / 21061259 rs7984261 chr13 48060899 T A 1.30E-05 Urinary metabolites / / 21572414 rs4284535 chr13 48066565 T C 1.30E-05 Urinary metabolites / / 21572414 rs9526342 chr13 48078169 C A 1.50E-05 Urinary metabolites / / 21572414 rs9595729 chr13 48092853 G A 3.58E-05 HIV-1 control / / 20041166 rs12877713 chr13 48132734 T C 2.78E-05 Multiple sclerosis / / 17660530 rs2478333 chr13 48162558 C A 4.00E-08 QT interval / / 20031603 rs7322390 chr13 48197420 C A 5.08E-04 Multiple complex diseases / / 17554300 rs1575891 chr13 48198716 T C 6.00E-06 Cardiac hypertrophy / / 21348951 rs7990134 chr13 48245353 C T 8.66E-07 Waist-Hip Ratio / / pha003029 rs1924799 chr13 48256560 C A 2.23E-04 Multiple complex diseases / / 17554300 rs4942668 chr13 48262045 C T 1.11E-06 Waist-Hip Ratio / / pha003029 rs9526387 chr13 48285610 T C 5.40E-05 Waist-Hip Ratio / / pha003029 rs7992993 chr13 48293134 T G 3.73E-06 Waist-Hip Ratio / / pha003029 rs7992993 chr13 48293134 T G 7.03E-05 Blood Pressure / / pha003043 rs7992993 chr13 48293134 T G 9.33E-05 Insulin Resistance / / pha003062 rs7992993 chr13 48293134 T G 7.03E-05 Insulin-related traits / / pha003063 rs2181958 chr13 48321975 T C 3.44E-04 Multiple complex diseases / / 17554300 rs2147493 chr13 48350699 G A 2.20E-06 Waist-Hip Ratio / / pha003029 rs9534824 chr13 48351446 T C 5.43E-05 Waist-Hip Ratio / / pha003029 rs7999699 chr13 48369730 A G 3.00E-06 Colorectal cancer (diet interaction) / / 24743840 rs1359393 chr13 48383104 G A 2.56E-05 Waist-Hip Ratio / / pha003029 rs8001976 chr13 48387722 C T 3.00E-06 Aging (time to event) / / 21782286 rs17070878 chr13 48392133 T C 2.21E-04 Alzheimer's disease (late onset) / / 21379329 rs17070878 chr13 48392133 T C 4.40E-04 Orofacial clefts / / 22419666 rs17070879 chr13 48393070 C T 3.61E-04 Body mass index / / 17255346 rs17070879 chr13 48393070 C T 5.52E-05 Bipolar disorder and schizophrenia / / 20889312 rs7989911 chr13 48393350 A G 6.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs9534842 chr13 48396385 T C 8.18E-04 Multiple complex diseases / / 17554300 rs12875794 chr13 48396708 G T 7.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs4609732 chr13 48399961 C T 8.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs9595798 chr13 48400502 C T 7.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs11620399 chr13 48436925 G T 5.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs7328313 chr13 48438999 T C 6.43E-05 Blood Pressure / / pha003045 rs2406690 chr13 48489658 G A 1.18E-05 Taste perception / / 22132133 rs9595835 chr13 48628449 T C 2.44E-04 Alcohol dependence / / 21314694 rs2104480 chr13 48640749 C G 1.70E-04 Iris characteristics / / 21835309 rs9316348 chr13 48666690 G A 3.07E-04 Alcohol dependence MED4 intron 21314694 rs7332363 chr13 48666761 C G 3.04E-25 Lymphocyte counts MED4 intron 22286170 rs9568001 chr13 48691985 T C 1.96E-04 Multiple complex diseases / / 17554300 rs9316363 chr13 48719072 A G 5.29E-04 Taste perception / / 22132133 rs1752135 chr13 48727109 G T 1.57E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9316367 chr13 48810789 C T 3.25E-04 Type 2 diabetes ITM2B intron 17463246 rs17071548 chr13 48844888 A G 3.16E-05 Multiple complex diseases / / 17554300 rs2804085 chr13 48955201 T A 2.33E-04 Multiple complex diseases RB1 intron 17554300 rs2227311 chr13 48987032 A G 2.50E-05 Sudden cardiac arrest LPAR6 UTR-5 21658281 rs4151601 chr13 49035693 G A 5.93E-04 Multiple complex diseases RB1 intron 17554300 rs7316991 chr13 49065565 A T 1.47E-04 Multiple complex diseases RCBTB2 intron 17554300 rs17071843 chr13 49077668 A G 9.09E-05 Multiple complex diseases RCBTB2 intron 17554300 rs10076 chr13 49079503 T C 1.67E-04 Multiple complex diseases RCBTB2 intron 17554300 rs12428581 chr13 49115452 A G 4.95E-04 Acute lung injury / / 22295056 rs3901587 chr13 49124361 T C 3.50E-04 Multiple complex diseases / / 17554300 rs4942767 chr13 49131769 A C 5.22E-04 White matter integrity / / 22425255 rs9535040 chr13 49153095 A G 6.65E-04 Multiple complex diseases LOC100129597 intron 17554300 rs6561463 chr13 49154037 C G 9.50E-05 Multiple complex diseases LOC100129597 intron 17554300 rs7335057 chr13 49198692 G A 2.23E-04 Multiple complex diseases / / 17554300 rs41485347 chr13 49206747 T G 3.20E-04 Multiple complex diseases / / 17554300 rs41487046 chr13 49206768 G A 3.35E-04 Multiple complex diseases / / 17554300 rs41431749 chr13 49208920 A G 4.89E-04 Multiple complex diseases / / 17554300 rs6561472 chr13 49222597 G T 3.44E-04 Multiple complex diseases / / 17554300 rs1323555 chr13 49250997 G A 2.00E-06 Response to inhaled corticosteroid treatment in asthma (percentage change of FEV1) / / 24792382 rs9595967 chr13 49268094 C G 0.00029 Erectile dysfunction after radiotherapy for prostate cancer / / 23021708 rs57565976 chr13 49298065 C G 2.98E-06 Personality dimensions / / 23658558 rs990466 chr13 49320468 C A 2.17E-04 Hypertension / / 21082022 rs9535077 chr13 49327710 A G 8.76E-04 Type 2 diabetes / / 17463246 rs41448845 chr13 49364888 C T 9.85E-04 Multiple complex diseases / / 17554300 rs9535083 chr13 49384046 C G 3.07E-04 Multiple complex diseases / / 17554300 rs7991136 chr13 49416436 C A 4.72E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs728329 chr13 49462380 G A 4.46E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs9562856 chr13 49464221 A G 2.64E-04 Hearing function / / 17255346 rs9562856 chr13 49464221 A G 5.60E-05 Amyotrophic lateral sclerosis / / 23624525 rs1449572 chr13 49466931 G T 8.00E-06 Multiple myeloma (IgH translocation) / / 23502783 rs9568123 chr13 49475780 A G 1.41E-04 Hearing function / / 17255346 rs17072496 chr13 49483734 T C 9.16E-04 Multiple complex diseases / / 17554300 rs665808 chr13 49485913 T C 4.92E-04 Iron levels / / pha002876 rs1449578 chr13 49499555 G C 9.01E-05 Bipolar disorder / / 19488044 rs4313714 chr13 49516872 G T 3.08E-05 Orofacial clefts / / 22419666 rs12429554 chr13 49613208 C T 7.42E-04 Amyotrophic Lateral Sclerosis FNDC3A intron 17827064 rs6561505 chr13 49753729 G A 2.15E-09 Atopy FNDC3A intron 21094521 rs6561505 chr13 49753729 G A 7.75E-05 Atopy FNDC3A intron 21094521 rs1013347 chr13 49810881 G T 3.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs9535170 chr13 49815405 G A 3.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs9526532 chr13 49821244 T C 3.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs10492507 chr13 49824290 C T 2.10E-04 Sleep and circadian phenotypes CDADC1 intron 17903308 rs6420299 chr13 49970938 G A 5.96E-05 Hemoglobin CAB39L intron pha003098 rs6420299 chr13 49970938 G A 9.44E-05 Erythrocyte counts CAB39L intron pha003099 rs17480924 chr13 49976235 T C 8.90E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CAB39L intron 20031582 rs9568196 chr13 49983055 C A 1.32E-05 Hemoglobin CAB39L intron pha003098 rs9568196 chr13 49983055 C A 2.01E-05 Erythrocyte counts CAB39L intron pha003099 rs7328100 chr13 49988458 T C 8.21E-05 Pancreatic cancer CAB39L intron pha002889 rs1885684 chr13 49993761 T C 8.55E-04 Type 2 diabetes CAB39L intron 17846125 rs9568202 chr13 49994410 T C 4.18E-04 Smoking initiation CAB39L intron 24665060 rs12429883 chr13 50031868 A G 8.76E-04 Alzheimer's disease SETDB2 intron 17998437 rs7995283 chr13 50044585 T G 7.10E-06 Urinary metabolites SETDB2 intron 21572414 rs2031532 chr13 50080847 A G 5.00E-06 Cardiac hypertrophy PHF11 cds-synon 21348951 rs2981 chr13 50101094 G A 3.78E-04 Type 2 diabetes PHF11 intron 17846125 rs9568239 chr13 50105055 C T 5.38E-04 Lymphocyte counts / / 22286170 rs9562900 chr13 50141362 G A 8.93E-04 Suicide attempts in bipolar disorder RCBTB1 cds-synon 21423239 rs7981396 chr13 50151926 C T 1.49E-04 Lymphocyte counts RCBTB1 intron 22286170 rs5007254 chr13 50182651 A G 3.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9568281 chr13 50185204 A G 3.00E-07 Multiple sclerosis / / 23412934 rs7331252 chr13 50185712 C T 9.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs7986690 chr13 50204331 A G 0.00078 Salmonella-induced pyroptosis ARL11 intron 22837397 rs2181184 chr13 50271072 G A 0.000000306 Schizophrenia / / 22440650 rs1407440 chr13 50286218 T C 1.99E-04 Response to taxane treatment (placlitaxel) KP/3 intron 23006423 rs1407441 chr13 50290990 T C 4.87E-04 Response to taxane treatment (placlitaxel) KP/3 intron 23006423 rs9535307 chr13 50291842 A C 8.00E-06 Obesity-related traits KP/3 intron 23251661 rs9535310 chr13 50296026 T C 2.92E-04 Response to taxane treatment (placlitaxel) KP/3 intron 23006423 rs1127021 chr13 50296115 C T 7.74E-06 Obesity-related traits KP/3 cds-synon 23251661 rs3736830 chr13 50306221 G C 9.00E-08 Menopause (age at onset) KP/3 intron 22267201 rs9316474 chr13 50313345 C A 4.12E-04 Response to taxane treatment (placlitaxel) KP/3 intron 23006423 rs11616903 chr13 50424677 T C 9.87E-05 Psoriasis / / 20953190 rs9535388 chr13 50441861 G A 3.95E-05 Psoriasis / / 20953190 rs7332385 chr13 50443418 C T 2.08E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9526615 chr13 50443678 T C 2.01E-05 Psoriasis / / 20953190 rs9562933 chr13 50446164 A G 1.66E-05 Psoriasis / / 20953190 rs9568359 chr13 50506233 C T 1.57E-08 Lymphocyte counts SPRYD7 intron 22286170 rs732729 chr13 50513535 T A 1.40E-05 Urinary metabolites / / 21572414 rs2490637 chr13 50545357 C A 1.98E-05 Attention deficit hyperactivity disorder / / 22420046 rs9596219 chr13 50563447 C T 1.00E-09 Height DLEU2 intron 23563607 rs2066557 chr13 50610270 T C 4.93E-04 Lymphocyte counts DLEU2 intron 22286170 rs6561575 chr13 50677611 G A 9.19E-04 Myopia (pathological) DLEU2 intron 21095009 rs706617 chr13 50703185 C T 1.74E-05 Attention deficit hyperactivity disorder / / 22420046 rs706615 chr13 50706551 C T 4.36E-05 Attention deficit hyperactivity disorder / / 22420046 rs809845 chr13 50724055 C T 1.45E-05 Psoriasis / / 20953190 rs790531 chr13 50725514 A G 1.50E-05 Attention deficit hyperactivity disorder / / 22420046 rs1750567 chr13 50737023 G A 2.23E-05 Bipolar disorder / / 20451256 rs1798968 chr13 50737869 T C 2.74E-05 Bipolar disorder / / 20451256 rs1750565 chr13 50738300 G A 2.36E-05 Bipolar disorder / / 20451256 rs809846 chr13 50748531 A G 3.17E-05 Bipolar disorder / / 20451256 rs2066614 chr13 50749978 G T 1.72E-05 Bipolar disorder / / 20451256 rs1149833 chr13 50750876 A T 1.91E-05 Bipolar disorder / / 20451256 rs2066615 chr13 50751758 G A 2.12E-05 Bipolar disorder / / 20451256 rs1149839 chr13 50751963 G A 8.30E-04 Multiple complex diseases / / 17554300 rs2703079 chr13 50803670 A C 6.22E-04 Taste perception / / 22132133 rs2762051 chr13 50835715 C T 7.00E-07 Celiac disease / / 20190752 rs806321 chr13 50841323 C T 5.00E-07 Multiple sclerosis / / 21833088 rs9596270 chr13 50842440 T C 5.06E-05 Multiple sclerosis / / 19525953 rs9596270 chr13 50842440 T C 7.00E-07 Multiple sclerosis / / 22190364 rs2703089 chr13 50845012 A G 2.70E-05 Urinary metabolites / / 21572414 rs17074055 chr13 50846748 T C 2.43E-04 Alzheimer's disease (late onset) / / 21379329 rs806323 chr13 50847315 A C 1.30E-05 Urinary metabolites / / 21572414 rs806326 chr13 50849536 T A 1.20E-05 Urinary metabolites / / 21572414 rs2066681 chr13 50857495 G T 1.40E-05 Urinary metabolites / / 21572414 rs2066683 chr13 50857616 G A 1.40E-05 Urinary metabolites / / 21572414 rs1359614 chr13 50858768 C T 1.50E-05 Urinary metabolites / / 21572414 rs9728909 chr13 50870427 T C 0.0000827 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs806301 chr13 50887560 C T 7.79E-04 White matter integrity / / 22425255 rs2740535 chr13 50902992 T C 1.20E-05 Urinary metabolites / / 21572414 rs2812212 chr13 50910525 A G 1.20E-05 Urinary metabolites / / 21572414 rs2532966 chr13 50916247 G C 2.70E-06 Urinary metabolites / / 21572414 rs11842790 chr13 50924448 C T 3.40E-04 Multiple complex diseases / / 17554300 rs17363566 chr13 50934892 G A 7.27E-05 Multiple complex diseases / / 17554300 rs12874278 chr13 50935922 C T 8.70E-04 Multiple complex diseases / / 17554300 rs12874278 chr13 50935922 C T 5.65E-05 Nicotine smoking / / 19268276 rs1262869 chr13 50938391 C T 4.94E-04 Multiple complex diseases / / 17554300 rs3095160 chr13 50946268 A G 3.80E-05 Kidney function and endocine traits / / 17903292 rs2812219 chr13 50948523 G T 4.76E-04 Multiple complex diseases / / 17554300 rs12864797 chr13 50949948 G T 9.41E-04 Depression (quantitative trait) / / 20800221 rs200220 chr13 50960378 A C 4.40E-04 Depression (quantitative trait) / / 20800221 rs200220 chr13 50960378 A C 9.23E-04 Oral cancers (chewing tobacco related) / / 22503698 rs188014 chr13 50969923 T C 3.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs188014 chr13 50969923 T C 7.85E-04 Oral cancers (chewing tobacco related) / / 22503698 rs201803 chr13 50980202 A G 3.22E-05 Oral cancers (chewing tobacco related) / / 22503698 rs201789 chr13 50986118 T C 6.00E-06 Anthropometric traits / / 19260139 rs1327647 chr13 51028510 G A 4.40E-05 Aortic root size / / 21223598 rs3118650 chr13 51029324 A G 8.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17074374 chr13 51039527 T C 9.95E-04 Type 2 diabetes / / 17463246 rs201768 chr13 51050243 T C 6.94E-04 Type 2 diabetes / / 17463246 rs1023055 chr13 51055196 C T 1.09E-05 Post-operative nausea and vomiting / / 21694509 rs201762 chr13 51065836 T G 6.75E-04 Height / / 20400458 rs1262781 chr13 51066171 C T 3.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1262778 chr13 51066623 C T 8.00E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1262778 chr13 51066623 C T 3.69E-06 Statin-induced myopathy / / 21826682 rs1262776 chr13 51068476 T C 7.90E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1262775 chr13 51068575 T C 7.90E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1262775 chr13 51068575 T C 7.27E-04 Major depressive disorder / / 22472876 rs1630605 chr13 51075385 C T 6.87E-04 Multiple complex diseases / / 17554300 rs1630605 chr13 51075385 C T 8.07E-04 Major depressive disorder / / 22472876 rs201754 chr13 51078446 T C 4.70E-04 Multiple complex diseases / / 17554300 rs1753637 chr13 51084173 T G 6.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs157164 chr13 51084523 G A 8.70E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs192492 chr13 51085697 A G 8.90E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs183950 chr13 51086092 C T 8.70E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs495838 chr13 51086107 T A 3.68E-04 Multiple complex diseases / / 17554300 rs3116597 chr13 51086364 G C 8.40E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1638703 chr13 51088356 G C 3.61E-04 Multiple complex diseases / / 17554300 rs9316500 chr13 51094114 T G 5.99E-05 Serum metabolites / / 19043545 rs9316500 chr13 51094114 T G 5.00E-06 Pulmonary function decline / / 22424883 rs3118905 chr13 51105334 G A 1.00E-45 Height / / 20881960 rs1239947 chr13 51106555 C T 8.00E-06 Height / / 18391951 rs3118906 chr13 51106788 G A 5.00E-06 Pubertal anthropometrics / / 23449627 rs3118906 chr13 51106788 G A 2.00E-24 Height / / 23563607 rs3118906 chr13 51106788 G A 1.95E-05 Lymphocyte counts / / pha003094 rs3116599 chr13 51107262 A G 8.89E-04 Multiple complex diseases / / 17554300 rs3116602 chr13 51111355 T G 6.17E-04 Multiple complex diseases / / 17554300 rs3116602 chr13 51111355 T G 7.00E-09 Height / / 18391952 rs3116602 chr13 51111355 T G 2.32E-09 Height / / 19570815 rs3118912 chr13 51111464 C T 7.39E-05 Left ventricular hypertrophy / / pha003052 rs3118913 chr13 51115287 A G 7.20E-04 Multiple complex diseases / / 17554300 rs3118914 chr13 51116901 G T 4.36E-04 Multiple complex diseases / / 17554300 rs3118914 chr13 51116901 G T 4.00E-10 Height / / 19343178 rs3118914 chr13 51116901 G T 5.51E-05 Left ventricular hypertrophy / / pha003052 rs3116605 chr13 51117562 T C 7.51E-05 Left ventricular hypertrophy / / pha003052 rs1239954 chr13 51119137 C T 9.00E-06 Obesity-related traits / / 23251661 rs1928123 chr13 51119845 A C 7.48E-04 Parkinson's disease / / 17052657 rs1149826 chr13 51130931 C A 2.42E-04 Heart Failure / / pha002884 rs3095527 chr13 51170755 A G 3.36E-04 Multiple complex diseases / / 17554300 rs4941673 chr13 51173240 G A 5.66E-04 Multiple complex diseases / / 17554300 rs4942930 chr13 51173280 C T 7.20E-04 Multiple complex diseases / / 17554300 rs4942931 chr13 51174311 C T 3.35E-04 Coronary heart disease / / 21606135 rs4942931 chr13 51174311 C T 1.39E-05 Height / / pha003010 rs4942931 chr13 51174311 C T 2.69E-06 Height / / pha003011 rs677585 chr13 51178170 T G 5.39E-04 Multiple complex diseases / / 17554300 rs677627 chr13 51178193 G C 5.18E-04 Multiple complex diseases / / 17554300 rs484304 chr13 51178370 C T 2.40E-06 Vascular dementia / / 22116812 rs484304 chr13 51178370 C T 1.84E-05 Height / / pha003010 rs484304 chr13 51178370 C T 9.91E-07 Height / / pha003011 rs2039100 chr13 51184928 G A 1.78E-05 Height / / pha003010 rs2039100 chr13 51184928 G A 4.84E-06 Height / / pha003011 rs2039100 chr13 51184928 G A 7.08E-05 Blood Pressure / / pha003046 rs573666 chr13 51194405 C T 9.00E-06 Osteosarcoma / / 23727862 rs706596 chr13 51211042 A G 2.29E-06 Height / / pha003010 rs706596 chr13 51211042 A G 1.92E-06 Height / / pha003011 rs706596 chr13 51211042 A G 8.05E-05 Blood Pressure / / pha003046 rs1341634 chr13 51219345 A C 1.24E-06 Blood Pressure / / pha003046 rs1341634 chr13 51219345 A C 1.11E-05 Blood Pressure / / pha003048 rs797512 chr13 51226954 T C 4.52E-05 Vascular dementia / / 22116812 rs797512 chr13 51226954 T C 5.38E-05 Height / / pha003010 rs797512 chr13 51226954 T C 7.55E-06 Height / / pha003011 rs797515 chr13 51227415 G A 5.93E-05 Vascular dementia / / 22116812 rs797516 chr13 51230621 A G 4.00E-05 Vascular dementia / / 22116812 rs3095526 chr13 51233566 A G 9.80E-05 Coronary heart disease / / pha003031 rs2796843 chr13 51240182 C A 7.20E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs2794467 chr13 51247210 G A 2.73E-05 Coronary heart disease / / pha003031 rs2540525 chr13 51254712 C T 3.27E-05 stroke (ischemic) / / 17434096 rs2540525 chr13 51254712 C T 5.25E-05 Telomere length / / 21573004 rs2540525 chr13 51254712 C T 9.55E-06 Vascular dementia / / 22116812 rs2540521 chr13 51275108 T C 3.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs2761843 chr13 51293037 T C 3.26E-04 Parkinson's disease DLEU7 intron 17052657 rs2761839 chr13 51299726 G A 1.68E-04 Alzheimer's disease DLEU7 intron 22005930 rs2260128 chr13 51301137 A G 7.77E-05 Alzheimer's disease DLEU7 intron 22005930 rs3118077 chr13 51302310 G A 1.96E-04 Gallstones DLEU7 intron 17632509 rs3118077 chr13 51302310 G A 9.25E-04 Insulin resistance DLEU7 intron 21901158 rs2706238 chr13 51307156 G A 7.40E-05 Alzheimer's disease DLEU7 intron 22005930 rs2706238 chr13 51307156 G A 5.79E-04 Smoking initiation DLEU7 intron 24665060 rs514960 chr13 51316115 G A 9.02E-05 Alzheimer's disease DLEU7 intron 22005930 rs675305 chr13 51322188 G A 6.21E-04 Alzheimer's disease DLEU7 intron 22005930 rs111932 chr13 51334138 G C 9.28E-04 Alzheimer's disease DLEU7 intron 22005930 rs588427 chr13 51334202 C G 6.54E-04 Alzheimer's disease DLEU7 intron 22005930 rs572387 chr13 51366715 C G 1.53E-04 Insulin resistance DLEU7 intron 21901158 rs7320457 chr13 51366753 T C 1.86E-04 Schizophrenia DLEU7 intron 20832056 rs9316505 chr13 51390598 G A 1.80E-04 Primary tooth development (time to first tooth eruption) DLEU7 intron 23704328 rs9316505 chr13 51390598 G A 3.00E-08 Primary tooth development (number of teeth) DLEU7 intron 23704328 rs563850 chr13 51427145 G A 9.33E-04 Parkinson's disease / / 17052657 rs2408213 chr13 51452751 T C 5.24E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs17649209 chr13 51463330 A C 1.10E-04 Alzheimer's disease (late onset) / / 21379329 rs9526706 chr13 51489121 G T 2.00E-04 Cognitive impairment induced by topiramate R/SEH2B intron 22091778 rs2094530 chr13 51564457 C T 6.53E-04 HIV-1 viral setpoint / / 17641165 rs3790022 chr13 51576170 G A 1.00E-06 Rheumatoid arthritis (ACPA-negative) GUCY1B2 intron 24532677 rs11617400 chr13 51577575 T C 3.73E-05 Bipolar disorder GUCY1B2 intron 20451256 rs9316514 chr13 51585390 C T 2.59E-04 Alzheimer's disease GUCY1B2 intron 17998437 rs9526715 chr13 51588003 C T 4.28E-04 Epilepsy GUCY1B2 intron 22116939 rs9568497 chr13 51603768 T C 8.44E-06 Bipolar disorder / / 20451256 rs2408291 chr13 51612776 C T 1.98E-05 Bilirubin levels,in serum GUCY1B2 intron 19389676 rs913467 chr13 51617861 G C 3.94E-04 Alzheimer's disease GUCY1B2 intron 17998437 rs9568516 chr13 51682803 T G 2.74E-04 Blood pressure LINC00371 intron 17255346 rs957434 chr13 51686166 C T 1.29E-04 Multiple complex diseases LINC00371 intron 17554300 rs9316522 chr13 51689383 T C 0.000622 Salmonella-induced pyroptosis LINC00371 intron 22837397 rs6561615 chr13 51697794 C A 4.90E-05 Iron levels LINC00371 intron 21208937 rs1340544 chr13 51701547 T C 1.78E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) LINC00371 intron 23648065 rs9563028 chr13 51709017 C A 1.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) LINC00371 intron 23648065 rs9563028 chr13 51709017 C A 8.13E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) LINC00371 intron 23648065 rs7325564 chr13 51724664 T C 5.00E-06 IgG glycosylation / / 23382691 rs2094278 chr13 51728207 C T 3.87E-04 Type 2 diabetes / / 17463246 rs11148211 chr13 51733048 A T 5.73E-04 Multiple complex diseases / / 17554300 rs7318961 chr13 51736083 G A 3.12E-05 Response to methylphenidate treatment / / 21130132 rs932807 chr13 51736855 T C 4.30E-04 Iron levels / / pha002876 rs4942969 chr13 51738888 T C 5.00E-04 Multiple complex diseases / / 17554300 rs4942969 chr13 51738888 T C 1.58E-05 Serum metabolites / / 19043545 rs4245354 chr13 51738988 C G 3.98E-05 Serum metabolites / / 19043545 rs2408296 chr13 51739168 G A 5.92E-04 Iron levels / / pha002876 rs9563030 chr13 51741276 A G 8.78E-04 Multiple complex diseases / / 17554300 rs9563030 chr13 51741276 A G 8.98E-06 Serum metabolites / / 19043545 rs17252027 chr13 51751705 C T 6.84E-04 Endometrial cancer / / 24096698 rs17252027 chr13 51751705 C T 7.49E-04 Endometrial cancer / / 24096698 rs9535611 chr13 51755319 C T 8.36E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9563035 chr13 51773007 G A 7.26E-05 Coronary heart disease / / pha003030 rs9563035 chr13 51773007 G A 6.08E-06 Coronary heart disease / / pha003031 rs4941694 chr13 51790688 A G 5.49E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs4941694 chr13 51790688 A G 7.29E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4942974 chr13 51794555 G C 5.40E-06 Urinary metabolites / / 21572414 rs17790709 chr13 51816122 G T 2.40E-04 Multiple complex diseases FAM124A intron 17554300 rs7337236 chr13 51820344 C T 3.95E-04 Alzheimer's disease FAM124A intron 17998437 rs11617293 chr13 51823185 T C 4.90E-04 Amyotrophic lateral sclerosis (sporadic) FAM124A intron 24529757 rs10492519 chr13 51824328 A G 5.60E-06 Prostate cancer FAM124A intron 18073375 rs7983188 chr13 51831286 G A 9.16E-05 Bipolar disorder FAM124A intron 22925353 rs973837 chr13 51839210 C T 4.91E-04 Alzheimer's disease (late onset) FAM124A intron 21379329 rs973837 chr13 51839210 C T 9.84E-05 Orofacial clefts FAM124A intron 22419666 rs17837210 chr13 51856010 A C 0.000284 Salmonella-induced pyroptosis FAM124A UTR-3 22837397 rs17252152 chr13 51858706 T C 0.000375 Salmonella-induced pyroptosis / / 22837397 rs7325958 chr13 51870961 G A 1.89E-05 Odorant perception / / 23910658 rs9563046 chr13 51919181 G A 4.61E-04 Heart Failure SERPINE3 intron pha002884 rs9535670 chr13 52029591 A G 9.81E-04 Multiple complex diseases / / 17554300 rs3930275 chr13 52039905 C T 7.24E-04 Alzheimer's disease / / 17998437 rs7998084 chr13 52073129 A G 9.15E-04 Multiple complex diseases / / 17554300 rs9535699 chr13 52077993 A G 4.15E-04 Heart Failure / / pha002884 rs9535720 chr13 52194944 T C 6.56E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy WDFY2 intron 23834954 rs17597531 chr13 52222222 C T 2.78E-04 Coronary Artery Disease WDFY2 intron 17634449 rs7327107 chr13 52260398 C G 2.74E-04 Alzheimer's disease WDFY2 intron 17998437 rs7327107 chr13 52260398 C G 1.25E-04 Lymphocyte counts WDFY2 intron 22286170 rs9563069 chr13 52303139 T C 9.16E-04 Amyotrophic Lateral Sclerosis WDFY2 intron 17362836 rs12146894 chr13 52326477 A G 4.73E-04 Coronary Artery Disease WDFY2 intron 17634449 rs9526793 chr13 52327020 G A 1.60E-04 Coronary Artery Disease WDFY2 intron 17634449 rs17075932 chr13 52340721 G T 2.37E-05 Multiple complex diseases / / 17554300 rs9526795 chr13 52341181 T C 5.48E-04 Coronary Artery Disease / / 17634449 rs2296028 chr13 52345637 G A,C 1.33E-04 Coronary Artery Disease DHRS12 intron 17634449 rs9535757 chr13 52352132 T C 5.51E-05 Monocyte chemoattractant protein-1 DHRS12 intron pha003071 rs975504 chr13 52391341 C T 1.22E-05 Telomere length LINC00282 intron 21573004 rs7326878 chr13 52416567 G A 2.54E-04 Multiple complex diseases LINC00282 intron 17554300 rs17600458 chr13 52416912 T G 0.000356 Salmonella-induced pyroptosis LINC00282 intron 22837397 rs913901 chr13 52418598 T C 0.000289 Salmonella-induced pyroptosis LINC00282 intron 22837397 rs9535772 chr13 52421676 T C 7.23E-05 Multiple complex diseases / / 17554300 rs9596596 chr13 52428066 A C 7.16E-05 Myopia (pathological) / / 21095009 rs9535776 chr13 52433564 C T 1.41E-04 Myopia (pathological) / / 21095009 rs932914 chr13 52441175 C T 2.53E-04 Myopia (pathological) / / 21095009 rs932913 chr13 52441188 A G 6.27E-08 Metabolite levels / / 23281178 rs9634848 chr13 52450757 C T 3.74E-04 Myopia (pathological) / / 21095009 rs9596608 chr13 52459324 G C 9.88E-04 Type 2 diabetes / / 17463246 rs9563077 chr13 52472868 C A 6.52E-04 Multiple complex diseases / / 17554300 rs1114598 chr13 52474086 T C 9.88E-04 Type 2 diabetes / / 17463246 rs9526816 chr13 52555288 C T 5.61E-04 Smoking initiation ATP7B intron 24665060 rs9535825 chr13 52565931 G A 4.51E-05 Serum metabolites ATP7B intron 19043545 rs732071 chr13 52570728 G A 3.00E-05 Inflammatory demyelinating disease ATP7B intron 19850125 rs7328090 chr13 52587806 G T 5.72E-04 Smoking initiation ALG11 intron 24665060 rs7320831 chr13 52593765 C T 4.20E-05 Inflammatory demyelinating disease ALG11 intron 19850125 rs9526823 chr13 52601053 T C 3.70E-05 Inflammatory demyelinating disease UTP14C intron 19850125 rs12430077 chr13 52609208 T C 5.00E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs4497567 chr13 52639298 C A 1.30E-13 Lymphocyte counts / / 22286170 rs2408611 chr13 52709742 G A 2.20E-05 Urinary metabolites NEK3 intron 21572414 rs2094354 chr13 52782584 A G 2.00E-04 Smoking initiation / / 24665060 rs4884452 chr13 52949784 T C 3.81E-04 Weight loss (gastric bypass surgery) / / 23643386 rs11618716 chr13 53046836 C T 7.87E-04 Weight loss (gastric bypass surgery) CKAP2 intron 23643386 rs17053105 chr13 53200363 A C 6.87E-04 Suicide attempts in bipolar disorder HNRNPA1L2 intron 21423239 rs7330220 chr13 53286950 C T 1.79E-04 Barrett's esophagus LECT1 missense 24121790 rs7330220 chr13 53286950 C T 6.74E-05 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) LECT1 missense 24121790 rs7139630 chr13 53306304 A G 5.69E-05 Cognitive test performance LECT1 intron 20125193 rs4885948 chr13 53309433 T C 5.49E-04 Insulin resistance LECT1 intron 21901158 rs12146944 chr13 53326437 G A 1.70E-05 Type 2 diabetes / / 23300278 rs235777 chr13 53340133 C T 2.00E-04 Sudden cardiac arrest / / 21658281 rs630031 chr13 53344197 T C 0.000853058 Hypertension (early onset hypertension) / / 22479346 rs17410833 chr13 53356397 T C 0.00052181 Hypertension (early onset hypertension) / / 22479346 rs235786 chr13 53359285 C T 2.80E-04 Alcohol dependence / / 20201924 rs235786 chr13 53359285 C T 6.50E-04 Alcohol dependence / / 20201924 rs9536287 chr13 53359412 G A 2.90E-04 Alcohol dependence / / 20201924 rs9536287 chr13 53359412 G A 7.80E-04 Alcohol dependence / / 20201924 rs886347 chr13 53367458 G A 3.33E-05 Longevity / / 20304771 rs476136 chr13 53413498 G A 5.31E-05 Cognitive performance / / 19734545 rs471680 chr13 53429453 G A 2.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs646902 chr13 53441018 A G 5.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs716409 chr13 53442711 C A 6.23E-05 Parkinson's disease / / 21738487 rs636937 chr13 53447545 G A 3.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1885848 chr13 53452688 A G 3.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7333164 chr13 53483062 C T 3.75E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17052520 chr13 53488158 C G,T 6.14E-04 Coronary Artery Disease / / 17634449 rs9536318 chr13 53494694 G A 8.00E-07 Airflow obstruction / / 22837378 rs8000082 chr13 53501200 T C 9.39E-04 Type 2 diabetes / / 17463246 rs1323113 chr13 53509475 G T 6.43E-04 Type 2 diabetes / / 17463246 rs17052824 chr13 53515799 G C 1.58E-05 Parkinson's disease (motor and cognition) / / 22658654 rs17052824 chr13 53515799 G C 1.58E-05 Immune response to anthrax vaccine / / 22658931 rs732949 chr13 53517884 A C 7.73E-06 Parkinson's disease (motor and cognition) / / 22658654 rs732949 chr13 53517884 A C 8.00E-06 Immune response to anthrax vaccine / / 22658931 rs2208989 chr13 53527973 C T 6.20E-04 Alcohol dependence / / 24277619 rs17053117 chr13 53543167 G A 4.37E-04 Alcohol dependence / / 24277619 rs4884303 chr13 53547536 C T 2.24E-04 Height / / 17255346 rs730371 chr13 53549370 G A 5.21E-05 Height / / 17255346 rs912093 chr13 53549773 G A 6.48E-05 Height / / 17255346 rs975500 chr13 53552014 C T 9.09E-05 Height / / 17255346 rs6561698 chr13 53553407 T C 3.36E-05 Height / / 17255346 rs7999909 chr13 53553518 C T 4.85E-05 Height / / 17255346 rs2226194 chr13 53555256 C T 9.97E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs9596742 chr13 53561568 C A 1.30E-04 Lung adenocarcinoma / / 21242121 rs11842725 chr13 53586101 C T 7.98E-05 Multiple complex diseases / / 17554300 rs7328628 chr13 53594925 G A 6.14E-05 Coronary heart disease / / pha003031 rs9568793 chr13 53602032 G A 8.93E-05 Coronary heart disease / / pha003031 rs2298230 chr13 53608479 G A 3.00E-04 Rheumatoid arthritis OLFM4 intron 21452313 rs3803260 chr13 53613125 T C 3.09E-06 Coronary heart disease OLFM4 intron pha003030 rs9568797 chr13 53613559 C T 1.00E-07 Amyotrophic lateral sclerosis (sporadic) OLFM4 intron 24529757 rs9563131 chr13 53619605 T C 0.000364586 Hypertension (early onset hypertension) OLFM4 intron 22479346 rs12866736 chr13 53627821 C T 4.06E-05 Telomere length / / 23001564 rs2806933 chr13 53643370 A C 2.40E-05 Urinary metabolites / / 21572414 rs2806949 chr13 53646138 A G 7.22E-05 Serum metabolites / / 19043545 rs2806974 chr13 53659930 C T 3.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2807000 chr13 53711303 A G 3.97E-04 Alzheimer's disease / / 22005930 rs2759688 chr13 53718221 T C 2.00E-04 Alzheimer's disease / / 22005930 rs17054878 chr13 53727472 G A 4.12E-05 Response to methylphenidate treatment / / 21130132 rs1322938 chr13 53731757 A G 7.15E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9568828 chr13 53768692 C T 8.15E-04 Alzheimer's disease / / 22005930 rs9596775 chr13 53859017 C T 1.70E-05 Urinary metabolites / / 21572414 rs7993087 chr13 53880086 T A 3.07E-05 Parkinson's disease (motor and cognition) / / 22658654 rs7993087 chr13 53880086 T A 3.07E-05 Immune response to anthrax vaccine / / 22658931 rs7997881 chr13 53880788 G A 5.98E-05 Parkinson's disease (motor and cognition) / / 22658654 rs7997881 chr13 53880788 G A 5.98E-05 Immune response to anthrax vaccine / / 22658931 rs2813583 chr13 53917706 T C 2.92E-04 Alzheimer's disease / / 22005930 rs10507577 chr13 53968091 T C 3.00E-06 Select biomarker traits / / 17903293 rs9568850 chr13 53984228 G A 4.85E-04 Type 2 diabetes / / 17463246 rs7492234 chr13 54060892 T C 8.78E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs9568856 chr13 54064981 G A 2.00E-09 Obesity / / 22484627 rs1927860 chr13 54066896 A C 9.23E-05 Neuroticism / / 23229837 rs9316628 chr13 54099849 C A 5.22E-04 Bone mass and geometry / / 17903296 rs9568867 chr13 54107352 G A 2.00E-09 Obesity / / 23563607 rs9568867 chr13 54107352 G A 4.00E-06 Body mass index / / 24861553 rs9536470 chr13 54160722 C A 2.03E-04 Multiple complex diseases / / 17554300 rs1970268 chr13 54174462 A G 3.00E-05 Personality dimensions / / 18957941 rs7317926 chr13 54175512 A G 0.000281742 Hypertension (early onset hypertension) / / 22479346 rs4884605 chr13 54227768 T C 1.10E-05 Lipid levels / / 18193043 rs7982424 chr13 54245972 T G 4.30E-04 Type 2 diabetes / / 17846126 rs9316650 chr13 54246729 T C 9.06E-04 Multiple complex diseases / / 17554300 rs3989552 chr13 54287978 G A 6.47E-05 Bipolar disorder and schizophrenia / / 20889312 rs7321508 chr13 54289391 A G 6.12E-05 Bipolar disorder and schizophrenia / / 20889312 rs2806731 chr13 54290333 C T 5.00E-06 Obesity-related traits / / 23251661 rs9316653 chr13 54292061 A T 5.12E-05 Bipolar disorder and schizophrenia / / 20889312 rs2806735 chr13 54296049 A G 9.10E-05 Malaria / / 19465909 rs957940 chr13 54301640 T C 3.28E-04 Diabetic retinopathy / / 20871662 rs2806739 chr13 54301779 T C 6.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7981543 chr13 54313476 G A 9.30E-05 Triglycerides / / 19074352 rs7328513 chr13 54319996 T C 4.32E-05 Bipolar disorder and schizophrenia / / 20889312 rs4293248 chr13 54333209 A G 9.63E-05 Bipolar disorder and schizophrenia / / 20889312 rs9536539 chr13 54345721 G C 2.95E-05 Bipolar disorder and schizophrenia / / 20889312 rs9536542 chr13 54351529 G A 4.73E-05 HIV-1 viral setpoint / / 17641165 rs2199043 chr13 54354967 G C 7.49E-05 Type 2 diabetes / / 17463246 rs9591534 chr13 54363861 G C 0.00000423 Sasang constitution (Soyang) / / 22394158 rs9591536 chr13 54377682 A G 6.13E-05 Bipolar disorder and schizophrenia / / 20889312 rs990157 chr13 54381248 C T 3.01E-05 Bipolar disorder and schizophrenia / / 20889312 rs7338269 chr13 54383477 A G 3.63E-05 Bipolar disorder and schizophrenia / / 20889312 rs17088941 chr13 54392420 C T 4.60E-05 Erythrocyte counts LINC00558 intron pha003099 rs4471558 chr13 54413349 T A 1.95E-05 Bipolar disorder and schizophrenia LINC00558 intron 20889312 rs1379831 chr13 54418506 G C 4.30E-05 Bipolar disorder and schizophrenia / / 20889312 rs7332511 chr13 54421334 C G 1.19E-04 Coronary Artery Disease LINC00558 intron 17634449 rs7995218 chr13 54427874 C G 4.16E-05 Bipolar disorder and schizophrenia LINC00558 intron 20889312 rs1458269 chr13 54434565 T C 1.30E-05 Bipolar disorder and schizophrenia LINC00558 intron 20889312 rs6561750 chr13 54435237 C T 9.00E-06 Bipolar disorder and schizophrenia LINC00558 intron 20889312 rs1419186 chr13 54444856 G T 4.38E-05 Bipolar disorder and schizophrenia LINC00558 intron 20889312 rs9536558 chr13 54445269 T C 5.74E-05 Bipolar disorder and schizophrenia LINC00558 intron 20889312 rs1870302 chr13 54446324 G A 3.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LINC00558 intron 20877124 rs4242932 chr13 54448513 T G 1.15E-05 Bipolar disorder and schizophrenia / / 20889312 rs9536560 chr13 54455196 T C 1.93E-05 Bipolar disorder and schizophrenia / / 20889312 rs963943 chr13 54458271 G T 6.40E-04 HIV-1 viral setpoint / / 17641165 rs9563190 chr13 54483253 A C 2.60E-05 Brain structure / / 22504417 rs11618633 chr13 54486173 A G 8.00E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs1379822 chr13 54507087 G A 1.32E-04 Multiple complex diseases / / 17554300 rs4307824 chr13 54567935 A C 4.07E-04 Type 2 diabetes / / 17463246 rs9596891 chr13 54567976 T A 2.72E-04 Parkinson's disease / / 16252231 rs9596891 chr13 54567976 T A 2.17E-04 Type 2 diabetes / / 17463246 rs9536579 chr13 54569365 G A 2.33E-05 Malignant pleural mesothelioma / / 23626673 rs7334767 chr13 54570654 T C 2.52E-04 Smoking initiation / / 24665060 rs9536591 chr13 54581087 A C 6.00E-06 Stroke / / 17434096 rs2104970 chr13 54603212 G C 6.95E-04 Type 2 diabetes / / 17463246 rs2104970 chr13 54603212 G C 4.41E-04 Multiple complex diseases / / 17554300 rs9527156 chr13 54603479 C T 6.95E-04 Type 2 diabetes / / 17463246 rs9527156 chr13 54603479 C T 4.78E-04 Multiple complex diseases / / 17554300 rs9596898 chr13 54615759 G T 1.34E-05 Multiple complex diseases / / 17554300 rs9596905 chr13 54633373 G A 2.00E-06 DNA methylation (variation) / / 23725790 rs9285195 chr13 54670212 C T 5.01E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9568979 chr13 54672835 C T 6.48E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9568981 chr13 54678589 A G 7.36E-05 Height / / pha003011 rs795659 chr13 54753972 T C 3.82E-05 Cognitive impairment induced by topiramate / / 22091778 rs795659 chr13 54753972 T C 1.24E-04 Response to alcohol consumption (flushing response) / / 24277619 rs584860 chr13 54770265 C A 5.27E-05 Multiple complex diseases / / 17554300 rs9563202 chr13 54773365 G T 8.83E-06 Cognitive impairment induced by topiramate / / 22091778 rs572761 chr13 54793133 A G 3.82E-05 Cognitive impairment induced by topiramate / / 22091778 rs681772 chr13 54794355 A G 6.13E-05 Multiple complex diseases / / 17554300 rs9536655 chr13 54829004 T C 2.80E-05 Response to alcohol consumption (flushing response) / / 24277619 rs9536666 chr13 54847192 G A 3.38E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs41436045 chr13 54848900 A T 9.11E-04 Multiple complex diseases / / 17554300 rs2782514 chr13 54873362 C T 2.81E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4884963 chr13 54885744 C T 2.51E-05 Hemoglobin / / pha003098 rs4884963 chr13 54885744 C T 5.89E-05 Erythrocyte counts / / pha003099 rs9596946 chr13 54895699 T C 1.61E-05 Cognitive performance / / 19734545 rs9569017 chr13 54905226 G T 7.55E-04 Type 2 diabetes / / 17463246 rs2818209 chr13 54909547 T G 5.34E-05 Multiple complex diseases / / 17554300 rs952766 chr13 54915506 G A 5.75E-04 Alcohol dependence / / 20201924 rs7336890 chr13 54947953 A T 2.66E-04 Aortic root size / / 21223598 rs9536697 chr13 54949602 A G 5.93E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7335107 chr13 54968613 C A 4.47E-04 Type 2 diabetes / / 17463246 rs1336988 chr13 54975006 T C 3.75E-04 Coronary heart disease / / 21971053 rs7321782 chr13 54996669 C A 2.01E-04 Parkinson's disease / / 17052657 rs9569033 chr13 55016002 G A 1.07E-04 Coronary heart disease / / 21971053 rs542131 chr13 55033079 C T 4.65E-04 Type 2 diabetes / / 23945395 rs9536735 chr13 55038096 A G 2.01E-04 Blood pressure / / 17255346 rs9536735 chr13 55038096 A G 7.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs17089525 chr13 55050498 A C 7.60E-04 Type 2 diabetes / / 17463246 rs2095575 chr13 55083287 C T 3.61E-04 Multiple complex diseases / / 17554300 rs2095575 chr13 55083287 C T 7.02E-04 Alzheimer's disease / / 22005930 rs1159586 chr13 55087532 C T 5.88E-05 White matter integrity / / 22425255 rs2225806 chr13 55090218 A C 4.07E-04 Alzheimer's disease / / 24755620 rs1592084 chr13 55095155 A G 2.06E-04 White matter integrity / / 22425255 rs9563233 chr13 55100373 A G 3.27E-04 Lung function (forced vital capacity) / / 24023788 rs9563233 chr13 55100373 A G 3.88E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs9563234 chr13 55106571 T C 4.73E-04 Lung function (forced vital capacity) / / 24023788 rs1318416 chr13 55106674 A T 9.42E-06 Type 2 diabetes / / 17463246 rs2095577 chr13 55106690 G A 7.34E-04 Multiple complex diseases / / 17554300 rs1539142 chr13 55133411 C A,G 1.83E-04 Type 2 diabetes / / 17463246 rs1360934 chr13 55143754 C T 2.12E-04 Coronary Artery Disease / / 17634449 rs17089667 chr13 55147853 A C 2.28E-04 Coronary Artery Disease / / 17634449 rs9597010 chr13 55153477 T A 2.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs2153713 chr13 55162405 C T 3.64E-08 Adiponectin levels / / 20887962 rs9527234 chr13 55182823 T C 0.000398043 Hypertension (early onset hypertension) / / 22479346 rs7318092 chr13 55188280 G T 2.84E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs993726 chr13 55243102 G A 0.000444467 Hypertension (early onset hypertension) / / 22479346 rs143707136 chr13 55251631 A G 0.0000904 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2493675 chr13 55256186 C T 4.63E-05 Coronary heart disease / / 21971053 rs17089742 chr13 55256771 T C 5.86E-04 Multiple complex diseases / / 17554300 rs1478652 chr13 55257871 G A 6.81E-04 Coronary heart disease / / 21971053 rs3000710 chr13 55270393 T G 1.84E-04 Coronary heart disease / / 21971053 rs7982323 chr13 55322141 C T 5.57E-04 Type 2 diabetes / / 17463246 rs1935285 chr13 55370484 G A 5.91E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs4316637 chr13 55427183 C T 6.24E-04 Coronary Artery Disease / / 17634449 rs17626674 chr13 55429964 T C 1.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7988140 chr13 55439167 G A 1.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9316753 chr13 55467929 A C 0.000000896 Coronary artery disease / / 23202125 rs9563258 chr13 55473732 C T 9.00E-04 Insulin resistance / / 21901158 rs1993776 chr13 55508485 T G 5.81E-04 Coronary heart disease / / 21971053 rs9536919 chr13 55523778 A G 4.48E-04 Coronary heart disease / / 21971053 rs9597065 chr13 55542323 G A 2.60E-05 Pericardial fat / / 22589742 rs54939 chr13 55552706 G T 9.20E-04 Coronary heart disease / / 21971053 rs263840 chr13 55559752 C A 8.93E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs263811 chr13 55563725 T C 6.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9316760 chr13 55624724 A G 2.87E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs17698374 chr13 55639125 T G 6.60E-06 Urinary metabolites / / 21572414 rs12872043 chr13 55688246 G A 1.23E-04 Breast cancer / / pha002853 rs1570751 chr13 55699568 T C 5.25E-04 Type 2 diabetes / / 22158537 rs1570750 chr13 55701343 G T 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs3120890 chr13 55711560 C T 8.10E-04 Type 2 diabetes / / 22158537 rs3120890 chr13 55711560 C T 5.25E-05 Attention deficit hyperactivity disorder / / 22420046 rs3120855 chr13 55725094 A G 9.82E-04 Type 2 diabetes / / 22158537 rs2316646 chr13 55730836 A G 2.80E-05 Urinary metabolites / / 21572414 rs1582147 chr13 55730924 T G 4.63E-04 Type 2 diabetes / / 22158537 rs3120865 chr13 55737834 G A 6.18E-04 Premature ovarian failure / / 19508998 rs4344605 chr13 55782265 T C 6.45E-05 Attention deficit hyperactivity disorder / / 22420046 rs2316652 chr13 55784500 C T 8.68E-04 Type 2 diabetes / / 22158537 rs9537011 chr13 55792940 T C 6.70E-05 Attention deficit hyperactivity disorder / / 22420046 rs12857116 chr13 55795115 T G 7.61E-04 Alcohol dependence / / 20201924 rs7990319 chr13 55796851 A G 6.11E-05 Attention deficit hyperactivity disorder / / 22420046 rs2575901 chr13 55803605 T C 2.40E-05 Urinary metabolites / / 21572414 rs2575906 chr13 55808127 T C 9.74E-04 Type 2 diabetes / / 22158537 rs2575907 chr13 55808339 G A 7.92E-05 Attention deficit hyperactivity disorder / / 22420046 rs9316772 chr13 55811409 C A 3.05E-04 Type 2 diabetes / / 22158537 rs9527340 chr13 55813993 A G 3.60E-04 Type 2 diabetes / / 22158537 rs9537036 chr13 55827231 A G 6.83E-04 Type 2 diabetes / / 22158537 rs7333724 chr13 55832667 G A 7.16E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1583560 chr13 55836303 T C 7.72E-04 Type 2 diabetes / / 22158537 rs4146540 chr13 55836730 A G 5.35E-04 Alcohol dependence / / 20201924 rs10781824 chr13 55836929 C T 5.13E-04 Type 2 diabetes / / 22158537 rs9527354 chr13 55841805 G A 7.09E-04 Type 2 diabetes / / 22158537 rs1370072 chr13 55841938 C T 3.28E-05 Attention deficit hyperactivity disorder / / 22420046 rs1370073 chr13 55841986 T A 7.81E-04 Type 2 diabetes / / 22158537 rs2217929 chr13 55842158 C G 7.61E-04 Type 2 diabetes / / 22158537 rs9537050 chr13 55853051 A G 5.68E-04 Alcohol dependence / / 20201924 rs1992097 chr13 55860118 G A 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs9316778 chr13 55861155 T C 5.35E-04 Alcohol dependence / / 20201924 rs641385 chr13 55873025 A C 8.58E-04 Type 2 diabetes / / 22158537 rs9597162 chr13 55921859 G A 4.75E-04 Alcohol dependence / / 20201924 rs3124427 chr13 55937333 A G 6.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3124427 chr13 55937333 A G 7.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2315885 chr13 55984996 C T 1.80E-06 Blood pressure / / 24001895 rs2315885 chr13 55984996 C T 2.00E-06 Blood pressure / / 24001895 rs2315882 chr13 55988637 A C 7.97E-04 Type 2 diabetes / / 17463246 rs9597180 chr13 56019891 A G 1.41E-04 Alcohol dependence / / 20201924 rs9597202 chr13 56109172 A G 3.86E-04 Alcohol dependence / / 20201924 rs9537164 chr13 56115403 G A 7.34E-05 Major depressive disorder / / 19107115 rs9569320 chr13 56146197 T C 5.78E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9569320 chr13 56146197 T C 6.55E-06 Left ventricular mass / / 21212386 rs639848 chr13 56149195 G A 3.13E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10507601 chr13 56149378 A G 2.00E-04 Type 2 diabetes / / 17846126 rs653366 chr13 56149887 A G 3.49E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs656055 chr13 56150522 A G 6.79E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs480215 chr13 56150637 A G 3.70E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs568745 chr13 56150727 C T 4.40E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs667915 chr13 56150863 A G 4.67E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs667958 chr13 56150885 T C 7.83E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs683882 chr13 56152128 C T 4.97E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9527415 chr13 56152352 G A 3.43E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2780465 chr13 56158484 C A,G,T 4.11E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9537193 chr13 56158843 C G 3.17E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9527419 chr13 56159009 T A 5.77E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9316812 chr13 56159054 C G 4.54E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9537197 chr13 56159937 C T 4.22E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9569336 chr13 56160148 A G 3.46E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1759956 chr13 56207932 G A 7.03E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2453217 chr13 56215194 A C 7.16E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2642313 chr13 56225338 T G 9.01E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs505013 chr13 56239259 T G 2.29E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11148349 chr13 56246710 T G 1.19E-04 Glycosylated haemoglobin levels / / 17255346 rs527560 chr13 56249209 A C 1.03E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs8001026 chr13 56279111 A G 4.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8001026 chr13 56279111 A G 4.84E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8001026 chr13 56279111 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9597244 chr13 56282951 C A 4.12E-04 Smoking initiation / / 24665060 rs7320008 chr13 56301126 A G 0.000707 Salmonella-induced pyroptosis / / 22837397 rs9597267 chr13 56370860 C T 5.15E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2997105 chr13 56378424 C T 3.87E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2997108 chr13 56383613 T A 4.38E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2997114 chr13 56389985 T G 3.10E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs3015418 chr13 56392267 C T 7.72E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2997121 chr13 56396551 A G 1.03E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2935461 chr13 56404249 G A 9.08E-05 Post-operative nausea and vomiting / / 21694509 rs1497298 chr13 56408926 G C 1.37E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs957550 chr13 56413360 C T 9.66E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2997098 chr13 56413673 A G,T 1.36E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2645919 chr13 56416218 C T 8.92E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2645920 chr13 56459234 T C 9.86E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9527458 chr13 56493079 T C 2.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2314014 chr13 56550803 G A 2.16E-04 Multiple complex diseases / / 17554300 rs637821 chr13 56623899 T C 1.94E-05 Serum metabolites / / 19043545 rs141065041 chr13 56648168 A AT 4.09E-04 Multiple complex diseases / / 17554300 rs9569425 chr13 56648168 A G 4.09E-04 Multiple complex diseases / / 17554300 rs166940 chr13 56663210 T C 2.32E-05 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs9569437 chr13 56698567 G T 7.53E-05 Serum metabolites / / 19043545 rs17617114 chr13 56699775 T C 9.83E-05 Serum metabolites / / 19043545 rs9563378 chr13 56699942 C T 4.34E-05 Serum metabolites / / 19043545 rs281659 chr13 56700250 G T 3.14E-06 Serum metabolites / / 19043545 rs190722 chr13 56714478 C T 3.54E-04 Multiple complex diseases / / 17554300 rs1512651 chr13 56772696 G A 6.00E-06 Warfarin maintenance dose / / 20833655 rs2137412 chr13 56774644 A G 5.35E-05 Serum metabolites / / 19043545 rs17052962 chr13 56843901 A C 2.89E-04 Multiple complex diseases / / 17554300 rs9527499 chr13 56886412 A G 6.57E-04 Psoriasis / / 20953187 rs7998333 chr13 56893428 A G 6.57E-04 Psoriasis / / 20953187 rs11842468 chr13 56935284 G T 6.97E-04 Alzheimer's disease (late onset) / / 20885792 rs2315031 chr13 57114277 G C 4.72E-05 Odorant perception / / 23910658 rs12859289 chr13 57193801 G A 2.69E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs806418 chr13 57256500 G A 4.85E-04 Multiple complex diseases / / 17554300 rs9569528 chr13 57336109 T C 1.50E-06 Urinary metabolites / / 21572414 rs9316869 chr13 57403877 C T 2.70E-06 Urinary metabolites / / 21572414 rs9563427 chr13 57426744 A C 3.04E-04 Stroke / / pha002886 rs7319121 chr13 57438062 G T 0.00000458 Autism spectrum disorders / / 22412387 rs7989726 chr13 57439337 G T 0.00000923 Autism spectrum disorders / / 22412387 rs9569548 chr13 57453331 C T 0.00000396 Autism spectrum disorders / / 22412387 rs9569549 chr13 57457404 C T 0.00000396 Autism spectrum disorders / / 22412387 rs6561901 chr13 57489776 A G 0.00000714 Autism spectrum disorders / / 22412387 rs6561906 chr13 57565194 C A 1.14E-04 Multiple complex diseases / / 17554300 rs6561906 chr13 57565194 C A 9.87E-05 Type 1 diabetes / / 18978792 rs9537552 chr13 57572602 A G 1.32E-05 Cognitive impairment induced by topiramate / / 22091778 rs9537556 chr13 57579391 T C 1.84E-04 Multiple complex diseases / / 17554300 rs4322543 chr13 57602909 A G 8.12E-04 Schizophrenia / / 19197363 rs9527585 chr13 57610809 A G 1.08E-04 Schizophrenia / / 19197363 rs4581598 chr13 57615842 C A 1.08E-04 Schizophrenia / / 19197363 rs790325 chr13 57629758 T C 8.28E-04 Type 2 diabetes / / 17463246 rs1929625 chr13 57647058 A G 1.37E-04 Multiple complex diseases / / 17554300 rs7999877 chr13 57667653 C A 7.76E-04 Insulin resistance / / 21901158 rs8000204 chr13 57667707 G A 4.43E-04 Insulin resistance / / 21901158 rs1412142 chr13 57673811 T C 2.38E-04 Multiple complex diseases / / 17554300 rs563765 chr13 57703019 C A 1.28E-04 Insulin resistance / / 21901158 rs526579 chr13 57792155 G A 5.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs567455 chr13 57797989 G A 1.50E-04 Smoking quantity / / 24665060 rs484772 chr13 57806675 T A 1.75E-05 Odorant perception / / 23910658 rs566105 chr13 57812625 C T 5.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs9537655 chr13 57814905 T C 5.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs7983551 chr13 57827157 C T 1.06E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1412160 chr13 57829319 T A 9.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs9537659 chr13 57833589 C A 8.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs9527628 chr13 57836305 T C 6.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs9537663 chr13 57836351 T A 6.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs4564470 chr13 57841784 A G 4.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs1892169 chr13 57888986 T C 6.00E-04 Smoking initiation / / 24665060 rs1449570 chr13 58023959 G A 6.37E-04 Insulin resistance / / 21901158 rs6561934 chr13 58033551 C T 5.22E-06 Alcohol dependence (age at onset) / / 24962325 rs7338789 chr13 58033793 T A 5.22E-06 Alcohol dependence (age at onset) / / 24962325 rs7337578 chr13 58033890 C T 6.59E-06 Alcohol dependence (age at onset) / / 24962325 rs57558300 chr13 58040592 A G 5.68E-06 Alcohol dependence (age at onset) / / 24962325 rs7984728 chr13 58049234 C G 5.47E-06 Alcohol dependence (age at onset) / / 24962325 rs11841410 chr13 58054783 A C 5.47E-06 Alcohol dependence (age at onset) / / 24962325 rs11840139 chr13 58054941 T C 5.47E-06 Alcohol dependence (age at onset) / / 24962325 rs61116530 chr13 58085565 T C 5.94E-06 Alcohol dependence (age at onset) / / 24962325 rs7997918 chr13 58090211 A C 5.94E-06 Alcohol dependence (age at onset) / / 24962325 rs1374483 chr13 58108355 A G 3.10E-04 Primary sclerosing cholangitis / / 19944697 rs11840092 chr13 58114748 T C 2.00E-06 Alcohol dependence (age at onset) / / 24962325 rs1374481 chr13 58158553 G T 7.72E-04 Smoking initiation / / 24665060 rs9569712 chr13 58167105 A G 5.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4886026 chr13 58243568 G A 7.86E-04 Smoking quantity PCDH17 intron 24665060 rs9569725 chr13 58251987 C T 3.70E-05 Lung adenocarcinoma PCDH17 intron 22797724 rs9563520 chr13 58254630 T C 4.86E-04 Smoking quantity PCDH17 intron 24665060 rs7328666 chr13 58280885 C T 6.40E-05 Lung adenocarcinoma PCDH17 intron 22797724 rs9569733 chr13 58316612 T C 3.62E-04 Obesity (extreme) / / 21935397 rs17178205 chr13 58327846 A G 1.53E-04 Multiple complex diseases / / 17554300 rs9569738 chr13 58330643 G A 9.91E-04 Obesity (extreme) / / 21935397 rs1113315 chr13 58351538 T G 1.99E-04 Multiple complex diseases / / 17554300 rs9537821 chr13 58402771 A G 4.88E-04 Multiple complex diseases / / 17554300 rs9537847 chr13 58461076 T A 9.45E-04 Alzheimer's disease / / 17998437 rs9537854 chr13 58480590 T C 7.56E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2118087 chr13 58541850 T C 1.07E-04 Multiple complex diseases / / 17554300 rs11148419 chr13 58605508 T C 4.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1445594 chr13 58675299 A G 3.06E-05 Serum metabolites / / 19043545 rs1445594 chr13 58675299 A G 4.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17054854 chr13 58768855 G C 4.00E-05 Prostate cancer / / 21743057 rs17191595 chr13 58777413 T C 0.00000155 Ovarian follicle number and menopause / / 22696150 rs6561963 chr13 58861684 G A 2.43E-04 Myopia (pathological) / / 21095009 rs10492603 chr13 58871821 A G 2.49E-04 Multiple complex diseases / / 17554300 rs10492603 chr13 58871821 A G 3.87E-04 Diabetic retinopathy / / 20871662 rs10492604 chr13 58904313 T C 4.00E-06 Sleep duration / / 17903308 rs9563600 chr13 58954194 G A 8.03E-04 Multiple complex diseases / / 17554300 rs7988007 chr13 58988271 A C 6.28E-05 Asthma / / 11022011 rs9597722 chr13 59003866 G A 3.85E-04 Alzheimer's disease (late onset) / / 21379329 rs9538078 chr13 59076730 C G 7.05E-05 Alzheimer's disease / / pha002879 rs9538085 chr13 59082282 A G 2.84E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9597750 chr13 59098436 C T 9.00E-05 Serum metabolites / / 19043545 rs9538102 chr13 59115332 A G 9.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs4415915 chr13 59116213 G T 8.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs7492039 chr13 59116552 G T 8.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs10454572 chr13 59116853 C G 8.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs4886088 chr13 59128526 A G 8.00E-06 Subcutaneous adipose tissue / / 22589738 rs1330748 chr13 59166575 C T 5.75E-04 Alzheimer's disease / / 17998437 rs1330748 chr13 59166575 C T 8.27E-04 Body mass index / / 21701565 rs1330748 chr13 59166575 C T 1.01E-04 Alzheimer's disease / / pha002879 rs1333537 chr13 59223986 C T 8.80E-06 Urinary metabolites / / 21572414 rs7320025 chr13 59228289 T C 4.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1537473 chr13 59245163 G C 7.53E-05 Asthma / / 11022011 rs9569918 chr13 59246294 T C 7.11E-05 Asthma / / 11022011 rs17055359 chr13 59262963 A G 3.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs12875717 chr13 59276146 C T 5.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs10507617 chr13 59281545 G A 8.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs12100026 chr13 59289653 A G 6.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs11843565 chr13 59293288 A G 3.47E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs12876391 chr13 59297519 T C 6.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs17055418 chr13 59300409 C T 8.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs1333521 chr13 59323146 T A 0.0003746 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1333521 chr13 59323146 T A 3.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9563646 chr13 59334734 C A 4.10E-05 Bone mineral density (BMD),in women / / 20164292 rs9563646 chr13 59334734 C A 6.92E-04 Aortic root size / / 21223598 rs9563648 chr13 59343944 C T 7.81E-04 Multiple complex diseases / / 17554300 rs7333252 chr13 59348264 T C 1.77E-04 Alcohol dependence / / 24277619 rs9563653 chr13 59369276 G A 8.74E-04 Alzheimer's disease / / 17998437 rs9538209 chr13 59369614 T C 8.44E-04 Alzheimer's disease / / 17998437 rs9538209 chr13 59369614 T C 9.30E-05 Cognitive function / / 24684796 rs9569993 chr13 59413679 A G 6.90E-04 Obesity (extreme) / / 21935397 rs9538228 chr13 59416119 A G 7.16E-04 Obesity (extreme) / / 21935397 rs2321884 chr13 59451732 C T 7.75E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs17608913 chr13 59453599 C T 9.28E-04 Obesity (extreme) / / 21935397 rs2019242 chr13 59476905 G A 5.83E-04 Schizophrenia / / 19197363 rs9597893 chr13 59477851 T C 7.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs9317024 chr13 59485570 T C 5.59E-05 Schizophrenia / / 20185149 rs9538246 chr13 59488129 A G 7.34E-05 Schizophrenia / / 20185149 rs1340565 chr13 59493337 C A 3.10E-06 Urinary metabolites / / 21572414 rs1340565 chr13 59493337 C A 7.94E-04 Alzheimer's disease / / 24755620 rs1417312 chr13 59495894 A G 8.15E-05 Schizophrenia / / 20185149 rs9597908 chr13 59499221 C G 3.69E-05 Schizophrenia / / 20185149 rs9597909 chr13 59499423 C T 7.99E-05 Schizophrenia / / 20185149 rs1417316 chr13 59510412 A G 3.32E-05 Schizophrenia / / 20185149 rs2321867 chr13 59517775 C G 1.60E-06 Urinary metabolites / / 21572414 rs2321867 chr13 59517775 C G 9.67E-04 Alzheimer's disease / / 24755620 rs1340570 chr13 59528155 G C 3.06E-05 Schizophrenia / / 20185149 rs9570012 chr13 59534161 T C 8.49E-04 Multiple complex diseases / / 17554300 rs1361473 chr13 59559577 C T 6.90E-06 Urinary metabolites / / 21572414 rs1340573 chr13 59575423 G A 3.91E-04 Longevity / / 22279548 rs6420320 chr13 59589590 T A 2.77E-04 Smoking quantity / / 24665060 rs1538856 chr13 59591592 G A 4.26E-04 Smoking quantity / / 24665060 rs8181851 chr13 59600358 C T 2.74E-04 Smoking quantity / / 24665060 rs9570026 chr13 59614334 A G 5.74E-04 Smoking quantity / / 24665060 rs6562004 chr13 59619818 A G 7.62E-04 Smoking quantity / / 24665060 rs2321998 chr13 59709598 G A 9.53E-05 Cognitive test performance / / 20125193 rs4627213 chr13 59713306 T C 6.31E-05 Lung adenocarcinoma / / 19836008 rs2322233 chr13 59717623 G A 5.45E-04 Smoking initiation / / 24665060 rs9527947 chr13 59722247 A G 1.30E-06 Urinary metabolites / / 21572414 rs7991723 chr13 59727520 C T 9.09E-04 Alcohol dependence / / 24277619 rs9570060 chr13 59754135 G A 6.94E-04 Type 2 diabetes / / 17463246 rs4886122 chr13 59759555 A G 5.22E-04 Alzheimer's disease / / 22005930 rs4886125 chr13 59760160 A G 1.20E-04 Multiple complex diseases / / 17554300 rs13378924 chr13 59797726 T C 7.39E-06 Serum metabolites / / 19043545 rs13378924 chr13 59797726 T C 0.0000013 Asthma / / 23040885 rs4243013 chr13 59799726 A T 3.84E-06 Serum metabolites / / 19043545 rs4886131 chr13 59799799 A G 3.25E-06 Serum metabolites / / 19043545 rs9634890 chr13 59804362 C T 3.49E-08 Metabolite levels / / 23281178 rs1536626 chr13 59805536 A G 1.94E-05 Serum metabolites / / 19043545 rs1536626 chr13 59805536 A G 2.70E-05 Urinary metabolites / / 21572414 rs1327956 chr13 59811521 A G 1.23E-04 Lung function (forced vital capacity) / / 24023788 rs9538344 chr13 59811662 T G 0.0000015 Asthma / / 23040885 rs9570072 chr13 59812089 T C 3.48E-08 Metabolite levels / / 23281178 rs9538345 chr13 59814259 T C 0.0000012 Asthma / / 23040885 rs9538346 chr13 59815206 A G 0.0000033 Asthma / / 23040885 rs9570076 chr13 59816481 G C 2.87E-05 Serum metabolites / / 19043545 rs9570077 chr13 59819143 T C 0.000000099 Asthma / / 23040885 rs7990817 chr13 59836564 C T 7.77E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs9317061 chr13 59838273 C G 4.29E-04 Type 2 diabetes / / 17463246 rs1998828 chr13 59844496 G T 4.29E-04 Type 2 diabetes / / 17463246 rs1998828 chr13 59844496 G T 2.70E-05 Crohn's disease (time to surgery) / / 23665963 rs7985611 chr13 59851785 C A 4.44E-04 Type 2 diabetes / / 17463246 rs9652215 chr13 59877041 A G 4.35E-04 Obesity (extreme) / / 21935397 rs12853955 chr13 59896534 A C 9.05E-04 Alzheimer's disease / / 24755620 rs9563711 chr13 59898114 A T 5.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs9597982 chr13 59911420 G C 4.90E-06 Urinary metabolites / / 21572414 rs7329285 chr13 59912786 T C 5.60E-06 Urinary metabolites / / 21572414 rs9597986 chr13 59912881 T C 4.80E-06 Urinary metabolites / / 21572414 rs12583100 chr13 59914434 G A 8.96E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12583100 chr13 59914434 G A 0.000205 Salmonella-induced pyroptosis / / 22837397 rs1409260 chr13 59919291 T C 2.30E-06 Urinary metabolites / / 21572414 rs9527970 chr13 59927689 A C 4.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17706633 chr13 59935600 C G 6.62E-23 Adiponectin levels / / 20887962 rs12585963 chr13 59953466 G A 2.00E-06 Breast size / / 22747683 rs923252 chr13 59980202 T C 6.73E-04 Response to TNF antagonist treatment / / 21061259 rs7996198 chr13 59989167 T C 4.18E-04 Iron levels / / pha002876 rs9538421 chr13 60009579 T A 2.20E-05 Urinary metabolites / / 21572414 rs10507631 chr13 60021501 A G 9.75E-04 Multiple complex diseases / / 17554300 rs1414976 chr13 60031893 A G 8.66E-05 Waist-Hip Ratio / / pha003028 rs9570136 chr13 60039063 A G 9.98E-04 Iron levels / / pha002876 rs12428128 chr13 60071355 T G 2.47E-06 Parkinson's disease / / 17052657 rs1630944 chr13 60078760 A G 2.81E-05 Personality dimensions / / 22628180 rs1631696 chr13 60078832 G A 4.57E-04 Multiple complex diseases / / 17554300 rs1631696 chr13 60078832 G A 2.67E-05 Personality dimensions / / 22628180 rs17056657 chr13 60085161 G A 4.91E-04 Aortic root size / / 21223598 rs1711774 chr13 60089243 T G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1711781 chr13 60101315 A G 3.07E-04 Multiple complex diseases / / 17554300 rs831223 chr13 60116104 T C 4.48E-04 Multiple complex diseases / / 17554300 rs831223 chr13 60116104 T C 2.62E-05 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines / / 21483694 rs831223 chr13 60116104 T C 1.40E-05 Height / / 21998595 rs1711792 chr13 60131564 G C 0.000023 Panic disorder / / 23149450 rs1711792 chr13 60131564 G C 2.30E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs9563740 chr13 60140976 A G 0.0000222 Panic disorder / / 23149450 rs9563740 chr13 60140976 A G 8.58E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs831207 chr13 60141047 C T 0.0000749 Panic disorder / / 23149450 rs831207 chr13 60141047 C T 7.49E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs862728 chr13 60153623 G C 0.000023 Panic disorder / / 23149450 rs862728 chr13 60153623 G C 2.30E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs831215 chr13 60154144 G T 0.0000229 Panic disorder / / 23149450 rs831215 chr13 60154144 G T 2.29E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs573497 chr13 60154768 C T 0.0000229 Panic disorder / / 23149450 rs573497 chr13 60154768 C T 2.29E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs670137 chr13 60154787 T A 0.0000226 Panic disorder / / 23149450 rs670137 chr13 60154787 T A 2.26E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs574291 chr13 60154822 C A 0.0000226 Panic disorder / / 23149450 rs574291 chr13 60154822 C A 2.26E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs669712 chr13 60154897 C T 0.0000226 Panic disorder / / 23149450 rs669712 chr13 60154897 C T 2.26E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs669188 chr13 60155039 T C 0.0000226 Panic disorder / / 23149450 rs669188 chr13 60155039 T C 2.26E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs489624 chr13 60155344 A G 0.0000225 Panic disorder / / 23149450 rs489624 chr13 60155344 A G 2.25E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs667039 chr13 60155445 T C 0.0000224 Panic disorder / / 23149450 rs667039 chr13 60155445 T C 2.24E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs491388 chr13 60155513 T C 0.0000223 Panic disorder / / 23149450 rs491388 chr13 60155513 T C 2.23E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs666550 chr13 60155600 C T 0.0000222 Panic disorder / / 23149450 rs666550 chr13 60155600 C T 2.22E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs654178 chr13 60156070 A G 0.0000222 Panic disorder / / 23149450 rs654178 chr13 60156070 A G 9.99E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs640694 chr13 60156754 G A 0.0000221 Panic disorder / / 23149450 rs640694 chr13 60156754 G A 2.21E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs527287 chr13 60157175 A C 0.000022 Panic disorder / / 23149450 rs527287 chr13 60157175 A C 2.20E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs549227 chr13 60157275 C A 0.000022 Panic disorder / / 23149450 rs549227 chr13 60157275 C A 2.20E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs1615781 chr13 60157813 T C 0.0000219 Panic disorder / / 23149450 rs1615781 chr13 60157813 T C 2.19E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs579303 chr13 60158264 T C 0.0000217 Panic disorder / / 23149450 rs579303 chr13 60158264 T C 2.17E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs473386 chr13 60158729 A T 0.0000216 Panic disorder / / 23149450 rs473386 chr13 60158729 A T 2.16E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs473611 chr13 60158815 T C 0.0000216 Panic disorder / / 23149450 rs473611 chr13 60158815 T C 2.16E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs610696 chr13 60158863 A T 0.0000216 Panic disorder / / 23149450 rs610696 chr13 60158863 A T 2.16E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs610640 chr13 60158910 G T 0.0000216 Panic disorder / / 23149450 rs610640 chr13 60158910 G T 2.16E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs501448 chr13 60159514 C T 0.0000216 Panic disorder / / 23149450 rs501448 chr13 60159514 C T 2.16E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs502140 chr13 60159536 G T 0.0000215 Panic disorder / / 23149450 rs502140 chr13 60159536 G T 2.15E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs502229 chr13 60159568 A C 0.0000215 Panic disorder / / 23149450 rs502229 chr13 60159568 A C 2.15E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs607560 chr13 60159625 T C 0.0000214 Panic disorder / / 23149450 rs607560 chr13 60159625 T C 2.14E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs607546 chr13 60159634 A G 0.0000223 Panic disorder / / 23149450 rs607546 chr13 60159634 A G 2.23E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs505095 chr13 60159914 T C 0.0000224 Panic disorder / / 23149450 rs505095 chr13 60159914 T C 2.24E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs506806 chr13 60160065 G A 0.0000224 Panic disorder / / 23149450 rs506806 chr13 60160065 G A 2.24E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs4609710 chr13 60160505 T C 0.0000225 Panic disorder / / 23149450 rs4609710 chr13 60160505 T C 2.25E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs4482172 chr13 60160545 A C 0.0000225 Panic disorder / / 23149450 rs4482172 chr13 60160545 A C 2.25E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs592255 chr13 60160738 G A 0.0000226 Panic disorder / / 23149450 rs592255 chr13 60160738 G A 2.26E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs670922 chr13 60161189 A G 0.0000225 Panic disorder / / 23149450 rs670922 chr13 60161189 A G 2.25E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs559909 chr13 60161305 C T 0.0000227 Panic disorder / / 23149450 rs559909 chr13 60161305 C T 2.27E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs562553 chr13 60161554 T G 0.0000227 Panic disorder / / 23149450 rs562553 chr13 60161554 T G 2.27E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs565500 chr13 60161927 T C 0.0000227 Panic disorder / / 23149450 rs565500 chr13 60161927 T C 2.27E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs1463449 chr13 60162048 A G 0.0000226 Panic disorder / / 23149450 rs1463449 chr13 60162048 A G 2.26E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs936336 chr13 60162503 G A 0.0000227 Panic disorder / / 23149450 rs936336 chr13 60162503 G A 6.22E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs936334 chr13 60162598 C G 0.0000221 Panic disorder / / 23149450 rs936334 chr13 60162598 C G 2.21E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs571049 chr13 60163668 T C 0.0000408 Panic disorder / / 23149450 rs571049 chr13 60163668 T C 4.08E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs486428 chr13 60164223 C T 0.0000219 Panic disorder / / 23149450 rs486428 chr13 60164223 C T 2.19E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs545142 chr13 60166033 A T 0.0000152 Panic disorder / / 23149450 rs545142 chr13 60166033 A T 1.52E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs677168 chr13 60174337 A C 0.0000222 Panic disorder / / 23149450 rs677168 chr13 60174337 A C 2.22E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs676655 chr13 60174482 G A 0.0000223 Panic disorder / / 23149450 rs676655 chr13 60174482 G A 2.23E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs496560 chr13 60174814 T C 0.0000227 Panic disorder / / 23149450 rs496560 chr13 60174814 T C 2.27E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs4884343 chr13 60178077 A G 0.0000228 Panic disorder / / 23149450 rs4884343 chr13 60178077 A G 2.28E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs492632 chr13 60178824 G C 0.0000233 Panic disorder / / 23149450 rs492632 chr13 60178824 G C 2.33E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs505299 chr13 60184047 C T 2.64E-04 Hypertension (young onset) / / 24892410 rs9528022 chr13 60226817 T G 2.98E-05 Multiple complex diseases / / 17554300 rs11839699 chr13 60237868 T C 0.000252 Salmonella-induced pyroptosis / / 22837397 rs12583057 chr13 60243351 C T 1.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DIAPH3 intron 20877124 rs1350361 chr13 60250843 G A 5.14E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) DIAPH3 intron 23648065 rs7333989 chr13 60255244 A G 9.88E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DIAPH3 intron 20877124 rs7336489 chr13 60273298 C T 5.38E-06 Alzheimer's disease DIAPH3 intron 17998437 rs7336489 chr13 60273298 C T 4.82E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) DIAPH3 intron 23648065 rs7336489 chr13 60273298 C T 8.33E-05 Alzheimer's disease DIAPH3 intron pha002879 rs342580 chr13 60296388 T C 6.40E-04 Response to cytidine analogues (gemcitabine) DIAPH3 intron 24483146 rs7337081 chr13 60331163 G C 6.54E-05 Multiple complex diseases DIAPH3 intron 17554300 rs9528037 chr13 60340678 T C 9.05E-05 Multiple complex diseases DIAPH3 intron 17554300 rs7997280 chr13 60356738 T G 5.75E-04 Response to cytidine analogues (gemcitabine) DIAPH3 intron 24483146 rs341557 chr13 60367014 A G 5.05E-05 Multiple complex diseases DIAPH3 intron 17554300 rs341557 chr13 60367014 A G 8.38E-04 Response to cytidine analogues (gemcitabine) DIAPH3 intron 24483146 rs408858 chr13 60373901 T C 3.36E-04 Response to cytidine analogues (gemcitabine) DIAPH3 intron 24483146 rs341522 chr13 60395902 T C 6.73E-04 Response to cytidine analogues (gemcitabine) DIAPH3 intron 24483146 rs341521 chr13 60399045 G A 4.24E-04 Response to cytidine analogues (gemcitabine) DIAPH3 intron 24483146 rs341521 chr13 60399045 G A 8.88E-05 Lung function (forced expiratory volume in 1 second) DIAPH3 intron pha003102 rs341508 chr13 60420106 G A 3.99E-04 Response to cytidine analogues (gemcitabine) DIAPH3 intron 24483146 rs17722872 chr13 60428044 C T 9.21E-04 Multiple complex diseases DIAPH3 intron 17554300 rs11842701 chr13 60431689 T A 7.77E-06 Hearing function DIAPH3 intron 21493956 rs180396 chr13 60437497 C T 9.94E-04 Response to cytidine analogues (gemcitabine) DIAPH3 intron 24483146 rs11844009 chr13 60438500 C T 8.74E-06 Hearing function DIAPH3 intron 21493956 rs340223 chr13 60466889 T G 6.22E-05 Lung function (forced expiratory volume in 1 second) DIAPH3 intron pha003102 rs340222 chr13 60467373 G T 4.40E-04 Response to cytidine analogues (gemcitabine) DIAPH3 intron 24483146 rs11616749 chr13 60475853 G A 1.27E-05 Breast Cancer in BRCA1 mutation carriers DIAPH3 intron 23544013 rs11616749 chr13 60475853 G A 5.15E-04 Breast Cancer in BRCA1 mutation carriers DIAPH3 intron 23544013 rs11616749 chr13 60475853 G A 5.94E-04 Breast Cancer in BRCA1 mutation carriers DIAPH3 intron 23544013 rs7339062 chr13 60476236 G A 2.80E-05 Urinary metabolites DIAPH3 intron 21572414 rs17729071 chr13 60480774 T C 5.48E-04 Multiple complex diseases DIAPH3 intron 17554300 rs73196173 chr13 60495833 T C 4.22E-07 Coronary heart disease DIAPH3 intron 22319020 rs339536 chr13 60551414 T C 6.15E-05 HDL particle features DIAPH3 intron pha002900 rs17057493 chr13 60553018 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) DIAPH3 intron 20708005 rs11841515 chr13 60578293 T C 5.83E-06 Hearing function DIAPH3 intron 21493956 rs11843015 chr13 60587200 T C 5.28E-06 Hearing function DIAPH3 UTR-5 21493956 rs3783040 chr13 60588530 C T 5.18E-06 Hearing function DIAPH3 intron 21493956 rs3783041 chr13 60588891 T A 5.14E-06 Hearing function DIAPH3 intron 21493956 rs7999592 chr13 60750006 T C 5.83E-04 Multiple complex diseases / / 17554300 rs4886217 chr13 60789907 G A 9.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs12874613 chr13 60791736 T C 2.56E-04 Insulin resistance / / 21901158 rs9538602 chr13 60792648 A G 9.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs5027969 chr13 60800933 A G 1.54E-04 Alzheimer's disease / / 17998437 rs9570277 chr13 60808641 C T 4.83E-04 Multiple complex diseases / / 17554300 rs777771 chr13 60812656 G A 6.69E-04 Smoking quantity / / 24665060 rs7984957 chr13 60814970 C G 1.50E-04 Multiple complex diseases / / 17554300 rs9570280 chr13 60818288 C A 5.58E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs8000104 chr13 60853801 T G 3.98E-06 Post-operative nausea and vomiting / / 21694509 rs17788814 chr13 60855317 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17788814 chr13 60855317 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12874151 chr13 60865538 C T 1.01E-04 Multiple complex diseases / / 17554300 rs17184874 chr13 60865719 C T 5.76E-04 Depression (quantitative trait) / / 20800221 rs17789007 chr13 60866744 C T 5.69E-04 Depression (quantitative trait) / / 20800221 rs17185068 chr13 60872589 T C 3.18E-05 Cognitive impairment induced by topiramate / / 22091778 rs17185068 chr13 60872589 T C 6.56E-05 Cognitive impairment induced by topiramate / / 22091778 rs867031 chr13 60893751 G A 5.66E-06 Cognitive decline / / 23207651 rs2039970 chr13 60910291 C T 2.46E-04 Heart Failure / / pha002885 rs9598123 chr13 60927098 C T 5.12E-04 Obesity (extreme) / / 21935397 rs9317115 chr13 60927896 G A 5.07E-04 Obesity (extreme) / / 21935397 rs9528119 chr13 60954630 C T 1.30E-05 Urinary metabolites / / 21572414 rs6562106 chr13 60954650 C T 2.60E-04 Multiple complex diseases / / 17554300 rs4886227 chr13 60990506 A G 1.50E-04 Alcohol dependence TDRD3 intron 20201924 rs4886227 chr13 60990506 A G 3.00E-04 Alcohol dependence TDRD3 intron 20201924 rs4886227 chr13 60990506 A G 2.00E-04 Cognitive impairment induced by topiramate TDRD3 intron 22091778 rs4886227 chr13 60990506 A G 2.00E-04 Cognitive impairment induced by topiramate TDRD3 intron 22091778 rs4886227 chr13 60990506 A G 8.04E-05 Cognitive impairment induced by topiramate TDRD3 intron 22091778 rs4886227 chr13 60990506 A G 4.64E-05 Body Mass Index TDRD3 intron pha003022 rs9538710 chr13 61035798 G A 7.70E-04 Alcohol dependence TDRD3 intron 20201924 rs9538710 chr13 61035798 G A 8.50E-04 Alcohol dependence TDRD3 intron 20201924 rs9538719 chr13 61052747 G A 1.80E-05 Urinary metabolites TDRD3 intron 21572414 rs9528146 chr13 61057691 A G 1.00E-04 Cognitive impairment induced by topiramate TDRD3 intron 22091778 rs9528146 chr13 61057691 A G 1.00E-04 Cognitive impairment induced by topiramate TDRD3 intron 22091778 rs9528146 chr13 61057691 A G 2.00E-04 Cognitive impairment induced by topiramate TDRD3 intron 22091778 rs9528146 chr13 61057691 A G 7.86E-05 Body Mass Index TDRD3 intron pha003022 rs9538737 chr13 61107313 A C 1.00E-04 Cognitive impairment induced by topiramate TDRD3 intron 22091778 rs9538737 chr13 61107313 A C 8.62E-05 Cognitive impairment induced by topiramate TDRD3 intron 22091778 rs9538737 chr13 61107313 A C 8.81E-05 Cognitive impairment induced by topiramate TDRD3 intron 22091778 rs9538740 chr13 61109963 A G 1.20E-04 Alcohol dependence TDRD3 intron 20201924 rs9538740 chr13 61109963 A G 2.50E-04 Alcohol dependence TDRD3 intron 20201924 rs9538740 chr13 61109963 A G 2.00E-04 Cognitive impairment induced by topiramate TDRD3 intron 22091778 rs9538741 chr13 61111797 G A 1.00E-04 Cognitive impairment induced by topiramate TDRD3 intron 22091778 rs9538741 chr13 61111797 G A 1.00E-04 Cognitive impairment induced by topiramate TDRD3 intron 22091778 rs9538741 chr13 61111797 G A 2.00E-04 Cognitive impairment induced by topiramate TDRD3 intron 22091778 rs9538741 chr13 61111797 G A 7.01E-05 Body Mass Index TDRD3 intron pha003022 rs4886238 chr13 61113739 G A 1.00E-10 Menopause (age at onset) TDRD3 intron 22267201 rs12865240 chr13 61119357 A G 7.30E-04 Alcohol dependence TDRD3 intron 20201924 rs12865240 chr13 61119357 A G 8.50E-04 Alcohol dependence TDRD3 intron 20201924 rs12865240 chr13 61119357 A G 1.00E-04 Cognitive impairment induced by topiramate TDRD3 intron 22091778 rs12865240 chr13 61119357 A G 8.54E-05 Cognitive impairment induced by topiramate TDRD3 intron 22091778 rs17058241 chr13 61149786 A G 3.53E-04 Multiple complex diseases / / 17554300 rs10507652 chr13 61187199 G A 1.10E-05 Urinary metabolites / / 21572414 rs995085 chr13 61188132 C T 8.00E-06 Crohn's disease / / 20570966 rs9317124 chr13 61201821 A G 9.62E-04 Multiple complex diseases / / 17554300 rs7332036 chr13 61201921 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1407575 chr13 61226586 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1407575 chr13 61226586 C T 5.82E-05 Cognitive impairment induced by topiramate / / 22091778 rs4886250 chr13 61251217 T C 8.86E-04 Alzheimer's disease / / 17998437 rs7318027 chr13 61264694 A G 6.03E-04 Taste perception / / 22132133 rs9570347 chr13 61295506 T C 9.04E-04 Type 2 diabetes / / 17463246 rs9598160 chr13 61295764 A T 7.80E-04 Type 2 diabetes / / 17463246 rs4142892 chr13 61297156 G A 4.81E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1399147 chr13 61306764 T G 5.70E-04 Smoking initiation / / 24665060 rs17058769 chr13 61319533 A G 7.80E-04 Multiple complex diseases / / 17554300 rs9528209 chr13 61322241 A G 6.89E-05 Multiple complex diseases / / 17554300 rs987104 chr13 61340411 G A 4.79E-04 Type 2 diabetes / / 17463246 rs3119852 chr13 61358370 T C 3.82E-05 Personality dimensions / / 18957941 rs1953100 chr13 61395831 A G 5.14E-04 Aortic root size / / 21223598 rs3119870 chr13 61407633 G C 5.44E-04 Multiple complex diseases / / 17554300 rs3119871 chr13 61407658 T C 3.30E-04 Multiple complex diseases / / 17554300 rs9528249 chr13 61409823 C T 6.19E-04 Multiple complex diseases / / 17554300 rs9528250 chr13 61410191 G A 5.93E-04 Multiple complex diseases / / 17554300 rs9528250 chr13 61410191 G A 2.20E-05 Urinary metabolites / / 21572414 rs1514171 chr13 61410527 C G 2.43E-04 Multiple complex diseases / / 17554300 rs3127053 chr13 61412076 C A 1.69E-04 Multiple complex diseases / / 17554300 rs1355904 chr13 61412681 T C 4.10E-04 Multiple complex diseases / / 17554300 rs3850088 chr13 61419624 G A 3.88E-04 Multiple complex diseases / / 17554300 rs3914416 chr13 61419993 T C 6.10E-06 Urinary metabolites / / 21572414 rs8001190 chr13 61425659 A T 1.20E-05 Urinary metabolites / / 21572414 rs159954 chr13 61432889 A G 4.28E-04 Multiple complex diseases / / 17554300 rs9528251 chr13 61434516 T G 8.00E-06 Urinary metabolites / / 21572414 rs167272 chr13 61436550 C T 3.66E-05 Multiple complex diseases / / 17554300 rs9598179 chr13 61450812 C A 9.39E-04 Multiple complex diseases / / 17554300 rs11840753 chr13 61451581 G A 8.04E-04 Multiple complex diseases / / 17554300 rs9563848 chr13 61456474 C G 9.97E-04 Multiple complex diseases / / 17554300 rs4886286 chr13 61465129 A C 1.10E-05 Parkinson's disease / / 17052657 rs4886286 chr13 61465129 A C 5.81E-04 Multiple complex diseases / / 17554300 rs17223208 chr13 61481945 A C 4.49E-05 Multiple complex diseases / / 17554300 rs7327571 chr13 61487601 C G 7.12E-05 Multiple complex diseases / / 17554300 rs7337573 chr13 61513669 T C 2.00E-08 Phospholipid levels (plasma) / / 22359512 rs2134867 chr13 61542214 T C 3.83E-05 Cognitive test performance / / 20125193 rs1949271 chr13 61580384 G A 7.81E-04 Multiple complex diseases / / 17554300 rs9570420 chr13 61602456 A G 6.00E-06 Urinary metabolites / / 21572414 rs7327426 chr13 61612740 A T 6.49E-04 Alzheimer's disease / / 17998437 rs9570428 chr13 61618853 C T 4.52E-06 Meningococcal disease / / 20694013 rs9570431 chr13 61620696 T C 4.00E-06 Urinary metabolites / / 21572414 rs10507661 chr13 61644179 T C 1.60E-05 Urinary metabolites / / 21572414 rs11619095 chr13 61655038 G C 1.52E-04 Alzheimer's disease / / 17998437 rs3106598 chr13 61678912 G A 1.00E-06 Longevity / / 20834067 rs7982892 chr13 61703026 G A 5.64E-04 HIV-1 viral setpoint / / 17641165 rs17059391 chr13 61711163 G A 1.87E-05 Cognitive test performance / / 20125193 rs7994213 chr13 61729112 T C 4.47E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs1483695 chr13 61729829 T C 3.62E-04 Multiple complex diseases / / 17554300 rs1483695 chr13 61729829 T C 8.18E-12 Narcolepsy / / 19629137 rs2323222 chr13 61731368 T C 2.01E-04 HIV-1 viral setpoint / / 17641165 rs1483693 chr13 61733711 G A 2.01E-04 HIV-1 viral setpoint / / 17641165 rs993877 chr13 61738208 C T 3.54E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs9570486 chr13 61739617 C T 1.56E-05 Cognitive test performance / / 20125193 rs7993782 chr13 61825718 G A 6.31E-04 HIV-1 viral setpoint / / 17641165 rs7338363 chr13 61826907 T C 2.37E-05 Cognitive test performance / / 20125193 rs1483701 chr13 61834014 C T 9.88E-04 HIV-1 viral setpoint / / 17641165 rs9539095 chr13 61867517 C T 5.91E-04 Parkinson's disease / / 17052657 rs9539095 chr13 61867517 C T 1.82E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs9539100 chr13 61873379 T C 2.76E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9539108 chr13 61883623 G A 7.28E-05 Coronary restenosis / / 21878436 rs9598262 chr13 61925049 T C 7.98E-04 Acute lung injury / / 22295056 rs959442 chr13 61934090 A C 7.09E-04 Acute lung injury / / 22295056 rs4886332 chr13 61944887 G T 3.72E-04 Acute lung injury / / 22295056 rs9598269 chr13 61945991 G A 4.40E-04 Acute lung injury / / 22295056 rs1590923 chr13 61954997 T G 7.10E-05 Blood Pressure / / pha003040 rs2323266 chr13 61965303 T G 5.11E-04 Tourette syndrome / / 22889924 rs2323266 chr13 61965303 T G 3.00E-06 Schizophrenia / / 23212062 rs2997415 chr13 62048616 G A 2.28E-04 Alcohol dependence / / 20201924 rs2329317 chr13 62070819 C A 1.30E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17059944 chr13 62074306 C A 1.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12427905 chr13 62077426 T A 1.12E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9539217 chr13 62131957 A C 1.09E-04 Birth weight / / 17255346 rs2329312 chr13 62161061 A G 2.03E-04 Height / / 17255346 rs7324363 chr13 62186105 G A 1.05E-04 Height / / 17255346 rs4243027 chr13 62188604 T G 2.55E-05 Height / / 17255346 rs4886362 chr13 62264368 C A 8.29E-04 Multiple complex diseases / / 17554300 rs6562208 chr13 62354467 C T 1.19E-05 Intelligence / / 21826061 rs2323533 chr13 62362156 T C 5.20E-06 Urinary metabolites / / 21572414 rs7982789 chr13 62426433 T G 2.85E-05 Intelligence / / 21826061 rs1412483 chr13 62446558 A G 2.32E-05 Intelligence / / 21826061 rs7986967 chr13 62495757 C T 8.59E-05 Intelligence / / 21826061 rs2183953 chr13 62511438 C T 5.30E-05 Diabetes Mellitus / / pha003059 rs9539380 chr13 62555475 A G 7.90E-06 Urinary metabolites / / 21572414 rs4128722 chr13 62558596 T C 4.69E-04 Parkinson's disease / / 16252231 rs9598403 chr13 62561800 C T 4.69E-05 Intelligence / / 21826061 rs9598404 chr13 62569634 T C 4.69E-05 Intelligence / / 21826061 rs10161939 chr13 62595610 A G 8.52E-05 Intelligence / / 21826061 rs4430638 chr13 62616399 C T 1.87E-05 Intelligence / / 21826061 rs9539394 chr13 62632653 T C 2.82E-04 Acute lung injury / / 22295056 rs1113779 chr13 62633050 G C 2.71E-04 Acute lung injury / / 22295056 rs9598419 chr13 62634077 T C 2.77E-04 Acute lung injury / / 22295056 rs4520738 chr13 62639663 G T 3.17E-04 Acute lung injury / / 22295056 rs11839700 chr13 62640800 G A 4.56E-04 Acute lung injury / / 22295056 rs11843331 chr13 62642843 A G 5.70E-04 Acute lung injury / / 22295056 rs12431315 chr13 62647035 T C 7.62E-04 Acute lung injury / / 22295056 rs8000211 chr13 62651049 A G 6.93E-04 Acute lung injury / / 22295056 rs1587937 chr13 62680052 G A 8.38E-04 Type 2 diabetes / / 17463246 rs308658 chr13 62702662 C G 2.90E-05 Urinary metabolites / / 21572414 rs308652 chr13 62705895 C T 1.10E-05 Urinary metabolites / / 21572414 rs308641 chr13 62714405 T C 6.90E-06 Urinary metabolites / / 21572414 rs2197627 chr13 62719919 A T 9.45E-04 Acute lung injury / / 22295056 rs7318359 chr13 62723602 T C 9.22E-04 Acute lung injury / / 22295056 rs9528473 chr13 62724190 T C 9.34E-04 Acute lung injury / / 22295056 rs2121505 chr13 62730174 G A 1.59E-04 Age-related macular degeneration / / 22125219 rs9598426 chr13 62740247 G A 6.69E-04 Obesity (extreme) / / 21935397 rs308541 chr13 62776642 A G 2.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs308541 chr13 62776642 A G 8.06E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17061126 chr13 62806063 C T 1.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17061126 chr13 62806063 C T 3.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs728545 chr13 62810065 G A 1.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs728545 chr13 62810065 G A 3.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1752812 chr13 62868719 G A 1.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1752812 chr13 62868719 G A 3.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs417155 chr13 62875397 G A 2.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9563960 chr13 62930300 A G 4.00E-06 IgG glycosylation / / 23382691 rs9563960 chr13 62930300 A G 7.00E-06 IgG glycosylation / / 23382691 rs17061343 chr13 62980593 A G 4.63E-07 Multiple complex diseases / / 17554300 rs17061417 chr13 63063671 A G 2.37E-05 Arthritis (juvenile idiopathic) / / 22354554 rs310929 chr13 63071787 C T 1.23E-04 Type 2 diabetes / / 17463246 rs17087443 chr13 63171569 T C 5.80E-04 Nicotine dependence / / 17158188 rs4884429 chr13 63280874 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9563967 chr13 63281939 C T 2.51E-05 Multiple complex diseases / / 17554300 rs9570731 chr13 63352571 C T 3.63E-04 Type 2 diabetes / / 17463246 rs9563982 chr13 63358172 A G 3.43E-04 Tourette syndrome / / 22889924 rs9317258 chr13 63358590 T C 3.71E-04 Type 2 diabetes / / 17463246 rs1402555 chr13 63376850 C T 1.45E-04 Multiple complex diseases / / 17554300 rs1335688 chr13 63394793 T C 1.00E-06 Plasma amyloid beta peptide concentrations (ABx-40) / / 24535457 rs7338657 chr13 63401288 G C 1.05E-06 Waist circumference / / 19557197 rs1521252 chr13 63424494 T C 2.48E-06 Waist circumference / / 19557197 rs4489877 chr13 63424975 A T 2.14E-28 Narcolepsy / / 19629137 rs9598518 chr13 63429993 T C 2.25E-06 Waist circumference / / 19557197 rs2204037 chr13 63436800 A G 5.00E-07 QT interval / / 23166209 rs9563990 chr13 63465307 T C 6.48E-04 Acute lung injury / / 22295056 rs6562302 chr13 63465875 G A 5.26E-04 Multiple complex diseases / / 17554300 rs9634897 chr13 63473872 A G 7.05E-04 Acute lung injury / / 22295056 rs9570755 chr13 63475770 A G 7.05E-04 Acute lung injury / / 22295056 rs2875248 chr13 63502576 C T 3.88E-04 Type 2 diabetes / / 17463246 rs2063587 chr13 63539680 G T 3.47E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs1512883 chr13 63551022 C T 9.75E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2669333 chr13 63574196 T C 1.95E-04 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs2669333 chr13 63574196 T C 9.97E-05 Smoking initiation / / 24665060 rs9317284 chr13 63634350 G A,C,T 2.00E-07 Bone mineral density / / 17903296 rs9564006 chr13 63636680 T C 7.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3119939 chr13 63638329 T C 8.00E-06 Asthma / / 21907864 rs1413065 chr13 63679702 C T 0.000435 Asthma / / 22502797 rs3106428 chr13 63707193 A G 8.04E-04 Multiple complex diseases / / 17554300 rs529145 chr13 63710953 C G 7.91E-04 Multiple complex diseases / / 17554300 rs558739 chr13 63721248 G C 5.79E-04 Multiple complex diseases / / 17554300 rs546203 chr13 63722781 A G 6.37E-04 Multiple complex diseases / / 17554300 rs9317289 chr13 63728981 C T 5.01E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9564010 chr13 63785757 T C 5.42E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17088075 chr13 63822060 C T 7.84E-04 Multiple complex diseases / / 17554300 rs9570815 chr13 63861989 A C 1.09E-04 Fibrinogen / / 17255346 rs7322931 chr13 63888089 T C 6.76E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9528614 chr13 63959044 C T 6.70E-05 Personality dimensions / / 18957941 rs9317308 chr13 63970688 G T 7.20E-05 Personality dimensions / / 18957941 rs5021253 chr13 63977037 G T 5.86E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs779551 chr13 64020810 G A 9.16E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2128966 chr13 64033647 T G 7.81E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1340489 chr13 64064405 A T 6.01E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1340490 chr13 64064588 G T 2.53E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1340491 chr13 64068153 G T 6.68E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs480001 chr13 64069417 A G 9.59E-04 Multiple complex diseases / / 17554300 rs9570919 chr13 64069697 A T 4.65E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs647460 chr13 64069836 C A 9.00E-06 Urinary metabolites / / 21572414 rs17088452 chr13 64078754 T C 5.60E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs649667 chr13 64079747 A G 5.84E-04 Multiple complex diseases / / 17554300 rs1412973 chr13 64097755 T G 3.60E-06 Urinary metabolites / / 21572414 rs1352757 chr13 64116574 A G 2.92E-05 Pancreatic cancer / / 23180869 rs9539806 chr13 64122619 A G 8.90E-06 Pancreatic cancer / / 23180869 rs6562317 chr13 64130319 A G 1.90E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2218400 chr13 64139074 C A 2.00E-04 Pancreatic cancer / / 23180869 rs1000589 chr13 64141913 G T 3.00E-06 Pancreatic cancer / / 23180869 rs7330800 chr13 64148071 A C 2.00E-04 Pancreatic cancer / / 23180869 rs9317355 chr13 64151347 C T 2.20E-05 HIV-1 control / / 20041166 rs9539818 chr13 64156606 A G 6.00E-05 Type 2 diabetes and other traits / / 19734900 rs1445550 chr13 64202212 A G 7.03E-04 Multiple complex diseases / / 17554300 rs2587602 chr13 64202642 C T 6.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1530404 chr13 64207520 C A 5.70E-04 Multiple complex diseases / / 17554300 rs4884502 chr13 64210398 A G 9.00E-06 Response to inhaled corticosteroid treatment in asthma (percentage change of FEV1) / / 24792382 rs2590931 chr13 64215667 C T 9.44E-06 Response to inhaled corticosteroid treatment in asthma (percentage change of FEV1) / / 24792382 rs7335314 chr13 64221351 A G 1.94E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1530485 chr13 64232341 C T 5.78E-04 Alcohol dependence / / 20201924 rs1530485 chr13 64232341 C T 3.52E-06 Alcohol dependence / / 20202923 rs2810864 chr13 64242114 G A 7.01E-04 Alcohol dependence / / 20201924 rs2810864 chr13 64242114 G A 9.00E-06 Alcohol dependence / / 20202923 rs2810865 chr13 64249224 G A 1.99E-04 Body mass index / / 21701565 rs12854386 chr13 64267937 A G 8.10E-05 Body mass index / / 21701565 rs9539843 chr13 64268981 G T 8.20E-05 Body mass index / / 21701565 rs6562327 chr13 64344469 C T 4.20E-04 Multiple complex diseases / / 17554300 rs7998251 chr13 64431856 T A 9.74E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9598671 chr13 64532484 T G 4.95E-05 Type 2 diabetes / / 22238593 rs9598681 chr13 64555770 A G 1.65E-04 Multiple complex diseases / / 17554300 rs2875356 chr13 64557142 G T 1.06E-04 Multiple complex diseases / / 17554300 rs12584386 chr13 64560481 C T 8.10E-04 Multiple complex diseases / / 17554300 rs7981251 chr13 64563311 T A 3.27E-04 Multiple complex diseases / / 17554300 rs9539891 chr13 64572127 C T 5.88E-05 Anorexia nervosa / / 24514567 rs17081669 chr13 64642029 G A 8.61E-04 Type 2 diabetes / / 17463246 rs9317390 chr13 64727530 A G 1.90E-04 Blood Phenotypes / / 17903294 rs17083563 chr13 64822214 C T 1.06E-04 Type 2 diabetes / / 17463246 rs17083563 chr13 64822214 C T 1.08E-04 Multiple complex diseases / / 17554300 rs2129554 chr13 64864422 A G 5.58E-04 Multiple complex diseases / / 17554300 rs2129554 chr13 64864422 A G 4.46E-05 Bipolar Disorder / / pha002858 rs1340332 chr13 64879355 T A 2.46E-04 Type 2 diabetes / / 17463246 rs11840858 chr13 64882827 T C 2.99E-04 Type 2 diabetes / / 17463246 rs17084751 chr13 64883431 C G 1.08E-04 Type 2 diabetes / / 17463246 rs17084847 chr13 64888510 A T 9.34E-05 Type 2 diabetes / / 17463246 rs11840383 chr13 64890026 G C 7.46E-05 Type 2 diabetes / / 17463246 rs11148643 chr13 64891197 T C 5.00E-07 Rheumatoid arthritis / / 21156761 rs10507705 chr13 64900936 T G 1.19E-04 Type 2 diabetes / / 17463246 rs17084970 chr13 64901015 C T 9.42E-05 Type 2 diabetes / / 17463246 rs17084970 chr13 64901015 C T 1.95E-04 Gallstones / / 17632509 rs41442349 chr13 64925018 T C 1.23E-04 Type 2 diabetes / / 17463246 rs1340317 chr13 64930995 T A 3.00E-07 Rheumatoid arthritis / / 21156761 rs9571178 chr13 64936243 G A 3.00E-07 Rheumatoid arthritis / / 21156761 rs4261405 chr13 64940267 T C 3.00E-07 Rheumatoid arthritis / / 21156761 rs9598781 chr13 64943791 T C 6.31E-04 Multiple complex diseases / / 17554300 rs9598783 chr13 64945174 C G 3.00E-07 Rheumatoid arthritis / / 21156761 rs2220327 chr13 64946698 T C 1.00E-07 Rheumatoid arthritis / / 21156761 rs2200574 chr13 64948553 A G 3.22E-04 Type 2 diabetes / / 17463246 rs1340319 chr13 64950422 T C 3.00E-07 Rheumatoid arthritis / / 21156761 rs11617469 chr13 64954154 C G 4.16E-04 Schizophrenia / / 20832056 rs9564172 chr13 64980383 G A 4.99E-04 Multiple complex diseases / / 17554300 rs9564173 chr13 64980805 C G 6.23E-04 Multiple complex diseases / / 17554300 rs7991961 chr13 65006947 A G 9.42E-05 Serum metabolites / / 19043545 rs17087395 chr13 65034144 A C 8.15E-04 Type 2 diabetes / / 17463246 rs589629 chr13 65181729 A G 3.44E-04 Hearing function / / 17255346 rs9592359 chr13 65215262 A G 4.87E-05 Major depressive disorder / / 19107115 rs17089462 chr13 65219173 G A 8.41E-05 Bipolar Disorder / / pha002863 rs7988602 chr13 65222862 C T 5.40E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs9540180 chr13 65228629 T G 8.12E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9598823 chr13 65228854 A G 8.12E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs359349 chr13 65229479 A G 9.87E-05 stroke (ischemic) / / 17434096 rs359349 chr13 65229479 A G 2.72E-05 Major depressive disorder / / 19107115 rs2324731 chr13 65230635 A G 8.12E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs359357 chr13 65232024 A G 7.38E-05 Major depressive disorder / / 19107115 rs9598832 chr13 65283136 C T 3.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs678954 chr13 65308657 G A 3.74E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9564193 chr13 65333539 A G 1.96E-04 Smoking cessation / / 24665060 rs9528817 chr13 65335886 T C 2.76E-04 Birth weight / / 17255346 rs995927 chr13 65337816 G A 2.00E-05 Birth weight / / 17255346 rs1832237 chr13 65338535 G A 2.34E-04 Birth weight / / 17255346 rs1407975 chr13 65338567 T C 8.61E-05 Birth weight / / 17255346 rs9540213 chr13 65339575 G T 8.20E-05 Parkinson's disease (age of onset) / / 19772629 rs9540221 chr13 65366000 T G 1.69E-05 Coronary heart disease / / pha003030 rs9540221 chr13 65366000 T G 6.74E-06 Coronary heart disease / / pha003031 rs9528833 chr13 65432262 T C 5.00E-06 Coronary heart disease / / pha003031 rs9528833 chr13 65432262 T C 1.40E-05 Soluble levels of adhesion molecules / / pha003072 rs13379032 chr13 65460917 T C 5.05E-05 Coronary heart disease / / pha003031 rs7329360 chr13 65499683 T C 6.20E-07 Aortic root size / / 21223598 rs9598869 chr13 65511382 C T 1.49E-04 Multiple complex diseases / / 17554300 rs4884590 chr13 65512989 C T 5.44E-05 Stroke (pediatric) / / 22990015 rs12872247 chr13 65514589 G T 1.87E-04 Multiple complex diseases / / 17554300 rs7994014 chr13 65528408 G A 2.47E-04 Multiple complex diseases / / 17554300 rs9592384 chr13 65541314 C G 2.28E-04 Multiple complex diseases / / 17554300 rs9592385 chr13 65541807 A G 4.84E-04 Multiple complex diseases / / 17554300 rs17065463 chr13 65568381 C T 0.000669 Salmonella-induced pyroptosis / / 22837397 rs9592395 chr13 65569749 G A 6.05E-04 Multiple complex diseases / / 17554300 rs9540307 chr13 65574211 G C 4.24E-04 Multiple complex diseases / / 17554300 rs9317477 chr13 65583172 G A 7.35E-04 Multiple complex diseases / / 17554300 rs9571324 chr13 65675975 A G 2.40E-05 Urinary metabolites / / 21572414 rs1415956 chr13 65676342 T G 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10161776 chr13 65690008 C T 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs17067365 chr13 65694134 T A 8.46E-04 Type 2 diabetes / / 17463246 rs17067365 chr13 65694134 T A 2.10E-05 Urinary metabolites / / 21572414 rs4526902 chr13 65714783 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1347207 chr13 65746533 T C 1.00E-05 Urinary metabolites / / 21572414 rs9571338 chr13 65855479 G A 1.50E-05 Urinary metabolites / / 21572414 rs17070716 chr13 65872831 G C 4.10E-05 Parkinson's disease (motor and cognition) / / 22658654 rs9564232 chr13 65879759 T A 4.15E-05 Parkinson's disease (motor and cognition) / / 22658654 rs965281 chr13 65900693 T C 0.000397 Schizophrenia / / 22440650 rs1333169 chr13 65907951 G A 5.12E-06 Parkinson's disease (motor and cognition) / / 22658654 rs1412906 chr13 65914066 T G 1.75E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs2875444 chr13 65925240 C T 7.06E-04 Multiple complex diseases / / 17554300 rs7336478 chr13 65978128 A G 7.73E-05 Serum metabolites / / 19043545 rs2038825 chr13 65985897 G A 1.28E-06 Multiple complex diseases / / 17554300 rs2038825 chr13 65985897 G A 8.02E-05 Serum metabolites / / 19043545 rs9540461 chr13 66091388 G A 3.46E-04 Tourette syndrome / / 22889924 rs7990200 chr13 66114004 A G 3.77E-04 Tourette syndrome / / 22889924 rs1333026 chr13 66120784 A G 8.00E-06 Body mass index / / 17903300 rs9564266 chr13 66159056 A G 0.0000832 Schizophrenia / / 22440650 rs9317526 chr13 66184513 G T 3.98E-05 Waist Circumference / / pha003025 rs11619878 chr13 66212020 G A 1.00E-07 IgG glycosylation / / 23382691 rs11839841 chr13 66218247 G C 9.97E-04 Multiple complex diseases / / 17554300 rs9571456 chr13 66284987 C T 5.61E-05 Orofacial clefts / / 22419666 rs7995678 chr13 66286953 T C 0.000714 Salmonella-induced pyroptosis / / 22837397 rs17077331 chr13 66356341 C T 4.00E-06 Pulmonary function decline / / 22424883 rs1380888 chr13 66440558 C T 4.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs1009193 chr13 66442251 G A 3.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs9540579 chr13 66443265 T C 3.68E-04 Smoking initiation / / 24665060 rs9564287 chr13 66446137 A T 4.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs7334963 chr13 66446232 C G 3.74E-04 Smoking initiation / / 24665060 rs1460657 chr13 66448287 A T 2.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs17078552 chr13 66452064 C A 0.000224 Salmonella-induced pyroptosis / / 22837397 rs9571509 chr13 66456615 T C 4.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs963213 chr13 66456820 G A,C,T 4.50E-05 Smoking initiation / / 24665060 rs9317543 chr13 66461229 A G 7.34E-04 Tuberculosis / / 22239941 rs9571513 chr13 66478225 T C 3.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs1599300 chr13 66479958 G T 4.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs1585440 chr13 66481815 G T 9.00E-06 Pancreatic cancer / / 20686608 rs9571517 chr13 66505349 T A 2.19E-04 Multiple complex diseases / / 17554300 rs9571517 chr13 66505349 T A 1.65E-04 Blood pressure (response to calcium channel blocker) / / 24192120 rs3904004 chr13 66521290 C T 7.12E-05 Multiple complex diseases / / 17554300 rs17252256 chr13 66524254 A G 8.95E-04 Type 2 diabetes / / 17463246 rs17837226 chr13 66536090 C T 4.37E-06 Crohn's disease / / 17804789 rs6562431 chr13 66546991 T C 1.84E-04 Multiple complex diseases / / 17554300 rs17837229 chr13 66563638 T C 6.94E-04 Type 2 diabetes / / 17463246 rs7337455 chr13 66588835 T C 3.22E-04 Multiple complex diseases / / 17554300 rs17837236 chr13 66589579 G A 2.69E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs9529010 chr13 66604211 T A 5.31E-04 Multiple complex diseases / / 17554300 rs17080594 chr13 66610034 A T 5.79E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs9599058 chr13 66612121 A C 7.93E-04 Multiple complex diseases / / 17554300 rs17837241 chr13 66613187 C A 3.52E-04 Cognitive decline / / 23732972 rs9529012 chr13 66657417 T C 7.91E-04 Alzheimer's disease / / 24755620 rs9529013 chr13 66658954 T A 1.10E-04 Multiple complex diseases / / 17554300 rs9540636 chr13 66673143 C T 4.32E-05 Response to metformin / / 21186350 rs9540643 chr13 66678457 A T 1.59E-04 Multiple complex diseases / / 17554300 rs4558292 chr13 66679368 C A 5.71E-04 Multiple complex diseases / / 17554300 rs4558292 chr13 66679368 C A 9.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4525375 chr13 66679585 G A 8.55E-04 Multiple complex diseases / / 17554300 rs4525375 chr13 66679585 G A 8.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7139910 chr13 66702033 T G 1.87E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs8181835 chr13 66703710 A G 1.84E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6562437 chr13 66711440 G A 1.75E-04 Coronary heart disease / / 21606135 rs9540668 chr13 66725233 A C,G,T 6.74E-05 Response to metformin / / 21186350 rs9599075 chr13 66726170 A T 4.04E-07 Facial morphology / / 22341974 rs1322726 chr13 66735565 A G 8.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs1322727 chr13 66735594 A G 9.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs12877123 chr13 66770598 A G 9.22E-05 Hemoglobin / / pha003098 rs17080965 chr13 66784032 T C 3.54E-04 Type 2 diabetes / / 17463246 rs9592458 chr13 66821916 G A 9.05E-05 Orofacial clefts / / 22419666 rs7328198 chr13 66822065 A G 6.40E-04 Multiple complex diseases / / 17554300 rs4884665 chr13 66863184 T C 7.80E-05 Schizophrenia / / 19571808 rs17081091 chr13 66867487 A T 2.17E-04 Type 2 diabetes / / 17463246 rs17579023 chr13 66888895 G A 5.01E-04 Response to radiotherapy in cancer (late toxicity) PCDH9 intron 24785509 rs1982305 chr13 66908399 G A 5.91E-04 Alcohol dependence PCDH9 intron 21314694 rs10507734 chr13 66933212 A G 7.05E-06 Glycemic traits (pregnancy) PCDH9 intron 23903356 rs166500 chr13 66965826 A G 1.52E-04 Schizophrenia PCDH9 intron 20832056 rs17081231 chr13 66967622 A G 5.44E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PCDH9 intron 20877124 rs17081231 chr13 66967622 A G 7.00E-07 Obesity PCDH9 intron 21552555 rs4883777 chr13 66974706 T C 7.50E-05 Intelligence (childhood) PCDH9 intron 23358156 rs7317477 chr13 67020878 C T 2.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) PCDH9 intron 17982456 rs9529086 chr13 67107760 C T 1.90E-05 Urinary metabolites PCDH9 intron 21572414 rs7319523 chr13 67143962 T C 3.25E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PCDH9 intron 21844884 rs7319523 chr13 67143962 T C 5.65E-05 Height PCDH9 intron pha003011 rs9540824 chr13 67148221 G A 8.49E-05 Height PCDH9 intron pha003011 rs2875481 chr13 67152075 G A 1.10E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PCDH9 intron 21844884 rs2875481 chr13 67152075 G A 3.18E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PCDH9 intron 21844884 rs9540827 chr13 67153952 C T 8.20E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PCDH9 intron 21844884 rs9540828 chr13 67154319 C T 2.94E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PCDH9 intron 21844884 rs2095618 chr13 67156486 C T 1.68E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PCDH9 intron 21844884 rs9540832 chr13 67158351 G A 1.27E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PCDH9 intron 21844884 rs11148708 chr13 67160681 A T 3.10E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines PCDH9 intron 21844884 rs11148709 chr13 67180045 T C 2.82E-05 Cognitive impairment induced by topiramate PCDH9 intron 22091778 rs17081554 chr13 67180370 A T 6.41E-04 Multiple complex diseases PCDH9 intron 17554300 rs7322694 chr13 67267982 A G 7.49E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) PCDH9 intron 23648065 rs2146743 chr13 67275691 C G 9.94E-04 Alzheimer's disease PCDH9 intron 17998437 rs9529123 chr13 67287621 C A 2.40E-05 Urinary metabolites PCDH9 intron 21572414 rs2146738 chr13 67298870 T A 9.94E-04 Alzheimer's disease PCDH9 intron 17998437 rs1442017 chr13 67331341 A G 1.30E-10 Fasting glucose-related traits PCDH9 intron 20152958 rs41378952 chr13 67338990 C T 8.85E-04 Multiple complex diseases PCDH9 intron 17554300 rs9571667 chr13 67346783 A G 4.01E-04 Multiple complex diseases PCDH9 intron 17554300 rs956277 chr13 67379709 C T 4.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) PCDH9 intron 23648065 rs7139567 chr13 67382987 T C 9.26E-05 Creatinine levels PCDH9 intron pha003069 rs7330331 chr13 67403123 A T 8.80E-04 Multiple complex diseases PCDH9 intron 17554300 rs9571682 chr13 67455787 A C 6.49E-05 HDL cholesterol PCDH9 intron pha003074 rs12430583 chr13 67468100 C T 2.07E-06 Serum metabolites PCDH9 intron 19043545 rs17587181 chr13 67474637 A C 8.57E-04 Multiple complex diseases PCDH9 intron 17554300 rs1323922 chr13 67487413 A G 2.13E-06 Venous thromboembolism PCDH9 intron 22672568 rs12875741 chr13 67488634 G A 3.37E-06 Serum metabolites PCDH9 intron 19043545 rs10492593 chr13 67494117 A G 3.82E-06 Venous thromboembolism PCDH9 intron 22672568 rs12427700 chr13 67500835 A T 3.91E-06 Serum metabolites PCDH9 intron 19043545 rs1323913 chr13 67520344 A G 7.60E-05 Diabetic retinopathy PCDH9 intron 21441570 rs17791001 chr13 67521014 A C 5.40E-06 Alcohol dependence PCDH9 intron 20202923 rs9571700 chr13 67522224 G C 9.20E-08 Health and aging,CVD and cancer age of onset PCDH9 intron 22174011 rs9540953 chr13 67523258 T C 3.42E-06 Alcohol dependence PCDH9 intron 20202923 rs9317632 chr13 67543448 A G 9.92E-05 Body mass (lean) PCDH9 intron 19268274 rs9317632 chr13 67543448 A G 4.99E-05 Postoperative ventricular dysfunction PCDH9 intron 21980348 rs1924311 chr13 67546580 T C 3.50E-07 Urinary metabolites PCDH9 intron 21572414 rs7324298 chr13 67572850 C T 3.00E-05 Prostate cancer PCDH9 intron 21743057 rs260140 chr13 67642917 A G 3.26E-04 Alzheimer's disease PCDH9 intron 17998437 rs260140 chr13 67642917 A G 1.00E-04 Spine bone size PCDH9 intron 21947420 rs2875517 chr13 67696145 G A 3.00E-06 Dental caries PCDH9 intron 23064961 rs7330064 chr13 67697374 C G 7.52E-04 Type 2 diabetes PCDH9 intron 17463246 rs9541012 chr13 67700236 A C 2.87E-04 Type 2 diabetes PCDH9 intron 17463246 rs718901 chr13 67717906 A C,G,T 5.80E-04 Type 2 diabetes and 6 quantitative traits PCDH9 intron 17848626 rs9599192 chr13 67728051 C T 5.97E-04 Response to taxane treatment (placlitaxel) PCDH9 intron 23006423 rs1998784 chr13 67737880 A G 9.42E-04 Tourette syndrome PCDH9 intron 22889924 rs9564376 chr13 67740920 G A 1.10E-04 Hypertension (young onset) PCDH9 intron 24892410 rs7324330 chr13 67748520 C T 1.36E-04 Type 2 diabetes PCDH9 intron 17463246 rs9529199 chr13 67762288 C A 2.45E-04 Multiple complex diseases PCDH9 intron 17554300 rs9317658 chr13 67813847 C T 9.79E-04 Type 2 diabetes / / 17463246 rs11148740 chr13 67845335 C T 1.60E-04 Hepatocellular carcinoma / / 22807686 rs1889344 chr13 67870208 C G 2.30E-07 Urinary metabolites / / 21572414 rs2991396 chr13 67889386 G A 4.43E-06 Male fertility / / 22633400 rs3013576 chr13 67895522 C T 6.13E-06 Male fertility / / 22633400 rs5027039 chr13 67897550 C A 1.80E-06 Urinary metabolites / / 21572414 rs1537542 chr13 67950822 A T 7.81E-04 Body mass index / / 21701565 rs11618728 chr13 67954880 A G 9.16E-04 Multiple complex diseases / / 17554300 rs1760854 chr13 67988042 C T 3.93E-04 Hemoglobin concentration / / 20534544 rs1937503 chr13 68019884 T C 1.84E-04 Hemoglobin concentration / / 20534544 rs1937506 chr13 68035371 G A 9.23E-06 Multiple complex diseases / / 17554300 rs4884738 chr13 68076885 G A 8.37E-05 Multiple complex diseases / / 17554300 rs17616675 chr13 68077089 G A 2.26E-04 Alzheimer's disease / / 17998437 rs11618001 chr13 68077756 G A 3.93E-04 Hemoglobin concentration / / 20534544 rs7319347 chr13 68079209 C T 3.00E-05 Male-pattern baldness / / 18849994 rs9541136 chr13 68082151 C T 2.36E-04 Multiple complex diseases / / 17554300 rs9541136 chr13 68082151 C T 7.00E-04 Cardiovascular heart disease in diabetics / / 23982368 rs1937519 chr13 68085885 A C 4.58E-04 Multiple complex diseases / / 17554300 rs9541141 chr13 68095175 C T 3.93E-04 Multiple complex diseases / / 17554300 rs2186136 chr13 68105088 A G 6.11E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs12430627 chr13 68111052 A G 6.48E-05 Hemoglobin concentration / / 20534544 rs4454841 chr13 68122238 T C 8.00E-04 Multiple complex diseases / / 17554300 rs7992379 chr13 68125620 T C 4.63E-04 Multiple complex diseases / / 17554300 rs7999802 chr13 68134441 T C 7.75E-04 Multiple complex diseases / / 17554300 rs9571817 chr13 68134691 T A 2.15E-04 Multiple complex diseases / / 17554300 rs4286009 chr13 68142421 C A 9.53E-04 White matter integrity / / 22425255 rs4544137 chr13 68174418 T C 2.44E-06 Osteoarthritis / / 22763110 rs9541173 chr13 68180116 C A 5.95E-05 White matter integrity / / 22425255 rs4371050 chr13 68195307 C T 8.66E-05 White matter integrity / / 22425255 rs17534659 chr13 68196273 C T 8.21E-04 White matter integrity / / 22425255 rs4338667 chr13 68196361 G T 2.71E-05 Serum alpha1-antitrypsin levels / / 23990791 rs4378516 chr13 68196847 C T 5.80E-06 Urinary metabolites / / 21572414 rs9541185 chr13 68197291 G A 2.30E-05 Urinary metabolites / / 21572414 rs9564420 chr13 68228994 G T 9.24E-04 Alzheimer's disease / / 24755620 rs9564421 chr13 68233366 A G 6.44E-04 Multiple complex diseases / / 17554300 rs7325638 chr13 68263150 A G 8.11E-04 Alzheimer's disease / / 17998437 rs7994526 chr13 68365830 A G 5.42E-05 Cognitive performance / / 19734545 rs7994526 chr13 68365830 A G 1.74E-06 Osteoarthritis / / 22763110 rs9564436 chr13 68435679 C G 2.34E-04 Substance dependence / / 21818250 rs4884747 chr13 68449856 G C 7.89E-05 Male fertility / / 22633400 rs289049 chr13 68462331 G A 1.70E-05 Urinary metabolites / / 21572414 rs17083015 chr13 68541377 G A 7.23E-05 Serum metabolites / / 19043545 rs7318913 chr13 68572037 C G 4.00E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs7320523 chr13 68654773 C T 7.40E-05 Obesity-related traits / / 17903300 rs17083114 chr13 68696393 C T 4.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs17083120 chr13 68700340 C T 4.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs17083124 chr13 68701094 A T 4.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs11840273 chr13 68708517 G A 4.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs2325107 chr13 68713789 G A 4.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs17083147 chr13 68733960 T C 4.95E-04 Suicide attempts in bipolar disorder / / 21041247 rs17083164 chr13 68762290 C T 4.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs1343615 chr13 68763922 T C 6.71E-04 Smoking cessation / / 24665060 rs7984473 chr13 68764315 A G 8.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs1146833 chr13 68825070 C T 5.25E-04 Alcohol dependence / / 20201924 rs891643 chr13 68846599 T C 7.18E-04 Coronary heart disease / / 21606135 rs9541316 chr13 68856078 A G 6.35E-04 Coronary heart disease / / 21606135 rs7338505 chr13 68860188 C A 3.18E-04 Myopia (pathological) / / 21095009 rs9541317 chr13 68863953 G A 6.85E-04 Coronary heart disease / / 21606135 rs6562522 chr13 68871429 C G 9.46E-04 Coronary heart disease / / 21606135 rs7332897 chr13 68875415 A G 7.85E-04 Coronary heart disease / / 21606135 rs9529327 chr13 68898856 A C 8.56E-04 Coronary heart disease / / 21606135 rs9541322 chr13 68907871 G A 7.93E-04 Coronary heart disease / / 21606135 rs7994400 chr13 68918806 G T 1.78E-04 Myopia (pathological) / / 21095009 rs12859844 chr13 68980367 A G 0.0000321 L2-L4 spine bone mineral density / / 23436924 rs12100446 chr13 69004773 C T 4.85E-04 Multiple complex diseases / / 17554300 rs17636489 chr13 69052007 G A 1.11E-04 Type 2 diabetes / / 17463246 rs749417 chr13 69060552 G C 1.58E-04 Type 2 diabetes / / 17463246 rs9541386 chr13 69064194 C A 1.74E-04 Type 2 diabetes / / 17463246 rs12584910 chr13 69065524 A G 5.94E-05 Multiple complex diseases / / 17554300 rs1499318 chr13 69083590 C T 6.29E-05 Multiple complex diseases / / 17554300 rs9571951 chr13 69132248 T C 3.42E-04 Multiple complex diseases / / 17554300 rs580859 chr13 69132440 A G 2.68E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs12862556 chr13 69161673 A G 5.32E-05 Cognitive performance / / 19734545 rs17083847 chr13 69218833 C G 7.33E-04 Multiple complex diseases / / 17554300 rs12428605 chr13 69226586 A G 5.32E-04 Multiple complex diseases / / 17554300 rs9805502 chr13 69234019 T A 3.18E-04 Type 2 diabetes / / 17463246 rs9571979 chr13 69236635 T C 4.67E-04 Alzheimer's disease (late onset) / / 21379329 rs9317716 chr13 69238595 G A 4.67E-04 Alzheimer's disease (late onset) / / 21379329 rs287354 chr13 69239952 A G 3.40E-08 Lipid traits / / 17903299 rs287355 chr13 69240180 T C 1.09E-04 Common variable immunodeficiency / / 21497890 rs287474 chr13 69275960 T A 6.30E-09 Lipid traits / / 17903299 rs10507753 chr13 69282276 C T 0.0000985 Coronary artery disease / / 23202125 rs1507203 chr13 69357784 T C 1.90E-04 Lipid traits / / 17903299 rs616735 chr13 69387655 T C 1.60E-05 Urinary metabolites / / 21572414 rs1438649 chr13 69427734 C T 6.03E-05 Bipolar disorder,affective / / 20528957 rs1659025 chr13 69433788 C T 3.80E-05 Cortisol secretion,in saliva / / 21316860 rs10507755 chr13 69457990 T C 1.10E-04 Lipid traits LINC00550 intron 17903299 rs1438653 chr13 69479988 A C 6.60E-04 Type 2 diabetes / / 17463246 rs10507756 chr13 69481602 G C 2.29E-04 Type 2 diabetes / / 17463246 rs10507756 chr13 69481602 G C 6.00E-05 Lipid traits / / 17903299 rs7334608 chr13 69504079 C T 4.33E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs8000981 chr13 69506215 T C 3.67E-04 Type 2 diabetes / / 17463246 rs1340720 chr13 69512812 T C 6.31E-04 Myopia (pathological) / / 21095009 rs1340745 chr13 69516214 T C 3.27E-04 Alzheimer's disease (late onset) / / 21379329 rs2066219 chr13 69530664 G A 9.18E-04 Type 2 diabetes / / 17463246 rs2066219 chr13 69530664 G A 9.00E-06 Diabetes related insulin traits / / 17903298 rs2066219 chr13 69530664 G A 4.00E-06 Urinary metabolites / / 21572414 rs9599369 chr13 69543129 C G 9.62E-04 Type 2 diabetes / / 17463246 rs9541658 chr13 69543849 A C 2.00E-06 Urinary metabolites / / 21572414 rs9541659 chr13 69544561 G A 9.43E-04 Multiple complex diseases / / 17554300 rs9541659 chr13 69544561 G A 2.00E-05 Urinary metabolites / / 21572414 rs2050854 chr13 69550115 A T 2.69E-04 Type 2 diabetes / / 17463246 rs9541665 chr13 69550861 G T 2.75E-04 Type 2 diabetes / / 17463246 rs9317757 chr13 69560429 C T 7.80E-05 Longevity and age-related phenotypes / / 17903295 rs9599374 chr13 69560790 C T 5.24E-04 Type 2 diabetes / / 17463246 rs9529473 chr13 69564539 T A 6.27E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs9529475 chr13 69565834 T C 6.27E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs9317760 chr13 69582685 T A 6.60E-04 Lipid traits / / 17903299 rs9541712 chr13 69583739 A C 5.64E-06 Bone mineral density / / 21124946 rs7321945 chr13 69620258 C A 6.39E-05 Heart Rate / / pha003051 rs9599395 chr13 69659912 A G 2.50E-05 Heart Rate / / pha003051 rs9285264 chr13 69667020 C T 9.87E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs76939729 chr13 69671273 G A 0.0002211 Sarcoidosis / / 22952805 rs76146281 chr13 69684105 C T 0.0001419 Sarcoidosis / / 22952805 rs79610039 chr13 69692467 G A 0.0001345 Sarcoidosis / / 22952805 rs9599412 chr13 69693751 A G 0.0001345 Sarcoidosis / / 22952805 rs1584204 chr13 69694289 G A 0.0001345 Sarcoidosis / / 22952805 rs9541789 chr13 69722212 T G 4.46E-08 Metabolite levels / / 23281178 rs9541789 chr13 69722212 T G 1.63E-05 Serum alpha1-antitrypsin levels / / 23990791 rs9529519 chr13 69722321 C T 4.46E-08 Metabolite levels / / 23281178 rs9529519 chr13 69722321 C T 1.68E-05 Serum alpha1-antitrypsin levels / / 23990791 rs9541790 chr13 69723025 A G 6.05E-08 Metabolite levels / / 23281178 rs9541790 chr13 69723025 A G 2.90E-05 Serum alpha1-antitrypsin levels / / 23990791 rs9599423 chr13 69725358 T C 4.46E-08 Metabolite levels / / 23281178 rs9599423 chr13 69725358 T C 1.31E-05 Serum alpha1-antitrypsin levels / / 23990791 rs1023818 chr13 69727042 A G 4.46E-08 Metabolite levels / / 23281178 rs1023818 chr13 69727042 A G 8.04E-06 Serum alpha1-antitrypsin levels / / 23990791 rs1446379 chr13 69728322 C A 4.42E-08 Metabolite levels / / 23281178 rs1446379 chr13 69728322 C A 7.61E-06 Serum alpha1-antitrypsin levels / / 23990791 rs1446378 chr13 69728606 G A 4.42E-08 Metabolite levels / / 23281178 rs1446378 chr13 69728606 G A 7.45E-06 Serum alpha1-antitrypsin levels / / 23990791 rs9541793 chr13 69730587 C A 4.00E-08 Metabolite levels / / 23281178 rs9541793 chr13 69730587 C A 7.37E-06 Serum alpha1-antitrypsin levels / / 23990791 rs9541803 chr13 69741249 G A 2.77E-08 Metabolite levels / / 23281178 rs9541803 chr13 69741249 G A 2.46E-05 Serum alpha1-antitrypsin levels / / 23990791 rs9592624 chr13 69745622 G T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9592624 chr13 69745622 G T 3.11E-05 Heart Rate / / pha003051 rs7328657 chr13 69752610 A C 9.36E-04 Acute lung injury / / 22295056 rs9572104 chr13 69757288 A G 1.00E-05 Urinary metabolites / / 21572414 rs8000906 chr13 69763228 C T 5.30E-04 Crohn's disease / / 17684544 rs17660169 chr13 69766019 A T 2.30E-05 Type 2 diabetes / / 17463246 rs9634953 chr13 69791693 G T 4.17E-04 Depression (quantitative trait) / / 20800221 rs2152563 chr13 69795334 G A 5.68E-04 Depression (quantitative trait) / / 20800221 rs7336505 chr13 69855608 T C 7.92E-05 Nicotine dependence / / 17158188 rs17605645 chr13 69880146 T G 9.21E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs17605645 chr13 69880146 T G 4.55E-04 Depression (quantitative trait) / / 20800221 rs1249772 chr13 69886213 G A 3.31E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2593522 chr13 69889861 T C 4.33E-04 Multiple complex diseases / / 17554300 rs2593525 chr13 69919399 C A 2.00E-06 Obesity-related traits / / 23251661 rs9541921 chr13 69959921 C A 8.50E-04 Alzheimer's disease / / 24755620 rs2484139 chr13 69978315 A G 7.45E-04 Multiple complex diseases / / 17554300 rs9541938 chr13 70011959 G A 7.10E-05 Body mass index / / 22446040 rs9541938 chr13 70011959 G A 3.50E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs352236 chr13 70023685 C T 2.00E-06 Obesity-related traits / / 23251661 rs17609144 chr13 70028138 C T 2.60E-05 Urinary metabolites / / 21572414 rs4468490 chr13 70051980 T C 1.30E-05 Urinary metabolites / / 21572414 rs9572182 chr13 70086330 T C 4.00E-07 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs9317821 chr13 70110404 A G 2.00E-04 Type 2 diabetes / / 17846126 rs1604614 chr13 70123567 T A 3.67E-04 Multiple complex diseases / / 17554300 rs9572198 chr13 70177551 G T 0.00000289 Major depressive disorder / / 23149448 rs9541994 chr13 70192467 A G 4.91E-04 Tourette syndrome / / 22889924 rs7338234 chr13 70239939 C T 4.64E-05 Height / / pha003010 rs9529625 chr13 70294316 T C 6.76E-04 Type 2 diabetes KLHL1 intron 17463246 rs9529633 chr13 70310426 A G 9.07E-06 Response to amphetamines KLHL1 intron 22952603 rs9529634 chr13 70311040 G A 8.95E-06 Response to amphetamines KLHL1 intron 22952603 rs9599501 chr13 70314230 T C 3.14E-06 Response to amphetamines KLHL1 intron 22952603 rs9599502 chr13 70318048 T A 3.60E-06 Response to amphetamines KLHL1 intron 22952603 rs73504006 chr13 70320255 A T 2.79E-06 Response to amphetamines KLHL1 intron 22952603 rs9592653 chr13 70323836 G C 2.16E-06 Response to amphetamines KLHL1 intron 22952603 rs9542073 chr13 70327693 A G 6.06E-06 Response to amphetamines KLHL1 intron 22952603 rs9542073 chr13 70327693 A G 3.00E-05 Height KLHL1 intron pha003010 rs9542073 chr13 70327693 A G 1.68E-05 Height KLHL1 intron pha003011 rs7986537 chr13 70329253 G A 6.05E-06 Response to amphetamines KLHL1 intron 22952603 rs73504022 chr13 70331528 A G 7.61E-06 Response to amphetamines KLHL1 intron 22952603 rs75105467 chr13 70331868 G A 3.80E-06 Response to amphetamines KLHL1 intron 22952603 rs73504023 chr13 70331900 C G,T 3.80E-06 Response to amphetamines KLHL1 intron 22952603 rs12429783 chr13 70332885 A G 3.17E-06 Response to amphetamines KLHL1 intron 22952603 rs7995720 chr13 70333713 T C 2.53E-06 Response to amphetamines KLHL1 intron 22952603 rs17085337 chr13 70334418 T C 3.93E-06 Response to amphetamines KLHL1 intron 22952603 rs75605606 chr13 70337100 T C 2.93E-06 Response to amphetamines KLHL1 intron 22952603 rs74726198 chr13 70338279 A G 2.45E-06 Response to amphetamines KLHL1 intron 22952603 rs12429437 chr13 70338364 C T 6.02E-06 Response to amphetamines KLHL1 intron 22952603 rs6650427 chr13 70343035 C T 4.25E-06 Response to amphetamines KLHL1 intron 22952603 rs17727284 chr13 70343283 G T 6.21E-06 Response to amphetamines KLHL1 intron 22952603 rs17085369 chr13 70347472 G C 2.14E-06 Response to amphetamines KLHL1 intron 22952603 rs77723045 chr13 70347653 T C 5.10E-06 Response to amphetamines KLHL1 intron 22952603 rs17085372 chr13 70347908 G A 5.31E-06 Response to amphetamines KLHL1 intron 22952603 rs12427812 chr13 70348256 T C 5.66E-06 Response to amphetamines KLHL1 intron 22952603 rs77184274 chr13 70349485 C T 5.40E-06 Response to amphetamines KLHL1 intron 22952603 rs17070810 chr13 70349943 A G 5.48E-06 Response to amphetamines KLHL1 intron 22952603 rs79082600 chr13 70352372 C A,G,T 5.03E-06 Response to amphetamines KLHL1 intron 22952603 rs77756912 chr13 70355632 T G 4.60E-06 Response to amphetamines KLHL1 intron 22952603 rs7988385 chr13 70355709 C T 6.62E-05 Cognitive performance KLHL1 intron 19734545 rs114003307 chr13 70355839 G A 4.66E-06 Response to amphetamines KLHL1 intron 22952603 rs12429752 chr13 70362693 A C 7.40E-06 Response to amphetamines KLHL1 intron 22952603 rs1890046 chr13 70364300 C T 1.70E-04 Type 2 diabetes and 6 quantitative traits KLHL1 intron 17848626 rs1890045 chr13 70364456 C G 3.73E-05 Type 2 diabetes KLHL1 intron 17463246 rs75845624 chr13 70365730 G C 7.76E-06 Response to amphetamines KLHL1 intron 22952603 rs76643702 chr13 70365939 A T 7.58E-06 Response to amphetamines KLHL1 intron 22952603 rs75812539 chr13 70366155 C G 7.52E-06 Response to amphetamines KLHL1 intron 22952603 rs77412148 chr13 70366197 T G 7.58E-06 Response to amphetamines KLHL1 intron 22952603 rs12429100 chr13 70372952 C A 8.45E-06 Response to amphetamines KLHL1 intron 22952603 rs17085397 chr13 70373477 T C 7.52E-06 Response to amphetamines KLHL1 intron 22952603 rs11618330 chr13 70373548 C T 4.71E-04 Type 2 diabetes KLHL1 intron 17463246 rs12429407 chr13 70373990 G C 7.59E-06 Response to amphetamines KLHL1 intron 22952603 rs73504085 chr13 70375207 G A 4.25E-06 Response to amphetamines KLHL1 intron 22952603 rs17085405 chr13 70375895 A G 7.24E-06 Response to amphetamines KLHL1 intron 22952603 rs12430221 chr13 70376369 G A 6.48E-06 Response to amphetamines KLHL1 intron 22952603 rs78302566 chr13 70377895 T C 6.35E-06 Response to amphetamines KLHL1 intron 22952603 rs112390105 chr13 70381676 A T 2.26E-06 Response to amphetamines KLHL1 intron 22952603 rs79460924 chr13 70381681 G T 7.49E-06 Response to amphetamines KLHL1 intron 22952603 rs112564139 chr13 70389442 C T 8.10E-06 Response to amphetamines KLHL1 intron 22952603 rs73506327 chr13 70392225 G A,C 9.98E-06 Response to amphetamines KLHL1 intron 22952603 rs12428267 chr13 70394606 C T 7.62E-06 Response to amphetamines KLHL1 intron 22952603 rs17085438 chr13 70394997 C A 4.70E-05 HIV-1 control KLHL1 intron 20041166 rs7330188 chr13 70399346 G A 4.70E-06 Response to amphetamines KLHL1 intron 22952603 rs1895571 chr13 70417016 A G 7.02E-06 Response to amphetamines KLHL1 intron 22952603 rs2911506 chr13 70419939 G A 4.70E-05 HIV-1 control KLHL1 intron 20041166 rs7317137 chr13 70421701 A C 3.17E-06 Response to amphetamines KLHL1 intron 22952603 rs9592662 chr13 70424208 C A 6.80E-06 Response to amphetamines KLHL1 intron 22952603 rs3012110 chr13 70427371 G A 6.55E-04 Alzheimer's disease KLHL1 intron 22005930 rs3012111 chr13 70427387 G C 6.55E-04 Alzheimer's disease KLHL1 intron 22005930 rs2911521 chr13 70427586 C T 6.51E-04 Alzheimer's disease KLHL1 intron 22005930 rs2911522 chr13 70427789 C G 6.50E-04 Alzheimer's disease KLHL1 intron 22005930 rs1019580 chr13 70428855 C T 9.26E-06 Response to amphetamines KLHL1 intron 22952603 rs1019581 chr13 70429047 T C 8.08E-06 Response to amphetamines KLHL1 intron 22952603 rs35788056 chr13 70429780 G A 8.45E-06 Response to amphetamines KLHL1 intron 22952603 rs35231947 chr13 70429955 G T 7.11E-06 Response to amphetamines KLHL1 intron 22952603 rs2325244 chr13 70430093 C A,T 8.00E-07 Response to amphetamines KLHL1 intron 22952603 rs7985162 chr13 70441521 A G 9.85E-05 Cognitive impairment induced by topiramate KLHL1 intron 22091778 rs11843309 chr13 70454960 C T 7.00E-06 Bilirubin levels KLHL1 intron 22085899 rs7984606 chr13 70455661 A C 8.00E-06 Cognitive performance KLHL1 intron 19734545 rs17085643 chr13 70487282 T C 4.86E-05 Heart Rate KLHL1 intron pha003053 rs11843948 chr13 70491587 C T 3.70E-06 Urinary metabolites KLHL1 intron 21572414 rs2439613 chr13 70629388 C T 0.0000063 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) KLHL1 intron 23080225 rs9564646 chr13 70646266 T C 1.44E-06 Height KLHL1 intron pha003010 rs9564646 chr13 70646266 T C 1.87E-07 Height KLHL1 intron pha003011 rs9564646 chr13 70646266 T C 9.23E-05 Lung function (forced vital capacity) KLHL1 intron pha003104 rs1550546 chr13 70658404 T C 5.47E-06 Orofacial clefts KLHL1 intron 20023658 rs7350672 chr13 70665192 G A 5.15E-06 Height KLHL1 intron pha003010 rs7350672 chr13 70665192 G A 9.53E-05 Height KLHL1 intron pha003011 rs928021 chr13 70706008 A C 6.42E-06 Height ATXN8OS intron pha003010 rs928021 chr13 70706008 A C 6.23E-06 Height ATXN8OS intron pha003011 rs9599553 chr13 70707721 T C 4.34E-04 Hemoglobin concentration ATXN8OS intron 20534544 rs167255 chr13 70708705 G A 1.06E-04 Hemoglobin concentration ATXN8OS intron 20534544 rs2498502 chr13 70746966 T A 3.05E-04 Multiple complex diseases / / 17554300 rs12585622 chr13 70749984 G T 7.97E-05 Elbow pain / / pha003008 rs2479923 chr13 70753243 A G 2.50E-05 Word reading / / 23738518 rs1157877 chr13 70753985 T C 7.67E-06 Cognitive decline / / 23207651 rs9542212 chr13 70767093 C T 2.59E-05 Non-word repetition / / 23738518 rs2479929 chr13 70767964 T C 7.82E-04 Multiple complex diseases / / 17554300 rs2498522 chr13 70800025 A G 1.20E-05 Word reading / / 23738518 rs7989551 chr13 70808508 C G 2.93E-05 Reading and spelling / / 23738518 rs7989551 chr13 70808508 C G 4.77E-06 Word reading / / 23738518 rs1928007 chr13 70810223 G A 2.18E-05 Reading and spelling / / 23738518 rs1928007 chr13 70810223 G A 5.00E-06 Word reading / / 23738518 rs9572423 chr13 70846203 G A 9.00E-06 Major depressive disorder / / 20125088 rs17086847 chr13 70926407 C T 6.84E-04 Coronary heart disease / / 21606135 rs9599646 chr13 70928075 G T 4.70E-06 Urinary metabolites / / 21572414 rs17086923 chr13 70937750 C T 4.29E-04 Coronary heart disease / / 21606135 rs17086945 chr13 70948065 T C 1.30E-04 Alcohol dependence / / 20201924 rs17086945 chr13 70948065 T C 6.60E-04 Alcohol dependence / / 20201924 rs7317253 chr13 70969302 T G 2.50E-05 Alcohol dependence / / 20201924 rs7317253 chr13 70969302 T G 3.10E-04 Alcohol dependence / / 20201924 rs7317253 chr13 70969302 T G 2.51E-05 Alcoholism / / pha002892 rs9572452 chr13 71015383 A C 8.46E-04 Multiple complex diseases / / 17554300 rs868349 chr13 71118926 A C 3.71E-04 Obesity (extreme) / / 21935397 rs9542376 chr13 71128750 A G 7.21E-05 Amyotrophic lateral sclerosis / / 20801717 rs9542387 chr13 71136143 G A 4.04E-04 Alcohol dependence / / 20201924 rs9529776 chr13 71137148 G A 2.24E-04 Alcohol dependence / / 20201924 rs9542404 chr13 71142214 A G 1.70E-06 Urinary metabolites / / 21572414 rs9542445 chr13 71195573 A G 1.46E-04 Smoking initiation / / 24665060 rs1495858 chr13 71242767 G A 6.64E-04 Alcohol dependence / / 20201924 rs9572529 chr13 71244289 T C 1.85E-04 Rheumatoid arthritis / / 21452313 rs186967887 chr13 71249529 T A 6.00E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs7987883 chr13 71280319 G A 1.08E-04 Multiple complex diseases / / 17554300 rs9572533 chr13 71280383 A G 2.01E-05 Serum metabolites / / 19043545 rs615018 chr13 71298236 C T 1.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1373090 chr13 71299706 A C 5.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs598351 chr13 71325052 T G 9.70E-06 Ankylosing spondylitis / / 20062062 rs930516 chr13 71327001 G A 5.67E-04 Schizophrenia / / 19197363 rs1280903 chr13 71339627 G C 7.05E-05 Major depressive disorder / / 21621269 rs6562646 chr13 71343278 C A 6.83E-04 Alcohol dependence / / 20201924 rs4471563 chr13 71346319 T C 1.67E-04 Alcohol dependence / / 20201924 rs17087508 chr13 71349751 G A 4.59E-04 Smoking initiation / / 24665060 rs10507787 chr13 71356401 G A 3.96E-08 Paclitaxel sensitivity in NCI60 cancer cell lines / / 21314952 rs2769493 chr13 71358187 G A 2.12E-04 Alcohol dependence / / 20201924 rs2769490 chr13 71368970 T C 3.43E-04 Alcohol dependence / / 20201924 rs2769490 chr13 71368970 T C 9.79E-04 Acute lung injury / / 22295056 rs9529811 chr13 71374944 A G 1.69E-04 Acute lung injury / / 22295056 rs9542515 chr13 71397287 G C 8.49E-05 Serum metabolites / / 19043545 rs9529814 chr13 71397844 G C 3.38E-05 Serum metabolites / / 19043545 rs12583288 chr13 71399481 T C 3.47E-05 Coronary heart disease / / pha003030 rs9572556 chr13 71400820 T C 0.000495 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9572556 chr13 71400820 T C 4.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9572557 chr13 71402370 A C 0.0005814 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9572557 chr13 71402370 A C 5.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9572557 chr13 71402370 A C 7.90E-06 Coronary heart disease / / pha003030 rs9572558 chr13 71404174 G A 0.0007137 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9572558 chr13 71404174 G A 7.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9572558 chr13 71404174 G A 4.80E-06 Coronary heart disease / / pha003030 rs9572560 chr13 71412983 C T 0.0006982 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9572560 chr13 71412983 C T 6.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7992811 chr13 71414528 A C 9.74E-04 Acute lung injury / / 22295056 rs10467606 chr13 71421801 T G 0.0000127 Asthma / / 22694930 rs10467606 chr13 71421801 T G 3.11E-05 Asthma / / pha003127 rs950942 chr13 71531809 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2202561 chr13 71544965 C T 6.68E-05 Melanoma / / 21926416 rs17691655 chr13 71547907 C T 5.31E-06 Melanoma / / 21926416 rs17620171 chr13 71585114 A G 7.72E-05 Multiple complex diseases / / 17554300 rs17620230 chr13 71585327 T C 1.46E-04 Multiple complex diseases / / 17554300 rs12873209 chr13 71585879 G A 1.26E-04 Multiple complex diseases / / 17554300 rs12874149 chr13 71585998 T C 0.000541435 Hypertension (early onset hypertension) / / 22479346 rs11620298 chr13 71594688 A T 1.08E-04 Multiple complex diseases / / 17554300 rs803798 chr13 71604672 C T 1.64E-04 Type 2 diabetes / / 17463246 rs11843091 chr13 71605574 G A 9.54E-05 Body Mass Index / / pha003014 rs803786 chr13 71621124 A G 2.80E-05 Urinary metabolites / / 21572414 rs9572630 chr13 71626311 T C 1.98E-04 Type 2 diabetes / / 17463246 rs809164 chr13 71630110 T C 8.36E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs9572650 chr13 71669695 T C 1.60E-05 Urinary metabolites / / 21572414 rs7331445 chr13 71719404 T A 8.90E-06 Urinary metabolites / / 21572414 rs12876742 chr13 71769020 C A 1.20E-05 Urinary metabolites / / 21572414 rs768826 chr13 71770641 T C 1.44E-05 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines / / 21483694 rs9564791 chr13 71798043 T C 1.60E-04 Major depressive disorder / / 21042317 rs7995527 chr13 71842431 T G 4.71E-04 Stroke / / pha002886 rs10162271 chr13 71871605 C T 5.01E-04 Coronary Artery Disease / / 17634449 rs12585402 chr13 71875071 G A 7.10E-07 Urinary metabolites / / 21572414 rs9599820 chr13 71881549 T G 4.98E-04 Multiple complex diseases / / 17554300 rs9572709 chr13 71881638 A G 3.44E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs9599823 chr13 71882912 T C 6.10E-05 Lipid levels / / 18193043 rs9592783 chr13 71883214 G A 1.00E-06 Longevity / / 20834067 rs2480555 chr13 71887309 C T 7.00E-07 Urinary metabolites / / 21572414 rs2875603 chr13 71887556 T A 5.40E-06 Urinary metabolites / / 21572414 rs2480558 chr13 71889867 A G 7.60E-06 Urinary metabolites / / 21572414 rs7333279 chr13 71889975 T A 1.20E-06 Urinary metabolites / / 21572414 rs11619311 chr13 71895965 T G 4.80E-07 Urinary metabolites / / 21572414 rs17789383 chr13 71900817 T G 5.40E-10 Urinary metabolites / / 21572414 rs9599828 chr13 71905358 A G 5.54E-04 Multiple complex diseases / / 17554300 rs9572719 chr13 71905517 G A 1.70E-04 Multiple complex diseases / / 17554300 rs1999603 chr13 71983341 A G 1.47E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs9318020 chr13 71983755 C T 7.20E-05 Type 1 diabetes / / 18978792 rs11843100 chr13 71994545 A G 3.70E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs8000025 chr13 71999805 A C 2.38E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs9529897 chr13 72031460 C T 1.49E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) DACH1 intron 23648065 rs17088289 chr13 72040212 A G 4.40E-06 Adverse response to lamotrigine and phenytoin DACH1 intron 22379998 rs9599848 chr13 72048096 A G 9.00E-06 Amyotrophic lateral sclerosis (sporadic) DACH1 intron 24529757 rs9572757 chr13 72152018 A T 6.26E-04 Type 2 diabetes DACH1 intron 17463246 rs9919839 chr13 72174353 C T 2.00E-06 Adverse response to lamotrigine and phenytoin DACH1 intron 22379998 rs17088358 chr13 72212976 C T 3.16E-04 Multiple complex diseases DACH1 intron 17554300 rs17088392 chr13 72257236 T C 1.63E-10 Gallstones DACH1 intron 17632509 rs9572772 chr13 72299073 G T 3.06E-36 Multiple complex diseases DACH1 intron 17554300 rs7139667 chr13 72337943 C T 5.42E-05 Angioedema in response to angiotensin-converting enzyme inhibitor DACH1 intron 23838604 rs17088471 chr13 72342436 C A 2.63E-04 Alcohol dependence DACH1 intron 21314694 rs584480 chr13 72345505 C T 9.00E-06 Urate levels DACH1 intron 23263486 rs626277 chr13 72347696 A C 3.00E-11 Chronic kidney disease DACH1 intron 20383146 rs626277 chr13 72347696 A C 2.85E-10 Chronic kidney disease DACH1 intron 22479191 rs303939 chr13 72371471 T A 1.30E-05 Biomarkers DACH1 intron 17903293 rs9529915 chr13 72376414 G A 8.19E-04 White matter integrity DACH1 intron 22425255 rs9542751 chr13 72397974 T C 1.88E-04 Type 2 diabetes DACH1 intron 17463246 rs966168 chr13 72401045 T C 4.07E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) DACH1 intron 24023788 rs17252752 chr13 72426823 A C 7.82E-04 Type 2 diabetes DACH1 intron 17463246 rs1408888 chr13 72428647 T G 9.10E-04 Type 2 diabetes (young onset) and obesity DACH1 intron 24465431 rs2810134 chr13 72497249 G A 7.99E-05 Celiac disease / / 23936387 rs2810135 chr13 72497776 G A 2.05E-04 Celiac disease / / 23936387 rs2612821 chr13 72498514 T C 1.35E-04 Multiple complex diseases / / 17554300 rs1563871 chr13 72503504 C T 2.99E-04 Celiac disease / / 23936387 rs17088583 chr13 72504788 T C 9.60E-04 Type 2 diabetes / / 17463246 rs9542781 chr13 72508894 A G 2.54E-04 Celiac disease / / 23936387 rs2706437 chr13 72565883 C G 6.35E-04 Multiple complex diseases / / 17554300 rs9542806 chr13 72583058 G A 8.25E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs78717763 chr13 72588224 C T 3.31E-05 Intracerebral hemorrhage / / 24656865 rs61973227 chr13 72593126 A G 3.17E-05 Intracerebral hemorrhage / / 24656865 rs61973246 chr13 72596058 G A 3.52E-05 Intracerebral hemorrhage / / 24656865 rs61973246 chr13 72596058 G A 4.36E-05 Intracerebral hemorrhage / / 24656865 rs2810127 chr13 72596771 G A 7.16E-04 Multiple complex diseases / / 17554300 rs2810131 chr13 72598561 A C 3.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2810131 chr13 72598561 A C 4.05E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2810131 chr13 72598561 A C 4.42E-05 Insulin Resistance / / pha003062 rs2810131 chr13 72598561 A C 3.12E-05 Insulin-related traits / / pha003063 rs4884983 chr13 72603001 T C 4.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4883903 chr13 72610261 A G 7.33E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17088724 chr13 72610915 G A 1.17E-05 Intracerebral hemorrhage / / 24656865 rs17088724 chr13 72610915 G A 6.44E-06 Intracerebral hemorrhage / / 24656865 rs9592820 chr13 72637208 A G 6.11E-05 Insulin Resistance / / pha003062 rs9592820 chr13 72637208 A G 5.44E-05 Insulin-related traits / / pha003063 rs11841600 chr13 72645867 A T 4.56E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs7992935 chr13 72649964 G A 5.69E-05 Insulin Resistance / / pha003062 rs7992935 chr13 72649964 G A 5.14E-05 Insulin-related traits / / pha003063 rs726251 chr13 72652585 T C 6.30E-05 Insulin Resistance / / pha003062 rs726251 chr13 72652585 T C 5.60E-05 Insulin-related traits / / pha003063 rs1022959 chr13 72656240 A G 1.90E-05 Urinary metabolites / / 21572414 rs775 chr13 72656475 G A 1.90E-05 Urinary metabolites / / 21572414 rs1033981 chr13 72668634 A C 6.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1326683 chr13 72672154 A G 4.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1409571 chr13 72672465 C A 3.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1033979 chr13 72672867 A G 6.60E-06 Urinary metabolites / / 21572414 rs1033979 chr13 72672867 A G 8.85E-05 Insulin Resistance / / pha003062 rs1033979 chr13 72672867 A G 7.99E-05 Insulin-related traits / / pha003063 rs9529961 chr13 72678274 C T 2.50E-05 Urinary metabolites / / 21572414 rs9652236 chr13 72688774 G T 5.00E-06 Obsessive-compulsive disorder / / 22889921 rs8001671 chr13 72707609 G A 8.74E-05 Insulin-related traits / / pha003063 rs1326684 chr13 72716732 G A 6.07E-05 Tardive dyskinesia / / 20939080 rs339758 chr13 72738783 C T 5.43E-05 Tardive dyskinesia / / 20939080 rs9572900 chr13 72754543 T C 1.88E-05 Cognitive performance / / 19734545 rs1421291 chr13 72763078 T C 6.08E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7322145 chr13 72765304 G A 2.57E-04 Type 2 diabetes / / 17463246 rs4083578 chr13 72768709 T G 8.00E-06 Cognitive performance / / 19734545 rs2483837 chr13 72813062 A G 4.83E-04 Alzheimer's disease / / 17998437 rs9318065 chr13 72813836 G A 9.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs9572917 chr13 72816103 T C 7.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs340528 chr13 72818694 G A 2.01E-04 Multiple complex diseases / / 17554300 rs340529 chr13 72818973 A G 2.04E-04 Multiple complex diseases / / 17554300 rs9572921 chr13 72828877 T C 1.22E-04 Multiple complex diseases / / 17554300 rs9572922 chr13 72829075 C T 1.90E-04 Multiple complex diseases / / 17554300 rs9572926 chr13 72829994 A T 2.76E-04 Multiple complex diseases / / 17554300 rs9572927 chr13 72830207 G A 3.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs9572928 chr13 72830659 G C 1.26E-04 Multiple complex diseases / / 17554300 rs9572929 chr13 72831646 A G 3.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs9572930 chr13 72834369 G A 6.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs9572931 chr13 72834379 A G 8.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs9572932 chr13 72834591 A G 8.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs792006 chr13 72847638 A C 5.71E-04 Multiple complex diseases / / 17554300 rs792006 chr13 72847638 A C 8.66E-04 Alzheimer's disease / / 17998437 rs9572943 chr13 72853201 T C 2.90E-04 Alzheimer's disease / / 17998437 rs3909263 chr13 72855221 G C 7.30E-07 Stroke (ischemic) / / 22384361 rs980585 chr13 72868689 G A 9.66E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1146849 chr13 72872206 A G 1.70E-06 Stroke (ischemic) / / 22384361 rs340575 chr13 72876358 A C 1.24E-05 Post-operative nausea and vomiting / / 21694509 rs1254236 chr13 72879259 T C 8.31E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs551719 chr13 72901529 T C 1.16E-04 Stroke / / pha002887 rs551719 chr13 72901529 T C 2.42E-05 Coronary heart disease / / pha003031 rs9564897 chr13 72912338 G T 0.0000198 Otitis media (children 3 years old or younger) / / 23133572 rs486299 chr13 72946009 G A 1.84E-05 HIV-1 control / / 20041166 rs4885001 chr13 72959394 C T 6.63E-04 Stroke / / pha002887 rs17089316 chr13 72960307 G T 4.91E-04 Multiple complex diseases / / 17554300 rs9542937 chr13 72978869 C T 8.86E-04 Obesity (extreme) / / 21935397 rs1924960 chr13 72988938 A G 2.43E-04 Alzheimer's disease (late onset) / / 21379329 rs9572975 chr13 72995967 T C 7.98E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9542951 chr13 73015958 G A 6.52E-04 Multiple complex diseases / / 17554300 rs10507802 chr13 73019325 T C 9.13E-04 Multiple complex diseases / / 17554300 rs2182003 chr13 73026724 G A 3.70E-04 Major depressive disorder / / 22472876 rs10507805 chr13 73031936 G A 1.96E-07 Statin-induced myopathy / / 21826682 rs9542974 chr13 73058598 A G 8.70E-06 Urinary metabolites / / 21572414 rs4465496 chr13 73058691 G C 1.10E-05 Urinary metabolites / / 21572414 rs9542977 chr13 73060235 C T 2.00E-05 Urinary metabolites / / 21572414 rs17089409 chr13 73065166 C A 6.02E-04 Multiple complex diseases / / 17554300 rs7981532 chr13 73083051 C T 4.60E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7982249 chr13 73083414 C T 6.10E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9542987 chr13 73085013 C T 8.31E-05 Amyotrophic lateral sclerosis / / 19193627 rs6562709 chr13 73087806 G T 6.20E-13 Triglycerides / / 23063622 rs9599966 chr13 73089892 A G 2.45E-04 Celiac disease / / 23936387 rs4053550 chr13 73090990 G A 3.91E-05 Multiple complex diseases / / 17554300 rs9542990 chr13 73095271 G A 6.20E-05 Vaspin levels / / 22907691 rs9542990 chr13 73095271 G A 0.000016 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs9542990 chr13 73095271 G A 0.000062 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs9530025 chr13 73095986 A G 1.97E-04 Multiple complex diseases / / 17554300 rs1924939 chr13 73100056 C T 4.96E-04 Major depressive disorder / / 22472876 rs1924939 chr13 73100056 C T 4.67E-05 Vaspin levels / / 22907691 rs1924939 chr13 73100056 C T 0.0000236 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs1924939 chr13 73100056 C T 0.0000467 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs4885005 chr13 73104056 T C 9.96E-05 Vaspin levels / / 22907691 rs4885005 chr13 73104056 T C 0.0000996 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs17244714 chr13 73104448 A G 2.40E-05 Urinary metabolites / / 21572414 rs2147556 chr13 73112471 A G 9.59E-06 Longevity / / 21612516 rs17089509 chr13 73130763 T G 9.79E-06 Hearing function / / 21493956 rs17089512 chr13 73133103 T G 9.77E-06 Hearing function / / 21493956 rs9599974 chr13 73134141 T C 9.80E-06 Hearing function / / 21493956 rs9599975 chr13 73134377 T C 9.77E-06 Hearing function / / 21493956 rs1370487 chr13 73152977 C T 3.52E-04 Alzheimer's disease (late onset) / / 21379329 rs1124204 chr13 73154223 G A 1.64E-05 Cognitive impairment induced by topiramate / / 22091778 rs1124204 chr13 73154223 G A 3.74E-04 Iron levels / / pha002876 rs17089550 chr13 73155993 C T 8.95E-05 Triglycerides / / pha003080 rs17089576 chr13 73163027 C T 3.18E-04 Fibrinogen / / 17255346 rs8002561 chr13 73174464 T C 5.36E-04 Type 2 diabetes / / 17463246 rs11840463 chr13 73174739 C T 1.32E-04 IgE levels / / 17255346 rs4883914 chr13 73182447 A G 8.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs9530043 chr13 73212819 T A 2.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs9543031 chr13 73213182 G T 2.00E-05 Urinary metabolites / / 21572414 rs1440869 chr13 73214229 T C 1.60E-05 Urinary metabolites / / 21572414 rs17089661 chr13 73223814 T A 3.70E-05 Height / / 22021425 rs8001639 chr13 73262337 G A 4.57E-05 Cognitive test performance / / 20125193 rs9318115 chr13 73285521 C T 6.68E-05 Cognitive test performance MZT1 intron 20125193 rs4885038 chr13 73319910 G C 1.38E-04 Multiple complex diseases BORA intron 17554300 rs9564915 chr13 73325142 A G 1.41E-04 Multiple complex diseases BORA intron 17554300 rs9564920 chr13 73398945 A G 7.78E-06 Hearing function PIBF1 intron 21493956 rs2325487 chr13 73407429 C T 7.66E-06 Hearing function PIBF1 intron 21493956 rs2186158 chr13 73508730 T G 5.96E-04 Smoking initiation PIBF1 intron 24665060 rs8002688 chr13 73559982 C T 2.00E-09 Blood pressure measurement (low sodium intervention) PIBF1 intron 24165912 rs8002688 chr13 73559982 C T 3.75E-04 Blood pressure measurement (low sodium intervention) PIBF1 intron 24165912 rs9318132 chr13 73571073 A C 3.19E-05 Self-reported allergy PIBF1 intron 23817569 rs1029093 chr13 73575455 C T 5.91E-05 Self-reported allergy PIBF1 intron 23817569 rs9600057 chr13 73578856 T C 3.08E-05 Self-reported allergy PIBF1 intron 23817569 rs9573083 chr13 73580963 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes PIBF1 intron 22628534 rs9573083 chr13 73580963 G A 5.96E-05 Self-reported allergy PIBF1 intron 23817569 rs9573084 chr13 73583592 C A 3.11E-05 Self-reported allergy PIBF1 intron 23817569 rs9318134 chr13 73589583 A G 2.21E-05 Self-reported allergy PIBF1 intron 23817569 rs4883921 chr13 73598576 T C 8.35E-04 Lymphocyte counts / / 22286170 rs9573092 chr13 73627275 A G 3.18E-04 Acute lung injury / / 22295056 rs11841945 chr13 73630059 G C 7.46E-05 Self-reported allergy / / 23817569 rs7998378 chr13 73641702 G A 8.20E-06 Liver disease in chronic hepatitis B virus infection KLF5 intron 24065354 rs3782933 chr13 73641750 A G 3.69E-04 Acute lung injury KLF5 intron 22295056 rs1333099 chr13 73691236 G A 6.89E-05 Serum metabolites / / 19043545 rs1333099 chr13 73691236 G A 1.28E-05 Colorectal cancer / / 24737748 rs1333100 chr13 73691303 T C 8.59E-04 Multiple complex diseases / / 17554300 rs1333100 chr13 73691303 T C 6.89E-05 Serum metabolites / / 19043545 rs2503690 chr13 73691528 T G 8.15E-04 Multiple complex diseases / / 17554300 rs9600079 chr13 73728139 G T 3.00E-09 Prostate cancer / / 20676098 rs11838472 chr13 73741149 C T 2.56E-04 Blood pressure / / 17255346 rs11838472 chr13 73741149 C T 3.00E-17 Myopia (pathological) / / 23049088 rs7322605 chr13 73743788 A G 2.56E-04 Blood pressure / / 17255346 rs17089941 chr13 73747083 A G 2.56E-04 Blood pressure / / 17255346 rs9600089 chr13 73765600 T C 6.17E-04 Alzheimer's disease / / 22005930 rs9543259 chr13 73769533 A G 4.89E-04 Alzheimer's disease / / 22005930 rs9543260 chr13 73769609 T G 6.72E-04 Alzheimer's disease / / 22005930 rs9543267 chr13 73779179 T A 4.66E-04 Multiple complex diseases / / 17554300 rs2183347 chr13 73793551 C T 2.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs17089968 chr13 73799611 C T 3.23E-05 Orofacial clefts / / 22419666 rs17089976 chr13 73810038 A T 4.90E-06 Urinary metabolites / / 21572414 rs9530176 chr13 73818728 T A 0.000000402 Ejection fraction / / 23275298 rs9530176 chr13 73818728 T A 0.000000402 Left ventricular systolic dysfunction / / 23275298 rs1041362 chr13 73824519 G A 7.43E-05 Serum metabolites / / 19043545 rs1410093 chr13 73838627 A G 9.22E-04 Multiple complex diseases / / 17554300 rs7998062 chr13 73847514 A G 2.40E-05 Urinary metabolites / / 21572414 rs1410104 chr13 73848013 C T 1.74E-05 Cognitive test performance / / 20125193 rs9543312 chr13 73864773 A G 2.05E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs4885088 chr13 73874376 T C 6.46E-04 Alzheimer's disease / / 22005930 rs1411327 chr13 73891737 C T 8.93E-05 Pancreatic cancer / / pha002889 rs2210077 chr13 73891902 T C 7.54E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9564966 chr13 73896221 A G 5.86E-08 Pancreatic cancer / / pha002889 rs287553 chr13 73904230 G A 5.17E-06 Pancreatic cancer / / pha002889 rs287551 chr13 73905165 T C 1.90E-05 Urinary metabolites / / 21572414 rs287548 chr13 73905783 T C 1.46E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs9573163 chr13 73908846 C G 5.00E-13 Pancreatic cancer / / 22158540 rs4885093 chr13 73910026 G A 2.67E-06 Pancreatic cancer / / 22158540 rs9543325 chr13 73916628 C T 3.00E-11 Pancreatic cancer / / 20101243 rs9543325 chr13 73916628 C T 3.00E-11 Nasopharyngeal carcinoma / / 20512145 rs9543325 chr13 73916628 C T 8.20E-05 Pancreatic cancer / / 21849791 rs9543325 chr13 73916628 C T 3.27E-11 Pancreatic cancer / / pha002889 rs9592907 chr13 73917625 A G 2.80E-05 Urinary metabolites / / 21572414 rs1411320 chr13 73922664 T C 7.73E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs9318166 chr13 73923885 G A 7.25E-06 Pancreatic cancer / / pha002889 rs12870000 chr13 73929891 A G 1.29E-05 Pancreatic cancer / / pha002889 rs1886449 chr13 73932114 C T 9.00E-06 Pancreatic cancer / / 20686608 rs9318170 chr13 73940726 C G 2.67E-04 Multiple complex diseases / / 17554300 rs6562760 chr13 73957681 A G 4.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9600121 chr13 73962520 A G 9.65E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17090128 chr13 73962540 T C 2.01E-05 Type 2 diabetes / / 17463246 rs8002929 chr13 73964519 A G 9.65E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4885099 chr13 73973132 C T 3.02E-04 Insulin resistance / / 21901158 rs1886452 chr13 73986854 A T 2.51E-04 Sudden cardiac arrest / / 21658281 rs9600123 chr13 73987891 G A 3.35E-04 Self-reported allergy / / 23817569 rs4144229 chr13 73989158 A T 5.57E-05 Colorectal cancer / / 24836286 rs7139757 chr13 73991242 T C 1.59E-04 Self-reported allergy / / 23817569 rs7316968 chr13 73991462 T C 1.54E-04 Self-reported allergy / / 23817569 rs9564996 chr13 74039264 G A 7.43E-05 Blood Pressure / / pha003045 rs9564996 chr13 74039264 G A 8.52E-06 Blood Pressure / / pha003047 rs10507815 chr13 74039881 A G 1.47E-05 Blood Pressure / / pha003045 rs10507815 chr13 74039881 A G 1.57E-06 Blood Pressure / / pha003047 rs3904775 chr13 74076138 A G 2.85E-06 Serum metabolites / / 19043545 rs17090302 chr13 74161876 A G 1.58E-04 IgE levels / / 23661040 rs7329016 chr13 74177850 C A 9.02E-04 Multiple complex diseases / / 17554300 rs8000977 chr13 74179252 T C 3.57E-05 Lung function (forced vital capacity) / / pha003104 rs2184896 chr13 74179586 A C 6.58E-05 Lung function (forced vital capacity) / / pha003104 rs9318198 chr13 74195341 C A 7.64E-04 Multiple complex diseases / / 17554300 rs17090381 chr13 74299830 T C 7.90E-06 Carotid intima media thickness KLF12 intron 21909108 rs7331759 chr13 74320522 T C 0.000336 Salmonella-induced pyroptosis KLF12 intron 22837397 rs9600160 chr13 74328404 T C 7.00E-04 Bipolar disorder KLF12 intron 17486107 rs4883948 chr13 74332616 C T 9.59E-04 Parkinson's disease KLF12 intron 16252231 rs9600162 chr13 74334196 G A 2.10E-06 Iron levels KLF12 intron 21208937 rs1886235 chr13 74335390 A C 3.69E-05 Tuberculosis KLF12 intron 24057671 rs9318212 chr13 74336276 G A 0.000815 Salmonella-induced pyroptosis KLF12 intron 22837397 rs2325562 chr13 74347092 G T 2.15E-05 Multiple complex diseases KLF12 intron 17554300 rs2325562 chr13 74347092 G T 3.59E-25 Narcolepsy KLF12 intron 19629137 rs9530244 chr13 74372931 G A 5.76E-04 Multiple complex diseases KLF12 intron 17554300 rs879800 chr13 74377445 C T 5.18E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy KLF12 intron 24578207 rs879800 chr13 74377445 C T 5.18E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy KLF12 intron 24578207 rs4883955 chr13 74433807 T G 3.00E-06 Bronchopulmonary dysplasia KLF12 intron 23897914 rs12428279 chr13 74434331 C T 6.59E-05 Response to platinum-based chemotherapy in small-cell lung cancer KLF12 intron 20463552 rs3764109 chr13 74436156 T C 2.00E-04 Information processing speed KLF12 intron 21130836 rs3764109 chr13 74436156 T C 4.59E-05 Age-related macular degeneration KLF12 intron pha002890 rs9573320 chr13 74449179 A G 3.93E-05 Meningococcal disease KLF12 intron 20694013 rs9565055 chr13 74453522 G A 3.93E-04 Multiple complex diseases KLF12 intron 17554300 rs9573322 chr13 74457689 C A 8.73E-06 Meningococcal disease KLF12 intron 20694013 rs2182665 chr13 74462922 T G 9.90E-05 Triglycerides KLF12 intron 19074352 rs9318226 chr13 74493986 T C 1.93E-04 Body mass index KLF12 intron 17255346 rs9318226 chr13 74493986 T C 6.52E-04 Type 2 diabetes KLF12 intron 17463246 rs9543486 chr13 74494276 T C 3.32E-04 Body mass index KLF12 intron 17255346 rs9543486 chr13 74494276 T C 8.88E-04 Type 2 diabetes KLF12 intron 17463246 rs9543493 chr13 74503665 T C 2.69E-04 Aortic root size KLF12 intron 21223598 rs1886512 chr13 74520186 T A 1.00E-08 QRS duration KLF12 intron 21076409 rs6562791 chr13 74521863 T C 5.28E-05 Waist Circumference KLF12 intron pha003024 rs5008128 chr13 74522827 C A 5.28E-05 Waist Circumference KLF12 intron pha003024 rs9318232 chr13 74530279 T C 1.58E-04 Alcohol dependence KLF12 intron 20201924 rs9318236 chr13 74535578 T C 1.62E-04 Amyotrophic lateral sclerosis (sporadic) KLF12 intron 24529757 rs9318238 chr13 74538020 T C 4.25E-04 Alcohol dependence KLF12 intron 20201924 rs2875670 chr13 74539068 A G 5.45E-04 Alcohol dependence KLF12 intron 20201924 rs10507820 chr13 74543786 C T 7.20E-05 Tunica Media KLF12 intron pha003036 rs9530268 chr13 74547792 T G 2.81E-05 Serum metabolites KLF12 intron 19043545 rs12871414 chr13 74558505 C T 4.43E-05 Tunica Media KLF12 intron pha003036 rs2025535 chr13 74598691 G A 8.14E-04 Type 2 diabetes KLF12 intron 17463246 rs1324914 chr13 74634972 A G 3.66E-04 Type 2 diabetes KLF12 intron 17463246 rs9565072 chr13 74639799 T C 7.71E-04 Type 2 diabetes KLF12 intron 17463246 rs958593 chr13 74644519 T C 6.82E-04 Lymphocyte counts KLF12 intron 22286170 rs7335050 chr13 74668378 T C 6.90E-04 Response to statin treatment (atorvastatin),change in cholesterol levels KLF12 intron 20031582 rs1184596 chr13 74674070 A G 3.30E-04 Body mass index KLF12 intron 21701565 rs7327607 chr13 74682702 T A 5.69E-04 Aortic root size KLF12 intron 21223598 rs8000245 chr13 74730392 C T 8.00E-06 optic disc size (rim) / / 20395239 rs7322073 chr13 74731479 T A 1.44E-04 Multiple complex diseases / / 17554300 rs9543542 chr13 74731637 G T 9.75E-04 Multiple complex diseases / / 17554300 rs4885158 chr13 74733471 C A 2.77E-04 Alzheimer's disease / / 17998437 rs12429889 chr13 74742322 T C 5.00E-20 Sudden cardiac arrest / / 21658281 rs4356363 chr13 74773253 A G 8.58E-05 Orofacial clefts / / 22419666 rs955174 chr13 74843913 G A 1.68E-05 Bone mineral density / / 19181680 rs4885161 chr13 74866723 A G 6.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs1041512 chr13 74866755 A G 2.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs4885165 chr13 74877655 C T 0.0000112 HDL cholesterol particle diameter / / 23263444 rs1331772 chr13 74902258 C T 9.96E-04 Multiple complex diseases / / 17554300 rs7326423 chr13 74910249 A G 4.44E-04 Multiple complex diseases / / 17554300 rs9600268 chr13 74911872 T C 5.96E-04 Coronary Artery Disease / / 17634449 rs2325620 chr13 74927727 C T 1.54E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs1576704 chr13 74931841 A G 6.90E-05 Cognitive function / / 24684796 rs2325622 chr13 74932425 C A 6.91E-04 Coronary Artery Disease / / 17634449 rs4403930 chr13 74932872 A G 7.16E-04 Type 2 diabetes / / 17463246 rs7983584 chr13 74934797 T G 7.85E-05 Celiac disease / / 23936387 rs9318258 chr13 74942895 G A 7.21E-04 Alzheimer's disease / / 22005930 rs9318258 chr13 74942895 G A 1.73E-04 Iron levels / / pha002876 rs17062658 chr13 74966721 G A 5.15E-04 Aortic root size / / 21223598 rs17714988 chr13 74995660 A G 3.00E-07 Immune reponse to smallpox (secreted IFN-alpha) / / 22610502 rs7995581 chr13 75011150 T C 2.78E-04 Blood pressure / / 17255346 rs1931959 chr13 75018738 T C 2.44E-04 Blood pressure / / 17255346 rs2184434 chr13 75024156 A G 2.23E-04 Smoking initiation / / 24665060 rs6562826 chr13 75024613 A G 2.27E-04 Major depressive disorder / / 22472876 rs1326711 chr13 75090802 G A 5.24E-05 Multiple complex diseases / / 17554300 rs9543671 chr13 75101810 C T 2.08E-05 Prostate cancer / / pha002877 rs9543671 chr13 75101810 C T 3.59E-06 Prostate cancer / / pha002878 rs9318284 chr13 75103828 G A 8.01E-04 Parkinson's disease / / 16252231 rs2038946 chr13 75121202 A G 1.10E-05 Menarche (age at onset) / / 19448622 rs2038946 chr13 75121202 A G 9.56E-06 Prostate cancer / / pha002878 rs17718828 chr13 75128114 C T 1.00E-08 Phospholipid levels (plasma) LINC00347 intron 22359512 rs9543698 chr13 75132568 G T 8.62E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10492492 chr13 75182525 C T 2.93E-04 Birth weight / / 17255346 rs1326699 chr13 75183238 G T 1.98E-04 Alzheimer's disease (late onset) / / 21379329 rs9593010 chr13 75202695 T A 0.00000539 HDL cholesterol particle diameter / / 23263444 rs4885212 chr13 75203476 G A 0.00000241 HDL cholesterol particle diameter / / 23263444 rs1359689 chr13 75204083 C T 0.00000235 HDL cholesterol particle diameter / / 23263444 rs9318297 chr13 75216684 G T 8.57E-05 Multiple complex diseases / / 17554300 rs2325630 chr13 75217454 T C 5.50E-05 Celiac disease / / 17558408 rs9318298 chr13 75218711 T C 2.81E-04 Taste perception / / 22132133 rs9565110 chr13 75218796 C T 3.24E-04 Birth weight / / 17255346 rs2031777 chr13 75224986 C A 4.35E-04 Myocardial Infarction / / pha002883 rs1410160 chr13 75228273 C T 3.98E-04 Multiple complex diseases / / 17554300 rs9543739 chr13 75234665 A T 3.06E-04 Multiple complex diseases / / 17554300 rs1410165 chr13 75235738 G A 2.78E-04 Birth weight / / 17255346 rs1410165 chr13 75235738 G A 4.40E-05 Response to statin therapy / / 20339536 rs1410166 chr13 75235817 C G 3.90E-05 Response to statin therapy / / 20339536 rs4271487 chr13 75251975 T C 9.67E-05 Monocyte chemoattractant protein-1 / / pha003071 rs1359872 chr13 75255071 T C 8.59E-05 Monocyte chemoattractant protein-1 / / pha003071 rs9530368 chr13 75270057 C A 5.96E-05 Monocyte chemoattractant protein-1 / / pha003071 rs2077779 chr13 75275720 C T 8.31E-05 Monocyte chemoattractant protein-1 / / pha003071 rs17063408 chr13 75281755 G A 7.55E-06 Arthritis (juvenile idiopathic) / / 22354554 rs869877 chr13 75282465 A G 2.32E-04 Multiple complex diseases / / 17554300 rs1359873 chr13 75296809 T C 4.76E-05 Vaspin levels / / 22907691 rs1359873 chr13 75296809 T C 0.0000476 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs17063489 chr13 75326558 G A 5.86E-04 Multiple complex diseases / / 17554300 rs11617463 chr13 75331093 C A 1.62E-05 Crohn's disease / / 17435756 rs1927260 chr13 75344738 T G 5.85E-05 stroke (ischemic) / / 17434096 rs356751 chr13 75532986 G A 1.70E-04 Fibrinogen / / 17255346 rs9318312 chr13 75591505 T C 5.80E-05 Longevity and age-related phenotypes / / 17903295 rs9318312 chr13 75591505 T C 3.60E-05 Diabetic nephropathy / / pha002866 rs10454657 chr13 75591823 C T 2.60E-05 Diabetic nephropathy / / pha002866 rs9600419 chr13 75599117 A G 2.90E-05 Diabetic nephropathy / / pha002866 rs1417549 chr13 75601353 C T 1.80E-05 Diabetic nephropathy / / pha002866 rs4885263 chr13 75601424 T G 3.60E-05 Diabetic nephropathy / / pha002866 rs1340900 chr13 75617619 G A 5.20E-05 Diabetic nephropathy / / pha002866 rs1536284 chr13 75625815 C T 5.20E-05 Diabetic nephropathy / / pha002866 rs1340902 chr13 75626490 A G 6.90E-05 Diabetic nephropathy / / pha002866 rs7995700 chr13 75644644 A G 9.33E-04 Multiple complex diseases / / 17554300 rs548097 chr13 75776268 G T 6.00E-07 Heart failure / / 20445134 rs548097 chr13 75776268 G T 4.87E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2060136 chr13 75810214 C A 8.74E-04 Alzheimer's disease / / 22005930 rs1888257 chr13 75814384 C T 5.17E-04 Heart Failure / / pha002884 rs9530416 chr13 75826235 G T 3.80E-05 Post-operative nausea and vomiting / / 21694509 rs4885280 chr13 75828041 G A 6.66E-04 Type 2 diabetes / / 17463246 rs9543879 chr13 75832323 T G 8.53E-06 Post-operative nausea and vomiting / / 21694509 rs9543882 chr13 75835859 T C 3.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9573510 chr13 75838662 C A 4.98E-04 Type 2 diabetes / / 17463246 rs9573510 chr13 75838662 C A 8.41E-06 Lymphocyte counts / / 22286170 rs9318335 chr13 75885418 G A 6.99E-05 Serum metabolites TBC1D4 intron 19043545 rs2274758 chr13 75894015 T C 4.69E-05 Serum metabolites TBC1D4 intron 19043545 rs724543 chr13 75897835 A G 4.77E-05 Serum metabolites TBC1D4 intron 19043545 rs2297204 chr13 75901478 T C 6.63E-05 Serum metabolites TBC1D4 intron 19043545 rs2297205 chr13 75901637 C T 6.63E-05 Serum metabolites TBC1D4 intron 19043545 rs8002876 chr13 75902863 T A 9.37E-05 Serum metabolites TBC1D4 intron 19043545 rs548191 chr13 75916026 T C 1.54E-05 Serum metabolites TBC1D4 intron 19043545 rs568040 chr13 75916380 T C 2.49E-05 Serum metabolites TBC1D4 intron 19043545 rs576810 chr13 75924784 A C 7.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TBC1D4 intron 20877124 rs2774170 chr13 75929628 T A 4.44E-04 Smoking initiation TBC1D4 intron 24665060 rs982925 chr13 75968785 C T 2.50E-05 Urinary metabolites TBC1D4 intron 21572414 rs1028794 chr13 75980741 T A 3.81E-04 Multiple complex diseases TBC1D4 intron 17554300 rs1028794 chr13 75980741 T A 6.31E-04 Coronary Artery Disease TBC1D4 intron 17634449 rs9530434 chr13 75982581 C T 1.44E-05 Multiple sclerosis (brain glutamate levels) TBC1D4 intron 20802204 rs9565163 chr13 75985231 G A 4.16E-06 Blood Pressure TBC1D4 intron pha003046 rs9565163 chr13 75985231 G A 2.57E-05 Blood Pressure TBC1D4 intron pha003048 rs9543928 chr13 76018807 A G 4.19E-05 Blood Pressure TBC1D4 intron pha003043 rs9543928 chr13 76018807 A G 7.45E-06 Blood Pressure TBC1D4 intron pha003046 rs9543928 chr13 76018807 A G 5.74E-05 Blood Pressure TBC1D4 intron pha003048 rs2328943 chr13 76020849 T C 2.80E-05 Urinary metabolites TBC1D4 intron 21572414 rs4883998 chr13 76030510 C G 1.62E-04 Response to cytidine analogues (gemcitabine) TBC1D4 intron 24483146 rs9573545 chr13 76031966 G A 8.40E-07 Diabetic retinopathy TBC1D4 intron 23562823 rs9573546 chr13 76032533 G A 6.65E-04 Suicide attempts in bipolar disorder TBC1D4 intron 21423239 rs9573546 chr13 76032533 G A 8.10E-07 Diabetic retinopathy TBC1D4 intron 23562823 rs17071227 chr13 76033157 G A 8.25E-04 Multiple complex diseases TBC1D4 intron 17554300 rs7988372 chr13 76037779 A G 7.71E-04 Suicide attempts in bipolar disorder TBC1D4 intron 21423239 rs9573553 chr13 76039328 G A 5.40E-07 Diabetic retinopathy TBC1D4 intron 23562823 rs9565164 chr13 76039376 T C 4.40E-07 Diabetic retinopathy TBC1D4 intron 23562823 rs9573555 chr13 76040318 T C 4.60E-06 Diabetic retinopathy TBC1D4 intron 23562823 rs4883999 chr13 76042885 T A 5.90E-06 Diabetic retinopathy TBC1D4 intron 23562823 rs7335576 chr13 76043318 A G 5.70E-06 Diabetic retinopathy TBC1D4 intron 23562823 rs9565165 chr13 76052790 G A 7.70E-07 Diabetic retinopathy TBC1D4 intron 23562823 rs9318349 chr13 76061946 C T 1.70E-05 Diabetic retinopathy / / 23562823 rs9565170 chr13 76064659 G C 1.20E-05 Diabetic retinopathy / / 23562823 rs17064600 chr13 76086163 T C 8.60E-04 Suicide attempts in bipolar disorder / / 21041247 rs9543956 chr13 76098660 T G 3.90E-06 Diabetic retinopathy / / 23562823 rs9543957 chr13 76099804 T A 4.10E-06 Diabetic retinopathy COMMD6 UTR-3 23562823 rs9573577 chr13 76103789 C T 5.90E-06 Diabetic retinopathy COMMD6 intron 23562823 rs4643195 chr13 76103840 G A 4.70E-06 Diabetic retinopathy COMMD6 intron 23562823 rs9573578 chr13 76104956 A G 4.70E-06 Diabetic retinopathy COMMD6 intron 23562823 rs4885308 chr13 76106493 G C 6.10E-06 Diabetic retinopathy COMMD6 intron 23562823 rs17350771 chr13 76115766 G C 4.22E-04 Multiple complex diseases / / 17554300 rs9543976 chr13 76136648 G A 7.00E-06 Diabetic retinopathy UCHL3 intron 23562823 rs9543976 chr13 76136648 G A 7.40E-06 Diabetic retinopathy UCHL3 intron 23562823 rs2328964 chr13 76138830 G T 6.70E-07 Diabetic retinopathy UCHL3 intron 23562823 rs2296146 chr13 76143572 T C 7.20E-07 Diabetic retinopathy UCHL3 intron 23562823 rs7982517 chr13 76162039 A G 3.00E-07 Diabetic retinopathy UCHL3 intron 23562823 rs3783028 chr13 76165282 T C 4.70E-07 Diabetic retinopathy UCHL3 intron 23562823 rs7317250 chr13 76167141 G A 4.70E-07 Diabetic retinopathy UCHL3 intron 23562823 rs2031236 chr13 76169777 G A 4.70E-07 Diabetic retinopathy UCHL3 intron 23562823 rs6562915 chr13 76170886 G T 4.70E-07 Diabetic retinopathy UCHL3 intron 23562823 rs6562916 chr13 76171222 A G 4.70E-07 Diabetic retinopathy UCHL3 intron 23562823 rs4885322 chr13 76171331 A G 3.16E-05 Alcohol and nictotine co-dependence UCHL3 intron 20158304 rs4885322 chr13 76171331 A G 4.70E-07 Diabetic retinopathy UCHL3 intron 23562823 rs4885323 chr13 76172414 C T 4.70E-07 Diabetic retinopathy UCHL3 intron 23562823 rs9543990 chr13 76172434 G C,T 4.70E-07 Diabetic retinopathy UCHL3 intron 23562823 rs7996884 chr13 76172744 T A 4.70E-07 Diabetic retinopathy UCHL3 intron 23562823 rs7339146 chr13 76173719 G A 5.00E-07 Diabetic retinopathy UCHL3 intron 23562823 rs2328963 chr13 76175526 C T 5.10E-07 Diabetic retinopathy UCHL3 intron 23562823 rs8192763 chr13 76179170 A T 5.20E-07 Diabetic retinopathy UCHL3 intron 23562823 rs1535724 chr13 76183273 G C 5.70E-07 Diabetic retinopathy / / 23562823 rs12872251 chr13 76192503 C T 8.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs7324195 chr13 76192522 G A 5.60E-07 Diabetic retinopathy / / 23562823 rs9565177 chr13 76195403 T G 5.60E-07 Diabetic retinopathy LMO7 UTR-5 23562823 rs3818355 chr13 76196867 C T 5.60E-07 Diabetic retinopathy LMO7 intron 23562823 rs7986566 chr13 76197931 C T 4.90E-07 Diabetic retinopathy LMO7 intron 23562823 rs17064819 chr13 76217085 C T 7.32E-05 Multiple complex diseases LMO7 intron 17554300 rs17704212 chr13 76223853 C T 7.74E-04 Smoking cessation LMO7 intron 24665060 rs9285297 chr13 76225179 A T 1.10E-04 Type 2 diabetes and 6 quantitative traits LMO7 intron 17848626 rs10507832 chr13 76225809 C T 1.20E-04 Type 2 diabetes and 6 quantitative traits LMO7 intron 17848626 rs78266166 chr13 76228992 C T 0.0000902 Nonsyndromic striae distensae (stretch marks) LMO7 intron 23633020 rs7337929 chr13 76244318 A G 5.79E-04 Multiple complex diseases LMO7 intron 17554300 rs11841001 chr13 76249103 G A 4.00E-06 Corneal astigmatism LMO7 intron 23761726 rs9530460 chr13 76259070 T C 4.02E-05 Multiple complex diseases LMO7 intron 17554300 rs9565188 chr13 76286399 T A,C,G 6.45E-04 Alzheimer's disease LMO7 intron 24755620 rs539514 chr13 76326282 A T 6.00E-11 Type 1 diabetes LMO7 intron 21980299 rs17065026 chr13 76353156 C T 8.86E-05 Hearing function LMO7 intron 17255346 rs1570555 chr13 76371876 A G 2.53E-05 Prostate cancer LMO7 intron pha002878 rs10507834 chr13 76376474 T A 9.50E-04 Diabetic retinopathy LMO7 intron 20871662 rs12871931 chr13 76387793 T G 9.44E-06 Cognitive impairment induced by topiramate LMO7 intron 22091778 rs9318376 chr13 76394459 G A 6.86E-05 Hearing function LMO7 intron 17255346 rs4884021 chr13 76397731 G A 4.13E-05 Waist Circumference LMO7 missense pha003024 rs4884023 chr13 76399147 A G 8.69E-05 Waist Circumference LMO7 intron pha003024 rs3736859 chr13 76408249 A G 0.000019 VLDL cholesterol particle diameter LMO7 intron 23263444 rs7988661 chr13 76427347 C A 1.00E-04 Waist Circumference LMO7 missense pha003024 rs1323565 chr13 76446482 A G 6.56E-05 Tuberculosis LOC729420 intron 20694014 rs9544058 chr13 76447196 T C 6.65E-05 Tuberculosis LOC729420 intron 20694014 rs1323566 chr13 76451240 A G 8.28E-05 Tuberculosis LOC729420 intron 20694014 rs7996822 chr13 76467157 T G 2.90E-05 Urinary metabolites / / 21572414 rs12431220 chr13 76467525 G A 9.22E-04 Obesity (extreme) / / 21935397 rs976503 chr13 76476085 C T 2.90E-05 Urinary metabolites / / 21572414 rs7994467 chr13 76479120 T C 4.04E-08 Metabolite levels / / 23281178 rs9544077 chr13 76488277 A G 5.00E-05 Coronary heart disease / / pha003035 rs7317138 chr13 76506805 T G 8.91E-04 Bipolar disorder / / 19259986 rs12584939 chr13 76510046 A C 3.20E-05 HIV-1 control / / 20041166 rs12584939 chr13 76510046 A C 6.14E-05 Lung function (forced vital capacity) / / 24023788 rs1538901 chr13 76516894 T C 3.64E-04 Alcohol dependence / / 20201924 rs1954138 chr13 76523209 T C 4.07E-04 Multiple complex diseases / / 17554300 rs9544105 chr13 76558153 T C 5.40E-06 Alzheimer's disease (late onset) / / 20885792 rs9544105 chr13 76558153 T C 5.40E-06 Alzheimer's disease (late onset) / / 21460841 rs9544105 chr13 76558153 T C 4.05E-05 Duodenal ulcer / / 22387998 rs9573695 chr13 76558890 C T 3.82E-04 Multiple complex diseases / / 17554300 rs17065554 chr13 76617108 T A 5.09E-04 Multiple complex diseases / / 17554300 rs9318400 chr13 76680819 T G 1.08E-04 Multiple complex diseases / / 17554300 rs1330442 chr13 76680921 A T 7.60E-04 Multiple complex diseases / / 17554300 rs2810434 chr13 76721663 C A 7.35E-04 Taste perception / / 22132133 rs1553712 chr13 76736390 A G 8.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs2810443 chr13 76742133 A T 1.21E-04 Multiple complex diseases / / 17554300 rs2036717 chr13 76747030 T C 7.04E-06 Osteoarthritis / / 22763110 rs2810449 chr13 76762552 C T 6.90E-05 Cognitive impairment induced by topiramate / / 22091778 rs1929750 chr13 76786654 T C 8.81E-05 Cognitive performance / / 19734545 rs9544212 chr13 76791053 A C 9.15E-05 Insulin Resistance / / pha003062 rs1929734 chr13 76793820 C T 8.38E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1929734 chr13 76793820 C T 4.77E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs1317839 chr13 76801227 A G 4.77E-05 Waist-Hip Ratio / / pha003013 rs1317839 chr13 76801227 A G 3.57E-05 Waist-Hip Ratio / / pha003028 rs9600681 chr13 76802404 A G 8.09E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1929755 chr13 76804991 T C 1.02E-04 Telomere length / / 21573004 rs1929752 chr13 76812217 G T 1.09E-04 Glycosylated haemoglobin levels / / 17255346 rs1929752 chr13 76812217 G T 3.10E-06 Type 2 diabetes / / 23209189 rs9544230 chr13 76819996 G A 7.83E-05 Multiple complex diseases / / 17554300 rs1929744 chr13 76827542 C T 9.25E-05 Multiple complex diseases / / 17554300 rs1343693 chr13 76829397 A G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs9573824 chr13 76833684 A G 3.51E-05 HDL cholesterol / / pha003074 rs885421 chr13 76840783 C T 2.86E-05 Osteoarthritis (knee and hip) / / 21177295 rs885421 chr13 76840783 C T 3.23E-05 Osteoarthritis (knee and hip) / / 21177295 rs4286013 chr13 76857474 A G 3.16E-04 Cognitive decline / / 23732972 rs1164503 chr13 76867745 T C 2.79E-05 Hypertension / / 21082022 rs1146878 chr13 76874973 C T 7.77E-07 HDL cholesterol / / pha003074 rs1146879 chr13 76875298 T C 8.78E-07 HDL cholesterol / / pha003074 rs10507851 chr13 76875383 T C 3.29E-05 Coronary heart disease / / pha003035 rs4884049 chr13 76879160 C T 8.86E-04 Type 2 diabetes / / 17463246 rs2777732 chr13 76884327 G A 2.76E-04 Cognitive decline / / 23732972 rs17066058 chr13 76887659 A G 4.24E-05 Type 2 diabetes / / 17463246 rs2647330 chr13 76889811 T C 9.66E-04 Multiple complex diseases / / 17554300 rs2647330 chr13 76889811 T C 3.97E-05 HDL cholesterol / / pha003074 rs1505136 chr13 76911211 C T 6.98E-04 Smoking quantity / / 24665060 rs9544250 chr13 76913184 G T 1.17E-04 Smoking quantity / / 24665060 rs9573838 chr13 76913334 G A 9.68E-04 Type 2 diabetes / / 17463246 rs1164435 chr13 76914527 T C 6.40E-05 HDL cholesterol / / pha003074 rs1757880 chr13 76926295 G A 1.21E-04 Smoking quantity / / 24665060 rs1394695 chr13 76931625 A C 2.80E-05 Urinary metabolites / / 21572414 rs2777737 chr13 76933620 T C 7.18E-05 Cardiovascular disease / / pha003064 rs9600699 chr13 76959024 G T 2.96E-04 Coronary heart disease / / 21606135 rs2173366 chr13 77029851 C T 2.60E-05 Serum metabolites / / 19043545 rs1005785 chr13 77038572 T C 1.89E-06 Sarcoidosis / / 19165924 rs493863 chr13 77063531 A G 2.96E-04 Alcohol dependence / / 20201924 rs433780 chr13 77065032 C T 8.36E-04 Alcohol dependence / / 20201924 rs1163885 chr13 77085795 C T 4.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs283982 chr13 77088323 C T 6.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs4885410 chr13 77096697 T C 1.70E-05 Urinary metabolites / / 21572414 rs4885410 chr13 77096697 T C 3.32E-11 Brain activation patterns in response to human facial expressions-for the negative faces task / / 22828495 rs4885410 chr13 77096697 T C 3.32E-11 Airflow obstruction / / 22837378 rs9530556 chr13 77101905 T C 5.07E-05 Orofacial clefts / / 22863734 rs7992136 chr13 77110530 A C 1.96E-06 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs7328592 chr13 77116269 G A 2.51E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs10492453 chr13 77123533 A G 9.90E-05 Orofacial clefts / / 22863734 rs285669 chr13 77125587 G A 2.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs12860990 chr13 77137812 G T 2.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs962359 chr13 77145502 G A 3.87E-04 Multiple complex diseases / / 17554300 rs11619128 chr13 77153385 G A 9.70E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs9573890 chr13 77184408 G A 5.97E-04 Multiple complex diseases / / 17554300 rs9573898 chr13 77197993 A G 2.84E-05 Multiple complex diseases / / 17554300 rs9544339 chr13 77218295 G A 6.92E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs2621953 chr13 77238483 C T 3.30E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs9530584 chr13 77257495 C T 1.00E-04 Prostate cancer / / 21743057 rs8001672 chr13 77295392 T C 0.00068718 Hypertension (early onset hypertension) / / 22479346 rs2328994 chr13 77354479 T C 7.23E-04 Type 2 diabetes / / 17463246 rs4640066 chr13 77354747 G A 1.50E-05 Urinary metabolites / / 21572414 rs8000613 chr13 77361753 A G 1.50E-05 Urinary metabolites / / 21572414 rs12865161 chr13 77361885 G A 1.50E-05 Urinary metabolites / / 21572414 rs8002006 chr13 77362243 G A 2.07E-04 Multiple complex diseases / / 17554300 rs10507857 chr13 77369257 A G 1.12E-04 Multiple complex diseases / / 17554300 rs4885427 chr13 77370409 G T 3.49E-04 Type 2 diabetes / / 17463246 rs17066730 chr13 77378965 G A 2.73E-04 Parkinson's disease / / 17052657 rs17066730 chr13 77378965 G A 6.80E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6562968 chr13 77381006 A G 1.23E-04 Type 2 diabetes / / 17463246 rs17747558 chr13 77381429 C T 4.08E-04 Multiple complex diseases / / 17554300 rs9544383 chr13 77413980 C T 7.93E-04 Lymphocyte counts / / 22286170 rs2876711 chr13 77416504 T C 2.40E-05 Type 2 diabetes / / 17293876 rs2876711 chr13 77416504 T C 2.40E-05 Type 2 diabetes / / 19184112 rs9544385 chr13 77418441 T C 2.21E-05 Cognitive impairment induced by topiramate / / 22091778 rs9544385 chr13 77418441 T C 2.03E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9544385 chr13 77418441 T C 5.24E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9544389 chr13 77421206 G A 9.70E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7319157 chr13 77432900 T C 3.59E-04 Type 2 diabetes / / 17463246 rs7318492 chr13 77433082 G A 4.28E-04 Type 2 diabetes / / 17463246 rs659628 chr13 77463236 G A 4.50E-05 Alzheimer's disease (late onset) / / 21460841 rs17066893 chr13 77476542 A T 9.20E-04 Type 2 diabetes / / 17463246 rs12431203 chr13 77488736 G A 0.00000245 Preeclampsia / / 22432041 rs2073831 chr13 77498699 C T 1.00E-05 Bipolar disorder / / 20386566 rs866449 chr13 77508812 C T 3.68E-04 Type 2 diabetes / / 17463246 rs9573956 chr13 77524101 C T 4.36E-05 Waist Circumference IRG1 intron pha003023 rs592425 chr13 77540631 C T 6.93E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs679090 chr13 77547791 C T 0.00003 Asthma / / 18401594 rs424391 chr13 77614437 T C 5.66E-04 Multiple complex diseases / / 17554300 rs624575 chr13 77622818 C T 1.50E-06 Preeclampsia MYCBP2 intron 23551011 rs7991286 chr13 77682508 A G 4.14E-04 Response to statin treatment (atorvastatin),change in cholesterol levels MYCBP2 intron 20031582 rs9544420 chr13 77687433 T C 9.02E-05 Acute lymphoblastic leukemia (childhood) MYCBP2 intron 19684603 rs7337686 chr13 77723410 G A 6.60E-06 Preeclampsia MYCBP2 intron 23551011 rs9530631 chr13 77862984 G A 5.91E-06 Preeclampsia MYCBP2 intron 23551011 rs7322722 chr13 77879376 G A 1.00E-06 Preeclampsia MYCBP2 intron 23551011 rs7986578 chr13 77908932 T G 0.000657 fMRI brain tests in schizophrenia / / 22440650 rs7985601 chr13 77909110 C T 0.000368 fMRI brain tests in schizophrenia / / 22440650 rs6562990 chr13 77912593 T C 0.000578 fMRI brain tests in schizophrenia / / 22440650 rs6563005 chr13 78000443 A G 7.75E-04 Taste perception / / 22132133 rs9600888 chr13 78008154 A G 2.46E-05 Psoriasis / / 20953190 rs17765211 chr13 78008374 A G 2.50E-06 Smoking initiation / / 24665060 rs10467634 chr13 78019766 T C 3.07E-05 Psoriasis / / 20953190 rs7317940 chr13 78021218 G A,C 7.83E-05 Psoriasis / / 20953190 rs7317940 chr13 78021218 G A,C 2.00E-06 Smoking initiation / / 24665060 rs4489889 chr13 78025986 C T 4.60E-04 Alcohol dependence / / 20201924 rs4489889 chr13 78025986 C T 7.20E-04 Alcohol dependence / / 20201924 rs17067747 chr13 78032193 A G 8.24E-04 Type 2 diabetes / / 17463246 rs12429367 chr13 78036512 C T 4.30E-06 Stroke (ischemic) / / 22384361 rs17067774 chr13 78038808 C A 1.90E-06 Stroke (ischemic) / / 22384361 rs7334557 chr13 78048096 C A 9.00E-04 Type 2 diabetes / / 17463246 rs9318486 chr13 78067058 G T 2.15E-05 Brain structure / / 22504417 rs9574076 chr13 78085279 A G 8.57E-04 Type 2 diabetes / / 17463246 rs1323619 chr13 78087265 C A 7.28E-04 Type 2 diabetes / / 17463246 rs546003 chr13 78105704 G A 1.98E-04 Multiple complex diseases / / 17554300 rs687456 chr13 78136839 T G 6.80E-05 Multiple complex diseases SCEL intron 17554300 rs1323617 chr13 78196060 A C 6.01E-04 Smoking quantity SCEL intron 24665060 rs1053985 chr13 78216873 A G 6.77E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SCEL cds-synon 24023788 rs10507873 chr13 78217691 G A 3.90E-05 Brain structure SCEL intron 22504417 rs3903828 chr13 78219649 T C 3.73E-04 Alzheimer's disease / / 17998437 rs3903828 chr13 78219649 T C 4.35E-05 Brain structure / / 22504417 rs9544561 chr13 78225526 G A 3.96E-05 Brain structure / / 22504417 rs2813740 chr13 78225665 C T 4.40E-04 Response to antidepressants / / 19736353 rs1937381 chr13 78242040 A G 5.84E-04 Coronary heart disease / / 21971053 rs9318496 chr13 78313550 C T 8.94E-04 Lymphocyte counts SLAIN1 intron 22286170 rs3812830 chr13 78317503 A G 4.98E-05 Schizophrenia SLAIN1 intron 20185149 rs3812830 chr13 78317503 A G 6.00E-05 Bipolar disorder SLAIN1 intron 20451256 rs9600927 chr13 78338016 A G 4.78E-05 Bipolar disorder SLAIN1 UTR-3 20451256 rs7999941 chr13 78358388 G A 2.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1146927 chr13 78365944 A G 2.85E-09 Hair color / / 23548203 rs8000788 chr13 78375813 C T 7.77E-05 Schizophrenia / / 20185149 rs8002271 chr13 78375921 T C 7.77E-05 Schizophrenia / / 20185149 rs975739 chr13 78381146 G T 2.00E-14 Hair color / / 23548203 rs9544609 chr13 78392656 C A 2.25E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10507874 chr13 78392758 T G 7.77E-05 Schizophrenia / / 20185149 rs10507874 chr13 78392758 T G 8.32E-04 Acute lung injury / / 22295056 rs623735 chr13 78406883 A G 8.42E-04 Acute lung injury LOC100505518 intron 22295056 rs1041620 chr13 78409534 G A 8.32E-04 Response to taxane treatment (placlitaxel) LOC100505518 intron 23006423 rs57641914 chr13 78409714 G GT 8.33E-08 Hair color LOC100505518 intron 23548203 rs58188699 chr13 78409714 G T 8.33E-08 Hair color LOC100505518 intron 23548203 rs66716405 chr13 78409714 GT G 8.33E-08 Hair color LOC100505518 intron 23548203 rs3027083 chr13 78428114 G A 8.53E-04 Acute lung injury LOC100505518 intron 22295056 rs605393 chr13 78430079 A G 1.18E-05 Schizophrenia LOC100505518 intron 20185149 rs605393 chr13 78430079 A G 9.22E-05 Bipolar disorder LOC100505518 intron 20451256 rs605393 chr13 78430079 A G 6.55E-04 Acute lung injury LOC100505518 intron 22295056 rs1924931 chr13 78445186 A G 6.55E-04 Acute lung injury LOC100505518 intron 22295056 rs7982196 chr13 78455692 A T 6.90E-04 Acute lung injury LOC100505518 intron 22295056 rs1951971 chr13 78457476 A G 7.19E-04 Acute lung injury LOC100505518 intron 22295056 rs1951970 chr13 78457501 T G 7.19E-04 Acute lung injury LOC100505518 intron 22295056 rs8000670 chr13 78458570 A G 6.07E-04 Acute lung injury LOC100505518 intron 22295056 rs1924921 chr13 78462723 A G 8.69E-04 Acute lung injury LOC100505518 intron 22295056 rs4885491 chr13 78470350 A G 1.91E-05 Schizophrenia LOC100505518 intron 20185149 rs4885491 chr13 78470350 A G 9.36E-05 Bipolar disorder LOC100505518 intron 20451256 rs4885491 chr13 78470350 A G 8.86E-04 Acute lung injury LOC100505518 intron 22295056 rs3818416 chr13 78474468 A C 6.80E-04 Coronary heart disease EDNRB intron 21966275 rs3027108 chr13 78477897 T C 4.88E-04 Multiple complex diseases EDNRB intron 17554300 rs2147555 chr13 78479385 A C 1.91E-04 Multiple complex diseases EDNRB intron 17554300 rs12720166 chr13 78491462 C T 0.00000115 Cholesterol,total EDNRB intron 23063622 rs12716722 chr13 78492856 T C 8.12E-04 Acute lung injury EDNRB UTR-5 22295056 rs4884074 chr13 78504047 T C 5.65E-04 Acute lung injury EDNRB intron 22295056 rs9544639 chr13 78504543 G A 8.59E-04 Acute lung injury EDNRB intron 22295056 rs2329049 chr13 78504855 G A 1.75E-05 Schizophrenia EDNRB intron 20185149 rs2329049 chr13 78504855 G A 5.65E-04 Acute lung injury EDNRB intron 22295056 rs1924917 chr13 78506126 T C 8.39E-04 Acute lung injury EDNRB intron 22295056 rs4885497 chr13 78513640 A G 6.97E-04 Acute lung injury EDNRB intron 22295056 rs2876718 chr13 78515576 C T 6.88E-04 Acute lung injury EDNRB intron 22295056 rs4884076 chr13 78541952 C T 1.27E-05 Schizophrenia EDNRB intron 20185149 rs4884076 chr13 78541952 C T 6.42E-05 Bipolar disorder EDNRB intron 20451256 rs7329997 chr13 78549428 G T 9.75E-04 Acute lung injury EDNRB intron 22295056 rs2329056 chr13 78561002 A G 9.57E-04 Acute lung injury / / 22295056 rs1556269 chr13 78561493 A T 9.57E-04 Acute lung injury / / 22295056 rs1330909 chr13 78571269 T C 9.37E-04 Acute lung injury / / 22295056 rs944378 chr13 78605893 G A 8.05E-05 Schizophrenia / / 20185149 rs1330897 chr13 78611929 G A 6.55E-05 Schizophrenia / / 20185149 rs2585524 chr13 78627489 T C 3.32E-04 Multiple complex diseases / / 17554300 rs1330882 chr13 78658903 T A 6.65E-04 Multiple complex diseases / / 17554300 rs17740589 chr13 78677267 T C 4.38E-04 Response to TNF antagonist treatment / / 21061259 rs1556268 chr13 78680225 G A 3.95E-06 Acute lung injury / / 22295056 rs1556267 chr13 78680420 A G 3.00E-06 Acute lung injury / / 22295056 rs2775107 chr13 78680489 G A 5.58E-05 Type 2 diabetes / / 17463246 rs1360367 chr13 78682863 T G 6.18E-05 Type 2 diabetes / / 17463246 rs2262459 chr13 78683234 T C 2.44E-05 Response to TNF antagonist treatment / / 21061259 rs1330884 chr13 78683509 T G 4.17E-04 Type 2 diabetes / / 17463246 rs2094839 chr13 78690029 G A 2.70E-05 Response to TNF antagonist treatment / / 21061259 rs7994003 chr13 78692012 A T 1.53E-05 Acute lung injury / / 22295056 rs2585509 chr13 78692881 T C 2.85E-04 Acute lung injury / / 22295056 rs2775094 chr13 78693301 C A 1.34E-05 Acute lung injury / / 22295056 rs41470246 chr13 78708064 T A 6.65E-04 Type 2 diabetes / / 17463246 rs9600980 chr13 78711714 C G 3.60E-06 Urinary metabolites / / 21572414 rs9600983 chr13 78711996 T C 4.10E-06 Urinary metabolites / / 21572414 rs2763404 chr13 78721716 C T 9.09E-04 Depression (quantitative trait) / / 20800221 rs9600989 chr13 78728716 G A 3.78E-04 Multiple complex diseases / / 17554300 rs10507880 chr13 78742120 T C 4.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs17742869 chr13 78749745 C T 2.64E-04 Multiple complex diseases / / 17554300 rs17069125 chr13 78758096 G A 2.50E-05 Urinary metabolites / / 21572414 rs9601000 chr13 78771115 C G 5.12E-04 Multiple complex diseases / / 17554300 rs9601006 chr13 78776249 G A 7.84E-05 Multiple complex diseases / / 17554300 rs9601007 chr13 78778897 C T 1.22E-04 Multiple complex diseases / / 17554300 rs9544748 chr13 78780169 G T 5.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs9574199 chr13 78808914 C A 7.00E-06 Total ventricular volume / / 21116278 rs1475483 chr13 78810199 A C 1.04E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1410738 chr13 78813179 A C 3.16E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17745309 chr13 78813972 G A 7.94E-05 Brain lesion load / / 19010793 rs1972227 chr13 78820747 T C 2.50E-05 Urinary metabolites / / 21572414 rs1854397 chr13 78828168 G T 5.30E-08 Urinary metabolites / / 21572414 rs1328818 chr13 78828199 A C 2.50E-06 Urinary metabolites / / 21572414 rs9565398 chr13 78833871 C T 5.30E-08 Urinary metabolites / / 21572414 rs9530771 chr13 78838831 T C 1.70E-08 Urinary metabolites / / 21572414 rs9544760 chr13 78848773 T C 1.80E-06 Urinary metabolites / / 21572414 rs1359391 chr13 78850070 T G 2.70E-08 Urinary metabolites / / 21572414 rs1853704 chr13 78852091 A G 3.10E-08 Urinary metabolites / / 21572414 rs9530773 chr13 78852243 T G 4.30E-06 Urinary metabolites / / 21572414 rs2057559 chr13 78859646 T C 4.00E-08 Urinary metabolites / / 21572414 rs1324794 chr13 78861536 C T 7.50E-08 Urinary metabolites / / 21572414 rs6563036 chr13 78874633 G A 6.86E-05 Pancreatic cancer / / pha002889 rs7996252 chr13 78876537 T C 8.44E-05 Pancreatic cancer / / pha002874 rs7996252 chr13 78876537 T C 2.72E-05 Pancreatic cancer / / pha002889 rs2243409 chr13 78899157 A G 5.35E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1328810 chr13 78903038 G A 9.39E-06 Lipid traits / / 21777205 rs988016 chr13 78904481 T G 7.60E-07 Urinary metabolites / / 21572414 rs2248525 chr13 78905243 G T 8.12E-05 Pancreatic cancer / / pha002874 rs2248525 chr13 78905243 G T 3.14E-05 Pancreatic cancer / / pha002889 rs9544774 chr13 78905831 G A 4.70E-08 Urinary metabolites / / 21572414 rs9574218 chr13 78915166 T C 7.54E-05 Serum metabolites / / 19043545 rs2256157 chr13 78922105 A T 4.80E-07 Urinary metabolites / / 21572414 rs9574221 chr13 78925775 T C 6.40E-06 Urinary metabolites / / 21572414 rs9565406 chr13 78938987 C T 4.50E-06 Urinary metabolites / / 21572414 rs9565407 chr13 78939372 A G 7.10E-08 Urinary metabolites / / 21572414 rs12585627 chr13 78942422 A G 2.46E-04 Longevity / / 22279548 rs2265775 chr13 78950623 A C 5.77E-05 Pancreatic cancer / / pha002874 rs2987526 chr13 78950936 C T 3.23E-05 Pancreatic cancer / / pha002874 rs2247034 chr13 78951880 G A 5.10E-08 Urinary metabolites / / 21572414 rs2247058 chr13 78952348 T C 1.77E-04 Prostate cancer mortality / / 20978177 rs2247058 chr13 78952348 T C 3.90E-09 Urinary metabolites / / 21572414 rs9544780 chr13 78952444 T C 4.80E-06 Urinary metabolites / / 21572414 rs2329072 chr13 78960814 C T 3.10E-07 Urinary metabolites / / 21572414 rs2329073 chr13 78961957 G T 4.85E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9565409 chr13 78963698 C T 8.52E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4255677 chr13 78971323 G T 1.20E-07 Urinary metabolites / / 21572414 rs9530781 chr13 78979249 G A 6.30E-07 Urinary metabolites / / 21572414 rs9565413 chr13 78994137 T A 4.33E-04 Alzheimer's disease / / 17998437 rs9565413 chr13 78994137 T A 2.20E-07 Urinary metabolites / / 21572414 rs11619850 chr13 79009488 G T 7.42E-04 Type 2 diabetes / / 17463246 rs1962594 chr13 79013151 G A 7.71E-04 Type 2 diabetes / / 17463246 rs2329088 chr13 79015505 G A 4.91E-04 Alzheimer's disease / / 17998437 rs9601050 chr13 79021410 A C 3.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs9318552 chr13 79025787 C T 5.00E-08 Diastolic blood pressure (alcohol consumption interaction) / / 24376456 rs12875746 chr13 79033684 T C 4.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs17069903 chr13 79035391 G A 2.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs17757313 chr13 79035670 A G 5.84E-04 Type 2 diabetes / / 17463246 rs17757325 chr13 79035819 A G 9.45E-04 Type 2 diabetes / / 17463246 rs12869757 chr13 79041185 C T 5.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs1986352 chr13 79045649 T C 3.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs1986353 chr13 79045749 A G 3.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs9544811 chr13 79048833 C G 4.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs7989592 chr13 79049841 T C 6.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs4884099 chr13 79059296 T G 2.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs1325619 chr13 79128568 A G 9.45E-05 Colorectal cancer / / 19723657 rs17070021 chr13 79148683 G T 7.60E-04 Type 2 diabetes / / 17463246 rs4304924 chr13 79238925 G A 3.90E-05 Stroke (ischemic) / / 24262325 rs4304924 chr13 79238925 G A 5.00E-06 Large artery stroke / / 24262325 rs1931035 chr13 79274470 A G 1.00E-04 Chronic fatigue syndrome / / 21912186 rs1359536 chr13 79275793 A G 5.00E-04 Chronic fatigue syndrome / / 21912186 rs2210608 chr13 79352680 T C 2.53E-04 Parkinson's disease / / 17052657 rs17070284 chr13 79359424 C T 3.00E-06 Cognitive performance / / 20125193 rs4884110 chr13 79361195 T C 7.37E-04 Insulin resistance / / 21901158 rs2184180 chr13 79380816 T G 5.00E-06 IgG glycosylation / / 23382691 rs9574309 chr13 79382101 T C 2.00E-06 IgG glycosylation / / 23382691 rs17832102 chr13 79395002 C T 2.54E-04 Multiple complex diseases / / 17554300 rs17770207 chr13 79397209 C T 6.13E-05 Major depressive disorder / / 21621269 rs17070361 chr13 79404819 G A 5.72E-16 Multiple complex diseases / / 17554300 rs11838918 chr13 79410574 T C 1.00E-08 Conduct disorder (symptom count) / / 20585324 rs11838918 chr13 79410574 T C 3.00E-06 Conduct disorder (symptom count) / / 20585324 rs11838918 chr13 79410574 T C 3.00E-07 Conduct disorder (symptom count) / / 20585324 rs9574320 chr13 79438168 G T 5.84E-04 Schizophrenia / / 19197363 rs1000629 chr13 79445857 G A 3.10E-05 Response to statin therapy / / 20339536 rs1000630 chr13 79445949 C T 3.10E-05 Response to statin therapy / / 20339536 rs1557042 chr13 79447610 T A 3.50E-05 Response to statin therapy / / 20339536 rs2780737 chr13 79449144 A G 4.20E-05 Response to statin therapy / / 20339536 rs9565452 chr13 79450276 G A 2.80E-05 Response to statin therapy / / 20339536 rs1218295 chr13 79451192 G A 2.60E-05 Response to statin therapy / / 20339536 rs4885585 chr13 79451837 G C 3.30E-05 Response to statin therapy / / 20339536 rs1218298 chr13 79453429 C T 2.30E-05 Response to statin therapy / / 20339536 rs1218299 chr13 79453552 C T 2.20E-05 Response to statin therapy / / 20339536 rs1218300 chr13 79453803 C T 2.30E-05 Response to statin therapy / / 20339536 rs1218277 chr13 79454076 A G 2.30E-05 Response to statin therapy / / 20339536 rs1218278 chr13 79454446 C T 2.20E-05 Response to statin therapy / / 20339536 rs1218279 chr13 79454504 A G 2.20E-05 Response to statin therapy / / 20339536 rs1218282 chr13 79455832 T C 5.00E-06 Response to statin therapy / / 20339536 rs1218285 chr13 79459745 G A 1.50E-05 Response to statin therapy / / 20339536 rs17177530 chr13 79461361 A G 1.20E-05 Response to statin therapy / / 20339536 rs17771893 chr13 79466495 T C 1.20E-05 Response to statin therapy / / 20339536 rs914936 chr13 79467539 T A 1.47E-05 Multiple sclerosis / / 17660530 rs1981255 chr13 79480381 A G 1.64E-04 Multiple complex diseases / / 17554300 rs1111835 chr13 79482718 A G 3.36E-04 Multiple complex diseases / / 17554300 rs1111837 chr13 79483491 G T 2.07E-04 Multiple complex diseases / / 17554300 rs7981145 chr13 79483603 C T 2.02E-04 Multiple complex diseases / / 17554300 rs7981758 chr13 79483726 G T 2.56E-04 Multiple complex diseases / / 17554300 rs9574326 chr13 79496273 A G 0.0000354 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs41463550 chr13 79512298 T A 1.67E-23 Narcolepsy / / 19629137 rs4884116 chr13 79521958 T C 7.39E-05 Fibrinogen / / pha003068 rs1417676 chr13 79536352 G A 4.95E-05 Type 2 diabetes / / 17463246 rs1341139 chr13 79541188 C A 7.23E-06 Bipolar disorder / / 18317468 rs12585805 chr13 79546979 C T 8.01E-04 Multiple complex diseases / / 17554300 rs7337382 chr13 79550458 G A 1.86E-05 Depression (quantitative trait) / / 20800221 rs7319358 chr13 79550934 C T 1.28E-04 Depression (quantitative trait) / / 20800221 rs7319358 chr13 79550934 C T 3.00E-06 Ulcerative colitis / / 20848476 rs7319850 chr13 79551013 G A 4.98E-05 Depression (quantitative trait) / / 20800221 rs4885589 chr13 79551294 C T 1.25E-05 Depression (quantitative trait) / / 20800221 rs1888678 chr13 79556040 G T 1.51E-04 Depression (quantitative trait) / / 20800221 rs4572267 chr13 79561176 C T 9.98E-04 Depression (quantitative trait) / / 20800221 rs9544946 chr13 79563430 G A 8.04E-04 Depression (quantitative trait) / / 20800221 rs1372177 chr13 79571869 G C 3.70E-06 Urinary metabolites / / 21572414 rs7988279 chr13 79630579 G T 3.05E-05 Parkinson's disease / / pha002868 rs638188 chr13 79706225 C T 1.62E-04 Multiple complex diseases / / 17554300 rs17253011 chr13 79722220 T C 5.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs588262 chr13 79723879 T C 6.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs2991497 chr13 79725454 C T 7.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs7990950 chr13 79736962 A G 3.91E-04 Type 2 diabetes / / 17463246 rs618304 chr13 79741889 C T 5.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs9601185 chr13 79743725 C T 8.77E-04 Type 2 diabetes / / 17463246 rs592560 chr13 79744323 G A 5.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs606519 chr13 79744738 C T 5.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs605216 chr13 79744855 G T 2.00E-04 Crohn's disease / / 17684544 rs605216 chr13 79744855 G T 5.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs2991488 chr13 79745997 C T 5.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs9574364 chr13 79746398 C T 5.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs9565470 chr13 79747030 A G 5.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs2991484 chr13 79750672 G T 5.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs2991483 chr13 79752467 G C 5.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs2988021 chr13 79754491 C T 5.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs2991478 chr13 79754928 C T 5.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs2991443 chr13 79756956 G A 7.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs605505 chr13 79759512 A G 1.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs2988026 chr13 79760147 G A 6.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs590108 chr13 79760657 T C 5.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs662113 chr13 79761528 G A 7.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs2988030 chr13 79762645 C T 6.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs2988031 chr13 79763872 C G 4.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs2988032 chr13 79763944 C T 5.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs2991501 chr13 79764195 A C,G 6.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs1316834 chr13 79782179 C T 1.90E-04 Type 2 diabetes / / 17463246 rs9545015 chr13 79782915 C T 7.61E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2329109 chr13 79792109 C T 1.41E-04 Type 2 diabetes / / 17463246 rs731287 chr13 79800956 G A 9.88E-05 Longevity / / 21612516 rs7339418 chr13 79820126 A G 9.37E-05 Waist Circumference / / pha003024 rs9545030 chr13 79826116 C T 7.46E-05 Waist Circumference / / pha003024 rs9574386 chr13 79834482 G A 7.72E-05 Pulmonary function in asthmatics / / 23541324 rs6563096 chr13 79858235 T C 4.00E-05 Cytomegalovirus antibody response / / 21993531 rs9635027 chr13 79869673 G A 4.48E-05 Cytomegalovirus antibody response / / 21993531 rs9545053 chr13 79870214 T G 4.51E-05 Cytomegalovirus antibody response / / 21993531 rs1324870 chr13 79872046 C T 9.81E-04 Multiple complex diseases / / 17554300 rs1328045 chr13 79885404 C A 1.62E-04 Multiple complex diseases / / 17554300 rs1155848 chr13 79888476 T C 5.00E-07 Response to anti-TNF alpha therapy in inflammatory bowel disease / / 20014019 rs9545067 chr13 79897564 A G 6.69E-05 Cytomegalovirus antibody response RBM26 intron 21993531 rs9574409 chr13 79915979 A C 7.31E-05 Cytomegalovirus antibody response RBM26 intron 21993531 rs7987769 chr13 79918100 C T 7.72E-05 Cytomegalovirus antibody response RBM26 intron 21993531 rs7327386 chr13 79922036 G A 8.06E-05 Cytomegalovirus antibody response RBM26 intron 21993531 rs9318627 chr13 79930079 A C 1.47E-04 Multiple complex diseases RBM26 intron 17554300 rs6563100 chr13 79957113 A G 4.70E-04 Multiple complex diseases RBM26 intron 17554300 rs3742122 chr13 79961196 G A 8.84E-05 Cytomegalovirus antibody response RBM26 intron 21993531 rs9530914 chr13 79963251 G T 9.35E-05 Cytomegalovirus antibody response RBM26 intron 21993531 rs9318638 chr13 79986153 T C 9.09E-05 Cytomegalovirus antibody response RBM26-AS1 intron 21993531 rs9545113 chr13 79996152 G A 6.86E-05 Cytomegalovirus antibody response / / 21993531 rs643778 chr13 79998072 T G 6.86E-05 Cytomegalovirus antibody response / / 21993531 rs2265377 chr13 79999620 G A 6.86E-05 Cytomegalovirus antibody response / / 21993531 rs2265378 chr13 79999716 T C 6.86E-05 Cytomegalovirus antibody response / / 21993531 rs2095477 chr13 80002004 T G 6.98E-05 Cytomegalovirus antibody response / / 21993531 rs9565500 chr13 80007551 A G 6.99E-05 Cytomegalovirus antibody response / / 21993531 rs11838700 chr13 80015847 G A 1.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs1475797 chr13 80093825 T G 4.39E-05 Multiple complex diseases NDFIP2 intron 17554300 rs2760105 chr13 80109867 A G 3.07E-04 Obesity (extreme) NDFIP2 intron 21935397 rs9545133 chr13 80121982 T C 9.29E-05 Polycystic ovary syndrome NDFIP2 intron 22178785 rs9601248 chr13 80169004 C T 2.00E-06 Major depressive disorder / / 23377640 rs2783130 chr13 80170160 A G 5.20E-04 Multiple complex diseases / / 17554300 rs7329551 chr13 80210971 C T 3.22E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9574450 chr13 80219665 C A 3.34E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2876747 chr13 80233541 T G 3.60E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9574455 chr13 80244736 G A 3.83E-05 Caffeine consumption / / 21490707 rs2329128 chr13 80257615 T G 5.09E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs3064655 chr13 80259569 T TG,TT 9.84E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs370624072 chr13 80259569 T TTATG 9.84E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2783084 chr13 80270336 G A 1.94E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7998397 chr13 80273223 T C 8.57E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4884137 chr13 80274415 A G 7.84E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2256665 chr13 80279185 A G 0.000346337 Hypertension (early onset hypertension) / / 22479346 rs2783074 chr13 80290999 G A 7.66E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2039553 chr13 80299722 A G 1.88E-05 IgE levels / / 17255346 rs2039553 chr13 80299722 A G 7.00E-06 Pancreatic cancer / / 20686608 rs2329119 chr13 80306570 G T 1.39E-04 IgE levels / / 17255346 rs2095470 chr13 80310295 T G 1.33E-04 IgE levels / / 17255346 rs1577404 chr13 80310771 G A 4.26E-04 IgE levels / / 17255346 rs4885678 chr13 80440491 G T 4.49E-04 Orofacial clefts / / 22863734 rs7139668 chr13 80450453 A G 7.89E-04 Multiple complex diseases / / 17554300 rs9593420 chr13 80479404 G A 2.12E-04 Multiple complex diseases / / 17554300 rs9318664 chr13 80591857 C T 6.98E-05 ldl cholesterol / / pha003076 rs17072115 chr13 80596978 G A 3.56E-04 Multiple complex diseases / / 17554300 rs3910574 chr13 80598357 T C 6.28E-04 Type 2 diabetes / / 17463246 rs3850071 chr13 80603592 A C 6.88E-04 Smoking cessation / / 24665060 rs17072135 chr13 80604445 G A 3.96E-04 Multiple complex diseases / / 17554300 rs7995973 chr13 80605786 A C 5.42E-06 Parkinson's disease / / 21248740 rs17072180 chr13 80615802 A G 4.93E-04 Multiple complex diseases / / 17554300 rs7990503 chr13 80620642 G T 1.17E-04 Parkinson's disease / / 21248740 rs7981942 chr13 80623346 A C 2.00E-06 Fasting insulin-related traits (interaction with BMI) / / 22581228 rs4885690 chr13 80628175 C T 8.54E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9574547 chr13 80631417 C A 4.20E-05 Parkinson's disease / / 21248740 rs9318669 chr13 80643643 G T 7.82E-04 Parkinson's disease / / 21248740 rs12431307 chr13 80644618 G A 5.00E-06 Obesity-related traits / / 23251661 rs9574565 chr13 80668874 T C 3.00E-07 Orofacial clefts / / 20023658 rs9574565 chr13 80668874 T C 3.80E-05 Orofacial clefts / / 22863734 rs9574565 chr13 80668874 T C 0.000874 Facial morphology / / 23028347 rs9601318 chr13 80673191 C T 5.84E-06 Orofacial clefts / / 22863734 rs1575900 chr13 80676704 A C 6.34E-05 Orofacial clefts / / 20023658 rs1575900 chr13 80676704 A C 1.74E-07 Orofacial clefts / / 22863734 rs7321752 chr13 80678014 G A 8.32E-04 Multiple complex diseases / / 17554300 rs11841646 chr13 80679302 T A 4.71E-11 Orofacial clefts / / 22863734 rs1327314 chr13 80683625 A G 2.46E-05 Orofacial clefts / / 22863734 rs1409904 chr13 80689877 G A 3.77E-10 Orofacial clefts / / 22863734 rs9318679 chr13 80690135 C A 2.96E-05 Orofacial clefts / / 20023658 rs9318679 chr13 80690135 C A 4.08E-07 Orofacial clefts / / 22863734 rs1215465 chr13 80691352 C T 3.12E-07 Orofacial clefts / / 20023658 rs1215465 chr13 80691352 C T 7.69E-08 Orofacial clefts / / 22863734 rs8001641 chr13 80692811 G A 3.13E-06 Orofacial clefts / / 19270707 rs8001641 chr13 80692811 G A 2.83E-07 Orofacial clefts / / 20023658 rs8001641 chr13 80692811 G A 1.61E-05 Cleft lip / / 20436469 rs8001641 chr13 80692811 G A 3.00E-10 Orofacial clefts / / 22863734 rs8001641 chr13 80692811 G A 9.00E-11 Orofacial clefts / / 22863734 rs11617692 chr13 80697435 A T 8.43E-08 Orofacial clefts / / 22863734 rs17215941 chr13 80698988 T C 7.98E-11 Orofacial clefts / / 22863734 rs9545330 chr13 80699166 A G 1.32E-05 Orofacial clefts / / 20023658 rs9545330 chr13 80699166 A G 2.17E-06 Orofacial clefts / / 22863734 rs9601323 chr13 80700397 G A 5.11E-11 Orofacial clefts / / 22863734 rs11842594 chr13 80701076 G C 3.83E-11 Orofacial clefts / / 22863734 rs1854110 chr13 80701485 T C 1.96E-11 Orofacial clefts / / 22863734 rs942233 chr13 80701848 C T 5.74E-05 Orofacial clefts / / 20023658 rs942233 chr13 80701848 C T 3.34E-07 Orofacial clefts / / 22863734 rs942233 chr13 80701848 C T 3.45E-05 Body mass index / / 23669352 rs4146682 chr13 80702065 A G 3.86E-07 Orofacial clefts / / 22863734 rs11616380 chr13 80705315 G T 1.27E-05 Type 2 diabetes / / 22158537 rs17072370 chr13 80705730 T A 3.01E-06 Type 2 diabetes / / 22158537 rs17072370 chr13 80705730 T A 2.80E-05 Self-reported allergy / / 23817569 rs1215470 chr13 80706455 T C 2.75E-04 Parkinson's disease / / 21248740 rs1215468 chr13 80707429 A G 2.47E-04 Multiple complex diseases / / 17554300 rs1215468 chr13 80707429 A G 2.31E-06 Type 2 diabetes / / 22158537 rs1327315 chr13 80708732 C T 2.55E-06 Type 2 diabetes / / 22158537 rs1215451 chr13 80715893 G A 9.43E-05 Parkinson's disease / / 21248740 rs1215451 chr13 80715893 G A 4.12E-06 Type 2 diabetes / / 22158537 rs1359790 chr13 80717156 G A 5.09E-04 Multiple complex diseases / / 17554300 rs1359790 chr13 80717156 G A 6.00E-09 Type 2 diabetes / / 20862305 rs1359790 chr13 80717156 G A 0.000000014 Type 2 diabetes / / 22885922 rs1359790 chr13 80717156 G A 0.000016 Type 2 diabetes (males) / / 22885922 rs1359790 chr13 80717156 G A 0.000067 Type 2 diabetes (females) / / 22885922 rs1359790 chr13 80717156 G A 0.00047 Fasting insulin-related traits / / 22885922 rs1359790 chr13 80717156 G A 5.30E-04 Type 2 diabetes / / 24390345 rs1359790 chr13 80717156 G A 6.00E-06 Type 2 diabetes / / 24509480 rs1215447 chr13 80719969 G A 6.95E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1237259 chr13 80720142 G A 3.96E-04 Parkinson's disease / / 21248740 rs8001401 chr13 80723012 A C 1.63E-04 Parkinson's disease / / 21248740 rs1215446 chr13 80723155 T C 2.63E-04 Multiple complex diseases / / 17554300 rs518569 chr13 80765797 A G 2.73E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs348043 chr13 80786457 T C 6.06E-04 Type 2 diabetes / / 17463246 rs348007 chr13 80804906 G T 1.38E-04 Type 2 diabetes / / 17463246 rs7994890 chr13 80850384 G A 8.35E-04 Multiple complex diseases / / 17554300 rs7994890 chr13 80850384 G A 6.39E-04 Type 2 diabetes / / 17846125 rs9574630 chr13 80903738 T C 2.10E-05 Cognitive impairment induced by topiramate / / 22091778 rs9593443 chr13 80947947 T G 3.88E-04 Multiple complex diseases / / 17554300 rs9593445 chr13 80948508 A T 1.72E-04 Multiple complex diseases / / 17554300 rs534870 chr13 80959207 G A 7.00E-08 Adiposity / / 21706003 rs558366 chr13 81006871 C T 2.50E-04 Breast cancer / / 22452962 rs1930336 chr13 81062941 T C 4.12E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1930336 chr13 81062941 T C 3.00E-06 Response to inhaled corticosteroid treatment in asthma (percentage change of FEV1) / / 24792382 rs1954504 chr13 81106573 C A 6.81E-05 Hematocrit / / pha003097 rs1857575 chr13 81111076 T G 2.01E-04 Lung function (forced vital capacity) / / 24023788 rs1984294 chr13 81135984 G A 9.76E-05 Blood Pressure / / pha003046 rs7327546 chr13 81138313 G A 3.56E-04 Response to alcohol consumption (flushing response) / / 24277619 rs2876759 chr13 81141484 T C 6.93E-05 Blood Pressure / / pha003046 rs7337769 chr13 81143093 T A 1.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs7318611 chr13 81143590 A G 1.96E-05 Hypertension / / pha003041 rs6563177 chr13 81146008 A G 4.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs7997421 chr13 81147917 C T 3.96E-05 Hypertension / / pha003041 rs7317238 chr13 81161299 T G 1.75E-04 Breast cancer / / 21060860 rs1105073 chr13 81173408 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1582191 chr13 81218793 T C 2.12E-05 Diabetes Mellitus / / pha003059 rs1417832 chr13 81228336 T C 2.12E-05 Diabetes Mellitus / / pha003059 rs12429202 chr13 81242652 T C 2.54E-04 Smoking initiation / / 24665060 rs2794240 chr13 81298166 G A 8.50E-04 Type 2 diabetes / / 17463246 rs9545540 chr13 81298245 G C 5.22E-04 Type 2 diabetes / / 17463246 rs7331180 chr13 81307566 G A 4.00E-04 Smoking initiation / / 24665060 rs2794246 chr13 81315134 T A 7.57E-05 Bipolar disorder and schizophrenia / / 20889312 rs10507912 chr13 81317733 G A 8.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs1322618 chr13 81321291 C T 6.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs12430526 chr13 81326266 G A 2.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs17073262 chr13 81330843 C A 5.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs10507785 chr13 81338279 G A 5.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs17073287 chr13 81352120 A T 9.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs9318714 chr13 81355623 G A 1.78E-04 Alcohol dependence / / 20201924 rs12585651 chr13 81357232 G A 5.22E-04 Type 2 diabetes / / 17463246 rs11149178 chr13 81357671 G A 7.00E-06 Major depressive disorder / / 23377640 rs12872241 chr13 81363869 T C 9.53E-05 Type 2 diabetes / / 17463246 rs9601461 chr13 81399493 A C 9.39E-04 Type 2 diabetes / / 17463246 rs9531117 chr13 81418558 T C 9.68E-04 Multiple complex diseases / / 17554300 rs2329172 chr13 81419379 G A 3.14E-04 Alcohol dependence / / 20201924 rs12874720 chr13 81434730 G A 6.93E-04 Type 2 diabetes / / 17463246 rs17073448 chr13 81441268 T C 4.13E-04 IgE levels / / 17255346 rs17073448 chr13 81441268 T C 5.83E-04 Type 2 diabetes / / 17463246 rs4379965 chr13 81493965 C A 8.05E-05 Response to citalopram treatment / / 19846067 rs11616409 chr13 81571690 G A 5.05E-05 Neuroblastoma / / pha002895 rs1333417 chr13 81610387 T G 7.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9318729 chr13 81666865 C T 7.61E-04 Type 2 diabetes / / 17846125 rs7995447 chr13 81716268 C T 6.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs12875423 chr13 81716853 G A 9.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs7321679 chr13 81718096 C A 8.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs1413028 chr13 81734587 T G 6.51E-04 Multiple complex diseases / / 17554300 rs17073814 chr13 81740673 C T 5.68E-04 Multiple complex diseases / / 17554300 rs1382561 chr13 81743819 A T 1.33E-04 Multiple complex diseases / / 17554300 rs9318741 chr13 81751408 T C 2.61E-05 Multiple complex diseases / / 17554300 rs12584499 chr13 81753314 C G 6.17E-05 Schizophrenia / / 19571811 rs1333420 chr13 81756427 A C 2.18E-05 Longevity / / 20304771 rs7319417 chr13 81757853 A G 1.42E-04 Multiple complex diseases / / 17554300 rs7324138 chr13 81762000 T C 1.43E-05 Longevity / / 20304771 rs7324138 chr13 81762000 T C 9.88E-04 Stroke / / pha002886 rs12854616 chr13 81762901 T C 3.28E-05 Longevity / / 20304771 rs12875277 chr13 81774710 A T 4.16E-05 Longevity / / 20304771 rs17073844 chr13 81775055 A T 4.19E-05 Longevity / / 20304771 rs7321904 chr13 81783189 C T 1.27E-05 Longevity / / 20304771 rs7325892 chr13 81788897 C T 5.12E-04 Smoking initiation / / 24665060 rs1333416 chr13 81793288 A C 6.67E-05 Longevity / / 20304771 rs9318756 chr13 81802406 T A 5.89E-04 Type 2 diabetes / / 17463246 rs17073955 chr13 81810858 C T 7.21E-05 Longevity / / 20304771 rs1904258 chr13 81815865 A G 4.91E-04 Type 2 diabetes / / 17463246 rs1026727 chr13 81824427 G T 6.50E-04 Type 2 diabetes / / 17463246 rs9574802 chr13 81833023 G A 4.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1287527 chr13 81833273 T C 6.10E-05 Type 2 diabetes / / 17463248 rs1287526 chr13 81836027 G A 6.40E-05 Type 2 diabetes / / 17463248 rs982864 chr13 81837626 C T 7.70E-05 Type 2 diabetes / / 17463248 rs2801597 chr13 81838044 G A 7.80E-05 Type 2 diabetes / / 17463248 rs1287533 chr13 81842649 A T 8.20E-05 Type 2 diabetes / / 17463248 rs1531575 chr13 81861482 G A 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs9565647 chr13 81890743 A G 4.97E-05 Cognitive impairment induced by topiramate / / 22091778 rs17074130 chr13 81923633 A G 2.45E-04 Body mass index / / 17255346 rs9318765 chr13 81932538 A C 8.30E-05 Body mass index / / 17255346 rs1334384 chr13 81976899 C T 7.01E-04 Heart Failure / / pha002884 rs1334385 chr13 81981842 T A 7.26E-05 Relative hand skill in reading disability / / 24068947 rs2876766 chr13 81984465 T C 8.06E-05 Relative hand skill in reading disability / / 24068947 rs9565661 chr13 81987257 A C 7.50E-05 Relative hand skill in reading disability / / 24068947 rs9545673 chr13 81993071 C T 8.56E-04 Type 2 diabetes / / 17463246 rs9635040 chr13 82008505 A G 4.54E-05 Relative hand skill in reading disability / / 24068947 rs1572217 chr13 82016030 G A 1.19E-05 Heart Failure / / pha002884 rs9574882 chr13 82026346 A G 4.14E-05 Relative hand skill in reading disability / / 24068947 rs17274376 chr13 82026889 A G 2.93E-05 Relative hand skill in reading disability / / 24068947 rs9574883 chr13 82027100 A G 7.52E-05 Relative hand skill in reading disability / / 24068947 rs7986860 chr13 82054377 G A 1.50E-05 Urinary metabolites / / 21572414 rs7986860 chr13 82054377 G A 3.17E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1413568 chr13 82072945 G A 1.83E-06 Obesity-related traits / / 23251661 rs9545740 chr13 82075592 G A 3.98E-05 Multiple complex diseases / / 17554300 rs9545740 chr13 82075592 G A 7.00E-07 Obesity-related traits / / 23251661 rs7320835 chr13 82088756 T C 6.65E-04 Type 2 diabetes / / 17463246 rs9545760 chr13 82100044 T A 9.52E-04 Type 2 diabetes / / 17463246 rs2151866 chr13 82112241 T C 5.15E-05 Sudden cardiac arrest / / 21658281 rs1953290 chr13 82117532 T C 4.80E-08 Breast cancer / / 22452962 rs7318830 chr13 82137523 G T 6.11E-04 Parkinson's disease / / 17052657 rs7318830 chr13 82137523 G T 6.67E-05 Erythrocyte counts / / pha003101 rs9593569 chr13 82141621 G A 1.42E-04 Alcohol dependence / / 20201924 rs7989215 chr13 82160317 G A 2.89E-04 Multiple complex diseases / / 17554300 rs9531226 chr13 82180791 A G 2.86E-04 Multiple complex diseases / / 17554300 rs10507922 chr13 82181945 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1602205 chr13 82232085 G A 9.81E-04 Multiple complex diseases / / 17554300 rs9545826 chr13 82238026 A G 2.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs9545827 chr13 82239682 A G 2.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs9545828 chr13 82239717 A C 2.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs1490022 chr13 82254472 T C 6.47E-05 Cognitive test performance / / 20125193 rs1490022 chr13 82254472 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9531237 chr13 82262814 G A 9.13E-04 Alzheimer's disease / / 17998437 rs923513 chr13 82297339 T C 9.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9318796 chr13 82300870 T C 8.20E-06 Urinary metabolites / / 21572414 rs261446 chr13 82300981 T C 8.64E-04 Alcohol dependence / / 20201924 rs1475720 chr13 82301380 A G 5.16E-04 Type 2 diabetes / / 17463246 rs9318797 chr13 82310763 A G 9.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs17295389 chr13 82315799 G A 6.50E-05 Nicotine smoking / / 19268276 rs9545851 chr13 82336887 T C 5.10E-05 Type 2 diabetes / / 17463248 rs17230016 chr13 82338338 T C 0.00000961 Rheumatoid arthritis / / 23143596 rs17230016 chr13 82338338 T C 0.000178 Rheumatoid arthritis (CCP positive) / / 23143596 rs9545852 chr13 82339494 C T 5.20E-05 Type 2 diabetes / / 17463248 rs9531246 chr13 82341572 C A 5.30E-05 Type 2 diabetes / / 17463248 rs1413144 chr13 82342424 T G 8.71E-05 Height / / pha003011 rs1540639 chr13 82344020 C T 8.71E-05 Height / / pha003011 rs9545853 chr13 82344578 T C 5.40E-05 Type 2 diabetes / / 17463248 rs9545868 chr13 82385608 C A 5.50E-05 Type 2 diabetes / / 17463248 rs9545870 chr13 82388273 A G 5.50E-05 Type 2 diabetes / / 17463248 rs9318803 chr13 82390255 C T 5.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7317522 chr13 82392692 T C 7.28E-05 Personality dimensions / / 18957941 rs3891591 chr13 82393968 C T 6.90E-05 Type 2 diabetes / / 17463248 rs261482 chr13 82402669 G A 6.83E-05 Height / / pha003011 rs1336738 chr13 82403042 G A 5.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9545880 chr13 82413369 C T 1.20E-05 Urinary metabolites / / 21572414 rs1591581 chr13 82415377 G A 1.00E-05 Urinary metabolites / / 21572414 rs9545886 chr13 82434210 G T 1.20E-05 Urinary metabolites / / 21572414 rs9545903 chr13 82446913 T C 7.20E-05 Type 2 diabetes / / 17463248 rs7333069 chr13 82458858 C A 3.40E-05 Psychosis (methamphetamine induced) / / 23594818 rs9545953 chr13 82591114 T C 1.07E-05 Brain structure / / 22504417 rs1497066 chr13 82627500 G T 1.17E-05 Brain structure / / 22504417 rs17174635 chr13 82635993 C G,T 3.12E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs981915 chr13 82640195 T C 1.07E-05 Brain structure / / 22504417 rs2173141 chr13 82641339 T C 1.03E-05 Brain structure / / 22504417 rs7329093 chr13 82641446 T C 1.04E-05 Brain structure / / 22504417 rs1999384 chr13 82674068 T A 1.60E-05 Bilirubin levels,in serum / / 19389676 rs6563272 chr13 82694749 A G 2.87E-05 Brain structure / / 22504417 rs9545990 chr13 82700330 C T 1.54E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs1576673 chr13 82706929 C T 3.79E-05 Brain structure / / 22504417 rs9565748 chr13 82736934 G T 3.40E-05 Brain structure / / 22504417 rs2329212 chr13 82766617 T C 4.38E-05 Brain structure / / 22504417 rs7984395 chr13 82773712 A G 4.00E-05 Prostate cancer / / 21743057 rs6563275 chr13 82792992 G A 3.59E-05 Brain structure / / 22504417 rs7992071 chr13 82797648 T A 4.00E-05 Prostate cancer / / 21743057 rs7320048 chr13 82852817 C T 3.31E-04 Multiple complex diseases / / 17554300 rs7984003 chr13 82866573 T C 4.00E-05 Prostate cancer / / 21743057 rs9546060 chr13 82900467 T C 8.24E-05 Serum metabolites / / 19043545 rs9318846 chr13 82912715 A G 9.76E-04 Kawasaki disease / / 21326860 rs9318847 chr13 82913040 A T 9.77E-04 Kawasaki disease / / 21326860 rs9531328 chr13 82927574 A G 9.76E-04 Kawasaki disease / / 21326860 rs9601891 chr13 82952578 A T 1.70E-05 Urinary metabolites / / 21572414 rs9318876 chr13 83096031 G A 3.03E-04 IgE levels / / 17255346 rs1333583 chr13 83139150 A T 3.40E-05 Volumetric brain MRI / / 17903297 rs9652250 chr13 83161193 C T 2.20E-04 Longevity / / 22279548 rs1333584 chr13 83173274 C T 5.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12870389 chr13 83187066 C T 1.17E-05 Platelet counts / / pha003100 rs1333587 chr13 83191238 G T 4.86E-04 Gallstones / / 17632509 rs9318892 chr13 83219407 G A 7.08E-07 Lactate dehydrogenase levels / / 20981236 rs1889202 chr13 83223898 G A 2.76E-05 Blood Pressure / / pha003050 rs1413164 chr13 83224404 G A 1.50E-05 Urinary metabolites / / 21572414 rs17349444 chr13 83224719 A G 6.83E-05 Fibrinogen / / 17255346 rs2329247 chr13 83262170 A G 8.00E-04 Pulmonary function / / 23932459 rs12585483 chr13 83298475 G A 6.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs2147630 chr13 83303285 G T 2.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17259922 chr13 83307212 A G 1.48E-04 Stroke / / pha002887 rs4254200 chr13 83315652 A G 6.39E-157 Multiple complex diseases / / 17554300 rs1386706 chr13 83416547 A G 3.13E-05 Follicular lymphoma / / 21533074 rs9602002 chr13 83466512 A G 8.32E-04 Type 2 diabetes / / 17463246 rs12584387 chr13 83476824 A C 7.03E-04 Type 2 diabetes / / 17463246 rs9318920 chr13 83498217 G T 5.30E-04 Type 2 diabetes / / 17463246 rs9546275 chr13 83502205 C T 7.00E-06 Prostate cancer / / 21743057 rs1471932 chr13 83505743 C T 4.00E-05 Prostate cancer / / 21743057 rs2876789 chr13 83598718 C T 8.30E-04 Type 2 diabetes / / 17463246 rs1512757 chr13 83805399 C A 6.90E-06 Urinary metabolites / / 21572414 rs2669192 chr13 83809691 G A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1512763 chr13 83841953 C T 9.42E-04 Multiple complex diseases / / 17554300 rs1342606 chr13 83861883 A G 7.19E-04 Multiple complex diseases / / 17554300 rs9546342 chr13 83875017 G A 1.30E-05 Urinary metabolites / / 21572414 rs2796877 chr13 83912516 T C 8.13E-04 Parkinson's disease / / 16252231 rs4134351 chr13 83953693 A C 1.60E-06 Adiposity / / 19461586 rs4287457 chr13 83989765 G A 9.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9318942 chr13 84030514 T C 8.72E-06 Asthma / / 20698975 rs9318943 chr13 84057221 T A 4.64E-04 IgE levels / / 17255346 rs1999513 chr13 84067742 C T 9.09E-04 Coronary heart disease / / 21971053 rs9318950 chr13 84068978 C T 6.82E-04 Coronary heart disease / / 21971053 rs9602209 chr13 84100930 A G 6.70E-05 Triglycerides / / 19074352 rs8000328 chr13 84109168 G C 3.46E-04 Multiple complex diseases / / 17554300 rs4447310 chr13 84121772 T A,C 2.81E-04 Alzheimer's disease / / 17998437 rs6563353 chr13 84130232 C T 2.00E-06 Response to citalopram treatment / / 22760553 rs1999514 chr13 84147879 T A 1.10E-05 Urinary metabolites / / 21572414 rs7322996 chr13 84214404 T C 5.24E-05 Leukocyte Counts / / pha003091 rs116261290 chr13 84260291 G A 3.85E-04 Tuberculosis / / 22306650 rs7334855 chr13 84282654 A C 5.99E-06 Progressive supranuclear palsy / / 21685912 rs1576741 chr13 84321857 A G 5.55E-05 Bipolar disorder and schizophrenia / / 20889312 rs17077369 chr13 84435347 A G 3.00E-04 Pancreatic cancer / / 23180869 rs12100439 chr13 84443892 C T 1.81E-05 Non-word repetition / / 23738518 rs7985031 chr13 84448389 C G 1.81E-05 Non-word repetition / / 23738518 rs1413854 chr13 84496768 A G 6.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9546549 chr13 84523003 C T 1.50E-04 Multiple complex diseases / / 17554300 rs35619358 chr13 84553875 C T 3.44E-04 Multiple complex diseases / / 17554300 rs7319428 chr13 84557071 A T 0.0007222 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7319428 chr13 84557071 A T 7.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7996569 chr13 84558654 T C 0.0007238 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7996569 chr13 84558654 T C 7.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10450860 chr13 84559497 G A 0.0007263 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10450860 chr13 84559497 G A 7.26E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4255684 chr13 84559815 G A 0.0007451 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4255684 chr13 84559815 G A 7.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9531535 chr13 84565923 T C 0.0003366 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9531535 chr13 84565923 T C 3.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7981723 chr13 84569365 A G 0.0004403 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7981723 chr13 84569365 A G 4.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9546562 chr13 84576029 C A 6.83E-06 Alcohol and nictotine co-dependence / / 20158304 rs9575502 chr13 84584366 C T 0.0004311 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9575502 chr13 84584366 C T 4.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4885902 chr13 84588638 C G 0.0004317 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4885902 chr13 84588638 C G 4.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9546566 chr13 84591862 A G 1.02E-05 Alcohol and nictotine co-dependence / / 20158304 rs4390476 chr13 84598570 A C 0.000203 Bipolar disorder / / 23637625 rs4885904 chr13 84600395 A G 2.45E-04 Acute lung injury / / 22295056 rs7992606 chr13 84606422 G A 2.93E-04 Acute lung injury / / 22295056 rs17354931 chr13 84606768 C G 3.07E-04 Acute lung injury / / 22295056 rs9575506 chr13 84608183 C G 2.15E-04 Acute lung injury / / 22295056 rs6563372 chr13 84608734 A G 2.15E-04 Acute lung injury / / 22295056 rs4503690 chr13 84612280 A C 2.15E-04 Acute lung injury / / 22295056 rs7327368 chr13 84612786 G C 2.15E-04 Acute lung injury / / 22295056 rs17355162 chr13 84613692 G A 2.15E-04 Acute lung injury / / 22295056 rs9602365 chr13 84616050 A G 6.66E-04 Acute lung injury / / 22295056 rs4885906 chr13 84618548 A G 2.14E-04 Acute lung injury / / 22295056 rs9575511 chr13 84619400 A G 2.19E-04 Acute lung injury / / 22295056 rs9602369 chr13 84633596 A G 3.58E-04 Coronary Artery Disease / / 17634449 rs9546594 chr13 84655224 G T 5.67E-04 Multiple complex diseases / / 17554300 rs7998092 chr13 84716454 G A 7.00E-05 Response to statin therapy / / 20339536 rs11617624 chr13 84724848 G T 7.50E-05 Response to statin therapy / / 20339536 rs9602377 chr13 84738055 G T 5.40E-05 Response to statin therapy / / 20339536 rs9602378 chr13 84739930 A G 5.70E-05 Response to statin therapy / / 20339536 rs1928925 chr13 84744158 G C 4.70E-05 Response to statin therapy / / 20339536 rs9602384 chr13 84747196 G A 4.80E-05 Response to statin therapy / / 20339536 rs1928927 chr13 84752069 G A 2.00E-05 Response to statin therapy / / 20339536 rs9602387 chr13 84755999 G T 7.90E-05 Response to statin therapy / / 20339536 rs11616562 chr13 84758025 A G 2.90E-05 Response to statin therapy / / 20339536 rs9546628 chr13 84762873 C G 0.0000246 Coronary artery calcification / / 23394302 rs7324586 chr13 84792045 A G 0.00000947 Primary sclerosing cholangitis / / 23603763 rs1541072 chr13 84921356 G A 9.34E-05 Cytomegalovirus antibody response / / 21993531 rs17078083 chr13 84956289 G A 2.74E-04 Multiple complex diseases / / 17554300 rs7490744 chr13 84976969 T G 1.30E-04 Major depressive disorder / / 21042317 rs9602470 chr13 84978573 A G 5.90E-04 Major depressive disorder / / 21042317 rs9593922 chr13 84980361 G A 3.00E-05 Temperament (bipolar disorder) / / 22365631 rs9546677 chr13 84995245 G A 3.10E-05 Temperament (bipolar disorder) / / 22365631 rs1888241 chr13 85006611 G A 5.40E-06 Temperament (bipolar disorder) / / 22365631 rs11149298 chr13 85016489 A G 2.70E-06 Temperament (bipolar disorder) / / 22365631 rs9531587 chr13 85021473 G T 3.10E-05 Temperament (bipolar disorder) / / 22365631 rs17371334 chr13 85032327 T G 4.31E-05 Nicotine smoking / / 19268276 rs17371334 chr13 85032327 T G 2.00E-06 Temperament (bipolar disorder) / / 22365631 rs9575582 chr13 85033012 G A 6.70E-05 Temperament (bipolar disorder) / / 22365631 rs9575583 chr13 85033223 G A 5.20E-05 Temperament (bipolar disorder) / / 22365631 rs7996298 chr13 85033851 T G 9.30E-05 Temperament (bipolar disorder) / / 22365631 rs9546711 chr13 85054266 G A 2.00E-06 Coronary heart disease / / 21347282 rs9575591 chr13 85079440 G T 5.30E-05 Personality dimensions / / 18957941 rs12583774 chr13 85079583 A G 1.50E-05 Urinary metabolites / / 21572414 rs7990593 chr13 85080889 C T 6.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs12875558 chr13 85084041 A G 5.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs9602490 chr13 85086195 T A 5.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs1947117 chr13 85087374 G A 8.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs11838449 chr13 85088681 G A 6.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs9319053 chr13 85091189 G A 8.81E-05 Personality dimensions / / 18957941 rs935422 chr13 85093990 G A 8.41E-05 Personality dimensions / / 18957941 rs9602492 chr13 85096335 A C,T 8.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs9575595 chr13 85098190 T C 7.82E-05 Personality dimensions / / 18957941 rs11149304 chr13 85098964 G A 9.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs10162021 chr13 85103561 G T 8.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs12876183 chr13 85114550 A T 4.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs17375766 chr13 85121427 A T 5.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs17322943 chr13 85122020 T C 5.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs7994999 chr13 85142670 T C 7.54E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs9546775 chr13 85166320 T G 8.14E-04 Premature ovarian failure / / 19508998 rs1446777 chr13 85172893 C T 2.33E-04 Multiple complex diseases / / 17554300 rs9602510 chr13 85175000 G A 3.50E-05 Multiple complex diseases / / 17554300 rs17377465 chr13 85176520 C A 4.04E-04 Multiple complex diseases / / 17554300 rs2197609 chr13 85177888 T G 0.0002337 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2197609 chr13 85177888 T G 2.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9575611 chr13 85182030 G A 5.43E-04 Multiple complex diseases / / 17554300 rs9575613 chr13 85183504 A C 7.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs1446792 chr13 85191936 G A 7.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs9575621 chr13 85204403 C A 8.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs9565949 chr13 85204881 A G 1.70E-05 Urinary metabolites / / 21572414 rs3099523 chr13 85209546 C T 5.45E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs3099523 chr13 85209546 C T 5.99E-05 Body Mass Index / / pha003021 rs13378761 chr13 85214296 C A 7.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs9602525 chr13 85216640 T A 7.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs11843965 chr13 85218788 C T 2.41E-04 Alzheimer's disease (late onset) / / 21379329 rs11843965 chr13 85218788 C T 2.64E-04 Rheumatoid arthritis / / 21452313 rs4885928 chr13 85221992 A T 8.97E-04 Multiple complex diseases / / 17554300 rs4885928 chr13 85221992 A T 0.0002406 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4885928 chr13 85221992 A T 2.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9565956 chr13 85223489 T C 6.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs9575636 chr13 85244065 G A 7.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs12100200 chr13 85245231 G A 7.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs9575637 chr13 85248534 C T 6.88E-04 Multiple complex diseases / / 17554300 rs9575638 chr13 85249158 G T 7.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs9319064 chr13 85251712 G A 3.00E-06 Obesity-related traits / / 23251661 rs9575643 chr13 85259059 G A 9.93E-04 Multiple complex diseases / / 17554300 rs9319065 chr13 85259237 A G 7.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs4456395 chr13 85260240 T C 0.0002253 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4456395 chr13 85260240 T C 2.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4480680 chr13 85265635 T C 8.15E-05 Major depressive disorder / / 22472876 rs7319590 chr13 85283911 C T 4.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs6563407 chr13 85285674 A G 6.19E-05 Major depressive disorder / / 22472876 rs7985182 chr13 85285855 G C 4.34E-05 Major depressive disorder / / 22472876 rs7491993 chr13 85292058 A G 0.0002196 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7491993 chr13 85292058 A G 2.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3923924 chr13 85299207 G A 7.78E-04 Multiple complex diseases / / 17554300 rs3923924 chr13 85299207 G A 0.000114 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs3923924 chr13 85299207 G A 1.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4077323 chr13 85303221 T C 8.59E-04 Multiple complex diseases / / 17554300 rs2204502 chr13 85313394 A G 9.82E-04 Iron levels / / pha002876 rs3013647 chr13 85323372 C T 7.98E-05 Soluble levels of adhesion molecules / / pha003072 rs1112443 chr13 85334802 G C 0.0000772 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1112443 chr13 85334802 G C 7.72E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17071783 chr13 85352431 A G 8.62E-04 Multiple complex diseases / / 17554300 rs9669823 chr13 85355843 T A 0.0000748 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9669823 chr13 85355843 T A 7.48E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1949891 chr13 85390088 G A 2.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2037712 chr13 85391175 G C 0.0004914 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2037712 chr13 85391175 G C 4.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1554726 chr13 85397248 T A 0.000509 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1554726 chr13 85397248 T A 5.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1554724 chr13 85416823 T C 1.22E-04 Amyotrophic lateral sclerosis / / 20801718 rs17078645 chr13 85428193 T A 3.51E-04 Multiple complex diseases / / 17554300 rs17078679 chr13 85456392 A G 4.10E-04 Alcohol dependence / / 20201924 rs17078679 chr13 85456392 A G 2.53E-05 Brain structure / / 22504417 rs17078679 chr13 85456392 A G 0.0005249 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17078679 chr13 85456392 A G 5.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2368311 chr13 85470916 T C 4.11E-04 Alzheimer's disease (late onset) / / 21460841 rs2037711 chr13 85476417 C A 8.82E-04 Alzheimer's disease / / 22005930 rs4911044 chr13 85528032 T G 3.14E-05 Epilepsy / / 22116939 rs9546986 chr13 85543153 G T 1.90E-04 Alzheimer's disease (late onset) / / 21460841 rs1537994 chr13 85546562 T C 9.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9531686 chr13 85549736 T G 9.00E-06 Anorexia nervosa / / 23568457 rs2485250 chr13 85551462 C A 3.13E-05 Serum metabolites / / 19043545 rs1932917 chr13 85555284 A G 0.00088 Prostate cancer / / 23555315 rs4911045 chr13 85557107 A C 1.46E-04 Alzheimer's disease (late onset) / / 21379329 rs11838719 chr13 85571238 C T 7.90E-05 Major depressive disorder / / 21042317 rs7331710 chr13 85571500 C A 4.30E-07 Urinary metabolites / / 21572414 rs7331710 chr13 85571500 C A 0.0000553 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7331710 chr13 85571500 C A 5.53E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7336959 chr13 85571724 C G 0.0000557 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7336959 chr13 85571724 C G 5.57E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17078997 chr13 85572420 C T 7.20E-07 Urinary metabolites / / 21572414 rs17078997 chr13 85572420 C T 0.000056 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17078997 chr13 85572420 C T 5.60E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17079005 chr13 85576712 C T 0.0000848 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17079005 chr13 85576712 C T 8.48E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17079019 chr13 85578989 G A 2.63E-05 Cognitive impairment induced by topiramate / / 22091778 rs1354033 chr13 85588545 T C 1.12E-06 Epilepsy / / 22116939 rs2496752 chr13 85603707 G T 2.60E-05 Urinary metabolites / / 21572414 rs9602630 chr13 85604717 G A 5.13E-04 Body mass index / / 21701565 rs9602630 chr13 85604717 G A 5.94E-04 Body mass index / / 21701565 rs2485241 chr13 85605946 T C 1.07E-06 Epilepsy / / 22116939 rs2485247 chr13 85609277 T C 3.97E-06 Epilepsy / / 22116939 rs8000505 chr13 85610544 C T 1.68E-04 Celiac disease / / 23936387 rs9319107 chr13 85611743 T C 1.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9319109 chr13 85612269 G C 2.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9319110 chr13 85612388 C T 3.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9531704 chr13 85616161 T G 0.0006534 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9531704 chr13 85616161 T G 6.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1932913 chr13 85617558 T C 1.88E-05 Lung Function (Forced Expiratory Volume in 1 second) / / 25044411 rs10459348 chr13 85619082 C T 9.84E-06 Lung Function (Forced Expiratory Volume in 1 second) / / 25044411 rs9566006 chr13 85631841 T C 4.09E-04 Bipolar disorder (mania) / / 23326512 rs9566009 chr13 85632014 T C 1.80E-04 Bipolar disorder (mania) / / 23326512 rs9602646 chr13 85635964 G A 8.65E-05 Bipolar disorder (mania) / / 23326512 rs2210933 chr13 85660059 T C 1.03E-04 Bipolar disorder (mania) / / 23326512 rs7321552 chr13 85660546 T C 1.06E-04 Bipolar disorder (mania) / / 23326512 rs7320384 chr13 85660638 C A 1.45E-04 Bipolar disorder (mania) / / 23326512 rs1500679 chr13 85661350 A G 7.99E-05 Bipolar disorder (mania) / / 23326512 rs17079247 chr13 85665879 C T 8.00E-06 Bipolar disorder (mania) / / 23326512 rs7319760 chr13 85666107 G A 1.03E-04 Bipolar disorder (mania) / / 23326512 rs7316927 chr13 85678043 C T 9.99E-07 Bipolar disorder (mania) / / 23326512 rs7987820 chr13 85687983 A C 1.17E-04 Bipolar disorder (mania) / / 23326512 rs11842896 chr13 85708459 T C 2.28E-04 Bipolar disorder (mania) / / 23326512 rs7317078 chr13 85716736 A G 2.75E-04 Bipolar disorder (mania) / / 23326512 rs9575786 chr13 85717330 T A 1.47E-05 QT interval / / 22726844 rs9575786 chr13 85717330 T A 1.67E-04 Bipolar disorder (mania) / / 23326512 rs9575786 chr13 85717330 T A 1.67E-04 Age-related macular degeneration / / 23326517 rs7327483 chr13 85722171 C A 8.62E-05 Serum metabolites / / 19043545 rs1953665 chr13 85728203 T C 1.83E-04 Bipolar disorder (mania) / / 23326512 rs9566037 chr13 85728432 T C 9.41E-06 Bipolar disorder (mania) / / 23326512 rs9575793 chr13 85728477 G T 1.12E-04 Bipolar disorder (mania) / / 23326512 rs9566044 chr13 85758871 T C 2.60E-05 Urinary metabolites / / 21572414 rs9566044 chr13 85758871 T C 7.70E-05 Bipolar disorder (mania) / / 23326512 rs9575818 chr13 85763314 G A 5.30E-07 Urinary metabolites / / 21572414 rs9575818 chr13 85763314 G A 1.54E-06 Bipolar disorder (mania) / / 23326512 rs9575820 chr13 85764196 T G 2.10E-06 Bipolar disorder (mania) / / 23326512 rs9575827 chr13 85772949 A G 2.12E-06 Bipolar disorder (mania) / / 23326512 rs7322604 chr13 85773768 C T 4.42E-06 Bipolar disorder (mania) / / 23326512 rs9566049 chr13 85806590 G A 3.94E-06 Bipolar disorder (mania) / / 23326512 rs9602697 chr13 85809508 C T 2.54E-06 Bipolar disorder (mania) / / 23326512 rs9575849 chr13 85810501 C A 2.09E-06 Bipolar disorder (mania) / / 23326512 rs9602702 chr13 85811376 T C 2.29E-06 Bipolar disorder (mania) / / 23326512 rs9635066 chr13 85812000 A G 1.84E-06 Bipolar disorder (mania) / / 23326512 rs2451433 chr13 85823540 C T 5.93E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9531750 chr13 85855551 A G 1.80E-05 Response to statin therapy / / 20339536 rs9547129 chr13 85857065 G A 2.30E-05 Response to statin therapy / / 20339536 rs9547132 chr13 85860898 G T 3.10E-05 Response to statin therapy / / 20339536 rs9575863 chr13 85863298 G A 1.22E-04 Bipolar disorder (mania) / / 23326512 rs9566062 chr13 85863733 A G 4.83E-04 Bipolar disorder (mania) / / 23326512 rs9547133 chr13 85864673 G A 5.76E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1873288 chr13 85881124 G A 1.99E-04 Osteoarthritis / / 19508968 rs17354288 chr13 85890716 C G 2.07E-04 Multiple complex diseases / / 17554300 rs1331567 chr13 85895815 G A 2.27E-05 Bilirubin levels,in serum / / 19389676 rs3929785 chr13 85902209 T C 5.71E-04 Multiple complex diseases / / 17554300 rs9602733 chr13 85924954 G A 0.0000977 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1331544 chr13 85976268 A T 9.02E-04 Bipolar disorder (mania) / / 23326512 rs10507950 chr13 85982980 T G 4.93E-04 Bipolar disorder (mania) / / 23326512 rs9602747 chr13 85997131 A G 7.14E-05 Cognitive impairment induced by topiramate / / 22091778 rs2210374 chr13 85999154 A G 9.71E-05 Smoking quantity / / 24665060 rs7336083 chr13 86003387 A G 9.49E-06 Tourette syndrome / / 22889924 rs12864432 chr13 86011610 A G 4.96E-05 Glycosylated haemoglobin levels / / 17255346 rs9319158 chr13 86019266 G A 2.97E-04 Blood pressure / / 17255346 rs9319159 chr13 86019440 C T 1.15E-05 Tourette syndrome / / 22889924 rs9531790 chr13 86023878 T C 2.86E-04 Tourette syndrome / / 22889924 rs9531790 chr13 86023878 T C 2.54E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1576669 chr13 86031048 T C 1.82E-05 Glycemic traits (pregnancy) / / 23903356 rs1576669 chr13 86031048 T C 3.78E-05 Glycemic traits (pregnancy) / / 23903356 rs7996533 chr13 86087381 A C 9.99E-04 Multiple complex diseases / / 17554300 rs4482178 chr13 86104089 C A 2.00E-07 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9547256 chr13 86114450 T G 2.28E-04 Alcohol dependence / / 20201924 rs2782994 chr13 86164315 T G 2.76E-04 Blood pressure / / 17255346 rs677733 chr13 86168153 T C 8.28E-05 Glycosylated haemoglobin levels / / 17255346 rs677733 chr13 86168153 T C 4.22E-05 Cognitive decline / / 22054870 rs9547283 chr13 86182094 C T 2.57E-04 Age-related macular degeneration / / 22125219 rs597354 chr13 86184204 C T 3.86E-05 Glycosylated haemoglobin levels / / 17255346 rs597354 chr13 86184204 C T 4.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs597354 chr13 86184204 C T 3.88E-05 Cognitive decline / / 22054870 rs1928129 chr13 86192376 G A 2.18E-04 Glycosylated haemoglobin levels / / 17255346 rs1928128 chr13 86192418 A C 8.00E-05 Personality dimensions / / 18957941 rs7323951 chr13 86193093 G A 1.90E-08 Urinary metabolites / / 21572414 rs9575922 chr13 86207862 A G 1.64E-04 Glycosylated haemoglobin levels / / 17255346 rs9575922 chr13 86207862 A G 7.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs9575922 chr13 86207862 A G 3.74E-05 Cognitive decline / / 22054870 rs9602785 chr13 86208404 T C 5.71E-06 Cognitive decline / / 22054870 rs7331757 chr13 86211594 G A 9.69E-05 Glycosylated haemoglobin levels / / 17255346 rs1764963 chr13 86259295 C T 2.27E-04 Glycosylated haemoglobin levels / / 17255346 rs1538050 chr13 86276094 A G 2.30E-05 Urinary metabolites / / 21572414 rs1538049 chr13 86276135 A G 1.20E-05 Urinary metabolites / / 21572414 rs9531827 chr13 86276176 C T 2.00E-05 Urinary metabolites / / 21572414 rs9547337 chr13 86289458 G A 1.70E-05 Urinary metabolites / / 21572414 rs688445 chr13 86326952 G A 7.72E-04 Coronary Artery Disease / / 17634449 rs17080149 chr13 86386087 G A 4.00E-05 Parkinson's disease (familial) / / 18985386 rs10220124 chr13 86408521 G A 6.12E-04 Multiple complex diseases / / 17554300 rs168556 chr13 86411855 C T 3.76E-05 Type 2 diabetes / / 17463246 rs1185648 chr13 86450210 T C 4.05E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs420100 chr13 86455076 A G 7.18E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17080277 chr13 86484499 C A 4.76E-04 Type 2 diabetes / / 17463246 rs17080277 chr13 86484499 C A 2.42E-04 Multiple complex diseases / / 17554300 rs1330049 chr13 86517153 C T 7.01E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4432164 chr13 86545903 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9547465 chr13 86551371 C T 3.95E-06 Meningococcal disease / / 20694013 rs9319187 chr13 86561495 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7329157 chr13 86575869 C T 7.53E-04 Multiple complex diseases / / 17554300 rs9594094 chr13 86578315 G A 2.50E-06 Urinary metabolites / / 21572414 rs4550343 chr13 86581867 A G 2.17E-05 Aging (time to event) / / 21782286 rs7982442 chr13 86584683 C G 2.52E-04 Multiple complex diseases / / 17554300 rs7333644 chr13 86588996 C T 8.00E-04 Multiple complex diseases / / 17554300 rs9531894 chr13 86592099 G T 5.11E-04 Myopia (pathological) / / 21095009 rs7983827 chr13 86615348 G A 4.60E-04 Alcohol dependence / / 20201924 rs9576007 chr13 86620040 G A 6.40E-04 Alcohol dependence / / 20201924 rs34324847 chr13 86642787 A T 6.48E-04 Multiple complex diseases / / 17554300 rs12430782 chr13 86650961 T A 4.83E-04 Multiple complex diseases / / 17554300 rs2184267 chr13 86655553 C T 5.30E-04 Multiple complex diseases / / 17554300 rs17705877 chr13 86666134 G T 3.86E-04 Multiple complex diseases / / 17554300 rs7992702 chr13 86671049 A C 2.07E-04 Multiple complex diseases / / 17554300 rs1413441 chr13 86682897 C T 1.36E-04 Multiple complex diseases / / 17554300 rs4503696 chr13 86686533 C A 2.24E-04 Multiple complex diseases / / 17554300 rs7984869 chr13 86690527 G T 3.00E-06 Economic and political preferences (fairness) / / 22566634 rs9319200 chr13 86711091 T C 2.15E-04 Glycosylated haemoglobin levels / / 17255346 rs2184263 chr13 86727743 C T 8.73E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9576027 chr13 86729008 A G 3.28E-04 Alcohol dependence / / 24277619 rs10507959 chr13 86732433 T C 1.10E-05 Urinary metabolites / / 21572414 rs9547563 chr13 86739256 G T 5.80E-06 Urinary metabolites / / 21572414 rs9301562 chr13 86913430 C T 5.48E-04 Alzheimer's disease / / 17998437 rs9519096 chr13 86927664 G A 4.18E-04 Alzheimer's disease / / 17998437 rs12585842 chr13 86953915 A T 1.70E-05 Urinary metabolites / / 21572414 rs7337110 chr13 86956812 C T 0.000840871 Hypertension (early onset hypertension) / / 22479346 rs7333303 chr13 86959695 C A 4.74E-04 Multiple complex diseases / / 17554300 rs4772827 chr13 86963707 T G 2.57E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4772827 chr13 86963707 T G 4.24E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs9805613 chr13 86982353 A G 0.000568453 Hypertension (early onset hypertension) / / 22479346 rs9302073 chr13 87002553 C T 0.000799283 Hypertension (early onset hypertension) / / 22479346 rs10467248 chr13 87004501 G A 0.000799283 Hypertension (early onset hypertension) / / 22479346 rs9513670 chr13 87045827 T C 5.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9518034 chr13 87050402 G T 3.65E-04 Parkinson's disease / / 16252231 rs36044533 chr13 87126545 A G 7.74E-04 Alzheimer's disease / / 17998437 rs7994659 chr13 87137686 G C 5.50E-06 Urinary metabolites / / 21572414 rs9555560 chr13 87139051 T C 1.00E-05 Urinary metabolites / / 21572414 rs4608205 chr13 87171055 G A 2.73E-05 Cognitive test performance / / 20125193 rs9555837 chr13 87176518 C A 1.38E-05 Hippocampal atrophy / / 19668339 rs9301535 chr13 87186282 G A 8.63E-06 Hippocampal atrophy / / 19668339 rs1410761 chr13 87195094 C A 4.14E-05 Hippocampal atrophy / / 19668339 rs7987256 chr13 87204838 A C 6.75E-05 Hippocampal atrophy / / 19668339 rs4773434 chr13 87223893 T C 2.10E-05 Urinary metabolites / / 21572414 rs4773442 chr13 87231949 C G 1.40E-05 Urinary metabolites / / 21572414 rs9560385 chr13 87238845 T C 2.19E-05 Hippocampal atrophy / / 19668339 rs4773460 chr13 87242857 C T 2.00E-06 Hippocampal atrophy / / 19668339 rs1578864 chr13 87255807 A T 8.62E-04 Type 2 diabetes / / 17463246 rs9301625 chr13 87270138 A C 1.44E-05 Hippocampal atrophy / / 19668339 rs9560656 chr13 87338840 C T 3.49E-05 Hippocampal atrophy / / 19668339 rs1578867 chr13 87353400 T C 0.000575 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1578867 chr13 87353400 T C 5.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4143138 chr13 87355150 G A 0.0007798 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4143138 chr13 87355150 G A 7.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9515892 chr13 87407377 C T 5.52E-05 Hippocampal atrophy / / 19668339 rs6492543 chr13 87427207 A T 6.95E-04 Multiple complex diseases / / 17554300 rs7991587 chr13 87428060 T C 3.77E-04 Multiple complex diseases / / 17554300 rs3015542 chr13 87451410 G C 7.41E-04 Multiple complex diseases / / 17554300 rs8000348 chr13 87453626 G A 3.02E-04 Multiple complex diseases / / 17554300 rs9515993 chr13 87478483 C G 6.23E-04 Multiple complex diseases / / 17554300 rs9301815 chr13 87536247 G A 4.37E-04 Taste perception / / 22132133 rs9523748 chr13 87549014 C T 1.93E-04 Alcohol consumption / / 23743675 rs7992214 chr13 87552751 G A 9.31E-04 Multiple complex diseases / / 17554300 rs9523806 chr13 87562029 A G 1.97E-04 Alcohol consumption / / 23743675 rs9589628 chr13 87564596 T C 3.71E-05 Triglycerides / / pha003081 rs9523810 chr13 87566383 A C 1.97E-04 Alcohol consumption / / 23743675 rs9523867 chr13 87579486 G A 1.97E-04 Alcohol consumption / / 23743675 rs9523884 chr13 87584738 C A 1.63E-04 Alcohol consumption / / 23743675 rs9523907 chr13 87593562 G A 1.68E-04 Alcohol consumption / / 23743675 rs9301857 chr13 87593939 C T 2.64E-04 Taste perception / / 22132133 rs1718018 chr13 87599109 A C 1.58E-04 Taste perception / / 22132133 rs9516185 chr13 87603603 G T 1.11E-04 Alcohol consumption / / 23743675 rs2685797 chr13 87604648 G A 6.36E-04 Taste perception / / 22132133 rs9523964 chr13 87606334 A G 9.86E-05 Alcohol consumption / / 23743675 rs9523979 chr13 87608482 G A 9.76E-05 Alcohol consumption / / 23743675 rs9523980 chr13 87608688 C T 9.86E-05 Alcohol consumption / / 23743675 rs9524032 chr13 87622377 C T 9.27E-05 Alcohol consumption / / 23743675 rs2265354 chr13 87628517 G A 5.82E-04 Taste perception / / 22132133 rs7326032 chr13 87638149 A G 7.16E-04 Taste perception / / 22132133 rs1522016 chr13 87660794 A C 8.60E-05 Alcohol consumption / / 23743675 rs2343145 chr13 87662337 A G 8.54E-04 Taste perception / / 22132133 rs9524259 chr13 87670460 T G 8.60E-05 Alcohol consumption / / 23743675 rs9516305 chr13 87671267 G A 8.60E-05 Alcohol consumption / / 23743675 rs7489737 chr13 87673423 C T 8.60E-05 Alcohol consumption / / 23743675 rs9584182 chr13 87692257 A G 1.04E-04 Alcohol consumption / / 23743675 rs9584183 chr13 87692279 T C 1.03E-04 Alcohol consumption / / 23743675 rs9516349 chr13 87694090 C G 1.05E-04 Alcohol consumption / / 23743675 rs17614422 chr13 87695071 C A 9.77E-05 Alcohol consumption / / 23743675 rs1855480 chr13 87699547 A G 1.05E-04 Alcohol consumption / / 23743675 rs9524349 chr13 87701135 T C 1.04E-04 Alcohol consumption / / 23743675 rs8002837 chr13 87701273 T G 9.46E-05 Alcohol consumption / / 23743675 rs17614444 chr13 87703218 T C 1.14E-04 Alcohol consumption / / 23743675 rs9524367 chr13 87703310 T G 8.55E-04 Multiple complex diseases / / 17554300 rs9524369 chr13 87705768 C T 1.11E-04 Alcohol consumption / / 23743675 rs9301944 chr13 87706345 G A 1.14E-04 Alcohol consumption / / 23743675 rs7328552 chr13 87707942 G T 1.15E-04 Alcohol consumption / / 23743675 rs9516375 chr13 87710008 C T 1.14E-04 Alcohol consumption / / 23743675 rs9524392 chr13 87711520 C T 8.21E-04 Multiple complex diseases / / 17554300 rs9524405 chr13 87713434 T C 1.19E-04 Alcohol consumption / / 23743675 rs9524427 chr13 87714690 G A 1.32E-04 Alcohol consumption / / 23743675 rs9524428 chr13 87715129 T A 1.25E-04 Alcohol consumption / / 23743675 rs9524429 chr13 87715193 C T 1.22E-04 Alcohol consumption / / 23743675 rs9516386 chr13 87715737 C G 1.15E-04 Alcohol consumption / / 23743675 rs9524431 chr13 87716228 A G 1.18E-04 Alcohol consumption / / 23743675 rs9516389 chr13 87716746 T G 1.10E-04 Alcohol consumption / / 23743675 rs9516391 chr13 87717263 A C 1.13E-04 Alcohol consumption / / 23743675 rs9524441 chr13 87718188 A G 1.13E-04 Alcohol consumption / / 23743675 rs9584217 chr13 87722164 C G 1.14E-04 Alcohol consumption / / 23743675 rs9584218 chr13 87722275 G C 1.12E-04 Alcohol consumption / / 23743675 rs9584222 chr13 87722819 G A 1.03E-04 Alcohol consumption / / 23743675 rs9524480 chr13 87724509 T G 1.11E-04 Alcohol consumption / / 23743675 rs4307816 chr13 87730252 A G 7.83E-05 Alcohol consumption / / 23743675 rs9516421 chr13 87731598 G T 1.06E-04 Alcohol consumption / / 23743675 rs10161716 chr13 87732390 C T 1.02E-04 Alcohol consumption / / 23743675 rs9301969 chr13 87734174 T C 1.05E-04 Alcohol consumption / / 23743675 rs9516428 chr13 87736353 T C 1.40E-04 Alcohol consumption / / 23743675 rs7323320 chr13 87737847 A G 1.15E-04 Alcohol consumption / / 23743675 rs9516430 chr13 87738464 T G 1.23E-04 Alcohol consumption / / 23743675 rs2880547 chr13 87740302 T C 1.29E-04 Alcohol consumption / / 23743675 rs6650324 chr13 87740425 T C 1.29E-04 Alcohol consumption / / 23743675 rs9524535 chr13 87741032 A G 1.29E-04 Alcohol consumption / / 23743675 rs9524536 chr13 87741078 T C 1.29E-04 Alcohol consumption / / 23743675 rs9524539 chr13 87741128 T C 1.35E-04 Alcohol consumption / / 23743675 rs9516432 chr13 87742283 G A 1.29E-04 Alcohol consumption / / 23743675 rs9516433 chr13 87742869 T C 1.29E-04 Alcohol consumption / / 23743675 rs9516435 chr13 87743576 A T 1.24E-04 Alcohol consumption / / 23743675 rs9301980 chr13 87744027 T G 1.27E-04 Alcohol consumption / / 23743675 rs9301982 chr13 87744305 T C 1.27E-04 Alcohol consumption / / 23743675 rs884093 chr13 87745110 T C 1.36E-04 Alcohol consumption / / 23743675 rs9516446 chr13 87745792 A C 1.27E-04 Alcohol consumption / / 23743675 rs9516447 chr13 87746085 T A 1.19E-04 Alcohol consumption / / 23743675 rs9301984 chr13 87746367 T C 1.19E-04 Alcohol consumption / / 23743675 rs9301985 chr13 87746522 A G 1.19E-04 Alcohol consumption / / 23743675 rs9301986 chr13 87746779 C T 1.19E-04 Alcohol consumption / / 23743675 rs9524571 chr13 87747466 G C 1.15E-04 Alcohol consumption / / 23743675 rs9524572 chr13 87747506 T A 1.15E-04 Alcohol consumption / / 23743675 rs9524574 chr13 87748116 A C 1.19E-04 Alcohol consumption / / 23743675 rs9524576 chr13 87748327 G A 1.18E-04 Alcohol consumption / / 23743675 rs9524579 chr13 87748687 C G 1.09E-04 Alcohol consumption / / 23743675 rs1568547 chr13 87748914 C T 1.13E-04 Alcohol consumption / / 23743675 rs1568548 chr13 87749053 G C 1.18E-04 Alcohol consumption / / 23743675 rs1568549 chr13 87749218 A T 1.18E-04 Alcohol consumption / / 23743675 rs9524582 chr13 87749509 A T 8.44E-04 Type 2 diabetes / / 17463246 rs9516456 chr13 87750178 G A 1.18E-04 Alcohol consumption / / 23743675 rs9301987 chr13 87751111 A G 1.18E-04 Alcohol consumption / / 23743675 rs9301988 chr13 87752517 G A 1.18E-04 Alcohol consumption / / 23743675 rs13378851 chr13 87753220 C T 1.18E-04 Alcohol consumption / / 23743675 rs9590055 chr13 87754380 G A 1.30E-04 Alcohol consumption / / 23743675 rs9524592 chr13 87754480 A G 1.30E-04 Alcohol consumption / / 23743675 rs9524593 chr13 87754623 G T 1.45E-04 Alcohol consumption / / 23743675 rs9524595 chr13 87755078 C A 1.13E-04 Alcohol consumption / / 23743675 rs9516465 chr13 87756076 A C 1.43E-04 Alcohol consumption / / 23743675 rs9584247 chr13 87757303 G C 1.54E-04 Alcohol consumption / / 23743675 rs9524600 chr13 87758209 A G 1.20E-04 Alcohol consumption / / 23743675 rs9524601 chr13 87758301 T A 1.06E-04 Alcohol consumption / / 23743675 rs9516471 chr13 87760867 G A 7.55E-05 Alcohol consumption / / 23743675 rs9516472 chr13 87760964 T C 7.64E-05 Alcohol consumption / / 23743675 rs993452 chr13 87762176 T C 7.63E-05 Alcohol consumption / / 23743675 rs9524641 chr13 87767861 G A 7.96E-05 Alcohol consumption / / 23743675 rs4129402 chr13 87808425 T C 1.71E-04 Alcohol consumption / / 23743675 rs9516565 chr13 87818537 G A 1.71E-04 Alcohol consumption / / 23743675 rs9516574 chr13 87820360 C G 1.71E-04 Alcohol consumption / / 23743675 rs2880705 chr13 87853961 T C 6.63E-05 Alcohol consumption / / 23743675 rs1330623 chr13 87890290 A G 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs55996493 chr13 87916330 G A,C,T 2.48E-04 Alcohol consumption / / 23743675 rs9513196 chr13 87977036 G A 6.53E-05 Tunica Media / / pha003036 rs7981141 chr13 88033666 C T 1.46E-04 Multiple complex diseases / / 17554300 rs7321756 chr13 88061028 A G 0.0000159 Colorectal cancer vs adenoma controls (males) / / 22532847 rs7984757 chr13 88134409 C T 3.66E-04 Amyotrophic Lateral Sclerosis MIR4500HG intron 17827064 rs9300492 chr13 88147047 A G 3.10E-04 Type 2 diabetes and 6 quantitative traits MIR4500HG intron 17848626 rs16956726 chr13 88236703 A G 2.20E-05 Urinary metabolites MIR4500HG intron 21572414 rs9554632 chr13 88260530 T C 6.03E-04 Longevity MIR4500HG intron 22279548 rs9585502 chr13 88361134 A C 7.90E-05 Serum metabolites / / 19043545 rs16958854 chr13 88407850 G A 2.68E-05 HIV-1 viral setpoint / / 22174851 rs953758 chr13 88484780 T G 1.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs953758 chr13 88484780 T G 8.86E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs953759 chr13 88484867 T A 4.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17527390 chr13 88487291 G A 5.21E-04 Taste perception / / 22132133 rs7992197 chr13 88496806 A G 7.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1335400 chr13 88502569 A C 1.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9300731 chr13 88511603 G A 9.06E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4772450 chr13 88533669 A G 0.0008646 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4772450 chr13 88533669 A G 8.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9300749 chr13 88542455 A G 0.0008611 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9300749 chr13 88542455 A G 8.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9586149 chr13 88622740 C T 9.87E-05 Cholesterol / / 17255346 rs1561859 chr13 88623302 C T 1.01E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs10492674 chr13 88634590 C G 3.29E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2119924 chr13 88636178 C T 1.48E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs7334817 chr13 88652531 G A 1.80E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1333822 chr13 88672327 A T 1.86E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1333822 chr13 88672327 A T 1.30E-05 Urinary metabolites / / 21572414 rs9558217 chr13 88676974 G A 2.23E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs7323893 chr13 88704706 T C 1.00E-07 Coronary heart disease / / 21347282 rs1999237 chr13 88735401 C T 9.39E-06 Cognitive performance / / 19734545 rs1333798 chr13 88750446 A G 9.39E-06 Cognitive performance / / 19734545 rs969962 chr13 88762346 C T 9.00E-06 Cognitive performance / / 19734545 rs4772631 chr13 88764864 A G 7.40E-04 Parkinson's disease / / 16252231 rs9558415 chr13 88770740 T C 7.68E-04 Body mass index / / 21701565 rs1834719 chr13 88770858 C A 2.80E-05 Urinary metabolites / / 21572414 rs1834719 chr13 88770858 C A 7.56E-04 Body mass index / / 21701565 rs9555127 chr13 88791291 A G 8.96E-04 Coronary Artery Disease / / 17634449 rs1072378 chr13 88798811 C T 7.50E-05 Glycosylated haemoglobin levels / / 17255346 rs1582815 chr13 88799243 G A 1.48E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs7334500 chr13 88807658 G T 5.13E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1333809 chr13 88823227 A G 2.21E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs16967807 chr13 88874373 G A 5.90E-06 Urinary metabolites / / 21572414 rs16967807 chr13 88874373 G A 2.42E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16967900 chr13 88877803 C T 4.66E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs4424782 chr13 88880421 G A 1.58E-04 Glycosylated haemoglobin levels / / 17255346 rs9583067 chr13 88892802 A G 1.66E-04 Glycosylated haemoglobin levels / / 17255346 rs9555216 chr13 88892954 T C 1.55E-04 Glycosylated haemoglobin levels / / 17255346 rs7339189 chr13 88893107 G T 2.36E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4477550 chr13 88896805 G A 8.60E-06 Urinary metabolites / / 21572414 rs4278614 chr13 88904350 T C 2.69E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs9558735 chr13 88910106 T C 1.17E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs202216875 chr13 88942502 AT A 1.26E-04 Glycosylated haemoglobin levels / / 17255346 rs9555256 chr13 88942502 A G 1.26E-04 Glycosylated haemoglobin levels / / 17255346 rs9520317 chr13 89002387 T C 8.31E-04 Smoking initiation / / 24665060 rs7317281 chr13 89005444 A G 1.43E-04 Smoking initiation / / 24665060 rs2783202 chr13 89013764 A G 4.55E-04 Smoking initiation / / 24665060 rs1074201 chr13 89017647 G A 3.84E-07 Statin-induced myopathy / / 21826682 rs338741 chr13 89024299 C T 7.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs338741 chr13 89024299 C T 5.25E-04 Smoking initiation / / 24665060 rs1020684 chr13 89051540 T G 2.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9520570 chr13 89059635 A T 4.21E-04 Fibrinogen / / 17255346 rs1334180 chr13 89063400 A G 1.85E-04 Multiple complex diseases / / 17554300 rs454007 chr13 89106210 A G 4.38E-04 Body mass index / / 17255346 rs338768 chr13 89127135 T G 2.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs338768 chr13 89127135 T G 7.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs674644 chr13 89140402 T C 5.80E-06 Urinary metabolites / / 21572414 rs519700 chr13 89164320 T C 9.06E-07 Autism / / 22843504 rs9521107 chr13 89179212 G A 4.30E-05 Lung function (forced vital capacity) / / 24023788 rs9521140 chr13 89189649 A G 5.05E-05 Lung function (forced vital capacity) / / 24023788 rs17659795 chr13 89195944 A G 3.05E-05 Heart Rate / / pha003054 rs8002245 chr13 89221776 C T 2.71E-05 Heart Rate / / pha003054 rs9587857 chr13 89224649 G A 2.12E-05 Heart Rate / / pha003054 rs2148430 chr13 89356442 T A 0.0000054 Mean arterial pressure / / 22510845 rs9515485 chr13 89474983 A G 4.03E-05 Serum metabolites / / 19043545 rs2808825 chr13 89489268 T C 4.64E-05 Brain structure / / 22504417 rs1336938 chr13 89571005 C A 1.60E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs796184 chr13 89717430 C T 1.90E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs1831434 chr13 89773664 A T 7.33E-05 Serum metabolites / / 19043545 rs2120871 chr13 89858500 A G 9.39E-05 Pancreatic cancer / / pha002874 rs314530 chr13 89921892 C A 0.00076 Prostate cancer / / 23555315 rs4773467 chr13 89978834 A G 1.06E-04 White matter integrity / / 22425255 rs2202322 chr13 89993752 T C 1.06E-04 White matter integrity / / 22425255 rs12854092 chr13 90008600 A C 1.52E-04 White matter integrity / / 22425255 rs1330944 chr13 90057665 G A 2.90E-05 Urinary metabolites / / 21572414 rs12871802 chr13 90061742 A C 0.00007567 Sarcoidosis / / 22952805 rs35001513 chr13 90067654 A G 0.00008675 Sarcoidosis / / 22952805 rs61958047 chr13 90068241 A G 0.00008675 Sarcoidosis / / 22952805 rs17394343 chr13 90071992 G T 0.00008675 Sarcoidosis / / 22952805 rs12874340 chr13 90074385 A C 0.00008675 Sarcoidosis / / 22952805 rs12873054 chr13 90074534 G A 0.00008675 Sarcoidosis / / 22952805 rs36063115 chr13 90078335 G A 0.00007522 Sarcoidosis / / 22952805 rs2102239 chr13 90081022 G A 0.00007522 Sarcoidosis / / 22952805 rs17394575 chr13 90081454 T C 0.00007522 Sarcoidosis / / 22952805 rs12866211 chr13 90082191 A T 0.00006603 Sarcoidosis / / 22952805 rs71444037 chr13 90083050 G A 0.00006309 Sarcoidosis / / 22952805 rs868919 chr13 90202055 T C 7.40E-05 Response to statin therapy / / 20339536 rs868919 chr13 90202055 T C 6.60E-04 Tourette syndrome / / 22889924 rs17630679 chr13 90202273 A G 8.10E-05 Response to statin therapy / / 20339536 rs9588656 chr13 90224633 A G 4.26E-04 Multiple complex diseases / / 17554300 rs883616 chr13 90230057 A G 7.87E-04 Multiple complex diseases / / 17554300 rs1201324 chr13 90253979 A G 3.93E-30 Narcolepsy / / 19629137 rs9634611 chr13 90256174 G T 2.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs7994475 chr13 90257706 G A 2.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs2209733 chr13 90259062 G A 6.22E-05 Type 2 diabetes / / 17463246 rs2655738 chr13 90259291 A G 6.91E-05 Sickle cell anemia (severity) / / 20029952 rs1948851 chr13 90260640 G T 8.59E-05 Blood Pressure / / pha003049 rs17549047 chr13 90263963 T C 1.66E-04 Amyotrophic lateral sclerosis / / 20801718 rs2768274 chr13 90274219 A G 8.89E-06 Post-operative nausea and vomiting / / 21694509 rs17630983 chr13 90274688 A G 1.99E-04 Type 2 diabetes / / 17463246 rs994066 chr13 90283758 C G 1.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs9560407 chr13 90288816 A G 1.79E-04 Suicide attempts in bipolar disorder / / 21041247 rs9522598 chr13 90289165 C T 6.22E-05 Blood Pressure / / pha003049 rs9555925 chr13 90292501 T C 1.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs9555926 chr13 90292531 G A 1.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs9301602 chr13 90309400 A T 4.32E-05 Cholesterol / / 17255346 rs6492439 chr13 90322929 T C 4.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs1327342 chr13 90323162 G C 1.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs4280104 chr13 90323195 T C 7.00E-04 Type 2 diabetes / / 17463246 rs1007241 chr13 90338898 G T 3.85E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1007241 chr13 90338898 G T 1.16E-05 Blood Pressure / / pha003049 rs9560417 chr13 90361716 A G 2.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs369223 chr13 90387808 A G 4.26E-04 Smoking cessation / / 24665060 rs9588748 chr13 90408366 A G 4.32E-05 Brain structure / / 22504417 rs317962 chr13 90409398 C T 1.92E-04 Smoking cessation / / 24665060 rs7329978 chr13 90420831 A G 4.19E-04 Suicide attempts in bipolar disorder / / 21041247 rs6492451 chr13 90422996 T C 4.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs7984054 chr13 90423293 C A,G,T 4.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs7990145 chr13 90424245 C G 3.94E-04 Smoking cessation / / 24665060 rs9301615 chr13 90431523 A G 1.78E-05 Smoking cessation / / 24665060 rs9515626 chr13 90432619 G A 8.52E-04 Obesity (extreme) / / 21935397 rs17550263 chr13 90433054 C T 8.18E-04 Obesity (extreme) / / 21935397 rs4773517 chr13 90433602 A T 8.20E-04 Obesity (extreme) / / 21935397 rs4773520 chr13 90433709 G A 8.25E-04 Obesity (extreme) / / 21935397 rs4773523 chr13 90434137 C T 3.68E-04 Smoking cessation / / 24665060 rs3939465 chr13 90436445 A C 8.74E-05 Personality dimensions / / 18957941 rs117708460 chr13 90451055 G A 0.0000558 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9515642 chr13 90505140 A G 6.97E-05 Lung cancer / / 18978787 rs953937 chr13 90522970 T C 3.00E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs7318897 chr13 90541300 G T 8.48E-05 Bipolar disorder / / 17486107 rs9515652 chr13 90541852 A G 7.35E-04 Response to TNF antagonist treatment / / 21061259 rs34773747 chr13 90569808 T TC 1.40E-04 Urinary metabolites / / 21572414 rs17551413 chr13 90576515 T C 6.02E-04 Acute lung injury / / 22295056 rs2882281 chr13 90622455 C G 1.00E-06 Longevity / / 20834067 rs9588824 chr13 90633423 A G 2.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs41322051 chr13 90646840 A G 9.98E-04 Type 2 diabetes / / 17463246 rs1491005 chr13 90689775 C T 4.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs9583770 chr13 90691075 G A 8.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs2637385 chr13 90694767 A C 5.39E-06 Sickle cell anemia (severity) / / 20029952 rs1491029 chr13 90703001 G A 2.73E-05 Bilirubin levels,in serum / / 19389676 rs9583775 chr13 90703298 G A 4.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs17722514 chr13 90713945 C T 3.14E-05 Attention deficit hyperactivity disorder / / 18980221 rs17722514 chr13 90713945 C T 5.14E-05 Attention deficit hyperactivity disorder / / pha002875 rs2805689 chr13 90715153 T G 3.29E-08 Metabolite levels / / 23281178 rs1491024 chr13 90715598 A G 9.99E-08 Metabolite levels / / 23281178 rs7325881 chr13 90762728 T C 2.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs7325881 chr13 90762728 T C 3.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs1388193 chr13 90767616 C T 0.000065 Pancreatic cancer and survival / / 22665904 rs9588875 chr13 90768248 T A 2.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs9588875 chr13 90768248 T A 4.21E-04 Suicide attempts in bipolar disorder / / 21041247 rs9805500 chr13 90768888 C T 2.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs9805500 chr13 90768888 C T 4.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs9583789 chr13 90771595 T C 6.47E-04 Smoking initiation / / 24665060 rs16944141 chr13 90865546 G A 8.53E-04 Multiple complex diseases / / 17554300 rs16944141 chr13 90865546 G A 3.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs2151588 chr13 90889233 T C 4.13E-04 Smoking quantity / / 24665060 rs12430757 chr13 90896884 A C 3.61E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12853685 chr13 90904839 G A 6.97E-05 Post-operative nausea and vomiting / / 21694509 rs17732411 chr13 90907803 T G 3.24E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7328705 chr13 90922824 G T 7.96E-04 Smoking cessation / / 24665060 rs9522935 chr13 90992534 G A 2.97E-04 Parkinson's disease / / 17052657 rs16944443 chr13 90998646 A C 0.00000407 Common carotid artery thickness (near walls) / / 23487405 rs12855016 chr13 91036455 C T 4.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12855016 chr13 91036455 C T 5.58E-05 Triglycerides / / pha003080 rs1325330 chr13 91048937 C A 4.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4540941 chr13 91069886 G A 2.30E-05 Urinary metabolites / / 21572414 rs7323450 chr13 91077023 C T 3.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9515742 chr13 91085354 G A 1.90E-04 Myasthenia gravis / / 23055271 rs7983386 chr13 91101943 T C 8.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9560635 chr13 91138220 T C 8.63E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs9560635 chr13 91138220 T C 5.49E-05 Lung function (forced vital capacity) / / pha003104 rs9301680 chr13 91151095 C T 7.98E-04 Type 2 diabetes / / 17463246 rs9515763 chr13 91162369 A C 8.29E-04 Type 2 diabetes / / 17463246 rs1888299 chr13 91185377 A G 1.28E-04 Telomere length / / 21573004 rs1929045 chr13 91188066 A G 7.72E-05 Neutrophil count / / pha003095 rs1929035 chr13 91203410 C T 7.09E-05 Lymphocyte counts / / pha003094 rs2183487 chr13 91224068 G A 0.0008514 Sarcoidosis / / 22952805 rs17553281 chr13 91226105 A T 3.25E-05 Depression (quantitative trait) / / 23290196 rs982790 chr13 91231773 C T 1.04E-04 Rheumatoid arthritis / / 21452313 rs982790 chr13 91231773 C T 8.87E-04 Coronary heart disease / / 21971053 rs9523030 chr13 91262300 T G 6.82E-04 Coronary heart disease / / 21971053 rs9583818 chr13 91264373 C T 4.75E-04 Multiple complex diseases / / 17554300 rs12584186 chr13 91336218 G A 4.72E-04 Multiple complex diseases / / 17554300 rs9301688 chr13 91412354 G T 9.66E-04 Type 2 diabetes / / 17463246 rs1332470 chr13 91417190 T C 6.99E-04 Taste perception / / 22132133 rs7997607 chr13 91458798 G T 1.57E-04 Birth weight / / 17255346 rs1572316 chr13 91462736 C T 8.90E-05 Birth weight / / 17255346 rs1572316 chr13 91462736 C T 4.36E-04 Multiple complex diseases / / 17554300 rs16944804 chr13 91463947 G C 6.80E-04 Multiple complex diseases / / 17554300 rs1335568 chr13 91486371 A G 7.59E-05 Cognitive test performance / / 20125193 rs9583834 chr13 91491689 T C 1.16E-04 Birth weight / / 17255346 rs9583835 chr13 91491721 T C 3.05E-04 Birth weight / / 17255346 rs9523165 chr13 91539735 T C 2.90E-04 Obesity,menopause / / 21424828 rs9589039 chr13 91547399 T G 0.00059126 Hypertension (early onset hypertension) LINC00410 intron 22479346 rs272093 chr13 91589940 C T 8.59E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9556062 chr13 91710986 G A 2.73E-04 Birth weight / / 17255346 rs7985964 chr13 91718880 C G 1.18E-04 Multiple complex diseases / / 17554300 rs61970269 chr13 91732770 A T 3.00E-06 Metabolite levels (5-HIAA) / / 23319000 rs1380336 chr13 91733167 C T 0.0003092 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1380336 chr13 91733167 C T 3.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12584748 chr13 91745197 G A 4.60E-05 Recombination rate / / 21698098 rs9560761 chr13 91763252 G C 0.0004367 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9560761 chr13 91763252 G C 4.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs515097 chr13 91769463 G T 2.48E-04 Type 2 diabetes / / 17463246 rs515097 chr13 91769463 G T 5.45E-05 Coronary heart disease / / pha003032 rs1174784 chr13 91772555 T C 7.05E-05 Coronary heart disease / / pha003032 rs684050 chr13 91780072 T C 3.12E-04 Type 2 diabetes / / 17463246 rs623637 chr13 91785866 G A 3.08E-04 Type 2 diabetes / / 17463246 rs76384 chr13 91793239 G A 6.91E-04 Type 2 diabetes / / 17463246 rs613553 chr13 91793753 C T 5.45E-04 Type 2 diabetes / / 17463246 rs287516 chr13 91803761 A G 6.06E-04 Type 2 diabetes / / 17463246 rs287514 chr13 91804188 T C 9.90E-04 Type 2 diabetes / / 17463246 rs7337223 chr13 91818095 C T 9.11E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs7984041 chr13 91820774 G A 9.11E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs167004 chr13 91845679 G C 4.01E-04 Type 2 diabetes / / 17463246 rs167004 chr13 91845679 G C 6.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7358999 chr13 91853436 G A 7.74E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9583901 chr13 91886715 C T 2.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9583901 chr13 91886715 C T 5.55E-04 Type 2 diabetes / / 22158537 rs7336176 chr13 91907475 A G 5.74E-05 Coronary heart disease / / pha003056 rs7336314 chr13 91914361 A G 2.61E-05 Coronary heart disease / / pha003056 rs16945688 chr13 91918799 G A 1.90E-06 Coronary heart disease / / pha003056 rs1330066 chr13 91926396 A G 5.06E-04 Myocardial Infarction / / pha002873 rs11619854 chr13 91949384 C T 5.80E-04 Smoking quantity / / 24665060 rs9523296 chr13 91949444 G A 3.82E-04 Multiple complex diseases / / 17554300 rs9515905 chr13 91949562 A G 3.98E-04 Multiple complex diseases / / 17554300 rs7986895 chr13 91950114 C A 3.87E-04 Multiple complex diseases / / 17554300 rs7994634 chr13 91953042 C T 4.30E-04 Multiple complex diseases / / 17554300 rs7491314 chr13 91953120 A G 3.84E-05 Multiple complex diseases / / 17554300 rs7989842 chr13 91956038 G T 3.03E-04 Multiple complex diseases / / 17554300 rs9589196 chr13 91974740 C T 5.32E-04 Smoking quantity / / 24665060 rs6492538 chr13 91993746 A C 0.0000488 Placental abruption / / 23205182 rs7322734 chr13 91994025 A G 3.53E-04 Alzheimer's disease / / 17998437 rs11842349 chr13 91995936 G A 4.66E-04 Alzheimer's disease / / 17998437 rs17667894 chr13 92014309 A G 7.83E-08 Multiple complex diseases / / 17554300 rs8002779 chr13 92015977 G A 3.00E-06 Height / / 20189936 rs8002779 chr13 92015977 G A 1.15E-04 Intracranial aneurysm / / 22286173 rs4773624 chr13 92019729 G A 0.0000078 Placental abruption / / 23205182 rs9523313 chr13 92020042 G A 4.30E-04 Multiple complex diseases / / 17554300 rs7319045 chr13 92024574 A G 1.00E-11 Height / / 20881960 rs4771831 chr13 92025752 G A 3.51E-04 Smoking quantity / / 24665060 rs7983063 chr13 92034062 G A 2.43E-04 Multiple complex diseases / / 17554300 rs1324062 chr13 92056911 T C 5.43E-05 Multiple complex diseases GPC5 intron 17554300 rs9523328 chr13 92058020 A C 8.60E-05 Multiple complex diseases GPC5 intron 17554300 rs9523330 chr13 92061878 G A 1.79E-04 Smoking quantity GPC5 intron 24665060 rs9589219 chr13 92063955 T C 8.70E-05 Hypothyroidism GPC5 intron 22493691 rs17668235 chr13 92076524 A G 2.00E-04 Cognitive impairment induced by topiramate GPC5 intron 22091778 rs4773630 chr13 92094974 G A 6.68E-04 Insulin resistance GPC5 intron 21901158 rs9560800 chr13 92108700 A C 5.87E-05 Insulin resistance GPC5 intron 21901158 rs494371 chr13 92150929 G A 3.30E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GPC5 intron 22566498 rs9589285 chr13 92192744 C A 1.18E-04 Multiple complex diseases GPC5 intron 17554300 rs16946160 chr13 92203813 G A 3.00E-07 Nephrotic syndrome (acquired) GPC5 intron 21441931 rs9523360 chr13 92204537 A G 5.75E-04 White matter integrity GPC5 intron 22425255 rs1414720 chr13 92210051 G A 6.43E-05 Coronary heart disease GPC5 intron pha003031 rs9589295 chr13 92220692 G A 5.34E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GPC5 intron 22566498 rs7981964 chr13 92221715 C T 9.93E-04 Insulin resistance GPC5 intron 21901158 rs17420943 chr13 92262991 C T 7.27E-04 Smoking initiation GPC5 intron 24665060 rs10492614 chr13 92283332 A G 7.72E-04 White matter integrity GPC5 intron 22425255 rs16946406 chr13 92303608 C T 8.33E-05 Multiple complex diseases GPC5 intron 17554300 rs560759 chr13 92345275 C G 2.49E-04 Aortic root size GPC5 intron 21223598 rs462954 chr13 92371090 A G 3.83E-04 Schizophrenia GPC5 intron 19197363 rs9523398 chr13 92372552 G A 1.24E-04 Response to alcohol consumption (flushing response) GPC5 intron 24277619 rs2174504 chr13 92410270 A C 4.87E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) GPC5 intron 24023788 rs2352028 chr13 92445229 C T 6.00E-06 Lung cancer GPC5 intron 20304703 rs16951984 chr13 92468364 G A 1.24E-06 Obesity-related traits GPC5 intron 23251661 rs7328464 chr13 92501664 C T 3.46E-04 White matter integrity GPC5 intron 22425255 rs7328464 chr13 92501664 C T 4.00E-07 Obesity-related traits GPC5 intron 23251661 rs7328464 chr13 92501664 C T 5.00E-06 Obesity-related traits GPC5 intron 23251661 rs7984514 chr13 92507887 G A 2.72E-04 White matter integrity GPC5 intron 22425255 rs7981515 chr13 92523014 G T 9.41E-07 Obesity-related traits GPC5 intron 23251661 rs9523451 chr13 92574422 A G 7.00E-06 Urinary metabolites GPC5 intron 21572414 rs7327372 chr13 92579249 C A 1.20E-05 Progressive supranuclear palsy GPC5 intron 21685912 rs2352195 chr13 92584162 T C 3.40E-06 Urinary metabolites GPC5 intron 21572414 rs12184638 chr13 92629857 A G 9.41E-05 Progressive supranuclear palsy GPC5 intron 21685912 rs41516148 chr13 92701666 G A 5.73E-04 Multiple complex diseases GPC5 intron 17554300 rs1411741 chr13 92753852 A G 4.13E-33 Narcolepsy GPC5 intron 19629137 rs9523513 chr13 92781385 T C 7.54E-04 Suicide attempts in bipolar disorder GPC5 intron 21423239 rs9560935 chr13 92792688 G A 8.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GPC5 intron 20877124 rs7984422 chr13 92808689 G A 9.13E-05 Attention deficit hyperactivity disorder GPC5 intron 22012869 rs6492589 chr13 92822102 T G 0.000569 Salmonella-induced pyroptosis GPC5 intron 22837397 rs2209651 chr13 92868073 C T 2.46E-04 Alzheimer's disease (late onset) GPC5 intron 21379329 rs9560988 chr13 92879723 C T 4.82E-04 Alzheimer's disease (late onset) GPC5 intron 21379329 rs7987675 chr13 92884370 C T 1 Drug response to Response to Interferon Beta Therapy GPC5 intron 19556317 rs1411751 chr13 92897508 G A 4.27E-04 Alzheimer's disease (late onset) GPC5 intron 21379329 rs9301789 chr13 92902903 T C 1.00E-04 Response to interferon beta in multiple sclerosis GPC5 intron 18195134 rs7327268 chr13 92924849 T C 2.74E-04 Multiple complex diseases GPC5 intron 17554300 rs9523575 chr13 92924969 A G 3.30E-04 Multiple complex diseases GPC5 intron 17554300 rs9523597 chr13 92941096 G A 5.01E-04 Urinary albumin excretion rate in type 1 diabetes GPC5 intron 24595857 rs1887156 chr13 92955371 G A 4.25E-05 Glucose levels GPC5 intron pha003061 rs7327328 chr13 92961151 A G 4.86E-05 Glucose levels GPC5 intron pha003061 rs716623 chr13 92981922 A G 5.26E-05 Alcohol and nictotine co-dependence GPC5 intron 20158304 rs4351927 chr13 92983668 C T 6.62E-04 Multiple complex diseases GPC5 intron 17554300 rs7982677 chr13 92988323 C A 3.00E-09 Tetralogy of Fallot GPC5 intron 23297363 rs4771856 chr13 92994509 C A 2.77E-07 Tetralogy of Fallot GPC5 intron 23297363 rs4771859 chr13 93088651 T C 1.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) GPC5 intron 23648065 rs2374015 chr13 93108320 G T 1.96E-04 Myopia (pathological) GPC5 intron 21095009 rs2374016 chr13 93108341 T C 1.03E-04 Myopia (pathological) GPC5 intron 21095009 rs12863416 chr13 93133782 A G 1.80E-05 Urinary metabolites GPC5 intron 21572414 rs9523707 chr13 93185910 T C 7.60E-04 Multiple complex diseases GPC5 intron 17554300 rs1413191 chr13 93213476 C T 5.00E-06 HIV-1 viral setpoint GPC5 intron 20205591 rs6492619 chr13 93258153 C T 8.76E-04 HIV-1 viral setpoint GPC5 intron 17641165 rs11840143 chr13 93284661 T C 1.06E-04 HIV-1 viral setpoint GPC5 intron 17641165 rs9523736 chr13 93284783 G T 1.25E-05 HIV-1 viral setpoint GPC5 intron 17641165 rs17267257 chr13 93302967 A C 5.56E-05 Serum metabolites GPC5 intron 19043545 rs17267257 chr13 93302967 A C 1.50E-05 Urinary metabolites GPC5 intron 21572414 rs9516112 chr13 93318138 T C 5.88E-04 Suicide attempts in bipolar disorder GPC5 intron 21423239 rs6492626 chr13 93319347 T A 7.64E-04 Suicide attempts in bipolar disorder GPC5 intron 21423239 rs10507991 chr13 93319687 C G 4.62E-06 Serum metabolites GPC5 intron 19043545 rs10507992 chr13 93319713 C T 4.96E-06 Serum metabolites GPC5 intron 19043545 rs10507993 chr13 93319737 A G 4.62E-06 Serum metabolites GPC5 intron 19043545 rs17267292 chr13 93323146 T C 1.00E-07 Metabolite levels GPC5 intron 19043545 rs17188557 chr13 93323269 A G 1.62E-05 Serum metabolites GPC5 intron 19043545 rs9523762 chr13 93331886 G A 1.00E-06 Multiple sclerosis GPC5 intron 19010793 rs1831867 chr13 93348178 A C 1.20E-05 Urinary metabolites GPC5 intron 21572414 rs10507995 chr13 93380513 T C 2.15E-05 Amyotrophic lateral sclerosis (sporadic) GPC5 intron 24529757 rs11842684 chr13 93396655 T G 8.79E-04 Stroke GPC5 intron pha002886 rs6492627 chr13 93418354 C T 9.45E-04 Type 2 diabetes GPC5 intron 17463246 rs1409263 chr13 93425642 C T 4.42E-04 Multiple complex diseases GPC5 intron 17554300 rs1409264 chr13 93425688 C A 4.93E-04 Multiple complex diseases GPC5 intron 17554300 rs7988257 chr13 93465539 C A 9.77E-07 Longevity,exceptional GPC5 intron 20595579 rs2148229 chr13 93483546 C A,G,T 4.06E-06 Body mass index GPC5 intron 22446040 rs2148229 chr13 93483546 C A,G,T 8.15E-04 Oral cancers (chewing tobacco related) GPC5 intron 22503698 rs9561179 chr13 93501013 A G 3.39E-05 Multiple complex diseases GPC5 intron 17554300 rs9523844 chr13 93574985 A C 4.33E-04 Alzheimer's disease / / 17998437 rs9523845 chr13 93575280 A G 5.03E-04 Alzheimer's disease / / 17998437 rs9523848 chr13 93581791 G T 3.00E-06 Breast size / / 22747683 rs1762792 chr13 93591750 G A 2.60E-05 Body mass index / / 22446040 rs9634630 chr13 93623240 A G 3.02E-04 Type 2 diabetes / / 17463246 rs3906867 chr13 93657802 A G 6.77E-04 Type 2 diabetes / / 17463246 rs160141 chr13 93662235 T C 1.00E-04 Adverse response to radiation therapy / / 23719583 rs1444227 chr13 93699203 G C 6.92E-04 Type 2 diabetes / / 17463246 rs1444227 chr13 93699203 G C 3.60E-05 Malaria / / 19465909 rs1158878 chr13 93712869 G A 3.90E-04 Type 2 diabetes / / 17463246 rs1158878 chr13 93712869 G A 4.20E-05 Malaria / / 19465909 rs11616856 chr13 93748609 T C 1.16E-04 Smoking cessation / / 24665060 rs7327794 chr13 93749624 G A 7.58E-04 Type 2 diabetes / / 17463246 rs160816 chr13 93751957 G A 9.20E-05 Alcohol consumption (maxi-drinks) / / 24277619 rs317305 chr13 93802656 C T 2.22E-04 Multiple complex diseases / / 17554300 rs319533 chr13 93814026 T C 6.92E-05 Bipolar disorder / / 17486107 rs319533 chr13 93814026 T C 8.32E-05 Multiple complex diseases / / 17554300 rs400337 chr13 93840053 T G 6.88E-05 Weight / / pha003027 rs445297 chr13 93855553 C T 5.88E-05 Multiple complex diseases / / 17554300 rs16948474 chr13 93869136 C A 8.20E-04 Multiple complex diseases / / 17554300 rs17702471 chr13 93877117 A G 1.48E-04 Longevity GPC6 nearGene-5 22279548 rs7985891 chr13 93879031 A G 2.00E-07 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy) GPC6 nearGene-5 24554482 rs1116260 chr13 93890670 G A 2.00E-06 Tonometry GPC6 intron 17903302 rs1116260 chr13 93890670 G A 2.00E-06 Tonometry GPC6 intron 17903302 rs16948547 chr13 93914063 A G 7.25E-04 Multiple complex diseases GPC6 intron 17554300 rs9589698 chr13 93924965 C T 1.30E-04 Suicidal ideation GPC6 intron 22030708 rs9523990 chr13 93929464 C T 1.53E-05 Sleep duration GPC6 intron 22105623 rs9523991 chr13 93929968 G A 1.49E-05 Sleep duration GPC6 intron 22105623 rs9523993 chr13 93930403 A G 8.22E-04 Type 2 diabetes GPC6 intron 17463246 rs9523996 chr13 93934631 C T 6.39E-04 Type 2 diabetes GPC6 intron 17463246 rs4142598 chr13 93935675 C T 1.66E-05 Sleep duration GPC6 intron 22105623 rs11839514 chr13 93938706 A G 4.00E-06 Visceral fat GPC6 intron 22589738 rs9523998 chr13 93939986 G A 2.43E-05 Sleep duration GPC6 intron 22105623 rs2025949 chr13 93944277 C T 1.20E-04 Suicidal ideation GPC6 intron 22030708 rs143258881 chr13 93945858 A T 7.00E-08 Alzheimer's disease (cognitive decline) GPC6 intron 23535033 rs9561305 chr13 93965579 G A 9.43E-04 Type 2 diabetes GPC6 intron 17463246 rs9561329 chr13 94011169 A G 1.00E-07 Neuroticism GPC6 intron 20634892 rs2038727 chr13 94074425 A G 8.20E-06 Urinary metabolites GPC6 intron 21572414 rs2762089 chr13 94087948 T A 9.69E-05 Depression (quantitative trait) GPC6 intron 23290196 rs1373834 chr13 94095160 A G 8.01E-05 Depression (quantitative trait) GPC6 intron 23290196 rs9524069 chr13 94097045 C A 6.94E-05 Depression (quantitative trait) GPC6 intron 23290196 rs9516233 chr13 94097301 C T 6.69E-05 Depression (quantitative trait) GPC6 intron 23290196 rs7992272 chr13 94097508 T G 1.34E-04 Response to cytidine analogues (gemcitabine) GPC6 intron 24483146 rs973303 chr13 94101539 G T 7.31E-05 Depression (quantitative trait) GPC6 intron 23290196 rs4412846 chr13 94101658 A T 7.84E-05 Depression (quantitative trait) GPC6 intron 23290196 rs2590556 chr13 94110198 C T 7.75E-04 Response to cytidine analogues (gemcitabine) GPC6 intron 24483146 rs974542 chr13 94119050 G A 8.06E-04 Multiple complex diseases GPC6 intron 17554300 rs9561361 chr13 94132998 G A 2.00E-04 Cognitive impairment induced by topiramate GPC6 intron 22091778 rs9516244 chr13 94155373 C A 1.86E-05 Cognitive impairment induced by topiramate GPC6 intron 22091778 rs9516245 chr13 94159800 T C 4.88E-04 Smoking initiation GPC6 intron 24665060 rs12184868 chr13 94161295 G A 1.96E-04 Multiple complex diseases GPC6 intron 17554300 rs7987887 chr13 94185296 T C 4.30E-07 Urinary metabolites GPC6 intron 21572414 rs3858839 chr13 94188119 A G 1.07E-04 Multiple complex diseases GPC6 intron 17554300 rs7317039 chr13 94192329 T C 3.80E-07 Urinary metabolites GPC6 intron 21572414 rs9524126 chr13 94200230 G T 6.04E-05 Cognitive impairment induced by topiramate GPC6 intron 22091778 rs3814275 chr13 94204243 G T 1.70E-07 Urinary metabolites GPC6 intron 21572414 rs9516255 chr13 94204904 C T 5.11E-04 Smoking initiation GPC6 intron 24665060 rs190494527 chr13 94208649 A G 7.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) GPC6 intron 24159190 rs9524131 chr13 94209956 T C 2.66E-05 Diabetes (gestational) GPC6 intron 22233651 rs7998314 chr13 94233129 A C 4.00E-07 Obesity-related traits GPC6 intron 23251661 rs7998314 chr13 94233129 A C 4.00E-07 Obesity-related traits GPC6 intron 23251661 rs7998314 chr13 94233129 A C 7.00E-07 Obesity-related traits GPC6 intron 23251661 rs9788393 chr13 94244337 G A 2.15E-06 Obesity-related traits GPC6 intron 23251661 rs9524154 chr13 94291902 T G 1.90E-05 Intelligence GPC6 intron 21826061 rs9524154 chr13 94291902 T G 9.72E-05 Hemoglobin GPC6 intron pha003098 rs9524157 chr13 94294144 A G 8.09E-05 Monocyte counts GPC6 intron pha003089 rs12585404 chr13 94312395 C A 2.38E-04 Obesity (extreme) GPC6 intron 21935397 rs7323912 chr13 94330109 C T 2.10E-05 Suicide attempts in bipolar disorder GPC6 intron 21423239 rs9561428 chr13 94341096 G A 9.00E-06 Bipolar disorder and schizophrenia GPC6 intron 20889312 rs9561428 chr13 94341096 G A 1.68E-04 Obesity (extreme) GPC6 intron 21935397 rs11839972 chr13 94345658 T C 1.78E-04 Suicide attempts in bipolar disorder GPC6 intron 21423239 rs7331448 chr13 94369759 A G 4.31E-04 Suicide attempts in bipolar disorder GPC6 intron 21423239 rs7985749 chr13 94373597 C A 1.12E-04 Suicide attempts in bipolar disorder GPC6 intron 21423239 rs16949138 chr13 94373954 A G 1.11E-04 Suicide attempts in bipolar disorder GPC6 intron 21423239 rs16949141 chr13 94374000 C G,T 5.97E-04 Suicide attempts in bipolar disorder GPC6 intron 21423239 rs17468092 chr13 94374302 A C 1.10E-04 Suicide attempts in bipolar disorder GPC6 intron 21423239 rs9561432 chr13 94376798 G T 1.42E-04 Obesity (extreme) GPC6 intron 21935397 rs11840833 chr13 94378307 T C 4.01E-05 Suicide attempts in bipolar disorder GPC6 intron 21423239 rs9301901 chr13 94382550 A G 1.41E-04 Obesity (extreme) GPC6 intron 21935397 rs16949153 chr13 94384580 T C 2.61E-05 Suicide attempts in bipolar disorder GPC6 intron 21423239 rs4144545 chr13 94385361 T C 5.57E-04 Suicide attempts in bipolar disorder GPC6 intron 21423239 rs4394948 chr13 94387877 C T 5.53E-04 Insulin resistance GPC6 intron 21901158 rs9589817 chr13 94388202 G A 9.63E-05 Suicide attempts in bipolar disorder GPC6 intron 21423239 rs9561435 chr13 94396514 C G 1.39E-04 Obesity (extreme) GPC6 intron 21935397 rs6492676 chr13 94398942 A G 8.75E-04 Multiple complex diseases GPC6 intron 17554300 rs4366594 chr13 94405336 G A 1.98E-04 Amyotrophic lateral sclerosis GPC6 intron 20801718 rs9524193 chr13 94406845 C T 5.95E-04 Response to cytadine analogues (cytosine arabinoside) GPC6 intron 24483146 rs7995215 chr13 94408506 A G 1.00E-08 Attention deficit hyperactivity disorder GPC6 intron 18839057 rs4612931 chr13 94424196 T G 7.85E-04 Obesity (extreme) GPC6 intron 21935397 rs9561441 chr13 94426306 G A 7.88E-04 Obesity (extreme) GPC6 intron 21935397 rs9556323 chr13 94426462 G A 7.93E-04 Obesity (extreme) GPC6 intron 21935397 rs9301908 chr13 94431085 A G 6.64E-04 Insulin resistance GPC6 intron 21901158 rs3759423 chr13 94445177 C T 2.77E-04 Insulin resistance GPC6 intron 21901158 rs9301909 chr13 94449198 G A 2.14E-05 Abdominal aortic aneurysm GPC6 intron 24046328 rs7317144 chr13 94455981 G A 7.96E-04 Insulin resistance GPC6 intron 21901158 rs2892667 chr13 94456939 A G 1.73E-04 Abdominal aortic aneurysm GPC6 intron 22055160 rs2892667 chr13 94456939 A G 2.56E-05 Abdominal aortic aneurysm GPC6 intron 24046328 rs12100033 chr13 94477025 C T 3.40E-04 Suicide attempts in bipolar disorder GPC6 intron 21423239 rs16949291 chr13 94479976 G A 3.05E-04 Suicide attempts in bipolar disorder GPC6 intron 21423239 rs9524249 chr13 94483733 A C 2.34E-05 Abdominal aortic aneurysm GPC6 intron 24046328 rs1330458 chr13 94490519 C T 6.53E-04 Multiple complex diseases GPC6 intron 17554300 rs1330458 chr13 94490519 C T 7.94E-05 Leukocyte Counts GPC6 intron pha003091 rs1330458 chr13 94490519 C T 4.58E-07 Platelet counts GPC6 intron pha003100 rs2150127 chr13 94491060 A G 6.37E-08 Suicide attempts in bipolar disorder GPC6 intron 21423239 rs12429608 chr13 94509576 T A 2.44E-05 Multiple complex diseases GPC6 intron 17554300 rs9524260 chr13 94513790 A G 2.70E-04 Primary sclerosing cholangitis GPC6 intron 19944697 rs1952699 chr13 94518225 T C 1.43E-06 Suicide attempts in bipolar disorder GPC6 intron 21423239 rs1411513 chr13 94519950 G A 2.55E-05 Abdominal aortic aneurysm GPC6 intron 24046328 rs9524264 chr13 94528418 A C 6.59E-05 Abdominal aortic aneurysm GPC6 intron 24046328 rs9561465 chr13 94558112 T G 8.31E-04 Obesity (extreme) GPC6 intron 21935397 rs878765 chr13 94589164 A G 2.84E-05 Amyotrophic lateral sclerosis GPC6 intron 20801717 rs7325794 chr13 94610876 T C 3.22E-06 Insulin-related traits GPC6 intron 22791750 rs4528446 chr13 94612412 T C 3.02E-06 Insulin-related traits GPC6 intron 22791750 rs9584175 chr13 94632164 A G 1.18E-06 Insulin-related traits GPC6 intron 22791750 rs9524298 chr13 94632820 G A 7.85E-07 Insulin-related traits GPC6 intron 22791750 rs9524299 chr13 94633244 T G 1.03E-06 Insulin-related traits GPC6 intron 22791750 rs9284277 chr13 94654146 T C 4.40E-04 Multiple complex diseases GPC6 intron 17554300 rs9516350 chr13 94750360 T G 1.70E-05 Urinary metabolites GPC6 intron 21572414 rs12428018 chr13 94754950 C T 4.68E-05 Polycystic ovary syndrome GPC6 intron 22178785 rs9301937 chr13 94767311 C T 1.20E-05 Urinary metabolites GPC6 intron 21572414 rs543019 chr13 94792504 A C 9.68E-06 Alzheimer's disease (late onset) GPC6 intron 21460841 rs644025 chr13 94798137 G A 1.72E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) GPC6 intron 24023788 rs544579 chr13 94799057 C A 3.30E-06 Urinary metabolites GPC6 intron 21572414 rs497836 chr13 94807508 G T 3.80E-05 Volumetric brain MRI GPC6 intron 17903297 rs1412935 chr13 94827241 T G 3.71E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GPC6 intron 22566498 rs9524352 chr13 94832097 G A 5.00E-05 Waist-Hip Ratio GPC6 intron pha003013 rs7984149 chr13 94861913 T C 7.39E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) GPC6 intron 23648065 rs1572050 chr13 94870765 G A 6.00E-06 Renal sinus fat GPC6 intron 22044751 rs1333261 chr13 94906103 C T 1.80E-04 Crohn's disease GPC6 intron 17684544 rs1537418 chr13 94906537 G T 1.91E-04 Parkinson's disease GPC6 intron 21248740 rs9301951 chr13 94952832 T C 9.00E-07 Disc degeneration (lumbar) GPC6 intron 22993228 rs17196161 chr13 94984210 T C 3.12E-05 Formal thought disorder in schizophrenia GPC6 intron 22648509 rs12876549 chr13 95000735 A G 3.60E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) GPC6 intron 24023788 rs9516401 chr13 95004765 C T 4.47E-05 Formal thought disorder in schizophrenia GPC6 intron 22648509 rs9524457 chr13 95009262 G A 6.55E-05 LDL lipoproteins GPC6 intron pha002902 rs9516403 chr13 95015438 T C 7.52E-05 Formal thought disorder in schizophrenia GPC6 intron 22648509 rs9524460 chr13 95015753 T C 9.84E-05 Formal thought disorder in schizophrenia GPC6 intron 22648509 rs9556365 chr13 95017238 T G 3.86E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) GPC6 intron 24023788 rs9524468 chr13 95032411 T C 9.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) GPC6 intron 23233662 rs17196177 chr13 95035636 G T 1.29E-04 Blood pressure GPC6 intron 17255346 rs4773789 chr13 95041977 A G 2.50E-05 Urinary metabolites GPC6 intron 21572414 rs9556369 chr13 95051560 A G 2.68E-05 Nicotine smoking GPC6 intron 19268276 rs9584224 chr13 95055726 G A 0.000000263 LDL cholesterol GPC6 UTR-3 23063622 rs7331021 chr13 95061492 C T 1.88E-05 Serum metabolites / / 19043545 rs9301957 chr13 95065159 C A 7.50E-06 Urinary metabolites / / 21572414 rs6650322 chr13 95069136 A G 3.57E-04 Multiple complex diseases / / 17554300 rs9524483 chr13 95069280 G A 4.41E-04 Multiple complex diseases / / 17554300 rs7989427 chr13 95076249 T A 9.68E-04 Depression (quantitative trait) / / 20800221 rs9524487 chr13 95079910 C T 1.20E-05 Urinary metabolites / / 21572414 rs1886049 chr13 95088866 G A 8.82E-05 Partial epilepsies / / 20522523 rs727299 chr13 95108501 C T 3.92E-07 Paclitaxel sensitivity in NCI60 cancer cell lines DCT intron 21314952 rs4773794 chr13 95121488 G A 0.000586 Salmonella-induced pyroptosis DCT intron 22837397 rs9561576 chr13 95157722 C T 1.46E-05 Serum metabolites / / 19043545 rs1886789 chr13 95157789 C G 1.46E-05 Serum metabolites / / 19043545 rs9301972 chr13 95164550 G A 1.70E-05 Serum metabolites / / 19043545 rs9561601 chr13 95169236 A C 5.07E-06 Serum metabolites / / 19043545 rs767925 chr13 95169735 C A 2.10E-05 Serum metabolites / / 19043545 rs9561602 chr13 95171986 G A 8.26E-04 Alzheimer's disease / / 22005930 rs2389137 chr13 95174031 C T 2.48E-05 Serum metabolites / / 19043545 rs2389137 chr13 95174031 C T 9.86E-04 Alzheimer's disease / / 22005930 rs9561604 chr13 95175692 A G 7.16E-04 Alzheimer's disease / / 22005930 rs9561606 chr13 95176364 C A 7.33E-04 Alzheimer's disease / / 22005930 rs7323407 chr13 95176687 C T 6.91E-04 Alzheimer's disease / / 22005930 rs7324016 chr13 95176998 C T 6.84E-04 Alzheimer's disease / / 22005930 rs9561607 chr13 95177293 A C 1.82E-05 Serum metabolites / / 19043545 rs9561607 chr13 95177293 A C 8.77E-04 Alzheimer's disease / / 22005930 rs9556395 chr13 95177689 G C 2.87E-04 Alzheimer's disease / / 22005930 rs9561611 chr13 95177769 A C 6.23E-04 Alzheimer's disease / / 22005930 rs7336995 chr13 95178317 T G 1.82E-05 Serum metabolites / / 19043545 rs7336995 chr13 95178317 T G 1.74E-04 Alzheimer's disease / / 22005930 rs7336997 chr13 95178520 A T 6.35E-04 Alzheimer's disease / / 22005930 rs7318895 chr13 95178537 T C 1.82E-05 Serum metabolites / / 19043545 rs7318895 chr13 95178537 T C 8.68E-04 Alzheimer's disease / / 22005930 rs9634483 chr13 95179293 T C 6.75E-04 Alzheimer's disease / / 22005930 rs17181801 chr13 95186249 C T 6.71E-04 Alzheimer's disease / / 22005930 rs17181808 chr13 95186815 G A 9.49E-04 Alzheimer's disease / / 22005930 rs9561619 chr13 95188134 C T 7.77E-04 Alzheimer's disease / / 22005930 rs9561620 chr13 95188326 C T 1.31E-05 Serum metabolites / / 19043545 rs9561620 chr13 95188326 C T 7.99E-04 Alzheimer's disease / / 22005930 rs9301973 chr13 95189401 G A 2.30E-05 Serum metabolites / / 19043545 rs9301973 chr13 95189401 G A 8.05E-04 Alzheimer's disease / / 22005930 rs9556397 chr13 95190377 A G 9.46E-04 Alzheimer's disease / / 22005930 rs7334290 chr13 95191331 T C 2.82E-05 Serum metabolites / / 19043545 rs7334290 chr13 95191331 T C 3.03E-04 Smoking initiation / / 24665060 rs9284279 chr13 95192032 G A 2.42E-04 Alzheimer's disease / / 22005930 rs9561623 chr13 95197183 A G 1.63E-05 Serum metabolites / / 19043545 rs8002991 chr13 95197273 C T 3.24E-05 Serum metabolites / / 19043545 rs8002991 chr13 95197273 C T 4.56E-04 Alzheimer's disease / / 22005930 rs9301975 chr13 95205884 G T 4.18E-05 Serum metabolites / / 19043545 rs9556403 chr13 95236825 A G 9.85E-05 Response to radiotherapy in cancer (late toxicity) TGDS intron 24785509 rs6492721 chr13 95258944 T C 9.29E-04 Type 2 diabetes GPR180 intron 17463246 rs6492721 chr13 95258944 T C 8.49E-05 Lymphocyte counts GPR180 intron 22286170 rs12429818 chr13 95273447 G A 5.65E-05 Myopia (pathological) GPR180 cds-synon 21095009 rs2298056 chr13 95281129 A G 2.70E-05 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy GPR180 UTR-3 23118302 rs7985331 chr13 95306489 A G 3.54E-05 AIDS / / 19754311 rs9561658 chr13 95321547 C T 8.68E-04 Multiple complex diseases / / 17554300 rs9584245 chr13 95331933 G A 4.57E-04 Multiple complex diseases / / 17554300 rs9516466 chr13 95370041 G A 2.83E-04 Blood pressure / / 17255346 rs9561674 chr13 95372854 A T 4.36E-04 Blood pressure / / 17255346 rs118187969 chr13 95387604 C T 7.21E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs7995237 chr13 95392487 A G 3.74E-04 Alzheimer's disease (late onset) / / 21379329 rs145398622 chr13 95399849 A C 6.89E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs9561694 chr13 95453071 C T 3.03E-04 Cognitive decline / / 23732972 rs9302001 chr13 95463392 C T 3.00E-07 Panic disorder / / 19165232 rs9302001 chr13 95463392 C T 0.000000226 Panic disorder / / 23149450 rs9302001 chr13 95463392 C T 2.26E-07 Serum tamsulosin hydrochloride concentration / / 23151678 rs11070098 chr13 95505262 T C 5.00E-06 Obesity-related traits / / 23251661 rs11070098 chr13 95505262 T C 8.00E-06 Obesity-related traits / / 23251661 rs927694 chr13 95514963 A G 1.67E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2209852 chr13 95517622 A G 6.00E-06 Parent of origin effect on language impairment (paternal) / / 24571439 rs9561704 chr13 95534065 C A 2.00E-05 Urinary metabolites / / 21572414 rs11617160 chr13 95541811 T C 5.74E-04 Alzheimer's disease / / 22005930 rs11617172 chr13 95541855 T C 6.41E-04 Alzheimer's disease / / 22005930 rs11620197 chr13 95541868 C A 7.14E-04 Alzheimer's disease / / 22005930 rs11616934 chr13 95541907 A G 4.70E-04 Alzheimer's disease / / 22005930 rs9590118 chr13 95567327 C A 9.16E-04 Alzheimer's disease / / 22005930 rs17792146 chr13 95572000 T C 2.96E-04 Alzheimer's disease / / 22005930 rs75978831 chr13 95585686 C T 9.12E-05 Epilepsy (remission after treatment) / / 23962720 rs9590131 chr13 95586210 C T 6.88E-05 Epilepsy (remission after treatment) / / 23962720 rs9590132 chr13 95586380 G T 5.76E-05 Epilepsy (remission after treatment) / / 23962720 rs11843212 chr13 95586991 A G 8.05E-05 Epilepsy (remission after treatment) / / 23962720 rs1925857 chr13 95587073 A G 4.83E-05 Suicidal ideation / / 20877300 rs1925857 chr13 95587073 A G 8.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs9590134 chr13 95587744 G A 5.94E-05 Epilepsy (remission after treatment) / / 23962720 rs9590135 chr13 95588741 C T 7.13E-05 Epilepsy (remission after treatment) / / 23962720 rs11839098 chr13 95590315 T C 9.54E-05 Epilepsy (remission after treatment) / / 23962720 rs113437459 chr13 95590692 G A 5.83E-05 Epilepsy (remission after treatment) / / 23962720 rs9590141 chr13 95603622 G A 8.76E-07 Blood pressure / / 21378095 rs7990574 chr13 95611364 A G 9.72E-04 Breast cancer / / 20852631 rs7998670 chr13 95628935 A G 3.78E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs1925877 chr13 95632056 A G 7.21E-06 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs9590154 chr13 95651354 T G 2.46E-04 Multiple complex diseases / / 17554300 rs7321486 chr13 95664889 T C 7.73E-04 Type 2 diabetes / / 17463246 rs11568688 chr13 95673866 T A,C,G 1.70E-42 Health and aging,CVD and cancer age of onset ABCC4 missense 22174011 rs11568688 chr13 95673866 T A,C,G 3.50E-08 Health and aging,CVD and cancer age of onset ABCC4 missense 22174011 rs11568688 chr13 95673866 T A,C,G 4.00E-13 Health and aging,CVD and cancer age of onset ABCC4 missense 22174011 rs11568688 chr13 95673866 T A,C,G 7.00E-27 Health and aging,CVD and cancer age of onset ABCC4 missense 22174011 rs4148546 chr13 95680285 G A 1.00E-06 Longevity ABCC4 intron 20834067 rs7996205 chr13 95681705 G A 4.13E-04 Multiple complex diseases ABCC4 intron 17554300 rs3782946 chr13 95711603 T C 5.81E-04 Insulin resistance ABCC4 intron 21901158 rs9561778 chr13 95713715 G A,T 1 Drug response to Cyclophosphamide ABCC4 intron 19696793 rs1751034 chr13 95714976 C T 1 Drug response to Tenofovir ABCC4 frameshift 17597712 rs1751034 chr13 95714976 C T 1 Drug response to Tenofovir ABCC4 frameshift 18398970 rs4771905 chr13 95717843 A G 6.06E-04 Amyotrophic Lateral Sclerosis ABCC4 intron 17362836 rs1678387 chr13 95717906 T C 0.00002 Bisphosphonate-induced osteonecrosis of the jaw ABCC4 intron 22267851 rs1678387 chr13 95717906 T C 9.00E-04 Amyotrophic lateral sclerosis (sporadic) ABCC4 intron 24529757 rs1624638 chr13 95731492 A G 2.82E-04 Alzheimer's disease (late onset) ABCC4 intron 21379329 rs1751050 chr13 95731496 G C 2.73E-04 Alzheimer's disease (late onset) ABCC4 intron 21379329 rs9590177 chr13 95736210 C T 0.000000209 LDL cholesterol ABCC4 intron 23063622 rs2619307 chr13 95756796 C T 0.00000151 HDL cholesterol ABCC4 intron 23063622 rs16950632 chr13 95761886 G A 2.49E-04 Multiple complex diseases ABCC4 intron 17554300 rs16950632 chr13 95761886 G A 6.35E-04 Alcohol dependence ABCC4 intron 20201924 rs11070109 chr13 95763826 C T 5.68E-04 Alzheimer's disease ABCC4 intron 17998437 rs16950650 chr13 95775432 C T 2.00E-07 non-small cell lung cancer ABCC4 intron 23478653 rs1189428 chr13 95780019 T C 2.40E-05 Diabetic nephropathy ABCC4 intron pha002866 rs9590190 chr13 95802526 C T 0.00015 Coronary artery calcification ABCC4 intron 23727086 rs7993619 chr13 95812745 A C 8.89E-04 Alzheimer's disease ABCC4 intron 17998437 rs3765534 chr13 95815415 C T 1 Drug response to Mercaptopurine ABCC4 missense 18593894 rs17189376 chr13 95824103 T C 2.54E-04 Obesity (extreme) ABCC4 intron 21935397 rs17189376 chr13 95824103 T C 3.05E-05 Elbow pain ABCC4 intron pha003008 rs4148490 chr13 95835578 A G 2.10E-05 Diabetic nephropathy ABCC4 intron pha002866 rs11568668 chr13 95839040 C T 1 Drug response to Adefovir Dipivoxil ABCC4 missense 19940846 rs11568668 chr13 95839040 C T 1 Drug response to Azidothymidine ABCC4 missense 19940846 rs1557069 chr13 95839296 T C 4.89E-05 Erythrocyte counts ABCC4 intron pha003101 rs9524822 chr13 95843575 T C 5.73E-05 Schizophrenia ABCC4 intron 19571809 rs1678384 chr13 95848393 G A 8.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ABCC4 intron 20877124 rs4148478 chr13 95849680 A G 7.57E-04 Alcohol dependence ABCC4 intron 21314694 rs17268163 chr13 95853235 C T 3.95E-04 Multiple complex diseases ABCC4 intron 17554300 rs17268163 chr13 95853235 C T 1.79E-05 Elbow pain ABCC4 intron pha003008 rs4148475 chr13 95853574 T A 4.40E-05 Diabetic nephropathy ABCC4 intron pha002866 rs1751027 chr13 95853870 A G 9.40E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) ABCC4 intron 23648065 rs9556465 chr13 95857517 G T 6.98E-10 HDL cholesterol ABCC4 intron 23063622 rs11568658 chr13 95863008 C A 1 Drug response to Adefovir Dipivoxil ABCC4 missense 19940846 rs11568658 chr13 95863008 C A 1 Drug response to Azidothymidine ABCC4 missense 19940846 rs17189467 chr13 95864966 A T 1.46E-04 Type 2 diabetes ABCC4 intron 17463246 rs1926657 chr13 95874956 T C 2.00E-06 Breast cancer ABCC4 intron 17903305 rs1926657 chr13 95874956 T C 2.00E-06 Nasopharyngeal carcinoma ABCC4 intron 20512145 rs9524856 chr13 95886276 T C 1.70E-05 Urinary metabolites ABCC4 intron 21572414 rs4148441 chr13 95898207 A G 7.00E-12 Platelet counts ABCC4 intron 22139419 rs11568689 chr13 95899303 G C 0.000052 Breast cancer(er negative) ABCC4 missense 23555315 rs9590213 chr13 95901825 A T 1.54E-04 Substance dependence ABCC4 intron 21818250 rs17268275 chr13 95912844 G A 6.60E-05 Corneal structure ABCC4 intron 22003120 rs9524870 chr13 95914654 T C 4.90E-06 Urinary metabolites ABCC4 intron 21572414 rs9590225 chr13 95916201 C T 8.95E-07 Asthma (childhood onset) ABCC4 intron 23829686 rs8002180 chr13 95922765 T C 8.00E-23 Blood metabolite levels ABCC4 intron 24816252 rs7336051 chr13 95926431 C T 7.63E-04 Type 2 diabetes ABCC4 intron 17463246 rs4773866 chr13 95929326 C T 5.99E-04 Multiple complex diseases ABCC4 intron 17554300 rs9302065 chr13 95971016 A G 3.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs9302065 chr13 95971016 A G 1.00E-19 Blood metabolite levels / / 24816252 rs10508015 chr13 96001195 T C 4.55E-04 Depression (quantitative trait) / / 20800221 rs12584768 chr13 96001280 T C 7.05E-04 Depression (quantitative trait) / / 20800221 rs9524936 chr13 96001330 C G 3.87E-04 Depression (quantitative trait) / / 20800221 rs9524937 chr13 96001349 T G 3.92E-04 Depression (quantitative trait) / / 20800221 rs9516572 chr13 96003663 C T 9.31E-04 Depression (quantitative trait) / / 20800221 rs11843128 chr13 96006041 A G 9.29E-04 Depression (quantitative trait) / / 20800221 rs11841659 chr13 96006171 C T 9.31E-04 Depression (quantitative trait) / / 20800221 rs3904878 chr13 96012790 A G 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs9590247 chr13 96013005 G T 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs4238314 chr13 96018546 A G 6.50E-05 Personality dimensions / / 18957941 rs10508013 chr13 96040032 G A 4.90E-05 Volumetric brain MRI / / 17903297 rs10508012 chr13 96040180 T A 3.30E-05 Volumetric brain MRI / / 17903297 rs9561869 chr13 96042020 G A 1.06E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2993561 chr13 96044531 A G 4.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1764423 chr13 96047070 A G 3.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9584299 chr13 96047924 A G 0.0008 Salmonella-induced pyroptosis / / 22837397 rs9584300 chr13 96050927 G A 0.000872 Salmonella-induced pyroptosis / / 22837397 rs9584304 chr13 96085685 C T 2.09E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7993213 chr13 96088852 T C 5.53E-05 Bipolar disorder CLDN10 intron 21771265 rs7988153 chr13 96124532 T C 0.00017 Endometrial cancer CLDN10 intron 22426144 rs870707 chr13 96126828 C A 2.95E-08 Systemic lupus erythematosus CLDN10 intron pha002867 rs7984974 chr13 96128857 G A 3.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) CLDN10 intron 23648065 rs946232 chr13 96129510 A G 3.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) CLDN10 intron 23648065 rs946228 chr13 96133018 G A 9.23E-04 Rheumatoid arthritis CLDN10 intron 21452313 rs12867610 chr13 96160762 C T 2.24E-05 Soluble levels of adhesion molecules CLDN10 intron pha003072 rs9302081 chr13 96208087 T G 4.70E-05 Amyotrophic lateral sclerosis (sporadic) CLDN10 intron 24529757 rs7324781 chr13 96234753 C T 4.37E-05 Crohn's disease DZIP1 intron 17684544 rs9525028 chr13 96238829 C A 6.56E-04 Response to statin treatment (atorvastatin),change in cholesterol levels DZIP1 intron 20031582 rs11070136 chr13 96239805 G A 8.80E-06 Urinary metabolites DZIP1 missense 21572414 rs11070136 chr13 96239805 G A 1.64E-05 Amyotrophic lateral sclerosis (sporadic) DZIP1 missense 24529757 rs7319952 chr13 96258410 A G 4.90E-06 Urinary metabolites DZIP1 intron 21572414 rs12583161 chr13 96281696 G A 4.52E-04 Multiple complex diseases DZIP1 intron 17554300 rs3843690 chr13 96311577 T C 5.36E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9302083 chr13 96374386 C T 9.71E-05 HDL particle features D/JC3 intron pha002900 rs6492820 chr13 96414818 C G 2.01E-04 Type 2 diabetes D/JC3 intron 17463246 rs35405829 chr13 96601679 C T 5.70E-06 Stroke (ischemic) UGGT2 cds-synon 22384361 rs541811 chr13 96672110 G C 8.40E-08 Progranulin levels UGGT2 intron 21087763 rs541811 chr13 96672110 G C 8.40E-08 Myocardial infarction UGGT2 intron 21211798 rs537571 chr13 96723887 A G 2.00E-05 Urinary metabolites / / 21572414 rs816122 chr13 96729594 C G 1.18E-04 Multiple complex diseases / / 17554300 rs9525135 chr13 96805547 T C 5.90E-06 Urinary metabolites HS6ST3 intron 21572414 rs7139605 chr13 96811028 G C 3.97E-04 Multiple complex diseases HS6ST3 intron 17554300 rs7992570 chr13 96819515 C T 7.17E-04 Suicide attempts in bipolar disorder HS6ST3 intron 21423239 rs1327625 chr13 96822422 T C 9.59E-04 Suicide attempts in bipolar disorder HS6ST3 intron 21423239 rs17675800 chr13 96826213 C A 8.36E-05 Glaucoma (primary open-angle) HS6ST3 intron 22605921 rs4415884 chr13 96826463 G A 8.42E-04 Suicide attempts in bipolar disorder HS6ST3 intron 21423239 rs7338412 chr13 96830881 T C 8.45E-04 Suicide attempts in bipolar disorder HS6ST3 intron 21423239 rs1410106 chr13 96831192 G A 8.44E-04 Suicide attempts in bipolar disorder HS6ST3 intron 21423239 rs4773940 chr13 96833699 T C 4.80E-05 Response to statin therapy HS6ST3 intron 20339536 rs4773940 chr13 96833699 T C 8.48E-04 Suicide attempts in bipolar disorder HS6ST3 intron 21423239 rs9525141 chr13 96836669 G A 6.70E-05 Response to statin therapy HS6ST3 intron 20339536 rs6492841 chr13 96842972 A T 7.40E-05 Response to statin therapy HS6ST3 intron 20339536 rs6492841 chr13 96842972 A T 8.48E-04 Suicide attempts in bipolar disorder HS6ST3 intron 21423239 rs1327627 chr13 96843611 G A 7.30E-05 Response to statin therapy HS6ST3 intron 20339536 rs1327627 chr13 96843611 G A 8.40E-04 Suicide attempts in bipolar disorder HS6ST3 intron 21423239 rs7331762 chr13 96845557 T C 1 Drug response to Etoposide HS6ST3 intron 17537913 rs6492843 chr13 96845745 A G 6.70E-05 Response to statin therapy HS6ST3 intron 20339536 rs6492843 chr13 96845745 A G 8.45E-04 Suicide attempts in bipolar disorder HS6ST3 intron 21423239 rs1327628 chr13 96847768 A G 7.00E-05 Response to statin therapy HS6ST3 intron 20339536 rs1327630 chr13 96848258 A G 7.00E-05 Response to statin therapy HS6ST3 intron 20339536 rs1327631 chr13 96848503 A C 5.05E-04 Multiple complex diseases HS6ST3 intron 17554300 rs7987437 chr13 96848817 A G 8.30E-05 Response to statin therapy HS6ST3 intron 20339536 rs4771926 chr13 96849018 A G 8.80E-05 Response to statin therapy HS6ST3 intron 20339536 rs4771927 chr13 96852599 G T 9.50E-05 Response to statin therapy HS6ST3 intron 20339536 rs4771928 chr13 96852699 A G 9.80E-05 Response to statin therapy HS6ST3 intron 20339536 rs4771929 chr13 96852913 G A 9.95E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) HS6ST3 intron 23648065 rs10492589 chr13 96860923 A T 1.22E-14 Gallbladder disease HS6ST3 intron pha001404 rs9562057 chr13 96897856 C T 0.0000108 Alpha-2-adrenoceptor-mediated vasoconstriction HS6ST3 intron 23337848 rs7322488 chr13 96916634 T C 3.34E-04 Nicotine smoking HS6ST3 intron 19268276 rs1927794 chr13 96921049 T C 3.33E-04 Self-reported allergy HS6ST3 intron 23817569 rs1927793 chr13 96921287 C G 7.09E-04 Multiple complex diseases HS6ST3 intron 17554300 rs1927793 chr13 96921287 C G 2.59E-08 Narcolepsy HS6ST3 intron 19629137 rs1927790 chr13 96922191 T C 5.23E-04 White matter integrity HS6ST3 intron 22425255 rs1927790 chr13 96922191 T C 1.10E-04 Self-reported allergy HS6ST3 intron 23817569 rs748457 chr13 96922449 G A 1.05E-04 Self-reported allergy HS6ST3 intron 23817569 rs2149315 chr13 96928767 T C 6.22E-04 Self-reported allergy HS6ST3 intron 23817569 rs2149314 chr13 96928908 T A 9.37E-04 Suicide attempts in bipolar disorder HS6ST3 intron 21423239 rs4773947 chr13 96929825 T C 9.04E-04 Self-reported allergy HS6ST3 intron 23817569 rs7983697 chr13 96942845 T G 8.95E-04 Suicide attempts in bipolar disorder HS6ST3 intron 21423239 rs11619328 chr13 96949697 A G 4.28E-04 Multiple complex diseases HS6ST3 intron 17554300 rs2038823 chr13 96951433 G T 5.00E-11 Diabetic retinopathy HS6ST3 intron 21310492 rs9300342 chr13 96951950 A G 9.08E-04 Type 2 diabetes HS6ST3 intron 17463246 rs9300342 chr13 96951950 A G 4.51E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) HS6ST3 intron 24023788 rs7331682 chr13 96965955 T C 6.88E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) HS6ST3 intron 23648065 rs9554338 chr13 96966314 G A 4.62E-04 Self-reported allergy HS6ST3 intron 23817569 rs7320184 chr13 96976345 C A 6.87E-04 White matter integrity HS6ST3 intron 22425255 rs4771934 chr13 96993756 A C 6.25E-04 White matter integrity HS6ST3 intron 22425255 rs9556570 chr13 96999093 T G 1.22E-04 Self-reported allergy HS6ST3 intron 23817569 rs1925111 chr13 96999480 A G 9.08E-04 Response to taxane treatment (placlitaxel) HS6ST3 intron 23006423 rs7328493 chr13 97000498 T G 2.86E-04 Self-reported allergy HS6ST3 intron 23817569 rs927710 chr13 97004796 T G 2.45E-04 Self-reported allergy HS6ST3 intron 23817569 rs11069237 chr13 97009453 A G 7.88E-05 Cognitive impairment induced by topiramate HS6ST3 intron 22091778 rs7989336 chr13 97017548 G A 1.00E-08 Obesity HS6ST3 intron 23563607 rs912690 chr13 97020705 C G 5.71E-04 Multiple complex diseases HS6ST3 intron 17554300 rs9554349 chr13 97023829 C T 3.18E-05 Depression (quantitative trait) HS6ST3 intron 23290196 rs4771252 chr13 97034989 A G 9.51E-04 Type 2 diabetes HS6ST3 intron 17463246 rs9516673 chr13 97037589 A G 5.77E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer HS6ST3 intron 22872573 rs912697 chr13 97048723 G A 1.59E-04 Multiple complex diseases HS6ST3 intron 17554300 rs1886560 chr13 97078552 C T 5.99E-04 Multiple complex diseases HS6ST3 intron 17554300 rs431500 chr13 97102003 T C 9.89E-04 Multiple complex diseases HS6ST3 intron 17554300 rs7335367 chr13 97105609 G A 4.09E-04 Type 2 diabetes HS6ST3 intron 17463246 rs7995242 chr13 97112165 G A 7.63E-05 Orofacial clefts HS6ST3 intron 22419666 rs6491294 chr13 97127709 G C 1.70E-07 Urinary metabolites HS6ST3 intron 21572414 rs6491294 chr13 97127709 G C 7.01E-04 Response to taxane treatment (placlitaxel) HS6ST3 intron 23006423 rs17760491 chr13 97167152 C A 9.87E-04 Multiple complex diseases HS6ST3 intron 17554300 rs7323929 chr13 97200777 G A 6.30E-04 Oral cancers (chewing tobacco related) HS6ST3 intron 22503698 rs3899870 chr13 97205718 G C 1.21E-05 Multiple sclerosis HS6ST3 intron 17660530 rs3899871 chr13 97205830 G A 1.74E-05 Multiple sclerosis HS6ST3 intron 17660530 rs7334107 chr13 97206214 C T 4.52E-05 Multiple sclerosis HS6ST3 intron 17660530 rs547571 chr13 97231270 A G 2.00E-04 Chronic fatigue syndrome HS6ST3 intron 21912186 rs1924587 chr13 97397379 G C 4.60E-04 Breast cancer and prostate cancer HS6ST3 intron 17903305 rs6491307 chr13 97454810 G A 9.57E-04 Obesity (extreme) HS6ST3 intron 21935397 rs9516761 chr13 97461067 C A 3.89E-05 Kawasaki disease HS6ST3 intron 22446961 rs16953622 chr13 97508739 C T 7.00E-06 Cognitive function / / 24684796 rs17699096 chr13 97508888 A T 4.29E-04 Multiple complex diseases / / 17554300 rs17771890 chr13 97511339 G A 4.80E-04 Multiple complex diseases / / 17554300 rs9513192 chr13 97530969 C A 7.38E-05 Longevity / / 22279548 rs1360437 chr13 97534204 C T 5.29E-05 Serum metabolites / / 19043545 rs16953634 chr13 97534223 A C 9.20E-06 Urinary metabolites / / 21572414 rs16953799 chr13 97672631 C G 5.65E-04 Multiple complex diseases / / 17554300 rs7330360 chr13 97698157 T C 6.05E-06 Suicide attempts in bipolar disorder / / 21423239 rs8000030 chr13 97735737 G A 1.86E-04 Myopia (pathological) / / 21095009 rs2055424 chr13 97758771 C T 1.65E-04 Multiple complex diseases / / 17554300 rs2282423 chr13 97788294 G A 1.76E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs2282424 chr13 97788446 G A 2.98E-05 Alcohol and nictotine co-dependence / / 20158304 rs9556684 chr13 97807422 C G 9.84E-04 Depression (quantitative trait) / / 20800221 rs4603415 chr13 97812638 G A 9.67E-04 Depression (quantitative trait) / / 20800221 rs4603415 chr13 97812638 G A 1.88E-05 Stroke (ischemic) / / 22941190 rs9556686 chr13 97817733 C G 7.16E-04 Depression (quantitative trait) / / 20800221 rs7990980 chr13 97826202 A G 9.22E-04 Myopia (pathological) LOC100507566 intron 21095009 rs9556688 chr13 97835876 C T 3.71E-05 Bipolar disorder and schizophrenia / / 20889312 rs9556688 chr13 97835876 C T 2.37E-05 Stroke (ischemic) / / 22941190 rs3902523 chr13 97837105 T C 4.73E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs4771267 chr13 97841268 G A 1.52E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs9556690 chr13 97846187 C T 2.50E-05 Stroke (ischemic) / / 22941190 rs9516865 chr13 97861011 A G 6.46E-04 Schizophrenia / / 19197363 rs9516865 chr13 97861011 A G 1.43E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs9300398 chr13 97892315 T C 1.46E-05 Male-pattern baldness MBNL2 intron 18849994 rs4771987 chr13 97901390 G A 1.88E-05 Male-pattern baldness MBNL2 intron 18849994 rs7321956 chr13 97902735 A T 8.30E-05 Cognitive function MBNL2 intron 24684796 rs6491343 chr13 97903739 T G 7.20E-05 Cognitive function MBNL2 intron 24684796 rs6491345 chr13 97915358 C T 5.22E-04 Multiple complex diseases MBNL2 intron 17554300 rs6491346 chr13 97915471 G A 1.95E-04 Blood pressure MBNL2 intron 17255346 rs7320723 chr13 97929154 G A 3.51E-05 Hemoglobin concentration MBNL2 intron 20534544 rs7999382 chr13 97941497 T G 3.64E-05 Psoriasis MBNL2 intron 20953187 rs4441122 chr13 97953046 C A 3.04E-04 Suicide,with and without major depression MBNL2 intron 22059935 rs10508030 chr13 97953090 C T 3.37E-04 Blood pressure MBNL2 intron 17255346 rs10508030 chr13 97953090 C T 9.22E-04 Type 2 diabetes MBNL2 intron 17463246 rs10508031 chr13 97953758 G A 3.37E-04 Blood pressure MBNL2 intron 17255346 rs10508031 chr13 97953758 G A 9.22E-04 Type 2 diabetes MBNL2 intron 17463246 rs4771992 chr13 97954425 G T 2.62E-04 Suicide,with and without major depression MBNL2 intron 22059935 rs1556086 chr13 97978485 A G 2.30E-05 Alcoholism (heaviness of drinking) MBNL2 intron 21529783 rs9582126 chr13 97980958 G A 2.07E-04 Blood pressure MBNL2 intron 17255346 rs9556711 chr13 98016416 G A 2.00E-06 Alcoholism (alcohol use disorder factor score) MBNL2 intron 21529783 rs9556711 chr13 98016416 G A 8.00E-07 Alcoholism (alcohol dependence factor score) MBNL2 intron 21529783 rs7318623 chr13 98021899 G T 1.00E-04 Cognitive impairment induced by topiramate MBNL2 intron 22091778 rs7986922 chr13 98035303 C T 2.00E-04 Blood pressure MBNL2 intron 17255346 rs1806507 chr13 98038577 G A 6.82E-04 Schizophrenia MBNL2 intron 19197363 rs1806507 chr13 98038577 G A 5.40E-05 HIV-1 control MBNL2 intron 20041166 rs4771996 chr13 98053792 G A 6.00E-06 Obesity-related traits / / 23251661 rs16954076 chr13 98054592 C A 6.68E-04 Multiple complex diseases / / 17554300 rs17468123 chr13 98055695 T C 5.79E-05 Blood pressure / / 17255346 rs9516923 chr13 98058165 T C 6.75E-04 Type 2 diabetes / / 17463246 rs9582133 chr13 98100047 C T 1.18E-04 Type 2 diabetes RAP2A intron 17463246 rs12873919 chr13 98119524 T C 1.30E-05 Urinary metabolites RAP2A UTR-3 21572414 rs9516953 chr13 98172508 A G 2.90E-05 Urinary metabolites / / 21572414 rs2769285 chr13 98177939 T A 2.98E-04 Type 2 diabetes / / 17463246 rs1328657 chr13 98183886 C T 1.00E-04 Schizophrenia / / 19197363 rs184729 chr13 98192735 A C 7.55E-04 Alcohol dependence / / 21314694 rs4771274 chr13 98193456 C T 2.40E-05 Urinary metabolites / / 21572414 rs349119 chr13 98195462 A G 4.64E-04 Type 2 diabetes / / 17463246 rs2770228 chr13 98200572 G A 9.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) / / 23934736 rs349114 chr13 98203727 G A 3.00E-06 Obesity-related traits / / 23251661 rs4143080 chr13 98212564 C A 2.90E-05 Urinary metabolites / / 21572414 rs4771276 chr13 98230575 C A 2.60E-05 Urinary metabolites / / 21572414 rs9516967 chr13 98232898 T C 1.60E-05 Urinary metabolites / / 21572414 rs1854226 chr13 98238242 T C 5.13E-06 Obesity-related traits / / 23251661 rs7984072 chr13 98244313 C A 4.30E-06 Urinary metabolites / / 21572414 rs1927341 chr13 98305477 G A 1.90E-05 Urinary metabolites / / 21572414 rs1327918 chr13 98308641 G A 4.75E-04 Schizophrenia / / 19197363 rs788178 chr13 98328559 T C 1.11E-04 Myocardial Infarction / / pha002873 rs2783482 chr13 98334937 C T 5.26E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1771428 chr13 98381813 G A 7.00E-05 Myocardial Infarction / / pha002873 rs2792967 chr13 98404519 C A,G,T 7.89E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2249531 chr13 98406102 A G 4.39E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2792969 chr13 98409719 G T 1.92E-05 Intracerebral hemorrhage / / 24656865 rs884415 chr13 98411113 G A 1.89E-05 Intracerebral hemorrhage / / 24656865 rs2793710 chr13 98412848 T G 2.57E-05 Intracerebral hemorrhage / / 24656865 rs9513299 chr13 98433916 T C 7.64E-05 Prion diseases / / 22210626 rs1340923 chr13 98441789 C T 1.41E-05 Prion diseases / / 22210626 rs7317109 chr13 98452561 T A 5.49E-05 Serum metabolites / / 19043545 rs7339318 chr13 98452776 C G 6.58E-05 Serum metabolites / / 19043545 rs16954516 chr13 98453492 G A 6.21E-05 Type 2 diabetes / / 17463246 rs882862 chr13 98454415 C A 4.11E-05 Type 2 diabetes / / 17463246 rs7988900 chr13 98478535 T C 2.71E-07 Colorectal cancer / / 21242260 rs7334771 chr13 98485390 C T 2.37E-05 Multiple complex diseases / / 17554300 rs12561190 chr13 98495165 C A,G,T 3.23E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1538187 chr13 98514241 G A 0.0000517 Major depressive disorder / / 23149448 rs7985904 chr13 98532757 G T 2.64E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7982669 chr13 98541219 T C 3.60E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7331943 chr13 98576691 A G 5.65E-04 White matter integrity / / 22425255 rs661567 chr13 98686582 T C 3.20E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs8001951 chr13 98695551 G T 5.44E-04 Multiple complex diseases / / 17554300 rs16954776 chr13 98700617 A G 9.00E-07 Smooth-surface caries / / 24556642 rs7330185 chr13 98706911 C T 8.73E-06 Smooth-surface caries / / 24556642 rs7328136 chr13 98709941 T C 2.43E-04 Smoking initiation / / 24665060 rs7326592 chr13 98713169 G A 8.37E-06 Smooth-surface caries / / 24556642 rs16954798 chr13 98716715 C T 2.56E-05 Smoking initiation / / 24665060 rs285028 chr13 98718161 T C 3.28E-04 Multiple complex diseases / / 17554300 rs17235905 chr13 98733003 A G 8.60E-06 Smooth-surface caries / / 24556642 rs501660 chr13 98733595 C T 8.22E-06 Smooth-surface caries / / 24556642 rs285063 chr13 98734952 G A 2.56E-06 Smooth-surface caries / / 24556642 rs285031 chr13 98786031 C G 3.11E-04 Multiple complex diseases / / 17554300 rs285097 chr13 98826997 G T 3.79E-05 Longevity FARP1 intron 21612516 rs285098 chr13 98827035 G C 2.89E-04 Migraine without aura FARP1 intron 23793025 rs285098 chr13 98827035 G C 6.76E-04 Migraine - clinic-based FARP1 intron 23793025 rs285098 chr13 98827035 G C 7.00E-06 Migraine FARP1 intron 23793025 rs9556893 chr13 98831595 C G 6.00E-06 Response to amphetamines FARP1 intron 22952603 rs285099 chr13 98834220 G A 5.40E-04 Multiple complex diseases FARP1 intron 17554300 rs1562901 chr13 98840004 G A 7.49E-04 Suicide attempts in bipolar disorder FARP1 intron 21423239 rs1322841 chr13 98845787 A G 6.12E-04 Suicide attempts in bipolar disorder FARP1 intron 21423239 rs10454523 chr13 98847198 A C 5.51E-04 Suicide attempts in bipolar disorder FARP1 intron 21423239 rs4772049 chr13 98853768 C T 2.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FARP1 intron 20877124 rs4772049 chr13 98853768 C T 6.04E-04 Suicide attempts in bipolar disorder FARP1 intron 21423239 rs7325009 chr13 98881563 T A 1.06E-05 Response to mTOR inhibitor (rapamycin) FARP1 intron 24009623 rs7989050 chr13 98882298 G A 6.00E-06 Breast cancer and prostate cancer FARP1 intron 17903305 rs626896 chr13 98938021 T C 9.68E-04 Multiple complex diseases FARP1 intron 17554300 rs9513393 chr13 98939102 A G 3.76E-05 Acne (severe) FARP1 intron 24927181 rs7337475 chr13 98942230 G A 3.91E-08 Metabolite levels FARP1 intron 23281178 rs654337 chr13 98946185 G T 7.93E-04 Multiple complex diseases FARP1 intron 17554300 rs9556929 chr13 98956599 T G 4.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FARP1 intron 20877124 rs624124 chr13 98958369 C G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) FARP1 intron 17982456 rs4318070 chr13 98960762 C T 7.00E-06 Total ventricular volume FARP1 intron 21116278 rs2772357 chr13 98961316 A G 1.46E-05 Response to cytadine analogues (cytosine arabinoside) FARP1 intron 24483146 rs688872 chr13 98966317 A G 1.00E-06 Brain structure FARP1 intron 20171287 rs688872 chr13 98966317 A G 4.44E-04 Iron levels FARP1 intron pha002876 rs9584805 chr13 98994030 A G 2.00E-06 Non-alcoholic fatty liver disease histology (lobular) FARP1 intron 20708005 rs11619050 chr13 99011920 A C 6.17E-05 Cognitive impairment induced by topiramate FARP1 intron 22091778 rs2892734 chr13 99017212 G A 8.39E-06 Cognitive impairment induced by topiramate FARP1 intron 22091778 rs587377 chr13 99017533 G A 2.86E-05 Cognitive impairment induced by topiramate FARP1 intron 22091778 rs2772353 chr13 99031300 G A 9.62E-06 Metabolite levels (MHPG) FARP1 intron 23319000 rs597455 chr13 99037584 T C 5.10E-04 Multiple complex diseases FARP1 intron 17554300 rs3825437 chr13 99042720 A G 3.02E-04 Multiple complex diseases FARP1 intron 17554300 rs583704 chr13 99045687 G A 3.30E-04 Schizophrenia FARP1 intron 19197363 rs9517283 chr13 99063471 C A 1.68E-04 Multiple complex diseases FARP1 intron 17554300 rs10450810 chr13 99066201 G A 6.28E-04 Type 2 diabetes FARP1 intron 17463246 rs10450810 chr13 99066201 G A 2.16E-04 Multiple complex diseases FARP1 intron 17554300 rs2274058 chr13 99069380 G A 4.59E-05 Amyotrophic lateral sclerosis FARP1 intron 19193627 rs7981744 chr13 99073062 A C 5.35E-04 Type 2 diabetes FARP1 intron 17463246 rs7981744 chr13 99073062 A C 1.65E-04 Multiple complex diseases FARP1 intron 17554300 rs7983237 chr13 99073103 T C 2.31E-04 Multiple complex diseases FARP1 intron 17554300 rs7996488 chr13 99078810 A G 2.72E-05 Amyotrophic lateral sclerosis FARP1 intron 19193627 rs3825435 chr13 99081097 A G 7.82E-04 Type 2 diabetes FARP1 intron 17463246 rs12868939 chr13 99084206 A G 6.42E-05 Body Fat Distribution FARP1 intron pha003016 rs12868939 chr13 99084206 A G 6.85E-05 Body Fat Distribution FARP1 intron pha003018 rs12868939 chr13 99084206 A G 6.34E-05 Waist Circumference FARP1 intron pha003025 rs6491426 chr13 99084709 G C 8.75E-04 Multiple complex diseases FARP1 intron 17554300 rs998733 chr13 99089156 C T 3.93E-05 Lung adenocarcinoma FARP1 intron 19836008 rs4772080 chr13 99092052 G T 8.81E-04 Suicide attempts in bipolar disorder FARP1 intron 21423239 rs9517302 chr13 99096034 A G 5.00E-06 Obesity-related traits FARP1 intron 23251661 rs9513426 chr13 99096425 C T 2.67E-04 Myopia (pathological) FARP1 intron 21095009 rs12869774 chr13 99100157 G A 7.96E-07 Bone mineral density FARP1 intron 21124946 rs12261 chr13 99100547 T C 1.15E-04 Suicide attempts in bipolar disorder FARP1 cds-synon 21423239 rs3783006 chr13 99111209 G C 8.00E-08 Educational attainment STK24 intron 23722424 rs3783005 chr13 99111337 A T 9.41E-04 Alzheimer's disease STK24 intron 17998437 rs9513429 chr13 99117841 C T 4.69E-04 Suicide attempts in bipolar disorder STK24 intron 21423239 rs9517320 chr13 99126303 A C 1.00E-06 Longevity STK24 intron 20834067 rs912330 chr13 99131294 C T 4.00E-06 Alzheimer's disease STK24 intron 22159054 rs6491428 chr13 99135370 T C 3.68E-04 Suicide attempts in bipolar disorder STK24 intron 21423239 rs4772089 chr13 99148086 G C 6.46E-04 Suicide attempts in bipolar disorder STK24 intron 21423239 rs7338502 chr13 99150010 C T 1.62E-08 Bone mineral density STK24 intron 21124946 rs10508036 chr13 99157398 C G 2.53E-04 Multiple complex diseases STK24 intron 17554300 rs9513433 chr13 99158924 C T 5.45E-04 Suicide attempts in bipolar disorder STK24 intron 21423239 rs9517329 chr13 99159019 A G 7.43E-04 Suicide attempts in bipolar disorder STK24 intron 21423239 rs17471066 chr13 99164699 T C 2.87E-04 Multiple complex diseases STK24 intron 17554300 rs12583333 chr13 99171326 C T 1.73E-08 Bone mineral density STK24 intron 21124946 rs9300484 chr13 99173263 T C 5.60E-04 Suicide attempts in bipolar disorder STK24 intron 21423239 rs17574550 chr13 99174651 T C 5.08E-04 Multiple complex diseases STK24 intron 17554300 rs11618611 chr13 99177868 G A 8.45E-05 Erythrocyte counts STK24 intron pha003101 rs7323905 chr13 99182693 T G 2.98E-06 Bone mineral density STK24 intron 21124946 rs9517338 chr13 99184059 G A 8.00E-05 Dengue shock syndrome STK24 intron 22001756 rs17471107 chr13 99190905 G A 9.85E-04 Multiple complex diseases STK24 intron 17554300 rs12853561 chr13 99195090 C T 9.92E-05 Schizophrenia STK24 intron 19571811 rs7985827 chr13 99223244 C T 7.97E-05 Dengue shock syndrome STK24 intron 22001756 rs11839442 chr13 99237843 G A 6.29E-04 Multiple complex diseases / / 17554300 rs9584885 chr13 99298291 G A 5.37E-05 IgE levels / / 22075330 rs2184903 chr13 99298809 T C 6.56E-04 Smoking cessation / / 24665060 rs9554486 chr13 99305631 A G 5.95E-04 Smoking cessation / / 24665060 rs9300499 chr13 99306767 G A 1.11E-04 Telomere length / / 21573004 rs9557026 chr13 99322790 T A 4.07E-04 Smoking cessation / / 24665060 rs6491438 chr13 99348887 G A 7.48E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SLC15A1 intron 22566498 rs8187817 chr13 99378642 A T 1 Drug response to Cephalexin SLC15A1 missense 19940846 rs4646213 chr13 99384598 G A 8.74E-04 Taste perception SLC15A1 intron 22132133 rs9582259 chr13 99385990 T G 8.29E-04 Parkinson's disease SLC15A1 intron 17052657 rs9582259 chr13 99385990 T G 3.00E-08 Immune reponse to smallpox (secreted IL-1beta) SLC15A1 intron 22610502 rs1331251 chr13 99392904 G A 0.0000227 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SLC15A1 intron 22628534 rs914300 chr13 99403702 G T 1.40E-05 Urinary metabolites SLC15A1 intron 21572414 rs7326447 chr13 99408540 C T 8.09E-04 Obesity (extreme) / / 21935397 rs9554503 chr13 99423564 A T 6.98E-05 Aging (time to event) / / 21782286 rs8000386 chr13 99426007 G T 9.68E-05 Serum metabolites / / 19043545 rs16955846 chr13 99435138 C T 2.00E-05 Urinary metabolites / / 21572414 rs16955846 chr13 99435138 C T 4.31E-04 Coronary heart disease / / 21606135 rs12427885 chr13 99442560 C T 8.66E-06 Cognitive impairment induced by topiramate / / 22091778 rs2282133 chr13 99449717 C T 0.00024 Prostate cancer DOCK9 cds-synon 23555315 rs772305 chr13 99459286 T C 5.02E-04 Acute lung injury DOCK9 intron 22295056 rs12859979 chr13 99462477 G A 1.52E-05 Response to methylphenidate treatment DOCK9 cds-synon 21130132 rs9557082 chr13 99474763 G A 2.47E-05 Coronary heart disease DOCK9 intron pha003031 rs9300518 chr13 99488663 T C 3.84E-04 Suicide attempts in bipolar disorder DOCK9 intron 21041247 rs7333687 chr13 99490559 A G 3.83E-04 Suicide attempts in bipolar disorder DOCK9 intron 21041247 rs913560 chr13 99495823 A G 3.18E-04 Suicide attempts in bipolar disorder DOCK9 intron 21041247 rs9582266 chr13 99496941 A G 8.40E-04 Suicide attempts in bipolar disorder DOCK9 intron 21041247 rs7986477 chr13 99499351 A G 7.91E-04 Suicide attempts in bipolar disorder DOCK9 intron 21041247 rs2296991 chr13 99502599 C T 3.03E-04 Suicide attempts in bipolar disorder DOCK9 intron 21041247 rs2026026 chr13 99503533 T C 5.86E-04 Suicide attempts in bipolar disorder DOCK9 intron 21041247 rs9582269 chr13 99503751 G A 5.93E-04 Suicide attempts in bipolar disorder DOCK9 intron 21041247 rs7321357 chr13 99504605 C T 4.96E-04 Suicide attempts in bipolar disorder DOCK9 intron 21041247 rs9513497 chr13 99505632 C T 7.33E-04 Suicide attempts in bipolar disorder DOCK9 intron 21041247 rs16955958 chr13 99506418 C T 7.62E-05 Erythrocyte counts DOCK9 intron pha003101 rs4772149 chr13 99507162 C T 5.14E-04 Suicide attempts in bipolar disorder DOCK9 intron 21041247 rs4772150 chr13 99507322 C T 8.73E-04 Suicide attempts in bipolar disorder DOCK9 intron 21041247 rs9517467 chr13 99513122 C A 7.97E-04 Suicide attempts in bipolar disorder DOCK9 intron 21041247 rs16955981 chr13 99518537 A C 1.34E-05 Myopia (severe) DOCK9 intron 23933737 rs16955981 chr13 99518537 A C 5.20E-07 Coronary heart disease DOCK9 intron pha003031 rs9517474 chr13 99536031 G A 1.93E-06 Coronary heart disease DOCK9 intron pha003031 rs2026025 chr13 99542553 C T 2.16E-04 Acute lung injury DOCK9 intron 22295056 rs1324982 chr13 99544133 T C 2.12E-06 Coronary heart disease DOCK9 intron pha003031 rs6491467 chr13 99551265 A G 0.0000558 Carotid intima media thickness DOCK9 intron 23152477 rs17710571 chr13 99552723 A C 5.55E-06 Multiple complex diseases DOCK9 intron 17554300 rs9513510 chr13 99571922 G C 9.02E-04 Acute lung injury DOCK9 intron 22295056 rs4444196 chr13 99571971 G A 9.71E-05 Myopia (severe) DOCK9 intron 23933737 rs4444196 chr13 99571971 G A 7.81E-05 Height DOCK9 intron pha003011 rs9517484 chr13 99572746 T C 9.37E-04 Acute lung injury DOCK9 intron 22295056 rs4772158 chr13 99574055 T C 8.34E-05 Myopia (severe) DOCK9 intron 23933737 rs4772158 chr13 99574055 T C 8.49E-05 Height DOCK9 intron pha003011 rs7984548 chr13 99575128 C T 9.97E-04 Acute lung injury DOCK9 intron 22295056 rs7318788 chr13 99578265 T C 9.70E-04 Acute lung injury DOCK9 intron 22295056 rs1028910 chr13 99579728 A G 9.70E-04 Acute lung injury DOCK9 intron 22295056 rs2094602 chr13 99583203 G A 9.70E-04 Acute lung injury DOCK9 intron 22295056 rs7337984 chr13 99590226 A G 9.81E-04 Acute lung injury DOCK9 intron 22295056 rs8001655 chr13 99591528 G A 4.02E-04 Acute lung injury DOCK9 intron 22295056 rs7985813 chr13 99592595 G A 6.31E-04 Acute lung injury DOCK9 intron 22295056 rs7987131 chr13 99593241 G A 4.92E-04 Acute lung injury DOCK9 intron 22295056 rs7986693 chr13 99593297 A G 9.09E-04 Acute lung injury DOCK9 intron 22295056 rs9517503 chr13 99600658 A G 5.14E-05 Height DOCK9 intron pha003011 rs12870904 chr13 99607008 T C 4.03E-04 Type 2 diabetes DOCK9 intron 17463246 rs8002389 chr13 99607911 A G 2.84E-06 Statin-induced myopathy DOCK9 intron 21826682 rs7338982 chr13 99610373 T C 2.80E-05 Caffeine consumption DOCK9 intron 21490707 rs7338982 chr13 99610373 T C 5.21E-05 Myopia (severe) DOCK9 intron 23933737 rs7338982 chr13 99610373 T C 5.63E-05 Height DOCK9 intron pha003011 rs9557106 chr13 99624564 A G 1.21E-06 Myopia (severe) DOCK9 intron 23933737 rs9517519 chr13 99630743 A G 1.73E-05 Myopia (severe) DOCK9 intron 23933737 rs9517529 chr13 99641977 C T 1.74E-06 Esophageal cancer (squamous cell) DOCK9 intron 22960999 rs730370 chr13 99649161 T C 5.71E-04 Heart Failure DOCK9 intron pha002885 rs12875358 chr13 99665922 G A 6.99E-04 Type 2 diabetes DOCK9 intron 17463246 rs4396395 chr13 99670271 A C 3.99E-05 Myopia (severe) DOCK9 intron 23933737 rs17724248 chr13 99693767 G A 7.11E-04 Type 2 diabetes DOCK9 intron 17463246 rs12859048 chr13 99696411 T C 4.62E-04 Lymphocyte counts DOCK9 intron 22286170 rs10492574 chr13 99696930 G T 3.51E-05 Myopia (severe) DOCK9 intron 23933737 rs2390184 chr13 99699439 C T 2.56E-05 Myopia (severe) DOCK9 intron 23933737 rs12428588 chr13 99705827 G A 1.94E-04 Lung function (forced expiratory volume in 1 second) DOCK9 intron 17255346 rs11620127 chr13 99723081 A G 1.14E-04 Lung function (forced expiratory volume in 1 second) DOCK9 intron 17255346 rs12871473 chr13 99730044 T C 7.16E-04 Type 2 diabetes DOCK9 intron 17463246 rs9554555 chr13 99759732 T C 4.12E-06 Esophageal cancer (squamous cell) / / 22960999 rs11069349 chr13 99774647 G A 5.00E-06 Self-reported allergy / / 23817569 rs2195 chr13 99783668 T C 7.95E-04 Bipolar disorder / / 19259986 rs7331698 chr13 99803593 C T 2.43E-04 Vaspin levels / / 22907691 rs7331698 chr13 99803593 C T 0.0002426 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs9517637 chr13 99841815 T C 5.85E-05 Self-reported allergy / / 23817569 rs2182885 chr13 99855124 G A 3.12E-05 Self-reported allergy UBAC2 intron 23817569 rs7338177 chr13 99869456 C T 8.97E-05 Self-reported allergy UBAC2 intron 23817569 rs731955 chr13 99870640 T A 5.42E-05 Self-reported allergy UBAC2 intron 23817569 rs9513584 chr13 99876281 G A 5.00E-04 Behcet's disease UBAC2 intron 19442274 rs7332672 chr13 99877471 C T 9.55E-05 Self-reported allergy UBAC2 intron 23817569 rs7322572 chr13 99879496 C T 9.18E-05 Self-reported allergy UBAC2 intron 23817569 rs3759443 chr13 99910322 A G 6.07E-05 Response to cytadine analogues (cytosine arabinoside) GPR18 intron 24483146 rs3809367 chr13 99912534 A G 2.03E-04 Response to cytadine analogues (cytosine arabinoside) UBAC2 intron 24483146 rs2182954 chr13 99937082 C T 7.03E-04 Multiple complex diseases UBAC2 intron 17554300 rs2230343 chr13 99948097 A G 7.56E-05 Body mass index GPR183 cds-synon 17255346 rs2230343 chr13 99948097 A G 1.16E-04 Response to cytadine analogues (cytosine arabinoside) GPR183 cds-synon 24483146 rs17472050 chr13 99955398 A G 5.45E-04 Multiple complex diseases GPR183 intron 17554300 rs9557195 chr13 99956622 T C 2.00E-14 Inflammatory bowel disease GPR183 intron 23128233 rs1923891 chr13 99959945 G A 4.87E-04 Response to cytadine analogues (cytosine arabinoside) UBAC2 intron 24483146 rs9517683 chr13 99968151 A G 2.30E-05 basal cell carcinoma UBAC2 intron 21700618 rs17472169 chr13 99968512 A G 8.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) UBAC2 intron 20877124 rs17575643 chr13 99984675 C T 5.33E-04 Multiple complex diseases UBAC2 intron 17554300 rs727263 chr13 100004108 G A 7.33E-04 Multiple complex diseases UBAC2 intron 17554300 rs17575699 chr13 100005745 G A 2.00E-04 Cognitive impairment induced by topiramate UBAC2 intron 22091778 rs7993715 chr13 100008313 C G 7.86E-05 Response to cytadine analogues (cytosine arabinoside) UBAC2 intron 24483146 rs7332161 chr13 100023469 G A 9.16E-04 Multiple complex diseases UBAC2 intron 17554300 rs9517701 chr13 100029540 A G 4.05E-04 Multiple complex diseases UBAC2 intron 17554300 rs7325747 chr13 100029932 C T 6.29E-04 Multiple complex diseases UBAC2 intron 17554300 rs912129 chr13 100033652 A G 7.52E-04 Multiple complex diseases UBAC2 intron 17554300 rs912129 chr13 100033652 A G 6.60E-04 Type 2 diabetes and 6 quantitative traits UBAC2 intron 17848626 rs912129 chr13 100033652 A G 4.40E-04 Self-reported allergy UBAC2 intron 23817569 rs4772190 chr13 100034116 A G 9.37E-04 Multiple complex diseases UBAC2 intron 17554300 rs1058143 chr13 100038336 T C 0.000027 Primary sclerosing cholangitis UBAC2 UTR-3 23603763 rs7335046 chr13 100041738 G C 3.00E-08 Basal cell carcinoma / / 21700618 rs7335046 chr13 100041738 G C 4.85E-04 Self-reported allergy / / 23817569 rs16956535 chr13 100048061 C T 4.63E-04 Multiple complex diseases / / 17554300 rs2892976 chr13 100058561 G A 9.36E-04 Multiple complex diseases / / 17554300 rs9557217 chr13 100068267 C T 1.51E-05 Self-reported allergy / / 23817569 rs4771332 chr13 100070457 T C 3.44E-04 Self-reported allergy / / 23817569 rs9557219 chr13 100070907 G A 2.22E-05 Body mass index / / 17255346 rs6491500 chr13 100073665 G A 1.44E-05 Type 1 diabetes / / 21980299 rs6491500 chr13 100073665 G A 1.14E-05 Self-reported allergy / / 23817569 rs9517711 chr13 100074280 G A 1.47E-05 Self-reported allergy / / 23817569 rs11838460 chr13 100076818 T C 1.03E-04 Multiple complex diseases / / 17554300 rs4772201 chr13 100086259 A G 0.00000866 Asthma / / 22694930 rs4772201 chr13 100086259 A G 4.58E-06 Asthma / / pha003127 rs9788413 chr13 100098120 G A 8.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs4369516 chr13 100100700 A G 9.00E-05 Prostate cancer / / 21743057 rs9300549 chr13 100103734 G A 2.50E-04 Multiple complex diseases / / 17554300 rs11618570 chr13 100103895 C T 6.47E-04 Multiple complex diseases / / 17554300 rs11616269 chr13 100106887 T C 3.54E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9517738 chr13 100112522 G A 6.46E-04 Self-reported allergy / / 23817569 rs9300551 chr13 100138079 A G 5.71E-05 Multiple complex diseases / / 17554300 rs9554603 chr13 100147082 G T 9.00E-06 Bipolar disorder / / 21738484 rs4772214 chr13 100155077 T C 3.18E-04 Multiple complex diseases TM9SF2 intron 17554300 rs2031426 chr13 100160345 A G 6.77E-04 Multiple complex diseases TM9SF2 intron 17554300 rs2147621 chr13 100162208 G C 7.08E-05 Multiple complex diseases TM9SF2 intron 17554300 rs9557251 chr13 100178627 A G 2.00E-04 Information processing speed TM9SF2 intron 21130836 rs9585118 chr13 100190504 A G 4.06E-04 Multiple complex diseases TM9SF2 intron 17554300 rs9513627 chr13 100196952 G A 4.00E-06 Obesity-related traits TM9SF2 intron 23251661 rs3803255 chr13 100201640 A G 5.89E-05 Multiple complex diseases TM9SF2 intron 17554300 rs9517765 chr13 100202206 C T 3.97E-05 Multiple complex diseases TM9SF2 intron 17554300 rs9517765 chr13 100202206 C T 2.00E-04 Information processing speed TM9SF2 intron 21130836 rs9517766 chr13 100202301 G A 1.31E-04 Multiple complex diseases TM9SF2 intron 17554300 rs9517767 chr13 100202369 C A 3.18E-04 Self-reported allergy TM9SF2 intron 23817569 rs7321735 chr13 100203573 C T 2.01E-05 Multiple complex diseases TM9SF2 intron 17554300 rs9585127 chr13 100205332 C T 2.61E-04 Multiple complex diseases TM9SF2 intron 17554300 rs4290346 chr13 100216909 T G 2.00E-04 Information processing speed / / 21130836 rs2793772 chr13 100231573 T G 3.30E-05 Volumetric brain MRI / / 17903297 rs17473024 chr13 100238193 T C 9.49E-05 Cleft lip / / 20436469 rs912659 chr13 100259210 C T 8.95E-05 Major depressive disorder (broad) CLYBL intron 20038947 rs9557276 chr13 100317088 G T 4.65E-05 Longevity CLYBL intron 22279548 rs12427494 chr13 100317494 T C 3.56E-05 Cleft lip CLYBL intron 20436469 rs1341399 chr13 100341178 G A 2.59E-05 Cognitive performance CLYBL intron 19734545 rs12184508 chr13 100352798 T C 4.94E-05 Cleft lip CLYBL intron 20436469 rs2806281 chr13 100389873 T C 1.30E-05 Personality dimensions CLYBL intron 18957941 rs725834 chr13 100456858 C A 4.69E-04 Multiple complex diseases CLYBL intron 17554300 rs12868139 chr13 100463508 C T 2.53E-04 Multiple complex diseases CLYBL intron 17554300 rs1555589 chr13 100480664 G A 4.00E-04 Chronic fatigue syndrome CLYBL intron 21912186 rs2761171 chr13 100480897 G A 4.10E-05 Kidney function and endocine traits CLYBL intron 17903292 rs9513675 chr13 100493160 G A 5.00E-06 Obesity-related traits CLYBL intron 23251661 rs1886035 chr13 100499373 A G 5.75E-05 Vitiligo CLYBL intron 19890347 rs41281112 chr13 100518634 C T 9.00E-10 Vitamin B12 levels CLYBL STOP-GAIN 22367966 rs9557321 chr13 100521101 T C 6.00E-08 Rheumatoid arthritis (ACPA-negative) CLYBL intron 24532677 rs7335739 chr13 100525859 G C 4.89E-04 Suicide attempts in bipolar disorder CLYBL intron 21423239 rs7334071 chr13 100531211 C T 3.46E-06 Esophageal cancer (squamous cell) CLYBL intron 22960999 rs8002475 chr13 100531456 G A 3.11E-04 Suicide attempts in bipolar disorder CLYBL intron 21423239 rs12584825 chr13 100545822 C T 5.09E-05 Multiple complex diseases CLYBL UTR-3 17554300 rs7992643 chr13 100555038 G C 5.00E-06 Attention deficit hyperactivity disorder / / 18821565 rs7992592 chr13 100555303 A T 3.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs7997714 chr13 100555353 G A 4.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs9585260 chr13 100555382 G A 3.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs9585276 chr13 100568167 G A 1.70E-04 Endometriosis / / 21151130 rs9300574 chr13 100575093 A G 4.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs9585279 chr13 100575855 G A 6.60E-04 Endometriosis / / 23104006 rs9300575 chr13 100578301 G A 8.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs9517921 chr13 100581201 C T 5.44E-04 Iron levels / / pha002876 rs9585291 chr13 100588166 T C 9.31E-04 Parkinson's disease / / 17052657 rs16957074 chr13 100593627 T C 7.39E-04 Multiple complex diseases / / 17554300 rs7324365 chr13 100601327 T C 6.88E-06 Amyotrophic Lateral Sclerosis / / 17827064 rs12869870 chr13 100617305 G A 6.54E-04 Iron levels ZIC5 UTR-3 pha002876 rs7330744 chr13 100629227 G A 8.95E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1334586 chr13 100635606 G A 3.66E-05 Cleft lip ZIC2 intron 20436469 rs13542 chr13 100638392 G A 9.33E-06 Cleft lip ZIC2 UTR-3 20436469 rs13542 chr13 100638392 G A 1.00E-06 Orofacial clefts ZIC2 UTR-3 22863734 rs2390334 chr13 100666633 C T 4.37E-04 Schizophrenia / / 19197363 rs4291789 chr13 100672921 C G 0.000000021 Myopia (Age of onset) / / 23468642 rs9554662 chr13 100697937 T G 5.44E-04 Schizophrenia / / 19197363 rs9557378 chr13 100747566 G A 4.35E-04 Schizophrenia PCCA intron 19197363 rs6491544 chr13 100751208 T C 5.78E-04 Schizophrenia PCCA intron 19197363 rs9300587 chr13 100767939 C G 2.36E-05 Multiple complex diseases PCCA intron 17554300 rs9300589 chr13 100786748 C T 5.34E-04 Response to taxane treatment (placlitaxel) PCCA intron 23006423 rs2184971 chr13 100818092 A G 2.00E-08 Refractive error PCCA intron 23396134 rs4772269 chr13 100830307 A G 6.22E-04 Response to taxane treatment (placlitaxel) PCCA intron 23006423 rs7997125 chr13 100839314 A G 1.33E-04 Multiple complex diseases PCCA intron 17554300 rs13378764 chr13 100853824 G A,T 0.0002 Migraine PCCA intron 22678113 rs9582378 chr13 100878484 A G 0.0002 Migraine PCCA intron 22678113 rs9582378 chr13 100878484 A G 9.45E-04 Response to taxane treatment (placlitaxel) PCCA intron 23006423 rs681561 chr13 100898529 A C 3.93E-04 Alcohol dependence PCCA intron 21314694 rs9554679 chr13 100989062 C T 2.92E-04 Smoking initiation PCCA intron 24665060 rs2038672 chr13 101134343 A G 4.28E-04 Major depressive disorder PCCA intron 22472876 rs9518080 chr13 101138776 A G 6.25E-05 Coronary heart disease PCCA intron pha003030 rs12864917 chr13 101148172 C T 3.46E-05 Cognitive impairment induced by topiramate PCCA intron 22091778 rs12100240 chr13 101164617 C A 1.28E-04 Insulin resistance PCCA intron 21901158 rs837322 chr13 101173401 C T 3.57E-05 Hemoglobin PCCA intron pha003098 rs837322 chr13 101173401 C T 7.56E-05 Erythrocyte counts PCCA intron pha003099 rs9554711 chr13 101276884 A G 5.65E-05 Nicotine smoking TMTC4 intron 19268276 rs17475653 chr13 101302436 A G 7.43E-05 Caffeine consumption TMTC4 intron 21490707 rs1283198 chr13 101324300 C T 9.40E-05 Cognitive test performance TMTC4 intron 20125193 rs1283198 chr13 101324300 C T 2.49E-05 Lymphocyte counts TMTC4 intron 22286170 rs1765738 chr13 101383090 C G 5.06E-05 Alcohol consumption / / pha001399 rs1283140 chr13 101390757 A C 4.28E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs9513795 chr13 101402225 C T 2.79E-04 Blood pressure / / 17255346 rs7985084 chr13 101441144 C T 9.78E-05 Heart Rate / / pha003054 rs1041015 chr13 101458632 A G 4.20E-05 Glaucoma (primary open-angle) / / 20835238 rs640769 chr13 101522666 A G 2.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs9518187 chr13 101522970 A G 7.14E-05 Suicide attempts in bipolar disorder / / 21423239 rs6491593 chr13 101524160 G A 7.66E-05 Suicide attempts in bipolar disorder / / 21423239 rs9513811 chr13 101524185 G A 6.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs1359555 chr13 101562581 C G 2.52E-04 Alzheimer's disease / / 22005930 rs4128360 chr13 101563379 A G 8.98E-04 Alzheimer's disease / / 22005930 rs3886777 chr13 101563771 G T 8.18E-04 Alzheimer's disease / / 22005930 rs7319187 chr13 101565381 A C 9.43E-04 Alzheimer's disease / / 22005930 rs9585547 chr13 101569999 A G 1.77E-04 Alzheimer's disease / / 22005930 rs4772347 chr13 101579484 C G 4.55E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17620154 chr13 101594539 T C 7.43E-05 Cognitive decline / / 22054870 rs9513824 chr13 101596322 T C 2.96E-05 Alzheimer's disease / / 24755620 rs9554742 chr13 101596542 G A 1.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs9513826 chr13 101596563 A C 8.91E-04 Type 2 diabetes / / 17463246 rs9554743 chr13 101596908 A C 2.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs17620178 chr13 101597507 G A 2.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs11617409 chr13 101599892 A G 1.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs9557559 chr13 101600585 C T 1.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs9518226 chr13 101600862 T C 3.84E-05 Alzheimer's disease / / 24755620 rs2803215 chr13 101602950 T G 8.89E-05 Alzheimer's disease / / 17998437 rs9634523 chr13 101603545 A C 3.38E-04 Alzheimer's disease / / 17998437 rs9557561 chr13 101604223 G A 2.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs2803213 chr13 101604450 A C 3.69E-04 Alzheimer's disease / / 24755620 rs1570900 chr13 101666047 C G 1.60E-05 Urinary metabolites / / 21572414 rs2765316 chr13 101671377 G A 3.71E-04 Multiple complex diseases / / 17554300 rs9645898 chr13 101677816 A C 5.33E-05 Depression (quantitative trait) / / 23290196 rs10508051 chr13 101693207 A T 6.77E-04 Type 2 diabetes / / 17463246 rs9554751 chr13 101699325 G A 9.04E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs678255 chr13 101700124 G C 1.47E-05 Bipolar disorder and schizophrenia / / 20889312 rs3751403 chr13 101701747 C T 4.55E-05 Schizophrenia / / 19571809 rs3751403 chr13 101701747 C T 3.36E-05 Bipolar disorder and schizophrenia / / 20889312 rs3751403 chr13 101701747 C T 2.10E-05 Schizophrenia / / pha002857 rs628949 chr13 101701764 G C 2.16E-05 Bipolar disorder and schizophrenia / / 20889312 rs12430088 chr13 101704076 C T 2.30E-05 Schizophrenia / / 19571809 rs12430088 chr13 101704076 C T 2.85E-05 Bipolar disorder and schizophrenia / / 20889312 rs12430088 chr13 101704076 C T 5.11E-05 Schizophrenia / / pha002857 rs2044117 chr13 101708310 G A 5.00E-07 Bipolar disorder and schizophrenia /LCN intron 20889312 rs2044117 chr13 101708310 G A 1.34E-05 Schizophrenia /LCN intron pha002857 rs17581500 chr13 101720487 T A 2.53E-06 Bipolar disorder and schizophrenia /LCN intron 20889312 rs12867417 chr13 101738035 G A 2.98E-05 Bipolar disorder and schizophrenia /LCN intron 20889312 rs4265682 chr13 101739994 G T 7.31E-04 Suicide attempts in bipolar disorder /LCN intron 21041247 rs9518301 chr13 101740910 T G 1.91E-04 Amyotrophic lateral sclerosis (sporadic) /LCN intron 24529757 rs640960 chr13 101762050 C T 1.00E-04 Cognitive impairment induced by topiramate /LCN intron 22091778 rs640960 chr13 101762050 C T 1.00E-04 Cognitive impairment induced by topiramate /LCN intron 22091778 rs640960 chr13 101762050 C T 4.56E-04 Cognitive impairment induced by topiramate /LCN intron 22091778 rs7323036 chr13 101767161 A C 4.95E-04 Multiple complex diseases /LCN intron 17554300 rs658424 chr13 101769546 T C 1.40E-05 Urinary metabolites /LCN intron 21572414 rs10508054 chr13 101792459 A C 1.44E-04 Lung function (forced expiratory volume in 1 second) /LCN intron 24023788 rs17621669 chr13 101805281 G A 3.95E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) /LCN intron 24023788 rs594524 chr13 101813637 T C 0.00030382 Hypertension (early onset hypertension) /LCN intron 22479346 rs9582456 chr13 101820412 C T 7.35E-04 Alzheimer's disease /LCN intron 17998437 rs10508058 chr13 101861912 C T 4.90E-04 Type 2 diabetes and 6 quantitative traits /LCN intron 17848626 rs7981947 chr13 101869582 T A 6.89E-05 Multiple complex diseases /LCN intron 17554300 rs11069433 chr13 101877620 T C 3.09E-04 Multiple complex diseases /LCN intron 17554300 rs9518346 chr13 101883084 T C 6.92E-04 Multiple complex diseases /LCN intron 17554300 rs2390576 chr13 101892245 G A 6.71E-04 Multiple complex diseases /LCN intron 17554300 rs1333758 chr13 101897883 A T 7.92E-05 Height /LCN intron 17255346 rs1333758 chr13 101897883 A T 2.58E-04 Multiple complex diseases /LCN intron 17554300 rs1333758 chr13 101897883 A T 2.03E-06 Smoking cessation /LCN intron 18519826 rs522342 chr13 101917089 A G 7.00E-04 Multiple complex diseases /LCN intron 17554300 rs9513877 chr13 101926339 G A 8.10E-05 Bipolar disorder /LCN intron 17486107 rs10508059 chr13 101932831 C T 1.28E-06 Bilirubin levels,in serum /LCN intron 19389676 rs544823 chr13 101933617 A G 9.67E-05 Non-alcoholic fatty liver disease histology (other) /LCN intron 20708005 rs554997 chr13 101944205 A C 4.10E-04 Taste perception /LCN intron 22132133 rs471071 chr13 101944809 T C 1.91E-05 Lipid traits /LCN intron 22028671 rs475328 chr13 101955751 G A 7.36E-04 Response to cytadine analogues (cytosine arabinoside) /LCN intron 24483146 rs545856 chr13 101956266 T C 8.12E-04 Response to cytadine analogues (cytosine arabinoside) /LCN intron 24483146 rs9518366 chr13 101959985 G A 9.14E-05 Bipolar Disorder /LCN intron pha002858 rs509933 chr13 101970556 T C 2.91E-05 Smoking cessation /LCN intron 18519826 rs509933 chr13 101970556 T C 7.36E-04 Smoking cessation /LCN intron 18519826 rs1931084 chr13 101981103 C T 2.60E-04 Multiple complex diseases /LCN intron 17554300 rs543167 chr13 101983430 C T 5.12E-04 Heart Failure /LCN intron pha002884 rs7326309 chr13 101994744 A G 0.0000042 Mean arterial pressure /LCN intron 22510845 rs7996217 chr13 102000945 T G 3.77E-04 IgE levels /LCN intron 17255346 rs7996217 chr13 102000945 T G 7.00E-07 HIV-associated dementia /LCN intron 22628157 rs7333463 chr13 102004504 A G 0.000012 Mean arterial pressure /LCN intron 22510845 rs17583885 chr13 102019538 G C 4.20E-06 Urinary metabolites /LCN intron 21572414 rs17486773 chr13 102019897 C T 1.40E-05 Urinary metabolites /LCN intron 21572414 rs3918319 chr13 102022883 T C 3.05E-04 Amyotrophic Lateral Sclerosis /LCN intron 17827064 rs3918319 chr13 102022883 T C 4.68E-04 Iron levels /LCN intron pha002876 rs1890234 chr13 102027130 C G 2.90E-05 Urinary metabolites /LCN intron 21572414 rs17584007 chr13 102027535 G A 7.60E-04 Multiple complex diseases /LCN intron 17554300 rs17584007 chr13 102027535 G A 2.80E-05 Urinary metabolites /LCN intron 21572414 rs4772372 chr13 102033686 C T 2.00E-05 Urinary metabolites /LCN intron 21572414 rs11617026 chr13 102045479 G A 1.70E-06 Alzheimer's disease /LCN intron 21059989 rs9557635 chr13 102051090 A G 9.00E-06 Non-small cell lung cancer /LCN intron 23144319 rs10508066 chr13 102055074 C T 7.05E-04 Smoking initiation /LCN intron 24665060 rs1572591 chr13 102060076 C T 3.00E-06 Psychosis (atypical) /LCN intron 24132900 rs34716843 chr13 102090037 G A 6.16E-04 Smoking initiation / / 24665060 rs2065764 chr13 102136339 G T 5.35E-05 Socioeconomic Factors ITGBL1 intron pha003067 rs1335587 chr13 102145560 C T 9.00E-06 Obesity-related traits ITGBL1 intron 23251661 rs9518426 chr13 102162080 C T 1.44E-04 Alcohol dependence ITGBL1 intron 20201924 rs9518426 chr13 102162080 C T 3.45E-05 Waist-Hip Ratio ITGBL1 intron pha003013 rs9518426 chr13 102162080 C T 4.48E-06 Waist-Hip Ratio ITGBL1 intron pha003028 rs875118 chr13 102175808 C A 5.67E-05 Serum metabolites ITGBL1 intron 19043545 rs9513909 chr13 102176244 T C 3.69E-05 Waist-Hip Ratio ITGBL1 intron pha003028 rs9300675 chr13 102181717 A G 6.66E-04 Myopia (pathological) ITGBL1 intron 21095009 rs9300679 chr13 102186445 A G 2.40E-04 Type 2 diabetes and 6 quantitative traits ITGBL1 intron 17848626 rs9557704 chr13 102227495 A T 2.00E-07 Waist-to-hip circumference ratio (interaction) ITGBL1 intron 23192594 rs3918322 chr13 102235519 A G 9.08E-04 Myopia (pathological) ITGBL1 intron 21095009 rs9300682 chr13 102243185 T C 4.70E-04 Type 2 diabetes and 6 quantitative traits ITGBL1 intron 17848626 rs16959194 chr13 102271135 G A 5.74E-04 Myopia (pathological) ITGBL1 intron 21095009 rs1125871 chr13 102272954 A C,G,T 7.00E-04 Type 2 diabetes and 6 quantitative traits ITGBL1 intron 17848626 rs9554813 chr13 102291577 A G 3.40E-04 Alcohol dependence ITGBL1 intron 20201924 rs9554813 chr13 102291577 A G 3.80E-04 Alcohol dependence ITGBL1 intron 20201924 rs9554815 chr13 102306889 T A 9.85E-04 Response to taxane treatment (placlitaxel) ITGBL1 intron 23006423 rs11069452 chr13 102311752 G A 2.65E-05 Suicide attempts in bipolar disorder ITGBL1 intron 21423239 rs11069452 chr13 102311752 G A 2.37E-05 Height ITGBL1 intron pha003011 rs7333553 chr13 102324615 A T 1.53E-05 Suicide attempts in bipolar disorder ITGBL1 intron 21423239 rs10508074 chr13 102338351 G A 1.22E-05 Suicide attempts in bipolar disorder ITGBL1 intron 21423239 rs1540460 chr13 102348705 A T 2.48E-04 Multiple complex diseases ITGBL1 intron 17554300 rs9805314 chr13 102358064 G C 2.07E-05 Suicide attempts in bipolar disorder ITGBL1 intron 21423239 rs9582518 chr13 102362267 T G 3.58E-05 Suicide attempts in bipolar disorder ITGBL1 intron 21423239 rs17686597 chr13 102365996 T C 1.49E-05 Suicide attempts in bipolar disorder ITGBL1 intron 21423239 rs2281991 chr13 102366825 A G 2.72E-05 Suicide attempts in bipolar disorder ITGBL1 cds-synon 21423239 rs2281991 chr13 102366825 A G 2.13E-05 Height ITGBL1 cds-synon pha003011 rs1469855 chr13 102367403 T C 1.72E-05 Suicide attempts in bipolar disorder ITGBL1 intron 21423239 rs1469854 chr13 102367442 A G 2.40E-05 Suicide attempts in bipolar disorder ITGBL1 intron 21423239 rs1469853 chr13 102367488 T C 1.49E-05 Suicide attempts in bipolar disorder ITGBL1 intron 21423239 rs17686644 chr13 102369263 T C 6.68E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12583229 chr13 102369606 C G 1.65E-05 Suicide attempts in bipolar disorder / / 21423239 rs17624707 chr13 102370510 T C 8.10E-06 Suicide attempts in bipolar disorder / / 21423239 rs17624707 chr13 102370510 T C 9.01E-06 Height / / pha003011 rs17624725 chr13 102370995 T C 6.16E-06 Suicide attempts in bipolar disorder / / 21423239 rs17624725 chr13 102370995 T C 3.43E-05 Height / / pha003010 rs17624725 chr13 102370995 T C 1.23E-06 Height / / pha003011 rs7336528 chr13 102380167 C G 1.54E-04 Suicide attempts in bipolar disorder FGF14 intron 21423239 rs9518506 chr13 102389449 C T 8.33E-05 Suicide attempts in bipolar disorder FGF14 intron 21423239 rs2149258 chr13 102391917 G A 8.32E-05 Suicide attempts in bipolar disorder FGF14 intron 21423239 rs4772409 chr13 102395881 C A 6.69E-04 Heart Failure FGF14 intron pha002885 rs9585764 chr13 102397075 C A 2.52E-05 Suicide attempts in bipolar disorder FGF14 intron 21423239 rs11069458 chr13 102402685 T C 8.21E-05 Suicide attempts in bipolar disorder FGF14 intron 21423239 rs1927711 chr13 102404956 T G 8.12E-04 Multiple complex diseases FGF14 intron 17554300 rs1927712 chr13 102411046 C G 9.50E-05 Suicide attempts in bipolar disorder FGF14 intron 21423239 rs4238230 chr13 102412314 G A 7.20E-04 Suicide attempts in bipolar disorder FGF14 intron 21423239 rs61966764 chr13 102437533 T C 0.00000465 Nonsyndromic striae distensae (stretch marks) FGF14 intron 23633020 rs1041255 chr13 102441669 C T 9.90E-06 Urinary metabolites FGF14 intron 21572414 rs7993025 chr13 102451029 G A 1.70E-05 Urinary metabolites FGF14 intron 21572414 rs7331453 chr13 102454467 G A 3.83E-05 Serum metabolites FGF14 intron 19043545 rs1322702 chr13 102459601 T C 3.22E-05 Common variable immunodeficiency FGF14 intron 21497890 rs10508076 chr13 102472252 T C 4.35E-06 Bone mass and geometry FGF14 intron 17903296 rs1980697 chr13 102478726 C T 3.86E-05 Lipoprotein-associated phospholipase A2 activity and mass FGF14 intron 20442857 rs2984835 chr13 102486443 C T 7.06E-04 Tourette syndrome FGF14 intron 22889924 rs1323194 chr13 102518690 G A 5.10E-04 Smoking quantity FGF14 intron 24665060 rs1570465 chr13 102536743 A G 3.03E-04 Smoking quantity FGF14 intron 24665060 rs9557754 chr13 102553248 G T 8.00E-06 QT interval FGF14 intron 23166209 rs2476230 chr13 102582443 G C 2.22E-04 Multiple complex diseases FGF14 intron 17554300 rs2476230 chr13 102582443 G C 2.00E-04 Response to antidepressant treatment (citalopram) FGF14 intron 23726668 rs10508078 chr13 102592110 T C 8.92E-05 Lipoprotein-associated phospholipase A2 activity and mass FGF14 intron 20442857 rs17631205 chr13 102607422 T G 3.90E-04 Type 2 diabetes FGF14 intron 17463246 rs17631205 chr13 102607422 T G 6.89E-06 Hearing function FGF14 intron 21493956 rs1407579 chr13 102607530 A G 0.000566 Salmonella-induced pyroptosis FGF14 intron 22837397 rs17687714 chr13 102611040 A G 5.78E-06 Hearing function FGF14 intron 21493956 rs7987221 chr13 102611766 A C 5.77E-06 Hearing function FGF14 intron 21493956 rs17687720 chr13 102611999 A C 5.76E-06 Hearing function FGF14 intron 21493956 rs7989226 chr13 102612043 T C 0.000877 Salmonella-induced pyroptosis FGF14 intron 22837397 rs17687732 chr13 102612067 A T 5.83E-06 Hearing function FGF14 intron 21493956 rs17631289 chr13 102612430 A C 6.35E-06 Hearing function FGF14 intron 21493956 rs12430805 chr13 102612770 C T 6.50E-06 Hearing function FGF14 intron 21493956 rs12430821 chr13 102612823 G A 6.66E-06 Hearing function FGF14 intron 21493956 rs4772428 chr13 102613718 C G 6.74E-06 Hearing function FGF14 intron 21493956 rs12427431 chr13 102614943 G T 6.88E-06 Hearing function FGF14 intron 21493956 rs12856393 chr13 102615145 T A 7.02E-06 Hearing function FGF14 intron 21493956 rs12427457 chr13 102615320 G A 7.07E-06 Hearing function FGF14 intron 21493956 rs12864397 chr13 102615673 A C 7.90E-04 Primary sclerosing cholangitis FGF14 intron 19944697 rs9557765 chr13 102624418 T C 3.20E-04 Lung function (forced expiratory volume in 1 second) FGF14 intron 17255346 rs2476236 chr13 102626423 A G 6.06E-04 Depression (quantitative trait) FGF14 intron 20800221 rs4772431 chr13 102627154 A G 4.06E-04 Depression (quantitative trait) FGF14 intron 20800221 rs2476238 chr13 102627365 C A 5.94E-04 Depression (quantitative trait) FGF14 intron 20800221 rs7324177 chr13 102627599 G A 3.50E-04 Alcohol dependence FGF14 intron 20201924 rs12708382 chr13 102646813 T C 2.75E-12 Multiple complex diseases FGF14 intron 17554300 rs11617740 chr13 102680126 G A 7.00E-07 Preeclampsia FGF14 intron 23551011 rs17688345 chr13 102685123 G A 9.46E-04 Suicide attempts in bipolar disorder FGF14 intron 21423239 rs41505644 chr13 102710976 G C 8.92E-04 Multiple complex diseases FGF14 intron 17554300 rs2765635 chr13 102719850 C T 8.16E-04 Multiple complex diseases FGF14 intron 17554300 rs652157 chr13 102764516 T C 6.41E-04 Schizophrenia FGF14 intron 19197363 rs660557 chr13 102773019 A G 8.26E-04 Depression (quantitative trait) FGF14 intron 20800221 rs478543 chr13 102773028 C T 8.27E-04 Depression (quantitative trait) FGF14 intron 20800221 rs648465 chr13 102773400 A G 8.30E-04 Depression (quantitative trait) FGF14 intron 20800221 rs674312 chr13 102775098 T C 8.78E-04 Depression (quantitative trait) FGF14 intron 20800221 rs502094 chr13 102775616 C T 7.26E-04 Depression (quantitative trait) FGF14 intron 20800221 rs498351 chr13 102776029 C G 9.00E-04 Depression (quantitative trait) FGF14 intron 20800221 rs7339421 chr13 102778025 T C 8.95E-04 Response to taxane treatment (placlitaxel) FGF14 intron 23006423 rs615746 chr13 102778965 C T 9.82E-04 Depression (quantitative trait) FGF14 intron 20800221 rs636559 chr13 102794587 C T 4.34E-04 Depression (quantitative trait) FGF14 intron 20800221 rs4772445 chr13 102803631 G A 4.88E-05 Schizophrenia FGF14 intron 19197363 rs17589077 chr13 102820000 G C 8.24E-04 Self-reported allergy FGF14 intron 23817569 rs9513989 chr13 102821641 G T 4.94E-05 Personality dimensions FGF14 intron 18957941 rs536863 chr13 102829599 T C 2.62E-05 Personality dimensions FGF14 intron 18957941 rs7322577 chr13 102836774 T G 4.19E-04 Alcohol dependence FGF14 intron 20201924 rs9518649 chr13 102839380 A G 1.69E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) FGF14 intron 24023788 rs544434 chr13 102849265 T C 6.00E-06 Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure) FGF14 intron 21130132 rs9582561 chr13 102851965 C T 8.16E-04 Tourette syndrome FGF14 intron 22889924 rs9518650 chr13 102853705 G A 7.43E-04 Type 2 diabetes FGF14 intron 17463246 rs626987 chr13 102853838 T A 8.44E-04 Multiple complex diseases FGF14 intron 17554300 rs531381 chr13 102854982 T C 5.36E-06 Body Fat Distribution FGF14 intron pha003017 rs1336703 chr13 102860527 A G 6.67E-05 Magnesium levels FGF14 intron pha003092 rs1336698 chr13 102863748 C T 5.76E-08 Common variable immunodeficiency FGF14 intron 21497890 rs6491676 chr13 102907408 G A 4.27E-04 Oral cancers (chewing tobacco related) FGF14 intron 22503698 rs9300729 chr13 102921869 T C 1.89E-04 Response to cholinesterase inhibitors in Alzheimer's disease FGF14 intron 23374588 rs1336712 chr13 102922620 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FGF14 intron 22628534 rs1336662 chr13 102953263 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FGF14 intron 22628534 rs2893086 chr13 102961123 C G 3.51E-04 Type 2 diabetes FGF14 intron 17463246 rs1336708 chr13 102965003 A G 0.0000331 Otitis media (children 3 years old or younger) FGF14 intron 23133572 rs1336708 chr13 102965003 A G 5.00E-09 Venous thromboembolism (gene x gene interaction) FGF14 intron 23509962 rs17505622 chr13 102974615 G A 1.29E-04 Alzheimer's disease FGF14 intron 24755620 rs11069485 chr13 103042097 G A 0.000238 Salmonella-induced pyroptosis FGF14 intron 22837397 rs17690152 chr13 103065062 T G 3.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16960147 chr13 103080052 A G 8.33E-04 Alzheimer's disease / / 24755620 rs1927369 chr13 103135443 C A 7.65E-05 Progressive supranuclear palsy / / 21685912 rs1927377 chr13 103139773 G T 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1927384 chr13 103145750 A G 2.60E-05 Type 2 diabetes / / 17903298 rs9557865 chr13 103149079 C T 3.83E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs7324714 chr13 103159647 A G 2.83E-05 Personality dimensions / / 22628180 rs7989266 chr13 103217875 A G 1.23E-04 Smoking initiation / / 24665060 rs4772492 chr13 103247624 G A 1.29E-04 Lymphocyte counts / / 22286170 rs4772492 chr13 103247624 G A 5.87E-05 Fibrinogen / / pha003068 rs680840 chr13 103296243 A G 7.08E-05 Brain lesion load TPP2 intron 19010793 rs664660 chr13 103301537 G T 2.46E-04 Blood pressure TPP2 intron 17255346 rs689358 chr13 103306987 C T 7.08E-05 Brain lesion load TPP2 intron 19010793 rs677594 chr13 103315210 G A 7.08E-05 Brain lesion load TPP2 intron 19010793 rs677594 chr13 103315210 G A 9.68E-05 Fibrinogen TPP2 intron pha003068 rs587250 chr13 103321211 A G 7.36E-05 Serum metabolites TPP2 intron 19043545 rs644005 chr13 103324673 G A 7.36E-05 Serum metabolites TPP2 intron 19043545 rs646784 chr13 103325324 G A 2.52E-05 Serum metabolites TPP2 intron 19043545 rs660596 chr13 103326042 A C 7.36E-05 Serum metabolites TPP2 intron 19043545 rs674929 chr13 103326950 G A 6.03E-05 Brain lesion load TPP2 intron 19010793 rs678994 chr13 103327897 A G 5.68E-05 Fibrinogen TPP2 intron pha003068 rs582372 chr13 103328086 T C 4.63E-05 Serum metabolites TPP2 intron 19043545 rs639862 chr13 103333089 G T 7.08E-05 Brain lesion load / / 19010793 rs654454 chr13 103344609 G A 1.26E-07 Erythrocyte counts METTL21C intron pha003101 rs966724 chr13 103347428 T G 5.21E-04 Smoking quantity / / 24665060 rs4772498 chr13 103350564 T C 3.04E-05 Cognitive test performance / / 20125193 rs4772498 chr13 103350564 T C 5.78E-04 Telomere length / / 23900074 rs9557916 chr13 103352613 T C 6.24E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs7323315 chr13 103362290 A G 4.40E-06 Urinary metabolites / / 21572414 rs9585977 chr13 103368613 C G 1.10E-05 Urinary metabolites / / 21572414 rs9585978 chr13 103370602 T C 1.60E-05 Urinary metabolites / / 21572414 rs9518820 chr13 103375125 A G 1.20E-07 Urinary metabolites / / 21572414 rs2167091 chr13 103375852 G A 5.30E-08 Urinary metabolites / / 21572414 rs7317303 chr13 103376384 T C 4.90E-08 Urinary metabolites / / 21572414 rs9554894 chr13 103377565 A C 5.30E-08 Urinary metabolites / / 21572414 rs1026158 chr13 103400083 G A 8.85E-05 Cognitive impairment induced by topiramate CCDC168 cds-synon 22091778 rs1047740 chr13 103449202 T C 2.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) KDELC1 missense 21239504 rs3809373 chr13 103453372 C T 9.81E-04 Stroke BIVM intron pha002887 rs10508096 chr13 103460864 T C 4.65E-04 Heart Failure BIVM intron pha002884 rs3825516 chr13 103471820 A G 1.88E-06 Odorant perception BIVM intron 23910658 rs2281885 chr13 103491392 C T 3.80E-05 Temperament (bipolar disorder) BIVM intron 22365631 rs2094258 chr13 103496759 C T 4.60E-05 Temperament (bipolar disorder) BIVM-ERCC5 intron 22365631 rs11069498 chr13 103503322 G A 9.23E-04 Type 2 diabetes ERCC5 intron 17463246 rs4150274 chr13 103507111 T C 3.25E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ERCC5 intron 24023788 rs3783236 chr13 103521114 C T 4.91E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ERCC5 intron 24023788 rs4150353 chr13 103523067 A G 2.23E-04 Multiple complex diseases ERCC5 intron 17554300 rs8002276 chr13 103526139 T C 9.50E-05 Hypothyroidism ERCC5 intron 22493691 rs4150383 chr13 103527230 G A 2.27E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ERCC5 intron 24023788 rs4486740 chr13 103549494 G A 1.87E-04 Coronary heart disease / / 21971053 rs8181825 chr13 103554171 C T 8.88E-04 Coronary heart disease / / 21971053 rs9514069 chr13 103556061 A G 4.80E-05 Hypothyroidism / / 22493691 rs16960708 chr13 103556192 G A 9.33E-04 Coronary heart disease / / 21971053 rs1830759 chr13 103558196 C T 4.63E-05 Bone mineral density / / 19181680 rs1570545 chr13 103563693 T C 5.85E-04 Alzheimer's disease / / 22005930 rs58752208 chr13 103569838 G C 0.0000487 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4772511 chr13 103571012 C T 1.38E-05 Bone mineral density / / 19181680 rs61967483 chr13 103576761 C A 0.0000604 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12872080 chr13 103576820 G A 5.90E-05 HIV-1 control / / 20041166 rs9557964 chr13 103595035 T A 9.09E-04 Depression (quantitative trait) / / 20800221 rs2078284 chr13 103600902 T C 6.45E-04 Depression (quantitative trait) / / 20800221 rs9554918 chr13 103622589 G A 0.0000176 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7324320 chr13 103627553 A G 0.0000111 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1808631 chr13 103630594 G A 0.0000157 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1808632 chr13 103630971 G A 0.000016 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11619346 chr13 103632257 G C 1.60E-06 Urinary metabolites / / 21572414 rs7322528 chr13 103632389 G A 2.80E-06 Urinary metabolites / / 21572414 rs12857732 chr13 103632621 G A 0.0000168 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12585665 chr13 103633842 C T 0.0000172 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11620536 chr13 103635394 G C 0.0000172 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12864485 chr13 103636947 C G 9.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs9554920 chr13 103637047 G A 0.0000172 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9557975 chr13 103637342 C T 0.0000168 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9557979 chr13 103639417 G A 0.000019 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12875265 chr13 103640342 G A 0.0000172 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2098901 chr13 103640663 C A 0.000019 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9300775 chr13 103642569 T C 0.0000204 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9554923 chr13 103642736 G A 0.0000194 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12871039 chr13 103647284 C T 6.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs9557983 chr13 103653075 T C 0.0000259 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9557984 chr13 103654207 T C 0.0000245 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1952590 chr13 103656104 G A 0.0000252 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9557986 chr13 103659405 A G 0.000035 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11069502 chr13 103661226 G A 0.0000404 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9586032 chr13 103662524 G A 5.41E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9586032 chr13 103662524 G A 8.35E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6491721 chr13 103667178 A C 2.74E-04 Heart Failure / / pha002885 rs11617883 chr13 103676537 G T 1.56E-04 Insulin resistance / / 21901158 rs1549836 chr13 103693229 T C 9.70E-06 Urinary metabolites / / 21572414 rs2301159 chr13 103697728 G A 1 Drug response to Docetaxel SLC10A2 UTR-3 20038957 rs2301159 chr13 103697728 G A 1 Drug response to Thalidomide SLC10A2 UTR-3 20038957 rs1329515 chr13 103703055 A G 1.30E-05 Urinary metabolites SLC10A2 intron 21572414 rs279937 chr13 103704077 G A 1.50E-05 Urinary metabolites SLC10A2 intron 21572414 rs279936 chr13 103704608 C A 1.40E-05 Urinary metabolites SLC10A2 intron 21572414 rs188096 chr13 103705044 A C 6.40E-06 Urinary metabolites / / 21572414 rs117447044 chr13 103710685 G A 0.0000114 Ratio of free to total prostate-specific antigen SLC10A2 missense 23555315 rs157266 chr13 103712499 A G 1.90E-06 Urinary metabolites SLC10A2 intron 21572414 rs9514093 chr13 103715668 A C 8.91E-04 Response to taxane treatment (placlitaxel) SLC10A2 intron 23006423 rs16961281 chr13 103718824 G A 3.37E-04 Response to taxane treatment (placlitaxel) SLC10A2 UTR-5 23006423 rs1648250 chr13 103752904 T A 5.32E-04 Multiple complex diseases / / 17554300 rs1648250 chr13 103752904 T A 4.48E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2699332 chr13 103784788 T G 5.39E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1406656 chr13 103865491 T G 5.78E-04 Alzheimer's disease / / 17998437 rs912969 chr13 103867104 C T 8.00E-06 Smoking behavior / / 19247474 rs2031046 chr13 103892013 A G 0.000345 Salmonella-induced pyroptosis / / 22837397 rs2699346 chr13 103899573 C A 0.000209 Salmonella-induced pyroptosis / / 22837397 rs2699357 chr13 103901773 A G 0.000137 Salmonella-induced pyroptosis / / 22837397 rs2390878 chr13 103902872 A G 4.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2049772 chr13 103905600 T C 1.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2806337 chr13 103907420 T C 1.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1609421 chr13 103914406 T C 5.12E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3916927 chr13 103927135 G A 0.0000837 Salmonella-induced pyroptosis / / 22837397 rs1529276 chr13 103928007 T A 2.00E-06 Prostate cancer / / 17903305 rs1529276 chr13 103928007 T A 2.00E-06 Nasopharyngeal carcinoma / / 20512145 rs4771450 chr13 103969491 G A 2.00E-06 Uric acid levels / / 18759275 rs6491738 chr13 103971436 T C 1.49E-04 Non-small cell lung cancer,hypertriglyceridemia with bexarotene treatment of / / 21737656 rs12872118 chr13 103974781 G A 3.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12863155 chr13 103976610 G A 2.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16961985 chr13 103978050 T C 8.48E-04 Type 2 diabetes / / 17463246 rs7333033 chr13 103978262 A C 3.18E-05 Non-small cell lung cancer,hypertriglyceridemia with bexarotene treatment of / / 21737656 rs7338381 chr13 103978417 G A 1.26E-04 Non-small cell lung cancer,hypertriglyceridemia with bexarotene treatment of / / 21737656 rs3918334 chr13 103978779 T G 4.76E-05 Gallbladder disease / / pha001403 rs7986685 chr13 103979494 T C 3.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3916931 chr13 103986357 T A 6.15E-05 Non-small cell lung cancer,hypertriglyceridemia with bexarotene treatment of / / 21737656 rs1411651 chr13 103988360 G A 3.62E-04 Depression (quantitative trait) / / 20800221 rs1411650 chr13 103988495 T C 3.52E-04 Depression (quantitative trait) / / 20800221 rs1411649 chr13 103988531 A G 3.50E-04 Depression (quantitative trait) / / 20800221 rs17298539 chr13 103988923 T C 3.56E-04 Depression (quantitative trait) / / 20800221 rs951348 chr13 103990187 G A 6.75E-04 Multiple complex diseases / / 17554300 rs951347 chr13 103990227 C T 4.10E-04 Depression (quantitative trait) / / 20800221 rs9518987 chr13 103990454 C T 4.27E-04 Depression (quantitative trait) / / 20800221 rs7994713 chr13 103991614 G C 4.69E-04 Depression (quantitative trait) / / 20800221 rs7994851 chr13 103991629 G A 6.54E-04 Depression (quantitative trait) / / 20800221 rs9518991 chr13 103991671 T G 4.68E-04 Depression (quantitative trait) / / 20800221 rs9518992 chr13 103991727 G C 4.65E-04 Depression (quantitative trait) / / 20800221 rs9518993 chr13 103991818 A G 4.63E-04 Depression (quantitative trait) / / 20800221 rs9518999 chr13 103992269 T C 4.62E-04 Depression (quantitative trait) / / 20800221 rs9514121 chr13 103993369 C T 4.83E-04 Depression (quantitative trait) / / 20800221 rs9519003 chr13 103993701 A C 5.05E-04 Depression (quantitative trait) / / 20800221 rs9519004 chr13 103993802 A G 5.13E-04 Depression (quantitative trait) / / 20800221 rs9519011 chr13 103994250 G A 5.31E-04 Depression (quantitative trait) / / 20800221 rs9519012 chr13 103994378 A G 5.37E-04 Depression (quantitative trait) / / 20800221 rs10162020 chr13 103994807 A G 5.88E-04 Depression (quantitative trait) / / 20800221 rs10161695 chr13 103994822 T C 5.91E-04 Depression (quantitative trait) / / 20800221 rs7991857 chr13 103995069 C T 8.62E-04 Depression (quantitative trait) / / 20800221 rs7992025 chr13 103995145 C T 9.17E-04 Depression (quantitative trait) / / 20800221 rs7998553 chr13 103996052 G A 5.54E-04 Depression (quantitative trait) / / 20800221 rs885520 chr13 103999061 G T 4.12E-05 Coronary restenosis / / 21878436 rs1330778 chr13 103999645 A G 7.33E-06 Coronary restenosis / / 21878436 rs9586147 chr13 104024550 G A 2.20E-05 Urinary metabolites / / 21572414 rs9519026 chr13 104034713 C G 3.16E-04 Insulin resistance / / 21901158 rs9300811 chr13 104036311 T C 0.000501 5-fluorouracil induced nausea/vomiting in response to colorectal cancer treatment / / 22310351 rs10220061 chr13 104047061 A G 3.85E-06 Phospholipid levels (plasma) / / 21829377 rs10220265 chr13 104049583 G A 6.67E-07 Phospholipid levels (plasma) / / 21829377 rs16962226 chr13 104058539 G C 9.00E-05 Prostate cancer / / 21743057 rs9586177 chr13 104059930 C T 4.21E-07 Phospholipid levels (plasma) / / 21829377 rs9586178 chr13 104060018 G T 4.19E-07 Phospholipid levels (plasma) / / 21829377 rs9586179 chr13 104060087 T C 4.00E-07 Phospholipid levels (plasma) / / 21829377 rs9586180 chr13 104060133 T C 4.19E-07 Phospholipid levels (plasma) / / 21829377 rs7490068 chr13 104060395 G A 4.26E-07 Phospholipid levels (plasma) / / 21829377 rs1330767 chr13 104060591 C T 4.21E-07 Phospholipid levels (plasma) / / 21829377 rs2210152 chr13 104061586 T C 8.95E-07 Phospholipid levels (plasma) / / 21829377 rs2210153 chr13 104061641 G A 9.00E-07 Phospholipid levels (plasma) / / 21829377 rs16962303 chr13 104068869 A G 3.28E-04 Hearing function / / 17255346 rs1888322 chr13 104073612 C T 8.26E-06 Response to amphetamines / / 22952603 rs9586187 chr13 104076389 A T 6.66E-04 Multiple complex diseases / / 17554300 rs7987146 chr13 104081964 T C 2.21E-04 Iron levels / / pha002876 rs1571628 chr13 104090166 T C 3.10E-05 Personality dimensions / / 18957941 rs7992207 chr13 104090183 G C 3.10E-05 Personality dimensions / / 18957941 rs9514131 chr13 104090848 G T 2.30E-05 Personality dimensions / / 18957941 rs583464 chr13 104091545 C T 3.00E-06 Response to amphetamines / / 22952603 rs576898 chr13 104091602 C A 5.12E-06 Response to amphetamines / / 22952603 rs1537420 chr13 104168613 T G 6.30E-04 Acute lung injury / / 22295056 rs1889141 chr13 104173290 A G 4.93E-05 Insulin resistance / / 21901158 rs7325773 chr13 104182490 G C 6.00E-04 Chronic fatigue syndrome / / 21912186 rs16962638 chr13 104186919 A G 6.00E-06 Insulin resistance / / 21901158 rs10508115 chr13 104188615 A G 7.32E-04 Multiple complex diseases / / 17554300 rs10508115 chr13 104188615 A G 6.33E-05 Insulin resistance / / 21901158 rs994513 chr13 104192413 A G 1.99E-05 Serum metabolites / / 19043545 rs9554968 chr13 104201017 A G 1.36E-04 Multiple complex diseases / / 17554300 rs9300826 chr13 104203175 G A 1.79E-05 Pulmonary function / / 17903307 rs16962675 chr13 104209333 C T 9.01E-05 Insulin resistance / / 21901158 rs2065547 chr13 104211295 C A 3.07E-05 Multiple complex diseases / / 17554300 rs9300831 chr13 104220115 C T 2.04E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9300831 chr13 104220115 C T 2.51E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3918315 chr13 104228373 C A 1.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3918315 chr13 104228373 C A 5.35E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9558120 chr13 104232588 A G 1.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9558120 chr13 104232588 A G 4.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1812394 chr13 104234048 T C 6.37E-04 Alzheimer's disease / / 24755620 rs7323217 chr13 104235245 G A 1.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7323217 chr13 104235245 G A 5.35E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1412951 chr13 104240652 G A 1.03E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1412951 chr13 104240652 G A 9.51E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2026357 chr13 104245113 G T 9.27E-04 Alzheimer's disease / / 24755620 rs2026356 chr13 104245152 C T 9.10E-04 Alzheimer's disease / / 24755620 rs9300834 chr13 104246529 C A 2.36E-05 Non-small cell lung cancer / / 21866343 rs9300834 chr13 104246529 C A 8.04E-04 Alzheimer's disease / / 24755620 rs9300835 chr13 104246861 G A 1.42E-05 Non-small cell lung cancer / / 21866343 rs9300835 chr13 104246861 G A 6.28E-04 Alzheimer's disease / / 24755620 rs1412953 chr13 104247071 G A 3.58E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1412953 chr13 104247071 G A 4.90E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16962734 chr13 104247969 C T 3.65E-04 Insulin resistance / / 21901158 rs9558122 chr13 104248009 T C 2.52E-05 Non-small cell lung cancer / / 21866343 rs9558122 chr13 104248009 T C 7.10E-04 Alzheimer's disease / / 24755620 rs9586225 chr13 104264843 A G 2.51E-04 Alzheimer's disease / / 24755620 rs7320001 chr13 104277179 A G 5.17E-05 Alzheimer's disease / / 24755620 rs1331535 chr13 104278019 C T 1.11E-04 Insulin resistance / / 21901158 rs9554982 chr13 104280699 A G 2.78E-04 Alzheimer's disease / / 24755620 rs7335085 chr13 104281106 G A 8.45E-04 Type 2 diabetes / / 17463246 rs7335085 chr13 104281106 G A 5.14E-05 Alzheimer's disease / / 24755620 rs1331523 chr13 104294778 A G 3.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1331523 chr13 104294778 A G 4.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs979300 chr13 104309176 G A 9.31E-04 Alzheimer's disease / / 24755620 rs7337511 chr13 104312598 C T 3.31E-04 Alzheimer's disease / / 24755620 rs1331519 chr13 104346132 A G 9.12E-05 Pancreatic cancer / / pha002889 rs4772583 chr13 104349373 T C 3.78E-04 Insulin resistance / / 21901158 rs1757387 chr13 104351911 G A 9.13E-05 Pancreatic cancer / / pha002874 rs1757387 chr13 104351911 G A 7.90E-06 Pancreatic cancer / / pha002889 rs16963075 chr13 104353957 T C 1.70E-05 Urinary metabolites / / 21572414 rs9300855 chr13 104354011 C T 3.89E-04 Hearing function / / 17255346 rs961765 chr13 104369113 G A 1.46E-04 Insulin resistance / / 21901158 rs12427557 chr13 104369267 A G 2.76E-05 Hearing function / / 17255346 rs7328544 chr13 104369448 C T 4.34E-05 Hearing function / / 17255346 rs7331772 chr13 104380700 C T 0.000307 Salmonella-induced pyroptosis / / 22837397 rs9554990 chr13 104391808 A G 2.93E-04 Hearing function / / 17255346 rs1412007 chr13 104404759 G T 2.26E-05 Lipoproteins / / pha003079 rs1415019 chr13 104442532 C T 4.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9586268 chr13 104464966 G A 3.03E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs9514187 chr13 104495618 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9558198 chr13 104536251 T G 8.64E-05 Multiple complex diseases / / 17554300 rs9519173 chr13 104536762 G A 3.06E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs9519173 chr13 104536762 G A 5.52E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs9586302 chr13 104536820 C A 5.21E-04 Type 2 diabetes / / 17463246 rs17344132 chr13 104541701 T C 1.70E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs9558199 chr13 104546369 C T 1.97E-04 Multiple complex diseases / / 17554300 rs16963727 chr13 104549770 G C 1.59E-04 Multiple complex diseases / / 17554300 rs7328957 chr13 104557841 T C 6.61E-05 Erythrocyte counts / / pha003090 rs9555012 chr13 104577309 T C 4.46E-05 Orofacial clefts / / 22419666 rs2575147 chr13 104622061 A G 3.63E-05 AIDS progression / / 19115949 rs2669484 chr13 104640449 G T 4.54E-04 Smoking initiation / / 24665060 rs2669459 chr13 104644145 C A 9.66E-04 Type 2 diabetes / / 17463246 rs2063609 chr13 104651305 C T 6.97E-04 Type 2 diabetes / / 17463246 rs9582776 chr13 104664854 T C 3.15E-04 Smoking initiation / / 24665060 rs9586349 chr13 104666065 C T 1.83E-04 Smoking initiation / / 24665060 rs9586352 chr13 104666668 C G 4.51E-05 Telomere length / / 20139977 rs1983272 chr13 104672517 T C 2.19E-04 Smoking initiation / / 24665060 rs7993313 chr13 104712843 G A 3.85E-04 Smoking initiation / / 24665060 rs1849450 chr13 104714253 C A 4.06E-05 Telomere length / / 20139977 rs1812779 chr13 104715034 T C 2.58E-04 Smoking initiation / / 24665060 rs1513031 chr13 104716086 C T 2.65E-05 Telomere length / / 20139977 rs1913208 chr13 104721789 T G 6.46E-05 Periodontitis (Chronic) / / 25008200 rs1028037 chr13 104738554 T G 2.60E-04 Type 2 diabetes / / 17463246 rs1828661 chr13 104747059 G A 2.26E-04 Type 2 diabetes / / 17463246 rs1828662 chr13 104747117 G T 3.24E-04 Type 2 diabetes / / 17463246 rs2669501 chr13 104747823 C T 2.90E-04 Type 2 diabetes / / 17463246 rs149773673 chr13 104749836 G A 4.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2669502 chr13 104752946 T C 9.34E-05 Serum metabolites / / 19043545 rs9300897 chr13 104773619 G T 0.000293 Salmonella-induced pyroptosis / / 22837397 rs10508129 chr13 104779543 T C 1.80E-05 Urinary metabolites / / 21572414 rs4553462 chr13 104812006 C T 4.60E-04 Fibrinogen / / 17255346 rs1923864 chr13 104828082 T C 4.00E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9558257 chr13 104828676 T C 9.04E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4772612 chr13 104833330 T A 4.03E-04 Type 2 diabetes / / 17463246 rs10161771 chr13 104873872 T G 6.02E-04 Alzheimer's disease / / 24755620 rs2146642 chr13 104900372 G A 5.75E-04 Multiple complex diseases / / 17554300 rs7997408 chr13 104918061 G T 5.17E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12430290 chr13 104919235 A G 9.35E-04 Acute lung injury / / 22295056 rs16964573 chr13 104963607 A C 1.10E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17382447 chr13 104992193 A G 2.73E-04 Type 2 diabetes / / 17463246 rs10508144 chr13 105001126 C T 1.41E-04 Heart Failure / / pha002884 rs1590919 chr13 105015223 G A 1.42E-06 Blood Pressure and Arterial Stiffness / / 17903302 rs11617701 chr13 105031365 G A 9.46E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs17450420 chr13 105039146 A G 3.37E-04 Type 2 diabetes / / 17463246 rs17450420 chr13 105039146 A G 5.00E-08 Esophageal cancer (alcohol interaction) / / 22960999 rs17385266 chr13 105058516 A G 9.29E-06 Magnesium levels / / pha003092 rs9300927 chr13 105074966 G A 8.26E-04 Multiple complex diseases / / 17554300 rs11842313 chr13 105087690 T C 8.18E-04 Multiple complex diseases / / 17554300 rs7987983 chr13 105091080 G A 0.000000187 Secreted IFN-gamma response to smallpox vaccine / / 22661280 rs7337090 chr13 105112042 G A 0.000000701 Secreted IFN-gamma response to smallpox vaccine / / 22661280 rs9300935 chr13 105153074 G T 7.94E-04 Multiple complex diseases / / 17554300 rs4772633 chr13 105166545 A G 9.19E-04 Type 2 diabetes / / 17463246 rs7333498 chr13 105183839 C G 3.19E-04 Type 2 diabetes / / 17463246 rs7327355 chr13 105190182 G T 2.79E-04 Scoliosis / / 21216876 rs9558336 chr13 105192858 G T 1.27E-04 Alzheimer's disease / / 17998437 rs9555072 chr13 105199316 G A 2.90E-05 Urinary metabolites / / 21572414 rs12876869 chr13 105202940 C A 5.98E-05 Scoliosis / / 21216876 rs16964920 chr13 105220468 G A 2.20E-04 Multiple complex diseases / / 17554300 rs12100035 chr13 105259708 A G 0.0002744 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12100035 chr13 105259708 A G 2.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7342442 chr13 105270325 T C 6.45E-05 Self-reported allergy / / 23817569 rs892534 chr13 105271418 T A 5.72E-05 Self-reported allergy / / 23817569 rs9519416 chr13 105272052 C T 5.79E-05 Self-reported allergy / / 23817569 rs9519416 chr13 105272052 C T 1.94E-05 Body Mass Index / / pha003019 rs9519416 chr13 105272052 C T 2.96E-05 Body Mass Index / / pha003020 rs9519419 chr13 105272749 C G 9.77E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs9558370 chr13 105272867 A G 7.50E-05 Parkinson's disease (age of onset) / / 19772629 rs16965259 chr13 105390529 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs16965259 chr13 105390529 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs16965259 chr13 105390529 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1652901 chr13 105400379 T G 3.29E-30 Narcolepsy / / 19629137 rs1764773 chr13 105415046 G T 2.42E-05 Multiple complex diseases / / 17554300 rs1652879 chr13 105415609 C T 8.78E-04 Depression (quantitative trait) / / 20800221 rs4281575 chr13 105416059 C T 1.34E-04 Depression (quantitative trait) / / 20800221 rs1337153 chr13 105417378 A T 1.32E-04 Depression (quantitative trait) / / 20800221 rs2782987 chr13 105418388 T C 3.85E-04 Depression (quantitative trait) / / 20800221 rs2567004 chr13 105418533 G A 3.78E-04 Depression (quantitative trait) / / 20800221 rs2782989 chr13 105418641 C T 6.15E-04 Depression (quantitative trait) / / 20800221 rs7331728 chr13 105421263 A G 0.0000036 Chronic obstructive pulmonary disease (moderate to severe) / / 22986903 rs9586631 chr13 105422464 G A 1.61E-04 Depression (quantitative trait) / / 20800221 rs9558386 chr13 105422917 G A 2.30E-04 Depression (quantitative trait) / / 20800221 rs9555088 chr13 105423946 G A 1.40E-04 Depression (quantitative trait) / / 20800221 rs9558392 chr13 105424397 A C 1.86E-05 Depression (quantitative trait) / / 20800221 rs9558393 chr13 105424546 T C 9.32E-05 Depression (quantitative trait) / / 20800221 rs9555090 chr13 105424713 A T 1.81E-05 Depression (quantitative trait) / / 20800221 rs9582905 chr13 105437106 T G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs16965374 chr13 105453695 C T 5.20E-04 Depression (quantitative trait) / / 20800221 rs323463 chr13 105454868 A C 8.69E-04 Type 2 diabetes / / 17463246 rs7324676 chr13 105457282 C T 0.0000421 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs323425 chr13 105460662 T C 2.33E-07 Height / / 20400458 rs4772643 chr13 105482056 G A 1.33E-24 Narcolepsy / / 19629137 rs1326452 chr13 105484735 A G 2.20E-04 Suicide attempts in bipolar disorder / / 21041247 rs9514322 chr13 105484822 T C 3.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs7997861 chr13 105485296 C T 2.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs7139884 chr13 105485683 A C 2.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs9519488 chr13 105486522 T A 2.60E-04 Suicide attempts in bipolar disorder / / 21041247 rs9519490 chr13 105486661 C T 7.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs1409470 chr13 105486950 G A 2.63E-04 Suicide attempts in bipolar disorder / / 21041247 rs1409470 chr13 105486950 G A 1.13E-04 Major depression (suicidal thoughts and behavior) / / 21750702 rs1853979 chr13 105487668 A G 2.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs2031635 chr13 105488375 A G 7.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs9514325 chr13 105489516 A G 3.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs11616302 chr13 105499027 T C 4.18E-05 Multiple complex diseases / / 17554300 rs11619564 chr13 105499069 C A 1.77E-04 Multiple complex diseases / / 17554300 rs9519500 chr13 105521506 C T 5.36E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs3916952 chr13 105552973 C A 7.18E-04 Premature ovarian failure / / 19508998 rs9558441 chr13 105641017 G T 0.0000015 Mean arterial pressure / / 22510845 rs9558453 chr13 105665669 G A 6.29E-05 Serum metabolites / / 19043545 rs3935930 chr13 105701736 G A 6.64E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs9558459 chr13 105702139 G A 4.11E-04 Multiple complex diseases / / 17554300 rs12428682 chr13 105716018 A G 1.65E-04 Breast cancer / / pha002853 rs9586708 chr13 105716407 G A 1.74E-04 Breast cancer / / pha002853 rs7139453 chr13 105717663 A G 1.34E-04 Breast cancer / / pha002853 rs4632004 chr13 105718642 C A 1.30E-04 Breast cancer / / pha002853 rs9519597 chr13 105736211 T C 6.84E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9519622 chr13 105781088 T C 4.57E-05 Multiple complex diseases / / 17554300 rs9586750 chr13 105782179 T C 1.10E-05 Urinary metabolites / / 21572414 rs4476030 chr13 105791807 G T 5.76E-04 Multiple complex diseases / / 17554300 rs16965962 chr13 105807023 C A 0.0000041 Mean arterial pressure / / 22510845 rs16965962 chr13 105807023 C A 3.00E-07 Response to citalopram treatment / / 22760553 rs16965964 chr13 105807382 A C 5.84E-04 Multiple complex diseases / / 17554300 rs16966085 chr13 105835170 C T 3.00E-06 Obesity-related traits / / 23251661 rs3007256 chr13 105839060 T A 3.59E-05 Cognitive decline / / 22054870 rs3015396 chr13 105839122 C T 1.95E-04 Type 2 diabetes / / 17463246 rs3015404 chr13 105845602 C T 7.80E-05 Endometriosis / / 21151130 rs3015407 chr13 105847545 C G 8.59E-06 Type 2 diabetes / / 17463246 rs16966149 chr13 105884314 A G 2.32E-05 Cognitive test performance / / 20125193 rs16966149 chr13 105884314 A G 4.21E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3015361 chr13 105901503 C A 1.30E-05 Vascular dementia / / 22116812 rs4485213 chr13 105908875 C T 2.57E-07 Vascular dementia / / 22116812 rs9586776 chr13 105909261 G T 2.03E-05 Cognitive decline / / 23732972 rs9582972 chr13 105913681 C T 1.14E-05 Panic disorder / / 19165232 rs3007238 chr13 105914144 A G 5.11E-04 Parkinson's disease / / 17052657 rs4238241 chr13 105919056 C A 2.30E-06 Stroke (ischemic) / / 22384361 rs9558521 chr13 105925554 T C 6.48E-05 Cognitive decline / / 23732972 rs7989487 chr13 105929262 C T 2.78E-05 Vascular dementia / / 22116812 rs4414333 chr13 105934424 C A 8.75E-05 Amyotrophic lateral sclerosis / / 23624525 rs8002122 chr13 105954138 C T 2.63E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1324745 chr13 105969667 G T 8.75E-06 Response to amphetamines / / 22952603 rs16966375 chr13 105979139 C T 3.94E-05 Aortic root size / / 21223598 rs3918339 chr13 105980800 A G 6.87E-05 Attention deficit hyperactivity disorder / / 22420046 rs3918339 chr13 105980800 A G 9.13E-05 HDL cholesterol / / pha003075 rs41451146 chr13 106059074 G A 8.00E-05 Multiple complex diseases / / 17554300 rs9586847 chr13 106062917 C T 4.86E-04 Type 2 diabetes / / 17463246 rs9586847 chr13 106062917 C T 4.65E-06 Multiple complex diseases / / 17554300 rs17655948 chr13 106067920 T A 7.00E-06 Periodontitis (DPAL) / / 24024966 rs4517638 chr13 106069209 G A 0.000011 Schizophrenia / / 23637625 rs9514383 chr13 106069789 C T 2.70E-05 Urinary metabolites / / 21572414 rs9301028 chr13 106076114 G T 2.69E-04 Multiple complex diseases / / 17554300 rs9519665 chr13 106077318 A T 4.15E-04 Multiple complex diseases / / 17554300 rs11618212 chr13 106096812 A G 5.00E-12 Myopia (pathological) / / 23049088 rs9301029 chr13 106098250 T C 3.92E-04 Celiac disease / / 23936387 rs10492528 chr13 106126886 A G 2.70E-06 Urinary metabolites DAOA intron 21572414 rs11840603 chr13 106153959 G T 2.90E-07 Urinary metabolites DAOA-AS1 intron 21572414 rs9586871 chr13 106155612 T C 5.71E-24 Multiple complex diseases DAOA-AS1 intron 17554300 rs9301037 chr13 106155686 G A 4.12E-05 Age-related macular degeneration DAOA-AS1 intron pha000002 rs778336 chr13 106156514 C T 7.23E-04 Amyotrophic Lateral Sclerosis DAOA-AS1 intron 17827064 rs778285 chr13 106178516 T C 7.70E-07 Urinary metabolites / / 21572414 rs2052383 chr13 106199528 G T 3.85E-05 Nicotine smoking / / 19268276 rs778305 chr13 106201214 C T 3.79E-05 Cognitive impairment induced by topiramate / / 22091778 rs1253837 chr13 106223313 A G 9.55E-04 Alzheimer's disease / / 17998437 rs16966917 chr13 106247257 A T 4.47E-04 Multiple complex diseases / / 17554300 rs1549059 chr13 106249309 T C 4.00E-06 Obesity-related traits / / 23251661 rs1253809 chr13 106250404 A G 4.12E-06 Obesity-related traits / / 23251661 rs1549053 chr13 106286156 C A 4.77E-04 Aortic root size / / 21223598 rs1549055 chr13 106286618 A G 4.22E-04 Aortic root size / / 21223598 rs16967008 chr13 106287438 C A 4.79E-04 Aortic root size / / 21223598 rs16967021 chr13 106290396 A G 4.79E-04 Aortic root size / / 21223598 rs7320321 chr13 106291063 A G 1.80E-04 Aortic root size / / 21223598 rs9586929 chr13 106304224 A G 5.26E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9519741 chr13 106340137 G A 1.53E-05 Cognitive test performance / / 20125193 rs4523809 chr13 106361393 G A 8.29E-04 Multiple complex diseases LINC00343 intron 17554300 rs4438165 chr13 106361518 G A 5.63E-04 Multiple complex diseases LINC00343 intron 17554300 rs4438165 chr13 106361518 G A 8.01E-04 Smoking cessation LINC00343 intron 24665060 rs2391234 chr13 106369935 C T 4.53E-04 Multiple complex diseases LINC00343 intron 17554300 rs2391236 chr13 106370277 T C 4.21E-04 Multiple complex diseases LINC00343 intron 17554300 rs9586962 chr13 106372957 T G 3.08E-04 Multiple complex diseases LINC00343 intron 17554300 rs1328068 chr13 106376216 T A 1.60E-04 Multiple complex diseases LINC00343 intron 17554300 rs9586965 chr13 106380757 T A 2.08E-04 Multiple complex diseases LINC00343 intron 17554300 rs1410347 chr13 106381879 G C 6.31E-04 Multiple complex diseases LINC00343 intron 17554300 rs7990201 chr13 106387047 A G 1.92E-04 Multiple complex diseases LINC00343 intron 17554300 rs9583036 chr13 106389385 T G 4.06E-04 Multiple complex diseases LINC00343 intron 17554300 rs4772702 chr13 106395336 T C 8.22E-05 Coronary heart disease LINC00343 intron pha003032 rs9514424 chr13 106411268 T A 4.47E-04 Aortic root size LINC00343 intron 21223598 rs1328101 chr13 106418016 T C 4.82E-04 Aortic root size / / 21223598 rs2391243 chr13 106420061 C T 3.81E-04 Aortic root size / / 21223598 rs1328098 chr13 106421869 G A 4.91E-04 Aortic root size / / 21223598 rs1576158 chr13 106422213 G A,C,T 4.17E-04 Aortic root size / / 21223598 rs16967263 chr13 106424640 A C 1.29E-04 Aortic root size / / 21223598 rs12870845 chr13 106424803 A C 4.69E-04 Aortic root size / / 21223598 rs1410348 chr13 106432605 T C 3.78E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4771503 chr13 106433709 A G 5.46E-06 Smoking initiation / / 24665060 rs9519787 chr13 106439247 A G 5.70E-06 Smoking initiation / / 24665060 rs7327673 chr13 106439366 A G 5.80E-04 Aortic root size / / 21223598 rs7327673 chr13 106439366 A G 4.00E-06 Smoking initiation / / 24665060 rs9586980 chr13 106441482 G A 2.64E-04 Aortic root size / / 21223598 rs967131 chr13 106442608 A G 1.89E-05 Smoking initiation / / 24665060 rs967131 chr13 106442608 A G 7.45E-06 Height / / pha003010 rs4393432 chr13 106450091 C T 8.14E-04 Depression (quantitative trait) / / 20800221 rs7998231 chr13 106454877 G C 9.53E-04 Depression (quantitative trait) / / 20800221 rs1328086 chr13 106458803 A G 2.13E-04 Aortic root size / / 21223598 rs9519793 chr13 106459844 G A 3.74E-04 Aortic root size / / 21223598 rs16967391 chr13 106460255 C T 1.83E-04 Aortic root size / / 21223598 rs3916978 chr13 106460490 A G 9.79E-04 Depression (quantitative trait) / / 20800221 rs16967398 chr13 106461440 G A 4.66E-04 Aortic root size / / 21223598 rs7322718 chr13 106461753 G A 3.14E-04 Aortic root size / / 21223598 rs16967411 chr13 106463863 A G 3.51E-04 Bipolar disorder,schizoaffective / / 19567891 rs16967411 chr13 106463863 A G 4.62E-05 Aortic root size / / 21223598 rs9519796 chr13 106464102 G A 9.84E-04 Depression (quantitative trait) / / 20800221 rs6491985 chr13 106464461 A G 4.79E-04 Aortic root size / / 21223598 rs7319025 chr13 106464877 A C,G,T 4.95E-04 Aortic root size / / 21223598 rs9519797 chr13 106464936 T A 3.77E-04 Aortic root size / / 21223598 rs1927571 chr13 106465157 C T 5.40E-05 Aortic root size / / 21223598 rs1328088 chr13 106467844 C T 1.49E-04 Aortic root size / / 21223598 rs10508167 chr13 106472028 C G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs9514439 chr13 106481568 G A 3.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6491991 chr13 106481817 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7322510 chr13 106482802 T A 3.79E-04 Type 2 diabetes / / 22238593 rs2479511 chr13 106505404 C A 5.80E-05 Coffee consumption / / 21357676 rs2479513 chr13 106509195 T A,C,G 1.87E-05 Lipoproteins / / pha003079 rs1288061 chr13 106513055 T C 1.49E-05 Lipoproteins / / pha003079 rs9558643 chr13 106522342 G A 1.60E-05 Lipoproteins / / pha003079 rs9519839 chr13 106556561 G A 1.53E-05 Cocaine dependence / / 23958962 rs9519839 chr13 106556561 G A 1.57E-04 Cocaine dependence / / 23958962 rs4772725 chr13 106567677 G A 5.51E-07 Socioeconomic Factors / / pha003067 rs17513245 chr13 106572171 C T 2.14E-05 Odorant perception / / 23910658 rs9519861 chr13 106588826 C T 3.69E-04 Depression (quantitative trait) / / 20800221 rs7336109 chr13 106589141 C T 9.00E-06 Visceral fat / / 22589738 rs16967746 chr13 106590596 G A 5.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs488248 chr13 106596719 C T 3.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs7317790 chr13 106603584 G C 1.50E-05 Urinary metabolites / / 21572414 rs2249972 chr13 106605137 T C 8.58E-04 Multiple complex diseases / / 17554300 rs1924397 chr13 106612466 C A 7.60E-06 Depression (quantitative trait) / / 20800221 rs1924397 chr13 106612466 C A 7.60E-06 Depression (quantitative trait) / / 23290196 rs2093814 chr13 106613610 C A 4.12E-04 Multiple complex diseases / / 17554300 rs7317081 chr13 106614005 G T 9.21E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs7995430 chr13 106619456 G A 3.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs7993835 chr13 106624765 C T 1.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs2243644 chr13 106625048 A C 3.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs2243644 chr13 106625048 A C 0.000268 Salmonella-induced pyroptosis / / 22837397 rs7990927 chr13 106627868 G A 1.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs2476734 chr13 106636014 G T 3.03E-04 Bipolar disorder / / 19259986 rs2476746 chr13 106642159 C T 5.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9587050 chr13 106642309 G A 6.70E-05 Parkinson's disease (age of onset) / / 19772629 rs2248399 chr13 106642473 T C 1.39E-05 Vaspin levels / / 22907691 rs2248399 chr13 106642473 T C 0.0000139 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs2248399 chr13 106642473 T C 0.0004141 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at minimum 6 weeks / / 22907730 rs1998560 chr13 106643525 C T 6.80E-05 Vaspin levels / / 22907691 rs1998560 chr13 106643525 C T 0.000068 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs16967843 chr13 106643871 A G 3.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs16967843 chr13 106643871 A G 1.00E-05 Urinary metabolites / / 21572414 rs2248174 chr13 106644450 A G 3.48E-05 Vaspin levels / / 22907691 rs2248174 chr13 106644450 A G 0.0000348 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs2248174 chr13 106644450 A G 0.0003448 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at minimum 6 weeks / / 22907730 rs1924403 chr13 106647859 G A 3.94E-06 Erythrocyte counts / / pha003090 rs9558661 chr13 106650093 C T 1.04E-05 Bipolar disorder and schizophrenia / / 20889312 rs4483718 chr13 106650744 T G 7.73E-06 Alcohol and nictotine co-dependence / / 20158304 rs4483718 chr13 106650744 T G 6.50E-05 Elbow pain / / pha003008 rs4297565 chr13 106650873 G T 2.40E-05 Bipolar disorder and schizophrenia / / 20889312 rs4996815 chr13 106651661 G T 1.00E-07 Bipolar disorder and schizophrenia / / 20889312 rs470422 chr13 106654538 A G 2.64E-06 Bipolar disorder and schizophrenia / / 20889312 rs113061713 chr13 106655765 T TC 5.03E-04 Smoking cessation / / 24665060 rs2478306 chr13 106655765 T C 5.03E-04 Smoking cessation / / 24665060 rs2478305 chr13 106656344 A G 7.03E-04 Smoking cessation / / 24665060 rs470137 chr13 106657451 T C 2.97E-04 Smoking cessation / / 24665060 rs470136 chr13 106657480 A G 3.79E-04 Smoking cessation / / 24665060 rs2254679 chr13 106661403 C T 4.12E-04 Smoking cessation / / 24665060 rs1442700 chr13 106686614 C T 5.57E-04 Smoking cessation / / 24665060 rs17519864 chr13 106692804 G A 5.98E-04 Type 2 diabetes / / 17463246 rs9634459 chr13 106696047 G A 2.88E-04 Smoking cessation / / 24665060 rs7988550 chr13 106701357 C T 5.82E-04 Smoking cessation / / 24665060 rs9519926 chr13 106702009 G A 8.12E-04 Smoking cessation / / 24665060 rs9514490 chr13 106702358 G A 5.78E-05 Prostate cancer / / 22923026 rs16968122 chr13 106717503 G A 7.26E-06 Bipolar disorder / / 19488044 rs16968122 chr13 106717503 G A 6.21E-06 Bipolar Disorder / / pha002863 rs4772757 chr13 106778622 A G 1.03E-05 Body mass (lean) / / 19268274 rs1867109 chr13 106781258 C T 2.53E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1372791 chr13 106785265 T C 4.00E-07 Immune reponse to smallpox (secreted IL-2) / / 22610502 rs9587100 chr13 106831787 A G 1.92E-05 Alcohol dependence / / 21703634 rs12872413 chr13 106843765 T C 3.84E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs10492650 chr13 106843807 T G 3.31E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs9555232 chr13 106848286 G T 5.70E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs9558712 chr13 106848374 G A 2.43E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs1536235 chr13 106850471 T A 5.84E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs9301121 chr13 106850510 C T 5.70E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs1969888 chr13 106850714 T C 9.92E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs1325784 chr13 106851006 C T 5.70E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs7324946 chr13 106851070 T C 5.70E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs9558721 chr13 106856166 T A 7.58E-04 Smoking initiation / / 24665060 rs7338679 chr13 106862224 G A 2.54E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs1325782 chr13 106876395 T A 2.92E-04 Multiple complex diseases / / 17554300 rs913607 chr13 106910804 G C 8.30E-04 Coronary heart disease / / 21966275 rs9558736 chr13 106916022 C T 3.40E-07 Urinary metabolites / / 21572414 rs354447 chr13 106924526 G A 2.40E-05 Urinary metabolites / / 21572414 rs9301126 chr13 106928014 T G 1.70E-05 Urinary metabolites / / 21572414 rs16968401 chr13 106941798 G A 0.00000035 Secreted IFN-gamma response to smallpox vaccine / / 22661280 rs1325778 chr13 106966571 T C 1.90E-05 Urinary metabolites / / 21572414 rs7995709 chr13 107012212 C T 9.40E-06 Urinary metabolites / / 21572414 rs7995709 chr13 107012212 C T 3.19E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs8001066 chr13 107042818 C T 8.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs9669949 chr13 107048116 A C 4.03E-04 Stroke / / pha002886 rs9520058 chr13 107057420 T G 1.01E-06 Osteoarthritis / / 22763110 rs11839053 chr13 107063042 T C 8.70E-10 Prostate cancer (early onset) / / 24740154 rs7317717 chr13 107068160 G C 9.36E-04 Alzheimer's disease / / 17998437 rs17254624 chr13 107068664 A T 6.20E-04 Multiple complex diseases / / 17554300 rs9587137 chr13 107074013 G T 8.44E-04 Schizophrenia / / 19197363 rs7988678 chr13 107086644 C A 7.21E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7335730 chr13 107105869 T C 4.63E-04 Alzheimer's disease (late onset) / / 21379329 rs911997 chr13 107111090 G A 2.30E-05 Urinary metabolites / / 21572414 rs9520076 chr13 107111889 T C 7.53E-05 Serum metabolites / / 19043545 rs7333309 chr13 107115437 T C 0.000375 Salmonella-induced pyroptosis / / 22837397 rs2391298 chr13 107125805 T C 7.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11840214 chr13 107162943 A G 1.44E-04 Progressive supranuclear palsy EFNB2 intron 21685912 rs41445545 chr13 107175254 T C 1.79E-04 Multiple complex diseases EFNB2 intron 17554300 rs9520094 chr13 107183056 T G 2.09E-04 Multiple complex diseases EFNB2 intron 17554300 rs9520094 chr13 107183056 T G 9.12E-04 Depression (quantitative trait) EFNB2 intron 20800221 rs2391347 chr13 107247127 T C 9.96E-06 Type 2 diabetes / / 17463246 rs17546403 chr13 107254553 A G 2.37E-05 Type 2 diabetes / / 17463246 rs17546403 chr13 107254553 A G 4.75E-05 Multiple complex diseases / / 17554300 rs9520124 chr13 107263918 C T 4.80E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9520124 chr13 107263918 C T 6.40E-05 Cognitive function / / 24684796 rs942330 chr13 107270929 T C 9.68E-05 Type 2 diabetes LINC00551 intron 17463246 rs4539440 chr13 107284513 C A 1.34E-04 Multiple complex diseases / / 17554300 rs16968969 chr13 107300743 G A 9.82E-05 Multiple complex diseases / / 17554300 rs9583110 chr13 107325261 T C 8.43E-06 Magnesium levels / / pha003092 rs1330950 chr13 107338801 C A 8.00E-07 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy) / / 24554482 rs16969024 chr13 107348624 A G 8.30E-04 Type 2 diabetes / / 17463246 rs9587180 chr13 107360401 A G 5.90E-04 Alcohol dependence / / 20201924 rs9558839 chr13 107391098 A G 9.45E-04 Type 2 diabetes / / 17463246 rs9558839 chr13 107391098 A G 8.18E-04 Multiple complex diseases / / 17554300 rs9558839 chr13 107391098 A G 9.70E-06 Urinary metabolites / / 21572414 rs1330948 chr13 107394231 T C 2.40E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs12323026 chr13 107398236 G A 7.47E-05 Bone mineral density / / 19181680 rs4772812 chr13 107398897 C T 2.00E-05 Urinary metabolites / / 21572414 rs2391376 chr13 107401368 G C 2.80E-05 Urinary metabolites / / 21572414 rs288726 chr13 107494419 G A 2.14E-05 Bone mineral density / / 19181680 rs7328987 chr13 107509926 C A 0.000530264 Hypertension (early onset hypertension) / / 22479346 rs288698 chr13 107534767 G A 2.93E-04 Body mass index / / 21701565 rs288700 chr13 107538282 A G 1.21E-04 Multiple complex diseases / / 17554300 rs288701 chr13 107538568 G A 4.77E-04 Body mass index / / 21701565 rs41388549 chr13 107543751 A G 1.64E-25 Narcolepsy / / 19629137 rs2774205 chr13 107544266 A G 1.04E-04 Multiple complex diseases / / 17554300 rs9301169 chr13 107555065 T C 6.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs9514591 chr13 107555235 T C 8.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs7321490 chr13 107557567 G A 4.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs671785 chr13 107558470 G C 6.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs9514592 chr13 107558936 C T 5.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs7334000 chr13 107559522 A C 6.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs12877767 chr13 107563267 A G 8.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs2200429 chr13 107563458 G A 5.85E-05 Diabetes Mellitus / / pha003059 rs840225 chr13 107566858 C T 2.98E-04 Psoriasis / / 20953187 rs433782 chr13 107579465 G A 0.0000048 Amygdala reactivity / / 22856363 rs9558908 chr13 107588046 G A 2.60E-05 Urinary metabolites / / 21572414 rs1475550 chr13 107592100 A G 1.40E-05 Urinary metabolites / / 21572414 rs9520249 chr13 107595783 G A 3.76E-04 Alzheimer's disease / / 17998437 rs9514597 chr13 107610721 C T 3.08E-12 Multiple complex diseases / / 17554300 rs4772832 chr13 107611597 T C 1.14E-04 Body mass index / / 21701565 rs4772832 chr13 107611597 T C 2.12E-05 Body mass index / / 21701565 rs9520256 chr13 107630055 C T 3.06E-06 Alopecia areata / / 22027810 rs7983935 chr13 107642135 G A 2.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4772838 chr13 107654811 G A 5.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7998574 chr13 107656393 C T 2.56E-04 Body mass index / / 21701565 rs7998574 chr13 107656393 C T 8.60E-05 Cognitive function / / 24684796 rs17427554 chr13 107658054 C T 8.42E-04 Type 2 diabetes / / 17463246 rs4509878 chr13 107668121 G T 4.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4287433 chr13 107679028 C T 1.23E-04 Multiple complex diseases / / 17554300 rs17429233 chr13 107699146 A G 0.000293 Salmonella-induced pyroptosis / / 22837397 rs9558942 chr13 107700218 T C 7.00E-06 Obesity-related traits / / 23251661 rs7325493 chr13 107702878 G A 1.69E-04 Lung function (forced vital capacity) / / 24023788 rs2479715 chr13 107717095 T C 5.46E-04 Multiple complex diseases / / 17554300 rs7338447 chr13 107723413 T C 2.51E-04 Lung function (forced vital capacity) / / 24023788 rs7338447 chr13 107723413 T C 3.56E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs11619794 chr13 107730749 T C 6.04E-04 Aortic root size / / 21223598 rs11618641 chr13 107730832 C T 3.30E-05 Aortic root size / / 21223598 rs9301191 chr13 107769104 T C 7.08E-06 Depression (quantitative trait) / / 20800221 rs9634463 chr13 107771235 C T 5.74E-06 Depression (quantitative trait) / / 20800221 rs713548 chr13 107772399 G T 5.93E-06 Depression (quantitative trait) / / 20800221 rs7329003 chr13 107773548 A G 8.99E-06 Personality dimensions / / 18957941 rs7329003 chr13 107773548 A G 5.80E-06 Depression (quantitative trait) / / 20800221 rs7329003 chr13 107773548 A G 9.00E-06 Personality dimensions / / 21173776 rs1927745 chr13 107780316 G A 5.00E-06 Depression (quantitative trait) / / 20800221 rs1927745 chr13 107780316 G A 4.70E-06 Depression (quantitative trait) / / 23290196 rs2806508 chr13 107784335 T C 1.60E-06 Vitamin D concentrations / / 20600896 rs2806508 chr13 107784335 T C 1.60E-06 Vitamin D concentrations / / 20600896 rs9558953 chr13 107784406 C G 3.20E-04 Depression (quantitative trait) / / 20800221 rs2769920 chr13 107793990 A G 0.00000263 Nicotine dependence (smoking) / / 23542338 rs7995063 chr13 107826524 C G 0.0005415 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FAM155A intron 23233654 rs7995063 chr13 107826524 C G 5.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) FAM155A intron 23233662 rs2769875 chr13 107835497 G T 9.20E-04 Type 2 diabetes FAM155A intron 17463246 rs9558965 chr13 107835637 C T 7.48E-04 Stroke FAM155A intron pha002887 rs9301194 chr13 107836674 C T 3.47E-04 Type 2 diabetes FAM155A intron 17463246 rs10508183 chr13 107839766 C A 0.0004796 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FAM155A intron 23233654 rs10508183 chr13 107839766 C A 4.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) FAM155A intron 23233662 rs9301196 chr13 107847432 C T 6.66E-06 Blood pressure FAM155A intron 21378095 rs4238255 chr13 107853969 G T 1.00E-04 Cognitive impairment induced by topiramate FAM155A intron 22091778 rs9555329 chr13 107871144 C T 8.15E-04 Type 2 diabetes FAM155A intron 17463246 rs16969868 chr13 107871712 G C 8.85E-04 Type 2 diabetes FAM155A intron 17463246 rs11840785 chr13 107871944 A G 5.14E-04 Type 2 diabetes FAM155A intron 17463246 rs9514629 chr13 107871966 T C 9.56E-04 Coronary Artery Disease FAM155A intron 17634449 rs11839802 chr13 107872336 T A 5.35E-04 Type 2 diabetes FAM155A intron 17463246 rs9558976 chr13 107878591 G A 0.000056 Migraine FAM155A intron 22678113 rs9558976 chr13 107878591 G A 5.60E-05 Migraine FAM155A intron 22683712 rs9301200 chr13 107882985 A G 0.000056 Migraine FAM155A intron 22678113 rs9301200 chr13 107882985 A G 5.60E-05 Migraine FAM155A intron 22683712 rs7993272 chr13 107898340 T C 7.84E-04 Schizophrenia FAM155A intron 19197363 rs4771568 chr13 107899441 G A 4.30E-04 Schizophrenia FAM155A intron 19197363 rs9555336 chr13 107904621 G A 8.29E-04 Body mass index FAM155A intron 21701565 rs7317862 chr13 107906038 A C 3.81E-10 Non-obstructive azoospermia FAM155A intron 22197933 rs9514645 chr13 107932846 C G 3.50E-04 Multiple complex diseases FAM155A intron 17554300 rs7997236 chr13 107933092 G A 3.26E-04 Body mass index FAM155A intron 21701565 rs17446175 chr13 107935480 A G 2.34E-05 Multiple complex diseases FAM155A intron 17554300 rs9587342 chr13 107936790 G A 9.30E-05 Hepatitis B vaccine response FAM155A intron 21764829 rs7318732 chr13 107937452 A G 1.00E-04 Cognitive impairment induced by topiramate FAM155A intron 22091778 rs9558996 chr13 107942432 C T 1.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM155A intron 20877124 rs11840489 chr13 108042181 C T 2.30E-04 Tourette syndrome FAM155A intron 22889924 rs7982576 chr13 108046786 C T 2.63E-04 Alzheimer's disease (late onset) FAM155A intron 21379329 rs6492053 chr13 108051084 T G 2.00E-04 Response to antidepressants FAM155A intron 19736353 rs10851200 chr13 108052337 C A 2.86E-04 Type 2 diabetes FAM155A intron 17463246 rs1535712 chr13 108062762 C G 6.44E-04 Type 2 diabetes FAM155A intron 17463246 rs1323668 chr13 108063405 G A 4.08E-04 Type 2 diabetes FAM155A intron 17463246 rs9583173 chr13 108064056 T C 4.52E-04 Type 2 diabetes FAM155A intron 17463246 rs16952146 chr13 108064504 C T 3.70E-06 Aortic stiffness FAM155A intron 22068335 rs9520428 chr13 108065209 A G 5.75E-04 Type 2 diabetes FAM155A intron 17463246 rs7321644 chr13 108065234 C T 5.80E-06 Aortic stiffness FAM155A intron 22068335 rs9520437 chr13 108071938 T C 9.58E-04 Myocardial Infarction FAM155A intron pha002873 rs1323672 chr13 108072515 C T 4.02E-04 Type 2 diabetes FAM155A intron 17463246 rs1323677 chr13 108081072 C T 3.53E-05 Blood Pressure FAM155A intron pha003040 rs7320409 chr13 108085618 T C 8.90E-04 Type 2 diabetes and 6 quantitative traits FAM155A intron 17848626 rs12428701 chr13 108086788 T G 2.48E-05 Blood Pressure FAM155A intron pha003040 rs9555361 chr13 108087499 C T 0.000147 Internal carotid artery thickness (average of near and far walls) FAM155A intron 23487405 rs16970118 chr13 108094967 A G 8.60E-05 Bone mineral density (BMD),in women FAM155A intron 20164292 rs16970118 chr13 108094967 A G 2.42E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM155A intron 20877124 rs9989059 chr13 108100801 T C 6.13E-05 Gallstones FAM155A intron 17632509 rs16970167 chr13 108121676 G A 1.07E-04 Multiple complex diseases FAM155A intron 17554300 rs744134 chr13 108124321 T C 1.10E-06 Lipid traits FAM155A intron 17903299 rs1323679 chr13 108129963 T C 9.84E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) FAM155A intron 23648065 rs9520462 chr13 108134909 A C 2.21E-05 Word reading FAM155A intron 23738518 rs9520462 chr13 108134909 A C 7.00E-06 Reading and spelling FAM155A intron 23738518 rs16970314 chr13 108150097 G C 6.26E-04 Multiple complex diseases FAM155A intron 17554300 rs9514694 chr13 108150747 G A 2.97E-05 Reading and spelling FAM155A intron 23738518 rs1555637 chr13 108151476 C A 7.18E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) FAM155A intron 23648065 rs2809285 chr13 108192120 C T 8.37E-04 Stroke FAM155A intron pha002886 rs7333466 chr13 108206269 A G 5.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM155A intron 20877124 rs7333466 chr13 108206269 A G 7.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM155A intron 20877124 rs9555372 chr13 108216109 T C 3.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM155A intron 20877124 rs9559062 chr13 108218260 T C 3.22E-04 Type 2 diabetes FAM155A intron 17463246 rs16970700 chr13 108225102 T C 2.60E-05 Urinary metabolites FAM155A intron 21572414 rs1853518 chr13 108233741 G A 5.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM155A intron 20877124 rs9587408 chr13 108248045 T C 8.96E-05 Waist Circumference FAM155A intron pha003024 rs957788 chr13 108257220 T C 8.00E-06 Anorexia nervosa FAM155A intron 21079607 rs1886228 chr13 108269796 A G 0.0000208 Circulating PCSK9 levels FAM155A intron 22460556 rs12868114 chr13 108325313 A G 4.80E-04 Type 2 diabetes FAM155A intron 17463246 rs1935133 chr13 108328054 T A 4.40E-04 Multiple complex diseases FAM155A intron 17554300 rs1935135 chr13 108328177 T C 4.00E-04 Acute lymphoblastic leukemia (childhood) FAM155A intron 20189245 rs9583190 chr13 108332074 C T 1.24E-06 Type 2 diabetes FAM155A intron 17463246 rs4772910 chr13 108336873 C T 9.95E-08 Metabolite levels FAM155A intron 23281178 rs9520550 chr13 108337054 A G 9.78E-08 Metabolite levels FAM155A intron 23281178 rs7139631 chr13 108344149 A G 9.37E-08 Metabolite levels FAM155A intron 23281178 rs9520558 chr13 108361903 T C 4.05E-04 Multiple complex diseases FAM155A intron 17554300 rs3915937 chr13 108374700 C T 1.32E-08 Metabolite levels FAM155A intron 23281178 rs9301253 chr13 108377875 T C 1.06E-08 Metabolite levels FAM155A intron 23281178 rs1557093 chr13 108378235 C T 2.27E-08 Metabolite levels FAM155A intron 23281178 rs1539134 chr13 108379263 G C 3.15E-08 Metabolite levels FAM155A intron 23281178 rs3905064 chr13 108383142 A G 6.79E-09 Metabolite levels FAM155A intron 23281178 rs2391566 chr13 108385247 G A 2.64E-08 Metabolite levels FAM155A intron 23281178 rs7330529 chr13 108385281 A G 2.64E-08 Metabolite levels FAM155A intron 23281178 rs9555405 chr13 108385374 A C 7.49E-09 Metabolite levels FAM155A intron 23281178 rs7319801 chr13 108386644 G A 5.98E-09 Metabolite levels FAM155A intron 23281178 rs10508187 chr13 108393903 G A 3.38E-07 Pure-tone audiometry FAM155A intron pha001966 rs9514730 chr13 108394275 C T 6.06E-04 Suicide attempts in bipolar disorder FAM155A intron 21423239 rs9520568 chr13 108394875 C T 6.46E-08 Metabolite levels FAM155A intron 23281178 rs2039955 chr13 108406614 C T 2.97E-04 Multiple complex diseases FAM155A intron 17554300 rs1547801 chr13 108416500 A G 8.36E-04 Suicide attempts in bipolar disorder FAM155A intron 21423239 rs3858803 chr13 108420794 C T 9.84E-04 Suicide attempts in bipolar disorder FAM155A intron 21423239 rs9301257 chr13 108422858 A G 9.26E-04 Suicide attempts in bipolar disorder FAM155A intron 21423239 rs2039953 chr13 108448109 T C 3.42E-04 Amyotrophic Lateral Sclerosis FAM155A intron 17362836 rs1014207 chr13 108450124 G C 3.21E-04 Suicide attempts in bipolar disorder FAM155A intron 21423239 rs3905075 chr13 108463219 T C 4.45E-05 Post-operative nausea and vomiting FAM155A intron 21694509 rs113226428 chr13 108470201 G GC 7.04E-48 Metabolite levels FAM155A intron 22286219 rs371373771 chr13 108470201 G C 7.04E-48 Metabolite levels FAM155A intron 22286219 rs7987548 chr13 108471811 G T 2.85E-04 Suicide attempts in bipolar disorder FAM155A intron 21423239 rs7994757 chr13 108473248 G A 5.57E-04 Suicide attempts in bipolar disorder FAM155A intron 21423239 rs16971221 chr13 108473323 T G 2.95E-04 Depression (quantitative trait) FAM155A intron 20800221 rs7325927 chr13 108475513 C T 4.61E-05 Sudden cardiac arrest FAM155A intron 21658281 rs10508196 chr13 108479966 G A 6.54E-05 Age-related macular degeneration FAM155A intron 22125219 rs2036707 chr13 108484454 G A 7.00E-06 Obesity-related traits FAM155A intron 23251661 rs1509091 chr13 108491592 C T 3.00E-06 Metabolite levels (Pyroglutamine) FAM155A intron 23934736 rs9520596 chr13 108492593 G A 7.75E-04 Multiple complex diseases FAM155A intron 17554300 rs7321280 chr13 108499418 G A 5.06E-04 Suicide attempts in bipolar disorder FAM155A intron 21423239 rs7330212 chr13 108502972 C T 3.89E-04 Suicide attempts in bipolar disorder FAM155A intron 21423239 rs1543002 chr13 108503356 C T 4.80E-06 Suicide attempts in bipolar disorder FAM155A intron 21423239 rs1543003 chr13 108503437 T C 7.62E-04 Suicide attempts in bipolar disorder FAM155A intron 21423239 rs817000 chr13 108510636 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes FAM155A intron 22628534 rs1771138 chr13 108516853 A G 4.60E-04 Taste perception FAM155A intron 22132133 rs9520609 chr13 108534926 T C 7.10E-06 Urinary metabolites / / 21572414 rs9559182 chr13 108539164 G A 7.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs9559187 chr13 108558911 A T 5.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs7328941 chr13 108564192 T C 6.64E-06 Major depressive disorder / / 22472876 rs2940695 chr13 108567155 G A 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs16971537 chr13 108586786 G A 6.30E-04 Multiple complex diseases / / 17554300 rs2136268 chr13 108611613 C G 5.38E-04 Multiple complex diseases / / 17554300 rs1359478 chr13 108611886 T C 5.75E-04 Multiple complex diseases / / 17554300 rs1359479 chr13 108612095 C T 4.91E-04 Multiple complex diseases / / 17554300 rs1325372 chr13 108633711 C T 3.31E-04 Hemoglobin concentration / / 20534544 rs9514775 chr13 108642305 C A 3.31E-04 Hemoglobin concentration / / 20534544 rs12871532 chr13 108668547 T C 5.10E-05 Hemoglobin concentration / / 20534544 rs12871532 chr13 108668547 T C 1.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs2391610 chr13 108670406 T C 1.69E-04 Lung function (forced vital capacity) / / 24023788 rs9514807 chr13 108684837 G C 1.03E-04 Multiple complex diseases / / 17554300 rs17731911 chr13 108704126 G A 4.66E-04 Multiple complex diseases / / 17554300 rs16971748 chr13 108705979 G A 2.40E-05 Urinary metabolites / / 21572414 rs9587504 chr13 108735573 G A 5.43E-04 Type 2 diabetes / / 17463246 rs9559249 chr13 108757663 A G 2.68E-04 Aortic root size / / 21223598 rs1223978 chr13 108775162 T C 3.42E-04 Bone mass and geometry / / 17903296 rs1223978 chr13 108775162 T C 3.66E-04 Hemoglobin concentration / / 20534544 rs1223978 chr13 108775162 T C 6.83E-05 Cognitive impairment induced by topiramate / / 22091778 rs9514816 chr13 108783122 A C 1.09E-05 Height / / pha003011 rs10492664 chr13 108816225 C T 1.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs9514823 chr13 108832436 G A 6.33E-04 White matter integrity / / 22425255 rs2150621 chr13 108838844 A G 1.01E-04 Multiple complex diseases / / 17554300 rs4144383 chr13 108843486 G A 6.61E-05 Blood Pressure / / pha003046 rs9559278 chr13 108845002 G A 3.60E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2391626 chr13 108847742 G T 8.47E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9520823 chr13 108873564 T G 5.46E-04 Response to cytidine analogues (gemcitabine) ABHD13 intron 24483146 rs12874831 chr13 108887442 T C 8.88E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17564220 chr13 108888011 C A 4.18E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1224176 chr13 108914674 C G 4.92E-04 Multiple complex diseases / / 17554300 rs9514827 chr13 108919403 T C 1.52E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs201543678 chr13 108922556 G A 0.000072 Prostate cancer (advanced) TNFSF13B missense 23555315 rs16972204 chr13 108926989 T C 6.07E-04 Multiple complex diseases TNFSF13B intron 17554300 rs17499386 chr13 108937313 T C 1.89E-39 Metabolite levels TNFSF13B intron 22286219 rs12583006 chr13 108937452 T A 6.06E-04 Response to taxane treatment (placlitaxel) TNFSF13B intron 23006423 rs11069727 chr13 108937833 A G 4.57E-05 Brain structure TNFSF13B intron 22504417 rs11069727 chr13 108937833 A G 5.06E-04 Response to taxane treatment (placlitaxel) TNFSF13B intron 23006423 rs12428930 chr13 108939705 A C 4.52E-04 Response to taxane treatment (placlitaxel) TNFSF13B intron 23006423 rs2893321 chr13 108943034 A G 2.24E-04 Response to taxane treatment (placlitaxel) TNFSF13B intron 23006423 rs9520835 chr13 108956317 G A 9.00E-06 Primary sclerosing cholangitis TNFSF13B intron 21151127 rs7333523 chr13 108992855 C T 6.46E-05 Insulin-related traits / / pha002901 rs11069734 chr13 109002358 C T 8.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17381373 chr13 109002944 G T 2.90E-04 Type 2 diabetes / / 17463246 rs9520864 chr13 109034702 A G 2.04E-05 Telomere length / / 23001564 rs7318477 chr13 109037961 C T 2.75E-04 Celiac disease / / 23936387 rs6492112 chr13 109056063 T C 6.07E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7139897 chr13 109081624 A G 2.60E-05 Type 2 diabetes / / 17903298 rs9587586 chr13 109092168 C G 5.04E-04 Multiple complex diseases / / 17554300 rs1924340 chr13 109092504 G A 2.75E-04 Multiple complex diseases / / 17554300 rs9514851 chr13 109108400 C T 7.55E-05 Coronary restenosis / / 21878436 rs4772972 chr13 109110414 C T 7.05E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs11618877 chr13 109171572 G A 2.60E-05 Bilirubin levels / / 19414484 rs1924348 chr13 109191801 A G 3.70E-05 Coronary heart disease / / pha003030 rs4255650 chr13 109202573 T C 5.57E-05 Heart Failure / / pha002885 rs4772980 chr13 109228442 C T 3.07E-05 Coronary heart disease / / pha003030 rs4771591 chr13 109236017 C T 5.01E-05 Coronary heart disease / / pha003030 rs9583266 chr13 109250314 G A 0.000685857 Hypertension (early onset hypertension) MYO16 intron 22479346 rs2182501 chr13 109255438 T C 0.000685857 Hypertension (early onset hypertension) MYO16 intron 22479346 rs2182501 chr13 109255438 T C 2.94E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) MYO16 intron 24023788 rs7988598 chr13 109257255 T C 7.50E-05 Cognitive impairment induced by topiramate MYO16 intron 22091778 rs4238264 chr13 109262379 C T 3.30E-04 Stroke MYO16 intron pha002887 rs3929748 chr13 109269987 A G 9.47E-04 Heart Failure MYO16 intron pha002885 rs9555490 chr13 109302520 T C 2.17E-04 Response to cytidine analogues (gemcitabine) MYO16 intron 24483146 rs9514878 chr13 109341054 A G 1.93E-05 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs7328598 chr13 109345421 C A 1.67E-05 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs7984522 chr13 109347659 T C 5.42E-04 Multiple complex diseases MYO16 intron 17554300 rs7984522 chr13 109347659 T C 1.15E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs7984522 chr13 109347659 T C 7.00E-07 Blood pressure MYO16 intron 22763476 rs1926501 chr13 109348151 C T 1.70E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs7334358 chr13 109349968 T C 8.11E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs1926502 chr13 109350605 G T 1.00E-05 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs1926503 chr13 109350774 T C 1.25E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs17389027 chr13 109351962 T C 7.72E-05 Response to taxane treatment (placlitaxel) MYO16 intron 23006423 rs1926509 chr13 109353462 G A 3.94E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs1117190 chr13 109354099 A G 2.29E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs1117191 chr13 109354176 G A 2.27E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs4575401 chr13 109354879 T C 4.07E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs1926510 chr13 109355555 T G 1.98E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs1926512 chr13 109355992 A G 2.98E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs9514882 chr13 109356090 C A 3.05E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs9284247 chr13 109356745 T C 2.66E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs1926532 chr13 109357620 T C 6.89E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs1926531 chr13 109357678 C G 9.43E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs9520969 chr13 109358120 A C 5.36E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs1926530 chr13 109358313 A G 4.92E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs11617857 chr13 109358330 C T 7.88E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs1926529 chr13 109358383 A C 5.50E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs1926528 chr13 109358405 T A 5.50E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs1926527 chr13 109358461 G A 5.50E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs1926525 chr13 109358626 A G 5.46E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs1926523 chr13 109358690 G T 5.50E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs9520970 chr13 109359007 G A 3.29E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs9520971 chr13 109359162 G C,T 4.78E-04 Suicide attempts in bipolar disorder MYO16 intron 21423239 rs4772987 chr13 109359792 T A 3.25E-04 Multiple complex diseases MYO16 intron 17554300 rs9520975 chr13 109364687 T C 8.17E-04 Multiple complex diseases MYO16 intron 17554300 rs10492418 chr13 109380726 A C 2.00E-06 Presence of antiphospholipid antibodies MYO16 intron 23509613 rs9583292 chr13 109448012 A G 5.09E-04 Multiple complex diseases MYO16 intron 17554300 rs196130 chr13 109452080 T C 7.05E-05 Postoperative ventricular dysfunction MYO16 intron 21980348 rs984300 chr13 109455835 G A 3.00E-06 Obesity-related traits MYO16 intron 23251661 rs9521061 chr13 109462949 C T 1.33E-05 Age-related macular degeneration MYO16 intron pha000002 rs17393344 chr13 109473946 G A 2.00E-08 Alzheimer's disease (cognitive decline) MYO16 intron 23535033 rs17485138 chr13 109502849 C T 7.00E-06 Dental caries MYO16 intron 23064961 rs7330740 chr13 109503016 A C,T 5.26E-04 Type 2 diabetes MYO16 intron 17463246 rs2759273 chr13 109508469 T C 4.60E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO16 intron 22566498 rs814141 chr13 109511059 T G 5.00E-06 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) MYO16 intron 24023788 rs196165 chr13 109520579 C A 7.20E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO16 intron 22566498 rs9521099 chr13 109574088 A T 2.92E-04 Multiple complex diseases MYO16 intron 17554300 rs4773010 chr13 109574994 G A 3.30E-04 Multiple complex diseases MYO16 intron 17554300 rs9587725 chr13 109591040 G A 1.33E-04 Sudden cardiac arrest MYO16 intron 21658281 rs9521108 chr13 109602395 A G 1.84E-04 Multiple complex diseases MYO16 intron 17554300 rs9587731 chr13 109605067 C T 1.09E-04 Stroke MYO16 intron pha002887 rs9521112 chr13 109616402 G A 4.12E-05 Coronary heart disease MYO16 intron pha003030 rs9521112 chr13 109616402 G A 5.93E-05 Coronary heart disease MYO16 intron pha003031 rs406685 chr13 109627586 A C 3.55E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) MYO16 intron 24023788 rs406685 chr13 109627586 A C 4.89E-06 Coronary heart disease MYO16 intron pha003030 rs13379035 chr13 109679138 G A 8.40E-04 Multiple complex diseases MYO16 intron 17554300 rs1001843 chr13 109679358 C T 7.70E-04 Type 2 diabetes and 6 quantitative traits MYO16 intron 17848626 rs2150597 chr13 109694966 A G 1.15E-05 Menarche (age at onset) MYO16 intron 19282985 rs277836 chr13 109710600 G A 4.35E-05 Magnesium levels MYO16 intron pha003092 rs277852 chr13 109724244 T C 4.78E-05 Cognitive impairment induced by topiramate MYO16 intron 22091778 rs156998 chr13 109752128 T C 3.65E-04 Alzheimer's disease MYO16 intron 24755620 rs157014 chr13 109762007 C T 3.85E-04 Alzheimer's disease MYO16 intron 24755620 rs9521184 chr13 109782568 T C 3.58E-04 Alzheimer's disease MYO16 intron 24755620 rs919597 chr13 109785845 C T 4.56E-04 Alcohol dependence MYO16 intron 20201924 rs9587782 chr13 109796792 A G 4.92E-04 Body mass index MYO16 intron 21701565 rs9587783 chr13 109814635 T G 5.09E-04 Insulin resistance MYO16 intron 21901158 rs10220141 chr13 109818064 G A 6.45E-04 Insulin resistance MYO16 intron 21901158 rs4976846 chr13 109821211 T C 1.72E-17 Meningococcal disease MYO16 intron 20694013 rs2181666 chr13 109856845 A G 1.52E-05 Alcohol consumption MYO16 intron 23953852 rs2391713 chr13 109858650 A G 3.50E-05 Cognitive test performance MYO16 intron 20125193 rs7994949 chr13 109861902 C T 3.91E-04 Multiple complex diseases / / 17554300 rs9521234 chr13 109877958 C T 8.32E-05 Cervical cancer / / 24700089 rs592398 chr13 109879222 A G 6.93E-05 Cervical cancer / / 24700089 rs9521254 chr13 109897922 C T 1.20E-05 Pericardial fat / / 22589742 rs7318834 chr13 109912499 G A 8.19E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs9515034 chr13 109912557 C T 1.01E-05 Alcohol consumption / / 23953852 rs9515035 chr13 109914830 A G 4.84E-05 Alcohol consumption / / 23953852 rs7322415 chr13 109916961 C T 4.40E-05 Alcohol consumption / / 23953852 rs9559537 chr13 109938855 C A 9.60E-04 Obesity (extreme) / / 21935397 rs7996435 chr13 109939520 A C 1.77E-114 Multiple complex diseases / / 17554300 rs4134382 chr13 109957290 T C 8.26E-04 Alcohol dependence / / 21314694 rs4134382 chr13 109957290 T C 6.92E-05 Cervical cancer / / 24700089 rs9521314 chr13 109979198 C T 8.22E-05 Alzheimer's disease (late onset) / / 21379329 rs9521314 chr13 109979198 C T 5.61E-05 Triglycerides / / pha003081 rs4238266 chr13 109981131 A T 4.02E-05 Cervical cancer / / 24700089 rs4773041 chr13 109982578 C A 1.20E-05 Urinary metabolites / / 21572414 rs9559567 chr13 110014023 C T 6.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7999199 chr13 110015570 A T 1.53E-04 Body mass index / / 21701565 rs7999199 chr13 110015570 A T 1.97E-04 Body mass index / / 21701565 rs1328240 chr13 110024844 C T 3.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1328240 chr13 110024844 C T 6.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7328247 chr13 110027023 G C 8.48E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7328247 chr13 110027023 G C 9.21E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2149202 chr13 110032665 G A 9.50E-04 Obesity (extreme) / / 21935397 rs9521345 chr13 110039905 G A 1.59E-04 Aortic root size / / 21223598 rs4771629 chr13 110039995 T C 8.38E-04 Multiple complex diseases / / 17554300 rs943769 chr13 110054960 A G 5.10E-05 Cognitive function / / 24684796 rs9559588 chr13 110055656 G A 8.20E-05 Response to statin therapy / / 20339536 rs1328250 chr13 110058631 T C 2.41E-04 Type 2 diabetes / / 17463246 rs9301382 chr13 110060748 G A 8.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9301382 chr13 110060748 G A 1.03E-05 Basophils / / pha003087 rs9521354 chr13 110067124 C A 9.41E-05 Type 2 diabetes / / 17463246 rs9521354 chr13 110067124 C A 0.00062 Autism / / 22935194 rs9521355 chr13 110067182 T C 1.88E-04 Type 2 diabetes / / 17463246 rs9521355 chr13 110067182 T C 0.000208 Autism / / 22935194 rs9521356 chr13 110067233 C A 2.10E-04 Type 2 diabetes / / 17463246 rs1328244 chr13 110083898 G A 1.80E-06 Urinary metabolites / / 21572414 rs7985759 chr13 110129583 G T 2.76E-04 Alzheimer's disease (late onset) / / 21379329 rs861145 chr13 110188419 C T 1.00E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs861145 chr13 110188419 C T 5.18E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9521420 chr13 110195659 C G 5.70E-06 Urinary metabolites / / 21572414 rs16974343 chr13 110197259 A G 2.60E-05 Urinary metabolites / / 21572414 rs9521430 chr13 110229996 G A 9.60E-06 Urinary metabolites / / 21572414 rs1041466 chr13 110244322 A G 3.10E-04 Diabetic nephropathy / / 19252134 rs1041466 chr13 110244322 A G 3.20E-06 Diabetic nephropathy / / 19252134 rs1041466 chr13 110244322 A G 6.80E-04 Diabetic nephropathy / / 19252134 rs1041466 chr13 110244322 A G 0.0000032 Diabetic nephropathy in Type 1 diabetes / / 22721967 rs1041466 chr13 110244322 A G 4.00E-05 Diabetic nephropathy / / pha002852 rs1041466 chr13 110244322 A G 3.67E-06 Diabetic nephropathy / / pha002864 rs1411766 chr13 110252160 G A 1.10E-04 Diabetic nephropathy / / 19252134 rs1411766 chr13 110252160 G A 1.80E-06 Diabetic nephropathy / / 19252134 rs1411766 chr13 110252160 G A 8.15E-06 Diabetic nephropathy / / pha002852 rs1411766 chr13 110252160 G A 1.82E-06 Diabetic nephropathy / / pha002864 rs17412858 chr13 110252608 A G 9.68E-06 Diabetic nephropathy / / pha002852 rs17412858 chr13 110252608 A G 2.11E-06 Diabetic nephropathy / / pha002864 rs6492208 chr13 110257726 T C 1.60E-04 Diabetic nephropathy / / 19252134 rs6492208 chr13 110257726 T C 6.10E-06 Diabetic nephropathy / / 19252134 rs6492208 chr13 110257726 T C 2.03E-05 Diabetic nephropathy / / pha002852 rs6492208 chr13 110257726 T C 7.41E-06 Diabetic nephropathy / / pha002864 rs2391777 chr13 110258243 G A 0.0000061 Diabetic nephropathy in Type 1 diabetes / / 22721967 rs2391777 chr13 110258243 G A 3.42E-05 Diabetic nephropathy / / pha002852 rs2391777 chr13 110258243 G A 1.12E-05 Diabetic nephropathy / / pha002864 rs2391778 chr13 110258553 T A 7.82E-04 Multiple complex diseases / / 17554300 rs2391778 chr13 110258553 T A 8.33E-05 Diabetic nephropathy / / pha002852 rs2391778 chr13 110258553 T A 2.08E-05 Diabetic nephropathy / / pha002864 rs9515085 chr13 110258782 T G 4.40E-05 Diabetic nephropathy / / pha002852 rs9515085 chr13 110258782 T G 1.40E-05 Diabetic nephropathy / / pha002864 rs1411765 chr13 110259068 A G 6.03E-04 Multiple complex diseases / / 17554300 rs1411765 chr13 110259068 A G 1.00E-04 End-stage renal disease / / 19929986 rs1411765 chr13 110259068 A G 8.24E-05 Diabetic nephropathy / / pha002852 rs1411765 chr13 110259068 A G 2.01E-05 Diabetic nephropathy / / pha002864 rs7989848 chr13 110283468 G A 7.00E-06 Diabetic nephropathy / / 19252134 rs7989848 chr13 110283468 G A 7.30E-05 Diabetic nephropathy / / 19252134 rs7989848 chr13 110283468 G A 0.000007 Diabetic nephropathy in Type 1 diabetes / / 22721967 rs7989848 chr13 110283468 G A 4.14E-05 Diabetic nephropathy / / pha002852 rs7989848 chr13 110283468 G A 7.02E-06 Diabetic nephropathy / / pha002864 rs1929210 chr13 110285478 T C 6.15E-04 Type 2 diabetes / / 17463246 rs1929210 chr13 110285478 T C 3.77E-05 Diabetic nephropathy / / pha002864 rs9521445 chr13 110285534 C A 2.30E-05 Diabetic nephropathy / / 19252134 rs9521445 chr13 110285534 C A 2.90E-06 Diabetic nephropathy / / 19252134 rs9521445 chr13 110285534 C A 1.21E-05 Diabetic nephropathy / / pha002852 rs9521445 chr13 110285534 C A 2.95E-06 Diabetic nephropathy / / pha002864 rs9515094 chr13 110309931 G A 6.86E-05 Fasting blood glucose / / 22885924 rs6492218 chr13 110325749 C T 3.00E-06 Alcohol dependence / / 21956439 rs9521469 chr13 110330521 G A 7.00E-05 Multiple complex diseases / / 17554300 rs9521469 chr13 110330521 G A 4.73E-04 Psoriasis / / 20953187 rs1821542 chr13 110348712 G A 8.19E-04 Coronary heart disease / / 21606135 rs9587963 chr13 110352489 A C 6.50E-05 Coronary heart disease / / 21606135 rs2391784 chr13 110353253 G A 2.19E-04 Alzheimer's disease (late onset) / / 21379329 rs1330544 chr13 110354802 T C 7.30E-05 Hypothyroidism / / 22493691 rs913947 chr13 110356731 A G 8.10E-06 Urinary metabolites / / 21572414 rs1411552 chr13 110371264 A C 5.70E-06 Urinary metabolites / / 21572414 rs1411552 chr13 110371264 A C 8.79E-04 Longevity / / 22279548 rs8001186 chr13 110376855 T G 4.51E-06 Coronary artery calcification / / 22144573 rs9521509 chr13 110421451 C T 1.69E-05 Weight IRS2 intron pha003026 rs9521509 chr13 110421451 C T 8.28E-05 Weight IRS2 intron pha003027 rs4773088 chr13 110421884 G A 7.09E-04 Response to statin treatment (atorvastatin),change in cholesterol levels IRS2 intron 20031582 rs7999797 chr13 110426000 G A 4.15E-05 Body Mass Index IRS2 intron pha003006 rs7999797 chr13 110426000 G A 3.84E-05 Body Mass Index IRS2 intron pha003007 rs7999797 chr13 110426000 G A 7.54E-05 Body Fat Distribution IRS2 intron pha003016 rs7999797 chr13 110426000 G A 7.79E-05 Body Fat Distribution IRS2 intron pha003018 rs7999797 chr13 110426000 G A 5.74E-06 Weight IRS2 intron pha003026 rs7999797 chr13 110426000 G A 7.52E-06 Weight IRS2 intron pha003027 rs7986346 chr13 110453607 G T 2.79E-05 Prostate cancer / / pha002877 rs8001174 chr13 110456226 T G 5.83E-04 Coronary heart disease / / 21606135 rs7984342 chr13 110457240 G A 4.26E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs745324 chr13 110465297 A G 5.11E-06 Body Mass Index / / pha003006 rs745324 chr13 110465297 A G 1.88E-05 Body Mass Index / / pha003007 rs745324 chr13 110465297 A G 4.89E-05 Body Fat Distribution / / pha003016 rs745324 chr13 110465297 A G 9.54E-05 Body Fat Distribution / / pha003018 rs745324 chr13 110465297 A G 4.71E-05 Waist Circumference / / pha003024 rs745324 chr13 110465297 A G 7.54E-06 Weight / / pha003026 rs745324 chr13 110465297 A G 1.77E-05 Weight / / pha003027 rs9301413 chr13 110491504 T C 0.000011 Mean arterial pressure / / 22510845 rs11069811 chr13 110500620 A G 8.90E-05 Primary sclerosing cholangitis / / 19944697 rs1024306 chr13 110528858 T G 7.83E-05 Body Mass Index / / pha003006 rs1414320 chr13 110535092 G A 2.33E-05 Asthma / / 22561531 rs9515124 chr13 110538523 C T 7.54E-04 Type 2 diabetes / / 17463246 rs336209 chr13 110548845 C A 1.10E-04 Lung function (forced vital capacity) / / 24023788 rs336208 chr13 110553400 T C 2.63E-04 Multiple complex diseases / / 17554300 rs1763038 chr13 110554933 G A 3.49E-04 Multiple complex diseases / / 17554300 rs1763037 chr13 110554952 T C 4.23E-04 Multiple complex diseases / / 17554300 rs1763034 chr13 110556113 A C 3.47E-04 Multiple complex diseases / / 17554300 rs381259 chr13 110556571 G A 2.43E-04 Lung function (forced vital capacity) / / 24023788 rs9634473 chr13 110561568 G A 4.68E-04 Multiple complex diseases / / 17554300 rs1014677 chr13 110564565 C G 4.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs1556573 chr13 110565022 A T 1.56E-04 Type 2 diabetes / / 17463246 rs9555648 chr13 110566204 T C 5.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs9559673 chr13 110570995 C G 2.49E-04 Type 2 diabetes / / 17463246 rs9559673 chr13 110570995 C G 5.57E-04 Multiple complex diseases / / 17554300 rs9559674 chr13 110571060 A G 5.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs9559674 chr13 110571060 A G 4.63E-05 Cognitive impairment induced by topiramate / / 22091778 rs9559674 chr13 110571060 A G 3.92E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs9559674 chr13 110571060 A G 7.56E-06 Lung function (forced vital capacity) / / 24023788 rs7323507 chr13 110572210 C T 5.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs7323507 chr13 110572210 C T 4.63E-05 Cognitive impairment induced by topiramate / / 22091778 rs7323507 chr13 110572210 C T 3.92E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7323507 chr13 110572210 C T 8.00E-06 Lung function (forced vital capacity) / / 24023788 rs9588036 chr13 110581571 C A 0.000886 Salmonella-induced pyroptosis / / 22837397 rs1333985 chr13 110581878 A G 9.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs6492231 chr13 110583053 T C 9.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs11069815 chr13 110590098 T A 7.33E-04 Alzheimer's disease / / 17998437 rs2095531 chr13 110603337 A G 5.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs7984646 chr13 110618831 C A 6.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs7984646 chr13 110618831 C A 3.11E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs11616866 chr13 110652684 G A 9.19E-05 Asthma / / 23181788 rs9559702 chr13 110653926 T C 7.79E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs2225778 chr13 110658084 T C 6.32E-05 Serum metabolites / / 19043545 rs2225777 chr13 110679470 T A 5.29E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs1335807 chr13 110680944 A G 8.89E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs1029204 chr13 110681212 A G 7.97E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs9588074 chr13 110684664 C A 1.94E-04 Smoking cessation / / 24665060 rs1335808 chr13 110688140 A T 4.26E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs4773116 chr13 110713452 T C 2.30E-05 Urinary metabolites / / 21572414 rs7995016 chr13 110713553 C T 8.24E-04 Insulin resistance / / 21901158 rs659071 chr13 110785526 G A 8.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs641862 chr13 110790232 T C 7.00E-07 Obesity-related traits / / 23251661 rs656533 chr13 110793123 G A 5.73E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs13260 chr13 110802123 G T 0.0000868 Coronary artery calcification COL4A1 UTR-3 23727086 rs1192201 chr13 110806490 G A 2.00E-06 Age-related nuclear cataracts COL4A1 intron 24951543 rs11617955 chr13 110818102 T A 8.85E-04 Type 2 diabetes COL4A1 intron 17463246 rs11617955 chr13 110818102 T A 0.000000686 Coronary artery disease COL4A1 intron 23202125 rs3742207 chr13 110818598 T G 5.00E-08 Arterial stiffness COL4A1 missense 20031579 rs12868126 chr13 110822524 G A 1.00E-04 Information processing speed COL4A1 intron 21130836 rs12868126 chr13 110822524 G A 8.40E-04 Atrial fibrillation COL4A1 intron 21846873 rs2131939 chr13 110831837 G A 8.90E-04 Diabetic nephropathy COL4A1 intron 20347642 rs2278673 chr13 110836044 G T 1.10E-05 Urinary metabolites COL4A1 intron 21572414 rs2391816 chr13 110836810 C T 1.30E-05 Urinary metabolites COL4A1 intron 21572414 rs2172725 chr13 110837456 G A 2.20E-05 Urinary metabolites COL4A1 intron 21572414 rs9515163 chr13 110844996 A G 4.32E-05 Type 2 diabetes COL4A1 intron 17463246 rs490727 chr13 110845043 A G 4.00E-05 Type 2 diabetes COL4A1 intron 17463246 rs9521642 chr13 110845060 G A 2.41E-04 Type 2 diabetes COL4A1 intron 17463246 rs9521642 chr13 110845060 G A 2.64E-04 Blood pressure COL4A1 intron 24001895 rs7996925 chr13 110848187 C T 4.76E-05 Type 2 diabetes COL4A1 intron 17463246 rs622486 chr13 110848291 G A 7.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL4A1 intron 20877124 rs622486 chr13 110848291 G A 8.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL4A1 intron 20877124 rs9515165 chr13 110848706 A G 5.65E-05 Type 2 diabetes COL4A1 intron 17463246 rs995223 chr13 110851036 T C 3.30E-05 Type 2 diabetes COL4A1 intron 17463246 rs1982315 chr13 110851436 T C 9.11E-05 Type 2 diabetes COL4A1 intron 17463246 rs1982314 chr13 110851495 C T 7.61E-06 Type 2 diabetes COL4A1 intron 17463246 rs538390 chr13 110855677 G T 1.84E-05 Lupus nephritis in systemic lupus erythematosus COL4A1 intron 24925725 rs648705 chr13 110856153 A C 1.09E-05 Lupus nephritis in systemic lupus erythematosus COL4A1 intron 24925725 rs645098 chr13 110856271 C T 1.80E-05 Lupus nephritis in systemic lupus erythematosus COL4A1 intron 24925725 rs482757 chr13 110857823 C T 1.80E-05 Lupus nephritis in systemic lupus erythematosus COL4A1 intron 24925725 rs677877 chr13 110857895 A G 1.80E-05 Lupus nephritis in systemic lupus erythematosus COL4A1 intron 24925725 rs598893 chr13 110859743 C T 1.75E-05 Lupus nephritis in systemic lupus erythematosus COL4A1 intron 24925725 rs529041 chr13 110860219 T C 2.77E-04 Type 2 diabetes COL4A1 intron 17463246 rs529041 chr13 110860219 T C 1.58E-05 Hypertension COL4A1 intron 21082022 rs9588117 chr13 110860343 C T 1.83E-04 Type 2 diabetes COL4A1 intron 17463246 rs9583467 chr13 110860861 A G 2.32E-04 Type 2 diabetes COL4A1 intron 17463246 rs9559744 chr13 110861444 C T 1.52E-05 Lupus nephritis in systemic lupus erythematosus COL4A1 intron 24925725 rs565510 chr13 110865501 C T 6.23E-05 Type 2 diabetes COL4A1 intron 17463246 rs9521650 chr13 110866265 G A 2.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL4A1 intron 20877124 rs9521650 chr13 110866265 G A 4.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL4A1 intron 20877124 rs616008 chr13 110878344 C T 6.19E-04 Multiple complex diseases COL4A1 intron 17554300 rs660433 chr13 110879033 G A 2.52E-04 Multiple complex diseases COL4A1 intron 17554300 rs16975654 chr13 110879245 G A 8.96E-04 Response to cytadine analogues (cytosine arabinoside) COL4A1 intron 24483146 rs672949 chr13 110879554 C T 6.10E-05 Multiple complex diseases COL4A1 intron 17554300 rs672949 chr13 110879554 C T 2.11E-04 Nicotine smoking COL4A1 intron 19268276 rs561168 chr13 110884208 C T 9.67E-05 Non-alcoholic fatty liver disease histology (other) COL4A1 intron 20708005 rs9521666 chr13 110897444 A G 1.91E-04 Alzheimer's disease (late onset) COL4A1 intron 21379329 rs12428227 chr13 110902292 A G 0.000052 Ankle-brachial index COL4A1 intron 22361517 rs562992 chr13 110908777 T G 1.97E-05 Parkinson's disease COL4A1 intron 17052657 rs562992 chr13 110908777 T G 8.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL4A1 intron 20877124 rs9634591 chr13 110909919 A G 5.48E-04 Coronary Artery Disease COL4A1 intron 17634449 rs9634591 chr13 110909919 A G 9.37E-04 Alzheimer's disease COL4A1 intron 17998437 rs9515177 chr13 110912634 G A 5.60E-04 Coronary Artery Disease COL4A1 intron 17634449 rs7139492 chr13 110915795 C T 0.00000196 Coronary artery disease COL4A1 intron 23202125 rs903352 chr13 110917524 A C 7.42E-05 Monocyte chemoattractant protein-1 COL4A1 intron pha003071 rs554882 chr13 110917782 C T 5.98E-04 Type 2 diabetes COL4A1 intron 17463246 rs12873154 chr13 110920852 A G 4.51E-08 Coronary artery disease COL4A1 intron 23202125 rs6492252 chr13 110922694 A G 7.20E-05 Monocyte chemoattractant protein-1 COL4A1 intron pha003071 rs9559759 chr13 110925809 C T 3.78E-04 Schizophrenia COL4A1 intron 20832056 rs7330914 chr13 110927061 C A 1.03E-08 LDL cholesterol COL4A1 intron 23063622 rs7330914 chr13 110927061 C A 1.41E-08 Cholesterol,total COL4A1 intron 23063622 rs494558 chr13 110929162 C T 5.00E-08 Obesity-related traits COL4A1 intron 23251661 rs599483 chr13 110930364 A G 7.58E-06 Hepatitis B vaccine response COL4A1 intron 21764829 rs599483 chr13 110930364 A G 1.85E-05 Waist Circumference COL4A1 intron pha003023 rs599483 chr13 110930364 A G 1.14E-05 Waist-Hip Ratio COL4A1 intron pha003029 rs561437 chr13 110936227 T C 5.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL4A1 intron 20877124 rs7998875 chr13 110941400 G T 0.000000154 HDL cholesterol COL4A1 intron 23063622 rs7998875 chr13 110941400 G T 2.25E-08 Triglycerides COL4A1 intron 23063622 rs953386 chr13 110943692 T C 5.90E-04 Type 2 diabetes and 6 quantitative traits COL4A1 intron 17848626 rs1411040 chr13 110943921 C T 4.70E-04 Type 2 diabetes and 6 quantitative traits COL4A1 intron 17848626 rs2391823 chr13 110944795 G A 7.90E-04 Type 2 diabetes and 6 quantitative traits COL4A1 intron 17848626 rs9559763 chr13 110945975 C T 8.94E-04 Multiple complex diseases COL4A1 intron 17554300 rs7317784 chr13 110955074 C T 5.68E-05 Response to hepatitis C treatment COL4A1 intron 19684573 rs7317784 chr13 110955074 C T 9.92E-04 Myocardial infarction COL4A1 intron 24916648 rs4773144 chr13 110960712 A G 4.00E-09 Coronary heart disease COL4A2 intron 21378990 rs4773144 chr13 110960712 A G 3.50E-08 Coronary heart disease COL4A2 intron 21966275 rs4773144 chr13 110960712 A G 1.65E-06 Coronary artery calcification COL4A2 intron 22144573 rs4773144 chr13 110960712 A G 3.84E-09 Pericardial fat COL4A2 intron 22589742 rs4773144 chr13 110960712 A G 0.000000132 Coronary artery disease (CAD) age >50 COL4A2 intron 23202125 rs4773144 chr13 110960712 A G 0.000000708 Coronary artery disease with myocardial infarction COL4A2 intron 23202125 rs4773144 chr13 110960712 A G 0.0000254 Coronary artery disease (CAD) age <=50 COL4A2 intron 23202125 rs4773144 chr13 110960712 A G 2.76E-09 Coronary artery disease (CAD) (males) COL4A2 intron 23202125 rs4773144 chr13 110960712 A G 7.43E-12 Coronary artery disease COL4A2 intron 23202125 rs4773144 chr13 110960712 A G 2.00E-06 Coronary artery disease COL4A2 intron 24262325 rs3809346 chr13 110960943 G A 1.00E-16 Progranulin levels COL4A2 intron 21087763 rs3809346 chr13 110960943 G A 1.00E-16 Myocardial infarction COL4A2 intron 21211798 rs3809346 chr13 110960943 G A 9.00E-07 Coronary artery calcification COL4A2 intron 22144573 rs2391824 chr13 110961282 G A 1.85E-04 Response to cytadine analogues (cytosine arabinoside) COL4A2 intron 24483146 rs4773155 chr13 110971066 A C 2.50E-08 Bone mineral density and osteoporosis-related phenotypes COL4A2 intron 22072498 rs4773156 chr13 110971125 C T 7.26E-04 Multiple complex diseases COL4A2 intron 17554300 rs7336920 chr13 110978725 T C 2.32E-05 Kawasaki disease COL4A2 intron 22446961 rs4447275 chr13 110982419 G A 5.30E-07 Bone mineral density and osteoporosis-related phenotypes COL4A2 intron 22072498 rs9521700 chr13 110984741 G A 4.50E-06 Urinary metabolites COL4A2 intron 21572414 rs7330111 chr13 110986721 G A 3.08E-04 Hearing function COL4A2 intron 17255346 rs9559772 chr13 110995528 C G 4.14E-05 Diabetes (gestational) COL4A2 intron 22233651 rs11619057 chr13 111008391 C T 0.000153 Coronary artery disease COL4A2 intron 23202125 rs872589 chr13 111015628 C T 5.27E-05 Multiple complex diseases COL4A2 intron 17554300 rs9521717 chr13 111016153 C T 6.47E-05 Multiple complex diseases COL4A2 intron 17554300 rs9521720 chr13 111018009 G C 1.89E-05 Multiple complex diseases COL4A2 intron 17554300 rs9559780 chr13 111018666 G A 9.79E-05 Multiple complex diseases COL4A2 intron 17554300 rs7333748 chr13 111018729 C G 5.87E-05 Multiple complex diseases COL4A2 intron 17554300 rs4773171 chr13 111019568 A G 5.11E-05 Multiple complex diseases COL4A2 intron 17554300 rs7318424 chr13 111021623 C G 3.50E-05 Multiple complex diseases COL4A2 intron 17554300 rs750597 chr13 111029256 T A 7.92E-05 Multiple complex diseases COL4A2 intron 17554300 rs7319311 chr13 111030578 A G 8.45E-04 Amyotrophic Lateral Sclerosis COL4A2 intron 17827064 rs7319311 chr13 111030578 A G 4.00E-06 Bipolar disorder and schizophrenia COL4A2 intron 20889312 rs7320755 chr13 111031092 G C 5.77E-06 Bipolar disorder and schizophrenia COL4A2 intron 20889312 rs9521730 chr13 111031180 G A 7.55E-05 Multiple complex diseases COL4A2 intron 17554300 rs9521731 chr13 111032699 G C 5.63E-05 Multiple complex diseases COL4A2 intron 17554300 rs9521733 chr13 111034542 T C 3.18E-05 Intracerebral hemorrhage COL4A2 intron 24656865 rs9515201 chr13 111040798 A C 2.67E-04 Multiple complex diseases COL4A2 intron 17554300 rs9515201 chr13 111040798 A C 0.000089 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes COL4A2 intron 22628534 rs9515201 chr13 111040798 A C 1.29E-08 Coronary artery disease COL4A2 intron 23202125 rs9515203 chr13 111049623 T C 0.0000014 Coronary artery disease with myocardial infarction COL4A2 intron 23202125 rs9515203 chr13 111049623 T C 0.00039 Coronary artery disease (CAD) age >50 COL4A2 intron 23202125 rs9515203 chr13 111049623 T C 1.68E-12 Coronary artery disease COL4A2 intron 23202125 rs9515203 chr13 111049623 T C 3.08E-09 Coronary artery disease (CAD) age <=50 COL4A2 intron 23202125 rs9515203 chr13 111049623 T C 5.39E-09 Coronary artery disease (CAD) (males) COL4A2 intron 23202125 rs9515203 chr13 111049623 T C 1.78E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) COL4A2 intron 23648065 rs9515203 chr13 111049623 T C 3.30E-05 Coronary artery disease COL4A2 intron 24262325 rs7328731 chr13 111056994 G A 2.24E-05 Coronary heart disease COL4A2 intron 21971053 rs9559792 chr13 111059093 C T 1.27E-04 Alzheimer's disease COL4A2 intron 17998437 rs4773179 chr13 111061884 A G 2.70E-05 Urinary metabolites COL4A2 intron 21572414 rs4773180 chr13 111062015 T G 3.20E-05 Melanoma COL4A2 intron 24980573 rs7140030 chr13 111064159 A G 6.59E-04 Coronary heart disease COL4A2 intron 21971053 rs9521755 chr13 111073710 C T 3.70E-06 Urinary metabolites COL4A2 intron 21572414 rs4512966 chr13 111082058 T C 0.0000252 Otitis media (children 3 years old or younger) COL4A2 intron 23133572 rs1018643 chr13 111096925 A G 9.14E-04 Multiple complex diseases COL4A2 intron 17554300 rs9555699 chr13 111100018 A G 2.99E-04 Multiple complex diseases COL4A2 intron 17554300 rs7995158 chr13 111111717 A G 6.36E-05 Hypertension COL4A2 intron 21082022 rs7995158 chr13 111111717 A G 1.44E-06 Reading disability and language impairment COL4A2 intron 24024963 rs1983931 chr13 111118102 G A 1.06E-06 Reading disability and language impairment COL4A2 intron 24024963 rs9521789 chr13 111119620 C T 7.59E-07 Reading disability and language impairment COL4A2 intron 24024963 rs3803229 chr13 111134780 G A 2.75E-05 Duodenal ulcer COL4A2 intron 22387998 rs2296851 chr13 111138255 G A 1.30E-04 Type 2 diabetes COL4A2 intron 17463246 rs7317733 chr13 111146513 A C 8.30E-05 Endometriosis COL4A2 intron 21151130 rs912946 chr13 111147846 G A 5.29E-05 Psoriasis COL4A2 intron 20953190 rs9555714 chr13 111151959 G A 1.20E-04 Endometriosis COL4A2 intron 21151130 rs12873113 chr13 111155230 G T 3.19E-04 Alzheimer's disease (late onset) COL4A2 intron 21379329 rs873294 chr13 111167417 G A 9.90E-06 Urinary metabolites / / 21572414 rs1467652 chr13 111187750 G A 4.12E-04 White matter integrity RAB20 intron 22425255 rs9521823 chr13 111189856 A G 3.70E-05 Hypothyroidism RAB20 intron 22493691 rs2391835 chr13 111190101 T C 4.80E-05 Hypothyroidism RAB20 intron 22493691 rs2148079 chr13 111191413 A G 2.33E-05 Cardiovascular disease RAB20 intron 17903304 rs2477912 chr13 111193470 A G 4.07E-04 Coronary heart disease RAB20 intron 21971053 rs9521826 chr13 111193959 A G 2.10E-05 Hypothyroidism RAB20 intron 22493691 rs11617401 chr13 111198459 C T 4.60E-04 Alzheimer's disease RAB20 intron 22005930 rs7986145 chr13 111231833 C T 7.89E-05 Cytomegalovirus antibody response / / 21993531 rs9559849 chr13 111243736 A G 1.58E-04 Schizophrenia / / 19197363 rs4773225 chr13 111245092 A G 7.90E-05 Endometriosis / / 21151130 rs7999799 chr13 111249968 G A 9.51E-04 Alzheimer's disease / / 22005930 rs7993863 chr13 111250334 G A 7.05E-04 Alzheimer's disease / / 22005930 rs912937 chr13 111250881 G A 7.37E-04 Alzheimer's disease / / 22005930 rs4773228 chr13 111254341 C A,T 2.10E-05 Urinary metabolites / / 21572414 rs4773229 chr13 111254499 C T 9.70E-06 Urinary metabolites / / 21572414 rs2765341 chr13 111270363 T C 4.24E-04 Multiple complex diseases CARKD intron 17554300 rs3759463 chr13 111286592 C T 4.71E-04 Multiple complex diseases CARKD intron 17554300 rs179356 chr13 111286607 G A 2.36E-04 Multiple complex diseases CARKD intron 17554300 rs146355429 chr13 111294796 C T 0.000079 Breast cancer (ER positive) CARS2 missense 23555315 rs7324648 chr13 111295695 C A 8.90E-05 Bipolar disorder and schizophrenia CARS2 intron 20889312 rs9670064 chr13 111308793 G A 3.84E-05 Bipolar disorder and schizophrenia CARS2 intron 20889312 rs7999702 chr13 111382264 G T 4.36E-04 Coronary Artery Disease / / 17634449 rs2083567 chr13 111425843 G A 1.68E-06 Glucose levels / / pha002899 rs12430668 chr13 111427813 C T 8.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2582890 chr13 111429202 G T 2.70E-06 Urinary metabolites / / 21572414 rs167890 chr13 111449115 G A 5.00E-06 Obesity-related traits / / 23251661 rs1055145 chr13 111463271 C A 1.60E-05 Urinary metabolites / / 21572414 rs767210 chr13 111470038 G A 3.00E-07 Cognitive performance / / 19734545 rs9515300 chr13 111488721 A G 0.000528963 Hypertension (early onset hypertension) / / 22479346 rs2391875 chr13 111492169 A C 8.80E-05 Lung adenocarcinoma / / 21242121 rs9521960 chr13 111492882 G A 0.000755442 Hypertension (early onset hypertension) / / 22479346 rs9555734 chr13 111495760 C T 6.40E-05 Response to statin therapy / / 20339536 rs9555734 chr13 111495760 C T 1.60E-05 Urinary metabolites / / 21572414 rs9559893 chr13 111496680 G A 2.50E-05 Response to statin therapy / / 20339536 rs9555736 chr13 111497851 C T 6.70E-05 Response to statin therapy / / 20339536 rs9559894 chr13 111497962 A G 6.70E-05 Response to statin therapy / / 20339536 rs4771711 chr13 111502659 A G 2.78E-04 Longevity / / 22279548 rs9521967 chr13 111510609 T C 3.52E-04 Multiple complex diseases / / 17554300 rs12855089 chr13 111514782 T G 5.98E-04 Aortic root size / / 21223598 rs2391883 chr13 111588967 T C 2.10E-06 Urinary metabolites / / 21572414 rs4771718 chr13 111595399 A G 6.04E-05 Platelet counts / / pha003100 rs11616301 chr13 111601705 C T 3.03E-05 Erythrocyte counts / / pha003101 rs11619139 chr13 111603736 A G 3.03E-05 Erythrocyte counts / / pha003101 rs9522028 chr13 111615709 A G 7.52E-05 Type 2 diabetes / / 17463246 rs9515327 chr13 111621733 A G 9.23E-06 Sleep duration / / 22105623 rs9515328 chr13 111624376 G T 9.38E-06 Sleep duration / / 22105623 rs9522031 chr13 111624836 T C 9.59E-06 Sleep duration / / 22105623 rs9515329 chr13 111625203 A G 9.11E-06 Sleep duration / / 22105623 rs9515330 chr13 111625921 C T 9.77E-06 Sleep duration / / 22105623 rs9522032 chr13 111626255 G A 9.54E-06 Sleep duration / / 22105623 rs9522033 chr13 111626286 T C 9.62E-06 Sleep duration / / 22105623 rs9559922 chr13 111637374 C T 5.40E-05 Endometriosis / / 21151130 rs4238282 chr13 111638313 A G 1.90E-07 Magnesium levels / / pha003092 rs11617259 chr13 111720463 C T 3.01E-05 Type 2 diabetes / / 17463246 rs7991608 chr13 111730645 C T 2.37E-05 Type 2 diabetes / / 17463246 rs12853515 chr13 111781060 C G 2.00E-06 Homeostasis model assessment of insulin resistance (interaction) ARHGEF7 intron 24204828 rs12853515 chr13 111781060 C G 4.00E-06 Fasting insulin (interaction) ARHGEF7 intron 24204828 rs831159 chr13 111782877 A T 5.69E-04 Obesity (extreme) ARHGEF7 intron 21935397 rs831167 chr13 111795544 C T 8.40E-06 Bilirubin levels ARHGEF7 intron 19414484 rs831169 chr13 111797920 G A 9.00E-06 Bilirubin levels ARHGEF7 intron 19414484 rs1891958 chr13 111817665 A G 8.30E-06 Bilirubin levels ARHGEF7 intron 19414484 rs4773330 chr13 111818832 A G 8.00E-06 Bilirubin levels ARHGEF7 intron 19414484 rs9301494 chr13 111821289 G C 7.80E-06 Bilirubin levels ARHGEF7 intron 19414484 rs7987430 chr13 111834095 G C 7.00E-06 Urinary metabolites ARHGEF7 intron 21572414 rs1164270 chr13 111854193 C T 7.90E-06 Urinary metabolites ARHGEF7 intron 21572414 rs2147686 chr13 111867501 C A 5.03E-05 Parent of origin effect on language impairment (maternal) ARHGEF7 intron 24571439 rs3742179 chr13 111958085 T C 2.00E-04 Nicotine smoking / / 19268276 rs2479967 chr13 111971731 G A 3.11E-05 Diabetic nephropathy / / pha002852 rs11841484 chr13 111973588 C T 4.43E-04 Schizophrenia TEX29 intron 19197363 rs2479955 chr13 111980478 A G 4.70E-04 Alcohol dependence TEX29 intron 20201924 rs2479956 chr13 111981399 T C 5.60E-04 Alcohol dependence TEX29 intron 20201924 rs1886558 chr13 111982615 A G 5.02E-04 Multiple complex diseases TEX29 intron 17554300 rs2479958 chr13 111984244 A G 4.57E-04 Smoking initiation TEX29 intron 24665060 rs2252557 chr13 112026623 T C 8.13E-04 Parkinson's disease / / 17052657 rs9555795 chr13 112042272 C T 9.05E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs9555795 chr13 112042272 C T 9.05E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs12875410 chr13 112042383 C T 1.90E-05 Iron levels / / 21208937 rs9560051 chr13 112042461 C T 4.60E-04 IgE levels / / 17255346 rs9588421 chr13 112049393 A T 4.31E-04 Insulin resistance / / 21901158 rs12876300 chr13 112051508 A G 3.05E-04 Insulin resistance / / 21901158 rs7332901 chr13 112054044 C T 2.60E-05 Sodium levels / / pha003093 rs1183680 chr13 112057748 C T 2.39E-04 Smoking initiation / / 24665060 rs11618990 chr13 112062542 A G 6.92E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11619721 chr13 112082513 G T 6.82E-05 Heart Failure / / pha002884 rs2770277 chr13 112100098 T C 2.80E-04 Lung function (forced vital capacity) / / 24023788 rs2770277 chr13 112100098 T C 4.14E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs9560083 chr13 112116890 C T 2.40E-04 Multiple complex diseases / / 17554300 rs1183183 chr13 112136705 A C 4.71E-05 Major depressive disorder / / 21621269 rs1151452 chr13 112139134 T G 1.84E-04 Smoking initiation / / 24665060 rs1151453 chr13 112139397 T C 3.53E-04 Smoking initiation / / 24665060 rs1151454 chr13 112140159 G A 1.26E-04 Smoking initiation / / 24665060 rs1151457 chr13 112143190 A G 3.66E-04 Smoking initiation / / 24665060 rs1163825 chr13 112143707 A G 7.63E-08 Coronary heart disease / / pha003030 rs1163825 chr13 112143707 A G 8.81E-07 Coronary heart disease / / pha003031 rs1163829 chr13 112146194 C A 4.03E-04 Multiple complex diseases / / 17554300 rs1163829 chr13 112146194 C A 1.59E-04 Parkinson's disease / / 21248740 rs9583610 chr13 112146667 G A 3.81E-04 Multiple complex diseases / / 17554300 rs1888306 chr13 112154862 T C 1.04E-06 Coronary heart disease / / pha003030 rs1888306 chr13 112154862 T C 5.94E-07 Coronary heart disease / / pha003031 rs1163860 chr13 112157919 C A 3.58E-04 Type 2 diabetes / / 17463246 rs1163852 chr13 112164871 G A 3.71E-05 Prostate cancer / / 18264096 rs953360 chr13 112174579 G A 1.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs9555810 chr13 112181437 C G 6.00E-08 Menarche (age at onset) / / 21102462 rs9522267 chr13 112196367 G A 5.78E-04 Type 2 diabetes / / 17463246 rs7333181 chr13 112221297 G A 3.00E-08 Menopause (age at onset) / / 19448619 rs9522285 chr13 112230701 G A 6.26E-04 Multiple complex diseases / / 17554300 rs4773396 chr13 112241717 G A 4.45E-05 Body mass index / / 19584900 rs4773396 chr13 112241717 G A 7.88E-05 Body mass index / / 19584900 rs8001653 chr13 112250110 T G 3.96E-04 Alzheimer's disease / / 22005930 rs7994242 chr13 112250394 C T 4.26E-04 Alzheimer's disease / / 22005930 rs9588477 chr13 112251578 T C 5.06E-04 Alzheimer's disease / / 22005930 rs557978640 chr13 112263431 G GACTCTGGGCCTCCA 7.33E-04 Alzheimer's disease / / 22005930 rs56047618 chr13 112263431 G GGACTCTGGGCCTCCA 7.33E-04 Alzheimer's disease / / 22005930 rs9522313 chr13 112263431 G A 7.33E-04 Alzheimer's disease / / 22005930 rs1111847 chr13 112281238 A G 2.95E-04 Multiple complex diseases / / 17554300 rs2039917 chr13 112287438 A C 7.10E-04 Multiple complex diseases / / 17554300 rs9560161 chr13 112338725 G A 4.82E-06 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs9549433 chr13 112523965 C A 7.40E-05 IgE levels in asthmatics / / 23967269 rs7336515 chr13 112530544 G A 1.19E-04 Aortic root size / / 21223598 rs9577618 chr13 112533866 C T 1.10E-05 Urinary metabolites / / 21572414 rs9577644 chr13 112537874 G A 4.30E-06 Urinary metabolites / / 21572414 rs2318060 chr13 112538105 A G 3.90E-06 Urinary metabolites / / 21572414 rs11164148 chr13 112548383 G A 1.00E-04 Prostate cancer / / 21743057 rs9577381 chr13 112575604 A T 2.00E-06 Axial length / / 24144296 rs9604365 chr13 112577197 G A 8.10E-07 Stroke (ischemic) / / 22384361 rs1923733 chr13 112582344 C T 1.84E-04 Multiple complex diseases / / 17554300 rs4907734 chr13 112584322 C T 2.50E-05 Urinary metabolites / / 21572414 rs9577173 chr13 112606210 C T 4.91E-05 Lymphocyte counts / / pha003094 rs9577173 chr13 112606210 C T 3.42E-05 Neutrophil count / / pha003095 rs1886187 chr13 112608187 A G 1.30E-05 Urinary metabolites / / 21572414 rs523042 chr13 112624185 T C 2.56E-05 Lymphocyte counts / / pha003094 rs523042 chr13 112624185 T C 1.39E-05 Neutrophil count / / pha003095 rs11164131 chr13 112628831 G T 2.01E-05 Lymphocyte counts / / pha003094 rs11164131 chr13 112628831 G T 1.19E-05 Neutrophil count / / pha003095 rs9549825 chr13 112696714 T C 4.24E-06 Triglycerides / / 19074352 rs9549825 chr13 112696714 T C 4.24E-06 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs2196579 chr13 112768834 G A 2.16E-04 White matter integrity / / 22425255 rs7991981 chr13 112784083 T G 5.33E-04 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs893209 chr13 112784507 A G 7.12E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs7989963 chr13 112812337 C A 6.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100506016 intron 20877124 rs9577631 chr13 112824589 C T 3.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1970331 chr13 112828992 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1538278 chr13 112829112 G A 5.19E-04 Type 2 diabetes / / 17463246 rs1538278 chr13 112829112 G A 5.27E-04 Multiple complex diseases / / 17554300 rs4907671 chr13 112834506 A G 6.12E-05 Cognitive impairment induced by topiramate / / 22091778 rs9324265 chr13 112835484 G A 1.72E-04 Type 2 diabetes / / 17463246 rs9324268 chr13 112836655 C T 2.00E-06 Renal transplant outcome / / 23432519 rs2774089 chr13 112837503 A C 4.00E-05 Suicidal ideation / / 22030708 rs2774089 chr13 112837503 A C 1.07E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs100224 chr13 112841134 G A 3.72E-04 Multiple complex diseases / / 17554300 rs9324272 chr13 112852538 C T 7.98E-04 Acute lung injury / / 22295056 rs4907674 chr13 112852673 T G 5.00E-05 Suicidal ideation / / 22030708 rs928194 chr13 112854202 C A 8.26E-04 Acute lung injury / / 22295056 rs7982118 chr13 112854793 G C 4.77E-04 Major depressive disorder / / 22472876 rs175970 chr13 112855199 G T 2.88E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs9549880 chr13 112862188 G A 5.93E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs928195 chr13 112865110 T C 5.49E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs7321489 chr13 112870029 A G 9.89E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs280814 chr13 112884595 G T 2.54E-04 Type 2 diabetes / / 17463246 rs280814 chr13 112884595 G T 4.75E-04 Multiple complex diseases / / 17554300 rs9635132 chr13 112911844 G A 0.000779 Salmonella-induced pyroptosis / / 22837397 rs9577321 chr13 112923019 T A 0.000834 Salmonella-induced pyroptosis / / 22837397 rs9549948 chr13 112931650 G A 1.85E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7995181 chr13 112966793 C A 6.00E-05 Response to statin therapy / / 20339536 rs7320500 chr13 112983664 G A 7.70E-04 Depression (quantitative trait) / / 20800221 rs1752739 chr13 113006942 C T 2.78E-04 Aortic root size / / 21223598 rs9577345 chr13 113011456 A T 3.52E-04 Obesity (extreme) / / 21935397 rs9577729 chr13 113020757 T C 1.70E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1887649 chr13 113074228 G T 4.30E-05 Inflammatory demyelinating disease SPACA7 intron 19850125 rs8001869 chr13 113090234 T C 8.16E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2149208 chr13 113125274 A C 7.50E-06 Urinary metabolites / / 21572414 rs9550130 chr13 113193984 C T 4.72E-05 Calcium levels TUBGCP3 intron pha003085 rs7139689 chr13 113211300 G C 1.01E-04 Smoking cessation TUBGCP3 intron 18519826 rs9577802 chr13 113215629 C T 5.95E-05 Calcium levels TUBGCP3 intron pha003085 rs4907726 chr13 113219158 A G 5.95E-05 Calcium levels TUBGCP3 intron pha003085 rs17121271 chr13 113223897 C T 7.09E-06 Heart Failure TUBGCP3 intron pha002885 rs9324313 chr13 113224567 A G 2.50E-04 Type 2 diabetes and 6 quantitative traits TUBGCP3 intron 17848626 rs9324313 chr13 113224567 A G 3.63E-04 Suicide,with and without major depression TUBGCP3 intron 22059935 rs9324313 chr13 113224567 A G 3.80E-04 Suicide,with and without major depression TUBGCP3 intron 22059935 rs9550153 chr13 113234278 T G 5.85E-05 Smoking cessation TUBGCP3 intron 18519826 rs7986446 chr13 113235062 G A 5.02E-05 Tunica Media TUBGCP3 intron pha003037 rs9550158 chr13 113244733 A G 8.10E-05 Calcium levels / / pha003085 rs1925888 chr13 113246945 G A 1.40E-05 White matter hyperintensity burden / / 21681796 rs9324315 chr13 113247331 G A 1.26E-04 Heart Failure / / pha002885 rs9577820 chr13 113248261 A G 6.17E-07 Smoking cessation / / 18519826 rs9604369 chr13 113250363 C T 1.50E-05 White matter hyperintensity burden / / 21681796 rs7327354 chr13 113254489 C T 1.60E-05 White matter hyperintensity burden / / 21681796 rs7333030 chr13 113254797 G C 1.70E-05 White matter hyperintensity burden / / 21681796 rs9989097 chr13 113255825 A G 1.70E-05 White matter hyperintensity burden / / 21681796 rs9989087 chr13 113256034 C A 1.70E-05 White matter hyperintensity burden / / 21681796 rs9989115 chr13 113256064 T C 1.80E-05 White matter hyperintensity burden / / 21681796 rs7990359 chr13 113256688 A G 1.80E-05 White matter hyperintensity burden / / 21681796 rs9604370 chr13 113257064 G T 1.80E-05 White matter hyperintensity burden / / 21681796 rs2274299 chr13 113257378 C T 1.60E-05 White matter hyperintensity burden / / 21681796 rs2274300 chr13 113257435 C G 1.60E-05 White matter hyperintensity burden / / 21681796 rs9604371 chr13 113257452 G T 1.60E-05 White matter hyperintensity burden / / 21681796 rs7337780 chr13 113259802 C T 1.60E-05 White matter hyperintensity burden / / 21681796 rs7995838 chr13 113261829 G A 3.03E-04 Type 2 diabetes / / 17463246 rs9603917 chr13 113284191 C T 8.37E-05 Asthma / / pha003127 rs1041385 chr13 113306882 A G 4.49E-04 Type 2 diabetes C13orf35 intron 17463246 rs17121478 chr13 113329401 C T 1.99E-06 Asthma C13orf35 intron pha003127 rs7998202 chr13 113331868 A G 5.00E-09 Glycated hemoglobin levels C13orf35 intron 20858683 rs282606 chr13 113339761 G A 1.17E-08 Glycated hemoglobin levels / / 22885924 rs422046 chr13 113419191 T C 7.77E-05 Brain derived neurotrophic factor levels,in serum ATP11A intron 22047184 rs374433 chr13 113420269 G C 7.72E-05 Brain derived neurotrophic factor levels,in serum ATP11A intron 22047184 rs282592 chr13 113431325 T C 5.45E-04 Multiple complex diseases ATP11A intron 17554300 rs9603948 chr13 113438020 C A 1.77E-05 Cervical cancer ATP11A intron 24700089 rs447590 chr13 113447211 A C 3.75E-05 Serum alpha1-antitrypsin levels ATP11A intron 23990791 rs9577855 chr13 113490165 G A 3.84E-04 Multiple complex diseases ATP11A intron 17554300 rs10492684 chr13 113513682 C G 6.11E-04 Type 2 diabetes ATP11A intron 17463246 rs1278776 chr13 113520362 A G 2.85E-05 Attention deficit hyperactivity disorder ATP11A intron 20732627 rs1278776 chr13 113520362 A G 6.85E-04 Insulin resistance ATP11A intron 21901158 rs1278760 chr13 113531675 C T 4.79E-05 Interstitial lung disease ATP11A intron 23583980 rs1278769 chr13 113536627 A G 7.00E-09 Interstitial lung disease ATP11A UTR-3 23583980 rs1278769 chr13 113536627 A G 9.11E-07 Interstitial lung disease ATP11A UTR-3 23583980 rs9603985 chr13 113554752 A G 7.94E-04 Acute lung injury LOC100506063 intron 22295056 rs9603986 chr13 113556357 C T 1.49E-04 Obesity (extreme) LOC100506063 intron 21935397 rs9603799 chr13 113556584 G A 1.49E-04 Obesity (extreme) / / 21935397 rs1320526 chr13 113560379 T C 2.77E-06 Non-obstructive azoospermia LOC100506063 intron 22541561 rs1933199 chr13 113582130 T C 8.57E-04 Parkinson's disease LOC100506063 intron 17052657 rs2993285 chr13 113636645 C A 9.47E-05 Non-alcoholic fatty liver disease histology (other) MCF2L intron 20708005 rs4907479 chr13 113659108 G A 3.00E-06 Bladder cancer MCF2L intron 24163127 rs149468042 chr13 113669159 C T 0.00029 Breast cancer MCF2L cds-synon 23555315 rs2993312 chr13 113683465 A G 7.54E-06 Coronary Artery Disease MCF2L intron 17634449 rs4907576 chr13 113692063 G A 6.30E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MCF2L intron 20877124 rs11842874 chr13 113694509 A G 2.00E-08 Osteoarthritis MCF2L intron 21871595 rs1888227 chr13 113695229 T C 6.75E-06 Osteoarthritis MCF2L intron 21871595 rs9577453 chr13 113716575 C G,T 1.80E-05 Urinary metabolites MCF2L intron 21572414 rs2476325 chr13 113737077 A G 1.58E-08 End-stage coagulation MCF2L intron 23381943 rs521720 chr13 113737144 C T 1.58E-08 End-stage coagulation MCF2L intron 23381943 rs2873281 chr13 113740602 G A 2.89E-08 End-stage coagulation MCF2L intron 23381943 rs9324220 chr13 113742595 C T 1.03E-08 End-stage coagulation MCF2L intron 23381943 rs534298 chr13 113743768 T C 2.35E-08 End-stage coagulation MCF2L intron 23381943 rs553702 chr13 113744669 A G 1.86E-14 End-stage coagulation MCF2L intron 23381943 rs7327099 chr13 113748690 C T 7.82E-19 End-stage coagulation MCF2L intron 23381943 rs2146752 chr13 113749475 G A 2.51E-11 End-stage coagulation MCF2L intron 23381943 rs2146751 chr13 113749645 A G 2.65E-11 End-stage coagulation MCF2L intron 23381943 rs10665 chr13 113752831 A G 2.00E-47 End-stage coagulation MCF2L UTR-3 23381943 rs2181540 chr13 113753164 T C 1.00E-46 End-stage coagulation MCF2L UTR-3 23381943 rs555212 chr13 113756540 A G 6.30E-166 FVII levels / / 21676895 rs555212 chr13 113756540 A G 8.45E-86 FVII levels / / 21676895 rs555212 chr13 113756540 A G 1.30E-35 Metabolic syndrome phenotype / / 22022282 rs555212 chr13 113756540 A G 1.80E-29 Metabolic syndrome phenotype / / 22022282 rs555212 chr13 113756540 A G 1.00E-15 End-stage coagulation / / 23381943 rs1755685 chr13 113757192 C A 1.42E-04 Body mass index / / 21701565 rs1755685 chr13 113757192 C A 3.00E-04 Body mass index / / 21701565 rs1755685 chr13 113757192 C A 1.86E-44 End-stage coagulation / / 23381943 rs3093230 chr13 113757968 G A 2.37E-09 FVII levels / / 21676895 rs201504247 chr13 113759755 G GT 1.50E-47 Metabolic syndrome phenotype F7 nearGene-5 22022282 rs201504247 chr13 113759755 G GT 4.90E-49 Metabolic syndrome phenotype F7 nearGene-5 22022282 rs201504247 chr13 113759755 G GT 2.08E-44 End-stage coagulation F7 nearGene-5 23381943 rs510335 chr13 113759755 G A,C,T 1.50E-47 Metabolic syndrome phenotype F7 nearGene-5 22022282 rs510335 chr13 113759755 G A,C,T 4.90E-49 Metabolic syndrome phenotype F7 nearGene-5 22022282 rs510335 chr13 113759755 G A,C,T 2.08E-44 End-stage coagulation F7 nearGene-5 23381943 rs561241 chr13 113760034 T C 5.00E-16 Factor VII F7 nearGene-5 17903294 rs561241 chr13 113760034 T C 6.78E-485 FVII levels F7 nearGene-5 21676895 rs561241 chr13 113760034 T C 8.0E-495 FVII levels F7 nearGene-5 21676895 rs561241 chr13 113760034 T C 4.00E-56 Prothrombin time F7 nearGene-5 22703881 rs561241 chr13 113760034 T C 2.59E-44 End-stage coagulation F7 nearGene-5 23381943 rs3093265 chr13 113769226 A C 1.47E-28 FVII levels F7 intron 21676895 rs3093265 chr13 113769226 A C 9.80E-17 FVII levels F7 intron 21676895 rs491098 chr13 113769346 G C 6.23E-04 Body mass index F7 intron 21701565 rs493833 chr13 113769639 T G 1.10E-47 FVII levels F7 intron 21676895 rs493833 chr13 113769639 T G 1.8E-494 FVII levels F7 intron 21676895 rs6042 chr13 113770068 C T 1.92E-45 End-stage coagulation F7 cds-synon 23381943 rs488703 chr13 113770876 G A 1.31E-08 FVII levels F7 intron 21676895 rs488703 chr13 113770876 G A 3.23E-45 End-stage coagulation F7 intron 23381943 rs6041 chr13 113772707 G A 2.00E-45 End-stage coagulation F7 intron 23381943 rs3093267 chr13 113772975 G A 1.60E-14 LDL cholesterol F7 missense 23063622 rs3093267 chr13 113772975 G A 2.43E-10 HDL cholesterol F7 missense 23063622 rs3093267 chr13 113772975 G A 6.77E-11 Triglycerides F7 missense 23063622 rs3093267 chr13 113772975 G A 7.46E-15 Cholesterol,total F7 missense 23063622 rs6046 chr13 113773159 G A,C,T 4.50E-16 Blood Phenotypes F7 missense 17903294 rs6046 chr13 113773159 G A,C,T 1.93E-45 End-stage coagulation F7 missense 23381943 rs3093253 chr13 113774092 G A 1.09E-43 End-stage coagulation F7 UTR-3 23381943 rs556694 chr13 113780041 T C 6.53E-34 End-stage coagulation F10 intron 23381943 rs474810 chr13 113780910 T C 7.87E-34 End-stage coagulation F10 intron 23381943 rs3211727 chr13 113781018 G A 1.40E-77 FVII levels F10 intron 21676895 rs3211727 chr13 113781018 G A 6.39E-13 FVII levels F10 intron 21676895 rs776905 chr13 113781942 A C 9.68E-35 End-stage coagulation F10 intron 23381943 rs776906 chr13 113784588 A G 2.27E-29 End-stage coagulation F10 intron 23381943 rs2480946 chr13 113784720 A G 2.25E-29 End-stage coagulation F10 intron 23381943 rs2026160 chr13 113792893 C A 7.87E-11 End-stage coagulation F10 intron 23381943 rs3211770 chr13 113793849 G A 3.00E-19 End-stage coagulation F10 intron 23381943 rs7337258 chr13 113794301 G A 0.000000682 Cholesterol,total F10 intron 23063622 rs511022 chr13 113822589 A G 2.51E-04 Multiple complex diseases PROZ intron 17554300 rs9577215 chr13 113855275 C T 3.57E-04 Rheumatoid arthritis PCID2 intron 21452313 rs12871648 chr13 113970662 A C 4.98E-05 Parkinson's disease LAMP1 intron pha002865 rs12871648 chr13 113970662 A C 9.90E-05 Coronary heart disease LAMP1 intron pha003032 rs7317038 chr13 114012898 C T 8.00E-12 Mean platelet volume GRTP1 intron 22139419 rs7999901 chr13 114056468 G A 4.15E-04 Coronary Artery Disease / / 17634449 rs8001629 chr13 114086782 C T 7.38E-04 Coronary heart disease ADPRHL1 intron 21606135 rs9577556 chr13 114116162 A G 8.50E-04 Amyotrophic Lateral Sclerosis DCUN1D2 intron 17362836 rs9577556 chr13 114116162 A G 8.50E-05 Response to statin therapy DCUN1D2 intron 20339536 rs2257442 chr13 114128782 T C 8.06E-04 Type 2 diabetes DCUN1D2 intron 20818381 rs9604140 chr13 114193833 T A 4.94E-04 Multiple complex diseases TMCO3 intron 17554300 rs9577281 chr13 114212852 T C 6.51E-04 Multiple complex diseases / / 17554300 rs9577281 chr13 114212852 T C 3.59E-04 Lymphocyte counts / / 22286170 rs7333011 chr13 114216892 T C 5.34E-04 Multiple complex diseases / / 17554300 rs11617870 chr13 114241227 G A,T 3.45E-06 Psoriasis TFDP1 intron 18364390 rs11843987 chr13 114244269 A G 2.88E-07 Esophageal cancer (squamous cell) TFDP1 intron 22960999 rs11164141 chr13 114259570 T C 5.53E-05 Monocyte chemoattractant protein-1 TFDP1 intron pha003071 rs2001275 chr13 114261808 C T 4.48E-05 Monocyte chemoattractant protein-1 TFDP1 intron pha003071 rs4150734 chr13 114265950 T C 4.07E-05 Monocyte chemoattractant protein-1 TFDP1 intron pha003071 rs12875059 chr13 114302622 G A 6.96E-05 Monocyte chemoattractant protein-1 / / pha003071 rs12020712 chr13 114308125 C T 6.75E-05 Bipolar Disorder ATP4B intron pha002863 rs9796234 chr13 114323997 T C 9.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7330442 chr13 114457173 C A 0.0000527 Asthma / / 22694930 rs7489746 chr13 114476911 C T 0.0000858 Asthma FAM70B intron 22694930 rs9550238 chr13 114494245 C T 5.24E-05 Response to platinum-based chemotherapy in small-cell lung cancer FAM70B intron 20463552 rs7492267 chr13 114495263 T C 2.30E-05 Urinary metabolites FAM70B intron 21572414 rs9329350 chr13 114507239 C T 8.00E-06 IgG glycosylation FAM70B intron 23382691 rs11842558 chr13 114526108 A G 6.59E-04 Tourette syndrome GAS6 intron 22889924 rs9604573 chr13 114542858 G A 5.59E-04 Amyotrophic Lateral Sclerosis GAS6 intron 17362836 rs6602910 chr13 114549015 T C 5.99E-05 Response to statin treatment (atorvastatin),change in cholesterol levels GAS6 intron 20031582 rs6602910 chr13 114549015 T C 0.000000015 Cholesterol,total GAS6 intron 23063622 rs6602910 chr13 114549015 T C 0.000000134 Triglycerides GAS6 intron 23063622 rs7994900 chr13 114553134 C T 0.0000021 Triglycerides GAS6 intron 23063622 rs7994900 chr13 114553134 C T 0.0000102 Cholesterol,total GAS6 intron 23063622 rs8000868 chr13 114559522 C T 6.58E-04 Amyotrophic Lateral Sclerosis GAS6 intron 17362836 rs7329468 chr13 114599851 C T 8.30E-07 Response to tocilizumab in rheumatoid arthritis FLJ44054 intron 22491018 rs11259844 chr13 114620051 C T 8.18E-05 Lung adenocarcinoma FLJ44054 intron 19836008 rs112630268 chr13 114622597 A AG 7.00E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs9604529 chr13 114622597 A G 7.00E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs9796292 chr13 114740938 G A 2.47E-04 Blood pressure / / 17255346 rs3895392 chr13 114752802 T C 9.94E-04 Type 2 diabetes RASA3 intron 17463246 rs4883641 chr13 114792330 A C 2.81E-04 Blood pressure RASA3 intron 17255346 rs7995126 chr13 114803885 G A 2.52E-05 Depression (quantitative trait) RASA3 intron 20800221 rs9525253 chr13 114852930 G A 5.71E-05 Cognitive impairment induced by topiramate RASA3 intron 22091778 rs4063 chr13 114861102 C T 5.57E-05 Suicide attempts in bipolar disorder RASA3 intron 21423239 rs4883650 chr13 114861938 C T 5.32E-05 Suicide attempts in bipolar disorder RASA3 intron 21423239 rs9525275 chr13 114886976 T C 0.0000199 post-traumatic stress disorder RASA3 intron 22869035 rs9525275 chr13 114886976 T C 1.99E-05 Schizophrenia RASA3 intron 22883433 rs4883652 chr13 114895565 G A 6.58E-05 Cognitive test performance RASA3 intron 20125193 rs7317882 chr13 114916406 G T 5.68E-05 Bipolar disorder and schizophrenia / / 20889312 rs446581 chr13 114916460 A C 1.35E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs367312 chr13 114930195 G A 0.000511116 Hypertension (early onset hypertension) / / 22479346 rs6560933 chr13 114937294 C T 0.000410258 Hypertension (early onset hypertension) / / 22479346 rs7982373 chr13 115007089 A G 3.95E-04 Lymphocyte counts CDC16 intron 22286170 rs11617448 chr13 115025398 G A 8.27E-05 Multiple complex diseases CDC16 intron 17554300 rs7316983 chr13 115074878 C T 1.05E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs9562200 chr13 115086044 C T 6.75E-04 Taste perception CHAMP1 intron 22132133 rs3813131 chr13 115090019 G A 1.05E-05 Amyotrophic Lateral Sclerosis CHAMP1 cds-synon 18057069 rs3813133 chr13 115090193 G A 1.67E-05 Amyotrophic Lateral Sclerosis CHAMP1 cds-synon 18057069 rs4246275 chr14 19793801 C G 6.66E-06 Serum metabolites / / 19043545 rs10498263 chr14 20215448 C T 8.30E-05 Longevity and age-related phenotypes / / 17903295 rs4412905 chr14 20267014 C T 7.44E-04 Alzheimer's disease / / 17998437 rs2873710 chr14 20350109 G A 9.09E-07 Red blood cell traits / / 23222517 rs2027405 chr14 20480547 G A 2.83E-05 Information processing speed / / 21130836 rs1015703 chr14 20486355 A T 4.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs1557000 chr14 20486724 G A 3.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs17276968 chr14 20487553 C T 4.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs17276982 chr14 20488148 T C 4.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs10484219 chr14 20488191 G A 3.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs10484221 chr14 20490612 T A 3.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs2039864 chr14 20495913 A G 1.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs2039863 chr14 20496983 A C 1.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs17211069 chr14 20497631 C G 9.74E-05 Suicide attempts in bipolar disorder / / 21423239 rs7141391 chr14 20497737 A C,G,T 2.79E-04 Alcohol dependence / / 20201924 rs2775259 chr14 20501368 T C 9.90E-06 Urinary metabolites / / 21572414 rs2775261 chr14 20501962 G C 8.04E-05 Suicide attempts in bipolar disorder / / 21423239 rs17277025 chr14 20502044 G T 7.00E-05 Suicide attempts in bipolar disorder OR4K13 missense 21423239 rs17122640 chr14 20503541 G A 6.40E-05 Suicide attempts in bipolar disorder / / 21423239 rs17122640 chr14 20503541 G A 3.00E-06 Prostate cancer / / 21743057 rs17122640 chr14 20503541 G A 9.95E-05 Body Mass Index / / pha003006 rs17122640 chr14 20503541 G A 8.92E-05 Body Mass Index / / pha003020 rs17122640 chr14 20503541 G A 7.72E-05 Asthma / / pha003128 rs10484224 chr14 20504435 A T 5.19E-05 Suicide attempts in bipolar disorder / / 21423239 rs10484226 chr14 20511107 T C 5.83E-05 Suicide attempts in bipolar disorder / / 21423239 rs2775220 chr14 20512772 G T 3.16E-05 Bipolar disorder / / 21771265 rs2792168 chr14 20515436 C T 4.53E-05 Information processing speed / / 21130836 rs2775233 chr14 20517501 T C 4.53E-05 Information processing speed / / 21130836 rs1953992 chr14 20521060 A C 7.24E-05 Blood Pressure / / pha003040 rs1953991 chr14 20521104 C T 5.98E-04 Smoking initiation / / 24665060 rs1958717 chr14 20528362 A G 5.09E-04 Smoking initiation OR4L1 cds-synon 24665060 rs200624036 chr14 20528362 A ATCG 5.09E-04 Smoking initiation OR4L1 cds-synon 24665060 rs995249 chr14 20534313 G A 6.52E-05 Suicide attempts in bipolar disorder / / 21423239 rs10136466 chr14 20550347 C T 1.00E-05 Urinary metabolites / / 21572414 rs17277088 chr14 20580112 G A 8.50E-06 Urinary metabolites / / 21572414 rs9323534 chr14 20586432 C T 1.80E-05 Urinary metabolites OR4K17 cds-synon 21572414 rs6573975 chr14 20590454 G A 0.00007488 Sarcoidosis / / 22952805 rs1888371 chr14 20594389 G A 0.00006888 Sarcoidosis / / 22952805 rs10149500 chr14 20599515 T C 1.40E-05 Urinary metabolites / / 21572414 rs1958730 chr14 20600154 T C 1.10E-05 Urinary metabolites / / 21572414 rs1958697 chr14 20603359 T A 5.20E-06 Urinary metabolites / / 21572414 rs17277102 chr14 20622221 T C 5.60E-06 Urinary metabolites / / 21572414 rs10135142 chr14 20635506 G A 7.30E-06 Urinary metabolites / / 21572414 rs11850259 chr14 20645916 T G 4.60E-06 Urinary metabolites / / 21572414 rs7143050 chr14 20646485 G A 2.40E-06 Urinary metabolites / / 21572414 rs1188538 chr14 20646940 C G 9.00E-04 Body mass index / / 24827717 rs10484229 chr14 20649375 G C 4.50E-06 Urinary metabolites / / 21572414 rs1188561 chr14 20655466 C T 9.87E-04 Multiple complex diseases / / 17554300 rs17277172 chr14 20659073 C T 8.90E-06 Urinary metabolites / / 21572414 rs10150103 chr14 20675194 G A 1.97E-05 HDL cholesterol / / pha003075 rs12891553 chr14 20692188 T C 8.90E-04 Parkinson's disease OR11H6 missense 17052657 rs12434822 chr14 20697600 T G 4.88E-04 Parkinson's disease / / 17052657 rs8014060 chr14 20709118 G A 6.56E-06 Erythrocyte counts / / pha003101 rs10873395 chr14 20775845 T C 2.10E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2297732 chr14 20781361 A G 1.96E-05 Schizophrenia CCNB1IP1 intron 24253340 rs10131909 chr14 20782165 T C 8.16E-05 Schizophrenia CCNB1IP1 intron 24253340 rs8022565 chr14 20796878 T C 9.24E-05 Multiple complex diseases CCNB1IP1 intron 17554300 rs10498267 chr14 20802315 T C 1.31E-11 Alcohol consumption / / pha001402 rs7159947 chr14 20809491 T C 2.52E-04 Multiple complex diseases / / 17554300 rs3093927 chr14 20823095 G A 1.38E-11 Alcohol consumption PARP2 cds-synon pha001402 rs4981158 chr14 20827797 T C 7.69E-04 Multiple complex diseases / / 17554300 rs7161611 chr14 20831406 C A 3.67E-04 Multiple complex diseases / / 17554300 rs1760907 chr14 20844859 T C 1.48E-06 Lymphocyte counts TEP1 intron 22286170 rs2275009 chr14 20872740 G A 7.80E-04 Type 2 diabetes TEP1 intron 17463246 rs1713435 chr14 20883930 A G 3.87E-04 Multiple complex diseases / / 17554300 rs1760955 chr14 20887962 A C 3.39E-04 Alzheimer's disease / / 17998437 rs1713428 chr14 20888180 C T 1.87E-04 Multiple complex diseases / / 17554300 rs8017682 chr14 20903778 G A 3.72E-05 F-cell distribution KLHL33 UTR-5 21326311 rs8017603 chr14 20903906 C T 8.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1760940 chr14 20938251 A C 2.70E-07 Menopause (age at onset) PNP intron 22267201 rs10498268 chr14 20951742 T C 1.03E-04 Heart Failure / / pha002884 rs10498268 chr14 20951742 T C 6.49E-04 Stroke / / pha002886 rs13379232 chr14 20955163 G A 2.54E-04 Myopia (pathological) / / 21095009 rs12147450 chr14 20957433 T C 8.04E-29 Narcolepsy / / 19629137 rs12147450 chr14 20957433 T C 6.00E-07 Response to antipsychotic therapy (extrapyramidal side effects) / / 19875103 rs17308401 chr14 20957471 A C 9.10E-04 Lymphocyte counts / / 22286170 rs4982140 chr14 20967644 T C 1.78E-04 Iron levels / / pha002876 rs17112925 chr14 20992497 A G 4.08E-10 Multiple complex diseases / / 17554300 rs1243705 chr14 21004037 A G 7.14E-08 Metabolite levels / / 23281178 rs1243704 chr14 21005062 G A 7.00E-07 Immune response to measles-mumps-rubella vaccine / / 24811271 rs1243647 chr14 21024619 A G 1.00E-06 Prostate cancer (gene x gene interaction) R/SE9 missense 22219177 rs4982207 chr14 21032624 C T 8.21E-06 Major depressive disorder / / 20516156 rs3827902 chr14 21058425 G T 1.50E-04 Amyotrophic lateral sclerosis (sporadic) R/SE12 UTR-3 24529757 rs7159639 chr14 21065017 C G 6.53E-05 Alzheimer's disease / / 24755620 rs2319375 chr14 21070264 G A 9.78E-04 Alzheimer's disease / / 24755620 rs12323741 chr14 21070826 A G 9.66E-04 Alzheimer's disease / / 24755620 rs1243658 chr14 21081410 G A 3.95E-04 Multiple complex diseases / / 17554300 rs1243658 chr14 21081410 G A 3.82E-04 Alzheimer's disease / / 24755620 rs1243659 chr14 21081507 T C 6.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1756548 chr14 21081658 A C 5.61E-05 Alzheimer's disease / / 24755620 rs1243661 chr14 21083433 T G 1.00E-05 Urinary metabolites / / 21572414 rs1271297 chr14 21091390 A G 9.91E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1243679 chr14 21093733 A G 1.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11622794 chr14 21109726 G A 6.60E-04 Multiple complex diseases OR6S1 missense 17554300 rs11156622 chr14 21109859 T C 8.40E-04 Multiple complex diseases / / 17554300 rs2115656 chr14 21111883 G C 7.04E-04 Multiple complex diseases / / 17554300 rs2319378 chr14 21112260 G A 3.88E-04 Multiple complex diseases / / 17554300 rs10135437 chr14 21123823 A G 1.20E-05 Urinary metabolites / / 21572414 rs9322855 chr14 21153299 A C 7.60E-04 Pulmonary function ANG intron 23932459 rs9322855 chr14 21153299 A C 2.17E-04 Stroke ANG intron pha002886 rs17211656 chr14 21167149 G A 0.0000156 HDL cholesterol particle diameter R/SE4 intron 23263444 rs11628398 chr14 21182800 G A 6.03E-04 Multiple complex diseases / / 17554300 rs8023192 chr14 21195471 A C 2.00E-04 Schizophrenia / / 19197363 rs8023192 chr14 21195471 A C 9.44E-05 Behcet's disease / / pha002888 rs17277606 chr14 21202633 G T 4.70E-06 Urinary metabolites / / 21572414 rs9671539 chr14 21203159 C T 2.81E-06 Waist-Hip Ratio / / pha003013 rs9671539 chr14 21203159 C T 2.48E-05 Waist Circumference / / pha003025 rs9671539 chr14 21203159 C T 7.73E-06 Waist-Hip Ratio / / pha003028 rs17211691 chr14 21215600 A G 0.000501229 Hypertension (early onset hypertension) EDDM3A intron 22479346 rs970014 chr14 21222926 T C 0.000521824 Hypertension (early onset hypertension) / / 22479346 rs10130129 chr14 21228818 T G 9.07E-06 Height / / pha003010 rs10130129 chr14 21228818 T G 5.76E-05 Height / / pha003011 rs11848484 chr14 21229453 C T 7.70E-06 Height / / pha003010 rs11848484 chr14 21229453 C T 5.00E-05 Height / / pha003011 rs10131121 chr14 21231575 C G 1.83E-04 Self-reported allergy / / 23817569 rs10131142 chr14 21231661 C A 9.72E-05 Waist-Hip Ratio / / pha003013 rs10131141 chr14 21261733 C T 8.00E-08 Obesity-related traits / / 23251661 rs4982364 chr14 21262431 G A 2.32E-06 Obesity-related traits / / 23251661 rs743249 chr14 21275334 G A 1.28E-04 Alzheimer's disease (late onset) / / 21379329 rs17182151 chr14 21278470 G A 1.50E-05 Urinary metabolites / / 21572414 rs8017622 chr14 21306257 T C 3.41E-04 Multiple complex diseases / / 17554300 rs8013858 chr14 21306502 A G 2.67E-04 Lung function (forced vital capacity) / / 24023788 rs7148287 chr14 21311146 C T 2.86E-04 Lung function (forced vital capacity) / / 24023788 rs7148287 chr14 21311146 C T 4.01E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs17254450 chr14 21325687 T C 1.21E-04 Myopia (pathological) / / 21095009 rs1889771 chr14 21326796 T C 8.30E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1889771 chr14 21326796 T C 1.74E-04 Myopia (pathological) / / 21095009 rs6571499 chr14 21341149 C T 2.00E-04 Information processing speed / / 21130836 rs1889774 chr14 21440463 G A 1.56E-04 Multiple complex diseases / / 17554300 rs2783786 chr14 21451545 C T 4.30E-06 Urinary metabolites / / 21572414 rs3827908 chr14 21451743 G A 2.68E-04 Multiple complex diseases / / 17554300 rs1952517 chr14 21452992 G A 8.40E-05 Personality dimensions / / 18957941 rs2771335 chr14 21453373 C G 2.20E-05 Urinary metabolites / / 21572414 rs2771342 chr14 21457048 C T 2.40E-06 Post-operative nausea and vomiting / / 21694509 rs4981349 chr14 21486387 G A 9.57E-06 Obesity-related traits NDRG2 cds-synon 23251661 rs12435011 chr14 21526044 T C 1.71E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs745696 chr14 21570273 T C 9.06E-04 Multiple complex diseases C14orf176 cds-synon 17554300 rs28733840 chr14 21653842 G A 2.54E-04 Smoking initiation / / 24665060 rs17102539 chr14 21674364 G A 6.02E-05 Arthritis (juvenile idiopathic) LOC283624 intron 22354554 rs7147840 chr14 21697858 T C 4.85E-04 Schizophrenia HNRNPC intron 19197363 rs17197037 chr14 21725654 G A 1.00E-04 Multiple complex diseases HNRNPC intron 17554300 rs17197037 chr14 21725654 G A 2.00E-06 Bipolar disorder HNRNPC intron 21738484 rs10136056 chr14 21752523 G A 6.44E-04 Multiple complex diseases / / 17554300 rs17792599 chr14 21770681 A G 8.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) RPGRIP1 cds-synon 23648065 rs12433536 chr14 21777712 G A 5.81E-04 Multiple complex diseases RPGRIP1 intron 17554300 rs10872898 chr14 21820454 G C 6.08E-05 Panic disorder SUPT16H UTR-3 19165232 rs17197086 chr14 21832776 C A,G,T 4.60E-04 Smoking initiation SUPT16H intron 24665060 rs8013500 chr14 21931199 C T 5.09E-04 Smoking quantity RAB2B intron 24665060 rs1061026 chr14 21967109 T G 7.30E-04 Response to statin treatment (atorvastatin),change in cholesterol levels TOX4 UTR-3 20031582 rs10145148 chr14 21999193 A T 7.10E-07 Urinary metabolites SALL2 intron 21572414 rs1041857 chr14 22011216 G A 6.95E-05 HDL cholesterol / / pha003075 rs17792778 chr14 22038659 T C 6.60E-05 Serum metabolites OR10G3 missense 19043545 rs10047948 chr14 22078529 A G 1.70E-05 Intraocular pressure / / 24002674 rs13379046 chr14 22079209 A G 1.91E-05 Post-operative nausea and vomiting / / 21694509 rs13379046 chr14 22079209 A G 0.0001846 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs13379046 chr14 22079209 A G 1.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17197324 chr14 22079359 C G 0.0001937 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17197324 chr14 22079359 C G 1.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7142691 chr14 22083298 G T 5.10E-04 Prostate cancer mortality / / 20978177 rs12434436 chr14 22094954 G A 0.0001504 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12434436 chr14 22094954 G A 1.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs193176078 chr14 22133463 A G 0.00000726 Ratio of free to total prostate-specific antigen OR4E2 missense 23555315 rs9323020 chr14 22158637 T G 6.50E-04 Multiple complex diseases / / 17554300 rs9323020 chr14 22158637 T G 3.29E-05 Neuroticism / / 23229837 rs17182761 chr14 22176920 T A 6.32E-04 Multiple complex diseases / / 17554300 rs28575550 chr14 22186982 C T 5.33E-04 Multiple complex diseases / / 17554300 rs11157162 chr14 22194319 T C 6.30E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs8022088 chr14 22195531 G A 7.27E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs10132760 chr14 22196541 A C 5.00E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs1997532 chr14 22197477 T C 9.26E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs8011509 chr14 22201104 T C 8.51E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs8006524 chr14 22201150 C T 9.20E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs7150049 chr14 22201888 A G 7.77E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs8011979 chr14 22201900 C T 9.09E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs11157167 chr14 22202711 T C 5.58E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs3817625 chr14 22205447 T G 8.12E-10 Multiple complex diseases / / 17554300 rs718433 chr14 22235890 G A 8.00E-06 Intraocular pressure / / 24002674 rs718433 chr14 22235890 G A 2.48E-05 C-Reactive Protein / / pha003070 rs7143791 chr14 22238121 A C 9.00E-05 HIV-1 control / / 20041166 rs12897392 chr14 22246805 C T 1.67E-04 Response to alcohol consumption (flushing response) / / 24277619 rs11846985 chr14 22254605 C G 5.85E-04 Multiple complex diseases / / 17554300 rs34668860 chr14 22265500 G A 6.90E-05 Response to alcohol consumption (flushing response) / / 24277619 rs17182809 chr14 22268268 A T 1.10E-05 Urinary metabolites / / 21572414 rs4982522 chr14 22363706 G T 8.50E-05 Cognitive test performance / / 20125193 rs10133186 chr14 22381424 C T 3.58E-04 Multiple complex diseases / / 17554300 rs11846233 chr14 22385771 A C 2.43E-04 Multiple complex diseases / / 17554300 rs723879 chr14 22391433 C T 4.70E-05 Cognitive test performance / / 20125193 rs2242539 chr14 22410026 G T 2.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2031069 chr14 22420837 C T 0.0000274 Panic disorder / / 23149450 rs2031069 chr14 22420837 C T 2.74E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs2331471 chr14 22421388 G A 0.0000439 Panic disorder / / 23149450 rs2331471 chr14 22421388 G A 4.39E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs12586624 chr14 22422976 C T 0.000056 Panic disorder / / 23149450 rs12586624 chr14 22422976 C T 5.60E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs1040296 chr14 22427935 A T 0.0000324 Panic disorder / / 23149450 rs1040296 chr14 22427935 A T 3.24E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs2331473 chr14 22428443 T A 0.0000351 Panic disorder / / 23149450 rs2331473 chr14 22428443 T A 3.51E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs1040297 chr14 22428984 G T 0.0000358 Panic disorder / / 23149450 rs1040297 chr14 22428984 G T 3.58E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs4982533 chr14 22429647 T C 0.0000362 Panic disorder / / 23149450 rs4982533 chr14 22429647 T C 3.62E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs11157339 chr14 22430340 G A 0.0000404 Panic disorder / / 23149450 rs11157339 chr14 22430340 G A 4.04E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs12589803 chr14 22433466 G A 0.0000433 Panic disorder / / 23149450 rs12589803 chr14 22433466 G A 4.33E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs10872970 chr14 22434606 C T 0.0000469 Panic disorder / / 23149450 rs10872970 chr14 22434606 C T 4.69E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs12587312 chr14 22445355 A G 0.000048 Panic disorder / / 23149450 rs12587312 chr14 22445355 A G 4.80E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs956037 chr14 22458695 A G 1.93E-04 Type 2 diabetes / / 17463246 rs3811321 chr14 22481824 A C 8.00E-08 Renal transplant outcome / / 23432519 rs17113353 chr14 22487698 T A 4.78E-04 Multiple complex diseases / / 17554300 rs979027 chr14 22488509 A G 1.35E-08 Neuroblastoma / / 19536264 rs17113407 chr14 22488581 T C 1.35E-08 Neuroblastoma / / 19536264 rs7147975 chr14 22490722 A G 1.35E-08 Neuroblastoma / / 19536264 rs12888049 chr14 22494738 A G 3.58E-08 Neuroblastoma / / 19536264 rs12888049 chr14 22494738 A G 2.70E-06 Endometriosis / / 21151130 rs8022710 chr14 22496029 C A 7.86E-08 Neuroblastoma / / 19536264 rs4982546 chr14 22513116 A G 3.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs10130648 chr14 22514389 A C 2.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs2331480 chr14 22517197 A T 6.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs2331490 chr14 22522345 T C 4.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs8022660 chr14 22535262 G A 2.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2877390 chr14 22547289 A G 3.21E-04 Alzheimer's disease (late onset) / / 21379329 rs7144892 chr14 22562798 C A 2.86E-04 Type 2 diabetes / / 17463246 rs7144892 chr14 22562798 C A 1.80E-05 Urinary metabolites / / 21572414 rs990962 chr14 22567561 C T 5.09E-08 Neuroblastoma / / 19536264 rs8022578 chr14 22570185 A G 3.46E-08 Neuroblastoma / / 19536264 rs6572261 chr14 22571898 C T 2.30E-08 Neuroblastoma / / 19536264 rs6572267 chr14 22576148 A G 9.46E-04 Multiple complex diseases / / 17554300 rs9323104 chr14 22578781 T C 9.81E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1040301 chr14 22580570 C G 1.55E-05 Bipolar disorder and schizophrenia / / 20889312 rs2331494 chr14 22586392 C T 1.80E-05 Lymphocyte counts / / pha003094 rs2331494 chr14 22586392 C T 4.02E-05 Neutrophil count / / pha003095 rs11621810 chr14 22590662 A G 8.36E-04 Alzheimer's disease / / 22005930 rs8018887 chr14 22591821 T C 3.82E-05 Bipolar disorder and schizophrenia / / 20889312 rs1474476 chr14 22607502 T G 5.00E-06 Obesity-related traits / / 23251661 rs17255510 chr14 22662856 T C 2.10E-05 Urinary metabolites / / 21572414 rs2242544 chr14 22694777 A G 1.82E-04 Bipolar disorder / / 19259986 rs2075496 chr14 22694926 C T 4.82E-04 Bipolar disorder / / 19259986 rs10483269 chr14 22697674 C T 7.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs764160 chr14 22698981 C G 1.50E-05 Urinary metabolites / / 21572414 rs7153175 chr14 22704237 A C 7.18E-04 Multiple complex diseases / / 17554300 rs6572331 chr14 22714842 G A 5.99E-10 Neuroblastoma / / 19536264 rs4982590 chr14 22718399 G A 7.85E-10 Neuroblastoma / / 19536264 rs4982590 chr14 22718399 G A 9.42E-04 Tourette syndrome / / 22889924 rs10148895 chr14 22722724 C T 4.90E-11 Neuroblastoma / / 19536264 rs17115801 chr14 22723346 T C 1.47E-04 Multiple complex diseases / / 17554300 rs7155927 chr14 22730981 A G 3.83E-13 Neuroblastoma / / 19536264 rs7141113 chr14 22735897 G T 2.11E-13 Neuroblastoma / / 19536264 rs6572349 chr14 22736248 C T 2.11E-13 Neuroblastoma / / 19536264 rs6572351 chr14 22736298 C T 2.50E-05 Breast cancer / / 17529974 rs6572351 chr14 22736298 C T 2.11E-13 Neuroblastoma / / 19536264 rs12881142 chr14 22736520 C A 2.11E-13 Neuroblastoma / / 19536264 rs2331599 chr14 22736661 T C 2.05E-14 Neuroblastoma / / 19536264 rs2331599 chr14 22736661 T C 3.23E-05 Blood Pressure / / pha003039 rs9972232 chr14 22737591 A G 1.58E-14 Neuroblastoma / / 19536264 rs7154855 chr14 22738051 C T 2.93E-04 Alzheimer's disease / / 17998437 rs3811272 chr14 22741734 C T 6.10E-15 Neuroblastoma / / 19536264 rs12586504 chr14 22744363 T A 9.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs2075503 chr14 22749282 G C 3.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2331601 chr14 22774695 G A 7.74E-06 Biliary atresia / / 20460270 rs11845134 chr14 22782377 C T 6.00E-06 Obesity-related traits / / 23251661 rs1474477 chr14 22786215 C T 7.81E-05 Hypertension (essential hypertension) / / 22184326 rs10047878 chr14 22787690 T A 2.56E-06 Obesity (extreme) / / 21935397 rs8007205 chr14 22789472 G A 3.81E-05 Obesity (extreme) / / 21935397 rs916048 chr14 22790920 C A 3.89E-06 Bipolar disorder,affective / / 20528957 rs916049 chr14 22791071 G C 9.64E-06 Obesity (extreme) / / 21935397 rs2204990 chr14 22791563 G A 3.53E-06 Obesity (extreme) / / 21935397 rs11847479 chr14 22792215 T C 3.80E-05 Obesity (extreme) / / 21935397 rs17116418 chr14 22792640 C T 2.40E-04 Obesity (extreme) / / 21935397 rs10139769 chr14 22793465 A G 4.63E-05 Obesity (extreme) / / 21935397 rs1107390 chr14 22795270 T C 3.90E-04 Obesity (extreme) / / 21935397 rs12587680 chr14 22799508 A G 3.64E-04 Obesity (extreme) / / 21935397 rs2213246 chr14 22803363 T C 1.30E-04 Obesity (extreme) / / 21935397 rs2213247 chr14 22803384 A G 1.30E-04 Obesity (extreme) / / 21935397 rs17793886 chr14 22806220 G C 2.99E-04 Cognitive decline / / 23732972 rs17183505 chr14 22807068 G C 3.29E-04 Obesity (extreme) / / 21935397 rs4981423 chr14 22808754 A G 1.32E-04 Obesity (extreme) / / 21935397 rs8014927 chr14 22838630 G A 1.16E-04 Obesity (extreme) / / 21935397 rs2051536 chr14 22841797 T C 1.19E-04 Obesity (extreme) / / 21935397 rs2877454 chr14 22849761 A C 1.51E-04 Obesity (extreme) / / 21935397 rs11623006 chr14 22851141 T A 2.99E-04 Cognitive decline / / 23732972 rs17183519 chr14 22851242 C A 5.06E-04 Obesity (extreme) / / 21935397 rs741711 chr14 22853685 C T 2.99E-16 Neuroblastoma / / 19536264 rs741711 chr14 22853685 C T 8.08E-04 Obesity (extreme) / / 21935397 rs1076548 chr14 22854566 C T 9.21E-05 Obesity (extreme) / / 21935397 rs3811250 chr14 22855970 G A 6.13E-16 Neuroblastoma / / 19536264 rs3811250 chr14 22855970 G A 2.99E-04 Obesity (extreme) / / 21935397 rs12434373 chr14 22856949 C T 2.78E-04 Obesity (extreme) / / 21935397 rs4982624 chr14 22857524 T C 2.61E-04 Obesity (extreme) / / 21935397 rs3811247 chr14 22858360 T C 5.80E-15 Neuroblastoma / / 19536264 rs3811244 chr14 22859482 G T 9.99E-15 Neuroblastoma / / 19536264 rs3811244 chr14 22859482 G T 3.57E-04 Obesity (extreme) / / 21935397 rs4982626 chr14 22860059 T A 3.53E-04 Obesity (extreme) / / 21935397 rs12896137 chr14 22861612 T C 3.32E-04 Obesity (extreme) / / 21935397 rs12891257 chr14 22861635 C T 2.51E-15 Neuroblastoma / / 19536264 rs4981424 chr14 22861729 T C 3.28E-04 Obesity (extreme) / / 21935397 rs4982628 chr14 22861890 C T 3.28E-04 Obesity (extreme) / / 21935397 rs6572425 chr14 22862196 G T 3.40E-04 Obesity (extreme) / / 21935397 rs9919897 chr14 22862876 T C 2.63E-04 Obesity (extreme) / / 21935397 rs9919922 chr14 22863124 G A 3.29E-04 Obesity (extreme) / / 21935397 rs10142552 chr14 22863635 G A 3.82E-15 Neuroblastoma / / 19536264 rs8011618 chr14 22864313 G A 3.29E-04 Obesity (extreme) / / 21935397 rs3811240 chr14 22867875 T C 1.88E-15 Neuroblastoma / / 19536264 rs1040303 chr14 22871778 G A 1.38E-15 Neuroblastoma / / 19536264 rs10149541 chr14 22873309 T C 9.27E-04 Multiple complex diseases / / 17554300 rs10149541 chr14 22873309 T C 3.28E-04 Obesity (extreme) / / 21935397 rs7150307 chr14 22873455 G T 5.96E-16 Neuroblastoma / / 19536264 rs11624054 chr14 22874496 G A 3.90E-16 Neuroblastoma / / 19536264 rs714795 chr14 22876618 C T 1.06E-15 Neuroblastoma / / 19536264 rs2014778 chr14 22876816 G T 3.53E-04 Obesity (extreme) / / 21935397 rs4982635 chr14 22879738 G A 1.20E-14 Neuroblastoma / / 19536264 rs760019 chr14 22883178 G A 1.20E-14 Neuroblastoma / / 19536264 rs3811236 chr14 22886319 C A,G,T 1.03E-12 Neuroblastoma / / 19536264 rs3811236 chr14 22886319 C A,G,T 9.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs2301201 chr14 22887730 A G 5.01E-13 Neuroblastoma / / 19536264 rs2331618 chr14 22890411 A G 6.08E-04 Multiple complex diseases / / 17554300 rs8012481 chr14 22892461 G A 5.37E-04 Multiple complex diseases / / 17554300 rs11846244 chr14 22895875 G A 2.26E-04 Obesity (extreme) / / 21935397 rs17183603 chr14 22900147 G C 2.25E-04 Obesity (extreme) / / 21935397 rs6572449 chr14 22900920 T G 1.37E-04 Multiple complex diseases / / 17554300 rs6572449 chr14 22900920 T G 1.46E-11 Neuroblastoma / / 19536264 rs7142158 chr14 22902990 C T 1.81E-11 Neuroblastoma / / 19536264 rs2141988 chr14 22903462 A G 2.04E-11 Neuroblastoma / / 19536264 rs3811232 chr14 22903931 G T 2.04E-11 Neuroblastoma / / 19536264 rs8021297 chr14 22905065 T C 2.04E-11 Neuroblastoma / / 19536264 rs11623995 chr14 22905725 A G 4.78E-11 Neuroblastoma / / 19536264 rs11157596 chr14 22907068 G A 1.70E-10 Neuroblastoma / / 19536264 rs12147516 chr14 22915816 G T 2.32E-12 Neuroblastoma / / 19536264 rs12147516 chr14 22915816 G T 7.05E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs10483273 chr14 22917046 A G 3.95E-12 Neuroblastoma / / 19536264 rs11848747 chr14 22921280 G T 2.08E-12 Neuroblastoma / / 19536264 rs2242545 chr14 22924194 G A 3.36E-11 Neuroblastoma / / 19536264 rs1882704 chr14 22925352 G A 1.38E-10 Neuroblastoma / / 19536264 rs1882704 chr14 22925352 G A 9.25E-04 Rheumatoid arthritis / / 21452313 rs1882704 chr14 22925352 G A 9.09E-05 Left ventricular hypertrophy / / pha003052 rs17794083 chr14 22926919 C A 6.74E-11 Neuroblastoma / / 19536264 rs10162417 chr14 22929700 T G 7.94E-10 Neuroblastoma / / 19536264 rs10131293 chr14 22930158 G A 7.56E-10 Neuroblastoma / / 19536264 rs2733776 chr14 22930787 A G 2.77E-10 Neuroblastoma / / 19536264 rs10483275 chr14 22933056 C T 6.17E-09 Neuroblastoma / / 19536264 rs12589282 chr14 22937656 A C 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs11850502 chr14 22938561 A T 9.69E-04 Multiple complex diseases / / 17554300 rs8020193 chr14 22939467 A C 1.23E-13 Neuroblastoma / / 19536264 rs10483277 chr14 22940842 C T 9.49E-04 Type 2 diabetes / / 17846124 rs10483277 chr14 22940842 C T 1.61E-12 Neuroblastoma / / 19536264 rs2293732 chr14 22942149 A C 1.69E-04 Multiple complex diseases / / 17554300 rs2293732 chr14 22942149 A C 5.96E-05 AIDS progression / / 19115949 rs2293732 chr14 22942149 A C 3.19E-12 Neuroblastoma / / 19536264 rs1076861 chr14 22942619 G A 4.08E-13 Neuroblastoma / / 19536264 rs1076861 chr14 22942619 G A 9.94E-05 Body Mass Index / / pha003020 rs2254272 chr14 22942890 G T 6.90E-13 Neuroblastoma / / 19536264 rs7161733 chr14 22945192 C T 9.16E-14 Neuroblastoma / / 19536264 rs10132733 chr14 22946231 A G 8.37E-13 Neuroblastoma / / 19536264 rs227859 chr14 22948471 T C 8.93E-11 Neuroblastoma / / 19536264 rs762578 chr14 22950248 G T 2.54E-10 Neuroblastoma / / 19536264 rs3811222 chr14 22951014 G A 7.09E-10 Neuroblastoma / / 19536264 rs3811221 chr14 22952952 C T 1.66E-09 Neuroblastoma / / 19536264 rs227867 chr14 22953861 G A 1.50E-09 Neuroblastoma / / 19536264 rs996165 chr14 22954684 C T 3.77E-10 Neuroblastoma / / 19536264 rs3811215 chr14 22954777 G T 5.48E-10 Neuroblastoma / / 19536264 rs227869 chr14 22956710 G A 4.00E-06 Relative hand skill in reading disability / / 24068947 rs227870 chr14 22957171 G A 1.21E-05 Suicidal ideation / / 20877300 rs227870 chr14 22957171 G A 3.67E-05 Glucose levels / / pha003057 rs1483971 chr14 22957488 G T 4.87E-05 Relative hand skill in reading disability / / 24068947 rs2128997 chr14 22961102 A G 7.57E-08 Neuroblastoma / / 19536264 rs1483974 chr14 22978775 A C 1.58E-05 Heart Failure / / pha002884 rs227003 chr14 23000062 T C 0.0000381 Breast cancer early age of onset / / 18463975 rs227003 chr14 23000062 T C 2.60E-05 Tunica Media / / pha003034 rs1154155 chr14 23002684 T G 2.70E-04 Multiple complex diseases / / 17554300 rs1154155 chr14 23002684 T G 3.00E-22 Narcolepsy / / 19412176 rs1154155 chr14 23002684 T G 5.00E-07 Narcolepsy / / 20711174 rs1154155 chr14 23002684 T G 8.87E-30 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs1154155 chr14 23002684 T G 5.00E-49 Narcolepsy / / 24204295 rs1263638 chr14 23009999 T C 1.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1263646 chr14 23017530 T G 5.41E-04 Multiple complex diseases / / 17554300 rs1263647 chr14 23017565 A G 1.40E-04 Multiple complex diseases / / 17554300 rs15795 chr14 23020638 T C 5.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs15795 chr14 23020638 T C 6.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1242930 chr14 23078520 G A 7.84E-04 Amyotrophic lateral sclerosis (sporadic) ABHD4 intron 24529757 rs7145202 chr14 23092105 C T 6.02E-04 Type 2 diabetes / / 17463246 rs1753425 chr14 23100909 A G 2.50E-05 Urinary metabolites / / 21572414 rs1753429 chr14 23102784 A G 3.67E-05 Lymphocyte counts / / 22286170 rs10147839 chr14 23111193 C T 2.41E-04 Multiple complex diseases / / 17554300 rs1242940 chr14 23120629 A T 9.99E-04 Prostate cancer mortality / / 20978177 rs7140697 chr14 23160194 A G 5.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs943889 chr14 23169536 G T 8.84E-05 Body Mass Index / / pha003021 rs1242744 chr14 23200170 G A 4.00E-04 Type 2 diabetes / / 17463246 rs2877489 chr14 23231074 C T 6.75E-05 Type 2 diabetes / / 17463246 rs8786 chr14 23240328 T A 1.43E-04 Multiple complex diseases OXA1L cds-synon 17554300 rs4981439 chr14 23247323 A C 7.83E-04 Taste perception SLC7A7 intron 22132133 rs5027249 chr14 23270596 C T 8.10E-05 Cognitive performance SLC7A7 intron 19734545 rs4982676 chr14 23278003 G A 2.43E-04 Alzheimer's disease SLC7A7 intron 17998437 rs7157654 chr14 23282750 A C 3.39E-05 Cognitive performance SLC7A7 intron 19734545 rs2281678 chr14 23284168 G A 2.92E-07 Lymphocyte counts SLC7A7 intron 22286170 rs1135641 chr14 23299135 G T 6.64E-04 Schizophrenia MRPL52 missense 21747397 rs9646148 chr14 23300095 T G 5.18E-06 Body Mass Index MRPL52 intron pha003014 rs17122962 chr14 23302565 A G 0.0007241 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MRPL52 intron 23233654 rs17122962 chr14 23302565 A G 7.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) MRPL52 intron 23233662 rs3751488 chr14 23304094 G A 3.14E-06 Lymphocyte counts MRPL52 UTR-3 22286170 rs3751488 chr14 23304094 G A 9.50E-04 Alzheimer's disease MRPL52 UTR-3 24755620 rs762052 chr14 23308986 A G 1.77E-04 Response to taxane treatment (placlitaxel) MMP14 intron 23006423 rs17243048 chr14 23311480 G A 7.27E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) MMP14 intron 23648065 rs17884841 chr14 23312474 A G 5.72E-18 Cholesterol,total MMP14 missense 23063622 rs17884841 chr14 23312474 A G 5.93E-28 LDL cholesterol MMP14 missense 23063622 rs2236304 chr14 23312863 C G 1.13E-05 Malignant pleural mesothelioma MMP14 intron 23626673 rs12891954 chr14 23354699 A G 8.17E-05 Longevity REM2 intron 20304771 rs3751490 chr14 23355548 G A 3.00E-04 Alzheimer's disease (late onset) REM2 intron 21379329 rs7155742 chr14 23358604 G A 1.65E-05 Longevity / / 20304771 rs1543505 chr14 23362628 G A 1.26E-05 Longevity / / 20304771 rs4982702 chr14 23363332 G A 1.51E-05 Longevity / / 20304771 rs4982703 chr14 23363472 A G 1.52E-05 Longevity / / 20304771 rs8012963 chr14 23365274 T C 1.51E-05 Longevity / / 20304771 rs4982705 chr14 23366578 C T 1.28E-05 Longevity / / 20304771 rs1570342 chr14 23368185 C A 4.65E-04 Alzheimer's disease (late onset) / / 21379329 rs17124097 chr14 23371611 T C 3.17E-05 Panic disorder RBM23 intron 19165232 rs10130976 chr14 23404706 T A 4.40E-07 Sick sinus syndrome / / 21378987 rs2295686 chr14 23416651 G A 1.10E-04 Alzheimer's disease (late onset) HAUS4 intron 21379329 rs997154 chr14 23464482 G A 3.00E-08 Primary tooth development (number of teeth) C14orf93 intron 23704328 rs997154 chr14 23464482 G A 7.00E-06 Primary tooth development (time to first tooth eruption) C14orf93 intron 23704328 rs8015600 chr14 23489788 A G 9.25E-04 Alzheimer's disease / / 22005930 rs941717 chr14 23494987 T C 8.41E-04 Alzheimer's disease / / 22005930 rs8010057 chr14 23506110 C T 1.33E-04 Tourette syndrome / / 22889924 rs34457782 chr14 23511579 G A 0.00081 Breast cancer PSMB11 missense 23555315 rs4982729 chr14 23576611 T C 7.31E-04 Multiple complex diseases / / 17554300 rs4982729 chr14 23576611 T C 2.88E-10 Acute lymphoblastic leukemia (childhood) / / 23512250 rs12887958 chr14 23582569 C T 3.16E-08 Acute lymphoblastic leukemia (childhood) / / 23512250 rs10143875 chr14 23584265 T C 1.04E-08 Acute lymphoblastic leukemia (B-cell precursor) / / 23996088 rs4982731 chr14 23585333 C T 8.97E-12 Acute lymphoblastic leukemia (childhood) / / 23512250 rs4982731 chr14 23585333 C T 9.00E-12 Acute lymphoblastic leukemia (childhood) / / 23512250 rs4982731 chr14 23585333 C T 2.58E-08 Acute lymphoblastic leukemia (B-cell precursor) / / 23996088 rs8015478 chr14 23586018 A C 4.35E-10 Acute lymphoblastic leukemia (childhood) CEBPE nearGene-3 23512250 rs2144827 chr14 23587231 G A 1.33E-05 Tunica Media CEBPE intron pha003036 rs12434881 chr14 23588642 G A 1.21E-15 Acute lymphoblastic leukemia (B-cell precursor) CEBPE UTR-5 23996088 rs2239633 chr14 23589057 G A 3.00E-07 Acute lymphoblastic leukemia (childhood) CEBPE nearGene-5 19684604 rs2239633 chr14 23589057 G A 3.00E-07 Nasopharyngeal carcinoma CEBPE nearGene-5 20512145 rs2239633 chr14 23589057 G A 1.00E-16 Acute lymphoblastic leukemia (B-cell precursor) CEBPE nearGene-5 23996088 rs17794251 chr14 23593442 C T 2.70E-05 Acute lymphoblastic leukemia (childhood) / / 23512250 rs761874 chr14 23596320 A G 5.85E-12 Acute lymphoblastic leukemia (B-cell precursor) SLC7A8 UTR-3 23996088 rs7157021 chr14 23598952 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) SLC7A8 cds-synon 20708005 rs7157021 chr14 23598952 A G 1.76E-06 Acute lymphoblastic leukemia (childhood) SLC7A8 cds-synon 23512250 rs7157021 chr14 23598952 A G 1.88E-11 Acute lymphoblastic leukemia (B-cell precursor) SLC7A8 cds-synon 23996088 rs6572981 chr14 23599252 G A 1.88E-06 Tunica Media SLC7A8 intron pha003036 rs1569951 chr14 23607271 C T 7.98E-05 Caffeine consumption SLC7A8 intron 21490707 rs1998055 chr14 23623827 G C 9.70E-11 Progranulin levels SLC7A8 intron 21087763 rs1998055 chr14 23623827 G C 9.70E-11 Myocardial infarction SLC7A8 intron 21211798 rs4982740 chr14 23664646 T C 6.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2064754 chr14 23682635 T G 3.62E-04 Multiple complex diseases / / 17554300 rs178758 chr14 23699064 A G 9.75E-05 Amyotrophic lateral sclerosis / / 20801718 rs1055061 chr14 23744932 C T 2.20E-05 Sick sinus syndrome HOMEZ missense 21378987 rs3210043 chr14 23779877 C A 2.00E-05 Height BCL2L2 UTR-3 21194676 rs3210043 chr14 23779877 C A 5.40E-08 Height BCL2L2 UTR-3 21194676 rs10149339 chr14 23780222 A G 3.01E-05 stroke (ischemic) BCL2L2 UTR-3 17434096 rs17090828 chr14 23819813 C G 2.63E-11 Esophageal cancer SLC22A17 intron 21642993 rs10137082 chr14 23840033 C T 6.00E-06 Type 1 diabetes / / 21980299 rs723840 chr14 23848311 C T 5.50E-04 Smoking initiation CMTM5 cds-synon 24665060 rs365990 chr14 23861811 A G 9.00E-11 Electrocardiographic traits MYH6 missense 20062063 rs365990 chr14 23861811 A G 1.00E-08 Sick sinus syndrome MYH6 missense 21378987 rs365990 chr14 23861811 A G 3.80E-05 Sick sinus syndrome MYH6 missense 21378987 rs365990 chr14 23861811 A G 6.90E-04 Sick sinus syndrome MYH6 missense 21378987 rs365990 chr14 23861811 A G 5.00E-45 Heart rate MYH6 missense 23583979 rs365990 chr14 23861811 A G 0.00026 Coronary artery calcification MYH6 missense 23727086 rs452036 chr14 23865885 G A 4.00E-14 Resting heart rate MYH6 intron 20639392 rs452036 chr14 23865885 G A 8.00E-07 Resting heart rate MYH6 intron 23183192 rs2295705 chr14 23939432 G A 3.50E-08 Metabolite levels NGDN intron 23281178 rs223110 chr14 23973043 G A 8.33E-04 Multiple complex diseases / / 17554300 rs223116 chr14 23977010 A G 3.00E-08 Resting heart rate / / 20639392 rs223116 chr14 23977010 A G 1.49E-05 Heart Rate / / pha003053 rs222671 chr14 23985973 A G 8.00E-05 Psoriasis THTPA intron 20953190 rs17794441 chr14 23986009 G T 4.77E-05 Psoriasis THTPA intron 20953190 rs222674 chr14 23987990 A G 1.74E-04 Amyotrophic Lateral Sclerosis THTPA intron 17362836 rs12894083 chr14 23988786 G A 3.58E-06 Psoriasis THTPA intron 20953190 rs12323646 chr14 23989097 G A 3.72E-04 Multiple complex diseases THTPA intron 17554300 rs4982766 chr14 23994517 A G 6.56E-05 Body Composition ZFHX2 missense pha003012 rs4982766 chr14 23994517 A G 3.15E-05 Body Mass Index ZFHX2 missense pha003021 rs3742489 chr14 24002887 G T 9.39E-05 Bipolar disorder and schizophrenia ZFHX2 missense 20889312 rs3783437 chr14 24008406 A G 3.45E-05 Bipolar disorder and schizophrenia THTPA intron 20889312 rs3783439 chr14 24014211 T C 9.67E-05 Non-alcoholic fatty liver disease histology (other) THTPA intron 20708005 rs12886523 chr14 24022182 C T 1.01E-04 Response to taxane treatment (placlitaxel) THTPA intron 23006423 rs35309020 chr14 24024026 G A 1.19E-04 Response to taxane treatment (placlitaxel) THTPA intron 23006423 rs28403575 chr14 24025340 C T 2.69E-04 Response to taxane treatment (placlitaxel) THTPA UTR-5 23006423 rs34015250 chr14 24026493 A G 6.53E-05 Response to taxane treatment (placlitaxel) THTPA missense 23006423 rs12897422 chr14 24033027 G A 1.00E-04 Information processing speed AP1G2 missense 21130836 rs2281680 chr14 24033070 C T 6.00E-08 Sudden cardiac arrest AP1G2 intron 21658281 rs10149510 chr14 24039559 C T 1.49E-05 Obsessive-compulsive disorder JPH4 intron 24821223 rs11844366 chr14 24041624 T C 1.00E-04 Asperger disorder JPH4 intron 21182207 rs222723 chr14 24098631 C T 4.57E-07 Common variable immunodeficiency / / 21497890 rs222605 chr14 24114754 A G 3.27E-04 Alzheimer's disease (late onset) DHRS2 UTR-3 21379329 rs17184233 chr14 24116109 A G 1.32E-04 Lymphocyte counts / / 22286170 rs222616 chr14 24120270 G A 1.96E-05 Vitiligo / / 22561518 rs17095687 chr14 24127064 G A 7.02E-04 Body mass index / / 21701565 rs12590792 chr14 24128135 G T 1.03E-04 Colorectal cancer / / 24448986 rs221704 chr14 24133911 G T 1.30E-05 Vitiligo / / 22561518 rs221703 chr14 24134545 T A 4.49E-05 Multiple complex diseases / / 17554300 rs221701 chr14 24135835 T G 2.87E-04 Multiple complex diseases / / 17554300 rs221698 chr14 24138106 G A 3.91E-04 Multiple complex diseases / / 17554300 rs1885593 chr14 24138152 A G 3.19E-05 Cognitive performance / / 19734545 rs1866226 chr14 24140007 G A 2.84E-05 Cognitive performance / / 19734545 rs17794525 chr14 24141455 C T 8.63E-05 Cognitive performance / / 19734545 rs2067644 chr14 24142675 T G 7.47E-04 Multiple complex diseases / / 17554300 rs221695 chr14 24142841 C G 7.40E-05 Parkinson's disease (familial) / / 18985386 rs4539523 chr14 24151625 C G 4.32E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs12883888 chr14 24161094 C T 5.36E-05 Cognitive performance / / 19734545 rs7142207 chr14 24164243 G T 9.86E-05 Calcium levels / / pha003085 rs2118499 chr14 24165672 C T 1.95E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs8009639 chr14 24196258 C T 4.21E-04 Alzheimer's disease / / 22005930 rs12894928 chr14 24197135 T G 5.07E-04 Multiple complex diseases / / 17554300 rs4340250 chr14 24215497 C T 8.84E-05 Type 2 diabetes / / 23300278 rs4982795 chr14 24225035 T C 1.90E-07 Lipid traits / / 17903299 rs17097288 chr14 24247400 T C 1.37E-05 Multiple complex diseases / / 17554300 rs1958305 chr14 24273124 G A 3.57E-05 Alzheimer's disease / / 17998437 rs12050360 chr14 24302673 C T 9.92E-05 Cognitive test performance / / 20125193 rs1958299 chr14 24306364 T A 3.32E-04 Multiple complex diseases / / 17554300 rs1958299 chr14 24306364 T A 8.47E-05 Alzheimer's disease / / 17998437 rs1958299 chr14 24306364 T A 8.22E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2031862 chr14 24323267 C T 1.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12436436 chr14 24381515 T C 5.00E-06 Bipolar disorder / / 18711365 rs10139204 chr14 24382905 G A 8.00E-05 Heart Rate / / pha003054 rs11628804 chr14 24394605 T C 2.01E-04 Multiple complex diseases C14orf165 intron 17554300 rs4981490 chr14 24401292 A C 8.11E-04 Multiple complex diseases C14orf165 intron 17554300 rs8005834 chr14 24505722 C G 3.99E-04 Fibrinogen DHRS4L1 missense 17255346 rs1951637 chr14 24529637 T G 5.06E-06 Serum metabolites LRRC16B intron 19043545 rs2277481 chr14 24587545 A G 2.07E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) DCAF11 intron 24023788 rs10134506 chr14 24589818 G C 1.94E-05 Response to cytadine analogues (cytosine arabinoside) DCAF11 intron 24483146 rs8010715 chr14 24609147 T C 9.00E-06 IgG glycosylation FAM158A intron 23382691 rs743272 chr14 24618859 A G 1.26E-04 Schizophrenia RNF31 intron 19197363 rs743272 chr14 24618859 A G 9.00E-04 Acute lymphoblastic leukemia (childhood) RNF31 intron 20189245 rs10583 chr14 24662177 C T 6.22E-04 Response to statin treatment (atorvastatin),change in cholesterol levels TM9SF1 missense 20031582 rs17184526 chr14 24667051 C T 1.86E-04 Smoking initiation / / 24665060 rs10141326 chr14 24709351 C T 9.23E-04 Multiple complex diseases TINF2 cds-synon 17554300 rs2229463 chr14 24718515 G A 2.32E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2273301 chr14 24732474 G A 4.34E-05 Weight TGM1 nearGene-5 pha003027 rs11627187 chr14 24751734 C A 6.77E-04 Iron levels / / pha002876 rs4568 chr14 24760009 G A 2.03E-05 Lipid levels DHRS1 UTR-3 19913121 rs4568 chr14 24760009 G A 2.41E-05 Lipid levels DHRS1 UTR-3 19913121 rs4568 chr14 24760009 G A 4.00E-04 Alcohol dependence DHRS1 UTR-3 20201924 rs2295310 chr14 24760255 C T 4.90E-04 Alcohol dependence DHRS1 intron 20201924 rs2295307 chr14 24765622 G A 4.87E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) DHRS1 intron 24023788 rs11158632 chr14 24769663 T G 1.93E-08 Multiple complex diseases C14orf21 cds-synon 17554300 rs11158632 chr14 24769663 T G 4.62E-08 Parent of origin effect on language impairment (paternal) C14orf21 cds-synon 24571439 rs12895335 chr14 24770369 A G 2.52E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) C14orf21 intron 24023788 rs4280164 chr14 24771285 G A 4.00E-08 Parent of origin effect on language impairment (paternal) C14orf21 missense 24571439 rs2144494 chr14 24773387 T C 4.94E-08 Parent of origin effect on language impairment (paternal) C14orf21 cds-synon 24571439 rs2281472 chr14 24775846 C T 1.12E-07 Parent of origin effect on language impairment (paternal) CIDEB intron 24571439 rs1046587 chr14 24786060 G A 0.000564363 Primary sclerosing cholangitis LTB4R UTR-3 23603763 rs3181384 chr14 24786976 T C 1.40E-07 Multiple complex diseases LTB4R UTR-3 17554300 rs3181384 chr14 24786976 T C 1.58E-06 Parent of origin effect on language impairment (paternal) LTB4R UTR-3 24571439 rs4981504 chr14 24791136 A G 1.45E-07 Multiple complex diseases ADCY4 intron 17554300 rs4981504 chr14 24791136 A G 6.90E-04 Type 2 diabetes and 6 quantitative traits ADCY4 intron 17848626 rs74387312 chr14 24792132 A G 0.0000029 Breast cancer (ER positive) ADCY4 missense 23555315 rs74387312 chr14 24792132 A G 0.000099 Breast cancer ADCY4 missense 23555315 rs17184682 chr14 24793762 T G 5.27E-05 Lipid levels ADCY4 intron 19913121 rs724165 chr14 24806229 G A 4.50E-04 Volumetric brain MRI RIPK3 intron 17903297 rs1950501 chr14 24806800 G A,C 7.73E-04 Multiple complex diseases RIPK3 intron 17554300 rs3212240 chr14 24810898 C T 3.41E-04 Hemoglobin concentration / / 20534544 rs8010276 chr14 24812694 C A 9.71E-04 Lymphocyte counts / / 22286170 rs2144490 chr14 24818907 C G 4.78E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1950500 chr14 24830850 T C 2.00E-18 Height / / 20881960 rs1950500 chr14 24830850 T C 1.00E-11 Height / / 23563607 rs12590407 chr14 24835115 G A 9.09E-07 Multiple complex diseases / / 17554300 rs12590407 chr14 24835115 G A 1.20E-07 Height / / 21194676 rs12590407 chr14 24835115 G A 1.50E-14 Height / / 21194676 rs12590407 chr14 24835115 G A 2.40E-08 Height / / 21194676 rs2295298 chr14 24843620 T C 2.87E-04 Hemoglobin concentration NFATC4 cds-synon 20534544 rs11628929 chr14 24844054 A G 2.87E-04 Hemoglobin concentration NFATC4 intron 20534544 rs3742517 chr14 24847951 C T 2.87E-04 Hemoglobin concentration NFATC4 UTR-3 20534544 rs8008583 chr14 24849127 C T 5.92E-04 Multiple complex diseases / / 17554300 rs8003430 chr14 24869834 A G 3.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NYNRIN intron 20877124 rs74036628 chr14 24877699 A G 0.00059 Prostate cancer (non-advanced prostate cancer) NYNRIN missense 23555315 rs12897153 chr14 24878485 G A 0.0000784 post-traumatic stress disorder NYNRIN cds-synon 22869035 rs12897153 chr14 24878485 G A 7.84E-05 Schizophrenia NYNRIN cds-synon 22883433 rs8017377 chr14 24883887 G A 4.00E-11 LDL cholesterol NYNRIN missense 20686565 rs8017377 chr14 24883887 G A 3.00E-15 LDL cholesterol NYNRIN missense 24097068 rs4982912 chr14 24903284 A G 2.73E-08 Lymphocyte counts KHNYN intron 22286170 rs12891613 chr14 24903964 T C 0.000000677 VLDL cholesterol particle diameter KHNYN intron 23263444 rs12890665 chr14 24931234 A G 1.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12892792 chr14 24934910 A G 8.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2076946 chr14 24951823 C T 3.52E-06 Smooth-surface caries / / 24556642 rs2877649 chr14 24954002 T C 1.83E-06 Smooth-surface caries / / 24556642 rs2877649 chr14 24954002 T C 2.00E-06 Smooth-surface caries / / 24556642 rs6573835 chr14 24954202 A G 7.43E-04 Aortic root size / / 21223598 rs1956922 chr14 24978174 T C 6.21E-04 Aortic root size / / 21223598 rs1956918 chr14 24980311 G A 5.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs987629 chr14 25005585 T C 8.48E-04 Celiac disease / / 23936387 rs17257083 chr14 25074711 T C 4.23E-04 HIV-1 viral setpoint / / 17641165 rs8192917 chr14 25102160 C T 3.00E-08 Vitiligo GZMB missense 20410501 rs8192917 chr14 25102160 C T 5.54E-06 Vitiligo GZMB missense 21326295 rs8192917 chr14 25102160 C T 5.60E-09 Vitiligo GZMB missense 22561518 rs206223 chr14 25193476 A G 4.94E-04 Type 2 diabetes / / 17463246 rs854406 chr14 25204351 A G 4.53E-04 Type 2 diabetes / / 17463246 rs854406 chr14 25204351 A G 7.40E-05 Tuberculosis / / 24057671 rs1381324 chr14 25209198 C T 2.36E-04 Age-related macular degeneration / / 22125219 rs712488 chr14 25209454 G A 5.00E-07 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs854345 chr14 25244806 A G 3.86E-05 Fibrinogen / / pha003068 rs854350 chr14 25247563 C G 8.11E-05 Multiple complex diseases / / 17554300 rs854360 chr14 25260507 G T 1.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs854379 chr14 25270158 G A 3.92E-04 Multiple complex diseases / / 17554300 rs854380 chr14 25270335 G A 2.99E-04 Multiple complex diseases / / 17554300 rs854384 chr14 25271520 T C 1.00E-06 MRI atrophy measures / / 21116278 rs854384 chr14 25271520 T C 1.80E-04 Endometriosis / / 21151130 rs9323560 chr14 25272926 G A 3.54E-04 Alcohol dependence / / 21314694 rs17257354 chr14 25273119 T C 1.36E-04 Multiple complex diseases / / 17554300 rs17257354 chr14 25273119 T C 5.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs7161311 chr14 25275554 T G 2.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2297060 chr14 25281219 T C 0.00023 Schizophrenia / / 22440650 rs725230 chr14 25282967 C T 5.53E-04 Heart Failure STXBP6 intron pha002885 rs898766 chr14 25284005 T C 4.60E-04 Multiple complex diseases STXBP6 intron 17554300 rs3759644 chr14 25290697 T C 2.94E-05 Psoriasis STXBP6 intron 20953190 rs1461645 chr14 25294889 G C 7.06E-04 Alzheimer's disease STXBP6 intron 17998437 rs1381318 chr14 25322599 C T 1.21E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) STXBP6 intron 24023788 rs854342 chr14 25339449 C T 4.80E-04 Response to taxane treatment (placlitaxel) STXBP6 intron 23006423 rs12884685 chr14 25365793 C G 8.91E-04 Multiple complex diseases STXBP6 intron 17554300 rs12885474 chr14 25381377 G A 6.90E-06 Brain infarcts,covert MRI-defined STXBP6 intron 20044523 rs4983039 chr14 25425222 A G 2.62E-04 Response to alcohol consumption (flushing response) STXBP6 intron 24277619 rs2004925 chr14 25445362 G A 1.50E-05 Urinary metabolites STXBP6 intron 21572414 rs912304 chr14 25476170 G T 9.69E-04 Bipolar disorder STXBP6 intron 19259986 rs11850957 chr14 25479542 C T 6.00E-06 Subcutaneous adipose tissue STXBP6 intron 22589738 rs11626966 chr14 25484284 T C 2.29E-05 Waist-Hip Ratio STXBP6 intron pha003013 rs11626966 chr14 25484284 T C 5.62E-05 Waist-Hip Ratio STXBP6 intron pha003028 rs8004569 chr14 25487816 C T 3.65E-05 Waist-Hip Ratio STXBP6 intron pha003013 rs8004569 chr14 25487816 C T 7.56E-05 Waist-Hip Ratio STXBP6 intron pha003028 rs10147992 chr14 25503799 A G 1.00E-08 White blood cell types STXBP6 intron 21738478 rs17109515 chr14 25505604 G A 7.89E-04 Suicide attempts in bipolar disorder STXBP6 intron 21423239 rs17109537 chr14 25514408 G A 6.23E-04 Suicide attempts in bipolar disorder STXBP6 intron 21423239 rs8020392 chr14 25522037 G A 0.0003609 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8020392 chr14 25522037 G A 3.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs726519 chr14 25522269 T G 0.0003606 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs726519 chr14 25522269 T G 3.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7142942 chr14 25526578 A G 0.0003521 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7142942 chr14 25526578 A G 3.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4617771 chr14 25529773 G A 1.32E-05 Brain structure / / 22504417 rs1958384 chr14 25530133 T G 0.0003599 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1958384 chr14 25530133 T G 3.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1958386 chr14 25530581 T A 0.0003424 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1958386 chr14 25530581 T A 3.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17795982 chr14 25532683 T C 1.70E-06 Type 2 diabetes / / 21647700 rs17109575 chr14 25553806 T C 7.95E-05 Waist-Hip Ratio / / pha003013 rs1952500 chr14 25555356 C A 0.000000412 Negative cognition (anxiety related behavioral questionnaire) in children / / 23565138 rs8020810 chr14 25573353 C G 1.63E-04 Arthritis (juvenile idiopathic) / / 22354554 rs4444253 chr14 25576986 C T 4.37E-05 Brain structure / / 22504417 rs1111763 chr14 25591537 C T 3.25E-04 Multiple complex diseases / / 17554300 rs1241486 chr14 25598159 G A 9.51E-05 Type 2 diabetes and other traits / / 19734900 rs9323605 chr14 25616536 G A 8.10E-04 Crohn's disease / / 17684544 rs1241513 chr14 25622059 G A 3.03E-04 Alzheimer's disease (late onset) / / 21379329 rs1241515 chr14 25623218 A G 5.12E-05 Hemoglobin / / pha003096 rs1241515 chr14 25623218 A G 1.93E-05 Hematocrit / / pha003097 rs1461549 chr14 25712300 G A 1.50E-05 Biomarkers / / 17903293 rs12586449 chr14 25717776 T G 6.37E-04 Insulin resistance / / 21901158 rs8003380 chr14 25722463 T A 8.01E-05 Insulin resistance / / 21901158 rs1956948 chr14 25776613 T C 4.87E-04 Multiple complex diseases / / 17554300 rs1241133 chr14 25780835 A G 8.98E-04 Multiple complex diseases / / 17554300 rs17109820 chr14 25869811 A G 1.28E-05 Blood Pressure / / pha003048 rs4983089 chr14 25882546 G A 0.000149 Breast cancer early age of onset / / 18463975 rs10483300 chr14 25919419 G A 3.00E-07 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs11627916 chr14 25956292 G A 6.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7140875 chr14 25993895 C G 4.07E-05 Aortic root size / / 21223598 rs1028493 chr14 26015217 A G 3.59E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1033602 chr14 26018424 G T 7.11E-04 Tourette syndrome / / 22889924 rs17110072 chr14 26020046 A G 2.50E-05 Urinary metabolites / / 21572414 rs11159403 chr14 26043929 T C 9.57E-04 Tourette syndrome / / 22889924 rs11159411 chr14 26069812 C T 1.50E-04 IgE levels in asthmatics / / 23967269 rs8020556 chr14 26071010 A G 2.41E-04 Multiple complex diseases / / 17554300 rs1951054 chr14 26077408 T C 0.0000186 Uterine leiomyomata / / 23040493 rs1951055 chr14 26077651 C A 6.18E-04 Type 2 diabetes / / 17463246 rs1951055 chr14 26077651 C A 2.09E-04 Body mass index / / 21701565 rs1951055 chr14 26077651 C A 4.06E-04 Body mass index / / 21701565 rs7350731 chr14 26110107 A G 3.80E-04 Suicidal ideation / / 22030708 rs7159800 chr14 26117875 T G 6.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10483303 chr14 26127838 A G 4.20E-05 Memory performance / / 22105620 rs1956798 chr14 26128089 A G 1.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1956798 chr14 26128089 A G 4.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12586774 chr14 26129566 G T 4.00E-07 Obesity-related traits / / 23251661 rs12434794 chr14 26130439 C T 6.94E-06 Obesity-related traits / / 23251661 rs8013661 chr14 26134815 T G 6.78E-04 Multiple complex diseases / / 17554300 rs969977 chr14 26216020 T C 7.55E-05 Post-operative nausea and vomiting / / 21694509 rs17470492 chr14 26220798 T C 4.87E-04 Coronary heart disease / / 21971053 rs4983133 chr14 26224597 A C 8.02E-04 Coronary heart disease / / 21971053 rs17110354 chr14 26227151 T C,G 2.31E-05 Post-operative nausea and vomiting / / 21694509 rs7144797 chr14 26259989 T C 5.42E-05 Attention deficit hyperactivity disorder / / 23728934 rs7144821 chr14 26260051 T A 5.63E-05 Attention deficit hyperactivity disorder / / 23728934 rs7143142 chr14 26264404 C T 2.03E-04 Coronary heart disease / / 21971053 rs2185518 chr14 26266439 A G 6.86E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1959778 chr14 26291049 T C 5.49E-05 Major depressive disorder / / 22472876 rs17110420 chr14 26312769 T G 2.49E-04 Multiple complex diseases / / 17554300 rs7161376 chr14 26389507 T C 1.38E-05 Cognitive test performance / / 20125193 rs10151818 chr14 26399110 G A 7.63E-04 Type 2 diabetes / / 17463246 rs10152034 chr14 26399366 G T 6.90E-04 Type 2 diabetes / / 17463246 rs1956607 chr14 26400554 G C 0.0004884 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1956607 chr14 26400554 G C 4.88E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1956608 chr14 26401540 T C 2.40E-05 Urinary metabolites / / 21572414 rs1950948 chr14 26412416 G A 2.30E-05 Urinary metabolites / / 21572414 rs1885036 chr14 26415165 C T 1.60E-05 Urinary metabolites / / 21572414 rs7140514 chr14 26461007 G A 4.30E-04 Type 2 diabetes / / 17463246 rs1956621 chr14 26462065 A G 3.62E-04 Multiple complex diseases / / 17554300 rs1956623 chr14 26462377 T C 6.18E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2753592 chr14 26462742 A T 7.11E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2753593 chr14 26465490 T C 7.11E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4489930 chr14 26466066 G A 2.33E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs8005034 chr14 26470460 G T 2.25E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs862946 chr14 26488467 T C 7.37E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs862946 chr14 26488467 T C 2.00E-07 Liver enzyme levels (aspartate transaminase) / / 24124411 rs1015165 chr14 26505853 C T 4.76E-04 Depression (quantitative trait) / / 20800221 rs718203 chr14 26512456 G A 1.00E-04 Prostate cancer / / 21743057 rs17475628 chr14 26575576 G A 2.34E-04 Insulin resistance / / 21901158 rs17476287 chr14 26590340 G A 8.30E-04 Multiple complex diseases / / 17554300 rs17110779 chr14 26599618 A C 1.82E-04 Multiple complex diseases / / 17554300 rs17110779 chr14 26599618 A C 2.50E-05 Major depressive disorder / / 21042317 rs4140867 chr14 26599785 G A 7.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs8016478 chr14 26600033 A T 7.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs17110783 chr14 26600297 A G 1.80E-05 Major depressive disorder / / 21042317 rs12887511 chr14 26602961 C T 7.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs17110793 chr14 26610421 C T 1.40E-05 Major depressive disorder / / 21042317 rs2179938 chr14 26627357 T C 8.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs962215 chr14 26637838 C T 6.91E-05 Lung adenocarcinoma / / 19836008 rs981218 chr14 26641807 T C 9.05E-05 Multiple complex diseases / / 17554300 rs11846075 chr14 26642477 G A 4.93E-05 Attention deficit hyperactivity disorder / / 22420046 rs1569794 chr14 26644332 T G 1.60E-05 Lung adenocarcinoma / / 19836008 rs4349058 chr14 26654291 C T 5.23E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs1950861 chr14 26690571 G A 2.29E-05 Heart Rate / / pha003051 rs17110924 chr14 26694503 C A 5.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs17491640 chr14 26702835 G A 7.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs12589337 chr14 26702910 G C 3.88E-04 Type 2 diabetes / / 17463246 rs2064835 chr14 26704160 A G 6.47E-05 Type 2 diabetes / / 17463246 rs2064835 chr14 26704160 A G 8.84E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12895893 chr14 26708629 A G 8.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs12896500 chr14 26710218 A C 8.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs17491857 chr14 26712840 C T 8.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs8015561 chr14 26716178 A G 5.78E-04 Acute lung injury / / 22295056 rs7145790 chr14 26754036 G T 6.72E-05 Intelligence / / 21826061 rs17571634 chr14 26776482 C T 2.32E-04 Smoking initiation / / 24665060 rs17111020 chr14 26776879 C T 1.42E-04 Multiple complex diseases / / 17554300 rs10142247 chr14 26784913 G A 1.12E-04 HIV-1 viral setpoint / / 21490045 rs2332694 chr14 26792218 C T 4.55E-04 Smoking initiation / / 24665060 rs1154750 chr14 26801713 A G 6.60E-04 Smoking initiation / / 24665060 rs10483318 chr14 26804141 A C 2.24E-04 Smoking initiation / / 24665060 rs1950874 chr14 26811721 C T 5.74E-06 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines / / 21483694 rs875461 chr14 26813028 C T 8.34E-05 Smoking initiation / / 24665060 rs1956500 chr14 26834569 A G 1.71E-04 Multiple complex diseases / / 17554300 rs12050270 chr14 26839426 C T 8.40E-05 HIV-1 viral setpoint / / 22174851 rs4983169 chr14 26851690 A G 8.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs1956494 chr14 26851982 G A 2.73E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs1956494 chr14 26851982 G A 9.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs10135384 chr14 26855272 C G 9.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs17111187 chr14 26863948 C T 4.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs1474966 chr14 26870128 G A 4.60E-05 Response to antidepressants / / 19736353 rs1474965 chr14 26877020 A G 1.10E-04 Response to antidepressants / / 19736353 rs1951387 chr14 26884848 C A 3.90E-04 Response to antidepressants / / 19736353 rs9989215 chr14 26891369 C T 5.93E-04 Smoking initiation / / 24665060 rs1245214 chr14 26935221 G A 5.83E-04 Schizophrenia NOVA1 intron 19197363 rs1245214 chr14 26935221 G A 2.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOVA1 intron 20877124 rs178205 chr14 26958004 T C 5.83E-04 Schizophrenia NOVA1 intron 19197363 rs178205 chr14 26958004 T C 1.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOVA1 intron 20877124 rs8014053 chr14 26958210 T G 1.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOVA1 intron 20877124 rs178193 chr14 26972984 T C 3.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOVA1 intron 20877124 rs178189 chr14 26974414 A C 2.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOVA1 intron 20877124 rs3794485 chr14 27059346 T C 2.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOVA1 intron 20877124 rs1950403 chr14 27082987 C G 6.49E-04 Type 2 diabetes / / 17846124 rs2144335 chr14 27132124 T C 1.30E-05 Urinary metabolites / / 21572414 rs1950420 chr14 27141020 C A 2.20E-05 Urinary metabolites / / 21572414 rs962075 chr14 27149295 T G 2.91E-04 Major depressive disorder / / 22472876 rs1950419 chr14 27154060 T C 1.52E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs1955838 chr14 27164087 T C 1.52E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs1956834 chr14 27208456 T C 9.37E-04 Depression (quantitative trait) / / 20800221 rs12435132 chr14 27212947 A G 8.82E-04 Depression (quantitative trait) / / 20800221 rs12172809 chr14 27244342 G A 1.62E-04 Body mass index / / 21701565 rs12172809 chr14 27244342 G A 3.79E-04 Body mass index / / 21701565 rs990173 chr14 27251495 C T 3.38E-04 Alzheimer's disease (late onset) / / 21379329 rs990173 chr14 27251495 C T 8.53E-04 Alzheimer's disease / / 24755620 rs1951082 chr14 27260043 T A 5.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs1951083 chr14 27262305 C T 5.64E-05 Alzheimer's disease (late onset) / / 21379329 rs12882548 chr14 27266981 T C 1.37E-04 Body mass index / / 21701565 rs12882548 chr14 27266981 T C 7.66E-05 Body mass index / / 21701565 rs1956830 chr14 27270848 T C 2.00E-04 Birth weight / / 17255346 rs2180820 chr14 27271382 C T 5.65E-04 Body mass index / / 21701565 rs12432469 chr14 27277152 A G 9.23E-07 Scoliosis / / 21216876 rs12432472 chr14 27277165 A C 9.23E-07 Scoliosis / / 21216876 rs1956817 chr14 27307814 T C 6.56E-05 Bipolar Disorder / / pha002858 rs12887210 chr14 27376899 T C 6.35E-04 Multiple complex diseases / / 17554300 rs1956073 chr14 27393439 T C 8.37E-04 Alzheimer's disease / / 17998437 rs11160092 chr14 27406001 T C 1.41E-04 Alzheimer's disease / / 17998437 rs17111920 chr14 27406892 G T 3.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs1956034 chr14 27451063 A G 2.03E-04 Alzheimer's disease / / 17998437 rs1998462 chr14 27508742 A C 1.96E-05 Neutrophil count / / pha003095 rs9323896 chr14 27510849 C T 5.45E-05 Lymphocyte counts / / pha003094 rs9323896 chr14 27510849 C T 4.21E-05 Neutrophil count / / pha003095 rs9323897 chr14 27510897 G A 6.67E-05 Lymphocyte counts / / pha003094 rs9323897 chr14 27510897 G A 6.05E-05 Neutrophil count / / pha003095 rs11850868 chr14 27520111 T G 9.40E-04 Parkinson's disease / / 17052657 rs11850868 chr14 27520111 T G 5.58E-05 Lymphocyte counts / / pha003094 rs11850868 chr14 27520111 T G 8.48E-06 Neutrophil count / / pha003095 rs1951755 chr14 27528240 T G 2.12E-04 Parkinson's disease / / 17052657 rs1951755 chr14 27528240 T G 6.96E-05 Neutrophil count / / pha003095 rs1951756 chr14 27535434 C T 4.93E-04 Multiple complex diseases / / 17554300 rs1951756 chr14 27535434 C T 9.92E-05 Heart Rate / / pha003054 rs1951758 chr14 27536252 A G 1.10E-05 Urinary metabolites / / 21572414 rs1951758 chr14 27536252 A G 7.07E-05 Heart Rate / / pha003054 rs8017862 chr14 27537116 C T 3.68E-04 Smoking initiation / / 24665060 rs12879232 chr14 27540584 G T 9.04E-04 Type 2 diabetes / / 17463246 rs10873451 chr14 27545903 T A 6.58E-04 Multiple complex diseases / / 17554300 rs6575421 chr14 27554812 C A 5.31E-04 Type 2 diabetes / / 17463246 rs2181461 chr14 27558795 C T 2.10E-04 Alzheimer's disease / / 24755620 rs9323908 chr14 27564140 C T 5.44E-05 Alzheimer's disease / / 24755620 rs749901 chr14 27571666 T C 9.78E-05 Alzheimer's disease / / 24755620 rs1245390 chr14 27596930 A G 4.43E-04 Alzheimer's disease / / 24755620 rs1909784 chr14 27612780 A G 8.11E-04 Alzheimer's disease / / 24755620 rs1245383 chr14 27613679 T C 7.55E-04 Type 2 diabetes / / 17463246 rs1245415 chr14 27627742 A G 7.96E-04 Type 2 diabetes / / 17463246 rs17434055 chr14 27629024 C T 6.03E-04 Alzheimer's disease / / 17998437 rs1245401 chr14 27643447 G T 6.63E-04 Type 2 diabetes / / 17463246 rs1500436 chr14 27654745 G A 3.68E-04 Type 2 diabetes / / 17463246 rs17528635 chr14 27659656 T C 5.92E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs8016760 chr14 27660064 A G 7.24E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7145050 chr14 27669536 C T 1.70E-05 Urinary metabolites / / 21572414 rs169381 chr14 27699322 T C 4.80E-06 Urinary metabolites / / 21572414 rs17112407 chr14 27723800 T C 0.000793 Salmonella-induced pyroptosis / / 22837397 rs8017992 chr14 27752103 G T 1.42E-04 Vaspin levels / / 22907691 rs8017992 chr14 27752103 G T 0.000142 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs8020822 chr14 27761190 A G 5.62E-06 Cortisol secretion,in saliva / / 21316860 rs8020438 chr14 27761335 C T 3.30E-06 Cortisol secretion,in saliva / / 21316860 rs17112465 chr14 27786866 C G 1.50E-05 Urinary metabolites / / 21572414 rs17112465 chr14 27786866 C G 1.80E-06 Bilirubin levels / / 23371916 rs2877832 chr14 27800177 C T 1.63E-06 Type 2 diabetes and 6 quantitative traits LOC728755 intron 17848626 rs2877832 chr14 27800177 C T 2.00E-06 Diabetes related insulin traits LOC728755 intron 17903298 rs2877832 chr14 27800177 C T 3.00E-06 Diabetes related insulin traits LOC728755 intron 17903298 rs7145681 chr14 27808931 T C 9.64E-04 Multiple complex diseases LOC728755 intron 17554300 rs1456796 chr14 27810471 A C 6.86E-05 Alcohol and nictotine co-dependence LOC728755 intron 20158304 rs10498288 chr14 27867946 T C 9.00E-05 Prostate cancer LOC728755 intron 21743057 rs1954668 chr14 27932338 A G 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs7146037 chr14 27933228 A G 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs2333000 chr14 27934202 A T 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs1954667 chr14 27936583 T C 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs1954665 chr14 27936709 T A 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs17112726 chr14 27942127 G C 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs17095472 chr14 27949721 G A 9.47E-09 Metabolite levels LOC728755 intron 23281178 rs1954664 chr14 27955256 A C 2.22E-08 Metabolite levels LOC728755 intron 23281178 rs1892554 chr14 27955331 A G 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs8013302 chr14 27955485 C T 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs1954662 chr14 27955582 G A 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs4983249 chr14 27959405 T G 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs4540992 chr14 27959932 G T 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs12894202 chr14 27964599 T G 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs4048265 chr14 27964971 C T 6.55E-08 Metabolite levels LOC728755 intron 23281178 rs10137892 chr14 27965466 G A 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs10132646 chr14 27965921 T C 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs10747305 chr14 27967215 T C 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs12590124 chr14 27968742 G T 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs8022659 chr14 27969658 C T 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs10144569 chr14 27972856 C T 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs10144572 chr14 27972869 C A,G 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs12890838 chr14 27973648 A G 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs1954661 chr14 27974421 T A 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs10130589 chr14 27975817 G C 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs12887064 chr14 27976615 C G 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs12897025 chr14 27977269 T A 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs8003670 chr14 27978817 C T 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs10132835 chr14 27979557 A T 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs11160470 chr14 27980401 A G 1.39E-08 Metabolite levels LOC728755 intron 23281178 rs2022868 chr14 27980968 A G 1.59E-08 Metabolite levels LOC728755 intron 23281178 rs2022867 chr14 27981132 A G 1.90E-08 Metabolite levels LOC728755 intron 23281178 rs8018341 chr14 27984523 G A 1.10E-05 Urinary metabolites LOC728755 intron 21572414 rs8018341 chr14 27984523 G A 0.00082 Breast cancer LOC728755 intron 23555315 rs1954684 chr14 27985160 T C 1.90E-08 Metabolite levels LOC728755 intron 23281178 rs2022907 chr14 27985691 C T 8.51E-08 Metabolite levels LOC728755 intron 23281178 rs2877857 chr14 27989143 C T 1.90E-08 Metabolite levels LOC728755 intron 23281178 rs4561380 chr14 27989471 A T 1.90E-08 Metabolite levels LOC728755 intron 23281178 rs2154408 chr14 27998179 A C 1.90E-08 Metabolite levels LOC728755 intron 23281178 rs12882804 chr14 27998843 G T 1.90E-08 Metabolite levels LOC728755 intron 23281178 rs2022900 chr14 27999055 C G 1.90E-08 Metabolite levels LOC728755 intron 23281178 rs8011939 chr14 28004044 C T 2.51E-04 Multiple complex diseases LOC728755 intron 17554300 rs2022897 chr14 28004367 A C 1.32E-04 Multiple complex diseases LOC728755 intron 17554300 rs2022896 chr14 28004630 G A 8.90E-07 Urinary metabolites LOC728755 intron 21572414 rs10873498 chr14 28019234 A C 8.60E-07 Urinary metabolites LOC728755 intron 21572414 rs1892555 chr14 28027925 T C 1.34E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) LOC728755 intron 24023788 rs2333057 chr14 28037991 A G 2.00E-06 Urinary metabolites LOC728755 intron 21572414 rs2333058 chr14 28038638 T A 9.50E-06 Urinary metabolites LOC728755 intron 21572414 rs1954675 chr14 28040100 A C 2.10E-06 Urinary metabolites LOC728755 intron 21572414 rs2022878 chr14 28044827 A C 7.53E-06 Retinopathy in non-diabetics LOC728755 intron 23393555 rs1954673 chr14 28057040 A T 6.40E-04 Type 2 diabetes and 6 quantitative traits LOC728755 intron 17848626 rs7148084 chr14 28064245 G T 6.86E-06 Uric acid levels LOC728755 intron 21294900 rs1954669 chr14 28065012 G A 4.95E-04 Myocardial Infarction LOC728755 intron pha002883 rs17112910 chr14 28068652 C G 8.01E-06 Uric acid levels LOC728755 intron 21294900 rs17112915 chr14 28069275 A G 8.01E-06 Uric acid levels LOC728755 intron 21294900 rs1246116 chr14 28070164 A C 8.41E-05 Cognitive impairment induced by topiramate LOC728755 intron 22091778 rs1246115 chr14 28070503 C A 1.29E-05 Cognitive impairment induced by topiramate LOC728755 intron 22091778 rs1246115 chr14 28070503 C A 7.15E-05 Cognitive impairment induced by topiramate LOC728755 intron 22091778 rs1246115 chr14 28070503 C A 8.49E-05 Cognitive impairment induced by topiramate LOC728755 intron 22091778 rs1954522 chr14 28071269 G T 8.28E-06 Uric acid levels LOC728755 intron 21294900 rs17112954 chr14 28114641 T C 7.47E-04 Multiple complex diseases LOC728755 intron 17554300 rs10130248 chr14 28119601 A G 4.61E-04 Alcohol dependence LOC728755 intron 24277619 rs4983262 chr14 28120994 T C 0.0000244 Alcohol craving with or without dependence LOC728755 intron 22481050 rs12431387 chr14 28148419 T C 5.02E-04 Coronary heart disease / / 21971053 rs10129845 chr14 28149319 A G 5.48E-04 Coronary heart disease / / 21971053 rs4981658 chr14 28164745 C T 7.49E-05 Blood Pressure / / pha002903 rs1954529 chr14 28164801 C T 2.33E-04 Type 2 diabetes / / 17463246 rs10137287 chr14 28294108 G A 1.71E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs8007744 chr14 28329396 A G 2.84E-05 Intracerebral hemorrhage / / 24656865 rs2333191 chr14 28358899 A G 1.30E-05 Alcohol consumption (maxi-drinks) / / 24277619 rs8020076 chr14 28458673 C T 8.20E-05 Lung adenocarcinoma / / 21242121 rs17113460 chr14 28497202 A G 5.90E-05 White matter hyperintensity burden / / 21681796 rs11851064 chr14 28498057 C A 3.20E-05 White matter hyperintensity burden / / 21681796 rs534906443 chr14 28498057 C CA 3.20E-05 White matter hyperintensity burden / / 21681796 rs1952840 chr14 28498781 A G 3.20E-05 White matter hyperintensity burden / / 21681796 rs17095485 chr14 28500775 C T 3.10E-05 White matter hyperintensity burden / / 21681796 rs17113464 chr14 28501307 G A 3.20E-05 White matter hyperintensity burden / / 21681796 rs17113467 chr14 28501360 C A 3.20E-05 White matter hyperintensity burden / / 21681796 rs17113470 chr14 28506099 T C 3.20E-05 White matter hyperintensity burden / / 21681796 rs17113473 chr14 28508132 A G 3.30E-05 White matter hyperintensity burden / / 21681796 rs1888386 chr14 28508633 C A 3.40E-05 White matter hyperintensity burden / / 21681796 rs1888387 chr14 28508652 C T 3.50E-05 White matter hyperintensity burden / / 21681796 rs1191373 chr14 28591117 C T 9.89E-06 Obesity-related traits / / 23251661 rs10142324 chr14 28644103 C T 3.30E-04 Heart Failure / / pha002885 rs1317377 chr14 28651889 T C 4.28E-05 Cytomegalovirus antibody response / / 21993531 rs1317377 chr14 28651889 T C 7.86E-05 Magnesium levels / / pha003092 rs9788536 chr14 28656746 G A 5.02E-05 Body mass index / / 17255346 rs4322586 chr14 28717021 T C 5.13E-04 Multiple complex diseases / / 17554300 rs4322586 chr14 28717021 T C 1.44E-04 Body mass index / / 21701565 rs4322586 chr14 28717021 T C 2.24E-04 Body mass index / / 21701565 rs6576132 chr14 28728111 C A 5.00E-08 Resting oxygen saturation in chronic obstructive pulmonary disease (pulse oxymetry) / / 24825563 rs17113859 chr14 28794895 T A 1.80E-28 Narcolepsy / / 19629137 rs10483336 chr14 28837590 G A 6.71E-04 Alzheimer's disease / / 17998437 rs10483336 chr14 28837590 G A 1.52E-04 Alzheimer's disease / / pha002879 rs11624042 chr14 28838076 C A 4.03E-04 IgE levels / / 17255346 rs11624042 chr14 28838076 C A 3.13E-04 Body mass index / / 21701565 rs11624042 chr14 28838076 C A 3.94E-04 Body mass index / / 21701565 rs2180892 chr14 28930312 G A 7.10E-05 Testicular dysgenesis syndrome / / 22140272 rs8019629 chr14 28944223 G A 6.86E-04 Body mass index / / 21701565 rs2224437 chr14 28990427 C T 5.83E-04 Parkinson's disease / / 17052657 rs2224437 chr14 28990427 C T 2.09E-05 Parkinson's disease / / pha002868 rs1885147 chr14 28993910 A G 7.22E-04 Parkinson's disease / / 17052657 rs10141935 chr14 29006754 A G 3.10E-05 Vitamin D concentrations / / 20600896 rs10141935 chr14 29006754 A G 3.10E-05 Vitamin D concentrations / / 20600896 rs10141935 chr14 29006754 A G 5.72E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10130237 chr14 29006941 C T 6.38E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4127784 chr14 29007295 C T 5.72E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10132568 chr14 29007707 G A 8.67E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2877929 chr14 29010312 T C 5.72E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12878206 chr14 29020054 A G 5.72E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7493138 chr14 29021928 C T 4.22E-05 Multiple sclerosis / / 17660530 rs7493138 chr14 29021928 C T 1.00E-06 Longevity / / 20834067 rs11621151 chr14 29024101 C T 9.91E-04 Heart Failure / / pha002885 rs2093075 chr14 29031632 G C 1.93E-04 Cognitive decline / / 23732972 rs10130803 chr14 29045712 A C 3.30E-04 Iron levels / / pha002876 rs10130803 chr14 29045712 A C 9.99E-05 Hypertension / / pha003042 rs4983306 chr14 29067027 C T 9.66E-05 AIDS / / 19754311 rs4981674 chr14 29070385 C A 2.38E-05 Cognitive test performance / / 20125193 rs2333423 chr14 29077188 T G 6.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7150852 chr14 29080047 C A 9.68E-05 Cognitive test performance / / 20125193 rs8012543 chr14 29087550 G A 6.60E-07 Phospholipid levels (plasma) / / 21829377 rs8004078 chr14 29088596 T A 1.46E-06 Phospholipid levels (plasma) / / 21829377 rs8016497 chr14 29092279 T C 0.00000201 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs7143014 chr14 29100439 G A 1.43E-06 Phospholipid levels (plasma) / / 21829377 rs12587311 chr14 29116695 T C 5.00E-07 Phospholipid levels (plasma) / / 21829377 rs7157409 chr14 29118242 A C 0.00000046 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs7157409 chr14 29118242 A C 0.00000138 Internal carotid artery thickness (far walls) / / 23487405 rs1033693 chr14 29125021 A G 3.60E-04 Multiple complex diseases / / 17554300 rs1956388 chr14 29132877 G A 2.00E-06 Ulcerative colitis / / 20848476 rs1956388 chr14 29132877 G A 1.82E-06 Phospholipid levels (plasma) / / 21829377 rs12895516 chr14 29136950 G C 1.46E-06 Phospholipid levels (plasma) / / 21829377 rs1956384 chr14 29139570 C T 1.40E-06 Phospholipid levels (plasma) / / 21829377 rs4442733 chr14 29142241 T C 1.50E-06 Phospholipid levels (plasma) / / 21829377 rs12886468 chr14 29187127 A C 2.45E-04 Type 2 diabetes / / 17463246 rs2884 chr14 29187404 C T 2.45E-04 Type 2 diabetes / / 17463246 rs1116671 chr14 29189774 A G 2.45E-04 Type 2 diabetes / / 17463246 rs4983328 chr14 29190652 C T 3.17E-04 Type 2 diabetes / / 17463246 rs2333455 chr14 29191625 A C 3.17E-04 Type 2 diabetes / / 17463246 rs11846427 chr14 29192421 T C 2.45E-04 Type 2 diabetes / / 17463246 rs1955449 chr14 29194272 T G 3.17E-04 Type 2 diabetes / / 17463246 rs10145220 chr14 29195007 T A 2.45E-04 Type 2 diabetes / / 17463246 rs2143951 chr14 29196215 T G 3.17E-04 Type 2 diabetes / / 17463246 rs12590411 chr14 29196856 T C 3.17E-04 Type 2 diabetes / / 17463246 rs968045 chr14 29198059 G A 9.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs910313 chr14 29198485 A G 6.50E-06 Stroke (ischemic) / / 22384361 rs10133970 chr14 29201775 C G 2.14E-04 Type 2 diabetes / / 17463246 rs735214 chr14 29212618 C T 7.78E-05 Response to hepatitis C treatment / / 19684573 rs4983330 chr14 29219844 T A 2.89E-04 Acute lung injury / / 22295056 rs4983332 chr14 29221709 G C 3.65E-04 Acute lung injury / / 22295056 rs17114266 chr14 29243242 G T 1.00E-04 Cognitive impairment induced by topiramate C14orf23 intron 22091778 rs17114266 chr14 29243242 G T 3.50E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) C14orf23 intron 23648065 rs2038256 chr14 29249349 T G 2.00E-06 Multiple sclerosis (brain glutamate levels) C14orf23 intron 20802204 rs17114286 chr14 29257152 T G 2.42E-04 Acute lung injury C14orf23 intron 22295056 rs17114301 chr14 29259725 C T 2.42E-04 Acute lung injury C14orf23 intron 22295056 rs4462524 chr14 29373283 A G 7.29E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1956595 chr14 29373308 C T 1.49E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12587874 chr14 29454041 A G 2.30E-05 Alcohol and nictotine co-dependence / / 20158304 rs11844475 chr14 29699411 T C 5.69E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10142843 chr14 29714864 A G 3.37E-04 Iron levels / / pha002876 rs41513155 chr14 29746614 T A 6.83E-04 Coronary Artery Disease / / 17634449 rs8011720 chr14 29762149 T C 9.26E-05 Heart Rate / / pha003051 rs8011720 chr14 29762149 T C 3.56E-05 Heart Rate / / pha003054 rs12883378 chr14 29824131 G A 8.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10134543 chr14 29828940 G C 0.000041 Salmonella-induced pyroptosis / / 22837397 rs10498305 chr14 29924433 G A 5.15E-05 Femoral neck bone geometry / / 22087292 rs11625659 chr14 29936683 G A 1.00E-04 Information processing speed / / 21130836 rs11629424 chr14 29939190 C T 7.24E-05 Information processing speed / / 21130836 rs17114837 chr14 29944713 T C 2.00E-06 Personality dimensions / / 18957941 rs10498307 chr14 29945853 C T 2.00E-06 Personality dimensions / / 18957941 rs10133829 chr14 29951368 C T 7.05E-05 Information processing speed / / 21130836 rs977123 chr14 29984126 G A 2.99E-04 Coronary heart disease / / 21606135 rs977122 chr14 29984298 C A 7.59E-04 Coronary heart disease / / 21606135 rs1191555 chr14 29992503 C T 5.68E-05 Age-related macular degeneration / / 22125219 rs1191545 chr14 30003238 G T 9.47E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs1211216 chr14 30012665 T C 6.40E-06 Type 2 diabetes / / 17463246 rs12431702 chr14 30088138 C A 8.00E-06 IgG glycosylation PRKD1 intron 23382691 rs1953722 chr14 30230638 A G 4.00E-04 Type 2 diabetes PRKD1 intron 23937595 rs1953205 chr14 30300361 T A 4.78E-04 Smoking quantity PRKD1 intron 24665060 rs2810043 chr14 30302188 T C 5.52E-05 Potassium levels PRKD1 intron pha003086 rs1958980 chr14 30312091 G A 9.25E-05 Soluble levels of adhesion molecules PRKD1 intron pha003072 rs11847351 chr14 30314078 G A 8.30E-05 Soluble levels of adhesion molecules PRKD1 intron pha003072 rs12589992 chr14 30387520 C T 9.13E-08 Lymphocyte counts PRKD1 intron 22286170 rs170475 chr14 30451426 T C 6.20E-05 Serum metabolites / / 19043545 rs10151686 chr14 30466466 G A 3.07E-06 Acute lung injury / / 22295056 rs8016859 chr14 30484722 G C 8.61E-06 Acute lung injury / / 22295056 rs8003383 chr14 30489090 A C 5.98E-06 Acute lung injury / / 22295056 rs718545 chr14 30489623 A G 9.00E-06 Obesity-related traits / / 23251661 rs10138555 chr14 30489965 G T 8.52E-06 Acute lung injury / / 22295056 rs1440983 chr14 30493261 G A 8.52E-06 Acute lung injury / / 22295056 rs10483389 chr14 30495719 C T 8.52E-06 Acute lung injury / / 22295056 rs10134333 chr14 30501371 C T 6.17E-06 Acute lung injury / / 22295056 rs10134820 chr14 30501885 C T 6.17E-06 Acute lung injury / / 22295056 rs11847697 chr14 30515112 C T 6.00E-11 Body mass index / / 20935630 rs11847697 chr14 30515112 C T 2.69E-05 Acute lung injury / / 22295056 rs11847697 chr14 30515112 C T 5.76E-11 Body mass index / / 23001569 rs11847697 chr14 30515112 C T 2.00E-06 Body mass index / / 23669352 rs225942 chr14 30525388 T C 5.30E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs41449149 chr14 30525601 C T 4.47E-04 Multiple complex diseases / / 17554300 rs142705539 chr14 30535709 A G 0.0000569 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9707389 chr14 30535726 T A 0.0000566 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9652310 chr14 30539282 G A 1.00E-04 Information processing speed / / 21130836 rs225845 chr14 30550776 T C 9.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs225836 chr14 30556514 T G 9.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs225871 chr14 30573298 T A 2.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs225848 chr14 30594657 G A 1.00E-06 Sexual dysfunction (SSRI/SNRI-related) / / 22445761 rs10142295 chr14 30600423 T C 8.74E-04 Rheumatoid arthritis / / 21452313 rs8019932 chr14 30606426 T G 1.90E-05 Breast cancer and prostate cancer / / 17903305 rs8005030 chr14 30607199 T C 3.94E-04 Multiple complex diseases / / 17554300 rs1033706 chr14 30649776 G A 2.60E-05 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines / / 21483694 rs6571338 chr14 30660543 G T 3.26E-04 Glycemic traits (pregnancy) / / 23903356 rs2877992 chr14 30676159 T A 6.46E-04 Multiple complex diseases / / 17554300 rs10132126 chr14 30692147 T C 6.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs4981741 chr14 30713366 G T 9.25E-05 Alzheimer's disease (age of onset) / / 22005931 rs4981744 chr14 30736458 A T 6.04E-05 Alzheimer's disease (age of onset) / / 22005931 rs12887892 chr14 30739000 C T 1.90E-05 Alzheimer's disease (age of onset) / / 22005931 rs12587094 chr14 30740659 T A 5.94E-05 Alzheimer's disease (age of onset) / / 22005931 rs17096475 chr14 30746181 G A 8.21E-05 Alzheimer's disease (age of onset) / / 22005931 rs179071 chr14 30780729 G T 7.79E-05 Serum albumin level / / pha003084 rs17336218 chr14 30803716 C G 4.81E-04 Parkinson's disease / / 16252231 rs8018224 chr14 30824870 G A 5.47E-05 Schizophrenia / / 19571811 rs179095 chr14 30846875 A G 6.64E-05 Height / / pha003010 rs17096653 chr14 30858389 A G 2.00E-09 Bilirubin levels,in serum / / 20639394 rs7155872 chr14 30889842 C T 7.90E-07 Urinary metabolites / / 21572414 rs1956974 chr14 30914821 T C 8.67E-04 Insulin resistance / / 21901158 rs17096880 chr14 30992691 G A 1.13E-04 Spine bone size / / 23207799 rs1454979 chr14 30994570 C T 2.85E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs229214 chr14 30999673 A G 1.70E-05 Parkinson's disease (familial) / / 18985386 rs183467 chr14 31009261 A T 2.60E-05 Urinary metabolites / / 21572414 rs7146136 chr14 31040974 A G 6.00E-06 Asthma G2E3 intron pha003127 rs17096941 chr14 31072622 G A 2.50E-05 Urinary metabolites G2E3 intron 21572414 rs12894695 chr14 31138378 G A 8.23E-05 Blood Pressure SCFD1 intron pha003043 rs17097160 chr14 31202740 A G 2.50E-05 Urinary metabolites SCFD1 intron 21572414 rs11847318 chr14 31217642 A G 8.49E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2070338 chr14 31220074 A G 5.77E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2070337 chr14 31220183 G A 6.33E-04 Type 2 diabetes / / 17463246 rs17097201 chr14 31223556 A C 3.17E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12885818 chr14 31242697 G A 3.49E-05 Erythrocyte counts / / pha003099 rs17437994 chr14 31243899 C A 2.42E-04 Lung function (forced vital capacity) / / 24023788 rs7159120 chr14 31243999 A G 1.39E-04 Multiple complex diseases / / 17554300 rs2106104 chr14 31249816 A G 1.23E-04 Depression (quantitative trait) / / 20800221 rs2518659 chr14 31271487 A G 5.66E-05 Orofacial clefts / / 20023658 rs2518659 chr14 31271487 A G 1.09E-05 Orofacial clefts / / 22863734 rs2213951 chr14 31276114 A G 7.55E-05 Orofacial clefts / / 22863734 rs4981786 chr14 31289757 A G 7.59E-04 Smoking initiation / / 24665060 rs4981791 chr14 31293900 C G 4.43E-05 Smoking initiation / / 24665060 rs4981792 chr14 31305469 C T 2.60E-05 Smoking initiation / / 24665060 rs4981796 chr14 31305751 A G 1.01E-04 Smoking initiation / / 24665060 rs7155926 chr14 31317214 T C 5.44E-05 Smoking initiation / / 24665060 rs179661 chr14 31328871 G A 2.54E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs12884979 chr14 31360281 C T 3.38E-04 Multiple complex diseases COCH nearGene-3 17554300 rs1474802 chr14 31384330 C A 4.09E-04 Heart Failure STRN3 intron pha002885 rs17449560 chr14 31529072 G C 1.46E-07 Multiple complex diseases AP4S1 intron 17554300 rs3784163 chr14 31534471 T C 2.74E-04 Taste perception AP4S1 intron 22132133 rs7157080 chr14 31553720 T G 1 Drug response to Etoposide AP4S1 intron 17537913 rs10130804 chr14 31558790 C T 9.74E-04 Multiple complex diseases AP4S1 intron 17554300 rs6571396 chr14 31681227 G T 1.15E-04 Cognitive decline / / 23732972 rs727675 chr14 31733642 G A 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1812760 chr14 31737548 C A 5.26E-05 Lung adenocarcinoma / / 19836008 rs6571432 chr14 31995737 C T 8.75E-04 Multiple complex diseases / / 17554300 rs8020297 chr14 32025638 G C 3.50E-06 Urinary metabolites / / 21572414 rs10143899 chr14 32032129 C T 0.0002571 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs10143899 chr14 32032129 C T 2.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs3759779 chr14 32034147 A T 0.0008079 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs3759779 chr14 32034147 A T 8.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs1947004 chr14 32034822 A G 0.0002592 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs1947004 chr14 32034822 A G 2.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs4143988 chr14 32035615 G A 0.000795 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs4143988 chr14 32035615 G A 7.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs1972925 chr14 32036119 A G 0.0002584 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs1972925 chr14 32036119 A G 2.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs1548057 chr14 32038162 T C 0.0008125 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs1548057 chr14 32038162 T C 8.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs8009647 chr14 32041012 C T 0.0003768 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs8009647 chr14 32041012 C T 3.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs8015282 chr14 32041977 C T 0.0002573 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs8015282 chr14 32041977 C T 2.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs7142098 chr14 32047217 T C 0.0002562 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL UTR-5 23233654 rs7142098 chr14 32047217 T C 2.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL UTR-5 23233662 rs4981857 chr14 32048000 C T 0.0002569 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs4981857 chr14 32048000 C T 2.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs8009531 chr14 32048172 C T 0.0002564 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs8009531 chr14 32048172 C T 2.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs8010049 chr14 32048488 C T 0.0002558 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs8010049 chr14 32048488 C T 2.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs9635155 chr14 32049276 G A 0.0007918 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs9635155 chr14 32049276 G A 7.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs12886052 chr14 32050286 G A 0.0002405 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs12886052 chr14 32050286 G A 2.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs7149572 chr14 32050888 C T 0.0002544 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs7149572 chr14 32050888 C T 2.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs7154174 chr14 32051122 A G 0.0002541 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs7154174 chr14 32051122 A G 2.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs17098014 chr14 32052703 C T 0.0002536 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs17098014 chr14 32052703 C T 2.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs11156691 chr14 32055469 A G 0.000253 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs11156691 chr14 32055469 A G 2.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs11156692 chr14 32055549 C T 0.0002526 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs11156692 chr14 32055549 C T 2.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs920729 chr14 32056044 A G 0.0007907 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs920729 chr14 32056044 A G 7.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs12434789 chr14 32056565 A T 0.0002509 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs12434789 chr14 32056565 A T 2.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs8022828 chr14 32059091 T C 0.0007872 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs8022828 chr14 32059091 T C 7.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs4497586 chr14 32061099 T C 0.0007745 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs4497586 chr14 32061099 T C 7.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs11625161 chr14 32061383 C A 0.0002276 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs11625161 chr14 32061383 C A 2.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs2378896 chr14 32063024 G A 0.0002383 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs2378896 chr14 32063024 G A 2.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs2378897 chr14 32063104 A G 0.0002382 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs2378897 chr14 32063104 A G 2.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs8013916 chr14 32066907 T C 0.000238 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs8013916 chr14 32066907 T C 2.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs4981105 chr14 32068242 A C 0.000238 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs4981105 chr14 32068242 A C 2.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs12885598 chr14 32071665 G A 0.0004264 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs12885598 chr14 32071665 G A 4.26E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs4981106 chr14 32072035 G A 0.0002373 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs4981106 chr14 32072035 G A 2.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs10139871 chr14 32073635 C T 0.00001684 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs10139871 chr14 32073635 C T 8.00E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs12882018 chr14 32074331 G A 0.000237 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs12882018 chr14 32074331 G A 2.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs11627332 chr14 32075750 G A 0.0002369 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs11627332 chr14 32075750 G A 2.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs8022163 chr14 32080473 G A 0.0002364 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs8022163 chr14 32080473 G A 2.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs17390625 chr14 32083365 A G 0.0008011 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs17390625 chr14 32083365 A G 8.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs7144102 chr14 32088227 G C 0.000349 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs7144102 chr14 32088227 G C 3.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs12432746 chr14 32089204 A C 0.0002948 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs12432746 chr14 32089204 A C 2.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs11628819 chr14 32092780 C T 0.0002346 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs11628819 chr14 32092780 C T 2.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs11621036 chr14 32093145 G T 0.0002345 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs11621036 chr14 32093145 G T 2.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs11620949 chr14 32093152 A G 0.0002343 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs11620949 chr14 32093152 A G 2.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs2165814 chr14 32093244 C T 0.0002343 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs2165814 chr14 32093244 C T 2.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs7142881 chr14 32093548 G A 2.00E-06 Response to iloperidone treatment (QT prolongation) NUBPL intron 18521091 rs7142881 chr14 32093548 G A 0.0008225 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs7142881 chr14 32093548 G A 8.23E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs4981868 chr14 32096383 A G 0.0002344 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs4981868 chr14 32096383 A G 2.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs12890184 chr14 32100600 C T 0.0002343 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs12890184 chr14 32100600 C T 2.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs12437209 chr14 32110519 C T 0.0002347 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs12437209 chr14 32110519 C T 2.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs1954441 chr14 32118713 G A 6.86E-05 Bipolar disorder NUBPL intron 20451256 rs1545275 chr14 32120224 G A 0.0002351 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs1545275 chr14 32120224 G A 2.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs1443144 chr14 32127450 A G 0.0002357 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs1443144 chr14 32127450 A G 2.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs4981876 chr14 32131273 G A 0.0002362 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs4981876 chr14 32131273 G A 2.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs2153560 chr14 32155617 G T 0.0002362 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs2153560 chr14 32155617 G T 2.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs11628555 chr14 32159549 C T 0.000237 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs11628555 chr14 32159549 C T 2.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs17098061 chr14 32162783 A G 0.0002373 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs17098061 chr14 32162783 A G 2.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs12433808 chr14 32164701 T C 0.0002372 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs12433808 chr14 32164701 T C 2.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs1560426 chr14 32165668 C A 0.0002372 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs1560426 chr14 32165668 C A 2.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs12890318 chr14 32167453 T C 0.0002373 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs12890318 chr14 32167453 T C 2.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs7157366 chr14 32167996 C T 0.0002374 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs7157366 chr14 32167996 C T 2.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs12895480 chr14 32168599 G C 0.0002376 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs12895480 chr14 32168599 G C 2.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs12895565 chr14 32168843 C T 0.0002376 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs12895565 chr14 32168843 C T 2.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs2226057 chr14 32169212 C A 0.000004514 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs2226057 chr14 32169212 C A 2.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs11621253 chr14 32171052 A G 0.0002391 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs11621253 chr14 32171052 A G 2.39E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs1470285 chr14 32172099 T G 0.0002395 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs1470285 chr14 32172099 T G 2.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs12147945 chr14 32177004 C T 0.0002407 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs12147945 chr14 32177004 C T 2.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs11621446 chr14 32178667 C T 0.0002412 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs11621446 chr14 32178667 C T 2.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs8019296 chr14 32180131 A G 0.0002412 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs8019296 chr14 32180131 A G 2.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs11621147 chr14 32181528 A G 0.0006043 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs11621147 chr14 32181528 A G 6.04E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs11624772 chr14 32183970 A T 0.0002416 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL UTR-5 23233654 rs11624772 chr14 32183970 A T 2.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL UTR-5 23233662 rs12897779 chr14 32184417 G A 0.00015 Coronary artery calcification NUBPL intron 23727086 rs767333 chr14 32186264 A T 0.0002421 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs767333 chr14 32186264 A T 2.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs4981891 chr14 32193959 G A 0.0003689 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs4981891 chr14 32193959 G A 3.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs720954 chr14 32195627 C A 0.0002438 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs720954 chr14 32195627 C A 2.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs8020397 chr14 32196242 G C 0.00037 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs8020397 chr14 32196242 G C 3.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs11156701 chr14 32198543 A G 0.0002438 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs11156701 chr14 32198543 A G 2.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs4981119 chr14 32200577 C G 0.0002449 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs4981119 chr14 32200577 C G 2.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs4981894 chr14 32200791 C T 0.0002451 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs4981894 chr14 32200791 C T 2.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs4981122 chr14 32201051 A T 0.0002453 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs4981122 chr14 32201051 A T 2.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs2378944 chr14 32202478 T C 0.000375 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs2378944 chr14 32202478 T C 3.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs11156703 chr14 32203421 G C 0.000376 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs11156703 chr14 32203421 G C 3.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs11156704 chr14 32203793 T A 0.0002472 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs11156704 chr14 32203793 T A 2.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs6571459 chr14 32204607 C T 0.0003772 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs6571459 chr14 32204607 C T 3.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs12896685 chr14 32205674 A C 0.0002478 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs12896685 chr14 32205674 A C 2.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs919521 chr14 32207890 C T 0.0003774 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs919521 chr14 32207890 C T 3.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs4981897 chr14 32215180 G A 0.0006324 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs4981897 chr14 32215180 G A 6.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs11628570 chr14 32217296 C T 0.0002475 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs11628570 chr14 32217296 C T 2.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs11156705 chr14 32219172 C T 0.0002468 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs11156705 chr14 32219172 C T 2.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs12886367 chr14 32221024 G T 0.0003758 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs12886367 chr14 32221024 G T 3.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs12886260 chr14 32221120 C A 0.0003755 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs12886260 chr14 32221120 C A 3.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs8022541 chr14 32223040 A C 0.0003747 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs8022541 chr14 32223040 A C 3.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs10141659 chr14 32223606 T A 0.0003736 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs10141659 chr14 32223606 T A 3.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs10129541 chr14 32223839 A C 0.0003731 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs10129541 chr14 32223839 A C 3.73E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs7493492 chr14 32228384 T A 0.0002432 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs7493492 chr14 32228384 T A 2.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs7149151 chr14 32228542 A G 0.0003709 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs7149151 chr14 32228542 A G 3.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs4981906 chr14 32233052 A G 0.000369 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs4981906 chr14 32233052 A G 3.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs11626466 chr14 32233087 C T 0.0002307 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs11626466 chr14 32233087 C T 2.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs7148166 chr14 32233685 G A 0.0005294 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs7148166 chr14 32233685 G A 5.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs17098152 chr14 32233900 A G 0.0002294 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs17098152 chr14 32233900 A G 2.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs7153475 chr14 32234382 C A 0.0002289 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs7153475 chr14 32234382 C A 2.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs1430428 chr14 32237086 G A 0.0002252 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs1430428 chr14 32237086 G A 2.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs1897141 chr14 32240738 T C 0.00001405 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs1897141 chr14 32240738 T C 3.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs11156707 chr14 32241873 C T 0.0002228 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs11156707 chr14 32241873 C T 2.23E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs891468 chr14 32243919 G A 0.0005068 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs891468 chr14 32243919 G A 5.07E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs10139898 chr14 32244010 G T 1.70E-05 Urinary metabolites NUBPL intron 21572414 rs4981909 chr14 32247091 G C 0.0004985 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs4981909 chr14 32247091 G C 4.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs12436891 chr14 32247665 C T 0.0003291 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs12436891 chr14 32247665 C T 3.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs1430425 chr14 32253973 A T 0.0007317 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs1430425 chr14 32253973 A T 7.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs8010603 chr14 32254735 T C 0.00003526 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs8010603 chr14 32254735 T C 7.89E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs11624178 chr14 32261618 G A 0.0007609 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs11624178 chr14 32261618 G A 7.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs4981911 chr14 32268269 A G 0.0007612 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs4981911 chr14 32268269 A G 7.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs4981912 chr14 32268469 C G 0.0007608 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs4981912 chr14 32268469 C G 7.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs1430431 chr14 32268792 C G 0.0007622 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs1430431 chr14 32268792 C G 7.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs7141411 chr14 32269806 C T 0.0004549 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs7141411 chr14 32269806 C T 4.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs12434666 chr14 32288327 T A 0.0006991 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs12434666 chr14 32288327 T A 6.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs12437440 chr14 32288386 A G 9.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs12431452 chr14 32288664 A C 9.90E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs7142429 chr14 32290611 G A 9.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs17379143 chr14 32295772 T A 9.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs8018901 chr14 32296609 A C 9.12E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs2378945 chr14 32300790 G A 0.0000201 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBPL intron 23233654 rs2378945 chr14 32300790 G A 8.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBPL intron 23233662 rs8016527 chr14 32322611 G A 7.20E-04 Multiple complex diseases NUBPL intron 17554300 rs8016004 chr14 32337997 G T 3.64E-05 Schizophrenia / / pha002857 rs9322878 chr14 32341906 G A 5.73E-05 Schizophrenia / / 19571809 rs9322878 chr14 32341906 G A 1.53E-05 Major depressive disorder (broad) / / 20038947 rs8009673 chr14 32342702 C A 9.54E-05 Chronic obstructive pulmonary disease / / 19300482 rs2151784 chr14 32344077 C T 7.51E-05 Schizophrenia / / 19571809 rs2151784 chr14 32344077 C T 3.65E-05 Schizophrenia / / pha002857 rs2039485 chr14 32353250 T C 6.00E-06 Brain lesion load / / 19010793 rs6571481 chr14 32355076 G T 2.24E-05 Schizophrenia / / 19571809 rs6571481 chr14 32355076 G T 1.55E-05 Schizophrenia / / pha002857 rs1278878 chr14 32384626 A G 2.03E-04 Celiac disease / / 23936387 rs1278918 chr14 32408184 G A 7.17E-05 Major depressive disorder / / 19107115 rs8007535 chr14 32419725 C T 8.80E-04 Tourette syndrome / / 22889924 rs1278951 chr14 32423630 A C 1.10E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs17098391 chr14 32426570 C T 3.24E-04 Height / / 17255346 rs1126132 chr14 32427778 A C 3.20E-04 Smoking initiation / / 24665060 rs915071 chr14 32433858 C T 3.94E-06 Schizophrenia / / 19571809 rs915071 chr14 32433858 C T 2.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs915071 chr14 32433858 C T 4.18E-06 Schizophrenia / / pha002857 rs972396 chr14 32435312 C T 3.15E-05 Schizophrenia / / 19571809 rs972396 chr14 32435312 C T 5.77E-06 Bipolar disorder and schizophrenia / / 20889312 rs972396 chr14 32435312 C T 7.82E-06 Schizophrenia / / pha002857 rs1952966 chr14 32438484 G A 6.80E-05 Bipolar disorder and schizophrenia / / 20889312 rs1952966 chr14 32438484 G A 4.84E-05 Schizophrenia / / pha002857 rs1952967 chr14 32438586 T G 8.15E-04 Multiple complex diseases / / 17554300 rs6571488 chr14 32452378 A G 3.98E-04 Multiple complex diseases / / 17554300 rs944464 chr14 32453861 A G 2.71E-05 Hypertension / / pha003042 rs8017647 chr14 32456358 T C 4.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs1952969 chr14 32457683 G T 4.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs10132087 chr14 32457991 T C 8.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs10143992 chr14 32458899 G C 4.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs10132140 chr14 32460060 A G 8.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs10483393 chr14 32460484 C T 4.48E-04 Suicide attempts in bipolar disorder / / 21041247 rs12437061 chr14 32470966 C T 5.83E-05 Hypertension / / pha003041 rs1013251 chr14 32472089 C T 7.56E-05 Hypertension / / pha003041 rs10135304 chr14 32473942 G T 2.78E-05 Bipolar disorder and schizophrenia / / 20889312 rs17091610 chr14 32489809 C T 6.03E-04 Type 2 diabetes / / 17463246 rs7140954 chr14 32554793 A G 0.000000788 Triglycerides ARHGAP5 intron 23063622 rs1958365 chr14 32671241 A G 1.44E-04 Obesity (extreme) / / 21935397 rs1958364 chr14 32672170 T C 1.22E-04 Obesity (extreme) / / 21935397 rs17388327 chr14 32676003 A C 1.13E-04 Obesity (extreme) / / 21935397 rs7155347 chr14 32697558 C T 7.02E-05 Obesity (extreme) / / 21935397 rs1951680 chr14 32699397 C T 2.40E-04 Obesity (extreme) / / 21935397 rs10145223 chr14 32701467 T C 2.33E-04 Obesity (extreme) / / 21935397 rs8011923 chr14 32701864 T C 2.37E-04 Obesity (extreme) / / 21935397 rs7144586 chr14 32713292 A G 4.11E-05 Obesity (extreme) / / 21935397 rs1007279 chr14 32714826 A T 4.01E-05 Obesity (extreme) / / 21935397 rs7161546 chr14 32719503 T C 3.32E-04 Obesity (extreme) / / 21935397 rs7160483 chr14 32719676 A C 3.68E-05 Obesity (extreme) / / 21935397 rs7161530 chr14 32721367 C T 1.30E-04 Obesity (extreme) / / 21935397 rs4981953 chr14 32722190 G C 1.91E-05 Obesity (extreme) / / 21935397 rs7142879 chr14 32725349 G A 6.38E-04 Tourette syndrome / / 22889924 rs6571501 chr14 32728233 C A 7.46E-05 Crohn's disease / / 20570966 rs6571507 chr14 32772327 A G 7.67E-06 Obesity (extreme) / / 21935397 rs11156735 chr14 32772850 G A 5.76E-05 Elbow pain / / pha003008 rs10872860 chr14 32772975 C T 7.84E-06 Obesity (extreme) / / 21935397 rs4573842 chr14 32774244 A G 1.40E-05 Urinary metabolites / / 21572414 rs2208869 chr14 32775851 C T 1.01E-05 Obesity (extreme) / / 21935397 rs2383310 chr14 32776136 T C 1.02E-05 Obesity (extreme) / / 21935397 rs8005191 chr14 32776302 T G 7.95E-06 Obesity (extreme) / / 21935397 rs9672094 chr14 32779347 G A 9.50E-04 Obesity (extreme) / / 21935397 rs6571510 chr14 32803443 A G 5.71E-04 Multiple complex diseases AKAP6 intron 17554300 rs717616 chr14 32811961 C T 7.87E-05 Cognitive test performance AKAP6 intron 20125193 rs10150574 chr14 32812532 C T 9.59E-05 Cognitive test performance AKAP6 intron 20125193 rs8020364 chr14 32819041 T C 4.49E-08 Narcolepsy AKAP6 intron 19629137 rs17484261 chr14 32826525 G A 4.73E-04 Multiple complex diseases AKAP6 intron 17554300 rs17406568 chr14 32841928 G A 4.41E-05 Anxiety in major depressive disorder AKAP6 intron 24047446 rs7494316 chr14 32842066 C T 7.54E-06 Coronary heart disease AKAP6 intron pha003031 rs11156740 chr14 32842189 G A 9.32E-04 Response to taxane treatment (placlitaxel) AKAP6 intron 23006423 rs942029 chr14 32849257 T C 6.71E-04 Tourette syndrome AKAP6 intron 22889924 rs1951681 chr14 32851025 G A 6.00E-06 Economic and political preferences (environmentalism) AKAP6 intron 22566634 rs2031106 chr14 32861709 A G 6.02E-04 HIV-1 viral setpoint AKAP6 intron 17641165 rs8013938 chr14 32881246 T G 7.41E-07 Selenium resistance in NCI60 cancer cell lines AKAP6 intron 20830292 rs12891308 chr14 32894281 C T 3.77E-04 Suicide attempts in bipolar disorder AKAP6 intron 21423239 rs12437337 chr14 32895633 C T 2.09E-04 Suicide attempts in bipolar disorder AKAP6 intron 21423239 rs11156744 chr14 32896067 G A 4.71E-04 Suicide attempts in bipolar disorder AKAP6 intron 21423239 rs7157747 chr14 32898620 C G 1.51E-04 Suicide attempts in bipolar disorder AKAP6 intron 21423239 rs2383302 chr14 32903616 T C 4.12E-04 Suicide attempts in bipolar disorder AKAP6 intron 21423239 rs941746 chr14 32904928 C T 3.03E-04 Suicide attempts in bipolar disorder AKAP6 intron 21423239 rs2224430 chr14 32909744 T C 8.29E-04 Suicide attempts in bipolar disorder AKAP6 intron 21423239 rs1957018 chr14 32911026 G A 9.31E-04 Suicide attempts in bipolar disorder AKAP6 intron 21423239 rs1957018 chr14 32911026 G A 1.94E-06 Asthma AKAP6 intron pha003128 rs1951189 chr14 32916986 C A 7.69E-04 Suicide attempts in bipolar disorder AKAP6 intron 21423239 rs6571518 chr14 32919779 T C 2.27E-06 Asthma AKAP6 intron pha003128 rs768750 chr14 32947946 A G 1.02E-04 Attention deficit hyperactivity disorder AKAP6 intron 22420046 rs4296166 chr14 32952367 A G 4.08E-06 Alzheimer's disease (late onset) AKAP6 intron 21460841 rs17412116 chr14 32966348 G A 3.25E-05 Alcohol withdrawal symptoms AKAP6 intron 22072270 rs8013209 chr14 32971599 G C 6.61E-04 QT interval AKAP6 intron 16648850 rs2145587 chr14 32981484 G A 9.73E-05 Cognitive performance AKAP6 intron 19734545 rs1998242 chr14 33011647 G A 7.09E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) AKAP6 intron 23648065 rs6571535 chr14 33019351 C A 7.72E-04 Body mass index AKAP6 intron 21701565 rs10143484 chr14 33022996 A G 5.95E-04 Multiple complex diseases AKAP6 intron 17554300 rs768787 chr14 33046471 T G 1.54E-05 Cognitive test performance AKAP6 intron 20125193 rs768787 chr14 33046471 T G 2.45E-07 Central corneal thickness AKAP6 intron 21098505 rs1950704 chr14 33047357 A G 1.65E-05 Cognitive test performance AKAP6 intron 20125193 rs4981990 chr14 33063900 G A 7.45E-05 Post-operative nausea and vomiting AKAP6 intron 21694509 rs10483414 chr14 33065586 A G 1.30E-05 Iron levels AKAP6 intron 21208937 rs1956217 chr14 33074970 A G 7.90E-06 Left ventricular hypertrophy AKAP6 intron 21828061 rs17099373 chr14 33096465 G C 4.95E-04 Multiple complex diseases AKAP6 intron 17554300 rs10135562 chr14 33128648 C T 1.20E-05 Urinary metabolites AKAP6 intron 21572414 rs10131533 chr14 33139950 G A 8.03E-05 Height AKAP6 intron pha003011 rs1569971 chr14 33154102 G A 3.17E-05 Alzheimer's disease AKAP6 intron 22005930 rs1950698 chr14 33161849 G T 3.39E-05 Alzheimer's disease AKAP6 intron 22005930 rs1956208 chr14 33164074 A C 3.49E-05 Alzheimer's disease AKAP6 intron 22005930 rs12892900 chr14 33164350 G T 3.56E-05 Alzheimer's disease AKAP6 intron 22005930 rs8013508 chr14 33172438 G A 3.14E-05 Alzheimer's disease AKAP6 intron 22005930 rs12431588 chr14 33174489 C T 5.69E-04 Alzheimer's disease AKAP6 intron 22005930 rs12431571 chr14 33174535 A T 4.38E-05 Alzheimer's disease AKAP6 intron 22005930 rs12435098 chr14 33178709 A G 6.99E-05 Cognitive performance AKAP6 intron 19734545 rs1950221 chr14 33191225 T C 2.72E-04 Alzheimer's disease (late onset) AKAP6 intron 21379329 rs2300831 chr14 33205501 A G 8.86E-04 Response to taxane treatment (placlitaxel) AKAP6 intron 23006423 rs17440692 chr14 33206507 T C 5.04E-04 Response to taxane treatment (placlitaxel) AKAP6 intron 23006423 rs2300835 chr14 33207522 C A 5.00E-07 Fasting insulin-related traits (interaction with BMI) AKAP6 intron 22581228 rs1955504 chr14 33221482 T C 2.00E-05 Lung cancer AKAP6 intron 18385738 rs8012632 chr14 33242349 T C 7.33E-05 Insulin resistance AKAP6 intron 21901158 rs17441370 chr14 33245114 C T 1.37E-11 Asthma AKAP6 intron 23181788 rs8005039 chr14 33269788 G A 2.63E-04 Response to cytidine analogues (gemcitabine) AKAP6 intron 24483146 rs10148694 chr14 33273511 C T 2.40E-05 Bone mineral density and osteoporosis-related phenotypes AKAP6 intron 22072498 rs7146994 chr14 33275517 T A 4.20E-05 Serum metabolites AKAP6 intron 19043545 rs12889349 chr14 33276036 T C 2.95E-05 Serum metabolites AKAP6 intron 19043545 rs7158720 chr14 33277871 C A 1.40E-07 Bone mineral density and osteoporosis-related phenotypes AKAP6 intron 22072498 rs7158720 chr14 33277871 C A 4.10E-05 Bone mineral density and osteoporosis-related phenotypes AKAP6 intron 22072498 rs2383378 chr14 33282470 C A 6.00E-06 Anorexia nervosa AKAP6 intron 21079607 rs1950214 chr14 33283757 C A 7.61E-04 Response to cytidine analogues (gemcitabine) AKAP6 intron 24483146 rs4647899 chr14 33293531 T A 3.39E-05 Response to cytidine analogues (gemcitabine) AKAP6 missense 24483146 rs2057121 chr14 33294042 G A 1.12E-04 Response to cytidine analogues (gemcitabine) AKAP6 intron 24483146 rs17522122 chr14 33302882 G T 3.23E-04 Body mass index / / 23669352 rs12894779 chr14 33305020 G A 1.54E-05 Anorexia nervosa / / 21079607 rs6571561 chr14 33308585 G T 2.06E-04 Spine bone size / / 23207799 rs1950216 chr14 33315424 C T 3.77E-04 Amyotrophic lateral sclerosis / / 23624525 rs990721 chr14 33327517 A G 3.97E-04 Amyotrophic lateral sclerosis / / 23624525 rs2891225 chr14 33345632 G A 9.77E-09 Post-operative nausea and vomiting / / 21694509 rs2891226 chr14 33359973 C T 2.81E-06 Post-operative nausea and vomiting / / 21694509 rs9322913 chr14 33369615 G T 0.00000003 Mean arterial pressure / / 22510845 rs8021455 chr14 33374069 T C 9.99E-04 Multiple complex diseases / / 17554300 rs4981166 chr14 33374542 A G 3.13E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs10141193 chr14 33378798 C T 8.41E-05 Femoral neck bone geometry / / 22087292 rs12146962 chr14 33381098 T C 7.30E-06 Alzheimer's disease (late onset) / / 21460841 rs12146962 chr14 33381098 T C 9.00E-06 Ankylosing spondylitis / / 22138694 rs10872871 chr14 33386759 C T 1.07E-05 Ankylosing spondylitis / / 22138694 rs1956002 chr14 33410749 A C 0.000022 Coronary artery calcification NPAS3 intron 23727086 rs12586198 chr14 33441616 T C 5.41E-04 Nicotine smoking NPAS3 intron 19268276 rs1953447 chr14 33442259 T C 8.54E-04 Taste perception NPAS3 intron 22132133 rs1953433 chr14 33445698 G A 1.65E-05 Lactate dehydrogenase levels NPAS3 intron 20981236 rs17099796 chr14 33452028 T C 4.93E-04 Multiple complex diseases NPAS3 intron 17554300 rs1953439 chr14 33472423 G T 8.65E-04 Major depressive disorder NPAS3 intron 22472876 rs4982029 chr14 33476266 G A 4.00E-06 Schizophrenia,bipolar disorder and depression (combined) NPAS3 intron 20713499 rs8015959 chr14 33480922 C T 5.00E-06 Bipolar disorder NPAS3 intron 18711365 rs9322914 chr14 33502199 C T 8.48E-04 Multiple complex diseases NPAS3 intron 17554300 rs8006993 chr14 33506970 A G 3.34E-04 Multiple complex diseases NPAS3 intron 17554300 rs1953444 chr14 33508925 G T 6.29E-04 Multiple complex diseases NPAS3 intron 17554300 rs8014371 chr14 33510133 A C 6.93E-07 Tunica Media NPAS3 intron pha003038 rs10136071 chr14 33510444 G T 3.92E-06 Tunica Media NPAS3 intron pha003038 rs17099987 chr14 33516335 G A 7.14E-04 Multiple complex diseases NPAS3 intron 17554300 rs17456727 chr14 33519935 A G 8.34E-04 Type 2 diabetes NPAS3 intron 17463246 rs8022434 chr14 33520919 C T 4.65E-04 Multiple complex diseases NPAS3 intron 17554300 rs10144956 chr14 33525951 C A 8.07E-04 Multiple complex diseases NPAS3 intron 17554300 rs10144956 chr14 33525951 C A 1.60E-05 Urinary metabolites NPAS3 intron 21572414 rs17100034 chr14 33528165 G A 6.11E-04 Multiple complex diseases NPAS3 intron 17554300 rs12894058 chr14 33532016 G A 1.90E-05 Methamphetamine dependence NPAS3 intron 23594818 rs952363 chr14 33550386 C T 5.61E-04 Parkinson's disease NPAS3 intron 17052657 rs2383437 chr14 33552449 A T 4.88E-04 Parkinson's disease NPAS3 intron 17052657 rs8014514 chr14 33552734 T C 1.79E-04 Breast cancer NPAS3 intron pha002853 rs974002 chr14 33574670 A G 2.81E-04 Myopia (pathological) NPAS3 intron 21095009 rs1279329 chr14 33576122 C T 6.89E-05 Lung function (forced expiratory volume in 1 second) NPAS3 intron pha003103 rs1958018 chr14 33576313 T C 6.47E-05 Insulin resistance NPAS3 intron 21901158 rs1299512 chr14 33584125 G A 8.34E-05 Systemic sclerosis NPAS3 intron 21750679 rs1279323 chr14 33585159 G A 1.89E-04 Parkinson's disease NPAS3 intron 17052657 rs17460823 chr14 33586563 G A 2.00E-06 Inflammatory biomarkers NPAS3 intron 22228203 rs8005131 chr14 33591105 G C 4.20E-04 Crohn's disease NPAS3 intron 17684544 rs10483425 chr14 33591214 A G 4.18E-05 Cognitive impairment induced by topiramate NPAS3 intron 22091778 rs10136259 chr14 33596724 T C 0.0000194 Transmission distortion NPAS3 intron 22377632 rs8013167 chr14 33610197 G A 6.32E-04 Suicide attempts in bipolar disorder NPAS3 intron 21041247 rs6571583 chr14 33610500 T C 7.79E-04 Suicide attempts in bipolar disorder NPAS3 intron 21041247 rs11621540 chr14 33630326 T G 6.75E-04 Schizophrenia NPAS3 intron 19197363 rs17100286 chr14 33630696 A T 1.20E-05 Urinary metabolites NPAS3 intron 21572414 rs10149827 chr14 33650231 A G 4.72E-04 White matter integrity NPAS3 intron 22425255 rs7144454 chr14 33651895 T C 1.90E-05 Urinary metabolites NPAS3 intron 21572414 rs17470464 chr14 33655557 G A 1.32E-05 Coronary Artery Disease NPAS3 intron 17634449 rs912855 chr14 33658745 C T 4.20E-05 Glaucoma (primary open-angle) NPAS3 intron 20835238 rs912855 chr14 33658745 C T 6.63E-05 Cognitive impairment induced by topiramate NPAS3 intron 22091778 rs12433161 chr14 33665589 C T 8.22E-04 Alzheimer's disease NPAS3 intron 17998437 rs17555909 chr14 33665939 T C 6.61E-05 Body Mass Index NPAS3 intron pha003006 rs17555909 chr14 33665939 T C 7.91E-05 Waist Circumference NPAS3 intron pha003024 rs12437038 chr14 33666018 T C 8.22E-04 Alzheimer's disease NPAS3 intron 17998437 rs4982061 chr14 33681031 G A 2.42E-04 Lung function (forced vital capacity) NPAS3 intron 24023788 rs4982061 chr14 33681031 G A 4.11E-04 Lung function (forced expiratory volume in 1 second) NPAS3 intron 24023788 rs10483431 chr14 33681464 C T 6.80E-04 Diabetic retinopathy NPAS3 intron 20871662 rs10483432 chr14 33682005 A G 2.00E-04 Statin-induced myopathy NPAS3 intron 21826682 rs12586992 chr14 33683746 T G 8.58E-05 Asthma NPAS3 intron pha003128 rs7151302 chr14 33684117 C T 2.00E-06 Plasma amyloid beta peptide concentrations (ABx-40) NPAS3 intron 24535457 rs12432716 chr14 33687731 G A 8.12E-04 Alzheimer's disease NPAS3 intron 17998437 rs10483433 chr14 33688809 G A 2.46E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) NPAS3 intron 17982456 rs8018494 chr14 33697927 A G 1.40E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) NPAS3 intron 24023788 rs17100409 chr14 33702082 A G 2.36E-05 Cognitive test performance NPAS3 intron 20125193 rs243284 chr14 33713054 T C 3.90E-04 Schizophrenia NPAS3 intron 20832056 rs17100461 chr14 33724886 T G 6.43E-04 Type 2 diabetes NPAS3 intron 17463246 rs243302 chr14 33735293 A G 2.63E-04 Multiple complex diseases NPAS3 intron 17554300 rs1875286 chr14 33744179 C T 7.50E-06 Urinary metabolites NPAS3 intron 21572414 rs7141967 chr14 33746372 A G 5.69E-05 Multiple complex diseases NPAS3 intron 17554300 rs12884344 chr14 33752832 A G 8.10E-05 Personality dimensions NPAS3 intron 18957941 rs4982066 chr14 33757906 A G 8.50E-05 Glaucoma (primary open-angle) NPAS3 intron 20835238 rs8007568 chr14 33764568 G C 4.50E-06 Statin-induced myopathy NPAS3 intron 21826682 rs912854 chr14 33765935 C T 1.30E-05 Urinary metabolites NPAS3 intron 21572414 rs6571593 chr14 33795813 C T 6.36E-25 Multiple complex diseases NPAS3 intron 17554300 rs1315139 chr14 33824393 A G 3.99E-05 Platelet counts NPAS3 intron pha003100 rs1315134 chr14 33827632 G A 4.99E-05 Suicide attempts in bipolar disorder NPAS3 intron 21423239 rs1315134 chr14 33827632 G A 9.54E-05 Body Mass Index NPAS3 intron pha003006 rs1315134 chr14 33827632 G A 5.69E-06 Weight NPAS3 intron pha003026 rs2274511 chr14 33829320 C T 6.70E-05 Glaucoma (primary open-angle) NPAS3 intron 20835238 rs2274511 chr14 33829320 C T 8.00E-07 QRS duration in Tripanosoma cruzi seropositivity NPAS3 intron 24324551 rs10483439 chr14 33837310 G A 6.08E-04 Smoking cessation NPAS3 intron 24665060 rs17100826 chr14 33837508 T C 5.78E-04 Smoking cessation NPAS3 intron 24665060 rs1948724 chr14 33837667 T G 3.95E-05 Tuberculosis NPAS3 intron 24057671 rs1948724 chr14 33837667 T G 6.28E-04 Smoking cessation NPAS3 intron 24665060 rs12436060 chr14 33839773 A G 8.87E-04 Response to cytidine analogues (gemcitabine) NPAS3 intron 24483146 rs12436060 chr14 33839773 A G 3.33E-04 Smoking cessation NPAS3 intron 24665060 rs17100838 chr14 33842053 C T 6.93E-04 Smoking cessation NPAS3 intron 24665060 rs17100845 chr14 33843257 T C 2.30E-04 Smoking cessation NPAS3 intron 24665060 rs8011352 chr14 33844003 C A 6.24E-04 Smoking cessation NPAS3 intron 24665060 rs10148795 chr14 33845322 A G 9.25E-04 Oral cancers (chewing tobacco related) NPAS3 intron 22503698 rs1315148 chr14 33848109 A G 5.80E-05 Response to statin therapy NPAS3 intron 20339536 rs1315148 chr14 33848109 A G 2.39E-05 Acne (severe) NPAS3 intron 24927181 rs1315151 chr14 33851122 G A 6.60E-05 Parkinson's disease (familial) NPAS3 intron 18985386 rs11851892 chr14 33851414 C T 2.80E-05 Effectiveness of iloperidone treatment in schizophrenia NPAS3 intron 18521090 rs11851892 chr14 33851414 C T 3.30E-06 Urinary metabolites NPAS3 intron 21572414 rs17100963 chr14 33862517 G A 1.20E-05 Urinary metabolites NPAS3 intron 21572414 rs4982083 chr14 33867115 T C 4.16E-04 Multiple complex diseases NPAS3 intron 17554300 rs17101003 chr14 33868380 G A 6.85E-04 Alcohol dependence NPAS3 intron 21314694 rs17571355 chr14 33869876 A C 2.92E-05 Alcoholism NPAS3 intron pha002893 rs12433945 chr14 33872102 A G 8.87E-05 Prion diseases NPAS3 intron 22210626 rs12433945 chr14 33872102 A G 4.03E-05 Attention deficit hyperactivity disorder NPAS3 intron 22420046 rs17101083 chr14 33895915 G A 9.71E-05 Smoking cessation NPAS3 intron 18519826 rs967440 chr14 33907747 A G 1.09E-04 Smoking cessation NPAS3 intron 18519826 rs12891017 chr14 33915286 G T 7.39E-06 Bipolar disorder,affective NPAS3 intron 20528957 rs4981191 chr14 33916616 G A 3.53E-04 Coronary heart disease NPAS3 intron 21606135 rs12897354 chr14 33916758 G A 1.93E-05 Bipolar disorder,affective NPAS3 intron 20528957 rs11845867 chr14 33918038 C G 6.00E-06 Self-reported allergy NPAS3 intron 23817569 rs17101181 chr14 33918337 C A,G,T 6.70E-05 Bipolar disorder,affective NPAS3 intron 20528957 rs17101237 chr14 33923292 C T 1.09E-04 Bipolar disorder,affective NPAS3 intron 20528957 rs8016929 chr14 33924170 G A 7.20E-05 Bipolar disorder,affective NPAS3 intron 20528957 rs1022726 chr14 33925842 A G 3.99E-05 Self-reported allergy NPAS3 intron 23817569 rs1030975 chr14 33925996 G A 3.48E-04 Suicide attempts in bipolar disorder NPAS3 intron 21423239 rs1030974 chr14 33926191 T G 4.41E-05 Self-reported allergy NPAS3 intron 23817569 rs1020157 chr14 33926425 T C 4.41E-05 Self-reported allergy NPAS3 intron 23817569 rs17496932 chr14 33938199 C T 3.14E-07 Multiple complex diseases NPAS3 intron 17554300 rs1570211 chr14 33955825 C T 2.75E-04 Myocardial Infarction NPAS3 intron pha002873 rs41464244 chr14 33959381 C T 6.76E-09 Multiple complex diseases NPAS3 intron 17554300 rs17101350 chr14 33972042 C T 2.97E-04 Taste perception NPAS3 intron 22132133 rs10141860 chr14 33973915 C G 9.45E-04 Type 2 diabetes NPAS3 intron 17463246 rs1957315 chr14 33976875 T C 1.15E-05 Body Composition NPAS3 intron pha003012 rs1957315 chr14 33976875 T C 5.11E-05 Body Mass Index NPAS3 intron pha003021 rs12887949 chr14 33978506 G A 1.36E-04 Smoking cessation NPAS3 intron 18519826 rs12887949 chr14 33978506 G A 2.34E-05 Smoking cessation NPAS3 intron 18519826 rs12889063 chr14 33978572 T C 2.16E-04 Multiple complex diseases NPAS3 intron 17554300 rs11156795 chr14 33980338 G C 2.30E-05 Urinary metabolites NPAS3 intron 21572414 rs2281629 chr14 33990197 T C 9.62E-04 Parkinson's disease NPAS3 intron 17052657 rs2281629 chr14 33990197 T C 1.18E-05 Body Composition NPAS3 intron pha003012 rs2281629 chr14 33990197 T C 3.55E-05 Body Mass Index NPAS3 intron pha003021 rs2281631 chr14 33990290 A C 5.35E-06 Body Composition NPAS3 intron pha003012 rs2281631 chr14 33990290 A C 8.77E-06 Body Mass Index NPAS3 intron pha003021 rs3848 chr14 33990676 G A 6.74E-05 Body Composition NPAS3 intron pha003012 rs3848 chr14 33990676 G A 3.92E-05 Body Mass Index NPAS3 intron pha003021 rs2180954 chr14 33999041 T G 2.50E-06 Urinary metabolites NPAS3 intron 21572414 rs11156798 chr14 34000503 A G,T 4.10E-06 Urinary metabolites NPAS3 intron 21572414 rs11624096 chr14 34007305 C T 7.60E-06 Urinary metabolites NPAS3 intron 21572414 rs10130952 chr14 34017946 C A 5.70E-06 Urinary metabolites NPAS3 intron 21572414 rs2210054 chr14 34022139 G A 3.70E-04 Myasthenia gravis NPAS3 intron 23055271 rs10142154 chr14 34022833 T C 2.34E-04 Alzheimer's disease NPAS3 intron pha002879 rs12586912 chr14 34023334 G T 2.00E-04 Adverse response to radiation therapy NPAS3 intron 23719583 rs12890353 chr14 34024434 G T 7.78E-04 Type 2 diabetes NPAS3 intron 17463246 rs1958539 chr14 34034087 C T 3.61E-04 Alzheimer's disease (late onset) NPAS3 intron 21379329 rs7143076 chr14 34040582 A G 5.12E-05 Schizophrenia NPAS3 intron 24253340 rs7143076 chr14 34040582 A G 2.37E-04 Alzheimer's disease NPAS3 intron 24755620 rs7148153 chr14 34040984 C T 4.09E-04 Smoking quantity NPAS3 intron 24665060 rs7155523 chr14 34042696 A G 2.88E-05 Odorant perception NPAS3 intron 23910658 rs1958555 chr14 34084149 G T 3.57E-05 Cognitive impairment induced by topiramate NPAS3 intron 22091778 rs12880401 chr14 34084336 G A 4.20E-05 HDL cholesterol NPAS3 intron pha003074 rs3905371 chr14 34126545 C T 8.60E-05 Varicose Veins NPAS3 intron pha001415 rs7152838 chr14 34137253 A G 6.71E-04 Smoking cessation NPAS3 intron 24665060 rs1952603 chr14 34149325 A G 9.42E-04 Suicide attempts in bipolar disorder NPAS3 intron 21423239 rs2297117 chr14 34149997 T C 2.54E-04 Suicide attempts in bipolar disorder NPAS3 intron 21423239 rs871608 chr14 34157086 A G 9.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) NPAS3 intron 23233662 rs9322925 chr14 34162510 T C 0.000236 Breast cancer early age of onset NPAS3 intron 18463975 rs4462505 chr14 34166008 C T 1.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NPAS3 intron 20877124 rs17487422 chr14 34166586 A G 1.88E-05 Smoking quantity NPAS3 intron 24665060 rs4277263 chr14 34168563 A G 6.58E-04 Smoking quantity NPAS3 intron 24665060 rs4528481 chr14 34168932 C T 1.97E-04 Myopia (pathological) NPAS3 intron 21095009 rs11848780 chr14 34169150 G A 1.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NPAS3 intron 20877124 rs944086 chr14 34177627 G A 2.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NPAS3 intron 20877124 rs7149368 chr14 34182124 C A 7.34E-04 Multiple complex diseases NPAS3 intron 17554300 rs7150043 chr14 34182289 G A 9.22E-04 Multiple complex diseases NPAS3 intron 17554300 rs1958055 chr14 34184786 G A 8.55E-06 ECG dimensions,brachial artery endothelial function,treadmill exercise responses NPAS3 intron 17903301 rs9806087 chr14 34186045 G A 3.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NPAS3 intron 20877124 rs9285571 chr14 34186611 T G 2.40E-05 Urinary metabolites NPAS3 intron 21572414 rs1958059 chr14 34187030 C T 2.67E-05 Cognitive performance NPAS3 intron 19734545 rs17410178 chr14 34189636 A G 1.08E-04 Bipolar disorder NPAS3 intron 17486107 rs17101773 chr14 34190982 C T 6.05E-05 Cognitive performance NPAS3 intron 19734545 rs17101773 chr14 34190982 C T 7.87E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NPAS3 intron 20877124 rs12880943 chr14 34209275 T C 2.78E-05 Triglycerides NPAS3 intron 19074352 rs12880943 chr14 34209275 T C 2.78E-05 Polyunsaturated fatty acid levels,in plasma NPAS3 intron 19148276 rs4982109 chr14 34232711 C T 3.51E-04 Lung function (forced expiratory volume in 1 second) NPAS3 intron 17255346 rs17101861 chr14 34232772 C T 6.96E-05 Multiple complex diseases NPAS3 intron 17554300 rs12895061 chr14 34247094 G A 4.20E-04 Multiple complex diseases NPAS3 intron 17554300 rs1958058 chr14 34260635 C T 8.94E-04 Bipolar disorder NPAS3 intron 19259986 rs1952157 chr14 34289438 C A 1.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17101927 chr14 34305898 G T 7.90E-05 White matter hyperintensity burden / / 21681796 rs9322929 chr14 34307720 T C 9.53E-05 Body Mass Index / / pha003022 rs2077841 chr14 34311717 A G 2.90E-05 White matter hyperintensity burden / / 21681796 rs17101967 chr14 34375576 T A 1.84E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1032015 chr14 34401104 T C 5.56E-05 Stroke EGLN3 intron pha002887 rs7142406 chr14 34436957 C T 4.44E-04 Schizophrenia / / 19197363 rs958722 chr14 34458014 G A 2.51E-04 Hemoglobin concentration / / 20534544 rs958721 chr14 34458097 G A 8.35E-05 Varicose Veins / / pha001413 rs994208 chr14 34461871 C G 2.05E-05 Self-employment / / 23593239 rs900360 chr14 34469881 C T 4.85E-04 Alzheimer's disease (late onset) / / 21379329 rs12897122 chr14 34471005 G T 3.09E-04 Alzheimer's disease (late onset) / / 21379329 rs1680672 chr14 34476980 C T 2.30E-05 Urinary metabolites / / 21572414 rs2000015 chr14 34480400 G T 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2000015 chr14 34480400 G T 4.38E-04 Acute lung injury / / 22295056 rs974673 chr14 34480514 C T 3.10E-05 Blood Phenotypes / / 17903294 rs1471639 chr14 34482526 A C,G 1.26E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs9322931 chr14 34488042 A G 4.44E-05 Basophils / / pha003087 rs1769582 chr14 34501834 A G 6.93E-05 Orofacial clefts / / 22419666 rs1680730 chr14 34503651 G T 1.71E-05 Neuroblastoma / / pha002895 rs1631523 chr14 34506293 T C 7.16E-04 Multiple complex diseases / / 17554300 rs1680715 chr14 34516946 C A 4.32E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1431057 chr14 34572675 G A 0.0000151 HDL cholesterol particle diameter / / 23263444 rs12887146 chr14 34573556 C T 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1431056 chr14 34574483 G A 0.00000807 HDL cholesterol particle diameter / / 23263444 rs11848011 chr14 34574977 A G 0.00000648 HDL cholesterol particle diameter / / 23263444 rs2027338 chr14 34586663 C T 0.0000112 HDL cholesterol particle diameter / / 23263444 rs712285 chr14 34627202 T C 8.04E-04 Response to alcohol consumption (flushing response) / / 24277619 rs797347 chr14 34638971 C T 4.02E-07 Red blood cell traits / / 23222517 rs1244379 chr14 34680351 T C 3.61E-04 Multiple complex diseases / / 17554300 rs6571636 chr14 34690056 A G 4.39E-04 Multiple complex diseases / / 17554300 rs6571636 chr14 34690056 A G 1.41E-05 Suicide attempts in bipolar disorder / / 21041247 rs6571636 chr14 34690056 A G 4.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs6571636 chr14 34690056 A G 8.05E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs1244367 chr14 34695709 T G 1.20E-05 Urinary metabolites / / 21572414 rs1244359 chr14 34697378 C T 1.80E-05 Urinary metabolites / / 21572414 rs12888812 chr14 34705610 C A 0.000516 Salmonella-induced pyroptosis / / 22837397 rs12879626 chr14 34721134 T G 4.58E-04 Multiple complex diseases / / 17554300 rs12879626 chr14 34721134 T G 1.75E-04 Aortic root size / / 21223598 rs11625107 chr14 34728127 C T 5.17E-05 Type 1 diabetes / / 18978792 rs11625217 chr14 34728231 G A 7.98E-04 Type 2 diabetes / / 17463246 rs11625217 chr14 34728231 G A 2.54E-04 Gallstones / / 17632509 rs11625217 chr14 34728231 G A 2.71E-05 Attention deficit hyperactivity disorder / / 20732627 rs12432593 chr14 34731592 C A 3.00E-05 Attention deficit hyperactivity disorder / / 20732627 rs17520436 chr14 34744031 A T 2.58E-04 Multiple complex diseases / / 17554300 rs17520436 chr14 34744031 A T 2.77E-04 Major depressive disorder / / 22472876 rs4624074 chr14 34744426 T C 3.10E-05 Attention deficit hyperactivity disorder / / 20732627 rs11627074 chr14 34777890 G A 4.45E-06 Waist-Hip Ratio / / pha003013 rs11627074 chr14 34777890 G A 1.05E-05 Waist-Hip Ratio / / pha003028 rs7144272 chr14 34783345 C T 8.30E-04 Type 2 diabetes / / 17463246 rs17442995 chr14 34794727 T G 8.27E-04 Multiple complex diseases / / 17554300 rs4982166 chr14 34806721 A C 3.53E-04 Multiple complex diseases / / 17554300 rs12050125 chr14 34838295 G A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1958589 chr14 34844376 T C 4.00E-06 Celiac disease / / 23936387 rs2383593 chr14 34851521 G A 2.64E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10134725 chr14 34909583 C T 1.21E-04 Response to cytadine analogues (cytosine arabinoside) SPTSSA intron 24483146 rs17523639 chr14 34967465 T C 7.60E-04 Acute lung injury / / 22295056 rs17102628 chr14 35076347 T G 5.81E-06 Narcolepsy SNX6 intron 20711174 rs8009551 chr14 35132687 T G 1.68E-05 Response to anti-TNF treatment in rheumatoid arthritis / / 23555300 rs8009551 chr14 35132687 T G 4.11E-05 Response to anti-TNF treatment in rheumatoid arthritis / / 23555300 rs7141276 chr14 35135186 A G 3.11E-04 Acute lung injury / / 22295056 rs7141276 chr14 35135186 A G 1.84E-06 Response to anti-TNF treatment in rheumatoid arthritis / / 23555300 rs7141276 chr14 35135186 A G 2.00E-06 Response to anti-TNF treatment in rheumatoid arthritis / / 23555300 rs7141276 chr14 35135186 A G 2.21E-05 Response to anti-TNF treatment in rheumatoid arthritis / / 23555300 rs6571672 chr14 35139682 G T 4.04E-05 Parkinson's disease (motor and cognition) / / 22658654 rs35273436 chr14 35158184 T C 6.23E-04 Smoking cessation / / 24665060 rs17526363 chr14 35211038 A G 5.39E-04 Multiple complex diseases / / 17554300 rs2010608 chr14 35219345 A G 5.00E-04 Schizophrenia / / 19197363 rs8015303 chr14 35246472 A G 8.89E-06 Osteoarthritis BAZ1A intron 22763110 rs4981250 chr14 35254473 A C 2.45E-04 Blood pressure (response to calcium channel blocker) BAZ1A intron 24192120 rs17102745 chr14 35263983 T C 5.50E-05 Personality dimensions BAZ1A cds-synon 18957941 rs7145614 chr14 35290846 T C 4.76E-04 Multiple complex diseases BAZ1A intron 17554300 rs7145614 chr14 35290846 T C 2.65E-04 Blood pressure (response to calcium channel blocker) BAZ1A intron 24192120 rs12587814 chr14 35299126 C T 2.81E-04 White matter integrity BAZ1A intron 22425255 rs7142040 chr14 35311272 A G 2.17E-04 White matter integrity BAZ1A intron 22425255 rs3783316 chr14 35337192 A G 7.36E-05 Cytomegalovirus antibody response BAZ1A intron 21993531 rs8011755 chr14 35342238 T C 8.22E-05 Major depressive disorder BAZ1A intron 22472876 rs8011755 chr14 35342238 T C 7.60E-05 Lung adenocarcinoma BAZ1A intron 22797724 rs811340 chr14 35359648 T C 7.85E-04 White matter integrity / / 22425255 rs1568199 chr14 35367889 G A 3.00E-08 Rheumatoid arthritis / / 19503088 rs712306 chr14 35395817 T G 4.96E-05 Waist Circumference / / pha003023 rs1568200 chr14 35419592 C T 6.64E-04 White matter integrity / / 22425255 rs2273154 chr14 35433187 C T 7.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs12433712 chr14 35468893 T A 0.0000104 Placental abruption SRP54 intron 23205182 rs17510813 chr14 35497266 C T 0.0000084 LDL cholesterol response after 40mg daily simvastatin treatment SRP54 intron 23100282 rs17510813 chr14 35497266 C T 0.0007 Apolipoprotein B levels response after 40mg daily simvastatin treatment SRP54 intron 23100282 rs799466 chr14 35503326 T C 2.89E-06 Lymphocyte counts / / 22286170 rs17595975 chr14 35540764 G T 0.0000098 LDL cholesterol response after 40mg daily simvastatin treatment FAM177A1 intron 23100282 rs1712354 chr14 35545938 A G 2.77E-06 Waist Circumference FAM177A1 intron pha003023 rs17103033 chr14 35556480 T C 6.75E-06 Celiac disease and Rheumatoid arthritis PPP2R3C intron 21383967 rs10483452 chr14 35556498 A C 1.21E-06 Waist Circumference PPP2R3C intron pha003023 rs10498331 chr14 35636369 T C 4.36E-05 Schizophrenia KIAA0391 intron 19571809 rs10498331 chr14 35636369 T C 1.12E-05 Schizophrenia KIAA0391 intron pha002859 rs7144806 chr14 35637717 C A 1.50E-05 Electrocardiographic conduction measures KIAA0391 intron 19389651 rs7144806 chr14 35637717 C A 4.96E-05 Schizophrenia KIAA0391 intron 19571809 rs7144806 chr14 35637717 C A 1.53E-05 Schizophrenia KIAA0391 intron pha002859 rs6571697 chr14 35640714 A G 6.47E-05 Schizophrenia KIAA0391 intron 19571809 rs6571697 chr14 35640714 A G 2.02E-05 Schizophrenia KIAA0391 intron pha002859 rs12586317 chr14 35682172 T C 2.00E-08 Psoriasis KIAA0391 intron 20953189 rs17103104 chr14 35690978 C G 8.16E-04 Multiple complex diseases KIAA0391 intron 17554300 rs7154637 chr14 35723566 G C 3.98E-04 Multiple complex diseases KIAA0391 intron 17554300 rs4982254 chr14 35755737 C T 8.90E-06 Urinary metabolites / / 21572414 rs17536892 chr14 35760062 C A 0.00036464 Primary sclerosing cholangitis PSMA6 nearGene-5 23603763 rs10135277 chr14 35823231 C T 5.11E-07 Schizophrenia / / 21926974 rs8016947 chr14 35832666 T G 2.00E-11 Psoriasis / / 20953190 rs8016947 chr14 35832666 T G 2.50E-17 Psoriasis / / 23143594 rs12435366 chr14 35838389 C T 6.56E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs200442025 chr14 35838389 CG C 6.56E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12884331 chr14 35838676 C T 4.15E-04 Obesity (extreme) / / 21935397 rs2145623 chr14 35839236 G C 5.01E-06 Psoriasis / / 20953188 rs8007950 chr14 35843785 A T 4.36E-04 Obesity (extreme) / / 21935397 rs8008408 chr14 35843816 G A 3.66E-05 Obesity (extreme) / / 21935397 rs8008408 chr14 35843816 G A 1.20E-04 Thyroid peroxidase antibody levels / / 24586183 rs12892002 chr14 35850184 G A 5.31E-04 Obesity (extreme) / / 21935397 rs7152826 chr14 35862404 C A 3.87E-04 Alcohol dependence / / 24277619 rs696 chr14 35871093 C T 1.80E-04 Psoriasis NFKBIA UTR-3 20953189 rs4982270 chr14 35880818 C G 7.32E-05 Serum metabolites / / 19043545 rs4982270 chr14 35880818 C G 4.47E-04 Smoking quantity / / 24665060 rs17103274 chr14 35883678 T C 2.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17103274 chr14 35883678 T C 3.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17103278 chr14 35883976 C T 1.21E-08 Metabolite levels / / 23281178 rs4982271 chr14 35893625 G T 3.43E-05 Non-word repetition / / 23738518 rs10132268 chr14 35947614 C T 1.07E-05 Erythrocyte counts / / pha003099 rs12895374 chr14 35958268 C T 6.00E-04 Type 2 diabetes / / 22158537 rs9322955 chr14 35975341 A G 9.48E-05 Erythrocyte counts / / pha003099 rs7157104 chr14 35998386 A G 5.76E-04 Type 2 diabetes / / 17463246 rs10483456 chr14 36036167 C T 8.11E-12 Multiple complex diseases RALGAPA1 intron 17554300 rs10135673 chr14 36066503 G C 9.67E-04 Type 2 diabetes RALGAPA1 intron 17463246 rs10135673 chr14 36066503 G C 1.04E-04 Alzheimer's disease RALGAPA1 intron 17998437 rs10138222 chr14 36066989 C T 4.38E-04 Alzheimer's disease RALGAPA1 intron 17998437 rs10132580 chr14 36118348 G T 1.32E-04 Alzheimer's disease RALGAPA1 intron 17998437 rs6571727 chr14 36141108 C T 3.49E-05 Alzheimer's disease RALGAPA1 intron 17998437 rs10132954 chr14 36141783 A G 1.44E-04 Alzheimer's disease RALGAPA1 intron 17998437 rs17103517 chr14 36236282 A G 1.62E-04 Smoking initiation RALGAPA1 intron 24665060 rs10130092 chr14 36274000 T C 1.30E-04 Alzheimer's disease RALGAPA1 intron 17998437 rs10141289 chr14 36301996 C T 4.47E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) BRMS1L intron 24023788 rs8014810 chr14 36325030 G T 2.00E-05 Alzheimer's disease BRMS1L intron 17998437 rs8014810 chr14 36325030 G T 1.54E-04 Alzheimer's disease BRMS1L intron pha002879 rs2415306 chr14 36331216 G T 8.33E-05 Alzheimer's disease BRMS1L intron 17998437 rs7157531 chr14 36387874 G A 9.67E-05 Bipolar disorder and schizophrenia / / 20889312 rs1168987 chr14 36397680 C T 5.00E-06 Response to antineoplastic agents / / 21659360 rs1168987 chr14 36397680 C T 4.06E-06 Heart Rate / / pha003053 rs1168978 chr14 36402546 T C 8.11E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs1168978 chr14 36402546 T C 7.30E-05 Body Fat Distribution / / pha003017 rs11850769 chr14 36422275 A G 0.0000148 Carotid intima media thickness / / 23152477 rs17103683 chr14 36426134 C T 4.38E-04 Body mass index / / 21701565 rs8013122 chr14 36430463 T C 1.62E-04 Attention deficit hyperactivity disorder / / 22420046 rs17103699 chr14 36437005 T G 6.44E-04 Alzheimer's disease / / 17998437 rs7147797 chr14 36449424 T C 2.69E-04 Myocardial Infarction / / pha002873 rs4981319 chr14 36453341 G T 7.69E-05 Myocardial Infarction / / pha002873 rs4982323 chr14 36454851 C A 1.04E-04 Myocardial Infarction / / pha002873 rs11851309 chr14 36477954 C T 2.40E-05 Urinary metabolites / / 21572414 rs372577 chr14 36478238 A C 2.50E-05 Urinary metabolites / / 21572414 rs12100904 chr14 36484980 A G 2.08E-04 Multiple complex diseases / / 17554300 rs1759758 chr14 36485241 A T 2.82E-04 Multiple complex diseases / / 17554300 rs2780310 chr14 36520058 A G 5.64E-04 Thyroid stimulating hormone / / 24852370 rs11156901 chr14 36535965 T A 4.61E-10 Multiple complex diseases / / 17554300 rs434052 chr14 36543648 A G 2.40E-05 Sleep and circadian phenotypes / / 17903308 rs1537424 chr14 36574018 C T 1.00E-08 Thyroid hormone levels / / 23408906 rs1537427 chr14 36586846 T C 6.90E-06 Serum metabolites / / 19043545 rs1537426 chr14 36587167 A G 1.53E-05 Serum metabolites / / 19043545 rs1958624 chr14 36597898 C T 7.29E-06 Serum metabolites / / 19043545 rs2415317 chr14 36609678 G A 5.81E-06 Serum metabolites / / 19043545 rs10130121 chr14 36624751 G T 5.89E-06 Hearing function / / 21493956 rs1169146 chr14 36632769 G A 3.40E-05 Serum metabolites / / 19043545 rs17461837 chr14 36644330 C T 6.29E-06 Hearing function / / 21493956 rs10137274 chr14 36644539 A G 6.35E-06 Hearing function / / 21493956 rs944289 chr14 36649246 C T 2.00E-09 Thyroid cancer / / 19198613 rs944289 chr14 36649246 C T 2.00E-09 Nasopharyngeal carcinoma / / 20512145 rs944289 chr14 36649246 C T 2.21E-04 Vaspin levels / / 22907691 rs944289 chr14 36649246 C T 0.0002207 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs10139184 chr14 36650047 C T 9.57E-06 Hearing function / / 21493956 rs7140782 chr14 36681985 C T 6.92E-04 Type 2 diabetes / / 17463246 rs116909374 chr14 36738361 C T 5.00E-11 Thyroid cancer / / 22267200 rs2415329 chr14 36740806 T A 7.52E-04 Aortic root size / / 21223598 rs3805355 chr14 36782984 G A 7.36E-04 Multiple complex diseases MBIP intron 17554300 rs4901597 chr14 36843139 G A 9.26E-04 Multiple complex diseases / / 17554300 rs12590640 chr14 36854136 C T 4.00E-06 Malaria / / 23717212 rs7158323 chr14 36875912 C A 5.64E-04 Multiple complex diseases / / 17554300 rs10483463 chr14 36889572 A G 5.24E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs12894630 chr14 36903354 C G 3.78E-05 Serum metabolites / / 19043545 rs8004126 chr14 36916860 G A 3.38E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs8009476 chr14 36917462 G A 4.75E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs927287 chr14 36924790 C T 1.31E-05 Cognitive test performance / / 20125193 rs1885123 chr14 36958086 A G 5.76E-04 Multiple complex diseases SFTA3 intron 17554300 rs4902467 chr14 36959027 A G 7.98E-05 Neuroblastoma SFTA3 intron pha002895 rs2076751 chr14 36989419 C A 7.00E-06 Menarche (age at onset) NKX2-1 UTR-5 23667675 rs17104630 chr14 37000049 A G 8.00E-06 Height / / 18391950 rs4899401 chr14 37004549 A G 6.74E-05 Aortic root size / / 21223598 rs11627968 chr14 37045098 T C 2.37E-04 Aortic root size / / 21223598 rs177322 chr14 37054311 C T 7.25E-04 Tourette syndrome / / 22889924 rs17104788 chr14 37061127 C T 4.18E-04 Aortic root size / / 21223598 rs1950359 chr14 37067244 C T 3.76E-04 Myopia (pathological) / / 21095009 rs2073250 chr14 37067307 A G 1.08E-04 Aortic root size / / 21223598 rs2415352 chr14 37069630 C T 3.76E-04 Myopia (pathological) / / 21095009 rs1955749 chr14 37086961 T C 1.59E-05 Cognitive test performance / / 20125193 rs1955749 chr14 37086961 T C 4.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs7143398 chr14 37087948 T C 7.27E-05 Cognitive test performance / / 20125193 rs11622332 chr14 37090029 G C 1.80E-04 Smoking initiation / / 24665060 rs7146941 chr14 37111215 A C 3.70E-06 Primary tooth development (number of teeth) / / 23704328 rs2236007 chr14 37132769 G A 2.00E-13 Breast cancer PAX9 intron 23535729 rs17104928 chr14 37142554 G A 2.70E-05 Glycosylated haemoglobin levels PAX9 intron 17255346 rs17176643 chr14 37142969 C A 3.51E-04 Acute lung injury PAX9 intron 22295056 rs1884213 chr14 37148962 T C 0.000133354 Hypertension (early onset hypertension) SLC25A21 UTR-3 22479346 rs17105095 chr14 37183614 A G 7.38E-04 Alzheimer's disease SLC25A21 intron 17998437 rs17105098 chr14 37183794 C A 3.03E-04 HIV-1 viral setpoint SLC25A21 intron 17641165 rs7160534 chr14 37192475 T A 5.17E-05 Type 2 diabetes SLC25A21 intron 17463246 rs7160534 chr14 37192475 T A 6.02E-04 Multiple complex diseases SLC25A21 intron 17554300 rs17105125 chr14 37194092 T C 8.11E-04 Alzheimer's disease SLC25A21 intron 17998437 rs17105164 chr14 37204382 A C 1.19E-04 Alzheimer's disease SLC25A21 intron 17998437 rs7152895 chr14 37207139 C T 3.86E-04 Type 2 diabetes SLC25A21 intron 17463246 rs8006116 chr14 37209071 A G 2.76E-04 Type 2 diabetes SLC25A21 intron 17463246 rs1033594 chr14 37211566 T C 0.000031 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SLC25A21 intron 22628534 rs1160547 chr14 37216354 A G 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SLC25A21 intron 22628534 rs10143550 chr14 37218627 C T 4.57E-04 Tourette syndrome SLC25A21 intron 22889924 rs17105233 chr14 37233892 T G 1.03E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs17105237 chr14 37234138 G C 9.79E-04 Type 2 diabetes SLC25A21 intron 17463246 rs17105249 chr14 37235140 C G 1.82E-04 Alzheimer's disease SLC25A21 intron 17998437 rs730643 chr14 37239147 G A 6.21E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs1806899 chr14 37239188 G A 6.21E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs2415363 chr14 37239854 A C 6.81E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs912814 chr14 37242061 A C 9.85E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs8004848 chr14 37244372 C A 7.88E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs8022501 chr14 37247476 G A 6.39E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs8022435 chr14 37247649 C T 6.00E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs17105308 chr14 37255137 T C 6.89E-05 Type 2 diabetes SLC25A21 intron 17463246 rs17105308 chr14 37255137 T C 1.72E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs17105311 chr14 37255159 A G 7.72E-05 Type 2 diabetes SLC25A21 intron 17463246 rs17105311 chr14 37255159 A G 1.72E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs17105314 chr14 37257671 C T 1.72E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs41434649 chr14 37258674 C T 1.27E-04 Type 2 diabetes SLC25A21 intron 17463246 rs17105347 chr14 37265451 T C 1.02E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs1325528 chr14 37268060 A G 1.21E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs17105367 chr14 37268610 A G 1.45E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs1594268 chr14 37269653 T C 5.36E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs1749930 chr14 37269816 G A 5.30E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs1408965 chr14 37270634 G A 4.89E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs8008462 chr14 37271811 A T 4.33E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs1429849 chr14 37273004 T A 8.74E-05 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs1367035 chr14 37273635 G A 1.27E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs7154494 chr14 37276436 G A 6.23E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs17105394 chr14 37276864 T C 1.28E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs1749935 chr14 37278147 C T 7.36E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs7144852 chr14 37278322 G A 6.03E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs1325541 chr14 37278347 G T 6.20E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs1652275 chr14 37278813 G C 5.91E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs1631933 chr14 37278964 A G 5.94E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs1749936 chr14 37279329 T G 5.69E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs1628408 chr14 37279425 A T 6.16E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs848086 chr14 37279716 G A 9.87E-04 Orofacial clefts SLC25A21 intron 22419666 rs848080 chr14 37285356 T C 2.00E-04 Cognitive impairment induced by topiramate SLC25A21 intron 22091778 rs1627412 chr14 37286729 G T 1.00E-04 Cognitive impairment induced by topiramate SLC25A21 intron 22091778 rs1999232 chr14 37288393 C T 1.37E-04 Smoking initiation SLC25A21 intron 24665060 rs848075 chr14 37290124 A G 4.92E-04 Smoking initiation SLC25A21 intron 24665060 rs17105421 chr14 37291105 T C 4.00E-04 Smoking initiation SLC25A21 intron 24665060 rs712344 chr14 37291650 G T 9.67E-06 Multiple complex diseases SLC25A21 intron 17554300 rs712346 chr14 37292135 A G 8.15E-04 Type 2 diabetes SLC25A21 intron 17463246 rs13353117 chr14 37292399 G A 1.32E-04 Smoking initiation SLC25A21 intron 24665060 rs712349 chr14 37293146 A G 1.86E-04 Type 2 diabetes SLC25A21 intron 17463246 rs712350 chr14 37293168 T C 2.09E-04 Smoking initiation SLC25A21 intron 24665060 rs712352 chr14 37293484 C T 8.72E-04 Type 2 diabetes SLC25A21 intron 17463246 rs10139981 chr14 37305207 A G 7.47E-04 Smoking initiation SLC25A21 intron 24665060 rs17105470 chr14 37305394 A C 4.46E-04 Smoking initiation SLC25A21 intron 24665060 rs1749943 chr14 37306091 G A 1.07E-05 Smoking initiation SLC25A21 intron 24665060 rs848053 chr14 37307940 A G 2.00E-04 Cognitive impairment induced by topiramate SLC25A21 intron 22091778 rs419693 chr14 37326037 A G 5.48E-04 Smoking initiation SLC25A21 intron 24665060 rs7144374 chr14 37327512 C A 4.65E-04 Coronary heart disease SLC25A21 intron 21971053 rs17105565 chr14 37335558 A G 9.21E-04 Multiple complex diseases SLC25A21 intron 17554300 rs995943 chr14 37350812 C A 1.44E-05 Multiple complex diseases SLC25A21 intron 17554300 rs17177725 chr14 37357412 T C 3.11E-04 Suicide attempts in bipolar disorder SLC25A21 intron 21423239 rs848694 chr14 37371724 C T 4.60E-05 Breast cancer (menopausal hormone therapy interaction) SLC25A21 intron 24080446 rs1367032 chr14 37383879 A G 6.34E-05 Major depressive disorder SLC25A21 intron 19107115 rs17105696 chr14 37387827 A G 7.85E-06 Major depressive disorder SLC25A21 intron 19107115 rs9635194 chr14 37389830 C T 3.13E-05 Major depressive disorder SLC25A21 intron 19107115 rs861928 chr14 37391570 A G 1.24E-05 Major depressive disorder SLC25A21 intron 19107115 rs7150167 chr14 37391907 G A 8.28E-06 Major depressive disorder SLC25A21 intron 19107115 rs7148646 chr14 37407036 A G 1.20E-05 Breast cancer (menopausal hormone therapy interaction) SLC25A21 intron 24080446 rs7145237 chr14 37415923 A G 8.28E-06 Major depressive disorder SLC25A21 intron 19107115 rs1429842 chr14 37417440 G A 5.40E-04 Longevity SLC25A21 intron 22279548 rs10137084 chr14 37429530 G A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SLC25A21 intron 22628534 rs17177982 chr14 37435295 G A 9.43E-05 Serum metabolites SLC25A21 intron 19043545 rs17177982 chr14 37435295 G A 9.94E-04 Response to taxane treatment (placlitaxel) SLC25A21 intron 23006423 rs8003131 chr14 37444794 T C 5.22E-04 Response to taxane treatment (placlitaxel) SLC25A21 intron 23006423 rs10483481 chr14 37445831 G C 4.92E-04 Response to taxane treatment (placlitaxel) SLC25A21 intron 23006423 rs9322971 chr14 37446359 A G 3.83E-04 Response to taxane treatment (placlitaxel) SLC25A21 intron 23006423 rs911008 chr14 37462847 C T 0.000003 Amygdala reactivity SLC25A21 intron 22856363 rs17105971 chr14 37490809 G A 1.22E-05 Multiple complex diseases SLC25A21 intron 17554300 rs10483485 chr14 37524505 G A 9.85E-04 Multiple complex diseases SLC25A21 intron 17554300 rs2144319 chr14 37558234 G A 6.60E-09 LDL cholesterol SLC25A21 intron 23063622 rs8014186 chr14 37564413 T C 7.03E-05 Asthma SLC25A21 intron pha003128 rs10483487 chr14 37573218 G A 8.55E-04 Multiple complex diseases SLC25A21 intron 17554300 rs7145475 chr14 37667503 C T 2.74E-05 Self-reported allergy MIPOL1 intron 23817569 rs4900700 chr14 37671059 A G 8.38E-05 Brain derived neurotrophic factor levels,in serum MIPOL1 intron 22047184 rs7143872 chr14 37691622 G T 9.05E-05 Basophils MIPOL1 intron pha003087 rs17554224 chr14 37714662 C T 2.76E-05 Self-reported allergy MIPOL1 intron 23817569 rs9989229 chr14 37809060 G C 2.05E-05 Self-reported allergy MIPOL1 intron 23817569 rs9989228 chr14 37809253 A C 4.04E-18 Multiple complex diseases MIPOL1 intron 17554300 rs12896336 chr14 37854785 A T 2.73E-05 Self-reported allergy MIPOL1 intron 23817569 rs10129645 chr14 37858832 A C 5.31E-05 Autism spectrum disorders (language delay) MIPOL1 intron 21519539 rs2006729 chr14 37867285 G T 2.56E-05 Self-reported allergy MIPOL1 intron 23817569 rs1955949 chr14 37890433 T C 3.13E-05 Self-reported allergy MIPOL1 intron 23817569 rs6571812 chr14 37894402 T C 2.61E-05 Self-reported allergy MIPOL1 intron 23817569 rs12894536 chr14 37894467 C T 2.61E-05 Self-reported allergy MIPOL1 intron 23817569 rs17768249 chr14 37898410 A G 2.38E-05 Self-reported allergy MIPOL1 intron 23817569 rs7145671 chr14 37901139 A T 2.24E-05 Self-reported allergy MIPOL1 intron 23817569 rs8008655 chr14 37913720 T G 1.48E-05 Self-reported allergy MIPOL1 intron 23817569 rs12896760 chr14 37919771 G A 1.53E-05 Self-reported allergy MIPOL1 intron 23817569 rs17179078 chr14 37923454 G A 1.60E-05 Self-reported allergy MIPOL1 intron 23817569 rs35889560 chr14 37923454 G GA 1.60E-05 Self-reported allergy MIPOL1 intron 23817569 rs1955943 chr14 37925120 A C 3.80E-05 Self-reported allergy MIPOL1 intron 23817569 rs7161366 chr14 37930016 G C 1.62E-05 Self-reported allergy MIPOL1 intron 23817569 rs1955934 chr14 37936489 A G 1.56E-05 Self-reported allergy MIPOL1 intron 23817569 rs7148547 chr14 37940459 T A 3.00E-05 Self-reported allergy MIPOL1 intron 23817569 rs1169875 chr14 37944290 G C 4.00E-05 Self-reported allergy MIPOL1 intron 23817569 rs1169873 chr14 37947289 G A 3.70E-05 Self-reported allergy MIPOL1 intron 23817569 rs2146133 chr14 37961201 T C 3.35E-05 Self-reported allergy MIPOL1 intron 23817569 rs7153426 chr14 37962952 G A 3.03E-05 Self-reported allergy MIPOL1 intron 23817569 rs1956433 chr14 37964263 C A 4.06E-05 Self-reported allergy MIPOL1 intron 23817569 rs1011818 chr14 37967865 A T 4.16E-05 Self-reported allergy MIPOL1 intron 23817569 rs10143976 chr14 37968636 G A 3.29E-05 Self-reported allergy MIPOL1 intron 23817569 rs4900918 chr14 37970692 C T 4.23E-05 Self-reported allergy MIPOL1 intron 23817569 rs1989084 chr14 37971257 T C 3.61E-05 Self-reported allergy MIPOL1 intron 23817569 rs1956435 chr14 37971443 G A 3.95E-05 Self-reported allergy MIPOL1 intron 23817569 rs1155456 chr14 37976663 G C 3.92E-05 Self-reported allergy MIPOL1 intron 23817569 rs1814005 chr14 37976976 G A 4.37E-05 Self-reported allergy MIPOL1 intron 23817569 rs7146299 chr14 37980622 G A 4.09E-05 Self-reported allergy MIPOL1 intron 23817569 rs1956437 chr14 37985131 G T 1.10E-05 Self-reported allergy MIPOL1 intron 23817569 rs11623989 chr14 37985647 T C 1.06E-05 Self-reported allergy MIPOL1 intron 23817569 rs7161326 chr14 37986676 C T 1.06E-05 Self-reported allergy MIPOL1 intron 23817569 rs4900945 chr14 37999098 T G 3.36E-05 Self-reported allergy MIPOL1 intron 23817569 rs12881012 chr14 37999686 A T 3.45E-05 Self-reported allergy MIPOL1 intron 23817569 rs1473715 chr14 38000905 T C 3.45E-05 Self-reported allergy MIPOL1 intron 23817569 rs10133438 chr14 38005688 G T 3.07E-05 Self-reported allergy MIPOL1 intron 23817569 rs1547009 chr14 38010727 C T 6.66E-06 Self-reported allergy MIPOL1 intron 23817569 rs1159151 chr14 38012152 C T 9.99E-06 Self-reported allergy MIPOL1 intron 23817569 rs7153867 chr14 38027633 T C 4.94E-06 Self-reported allergy / / 23817569 rs1956442 chr14 38029471 A G 4.69E-06 Self-reported allergy / / 23817569 rs1956443 chr14 38030512 G A 5.00E-06 Self-reported allergy / / 23817569 rs11156962 chr14 38032858 C T 5.08E-06 Self-reported allergy / / 23817569 rs996916 chr14 38036990 G T 8.55E-06 Self-reported allergy / / 23817569 rs981794 chr14 38040755 A G 0.0000964 Nicotine dependence (smoking) / / 22377092 rs11846416 chr14 38041895 G T 1.08E-05 Self-reported allergy / / 23817569 rs9322981 chr14 38043991 T C 1.78E-05 Self-reported allergy / / 23817569 rs8016138 chr14 38045262 C T 5.69E-06 Self-reported allergy / / 23817569 rs59290731 chr14 38046611 C A 7.33E-06 Periodontitis (CDC/AAP) / / 24024966 rs11621659 chr14 38047443 G A 0.0000759 Nicotine dependence (smoking) / / 22377092 rs7144658 chr14 38061742 C T 3.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FOXA1 missense 20877124 rs72674251 chr14 38062732 T C 8.23E-06 Periodontitis (CDC/AAP) FOXA1 intron 24024966 rs76470659 chr14 38065020 G A 7.81E-06 Periodontitis (CDC/AAP) / / 24024966 rs2181180 chr14 38066548 C T 7.53E-06 Periodontitis (CDC/AAP) / / 24024966 rs12587630 chr14 38066575 A G 7.00E-06 Periodontitis (CDC/AAP) / / 24024966 rs34249416 chr14 38067315 T A 7.47E-06 Periodontitis (CDC/AAP) / / 24024966 rs968350 chr14 38070974 G A 7.64E-04 Smoking initiation / / 24665060 rs1008236 chr14 38074239 C A 7.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100652767 intron 20877124 rs11627844 chr14 38075286 A G 6.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100652767 intron 20877124 rs11627844 chr14 38075286 A G 8.22E-06 Self-reported allergy LOC100652767 intron 23817569 rs1998359 chr14 38077148 C G 5.00E-08 Self-reported allergy LOC100652767 intron 23817569 rs12147245 chr14 38085277 T A 0.000000021 Chronic obstructive pulmonary disease (moderate to severe) LOC100652767 intron 22986903 rs12147245 chr14 38085277 T A 8.70E-06 Self-reported allergy LOC100652767 intron 23817569 rs17179288 chr14 38088359 T C 1.60E-07 Self-reported allergy LOC100652767 intron 23817569 rs177852 chr14 38111870 C T 0.000000063 Chronic obstructive pulmonary disease (moderate to severe) / / 22986903 rs177852 chr14 38111870 C T 8.82E-06 Self-reported allergy / / 23817569 rs177857 chr14 38116255 C T 6.79E-08 Self-reported allergy / / 23817569 rs177858 chr14 38116311 T G 0.00000099 Chronic obstructive pulmonary disease (moderate to severe) / / 22986903 rs177858 chr14 38116311 T G 1.26E-07 Self-reported allergy / / 23817569 rs177859 chr14 38116960 G A 0.00000099 Chronic obstructive pulmonary disease (moderate to severe) / / 22986903 rs177859 chr14 38116960 G A 5.63E-06 Self-reported allergy / / 23817569 rs177861 chr14 38118762 G C 6.33E-06 Self-reported allergy / / 23817569 rs177863 chr14 38119850 C A 1.18E-05 Self-reported allergy / / 23817569 rs177867 chr14 38123128 T A 1.08E-05 Self-reported allergy / / 23817569 rs9671863 chr14 38127875 A G 4.96E-08 Self-reported allergy / / 23817569 rs11848078 chr14 38138176 A G 7.24E-06 Self-reported allergy / / 23817569 rs11849126 chr14 38144592 G A 7.74E-06 Self-reported allergy / / 23817569 rs17106954 chr14 38170092 A G 4.46E-06 Self-reported allergy TTC6 intron 23817569 rs17179330 chr14 38171159 C A 1.33E-07 Self-reported allergy TTC6 intron 23817569 rs8022736 chr14 38180104 A G 2.85E-05 Self-reported allergy TTC6 intron 23817569 rs1022804 chr14 38180813 G A 3.20E-07 Self-reported allergy TTC6 intron 23817569 rs10483492 chr14 38182281 C G 3.83E-07 Self-reported allergy TTC6 intron 23817569 rs4901140 chr14 38185661 A G 1.90E-05 Crohn's disease (time to surgery) TTC6 intron 23665963 rs4901140 chr14 38185661 A G 1.09E-04 Heart Failure TTC6 intron pha002884 rs1535540 chr14 38191651 C T 3.75E-05 Self-reported allergy TTC6 intron 23817569 rs1014991 chr14 38203720 G C 3.69E-04 Smoking cessation TTC6 intron 24665060 rs12431986 chr14 38214515 T G 2.66E-04 Smoking cessation TTC6 intron 24665060 rs6571820 chr14 38221992 A G 1.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TTC6 intron 20877124 rs6571820 chr14 38221992 A G 8.99E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TTC6 intron 20877124 rs4898760 chr14 38261108 C T 6.96E-04 Suicide attempts in bipolar disorder TTC6 intron 21423239 rs11156970 chr14 38271650 A G 7.68E-04 Multiple complex diseases TTC6 intron 17554300 rs10483493 chr14 38273361 T G 9.85E-04 Suicide attempts in bipolar disorder TTC6 intron 21423239 rs10483493 chr14 38273361 T G 5.96E-05 Longevity TTC6 intron 22279548 rs12896790 chr14 38273922 T G 3.63E-07 Longevity,exceptional TTC6 missense 20595579 rs12896790 chr14 38273922 T G 0.0000359 Gains in maximal O2 uptake response TTC6 missense 21183627 rs4901284 chr14 38277999 C T 6.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs4901285 chr14 38278611 T C 5.27E-04 Suicide attempts in bipolar disorder LOC100652860 intron 21423239 rs1951642 chr14 38279008 C T 4.09E-04 Suicide attempts in bipolar disorder LOC100652860 intron 21423239 rs8018889 chr14 38283591 C T 0.0000525 Gains in maximal O2 uptake response LOC100652860 intron 21183627 rs4898763 chr14 38289012 G A 7.67E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100652860 intron 20877124 rs4898763 chr14 38289012 G A 4.43E-04 Myopia (pathological) LOC100652860 intron 21095009 rs4898763 chr14 38289012 G A 8.39E-04 Response to cytidine analogues (gemcitabine) LOC100652860 intron 24483146 rs17107176 chr14 38296497 A T 4.35E-04 Multiple complex diseases LOC100652860 missense 17554300 rs7155567 chr14 38304280 G A 3.12E-04 Coronary heart disease LOC100652860 intron 21971053 rs1952790 chr14 38342676 G A 1.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1952790 chr14 38342676 G A 3.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10134624 chr14 38437611 C T 4.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17554993 chr14 38438256 T C 1.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17554993 chr14 38438256 T C 4.72E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10132279 chr14 38533095 T C 1.13E-04 Attention deficit hyperactivity disorder / / 23728934 rs1954025 chr14 38555642 T C 9.74E-05 Gout / / pha001405 rs869025 chr14 38558925 C T 0.000424496 Hypertension (early onset hypertension) / / 22479346 rs17557166 chr14 38591024 T C 4.08E-06 Hemoglobin / / pha003096 rs17557166 chr14 38591024 T C 3.45E-05 Hematocrit / / pha003097 rs2803902 chr14 38646832 C T 8.31E-04 Body mass index / / 21701565 rs10498338 chr14 38666514 G A 5.32E-04 Body mass index / / 21701565 rs2812094 chr14 38666890 T C 3.62E-05 Coronary heart disease / / pha003032 rs11622412 chr14 38683261 C T 5.00E-08 Metabolite levels (5-HIAA/ MHPG Ratio) / / 23319000 rs11628551 chr14 38693936 G T 9.37E-04 Tourette syndrome / / 22889924 rs2249395 chr14 38720725 C T 1.16E-05 Bipolar disorder / / 21771265 rs11626142 chr14 38776557 C T 7.44E-05 Body Fat Distribution / / pha003017 rs17107815 chr14 38784390 A C 8.36E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1952566 chr14 38787583 G A 1.50E-04 Alzheimer's disease / / 17998437 rs1952566 chr14 38787583 G A 1.68E-04 Heart Failure / / pha002884 rs1952568 chr14 38787654 G C 1.05E-04 Alzheimer's disease / / 17998437 rs10133904 chr14 38838622 G A 2.00E-06 Urinary metabolites / / 21572414 rs1168551 chr14 38859403 G A 3.68E-04 Multiple complex diseases / / 17554300 rs1184875 chr14 38860378 A C 7.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs34310550 chr14 38912395 C T 9.00E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs10498341 chr14 38926032 A C 9.95E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs4128733 chr14 38926855 A C 8.38E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs2415482 chr14 38958967 A G 3.49E-04 Age-related macular degeneration / / 22125219 rs8003056 chr14 38991928 T C 4.12E-04 Longevity / / 22279548 rs10151543 chr14 38998524 T G 8.15E-05 Aortic root size / / 21223598 rs10498342 chr14 39001036 C T 7.66E-04 Longevity / / 22279548 rs17108159 chr14 39017395 C A 2.00E-04 Coronary spasm / / 18075462 rs17108159 chr14 39017395 C A 4.09E-05 Serum metabolites / / 19043545 rs11851568 chr14 39019660 A G 8.10E-05 Coronary spasm / / 18075462 rs11847817 chr14 39019800 T C 3.28E-06 Colorectal cancer / / 21242260 rs10498345 chr14 39020505 T A 9.00E-07 Coronary spasm / / 18075462 rs10498346 chr14 39024995 A T 3.10E-06 Coronary spasm / / 18075462 rs10131272 chr14 39038281 A G 7.70E-05 Smoking quantity / / 24665060 rs2415493 chr14 39053121 A G 1.99E-05 Colorectal cancer / / 21242260 rs10135197 chr14 39053660 T C 6.10E-05 Type 2 diabetes / / 17463248 rs8014198 chr14 39062778 G A 7.00E-05 Type 2 diabetes / / 17463248 rs9788490 chr14 39062938 C G 5.50E-05 Type 2 diabetes / / 17463248 rs11849174 chr14 39077398 G A 5.40E-05 Type 2 diabetes / / 17463248 rs10145493 chr14 39081388 G A 5.60E-05 Type 2 diabetes / / 17463248 rs12435438 chr14 39084444 T C 1.70E-05 Type 2 diabetes / / 17463248 rs1349241 chr14 39085438 T C 1.80E-05 Type 2 diabetes / / 17463248 rs10141957 chr14 39087269 G A 1.10E-05 Type 2 diabetes / / 17463248 rs2122331 chr14 39093607 G C 5.20E-05 Type 2 diabetes / / 17463248 rs8010489 chr14 39093867 G A 4.50E-05 Type 2 diabetes / / 17463248 rs1449720 chr14 39095567 A G 6.80E-05 Type 2 diabetes / / 17463248 rs9630378 chr14 39102852 C T 4.50E-05 Type 2 diabetes / / 17463248 rs10138342 chr14 39116357 A C 4.00E-05 Type 2 diabetes / / 17463248 rs7153699 chr14 39119056 C T 4.40E-05 Type 2 diabetes / / 17463248 rs6571865 chr14 39121670 T C 4.10E-05 Type 2 diabetes / / 17463248 rs7141696 chr14 39122375 T C 4.00E-05 Type 2 diabetes / / 17463248 rs8006474 chr14 39126497 G C 3.10E-05 Type 2 diabetes / / 17463248 rs12887285 chr14 39127886 A G 2.33E-07 Platelet counts / / pha003100 rs10141939 chr14 39138477 T G 9.20E-05 HIV-1 control / / 20041166 rs2415498 chr14 39140536 C T 1.77E-07 Platelet counts / / pha003100 rs2122333 chr14 39163368 C T 5.30E-06 Type 2 diabetes / / 17463248 rs1449725 chr14 39176821 C T 4.90E-06 Type 2 diabetes / / 17463248 rs6571869 chr14 39178459 G T 1.47E-04 Schizophrenia / / 21674006 rs2899883 chr14 39185853 G T 7.00E-06 Type 2 diabetes / / 17463248 rs10498347 chr14 39191388 T G 5.30E-04 Type 2 diabetes / / 17463246 rs1470655 chr14 39192032 A G 1.22E-04 Schizophrenia / / 21674006 rs8022685 chr14 39201336 C A 4.10E-05 HIV-1 control / / 20041166 rs2899884 chr14 39202690 A G 3.13E-05 Platelet counts / / pha003100 rs41351046 chr14 39207290 T C 4.77E-05 Multiple complex diseases / / 17554300 rs12880269 chr14 39210739 T G 3.60E-05 HIV-1 control / / 20041166 rs12888769 chr14 39219051 A G 2.50E-05 HIV-1 control LOC283547 intron 20041166 rs12893313 chr14 39225303 A C,G,T 2.50E-05 HIV-1 control LOC283547 intron 20041166 rs12893659 chr14 39255581 A G 2.50E-05 HIV-1 control LOC283547 intron 20041166 rs11850521 chr14 39279490 G A 3.40E-05 HIV-1 control LOC283547 intron 20041166 rs12887714 chr14 39294566 T C 8.30E-05 HIV-1 control LOC283547 intron 20041166 rs17108400 chr14 39311022 G A 2.39E-05 Multiple complex diseases LOC283547 intron 17554300 rs17108400 chr14 39311022 G A 9.69E-04 Alzheimer's disease LOC283547 intron 17998437 rs17108400 chr14 39311022 G A 4.63E-05 Alzheimer's disease LOC283547 intron pha002879 rs8008452 chr14 39336152 A G 2.87E-05 Socioeconomic Factors LOC283547 intron pha003066 rs6571877 chr14 39340700 A G 2.27E-04 Response to cholinesterase inhibitors in Alzheimer's disease LOC283547 intron 23374588 rs10483546 chr14 39341845 C A,G,T 9.61E-06 Systemic lupus erythematosus LOC283547 intron pha002867 rs12432214 chr14 39350566 A G 5.97E-05 Multiple complex diseases LOC283547 intron 17554300 rs12432214 chr14 39350566 A G 5.23E-04 Alzheimer's disease LOC283547 intron 17998437 rs12432214 chr14 39350566 A G 1.18E-04 Alzheimer's disease LOC283547 intron pha002879 rs979002 chr14 39369538 C T 1.93E-05 Response to Vitamin E supplementation LOC283547 intron 22437554 rs17108543 chr14 39371789 G C 1.20E-04 Acute lymphoblastic leukemia (childhood) LOC283547 intron 22076464 rs1951226 chr14 39374796 C A 8.29E-05 Platelet counts LOC283547 intron pha003100 rs1957064 chr14 39379670 A G 6.44E-05 Coronary restenosis LOC283547 intron 21878436 rs4902240 chr14 39398046 T G 6.68E-05 Coronary restenosis / / 21878436 rs1007415 chr14 39399093 T C 2.31E-05 Platelet counts / / pha003100 rs983694 chr14 39413191 A G 1.30E-05 Urinary metabolites / / 21572414 rs1015532 chr14 39425673 A C 9.87E-04 Alzheimer's disease / / 17998437 rs12885731 chr14 39433803 C T 6.74E-05 Platelet counts / / pha003100 rs10150709 chr14 39440106 T C 1.17E-05 Intracerebral hemorrhage / / 24656865 rs1955918 chr14 39440532 A T 5.83E-04 Type 2 diabetes / / 17463246 rs10137988 chr14 39452827 C T 3.75E-04 Type 2 diabetes / / 17463246 rs2415523 chr14 39472901 C T 2.60E-05 Urinary metabolites / / 21572414 rs2038358 chr14 39492645 T C 1.56E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7157388 chr14 39504996 A G 4.28E-04 Type 2 diabetes SEC23A intron 17463246 rs117064050 chr14 39505997 G A 2.97E-05 Epilepsy (remission after treatment) SEC23A intron 23962720 rs139047393 chr14 39587798 A T 0.0006 Breast cancer GEMIN2 missense 23555315 rs8011855 chr14 39604035 A G 1.54E-13 Multiple complex diseases GEMIN2 intron 17554300 rs2038359 chr14 39630053 T C 6.27E-05 Platelet counts TRAPPC6B intron pha003100 rs1998193 chr14 39690756 T G 1.15E-05 Asthma / / pha003128 rs34843498 chr14 39691529 T C 5.40E-05 Urinary metabolites / / 21572414 rs9322996 chr14 39693018 T G 5.82E-05 Body Mass Index / / pha003015 rs10147286 chr14 39696065 A G 2.04E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7140766 chr14 39706741 T G 2.76E-05 Platelet counts MIA2 intron pha003100 rs7154632 chr14 39710813 T C 3.55E-05 Platelet counts MIA2 intron pha003100 rs11845046 chr14 39716201 A G 1.93E-04 Response to statin treatment (atorvastatin),change in cholesterol levels MIA2 missense 20031582 rs10134365 chr14 39722023 G C 2.50E-05 Chronic obstructive pulmonary disease MIA2 missense 19300482 rs10134365 chr14 39722023 G C 2.50E-05 Response to statin treatment (atorvastatin),change in cholesterol levels MIA2 missense 20031582 rs12882375 chr14 39816781 C T 2.20E-05 Urinary metabolites CTAGE5 intron 21572414 rs8006182 chr14 39837040 T C 9.88E-05 Platelet counts / / pha003100 rs8019328 chr14 39890545 T G 3.23E-05 Squamous cell carcinoma FBXO33 intron 23341777 rs17109219 chr14 39894876 G A 1.00E-04 Cognitive impairment induced by topiramate FBXO33 intron 22091778 rs7146753 chr14 39908172 C T 2.27E-05 Cognitive impairment induced by topiramate / / 22091778 rs2057137 chr14 39943541 A G 8.02E-05 Type 2 diabetes / / 17463246 rs17109300 chr14 39950358 G A 8.97E-05 Type 2 diabetes / / 17463246 rs17696574 chr14 39967531 G A 1.86E-05 Platelet counts / / pha003100 rs10140059 chr14 39979753 A G 2.36E-04 Obesity (extreme) / / 21935397 rs2038279 chr14 39982427 T A 8.62E-04 Obesity (extreme) / / 21935397 rs1950339 chr14 39983829 T G 8.81E-04 Obesity (extreme) / / 21935397 rs11624961 chr14 39998458 T C 8.56E-04 Obesity (extreme) / / 21935397 rs11623451 chr14 40005974 C T 8.69E-04 Obesity (extreme) / / 21935397 rs8017099 chr14 40006659 C T 5.78E-04 Obesity (extreme) / / 21935397 rs1950321 chr14 40007184 C G 4.43E-06 Diabetic nephropathy / / 21150874 rs1950321 chr14 40007184 C G 3.31E-04 Type 2 diabetes / / 22238593 rs1955705 chr14 40012452 T C 6.57E-04 Obesity (extreme) / / 21935397 rs4902768 chr14 40016692 T C 8.63E-05 Obesity (extreme) / / 21935397 rs10134241 chr14 40022963 A G 1.96E-04 Obesity (extreme) / / 21935397 rs10483536 chr14 40026898 A G 1.69E-04 Obesity (extreme) / / 21935397 rs4902773 chr14 40031988 G A 1.80E-04 Obesity (extreme) / / 21935397 rs1955711 chr14 40033189 C T 1.90E-04 Obesity (extreme) / / 21935397 rs3065119 chr14 40033933 C CTTAT 4.00E-04 Aortic root size / / 21223598 rs397710670 chr14 40033933 C CTTAT 4.00E-04 Aortic root size / / 21223598 rs1014896 chr14 40037233 T C 6.58E-05 Obesity (extreme) / / 21935397 rs12881979 chr14 40038038 C T 1.77E-04 Obesity (extreme) / / 21935397 rs175677 chr14 40049695 G A 1.74E-04 Obesity (extreme) / / 21935397 rs175678 chr14 40052519 A G 6.08E-05 Obesity (extreme) / / 21935397 rs175686 chr14 40060688 G C 8.45E-05 Obesity (extreme) / / 21935397 rs6571945 chr14 40067248 A G 5.98E-05 Obesity (extreme) / / 21935397 rs1010747 chr14 40095857 T A 1.10E-05 Urinary metabolites / / 21572414 rs744511 chr14 40096985 A G 2.10E-05 Biomarkers / / 17903293 rs1956154 chr14 40117812 G T 7.13E-04 Heart Failure / / pha002884 rs12437332 chr14 40123222 C T 4.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1956156 chr14 40137383 G T 3.70E-04 Alzheimer's disease / / 22005930 rs1956157 chr14 40137400 T G 2.76E-04 Hemoglobin concentration / / 20534544 rs10142887 chr14 40145013 G A 4.12E-04 Alzheimer's disease / / 22005930 rs11157085 chr14 40153281 T C 5.57E-04 Alzheimer's disease / / 22005930 rs10141833 chr14 40157336 C T 6.32E-04 Alzheimer's disease / / 22005930 rs10137253 chr14 40160967 C A 5.05E-04 Alzheimer's disease / / 22005930 rs10138327 chr14 40161946 G A 5.28E-04 Alzheimer's disease / / 22005930 rs8017124 chr14 40173886 G T 3.04E-04 Alzheimer's disease / / 22005930 rs2749494 chr14 40177306 A G 4.11E-04 Hemoglobin concentration / / 20534544 rs2749496 chr14 40178980 T C 4.82E-04 Type 2 diabetes / / 17463246 rs2749497 chr14 40179318 C T 7.36E-04 Type 2 diabetes / / 17463246 rs1956146 chr14 40180117 G A 3.43E-04 Alzheimer's disease / / 22005930 rs2224233 chr14 40181773 T G 3.61E-04 Alzheimer's disease / / 22005930 rs2144823 chr14 40186964 A G 9.74E-06 Heart Failure / / pha002884 rs2781333 chr14 40190854 G C 7.84E-05 Alzheimer's disease / / 22005930 rs2781333 chr14 40190854 G C 2.09E-05 Personality dimensions / / 22628180 rs12435520 chr14 40191412 G T 5.52E-04 Smoking initiation / / 24665060 rs12896290 chr14 40208975 G C 6.00E-06 Urinary metabolites / / 21572414 rs8020871 chr14 40223352 C T 0.0000368 Panic disorder / / 23149450 rs8020871 chr14 40223352 C T 3.68E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs17109786 chr14 40233121 T A 2.08E-22 Narcolepsy / / 19629137 rs17109789 chr14 40233985 A T 9.91E-04 Multiple complex diseases / / 17554300 rs11626685 chr14 40251879 C G 4.48E-04 Obesity (extreme) / / 21935397 rs1001900 chr14 40258812 C G 6.37E-04 Multiple complex diseases / / 17554300 rs4313723 chr14 40296775 C T 2.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1953192 chr14 40297539 G T 3.26E-04 Hemoglobin concentration / / 20534544 rs8012860 chr14 40401266 C T 7.00E-06 Prostate cancer / / 21743057 rs1018545 chr14 40401988 A G 3.84E-05 Waist Circumference / / pha003023 rs10134315 chr14 40408290 A G 7.00E-06 Prostate cancer / / 21743057 rs10149309 chr14 40423929 A C 2.00E-06 Prostate cancer / / 21743057 rs12050352 chr14 40429562 A G 2.00E-06 Prostate cancer / / 21743057 rs10138216 chr14 40439847 G C 1.00E-05 Prostate cancer / / 21743057 rs417245 chr14 40447700 T C 1.00E-06 Prostate cancer / / 21743057 rs395080 chr14 40452133 C T 1.00E-06 Prostate cancer / / 21743057 rs365586 chr14 40453714 G A 1.00E-06 Prostate cancer / / 21743057 rs438079 chr14 40460206 T A,C,G 4.00E-06 Prostate cancer / / 21743057 rs380886 chr14 40467749 G A 4.00E-06 Prostate cancer / / 21743057 rs4903274 chr14 40524965 G A 1.00E-04 Prostate cancer / / 21743057 rs11157095 chr14 40534612 G T 4.00E-05 Prostate cancer / / 21743057 rs996183 chr14 40541480 G A 4.00E-05 Prostate cancer / / 21743057 rs4134425 chr14 40545454 T C 6.60E-04 Lipid traits / / 17903299 rs4134425 chr14 40545454 T C 4.00E-05 Prostate cancer / / 21743057 rs8011680 chr14 40547273 G C 4.00E-05 Prostate cancer / / 21743057 rs11157097 chr14 40548650 C T 4.00E-05 Prostate cancer / / 21743057 rs12883545 chr14 40559143 A G 4.00E-05 Prostate cancer / / 21743057 rs12886023 chr14 40559775 T C 4.00E-05 Prostate cancer / / 21743057 rs2208197 chr14 40562197 C T 4.00E-05 Prostate cancer / / 21743057 rs17196 chr14 40566655 G C 4.00E-05 Prostate cancer / / 21743057 rs1018511 chr14 40580535 T C 9.00E-05 Prostate cancer / / 21743057 rs4899568 chr14 40581247 C T 4.39E-06 Serum metabolites / / 19043545 rs1116864 chr14 40585147 T C 1.37E-04 Insulin resistance / / 21901158 rs11625373 chr14 40586440 C A 9.00E-05 Prostate cancer / / 21743057 rs6571985 chr14 40588184 A C 9.00E-05 Prostate cancer / / 21743057 rs7146621 chr14 40601252 G C 9.00E-05 Prostate cancer / / 21743057 rs11157107 chr14 40602103 A G 8.00E-05 Prostate cancer / / 21743057 rs11626582 chr14 40608324 T C 8.00E-05 Prostate cancer / / 21743057 rs17110290 chr14 40608928 T G 4.28E-07 Multiple complex diseases / / 17554300 rs11623348 chr14 40623598 T C 1.00E-04 Prostate cancer / / 21743057 rs2208195 chr14 40624311 A G 1.10E-04 Coronary Artery Disease / / 17634449 rs2208195 chr14 40624311 A G 1.66E-05 Serum metabolites / / 19043545 rs7157781 chr14 40624468 A G 8.17E-05 Serum metabolites / / 19043545 rs1955533 chr14 40639294 G T 1.00E-04 Prostate cancer / / 21743057 rs1955530 chr14 40647649 G A 8.56E-05 Serum metabolites / / 19043545 rs2144031 chr14 40647832 C A 1.00E-04 Prostate cancer / / 21743057 rs7161024 chr14 40651337 G C 1.00E-04 Prostate cancer / / 21743057 rs11157114 chr14 40651864 A C 1.00E-04 Prostate cancer / / 21743057 rs1983651 chr14 40653830 T A 1.00E-04 Prostate cancer / / 21743057 rs41505351 chr14 40657064 C A 1.20E-06 Urinary metabolites / / 21572414 rs10148725 chr14 40657254 T C 5.00E-05 Coronary Artery Disease / / 17634449 rs10148725 chr14 40657254 T C 4.83E-05 Serum metabolites / / 19043545 rs6571989 chr14 40675945 A G 1.69E-05 Common variable immunodeficiency / / 21497890 rs1950250 chr14 40754436 G A 3.84E-04 Multiple complex diseases / / 17554300 rs1955554 chr14 40756061 G A 7.97E-04 Multiple complex diseases / / 17554300 rs17110454 chr14 40771636 C A 6.66E-06 Tuberculosis / / 22306650 rs2415589 chr14 40776378 C A 2.24E-04 Smoking cessation / / 24665060 rs8012092 chr14 40781093 C T 8.87E-04 Multiple complex diseases / / 17554300 rs10141455 chr14 40813248 T C 8.56E-04 Multiple complex diseases / / 17554300 rs10141455 chr14 40813248 T C 2.62E-04 Smoking cessation / / 24665060 rs1569790 chr14 40815721 T C 2.15E-04 Smoking cessation / / 24665060 rs7148179 chr14 40832156 C T 4.15E-04 Smoking cessation / / 24665060 rs17110518 chr14 40833342 T C 2.20E-05 Insulin resistance / / 21901158 rs1958888 chr14 40863544 T C 2.97E-04 Multiple complex diseases / / 17554300 rs1952938 chr14 40864912 G A 7.42E-05 Multiple complex diseases / / 17554300 rs10142167 chr14 40880840 C A 9.08E-04 Multiple complex diseases / / 17554300 rs8011258 chr14 40909874 T C 6.84E-04 Multiple complex diseases / / 17554300 rs2415603 chr14 40912447 G A 3.27E-06 Neuroblastoma / / pha002895 rs8015594 chr14 40942142 C G 4.81E-04 Multiple complex diseases / / 17554300 rs2415621 chr14 41044527 T C 3.80E-05 Lipid traits / / 17903299 rs2415626 chr14 41081450 T G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7143930 chr14 41097687 C T 5.73E-04 Multiple complex diseases / / 17554300 rs7143930 chr14 41097687 C T 4.84E-04 Aortic root size / / 21223598 rs7143815 chr14 41097746 A C 4.09E-04 Aortic root size / / 21223598 rs8013004 chr14 41098283 T C 5.00E-04 Multiple complex diseases / / 17554300 rs7153364 chr14 41104038 G A 6.06E-04 Aortic root size / / 21223598 rs10083519 chr14 41104823 T C 2.50E-04 Aortic root size / / 21223598 rs1959260 chr14 41106600 A G 4.79E-04 Aortic root size / / 21223598 rs2050480 chr14 41107539 A G 5.84E-04 Aortic root size / / 21223598 rs12436624 chr14 41108018 C T 7.04E-04 Aortic root size / / 21223598 rs1959259 chr14 41112890 A G 0.000011 Colorectal adenoma (excluding hyperplasic) / / 23677573 rs1959259 chr14 41112890 A G 0.000011 Colorectal adenoma (including hyperplasic) / / 23677573 rs11157160 chr14 41194262 G A 3.29E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs7145103 chr14 41203092 C G 4.78E-04 Multiple complex diseases / / 17554300 rs10498358 chr14 41285612 C T 3.55E-04 Type 2 diabetes / / 17463246 rs17111164 chr14 41285921 A G 2.10E-04 Multiple complex diseases / / 17554300 rs17111166 chr14 41286285 A G 6.34E-05 Serum metabolites / / 19043545 rs10136288 chr14 41286981 G T 6.34E-05 Serum metabolites / / 19043545 rs11157173 chr14 41315524 G A 7.91E-05 Serum metabolites / / 19043545 rs1349568 chr14 41315945 A C 2.50E-04 Alcohol dependence / / 20201924 rs8019041 chr14 41322994 A C 1.70E-05 Urinary metabolites / / 21572414 rs1349124 chr14 41339753 A G 1.40E-05 Urinary metabolites / / 21572414 rs12897166 chr14 41339819 T G 8.59E-04 Alzheimer's disease / / 24755620 rs6572042 chr14 41372086 T C 1.20E-05 Urinary metabolites / / 21572414 rs1158543 chr14 41373499 G A 2.30E-05 Urinary metabolites / / 21572414 rs1987295 chr14 41382795 C T 0.000179 Breast cancer early age of onset / / 18463975 rs11848229 chr14 41394129 G A 7.75E-05 Asthma / / pha003127 rs12890528 chr14 41405093 C T 7.00E-06 Alcohol dependence / / 21956439 rs1176964 chr14 41417718 T C 1.10E-05 Urinary metabolites / / 21572414 rs1176968 chr14 41433306 G A 9.00E-06 Alcohol dependence / / 21956439 rs4899845 chr14 41435213 G A 3.50E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs1176970 chr14 41435764 G C 3.20E-04 Schizophrenia / / 20832056 rs1176970 chr14 41435764 G C 5.30E-06 Urinary metabolites / / 21572414 rs1176971 chr14 41435835 A G 1.20E-05 Urinary metabolites / / 21572414 rs1176974 chr14 41437036 G A 5.61E-05 Asthma / / pha003127 rs12889050 chr14 41440331 C T 7.00E-06 Alcohol dependence / / 21956439 rs1901475 chr14 41447041 C T 4.14E-05 Asthma / / pha003127 rs1779597 chr14 41468933 G C 1.60E-05 Urinary metabolites / / 21572414 rs1779598 chr14 41469731 G A 5.80E-06 Urinary metabolites / / 21572414 rs1779602 chr14 41472098 C T 9.50E-06 Urinary metabolites / / 21572414 rs1612454 chr14 41477679 A T 1.00E-05 Urinary metabolites / / 21572414 rs2799791 chr14 41485440 A T 1.30E-05 Urinary metabolites / / 21572414 rs2600578 chr14 41486622 G A 4.35E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2799796 chr14 41488833 C G 1.30E-05 Urinary metabolites / / 21572414 rs2799799 chr14 41492296 C T 1.40E-05 Urinary metabolites / / 21572414 rs1959934 chr14 41504619 T C 2.70E-05 Urinary metabolites / / 21572414 rs12586490 chr14 41516216 A T 8.22E-04 Type 2 diabetes / / 17463246 rs1959947 chr14 41523462 A G 7.00E-06 Hemostatic factors and hematological phenotypes / / 22443383 rs11157194 chr14 41554600 G T 1.84E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1954456 chr14 41555764 T C 5.73E-05 Alcohol and nictotine co-dependence / / 20158304 rs1954456 chr14 41555764 T C 6.38E-05 HDL cholesterol / / pha003075 rs1959909 chr14 41557328 A C 5.73E-05 Alcohol and nictotine co-dependence / / 20158304 rs1959908 chr14 41557601 T C 3.70E-06 Urinary metabolites / / 21572414 rs2185992 chr14 41565756 G A 1.05E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs11849244 chr14 41572968 C T 5.00E-05 Type 2 diabetes / / 17463246 rs17111521 chr14 41633385 C A 4.84E-07 Asthma (childhood onset) / / 23829686 rs1782167 chr14 41673714 G A 3.30E-04 Nicotine dependence / / 17158188 rs2799789 chr14 41692986 A C 1.77E-04 Nicotine dependence / / 17158188 rs1782180 chr14 41696565 C A 1.74E-04 Nicotine dependence / / 17158188 rs1782181 chr14 41696696 G A 1.57E-04 Nicotine dependence / / 17158188 rs1778379 chr14 41696954 A G 2.18E-04 Nicotine dependence / / 17158188 rs1782182 chr14 41697141 G A 5.28E-05 Nicotine dependence / / 17158188 rs1779534 chr14 41699404 T C 1.31E-04 Nicotine dependence / / 17158188 rs1779530 chr14 41701318 C T 2.01E-04 Nicotine dependence / / 17158188 rs1779528 chr14 41701668 C T 1.50E-04 Nicotine dependence / / 17158188 rs1612141 chr14 41702598 G A 5.00E-06 QT interval (interaction) / / 23459443 rs1611914 chr14 41702683 C T 1.80E-04 Nicotine dependence / / 17158188 rs1778392 chr14 41715504 G T 1.41E-04 Nicotine dependence / / 17158188 rs1782134 chr14 41715568 T C 8.18E-05 Nicotine dependence / / 17158188 rs1782135 chr14 41716000 A G 2.05E-04 Nicotine dependence / / 17158188 rs1778399 chr14 41719366 G A 1.69E-04 Nicotine dependence / / 17158188 rs1778400 chr14 41720138 T A 1.43E-04 Nicotine dependence / / 17158188 rs1779521 chr14 41721058 T C 1.27E-04 Nicotine dependence / / 17158188 rs1778401 chr14 41721761 A G 1.29E-04 Nicotine dependence / / 17158188 rs1782139 chr14 41723585 A G 1.06E-04 Nicotine dependence / / 17158188 rs1782141 chr14 41726171 A G 9.20E-05 Nicotine dependence / / 17158188 rs1782144 chr14 41729773 G A 9.88E-05 Nicotine dependence / / 17158188 rs1782145 chr14 41730376 C T 9.06E-05 Nicotine dependence / / 17158188 rs1779517 chr14 41730521 C A,G,T 1.12E-04 Nicotine dependence / / 17158188 rs1612945 chr14 41735941 C T 8.91E-05 Nicotine dependence / / 17158188 rs1778408 chr14 41744194 T C 4.37E-04 Nicotine dependence / / 17158188 rs1782155 chr14 41751598 G A 1.20E-04 Nicotine dependence / / 17158188 rs17111761 chr14 41752280 T C 0.000886 Salmonella-induced pyroptosis / / 22837397 rs1622804 chr14 41752589 G A 1.81E-04 Cognitive decline / / 23732972 rs1782156 chr14 41752669 T A 3.71E-04 Nicotine dependence / / 17158188 rs1782156 chr14 41752669 T A 2.73E-04 Cognitive decline / / 23732972 rs1779516 chr14 41753964 A G 1.74E-04 Cognitive decline / / 23732972 rs2799787 chr14 41754550 G A 1.63E-04 Nicotine dependence / / 17158188 rs1782159 chr14 41756569 C T 1.87E-05 Nicotine dependence / / 17158188 rs1782163 chr14 41765929 C T 3.77E-04 Nicotine dependence / / 17158188 rs1652920 chr14 41766284 T A 2.05E-04 Nicotine dependence / / 17158188 rs1778365 chr14 41766561 A G 3.93E-04 Nicotine dependence / / 17158188 rs1431041 chr14 41767006 C T 1.94E-04 Nicotine dependence / / 17158188 rs1778369 chr14 41768745 T G 3.29E-04 Nicotine dependence / / 17158188 rs2802067 chr14 41770523 G A 1.80E-04 Nicotine dependence / / 17158188 rs2798983 chr14 41772233 T C 4.77E-05 Nicotine dependence / / 17158188 rs17678541 chr14 41773741 T C 8.95E-05 Cognitive decline / / 23732972 rs11157218 chr14 41773780 A T 4.27E-04 Nicotine dependence / / 17158188 rs7146332 chr14 41777901 A G 7.90E-04 Suicidal ideation / / 22030708 rs11157219 chr14 41782701 A G 8.78E-05 Nicotine dependence / / 17158188 rs1431031 chr14 41784701 T C 2.97E-04 Nicotine dependence / / 17158188 rs7160688 chr14 41786179 T A 1.93E-04 Nicotine dependence / / 17158188 rs1431032 chr14 41788077 G A 1.76E-04 Cognitive decline / / 23732972 rs7153633 chr14 41790667 T A 7.55E-04 Nicotine dependence / / 17158188 rs1897224 chr14 41801229 T G 7.64E-04 Nicotine dependence / / 17158188 rs8011741 chr14 41817982 A G 2.23E-04 Cognitive decline / / 23732972 rs10147227 chr14 41875090 C T 2.40E-05 HIV-1 control / / 20041166 rs8003409 chr14 41938321 A G 6.95E-05 Waist-Hip Ratio / / pha003013 rs7154122 chr14 41941986 G A 4.92E-04 White matter integrity / / 22425255 rs9323049 chr14 41953160 T A 7.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12884090 chr14 41953762 A G 7.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7140726 chr14 41959784 G C 7.98E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1103437 chr14 41999902 T A 8.02E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs712405 chr14 42114227 G A 5.88E-05 Serum metabolites LRFN5 intron 19043545 rs8009571 chr14 42145815 G C 1.67E-05 Serum metabolites LRFN5 intron 19043545 rs11157247 chr14 42168893 G A 6.92E-06 Serum metabolites LRFN5 intron 19043545 rs41319550 chr14 42200279 A T 4.23E-04 Multiple complex diseases LRFN5 intron 17554300 rs4904757 chr14 42204916 T G 4.30E-04 Sudden cardiac arrest LRFN5 intron 21658281 rs4304945 chr14 42220920 A G 7.39E-05 Serum metabolites LRFN5 intron 19043545 rs2084347 chr14 42239540 T C 2.32E-05 Serum metabolites LRFN5 intron 19043545 rs4900098 chr14 42309260 T C 7.12E-04 Type 2 diabetes LRFN5 intron 17463246 rs61988414 chr14 42313443 A G 0.0000004 Myopia (Age of onset) LRFN5 intron 23468642 rs12895832 chr14 42314553 T G 7.76E-04 Multiple complex diseases LRFN5 intron 17554300 rs12895832 chr14 42314553 T G 8.46E-05 Major depressive disorder LRFN5 intron 22472876 rs10131436 chr14 42319212 A G 7.59E-04 Type 2 diabetes LRFN5 intron 17463246 rs17781474 chr14 42321101 A T 7.95E-04 Multiple complex diseases LRFN5 intron 17554300 rs17781474 chr14 42321101 A T 7.34E-05 Major depressive disorder LRFN5 intron 22472876 rs12884688 chr14 42321934 C T 6.44E-04 Multiple complex diseases LRFN5 intron 17554300 rs12884688 chr14 42321934 C T 6.07E-05 Major depressive disorder LRFN5 intron 22472876 rs912384 chr14 42336575 T G 3.99E-05 HDL cholesterol LRFN5 intron pha003074 rs17112350 chr14 42340281 A G 2.50E-05 Urinary metabolites LRFN5 intron 21572414 rs6572117 chr14 42360633 T C 9.67E-06 Intelligence LRFN5 cds-synon 21826061 rs11846415 chr14 42408943 G T 1.04E-05 Intelligence / / 21826061 rs1951882 chr14 42413647 A G 3.18E-05 Intelligence / / 21826061 rs11157257 chr14 42430719 C T 0.0000136 HDL cholesterol particle diameter / / 23263444 rs8013963 chr14 42431239 G A 1.02E-05 Intelligence / / 21826061 rs7152201 chr14 42431701 C T 6.07E-05 Intelligence / / 21826061 rs12589908 chr14 42440012 C T 0.0000138 HDL cholesterol particle diameter / / 23263444 rs945316 chr14 42446967 A G 5.33E-05 Intelligence / / 21826061 rs17112462 chr14 42455373 T G 1.60E-05 HIV-1 control / / 20041166 rs1684716 chr14 42498031 T G 6.80E-06 Alcoholism (heaviness of drinking) / / 21529783 rs1632694 chr14 42511847 C T 6.50E-05 Alcoholism (heaviness of drinking) / / 21529783 rs9323055 chr14 42525361 G A 7.31E-04 Myopia (pathological) / / 21095009 rs8004273 chr14 42542317 G A 7.69E-04 Schizophrenia / / 19197363 rs8004273 chr14 42542317 G A 7.39E-04 Myopia (pathological) / / 21095009 rs1684696 chr14 42547019 G A 3.14E-04 Cognitive decline / / 23732972 rs4451874 chr14 42547320 A G 8.20E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs1684693 chr14 42548257 T G 4.20E-05 Alcoholism (heaviness of drinking) / / 21529783 rs1542668 chr14 42548912 A G 6.49E-04 Schizophrenia / / 19197363 rs1542668 chr14 42548912 A G 2.70E-05 Alcoholism (heaviness of drinking) / / 21529783 rs1684675 chr14 42584436 A C 2.41E-04 Cognitive decline / / 23732972 rs11627720 chr14 42593535 A C 6.21E-05 Age-related macular degeneration / / pha002890 rs11627720 chr14 42593535 A C 3.81E-05 Waist-Hip Ratio / / pha003013 rs11627720 chr14 42593535 A C 6.52E-05 Waist-Hip Ratio / / pha003028 rs10146319 chr14 42605529 A G 3.01E-04 Cognitive decline / / 23732972 rs8006978 chr14 42634072 G T 2.10E-05 Alcoholism (heaviness of drinking) / / 21529783 rs10135407 chr14 42644617 A G 2.90E-05 Alcoholism (heaviness of drinking) / / 21529783 rs2154294 chr14 42655275 A G 3.00E-06 Alcoholism (12-month weekly alcohol consumption) / / 21529783 rs6572138 chr14 42671745 C G 2.51E-04 Cognitive decline / / 23732972 rs12895935 chr14 42698006 C T 3.79E-05 Prostate cancer / / 22923026 rs12434985 chr14 42699090 A G 1.18E-05 Prostate cancer / / 22923026 rs1393835 chr14 42717951 G A 3.51E-04 Obesity (extreme) / / 21935397 rs1393835 chr14 42717951 G A 2.64E-05 Prostate cancer / / 22923026 rs2806246 chr14 42755963 A C 8.12E-05 Body Mass Index / / pha003009 rs8004909 chr14 42822116 A C 2.34E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs12883508 chr14 42831898 T C 2.21E-05 Vaspin levels / / 22907691 rs2626412 chr14 42833851 G A 4.31E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs12435396 chr14 42835190 G A 4.46E-04 Alzheimer's disease / / 22005930 rs10498368 chr14 42866223 T C 7.18E-04 Alzheimer's disease / / 22005930 rs11157288 chr14 42872521 C G 9.90E-04 Alzheimer's disease / / 22005930 rs7157217 chr14 42907447 C T 8.30E-04 Alcohol dependence / / 20201924 rs7157217 chr14 42907447 C T 0.000353456 Hypertension (early onset hypertension) / / 22479346 rs17113034 chr14 42909013 T C 6.80E-04 Alcohol dependence / / 20201924 rs17113034 chr14 42909013 T C 0.000353456 Hypertension (early onset hypertension) / / 22479346 rs8006285 chr14 42910684 A C 6.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8018875 chr14 42919855 T A 6.19E-04 Alzheimer's disease / / 17998437 rs10130263 chr14 42922411 T C 4.63E-04 Alzheimer's disease / / 17998437 rs2047530 chr14 42932065 G C 2.34E-04 Alzheimer's disease / / 17998437 rs11157293 chr14 42952536 C G 9.32E-04 Alzheimer's disease / / 22005930 rs10498369 chr14 42962956 T C 8.81E-04 Alzheimer's disease / / 22005930 rs10498370 chr14 42965717 C A 8.80E-04 Alzheimer's disease / / 22005930 rs17092325 chr14 42974022 G A 8.98E-04 Alzheimer's disease / / 22005930 rs17092327 chr14 42974131 G T 8.76E-04 Alzheimer's disease / / 22005930 rs17113115 chr14 42982934 G A 9.08E-04 Alzheimer's disease / / 22005930 rs2062469 chr14 43008929 A G 8.84E-04 Alzheimer's disease / / 22005930 rs12432241 chr14 43009653 A T 9.35E-04 Alzheimer's disease / / 22005930 rs8020679 chr14 43064725 G A 4.88E-04 Type 2 diabetes / / 17463246 rs12878560 chr14 43084486 A G 6.43E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10141502 chr14 43093389 A G 8.57E-04 Multiple complex diseases / / 17554300 rs12880322 chr14 43093687 G C 7.75E-04 Multiple complex diseases / / 17554300 rs12895543 chr14 43110221 A C 2.40E-05 Urinary metabolites / / 21572414 rs1620034 chr14 43140771 G A 8.25E-06 Hearing function / / 17255346 rs1698507 chr14 43152763 A G 7.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1627411 chr14 43171328 T C 8.83E-07 Osteoarthritis / / 22763110 rs1698535 chr14 43172692 A G 3.01E-05 Bipolar disorder / / 20451256 rs1777080 chr14 43182538 A G 6.70E-05 Bipolar disorder / / 20451256 rs10498375 chr14 43188315 A C 5.61E-05 Bipolar disorder / / 20451256 rs10498375 chr14 43188315 A C 2.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs1712699 chr14 43188812 A C 2.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs1777077 chr14 43188910 C T 8.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs1777077 chr14 43188910 C T 1.70E-04 Major depression (suicidal thoughts and behavior) / / 21750702 rs1698517 chr14 43188972 T C 2.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs17633001 chr14 43191360 A G 3.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs1777075 chr14 43192241 G A 3.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs10149887 chr14 43192832 T A 3.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs1712704 chr14 43200364 T C 1.13E-05 Multiple complex diseases / / 17554300 rs1777069 chr14 43205382 C A 0.000739669 Hypertension (early onset hypertension) / / 22479346 rs2415770 chr14 43291255 G A 5.66E-04 Alzheimer's disease / / 24755620 rs6572182 chr14 43317669 A G 4.93E-04 Multiple complex diseases / / 17554300 rs17541557 chr14 43335584 A G 0.00075999 Hypertension (early onset hypertension) / / 22479346 rs978091 chr14 43344558 A G 8.86E-06 Hearing function / / 21493956 rs17113620 chr14 43354861 C T 8.17E-07 Systemic lupus erythematosus / / pha002867 rs11157317 chr14 43403459 C T 9.00E-06 Multiple myeloma (hyperdiploidy) / / 23502783 rs17113722 chr14 43433918 T C 0.0000166 Panic disorder / / 23149450 rs17113722 chr14 43433918 T C 1.66E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs1037298 chr14 43435164 G T 8.56E-04 Type 2 diabetes / / 17463246 rs1037298 chr14 43435164 G T 3.03E-04 Multiple complex diseases / / 17554300 rs1037298 chr14 43435164 G T 1.00E-04 Information processing speed / / 21130836 rs8022097 chr14 43450454 C T 1.00E-04 Information processing speed / / 21130836 rs11848994 chr14 43472877 C T 7.38E-04 Alzheimer's disease / / 22005930 rs1584547 chr14 43474406 G A 8.52E-05 Longevity / / 21612516 rs1954383 chr14 43517854 G A 3.66E-04 Multiple complex diseases / / 17554300 rs2185893 chr14 43519847 G T 2.39E-04 Alzheimer's disease / / 22005930 rs1959864 chr14 43523560 G C 2.73E-04 Alzheimer's disease / / 22005930 rs2455956 chr14 43524687 G A 2.76E-04 Alzheimer's disease / / 22005930 rs2000270 chr14 43530759 C T 2.87E-04 Alzheimer's disease / / 22005930 rs2488868 chr14 43545591 A C 3.51E-04 Alzheimer's disease / / 22005930 rs2154001 chr14 43552008 G C 9.60E-04 Multiple complex diseases / / 17554300 rs2488872 chr14 43552280 C T 3.65E-04 Alzheimer's disease / / 22005930 rs8014461 chr14 43570234 T G 9.72E-04 Alzheimer's disease / / 22005930 rs2488885 chr14 43571743 G T 5.14E-04 Alzheimer's disease / / 22005930 rs2248324 chr14 43579262 T A 5.41E-04 Alzheimer's disease / / 22005930 rs2807785 chr14 43582719 A G 5.94E-04 Alzheimer's disease / / 22005930 rs2254834 chr14 43596185 C A 7.70E-04 Alzheimer's disease / / 22005930 rs2154002 chr14 43597082 T C 7.85E-04 Alzheimer's disease / / 22005930 rs17113911 chr14 43601669 A G 5.89E-05 Multiple complex diseases / / 17554300 rs1954396 chr14 43601836 G A 8.46E-04 Alzheimer's disease / / 22005930 rs2798405 chr14 43604323 G A 8.32E-04 Alzheimer's disease / / 22005930 rs1899157 chr14 43696733 C T 4.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2165341 chr14 43744757 A G 5.22E-04 Alzheimer's disease / / 22005930 rs9323077 chr14 43799609 T C 4.29E-05 Multiple complex diseases / / 17554300 rs4641644 chr14 43803481 C A 7.31E-07 Prostate cancer / / pha002878 rs10498389 chr14 43959213 A G 3.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8005625 chr14 44010789 G T 3.24E-05 Attention deficit hyperactivity disorder / / 20732627 rs4906476 chr14 44033406 C T 4.30E-04 Tourette syndrome / / 22889924 rs7146515 chr14 44039374 G A 5.76E-04 Tourette syndrome / / 22889924 rs7146515 chr14 44039374 G A 2.90E-05 Myasthenia gravis / / 23055271 rs8019581 chr14 44055539 A G 8.76E-04 Tourette syndrome / / 22889924 rs8011986 chr14 44085768 T C 1.40E-05 Attention deficit hyperactivity disorder / / 20732627 rs7146388 chr14 44090928 A G 1.85E-05 Attention deficit hyperactivity disorder / / 20732627 rs7140723 chr14 44105698 C A 3.27E-05 Attention deficit hyperactivity disorder / / 20732627 rs4900643 chr14 44130700 G T 1.94E-04 Epilepsy / / 22116939 rs2038532 chr14 44179054 C T 1.00E-04 Myasthenia gravis / / 23055271 rs1957265 chr14 44188271 C T 1.68E-05 Magnesium levels / / pha003092 rs9323081 chr14 44193257 G A 1.30E-04 Myasthenia gravis / / 23055271 rs11848605 chr14 44197212 A G 6.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs11849993 chr14 44198833 A G 5.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs8017717 chr14 44199587 A G 9.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs1957267 chr14 44200467 C T 3.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs1957268 chr14 44200728 T G 2.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs986074 chr14 44201323 T C 5.51E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10141219 chr14 44202232 C T 6.82E-07 Magnesium levels / / pha003092 rs1951347 chr14 44204571 T C 4.51E-07 Magnesium levels / / pha003092 rs10140619 chr14 44205699 T C 4.10E-06 Magnesium levels / / pha003092 rs17309078 chr14 44207575 G A 0.0001497 Sarcoidosis / / 22952805 rs17309078 chr14 44207575 G A 2.80E-04 Myasthenia gravis / / 23055271 rs17309085 chr14 44208416 A G 0.00008509 Sarcoidosis / / 22952805 rs61998481 chr14 44214035 T C 0.00009359 Sarcoidosis / / 22952805 rs1957260 chr14 44251093 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1951342 chr14 44256254 A G 0.000378 Breast cancer early age of onset / / 18463975 rs2182977 chr14 44279080 G A 8.71E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1958249 chr14 44293141 C T 8.42E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs17212596 chr14 44294354 G A 3.52E-04 Sudden cardiac arrest / / 21658281 rs8016223 chr14 44331104 A G 3.07E-06 Erythrocyte counts / / pha003090 rs12434045 chr14 44335337 T C 2.30E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs8011002 chr14 44416205 T C 5.01E-04 Multiple complex diseases / / 17554300 rs8011520 chr14 44416489 T C 8.90E-04 Multiple complex diseases / / 17554300 rs12896525 chr14 44418536 C T 1.39E-04 Multiple complex diseases / / 17554300 rs12896523 chr14 44418575 A G 8.76E-04 Multiple complex diseases / / 17554300 rs1885587 chr14 44422702 A G 3.80E-05 Hemoglobin / / pha003096 rs1885587 chr14 44422702 A G 5.22E-05 Hematocrit / / pha003097 rs4906510 chr14 44427705 A G 1.30E-05 Urinary metabolites / / 21572414 rs1957496 chr14 44438039 T G 1.13E-06 Hemoglobin / / pha003096 rs1957496 chr14 44438039 T G 5.52E-06 Hematocrit / / pha003097 rs17278712 chr14 44441086 C T 1.05E-04 Aortic root size / / 21223598 rs10141817 chr14 44445910 C T 8.10E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7154601 chr14 44447264 T G 9.30E-07 Hemoglobin / / pha003096 rs7154601 chr14 44447264 T G 4.52E-06 Hematocrit / / pha003097 rs941944 chr14 44447955 T G 2.54E-05 Aortic root size / / 21223598 rs17278753 chr14 44454909 C A 5.50E-06 Urinary metabolites / / 21572414 rs11849451 chr14 44467189 T C 3.30E-06 Urinary metabolites / / 21572414 rs11624324 chr14 44469242 A G 5.53E-04 Aortic root size / / 21223598 rs10151230 chr14 44471476 A C 2.05E-06 Triglycerides / / pha003081 rs10151230 chr14 44471476 A C 2.10E-05 Lipid levels / / pha003082 rs9323093 chr14 44486343 C T 1.48E-05 Hemoglobin / / pha003096 rs9323093 chr14 44486343 C T 5.13E-05 Hematocrit / / pha003097 rs10484235 chr14 44507655 A G 1.40E-05 Urinary metabolites / / 21572414 rs6572235 chr14 44519214 A G 8.36E-05 Celiac disease / / 23936387 rs1950538 chr14 44530722 C T 2.09E-04 Celiac disease / / 23936387 rs2069195 chr14 44536667 A G 1.40E-05 Urinary metabolites / / 21572414 rs2415836 chr14 44540560 A C 7.52E-05 Celiac disease / / 23936387 rs17243607 chr14 44610332 T C 8.66E-05 Attention deficit hyperactivity disorder / / 22420046 rs4906520 chr14 44612482 C T 3.60E-04 Major depressive disorder / / 21042317 rs17114737 chr14 44614966 G A 3.86E-04 Multiple complex diseases / / 17554300 rs8017211 chr14 44618063 A G 3.10E-04 Major depressive disorder / / 21042317 rs10147827 chr14 44623260 A G 7.37E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs10484231 chr14 44630495 T G 2.32E-04 Stroke / / pha002887 rs10484230 chr14 44631197 T C 3.80E-05 Fibrinogen / / pha003068 rs8012559 chr14 44640483 A G 2.88E-04 Type 2 diabetes / / 17463246 rs1040691 chr14 44641635 T C 0.0000761 Carotid intima media thickness / / 23152477 rs17114832 chr14 44795327 C G 9.83E-04 Type 2 diabetes / / 17463246 rs1959205 chr14 44807913 G C 1.52E-04 Alzheimer's disease / / 17998437 rs1953468 chr14 44812770 C T 4.22E-04 Stroke / / pha002886 rs17543459 chr14 44827439 G A 8.12E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7143770 chr14 44829276 G A 1.97E-04 Alzheimer's disease / / 17998437 rs1952578 chr14 44874995 A C 7.22E-05 Parkinson's disease / / 17052657 rs12894164 chr14 44879053 G T 4.39E-04 Multiple complex diseases / / 17554300 rs10484178 chr14 44896629 G A 7.80E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10146815 chr14 44906192 A G 4.73E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12435942 chr14 44911686 A C 1.62E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs944044 chr14 44914034 G T 5.31E-04 Myopia (pathological) / / 21095009 rs435340 chr14 44934507 G A 3.47E-04 Multiple complex diseases / / 17554300 rs2282277 chr14 44947663 G A 6.99E-10 Non-obstructive azoospermia / / 22197933 rs12893426 chr14 44998349 T C 8.03E-06 Personality dimensions / / 23658558 rs1953582 chr14 45006478 C T 2.75E-04 Scoliosis / / 21216876 rs76523308 chr14 45045390 C T 1.65E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs79842714 chr14 45045798 G T 6.89E-07 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs113317269 chr14 45046629 C T 6.00E-07 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs80035764 chr14 45046654 C T 6.49E-07 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs78526838 chr14 45047524 C T 9.54E-07 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs78553409 chr14 45048218 C T 9.67E-07 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs79983672 chr14 45048781 T C 9.75E-07 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs114431653 chr14 45049517 G A 9.85E-07 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs112685649 chr14 45049594 C A 9.88E-07 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs113037884 chr14 45049884 T G 9.93E-07 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs140090782 chr14 45050584 T C 1.02E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs112229095 chr14 45051231 T C 1.02E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs12161896 chr14 45066033 A G 2.31E-05 Brain structure / / 22504417 rs12884395 chr14 45106632 A G 9.00E-06 Obesity-related traits / / 23251661 rs12896581 chr14 45110153 C A 5.70E-04 Alcohol dependence / / 20201924 rs12896581 chr14 45110153 C A 2.45E-04 Tourette syndrome / / 22889924 rs1959515 chr14 45149546 G A 8.46E-05 Orofacial clefts / / 22419666 rs807331 chr14 45169289 C T 1.60E-05 Intraocular pressure / / 24002674 rs17115444 chr14 45188966 T C 2.70E-04 Alcohol dependence / / 20201924 rs17115446 chr14 45189702 T C 4.40E-04 Alcohol dependence / / 20201924 rs2018267 chr14 45192373 G A 7.23E-04 Multiple complex diseases / / 17554300 rs712414 chr14 45201353 A G 0.00000636 Tuberculosis with early age of onset / / 22551897 rs7157755 chr14 45208776 A G 2.91E-04 Lung function (forced vital capacity) / / 24023788 rs7157755 chr14 45208776 A G 3.90E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs229701 chr14 45237624 C T 6.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs229683 chr14 45247021 C T 7.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10483552 chr14 45256268 G C 4.56E-05 Type 1 diabetes nephropathy / / 23028342 rs10483551 chr14 45257347 A G 9.73E-06 Type 1 diabetes nephropathy / / 23028342 rs7154123 chr14 45283699 C T 0.000717 Salmonella-induced pyroptosis / / 22837397 rs172967 chr14 45289062 A C 9.11E-04 Tourette syndrome / / 22889924 rs179350 chr14 45296993 C T 2.74E-04 Multiple complex diseases / / 17554300 rs179350 chr14 45296993 C T 4.35E-04 Aortic root size / / 21223598 rs229752 chr14 45297050 A G 3.08E-04 Aortic root size / / 21223598 rs8016855 chr14 45329930 A G 9.61E-05 Tourette syndrome / / 22889924 rs17115674 chr14 45339443 T C 7.76E-06 Asthma / / 11022011 rs11844725 chr14 45345520 A G 9.69E-05 Tourette syndrome / / 22889924 rs11848799 chr14 45415597 T C 1.62E-04 Alcohol dependence KLHL28 intron 21314694 rs10152101 chr14 45420311 C A 7.47E-04 Rheumatoid arthritis KLHL28 intron 21452313 rs10135890 chr14 45452702 A G 4.94E-04 Tourette syndrome FAM179B intron 22889924 rs10132762 chr14 45476025 A G 3.91E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines FAM179B intron 21844884 rs11847336 chr14 45578043 A G 9.59E-04 Amyotrophic lateral sclerosis (sporadic) PRPF39 intron 24529757 rs11157432 chr14 45619217 A G 1.70E-06 Urinary metabolites FANCM intron 21572414 rs8017226 chr14 45644627 T C 1.16E-09 HDL cholesterol FANCM cds-synon 23063622 rs10150209 chr14 45650533 C T 9.85E-04 Acute lung injury FANCM intron 22295056 rs226981 chr14 45662325 T C 0.00031 Coronary artery calcification FANCM intron 23727086 rs17115900 chr14 45674669 T C 7.32E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MIS18BP1 intron 21844884 rs17115932 chr14 45711889 C T 8.55E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MIS18BP1 intron 21844884 rs1951478 chr14 45748246 T C 9.40E-04 Endometriosis / / 23104006 rs1957395 chr14 45759489 G A 7.11E-06 Acute lung injury / / 22295056 rs17729474 chr14 45829229 T C 1.00E-05 Urinary metabolites / / 21572414 rs17116051 chr14 45850443 A G 5.69E-04 Multiple complex diseases / / 17554300 rs1952728 chr14 45893092 C T 2.42E-04 Insulin resistance / / 21901158 rs2415888 chr14 45994633 G A 6.14E-05 Blood Pressure / / pha003045 rs7140958 chr14 46029687 C T 5.53E-04 Multiple complex diseases / / 17554300 rs7140958 chr14 46029687 C T 1.87E-10 Bilirubin levels,in serum / / 20639394 rs2415908 chr14 46086717 T C 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1750083 chr14 46091372 C T 6.41E-04 Smoking initiation / / 24665060 rs2014547 chr14 46151282 C T 2.26E-04 Longevity / / 22279548 rs1906794 chr14 46196397 T C 7.28E-05 Diabetes Mellitus / / pha003060 rs1266236 chr14 46208983 T C 1.98E-04 Glycosylated haemoglobin levels / / 17255346 rs1266294 chr14 46232854 A C 7.60E-05 Alcoholism (heaviness of drinking) / / 21529783 rs1686312 chr14 46241497 G T 9.50E-05 Alcoholism (heaviness of drinking) / / 21529783 rs4900680 chr14 46268185 A G 8.90E-05 Alcoholism (heaviness of drinking) / / 21529783 rs8018890 chr14 46301799 C G 1.30E-05 Urinary metabolites / / 21572414 rs981951 chr14 46327520 T C 1.16E-04 Multiple complex diseases / / 17554300 rs393652 chr14 46338255 G T 1.00E-04 Information processing speed / / 21130836 rs397080 chr14 46347305 A G 1.00E-04 Information processing speed / / 21130836 rs17726637 chr14 46366562 C T 1.20E-05 Malaria / / 19465909 rs4143719 chr14 46371175 C T 8.33E-04 Body mass index / / 21701565 rs17726882 chr14 46372835 T C 0.0000969 Coronary artery calcification / / 23394302 rs12147297 chr14 46408343 C T 1.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12147297 chr14 46408343 C T 5.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10140872 chr14 46420202 C T 2.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8017871 chr14 46426219 G T 1.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8017871 chr14 46426219 G T 5.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1957165 chr14 46429763 A G 2.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6572335 chr14 46434585 A G 9.30E-07 Malaria / / 19465909 rs762015 chr14 46435484 C T 3.15E-04 Multiple complex diseases / / 17554300 rs762015 chr14 46435484 C T 3.87E-05 Serum metabolites / / 19043545 rs762014 chr14 46435899 T C 5.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7147183 chr14 46458696 G A 7.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1543480 chr14 46463839 T C 5.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17728971 chr14 46467831 A G 6.50E-07 Malaria / / 19465909 rs17116830 chr14 46474336 A G 4.98E-04 Smoking cessation / / 24665060 rs1957138 chr14 46474415 T C 2.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12897911 chr14 46490630 G T 6.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10138440 chr14 46531972 C T 0.00000892 Coronary artery calcification / / 23394302 rs1754298 chr14 46548312 C T 3.89E-04 Intracranial aneurysm / / 20613766 rs1754298 chr14 46548312 C T 4.52E-08 Metabolite levels / / 23281178 rs1742652 chr14 46553467 A G 5.61E-04 Smoking cessation / / 24665060 rs1754305 chr14 46554838 A T 5.94E-08 Metabolite levels / / 23281178 rs1957179 chr14 46559671 T C 4.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4539517 chr14 46583668 A G 8.64E-05 Serum metabolites / / 19043545 rs8008719 chr14 46607899 T C 6.10E-05 Information processing speed / / 21130836 rs858870 chr14 46666812 A C 1.46E-05 Serum metabolites / / 19043545 rs8017858 chr14 46741726 A G 9.91E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs10137970 chr14 46750607 A G 1.81E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs12437173 chr14 46789696 A G 2.84E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs12895351 chr14 46824825 G A 2.30E-05 Urinary metabolites / / 21572414 rs12879458 chr14 46825242 C T 6.84E-05 Interstitial lung disease / / 23583980 rs11625735 chr14 46825325 T C 1.10E-05 Urinary metabolites / / 21572414 rs2010338 chr14 46825881 T C 1.10E-05 Urinary metabolites / / 21572414 rs2415974 chr14 46837112 C T 2.00E-05 Urinary metabolites / / 21572414 rs4341669 chr14 46837636 G A 6.67E-04 Multiple complex diseases / / 17554300 rs8018652 chr14 46845616 C A 2.64E-04 Multiple complex diseases / / 17554300 rs10498398 chr14 46867489 C T 2.50E-05 Urinary metabolites / / 21572414 rs1761011 chr14 46904345 G C 5.05E-04 Acute lung injury / / 22295056 rs1669796 chr14 46913902 C A 1.22E-04 Acute lung injury / / 22295056 rs12434073 chr14 46921265 G A 2.03E-05 Colorectal cancer / / 21242260 rs17672599 chr14 46922081 C G 1.17E-04 Acute lung injury / / 22295056 rs11846013 chr14 46932291 G A,C,T 4.99E-06 Blood pressure / / 21378095 rs1389608 chr14 46957777 C A 4.08E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs2600814 chr14 46984498 T C 1.72E-06 Colorectal cancer / / 21242260 rs2600808 chr14 46992499 A C 8.10E-04 Acute lung injury / / 22295056 rs10134558 chr14 46997073 G A 7.63E-04 Acute lung injury / / 22295056 rs10134890 chr14 46997620 C T 5.80E-05 Lung adenocarcinoma / / 19836008 rs10134890 chr14 46997620 C T 7.44E-04 Acute lung injury / / 22295056 rs6572380 chr14 47006889 T C 2.55E-05 Coronary heart disease / / pha003055 rs10150421 chr14 47021511 T C 7.12E-04 Acute lung injury / / 22295056 rs10139381 chr14 47083005 T C 1.62E-04 Schizophrenia / / 19197363 rs10139381 chr14 47083005 T C 3.78E-04 Acute lung injury / / 22295056 rs10139381 chr14 47083005 T C 7.43E-05 Interstitial lung disease / / 23583980 rs10133870 chr14 47085242 C T 2.78E-04 Acute lung injury / / 22295056 rs1020895 chr14 47087356 T A 3.78E-04 Acute lung injury / / 22295056 rs11157514 chr14 47092923 C T 3.78E-04 Acute lung injury / / 22295056 rs4898555 chr14 47115662 A G 2.01E-04 Acute lung injury / / 22295056 rs1381640 chr14 47128019 C T 7.61E-05 Coronary heart disease / / pha003055 rs10148225 chr14 47128419 T C 8.69E-04 Acute lung injury / / 22295056 rs1388564 chr14 47270327 G A 4.00E-04 Cardiovascular heart disease in diabetics / / 23982368 rs2860310 chr14 47315946 T A 7.24E-04 Acute lung injury MDGA2 intron 22295056 rs2172237 chr14 47366275 T C 5.71E-04 Acute lung injury MDGA2 intron 22295056 rs3007103 chr14 47366340 A G 3.65E-04 Acute lung injury MDGA2 intron 22295056 rs3007103 chr14 47366340 A G 3.38E-07 Obesity-related traits MDGA2 intron 23251661 rs12888829 chr14 47395801 G T 3.04E-04 Cholesterol MDGA2 intron 17255346 rs12883384 chr14 47403684 A C 7.00E-07 Neuroticism MDGA2 intron 18762592 rs1954232 chr14 47417588 G A 1.40E-05 Urinary metabolites MDGA2 intron 21572414 rs6572396 chr14 47422710 C G 3.79E-04 Acute lung injury MDGA2 intron 22295056 rs11847893 chr14 47423795 A G 4.66E-04 Acute lung injury MDGA2 intron 22295056 rs1539222 chr14 47424387 C G 4.66E-04 Acute lung injury MDGA2 intron 22295056 rs1539221 chr14 47424790 G T 4.56E-04 Acute lung injury MDGA2 intron 22295056 rs1954231 chr14 47428100 A G 7.72E-04 Acute lung injury MDGA2 intron 22295056 rs11627056 chr14 47454986 G A 3.00E-07 Obesity-related traits MDGA2 intron 23251661 rs11627056 chr14 47454986 G A 4.82E-04 Alzheimer's disease MDGA2 intron 24755620 rs17560594 chr14 47461203 T C 5.84E-04 Response to taxane treatment (placlitaxel) MDGA2 intron 23006423 rs17560594 chr14 47461203 T C 5.05E-05 Hemoglobin MDGA2 intron pha003096 rs17641214 chr14 47467145 T C 5.04E-04 Response to taxane treatment (placlitaxel) MDGA2 intron 23006423 rs10135113 chr14 47499386 A C 9.66E-05 Response to taxane treatment (placlitaxel) MDGA2 intron 23006423 rs1539213 chr14 47503489 A G 3.62E-05 Colorectal cancer MDGA2 intron 24448986 rs7155342 chr14 47510417 T G 1.00E-04 Prostate cancer MDGA2 intron 21743057 rs17117955 chr14 47517151 C A 9.30E-04 Myopia (pathological) MDGA2 intron 21095009 rs11157536 chr14 47518240 A G 6.00E-05 Prostate cancer MDGA2 intron 21743057 rs11624702 chr14 47518437 C T 0.00000118 Change in depression severity with antidepressants (NRI or SRI) MDGA2 intron 23091423 rs961616 chr14 47521489 T C 5.00E-05 Prostate cancer MDGA2 intron 21743057 rs1573007 chr14 47525103 T A 5.00E-05 Prostate cancer MDGA2 intron 21743057 rs1547809 chr14 47532254 T C 3.06E-04 Hemoglobin concentration MDGA2 intron 20534544 rs1954244 chr14 47533399 G A 7.80E-06 Urinary metabolites MDGA2 intron 21572414 rs10134228 chr14 47534306 G A 6.00E-05 Prostate cancer MDGA2 intron 21743057 rs17118000 chr14 47537891 G A 1.00E-04 Prostate cancer MDGA2 intron 21743057 rs7159021 chr14 47539662 C T 1.00E-04 Prostate cancer MDGA2 intron 21743057 rs9972259 chr14 47540754 T G 1.00E-04 Prostate cancer MDGA2 intron 21743057 rs12888648 chr14 47543188 T C 1.00E-04 Prostate cancer MDGA2 intron 21743057 rs10135298 chr14 47543336 T C 1.00E-04 Prostate cancer MDGA2 intron 21743057 rs9806090 chr14 47587343 T C 2.70E-06 Urinary metabolites MDGA2 intron 21572414 rs17118076 chr14 47587390 A G 4.62E-04 Multiple complex diseases MDGA2 intron 17554300 rs6572408 chr14 47590665 T A 3.19E-04 Multiple complex diseases MDGA2 intron 17554300 rs41534646 chr14 47636016 A G 7.42E-04 Multiple complex diseases MDGA2 intron 17554300 rs4505228 chr14 47653221 C T 2.42E-04 Response to cholinesterase inhibitors in Alzheimer's disease MDGA2 intron 23374588 rs17118171 chr14 47683996 C T 1.40E-04 Multiple complex diseases MDGA2 intron 17554300 rs4594173 chr14 47780727 A G 4.88E-05 Longevity MDGA2 intron 21612516 rs2277472 chr14 47812071 G A 3.88E-05 Longevity MDGA2 intron 21612516 rs10134155 chr14 47826136 T C 1.01E-04 Parkinson's disease MDGA2 intron 21248740 rs10134155 chr14 47826136 T C 1.56E-04 Insulin resistance MDGA2 intron 21901158 rs10134155 chr14 47826136 T C 4.37E-04 Tourette syndrome MDGA2 intron 22889924 rs8021759 chr14 47858145 A C 3.24E-04 Coronary Artery Disease MDGA2 intron 17634449 rs8021759 chr14 47858145 A C 6.68E-04 Tourette syndrome MDGA2 intron 22889924 rs10483573 chr14 47862477 C G 5.60E-05 Neuroticism MDGA2 intron 17667963 rs7159841 chr14 47863835 C T 2.00E-07 Hemostatic factors and hematological phenotypes MDGA2 intron 17903294 rs17118552 chr14 47874557 A G 2.00E-07 Response to tocilizumab in rheumatoid arthritis MDGA2 intron 22491018 rs4900756 chr14 47878968 C T 8.50E-05 Endometriosis MDGA2 intron 21151130 rs4900756 chr14 47878968 C T 5.59E-04 Tourette syndrome MDGA2 intron 22889924 rs2416069 chr14 47882031 G T 5.47E-04 Taste perception MDGA2 intron 22132133 rs12897676 chr14 47886106 G A 7.00E-05 Prostate cancer MDGA2 intron 21743057 rs7142096 chr14 47886923 T C 2.00E-05 Prostate cancer MDGA2 intron 21743057 rs7152765 chr14 47888104 T C 1.00E-04 Prostate cancer MDGA2 intron 21743057 rs7159493 chr14 47889952 G T 7.00E-05 Prostate cancer MDGA2 intron 21743057 rs7159493 chr14 47889952 G T 4.35E-05 Blood pressure (response to calcium channel blocker) MDGA2 intron 24192120 rs8016913 chr14 47890381 T A 4.35E-05 Blood pressure (response to calcium channel blocker) MDGA2 intron 24192120 rs2002293 chr14 47890816 T G 4.35E-05 Blood pressure (response to calcium channel blocker) MDGA2 intron 24192120 rs7148160 chr14 47896869 G A 8.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MDGA2 intron 20877124 rs8007707 chr14 47899386 T C 4.35E-05 Blood pressure (response to calcium channel blocker) MDGA2 intron 24192120 rs2416075 chr14 47904650 A G 7.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MDGA2 intron 20877124 rs9323139 chr14 47905531 T A 4.35E-05 Blood pressure (response to calcium channel blocker) MDGA2 intron 24192120 rs7146722 chr14 47908783 T C 1.49E-04 Tourette syndrome MDGA2 intron 22889924 rs10467790 chr14 47910244 G A 4.84E-05 Blood pressure (response to calcium channel blocker) MDGA2 intron 24192120 rs2416082 chr14 47916279 T C 4.82E-05 Blood pressure (response to calcium channel blocker) MDGA2 intron 24192120 rs10131923 chr14 47917007 G T 4.82E-05 Blood pressure (response to calcium channel blocker) MDGA2 intron 24192120 rs4898568 chr14 47922676 G A 4.82E-05 Blood pressure (response to calcium channel blocker) MDGA2 intron 24192120 rs4900764 chr14 47922766 T A 4.82E-05 Blood pressure (response to calcium channel blocker) MDGA2 intron 24192120 rs10147486 chr14 47985019 G T 9.20E-07 Parkinson's disease (age of onset) MDGA2 intron 19772629 rs17118851 chr14 47990133 A G 4.84E-05 Tardive dyskinesia MDGA2 intron 20939080 rs1955811 chr14 48004600 A T 1.44E-23 Narcolepsy MDGA2 intron 19629137 rs1955807 chr14 48013601 T C 9.39E-04 Tourette syndrome MDGA2 intron 22889924 rs1160351 chr14 48015982 A C 3.00E-07 Sexual dysfunction (SSRI/SNRI-related) MDGA2 intron 22445761 rs1160351 chr14 48015982 A C 4.40E-05 Blood pressure (response to calcium channel blocker) MDGA2 intron 24192120 rs10483565 chr14 48016703 C T 4.40E-05 Blood pressure (response to calcium channel blocker) MDGA2 intron 24192120 rs2416095 chr14 48034860 T G 1.13E-04 Response to taxane treatment (placlitaxel) MDGA2 intron 23006423 rs7144383 chr14 48040375 G A 4.00E-06 Idiopathic pulmonary fibrosis MDGA2 intron 24429156 rs12891099 chr14 48045792 G A 9.00E-04 Response to taxane treatment (placlitaxel) MDGA2 intron 23006423 rs12894376 chr14 48049641 T C 9.00E-04 Response to taxane treatment (placlitaxel) MDGA2 intron 23006423 rs4143912 chr14 48054159 A G 6.00E-06 IgG glycosylation MDGA2 intron 23382691 rs4143912 chr14 48054159 A G 7.00E-06 IgG glycosylation MDGA2 intron 23382691 rs6572437 chr14 48084219 C A 1.10E-05 Parkinson's disease (age of onset) MDGA2 intron 19772629 rs7154720 chr14 48137514 A C 7.36E-04 Amyotrophic Lateral Sclerosis MDGA2 intron 17827064 rs2022690 chr14 48167200 T G 2.18E-04 Body mass index / / 21701565 rs2022690 chr14 48167200 T G 2.94E-05 Body mass index / / 21701565 rs7147755 chr14 48178606 T C 0.0003316 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7147755 chr14 48178606 T C 3.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8021382 chr14 48179997 A G 0.0000879 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs8021558 chr14 48180090 A G 4.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs10151687 chr14 48180584 A C 4.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs2022699 chr14 48182145 T C 4.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs10141942 chr14 48184712 C T 4.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs8005603 chr14 48184959 C T 4.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs4243549 chr14 48191610 T A 8.48E-04 Body mass index / / 21701565 rs2840260 chr14 48191787 A G 2.53E-04 Body mass index / / 21701565 rs11157574 chr14 48192256 A G 1.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs7158852 chr14 48192733 A G 1.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs8006626 chr14 48193936 C T 3.61E-04 Body mass index / / 21701565 rs7146384 chr14 48197659 G A 1.00E-04 QT interval / / 16648850 rs7146384 chr14 48197659 G A 7.82E-05 Glucose levels / / pha003057 rs8016883 chr14 48200491 T C 4.89E-04 Body mass index / / 21701565 rs10467722 chr14 48200882 G A 7.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs12887008 chr14 48203133 G A 6.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs8009748 chr14 48206563 C T 9.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs12890111 chr14 48207472 C T 9.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs2022705 chr14 48207945 C G 9.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs12895625 chr14 48208192 G A 9.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs11625818 chr14 48209561 A C 9.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs10142906 chr14 48209872 A T 9.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs12892345 chr14 48216549 T G 9.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs12323566 chr14 48243041 G A 7.36E-04 Body mass index LOC100506433 intron 21701565 rs11625446 chr14 48244558 C A 2.52E-04 Body mass index LOC100506433 intron 21701565 rs10135019 chr14 48249626 G A 2.01E-04 Body mass index LOC100506433 intron 21701565 rs4898580 chr14 48251282 C G 2.95E-04 Body mass index LOC100506433 intron 21701565 rs4898580 chr14 48251282 C G 8.81E-04 Body mass index LOC100506433 intron 21701565 rs17119161 chr14 48296993 C T 3.18E-04 Depression (quantitative trait) / / 20800221 rs10148160 chr14 48304259 G T 5.93E-04 Multiple complex diseases / / 17554300 rs6572456 chr14 48308114 C T 3.57E-04 Multiple complex diseases / / 17554300 rs6572457 chr14 48308231 T C 2.70E-04 Multiple complex diseases / / 17554300 rs6572458 chr14 48308299 C G 2.70E-04 Multiple complex diseases / / 17554300 rs8004171 chr14 48309387 A G 9.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs1597734 chr14 48311466 G C 8.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs12589205 chr14 48315274 G T 9.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs386019 chr14 48319030 T C 8.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs382713 chr14 48321820 A T 4.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs403794 chr14 48325027 C T 9.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs373389 chr14 48327132 T C 8.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs451505 chr14 48329638 T C 1.00E-04 Information processing speed / / 21130836 rs374842 chr14 48333747 C T 8.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs1451928 chr14 48340741 A C 7.31E-04 Depression (quantitative trait) / / 20800221 rs4417486 chr14 48344724 A G 7.10E-04 Depression (quantitative trait) / / 20800221 rs8011411 chr14 48349615 C T 7.28E-04 Depression (quantitative trait) / / 20800221 rs17763705 chr14 48352461 C T 5.57E-04 Depression (quantitative trait) / / 20800221 rs8004167 chr14 48353892 A C 3.09E-04 Depression (quantitative trait) / / 20800221 rs8009188 chr14 48354372 A G 3.09E-04 Depression (quantitative trait) / / 20800221 rs10135568 chr14 48355121 A G 2.16E-04 Multiple complex diseases / / 17554300 rs10135568 chr14 48355121 A G 3.10E-04 Depression (quantitative trait) / / 20800221 rs8015225 chr14 48355496 C T 2.94E-04 Multiple complex diseases / / 17554300 rs8015225 chr14 48355496 C T 3.11E-04 Depression (quantitative trait) / / 20800221 rs1958334 chr14 48357909 C T 3.40E-04 Multiple complex diseases / / 17554300 rs1958334 chr14 48357909 C T 3.24E-04 Depression (quantitative trait) / / 20800221 rs12885212 chr14 48382790 A G 4.88E-05 Cognitive performance / / 19734545 rs2770417 chr14 48386664 T A 1.41E-04 Depression (quantitative trait) / / 20800221 rs2480020 chr14 48389312 T G 1.46E-04 Depression (quantitative trait) / / 20800221 rs1952447 chr14 48389981 C G 1.46E-04 Depression (quantitative trait) / / 20800221 rs2683951 chr14 48390700 C T 1.48E-04 Depression (quantitative trait) / / 20800221 rs2770415 chr14 48392457 C T 1.48E-04 Depression (quantitative trait) / / 20800221 rs2683943 chr14 48395224 T A 1.46E-04 Depression (quantitative trait) / / 20800221 rs2770411 chr14 48397467 T G 1.45E-04 Depression (quantitative trait) / / 20800221 rs2770409 chr14 48398521 T C 6.92E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs2770407 chr14 48399463 G C 1.43E-04 Depression (quantitative trait) / / 20800221 rs1879520 chr14 48400975 C T 1.43E-04 Depression (quantitative trait) / / 20800221 rs1879520 chr14 48400975 C T 2.11E-05 Glucose levels / / pha003057 rs2683942 chr14 48401634 C G 1.43E-04 Depression (quantitative trait) / / 20800221 rs2770402 chr14 48406256 A G 1.63E-04 Depression (quantitative trait) / / 20800221 rs1521166 chr14 48417779 A T 2.10E-04 Depression (quantitative trait) / / 20800221 rs1879519 chr14 48418655 C G,T 2.10E-04 Depression (quantitative trait) / / 20800221 rs2245010 chr14 48419159 A G 9.67E-04 Depression (quantitative trait) / / 20800221 rs1357041 chr14 48425184 C T 3.11E-04 Depression (quantitative trait) / / 20800221 rs2183087 chr14 48431833 C A 7.28E-04 Depression (quantitative trait) / / 20800221 rs1357040 chr14 48435689 G T 2.62E-04 Depression (quantitative trait) / / 20800221 rs712429 chr14 48445047 T C 2.70E-04 Depression (quantitative trait) / / 20800221 rs712435 chr14 48450084 C T 2.27E-04 Depression (quantitative trait) / / 20800221 rs698298 chr14 48450886 A G 2.19E-04 Depression (quantitative trait) / / 20800221 rs712436 chr14 48451434 T C 4.21E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs712437 chr14 48452592 C G 4.59E-04 Depression (quantitative trait) / / 20800221 rs11622479 chr14 48460210 G C 5.99E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs810768 chr14 48466116 G A 5.12E-04 Depression (quantitative trait) / / 20800221 rs698305 chr14 48467048 T A,C,G 3.51E-04 Smoking initiation / / 24665060 rs4900829 chr14 48489537 C T 7.66E-05 Kawasaki disease / / 22081228 rs4900829 chr14 48489537 C T 4.61E-04 Myocardial Infarction / / pha002883 rs712476 chr14 48510590 G T 7.82E-05 Schizophrenia / / 20832056 rs712476 chr14 48510590 G T 3.48E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs698321 chr14 48524239 T G 1.25E-05 Glucose levels / / pha003057 rs698331 chr14 48536772 A G 1.10E-05 Urinary metabolites / / 21572414 rs9788469 chr14 48555664 A G 1.43E-05 Chronic obstructive pulmonary disease / / 19300482 rs9788469 chr14 48555664 A G 1.43E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12882827 chr14 48558259 C T 1.28E-05 Glucose levels / / pha003057 rs8008340 chr14 48558436 C T 8.86E-06 Glucose levels / / pha003057 rs7151223 chr14 48564956 G A 1.00E-06 Cognitive performance / / 20125193 rs1584157 chr14 48570466 G A,C,T 2.00E-06 Cognitive test performance / / 20125193 rs11628863 chr14 48574656 T G 2.20E-06 Urinary metabolites / / 21572414 rs8021638 chr14 48581772 G T 1.36E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs9323159 chr14 48584544 G A 1.27E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs11848228 chr14 48585580 C T 3.10E-06 Urinary metabolites / / 21572414 rs11848317 chr14 48585711 G A 3.40E-06 Urinary metabolites / / 21572414 rs767212 chr14 48594630 G C 3.10E-06 Urinary metabolites / / 21572414 rs1900100 chr14 48621120 G A 1.95E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs9323160 chr14 48633415 C T 1.95E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs8013481 chr14 48673794 T C 2.97E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs8008274 chr14 48676383 A G 2.08E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs7157790 chr14 48690325 A T 1.30E-05 Urinary metabolites / / 21572414 rs10134075 chr14 48699349 T C 1.23E-06 Lung function (forced expiratory volume in 1 second) / / pha003103 rs4589454 chr14 48701394 C T 3.66E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7150200 chr14 48710261 A G 9.34E-05 Aortic root size / / 21223598 rs8013860 chr14 48710866 A G 6.65E-04 Aortic root size / / 21223598 rs10149330 chr14 48711150 C T 2.49E-04 Aortic root size / / 21223598 rs12434842 chr14 48830461 T C 1.67E-04 Attention deficit hyperactivity disorder / / 23728934 rs12434887 chr14 48830578 T C 1.67E-04 Attention deficit hyperactivity disorder / / 23728934 rs12896339 chr14 48863322 G A 3.19E-05 Suicide attempts in bipolar disorder / / 21423239 rs12589623 chr14 48864985 A C 2.00E-05 Suicidal ideation / / 22030708 rs2416174 chr14 48877793 G A 8.24E-05 Suicide attempts in bipolar disorder / / 21423239 rs12896364 chr14 48891256 A T 1.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs12897104 chr14 48891444 G T 1.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs12434640 chr14 48900478 T G 3.98E-06 Coronary heart disease / / 21606135 rs10134003 chr14 48905055 T C 4.48E-04 Multiple complex diseases / / 17554300 rs10083389 chr14 48920008 A G 2.13E-05 Coronary heart disease / / 21606135 rs1385599 chr14 48929461 G A 9.71E-05 Post-operative nausea and vomiting / / 21694509 rs10140519 chr14 48937119 T C 3.98E-04 Longevity / / 22279548 rs2900032 chr14 48937931 T C 5.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs8020374 chr14 48942114 G A 1.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs1601422 chr14 48948553 T G 7.21E-04 Coronary Artery Disease / / 17634449 rs4424840 chr14 48959174 G T 1.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs1905825 chr14 48964920 A T 6.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs8014824 chr14 48978657 C T 5.17E-05 Suicide attempts in bipolar disorder / / 21423239 rs7152035 chr14 48981687 G C 4.39E-05 Suicide attempts in bipolar disorder / / 21423239 rs4078432 chr14 48997206 C T 2.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs10140638 chr14 49004194 A T 3.78E-05 Suicide attempts in bipolar disorder / / 21423239 rs12323417 chr14 49010274 T C 4.28E-05 Alzheimer's disease / / 17998437 rs4243557 chr14 49039024 A G 1.62E-04 Alzheimer's disease (late onset) / / 21379329 rs12435120 chr14 49047556 G A 5.87E-05 Dengue shock syndrome / / 22001756 rs12432015 chr14 49052782 T C 8.46E-05 Dengue shock syndrome / / 22001756 rs10498405 chr14 49056667 G A 6.27E-04 Diabetic retinopathy / / 20871662 rs1953901 chr14 49064582 G A 9.15E-04 Diabetic retinopathy / / 20871662 rs1959541 chr14 49072089 A G 1.30E-05 Personality dimensions / / 18957941 rs1953894 chr14 49126265 C G 3.39E-04 Type 2 diabetes / / 17463246 rs7492685 chr14 49135061 T C 3.10E-04 Multiple complex diseases / / 17554300 rs9323164 chr14 49152571 T C 9.12E-06 Venous thromboembolism / / 22672568 rs2000007 chr14 49155839 A G 9.27E-05 Blood Pressure / / pha003043 rs2790512 chr14 49218884 A C 3.60E-04 Multiple complex diseases / / 17554300 rs2585356 chr14 49250530 A G 8.50E-04 Multiple complex diseases / / 17554300 rs11157653 chr14 49318049 A G 1.68E-05 Cognitive impairment induced by topiramate / / 22091778 rs12587684 chr14 49364003 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2352904 chr14 49372801 A C 2.00E-06 Cognitive test performance / / 17903297 rs1986410 chr14 49378248 C T 7.66E-04 Type 2 diabetes / / 17846124 rs1986410 chr14 49378248 C T 6.96E-04 Rheumatoid arthritis / / 21452313 rs7148242 chr14 49391003 C A 8.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12147817 chr14 49395873 G A 6.38E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10136865 chr14 49399448 A G 5.05E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7158872 chr14 49426842 G T 2.00E-06 Post-traumatic stress disorder (asjusted for relatedness) / / 23726511 rs7158872 chr14 49426842 G T 3.00E-06 Post-traumatic stress disorder (asjusted for relatedness) / / 23726511 rs2352908 chr14 49437931 T G 1.00E-06 Social communication problems / / 24047820 rs11845208 chr14 49463484 A G 1.00E-07 Immune reponse to smallpox (secreted IL-2) / / 22610502 rs8013477 chr14 49534425 G C 4.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs10483554 chr14 49831095 A G 7.89E-04 Multiple complex diseases / / 17554300 rs7148751 chr14 49868900 G A 8.08E-04 Alcohol dependence / / 20201924 rs1530947 chr14 49951350 T C 5.00E-06 Visceral fat / / 22589738 rs8008323 chr14 49952834 A G 5.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12323544 chr14 49957353 T C 3.44E-05 Lung function (forced vital capacity) / / pha003104 rs4900925 chr14 50012325 C T 1.57E-04 Multiple complex diseases / / 17554300 rs17701513 chr14 50017291 T A 4.02E-04 Multiple complex diseases / / 17554300 rs4900928 chr14 50020817 A G 1.16E-04 Multiple complex diseases / / 17554300 rs7154992 chr14 50024139 C T 4.91E-04 Multiple complex diseases / / 17554300 rs4898626 chr14 50039050 C T 1.75E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2354445 chr14 50074014 G T 4.23E-04 Multiple complex diseases LRR1 intron 17554300 rs17121610 chr14 50083801 T C 8.05E-04 Multiple complex diseases / / 17554300 rs9989177 chr14 50092471 T C 1.38E-05 Telomere length D/AF2 missense 23001564 rs9989177 chr14 50092471 T C 1.72E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) D/AF2 missense 24023788 rs2985697 chr14 50092902 T C 3.51E-04 Multiple complex diseases D/AF2 intron 17554300 rs7146248 chr14 50112067 C T 6.09E-04 Multiple complex diseases POLE2 intron 17554300 rs7147722 chr14 50112712 G T 4.92E-04 Multiple complex diseases POLE2 intron 17554300 rs11625706 chr14 50145057 G A 1.57E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) POLE2 intron 24023788 rs10146912 chr14 50164452 G A 6.80E-05 Multiple complex diseases KLHDC1 intron 17554300 rs10146912 chr14 50164452 G A 4.00E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) KLHDC1 intron 24023788 rs12434721 chr14 50215357 G A 5.47E-05 Multiple complex diseases KLHDC1 intron 17554300 rs3126184 chr14 50372535 T C 9.42E-04 Alzheimer's disease / / 22005930 rs7159113 chr14 50406826 C T 7.05E-04 Tourette syndrome LOC100506446 intron 22889924 rs7155791 chr14 50418230 C T 9.52E-06 Osteoarthritis LOC100506446 intron 22763110 rs2236146 chr14 50429412 A G 9.51E-05 Type 2 diabetes / / 17463246 rs7159782 chr14 50454220 A G 1.73E-06 Magnesium levels C14orf182 intron pha003092 rs6572635 chr14 50472405 G A 6.09E-04 Tourette syndrome C14orf182 missense 22889924 rs10141751 chr14 50486225 G T 5.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs10142191 chr14 50486912 A G 8.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs8013833 chr14 50514353 G A 9.42E-05 Bipolar disorder / / 19488044 rs8013833 chr14 50514353 G A 6.01E-05 Bipolar Disorder / / pha002858 rs11628742 chr14 50515075 T C 1.95E-04 Multiple complex diseases / / 17554300 rs11625406 chr14 50516192 C A 1.71E-05 Longevity / / 20304771 rs11157721 chr14 50516714 T C 5.02E-04 Multiple complex diseases / / 17554300 rs11157721 chr14 50516714 T C 1.66E-05 Longevity / / 20304771 rs9323180 chr14 50518581 T C 2.95E-05 Longevity / / 20304771 rs1950705 chr14 50520406 C T 3.31E-05 Longevity / / 20304771 rs17122027 chr14 50521124 C T 7.43E-04 Multiple complex diseases / / 17554300 rs941604 chr14 50523074 A G 7.50E-04 Multiple complex diseases / / 17554300 rs941604 chr14 50523074 A G 2.94E-05 Longevity / / 20304771 rs7157296 chr14 50566882 G A 1.01E-04 Multiple complex diseases / / 17554300 rs7157296 chr14 50566882 G A 4.51E-04 Insulin resistance / / 21901158 rs7141328 chr14 50567129 T C 1.65E-04 Multiple complex diseases / / 17554300 rs7141328 chr14 50567129 T C 1.04E-05 Waist-Hip Ratio / / pha003013 rs7141328 chr14 50567129 T C 2.54E-06 Waist Circumference / / pha003025 rs7141328 chr14 50567129 T C 3.91E-05 Waist-Hip Ratio / / pha003028 rs2227276 chr14 50585248 C A,G,T 9.97E-05 Psoriasis SOS2 cds-synon 20953187 rs3742467 chr14 50639534 C T 3.97E-05 Self-employment SOS2 intron 23593239 rs8017367 chr14 50675487 C T 4.68E-06 Waist Circumference SOS2 intron pha003025 rs12879091 chr14 50676617 T C 5.72E-05 Socioeconomic Factors SOS2 intron pha003067 rs4901007 chr14 50729250 A G 2.60E-05 Urinary metabolites L2HGDH intron 21572414 rs4901008 chr14 50737669 A G 2.90E-05 Urinary metabolites L2HGDH intron 21572414 rs2275591 chr14 50778816 A C 4.94E-05 Waist Circumference L2HGDH missense pha003025 rs12433794 chr14 50786004 A G 9.31E-05 Waist Circumference ATP5S intron pha003025 rs7154788 chr14 50798037 A G 1.56E-04 Lymphocyte counts CDKL1 intron 22286170 rs4901015 chr14 50798665 C T 5.90E-05 Waist Circumference CDKL1 intron pha003025 rs11570877 chr14 50798856 C G 1.42E-04 Insulin resistance CDKL1 intron 21901158 rs7151406 chr14 50806723 G A 2.57E-05 Waist Circumference CDKL1 intron pha003025 rs8010877 chr14 50841107 G A 1.30E-05 Urinary metabolites CDKL1 intron 21572414 rs8010877 chr14 50841107 G A 7.78E-05 Sudden cardiac arrest CDKL1 intron 21658281 rs8010877 chr14 50841107 G A 7.87E-07 Lymphocyte counts CDKL1 intron 22286170 rs10162481 chr14 50847900 A G 1.69E-05 Myopia (pathological) CDKL1 intron 21095009 rs3783412 chr14 50856641 A G 8.66E-06 Uric acid levels CDKL1 intron 21294900 rs3783412 chr14 50856641 A G 8.00E-06 Periodontal disease-related phenotypes CDKL1 intron 24347629 rs1538903 chr14 50857478 A C 2.30E-05 Urinary metabolites CDKL1 intron 21572414 rs1265879 chr14 50877983 A G 4.00E-06 Cognitive performance / / 20125193 rs1265879 chr14 50877983 A G 9.21E-05 Prostate cancer / / 22923026 rs1265879 chr14 50877983 A G 0.00016 Prostate cancer / / 23555315 rs17122524 chr14 50894428 T C 9.18E-04 Suicide attempts in bipolar disorder MAP4K5 intron 21423239 rs2144973 chr14 50902871 T C 6.60E-04 Suicide attempts in bipolar disorder MAP4K5 intron 21423239 rs10131375 chr14 50905685 T C 6.79E-04 Suicide attempts in bipolar disorder MAP4K5 intron 21423239 rs2144974 chr14 50906090 C A 6.96E-04 Suicide attempts in bipolar disorder MAP4K5 intron 21423239 rs2180497 chr14 50906471 C A 7.27E-04 Suicide attempts in bipolar disorder MAP4K5 intron 21423239 rs10141280 chr14 50917947 C T 6.45E-04 Suicide attempts in bipolar disorder MAP4K5 intron 21423239 rs4898658 chr14 50939208 A C 4.59E-04 Suicide attempts in bipolar disorder MAP4K5 intron 21423239 rs11157745 chr14 50947472 A C 7.50E-04 Suicide attempts in bipolar disorder MAP4K5 intron 21423239 rs1950731 chr14 50966820 C A 4.92E-04 Suicide attempts in bipolar disorder MAP4K5 intron 21423239 rs17718580 chr14 50973632 C T 8.00E-07 Cognitive performance MAP4K5 intron 20125193 rs3783409 chr14 50990400 C T 5.34E-04 Suicide attempts in bipolar disorder MAP4K5 intron 21423239 rs4257133 chr14 50992644 A C 5.06E-04 Suicide attempts in bipolar disorder MAP4K5 intron 21423239 rs7160618 chr14 50992936 T C 6.58E-04 Suicide attempts in bipolar disorder MAP4K5 intron 21423239 rs2356450 chr14 51005599 G A 4.97E-04 Suicide attempts in bipolar disorder ATL1 intron 21423239 rs7152982 chr14 51007615 A C 5.16E-04 Suicide attempts in bipolar disorder ATL1 intron 21423239 rs12587721 chr14 51016600 A G 6.92E-04 Suicide attempts in bipolar disorder ATL1 intron 21423239 rs3759589 chr14 51052968 G T 1.17E-04 Cholesterol ATL1 intron 17255346 rs1032466 chr14 51074461 A C 2.78E-04 Response to alcohol consumption (flushing response) ATL1 intron 24277619 rs10146136 chr14 51079426 G A 5.78E-05 Cognitive impairment induced by topiramate ATL1 intron 22091778 rs10146136 chr14 51079426 G A 3.22E-05 Body Mass Index ATL1 intron pha003022 rs4901043 chr14 51083594 T C 8.50E-08 Progranulin levels ATL1 intron 21087763 rs4901043 chr14 51083594 T C 8.50E-08 Myocardial infarction ATL1 intron 21211798 rs17122693 chr14 51084235 T C 3.00E-07 Cognitive performance ATL1 intron 20125193 rs2047150 chr14 51086387 A G 2.63E-07 Cognitive test performance ATL1 intron 20125193 rs2934693 chr14 51101641 G A 3.46E-04 Type 2 diabetes SAV1 UTR-3 17463246 rs6572681 chr14 51117059 T C 5.22E-05 Cholesterol SAV1 intron 17255346 rs6572681 chr14 51117059 T C 7.97E-04 Type 2 diabetes SAV1 intron 17463246 rs4901047 chr14 51124227 T C 1.47E-05 Cognitive test performance SAV1 intron 20125193 rs7159861 chr14 51144660 A G 9.00E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3015471 chr14 51155535 G C 4.77E-04 Type 2 diabetes / / 17463246 rs3015469 chr14 51157160 G A 8.00E-07 Plasma amyloid beta peptide concentrations (ABx-40) / / 24535457 rs8020441 chr14 51170879 T C,G 5.00E-07 Cognitive performance / / 20125193 rs8020441 chr14 51170879 T C,G 3.62E-04 Myopia (pathological) / / 21095009 rs10144234 chr14 51172219 C A 4.00E-04 Type 2 diabetes / / 17463246 rs7148925 chr14 51172710 T C 2.54E-04 Myopia (pathological) / / 21095009 rs6572692 chr14 51176739 C A 1.65E-04 Myopia (pathological) / / 21095009 rs4534750 chr14 51188124 G A 9.94E-06 Cognitive test performance NIN UTR-3 20125193 rs1599969 chr14 51191734 C T 3.14E-04 Cholesterol NIN intron 17255346 rs2984272 chr14 51193213 A T 1.05E-04 Asthma NIN intron 23181788 rs2984274 chr14 51196142 T C 4.27E-05 Brain lesion load NIN intron 19010793 rs10148309 chr14 51201711 C T 2.35E-04 Smoking initiation NIN intron 24665060 rs11624766 chr14 51214930 T C 7.68E-05 Lupus nephritis in systemic lupus erythematosus NIN intron 24925725 rs4901053 chr14 51217574 T G 1.98E-04 Schizophrenia NIN intron 19197363 rs4901053 chr14 51217574 T G 6.41E-05 Cognitive test performance NIN intron 20125193 rs10132785 chr14 51221672 A C 5.73E-05 Lupus nephritis in systemic lupus erythematosus NIN intron 24925725 rs4901055 chr14 51227000 A G 1.17E-05 Lupus nephritis in systemic lupus erythematosus NIN cds-synon 24925725 rs10141242 chr14 51227322 T C 6.12E-06 Lupus nephritis in systemic lupus erythematosus NIN intron 24925725 rs7153562 chr14 51231298 C A 2.02E-05 Lupus nephritis in systemic lupus erythematosus NIN intron 24925725 rs6572695 chr14 51232335 C T 2.70E-05 Lupus nephritis in systemic lupus erythematosus NIN intron 24925725 rs8012283 chr14 51234160 A G 3.00E-07 Lupus nephritis in systemic lupus erythematosus NIN intron 24925725 rs61985512 chr14 51238416 T A 9.71E-06 Stroke (ischemic) NIN intron 21957438 rs8015968 chr14 51238759 C A 1.89E-06 Lupus nephritis in systemic lupus erythematosus NIN intron 24925725 rs11157764 chr14 51250337 G A 1.07E-05 Lupus nephritis in systemic lupus erythematosus NIN intron 24925725 rs10137294 chr14 51261672 T C 3.08E-05 Lupus nephritis in systemic lupus erythematosus NIN intron 24925725 rs10148502 chr14 51261957 G A 6.61E-04 Type 2 diabetes NIN intron 17463246 rs3759526 chr14 51292535 C T 4.09E-04 Premature ovarian failure NIN intron 19508998 rs2181083 chr14 51293706 C T 4.01E-05 Progressive supranuclear palsy NIN intron 21685912 rs8016526 chr14 51310466 T C 6.13E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs8019546 chr14 51323742 G A 5.00E-06 Dietary macronutrient intake / / 23636237 rs7143869 chr14 51328222 C T 5.39E-05 Body Fat Distribution / / pha003017 rs12889998 chr14 51347023 T C 3.53E-04 Smoking initiation ABHD12B intron 24665060 rs12589665 chr14 51364371 T C 9.88E-04 Alzheimer's disease ABHD12B intron 24755620 rs17123103 chr14 51368495 G A 7.49E-04 Alzheimer's disease ABHD12B intron 24755620 rs28564871 chr14 51368610 A G 7.49E-04 Alzheimer's disease ABHD12B missense 24755620 rs11157780 chr14 51371130 C T 8.66E-04 Alzheimer's disease ABHD12B UTR-3 24755620 rs11157781 chr14 51371150 C T 8.66E-04 Alzheimer's disease ABHD12B UTR-3 24755620 rs11157782 chr14 51371524 C T 8.86E-04 Alzheimer's disease ABHD12B UTR-3 24755620 rs2027341 chr14 51372606 G A 9.91E-04 Alzheimer's disease PYGL intron 24755620 rs2356535 chr14 51375250 G T 7.14E-04 Alzheimer's disease PYGL intron 24755620 rs10132049 chr14 51376237 A G 3.69E-04 Alzheimer's disease PYGL intron 24755620 rs946617 chr14 51387590 T G 2.18E-05 Hepatitis B PYGL intron 21750111 rs7142143 chr14 51403531 T C 1.62E-04 Multiple complex diseases PYGL intron 17554300 rs7142143 chr14 51403531 T C 7.00E-09 Acute lymphoblastic leukemia (childhood) PYGL intron 23007406 rs1890706 chr14 51407580 C T 6.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PYGL intron 20877124 rs17123244 chr14 51411029 A G 7.27E-04 Type 2 diabetes PYGL cds-synon 17463246 rs111345281 chr14 51411707 C A 0.0000141 Sarcoidosis PYGL nearGene-5 22952805 rs17123266 chr14 51428551 G T 5.91E-04 Type 2 diabetes / / 17463246 rs10483609 chr14 51433884 G A 7.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1959536 chr14 51446771 T G 8.00E-07 Psychosis (atypical) TRIM9 intron 24132900 rs17796080 chr14 51447669 T C 6.83E-04 Coronary Artery Disease TRIM9 intron 17634449 rs10873039 chr14 51449906 G C 5.16E-04 Type 2 diabetes TRIM9 intron 22158537 rs2275460 chr14 51454134 T C 8.26E-04 Type 2 diabetes TRIM9 intron 22158537 rs8007373 chr14 51455102 A G 5.80E-04 Type 2 diabetes TRIM9 intron 22158537 rs9944007 chr14 51455166 T C 4.86E-04 Multiple complex diseases TRIM9 intron 17554300 rs8014229 chr14 51461929 T C 7.92E-04 Type 2 diabetes TRIM9 intron 22158537 rs10483607 chr14 51463322 A G 3.03E-04 Type 2 diabetes TRIM9 UTR-3 17463246 rs12323589 chr14 51466259 A C 7.45E-04 Type 2 diabetes TRIM9 intron 22158537 rs10151412 chr14 51466641 T C 7.23E-04 Type 2 diabetes TRIM9 intron 22158537 rs1953887 chr14 51475116 G C 9.22E-04 Type 2 diabetes TRIM9 intron 22158537 rs2039795 chr14 51477753 G A 7.94E-04 Type 2 diabetes TRIM9 intron 22158537 rs7157686 chr14 51478393 T C 7.09E-04 Type 2 diabetes TRIM9 intron 22158537 rs1953883 chr14 51479571 C G 6.92E-04 Multiple complex diseases TRIM9 intron 17554300 rs8019419 chr14 51481912 T C 8.90E-04 Type 2 diabetes TRIM9 intron 17463246 rs1556927 chr14 51495896 C A 6.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRIM9 intron 20877124 rs8009082 chr14 51499344 C A 5.01E-05 Nicotine smoking TRIM9 intron 19268276 rs4609754 chr14 51518925 T C 0.0000136 LDL cholesterol particle diameter TRIM9 intron 23263444 rs8006348 chr14 51525473 A G 4.91E-05 Bipolar disorder TRIM9 intron 21926972 rs12101017 chr14 51529229 T G 0.0000162 LDL cholesterol particle diameter TRIM9 intron 23263444 rs4606614 chr14 51529970 C T 0.0000162 LDL cholesterol particle diameter TRIM9 intron 23263444 rs11157796 chr14 51544623 C T 3.58E-05 Coronary heart disease TRIM9 intron pha003030 rs4400967 chr14 51548540 G A 6.68E-05 Serum metabolites TRIM9 intron 19043545 rs4901076 chr14 51552126 G A 6.31E-32 Narcolepsy TRIM9 intron 19629137 rs2999394 chr14 51560029 G A 8.59E-04 HIV-1 viral setpoint TRIM9 intron 17641165 rs2999394 chr14 51560029 G A 0.00000614 LDL cholesterol particle diameter TRIM9 intron 23263444 rs17252296 chr14 51580921 A C 8.59E-05 Nicotine smoking / / 19268276 rs10129181 chr14 51637140 T C 4.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs4465517 chr14 51673715 C A 5.29E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4078418 chr14 51756999 G T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4526942 chr14 51762689 A G 1.20E-05 Cognitive impairment induced by topiramate / / 22091778 rs4432175 chr14 51776897 T G 8.47E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7160689 chr14 51795860 G T 5.12E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs7160689 chr14 51795860 G T 8.35E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs2884058 chr14 51799925 A G 5.06E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs2884058 chr14 51799925 A G 8.34E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs2884058 chr14 51799925 A G 2.85E-05 Systemic lupus erythematosus / / pha002867 rs11157816 chr14 51802911 C T 2.26E-05 Schizophrenia LOC283553 intron 19571809 rs11157816 chr14 51802911 C T 7.91E-05 Schizophrenia LOC283553 intron pha002859 rs10149162 chr14 51821239 A G 1.71E-04 Lung function (forced vital capacity) LOC283553 intron 24023788 rs17123825 chr14 51823881 C G 1.59E-04 Multiple complex diseases LOC283553 intron 17554300 rs2356895 chr14 51828412 C T 0.00000128 Antithrombin LOC283553 intron 23705025 rs8019638 chr14 51830366 G A 4.40E-05 Parkinson's disease (age of onset) LOC283553 intron 19772629 rs8003741 chr14 51859547 G A 6.42E-05 Cognitive impairment induced by topiramate / / 22091778 rs4901119 chr14 51862526 A G 5.97E-06 Alzheimer's disease / / 21627779 rs10498424 chr14 51865340 T A 0.0000235 Panic disorder / / 23149450 rs10498424 chr14 51865340 T A 2.35E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs530874840 chr14 51865340 TAAG T 0.0000235 Panic disorder / / 23149450 rs530874840 chr14 51865340 TAAG T 2.35E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs17123863 chr14 51865549 A T 6.86E-04 Type 2 diabetes / / 17463246 rs11847121 chr14 51866997 C T 4.46E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17123873 chr14 51867875 A G 3.75E-04 Multiple complex diseases / / 17554300 rs17831163 chr14 51875282 T C 4.03E-04 Type 2 diabetes / / 17463246 rs199893941 chr14 51878807 A AG 4.51E-06 Non-obstructive azoospermia / / 22541561 rs7149094 chr14 51878807 A G 4.51E-06 Non-obstructive azoospermia / / 22541561 rs10142129 chr14 51896641 G A 3.91E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4597233 chr14 51900329 G A 5.77E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12432629 chr14 51905996 G C 9.87E-04 Insulin resistance / / 21901158 rs142309106 chr14 51908821 T C 0.0000729 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7148299 chr14 51911175 T G 2.05E-04 Smoking initiation / / 24665060 rs12890680 chr14 51919684 C T 1.64E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7153703 chr14 51919822 A G 3.00E-06 Total ventricular volume / / 21116278 rs2356918 chr14 51920712 G A 1.64E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12889345 chr14 51924923 C T 1.73E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12879130 chr14 51926072 C A 6.65E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12879130 chr14 51926072 C A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7152689 chr14 51933640 C T 2.36E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17123958 chr14 51942124 C T 7.59E-05 Alzheimer's disease / / 17998437 rs17123958 chr14 51942124 C T 7.59E-05 Alzheimer's disease / / 22190428 rs17123958 chr14 51942124 C T 1.04E-04 Alzheimer's disease / / pha002879 rs17123969 chr14 51946458 A G 7.72E-05 Alzheimer's disease / / 17998437 rs1570127 chr14 51946778 G A 8.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10484092 chr14 51956234 A G 8.12E-04 Type 2 diabetes FRMD6 intron 17463246 rs8015746 chr14 51958312 A G 4.56E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) FRMD6 intron 24023788 rs17660434 chr14 51962911 C T 5.17E-05 Cholesterol FRMD6 intron pha003073 rs17660434 chr14 51962911 C T 6.56E-05 Cholesterol FRMD6 intron pha003078 rs4898695 chr14 51966593 G A 2.70E-05 Urinary metabolites FRMD6 intron 21572414 rs10400789 chr14 51967896 T C 1.20E-05 Urinary metabolites FRMD6 intron 21572414 rs12437336 chr14 51973660 T C 9.70E-06 Urinary metabolites FRMD6 intron 21572414 rs1950918 chr14 51979393 C T 2.31E-05 Hypertension FRMD6 intron 22384028 rs17124092 chr14 51989461 G A 2.30E-05 Urinary metabolites FRMD6 intron 21572414 rs11157829 chr14 52001770 C G 1.90E-05 Urinary metabolites FRMD6 intron 21572414 rs4901134 chr14 52003903 C T 2.50E-05 Urinary metabolites FRMD6 intron 21572414 rs10149874 chr14 52004575 G A 1.70E-05 Urinary metabolites FRMD6 intron 21572414 rs1950916 chr14 52005146 C T 9.67E-05 Non-alcoholic fatty liver disease histology (other) FRMD6 intron 20708005 rs7140150 chr14 52010799 C T 5.00E-07 Brain structure FRMD6 intron 20171287 rs17586545 chr14 52035018 C T 4.18E-05 Alzheimer's disease FRMD6 intron 22190428 rs4898700 chr14 52048393 G A 1.36E-05 Suicide attempts in bipolar disorder FRMD6 intron 21423239 rs1956586 chr14 52051123 A G 5.31E-04 Suicide attempts in bipolar disorder FRMD6 intron 21423239 rs4898701 chr14 52051189 A G 6.50E-04 Suicide attempts in bipolar disorder FRMD6 intron 21423239 rs4898703 chr14 52054873 A C 8.11E-04 Suicide attempts in bipolar disorder FRMD6 intron 21423239 rs11626565 chr14 52075152 A C 2.45E-05 Alzheimer's disease FRMD6 intron 22190428 rs12885443 chr14 52075653 A C 5.34E-04 Alzheimer's disease FRMD6 intron 22190428 rs1006973 chr14 52077089 T C 8.00E-06 Anticoagulant levels FRMD6 intron 22216198 rs17124283 chr14 52077921 G A 9.48E-04 Suicide attempts in bipolar disorder FRMD6 intron 21423239 rs1950926 chr14 52079265 T G 7.12E-04 Depression (quantitative trait) FRMD6 intron 20800221 rs10484085 chr14 52081004 G A 3.53E-04 Multiple complex diseases FRMD6 intron 17554300 rs1008924 chr14 52083080 G A 5.55E-07 Inflammatory biomarkers FRMD6 intron 22291609 rs2010518 chr14 52086595 C G 6.92E-04 Alzheimer's disease FRMD6 intron 17998437 rs2010520 chr14 52086630 A G 5.08E-04 Alzheimer's disease FRMD6 intron 17998437 rs4898705 chr14 52109999 T G 9.86E-04 Multiple complex diseases FRMD6 intron 17554300 rs8019441 chr14 52110329 G A 4.25E-04 Multiple complex diseases FRMD6 intron 17554300 rs9671722 chr14 52127059 A G 1.00E-04 Prostate cancer FRMD6 intron 21743057 rs9805984 chr14 52131743 G T 6.38E-04 Bipolar disorder,schizoaffective FRMD6 intron 19567891 rs9805984 chr14 52131743 G T 1.00E-05 Drug-induced torsades de pointes FRMD6 intron 24223155 rs11847326 chr14 52131756 G A 3.48E-04 Multiple complex diseases FRMD6 intron 17554300 rs10141001 chr14 52132201 G A 1.00E-05 Drug-induced torsades de pointes FRMD6 intron 24223155 rs6572783 chr14 52132331 A G 7.33E-04 Heart Failure FRMD6 intron pha002885 rs4277270 chr14 52140055 T G 7.39E-04 Multiple complex diseases FRMD6 intron 17554300 rs7149810 chr14 52195320 A G 3.83E-05 Basophils FRMD6 UTR-3 pha003087 rs11626056 chr14 52233276 C T 1.00E-06 Hippocampal atrophy / / 19668339 rs11625641 chr14 52245421 C T 3.39E-05 Suicide attempts in bipolar disorder / / 21423239 rs17831283 chr14 52248392 C G 4.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs4528474 chr14 52248893 G T 6.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs4272956 chr14 52248924 C A 3.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs4300564 chr14 52249654 G C 3.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs4580078 chr14 52249732 G A 3.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs4281635 chr14 52250159 C T 4.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs4441186 chr14 52250365 T C 6.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs11628927 chr14 52253365 A G 5.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs10140352 chr14 52253749 T C 6.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs12896792 chr14 52253769 G A 1.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs4411416 chr14 52254516 T C 8.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs11844371 chr14 52257555 T A 7.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs8018469 chr14 52270381 T G 7.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs8017705 chr14 52270471 G A 7.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs8023017 chr14 52271327 G A 7.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs4445814 chr14 52272452 G C 7.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs7145953 chr14 52272501 C A 7.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs17831313 chr14 52276962 C G 7.31E-05 Aging (time to event) / / 21782286 rs10141199 chr14 52285245 G A 8.34E-04 Acute lung injury / / 22295056 rs9652338 chr14 52286816 A T 8.25E-04 Acute lung injury / / 22295056 rs10498433 chr14 52289531 A G 8.25E-04 Acute lung injury / / 22295056 rs10147376 chr14 52292905 G T 8.20E-04 Acute lung injury / / 22295056 rs4898718 chr14 52297987 T C 5.09E-05 Multiple complex diseases / / 17554300 rs10498435 chr14 52300278 C G 7.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10220428 chr14 52301953 C T 7.37E-06 Multiple complex diseases / / 17554300 rs8015138 chr14 52310104 A C 7.00E-08 Non-melanoma skin cancer / / 23548203 rs4468527 chr14 52325131 A G 9.97E-05 Multiple sclerosis / / 19525953 rs12878420 chr14 52336682 G T 1.30E-05 Urinary metabolites GNG2 intron 21572414 rs10138800 chr14 52339351 G A 8.54E-04 Alzheimer's disease GNG2 intron 17998437 rs10131301 chr14 52349774 A T 4.83E-04 Alzheimer's disease GNG2 intron 17998437 rs10131301 chr14 52349774 A T 1.40E-05 Urinary metabolites GNG2 intron 21572414 rs1959518 chr14 52352912 A G 0.0000048 Mean arterial pressure GNG2 intron 22510845 rs1959517 chr14 52352950 A T 0.0000037 Mean arterial pressure GNG2 intron 22510845 rs10133203 chr14 52355387 A G 1.06E-05 Leprosy GNG2 intron pha002872 rs7154422 chr14 52356663 A G 4.12E-05 Telomere length GNG2 intron 23001564 rs1316298 chr14 52365774 A G 7.00E-06 Lung cancer (smoking interaction) GNG2 intron 24658283 rs11157865 chr14 52367075 C T 4.50E-06 Urinary metabolites GNG2 intron 21572414 rs3742539 chr14 52380187 G A 3.60E-05 Hypothyroidism GNG2 intron 22493691 rs1253687 chr14 52381244 G A 3.74E-04 Multiple complex diseases GNG2 intron 17554300 rs1253672 chr14 52389388 T C 6.35E-05 Multiple complex diseases GNG2 intron 17554300 rs10498440 chr14 52413573 T C 2.50E-04 Crohn's disease GNG2 intron 17684544 rs17124772 chr14 52420144 G C 2.38E-04 Multiple complex diseases GNG2 intron 17554300 rs1253647 chr14 52428112 A G 6.77E-04 Multiple complex diseases GNG2 intron 17554300 rs1253654 chr14 52428836 T A 8.24E-04 Multiple complex diseases GNG2 intron 17554300 rs1151581 chr14 52480597 C T 1.70E-05 Urinary metabolites NID2 intron 21572414 rs2073622 chr14 52500178 G A 2.91E-04 Lung function (forced expiratory volume in 1 second) NID2 intron 24023788 rs730532 chr14 52518811 G A 6.00E-06 Pulmonary function NID2 intron 17903307 rs971394 chr14 52522539 A C,G,T 0.00005136 Sarcoidosis NID2 intron 22952805 rs2013412 chr14 52523365 T C 0.00005085 Sarcoidosis NID2 intron 22952805 rs1032579 chr14 52523887 A G 0.00006025 Sarcoidosis NID2 intron 22952805 rs10498441 chr14 52544224 G A 1.06E-05 Pulmonary function / / 17903307 rs1956286 chr14 52553691 G T 6.75E-04 Type 2 diabetes / / 17463246 rs2357313 chr14 52556505 C T 6.23E-04 Rheumatoid arthritis / / 21452313 rs8005920 chr14 52560934 C T 2.27E-05 Coronary heart disease / / pha003031 rs1998094 chr14 52583459 C T 7.91E-07 Osteoarthritis / / 22763110 rs8004270 chr14 52607417 T C 4.13E-04 Insulin resistance / / 21901158 rs941612 chr14 52621668 A G 7.40E-05 Alcoholism (heaviness of drinking) / / 21529783 rs941614 chr14 52621833 A G 9.71E-05 Otosclerosis / / 19230858 rs8004859 chr14 52625394 A T 2.81E-05 Pulmonary function / / 20010835 rs10129786 chr14 52630696 G T 2.78E-05 Pulmonary function / / 20010835 rs4505230 chr14 52638672 A G 2.47E-05 Pulmonary function / / 20010835 rs1950739 chr14 52639401 C T 2.69E-05 Pulmonary function / / 20010835 rs1950740 chr14 52639485 C T 2.71E-05 Pulmonary function / / 20010835 rs11459929 chr14 52640158 C CT 2.74E-05 Pulmonary function / / 20010835 rs7147043 chr14 52640158 C T 2.74E-05 Pulmonary function / / 20010835 rs7147188 chr14 52640208 C T 2.75E-05 Pulmonary function / / 20010835 rs4901225 chr14 52640760 A T 2.80E-05 Pulmonary function / / 20010835 rs5020509 chr14 52641472 A G 7.70E-04 Multiple complex diseases / / 17554300 rs5020509 chr14 52641472 A G 2.80E-05 Pulmonary function / / 20010835 rs8021782 chr14 52642436 G A 2.79E-05 Pulmonary function / / 20010835 rs4901226 chr14 52642487 A T 2.69E-05 Pulmonary function / / 20010835 rs4901227 chr14 52642530 C A 2.72E-05 Pulmonary function / / 20010835 rs4901229 chr14 52642808 C T 2.76E-05 Pulmonary function / / 20010835 rs4901230 chr14 52642874 C A 2.80E-05 Pulmonary function / / 20010835 rs7143674 chr14 52643143 A G 2.92E-05 Pulmonary function / / 20010835 rs2357453 chr14 52643193 A T 2.91E-05 Pulmonary function / / 20010835 rs2357454 chr14 52643336 G A 2.88E-05 Pulmonary function / / 20010835 rs1956264 chr14 52644729 A G 6.42E-05 Pulmonary function / / 20010835 rs1950742 chr14 52645492 T C 6.40E-05 Pulmonary function / / 20010835 rs8018851 chr14 52645708 A G 6.75E-05 Pulmonary function / / 20010835 rs8003616 chr14 52646094 G A 2.39E-04 Multiple complex diseases / / 17554300 rs11851721 chr14 52649348 A C,G,T 2.50E-05 Urinary metabolites / / 21572414 rs893298 chr14 52690059 T G 6.18E-04 Sleep duration / / 23728906 rs708486 chr14 52740971 A G 1.00E-05 White matter hyperintensity burden PTGDR intron 21681796 rs708486 chr14 52740971 A G 1.57E-04 Stroke (pediatric) PTGDR intron 22990015 rs810633 chr14 52741950 A G 4.83E-04 Coronary heart disease PTGDR UTR-3 21971053 rs17831706 chr14 52755385 C T 2.70E-05 Anger / / 24489884 rs1495790 chr14 52756283 T C 1.80E-05 White matter hyperintensity burden / / 21681796 rs11623395 chr14 52757875 G A 1.60E-05 White matter hyperintensity burden / / 21681796 rs11625623 chr14 52759346 A G 7.70E-06 White matter hyperintensity burden / / 21681796 rs1390375 chr14 52761693 T G 1.00E-05 White matter hyperintensity burden / / 21681796 rs708491 chr14 52764944 A G 0.0000214 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs708491 chr14 52764944 A G 2.14E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8008292 chr14 52768564 T C 2.60E-04 Alcohol dependence / / 20201924 rs8008292 chr14 52768564 T C 4.20E-04 Alcohol dependence / / 20201924 rs7158953 chr14 52800735 C A 1.40E-05 IgE levels / / 22075330 rs708511 chr14 52809937 T C 5.50E-07 Urinary metabolites / / 21572414 rs11848946 chr14 52810800 A G 8.55E-05 IgE levels / / 22075330 rs2357624 chr14 52811145 A C 7.70E-06 Urinary metabolites / / 21572414 rs17125437 chr14 52832692 C T 1.80E-05 Urinary metabolites / / 21572414 rs12433695 chr14 52858255 C G 4.10E-06 Urinary metabolites / / 21572414 rs17831748 chr14 52858431 T C 3.90E-06 Urinary metabolites / / 21572414 rs6572843 chr14 52864237 C T 4.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs2859837 chr14 52867736 C T 5.05E-06 Kawasaki disease / / 21221998 rs34246750 chr14 52868757 G C 6.90E-07 Kawasaki disease / / 21221998 rs34246750 chr14 52868757 G C 1.90E-05 Urinary metabolites / / 21572414 rs11621817 chr14 52874046 G A 3.95E-04 Birth weight / / 17255346 rs11621817 chr14 52874046 G A 3.47E-06 Kawasaki disease / / 21221998 rs8008348 chr14 52874145 A G 6.90E-07 Kawasaki disease / / 21221998 rs17125480 chr14 52877037 C G 7.16E-05 Multiple complex diseases / / 17554300 rs10143866 chr14 52884355 T C 5.19E-04 Renal cell carcinoma / / 22010048 rs10143866 chr14 52884355 T C 2.00E-06 Smooth-surface caries / / 24556642 rs781377 chr14 52895084 C T 9.44E-05 Cognitive impairment induced by topiramate / / 22091778 rs745080 chr14 52989228 G A 8.00E-07 Orofacial clefts TXNDC16 intron 22419666 rs7144509 chr14 53023607 G A 2.29E-05 Orofacial clefts GPR137C intron 22419666 rs1458114 chr14 53023847 T C 3.24E-06 White blood cell count GPR137C intron 21738479 rs10483611 chr14 53033531 T C 3.48E-05 Heart Failure GPR137C intron pha002885 rs4901286 chr14 53046601 G A 3.29E-04 Alcohol dependence GPR137C intron 20201924 rs1007894 chr14 53094595 G A 7.84E-04 Alcohol dependence GPR137C intron 24277619 rs7150290 chr14 53151109 T C 4.28E-05 Melanoma ERO1L intron 21926416 rs11157928 chr14 53151190 T A 4.43E-05 Type 2 diabetes ERO1L intron 17463246 rs10483614 chr14 53151428 T C 1.93E-04 Type 2 diabetes ERO1L intron 17463246 rs12590590 chr14 53161736 G T 2.40E-04 Acute lung injury ERO1L intron 22295056 rs2884343 chr14 53192357 T C 4.68E-04 Response to taxane treatment (placlitaxel) PSMC6 intron 23006423 rs8004624 chr14 53197711 A G 5.99E-05 Tourette syndrome STYX intron 22889924 rs4898764 chr14 53265071 A G 3.00E-04 Tourette syndrome / / 22889924 rs12586707 chr14 53298277 A G 4.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2884345 chr14 53323211 G A 2.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11157934 chr14 53365816 T C 5.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FERMT2 intron 20877124 rs11157934 chr14 53365816 T C 3.34E-04 Body mass index FERMT2 intron 21701565 rs8008270 chr14 53372330 T C 2.00E-14 Prostate cancer FERMT2 intron 23535732 rs8009633 chr14 53386836 G C 1.10E-05 Blood pressure FERMT2 intron 21909110 rs7157639 chr14 53388161 C T 1.78E-05 Cognitive test performance FERMT2 intron 20125193 rs17125924 chr14 53391680 A G 1.39E-05 Alzheimer's disease (late onset) FERMT2 intron 21460841 rs17125944 chr14 53400629 T C 1.32E-05 Alzheimer's disease (late onset) FERMT2 intron 21460841 rs17125944 chr14 53400629 T C 8.00E-09 Alzheimer's disease (late onset) FERMT2 intron 24162737 rs11628434 chr14 53469463 C T 4.04E-05 Cognitive test performance / / 20125193 rs1124055 chr14 53476104 G A 8.11E-05 Cognitive test performance / / 20125193 rs12432063 chr14 53486725 G A 9.83E-04 Type 2 diabetes / / 17463246 rs17126072 chr14 53507684 G A 0.00000002 Brain microstructure and intellectual performance DDHD1 UTR-3 22723713 rs12882412 chr14 53525427 C T 4.26E-04 Depression (quantitative trait) DDHD1 intron 20800221 rs2065345 chr14 53531579 G A 4.33E-04 Depression (quantitative trait) DDHD1 intron 20800221 rs1889813 chr14 53624640 C T 1.67E-04 Multiple complex diseases / / 17554300 rs4901366 chr14 53682895 G C 5.14E-04 Acute lung injury / / 22295056 rs7151611 chr14 53702279 G C 4.29E-04 Type 2 diabetes / / 17463246 rs2052656 chr14 53703744 C G 4.00E-04 Type 2 diabetes / / 17463246 rs763328 chr14 53707009 A G 2.58E-05 Magnesium levels / / pha003092 rs4901374 chr14 53707828 C T 5.58E-04 Multiple complex diseases / / 17554300 rs1156651 chr14 53712944 G A 5.14E-04 Type 2 diabetes / / 17463246 rs10143447 chr14 53731553 A G 5.80E-04 Type 2 diabetes / / 17463246 rs1255331 chr14 53812252 C G 2.93E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs1255329 chr14 53813420 T C 3.04E-05 Blood Pressure / / pha003048 rs1255311 chr14 53819557 A G 3.04E-05 Blood Pressure / / pha003048 rs1255277 chr14 53833926 C T 2.95E-05 Blood Pressure / / pha003048 rs12434047 chr14 53837485 G A 3.00E-06 Economic and political preferences (fairness) / / 22566634 rs11157967 chr14 53857356 G A 8.09E-04 Alzheimer's disease / / 17998437 rs11157968 chr14 53857420 T A 5.86E-04 Alzheimer's disease / / 17998437 rs10498449 chr14 53866002 C G 3.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10498449 chr14 53866002 C G 1.34E-05 Alcohol consumption / / pha001399 rs10873072 chr14 53922251 G C 7.52E-05 Multiple complex diseases / / 17554300 rs17126540 chr14 53924569 A G 6.99E-04 Multiple complex diseases / / 17554300 rs12434473 chr14 53937965 A G 8.94E-08 Metabolite levels / / 23281178 rs17126556 chr14 53942788 A G 9.94E-04 Multiple complex diseases / / 17554300 rs17126556 chr14 53942788 A G 1.80E-08 Metabolite levels / / 23281178 rs1959824 chr14 53944929 A G 3.32E-04 Multiple complex diseases / / 17554300 rs11623357 chr14 53945798 T C 4.86E-04 Multiple complex diseases / / 17554300 rs1317805 chr14 53947075 G A 6.55E-08 Metabolite levels / / 23281178 rs1954315 chr14 53953798 A G 1.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs17253291 chr14 53962563 A G 3.40E-04 Multiple complex diseases / / 17554300 rs2185821 chr14 53962624 A T 2.41E-04 Multiple complex diseases / / 17554300 rs4901431 chr14 53979814 A G 1.90E-04 Multiple complex diseases / / 17554300 rs2251294 chr14 53990568 A G 8.55E-05 Multiple complex diseases / / 17554300 rs2251589 chr14 53992930 G A 8.73E-05 Multiple complex diseases / / 17554300 rs17126648 chr14 54002960 T C 5.80E-04 Multiple complex diseases / / 17554300 rs1380131 chr14 54072858 C T 9.00E-06 Alcoholism (heaviness of drinking) / / 21529783 rs7149928 chr14 54098459 A G 9.91E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17126688 chr14 54099802 T C 1.32E-04 Type 2 diabetes / / 17463246 rs41527044 chr14 54125783 A G 6.39E-04 Type 2 diabetes / / 17463246 rs10141869 chr14 54132654 A C 5.21E-05 Bipolar disorder and schizophrenia / / 20889312 rs10141869 chr14 54132654 A C 6.36E-08 Metabolite levels / / 23281178 rs1380122 chr14 54137424 T C 6.79E-08 Metabolite levels / / 23281178 rs7146962 chr14 54145317 T C 3.29E-05 Bipolar disorder and schizophrenia / / 20889312 rs17126761 chr14 54148442 A G 2.30E-04 Type 2 diabetes / / 17463246 rs17126775 chr14 54150245 C T 2.30E-04 Type 2 diabetes / / 17463246 rs1563719 chr14 54151685 A G 2.30E-04 Type 2 diabetes / / 17463246 rs1563719 chr14 54151685 A G 7.10E-05 Multiple complex diseases / / 17554300 rs1380127 chr14 54152188 G A 9.78E-08 Metabolite levels / / 23281178 rs17126790 chr14 54160152 T A 3.58E-04 Multiple complex diseases / / 17554300 rs210360 chr14 54164706 C T 3.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs210360 chr14 54164706 C T 6.12E-05 Atopy / / 21625490 rs210359 chr14 54167472 A C 8.00E-08 Immune reponse to smallpox (secreted IFN-alpha) / / 22610502 rs964254 chr14 54168117 G A 9.10E-05 Hypothyroidism / / 22493691 rs210352 chr14 54173539 A G 3.40E-05 Hypothyroidism / / 22493691 rs210343 chr14 54180599 A G 7.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs210341 chr14 54180713 A C 7.41E-04 Smoking initiation / / 24665060 rs210332 chr14 54192472 C T 2.28E-05 Longevity / / 20304771 rs210332 chr14 54192472 C T 1.67E-04 Alzheimer's disease (late onset) / / 21379329 rs9323246 chr14 54210786 T C 9.60E-05 Parkinson's disease (familial) / / 18985386 rs2358367 chr14 54212219 G A 5.80E-06 Parkinson's disease (familial) / / 18985386 rs12894060 chr14 54226373 A G 3.15E-04 Esophageal adenocarcinoma / / 24121790 rs1958654 chr14 54228517 T C 2.46E-04 Osteoarthritis / / 19508968 rs1958654 chr14 54228517 T C 3.24E-05 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs1958654 chr14 54228517 T C 9.96E-06 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs17126872 chr14 54235530 G A 2.58E-20 Varicose Veins / / pha001412 rs1999276 chr14 54250364 G A 1.18E-04 Multiple complex diseases / / 17554300 rs12431733 chr14 54290830 T C 3.00E-06 Parkinson's disease / / 19915575 rs12431733 chr14 54290830 T C 1.52E-06 Parkinson's disease / / pha002868 rs8005200 chr14 54306401 T G 1.38E-05 Age-related macular degeneration / / pha000001 rs7160860 chr14 54339493 T C 2.69E-06 Multiple sclerosis / / 17660530 rs17127035 chr14 54358137 T C 8.32E-04 Smoking cessation / / 24665060 rs1957859 chr14 54409113 T C 9.08E-05 Multiple complex diseases / / 17554300 rs4444235 chr14 54410919 T C 8.00E-10 Colorectal cancer / / 19011631 rs4444235 chr14 54410919 T C 8.00E-10 Nasopharyngeal carcinoma / / 20512145 rs66913363 chr14 54413001 G C 0.000000017 Myopia (Age of onset) / / 23468642 rs11623717 chr14 54414132 A G 2.10E-05 Urinary metabolites / / 21572414 rs17563 chr14 54417522 A G 3.60E-04 Primary tooth development (number of teeth) BMP4 missense 23704328 rs17563 chr14 54417522 A G 9.00E-17 Primary tooth development (time to first tooth eruption) BMP4 missense 23704328 rs2071047 chr14 54418411 G A 3.51E-04 Abdominal aortic aneurysm BMP4 intron 22055160 rs35107139 chr14 54419106 A C 1.39E-04 Colorectal cancer BMP4 intron 24737748 rs2761887 chr14 54425052 C A 1.70E-05 Urinary metabolites BMP4 nearGene-5 21572414 rs12434228 chr14 54427602 C T 5.76E-04 Multiple complex diseases / / 17554300 rs6572930 chr14 54439404 T G 6.20E-06 Retinopathy in non-diabetics / / 23393555 rs942316 chr14 54440983 A C 3.92E-06 Retinopathy in non-diabetics / / 23393555 rs4316669 chr14 54442668 C T 2.67E-06 Retinopathy in non-diabetics / / 23393555 rs1957844 chr14 54458078 C T 8.16E-04 Alzheimer's disease / / 22005930 rs1983786 chr14 54513277 C A 4.82E-04 Type 2 diabetes / / 17463246 rs1951659 chr14 54519973 G A 8.55E-04 HIV-1 viral setpoint / / 17641165 rs713424 chr14 54582334 C T 0.0000362 Colorectal adenoma (excluding hyperplasic) / / 23677573 rs713424 chr14 54582334 C T 0.0000362 Colorectal adenoma (including hyperplasic) / / 23677573 rs708544 chr14 54612799 C T 6.10E-04 Multiple complex diseases / / 17554300 rs743276 chr14 54631431 C T 1.96E-04 Multiple complex diseases / / 17554300 rs811140 chr14 54635002 C T 1.98E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs1953743 chr14 54652479 C T 5.77E-06 Lipid traits / / 21777205 rs1953743 chr14 54652479 C T 2.00E-06 Dental caries / / 23259602 rs8009160 chr14 54659622 C G 2.82E-06 Lipid traits / / 21777205 rs1541164 chr14 54660415 G T 3.31E-06 Lipid traits / / 21777205 rs8012357 chr14 54661897 T C 2.82E-06 Lipid traits / / 21777205 rs17712056 chr14 54678978 C A 7.65E-04 Parkinson's disease / / 16252231 rs1187426 chr14 54688865 G C 1.56E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs2143960 chr14 54715845 G A 3.64E-04 Multiple complex diseases / / 17554300 rs2143962 chr14 54716000 A G 3.63E-04 Multiple complex diseases / / 17554300 rs2143963 chr14 54723923 C T 9.00E-06 Metabolite levels (X-11787) / / 23934736 rs10151226 chr14 54742851 C T 6.20E-05 Cognitive function / / 24684796 rs7155360 chr14 54750415 T G 7.90E-05 Cognitive function / / 24684796 rs1950209 chr14 54767649 G A 8.90E-05 Cognitive function / / 24684796 rs9323260 chr14 54774934 T G 4.96E-04 Multiple complex diseases / / 17554300 rs11627716 chr14 54778603 G A 2.62E-04 Multiple complex diseases / / 17554300 rs17093094 chr14 54796901 A G 1.87E-04 Multiple complex diseases / / 17554300 rs10483636 chr14 54800845 A G 9.67E-04 Multiple complex diseases / / 17554300 rs4901509 chr14 54836000 G A 5.22E-04 Type 2 diabetes / / 17463246 rs4293296 chr14 54857286 G A 3.00E-06 Response to antipsychotic treatment in schizophrenia (working memory) / / 21107309 rs2179896 chr14 54875514 A G 1.70E-05 Electrocardiographic traits and heart rate variability CDKN3 intron 17903306 rs4251631 chr14 54876184 T C 2.00E-06 Dental caries CDKN3 intron 23259602 rs4251631 chr14 54876184 T C 2.00E-07 Dental caries CDKN3 intron 23259602 rs4251647 chr14 54880522 C G 6.25E-04 Smoking initiation CDKN3 intron 24665060 rs17127558 chr14 54889136 T C 1.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs3204303 chr14 54890379 C A 0.0000874 Antisocial behavior / / 23077488 rs3783635 chr14 54894792 C T 3.09E-04 Suicide attempts in bipolar disorder CNIH intron 21423239 rs10400770 chr14 54897265 T G 3.10E-04 Suicide attempts in bipolar disorder CNIH intron 21423239 rs10400772 chr14 54897359 T A 3.06E-04 Suicide attempts in bipolar disorder CNIH intron 21423239 rs2298078 chr14 54903617 C A 3.15E-04 Suicide attempts in bipolar disorder CNIH intron 21423239 rs3759655 chr14 54908737 A T 3.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs17127578 chr14 54912092 T C 2.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs17127582 chr14 54920203 C T 0.000192 Antisocial behavior / / 23077488 rs8021120 chr14 54930770 T A 1.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs10132802 chr14 54935892 T C 2.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs7148766 chr14 54957041 A G 2.70E-05 Urinary metabolites / / 21572414 rs4898839 chr14 54961732 G A,C 3.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs3759658 chr14 54975632 G A 6.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs8022285 chr14 54992165 G T 6.93E-04 Suicide attempts in bipolar disorder CGRRF1 intron 21423239 rs17127622 chr14 54996630 G A 6.65E-04 Suicide attempts in bipolar disorder CGRRF1 intron 21423239 rs17127624 chr14 54998322 C G 7.36E-04 Suicide attempts in bipolar disorder CGRRF1 intron 21423239 rs4901519 chr14 55019180 A C 7.56E-05 Parkinson's disease / / pha002865 rs7141041 chr14 55022792 T C 3.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs1212968 chr14 55043520 C A 9.99E-04 Type 2 diabetes SAMD4A intron 17463246 rs1187586 chr14 55047189 T C 1.70E-05 Elbow pain SAMD4A intron pha003008 rs7141453 chr14 55047949 A C 4.46E-04 Aortic root size SAMD4A intron 21223598 rs1202668 chr14 55048710 G A 4.20E-06 Elbow pain SAMD4A intron pha003008 rs1187590 chr14 55053210 C T 3.90E-05 Parkinson's disease (familial) SAMD4A intron 18985386 rs1187590 chr14 55053210 C T 1.62E-05 Recombination rate SAMD4A intron 21698098 rs17253494 chr14 55073144 C T 9.94E-04 Multiple complex diseases SAMD4A intron 17554300 rs17127663 chr14 55076383 T C 8.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SAMD4A intron 20877124 rs11624583 chr14 55080261 C G 7.82E-04 Multiple complex diseases SAMD4A intron 17554300 rs881970 chr14 55094787 G A 1.60E-05 Urinary metabolites SAMD4A intron 21572414 rs2147536 chr14 55098064 A G 4.83E-04 Multiple complex diseases SAMD4A intron 17554300 rs6572964 chr14 55099629 A G 8.41E-04 Multiple complex diseases SAMD4A intron 17554300 rs10129926 chr14 55105821 T C 1.70E-04 Aortic root size SAMD4A intron 21223598 rs17127713 chr14 55122918 A G 3.00E-06 Obesity-related traits SAMD4A intron 23251661 rs10483637 chr14 55157430 C T 1.00E-04 Cognitive impairment induced by topiramate SAMD4A intron 22091778 rs4324049 chr14 55173406 T G 7.99E-05 Waist Circumference SAMD4A intron pha003023 rs17657012 chr14 55176344 A G 9.00E-06 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SAMD4A intron 24023788 rs11628843 chr14 55180343 T G 8.89E-05 Waist Circumference SAMD4A intron pha003023 rs11845379 chr14 55194464 T C 8.49E-04 Alcohol dependence SAMD4A intron 21314694 rs17127840 chr14 55199914 C G 2.71E-04 Type 2 diabetes SAMD4A intron 17463246 rs4901536 chr14 55200534 T C 0.000000997 Carotid intima media thickness SAMD4A intron 23152477 rs7156891 chr14 55201507 G A 2.47E-09 Protein biomarker SAMD4A intron 23056639 rs7156787 chr14 55201681 A G 2.38E-09 Protein biomarker SAMD4A intron 23056639 rs10144855 chr14 55212242 G C 5.48E-05 Multiple complex diseases SAMD4A intron 17554300 rs6572972 chr14 55212289 C T 8.70E-05 Blood pressure (response to calcium channel blocker) SAMD4A intron 24192120 rs1957358 chr14 55222475 T C 6.75E-04 Multiple complex diseases SAMD4A intron 17554300 rs1957358 chr14 55222475 T C 4.24E-04 Oral cancers (chewing tobacco related) SAMD4A intron 22503698 rs4898850 chr14 55227914 T C 8.44E-04 Type 2 diabetes SAMD4A intron 17463246 rs4901542 chr14 55235767 C A 2.52E-04 Multiple complex diseases SAMD4A intron 17554300 rs9323270 chr14 55241049 C A 2.69E-05 Tuberculosis SAMD4A intron 20694014 rs9323270 chr14 55241049 C A 9.50E-04 Amyotrophic lateral sclerosis (sporadic) SAMD4A intron 24529757 rs9323271 chr14 55241645 C G 2.56E-05 Tuberculosis SAMD4A intron 20694014 rs709939 chr14 55249345 C T 3.41E-06 Multiple complex diseases SAMD4A intron 17554300 rs709939 chr14 55249345 C T 1.70E-06 Height SAMD4A intron 21194676 rs709939 chr14 55249345 C T 1.80E-07 Height SAMD4A intron 21194676 rs10138916 chr14 55264973 G A 6.06E-06 Multiple complex diseases / / 17554300 rs927382 chr14 55265264 G C 8.57E-06 Multiple complex diseases / / 17554300 rs8021957 chr14 55265529 T C 1.95E-05 Multiple complex diseases / / 17554300 rs8021151 chr14 55265571 G A 1.15E-05 Multiple complex diseases / / 17554300 rs7144602 chr14 55285588 T G 1.27E-62 Protein biomarker / / 23056639 rs9323272 chr14 55288924 G A 1.24E-62 Protein biomarker / / 23056639 rs7141685 chr14 55290469 G T 1.24E-62 Protein biomarker / / 23056639 rs10135789 chr14 55292020 A G 1.16E-62 Protein biomarker / / 23056639 rs7151058 chr14 55295940 C G 5.47E-51 Protein biomarker / / 23056639 rs2057368 chr14 55304009 G A 3.17E-05 Response to hepatitis C treatment / / 19684573 rs2057368 chr14 55304009 G A 2.42E-53 Protein biomarker / / 23056639 rs2057369 chr14 55304061 G A 2.45E-53 Protein biomarker / / 23056639 rs2145945 chr14 55304080 G A 4.73E-64 Protein biomarker / / 23056639 rs17128004 chr14 55306240 C A 2.16E-53 Protein biomarker / / 23056639 rs10483639 chr14 55306457 G C 2.15E-53 Protein biomarker / / 23056639 rs7142517 chr14 55306804 C A 5.50E-04 Obesity-related traits / / 17903300 rs7142517 chr14 55306804 C A 1.71E-18 Protein biomarker / / 23056639 rs841 chr14 55310492 G A 2.20E-53 Protein biomarker GCH1 UTR-3 23056639 rs752688 chr14 55311569 C T 2.21E-53 Protein biomarker GCH1 intron 23056639 rs10131232 chr14 55315908 G A 8.27E-64 Protein biomarker GCH1 intron 23056639 rs10133662 chr14 55316270 A G 8.12E-64 Protein biomarker GCH1 intron 23056639 rs4411417 chr14 55320563 T C 2.16E-53 Protein biomarker GCH1 intron 23056639 rs2878168 chr14 55320785 G A 2.57E-53 Protein biomarker GCH1 intron 23056639 rs7155309 chr14 55322851 T C 2.12E-53 Protein biomarker GCH1 intron 23056639 rs8007201 chr14 55324848 A G 7.65E-64 Protein biomarker GCH1 intron 23056639 rs12587434 chr14 55325583 T G 1.86E-53 Protein biomarker GCH1 intron 23056639 rs17128028 chr14 55325823 C T 3.29E-17 HDL cholesterol GCH1 intron 23063622 rs12589758 chr14 55325862 A T 2.02E-53 Protein biomarker GCH1 intron 23056639 rs9671371 chr14 55328635 C T 2.81E-63 Protein biomarker GCH1 intron 23056639 rs9671455 chr14 55329080 C G 7.18E-54 Protein biomarker GCH1 intron 23056639 rs2183081 chr14 55336751 A G 1.03E-38 Protein biomarker GCH1 intron 23056639 rs17128050 chr14 55343879 T C 5.22E-06 Obesity-related traits GCH1 intron 23251661 rs3783637 chr14 55348118 C T 2.00E-06 Rheumatoid arthritis GCH1 intron 22446963 rs3783637 chr14 55348118 C T 1.00E-06 Obesity-related traits GCH1 intron 23251661 rs3783637 chr14 55348118 C T 6.00E-08 Obesity-related traits GCH1 intron 23251661 rs8004018 chr14 55350696 A G 7.55E-06 Obesity-related traits GCH1 intron 23251661 rs10498472 chr14 55354869 T G 5.55E-08 Protein biomarker GCH1 intron 23056639 rs998259 chr14 55355031 C T 3.59E-06 Atrial fibrillation GCH1 intron 21846873 rs998259 chr14 55355031 C T 2.58E-13 Protein biomarker GCH1 intron 23056639 rs10149080 chr14 55356394 C T 4.25E-16 HDL cholesterol GCH1 intron 23063622 rs17128052 chr14 55356525 G C 1.49E-62 Protein biomarker GCH1 intron 23056639 rs7147286 chr14 55358665 G A 7.55E-05 Parkinson's disease GCH1 intron 21738487 rs7147286 chr14 55358665 G A 5.11E-42 Protein biomarker GCH1 intron 23056639 rs7147201 chr14 55358877 A G 8.41E-63 Protein biomarker GCH1 intron 23056639 rs17832263 chr14 55359822 G A 2.35E-08 Protein biomarker GCH1 intron 23056639 rs3783641 chr14 55360139 T A 4.52E-63 Protein biomarker GCH1 intron 23056639 rs3783642 chr14 55360203 T C 2.95E-53 Protein biomarker GCH1 intron 23056639 rs8017210 chr14 55361836 G A 2.54E-63 Protein biomarker GCH1 intron 23056639 rs3759664 chr14 55371579 C T 8.49E-63 Protein biomarker / / 23056639 rs2878172 chr14 55373670 A G 1.76E-55 Protein biomarker / / 23056639 rs11847771 chr14 55374601 T A 2.84E-62 Protein biomarker / / 23056639 rs11621165 chr14 55375426 G A 1.69E-62 Protein biomarker / / 23056639 rs8007267 chr14 55378991 C T 4.22E-63 Protein biomarker / / 23056639 rs11158028 chr14 55381070 C T 2.50E-63 Protein biomarker / / 23056639 rs8022453 chr14 55381790 G A 9.02E-63 Protein biomarker / / 23056639 rs943912 chr14 55385327 C G 1.05E-64 Protein biomarker / / 23056639 rs10140164 chr14 55406123 A G 5.71E-64 Protein biomarker WDHD1 UTR-3 23056639 rs8020545 chr14 55409070 T A 2.95E-42 Protein biomarker WDHD1 intron 23056639 rs8019390 chr14 55409084 C G 2.60E-42 Protein biomarker WDHD1 intron 23056639 rs7146285 chr14 55412869 T C 3.73E-48 Protein biomarker WDHD1 intron 23056639 rs8009997 chr14 55421911 T G 3.77E-42 Protein biomarker WDHD1 intron 23056639 rs8012152 chr14 55425567 T C 2.33E-05 Parkinson's disease WDHD1 intron 21738487 rs8012152 chr14 55425567 T C 4.35E-48 Protein biomarker WDHD1 intron 23056639 rs11627963 chr14 55426547 C G 1.50E-60 Protein biomarker WDHD1 intron 23056639 rs9285583 chr14 55431435 T C 6.09E-48 Protein biomarker WDHD1 intron 23056639 rs17832269 chr14 55432091 C T 3.38E-42 Protein biomarker WDHD1 intron 23056639 rs943914 chr14 55440068 C A 3.37E-05 Parkinson's disease WDHD1 intron 21738487 rs943914 chr14 55440068 C A 4.50E-44 Protein biomarker WDHD1 intron 23056639 rs7151670 chr14 55452759 C G 4.58E-44 Protein biomarker WDHD1 intron 23056639 rs8018800 chr14 55453306 A G 1.27E-49 Protein biomarker WDHD1 intron 23056639 rs8019220 chr14 55453469 C T 1.07E-49 Protein biomarker WDHD1 intron 23056639 rs8022049 chr14 55462869 T C 5.06E-44 Protein biomarker WDHD1 intron 23056639 rs17253633 chr14 55469917 T C 1.21E-58 Protein biomarker WDHD1 intron 23056639 rs2878174 chr14 55470624 T C 4.53E-69 Protein biomarker WDHD1 intron 23056639 rs4335711 chr14 55470863 G C 2.26E-44 Protein biomarker WDHD1 intron 23056639 rs7153937 chr14 55470875 A G 3.96E-50 Protein biomarker WDHD1 intron 23056639 rs3783646 chr14 55471887 T C 2.23E-44 Protein biomarker WDHD1 intron 23056639 rs2183085 chr14 55472391 A C 1.88E-50 Protein biomarker WDHD1 intron 23056639 rs17128120 chr14 55474598 C T 1.78E-50 Protein biomarker WDHD1 intron 23056639 rs10139354 chr14 55478602 C T 1.54E-50 Protein biomarker WDHD1 intron 23056639 rs28489712 chr14 55483786 A C 3.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy) WDHD1 intron 24554482 rs1187883 chr14 55488234 T C 3.28E-117 Protein biomarker WDHD1 intron 23056639 rs1187882 chr14 55488747 C G 3.22E-76 Protein biomarker WDHD1 intron 23056639 rs1209087 chr14 55493220 C T 7.78E-120 Protein biomarker WDHD1 intron 23056639 rs1187878 chr14 55493350 T C 1.78E-77 Protein biomarker WDHD1 intron 23056639 rs1201378 chr14 55493408 T C 7.83E-120 Protein biomarker WDHD1 intron 23056639 rs1212641 chr14 55496131 G C 8.07E-47 Protein biomarker SOCS4 intron 23056639 rs1952438 chr14 55497948 G A 1.90E-15 Protein biomarker SOCS4 intron 23056639 rs1952438 chr14 55497948 G A 5.75E-04 Smoking initiation SOCS4 intron 24665060 rs1187874 chr14 55498103 A G 6.51E-47 Protein biomarker SOCS4 intron 23056639 rs1187873 chr14 55500251 T C 6.05E-47 Protein biomarker SOCS4 intron 23056639 rs11851178 chr14 55502129 A G 3.94E-78 Protein biomarker SOCS4 intron 23056639 rs17128132 chr14 55506757 C T 3.75E-78 Protein biomarker SOCS4 intron 23056639 rs8008134 chr14 55507520 T C 2.78E-120 Protein biomarker SOCS4 intron 23056639 rs7149965 chr14 55508191 G A 3.45E-78 Protein biomarker SOCS4 intron 23056639 rs7150145 chr14 55508260 G A 3.78E-78 Protein biomarker SOCS4 intron 23056639 rs17128136 chr14 55510110 G A 4.00E-14 Protein biomarker SOCS4 cds-synon 23056639 rs1952085 chr14 55512273 C A 6.11E-78 Protein biomarker SOCS4 UTR-3 23056639 rs2340943 chr14 55518007 C T 2.97E-47 Protein biomarker / / 23056639 rs2251366 chr14 55518156 A G 1.41E-119 Protein biomarker / / 23056639 rs1002054 chr14 55528913 A C 3.85E-120 Protein biomarker MAPK1IP1L intron 23056639 rs3742564 chr14 55530120 T C 7.42E-04 Multiple complex diseases MAPK1IP1L intron 17554300 rs3742564 chr14 55530120 T C 2.72E-81 Protein biomarker MAPK1IP1L intron 23056639 rs17128143 chr14 55533588 C G 1.87E-28 Protein biomarker MAPK1IP1L UTR-3 23056639 rs7144652 chr14 55537718 G A 5.49E-124 Protein biomarker LOC100652890 intron 23056639 rs13379159 chr14 55540801 C T 6.26E-124 Protein biomarker / / 23056639 rs17253660 chr14 55541366 G T 8.28E-17 Protein biomarker / / 23056639 rs17253660 chr14 55541366 G T 5.56E-04 Smoking initiation / / 24665060 rs749053 chr14 55544476 T C 2.54E-17 Protein biomarker / / 23056639 rs873061 chr14 55546326 T C 2.61E-70 Protein biomarker / / 23056639 rs7157678 chr14 55548739 C G 6.00E-78 Protein biomarker / / 23056639 rs8004416 chr14 55549553 A G 4.25E-129 Protein biomarker / / 23056639 rs8012156 chr14 55552500 G T 5.48E-128 Protein biomarker / / 23056639 rs17128156 chr14 55553220 G A 2.64E-26 Protein biomarker / / 23056639 rs11625204 chr14 55554917 A G 4.36E-49 Protein biomarker / / 23056639 rs8019978 chr14 55557284 G A 6.26E-124 Protein biomarker / / 23056639 rs2147966 chr14 55558836 C G 2.08E-18 Protein biomarker / / 23056639 rs2147965 chr14 55559302 G C 2.60E-18 Protein biomarker / / 23056639 rs9671895 chr14 55559662 T C 5.30E-78 Protein biomarker / / 23056639 rs9806061 chr14 55561130 C T 7.21E-19 Protein biomarker / / 23056639 rs2340921 chr14 55563705 A G 3.60E-125 Protein biomarker / / 23056639 rs2147964 chr14 55564395 T A,G 3.47E-125 Protein biomarker / / 23056639 rs2147963 chr14 55564473 T C 5.36E-49 Protein biomarker / / 23056639 rs11622128 chr14 55564526 G T 5.17E-78 Protein biomarker / / 23056639 rs11626816 chr14 55564641 T C 4.37E-78 Protein biomarker / / 23056639 rs11627884 chr14 55565165 T C 3.72E-78 Protein biomarker / / 23056639 rs10147667 chr14 55570849 T C 2.89E-171 Protein biomarker / / 23056639 rs17253695 chr14 55574610 A T 2.32E-97 Protein biomarker / / 23056639 rs8007944 chr14 55576816 A C 1.26E-164 Protein biomarker / / 23056639 rs17128183 chr14 55579513 A G 1.03E-165 Protein biomarker / / 23056639 rs8009670 chr14 55583477 G A 1.99E-167 Protein biomarker / / 23056639 rs17253702 chr14 55583883 G A 1.27E-60 Protein biomarker / / 23056639 rs7153322 chr14 55584614 G A 1.89E-07 Multiple complex diseases / / 17554300 rs2147961 chr14 55585381 T C 5.04E-168 Protein biomarker / / 23056639 rs7158989 chr14 55585558 C T 3.99E-07 Facial morphology / / 22341974 rs7158989 chr14 55585558 C T 2.84E-36 Protein biomarker / / 23056639 rs8007614 chr14 55586575 T C 2.66E-169 Protein biomarker / / 23056639 rs8007620 chr14 55586587 T C 8.38E-170 Protein biomarker / / 23056639 rs3825613 chr14 55593172 A C 1.30E-185 Protein biomarker / / 23056639 rs1009977 chr14 55603002 T G 8.74E-184 Protein biomarker LGALS3 intron 23056639 rs1009978 chr14 55603061 C G 1.95E-186 Protein biomarker LGALS3 intron 23056639 rs4644 chr14 55604935 C A 2.06E-187 Protein biomarker LGALS3 missense 23056639 rs4652 chr14 55605036 A C 3.49E-173 Protein biomarker LGALS3 missense 23056639 rs8004787 chr14 55607366 C T 3.52E-173 Protein biomarker LGALS3 intron 23056639 rs2075601 chr14 55609234 C T 4.30E-173 Protein biomarker LGALS3 intron 23056639 rs2075602 chr14 55609774 A G 2.60E-173 Protein biomarker LGALS3 intron 23056639 rs2075603 chr14 55609955 C A 1.39E-187 Protein biomarker LGALS3 intron 23056639 rs8013027 chr14 55610940 C G 8.75E-187 Protein biomarker LGALS3 intron 23056639 rs10498475 chr14 55612480 C T 6.89E-47 Protein biomarker LGALS3 nearGene-3 23056639 rs2274273 chr14 55614636 G A 2.00E-188 Protein biomarker / / 23056639 rs2340931 chr14 55616937 T G 1.14E-186 Protein biomarker DLGAP5 intron 23056639 rs11622740 chr14 55617844 G A 4.03E-188 Protein biomarker DLGAP5 intron 23056639 rs15870 chr14 55619311 A G 1.03E-187 Protein biomarker DLGAP5 cds-synon 23056639 rs10140857 chr14 55619611 G C 4.09E-187 Protein biomarker DLGAP5 intron 23056639 rs17128262 chr14 55619768 G A 3.57E-05 Multiple complex diseases DLGAP5 intron 17554300 rs3818451 chr14 55621116 C G 1.29E-169 Protein biomarker DLGAP5 intron 23056639 rs7159808 chr14 55624327 G T 4.30E-170 Protein biomarker DLGAP5 intron 23056639 rs2296489 chr14 55624977 T C 1.15E-101 Protein biomarker DLGAP5 intron 23056639 rs6573007 chr14 55625938 T G 3.27E-170 Protein biomarker DLGAP5 intron 23056639 rs8011834 chr14 55625977 A C 3.10E-188 Protein biomarker DLGAP5 intron 23056639 rs10134800 chr14 55635209 A G 1.77E-169 Protein biomarker DLGAP5 intron 23056639 rs10134983 chr14 55635323 C T 6.31E-40 Protein biomarker DLGAP5 intron 23056639 rs8018110 chr14 55641714 C T 6.73E-169 Protein biomarker DLGAP5 intron 23056639 rs8009244 chr14 55643752 A G 2.70E-04 Atrial fibrillation DLGAP5 intron 21846873 rs10144326 chr14 55643908 A G 7.57E-41 Protein biomarker DLGAP5 cds-synon 23056639 rs8003961 chr14 55651553 A G 1.58E-37 Protein biomarker DLGAP5 intron 23056639 rs7159490 chr14 55654409 C T 6.27E-40 Protein biomarker DLGAP5 intron 23056639 rs6573008 chr14 55655083 C A 2.20E-44 Protein biomarker DLGAP5 intron 23056639 rs2274271 chr14 55655692 C T 6.50E-41 Protein biomarker DLGAP5 missense 23056639 rs3759667 chr14 55658421 A G 1.47E-100 Protein biomarker / / 23056639 rs17671923 chr14 55663918 A G 2.57E-43 Protein biomarker / / 23056639 rs17739689 chr14 55665275 T A 2.45E-62 Protein biomarker / / 23056639 rs10147434 chr14 55674847 C T 9.90E-172 Protein biomarker / / 23056639 rs4040064 chr14 55678088 G T 1.09E-97 Protein biomarker / / 23056639 rs7160411 chr14 55679032 C T 2.15E-37 Protein biomarker / / 23056639 rs6573009 chr14 55682324 T G 1.98E-169 Protein biomarker / / 23056639 rs1952087 chr14 55683211 A C 1.39E-169 Protein biomarker / / 23056639 rs11845284 chr14 55683908 T C 1.21E-29 Protein biomarker / / 23056639 rs7141706 chr14 55686601 C G 6.45E-40 Protein biomarker / / 23056639 rs751059 chr14 55690525 C G 3.10E-55 Protein biomarker / / 23056639 rs9919921 chr14 55695505 A G 3.47E-97 Protein biomarker / / 23056639 rs17672364 chr14 55705904 G T 2.32E-97 Protein biomarker / / 23056639 rs17672376 chr14 55707363 C T 5.84E-39 Protein biomarker / / 23056639 rs8013528 chr14 55714840 A T 5.41E-28 Protein biomarker / / 23056639 rs8009718 chr14 55717379 A G 3.19E-28 Protein biomarker / / 23056639 rs8003311 chr14 55721274 T C 5.49E-85 Protein biomarker / / 23056639 rs6573010 chr14 55721592 T C 3.11E-166 Protein biomarker / / 23056639 rs10467798 chr14 55724927 C T 1.18E-165 Protein biomarker / / 23056639 rs2341621 chr14 55726425 C T 1.24E-165 Protein biomarker / / 23056639 rs17740413 chr14 55728775 C T 4.21E-39 Protein biomarker / / 23056639 rs3825614 chr14 55729387 G A 7.05E-97 Protein biomarker / / 23056639 rs10140801 chr14 55730404 C T 4.29E-173 Protein biomarker / / 23056639 rs6573013 chr14 55735873 T G 8.43E-165 Protein biomarker / / 23056639 rs6573014 chr14 55735892 T C 5.04E-166 Protein biomarker / / 23056639 rs2341622 chr14 55737243 C A 5.09E-166 Protein biomarker / / 23056639 rs2880103 chr14 55737832 A C 3.21E-94 Protein biomarker / / 23056639 rs2880103 chr14 55737832 A C 2.25E-04 Smoking initiation / / 24665060 rs10146637 chr14 55744810 G A 3.21E-95 Protein biomarker FBXO34 intron 23056639 rs10146637 chr14 55744810 G A 2.33E-04 Smoking initiation FBXO34 intron 24665060 rs10141552 chr14 55746091 T C 6.31E-167 Protein biomarker FBXO34 intron 23056639 rs10141552 chr14 55746091 T C 6.49E-04 Smoking initiation FBXO34 intron 24665060 rs8021583 chr14 55749607 G A 5.60E-167 Protein biomarker FBXO34 intron 23056639 rs11158034 chr14 55753560 C T 3.95E-95 Protein biomarker FBXO34 intron 23056639 rs17672950 chr14 55756218 G A 4.76E-39 Protein biomarker FBXO34 intron 23056639 rs11625001 chr14 55758160 T C 8.61E-167 Protein biomarker FBXO34 intron 23056639 rs17740741 chr14 55762712 G C 2.58E-173 Protein biomarker FBXO34 intron 23056639 rs7158768 chr14 55763612 A C 3.08E-165 Protein biomarker FBXO34 intron 23056639 rs8023197 chr14 55767395 G T 7.68E-167 Protein biomarker FBXO34 intron 23056639 rs7159824 chr14 55772536 C T 7.28E-95 Protein biomarker FBXO34 intron 23056639 rs7159824 chr14 55772536 C T 1.84E-04 Smoking initiation FBXO34 intron 24665060 rs11628437 chr14 55775468 G A 1.20E-166 Protein biomarker FBXO34 intron 23056639 rs10129505 chr14 55776375 C T 7.29E-95 Protein biomarker FBXO34 intron 23056639 rs7147247 chr14 55777713 A T 6.44E-95 Protein biomarker FBXO34 intron 23056639 rs7147247 chr14 55777713 A T 5.15E-04 Smoking initiation FBXO34 intron 24665060 rs4580079 chr14 55780366 G A 5.84E-95 Protein biomarker FBXO34 intron 23056639 rs2341534 chr14 55784737 G C 2.10E-27 Protein biomarker FBXO34 intron 23056639 rs1972221 chr14 55785381 C A 2.82E-95 Protein biomarker FBXO34 intron 23056639 rs7151581 chr14 55788445 C T 3.18E-95 Protein biomarker FBXO34 intron 23056639 rs2026633 chr14 55789177 G A 2.09E-95 Protein biomarker FBXO34 intron 23056639 rs2026633 chr14 55789177 G A 2.64E-04 Smoking initiation FBXO34 intron 24665060 rs10134317 chr14 55793448 C T 2.59E-95 Protein biomarker FBXO34 intron 23056639 rs10134317 chr14 55793448 C T 4.27E-05 Smoking initiation FBXO34 intron 24665060 rs10140869 chr14 55795283 G A 2.13E-175 Protein biomarker FBXO34 intron 23056639 rs8005450 chr14 55799165 A T 2.26E-95 Protein biomarker FBXO34 intron 23056639 rs9323280 chr14 55801687 A C 4.18E-38 Protein biomarker FBXO34 intron 23056639 rs6573017 chr14 55802243 G A 1.37E-168 Protein biomarker FBXO34 intron 23056639 rs17741542 chr14 55805861 G A 1.49E-168 Protein biomarker FBXO34 intron 23056639 rs17741560 chr14 55805893 C T 7.67E-28 Protein biomarker FBXO34 intron 23056639 rs7154889 chr14 55806885 G A 2.02E-168 Protein biomarker FBXO34 intron 23056639 rs17673930 chr14 55808151 A G 1.89E-40 Protein biomarker FBXO34 intron 23056639 rs17741681 chr14 55810715 A G 2.42E-40 Protein biomarker FBXO34 intron 23056639 rs7152390 chr14 55811701 C T 1.77E-95 Protein biomarker FBXO34 intron 23056639 rs8006525 chr14 55813394 T G 3.17E-168 Protein biomarker FBXO34 intron 23056639 rs9919926 chr14 55813890 G C 1.41E-175 Protein biomarker FBXO34 intron 23056639 rs9919932 chr14 55814080 A G 2.79E-95 Protein biomarker FBXO34 intron 23056639 rs7148669 chr14 55814346 G A 4.01E-44 Protein biomarker FBXO34 intron 23056639 rs10134339 chr14 55814380 T C 4.22E-168 Protein biomarker FBXO34 intron 23056639 rs17741825 chr14 55814761 G T 2.25E-40 Protein biomarker FBXO34 intron 23056639 rs11851169 chr14 55815932 G A 5.21E-168 Protein biomarker FBXO34 intron 23056639 rs11851870 chr14 55815982 A C 3.40E-63 Protein biomarker FBXO34 intron 23056639 rs17741831 chr14 55816715 T A 1.57E-168 Protein biomarker FBXO34 intron 23056639 rs10141396 chr14 55816925 T G 9.49E-96 Protein biomarker FBXO34 intron 23056639 rs10141396 chr14 55816925 T G 2.53E-04 Smoking initiation FBXO34 intron 24665060 rs10144418 chr14 55817708 T C 4.86E-176 Protein biomarker FBXO34 cds-synon 23056639 rs1045002 chr14 55818517 T A 3.99E-168 Protein biomarker FBXO34 missense 23056639 rs3742569 chr14 55818706 T C 4.39E-168 Protein biomarker FBXO34 missense 23056639 rs3742569 chr14 55818706 T C 6.19E-04 Smoking initiation FBXO34 missense 24665060 rs1045004 chr14 55819791 G A 3.52E-63 Protein biomarker FBXO34 UTR-3 23056639 rs7153110 chr14 55820628 A G 1.42E-168 Protein biomarker / / 23056639 rs7159144 chr14 55821324 G A 2.23E-168 Protein biomarker / / 23056639 rs10150760 chr14 55821548 A G 2.42E-168 Protein biomarker / / 23056639 rs11621265 chr14 55822095 G T 6.72E-122 Protein biomarker / / 23056639 rs7144737 chr14 55822946 G A 2.52E-168 Protein biomarker / / 23056639 rs7144737 chr14 55822946 G A 7.47E-04 Smoking initiation / / 24665060 rs17674463 chr14 55824863 A T 3.76E-168 Protein biomarker / / 23056639 rs7147136 chr14 55826688 G C 4.77E-174 Protein biomarker / / 23056639 rs10147765 chr14 55827826 G A 1.64E-174 Protein biomarker / / 23056639 rs7158791 chr14 55828607 A G 1.06E-95 Protein biomarker / / 23056639 rs17674563 chr14 55831125 G A 8.33E-176 Protein biomarker / / 23056639 rs11158037 chr14 55832152 C A 2.01E-04 Smoking initiation / / 24665060 rs2297816 chr14 55833038 A G 8.18E-97 Protein biomarker / / 23056639 rs2297816 chr14 55833038 A G 2.01E-04 Smoking initiation / / 24665060 rs1572611 chr14 55833874 T A 7.36E-175 Protein biomarker ATG14 UTR-3 23056639 rs10136596 chr14 55836773 A G 2.18E-168 Protein biomarker ATG14 intron 23056639 rs10142448 chr14 55838108 A C 9.33E-05 Multiple complex diseases ATG14 intron 17554300 rs10142448 chr14 55838108 A C 3.69E-168 Protein biomarker ATG14 intron 23056639 rs2009291 chr14 55838230 C A 3.50E-168 Protein biomarker ATG14 intron 23056639 rs7150763 chr14 55839801 A G 3.12E-95 Protein biomarker ATG14 intron 23056639 rs7150763 chr14 55839801 A G 2.01E-04 Smoking initiation ATG14 intron 24665060 rs10131730 chr14 55840092 C T 2.26E-95 Protein biomarker ATG14 intron 23056639 rs9323283 chr14 55840785 C T 8.58E-52 Protein biomarker ATG14 intron 23056639 rs8013713 chr14 55841252 C T 3.17E-168 Protein biomarker ATG14 intron 23056639 rs8015211 chr14 55841447 T C 1.64E-05 Prostate cancer(aggressive) ATG14 intron 21467234 rs8015211 chr14 55841447 T C 1.73E-95 Protein biomarker ATG14 intron 23056639 rs8015211 chr14 55841447 T C 2.08E-04 Smoking initiation ATG14 intron 24665060 rs8014477 chr14 55841477 G A 2.15E-95 Protein biomarker ATG14 intron 23056639 rs8014477 chr14 55841477 G A 2.01E-04 Smoking initiation ATG14 intron 24665060 rs8014540 chr14 55841688 C A 1.90E-95 Protein biomarker ATG14 intron 23056639 rs10137307 chr14 55845185 T C 9.10E-171 Protein biomarker ATG14 intron 23056639 rs946059 chr14 55847466 A G 3.45E-168 Protein biomarker ATG14 intron 23056639 rs3783650 chr14 55848972 A C 1.69E-167 Protein biomarker ATG14 intron 23056639 rs3783651 chr14 55850973 G C 1.25E-95 Protein biomarker ATG14 intron 23056639 rs4597235 chr14 55851987 A G 2.95E-166 Protein biomarker ATG14 intron 23056639 rs3825616 chr14 55853288 G C 4.06E-168 Protein biomarker ATG14 intron 23056639 rs17128434 chr14 55853528 G A 6.98E-04 Nicotine dependence ATG14 intron 17158188 rs17742621 chr14 55853724 T C 1.56E-32 Protein biomarker ATG14 intron 23056639 rs3783652 chr14 55854208 A G 2.67E-169 Protein biomarker ATG14 intron 23056639 rs3783653 chr14 55855007 G A 8.53E-52 Protein biomarker ATG14 intron 23056639 rs17742719 chr14 55855596 G T 2.16E-61 Protein biomarker ATG14 intron 23056639 rs17675052 chr14 55855704 C T 4.16E-38 Protein biomarker ATG14 intron 23056639 rs9323285 chr14 55863829 C A 1.31E-93 Protein biomarker ATG14 intron 23056639 rs9323285 chr14 55863829 C A 4.98E-04 Smoking initiation ATG14 intron 24665060 rs8003279 chr14 55864130 A G 5.40E-93 Protein biomarker ATG14 cds-synon 23056639 rs6573020 chr14 55871452 C T 2.53E-167 Protein biomarker ATG14 intron 23056639 rs946057 chr14 55877398 A T 3.61E-132 Protein biomarker ATG14 intron 23056639 rs1538257 chr14 55879277 T G 7.54E-130 Protein biomarker / / 23056639 rs10138446 chr14 55879685 A G 3.44E-130 Protein biomarker / / 23056639 rs11624331 chr14 55879827 C G 8.78E-127 Protein biomarker / / 23056639 rs1009647 chr14 55880047 G A 1.49E-70 Protein biomarker / / 23056639 rs1009647 chr14 55880047 G A 5.89E-04 Smoking initiation / / 24665060 rs1009648 chr14 55880169 T C 2.52E-71 Protein biomarker / / 23056639 rs1572610 chr14 55880341 G C 1.15E-32 Protein biomarker / / 23056639 rs1890256 chr14 55881276 C T 2.18E-71 Protein biomarker TBPL2 intron 23056639 rs1890256 chr14 55881276 C T 2.22E-04 Smoking initiation TBPL2 intron 24665060 rs8010013 chr14 55884828 A C 1.10E-38 Protein biomarker TBPL2 intron 23056639 rs8014526 chr14 55885054 C G 1.82E-38 Protein biomarker TBPL2 intron 23056639 rs4901560 chr14 55888533 T C 5.20E-05 Parkinson's disease (familial) TBPL2 intron 18985386 rs4901560 chr14 55888533 T C 2.80E-05 Urinary metabolites TBPL2 intron 21572414 rs8019209 chr14 55891329 G A 2.20E-05 Urinary metabolites TBPL2 intron 21572414 rs8019080 chr14 55891372 C T 5.20E-05 Parkinson's disease (familial) TBPL2 intron 18985386 rs8019080 chr14 55891372 C T 2.20E-05 Urinary metabolites TBPL2 intron 21572414 rs8003684 chr14 55892038 A C 4.22E-41 Protein biomarker TBPL2 intron 23056639 rs8016239 chr14 55894584 A C 4.20E-08 Protein biomarker TBPL2 intron 23056639 rs2341538 chr14 55895174 C G 7.10E-05 Parkinson's disease (familial) TBPL2 intron 18985386 rs2341538 chr14 55895174 C G 1.10E-05 Urinary metabolites TBPL2 intron 21572414 rs17743484 chr14 55897498 T C 9.62E-34 Protein biomarker TBPL2 intron 23056639 rs4470077 chr14 55897538 A G 9.04E-06 Cardiovascular disease TBPL2 intron 18179892 rs4470077 chr14 55897538 A G 6.13E-41 Protein biomarker TBPL2 intron 23056639 rs10146736 chr14 55897924 C T 4.25E-43 Protein biomarker TBPL2 intron 23056639 rs11848576 chr14 55901282 C T 2.21E-08 Protein biomarker TBPL2 intron 23056639 rs1959443 chr14 55901321 A G 1.31E-33 Protein biomarker TBPL2 intron 23056639 rs4901562 chr14 55901373 G A 6.35E-37 Protein biomarker TBPL2 intron 23056639 rs10483641 chr14 55901969 T A 3.79E-33 Protein biomarker TBPL2 intron 23056639 rs7149317 chr14 55902542 G A 5.20E-11 Protein biomarker TBPL2 intron 23056639 rs1953739 chr14 55903857 T C 3.00E-08 Protein biomarker TBPL2 intron 23056639 rs713475 chr14 55904650 T G 3.45E-33 Protein biomarker TBPL2 intron 23056639 rs713473 chr14 55904696 C T 3.20E-33 Protein biomarker TBPL2 intron 23056639 rs8014621 chr14 55906849 A C 3.82E-37 Protein biomarker TBPL2 intron 23056639 rs8019270 chr14 55907172 C G 3.04E-14 Protein biomarker TBPL2 missense 23056639 rs7142204 chr14 55908436 A C 9.89E-37 Protein biomarker / / 23056639 rs1572613 chr14 55909897 C T 9.97E-37 Protein biomarker / / 23056639 rs4901568 chr14 55912789 T A 1.36E-36 Protein biomarker / / 23056639 rs4901569 chr14 55912880 C T 1.80E-05 Urinary metabolites / / 21572414 rs4901569 chr14 55912880 C T 3.56E-12 Protein biomarker / / 23056639 rs8015252 chr14 55915393 G A 3.82E-05 Lymphocyte counts / / 22286170 rs8015252 chr14 55915393 G A 1.13E-32 Protein biomarker / / 23056639 rs17128488 chr14 55917537 G C 1.06E-32 Protein biomarker / / 23056639 rs7143800 chr14 55917734 A G 1.60E-05 Urinary metabolites / / 21572414 rs7143800 chr14 55917734 A G 3.51E-11 Protein biomarker / / 23056639 rs7143800 chr14 55917734 A G 2.40E-04 Smoking initiation / / 24665060 rs998871 chr14 55918302 G A 3.20E-10 Protein biomarker / / 23056639 rs998871 chr14 55918302 G A 4.71E-04 Smoking initiation / / 24665060 rs10483642 chr14 55920460 G A 5.58E-05 Height / / pha003011 rs1890255 chr14 55920781 T C 5.31E-04 Smoking initiation / / 24665060 rs946065 chr14 55932919 C A 9.22E-05 Bipolar disorder / / 18317468 rs12433615 chr14 55949626 A G 4.06E-05 Prostate cancer(aggressive) / / 21467234 rs7146055 chr14 55965724 G A 2.93E-10 Protein biomarker / / 23056639 rs1307315 chr14 55967795 C T 6.74E-16 Protein biomarker / / 23056639 rs1188069 chr14 55969956 T G 6.38E-05 Prostate cancer(aggressive) / / 21467234 rs1188074 chr14 55971831 C T 6.18E-10 Protein biomarker / / 23056639 rs10140999 chr14 55973715 C T 8.71E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1188076 chr14 55974475 A G 2.54E-15 Protein biomarker / / 23056639 rs17745017 chr14 55978825 G A 6.75E-09 Protein biomarker / / 23056639 rs1009714 chr14 55979538 A T 8.00E-10 Protein biomarker / / 23056639 rs2341883 chr14 55985012 G A 1.01E-04 Prostate cancer(aggressive) / / 21467234 rs10134019 chr14 55996992 T G 7.86E-08 Protein biomarker / / 23056639 rs17128552 chr14 56005933 T C 6.93E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs8011732 chr14 56006169 A G 1.62E-08 Protein biomarker / / 23056639 rs8011732 chr14 56006169 A G 0.0000235 Panic disorder / / 23149450 rs8011732 chr14 56006169 A G 2.35E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs8011732 chr14 56006169 A G 2.35E-05 Schizophrenia / / 23212062 rs4901589 chr14 56015498 G A,C 0.0000113 Panic disorder / / 23149450 rs4901589 chr14 56015498 G A,C 1.13E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs942317 chr14 56023822 A C 1.50E-08 Protein biomarker / / 23056639 rs942317 chr14 56023822 A C 0.0000576 Panic disorder / / 23149450 rs942317 chr14 56023822 A C 5.76E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs942317 chr14 56023822 A C 5.76E-05 Schizophrenia / / 23212062 rs10151664 chr14 56029533 A G 5.70E-06 Urinary metabolites / / 21572414 rs10138893 chr14 56046561 T G 0.000899 Salmonella-induced pyroptosis KTN1-AS1 intron 22837397 rs17746106 chr14 56069168 G A 1.20E-05 Urinary metabolites KTN1 intron 21572414 rs3783654 chr14 56136562 C A 0.0000487 Panic disorder KTN1 intron 23149450 rs3783654 chr14 56136562 C A 4.87E-05 Serum tamsulosin hydrochloride concentration KTN1 intron 23151678 rs3736877 chr14 56142480 A G 0.0000488 Panic disorder KTN1 intron 23149450 rs3736877 chr14 56142480 A G 4.88E-05 Serum tamsulosin hydrochloride concentration KTN1 intron 23151678 rs12589864 chr14 56149586 T A 8.90E-04 Alzheimer's disease KTN1 intron 22005930 rs1953356 chr14 56150151 A G 0.000086 Panic disorder KTN1 intron 23149450 rs1953356 chr14 56150151 A G 8.60E-05 Serum tamsulosin hydrochloride concentration KTN1 intron 23151678 rs6573053 chr14 56153307 C T 6.74E-08 Protein biomarker / / 23056639 rs8003149 chr14 56156504 T C 9.78E-04 Alzheimer's disease / / 22005930 rs17128690 chr14 56158826 A G 9.70E-04 Alzheimer's disease / / 22005930 rs12588185 chr14 56159365 T C 9.61E-04 Alzheimer's disease / / 22005930 rs8015588 chr14 56160904 C A 8.52E-04 Alzheimer's disease / / 22005930 rs7147303 chr14 56175634 C T 1.31E-09 Protein biomarker / / 23056639 rs7152314 chr14 56176012 C T 1.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs7152314 chr14 56176012 C T 2.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs8015301 chr14 56176458 C T 1.53E-04 Suicide attempts in bipolar disorder / / 21041247 rs8015301 chr14 56176458 C T 2.95E-04 Suicide attempts in bipolar disorder / / 21041247 rs2880396 chr14 56176859 C A 1.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs2880396 chr14 56176859 C A 3.06E-04 Suicide attempts in bipolar disorder / / 21041247 rs2342585 chr14 56176988 T A 1.35E-09 Protein biomarker / / 23056639 rs2342586 chr14 56177088 G A 1.60E-09 Protein biomarker / / 23056639 rs8021103 chr14 56177363 G T 2.18E-09 Protein biomarker / / 23056639 rs12431962 chr14 56178493 G A 1.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs12431962 chr14 56178493 G A 3.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs12432019 chr14 56178706 G C 1.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs12432019 chr14 56178706 G C 3.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs10498477 chr14 56180099 G A 1.95E-09 Protein biomarker / / 23056639 rs11621130 chr14 56181300 C T 2.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs11621130 chr14 56181300 C T 3.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs10130783 chr14 56181518 G A 1.36E-09 Protein biomarker / / 23056639 rs12587803 chr14 56183127 G A 2.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs12587803 chr14 56183127 G A 3.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs17832389 chr14 56185836 A G 2.50E-06 Urinary metabolites / / 21572414 rs11158050 chr14 56206214 A T 1.59E-11 Protein biomarker / / 23056639 rs945269 chr14 56206709 G A 2.48E-12 Protein biomarker / / 23056639 rs8004764 chr14 56209245 T C 8.02E-04 Multiple complex diseases / / 17554300 rs17128777 chr14 56220713 T C 4.92E-04 Multiple complex diseases / / 17554300 rs10149261 chr14 56222721 A G 1.50E-06 Urinary metabolites / / 21572414 rs8014482 chr14 56225235 C T 7.30E-06 Kawasaki disease / / 22446962 rs7143300 chr14 56227332 G A 9.51E-04 Alzheimer's disease / / 22005930 rs7494275 chr14 56231800 A C 9.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs10141372 chr14 56232449 C G 7.60E-04 Alzheimer's disease / / 22005930 rs12887389 chr14 56237212 G A 8.77E-04 White matter integrity / / 22425255 rs10150228 chr14 56238629 T G 5.40E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs4243601 chr14 56245474 G C 8.31E-05 Alzheimer's disease / / 22005930 rs7147190 chr14 56245824 T A 3.12E-05 Alzheimer's disease / / 22005930 rs17832456 chr14 56246011 A G 1.37E-05 Alzheimer's disease / / 22005930 rs7157819 chr14 56247593 C T 2.31E-05 Alzheimer's disease / / 22005930 rs7142488 chr14 56248010 T C 4.09E-04 Insulin resistance / / 21901158 rs7142488 chr14 56248010 T C 2.83E-05 Alzheimer's disease / / 22005930 rs12880540 chr14 56248206 T G 6.10E-04 Alzheimer's disease / / 22005930 rs8004650 chr14 56262779 C A 2.20E-05 Urinary metabolites LINC00520 intron 21572414 rs1959095 chr14 56292370 C T 1.61E-04 Multiple complex diseases / / 17554300 rs945275 chr14 56292672 C T 7.90E-06 Urinary metabolites / / 21572414 rs2880397 chr14 56293564 G T 5.80E-06 Urinary metabolites / / 21572414 rs7350721 chr14 56333513 A G 2.00E-06 Body mass index (interaction) / / 23192594 rs7350721 chr14 56333513 A G 6.00E-07 Body mass index (interaction) / / 23192594 rs7148653 chr14 56360285 G A 5.36E-08 Protein biomarker / / 23056639 rs17128903 chr14 56368377 C A,G,T 6.99E-10 Protein biomarker / / 23056639 rs17128904 chr14 56369065 C G 2.63E-09 Protein biomarker / / 23056639 rs1112305 chr14 56376249 C T 3.25E-08 Protein biomarker / / 23056639 rs12434440 chr14 56381207 T C 4.00E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs9323291 chr14 56395047 G A 2.43E-04 Nonalcoholic fatty liver disease / / 21423719 rs4901623 chr14 56398082 T C 8.79E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10151037 chr14 56418119 G T 8.00E-06 Obesity-related traits / / 23251661 rs1982672 chr14 56421080 C T 3.43E-05 Myopia (pathological) / / 23049088 rs1188144 chr14 56435821 T A 4.01E-04 Response to TNF antagonist treatment / / 21061259 rs1471548 chr14 56438249 A G 9.10E-04 Response to TNF antagonist treatment / / 21061259 rs1188157 chr14 56454074 C T 1.58E-04 Crohn's disease / / 17435756 rs11622704 chr14 56473049 G A 5.90E-06 Urinary metabolites / / 21572414 rs1188211 chr14 56503838 T A 8.25E-04 Type 2 diabetes / / 17463246 rs241526 chr14 56512919 C T 7.27E-04 Multiple complex diseases / / 17554300 rs7146622 chr14 56516779 G C 1.37E-04 Multiple complex diseases / / 17554300 rs398652 chr14 56525569 G A 2.00E-06 Telomere length / / 21460395 rs431718 chr14 56531186 G A 4.38E-04 Multiple complex diseases / / 17554300 rs17760428 chr14 56549290 G C 2.92E-05 Bipolar disorder,affective / / 20528957 rs241519 chr14 56563894 A C 4.88E-04 Premature ovarian failure / / 19508998 rs8004543 chr14 56582782 C A 7.90E-04 Type 2 diabetes / / 17463246 rs3186565 chr14 56584499 C T 2.59E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs3912201 chr14 56594420 T C 1.86E-04 Multiple complex diseases PELI2 intron 17554300 rs3912201 chr14 56594420 T C 1.02E-05 Serum metabolites PELI2 intron 19043545 rs10150333 chr14 56597317 T C 8.72E-04 Multiple complex diseases PELI2 intron 17554300 rs10150333 chr14 56597317 T C 5.76E-05 Serum metabolites PELI2 intron 19043545 rs10150333 chr14 56597317 T C 6.82E-04 Insulin resistance PELI2 intron 21901158 rs7157209 chr14 56602704 T C 3.52E-04 Multiple complex diseases PELI2 intron 17554300 rs4127813 chr14 56604125 C T 9.63E-05 Smoking quantity PELI2 intron 24665060 rs17688725 chr14 56604840 C T 4.51E-04 Smoking quantity PELI2 intron 24665060 rs17688801 chr14 56607659 G A 2.91E-04 Smoking quantity PELI2 intron 24665060 rs7145330 chr14 56616639 T G 2.24E-04 Multiple complex diseases PELI2 intron 17554300 rs7145330 chr14 56616639 T G 6.02E-04 Insulin resistance PELI2 intron 21901158 rs2343376 chr14 56618078 C A 3.27E-04 Smoking quantity PELI2 intron 24665060 rs17762499 chr14 56645265 C T 3.27E-04 Smoking quantity PELI2 intron 24665060 rs17689278 chr14 56651700 G A 7.93E-04 Smoking quantity PELI2 intron 24665060 rs1479748 chr14 56683530 G A 6.56E-04 Schizophrenia PELI2 intron 19197363 rs242581 chr14 56721596 C T 5.33E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PELI2 intron 21844884 rs12894473 chr14 56736585 T G 4.67E-04 Myopia (pathological) PELI2 intron 21095009 rs1152498 chr14 56815814 T A,C,G 7.35E-04 Parkinson's disease / / 17052657 rs12889725 chr14 56818843 A G 7.80E-04 Major depressive disorder / / 21042317 rs17091341 chr14 56819577 T C 4.94E-04 Multiple complex diseases / / 17554300 rs1152509 chr14 56831820 C T 3.94E-04 Stroke / / pha002886 rs979120 chr14 56846379 A T 8.55E-04 Type 2 diabetes / / 17463246 rs17093200 chr14 56846625 G C 7.55E-04 Smoking quantity / / 24665060 rs12883104 chr14 56861581 G A 6.20E-05 Hematology traits / / 23303382 rs1834804 chr14 56866424 T C 3.20E-04 Smoking quantity / / 24665060 rs1189025 chr14 56872132 C T 6.03E-04 Multiple complex diseases / / 17554300 rs1189136 chr14 56884403 C A 6.81E-05 Prostate cancer / / 22923026 rs12433428 chr14 56885925 A G 2.00E-05 Urinary metabolites / / 21572414 rs17091437 chr14 56886210 C T 4.49E-04 Type 2 diabetes / / 17463246 rs17832777 chr14 56886686 A C 6.00E-06 Chronic obstructive pulmonary disease-related biomarkers / / 23144326 rs9323293 chr14 56954687 C T 3.50E-05 Bilirubin levels / / 19414484 rs8011955 chr14 56969118 T C 9.61E-04 Type 2 diabetes / / 17463246 rs8012512 chr14 56971378 A G 6.76E-04 Type 2 diabetes / / 17463246 rs1959060 chr14 56972465 A G 1.20E-04 Multiple complex diseases / / 17554300 rs4274344 chr14 56972638 C T 1.31E-04 Multiple complex diseases / / 17554300 rs10138860 chr14 56972779 T C 3.18E-04 Fibrinogen / / 17255346 rs7142502 chr14 56980380 A G 8.83E-04 Multiple complex diseases / / 17554300 rs10133451 chr14 57002857 A G 4.15E-04 Smoking quantity / / 24665060 rs9285584 chr14 57003182 T G 5.57E-04 Smoking quantity / / 24665060 rs17091696 chr14 57025444 A T 4.32E-04 Multiple complex diseases / / 17554300 rs2104979 chr14 57029601 C T 7.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs11623335 chr14 57033076 G A 3.00E-07 Alcohol dependence / / 21956439 rs10138354 chr14 57037260 T C 4.28E-04 Alzheimer's disease (late onset) / / 21379329 rs11628364 chr14 57037520 A G 6.64E-04 Smoking quantity / / 24665060 rs11158120 chr14 57040343 C T 1.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs9788597 chr14 57042804 A G 8.85E-04 Type 2 diabetes / / 17463246 rs9788532 chr14 57043183 T C 1.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs12436047 chr14 57045048 T G 7.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs10150734 chr14 57046606 T A 0.0000289 Nonsyndromic striae distensae (stretch marks) C14orf101 UTR-5 23633020 rs8004462 chr14 57047350 C G 0.0000352 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs10137244 chr14 57058547 C T 0.0000348 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs2345150 chr14 57058948 G A 0.0000386 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs10139142 chr14 57060949 T C 0.0000362 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs2345151 chr14 57061182 A G 0.0000363 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs8012000 chr14 57066167 A G 6.45E-05 Type 2 diabetes C14orf101 intron 17463246 rs60224514 chr14 57066997 T C 0.0000861 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs10149528 chr14 57067695 C A 2.82E-04 Type 2 diabetes C14orf101 intron 17463246 rs10149528 chr14 57067695 C A 0.0000655 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs10149699 chr14 57067724 G A 2.04E-05 Type 2 diabetes C14orf101 intron 17463246 rs10149699 chr14 57067724 G A 0.0000968 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs10149712 chr14 57067875 C T 0.0000976 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs10129171 chr14 57068241 A G 0.000096 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs8005220 chr14 57068660 T A 0.0000951 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs8004012 chr14 57068795 A G 0.0000646 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs3737170 chr14 57072338 C T 0.0000698 Nonsyndromic striae distensae (stretch marks) C14orf101 cds-synon 23633020 rs3737169 chr14 57072643 A C 0.0000756 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs3818776 chr14 57072693 C T 0.0000754 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs7161054 chr14 57072999 T C 9.38E-04 Type 2 diabetes C14orf101 intron 17463246 rs28506925 chr14 57073551 T C 0.0000721 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs10134745 chr14 57075022 G A 0.0000141 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs28379806 chr14 57077226 C T 0.0000138 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs144756318 chr14 57081013 G A 0.0000132 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs7148317 chr14 57085657 A G 7.58E-04 Type 2 diabetes C14orf101 intron 17463246 rs7148317 chr14 57085657 A G 0.0000122 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs10139575 chr14 57087118 A G 0.00000945 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs12589087 chr14 57088433 A T 0.0000112 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs12589117 chr14 57088506 C T 0.00000906 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs7150339 chr14 57089099 C T 0.0000111 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs74052078 chr14 57089909 T C 0.0000109 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs8005961 chr14 57093497 C T 1.59E-04 Hearing function C14orf101 intron 17255346 rs8023068 chr14 57096346 G A 0.0000214 Nonsyndromic striae distensae (stretch marks) C14orf101 intron 23633020 rs1952589 chr14 57105330 A C 1.65E-04 Hearing function C14orf101 intron 17255346 rs8007927 chr14 57126989 G A,C,T 8.66E-04 Type 2 diabetes / / 17463246 rs4901724 chr14 57142883 G A 6.99E-05 Multiple complex diseases / / 17554300 rs12431592 chr14 57144240 G C 0.00000131 Sasang constitution (Soyang) / / 22394158 rs2149768 chr14 57147936 C A 3.22E-04 Multiple complex diseases / / 17554300 rs2149767 chr14 57148171 A G 1.07E-04 Multiple complex diseases / / 17554300 rs17091952 chr14 57154646 C T 3.66E-04 Multiple complex diseases / / 17554300 rs10873099 chr14 57160939 G A 1.98E-04 Multiple complex diseases / / 17554300 rs10873099 chr14 57160939 G A 7.07E-04 Coronary heart disease / / 21606135 rs1952587 chr14 57161217 T A 4.98E-06 Hearing function / / 21493956 rs17091976 chr14 57170111 A G 9.76E-06 Hearing function / / 21493956 rs928108 chr14 57170474 A G 7.45E-06 Hearing function / / 21493956 rs928107 chr14 57170671 G A 7.17E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs913741 chr14 57171273 A G 9.28E-06 Hearing function / / 21493956 rs6573103 chr14 57173763 T C 1.97E-04 Multiple complex diseases / / 17554300 rs6573103 chr14 57173763 T C 4.67E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs198247 chr14 57188907 C T 3.88E-04 Iron levels / / pha002876 rs6573104 chr14 57196255 A C 1.37E-04 Glaucoma (primary open-angle) / / 22419738 rs7151335 chr14 57200394 A T 7.10E-05 Type 2 diabetes / / 17463246 rs4901735 chr14 57204059 A G 1.10E-06 Leprosy / / 22019778 rs878889 chr14 57221139 G A 8.00E-07 Type 1 diabetes nephropathy / / 23028342 rs198223 chr14 57235592 C T 8.07E-05 Lung adenocarcinoma / / 19836008 rs17716816 chr14 57239835 T C 7.65E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12880053 chr14 57297563 C A 2.44E-04 Barrett's esophagus OTX2OS1 intron 24121790 rs12880053 chr14 57297563 C A 7.64E-04 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) OTX2OS1 intron 24121790 rs17092290 chr14 57305815 G T 6.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OTX2OS1 intron 20877124 rs17092290 chr14 57305815 G T 2.47E-04 Myopia (pathological) OTX2OS1 intron 21095009 rs198253 chr14 57306910 A G 5.67E-04 Myopia (pathological) OTX2OS1 intron 21095009 rs7161116 chr14 57309063 G A 2.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OTX2OS1 intron 20877124 rs6573109 chr14 57321050 G T 6.61E-04 Bipolar disorder,schizoaffective OTX2OS1 intron 19567891 rs10483676 chr14 57322091 G A 6.25E-04 Bipolar disorder,schizoaffective OTX2OS1 intron 19567891 rs11158135 chr14 57346872 A G 2.00E-04 Information processing speed OTX2OS1 intron 21130836 rs9646156 chr14 57370091 T C 5.90E-04 Alzheimer's disease OTX2OS1 intron 22005930 rs17092455 chr14 57376044 A G 4.60E-05 Hemoglobin OTX2OS1 intron pha003098 rs850272 chr14 57379608 G A 8.60E-06 Urinary metabolites OTX2OS1 intron 21572414 rs7154511 chr14 57401859 A G 1.70E-05 Urinary metabolites / / 21572414 rs2296091 chr14 57419385 C T 3.82E-04 Stroke / / pha002887 rs17719756 chr14 57454439 C T 9.23E-05 Height / / 17255346 rs2345838 chr14 57459136 C T 3.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1570526 chr14 57461807 G A 4.67E-04 Fibrinogen / / 17255346 rs1027728 chr14 57462256 G A 3.19E-05 Triglycerides / / pha003081 rs1504608 chr14 57472288 C T 3.88E-04 Diabetic nephropathy / / 21150874 rs1504608 chr14 57472288 C T 3.42E-04 Type 2 diabetes / / 22238593 rs10149366 chr14 57474039 A G 2.08E-05 Triglycerides / / pha003081 rs10149366 chr14 57474039 A G 9.11E-05 Lipid levels / / pha003082 rs1504610 chr14 57474965 C T 5.68E-04 Obesity (extreme) / / 21935397 rs4901754 chr14 57489712 G A 9.62E-05 Depression (quantitative trait) / / 23290196 rs12886032 chr14 57513124 A G 3.97E-07 Lipoproteins / / pha003079 rs17092814 chr14 57526153 G A 4.68E-04 Insulin resistance / / 21901158 rs1189827 chr14 57533464 G A 6.06E-07 Carotenoid and tocopherol levels / / 19185284 rs9805964 chr14 57535645 G T 6.81E-07 Carotenoid and tocopherol levels / / 19185284 rs4901761 chr14 57563519 C T 8.22E-04 Tourette syndrome / / 22889924 rs17092866 chr14 57585193 A G 6.40E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7144018 chr14 57607067 T C 9.00E-06 Multiple myeloma (IgH translocation) / / 23502783 rs2186075 chr14 57618262 G A 1.00E-04 Prostate cancer / / 21743057 rs8019635 chr14 57618423 T C 1.00E-04 Prostate cancer / / 21743057 rs8011432 chr14 57659190 T C 4.40E-04 Multiple complex diseases / / 17554300 rs6573135 chr14 57664374 G C 7.97E-05 Alcohol consumption / / 23743675 rs1961293 chr14 57665079 G A 7.83E-05 Alcohol consumption / / 23743675 rs2078519 chr14 57665499 A G 7.90E-05 Alcohol consumption / / 23743675 rs10135962 chr14 57665707 C G 8.16E-05 Alcohol consumption / / 23743675 rs10136042 chr14 57665761 C A 7.90E-05 Alcohol consumption / / 23743675 rs2881345 chr14 57667723 C A 7.70E-05 Alcohol consumption / / 23743675 rs10145188 chr14 57667996 G T 7.46E-05 Alcohol consumption / / 23743675 rs10135064 chr14 57668859 T G 7.61E-05 Alcohol consumption / / 23743675 rs10137456 chr14 57669003 T C 4.24E-05 Alcohol consumption / / 23743675 rs11851015 chr14 57669533 A G 9.00E-06 Alcohol consumption EXOC5 UTR-3 23743675 rs10134311 chr14 57670042 C T 3.52E-05 Alcohol consumption EXOC5 UTR-3 23743675 rs4612984 chr14 57670959 T C 3.79E-05 Alcohol consumption EXOC5 UTR-3 23743675 rs7157608 chr14 57671215 T C 3.84E-05 Alcohol consumption EXOC5 UTR-3 23743675 rs8003535 chr14 57672004 G T 6.05E-05 Alcohol consumption EXOC5 UTR-3 23743675 rs3742577 chr14 57672540 T C 6.19E-05 Alcohol consumption EXOC5 UTR-3 23743675 rs3742578 chr14 57672715 C T 3.18E-05 Alcohol consumption EXOC5 UTR-3 23743675 rs7141911 chr14 57672871 A G 6.08E-05 Alcohol consumption EXOC5 UTR-3 23743675 rs10137379 chr14 57674867 T C 2.56E-04 Multiple complex diseases EXOC5 UTR-3 17554300 rs10137379 chr14 57674867 T C 1.23E-05 Alcohol consumption EXOC5 UTR-3 23743675 rs10150771 chr14 57675185 C G,T 3.50E-05 Alcohol consumption EXOC5 UTR-3 23743675 rs10140993 chr14 57679457 C T 4.16E-05 Alcohol consumption EXOC5 intron 23743675 rs4569162 chr14 57681780 T C 4.72E-05 Alcohol consumption EXOC5 intron 23743675 rs10135879 chr14 57684134 T C 3.78E-05 Alcohol consumption EXOC5 intron 23743675 rs60328452 chr14 57684301 A T 3.73E-05 Alcohol consumption EXOC5 intron 23743675 rs1555788 chr14 57685172 A C 3.79E-05 Alcohol consumption EXOC5 intron 23743675 rs11846972 chr14 57688856 A T 3.59E-05 Alcohol consumption EXOC5 intron 23743675 rs10147790 chr14 57693036 T A 8.53E-05 Alcohol consumption EXOC5 intron 23743675 rs7155721 chr14 57697430 A C 2.96E-05 Alcohol consumption EXOC5 intron 23743675 rs6573137 chr14 57699904 A G 7.56E-05 Alcohol consumption EXOC5 intron 23743675 rs9323304 chr14 57712482 A C 8.78E-05 Alcohol consumption EXOC5 intron 23743675 rs2038860 chr14 57713422 C T 8.32E-05 Hypertension (essential hypertension) EXOC5 intron 22184326 rs10130359 chr14 57716393 C T 8.65E-05 Alcohol consumption EXOC5 intron 23743675 rs7147218 chr14 57722057 T C,G 6.81E-05 Alcohol consumption EXOC5 intron 23743675 rs10133300 chr14 57722893 G T 7.99E-05 Alcohol consumption EXOC5 intron 23743675 rs716690 chr14 57728652 C T 6.39E-05 Alcohol consumption EXOC5 intron 23743675 rs10141811 chr14 57730748 C T 6.01E-05 Alcohol consumption EXOC5 intron 23743675 rs10141911 chr14 57730851 C T 3.71E-05 Alcohol consumption EXOC5 intron 23743675 rs11850616 chr14 57731973 C T 6.61E-05 Alcohol consumption EXOC5 intron 23743675 rs10147752 chr14 57732270 A G 4.30E-05 Alcohol consumption EXOC5 intron 23743675 rs6573140 chr14 57732994 T G 4.73E-05 Alcohol consumption EXOC5 intron 23743675 rs17093036 chr14 57734020 C G 7.16E-05 Alcohol consumption EXOC5 intron 23743675 rs10140245 chr14 57749700 A C 0.00054 Breast cancer MUDENG missense 23555315 rs10498486 chr14 57759392 T C 9.88E-05 Alcohol consumption / / 23743675 rs8021868 chr14 57791313 C G 4.65E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17093081 chr14 57813513 C T 3.53E-05 Serum albumin level / / pha003084 rs7144649 chr14 57822216 G A 2.69E-04 Premature ovarian failure / / 19508998 rs7144649 chr14 57822216 G A 4.00E-06 Alcohol consumption / / 23743675 rs11158157 chr14 57826995 A G 2.71E-05 Intelligence / / 21826061 rs11851781 chr14 57827961 G A,C 2.22E-04 Coronary Artery Disease / / 17634449 rs11620639 chr14 57876265 G A 1.59E-05 Age-related macular degeneration /A30 UTR-3 pha000001 rs7144713 chr14 57899894 T C 7.10E-04 Alcohol dependence / / 20201924 rs10162518 chr14 57909140 A G 8.52E-04 Multiple complex diseases / / 17554300 rs1152519 chr14 57952268 A G 1.11E-04 Multiple complex diseases C14orf105 intron 17554300 rs2346471 chr14 57962977 A G 5.48E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs268843 chr14 57998460 G A 0.0000752 Sarcoidosis / / 22952805 rs17795775 chr14 57998867 C T 6.47E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs17796038 chr14 58014195 G T 3.09E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs11623923 chr14 58042753 G A 3.07E-04 Alcohol consumption (maxi-drinks) SLC35F4 intron 24277619 rs1745689 chr14 58070892 T C 9.66E-05 Male fertility SLC35F4 intron 22633400 rs994941 chr14 58102719 G A 4.91E-05 Odorant perception SLC35F4 intron 23910658 rs10483687 chr14 58115496 G T 3.32E-04 Amyotrophic lateral sclerosis (sporadic) SLC35F4 intron 24529757 rs10134944 chr14 58119196 C T 7.00E-06 Bipolar disorder SLC35F4 intron 17554300 rs10134944 chr14 58119196 C T 1.00E-06 Bipolar disorder SLC35F4 intron 21254220 rs12890287 chr14 58121645 C T 2.06E-05 Multiple complex diseases SLC35F4 intron 17554300 rs11622600 chr14 58124389 C T 1.70E-05 Multiple complex diseases SLC35F4 intron 17554300 rs17093240 chr14 58126646 T C 4.84E-05 Multiple complex diseases SLC35F4 intron 17554300 rs10431700 chr14 58141799 A G 2.21E-05 Multiple complex diseases SLC35F4 intron 17554300 rs10431700 chr14 58141799 A G 9.63E-05 Erythrocyte counts SLC35F4 intron pha003090 rs4304940 chr14 58152836 A G 7.35E-04 Multiple complex diseases SLC35F4 intron 17554300 rs964431 chr14 58157728 C T 4.60E-04 Multiple complex diseases SLC35F4 intron 17554300 rs8020764 chr14 58180290 A C 5.79E-04 Multiple complex diseases SLC35F4 intron 17554300 rs1092015 chr14 58200725 A G 5.25E-05 Bipolar disorder SLC35F4 intron 19488044 rs1092015 chr14 58200725 A G 8.00E-06 Bipolar disorder and schizophrenia SLC35F4 intron 20889312 rs1092015 chr14 58200725 A G 2.23E-05 Bipolar Disorder SLC35F4 intron pha002858 rs1073382 chr14 58203151 T G 7.63E-04 Bipolar disorder SLC35F4 intron 19259986 rs1950996 chr14 58236413 G A 1.42E-04 Vaspin levels SLC35F4 intron 22907691 rs1950996 chr14 58236413 G A 0.0001423 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks SLC35F4 intron 22907730 rs8008397 chr14 58294425 A G 4.27E-04 Multiple complex diseases SLC35F4 intron 17554300 rs17093726 chr14 58297376 C T 7.89E-04 Multiple complex diseases SLC35F4 intron 17554300 rs17093753 chr14 58305649 T C 8.97E-05 Information processing speed SLC35F4 intron 21130836 rs927251 chr14 58311135 T A 7.08E-04 Multiple complex diseases SLC35F4 intron 17554300 rs763933 chr14 58319838 C T 4.89E-04 Response to cytidine analogues (gemcitabine) SLC35F4 intron 24483146 rs8013190 chr14 58355048 A G 7.00E-08 HIV-1 control / / 20041166 rs808241 chr14 58364863 A G 6.30E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1335515 chr14 58385365 T C 8.00E-06 Attention deficit hyperactivity disorder (time to onset) / / 18937294 rs811732 chr14 58386985 A C 1.30E-05 Pulmonary function / / 17903307 rs808225 chr14 58397916 A G 7.00E-06 Pulmonary function / / 17903307 rs878086 chr14 58405614 C G 7.26E-05 Bipolar disorder / / 22925353 rs878085 chr14 58405679 C T 7.83E-04 Depression (quantitative trait) / / 20800221 rs10135394 chr14 58443167 G A 4.56E-04 Multiple complex diseases / / 17554300 rs12435597 chr14 58446069 G C 8.95E-04 Multiple complex diseases / / 17554300 rs12435601 chr14 58446097 G T 9.91E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs1028458 chr14 58446570 T C 9.82E-04 Multiple complex diseases / / 17554300 rs808208 chr14 58452939 G A 8.08E-05 Leukocyte Counts / / pha003091 rs710002 chr14 58458567 A G 0.000776977 Hypertension (early onset hypertension) / / 22479346 rs1046451 chr14 58460588 G A 8.16E-05 Hypertension (early onset hypertension) / / 22479346 rs1046451 chr14 58460588 G A 4.42E-05 Waist Circumference / / pha003023 rs2747099 chr14 58462362 C T 2.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2747100 chr14 58464986 G C 1.13E-04 Attention deficit hyperactivity disorder / / pha002875 rs2747104 chr14 58470403 G A 1.26E-04 Attention deficit hyperactivity disorder / / pha002875 rs17734691 chr14 58474350 G A 9.38E-05 Bipolar disorder C14orf37 intron 20451256 rs17094212 chr14 58481792 G A 8.66E-05 Cognitive decline C14orf37 intron 22054870 rs11851796 chr14 58539532 T C 6.00E-07 Urinary metabolites C14orf37 intron 21572414 rs10140125 chr14 58541406 T C 5.00E-07 Urinary metabolites C14orf37 intron 21572414 rs8015039 chr14 58547391 C A 1.40E-05 Urinary metabolites C14orf37 intron 21572414 rs7143063 chr14 58549178 C T 6.50E-06 Urinary metabolites C14orf37 intron 21572414 rs12884702 chr14 58555329 A T 9.70E-06 Urinary metabolites C14orf37 intron 21572414 rs11623561 chr14 58556776 A C 1.90E-05 Urinary metabolites C14orf37 intron 21572414 rs4901847 chr14 58559241 C T 2.00E-06 Lupus nephritis in systemic lupus erythematosus C14orf37 intron 24925725 rs10144575 chr14 58560531 T C 2.90E-06 Urinary metabolites C14orf37 intron 21572414 rs7157794 chr14 58562040 G A 1.30E-06 Urinary metabolites C14orf37 intron 21572414 rs2273442 chr14 58563694 G C 1.20E-06 Urinary metabolites C14orf37 missense 21572414 rs10134110 chr14 58573183 C G 2.10E-06 Urinary metabolites C14orf37 intron 21572414 rs7151771 chr14 58580310 G A 3.80E-07 Urinary metabolites C14orf37 intron 21572414 rs980468 chr14 58586031 G A 1.90E-05 Urinary metabolites C14orf37 intron 21572414 rs17094388 chr14 58624679 T C 4.55E-04 Multiple complex diseases / / 17554300 rs10151525 chr14 58772018 A G 2.32E-05 Smoking initiation ARID4A intron 24665060 rs8014077 chr14 58839339 A C 1.03E-04 Smoking initiation ARID4A UTR-3 24665060 rs10151824 chr14 59013018 A G 4.95E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) KIAA0586 intron 24023788 rs3850301 chr14 59081132 T C 2.80E-05 Lipid traits / / 17903299 rs167481 chr14 59108678 T C 4.01E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) DACT1 intron 24023788 rs311840 chr14 59137233 A G 4.90E-04 Alzheimer's disease (late onset) / / 21379329 rs311844 chr14 59138971 G T 3.69E-22 Narcolepsy / / 19629137 rs385803 chr14 59142509 G A 1.69E-05 Cognitive test performance / / 20125193 rs710018 chr14 59163623 A G 7.90E-04 Multiple complex diseases / / 17554300 rs1368008 chr14 59175415 T C 1.41E-04 Alzheimer's disease (late onset) / / 21379329 rs1368008 chr14 59175415 T C 3.17E-05 Alzheimer's disease (late onset) / / 21460841 rs8022761 chr14 59180300 T C 3.35E-05 Leukocyte Counts / / pha003091 rs17833053 chr14 59181924 G A 1.25E-04 Glycosylated haemoglobin levels / / 17255346 rs17094971 chr14 59183198 A T 9.35E-07 Colorectal cancer / / 23266556 rs856288 chr14 59184103 T C 3.06E-04 Birth weight / / 17255346 rs7141538 chr14 59184529 C T 9.41E-07 Colorectal cancer / / 23266556 rs1432096 chr14 59185056 G T 8.92E-07 Colorectal cancer / / 23266556 rs17094983 chr14 59189361 G A 3.00E-06 Colorectal cancer / / 23266556 rs2651256 chr14 59192645 C T 5.51E-05 Waist Circumference / / pha003023 rs311854 chr14 59193020 G A 4.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs311850 chr14 59195739 G A 7.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs1119783 chr14 59197545 C A 4.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs422683 chr14 59197787 A G 9.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs10134791 chr14 59198137 C T 6.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs311847 chr14 59202529 C A 4.77E-04 Multiple complex diseases / / 17554300 rs966735 chr14 59208732 G A 7.45E-04 Type 2 diabetes / / 17463246 rs311874 chr14 59209182 C T 6.27E-04 Alzheimer's disease / / 17998437 rs311874 chr14 59209182 C T 1.30E-05 Urinary metabolites / / 21572414 rs182582 chr14 59209282 C A,G,T 9.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs710007 chr14 59210335 G A 6.02E-06 Colorectal cancer / / 23266556 rs856380 chr14 59210489 T G 7.44E-06 Colorectal cancer / / 23266556 rs856379 chr14 59210646 A G 7.15E-06 Colorectal cancer / / 23266556 rs311872 chr14 59210775 G A 2.50E-04 Type 2 diabetes / / 17463246 rs856378 chr14 59210881 G A 4.03E-06 Colorectal cancer / / 23266556 rs856377 chr14 59210944 T C 6.44E-06 Colorectal cancer / / 23266556 rs856376 chr14 59210957 G A 4.93E-06 Colorectal cancer / / 23266556 rs710005 chr14 59211420 T C 5.82E-04 Alzheimer's disease / / 17998437 rs710005 chr14 59211420 T C 5.26E-06 Colorectal cancer / / 23266556 rs856375 chr14 59211557 T G 7.74E-04 Alzheimer's disease / / 17998437 rs856375 chr14 59211557 T G 6.25E-06 Colorectal cancer / / 23266556 rs377425 chr14 59224735 T C 3.72E-04 Colorectal cancer / / 23266556 rs385902 chr14 59226554 T G 3.94E-04 Colorectal cancer / / 23266556 rs856204 chr14 59233594 T G 5.83E-04 Colorectal cancer / / 23266556 rs7149631 chr14 59233754 A G 4.44E-04 Alzheimer's disease / / 17998437 rs17095071 chr14 59233935 T G 4.40E-04 Multiple complex diseases / / 17554300 rs856208 chr14 59236137 G C 5.89E-04 Colorectal cancer / / 23266556 rs856209 chr14 59236388 T C 5.96E-04 Colorectal cancer / / 23266556 rs710003 chr14 59239300 A G 4.46E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs856213 chr14 59239852 A G 6.59E-04 Colorectal cancer / / 23266556 rs17095082 chr14 59240213 T C 9.32E-04 Multiple complex diseases / / 17554300 rs17095088 chr14 59240410 G A 2.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs10149208 chr14 59243338 A G 1.28E-04 Alzheimer's disease / / 22005930 rs17093292 chr14 59243951 A T 3.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs856218 chr14 59246693 T C 6.26E-04 Alzheimer's disease / / 22005930 rs10136607 chr14 59246866 C T 0.0000183 HDL cholesterol particle diameter / / 23263444 rs856221 chr14 59249294 G A 4.24E-04 Alzheimer's disease (late onset) / / 21379329 rs417454 chr14 59255462 C G 6.26E-04 Multiple complex diseases / / 17554300 rs8018026 chr14 59255726 T C 1.39E-04 Alzheimer's disease (late onset) / / 21379329 rs6573225 chr14 59284887 C A 1.56E-06 Reading disability and language impairment / / 24024963 rs444027 chr14 59285080 C T 6.47E-05 Alzheimer's disease / / 22005930 rs7145068 chr14 59285311 A G 6.54E-05 Alzheimer's disease / / 22005930 rs8008303 chr14 59285515 C A 6.72E-05 Alzheimer's disease / / 22005930 rs396309 chr14 59286228 G A 6.53E-05 Alzheimer's disease / / 22005930 rs438311 chr14 59286741 C T 6.85E-05 Alzheimer's disease / / 22005930 rs370546 chr14 59287538 T C 6.84E-05 Alzheimer's disease / / 22005930 rs403456 chr14 59287696 G A 7.01E-05 Alzheimer's disease / / 22005930 rs414544 chr14 59288237 G A,C,T 1.53E-04 Alzheimer's disease / / 22005930 rs1252743 chr14 59289234 T C 2.91E-04 Alzheimer's disease / / 22005930 rs382449 chr14 59289746 C A 3.09E-04 Alzheimer's disease / / 22005930 rs413819 chr14 59293220 A G 3.28E-05 Alzheimer's disease / / 22005930 rs442555 chr14 59296184 T C 9.80E-05 Alcoholism (heaviness of drinking) / / 21529783 rs442555 chr14 59296184 T C 2.38E-06 Reading disability and language impairment / / 24024963 rs2162491 chr14 59296247 C T 8.37E-05 Birth weight / / 17255346 rs2162491 chr14 59296247 C T 4.50E-06 Urinary metabolites / / 21572414 rs417483 chr14 59298447 G A 2.45E-05 Alzheimer's disease / / 22005930 rs387425 chr14 59301909 A G 2.54E-05 Alzheimer's disease / / 22005930 rs418434 chr14 59304643 G A 2.49E-05 Alzheimer's disease / / 22005930 rs10149194 chr14 59308198 C T 1.30E-05 Urinary metabolites / / 21572414 rs444219 chr14 59309795 C T 2.13E-05 Alzheimer's disease / / 22005930 rs414395 chr14 59322516 G C 8.51E-05 Alzheimer's disease / / 22005930 rs375197 chr14 59329966 A G 1.50E-04 Alzheimer's disease / / 22005930 rs448031 chr14 59332166 A G 1.50E-05 Urinary metabolites / / 21572414 rs448031 chr14 59332166 A G 1.56E-04 Alzheimer's disease / / 22005930 rs366518 chr14 59333084 C T 1.55E-04 Alzheimer's disease / / 22005930 rs367617 chr14 59333386 C T 1.56E-04 Alzheimer's disease / / 22005930 rs367717 chr14 59333467 C G 1.57E-04 Alzheimer's disease / / 22005930 rs4901869 chr14 59334128 A G 6.00E-06 Panic disorder / / 19165232 rs437101 chr14 59334928 T C 2.22E-04 Alzheimer's disease / / 22005930 rs413261 chr14 59336017 A T 1.90E-04 Alzheimer's disease / / 22005930 rs1252705 chr14 59337564 T A 7.00E-06 Urinary metabolites / / 21572414 rs418239 chr14 59338470 C G 1.99E-04 Alzheimer's disease / / 22005930 rs9806019 chr14 59340989 A T 9.60E-07 Urinary metabolites / / 21572414 rs442945 chr14 59343149 A T 2.05E-04 Alzheimer's disease / / 22005930 rs450287 chr14 59345154 A T 7.88E-04 Multiple complex diseases / / 17554300 rs2114618 chr14 59345566 A C 8.10E-06 Urinary metabolites / / 21572414 rs17254871 chr14 59345637 T C 1.87E-05 Cognitive impairment induced by topiramate / / 22091778 rs17254871 chr14 59345637 T C 5.52E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs436993 chr14 59347241 C A 2.48E-04 Alzheimer's disease / / 22005930 rs10134508 chr14 59351820 C T 8.08E-05 Orofacial clefts / / 22419666 rs419256 chr14 59353176 A G 2.41E-04 Alzheimer's disease / / 22005930 rs397354 chr14 59353750 G A 2.33E-04 Alzheimer's disease / / 22005930 rs404799 chr14 59353999 G T 2.60E-04 Alzheimer's disease / / 22005930 rs444599 chr14 59354277 C T 2.63E-04 Alzheimer's disease / / 22005930 rs407263 chr14 59354913 G A 4.11E-04 Alzheimer's disease / / 22005930 rs395335 chr14 59358408 T C 2.88E-04 Alzheimer's disease / / 22005930 rs1427325 chr14 59360600 C A 3.54E-04 Alzheimer's disease / / 22005930 rs427170 chr14 59362972 G C 3.03E-04 Alzheimer's disease / / 22005930 rs380942 chr14 59363770 A G 3.04E-04 Alzheimer's disease / / 22005930 rs1427324 chr14 59364693 C T 3.50E-05 Attention deficit hyperactivity disorder / / 18980221 rs1427324 chr14 59364693 C T 4.05E-06 Obesity-related traits / / 23251661 rs1427324 chr14 59364693 C T 3.73E-06 Attention deficit hyperactivity disorder / / pha002875 rs402257 chr14 59365017 T C 3.08E-04 Alzheimer's disease / / 22005930 rs411258 chr14 59366054 T G 3.09E-04 Alzheimer's disease / / 22005930 rs405460 chr14 59366315 G T 6.00E-07 Obesity-related traits / / 23251661 rs387516 chr14 59366684 A G 3.14E-04 Alzheimer's disease / / 22005930 rs409688 chr14 59367032 G A 3.13E-04 Alzheimer's disease / / 22005930 rs1252687 chr14 59370105 C G 2.83E-04 Alzheimer's disease / / 22005930 rs367390 chr14 59371121 G A 1.79E-04 Alzheimer's disease / / 22005930 rs367089 chr14 59371161 G A 2.53E-04 Alzheimer's disease / / 22005930 rs436623 chr14 59372615 A G 8.77E-05 Alzheimer's disease / / 22005930 rs433637 chr14 59375748 T C 2.18E-04 Alzheimer's disease / / 22005930 rs2295426 chr14 59376455 T C 1.00E-05 Attention deficit hyperactivity disorder / / 18980221 rs2295426 chr14 59376455 T C 3.16E-06 Attention deficit hyperactivity disorder / / pha002875 rs177724 chr14 59376799 T A 1.98E-04 Alzheimer's disease / / 22005930 rs177727 chr14 59377448 C T 1.93E-04 Alzheimer's disease / / 22005930 rs177733 chr14 59380371 G A 1.89E-04 Alzheimer's disease / / 22005930 rs177735 chr14 59380528 A T 1.87E-04 Alzheimer's disease / / 22005930 rs10150328 chr14 59380832 T C 2.08E-05 Schizophrenia / / 19571811 rs177738 chr14 59381495 C T 1.73E-04 Alzheimer's disease / / 22005930 rs177739 chr14 59381750 T G 1.62E-04 Alzheimer's disease / / 22005930 rs17833380 chr14 59383756 C T 1.68E-22 Narcolepsy / / 19629137 rs85425 chr14 59384953 T C 5.17E-04 Multiple complex diseases / / 17554300 rs85425 chr14 59384953 T C 0.0002 Migraine / / 22678113 rs6573229 chr14 59400491 T C 3.57E-05 Myopia (severe) / / 23933737 rs10483707 chr14 59407805 G A 8.99E-07 Myopia (severe) / / 23933737 rs7161189 chr14 59409500 G A 3.09E-05 Myopia (severe) / / 23933737 rs2093000 chr14 59422261 T A 9.54E-04 Alzheimer's disease / / 22005930 rs7145622 chr14 59424395 T C 9.21E-04 Alzheimer's disease / / 22005930 rs2882029 chr14 59425014 G A 9.04E-04 Alzheimer's disease / / 22005930 rs17095466 chr14 59430018 T G 4.67E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2024882 chr14 59434893 G A 8.25E-04 Alzheimer's disease / / 22005930 rs1956182 chr14 59443532 G A 7.95E-04 Alzheimer's disease / / 22005930 rs11158240 chr14 59454775 G A 1.58E-04 Multiple complex diseases / / 17554300 rs10132731 chr14 59458350 C T 7.40E-05 Tooth agenesis (mandibular third molar) / / 24172245 rs17833464 chr14 59462340 T C 8.86E-05 Multiple complex diseases / / 17554300 rs6573233 chr14 59469737 G A 3.84E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1956197 chr14 59477414 C T 0.0000143 Gains in maximal O2 uptake response / / 21183627 rs17095545 chr14 59485611 G A 5.05E-04 Multiple complex diseases / / 17554300 rs10135889 chr14 59492768 C A 3.03E-04 Fibrinogen / / 17255346 rs10137571 chr14 59505553 A G 9.66E-05 Fibrinogen / / 17255346 rs10220668 chr14 59509205 A G 8.94E-07 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs10136093 chr14 59538065 T C 1.88E-04 Fibrinogen / / 17255346 rs17255276 chr14 59580956 T C 2.91E-04 Fibrinogen / / 17255346 rs12372908 chr14 59584673 A G 5.60E-06 Urinary metabolites / / 21572414 rs17255290 chr14 59585670 A T 3.22E-05 Schizophrenia / / 19571809 rs2000074 chr14 59591509 T C 3.40E-06 Urinary metabolites / / 21572414 rs8006768 chr14 59612400 T C 8.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8006768 chr14 59612400 T C 5.21E-04 Smoking cessation / / 24665060 rs11627657 chr14 59626498 A G 2.30E-05 Urinary metabolites / / 21572414 rs17095819 chr14 59643961 A G 8.61E-05 Suicide attempts in bipolar disorder / / 21423239 rs17095823 chr14 59645207 C G 8.54E-04 Multiple complex diseases / / 17554300 rs1438521 chr14 59653800 T C 4.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs1252917 chr14 59664770 A G 6.64E-04 Bipolar disorder,schizoaffective DAAM1 intron 19567891 rs1152566 chr14 59666276 A G 6.19E-04 Bipolar disorder,schizoaffective DAAM1 intron 19567891 rs17255388 chr14 59666401 T C 3.79E-04 Smoking initiation DAAM1 intron 24665060 rs721069 chr14 59687305 A G 1.87E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) DAAM1 intron 24023788 rs10483710 chr14 59699000 G A 3.56E-04 Coronary Artery Disease DAAM1 intron 17634449 rs7154112 chr14 59714317 T C 8.20E-05 Hypothyroidism DAAM1 intron 22493691 rs10138516 chr14 59736275 C T 3.03E-05 Multiple complex diseases DAAM1 intron 17554300 rs7143698 chr14 59804127 G A 2.01E-04 Stroke DAAM1 intron pha002887 rs941886 chr14 59814502 C A 1.41E-04 Sarcoidosis DAAM1 intron 19165924 rs755011 chr14 59815040 C T 6.72E-05 Sarcoidosis DAAM1 intron 19165924 rs4901921 chr14 59839129 C T 1.17E-04 Sarcoidosis / / 19165924 rs4901921 chr14 59839129 C T 6.45E-04 Acute lymphoblastic leukemia (childhood) / / 22076464 rs3850302 chr14 59857577 T C 4.38E-04 Coronary Artery Disease / / 17634449 rs3850302 chr14 59857577 T C 3.40E-05 Sarcoidosis / / 19165924 rs1266212 chr14 59890957 C G 6.70E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1271183 chr14 59891791 C T 6.86E-06 Left ventricular mass / / 21212386 rs2774052 chr14 59900020 A G 8.42E-04 Coronary Artery Disease / / 17634449 rs2774052 chr14 59900020 A G 2.34E-04 Sarcoidosis / / 19165924 rs2774052 chr14 59900020 A G 4.80E-17 Progranulin levels / / 21087763 rs2774052 chr14 59900020 A G 4.80E-17 Myocardial infarction / / 21211798 rs1262135 chr14 59909768 T C 2.17E-04 Coronary Artery Disease / / 17634449 rs1271510 chr14 59920337 G A 8.13E-04 Multiple complex diseases / / 17554300 rs4898989 chr14 59935344 G A 1.92E-05 Type 2 diabetes / / 17463246 rs1273153 chr14 59946459 T C 1.74E-04 Lymphocyte counts C14orf149 intron 22286170 rs1273153 chr14 59946459 T C 7.34E-05 Type 2 diabetes C14orf149 intron 23300278 rs1253103 chr14 59949448 G C 1.06E-04 Sarcoidosis C14orf149 intron 19165924 rs1253113 chr14 59961244 G A 6.02E-05 Type 2 diabetes JKAMP intron 17463246 rs1253114 chr14 59961342 T A 5.85E-05 Type 2 diabetes JKAMP intron 17463246 rs7560 chr14 59971039 T G 9.49E-04 Parkinson's disease JKAMP UTR-3 17052657 rs6573260 chr14 59976589 T C 2.81E-04 Type 2 diabetes C14orf38 intron 17463246 rs7151295 chr14 59978072 G A 9.52E-05 Type 2 diabetes C14orf38 intron 17463246 rs6573270 chr14 60029167 T C 1.07E-05 Type 2 diabetes C14orf38 intron 17463246 rs8008450 chr14 60035354 C T 1.97E-05 Erythrocyte counts C14orf38 intron pha003101 rs17255933 chr14 60042939 T A 9.25E-04 Type 2 diabetes C14orf38 intron 17463246 rs12896175 chr14 60046581 C T 1.38E-05 Erythrocyte counts / / pha003101 rs7143940 chr14 60047545 C G 1.79E-04 Multiple complex diseases / / 17554300 rs11158264 chr14 60050256 G A 1.89E-04 Type 2 diabetes / / 17463246 rs11158264 chr14 60050256 G A 2.54E-04 Alzheimer's disease / / pha002879 rs4144153 chr14 60051619 G C 1.47E-04 Alzheimer's disease / / 17998437 rs11848964 chr14 60094215 T C 0.0000132 HDL cholesterol particle diameter RTN1 intron 23263444 rs17804446 chr14 60140020 T G 7.42E-04 Alzheimer's disease RTN1 intron 17998437 rs17804446 chr14 60140020 T G 1.83E-04 Alzheimer's disease RTN1 intron pha002879 rs1952043 chr14 60146555 A G 1.09E-06 Major depressive disorder RTN1 intron 19107115 rs1013822 chr14 60149910 G A 4.26E-06 Major depressive disorder RTN1 intron 19107115 rs8011499 chr14 60283880 C T 5.00E-06 Urinary metabolites RTN1 intron 21572414 rs7401258 chr14 60361153 C A 5.33E-04 Type 2 diabetes / / 17463246 rs219326 chr14 60443190 C T 8.51E-06 Pulmonary function LRRC9 intron 17903307 rs219349 chr14 60455415 C T 6.15E-06 Pulmonary function LRRC9 intron 17903307 rs219391 chr14 60484931 C T 6.18E-06 Pulmonary function LRRC9 intron 17903307 rs461951 chr14 60539233 G T 3.63E-05 Pulmonary function / / 17903307 rs3742642 chr14 60591199 A T 0.00023 Prostate cancer C14orf135 missense 23555315 rs216518 chr14 60683430 C A 2.00E-06 Allergic rhinitis / / 22036096 rs8019531 chr14 60707411 G A 9.47E-04 Type 2 diabetes / / 17463246 rs11628587 chr14 60707431 C T 8.61E-04 Type 2 diabetes / / 17463246 rs11628628 chr14 60707546 C A 8.61E-04 Type 2 diabetes / / 17463246 rs8011227 chr14 60718276 A G 9.25E-04 Type 2 diabetes PPM1A intron 17463246 rs10142834 chr14 60734963 A G 6.13E-04 Body mass index PPM1A intron 21701565 rs1887104 chr14 60740326 T G 7.34E-05 IgE levels in asthmatics (D.p. specific) PPM1A intron 23967269 rs1887103 chr14 60743219 A G 7.95E-04 Body mass index PPM1A intron 21701565 rs2273623 chr14 60765245 A G 2.98E-05 IgE levels in asthmatics (D.p. specific) PPM1A UTR-3 23967269 rs2273623 chr14 60765245 A G 3.16E-05 IgE levels in asthmatics (D.f. specific) PPM1A UTR-3 23967269 rs1998225 chr14 60777483 A T 9.47E-04 Type 2 diabetes / / 17463246 rs8004280 chr14 60780429 A G 8.64E-04 Body mass index / / 21701565 rs4901977 chr14 60789176 C T 3.37E-08 Glaucoma (primary open-angle) / / 22570617 rs2350892 chr14 60792103 A G 1.52E-06 Glaucoma (primary open-angle) / / 22419738 rs1885095 chr14 60794782 T C 2.82E-05 Glaucoma (primary open-angle) / / 22419738 rs2180833 chr14 60796648 T C 1.37E-06 Glaucoma (primary open-angle) / / 22419738 rs6573307 chr14 60798009 T G 6.49E-07 Glaucoma (primary open-angle) / / 22419738 rs6573308 chr14 60806976 C T 1.15E-06 Glaucoma (primary open-angle) / / 22419738 rs4436712 chr14 60808002 G T 1.19E-06 Glaucoma (primary open-angle) / / 22419738 rs1254274 chr14 60845309 T A 3.59E-05 Odorant perception / / 23910658 rs1254276 chr14 60847001 C T 2.25E-06 Glaucoma (primary open-angle) / / 22419738 rs1313237 chr14 60848224 A C 2.51E-06 Glaucoma (primary open-angle) / / 22419738 rs1272131 chr14 60886150 T C 1.88E-06 Glaucoma (primary open-angle) / / 22419738 rs1254319 chr14 60903757 G A 1.00E-08 Refractive error C14orf39 missense 23396134 rs4901985 chr14 60948318 T G 8.67E-06 Tardive dyskinesia C14orf39 intron 20939080 rs2093210 chr14 60957279 C T 6.00E-17 Height / / 20881960 rs2093210 chr14 60957279 C T 2.41E-06 Glaucoma (primary open-angle) / / 22419738 rs2093210 chr14 60957279 C T 8.00E-13 Height / / 23563607 rs1018533 chr14 60971137 T C 5.43E-08 Glaucoma (primary open-angle) / / 22570617 rs3759688 chr14 60975579 A C 8.00E-04 Chronic fatigue syndrome SIX6 nearGene-5 21912186 rs33912345 chr14 60976537 C A 2.74E-06 Glaucoma (primary open-angle) SIX6 missense 22419738 rs12436579 chr14 60983087 C A 1.42E-06 Glaucoma (primary open-angle) / / 22570617 rs7152532 chr14 61000665 C T 2.62E-05 Glaucoma (primary open-angle) / / 22570617 rs4899012 chr14 61003889 G C 3.04E-06 Glaucoma (primary open-angle) / / 22419738 rs1010053 chr14 61005625 A G 9.48E-08 Glaucoma (primary open-angle) / / 22570617 rs7159392 chr14 61008596 T C 2.98E-06 Glaucoma (primary open-angle) / / 22419738 rs2351174 chr14 61013237 G T 3.43E-06 Glaucoma (primary open-angle) / / 22419738 rs1955695 chr14 61021891 A G 3.77E-06 Glaucoma (primary open-angle) / / 22419738 rs4442732 chr14 61025617 A G 3.79E-06 Glaucoma (primary open-angle) / / 22419738 rs10150234 chr14 61031284 G C 5.45E-05 Tardive dyskinesia / / 20939080 rs10483727 chr14 61072875 T C 9.00E-06 optic disc size (rim) / / 20395239 rs10483727 chr14 61072875 T C 1.00E-11 Vertical cup-disc ratio / / 20548946 rs10483727 chr14 61072875 T C 9.00E-08 Glaucoma (primary open-angle) / / 22419738 rs10483727 chr14 61072875 T C 4.00E-11 Glaucoma (primary open-angle) / / 22570617 rs10142842 chr14 61085205 T C 2.60E-05 Tardive dyskinesia / / 20939080 rs34935520 chr14 61091401 G A 4.88E-06 Glaucoma (primary open-angle) / / 22419738 rs35155027 chr14 61095174 G C 4.97E-06 Glaucoma (primary open-angle) / / 22419738 rs35320790 chr14 61108825 C A 6.59E-06 Glaucoma (primary open-angle) / / 22419738 rs10143202 chr14 61124940 A G 2.15E-05 Glaucoma (primary open-angle) / / 22605921 rs964412 chr14 61154768 G C 2.21E-04 Body mass index / / 21701565 rs964412 chr14 61154768 G C 7.77E-04 Body mass index / / 21701565 rs1018457 chr14 61158870 C G 2.21E-04 Body mass index / / 21701565 rs1018457 chr14 61158870 C G 7.77E-04 Body mass index / / 21701565 rs1955689 chr14 61164030 A G 2.75E-04 Body mass index / / 21701565 rs1955689 chr14 61164030 A G 9.20E-05 Body mass index / / 21701565 rs3742636 chr14 61180657 T G 0.00004 Prostate cancer SIX4 missense 23555315 rs3742636 chr14 61180657 T G 0.000086 Prostate cancer (non-advanced prostate cancer) SIX4 missense 23555315 rs7141965 chr14 61185648 G A 9.67E-04 Type 2 diabetes SIX4 intron 22158537 rs7141362 chr14 61215657 A G 7.33E-04 Type 2 diabetes M/T1 intron 22158537 rs4151177 chr14 61241148 A G 1.83E-04 Multiple complex diseases M/T1 intron 17554300 rs4151179 chr14 61241358 T G 4.53E-04 Type 2 diabetes M/T1 intron 22158537 rs4151184 chr14 61242028 G A 6.20E-04 Type 2 diabetes M/T1 intron 22158537 rs7153035 chr14 61261655 G A 1.53E-04 Multiple complex diseases M/T1 intron 17554300 rs2284703 chr14 61273548 T G 2.28E-04 Multiple complex diseases M/T1 intron 17554300 rs6573332 chr14 61292920 A G 2.22E-06 Carotenoid and tocopherol levels M/T1 intron 19185284 rs6573333 chr14 61308337 T G 8.46E-06 Carotenoid and tocopherol levels M/T1 intron 19185284 rs6573333 chr14 61308337 T G 8.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) M/T1 intron 20877124 rs6573333 chr14 61308337 T G 3.00E-10 Immune reponse to smallpox (secreted IFN-alpha) M/T1 intron 22610502 rs8018438 chr14 61323938 A G 1.95E-04 Multiple complex diseases M/T1 intron 17554300 rs6573339 chr14 61342218 A G 3.17E-04 Multiple complex diseases M/T1 intron 17554300 rs8022005 chr14 61345381 A G 1.38E-04 Multiple complex diseases M/T1 intron 17554300 rs4151315 chr14 61359789 A G 2.30E-06 Urinary metabolites M/T1 intron 21572414 rs4902014 chr14 61366702 G A 1.33E-04 Multiple complex diseases M/T1 intron 17554300 rs7150492 chr14 61368033 T C 2.22E-06 Carotenoid and tocopherol levels M/T1 intron 19185284 rs4151374 chr14 61401953 G A 6.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) M/T1 intron 20877124 rs10133880 chr14 61410039 A C 9.92E-04 Multiple complex diseases M/T1 intron 17554300 rs10135773 chr14 61465860 G T 1.85E-05 Serum metabolites SLC38A6 intron 19043545 rs6573361 chr14 61615710 C T 9.70E-05 Major depressive disorder / / 21042317 rs724200 chr14 61619761 C A 9.40E-05 Major depressive disorder / / 21042317 rs8005165 chr14 61629053 A G 2.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4902033 chr14 61643045 C A 5.13E-05 Bladder cancer / / 19648920 rs12147034 chr14 61652327 C T 4.84E-05 Height / / pha003011 rs12887312 chr14 61653468 G T 4.48E-04 Smoking quantity / / 24665060 rs4457900 chr14 61689892 T G 2.52E-04 Celiac disease / / 23936387 rs6573374 chr14 61692955 T C 9.74E-04 Celiac disease / / 23936387 rs17098148 chr14 61693199 A G 1.01E-04 Type 2 diabetes / / 17463246 rs7145344 chr14 61696850 A G 6.14E-05 Multiple complex diseases / / 17554300 rs4902035 chr14 61697252 C T 1.11E-05 Multiple complex diseases / / 17554300 rs868825 chr14 61701500 G A 9.90E-06 Urinary metabolites / / 21572414 rs868826 chr14 61701643 G A 0.00019 Endometrial cancer / / 22426144 rs868827 chr14 61701729 G A 7.22E-04 Type 2 diabetes / / 17463246 rs868827 chr14 61701729 G A 2.56E-04 Multiple complex diseases / / 17554300 rs17806459 chr14 61714103 A G 4.81E-05 Coronary heart disease / / pha003031 rs7141238 chr14 61734640 T G 3.00E-06 Obesity-related traits / / 23251661 rs2351807 chr14 61752201 G A 6.80E-06 Obesity-related traits / / 23251661 rs12437296 chr14 61755153 T C 9.22E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4902046 chr14 61789505 A C 1.04E-08 Multiple complex diseases PRKCH intron 17554300 rs12101174 chr14 61798825 A G 6.07E-04 Nicotine smoking PRKCH intron 19268276 rs2025526 chr14 61806908 G A 8.90E-04 Atrial fibrillation PRKCH intron 21846873 rs1957902 chr14 61813263 G C 7.64E-05 Serum metabolites PRKCH intron 19043545 rs4899039 chr14 61833376 A T 6.65E-06 Suicide attempts in bipolar disorder PRKCH intron 21423239 rs4902049 chr14 61835400 A G 6.16E-06 Suicide attempts in bipolar disorder PRKCH intron 21423239 rs7148421 chr14 61841471 G A 1.47E-05 Suicide attempts in bipolar disorder PRKCH intron 21423239 rs1886467 chr14 61852793 A G 1.86E-08 Brain activation patterns in response to human facial expressions-for the negative faces task PRKCH intron 22828495 rs1886467 chr14 61852793 A G 1.86E-08 Airflow obstruction PRKCH intron 22837378 rs4902052 chr14 61853796 G A 8.52E-06 Suicide attempts in bipolar disorder PRKCH intron 21423239 rs12892373 chr14 61860066 A G 6.92E-06 White blood cell count PRKCH intron 21738479 rs1957912 chr14 61865279 A G 5.60E-06 Urinary metabolites PRKCH intron 21572414 rs56237529 chr14 61869241 G A 0.0000696 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs11626354 chr14 61869482 A C 0.0000798 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs767757 chr14 61874374 G T 1.60E-06 Urinary metabolites PRKCH intron 21572414 rs767757 chr14 61874374 G T 0.0000502 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs767755 chr14 61874448 G A 1.49E-04 Alcohol dependence PRKCH intron 24277619 rs7145570 chr14 61874821 G A 0.0000533 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs60104503 chr14 61876586 G A 0.0000546 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs912620 chr14 61877064 T G 0.0000596 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs12433282 chr14 61882731 G A 0.0000648 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs10136110 chr14 61882851 A G 0.0000686 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs912621 chr14 61883589 G A 0.0000627 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs12434139 chr14 61883685 G C 0.000063 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs1951966 chr14 61884022 G A 0.0000709 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs1951967 chr14 61884127 A G 0.0000676 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs2209386 chr14 61884484 G A 0.000078 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs2209387 chr14 61884632 T C 0.0000703 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs2209388 chr14 61884646 A G 0.00000373 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs4605077 chr14 61885440 G A 0.0000692 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs11850051 chr14 61885825 G A 0.00000169 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs11627158 chr14 61885857 G A 0.0000629 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs11158344 chr14 61886264 A C 0.0000716 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs7155214 chr14 61886406 A G 0.0000829 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs12590371 chr14 61886746 C A 0.00000392 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs12590425 chr14 61886770 G A 0.00000766 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs12436712 chr14 61886905 G A 0.0000863 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs11848272 chr14 61887202 T A 0.00000794 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs58366462 chr14 61888971 A G 0.00000535 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs59831259 chr14 61888980 T C 0.00000539 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs11627926 chr14 61889807 T C 0.00000738 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs60479750 chr14 61890595 T C 0.0000149 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs4899043 chr14 61890825 A G 0.0000155 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs1957891 chr14 61891927 A G 0.0000202 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs7159151 chr14 61892191 A G 0.0000333 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs13379453 chr14 61892441 A G 0.000039 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs13379462 chr14 61892767 A G 0.0000324 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs13379465 chr14 61892815 C T 0.0000145 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs13379301 chr14 61892967 T C 0.0000424 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs4902057 chr14 61893944 A G 0.0000316 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs4899044 chr14 61893963 T A 0.0000446 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs8012877 chr14 61894331 G T 0.0000505 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs11158345 chr14 61895045 T C 1.32E-05 Reading and spelling PRKCH intron 23738518 rs11158345 chr14 61895045 T C 3.00E-06 Word reading PRKCH intron 23738518 rs1957892 chr14 61896497 T A 0.0000425 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs12589412 chr14 61897526 G T 0.0000221 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs2352088 chr14 61897956 T C 0.0000204 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs17098351 chr14 61898580 T G 0.0000403 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs17098356 chr14 61898839 T G 0.0000196 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs17098356 chr14 61898839 T G 1.14E-05 Word reading PRKCH intron 23738518 rs17098356 chr14 61898839 T G 6.00E-06 Reading and spelling PRKCH intron 23738518 rs12590817 chr14 61899482 G A 1.73E-05 Word reading PRKCH intron 23738518 rs2025525 chr14 61903156 T A 0.0000435 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs58610243 chr14 61904450 A C 0.0000638 Nonsyndromic striae distensae (stretch marks) PRKCH intron 23633020 rs1957894 chr14 61908111 T G 3.00E-10 Obesity (early onset extreme) PRKCH intron 23563609 rs1957895 chr14 61908332 G T 4.00E-07 Rheumatoid arthritis PRKCH intron 22446963 rs3783799 chr14 61919216 C T 4.73E-06 Stroke PRKCH intron 17206144 rs146597366 chr14 61924092 GGT G 9.57E-06 Stroke PRKCH intron 17206144 rs2296276 chr14 61924092 G T 9.57E-06 Stroke PRKCH intron 17206144 rs2230500 chr14 61924239 G A 5.10E-07 Stroke PRKCH missense 17206144 rs2230501 chr14 61924241 A C 9.84E-06 Stroke PRKCH cds-synon 17206144 rs959728 chr14 61934018 C T 8.85E-04 Stroke PRKCH intron 17206144 rs8011286 chr14 61936174 T A 5.67E-04 Depression (quantitative trait) PRKCH intron 20800221 rs3783789 chr14 61936800 G A 4.48E-04 Stroke PRKCH intron 17206144 rs10483734 chr14 61937801 T C 1.20E-05 Alcohol dependence PRKCH intron 19581569 rs4899049 chr14 61938155 C T 8.18E-04 Depression (quantitative trait) PRKCH intron 20800221 rs3783782 chr14 61940675 G A 2.00E-09 Rheumatoid arthritis PRKCH intron 24390342 rs3783782 chr14 61940675 G A 4.00E-09 Rheumatoid arthritis PRKCH intron 24390342 rs8008798 chr14 61948002 T C 8.33E-04 Obesity (extreme) PRKCH intron 21935397 rs1886464 chr14 61949051 G A 1.08E-05 Glaucoma (primary open-angle) PRKCH intron 22419738 rs10483736 chr14 61949217 C T 1.34E-04 Rheumatoid arthritis PRKCH intron 21452313 rs912619 chr14 61949933 T C 1.06E-05 Glaucoma (primary open-angle) PRKCH intron 22419738 rs3783774 chr14 61951101 C G 1.06E-05 Glaucoma (primary open-angle) PRKCH intron 22419738 rs1957898 chr14 61953406 T C 8.56E-06 Glaucoma (primary open-angle) PRKCH intron 22419738 rs4902063 chr14 61953839 C T 8.00E-06 Glaucoma (primary open-angle) PRKCH intron 22419738 rs12886896 chr14 61954272 C T 8.20E-06 Glaucoma (primary open-angle) PRKCH intron 22419738 rs11622805 chr14 61954594 G A 7.40E-06 Glaucoma (primary open-angle) PRKCH intron 22419738 rs35014123 chr14 61954761 C A 7.61E-06 Glaucoma (primary open-angle) PRKCH intron 22419738 rs4902064 chr14 61956824 C T 2.20E-06 Urinary metabolites PRKCH intron 21572414 rs4902067 chr14 61956958 C G 5.94E-04 Obesity (extreme) PRKCH intron 21935397 rs4902067 chr14 61956958 C G 6.07E-06 Glaucoma (primary open-angle) PRKCH intron 22419738 rs17098533 chr14 61957000 G T 6.86E-04 Response to taxane treatment (placlitaxel) PRKCH intron 23006423 rs10136208 chr14 61958044 T C 7.90E-04 Obesity (extreme) PRKCH intron 21935397 rs17098542 chr14 61958290 C T 5.40E-06 Urinary metabolites PRKCH intron 21572414 rs17098542 chr14 61958290 C T 3.18E-04 Response to taxane treatment (placlitaxel) PRKCH intron 23006423 rs4902069 chr14 61960492 A G 1.29E-04 Rheumatoid arthritis PRKCH intron 21452313 rs12433533 chr14 61960906 A G 4.90E-06 Urinary metabolites PRKCH intron 21572414 rs12897140 chr14 61961410 G C 1.10E-06 Glaucoma (primary open-angle) PRKCH intron 22419738 rs4902071 chr14 61963561 C T 1.16E-06 Glaucoma (primary open-angle) PRKCH intron 22419738 rs10459519 chr14 61965444 A C 7.30E-06 Urinary metabolites PRKCH intron 21572414 rs12885342 chr14 61966744 A G 7.04E-04 Acute lung injury PRKCH intron 22295056 rs3783763 chr14 61968168 A G 6.24E-04 Acute lung injury PRKCH intron 22295056 rs1126133 chr14 61975278 T C 9.37E-05 Rheumatoid arthritis PRKCH intron 21452313 rs1088681 chr14 61976105 G C 2.10E-06 Urinary metabolites PRKCH intron 21572414 rs1091679 chr14 61978278 C T 2.19E-04 Rheumatoid arthritis PRKCH intron 21452313 rs1088683 chr14 61978571 C T 1.56E-05 Glaucoma (primary open-angle) PRKCH intron 22419738 rs7159288 chr14 61980098 A G 1.25E-04 Rheumatoid arthritis PRKCH intron 21452313 rs3783759 chr14 61981764 G A 2.80E-04 Rheumatoid arthritis PRKCH intron 21452313 rs17098663 chr14 61982226 T C 4.82E-09 Cholesterol,total PRKCH intron 23063622 rs1091680 chr14 61984087 A G 1.94E-05 Glaucoma (primary open-angle) PRKCH intron 22419738 rs2252267 chr14 61984684 A G 1.54E-05 Glaucoma (primary open-angle) PRKCH intron 22419738 rs3751295 chr14 61984737 T A 7.95E-04 Response to taxane treatment (placlitaxel) PRKCH intron 23006423 rs17095992 chr14 61986153 G T 7.25E-04 Amyotrophic lateral sclerosis (sporadic) PRKCH intron 24529757 rs10483741 chr14 61989701 A G 6.30E-05 Kidney function and endocine traits PRKCH intron 17903292 rs2253026 chr14 61990633 G A 8.74E-06 Glaucoma (primary open-angle) PRKCH intron 22419738 rs12883769 chr14 61990861 C T 9.12E-05 Schizophrenia PRKCH intron 21747397 rs12883769 chr14 61990861 C T 2.79E-05 Glaucoma (primary open-angle) PRKCH intron 22419738 rs12883769 chr14 61990861 C T 8.55E-04 Tourette syndrome PRKCH intron 22889924 rs1088667 chr14 61991812 C G 2.55E-05 Glaucoma (primary open-angle) PRKCH intron 22419738 rs2463117 chr14 61995673 C T 0.0000016 LDL cholesterol PRKCH intron 23236364 rs1088680 chr14 61997226 C T 1.42E-04 Rheumatoid arthritis PRKCH cds-synon 21452313 rs1091331 chr14 61998747 C T 1.85E-05 Glaucoma (primary open-angle) PRKCH intron 22419738 rs12587495 chr14 62000170 A G 4.36E-05 Atrial fibrillation PRKCH intron 21846873 rs1088673 chr14 62005648 C A,G,T 5.14E-04 Multiple complex diseases PRKCH intron 17554300 rs2184633 chr14 62014289 T A 5.52E-05 Multiple complex diseases PRKCH intron 17554300 rs1092095 chr14 62018292 G A 5.46E-05 Multiple complex diseases / / 17554300 rs2251244 chr14 62023264 A C 1.11E-04 Multiple complex diseases / / 17554300 rs10483744 chr14 62032125 A C 4.96E-04 Multiple complex diseases / / 17554300 rs17098846 chr14 62032938 C T 1.29E-05 Multiple complex diseases / / 17554300 rs2248230 chr14 62033131 A G 9.84E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs798791 chr14 62037683 G A 1.26E-04 Multiple complex diseases FLJ22447 intron 17554300 rs798788 chr14 62038495 G A 4.39E-04 Multiple complex diseases FLJ22447 intron 17554300 rs2255998 chr14 62051682 G A 5.64E-05 Bipolar disorder and schizophrenia FLJ22447 intron 20889312 rs17098915 chr14 62059931 C G 7.78E-05 Multiple complex diseases FLJ22447 intron 17554300 rs17834568 chr14 62074238 A G 2.36E-05 Bipolar disorder and schizophrenia FLJ22447 intron 20889312 rs17834568 chr14 62074238 A G 1.12E-05 Alzheimer's disease (late onset) FLJ22447 intron 21379329 rs2244057 chr14 62092873 C T 4.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FLJ22447 intron 20877124 rs2244057 chr14 62092873 C T 6.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FLJ22447 intron 20877124 rs2244057 chr14 62092873 C T 1.90E-04 Suicidal ideation FLJ22447 intron 22030708 rs710063 chr14 62104213 G A 1.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FLJ22447 intron 20877124 rs710063 chr14 62104213 G A 7.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FLJ22447 intron 20877124 rs17099010 chr14 62109630 C T 1.45E-05 Bipolar disorder and schizophrenia FLJ22447 intron 20889312 rs7156083 chr14 62117489 C T 7.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FLJ22447 intron 20877124 rs7156573 chr14 62177821 G A 0.000001 Mean arterial pressure HIF1A intron 22510845 rs10138032 chr14 62184182 A G 0.000000824 Triglycerides HIF1A intron 23063622 rs8005745 chr14 62185295 T A 4.00E-06 Select biomarker traits HIF1A intron 17903293 rs1957757 chr14 62196948 T C 9.45E-06 Blood Pressure HIF1A intron pha003046 rs2301113 chr14 62206548 C A 6.10E-04 Atrial fibrillation HIF1A intron 21846873 rs7145164 chr14 62228299 A G 2.87E-04 Alzheimer's disease / / 24755620 rs6573400 chr14 62239572 A G 1.93E-04 Alzheimer's disease S/PC1 intron 24755620 rs2255627 chr14 62240033 A G 2.11E-04 Alzheimer's disease S/PC1 intron 24755620 rs17099239 chr14 62267508 A G 4.07E-04 Hemoglobin concentration / / 20534544 rs7148769 chr14 62359041 C T 6.19E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10483748 chr14 62371953 C T 6.33E-06 Lymphocyte counts / / 22286170 rs217635 chr14 62375195 C T 1.60E-06 Urinary metabolites / / 21572414 rs217632 chr14 62377774 C G 1.20E-06 Urinary metabolites / / 21572414 rs17099345 chr14 62401183 G A 6.93E-05 Chronic obstructive pulmonary disease / / 19300482 rs2784505 chr14 62432013 A G 9.00E-06 Longevity (90 years and older) / / 24688116 rs12372849 chr14 62445986 T C 4.40E-04 Smoking initiation / / 24665060 rs11158369 chr14 62455947 G T 4.30E-05 Smoking cessation / / 24665060 rs7160998 chr14 62482468 A T 5.86E-04 Type 2 diabetes SYT16 intron 17463246 rs4899063 chr14 62487868 C A 4.62E-04 Type 2 diabetes SYT16 intron 17463246 rs1254910 chr14 62502992 G A 5.09E-04 Smoking cessation SYT16 intron 24665060 rs6573416 chr14 62518348 C G 3.00E-06 Self-rated health SYT16 intron 20707712 rs17099461 chr14 62527863 C T 1.78E-04 Multiple complex diseases SYT16 intron 17554300 rs4902100 chr14 62549819 G A 4.00E-06 Telomere length SYT16 intron 24478790 rs74675259 chr14 62551085 G A 0.00087 Breast cancer SYT16 missense 23555315 rs2154110 chr14 62552783 G T 4.12E-06 Telomere length SYT16 intron 24478790 rs1954488 chr14 62554867 C T 1.00E-04 Cognitive impairment induced by topiramate SYT16 intron 22091778 rs8021440 chr14 62589404 T C 1.90E-05 Urinary metabolites FLJ43390 intron 21572414 rs12147829 chr14 62611803 C T 8.16E-05 Neutrophil count / / pha003095 rs11623538 chr14 62650827 C T 8.40E-06 HIV-1 viral setpoint / / 17641165 rs973968 chr14 62654698 G A 3.00E-06 Iron status biomarkers / / 19084217 rs12588811 chr14 62655502 T A 9.09E-04 Type 2 diabetes / / 17463246 rs7145104 chr14 62659466 T C 7.41E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1514928 chr14 62678303 C A 3.00E-06 Attention deficit hyperactivity disorder / / 18821565 rs17099628 chr14 62727000 T C 1.40E-05 Urinary metabolites / / 21572414 rs4902121 chr14 62730395 A C 1.45E-04 Birth weight / / 17255346 rs10146615 chr14 62732664 T C 7.00E-06 Economic and political preferences (immigration/crime) / / 22566634 rs11625068 chr14 62734152 G A 4.20E-05 Waist-Hip Ratio / / pha003013 rs11625068 chr14 62734152 G A 5.84E-05 Waist-Hip Ratio / / pha003028 rs2354331 chr14 62763347 C T 5.56E-05 Cognitive test performance / / 20125193 rs1892236 chr14 62767872 T C 9.54E-04 HIV-1 viral setpoint / / 17641165 rs4644784 chr14 62805991 A G 2.74E-05 Multiple complex diseases / / 17554300 rs10459520 chr14 62833297 A G 2.34E-04 HIV-1 viral setpoint / / 17641165 rs8013550 chr14 62836092 T G 6.26E-04 HIV-1 viral setpoint / / 17641165 rs12892347 chr14 62872715 G A 2.70E-05 Urinary metabolites / / 21572414 rs12434189 chr14 62892244 A G 1.40E-05 Urinary metabolites / / 21572414 rs7144807 chr14 62893532 A G 1.70E-05 Urinary metabolites / / 21572414 rs8004060 chr14 62896129 G A 1.12E-05 Cognitive test performance / / 20125193 rs4627229 chr14 62917673 A G 3.22E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4627229 chr14 62917673 A G 4.43E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs12589358 chr14 62918854 C T 4.49E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11158415 chr14 62935762 C G 4.14E-04 Multiple complex diseases / / 17554300 rs1489854 chr14 62937342 A G 5.71E-04 Multiple complex diseases / / 17554300 rs17749359 chr14 62938313 G T 4.73E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs17100008 chr14 62952842 C T 3.40E-04 Attention deficit hyperactivity disorder / / 23728934 rs17811629 chr14 62953939 A G 1.05E-05 Cognitive test performance / / 20125193 rs10498500 chr14 62960508 A G 6.25E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs9323410 chr14 62960755 C T 6.62E-05 stroke (ischemic) / / 17434096 rs4902141 chr14 62968395 T C 1.00E-07 Estradiol plasma levels (breast cancer) / / 23518928 rs6573445 chr14 62982107 A G 5.94E-05 Tunica Media / / pha003038 rs9323416 chr14 63000758 G A 9.64E-05 stroke (ischemic) / / 17434096 rs10136207 chr14 63016203 A C,G,T 7.24E-04 HIV-1 viral setpoint / / 17641165 rs10151267 chr14 63061920 C T 7.06E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7154189 chr14 63083581 C G 3.44E-04 Type 2 diabetes / / 17463246 rs9788478 chr14 63091941 G A 7.12E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4902158 chr14 63096149 G A 3.97E-04 Type 2 diabetes / / 17463246 rs1953248 chr14 63123007 T C 1.25E-06 Estradiol plasma levels (breast cancer) / / 23518928 rs1120557 chr14 63129440 A G 2.10E-07 Fasting plasma glucose / / 19060907 rs1120557 chr14 63129440 A G 3.62E-05 Brain structure / / 22504417 rs1106494 chr14 63131981 G A 1.61E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs4902176 chr14 63174960 C T 4.65E-07 White blood cell count KCNH5 missense 21738479 rs869834 chr14 63177144 T C 2.00E-06 Subcutaneous adipose tissue KCNH5 intron 22589738 rs12587728 chr14 63183926 T C 1.92E-06 White blood cell count KCNH5 intron 21738479 rs8022157 chr14 63188086 G A 4.15E-06 White blood cell count KCNH5 intron 21738479 rs11158449 chr14 63189770 T A,C,G 5.97E-06 White blood cell count KCNH5 intron 21738479 rs10483754 chr14 63191094 A G 5.36E-06 White blood cell count KCNH5 intron 21738479 rs11627747 chr14 63201045 C T 1.29E-06 White blood cell count KCNH5 intron 21738479 rs7143550 chr14 63206951 T C 5.25E-07 White blood cell count KCNH5 intron 21738479 rs8017931 chr14 63210951 C T 1.89E-06 White blood cell count KCNH5 intron 21738479 rs8022524 chr14 63211350 C T 4.00E-06 White blood cell count KCNH5 intron 21738479 rs243144 chr14 63270121 C A 8.33E-04 Stroke KCNH5 intron pha002887 rs171457 chr14 63305545 G A 2.66E-04 Hemoglobin concentration KCNH5 intron 20534544 rs8012941 chr14 63322347 A G 4.00E-06 Major depressive disorder KCNH5 intron 23377640 rs10136789 chr14 63356253 T C 5.00E-07 Body mass index KCNH5 intron 24348519 rs1956027 chr14 63364595 C T 4.85E-04 Smoking quantity KCNH5 intron 24665060 rs4086351 chr14 63427259 C A 4.90E-05 Cognitive function KCNH5 intron 24684796 rs3910328 chr14 63473480 A G 2.10E-05 Urinary metabolites KCNH5 intron 21572414 rs1950986 chr14 63499833 C T 2.10E-06 Urinary metabolites KCNH5 intron 21572414 rs1951805 chr14 63568154 T G 7.82E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) KCNH5 intron 17982456 rs9323431 chr14 63568488 A C 3.60E-05 Subclinical atherosclerosis KCNH5 intron 17903303 rs10129357 chr14 63572267 T G 1.14E-04 Birth weight / / 17255346 rs2883863 chr14 63597544 T C 6.93E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10129516 chr14 63600090 T C 3.47E-05 Birth weight / / 17255346 rs17100818 chr14 63649152 A C 2.65E-04 Taste perception / / 22132133 rs17100839 chr14 63668645 T C 6.67E-04 Taste perception / / 22132133 rs1957779 chr14 63669647 A G 2.74E-11 Multiple complex diseases / / 17554300 rs17100849 chr14 63670005 A G 2.65E-04 Taste perception / / 22132133 rs762102 chr14 63678922 G A 2.93E-04 Blood pressure (response to angiotensin II receptor blocker) RHOJ intron 24192120 rs17177789 chr14 63679709 C A 7.00E-04 Acute lymphoblastic leukemia (childhood) RHOJ intron 20189245 rs17100876 chr14 63696608 T C 1.50E-05 Urinary metabolites RHOJ intron 21572414 rs8013013 chr14 63732733 A C 4.50E-05 Body Mass Index RHOJ intron pha003022 rs17100993 chr14 63758432 A G 1.77E-04 Multiple complex diseases RHOJ UTR-3 17554300 rs1255565 chr14 63775684 T C 3.01E-05 Soluble levels of adhesion molecules / / pha003072 rs728525 chr14 63780711 C T 7.81E-05 Erythrocyte counts GPHB5 intron pha003099 rs6573513 chr14 63855760 C T 1.55E-05 Blood Pressure PPP2R5E intron pha003047 rs743221 chr14 63857808 G A 1.55E-05 Blood Pressure PPP2R5E intron pha003047 rs1033742 chr14 63934137 C T 3.01E-04 Type 2 diabetes PPP2R5E intron 17846124 rs11158493 chr14 63953522 C T 9.00E-07 Response to antineoplastic agents PPP2R5E intron 21659360 rs17101245 chr14 63962770 T C 3.04E-05 Multiple complex diseases PPP2R5E intron 17554300 rs10148041 chr14 63972131 T C 3.82E-04 Taste perception PPP2R5E intron 22132133 rs10498508 chr14 64019647 C T 2.10E-06 Carotenoid and tocopherol levels / / 19185284 rs972984 chr14 64022208 T C 8.86E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1255752 chr14 64034457 A G 5.84E-04 Multiple complex diseases / / 17554300 rs7160317 chr14 64068806 G A 0.000555884 Hypertension (early onset hypertension) WDR89 intron 22479346 rs11158505 chr14 64174022 C T 7.27E-04 Suicide attempts in bipolar disorder SGPP1 intron 21423239 rs11845765 chr14 64191750 T G 1.62E-04 Alcohol dependence SGPP1 intron 20201924 rs8020821 chr14 64214808 C T 4.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs4902242 chr14 64230089 T C 8.13E-54 Sphingolipid levels / / 19798445 rs17101394 chr14 64232386 G A 3.00E-57 Sphingolipid levels / / 22359512 rs4902243 chr14 64234243 A G 3.00E-37 Blood metabolite levels / / 24816252 rs7157785 chr14 64235556 G T 9.00E-66 Sphingolipid levels / / 19798445 rs7157785 chr14 64235556 G T 1.00E-133 Blood metabolite ratios / / 24816252 rs7157785 chr14 64235556 G T 7.00E-87 Blood metabolite levels / / 24816252 rs12589129 chr14 64263364 G A 5.02E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7144584 chr14 64275812 T C 6.00E-07 Pulmonary function decline / / 22424883 rs2150291 chr14 64331423 T C 2.83E-07 Autism SYNE2 intron 22843504 rs1959033 chr14 64335586 G A 6.63E-13 Sphingolipid levels SYNE2 intron 19798445 rs4459477 chr14 64346190 C T 8.33E-29 Sphingolipid levels SYNE2 intron 19798445 rs11158519 chr14 64364585 G A 1.50E-27 Serum metabolites SYNE2 intron 20037589 rs1953241 chr14 64374254 G A 4.46E-04 Amyotrophic lateral sclerosis (sporadic) SYNE2 intron 24529757 rs17101457 chr14 64386861 T G 9.08E-05 Pulmonary function SYNE2 intron 20010835 rs12889954 chr14 64387468 T C 2.95E-33 Sphingolipid levels SYNE2 intron 19798445 rs17101464 chr14 64399556 A G 2.20E-05 Urinary metabolites SYNE2 intron 21572414 rs17101465 chr14 64399574 C T 7.11E-04 Suicide attempts in bipolar disorder SYNE2 intron 21423239 rs11158521 chr14 64401255 T A 6.39E-04 Suicide attempts in bipolar disorder SYNE2 intron 21423239 rs2275019 chr14 64408108 G C 5.68E-04 Alcohol dependence SYNE2 intron 21314694 rs11158524 chr14 64473899 A G 5.66E-04 Multiple complex diseases SYNE2 cds-synon 17554300 rs1890908 chr14 64519035 A G 0.00047 Prostate cancer SYNE2 missense 23555315 rs8007972 chr14 64564527 C T 2.14E-06 Lipid traits SYNE2 intron 21777205 rs1029145 chr14 64600687 A G 2.36E-04 Smoking initiation SYNE2 intron 24665060 rs12881815 chr14 64604595 G A 7.71E-10 Sphingolipid levels SYNE2 missense 19798445 rs1268656 chr14 64647646 T G 3.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SYNE2 intron 20877124 rs8021944 chr14 64679298 T G 3.50E-06 Urinary metabolites SYNE2 intron 21572414 rs8022694 chr14 64679747 T C 1.20E-05 Urinary metabolites SYNE2 intron 21572414 rs1152591 chr14 64680848 A G 6.00E-13 Atrial fibrillation SYNE2 intron 22544366 rs1255998 chr14 64693871 G C 5.90E-04 Coronary heart disease ESR2 UTR-3 21966275 rs8006145 chr14 64699450 C A 1.06E-06 Non-obstructive azoospermia ESR2 intron 22541561 rs4986938 chr14 64699816 C T 1 Drug response to Tamoxifen ESR2 UTR-3 17713466 rs1256063 chr14 64702217 A G 1.56E-05 Stroke ESR2 intron pha002887 rs1256061 chr14 64703593 G T 3.04E-07 Red blood cell traits ESR2 intron 23222517 rs11850375 chr14 64711377 C T 3.30E-09 HDL cholesterol ESR2 intron 23063622 rs10459452 chr14 64711861 A G 4.94E-08 Triglycerides ESR2 intron 23063622 rs4365213 chr14 64720264 T C 8.79E-07 Red blood cell traits ESR2 intron 23222517 rs12435857 chr14 64723525 G A 8.44E-07 Red blood cell traits ESR2 intron 23222517 rs7154455 chr14 64736660 G C 2.67E-05 Height ESR2 intron 22021425 rs1256033 chr14 64745399 T C 6.45E-07 Red blood cell traits ESR2 intron 23222517 rs1256031 chr14 64746179 G A 6.93E-07 Red blood cell traits ESR2 intron 23222517 rs1256030 chr14 64747170 A G 4.73E-07 Red blood cell traits ESR2 intron 23222517 rs1952586 chr14 64759419 T C 2.48E-04 Suicide attempts in bipolar disorder ESR2 intron 21423239 rs10137185 chr14 64775776 C T 3.43E-04 Suicide attempts in bipolar disorder ESR2 intron 21423239 rs17101774 chr14 64793581 T C 4.82E-04 Insulin resistance ESR2 intron 21901158 rs1256116 chr14 64807883 G C 0.000126 Body mass index / / 23001569 rs1256114 chr14 64810005 G A 6.80E-04 Coronary heart disease / / 21966275 rs2987969 chr14 64829016 T C 6.79E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8018032 chr14 64833333 T C 2.66E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17751556 chr14 64884106 T C 2.98E-04 Obesity (extreme) MTHFD1 intron 21935397 rs1885031 chr14 64888055 C T 1.27E-04 Smoking initiation MTHFD1 intron 24665060 rs10498514 chr14 64899055 A C 8.00E-07 Cognitive performance MTHFD1 intron 19734545 rs2295639 chr14 64902116 T C 5.00E-06 Cognitive performance MTHFD1 intron 19734545 rs8012229 chr14 64911562 T C 2.90E-05 White matter hyperintensity burden MTHFD1 intron 21681796 rs1256143 chr14 64911627 T C 0.0000143 Ankle-brachial index MTHFD1 intron 22361517 rs11629135 chr14 64913111 G A 8.60E-06 White matter hyperintensity burden MTHFD1 intron 21681796 rs11629135 chr14 64913111 G A 0.000344 white matter hyperintensity burden MTHFD1 intron 23674528 rs3818239 chr14 64914537 T C 3.70E-05 White matter hyperintensity burden MTHFD1 intron 21681796 rs3818239 chr14 64914537 T C 9.36E-04 Acute lung injury MTHFD1 intron 22295056 rs2236222 chr14 64915182 A G 2.60E-05 White matter hyperintensity burden MTHFD1 intron 21681796 rs2281603 chr14 64926097 T C 6.50E-05 Eosinophil counts MTHFD1 intron pha003088 rs2230491 chr14 64935411 C T 7.06E-06 Personality dimensions AKAP5 missense 21173776 rs3742609 chr14 64936652 T C 2.67E-04 Intracranial aneurysm AKAP5 UTR-3 20613766 rs2198347 chr14 64969342 C A 1.06E-06 Lymphocyte counts ZBTB25 intron 22286170 rs1542313 chr14 65000038 A C 3.35E-04 Intracranial aneurysm ZBTB1 UTR-3 20613766 rs11620680 chr14 65017109 T A 4.00E-05 White matter hyperintensity burden PPP1R36 intron 21681796 rs3742604 chr14 65026242 G A 5.03E-05 Personality dimensions PPP1R36 intron 18957941 rs3742604 chr14 65026242 G A 9.77E-05 Schizophrenia PPP1R36 intron 19571809 rs11622168 chr14 65027753 G C 9.20E-04 Multiple complex diseases PPP1R36 intron 17554300 rs11622168 chr14 65027753 G C 7.78E-05 Personality dimensions PPP1R36 intron 18957941 rs4902293 chr14 65031572 A G 7.34E-05 Personality dimensions PPP1R36 intron 18957941 rs17824827 chr14 65032278 G A 2.40E-05 White matter hyperintensity burden PPP1R36 intron 21681796 rs2123461 chr14 65040680 G A 7.44E-04 Multiple complex diseases PPP1R36 intron 17554300 rs2123461 chr14 65040680 G A 6.93E-05 Schizophrenia PPP1R36 intron 19571809 rs2123461 chr14 65040680 G A 1.66E-05 Schizophrenia PPP1R36 intron pha002859 rs9671808 chr14 65041483 A G 3.69E-04 Obesity (extreme) PPP1R36 intron 21935397 rs12588509 chr14 65047272 G A 3.40E-04 Multiple complex diseases PPP1R36 intron 17554300 rs45482504 chr14 65053999 T C 0.00024 Breast cancer PPP1R36 missense 23555315 rs723594 chr14 65054858 T C 2.40E-05 White matter hyperintensity burden PPP1R36 cds-synon 21681796 rs723594 chr14 65054858 T C 8.58E-04 Acute lung injury PPP1R36 cds-synon 22295056 rs2123456 chr14 65056576 G A 2.30E-05 White matter hyperintensity burden / / 21681796 rs2123456 chr14 65056576 G A 7.53E-04 Acute lung injury / / 22295056 rs11622028 chr14 65057545 G A 1.90E-05 White matter hyperintensity burden / / 21681796 rs11622028 chr14 65057545 G A 8.58E-04 Acute lung injury / / 22295056 rs11623381 chr14 65058670 G T 2.60E-05 White matter hyperintensity burden / / 21681796 rs2123457 chr14 65059119 A T 2.60E-05 White matter hyperintensity burden / / 21681796 rs971736 chr14 65061986 A G 9.81E-04 Type 2 diabetes / / 17463246 rs4902304 chr14 65119676 C T 3.15E-05 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs41391149 chr14 65138393 C T 2.32E-04 Multiple complex diseases / / 17554300 rs4902306 chr14 65149199 A G 7.08E-04 Obesity (extreme) / / 21935397 rs11158557 chr14 65153186 G A 8.43E-04 Obesity (extreme) / / 21935397 rs229677 chr14 65154835 G T 9.75E-06 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs179336 chr14 65160584 C T 8.40E-04 Obesity (extreme) / / 21935397 rs229660 chr14 65174586 T C 1.13E-04 Type 2 diabetes PLEKHG3 intron 17463246 rs17767188 chr14 65188240 G A 5.36E-04 Type 2 diabetes PLEKHG3 intron 17463246 rs106111 chr14 65190439 A G 7.28E-04 Acute lung injury PLEKHG3 intron 22295056 rs229624 chr14 65197767 G A 1.30E-04 Response to antidepressants PLEKHG3 cds-synon 19736353 rs229621 chr14 65200821 G T 4.74E-04 Acute lung injury PLEKHG3 intron 22295056 rs7160627 chr14 65201986 C G 2.12E-04 Multiple complex diseases PLEKHG3 intron 17554300 rs170679 chr14 65229364 A G 9.14E-04 Obesity (extreme) SPTB intron 21935397 rs4902309 chr14 65238171 C T 2.36E-04 Type 2 diabetes SPTB intron 17463246 rs747860 chr14 65239894 C T 2.35E-04 Type 2 diabetes SPTB intron 17463246 rs11158559 chr14 65240949 C T 1.00E-06 Obesity-related traits SPTB intron 23251661 rs11158559 chr14 65240949 C T 6.00E-06 Obesity-related traits SPTB intron 23251661 rs2269304 chr14 65254054 C A 8.03E-05 Type 2 diabetes SPTB intron 17463246 rs1875053 chr14 65255018 C T 5.55E-04 Alcohol consumption (maxi-drinks) SPTB intron 24277619 rs229673 chr14 65281944 A G 6.70E-04 stroke (ischemic) SPTB intron 17434096 rs229612 chr14 65297854 C T 1.55E-04 Glycosylated haemoglobin levels / / 17255346 rs229609 chr14 65299810 G A 5.81E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2649196 chr14 65303251 T C 9.03E-04 Iron levels / / pha002876 rs1570295 chr14 65310367 C T 6.35E-04 Myopia (pathological) / / 21095009 rs35955841 chr14 65319361 G A 3.00E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs2828 chr14 65336050 T G 9.98E-05 Leukocyte Counts / / pha003091 rs743264 chr14 65356936 C G 1.60E-05 Urinary metabolites / / 21572414 rs1957425 chr14 65358576 C T 2.14E-04 Glycosylated haemoglobin levels / / 17255346 rs12881353 chr14 65363615 A G 2.20E-04 Glycosylated haemoglobin levels / / 17255346 rs1064108 chr14 65400265 C T 9.27E-04 Myopia (pathological) CHURC1 UTR-3 21095009 rs1064108 chr14 65400265 C T 1.07E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy CHURC1 UTR-3 23834954 rs2412065 chr14 65407657 C G 1.30E-05 Urinary metabolites GPX2 intron 21572414 rs2412065 chr14 65407657 C G 1.87E-41 Lymphocyte counts GPX2 intron 22286170 rs2277501 chr14 65412441 T C 8.99E-04 Myopia (pathological) CHURC1-FNTB intron 21095009 rs8006570 chr14 65412710 G A 0.000000341 HDL cholesterol RAB15 UTR-3 23063622 rs8006570 chr14 65412710 G A 5.05E-09 LDL cholesterol RAB15 UTR-3 23063622 rs4902348 chr14 65419952 G A 1.60E-05 Urinary metabolites RAB15 intron 21572414 rs7148590 chr14 65473196 G A 1.29E-08 Other erythrocyte phenotypes FNTB intron 19862010 rs7148590 chr14 65473196 G A 2.79E-11 Red blood cell traits FNTB intron 23222517 rs7148590 chr14 65473196 G A 1.00E-07 Blood trace element (Zn levels) FNTB intron 23720494 rs4586342 chr14 65473875 G C 1.81E-10 Red blood cell traits FNTB intron 23222517 rs4466998 chr14 65475540 C A 5.00E-08 Mean corpuscular volume FNTB intron 19862010 rs4466998 chr14 65475540 C A 1.02E-08 Red blood cell traits FNTB intron 23222517 rs2296322 chr14 65478948 T G 2.86E-08 Red blood cell traits FNTB intron 23222517 rs4899159 chr14 65480595 A G 1.33E-08 Other erythrocyte phenotypes FNTB intron 19862010 rs4899159 chr14 65480595 A G 2.82E-09 Red blood cell traits FNTB intron 23222517 rs11627531 chr14 65487796 T C 1.42E-08 Other erythrocyte phenotypes FNTB intron 19862010 rs11627531 chr14 65487796 T C 1.33E-11 Red blood cell traits FNTB intron 23222517 rs11620955 chr14 65491255 A G 3.98E-09 Red blood cell traits FNTB intron 23222517 rs726668 chr14 65495816 A G 1.69E-08 Other erythrocyte phenotypes FNTB intron 19862010 rs726668 chr14 65495816 A G 8.79E-10 Red blood cell traits FNTB intron 23222517 rs7148144 chr14 65499450 G A 6.30E-04 Alcohol dependence FNTB intron 20201924 rs7148144 chr14 65499450 G A 6.70E-04 Alcohol dependence FNTB intron 20201924 rs12435835 chr14 65499909 T G 2.33E-08 Other erythrocyte phenotypes FNTB intron 19862010 rs12435835 chr14 65499909 T G 3.15E-12 Red blood cell traits FNTB intron 23222517 rs8006419 chr14 65500735 A G 2.40E-08 Other erythrocyte phenotypes FNTB intron 19862010 rs8006419 chr14 65500735 A G 6.43E-10 Red blood cell traits FNTB intron 23222517 rs7155454 chr14 65502239 G A 2.57E-08 Other erythrocyte phenotypes FNTB intron 19862010 rs7155454 chr14 65502239 G A 2.00E-12 Red blood cell traits FNTB intron 23222517 rs11628273 chr14 65509878 C T 2.13E-08 Other erythrocyte phenotypes FNTB intron 19862010 rs11628273 chr14 65509878 C T 8.27E-10 Red blood cell traits FNTB intron 23222517 rs868814 chr14 65584508 G A 9.24E-05 Tunica Media / / pha003036 rs11158577 chr14 65596490 A G 4.59E-06 Obesity-related traits / / 23251661 rs10873180 chr14 65604361 C T 5.61E-05 Tunica Media / / pha003036 rs17102423 chr14 65604728 G T 4.00E-07 Obesity-related traits / / 23251661 rs2411993 chr14 65618655 A C 3.90E-04 Myopia (pathological) / / 21095009 rs4902371 chr14 65619418 T G 6.06E-05 Cognitive impairment induced by topiramate / / 22091778 rs8007389 chr14 65643347 A C 1.96E-04 Alzheimer's disease / / 22005930 rs8007878 chr14 65643588 A G 2.71E-04 Alzheimer's disease / / 22005930 rs12147743 chr14 65644204 C T 8.53E-04 Alzheimer's disease / / 22005930 rs7151493 chr14 65644743 A G 3.11E-04 Alzheimer's disease / / 22005930 rs7158173 chr14 65645250 T C 4.00E-06 Anthropometric traits / / 19260139 rs7158173 chr14 65645250 T C 9.92E-04 Alzheimer's disease / / 22005930 rs7141753 chr14 65646445 C T 3.81E-04 Alcohol dependence / / 21314694 rs7141780 chr14 65646536 A G 4.54E-04 Alzheimer's disease / / 22005930 rs2035365 chr14 65647145 C T 4.50E-04 Alzheimer's disease / / 22005930 rs7155464 chr14 65648544 T C 3.25E-04 Alzheimer's disease / / 22005930 rs1760981 chr14 65653895 T G 5.38E-04 Alcohol dependence / / 20201924 rs753648 chr14 65658324 G C 6.27E-04 Alzheimer's disease / / 22005930 rs1679879 chr14 65659664 C T 3.68E-04 Alzheimer's disease / / 22005930 rs766907 chr14 65660568 G A 5.18E-04 Alzheimer's disease / / 22005930 rs1679870 chr14 65671947 G A 4.37E-04 Alzheimer's disease / / 22005930 rs12147965 chr14 65698095 C T 5.62E-04 Alzheimer's disease / / 22005930 rs4299072 chr14 65705258 G A 8.09E-07 Common variable immunodeficiency / / 21497890 rs2151754 chr14 65706015 T C 1.98E-04 Alzheimer's disease / / 17998437 rs8021641 chr14 65712420 T C 6.57E-04 Alzheimer's disease / / 22005930 rs1256500 chr14 65716967 A G 6.91E-04 Type 2 diabetes / / 17463246 rs6573597 chr14 65720883 G A 3.83E-04 Alzheimer's disease / / 17998437 rs1256515 chr14 65735357 C T 8.01E-05 Cognitive performance / / 19734545 rs1256517 chr14 65735684 T C 4.60E-05 Type 2 diabetes / / 17293876 rs1256517 chr14 65735684 T C 4.60E-05 Type 2 diabetes / / 19184112 rs1256526 chr14 65739905 T G 4.70E-06 Type 2 diabetes / / 17293876 rs1256526 chr14 65739905 T G 4.70E-06 Type 2 diabetes / / 19184112 rs1256531 chr14 65747759 A G 4.00E-06 Conduct disorder (symptom count) / / 20585324 rs7159888 chr14 65758642 G A 3.00E-18 N-glycan levels / / 21203500 rs7159888 chr14 65758642 G A 1.15E-12 N-glycan levels,in plasma / / 21908519 rs7159888 chr14 65758642 G A 2.06E-21 N-glycan levels,in plasma / / 21908519 rs7159888 chr14 65758642 G A 2.08E-22 N-glycan levels,in plasma / / 21908519 rs7159888 chr14 65758642 G A 2.77E-13 N-glycan levels,in plasma / / 21908519 rs7159888 chr14 65758642 G A 2.97E-11 N-glycan levels,in plasma / / 21908519 rs7159888 chr14 65758642 G A 5.13E-13 N-glycan levels,in plasma / / 21908519 rs7159888 chr14 65758642 G A 5.36E-12 N-glycan levels,in plasma / / 21908519 rs7159888 chr14 65758642 G A 7.51E-22 N-glycan levels,in plasma / / 21908519 rs7159888 chr14 65758642 G A 9.25E-11 N-glycan levels,in plasma / / 21908519 rs7159888 chr14 65758642 G A 2.00E-06 IgG glycosylation / / 23382691 rs1269068 chr14 65767333 C T 4.05E-05 Alcohol dependence / / 19581569 rs1269068 chr14 65767333 C T 2.23E-16 N-glycan levels,in plasma / / 21908519 rs1269068 chr14 65767333 C T 2.39E-12 N-glycan levels,in plasma / / 21908519 rs1269068 chr14 65767333 C T 4.40E-18 N-glycan levels,in plasma / / 21908519 rs1269068 chr14 65767333 C T 4.84E-08 N-glycan levels,in plasma / / 21908519 rs1269068 chr14 65767333 C T 5.05E-18 N-glycan levels,in plasma / / 21908519 rs1269068 chr14 65767333 C T 5.76E-12 N-glycan levels,in plasma / / 21908519 rs1269068 chr14 65767333 C T 7.68E-12 N-glycan levels,in plasma / / 21908519 rs11847263 chr14 65775695 T G 1.00E-10 IgG glycosylation / / 23382691 rs11847263 chr14 65775695 T G 1.00E-22 IgG glycosylation / / 23382691 rs11847263 chr14 65775695 T G 2.00E-06 IgG glycosylation / / 23382691 rs11847263 chr14 65775695 T G 2.00E-13 IgG glycosylation / / 23382691 rs11847263 chr14 65775695 T G 2.00E-13 IgG glycosylation / / 23382691 rs11847263 chr14 65775695 T G 2.00E-19 IgG glycosylation / / 23382691 rs11847263 chr14 65775695 T G 3.00E-08 IgG glycosylation / / 23382691 rs11847263 chr14 65775695 T G 3.00E-14 IgG glycosylation / / 23382691 rs11847263 chr14 65775695 T G 3.00E-17 IgG glycosylation / / 23382691 rs11847263 chr14 65775695 T G 3.00E-21 IgG glycosylation / / 23382691 rs11847263 chr14 65775695 T G 5.00E-15 IgG glycosylation / / 23382691 rs11847263 chr14 65775695 T G 6.00E-06 IgG glycosylation / / 23382691 rs11847263 chr14 65775695 T G 7.00E-14 IgG glycosylation / / 23382691 rs11847263 chr14 65775695 T G 8.00E-20 IgG glycosylation / / 23382691 rs10132229 chr14 65777560 A G 1.05E-15 N-glycan levels,in plasma / / 21908519 rs10132229 chr14 65777560 A G 2.02E-12 N-glycan levels,in plasma / / 21908519 rs10132229 chr14 65777560 A G 3.63E-08 N-glycan levels,in plasma / / 21908519 rs10132229 chr14 65777560 A G 4.70E-15 N-glycan levels,in plasma / / 21908519 rs10132229 chr14 65777560 A G 4.73E-10 N-glycan levels,in plasma / / 21908519 rs10132229 chr14 65777560 A G 5.35E-11 N-glycan levels,in plasma / / 21908519 rs6573604 chr14 65787941 T C 1.47E-10 N-glycan levels,in plasma / / 21908519 rs6573604 chr14 65787941 T C 1.51E-15 N-glycan levels,in plasma / / 21908519 rs6573604 chr14 65787941 T C 1.76E-12 N-glycan levels,in plasma / / 21908519 rs6573604 chr14 65787941 T C 1.97E-12 N-glycan levels,in plasma / / 21908519 rs6573604 chr14 65787941 T C 2.16E-10 N-glycan levels,in plasma / / 21908519 rs6573604 chr14 65787941 T C 2.44E-18 N-glycan levels,in plasma / / 21908519 rs6573604 chr14 65787941 T C 4.81E-09 N-glycan levels,in plasma / / 21908519 rs6573604 chr14 65787941 T C 7.29E-11 N-glycan levels,in plasma / / 21908519 rs6573604 chr14 65787941 T C 9.88E-19 N-glycan levels,in plasma / / 21908519 rs7143109 chr14 65801024 G A 1.66E-05 Platelet counts / / pha003100 rs12881755 chr14 65801811 A G 1.99E-04 Coronary heart disease / / 21971053 rs12886168 chr14 65809286 C A 3.73E-05 Coronary heart disease / / 21971053 rs11158590 chr14 65821140 G T 3.64E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs7141874 chr14 65821994 G A 7.20E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs11621121 chr14 65822493 C T 2.70E-05 Urinary metabolites / / 21572414 rs11621121 chr14 65822493 C T 1.22E-12 N-glycan levels,in plasma / / 21908519 rs11621121 chr14 65822493 C T 1.33E-09 N-glycan levels,in plasma / / 21908519 rs11621121 chr14 65822493 C T 1.69E-23 N-glycan levels,in plasma / / 21908519 rs11621121 chr14 65822493 C T 1.72E-16 N-glycan levels,in plasma / / 21908519 rs11621121 chr14 65822493 C T 1.94E-14 N-glycan levels,in plasma / / 21908519 rs11621121 chr14 65822493 C T 2.92E-08 N-glycan levels,in plasma / / 21908519 rs11621121 chr14 65822493 C T 5.34E-20 N-glycan levels,in plasma / / 21908519 rs11621121 chr14 65822493 C T 8.34E-17 N-glycan levels,in plasma / / 21908519 rs11621121 chr14 65822493 C T 5.00E-04 Coronary heart disease / / 21971053 rs7147624 chr14 65865625 T G 1.90E-05 Type 2 diabetes / / 17903298 rs7147624 chr14 65865625 T G 8.14E-05 Cognitive impairment induced by topiramate / / 22091778 rs7147624 chr14 65865625 T G 5.00E-06 Chronic obstructive pulmonary disease-related biomarkers / / 23144326 rs8013442 chr14 65871861 A G 1.39E-10 N-glycan levels,in plasma / / 21908519 rs8013442 chr14 65871861 A G 3.74E-08 N-glycan levels,in plasma / / 21908519 rs8013442 chr14 65871861 A G 3.93E-08 N-glycan levels,in plasma / / 21908519 rs8013442 chr14 65871861 A G 4.83E-08 N-glycan levels,in plasma / / 21908519 rs8005892 chr14 65873921 T C 4.33E-04 Multiple complex diseases / / 17554300 rs2411822 chr14 65878395 A G 1.43E-18 N-glycan levels,in plasma FUT8 UTR-5 21908519 rs2411822 chr14 65878395 A G 1.71E-10 N-glycan levels,in plasma FUT8 UTR-5 21908519 rs2411822 chr14 65878395 A G 1.92E-13 N-glycan levels,in plasma FUT8 UTR-5 21908519 rs2411822 chr14 65878395 A G 2.14E-15 N-glycan levels,in plasma FUT8 UTR-5 21908519 rs2411822 chr14 65878395 A G 5.14E-14 N-glycan levels,in plasma FUT8 UTR-5 21908519 rs2411822 chr14 65878395 A G 9.18E-12 N-glycan levels,in plasma FUT8 UTR-5 21908519 rs1953416 chr14 65878807 C T 1.26E-11 N-glycan levels,in plasma FUT8 intron 21908519 rs1953416 chr14 65878807 C T 1.96E-18 N-glycan levels,in plasma FUT8 intron 21908519 rs1953416 chr14 65878807 C T 2.18E-10 N-glycan levels,in plasma FUT8 intron 21908519 rs1953416 chr14 65878807 C T 2.72E-13 N-glycan levels,in plasma FUT8 intron 21908519 rs1953416 chr14 65878807 C T 2.94E-15 N-glycan levels,in plasma FUT8 intron 21908519 rs1953416 chr14 65878807 C T 7.29E-14 N-glycan levels,in plasma FUT8 intron 21908519 rs1953417 chr14 65878909 C T 1.86E-09 N-glycan levels,in plasma FUT8 intron 21908519 rs1953417 chr14 65878909 C T 7.56E-09 N-glycan levels,in plasma FUT8 intron 21908519 rs7145500 chr14 65884212 G A 4.32E-08 N-glycan levels,in plasma FUT8 intron 21908519 rs7145500 chr14 65884212 G A 9.45E-10 N-glycan levels,in plasma FUT8 intron 21908519 rs10483776 chr14 65914867 A G 1.00E-08 N-glycan levels FUT8 intron 21203500 rs10483776 chr14 65914867 A G 1.03E-14 N-glycan levels,in plasma FUT8 intron 21908519 rs10483776 chr14 65914867 A G 1.28E-08 N-glycan levels,in plasma FUT8 intron 21908519 rs10483776 chr14 65914867 A G 1.50E-08 N-glycan levels,in plasma FUT8 intron 21908519 rs10483776 chr14 65914867 A G 1.83E-12 N-glycan levels,in plasma FUT8 intron 21908519 rs10483776 chr14 65914867 A G 1.99E-09 N-glycan levels,in plasma FUT8 intron 21908519 rs10483776 chr14 65914867 A G 2.68E-11 N-glycan levels,in plasma FUT8 intron 21908519 rs10483776 chr14 65914867 A G 2.70E-10 N-glycan levels,in plasma FUT8 intron 21908519 rs10483776 chr14 65914867 A G 3.18E-11 N-glycan levels,in plasma FUT8 intron 21908519 rs10483776 chr14 65914867 A G 6.60E-10 N-glycan levels,in plasma FUT8 intron 21908519 rs10483776 chr14 65914867 A G 8.79E-11 N-glycan levels,in plasma FUT8 intron 21908519 rs10483776 chr14 65914867 A G 9.28E-10 N-glycan levels,in plasma FUT8 intron 21908519 rs1959144 chr14 65946051 T G 3.54E-11 N-glycan levels,in plasma FUT8 intron 21908519 rs1959144 chr14 65946051 T G 4.09E-09 N-glycan levels,in plasma FUT8 intron 21908519 rs1959144 chr14 65946051 T G 4.39E-08 N-glycan levels,in plasma FUT8 intron 21908519 rs4902399 chr14 65956897 A G 5.54E-09 N-glycan levels,in plasma FUT8 intron 21908519 rs4902399 chr14 65956897 A G 7.35E-11 N-glycan levels,in plasma FUT8 intron 21908519 rs2229677 chr14 66028446 A G 3.41E-08 N-glycan levels,in plasma FUT8 cds-synon 21908519 rs2229677 chr14 66028446 A G 4.78E-08 N-glycan levels,in plasma FUT8 cds-synon 21908519 rs2229677 chr14 66028446 A G 5.06E-09 N-glycan levels,in plasma FUT8 cds-synon 21908519 rs2229677 chr14 66028446 A G 6.77E-11 N-glycan levels,in plasma FUT8 cds-synon 21908519 rs7161123 chr14 66052901 G A,C 1.07E-14 N-glycan levels,in plasma FUT8 intron 21908519 rs7161123 chr14 66052901 G A,C 1.10E-19 N-glycan levels,in plasma FUT8 intron 21908519 rs7161123 chr14 66052901 G A,C 1.40E-16 N-glycan levels,in plasma FUT8 intron 21908519 rs7161123 chr14 66052901 G A,C 1.47E-14 N-glycan levels,in plasma FUT8 intron 21908519 rs7161123 chr14 66052901 G A,C 1.54E-12 N-glycan levels,in plasma FUT8 intron 21908519 rs7161123 chr14 66052901 G A,C 2.62E-11 N-glycan levels,in plasma FUT8 intron 21908519 rs4581615 chr14 66055943 C A 5.89E-05 Personality dimensions FUT8 intron 23903073 rs743085 chr14 66068133 A G 1.19E-16 N-glycan levels,in plasma FUT8 intron 21908519 rs743085 chr14 66068133 A G 1.81E-11 N-glycan levels,in plasma FUT8 intron 21908519 rs743085 chr14 66068133 A G 8.03E-15 N-glycan levels,in plasma FUT8 intron 21908519 rs743085 chr14 66068133 A G 8.49E-20 N-glycan levels,in plasma FUT8 intron 21908519 rs743085 chr14 66068133 A G 9.01E-15 N-glycan levels,in plasma FUT8 intron 21908519 rs743085 chr14 66068133 A G 9.86E-13 N-glycan levels,in plasma FUT8 intron 21908519 rs10483782 chr14 66083170 A G 9.70E-05 Non-alcoholic fatty liver disease histology (other) FUT8 intron 20708005 rs10483782 chr14 66083170 A G 1.88E-04 Lung function (forced expiratory volume in 1 second) FUT8 intron 24023788 rs10483782 chr14 66083170 A G 4.77E-04 Lung function (forced vital capacity) FUT8 intron 24023788 rs2268957 chr14 66113233 C T 1.49E-09 N-glycan levels,in plasma FUT8 intron 21908519 rs2268957 chr14 66113233 C T 5.42E-09 N-glycan levels,in plasma FUT8 intron 21908519 rs17181388 chr14 66118012 C A,G,T 3.81E-04 Multiple complex diseases FUT8 intron 17554300 rs7144971 chr14 66120650 G A 3.62E-09 N-glycan levels,in plasma FUT8 intron 21908519 rs7144971 chr14 66120650 G A 8.26E-09 N-glycan levels,in plasma FUT8 intron 21908519 rs2300871 chr14 66147694 A C 3.43E-09 N-glycan levels,in plasma FUT8 intron 21908519 rs2300871 chr14 66147694 A C 4.70E-08 N-glycan levels,in plasma FUT8 intron 21908519 rs2300871 chr14 66147694 A C 7.08E-10 N-glycan levels,in plasma FUT8 intron 21908519 rs2411351 chr14 66171541 T C 1.02E-14 N-glycan levels,in plasma FUT8 intron 21908519 rs2411351 chr14 66171541 T C 1.40E-11 N-glycan levels,in plasma FUT8 intron 21908519 rs2411351 chr14 66171541 T C 2.20E-15 N-glycan levels,in plasma FUT8 intron 21908519 rs2411351 chr14 66171541 T C 3.37E-20 N-glycan levels,in plasma FUT8 intron 21908519 rs2411351 chr14 66171541 T C 3.69E-17 N-glycan levels,in plasma FUT8 intron 21908519 rs2411351 chr14 66171541 T C 9.68E-13 N-glycan levels,in plasma FUT8 intron 21908519 rs10129472 chr14 66188209 C T 9.82E-04 Multiple complex diseases FUT8 intron 17554300 rs3742597 chr14 66200177 A G 1.44E-08 N-glycan levels,in plasma FUT8 intron 21908519 rs3742597 chr14 66200177 A G 1.52E-14 N-glycan levels,in plasma FUT8 intron 21908519 rs3742597 chr14 66200177 A G 1.76E-22 N-glycan levels,in plasma FUT8 intron 21908519 rs3742597 chr14 66200177 A G 3.13E-09 N-glycan levels,in plasma FUT8 intron 21908519 rs3742597 chr14 66200177 A G 3.63E-13 N-glycan levels,in plasma FUT8 intron 21908519 rs3742597 chr14 66200177 A G 4.92E-18 N-glycan levels,in plasma FUT8 intron 21908519 rs3742597 chr14 66200177 A G 8.99E-10 N-glycan levels,in plasma FUT8 intron 21908519 rs3742597 chr14 66200177 A G 9.46E-21 N-glycan levels,in plasma FUT8 intron 21908519 rs3742597 chr14 66200177 A G 9.72E-15 N-glycan levels,in plasma FUT8 intron 21908519 rs8021889 chr14 66214811 A G 7.83E-05 Cognitive impairment induced by topiramate / / 22091778 rs10483785 chr14 66219517 G A 1.85E-12 N-glycan levels,in plasma / / 21908519 rs10483785 chr14 66219517 G A 2.11E-17 N-glycan levels,in plasma / / 21908519 rs10483785 chr14 66219517 G A 2.90E-13 N-glycan levels,in plasma / / 21908519 rs10483785 chr14 66219517 G A 2.92E-20 N-glycan levels,in plasma / / 21908519 rs10483785 chr14 66219517 G A 5.35E-15 N-glycan levels,in plasma / / 21908519 rs10483785 chr14 66219517 G A 6.83E-16 N-glycan levels,in plasma / / 21908519 rs4073416 chr14 66259394 T C 1.27E-14 N-glycan levels,in plasma / / 21908519 rs4073416 chr14 66259394 T C 1.50E-19 N-glycan levels,in plasma / / 21908519 rs4073416 chr14 66259394 T C 1.61E-18 N-glycan levels,in plasma / / 21908519 rs4073416 chr14 66259394 T C 2.72E-09 N-glycan levels,in plasma / / 21908519 rs4073416 chr14 66259394 T C 2.73E-17 N-glycan levels,in plasma / / 21908519 rs4073416 chr14 66259394 T C 7.47E-15 N-glycan levels,in plasma / / 21908519 rs4073416 chr14 66259394 T C 8.37E-14 N-glycan levels,in plasma / / 21908519 rs8007846 chr14 66262963 A G 9.00E-06 Multiple sclerosis (brain glutamate levels) / / 20802204 rs8007846 chr14 66262963 A G 1.07E-12 N-glycan levels,in plasma / / 21908519 rs8007846 chr14 66262963 A G 1.36E-09 N-glycan levels,in plasma / / 21908519 rs8007846 chr14 66262963 A G 4.51E-08 N-glycan levels,in plasma / / 21908519 rs8007846 chr14 66262963 A G 7.48E-10 N-glycan levels,in plasma / / 21908519 rs9323465 chr14 66266677 G T 4.15E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10149325 chr14 66277367 G A 9.71E-04 Alzheimer's disease / / 17998437 rs7494064 chr14 66287910 C T 8.00E-06 Obesity-related traits / / 23251661 rs3935480 chr14 66287921 C A 6.96E-04 Acute lung injury / / 22295056 rs12589188 chr14 66290966 A G 3.41E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs8010134 chr14 66300153 G A 8.06E-04 Alzheimer's disease / / 24755620 rs11624914 chr14 66302952 A C 8.87E-05 Body Mass Index / / pha003009 rs7160924 chr14 66318401 G A 5.63E-04 Alzheimer's disease / / 22005930 rs6573640 chr14 66335141 A G 1.62E-10 Multiple complex diseases / / 17554300 rs12894020 chr14 66344197 C A 4.68E-05 Bipolar disorder / / 21771265 rs17753596 chr14 66346271 G T 5.00E-05 Lipid levels / / 18193043 rs77677743 chr14 66364190 T C 3.88E-05 Epilepsy (remission after treatment) / / 23962720 rs79603482 chr14 66364191 T A 3.88E-05 Epilepsy (remission after treatment) / / 23962720 rs2318310 chr14 66397186 C T 6.52E-05 Weight / / pha003026 rs7142317 chr14 66403148 G A 1.10E-06 Urinary metabolites / / 21572414 rs4902439 chr14 66405430 T A 6.24E-04 Multiple complex diseases / / 17554300 rs4902439 chr14 66405430 T A 3.80E-06 Urinary metabolites / / 21572414 rs7146427 chr14 66407339 T C 1.31E-04 Multiple complex diseases / / 17554300 rs7146427 chr14 66407339 T C 8.60E-06 Urinary metabolites / / 21572414 rs8013361 chr14 66413390 T C 3.96E-04 Schizophrenia / / 19197363 rs8013361 chr14 66413390 T C 5.88E-04 Smoking quantity / / 24665060 rs10130284 chr14 66424895 C T 5.18E-05 Smoking quantity / / 24665060 rs7145321 chr14 66437563 A G 5.56E-04 Multiple complex diseases / / 17554300 rs1663330 chr14 66443496 A G 4.54E-05 Asthma (bronchodilator response) / / 23508266 rs1663332 chr14 66444344 C T 8.07E-05 Asthma (bronchodilator response) / / 23508266 rs1663332 chr14 66444344 C T 4.29E-04 Smoking quantity / / 24665060 rs1147455 chr14 66448348 A G 0.000556308 Hypertension (early onset hypertension) / / 22479346 rs1147455 chr14 66448348 A G 8.09E-04 Iron levels / / pha002876 rs1147451 chr14 66451253 C T 0.0000512 Colorectal cancer vs. adenoma controls / / 22532847 rs11849977 chr14 66459393 A C 9.43E-04 Multiple complex diseases / / 17554300 rs12435895 chr14 66459694 A G 3.62E-05 Iron levels / / 19880490 rs12435895 chr14 66459694 A G 3.62E-05 Iron levels / / pha002876 rs1147443 chr14 66468761 C T 2.21E-04 Iron levels / / pha002876 rs894921 chr14 66476252 T C 7.68E-05 Body Mass Index / / pha003009 rs12589911 chr14 66487919 G A 3.76E-04 Multiple complex diseases / / 17554300 rs874113 chr14 66504726 T C 1.89E-04 Multiple complex diseases / / 17554300 rs768973 chr14 66507076 T C 3.06E-04 Multiple complex diseases / / 17554300 rs17103248 chr14 66516668 G A 5.14E-04 Iron levels / / pha002876 rs10498522 chr14 66518575 G A 9.51E-04 Multiple complex diseases / / 17554300 rs13379041 chr14 66519062 A G 6.19E-04 Multiple complex diseases / / 17554300 rs10498523 chr14 66520139 C T 4.87E-04 Multiple complex diseases / / 17554300 rs7148664 chr14 66559749 C T 6.97E-05 Schizophrenia / / 19571811 rs7144087 chr14 66625679 C T 0.00000799 Alpha-2-adrenoceptor-mediated vasoconstriction / / 23337848 rs17779877 chr14 66771210 C G 5.55E-05 Coronary heart disease / / 21606135 rs2385098 chr14 66776913 G A 0.00000538 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7160622 chr14 66800879 C T 1.55E-04 Coronary heart disease / / 21606135 rs7149488 chr14 66823672 C T 3.34E-04 Coronary heart disease / / 21606135 rs12589479 chr14 66893720 G A 2.56E-04 Coronary heart disease / / 21606135 rs735957 chr14 66895724 G A 3.12E-04 Coronary heart disease / / 21606135 rs933039 chr14 66903247 A G 1.23E-04 Coronary heart disease / / 21606135 rs7146723 chr14 66969095 A T 1.90E-05 Coronary heart disease / / 21606135 rs7159831 chr14 67029033 G A 8.90E-04 Alcohol dependence GPHN intron 20201924 rs7146849 chr14 67032070 T C 1.69E-04 Coronary heart disease GPHN intron 21606135 rs2319392 chr14 67067091 A T 5.00E-05 Type 2 diabetes GPHN intron 17463248 rs11624733 chr14 67101475 T A 7.40E-06 Iron levels GPHN intron 21208937 rs9783601 chr14 67148939 T C 3.12E-04 Coronary heart disease GPHN intron 21606135 rs6573706 chr14 67150764 T A 2.72E-04 Coronary heart disease GPHN intron 21606135 rs7157740 chr14 67161341 A G 2.19E-04 Coronary heart disease GPHN intron 21606135 rs7154017 chr14 67164083 A C 2.69E-04 Coronary heart disease GPHN intron 21606135 rs1885198 chr14 67164760 C T 4.03E-04 Coronary heart disease GPHN intron 21606135 rs17836572 chr14 67193023 A G 1.36E-04 Coronary heart disease GPHN intron 21606135 rs6573719 chr14 67208648 T C 2.14E-04 Coronary heart disease GPHN intron 21606135 rs17247749 chr14 67223083 A G 2.67E-04 Coronary heart disease GPHN intron 21606135 rs10129827 chr14 67232573 G A 1.37E-05 Major depressive disorder GPHN intron 22472876 rs8008773 chr14 67263163 A T 7.48E-05 Depression (quantitative trait) GPHN intron 23290196 rs12587989 chr14 67270123 A G 1.50E-05 Major depressive disorder GPHN intron 22472876 rs10483790 chr14 67298170 C T 3.82E-05 Hearing function GPHN intron 17255346 rs10135117 chr14 67399391 G T 1.53E-04 Hearing function GPHN intron 17255346 rs11621555 chr14 67449344 T C 9.93E-05 Height GPHN intron pha003011 rs8020095 chr14 67453858 G A 3.00E-06 Depression (quantitative trait) GPHN intron 23290196 rs7152001 chr14 67461348 C G 3.08E-06 Depression (quantitative trait) GPHN intron 23290196 rs7142068 chr14 67463012 C T 6.94E-05 Major depressive disorder GPHN intron 22472876 rs10483792 chr14 67527133 A G 6.67E-05 Hearing function GPHN intron 17255346 rs3784077 chr14 67559670 A C 3.68E-05 Hearing function GPHN intron 17255346 rs10431718 chr14 67682636 C A 2.54E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines FAM71D intron 21844884 rs10431718 chr14 67682636 C A 7.66E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines FAM71D intron 21844884 rs17781436 chr14 67687852 A G 4.78E-04 Multiple complex diseases FAM71D intron 17554300 rs10141879 chr14 67695190 G A 4.21E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines FAM71D UTR-3 21844884 rs8015862 chr14 67711174 G T 5.72E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MPP5 intron 21844884 rs1073607 chr14 67712684 A G 5.62E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MPP5 intron 21844884 rs8015454 chr14 67739285 T C 1.82E-04 Response to cytadine analogues (cytosine arabinoside) MPP5 intron 24483146 rs10146722 chr14 67769045 G A 1.68E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MPP5 intron 21844884 rs2146229 chr14 67775692 C G 5.78E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MPP5 intron 21844884 rs2146229 chr14 67775692 C G 6.51E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MPP5 intron 21844884 rs10138824 chr14 67789557 G A 3.63E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MPP5 intron 21844884 rs10138824 chr14 67789557 G A 8.15E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MPP5 intron 21844884 rs17248616 chr14 67796667 G C 6.82E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MPP5 intron 21844884 rs1813 chr14 67804375 C T 1.00E-04 Hearing function / / 17255346 rs8008724 chr14 67847218 T G 5.24E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines EIF2S1 intron 21844884 rs8008724 chr14 67847218 T G 8.60E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines EIF2S1 intron 21844884 rs2296561 chr14 67849139 A T 6.22E-05 Depression (quantitative trait) EIF2S1 intron 23290196 rs9323497 chr14 67873128 C T 1.57E-06 Major depressive disorder PLEK2 intron 22472876 rs8013144 chr14 67888775 G A 1.05E-06 Major depressive disorder / / 22472876 rs4902468 chr14 67899267 C T 7.06E-05 Celiac disease / / 23936387 rs3742855 chr14 67912792 A G 6.85E-04 Type 2 diabetes / / 17463246 rs3742855 chr14 67912792 A G 1.30E-05 Urinary metabolites / / 21572414 rs7156173 chr14 67919683 C A 9.67E-04 Iron levels / / pha002876 rs1315731 chr14 67938472 C A 9.82E-04 Amyotrophic lateral sclerosis (sporadic) TMEM229B UTR-3 24529757 rs17104363 chr14 67939483 T C 5.00E-08 Obesity-related traits TMEM229B UTR-3 23251661 rs17249111 chr14 67949074 A G 9.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) TMEM229B intron 23648065 rs1077989 chr14 67975822 A C 9.00E-18 Phospholipid levels (plasma) TMEM229B intron 22359512 rs7156144 chr14 67979713 G A 1.70E-28 Serum metabolites TMEM229B intron 20037589 rs17836787 chr14 67990429 A C 6.00E-05 Personality dimensions / / 18957941 rs8023027 chr14 67992490 A G 6.72E-04 Type 2 diabetes / / 17463246 rs17249216 chr14 67994245 A G 1.71E-04 Hearing function / / 17255346 rs4902479 chr14 67998204 G C 7.41E-04 Type 2 diabetes / / 17463246 rs4902482 chr14 68001781 C T 9.10E-04 Type 2 diabetes PLEKHH1 intron 17463246 rs3742867 chr14 68008867 G A 2.75E-05 Odorant perception PLEKHH1 intron 23910658 rs731681 chr14 68010224 G C 4.21E-04 Type 2 diabetes PLEKHH1 intron 17463246 rs10873205 chr14 68015472 A C 7.62E-04 Type 2 diabetes PLEKHH1 intron 17463246 rs6573780 chr14 68025058 A C 2.23E-04 Type 2 diabetes PLEKHH1 intron 17463246 rs17249299 chr14 68049117 C T 9.74E-04 Alzheimer's disease PLEKHH1 intron 24755620 rs734028 chr14 68053802 T C 4.93E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) PLEKHH1 cds-synon 24023788 rs8005363 chr14 68056390 G A 8.80E-05 Lung function (forced expiratory volume in 1 second) PIGH UTR-3 24023788 rs8007199 chr14 68065321 T C 2.82E-07 Magnesium levels PIGH intron pha003092 rs17249444 chr14 68101454 G C 1.25E-04 Progressive supranuclear palsy ARG2 intron 21685912 rs17782603 chr14 68137101 T C 6.86E-05 Serum metabolites VTI1B intron 19043545 rs3759763 chr14 68142940 G A 6.50E-05 Serum metabolites / / 19043545 rs12147616 chr14 68171340 T C 1.07E-05 Smoking behavior RDH12 intron 19188921 rs12882315 chr14 68171728 C A 2.00E-05 Smoking behavior RDH12 intron 19188921 rs1117516 chr14 68172894 C T 6.69E-05 Serum metabolites RDH12 intron 19043545 rs12891047 chr14 68243075 C A 6.00E-07 Amyotrophic lateral sclerosis (sporadic) ZFYVE26 intron 24529757 rs7143559 chr14 68257005 T G 7.46E-05 Panic disorder ZFYVE26 intron 19165232 rs7157699 chr14 68296900 A C 3.67E-04 Multiple complex diseases RAD51B intron 17554300 rs10133652 chr14 68367581 C G 1.80E-04 Multiple complex diseases RAD51B intron 17554300 rs10133262 chr14 68407938 G A 5.88E-06 Height RAD51B intron 22021425 rs4902538 chr14 68424809 C T 2.42E-04 Alzheimer's disease (late onset) RAD51B intron 21379329 rs4902538 chr14 68424809 C T 6.62E-04 Longevity RAD51B intron 22279548 rs17192558 chr14 68451456 C T 1.34E-05 Height RAD51B intron 22021425 rs11846344 chr14 68452019 T A 6.92E-06 Height RAD51B intron 22021425 rs11850191 chr14 68452058 A G 6.89E-06 Height RAD51B intron 22021425 rs17192586 chr14 68454505 G A 4.32E-04 Alzheimer's disease (late onset) RAD51B intron 21379329 rs7154646 chr14 68456453 C T 7.34E-06 Height RAD51B intron 22021425 rs10143455 chr14 68479451 T G 3.80E-06 Height RAD51B intron 22021425 rs10132022 chr14 68500751 A G 1.85E-05 Amyotrophic lateral sclerosis (sporadic) RAD51B intron 24529757 rs11623355 chr14 68510317 T C 9.83E-06 Height RAD51B intron 22021425 rs8022206 chr14 68520906 G A 2.00E-10 Platelet counts RAD51B intron 22139419 rs2588827 chr14 68614441 C T 2.40E-10 Breast cancer (male) RAD51B intron 23001122 rs2588819 chr14 68628680 T C 2.85E-10 Breast cancer (male) RAD51B intron 23001122 rs2588818 chr14 68630578 A G 3.97E-10 Breast cancer (male) RAD51B intron 23001122 rs1952246 chr14 68631812 G A 2.47E-10 Breast cancer (male) RAD51B intron 23001122 rs1952245 chr14 68631935 T C 3.52E-05 Height RAD51B intron 22021425 rs1958116 chr14 68632826 A G 3.81E-05 Height RAD51B intron 22021425 rs2243905 chr14 68633413 G A 3.81E-10 Breast cancer (male) RAD51B intron 23001122 rs2767384 chr14 68636711 G T 3.68E-10 Breast cancer (male) RAD51B intron 23001122 rs1958115 chr14 68637665 C A 2.46E-10 Breast cancer (male) RAD51B intron 23001122 rs1958113 chr14 68637906 A G,T 4.08E-10 Breast cancer (male) RAD51B intron 23001122 rs2588814 chr14 68643798 G A 2.40E-10 Breast cancer (male) RAD51B intron 23001122 rs2767382 chr14 68644046 A G 1.75E-10 Breast cancer (male) RAD51B intron 23001122 rs2094326 chr14 68647631 G T 2.50E-04 Insulin resistance RAD51B intron 21901158 rs17105102 chr14 68647665 C T 1.52E-04 Insulin resistance RAD51B intron 21901158 rs2038979 chr14 68649776 G A 2.34E-10 Breast cancer (male) RAD51B intron 23001122 rs2588808 chr14 68660181 A G 3.11E-10 Breast cancer (male) RAD51B intron 23001122 rs2588809 chr14 68660428 T C 3.56E-10 Breast cancer (male) RAD51B intron 23001122 rs2588809 chr14 68660428 T C 1.00E-10 Breast cancer RAD51B intron 23535729 rs6573820 chr14 68662213 C T 1.08E-04 Insulin resistance RAD51B intron 21901158 rs2767378 chr14 68663266 T C 2.45E-10 Breast cancer (male) RAD51B intron 23001122 rs2255767 chr14 68663437 A G 2.68E-10 Breast cancer (male) RAD51B intron 23001122 rs1274638 chr14 68666722 T C 2.70E-10 Breast cancer (male) RAD51B intron 23001122 rs1274639 chr14 68668499 C A 1.48E-10 Breast cancer (male) RAD51B intron 23001122 rs1274640 chr14 68668528 C T 3.75E-10 Breast cancer (male) RAD51B intron 23001122 rs1028842 chr14 68671723 C A 1.47E-10 Breast cancer (male) RAD51B intron 23001122 rs1274642 chr14 68672703 G A 1.66E-10 Breast cancer (male) RAD51B intron 23001122 rs1274643 chr14 68673079 T C 3.13E-10 Breast cancer (male) RAD51B intron 23001122 rs1274644 chr14 68673117 G A 1.66E-10 Breast cancer (male) RAD51B intron 23001122 rs1274645 chr14 68673326 G A 1.66E-10 Breast cancer (male) RAD51B intron 23001122 rs1274646 chr14 68673389 G A 1.66E-10 Breast cancer (male) RAD51B intron 23001122 rs1274647 chr14 68673844 T C 1.70E-10 Breast cancer (male) RAD51B intron 23001122 rs1274648 chr14 68673885 T C 3.14E-10 Breast cancer (male) RAD51B intron 23001122 rs1274649 chr14 68674300 T G 1.66E-10 Breast cancer (male) RAD51B intron 23001122 rs725453 chr14 68675858 C T 3.14E-10 Breast cancer (male) RAD51B intron 23001122 rs1274650 chr14 68676173 G A 1.64E-10 Breast cancer (male) RAD51B intron 23001122 rs1274651 chr14 68676418 C T 1.64E-10 Breast cancer (male) RAD51B intron 23001122 rs1274652 chr14 68676520 C G 3.24E-10 Breast cancer (male) RAD51B intron 23001122 rs1298340 chr14 68677492 G C 7.40E-05 Cardiovascular disease RAD51B intron 17903304 rs1298340 chr14 68677492 G C 3.18E-10 Breast cancer (male) RAD51B intron 23001122 rs1274655 chr14 68677978 G C 3.18E-10 Breast cancer (male) RAD51B intron 23001122 rs1295780 chr14 68678632 C T 1.63E-10 Breast cancer (male) RAD51B intron 23001122 rs1274656 chr14 68679481 G A 3.18E-10 Breast cancer (male) RAD51B intron 23001122 rs1274657 chr14 68679715 C G 1.63E-10 Breast cancer (male) RAD51B intron 23001122 rs1274658 chr14 68680007 G A 1.63E-10 Breast cancer (male) RAD51B intron 23001122 rs1274659 chr14 68680649 C G 1.63E-10 Breast cancer (male) RAD51B intron 23001122 rs1744947 chr14 68681476 C T 1.63E-10 Breast cancer (male) RAD51B intron 23001122 rs1296527 chr14 68685460 T C 3.18E-10 Breast cancer (male) RAD51B intron 23001122 rs1744949 chr14 68686394 C T 1.59E-10 Breast cancer (male) RAD51B intron 23001122 rs117351774 chr14 68688639 T C 1.60E-10 Breast cancer (male) RAD51B intron 23001122 rs116264287 chr14 68688702 C T 1.60E-10 Breast cancer (male) RAD51B intron 23001122 rs1274661 chr14 68689219 G A 1.60E-10 Breast cancer (male) RAD51B intron 23001122 rs1290939 chr14 68689813 C G 1.96E-10 Breast cancer (male) RAD51B intron 23001122 rs1295782 chr14 68690442 C T 1.60E-10 Breast cancer (male) RAD51B intron 23001122 rs1751382 chr14 68692650 C T 5.14E-05 Cardiovascular disease RAD51B intron 17903304 rs1751382 chr14 68692650 C T 2.14E-10 Breast cancer (male) RAD51B intron 23001122 rs1314912 chr14 68698372 G A 1.83E-10 Breast cancer (male) RAD51B intron 23001122 rs1316170 chr14 68698472 A C 3.58E-10 Breast cancer (male) RAD51B intron 23001122 rs1316014 chr14 68699370 T G 1.84E-10 Breast cancer (male) RAD51B intron 23001122 rs1314913 chr14 68699594 C T 5.53E-05 Cardiovascular disease RAD51B intron 17903304 rs1314913 chr14 68699594 C T 3.00E-13 Breast cancer (male) RAD51B intron 23001122 rs1316118 chr14 68700097 T C 4.00E-10 Breast cancer (male) RAD51B intron 23001122 rs1314914 chr14 68703076 C T 3.90E-10 Breast cancer (male) RAD51B intron 23001122 rs11628885 chr14 68724790 A G 0.0000417 Placental abruption RAD51B intron 23205182 rs17105278 chr14 68728479 T C 2.10E-06 Primary tooth development (time to first tooth eruption) RAD51B intron 23704328 rs1957572 chr14 68736471 C T 1.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RAD51B intron 20877124 rs7148882 chr14 68740924 A G 0.0000016 Primary biliary cirrhosis RAD51B intron 22936693 rs7148416 chr14 68747868 A T 1.74E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) RAD51B intron 24236485 rs3784099 chr14 68749927 G A 2.37E-09 Primary biliary cirrhosis RAD51B intron 21399635 rs3784099 chr14 68749927 G A 1.00E-07 Breast cancer (survival) RAD51B intron 22232737 rs3784099 chr14 68749927 G A 3.00E-07 Breast cancer (survival) RAD51B intron 22232737 rs3784099 chr14 68749927 G A 2.23E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) RAD51B intron 24236485 rs3784099 chr14 68749927 G A 7.10E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) RAD51B intron 24236485 rs8008961 chr14 68752643 C T 6.00E-06 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) RAD51B intron 24236485 rs2208397 chr14 68753287 T G 5.71E-09 Primary biliary cirrhosis RAD51B intron 21399635 rs911263 chr14 68753593 C T 2.00E-11 Primary biliary cirrhosis RAD51B intron 21399635 rs911263 chr14 68753593 C T 0.00000239 Primary biliary cirrhosis (anti-mitochondrial antibody positive) RAD51B intron 22936693 rs911263 chr14 68753593 C T 0.00000343 Primary biliary cirrhosis RAD51B intron 22936693 rs911263 chr14 68753593 C T 0.0000991 Primary biliary cirrhosis in females RAD51B intron 22936693 rs911263 chr14 68753593 C T 9.95E-11 Primary biliary cirrhosis RAD51B intron 22961000 rs911263 chr14 68753593 C T 0.00000228 Rheumatoid arthritis (CCP positive) RAD51B intron 23143596 rs911263 chr14 68753593 C T 0.000459 Rheumatoid arthritis RAD51B intron 23143596 rs1950897 chr14 68760141 C T 1.10E-04 Rheumatoid arthritis RAD51B intron 24390342 rs1950897 chr14 68760141 C T 5.00E-08 Rheumatoid arthritis RAD51B intron 24390342 rs1950897 chr14 68760141 C T 8.00E-11 Rheumatoid arthritis RAD51B intron 24390342 rs911256 chr14 68773580 G C 4.43E-04 IgE levels RAD51B intron 17255346 rs8017304 chr14 68785077 G A 9.00E-11 Age-related macular degeneration RAD51B intron 23455636 rs1956529 chr14 68788924 C T 3.00E-08 Primary tooth development (number of teeth) RAD51B intron 20195514 rs1956529 chr14 68788924 C T 3.61E-05 Permanent tooth development RAD51B intron 21931568 rs1956529 chr14 68788924 C T 6.40E-07 Primary tooth development (number of teeth) RAD51B intron 23704328 rs1570106 chr14 68813115 T C 8.00E-09 Height RAD51B intron 20881960 rs1570106 chr14 68813115 T C 9.17E-04 Permanent tooth development RAD51B intron 21931568 rs2877461 chr14 68837882 A C 3.67E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) RAD51B intron 24023788 rs3784115 chr14 68846822 A G 4.87E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) RAD51B intron 24023788 rs4899241 chr14 68864311 T C 9.46E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) RAD51B intron 24236485 rs4902580 chr14 68887568 A G 2.38E-04 Multiple complex diseases RAD51B intron 17554300 rs2025010 chr14 68919143 G A 6.29E-04 Type 2 diabetes RAD51B intron 17463246 rs3784131 chr14 68962504 T G 3.09E-04 Multiple complex diseases RAD51B intron 17554300 rs765899 chr14 68963746 C T 2.00E-06 Breast cancer RAD51B intron 23468962 rs757369 chr14 68973546 A G 2.83E-05 F-cell distribution RAD51B intron 21326311 rs11624164 chr14 68986157 C T 5.00E-06 Obesity-related traits RAD51B intron 23251661 rs10134446 chr14 68997635 G A 4.32E-05 Cognitive impairment induced by topiramate RAD51B intron 22091778 rs2189517 chr14 69002988 A G 4.32E-05 Cognitive impairment induced by topiramate RAD51B intron 22091778 rs11158750 chr14 69006755 T C 5.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RAD51B intron 20877124 rs999737 chr14 69034682 C T 2.00E-07 Breast cancer RAD51B intron 19330030 rs999737 chr14 69034682 C T 2.00E-07 Nasopharyngeal carcinoma RAD51B intron 20512145 rs999737 chr14 69034682 C T 3.00E-19 Breast cancer RAD51B intron 23535729 rs6573842 chr14 69037937 T C 7.80E-04 Multiple complex diseases RAD51B intron 17554300 rs2253168 chr14 69050465 A G 2.80E-04 Major depressive disorder RAD51B intron 21042317 rs2256639 chr14 69056174 G A 3.36E-04 Multiple complex diseases RAD51B intron 17554300 rs12896969 chr14 69073392 C T 5.75E-05 Prion diseases / / 22210626 rs4902610 chr14 69073826 C T 4.43E-05 Major depressive disorder / / 21621269 rs4902610 chr14 69073826 C T 2.99E-05 Major depressive disorder / / pha002850 rs2331780 chr14 69085713 G A 1.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2331780 chr14 69085713 G A 2.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12890882 chr14 69100618 C T 6.91E-05 Tuberculosis / / 20694014 rs8006890 chr14 69123935 G A 1.00E-04 Information processing speed / / 21130836 rs7141529 chr14 69126744 T C 3.00E-10 Prostate cancer / / 23535732 rs17835218 chr14 69131962 C T 1.00E-04 Information processing speed / / 21130836 rs4899251 chr14 69149814 C T 3.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1274762 chr14 69155627 G A 7.73E-04 Endometrial cancer / / 24096698 rs1007840 chr14 69156100 T C 3.68E-04 Type 2 diabetes / / 17463246 rs11624401 chr14 69159748 C T 8.66E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1274757 chr14 69160487 G A 4.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17106154 chr14 69161174 T C 1.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12437105 chr14 69161331 G A 2.29E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2180957 chr14 69168821 C T 7.44E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs8019389 chr14 69201190 G T 1.96E-05 Alcohol and nictotine co-dependence / / 20158304 rs4902642 chr14 69210199 G A 2.00E-10 Crohn's disease / / 21102463 rs4902642 chr14 69210199 G A 8.07E-04 Acute lung injury / / 22295056 rs4902642 chr14 69210199 G A 8.54E-04 Iron levels / / pha002876 rs451066 chr14 69225685 G A 0.00000109 Joint damage severity in rheumatoid arthritis / / 23696630 rs11629182 chr14 69226816 G A 2.44E-05 AIDS / / 19754311 rs11629182 chr14 69226816 G A 7.97E-04 Acute lung injury / / 22295056 rs201190673 chr14 69226816 GC G 2.44E-05 AIDS / / 19754311 rs201190673 chr14 69226816 GC G 7.97E-04 Acute lung injury / / 22295056 rs189866 chr14 69227099 C G 0.00000109 Joint damage severity in rheumatoid arthritis / / 23696630 rs11626077 chr14 69227332 T C 7.04E-04 Acute lung injury / / 22295056 rs12434551 chr14 69253364 A T 1.59E-08 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs12434551 chr14 69253364 A T 3.84E-08 Oligoarticular juvenile idiopathic arthritis / / 23603761 rs4902647 chr14 69254191 C T 8.78E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4902647 chr14 69254191 C T 9.00E-12 Multiple sclerosis / / 21833088 rs4902647 chr14 69254191 C T 2.20E-04 Multiple sclerosis / / 24234648 rs927292 chr14 69258841 C G 6.78E-07 Type 1 diabetes ZFP36L1 intron 21980299 rs11851414 chr14 69259502 T C 4.70E-08 Celiac disease ZFP36L1 intron 22057235 rs3825568 chr14 69260588 C T 1.24E-08 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) ZFP36L1 UTR-5 23603761 rs1465788 chr14 69263599 T C 3.67E-04 Multiple complex diseases / / 17554300 rs1465788 chr14 69263599 T C 2.00E-12 Type 1 diabetes / / 19430480 rs1465788 chr14 69263599 T C 1.80E-12 Multiple sclerosis / / 22190364 rs194749 chr14 69273905 T C 3.00E-10 Inflammatory bowel disease / / 23128233 rs4899260 chr14 69278204 C T 4.00E-07 Celiac disease / / 20190752 rs434943 chr14 69314059 G A 1.00E-08 Fibrinogen / / 23969696 rs57418859 chr14 69316515 A G 0.00000043 Joint damage severity in rheumatoid arthritis / / 23696630 rs1561193 chr14 69318251 G A 2.49E-06 Lipid traits / / 21777205 rs194722 chr14 69320947 G T 8.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs181455 chr14 69340569 T G 3.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ACTN1 nearGene-3 20877124 rs181484 chr14 69358174 C T 2.58E-04 Suicide attempts in bipolar disorder ACTN1 intron 21423239 rs12050161 chr14 69360631 T C 6.26E-04 Suicide attempts in bipolar disorder ACTN1 intron 21423239 rs12050161 chr14 69360631 T C 4.00E-06 Periodontitis (Mean PAL) ACTN1 intron 24024966 rs761900 chr14 69365255 C T 8.06E-05 Coronary heart disease ACTN1 intron pha003032 rs743128 chr14 69376658 A C 8.89E-05 Coronary heart disease ACTN1 intron pha003032 rs3784137 chr14 69388765 G T 5.96E-04 Suicide attempts in bipolar disorder ACTN1 intron 21423239 rs4899272 chr14 69392264 T G 7.99E-05 Coronary heart disease ACTN1 intron pha003032 rs10136833 chr14 69401094 T C 4.93E-04 Response to cytadine analogues (cytosine arabinoside) ACTN1 intron 24483146 rs2300877 chr14 69405840 G T 8.47E-04 Alcohol consumption (maxi-drinks) ACTN1 intron 24277619 rs2268983 chr14 69408697 G A 7.00E-06 Smoking behavior ACTN1 intron 19247474 rs2268977 chr14 69418425 G A 6.46E-04 Multiple complex diseases ACTN1 intron 17554300 rs7146225 chr14 69421378 A G 4.23E-05 Brain structure ACTN1 intron 22504417 rs2268974 chr14 69423164 A G 5.50E-04 Alcohol consumption (maxi-drinks) ACTN1 intron 24277619 rs2268973 chr14 69424022 C T 2.46E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ACTN1 intron 20877124 rs4902681 chr14 69426617 C T 5.20E-05 Coronary heart disease ACTN1 intron pha003032 rs1007407 chr14 69446960 T C 2.10E-05 Coronary heart disease ACTN1 nearGene-5 pha003056 rs242100 chr14 69470433 G A 3.52E-04 Alzheimer's disease / / 24755620 rs242091 chr14 69475189 T C 7.42E-04 Alzheimer's disease / / 24755620 rs1950712 chr14 69480564 A G 1.79E-04 Parkinson's disease / / 17052657 rs1275207 chr14 69491083 G T 1.08E-04 Height / / 17255346 rs8008735 chr14 69604244 A C 8.66E-04 Amyotrophic lateral sclerosis (sporadic) DCAF5 intron 24529757 rs1275419 chr14 69619173 A C 9.77E-05 Coronary heart disease DCAF5 intron pha003031 rs4243633 chr14 69701863 C A 9.31E-04 Myopia (pathological) EXD2 intron 21095009 rs4902704 chr14 69703588 G C 1.63E-04 Bulimia nervosa EXD2 intron 23568457 rs8007859 chr14 69704553 G T 6.29E-04 Height EXD2 missense 17255346 rs11620883 chr14 69721780 C T 5.12E-05 Parkinson's disease / / 17052657 rs2331957 chr14 69733985 C T 3.14E-04 Alzheimer's disease GALNTL1 intron 24755620 rs7493080 chr14 69738079 G A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes GALNTL1 intron 22628534 rs11623840 chr14 69748866 G A 9.80E-06 Tunica Media GALNTL1 intron pha003036 rs4902710 chr14 69752603 C T 3.09E-04 Alzheimer's disease GALNTL1 intron 24755620 rs7143324 chr14 69755470 A G 4.01E-04 Lung function (forced expiratory volume in 1 second) GALNTL1 intron 24023788 rs1890942 chr14 69765644 A G 4.72E-04 Alzheimer's disease GALNTL1 intron 24755620 rs8008878 chr14 69768016 A C 3.11E-04 Alzheimer's disease GALNTL1 intron 24755620 rs4902713 chr14 69770939 C T 2.95E-04 Suicide attempts in bipolar disorder GALNTL1 intron 21423239 rs8017671 chr14 69771213 T G 5.02E-04 Suicide attempts in bipolar disorder GALNTL1 intron 21423239 rs10146252 chr14 69774008 C G 9.11E-04 Suicide attempts in bipolar disorder GALNTL1 intron 21423239 rs897325 chr14 69777216 A G 4.15E-04 Alzheimer's disease GALNTL1 intron 24755620 rs897327 chr14 69779227 A G 5.98E-04 Alzheimer's disease GALNTL1 intron 24755620 rs897327 chr14 69779227 A G 8.04E-05 Height GALNTL1 intron pha003010 rs877266 chr14 69779461 A G 7.45E-05 Cognitive performance GALNTL1 intron 19734545 rs1147474 chr14 69781395 G A 6.02E-04 Type 2 diabetes GALNTL1 intron 17463246 rs1016692 chr14 69788903 A G 1.17E-05 Height GALNTL1 intron pha003010 rs3902951 chr14 69789755 T G 0.0000825 post-traumatic stress disorder GALNTL1 intron 22869035 rs3902951 chr14 69789755 T G 8.25E-05 Schizophrenia GALNTL1 intron 22883433 rs3742902 chr14 69815882 G A 5.08E-04 Multiple complex diseases GALNTL1 intron 17554300 rs1275691 chr14 69816344 G A 2.58E-05 Pulmonary function GALNTL1 intron 20010835 rs12884802 chr14 69826159 G A 9.61E-06 Bipolar disorder,affective / / 20528957 rs8007612 chr14 69830974 A G 3.74E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7144886 chr14 69831037 A G 1 Drug response to Etoposide / / 17537913 rs12385913 chr14 69866838 G A 5.99E-07 Red blood cell traits SLC39A9 intron 23222517 rs12884741 chr14 69870944 A G 5.37E-06 Height SLC39A9 intron pha003011 rs17106979 chr14 69878330 T A 7.73E-07 Red blood cell traits SLC39A9 intron 23222517 rs1045301 chr14 69928307 G T 3.94E-05 Depression (quantitative trait) SLC39A9 UTR-3 23290196 rs7156420 chr14 69942127 A G 7.18E-04 Parkinson's disease / / 16252231 rs8013985 chr14 69948858 G A 3.91E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12050204 chr14 69954376 G T 3.81E-05 Depression (quantitative trait) PLEKHD1 intron 23290196 rs17764280 chr14 69971598 T C 8.73E-05 Elbow pain PLEKHD1 intron pha003008 rs2756966 chr14 69984560 G A 6.24E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) PLEKHD1 intron 23648065 rs2756966 chr14 69984560 G A 5.20E-04 Myocardial Infarction PLEKHD1 intron pha002883 rs4899298 chr14 69985498 G A 8.61E-04 Myocardial Infarction PLEKHD1 intron pha002883 rs17107061 chr14 69997059 T G 9.35E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs6573893 chr14 70047167 C T 3.71E-04 IgA nephropathy / / 22197929 rs2332094 chr14 70069672 A G 6.64E-05 HIV-1 control / / 20041166 rs2152373 chr14 70146993 C T 1.78E-04 Cholesterol KIAA0247 intron 17255346 rs2184599 chr14 70151933 G A 1.44E-04 Multiple complex diseases KIAA0247 intron 17554300 rs1999722 chr14 70156668 A C 6.78E-05 HIV-1 control KIAA0247 intron 20041166 rs11629054 chr14 70206417 A G 8.84E-04 Multiple complex diseases / / 17554300 rs55987626 chr14 70206808 G A 4.44E-05 Intracerebral hemorrhage / / 24656865 rs11625932 chr14 70219842 T C 3.13E-05 Intracerebral hemorrhage / / 24656865 rs11625731 chr14 70221010 G A 4.59E-05 Intracerebral hemorrhage / / 24656865 rs56074637 chr14 70222722 C G 3.23E-05 Intracerebral hemorrhage / / 24656865 rs1953399 chr14 70223570 G T 7.55E-04 Type 2 diabetes / / 17463246 rs1953399 chr14 70223570 G T 3.17E-05 Intracerebral hemorrhage / / 24656865 rs57492222 chr14 70223987 G A 3.16E-05 Intracerebral hemorrhage / / 24656865 rs72725724 chr14 70226387 C T 3.24E-05 Intracerebral hemorrhage / / 24656865 rs7153985 chr14 70226487 T C 7.00E-04 Type 2 diabetes / / 17463246 rs7153985 chr14 70226487 T C 9.66E-04 Multiple complex diseases / / 17554300 rs7153985 chr14 70226487 T C 3.92E-05 Intracerebral hemorrhage / / 24656865 rs4899313 chr14 70230771 G A 3.58E-05 Intracerebral hemorrhage / / 24656865 rs3809399 chr14 70233632 C T 3.21E-05 Intracerebral hemorrhage / / 24656865 rs55724465 chr14 70246412 G A 3.29E-05 Intracerebral hemorrhage SLC10A1 intron 24656865 rs28437822 chr14 70246718 A G 3.30E-05 Intracerebral hemorrhage SLC10A1 intron 24656865 rs72725740 chr14 70252100 A G 3.57E-05 Intracerebral hemorrhage SLC10A1 intron 24656865 rs11621916 chr14 70255617 A G 3.79E-05 Intracerebral hemorrhage SLC10A1 intron 24656865 rs58582364 chr14 70256407 G T 3.73E-05 Intracerebral hemorrhage SLC10A1 intron 24656865 rs72725743 chr14 70257099 T G 3.74E-05 Intracerebral hemorrhage SLC10A1 intron 24656865 rs11624532 chr14 70257661 C T 3.84E-05 Intracerebral hemorrhage SLC10A1 intron 24656865 rs72725745 chr14 70258001 G A 3.76E-05 Intracerebral hemorrhage SLC10A1 intron 24656865 rs11622925 chr14 70261665 C T 3.85E-05 Intracerebral hemorrhage SLC10A1 intron 24656865 rs4646285 chr14 70263648 C T 3.86E-05 Intracerebral hemorrhage SLC10A1 cds-synon 24656865 rs61356864 chr14 70266371 G A 3.94E-05 Intracerebral hemorrhage / / 24656865 rs10162497 chr14 70334308 G A 8.33E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs2332172 chr14 70338918 T G 3.25E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs11158820 chr14 70347348 A G 1.30E-06 Digit length ratio SMOC1 intron 20303062 rs11158820 chr14 70347348 A G 8.10E-05 Pericardial fat SMOC1 intron 22589742 rs11158820 chr14 70347348 A G 2.00E-11 Digit length ratio SMOC1 intron 23263445 rs11621436 chr14 70355319 C T 3.30E-06 Digit length ratio SMOC1 intron 20303062 rs10782458 chr14 70359772 C T 6.44E-08 Red blood cell traits SMOC1 intron 23222517 rs1952202 chr14 70362074 A G 8.19E-08 Red blood cell traits SMOC1 intron 23222517 rs4899321 chr14 70362148 A G 8.23E-07 Red blood cell traits SMOC1 intron 23222517 rs11627546 chr14 70365924 A C 1.00E-09 Red blood cell traits SMOC1 intron 23222517 rs4902765 chr14 70368337 G A 5.30E-07 Red blood cell traits SMOC1 intron 23222517 rs1275849 chr14 70371202 A G 3.21E-07 Red blood cell traits SMOC1 intron 23222517 rs1275847 chr14 70371703 G T 2.67E-07 Red blood cell traits SMOC1 intron 23222517 rs1275844 chr14 70372474 A C 8.05E-07 Red blood cell traits SMOC1 intron 23222517 rs7145070 chr14 70376850 T C 2.63E-04 Response to cytadine analogues (cytosine arabinoside) SMOC1 intron 24483146 rs6573919 chr14 70422682 G A 4.02E-04 Taste perception SMOC1 intron 22132133 rs227446 chr14 70440210 G C 9.90E-05 Pancreatic cancer SMOC1 intron pha002889 rs227425 chr14 70456699 T G 1.00E-06 Bone mineral density SMOC1 intron 24249740 rs227425 chr14 70456699 T G 1.63E-04 Bone mineral density SMOC1 intron 24249740 rs227425 chr14 70456699 T G 2.00E-06 Bone mineral density SMOC1 intron 24249740 rs227425 chr14 70456699 T G 4.00E-07 Bone mineral density SMOC1 intron 24249740 rs227425 chr14 70456699 T G 4.00E-13 Bone mineral density SMOC1 intron 24249740 rs61305 chr14 70460031 G A 6.97E-05 Post-operative nausea and vomiting SMOC1 intron 21694509 rs227416 chr14 70460609 T G 1.00E-05 Smoking behavior SMOC1 intron 20418888 rs17107578 chr14 70463247 C A 5.99E-04 Multiple complex diseases SMOC1 intron 17554300 rs1459705 chr14 70464703 T C 2.84E-04 Fibrinogen SMOC1 intron 17255346 rs17107592 chr14 70467365 A T 4.40E-05 Coffee consumption SMOC1 intron 21357676 rs3825739 chr14 70477508 C T 1.04E-05 Erythrocyte counts SMOC1 cds-synon pha003101 rs11626232 chr14 70487396 C T 4.82E-06 Personality dimensions SMOC1 intron 18957941 rs11626232 chr14 70487396 C T 4.80E-06 Personality dimensions SMOC1 intron 21173776 rs7155538 chr14 70493965 C T 3.49E-04 Parkinson's disease SMOC1 intron 17052657 rs7155538 chr14 70493965 C T 1.44E-04 Response to cytadine analogues (cytosine arabinoside) SMOC1 intron 24483146 rs227402 chr14 70496867 C T 6.69E-05 Personality dimensions SMOC1 intron 18957941 rs17175227 chr14 70502050 G A 2.82E-04 Coronary Artery Disease / / 17634449 rs17175227 chr14 70502050 G A 9.00E-09 Tuberculosis / / 24057671 rs17764944 chr14 70503702 G A 5.72E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1380429 chr14 70505022 T G 1.73E-05 Serum metabolites / / 19043545 rs1156445 chr14 70505529 C G 1.66E-04 Type 2 diabetes / / 17463246 rs12883884 chr14 70517183 T G 8.00E-06 Cystic fibrosis severity SLC8A3 intron 21602797 rs2839867 chr14 70521570 A C 7.24E-05 Serum metabolites SLC8A3 intron 19043545 rs1000521 chr14 70522484 A G 8.61E-04 Parkinson's disease SLC8A3 intron 17052657 rs11627233 chr14 70523905 A G 5.97E-05 Response to cytadine analogues (cytosine arabinoside) SLC8A3 intron 24483146 rs7141091 chr14 70525531 G A 7.77E-04 Smoking initiation SLC8A3 intron 24665060 rs10136340 chr14 70527933 A G 3.01E-04 Iron levels SLC8A3 intron pha002876 rs150950 chr14 70535899 C T 7.33E-06 Post-operative nausea and vomiting SLC8A3 intron 21694509 rs150942 chr14 70542102 G A 9.50E-04 Type 2 diabetes SLC8A3 intron 17463246 rs1035717 chr14 70578699 A G 0.00000636 Alcohol dependence SLC8A3 intron 23691058 rs4902778 chr14 70580236 C T 8.05E-05 Serum metabolites SLC8A3 intron 19043545 rs4902778 chr14 70580236 C T 2.91E-04 Alcohol dependence SLC8A3 intron 21314694 rs913479 chr14 70620246 A G 3.53E-04 Lung function (forced vital capacity) SLC8A3 intron 24023788 rs4899329 chr14 70620642 C A 5.00E-06 IgG glycosylation SLC8A3 intron 23382691 rs17107925 chr14 70640391 T C 1.29E-05 Bilirubin levels,in serum SLC8A3 intron 19389676 rs7146198 chr14 70644169 A C 4.00E-06 Corneal curvature SLC8A3 intron 22969067 rs7144262 chr14 70647108 T C 5.37E-06 Corneal curvature SLC8A3 intron 22969067 rs1999052 chr14 70647191 A G 6.24E-06 Corneal curvature SLC8A3 intron 22969067 rs41525145 chr14 70649735 G A 4.56E-04 Type 2 diabetes SLC8A3 intron 17463246 rs17093693 chr14 70649792 T G 6.33E-06 Corneal curvature SLC8A3 intron 22969067 rs17107951 chr14 70651194 T C 1.50E-05 Urinary metabolites SLC8A3 intron 21572414 rs17765625 chr14 70651613 G A 4.58E-04 Type 2 diabetes SLC8A3 intron 17463246 rs17765625 chr14 70651613 G A 1.50E-05 Urinary metabolites SLC8A3 intron 21572414 rs17765625 chr14 70651613 G A 1.76E-04 Coronary heart disease SLC8A3 intron 21606135 rs10137139 chr14 70721260 A T 5.81E-04 Multiple complex diseases / / 17554300 rs1015585 chr14 70744563 T C 7.14E-04 Parkinson's disease / / 17052657 rs7150152 chr14 70744976 C A 8.02E-04 Bipolar disorder / / 19259986 rs12889575 chr14 70754507 G A 8.00E-05 Insulin Resistance / / pha003062 rs2877626 chr14 70754807 A G 6.17E-04 Alcohol dependence / / 21314694 rs11158850 chr14 70757172 C A 6.50E-04 Alzheimer's disease / / 17998437 rs2332422 chr14 70805268 T C 2.30E-04 Alzheimer's disease COX16 intron 17998437 rs10142102 chr14 70805624 G A 7.82E-04 Multiple complex diseases COX16 intron 17554300 rs7149261 chr14 70875513 G T 2.66E-05 Hepatocellular carcinoma SYNJ2BP intron 22807686 rs10143078 chr14 70881489 A C 6.00E-07 Blood pressure SYNJ2BP intron 24954895 rs4143920 chr14 70924072 A G 0.00082 Prostate cancer ADAM21 UTR-5 22367438 rs2293877 chr14 70935875 A G 4.55E-05 Prostate cancer / / pha002878 rs12590471 chr14 71001100 G A 6.50E-06 Multiple complex diseases ADAM20 intron 17554300 rs4902833 chr14 71104081 C G 3.63E-04 Coronary Artery Disease / / 17634449 rs11626181 chr14 71119672 G C 1.11E-05 Coronary Artery Disease TTC9 intron 17634449 rs10139234 chr14 71123560 G A 2.51E-04 Suicide attempts in bipolar disorder TTC9 intron 21423239 rs10139234 chr14 71123560 G A 6.47E-04 Response to cytadine analogues (cytosine arabinoside) TTC9 intron 24483146 rs1205235 chr14 71129793 A G 7.98E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TTC9 intron 20877124 rs1205235 chr14 71129793 A G 4.04E-04 Suicide attempts in bipolar disorder TTC9 intron 21423239 rs8688 chr14 71139279 G T 7.16E-05 Triglycerides TTC9 UTR-3 pha002904 rs4899366 chr14 71150421 G A 7.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10148050 chr14 71155984 A G 9.10E-06 Urinary metabolites / / 21572414 rs4902841 chr14 71179711 G A 6.93E-05 Obesity (extreme) / / 21935397 rs8021668 chr14 71188597 T C 9.47E-05 Obesity (extreme) / / 21935397 rs3742848 chr14 71191423 C T 9.66E-05 Obesity (extreme) / / 21935397 rs7156271 chr14 71193303 A G 7.07E-05 Obesity (extreme) / / 21935397 rs17108442 chr14 71193416 C T 4.50E-05 Iron levels / / 21208937 rs11844774 chr14 71198551 C T 1.12E-04 Obesity (extreme) MAP3K9 intron 21935397 rs3829955 chr14 71199452 G A 1.30E-04 Acute lung injury MAP3K9 cds-synon 22295056 rs17108454 chr14 71201451 A C 1.32E-04 Acute lung injury MAP3K9 intron 22295056 rs7153601 chr14 71204973 C T 1.04E-04 Acute lung injury MAP3K9 cds-synon 22295056 rs4902843 chr14 71209025 C A 1.90E-05 Tooth agenesis (mandibular third molar) MAP3K9 intron 24172245 rs2158530 chr14 71246995 T C 1.60E-05 Tooth agenesis (mandibular third molar) MAP3K9 intron 24172245 rs10141804 chr14 71249230 C T 1.60E-05 Tooth agenesis (mandibular third molar) MAP3K9 intron 24172245 rs17108533 chr14 71249802 C T 1.00E-06 Response to antipsychotic treatment in schizophrenia (reasoning) MAP3K9 intron 21107309 rs17108533 chr14 71249802 C T 9.34E-05 Acute lung injury MAP3K9 intron 22295056 rs17108540 chr14 71255496 G C 8.59E-04 Suicide attempts in bipolar disorder MAP3K9 intron 21423239 rs17108540 chr14 71255496 G C 1.21E-04 Acute lung injury MAP3K9 intron 22295056 rs12883168 chr14 71260563 G A 1.31E-04 Acute lung injury MAP3K9 intron 22295056 rs7157405 chr14 71290125 C T 8.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs979536 chr14 71309483 A G 3.77E-05 Osteoarthritis / / 19508968 rs1990037 chr14 71314581 C A 4.95E-05 Osteoarthritis / / 19508968 rs12882533 chr14 71316914 C T 8.77E-04 Acute lung injury / / 22295056 rs4899377 chr14 71317212 G A 1.60E-05 Tooth agenesis (mandibular third molar) / / 24172245 rs12879624 chr14 71319317 T C 1.70E-05 Tooth agenesis (mandibular third molar) / / 24172245 rs12893709 chr14 71348847 C T 2.50E-05 Urinary metabolites / / 21572414 rs17108669 chr14 71352498 T A 9.30E-04 Multiple complex diseases / / 17554300 rs36563 chr14 71352648 T G 5.00E-06 Alcohol dependence / / 19581569 rs36556 chr14 71356175 C T 9.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs40356 chr14 71357624 C G 4.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs714421 chr14 71359585 T C 3.41E-05 Type 2 diabetes / / 17463246 rs2189807 chr14 71363031 G A 3.29E-04 Type 2 diabetes / / 17463246 rs2189807 chr14 71363031 G A 1.14E-04 Cognitive decline / / 23732972 rs2810077 chr14 71363814 A G 1.27E-05 Type 2 diabetes / / 17463246 rs2810073 chr14 71383848 T C 9.79E-04 Type 2 diabetes PCNX intron 17463246 rs2810073 chr14 71383848 T C 5.77E-05 Cognitive decline PCNX intron 23732972 rs2810114 chr14 71395604 C A 4.00E-06 Alcohol dependence PCNX intron 22004471 rs917066 chr14 71397183 C T 5.69E-04 Aortic root size PCNX intron 21223598 rs2526856 chr14 71412717 C T 4.38E-05 Type 2 diabetes PCNX intron 17463246 rs2810104 chr14 71424813 A G 2.30E-05 Lymphocyte counts PCNX intron 22286170 rs2810098 chr14 71433911 A G 8.34E-04 Type 2 diabetes PCNX intron 17463246 rs2810098 chr14 71433911 A G 5.69E-05 Cognitive decline PCNX intron 23732972 rs17108804 chr14 71441524 C T 1.95E-04 Cognitive decline PCNX intron 23732972 rs4366661 chr14 71452316 A T 3.80E-05 Type 2 diabetes PCNX intron 17463246 rs8007026 chr14 71464384 G C 1.03E-04 Cognitive decline PCNX intron 23732972 rs12100737 chr14 71471100 G A 5.42E-04 Type 2 diabetes PCNX intron 17463246 rs17108910 chr14 71497699 A G 5.10E-04 Multiple complex diseases PCNX intron 17554300 rs2158997 chr14 71497794 G C 4.25E-04 Type 2 diabetes PCNX intron 17463246 rs2158997 chr14 71497794 G C 1.12E-04 Cognitive decline PCNX intron 23732972 rs4467005 chr14 71498656 C T 2.28E-05 Type 2 diabetes PCNX intron 17463246 rs11848070 chr14 71507601 G A 6.00E-06 Alzheimer's disease (late onset) PCNX intron 22881374 rs7152845 chr14 71527223 A G 4.74E-04 Smoking initiation PCNX intron 24665060 rs2240533 chr14 71541026 T C 1.01E-04 Amyotrophic lateral sclerosis PCNX intron 23624525 rs221917 chr14 71590003 C T 4.37E-05 Type 2 diabetes / / 17463246 rs221906 chr14 71597393 C G 1.64E-04 Type 2 diabetes / / 17463246 rs221903 chr14 71600208 T C 2.40E-04 Response to diuretic therapy in hypertension / / 23753411 rs11846003 chr14 71602085 T A 5.95E-04 Multiple complex diseases / / 17554300 rs221901 chr14 71602226 C T 2.87E-05 Type 2 diabetes / / 17463246 rs221900 chr14 71604354 T C 6.96E-07 Type 2 diabetes / / 17463246 rs221899 chr14 71605268 A G 8.27E-05 Type 2 diabetes / / 17463246 rs221899 chr14 71605268 A G 5.69E-05 Cognitive decline / / 23732972 rs221898 chr14 71605516 C T 1.81E-06 Type 2 diabetes / / 17463246 rs1012725 chr14 71605711 A G 9.38E-04 Type 2 diabetes / / 17463246 rs17109069 chr14 71615357 T C 2.18E-04 Alzheimer's disease / / 17998437 rs12431920 chr14 71647132 G A 6.70E-05 Lung adenocarcinoma / / 22797724 rs11623881 chr14 71649124 C T 1.17E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs6574008 chr14 71652891 C G 4.51E-05 Serum alpha1-antitrypsin levels / / 23990791 rs10145569 chr14 71653170 T A 4.03E-05 Serum alpha1-antitrypsin levels / / 23990791 rs8016108 chr14 71654121 C T 5.02E-04 Alcohol dependence / / 20201924 rs17767225 chr14 71666297 C T 8.00E-06 Alzheimer's disease (late onset) / / 22881374 rs17109147 chr14 71675402 C T 9.37E-04 Type 2 diabetes / / 17463246 rs1476611 chr14 71696037 C A 3.18E-04 Insulin resistance C14orf56 intron 21901158 rs1000448 chr14 71707633 G A 2.77E-04 Cognitive decline C14orf56 intron 23732972 rs17109189 chr14 71709355 C A 1.53E-04 Cognitive decline C14orf56 intron 23732972 rs2190863 chr14 71712343 T C 9.17E-05 Blood Pressure C14orf56 intron pha003049 rs976044 chr14 71716231 C T 4.06E-05 Asthma C14orf56 intron pha003128 rs11158904 chr14 71735151 A C 4.14E-04 Smoking cessation C14orf56 intron 24665060 rs11623996 chr14 71737314 A G 5.55E-05 Osteoarthritis C14orf56 intron 19508968 rs11623996 chr14 71737314 A G 3.66E-04 Smoking cessation C14orf56 intron 24665060 rs17178045 chr14 71756358 A G 6.79E-04 Suicide attempts in bipolar disorder C14orf56 intron 21423239 rs7140354 chr14 71759616 C A 7.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs17767392 chr14 71764777 C T 6.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs723966 chr14 71765910 A G 5.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs17767398 chr14 71770485 C G 8.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs8007068 chr14 71770710 T A 8.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs17767410 chr14 71771967 C G,T 5.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs1990241 chr14 71774052 T G 5.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs2108707 chr14 71791170 G C 7.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs2108706 chr14 71799175 T G 6.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs370369893 chr14 71799175 T TAG 6.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs7147434 chr14 71811526 G T 7.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs8015579 chr14 71812414 G A 5.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs17767446 chr14 71820963 G A 4.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs12894478 chr14 71825113 T C 4.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs41220 chr14 71837479 A C 9.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs8015644 chr14 71842729 C T 7.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs7152842 chr14 71849740 A G 2.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs41216 chr14 71851912 C T 1.47E-04 Osteoarthritis / / 19508968 rs7156460 chr14 71855334 A T 4.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs12878989 chr14 71856184 G A 4.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs4902931 chr14 71858514 A G 7.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs17767499 chr14 71867275 T C 7.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs17178192 chr14 71875909 A G 3.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs725673 chr14 71878468 A C 5.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs17178206 chr14 71880093 A G 5.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs17767523 chr14 71880739 G C 5.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs12880291 chr14 71884567 G T 5.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs12880291 chr14 71884567 G T 2.39E-04 Peripartum cardiomyopathy / / 21665988 rs2877729 chr14 71887868 G A 6.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs2109276 chr14 71889767 G A 6.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs12881957 chr14 71909854 C T 6.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs12881957 chr14 71909854 C T 1.85E-04 Peripartum cardiomyopathy / / 21665988 rs17767553 chr14 71910587 T A 5.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs36533 chr14 71921013 G A 1.80E-05 Response to alcohol consumption (flushing response) / / 24277619 rs12896986 chr14 71922893 T G 6.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs12889866 chr14 71937439 C T 5.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs36529 chr14 71939892 A T 3.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs14030 chr14 71956141 A C 6.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs12127 chr14 71956270 T C 6.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs12896900 chr14 71970625 A G 5.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs11158907 chr14 71987065 A G 9.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs11158907 chr14 71987065 A G 2.00E-06 Response to alcohol consumption (flushing response) / / 24277619 rs17767680 chr14 71997594 G A 6.39E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs17178387 chr14 71997723 A G 5.45E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs17178387 chr14 71997723 A G 2.38E-04 Peripartum cardiomyopathy SIPA1L1 intron 21665988 rs7157241 chr14 72001296 A T 9.13E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs10483836 chr14 72001614 T G 5.20E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs12885344 chr14 72003224 G A 6.23E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs17767686 chr14 72006744 C T 7.90E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs3784066 chr14 72007454 A T 6.00E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs12880188 chr14 72009745 G C 6.27E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs9672060 chr14 72010126 G T 8.15E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs12897977 chr14 72014544 A G 1.00E-05 Response to alcohol consumption (flushing response) SIPA1L1 intron 24277619 rs757850 chr14 72016006 C G 8.85E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs7152674 chr14 72016613 G T 2.80E-04 Peripartum cardiomyopathy SIPA1L1 intron 21665988 rs8013161 chr14 72021499 G A 7.72E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs2108057 chr14 72022750 G A 8.70E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs11628525 chr14 72022891 A G 9.19E-06 Response to alcohol consumption (flushing response) SIPA1L1 intron 24277619 rs7140501 chr14 72023175 C G 7.83E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs7142343 chr14 72023489 T C 7.71E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs2190240 chr14 72024889 T C 9.21E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs2214836 chr14 72025078 G T 6.86E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs2332638 chr14 72028915 A G 4.44E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs12433040 chr14 72030555 G A 7.11E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs10135680 chr14 72030809 G A 7.08E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs9323561 chr14 72031563 A C 7.19E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs1981588 chr14 72039689 G A 7.19E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs6574016 chr14 72040525 G A 7.15E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs7492599 chr14 72041458 A G 6.19E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs1029570 chr14 72043200 A G 9.49E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs2332640 chr14 72044547 C T 9.47E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs2332641 chr14 72044728 T G 6.82E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs8008605 chr14 72045544 C G 5.90E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs8014349 chr14 72046496 C A 5.68E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs7156313 chr14 72052310 G C 5.78E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs3825719 chr14 72053097 G A 5.59E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs11848785 chr14 72057355 G A 1.00E-10 Ventricular conduction SIPA1L1 intron 21076409 rs11848785 chr14 72057355 G A 8.32E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs11848785 chr14 72057355 G A 2.40E-04 Peripartum cardiomyopathy SIPA1L1 intron 21665988 rs3784064 chr14 72059551 G A 8.65E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs3784064 chr14 72059551 G A 2.79E-04 Peripartum cardiomyopathy SIPA1L1 intron 21665988 rs10147863 chr14 72064096 G A 1.53E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs7154841 chr14 72073422 A G 7.42E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs12587301 chr14 72086717 T C 1.50E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs8017465 chr14 72117156 T C 3.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs17096112 chr14 72148047 G A 9.80E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs17096112 chr14 72148047 G A 8.68E-05 HIV-1 viral setpoint SIPA1L1 intron 22174851 rs17096112 chr14 72148047 G A 2.70E-05 Response to alcohol consumption (flushing response) SIPA1L1 intron 24277619 rs4140798 chr14 72162901 A G 3.10E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs17100307 chr14 72184751 G A 3.85E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs11158912 chr14 72188753 A G 1.87E-04 Suicide attempts in bipolar disorder SIPA1L1 intron 21423239 rs11850220 chr14 72192380 C T 2.02E-06 Obesity-related traits SIPA1L1 intron 23251661 rs17100926 chr14 72194401 C T 1.00E-06 Obesity-related traits SIPA1L1 intron 23251661 rs6574018 chr14 72213258 G T 6.70E-06 Urinary metabolites / / 21572414 rs2154409 chr14 72259455 A G 5.43E-04 Type 2 diabetes / / 17463246 rs1343922 chr14 72265949 G A 2.54E-05 Coronary restenosis / / 21878436 rs1205083 chr14 72289633 C T 9.58E-05 Coronary restenosis / / 21878436 rs7151501 chr14 72317837 C T 3.62E-04 Multiple complex diseases / / 17554300 rs36457 chr14 72330874 G A 8.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17768054 chr14 72331609 G A 6.45E-04 Insulin resistance / / 21901158 rs752515 chr14 72333601 A G 7.23E-04 HIV-1 viral setpoint / / 17641165 rs752515 chr14 72333601 A G 4.53E-05 Coronary restenosis / / 21878436 rs8009500 chr14 72334328 G A 1.37E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10138587 chr14 72350212 C T 3.18E-08 CD8+ T cell IFN-gamma response to smallpox vaccine / / 22661280 rs17104354 chr14 72374784 A G 1.22E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs714975 chr14 72416763 C T 6.37E-05 Schizophrenia RGS6 intron 21926974 rs4902960 chr14 72432149 G A 1.00E-06 Economic and political preferences (environmentalism) RGS6 intron 22566634 rs17105032 chr14 72434531 G T 9.18E-04 Response to taxane treatment (placlitaxel) RGS6 intron 23006423 rs2238277 chr14 72434662 G C 6.61E-06 Multiple complex diseases RGS6 intron 17554300 rs4899409 chr14 72438375 G A 4.93E-04 Multiple complex diseases RGS6 intron 17554300 rs3784056 chr14 72449351 A G 2.45E-04 Multiple complex diseases RGS6 intron 17554300 rs17105346 chr14 72452471 C G 5.86E-04 Multiple complex diseases RGS6 intron 17554300 rs2238276 chr14 72456227 C T 3.59E-04 Response to taxane treatment (placlitaxel) RGS6 intron 23006423 rs8012646 chr14 72456511 G A 3.82E-04 Multiple complex diseases RGS6 intron 17554300 rs1860105 chr14 72456913 G A 9.93E-04 Response to taxane treatment (placlitaxel) RGS6 intron 23006423 rs2238275 chr14 72457365 T G 3.45E-04 Response to taxane treatment (placlitaxel) RGS6 intron 23006423 rs2238274 chr14 72458188 G A 8.61E-04 Response to taxane treatment (placlitaxel) RGS6 intron 23006423 rs2238273 chr14 72459258 C T 5.43E-05 Socioeconomic Factors RGS6 intron pha003066 rs11623535 chr14 72462381 G A 2.91E-04 Response to taxane treatment (placlitaxel) RGS6 intron 23006423 rs4354860 chr14 72464107 C T 3.88E-04 Response to taxane treatment (placlitaxel) RGS6 intron 23006423 rs4899412 chr14 72464262 T C 3.88E-04 Response to taxane treatment (placlitaxel) RGS6 intron 23006423 rs11158927 chr14 72466149 G C 4.36E-04 Response to taxane treatment (placlitaxel) RGS6 intron 23006423 rs2332706 chr14 72470077 A G 7.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RGS6 intron 20877124 rs4902972 chr14 72471274 A G 7.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RGS6 intron 20877124 rs12148043 chr14 72472427 G A 8.05E-04 Multiple complex diseases RGS6 intron 17554300 rs6574039 chr14 72491015 T C 3.25E-04 Insulin resistance RGS6 intron 21901158 rs17105918 chr14 72494808 G T 4.59E-04 Multiple complex diseases RGS6 intron 17554300 rs735157 chr14 72496063 C T 2.18E-05 Tourette syndrome RGS6 intron 22889924 rs4899419 chr14 72502596 T C 5.83E-04 Amyotrophic Lateral Sclerosis RGS6 intron 17362836 rs4899419 chr14 72502596 T C 1.58E-04 Tourette syndrome RGS6 intron 22889924 rs11848472 chr14 72507877 T C 7.15E-04 Amyotrophic Lateral Sclerosis RGS6 intron 17362836 rs2332712 chr14 72538193 A G 1.18E-05 Smoking cessation RGS6 intron 18519826 rs2158992 chr14 72555895 T C 5.92E-05 Cognitive performance RGS6 intron 19734545 rs2158992 chr14 72555895 T C 1.21E-04 Response to cytadine analogues (cytosine arabinoside) RGS6 intron 24483146 rs6574046 chr14 72557579 G C 7.84E-04 Response to cytadine analogues (cytosine arabinoside) RGS6 intron 24483146 rs8008342 chr14 72559891 G A 6.60E-04 Response to cytadine analogues (cytosine arabinoside) RGS6 intron 24483146 rs2238256 chr14 72600223 T C 5.20E-04 Insulin response RGS6 intron 19430760 rs17179734 chr14 72601090 A G 1.52E-04 Lung function (forced expiratory volume in 1 second) RGS6 intron 17255346 rs17108294 chr14 72623954 G A 1.68E-04 Smoking cessation RGS6 intron 18519826 rs17108294 chr14 72623954 G A 3.30E-05 Smoking cessation RGS6 intron 18519826 rs17108326 chr14 72628507 A G 0.000019 Tuberculosis with early age of onset RGS6 intron 22551897 rs149670 chr14 72632217 A G 2.22E-04 Response to cytadine analogues (cytosine arabinoside) RGS6 intron 24483146 rs149667 chr14 72635437 A G 2.79E-04 Response to cytadine analogues (cytosine arabinoside) RGS6 intron 24483146 rs149660 chr14 72640190 A G 4.76E-04 Response to cytadine analogues (cytosine arabinoside) RGS6 intron 24483146 rs123241 chr14 72641249 G A 3.00E-04 Response to cytadine analogues (cytosine arabinoside) RGS6 intron 24483146 rs20838 chr14 72644526 A T 2.28E-04 Smoking cessation RGS6 intron 18519826 rs20838 chr14 72644526 A T 5.98E-04 Response to cytadine analogues (cytosine arabinoside) RGS6 intron 24483146 rs2238247 chr14 72657528 A G 5.79E-05 Waist Circumference RGS6 intron pha003025 rs699363 chr14 72692493 G A 5.00E-06 Obesity (extreme) RGS6 intron 21935397 rs847260 chr14 72708057 A C 5.80E-05 Cognitive impairment induced by topiramate RGS6 intron 22091778 rs1356838 chr14 72714281 C T 8.51E-04 Type 2 diabetes RGS6 intron 17463246 rs847235 chr14 72723421 A G 1.61E-04 Type 2 diabetes RGS6 intron 17463246 rs2139594 chr14 72723964 C T 1.92E-04 Type 2 diabetes RGS6 intron 17463246 rs2139594 chr14 72723964 C T 6.16E-04 Multiple complex diseases RGS6 intron 17554300 rs8007922 chr14 72726896 G C 1.31E-04 Type 2 diabetes RGS6 intron 17463246 rs8007922 chr14 72726896 G C 7.20E-04 Multiple complex diseases RGS6 intron 17554300 rs740337 chr14 72731972 C G 5.15E-05 Type 2 diabetes RGS6 intron 17463246 rs740337 chr14 72731972 C G 8.63E-04 Multiple complex diseases RGS6 intron 17554300 rs1076317 chr14 72732318 C G 3.04E-04 Type 2 diabetes RGS6 intron 17463246 rs1076317 chr14 72732318 C G 1.05E-06 Smoking cessation RGS6 intron 18519826 rs2239260 chr14 72734342 G A 1.00E-04 Cognitive impairment induced by topiramate RGS6 intron 22091778 rs2239257 chr14 72735003 T C 9.78E-05 Cognitive impairment induced by topiramate RGS6 intron 22091778 rs9323567 chr14 72735347 C T 4.17E-06 Glaucoma (primary open-angle) RGS6 intron 22605921 rs847342 chr14 72736038 G A 1.30E-05 Volumetric brain MRI RGS6 intron 17903297 rs1568404 chr14 72736969 C T 6.69E-04 Type 2 diabetes RGS6 intron 17463246 rs1568404 chr14 72736969 C T 6.76E-04 Multiple complex diseases RGS6 intron 17554300 rs1568404 chr14 72736969 C T 5.11E-05 Smoking cessation RGS6 intron 18519826 rs7144038 chr14 72740856 C G 3.70E-04 Type 2 diabetes RGS6 intron 17463246 rs7144185 chr14 72740895 C T 6.47E-04 Type 2 diabetes RGS6 intron 17463246 rs7152907 chr14 72745114 T C 5.51E-04 Type 2 diabetes RGS6 intron 17463246 rs12184980 chr14 72745259 G A 5.83E-04 Type 2 diabetes RGS6 intron 17463246 rs12184980 chr14 72745259 G A 1.27E-04 Smoking cessation RGS6 intron 18519826 rs2079500 chr14 72745815 A C 5.83E-04 Type 2 diabetes RGS6 intron 17463246 rs737499 chr14 72746118 T C 5.81E-04 Type 2 diabetes RGS6 intron 17463246 rs737498 chr14 72746493 A G 6.02E-04 Type 2 diabetes RGS6 intron 17463246 rs847362 chr14 72768879 G A 8.46E-05 Type 2 diabetes RGS6 intron 17463246 rs7147236 chr14 72788246 G A 5.00E-04 Adiposity RGS6 intron 19461586 rs2239249 chr14 72797361 C G 2.52E-04 Multiple complex diseases RGS6 intron 17554300 rs2238199 chr14 72799003 C A 5.33E-04 Multiple complex diseases RGS6 intron 17554300 rs765221 chr14 72801060 C T 6.97E-04 Type 2 diabetes RGS6 intron 17463246 rs2239247 chr14 72802236 G A 1.20E-04 Adiposity RGS6 intron 19461586 rs2283391 chr14 72802433 T C 1.39E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs1520332 chr14 72802666 G A 1.87E-04 Multiple complex diseases RGS6 intron 17554300 rs1520332 chr14 72802666 G A 4.46E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs1520331 chr14 72802736 T C 1.77E-04 Multiple complex diseases RGS6 intron 17554300 rs1520331 chr14 72802736 T C 4.89E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2283390 chr14 72803482 C A 4.73E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs1915132 chr14 72805490 T C 1.92E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2681771 chr14 72806117 C A 2.18E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2239243 chr14 72806264 G A 2.66E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2239241 chr14 72807042 G A 1.93E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2681769 chr14 72807278 T C 2.00E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2681768 chr14 72807405 C T 2.00E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs7155750 chr14 72807520 C G 1.90E-05 Urinary metabolites RGS6 intron 21572414 rs2079506 chr14 72807559 A G 1.67E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2681767 chr14 72807622 G A 1.64E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2079505 chr14 72807663 A G 2.00E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2079504 chr14 72807682 C T 1.95E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs8019358 chr14 72807815 T A 2.00E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs8003559 chr14 72808083 T C 1.96E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs8022956 chr14 72808138 G A 1.96E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs8003591 chr14 72808157 T C 1.96E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs8022859 chr14 72808321 A G 2.83E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2239239 chr14 72808692 A G 2.85E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2239238 chr14 72808848 G A 3.98E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2283388 chr14 72809040 A G 3.95E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs929413 chr14 72810140 T C 4.09E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs1812041 chr14 72810256 G A 2.74E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2877805 chr14 72810345 T C 1.89E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2247090 chr14 72810384 C G 2.74E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs886826 chr14 72810663 C T 2.74E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2239235 chr14 72811156 T C 2.61E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2681727 chr14 72811484 A C 1.73E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2681728 chr14 72811529 A G 6.27E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2681730 chr14 72811992 A G 2.19E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2681731 chr14 72812162 G A 2.53E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2681733 chr14 72812219 A G 2.19E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs8016719 chr14 72812230 T A 3.89E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs8016720 chr14 72812231 T A 3.79E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs8015917 chr14 72812274 G A 2.32E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2681734 chr14 72812326 T G 1.74E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2681735 chr14 72812525 A G 1.00E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2681736 chr14 72812684 G T 2.18E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2529472 chr14 72812723 T C 3.29E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2681737 chr14 72812724 G A 3.76E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2529471 chr14 72813269 A C 1.71E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2529470 chr14 72813592 T C 1.70E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2529469 chr14 72813721 T C 1.70E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2239234 chr14 72813956 G A 1.30E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2239233 chr14 72814124 C A 1.92E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2239232 chr14 72814130 G A 1.67E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs1356841 chr14 72814415 T C 2.43E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs1356843 chr14 72814653 G T 1.55E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2681741 chr14 72814857 A G 9.52E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2681743 chr14 72815145 T C 8.75E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2681744 chr14 72815284 C A 8.59E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2681745 chr14 72815405 T G 9.35E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2681754 chr14 72819684 G A 7.55E-04 Multiple complex diseases RGS6 intron 17554300 rs10129799 chr14 72826071 A G 8.85E-06 Antibody status in Tripanosoma cruzi seropositivity RGS6 intron 24324551 rs2239227 chr14 72829979 A G 2.70E-04 Adiposity RGS6 intron 19461586 rs2239226 chr14 72832975 G A 1.86E-04 Birth weight RGS6 intron 17255346 rs2190508 chr14 72834466 A G 9.94E-04 Type 2 diabetes RGS6 intron 17463246 rs6574069 chr14 72839100 T C 6.00E-04 Adiposity RGS6 intron 19461586 rs2239221 chr14 72852109 T G 9.59E-04 Type 2 diabetes RGS6 intron 17463246 rs2239219 chr14 72852820 A G 5.84E-04 Type 2 diabetes RGS6 intron 17463246 rs10149848 chr14 72855162 G A 2.73E-04 Multiple complex diseases RGS6 intron 17554300 rs11158954 chr14 72882397 C T 8.30E-04 Response to alcohol consumption (flushing response) RGS6 intron 24277619 rs11158954 chr14 72882397 C T 9.35E-04 Alcohol dependence RGS6 intron 24277619 rs2877796 chr14 72882983 A G 2.54E-05 Bladder cancer RGS6 intron 19648920 rs7159300 chr14 72883874 G A 4.00E-06 Smoking cessation RGS6 intron 20811658 rs17115530 chr14 72892231 A T 9.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) RGS6 intron 23233662 rs2238187 chr14 72908102 A G 4.30E-04 Acute lung injury RGS6 intron 22295056 rs2283380 chr14 72909738 G A 5.57E-06 Bipolar disorder RGS6 intron 21771265 rs4903024 chr14 72920607 C T 2.84E-05 Bipolar disorder RGS6 intron 21771265 rs10131300 chr14 72939495 C A 5.00E-06 Amyotrophic lateral sclerosis (sporadic) RGS6 intron 24529757 rs2190937 chr14 72954653 G A 3.78E-05 Bipolar disorder RGS6 intron 21771265 rs1548687 chr14 72958469 G A 1.70E-05 Urinary metabolites RGS6 intron 21572414 rs7144114 chr14 72977997 C T 3.86E-04 Insulin resistance RGS6 intron 21901158 rs2283374 chr14 73015223 G A 8.20E-04 Type 2 diabetes and 6 quantitative traits RGS6 intron 17848626 rs4903031 chr14 73019236 A G 5.00E-06 C-reactive protein RGS6 intron 21300955 rs17117377 chr14 73020452 A G 4.65E-04 Multiple complex diseases RGS6 intron 17554300 rs2074647 chr14 73029178 G A 1.48E-05 Orofacial clefts RGS6 UTR-3 22419666 rs10142046 chr14 73047964 G A 8.33E-05 Alzheimer's disease / / 21098978 rs11625679 chr14 73048342 C G 7.60E-05 Alzheimer's disease / / 21098978 rs12587303 chr14 73058614 C A 4.44E-05 Alzheimer's disease / / 21098978 rs2803947 chr14 73059305 G A 5.74E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2526944 chr14 73059828 A G 5.74E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17780651 chr14 73061726 C G 3.23E-06 Alzheimer's disease / / 21098978 rs7492545 chr14 73062428 C T 1.50E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7160623 chr14 73070655 T C 4.30E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2803952 chr14 73070834 A G 5.53E-05 Cognitive performance / / 19734545 rs2803953 chr14 73071503 C T 2.00E-04 Alcohol dependence / / 20201924 rs2803953 chr14 73071503 C T 8.90E-04 Alcohol dependence / / 20201924 rs11625926 chr14 73071853 C A,T 5.75E-04 Body mass index / / 21701565 rs2526932 chr14 73081068 A G 6.00E-13 C-reactive protein and white blood cell count / / 22788528 rs2526919 chr14 73107771 A G 7.40E-04 Alcohol dependence / / 20201924 rs4899437 chr14 73121233 C G 6.92E-05 Bipolar disorder / / 20451256 rs2803980 chr14 73126531 A G 8.44E-05 Bipolar disorder / / 20451256 rs10129954 chr14 73150701 C T 3.86E-05 Male fertility DPF3 intron 22633400 rs2526941 chr14 73155735 T C 6.41E-04 Type 2 diabetes DPF3 intron 17463246 rs7140455 chr14 73170981 T C 4.11E-04 Type 2 diabetes DPF3 intron 17463246 rs7140455 chr14 73170981 T C 5.07E-04 Body mass index DPF3 intron 21701565 rs7155359 chr14 73177722 A G 2.83E-04 Type 2 diabetes DPF3 intron 17463246 rs7155359 chr14 73177722 A G 2.12E-04 Body mass index DPF3 intron 21701565 rs10139937 chr14 73181580 A G 1.80E-05 Urinary metabolites DPF3 intron 21572414 rs17120272 chr14 73219452 G A 1.17E-04 Multiple complex diseases DPF3 intron 17554300 rs8008338 chr14 73242470 T C 4.23E-04 Multiple complex diseases DPF3 intron 17554300 rs11622025 chr14 73246426 C A 9.60E-05 Psoriasis DPF3 intron 20953190 rs758915 chr14 73247540 A G 8.84E-05 Psoriasis DPF3 intron 20953190 rs7154229 chr14 73247844 G A 0.000000224 Narcolepsy (non-HLA narcolepsy) DPF3 intron 23459209 rs12435078 chr14 73249806 C T 1.70E-05 Urinary metabolites DPF3 intron 21572414 rs111724826 chr14 73253019 T C 6.69E-05 Acne (severe) DPF3 intron 24927181 rs12435382 chr14 73260377 G A 8.31E-05 Psoriasis DPF3 intron 20953190 rs12435382 chr14 73260377 G A 1.24E-04 Breast cancer DPF3 intron pha002853 rs12435412 chr14 73260475 G A 7.92E-05 Psoriasis DPF3 intron 20953190 rs12435412 chr14 73260475 G A 1.70E-05 Urinary metabolites DPF3 intron 21572414 rs12435412 chr14 73260475 G A 1.27E-04 Breast cancer DPF3 intron pha002853 rs60344050 chr14 73261871 G A 1.45E-04 Acne (severe) DPF3 intron 24927181 rs11621216 chr14 73263476 A T 2.90E-05 Urinary metabolites DPF3 intron 21572414 rs758913 chr14 73264461 T C 9.77E-05 Smoking cessation DPF3 intron 18519826 rs4903062 chr14 73273963 T C 6.61E-05 Diabetes Mellitus DPF3 intron pha003059 rs4903062 chr14 73273963 T C 8.63E-05 Diabetes Mellitus DPF3 intron pha003060 rs4243643 chr14 73294544 G A 4.29E-05 Smoking cessation DPF3 intron 18519826 rs11627334 chr14 73301462 G A 9.91E-04 Multiple complex diseases DPF3 intron 17554300 rs4903072 chr14 73315898 C A 3.42E-04 Amyotrophic Lateral Sclerosis DPF3 intron 17362836 rs9671327 chr14 73316539 G T 2.70E-05 Urinary metabolites DPF3 intron 21572414 rs17781661 chr14 73326538 G A 5.20E-04 Amyotrophic lateral sclerosis (sporadic) DPF3 intron 24529757 rs6574101 chr14 73328836 C T 7.46E-04 Response to cytidine analogues (gemcitabine) DPF3 intron 24483146 rs17181993 chr14 73333925 T C 1.78E-04 Multiple complex diseases DPF3 intron 17554300 rs982972 chr14 73343715 C T 6.44E-06 Lung adenocarcinoma DPF3 intron 19836008 rs4899449 chr14 73353275 G A 8.77E-04 Multiple complex diseases DPF3 intron 17554300 rs2333006 chr14 73357254 C G 2.75E-04 Multiple complex diseases DPF3 intron 17554300 rs2333006 chr14 73357254 C G 1.85E-04 Smoking cessation DPF3 intron 18519826 rs3814864 chr14 73361270 G A 6.02E-06 Lung adenocarcinoma / / 19836008 rs7493767 chr14 73365216 C T 4.52E-05 Multiple complex diseases / / 17554300 rs7144189 chr14 73367386 G A 7.69E-05 Lung adenocarcinoma / / 19836008 rs2052219 chr14 73371268 G A 1.02E-05 Lung adenocarcinoma / / 19836008 rs759282 chr14 73375101 G C 5.54E-05 Multiple complex diseases / / 17554300 rs765943 chr14 73385501 G A 6.50E-05 Multiple complex diseases / / 17554300 rs3213729 chr14 73393246 G C 1.00E-05 Asthma (aspirin-intolerant) DCAF4 UTR-5 21072201 rs2243443 chr14 73413965 G C 2.87E-04 Multiple complex diseases DCAF4 intron 17554300 rs2806040 chr14 73415065 T C 3.96E-04 Multiple complex diseases DCAF4 intron 17554300 rs2535913 chr14 73415233 G A 3.24E-04 Multiple complex diseases DCAF4 intron 17554300 rs2806039 chr14 73415817 T C 3.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DCAF4 intron 20877124 rs2806034 chr14 73422350 T G 4.30E-04 Multiple complex diseases DCAF4 cds-synon 17554300 rs7144738 chr14 73425681 A C 7.56E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DCAF4 UTR-3 20877124 rs7144738 chr14 73425681 A C 1.00E-04 Prostate cancer DCAF4 UTR-3 21743057 rs2243596 chr14 73428660 G A 7.96E-05 Femoral neck bone geometry / / 22087292 rs2535897 chr14 73434222 G A 4.53E-04 Multiple complex diseases / / 17554300 rs12880210 chr14 73467759 A C 2.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZFYVE1 intron 20877124 rs3742829 chr14 73489268 C T 6.73E-05 Aspirin exacerbated respiratory disease in asthmatics ZFYVE1 intron 23180272 rs12884060 chr14 73492735 G A 2.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZFYVE1 intron 20877124 rs12432987 chr14 73493195 A C 4.27E-04 Alzheimer's disease ZFYVE1 intron 17998437 rs12432987 chr14 73493195 A C 7.02E-05 Aspirin exacerbated respiratory disease in asthmatics ZFYVE1 intron 23180272 rs2333022 chr14 73500114 C G 5.10E-04 Type 2 diabetes / / 17463246 rs8005215 chr14 73530678 T C 1.11E-04 Aspirin exacerbated respiratory disease in asthmatics RBM25 intron 23180272 rs362439 chr14 73582301 C T 7.09E-04 Type 2 diabetes RBM25 intron 17463246 rs17124867 chr14 73618080 A G 5.82E-04 Multiple complex diseases PSEN1 intron 17554300 rs177413 chr14 73683194 T C 4.76E-05 Telomere length PSEN1 intron 23001564 rs11628713 chr14 73721775 C T 6.20E-07 Suicidal ideation with citalopram treatment PAPLN intron 19724244 rs11628713 chr14 73721775 C T 4.58E-04 Amyotrophic lateral sclerosis (sporadic) PAPLN intron 24529757 rs177389 chr14 73727509 T C,G 5.68E-07 Personality dimensions PAPLN missense 23658558 rs932256 chr14 73740649 C G 3.31E-04 Coronary Artery Disease PAPLN UTR-3 17634449 rs8013402 chr14 73748498 T C 2.00E-04 Cognitive impairment induced by topiramate NUMB intron 22091778 rs17126584 chr14 73754746 G A 7.98E-04 Response to taxane treatment (placlitaxel) NUMB intron 23006423 rs10483853 chr14 73756299 A G 6.00E-06 Coronary artery calcification NUMB intron 17903303 rs2333194 chr14 73767214 G A 7.00E-07 Bipolar disorder (mood-incongruent) NUMB intron 23092984 rs17781962 chr14 73773186 G A 2.75E-04 Coronary Artery Disease NUMB intron 17634449 rs10141031 chr14 73773609 C G 8.93E-05 Response to methylphenidate treatment NUMB intron 21130132 rs17126867 chr14 73791271 T C 2.00E-04 Cognitive impairment induced by topiramate NUMB intron 22091778 rs10220356 chr14 73809476 T C 2.13E-04 Multiple complex diseases NUMB intron 17554300 rs10142258 chr14 73810217 T C 2.00E-04 Cognitive impairment induced by topiramate NUMB intron 22091778 rs41499146 chr14 73814684 G C 6.16E-05 Coronary Artery Disease NUMB intron 17634449 rs7148830 chr14 73865975 C T 7.00E-04 Multiple complex diseases NUMB intron 17554300 rs7148830 chr14 73865975 C T 8.55E-04 Coronary Artery Disease NUMB intron 17634449 rs17182398 chr14 73872613 A C 4.04E-04 HIV-1 viral setpoint NUMB intron 17641165 rs17182398 chr14 73872613 A C 4.17E-04 Iron levels NUMB intron pha002876 rs10135747 chr14 73889452 G A 1.00E-04 Cognitive impairment induced by topiramate NUMB intron 22091778 rs8016448 chr14 73891887 A T 5.90E-04 Pulmonary function NUMB intron 23932459 rs4519287 chr14 73961821 T C 5.67E-04 Myopia (pathological) HEATR4 intron 21095009 rs2041073 chr14 73972535 T C 3.00E-13 Blood metabolite levels HEATR4 intron 24816252 rs8018967 chr14 73976934 T C 6.00E-19 Blood metabolite ratios HEATR4 intron 24816252 rs758053 chr14 73986914 T C 4.42E-05 Cognitive performance HEATR4 intron 19734545 rs11545737 chr14 74035671 A G 5.49E-04 Response to taxane treatment (placlitaxel) ACOT2 intron 23006423 rs4903128 chr14 74075935 T C 6.41E-06 Lymphocyte counts / / 22286170 rs10139531 chr14 74076979 T G 1.54E-06 Lymphocyte counts / / 22286170 rs17128948 chr14 74083901 G A 3.20E-04 Suicide attempts in bipolar disorder ACOT6 intron 21423239 rs887506 chr14 74219367 A G 5.00E-06 Hypertension C14orf43 intron 22384028 rs11626364 chr14 74249810 T C 4.99E-04 Amyotrophic lateral sclerosis C14orf43 intron 23624525 rs12878166 chr14 74250715 C T 8.61E-04 Coronary heart disease C14orf43 intron 21971053 rs9788450 chr14 74263752 T C 4.59E-04 Acute lung injury LOC100506476 intron 22295056 rs10483855 chr14 74283413 G A 8.15E-04 Bipolar disorder / / 19259986 rs1024603 chr14 74295380 A G 8.12E-04 Lymphocyte counts LOC100506498 intron 22286170 rs1860139 chr14 74296651 T C 2.64E-04 Multiple complex diseases / / 17554300 rs12431457 chr14 74315163 T C 4.80E-04 Multiple complex diseases / / 17554300 rs17782222 chr14 74338549 T A 2.85E-04 Multiple complex diseases PTGR2 intron 17554300 rs6574151 chr14 74348819 A G 4.23E-04 Multiple complex diseases PTGR2 intron 17554300 rs11626813 chr14 74355678 T C 3.16E-04 Multiple complex diseases ZNF410 intron 17554300 rs6574155 chr14 74399212 C T 6.68E-04 Multiple complex diseases / / 17554300 rs7157725 chr14 74406031 C T 4.44E-04 Multiple complex diseases FAM161B intron 17554300 rs11624780 chr14 74406611 T C 3.25E-06 Blood Pressure FAM161B intron pha003044 rs740507 chr14 74408223 G A 2.04E-04 Multiple complex diseases FAM161B intron 17554300 rs2098030 chr14 74421321 C T 4.56E-06 Serum metabolites COQ6 intron 19043545 rs740505 chr14 74426854 T C 9.85E-04 Alzheimer's disease COQ6 intron 22005930 rs10873263 chr14 74426942 A C 2.96E-04 Multiple complex diseases COQ6 intron 17554300 rs8500 chr14 74428445 G A 2.91E-06 Blood Pressure COQ6 missense pha003044 rs758240 chr14 74441345 G T 6.86E-04 Multiple complex diseases ENTPD5 intron 17554300 rs2074933 chr14 74441537 T C 5.96E-04 Multiple complex diseases ENTPD5 intron 17554300 rs2074932 chr14 74441684 G A 6.18E-04 Multiple complex diseases ENTPD5 cds-synon 17554300 rs7148202 chr14 74452465 C T 4.07E-04 Multiple complex diseases ENTPD5 intron 17554300 rs11621118 chr14 74460126 C T 7.89E-04 Multiple complex diseases ENTPD5 intron 17554300 rs4903168 chr14 74468613 C T 2.44E-05 Bipolar disorder ENTPD5 intron 17486107 rs3742810 chr14 74477488 A C 1.29E-04 Type 2 diabetes ENTPD5 intron 17463246 rs41435451 chr14 74479217 C T 3.84E-04 Type 2 diabetes ENTPD5 intron 17463246 rs7147063 chr14 74483568 T C 3.40E-04 Type 2 diabetes ENTPD5 intron 17463246 rs17182762 chr14 74507320 G A 7.28E-04 Insulin resistance C14orf45 missense 21901158 rs7153587 chr14 74509660 A G 5.50E-07 Common traits (Other) C14orf45 intron 20585627 rs2336751 chr14 74511878 T C 2.64E-04 Type 2 diabetes C14orf45 intron 17463246 rs3742809 chr14 74523869 A G 7.86E-07 Red blood cell traits C14orf45 missense 23222517 rs139579994 chr14 74535660 G A 0.00073 Prostate cancer ALDH6A1 missense 23555315 rs2072293 chr14 74537885 T G 4.47E-07 Common traits (Other) ALDH6A1 intron 20585627 rs4243645 chr14 74538308 T C 5.05E-04 Type 2 diabetes ALDH6A1 intron 17463246 rs4243645 chr14 74538308 T C 5.88E-04 Multiple complex diseases ALDH6A1 intron 17554300 rs4646861 chr14 74538706 A G 2.77E-04 Type 2 diabetes ALDH6A1 intron 17463246 rs765719 chr14 74541484 A C 3.60E-04 Alzheimer's disease ALDH6A1 intron 22005930 rs2239557 chr14 74551970 G C 3.00E-07 Common traits (Other) LIN52 intron 20585627 rs2300193 chr14 74567736 T C 3.13E-04 Type 2 diabetes LIN52 intron 17463246 rs2878783 chr14 74571058 C G 1.07E-04 Type 2 diabetes LIN52 intron 17463246 rs8013357 chr14 74574163 G A,C,T 1.63E-08 Lymphocyte counts LIN52 intron 22286170 rs17096584 chr14 74577697 C T 3.24E-04 Type 2 diabetes LIN52 intron 17463246 rs12587033 chr14 74617677 T A 3.08E-04 Type 2 diabetes LIN52 intron 17463246 rs8004420 chr14 74625694 C T 3.87E-04 Type 2 diabetes LIN52 intron 17463246 rs6574166 chr14 74627634 C T 3.14E-04 Type 2 diabetes LIN52 intron 17463246 rs1966402 chr14 74646077 T G 7.13E-04 Type 2 diabetes LIN52 intron 17463246 rs8021337 chr14 74651441 C T 3.03E-04 Type 2 diabetes LIN52 intron 17463246 rs2109750 chr14 74671256 G A 4.41E-05 Blood Pressure / / pha003044 rs12889182 chr14 74671355 A T 8.57E-04 Alzheimer's disease / / 22005930 rs11159071 chr14 74682373 C T 1.79E-05 Coronary heart disease / / pha003030 rs10873266 chr14 74685613 C T 6.18E-04 Type 2 diabetes / / 17463246 rs4291856 chr14 74687417 C T 1.08E-05 Coronary heart disease / / pha003030 rs8019455 chr14 74690983 G A 3.67E-04 Lymphocyte counts / / 22286170 rs12435198 chr14 74701569 T C 9.43E-04 Obesity (extreme) / / 21935397 rs12435201 chr14 74701607 T G 8.86E-04 Obesity (extreme) / / 21935397 rs1860714 chr14 74705352 C T 1.06E-04 Type 2 diabetes VSX2 nearGene-5 17463246 rs10130040 chr14 74713682 A C 9.74E-04 Obesity (extreme) VSX2 intron 21935397 rs10142706 chr14 74717304 A G 8.93E-04 Obesity (extreme) VSX2 intron 21935397 rs11627178 chr14 74718280 G C 8.83E-04 Obesity (extreme) VSX2 intron 21935397 rs17098943 chr14 74732209 C T 7.23E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs879823 chr14 74782515 A G 1.52E-06 Glaucoma (primary open-angle) / / 22605921 rs10140575 chr14 74829160 G T 4.39E-05 Bone mineral density / / 19181680 rs4903219 chr14 74860214 A G 3.44E-04 Multiple complex diseases / / 17554300 rs4903219 chr14 74860214 A G 3.31E-04 Lymphocyte counts / / 22286170 rs2190875 chr14 74862010 C T 6.65E-04 Depression (quantitative trait) / / 20800221 rs11625667 chr14 74870518 G A 1.70E-05 Social communication problems / / 24047820 rs1125221 chr14 74912830 G A 7.10E-06 Multiple sclerosis / / 21833088 rs17100386 chr14 74926792 T C 5.01E-04 Smoking initiation / / 24665060 rs10220503 chr14 74947092 C A 3.84E-56 Cholesterol,total NPC2 intron 23063622 rs2286412 chr14 74969167 C T 6.00E-18 Progranulin levels LTBP2 intron 21087763 rs2286412 chr14 74969167 C T 6.00E-18 Myocardial infarction LTBP2 intron 21211798 rs2302114 chr14 74983841 C T 1.02E-04 Amyotrophic Lateral Sclerosis LTBP2 intron 17362836 rs862034 chr14 74990746 A G 7.00E-14 Height LTBP2 intron 20881960 rs862026 chr14 74998875 G A 4.24E-04 Multiple complex diseases LTBP2 intron 17554300 rs10136102 chr14 75021783 G A 7.69E-05 Suicide attempts in bipolar disorder LTBP2 intron 21423239 rs2304707 chr14 75022271 G T 8.54E-05 Suicide attempts in bipolar disorder LTBP2 missense 21423239 rs4903240 chr14 75035577 C A 9.44E-05 Suicide attempts in bipolar disorder LTBP2 intron 21423239 rs3784025 chr14 75035893 G A 1.93E-04 Suicide attempts in bipolar disorder LTBP2 intron 21423239 rs8006807 chr14 75041138 A T 1.98E-04 Suicide attempts in bipolar disorder LTBP2 intron 21423239 rs10146172 chr14 75042338 A G 1.91E-04 Suicide attempts in bipolar disorder LTBP2 intron 21423239 rs3825709 chr14 75042917 C T 2.07E-04 Suicide attempts in bipolar disorder LTBP2 intron 21423239 rs4903243 chr14 75044030 C A 1.22E-04 Suicide attempts in bipolar disorder LTBP2 intron 21423239 rs2043948 chr14 75073048 C T 4.44E-07 Alzheimer's disease (late onset) LTBP2 intron 21460841 rs888414 chr14 75104905 G A 4.15E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs888417 chr14 75110437 G A 1.40E-06 Urinary metabolites / / 21572414 rs2193596 chr14 75234101 T G 6.44E-04 Type 2 diabetes YLPM1 intron 17463246 rs7159354 chr14 75253847 A G 4.14E-04 Type 2 diabetes YLPM1 intron 17463246 rs12887044 chr14 75255659 C T 4.14E-04 Type 2 diabetes YLPM1 intron 17463246 rs2111705 chr14 75261641 G A 2.85E-05 Caffeine consumption YLPM1 intron 21490707 rs10483861 chr14 75279039 T C 1.00E-06 Urinary metabolites YLPM1 intron 21572414 rs10144860 chr14 75286426 T C 4.17E-05 Pulmonary function YLPM1 intron 20010835 rs2058919 chr14 75310812 G C 1.20E-04 Type 2 diabetes / / 17463246 rs2058919 chr14 75310812 G C 3.29E-05 Serum metabolites / / 19043545 rs2058919 chr14 75310812 G C 8.25E-06 Schizophrenia / / 19571811 rs10483863 chr14 75322327 A G 1.20E-04 Obesity,menopause PROX2 intron 21424828 rs8014204 chr14 75322794 G A 5.00E-06 Caffeine consumption PROX2 intron 21490707 rs722599 chr14 75327443 T C 1.53E-04 Type 2 diabetes PROX2 intron 17463246 rs722599 chr14 75327443 T C 8.00E-06 IgG glycosylation PROX2 intron 23382691 rs28447028 chr14 75340133 G T 6.66E-04 Multiple complex diseases / / 17554300 rs28447028 chr14 75340133 G T 9.80E-06 Urinary metabolites / / 21572414 rs8006560 chr14 75349101 T C 2.37E-04 Major depressive disorder DLST intron 22472876 rs2300599 chr14 75359441 T C 9.35E-04 Type 2 diabetes DLST intron 17463246 rs17093914 chr14 75363641 C T 2.11E-04 Type 2 diabetes DLST intron 17463246 rs2080087 chr14 75365062 A G 9.18E-06 Caffeine consumption DLST intron 21490707 rs732765 chr14 75365729 A G 7.00E-06 Non-small cell lung cancer DLST intron 23144319 rs2286913 chr14 75386576 G A 0.00057 Breast cancer RPS6KL1 missense 23555315 rs7156652 chr14 75439819 G A 4.10E-05 Diabetic retinopathy / / 21441570 rs10146482 chr14 75574087 C T 2.02E-04 Lymphocyte counts NEK9 missense 22286170 rs910316 chr14 75626042 A C 1.00E-07 Height TMED10 intron 19343178 rs11159121 chr14 75666029 A T 1.53E-04 Aortic root size / / 21223598 rs7147712 chr14 75670707 G C 4.99E-04 Aortic root size / / 21223598 rs8004504 chr14 75682982 G A 3.97E-05 Alzheimer's disease / / 17998437 rs11159122 chr14 75686858 C T 5.47E-05 Alzheimer's disease / / 17998437 rs741197 chr14 75694927 G A 5.49E-04 Schizophrenia / / 19197363 rs12433287 chr14 75697380 T C 2.64E-04 Sleep duration / / 23728906 rs4899554 chr14 75701221 C T 3.00E-08 Inflammatory bowel disease / / 23128233 rs8013918 chr14 75709566 T C 1.56E-04 Rheumatoid arthritis / / 21452313 rs17183482 chr14 75729732 G A 9.88E-05 Body Mass Index / / pha003006 rs8023205 chr14 75733998 C G 2.99E-13 Triglycerides / / 23063622 rs8004059 chr14 75734471 G A 9.61E-05 Ulcerative colitis / / 19915573 rs2205189 chr14 75735508 A T 9.52E-04 Multiple complex diseases / / 17554300 rs1063169 chr14 75747118 G T 1.20E-05 Ulcerative colitis FOS intron 23511034 rs11621202 chr14 75780080 C T 1.58E-05 Type 2 diabetes / / 17463246 rs7149377 chr14 75781361 A C 2.51E-05 Type 2 diabetes / / 17463246 rs2005292 chr14 75784556 A G 6.77E-04 Tourette syndrome / / 22889924 rs8013053 chr14 75790221 G A 5.43E-05 Glucose levels / / pha002899 rs12895755 chr14 75795136 C T 7.43E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs12879500 chr14 75801084 C A 1.19E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11621969 chr14 75814028 T C 9.00E-07 Periodontal microbiota / / 22699663 rs7159908 chr14 75855798 A C 1.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs84044 chr14 75916464 T G 7.00E-06 Obesity-related traits JDP2 intron 23251661 rs7359140 chr14 75928973 G C 1.06E-04 Arthritis (juvenile idiopathic) JDP2 intron 22354554 rs7359152 chr14 75929017 T A 1.32E-04 Arthritis (juvenile idiopathic) JDP2 intron 22354554 rs11848255 chr14 75931551 G A 0.000000681 Interventricular septal wall thickness JDP2 intron 23275298 rs12147331 chr14 75958208 T C 8.18E-05 HIV-1 viral setpoint / / 22174851 rs7155603 chr14 75960536 A G 1.00E-07 Rheumatoid arthritis / / 20453842 rs2215909 chr14 75987710 A G 0.000243 Salmonella-induced pyroptosis / / 22837397 rs3784008 chr14 75990517 G C 6.74E-04 Type 2 diabetes BATF intron 17463246 rs7161377 chr14 76001394 T C 4.13E-05 Multiple complex diseases BATF intron 17554300 rs7161377 chr14 76001394 T C 2.25E-05 Crohn's disease BATF intron 18587394 rs2300603 chr14 76005557 T C 2.00E-08 Multiple sclerosis BATF intron 21833088 rs6574241 chr14 76012216 A G 2.00E-04 Multiple complex diseases BATF intron 17554300 rs7145649 chr14 76018784 A G 1.19E-05 Body Mass Index / / pha003022 rs8021741 chr14 76022400 T G 5.36E-04 Multiple complex diseases / / 17554300 rs7159570 chr14 76031313 A G 1.80E-05 Crohn's disease (need for surgery) / / 23665963 rs11850801 chr14 76046144 G A 5.48E-04 Insulin resistance FLVCR2 intron 21901158 rs8181959 chr14 76049334 G A 4.59E-04 Response to taxane treatment (placlitaxel) FLVCR2 intron 23006423 rs8011085 chr14 76054114 A G 2.91E-04 Multiple complex diseases FLVCR2 intron 17554300 rs2110566 chr14 76060181 G A 3.38E-06 Prostate cancer FLVCR2 intron pha002878 rs2075140 chr14 76064624 G A 1.92E-05 Lipoproteins FLVCR2 intron pha003079 rs10483871 chr14 76071281 G C 4.50E-05 Sleep and circadian phenotypes FLVCR2 intron 17903308 rs3784006 chr14 76071694 C T 4.34E-05 Lipoproteins FLVCR2 intron pha003079 rs7142350 chr14 76074655 C T 5.82E-05 Lipoproteins FLVCR2 intron pha003079 rs3784005 chr14 76077231 A G 3.57E-05 Multiple complex diseases FLVCR2 intron 17554300 rs3784004 chr14 76081664 A T 4.37E-04 Multiple complex diseases FLVCR2 intron 17554300 rs3784003 chr14 76083582 A C 6.49E-04 Multiple complex diseases FLVCR2 intron 17554300 rs724743 chr14 76129591 A G 1.00E-07 Height TTLL5 intron 21998595 rs10483872 chr14 76169308 C T 4.50E-05 Obesity-related traits TTLL5 intron 17903300 rs1005224 chr14 76173860 T A 1.00E-07 Large artery stroke TTLL5 intron 24262325 rs8015239 chr14 76370358 A C 9.38E-05 Psoriasis TTLL5 intron 18364390 rs4903352 chr14 76371658 G C 1.33E-05 Parkinson's disease (motor and cognition) TTLL5 intron 22658654 rs11621464 chr14 76379798 C G 1.91E-05 Lymphocyte counts TTLL5 intron 22286170 rs11621464 chr14 76379798 C G 1.70E-05 Parkinson's disease (motor and cognition) TTLL5 intron 22658654 rs3917210 chr14 76427780 T A 1.70E-07 Height TGFB3 intron 21194676 rs4252340 chr14 76430993 T C 1.90E-05 Height TGFB3 intron 21998595 rs3917194 chr14 76431533 T A 2.20E-05 Height TGFB3 intron 21998595 rs4252320 chr14 76440767 G A 3.48E-06 Lipid levels TGFB3 intron 19913121 rs3917153 chr14 76445265 C T 3.06E-09 Cholesterol,total TGFB3 intron 23063622 rs3917153 chr14 76445265 C T 4.13E-09 Triglycerides TGFB3 intron 23063622 rs3917151 chr14 76446047 C A,G,T 3.40E-05 HDL particle features TGFB3 intron 21283740 rs3917148 chr14 76446521 T G 1.70E-04 Coronary heart disease TGFB3 intron 21966275 rs11466414 chr14 76447850 G A 8.70E-04 Coronary heart disease TGFB3 UTR-5 21606135 rs9323624 chr14 76500303 T C 1.00E-06 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) IFT43 intron 24236485 rs9323624 chr14 76500303 T C 1.30E-06 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) IFT43 intron 24236485 rs9323624 chr14 76500303 T C 9.06E-05 Blood Pressure IFT43 intron pha003040 rs10483873 chr14 76508770 G A 8.78E-06 Lipid levels IFT43 intron 19016617 rs2302856 chr14 76525515 A C 8.55E-05 Blood Pressure IFT43 UTR-3 pha003040 rs11159170 chr14 76540682 T G 2.69E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) IFT43 intron 24023788 rs11159170 chr14 76540682 T G 9.34E-05 Blood Pressure IFT43 intron pha003040 rs8011069 chr14 76561318 G A 6.43E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs741510 chr14 76570562 C T 3.89E-04 Aortic root size / / 21223598 rs741510 chr14 76570562 C T 5.68E-05 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs2591089 chr14 76587800 A C 5.08E-06 Orofacial clefts / / 22419666 rs2543356 chr14 76588286 T C 2.02E-05 Orofacial clefts / / 22419666 rs2543359 chr14 76590473 C A 2.52E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17183991 chr14 76601154 C T 1.20E-06 Urinary metabolites / / 21572414 rs935334 chr14 76613678 T C 3.00E-06 Blood pressure / / 17903302 rs935334 chr14 76613678 T C 3.20E-06 Urinary metabolites / / 21572414 rs2543380 chr14 76619746 T C 8.59E-04 Myopia (pathological) C14orf118 intron 21095009 rs4442739 chr14 76647645 A C 1.20E-06 Urinary metabolites C14orf118 intron 21572414 rs2121070 chr14 76650764 T C 5.00E-06 Blood pressure C14orf118 intron 17903302 rs1900125 chr14 76657470 C T 1.00E-06 Urinary metabolites C14orf118 intron 21572414 rs8005754 chr14 76676827 T C 8.31E-04 Multiple complex diseases / / 17554300 rs12587652 chr14 76688613 T A 3.20E-06 Urinary metabolites / / 21572414 rs7156960 chr14 76703351 C G 1.00E-06 Acute lymphoblastic leukemia (childhood) / / 22076464 rs7156960 chr14 76703351 C G 3.00E-06 Acute lymphoblastic leukemia (childhood) / / 22076464 rs951304 chr14 76705850 A G 6.03E-04 Calcium intake levels and metabolic syndrome / / 22170361 rs4903393 chr14 76734188 T G 4.39E-04 Calcium intake levels and metabolic syndrome / / 22170361 rs755212 chr14 76792505 T C 1.96E-04 Type 2 diabetes / / 17846124 rs13379450 chr14 76807874 G A 4.85E-04 Type 2 diabetes / / 17463246 rs2360997 chr14 76812491 G C 8.00E-06 Attention deficit hyperactivity disorder symptoms (interaction) / / 18846501 rs4561383 chr14 76812553 C T 1.69E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12882037 chr14 76817185 T C 2.65E-05 Blood Pressure / / pha003049 rs2360999 chr14 76818989 A C 2.23E-05 Acne (severe teenage) / / 24114350 rs2361329 chr14 76841434 A G 7.42E-04 Smoking cessation ESRRB intron 24665060 rs12588179 chr14 76846138 C A 9.72E-05 Hematocrit ESRRB intron pha003097 rs8021398 chr14 76846926 C T 4.35E-05 Multiple complex diseases ESRRB intron 17554300 rs4344663 chr14 76851399 C T 2.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ESRRB intron 20877124 rs4344663 chr14 76851399 C T 3.00E-04 Body mass index ESRRB intron 24827717 rs12588035 chr14 76858600 A G 9.09E-04 Suicide attempts in bipolar disorder ESRRB intron 21423239 rs12588092 chr14 76858649 G C 9.19E-04 Suicide attempts in bipolar disorder ESRRB intron 21423239 rs12586444 chr14 76861565 C T 3.98E-05 Information processing speed ESRRB intron 21130836 rs4903407 chr14 76862907 T C 4.19E-05 Information processing speed ESRRB intron 21130836 rs4903408 chr14 76863165 C T 6.82E-04 Tourette syndrome ESRRB intron 22889924 rs1077428 chr14 76897808 C T 9.12E-04 Multiple complex diseases ESRRB intron 17554300 rs11846937 chr14 76928730 A G 4.07E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ESRRB intron 24023788 rs730452 chr14 76943682 G C 1.02E-04 Alzheimer's disease ESRRB intron 17998437 rs10147732 chr14 76949292 C T 4.06E-05 Brain structure ESRRB intron 22504417 rs7149569 chr14 76957341 T C 1.60E-05 Urinary metabolites ESRRB intron 21572414 rs2860216 chr14 77006008 C T 5.26E-04 Taste perception / / 22132133 rs1676235 chr14 77018566 G A 2.68E-04 Celiac disease / / 23936387 rs10146584 chr14 77019135 C T 3.80E-04 Alzheimer's disease (late onset) / / 21379329 rs7143462 chr14 77023233 A G 3.64E-04 Alzheimer's disease (late onset) / / 21379329 rs850739 chr14 77106456 C T 4.31E-04 Multiple complex diseases / / 17554300 rs17104722 chr14 77138110 G C 4.14E-48 Multiple complex diseases / / 17554300 rs17104722 chr14 77138110 G C 3.90E-06 Ulcerative colitis / / 19915572 rs1558709 chr14 77143382 A G 8.03E-04 Multiple complex diseases / / 17554300 rs1011356 chr14 77145214 C G 1.75E-22 Narcolepsy / / 19629137 rs2041825 chr14 77151335 A G 2.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs9919901 chr14 77160569 T G 4.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8016728 chr14 77164329 T A 9.18E-05 Suicide attempts in bipolar disorder / / 21423239 rs10873294 chr14 77165690 A T 2.08E-05 Suicide attempts in bipolar disorder / / 21423239 rs1861422 chr14 77168503 G A 3.86E-05 Suicide attempts in bipolar disorder / / 21423239 rs7157437 chr14 77168798 G A 4.76E-05 Suicide attempts in bipolar disorder / / 21423239 rs4899609 chr14 77170287 T C 6.09E-05 Suicide attempts in bipolar disorder / / 21423239 rs7155817 chr14 77210251 A G 7.13E-04 Longevity / / 22279548 rs1861426 chr14 77231768 C T 5.41E-04 Insulin resistance VASH1 intron 21901158 rs1076584 chr14 77254099 G A 4.57E-04 Longevity ANGEL1 UTR-3 22279548 rs2075773 chr14 77269788 A C 4.36E-04 Longevity ANGEL1 missense 22279548 rs8003586 chr14 77315031 A G 4.88E-05 Coronary heart disease C14orf166B intron pha003035 rs1467372 chr14 77329965 C T 4.58E-05 Coronary heart disease C14orf166B intron pha003031 rs4903503 chr14 77331850 T C 2.46E-05 Multiple complex diseases C14orf166B intron 17554300 rs1554958 chr14 77354918 G A 8.39E-04 Alzheimer's disease / / 24755620 rs12588405 chr14 77378687 C T 1.83E-04 Type 2 diabetes / / 17463246 rs17105063 chr14 77411106 A G 5.73E-05 Multiple complex diseases / / 17554300 rs2041962 chr14 77431758 A G 1.00E-04 Tunica Media / / pha003036 rs2041963 chr14 77431904 C G 9.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs6574344 chr14 77432244 A G 5.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs1120277 chr14 77477664 T C 2.84E-08 Lymphocyte counts / / 22286170 rs10873300 chr14 77488920 A T 4.40E-06 Urinary metabolites / / 21572414 rs879027 chr14 77492891 G A 9.51E-04 Graves' disease IRF2BPL cds-synon 21841780 rs7157305 chr14 77497368 C T 2.20E-04 Alzheimer's disease / / 22005930 rs7157305 chr14 77497368 C T 7.57E-07 Blood Pressure / / pha003043 rs6574349 chr14 77497666 G A 5.24E-04 Alzheimer's disease / / 22005930 rs6574349 chr14 77497666 G A 5.65E-05 Blood Pressure / / pha003043 rs183266 chr14 77497975 C A 5.00E-06 Adverse response to lamotrigine and phenytoin / / 22379998 rs183266 chr14 77497975 C A 0.000162 Salmonella-induced pyroptosis / / 22837397 rs17105195 chr14 77499279 G A 4.43E-05 Alzheimer's disease / / 22005930 rs1106847 chr14 77499459 T C 5.61E-04 Depression (quantitative trait) / / 20800221 rs10873301 chr14 77507205 G T 5.43E-04 Graves' disease / / 21841780 rs1986116 chr14 77513844 T C 1.00E-06 Sleep quality / / 23728906 rs17105232 chr14 77518302 G A 1.50E-05 Neuroblastoma / / pha002895 rs17105232 chr14 77518302 G A 2.15E-06 Blood Pressure / / pha003043 rs4021419 chr14 77519693 T C 2.04E-06 Graves' disease / / 21841780 rs8022640 chr14 77524587 G A 5.36E-05 Graves' disease / / 21841780 rs4903539 chr14 77532688 T G 3.26E-04 Graves' disease / / 21841780 rs204983 chr14 77554876 A G 7.15E-04 Alzheimer's disease / / 22005930 rs204984 chr14 77555134 G T 6.69E-04 Alzheimer's disease / / 22005930 rs17811635 chr14 77573757 C A 3.60E-04 Alzheimer's disease KIAA1737 intron 22005930 rs3813543 chr14 77581481 C A 5.78E-04 Graves' disease KIAA1737 UTR-3 21841780 rs1465330 chr14 77601819 T A 4.00E-07 Large artery stroke ZDHHC22 intron 24262325 rs10144557 chr14 77608719 A G 7.13E-04 Alzheimer's disease / / 24755620 rs2021853 chr14 77618857 G A 7.28E-04 Alzheimer's disease / / 24755620 rs158112 chr14 77624366 C T 1.39E-05 Serum metabolites / / 19043545 rs9989201 chr14 77625148 C T 4.04E-04 Alzheimer's disease / / 24755620 rs8021745 chr14 77649524 A G 2.49E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TMEM63C intron 24023788 rs11628257 chr14 77650690 A T 3.60E-04 Alzheimer's disease TMEM63C intron 24755620 rs11844745 chr14 77664331 G A 4.74E-04 Response to cytadine analogues (cytosine arabinoside) TMEM63C intron 24483146 rs207801 chr14 77676449 A G 2.48E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TMEM63C intron 24023788 rs8014837 chr14 77681128 G A 1.79E-04 Smoking quantity TMEM63C intron 24665060 rs4467006 chr14 77684670 C G 7.00E-06 Bipolar disorder TMEM63C intron 22925353 rs2287375 chr14 77684842 A T 5.00E-06 Bipolar disorder TMEM63C intron 22925353 rs11627633 chr14 77693815 T C 1.46E-04 Multiple complex diseases TMEM63C intron 17554300 rs369059 chr14 77697371 T C 9.74E-04 Multiple complex diseases TMEM63C intron 17554300 rs376645 chr14 77698337 A G 9.50E-04 Multiple complex diseases TMEM63C intron 17554300 rs17750404 chr14 77699933 C T 6.40E-05 Diabetic nephropathy TMEM63C intron pha002866 rs2287381 chr14 77710433 G T 0.000218701 Hypertension (early onset hypertension) TMEM63C intron 22479346 rs2287386 chr14 77718621 C A 1.23E-05 Alcohol and nictotine co-dependence TMEM63C intron 20158304 rs888060 chr14 77726733 C T 9.15E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs438931 chr14 77746310 G A 1.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) POMT2 intron 20877124 rs4899649 chr14 77759597 T C 7.31E-05 Schizophrenia POMT2 intron 19571811 rs2042045 chr14 77767978 C A 8.98E-05 Alzheimer's disease POMT2 intron 21098978 rs3815626 chr14 77770834 A G 5.05E-05 Alzheimer's disease POMT2 intron 21098978 rs2363641 chr14 77783134 A G 5.00E-05 Alzheimer's disease POMT2 intron 21098978 rs2111699 chr14 77788597 A G 5.28E-05 Alzheimer's disease GSTZ1 intron 21098978 rs8177544 chr14 77788788 C T 4.05E-05 Major depressive disorder (broad) GSTZ1 intron 20038947 rs2363643 chr14 77788908 G A 5.60E-05 Alzheimer's disease GSTZ1 UTR-5 21098978 rs4147578 chr14 77790416 G A 5.34E-05 Alzheimer's disease GSTZ1 intron 21098978 rs8016187 chr14 77790872 T A 4.72E-05 Alzheimer's disease GSTZ1 intron 21098978 rs2287395 chr14 77791519 A G 5.49E-05 Alzheimer's disease GSTZ1 intron 21098978 rs2287395 chr14 77791519 A G 4.56E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) GSTZ1 intron 24023788 rs8004561 chr14 77792053 C T 4.19E-05 Major depressive disorder (broad) GSTZ1 intron 20038947 rs2270423 chr14 77795638 G A 5.53E-05 Alzheimer's disease GSTZ1 intron 21098978 rs7142380 chr14 77931231 T C 4.59E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) AHSA1 intron 24023788 rs3825694 chr14 77934587 T C 2.42E-05 Alcohol and nictotine co-dependence AHSA1 intron 20158304 rs3742732 chr14 77942316 G A 7.39E-04 Multiple complex diseases ISM2 cds-synon 17554300 rs2142188 chr14 77943842 G A 4.39E-05 Serum metabolites ISM2 intron 19043545 rs2013932 chr14 77947706 T C 9.29E-05 Multiple complex diseases ISM2 intron 17554300 rs17105886 chr14 77973096 T C 1.86E-08 Lymphocyte counts SPTLC2 UTR-3 22286170 rs7145386 chr14 77993060 T C 9.63E-05 Tunica Media SPTLC2 intron pha003038 rs2284230 chr14 78015897 C T 0.0000488 Uterine leiomyomata SPTLC2 intron 23040493 rs11159275 chr14 78018246 T C 6.74E-04 Suicide attempts in bipolar disorder SPTLC2 intron 21041247 rs4903604 chr14 78028378 C T 2.65E-05 Multiple complex diseases SPTLC2 intron 17554300 rs4903604 chr14 78028378 C T 3.41E-05 Height SPTLC2 intron 22021425 rs2091915 chr14 78030479 C G 8.89E-04 Multiple complex diseases SPTLC2 intron 17554300 rs2299927 chr14 78066661 G A 5.50E-04 Glycemic traits (pregnancy) SPTLC2 intron 23903356 rs17752262 chr14 78119369 C T 8.86E-06 Multiple complex diseases / / 17554300 rs2284235 chr14 78163423 T C 6.60E-04 Multiple complex diseases ALKBH1 intron 17554300 rs17825554 chr14 78173748 T C 2.80E-05 Urinary metabolites ALKBH1 intron 21572414 rs1076496 chr14 78176851 A G 5.60E-05 Parkinson's disease (age of onset) SLIRP intron 19772629 rs176980 chr14 78198449 C G 3.70E-05 Personality dimensions SNW1 intron 18957941 rs17752628 chr14 78198786 T C 2.50E-05 Urinary metabolites SNW1 intron 21572414 rs4632066 chr14 78247282 T C 4.50E-05 Personality dimensions / / 18957941 rs1006039 chr14 78263196 A G 1.70E-05 Personality dimensions / / 18957941 rs2080816 chr14 78310762 T G 4.10E-05 Parkinson's disease (age of onset) ADCK1 intron 19772629 rs17753195 chr14 78351762 G A 5.14E-04 Alcohol dependence ADCK1 intron 21314694 rs2287648 chr14 78353758 C G 1.90E-05 Urinary metabolites ADCK1 intron 21572414 rs17106558 chr14 78363932 G A 6.60E-04 Alcohol dependence ADCK1 intron 20201924 rs7144239 chr14 78389173 T G 4.05E-06 Alzheimer's disease (late onset) ADCK1 intron 21379329 rs2287652 chr14 78397448 A G 5.15E-05 HIV(mother-to-child transmission) ADCK1 intron 20487506 rs2287652 chr14 78397448 A G 4.39E-05 Cognitive impairment induced by topiramate ADCK1 intron 22091778 rs2287652 chr14 78397448 A G 9.20E-05 Attention deficit hyperactivity disorder ADCK1 intron 22420046 rs8009619 chr14 78400320 T G 8.08E-05 Orofacial clefts / / 22863734 rs759807 chr14 78410426 G A 5.59E-04 Multiple complex diseases / / 17554300 rs4899685 chr14 78421058 G A 4.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy) / / 24554482 rs7144528 chr14 78421203 G A 2.77E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs11622927 chr14 78496032 C A 1.87E-05 Triglycerides / / 19074352 rs11622927 chr14 78496032 C A 1.87E-05 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs3850370 chr14 78534906 G T 4.00E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 22872573 rs4903705 chr14 78555941 C T 5.20E-04 Alcohol dependence / / 20201924 rs10483889 chr14 78557505 T G 3.40E-04 Alcohol dependence / / 20201924 rs10483889 chr14 78557505 T G 8.30E-04 Alcohol dependence / / 20201924 rs8020238 chr14 78557924 C T 4.00E-04 Polycystic ovary syndrome / / 22178785 rs10873314 chr14 78559361 T C 2.31E-06 Height / / pha003010 rs10873314 chr14 78559361 T C 5.67E-06 Height / / pha003011 rs4624102 chr14 78562248 A C 3.57E-05 Cognitive test performance / / 20125193 rs3952583 chr14 78568445 A G 2.57E-04 Taste perception / / 22132133 rs10483891 chr14 78608741 C T 8.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10483891 chr14 78608741 C T 1.00E-05 Lung cancer / / 18978790 rs10483891 chr14 78608741 C T 6.56E-04 Depression (quantitative trait) / / 20800221 rs1541616 chr14 78612418 C T 1.51E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4903711 chr14 78614217 C T 3.46E-04 Coronary heart disease / / 21606135 rs4903712 chr14 78615593 T C 0.00000167 Alcohol dependence / / 23691058 rs17754467 chr14 78622523 A G 1.50E-05 Alcohol dependence / / 20201924 rs17754467 chr14 78622523 A G 2.70E-05 Alcohol dependence / / 20201924 rs17754467 chr14 78622523 A G 0.000000554 Alcohol dependence / / 23691058 rs17754467 chr14 78622523 A G 1.55E-05 Alcoholism / / pha002892 rs17754467 chr14 78622523 A G 2.71E-05 Alcoholism / / pha002893 rs7144274 chr14 78625653 G A 9.94E-05 Asthma / / 20159242 rs12587659 chr14 78632159 A C 5.90E-06 Urinary metabolites / / 21572414 rs8016646 chr14 78632808 A G 8.80E-04 Multiple complex diseases / / 17554300 rs213565 chr14 78642215 C T 7.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs862327 chr14 78648558 G A 5.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs10144429 chr14 78652519 G A 8.48E-06 Osteoarthritis / / 22763110 rs4899701 chr14 78653922 A T 6.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs4903720 chr14 78657023 C T 6.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs17107130 chr14 78671388 C A 5.71E-07 Multiple complex diseases / / 17554300 rs10444740 chr14 78671826 G C 5.01E-04 Coronary heart disease / / 21606135 rs4903725 chr14 78678923 T C 3.46E-05 Relative hand skill / / 24068947 rs17754783 chr14 78687360 T C 3.38E-05 Relative hand skill / / 24068947 rs17827758 chr14 78688533 A G 8.18E-05 Relative hand skill / / 24068947 rs1004667 chr14 78734765 T C 6.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1004667 chr14 78734765 T C 8.45E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4903735 chr14 78744157 C A 1.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4903735 chr14 78744157 C A 7.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4903736 chr14 78745431 G A 0.000045 Pancreatic cancer and survival / / 22665904 rs8008429 chr14 78746985 C T 2.35E-04 Smoking initiation / / 24665060 rs10483897 chr14 78747216 G C 6.88E-11 Pure-tone audiometry / / pha001966 rs2272582 chr14 78748726 T C 5.66E-04 Smoking initiation / / 24665060 rs11159346 chr14 78750987 C A 8.85E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1028256 chr14 78754803 G A 5.67E-04 Acute lung injury / / 22295056 rs12891942 chr14 78757435 T C 4.78E-04 Smoking initiation / / 24665060 rs7160443 chr14 78758796 A G 1.10E-05 Urinary metabolites / / 21572414 rs7160443 chr14 78758796 A G 3.31E-04 Smoking initiation / / 24665060 rs12588277 chr14 78763870 G A 2.30E-04 Type 2 diabetes / / 17463246 rs12588277 chr14 78763870 G A 2.91E-04 Gallstones / / 17632509 rs4903741 chr14 78766644 T C 0.000087 Pancreatic cancer and survival / / 22665904 rs1523132 chr14 78768884 C T 3.53E-04 Type 2 diabetes / / 17463246 rs7155434 chr14 78775306 A C 6.74E-05 Cognitive test performance / / 20125193 rs7155434 chr14 78775306 A C 7.82E-06 Temporal lobe volumes / / 20197096 rs17107326 chr14 78781995 T C 1.38E-04 Celiac disease / / 23936387 rs11624704 chr14 78786077 A C 3.00E-09 Obesity / / 21552555 rs6574433 chr14 78786159 A G 6.00E-06 Cognitive performance / / 20125193 rs8019786 chr14 78789686 G A 8.40E-06 Cognitive test performance / / 20125193 rs17107347 chr14 78790093 G A 9.06E-04 Type 2 diabetes / / 17463246 rs11623035 chr14 78796967 G A 3.92E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1112573 chr14 78845328 G T 7.18E-04 HIV-1 viral setpoint / / 17641165 rs12432856 chr14 78853596 T C 6.87E-04 HIV-1 viral setpoint / / 17641165 rs2192420 chr14 78862719 A G 5.77E-05 Schizophrenia / / 19571809 rs12893431 chr14 78879227 G A 4.65E-04 Smoking quantity NRXN3 intron 24665060 rs17107542 chr14 78891051 T A 7.51E-05 Diabetic nephropathy NRXN3 intron pha002852 rs10483901 chr14 78898025 G A 5.67E-04 Smoking quantity NRXN3 intron 24665060 rs2192412 chr14 78927284 C T 8.26E-05 Schizophrenia NRXN3 intron 19571809 rs2192412 chr14 78927284 C T 7.08E-04 Smoking quantity NRXN3 intron 24665060 rs11625200 chr14 78929366 C A 7.94E-04 Suicide attempts in bipolar disorder NRXN3 intron 21041247 rs1003364 chr14 78933774 A G 7.86E-04 Multiple complex diseases NRXN3 intron 17554300 rs10431730 chr14 78942478 A G 6.59E-04 Suicide attempts in bipolar disorder NRXN3 intron 21041247 rs1990531 chr14 78947081 G A 4.08E-04 Suicide attempts in bipolar disorder NRXN3 intron 21041247 rs11622766 chr14 78957858 A G 3.68E-04 Suicide attempts in bipolar disorder NRXN3 intron 21041247 rs1544623 chr14 78960255 A G 8.41E-04 Suicide attempts in bipolar disorder NRXN3 intron 21041247 rs1544623 chr14 78960255 A G 9.57E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) NRXN3 intron 24236485 rs1122840 chr14 78965754 G A 5.47E-04 Suicide attempts in bipolar disorder NRXN3 intron 21041247 rs11629123 chr14 78983502 C T 4.19E-04 Suicide attempts in bipolar disorder NRXN3 intron 21041247 rs1030123 chr14 78990329 G A 4.37E-04 Suicide attempts in bipolar disorder NRXN3 intron 21041247 rs1030124 chr14 78990463 G T 4.38E-04 Suicide attempts in bipolar disorder NRXN3 intron 21041247 rs2160904 chr14 78990882 T A 2.30E-05 Urinary metabolites NRXN3 intron 21572414 rs10483906 chr14 78998012 C T 2.72E-04 Multiple complex diseases NRXN3 intron 17554300 rs4243660 chr14 78998187 T C 4.36E-04 Suicide attempts in bipolar disorder NRXN3 intron 21041247 rs2193670 chr14 79015849 G A 4.29E-04 Suicide attempts in bipolar disorder NRXN3 intron 21041247 rs10483907 chr14 79016165 G A 5.22E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) NRXN3 intron 24236485 rs1015964 chr14 79017115 A G 9.00E-04 Suicide attempts in bipolar disorder NRXN3 intron 21041247 rs2098518 chr14 79017836 C G 4.27E-04 Suicide attempts in bipolar disorder NRXN3 intron 21041247 rs12100603 chr14 79020160 A G 7.85E-04 Type 2 diabetes NRXN3 intron 17463246 rs17107847 chr14 79021758 C A 9.23E-05 Schizophrenia NRXN3 intron 19571809 rs17835229 chr14 79027504 C T 4.95E-04 Type 2 diabetes NRXN3 intron 17463246 rs17835229 chr14 79027504 C T 1.38E-04 Amyotrophic lateral sclerosis (sporadic) NRXN3 intron 24529757 rs17107912 chr14 79073108 G A 5.22E-04 Prostate cancer mortality NRXN3 intron 20978177 rs12432833 chr14 79151186 A G 8.35E-04 Response to statin treatment (atorvastatin),change in cholesterol levels NRXN3 intron 20031582 rs12432833 chr14 79151186 A G 2.33E-05 Coronary heart disease NRXN3 intron pha003056 rs12432833 chr14 79151186 A G 2.27E-05 Monocyte chemoattractant protein-1 NRXN3 intron pha003071 rs12147249 chr14 79176154 G C 1.23E-04 Response to statin treatment (atorvastatin),change in cholesterol levels NRXN3 intron 20031582 rs8013671 chr14 79186485 C T 7.34E-04 Intracranial aneurysm NRXN3 intron 20613766 rs970465 chr14 79194169 G A 5.27E-04 Response to statin treatment (atorvastatin),change in cholesterol levels NRXN3 intron 20031582 rs8020920 chr14 79226876 G A 4.79E-05 Blood Pressure NRXN3 intron pha003043 rs10133425 chr14 79233907 G T 7.58E-04 Multiple complex diseases NRXN3 intron 17554300 rs10145149 chr14 79242780 A T 2.11E-04 Multiple complex diseases NRXN3 intron 17554300 rs987644 chr14 79244045 A G 2.40E-05 Lipid levels NRXN3 intron 19913121 rs150568 chr14 79288523 A G 9.45E-04 Type 2 diabetes NRXN3 intron 17463246 rs1396618 chr14 79291904 A C 1.00E-06 Smoking behavior NRXN3 intron 20418888 rs1396618 chr14 79291904 A C 1.98E-05 Lung function (forced expiratory volume in 1 second) NRXN3 intron pha003103 rs215502 chr14 79298727 G A 9.09E-05 Multiple complex diseases NRXN3 intron 17554300 rs4899727 chr14 79324853 A G 1.07E-04 Prion diseases NRXN3 intron 22210626 rs2370876 chr14 79346136 A G 2.94E-04 Celiac disease NRXN3 intron 23936387 rs150773 chr14 79398723 T C 1.53E-04 Type 2 diabetes NRXN3 intron 17463246 rs150775 chr14 79401388 G T 1.01E-04 Type 2 diabetes NRXN3 intron 17463246 rs7142134 chr14 79406904 T C 6.64E-04 Multiple complex diseases NRXN3 intron 17554300 rs31444 chr14 79409422 T C 1.29E-04 Type 2 diabetes NRXN3 intron 17463246 rs31420 chr14 79429931 T G 5.25E-04 Fibrinogen NRXN3 intron 17255346 rs31416 chr14 79433112 T C 9.33E-05 Glycosylated haemoglobin levels NRXN3 intron 17255346 rs8012310 chr14 79443296 A G 1.03E-05 Glycosylated haemoglobin levels NRXN3 intron 17255346 rs2653540 chr14 79585481 C T 6.64E-04 Multiple complex diseases NRXN3 intron 17554300 rs6574495 chr14 79599274 T C 8.90E-05 Obesity,menopause NRXN3 intron 21424828 rs11622810 chr14 79635054 C T 2.72E-04 Multiple complex diseases NRXN3 intron 17554300 rs10162396 chr14 79681450 G A 2.94E-04 Lung function (forced vital capacity) NRXN3 intron 24023788 rs8008654 chr14 79692430 G A 4.77E-04 Suicide attempts in bipolar disorder NRXN3 intron 21423239 rs10151613 chr14 79698367 C A 7.57E-04 Suicide attempts in bipolar disorder NRXN3 intron 21423239 rs8011208 chr14 79705038 A G 9.65E-04 Suicide attempts in bipolar disorder NRXN3 intron 21423239 rs4899737 chr14 79709510 G T 5.77E-04 Suicide attempts in bipolar disorder NRXN3 intron 21423239 rs12882688 chr14 79713597 G A 7.21E-04 Suicide attempts in bipolar disorder NRXN3 intron 21423239 rs11627269 chr14 79714572 C T 3.52E-04 Suicide attempts in bipolar disorder NRXN3 intron 21423239 rs7153957 chr14 79727238 A G 5.39E-04 Suicide attempts in bipolar disorder NRXN3 intron 21423239 rs2219846 chr14 79727663 G A 2.18E-04 Suicide attempts in bipolar disorder NRXN3 intron 21423239 rs7161543 chr14 79730086 C T 2.58E-04 Suicide attempts in bipolar disorder NRXN3 intron 21423239 rs4359363 chr14 79732170 G A 2.54E-04 Suicide attempts in bipolar disorder NRXN3 intron 21423239 rs1184263 chr14 79732478 G A 1.75E-04 Suicide attempts in bipolar disorder NRXN3 intron 21423239 rs7144015 chr14 79734767 C G 6.25E-04 Smoking quantity NRXN3 intron 24665060 rs17109025 chr14 79744273 G A 3.96E-04 Smoking quantity NRXN3 intron 24665060 rs12432262 chr14 79747043 A C 9.96E-05 Suicide attempts in bipolar disorder NRXN3 intron 21423239 rs1868635 chr14 79747251 C T 8.50E-05 Suicide attempts in bipolar disorder NRXN3 intron 21423239 rs7492515 chr14 79755176 G A 8.19E-05 Suicide attempts in bipolar disorder NRXN3 intron 21423239 rs4899738 chr14 79759987 A G 1.28E-04 Suicide attempts in bipolar disorder NRXN3 intron 21423239 rs12884217 chr14 79770232 A G 1.20E-04 Suicide attempts in bipolar disorder NRXN3 intron 21423239 rs2218786 chr14 79785699 A T 6.88E-04 Suicide attempts in bipolar disorder NRXN3 intron 21423239 rs6574505 chr14 79807197 C A 6.62E-04 Suicide attempts in bipolar disorder NRXN3 intron 21423239 rs10146690 chr14 79890456 G A 4.00E-06 Waist circumference NRXN3 intron 19557197 rs2370982 chr14 79890677 C T 4.13E-06 Waist circumference NRXN3 intron 19557197 rs10150482 chr14 79891882 G A 3.96E-06 Waist circumference NRXN3 intron 19557197 rs7141420 chr14 79899454 C T 1.00E-17 Obesity NRXN3 intron 23563607 rs7141420 chr14 79899454 C T 7.10E-05 Smoking initiation NRXN3 intron 24665060 rs2370983 chr14 79903376 G A 3.00E-09 Obesity NRXN3 intron 23563607 rs2003615 chr14 79903984 A G 5.95E-05 Odorant perception NRXN3 intron 23910658 rs17109221 chr14 79910119 C T 1.58E-06 Waist circumference NRXN3 intron 19557197 rs17836088 chr14 79932041 G C 1.33E-06 Waist circumference NRXN3 intron 19557197 rs10150332 chr14 79936964 T C 7.22E-07 Waist circumference NRXN3 intron 19557197 rs10150332 chr14 79936964 T C 3.00E-11 Body mass index NRXN3 intron 20935630 rs10150332 chr14 79936964 T C 2.75E-11 Body mass index NRXN3 intron 23001569 rs10145154 chr14 79939525 C T 6.76E-07 Waist circumference NRXN3 intron 19557197 rs17109256 chr14 79939993 G A 6.61E-07 Waist circumference NRXN3 intron 19557197 rs7144011 chr14 79940383 G T 6.55E-07 Waist circumference NRXN3 intron 19557197 rs7156625 chr14 79942647 G A 1.10E-06 Waist circumference NRXN3 intron 19557197 rs10146997 chr14 79945162 A G 5.00E-08 Waist circumference NRXN3 intron 19557197 rs2196447 chr14 79950488 A G 2.83E-07 Delayed encephalopathy in acute carbon monoxide poisoning NRXN3 intron 24265751 rs2196447 chr14 79950488 A G 5.30E-07 Delayed encephalopathy in acute carbon monoxide poisoning NRXN3 intron 24265751 rs11845632 chr14 79953814 G A 1.27E-08 Delayed encephalopathy in acute carbon monoxide poisoning NRXN3 intron 24265751 rs11845632 chr14 79953814 G A 1.49E-07 Delayed encephalopathy in acute carbon monoxide poisoning NRXN3 intron 24265751 rs8021408 chr14 79955415 C T 6.09E-04 Amyotrophic Lateral Sclerosis NRXN3 intron 17362836 rs7145128 chr14 79965456 A G 7.71E-04 Amyotrophic Lateral Sclerosis NRXN3 intron 17362836 rs8022699 chr14 79983619 G A 3.00E-05 Prostate cancer NRXN3 intron 21743057 rs10083466 chr14 79984718 C A 1.00E-04 Information processing speed NRXN3 intron 21130836 rs10149537 chr14 79985980 G C 3.00E-05 Prostate cancer NRXN3 intron 21743057 rs10130369 chr14 79987789 C T 3.85E-05 Coronary heart disease NRXN3 intron pha003030 rs2371100 chr14 79993106 C T 4.00E-05 Prostate cancer NRXN3 intron 21743057 rs12885724 chr14 79997085 G T 7.01E-04 Multiple complex diseases NRXN3 intron 17554300 rs9652378 chr14 80001655 G A 4.00E-05 Prostate cancer NRXN3 intron 21743057 rs7146075 chr14 80002042 A G 7.75E-04 Multiple complex diseases NRXN3 intron 17554300 rs7147705 chr14 80002096 T C 3.54E-04 Multiple complex diseases NRXN3 intron 17554300 rs7147705 chr14 80002096 T C 6.00E-06 Amyotrophic lateral sclerosis (age of onset) NRXN3 intron 22959728 rs1424849 chr14 80002462 G A 3.00E-05 Prostate cancer NRXN3 intron 21743057 rs977321 chr14 80002534 A G 2.60E-05 Urinary metabolites NRXN3 intron 21572414 rs977320 chr14 80002632 A G 4.07E-04 Smoking initiation NRXN3 intron 24665060 rs1424846 chr14 80008914 G A 4.00E-05 Prostate cancer NRXN3 intron 21743057 rs4903864 chr14 80011222 G A 3.58E-04 Multiple complex diseases NRXN3 intron 17554300 rs1895671 chr14 80013024 A C 5.92E-05 Hypertension NRXN3 intron pha003041 rs920123 chr14 80028002 C T 1.78E-04 Acute lung injury NRXN3 intron 22295056 rs4448862 chr14 80030868 T C 1.78E-04 Acute lung injury NRXN3 intron 22295056 rs12587614 chr14 80049046 G A 1.40E-04 Acute lung injury NRXN3 intron 22295056 rs7153625 chr14 80049262 G A 3.76E-04 Multiple complex diseases NRXN3 intron 17554300 rs17764096 chr14 80050506 G T 4.13E-04 Multiple complex diseases NRXN3 intron 17554300 rs17109557 chr14 80065001 T G 2.74E-04 Acute lung injury NRXN3 intron 22295056 rs11845389 chr14 80095328 G T 9.04E-05 Multiple complex diseases NRXN3 intron 17554300 rs17109649 chr14 80104576 G T 4.51E-05 Blood Pressure NRXN3 intron pha003043 rs2270446 chr14 80130628 G A 4.04E-04 Acute lung injury NRXN3 intron 22295056 rs17109704 chr14 80134013 A G 3.97E-04 Acute lung injury NRXN3 intron 22295056 rs17109716 chr14 80136845 G A 9.09E-04 Multiple complex diseases NRXN3 intron 17554300 rs1030127 chr14 80161440 T C 2.34E-05 Cognitive test performance NRXN3 intron 20125193 rs17109778 chr14 80170573 C T 8.00E-05 Response to lithium treatment in bipolar disorder NRXN3 intron 19448189 rs178377 chr14 80178026 C T 8.47E-04 Response to alcohol consumption (flushing response) NRXN3 intron 24277619 rs12586263 chr14 80189374 G A 2.37E-04 Response to taxane treatment (placlitaxel) NRXN3 intron 23006423 rs7158292 chr14 80190556 C A 2.56E-04 Response to taxane treatment (placlitaxel) NRXN3 intron 23006423 rs12589656 chr14 80192862 C T 2.81E-04 Response to taxane treatment (placlitaxel) NRXN3 intron 23006423 rs12431759 chr14 80207193 C G 8.95E-04 Alzheimer's disease NRXN3 intron 17998437 rs17764590 chr14 80213080 G A 9.93E-05 Major depressive disorder NRXN3 intron 22472876 rs17764668 chr14 80242216 A G 9.84E-06 Alzheimer's disease (age of onset) NRXN3 intron 22005931 rs2293829 chr14 80300677 C A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes NRXN3 intron 22628534 rs2293839 chr14 80317460 G A 7.33E-04 Substance dependence NRXN3 intron 21818250 rs2293843 chr14 80320748 C T 3.62E-04 Alcohol consumption (maxi-drinks) NRXN3 intron 24277619 rs2293847 chr14 80327082 T C 4.29E-04 Response to taxane treatment (placlitaxel) NRXN3 intron 23006423 rs993920 chr14 80346011 G T 8.63E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs8012341 chr14 80347621 T C 9.49E-05 Glucose levels / / pha003057 rs727729 chr14 80362291 T C 5.75E-05 Waist Circumference / / pha003023 rs10483936 chr14 80373231 G A 6.47E-04 Schizophrenia / / 21674006 rs7154805 chr14 80381597 T C 6.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1534837 chr14 80383025 G A 6.50E-04 Asthma / / 20698975 rs956265 chr14 80398187 A C 3.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2205208 chr14 80398877 A G 5.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10135446 chr14 80409478 G T 4.47E-06 Blood pressure / / 21378095 rs10483939 chr14 80415077 G A 1.87E-04 Prion diseases / / 22210626 rs2049829 chr14 80432157 G A 9.85E-06 Obesity-related traits / / 23251661 rs1468843 chr14 80468443 A G 6.05E-06 Lung adenocarcinoma / / 19836008 rs10483942 chr14 80478417 T C 9.98E-05 Lung adenocarcinoma / / 19836008 rs12323429 chr14 80540936 T C 7.58E-05 Lung adenocarcinoma / / 19836008 rs1181353 chr14 80544121 A G 4.96E-05 Sarcoidosis / / 19165924 rs10483944 chr14 80566306 A G 8.17E-05 Intelligence / / 21826061 rs1491493 chr14 80572050 G A 1.37E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10138520 chr14 80572248 T C 3.42E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1491491 chr14 80577818 A G 1.25E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs17110315 chr14 80580335 A T 8.85E-04 Type 2 diabetes / / 17463246 rs1181352 chr14 80583274 T G 2.43E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10483946 chr14 80584527 T G 3.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10220309 chr14 80587141 T C 2.71E-04 Lung function (forced vital capacity) / / 24023788 rs10220309 chr14 80587141 T C 6.00E-06 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10220309 chr14 80587141 T C 9.97E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10140593 chr14 80591998 A G 1.55E-04 Obesity (extreme) / / 21935397 rs9806107 chr14 80607013 G T 5.13E-04 Type 2 diabetes / / 17463246 rs9806104 chr14 80607084 C T 4.04E-04 Type 2 diabetes / / 17463246 rs9788417 chr14 80608412 C T 9.00E-06 Urinary metabolites / / 21572414 rs17110368 chr14 80614217 G A 6.00E-06 Urinary metabolites / / 21572414 rs433163 chr14 80621907 A G 8.00E-06 Urinary metabolites / / 21572414 rs2267873 chr14 80673814 A G 6.76E-04 Type 2 diabetes DIO2 intron 17463246 rs1907526 chr14 80687879 C T 4.62E-04 Type 2 diabetes DIO2 intron 17463246 rs9989235 chr14 80767727 C A 3.24E-04 Birth weight LOC100628307 intron 17255346 rs9989235 chr14 80767727 C A 1.47E-04 Type 2 diabetes LOC100628307 intron 17463246 rs17110502 chr14 80768079 A G 3.21E-04 Birth weight LOC100628307 intron 17255346 rs17110502 chr14 80768079 A G 1.09E-04 Type 2 diabetes LOC100628307 intron 17463246 rs2273173 chr14 80770951 C T 3.59E-04 Birth weight LOC100628307 intron 17255346 rs2273173 chr14 80770951 C T 2.96E-04 Type 2 diabetes LOC100628307 intron 17463246 rs2160355 chr14 80771247 G T 4.68E-04 Type 2 diabetes LOC100628307 intron 17463246 rs7159995 chr14 80773227 T G 3.88E-04 Birth weight LOC100628307 intron 17255346 rs7159995 chr14 80773227 T G 1.87E-04 Type 2 diabetes LOC100628307 intron 17463246 rs17110521 chr14 80773370 T G 5.23E-04 Type 2 diabetes LOC100628307 intron 17463246 rs10131076 chr14 80774385 G A 2.65E-04 Birth weight LOC100628307 intron 17255346 rs10131076 chr14 80774385 G A 1.37E-04 Type 2 diabetes LOC100628307 intron 17463246 rs10483947 chr14 80775115 C T 3.22E-04 Type 2 diabetes LOC100628307 intron 17463246 rs8013239 chr14 80803763 A G 6.60E-05 HIV-1 control LOC100628307 intron 20041166 rs8011737 chr14 80824532 C T 6.55E-05 Lung adenocarcinoma LOC100628307 intron 19836008 rs8011737 chr14 80824532 C T 1.72E-04 Amyotrophic lateral sclerosis LOC100628307 intron 20801718 rs2043061 chr14 80838074 A C 2.27E-05 Amyotrophic lateral sclerosis LOC100628307 intron 20801718 rs12882445 chr14 80848449 G T 4.63E-04 Multiple complex diseases LOC100628307 intron 17554300 rs10152064 chr14 80856675 C T 5.53E-04 Multiple complex diseases LOC100628307 intron 17554300 rs10152064 chr14 80856675 C T 8.11E-04 Amyotrophic lateral sclerosis (sporadic) LOC100628307 intron 24529757 rs17600960 chr14 80929699 C T 8.74E-05 Cognitive impairment induced by topiramate / / 22091778 rs17528984 chr14 80949193 G A 5.46E-05 Type 2 diabetes / / 17463246 rs4899770 chr14 80962048 T C 8.62E-04 Type 2 diabetes / / 17463246 rs2371353 chr14 80995077 T C 5.57E-04 Type 2 diabetes CEP128 intron 17463246 rs10498541 chr14 81002263 G A 9.86E-04 Alzheimer's disease CEP128 intron 17998437 rs12437092 chr14 81005140 T G 6.47E-05 Blood Pressure CEP128 intron pha003047 rs1868633 chr14 81009228 C T 4.14E-05 Lipoproteins CEP128 intron pha003079 rs10498544 chr14 81015420 C T 4.93E-04 Type 2 diabetes CEP128 intron 17846125 rs10138951 chr14 81026314 T C 9.16E-04 Response to taxane treatment (placlitaxel) CEP128 intron 23006423 rs10498545 chr14 81040268 C G 1.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) CEP128 intron 17982456 rs17110818 chr14 81051353 T A 1.60E-05 Height CEP128 intron 19396169 rs7350746 chr14 81052376 T C 0.0000713 Salmonella-induced pyroptosis CEP128 intron 22837397 rs7145447 chr14 81054669 C T 2.74E-04 Type 2 diabetes CEP128 intron 17846125 rs6574590 chr14 81081474 C T 1.66E-09 Multiple complex diseases CEP128 intron 17554300 rs9323690 chr14 81087228 C T 2.04E-05 Fibrinogen CEP128 intron 17255346 rs9323690 chr14 81087228 C T 3.51E-05 Hemoglobin CEP128 intron pha003096 rs17519 chr14 81087894 G A 5.21E-04 Type 2 diabetes CEP128 intron 17846125 rs8016670 chr14 81096699 C T 2.25E-04 Fibrinogen CEP128 intron 17255346 rs8016670 chr14 81096699 C T 2.09E-05 Hemoglobin CEP128 intron pha003096 rs10498547 chr14 81124666 T G 6.60E-04 Type 2 diabetes CEP128 intron 17846125 rs6574598 chr14 81131831 C T 4.80E-04 Intelligence (childhood) CEP128 intron 23358156 rs6574598 chr14 81131831 C T 2.27E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CEP128 intron 24023788 rs2167061 chr14 81141399 C A 2.64E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CEP128 intron 24023788 rs2167061 chr14 81141399 C A 9.83E-05 Coronary heart disease CEP128 intron pha003031 rs7156519 chr14 81144044 T C 1.85E-04 Multiple complex diseases CEP128 intron 17554300 rs9783629 chr14 81150895 T C 1.61E-05 Coronary heart disease CEP128 intron pha003031 rs4903934 chr14 81159295 T C 6.74E-04 Multiple complex diseases CEP128 intron 17554300 rs328239 chr14 81207288 T G 7.97E-05 Response to mTOR inhibitor (rapamycin) CEP128 intron 24009623 rs327435 chr14 81214893 C T 3.89E-04 Taste perception CEP128 intron 22132133 rs327465 chr14 81230040 T C 9.99E-05 Response to mTOR inhibitor (rapamycin) CEP128 intron 24009623 rs327463 chr14 81251255 T C 2.81E-04 Taste perception CEP128 missense 22132133 rs162171 chr14 81260377 A C 4.55E-06 Graves' disease CEP128 intron 21841780 rs327434 chr14 81271071 G A 2.70E-06 Graves' disease CEP128 intron 21841780 rs162174 chr14 81294256 C T 5.08E-06 Graves' disease CEP128 intron 21841780 rs17542712 chr14 81306335 G A 5.87E-05 Coronary heart disease CEP128 intron pha003031 rs7158936 chr14 81315792 A G 2.65E-06 Graves' disease CEP128 intron 21841780 rs2556611 chr14 81346166 G A 9.81E-06 Graves' disease CEP128 intron 21841780 rs12050151 chr14 81368817 T C 3.88E-10 Graves' disease CEP128 intron 21841780 rs1013890 chr14 81386625 A G 3.93E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CEP128 intron 24023788 rs6574612 chr14 81404074 C T 2.13E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CEP128 intron 24023788 rs12587252 chr14 81405922 C T 2.00E-06 Palmitoleic acid (16:1n-7) plasma levels / / 23362303 rs2371461 chr14 81411757 A G 1.24E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2217177 chr14 81415154 T C 8.43E-09 Graves' disease / / 21841780 rs2217177 chr14 81415154 T C 9.22E-05 Lipoproteins / / pha003079 rs2371462 chr14 81420774 T C 7.70E-06 Graves' disease TSHR nearGene-5 21841780 rs8022600 chr14 81421423 G T 4.80E-09 Graves' disease TSHR nearGene-5 21841780 rs179247 chr14 81432546 A G 5.83E-22 Graves' disease TSHR intron 21841780 rs179249 chr14 81435199 C T 2.05E-10 Graves' disease TSHR intron 21841780 rs179260 chr14 81442055 T C 6.55E-06 Asthma TSHR intron 23181788 rs2284720 chr14 81443167 A G 1.63E-10 Graves' disease TSHR intron 21841780 rs2284722 chr14 81444367 G A 5.15E-15 Graves' disease TSHR intron 21841780 rs3783950 chr14 81448282 C G 1.38E-06 Obesity (early onset extreme) TSHR intron 18159244 rs3783949 chr14 81448382 T G 3.45E-07 Graves' disease TSHR intron 21841780 rs12101261 chr14 81451229 C T 7.00E-24 Graves' disease TSHR intron 21841780 rs10145099 chr14 81456694 C T 6.49E-07 Graves' disease TSHR intron 21841780 rs17545038 chr14 81457572 T C 1.56E-10 Graves' disease TSHR intron 21841780 rs2300519 chr14 81458762 T A 1.34E-38 Graves' disease TSHR intron 22922229 rs56885347 chr14 81458762 T TAAA 1.34E-38 Graves' disease TSHR intron 22922229 rs2300520 chr14 81459186 G A 8.79E-04 Alzheimer's disease TSHR intron 22005930 rs2268464 chr14 81467594 C A 8.70E-06 Urinary metabolites TSHR intron 21572414 rs2268464 chr14 81467594 C A 8.92E-04 Myocardial Infarction TSHR intron pha002883 rs4903964 chr14 81468954 G A 1.28E-18 Graves' disease TSHR intron 21841780 rs3783943 chr14 81471446 A G 6.96E-06 Graves' disease TSHR intron 21841780 rs10131915 chr14 81480287 A C 0.0000366 Primary sclerosing cholangitis TSHR intron 23603763 rs2300525 chr14 81497393 T C 1.70E-04 Bipolar disorder,affective TSHR intron 20528957 rs2300525 chr14 81497393 T C 6.66E-07 Graves' disease TSHR intron 21841780 rs2300525 chr14 81497393 T C 8.53E-05 Taste perception TSHR intron 22132133 rs2110697 chr14 81498066 C T 1.19E-04 Taste perception TSHR intron 22132133 rs12323621 chr14 81500598 G T 1.00E-04 Bipolar disorder,affective TSHR intron 20528957 rs726627 chr14 81500884 G T 2.97E-05 Taste perception TSHR intron 22132133 rs11159483 chr14 81501311 C T 8.53E-05 Taste perception TSHR intron 22132133 rs13353125 chr14 81504423 T C 1.44E-04 Taste perception TSHR intron 22132133 rs2024424 chr14 81520379 G C 5.56E-06 Uric acid levels TSHR intron 21294900 rs17111394 chr14 81523128 T C 4.00E-06 optic disc size (rim) TSHR intron 20395239 rs17111394 chr14 81523128 T C 1.64E-09 Graves' disease TSHR intron 21841780 rs17111396 chr14 81524054 T A 1.35E-06 Uric acid levels TSHR intron 21294900 rs2268474 chr14 81524407 T C 5.22E-04 Bipolar disorder,affective TSHR intron 20528957 rs2268474 chr14 81524407 T C 2.04E-05 Graves' disease TSHR intron 21841780 rs11845164 chr14 81531754 T C 4.04E-05 Taste perception TSHR intron 22132133 rs11159490 chr14 81534440 T C 3.70E-05 Taste perception TSHR intron 22132133 rs10151660 chr14 81537484 T C 4.04E-05 Taste perception TSHR intron 22132133 rs6574625 chr14 81549533 G A 2.18E-04 Bipolar disorder,affective TSHR intron 20528957 rs2300527 chr14 81550888 A G 9.00E-04 Bipolar disorder,affective TSHR intron 20528957 rs2300528 chr14 81551260 T A 1.84E-04 Bipolar disorder,affective TSHR intron 20528957 rs2284734 chr14 81553733 G A 6.49E-04 Taste perception TSHR intron 22132133 rs2075173 chr14 81554617 A G 3.94E-04 Bipolar disorder,affective TSHR intron 20528957 rs2241119 chr14 81558965 A G 4.00E-05 Type 2 diabetes and 6 quantitative traits TSHR intron 17848626 rs2241119 chr14 81558965 A G 6.17E-05 Bipolar disorder,affective TSHR intron 20528957 rs2241119 chr14 81558965 A G 5.85E-05 Taste perception TSHR intron 22132133 rs2075177 chr14 81559221 G A 9.48E-05 Bipolar disorder,affective TSHR intron 20528957 rs10142999 chr14 81561425 G A 1.95E-04 Bipolar disorder,affective TSHR intron 20528957 rs2075179 chr14 81562998 T C 4.37E-05 Taste perception TSHR cds-synon 22132133 rs10129380 chr14 81564339 A T 4.37E-05 Taste perception TSHR intron 22132133 rs2300534 chr14 81567080 C A 3.29E-04 Taste perception TSHR intron 22132133 rs7143914 chr14 81568600 A G 7.28E-06 Hair morphology TSHR intron 19896111 rs2080305 chr14 81575419 T C 2.08E-05 Taste perception TSHR intron 22132133 rs8017455 chr14 81575454 T C 6.00E-06 Hair morphology TSHR intron 19896111 rs3783938 chr14 81594380 C T 8.00E-07 Visceral fat TSHR intron 22589738 rs17111530 chr14 81598912 T C 1.00E-06 Smooth-surface caries TSHR intron 24556642 rs17111530 chr14 81598912 T C 1.15E-06 Smooth-surface caries TSHR intron 24556642 rs1957547 chr14 81604138 A G 4.87E-04 Gallstones TSHR intron 17632509 rs11625193 chr14 81604362 T C 2.02E-06 Smooth-surface caries TSHR intron 24556642 rs12883801 chr14 81614514 A G 9.89E-05 Fibrinogen / / pha003068 rs10131728 chr14 81635323 C T 2.00E-07 IgG glycosylation / / 23382691 rs4899786 chr14 81643800 G T 8.14E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs8007841 chr14 81647878 T C 5.13E-05 Bipolar disorder and schizophrenia GTF2A1 intron 20889312 rs7142641 chr14 81677454 A G 8.14E-05 Angioedema in response to angiotensin-converting enzyme inhibitor GTF2A1 intron 23838604 rs7148747 chr14 81727516 G A 5.09E-04 Response to statin treatment (atorvastatin),change in cholesterol levels STON2 UTR-3 20031582 rs17550045 chr14 81757197 C T 1.15E-05 Cortisol secretion,in saliva STON2 intron 21316860 rs4903976 chr14 81761745 C A 4.73E-06 Obesity-related traits STON2 intron 23251661 rs17111687 chr14 81763478 G A 9.60E-05 Substance dependence STON2 intron 21818250 rs6574638 chr14 81767047 G A 8.25E-06 Obesity-related traits STON2 intron 23251661 rs6574644 chr14 81778644 G A 5.00E-06 Obesity-related traits STON2 intron 23251661 rs8013992 chr14 81789479 A G 1.45E-05 Panic disorder STON2 intron 19165232 rs8009171 chr14 81820060 G A 7.88E-05 HIV-1 control STON2 intron 20041166 rs1569012 chr14 81853407 C T 2.80E-05 Malaria STON2 intron 19465909 rs17111790 chr14 81877107 A G 9.59E-04 Response to cytadine analogues (cytosine arabinoside) STON2 intron 24483146 rs8022070 chr14 81877382 C T 8.10E-05 Chronic obstructive pulmonary disease STON2 intron 19300482 rs8022070 chr14 81877382 C T 8.10E-05 Response to statin treatment (atorvastatin),change in cholesterol levels STON2 intron 20031582 rs10134056 chr14 81919396 A G 5.61E-05 Longevity / / 21612516 rs961096 chr14 81921236 G T 6.24E-06 Post-operative nausea and vomiting / / 21694509 rs11847584 chr14 81938947 C T 2.26E-08 Multiple complex diseases SEL1L UTR-3 17554300 rs7152966 chr14 82055420 T C 1.92E-05 Multiple complex diseases / / 17554300 rs7159238 chr14 82065638 C T 6.20E-06 Celiac disease / / 17558408 rs4573871 chr14 82075590 T C 5.15E-04 Insulin resistance / / 21901158 rs1958208 chr14 82125040 G A 1.10E-05 Blood Phenotypes / / 17903294 rs11845075 chr14 82158095 T A 8.35E-04 Type 2 diabetes / / 17463246 rs8016575 chr14 82170943 C T 9.93E-05 Insulin resistance / / 21901158 rs1958218 chr14 82182430 A G 4.92E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs17650895 chr14 82186826 A T 0.0003601 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17650895 chr14 82186826 A T 3.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7157467 chr14 82188199 C T 7.23E-05 Multiple complex diseases / / 17554300 rs7157467 chr14 82188199 C T 0.0003616 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7157467 chr14 82188199 C T 3.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8020609 chr14 82188356 T C 0.0003616 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8020609 chr14 82188356 T C 3.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17572297 chr14 82197200 G A 0.000377 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17572297 chr14 82197200 G A 3.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17651267 chr14 82201762 A G 0.0003886 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17651267 chr14 82201762 A G 3.89E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17572432 chr14 82202541 G A 1.02E-05 Multiple complex diseases / / 17554300 rs17572432 chr14 82202541 G A 0.0003889 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17572432 chr14 82202541 G A 3.89E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1958226 chr14 82204614 A G 0.0003896 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1958226 chr14 82204614 A G 3.90E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1571381 chr14 82209034 G A 2.84E-06 Conotruncal heart defects / / 24800985 rs17572523 chr14 82209447 A G 0.0003762 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17572523 chr14 82209447 A G 3.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17651368 chr14 82209820 A C 0.0003717 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17651368 chr14 82209820 A C 3.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17651392 chr14 82210230 A G 0.0003705 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11847850 chr14 82211857 T C 0.0003202 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11847850 chr14 82211857 T C 3.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17572697 chr14 82216011 C T 6.48E-04 Multiple complex diseases / / 17554300 rs11850035 chr14 82252646 G A 9.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8006442 chr14 82258639 G T 9.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1887735 chr14 82262489 A G 9.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17115911 chr14 82265733 C T 1.50E-05 Urinary metabolites / / 21572414 rs8020020 chr14 82270963 T C 9.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8007879 chr14 82276342 G T 9.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1571379 chr14 82289937 T C 3.82E-05 Prostate cancer / / 22923026 rs12589327 chr14 82299173 A T 7.00E-06 Periodontal disease-related phenotypes / / 24347629 rs11845771 chr14 82331671 C T 5.32E-05 Platelet counts / / pha003100 rs1959122 chr14 82337665 C T 9.00E-07 Conotruncal heart defects / / 24800985 rs7149815 chr14 82347524 G A 8.16E-05 Platelet counts / / pha003100 rs11159521 chr14 82444077 A G 1.20E-05 Urinary metabolites / / 21572414 rs950016 chr14 82444640 G A 1.34E-04 Bipolar disorder / / 19259986 rs950016 chr14 82444640 G A 9.86E-05 Body Mass Index / / pha003014 rs1198014 chr14 82451647 T C 3.68E-04 Bipolar disorder / / 19259986 rs1959493 chr14 82452641 T A 2.30E-05 Urinary metabolites / / 21572414 rs17116229 chr14 82453685 C T 7.13E-04 Myopia (pathological) / / 21095009 rs11627621 chr14 82453928 A G 9.93E-04 Myopia (pathological) / / 21095009 rs1953846 chr14 82456826 A G 4.23E-04 Bipolar disorder / / 19259986 rs1962643 chr14 82508199 T C 2.12E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2217448 chr14 82510077 C T 1.58E-04 Type 2 diabetes / / 17463246 rs4078830 chr14 82546542 G A 1.10E-04 Asperger disorder / / 21182207 rs1430480 chr14 82559833 T C 8.30E-05 Cholesterol / / pha003078 rs1652605 chr14 82586324 A G 1.70E-05 Urinary metabolites / / 21572414 rs17116370 chr14 82595077 A C 4.57E-04 Hemoglobin concentration / / 20534544 rs17116374 chr14 82598517 T A 1.19E-04 Body mass index / / 21701565 rs799047 chr14 82616136 A G 1.00E-05 Urinary metabolites / / 21572414 rs9323719 chr14 82669795 C T 1.37E-06 Ulcerative colitis / / 19915573 rs17116449 chr14 82679207 G A 8.00E-04 Body mass index / / 21701565 rs1457979 chr14 82683633 G A 4.00E-05 Body Fat Distribution / / pha003017 rs1457979 chr14 82683633 G A 2.24E-05 Body Fat Distribution / / pha003018 rs2066041 chr14 82773840 A C 3.80E-05 Type 2 diabetes / / 17460697 rs1457987 chr14 82810830 C G 4.77E-04 Smoking quantity / / 24665060 rs921997 chr14 82811199 C A 7.17E-04 Smoking quantity / / 24665060 rs4904058 chr14 82813654 G A 6.99E-04 Smoking quantity / / 24665060 rs4899801 chr14 82822341 A G 4.35E-04 Smoking quantity / / 24665060 rs1993534 chr14 82827370 T C 6.76E-04 Smoking quantity / / 24665060 rs10483957 chr14 82830219 C T 4.20E-05 Type 2 diabetes / / 17460697 rs11846669 chr14 82886554 C T 6.79E-04 Myopia (pathological) / / 21095009 rs12147730 chr14 82919358 G A 2.01E-05 Postoperative ventricular dysfunction / / 21980348 rs1198416 chr14 82922925 G A 6.78E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1343687 chr14 82937234 T G 3.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10145849 chr14 82941991 G A 6.15E-05 Postoperative ventricular dysfunction / / 21980348 rs10146004 chr14 82942388 A G 2.88E-05 Postoperative ventricular dysfunction / / 21980348 rs7140805 chr14 82944156 G A 6.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17116851 chr14 82974228 G A 1.34E-04 Multiple complex diseases / / 17554300 rs7149484 chr14 82982896 A G 8.23E-05 Waist Circumference / / pha003023 rs17116928 chr14 82994159 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2372200 chr14 83029545 A G 4.00E-04 Chronic fatigue syndrome / / 21912186 rs2798389 chr14 83051150 C T 0.0000929 Oxaliplatin induced haematologic in response to colorectal cancer treatment / / 22310351 rs10131468 chr14 83066038 T C 7.24E-06 Esophageal cancer (squamous cell) / / 22960999 rs2798370 chr14 83096926 G T 2.54E-04 Coronary Artery Disease / / 17634449 rs1756351 chr14 83101837 C T 3.59E-04 Height / / 17255346 rs951200 chr14 83117679 C T 3.27E-04 Fibrinogen / / 17255346 rs1629912 chr14 83121689 C G 1.21E-05 Serum metabolites / / 19043545 rs2150333 chr14 83170722 A T 2.90E-06 Prostate cancer (early onset) / / 24740154 rs10484135 chr14 83184136 G A 7.64E-04 Multiple complex diseases / / 17554300 rs10134460 chr14 83192028 G A 9.68E-05 Bipolar disorder / / 20451256 rs1242551 chr14 83211803 G A 5.32E-04 Multiple complex diseases / / 17554300 rs972811 chr14 83214634 C T 4.11E-04 Multiple complex diseases / / 17554300 rs1152358 chr14 83219238 G A 2.80E-04 Multiple complex diseases / / 17554300 rs1036570 chr14 83225103 A G 4.88E-05 Systemic sclerosis / / 21750679 rs746630 chr14 83255205 G C 4.00E-06 Obesity-related traits / / 23251661 rs17117349 chr14 83258404 A G 7.59E-04 Multiple complex diseases / / 17554300 rs12588957 chr14 83263757 T G 4.74E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10484138 chr14 83274513 G A 6.50E-04 Multiple complex diseases / / 17554300 rs2372243 chr14 83304672 C T 2.50E-06 Urinary metabolites / / 21572414 rs5012867 chr14 83304803 T C 9.80E-06 Urinary metabolites / / 21572414 rs6574721 chr14 83306196 A G 3.68E-06 Alzheimer's disease (late onset) / / 21379329 rs6574721 chr14 83306196 A G 8.22E-05 Blood Pressure / / pha003039 rs17676330 chr14 83319876 G A 1.67E-06 Alzheimer's disease (late onset) / / 21379329 rs10130259 chr14 83342322 T C 4.00E-06 Obesity-related traits / / 23251661 rs10130259 chr14 83342322 T C 7.41E-06 Word reading / / 23738518 rs10130429 chr14 83342471 T C 4.28E-06 Obesity-related traits / / 23251661 rs8009067 chr14 83342978 C G 4.40E-04 Type 2 diabetes / / 17463246 rs7161595 chr14 83349134 A G 4.28E-06 Obesity-related traits / / 23251661 rs12050412 chr14 83378003 T G 5.00E-06 Word reading / / 23738518 rs7160795 chr14 83382211 C T 2.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs12889574 chr14 83393115 G A 8.06E-04 Alzheimer's disease / / 22005930 rs11628311 chr14 83397783 A G 6.35E-04 Aortic root size / / 21223598 rs1959736 chr14 83417873 T G 7.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs4591055 chr14 83448620 G C 1.00E-05 Urinary metabolites / / 21572414 rs8016995 chr14 83448834 C T 9.50E-06 Urinary metabolites / / 21572414 rs1263459 chr14 83454485 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1263464 chr14 83460727 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17117825 chr14 83463042 G A 8.69E-05 Weight / / pha003026 rs10132156 chr14 83492831 G A 8.24E-04 Multiple complex diseases / / 17554300 rs17618463 chr14 83553735 T C 9.67E-04 Multiple complex diseases / / 17554300 rs17680635 chr14 83553815 C G 7.72E-04 Multiple complex diseases / / 17554300 rs7152994 chr14 83636517 G C 9.89E-04 Coronary heart disease / / 21606135 rs1457011 chr14 83650210 C G 4.79E-04 Coronary heart disease / / 21606135 rs10484152 chr14 83650541 C T 3.90E-04 Coronary heart disease / / 21606135 rs1457020 chr14 83739407 T A,C,G 1.18E-04 Attention deficit hyperactivity disorder / / 22420046 rs162637 chr14 83761493 T C 5.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs7152555 chr14 83882897 G A 6.83E-04 Depression (quantitative trait) / / 20800221 rs229817 chr14 83920369 C T 1.59E-04 Multiple complex diseases / / 17554300 rs4904117 chr14 83941267 G A 3.78E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10144243 chr14 83974996 C A 1.14E-12 Multiple complex diseases / / 17554300 rs1241940 chr14 84008852 T A,C,G 5.62E-04 Acute lung injury / / 22295056 rs12888722 chr14 84016206 A G 9.63E-04 Acute lung injury / / 22295056 rs1007383 chr14 84017138 C T 6.70E-05 Multiple complex diseases / / 17554300 rs12895787 chr14 84017914 C T 9.63E-04 Acute lung injury / / 22295056 rs17695289 chr14 84026578 T C 5.76E-04 Acute lung injury / / 22295056 rs1241956 chr14 84041841 T C 3.93E-05 Multiple complex diseases / / 17554300 rs17118868 chr14 84062199 T G 4.10E-05 Lung adenocarcinoma / / 22797724 rs8023044 chr14 84118602 G A 5.29E-04 Insulin resistance / / 21901158 rs1958438 chr14 84160459 G A 5.30E-04 Suicidal ideation / / 22030708 rs1958421 chr14 84180243 T C 1.30E-04 Suicidal ideation / / 22030708 rs1958420 chr14 84180364 T G 8.19E-04 Alcohol dependence / / 20201924 rs10873350 chr14 84180869 G A 8.19E-04 Alcohol dependence / / 20201924 rs9323737 chr14 84182662 A G 8.19E-04 Alcohol dependence / / 20201924 rs9323737 chr14 84182662 A G 3.80E-04 Suicidal ideation / / 22030708 rs12587990 chr14 84184538 C A 1.09E-04 Substance dependence / / 21818250 rs877800 chr14 84192245 C T 8.19E-04 Alcohol dependence / / 20201924 rs17709382 chr14 84243988 T C 9.30E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2372533 chr14 84253909 C G 6.68E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1958442 chr14 84263901 G T 1.09E-04 Bladder cancer / / 19648920 rs10484109 chr14 84265278 T C 6.68E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10484108 chr14 84272455 T C 8.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs17710986 chr14 84307993 C T 3.00E-05 Personality dimensions / / 18957941 rs7140996 chr14 84311967 A G 7.53E-05 Cognitive impairment induced by topiramate / / 22091778 rs1705664 chr14 84377743 G A 3.16E-04 HIV-1 viral setpoint / / 17641165 rs1015277 chr14 84438074 A C 3.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs10134295 chr14 84447293 T G 9.40E-06 Urinary metabolites / / 21572414 rs10130868 chr14 84455151 G A 3.79E-04 Smoking initiation / / 24665060 rs7140245 chr14 84463633 T G 2.57E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs17119456 chr14 84485390 A G 7.57E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs10484124 chr14 84500349 C A 9.86E-06 Glycemic traits (pregnancy) / / 23903356 rs17119553 chr14 84509670 A G 4.02E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs4904156 chr14 84519486 A G 3.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2787452 chr14 84530365 A C 2.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2787448 chr14 84534997 T C 4.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1381608 chr14 84546472 G A 1.34E-04 Fibrinogen / / 17255346 rs1766151 chr14 84555125 T C 1.47E-04 Fibrinogen / / 17255346 rs1766151 chr14 84555125 T C 7.98E-04 Multiple complex diseases / / 17554300 rs3850371 chr14 84555365 C T 1.08E-05 Fibrinogen / / 17255346 rs3850371 chr14 84555365 C T 5.67E-04 Multiple complex diseases / / 17554300 rs12882862 chr14 84559716 G A 3.97E-05 Fibrinogen / / 17255346 rs17697055 chr14 84578739 C T 3.85E-04 Fibrinogen / / 17255346 rs17624113 chr14 84586058 C G 3.89E-06 Fibrinogen / / 17255346 rs17624209 chr14 84589814 T G 4.75E-04 Schizophrenia / / 20832056 rs8022461 chr14 84591761 T C 3.26E-05 Fibrinogen / / 17255346 rs7152554 chr14 84597385 G A,C 6.00E-06 Obesity-related traits / / 23251661 rs1947722 chr14 84598224 A G 3.28E-05 Fibrinogen / / 17255346 rs8021483 chr14 84600385 C A 3.59E-06 Fibrinogen / / 17255346 rs17624978 chr14 84611612 C A 5.95E-06 Fibrinogen / / 17255346 rs1031786 chr14 84615814 C T 5.95E-06 Fibrinogen / / 17255346 rs17119756 chr14 84634432 A G 4.68E-04 Fibrinogen / / 17255346 rs7142799 chr14 84634736 T C 4.68E-04 Fibrinogen / / 17255346 rs7147015 chr14 84635493 A G 3.84E-04 Fibrinogen / / 17255346 rs61541620 chr14 84720051 T G 3.05E-13 Metabolite levels / / 22286219 rs11159642 chr14 84730585 A G 2.31E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs8009583 chr14 84765763 T C 9.21E-04 Multiple complex diseases / / 17554300 rs11159647 chr14 84775209 G A 2.00E-06 Alzheimer's disease / / 18976728 rs11159647 chr14 84775209 G A 2.00E-06 Alzheimer's disease (late onset) / / 21460841 rs4309338 chr14 84792063 C T 4.07E-04 Bipolar disorder / / 19259986 rs4350505 chr14 84793767 A G 1.88E-06 Erythrocyte counts / / pha003101 rs4326978 chr14 84798827 G T 1.63E-06 Erythrocyte counts / / pha003101 rs4411445 chr14 84859706 C T 8.97E-05 Pancreatic cancer / / pha002874 rs8006640 chr14 84909306 A G 4.10E-04 Blood pressure / / 17255346 rs12883344 chr14 84911548 C A 3.85E-04 Blood pressure / / 17255346 rs10136356 chr14 84928889 G A 2.15E-05 Fibrinogen / / pha003068 rs1349176 chr14 84963412 A G 5.78E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs1449095 chr14 85019897 C A 5.32E-05 Birth weight / / 17255346 rs1813404 chr14 85046837 T C 6.66E-05 Glucose levels / / pha003061 rs1449114 chr14 85072563 A G 9.25E-05 Glucose levels / / pha003061 rs2922656 chr14 85081491 A C 8.35E-04 Tourette syndrome / / 22889924 rs17185981 chr14 85096819 A C 8.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs17258171 chr14 85097147 T C 8.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs2372780 chr14 85100598 A G 8.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs2372781 chr14 85100726 T C 8.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs12587920 chr14 85101276 T A 7.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs13285529 chr14 85116699 T C 6.08E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs36179278 chr14 85116699 TAA TA,TG 6.08E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs726957 chr14 85125287 G A 5.00E-05 Personality dimensions / / 18957941 rs4577002 chr14 85131164 T C 4.71E-04 Iron levels / / pha002876 rs1564525 chr14 85137336 T C 8.76E-05 Iron levels / / 19880490 rs1564525 chr14 85137336 T C 8.76E-05 Iron levels / / pha002876 rs2819809 chr14 85144255 G C 6.14E-04 Smoking quantity / / 24665060 rs1481422 chr14 85184521 T C 2.50E-06 Urinary metabolites / / 21572414 rs1110774 chr14 85203088 T G 7.68E-05 AIDS progression / / 19115949 rs2623147 chr14 85210758 G A 6.00E-06 Urinary metabolites / / 21572414 rs1126059 chr14 85211171 G A 4.20E-06 Urinary metabolites / / 21572414 rs1952170 chr14 85211308 A C 9.90E-06 Urinary metabolites / / 21572414 rs1481424 chr14 85216881 A T 1.20E-05 Urinary metabolites / / 21572414 rs2819818 chr14 85224533 C T 3.40E-06 Urinary metabolites / / 21572414 rs1120177 chr14 85251067 A T 2.80E-05 Urinary metabolites / / 21572414 rs1481407 chr14 85260065 A G 4.70E-06 Urinary metabolites / / 21572414 rs2623106 chr14 85264742 C T 5.26E-05 Cognitive test performance / / 20125193 rs1483065 chr14 85310791 G A 2.50E-05 Urinary metabolites / / 21572414 rs1483066 chr14 85310887 G A 2.20E-05 Urinary metabolites / / 21572414 rs17120398 chr14 85355544 C T 8.09E-04 Endometrial cancer / / 24096698 rs10144260 chr14 85355572 G A 1.10E-08 Multiple complex diseases / / 17554300 rs17120641 chr14 85469390 A G 5.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs8017468 chr14 85469906 G A 1.30E-06 Urinary metabolites / / 21572414 rs17120648 chr14 85473581 C T 4.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs12435212 chr14 85483485 G T 6.14E-05 Attention deficit hyperactivity disorder / / 23728934 rs863127 chr14 85495988 C G 4.18E-05 Attention deficit hyperactivity disorder / / 23728934 rs856627 chr14 85499165 G A 4.85E-05 Attention deficit hyperactivity disorder / / 23728934 rs17120704 chr14 85506172 T C 2.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs17672436 chr14 85507167 C T 1.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs17672502 chr14 85512024 A T 7.46E-05 Suicide attempts in bipolar disorder / / 21423239 rs8008253 chr14 85513165 T G 9.23E-05 Suicide attempts in bipolar disorder / / 21423239 rs8007738 chr14 85513454 G A 6.70E-05 Suicide attempts in bipolar disorder / / 21423239 rs17740265 chr14 85516115 A G 1.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs17740265 chr14 85516115 A G 2.20E-05 Urinary metabolites / / 21572414 rs17672580 chr14 85516429 G C 1.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs10129777 chr14 85516453 A G 7.08E-05 Suicide attempts in bipolar disorder / / 21423239 rs34847526 chr14 85517841 C CG 1.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs7148246 chr14 85517841 C T 1.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs1480406 chr14 85526690 G T 1.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs10220453 chr14 85536444 C T 3.04E-05 Erythrocyte counts / / pha003090 rs12887386 chr14 85565927 A G 7.90E-04 Multiple complex diseases / / 17554300 rs17120763 chr14 85590648 G A 3.33E-04 Alzheimer's disease / / 17998437 rs11851675 chr14 85591072 A G 4.76E-04 Alzheimer's disease / / 17998437 rs9671744 chr14 85643640 C T 4.98E-04 Multiple complex diseases / / 17554300 rs16917 chr14 85648419 A C 1.86E-04 Alzheimer's disease / / 17998437 rs12436689 chr14 85654019 T C 7.00E-06 Pulmonary function decline / / 22424883 rs8016502 chr14 85657757 T G 5.47E-04 Insulin resistance / / 21901158 rs1442574 chr14 85661805 G T 8.45E-04 Multiple complex diseases / / 17554300 rs8004329 chr14 85664479 C T 2.62E-05 Lipoproteins / / pha003079 rs1667540 chr14 85673224 C T 9.75E-06 Lipoproteins / / pha003079 rs1550584 chr14 85683053 C T 7.00E-06 IgG glycosylation / / 23382691 rs1562694 chr14 85684590 A G 2.67E-07 Multiple complex diseases / / 17554300 rs2767538 chr14 85689875 G A 5.15E-05 Multiple complex diseases / / 17554300 rs17796639 chr14 85712941 A G 4.14E-04 Alzheimer's disease / / 24755620 rs10498581 chr14 85736868 G A 5.73E-04 Alzheimer's disease / / 24755620 rs1867082 chr14 85737169 A G 1.00E-06 QRS duration / / 23534349 rs1867082 chr14 85737169 A G 8.30E-04 Heart Failure / / pha002885 rs2053514 chr14 85740426 T C 4.90E-05 Bilirubin levels / / 19414484 rs8008671 chr14 85744057 C T 4.05E-04 Myopia (pathological) / / 21095009 rs35195423 chr14 85792358 G A 8.09E-04 Type 2 diabetes / / 17463246 rs34128774 chr14 85792401 C T 6.99E-04 Type 2 diabetes / / 17463246 rs12889354 chr14 85794251 G C 9.03E-04 Type 2 diabetes / / 17463246 rs7154225 chr14 85797984 A G 3.61E-04 Multiple complex diseases / / 17554300 rs17796783 chr14 85809911 T C 3.00E-13 Heart rate / / 23583979 rs7141559 chr14 85838792 G A 6.57E-04 Type 2 diabetes / / 17463246 rs17796831 chr14 85854480 C T 1.94E-04 Type 2 diabetes / / 17463246 rs1957325 chr14 85896161 C T 4.05E-05 Type 2 diabetes and other traits / / 19734900 rs17635276 chr14 85910242 T G 8.55E-04 Alzheimer's disease / / 22005930 rs7143371 chr14 85914411 G A 8.44E-04 Alzheimer's disease / / 22005930 rs11845253 chr14 85918958 A T 8.37E-04 Alzheimer's disease / / 22005930 rs8014131 chr14 85963856 C A 3.00E-07 Menarche (age at onset) / / 23599027 rs6574824 chr14 85978782 T A 2.37E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1955436 chr14 85987317 T G 1.47E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1884009 chr14 85987605 G T 3.98E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1884009 chr14 85987605 G T 5.04E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11847175 chr14 86004208 T C 1.29E-04 Response to cytadine analogues (cytosine arabinoside) FLRT2 intron 24483146 rs7160530 chr14 86010805 A G 5.68E-04 Response to cytadine analogues (cytosine arabinoside) FLRT2 intron 24483146 rs12882499 chr14 86011731 C T 5.54E-04 Response to cytadine analogues (cytosine arabinoside) FLRT2 intron 24483146 rs12889429 chr14 86012725 T C 1.52E-04 Response to cytadine analogues (cytosine arabinoside) FLRT2 intron 24483146 rs1955412 chr14 86012794 T C 8.74E-05 Response to cytadine analogues (cytosine arabinoside) FLRT2 intron 24483146 rs1950177 chr14 86017306 T G 1.01E-04 Bipolar disorder FLRT2 intron 18317468 rs985620 chr14 86017922 A G 1.98E-04 Substance dependence FLRT2 intron 21818250 rs2057116 chr14 86020346 C T 7.32E-04 Alzheimer's disease FLRT2 intron 17998437 rs910311 chr14 86050860 C G 8.22E-04 Type 2 diabetes FLRT2 intron 17463246 rs910311 chr14 86050860 C G 4.07E-04 Multiple complex diseases FLRT2 intron 17554300 rs17712565 chr14 86053777 T C 6.69E-05 Attention deficit hyperactivity disorder FLRT2 intron 23728934 rs1075612 chr14 86108018 A C 1.54E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs8008317 chr14 86133451 A G 5.27E-05 Colorectal cancer / / 19723657 rs2638801 chr14 86145047 T C 6.93E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12887050 chr14 86146583 A G 6.30E-05 Coronary Artery Disease / / 17634449 rs12888694 chr14 86146748 T C 5.98E-05 Coronary Artery Disease / / 17634449 rs7146639 chr14 86158107 A G 8.25E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4312250 chr14 86163285 C T 9.31E-04 Multiple complex diseases / / 17554300 rs8003655 chr14 86197347 T C 4.43E-05 Major depressive disorder / / 19107115 rs111063687 chr14 86314568 A C 4.78E-05 Intracerebral hemorrhage / / 24656865 rs72695282 chr14 86328096 A G 3.87E-05 Intracerebral hemorrhage / / 24656865 rs58915059 chr14 86329630 A G 3.67E-05 Intracerebral hemorrhage / / 24656865 rs72695288 chr14 86330884 G A 1.50E-05 Intracerebral hemorrhage / / 24656865 rs2888473 chr14 86333289 A T 7.82E-06 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines / / 21483694 rs2888473 chr14 86333289 A T 4.73E-05 Intracerebral hemorrhage / / 24656865 rs1959456 chr14 86333800 A G 1.38E-05 Intracerebral hemorrhage / / 24656865 rs61991281 chr14 86334062 G A 1.49E-05 Intracerebral hemorrhage / / 24656865 rs61991282 chr14 86334519 C T 1.36E-05 Intracerebral hemorrhage / / 24656865 rs17796903 chr14 86334948 A G 1.46E-05 Intracerebral hemorrhage / / 24656865 rs61991283 chr14 86335280 C T 1.44E-05 Intracerebral hemorrhage / / 24656865 rs8017965 chr14 86335746 T C 1.32E-05 Intracerebral hemorrhage / / 24656865 rs12323916 chr14 86335966 C T 7.41E-04 Multiple complex diseases / / 17554300 rs2888474 chr14 86336017 C T 1.28E-05 Intracerebral hemorrhage / / 24656865 rs2373035 chr14 86336203 C T 1.54E-05 Intracerebral hemorrhage / / 24656865 rs7144499 chr14 86337292 C A 1.25E-05 Intracerebral hemorrhage / / 24656865 rs7145800 chr14 86337346 T C 1.25E-05 Intracerebral hemorrhage / / 24656865 rs72695296 chr14 86340774 T A 5.84E-06 Intracerebral hemorrhage / / 24656865 rs6574859 chr14 86358567 A C 3.73E-05 LDL lipoproteins / / pha002902 rs12587372 chr14 86483988 G A 7.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17202185 chr14 86528168 C A 9.10E-06 Urinary metabolites / / 21572414 rs2153493 chr14 86590481 G A 2.50E-05 Urinary metabolites / / 21572414 rs2153492 chr14 86590607 T C 1.90E-05 Urinary metabolites / / 21572414 rs9323783 chr14 86611366 C T 9.60E-05 Intelligence (childhood) / / 23358156 rs41348245 chr14 86650616 T C 4.72E-04 Multiple complex diseases / / 17554300 rs12437116 chr14 86691435 T C 7.83E-04 Alcohol dependence / / 20201924 rs17121961 chr14 86718794 A G 2.48E-05 Multiple complex diseases / / 17554300 rs17122098 chr14 86764004 T C 4.20E-05 Type 2 diabetes / / 17463246 rs17122103 chr14 86764590 A G 5.10E-05 Type 2 diabetes / / 17463246 rs10133064 chr14 86774395 G T 9.38E-04 Stroke / / pha002886 rs17122153 chr14 86794035 C T 6.13E-04 Insulin resistance / / 21901158 rs1106098 chr14 86794215 C T 2.58E-04 Type 2 diabetes / / 17463246 rs1505150 chr14 86795084 C T 2.45E-04 Myopia (pathological) / / 21095009 rs10484099 chr14 86799697 G A 1.45E-04 Type 2 diabetes / / 17463246 rs1394708 chr14 86802664 A C 7.76E-05 Type 2 diabetes / / 17463246 rs1505172 chr14 86802726 T C 6.47E-04 Myopia (pathological) / / 21095009 rs10484100 chr14 86817096 A G 3.00E-06 Blood trace element (Zn levels) / / 23720494 rs10147870 chr14 86824930 C T 9.78E-05 Serum metabolites / / 19043545 rs10147870 chr14 86824930 C T 7.57E-04 Myopia (pathological) / / 21095009 rs17122241 chr14 86827614 A G 9.70E-05 Type 2 diabetes / / 17463246 rs804942 chr14 86828436 C T 9.73E-05 Type 2 diabetes / / 17463246 rs11159770 chr14 86830693 C T 7.27E-05 Serum metabolites / / 19043545 rs804930 chr14 86850928 C T 1.09E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs2185499 chr14 86878566 A T 3.40E-06 Urinary metabolites / / 21572414 rs10146128 chr14 86884989 T G 4.90E-06 Urinary metabolites / / 21572414 rs12589989 chr14 86889368 C T 7.59E-04 Multiple complex diseases / / 17554300 rs12589989 chr14 86889368 C T 1.80E-06 Urinary metabolites / / 21572414 rs10147647 chr14 86889501 G A 9.80E-06 Urinary metabolites / / 21572414 rs4899900 chr14 86895007 T A 1.80E-06 Urinary metabolites / / 21572414 rs7157820 chr14 86895654 G A 9.29E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10484102 chr14 86898200 G A 8.99E-05 Post-operative nausea and vomiting / / 21694509 rs10484102 chr14 86898200 G A 1.11E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs12882718 chr14 86902054 C T 6.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs2185498 chr14 86911489 G A 3.20E-06 Urinary metabolites / / 21572414 rs17122386 chr14 86916425 T C 2.09E-04 Myopia (pathological) / / 21095009 rs2022775 chr14 86919888 C T 1.80E-06 Urinary metabolites / / 21572414 rs1538873 chr14 86920273 C T 1.20E-06 Urinary metabolites / / 21572414 rs10132264 chr14 86923368 T C 4.28E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs1959798 chr14 86973356 T G 4.04E-05 Alzheimer's disease / / 17998437 rs1959302 chr14 87049980 C T 4.06E-04 Multiple complex diseases / / 17554300 rs1959305 chr14 87050806 A G 4.40E-04 Schizophrenia / / 19197363 rs8014279 chr14 87063954 T C 5.18E-04 Schizophrenia / / 19197363 rs1889800 chr14 87072238 C T 5.49E-05 Basophils / / pha003087 rs1953532 chr14 87090865 G A 2.47E-04 Multiple complex diseases / / 17554300 rs1959287 chr14 87112621 G A 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12100975 chr14 87124246 C T 3.72E-04 Alzheimer's disease (late onset) / / 21379329 rs1891547 chr14 87129218 C T 5.39E-04 Dental caries / / 21940522 rs1959290 chr14 87138729 T C 2.07E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs17797254 chr14 87140692 T C 3.60E-06 Urinary metabolites / / 21572414 rs11844457 chr14 87185430 A C 4.96E-05 Tuberculosis / / 24057671 rs17797290 chr14 87223305 C T 8.80E-04 Type 2 diabetes / / 17463246 rs241493 chr14 87243663 G T 4.34E-04 Smoking initiation / / 24665060 rs1775681 chr14 87245904 A T 3.36E-04 Smoking initiation / / 24665060 rs1362721 chr14 87248601 T C 2.09E-04 Smoking initiation / / 24665060 rs1775677 chr14 87253751 T C 2.10E-04 Smoking initiation / / 24665060 rs17202576 chr14 87264193 A G 5.61E-04 Type 2 diabetes / / 17463246 rs11625263 chr14 87266394 A G 4.73E-04 Type 2 diabetes / / 17463246 rs11625263 chr14 87266394 A G 0.000555 Salmonella-induced pyroptosis / / 22837397 rs76400209 chr14 87287238 G C 0.0000793 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs74913737 chr14 87291291 G A 0.0000778 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs74244238 chr14 87305944 T G 0.0000554 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17122755 chr14 87307717 G A 9.49E-04 Multiple complex diseases / / 17554300 rs1003205 chr14 87313907 T C 9.81E-04 Multiple complex diseases / / 17554300 rs1362719 chr14 87317210 T C 2.20E-13 Multiple complex diseases / / 17554300 rs10498606 chr14 87320278 C A 8.56E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs10144609 chr14 87325168 G A 6.03E-04 Smoking cessation / / 24665060 rs1019367 chr14 87357329 A C 5.00E-04 Smoking initiation / / 24665060 rs1420813 chr14 87476592 A C 0.0000615 Amyotrophic lateral sclerosis / / 23587638 rs1638721 chr14 87500916 C T 1.40E-05 Urinary metabolites / / 21572414 rs11624056 chr14 87506248 A T 3.00E-08 Sudden cardiac arrest / / 21658281 rs17122932 chr14 87513138 G A 1.94E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs1978243 chr14 87526407 C T 6.25E-04 Diabetic nephropathy / / 21150874 rs1978243 chr14 87526407 C T 7.53E-04 Type 2 diabetes / / 22238593 rs17122951 chr14 87528276 C T 4.46E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs3925163 chr14 87565486 G A 6.46E-04 Alzheimer's disease / / 17998437 rs11624852 chr14 87612890 C T 6.27E-06 Cognitive decline / / 23207651 rs12586790 chr14 87613844 T C 9.91E-04 Multiple complex diseases / / 17554300 rs2776546 chr14 87628156 C A 7.07E-07 Response to diuretic therapy in hypertension / / 23753411 rs12436096 chr14 87632485 A G 7.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs17123087 chr14 87656775 G A 7.00E-06 Urinary metabolites / / 21572414 rs1484981 chr14 87672957 C A 9.67E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs1484986 chr14 87720023 T G 5.26E-04 Smoking initiation / / 24665060 rs723843 chr14 87727036 A G 6.38E-04 Smoking initiation / / 24665060 rs17123224 chr14 87740087 C T 4.32E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs1756650 chr14 87741025 C T 2.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs7142552 chr14 87752261 A G 3.18E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs1385397 chr14 87756478 G C 5.12E-05 Bipolar disorder / / 19488044 rs1385397 chr14 87756478 G C 5.84E-05 Bipolar Disorder / / pha002863 rs1365524 chr14 87770671 T G 6.54E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs10141127 chr14 87773053 C A 1.80E-05 Urinary metabolites / / 21572414 rs2148330 chr14 87780440 G A 7.35E-04 Multiple complex diseases / / 17554300 rs1430561 chr14 87795892 G A 8.02E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs1367357 chr14 87805723 G C 9.62E-04 Type 2 diabetes / / 17463246 rs1430566 chr14 87809766 C T 2.21E-05 Word reading / / 23738518 rs1426790 chr14 87845954 C T 8.90E-05 Serum metabolites / / 19043545 rs10149148 chr14 87872121 T C 2.19E-04 Multiple complex diseases / / 17554300 rs7158884 chr14 87904340 G A 5.96E-05 Diabetes Mellitus / / pha003059 rs8006733 chr14 87935883 C T 9.65E-04 Obesity (extreme) / / 21935397 rs11850024 chr14 87945375 C A 9.29E-04 Obesity (extreme) / / 21935397 rs10483999 chr14 87948873 T C 8.81E-04 Obesity (extreme) / / 21935397 rs2401694 chr14 87949162 G T 8.62E-04 Obesity (extreme) / / 21935397 rs11852146 chr14 87952746 C T 7.39E-04 Obesity (extreme) / / 21935397 rs11845141 chr14 87981391 G A 3.97E-04 Obesity (extreme) / / 21935397 rs11848625 chr14 87984591 C A 4.15E-04 Obesity (extreme) / / 21935397 rs10139298 chr14 88008255 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6574951 chr14 88039897 G A 9.37E-04 Alzheimer's disease / / 22005930 rs10146942 chr14 88049175 T C 8.67E-04 Depression (quantitative trait) / / 20800221 rs10137222 chr14 88055411 A C 8.48E-04 Depression (quantitative trait) / / 20800221 rs1887351 chr14 88057863 T C 9.87E-04 Depression (quantitative trait) / / 20800221 rs4517714 chr14 88059134 C T 8.34E-04 Depression (quantitative trait) / / 20800221 rs1952274 chr14 88060316 A G 8.31E-04 Depression (quantitative trait) / / 20800221 rs1958133 chr14 88061751 C T 8.27E-04 Depression (quantitative trait) / / 20800221 rs10220500 chr14 88061930 G C 9.57E-04 Depression (quantitative trait) / / 20800221 rs8013318 chr14 88063050 T C 8.23E-04 Depression (quantitative trait) / / 20800221 rs8012556 chr14 88063092 G A 8.23E-04 Depression (quantitative trait) / / 20800221 rs1887349 chr14 88063607 C T 8.14E-04 Depression (quantitative trait) / / 20800221 rs1958132 chr14 88065605 G A,C,T 9.17E-04 Depression (quantitative trait) / / 20800221 rs17123606 chr14 88069412 T G 7.90E-04 Depression (quantitative trait) / / 20800221 rs980433 chr14 88071134 C T 7.82E-04 Depression (quantitative trait) / / 20800221 rs10147942 chr14 88076191 C T 7.55E-04 Depression (quantitative trait) / / 20800221 rs7155892 chr14 88076592 T C 7.51E-04 Depression (quantitative trait) / / 20800221 rs11851496 chr14 88080181 G A 7.99E-04 Depression (quantitative trait) / / 20800221 rs7492509 chr14 88081186 C T 7.08E-04 Depression (quantitative trait) / / 20800221 rs10130944 chr14 88081876 G T 7.59E-04 Depression (quantitative trait) / / 20800221 rs10145369 chr14 88082002 T G 6.89E-04 Depression (quantitative trait) / / 20800221 rs8006184 chr14 88090264 G A 5.15E-04 Depression (quantitative trait) / / 20800221 rs7156776 chr14 88092872 G A 5.53E-04 Depression (quantitative trait) / / 20800221 rs8006574 chr14 88097901 C T 5.33E-04 Depression (quantitative trait) / / 20800221 rs7154870 chr14 88099099 G C 4.95E-04 Depression (quantitative trait) / / 20800221 rs7149626 chr14 88099985 C A 5.31E-04 Depression (quantitative trait) / / 20800221 rs1958129 chr14 88101258 A G 4.92E-04 Depression (quantitative trait) / / 20800221 rs8015320 chr14 88104313 C A 5.26E-04 Depression (quantitative trait) / / 20800221 rs8015799 chr14 88104600 C T 5.25E-04 Depression (quantitative trait) / / 20800221 rs8022231 chr14 88105892 G T 5.23E-04 Depression (quantitative trait) / / 20800221 rs752146 chr14 88106258 A T 5.23E-04 Depression (quantitative trait) / / 20800221 rs1075941 chr14 88106865 G A 4.86E-04 Depression (quantitative trait) / / 20800221 rs10134221 chr14 88107174 C T 5.21E-04 Depression (quantitative trait) / / 20800221 rs10134597 chr14 88107423 G A 5.21E-04 Depression (quantitative trait) / / 20800221 rs8018749 chr14 88108630 G A 5.20E-04 Depression (quantitative trait) / / 20800221 rs10162364 chr14 88137295 C T 2.54E-04 Smoking initiation / / 24665060 rs11845651 chr14 88163726 T G 5.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs11845651 chr14 88163726 T G 2.77E-04 Smoking initiation / / 24665060 rs1959715 chr14 88165210 A G 3.34E-04 Height / / 17255346 rs7155433 chr14 88168175 C T 1.29E-04 Coronary heart disease / / 21606135 rs1959718 chr14 88180858 C T 1.60E-05 Bipolar disorder / / 21771265 rs17259751 chr14 88187220 T C 3.90E-04 Coronary heart disease / / 21606135 rs1288709 chr14 88221584 C T 6.26E-04 Schizophrenia / / 19197363 rs1288729 chr14 88255903 A G 4.97E-04 Multiple complex diseases / / 17554300 rs2401711 chr14 88273845 G T 9.82E-05 Neuroblastoma / / pha002895 rs12881243 chr14 88275954 C A 4.32E-04 Schizophrenia / / 19197363 rs8006648 chr14 88289299 C T 2.83E-05 Lipid levels / / pha003082 rs2167239 chr14 88291305 G A 6.14E-06 Rheumatoid arthritis / / 19503088 rs2167239 chr14 88291305 G A 3.35E-05 LDL lipoproteins / / pha002902 rs8013356 chr14 88292100 A T 9.38E-04 Spine bone size / / 23207799 rs4322600 chr14 88295600 A G 4.00E-06 Breast cancer / / 22923054 rs7148834 chr14 88304232 A G 1.69E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12435864 chr14 88328980 C T 8.26E-04 Multiple complex diseases / / 17554300 rs6574964 chr14 88343126 G T 9.76E-04 Multiple complex diseases / / 17554300 rs11159828 chr14 88345181 T C 4.20E-05 Heart Rate / / pha003054 rs12881360 chr14 88349471 A G 5.89E-05 Heart Rate / / pha003053 rs12881360 chr14 88349471 A G 6.29E-05 Heart Rate / / pha003054 rs12885749 chr14 88354978 T C 7.52E-04 Multiple complex diseases / / 17554300 rs10133218 chr14 88355122 G T 6.16E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs2208984 chr14 88356757 A G 8.79E-04 Multiple complex diseases / / 17554300 rs11159830 chr14 88356935 C T 8.15E-04 Type 2 diabetes / / 17463246 rs7152233 chr14 88361176 G A 7.28E-06 Neuroblastoma / / pha002895 rs17123886 chr14 88361606 T C 8.03E-04 Type 2 diabetes / / 17463246 rs7154214 chr14 88377390 T C 1.21E-04 Multiple complex diseases / / 17554300 rs398607 chr14 88407888 A G 3.53E-04 Myopia (pathological) GALC missense 21095009 rs2285008 chr14 88409527 G T 5.19E-04 Myopia (pathological) GALC intron 21095009 rs415076 chr14 88411295 A G 3.53E-04 Myopia (pathological) GALC intron 21095009 rs378816 chr14 88412641 A C 4.49E-04 Myopia (pathological) GALC intron 21095009 rs449615 chr14 88415750 A G 5.75E-04 Amyotrophic lateral sclerosis (sporadic) GALC intron 24529757 rs10139328 chr14 88471562 T C 9.72E-04 Type 2 diabetes GPR65 UTR-5 17463246 rs10139328 chr14 88471562 T C 2.80E-05 Urinary metabolites GPR65 UTR-5 21572414 rs8005161 chr14 88472595 C T 4.00E-18 Crohn's disease GPR65 intron 21102463 rs8005161 chr14 88472595 C T 4.00E-18 Asthma GPR65 intron 21907864 rs8005161 chr14 88472595 C T 2.00E-14 Inflammatory bowel disease GPR65 intron 23128233 rs1372364 chr14 88473299 T C 7.35E-04 Myocardial Infarction GPR65 intron pha002883 rs6574978 chr14 88477413 C T 8.72E-04 Type 2 diabetes GPR65 cds-synon 17463246 rs2119704 chr14 88487689 C A 2.00E-10 Multiple sclerosis / / 21833088 rs8017372 chr14 88502695 A G 9.00E-06 Urinary metabolites LOC283587 intron 21572414 rs7151916 chr14 88514017 C T 9.65E-06 White blood cell count LOC283587 intron 21738479 rs989274 chr14 88516881 A C 4.75E-06 Lymphocyte counts LOC283587 intron 22286170 rs12885067 chr14 88529591 G A 2.70E-05 Urinary metabolites LOC283587 intron 21572414 rs4144361 chr14 88533234 A G 2.00E-06 Urinary metabolites LOC283587 intron 21572414 rs7156276 chr14 88550163 A G 2.60E-06 Urinary metabolites LOC283587 intron 21572414 rs17124045 chr14 88550924 A G 9.31E-04 Amyotrophic lateral sclerosis (sporadic) LOC283587 intron 24529757 rs11159840 chr14 88556525 G T 3.00E-06 Urinary metabolites / / 21572414 rs6574988 chr14 88559992 T C 5.65E-06 Multiple complex diseases / / 17554300 rs6574988 chr14 88559992 T C 4.00E-06 Bipolar disorder / / 21254220 rs11159841 chr14 88587120 T C 3.98E-05 Prostate cancer / / pha002878 rs2208547 chr14 88604515 C T 4.10E-06 Urinary metabolites / / 21572414 rs1940532 chr14 88612417 T C 1.95E-04 Schizophrenia / / 20832056 rs1940532 chr14 88612417 T C 5.80E-06 Urinary metabolites / / 21572414 rs6574994 chr14 88614541 A G 5.73E-06 Prostate cancer / / pha002878 rs8010969 chr14 88626243 G A 8.04E-06 White blood cell count / / 21738479 rs10147860 chr14 88641335 C A 8.28E-04 Multiple complex diseases / / 17554300 rs7157457 chr14 88645857 C T 6.95E-04 Alcohol dependence / / 24277619 rs411418 chr14 88647006 A C 1.10E-05 Urinary metabolites KCNK10 UTR-3 21572414 rs17124243 chr14 88661229 G A 4.76E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNK10 intron 20877124 rs17124276 chr14 88685076 C T 7.00E-04 Pancreatic cancer KCNK10 intron 23180869 rs6574998 chr14 88689339 T C 1.25E-04 Body mass index KCNK10 intron 21701565 rs1956541 chr14 88698643 G A 1.35E-04 Body mass index KCNK10 intron 21701565 rs11849247 chr14 88708503 T C 0.00000444 Alcohol craving with or without dependence KCNK10 intron 22481050 rs10150163 chr14 88719598 A G 4.48E-06 Orofacial clefts KCNK10 intron 22419666 rs2401756 chr14 88720908 G A 6.84E-06 Orofacial clefts KCNK10 intron 22419666 rs11625905 chr14 88722446 G T 1.68E-04 Body mass index KCNK10 intron 21701565 rs10148709 chr14 88724003 C T 1.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNK10 intron 20877124 rs724611 chr14 88727027 G A 7.47E-05 Celiac disease KCNK10 intron 23936387 rs7150286 chr14 88753652 G A 1.31E-04 Suicide attempts in bipolar disorder KCNK10 intron 21423239 rs2025078 chr14 88758486 T C 7.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNK10 intron 20877124 rs2025078 chr14 88758486 T C 1.78E-04 Suicide attempts in bipolar disorder KCNK10 intron 21423239 rs12434331 chr14 88759985 T C 6.34E-05 Neuroblastoma KCNK10 intron pha002895 rs7149354 chr14 88765833 T G 2.44E-04 Suicide attempts in bipolar disorder KCNK10 intron 21423239 rs4904445 chr14 88774886 A G 2.74E-04 Suicide attempts in bipolar disorder KCNK10 intron 21423239 rs10148955 chr14 88775312 T C 7.46E-04 Suicide attempts in bipolar disorder KCNK10 intron 21423239 rs17772064 chr14 88822871 C T 4.50E-06 Urinary metabolites / / 21572414 rs17698817 chr14 88822976 G C 5.40E-06 Urinary metabolites / / 21572414 rs1955598 chr14 88823655 A G 3.68E-05 Schizophrenia / / 19571809 rs17772222 chr14 88826482 A G 5.20E-06 Urinary metabolites / / 21572414 rs17772222 chr14 88826482 A G 3.00E-06 Coronary artery calcification / / 23870195 rs17124581 chr14 88826682 T C 3.00E-06 Information processing speed / / 21130836 rs17124581 chr14 88826682 T C 6.00E-05 Cognitive impairment induced by topiramate / / 22091778 rs12586714 chr14 88826841 C A 3.19E-05 Schizophrenia / / 19571809 rs4904448 chr14 88852166 G A 4.69E-05 Schizophrenia SPATA7 missense 19571809 rs12589480 chr14 88881270 C T 5.01E-06 Coronary artery calcification SPATA7 intron 23870195 rs17124700 chr14 88905629 C T 3.89E-06 Coronary artery calcification / / 23870195 rs3814855 chr14 88933360 G A 2.90E-06 Urinary metabolites PTPN21 UTR-3 21572414 rs2274736 chr14 88938652 A G 7.97E-06 Schizophrenia PTPN21 missense 19571809 rs2274736 chr14 88938652 A G 0.00000159 Ovarian cancer survival PTPN21 missense 22891074 rs2401751 chr14 88946622 G A 7.87E-06 Schizophrenia PTPN21 missense 19571809 rs1864744 chr14 88951006 C G 7.59E-06 Schizophrenia PTPN21 intron 19571809 rs816069 chr14 88967336 C A 2.21E-05 Schizophrenia PTPN21 intron 19571809 rs7160647 chr14 88973684 C T 3.49E-05 Schizophrenia PTPN21 intron 19571809 rs7160647 chr14 88973684 C T 4.00E-06 Urinary metabolites PTPN21 intron 21572414 rs10138002 chr14 88976415 C T 9.19E-06 Schizophrenia PTPN21 intron 19571809 rs10138002 chr14 88976415 C T 4.50E-06 Urinary metabolites PTPN21 intron 21572414 rs10150311 chr14 88976472 T C 5.27E-05 Schizophrenia PTPN21 intron 19571809 rs10150311 chr14 88976472 T C 3.80E-06 Urinary metabolites PTPN21 intron 21572414 rs11847417 chr14 88976950 C T 3.65E-05 Schizophrenia PTPN21 intron 19571809 rs11847417 chr14 88976950 C T 4.00E-06 Urinary metabolites PTPN21 intron 21572414 rs10143767 chr14 88981211 A C 2.90E-06 Urinary metabolites PTPN21 intron 21572414 rs8017811 chr14 89000903 G A 3.91E-05 Schizophrenia PTPN21 intron 19571809 rs1144918 chr14 89102558 T C 2.79E-06 Schizophrenia EML5 intron 19571809 rs1287825 chr14 89105536 A G 1.32E-06 Schizophrenia EML5 intron 19571809 rs11159863 chr14 89108778 G A 5.12E-05 Potassium levels EML5 intron pha003086 rs2033417 chr14 89118691 C T 5.64E-05 Potassium levels EML5 intron pha003086 rs1956411 chr14 89134360 C T 4.41E-06 Schizophrenia EML5 intron 19571809 rs12589481 chr14 89149210 G A 7.54E-06 Potassium levels EML5 intron pha003086 rs6575018 chr14 89162543 T C 3.11E-04 Multiple complex diseases EML5 intron 17554300 rs201948547 chr14 89178711 T C 0.000042 Breast cancer(er negative) EML5 missense 23555315 rs10132509 chr14 89203781 A G 7.27E-06 Schizophrenia EML5 intron 19571809 rs10140896 chr14 89218538 C A,G 9.49E-07 Schizophrenia EML5 intron 19571809 rs12880096 chr14 89218815 T C 9.28E-06 Schizophrenia EML5 intron 19571809 rs7147796 chr14 89228569 C G 3.50E-05 Schizophrenia EML5 intron 19571809 rs7156823 chr14 89240649 G A 1.22E-05 Potassium levels EML5 intron pha003086 rs10141775 chr14 89257187 T C 2.11E-04 Suicide attempts in bipolar disorder EML5 intron 21423239 rs11845781 chr14 89276431 C T 9.94E-05 Schizophrenia / / 19571809 rs6575022 chr14 89279099 A G 8.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs1950807 chr14 89280790 G A 8.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs6575023 chr14 89283221 C T 9.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs7144459 chr14 89289279 C T 5.09E-04 Suicide attempts in bipolar disorder TTC8 nearGene-5 21423239 rs12896101 chr14 89293260 T G 6.41E-04 Suicide attempts in bipolar disorder TTC8 intron 21423239 rs3850391 chr14 89295862 A G 5.62E-04 Suicide attempts in bipolar disorder TTC8 intron 21423239 rs10141094 chr14 89297450 T A 5.43E-04 Suicide attempts in bipolar disorder TTC8 intron 21423239 rs10484010 chr14 89298288 T A 2.70E-05 Urinary metabolites TTC8 intron 21572414 rs12435504 chr14 89298740 T C 5.91E-04 Suicide attempts in bipolar disorder TTC8 intron 21423239 rs3850392 chr14 89299630 G A 5.92E-04 Suicide attempts in bipolar disorder TTC8 intron 21423239 rs17124889 chr14 89300901 A G 5.83E-04 Suicide attempts in bipolar disorder TTC8 intron 21423239 rs12879875 chr14 89306550 T C 6.34E-04 Suicide attempts in bipolar disorder TTC8 intron 21423239 rs7141448 chr14 89306872 A G 5.76E-04 Suicide attempts in bipolar disorder TTC8 intron 21423239 rs10150833 chr14 89309640 A G 5.20E-04 Suicide attempts in bipolar disorder TTC8 intron 21423239 rs7155535 chr14 89310346 T C 5.55E-04 Suicide attempts in bipolar disorder TTC8 intron 21423239 rs17124909 chr14 89311519 T G 6.96E-04 Suicide attempts in bipolar disorder TTC8 intron 21423239 rs10132019 chr14 89312024 T C 3.75E-04 Suicide attempts in bipolar disorder TTC8 intron 21423239 rs1013794 chr14 89313745 C T 3.17E-04 Suicide attempts in bipolar disorder TTC8 intron 21423239 rs10131962 chr14 89328429 A G 1.56E-04 Suicide attempts in bipolar disorder TTC8 intron 21423239 rs9671813 chr14 89330291 A G 1.63E-04 Suicide attempts in bipolar disorder TTC8 intron 21423239 rs10134036 chr14 89334166 A G 1.95E-04 Suicide attempts in bipolar disorder TTC8 intron 21423239 rs10137225 chr14 89335098 A T 3.46E-04 Suicide attempts in bipolar disorder TTC8 intron 21423239 rs9323834 chr14 89335613 T C 2.31E-04 Suicide attempts in bipolar disorder TTC8 intron 21423239 rs7145375 chr14 89342573 G A 3.17E-04 Suicide attempts in bipolar disorder TTC8 intron 21423239 rs9323835 chr14 89343321 G A 2.85E-04 Suicide attempts in bipolar disorder TTC8 intron 21423239 rs10142228 chr14 89345510 T C 2.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs911454 chr14 89345674 A T 2.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs10139817 chr14 89348612 A G 3.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs11159875 chr14 89349936 C A 3.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs7151457 chr14 89351991 G A 4.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs1014895 chr14 89355534 G T 4.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs17124955 chr14 89372751 A G 9.00E-06 Obesity-related traits / / 23251661 rs11851413 chr14 89374479 G T 2.67E-05 Multiple complex diseases / / 17554300 rs1885189 chr14 89387328 T G 3.57E-04 White matter integrity / / 22425255 rs2093288 chr14 89388669 T C 7.33E-04 White matter integrity / / 22425255 rs7142654 chr14 89403590 G A 6.57E-04 Multiple complex diseases / / 17554300 rs7148738 chr14 89413325 A G 8.66E-04 Alzheimer's disease / / 22005930 rs4904480 chr14 89415942 G A 6.62E-04 Alzheimer's disease / / 22005930 rs4904481 chr14 89416057 G T 5.28E-04 Alzheimer's disease / / 22005930 rs4904482 chr14 89416337 G A 6.31E-04 Alzheimer's disease / / 22005930 rs10132345 chr14 89416371 G A 6.77E-04 Alzheimer's disease / / 22005930 rs2401785 chr14 89417252 G A 6.62E-04 Alzheimer's disease / / 22005930 rs12101238 chr14 89420062 C T 7.15E-04 Alzheimer's disease / / 22005930 rs12100851 chr14 89420156 T C 7.23E-04 Alzheimer's disease / / 22005930 rs4904483 chr14 89421179 T A 7.22E-04 Alzheimer's disease / / 22005930 rs4904484 chr14 89421231 A G 7.11E-04 Alzheimer's disease / / 22005930 rs7150792 chr14 89422573 G A 7.10E-04 Alzheimer's disease / / 22005930 rs2896093 chr14 89422861 C G 6.98E-04 Alzheimer's disease / / 22005930 rs1951337 chr14 89423736 C A 6.94E-04 Alzheimer's disease / / 22005930 rs1957242 chr14 89424174 C G 6.90E-04 Alzheimer's disease / / 22005930 rs762018 chr14 89425304 T A 6.62E-04 Alzheimer's disease / / 22005930 rs10484001 chr14 89426270 T C 5.69E-04 Alzheimer's disease / / 22005930 rs17125091 chr14 89427951 A T 5.70E-04 Alzheimer's disease / / 22005930 rs8011491 chr14 89429044 C T 5.78E-04 Alzheimer's disease / / 22005930 rs1885187 chr14 89429990 A C 5.80E-04 Alzheimer's disease / / 22005930 rs1885186 chr14 89430056 C T 6.09E-04 Alzheimer's disease / / 22005930 rs7145541 chr14 89430523 G A 5.82E-04 Alzheimer's disease / / 22005930 rs7152127 chr14 89431247 T C 5.78E-04 Alzheimer's disease / / 22005930 rs9671907 chr14 89431272 C T 5.88E-04 Alzheimer's disease / / 22005930 rs4904485 chr14 89431494 G A 5.86E-04 Alzheimer's disease / / 22005930 rs6575028 chr14 89433768 C T 5.31E-04 Alzheimer's disease / / 22005930 rs17125127 chr14 89434380 T G 7.83E-04 Alzheimer's disease / / 22005930 rs12589060 chr14 89437416 A G 9.00E-06 Follicle stimulating hormone / / 24049095 rs12589063 chr14 89437440 A G 3.23E-04 Parkinson's disease / / 17052657 rs7146193 chr14 89446796 A G 2.08E-04 Parkinson's disease / / 17052657 rs12889015 chr14 89461680 G A 1.34E-04 Cognitive function / / 24684796 rs10136453 chr14 89523166 A G 4.94E-04 Multiple complex diseases / / 17554300 rs2093758 chr14 89547057 C T 7.36E-04 Type 2 diabetes / / 17463246 rs10151996 chr14 89563518 C T 5.02E-04 Multiple complex diseases / / 17554300 rs4904502 chr14 89564988 T G 2.77E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4904502 chr14 89564988 T G 7.17E-04 HIV-1 viral setpoint / / 17641165 rs1815281 chr14 89577413 G A 2.43E-04 Sudden cardiac arrest / / 21658281 rs8021839 chr14 89582114 A G 2.38E-04 Acute lung injury / / 22295056 rs8021839 chr14 89582114 A G 1.42E-05 Heart Failure / / pha002885 rs10149891 chr14 89585102 G A 2.93E-04 Type 2 diabetes / / 17463246 rs2224804 chr14 89586657 G T 2.93E-04 Type 2 diabetes / / 17463246 rs10133508 chr14 89587523 A C 2.70E-04 Type 2 diabetes / / 17463246 rs10133593 chr14 89587535 C T 2.70E-04 Type 2 diabetes / / 17463246 rs11622570 chr14 89587920 G A 2.93E-04 Type 2 diabetes / / 17463246 rs1957841 chr14 89588834 G A 4.82E-05 HDL cholesterol / / pha003074 rs4904509 chr14 89591394 T C 2.00E-04 Adverse response to radiation therapy / / 23719583 rs10133171 chr14 89592955 G A 2.93E-04 Type 2 diabetes / / 17463246 rs4904510 chr14 89593013 T C 2.64E-04 Smoking initiation / / 24665060 rs10147574 chr14 89593039 T C 2.70E-04 Type 2 diabetes / / 17463246 rs10135692 chr14 89593273 C T 2.93E-04 Type 2 diabetes / / 17463246 rs10135609 chr14 89593284 A G 2.93E-04 Type 2 diabetes / / 17463246 rs7158359 chr14 89594295 A G 5.00E-06 Weight loss (gastric bypass surgery) / / 23643386 rs4904511 chr14 89595416 T A 5.07E-05 Smoking initiation / / 24665060 rs4904512 chr14 89595945 C T 7.13E-04 Smoking initiation / / 24665060 rs1957834 chr14 89597527 A G 2.93E-04 Type 2 diabetes / / 17463246 rs927617 chr14 89600010 C T 5.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10220603 chr14 89644318 A G 8.14E-04 Myocardial Infarction FOXN3 intron pha002883 rs8007081 chr14 89664502 G T 1.44E-04 Multiple complex diseases FOXN3 intron 17554300 rs7147651 chr14 89669968 G A 8.74E-04 Multiple complex diseases FOXN3 intron 17554300 rs8022846 chr14 89686223 A G 6.12E-05 Serum metabolites FOXN3 intron 19043545 rs10132162 chr14 89692940 G A 6.66E-04 Suicide attempts in bipolar disorder FOXN3 intron 21423239 rs8005433 chr14 89704720 A G 5.74E-04 Suicide attempts in bipolar disorder FOXN3 intron 21423239 rs8005433 chr14 89704720 A G 5.82E-04 Acute lung injury FOXN3 intron 22295056 rs1986775 chr14 89706057 G A 5.40E-04 Acute lung injury FOXN3 intron 22295056 rs12434332 chr14 89707491 A C 5.56E-04 Acute lung injury FOXN3 intron 22295056 rs2401815 chr14 89709436 G A 6.48E-04 Acute lung injury FOXN3 intron 22295056 rs6575047 chr14 89709906 T C 5.90E-04 Acute lung injury FOXN3 intron 22295056 rs6575048 chr14 89710235 C G 5.90E-04 Acute lung injury FOXN3 intron 22295056 rs6575049 chr14 89710432 T C 5.90E-04 Acute lung injury FOXN3 intron 22295056 rs6575050 chr14 89710529 C T 5.90E-04 Acute lung injury FOXN3 intron 22295056 rs7153437 chr14 89711887 A G 5.90E-04 Acute lung injury FOXN3 intron 22295056 rs4904521 chr14 89713543 A G 5.90E-04 Acute lung injury FOXN3 intron 22295056 rs4904521 chr14 89713543 A G 2.41E-05 Body Composition FOXN3 intron pha003012 rs4904521 chr14 89713543 A G 2.43E-05 Body Mass Index FOXN3 intron pha003021 rs4904522 chr14 89713583 C T 5.90E-04 Acute lung injury FOXN3 intron 22295056 rs4904522 chr14 89713583 C T 2.44E-05 Body Composition FOXN3 intron pha003012 rs4904522 chr14 89713583 C T 2.44E-05 Body Mass Index FOXN3 intron pha003021 rs9323838 chr14 89719600 C T 4.30E-04 Acute lung injury FOXN3 intron 22295056 rs7152783 chr14 89720032 A G 3.82E-04 Acute lung injury FOXN3 intron 22295056 rs7144268 chr14 89722228 G C 4.79E-04 Acute lung injury FOXN3 intron 22295056 rs7144396 chr14 89722273 G T 5.26E-04 Acute lung injury FOXN3 intron 22295056 rs10142440 chr14 89734415 T C 1.21E-04 IgE levels FOXN3 intron 17255346 rs8007023 chr14 89734879 T C 1.18E-04 IgE levels FOXN3 intron 17255346 rs8007023 chr14 89734879 T C 1.51E-04 Multiple complex diseases FOXN3 intron 17554300 rs17125613 chr14 89756496 T C 8.73E-05 Serum metabolites FOXN3 intron 19043545 rs759364 chr14 89758611 G A 1.32E-04 Type 2 diabetes FOXN3 intron 17463246 rs759363 chr14 89759141 G C 9.18E-05 Serum metabolites FOXN3 intron 19043545 rs11159897 chr14 89759441 G C 9.61E-05 Serum metabolites FOXN3 intron 19043545 rs17773812 chr14 89762808 A G 4.00E-05 Pericardial fat FOXN3 intron 22589742 rs763972 chr14 89772115 T G 3.05E-05 Cholesterol FOXN3 intron pha003073 rs763972 chr14 89772115 T G 3.81E-05 Cholesterol FOXN3 intron pha003078 rs10134863 chr14 89781247 G C 3.73E-04 Multiple complex diseases FOXN3 intron 17554300 rs3783853 chr14 89803269 A G 5.83E-07 Schizophrenia FOXN3 intron 21926974 rs4904551 chr14 89808740 T C 1.94E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) FOXN3 intron 24023788 rs7158631 chr14 89819880 T G 7.13E-05 Elbow pain FOXN3 intron pha003008 rs7158631 chr14 89819880 T G 6.41E-05 Height FOXN3 intron pha003010 rs10148621 chr14 89894880 T A 2.50E-07 Urinary metabolites FOXN3 intron 21572414 rs4904578 chr14 89901260 C T 8.50E-05 Response to statin therapy FOXN3 intron 20339536 rs12885505 chr14 89901962 T A 2.95E-05 Clubfoot FOXN3 intron 24667120 rs1952182 chr14 89909200 A G 8.60E-05 Pulmonary function FOXN3 intron 20010835 rs11623367 chr14 89924833 C T 4.90E-05 Parkinson's disease (familial) FOXN3 intron 18985386 rs1287408 chr14 89945367 T C 1.64E-04 Lung function (forced vital capacity) FOXN3 intron 24023788 rs4900000 chr14 89974582 T C 2.33E-04 Response to taxane treatment (placlitaxel) FOXN3 intron 23006423 rs389960 chr14 89980929 A G 7.04E-04 Smoking initiation FOXN3 intron 24665060 rs1287404 chr14 89983256 C T 8.31E-05 Heart Failure FOXN3 intron pha002884 rs373655 chr14 89995263 A G 7.77E-05 Cognitive test performance FOXN3 intron 20125193 rs373655 chr14 89995263 A G 2.02E-04 Suicide,with and without major depression FOXN3 intron 22059935 rs373655 chr14 89995263 A G 2.82E-04 Suicide,with and without major depression FOXN3 intron 22059935 rs373655 chr14 89995263 A G 1.71E-04 Heart Failure FOXN3 intron pha002884 rs394499 chr14 90002148 A G 3.64E-05 Brain structure FOXN3 intron 22504417 rs10484012 chr14 90002230 T C 6.30E-04 Type 2 diabetes and 6 quantitative traits FOXN3 intron 17848626 rs243218 chr14 90004262 G C 2.30E-05 Urinary metabolites FOXN3 intron 21572414 rs243183 chr14 90031107 G A 3.41E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) FOXN3 intron 23648065 rs10146976 chr14 90033439 G A 2.20E-05 Urinary metabolites FOXN3 intron 21572414 rs10146908 chr14 90033531 C T 2.30E-05 Urinary metabolites FOXN3 intron 21572414 rs8020333 chr14 90034849 C T 0.000000362 Fasting blood glucose FOXN3 intron 22885924 rs8004664 chr14 90034972 G A 3.00E-06 Fasting glucose-related traits (interaction with BMI) FOXN3 intron 22581228 rs243196 chr14 90043381 C A 6.11E-04 Endometrial cancer FOXN3 intron 24096698 rs10142749 chr14 90044729 C A 7.15E-05 Acne (severe) FOXN3 intron 24927181 rs17126136 chr14 90077667 G A 4.93E-04 Multiple complex diseases FOXN3 intron 17554300 rs2632185 chr14 90115421 G A 7.27E-04 Coronary Artery Disease / / 17634449 rs2761355 chr14 90119626 T C 8.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs998564 chr14 90139311 C T 1.02E-05 Coronary Artery Disease / / 17634449 rs8019799 chr14 90148832 G A 2.22E-04 Depression (quantitative trait) / / 20800221 rs7350724 chr14 90192128 C T 3.45E-04 Alzheimer's disease (late onset) / / 21379329 rs2401851 chr14 90197007 A G 4.25E-05 Height / / pha003011 rs10137250 chr14 90202764 C T 1.54E-04 Alzheimer's disease (late onset) / / 21379329 rs1028723 chr14 90208263 G A 1.86E-05 Serum albumin level / / pha003084 rs2093746 chr14 90227251 C G 2.00E-07 IgG glycosylation / / 23382691 rs2093746 chr14 90227251 C G 3.00E-07 IgG glycosylation / / 23382691 rs12589630 chr14 90270557 C A 4.62E-04 Rheumatoid arthritis EFCAB11 intron 21452313 rs17126333 chr14 90272968 C T 0.000509024 Hypertension (early onset hypertension) EFCAB11 intron 22479346 rs11627827 chr14 90288595 A T 3.12E-06 Metabolite levels (MHPG) EFCAB11 intron 23319000 rs8021963 chr14 90298275 C T 2.00E-06 Metabolite levels (HVA/MHPG ratio) EFCAB11 intron 23319000 rs8007947 chr14 90299541 C T 9.89E-04 White matter integrity EFCAB11 intron 22425255 rs12100561 chr14 90301035 A G 4.00E-06 Hepatocellular carcinoma EFCAB11 intron 21105107 rs12100561 chr14 90301035 A G 4.00E-06 Hepatocellular carcinoma (hepatitis B virus related) EFCAB11 intron 23242368 rs4900016 chr14 90305660 A G 3.53E-05 Behcet's disease EFCAB11 intron pha002888 rs10137248 chr14 90320818 A G 0.000177 Salmonella-induced pyroptosis EFCAB11 intron 22837397 rs17126404 chr14 90321331 A G 5.87E-04 Smoking initiation EFCAB11 intron 24665060 rs1286947 chr14 90350097 C T 5.39E-05 Lymphocyte counts EFCAB11 intron 22286170 rs12889533 chr14 90369749 C T 8.52E-06 Thiazide-induced adverse metabolic effects in hypertensive patients EFCAB11 intron 23400010 rs10139734 chr14 90379238 T C 4.89E-04 Multiple complex diseases EFCAB11 intron 17554300 rs10150928 chr14 90379615 C T 9.76E-04 Multiple complex diseases EFCAB11 intron 17554300 rs7158821 chr14 90382851 C G 2.08E-05 Multiple complex diseases EFCAB11 intron 17554300 rs7147996 chr14 90396574 T A 6.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients EFCAB11 intron 23400010 rs9919909 chr14 90403424 C T 8.46E-04 Obesity (extreme) EFCAB11 intron 21935397 rs10148012 chr14 90406653 C T 8.40E-04 Obesity (extreme) EFCAB11 intron 21935397 rs9488 chr14 90509564 C T 4.12E-05 Multiple complex diseases TDP1 UTR-3 17554300 rs17188417 chr14 90517902 A C 8.28E-04 Aortic root size / / 21223598 rs4462529 chr14 90601397 T C 1.20E-05 Urinary metabolites KCNK13 intron 21572414 rs12434638 chr14 90610080 C T 7.67E-04 Parkinson's disease KCNK13 intron 17052657 rs4900022 chr14 90615513 G A 4.00E-06 Coronary artery calcification KCNK13 intron 23870195 rs4900026 chr14 90628634 G A 5.30E-05 Triglycerides KCNK13 intron pha002904 rs7149330 chr14 90636206 G A 8.50E-05 Alcohol dependence KCNK13 intron 22096494 rs8017423 chr14 90679910 T C 7.00E-06 Heart failure / / 20400778 rs11626011 chr14 90693572 G A 6.30E-06 Serum metabolites / / 19043545 rs11624725 chr14 90713609 T G 2.45E-05 Serum metabolites / / 19043545 rs11628812 chr14 90713720 A C 2.45E-05 Serum metabolites / / 19043545 rs11621045 chr14 90714003 G A 2.45E-05 Serum metabolites / / 19043545 rs11159956 chr14 90715890 T C 2.45E-05 Serum metabolites / / 19043545 rs11159957 chr14 90715972 G A 2.45E-05 Serum metabolites / / 19043545 rs7146640 chr14 90720114 G A 9.21E-06 Serum metabolites / / 19043545 rs17188598 chr14 90722473 A T 2.45E-05 Serum metabolites / / 19043545 rs7150093 chr14 90724661 A G 2.58E-05 Serum metabolites PSMC1 intron 19043545 rs7151776 chr14 90724803 T C 4.11E-05 Serum metabolites PSMC1 intron 19043545 rs6575120 chr14 90725094 G A 2.45E-05 Serum metabolites PSMC1 intron 19043545 rs2236403 chr14 90736325 C T 1.40E-05 Serum metabolites PSMC1 intron 19043545 rs3737035 chr14 90745422 T C 5.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) C14orf102 missense 21239504 rs6575122 chr14 90753556 A G 5.91E-05 Lung function (forced expiratory volume in 1 second) C14orf102 intron 24023788 rs6575122 chr14 90753556 A G 9.46E-05 Lung function (forced vital capacity) C14orf102 intron 24023788 rs149141901 chr14 90755014 C T 0.00043 Prostate cancer (non-advanced prostate cancer) C14orf102 missense 23555315 rs2282032 chr14 90758891 G T 1.19E-05 Asthma C14orf102 intron 11022011 rs2282032 chr14 90758891 G T 5.33E-04 Alzheimer's disease C14orf102 intron 17998437 rs2282032 chr14 90758891 G T 1.00E-06 Longevity C14orf102 intron 20834067 rs2282033 chr14 90769635 T G 6.06E-05 Serum metabolites C14orf102 intron 19043545 rs8005973 chr14 90774951 C T 2.90E-05 Lung function (forced expiratory volume in 1 second) C14orf102 intron 24023788 rs8005973 chr14 90774951 C T 6.85E-05 Lung function (forced vital capacity) C14orf102 intron 24023788 rs11845372 chr14 90785711 A T 3.40E-05 Response to statin therapy C14orf102 intron 20339536 rs11626869 chr14 90788985 A G 4.62E-05 Serum metabolites C14orf102 intron 19043545 rs1958349 chr14 90834860 C T 3.30E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1958349 chr14 90834860 C T 4.15E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17126685 chr14 90843908 T C 4.31E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs2268433 chr14 90866346 C T 4.24E-05 Telomere length CALM1 intron 20139977 rs3213718 chr14 90869913 C T 3.22E-05 Stroke (pediatric) CALM1 intron 22990015 rs741099 chr14 90915946 A G 3.91E-04 Alzheimer's disease (late onset) / / 21379329 rs2215719 chr14 90937740 G T 4.39E-04 Sarcoidosis / / 19165924 rs2401890 chr14 90947230 T C 4.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1640246 chr14 90966606 T G 1.45E-04 Alzheimer's disease (late onset) / / 21379329 rs10148969 chr14 90968374 C T 1.08E-05 Information processing speed / / 21130836 rs941501 chr14 90975018 C T 4.91E-05 Waist-Hip Ratio / / pha003029 rs941501 chr14 90975018 C T 5.13E-05 Triglycerides / / pha003080 rs1299015 chr14 90985468 A G 5.07E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1294544 chr14 90986846 A C 3.62E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1294559 chr14 91003013 C T 2.85E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1294575 chr14 91013276 C T 4.93E-05 Cytomegalovirus antibody response TTC7B intron 21993531 rs17793829 chr14 91022185 C T 9.00E-06 Cytomegalovirus antibody response TTC7B intron 21993531 rs1298210 chr14 91024730 G C 4.79E-05 Cytomegalovirus antibody response TTC7B intron 21993531 rs1286496 chr14 91027608 A G 6.29E-05 Cytomegalovirus antibody response TTC7B intron 21993531 rs7152651 chr14 91043744 C T 6.86E-06 C-reactive protein TTC7B intron 22492993 rs1286474 chr14 91054072 C T 1.51E-06 Iron levels TTC7B intron 19880490 rs1286474 chr14 91054072 C T 1.51E-06 Iron levels TTC7B intron pha002876 rs1014527 chr14 91070788 C T 4.68E-04 Iron levels TTC7B intron pha002876 rs2343 chr14 91094500 C T 8.25E-04 Type 2 diabetes TTC7B intron 17463246 rs11627718 chr14 91096544 C T 6.66E-05 Lung function (forced expiratory volume in 1 second) TTC7B intron pha003103 rs1286439 chr14 91099211 T C 9.10E-04 Type 2 diabetes TTC7B intron 17463246 rs1286439 chr14 91099211 T C 4.44E-05 Lung function (forced expiratory volume in 1 second) TTC7B intron pha003103 rs942746 chr14 91112078 C T 0.00000341 Antisocial behavior TTC7B intron 23077488 rs2277512 chr14 91113471 G A 0.00000855 Antisocial behavior TTC7B intron 23077488 rs1286422 chr14 91113537 A G 4.44E-05 Lung function (forced expiratory volume in 1 second) TTC7B intron pha003103 rs961196 chr14 91134661 C T 0.000296 Bipolar disorder TTC7B intron 23637625 rs942740 chr14 91158869 G A 2.20E-04 Type 2 diabetes TTC7B intron 17668382 rs1749718 chr14 91183327 C T 3.20E-04 Type 2 diabetes TTC7B intron 17668382 rs1742083 chr14 91186670 G A 5.23E-05 Cardiovascular disease TTC7B intron 17903304 rs730043 chr14 91209615 C A 3.66E-05 Post-operative nausea and vomiting TTC7B intron 21694509 rs8003457 chr14 91233834 G A 1.36E-04 Multiple complex diseases TTC7B intron 17554300 rs8003457 chr14 91233834 G A 2.00E-06 Urinary metabolites TTC7B intron 21572414 rs8003457 chr14 91233834 G A 0.0000239 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes TTC7B intron 22628534 rs10137818 chr14 91239728 T C 7.42E-05 Lung function (forced expiratory volume in 1 second) TTC7B intron pha003102 rs8012052 chr14 91247477 A G 1.95E-04 Alcohol dependence TTC7B intron 21314694 rs4904729 chr14 91248030 T C 1.41E-04 Multiple complex diseases TTC7B intron 17554300 rs4904729 chr14 91248030 T C 1.30E-06 Urinary metabolites TTC7B intron 21572414 rs4904729 chr14 91248030 T C 0.0000828 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes TTC7B intron 22628534 rs10132942 chr14 91251968 G T 1.78E-04 Multiple complex diseases TTC7B intron 17554300 rs10132942 chr14 91251968 G T 1.90E-06 Urinary metabolites TTC7B intron 21572414 rs11629240 chr14 91263159 C T 3.85E-04 Response to taxane treatment (placlitaxel) TTC7B intron 23006423 rs1286328 chr14 91267866 A G 4.98E-05 Intracerebral hemorrhage TTC7B intron 24656865 rs7140548 chr14 91298236 T C 7.40E-04 Multiple complex diseases / / 17554300 rs1286290 chr14 91313812 G C 4.73E-04 Obesity (extreme) / / 21935397 rs1152431 chr14 91373290 G A 4.98E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1286135 chr14 91375781 C A 1.84E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1286133 chr14 91378820 T C 1.82E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1286133 chr14 91378820 T C 1.71E-05 Height RPS6KA5 intron pha003010 rs1286124 chr14 91395131 G T 1.81E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1286118 chr14 91408228 T A 1.43E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1286112 chr14 91412761 C G 1.43E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1286110 chr14 91415643 T A 1.43E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1286109 chr14 91416552 A G 3.09E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1286106 chr14 91418434 C G 1.51E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1296092 chr14 91425021 C T 1.44E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1296092 chr14 91425021 C T 7.89E-06 Height RPS6KA5 intron pha003010 rs1286097 chr14 91427257 T C 1.45E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1286097 chr14 91427257 T C 7.88E-06 Height RPS6KA5 intron pha003010 rs1297776 chr14 91427595 A G 1.54E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1286096 chr14 91427662 C T 1.51E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs3783833 chr14 91435590 T C 6.10E-05 Bone mineral density (spine) RPS6KA5 intron 19079262 rs3783832 chr14 91435705 C T 6.43E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs2401952 chr14 91437433 G A 8.34E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1286083 chr14 91442779 T C 2.00E-15 Bone mineral density RPS6KA5 intron 22504420 rs1286083 chr14 91442779 T C 1.23E-05 Bone mineral density RPS6KA5 intron 24249740 rs1286083 chr14 91442779 T C 1.93E-06 Bone mineral density RPS6KA5 intron 24249740 rs1286083 chr14 91442779 T C 4.46E-06 Bone mineral density RPS6KA5 intron 24249740 rs1286083 chr14 91442779 T C 5.20E-05 Bone mineral density (paediatric,lower limb) RPS6KA5 intron 24945404 rs1286083 chr14 91442779 T C 6.00E-05 Bone mineral density (paediatric,total body less head) RPS6KA5 intron 24945404 rs1286065 chr14 91451783 C T 1.30E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1286147 chr14 91467567 A C 1.50E-05 Bone mineral density (spine) RPS6KA5 intron 19079262 rs1286146 chr14 91474448 G A 1.39E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1286144 chr14 91477186 C G 1.25E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1286142 chr14 91479563 T C 1.57E-04 Multiple complex diseases RPS6KA5 intron 17554300 rs1296093 chr14 91482205 A G 1.24E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1286138 chr14 91485445 T G 1.26E-05 Obesity (extreme) RPS6KA5 intron 21935397 rs7150723 chr14 91490029 A C 1.20E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs7151354 chr14 91490105 G A 1.74E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs7157525 chr14 91491113 G A 4.80E-05 Cognitive test performance RPS6KA5 intron 20125193 rs8003112 chr14 91495373 T C 1.14E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs6575169 chr14 91497929 T C 1.12E-05 Obesity (extreme) RPS6KA5 intron 21935397 rs2012280 chr14 91501072 G T 1.98E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs7156252 chr14 91503118 T C 1.99E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs11848357 chr14 91504455 T A 3.29E-07 Bone mineral density RPS6KA5 intron 24249740 rs11848357 chr14 91504455 T A 6.12E-05 Bone mineral density RPS6KA5 intron 24249740 rs1951454 chr14 91505368 A G 2.35E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs10150964 chr14 91507280 T C 1.89E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1951455 chr14 91512339 T C 1.77E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs66671133 chr14 91512339 TT TCC,TTT 1.77E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1951456 chr14 91512340 T C 1.72E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs7156757 chr14 91512599 A G 1.39E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1285998 chr14 91512951 G C 1.40E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1285997 chr14 91513029 C G 1.41E-04 Obesity (extreme) RPS6KA5 intron 21935397 rs1075014 chr14 91531030 A G 1.53E-04 Obesity (extreme) / / 21935397 rs11159988 chr14 91531174 T C 1.53E-04 Obesity (extreme) / / 21935397 rs11624274 chr14 91537234 A G 1.52E-04 Obesity (extreme) / / 21935397 rs7492628 chr14 91547136 C G 7.26E-05 Obesity (extreme) / / 21935397 rs10438207 chr14 91563816 A G 2.14E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11627189 chr14 91590956 A G 9.90E-04 Obesity (extreme) C14orf159 intron 21935397 rs4900070 chr14 91590988 A G 8.75E-04 Response to taxane treatment (placlitaxel) C14orf159 intron 23006423 rs11628275 chr14 91621448 G A 5.53E-04 Obesity (extreme) C14orf159 intron 21935397 rs2145143 chr14 91628549 C G 1.47E-04 Obesity (extreme) C14orf159 intron 21935397 rs2295527 chr14 91662615 A G 4.93E-05 Aging (time to event) C14orf159 intron 21782286 rs11622455 chr14 91669929 T C 2.40E-05 Urinary metabolites C14orf159 intron 21572414 rs12587020 chr14 91678546 C A,T 9.62E-04 Multiple complex diseases C14orf159 intron 17554300 rs933528 chr14 91705188 G A 6.81E-04 Response to taxane treatment (placlitaxel) GPR68 intron 23006423 rs2540879 chr14 91708195 C T 5.41E-04 Response to taxane treatment (placlitaxel) GPR68 intron 23006423 rs933531 chr14 91708247 G A 5.90E-05 Parkinson's disease (age of onset) GPR68 intron 19772629 rs2540875 chr14 91711471 A G 9.24E-04 Response to taxane treatment (placlitaxel) GPR68 intron 23006423 rs941920 chr14 91739081 A G 2.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) CCDC88C missense 21239504 rs2277509 chr14 91749595 C A 1.78E-04 Longevity CCDC88C intron 22279548 rs4904763 chr14 91752509 T G 1.30E-05 Urinary metabolites CCDC88C intron 21572414 rs941921 chr14 91764302 G C 6.14E-04 Multiple complex diseases CCDC88C intron 17554300 rs8012328 chr14 91766712 T C 3.26E-04 Multiple complex diseases CCDC88C intron 17554300 rs1285803 chr14 91817829 A G 2.66E-04 Multiple complex diseases CCDC88C intron 17554300 rs12589229 chr14 91820675 C T 2.42E-07 Schizophrenia CCDC88C intron 22037555 rs11621845 chr14 91836453 A C 9.33E-05 Body Mass Index CCDC88C intron pha003019 rs11621845 chr14 91836453 A C 1.17E-05 Body Mass Index CCDC88C intron pha003020 rs11621845 chr14 91836453 A C 5.95E-06 Insulin Resistance CCDC88C intron pha003062 rs11621845 chr14 91836453 A C 1.66E-06 Insulin-related traits CCDC88C intron pha003063 rs941764 chr14 91841069 A G 4.00E-10 Breast cancer CCDC88C intron 23535729 rs4904770 chr14 91841181 G T 7.10E-06 Urinary metabolites CCDC88C intron 21572414 rs8015982 chr14 91846680 C A 3.56E-04 Multiple complex diseases CCDC88C intron 17554300 rs10131741 chr14 91848845 G C 4.89E-04 Multiple complex diseases CCDC88C intron 17554300 rs8008996 chr14 91850196 T C 4.06E-04 Multiple complex diseases CCDC88C intron 17554300 rs8007791 chr14 91850296 A G 3.75E-04 Multiple complex diseases CCDC88C intron 17554300 rs1951251 chr14 91859263 G A 5.98E-05 Waist Circumference CCDC88C intron pha003023 rs17127347 chr14 91861823 G A 0.00003 Salmonella-induced pyroptosis CCDC88C intron 22837397 rs17224453 chr14 91928908 C G 6.25E-04 Multiple complex diseases SMEK1 intron 17554300 rs876561 chr14 91944911 G A 7.48E-04 Heart Failure SMEK1 intron pha002885 rs11160011 chr14 91993864 C A 1.94E-05 Cognitive performance / / 19734545 rs12590997 chr14 91993901 G T 1.96E-05 Cognitive performance / / 19734545 rs12898166 chr14 92032755 C T 7.94E-06 Platelet counts / / pha003100 rs1298989 chr14 92086713 A G 2.70E-05 Bone mineral density (BMD),in women CATSPERB intron 20164292 rs1285635 chr14 92088855 A G 3.00E-05 Bone mineral density (BMD),in women CATSPERB intron 20164292 rs17127482 chr14 92102069 G A 3.52E-04 Multiple complex diseases CATSPERB intron 17554300 rs17127484 chr14 92102759 A G 1.76E-04 Obesity (extreme) CATSPERB intron 21935397 rs2756166 chr14 92126827 T C 3.35E-04 Amyotrophic lateral sclerosis (sporadic) CATSPERB intron 24529757 rs1285655 chr14 92140428 G A 5.59E-04 Obesity (extreme) CATSPERB intron 21935397 rs12889912 chr14 92147845 C T 5.36E-05 Height CATSPERB intron pha003011 rs12050168 chr14 92168495 G A 2.37E-04 Body mass index CATSPERB intron 21701565 rs12050168 chr14 92168495 G A 2.37E-04 Body mass index CATSPERB intron 21701565 rs12883757 chr14 92176823 A G 8.75E-04 Suicide attempts in bipolar disorder CATSPERB intron 21423239 rs12883757 chr14 92176823 A G 2.26E-04 Body mass index CATSPERB intron 21701565 rs12883757 chr14 92176823 A G 7.58E-04 Body mass index CATSPERB intron 21701565 rs2136674 chr14 92178552 A G 8.48E-04 Suicide attempts in bipolar disorder CATSPERB intron 21423239 rs7159064 chr14 92178799 G A 8.53E-04 Suicide attempts in bipolar disorder CATSPERB intron 21423239 rs7159064 chr14 92178799 G A 1.23E-04 Body mass index CATSPERB intron 21701565 rs7159064 chr14 92178799 G A 3.31E-05 Body mass index CATSPERB intron 21701565 rs7159064 chr14 92178799 G A 5.07E-04 Body mass index CATSPERB intron 21701565 rs17783516 chr14 92185731 G A 8.40E-04 Suicide attempts in bipolar disorder CATSPERB intron 21423239 rs1397164 chr14 92190132 A C 3.73E-05 Suicide attempts in bipolar disorder CATSPERB intron 21423239 rs1397164 chr14 92190132 A C 3.08E-05 Depression (quantitative trait) CATSPERB intron 23290196 rs17565434 chr14 92192079 C T 3.97E-04 Body mass index CATSPERB intron 21701565 rs17565434 chr14 92192079 C T 4.09E-04 Body mass index CATSPERB intron 21701565 rs972905 chr14 92199558 C T 9.97E-05 Suicide attempts in bipolar disorder / / 21423239 rs10162491 chr14 92200291 T G 1.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs2402063 chr14 92207255 A G 5.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs3742648 chr14 92222410 C T 2.45E-04 Body mass index / / 21701565 rs11160026 chr14 92226474 G T 5.56E-04 Body mass index / / 21701565 rs11160026 chr14 92226474 G T 8.61E-04 Body mass index / / 21701565 rs10132770 chr14 92243283 A G 2.00E-05 HIV-1 control / / 20041166 rs7158030 chr14 92257063 T C 2.00E-05 HIV-1 control TC2N intron 20041166 rs8007195 chr14 92276821 A G 5.30E-05 HIV-1 control TC2N intron 20041166 rs17127600 chr14 92279983 T G 2.74E-05 Schizophrenia TC2N intron pha002857 rs10134181 chr14 92280037 T C 7.40E-04 Suicide attempts in bipolar disorder TC2N intron 21423239 rs4900088 chr14 92290681 A G 2.58E-04 Suicide attempts in bipolar disorder TC2N intron 21423239 rs10133762 chr14 92292769 T G 7.33E-04 Suicide attempts in bipolar disorder TC2N intron 21423239 rs10133762 chr14 92292769 T G 5.38E-04 Body mass index TC2N intron 21701565 rs2402074 chr14 92293518 A G 2.47E-04 Suicide attempts in bipolar disorder TC2N intron 21423239 rs1884841 chr14 92309229 A G 2.65E-04 Suicide attempts in bipolar disorder TC2N intron 21423239 rs1884841 chr14 92309229 A G 5.49E-04 Body mass index TC2N intron 21701565 rs1884840 chr14 92309325 A G 3.02E-04 Suicide attempts in bipolar disorder TC2N intron 21423239 rs10145714 chr14 92310699 G T 5.21E-04 Suicide attempts in bipolar disorder TC2N intron 21423239 rs10151688 chr14 92312369 A G 9.01E-04 Suicide attempts in bipolar disorder TC2N intron 21423239 rs8005894 chr14 92316755 G A 4.94E-04 Suicide attempts in bipolar disorder TC2N intron 21423239 rs12891090 chr14 92318172 C T 7.59E-04 Suicide attempts in bipolar disorder TC2N intron 21423239 rs12891605 chr14 92318334 G A 6.11E-04 Suicide attempts in bipolar disorder TC2N intron 21423239 rs12891605 chr14 92318334 G A 8.34E-04 Body mass index TC2N intron 21701565 rs11160029 chr14 92319779 G A 9.44E-04 Suicide attempts in bipolar disorder TC2N intron 21423239 rs11160029 chr14 92319779 G A 7.25E-04 Body mass index TC2N intron 21701565 rs759232 chr14 92323910 G A 2.35E-05 Lung function (forced vital capacity) TC2N intron 24023788 rs2498854 chr14 92326415 G T 1.11E-05 Lung function (forced vital capacity) TC2N intron 24023788 rs2052204 chr14 92330819 G A 1.60E-05 Information processing speed TC2N intron 21130836 rs2430340 chr14 92337774 G A 8.57E-05 Triglycerides FBLN5 intron pha003081 rs7143288 chr14 92337877 T C 2.51E-06 Lymphocyte counts FBLN5 intron 22286170 rs7143288 chr14 92337877 T C 2.73E-05 Triglycerides FBLN5 intron pha003081 rs7143288 chr14 92337877 T C 1.02E-05 Lipid levels FBLN5 intron pha003082 rs12586948 chr14 92338342 G A 9.14E-04 Multiple complex diseases FBLN5 intron 17554300 rs2498841 chr14 92351587 A C 6.50E-04 Type 2 diabetes FBLN5 intron 17463246 rs966382 chr14 92351652 T A 7.11E-04 Type 2 diabetes FBLN5 intron 17463246 rs2248052 chr14 92352114 C T 7.11E-04 Type 2 diabetes FBLN5 intron 17463246 rs2267994 chr14 92356946 A G 1.00E-04 Information processing speed FBLN5 intron 21130836 rs917908 chr14 92363786 T C 3.38E-04 Multiple complex diseases FBLN5 intron 17554300 rs2430363 chr14 92365051 G A 1.02E-05 Response to taxane treatment (placlitaxel) FBLN5 intron 23006423 rs1861085 chr14 92371234 T C 0.00044 Coronary artery calcification FBLN5 intron 23727086 rs2284342 chr14 92389372 G A 9.55E-04 Type 2 diabetes FBLN5 intron 17463246 rs2246416 chr14 92390620 A G 1.80E-04 HDL particle features FBLN5 intron 21283740 rs2246416 chr14 92390620 A G 6.20E-06 HDL particle features FBLN5 intron 21283740 rs2268002 chr14 92396750 C G 3.08E-04 Multiple complex diseases FBLN5 intron 17554300 rs3783937 chr14 92407693 C T 3.10E-04 Height FBLN5 intron 21194676 rs13379480 chr14 92407766 C G 6.76E-04 Alzheimer's disease FBLN5 intron 22005930 rs13379081 chr14 92408309 A G 6.41E-04 Alzheimer's disease FBLN5 intron 22005930 rs17127768 chr14 92409333 T C 4.67E-04 Alzheimer's disease FBLN5 intron 22005930 rs17127770 chr14 92409524 T C 6.45E-04 Alzheimer's disease FBLN5 intron 22005930 rs2498828 chr14 92421275 T C 2.42E-05 Asthma / / pha003127 rs4904828 chr14 92427126 T C 6.11E-04 Type 2 diabetes / / 17463246 rs7153027 chr14 92427222 A C 1.00E-10 Height / / 18391951 rs7154721 chr14 92427348 T C 3.91E-04 Lymphocyte counts / / 22286170 rs1040617 chr14 92432308 A G 5.98E-04 Type 2 diabetes / / 17463246 rs8007661 chr14 92459958 C T 6.00E-10 Height TRIP11 intron 18391950 rs137974620 chr14 92460176 C G 0.00016 Breast cancer TRIP11 missense 23555315 rs10144861 chr14 92465346 A G 2.31E-04 Lung function (forced expiratory volume in 1 second) TRIP11 intron 24023788 rs10144861 chr14 92465346 A G 4.35E-04 Lung function (forced vital capacity) TRIP11 intron 24023788 rs7155279 chr14 92485881 G T 1.00E-10 Height TRIP11 intron 20881960 rs8004149 chr14 92534915 C T 9.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ATXN3 intron 23648065 rs12588287 chr14 92536959 T C 9.00E-06 Coronary artery calcification ATXN3 intron 23870195 rs1048755 chr14 92548785 C T 7.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ATXN3 missense 23648065 rs17807815 chr14 92556055 T C 3.48E-04 Alcohol dependence ATXN3 intron 21314694 rs17807815 chr14 92556055 T C 6.00E-06 Orofacial clefts ATXN3 intron 22419666 rs1997919 chr14 92559862 C T 7.38E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ATXN3 intron 23648065 rs8021276 chr14 92576506 A G,T 7.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7151027 chr14 92588917 T A 9.07E-06 Lymphocyte counts CPSF2 intron 22286170 rs17807992 chr14 92600177 G A 1.00E-04 Information processing speed CPSF2 intron 21130836 rs117009742 chr14 92624111 A G 0.00041 Prostate cancer CPSF2 cds-synon 23555315 rs117009742 chr14 92624111 A G 0.00052 Prostate cancer (non-advanced prostate cancer) CPSF2 cds-synon 23555315 rs1009170 chr14 92636713 A T 2.00E-06 Dialysis-related mortality / / 21546767 rs1241694 chr14 92656568 T C 3.62E-05 Alzheimer's disease (late onset) / / 21379329 rs1241711 chr14 92668898 C T 8.72E-04 Response to alcohol consumption (flushing response) / / 24277619 rs7143409 chr14 92670873 A T 2.10E-05 Urinary metabolites / / 21572414 rs7144819 chr14 92670928 T C 1.20E-05 Urinary metabolites / / 21572414 rs7148418 chr14 92671089 G A 1.60E-05 Urinary metabolites / / 21572414 rs7148133 chr14 92671121 C T 1.20E-05 Urinary metabolites / / 21572414 rs7148148 chr14 92671185 A G 1.20E-05 Urinary metabolites / / 21572414 rs8014430 chr14 92675691 C T 2.60E-05 Urinary metabolites / / 21572414 rs8005444 chr14 92677528 G A 1.20E-05 Urinary metabolites / / 21572414 rs8005613 chr14 92677581 G A 1.30E-05 Urinary metabolites / / 21572414 rs1741439 chr14 92702596 C T 3.00E-06 Obesity-related traits / / 23251661 rs2002627 chr14 92723034 C A 6.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10143434 chr14 92723644 C A 7.84E-04 Alzheimer's disease / / 22005930 rs4904853 chr14 92726813 C G 9.53E-04 Alzheimer's disease / / 22005930 rs12434996 chr14 92735945 G A 1.55E-05 Hepatitis B / / 21750111 rs2093290 chr14 92740161 T A 8.79E-05 Relative hand skill in reading disability / / 24068947 rs2025074 chr14 92752200 A G 2.88E-06 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines / / 21483694 rs2025074 chr14 92752200 A G 6.58E-05 Relative hand skill in reading disability / / 24068947 rs8016079 chr14 92758445 G A 1.92E-04 Parkinson's disease / / 17052657 rs8016079 chr14 92758445 G A 4.20E-08 Skin sensitivity to sun / / 18488028 rs6575242 chr14 92759373 T C 8.51E-07 Common traits (Other) / / 20585627 rs4900109 chr14 92763391 G T 8.00E-21 Iris characteristics / / 21835309 rs4904864 chr14 92764519 A G 5.90E-11 Hair,eye and skin pigmentation / / 17952075 rs4904864 chr14 92764519 A G 1.00E-16 Skin sensitivity to sun / / 18488028 rs12896399 chr14 92773663 G T 1.00E-48 Blond vs. brown hair color / / 17952075 rs12896399 chr14 92773663 G T 4.00E-38 Blue vs. green eyes / / 17952075 rs12896399 chr14 92773663 G T 8.00E-21 Black vs. red hair color / / 18483556 rs12896399 chr14 92773663 G T 1.00E-16 Eye color / / 20585627 rs12896399 chr14 92773663 G T 2.00E-23 Eye color / / 20585627 rs12896399 chr14 92773663 G T 5.00E-13 Hair color / / 20585627 rs12896399 chr14 92773663 G T 2.00E-36 Hair color / / 23548203 rs12896399 chr14 92773663 G T 3.00E-07 Eye color / / 23548203 rs12896399 chr14 92773663 G T 4.00E-11 Eye color / / 23548203 rs8018017 chr14 92776418 G C 6.54E-05 Personality dimensions / / 18957941 rs17128162 chr14 92780357 G A 3.09E-08 Common traits (Other) / / 20585627 rs4904868 chr14 92781001 T C 7.50E-14 Hair,eye and skin pigmentation / / 17952075 rs4904868 chr14 92781001 T C 1.00E-20 Skin sensitivity to sun / / 18488028 rs2402130 chr14 92801203 G A 3.70E-09 Hair,eye and skin pigmentation SLC24A4 intron 17952075 rs2402130 chr14 92801203 G A 9.40E-13 Skin sensitivity to sun SLC24A4 intron 18488028 rs11160059 chr14 92807330 T C 1.54E-08 Blood pressure SLC24A4 intron 21378095 rs17128179 chr14 92813655 A G 2.37E-04 Multiple complex diseases SLC24A4 intron 17554300 rs8012948 chr14 92833681 A C 4.37E-06 Multiple complex diseases SLC24A4 intron 17554300 rs1884679 chr14 92843562 T A 1 Drug response to Etoposide SLC24A4 intron 17537913 rs1884679 chr14 92843562 T A 8.63E-05 Multiple complex diseases SLC24A4 intron 17554300 rs1884678 chr14 92843680 T C 1.30E-04 Multiple complex diseases SLC24A4 intron 17554300 rs1884677 chr14 92843828 G A 1 Drug response to Etoposide SLC24A4 intron 17537913 rs1884677 chr14 92843828 G A 2.36E-04 Multiple complex diseases SLC24A4 intron 17554300 rs4904886 chr14 92844370 G A 3.13E-04 Multiple complex diseases SLC24A4 intron 17554300 rs12891074 chr14 92846294 G A 9.86E-04 Aortic root size SLC24A4 intron 21223598 rs4444267 chr14 92848001 G A 1.78E-04 Multiple complex diseases SLC24A4 intron 17554300 rs12435905 chr14 92849447 A G 1 Drug response to Etoposide SLC24A4 intron 17537913 rs12435920 chr14 92849466 A G 1 Drug response to Etoposide SLC24A4 intron 17537913 rs4904887 chr14 92855520 C G 4.16E-04 Multiple complex diseases SLC24A4 intron 17554300 rs12590749 chr14 92868468 C A 7.16E-04 Insulin resistance SLC24A4 intron 21901158 rs11626106 chr14 92869643 T C 1.53E-05 Insulin resistance SLC24A4 intron 21901158 rs7152962 chr14 92895038 G A 6.69E-04 Response to TNF antagonist treatment SLC24A4 intron 21061259 rs734504 chr14 92898808 A G 7.20E-06 Urinary metabolites SLC24A4 intron 21572414 rs941650 chr14 92909073 T C 7.36E-04 Response to cytadine analogues (cytosine arabinoside) SLC24A4 cds-synon 24483146 rs12588868 chr14 92909309 T C 5.38E-05 Intelligence SLC24A4 intron 21826061 rs7143416 chr14 92918793 A G 3.22E-04 Alzheimer's disease SLC24A4 intron 24755620 rs10145865 chr14 92919834 G A 3.60E-04 Multiple complex diseases SLC24A4 intron 17554300 rs10137770 chr14 92922442 A G 2.30E-05 Temporomandibular joint disorders SLC24A4 intron 23746317 rs7156567 chr14 92922542 A G 5.80E-05 Temporomandibular joint disorders SLC24A4 intron 23746317 rs10498633 chr14 92926952 G T 6.00E-09 Alzheimer's disease (late onset) SLC24A4 intron 24162737 rs4904920 chr14 92927655 G A 7.00E-04 Acute lymphoblastic leukemia (childhood) SLC24A4 intron 20189245 rs8019291 chr14 92931164 G T 8.09E-06 Nicotine smoking SLC24A4 intron 19268276 rs1952324 chr14 92947116 C G 1.26E-08 Pure-tone audiometry SLC24A4 intron pha001968 rs4900134 chr14 92967120 T C 0.000225173 Hypertension (early onset hypertension) SLC24A4 UTR-3 22479346 rs4904947 chr14 92972162 C T 8.00E-06 Dialysis-related mortality / / 21546767 rs7141239 chr14 92988495 C T 1.50E-05 Urinary metabolites RIN3 intron 21572414 rs4374096 chr14 93003450 A G 8.00E-06 Urinary metabolites RIN3 intron 21572414 rs10467867 chr14 93008185 G A 2.40E-07 Urinary metabolites RIN3 intron 21572414 rs12880596 chr14 93027770 G T 3.21E-05 Lymphocyte counts RIN3 intron 22286170 rs10134299 chr14 93037133 T G 3.32E-04 Multiple complex diseases RIN3 intron 17554300 rs2104239 chr14 93037807 G A 5.61E-04 Age-related macular degeneration RIN3 intron 22125219 rs2104237 chr14 93038681 T C 6.51E-04 Multiple complex diseases RIN3 intron 17554300 rs2402171 chr14 93050146 A G 9.79E-04 Multiple complex diseases RIN3 intron 17554300 rs12433867 chr14 93065083 A G 6.88E-04 Multiple complex diseases RIN3 intron 17554300 rs11628180 chr14 93068516 G A 0.0008562 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RIN3 intron 23233654 rs11628180 chr14 93068516 G A 8.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) RIN3 intron 23233662 rs11626417 chr14 93079382 C A 2.62E-05 Bipolar disorder RIN3 intron 20451256 rs749647 chr14 93080703 A C 8.77E-05 Rheumatoid arthritis RIN3 intron 17804836 rs8010344 chr14 93086918 A G 5.00E-08 Bone mineral density (paediatric,total body less head) RIN3 intron 24945404 rs8010344 chr14 93086918 A G 9.50E-10 Bone mineral density (paediatric,lower limb) RIN3 intron 24945404 rs11160080 chr14 93089242 T C 6.77E-05 Blood Pressure RIN3 intron pha003039 rs12882803 chr14 93091341 G A,C 2.40E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs12882803 chr14 93091341 G A,C 5.93E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs2181378 chr14 93091497 G A 2.50E-08 Bone mineral density (paediatric,lower limb) RIN3 intron 24945404 rs61975788 chr14 93091558 C T 2.57E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs61975788 chr14 93091558 C T 6.36E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs2181377 chr14 93093155 G C 2.28E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs2181377 chr14 93093155 G C 5.35E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11160083 chr14 93093798 G A 2.30E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11160083 chr14 93093798 G A 5.08E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11623779 chr14 93096391 T C 3.90E-08 Bone mineral density (paediatric,total body less head) RIN3 intron 24945404 rs11623779 chr14 93096391 T C 7.40E-10 Bone mineral density (paediatric,lower limb) RIN3 intron 24945404 rs12590196 chr14 93096561 C T 1.81E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs12590196 chr14 93096561 C T 3.90E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs12590180 chr14 93096616 A G 1.18E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs12590180 chr14 93096616 A G 2.85E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs12590218 chr14 93096711 C A 1.85E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs12590218 chr14 93096711 C A 3.93E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11621441 chr14 93098070 C T 1.57E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11621441 chr14 93098070 C T 3.44E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11621587 chr14 93098339 G C 8.50E-10 Bone mineral density (paediatric,lower limb) RIN3 intron 24945404 rs11626270 chr14 93098452 T C 1.42E-04 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11626270 chr14 93098452 T C 5.90E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11621652 chr14 93098472 G A 9.97E-06 Bipolar disorder RIN3 intron 20451256 rs11621652 chr14 93098472 G A 1.46E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11621652 chr14 93098472 G A 2.42E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11627441 chr14 93099234 T A 4.80E-10 Bone mineral density (paediatric,lower limb) RIN3 intron 24945404 rs11627441 chr14 93099234 T A 4.90E-08 Bone mineral density (paediatric,total body less head) RIN3 intron 24945404 rs11160084 chr14 93099369 G A 2.14E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11160084 chr14 93099369 G A 9.90E-06 Alzheimer's disease (late onset) RIN3 intron 23565137 rs4904964 chr14 93099867 A C 0.0008841 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RIN3 intron 23233654 rs4904964 chr14 93099867 A C 8.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) RIN3 intron 23233662 rs4904964 chr14 93099867 A C 1.14E-04 Alzheimer's disease (late onset) RIN3 intron 23565137 rs4904964 chr14 93099867 A C 4.53E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs7146689 chr14 93100024 T C 7.37E-04 Multiple complex diseases RIN3 intron 17554300 rs7146689 chr14 93100024 T C 1.10E-09 Bone mineral density (paediatric,lower limb) RIN3 intron 24945404 rs8015224 chr14 93101074 T G 1.20E-04 Alzheimer's disease (late onset) RIN3 intron 23565137 rs8015224 chr14 93101074 T G 4.60E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs17184313 chr14 93102251 C T 7.00E-05 Breast cancer RIN3 intron 19330027 rs17184313 chr14 93102251 C T 4.20E-08 Bone mineral density (paediatric,total body less head) RIN3 intron 24945404 rs17184313 chr14 93102251 C T 7.90E-10 Bone mineral density (paediatric,lower limb) RIN3 intron 24945404 rs10498635 chr14 93103309 C T 8.78E-05 HIV-1 control RIN3 intron 20041166 rs10498635 chr14 93103309 C T 9.69E-08 Paget's disease RIN3 intron 20436471 rs10498635 chr14 93103309 C T 3.00E-11 Paget's disease RIN3 intron 21623375 rs10498635 chr14 93103309 C T 4.20E-08 Bone mineral density (paediatric,total body less head) RIN3 intron 24945404 rs10498635 chr14 93103309 C T 7.90E-10 Bone mineral density (paediatric,lower limb) RIN3 intron 24945404 rs4900138 chr14 93104025 G C 9.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) RIN3 intron 23233662 rs4900138 chr14 93104025 G C 1.19E-04 Alzheimer's disease (late onset) RIN3 intron 23565137 rs4900138 chr14 93104025 G C 4.41E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11627032 chr14 93104072 T C 9.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) RIN3 intron 23233662 rs11627032 chr14 93104072 T C 1.58E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11627032 chr14 93104072 T C 3.14E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11627032 chr14 93104072 T C 5.00E-08 Bone mineral density (paediatric,lower limb) RIN3 intron 24945404 rs11623618 chr14 93104959 G A 1.46E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11623618 chr14 93104959 G A 3.19E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs1075472 chr14 93108131 A G 3.50E-08 Bone mineral density (paediatric,total body less head) RIN3 intron 24945404 rs1075472 chr14 93108131 A G 7.30E-10 Bone mineral density (paediatric,lower limb) RIN3 intron 24945404 rs35268629 chr14 93110372 G A 2.57E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs35268629 chr14 93110372 G A 9.49E-06 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11624512 chr14 93111120 C T 2.10E-09 Bone mineral density (paediatric,lower limb) RIN3 intron 24945404 rs11160085 chr14 93112102 T C 1.21E-04 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11160085 chr14 93112102 T C 4.88E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs7151520 chr14 93113538 T C 2.08E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs7151520 chr14 93113538 T C 6.86E-06 Alzheimer's disease (late onset) RIN3 intron 23565137 rs7151531 chr14 93113547 T C 2.45E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs7151531 chr14 93113547 T C 8.55E-06 Alzheimer's disease (late onset) RIN3 intron 23565137 rs7150776 chr14 93113821 C T 2.40E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs7150776 chr14 93113821 C T 8.29E-06 Alzheimer's disease (late onset) RIN3 intron 23565137 rs35326193 chr14 93114055 A T 2.23E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs35326193 chr14 93114055 A T 7.82E-06 Alzheimer's disease (late onset) RIN3 intron 23565137 rs754388 chr14 93115410 G C 5.00E-09 Chronic obstructive pulmonary disease (moderate to severe) RIN3 intron 24621683 rs754388 chr14 93115410 G C 7.00E-08 Chronic obstructive pulmonary disease (severe) RIN3 intron 24621683 rs754388 chr14 93115410 G C 1.00E-10 Bone mineral density (paediatric,lower limb) RIN3 intron 24945404 rs754388 chr14 93115410 G C 2.00E-09 Bone mineral density (paediatric,lower limb) RIN3 intron 24945404 rs754388 chr14 93115410 G C 3.00E-09 Bone mineral density (paediatric,total body less head) RIN3 intron 24945404 rs754388 chr14 93115410 G C 5.00E-08 Bone mineral density (paediatric,total body less head) RIN3 intron 24945404 rs11621843 chr14 93116124 A G 7.95E-05 Bipolar disorder RIN3 intron 20451256 rs11621843 chr14 93116124 A G 5.19E-06 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11621843 chr14 93116124 A G 5.96E-06 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11621843 chr14 93116124 A G 8.10E-04 Alzheimer's disease (late onset) RIN3 intron 23565137 rs3829948 chr14 93116826 T G 5.63E-06 Alzheimer's disease (late onset) RIN3 intron 23565137 rs3829948 chr14 93116826 T G 7.95E-06 Alzheimer's disease (late onset) RIN3 intron 23565137 rs2402173 chr14 93116878 G C 9.95E-05 Bipolar disorder RIN3 intron 20451256 rs2402173 chr14 93116878 G C 5.29E-06 Alzheimer's disease (late onset) RIN3 intron 23565137 rs2402173 chr14 93116878 G C 7.45E-06 Alzheimer's disease (late onset) RIN3 intron 23565137 rs3814830 chr14 93118198 C T 1.78E-05 Alzheimer's disease (late onset) RIN3 cds-synon 23565137 rs3814830 chr14 93118198 C T 2.06E-05 Alzheimer's disease (late onset) RIN3 cds-synon 23565137 rs61992600 chr14 93119725 G A 4.89E-06 Alzheimer's disease (late onset) RIN3 intron 23565137 rs61992600 chr14 93119725 G A 6.77E-06 Alzheimer's disease (late onset) RIN3 intron 23565137 rs7160920 chr14 93120620 C T 4.71E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs7160920 chr14 93120620 C T 6.23E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11629324 chr14 93120719 C T 1.53E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11629324 chr14 93120719 C T 1.89E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11849307 chr14 93121370 T C 1.49E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11849307 chr14 93121370 T C 1.84E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11624035 chr14 93123142 A G 1.49E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11624035 chr14 93123142 A G 1.86E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs56019622 chr14 93124994 C G 1.35E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs56019622 chr14 93124994 C G 1.76E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs12885166 chr14 93125282 G T 2.76E-05 Rheumatoid arthritis RIN3 intron 17804836 rs7155457 chr14 93126557 T C 1.39E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs7155457 chr14 93126557 T C 1.67E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11160087 chr14 93129982 G A 2.56E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs11160087 chr14 93129982 G A 2.61E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs4900140 chr14 93130227 A G 2.54E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs4900140 chr14 93130227 A G 2.72E-05 Alzheimer's disease (late onset) RIN3 intron 23565137 rs2250672 chr14 93170741 T C 3.45E-04 Response to platinum-based chemotherapy in small-cell lung cancer LGMN intron 20463552 rs2402189 chr14 93170901 A C 2.80E-05 Urinary metabolites LGMN intron 21572414 rs4904977 chr14 93171553 A C 9.40E-06 Urinary metabolites LGMN intron 21572414 rs8177528 chr14 93177651 T C 9.03E-04 Multiple complex diseases LGMN intron 17554300 rs8177528 chr14 93177651 T C 9.86E-05 Parkinson's disease (motor and cognition) LGMN intron 22658654 rs8177528 chr14 93177651 T C 9.86E-05 Immune response to anthrax vaccine LGMN intron 22658931 rs12586718 chr14 93186594 C T 1.79E-04 Hearing function LGMN intron 17255346 rs7160685 chr14 93223990 C T 8.00E-06 IgG glycosylation / / 23382691 rs4904984 chr14 93247868 T G 2.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2402198 chr14 93278297 T C 8.64E-05 Lipoproteins GOLGA5 intron pha003079 rs11622505 chr14 93317566 A G 3.46E-05 HIV-1 progression / / 20064070 rs12434641 chr14 93358111 T C 4.97E-05 Progressive supranuclear palsy / / 21685912 rs7146688 chr14 93359493 C A 3.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2295394 chr14 93412743 G A 1.50E-15 Progranulin levels ITPK1 cds-synon 21087763 rs2295394 chr14 93412743 G A 1.50E-15 Myocardial infarction ITPK1 cds-synon 21211798 rs12435325 chr14 93461310 G A 8.12E-04 Alzheimer's disease ITPK1 intron 22005930 rs4905029 chr14 93468931 C T 7.74E-05 Blood Pressure ITPK1 intron pha003039 rs4905029 chr14 93468931 C T 6.38E-05 Blood Pressure ITPK1 intron pha003045 rs8006385 chr14 93501026 A G 1.00E-10 Platelet counts ITPK1 intron 22139419 rs749619 chr14 93523894 C T 2.64E-06 Biliary atresia ITPK1 intron 20460270 rs1740689 chr14 93544174 C T 2.30E-05 Urinary metabolites ITPK1 intron 21572414 rs4905043 chr14 93550009 G A 3.31E-05 Celiac disease ITPK1 intron 23936387 rs941541 chr14 93560657 G A 2.71E-04 Blood pressure ITPK1 intron 17255346 rs10143112 chr14 93561675 C T 7.41E-04 Multiple complex diseases ITPK1 intron 17554300 rs11624776 chr14 93595591 A C 2.00E-09 Thyroid hormone levels / / 23408906 rs11624776 chr14 93595591 A C 3.00E-06 Thyroid hormone levels / / 23408906 rs7150624 chr14 93611243 T C 9.68E-05 Major depressive disorder (broad) / / 20038947 rs7151193 chr14 93611535 T G 6.38E-05 Major depressive disorder (broad) / / 20038947 rs17128893 chr14 93615607 A G 1.47E-04 Coronary heart disease / / 21606135 rs1268843 chr14 93644379 A C 3.00E-06 Endometriosis / / 23472165 rs3783899 chr14 93682861 C T 3.17E-04 Lung function (forced expiratory volume in 1 second) UBR7 intron 24023788 rs10132640 chr14 93684814 T C 5.00E-04 Acute lymphoblastic leukemia (childhood) UBR7 intron 20189245 rs17128941 chr14 93685097 C T 5.52E-06 Glaucoma (primary open-angle) UBR7 intron 22605921 rs76828246 chr14 93685577 G A 0.0004 Prostate cancer (non-advanced prostate cancer) UBR7 missense 23555315 rs17128943 chr14 93687258 G A 5.64E-04 Psoriasis UBR7 intron 20953187 rs1044780 chr14 93705124 T C 3.38E-04 Alzheimer's disease BTBD7 UTR-3 17998437 rs10484032 chr14 93738663 T C 4.11E-04 Alzheimer's disease BTBD7 intron 17998437 rs6575330 chr14 93840193 A G 9.40E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) UNC79 intron 24236485 rs10152071 chr14 93861652 T C 7.20E-04 Multiple complex diseases UNC79 intron 17554300 rs10152071 chr14 93861652 T C 7.29E-05 Serum metabolites UNC79 intron 19043545 rs1950900 chr14 93876312 G A 9.40E-04 Multiple complex diseases UNC79 intron 17554300 rs10747303 chr14 93903352 A G 3.13E-04 Multiple complex diseases UNC79 intron 17554300 rs8004254 chr14 93908962 A G 1.89E-04 Multiple complex diseases UNC79 intron 17554300 rs10149904 chr14 93913432 T C 4.39E-04 Multiple complex diseases UNC79 intron 17554300 rs1242762 chr14 93935968 G A 3.28E-04 Multiple complex diseases UNC79 intron 17554300 rs12882384 chr14 93985447 A G 1.94E-05 Alcohol and nictotine co-dependence UNC79 intron 20158304 rs12882384 chr14 93985447 A G 4.86E-08 Alcohol and nictotine co-dependence UNC79 intron 20158304 rs1004553 chr14 93988980 G A 3.97E-04 Multiple complex diseases UNC79 intron 17554300 rs17129086 chr14 93989480 T C 3.46E-04 Multiple complex diseases UNC79 intron 17554300 rs17129088 chr14 93989679 G A 2.10E-05 Urinary metabolites UNC79 intron 21572414 rs7151505 chr14 94000942 G A 1.80E-04 Obesity,menopause UNC79 intron 21424828 rs12586978 chr14 94042220 C G 7.14E-05 Alzheimer's disease UNC79 intron 17998437 rs2148561 chr14 94102740 G A 3.50E-06 Urinary metabolites UNC79 intron 21572414 rs4905082 chr14 94103602 G A 9.26E-04 Coronary Artery Disease UNC79 cds-synon 17634449 rs2296687 chr14 94121728 A G 0.00078 Prostate cancer UNC79 missense 23555315 rs2209675 chr14 94147954 A G 5.88E-04 Insulin resistance UNC79 intron 21901158 rs943323 chr14 94160521 C A 9.00E-06 Asthma UNC79 intron 21790008 rs12434848 chr14 94198128 C A 2.05E-04 Alzheimer's disease (late onset) PRIMA1 intron 21379329 rs6575353 chr14 94205345 G A 2.30E-06 Urinary metabolites PRIMA1 intron 21572414 rs6575353 chr14 94205345 G A 1.00E-06 Insomnia (caffeine-induced) PRIMA1 intron 22754043 rs11851391 chr14 94218148 C T 2.22E-05 Amyotrophic lateral sclerosis (sporadic) PRIMA1 intron 24529757 rs566087995 chr14 94218148 CGTA C 2.22E-05 Amyotrophic lateral sclerosis (sporadic) PRIMA1 intron 24529757 rs12891890 chr14 94235393 T G 3.33E-04 Suicide attempts in bipolar disorder PRIMA1 intron 21423239 rs8021473 chr14 94236323 G A 2.51E-04 Suicide attempts in bipolar disorder PRIMA1 intron 21423239 rs4905086 chr14 94236801 C T 3.80E-04 Suicide attempts in bipolar disorder PRIMA1 intron 21423239 rs10151424 chr14 94236808 A C 4.37E-04 Suicide attempts in bipolar disorder PRIMA1 intron 21423239 rs1950969 chr14 94236929 A G 1.46E-04 Alzheimer's disease (late onset) PRIMA1 intron 21379329 rs1950969 chr14 94236929 A G 3.93E-04 Suicide attempts in bipolar disorder PRIMA1 intron 21423239 rs1950970 chr14 94236975 T C 3.63E-04 Suicide attempts in bipolar disorder PRIMA1 intron 21423239 rs2145472 chr14 94237254 T G 1.07E-04 Alzheimer's disease (late onset) PRIMA1 intron 21379329 rs2145472 chr14 94237254 T G 3.61E-04 Suicide attempts in bipolar disorder PRIMA1 intron 21423239 rs4347553 chr14 94237615 G C 3.74E-04 Suicide attempts in bipolar disorder PRIMA1 intron 21423239 rs4500654 chr14 94237627 C G 4.89E-04 Suicide attempts in bipolar disorder PRIMA1 intron 21423239 rs4577008 chr14 94237644 A G 6.19E-04 Suicide attempts in bipolar disorder PRIMA1 intron 21423239 rs17129207 chr14 94299958 C T 0.0002485 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17129207 chr14 94299958 C T 2.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs761979 chr14 94304448 A G 8.33E-05 Sarcoidosis / / 19165924 rs8010621 chr14 94308213 A G 0.0004603 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8010621 chr14 94308213 A G 4.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10133685 chr14 94308518 A C 0.0004604 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10133685 chr14 94308518 A C 4.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10133845 chr14 94308590 C T 0.0004599 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10133845 chr14 94308590 C T 4.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12147189 chr14 94308934 G A 0.0004563 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12147189 chr14 94308934 G A 4.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8003225 chr14 94312334 A C 7.72E-04 Type 2 diabetes / / 17463246 rs8003225 chr14 94312334 A C 0.0003274 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8003225 chr14 94312334 A C 3.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8020379 chr14 94315316 A G 1.43E-04 Multiple complex diseases / / 17554300 rs7140158 chr14 94319160 G A 4.05E-04 Type 2 diabetes / / 17463246 rs1001381 chr14 94319184 C A 2.09E-04 Type 2 diabetes / / 17463246 rs753642 chr14 94320586 C T 5.96E-04 Type 2 diabetes / / 17463246 rs753642 chr14 94320586 C T 1.32E-04 Multiple complex diseases / / 17554300 rs17129234 chr14 94322222 C A 4.66E-04 Type 2 diabetes / / 17463246 rs4900199 chr14 94325812 T C 8.10E-04 Multiple complex diseases / / 17554300 rs10134755 chr14 94326457 C T 6.74E-05 Cognitive performance / / 19734545 rs10484038 chr14 94327474 C T 9.55E-06 Cognitive performance / / 19734545 rs9323895 chr14 94340130 A G 7.38E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17813053 chr14 94358245 G A 4.24E-05 Telomere length / / 21573004 rs17129300 chr14 94359824 C T 2.47E-05 Cognitive performance / / 19734545 rs927234 chr14 94397813 G A 5.09E-05 Tourette syndrome / / 22889924 rs11555542 chr14 94417531 T C 0.00075 Breast cancer ASB2 missense 23555315 rs4243701 chr14 94419888 A G 6.67E-04 Multiple complex diseases ASB2 intron 17554300 rs12882974 chr14 94422192 C T 4.88E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) ASB2 intron 23648065 rs730959 chr14 94422346 A G 7.93E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) ASB2 intron 23648065 rs730959 chr14 94422346 A G 2.52E-05 Coronary heart disease ASB2 intron pha003055 rs3765492 chr14 94422467 G A 2.37E-04 Multiple complex diseases ASB2 intron 17554300 rs10873444 chr14 94434716 G T 3.41E-05 Hemoglobin ASB2 intron pha003096 rs11624088 chr14 94445201 G A 2.93E-05 Intracerebral hemorrhage / / 24656865 rs11624088 chr14 94445201 G A 3.22E-05 Intracerebral hemorrhage / / 24656865 rs11844114 chr14 94460529 A T 3.04E-04 Multiple complex diseases / / 17554300 rs4905135 chr14 94461601 C T 1.26E-04 Multiple complex diseases / / 17554300 rs10149388 chr14 94466834 C T 0.000225 Alpha-1 globulin (%) LINC00521 intron 23696881 rs8010454 chr14 94477681 C T 4.72E-04 Type 2 diabetes / / 17463246 rs877339 chr14 94488692 C T 7.88E-05 Pulmonary function / / 20010835 rs2180080 chr14 94490701 C T 7.20E-04 Pulmonary function / / 23932459 rs8022950 chr14 94498929 T C 0.00061 Endometrial cancer OTUB2 intron 22426144 rs11621705 chr14 94501438 G A 8.69E-04 Type 2 diabetes OTUB2 intron 17463246 rs2295216 chr14 94505283 C G 7.60E-05 Parkinson's disease (age of onset) OTUB2 intron 19772629 rs12433627 chr14 94506591 T C 1.10E-04 Multiple complex diseases OTUB2 intron 17554300 rs4905146 chr14 94508242 A G 3.35E-05 Serum metabolites OTUB2 intron 19043545 rs148489393 chr14 94545604 C T 0.00037 Prostate cancer (non-advanced prostate cancer) DDX24 missense 23555315 rs148489393 chr14 94545604 C T 0.00042 Prostate cancer DDX24 missense 23555315 rs3790043 chr14 94546465 A G 3.23E-04 Parkinson's disease DDX24 intron 17052657 rs998518 chr14 94554550 T G 1.16E-04 Breast cancer IFI27L1 intron 21060860 rs17190904 chr14 94555248 A G 7.87E-05 Coronary heart disease IFI27L1 intron pha003032 rs7157940 chr14 94563193 T C 3.00E-06 Anthropometric traits IFI27L1 UTR-5 19260139 rs958187 chr14 94594768 T G 8.13E-05 Personality dimensions IFI27L2 intron 18957941 rs4905166 chr14 94598617 G A 2.90E-04 Multiple complex diseases / / 17554300 rs11621291 chr14 94599583 T G 6.60E-04 Multiple complex diseases / / 17554300 rs10131174 chr14 94599936 T C 6.93E-04 Multiple complex diseases / / 17554300 rs10149497 chr14 94612518 C T 1.40E-04 Multiple complex diseases / / 17554300 rs10134615 chr14 94627188 A G 7.09E-05 Multiple complex diseases / / 17554300 rs1956455 chr14 94641867 G T 2.66E-05 Orofacial clefts PPP4R4 intron 20023658 rs8011557 chr14 94690165 A G 8.70E-06 Urinary metabolites PPP4R4 intron 21572414 rs4569189 chr14 94696688 G A 1.50E-05 Urinary metabolites PPP4R4 intron 21572414 rs7160963 chr14 94713390 G A 1.10E-05 Urinary metabolites PPP4R4 intron 21572414 rs2224237 chr14 94719315 C T 1.10E-05 Urinary metabolites PPP4R4 intron 21572414 rs8010043 chr14 94748346 A T 1.60E-05 Urinary metabolites / / 21572414 rs2232701 chr14 94756344 C T 0.00000214 LDL cholesterol SERPI/10 missense 23063622 rs2232701 chr14 94756344 C T 8.71E-08 Cholesterol,total SERPI/10 missense 23063622 rs4900224 chr14 94763493 T C 8.40E-04 Atrial fibrillation / / 21846873 rs7147098 chr14 94769817 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2144834 chr14 94773634 G A 1.29E-04 Response to cytadine analogues (cytosine arabinoside) SERPI/6 intron 24483146 rs11627241 chr14 94785451 T C 3.00E-06 Urinary metabolites SERPI/6 intron 21572414 rs1956177 chr14 94789810 T G 5.70E-06 Urinary metabolites SERPI/6 nearGene-5 21572414 rs4905179 chr14 94795492 A G 9.80E-06 Emphysema-related traits / / 20709820 rs61280460 chr14 94796184 A T 8.00E-07 Breast size / / 22747683 rs1950654 chr14 94805411 C T 4.60E-06 Urinary metabolites / / 21572414 rs3748319 chr14 94835647 C T 4.10E-04 Atrial fibrillation SERPI/2 intron 21846873 rs112635299 chr14 94838142 G T 2.51E-12 Alpha-1 globulin (%) SERPI/2 intron 23696881 rs1243167 chr14 94841641 G A 2.20E-05 Urinary metabolites / / 21572414 rs1243164 chr14 94844470 C A 8.70E-06 Prion diseases SERPI/1 UTR-3 22210626 rs1303 chr14 94844843 T G 5.00E-48 Metabolite levels (atherosclerosis) SERPI/1 missense 22916037 rs11846959 chr14 94846316 G A 1.50E-05 Urinary metabolites SERPI/1 intron 21572414 rs2144831 chr14 94849970 A T 1.70E-06 Urinary metabolites SERPI/1 intron 21572414 rs8010121 chr14 94850614 A G 9.04E-05 Prion diseases SERPI/1 intron 22210626 rs1980618 chr14 94852423 A T 9.30E-06 Urinary metabolites SERPI/1 intron 21572414 rs3748317 chr14 94853679 C A 0.00000739 Femoral neck bone mineral density SERPI/1 intron 22692763 rs11629242 chr14 94861516 A G 9.77E-05 Multiple sclerosis (age of onset) / / 19010793 rs11629242 chr14 94861516 A G 2.97E-05 Blood Pressure / / pha003048 rs8008466 chr14 94862149 T C 1.10E-05 Multiple sclerosis (age of onset) / / 19010793 rs8008466 chr14 94862149 T C 3.31E-04 Smoking initiation / / 24665060 rs8008466 chr14 94862149 T C 4.41E-05 Blood Pressure / / pha003048 rs7151526 chr14 94863636 C A 2.00E-09 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs2896268 chr14 94865708 A C 6.72E-04 Alzheimer's disease / / 17998437 rs2402446 chr14 94866137 T A 3.70E-04 Alzheimer's disease / / 17998437 rs1956705 chr14 94869983 T A 4.14E-05 Alzheimer's disease / / 17998437 rs1956702 chr14 94873290 T A 7.78E-05 Alzheimer's disease / / 17998437 rs8020968 chr14 94873771 G A 9.42E-05 Alzheimer's disease / / 17998437 rs1956701 chr14 94874009 T A 1.32E-04 Alzheimer's disease / / 17998437 rs743206 chr14 94879662 G A 2.79E-04 White matter integrity / / 22425255 rs17090790 chr14 94881465 T C 9.04E-04 White matter integrity / / 22425255 rs7144888 chr14 94888077 T C 5.83E-04 White matter integrity / / 22425255 rs2145497 chr14 94891641 G T 7.71E-04 Multiple complex diseases / / 17554300 rs2145497 chr14 94891641 G T 1.50E-05 Personality dimensions / / 18957941 rs2180813 chr14 94928140 C T 2.52E-04 Nicotine dependence / / 17158188 rs12892340 chr14 94934176 G A 8.93E-04 Alcohol dependence SERPI/9 intron 21314694 rs6575434 chr14 94937398 T C 6.11E-04 Type 2 diabetes SERPI/9 intron 17463246 rs11160184 chr14 94937991 C T 4.71E-04 Multiple complex diseases SERPI/9 intron 17554300 rs17752593 chr14 94938028 C A 1.74E-04 Multiple complex diseases SERPI/9 intron 17554300 rs17752593 chr14 94938028 C A 2.40E-06 Iron levels SERPI/9 intron 21208937 rs17090939 chr14 94939550 G A 1.57E-04 Response to cytadine analogues (cytosine arabinoside) SERPI/9 intron 24483146 rs11626091 chr14 94941587 G A 2.74E-05 Substance dependence SERPI/9 intron 21818250 rs11626701 chr14 94954368 A G 5.64E-04 Multiple complex diseases SERPI/12 intron 17554300 rs1998207 chr14 94957714 G T 1.00E-06 Obesity-related traits SERPI/12 intron 23251661 rs1998207 chr14 94957714 G T 3.00E-06 Obesity-related traits SERPI/12 intron 23251661 rs1998207 chr14 94957714 G T 7.00E-06 Obesity-related traits SERPI/12 intron 23251661 rs2236241 chr14 94960149 A G 3.37E-04 Multiple complex diseases SERPI/12 intron 17554300 rs7152296 chr14 94960384 A G 0.0000187 Paraoxonase activity SERPI/12 intron 23160181 rs10140797 chr14 94965685 C A 9.76E-06 Obesity-related traits SERPI/12 intron 23251661 rs17825787 chr14 94965837 G A 6.59E-04 Type 2 diabetes SERPI/12 intron 17463246 rs10145558 chr14 94971978 A G 2.10E-05 Urinary metabolites SERPI/12 intron 21572414 rs11627075 chr14 94972242 C A 3.00E-06 Obesity-related traits SERPI/12 intron 23251661 rs11625754 chr14 94981547 G A 3.91E-06 Obesity-related traits SERPI/12 intron 23251661 rs11160190 chr14 95012384 A G 4.00E-41 Vaspin levels / / 22907691 rs11160190 chr14 95012384 A G 2.52E-04 Smoking initiation / / 24665060 rs2896287 chr14 95016780 G A 2.57E-05 Gallstones / / 17632509 rs17091075 chr14 95034082 A G 1.53E-04 Type 2 diabetes SERPI/4 intron 17463246 rs10139629 chr14 95035277 G A 8.11E-04 Response to cytadine analogues (cytosine arabinoside) SERPI/4 intron 24483146 rs1475937 chr14 95046957 C T 1.53E-04 Type 2 diabetes / / 17463246 rs10484047 chr14 95049228 G A 2.28E-04 Response to taxane treatment (placlitaxel) SERPI/5 intron 23006423 rs2069956 chr14 95052320 C T 2.98E-04 Smoking initiation SERPI/5 intron 24665060 rs2069962 chr14 95052559 A C 5.14E-04 Multiple complex diseases SERPI/5 intron 17554300 rs2069970 chr14 95053286 G A 1.40E-05 Iron levels SERPI/5 intron 21208937 rs4900239 chr14 95073431 C T 6.10E-04 Multiple complex diseases / / 17554300 rs56871159 chr14 95080786 G A 0.000000001 LDL cholesterol SERPI/3 missense 23063622 rs2896288 chr14 95081744 G A 4.59E-04 Multiple complex diseases SERPI/3 intron 17554300 rs8005845 chr14 95094397 C T 5.00E-06 Body mass index / / 23669352 rs12885542 chr14 95095002 A G 1.29E-05 Bipolar disorder,affective / / 20528957 rs1955659 chr14 95096153 T A 1.18E-05 Bipolar disorder,affective / / 20528957 rs1154824 chr14 95096255 A C 1.18E-05 Bipolar disorder,affective / / 20528957 rs12879878 chr14 95106408 T C 2.09E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12878973 chr14 95106436 G C 6.47E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4905226 chr14 95107973 C T 4.00E-06 Social communication problems / / 24564958 rs4905226 chr14 95107973 C T 1.09E-04 Heart Failure / / pha002884 rs1569808 chr14 95132835 T C 3.27E-04 Type 2 diabetes / / 17463246 rs17753662 chr14 95132892 G A 2.51E-04 Tourette syndrome / / 22889924 rs1955650 chr14 95133688 G A 2.26E-04 Alzheimer's disease (late onset) / / 21379329 rs2402500 chr14 95134471 A G 2.27E-04 Alzheimer's disease (late onset) / / 21379329 rs11622883 chr14 95155776 T A 9.40E-05 Alzheimer's disease (late onset) / / 21460841 rs59233955 chr14 95172541 G A 6.18E-05 Epilepsy (remission after treatment) / / 23962720 rs11851301 chr14 95174266 A G 9.31E-04 Type 2 diabetes / / 17463246 rs8004970 chr14 95175605 G T 1.90E-05 Urinary metabolites / / 21572414 rs9788623 chr14 95190406 G A 9.72E-05 Cholesterol / / pha003073 rs9788623 chr14 95190406 G A 5.32E-05 Cholesterol / / pha003078 rs2896294 chr14 95207147 T C 3.00E-04 Alcohol dependence / / 20201924 rs8006225 chr14 95219657 G T 8.27E-04 Tourette syndrome / / 22889924 rs4905243 chr14 95231113 G A 7.69E-05 Cognitive impairment induced by topiramate / / 22091778 rs8018930 chr14 95239366 C T 2.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8018930 chr14 95239366 C T 1.05E-04 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs10138130 chr14 95253771 C T 3.80E-04 Multiple complex diseases / / 17554300 rs11624885 chr14 95266464 G A 2.12E-04 Smoking initiation / / 24665060 rs3850403 chr14 95275905 T G 7.10E-04 Response to alcohol consumption (flushing response) / / 24277619 rs10139313 chr14 95278899 G A 2.14E-04 Multiple complex diseases / / 17554300 rs10134921 chr14 95280334 G T 8.46E-04 Multiple complex diseases / / 17554300 rs10147231 chr14 95280592 T G 2.32E-04 Multiple complex diseases / / 17554300 rs748752 chr14 95288638 G A 5.21E-04 Coronary heart disease / / 21606135 rs11624318 chr14 95306012 C A 2.70E-07 Type 1 diabetes / / 19875614 rs11624318 chr14 95306012 C A 7.60E-06 Type 1 diabetes / / 19875614 rs11624318 chr14 95306012 C A 9.68E-04 Myopia (pathological) / / 21095009 rs7141561 chr14 95312647 A G 1.11E-05 HDL cholesterol / / pha003075 rs1243500 chr14 95312660 G T 3.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17754604 chr14 95315651 G A 3.94E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10133971 chr14 95322798 C T 2.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs11160216 chr14 95324287 G A 3.71E-04 Suicide attempts in bipolar disorder / / 21041247 rs7156858 chr14 95327206 A C 7.75E-04 Suicide attempts in bipolar disorder / / 21041247 rs7157079 chr14 95327349 A G 4.40E-04 Parkinson's disease / / 17052657 rs7157079 chr14 95327349 A G 7.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs7157079 chr14 95327349 A G 2.22E-04 Stroke / / pha002887 rs7157782 chr14 95327606 C T 8.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs11160219 chr14 95335491 A G 3.40E-05 Type 1 diabetes / / 19875614 rs11160219 chr14 95335491 A G 4.30E-07 Type 1 diabetes / / 19875614 rs4636839 chr14 95336598 C T 3.09E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4608262 chr14 95336703 C T 1.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8007115 chr14 95337488 T C 4.10E-05 Type 1 diabetes / / 19875614 rs8007115 chr14 95337488 T C 5.40E-07 Type 1 diabetes / / 19875614 rs12881798 chr14 95346558 C A 8.40E-05 Bone mineral density (BMD),in women / / 20164292 rs1768112 chr14 95361689 G A 4.85E-06 Orofacial clefts / / 20023658 rs1341001 chr14 95362696 A G 6.83E-06 Orofacial clefts / / 20023658 rs2983478 chr14 95364090 C T 0.0000401 Follicular lymphoma / / 23025665 rs2983478 chr14 95364090 C T 4.04E-05 Diabetes Mellitus / / pha003059 rs941657 chr14 95370947 C T 8.98E-04 Heart Failure / / pha002884 rs10130003 chr14 95382880 T C 9.36E-04 Coronary heart disease / / 21606135 rs1243578 chr14 95385507 G A 8.14E-04 Insulin resistance / / 21901158 rs3861665 chr14 95390794 A G 4.06E-04 Suicide attempts in bipolar disorder / / 21041247 rs8018330 chr14 95397127 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1105567 chr14 95402119 T C 1.72E-05 HDL cholesterol / / pha003074 rs2789382 chr14 95409161 A G 1.94E-04 Smoking initiation / / 24665060 rs10133840 chr14 95410529 C G 1.00E-06 Body mass index (interaction) / / 23192594 rs10133840 chr14 95410529 C G 4.00E-07 Body mass index (interaction) / / 23192594 rs41412245 chr14 95414731 G T 2.53E-04 Multiple complex diseases / / 17554300 rs8019257 chr14 95415113 G C 8.50E-05 Schizophrenia / / pha002859 rs2798823 chr14 95420372 C T 0.000476 Ovarian cancer / / 22794196 rs2798820 chr14 95422876 A G 4.70E-04 HIV-1 viral setpoint / / 17641165 rs2798819 chr14 95423041 T G 4.04E-04 Type 2 diabetes / / 17463246 rs2798819 chr14 95423041 T G 7.07E-04 Sarcoidosis / / 19165924 rs2798819 chr14 95423041 T G 9.40E-05 Pulmonary function / / 19300500 rs12889327 chr14 95423213 C T 5.40E-05 HIV-1 viral setpoint / / 17641165 rs12881250 chr14 95425711 A C 8.77E-05 HIV-1 viral setpoint / / 17641165 rs7154873 chr14 95441562 A G 5.85E-04 Schizophrenia / / 19197363 rs8014347 chr14 95444561 G A 5.20E-05 Multiple complex diseases / / 17554300 rs7148434 chr14 95477759 A G 9.15E-04 Alcohol dependence / / 21314694 rs2353567 chr14 95478823 T C 6.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7147709 chr14 95480924 A G 5.80E-04 Type 2 diabetes / / 17463246 rs7147709 chr14 95480924 A G 6.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7159427 chr14 95498187 C T 6.17E-05 Recombination rate / / 21698098 rs12878043 chr14 95528862 T C 0.0006923 Hypertension (early onset hypertension) / / 22479346 rs11622488 chr14 95535622 G A 5.08E-04 Obesity (extreme) / / 21935397 rs8014827 chr14 95541409 A G 9.54E-05 Personality dimensions / / 18957941 rs1187652 chr14 95555205 C T 8.23E-05 Obesity (extreme) DICER1 UTR-3 21935397 rs114947750 chr14 95582086 C A 0.00028 Prostate cancer DICER1 missense 23555315 rs114947750 chr14 95582086 C A 0.00029 Prostate cancer (non-advanced prostate cancer) DICER1 missense 23555315 rs6575501 chr14 95640329 C A 4.50E-05 LDL lipoproteins DICER1-AS1 intron pha002902 rs3829946 chr14 95651589 T C 1.83E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CLMN UTR-3 24023788 rs2282273 chr14 95660684 T C 9.24E-04 Multiple complex diseases CLMN intron 17554300 rs1187628 chr14 95663986 C T 0.000375 fMRI brain tests in schizophrenia CLMN intron 22440650 rs1187614 chr14 95671871 G T 2.00E-07 Response to antipsychotic treatment CLMN intron 20195266 rs941567 chr14 95701542 C T 1.94E-05 Coronary heart disease CLMN intron pha003055 rs941567 chr14 95701542 C T 2.32E-05 Coronary heart disease CLMN intron pha003056 rs7144864 chr14 95705604 A C 2.81E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CLMN intron 20031582 rs17091967 chr14 95717610 A G 8.75E-05 Heart Rate CLMN intron pha003054 rs8014194 chr14 95720678 T A 2.00E-08 Response to statin therapy CLMN intron 20339536 rs17091981 chr14 95728305 A G 4.30E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CLMN intron 20031582 rs1884535 chr14 95736447 C T 4.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CLMN intron 20877124 rs11628095 chr14 95749011 T C 7.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CLMN intron 20877124 rs115102486 chr14 95764564 A G 2.00E-08 Alzheimer's disease (cognitive decline) CLMN intron 23535033 rs12894609 chr14 95767380 T C 4.29E-05 Bipolar disorder CLMN intron 17486107 rs12885098 chr14 95790047 G A 5.36E-06 Coronary heart disease / / pha003030 rs12885098 chr14 95790047 G A 4.01E-05 Coronary heart disease / / pha003031 rs999986 chr14 95803856 C A 7.32E-05 Nicotine smoking / / 19268276 rs12432945 chr14 95815413 T A 2.40E-05 Femoral neck bone geometry / / 22087292 rs8010752 chr14 95820298 G A 1.18E-05 Femoral neck bone geometry / / 22087292 rs1187717 chr14 95836056 C T 7.12E-04 Depression (quantitative trait) / / 20800221 rs12432260 chr14 95848294 C T 8.00E-06 Obesity-related traits / / 23251661 rs10151010 chr14 95859378 A C 5.95E-04 Smoking quantity / / 24665060 rs1307297 chr14 95860206 T C 8.87E-04 Multiple complex diseases / / 17554300 rs10136944 chr14 95860287 A G,T 8.10E-04 Type 2 diabetes / / 17463246 rs57271070 chr14 95860287 A AT 8.10E-04 Type 2 diabetes / / 17463246 rs67531416 chr14 95860287 A AT 8.10E-04 Type 2 diabetes / / 17463246 rs12892702 chr14 95876466 C A 1.60E-05 Urinary metabolites / / 21572414 rs12892702 chr14 95876466 C A 1.29E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12882488 chr14 95881221 C T 1.79E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12882569 chr14 95888491 C T 1.03E-05 Type 2 diabetes C14orf49 intron 17463246 rs1628817 chr14 95888842 G A 2.34E-05 Type 2 diabetes C14orf49 intron 17463246 rs12895389 chr14 95892274 G A 2.00E-07 Follicle stimulating hormone C14orf49 intron 24049095 rs1187754 chr14 95892341 T C 0.0000032 Composite episodic memory score C14orf49 intron 22865056 rs2103924 chr14 95896123 T C 8.72E-04 Coronary Artery Disease C14orf49 intron 17634449 rs17092227 chr14 95900494 T C 3.71E-04 Type 2 diabetes C14orf49 intron 17463246 rs10144421 chr14 95911835 T C 8.77E-05 Response to acetaminophen (hepatotoxicity) C14orf49 intron 21177773 rs4905326 chr14 95931254 T C 2.01E-04 Depression (quantitative trait) C14orf49 intron 20800221 rs12434921 chr14 95932223 A G 5.28E-04 Depression (quantitative trait) C14orf49 intron 20800221 rs8018925 chr14 95934902 C G 1.55E-04 Depression (quantitative trait) C14orf49 intron 20800221 rs8021292 chr14 95938083 T G 5.95E-04 Amyotrophic Lateral Sclerosis C14orf49 intron 17362836 rs8021292 chr14 95938083 T G 5.44E-05 Lipoproteins C14orf49 intron pha003079 rs11622887 chr14 95942447 A C 2.10E-05 Diabetic retinopathy / / 21441570 rs11622887 chr14 95942447 A C 3.00E-07 non-small cell lung cancer / / 23478653 rs11622887 chr14 95942447 A C 1.48E-05 Lipoproteins / / pha003079 rs8020368 chr14 95943548 T C 2.00E-05 Diabetic retinopathy / / 21441570 rs11628959 chr14 95943833 T C 3.00E-05 Diabetic retinopathy / / 21441570 rs12586386 chr14 95944152 T C 1.60E-05 Diabetic retinopathy / / 21441570 rs12588815 chr14 95944792 C T 6.12E-05 Lipoproteins / / pha003079 rs17829133 chr14 95944899 A C 5.70E-05 Diabetic retinopathy / / 21441570 rs10484051 chr14 95969082 C A 1.90E-05 Urinary metabolites / / 21572414 rs17092593 chr14 95969254 A G 3.25E-04 Multiple complex diseases / / 17554300 rs179158 chr14 95973610 C T 1.54E-04 Taste perception / / 22132133 rs17756537 chr14 95992431 C T 8.00E-06 Urinary metabolites / / 21572414 rs716315 chr14 96009307 C T 2.08E-06 Obesity-related traits GLRX5 intron 23251661 rs7120 chr14 96010589 G A 2.00E-06 Obesity-related traits GLRX5 UTR-3 23251661 rs9323927 chr14 96013584 A G 3.69E-05 Major depressive disorder / / 21621269 rs9323927 chr14 96013584 A G 1.65E-05 Leprosy / / 22019778 rs11624680 chr14 96026450 G A 1.13E-05 Tuberculosis / / 20694014 rs8005962 chr14 96027153 C T 8.00E-06 Tuberculosis / / 20694014 rs2887395 chr14 96029214 G A 4.57E-05 Tuberculosis / / 20694014 rs2369019 chr14 96029588 G A 6.81E-05 Tuberculosis / / 20694014 rs7152619 chr14 96030442 T C 1.96E-06 Tuberculosis / / 20694014 rs8014367 chr14 96030763 C T 1.15E-06 Tuberculosis / / 20694014 rs9323929 chr14 96031957 C T 1.07E-06 Tuberculosis / / 20694014 rs17092772 chr14 96032709 C T 6.21E-04 Multiple complex diseases / / 17554300 rs2208663 chr14 96042876 T G 1.20E-05 Hypothyroidism LOC100506999 intron 22493691 rs8011929 chr14 96049852 C T 4.43E-05 Tuberculosis / / 20694014 rs1951462 chr14 96060745 A G 6.70E-05 Hypothyroidism / / 22493691 rs12895778 chr14 96061668 T C 6.40E-05 Hypothyroidism / / 22493691 rs11621622 chr14 96066715 A T 9.67E-04 Alzheimer's disease / / 17998437 rs911666 chr14 96071125 C T 2.99E-05 Post-operative nausea and vomiting / / 21694509 rs911669 chr14 96071705 T C 3.71E-04 Alzheimer's disease / / 17998437 rs7140430 chr14 96081670 C G 2.04E-04 Alzheimer's disease / / 17998437 rs7140461 chr14 96081759 A T 1.44E-04 Alzheimer's disease / / 17998437 rs7142095 chr14 96081920 T G 1.81E-04 Alzheimer's disease / / 17998437 rs2145975 chr14 96097584 C A 9.82E-06 Blood pressure / / 24001895 rs7148498 chr14 96107955 C T 7.04E-05 Alzheimer's disease (late onset) / / 21379329 rs7148498 chr14 96107955 C T 1.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6575534 chr14 96109585 A G 6.21E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs8015016 chr14 96122408 A G 5.00E-07 QT interval TCL6 intron 20031603 rs1748932 chr14 96140084 G A 6.26E-04 Smoking initiation / / 24665060 rs7158782 chr14 96169131 A G 8.00E-07 Adverse response to aromatase inhibitors / / 20876420 rs11849538 chr14 96175978 C G 7.00E-07 Adverse response to aromatase inhibitors / / 21172079 rs1984968 chr14 96181582 A G 9.08E-04 Type 2 diabetes / / 17463246 rs2369304 chr14 96206070 G A 9.00E-06 Neutrophil count LOC100133207 intron 21507922 rs1107727 chr14 96206829 G T 3.00E-05 Suicide attempts in bipolar disorder LOC100133207 intron 21423239 rs7492479 chr14 96206846 T C 2.79E-05 Suicide attempts in bipolar disorder LOC100133207 intron 21423239 rs2369306 chr14 96207358 C A 3.21E-04 Suicide attempts in bipolar disorder LOC100133207 intron 21423239 rs744439 chr14 96207790 G T 4.21E-05 Suicide attempts in bipolar disorder LOC100133207 intron 21423239 rs1005949 chr14 96213247 T A 4.43E-04 Body mass index LOC100133207 intron 17255346 rs1998687 chr14 96219175 C A 4.45E-05 Suicide attempts in bipolar disorder LOC100133207 intron 21423239 rs2369310 chr14 96219566 C A 5.15E-05 Suicide attempts in bipolar disorder LOC100133207 intron 21423239 rs17093381 chr14 96220183 A G 5.53E-05 Suicide attempts in bipolar disorder LOC100133207 intron 21423239 rs28490018 chr14 96220437 C T 1.12E-05 Suicide attempts in bipolar disorder LOC100133207 intron 21423239 rs7141057 chr14 96224079 C T 3.55E-05 Suicide attempts in bipolar disorder / / 21423239 rs10132992 chr14 96225224 C T 2.86E-05 Suicide attempts in bipolar disorder / / 21423239 rs7493192 chr14 96225618 A G 3.31E-04 Lymphocyte counts / / 22286170 rs4905388 chr14 96260139 G C 8.72E-04 Multiple complex diseases / / 17554300 rs10498644 chr14 96262648 T C 3.07E-04 Smoking initiation / / 24665060 rs10498645 chr14 96262752 G A 7.10E-05 Information processing speed / / 21130836 rs4905392 chr14 96265651 G T 2.01E-05 Information processing speed / / 21130836 rs2147603 chr14 96265970 G A 4.31E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4328368 chr14 96275153 G T 1.17E-05 Height / / pha003010 rs4328368 chr14 96275153 G T 4.23E-06 Height / / pha003011 rs12889368 chr14 96277341 C T 9.79E-04 Multiple complex diseases / / 17554300 rs1957927 chr14 96280829 G T 7.72E-04 Multiple complex diseases / / 17554300 rs8017801 chr14 96284533 T C 1.73E-06 Height / / pha003010 rs8017801 chr14 96284533 T C 1.66E-05 Height / / pha003011 rs7159743 chr14 96285086 A G 8.70E-04 Stroke / / pha002887 rs10142784 chr14 96291861 C T 7.04E-05 Information processing speed / / 21130836 rs17093490 chr14 96297361 C T 7.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs17093506 chr14 96310764 C T 4.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs12891775 chr14 96323265 A G 2.33E-06 Osteoarthritis / / 21871595 rs61983843 chr14 96328262 A C 2.28E-06 Osteoarthritis / / 21871595 rs35074918 chr14 96334783 A C 2.18E-06 Osteoarthritis / / 21871595 rs61984878 chr14 96338601 T A 2.15E-06 Osteoarthritis / / 21871595 rs34767699 chr14 96354124 G A 4.82E-06 Osteoarthritis LOC100507043 intron 21871595 rs2369319 chr14 96355334 G A 1.05E-04 Heart Failure LOC100507043 intron pha002885 rs12888779 chr14 96356164 G A 5.46E-06 Osteoarthritis LOC100507043 intron 21871595 rs7143517 chr14 96395246 A G 5.14E-04 Type 2 diabetes / / 17463246 rs7155379 chr14 96402921 C T 2.67E-04 Type 2 diabetes / / 17463246 rs4905408 chr14 96404779 T C 2.72E-04 Type 2 diabetes / / 17463246 rs2145631 chr14 96410360 C T 5.45E-04 Heart Failure / / pha002884 rs2369443 chr14 96411318 C A 3.60E-04 Type 2 diabetes / / 17463246 rs941774 chr14 96411518 G T 6.58E-04 Type 2 diabetes / / 17463246 rs1951302 chr14 96415110 T C 3.50E-04 Type 2 diabetes / / 17463246 rs12893706 chr14 96418694 T C 6.58E-04 Type 2 diabetes / / 17463246 rs999200 chr14 96418879 G T 3.22E-04 Heart Failure / / pha002884 rs12885123 chr14 96422899 A G 2.60E-05 Urinary metabolites / / 21572414 rs1984548 chr14 96425799 G T 9.20E-05 Serum metabolites / / 19043545 rs1951297 chr14 96434242 G A 5.10E-04 Endometriosis / / 21151130 rs12890394 chr14 96511357 C T 1.56E-05 Alcohol consumption C14orf132 intron 23953852 rs11847860 chr14 96512017 T G 1.48E-05 Alcohol consumption C14orf132 intron 23953852 rs9788546 chr14 96525466 T G 1.67E-05 Alcohol consumption C14orf132 intron 23953852 rs12435820 chr14 96526774 T C 6.11E-04 Type 2 diabetes C14orf132 intron 17463246 rs10143064 chr14 96552053 G A 3.19E-04 Alzheimer's disease C14orf132 intron 17998437 rs10143064 chr14 96552053 G A 5.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C14orf132 intron 20877124 rs3742480 chr14 96556268 G T 2.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C14orf132 UTR-3 20877124 rs3742480 chr14 96556268 G T 3.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C14orf132 UTR-3 20877124 rs3742480 chr14 96556268 G T 4.92E-05 F-cell distribution C14orf132 UTR-3 21326311 rs1058102 chr14 96558235 T C 9.22E-04 Parkinson's disease C14orf132 UTR-3 17052657 rs1043516 chr14 96559723 G A 8.96E-04 Parkinson's disease C14orf132 UTR-3 17052657 rs1043516 chr14 96559723 G A 5.98E-04 Taste perception C14orf132 UTR-3 22132133 rs3825577 chr14 96560092 G A 5.61E-04 Taste perception C14orf132 UTR-3 22132133 rs11160311 chr14 96589360 T C 0.0000178 Panic disorder / / 23149450 rs11160311 chr14 96589360 T C 1.78E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs4905446 chr14 96597957 A C 7.41E-04 Type 2 diabetes / / 22158537 rs4905446 chr14 96597957 A C 0.0000696 Panic disorder / / 23149450 rs4905446 chr14 96597957 A C 6.96E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs12888576 chr14 96611391 A G 6.57E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs11846417 chr14 96620556 A G 3.48E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7146347 chr14 96626596 C T 9.82E-05 Prion diseases / / 22210626 rs10149792 chr14 96633127 T G 5.64E-05 Multiple complex diseases / / 17554300 rs11160316 chr14 96635035 T C 3.82E-05 Multiple complex diseases / / 17554300 rs10144552 chr14 96635447 G A 0.00000102 Panic disorder / / 23149450 rs10144552 chr14 96635447 G A 3.62E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs10143836 chr14 96640876 A G 0.000141892 Primary sclerosing cholangitis / / 23603763 rs10498648 chr14 96645037 A C 6.44E-05 Serum metabolites / / 19043545 rs11624761 chr14 96646219 C A 8.93E-05 Serum metabolites / / 19043545 rs10132489 chr14 96656687 C A 4.33E-05 Serum metabolites / / 19043545 rs4900310 chr14 96659673 T C 2.00E-05 Serum metabolites / / 19043545 rs11160320 chr14 96661993 G A 8.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11625405 chr14 96664898 A G 2.60E-05 Urinary metabolites / / 21572414 rs4900312 chr14 96678974 A G 5.13E-05 Rheumatoid arthritis BDKRB2 intron 17804836 rs945040 chr14 96683973 G A 7.14E-04 Acute lung injury BDKRB2 intron 22295056 rs11160322 chr14 96685704 T C 2.85E-04 Acute lung injury BDKRB2 intron 22295056 rs4905470 chr14 96693211 G A 7.41E-06 Alcohol consumption BDKRB2 intron 23953852 rs2069574 chr14 96702423 C T 4.00E-06 Urinary metabolites BDKRB2 intron 21572414 rs2069596 chr14 96711179 G A 9.78E-06 Obesity-related traits / / 23251661 rs2069596 chr14 96711179 G A 5.14E-05 Coronary heart disease / / pha003056 rs10142830 chr14 96717797 G A 6.60E-04 Alzheimer's disease / / 17998437 rs10147171 chr14 96727874 T C 3.19E-04 Multiple complex diseases BDKRB1 intron 17554300 rs10137303 chr14 96728002 A G 5.05E-04 Multiple complex diseases BDKRB1 intron 17554300 rs2071083 chr14 96729846 G A 6.39E-04 Taste perception BDKRB1 intron 22132133 rs2229459 chr14 96730768 C T 1.14E-08 LDL cholesterol BDKRB1 missense 23063622 rs875964 chr14 96732991 T C 8.22E-04 Lymphocyte counts / / 22286170 rs11160325 chr14 96738504 G A 1.47E-05 Rheumatoid arthritis / / 17804836 rs945034 chr14 96739874 G A 2.57E-06 Rheumatoid arthritis / / 17804836 rs945033 chr14 96740082 G A 9.91E-04 Multiple complex diseases / / 17554300 rs4900321 chr14 96749381 A T 1.39E-06 Lymphocyte counts ATG2B UTR-3 22286170 rs17094001 chr14 96759056 G A 4.22E-05 HIV-1 control ATG2B intron 20041166 rs4905480 chr14 96759853 A C 2.22E-05 HIV-1 control ATG2B intron 20041166 rs7158298 chr14 96760563 G A 2.01E-05 HIV-1 control ATG2B intron 20041166 rs201736391 chr14 96781800 T C 0.00038 Prostate cancer ATG2B missense 23555315 rs8005907 chr14 96787747 T C 4.16E-04 Alzheimer's disease ATG2B intron 22005930 rs17094037 chr14 96812904 T A 1.80E-05 Urinary metabolites ATG2B intron 21572414 rs8013088 chr14 96815354 G C 1.70E-05 Urinary metabolites ATG2B intron 21572414 rs2274795 chr14 96994682 T C 5.40E-07 Rheumatoid arthritis PAPOLA intron 19503088 rs8013517 chr14 97012908 G A 9.01E-06 Rheumatoid arthritis PAPOLA intron 19503088 rs12147439 chr14 97040579 A G 5.74E-06 Rheumatoid arthritis / / 19503088 rs7160641 chr14 97056727 G A 1.38E-05 Attention deficit hyperactivity disorder / / 23728934 rs7149784 chr14 97057998 G A 5.38E-04 Alcohol dependence / / 20201924 rs7149784 chr14 97057998 G A 4.19E-05 Attention deficit hyperactivity disorder / / 23728934 rs2025366 chr14 97075308 A C 3.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2025366 chr14 97075308 A C 3.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs234601 chr14 97076516 C T 4.31E-05 Hepatocellular carcinoma / / 22807686 rs234600 chr14 97080601 T C 1.25E-04 Response to TNF antagonist treatment / / 21061259 rs234592 chr14 97087097 G A 4.36E-05 Rheumatoid arthritis / / 17804836 rs234577 chr14 97099626 C T 8.09E-05 Longevity / / 20304771 rs17094273 chr14 97103807 G A 9.00E-08 Tanning / / 19340012 rs6575594 chr14 97130612 G A 3.05E-05 Intracerebral hemorrhage / / 24656865 rs6575594 chr14 97130612 G A 9.06E-06 Intracerebral hemorrhage / / 24656865 rs1957819 chr14 97131992 T C 3.10E-05 Intracerebral hemorrhage / / 24656865 rs1957819 chr14 97131992 T C 9.27E-06 Intracerebral hemorrhage / / 24656865 rs912339 chr14 97133001 G A 3.11E-05 Intracerebral hemorrhage / / 24656865 rs912339 chr14 97133001 G A 9.33E-06 Intracerebral hemorrhage / / 24656865 rs9323947 chr14 97136353 A G 4.26E-05 Intracerebral hemorrhage / / 24656865 rs9323947 chr14 97136353 A G 8.85E-06 Intracerebral hemorrhage / / 24656865 rs1951834 chr14 97137681 C A 5.39E-04 Multiple complex diseases / / 17554300 rs11160357 chr14 97145352 T C 1.83E-05 Intracerebral hemorrhage / / 24656865 rs11160357 chr14 97145352 T C 1.92E-05 Intracerebral hemorrhage / / 24656865 rs11160358 chr14 97145420 A G 2.03E-05 Intracerebral hemorrhage / / 24656865 rs11160358 chr14 97145420 A G 2.26E-05 Intracerebral hemorrhage / / 24656865 rs1957817 chr14 97146057 A G 2.50E-05 Intracerebral hemorrhage / / 24656865 rs1957817 chr14 97146057 A G 2.88E-05 Intracerebral hemorrhage / / 24656865 rs2025364 chr14 97147270 T C 2.47E-05 Intracerebral hemorrhage / / 24656865 rs2025364 chr14 97147270 T C 2.62E-05 Intracerebral hemorrhage / / 24656865 rs2025362 chr14 97147386 C G 2.53E-05 Intracerebral hemorrhage / / 24656865 rs2025362 chr14 97147386 C G 2.68E-05 Intracerebral hemorrhage / / 24656865 rs11160359 chr14 97147660 A G 3.60E-05 Intracerebral hemorrhage / / 24656865 rs11160359 chr14 97147660 A G 3.74E-05 Intracerebral hemorrhage / / 24656865 rs6575597 chr14 97149309 T C 3.09E-05 Intracerebral hemorrhage / / 24656865 rs6575597 chr14 97149309 T C 3.84E-05 Intracerebral hemorrhage / / 24656865 rs8009263 chr14 97149701 G C 4.64E-05 Intracerebral hemorrhage / / 24656865 rs11847777 chr14 97153343 G C 9.19E-04 Nicotine dependence / / 17158188 rs7140622 chr14 97157452 A G 1.98E-05 Intracerebral hemorrhage / / 24656865 rs7140622 chr14 97157452 A G 2.10E-05 Intracerebral hemorrhage / / 24656865 rs7141431 chr14 97157621 G A 2.09E-05 Intracerebral hemorrhage / / 24656865 rs7141431 chr14 97157621 G A 2.37E-05 Intracerebral hemorrhage / / 24656865 rs1957828 chr14 97160567 A C 1.78E-05 Intracerebral hemorrhage / / 24656865 rs1957828 chr14 97160567 A C 1.91E-05 Intracerebral hemorrhage / / 24656865 rs7154628 chr14 97161505 C T 1.53E-05 Intracerebral hemorrhage / / 24656865 rs7154628 chr14 97161505 C T 1.64E-05 Intracerebral hemorrhage / / 24656865 rs1969795 chr14 97168780 A G 3.51E-04 Birth weight / / 17255346 rs17244419 chr14 97171075 C T 8.00E-06 Cognitive function / / 24684796 rs11849294 chr14 97179705 C T 8.12E-04 Alzheimer's disease / / 22005930 rs17280464 chr14 97180674 A G 5.15E-04 Alzheimer's disease / / 22005930 rs8022127 chr14 97181630 C T 3.84E-04 Alzheimer's disease / / 22005930 rs4900337 chr14 97181785 A G 7.72E-04 Alzheimer's disease / / 22005930 rs4551969 chr14 97184468 T G 4.23E-04 Alzheimer's disease / / 22005930 rs17094372 chr14 97188009 C T 9.90E-06 Urinary metabolites / / 21572414 rs17310190 chr14 97190794 A G 8.14E-04 White matter integrity / / 22425255 rs17094400 chr14 97198994 C T 8.91E-04 Multiple complex diseases / / 17554300 rs10873474 chr14 97236360 G A 8.18E-04 Smoking initiation / / 24665060 rs17310204 chr14 97242600 G A 8.28E-04 Smoking initiation / / 24665060 rs10149171 chr14 97243961 G A 6.05E-04 Smoking initiation / / 24665060 rs10135222 chr14 97252301 G T 8.91E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10135222 chr14 97252301 G T 8.33E-04 Smoking initiation / / 24665060 rs10145396 chr14 97255679 G T 4.01E-05 Cognitive impairment induced by topiramate / / 22091778 rs10145396 chr14 97255679 G T 7.05E-05 Cognitive impairment induced by topiramate / / 22091778 rs2224442 chr14 97272382 T G 2.00E-04 Cognitive impairment induced by topiramate VRK1 intron 22091778 rs2224442 chr14 97272382 T G 8.99E-05 Smoking initiation VRK1 intron 24665060 rs12878184 chr14 97275256 A G 5.87E-04 Response to cytadine analogues (cytosine arabinoside) VRK1 intron 24483146 rs4905546 chr14 97278652 C T 4.31E-04 Smoking initiation VRK1 intron 24665060 rs9285600 chr14 97279220 T C 4.70E-04 Smoking initiation VRK1 intron 24665060 rs9323955 chr14 97294935 A G 3.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VRK1 intron 20877124 rs2230532 chr14 97321689 C T 3.80E-04 Smoking initiation VRK1 cds-synon 24665060 rs10135704 chr14 97331618 T C 9.51E-04 Epilepsy VRK1 intron 22116939 rs736929 chr14 97343323 T C 2.79E-04 Smoking initiation VRK1 intron 24665060 rs4905558 chr14 97345806 G A 8.00E-06 Neutrophil count VRK1 intron 21507922 rs4905558 chr14 97345806 G A 6.33E-04 Response to cytadine analogues (cytosine arabinoside) VRK1 intron 24483146 rs12590723 chr14 97357702 A G 1.04E-05 Cognitive impairment induced by topiramate / / 22091778 rs12590723 chr14 97357702 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12590723 chr14 97357702 A G 9.02E-06 Cognitive impairment induced by topiramate / / 22091778 rs12590723 chr14 97357702 A G 4.53E-05 Smoking initiation / / 24665060 rs12435963 chr14 97359800 T G 1.00E-05 Smoking initiation / / 24665060 rs4905564 chr14 97365090 C T 8.54E-04 Acute lung injury / / 22295056 rs1385551 chr14 97374996 C T 0.00000963 Antisocial behavior / / 23077488 rs8016620 chr14 97393685 C T 5.00E-06 Obesity-related traits / / 23251661 rs856227 chr14 97400582 A G 4.95E-04 Multiple complex diseases / / 17554300 rs1290233 chr14 97467801 G A 3.99E-04 Alzheimer's disease (late onset) / / 21379329 rs856232 chr14 97476550 C T 7.17E-05 Alzheimer's disease (late onset) / / 21379329 rs1983655 chr14 97480186 C G 9.58E-05 Serum metabolites / / 19043545 rs710270 chr14 97486738 G C 9.17E-04 Type 2 diabetes / / 17463246 rs7149193 chr14 97505099 C T 1.91E-04 Type 2 diabetes / / 23300278 rs1950268 chr14 97508288 T C 1.83E-05 Vascular dementia / / 22116812 rs724210 chr14 97523745 C T 8.00E-07 DNA methylation (variation) / / 23725790 rs1022588 chr14 97529354 C T 4.47E-06 DNA methylation (variation) / / 23725790 rs1622472 chr14 97529421 T C 6.71E-05 Chronic obstructive pulmonary disease / / 19300482 rs8020941 chr14 97533362 G T 4.89E-04 Acute lung injury / / 22295056 rs1738899 chr14 97535923 G A 6.09E-05 Chronic obstructive pulmonary disease / / 19300482 rs11627513 chr14 97539171 C T 1.56E-05 Multiple complex diseases / / 17554300 rs2024664 chr14 97584792 A G 6.40E-05 Memory performance / / 22105620 rs1955588 chr14 97585420 T C 9.87E-05 Tunica Media / / pha003036 rs12436690 chr14 97585889 G A 1.50E-07 Memory performance / / 22105620 rs4316684 chr14 97587036 C A 3.81E-05 Cognitive performance / / 19734545 rs4316684 chr14 97587036 C A 1.41E-05 Tunica Media / / pha003036 rs12883143 chr14 97592627 T C 4.23E-04 Alzheimer's disease (late onset) / / 21379329 rs12883143 chr14 97592627 T C 5.00E-06 Asthma / / 21790008 rs12883143 chr14 97592627 T C 6.63E-05 Body Fat Distribution / / pha003018 rs12883143 chr14 97592627 T C 9.54E-05 Heart Rate / / pha003054 rs12050188 chr14 97606052 G A 4.68E-05 Heart Rate / / pha003054 rs7145415 chr14 97608754 G A 6.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs12586664 chr14 97613826 T C 8.69E-05 Cognitive impairment induced by topiramate / / 22091778 rs7153003 chr14 97618412 T C 9.63E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7153003 chr14 97618412 T C 9.11E-05 Vaspin levels / / 22907691 rs7153003 chr14 97618412 T C 0.0000911 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs12432865 chr14 97623593 G A 6.61E-04 Iron levels / / pha002876 rs17191541 chr14 97641378 G A 6.46E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs10498649 chr14 97655295 T C 7.30E-05 Diabetic retinopathy / / 21441570 rs10498649 chr14 97655295 T C 7.82E-05 Body mass index / / 22446040 rs8009842 chr14 97656103 T G 6.90E-05 Diabetic retinopathy / / 21441570 rs4905587 chr14 97680238 G T 8.49E-05 Tunica Media / / pha003037 rs2370267 chr14 97711511 G A 2.89E-05 Tunica Media / / pha003037 rs1279882 chr14 97744445 A G 4.06E-04 Multiple complex diseases / / 17554300 rs17095151 chr14 97753703 C T 3.33E-04 Multiple complex diseases / / 17554300 rs8008701 chr14 97774161 A G 4.01E-04 Multiple complex diseases / / 17554300 rs17095290 chr14 97835644 A T 2.26E-04 Multiple complex diseases / / 17554300 rs234460 chr14 97849962 A G 1.23E-05 Colorectal cancer / / 21242260 rs8011773 chr14 97857732 C T 5.40E-04 Crohn's disease / / 17684544 rs10137783 chr14 97886219 T C 4.16E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3912371 chr14 97887489 G C 4.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17095432 chr14 97903213 C T 8.36E-04 Multiple complex diseases / / 17554300 rs9671232 chr14 97917828 C T 1.90E-05 Personality dimensions / / 22628180 rs1384981 chr14 97960375 A G 5.65E-05 Diabetes Mellitus / / pha003059 rs2781413 chr14 97968987 C T 2.91E-05 Interstitial lung disease / / 23583980 rs2220121 chr14 97974524 G A 2.51E-05 Body mass index / / 17255346 rs2170819 chr14 97976764 C A 2.67E-05 Personality dimensions / / 18957941 rs1545884 chr14 97976854 G A 3.51E-05 Personality dimensions / / 18957941 rs1001504 chr14 97983221 C A 3.99E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs8022296 chr14 97987857 G A 7.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs727069 chr14 97990800 A T 1.60E-05 Urinary metabolites / / 21572414 rs7152926 chr14 97991917 G A 3.09E-04 Body mass index / / 17255346 rs1552126 chr14 97994090 C T 7.84E-04 Multiple complex diseases / / 17554300 rs1552126 chr14 97994090 C T 1.86E-04 Follicular lymphoma / / 21533074 rs1552126 chr14 97994090 C T 9.45E-05 Interstitial lung disease / / 23583980 rs11850997 chr14 97995019 T A 3.09E-04 Body mass index / / 17255346 rs11850997 chr14 97995019 T A 6.05E-04 Multiple complex diseases / / 17554300 rs11846702 chr14 97995064 C A 3.09E-04 Body mass index / / 17255346 rs234202 chr14 97997005 T C 3.09E-04 Body mass index / / 17255346 rs234202 chr14 97997005 T C 1.24E-09 Multiple complex diseases / / 17554300 rs234205 chr14 97998426 A C 3.09E-04 Body mass index / / 17255346 rs17095542 chr14 98000813 G A 3.75E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs17095561 chr14 98018961 C T 3.18E-04 Body mass index / / 17255346 rs17095577 chr14 98028428 A G 3.45E-06 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs17095577 chr14 98028428 A G 9.33E-04 Obesity (extreme) / / 21935397 rs8008246 chr14 98103058 G A 6.86E-05 Adipocyte fatty acid-binding protein concentration,in serum LOC100129345 intron 21863005 rs170886 chr14 98116177 G C 6.57E-04 Type 2 diabetes LOC100129345 intron 17463246 rs234127 chr14 98122545 C G 5.72E-04 Multiple complex diseases LOC100129345 intron 17554300 rs234182 chr14 98133191 G A 5.49E-05 Serum metabolites LOC100129345 intron 19043545 rs234146 chr14 98154512 T C 4.15E-07 Type 2 diabetes / / 22961080 rs234148 chr14 98155019 T C 5.30E-07 Fasting plasma glucose / / 19060907 rs721919 chr14 98170611 C T 7.89E-04 Schizophrenia / / 21674006 rs721919 chr14 98170611 C T 9.82E-06 Post-operative nausea and vomiting / / 21694509 rs1003229 chr14 98171617 G A 2.70E-04 Coronary heart disease / / 21966275 rs12587635 chr14 98173538 G A 5.07E-04 Multiple complex diseases / / 17554300 rs7159075 chr14 98174479 C T 6.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10149128 chr14 98177573 C T 7.31E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs966596 chr14 98192348 C G 7.32E-04 Multiple complex diseases / / 17554300 rs4600405 chr14 98240457 G T 5.99E-04 Multiple complex diseases / / 17554300 rs4905623 chr14 98266772 T C 1.55E-04 Body mass index / / 17255346 rs10135506 chr14 98299798 T C 7.25E-04 Alzheimer's disease / / 24755620 rs1471356 chr14 98303331 A G 9.00E-06 Radiation response / / 20923822 rs7150469 chr14 98308170 A G 7.88E-05 Cognitive performance / / 19734545 rs1841722 chr14 98322480 G T 4.85E-04 Celiac disease / / 23936387 rs10149347 chr14 98323250 G A 3.71E-04 Multiple complex diseases / / 17554300 rs1462275 chr14 98323343 C T 6.76E-04 Multiple complex diseases / / 17554300 rs1462275 chr14 98323343 C T 5.80E-05 Type 1 diabetes / / 18978792 rs11626752 chr14 98325432 T C 3.73E-04 Multiple complex diseases / / 17554300 rs1350924 chr14 98327764 T G 7.07E-04 Multiple complex diseases / / 17554300 rs2809143 chr14 98351603 C T 8.84E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs2607045 chr14 98393994 A G 9.54E-04 Suicide attempts in bipolar disorder C14orf64 intron 21423239 rs4905631 chr14 98400165 C T 6.23E-04 Type 2 diabetes C14orf64 intron 17463246 rs2809115 chr14 98406425 A T 6.89E-06 Mathematical ability C14orf64 intron 24801482 rs2616774 chr14 98408177 G A 8.28E-04 Tourette syndrome C14orf64 intron 22889924 rs2809117 chr14 98412754 C T 9.57E-04 Multiple complex diseases C14orf64 intron 17554300 rs2809119 chr14 98418324 T A 2.35E-04 Multiple complex diseases C14orf64 intron 17554300 rs2274818 chr14 98426655 C T 6.40E-04 Multiple complex diseases C14orf64 intron 17554300 rs2616767 chr14 98430382 A G 8.30E-04 Suicide attempts in bipolar disorder C14orf64 intron 21423239 rs7140601 chr14 98463157 T C 7.00E-07 Immune response to smallpox vaccine (IL-6) / / 22542470 rs8010161 chr14 98483776 T C 6.38E-04 Type 2 diabetes / / 17463246 rs8013335 chr14 98484034 C G 7.15E-04 Type 2 diabetes / / 17463246 rs8013518 chr14 98484207 A G 6.36E-04 Type 2 diabetes / / 17463246 rs10142119 chr14 98486545 G A 2.00E-07 IgE levels in asthmatics (D.f. specific) / / 23967269 rs10142119 chr14 98486545 G A 2.86E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs1456988 chr14 98488007 G T 5.00E-09 Graves' disease / / 23612905 rs1456988 chr14 98488007 G T 1.11E-06 IgE levels in asthmatics (D.f. specific) / / 23967269 rs1350277 chr14 98492843 C T 6.24E-04 Coronary heart disease / / 21606135 rs8019853 chr14 98494079 A G 1.83E-05 Attention deficit hyperactivity disorder / / 20732625 rs12888770 chr14 98496873 T C 2.25E-04 Insulin resistance / / 21901158 rs12590389 chr14 98497054 T C 2.47E-06 IgE levels in asthmatics (D.f. specific) / / 23967269 rs12892356 chr14 98497179 G T 2.21E-05 Attention deficit hyperactivity disorder / / 20732625 rs4900384 chr14 98498951 A G 4.00E-09 Type 1 diabetes / / 19430480 rs4900384 chr14 98498951 A G 3.70E-09 Multiple sclerosis / / 22190364 rs10144042 chr14 98499458 G A 2.00E-06 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy / / 23118302 rs8015529 chr14 98502219 C G 2.30E-06 Aortic stiffness / / 22068335 rs1456975 chr14 98505089 T C 2.98E-04 Alzheimer's disease (late onset) / / 21379329 rs12589559 chr14 98508579 T C 2.41E-04 Alzheimer's disease (late onset) / / 21379329 rs857063 chr14 98512743 A C 4.39E-04 Alzheimer's disease (late onset) / / 21379329 rs857063 chr14 98512743 A C 1.45E-05 Height / / pha003010 rs857063 chr14 98512743 A C 9.41E-05 Height / / pha003011 rs12436399 chr14 98518162 G T 2.55E-05 Height / / pha003010 rs857062 chr14 98520456 T C 1.99E-05 Sodium levels / / pha003093 rs698050 chr14 98537394 A T 1.70E-07 Aortic stiffness / / 22068335 rs61980016 chr14 98549415 G T 0.0000136 Colorectal adenoma / / 23677573 rs61980016 chr14 98549415 G T 0.0000136 Colorectal adenoma (including hyperplasic) / / 23677573 rs61980016 chr14 98549415 G T 0.0000417 Colorectal adenoma (excluding hyperplasic) / / 23677573 rs2183623 chr14 98551256 G T 4.55E-04 Coronary heart disease / / 21606135 rs17096405 chr14 98558834 C T 2.79E-05 Monocyte counts / / pha003089 rs17773233 chr14 98582659 G T 1.40E-07 Aortic stiffness / / 22068335 rs9323989 chr14 98587669 T C 5.00E-09 Aortic stiffness / / 22068335 rs7152623 chr14 98588321 G A 3.00E-15 Aortic stiffness / / 22068335 rs1461587 chr14 98603851 T G 1.30E-06 Aortic stiffness / / 22068335 rs7160893 chr14 98607294 G T 9.00E-06 Aortic stiffness / / 22068335 rs1381281 chr14 98615771 T C 1.07E-05 Staphylococcus aureus infection / / 24847357 rs857230 chr14 98615989 G A 2.76E-04 Myocardial Infarction / / pha002873 rs2225442 chr14 98622594 A C 9.40E-08 Aortic stiffness / / 22068335 rs987514 chr14 98628943 C T 1.30E-08 Aortic stiffness / / 22068335 rs987514 chr14 98628943 C T 1.95E-05 Staphylococcus aureus infection / / 24847357 rs7152530 chr14 98641215 G A 8.00E-07 Staphylococcus aureus infection / / 24847357 rs10484128 chr14 98642572 C A,G,T 6.00E-06 Hemostatic factors and hematological phenotypes / / 17903294 rs1381273 chr14 98649060 C T 5.80E-06 Aortic stiffness / / 22068335 rs9323992 chr14 98649816 C T 1.31E-05 Musician's dystonia / / 24375517 rs857228 chr14 98670158 A C 3.00E-06 Sexual dysfunction (SSRI/SNRI-related) / / 22445761 rs857229 chr14 98670924 C T 1.87E-05 Cognitive test performance / / 20125193 rs1257907 chr14 98679536 T G 4.57E-05 Glucose levels / / pha003058 rs1257907 chr14 98679536 T G 7.20E-05 Glucose levels / / pha003061 rs4905653 chr14 98682107 C T 9.97E-05 Diabetes Mellitus / / pha003060 rs1257917 chr14 98686768 G A 5.59E-05 Glucose levels / / pha003058 rs7157627 chr14 98689166 T C 1.91E-05 Glucose levels / / pha003058 rs7157627 chr14 98689166 T C 4.44E-05 Glucose levels / / pha003061 rs11625757 chr14 98692756 C T 3.77E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1257934 chr14 98697337 G A 3.30E-05 Intelligence (childhood) / / 23358156 rs1271087 chr14 98700689 A G 6.24E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1271087 chr14 98700689 A G 3.60E-08 Metabolite levels / / 23281178 rs7149754 chr14 98702475 A G 1.94E-05 Bipolar disorder / / 17486107 rs7149754 chr14 98702475 A G 6.00E-04 Longevity / / 22279548 rs7149754 chr14 98702475 A G 5.55E-05 Body Mass Index / / pha003020 rs7155597 chr14 98703195 C G 3.77E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10149929 chr14 98712488 G A 7.18E-09 Metabolite levels / / 23281178 rs12880106 chr14 98713221 T C 3.77E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4905662 chr14 98714883 C T 3.36E-05 Body Mass Index / / pha003006 rs1892234 chr14 98720904 G A 1.38E-05 Staphylococcus aureus infection / / 24847357 rs1959997 chr14 98729929 A C 9.96E-05 Coronary restenosis / / 21878436 rs2186077 chr14 98730479 C T 9.96E-05 Coronary restenosis / / 21878436 rs7492597 chr14 98730971 C T 2.69E-05 Odorant perception / / 23910658 rs11621426 chr14 98731550 G T 9.44E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1892231 chr14 98734567 A C 6.47E-05 Glucose levels / / pha003058 rs1892231 chr14 98734567 A C 7.95E-05 Glucose levels / / pha003061 rs8015019 chr14 98745040 C T 5.81E-05 Diabetes Mellitus / / pha003060 rs8015373 chr14 98745307 A C 9.70E-05 Glucose levels / / pha003058 rs8015373 chr14 98745307 A C 5.81E-05 Diabetes Mellitus / / pha003060 rs8022740 chr14 98755533 G C 9.95E-05 Personality dimensions / / 18957941 rs8022740 chr14 98755533 G C 2.60E-04 Insulin resistance / / 21901158 rs11621305 chr14 98761519 A C 1.47E-04 Vaspin levels / / 22907691 rs11621305 chr14 98761519 A C 0.0001467 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs8018467 chr14 98763881 C T 2.22E-04 Longevity / / 22279548 rs9743626 chr14 98774992 G A 1.24E-05 Systolic blood pressure in sickle cell anemia / / 24058526 rs1888569 chr14 98785920 A G 9.78E-04 Insulin resistance / / 21901158 rs1954552 chr14 98786532 G A 6.65E-04 Insulin resistance / / 21901158 rs7148865 chr14 98788406 G T 1.40E-04 Myasthenia gravis / / 23055271 rs1459128 chr14 98790506 T G 7.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs1888571 chr14 98790904 T C 7.13E-05 Height / / pha003010 rs1888571 chr14 98790904 T C 9.91E-05 Height / / pha003011 rs10139457 chr14 98804111 A G 2.08E-05 Insulin resistance / / 21901158 rs11160450 chr14 98807725 A G 5.96E-05 Height / / pha003010 rs11627023 chr14 98811932 A G 7.39E-04 Aortic root size / / 21223598 rs8016542 chr14 98812167 A C 5.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs1459134 chr14 98814319 A C 3.00E-04 Multiple complex diseases / / 17554300 rs7152787 chr14 98815286 T C 4.80E-05 Myasthenia gravis / / 23055271 rs12885202 chr14 98818216 A C 7.97E-04 Insulin resistance / / 21901158 rs12890277 chr14 98824486 G C 9.44E-04 Insulin resistance / / 21901158 rs1459148 chr14 98840443 C T 2.00E-06 Response to antipsychotic therapy (extrapyramidal side effects) / / 19875103 rs873196 chr14 98845531 C T 5.33E-05 Alcohol withdrawal symptoms / / 22072270 rs1459124 chr14 98852888 C T 5.55E-05 Alcohol withdrawal symptoms / / 22072270 rs10141191 chr14 98887510 G A 1.78E-05 Alcohol withdrawal symptoms / / 22072270 rs7161221 chr14 98892883 A C 2.86E-05 Alcohol withdrawal symptoms / / 22072270 rs1952863 chr14 98898086 C T 6.48E-05 stroke (ischemic) / / 17434096 rs6575671 chr14 98924613 G A 7.64E-05 Alzheimer's disease / / 17998437 rs10139309 chr14 98925890 T C 9.04E-04 Alzheimer's disease / / 17998437 rs2776498 chr14 98935094 G C 5.58E-04 Alzheimer's disease / / 17998437 rs8003296 chr14 98970164 G A 9.74E-05 Prostate cancer mortality / / 20978177 rs8003296 chr14 98970164 G A 3.49E-04 Aortic root size / / 21223598 rs8003296 chr14 98970164 G A 2.00E-05 Urinary metabolites / / 21572414 rs7161086 chr14 98973882 T G 3.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7161086 chr14 98973882 T G 7.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17097084 chr14 98978300 C T 4.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17097084 chr14 98978300 C T 5.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17097094 chr14 98982672 C T 5.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17097094 chr14 98982672 C T 6.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8022320 chr14 98987472 G A 2.17E-04 Prostate cancer mortality / / 20978177 rs10139212 chr14 98992552 G A 1.10E-06 Urinary metabolites / / 21572414 rs11850908 chr14 98995186 A T 2.50E-06 Urinary metabolites / / 21572414 rs10138364 chr14 98995955 T C 2.70E-06 Urinary metabolites / / 21572414 rs10151617 chr14 98996159 A G 7.72E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs10151617 chr14 98996159 A G 7.72E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs17595289 chr14 99006725 T C 3.60E-06 Urinary metabolites / / 21572414 rs8012854 chr14 99012062 A G 3.98E-05 Multiple complex diseases / / 17554300 rs7159781 chr14 99017287 A C 2.15E-05 Body mass index / / 22446040 rs1956859 chr14 99024973 A C 1.70E-04 Attention deficit hyperactivity disorder / / 22420046 rs995365 chr14 99032983 A G 1.09E-04 Multiple complex diseases / / 17554300 rs17097328 chr14 99034883 C T 6.53E-05 Attention deficit hyperactivity disorder / / 22420046 rs7154523 chr14 99046062 T A 5.00E-05 Prostate cancer / / 21743057 rs7153428 chr14 99046230 C T 5.00E-05 Prostate cancer / / 21743057 rs2145524 chr14 99049575 T C 9.89E-04 Multiple complex diseases / / 17554300 rs2145524 chr14 99049575 T C 5.00E-05 Prostate cancer / / 21743057 rs8005917 chr14 99053053 T C 1.70E-06 Alcohol dependence / / 23089632 rs4905720 chr14 99053964 A G 3.86E-06 Alcohol dependence / / 23089632 rs4900409 chr14 99056611 C T 1.38E-04 Progressive supranuclear palsy / / 21685912 rs11627708 chr14 99060484 A G 0.00007792 Sarcoidosis / / 22952805 rs7158580 chr14 99061068 C T 0.00007825 Sarcoidosis / / 22952805 rs11160465 chr14 99061519 G A 0.00007778 Sarcoidosis / / 22952805 rs11624950 chr14 99061722 T C 0.00007778 Sarcoidosis / / 22952805 rs11621154 chr14 99061986 A T 0.00008334 Sarcoidosis / / 22952805 rs12895564 chr14 99077039 A G 6.90E-04 Multiple complex diseases / / 17554300 rs11850863 chr14 99083489 G T 5.69E-04 Multiple complex diseases / / 17554300 rs7161615 chr14 99093486 G A 7.46E-04 Type 2 diabetes / / 17463246 rs12898099 chr14 99093555 G A 8.62E-04 Type 2 diabetes / / 17463246 rs1543422 chr14 99182771 A G 7.96E-05 Alzheimer's disease (late onset) C14orf177 intron 21379329 rs8005204 chr14 99185399 A G 3.72E-05 Multiple complex diseases / / 17554300 rs17097734 chr14 99189252 A C 2.49E-05 Multiple complex diseases / / 17554300 rs17531821 chr14 99195871 G A 4.21E-04 Heart Failure / / pha002885 rs17097752 chr14 99197381 G C 8.72E-05 Multiple complex diseases / / 17554300 rs10144711 chr14 99207528 C A 7.41E-04 Multiple complex diseases / / 17554300 rs4343209 chr14 99216959 A G 9.40E-05 Type 2 diabetes / / 17463249 rs4343209 chr14 99216959 A G 9.40E-05 Multiple complex diseases / / 17554300 rs17533457 chr14 99236033 T C 3.74E-06 Multiple complex diseases / / 17554300 rs7146951 chr14 99237348 A G 6.24E-04 Heart Failure / / pha002885 rs11623713 chr14 99240316 G A 8.00E-06 Obesity-related traits / / 23251661 rs1950463 chr14 99259368 C T 6.32E-04 Type 2 diabetes / / 17463246 rs11627674 chr14 99261024 A G 7.88E-04 Type 2 diabetes / / 17463246 rs11623562 chr14 99261071 T C 9.21E-04 Type 2 diabetes / / 17463246 rs8021463 chr14 99348873 G T 0.0006763 Sarcoidosis / / 22952805 rs6575700 chr14 99349617 G A 1.73E-04 Multiple complex diseases / / 17554300 rs12323921 chr14 99357483 C G 1.50E-04 Lipid levels / / 18193043 rs200354 chr14 99375321 G T 8.24E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs200354 chr14 99375321 G T 2.22E-06 Crohn's disease / / 17684544 rs7143696 chr14 99379068 T C 6.64E-04 Coronary Artery Disease / / 17634449 rs17098020 chr14 99383264 G A 8.78E-05 Hypertension (early onset hypertension) / / 22479346 rs200331 chr14 99387545 A G 4.33E-05 Neutrophil count / / pha003095 rs9652400 chr14 99387992 G T 0.000522876 Hypertension (early onset hypertension) / / 22479346 rs10484064 chr14 99390198 C T 5.23E-04 Alzheimer's disease / / 17998437 rs200324 chr14 99390803 T G 3.42E-05 Neutrophil count / / pha003095 rs200303 chr14 99402433 G T 7.96E-05 Chronic obstructive pulmonary disease / / 19300482 rs1022705 chr14 99411801 C T 9.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs807339 chr14 99413672 C G 1.90E-05 Breast cancer / / 21060860 rs17098179 chr14 99475374 T C 2.21E-05 Type 1 diabetes / / 21980299 rs718654 chr14 99476343 A G 1.50E-04 Taste perception / / 22132133 rs4905794 chr14 99479669 G A 7.62E-05 Lipoproteins / / pha003079 rs12889506 chr14 99484345 G A 6.85E-04 Multiple complex diseases / / 17554300 rs1257667 chr14 99490873 G A 8.39E-04 Type 2 diabetes / / 17463246 rs1257670 chr14 99492973 G A 3.63E-04 Type 2 diabetes / / 17463246 rs1257670 chr14 99492973 G A 0.0000363 Uterine leiomyomata / / 23040493 rs1257672 chr14 99493934 A G 6.27E-04 Type 2 diabetes / / 17463246 rs9324006 chr14 99505534 G A 1.31E-04 Gallstones / / 17632509 rs8019310 chr14 99506427 G A 7.70E-04 Type 2 diabetes / / 17463246 rs1257580 chr14 99513836 A C 2.30E-06 Amyotrophic Lateral Sclerosis / / 17362836 rs11625640 chr14 99530939 A G 2.70E-05 Urinary metabolites / / 21572414 rs807367 chr14 99536623 G A 1.10E-05 Urinary metabolites / / 21572414 rs807372 chr14 99539475 T A 1.30E-05 Urinary metabolites / / 21572414 rs7141841 chr14 99551298 T C 2.51E-06 Parent of origin effect on language impairment (maternal) / / 24571439 rs7141841 chr14 99551298 T C 1.75E-05 Coronary heart disease / / pha003033 rs12437288 chr14 99563682 C T 3.61E-04 Multiple complex diseases / / 17554300 rs12437288 chr14 99563682 C T 6.10E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11625944 chr14 99583371 C A 7.38E-04 Coronary heart disease / / 21606135 rs1269096 chr14 99603119 C T 1.78E-04 Alzheimer's disease / / 17998437 rs2693676 chr14 99607480 A G 7.00E-06 Corneal curvature / / 22969067 rs1273226 chr14 99607842 C T 7.39E-06 Corneal curvature / / 22969067 rs1273225 chr14 99609217 T C 7.29E-06 Corneal curvature / / 22969067 rs1152774 chr14 99623030 C T 2.98E-04 Alzheimer's disease (late onset) / / 21379329 rs807443 chr14 99628504 A G 8.12E-06 Corneal curvature / / 22969067 rs2664292 chr14 99676807 A G 6.79E-05 Serum metabolites BCL11B intron 19043545 rs1257412 chr14 99712301 G A 3.82E-05 Epilepsy (remission after treatment) BCL11B intron 23962720 rs941519 chr14 99729963 A G 3.98E-05 Lung adenocarcinoma BCL11B intron 19836008 rs2664299 chr14 99742187 T C 9.00E-06 IgG glycosylation / / 23382691 rs2614463 chr14 99746274 A T 7.00E-06 IgG glycosylation / / 23382691 rs2614461 chr14 99747991 C T 2.68E-04 Major depressive disorder / / 22472876 rs2614488 chr14 99751588 G A 4.18E-04 Body mass index / / 17255346 rs8018158 chr14 99782579 C T 8.33E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs11160509 chr14 99793564 T C 7.45E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs906933 chr14 99812577 C A 1.81E-04 Acne (severe) / / 24927181 rs1257282 chr14 99828776 G A 4.80E-05 Lymphocyte counts / / 22286170 rs1257267 chr14 99858970 C A 8.55E-05 Diabetes (gestational) / / 22233651 rs11160518 chr14 99860840 A G 8.91E-05 Hepatitis B vaccine response / / 21764829 rs11629067 chr14 99860911 T G 6.97E-04 Taste perception / / 22132133 rs12100924 chr14 99861619 G A 3.02E-04 Taste perception / / 22132133 rs2295697 chr14 99863065 C T 0.00043 Breast cancer / / 23555315 rs2400672 chr14 99932638 A G 2.26E-04 Multiple complex diseases SETD3 intron 17554300 rs4905848 chr14 99996774 G A 9.78E-04 Bulimia nervosa CCDC85C intron 23568457 rs11160533 chr14 100075773 C T 8.23E-04 Multiple complex diseases LOC100507108 intron 17554300 rs4905865 chr14 100076059 T G 3.00E-04 Multiple complex diseases LOC100507108 intron 17554300 rs17098912 chr14 100104329 G A 0.000248 Oxaliplatin induced mucositis in response to colorectal cancer treatment / / 22310351 rs4624107 chr14 100127440 G C 6.75E-09 Coronary heart disease HHIPL1 intron 21378990 rs2895811 chr14 100133942 T C 1.00E-10 Coronary heart disease HHIPL1 intron 21378990 rs2895811 chr14 100133942 T C 1.14E-10 Pericardial fat HHIPL1 intron 22589742 rs2895811 chr14 100133942 T C 1.03E-11 Coronary artery disease (CAD) (females) HHIPL1 intron 23202125 rs2895811 chr14 100133942 T C 1.35E-31 Coronary artery disease (CAD) (males) HHIPL1 intron 23202125 rs2895811 chr14 100133942 T C 2.10E-21 Coronary artery disease (CAD) age <=50 HHIPL1 intron 23202125 rs2895811 chr14 100133942 T C 3.04E-31 Coronary artery disease (CAD) age >50 HHIPL1 intron 23202125 rs2895811 chr14 100133942 T C 4.08E-10 Coronary artery disease HHIPL1 intron 23202125 rs2895811 chr14 100133942 T C 7.47E-31 Coronary artery disease with myocardial infarction HHIPL1 intron 23202125 rs2895811 chr14 100133942 T C 1.18E-05 Coronary artery disease HHIPL1 intron 24262325 rs7158073 chr14 100141689 T C 2.58E-04 Parkinson's disease HHIPL1 missense 17052657 rs2146238 chr14 100172729 T G 2.50E-05 Urinary metabolites CYP46A1 intron 21572414 rs2273840 chr14 100188144 A C 5.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CYP46A1 intron 20877124 rs4905893 chr14 100233622 C T 3.13E-04 Type 2 diabetes / / 17463246 rs8015306 chr14 100248124 A G 2.90E-04 Intelligence (childhood) / / 23358156 rs17099052 chr14 100255980 T C 5.71E-04 Multiple complex diseases / / 17554300 rs4905897 chr14 100275413 T C 6.79E-04 Alzheimer's disease EML1 intron 17998437 rs4905898 chr14 100275698 C G 3.61E-05 Alzheimer's disease EML1 intron 17998437 rs4905898 chr14 100275698 C G 5.84E-05 Alzheimer's disease EML1 intron pha002879 rs10141863 chr14 100276707 G A 2.29E-04 Alzheimer's disease EML1 intron 17998437 rs10141863 chr14 100276707 G A 3.75E-06 Alzheimer's disease EML1 intron pha002879 rs12891247 chr14 100278855 A C 6.53E-05 Alzheimer's disease EML1 intron pha002879 rs4905908 chr14 100330046 T C 4.59E-04 Response to cytadine analogues (cytosine arabinoside) EML1 intron 24483146 rs11160553 chr14 100331876 T C 6.02E-04 Myopia (pathological) EML1 cds-synon 21095009 rs1957509 chr14 100333862 G A 4.19E-04 Response to cytadine analogues (cytosine arabinoside) EML1 intron 24483146 rs6575751 chr14 100340583 C T 2.40E-04 Response to cytadine analogues (cytosine arabinoside) EML1 intron 24483146 rs2145859 chr14 100376715 G A 9.33E-04 Response to cytadine analogues (cytosine arabinoside) EML1 intron 24483146 rs2273704 chr14 100384232 A C 5.66E-04 Multiple complex diseases EML1 intron 17554300 rs2273704 chr14 100384232 A C 2.80E-04 Smoking initiation EML1 intron 24665060 rs11160559 chr14 100386584 A G 5.51E-04 Dental caries EML1 intron 21940522 rs7157261 chr14 100398318 C T 6.84E-05 Lung adenocarcinoma EML1 intron 19836008 rs8020741 chr14 100400513 C T 6.41E-04 Type 2 diabetes EML1 intron 17463246 rs11160562 chr14 100403616 A G 0.000693 Bipolar disorder EML1 intron 23637625 rs2236282 chr14 100405757 C T 2.63E-06 Lung adenocarcinoma EML1 intron 19836008 rs12434820 chr14 100517825 A G 6.85E-05 Cognitive test performance / / 20125193 rs3783330 chr14 100572954 G T 6.57E-05 Tunica Media EVL intron pha003038 rs12588659 chr14 100587813 C A 6.00E-08 Smoking behavior EVL intron 20418888 rs10138425 chr14 100604334 A G 3.91E-05 Taste perception EVL intron 22132133 rs12879635 chr14 100604976 G A 1.10E-04 Taste perception EVL intron 22132133 rs2236317 chr14 100613093 C T 5.85E-05 Taste perception DEGS2 UTR-3 22132133 rs2236317 chr14 100613093 C T 6.88E-05 Tunica Media DEGS2 UTR-3 pha003038 rs2281660 chr14 100615205 G C 2.95E-05 Taste perception DEGS2 intron 22132133 rs4905937 chr14 100615961 C T 1.25E-05 Taste perception DEGS2 missense 22132133 rs2895845 chr14 100618474 G A 2.19E-07 Multiple complex diseases DEGS2 intron 17554300 rs7157599 chr14 100625902 C T 1.00E-07 Sudden cardiac arrest DEGS2 missense 21658281 rs7157599 chr14 100625902 C T 5.39E-07 Cognitive decline DEGS2 missense 23732972 rs10140406 chr14 100639981 C A 2.30E-07 Health and aging,CVD and cancer age of onset / / 22174011 rs2766692 chr14 100684192 A G 2.00E-06 Electroencephalographic traits in alcoholism / / 22554406 rs1059264 chr14 100769163 C T 2.13E-05 Lung function (forced expiratory volume in 1 second) SLC25A29 intron 24023788 rs4905949 chr14 100788977 G A 0.000357426 Hypertension (early onset hypertension) / / 22479346 rs10438233 chr14 100826200 G A 3.76E-05 Multiple complex diseases WARS intron 17554300 rs10438234 chr14 100826260 G C 9.69E-04 Multiple complex diseases WARS intron 17554300 rs3783347 chr14 100839261 G T 1.30E-10 Fasting blood glucose WARS intron 22885924 rs12897338 chr14 100844368 C T 3.68E-05 Post-operative nausea and vomiting WDR25 intron 21694509 rs12882934 chr14 100845457 C A 8.74E-04 Multiple complex diseases WDR25 intron 17554300 rs2273800 chr14 100847707 A G 1.70E-04 Multiple complex diseases WDR25 missense 17554300 rs2273800 chr14 100847707 A G 5.68E-05 Progressive supranuclear palsy WDR25 missense 21685912 rs3742387 chr14 100847930 A G 2.04E-04 Multiple complex diseases WDR25 cds-synon 17554300 rs3742387 chr14 100847930 A G 5.91E-05 Progressive supranuclear palsy WDR25 cds-synon 21685912 rs941924 chr14 100892749 G A 2.05E-04 Alzheimer's disease WDR25 intron 17998437 rs7157695 chr14 100896800 A G 7.74E-06 Asthma (childhood onset) WDR25 intron 23829686 rs4905962 chr14 100933029 T C 3.99E-05 Serum metabolites WDR25 intron 19043545 rs8005782 chr14 100936793 A G 1.73E-05 Serum metabolites WDR25 intron 19043545 rs6575793 chr14 101032217 T C 1.00E-08 Menarche (age at onset) BEGAIN intron 21102462 rs7140556 chr14 101036458 C A 7.96E-05 Serum metabolites / / 19043545 rs2776544 chr14 101054029 T G 2.88E-04 Alzheimer's disease / / 22005930 rs4905976 chr14 101060605 G A 6.66E-04 Alzheimer's disease / / 22005930 rs1190856 chr14 101065987 T C 7.42E-04 Alzheimer's disease / / 22005930 rs4243729 chr14 101066656 A C 7.27E-04 Alzheimer's disease / / 22005930 rs1190862 chr14 101067773 T G 7.29E-04 Alzheimer's disease / / 22005930 rs1190872 chr14 101069704 A G 7.21E-04 Alzheimer's disease / / 22005930 rs879059 chr14 101069954 T A 7.19E-04 Alzheimer's disease / / 22005930 rs873076 chr14 101070559 A G 7.31E-04 Alzheimer's disease / / 22005930 rs1190876 chr14 101071592 A T 2.86E-04 Alzheimer's disease / / 22005930 rs1190903 chr14 101096414 C T 7.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs1190906 chr14 101099142 T C 8.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs1190907 chr14 101099364 A G 8.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs1018534 chr14 101120234 T G 9.06E-05 Type 1 diabetes nephropathy / / 23028342 rs1467537 chr14 101121274 T C 2.42E-04 Type 1 diabetes nephropathy / / 23028342 rs8017950 chr14 101123868 G A 7.22E-06 Neuroblastoma / / pha002895 rs4905992 chr14 101141090 C T 4.40E-04 Obesity (extreme) / / 21935397 rs730570 chr14 101142890 G A 8.00E-06 Type 2 diabetes / / 21573907 rs7149242 chr14 101159416 T G 3.00E-08 Platelet counts / / 22139419 rs17099617 chr14 101170488 A G 2.30E-04 Alzheimer's disease (late onset) / / 21379329 rs17577580 chr14 101189205 C T 1.00E-05 Alcohol consumption / / 23743675 rs8022367 chr14 101189457 A T 1.79E-05 Alcohol consumption / / 23743675 rs2273608 chr14 101198741 C T 4.10E-05 Kawasaki disease DLK1 intron 22446962 rs1555406 chr14 101204235 C T 3.34E-05 Bipolar disorder / / 19488044 rs6575801 chr14 101243808 A G 6.12E-04 Taste perception / / 22132133 rs1884537 chr14 101251989 C T 2.00E-06 optic disc size (disc) / / 20395239 rs1884539 chr14 101277786 A G 2.70E-05 Urinary metabolites / / 21572414 rs4906018 chr14 101280405 T C 6.60E-06 Urinary metabolites / / 21572414 rs4906019 chr14 101288031 C T 7.95E-04 Multiple complex diseases / / 17554300 rs11160606 chr14 101301261 C T 0.000016 Narcolepsy (non-HLA narcolepsy) MEG3 intron 23459209 rs12890215 chr14 101302305 T C 0.0000784 Narcolepsy (non-HLA narcolepsy) MEG3 intron 23459209 rs941576 chr14 101306045 A G 1.00E-10 Type 1 diabetes MEG3 intron 19966805 rs941576 chr14 101306045 A G 9.33E-05 Type 1 diabetes MEG3 intron 21980299 rs112608318 chr14 101348572 C T 0.00031 Breast cancer RTL1 missense 23555315 rs3825569 chr14 101350298 T C 3.70E-05 Type 2 diabetes RTL1 cds-synon 17463248 rs3809404 chr14 101356010 A G 1.02E-05 Alcohol consumption / / 23953852 rs7160787 chr14 101360168 C T 1.76E-05 Psoriasis / / 18364390 rs7146460 chr14 101361878 C T 6.00E-04 Response to TNF antagonist treatment MEG8 intron 21061259 rs10145110 chr14 101474870 C T 1.00E-07 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10132943 chr14 101493300 G A 5.23E-05 Femoral neck bone geometry / / 22087292 rs7161441 chr14 101513245 G T 2.44E-04 Aortic root size / / 21223598 rs10144193 chr14 101514950 A T 7.54E-04 Aortic root size / / 21223598 rs4525426 chr14 101525156 A G 8.00E-05 Major depressive disorder / / 21042317 rs2007288 chr14 101536027 C A 4.60E-05 Alzheimer's disease / / 17998437 rs2295655 chr14 101539131 G A 3.60E-05 Crohn's disease (need for surgery) / / 23665963 rs7147503 chr14 101539384 C T 5.00E-06 Corneal astigmatism / / 23322567 rs7147503 chr14 101539384 C T 1.71E-04 Alzheimer's disease / / 24755620 rs12147287 chr14 101554839 A G 2.21E-04 Celiac disease / / 23936387 rs6575819 chr14 101559243 C G 1.50E-06 Urinary metabolites / / 21572414 rs4906041 chr14 101560509 T A 7.40E-07 Urinary metabolites / / 21572414 rs4906047 chr14 101584818 T C 8.00E-05 Iron levels / / 21208937 rs11623343 chr14 101589330 G A 3.96E-05 Type 1 diabetes / / 18978792 rs2039588 chr14 101593861 A T 1.20E-05 Urinary metabolites / / 21572414 rs915364 chr14 101598942 C A 2.75E-07 Post-operative nausea and vomiting / / 21694509 rs12433938 chr14 101616695 T C 3.49E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs4906066 chr14 101643065 C T 3.73E-04 Type 2 diabetes / / 17463246 rs4906066 chr14 101643065 C T 4.89E-05 Odorant perception / / 23910658 rs6575836 chr14 101679255 G A 8.00E-06 Tuberculosis / / 24057671 rs8020818 chr14 101683461 T C 8.50E-05 Cognitive performance / / 19734545 rs8020818 chr14 101683461 T C 2.14E-05 Asthma / / 20159242 rs8008758 chr14 101690045 G T 3.00E-06 Body mass index (interaction) / / 23192594 rs883758 chr14 101706766 C T 1.24E-04 Multiple complex diseases / / 17554300 rs915378 chr14 101713910 T C 2.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7160374 chr14 101717179 G A 6.60E-06 Urinary metabolites / / 21572414 rs11621670 chr14 101718646 C T 6.30E-06 Urinary metabolites / / 21572414 rs2400997 chr14 101727107 C T 3.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs4548801 chr14 101749844 G A 5.79E-04 Type 2 diabetes / / 17463246 rs11624822 chr14 101752719 T C 2.30E-05 Diabetic retinopathy / / 21441570 rs17100132 chr14 101753961 C T 2.60E-05 Diabetic retinopathy / / 21441570 rs8017800 chr14 101755594 G A 3.20E-05 Diabetic retinopathy / / 21441570 rs7145788 chr14 101757281 G A 7.68E-04 Taste perception / / 22132133 rs9671810 chr14 101757810 C T 3.10E-05 Diabetic retinopathy / / 21441570 rs2401012 chr14 101760286 G A 3.14E-04 Multiple complex diseases / / 17554300 rs11851321 chr14 101792249 G C 2.31E-04 Multiple complex diseases / / 17554300 rs7147114 chr14 101794076 G A 1.70E-05 Diabetic retinopathy / / 21441570 rs4572321 chr14 101805492 A C 4.61E-04 Obesity (extreme) / / 21935397 rs11626278 chr14 101815357 C A 4.52E-04 Obesity (extreme) / / 21935397 rs1959021 chr14 101816695 A G 4.51E-04 Obesity (extreme) / / 21935397 rs11629011 chr14 101817804 G A 3.82E-04 Obesity (extreme) / / 21935397 rs11621338 chr14 101818580 G A 4.50E-04 Obesity (extreme) / / 21935397 rs4900501 chr14 101820353 T C 4.79E-04 Obesity (extreme) / / 21935397 rs12879397 chr14 101823513 G A 5.32E-04 Obesity (extreme) / / 21935397 rs4900502 chr14 101828065 C G 4.83E-04 Obesity (extreme) / / 21935397 rs7149987 chr14 101828366 C T 4.78E-04 Obesity (extreme) / / 21935397 rs10138500 chr14 101829508 T C 7.05E-04 Obesity (extreme) / / 21935397 rs7494167 chr14 101852207 G A 1.50E-04 IgE levels in asthmatics / / 23967269 rs2401019 chr14 101864614 G A 8.73E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2401019 chr14 101864614 G A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2275016 chr14 101872299 G A 4.36E-06 Rheumatoid arthritis / / 19503088 rs12586334 chr14 101888862 A C 3.18E-05 Parkinson's disease / / 21248740 rs11626687 chr14 101898171 C T 0.0006613 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11626687 chr14 101898171 C T 6.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8015995 chr14 101899240 A G 0.0006911 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8015995 chr14 101899240 A G 6.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8019453 chr14 101910778 C T 4.39E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12431547 chr14 101911402 A G 7.59E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs8013347 chr14 101916021 T G 1.07E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4906120 chr14 101936521 G A 3.93E-05 Glycosylated haemoglobin levels / / 17255346 rs4906120 chr14 101936521 G A 4.50E-04 Alzheimer's disease / / 17998437 rs4906122 chr14 101937865 G T 8.45E-05 Glycosylated haemoglobin levels / / 17255346 rs4906122 chr14 101937865 G T 3.75E-04 Alzheimer's disease / / 17998437 rs2144066 chr14 101938855 C T 8.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs12883030 chr14 101945484 T G 7.41E-05 Suicide attempts in bipolar disorder / / 21423239 rs12882330 chr14 101945591 G A 7.63E-05 Suicide attempts in bipolar disorder / / 21423239 rs7149744 chr14 101960648 C T 4.07E-05 Attention deficit hyperactivity disorder / / 23728934 rs11623832 chr14 101968668 C G 6.01E-04 Type 2 diabetes / / 17463246 rs3818077 chr14 101978769 A G 1.41E-04 Intraocular pressure / / 23836780 rs3818079 chr14 101979288 G A 9.99E-06 Intraocular pressure / / 23836780 rs12586651 chr14 101985928 T G 4.17E-04 Multiple complex diseases / / 17554300 rs12432028 chr14 101989051 C T 1.44E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1190712 chr14 102003864 A G 7.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs945006 chr14 102029277 T G 9.97E-04 Tourette syndrome DIO3 UTR-3 22889924 rs2895917 chr14 102052775 C T 5.70E-05 Barrett's esophagus / / 24121790 rs1190725 chr14 102071663 C T 6.51E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs12436143 chr14 102080736 G A 2.77E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs1958956 chr14 102130527 C T 5.71E-05 Coronary heart disease / / 21606135 rs11625483 chr14 102251737 G C 1.94E-04 Coronary heart disease PPP2R5C intron 21606135 rs1746598 chr14 102263464 A C 0.000575 Salmonella-induced pyroptosis PPP2R5C intron 22837397 rs8016207 chr14 102297215 C G 1.90E-05 Urinary metabolites PPP2R5C intron 21572414 rs1678002 chr14 102307380 T C 0.00032 Salmonella-induced pyroptosis PPP2R5C intron 22837397 rs8015021 chr14 102309693 C T 6.38E-04 Response to cytadine analogues (cytosine arabinoside) PPP2R5C intron 24483146 rs1746595 chr14 102315916 A G 6.08E-04 Multiple complex diseases PPP2R5C intron 17554300 rs1678022 chr14 102325737 T C 4.00E-04 Response to cytidine analogues (gemcitabine) PPP2R5C intron 24483146 rs2476522 chr14 102337101 T C 4.39E-05 Response to cytidine analogues (gemcitabine) PPP2R5C intron 24483146 rs2144986 chr14 102339561 T G 8.30E-05 Response to cytidine analogues (gemcitabine) PPP2R5C intron 24483146 rs1904298 chr14 102356475 C T 3.80E-06 Urinary metabolites PPP2R5C intron 21572414 rs7142002 chr14 102360745 T C 3.00E-06 Autism PPP2R5C intron 20663923 rs1612684 chr14 102376212 G T 7.52E-04 Nicotine smoking PPP2R5C intron 19268276 rs3783369 chr14 102381357 A G 1.21E-05 Orofacial clefts PPP2R5C intron 22419666 rs3783370 chr14 102385457 C T 1.64E-05 Orofacial clefts PPP2R5C intron 22419666 rs3742424 chr14 102391577 G C 0.00056 Prostate cancer PPP2R5C missense 23555315 rs2448241 chr14 102414767 G A 8.01E-05 Bladder cancer / / 19648920 rs2448241 chr14 102414767 G A 9.31E-04 White matter integrity / / 22425255 rs1741153 chr14 102423214 A G 2.15E-04 Multiple complex diseases / / 17554300 rs3818188 chr14 102446161 G A 2.73E-05 Blood Pressure DYNC1H1 cds-synon pha003043 rs4906172 chr14 102454933 C A 3.00E-06 Menopause (age at onset) DYNC1H1 intron 19448619 rs10142230 chr14 102473249 T C 3.69E-04 Insulin resistance DYNC1H1 intron 21901158 rs2253998 chr14 102496352 C A 2.69E-05 Menopause (age at onset) DYNC1H1 intron 19448619 rs17512996 chr14 102517132 C T 5.70E-05 HIV-1 control DYNC1H1 UTR-3 20041166 rs7157967 chr14 102586213 T C 7.90E-05 Creatinine levels HSP90AA1 intron 20222955 rs1190596 chr14 102595625 A G 4.00E-06 Behavioural disinhibition (generation interaction) HSP90AA1 intron 23942779 rs12323572 chr14 102616545 C T 5.95E-04 Smoking quantity WDR20 intron 24665060 rs10130705 chr14 102670577 T A 1.10E-05 Urinary metabolites WDR20 intron 21572414 rs12888595 chr14 102675837 G T 5.05E-04 Response to statin treatment (atorvastatin),change in cholesterol levels WDR20 missense 20031582 rs11160674 chr14 102687856 T C 1.60E-05 Creatinine levels WDR20 intron 20222955 rs7148939 chr14 102715656 A G 1.60E-05 Urinary metabolites MOK intron 21572414 rs12878795 chr14 102784274 G C 4.12E-07 Red blood cell traits / / 23222517 rs7158731 chr14 102792386 T C 1.53E-04 Amyotrophic lateral sclerosis ZNF839 missense 20801718 rs17100811 chr14 102800203 C A 6.49E-05 Orofacial clefts ZNF839 intron 22419666 rs150571175 chr14 102845867 G A 2.00E-07 Birdshot chorioretinopathy TECPR2 intron 24957906 rs2181343 chr14 102993303 C A 8.26E-04 Multiple complex diseases / / 17554300 rs942016 chr14 103018554 A C 1.48E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11628318 chr14 103040087 T A 2.00E-10 Platelet counts / / 22139419 rs941725 chr14 103111823 T C 1.50E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) RCOR1 intron 17982456 rs12184950 chr14 103200081 T G 6.91E-05 Parkinson's disease / / 21248740 rs12590361 chr14 103202717 C T 5.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12590361 chr14 103202717 C T 7.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11160697 chr14 103230005 G C 5.21E-04 Self-reported allergy / / 23817569 rs8008676 chr14 103234562 C T 4.10E-04 Myasthenia gravis / / 23055271 rs8008676 chr14 103234562 C T 3.07E-04 Self-reported allergy / / 23817569 rs8010932 chr14 103238458 A G 2.62E-04 Self-reported allergy / / 23817569 rs8010932 chr14 103238458 A G 1.00E-05 Asthma and hay fever / / 24388013 rs12586226 chr14 103251003 C T 1.92E-04 Self-reported allergy TRAF3 intron 23817569 rs7152791 chr14 103293716 C T 9.13E-04 Self-reported allergy TRAF3 intron 23817569 rs7143963 chr14 103304425 C T 7.46E-05 Brain imaging in schizophrenia (interaction) TRAF3 intron 19023125 rs7143963 chr14 103304425 C T 1.70E-04 Myasthenia gravis TRAF3 intron 23055271 rs7145509 chr14 103329430 C A 7.71E-04 Alzheimer's disease TRAF3 intron 17998437 rs10144464 chr14 103331590 A T 3.20E-04 Self-reported allergy TRAF3 intron 23817569 rs2295402 chr14 103338324 T A 5.23E-04 Self-reported allergy TRAF3 intron 23817569 rs1131877 chr14 103342049 T C 2.10E-04 Myasthenia gravis TRAF3 missense 23055271 rs12588538 chr14 103360000 A G 5.30E-04 Self-reported allergy TRAF3 intron 23817569 rs11160706 chr14 103361736 G A 6.98E-04 Alzheimer's disease TRAF3 intron 17998437 rs4906269 chr14 103362017 A C 2.20E-05 Myasthenia gravis TRAF3 intron 23055271 rs4906269 chr14 103362017 A C 6.61E-04 Self-reported allergy TRAF3 intron 23817569 rs10133111 chr14 103377321 G A 5.00E-06 Brain imaging in schizophrenia (interaction) TRAF3 UTR-3 19023125 rs10133111 chr14 103377321 G A 1.70E-04 Myasthenia gravis TRAF3 UTR-3 23055271 rs10138676 chr14 103412101 C T 4.78E-04 Suicide attempts in bipolar disorder CDC42BPB intron 21423239 rs17101126 chr14 103440684 C T 6.47E-05 Suicide attempts in bipolar disorder CDC42BPB intron 21423239 rs17101126 chr14 103440684 C T 6.90E-06 Urinary metabolites CDC42BPB intron 21572414 rs2285014 chr14 103443232 A G 3.96E-05 Intracerebral hemorrhage CDC42BPB intron 24656865 rs3818288 chr14 103453109 C T 7.80E-04 Alzheimer's disease CDC42BPB intron 17998437 rs7157813 chr14 103463561 G A 4.80E-05 Cognitive test performance CDC42BPB intron 20125193 rs17101146 chr14 103463599 G A 9.10E-05 Suicide attempts in bipolar disorder CDC42BPB intron 21423239 rs17101146 chr14 103463599 G A 6.10E-06 Urinary metabolites CDC42BPB intron 21572414 rs751837 chr14 103484825 T C 3.00E-07 Large B-cell lymphoma CDC42BPB intron 21471979 rs1106679 chr14 103485652 A G 2.29E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) CDC42BPB intron 17982456 rs7149097 chr14 103539669 A G 4.17E-04 Myopia (pathological) / / 21095009 rs7149097 chr14 103539669 A G 8.58E-05 Response to gemcitabine in pancreatic cancer / / 22142827 rs8017161 chr14 103563195 G A 3.00E-13 Primary biliary cirrhosis / / 21399635 rs8017161 chr14 103563195 G A 1.90E-07 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs2297067 chr14 103566785 C T 3.74E-12 Primary biliary cirrhosis EXOC3L4 missense 21399635 rs2297067 chr14 103566785 C T 7.50E-11 Gamma gluatamyl transferase levels (interaction with age) EXOC3L4 missense 22010049 rs2297067 chr14 103566785 C T 2.00E-10 Platelet counts EXOC3L4 missense 22139419 rs10131298 chr14 103568614 T A 3.70E-10 Gamma gluatamyl transferase levels (interaction with age) EXOC3L4 missense 22010049 rs944002 chr14 103572815 A G 6.00E-29 Liver enzyme levels (gamma-glutamyl transferase) EXOC3L4 intron 22001757 rs944002 chr14 103572815 A G 5.00E-13 Gamma gluatamyl transferase levels EXOC3L4 intron 22010049 rs944002 chr14 103572815 A G 5.00E-11 Mean platelet volume EXOC3L4 intron 22139419 rs944002 chr14 103572815 A G 2.00E-04 Mean platelet volume EXOC3L4 intron 24026423 rs7155575 chr14 103582802 C T 1.49E-05 Multiple complex diseases / / 17554300 rs8011165 chr14 103618754 C A 6.20E-04 Obesity (extreme) / / 21935397 rs4457930 chr14 103626593 G A 8.63E-04 Multiple complex diseases / / 17554300 rs4906296 chr14 103658864 A G 2.83E-05 Tuberculosis / / 22306650 rs1958404 chr14 103665118 C T 2.08E-04 Multiple complex diseases / / 17554300 rs2763540 chr14 103675360 T G 0.000363 Salmonella-induced pyroptosis / / 22837397 rs2771371 chr14 103681129 A G 1.24E-04 Multiple complex diseases / / 17554300 rs2763550 chr14 103682234 A G 9.26E-04 Multiple complex diseases / / 17554300 rs2771369 chr14 103682578 C T 7.57E-05 Multiple complex diseases / / 17554300 rs11160738 chr14 103717242 T C 0.0000475 Panic disorder / / 23149450 rs11160738 chr14 103717242 T C 4.75E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs17616316 chr14 103822762 C G 8.00E-11 Red blood cell traits / / 23222517 rs2010281 chr14 103862322 G A 1.80E-09 Bone mineral density (spine) MARK3 intron 19079262 rs2065018 chr14 103879187 T C 3.68E-04 Multiple complex diseases MARK3 intron 17554300 rs11623869 chr14 103883633 G T 5.00E-16 Bone mineral density MARK3 intron 22504420 rs12894275 chr14 103901424 G A 2.22E-04 Multiple complex diseases MARK3 intron 17554300 rs12894275 chr14 103901424 G A 3.74E-05 Height MARK3 intron 19570815 rs2065015 chr14 103904061 T G 2.36E-04 Multiple complex diseases MARK3 intron 17554300 rs3783397 chr14 103947289 A G 2.94E-04 Multiple complex diseases MARK3 intron 17554300 rs3783398 chr14 103949378 T C 3.11E-04 Multiple complex diseases MARK3 intron 17554300 rs10129426 chr14 104018455 G A 0.000388 Rate of forced expiratory volume in 1 second (FEV1) decline (young adult women) / / 23527081 rs7148456 chr14 104028270 T C 8.47E-04 Multiple complex diseases BAG5 cds-synon 17554300 rs2296482 chr14 104029819 T G 3.31E-05 Osteoarthritis (knee and hip) APOPT1 intron 21177295 rs2296482 chr14 104029819 T G 3.83E-04 Osteoarthritis (knee and hip) APOPT1 intron 21177295 rs2296482 chr14 104029819 T G 3.94E-05 Osteoarthritis (knee and hip) APOPT1 intron 21177295 rs2403199 chr14 104062068 A C 4.68E-04 Alcohol dependence / / 20201924 rs729438 chr14 104092789 G A 9.12E-04 Multiple complex diseases / / 17554300 rs729438 chr14 104092789 G A 5.80E-04 Breast cancer (survival) / / 22232737 rs7154572 chr14 104105414 C T 9.41E-05 Kawasaki disease KLC1 intron 22446961 rs3212121 chr14 104164522 T C 1.76E-08 LDL cholesterol XRCC3 UTR-3 23063622 rs2368561 chr14 104283104 A C 7.02E-05 Coronary heart disease PPP1R13B intron 21971053 rs10438243 chr14 104345822 A G 2.47E-04 Parkinson's disease / / 17052657 rs10438244 chr14 104346185 T C 7.94E-05 Multiple complex diseases / / 17554300 rs4144027 chr14 104357638 T C 1.00E-11 Blood metabolite levels / / 24816252 rs8021692 chr14 104428576 C G 2.97E-06 Multiple complex diseases TDRD9 intron 17554300 rs10142229 chr14 104464809 C T 2.45E-05 Colorectal cancer TDRD9 intron 21242260 rs11622475 chr14 104509076 C T 8.00E-06 Bipolar disorder TDRD9 intron 17554300 rs11622475 chr14 104509076 C T 2.00E-06 Bipolar disorder TDRD9 intron 21254220 rs10139481 chr14 104521894 G A 8.71E-04 Multiple complex diseases / / 17554300 rs941953 chr14 104559852 T C 2.09E-05 Parent of origin effect on language impairment (maternal) ASPG cds-synon 24571439 rs737393 chr14 104566119 C T 7.60E-07 Hypertension ASPG intron pha003041 rs1744296 chr14 104567722 C T 1.06E-05 Hypertension ASPG intron pha003041 rs1744296 chr14 104567722 C T 2.16E-05 Blood Pressure ASPG intron pha003048 rs1744296 chr14 104567722 C T 9.38E-05 Blood Pressure ASPG intron pha003050 rs12588869 chr14 104587348 G A 1.51E-04 Smoking cessation / / 24665060 rs2487306 chr14 104632732 G C 2.40E-05 Urinary metabolites KIF26A intron 21572414 rs1890982 chr14 104637327 T G 3.64E-04 Parkinson's disease KIF26A intron 17052657 rs2275593 chr14 104640011 T C 7.04E-05 Blood Pressure KIF26A intron pha003047 rs1547350 chr14 104646326 A C 7.07E-05 Information processing speed KIF26A UTR-3 21130836 rs1890981 chr14 104647606 G A 3.12E-05 Waist Circumference / / pha003023 rs11628649 chr14 104695636 C T 1.50E-05 Urinary metabolites / / 21572414 rs4906434 chr14 104764853 C T 7.94E-05 Response to hepatitis C treatment / / 19684573 rs11160804 chr14 104792254 G A 3.73E-05 Response to hepatitis C treatment / / 19684573 rs10135875 chr14 104798785 A T 1.23E-04 Alzheimer's disease / / 17998437 rs10135875 chr14 104798785 A T 2.20E-05 Urinary metabolites / / 21572414 rs4906450 chr14 104800200 A G 9.06E-05 Response to hepatitis C treatment / / 19684573 rs8016091 chr14 104807712 G A 1.76E-04 Alzheimer's disease / / 17998437 rs8016091 chr14 104807712 G A 4.10E-06 Emphysema-related traits / / 20709820 rs8019526 chr14 104859419 A G 5.55E-04 Stroke / / pha002887 rs11622864 chr14 104921616 C T 1.19E-04 White matter integrity / / 22425255 rs4983504 chr14 104924334 T C 6.49E-06 Bipolar disorder,affective / / 20528957 rs4254262 chr14 104963839 T C 5.47E-05 White matter integrity / / 22425255 rs10146433 chr14 104978460 G A 2.10E-05 Urinary metabolites / / 21572414 rs4264325 chr14 104979486 T C 3.39E-05 Orofacial clefts / / 22419666 rs4983566 chr14 104982013 C T 1.75E-04 Prion diseases / / 22210626 rs4983568 chr14 104983655 T G 8.02E-05 Pancreatic cancer / / pha002889 rs12434169 chr14 104989254 G A 1.70E-05 Urinary metabolites / / 21572414 rs4983408 chr14 105025462 G T 6.57E-04 Aortic root size / / 21223598 rs3809457 chr14 105058810 G T 3.61E-05 Fibrinogen / / pha003068 rs12880486 chr14 105084774 C T 4.76E-04 Multiple complex diseases / / 17554300 rs11625777 chr14 105085077 C T 3.79E-04 Multiple complex diseases / / 17554300 rs10137814 chr14 105088609 G A 2.59E-04 Multiple complex diseases / / 17554300 rs7146661 chr14 105090555 C G 1.82E-04 Multiple complex diseases / / 17554300 rs10146871 chr14 105110417 T C 2.09E-06 Nasopharyngeal carcinoma / / 23209447 rs4983522 chr14 105146579 A C 7.31E-05 Information processing speed / / 21130836 rs11851852 chr14 105168428 C T 2.00E-05 Rheumatoid arthritis INF2 intron 17804836 rs9783669 chr14 105215351 C T 4.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2494731 chr14 105237680 G C 7.46E-04 Multiple complex diseases AKT1 intron 17554300 rs2494731 chr14 105237680 G C 2.52E-05 Serum metabolites AKT1 intron 19043545 rs2494732 chr14 105239192 T C 1 Drug response to Risperidone AKT1 intron 18855532 rs4983387 chr14 105268228 G A 2.91E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZBTB42 missense 20877124 rs3803300 chr14 105269779 T C 1 Drug response to Risperidone ZBTB42 UTR-3 18855532 rs4983559 chr14 105277209 G A 1.00E-08 HDL cholesterol / / 24097068 rs2841233 chr14 105346907 T C 7.00E-06 IgG glycosylation KIAA0284 intron 23382691 rs2028414 chr14 105349388 A C 8.00E-06 IgG glycosylation KIAA0284 cds-synon 23382691 rs2841269 chr14 105386149 G C 3.69E-04 Alcohol dependence / / 21314694 rs2841277 chr14 105391005 C T 2.00E-14 Rheumatoid arthritis / / 22446963 rs2582532 chr14 105392837 T C 3.00E-07 Rheumatoid arthritis PLD4 intron 24390342 rs2582532 chr14 105392837 T C 5.00E-08 Rheumatoid arthritis PLD4 intron 24390342 rs10083490 chr14 105402418 C T 6.95E-04 Alcohol dependence / / 21314694 rs201648026 chr14 105407770 T A 0.000051 Prostate cancer (advanced) AH/K2 missense 23555315 rs10133292 chr14 105457161 T C 3.49E-04 Alcohol dependence C14orf79 intron 21314694 rs10149501 chr14 105581973 A G 8.40E-05 Temperament (bipolar disorder) / / 22365631 rs7159216 chr14 105585608 G A 1.30E-05 Temperament (bipolar disorder) / / 22365631 rs4464011 chr14 105589636 T C 3.10E-05 Temperament (bipolar disorder) / / 22365631 rs9972231 chr14 105615648 C T 2.20E-04 Stroke JAG2 missense pha002887 rs2293806 chr14 105617891 C T 3.94E-04 Smoking initiation JAG2 intron 24665060 rs2238286 chr14 105636112 T C 4.10E-04 Smoking initiation / / 24665060 rs3784233 chr14 105637747 G A 6.97E-04 Smoking initiation / / 24665060 rs880616 chr14 105642138 C T 5.44E-06 Stroke (ischemic) NUDT14 intron 22941190 rs10139596 chr14 105643619 G A 3.78E-06 Stroke (ischemic) NUDT14 intron 22941190 rs1882848 chr14 105644151 T C 2.65E-06 Stroke (ischemic) NUDT14 intron 22941190 rs10140111 chr14 105644282 C G 1.87E-06 Stroke (ischemic) NUDT14 intron 22941190 rs11625862 chr14 105644382 G A 1.33E-06 Stroke (ischemic) NUDT14 intron 22941190 rs11625865 chr14 105644421 G A 2.50E-06 Stroke (ischemic) NUDT14 intron 22941190 rs4983590 chr14 105646179 G A 5.01E-06 Stroke (ischemic) NUDT14 intron 22941190 rs11160839 chr14 105648963 T A 7.41E-06 Stroke (ischemic) / / 22941190 rs3000073 chr14 105729792 G A 3.00E-11 Mean platelet volume BRF1 intron 22139419 rs3000073 chr14 105729792 G A 7.00E-04 Mean platelet volume BRF1 intron 24026423 rs11847920 chr14 105850045 A G 7.09E-04 Insulin resistance PACS2 intron 21901158 rs11621365 chr14 105871769 G A 7.11E-04 Multiple complex diseases TEX22 intron 17554300 rs9743822 chr14 105903724 G A 1.35E-05 Age-related macular degeneration MTA1 intron pha000001 rs4983411 chr14 105916797 G A 3.45E-04 Taste perception MTA1 intron 22132133 rs4983425 chr14 105961529 G A 1.59E-04 Multiple complex diseases C14orf80 intron 17554300 rs4983425 chr14 105961529 G A 0.00000554 Primary sclerosing cholangitis C14orf80 intron 23603763 rs10151805 chr14 105974781 T C 2.37E-05 Partial epilepsies / / 20522523 rs4074453 chr14 105998544 T C 2.77E-06 Rheumatoid arthritis / / 19503088 rs4074453 chr14 105998544 T C 8.48E-05 Partial epilepsies / / 20522523 rs10142224 chr14 106008645 C T 4.01E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs10136766 chr14 106232585 A G 8.00E-16 IgG levels / / 23225573 rs17112693 chr14 106273250 C T 1.94E-15 Multiple complex diseases / / 17554300 rs1981496 chr14 106645846 A T 9.95E-05 Multiple complex diseases / / 17554300 rs7149857 chr14 106715489 T A 5.35E-04 Multiple complex diseases / / 17554300 rs8005760 chr14 106912037 C T 9.69E-05 Bipolar disorder / / 22925353 rs7359080 chr14 106939916 A C 2.44E-04 Multiple complex diseases LINC00221 intron 17554300 rs9324088 chr14 106970119 A G 2.00E-04 Alzheimer's disease (late onset) / / 21460841 rs4774001 chr14 107033511 C T 4.88E-05 Type 2 diabetes / / 17463246 rs17113217 chr14 107109026 A G 7.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17113276 chr14 107139502 T C 6.10E-04 Type 2 diabetes / / 17463246 rs17113281 chr14 107139583 T C 5.04E-04 Type 2 diabetes / / 17463246 rs6576201 chr14 107139713 G A 1.92E-04 Multiple complex diseases / / 17554300 rs9324092 chr14 107139823 C T 3.55E-04 Multiple complex diseases / / 17554300 rs17113284 chr14 107140493 T C 1.08E-05 Kawasaki disease / / 21326860 rs8005468 chr14 107142448 G A 8.93E-06 Kawasaki disease / / 21326860 rs3858878 chr14 107144078 G A 6.15E-04 Type 2 diabetes / / 17463246 rs7146073 chr14 107160654 T G 8.58E-04 Type 2 diabetes / / 17463246 rs3814922 chr14 107167782 G C 5.80E-04 Multiple complex diseases / / 17554300 rs10129255 chr14 107176213 C T 7.00E-06 Kawasaki disease / / 21326860 rs2007467 chr14 107179847 C T 1.28E-05 Kawasaki disease / / 21326860 rs756581 chr14 107180224 G T 5.71E-04 Type 2 diabetes / / 17463246 rs2337406 chr14 107180574 C T 3.00E-07 Alzheimer's disease (late onset) / / 24162737 rs10150241 chr14 107184184 T A 1.08E-05 Kawasaki disease / / 21326860 rs12590667 chr14 107187462 C T 1.27E-05 Kawasaki disease / / 21326860 rs7149473 chr14 107223238 G C 8.08E-05 Multiple complex diseases / / 17554300 rs7140253 chr14 107233999 A G 7.00E-04 Alzheimer's disease (late onset) / / 21460841 rs726996 chr14 107240991 C T 9.80E-04 Alzheimer's disease / / 17998437 rs885883 chr14 107274052 C T 1.50E-05 Adiposity / / 19461586 rs1544317 chr14 107281980 A G 5.90E-04 Type 2 diabetes / / 17463246 rs6599770 chr15 20161372 A C 4.40E-05 Cognitive test performance / / 20125193 rs4932079 chr15 20192011 C A 7.56E-05 Cognitive test performance / / 20125193 rs7167893 chr15 22427966 G A 2.09E-04 Celiac disease / / 23936387 rs12900257 chr15 22784095 G T 4.78E-04 Multiple complex diseases / / 17554300 rs17742788 chr15 22863262 A G 4.12E-04 Response to cytidine analogues (gemcitabine) TUBGCP5 intron 24483146 rs2289814 chr15 22869764 A G 6.50E-04 Multiple complex diseases TUBGCP5 intron 17554300 rs12899205 chr15 22871248 G C 3.62E-04 Multiple complex diseases TUBGCP5 intron 17554300 rs12595681 chr15 22880726 C G,T 2.35E-04 Multiple complex diseases / / 17554300 rs12439364 chr15 22905631 T C 8.22E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CYFIP1 intron 24578207 rs12439364 chr15 22905631 T C 8.22E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy CYFIP1 intron 24578207 rs7171787 chr15 22922576 T G 9.83E-04 HIV-1 viral setpoint CYFIP1 intron 17641165 rs722410 chr15 22924097 T G 4.32E-05 HIV-1 viral setpoint CYFIP1 intron 17641165 rs2120968 chr15 22932511 C T 1.36E-04 HIV-1 viral setpoint CYFIP1 intron 17641165 rs12594495 chr15 22948004 A G 6.09E-05 Multiple complex diseases CYFIP1 intron 17554300 rs1579821 chr15 22949828 A G 2.19E-05 Multiple sclerosis CYFIP1 intron 20598377 rs2289816 chr15 22955013 T G 6.90E-05 Waist Circumference CYFIP1 intron pha003025 rs11263677 chr15 22965525 C T 6.43E-04 Type 2 diabetes CYFIP1 intron 17463246 rs11263677 chr15 22965525 C T 2.08E-05 Multiple complex diseases CYFIP1 intron 17554300 rs1009153 chr15 22976911 G A 6.41E-04 Parkinson's disease CYFIP1 intron 17052657 rs4778464 chr15 22985688 G T 1.85E-05 Body Mass Index CYFIP1 intron pha003019 rs4778464 chr15 22985688 G T 9.92E-05 Body Mass Index CYFIP1 intron pha003020 rs4778464 chr15 22985688 G T 4.67E-05 Body Mass Index CYFIP1 intron pha003022 rs999842 chr15 23000272 A G 8.34E-05 Rheumatoid arthritis CYFIP1 intron 17804836 rs4778441 chr15 23001691 A G 8.22E-05 Body Mass Index CYFIP1 intron pha003019 rs4778441 chr15 23001691 A G 9.20E-05 Body Mass Index CYFIP1 intron pha003022 rs3764213 chr15 23027667 C G 9.31E-05 Nicotine smoking NIPA2 intron 19268276 rs4592619 chr15 23033803 T C 6.99E-05 Body Mass Index NIPA2 intron pha003019 rs12439636 chr15 23042155 A G 3.20E-04 Alzheimer's disease (late onset) / / 21379329 rs6606820 chr15 23046314 C G 4.39E-04 Multiple complex diseases NIPA1 UTR-3 17554300 rs12902722 chr15 23046404 T C 1.23E-04 Type 2 diabetes NIPA1 UTR-3 17463246 rs1059774 chr15 23047702 G C 6.62E-04 Multiple complex diseases NIPA1 UTR-3 17554300 rs7168367 chr15 23066736 C T 4.03E-05 Duodenal ulcer NIPA1 intron 22387998 rs7174119 chr15 23078384 A G 2.29E-04 Bronchopulmonary dysplasia NIPA1 intron 23897914 rs8033142 chr15 23140114 C T 1.73E-04 Celiac disease / / 23936387 rs11263693 chr15 23222284 T G 5.38E-05 Multiple complex diseases / / 17554300 rs183418565 chr15 23647749 T C 2.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs6576313 chr15 23682708 T G 7.61E-04 HIV-1 viral setpoint / / 17641165 rs4778531 chr15 23688944 A G 3.63E-04 HIV-1 viral setpoint GOLGA6L2 missense 17641165 rs17118269 chr15 23693406 G A 1.55E-04 HIV-1 viral setpoint / / 17641165 rs11638103 chr15 23746396 A T 6.87E-05 Major depressive disorder / / 22472876 rs4362366 chr15 23747125 G T 6.61E-05 Major depressive disorder / / 22472876 rs1608962 chr15 23750690 C T 9.54E-05 Major depressive disorder / / 22472876 rs9806254 chr15 23752506 G A 5.38E-05 Major depressive disorder / / 22472876 rs8024130 chr15 23762842 T G 3.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs8036730 chr15 23771443 T G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4778549 chr15 23775544 G A 6.08E-05 Type 2 diabetes / / 17463246 rs4778319 chr15 23778772 G T 7.30E-05 Type 2 diabetes / / 17463246 rs12904911 chr15 23781448 C T 1.15E-04 Type 2 diabetes / / 17463246 rs369760936 chr15 23781448 C CT 1.15E-04 Type 2 diabetes / / 17463246 rs7497492 chr15 23782134 A G 3.03E-05 Type 2 diabetes / / 17463246 rs8029013 chr15 23782545 T C 3.50E-05 Type 2 diabetes / / 17463246 rs6576461 chr15 23814372 G A 3.05E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4778564 chr15 23816185 C T 1.47E-04 Multiple complex diseases / / 17554300 rs2900 chr15 23817721 G A 4.00E-06 IgG glycosylation / / 23382691 rs12441183 chr15 23833777 T C 7.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6576529 chr15 23847508 G A 2.81E-05 Telomere length / / 23001564 rs7169369 chr15 23877411 G A 2.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs7181128 chr15 23879149 A C 1.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs11161318 chr15 23888266 G A 1.50E-05 Urinary metabolites MAGEL2 nearGene-3 21572414 rs850823 chr15 23888309 G C 7.94E-05 Suicide attempts in bipolar disorder MAGEL2 nearGene-3 21423239 rs8920 chr15 23888891 A T 9.02E-05 Suicide attempts in bipolar disorder MAGEL2 UTR-3 21423239 rs138628273 chr15 23889873 G C 0.000029 Breast cancer MAGEL2 missense 23555315 rs850818 chr15 23893311 A G 4.77E-04 Suicide attempts in bipolar disorder MAGEL2 nearGene-5 21423239 rs850817 chr15 23893689 G A 4.82E-04 Suicide attempts in bipolar disorder MAGEL2 nearGene-5 21423239 rs850815 chr15 23894745 C T 4.69E-04 Suicide attempts in bipolar disorder MAGEL2 nearGene-5 21423239 rs850814 chr15 23894967 A G 5.11E-05 Suicide attempts in bipolar disorder MAGEL2 nearGene-5 21423239 rs850813 chr15 23895635 G A 2.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs850810 chr15 23897899 C G 4.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs850807 chr15 23898129 T C 4.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs10519442 chr15 23908687 A G 7.90E-05 Alcohol consumption / / 23953852 rs8029455 chr15 23920534 C A 1.60E-05 Urinary metabolites / / 21572414 rs1722791 chr15 23952738 A C 0.000656 Salmonella-induced pyroptosis / / 22837397 rs824192 chr15 24002327 C T 9.15E-04 Coronary heart disease / / 21971053 rs824205 chr15 24008071 T C 0.0000345 Gains in maximal O2 uptake response / / 21183627 rs824198 chr15 24014325 C T 8.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs1717853 chr15 24017340 T A 3.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs2955818 chr15 24017424 G C 3.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs2955818 chr15 24017424 G C 8.10E-06 Urinary metabolites / / 21572414 rs1094837 chr15 24021115 G T 7.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs824179 chr15 24022222 G C 8.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs17117531 chr15 24026111 T C 8.86E-95 Multiple complex diseases / / 17554300 rs1717831 chr15 24027532 A C 5.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs17812706 chr15 24032521 C T 7.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs11161351 chr15 24035973 T C 1.59E-06 White blood cell count / / 21738479 rs1879697 chr15 24038355 C T 8.57E-05 Femoral neck bone geometry / / 22087292 rs10519449 chr15 24050205 T C 8.60E-04 Crohn's disease / / 17684544 rs1524845 chr15 24061497 G A 3.66E-06 Blood Pressure / / pha003045 rs1524845 chr15 24061497 G A 2.56E-06 Blood Pressure / / pha003047 rs7164923 chr15 24062915 C T 5.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs17757180 chr15 24082747 G A 1.81E-05 Major depressive disorder / / 21621269 rs7173902 chr15 24088014 G T 2.77E-05 Personality dimensions / / 22628180 rs8039055 chr15 24088507 G C 2.62E-05 Personality dimensions / / 22628180 rs12438172 chr15 24088975 T C 1.75E-05 Personality dimensions / / 22628180 rs1120970 chr15 24089418 G A 2.22E-05 Personality dimensions / / 22628180 rs4778338 chr15 24089570 G T 1.92E-05 Personality dimensions / / 22628180 rs17813715 chr15 24089841 T C 2.65E-05 Personality dimensions / / 22628180 rs4778340 chr15 24090025 G T 4.13E-05 Hemoglobin / / pha003096 rs4778340 chr15 24090025 G T 2.37E-05 Erythrocyte counts / / pha003101 rs12905338 chr15 24096986 C A 2.90E-04 Acute lung injury / / 22295056 rs1563819 chr15 24107440 G A 2.61E-04 Type 2 diabetes / / 17463246 rs11636636 chr15 24117029 A G 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs8042584 chr15 24123137 G C 2.06E-04 Type 2 diabetes / / 17463246 rs2169123 chr15 24126311 T C 1.31E-04 Type 2 diabetes / / 17463246 rs3858932 chr15 24126392 T C 4.10E-04 Multiple complex diseases / / 17554300 rs10162946 chr15 24138305 A G 2.00E-05 Homocysteine levels,in plasma / / 19525478 rs12591922 chr15 24144958 A G 7.55E-04 Multiple complex diseases / / 17554300 rs2030484 chr15 24146722 G A 6.31E-04 Myopia (pathological) / / 21095009 rs12440005 chr15 24158210 C T 2.11E-04 Acute lung injury / / 22295056 rs2353506 chr15 24175851 G A 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4778264 chr15 24178859 G T 4.73E-04 Response to TNF antagonist treatment / / 21061259 rs4778359 chr15 24193582 G T 4.00E-06 Vitamin D concentrations / / 20600896 rs4778359 chr15 24193582 G T 4.00E-06 Vitamin D concentrations / / 20600896 rs12594273 chr15 24216870 A G 4.26E-04 Alzheimer's disease (late onset) / / 21379329 rs11630255 chr15 24249141 T C 7.45E-06 Cortisol secretion,in saliva / / 21316860 rs8026512 chr15 24257659 T C 1.94E-05 Cortisol secretion,in saliva / / 21316860 rs8026512 chr15 24257659 T C 6.04E-06 Cortisol secretion,in saliva / / 21316860 rs328642 chr15 24274570 C T 1.96E-04 Taste perception / / 22132133 rs2677408 chr15 24279260 G A 2.81E-04 Taste perception / / 22132133 rs3914576 chr15 24304718 A C 7.18E-05 Taste perception / / 22132133 rs1976756 chr15 24317333 G A 3.03E-05 Taste perception / / 22132133 rs1110961 chr15 24369643 T C 4.86E-05 Schizophrenia / / 19197363 rs1850475 chr15 24397619 T C 1.49E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4778426 chr15 24457587 C T 9.80E-06 Urinary metabolites / / 21572414 rs2007159 chr15 24485160 G A 6.85E-04 Schizophrenia / / 19197363 rs17118727 chr15 24503660 A C 9.74E-04 Type 2 diabetes / / 17463246 rs1532517 chr15 24532602 A G 2.00E-05 Post-operative nausea and vomiting / / 21694509 rs11161090 chr15 24669745 G C 7.86E-04 Type 2 diabetes / / 17463246 rs11161090 chr15 24669745 G C 4.20E-06 Non-small cell lung cancer / / 21866343 rs35600665 chr15 24741291 C T 7.00E-06 Obesity-related traits / / 23251661 rs7496073 chr15 24748768 G T 3.96E-04 Type 2 diabetes / / 17463246 rs3901472 chr15 24814582 A G 0.00000103 Platelet thrombus as measured by PFA-100ColA closure time upon shear stress PWRN1 intron 22550155 rs11858159 chr15 24824188 G A 0.000000919 Platelet thrombus as measured by PFA-100ColA closure time upon shear stress PWRN1 intron 22550155 rs8025557 chr15 24826558 C T 2.50E-05 Urinary metabolites PWRN1 intron 21572414 rs6576352 chr15 24838459 G T 3.13E-04 Smoking initiation / / 24665060 rs8038746 chr15 24853607 C T 5.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8025033 chr15 24855158 C T 3.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11858344 chr15 24862280 A G 6.52E-04 Multiple complex diseases / / 17554300 rs7495407 chr15 24909327 C T 8.35E-05 Serum metabolites / / 19043545 rs12902137 chr15 24924663 T C 6.00E-06 Periodontitis (DPAL) C15orf2 UTR-3 24024966 rs12902295 chr15 24924729 T C 2.84E-04 Premature ovarian failure C15orf2 UTR-3 19508998 rs12102021 chr15 24940793 G C 6.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs8027714 chr15 24964597 G A 5.65E-43 Pelvic organ prolapse / / 22105264 rs975907 chr15 24980273 G A 5.94E-04 Parkinson's disease / / 17052657 rs11858016 chr15 24999291 G A 7.67E-06 Periodontitis (DPAL) / / 24024966 rs11854309 chr15 25003041 G A 0.0000819 Asthma / / 22694930 rs8030136 chr15 25022988 C T 6.00E-06 Periodontitis (DPAL) / / 24024966 rs17114720 chr15 25031018 T C 7.70E-05 Hepatitis B vaccine response / / 21764829 rs7167541 chr15 25058041 C T 6.15E-04 Type 2 diabetes / / 17463246 rs17114774 chr15 25063397 G A 1.11E-04 Epilepsy / / 22116939 rs1037461 chr15 25064327 G A 9.92E-04 Acute lung injury / / 22295056 rs7171320 chr15 25064483 T C 1.20E-04 Epilepsy / / 22116939 rs8034612 chr15 25065297 C G 7.54E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1453556 chr15 25066360 G A 4.52E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1498305 chr15 25071966 C T 5.72E-04 Coronary Artery Disease SNRPN intron 17634449 rs7178705 chr15 25077944 T C 5.52E-04 Multiple complex diseases SNRPN intron 17554300 rs4028398 chr15 25078742 C T 5.70E-04 Multiple complex diseases SNRPN intron 17554300 rs3867498 chr15 25078787 G A 1.00E-06 Pulmonary function SNRPN intron 17903307 rs4028395 chr15 25079015 A T 5.49E-04 Multiple complex diseases SNRPN intron 17554300 rs7164989 chr15 25097227 A G 5.49E-04 Acute lung injury SNRPN intron 22295056 rs752874 chr15 25102073 T C 5.02E-04 Acute lung injury SNRPN intron 22295056 rs1391516 chr15 25107083 G A 2.08E-04 Acute lung injury SNRPN intron 22295056 rs12592279 chr15 25115126 C T 1.09E-04 Stroke SNRPN intron pha002886 rs3867499 chr15 25119954 C T 1.37E-04 Smoking cessation SNRPN intron 24665060 rs7183510 chr15 25129974 T G 3.30E-05 Corneal curvature SNRPN intron 24963161 rs2030062 chr15 25133986 A G 2.00E-06 Obesity-related traits SNRPN intron 23251661 rs7175782 chr15 25151087 G A 2.06E-04 Alzheimer's disease (late onset) SNRPN intron 21460841 rs2647355 chr15 25161431 G A 3.03E-06 Glycemic traits (pregnancy) SNRPN intron 23903356 rs220027 chr15 25196960 C G 3.88E-06 Type 2 diabetes SNRPN intron 17463246 rs220030 chr15 25199768 T C 2.95E-05 Type 2 diabetes SNRPN intron 17463246 rs17786183 chr15 25241791 C T 1.04E-04 Celiac disease / / 23936387 rs17114990 chr15 25243304 A G 0.00055 Salmonella-induced pyroptosis / / 22837397 rs8038349 chr15 25270440 G T 0.00071 Salmonella-induced pyroptosis / / 22837397 rs6576402 chr15 25310440 A G 9.68E-04 Type 2 diabetes / / 17463246 rs17115191 chr15 25326695 A G 0.0002036 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17115191 chr15 25326695 A G 2.04E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17115198 chr15 25328295 A C 0.0002037 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17115198 chr15 25328295 A C 2.04E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7171528 chr15 25329309 G A 0.000204 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7171937 chr15 25329547 G A 0.000204 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7171937 chr15 25329547 G A 2.04E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1477599 chr15 25330302 G C 0.000204 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1477599 chr15 25330302 G C 2.04E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6576404 chr15 25332718 T C 4.67E-04 Multiple complex diseases / / 17554300 rs3825770 chr15 25332965 T C 0.0002049 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs3825770 chr15 25332965 T C 2.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1477597 chr15 25335561 T C 0.0002049 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1477597 chr15 25335561 T C 2.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1477598 chr15 25335877 C T 0.0002052 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1477598 chr15 25335877 C T 2.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7176900 chr15 25341747 T C 0.0002047 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7176900 chr15 25341747 T C 2.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7172180 chr15 25341838 A G 0.0002045 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7172180 chr15 25341838 A G 2.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7170404 chr15 25341960 G A 0.0002041 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7170404 chr15 25341960 G A 2.04E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17115224 chr15 25345026 G T 0.0002038 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17115224 chr15 25345026 G T 2.04E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8034408 chr15 25346212 T C 0.0002034 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8034408 chr15 25346212 T C 2.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7168122 chr15 25353217 C T 0.0002092 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7168122 chr15 25353217 C T 2.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8030752 chr15 25355468 C T 8.19E-04 Type 2 diabetes / / 17463246 rs8036401 chr15 25355829 T G 5.27E-05 Multiple complex diseases / / 17554300 rs17115258 chr15 25362231 A G 0.0002454 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17115258 chr15 25362231 A G 2.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs691 chr15 25364795 C T 9.82E-04 Type 2 diabetes / / 17463246 rs11856501 chr15 25401807 T G 3.60E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2739831 chr15 25406655 G A 1.05E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs8025093 chr15 25602950 A C 4.00E-06 Obesity-related traits UBE3A intron 23251661 rs780 chr15 25695039 T C 2.00E-04 Information processing speed / / 21130836 rs4906952 chr15 25696179 C A,G,T 7.50E-06 Urinary metabolites / / 21572414 rs6576426 chr15 25703563 G A 2.70E-06 Urinary metabolites / / 21572414 rs6576426 chr15 25703563 G A 6.40E-05 Type 2 diabetes / / 21874001 rs11161183 chr15 25728835 T C 2.20E-05 Type 2 diabetes / / 23209189 rs12916907 chr15 25732547 A G 8.19E-04 Type 2 diabetes / / 17463246 rs2584808 chr15 25744443 T C 3.30E-05 Type 2 diabetes / / 23209189 rs12595506 chr15 25744981 C T 6.10E-05 Type 2 diabetes / / 23209189 rs12917037 chr15 25747008 A G 8.44E-04 Type 2 diabetes / / 17463246 rs4906719 chr15 25747577 G T 7.20E-05 Type 2 diabetes / / 23209189 rs1000040 chr15 25750941 G A 3.00E-04 Type 2 diabetes / / 23209189 rs7496458 chr15 25771369 G A 1.64E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs718979 chr15 25774277 G A 6.82E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2906029 chr15 25776863 A G 2.52E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2906037 chr15 25780306 C T 3.44E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2925239 chr15 25781675 T C 5.35E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2906041 chr15 25781923 G A 1.67E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2906013 chr15 25786438 T A 1.30E-05 Urinary metabolites / / 21572414 rs10519500 chr15 25787619 C A 2.60E-05 Urinary metabolites / / 21572414 rs1008531 chr15 25825753 C A 1.10E-05 Urinary metabolites / / 21572414 rs4906728 chr15 25838550 T C 1.16E-04 Multiple complex diseases / / 17554300 rs17734670 chr15 25839396 C G 2.41E-04 Multiple complex diseases / / 17554300 rs2930596 chr15 25853563 G A 3.63E-04 Type 2 diabetes / / 17463246 rs2930597 chr15 25853824 G C 2.99E-04 Type 2 diabetes / / 17463246 rs4502193 chr15 25858646 T C 1.06E-04 Type 2 diabetes / / 17463246 rs1008717 chr15 25859062 A G 3.49E-04 Type 2 diabetes / / 17463246 rs2930603 chr15 25860911 G A 3.03E-04 Type 2 diabetes / / 17463246 rs11631211 chr15 25861111 A G 4.34E-05 Type 2 diabetes / / 17463246 rs9806169 chr15 25864062 G T 3.86E-05 Psoriasis / / 18364390 rs12911594 chr15 25869112 C T 3.49E-04 Type 2 diabetes / / 17463246 rs2086908 chr15 25873273 C T 1.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs36053934 chr15 25873273 C CC,CT 1.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs7176242 chr15 25877721 G A 5.17E-04 Type 2 diabetes / / 17463246 rs6576443 chr15 25894658 C T 6.00E-09 Immune reponse to smallpox (secreted IFN-alpha) / / 22610502 rs17636733 chr15 25912339 T C 2.00E-07 Cardiac hypertrophy / / 21348951 rs2930629 chr15 25917966 G A 5.39E-05 Breast cancer / / pha002853 rs8028506 chr15 25931015 A G 5.19E-10 Brain activation patterns in response to human facial expressions-for the negative faces task ATP10A intron 22828495 rs8036650 chr15 26025991 G A 1.47E-04 Vaspin levels ATP10A intron 22907691 rs8036650 chr15 26025991 G A 0.0001465 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit ATP10A intron 22907730 rs11632263 chr15 26028702 C T 4.20E-06 Urinary metabolites ATP10A intron 21572414 rs8042764 chr15 26033764 C A 2.60E-06 Urinary metabolites ATP10A intron 21572414 rs8042764 chr15 26033764 C A 7.85E-07 Body Mass Index ATP10A intron pha003019 rs8042764 chr15 26033764 C A 9.25E-06 Body Mass Index ATP10A intron pha003020 rs8042764 chr15 26033764 C A 6.62E-06 Body Mass Index ATP10A intron pha003022 rs7359209 chr15 26035610 T C 1.71E-04 Lung function (forced vital capacity) ATP10A intron 24023788 rs7359209 chr15 26035610 T C 7.71E-05 Lung function (forced expiratory volume in 1 second) ATP10A intron 24023788 rs7359209 chr15 26035610 T C 9.69E-05 Glucose levels ATP10A intron pha002899 rs7162581 chr15 26035811 C T 8.77E-06 Tunica Media ATP10A intron pha003034 rs874489 chr15 26047896 A T 1.94E-04 Multiple complex diseases ATP10A intron 17554300 rs872538 chr15 26048035 G A 3.65E-04 Multiple complex diseases ATP10A intron 17554300 rs1867511 chr15 26048579 A G 6.09E-05 Multiple complex diseases ATP10A intron 17554300 rs4906777 chr15 26049057 A G 4.81E-04 Multiple complex diseases ATP10A intron 17554300 rs12907525 chr15 26049694 C T 1.05E-04 Multiple complex diseases ATP10A intron 17554300 rs12591964 chr15 26053072 C T 9.13E-04 Multiple complex diseases ATP10A intron 17554300 rs11161223 chr15 26054222 T C 3.94E-04 Multiple complex diseases ATP10A intron 17554300 rs8041978 chr15 26054925 C T 2.86E-04 Multiple complex diseases ATP10A intron 17554300 rs1822749 chr15 26059592 C G 7.33E-04 Multiple complex diseases ATP10A intron 17554300 rs11629954 chr15 26060060 T C 3.77E-04 Alzheimer's disease (late onset) ATP10A intron 21379329 rs1373564 chr15 26061651 T C 3.39E-04 Alzheimer's disease (late onset) ATP10A intron 21379329 rs2197404 chr15 26070826 A G 3.18E-05 Bipolar disorder ATP10A intron 20451256 rs12904249 chr15 26071352 A G 4.66E-05 Bipolar disorder ATP10A intron 20451256 rs11630010 chr15 26079994 C G 7.27E-04 Multiple complex diseases ATP10A intron 17554300 rs2044313 chr15 26083867 C T 5.21E-05 Bipolar disorder ATP10A intron 20451256 rs2044313 chr15 26083867 C T 9.51E-04 Stroke ATP10A intron pha002887 rs11161239 chr15 26084811 A G 6.77E-05 Bipolar disorder ATP10A intron 20451256 rs7166725 chr15 26106233 A G 4.46E-04 Suicide attempts in bipolar disorder ATP10A intron 21423239 rs2076748 chr15 26109985 C T 6.78E-05 Bone mineral density ATP10A nearGene-5 19181680 rs1553896 chr15 26114300 C T 1.90E-05 Inflammation / / pha002897 rs4260026 chr15 26133384 G A 2.01E-05 Bone mineral density / / 19181680 rs4260026 chr15 26133384 G A 2.38E-05 Basophils / / pha003087 rs17116307 chr15 26136024 C T 7.88E-04 Rheumatoid arthritis / / 21452313 rs17116307 chr15 26136024 C T 0.000688533 Hypertension (early onset hypertension) / / 22479346 rs968332 chr15 26138015 G A 4.82E-04 Multiple complex diseases / / 17554300 rs17643428 chr15 26142750 G A 6.85E-04 Rheumatoid arthritis / / 21452313 rs17643428 chr15 26142750 G A 0.000493841 Hypertension (early onset hypertension) / / 22479346 rs1116367 chr15 26175282 C T 1.26E-04 Glycosylated haemoglobin levels LOC100128714 intron 17255346 rs7177666 chr15 26178683 C A 2.33E-04 Glycosylated haemoglobin levels LOC100128714 intron 17255346 rs7166365 chr15 26193097 C A 8.40E-06 Urinary metabolites LOC100128714 intron 21572414 rs938076 chr15 26232919 G A 3.72E-05 Osteoarthritis LOC100128714 intron 19508968 rs12437822 chr15 26260477 T C 3.58E-04 Amyotrophic Lateral Sclerosis LOC100128714 intron 17827064 rs17736307 chr15 26265595 A G 1.10E-04 White matter integrity LOC100128714 intron 22425255 rs7164409 chr15 26277079 A C 4.91E-04 Lung function (forced vital capacity) LOC100128714 intron 24023788 rs4906844 chr15 26277545 A G 1.00E-08 Cortical thickness LOC100128714 intron 21810643 rs4243759 chr15 26282446 G A 8.85E-04 Suicide attempts in bipolar disorder LOC100128714 intron 21423239 rs4243761 chr15 26282791 G T 0.0000513 5-fluorouracil and oxaliplatin combined induced haematologic in response to colorectal cancer treatment LOC100128714 intron 22310351 rs4243761 chr15 26282791 G T 0.0000513 Oxaliplatin induced haematologic in response to colorectal cancer treatment LOC100128714 intron 22310351 rs4243761 chr15 26282791 G T 6.37E-05 Formal thought disorder in schizophrenia LOC100128714 intron 22648509 rs4906849 chr15 26283851 C A,T 6.38E-04 Suicide attempts in bipolar disorder LOC100128714 intron 21423239 rs8026527 chr15 26288326 T C 1.01E-05 Insulin resistance LOC100128714 intron 21901158 rs6576507 chr15 26288394 T C 4.00E-07 Insulin resistance LOC100128714 intron 21901158 rs6576507 chr15 26288394 T C 7.00E-06 Insulin resistance LOC100128714 intron 21901158 rs1403590 chr15 26297624 C T 1.41E-05 Triglycerides / / pha003080 rs1403590 chr15 26297624 C T 8.37E-05 Lymphocyte counts / / pha003094 rs1403589 chr15 26297917 G A 8.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs1403588 chr15 26298028 C T 6.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs4906853 chr15 26299078 C A 2.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs8042941 chr15 26327466 C T 6.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs12591345 chr15 26331221 A G 4.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12438795 chr15 26333027 A G 3.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8024188 chr15 26336463 A G 2.91E-04 Celiac disease / / 23936387 rs2030600 chr15 26344449 C T 2.10E-05 Urinary metabolites / / 21572414 rs17116595 chr15 26355575 C T 2.92E-04 Multiple complex diseases / / 17554300 rs8036922 chr15 26356400 C T 1.60E-05 Urinary metabolites / / 21572414 rs7167127 chr15 26358387 C A 1.60E-05 Urinary metabolites / / 21572414 rs4906857 chr15 26359815 A C 8.97E-04 Acute lung injury / / 22295056 rs1916329 chr15 26360909 A G 8.97E-04 Acute lung injury / / 22295056 rs1880028 chr15 26361669 G A 8.54E-04 Acute lung injury LOC503519 intron 22295056 rs1880027 chr15 26361755 G T 8.54E-04 Acute lung injury LOC503519 intron 22295056 rs11856850 chr15 26362346 C G,T 8.54E-04 Acute lung injury LOC503519 intron 22295056 rs11856629 chr15 26362387 G A 8.54E-04 Acute lung injury LOC503519 intron 22295056 rs1561064 chr15 26381943 C A 2.10E-05 Urinary metabolites / / 21572414 rs8031119 chr15 26389687 T C 8.40E-04 Type 2 diabetes / / 17463246 rs487586 chr15 26416043 A G 5.67E-04 Age-related macular degeneration / / 22125219 rs1282810 chr15 26417594 C A 1.48E-04 Age-related macular degeneration / / 22125219 rs547843 chr15 26424047 C G,T 6.00E-07 Smoking behavior / / 22832964 rs7166151 chr15 26443944 T G 1.56E-04 Age-related macular degeneration / / 22125219 rs2078094 chr15 26449405 T C 2.98E-04 Multiple complex diseases / / 17554300 rs17116687 chr15 26464504 C A 2.72E-04 Age-related macular degeneration / / 22125219 rs28418686 chr15 26464654 T C 9.90E-04 Type 2 diabetes / / 17463246 rs4906871 chr15 26469513 T C 6.89E-04 Type 2 diabetes / / 17463246 rs7174716 chr15 26470256 G A 6.85E-04 Type 2 diabetes / / 17463246 rs1435831 chr15 26480712 C T 4.18E-05 Cholesterol / / pha003073 rs1435831 chr15 26480712 C T 6.31E-05 Cholesterol / / pha003078 rs7168022 chr15 26541717 C G 2.00E-05 Urinary metabolites / / 21572414 rs11161293 chr15 26602423 T G 8.11E-05 Blood Pressure / / pha003050 rs12440636 chr15 26602597 C A 6.45E-05 Blood Pressure / / pha003048 rs12440636 chr15 26602597 C A 7.34E-05 Blood Pressure / / pha003050 rs12915268 chr15 26604642 T C 8.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11853420 chr15 26605384 G A 1.26E-05 Blood Pressure / / pha003050 rs10431855 chr15 26613765 A G 0.000216 Salmonella-induced pyroptosis / / 22837397 rs11854437 chr15 26614130 G A 0.000349 Salmonella-induced pyroptosis / / 22837397 rs8035991 chr15 26618949 C T 9.27E-08 Schizophrenia / / 21926974 rs4078789 chr15 26620927 G A 6.68E-04 Acute lung injury / / 22295056 rs890510 chr15 26621500 T C 9.03E-04 Acute lung injury / / 22295056 rs11632951 chr15 26627762 A G 4.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11161304 chr15 26636672 A G 5.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7169488 chr15 26641589 T C 5.31E-35 Narcolepsy / / 19629137 rs12593142 chr15 26657600 T C 2.74E-05 Femoral neck bone geometry / / 22087292 rs2059637 chr15 26677809 A G 8.83E-04 Multiple complex diseases / / 17554300 rs6576576 chr15 26692455 G A 1.64E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1426891 chr15 26717893 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17117041 chr15 26719790 C T 1.50E-04 Multiple complex diseases / / 17554300 rs8027455 chr15 26738785 A C 7.76E-04 Alzheimer's disease / / 24755620 rs2114484 chr15 26754276 C G 8.72E-04 Type 2 diabetes / / 17463246 rs4523899 chr15 26766649 T C 1.00E-05 Major depressive disorder / / 22472876 rs1365591 chr15 26766746 A G 7.76E-04 Multiple complex diseases / / 17554300 rs1365593 chr15 26767183 A G 7.65E-06 Major depressive disorder / / 22472876 rs61996546 chr15 26804131 T C 3.00E-06 Response to methotrexate in juvenile idiopathic arthritis GABRB3 intron 24709693 rs8030011 chr15 26818362 G A 6.11E-05 Response to taxane treatment (placlitaxel) GABRB3 intron 23006423 rs8030011 chr15 26818362 G A 1.30E-05 Response to methotrexate in juvenile idiopathic arthritis GABRB3 intron 24709693 rs17646474 chr15 26829700 T C 2.19E-04 Blood pressure GABRB3 intron 17255346 rs8024723 chr15 26833362 G A 5.96E-05 Response to taxane treatment (placlitaxel) GABRB3 intron 23006423 rs17646555 chr15 26837651 G A 2.44E-04 Blood pressure GABRB3 intron 17255346 rs8036052 chr15 26840445 C A 3.28E-04 Blood pressure GABRB3 intron 17255346 rs8036052 chr15 26840445 C A 7.41E-06 Height GABRB3 intron pha003010 rs8036052 chr15 26840445 C A 9.13E-07 Height GABRB3 intron pha003011 rs4906888 chr15 26859531 G A 5.51E-06 Height GABRB3 intron pha003010 rs4906888 chr15 26859531 G A 2.04E-06 Height GABRB3 intron pha003011 rs1897356 chr15 26865535 A G 5.58E-05 Response to taxane treatment (placlitaxel) GABRB3 intron 23006423 rs17117177 chr15 26865632 C A 3.25E-04 Response to taxane treatment (placlitaxel) GABRB3 intron 23006423 rs17117178 chr15 26867109 T C 4.73E-04 Response to taxane treatment (placlitaxel) GABRB3 intron 23006423 rs2873027 chr15 26867409 C T 4.32E-04 Schizophrenia GABRB3 intron 19197363 rs2315906 chr15 26867573 A G 4.32E-04 Schizophrenia GABRB3 intron 19197363 rs7173713 chr15 26886154 C T 8.00E-05 Response to taxane treatment (placlitaxel) GABRB3 intron 23006423 rs7179684 chr15 26896104 G A 3.04E-04 Type 2 diabetes GABRB3 intron 17463246 rs890319 chr15 26913634 C T 6.64E-04 Bipolar disorder,schizoaffective GABRB3 intron 19567891 rs17561112 chr15 26922278 A G 2.05E-06 Glucose levels GABRB3 intron pha003058 rs17561112 chr15 26922278 A G 7.06E-05 Glucose levels GABRB3 intron pha003061 rs4906892 chr15 26923648 A G 4.35E-05 Glucose levels GABRB3 intron pha003058 rs10873637 chr15 26926765 A C 5.04E-08 Glucose levels GABRB3 intron pha003058 rs10873637 chr15 26926765 A C 2.68E-05 Glucose levels GABRB3 intron pha003061 rs17646890 chr15 26929276 T C 8.73E-05 Glucose levels GABRB3 intron pha003058 rs1000347 chr15 26929735 C T 8.55E-04 Multiple complex diseases GABRB3 intron 17554300 rs4906895 chr15 26953897 G A 2.60E-05 Urinary metabolites GABRB3 intron 21572414 rs718304 chr15 26956418 C T 2.86E-05 Response to radiotherapy in cancer (late toxicity) GABRB3 intron 24785509 rs718304 chr15 26956418 C T 4.06E-05 Response to radiotherapy in cancer (late toxicity) GABRB3 intron 24785509 rs8043440 chr15 26973086 T C 2.00E-06 Cognitive performance GABRB3 intron 19734545 rs919075 chr15 26974124 C T 2.13E-09 Metabolite levels GABRB3 intron 23281178 rs11631129 chr15 26977173 G C 2.13E-09 Metabolite levels GABRB3 intron 23281178 rs4906898 chr15 26978747 A T 6.54E-10 Metabolite levels GABRB3 intron 23281178 rs890318 chr15 26982378 T C 1.21E-10 Metabolite levels GABRB3 intron 23281178 rs10519567 chr15 26983850 G A 5.81E-04 Nicotine smoking GABRB3 intron 19268276 rs10152421 chr15 26985509 G A 5.28E-05 Partial epilepsies GABRB3 intron 20522523 rs8038471 chr15 26990651 G A 7.57E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) GABRB3 intron 23648065 rs12910337 chr15 26993243 C T 4.91E-10 Metabolite levels GABRB3 intron 23281178 rs8035503 chr15 26993659 G A 2.54E-04 Alzheimer's disease (late onset) GABRB3 intron 21379329 rs8035503 chr15 26993659 G A 2.70E-04 Cognitive impairment induced by topiramate GABRB3 intron 22091778 rs8035503 chr15 26993659 G A 4.91E-10 Metabolite levels GABRB3 intron 23281178 rs6576604 chr15 26995197 A T 2.94E-10 Metabolite levels GABRB3 intron 23281178 rs4243766 chr15 27000625 A T 3.07E-05 Pulmonary function GABRB3 intron 20010835 rs6576606 chr15 27007584 A G 9.46E-10 Metabolite levels GABRB3 intron 23281178 rs3212343 chr15 27009526 T C 2.09E-04 Alzheimer's disease (late onset) GABRB3 intron 21379329 rs3212343 chr15 27009526 T C 9.46E-10 Metabolite levels GABRB3 intron 23281178 rs3212335 chr15 27012141 C T 1.00E-06 Longevity GABRB3 intron 20834067 rs3212332 chr15 27013953 T A 9.46E-10 Metabolite levels GABRB3 intron 23281178 rs4392030 chr15 27022331 G C 6.16E-04 Type 2 diabetes / / 17463246 rs4392030 chr15 27022331 G C 9.36E-10 Metabolite levels / / 23281178 rs7182514 chr15 27024221 A G 8.31E-10 Metabolite levels / / 23281178 rs7165224 chr15 27024336 T C 8.31E-10 Metabolite levels / / 23281178 rs9324132 chr15 27028577 C G 9.05E-04 Type 2 diabetes / / 17463246 rs9324132 chr15 27028577 C G 5.38E-09 Metabolite levels / / 23281178 rs7174912 chr15 27028841 C G 1.56E-09 Metabolite levels / / 23281178 rs7170353 chr15 27031278 C T 7.77E-10 Metabolite levels / / 23281178 rs7497827 chr15 27033404 G T 1.03E-09 Metabolite levels / / 23281178 rs7183073 chr15 27034025 G T 1.14E-09 Metabolite levels / / 23281178 rs4906904 chr15 27034085 A G 8.20E-09 Metabolite levels / / 23281178 rs4906905 chr15 27034245 T A 1.14E-09 Metabolite levels / / 23281178 rs6576611 chr15 27034293 T A 1.35E-09 Metabolite levels / / 23281178 rs4906906 chr15 27034523 A C 9.46E-10 Metabolite levels / / 23281178 rs8028779 chr15 27034731 C T 1.14E-09 Metabolite levels / / 23281178 rs4632102 chr15 27035034 C T 1.14E-09 Metabolite levels / / 23281178 rs7168574 chr15 27035094 C T 8.90E-04 Sleep quality / / 23728906 rs4906908 chr15 27040082 T G 8.95E-05 Socioeconomic Factors / / pha003066 rs6576619 chr15 27046405 A T 5.20E-05 Personality dimensions / / 18957941 rs6576619 chr15 27046405 A T 1.14E-09 Metabolite levels / / 23281178 rs4517759 chr15 27048768 G A 8.35E-04 Taste perception / / 22132133 rs6576636 chr15 27083406 T C 2.15E-05 Cognitive impairment induced by topiramate / / 22091778 rs7496487 chr15 27083910 T C 2.33E-04 Multiple complex diseases / / 17554300 rs7403139 chr15 27095320 A G 1.37E-05 Cognitive impairment induced by topiramate / / 22091778 rs17561681 chr15 27178475 C T 1.43E-05 Multiple complex diseases GABRA5 intron 17554300 rs17561681 chr15 27178475 C T 2.52E-04 Bipolar disorder,schizoaffective GABRA5 intron 19567891 rs1864793 chr15 27183589 C T 9.07E-05 Serum metabolites GABRA5 intron 19043545 rs28551016 chr15 27185306 C T 8.86E-04 Substance dependence GABRA5 intron 21818250 rs10519587 chr15 27186086 T G 0.00042 Coronary artery calcification GABRA5 intron 23727086 rs140683 chr15 27188335 T A 7.66E-05 Serum metabolites GABRA5 intron 19043545 rs12185122 chr15 27200942 A G 1.20E-06 Urinary metabolites / / 21572414 rs12902711 chr15 27222824 G A 8.87E-04 Alzheimer's disease GABRG3 intron 22005930 rs12902711 chr15 27222824 G A 4.33E-05 Blood Pressure GABRG3 intron pha003043 rs7180500 chr15 27253179 C A 6.35E-05 Parkinson's disease GABRG3 intron 16252231 rs12050529 chr15 27274715 A C 8.90E-05 Aortic root size GABRG3 intron 21223598 rs17562125 chr15 27278539 A G 4.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GABRG3 intron 20877124 rs7177870 chr15 27279444 C T 6.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GABRG3 intron 20877124 rs17671490 chr15 27281090 G T 2.00E-04 Cognitive impairment induced by topiramate GABRG3 intron 22091778 rs7494955 chr15 27299817 T C 2.55E-05 Coronary Artery Disease GABRG3 intron 17634449 rs11852692 chr15 27303219 T C 1.00E-04 Cognitive impairment induced by topiramate GABRG3 intron 22091778 rs6606866 chr15 27305701 G A 4.10E-04 Cognitive impairment induced by topiramate GABRG3 intron 22091778 rs17648036 chr15 27311111 T C 3.31E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) GABRG3 intron 24023788 rs17648036 chr15 27311111 T C 3.65E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) GABRG3 intron 24023788 rs8035064 chr15 27316991 T C 2.07E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) GABRG3 intron 24023788 rs8035064 chr15 27316991 T C 6.29E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) GABRG3 intron 24023788 rs9330237 chr15 27317600 G A 2.30E-04 Cognitive impairment induced by topiramate GABRG3 intron 22091778 rs4398085 chr15 27341954 C T 5.10E-05 Bone mineral density (BMD),in women GABRG3 intron 20164292 rs4398085 chr15 27341954 C T 3.84E-04 Suicide attempts in bipolar disorder GABRG3 intron 21423239 rs12905022 chr15 27344750 G A 7.43E-04 Suicide attempts in bipolar disorder GABRG3 intron 21423239 rs7182802 chr15 27347206 C T 9.94E-06 Hearing function GABRG3 intron 21493956 rs6606873 chr15 27348819 C T 4.27E-04 Cognitive impairment induced by topiramate GABRG3 intron 22091778 rs4410042 chr15 27359563 A G 8.36E-04 Type 2 diabetes GABRG3 intron 17463246 rs12372994 chr15 27378701 T A 7.00E-04 Body mass index GABRG3 intron 21701565 rs4563018 chr15 27381140 G A 5.38E-04 Body mass index GABRG3 intron 21701565 rs208165 chr15 27391724 T C 3.24E-04 Major depressive disorder GABRG3 intron 22472876 rs1073136 chr15 27398550 A G 2.14E-05 Smoking initiation GABRG3 intron 24665060 rs7402147 chr15 27409995 G A 7.04E-05 Parkinson's disease GABRG3 intron 21738487 rs11639449 chr15 27415802 T G 8.67E-04 Type 2 diabetes GABRG3 intron 22158537 rs6606882 chr15 27419852 A G 7.61E-04 Type 2 diabetes GABRG3 intron 22158537 rs1378101 chr15 27423563 G A 6.70E-04 Heroin addiction GABRG3 intron 20520587 rs12594801 chr15 27451961 G A 1.20E-05 Urinary metabolites GABRG3 intron 21572414 rs997140 chr15 27453278 G A 3.06E-04 Smoking initiation GABRG3 intron 24665060 rs968671 chr15 27453908 A G 2.46E-06 Type 2 diabetes GABRG3 intron 17463246 rs968671 chr15 27453908 A G 2.56E-04 Multiple complex diseases GABRG3 intron 17554300 rs10519593 chr15 27457439 C A 2.44E-04 Type 2 diabetes GABRG3 intron 17463246 rs6422905 chr15 27458435 G A 1.00E-05 Urinary metabolites GABRG3 intron 21572414 rs17137668 chr15 27459196 C T 6.90E-05 Type 2 diabetes GABRG3 intron 17463246 rs17137668 chr15 27459196 C T 7.94E-04 Multiple complex diseases GABRG3 intron 17554300 rs9972311 chr15 27459234 G A 9.25E-04 Aortic root size GABRG3 intron 21223598 rs8036270 chr15 27463874 A G 0.0000868 Tuberculosis with early age of onset GABRG3 intron 22551897 rs7173587 chr15 27464852 C T 6.45E-04 Cognitive impairment induced by topiramate GABRG3 intron 22091778 rs17137734 chr15 27507773 C T 9.00E-06 Corneal curvature GABRG3 intron 22969067 rs10152293 chr15 27510350 A C 9.59E-06 Corneal curvature GABRG3 intron 22969067 rs10152133 chr15 27510522 G A 9.31E-06 Corneal curvature GABRG3 intron 22969067 rs10152135 chr15 27510537 G T 9.35E-06 Corneal curvature GABRG3 intron 22969067 rs17648940 chr15 27516568 G A 1.41E-04 Response to cholinesterase inhibitors in Alzheimer's disease GABRG3 intron 23374588 rs7497939 chr15 27557532 G T 4.98E-07 Hepatitis B GABRG3 intron 24162738 rs9707971 chr15 27608150 A G 8.29E-05 Alcohol consumption GABRG3 intron 23743675 rs10083616 chr15 27609171 G A 8.20E-05 Alcohol consumption GABRG3 intron 23743675 rs28668284 chr15 27609193 G A 7.89E-05 Alcohol consumption GABRG3 intron 23743675 rs6497269 chr15 27706279 G A 2.80E-267 Iris color GABRG3 intron 18252221 rs74006954 chr15 27712644 G A 3.00E-07 Alzheimer's disease (cognitive decline) GABRG3 intron 23535033 rs12899403 chr15 27747635 G T 5.20E-04 Tourette syndrome GABRG3 intron 22889924 rs3101640 chr15 27769859 C T 1.54E-10 Narcolepsy GABRG3 intron 19629137 rs140679 chr15 27772676 C T 2.10E-05 Urinary metabolites GABRG3 cds-synon 21572414 rs3097490 chr15 27773791 G A 6.70E-05 Malaria GABRG3 intron 19465909 rs3097489 chr15 27776043 T C 8.00E-05 Iris characteristics GABRG3 intron 21835309 rs3101618 chr15 27825173 G A 4.37E-04 Alzheimer's disease / / 22005930 rs3101615 chr15 27827203 C T 4.50E-04 Alzheimer's disease / / 22005930 rs3101614 chr15 27827448 T G 5.19E-04 Alzheimer's disease / / 22005930 rs3098538 chr15 27827537 C T 4.07E-04 Alzheimer's disease / / 22005930 rs3101613 chr15 27828301 C T 4.79E-04 Alzheimer's disease / / 22005930 rs3097464 chr15 27831212 T G 4.09E-04 Alzheimer's disease / / 22005930 rs3098535 chr15 27831417 C A 2.46E-04 Alzheimer's disease / / 22005930 rs3097463 chr15 27831506 T C 4.41E-04 Alzheimer's disease / / 22005930 rs3097462 chr15 27831591 A G 4.44E-04 Alzheimer's disease / / 22005930 rs3098534 chr15 27831684 C T 4.45E-04 Alzheimer's disease / / 22005930 rs3098533 chr15 27832367 C T 4.41E-04 Alzheimer's disease / / 22005930 rs1477812 chr15 27833153 G A 4.38E-04 Alzheimer's disease / / 22005930 rs1477813 chr15 27833238 T C 4.52E-04 Alzheimer's disease / / 22005930 rs3097461 chr15 27833502 G T 4.76E-04 Alzheimer's disease / / 22005930 rs1079043 chr15 27841836 T C 4.76E-04 Alzheimer's disease / / 22005930 rs3097438 chr15 27871603 A C 8.31E-05 Blood pressure / / 17255346 rs7173054 chr15 27877061 C A 2.61E-05 Dental caries / / 21940522 rs17650265 chr15 27878591 T A 5.96E-04 Type 2 diabetes / / 17463246 rs16950272 chr15 27878901 C A 6.49E-04 Type 2 diabetes / / 17463246 rs17565175 chr15 27882697 C T 5.24E-04 Multiple complex diseases / / 17554300 rs1841875 chr15 27890359 T C 7.50E-05 Vitiligo / / 22561518 rs1841875 chr15 27890359 T C 3.86E-04 Tourette syndrome / / 22889924 rs1968813 chr15 27898527 A C 6.12E-05 Blood Pressure / / pha003043 rs3097535 chr15 27910635 A G 8.56E-05 Blood Pressure / / pha003043 rs3097534 chr15 27910697 C T 8.20E-06 Aortic stiffness / / 22068335 rs12591822 chr15 27911483 T C 2.20E-06 Urinary metabolites / / 21572414 rs17746385 chr15 27911949 C G 9.08E-04 Multiple complex diseases / / 17554300 rs1382054 chr15 27913990 G T 6.38E-05 Blood Pressure / / pha003043 rs1603785 chr15 27940159 A G 5.51E-04 Type 2 diabetes / / 17463246 rs7182551 chr15 27948277 G A 2.62E-06 Adiponectin levels / / 20887962 rs1107267 chr15 27971639 G A 1.74E-12 Common traits (Other) / / 20585627 rs1107267 chr15 27971639 G A 4.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12908103 chr15 27988932 G A 3.10E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4778117 chr15 27992008 T C 8.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17565841 chr15 27997247 G A 3.00E-06 Parkinson's disease (age of onset) / / 19772629 rs989869 chr15 28006306 C T 1.77E-05 Prion diseases OCA2 intron 22210626 rs11637518 chr15 28009556 A G 9.98E-04 Type 2 diabetes OCA2 intron 17463246 rs1498519 chr15 28011651 G T 4.00E-08 Skin sensitivity to sun OCA2 intron 18488028 rs1498519 chr15 28011651 G T 1.70E-07 Common traits (Other) OCA2 intron 20585627 rs3947367 chr15 28014104 C T 4.50E-05 Prion diseases OCA2 intron 22210626 rs12592078 chr15 28017436 T C 0.0006365 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) OCA2 intron 23233654 rs12592078 chr15 28017436 T C 6.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) OCA2 intron 23233662 rs17565953 chr15 28018655 G T 1.15E-11 Common traits (Other) OCA2 intron 20585627 rs11631195 chr15 28021888 G A 5.37E-10 Common traits (Other) OCA2 intron 20585627 rs2279727 chr15 28021961 T G 0.0007437 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) OCA2 intron 23233654 rs2279727 chr15 28021961 T G 7.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) OCA2 intron 23233662 rs904373 chr15 28026935 G A 0.0006587 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) OCA2 intron 23233654 rs904373 chr15 28026935 G A 6.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) OCA2 intron 23233662 rs750358 chr15 28028248 A G 0.0006624 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) OCA2 intron 23233654 rs750358 chr15 28028248 A G 6.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) OCA2 intron 23233662 rs3930739 chr15 28040342 C T 4.17E-12 Common traits (Other) OCA2 intron 20585627 rs4778180 chr15 28041803 C T 0.0007243 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) OCA2 intron 23233654 rs4778180 chr15 28041803 C T 7.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) OCA2 intron 23233662 rs17674023 chr15 28042154 G A 0.0005972 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) OCA2 intron 23233654 rs17674023 chr15 28042154 G A 5.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) OCA2 intron 23233662 rs12592159 chr15 28042432 C T 0.0001927 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) OCA2 intron 23233654 rs12592159 chr15 28042432 C T 1.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) OCA2 intron 23233662 rs8036718 chr15 28053557 A G 9.38E-04 HIV-1 viral setpoint OCA2 intron 17641165 rs8036718 chr15 28053557 A G 2.34E-11 Common traits (Other) OCA2 intron 20585627 rs6497238 chr15 28053778 C T 1.92E-08 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) OCA2 intron 17982456 rs6497238 chr15 28053778 C T 3.72E-11 Common traits (Other) OCA2 intron 20585627 rs1846326 chr15 28063878 A T 7.32E-04 Suicide attempts in bipolar disorder OCA2 intron 21423239 rs2311469 chr15 28069068 T G 6.10E-04 HIV-1 viral setpoint OCA2 intron 17641165 rs2311469 chr15 28069068 T G 4.47E-09 Common traits (Other) OCA2 intron 20585627 rs4547287 chr15 28071933 C T 0.0000763 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) OCA2 intron 23233654 rs4547287 chr15 28071933 C T 7.63E-05 Methotrexate clearance (acute lymphoblastic leukemia) OCA2 intron 23233662 rs1553110 chr15 28071960 G A 0.0000786 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) OCA2 intron 23233654 rs1553110 chr15 28071960 G A 7.86E-05 Methotrexate clearance (acute lymphoblastic leukemia) OCA2 intron 23233662 rs4778189 chr15 28072228 A G 5.72E-04 HIV-1 viral setpoint OCA2 intron 17641165 rs4778189 chr15 28072228 A G 3.72E-09 Common traits (Other) OCA2 intron 20585627 rs7183532 chr15 28075150 G A 0.0000952 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) OCA2 intron 23233654 rs7183532 chr15 28075150 G A 9.52E-05 Methotrexate clearance (acute lymphoblastic leukemia) OCA2 intron 23233662 rs8030664 chr15 28079860 G A 0.0000901 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) OCA2 intron 23233654 rs8030664 chr15 28079860 G A 9.01E-05 Methotrexate clearance (acute lymphoblastic leukemia) OCA2 intron 23233662 rs4778192 chr15 28080061 C T 3.79E-04 HIV-1 viral setpoint OCA2 intron 17641165 rs4778192 chr15 28080061 C T 1.73E-05 AIDS progression OCA2 intron 19115949 rs4778192 chr15 28080061 C T 2.19E-09 Common traits (Other) OCA2 intron 20585627 rs8035334 chr15 28080367 A G 9.55E-09 Common traits (Other) OCA2 intron 20585627 rs11855481 chr15 28082218 G A 0.0000664 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) OCA2 intron 23233654 rs11855481 chr15 28082218 G A 6.64E-05 Methotrexate clearance (acute lymphoblastic leukemia) OCA2 intron 23233662 rs12440423 chr15 28097085 C T 9.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) OCA2 intron 23233662 rs7177529 chr15 28111746 C T 9.65E-04 Type 2 diabetes OCA2 intron 17463246 rs2594895 chr15 28141304 G A 6.62E-04 Type 2 diabetes OCA2 intron 17463246 rs2594897 chr15 28145050 T C 9.21E-04 HIV-1 viral setpoint OCA2 intron 17641165 rs2594897 chr15 28145050 T C 4.47E-07 Common traits (Other) OCA2 intron 20585627 rs2703978 chr15 28147206 T C 9.12E-07 Common traits (Other) OCA2 intron 20585627 rs2594909 chr15 28151062 C T 5.37E-08 Common traits (Other) OCA2 intron 20585627 rs1584407 chr15 28157259 G T 1.10E-07 Hair,eye and skin pigmentation OCA2 intron 17952075 rs1584407 chr15 28157259 G T 4.00E-10 Skin sensitivity to sun OCA2 intron 18488028 rs2703936 chr15 28158075 C A 8.71E-08 Common traits (Other) OCA2 intron 20585627 rs1800416 chr15 28171294 T G 3.07E-21 Multiple complex diseases OCA2 cds-synon 17554300 rs977588 chr15 28179306 C A 2.82E-09 Common traits (Other) OCA2 intron 20585627 rs977588 chr15 28179306 C A 2.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OCA2 intron 20877124 rs977588 chr15 28179306 C A 7.98E-07 Post-operative nausea and vomiting OCA2 intron 21694509 rs977589 chr15 28179603 C T 1.74E-14 Common traits (Other) OCA2 intron 20585627 rs2703952 chr15 28181981 T G 3.70E-12 Hair,eye and skin pigmentation OCA2 intron 17952075 rs2703952 chr15 28181981 T G 2.80E-15 Skin sensitivity to sun OCA2 intron 18488028 rs2703952 chr15 28181981 T G 8.71E-18 Common traits (Other) OCA2 intron 20585627 rs2311843 chr15 28183354 C T 8.39E-05 Multiple complex diseases OCA2 intron 17554300 rs2594935 chr15 28185038 G A 1.45E-10 Iris color OCA2 intron 18252221 rs2594935 chr15 28185038 G A 1.20E-11 Skin sensitivity to sun OCA2 intron 18488028 rs2594935 chr15 28185038 G A 5.89E-20 Common traits (Other) OCA2 intron 20585627 rs7170451 chr15 28192224 A G 3.31E-27 Common traits (Other) OCA2 intron 20585627 rs7173419 chr15 28196821 T C 1.00E-07 Eye color OCA2 intron 23548203 rs728405 chr15 28199853 C A 1.10E-09 Hair,eye and skin pigmentation OCA2 intron 17952075 rs728405 chr15 28199853 C A 3.75E-09 Iris color OCA2 intron 18252221 rs728405 chr15 28199853 C A 4.70E-18 Skin sensitivity to sun OCA2 intron 18488028 rs728405 chr15 28199853 C A 1.23E-20 Common traits (Other) OCA2 intron 20585627 rs12593141 chr15 28205100 G A 2.20E-05 Urinary metabolites OCA2 intron 21572414 rs4778214 chr15 28205564 A G 9.00E-06 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) OCA2 intron 24023788 rs1800411 chr15 28211921 G A 1.05E-23 Common traits (Other) OCA2 cds-synon 20585627 rs1448488 chr15 28216857 C T 1.20E-12 Skin sensitivity to sun OCA2 intron 18488028 rs1448488 chr15 28216857 C T 6.92E-24 Common traits (Other) OCA2 intron 20585627 rs4778220 chr15 28221138 G A 1.20E-07 Hair,eye and skin pigmentation OCA2 intron 17952075 rs4778220 chr15 28221138 G A 4.10E-14 Skin sensitivity to sun OCA2 intron 18488028 rs4778220 chr15 28221138 G A 2.63E-21 Common traits (Other) OCA2 intron 20585627 rs12910433 chr15 28228644 G A 3.98E-23 Common traits (Other) OCA2 intron 20585627 rs12910433 chr15 28228644 G A 8.26E-05 Socioeconomic Factors OCA2 intron pha003067 rs1900758 chr15 28230097 C T 5.13E-23 Common traits (Other) OCA2 intron 20585627 rs1037208 chr15 28231357 G T 5.60E-05 Skin pigmentation OCA2 intron 17999355 rs1037208 chr15 28231357 G T 1.26E-20 Common traits (Other) OCA2 intron 20585627 rs1800404 chr15 28235773 C T 3.39E-15 Common traits (Other) OCA2 cds-synon 20585627 rs7178315 chr15 28237909 T C 6.31E-15 Common traits (Other) OCA2 intron 20585627 rs17567131 chr15 28251513 G A 8.84E-04 Alcohol consumption (maxi-drinks) OCA2 intron 24277619 rs4640131 chr15 28259863 A G 8.84E-04 Alcohol consumption (maxi-drinks) OCA2 intron 24277619 rs1800401 chr15 28260053 G A 1.62E-07 Common traits (Other) OCA2 missense 20585627 rs12438490 chr15 28260309 C T 2.10E-05 Urinary metabolites OCA2 intron 21572414 rs12438490 chr15 28260309 C T 1.02E-07 Esophageal cancer (squamous cell) OCA2 intron 22960999 rs2871875 chr15 28264854 A G 2.69E-13 Common traits (Other) OCA2 intron 20585627 rs2305252 chr15 28267338 C T 3.83E-04 Hemoglobin concentration OCA2 intron 20534544 rs749846 chr15 28268990 C A 2.95E-35 Common traits (Other) OCA2 intron 20585627 rs3794604 chr15 28272065 C T 8.50E-12 Iris color OCA2 intron 18252221 rs3794604 chr15 28272065 C T 4.27E-24 Common traits (Other) OCA2 intron 20585627 rs3829488 chr15 28276686 G T 6.28E-06 Hemoglobin concentration OCA2 intron 20534544 rs3829488 chr15 28276686 G T 2.22E-05 Hypertension (early onset hypertension) OCA2 intron 22479346 rs13329466 chr15 28276762 G A 7.94E-10 Common traits (Other) OCA2 intron 20585627 rs7176759 chr15 28278606 C G 4.14E-04 Multiple complex diseases OCA2 intron 17554300 rs4238497 chr15 28280835 A G 0.0002 Migraine OCA2 intron 22678113 rs4778232 chr15 28281765 C T 2.47E-13 Iris color OCA2 intron 18252221 rs4778232 chr15 28281765 C T 1.78E-39 Common traits (Other) OCA2 intron 20585627 rs1448485 chr15 28282741 G T 7.37E-04 Multiple complex diseases OCA2 intron 17554300 rs1448485 chr15 28282741 G T 3.39E-08 Iris color OCA2 intron 18252221 rs1448485 chr15 28282741 G T 2.63E-34 Common traits (Other) OCA2 intron 20585627 rs16950821 chr15 28283507 G A 3.86E-04 Multiple complex diseases OCA2 intron 17554300 rs16950821 chr15 28283507 G A 2.04E-30 Common traits (Other) OCA2 intron 20585627 rs8024968 chr15 28283689 C T 4.26E-04 Multiple complex diseases OCA2 intron 17554300 rs8024968 chr15 28283689 C T 1.48E-11 Iris color OCA2 intron 18252221 rs8024968 chr15 28283689 C T 9.55E-31 Common traits (Other) OCA2 intron 20585627 rs1470608 chr15 28288121 G T 3.24E-43 Common traits (Other) OCA2 intron 20585627 rs6497253 chr15 28288549 G A 3.39E-44 Common traits (Other) OCA2 intron 20585627 rs7170869 chr15 28288748 A G 1.60E-08 Skin sensitivity to sun OCA2 intron 18488028 rs7170869 chr15 28288748 A G 9.77E-43 Common traits (Other) OCA2 intron 20585627 rs1597196 chr15 28294922 G T 9.10E-18 Iris color OCA2 intron 18252221 rs1597196 chr15 28294922 G T 1.32E-32 Common traits (Other) OCA2 intron 20585627 rs11857677 chr15 28299608 C T 1.54E-04 Sudden cardiac arrest OCA2 intron 21658281 rs7496968 chr15 28310974 A G 1.32E-10 Common traits (Other) OCA2 intron 20585627 rs7496968 chr15 28310974 A G 0.000194119 Hypertension (early onset hypertension) OCA2 intron 22479346 rs7179994 chr15 28323770 A G 5.35E-13 Iris color OCA2 intron 18252221 rs7179994 chr15 28323770 A G 8.91E-29 Common traits (Other) OCA2 intron 20585627 rs7174027 chr15 28328765 G A 7.26E-10 Black vs. red hair color OCA2 intron 18483556 rs4778138 chr15 28335820 A G 2.00E-24 Black vs. blond hair color OCA2 intron 18483556 rs4778138 chr15 28335820 A G 6.00E-20 Black vs. red hair color OCA2 intron 18483556 rs4778138 chr15 28335820 A G 9.30E-36 Hair,eye and skin pigmentation OCA2 intron 17952075 rs4778138 chr15 28335820 A G 5.40E-211 Iris color OCA2 intron 18252221 rs4778138 chr15 28335820 A G 2.00E-24 Black vs. red hair color OCA2 intron 18483556 rs4778138 chr15 28335820 A G 8.80E-32 Skin sensitivity to sun OCA2 intron 18488028 rs4778241 chr15 28338713 A C 4.10E-56 Hair,eye and skin pigmentation OCA2 intron 17952075 rs4778241 chr15 28338713 A C 3.66E-19 Iris color OCA2 intron 18252221 rs4778241 chr15 28338713 A C 8.40E-51 Skin sensitivity to sun OCA2 intron 18488028 rs7495174 chr15 28344238 A G 3.20E-36 Hair,eye and skin pigmentation OCA2 intron 17952075 rs7495174 chr15 28344238 A G 1.40E-239 Iris color OCA2 intron 18252221 rs7495174 chr15 28344238 A G 1.54E-10 Black vs. red hair color OCA2 intron 18483556 rs7495174 chr15 28344238 A G 2.70E-56 Skin sensitivity to sun OCA2 intron 18488028 rs7495174 chr15 28344238 A G 1.45E-08 Brown eye color OCA2 intron 23486544 rs7495174 chr15 28344238 A G 4.51E-09 Eye color OCA2 intron 23486544 rs7495174 chr15 28344238 A G 7.43E-04 Alzheimer's disease OCA2 intron 24755620 rs1129038 chr15 28356859 C T 2.58E-08 Melanoma HERC2 UTR-3 21926416 rs1129038 chr15 28356859 C T 4.00E-08 Vitiligo HERC2 UTR-3 22561518 rs1129038 chr15 28356859 C T 3.61E-31 Brown eye color HERC2 UTR-3 23486544 rs1129038 chr15 28356859 C T 4.99E-37 Eye color HERC2 UTR-3 23486544 rs12593929 chr15 28359258 G A 1.01E-09 Eye color HERC2 intron 23486544 rs12593929 chr15 28359258 G A 1.94E-09 Brown eye color HERC2 intron 23486544 rs12913832 chr15 28365618 A G 1.00E-77 Black vs. red hair color HERC2 intron 18483556 rs12913832 chr15 28365618 A G 4.00E-103 Black vs. red hair color HERC2 intron 18483556 rs12913832 chr15 28365618 A G 1.00E-300 Eye color HERC2 intron 20463881 rs12913832 chr15 28365618 A G 1.00E-300 Eye color HERC2 intron 20585627 rs12913832 chr15 28365618 A G 3.00E-52 Eye color HERC2 intron 20585627 rs12913832 chr15 28365618 A G 9.00E-88 Hair color HERC2 intron 20585627 rs12913832 chr15 28365618 A G 4.31E-08 Melanoma HERC2 intron 21926416 rs12913832 chr15 28365618 A G 4.50E-05 Vitiligo HERC2 intron 22561518 rs12913832 chr15 28365618 A G 3.61E-31 Brown eye color HERC2 intron 23486544 rs12913832 chr15 28365618 A G 4.99E-37 Eye color HERC2 intron 23486544 rs12913832 chr15 28365618 A G 1.00E-158 Eye color HERC2 intron 23548203 rs12913832 chr15 28365618 A G 1.00E-167 Hair color HERC2 intron 23548203 rs12913832 chr15 28365618 A G 1.00E-177 Eye color HERC2 intron 23548203 rs12913832 chr15 28365618 A G 1.00E-22 Tanning HERC2 intron 23548203 rs12913832 chr15 28365618 A G 2.10E-05 Sunburns HERC2 intron 23548203 rs7183877 chr15 28365733 C A 2.20E-72 Hair,eye and skin pigmentation HERC2 intron 17952075 rs7183877 chr15 28365733 C A 6.18E-11 Iris color HERC2 intron 18252221 rs7183877 chr15 28365733 C A 1.50E-107 Skin sensitivity to sun HERC2 intron 18488028 rs11635884 chr15 28368969 C T 5.01E-20 Common traits (Other) HERC2 intron 20585627 rs3935591 chr15 28374012 T C 1.44E-13 Eye color HERC2 intron 23486544 rs3935591 chr15 28374012 T C 6.23E-12 Brown eye color HERC2 intron 23486544 rs11636232 chr15 28386626 C T 1.98E-12 Black vs. red hair color HERC2 cds-synon 18483556 rs11636232 chr15 28386626 C T 1.28E-10 Eye color HERC2 cds-synon 23486544 rs11636232 chr15 28386626 C T 4.27E-09 Brown eye color HERC2 cds-synon 23486544 rs6497287 chr15 28440287 T C 5.05E-15 Iris color HERC2 intron 18252221 rs6497287 chr15 28440287 T C 5.20E-05 Prostate cancer(aggressive) HERC2 intron 21467234 rs8041209 chr15 28443658 G T 2.03E-05 Multiple complex diseases HERC2 intron 17554300 rs8041209 chr15 28443658 G T 6.60E-22 Iris color HERC2 intron 18252221 rs8028689 chr15 28488888 T C 6.06E-04 Multiple complex diseases HERC2 intron 17554300 rs8028689 chr15 28488888 T C 7.30E-38 Hair,eye and skin pigmentation HERC2 intron 17952075 rs8028689 chr15 28488888 T C 1.22E-21 Iris color HERC2 intron 18252221 rs8028689 chr15 28488888 T C 5.66E-08 Black vs. red hair color HERC2 intron 18483556 rs8028689 chr15 28488888 T C 3.60E-58 Skin sensitivity to sun HERC2 intron 18488028 rs8028689 chr15 28488888 T C 1.11E-07 Eye color HERC2 intron 23118974 rs8028689 chr15 28488888 T C 7.00E-06 Multiple myeloma (IgH translocation) HERC2 intron 23502783 rs2240204 chr15 28494032 G A 7.30E-38 Hair,eye and skin pigmentation HERC2 intron 17952075 rs2240204 chr15 28494032 G A 7.15E-11 Iris color HERC2 intron 18252221 rs2240204 chr15 28494032 G A 3.60E-58 Skin sensitivity to sun HERC2 intron 18488028 rs6497292 chr15 28496195 A G 3.99E-04 Multiple complex diseases HERC2 intron 17554300 rs6497292 chr15 28496195 A G 8.16E-14 Iris color HERC2 intron 18252221 rs2240202 chr15 28510895 G A 2.23E-22 Iris color HERC2 intron 18252221 rs916977 chr15 28513364 T C 1.00E-43 Iris color HERC2 intron 18252221 rs916977 chr15 28513364 T C 5.42E-08 Black vs. red hair color HERC2 intron 18483556 rs916977 chr15 28513364 T C 3.29E-16 Eye color HERC2 intron 23486544 rs916977 chr15 28513364 T C 6.35E-14 Brown eye color HERC2 intron 23486544 rs916976 chr15 28513513 A G 8.17E-05 Asthma HERC2 intron pha003128 rs8039195 chr15 28516084 C T 8.80E-99 Hair,eye and skin pigmentation HERC2 intron 17952075 rs8039195 chr15 28516084 C T 1.78E-23 Iris color HERC2 intron 18252221 rs8039195 chr15 28516084 C T 5.42E-08 Black vs. red hair color HERC2 intron 18483556 rs8039195 chr15 28516084 C T 4.00E-150 Skin sensitivity to sun HERC2 intron 18488028 rs8039195 chr15 28516084 C T 2.77E-18 Eye color HERC2 intron 23118974 rs16950979 chr15 28520506 A G 7.30E-38 Hair,eye and skin pigmentation HERC2 intron 17952075 rs16950979 chr15 28520506 A G 7.02E-11 Iris color HERC2 intron 18252221 rs16950979 chr15 28520506 A G 3.80E-58 Skin sensitivity to sun HERC2 intron 18488028 rs2346050 chr15 28522684 T C 6.32E-19 Iris color HERC2 intron 18252221 rs16950987 chr15 28526228 G A 7.30E-38 Hair,eye and skin pigmentation HERC2 intron 17952075 rs16950987 chr15 28526228 G A 8.28E-11 Iris color HERC2 intron 18252221 rs16950987 chr15 28526228 G A 3.60E-58 Skin sensitivity to sun HERC2 intron 18488028 rs16950987 chr15 28526228 G A 1.12E-08 Eye color HERC2 intron 23118974 rs1667394 chr15 28530182 C T 1.00E-241 Blue vs. brown eyes HERC2 intron 17952075 rs1667394 chr15 28530182 C T 2.00E-53 Blue vs. green eyes HERC2 intron 17952075 rs1667394 chr15 28530182 C T 6.00E-35 Blond vs. brown hair color HERC2 intron 17952075 rs1667394 chr15 28530182 C T 8.47E-31 Iris color HERC2 intron 18252221 rs1667394 chr15 28530182 C T 6.10E-173 Skin sensitivity to sun HERC2 intron 18488028 rs1667394 chr15 28530182 C T 2.00E-20 Eye color HERC2 intron 23118974 rs1667394 chr15 28530182 C T 4.92E-16 Eye color HERC2 intron 23486544 rs1667394 chr15 28530182 C T 7.95E-14 Brown eye color HERC2 intron 23486544 rs12592730 chr15 28530359 G A 2.58E-22 Iris color HERC2 intron 18252221 rs1635168 chr15 28535266 A C 5.90E-28 Hair,eye and skin pigmentation HERC2 intron 17952075 rs1635168 chr15 28535266 A C 1.48E-11 Iris color HERC2 intron 18252221 rs1635168 chr15 28535266 A C 1.40E-44 Skin sensitivity to sun HERC2 intron 18488028 rs1635168 chr15 28535266 A C 1.17E-09 Eye color HERC2 intron 23118974 rs8033165 chr15 29006093 C T 2.00E-12 Black vs. red hair color / / 18483556 rs8033165 chr15 29006093 C T 5.00E-11 Black vs. red hair color / / 18483556 rs1828774 chr15 29013164 G A 9.00E-05 Multiple complex diseases / / 17554300 rs1565407 chr15 29236593 C T 3.90E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers APBA2 intron 21775533 rs902272 chr15 29236675 C T 1.40E-05 Urinary metabolites APBA2 intron 21572414 rs17680945 chr15 29239817 G A 2.00E-06 Temperament APBA2 intron 22832960 rs16954821 chr15 29247534 A G 2.50E-04 Multiple complex diseases APBA2 intron 17554300 rs937048 chr15 29283766 C T 2.18E-04 Type 2 diabetes APBA2 intron 17463246 rs937050 chr15 29284059 C T 2.60E-04 Type 2 diabetes APBA2 intron 17463246 rs10519643 chr15 29288420 T C 3.86E-04 Type 2 diabetes APBA2 intron 17463246 rs17681130 chr15 29301571 A G 1.40E-05 Urinary metabolites APBA2 intron 21572414 rs7181045 chr15 29314772 G A 3.63E-07 Common traits (Other) APBA2 intron 20585627 rs1873283 chr15 29338502 C T 6.00E-06 Response to mTOR inhibitor (rapamycin) APBA2 intron 24009623 rs8037972 chr15 29386593 G A 3.45E-05 Alcohol consumption APBA2 intron 23953852 rs4779804 chr15 29413095 T G 8.76E-04 Amyotrophic Lateral Sclerosis FAM189A1 UTR-3 17362836 rs2636066 chr15 29420381 C T 8.52E-04 Amyotrophic Lateral Sclerosis FAM189A1 intron 17362836 rs2636061 chr15 29424755 A G 2.45E-05 HIV-1 viral setpoint FAM189A1 intron 22174851 rs2636061 chr15 29424755 A G 7.00E-06 Obesity-related traits FAM189A1 intron 23251661 rs7167473 chr15 29429017 G C 2.00E-05 Urinary metabolites FAM189A1 intron 21572414 rs1877910 chr15 29429088 G A 1.50E-06 Urinary metabolites FAM189A1 intron 21572414 rs7166867 chr15 29443122 G A 6.31E-04 Acute lung injury FAM189A1 intron 22295056 rs7167234 chr15 29443267 G A 8.36E-04 Acute lung injury FAM189A1 intron 22295056 rs7176970 chr15 29443314 T C 8.36E-04 Acute lung injury FAM189A1 intron 22295056 rs7167438 chr15 29443392 G A 9.42E-04 Acute lung injury FAM189A1 intron 22295056 rs7177161 chr15 29443426 T C 7.32E-04 Acute lung injury FAM189A1 intron 22295056 rs12915679 chr15 29443548 T C 8.30E-04 Acute lung injury FAM189A1 intron 22295056 rs3764207 chr15 29443707 C T 8.53E-04 Acute lung injury FAM189A1 intron 22295056 rs3764210 chr15 29443857 A C 7.40E-04 Acute lung injury FAM189A1 intron 22295056 rs3764211 chr15 29443949 A G 8.80E-04 Acute lung injury FAM189A1 cds-synon 22295056 rs12439508 chr15 29444078 A G 5.99E-04 Acute lung injury FAM189A1 intron 22295056 rs12440302 chr15 29444156 T C 7.30E-04 Acute lung injury FAM189A1 intron 22295056 rs12910901 chr15 29462834 C A 5.04E-05 Body Mass Index FAM189A1 intron pha003006 rs12910901 chr15 29462834 C A 6.98E-05 Body Mass Index FAM189A1 intron pha003020 rs11634079 chr15 29479038 G A 8.38E-04 Response to cytadine analogues (cytosine arabinoside) FAM189A1 intron 24483146 rs11638382 chr15 29496888 C T 8.03E-05 Response to cytadine analogues (cytosine arabinoside) FAM189A1 intron 24483146 rs12911875 chr15 29517620 A G 4.38E-04 Depression (quantitative trait) FAM189A1 intron 20800221 rs1445490 chr15 29518889 C T 2.62E-04 Depression (quantitative trait) FAM189A1 intron 20800221 rs8182074 chr15 29519164 G C 8.50E-05 Depression (quantitative trait) FAM189A1 intron 20800221 rs767035 chr15 29519813 A G 2.84E-04 Depression (quantitative trait) FAM189A1 intron 20800221 rs11635026 chr15 29521213 A C 2.95E-04 Depression (quantitative trait) FAM189A1 intron 20800221 rs11635074 chr15 29521322 A T 9.25E-04 Multiple complex diseases FAM189A1 intron 17554300 rs11635074 chr15 29521322 A T 2.85E-04 Depression (quantitative trait) FAM189A1 intron 20800221 rs4441240 chr15 29523475 C T 2.87E-04 Depression (quantitative trait) FAM189A1 intron 20800221 rs17681991 chr15 29523992 T C 1.30E-04 Depression (quantitative trait) FAM189A1 intron 20800221 rs12903523 chr15 29525591 G A 1.30E-04 Depression (quantitative trait) FAM189A1 intron 20800221 rs12912628 chr15 29525855 T C 1.31E-04 Depression (quantitative trait) FAM189A1 intron 20800221 rs11071543 chr15 29526279 C T 3.42E-04 Depression (quantitative trait) FAM189A1 intron 20800221 rs17653077 chr15 29526725 T C 5.21E-04 Response to cytadine analogues (cytosine arabinoside) FAM189A1 intron 24483146 rs11634635 chr15 29526921 T A 2.36E-04 Depression (quantitative trait) FAM189A1 intron 20800221 rs11637568 chr15 29527212 G C 2.35E-04 Depression (quantitative trait) FAM189A1 intron 20800221 rs12324268 chr15 29528229 C T 2.84E-04 Depression (quantitative trait) FAM189A1 intron 20800221 rs12594866 chr15 29528928 T G 2.34E-04 Depression (quantitative trait) FAM189A1 intron 20800221 rs12904918 chr15 29529018 A G 2.83E-04 Depression (quantitative trait) FAM189A1 intron 20800221 rs12901764 chr15 29530483 G A 2.29E-04 Depression (quantitative trait) FAM189A1 intron 20800221 rs720644 chr15 29531333 A G 2.78E-04 Depression (quantitative trait) FAM189A1 intron 20800221 rs7175678 chr15 29533378 C T 3.48E-04 Depression (quantitative trait) FAM189A1 intron 20800221 rs10519634 chr15 29542955 T C 9.35E-05 Blood Pressure FAM189A1 intron pha003040 rs8024985 chr15 29559600 A G 9.09E-05 Blood Pressure FAM189A1 intron pha003040 rs570956 chr15 29568587 T C 3.20E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) FAM189A1 intron 24023788 rs570956 chr15 29568587 T C 3.87E-04 Lung function (forced expiratory volume in 1 second) FAM189A1 intron 24023788 rs4780054 chr15 29600003 C T 9.33E-07 Longevity,exceptional FAM189A1 intron 20595579 rs10519646 chr15 29603003 C T 1.00E-04 Prostate cancer FAM189A1 intron 21743057 rs16955362 chr15 29640307 A C 3.30E-04 Lung function (forced expiratory volume in 1 second) FAM189A1 intron 17255346 rs1829590 chr15 29665953 C A 4.90E-05 Coronary heart disease FAM189A1 intron pha003032 rs12911188 chr15 29671219 A G 4.37E-04 Lung function (forced expiratory volume in 1 second) FAM189A1 intron 17255346 rs4779623 chr15 29675431 G A 9.96E-06 Coronary heart disease FAM189A1 intron pha003032 rs9920343 chr15 29684952 T C 8.65E-05 Coronary heart disease FAM189A1 intron pha003032 rs1195491 chr15 29687453 T C 3.78E-05 Coronary heart disease FAM189A1 intron pha003032 rs1655645 chr15 29692680 C T 9.42E-05 Vaspin levels FAM189A1 intron 22907691 rs1655645 chr15 29692680 C T 0.0000662 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit FAM189A1 intron 22907730 rs1655645 chr15 29692680 C T 0.0000942 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks FAM189A1 intron 22907730 rs585137 chr15 29703452 G A 1.43E-04 Birth weight FAM189A1 intron 17255346 rs1520936 chr15 29704993 T C 1.99E-04 Vaspin levels FAM189A1 intron 22907691 rs1520936 chr15 29704993 T C 0.0001994 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks FAM189A1 intron 22907730 rs1520936 chr15 29704993 T C 0.0002084 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit FAM189A1 intron 22907730 rs554755 chr15 29714747 T A 4.59E-05 Birth weight FAM189A1 intron 17255346 rs41326150 chr15 29715272 T C 4.76E-05 Insulin resistance FAM189A1 intron 21901158 rs11856277 chr15 29722088 A G 5.40E-04 Multiple complex diseases FAM189A1 intron 17554300 rs17682576 chr15 29725663 T C 6.85E-04 Multiple complex diseases FAM189A1 intron 17554300 rs4780224 chr15 29730152 G T 3.34E-04 Birth weight FAM189A1 intron 17255346 rs11856574 chr15 29731444 G A 5.00E-06 Life threatening arrhythmia FAM189A1 intron 22247754 rs11635850 chr15 29766306 C T 3.50E-04 Multiple complex diseases FAM189A1 intron 17554300 rs2337124 chr15 29855411 A C 2.36E-04 Alzheimer's disease (late onset) FAM189A1 intron 21379329 rs7180563 chr15 29867047 A C 3.98E-05 Alzheimer's disease (late onset) / / 21379329 rs1563755 chr15 29873571 C T 1.58E-04 Alzheimer's disease (late onset) / / 21379329 rs8031323 chr15 29874750 G A 1.47E-04 Alzheimer's disease (late onset) / / 21379329 rs6495788 chr15 29875999 C A 4.72E-04 Alzheimer's disease (late onset) / / 21379329 rs4780247 chr15 29883599 A G 2.04E-04 Alzheimer's disease (late onset) / / 21379329 rs11852844 chr15 29884907 T G 5.26E-05 Prion diseases / / 22210626 rs1471225 chr15 29888396 T C 8.00E-06 Inattentive symptoms / / 18821565 rs7171078 chr15 29900518 A C 8.40E-05 Heart Rate / / pha003051 rs12898582 chr15 29902330 T C 7.87E-05 Heart Rate / / pha003051 rs2125657 chr15 29905861 C T 3.62E-05 Depression (quantitative trait) / / 23290196 rs2125659 chr15 29905953 T C 3.21E-05 Depression (quantitative trait) / / 23290196 rs2337127 chr15 29906219 A C 3.95E-05 Depression (quantitative trait) / / 23290196 rs7177816 chr15 29906312 G A 2.88E-05 Depression (quantitative trait) / / 23290196 rs7182611 chr15 29906544 G C 2.67E-05 Depression (quantitative trait) / / 23290196 rs7182991 chr15 29906749 G T 2.58E-05 Depression (quantitative trait) / / 23290196 rs7170422 chr15 29906788 T C 3.08E-05 Depression (quantitative trait) / / 23290196 rs17750582 chr15 29906878 C A 3.25E-05 Depression (quantitative trait) / / 23290196 rs6495807 chr15 29911820 A G 1.48E-04 Bipolar disorder / / 18317468 rs4489949 chr15 29914070 A G 2.74E-05 Depression (quantitative trait) / / 23290196 rs8030855 chr15 29915360 G C 2.43E-05 Depression (quantitative trait) / / 23290196 rs16955611 chr15 29928780 A G 5.25E-05 Depression (quantitative trait) / / 23290196 rs260544 chr15 29974864 C T 3.69E-04 Alzheimer's disease (late onset) / / 21379329 rs10519663 chr15 29979340 A C 2.25E-05 Alcohol and nictotine co-dependence / / 20158304 rs17683205 chr15 30001328 C T 1.07E-05 Alcohol and nictotine co-dependence TJP1 intron 20158304 rs4362339 chr15 30005529 A G 5.60E-04 Type 2 diabetes TJP1 intron 17463246 rs4780257 chr15 30008279 A T 0.0004672 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TJP1 intron 23233654 rs4780257 chr15 30008279 A T 4.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) TJP1 intron 23233662 rs2229515 chr15 30018627 T C 2.35E-06 Alcohol and nictotine co-dependence TJP1 missense 20158304 rs11857601 chr15 30061280 C G 8.42E-04 Multiple complex diseases TJP1 intron 17554300 rs899848 chr15 30061630 T C 1.48E-97 Multiple complex diseases TJP1 intron 17554300 rs1552077 chr15 30071117 G T 4.57E-04 Type 2 diabetes TJP1 intron 17463246 rs12916064 chr15 30071279 C A 0.000407 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TJP1 intron 23233654 rs12916064 chr15 30071279 C A 4.07E-04 Methotrexate clearance (acute lymphoblastic leukemia) TJP1 intron 23233662 rs41280060 chr15 30112896 G C 0.0000433 Nonsyndromic striae distensae (stretch marks) TJP1 intron 23633020 rs1403253 chr15 30137080 C T 5.74E-05 Monocyte chemoattractant protein-1 / / pha003071 rs11853442 chr15 30142373 G A 3.41E-08 Narcolepsy / / 19629137 rs785448 chr15 30146263 A G 1.49E-05 Type 2 diabetes / / 17463246 rs12592592 chr15 30162502 T C 9.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs785422 chr15 30173885 C T 3.00E-11 Corneal structure / / 23291589 rs785429 chr15 30188232 C T 1.71E-09 Corneal structure / / 23291589 rs711355 chr15 30193468 T C 1.75E-04 Vaspin levels / / 22907691 rs711355 chr15 30193468 T C 0.0001745 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs711355 chr15 30193468 T C 2.00E-07 Response to antipsychotic treatment / / 23241943 rs8027720 chr15 30208470 G A 0.00009533 Sarcoidosis / / 22952805 rs2140175 chr15 30213184 T C 2.69E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11856975 chr15 30226502 C T 8.02E-05 Aortic root size / / 21223598 rs4779681 chr15 30227125 C T 1.12E-04 HIV-1 viral setpoint / / 17641165 rs10519673 chr15 30239089 C A 4.75E-04 Aortic root size / / 21223598 rs17762345 chr15 30249384 C G 7.20E-07 Urinary metabolites / / 21572414 rs2222420 chr15 30260500 A G 6.52E-06 Schizophrenia / / 22037555 rs4497630 chr15 30276341 G A 4.70E-06 Urinary metabolites / / 21572414 rs7181263 chr15 30281105 T C 1.55E-04 Multiple complex diseases / / 17554300 rs16954903 chr15 30286608 T C 4.97E-04 Multiple complex diseases / / 17554300 rs16954907 chr15 30286732 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4374114 chr15 30293789 C A 7.66E-05 Cholesterol / / pha003083 rs2030559 chr15 30296844 G T 7.55E-04 Taste perception / / 22132133 rs7403602 chr15 30297008 T C 7.42E-04 Type 2 diabetes / / 17463246 rs7403602 chr15 30297008 T C 2.77E-04 Insulin resistance / / 21901158 rs8040523 chr15 30297758 G A 8.99E-04 Obesity (extreme) / / 21935397 rs11857486 chr15 30354303 A G 2.30E-05 Urinary metabolites / / 21572414 rs62017513 chr15 30781885 C T 2.41E-05 Epilepsy (remission after treatment) LOC100652840 intron 23962720 rs143536437 chr15 30898332 C T 3.00E-06 Epilepsy (remission after treatment) GOLGA8H intron 23962720 rs62018322 chr15 30898630 C A 2.55E-06 Epilepsy (remission after treatment) GOLGA8H intron 23962720 rs62018335 chr15 30913755 A T 3.35E-06 Epilepsy (remission after treatment) / / 23962720 rs113940128 chr15 30929984 C T 1.38E-05 Epilepsy (remission after treatment) ARHGAP11B intron 23962720 rs112084240 chr15 30939058 G A 2.51E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs62014599 chr15 30943789 T C 2.39E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs11630637 chr15 30946123 A T 2.01E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs62014600 chr15 30948120 T G 1.35E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs62014601 chr15 30949425 G T 1.96E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs7166258 chr15 30950529 T C 1.95E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs62014603 chr15 30951076 T G 1.94E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs62014604 chr15 30951191 C T 1.94E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs111302192 chr15 30952231 T A 1.93E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs62014606 chr15 30952959 A G 1.92E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs10152321 chr15 30954833 C G 2.51E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs62014607 chr15 30963685 T C 1.72E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs4779759 chr15 30964572 G A 1.79E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs11633786 chr15 30965411 T C 4.09E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs4779762 chr15 30971831 A G 3.49E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs61998333 chr15 30973270 C T 3.57E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs7177350 chr15 30974606 G A 3.37E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs62001229 chr15 31003255 G A 4.82E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs58826842 chr15 31004818 G A 6.14E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs4779766 chr15 31010802 T C 5.30E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs734711 chr15 31016584 T C 5.31E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs60458654 chr15 31016590 C A 4.97E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs62001237 chr15 31019578 C A 5.42E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs4779768 chr15 31020467 G A 5.33E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs61998393 chr15 31022261 A G 5.29E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs8031106 chr15 31026297 A C 5.30E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs61998397 chr15 31032965 G A 2.63E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs11638525 chr15 31054012 G A 8.78E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs61998401 chr15 31054148 A G 8.78E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs61998402 chr15 31056383 C T 6.14E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs4779776 chr15 31056470 G A 9.27E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs61998403 chr15 31057144 C T 9.58E-05 Epilepsy (remission after treatment) LOC100288637 intron 23962720 rs12438793 chr15 31094479 A G 9.85E-04 Stroke HERC2P10 intron pha002887 rs4779794 chr15 31197564 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) FAN1 missense 20708005 rs4779794 chr15 31197564 G A 1.03E-05 Cortisol secretion,in saliva FAN1 missense 21316860 rs16956362 chr15 31198972 A G 8.33E-05 Caffeine consumption FAN1 intron 21490707 rs2293314 chr15 31210651 A G 1.76E-05 Cortisol secretion,in saliva FAN1 intron 21316860 rs7178375 chr15 31215935 C T 6.00E-06 Hypertriglyceridemia FAN1 intron 23505323 rs565 chr15 31231190 T C 7.38E-04 Alzheimer's disease MTMR10 UTR-3 17998437 rs6493352 chr15 31234064 C T 3.60E-05 Malaria MTMR10 missense 19465909 rs2955790 chr15 31244083 T G 1.94E-05 Cortisol secretion,in saliva MTMR10 intron 21316860 rs2860452 chr15 31248010 A G 5.48E-04 Alzheimer's disease MTMR10 intron 17998437 rs2949574 chr15 31251781 T C 1.04E-06 Cortisol secretion,in saliva MTMR10 intron 21316860 rs2955788 chr15 31255011 T G 7.72E-04 Alzheimer's disease MTMR10 intron 17998437 rs10047979 chr15 31285750 G A 4.23E-04 Alzheimer's disease / / 17998437 rs11638295 chr15 31289449 C A 9.76E-04 Multiple complex diseases / / 17554300 rs8040989 chr15 31290447 G T 9.46E-04 Multiple complex diseases / / 17554300 rs7177217 chr15 31316015 A G 1.92E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers TRPM1 intron 21775533 rs2113945 chr15 31324531 G A 7.20E-05 Subclinical atherosclerosis TRPM1 intron 17903303 rs17815774 chr15 31334362 C T 3.00E-06 Response to antipsychotic treatment TRPM1 missense 19721433 rs11636121 chr15 31339151 A C 5.38E-04 Obesity (extreme) TRPM1 intron 21935397 rs11070764 chr15 31340812 T C 2.61E-13 Metabolite levels TRPM1 intron 22286219 rs17228080 chr15 31341564 T C 4.15E-04 Multiple complex diseases TRPM1 intron 17554300 rs12902840 chr15 31352983 C T 4.50E-06 Gamma gluatamyl transferase levels (interaction with age) TRPM1 intron 22010049 rs4779814 chr15 31356425 T C 9.37E-04 Amyotrophic Lateral Sclerosis TRPM1 intron 17362836 rs16956509 chr15 31356726 C T 0.00072 Salmonella-induced pyroptosis TRPM1 intron 22837397 rs919001 chr15 31357138 A G 3.40E-04 Amyotrophic Lateral Sclerosis TRPM1 intron 17362836 rs919001 chr15 31357138 A G 9.09E-04 Response to taxane treatment (placlitaxel) TRPM1 intron 23006423 rs3784600 chr15 31359552 C T 7.20E-06 Gamma gluatamyl transferase levels (interaction with age) TRPM1 intron 22010049 rs2241493 chr15 31362352 C T 1.03E-04 Amyotrophic Lateral Sclerosis TRPM1 missense 17362836 rs890158 chr15 31370637 G A 8.30E-04 Amyotrophic Lateral Sclerosis TRPM1 intron 17362836 rs12441329 chr15 31377573 C T 3.94E-04 Response to taxane treatment (placlitaxel) TRPM1 intron 23006423 rs8033330 chr15 31396633 G A 7.17E-04 Multiple complex diseases TRPM1 intron 17554300 rs11635657 chr15 31398082 T C 8.90E-05 White matter hyperintensity burden TRPM1 intron 21681796 rs8025698 chr15 31398718 C T 1.70E-05 White matter hyperintensity burden TRPM1 intron 21681796 rs8025698 chr15 31398718 C T 0.0004614 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRPM1 intron 23233654 rs8025698 chr15 31398718 C T 4.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRPM1 intron 23233662 rs12592518 chr15 31401319 T A 1.70E-05 White matter hyperintensity burden TRPM1 intron 21681796 rs12592518 chr15 31401319 T A 0.0004626 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRPM1 intron 23233654 rs12592518 chr15 31401319 T A 4.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRPM1 intron 23233662 rs7179254 chr15 31402386 T G 1.70E-05 White matter hyperintensity burden TRPM1 intron 21681796 rs7179254 chr15 31402386 T G 0.0004581 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRPM1 intron 23233654 rs7179254 chr15 31402386 T G 4.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRPM1 intron 23233662 rs12916281 chr15 31403002 A G 2.30E-05 White matter hyperintensity burden TRPM1 intron 21681796 rs12916281 chr15 31403002 A G 0.00001529 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRPM1 intron 23233654 rs12916281 chr15 31403002 A G 3.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRPM1 intron 23233662 rs4779824 chr15 31404294 T C 4.98E-04 Coronary heart disease TRPM1 intron 21606135 rs6493462 chr15 31404854 T C 4.50E-05 White matter hyperintensity burden TRPM1 intron 21681796 rs6493462 chr15 31404854 T C 0.0008194 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRPM1 intron 23233654 rs6493462 chr15 31404854 T C 8.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRPM1 intron 23233662 rs2338853 chr15 31406043 A G 5.55E-04 Coronary heart disease TRPM1 intron 21606135 rs11070816 chr15 31406335 T A 4.90E-05 White matter hyperintensity burden TRPM1 intron 21681796 rs11070816 chr15 31406335 T A 0.0008288 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRPM1 intron 23233654 rs11070816 chr15 31406335 T A 8.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRPM1 intron 23233662 rs2879275 chr15 31409090 C T 4.90E-05 White matter hyperintensity burden TRPM1 intron 21681796 rs2879275 chr15 31409090 C T 0.0008399 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TRPM1 intron 23233654 rs2879275 chr15 31409090 C T 8.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) TRPM1 intron 23233662 rs10467997 chr15 31410843 G A,C,T 5.50E-05 White matter hyperintensity burden TRPM1 intron 21681796 rs11638121 chr15 31425002 C T 8.96E-05 Alzheimer's disease (late onset) TRPM1 intron 21460841 rs803534 chr15 31428256 T C 2.95E-04 Smoking initiation TRPM1 intron 24665060 rs1672409 chr15 31441308 G A 4.33E-04 Multiple complex diseases TRPM1 intron 17554300 rs1580141 chr15 31444770 A G 2.91E-04 Schizophrenia TRPM1 intron 19197363 rs7169523 chr15 31463378 G A 2.00E-06 Myasthenia gravis / / 23055271 rs7169523 chr15 31463378 G A 7.99E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs8032385 chr15 31479241 A T 8.99E-04 Multiple complex diseases / / 17554300 rs1477534 chr15 31484687 G A 6.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs999876 chr15 31485334 C T 6.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1863279 chr15 31495113 T G 5.32E-04 Parkinson's disease / / 17052657 rs1863279 chr15 31495113 T G 2.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1863279 chr15 31495113 T G 3.44E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7166174 chr15 31495821 C T 8.75E-04 Multiple complex diseases / / 17554300 rs278357 chr15 31497047 A G 3.39E-04 Parkinson's disease / / 17052657 rs1978801 chr15 31507036 A G 2.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1978801 chr15 31507036 A G 4.77E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8038787 chr15 31538374 A G 7.89E-04 Type 2 diabetes / / 17463246 rs7172576 chr15 31555326 G T 5.99E-06 Uric acid levels / / 21294900 rs12915289 chr15 31594828 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1865872 chr15 31623012 G C 7.43E-04 Type 2 diabetes KLF13 intron 17463246 rs66501706 chr15 31629058 G A 7.32E-07 Blood pressure KLF13 intron 21996601 rs12439853 chr15 31634743 G A 8.39E-04 Multiple complex diseases KLF13 intron 17554300 rs4779520 chr15 31665443 C T 3.55E-05 Graves' disease / / 23612905 rs8034505 chr15 31672947 A G 2.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8042404 chr15 31680016 G A 1 Drug response to Etoposide / / 17537913 rs753636 chr15 31691053 G A 5.48E-05 Schizophrenia / / 19197363 rs4354896 chr15 31706775 C G 0.000254 Salmonella-induced pyroptosis / / 22837397 rs6493659 chr15 31712357 A C 0.000363 Salmonella-induced pyroptosis / / 22837397 rs11071016 chr15 31722729 T G 0.000624 Salmonella-induced pyroptosis / / 22837397 rs12592342 chr15 31749336 T C 3.30E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs898213 chr15 31763778 A G 1.60E-06 Urinary metabolites / / 21572414 rs7164569 chr15 31793930 A G 3.00E-06 Venous thromboembolism OTUD7A cds-synon 23650146 rs7181743 chr15 31809253 A G 3.93E-05 Brain structure OTUD7A intron 22504417 rs4779889 chr15 31814203 G T 5.42E-05 Type 2 diabetes OTUD7A intron 17463246 rs16956830 chr15 31816221 A T 7.59E-06 White blood cell count OTUD7A intron 21738479 rs2338679 chr15 31820841 T C 2.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OTUD7A intron 20877124 rs17228394 chr15 31820909 T A 5.02E-05 Type 2 diabetes OTUD7A intron 17463246 rs2125623 chr15 31829707 C T 1.00E-06 Heart failure OTUD7A intron 20400778 rs12908729 chr15 31830739 C A 9.51E-04 Multiple complex diseases OTUD7A intron 17554300 rs16956867 chr15 31848587 G A 5.58E-04 Multiple complex diseases OTUD7A intron 17554300 rs721548 chr15 31856404 A G 6.53E-04 Multiple complex diseases OTUD7A intron 17554300 rs2219507 chr15 31859635 G T 4.37E-04 Multiple complex diseases OTUD7A intron 17554300 rs3903373 chr15 31863960 A G 8.78E-05 Serum metabolites OTUD7A intron 19043545 rs12909737 chr15 31869519 A T 5.18E-04 Multiple complex diseases OTUD7A intron 17554300 rs11854065 chr15 31877238 G A 3.89E-04 Multiple complex diseases OTUD7A intron 17554300 rs12050677 chr15 31877802 C T 7.63E-05 Serum metabolites OTUD7A intron 19043545 rs12050678 chr15 31877920 C T 4.93E-04 Multiple complex diseases OTUD7A intron 17554300 rs8035863 chr15 31882754 T C 5.25E-04 Multiple complex diseases OTUD7A intron 17554300 rs12907720 chr15 31897012 T C 2.98E-04 Multiple complex diseases OTUD7A intron 17554300 rs12901904 chr15 31897092 G C 5.04E-04 Multiple complex diseases OTUD7A intron 17554300 rs7170060 chr15 31897837 T C 3.42E-04 Multiple complex diseases OTUD7A intron 17554300 rs2654155 chr15 31941218 C T 7.57E-06 PR interval in Tripanosoma cruzi seropositivity OTUD7A intron 24324551 rs7496896 chr15 31949169 G T 2.67E-04 Blood pressure / / 17255346 rs192142097 chr15 31986243 A G 4.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs12898600 chr15 32029693 G A 8.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1160721 chr15 32084744 G C 8.48E-04 Prostate cancer mortality / / 20978177 rs12594231 chr15 32176304 T C 6.36E-07 Rheumatoid arthritis / / 19503088 rs4417522 chr15 32187120 A G 3.39E-05 Cognitive test performance / / 20125193 rs7164876 chr15 32190011 A G 4.81E-05 Cognitive test performance / / 20125193 rs17228452 chr15 32197096 G A 2.27E-06 Scoliosis / / 21216876 rs17228459 chr15 32198339 C T 9.90E-07 Urinary metabolites / / 21572414 rs10519712 chr15 32209870 T C 4.59E-04 Bipolar disorder / / 19259986 rs2137858 chr15 32215028 T C 6.40E-05 Coffee consumption / / 21357676 rs11071406 chr15 32229483 T C 2.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7177058 chr15 32230940 G C 4.43E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6494074 chr15 32237709 G A 4.16E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11636101 chr15 32274157 C A 3.00E-04 Myasthenia gravis / / 23055271 rs2063722 chr15 32296373 C A 1.20E-04 Myasthenia gravis / / 23055271 rs1567887 chr15 32299953 C T 3.60E-04 Alcohol dependence / / 20201924 rs1567887 chr15 32299953 C T 4.40E-04 Alcohol dependence / / 20201924 rs9920394 chr15 32310810 A G 3.61E-05 Multiple complex diseases / / 17554300 rs11071512 chr15 32345139 T C 8.34E-04 Response to taxane treatment (placlitaxel) CHR/7 intron 23006423 rs35114543 chr15 32347464 T C 0.00076 Prostate cancer CHR/7 intron 23555315 rs11637923 chr15 32350775 C T 3.98E-05 Telomere length CHR/7 intron 23001564 rs7179733 chr15 32373693 C T 3.40E-04 Alcohol dependence CHR/7 intron 20201924 rs4779978 chr15 32420408 C T 3.36E-04 Height CHR/7 intron 17255346 rs2611603 chr15 32441532 G A,C,T 1.51E-05 Cognitive impairment induced by topiramate CHR/7 intron 22091778 rs2611605 chr15 32441633 C T 1.42E-04 Attention deficit hyperactivity disorder CHR/7 intron 22420046 rs4779984 chr15 32514926 A G 1.58E-05 Neuroblastoma / / pha002895 rs7179495 chr15 32900295 A C 1.19E-07 Obesity-related traits / / 23251661 rs11634439 chr15 32922947 T G 6.76E-08 Obesity-related traits ARHGAP11A intron 23251661 rs11632524 chr15 32926076 C T 1.18E-07 Obesity-related traits ARHGAP11A intron 23251661 rs8037818 chr15 32927476 C T 5.00E-08 Obesity-related traits ARHGAP11A intron 23251661 rs4544214 chr15 32931904 T A 9.00E-05 Suicidal ideation / / 22030708 rs28670903 chr15 32932305 G T 1.86E-07 Obesity-related traits / / 23251661 rs8037102 chr15 32932650 A G 1.37E-07 Obesity-related traits / / 23251661 rs11635997 chr15 32934093 G A 1.84E-06 Obesity-related traits SCG5 intron 23251661 rs8023613 chr15 32952193 G T 3.28E-05 Orofacial clefts SCG5 intron 20023658 rs7161975 chr15 32967839 G A 6.06E-06 Blood Pressure SCG5 intron pha003040 rs7162000 chr15 32967880 G A 1.15E-04 Alzheimer's disease (late onset) SCG5 intron 21379329 rs1881536 chr15 32970550 A G 9.18E-04 Coronary heart disease SCG5 intron 21971053 rs16969344 chr15 32991713 C G 2.40E-04 Bipolar disorder / / 18317468 rs12708490 chr15 32992487 G T 8.95E-05 Psoriasis / / 20953187 rs16969816 chr15 32993645 G A 4.27E-05 Orofacial clefts / / 20023658 rs16969862 chr15 32994001 A G 6.70E-05 Waist-Hip Ratio / / pha003013 rs4779584 chr15 32994756 T C 5.00E-07 Colorectal cancer / / 18372905 rs4779584 chr15 32994756 T C 1.70E-08 Colorectal cancer / / 19011631 rs4779584 chr15 32994756 T C 5.00E-07 Nasopharyngeal carcinoma / / 20512145 rs4779584 chr15 32994756 T C 2.00E-08 Colorectal cancer / / 21761138 rs4779584 chr15 32994756 T C 5.00E-07 Colorectal cancer / / 23266556 rs4780035 chr15 33003258 G A 3.79E-04 Taste perception / / 22132133 rs73376930 chr15 33012502 A G 1.00E-11 Colorectal cancer GREM1 intron 24737748 rs10519738 chr15 33016478 G C 5.58E-04 Type 2 diabetes GREM1 intron 17846125 rs10318 chr15 33025979 C T 1.20E-07 Colorectal cancer GREM1 UTR-3 19011631 rs1919360 chr15 33043455 C T 9.85E-04 Orofacial clefts / / 22863734 rs1919362 chr15 33043657 C T 2.44E-05 Orofacial clefts / / 20023658 rs1919362 chr15 33043657 C T 2.80E-05 Orofacial clefts / / 22863734 rs1258763 chr15 33050423 C T 1.00E-06 Orofacial clefts / / 20023658 rs1258763 chr15 33050423 C T 2.00E-06 Orofacial clefts / / 22863734 rs2840190 chr15 33060407 G A 4.91E-06 Orofacial clefts FMN1 UTR-3 20023658 rs3743106 chr15 33063809 T G 2.10E-05 Orofacial clefts FMN1 UTR-3 19270707 rs3743106 chr15 33063809 T G 1.63E-05 Orofacial clefts FMN1 UTR-3 20023658 rs3743106 chr15 33063809 T G 2.34E-06 Orofacial clefts FMN1 UTR-3 22863734 rs12911544 chr15 33079488 G A 4.58E-04 Amyotrophic Lateral Sclerosis FMN1 intron 17362836 rs16958859 chr15 33080680 C A 2.40E-04 Insulin resistance FMN1 intron 21901158 rs12915737 chr15 33083841 C T 4.58E-04 Type 2 diabetes FMN1 intron 17463246 rs11634255 chr15 33087472 G A 1.34E-06 Osteoarthritis FMN1 intron 22763110 rs11629595 chr15 33089570 G A 4.53E-06 Hearing function FMN1 intron 21493956 rs2123068 chr15 33090884 T G 4.65E-06 Hearing function FMN1 intron 21493956 rs17816387 chr15 33092734 T C 4.41E-06 Hearing function FMN1 intron 21493956 rs12593223 chr15 33092962 G A 1.35E-05 Tetralogy of Fallot FMN1 intron 23297363 rs9806641 chr15 33095895 C A 8.11E-06 Hearing function FMN1 intron 21493956 rs11631339 chr15 33097894 C T 8.91E-06 Hearing function FMN1 intron 21493956 rs12906330 chr15 33098114 A G 9.29E-06 Hearing function FMN1 intron 21493956 rs13329443 chr15 33101473 T G 8.44E-05 Lung adenocarcinoma FMN1 intron 19836008 rs16959110 chr15 33106236 G T 2.18E-04 Alzheimer's disease FMN1 intron 22005930 rs16959182 chr15 33116425 C T 8.00E-04 Alzheimer's disease FMN1 intron 22005930 rs921510 chr15 33117302 C A 3.28E-04 Alzheimer's disease FMN1 intron 22005930 rs16959223 chr15 33121339 T A 4.98E-04 Alzheimer's disease FMN1 intron 22005930 rs725807 chr15 33122379 A G 5.00E-04 Alzheimer's disease FMN1 intron 22005930 rs1258769 chr15 33123153 A C 0.0000864 Circulating PCSK9 levels FMN1 intron 22460556 rs1258767 chr15 33126454 A G 8.30E-04 Alzheimer's disease FMN1 intron 22005930 rs1258767 chr15 33126454 A G 7.00E-07 Bladder cancer (smoking interaction) FMN1 intron 24662972 rs16959442 chr15 33129322 G C 4.82E-04 Alzheimer's disease FMN1 intron 22005930 rs8034124 chr15 33149059 C T 2.50E-05 Urinary metabolites FMN1 intron 21572414 rs4779592 chr15 33151107 A G 3.06E-04 Coronary heart disease FMN1 intron 21606135 rs4780050 chr15 33151160 T C 7.27E-04 Coronary heart disease FMN1 intron 21606135 rs4780051 chr15 33151362 G C 4.98E-04 Coronary heart disease FMN1 intron 21606135 rs10519759 chr15 33151815 G A 3.93E-04 Coronary heart disease FMN1 intron 21606135 rs16960230 chr15 33161031 A G 7.26E-04 Multiple complex diseases FMN1 intron 17554300 rs1451890 chr15 33167529 C A 9.69E-05 Multiple complex diseases FMN1 intron 17554300 rs4780055 chr15 33168360 C T 4.00E-07 Facial morphology FMN1 intron 22341974 rs4780056 chr15 33168756 G C 4.00E-07 Facial morphology FMN1 intron 22341974 rs8026174 chr15 33169205 G A 4.00E-07 Facial morphology FMN1 intron 22341974 rs580115 chr15 33172708 G A 5.09E-05 Cognitive test performance FMN1 intron 20125193 rs9920451 chr15 33186387 A G 1.64E-05 Multiple complex diseases FMN1 intron 17554300 rs10519763 chr15 33198265 G A 9.42E-04 Alzheimer's disease FMN1 intron 17998437 rs10519765 chr15 33205424 G A 6.39E-05 Diabetic retinopathy FMN1 intron 20871662 rs11635135 chr15 33213273 A G 4.53E-05 Orofacial clefts FMN1 intron 20023658 rs11635135 chr15 33213273 A G 3.61E-05 Orofacial clefts FMN1 intron 22863734 rs7168080 chr15 33261838 T C 5.10E-07 Urinary metabolites FMN1 intron 21572414 rs1871362 chr15 33288924 C T 6.34E-04 Iron levels FMN1 intron pha002876 rs343908 chr15 33339826 G A 4.26E-08 Breast cancer FMN1 intron 20852631 rs345751 chr15 33344266 A C 1.23E-04 Bipolar disorder FMN1 intron 18317468 rs1349964 chr15 33352989 C T 2.74E-05 Response to hepatitis C treatment FMN1 intron 19684573 rs12904922 chr15 33356715 G A 7.15E-04 Smoking cessation FMN1 intron 24665060 rs11858145 chr15 33359574 C A 3.71E-05 Response to hepatitis C treatment FMN1 missense 19684573 rs345800 chr15 33382657 G A 8.14E-06 Response to hepatitis C treatment / / 19684573 rs345802 chr15 33383441 T G 4.50E-04 Smoking cessation / / 24665060 rs345779 chr15 33397025 G T 4.31E-06 Hemoglobin / / pha003098 rs345779 chr15 33397025 G T 3.76E-05 Erythrocyte counts / / pha003099 rs2444955 chr15 33412013 T G 3.97E-06 Gallstones / / 17632509 rs2444956 chr15 33412471 A C 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1454985 chr15 33414466 T C 2.76E-04 Smoking cessation / / 24665060 rs4780082 chr15 33415482 A G 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs16965431 chr15 33426091 A G 5.71E-04 Multiple complex diseases / / 17554300 rs2444962 chr15 33426767 G A 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2444969 chr15 33435073 T A 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2444970 chr15 33435257 G A 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2444983 chr15 33443920 G A 5.31E-04 Type 2 diabetes / / 17463246 rs4350544 chr15 33449784 C T 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs7171392 chr15 33487521 T C 6.63E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12910336 chr15 33487737 A G 8.10E-06 Cognitive decline / / 23207651 rs6494964 chr15 33493221 G A 6.00E-06 IgG glycosylation / / 23382691 rs6494964 chr15 33493221 G A 8.00E-06 IgG glycosylation / / 23382691 rs4780094 chr15 33500065 G A 4.76E-04 Schizophrenia / / 19197363 rs974379 chr15 33505067 C A 8.00E-06 Major depressive disorder / / 23377640 rs11072342 chr15 33524115 T C 3.18E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2292548 chr15 33528078 T C 9.05E-05 Celiac disease / / 23936387 rs16967388 chr15 33535342 A G 2.46E-05 Brain structure TMCO5B intron 22504417 rs8030609 chr15 33543268 G A 1.78E-05 Parkinson's disease / / 21812969 rs1399074 chr15 33544435 C G 3.44E-04 Multiple complex diseases / / 17554300 rs17817048 chr15 33551767 G T 3.75E-05 Meningococcal disease / / 20694013 rs6495001 chr15 33552093 G T 8.90E-05 Neuroblastoma / / pha002895 rs8043175 chr15 33554336 G A 4.06E-05 Brain structure / / 22504417 rs4780098 chr15 33557850 T C 1.79E-04 Vaspin levels / / 22907691 rs4780098 chr15 33557850 T C 0.0001792 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs8035094 chr15 33564482 C T 5.00E-05 Meningococcal disease / / 20694013 rs11072374 chr15 33568763 G A 2.40E-06 Urinary metabolites / / 21572414 rs4485323 chr15 33583343 C T 5.06E-04 Multiple complex diseases / / 17554300 rs3924013 chr15 33583485 G T 5.31E-04 Multiple complex diseases / / 17554300 rs8031347 chr15 33590617 G A 7.81E-05 Multiple complex diseases / / 17554300 rs2676062 chr15 33590648 T A 3.32E-04 Multiple complex diseases / / 17554300 rs2676071 chr15 33597076 C T 7.00E-06 Periodontitis (Mean PAL) / / 24024966 rs2251107 chr15 33598402 T G 4.42E-04 Type 2 diabetes / / 17463246 rs2251110 chr15 33598537 G T 2.44E-04 Type 2 diabetes / / 17463246 rs2670947 chr15 33598850 C T 3.59E-04 Type 2 diabetes / / 17463246 rs1024124 chr15 33617064 C T 4.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RYR3 intron 20877124 rs2676034 chr15 33653543 G A 9.30E-07 Lipid levels RYR3 intron 18193043 rs17236010 chr15 33688687 C T 9.61E-04 Alcohol dependence RYR3 intron 21314694 rs2256383 chr15 33702695 C A 8.98E-05 Serum metabolites RYR3 intron 19043545 rs2676029 chr15 33722802 C T 3.61E-04 Nicotine smoking RYR3 intron 19268276 rs16970947 chr15 33731136 G C 2.69E-04 Multiple complex diseases RYR3 intron 17554300 rs16970977 chr15 33735116 T C 8.56E-05 Schizophrenia RYR3 intron 19571809 rs2676087 chr15 33748753 A T 3.36E-04 Alzheimer's disease RYR3 intron 17998437 rs2676092 chr15 33754487 T C 8.05E-04 Suicide attempts in bipolar disorder RYR3 intron 21423239 rs2676093 chr15 33754540 G A 5.22E-05 Monocyte chemoattractant protein-1 RYR3 intron pha003071 rs2596163 chr15 33757840 G A 7.49E-04 Alzheimer's disease RYR3 intron 17998437 rs2018899 chr15 33759204 C A 6.20E-04 Suicide attempts in bipolar disorder RYR3 intron 21423239 rs2572169 chr15 33779491 T C 1.92E-05 Bipolar disorder and schizophrenia RYR3 intron 20889312 rs1369308 chr15 33785483 C T 1.58E-05 Osteoarthritis (knee and hip) RYR3 intron 21177295 rs1369308 chr15 33785483 C T 6.20E-05 Osteoarthritis (knee and hip) RYR3 intron 21177295 rs1369308 chr15 33785483 C T 8.39E-04 Aortic root size RYR3 intron 21223598 rs2572162 chr15 33788629 T C 3.22E-05 Cognitive impairment induced by topiramate RYR3 intron 22091778 rs2596210 chr15 33791935 A G 1.00E-04 Cognitive impairment induced by topiramate RYR3 intron 22091778 rs4144333 chr15 33794552 A G 1.96E-05 Alcohol dependence RYR3 intron 19581569 rs6495130 chr15 33810168 G A 9.57E-06 Obesity-related traits RYR3 intron 23251661 rs6495130 chr15 33810168 G A 3.72E-05 Celiac disease RYR3 intron 23936387 rs8026464 chr15 33812915 A C 1.65E-04 Type 2 diabetes RYR3 intron 17463246 rs8026464 chr15 33812915 A C 7.89E-04 Alzheimer's disease RYR3 intron 17998437 rs12900227 chr15 33822969 T C 9.01E-05 Celiac disease RYR3 intron 23936387 rs12909478 chr15 33829250 C T 3.40E-05 Celiac disease RYR3 intron 23936387 rs1529849 chr15 33843336 A G 7.29E-04 Response to taxane treatment (placlitaxel) RYR3 intron 23006423 rs967091 chr15 33849232 C A 0.0000396 Sarcoidosis RYR3 intron 22952805 rs9806564 chr15 33865067 G C 0.00006303 Sarcoidosis RYR3 intron 22952805 rs968275 chr15 33865825 T C 0.00004805 Sarcoidosis RYR3 intron 22952805 rs682639 chr15 33866278 T C 0.00004621 Sarcoidosis RYR3 intron 22952805 rs619196 chr15 33866300 T C 0.00004621 Sarcoidosis RYR3 intron 22952805 rs680792 chr15 33866670 G T 0.00004233 Sarcoidosis RYR3 intron 22952805 rs680388 chr15 33866766 G T 0.00001656 Sarcoidosis RYR3 intron 22952805 rs604934 chr15 33867175 T C 0.00003725 Sarcoidosis RYR3 intron 22952805 rs666342 chr15 33867607 A T 0.00003452 Sarcoidosis RYR3 intron 22952805 rs2643365 chr15 33871487 T C 3.95E-04 Response to taxane treatment (placlitaxel) RYR3 intron 23006423 rs659517 chr15 33877066 G T 8.83E-05 Major depressive disorder RYR3 intron 19107115 rs1495286 chr15 33877585 G A 3.73E-05 Major depressive disorder RYR3 intron 19107115 rs16972837 chr15 33879387 G A 8.27E-06 Major depressive disorder RYR3 intron 19107115 rs658750 chr15 33880181 G A 4.76E-05 Schizophrenia RYR3 intron 24253340 rs16973062 chr15 33892297 T C 4.62E-04 Alcohol dependence RYR3 intron 20201924 rs2467565 chr15 33892584 G A 5.82E-05 Response to methylphenidate treatment RYR3 intron 21130132 rs2437143 chr15 33893484 C T 1.65E-05 Bone mineral traits,in men RYR3 intron 21427758 rs2437143 chr15 33893484 C T 6.97E-06 Bone mineral traits,in men RYR3 intron 21427758 rs10519834 chr15 33894526 A T 2.95E-04 Type 2 diabetes RYR3 intron 17463246 rs1565937 chr15 33896191 C T 1.74E-04 Alcohol dependence RYR3 intron 20201924 rs2229116 chr15 33905410 A G 3.00E-08 Carotid atherosclerosis in HIV infection RYR3 missense 20009918 rs11637847 chr15 33907051 A G 8.92E-04 Suicide attempts in bipolar disorder RYR3 intron 21041247 rs4238566 chr15 33907628 A C 4.66E-04 Suicide attempts in bipolar disorder RYR3 intron 21041247 rs10519837 chr15 33907954 A G 3.13E-04 Blood pressure RYR3 intron 17255346 rs12593288 chr15 33908103 C T 2.91E-04 Cholesterol RYR3 intron 17255346 rs12593288 chr15 33908103 C T 4.03E-04 Suicide attempts in bipolar disorder RYR3 intron 21041247 rs10519839 chr15 33908316 G T 6.12E-04 Multiple complex diseases RYR3 intron 17554300 rs10519839 chr15 33908316 G T 2.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RYR3 intron 20877124 rs10519839 chr15 33908316 G T 3.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RYR3 intron 20877124 rs16973323 chr15 33909822 C T 2.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RYR3 intron 20877124 rs16973323 chr15 33909822 C T 3.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RYR3 intron 20877124 rs4780135 chr15 33911837 C T 6.89E-05 Cholesterol RYR3 intron 17255346 rs2279661 chr15 33916380 T C 8.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RYR3 intron 20877124 rs951442 chr15 33917942 T C 1.35E-04 Cardiovascular disease RYR3 intron 17903304 rs16973392 chr15 33921082 C G 9.00E-04 Acute lymphoblastic leukemia (childhood) RYR3 intron 20189245 rs2291730 chr15 33923690 C T 2.38E-05 Cholesterol RYR3 intron 17255346 rs3816940 chr15 33925062 G A 6.25E-06 Cholesterol RYR3 intron 17255346 rs12901506 chr15 33929755 G C 2.55E-05 Cholesterol RYR3 intron 17255346 rs1565934 chr15 33937462 G C 4.00E-05 Personality dimensions RYR3 intron 18957941 rs1979738 chr15 33950728 A G 3.74E-05 HIV-1 progression to AIDS and death RYR3 intron 21811574 rs4780144 chr15 33954652 C T 1.73E-04 Height RYR3 missense 17255346 rs4780144 chr15 33954652 C T 2.16E-04 Stroke RYR3 missense pha002886 rs1390158 chr15 33957357 A G 9.55E-04 Stroke RYR3 intron pha002886 rs2088143 chr15 33983545 C T 1.37E-05 Intelligence RYR3 intron 21826061 rs1353348 chr15 33984848 C T 9.74E-04 Acute lymphoblastic leukemia (childhood) RYR3 intron 22076464 rs10519861 chr15 33986058 G T 6.52E-05 Postoperative ventricular dysfunction RYR3 intron 21980348 rs2339298 chr15 33987505 C T 7.40E-05 ldl cholesterol RYR3 intron pha003076 rs11363538 chr15 33987637 T A 9.93E-04 Insulin resistance RYR3 intron 21901158 rs16957550 chr15 33988334 T C 5.41E-04 Insulin resistance RYR3 intron 21901158 rs17817518 chr15 33990620 G A 8.20E-04 Type 2 diabetes RYR3 intron 17463246 rs11629683 chr15 33993143 G C 5.52E-04 Alzheimer's disease RYR3 intron 17998437 rs2280417 chr15 33993483 A G 2.70E-05 Urinary metabolites RYR3 intron 21572414 rs2280417 chr15 33993483 A G 6.99E-05 Blood Pressure RYR3 intron pha003049 rs17236476 chr15 33996777 T C 1.28E-05 Glucose levels RYR3 intron pha003061 rs11635223 chr15 34014753 T C 4.23E-05 Type 2 diabetes RYR3 intron 17463246 rs6495228 chr15 34016274 G A 4.70E-04 Response to statin treatment (atorvastatin),change in cholesterol levels RYR3 missense 20031582 rs12148238 chr15 34046474 C A 1.09E-04 IgE levels RYR3 intron 17255346 rs16957964 chr15 34056887 G A 4.70E-05 Coffee consumption RYR3 intron 21357676 rs7164080 chr15 34064798 G A 5.98E-04 Response to cytidine analogues (gemcitabine) RYR3 intron 24483146 rs12901404 chr15 34075300 T C 7.78E-07 Osteoarthritis RYR3 intron 19508968 rs10519875 chr15 34077664 A G 4.57E-04 Cognition,early reading ability RYR3 intron 17684495 rs12900756 chr15 34089496 A G 3.62E-04 Osteoarthritis RYR3 intron 19508968 rs12900756 chr15 34089496 A G 2.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RYR3 intron 20877124 rs2879436 chr15 34099822 G A 5.65E-04 Obesity (extreme) RYR3 intron 21935397 rs967232 chr15 34115798 T C 5.30E-05 Magnesium levels RYR3 intron pha003092 rs4780184 chr15 34132875 G A 9.41E-04 Obesity (extreme) RYR3 intron 21935397 rs7179722 chr15 34133502 A T 7.25E-04 Nonalcoholic fatty liver disease RYR3 intron 21423719 rs7163140 chr15 34134590 C T 1.73E-05 Multiple complex diseases RYR3 intron 17554300 rs10519884 chr15 34136365 A G 2.20E-05 Urinary metabolites RYR3 intron 21572414 rs2278314 chr15 34140735 A G 8.80E-07 Urinary metabolites RYR3 intron 21572414 rs7172406 chr15 34141505 G T 1.32E-05 Nicotine smoking RYR3 intron 19268276 rs1862917 chr15 34210542 G A 3.10E-05 Triglycerides AVEN intron pha003081 rs1862917 chr15 34210542 G A 4.59E-05 Lipid levels AVEN intron pha003082 rs604289 chr15 34215675 G A 5.70E-04 Amyotrophic Lateral Sclerosis AVEN intron 17362836 rs485191 chr15 34221265 C T 0.0000356 Panic disorder AVEN intron 23149450 rs485191 chr15 34221265 C T 3.56E-05 Serum tamsulosin hydrochloride concentration AVEN intron 23151678 rs597414 chr15 34221492 A T 2.12E-08 Multiple complex diseases AVEN intron 17554300 rs525243 chr15 34238804 C T 6.15E-05 Pancreatic cancer AVEN intron pha002889 rs2702313 chr15 34241882 G A 6.74E-05 Body Fat Distribution AVEN intron pha003017 rs8038887 chr15 34247027 G T 5.90E-04 Type 2 diabetes and 6 quantitative traits AVEN intron 17848626 rs12592769 chr15 34254194 C T 4.21E-04 Taste perception AVEN intron 22132133 rs501432 chr15 34257113 T G 1.49E-04 Insulin resistance AVEN intron 21901158 rs661968 chr15 34261069 C T 5.26E-07 Systemic lupus erythematosus and Systemic sclerosis AVEN intron 23740937 rs606126 chr15 34270932 A G 6.29E-04 Insulin resistance CHRM5 intron 21901158 rs16954025 chr15 34275568 C T 3.30E-06 Urinary metabolites CHRM5 intron 21572414 rs8035125 chr15 34276169 A G 7.67E-05 Post-operative nausea and vomiting CHRM5 intron 21694509 rs8042524 chr15 34281623 T C 8.83E-05 Orofacial clefts CHRM5 intron 22419666 rs17236700 chr15 34281733 C T 8.89E-05 Orofacial clefts CHRM5 intron 22419666 rs2879446 chr15 34289030 A G 8.87E-04 Suicide attempts in bipolar disorder CHRM5 intron 21423239 rs991755 chr15 34289240 G T 5.82E-04 Suicide attempts in bipolar disorder CHRM5 intron 21423239 rs1424399 chr15 34289726 C T 9.64E-04 Suicide attempts in bipolar disorder CHRM5 intron 21423239 rs7182790 chr15 34290020 G A 7.10E-04 Suicide attempts in bipolar disorder CHRM5 intron 21423239 rs12050692 chr15 34290198 C T 7.10E-04 Suicide attempts in bipolar disorder CHRM5 intron 21423239 rs12050519 chr15 34290331 T C 5.58E-04 Suicide attempts in bipolar disorder CHRM5 intron 21423239 rs563895 chr15 34291269 A G 5.89E-04 Suicide attempts in bipolar disorder CHRM5 intron 21423239 rs2018672 chr15 34291524 C T 5.66E-04 Suicide attempts in bipolar disorder CHRM5 intron 21423239 rs7170890 chr15 34301764 A T 9.13E-04 Suicide attempts in bipolar disorder CHRM5 intron 21423239 rs16958595 chr15 34315025 G A 2.03E-04 Suicide attempts in bipolar disorder CHRM5 intron 21423239 rs2702282 chr15 34316062 C A 9.00E-04 Acute lymphoblastic leukemia (childhood) CHRM5 intron 20189245 rs2705338 chr15 34370487 T C 5.44E-04 Stroke / / pha002887 rs11639310 chr15 34421951 C T 6.50E-04 Alcohol dependence / / 20201924 rs17817770 chr15 34433347 T C 1.89E-04 Taste perception C15orf29 UTR-3 22132133 rs7168761 chr15 34506218 G A 1.60E-05 Urinary metabolites / / 21572414 rs8036468 chr15 34506803 A G 5.12E-06 Left ventricular mass / / 21212386 rs16958878 chr15 34534723 A G 2.30E-05 Urinary metabolites SLC12A6 intron 21572414 rs4238572 chr15 34538560 G T 3.90E-05 Height SLC12A6 intron pha003010 rs4238572 chr15 34538560 G T 4.08E-06 Height SLC12A6 intron pha003011 rs4780235 chr15 34546043 G A 1.61E-05 Height SLC12A6 intron pha003011 rs12591967 chr15 34574330 T C 3.15E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SLC12A6 intron 24023788 rs6495662 chr15 34630582 A G 7.89E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SLC12A6 nearGene-5 24023788 rs8031404 chr15 34637696 C A 2.19E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) C15orf55 nearGene-5 24023788 rs12595504 chr15 34638198 A G 2.19E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) C15orf55 UTR-5 24023788 rs11631776 chr15 34641974 C G 5.40E-05 Sarcoidosis C15orf55 intron 19165924 rs7162607 chr15 34650986 G A 3.10E-05 Heart Rate / / pha003051 rs7162607 chr15 34650986 G A 9.64E-05 Lipid levels / / pha003082 rs17817878 chr15 34742839 T C 5.34E-05 Erythrocyte counts / / pha003090 rs16954263 chr15 34901430 G A 3.50E-04 Myasthenia gravis / / 23055271 rs7498116 chr15 34928486 G A 8.06E-04 Gallbladder cancer / / 22318345 rs11633375 chr15 34929371 T C 4.58E-04 Insulin resistance / / 21901158 rs11632459 chr15 34931178 C A 6.42E-05 Height / / pha003011 rs1436918 chr15 34936921 A G 2.80E-06 Amyotrophic Lateral Sclerosis / / 17362836 rs1347638 chr15 34941957 C T 8.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7497057 chr15 34953986 C T 8.50E-05 Celiac disease / / 17558408 rs11073055 chr15 34963958 G T 3.50E-06 Urinary metabolites / / 21572414 rs12915800 chr15 34964696 T C 4.11E-05 Cognitive test performance / / 20125193 rs16959401 chr15 34966357 G A 2.70E-05 Urinary metabolites / / 21572414 rs2118157 chr15 34981944 A G 6.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2118157 chr15 34981944 A G 2.90E-06 Axial length / / 24144296 rs2118156 chr15 34981998 C T 2.08E-06 Axial length / / 24144296 rs2118155 chr15 34982234 C T 2.44E-06 Axial length / / 24144296 rs8031068 chr15 34982578 A G 7.37E-08 Axial length / / 24144296 rs1370156 chr15 34984883 G C 4.24E-07 Axial length / / 24144296 rs6495708 chr15 34985414 T C 7.72E-07 Axial length / / 24144296 rs2028099 chr15 34985743 G C 5.26E-06 Gallstones / / 17632509 rs2028099 chr15 34985743 G C 4.65E-07 Axial length / / 24144296 rs4924125 chr15 34985984 A T 5.28E-07 Axial length / / 24144296 rs11857049 chr15 34989053 G A 1.74E-07 Axial length / / 24144296 rs11073058 chr15 34989626 G T 8.45E-12 Refractive error / / 20835239 rs11073058 chr15 34989626 G T 4.00E-11 Axial length / / 24144296 rs11073059 chr15 34989674 T A 8.45E-12 Refractive error / / 20835239 rs11073059 chr15 34989674 T A 4.52E-11 Axial length / / 24144296 rs11073060 chr15 34989851 C A 3.65E-12 Refractive error / / 20835239 rs11073060 chr15 34989851 C A 5.05E-11 Axial length / / 24144296 rs7163001 chr15 34990574 G A 5.61E-12 Refractive error / / 20835239 rs7163001 chr15 34990574 G A 5.72E-11 Axial length / / 24144296 rs2461367 chr15 34990604 C T 2.47E-07 Axial length / / 24144296 rs1357179 chr15 34990625 T G 1.30E-07 Axial length / / 24144296 rs8032019 chr15 34991490 A G 3.71E-10 Refractive error / / 20835239 rs8032019 chr15 34991490 A G 1.22E-09 Axial length / / 24144296 rs4924134 chr15 34994565 A G 1.36E-12 Refractive error / / 20835239 rs4924134 chr15 34994565 A G 1.08E-10 Axial length / / 24144296 rs619788 chr15 34995106 C A 2.53E-11 Refractive error / / 20835239 rs619788 chr15 34995106 C A 1.51E-10 Axial length / / 24144296 rs580839 chr15 34998829 G A 2.53E-11 Refractive error / / 20835239 rs580839 chr15 34998829 G A 1.89E-10 Axial length / / 24144296 rs688220 chr15 34998875 G A 2.79E-11 Refractive error / / 20835239 rs688220 chr15 34998875 G A 1.23E-10 Axial length / / 24144296 rs7176510 chr15 34999479 C T 6.25E-11 Refractive error / / 20835239 rs7176510 chr15 34999479 C T 1.24E-10 Axial length / / 24144296 rs560766 chr15 35000942 G A 2.49E-11 Refractive error / / 20835239 rs560766 chr15 35000942 G A 3.66E-10 Axial length / / 24144296 rs493085 chr15 35004749 C T 6.22E-07 Axial length / / 24144296 rs524952 chr15 35005886 T A 3.18E-14 Refractive error / / 20835239 rs524952 chr15 35005886 T A 1.00E-15 Refractive error / / 23396134 rs524952 chr15 35005886 T A 5.60E-19 Myopia (Age of onset) / / 23468642 rs524952 chr15 35005886 T A 1.00E-09 Axial length / / 24144296 rs634990 chr15 35006073 T C 2.00E-14 Refractive error / / 20835239 rs634990 chr15 35006073 T C 1.50E-10 Axial length / / 24144296 rs553565 chr15 35006724 A G 2.26E-04 Lymphocyte counts / / 22286170 rs553565 chr15 35006724 A G 3.55E-05 Telomere length / / 23001564 rs685352 chr15 35008335 A G 4.19E-12 Refractive error / / 20835239 rs684000 chr15 35008634 A G 2.08E-04 Alzheimer's disease (late onset) / / 21379329 rs559747 chr15 35012179 C G 5.19E-05 Femoral neck bone geometry / / 22087292 rs636751 chr15 35012584 A C 6.68E-05 Femoral neck bone geometry / / 22087292 rs4147419 chr15 35030571 G C 9.71E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7174852 chr15 35053555 A C 9.12E-04 Multiple complex diseases / / 17554300 rs11634692 chr15 35057816 G A 8.92E-05 Femoral neck bone geometry / / 22087292 rs16959728 chr15 35058220 G A 7.17E-04 Multiple complex diseases / / 17554300 rs688921 chr15 35062343 G C 9.74E-05 Femoral neck bone geometry / / 22087292 rs10459664 chr15 35064934 C T 5.91E-05 Femoral neck bone geometry / / 22087292 rs628118 chr15 35065284 C T 4.39E-05 Femoral neck bone geometry / / 22087292 rs609730 chr15 35067109 C T 8.31E-05 Femoral neck bone geometry / / 22087292 rs543686 chr15 35068309 C T 4.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs2067724 chr15 35098155 C A 3.89E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs11852984 chr15 35105657 A C 8.89E-04 Type 2 diabetes / / 17463246 rs11852984 chr15 35105657 A C 2.23E-04 Sudden cardiac arrest / / 21658281 rs1545484 chr15 35115869 T C 1.39E-04 Multiple complex diseases / / 17554300 rs2339648 chr15 35122648 G A 1.31E-04 Smoking quantity / / 24665060 rs7167879 chr15 35123180 A G 4.22E-04 Smoking quantity / / 24665060 rs11854124 chr15 35129095 T C 3.83E-04 Smoking quantity / / 24665060 rs11635293 chr15 35130267 A T 2.31E-04 Smoking quantity / / 24665060 rs11073074 chr15 35131776 G C 2.19E-04 Smoking quantity / / 24665060 rs17237191 chr15 35133441 C A 1.81E-04 Smoking quantity / / 24665060 rs8033479 chr15 35141453 G A 1.80E-06 Urinary metabolites / / 21572414 rs12102243 chr15 35141832 G C 2.86E-04 Smoking quantity / / 24665060 rs12591523 chr15 35142566 G A 3.74E-04 Smoking quantity / / 24665060 rs1055356 chr15 35148102 T C 3.30E-05 Osteoarthritis / / 19508968 rs1055356 chr15 35148102 T C 6.62E-04 Smoking quantity / / 24665060 rs3858931 chr15 35152649 T C 3.31E-04 Osteoarthritis AQR intron 19508968 rs10519967 chr15 35177507 G A 6.32E-04 Oral cancers (chewing tobacco related) AQR intron 22503698 rs1376784 chr15 35179643 G T 5.38E-04 Oral cancers (chewing tobacco related) AQR intron 22503698 rs717941 chr15 35196878 A C 1.63E-04 Osteoarthritis AQR intron 19508968 rs7169701 chr15 35217536 T C 2.47E-04 Osteoarthritis AQR intron 19508968 rs963425 chr15 35227613 T C 4.26E-04 Oral cancers (chewing tobacco related) AQR intron 22503698 rs2060810 chr15 35254596 A G 7.43E-04 Oral cancers (chewing tobacco related) AQR intron 22503698 rs12439825 chr15 35278475 A G 0.000634 Salmonella-induced pyroptosis ZNF770 intron 22837397 rs10459665 chr15 35335679 G A 4.70E-05 Response to statin therapy / / 20339536 rs16960314 chr15 35343812 C T 7.63E-06 Suicide attempts in bipolar disorder / / 21423239 rs4924504 chr15 35343954 G A 5.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs10162694 chr15 35346541 C A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10162694 chr15 35346541 C A 9.00E-06 Bronchopulmonary dysplasia / / 23897914 rs10162694 chr15 35346541 C A 9.20E-06 Bronchopulmonary dysplasia / / 23897914 rs10851971 chr15 35346995 A G 4.15E-05 Suicide attempts in bipolar disorder / / 21423239 rs11633273 chr15 35348947 A G 3.90E-05 Suicide attempts in bipolar disorder / / 21423239 rs16960370 chr15 35395724 A G 9.17E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs6495758 chr15 35465985 C A 8.79E-04 Multiple complex diseases / / 17554300 rs4924647 chr15 35494907 G T 3.82E-05 Sodium levels / / pha003093 rs10519989 chr15 35530573 G T 9.76E-04 Type 2 diabetes / / 17846124 rs318339 chr15 35537031 G T 6.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs10162934 chr15 35541843 C G 3.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs2622756 chr15 35548468 A G 6.86E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs16960826 chr15 35661497 A C 1.40E-05 Urinary metabolites / / 21572414 rs3898039 chr15 35727365 C T 9.08E-04 Amyotrophic Lateral Sclerosis ATPBD4 intron 17362836 rs3898039 chr15 35727365 C T 8.43E-05 Response to mTOR inhibitor (everolimus) ATPBD4 intron 24009623 rs6495768 chr15 35729175 T C 4.13E-04 Multiple complex diseases ATPBD4 intron 17554300 rs8037827 chr15 35734548 T C 5.04E-05 Response to mTOR inhibitor (everolimus) ATPBD4 intron 24009623 rs9920994 chr15 35735304 A G 2.26E-04 Acute lung injury ATPBD4 intron 22295056 rs1542376 chr15 35740476 C T 6.15E-04 Acute lung injury ATPBD4 intron 22295056 rs1037575 chr15 35740582 G A 8.36E-04 Acute lung injury ATPBD4 intron 22295056 rs11853690 chr15 35742076 A G 5.49E-04 Acute lung injury ATPBD4 intron 22295056 rs9788708 chr15 35742368 A G 5.20E-04 Acute lung injury ATPBD4 intron 22295056 rs8030971 chr15 35747371 G A 4.66E-04 Acute lung injury ATPBD4 intron 22295056 rs4923687 chr15 35748605 T C 6.08E-04 Acute lung injury ATPBD4 intron 22295056 rs7167641 chr15 35750017 C T 6.43E-05 Response to mTOR inhibitor (everolimus) ATPBD4 intron 24009623 rs16961040 chr15 35763444 G T 7.96E-04 Amyotrophic Lateral Sclerosis ATPBD4 intron 17362836 rs6495785 chr15 35858583 A G 5.00E-06 Menopause (age at onset) LOC100507466 intron 24045676 rs16961267 chr15 35875453 C T 7.90E-05 Response to statin therapy LOC100507466 intron 20339536 rs7168498 chr15 35876872 C T 8.00E-05 Response to statin therapy LOC100507466 intron 20339536 rs1822530 chr15 35877988 C T 6.50E-05 Response to statin therapy LOC100507466 intron 20339536 rs6495789 chr15 35880265 G T 8.60E-05 Response to statin therapy LOC100507466 intron 20339536 rs7162295 chr15 35885113 G T 8.40E-05 Response to statin therapy LOC100507466 intron 20339536 rs11857738 chr15 35905729 T G 9.00E-05 Response to statin therapy LOC100507466 intron 20339536 rs12595392 chr15 35938451 C T 2.00E-04 Cognitive impairment induced by topiramate LOC100507466 intron 22091778 rs12595392 chr15 35938451 C T 3.34E-05 Cognitive impairment induced by topiramate LOC100507466 intron 22091778 rs12595392 chr15 35938451 C T 5.46E-06 Cognitive impairment induced by topiramate LOC100507466 intron 22091778 rs16961362 chr15 35944606 G A 8.14E-06 Multiple complex diseases LOC100507466 intron 17554300 rs319891 chr15 35950167 T A 1.20E-05 Urinary metabolites LOC100507466 intron 21572414 rs319889 chr15 35950483 C T 9.00E-06 Urinary metabolites LOC100507466 intron 21572414 rs9920863 chr15 35961083 T G 2.60E-05 Urinary metabolites LOC100507466 intron 21572414 rs9672669 chr15 35967179 T C 3.09E-04 Hearing function LOC100507466 intron 17255346 rs6495794 chr15 35981314 G A 6.56E-04 Response to taxane treatment (placlitaxel) LOC100507466 intron 23006423 rs41495944 chr15 35987238 C T 2.10E-04 Insulin resistance LOC100507466 intron 21901158 rs2879653 chr15 36008792 T C 1.66E-06 Heart Rate LOC100507466 intron pha003054 rs5017692 chr15 36016085 C T 8.03E-04 Alzheimer's disease LOC100507466 intron 24755620 rs12909885 chr15 36034093 T C 4.37E-04 Lung function (forced expiratory volume in 1 second) LOC100507466 intron 17255346 rs4924017 chr15 36041183 T G 3.09E-05 Waist-Hip Ratio LOC100507466 intron pha003029 rs2947253 chr15 36049492 G A 4.00E-06 Paclitaxel-induced neuropathy LOC100507466 intron 23776197 rs12438858 chr15 36090377 T A 2.90E-05 Urinary metabolites LOC100507466 intron 21572414 rs11073126 chr15 36116795 G A 1.30E-04 Endometrial cancer LOC100507466 intron 24096698 rs11073126 chr15 36116795 G A 8.47E-05 Endometrial cancer LOC100507466 intron 24096698 rs7168742 chr15 36125529 T C 1.47E-04 Bipolar disorder,schizoaffective LOC100507466 intron 19567891 rs2683111 chr15 36135207 C G 2.58E-05 Multiple complex diseases LOC100507466 intron 17554300 rs16961825 chr15 36136563 A G 2.95E-05 Bipolar disorder,schizoaffective LOC100507466 intron 19567891 rs35368750 chr15 36194143 C G 6.47E-05 Epilepsy (remission after treatment) / / 23962720 rs12438903 chr15 36202556 T G 2.49E-04 Birth weight / / 17255346 rs789774 chr15 36219977 A G 0.0000159 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12439433 chr15 36220035 A G 3.21E-04 Birth weight / / 17255346 rs1510372 chr15 36224241 T C 0.0000241 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs9920203 chr15 36229113 A G 1.24E-04 Smoking initiation / / 24665060 rs9920178 chr15 36229265 C T 2.69E-04 Smoking initiation / / 24665060 rs12917416 chr15 36263447 G A 5.97E-04 Type 2 diabetes / / 17463246 rs2202979 chr15 36267297 C T 6.55E-04 Type 2 diabetes / / 17463246 rs4923705 chr15 36293605 G A 2.00E-06 Attention deficit hyperactivity disorder / / 20732626 rs10520043 chr15 36312948 G A 6.67E-04 Schizophrenia / / 21674006 rs10520045 chr15 36313965 G T 7.00E-06 Major depressive disorder / / 20673876 rs1898036 chr15 36349846 T C 2.00E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs1435687 chr15 36350350 C A 1.81E-05 Height / / 22021425 rs16962468 chr15 36368303 C T 1.11E-04 Cholesterol / / 17255346 rs1435682 chr15 36410170 A G 1.83E-04 Multiple complex diseases / / 17554300 rs1435682 chr15 36410170 A G 4.46E-05 Telomere length / / 20139977 rs1435683 chr15 36410288 C T 2.82E-04 Type 2 diabetes / / 17463246 rs1435683 chr15 36410288 C T 5.92E-04 Multiple complex diseases / / 17554300 rs16962603 chr15 36421965 A G 1.03E-04 Cholesterol / / 17255346 rs17696730 chr15 36427849 A T 6.28E-04 Obesity (extreme) / / 21935397 rs12907985 chr15 36435865 A C 6.63E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11853113 chr15 36443358 T C 1.90E-05 Urinary metabolites / / 21572414 rs4924052 chr15 36448955 A G 1.00E-05 Urinary metabolites / / 21572414 rs11857996 chr15 36450552 C T 1.30E-05 Urinary metabolites / / 21572414 rs1012168 chr15 36452658 C A 1.84E-04 Multiple complex diseases / / 17554300 rs1012168 chr15 36452658 C A 2.95E-04 Alzheimer's disease (late onset) / / 21379329 rs1347457 chr15 36469794 G A 6.80E-06 Urinary metabolites / / 21572414 rs723804 chr15 36471670 T C 4.81E-05 Alzheimer's disease (late onset) / / 21379329 rs17697225 chr15 36474180 A G 4.51E-05 Alzheimer's disease (late onset) / / 21379329 rs11629908 chr15 36476873 C T 7.55E-04 Obesity (extreme) / / 21935397 rs35852281 chr15 36520994 C T 8.90E-04 Alcohol dependence / / 20201924 rs16962759 chr15 36548888 T C 6.40E-05 Alcohol dependence / / 20201924 rs16962759 chr15 36548888 T C 8.30E-05 Alcohol dependence / / 20201924 rs16962759 chr15 36548888 T C 6.38E-05 Alcoholism / / pha002892 rs16962759 chr15 36548888 T C 8.28E-05 Alcoholism / / pha002893 rs1517867 chr15 36553907 G C 6.44E-04 Schizophrenia / / 21674006 rs7497772 chr15 36592031 A G 8.30E-05 Alzheimer's disease (age of onset) / / 22005931 rs10518869 chr15 36594667 A G 5.98E-05 Body Mass Index / / pha003015 rs6495829 chr15 36643077 C T 8.72E-04 Type 2 diabetes / / 17463246 rs4923710 chr15 36644041 G A 9.31E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7178364 chr15 36644388 A G 1.20E-05 Malignant pleural mesothelioma / / 23626673 rs7178364 chr15 36644388 A G 5.66E-04 Malignant pleural mesothelioma / / 23626673 rs1568221 chr15 36647577 C T 7.81E-04 HIV-1 viral setpoint / / 17641165 rs12906495 chr15 36647780 T C 2.02E-05 Telomere length / / 23001564 rs1517880 chr15 36648330 C A 8.22E-04 Multiple complex diseases / / 17554300 rs12908082 chr15 36649320 C T 9.36E-04 Type 2 diabetes / / 17463246 rs4130461 chr15 36651838 T G 2.15E-04 Smoking initiation / / 24665060 rs4130461 chr15 36651838 T G 4.52E-05 Pancreatic cancer / / pha002874 rs8028529 chr15 36654597 C T 9.12E-05 Aortic root size / / 21223598 rs8028529 chr15 36654597 C T 1.51E-06 Pancreatic cancer / / pha002874 rs4459505 chr15 36656022 A G 1.12E-04 Pancreatic cancer / / pha002874 rs6495836 chr15 36748505 A G 9.29E-04 Alzheimer's disease / / 22005930 rs2467364 chr15 36751845 C T 6.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17703807 chr15 36766056 T C 2.03E-04 Celiac disease / / 23936387 rs2467350 chr15 36772809 A C 1.87E-05 Job-related exhaustion / / 23620144 rs2444751 chr15 36777549 C A 1.96E-05 Job-related exhaustion / / 23620144 rs7162200 chr15 36780493 C T 1.84E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs10518883 chr15 36784720 C T 6.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2034705 chr15 36832625 T C 4.20E-06 Job-related exhaustion / / 23620144 rs10152393 chr15 36833218 C T 9.29E-05 Potassium levels / / pha003086 rs12912283 chr15 36861223 C T 1.30E-04 Parkinson's disease / / 21248740 rs8026972 chr15 36880661 T C 9.47E-04 Type 2 diabetes C15orf41 intron 17463246 rs2054016 chr15 36882290 G A 3.59E-05 Potassium levels C15orf41 intron pha003086 rs2602923 chr15 36891254 T C 7.84E-04 Response to taxane treatment (placlitaxel) C15orf41 intron 23006423 rs16963669 chr15 36895605 T C 3.82E-04 Multiple complex diseases C15orf41 intron 17554300 rs1840243 chr15 36899727 G A 4.60E-04 HIV-1 viral setpoint C15orf41 intron 17641165 rs4923719 chr15 36904777 C G 6.57E-04 Type 2 diabetes C15orf41 intron 17463246 rs4924088 chr15 36907791 T G 9.15E-05 Body Mass Index C15orf41 intron pha003006 rs4923720 chr15 36909267 G A 6.26E-04 Type 2 diabetes C15orf41 intron 17463246 rs16963720 chr15 36920046 C G 5.24E-04 Multiple complex diseases C15orf41 intron 17554300 rs7163933 chr15 36933883 A G 4.32E-04 Multiple complex diseases C15orf41 intron 17554300 rs4924092 chr15 36938605 A G 7.62E-04 Multiple complex diseases C15orf41 intron 17554300 rs974849 chr15 36985645 T C 3.53E-04 Bipolar disorder C15orf41 intron 18317468 rs41465054 chr15 36991765 A C 6.91E-04 Multiple complex diseases C15orf41 intron 17554300 rs12595466 chr15 37031944 A G 1.93E-04 Bipolar disorder C15orf41 intron 18317468 rs2160420 chr15 37053920 C G 7.65E-04 Multiple complex diseases C15orf41 intron 17554300 rs2160420 chr15 37053920 C G 5.19E-04 Response to cytidine analogues (gemcitabine) C15orf41 intron 24483146 rs2193000 chr15 37054243 A G 2.00E-04 Response to cytadine analogues (cytosine arabinoside) C15orf41 intron 24483146 rs8041016 chr15 37085127 G A 2.00E-04 Cognitive impairment induced by topiramate C15orf41 intron 22091778 rs8039481 chr15 37163634 G A 8.91E-04 Prostate cancer mortality LOC145845 intron 20978177 rs8037890 chr15 37166268 T G 0.00000449 Cytarabine sensitivity LOC145845 intron 23538338 rs8036656 chr15 37172064 C A 3.90E-04 Telomere length / / 24795349 rs12595046 chr15 37174337 A G 3.39E-04 Tourette syndrome LOC145845 intron 22889924 rs17432433 chr15 37174748 A G 4.53E-05 Left ventricular hypertrophy LOC145845 intron pha003052 rs16964247 chr15 37177687 G A 9.14E-05 Response to taxane treatment (placlitaxel) LOC145845 intron 23006423 rs16964270 chr15 37199124 A G 2.59E-04 Multiple complex diseases MEIS2 intron 17554300 rs837136 chr15 37212897 G A 4.22E-05 Alcohol dependence MEIS2 intron 21703634 rs837134 chr15 37215855 G A 7.43E-04 Response to taxane treatment (placlitaxel) MEIS2 intron 23006423 rs8026749 chr15 37217621 C A 4.27E-04 Smoking cessation MEIS2 intron 24665060 rs8026755 chr15 37247722 C A 4.03E-05 Obsessive-compulsive disorder MEIS2 intron 24821223 rs17526329 chr15 37263071 T A 6.71E-04 Acute lung injury MEIS2 intron 22295056 rs11636673 chr15 37273292 T C 9.79E-05 Waist Circumference MEIS2 intron pha003023 rs1916306 chr15 37281694 G A,C 2.88E-04 Multiple complex diseases MEIS2 intron 17554300 rs1916306 chr15 37281694 G A,C 8.31E-04 Insulin resistance MEIS2 intron 21901158 rs8041147 chr15 37298358 C T 6.43E-04 Multiple complex diseases MEIS2 intron 17554300 rs4924116 chr15 37299151 C T 9.64E-04 Multiple complex diseases MEIS2 intron 17554300 rs4989607 chr15 37332109 A G 1.29E-04 Lung function (forced expiratory volume in 1 second) MEIS2 intron 24023788 rs4989607 chr15 37332109 A G 5.12E-05 Lung function (forced vital capacity) MEIS2 intron 24023788 rs16964591 chr15 37338453 T C 2.58E-04 Multiple complex diseases MEIS2 intron 17554300 rs8041675 chr15 37342602 T C 4.00E-06 Hyperactive-impulsive symptoms MEIS2 intron 18821565 rs8041675 chr15 37342602 T C 6.83E-04 Taste perception MEIS2 intron 22132133 rs1568679 chr15 37349802 T C 1.00E-08 Response to antipsychotic treatment MEIS2 intron 20195266 rs4625687 chr15 37364254 G A 9.65E-05 Eosinophil counts MEIS2 intron pha003088 rs7161976 chr15 37374185 A C 5.78E-04 White matter integrity MEIS2 intron 22425255 rs2701516 chr15 37417719 T C 3.83E-04 Multiple complex diseases / / 17554300 rs2701516 chr15 37417719 T C 8.40E-06 Urinary metabolites / / 21572414 rs28405328 chr15 37425814 A T 6.35E-06 Response to amphetamines / / 22952603 rs1401898 chr15 37427827 T C 6.08E-06 Response to amphetamines / / 22952603 rs7172336 chr15 37433710 G A 8.59E-06 Response to amphetamines / / 22952603 rs76693256 chr15 37437480 C G 8.85E-06 Response to amphetamines / / 22952603 rs17530206 chr15 37439198 G A 7.45E-04 Multiple complex diseases / / 17554300 rs2139509 chr15 37442026 A G 5.21E-06 Response to amphetamines / / 22952603 rs28821768 chr15 37443896 A C 4.44E-06 Response to amphetamines / / 22952603 rs28421704 chr15 37445449 C T 5.33E-06 Response to amphetamines / / 22952603 rs28738691 chr15 37446359 G A 7.75E-06 Response to amphetamines / / 22952603 rs17439560 chr15 37449619 G A,T 4.00E-06 Response to amphetamines / / 22952603 rs2701513 chr15 37459187 A G 1.08E-04 Smoking cessation / / 24665060 rs6495894 chr15 37460759 C T 1.55E-04 Smoking cessation / / 24665060 rs8038390 chr15 37464707 G T 5.44E-04 Smoking cessation / / 24665060 rs7171671 chr15 37485094 G A 1.45E-04 Smoking cessation / / 24665060 rs10431820 chr15 37490771 A G 1.39E-04 Smoking cessation / / 24665060 rs10431821 chr15 37491094 T C 1.34E-04 Smoking cessation / / 24665060 rs12908778 chr15 37492493 G A 6.70E-05 Smoking cessation / / 24665060 rs10518930 chr15 37493586 T C 7.82E-04 Smoking cessation / / 24665060 rs10518931 chr15 37494741 A G 7.09E-05 Smoking cessation / / 24665060 rs999736 chr15 37495601 A G 1.99E-04 Smoking cessation / / 24665060 rs16964797 chr15 37496198 A G 4.46E-04 Smoking cessation / / 24665060 rs8029152 chr15 37501850 C T 4.68E-04 Smoking cessation / / 24665060 rs884771 chr15 37502929 T A 4.34E-04 Smoking cessation / / 24665060 rs12438456 chr15 37510641 A G 3.88E-04 Smoking cessation / / 24665060 rs7177907 chr15 37512404 T C 6.48E-04 Smoking cessation / / 24665060 rs17531839 chr15 37537647 T C 9.81E-04 Obesity (extreme) / / 21935397 rs4350533 chr15 37547534 A G 9.48E-04 Alzheimer's disease / / 24755620 rs1356783 chr15 37554968 T C 5.11E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7173469 chr15 37625681 G A,C,T 3.90E-04 Multiple complex diseases / / 17554300 rs4924148 chr15 37630365 T C 4.90E-06 Intraocular pressure / / 24002674 rs587847 chr15 37660049 C A 1.00E-06 Intraocular pressure / / 24002674 rs603165 chr15 37675583 C T 1.50E-05 Intraocular pressure / / 24002674 rs10438401 chr15 37689941 T C 6.77E-04 Alzheimer's disease / / 22005930 rs17541672 chr15 37690334 T C 5.92E-04 Alzheimer's disease / / 22005930 rs28887513 chr15 37772066 A G 3.42E-05 Cocaine dependence / / 23958962 rs1902623 chr15 37804169 C T 5.86E-05 Multiple complex diseases / / 17554300 rs1824183 chr15 37816500 G A 1.95E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11073247 chr15 37817574 T G 7.10E-04 Multiple complex diseases / / 17554300 rs16965184 chr15 37819889 G A 3.50E-04 Multiple complex diseases / / 17554300 rs16965185 chr15 37820469 A G 3.33E-04 Multiple complex diseases / / 17554300 rs16965201 chr15 37823655 A G 6.85E-04 Multiple complex diseases / / 17554300 rs7172790 chr15 37828600 T C 2.79E-04 Multiple complex diseases / / 17554300 rs7182406 chr15 37833106 C T 3.36E-04 Smoking initiation / / 24665060 rs12592037 chr15 37835979 T C 1.40E-05 Non-obstructive azoospermia / / 22541561 rs8036621 chr15 37847632 A C 2.08E-04 Schizophrenia / / 19197363 rs8030155 chr15 37890727 A T 9.80E-05 Serum metabolites / / 19043545 rs11856650 chr15 38025137 G A 2.20E-05 Urinary metabolites / / 21572414 rs11073266 chr15 38038476 A G 2.90E-05 Urinary metabolites / / 21572414 rs16965556 chr15 38059688 C A 2.70E-05 Urinary metabolites / / 21572414 rs16965564 chr15 38063744 G T 7.97E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16965617 chr15 38066386 C T 2.50E-05 Urinary metabolites / / 21572414 rs1498420 chr15 38093931 C G 4.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs1498416 chr15 38104647 T A 4.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs7176262 chr15 38105366 C T 4.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs7176262 chr15 38105366 C T 1.28E-04 Body mass index / / 21701565 rs10852005 chr15 38105689 A C 8.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs1909205 chr15 38109242 T C 4.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs6495924 chr15 38113868 T C 9.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs8036460 chr15 38118653 C A 5.83E-05 Osteosarcoma / / 23727862 rs12915211 chr15 38120181 C A 3.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs11073269 chr15 38120848 T A 3.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs4924193 chr15 38121491 G A 2.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs12913238 chr15 38125674 T C 5.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs7496958 chr15 38126542 T C 6.63E-04 Multiple complex diseases / / 17554300 rs8030415 chr15 38126595 G C 3.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs6495926 chr15 38127856 C T 2.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs1502409 chr15 38129204 T G 2.00E-04 Polycystic ovary syndrome / / 22178785 rs1604531 chr15 38133126 A G 2.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs12904089 chr15 38133881 C T 4.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs1502412 chr15 38133987 C T 4.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs1964044 chr15 38134706 C T 4.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs982308 chr15 38135825 T C 3.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs1393411 chr15 38136159 G A 3.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs1393412 chr15 38136228 T C 3.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs1847159 chr15 38136481 C A 4.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs1502413 chr15 38136828 G A 4.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs7173308 chr15 38144177 T C 5.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs6495928 chr15 38144877 C G 3.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs6495928 chr15 38144877 C G 7.99E-04 Smoking quantity / / 24665060 rs4924198 chr15 38145866 G A 3.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs1393404 chr15 38146492 G A 1.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs7175992 chr15 38149269 G T 1.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs1472646 chr15 38151370 G A 3.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs8029216 chr15 38152318 T C 8.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs8182075 chr15 38154488 A C 1.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs6495930 chr15 38157362 A G 9.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs1910151 chr15 38158699 A G 4.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs3752855 chr15 38158758 T G 1.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs931758 chr15 38159018 T C 6.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs16923 chr15 38159054 C T 7.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs1553358 chr15 38159430 C T 7.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs4436739 chr15 38159534 C A 7.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs7166157 chr15 38159683 G A 7.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs7167536 chr15 38159686 C G 7.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs7167727 chr15 38159786 C T 8.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs4550408 chr15 38160817 A G 1.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs4924201 chr15 38161135 G T 1.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs4924202 chr15 38161374 A T 7.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs12595054 chr15 38161873 G T 1.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs12593433 chr15 38161914 T C 1.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs11073277 chr15 38161937 G T 1.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs11633555 chr15 38162390 A G 1.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs11629527 chr15 38162781 C A 1.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs8026871 chr15 38164397 A T 1.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs1553356 chr15 38164627 G T 1.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs1553355 chr15 38164649 A G 1.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs2036432 chr15 38165476 A C 1.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs11073278 chr15 38166513 T C 1.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs12148658 chr15 38168279 G A 1.00E-04 Asthma / / 11022011 rs16965853 chr15 38171825 A G 7.33E-05 Cognitive test performance / / 20125193 rs17637185 chr15 38178643 C T 9.90E-04 Coronary Artery Disease / / 17634449 rs17637185 chr15 38178643 C T 2.90E-06 Urinary metabolites / / 21572414 rs12594688 chr15 38193610 T G 3.51E-04 Multiple complex diseases / / 17554300 rs8035530 chr15 38297066 C T 1.50E-05 Carotid intima media thickness / / 19679847 rs11073286 chr15 38320909 T G 4.18E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11073286 chr15 38320909 T G 4.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9806524 chr15 38327154 A G 1.70E-04 Type 2 diabetes / / 17463246 rs12439022 chr15 38332096 A G 7.19E-04 Tourette syndrome / / 22889924 rs8034546 chr15 38337341 C A 0.00004 Pancreatic cancer and survival / / 22665904 rs12324479 chr15 38398000 G A 3.40E-05 Major depressive disorder / / 21042317 rs17559713 chr15 38399917 A G 0.0000534 Primary sclerosing cholangitis / / 23603763 rs6495949 chr15 38424060 T A 7.40E-04 Major depressive disorder / / 21042317 rs10468092 chr15 38434891 A G 4.00E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs16966389 chr15 38464874 G A 7.00E-07 Hypersomnia (HLA-DQB1*06:02 negative) / / 23646285 rs16966413 chr15 38479899 A G 4.74E-05 Bipolar disorder / / 21926972 rs16966413 chr15 38479899 A G 0.00000593 Bipolar disorder / / 23070075 rs970498 chr15 38482004 G A 1.47E-04 Multiple complex diseases / / 17554300 rs2174009 chr15 38487063 C G 1.02E-05 Hypersomnia (HLA-DQB1*06:02 negative) / / 23646285 rs2134333 chr15 38488839 A G 2.05E-05 Hypersomnia (HLA-DQB1*06:02 negative) / / 23646285 rs4923776 chr15 38490244 A T 7.80E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs11854769 chr15 38502243 C T 7.15E-06 Hypersomnia (HLA-DQB1*06:02 negative) / / 23646285 rs867043 chr15 38509927 T C 6.18E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16966460 chr15 38511983 C G 4.00E-06 Bipolar disorder / / 18711365 rs16966460 chr15 38511983 C G 6.70E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs8034300 chr15 38512492 A G 9.93E-04 Insulin resistance / / 21901158 rs8032887 chr15 38512759 G A 6.80E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs10520058 chr15 38550000 G T 5.40E-04 Lung adenocarcinoma SPRED1 intron 21242121 rs16966816 chr15 38637268 C T 3.90E-04 Multiple complex diseases SPRED1 intron 17554300 rs11073319 chr15 38642511 A T 5.93E-30 Multiple complex diseases SPRED1 intron 17554300 rs8030388 chr15 38670161 T C 9.61E-05 Stroke (ischemic) / / 22941190 rs8023597 chr15 38674713 A C 3.38E-05 Stroke (ischemic) / / 22941190 rs4924268 chr15 38721250 G A 5.70E-05 Bipolar disorder / / 21771265 rs8029989 chr15 38733847 A G 4.00E-06 Psychosis (atypical) / / 24132900 rs12905733 chr15 38739298 T G 7.40E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs8039162 chr15 38740829 C T 5.44E-04 Multiple complex diseases / / 17554300 rs11073328 chr15 38764843 C T 8.13E-04 Multiple complex diseases FAM98B intron 17554300 rs11073328 chr15 38764843 C T 1.00E-14 Systemic lupus erythematosus FAM98B intron 24871463 rs12591633 chr15 38779626 A G 7.05E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs7181389 chr15 38783682 G A 7.40E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) RASGRP1 intron 23648065 rs4334257 chr15 38791826 A C 7.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) RASGRP1 intron 23648065 rs7403531 chr15 38822905 T C 2.00E-04 Information processing speed RASGRP1 intron 21130836 rs7403531 chr15 38822905 T C 4.00E-09 Type 2 diabetes RASGRP1 intron 22961080 rs8043085 chr15 38828140 G T 6.15E-05 Type 2 diabetes RASGRP1 intron 22961080 rs8043085 chr15 38828140 G T 4.78E-12 Rheumatoid arthritis RASGRP1 intron 23143596 rs8043085 chr15 38828140 G T 4.82E-11 Rheumatoid arthritis (CCP positive) RASGRP1 intron 23143596 rs8032939 chr15 38834033 T C 2.00E-18 Rheumatoid arthritis RASGRP1 intron 24390342 rs8032939 chr15 38834033 T C 3.00E-14 Rheumatoid arthritis RASGRP1 intron 24390342 rs8032939 chr15 38834033 T C 9.00E-06 Rheumatoid arthritis RASGRP1 intron 24390342 rs8035957 chr15 38838264 T C 4.00E-06 Type 1 diabetes RASGRP1 intron 18840781 rs12593201 chr15 38844106 G A 4.13E-05 Type 2 diabetes RASGRP1 intron 22961080 rs12324139 chr15 38867209 G A 9.42E-05 Pulmonary function / / 20010835 rs12324161 chr15 38867290 C A 9.40E-05 Pulmonary function / / 20010835 rs11073338 chr15 38867413 T G 8.97E-05 Pulmonary function / / 20010835 rs11858911 chr15 38867914 T C 3.72E-04 Insulin resistance / / 21901158 rs13329072 chr15 38868788 A C 5.43E-04 Multiple complex diseases / / 17554300 rs11073339 chr15 38871876 T C 8.70E-05 Pulmonary function / / 20010835 rs11631064 chr15 38872059 G C 9.06E-05 Pulmonary function / / 20010835 rs11637664 chr15 38872225 T A 9.18E-05 Pulmonary function / / 20010835 rs11073340 chr15 38872908 G A 9.14E-05 Pulmonary function / / 20010835 rs16967103 chr15 38899190 T C 4.00E-09 Crohn's disease / / 23128233 rs17574546 chr15 38902476 A C 2.79E-05 Multiple complex diseases / / 17554300 rs7171171 chr15 38907041 A G 9.28E-05 Pulmonary function / / 20010835 rs7171171 chr15 38907041 A G 2.00E-07 Type 1 diabetes autoantibodies / / 21829393 rs16967120 chr15 38920447 C T 1.74E-04 Multiple complex diseases / / 17554300 rs12908309 chr15 38928677 G A 4.31E-08 Type 1 diabetes / / 21980299 rs9972494 chr15 38930523 C T 3.10E-05 Lymphocyte counts / / 22286170 rs13329279 chr15 38933948 T C 1.31E-04 Alzheimer's disease (late onset) / / 21379329 rs10438404 chr15 38938017 G T 4.37E-04 Suicide attempts in bipolar disorder / / 21041247 rs3923022 chr15 38938538 G A 4.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs1122891 chr15 38938677 C G 4.60E-04 Suicide attempts in bipolar disorder / / 21041247 rs1004496 chr15 38941557 C A 8.00E-05 Bipolar disorder and schizophrenia / / 20889312 rs1004496 chr15 38941557 C A 1.50E-05 Urinary metabolites / / 21572414 rs10852029 chr15 38943137 G A 2.38E-05 Bipolar disorder and schizophrenia / / 20889312 rs8031623 chr15 38944052 G A 8.57E-05 Multiple sclerosis / / 20598377 rs12439130 chr15 38950906 T C 1.39E-04 Insulin resistance / / 21901158 rs4924281 chr15 38955647 C T 4.14E-04 Insulin resistance / / 21901158 rs7168475 chr15 38960882 A C,G,T 0.00000198 Alcohol dependence / / 23089632 rs7168475 chr15 38960882 A C,G,T 0.000466 Alcohol dependence / / 23089632 rs1874252 chr15 38962756 G T 7.00E-06 Alcohol dependence (age at onset) / / 24962325 rs77397211 chr15 38970496 T C 0.000113 Rheumatoid arthritis / / 23143596 rs4924287 chr15 38972177 A G 4.40E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs4924287 chr15 38972177 A G 4.88E-06 Major depressive disorder / / 22472876 rs7174485 chr15 38977710 C A 1.49E-04 Multiple complex diseases / / 17554300 rs7174485 chr15 38977710 C A 7.50E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs7174485 chr15 38977710 C A 2.34E-05 Major depressive disorder / / 22472876 rs12912251 chr15 38986368 G T 1.00E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs12912251 chr15 38986368 G T 3.00E-06 Bipolar disorder / / 21926972 rs12912251 chr15 38986368 G T 3.57E-05 Major depressive disorder / / 22472876 rs12912251 chr15 38986368 G T 0.000000294 Bipolar disorder / / 23070075 rs12912251 chr15 38986368 G T 4.56E-08 Alcohol dependence / / 23089632 rs12898460 chr15 38986813 C T 1.00E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs12898460 chr15 38986813 C T 4.71E-08 Alcohol dependence / / 23089632 rs7496809 chr15 38987380 G A 1.37E-04 Major depressive disorder / / 22472876 rs12903120 chr15 38988097 G T 1.70E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs12903120 chr15 38988097 G T 4.16E-05 Major depressive disorder / / 22472876 rs12903120 chr15 38988097 G T 0.00000762 Alcohol dependence / / 23089632 rs12903120 chr15 38988097 G T 5.45E-08 Alcohol dependence / / 23089632 rs35102843 chr15 38988107 C A 4.55E-08 Alcohol dependence / / 23089632 rs7163869 chr15 38988391 G C 2.10E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs7163869 chr15 38988391 G C 9.32E-08 Alcohol dependence / / 23089632 rs7171233 chr15 38988760 T A 2.40E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs7171233 chr15 38988760 T A 8.45E-08 Alcohol dependence / / 23089632 rs7165988 chr15 38988815 C G 2.50E-06 Bipolar disorder and major depressive disorder (combined) C15orf53 missense 20351715 rs7165988 chr15 38988815 C G 0.000000097 Alcohol dependence C15orf53 missense 23089632 rs34356257 chr15 38989605 T C 0.000000101 Alcohol dependence C15orf53 intron 23089632 rs34141940 chr15 38989657 G A 0.000000107 Alcohol dependence C15orf53 intron 23089632 rs34281605 chr15 38989674 G A 0.000000125 Alcohol dependence C15orf53 intron 23089632 rs35024396 chr15 38989770 G A 0.000000123 Alcohol dependence C15orf53 intron 23089632 rs2172835 chr15 38990171 C T 2.63E-05 Bipolar disorder C15orf53 intron 18317468 rs2172835 chr15 38990171 C T 2.20E-06 Bipolar disorder and major depressive disorder (combined) C15orf53 intron 20351715 rs2172835 chr15 38990171 C T 2.97E-05 Major depressive disorder C15orf53 intron 22472876 rs2172835 chr15 38990171 C T 0.000000201 Alcohol dependence C15orf53 intron 23089632 rs17654449 chr15 38991164 C T 4.73E-04 Multiple complex diseases C15orf53 UTR-3 17554300 rs1495186 chr15 38991456 G A 3.09E-05 Bipolar disorder and schizophrenia C15orf53 UTR-3 20889312 rs12916379 chr15 38991520 A G 3.10E-06 Bipolar disorder and major depressive disorder (combined) C15orf53 UTR-3 20351715 rs12916379 chr15 38991520 A G 6.05E-05 Major depressive disorder C15orf53 UTR-3 22472876 rs12916379 chr15 38991520 A G 0.000000174 Alcohol dependence C15orf53 UTR-3 23089632 rs12916379 chr15 38991520 A G 0.0000406 Alcohol dependence C15orf53 UTR-3 23089632 rs2132157 chr15 38992547 A G 8.50E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs2132157 chr15 38992547 A G 8.67E-05 Major depressive disorder / / 22472876 rs2132157 chr15 38992547 A G 0.000000192 Alcohol dependence / / 23089632 rs2132157 chr15 38992547 A G 0.0000435 Alcohol dependence / / 23089632 rs12901215 chr15 38992893 G A 1.60E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs12901215 chr15 38992893 G A 0.000000438 Alcohol dependence / / 23089632 rs12899449 chr15 38995491 A G 4.00E-07 Bipolar disorder / / 18711365 rs12899449 chr15 38995491 A G 3.30E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs12899449 chr15 38995491 A G 2.19E-04 Major depressive disorder / / 22472876 rs12899449 chr15 38995491 A G 0.0000126 Alcohol dependence / / 23089632 rs7183893 chr15 38996981 A C 4.40E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs7183893 chr15 38996981 A C 0.00000082 Alcohol dependence / / 23089632 rs36094159 chr15 38998395 G A 0.000000694 Alcohol dependence / / 23089632 rs35795311 chr15 38998669 C G 0.000000644 Alcohol dependence / / 23089632 rs903530 chr15 38999048 G A 6.97E-05 Bipolar disorder and schizophrenia / / 20889312 rs7177621 chr15 38999394 G C 8.60E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs2643217 chr15 39003763 C T 7.66E-05 Bipolar disorder / / 19488044 rs2643217 chr15 39003763 C T 6.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs2643217 chr15 39003763 C T 6.67E-05 Bipolar Disorder / / pha002858 rs4924292 chr15 39005898 C T 2.84E-04 Multiple complex diseases / / 17554300 rs4924292 chr15 39005898 C T 4.60E-04 Prostate cancer mortality / / 20978177 rs8024474 chr15 39012579 C T 7.53E-05 Prostate cancer / / pha002878 rs17655894 chr15 39019106 A C 8.13E-04 Alzheimer's disease / / 17998437 rs7163834 chr15 39020093 C T 8.02E-05 Pulmonary function / / 20010835 rs2319753 chr15 39020455 T G 1.16E-05 Erythrocyte counts / / pha003101 rs11073348 chr15 39021360 G A 6.84E-06 Pulmonary function / / 20010835 rs2958295 chr15 39029326 A G 5.04E-06 Erythrocyte counts / / pha003101 rs2929648 chr15 39041813 G A 4.87E-05 Pulmonary function / / 20010835 rs2929649 chr15 39042370 A C 4.88E-05 Pulmonary function / / 20010835 rs1465510 chr15 39046198 G A 7.59E-05 Pulmonary function / / 20010835 rs1465511 chr15 39046212 G T 9.16E-05 Pulmonary function / / 20010835 rs2912368 chr15 39054256 T C 3.27E-04 Multiple complex diseases / / 17554300 rs10520109 chr15 39102235 G A 6.59E-04 Stroke / / pha002887 rs2624261 chr15 39114446 C T 0.0000188 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2624261 chr15 39114446 C T 1.88E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs16967544 chr15 39120891 A G 4.96E-04 Smoking initiation / / 24665060 rs2725793 chr15 39138790 G C 2.16E-05 Job-related exhaustion / / 23620144 rs2624265 chr15 39148649 T C 4.00E-07 Metabolic traits / / 19060910 rs2624265 chr15 39148649 T C 5.75E-06 Job-related exhaustion / / 23620144 rs2624265 chr15 39148649 T C 4.31E-07 Triglycerides / / pha002904 rs11852946 chr15 39188421 A C 5.72E-06 Rheumatoid arthritis / / 17804836 rs11073362 chr15 39194778 G A 9.49E-05 Bipolar disorder and schizophrenia / / 20889312 rs724234 chr15 39205447 A G 7.70E-04 Smoking initiation / / 24665060 rs768269 chr15 39235357 C A 6.82E-04 Smoking initiation / / 24665060 rs6492848 chr15 39264809 T C 2.75E-05 Blood Pressure / / pha003043 rs11639006 chr15 39313182 C A 3.51E-05 HIV-1 viral setpoint / / 22174851 rs11639006 chr15 39313182 C A 7.92E-05 Blood Pressure / / pha003043 rs16967959 chr15 39313960 G C 4.94E-04 Multiple complex diseases / / 17554300 rs12907914 chr15 39315358 G C 1.00E-06 Cardiac hypertrophy / / 21348951 rs973932 chr15 39315489 G C 8.57E-04 Multiple complex diseases / / 17554300 rs724729 chr15 39396761 C T 0.000047 Schizophrenia / / 23637625 rs1380934 chr15 39401850 A G 1.84E-04 Smoking initiation / / 24665060 rs16968186 chr15 39402251 A G 2.00E-04 Smoking initiation / / 24665060 rs275203 chr15 39438795 A G 1.30E-06 Urinary metabolites / / 21572414 rs2852078 chr15 39488869 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10520122 chr15 39492267 T C 3.12E-04 Type 2 diabetes / / 17463246 rs7183427 chr15 39503508 T G 3.53E-05 Information processing speed / / 21130836 rs7183427 chr15 39503508 T G 2.65E-04 Lung function (forced vital capacity) / / 24023788 rs9920660 chr15 39506360 C A 3.99E-04 Type 2 diabetes / / 17463246 rs276863 chr15 39520912 T C 5.03E-04 Heart Failure / / pha002884 rs17691453 chr15 39543946 T C 1.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) C15orf54 intron 23934736 rs11637020 chr15 39567305 A C 3.33E-04 Multiple complex diseases / / 17554300 rs11637020 chr15 39567305 A C 4.97E-04 Alzheimer's disease / / 17998437 rs12595668 chr15 39573535 A G 9.00E-06 PR interval / / 23534349 rs746265 chr15 39576560 A C 8.00E-06 PR interval / / 23534349 rs8037045 chr15 39582337 G C 7.14E-04 Multiple complex diseases / / 17554300 rs2053445 chr15 39589387 C G 4.96E-04 Multiple complex diseases / / 17554300 rs1530219 chr15 39602380 A G 1.52E-05 Type 2 diabetes / / 17463246 rs11634774 chr15 39611046 A G 6.00E-05 Type 2 diabetes / / 17463246 rs1978915 chr15 39615145 C A 1.24E-04 Body mass index / / 17255346 rs11631318 chr15 39618899 T C 3.69E-04 Body mass index / / 17255346 rs7181250 chr15 39622593 T C 7.02E-04 Alcohol dependence / / 21314694 rs2119404 chr15 39624418 T C 8.17E-05 Body Mass Index / / pha003006 rs1080066 chr15 39634222 A G 7.81E-05 Type 2 diabetes / / 17463246 rs17694988 chr15 39636227 T C 6.82E-05 Type 2 diabetes / / 17463246 rs2053446 chr15 39648969 T C 7.50E-06 Urinary metabolites / / 21572414 rs7496544 chr15 39651534 G A 4.30E-06 Urinary metabolites / / 21572414 rs11633745 chr15 39655924 T C 5.12E-05 Dengue shock syndrome / / 22001756 rs7350779 chr15 39725242 T C 8.84E-05 Type 2 diabetes / / 17463246 rs11857970 chr15 39739456 T A 7.87E-04 Multiple complex diseases / / 17554300 rs4244571 chr15 39761669 A G 1.96E-04 Type 2 diabetes / / 17463246 rs8042191 chr15 39765961 G A 3.40E-04 Multiple complex diseases / / 17554300 rs8032900 chr15 39767878 A G 4.18E-04 Type 2 diabetes / / 17463246 rs8032900 chr15 39767878 A G 1.10E-05 Urinary metabolites / / 21572414 rs16952145 chr15 39769296 A G 3.38E-04 Multiple complex diseases / / 17554300 rs4924361 chr15 39781789 T A 9.49E-05 Type 2 diabetes / / 17463246 rs8025111 chr15 39787426 A G 6.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs16969143 chr15 39795854 T C 4.40E-06 Urinary metabolites / / 21572414 rs936532 chr15 39798115 A G 4.40E-04 Endometriosis / / 21151130 rs2618157 chr15 39844315 G A 0.000067 Breast cancer / / 23555315 rs16969251 chr15 39845608 A C 2.66E-04 Multiple complex diseases / / 17554300 rs16969352 chr15 39869284 T C 0.000000316 HDL cholesterol / / 23063622 rs2292304 chr15 39880941 G T 4.86E-06 Lipid levels THBS1 intron 19913121 rs201454661 chr15 39881431 A G 0.000039 Breast cancer (ER positive) THBS1 missense 23555315 rs201454661 chr15 39881431 A G 0.000062 Breast cancer THBS1 missense 23555315 rs2412412 chr15 39920140 A G 8.16E-04 Suicide attempts in bipolar disorder FSIP1 intron 21423239 rs4572354 chr15 40014104 A G 7.51E-05 Cognitive impairment induced by topiramate FSIP1 intron 22091778 rs11070231 chr15 40021576 A C 6.59E-04 Suicide attempts in bipolar disorder FSIP1 intron 21423239 rs7171939 chr15 40022773 A G 2.79E-04 Suicide attempts in bipolar disorder FSIP1 intron 21423239 rs16952186 chr15 40025225 A G 4.31E-04 Type 2 diabetes FSIP1 intron 17463246 rs2171310 chr15 40025544 C T 6.27E-04 Suicide attempts in bipolar disorder FSIP1 intron 21423239 rs8033957 chr15 40038433 T C 3.77E-05 Asthma FSIP1 intron 11022011 rs8033957 chr15 40038433 T C 2.00E-06 Obesity-related traits FSIP1 intron 23251661 rs2576933 chr15 40058493 T C 5.30E-05 Age-related macular degeneration FSIP1 intron 20861866 rs1166722 chr15 40064140 C G 5.00E-05 Age-related macular degeneration FSIP1 intron 20861866 rs1602543 chr15 40066355 C T 1.42E-04 Multiple complex diseases FSIP1 intron 17554300 rs594863 chr15 40080045 G A 5.80E-06 Urinary metabolites / / 21572414 rs16952190 chr15 40085637 C T 6.61E-05 Coronary heart disease / / pha003031 rs275715 chr15 40112319 G A 1.97E-30 Varicose Veins GPR176 intron pha001414 rs275718 chr15 40113516 G A 1.80E-05 Urinary metabolites GPR176 intron 21572414 rs17718330 chr15 40123349 T C 7.13E-04 Response to TNF antagonist treatment GPR176 intron 21061259 rs17718330 chr15 40123349 T C 5.67E-05 Alcohol withdrawal symptoms GPR176 intron 22072270 rs1865753 chr15 40159878 C A 8.26E-04 Amyotrophic Lateral Sclerosis GPR176 intron 17362836 rs1836847 chr15 40176196 C T 9.00E-04 Type 2 diabetes GPR176 intron 17463246 rs4923846 chr15 40255430 G A 4.65E-04 Alzheimer's disease (late onset) EIF2AK4 intron 21379329 rs7176881 chr15 40266836 C T 1.70E-06 Brachial circumference EIF2AK4 intron 22479309 rs16970130 chr15 40281538 T C 1.50E-05 Urinary metabolites EIF2AK4 intron 21572414 rs2412459 chr15 40295959 C T 9.00E-06 Response to haloperidol in psychosis EIF2AK4 intron 24751813 rs3816900 chr15 40302243 C T 5.29E-04 Self-reported allergy EIF2AK4 intron 23817569 rs12592831 chr15 40302441 G A 5.28E-04 Self-reported allergy EIF2AK4 intron 23817569 rs2412464 chr15 40303842 G A 4.84E-04 Self-reported allergy EIF2AK4 intron 23817569 rs2307101 chr15 40322460 C T 8.41E-06 Corneal curvature EIF2AK4 intron 22969067 rs2250402 chr15 40322552 G T 6.00E-06 Corneal curvature EIF2AK4 intron 22969067 rs4432245 chr15 40324481 T C 1.00E-06 Body mass index EIF2AK4 intron 24827717 rs4432245 chr15 40324481 T C 6.39E-06 Body mass index EIF2AK4 intron 24827717 rs711906 chr15 40325691 C T 4.38E-06 Body mass index EIF2AK4 intron 24827717 rs711906 chr15 40325691 C T 4.38E-06 Body mass index EIF2AK4 intron 24827717 rs7497289 chr15 40333657 G A 7.30E-09 Dehydroepiandrosterone sulphate levels LOC100131089 intron 21533175 rs2412475 chr15 40334576 G A 2.00E-06 Obesity-related traits LOC100131089 intron 23251661 rs8026641 chr15 40338861 G A 2.17E-09 Dehydroepiandrosterone sulphate levels LOC100131089 intron 21533175 rs8026641 chr15 40338861 G A 3.90E-09 Ewing sarcoma LOC100131089 intron 22327514 rs4924410 chr15 40339494 A C 1.99E-09 Dehydroepiandrosterone sulphate levels LOC100131089 intron 21533175 rs4924410 chr15 40339494 A C 7.00E-09 Ewing sarcoma LOC100131089 intron 22327514 rs4924412 chr15 40344885 G A 4.67E-08 Dehydroepiandrosterone sulphate levels LOC100131089 intron 21533175 rs4924413 chr15 40348697 G A 3.08E-09 Dehydroepiandrosterone sulphate levels LOC100131089 intron 21533175 rs4497657 chr15 40359433 A T 4.87E-09 Dehydroepiandrosterone sulphate levels / / 21533175 rs7181230 chr15 40360741 A G 5.22E-05 Serum metabolites / / 19043545 rs7181230 chr15 40360741 A G 5.00E-11 Dehydroepiandrosterone sulphate levels / / 21533175 rs16970291 chr15 40363336 A T 1.05E-04 Multiple complex diseases / / 17554300 rs17723133 chr15 40365418 G A 6.62E-09 Dehydroepiandrosterone sulphate levels / / 21533175 rs9972424 chr15 40365851 A G 7.21E-11 Dehydroepiandrosterone sulphate levels / / 21533175 rs3923235 chr15 40371121 A G 6.60E-09 Dehydroepiandrosterone sulphate levels / / 21533175 rs16970325 chr15 40373131 C T 2.11E-05 Body Fat Distribution / / pha003017 rs16970325 chr15 40373131 C T 2.85E-05 Body Fat Distribution / / pha003018 rs7183977 chr15 40377092 T C 7.03E-11 Dehydroepiandrosterone sulphate levels / / 21533175 rs998713 chr15 40378467 A G 7.62E-09 Dehydroepiandrosterone sulphate levels / / 21533175 rs41500744 chr15 40379030 A C 8.50E-06 Multiple complex diseases / / 17554300 rs8024033 chr15 40403657 C G 2.71E-10 Chronic lymphocytic leukemia / / 23770605 rs11630670 chr15 40410840 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11630670 chr15 40410840 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs8023845 chr15 40414116 G T 2.00E-06 Chronic lymphocytic leukemia / / 24292274 rs4924428 chr15 40444347 T G 6.97E-05 Multiple complex diseases / / 17554300 rs3759839 chr15 40451588 A G 1.00E-04 Cognitive impairment induced by topiramate BUB1B nearGene-5 22091778 rs1031963 chr15 40451782 T C 1.42E-04 Multiple complex diseases BUB1B nearGene-5 17554300 rs1565866 chr15 40455894 T G 2.00E-04 Cognitive impairment induced by topiramate BUB1B intron 22091778 rs12915249 chr15 40490711 A G 4.02E-04 Sudden cardiac arrest BUB1B intron 21658281 rs4924439 chr15 40532868 G A 1.00E-06 Obesity-related traits PAK6 UTR-5 23251661 rs8034964 chr15 40534077 A G 2.21E-04 Lung function (forced vital capacity) PAK6 intron 24023788 rs900054 chr15 40546291 A G 2.31E-05 Lymphocyte counts PAK6 intron 22286170 rs731497 chr15 40555065 T C 4.05E-04 Iron levels PAK6 intron pha002876 rs2016902 chr15 40558087 G A 1.42E-06 Crohn's disease and psoriasis PAK6 cds-synon 22482804 rs936212 chr15 40581543 T C 6.61E-09 Triglycerides PLCB2 missense 23063622 rs1869901 chr15 40595627 G A 3.00E-06 Schizophrenia PLCB2 intron 21926974 rs1869901 chr15 40595627 G A 8.89E-04 Obesity (extreme) PLCB2 intron 21935397 rs1869901 chr15 40595627 G A 0.000203 Schizophrenia PLCB2 intron 23637625 rs3784397 chr15 40596844 C T 9.38E-04 Obesity (extreme) PLCB2 intron 21935397 rs961090 chr15 40617414 T C 2.39E-04 Multiple complex diseases / / 17554300 rs961090 chr15 40617414 T C 2.40E-04 Rheumatoid arthritis / / 22446963 rs2412511 chr15 40621701 G A 4.40E-04 Primary sclerosing cholangitis / / 19944697 rs2118960 chr15 40622941 A G 7.11E-05 Information processing speed / / 21130836 rs4244577 chr15 40643706 A G 8.80E-06 Urinary metabolites PHGR1 intron 21572414 rs11070266 chr15 40644776 C A 2.52E-04 Lung function (forced vital capacity) PHGR1 intron 24023788 rs1007177 chr15 40651838 A G 2.44E-08 Interstitial lung disease DISP2 intron 23583980 rs1007177 chr15 40651838 A G 5.59E-08 Interstitial lung disease DISP2 intron 23583980 rs7165012 chr15 40654038 A G 5.33E-04 Body mass index DISP2 intron 21701565 rs1898883 chr15 40655845 C G 0.0000411 Panic disorder DISP2 missense 23149450 rs1898883 chr15 40655845 C G 4.11E-05 Serum tamsulosin hydrochloride concentration DISP2 missense 23151678 rs1992272 chr15 40658970 T C 0.000024 Panic disorder DISP2 intron 23149450 rs1992272 chr15 40658970 T C 2.40E-05 Serum tamsulosin hydrochloride concentration DISP2 intron 23151678 rs1992272 chr15 40658970 T C 1.48E-08 Interstitial lung disease DISP2 intron 23583980 rs1992272 chr15 40658970 T C 3.49E-08 Interstitial lung disease DISP2 intron 23583980 rs7176592 chr15 40676997 C T 3.45E-04 Type 2 diabetes C15orf23 intron 17463246 rs7176592 chr15 40676997 C T 5.56E-04 Multiple complex diseases C15orf23 intron 17554300 rs6492944 chr15 40681676 T A 9.00E-04 Iris characteristics C15orf23 intron 21835309 rs2289332 chr15 40683780 G A 2.14E-05 Interstitial lung disease C15orf23 intron 23583980 rs8037941 chr15 40685508 T C 2.82E-05 Type 2 diabetes C15orf23 UTR-3 17463246 rs11541643 chr15 40685850 A G 2.89E-05 Type 2 diabetes C15orf23 UTR-3 17463246 rs11636361 chr15 40687828 G A 6.53E-06 Interstitial lung disease / / 23583980 rs1984793 chr15 40699373 C A 2.14E-04 Lymphocyte counts IVD intron 22286170 rs1984793 chr15 40699373 C A 5.74E-10 Interstitial lung disease IVD intron 23583980 rs2289331 chr15 40699940 T C 6.47E-10 Interstitial lung disease IVD intron 23583980 rs10518693 chr15 40700022 C T 8.63E-04 Body mass index IVD intron 21701565 rs10518693 chr15 40700022 C T 1.00E-13 Metabolic traits IVD intron 21886157 rs10518693 chr15 40700022 C T 1.90E-04 Myasthenia gravis IVD intron 23055271 rs10518693 chr15 40700022 C T 2.93E-06 Interstitial lung disease IVD intron 23583980 rs10518693 chr15 40700022 C T 4.01E-05 Angioedema in response to angiotensin-converting enzyme inhibitor IVD intron 23838604 rs9635324 chr15 40703211 A G 2.00E-35 Blood metabolite levels IVD intron 24816252 rs9635324 chr15 40703211 A G 9.00E-43 Blood metabolite ratios IVD intron 24816252 rs12440317 chr15 40704394 G A 1.24E-04 Alzheimer's disease (late onset) IVD intron 21379329 rs875767 chr15 40707456 C T 2.30E-04 Iris characteristics IVD intron 21835309 rs11070270 chr15 40708422 A G 1.00E-09 Interstitial lung disease IVD intron 23583980 rs11070270 chr15 40708422 A G 9.90E-10 Interstitial lung disease IVD intron 23583980 rs2075624 chr15 40710723 G A 4.60E-17 Progranulin levels IVD UTR-3 21087763 rs2075624 chr15 40710723 G A 4.60E-17 Myocardial infarction IVD UTR-3 21211798 rs1001528 chr15 40713774 A G 1.83E-10 Interstitial lung disease IVD nearGene-3 23583980 rs12914710 chr15 40713849 G A 8.41E-10 Interstitial lung disease IVD nearGene-3 23583980 rs12914315 chr15 40713878 A G 8.48E-10 Interstitial lung disease IVD nearGene-3 23583980 rs2034650 chr15 40717302 G A 7.15E-04 Type 2 diabetes / / 17463246 rs2034650 chr15 40717302 G A 3.20E-04 Myasthenia gravis / / 23055271 rs2034650 chr15 40717302 G A 1.00E-11 Interstitial lung disease / / 23583980 rs2034650 chr15 40717302 G A 1.86E-09 Interstitial lung disease / / 23583980 rs2034650 chr15 40717302 G A 2.27E-10 Interstitial lung disease / / 23583980 rs2034650 chr15 40717302 G A 3.65E-06 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs8034217 chr15 40721700 T C 5.32E-10 Interstitial lung disease / / 23583980 rs11070272 chr15 40725263 A G 5.88E-10 Interstitial lung disease / / 23583980 rs12368 chr15 40728036 C T 5.82E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs1453184 chr15 40729400 A G 2.73E-09 Interstitial lung disease / / 23583980 rs603104 chr15 40757035 A C 8.14E-05 Interstitial lung disease BAHD1 intron 23583980 rs667623 chr15 40765360 C T 2.38E-05 Lymphocyte counts CHST14 nearGene-3 22286170 rs16970734 chr15 40771097 A G 5.54E-06 Multiple complex diseases / / 17554300 rs4923876 chr15 40840557 A G 6.73E-04 Cognition,early reading ability / / 17684495 rs2412546 chr15 41006523 G A 7.02E-04 Alcohol dependence RAD51 intron 21314694 rs2412546 chr15 41006523 G A 1.20E-05 Lymphocyte counts RAD51 intron 22286170 rs957603 chr15 41009668 A G 1.50E-04 Volumetric brain MRI RAD51 intron 17903297 rs4923884 chr15 41036448 G A 1.65E-04 Lymphocyte counts FAM82A2 intron 22286170 rs3743033 chr15 41101124 C G 8.91E-09 Lymphocyte counts ZFYVE19 intron 22286170 rs17658212 chr15 41145919 C T 1.89E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SPINT1 cds-synon 21844884 rs7176208 chr15 41183441 C T 9.88E-05 Response to methylphenidate treatment / / 21130132 rs8036080 chr15 41196384 G A 3.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs6492971 chr15 41233035 G A 2.23E-05 Cognitive performance / / 19734545 rs3887640 chr15 41249871 T G 3.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs2928148 chr15 41401550 G A 4.04E-08 Chronic kidney disease INO80 intron 22479191 rs8030683 chr15 41511916 A G 6.42E-04 Multiple complex diseases EXD1 intron 17554300 rs6492995 chr15 41529712 T C 6.29E-04 Amyotrophic Lateral Sclerosis CHP intron 17362836 rs8034073 chr15 41545613 T G 1.89E-04 Amyotrophic Lateral Sclerosis CHP intron 17362836 rs16971733 chr15 41562030 C A 5.53E-04 Amyotrophic Lateral Sclerosis CHP intron 17362836 rs28374715 chr15 41563950 A G 2.00E-08 Ulcerative colitis CHP intron 23128233 rs7163649 chr15 41586798 A G 9.39E-04 Multiple complex diseases OIP5-AS1 intron 17554300 rs9302109 chr15 41612180 G T 0.00004 Glomerular filtration rate OIP5 intron 22962313 rs8023530 chr15 41647775 T C 1.99E-04 Body mass index NUSAP1 intron 17255346 rs11070328 chr15 41651569 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) NUSAP1 intron 20708005 rs11070328 chr15 41651569 T C 5.00E-08 Menopause (age at onset) NUSAP1 intron 22267201 rs7168431 chr15 41672384 A G 5.21E-05 Body mass index NUSAP1 cds-synon 17255346 rs3204853 chr15 41689166 C A 2.77E-04 Body mass index NDUFAF1 missense 17255346 rs1899 chr15 41689232 C T 4.12E-05 Body mass index NDUFAF1 missense 17255346 rs3743038 chr15 41694743 C T 6.80E-04 Amyotrophic lateral sclerosis (sporadic) NDUFAF1 nearGene-5 24529757 rs7164211 chr15 41705041 A T 3.19E-04 Body mass index / / 17255346 rs316604 chr15 41775221 C T 7.10E-04 Self-reported allergy RTF1 UTR-3 23817569 rs1757463 chr15 41783814 A G 4.60E-05 ldl cholesterol / / pha003076 rs1757456 chr15 41793494 A T 1.34E-04 Self-reported allergy ITPKA intron 23817569 rs1757457 chr15 41794454 C T 1.62E-04 Self-reported allergy ITPKA intron 23817569 rs316618 chr15 41796498 T A 1.72E-04 Self-reported allergy LTK intron 23817569 rs170296 chr15 41796901 G T 3.79E-05 Self-reported allergy LTK intron 23817569 rs141055831 chr15 41810286 C T 0.00035 Prostate cancer (non-advanced prostate cancer) RPAP1 missense 23555315 rs16971861 chr15 41846017 G C 2.85E-04 Type 2 diabetes / / 17463246 rs1200341 chr15 41860073 A G 6.56E-05 Blood Pressure TYRO3 intron pha003050 rs12259 chr15 41871492 A G 3.40E-06 Systemic lupus erythematosus TYRO3 UTR-3 24871463 rs17676742 chr15 41903048 A G 8.93E-07 Red blood cell traits / / 23222517 rs4924564 chr15 41909793 A T 2.37E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7176474 chr15 41931506 G A 5.90E-04 Type 2 diabetes / / 17463246 rs16971976 chr15 41989926 A G 5.10E-04 Type 2 diabetes MGA intron 17463246 rs16971976 chr15 41989926 A G 4.46E-04 Response to cytidine analogues (gemcitabine) MGA intron 24483146 rs2577949 chr15 42033682 T C 0.000706044 Hypertension (early onset hypertension) MGA intron 22479346 rs1918310 chr15 42065253 A C 8.72E-05 Multiple complex diseases / / 17554300 rs8035855 chr15 42077961 G A 2.65E-04 Response to cytidine analogues (gemcitabine) MAPKBP1 intron 24483146 rs11635086 chr15 42090101 A G 0.0000086 LDL cholesterol particle diameter MAPKBP1 intron 23263444 rs2925339 chr15 42091212 A G 5.06E-04 Type 2 diabetes MAPKBP1 intron 17463246 rs1197690 chr15 42097736 G A 0.000370758 Hypertension (early onset hypertension) MAPKBP1 intron 22479346 rs2303518 chr15 42109975 T G 8.64E-04 Response to cytidine analogues (gemcitabine) MAPKBP1 intron 24483146 rs1043627 chr15 42119900 T C 0.000707405 Hypertension (early onset hypertension) MAPKBP1 UTR-3 22479346 rs2241522 chr15 42127734 A G 4.79E-04 Response to cytidine analogues (gemcitabine) JMJD7-PLA2G4B intron 24483146 rs8031483 chr15 42152490 C T 6.51E-04 Multiple complex diseases SPTBN5 intron 17554300 rs4923918 chr15 42160943 G A 3.80E-13 Progranulin levels SPTBN5 intron 21087763 rs4923918 chr15 42160943 G A 3.80E-13 Myocardial infarction SPTBN5 intron 21211798 rs1197701 chr15 42187492 T C 0.0000846 Nicotine dependence (smoking) LOC100289090 missense 22377092 rs1672461 chr15 42190196 C T 7.17E-04 Alcohol dependence / / 21314694 rs12441018 chr15 42193571 T G 2.54E-04 Cocaine dependence EHD4 intron 23958962 rs17687331 chr15 42221302 G A 1.70E-04 Amyotrophic lateral sclerosis (sporadic) EHD4 intron 24529757 rs1648811 chr15 42222390 A G 0.0000828 Nicotine dependence (smoking) EHD4 intron 22377092 rs17687882 chr15 42233077 C T 2.06E-05 Lymphocyte counts EHD4 intron pha003094 rs17687882 chr15 42233077 C T 5.28E-05 Neutrophil count EHD4 intron pha003095 rs1614170 chr15 42239405 T C 4.32E-04 Multiple complex diseases EHD4 intron 17554300 rs1704405 chr15 42243801 G A 0.0000448 Cognitive impairment (no dementia) EHD4 intron 23042215 rs1704405 chr15 42243801 G A 0.0002377 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) EHD4 intron 23233654 rs1704405 chr15 42243801 G A 2.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) EHD4 intron 23233662 rs1704407 chr15 42250551 A G 0.0003502 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) EHD4 intron 23233654 rs1704407 chr15 42250551 A G 3.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) EHD4 intron 23233662 rs1530837 chr15 42281790 A G 5.14E-04 Amyotrophic Lateral Sclerosis PLA2G4E intron 17362836 rs1704352 chr15 42281805 C T 1.20E-05 Urinary metabolites PLA2G4E intron 21572414 rs12442207 chr15 42301334 T C 9.56E-04 Mammographic density PLA2G4E intron 22532574 rs1628549 chr15 42305698 C A 5.64E-04 Response to TNF antagonist treatment PLA2G4E intron 21061259 rs1623753 chr15 42307678 G C 3.43E-04 Response to TNF antagonist treatment PLA2G4E intron 21061259 rs11633848 chr15 42324845 C T 4.31E-04 Multiple complex diseases PLA2G4E intron 17554300 rs2665210 chr15 42327353 G A 8.69E-05 Multiple complex diseases PLA2G4E intron 17554300 rs2665211 chr15 42327556 C T 5.29E-05 Sodium levels PLA2G4E intron pha003093 rs16972565 chr15 42350013 C A 6.12E-05 Type 2 diabetes / / 17463246 rs16972584 chr15 42355706 C T 8.34E-05 Type 2 diabetes / / 17463246 rs1668589 chr15 42363769 A G 2.18E-04 Alcohol consumption PLA2G4D intron 23743675 rs639560 chr15 42381240 C T 4.66E-05 Mammographic density PLA2G4D intron 22532574 rs2034521 chr15 42415270 C A 9.17E-04 Stroke / / pha002887 rs682359 chr15 42426833 G T 1.14E-04 Stroke / / pha002887 rs1356410 chr15 42434837 T C 3.50E-05 Alcoholism (heaviness of drinking) PLA2G4F missense 21529783 rs1356410 chr15 42434837 T C 3.00E-06 QRS duration in Tripanosoma cruzi seropositivity PLA2G4F missense 24324551 rs1356410 chr15 42434837 T C 8.00E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity PLA2G4F missense 24324551 rs4923929 chr15 42439376 G A 8.72E-04 Mammographic density PLA2G4F cds-synon 22532574 rs593910 chr15 42447943 T A 9.07E-04 Multiple complex diseases PLA2G4F intron 17554300 rs1626437 chr15 42453278 A C 5.99E-04 Acute lung injury VPS39 intron 22295056 rs1679010 chr15 42460251 A G 3.10E-06 Urinary metabolites VPS39 intron 21572414 rs2138831 chr15 42493052 G A 2.80E-06 Urinary metabolites VPS39 intron 21572414 rs2663095 chr15 42502018 C A 1.76E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1678986 chr15 42521188 G C 2.70E-05 Urinary metabolites TMEM87A intron 21572414 rs1678985 chr15 42522010 T C 4.60E-04 Type 2 diabetes and 6 quantitative traits TMEM87A intron 17848626 rs10518756 chr15 42522792 G C 4.67E-05 Response to cytadine analogues (cytosine arabinoside) TMEM87A intron 24483146 rs1630294 chr15 42524065 T C 6.52E-04 Smoking initiation TMEM87A intron 24665060 rs7169546 chr15 42524374 G A 6.11E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines TMEM87A intron 21844884 rs2620387 chr15 42527218 A C 8.80E-05 Multiple complex diseases TMEM87A intron 17554300 rs1679012 chr15 42528676 C T 1.49E-04 Stroke TMEM87A intron pha002887 rs2277533 chr15 42565588 C A 2.82E-04 Response to cytadine analogues (cytosine arabinoside) TMEM87A cds-synon 24483146 rs8037020 chr15 42573067 C T 1.40E-06 Urinary metabolites GANC intron 21572414 rs8031315 chr15 42579110 G A 1.30E-06 Urinary metabolites GANC intron 21572414 rs12903690 chr15 42615305 A G 5.00E-05 Asperger disorder GANC intron 21182207 rs7164437 chr15 42635943 G A 1.90E-05 Urinary metabolites GANC intron 21572414 rs7183546 chr15 42638503 T C 1.40E-06 Urinary metabolites GANC intron 21572414 rs10518763 chr15 42639995 A G 7.65E-04 Multiple complex diseases GANC intron 17554300 rs16973148 chr15 42641263 A G 8.65E-04 Multiple complex diseases GANC intron 17554300 rs3743006 chr15 42645768 G A 3.20E-06 Urinary metabolites GANC UTR-3 21572414 rs1359003 chr15 42656939 C T 9.40E-07 Urinary metabolites CAPN3 intron 21572414 rs2412710 chr15 42683787 G A 2.00E-08 Triglycerides CAPN3 intron 20686565 rs2412710 chr15 42683787 G A 2.00E-11 Triglycerides CAPN3 intron 24097068 rs28364475 chr15 42692393 C T 5.13E-04 Smoking initiation CAPN3 intron 24665060 rs28364491 chr15 42694466 T C 7.08E-04 Smoking initiation CAPN3 intron 24665060 rs7163986 chr15 42696158 A T 3.10E-06 Urinary metabolites CAPN3 intron 21572414 rs28364503 chr15 42697343 G A 7.43E-04 Smoking initiation CAPN3 intron 24665060 rs3115881 chr15 42698551 A G 3.50E-06 Urinary metabolites CAPN3 intron 21572414 rs3115883 chr15 42701688 T C 5.47E-04 Stroke CAPN3 intron pha002887 rs12440118 chr15 42744094 A G 3.40E-04 Acute lung injury ZFP106 missense 22295056 rs2617237 chr15 42765624 G A 4.93E-05 Body Composition / / pha003012 rs2617237 chr15 42765624 G A 1.20E-05 Body Mass Index / / pha003021 rs17709596 chr15 42767981 G A 4.69E-04 Multiple complex diseases / / 17554300 rs12913324 chr15 42768379 T C 8.88E-04 Multiple complex diseases / / 17554300 rs17766258 chr15 42785137 G A 1.48E-04 Multiple complex diseases / / 17554300 rs17766258 chr15 42785137 G A 5.59E-04 Acute lung injury / / 22295056 rs11636209 chr15 42788107 A G 6.21E-04 Acute lung injury S/P23 intron 22295056 rs17709867 chr15 42800767 C T 8.67E-04 Acute lung injury S/P23 intron 22295056 rs11635889 chr15 42818987 T C 6.34E-04 Acute lung injury S/P23 intron 22295056 rs12439377 chr15 42861362 C T 1.03E-04 Multiple complex diseases HAUS2 UTR-3 17554300 rs12439377 chr15 42861362 C T 7.74E-04 Acute lung injury HAUS2 UTR-3 22295056 rs9783683 chr15 42875276 C A 6.21E-04 Acute lung injury STARD9 intron 22295056 rs7168835 chr15 42876014 T C 6.21E-04 Acute lung injury STARD9 intron 22295056 rs12903416 chr15 42881039 C T 5.52E-04 Acute lung injury STARD9 intron 22295056 rs17767264 chr15 42886656 C T 7.77E-04 Suicide attempts in bipolar disorder STARD9 intron 21423239 rs17767264 chr15 42886656 C T 1.78E-04 Acute lung injury STARD9 intron 22295056 rs1667493 chr15 42889170 C T 3.28E-04 Acute lung injury STARD9 intron 22295056 rs17767270 chr15 42898612 C T 2.93E-04 Multiple complex diseases STARD9 intron 17554300 rs17767270 chr15 42898612 C T 4.40E-04 Suicide attempts in bipolar disorder STARD9 intron 21423239 rs17767270 chr15 42898612 C T 1.79E-04 Acute lung injury STARD9 intron 22295056 rs12910538 chr15 42910357 G C 6.79E-04 Suicide attempts in bipolar disorder STARD9 intron 21423239 rs12910538 chr15 42910357 G C 2.25E-04 Acute lung injury STARD9 intron 22295056 rs623271 chr15 42928208 A G 7.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) STARD9 intron 20877124 rs8043472 chr15 42948862 A G 3.99E-04 Stroke STARD9 intron pha002887 rs8030587 chr15 42981806 G A 4.21E-05 Cognitive performance STARD9 missense 19734545 rs8030587 chr15 42981806 G A 1.53E-04 Stroke STARD9 missense pha002887 rs16957063 chr15 42984288 A G 5.00E-07 Protein quantitative trait loci STARD9 cds-synon 18464913 rs8039217 chr15 42987137 C A 1.27E-08 Cholesterol,total STARD9 intron 23063622 rs8039217 chr15 42987137 C A 4.11E-14 HDL cholesterol STARD9 intron 23063622 rs8039217 chr15 42987137 C A 5.85E-13 LDL cholesterol STARD9 intron 23063622 rs6493061 chr15 42988412 C A 4.42E-05 Cognitive performance STARD9 intron 19734545 rs6493061 chr15 42988412 C A 2.87E-04 Stroke STARD9 intron pha002887 rs4924694 chr15 42991066 T A 9.32E-04 Alcohol dependence STARD9 intron 21314694 rs16957091 chr15 43017426 T G 4.04E-04 Multiple complex diseases CDAN1 cds-synon 17554300 rs12917189 chr15 43023482 T C 1.78E-04 Stroke CDAN1 missense pha002887 rs7167392 chr15 43028592 G A 9.21E-04 Major depressive disorder CDAN1 cds-synon 22472876 rs7175582 chr15 43039063 G A 9.88E-04 Major depressive disorder TTBK2 intron 22472876 rs7166775 chr15 43042690 G A 6.10E-04 Multiple complex diseases TTBK2 intron 17554300 rs7166775 chr15 43042690 G A 6.26E-04 Alcohol dependence TTBK2 intron 21314694 rs7182141 chr15 43062548 T C 7.69E-04 Multiple complex diseases TTBK2 intron 17554300 rs12915116 chr15 43074680 C T 2.42E-04 Alcohol dependence TTBK2 intron 21314694 rs9806313 chr15 43176466 G A 5.78E-04 Smoking initiation TTBK2 intron 24665060 rs9920182 chr15 43202550 G A 7.06E-04 Major depressive disorder TTBK2 intron 22472876 rs2277532 chr15 43244699 A G 3.55E-06 Lung adenocarcinoma UBR1 intron 19836008 rs16957284 chr15 43247567 T C 9.55E-04 Response to taxane treatment (placlitaxel) UBR1 intron 23006423 rs12050604 chr15 43357406 A C 5.93E-33 Multiple complex diseases UBR1 intron 17554300 rs12050604 chr15 43357406 A C 9.75E-06 Lung adenocarcinoma UBR1 intron 19836008 rs17720657 chr15 43377604 G A 2.00E-05 Urinary metabolites UBR1 intron 21572414 rs7166467 chr15 43440522 G A 8.21E-05 Asthma TMEM62 intron pha003128 rs11070396 chr15 43522922 C A 7.70E-04 Multiple complex diseases / / 17554300 rs11070396 chr15 43522922 C A 8.89E-04 Iron levels / / pha002876 rs7183814 chr15 43529630 A G 4.05E-04 Multiple complex diseases TGM5 intron 17554300 rs16957511 chr15 43540117 C A 7.80E-04 Iron levels TGM5 intron pha002876 rs542036 chr15 43541139 C T 8.70E-04 Coronary heart disease TGM5 intron 21606135 rs825735 chr15 43542702 T A 3.80E-06 Urinary metabolites TGM5 intron 21572414 rs574065 chr15 43550655 A G 2.07E-10 Lymphocyte counts TGM5 intron 22286170 rs504417 chr15 43554226 A G 3.11E-06 Lung cancer TGM5 intron 19654303 rs504417 chr15 43554226 A G 2.08E-05 Lung adenocarcinoma TGM5 intron 19836008 rs11853991 chr15 43557549 A G 3.61E-06 Lung cancer TGM5 intron 19654303 rs471122 chr15 43558574 A G 1.59E-05 Lung adenocarcinoma TGM5 intron 19836008 rs471122 chr15 43558574 A G 1.52E-17 Lymphocyte counts TGM5 intron 22286170 rs748404 chr15 43559231 T C 1.00E-06 Lung cancer TGM5 nearGene-5 19654303 rs748404 chr15 43559231 T C 1.00E-06 Nasopharyngeal carcinoma TGM5 nearGene-5 20512145 rs2412777 chr15 43573724 C T 1.51E-05 Parkinson's disease TGM7 intron 21248740 rs17779494 chr15 43579223 C T 1.82E-04 Coronary heart disease TGM7 intron 21606135 rs514438 chr15 43620443 T A,C,G 2.13E-04 Coronary heart disease LCMT2 UTR-3 21606135 rs9920879 chr15 43639770 A G 1.10E-04 Parkinson's disease ADAL intron 21248740 rs6493084 chr15 43647627 A G 1.10E-04 Parkinson's disease / / 21248740 rs10518812 chr15 43652937 A C 2.49E-04 Coronary heart disease ZSCAN29 UTR-3 21606135 rs2412779 chr15 43655927 A G 3.33E-04 Bulimia nervosa ZSCAN29 intron 23568457 rs3809482 chr15 43661802 T C 1.18E-04 Parkinson's disease ZSCAN29 missense 21248740 rs17780920 chr15 43662362 C T 2.50E-04 Coronary heart disease / / 21606135 rs16957715 chr15 43708737 T G 1.22E-04 Coronary heart disease TP53BP1 intron 21606135 rs2602141 chr15 43724646 T G 8.00E-05 Parkinson's disease TP53BP1 missense 21248740 rs12899865 chr15 43741017 G A 2.11E-04 Coronary heart disease TP53BP1 intron 21606135 rs690367 chr15 43748304 A G 9.66E-08 Tumor biomarkers TP53BP1 cds-synon 23300138 rs2439832 chr15 43779686 C T 9.27E-05 Attention deficit hyperactivity disorder TP53BP1 intron pha002875 rs17782975 chr15 43798039 T C 4.46E-05 Parkinson's disease TP53BP1 intron 21248740 rs2253268 chr15 43800968 A C 9.48E-08 Tumor biomarkers TP53BP1 intron 23300138 rs506120 chr15 43802024 C T 4.25E-05 Lung adenocarcinoma TP53BP1 intron 19836008 rs506120 chr15 43802024 C T 1.12E-04 Parkinson's disease TP53BP1 intron 21248740 rs506120 chr15 43802024 C T 6.08E-08 Tumor biomarkers TP53BP1 intron 23300138 rs1869258 chr15 43803621 A C 6.16E-08 Tumor biomarkers / / 23300138 rs529611 chr15 43805988 T C 6.12E-08 Tumor biomarkers / / 23300138 rs694985 chr15 43813387 T C 3.95E-08 Tumor biomarkers MAP1A intron 23300138 rs2245715 chr15 43818052 G A 8.70E-04 Smoking behavior MAP1A missense 20418888 rs2245715 chr15 43818052 G A 8.90E-08 Tumor biomarkers MAP1A missense 23300138 rs2245715 chr15 43818052 G A 1.44E-04 Attention deficit hyperactivity disorder MAP1A missense pha002875 rs572837 chr15 43823813 A G 9.57E-08 Tumor biomarkers MAP1A UTR-3 23300138 rs689797 chr15 43826557 C A,G,T 8.03E-05 Parkinson's disease PPIP5K1 UTR-3 21248740 rs689797 chr15 43826557 C A,G,T 5.98E-08 Tumor biomarkers PPIP5K1 UTR-3 23300138 rs2255663 chr15 43829008 C T 7.15E-05 Parkinson's disease PPIP5K1 intron 21248740 rs2255663 chr15 43829008 C T 6.51E-08 Tumor biomarkers PPIP5K1 intron 23300138 rs2255440 chr15 43830467 T C 9.34E-08 Tumor biomarkers PPIP5K1 intron 23300138 rs2255410 chr15 43831097 G A 7.45E-08 Tumor biomarkers PPIP5K1 intron 23300138 rs496584 chr15 43831923 C T 6.08E-08 Tumor biomarkers PPIP5K1 intron 23300138 rs2255042 chr15 43834318 C T 5.71E-08 Tumor biomarkers PPIP5K1 intron 23300138 rs2251844 chr15 43836478 T C 1.00E-14 Tumor biomarkers PPIP5K1 intron 23300138 rs486301 chr15 43836949 G A 5.34E-08 Tumor biomarkers PPIP5K1 intron 23300138 rs2927071 chr15 43919081 T C 1.16E-04 Parkinson's disease / / 21248740 rs17795279 chr15 43929378 C T 1.81E-04 Coronary heart disease CATSPER2 intron 21606135 rs10438303 chr15 44016417 T C 0.000000316 Triglycerides / / 23063622 rs11070411 chr15 44058634 G C 1.19E-04 Coronary heart disease PDIA3 intron 21606135 rs3087657 chr15 44063859 G A 1.13E-04 Parkinson's disease PDIA3 UTR-3 21248740 rs663214 chr15 44113782 T G 1.22E-04 Parkinson's disease MFAP1 intron 21248740 rs663214 chr15 44113782 T G 0.00000301 Triglycerides MFAP1 intron 23063622 rs2930531 chr15 44121570 G A 1.82E-04 Coronary heart disease WDR76 intron 21606135 rs11854565 chr15 44148142 C T 4.35E-05 Cognitive performance WDR76 intron 19734545 rs524908 chr15 44187991 C A 5.52E-05 Parkinson's disease FRMD5 intron 21248740 rs2016840 chr15 44211868 G A 2.47E-04 Multiple complex diseases FRMD5 intron 17554300 rs483800 chr15 44218366 A G 5.00E-05 Prostate cancer FRMD5 intron 21743057 rs16948098 chr15 44219607 G A 2.00E-08 Serum albumin level FRMD5 intron 23022100 rs2412823 chr15 44227270 C T 8.40E-04 Response to platinum-based chemotherapy in non-small-cell lung cancer FRMD5 intron 21483023 rs8035382 chr15 44244523 T C 2.00E-05 Prostate cancer FRMD5 intron 21743057 rs2929282 chr15 44245931 A T 2.00E-11 Triglycerides FRMD5 intron 20686565 rs2929282 chr15 44245931 A T 2.00E-05 Prostate cancer FRMD5 intron 21743057 rs2929282 chr15 44245931 A T 2.00E-09 Triglycerides FRMD5 intron 24097068 rs2929281 chr15 44266081 G T 8.00E-05 Prostate cancer FRMD5 intron 21743057 rs2412845 chr15 44266692 C T 8.00E-05 Prostate cancer FRMD5 intron 21743057 rs2412846 chr15 44269353 G A 8.00E-05 Prostate cancer FRMD5 intron 21743057 rs2930528 chr15 44270531 A G 9.00E-05 Prostate cancer FRMD5 intron 21743057 rs2412851 chr15 44278441 G A 8.00E-05 Prostate cancer FRMD5 intron 21743057 rs10851415 chr15 44284168 G A 8.00E-05 Prostate cancer FRMD5 intron 21743057 rs6493092 chr15 44289418 C T 8.00E-05 Prostate cancer FRMD5 intron 21743057 rs4924729 chr15 44291244 T C 8.00E-05 Prostate cancer FRMD5 intron 21743057 rs4924731 chr15 44296724 A G 8.00E-05 Prostate cancer FRMD5 intron 21743057 rs10851416 chr15 44304308 G A 8.00E-05 Prostate cancer FRMD5 intron 21743057 rs6493093 chr15 44305495 C G 8.00E-05 Prostate cancer FRMD5 intron 21743057 rs9920249 chr15 44310206 T A 8.00E-05 Prostate cancer FRMD5 intron 21743057 rs11070419 chr15 44327179 C G 8.00E-05 Prostate cancer FRMD5 intron 21743057 rs2899103 chr15 44340555 A T 8.00E-05 Prostate cancer FRMD5 intron 21743057 rs4924737 chr15 44364901 T A 8.00E-05 Prostate cancer FRMD5 intron 21743057 rs2555375 chr15 44380904 G A 1.00E-04 Prostate cancer FRMD5 intron 21743057 rs2733221 chr15 44389870 T C 1.00E-04 Prostate cancer FRMD5 intron 21743057 rs2615297 chr15 44406021 A C 1.00E-04 Prostate cancer FRMD5 intron 21743057 rs2615294 chr15 44412620 C A 1.00E-04 Prostate cancer FRMD5 intron 21743057 rs2555389 chr15 44431145 A G 1.00E-04 Prostate cancer FRMD5 intron 21743057 rs2162365 chr15 44433142 G A 1.00E-04 Prostate cancer FRMD5 intron 21743057 rs2217108 chr15 44433377 C T 1.00E-04 Prostate cancer FRMD5 intron 21743057 rs1834641 chr15 44434312 T G 1.00E-04 Prostate cancer FRMD5 intron 21743057 rs2162366 chr15 44439380 G A 1.00E-04 Prostate cancer FRMD5 intron 21743057 rs2706462 chr15 44475328 A G 1.05E-04 Multiple complex diseases FRMD5 intron 17554300 rs2447334 chr15 44478894 C T 2.43E-04 Multiple complex diseases FRMD5 intron 17554300 rs2706464 chr15 44486511 C T 5.56E-04 Suicide attempts in bipolar disorder FRMD5 intron 21423239 rs2615300 chr15 44491604 G A 5.43E-04 Smoking initiation / / 24665060 rs870161 chr15 44502266 T C 6.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs2615258 chr15 44504115 A C 6.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs2696082 chr15 44507403 T G 5.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs2615257 chr15 44513090 C T 4.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs2957586 chr15 44516005 A G 9.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs8024461 chr15 44582886 G A 3.17E-05 Alcohol dependence CASC4 intron 21703634 rs1021800 chr15 44609796 T C 1.00E-04 Cognitive impairment induced by topiramate CASC4 intron 22091778 rs12148618 chr15 44614684 A G 1.41E-04 Stroke CASC4 intron pha002887 rs12594110 chr15 44620129 C T 1.85E-04 Multiple complex diseases CASC4 intron 17554300 rs11856569 chr15 44674840 A C 1.48E-05 Alcohol dependence CASC4 intron 21703634 rs10518985 chr15 44724287 C T 4.90E-04 Type 2 diabetes and 6 quantitative traits CTDSPL2 intron 17848626 rs2453274 chr15 44774202 C T 0.00000232 Preeclampsia CTDSPL2 intron 22432041 rs2556560 chr15 44821843 A G 1.77E-05 Alcohol dependence / / 21703634 rs2556568 chr15 44852101 G A 2.03E-05 HIV-1 viral setpoint EIF3J intron 21490045 rs3759871 chr15 44943757 A G 2.46E-05 Alcohol dependence SPG11 missense 21703634 rs10152685 chr15 44959112 T C 4.30E-05 Multiple complex diseases PATL2 intron 17554300 rs7165535 chr15 45016345 A G 2.00E-05 Urinary metabolites / / 21572414 rs4923993 chr15 45026900 T C 2.05E-04 Multiple complex diseases / / 17554300 rs2084835 chr15 45049695 T C 2.50E-05 Urinary metabolites TRIM69 intron 21572414 rs3100141 chr15 45056132 T C 5.07E-04 Amyotrophic lateral sclerosis (sporadic) TRIM69 intron 24529757 rs17518970 chr15 45095902 A G 3.32E-05 Monocyte chemoattractant protein-1 / / pha003071 rs1288097 chr15 45141373 G A 8.52E-04 Stroke / / pha002887 rs735480 chr15 45152371 T C 2.20E-04 Stroke / / pha002887 rs8043226 chr15 45321593 G A 4.94E-04 Hemoglobin concentration SORD intron 20534544 rs269866 chr15 45394406 G A 1.80E-04 Hemoglobin concentration DUOX2 intron 20534544 rs139786814 chr15 45401034 C T 0.0002 Breast cancer (ER positive) DUOX2 missense 23555315 rs2001616 chr15 45404066 G A 0.0000052 Stroke DUOX2 missense 23422753 rs175088 chr15 45413672 A G 1.21E-04 Hemoglobin concentration DUOXA1 intron 20534544 rs1648282 chr15 45425864 G A 3.20E-05 HDL cholesterol DUOX1 intron pha003074 rs150683309 chr15 45434309 G A 0.00011 Breast cancer DUOX1 cds-synon 23555315 rs1617207 chr15 45447262 A G 3.64E-05 Depression (quantitative trait) DUOX1 intron 20800221 rs3959644 chr15 45488132 G T 3.49E-04 Stroke SHF intron pha002887 rs765787 chr15 45500047 A G 3.00E-06 Uric acid levels / / 22229870 rs1060896 chr15 45554267 C A 1 Drug response to Gemcitabine SLC28A2 missense 15224082 rs16941355 chr15 45568862 T C 6.42E-04 Multiple complex diseases / / 17554300 rs2453533 chr15 45641225 C A 5.00E-22 Chronic kidney disease / / 20383146 rs2453533 chr15 45641225 C A 4.03E-22 Chronic kidney disease / / 22479191 rs1153859 chr15 45644709 C T 1.08E-04 Chronic kidney disease / / 21931561 rs1153859 chr15 45644709 C T 1.08E-04 Chronic kidney disease / / 21931561 rs1153859 chr15 45644709 C T 2.20E-04 Chronic kidney disease / / 21931561 rs1153858 chr15 45652703 C T 1.00E-45 Homoarginine levels / / 24047826 rs2433610 chr15 45686091 C T 9.00E-12 Metabolite levels / / 24625756 rs2467853 chr15 45698793 T G 6.00E-14 Renal function and chronic kidney disease SPATA5L1 intron 19430482 rs17536527 chr15 45719187 G C 8.00E-10 Glomerular filtration rate / / 23535967 rs1547489 chr15 45724130 G A 4.99E-04 Multiple complex diseases C15orf48 intron 17554300 rs2453518 chr15 45728737 A G 1.20E-05 Urinary metabolites / / 21572414 rs17537244 chr15 45742278 C A,G,T 9.20E-06 Urinary metabolites / / 21572414 rs1153831 chr15 45772448 G A 1.60E-05 Urinary metabolites / / 21572414 rs950027 chr15 45801035 T C 5.00E-06 Response to fenofibrate (adiponectin levels) SLC30A4 intron 23149075 rs8042811 chr15 45847921 T C 2.30E-04 Endometriosis / / 23104006 rs755165 chr15 45856592 T C 3.00E-05 Panic disorder / / 19165232 rs8025407 chr15 45862452 C T 1.67E-04 Multiple complex diseases / / 17554300 rs8025407 chr15 45862452 C T 8.80E-06 Urinary metabolites / / 21572414 rs607541 chr15 45934869 C A 8.00E-06 Obesity-related traits SQRDL intron 23251661 rs682805 chr15 45945513 C T 4.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SQRDL intron 20877124 rs6493165 chr15 45947619 G A 4.08E-04 Multiple complex diseases SQRDL intron 17554300 rs676476 chr15 45950569 G A 8.93E-04 Suicide attempts in bipolar disorder SQRDL intron 21423239 rs12910629 chr15 45969780 C T 8.93E-05 Prion diseases SQRDL intron 22210626 rs12594515 chr15 45985071 G C 5.00E-06 Weight / / 20966902 rs12594515 chr15 45985071 G C 7.00E-06 Waist circumference / / 20966902 rs7172161 chr15 45990780 A G 8.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs654994 chr15 46012269 G A 3.96E-05 Scoliosis / / 21216876 rs588590 chr15 46032151 C T 2.25E-05 Body mass index / / 22446040 rs12915209 chr15 46040457 T G 4.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12900165 chr15 46078851 C T 3.11E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs68120365 chr15 46103368 G A 1.47E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs35325894 chr15 46105237 A G 1.33E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs35325894 chr15 46105237 A G 9.21E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs35053544 chr15 46122936 T C 6.00E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs35053544 chr15 46122936 T C 8.00E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs2460641 chr15 46125769 A C 4.97E-04 Parkinson's disease / / 16252231 rs2252546 chr15 46126991 T C 8.95E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs17637724 chr15 46141171 T C 3.43E-05 Non-word repetition / / 23738518 rs10519038 chr15 46172202 A G 5.60E-05 Multiple complex diseases / / 17554300 rs2463370 chr15 46211086 C T 1.26E-05 Cholesterol / / pha003083 rs11855962 chr15 46216155 T C 4.21E-06 Cholesterol / / pha003083 rs12914725 chr15 46564005 C T 3.51E-04 Type 2 diabetes / / 22158537 rs17649182 chr15 46564443 C T 5.13E-04 Multiple complex diseases / / 17554300 rs6493206 chr15 46569466 G T 4.00E-06 Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure) / / 21130132 rs17649891 chr15 46588068 T A 4.94E-04 Multiple complex diseases / / 17554300 rs721443 chr15 46594887 T A 8.11E-04 Multiple complex diseases / / 17554300 rs16953594 chr15 46595789 T C 7.40E-04 Multiple complex diseases / / 17554300 rs2571249 chr15 46605277 G A 4.10E-04 Multiple complex diseases / / 17554300 rs2571249 chr15 46605277 G A 3.50E-05 Parkinson's disease (familial) / / 18985386 rs2571249 chr15 46605277 G A 4.14E-06 Coronary heart disease / / pha003035 rs1843089 chr15 46606631 G A 4.53E-06 Coronary heart disease / / pha003035 rs10459609 chr15 46616220 G A 4.59E-04 Multiple complex diseases / / 17554300 rs10459609 chr15 46616220 G A 2.00E-05 Parkinson's disease (familial) / / 18985386 rs10459609 chr15 46616220 G A 1.05E-05 Coronary heart disease / / pha003035 rs4775302 chr15 46639808 G A 4.00E-08 Prostate cancer / / 22130093 rs1564781 chr15 46640863 T C 5.18E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs4503732 chr15 46642263 C A 4.56E-07 Esophageal cancer (squamous cell) / / 22960999 rs2062308 chr15 46700711 C T 2.37E-05 Bipolar disorder and schizophrenia / / 20889312 rs1385073 chr15 46703608 A G 4.06E-05 Bipolar disorder and schizophrenia / / 20889312 rs11070519 chr15 46706608 G A 5.56E-05 Bipolar disorder and schizophrenia / / 20889312 rs1484192 chr15 46708274 T C 7.03E-04 Taste perception / / 22132133 rs11853849 chr15 46712299 C T 7.56E-05 Bipolar disorder and schizophrenia / / 20889312 rs11853869 chr15 46712371 C T 1.97E-05 Attention deficit hyperactivity disorder / / 20732627 rs10431772 chr15 46715957 G C 5.63E-05 Bipolar disorder and schizophrenia / / 20889312 rs12148240 chr15 46742015 A G 1.40E-05 Urinary metabolites / / 21572414 rs17596339 chr15 46743643 G A 8.56E-04 Glycemic traits (pregnancy) / / 23903356 rs165030 chr15 46747113 T C 7.40E-06 Urinary metabolites / / 21572414 rs1897315 chr15 46749063 A G 2.30E-06 Urinary metabolites / / 21572414 rs996215 chr15 46789822 A G 2.10E-05 Urinary metabolites / / 21572414 rs8029968 chr15 46842308 T C 2.26E-06 Bipolar disorder / / 18317468 rs8029968 chr15 46842308 T C 2.70E-05 Urinary metabolites / / 21572414 rs10519059 chr15 46845278 A C 8.06E-04 Type 2 diabetes / / 17846125 rs10519060 chr15 46845521 A G 2.70E-05 Urinary metabolites / / 21572414 rs10519060 chr15 46845521 A G 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs8031287 chr15 46846206 C T 9.73E-07 Bipolar disorder / / 18317468 rs8031287 chr15 46846206 C T 2.40E-05 Urinary metabolites / / 21572414 rs1155904 chr15 46870196 C T 4.21E-04 Multiple complex diseases / / 17554300 rs8027451 chr15 46870334 G A 1.71E-04 Multiple complex diseases / / 17554300 rs701464 chr15 46870855 C T 5.87E-06 Esophageal cancer (squamous cell) / / 22960999 rs2203646 chr15 46884236 G A 5.83E-05 Hemoglobin concentration / / 20534544 rs4775639 chr15 46895298 T G 8.22E-05 Cognitive impairment induced by topiramate / / 22091778 rs576486 chr15 46904293 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs535481 chr15 46936563 A G 5.28E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs552806 chr15 46937053 A G 5.53E-05 Intelligence / / 21826061 rs1402135 chr15 46985805 T G 1.40E-05 Urinary metabolites / / 21572414 rs11636906 chr15 46994087 C A 6.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs6493231 chr15 47000090 T C 2.00E-06 Urinary metabolites / / 21572414 rs4338736 chr15 47003069 C A 4.99E-05 Myopia (pathological) / / 21095009 rs4338736 chr15 47003069 C A 2.21E-04 Rheumatoid arthritis / / 21452313 rs12441872 chr15 47021458 A G 3.39E-04 Myopia (pathological) / / 21095009 rs12441872 chr15 47021458 A G 4.46E-04 Rheumatoid arthritis / / 21452313 rs12442123 chr15 47022264 C A 2.72E-04 Rheumatoid arthritis / / 21452313 rs16958536 chr15 47029906 A G 4.00E-06 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs16958536 chr15 47029906 A G 6.95E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs10519075 chr15 47032623 C T 2.12E-04 Myopia (pathological) / / 21095009 rs10519075 chr15 47032623 C T 5.63E-04 Rheumatoid arthritis / / 21452313 rs12440351 chr15 47050146 G A 3.63E-04 Rheumatoid arthritis / / 21452313 rs11854033 chr15 47051699 T C 3.02E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs12439073 chr15 47068203 G A 7.62E-04 Multiple complex diseases / / 17554300 rs1918662 chr15 47093850 G A 7.21E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17271669 chr15 47156634 G A 6.43E-05 Cognitive performance / / 19734545 rs7183100 chr15 47221365 T C 2.07E-04 Coronary heart disease / / 21606135 rs9806695 chr15 47241455 G T 4.99E-04 Type 2 diabetes / / 17463246 rs12443493 chr15 47289718 G A 9.32E-04 Type 2 diabetes / / 17463246 rs12443493 chr15 47289718 G A 7.65E-04 Coronary heart disease / / 21606135 rs10431773 chr15 47293475 C T 4.74E-04 Coronary heart disease / / 21606135 rs8031753 chr15 47310628 C T 8.77E-05 Cognitive performance / / 19734545 rs8031753 chr15 47310628 C T 4.82E-05 Erythrocyte counts / / pha003090 rs1515744 chr15 47335670 A G 8.41E-04 Coronary heart disease / / 21606135 rs17282187 chr15 47395490 T C 4.26E-04 Type 2 diabetes / / 17463246 rs10519101 chr15 47406817 T C 9.60E-04 Type 2 diabetes / / 17463246 rs2175573 chr15 47407064 T C 8.04E-04 Type 2 diabetes / / 17463246 rs1949320 chr15 47432793 C A 2.80E-06 Urinary metabolites / / 21572414 rs1588913 chr15 47438046 G A 8.52E-04 White matter integrity / / 22425255 rs17355029 chr15 47447605 T C 8.20E-05 Tooth agenesis (mandibular third molar) / / 24172245 rs1037552 chr15 47449924 G A 6.70E-06 Urinary metabolites / / 21572414 rs1972118 chr15 47470383 T C 2.50E-05 Urinary metabolites / / 21572414 rs13329602 chr15 47472264 C T 2.02E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9806619 chr15 47472400 G T 9.05E-04 Type 2 diabetes / / 17463246 rs7176566 chr15 47496491 C T 1.41E-04 Alzheimer's disease SEMA6D intron 17998437 rs7178456 chr15 47496801 T C 5.49E-04 Multiple complex diseases SEMA6D intron 17554300 rs7178456 chr15 47496801 T C 7.22E-05 Alzheimer's disease SEMA6D intron 17998437 rs1040148 chr15 47503152 G T 9.39E-04 Multiple complex diseases SEMA6D intron 17554300 rs1040148 chr15 47503152 G T 2.77E-04 Alzheimer's disease SEMA6D intron 17998437 rs9944240 chr15 47504936 C T 6.87E-04 Multiple complex diseases SEMA6D intron 17554300 rs9944240 chr15 47504936 C T 5.42E-04 Alzheimer's disease SEMA6D intron 17998437 rs282518 chr15 47505723 C T 8.78E-04 Multiple complex diseases SEMA6D intron 17554300 rs11856940 chr15 47511314 A T 3.10E-04 Alzheimer's disease SEMA6D intron 17998437 rs6493265 chr15 47513253 C T 2.63E-04 Alzheimer's disease SEMA6D intron 17998437 rs6493265 chr15 47513253 C T 4.53E-05 Lung adenocarcinoma SEMA6D intron 19836008 rs1563245 chr15 47518807 T G 3.83E-04 Alzheimer's disease SEMA6D intron 17998437 rs903979 chr15 47587757 C T 0.000014 LDL cholesterol particle diameter SEMA6D intron 23263444 rs12916429 chr15 47603058 G C 3.15E-04 Multiple complex diseases SEMA6D intron 17554300 rs6493270 chr15 47613403 T C 4.44E-05 Vaspin levels SEMA6D intron 22907691 rs6493270 chr15 47613403 T C 0.0000444 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks SEMA6D intron 22907730 rs6493270 chr15 47613403 T C 0.0000558 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit SEMA6D intron 22907730 rs4774494 chr15 47651161 T C 6.04E-04 White matter integrity SEMA6D intron 22425255 rs4774495 chr15 47651362 T C 5.48E-04 White matter integrity SEMA6D intron 22425255 rs6493274 chr15 47676489 A C 9.83E-04 White matter integrity SEMA6D intron 22425255 rs6493274 chr15 47676489 A C 1.56E-04 Vaspin levels SEMA6D intron 22907691 rs6493274 chr15 47676489 A C 0.0001557 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks SEMA6D intron 22907730 rs16959379 chr15 47678343 G A 6.26E-04 Acute lung injury SEMA6D intron 22295056 rs281286 chr15 47681250 T C 5.02E-04 White matter integrity SEMA6D intron 22425255 rs281291 chr15 47682428 A G 2.01E-04 Coronary Artery Disease SEMA6D intron 17634449 rs4359384 chr15 47684464 C T 7.56E-04 Acute lung injury SEMA6D intron 22295056 rs4356418 chr15 47684632 C G 3.39E-04 Coronary Artery Disease SEMA6D intron 17634449 rs281296 chr15 47685010 G A 3.05E-04 Coronary Artery Disease SEMA6D intron 17634449 rs1025144 chr15 47685080 A G 1.52E-04 Coronary Artery Disease SEMA6D intron 17634449 rs1025145 chr15 47685306 A G 5.71E-04 White matter integrity SEMA6D intron 22425255 rs962949 chr15 47685378 A G 3.70E-04 Coronary Artery Disease SEMA6D intron 17634449 rs281297 chr15 47685504 T C 6.97E-05 Coronary Artery Disease SEMA6D intron 17634449 rs281299 chr15 47686081 C T 2.44E-04 Coronary heart disease SEMA6D intron 21606135 rs281236 chr15 47723113 A G 8.18E-05 Waist-Hip Ratio SEMA6D intron pha003029 rs16959499 chr15 47732499 T G 6.85E-04 Parkinson's disease SEMA6D intron 17052657 rs8034783 chr15 47763726 C T 7.95E-04 Parkinson's disease SEMA6D intron 17052657 rs8034783 chr15 47763726 C T 1.00E-04 White matter integrity SEMA6D intron 22425255 rs12439521 chr15 47794201 A G 1.80E-05 Urinary metabolites SEMA6D intron 21572414 rs12441744 chr15 47812196 G A 1.77E-04 Multiple complex diseases SEMA6D intron 17554300 rs12441744 chr15 47812196 G A 1.80E-05 Urinary metabolites SEMA6D intron 21572414 rs12441302 chr15 47814745 T A 1.12E-04 Multiple complex diseases SEMA6D intron 17554300 rs8032090 chr15 47816319 A G 1.80E-05 Urinary metabolites SEMA6D intron 21572414 rs2304413 chr15 47817840 A G 1.98E-04 Multiple complex diseases SEMA6D intron 17554300 rs2304413 chr15 47817840 A G 1.80E-05 Urinary metabolites SEMA6D intron 21572414 rs11070592 chr15 47821138 G A 2.79E-04 Type 2 diabetes SEMA6D intron 17463246 rs8027222 chr15 47832577 G A 1.30E-05 Urinary metabolites SEMA6D intron 21572414 rs1025141 chr15 47832827 G C 9.90E-04 Type 2 diabetes SEMA6D intron 17463246 rs1797230 chr15 47834003 T A 9.90E-04 Type 2 diabetes SEMA6D intron 17463246 rs16959696 chr15 47866316 A G 1.50E-05 Urinary metabolites SEMA6D intron 21572414 rs1865647 chr15 47870186 G T 7.93E-04 Type 2 diabetes SEMA6D intron 17463246 rs1865647 chr15 47870186 G T 3.48E-04 Multiple complex diseases SEMA6D intron 17554300 rs16959700 chr15 47872281 T C 1.84E-04 Multiple complex diseases SEMA6D intron 17554300 rs4775698 chr15 47873477 T G 2.26E-04 Type 2 diabetes SEMA6D intron 17463246 rs4603502 chr15 47874654 T C 3.15E-05 Parkinson's disease SEMA6D intron pha002868 rs1865648 chr15 47878621 G T 1.57E-05 Parkinson's disease SEMA6D intron pha002868 rs8043206 chr15 47886702 C T 5.00E-04 Cognition,early reading ability SEMA6D intron 17684495 rs1898111 chr15 47892298 G A 3.05E-04 Parkinson's disease SEMA6D intron 17052657 rs1898111 chr15 47892298 G A 8.00E-06 Eating disorders SEMA6D intron 22911880 rs12438247 chr15 47892505 C T 1.35E-04 Multiple complex diseases SEMA6D intron 17554300 rs16959754 chr15 47893136 G C 1.49E-04 Multiple complex diseases SEMA6D intron 17554300 rs999128 chr15 47895214 T C 7.01E-04 Premature ovarian failure SEMA6D intron 19508998 rs16959825 chr15 47903008 A G 1.25E-04 Multiple complex diseases SEMA6D intron 17554300 rs16959883 chr15 47911263 C T 2.32E-04 Multiple complex diseases SEMA6D intron 17554300 rs1529883 chr15 47916872 G C 5.46E-04 Multiple complex diseases SEMA6D intron 17554300 rs2573564 chr15 47919317 C T 9.91E-05 Lung function (forced vital capacity) SEMA6D intron 24023788 rs1435754 chr15 47930421 C G 1.60E-04 Multiple complex diseases SEMA6D intron 17554300 rs7163692 chr15 47932453 C G 2.32E-04 Multiple complex diseases SEMA6D intron 17554300 rs1224674 chr15 47944152 C T 7.67E-04 Multiple complex diseases SEMA6D intron 17554300 rs1912638 chr15 47973744 G C 3.30E-04 Multiple complex diseases SEMA6D intron 17554300 rs12593611 chr15 47986612 T G 3.46E-04 Rheumatoid arthritis SEMA6D intron 21452313 rs1912640 chr15 47986973 T C 7.53E-09 Skin pigmentation SEMA6D intron 17999355 rs8032760 chr15 47994054 T C 4.64E-04 Rheumatoid arthritis SEMA6D intron 21452313 rs17328497 chr15 47994152 T C 8.78E-05 Rheumatoid arthritis SEMA6D intron 21452313 rs1224652 chr15 47995015 A G 2.50E-05 Urinary metabolites SEMA6D intron 21572414 rs1224657 chr15 47999160 T C 4.59E-04 Alzheimer's disease (late onset) SEMA6D intron 21379329 rs8028579 chr15 48005470 G T 7.00E-06 Coronary artery calcification SEMA6D intron 23870195 rs3985863 chr15 48033368 G A 5.67E-06 Uric acid levels SEMA6D intron 21294900 rs11855134 chr15 48047676 A G 8.10E-04 Tourette syndrome SEMA6D intron 22889924 rs3743276 chr15 48055119 T C 9.45E-04 Tourette syndrome SEMA6D intron 22889924 rs3743281 chr15 48056958 C T 2.00E-04 Cognitive impairment induced by topiramate SEMA6D cds-synon 22091778 rs603569 chr15 48058929 G A 4.03E-05 Cognitive impairment induced by topiramate SEMA6D intron 22091778 rs8037600 chr15 48060331 A G 2.00E-04 Cognitive impairment induced by topiramate SEMA6D intron 22091778 rs494230 chr15 48116397 T C 6.24E-10 Skin pigmentation / / 17999355 rs1453846 chr15 48126932 C A 1.03E-05 Tunica Media / / pha003037 rs785016 chr15 48135564 C T 1.10E-04 Skin pigmentation / / 17999355 rs16960244 chr15 48154582 T C 5.57E-05 Skin pigmentation / / 17999355 rs669653 chr15 48156986 G A 1.67E-05 Skin pigmentation / / 17999355 rs504376 chr15 48170377 C G 3.68E-12 Skin pigmentation / / 17999355 rs481234 chr15 48171741 A G 2.12E-05 Type 2 diabetes / / 17463246 rs491996 chr15 48178246 T A 1.39E-04 Skin pigmentation / / 17999355 rs677207 chr15 48182753 G C 6.41E-04 Skin pigmentation / / 17999355 rs16960341 chr15 48209718 C T 2.25E-04 Aortic root size / / 21223598 rs2934178 chr15 48218221 G C 1.97E-04 Multiple complex diseases / / 17554300 rs2924572 chr15 48252038 T A 1.85E-11 Skin pigmentation / / 17999355 rs2934193 chr15 48259719 T C 7.96E-04 Stroke / / pha002887 rs2965317 chr15 48261720 C T 1.97E-16 Skin pigmentation / / 17999355 rs2965318 chr15 48264495 T G 1.65E-16 Skin pigmentation / / 17999355 rs2924567 chr15 48268486 G T 1.63E-12 Skin pigmentation / / 17999355 rs2924566 chr15 48268761 G A 7.65E-27 Skin pigmentation / / 17999355 rs16960434 chr15 48274715 G C 2.78E-10 Skin pigmentation / / 17999355 rs16960450 chr15 48282228 C T 1.00E-10 Skin pigmentation / / 17999355 rs16960451 chr15 48282486 C T 9.01E-12 Skin pigmentation / / 17999355 rs16960453 chr15 48283136 C G 2.51E-04 Multiple complex diseases / / 17554300 rs16960453 chr15 48283136 C G 2.86E-10 Skin pigmentation / / 17999355 rs4775728 chr15 48291565 C G 1.23E-09 Skin pigmentation / / 17999355 rs1869454 chr15 48293449 C T 6.05E-11 Skin pigmentation / / 17999355 rs4775730 chr15 48300178 T C 2.10E-25 Skin pigmentation / / 17999355 rs7164700 chr15 48310341 G A 3.07E-18 Skin pigmentation / / 17999355 rs9788730 chr15 48311410 A C 6.84E-24 Skin pigmentation / / 17999355 rs16960508 chr15 48321236 C T 6.89E-05 Multiple complex diseases / / 17554300 rs16960541 chr15 48370103 G T 1.93E-16 Skin pigmentation / / 17999355 rs1834640 chr15 48392165 A G 1.00E-50 Skin pigmentation / / 17999355 rs4775737 chr15 48421329 G A 6.58E-04 Multiple complex diseases SLC24A5 intron 17554300 rs8040016 chr15 48424747 C T 1.18E-04 Multiple complex diseases SLC24A5 intron 17554300 rs8040016 chr15 48424747 C T 4.32E-09 Myocardial Infarction SLC24A5 intron pha002883 rs1426654 chr15 48426484 A G 1.06E-18 Skin pigmentation SLC24A5 missense 17999355 rs1426654 chr15 48426484 A G 1.42E-05 Age-related macular degeneration SLC24A5 missense pha000001 rs9652449 chr15 48452799 G T 2.92E-05 Myocardial Infarction MYEF2 intron pha002883 rs11070627 chr15 48471524 A T 6.63E-41 Skin pigmentation / / 17999355 rs12913316 chr15 48487854 C T 3.18E-41 Skin pigmentation CTXN2 intron 17999355 rs1320052 chr15 48495508 C T 2.30E-10 Skin pigmentation CTXN2 UTR-3 17999355 rs16960682 chr15 48519662 G A,C 1.46E-19 Skin pigmentation SLC12A1 intron 17999355 rs1843144 chr15 48524522 G C 5.85E-09 Skin pigmentation SLC12A1 intron 17999355 rs1531916 chr15 48526271 G A 2.69E-09 Skin pigmentation SLC12A1 intron 17999355 rs1531916 chr15 48526271 G A 4.50E-06 Urinary metabolites SLC12A1 intron 21572414 rs2413890 chr15 48526362 G T 1.07E-11 Skin pigmentation SLC12A1 intron 17999355 rs11070629 chr15 48528113 G A 2.37E-13 Metabolite levels SLC12A1 intron 22286219 rs11633336 chr15 48529940 A G 5.00E-06 Asthma SLC12A1 intron 21790008 rs2291340 chr15 48547976 T C 6.54E-05 Type 2 diabetes SLC12A1 intron 17463246 rs6493315 chr15 48567014 T C 1.05E-04 Type 2 diabetes SLC12A1 intron 17463246 rs9635331 chr15 48570137 A T 1.41E-04 Type 2 diabetes SLC12A1 intron 17463246 rs964611 chr15 48597514 C A 5.91E-05 Type 2 diabetes / / 17463246 rs964611 chr15 48597514 C A 8.00E-06 Metabolite levels (Pyroglutamine) / / 23934736 rs8030330 chr15 48604477 A G 3.69E-05 Acne (severe) / / 24927181 rs8032357 chr15 48618819 A G 7.85E-05 Type 2 diabetes / / 17463246 rs16960781 chr15 48627917 A G 5.80E-04 Multiple complex diseases DUT intron 17554300 rs11637235 chr15 48633153 C T 2.53E-22 Skin pigmentation DUT intron 17999355 rs11637235 chr15 48633153 C T 3.00E-06 Protein quantitative trait loci DUT intron 18464913 rs8027003 chr15 48647426 T C 4.66E-04 Type 2 diabetes / / 17463246 rs1872304 chr15 48658788 A G 1.95E-08 Skin pigmentation / / 17999355 rs10519169 chr15 48665026 G A 9.91E-04 Type 2 diabetes / / 17463246 rs16960843 chr15 48666825 A G 3.28E-08 Skin pigmentation / / 17999355 rs1426721 chr15 48670608 C A 3.84E-04 Schizophrenia / / 20832056 rs919129 chr15 48675227 G A 9.46E-04 Myocardial Infarction / / pha002883 rs9635332 chr15 48676490 G C 2.95E-04 Schizophrenia / / 20832056 rs1820489 chr15 48685101 C T 3.71E-15 Skin pigmentation / / 17999355 rs10519170 chr15 48686175 A G 1.03E-16 Skin pigmentation / / 17999355 rs8042740 chr15 48686310 C T 2.66E-04 Body mass index / / 17255346 rs7171330 chr15 48692460 T A 3.40E-04 Thoracic aortic aneurysms and dissections / / 21909107 rs2013984 chr15 48698503 T C 3.50E-04 Thoracic aortic aneurysms and dissections / / 21909107 rs16960886 chr15 48699486 G A 3.70E-07 Thoracic aortic aneurysms and dissections / / 21909107 rs2114438 chr15 48699929 T C 1.60E-04 Thoracic aortic aneurysms and dissections / / 21909107 rs1042078 chr15 48702873 G A 5.10E-08 Thoracic aortic aneurysms and dissections FBN1 UTR-3 21909107 rs16960901 chr15 48705206 T C 1.70E-10 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs12916536 chr15 48706571 A G 2.40E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs1467953 chr15 48714838 T G 2.30E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs9920570 chr15 48715448 A G 2.30E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs2015637 chr15 48716853 T C 2.70E-07 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs3929051 chr15 48720271 C T 1.70E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs8034591 chr15 48724768 C T 1.90E-08 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs2042747 chr15 48728634 C T 6.90E-11 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs113577372 chr15 48734008 C A 0.0000027 Breast cancer (ER positive) FBN1 missense 23555315 rs12595828 chr15 48734702 C T 9.82E-04 Type 2 diabetes FBN1 intron 17463246 rs2303502 chr15 48736684 A T 5.00E-11 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs2303500 chr15 48739274 A G 1 Drug response to Etoposide FBN1 intron 17537913 rs2303500 chr15 48739274 A G 4.70E-11 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs8029993 chr15 48740097 C T 8.20E-05 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs4775762 chr15 48744005 T C 5.00E-11 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs2555470 chr15 48747440 C T 7.50E-05 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs1812873 chr15 48750520 C A 7.20E-05 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs714290 chr15 48751329 C G 6.70E-11 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs2466792 chr15 48753145 C A 7.00E-05 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs2433394 chr15 48753624 C A 6.90E-05 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs10519177 chr15 48757195 A G 6.40E-05 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs4774517 chr15 48759291 G T 3.80E-11 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs7174973 chr15 48763754 A G 1.30E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs9806323 chr15 48766015 T A 1.20E-10 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs2413906 chr15 48770580 A G 7.30E-05 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs11634866 chr15 48774288 A G 4.30E-11 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs11635140 chr15 48782563 T C 2.20E-08 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs11070644 chr15 48784497 T C 7.50E-05 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs11635605 chr15 48786917 C T 1.70E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs6493325 chr15 48787245 T C 1.70E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs140605 chr15 48789634 T C 4.30E-11 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs9806163 chr15 48803839 T C 4.70E-11 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs2306352 chr15 48805637 G A 4.40E-11 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs8034829 chr15 48806027 T C 1.50E-07 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs16961065 chr15 48806539 C T 1.40E-07 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs6493327 chr15 48809428 G A 1.50E-07 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs7184016 chr15 48810499 G T 4.70E-11 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs755251 chr15 48812020 A G 7.50E-05 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs11634611 chr15 48814297 G A 1.50E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs6493328 chr15 48819502 G A 1.70E-08 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs8026752 chr15 48823770 A G 1.00E-07 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs598029 chr15 48834860 A G 3.30E-05 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs8041668 chr15 48835355 T C 5.40E-11 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs589668 chr15 48835935 C T 6.00E-11 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs595244 chr15 48840835 C T 1.40E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs626492 chr15 48843598 C T 3.30E-05 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs683282 chr15 48847733 T C 2.90E-05 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs2437948 chr15 48849728 C T 4.30E-05 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs12441775 chr15 48850657 C G 4.93E-04 Skin pigmentation FBN1 intron 17999355 rs2448485 chr15 48859733 A G 5.60E-11 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs10744953 chr15 48859966 T C 1.60E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs682938 chr15 48864367 A G 6.80E-11 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs1678978 chr15 48876157 C T 2.30E-05 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs627634 chr15 48879291 C T 1.20E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs1354738 chr15 48883696 T C 4.00E-11 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs686861 chr15 48885005 A G 1.10E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs2456475 chr15 48885877 G A 1.10E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs1506524 chr15 48888988 A T 5.00E-05 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs655015 chr15 48891107 T C 1.10E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs682737 chr15 48891771 G A 1.10E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs668842 chr15 48891965 C T 2.30E-05 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs920184 chr15 48892939 C T 2.10E-11 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs2455925 chr15 48893649 T C 1.10E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs591519 chr15 48894200 A T 1.10E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs1678979 chr15 48896830 T C 2.30E-05 Urinary metabolites FBN1 intron 21572414 rs1678979 chr15 48896830 T C 2.80E-05 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs636178 chr15 48897282 C T 1.10E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs2466790 chr15 48899399 G A 1.10E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs1678981 chr15 48900097 C T 1.00E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs1876206 chr15 48900586 T C 6.00E-06 Breast cancer FBN1 intron 17903305 rs1876206 chr15 48900586 T C 6.00E-06 Nasopharyngeal carcinoma FBN1 intron 20512145 rs1678982 chr15 48901420 C G 1.00E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs612617 chr15 48906577 A G 2.70E-05 Urinary metabolites FBN1 intron 21572414 rs612617 chr15 48906577 A G 2.60E-05 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs1807301 chr15 48910240 A G 5.20E-05 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs1036476 chr15 48914775 T C 6.00E-13 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs1036477 chr15 48914926 A G 1.96E-05 Skin pigmentation FBN1 intron 17999355 rs1036477 chr15 48914926 A G 1.40E-07 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs2118181 chr15 48915884 T C 1.30E-07 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs689304 chr15 48922360 C T 1.30E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs2437946 chr15 48926002 G A 1.20E-10 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs625034 chr15 48926202 T C 2.30E-04 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs1678983 chr15 48930645 T C 3.00E-07 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs2247876 chr15 48931451 T C 1.40E-10 Thoracic aortic aneurysms and dissections FBN1 intron 21909107 rs7183641 chr15 48935763 A T 5.82E-04 Multiple complex diseases FBN1 intron 17554300 rs6493333 chr15 48939046 T C 1.10E-11 Thoracic aortic aneurysms and dissections LOC100506059 intron 21909107 rs2289136 chr15 48944272 G A 5.10E-05 Schizophrenia / / 19571808 rs2289136 chr15 48944272 G A 2.20E-11 Thoracic aortic aneurysms and dissections / / 21909107 rs4775770 chr15 48944563 A G 7.00E-12 Thoracic aortic aneurysms and dissections / / 21909107 rs7162626 chr15 48944615 G A 3.55E-04 Skin pigmentation / / 17999355 rs1848053 chr15 48947962 G A 2.00E-04 Thoracic aortic aneurysms and dissections / / 21909107 rs8042197 chr15 48948291 C T 1.60E-04 Thoracic aortic aneurysms and dissections / / 21909107 rs7166445 chr15 48949078 G A 6.70E-04 Thoracic aortic aneurysms and dissections / / 21909107 rs1857910 chr15 48949710 C T 2.60E-04 Thoracic aortic aneurysms and dissections / / 21909107 rs893160 chr15 48950277 G C 1.70E-04 Thoracic aortic aneurysms and dissections / / 21909107 rs2099562 chr15 48951277 A G 2.50E-09 Thoracic aortic aneurysms and dissections / / 21909107 rs7173026 chr15 48951550 C T 2.10E-09 Thoracic aortic aneurysms and dissections / / 21909107 rs7173410 chr15 48951774 C T 2.10E-09 Thoracic aortic aneurysms and dissections / / 21909107 rs931782 chr15 48954766 A T 3.10E-09 Thoracic aortic aneurysms and dissections / / 21909107 rs8038489 chr15 48956267 T C 3.40E-09 Thoracic aortic aneurysms and dissections / / 21909107 rs2043682 chr15 48957743 C A 3.00E-09 Thoracic aortic aneurysms and dissections / / 21909107 rs4775771 chr15 48960590 G T 4.00E-09 Thoracic aortic aneurysms and dissections / / 21909107 rs12442299 chr15 48964367 G A 8.90E-09 Thoracic aortic aneurysms and dissections / / 21909107 rs1566816 chr15 48965218 C T 9.90E-09 Thoracic aortic aneurysms and dissections / / 21909107 rs1995620 chr15 48966363 G A 5.50E-04 Thoracic aortic aneurysms and dissections / / 21909107 rs1506523 chr15 48967332 G A 2.00E-08 Thoracic aortic aneurysms and dissections / / 21909107 rs10851469 chr15 48968413 C T 1.30E-08 Thoracic aortic aneurysms and dissections / / 21909107 rs10851470 chr15 48970280 G A 3.00E-08 Thoracic aortic aneurysms and dissections / / 21909107 rs8038940 chr15 48973897 G A 2.10E-08 Thoracic aortic aneurysms and dissections / / 21909107 rs2045889 chr15 48984446 T A 1.50E-08 Thoracic aortic aneurysms and dissections / / 21909107 rs12907144 chr15 48984822 A G 9.20E-09 Thoracic aortic aneurysms and dissections / / 21909107 rs2045891 chr15 48987719 C T 1.40E-08 Thoracic aortic aneurysms and dissections / / 21909107 rs2126905 chr15 48988044 C T 7.50E-09 Thoracic aortic aneurysms and dissections / / 21909107 rs12910178 chr15 48988951 C T 7.70E-09 Thoracic aortic aneurysms and dissections / / 21909107 rs2725544 chr15 48992897 C A 2.00E-06 Insomnia / / 23728906 rs17463995 chr15 49003772 T C 3.50E-05 Parkinson's disease / / 16252231 rs17463995 chr15 49003772 T C 6.99E-06 Skin pigmentation / / 17999355 rs2413913 chr15 49011049 C T 7.42E-05 Alcohol dependence / / 21314694 rs784416 chr15 49012925 G C 5.05E-11 Skin pigmentation / / 17999355 rs12914304 chr15 49013543 T A 5.85E-04 Skin pigmentation / / 17999355 rs784411 chr15 49039797 T C 1.07E-05 Skin pigmentation CEP152 intron 17999355 rs784411 chr15 49039797 T C 1.00E-07 Prostate cancer (gene x gene interaction) CEP152 intron 22219177 rs16961557 chr15 49048128 A G 5.00E-06 Obesity-related traits CEP152 missense 23251661 rs8035547 chr15 49056289 A G 3.40E-04 Type 2 diabetes and 6 quantitative traits CEP152 intron 17848626 rs8041414 chr15 49056670 T G 4.15E-06 Skin pigmentation CEP152 intron 17999355 rs199690309 chr15 49059638 G A 0.000089 Breast cancer(er negative) CEP152 missense 23555315 rs16961610 chr15 49060083 G T 2.80E-10 Skin pigmentation CEP152 intron 17999355 rs7176696 chr15 49073903 A G 1.48E-05 Skin pigmentation CEP152 intron 17999355 rs2289179 chr15 49074539 C T 9.29E-04 Type 2 diabetes CEP152 intron 17463246 rs11631496 chr15 49075918 T C 8.50E-04 Alcohol dependence CEP152 intron 20201924 rs2899423 chr15 49102037 G A 6.25E-05 Meningococcal disease CEP152 intron 20694013 rs2304546 chr15 49103244 T C 1.87E-04 Skin pigmentation CEP152 UTR-5 17999355 rs7182710 chr15 49104934 A T 1.04E-04 Skin pigmentation CEP152 nearGene-5 17999355 rs4775777 chr15 49131611 A G 4.75E-04 Skin pigmentation SHC4 intron 17999355 rs1544877 chr15 49134713 C T 1.40E-04 Statin-induced myopathy SHC4 intron 21826682 rs8036806 chr15 49138954 A T 5.09E-04 Coronary heart disease SHC4 intron 21606135 rs17467239 chr15 49143232 G T 2.39E-05 Skin pigmentation SHC4 intron 17999355 rs16961743 chr15 49149259 C T 5.07E-04 Coronary heart disease SHC4 intron 21606135 rs9672326 chr15 49157606 T G 1.41E-04 Coronary heart disease SHC4 intron 21606135 rs10162880 chr15 49159098 G A 7.55E-08 Metabolite levels SHC4 intron 23281178 rs10519193 chr15 49162953 T C 8.88E-06 Kawasaki disease SHC4 intron 21221998 rs10519193 chr15 49162953 T C 7.98E-08 Metabolite levels SHC4 intron 23281178 rs10519193 chr15 49162953 T C 2.23E-05 Parent of origin effect on language impairment (paternal) SHC4 intron 24571439 rs10519195 chr15 49163184 C T 6.99E-04 Coronary heart disease SHC4 intron 21606135 rs10519196 chr15 49164501 C T 7.70E-05 Coronary heart disease SHC4 intron 21606135 rs4774527 chr15 49184681 G A 4.09E-14 Skin pigmentation SHC4 intron 17999355 rs8023445 chr15 49192791 T C 9.00E-06 Major depressive disorder SHC4 intron 19065144 rs8023445 chr15 49192791 T C 2.98E-13 Narcolepsy SHC4 intron 19629137 rs8023445 chr15 49192791 T C 5.42E-05 Major depressive disorder (broad) SHC4 intron 20038947 rs8023445 chr15 49192791 T C 2.00E-06 Major depressive disorder SHC4 intron 21621269 rs8023445 chr15 49192791 T C 1.12E-05 Major depressive disorder SHC4 intron pha002850 rs12441521 chr15 49194041 A G 6.58E-05 Major depressive disorder (broad) SHC4 intron 20038947 rs12232276 chr15 49198931 C T 7.52E-05 Major depressive disorder (broad) SHC4 intron 20038947 rs12232359 chr15 49198978 T C 7.38E-05 Major depressive disorder (broad) SHC4 intron 20038947 rs11854994 chr15 49199392 G A 2.65E-13 Skin pigmentation SHC4 intron 17999355 rs11629867 chr15 49208793 A T 8.37E-04 Multiple complex diseases SHC4 intron 17554300 rs10519201 chr15 49221591 G T 6.00E-06 Eating disorders SHC4 intron 22911880 rs10519201 chr15 49221591 G T 3.82E-05 Malignant pleural mesothelioma SHC4 intron 23626673 rs7178085 chr15 49225123 C A 9.71E-04 Heart Failure SHC4 intron pha002884 rs12323963 chr15 49231111 G A 5.35E-05 Orofacial clefts SHC4 intron 22419666 rs16961929 chr15 49233378 C T 6.05E-04 Body mass index SHC4 intron 21701565 rs17469978 chr15 49237476 T C 6.75E-06 Common variable immunodeficiency SHC4 intron 21497890 rs16961946 chr15 49253893 G A 1.25E-05 Iron levels SHC4 intron 19880490 rs16961946 chr15 49253893 G A 8.39E-04 Obesity (extreme) SHC4 intron 21935397 rs16961946 chr15 49253893 G A 1.25E-05 Iron levels SHC4 intron pha002876 rs8031813 chr15 49253961 C A 6.81E-04 Alcohol dependence SHC4 intron 24277619 rs12906122 chr15 49257201 G T 3.66E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7167402 chr15 49301293 A C 4.27E-05 Orofacial clefts SECISBP2L intron 22419666 rs8029751 chr15 49323855 A C 4.72E-05 Orofacial clefts SECISBP2L intron 22419666 rs8029751 chr15 49323855 A C 8.31E-04 Tourette syndrome SECISBP2L intron 22889924 rs3743293 chr15 49325081 G A 9.35E-05 Lung adenocarcinoma SECISBP2L intron 19836008 rs11070681 chr15 49358517 A G 3.19E-04 Tourette syndrome / / 22889924 rs12148348 chr15 49396864 T C 2.78E-05 Orofacial clefts / / 22419666 rs16962067 chr15 49415696 T C 7.10E-05 Cognitive function / / 24684796 rs577659 chr15 49461248 C T 8.21E-04 Coronary heart disease GALK2 intron 21606135 rs3105864 chr15 49464561 G A 8.73E-04 Body mass index GALK2 intron 21701565 rs16962177 chr15 49534702 T C 6.20E-05 Cognitive function GALK2 intron 24684796 rs2086256 chr15 49558026 T C 8.70E-04 Tourette syndrome GALK2 intron 22889924 rs16962243 chr15 49562732 C T 2.71E-04 Tourette syndrome GALK2 intron 22889924 rs16962244 chr15 49563046 A G 7.10E-05 Cognitive function GALK2 intron 24684796 rs16962257 chr15 49568617 A T 5.70E-05 Cognitive function GALK2 intron 24684796 rs12910584 chr15 49622269 C T 2.83E-05 Prostate cancer C15orf33 intron 22923026 rs10851475 chr15 49625930 A G 2.06E-05 Orofacial clefts C15orf33 intron 22419666 rs12902096 chr15 49645339 T C 7.64E-04 Amyotrophic lateral sclerosis (sporadic) C15orf33 intron 24529757 rs16962414 chr15 49676889 A G 2.28E-05 Prostate cancer C15orf33 intron 22923026 rs16962418 chr15 49684785 C T 5.35E-05 Prostate cancer C15orf33 intron 22923026 rs12591300 chr15 49704741 G A 7.90E-07 chronic obstructive pulmonary disease C15orf33 intron 21921092 rs1429555 chr15 49712097 C T 3.42E-05 Prostate cancer C15orf33 intron 22923026 rs4338740 chr15 49735297 T C 1.00E-12 Thyroid volume FGF7 intron 21565293 rs4338740 chr15 49735297 T C 3.00E-13 Thyroid volume FGF7 intron 21565293 rs10519227 chr15 49746364 T A 1.00E-11 Thyroid hormone levels FGF7 intron 23408906 rs10519227 chr15 49746364 T A 6.00E-10 Thyroid hormone levels FGF7 intron 23408906 rs7167041 chr15 49754744 C G 6.29E-04 Coronary heart disease FGF7 intron 21606135 rs4480740 chr15 49755842 G A 1.03E-06 chronic obstructive pulmonary disease FGF7 intron 21921092 rs12901446 chr15 49771796 G T 8.83E-04 Response to taxane treatment (placlitaxel) FGF7 intron 23006423 rs552340379 chr15 49771796 GTTTTTT G 8.83E-04 Response to taxane treatment (placlitaxel) FGF7 intron 23006423 rs56097665 chr15 49771796 GT G 8.83E-04 Response to taxane treatment (placlitaxel) FGF7 intron 23006423 rs1588127 chr15 49848011 T C 7.00E-04 Type 2 diabetes and 6 quantitative traits C15orf33 intron 17848626 rs1588127 chr15 49848011 T C 1.17E-05 HIV-1 viral setpoint C15orf33 intron 22174851 rs10519233 chr15 49906370 T C 1.17E-05 HIV-1 viral setpoint C15orf33 intron 22174851 rs8039808 chr15 49939846 C A,G,T 5.00E-07 Response to antidepressant treatment / / 22041458 rs2202713 chr15 49961386 C T 9.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17482833 chr15 49971495 A C 5.98E-05 HIV-1 viral setpoint / / 22174851 rs16962755 chr15 49990209 C G 3.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17404727 chr15 50004083 T C 7.17E-07 chronic obstructive pulmonary disease / / 21921092 rs548780 chr15 50012256 T C 3.40E-06 Urinary metabolites / / 21572414 rs8024469 chr15 50012403 G A 7.85E-04 Smoking cessation / / 24665060 rs559561 chr15 50016296 A G 8.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs629859 chr15 50046349 A C 1.47E-04 Multiple complex diseases / / 17554300 rs516375 chr15 50049054 G A 6.26E-04 Multiple complex diseases / / 17554300 rs675344 chr15 50049587 A C 5.36E-04 Multiple complex diseases / / 17554300 rs675794 chr15 50049686 G A 6.49E-04 Multiple complex diseases / / 17554300 rs620739 chr15 50065412 G A 2.10E-04 Type 2 diabetes / / 21874001 rs2456844 chr15 50084276 T G 5.50E-04 Multiple complex diseases / / 17554300 rs2456845 chr15 50084292 T A 7.34E-04 Multiple complex diseases / / 17554300 rs11070722 chr15 50107326 C T 2.53E-13 Metabolite levels / / 22286219 rs2413969 chr15 50122727 G A 5.62E-05 Serum metabolites / / 19043545 rs11634538 chr15 50124762 G A 7.83E-05 Serum metabolites / / 19043545 rs8025533 chr15 50138224 G T 8.68E-06 White blood cell count / / 21738479 rs8025533 chr15 50138224 G T 6.63E-04 Response to alcohol consumption (flushing response) / / 24277619 rs4775845 chr15 50178422 C T 7.87E-05 Information processing speed ATP8B4 intron 21130836 rs2413975 chr15 50189303 A G 9.24E-04 Type 2 diabetes ATP8B4 intron 17463246 rs16963041 chr15 50197355 G A 5.51E-04 Multiple complex diseases ATP8B4 intron 17554300 rs7169870 chr15 50198481 T C 4.12E-04 Aortic root size ATP8B4 intron 21223598 rs2413987 chr15 50250353 G A 8.87E-05 Information processing speed ATP8B4 intron 21130836 rs12593937 chr15 50264532 T C 9.12E-05 Brain lesion load ATP8B4 intron 19010793 rs8039142 chr15 50272460 C T 9.04E-04 Skin pigmentation ATP8B4 intron 17999355 rs7180653 chr15 50280248 G A 1.68E-04 Coronary heart disease ATP8B4 intron 21606135 rs8029355 chr15 50286981 G A 5.58E-05 Coronary heart disease ATP8B4 intron pha003055 rs2413998 chr15 50290295 A G 1.23E-04 Coronary heart disease ATP8B4 intron 21606135 rs2413998 chr15 50290295 A G 3.31E-05 Anxiety in major depressive disorder ATP8B4 intron 24047446 rs7182041 chr15 50306583 A C 4.79E-04 Alzheimer's disease (late onset) ATP8B4 intron 21379329 rs7170142 chr15 50324060 C A 1.47E-04 Coronary heart disease ATP8B4 intron 21606135 rs4522364 chr15 50342224 T C 6.36E-04 Premature ovarian failure ATP8B4 intron 19508998 rs6493395 chr15 50343984 T C 9.48E-05 Coronary heart disease ATP8B4 intron pha003056 rs8024393 chr15 50352887 A G 3.35E-04 Alcohol dependence ATP8B4 intron 21314694 rs41362650 chr15 50369375 A G 3.26E-04 Type 2 diabetes ATP8B4 intron 17463246 rs11070747 chr15 50376439 G C 4.57E-05 Bipolar disorder ATP8B4 intron 20451256 rs7172916 chr15 50380740 G A 4.08E-05 Bipolar disorder ATP8B4 intron 20451256 rs7170781 chr15 50392995 C G 8.85E-10 Skin pigmentation ATP8B4 intron 17999355 rs6493402 chr15 50397504 C T 4.79E-04 Stroke ATP8B4 intron pha002887 rs11639262 chr15 50399646 A G 9.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) ATP8B4 intron 23233662 rs12909011 chr15 50409125 G A 0.000558 Salmonella-induced pyroptosis ATP8B4 intron 22837397 rs12904370 chr15 50414885 A G 8.54E-04 Alzheimer's disease / / 17998437 rs11630182 chr15 50417520 C T 0.000711 Salmonella-induced pyroptosis / / 22837397 rs8036777 chr15 50421418 C T 6.80E-04 Multiple complex diseases / / 17554300 rs7177316 chr15 50421830 A G 8.75E-04 Multiple complex diseases / / 17554300 rs10519262 chr15 50432494 G A 1.49E-06 Alzheimer's disease / / 17998437 rs10519262 chr15 50432494 G A 4.50E-06 Alzheimer's disease (late onset) / / 21460841 rs7165446 chr15 50435909 A G 6.92E-04 Multiple complex diseases / / 17554300 rs1365505 chr15 50477138 C T 4.00E-14 Blood metabolite ratios SLC27A2 intron 24816252 rs1365507 chr15 50477235 A G 6.89E-04 Alcohol dependence SLC27A2 intron 21314694 rs4238381 chr15 50484714 T A 1.30E-05 Age-related macular degeneration SLC27A2 intron 20861866 rs16963416 chr15 50512369 C G 9.68E-04 Coronary heart disease SLC27A2 intron 21606135 rs2853766 chr15 50548243 C T 5.82E-04 Body mass index HDC intron 21701565 rs2853766 chr15 50548243 C T 1.34E-04 Stroke HDC intron pha002887 rs2238292 chr15 50551632 G T 2.32E-04 Body mass index HDC intron 21701565 rs2238292 chr15 50551632 G T 7.95E-04 Body mass index HDC intron 21701565 rs860526 chr15 50555011 C T 9.40E-05 Intelligence (childhood) HDC intron 23358156 rs8034597 chr15 50564358 G C 4.30E-05 Relative hand skill in reading disability / / 24068947 rs12923 chr15 50570036 A G 5.09E-05 Relative hand skill in reading disability GABPB1 UTR-3 24068947 rs12923 chr15 50570036 A G 5.26E-05 Waist-Hip Ratio GABPB1 UTR-3 pha003028 rs4775872 chr15 50571444 T C 5.03E-05 Relative hand skill in reading disability GABPB1 intron 24068947 rs12910368 chr15 50572601 A G 1.00E-04 Relative hand skill in reading disability GABPB1 intron 24068947 rs11635546 chr15 50574621 G A 3.50E-05 Relative hand skill in reading disability GABPB1 intron 24068947 rs12440811 chr15 50577794 T C 5.14E-05 Relative hand skill in reading disability GABPB1 intron 24068947 rs12908591 chr15 50584703 C T 1.95E-05 Relative hand skill in reading disability GABPB1 intron 24068947 rs8024514 chr15 50587336 G A 1.94E-05 Relative hand skill in reading disability GABPB1 intron 24068947 rs17508371 chr15 50590794 T C 5.81E-04 Smoking initiation GABPB1 intron 24665060 rs2081628 chr15 50592543 C T 5.08E-04 Smoking initiation GABPB1 intron 24665060 rs141883945 chr15 50593003 T C 0.0000059 Breast cancer(er negative) GABPB1 missense 23555315 rs7164798 chr15 50596070 T C 1.52E-05 Relative hand skill in reading disability GABPB1 intron 24068947 rs7175150 chr15 50603339 G A 1.68E-05 Relative hand skill in reading disability GABPB1 intron 24068947 rs4775873 chr15 50604559 T C 1.68E-05 Relative hand skill in reading disability GABPB1 intron 24068947 rs11636908 chr15 50605585 G A 3.55E-05 Relative hand skill in reading disability GABPB1 intron 24068947 rs11631197 chr15 50608855 C G 1.53E-05 Relative hand skill in reading disability GABPB1 intron 24068947 rs11855823 chr15 50619715 G A 2.44E-04 Smoking initiation GABPB1 intron 24665060 rs7167471 chr15 50658358 C G 2.27E-05 Relative hand skill in reading disability / / 24068947 rs11637276 chr15 50658507 A T 2.00E-05 Relative hand skill in reading disability / / 24068947 rs12595107 chr15 50669718 A G 2.80E-05 Relative hand skill in reading disability / / 24068947 rs4775878 chr15 50672420 C T 6.71E-05 Relative hand skill in reading disability / / 24068947 rs8027243 chr15 50679191 G A 1.29E-05 Relative hand skill in reading disability / / 24068947 rs934638 chr15 50690071 A T 2.42E-05 Relative hand skill in reading disability / / 24068947 rs7174015 chr15 50717068 G A 9.38E-05 Multiple sclerosis USP8 intron 17660530 rs7174015 chr15 50717068 G A 3.57E-05 Male fertility USP8 intron 22633400 rs12050594 chr15 50772736 A T 3.62E-07 Facial morphology USP8 intron 22341974 rs3743044 chr15 50773787 A G 0.00079 Breast cancer USP8 missense 23555315 rs3131583 chr15 50848996 A G 1.97E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) TRPM7 nearGene-3 24023788 rs2414059 chr15 50873344 T A 2.00E-06 QT interval TRPM7 intron 23166209 rs539383 chr15 50878478 G A 6.45E-06 QT interval TRPM7 intron 23166209 rs3848128 chr15 50891790 G T 1.01E-04 Alzheimer's disease (late onset) TRPM7 intron 21460841 rs150072757 chr15 50904954 T C 0.000051 Breast cancer TRPM7 missense 23555315 rs150072757 chr15 50904954 T C 0.000078 Breast cancer (ER positive) TRPM7 missense 23555315 rs7173321 chr15 50922600 C G 3.24E-05 Nicotine smoking TRPM7 intron 19268276 rs8042172 chr15 50932981 T C 9.15E-05 Alzheimer's disease (late onset) TRPM7 intron 21460841 rs2899463 chr15 50938978 T C 7.52E-04 Multiple complex diseases TRPM7 intron 17554300 rs12593556 chr15 50948476 T A 9.01E-05 Alzheimer's disease (late onset) TRPM7 intron 21460841 rs11635825 chr15 50954947 T C 5.50E-04 Type 2 diabetes TRPM7 intron 23209189 rs2414063 chr15 50955655 T G 1.34E-05 Alzheimer's disease (late onset) TRPM7 intron 21460841 rs12592778 chr15 50992311 G A 8.10E-06 Alzheimer's disease (late onset) / / 21460841 rs12442197 chr15 50995362 A C 5.03E-06 Alzheimer's disease (late onset) / / 21460841 rs12437803 chr15 50997266 G A 4.73E-06 Alzheimer's disease (late onset) / / 21460841 rs12437770 chr15 50997304 C A 4.15E-06 Alzheimer's disease (late onset) / / 21460841 rs12440864 chr15 51005957 A G 3.59E-06 Alzheimer's disease (late onset) SPPL2A intron 21460841 rs12595082 chr15 51007729 C T 4.19E-06 Alzheimer's disease (late onset) SPPL2A intron 21460841 rs12442145 chr15 51013595 T A 1.06E-05 Alzheimer's disease (late onset) SPPL2A intron 21460841 rs17646025 chr15 51019812 C T 1.00E-05 Alzheimer's disease (late onset) SPPL2A intron 21460841 rs12917408 chr15 51033389 T C 6.75E-04 Type 2 diabetes SPPL2A intron 17463246 rs17599340 chr15 51039891 T C 4.67E-04 Endometrial cancer SPPL2A intron 24096698 rs17599340 chr15 51039891 T C 6.57E-04 Endometrial cancer SPPL2A intron 24096698 rs8035452 chr15 51040798 T C 3.00E-07 Alzheimer's disease (late onset) SPPL2A intron 24162737 rs12917005 chr15 51042252 C T 6.13E-04 Type 2 diabetes SPPL2A intron 17463246 rs12440570 chr15 51045564 C T 1.36E-05 Alzheimer's disease (late onset) SPPL2A intron 21460841 rs12915708 chr15 51048602 G C 7.00E-10 Fibrinogen SPPL2A intron 23969696 rs12912192 chr15 51057181 G A 1.75E-04 HIV-1 viral setpoint SPPL2A intron 17641165 rs9302158 chr15 51115086 G A 2.40E-04 Type 2 diabetes / / 23209189 rs2614763 chr15 51142733 C A 1.70E-04 Type 2 diabetes / / 17463246 rs2614793 chr15 51209674 A G 3.69E-05 Cognitive test performance AP4E1 intron 20125193 rs6493469 chr15 51224896 G T 2.31E-04 Type 2 diabetes AP4E1 intron 17463246 rs8031702 chr15 51236304 C T 2.30E-04 Type 2 diabetes AP4E1 intron 17463246 rs6493470 chr15 51284680 G A 5.24E-05 Multiple complex diseases AP4E1 intron 17554300 rs7181201 chr15 51288651 G A 7.04E-04 Type 2 diabetes AP4E1 intron 17463246 rs1124769 chr15 51352249 A G 9.00E-06 Cognitive performance TNFAIP8L3 intron 20125193 rs16964077 chr15 51428106 C G 9.84E-04 Multiple complex diseases / / 17554300 rs2165027 chr15 51445840 T C 6.52E-04 Body mass index / / 21701565 rs1025738 chr15 51450781 G C 4.63E-04 Multiple complex diseases / / 17554300 rs7179084 chr15 51451746 T C 9.46E-04 Multiple complex diseases / / 17554300 rs12441919 chr15 51471700 A C 9.97E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs2414093 chr15 51478285 A G 1.09E-04 Multiple complex diseases / / 17554300 rs2899469 chr15 51481922 A G 9.35E-05 Cognitive test performance / / 20125193 rs1108463 chr15 51492972 G A 2.10E-04 Multiple complex diseases / / 17554300 rs934632 chr15 51495830 A G 9.60E-05 Information processing speed / / 21130836 rs4646 chr15 51502844 A C 1 Drug response to Letrozole CYP19A1 UTR-3 18245543 rs6493487 chr15 51513729 G A 7.90E-04 Testosterone levels CYP19A1 intron 22675492 rs6493487 chr15 51513729 G A 8.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients CYP19A1 intron 23400010 rs16964201 chr15 51515351 C T 6.34E-04 Alzheimer's disease CYP19A1 intron 17998437 rs2899472 chr15 51516055 C A 2.00E-09 AB1-42 levels CYP19A1 intron 20932310 rs12595627 chr15 51517100 T C 7.00E-04 Testosterone levels CYP19A1 intron 22675492 rs2899473 chr15 51519073 C T 6.22E-04 Alzheimer's disease CYP19A1 intron 17998437 rs4775935 chr15 51519276 T G 8.00E-04 Testosterone levels CYP19A1 intron 22675492 rs2414095 chr15 51524292 A G 7.40E-04 Testosterone levels CYP19A1 intron 22675492 rs2414095 chr15 51524292 A G 2.00E-16 Follicle stimulating hormone CYP19A1 intron 24049095 rs2414095 chr15 51524292 A G 7.00E-31 Follicle stimulating hormone CYP19A1 intron 24049095 rs12592697 chr15 51525173 T C 7.20E-04 Testosterone levels CYP19A1 intron 22675492 rs3759811 chr15 51529265 T C 7.48E-05 Serum metabolites CYP19A1 intron 19043545 rs2414097 chr15 51529835 G A 6.40E-04 Testosterone levels CYP19A1 intron 22675492 rs17703883 chr15 51530097 T C 5.10E-04 Testosterone levels CYP19A1 intron 22675492 rs16964211 chr15 51530495 G A 2.00E-09 Height CYP19A1 intron 20881960 rs7175531 chr15 51534055 T C 5.00E-04 Testosterone levels CYP19A1 intron 22675492 rs727479 chr15 51534547 C A 5.00E-07 Estradiol levels CYP19A1 intron 22675492 rs12907866 chr15 51545454 A G 4.00E-07 Menarche (age at onset) CYP19A1 intron 23599027 rs11636403 chr15 51548744 C T 5.64E-04 Coronary Artery Disease CYP19A1 intron 17634449 rs17601876 chr15 51553909 A G 6.80E-04 Testosterone levels CYP19A1 intron 22675492 rs17647707 chr15 51568020 G T 9.98E-04 Alzheimer's disease CYP19A1 intron 17998437 rs2305707 chr15 51569410 A G 7.00E-07 Height CYP19A1 intron 20189936 rs2305707 chr15 51569410 A G 0.00081 Breast cancer CYP19A1 intron 23555315 rs3751599 chr15 51573533 G A 5.00E-10 Height CYP19A1 intron 23456168 rs7167343 chr15 51578594 A G 8.75E-05 Multiple complex diseases CYP19A1 intron 17554300 rs936306 chr15 51579598 C T 1.26E-04 Suicide,with and without major depression CYP19A1 intron 22059935 rs936306 chr15 51579598 C T 4.13E-05 Suicide,with and without major depression CYP19A1 intron 22059935 rs17523880 chr15 51592543 C A 7.70E-06 Urinary metabolites CYP19A1 intron 21572414 rs3751591 chr15 51606710 A G 6.00E-04 Longevity and age-related phenotypes CYP19A1 intron 17903295 rs3751591 chr15 51606710 A G 2.20E-08 Height CYP19A1 intron 21194676 rs3751591 chr15 51606710 A G 7.40E-09 Height CYP19A1 intron 21194676 rs2445762 chr15 51617708 T C 8.00E-28 Follicle stimulating hormone CYP19A1 intron 24049095 rs6493497 chr15 51630835 G A 1 Drug response to Anastrozole LOC100506192 intron 20048079 rs6493497 chr15 51630835 G A 1 Drug response to Exemestane LOC100506192 intron 20048079 rs6493497 chr15 51630835 G A 1 Drug response to Letrozole LOC100506192 intron 20048079 rs7176005 chr15 51631279 C T 1 Drug response to Anastrozole LOC100506192 intron 20048079 rs7176005 chr15 51631279 C T 1 Drug response to Exemestane LOC100506192 intron 20048079 rs7176005 chr15 51631279 C T 1 Drug response to Letrozole LOC100506192 intron 20048079 rs2445765 chr15 51634898 G C 3.47E-04 Menarche (age at onset) GLDN intron 21102462 rs2445766 chr15 51635246 A G 3.51E-04 Menarche (age at onset) GLDN intron 21102462 rs17704365 chr15 51642489 A G 3.16E-08 Metabolite levels GLDN intron 23281178 rs1458928 chr15 51644999 T G 3.60E-04 Menarche (age at onset) GLDN intron 21102462 rs1973118 chr15 51645911 T A 3.29E-04 Menarche (age at onset) GLDN intron 21102462 rs2446405 chr15 51646793 A T 2.45E-04 Menarche (age at onset) GLDN intron 21102462 rs2470187 chr15 51653014 C T 1.05E-04 Multiple complex diseases GLDN intron 17554300 rs12148477 chr15 51653119 A G 7.00E-07 Follicle stimulating hormone GLDN intron 24049095 rs12148492 chr15 51653193 G T 9.21E-04 Acute lung injury GLDN intron 22295056 rs4533220 chr15 51667713 T G 1.12E-08 Metabolite levels GLDN intron 23281178 rs2470180 chr15 51682775 G A 7.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GLDN intron 20877124 rs2445751 chr15 51696003 T C 4.30E-05 Lung adenocarcinoma GLDN intron 22797724 rs140921435 chr15 51763587 G A 0.00012 Breast cancer (ER positive) DMXL2 missense 23555315 rs12102203 chr15 51791559 A G 4.03E-05 Cholesterol DMXL2 missense pha003083 rs4775953 chr15 51873173 G T 6.50E-04 Lymphocyte counts DMXL2 intron 22286170 rs184120294 chr15 51878548 A G 9.63E-05 Acne (severe) DMXL2 intron 24927181 rs882385 chr15 51882369 C T 8.47E-04 Type 2 diabetes DMXL2 intron 17846125 rs6493511 chr15 51901605 A G 9.86E-04 Alcohol dependence DMXL2 intron 21314694 rs750163 chr15 51906987 A G 5.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DMXL2 intron 20877124 rs2606143 chr15 51942455 C T 3.41E-04 Birth weight / / 17255346 rs1471072 chr15 51968401 T C 9.21E-04 Hodgkin's lymphoma / / 24149102 rs17525472 chr15 51969668 T C 2.00E-06 Asthma / / 20159242 rs2622770 chr15 51971322 A G 2.46E-04 Birth weight / / 17255346 rs2606136 chr15 51971533 G A 2.46E-04 Birth weight / / 17255346 rs3764220 chr15 51972058 A G 1.90E-06 Obesity (extreme) SCG3 nearGene-5 17200173 rs16964465 chr15 51972347 A C 4.30E-06 Obesity (extreme) SCG3 nearGene-5 17200173 rs3809498 chr15 51973485 G C 4.30E-06 Obesity (extreme) SCG3 nearGene-5 17200173 rs16964476 chr15 51974224 A G 3.90E-06 Obesity (extreme) SCG3 intron 17200173 rs41286490 chr15 51974512 C T 4.30E-06 Obesity (extreme) SCG3 intron 17200173 rs3214014 chr15 51974639 A C 4.30E-06 Obesity (extreme) SCG3 intron 17200173 rs2124591 chr15 51974985 A G 5.66E-04 Hodgkin's lymphoma SCG3 intron 24149102 rs2124591 chr15 51974985 A G 8.01E-05 Blood Pressure SCG3 intron pha003045 rs2124591 chr15 51974985 A G 7.52E-05 Blood Pressure SCG3 intron pha003047 rs2305709 chr15 51975585 C A 2.50E-06 Obesity (extreme) SCG3 cds-synon 17200173 rs3816544 chr15 51975758 A G 3.90E-06 Obesity (extreme) SCG3 intron 17200173 rs2622769 chr15 51976230 G T 3.26E-04 Birth weight SCG3 intron 17255346 rs10519316 chr15 51977312 C T 8.41E-04 Multiple complex diseases SCG3 intron 17554300 rs1456295 chr15 51979655 C T 4.09E-05 Hodgkin's lymphoma SCG3 intron 24149102 rs1840707 chr15 51979674 G A 2.90E-04 Birth weight SCG3 intron 17255346 rs1840707 chr15 51979674 G A 3.14E-05 Hodgkin's lymphoma SCG3 intron 24149102 rs716986 chr15 51979813 G A 2.81E-04 Birth weight SCG3 intron 17255346 rs2305715 chr15 51981276 G A 3.40E-05 Obesity (extreme) SCG3 intron 17200173 rs2305716 chr15 51981291 C T 4.74E-05 Psoriasis SCG3 intron 18364390 rs2305719 chr15 51984242 C T 3.80E-06 Obesity (extreme) SCG3 intron 17200173 rs41286492 chr15 51988213 T C 3.50E-06 Obesity (extreme) SCG3 intron 17200173 rs3765067 chr15 51991651 T C 1.60E-06 Obesity (extreme) SCG3 intron 17200173 rs182326997 chr15 51995459 T C 1.58E-05 Acne (severe) SCG3 intron 24927181 rs2607120 chr15 51995763 C T 2.33E-04 Hodgkin's lymphoma SCG3 intron 24149102 rs7174616 chr15 52018096 A C 5.76E-04 Iron levels LYSMD2 intron pha002876 rs16964508 chr15 52058184 A G 8.69E-04 Iron levels TMOD2 intron pha002876 rs16964657 chr15 52274413 C T 1.41E-07 Non-obstructive azoospermia / / 22541561 rs10518674 chr15 52318146 T G 1.90E-05 Electrocardiographic traits and heart rate variability MAPK6 intron 17903306 rs4627278 chr15 52349355 G A 3.68E-05 Psoriasis MAPK6 intron 18364390 rs3825801 chr15 52517714 C T 3.87E-04 IgE levels MYO5C missense 17255346 rs3751624 chr15 52575170 C T 9.63E-05 Non-alcoholic fatty liver disease histology (other) MYO5C intron 20708005 rs7176862 chr15 52597838 A G 8.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs1045700 chr15 52601189 C T 6.94E-04 Schizophrenia MYO5A UTR-3 19197363 rs1045699 chr15 52601220 G A 1.46E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) MYO5A UTR-3 24023788 rs1045699 chr15 52601220 G A 2.98E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) MYO5A UTR-3 24023788 rs3751619 chr15 52601591 C A 3.63E-05 Prion diseases MYO5A UTR-3 22210626 rs7176482 chr15 52603363 G A 5.72E-05 Suicide attempts in bipolar disorder MYO5A UTR-3 21423239 rs17613475 chr15 52607262 G A 1.07E-04 Suicide attempts in bipolar disorder MYO5A intron 21423239 rs4280181 chr15 52608556 A G 7.40E-05 Suicide attempts in bipolar disorder MYO5A intron 21423239 rs12324121 chr15 52608834 A G 6.22E-05 Suicide attempts in bipolar disorder MYO5A intron 21423239 rs4519295 chr15 52623303 C T 1.75E-04 Suicide attempts in bipolar disorder MYO5A intron 21423239 rs10467925 chr15 52625738 A G 1.61E-04 Suicide attempts in bipolar disorder MYO5A intron 21423239 rs752866 chr15 52631793 C G 1.80E-05 Suicide attempts in bipolar disorder MYO5A intron 21423239 rs752865 chr15 52631817 T C 4.54E-05 Suicide attempts in bipolar disorder MYO5A intron 21423239 rs7182150 chr15 52638429 T A 7.80E-05 Suicide attempts in bipolar disorder MYO5A intron 21423239 rs4776037 chr15 52640650 C T 7.25E-05 Suicide attempts in bipolar disorder MYO5A intron 21423239 rs12324100 chr15 52641688 C T 1.05E-04 Suicide attempts in bipolar disorder MYO5A intron 21423239 rs8028033 chr15 52649116 A G 3.44E-05 Suicide attempts in bipolar disorder MYO5A intron 21423239 rs3794565 chr15 52655366 A G 2.40E-05 Bipolar disorder and schizophrenia MYO5A intron 20889312 rs7176639 chr15 52660686 T C 1.59E-04 Suicide attempts in bipolar disorder MYO5A intron 21423239 rs2242057 chr15 52671308 T C 1.81E-04 Suicide attempts in bipolar disorder MYO5A intron 21423239 rs2242058 chr15 52671784 C T 1.16E-04 Suicide attempts in bipolar disorder MYO5A intron 21423239 rs2242058 chr15 52671784 C T 2.91E-04 Celiac disease MYO5A intron 23936387 rs12914979 chr15 52677424 T C 1.25E-04 Suicide attempts in bipolar disorder MYO5A intron 21423239 rs2414148 chr15 52685483 G A 1.70E-05 Prion diseases MYO5A intron 22210626 rs10518687 chr15 52687433 G A 1.42E-04 Suicide attempts in bipolar disorder MYO5A intron 21423239 rs10518687 chr15 52687433 G A 2.89E-04 Celiac disease MYO5A intron 23936387 rs2414150 chr15 52693688 T G 1.77E-04 Suicide attempts in bipolar disorder MYO5A intron 21423239 rs13329087 chr15 52701122 C T 7.35E-04 Insulin resistance MYO5A intron 21901158 rs10083673 chr15 52710340 G A 9.62E-05 Celiac disease MYO5A intron 23936387 rs2222656 chr15 52773023 A G 2.00E-06 Metabolite levels (Pyroglutamine) MYO5A intron 23934736 rs34602777 chr15 52795794 C T 2.96E-06 Insulin-related traits MYO5A intron 22791750 rs11853179 chr15 52829789 C T 1.84E-11 Lymphocyte counts / / 22286170 rs1724611 chr15 52860553 G A 1.05E-05 Thiazide-induced adverse metabolic effects in hypertensive patients ARPP19 intron 23400010 rs8034728 chr15 52864885 A C 5.68E-04 Type 2 diabetes / / 17463246 rs11070902 chr15 52869581 G A 2.09E-05 Kawasaki disease / / 22446961 rs4776065 chr15 52929716 C T 8.90E-05 Multiple complex diseases FAM214A intron 17554300 rs4390542 chr15 52937960 T C 9.12E-05 Alzheimer's disease FAM214A intron 22832961 rs1863512 chr15 52959687 G A 2.04E-04 Multiple complex diseases FAM214A intron 17554300 rs4776071 chr15 52986962 T C 8.89E-05 Monocyte counts / / pha003089 rs2433285 chr15 52997976 T C 3.88E-04 Alcohol dependence / / 21314694 rs11070918 chr15 53038488 T C 7.43E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs8037939 chr15 53044635 G A 5.64E-05 Multiple complex diseases / / 17554300 rs2440335 chr15 53046210 C T 9.09E-04 Stroke / / pha002887 rs2440327 chr15 53061156 T C 2.90E-04 Primary sclerosing cholangitis ONECUT1 intron 19944697 rs2440327 chr15 53061156 T C 3.58E-04 Response to taxane treatment (placlitaxel) ONECUT1 intron 23006423 rs1899750 chr15 53068506 C T 1.24E-04 Cognitive function ONECUT1 intron 24684796 rs2165990 chr15 53069747 A G 9.12E-06 Pulmonary function ONECUT1 intron 19300500 rs7180600 chr15 53070141 G A 3.04E-05 Pulmonary function ONECUT1 intron 19300500 rs2440322 chr15 53071746 T G 2.60E-05 Pulmonary function ONECUT1 intron 19300500 rs10518694 chr15 53072673 C A 9.35E-06 Pulmonary function ONECUT1 intron 19300500 rs2460 chr15 53073084 G A 9.65E-05 Pulmonary function ONECUT1 intron 19300500 rs2456525 chr15 53080413 C T 5.50E-06 Pulmonary function ONECUT1 intron 19300500 rs2440315 chr15 53084353 T G 4.76E-05 Pulmonary function / / 19300500 rs2456526 chr15 53089442 T C 5.24E-06 Pulmonary function / / 19300500 rs2440376 chr15 53091870 G A 6.60E-06 Pulmonary function / / 19300500 rs2456531 chr15 53091896 A C 4.88E-05 Pulmonary function / / 19300500 rs2456532 chr15 53092520 G C 6.74E-06 Pulmonary function / / 19300500 rs2243790 chr15 53092620 G A 6.82E-06 Pulmonary function / / 19300500 rs1899752 chr15 53092937 A G 4.94E-05 Pulmonary function / / 19300500 rs2120450 chr15 53101580 T A 4.85E-05 Pulmonary function / / 19300500 rs2165991 chr15 53101700 A G 4.99E-04 Coronary heart disease / / 21606135 rs16965202 chr15 53125377 T C 7.27E-04 Multiple complex diseases / / 17554300 rs1317318 chr15 53133063 T C 1.14E-04 Diabetic retinopathy / / 20871662 rs2440352 chr15 53145219 T G 6.93E-04 Coronary heart disease / / 21606135 rs2120441 chr15 53160991 G A 1.85E-04 Multiple complex diseases / / 17554300 rs2120445 chr15 53166409 G A 2.33E-05 Attention deficit hyperactivity disorder / / 20732625 rs7181025 chr15 53166673 G A 2.50E-05 Urinary metabolites / / 21572414 rs7177989 chr15 53169965 C T 7.26E-05 Depression (quantitative trait) / / 23290196 rs4776080 chr15 53175197 T C 4.12E-05 Depression (quantitative trait) / / 23290196 rs2414188 chr15 53184191 T C 7.80E-05 Depression (quantitative trait) / / 23290196 rs2414195 chr15 53188169 G A 2.98E-05 Depression (quantitative trait) / / 23290196 rs2414196 chr15 53188893 G C 2.78E-05 Depression (quantitative trait) / / 23290196 rs8026763 chr15 53189150 T C 3.30E-05 Depression (quantitative trait) / / 23290196 rs12594080 chr15 53189358 C G 6.92E-05 Bipolar disorder / / 20451256 rs10851526 chr15 53189424 T C 3.09E-05 Depression (quantitative trait) / / 23290196 rs2414208 chr15 53203301 A G 2.00E-06 Obesity-related traits / / 23251661 rs9920330 chr15 53222788 A G 2.06E-06 Obesity-related traits / / 23251661 rs9920982 chr15 53224469 T C 2.06E-06 Obesity-related traits / / 23251661 rs17658667 chr15 53236898 A G 9.74E-04 Multiple complex diseases / / 17554300 rs12441046 chr15 53239875 G T 4.65E-05 Depression (quantitative trait) / / 23290196 rs12441966 chr15 53241227 C T 3.62E-06 Recombination rate / / 21698098 rs727614 chr15 53245117 A T 1.29E-05 Lactate dehydrogenase levels / / 20981236 rs2414217 chr15 53245436 T C 4.26E-05 Depression (quantitative trait) / / 23290196 rs2414218 chr15 53246999 T C 4.13E-05 Depression (quantitative trait) / / 23290196 rs7177754 chr15 53251332 A G 8.30E-04 Multiple complex diseases / / 17554300 rs719714 chr15 53279378 A G 4.00E-08 Cognitive function / / 22126837 rs2414223 chr15 53288387 C A 6.89E-04 Premature ovarian failure / / 19508998 rs2414223 chr15 53288387 C A 5.02E-06 Body Mass Index / / pha003007 rs2414223 chr15 53288387 C A 2.17E-05 Body Fat Distribution / / pha003016 rs2414223 chr15 53288387 C A 8.18E-05 Body Fat Distribution / / pha003017 rs2414223 chr15 53288387 C A 3.97E-05 Body Fat Distribution / / pha003018 rs2414223 chr15 53288387 C A 7.99E-06 Waist Circumference / / pha003025 rs2414223 chr15 53288387 C A 4.72E-06 Weight / / pha003027 rs2639679 chr15 53321829 T C 2.40E-05 Urinary metabolites / / 21572414 rs17710168 chr15 53364996 A C 2.40E-05 Urinary metabolites / / 21572414 rs1508033 chr15 53375201 C A 7.90E-05 Serum metabolites / / 19043545 rs2175372 chr15 53395741 C T 7.91E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs906499 chr15 53398986 C A 4.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17545046 chr15 53402010 G A 4.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs11858823 chr15 53403112 G A 1.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs17545090 chr15 53406393 C A 7.87E-04 Body mass index / / 21701565 rs690535 chr15 53406709 G T 1.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs689991 chr15 53408197 A G 6.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs584758 chr15 53408253 A G 6.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs12442241 chr15 53408498 A T 2.20E-04 Suicide attempts in bipolar disorder / / 21041247 rs17627721 chr15 53426788 G T 4.23E-05 Suicide attempts in bipolar disorder / / 21041247 rs17545312 chr15 53427012 A G 4.22E-05 Suicide attempts in bipolar disorder / / 21041247 rs16965587 chr15 53438363 G T 6.25E-05 Suicide attempts in bipolar disorder / / 21041247 rs12592602 chr15 53442190 T C 3.03E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7181898 chr15 53447103 G A 6.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs8041435 chr15 53447227 C T 4.77E-05 Heart Rate / / pha003053 rs11070957 chr15 53450996 G T 3.60E-05 Suicide attempts in bipolar disorder / / 21041247 rs10518706 chr15 53453509 C T 3.59E-05 Suicide attempts in bipolar disorder / / 21041247 rs10518710 chr15 53458335 G C 1.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs12594449 chr15 53466413 C T 1.11E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12594449 chr15 53466413 C T 2.14E-04 Type 2 diabetes / / 17463246 rs4776117 chr15 53471041 G A 8.60E-04 Acute lung injury / / 22295056 rs493218 chr15 53490262 T C 2.40E-04 Type 1 diabetes / / 19875614 rs493218 chr15 53490262 T C 5.20E-07 Type 1 diabetes / / 19875614 rs493218 chr15 53490262 T C 5.40E-07 Type 1 diabetes / / 19875614 rs17545973 chr15 53501553 C T 3.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs572221 chr15 53504632 G A 3.60E-04 Type 1 diabetes / / 19875614 rs572221 chr15 53504632 G A 6.60E-07 Type 1 diabetes / / 19875614 rs572221 chr15 53504632 G A 6.80E-07 Type 1 diabetes / / 19875614 rs566369 chr15 53508592 A G 3.40E-04 Type 1 diabetes / / 19875614 rs566369 chr15 53508592 A G 5.00E-07 Type 1 diabetes / / 19875614 rs566369 chr15 53508592 A G 5.10E-07 Type 1 diabetes / / 19875614 rs482541 chr15 53509194 A G 3.40E-04 Type 1 diabetes / / 19875614 rs482541 chr15 53509194 A G 3.50E-07 Type 1 diabetes / / 19875614 rs482541 chr15 53509194 A G 5.00E-07 Type 1 diabetes / / 19875614 rs482541 chr15 53509194 A G 5.10E-07 Type 1 diabetes / / 19875614 rs7168646 chr15 53518466 A G 5.93E-05 Suicide attempts in bipolar disorder / / 21041247 rs7170453 chr15 53520545 C T 3.34E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7170453 chr15 53520545 C T 0.0000372 Nicotine dependence (smoking) / / 22377092 rs4109296 chr15 53528305 C G 4.98E-04 Type 2 diabetes / / 17463246 rs17628504 chr15 53534944 A G 1.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs529413 chr15 53542745 C A 9.50E-05 Type 1 diabetes / / 18978792 rs496043 chr15 53544879 T C 3.77E-04 Multiple complex diseases / / 17554300 rs492391 chr15 53545261 G A 2.00E-05 Malaria / / 19465909 rs4776123 chr15 53547680 G A 4.33E-04 Type 2 diabetes / / 17463246 rs512828 chr15 53548179 A G 3.78E-04 Type 2 diabetes / / 17463246 rs11635037 chr15 53552997 G T 4.96E-05 Kawasaki disease / / 22446961 rs10851537 chr15 53555661 T C 1.16E-05 Cognitive impairment induced by topiramate / / 22091778 rs2200520 chr15 53584893 A G 4.82E-05 Telomere length / / 21573004 rs11639284 chr15 53613980 C G 9.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs751175 chr15 53616705 G T 1.31E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs751175 chr15 53616705 G T 3.76E-04 Lung function (forced vital capacity) / / 24023788 rs272788 chr15 53653662 G A 8.44E-04 Multiple complex diseases / / 17554300 rs1813171 chr15 53669574 G A 5.28E-06 Magnesium levels / / pha003092 rs7181647 chr15 53683037 C T 8.87E-06 Magnesium levels / / pha003092 rs8029757 chr15 53688298 A G 8.24E-05 Magnesium levels / / pha003092 rs7180947 chr15 53689742 G T 8.26E-05 Magnesium levels / / pha003092 rs592248 chr15 53699422 G T 6.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12911817 chr15 53702840 T G 4.41E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs1711029 chr15 53704410 C T 3.61E-12 Multiple complex diseases / / 17554300 rs4776147 chr15 53709744 T C 7.69E-04 Tourette syndrome / / 22889924 rs4776147 chr15 53709744 T C 4.20E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs111882051 chr15 53711783 C G 2.46E-11 Metabolite levels / / 22286219 rs17548303 chr15 53740000 C G 4.08E-04 Type 2 diabetes / / 17463246 rs4776152 chr15 53745574 G A 1.60E-05 Urinary metabolites / / 21572414 rs8030357 chr15 53746169 G T 1.45E-04 Type 2 diabetes / / 17463246 rs8030357 chr15 53746169 G T 1.90E-05 Urinary metabolites / / 21572414 rs685850 chr15 53751702 A G 9.60E-06 Endometriosis / / 21151130 rs671948 chr15 53758922 A C 4.37E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs7164175 chr15 53769721 G A 9.99E-04 Type 2 diabetes / / 17463246 rs2202069 chr15 53770554 C T 7.61E-04 Multiple complex diseases / / 17554300 rs2202069 chr15 53770554 C T 3.43E-05 Personality dimensions / / 18957941 rs17630455 chr15 53778448 G A 1.43E-08 Metabolite levels / / 23281178 rs582894 chr15 53805321 A T 5.84E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs582894 chr15 53805321 A T 7.14E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7168365 chr15 53805825 C A 1.00E-06 Longevity WDR72 nearGene-3 20834067 rs7180991 chr15 53807964 A C 8.33E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines WDR72 UTR-3 21844884 rs10518724 chr15 53808232 C A 8.30E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines WDR72 UTR-3 21844884 rs16966157 chr15 53809324 G C 8.33E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines WDR72 UTR-3 21844884 rs574376 chr15 53812704 G A 8.31E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines WDR72 intron 21844884 rs10518725 chr15 53815752 G A 2.07E-04 Longevity WDR72 intron 22279548 rs10518725 chr15 53815752 G A 1.85E-08 Metabolite levels WDR72 intron 23281178 rs562025 chr15 53816808 G C 4.33E-05 Bilirubin levels,in serum WDR72 intron 19389676 rs10220757 chr15 53841476 T C 8.19E-04 Multiple complex diseases WDR72 intron 17554300 rs17549027 chr15 53844711 A T 5.98E-08 Metabolite levels WDR72 intron 23281178 rs17630899 chr15 53844864 G C 5.98E-08 Metabolite levels WDR72 intron 23281178 rs11853370 chr15 53845601 G A 5.98E-08 Metabolite levels WDR72 intron 23281178 rs1906429 chr15 53858438 C T 1.50E-05 Urinary metabolites WDR72 intron 21572414 rs11635835 chr15 53866692 G A 7.77E-05 Serum metabolites WDR72 intron 19043545 rs9672398 chr15 53879241 T G 8.44E-04 Multiple complex diseases WDR72 intron 17554300 rs4448885 chr15 53879543 T C 8.70E-05 Cognitive function WDR72 intron 24684796 rs16966247 chr15 53881945 G C 2.00E-04 Chronic kidney disease WDR72 intron 21931561 rs4332691 chr15 53890362 C T 2.75E-04 Stroke WDR72 intron pha002887 rs2899517 chr15 53892200 T G 5.71E-04 Type 2 diabetes WDR72 intron 17463246 rs17730281 chr15 53907948 G A 3.00E-11 Renal function-related traits (BUN) WDR72 missense 22797727 rs11858440 chr15 53926729 A G 2.30E-05 Urinary metabolites WDR72 intron 21572414 rs16966341 chr15 53929524 G A 3.93E-04 Multiple complex diseases WDR72 intron 17554300 rs2926881 chr15 53935071 G T 7.15E-04 Alzheimer's disease WDR72 intron 24755620 rs10518733 chr15 53940307 A C 1.74E-08 Blood cell counts and other traits WDR72 intron 20139978 rs10518733 chr15 53940307 A C 2.00E-08 Blood cell counts and other traits WDR72 intron 20139978 rs17730436 chr15 53942928 T C 1.00E-13 Renal function-related traits (sCR) WDR72 intron 22797727 rs17730436 chr15 53942928 T C 6.00E-13 Renal function-related traits (eGRFcrea) WDR72 intron 22797727 rs491567 chr15 53946593 A C 3.00E-13 Chronic kidney disease WDR72 intron 20383146 rs491567 chr15 53946593 A C 3.54E-11 Chronic kidney disease WDR72 intron 22479191 rs3911726 chr15 53964746 G A 2.40E-05 Urinary metabolites WDR72 intron 21572414 rs572528 chr15 53972484 A G 2.20E-05 Cognitive function WDR72 intron 24684796 rs17663138 chr15 53994126 G A 2.49E-04 Type 2 diabetes WDR72 intron 17463246 rs551225 chr15 54003091 G A 2.00E-04 Information processing speed WDR72 missense 21130836 rs690337 chr15 54008795 T C 3.77E-04 Alzheimer's disease WDR72 intron 24755620 rs690487 chr15 54028917 T A,G 5.75E-04 Multiple complex diseases WDR72 intron 17554300 rs689654 chr15 54029475 C T 1.79E-04 Multiple complex diseases WDR72 intron 17554300 rs17632301 chr15 54110858 C A 8.82E-04 Alzheimer's disease / / 22005930 rs12594745 chr15 54114172 G A 4.71E-04 Smoking cessation / / 24665060 rs4776182 chr15 54125399 T G 8.79E-04 Alzheimer's disease / / 22005930 rs17198194 chr15 54126464 T C 8.92E-04 Alzheimer's disease / / 22005930 rs8040820 chr15 54127830 G A 9.38E-04 Alzheimer's disease / / 22005930 rs8040564 chr15 54127905 A G 7.34E-04 Alzheimer's disease / / 22005930 rs8040564 chr15 54127905 A G 2.92E-05 Behcet's disease / / 23291587 rs1871119 chr15 54128407 G A 7.42E-04 Alzheimer's disease / / 22005930 rs1478214 chr15 54128423 T C 7.46E-04 Alzheimer's disease / / 22005930 rs7165549 chr15 54129073 G A 1.14E-05 Behcet's disease / / 23291587 rs1841943 chr15 54145141 A G 1.83E-04 Myopia (pathological) / / 21095009 rs9672427 chr15 54167876 C A 6.47E-04 Alzheimer's disease / / 22005930 rs2248141 chr15 54172552 G A 9.18E-04 Tourette syndrome / / 22889924 rs8034462 chr15 54177677 T C 7.65E-05 Dengue shock syndrome / / 22001756 rs2725627 chr15 54192492 G A 7.54E-04 Bipolar disorder,schizoaffective / / 19567891 rs2616897 chr15 54196492 T G 4.51E-05 Cholesterol / / pha003083 rs2616894 chr15 54197327 C T 4.88E-05 Cholesterol / / pha003083 rs8031935 chr15 54211300 C T 1.78E-04 Type 2 diabetes / / 17463246 rs17198272 chr15 54211621 T C 6.64E-04 Type 2 diabetes / / 17463246 rs4776196 chr15 54264891 C T 2.33E-04 Type 2 diabetes / / 17463246 rs2414277 chr15 54270793 C T 3.99E-04 Type 2 diabetes / / 17463246 rs2711588 chr15 54274326 A G 1.70E-04 Birth weight / / 17255346 rs2616910 chr15 54276583 T C 1.70E-04 Birth weight / / 17255346 rs2725591 chr15 54278047 G A 2.88E-04 Birth weight / / 17255346 rs2725597 chr15 54287881 C T 0.00000559 LDL cholesterol particle diameter / / 23263444 rs2616917 chr15 54288558 C T 4.74E-05 Meningococcal disease / / 20694013 rs11856192 chr15 54289389 T C 2.25E-04 Premature ovarian failure / / 19508998 rs2565210 chr15 54298027 A G 5.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs1897042 chr15 54303459 A T 7.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs137929834 chr15 54305612 G A 0.000062 Breast cancer(er negative) UNC13C missense 23555315 rs12592703 chr15 54311885 C T 4.10E-04 Suicide attempts in bipolar disorder UNC13C intron 21041247 rs1897036 chr15 54318481 G A 6.64E-04 Suicide attempts in bipolar disorder UNC13C intron 21423239 rs17552199 chr15 54320533 T C 6.03E-04 Suicide attempts in bipolar disorder UNC13C intron 21423239 rs17633721 chr15 54320572 A T 4.74E-04 Suicide attempts in bipolar disorder UNC13C intron 21423239 rs2163196 chr15 54321576 G A 6.24E-04 Suicide attempts in bipolar disorder UNC13C intron 21423239 rs12917513 chr15 54321728 A T 1.77E-04 Suicide attempts in bipolar disorder UNC13C intron 21041247 rs1897031 chr15 54341465 G A 1.00E-06 Cognitive performance UNC13C intron 19734545 rs17634084 chr15 54363105 C A 2.92E-04 Prostate cancer mortality UNC13C intron 20978177 rs17634084 chr15 54363105 C A 2.30E-05 Urinary metabolites UNC13C intron 21572414 rs12913167 chr15 54366928 G C 7.38E-04 Multiple complex diseases UNC13C intron 17554300 rs1897023 chr15 54368844 A G 1.25E-04 Prostate cancer mortality UNC13C intron 20978177 rs11071033 chr15 54380200 T C 3.00E-06 Menarche (age at onset) UNC13C intron 23599027 rs11071033 chr15 54380200 T C 7.00E-06 Menarche (age at onset) UNC13C intron 23599027 rs11071033 chr15 54380200 T C 7.12E-06 Menarche (age at onset) UNC13C intron 23599027 rs12898716 chr15 54381500 T G 6.63E-04 Multiple complex diseases UNC13C intron 17554300 rs12901124 chr15 54386040 G T 8.01E-05 Prostate cancer mortality UNC13C intron 20978177 rs12594549 chr15 54387319 A G 3.80E-05 Parkinson's disease (age of onset) UNC13C intron 19772629 rs2115820 chr15 54387969 T G 4.00E-05 Parkinson's disease (age of onset) UNC13C intron 19772629 rs2414270 chr15 54388623 C T 1.62E-04 Prostate cancer mortality UNC13C intron 20978177 rs2899527 chr15 54388892 G A 1.62E-04 Prostate cancer mortality UNC13C intron 20978177 rs2899527 chr15 54388892 G A 1.10E-05 Urinary metabolites UNC13C intron 21572414 rs11071038 chr15 54389871 T C 8.33E-04 Parkinson's disease UNC13C intron 17052657 rs11636356 chr15 54392343 C T 9.23E-04 HIV-1 viral setpoint UNC13C intron 17641165 rs934192 chr15 54395278 G A 8.92E-04 HIV-1 viral setpoint UNC13C intron 17641165 rs9302173 chr15 54425797 T C 7.41E-04 Multiple complex diseases UNC13C intron 17554300 rs1897067 chr15 54439156 C G 3.23E-04 Multiple complex diseases UNC13C intron 17554300 rs1864421 chr15 54442615 C A 3.69E-04 Depression (quantitative trait) UNC13C intron 20800221 rs12902387 chr15 54443986 T A 3.86E-04 Depression (quantitative trait) UNC13C intron 20800221 rs12916905 chr15 54446522 A C 4.49E-04 Depression (quantitative trait) UNC13C intron 20800221 rs12899222 chr15 54446783 T G 6.45E-04 Depression (quantitative trait) UNC13C intron 20800221 rs9788712 chr15 54453774 C T 3.65E-04 Depression (quantitative trait) UNC13C intron 20800221 rs12900128 chr15 54455757 T C 3.66E-04 Depression (quantitative trait) UNC13C intron 20800221 rs8036265 chr15 54476135 G A 6.30E-04 Alcohol dependence UNC13C intron 20201924 rs8036265 chr15 54476135 G A 6.70E-04 Alcohol dependence UNC13C intron 20201924 rs11634827 chr15 54513878 A G 4.61E-05 Monocyte counts UNC13C intron pha003089 rs12914335 chr15 54529111 A G 3.65E-05 Alzheimer's disease UNC13C intron 22832961 rs11071063 chr15 54531423 C T 6.25E-04 HIV-1 viral setpoint UNC13C intron 17641165 rs10518762 chr15 54537760 C T 6.36E-04 Tourette syndrome UNC13C intron 22889924 rs7171614 chr15 54588348 A G 1.16E-04 Tourette syndrome UNC13C intron 22889924 rs17237459 chr15 54596482 C T 9.83E-04 Type 2 diabetes UNC13C intron 17463246 rs4430687 chr15 54602220 C G 3.25E-04 Nicotine dependence UNC13C intron 17158188 rs17237466 chr15 54612128 G T 3.24E-04 Birth weight UNC13C intron 17255346 rs1158075 chr15 54615251 A G 5.25E-04 HIV-1 viral setpoint UNC13C intron 17641165 rs16974514 chr15 54622761 A G 1.71E-04 Body mass index UNC13C intron 17255346 rs1511787 chr15 54623056 T C 8.81E-04 HIV-1 viral setpoint UNC13C intron 17641165 rs1398003 chr15 54623246 G A 9.01E-04 HIV-1 viral setpoint UNC13C intron 17641165 rs1511789 chr15 54654760 T C 1.88E-05 Hypertension (essential hypertension) UNC13C intron 22184326 rs563881 chr15 54662650 A G 4.52E-05 Hypertension (essential hypertension) UNC13C intron 22184326 rs573320 chr15 54678314 A C 4.41E-04 Parkinson's disease UNC13C intron 17052657 rs573320 chr15 54678314 A C 1.20E-04 Type 2 diabetes UNC13C intron 17463246 rs10518765 chr15 54680632 A C 3.02E-07 Parkinson's disease UNC13C intron 17052657 rs10518765 chr15 54680632 A C 1.00E-06 Select biomarker traits UNC13C intron 17903293 rs573740 chr15 54683431 C T 7.10E-05 Hypertension (essential hypertension) UNC13C intron 22184326 rs11853893 chr15 54715550 T G 1.40E-05 Height UNC13C intron 21998595 rs11857095 chr15 54715699 C T 2.83E-05 Body Mass Index UNC13C intron pha003019 rs11857095 chr15 54715699 C T 4.35E-06 Body Mass Index UNC13C intron pha003020 rs11857099 chr15 54715768 A G 6.83E-05 Body Mass Index UNC13C intron pha003019 rs11857099 chr15 54715768 A G 4.11E-05 Body Mass Index UNC13C intron pha003020 rs8035405 chr15 54716538 A G 6.06E-05 Body Mass Index UNC13C intron pha003019 rs8035405 chr15 54716538 A G 3.70E-05 Body Mass Index UNC13C intron pha003020 rs17237606 chr15 54722335 A G 9.92E-06 QT interval UNC13C intron 23534349 rs12437618 chr15 54748343 G A 2.30E-05 Age-related macular degeneration UNC13C intron 20861866 rs8038316 chr15 54773440 G A 9.64E-06 Depression (quantitative trait) UNC13C intron 23290196 rs8023474 chr15 54774436 C T 2.30E-05 Age-related macular degeneration UNC13C intron 20861866 rs885203 chr15 54775200 C T 2.20E-05 Age-related macular degeneration UNC13C intron 20861866 rs6493686 chr15 54779611 C G 1.89E-05 Depression (quantitative trait) UNC13C intron 23290196 rs8033074 chr15 54780167 A C 1.90E-05 Depression (quantitative trait) UNC13C intron 23290196 rs556837 chr15 54780599 A G 2.50E-04 Amyotrophic Lateral Sclerosis UNC13C intron 17362836 rs8025195 chr15 54792428 A G 3.40E-05 Age-related macular degeneration UNC13C intron 20861866 rs667292 chr15 54802291 A G 5.45E-05 Lymphocyte counts UNC13C intron pha003094 rs533450 chr15 54810371 A G 2.07E-04 Lung function (forced vital capacity) UNC13C intron 24023788 rs8039515 chr15 54847509 G T 8.10E-05 Intelligence (childhood) UNC13C intron 23358156 rs2553218 chr15 54868668 G T 8.00E-07 Immune response to smallpox vaccine (IL-6) UNC13C intron 22542470 rs2553218 chr15 54868668 G T 3.27E-04 Lung function (forced vital capacity) UNC13C intron 24023788 rs2553218 chr15 54868668 G T 4.92E-04 Lung function (forced expiratory volume in 1 second) UNC13C intron 24023788 rs1850999 chr15 54876423 T C 2.17E-04 Lung function (forced vital capacity) UNC13C intron 24023788 rs10152907 chr15 54891716 A G 1.44E-04 Progressive supranuclear palsy UNC13C intron 21685912 rs4774702 chr15 54967609 G A,C 8.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2414358 chr15 54974499 T A 9.86E-04 Alcohol dependence / / 21314694 rs4776246 chr15 54988820 C T 3.31E-04 Type 2 diabetes / / 17463246 rs4500668 chr15 55002218 C A 7.04E-04 Type 2 diabetes / / 17463246 rs7173766 chr15 55003439 A G 6.29E-07 Body mass index / / 19584900 rs7173766 chr15 55003439 A G 8.88E-05 Body mass index / / 19584900 rs2414371 chr15 55011324 C T 3.26E-05 Coronary heart disease / / pha003032 rs4776247 chr15 55022157 T G 5.85E-05 Coronary heart disease / / pha003032 rs2062639 chr15 55026455 T C 7.56E-05 Coronary heart disease / / pha003032 rs924552 chr15 55086936 G A 2.12E-04 Body mass index / / 17255346 rs8025011 chr15 55125380 G T 1.47E-04 Epilepsy / / 22116939 rs7497796 chr15 55136506 A C 1.10E-06 Urinary metabolites / / 21572414 rs7497796 chr15 55136506 A C 1.09E-04 Alzheimer's disease / / 24755620 rs2414382 chr15 55136755 T C 3.50E-06 Urinary metabolites / / 21572414 rs2899565 chr15 55139422 A G 8.40E-05 Cognitive test performance / / 20125193 rs10518790 chr15 55142751 A C 8.40E-05 Cognitive test performance / / 20125193 rs1501395 chr15 55172766 G A 1.50E-05 Urinary metabolites / / 21572414 rs10162662 chr15 55175902 C A 3.17E-06 Schizophrenia / / 19571811 rs4774725 chr15 55193334 T A 0.000212 Breast cancer early age of onset / / 18463975 rs4774726 chr15 55193396 G C 7.21E-04 Type 2 diabetes / / 17463246 rs1915215 chr15 55199477 C A 2.80E-05 Urinary metabolites / / 21572414 rs4126006 chr15 55257418 A G 4.25E-04 Response to TNF antagonist treatment / / 21061259 rs9806663 chr15 55257879 G A 3.42E-04 Response to TNF antagonist treatment / / 21061259 rs1194463 chr15 55272996 T C 9.11E-05 Response to TNF antagonist treatment / / 21061259 rs1994890 chr15 55279251 G A 2.32E-04 Heart Failure / / pha002884 rs1528470 chr15 55290575 C T 5.28E-05 Orofacial clefts / / 22419666 rs1728897 chr15 55301370 T C 1.61E-26 Narcolepsy / / 19629137 rs10518795 chr15 55344287 C T 1.10E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs2641575 chr15 55351601 T A 2.01E-04 Type 2 diabetes / / 17463246 rs1528462 chr15 55352945 C T 0.000058 post-traumatic stress disorder / / 22869035 rs1528462 chr15 55352945 C T 5.80E-05 Schizophrenia / / 22883433 rs473758 chr15 55382590 G A 3.10E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs551132 chr15 55385185 G T 0.000637 Salmonella-induced pyroptosis / / 22837397 rs2697377 chr15 55385884 C A 0.000634 Salmonella-induced pyroptosis / / 22837397 rs10444801 chr15 55402038 G A 6.35E-06 Height / / 20400458 rs564719 chr15 55408307 A T 4.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16975962 chr15 55411860 G A 7.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7163282 chr15 55443674 G A 4.06E-04 Multiple complex diseases / / 17554300 rs16976033 chr15 55456510 A G 7.00E-06 Neutrophil count / / 21507922 rs17238192 chr15 55514946 C T 6.87E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) RAB27A intron 24023788 rs2289059 chr15 55516393 A G 1.30E-05 Urinary metabolites RAB27A intron 21572414 rs16976218 chr15 55538549 G A 9.82E-04 Type 2 diabetes RAB27A intron 17463246 rs16976218 chr15 55538549 G A 4.61E-05 Telomere length RAB27A intron 20139977 rs4261468 chr15 55555602 A G 5.19E-04 Alcohol dependence RAB27A intron 20201924 rs11639418 chr15 55555694 G A 8.61E-04 Response to cytidine analogues (gemcitabine) RAB27A intron 24483146 rs12050885 chr15 55558624 T G 1.37E-04 Response to cytidine analogues (gemcitabine) RAB27A intron 24483146 rs11071175 chr15 55560425 A G 7.65E-04 Alcohol dependence RAB27A intron 20201924 rs11071175 chr15 55560425 A G 2.58E-04 Hemoglobin concentration RAB27A intron 20534544 rs4774760 chr15 55589212 T A 3.63E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs11636687 chr15 55605152 T C 1.53E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12902710 chr15 55611126 T C 1.20E-04 Hemoglobin concentration LOC100506294 intron 20534544 rs28668016 chr15 55611433 A G 1.31E-04 Response to cytidine analogues (gemcitabine) PIGB UTR-5 24483146 rs7174876 chr15 55619561 G A 4.06E-04 Response to cytidine analogues (gemcitabine) PIGB intron 24483146 rs2290344 chr15 55619796 T C 1.75E-05 Response to cytidine analogues (gemcitabine) PIGB missense 24483146 rs7183960 chr15 55622695 T C 2.37E-04 Response to cytidine analogues (gemcitabine) PIGB intron 24483146 rs12050587 chr15 55627528 A G 1.23E-04 Response to cytidine analogues (gemcitabine) PIGB intron 24483146 rs2414409 chr15 55631717 T C 1.62E-04 Response to cytidine analogues (gemcitabine) PIGB intron 24483146 rs678892 chr15 55632859 G A,C,T 1.20E-04 Hemoglobin concentration PIGB missense 20534544 rs678892 chr15 55632859 G A,C,T 2.32E-04 Cocaine dependence PIGB missense 23958962 rs678892 chr15 55632859 G A,C,T 2.45E-04 Cocaine dependence PIGB missense 23958962 rs8024695 chr15 55639305 T C 5.00E-05 Response to cytidine analogues (gemcitabine) PIGB intron 24483146 rs501231 chr15 55653031 A G 3.07E-04 Acute lung injury CCPG1 cds-synon 22295056 rs493968 chr15 55663240 A G 7.08E-04 Acute lung injury CCPG1 intron 22295056 rs472579 chr15 55668414 C G 6.92E-04 Acute lung injury CCPG1 intron 22295056 rs549914 chr15 55669784 C A 2.03E-04 Acute lung injury CCPG1 intron 22295056 rs7169179 chr15 55687774 A G 9.22E-04 Acute lung injury CCPG1 intron 22295056 rs7169948 chr15 55687897 G C 6.34E-04 Acute lung injury CCPG1 intron 22295056 rs7170993 chr15 55687969 T C 6.61E-04 Acute lung injury CCPG1 intron 22295056 rs11637024 chr15 55689629 G T 6.57E-04 Acute lung injury CCPG1 intron 22295056 rs9920450 chr15 55693204 T C 5.37E-04 Acute lung injury CCPG1 intron 22295056 rs11071185 chr15 55694830 A G 8.54E-04 Acute lung injury CCPG1 intron 22295056 rs12148682 chr15 55696532 A T 8.98E-04 Acute lung injury CCPG1 intron 22295056 rs622097 chr15 55739838 T C 2.92E-04 Acute lung injury DYX1C1 intron 22295056 rs600753 chr15 55759193 T C 3.37E-04 Acute lung injury DYX1C1 missense 22295056 rs692690 chr15 55760522 T C 3.39E-04 Acute lung injury DYX1C1 intron 22295056 rs692062 chr15 55772772 T C 1.90E-04 Response to cytidine analogues (gemcitabine) DYX1C1 intron 24483146 rs16976351 chr15 55788832 C T 5.50E-05 Multiple sclerosis (age of onset) DYX1C1 intron 19010793 rs8040756 chr15 55798599 G A 7.52E-04 Parkinson's disease DYX1C1 intron 17052657 rs9806182 chr15 55823602 A G 2.32E-04 Celiac disease / / 23936387 rs11636556 chr15 55884615 G A 9.73E-04 Type 2 diabetes / / 17463246 rs7175728 chr15 55894558 C T 2.79E-05 Schizophrenia / / 19197363 rs148011047 chr15 55916703 T G 0.00048 Prostate cancer PRTG missense 23555315 rs1550326 chr15 55933199 G T 6.69E-04 Type 2 diabetes PRTG intron 17463246 rs572531 chr15 55944517 G A 4.32E-04 Type 2 diabetes PRTG intron 17463246 rs572531 chr15 55944517 G A 7.99E-05 Type 2 diabetes PRTG intron 22158537 rs9920076 chr15 55945381 T A 3.94E-04 Type 2 diabetes PRTG intron 22158537 rs9920246 chr15 55945453 A G 1.25E-04 Type 2 diabetes PRTG intron 22158537 rs7171318 chr15 55946466 A C 3.79E-04 Type 2 diabetes PRTG intron 22158537 rs9920546 chr15 55946732 C T 5.06E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) PRTG intron 23648065 rs7178379 chr15 55947552 G A 3.22E-04 Type 2 diabetes PRTG intron 22158537 rs10851589 chr15 55949749 C T 2.86E-04 Type 2 diabetes PRTG intron 22158537 rs11071200 chr15 55950082 C A 9.00E-07 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) PRTG intron 23648065 rs4774800 chr15 55950941 C T 7.34E-04 Type 2 diabetes PRTG intron 22158537 rs495381 chr15 55973398 A T 4.69E-04 Multiple complex diseases PRTG intron 17554300 rs11852746 chr15 55984265 T C 2.86E-05 Orofacial clefts PRTG intron 20023658 rs687128 chr15 55984605 A C 1.80E-04 Multiple complex diseases PRTG intron 17554300 rs1011061 chr15 55987498 A G 1.21E-05 Orofacial clefts PRTG intron 20023658 rs11858195 chr15 55998595 A C 1.07E-04 Multiple complex diseases PRTG intron 17554300 rs2414424 chr15 56000063 C T 4.30E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) PRTG intron 23648065 rs2414431 chr15 56030846 T G 2.60E-04 Type 2 diabetes PRTG intron 17463246 rs6493814 chr15 56031671 G A 1.47E-04 Multiple complex diseases PRTG intron 17554300 rs12442771 chr15 56032099 A G 1.94E-04 Multiple complex diseases PRTG intron 17554300 rs185716584 chr15 56032665 C G 0.00015 Breast cancer (ER positive) PRTG missense 23555315 rs2414433 chr15 56044189 T C 1.70E-05 Alcoholism (heaviness of drinking) / / 21529783 rs8036481 chr15 56047546 G C 9.95E-07 Red blood cell traits / / 23222517 rs12438264 chr15 56063653 A G 4.67E-07 Red blood cell traits / / 23222517 rs4774822 chr15 56067671 T A,G 9.13E-04 Coronary heart disease / / 21606135 rs7169234 chr15 56090642 G A 2.78E-04 Acute lung injury / / 22295056 rs12439559 chr15 56118175 A C 3.78E-04 Smoking initiation / / 24665060 rs2288346 chr15 56139153 T C 1.57E-04 Smoking initiation NEDD4 intron 24665060 rs1912401 chr15 56161609 G A 8.61E-05 Smoking initiation NEDD4 intron 24665060 rs2414451 chr15 56172652 T G 1.34E-04 Smoking initiation NEDD4 intron 24665060 rs10518825 chr15 56188171 C T 4.80E-05 Smoking initiation NEDD4 intron 24665060 rs12916104 chr15 56192861 C T 8.95E-05 Parkinson's disease (motor and cognition) NEDD4 intron 22658654 rs12916104 chr15 56192861 C T 8.95E-05 Immune response to anthrax vaccine NEDD4 intron 22658931 rs8032158 chr15 56194877 T C 6.00E-13 Keloid NEDD4 intron 20711176 rs10518828 chr15 56199712 C A 5.90E-04 Heart Failure NEDD4 intron pha002885 rs17819300 chr15 56210929 A G 1.00E-10 Brain connectivity NEDD4 intron 23471985 rs7497861 chr15 56263532 C G 7.53E-04 Multiple complex diseases NEDD4 intron 17554300 rs7494783 chr15 56321602 T C 2.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7169431 chr15 56340896 A G 5.00E-07 Chronic lymphocytic leukemia / / 20062064 rs7169431 chr15 56340896 A G 5.00E-07 Nasopharyngeal carcinoma / / 20512145 rs7169431 chr15 56340896 A G 2.65E-05 Chronic lymphocytic leukemia / / 22700719 rs7169431 chr15 56340896 A G 2.65E-05 Erectile dysfunction / / 22704111 rs7169431 chr15 56340896 A G 1.72E-05 Chronic lymphocytic leukemia / / 23770605 rs8027409 chr15 56344059 C A 9.04E-05 Diabetes Mellitus / / pha003060 rs34979470 chr15 56363698 A G 2.80E-04 Hemoglobin concentration / / 20534544 rs16976734 chr15 56382295 A G 4.00E-07 Chronic lymphocytic leukemia / / 24292274 rs2584689 chr15 56484288 A G 7.71E-04 Type 2 diabetes RFX7 intron 17846125 rs2713935 chr15 56546212 C T 9.40E-05 Age-related macular degeneration / / 20861866 rs2713935 chr15 56546212 C T 3.62E-05 Age-related macular degeneration / / 21197116 rs2713935 chr15 56546212 C T 6.25E-05 Relative hand skill in reading disability / / 24068947 rs2947021 chr15 56555621 C A 2.95E-05 Relative hand skill in reading disability / / 24068947 rs2718934 chr15 56557418 G A 1.51E-05 Relative hand skill in reading disability / / 24068947 rs2249090 chr15 56558014 G A 1.38E-05 Relative hand skill in reading disability / / 24068947 rs2682070 chr15 56572810 A G 1.18E-05 Relative hand skill in reading disability / / 24068947 rs2682071 chr15 56574051 G A 2.53E-05 Relative hand skill in reading disability / / 24068947 rs2725854 chr15 56577831 C T 1.49E-05 Relative hand skill in reading disability / / 24068947 rs2718952 chr15 56588605 A G 1.09E-05 Relative hand skill in reading disability / / 24068947 rs547435494 chr15 56588605 AT A 1.09E-05 Relative hand skill in reading disability / / 24068947 rs61249027 chr15 56588605 AT A 1.09E-05 Relative hand skill in reading disability / / 24068947 rs2718955 chr15 56590272 G A 1.98E-05 Relative hand skill in reading disability / / 24068947 rs2460646 chr15 56642876 G T 2.05E-05 Relative hand skill in reading disability / / 24068947 rs12905782 chr15 56654125 G C 1.73E-05 Relative hand skill in reading disability / / 24068947 rs12900678 chr15 56677730 A G 9.47E-06 Relative hand skill in reading disability TEX9 intron 24068947 rs17819438 chr15 56680321 G T 2.25E-05 Relative hand skill in reading disability TEX9 intron 24068947 rs6493856 chr15 56687359 C A 9.80E-05 Age-related macular degeneration TEX9 intron 21197116 rs6493856 chr15 56687359 C A 1.45E-05 Relative hand skill in reading disability TEX9 intron 24068947 rs2414476 chr15 56701500 C A 8.71E-09 Crohn's disease TEX9 intron 17804789 rs1549452 chr15 56702355 C T 1.76E-05 Relative hand skill in reading disability TEX9 intron 24068947 rs2303441 chr15 56704170 A G 1.41E-05 Relative hand skill in reading disability TEX9 intron 24068947 rs3817406 chr15 56721875 A G 8.07E-06 Relative hand skill in reading disability MNS1 intron 24068947 rs3784552 chr15 56722732 T C 1.52E-05 Relative hand skill in reading disability MNS1 intron 24068947 rs795790 chr15 56724664 T C 2.50E-05 Relative hand skill in reading disability MNS1 intron 24068947 rs11630363 chr15 56726802 T C 1.18E-05 Relative hand skill in reading disability MNS1 intron 24068947 rs6493858 chr15 56736478 G A 4.00E-06 Relative hand skill in reading disability MNS1 intron 24068947 rs7170307 chr15 56737297 A C 2.26E-05 Relative hand skill in reading disability MNS1 intron 24068947 rs1477590 chr15 56745305 T G 4.55E-05 Relative hand skill in reading disability MNS1 intron 24068947 rs1715919 chr15 56756285 T G 3.43E-04 Amyotrophic lateral sclerosis (sporadic) MNS1 missense 24529757 rs7181320 chr15 56760140 A C 7.05E-05 Relative hand skill in reading disability / / 24068947 rs11856746 chr15 56763193 A C 5.61E-05 Serum metabolites / / 19043545 rs2899598 chr15 56771245 C T 9.52E-04 Multiple complex diseases / / 17554300 rs2899598 chr15 56771245 C T 2.84E-04 Lymphocyte counts / / 22286170 rs11636802 chr15 56775597 A G 2.00E-13 Chronic lymphocytic leukemia / / 23770605 rs11634865 chr15 56792436 C T 4.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs11531318 chr15 56812698 C T 4.83E-04 Alzheimer's disease / / 17998437 rs4774885 chr15 56945448 A G 6.29E-04 Body mass index ZNF280D intron 21701565 rs10518876 chr15 57065787 G A 9.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs7175191 chr15 57186397 A G 1.64E-05 Parkinson's disease LOC145783 intron pha002868 rs3803455 chr15 57210297 G A 7.76E-05 Receptive language ability / / 24687471 rs715338 chr15 57215867 G A 4.96E-05 Receptive language ability TCF12 intron 24687471 rs213168 chr15 57241657 A C 3.09E-05 Cardiovascular disease TCF12 intron 17903304 rs10518890 chr15 57332576 C T 8.02E-05 Magnesium levels TCF12 intron pha003092 rs1820996 chr15 57333209 T G 2.83E-05 Cardiovascular disease TCF12 intron 17903304 rs2962994 chr15 57342699 A G 1.98E-05 Cardiovascular disease TCF12 intron 17903304 rs7176873 chr15 57349162 G A 1.15E-05 Parkinson's disease TCF12 intron pha002868 rs2585110 chr15 57352893 T C 3.69E-04 Body mass index TCF12 intron 21701565 rs2703580 chr15 57353034 C T 5.34E-05 Parent of origin effect on language impairment (paternal) TCF12 intron 24571439 rs11631541 chr15 57361676 C G 6.83E-05 Receptive language ability TCF12 intron 24687471 rs2252289 chr15 57372772 G A 9.71E-05 Rheumatoid arthritis TCF12 intron 17804836 rs12900589 chr15 57373236 T C 9.66E-05 Parent of origin effect on language impairment (paternal) TCF12 intron 24571439 rs2703589 chr15 57381332 A G 9.10E-04 Suicide attempts in bipolar disorder TCF12 intron 21423239 rs2733332 chr15 57388349 C T 3.16E-05 Parent of origin effect on language impairment (paternal) TCF12 intron 24571439 rs16977243 chr15 57394005 A C 2.74E-05 Parkinson's disease TCF12 intron pha002868 rs10518895 chr15 57404113 A T 6.38E-04 Alzheimer's disease TCF12 intron 17998437 rs967514 chr15 57413776 A G 3.91E-05 Parent of origin effect on language impairment (paternal) TCF12 intron 24571439 rs2733333 chr15 57435926 A G 9.31E-06 Parkinson's disease TCF12 intron pha002868 rs2733330 chr15 57551789 A G 4.38E-05 Rheumatoid arthritis TCF12 intron 17804836 rs2733330 chr15 57551789 A G 6.93E-04 Iron levels TCF12 intron pha002876 rs3803452 chr15 57579746 T C 3.34E-05 Lymphocyte counts TCF12 UTR-3 pha003094 rs2921430 chr15 57581413 T C 8.14E-04 Iron levels / / pha002876 rs2440979 chr15 57594066 T C 5.14E-04 Substance dependence LOC283663 intron 21818250 rs2243504 chr15 57597280 T G 2.17E-05 Parent of origin effect on language impairment (paternal) LOC283663 intron 24571439 rs4774925 chr15 57604402 T C 9.85E-05 Nicotine smoking / / 19268276 rs4774925 chr15 57604402 T C 7.62E-04 Substance dependence / / 21818250 rs2431016 chr15 57608692 T G 6.40E-06 Urinary metabolites / / 21572414 rs2544132 chr15 57609441 C G 1.40E-05 Urinary metabolites / / 21572414 rs2544143 chr15 57627451 T C 2.19E-04 Multiple complex diseases / / 17554300 rs734490 chr15 57647707 T G 9.88E-04 Multiple complex diseases / / 17554300 rs4609782 chr15 57653702 A G 0.0000202 Colorectal adenoma (excluding hyperplasic) / / 23677573 rs4609782 chr15 57653702 A G 0.0000202 Colorectal adenoma (including hyperplasic) / / 23677573 rs2440961 chr15 57659871 A G 8.90E-04 Multiple complex diseases / / 17554300 rs2431043 chr15 57659991 G A 7.88E-04 Insulin resistance / / 21901158 rs9888667 chr15 57665702 T A 0.0000416 Colorectal adenoma (excluding hyperplasic) / / 23677573 rs9888667 chr15 57665702 T A 0.0000416 Colorectal adenoma (including hyperplasic) / / 23677573 rs1039979 chr15 57672835 A T 1.69E-05 Type 2 diabetes CGNL1 intron 17463246 rs16977428 chr15 57674330 C T 2.64E-04 Type 2 diabetes CGNL1 intron 17463246 rs1664462 chr15 57677266 C T 3.79E-04 Type 2 diabetes CGNL1 intron 17463246 rs12440459 chr15 57694938 C T 6.76E-05 Alcohol dependence CGNL1 intron 21314694 rs12909509 chr15 57697029 G A 5.77E-04 Response to taxane treatment (placlitaxel) CGNL1 intron 23006423 rs12909385 chr15 57697075 C T 2.65E-04 Response to taxane treatment (placlitaxel) CGNL1 intron 23006423 rs16977474 chr15 57700569 C A 8.71E-08 Metabolite levels CGNL1 intron 23281178 rs11857181 chr15 57712426 G A 1.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CGNL1 intron 20877124 rs1567619 chr15 57726105 A C 1.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CGNL1 intron 20877124 rs1280396 chr15 57731728 A G 9.96E-04 Longevity CGNL1 missense 22279548 rs8034838 chr15 57734187 G C 3.49E-04 Alcohol dependence CGNL1 intron 21314694 rs11071319 chr15 57741261 A G 4.32E-04 Alzheimer's disease (late onset) CGNL1 intron 21379329 rs2271406 chr15 57744080 A C 8.45E-05 Suicide attempts in bipolar disorder CGNL1 intron 21423239 rs2934442 chr15 57762793 C T 1.00E-06 Bipolar disorder (age of onset and psychomotor symptoms) CGNL1 intron 21305692 rs1297111 chr15 57764621 A G 9.73E-04 Parkinson's disease CGNL1 intron 17052657 rs2934444 chr15 57766519 G C 1.53E-04 Multiple complex diseases CGNL1 intron 17554300 rs2922219 chr15 57767982 G T 3.60E-04 Response to antidepressants CGNL1 intron 19736353 rs10518922 chr15 57782249 T C 9.43E-05 Non-alcoholic fatty liver disease histology (other) CGNL1 intron 20708005 rs10518923 chr15 57786246 A C 3.45E-04 Type 2 diabetes CGNL1 intron 17463246 rs1280368 chr15 57786420 T C 3.39E-04 Amyotrophic lateral sclerosis (sporadic) CGNL1 intron 24529757 rs12437888 chr15 57787148 C G 2.79E-04 Type 2 diabetes CGNL1 intron 17463246 rs2942043 chr15 57788387 G T 3.31E-04 Type 2 diabetes CGNL1 intron 17463246 rs11071323 chr15 57791332 A G 7.47E-04 Type 2 diabetes CGNL1 intron 17463246 rs1994887 chr15 57793765 C A 1.84E-05 Acne (severe teenage) CGNL1 intron 24114350 rs2131740 chr15 57802406 A G 2.82E-04 Type 2 diabetes CGNL1 intron 17463246 rs12595135 chr15 57803432 A T 2.46E-04 Type 2 diabetes CGNL1 intron 17463246 rs16977561 chr15 57807965 G A 2.83E-04 Type 2 diabetes CGNL1 intron 17463246 rs2279605 chr15 57824330 A G 7.06E-05 Bipolar disorder CGNL1 intron 18317468 rs2172614 chr15 57825607 G C 7.90E-04 Type 2 diabetes CGNL1 intron 17463246 rs16977594 chr15 57839587 A G 7.68E-05 Body mass index CGNL1 missense 17255346 rs16977597 chr15 57844884 G A,C,T 1.15E-04 Body mass index / / 17255346 rs16977597 chr15 57844884 G A,C,T 3.15E-04 Multiple complex diseases / / 17554300 rs2414514 chr15 57851576 G A 1.67E-04 Body mass index / / 17255346 rs7179379 chr15 57859727 C T 5.80E-04 Alcohol dependence / / 20201924 rs2635382 chr15 57864812 T C 4.38E-05 Coronary heart disease / / 21606135 rs1666577 chr15 57866927 T G 4.06E-05 Coronary heart disease / / 21606135 rs7181170 chr15 57868448 T A 5.29E-05 Coronary heart disease / / 21606135 rs935549 chr15 57873438 C T 1.70E-04 Alcohol dependence / / 20201924 rs935549 chr15 57873438 C T 3.90E-06 Alcohol dependence / / 20201924 rs935549 chr15 57873438 C T 3.91E-06 Alcoholism / / pha002892 rs1873993 chr15 57876670 A G 4.03E-04 Alzheimer's disease / / 17998437 rs11071334 chr15 57878811 T C 4.60E-04 Alcohol dependence / / 20201924 rs17820515 chr15 57879310 T C 2.58E-04 Aortic root size / / 21223598 rs1690325 chr15 57879723 C T 4.80E-04 Aortic root size / / 21223598 rs1690325 chr15 57879723 C T 2.29E-04 Coronary heart disease / / 21606135 rs1690326 chr15 57880169 G A 4.19E-04 Aortic root size / / 21223598 rs1868243 chr15 57880518 T C 4.39E-04 Aortic root size / / 21223598 rs744318 chr15 57881889 T G 2.10E-04 Alcohol dependence / / 20201924 rs744318 chr15 57881889 T G 3.60E-06 Alcohol dependence / / 20201924 rs744318 chr15 57881889 T G 3.60E-06 Alcoholism / / pha002892 rs1690327 chr15 57882546 A C 4.41E-04 Aortic root size / / 21223598 rs1908204 chr15 57883178 T G 3.66E-04 Aortic root size / / 21223598 rs11071335 chr15 57888589 A G 4.16E-04 Aortic root size GCOM1 intron 21223598 rs11637891 chr15 57890894 C G 1.95E-04 Aortic root size GCOM1 intron 21223598 rs7178159 chr15 57894443 T G 3.81E-04 Aortic root size GCOM1 intron 21223598 rs4774275 chr15 57895353 G A 3.98E-04 Aortic root size GCOM1 intron 21223598 rs750648 chr15 57897054 A C 4.15E-04 Aortic root size GCOM1 intron 21223598 rs9920308 chr15 57902231 C A 3.69E-04 Aortic root size GCOM1 intron 21223598 rs9920308 chr15 57902231 C A 3.51E-06 Cocaine dependence GCOM1 intron 23958962 rs9920308 chr15 57902231 C A 4.97E-06 Cocaine dependence GCOM1 intron 23958962 rs2451181 chr15 57902875 A T 3.65E-04 Aortic root size GCOM1 intron 21223598 rs9806498 chr15 57903204 C T 4.79E-04 Aortic root size GCOM1 intron 21223598 rs2453096 chr15 57904121 G A 2.52E-04 Aortic root size GCOM1 intron 21223598 rs2453098 chr15 57905077 T C 2.42E-04 Aortic root size GCOM1 intron 21223598 rs937254 chr15 57910164 G A 1.00E-06 Coronary heart disease GCOM1 intron 21347282 rs17239999 chr15 57918574 C T 8.00E-04 Alcohol dependence GCOM1 intron 20201924 rs7176042 chr15 57934701 G A 2.93E-05 Serum metabolites GCOM1 intron 19043545 rs7176042 chr15 57934701 G A 6.10E-04 Alcohol dependence GCOM1 intron 20201924 rs2433196 chr15 57935419 A C 6.60E-04 Alcohol dependence GCOM1 intron 20201924 rs2733604 chr15 57955329 G T 8.99E-05 Serum metabolites GCOM1 intron 19043545 rs1425948 chr15 57957314 A G 2.84E-05 Serum metabolites GCOM1 intron 19043545 rs1425948 chr15 57957314 A G 8.80E-04 Alcohol dependence GCOM1 intron 20201924 rs9302201 chr15 57957824 C T 1.14E-04 Gallstones GCOM1 intron 17632509 rs9302201 chr15 57957824 C T 6.28E-05 Serum metabolites GCOM1 intron 19043545 rs9302201 chr15 57957824 C T 2.26E-06 Kawasaki disease GCOM1 intron 21221998 rs10162772 chr15 57957964 G A 5.80E-05 Serum metabolites GCOM1 intron 19043545 rs17240055 chr15 57958484 C T 2.93E-04 Height GCOM1 intron 17255346 rs17240055 chr15 57958484 C T 7.42E-05 Serum metabolites GCOM1 intron 19043545 rs16977643 chr15 58004746 A G 2.82E-12 Multiple complex diseases POLR2M intron 17554300 rs7174390 chr15 58025960 T C 1.27E-04 Alzheimer's disease (late onset) / / 21379329 rs598729 chr15 58060795 T C 4.15E-05 stroke (ischemic) / / 17434096 rs552702 chr15 58062001 G T 8.57E-05 stroke (ischemic) / / 17434096 rs1991253 chr15 58066690 G A 4.85E-04 Multiple complex diseases / / 17554300 rs1559777 chr15 58080617 G A 1.00E-06 Myopia (pathological) / / 23049088 rs10518933 chr15 58086464 T C 9.81E-11 Metabolite levels / / 22286219 rs597804 chr15 58100949 G A 5.59E-05 Behcet's disease / / pha002888 rs752989 chr15 58116800 C G 8.29E-05 Relative hand skill in reading disability / / 24068947 rs12913297 chr15 58117537 T C 6.65E-05 Relative hand skill in reading disability / / 24068947 rs17820733 chr15 58121461 T C 5.70E-06 Urinary metabolites / / 21572414 rs16977758 chr15 58150749 G A 2.26E-04 Multiple complex diseases / / 17554300 rs10518943 chr15 58155349 G T 8.10E-06 Urinary metabolites / / 21572414 rs11857195 chr15 58176513 T C 1.80E-05 Urinary metabolites / / 21572414 rs8036420 chr15 58177487 T C 2.20E-05 Urinary metabolites / / 21572414 rs894342 chr15 58177591 C T 1.18E-04 Type 2 diabetes / / 17463246 rs1441824 chr15 58185362 G A 0.000776 Salmonella-induced pyroptosis / / 22837397 rs1441826 chr15 58185488 T C 2.18E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1441826 chr15 58185488 T C 8.18E-04 White matter integrity / / 22425255 rs10518945 chr15 58186968 A G 6.19E-05 Bone mass and geometry / / 17903296 rs10518945 chr15 58186968 A G 4.19E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7497094 chr15 58187140 A C 1.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11637779 chr15 58210820 T C 4.34E-04 Antisocial behavior / / 20345837 rs1550576 chr15 58213414 C T 3.00E-06 Hypertension / / 19609347 rs1550576 chr15 58213414 C T 3.00E-06 Coronary heart disease / / 21347282 rs3204689 chr15 58246802 G C 1.00E-11 Osteoarthritis (hand,severe) ALDH1A2 UTR-3 24728293 rs3204689 chr15 58246802 G C 5.10E-17 Osteoarthritis (hand,severe) ALDH1A2 UTR-3 24728293 rs3204689 chr15 58246802 G C 5.60E-12 Osteoarthritis (hand,severe) ALDH1A2 UTR-3 24728293 rs3784262 chr15 58253106 T C 4.00E-07 Barrett's esophagus ALDH1A2 intron 24121790 rs3784262 chr15 58253106 T C 7.00E-07 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) ALDH1A2 intron 24121790 rs4646626 chr15 58256127 C T 8.86E-06 Osteoarthritis ALDH1A2 missense 22763110 rs6493973 chr15 58292636 T C 0.000044 Otitis media (children 3 years old or younger) ALDH1A2 intron 23133572 rs2218261 chr15 58294022 T C 0.000044 Otitis media (children 3 years old or younger) ALDH1A2 intron 23133572 rs12903202 chr15 58306793 A G 0.00000915 Bisphosphonate-induced osteonecrosis of the jaw ALDH1A2 intron 22267851 rs2899611 chr15 58327347 T G 2.26E-05 Multiple sclerosis (brain glutamate levels) ALDH1A2 intron 20802204 rs2704219 chr15 58328448 T C 0.0000372 Otitis media (children 3 years old or younger) ALDH1A2 intron 23133572 rs16939707 chr15 58332804 A C 5.27E-05 Kawasaki disease ALDH1A2 intron 22081228 rs4238326 chr15 58336000 T C 1.50E-08 Osteoarthritis (hand,severe) ALDH1A2 intron 24728293 rs4238326 chr15 58336000 T C 2.00E-11 Osteoarthritis (hand,severe) ALDH1A2 intron 24728293 rs4238326 chr15 58336000 T C 8.60E-11 Osteoarthritis (hand,severe) ALDH1A2 intron 24728293 rs1874158 chr15 58340072 T C 2.00E-04 Cognitive impairment induced by topiramate ALDH1A2 intron 22091778 rs11635486 chr15 58361124 G A 1.45E-12 Metabolite levels / / 22286219 rs2704188 chr15 58371682 G A 8.13E-06 Cognitive impairment induced by topiramate / / 22091778 rs2704188 chr15 58371682 G A 8.51E-04 Acute lung injury / / 22295056 rs2704207 chr15 58412543 A G 4.62E-05 Blood Pressure / / pha003048 rs12440934 chr15 58425804 A C 1.38E-04 Type 2 diabetes / / 17463246 rs17571313 chr15 58426242 C T 2.09E-04 Type 2 diabetes / / 17463246 rs8037263 chr15 58436883 G C 1.77E-05 Type 2 diabetes AQP9 intron 17463246 rs16939816 chr15 58437346 A G 7.95E-04 Type 2 diabetes AQP9 intron 17463246 rs16953360 chr15 58448194 A G 5.36E-04 Type 2 diabetes AQP9 intron 17463246 rs16953360 chr15 58448194 A G 1.05E-22 Metabolite levels AQP9 intron 22286219 rs4643260 chr15 58451807 A G 6.91E-04 Suicide attempts in bipolar disorder AQP9 intron 21423239 rs7167911 chr15 58452907 T G 4.13E-04 Premature ovarian failure AQP9 intron 19508998 rs12441883 chr15 58456850 G A 2.39E-18 Metabolite levels AQP9 intron 22286219 rs2292711 chr15 58464947 C T 1.13E-04 Alzheimer's disease (late onset) AQP9 intron 21379329 rs16939881 chr15 58471979 G C 2.33E-24 Metabolite levels AQP9 intron 22286219 rs16939881 chr15 58471979 G C 3.00E-27 Metabolite levels (atherosclerosis) AQP9 intron 22916037 rs11854297 chr15 58475125 T C 5.15E-04 Alcohol dependence AQP9 intron 21314694 rs143394617 chr15 58476204 T C 0.000076 Prostate cancer (advanced) AQP9 missense 23555315 rs2077737 chr15 58478950 T C 2.58E-13 Metabolite levels / / 22286219 rs2077735 chr15 58479025 A G 5.66E-04 Multiple complex diseases / / 17554300 rs12900815 chr15 58485682 C T 1.39E-14 Metabolite levels / / 22286219 rs11857136 chr15 58500779 T A 1.62E-12 Metabolite levels / / 22286219 rs56227417 chr15 58500956 T C 4.30E-13 Metabolite levels / / 22286219 rs4350519 chr15 58501146 C G 7.12E-13 Metabolite levels / / 22286219 rs1618701 chr15 58501282 T A 7.57E-13 Metabolite levels / / 22286219 rs7180071 chr15 58502472 A G 1.08E-12 Metabolite levels / / 22286219 rs2414551 chr15 58503128 T C 2.20E-12 Metabolite levels / / 22286219 rs1663253 chr15 58504678 C T 5.79E-11 Metabolite levels / / 22286219 rs2017566 chr15 58505040 T C 5.59E-11 Metabolite levels / / 22286219 rs1663254 chr15 58513993 G A 1.14E-11 Metabolite levels / / 22286219 rs1663255 chr15 58514242 C T 1.16E-11 Metabolite levels / / 22286219 rs11632498 chr15 58532507 T C 1.48E-05 Vascular dementia / / 22116812 rs8034444 chr15 58536395 C G 8.62E-04 Type 2 diabetes / / 17463246 rs62000518 chr15 58546178 T C 6.68E-11 Metabolite levels / / 22286219 rs56314708 chr15 58546697 C A 7.12E-11 Metabolite levels / / 22286219 rs7183294 chr15 58546728 T C 2.75E-11 Metabolite levels / / 22286219 rs7183294 chr15 58546728 T C 6.88E-04 Smoking initiation / / 24665060 rs7182541 chr15 58547018 C T 4.08E-11 Metabolite levels / / 22286219 rs6493993 chr15 58547457 T C,G 5.02E-11 Metabolite levels / / 22286219 rs7173510 chr15 58549361 C T 8.99E-11 Metabolite levels / / 22286219 rs7179597 chr15 58549515 T G 8.99E-11 Metabolite levels / / 22286219 rs7179609 chr15 58549532 T C 6.55E-11 Metabolite levels / / 22286219 rs7179609 chr15 58549532 T C 6.68E-05 Smoking initiation / / 24665060 rs7178320 chr15 58549547 C T 8.73E-11 Metabolite levels / / 22286219 rs7178332 chr15 58549559 C T 8.99E-11 Metabolite levels / / 22286219 rs7178337 chr15 58549612 A C 8.98E-11 Metabolite levels / / 22286219 rs7178779 chr15 58549619 G T 8.98E-11 Metabolite levels / / 22286219 rs34458264 chr15 58549743 C T 8.94E-11 Metabolite levels / / 22286219 rs62000520 chr15 58549784 A G 8.92E-11 Metabolite levels / / 22286219 rs17240685 chr15 58549812 T A 8.90E-11 Metabolite levels / / 22286219 rs35348919 chr15 58549954 A C 8.90E-11 Metabolite levels / / 22286219 rs34890778 chr15 58549978 A G 8.87E-11 Metabolite levels / / 22286219 rs34149555 chr15 58550000 G A 8.85E-11 Metabolite levels / / 22286219 rs2414561 chr15 58551444 C T 9.60E-12 Metabolite levels / / 22286219 rs935214 chr15 58554685 C T 6.10E-05 Body Mass Index / / pha003007 rs935214 chr15 58554685 C T 3.19E-05 Waist Circumference / / pha003025 rs12899324 chr15 58555709 C T 3.43E-05 Smoking initiation / / 24665060 rs17821159 chr15 58557062 A G 1.25E-10 Metabolite levels / / 22286219 rs17821159 chr15 58557062 A G 3.77E-08 Metabolite levels / / 23281178 rs7179726 chr15 58558746 C T 4.00E-11 Metabolite levels / / 22286219 rs12904030 chr15 58562270 C T 2.49E-11 Metabolite levels / / 22286219 rs8033046 chr15 58563209 C T 2.00E-05 Cognitive performance / / 19734545 rs4542601 chr15 58565099 C T 2.89E-11 Metabolite levels / / 22286219 rs8042351 chr15 58568093 T A,C,G 3.96E-11 Metabolite levels / / 22286219 rs11854242 chr15 58571910 C T 6.53E-12 Metabolite levels / / 22286219 rs11854318 chr15 58571982 G A 3.73E-12 Metabolite levels / / 22286219 rs1711037 chr15 58576350 A T 9.80E-14 Metabolite levels / / 22286219 rs12903590 chr15 58577777 A T 1.25E-13 Metabolite levels / / 22286219 rs12910051 chr15 58580525 A G 6.81E-14 Metabolite levels / / 22286219 rs17240713 chr15 58580921 C T 6.24E-05 Body Mass Index / / pha003014 rs17240713 chr15 58580921 C T 9.80E-05 Waist Circumference / / pha003024 rs17240713 chr15 58580921 C T 1.72E-05 Waist Circumference / / pha003025 rs7179728 chr15 58581426 G C 2.18E-13 Metabolite levels / / 22286219 rs938507 chr15 58582034 G A 2.55E-13 Metabolite levels / / 22286219 rs1318175 chr15 58586129 C T 3.81E-15 Metabolite levels / / 22286219 rs4775027 chr15 58588104 G A 8.26E-04 Multiple complex diseases / / 17554300 rs1663239 chr15 58588605 C T 9.45E-04 Multiple complex diseases / / 17554300 rs1711041 chr15 58590621 G T 6.05E-11 Metabolite levels / / 22286219 rs12899879 chr15 58591415 T C 6.01E-11 Metabolite levels / / 22286219 rs6493997 chr15 58592280 C T 4.43E-04 Multiple complex diseases / / 17554300 rs10518968 chr15 58592926 T C 5.89E-05 Waist Circumference / / pha003024 rs28697198 chr15 58593566 C A,T 1.95E-12 Metabolite levels / / 22286219 rs10518969 chr15 58593997 A G 5.01E-04 Multiple complex diseases / / 17554300 rs7172930 chr15 58601804 G A 3.44E-05 Waist-Hip Ratio / / pha003029 rs187774 chr15 58619167 C G 3.56E-06 Serum metabolites / / 19043545 rs1122208 chr15 58623525 T C 2.82E-05 Educational attainment / / 21694764 rs12910827 chr15 58630019 G T 1.30E-06 Type 2 diabetes / / 17463248 rs261318 chr15 58634768 G C 6.10E-04 Multiple complex diseases / / 17554300 rs4775031 chr15 58635583 C A 2.00E-06 Cognitive performance / / 20125193 rs557108 chr15 58641311 C T 5.44E-14 Metabolite levels / / 22286219 rs4622454 chr15 58646332 C T 9.75E-15 Metabolite levels / / 22286219 rs8037464 chr15 58649477 T C 2.11E-11 Metabolite levels / / 22286219 rs8036597 chr15 58649668 C G 2.03E-14 Metabolite levels / / 22286219 rs17821268 chr15 58651297 T C 1.70E-16 Metabolite levels / / 22286219 rs62001733 chr15 58662090 A C 2.43E-11 Metabolite levels / / 22286219 rs567496 chr15 58665952 T A 1.35E-13 Metabolite levels / / 22286219 rs479084 chr15 58666087 C G 3.09E-13 Metabolite levels / / 22286219 rs473422 chr15 58666341 C T 1.03E-05 Migraine / / 20802479 rs473422 chr15 58666341 C T 3.00E-14 Metabolite levels / / 22286219 rs1838504 chr15 58666410 A T 4.23E-19 Metabolite levels / / 22286219 rs1444938 chr15 58666425 T A 4.72E-12 Metabolite levels / / 22286219 rs185481 chr15 58666679 T C 5.98E-22 Metabolite levels / / 22286219 rs4775039 chr15 58670897 C G 4.80E-06 Response to statin therapy / / 20339536 rs4775039 chr15 58670897 C G 1.60E-32 Metabolite levels / / 22286219 rs10152355 chr15 58671178 C A 1.95E-15 Metabolite levels / / 22286219 rs1601933 chr15 58671559 C T 1.46E-47 Metabolite levels / / 22286219 rs1601935 chr15 58671765 G T 3.45E-54 Metabolite levels / / 22286219 rs12908474 chr15 58672134 C T 4.00E-06 Response to statin therapy / / 20339536 rs12908474 chr15 58672134 C T 9.25E-44 Metabolite levels / / 22286219 rs371125 chr15 58672997 T C 3.51E-04 Alzheimer's disease (late onset) / / 21379329 rs62001736 chr15 58674051 G A 1.39E-20 Metabolite levels / / 22286219 rs2043082 chr15 58674308 G A 4.88E-64 Metabolite levels / / 22286219 rs539901 chr15 58674669 T G 8.00E-06 Non-small cell lung cancer / / 23144319 rs4775041 chr15 58674695 G C 2.75E-04 Type 2 diabetes / / 17463246 rs4775041 chr15 58674695 G C 2.00E-08 Triglycerides / / 18193043 rs4775041 chr15 58674695 G C 3.00E-20 HDL cholesterol / / 18193043 rs4775041 chr15 58674695 G C 1.00E-07 Metabolite levels / / 19043545 rs4775041 chr15 58674695 G C 1.77E-09 Triglycerides / / 19060911 rs4775041 chr15 58674695 G C 5.80E-09 Lipid levels / / 19913121 rs4775041 chr15 58674695 G C 6.63E-08 Lipid levels / / 19913121 rs4775041 chr15 58674695 G C 1.00E-08 Response to statin therapy / / 20339536 rs4775041 chr15 58674695 G C 3.00E-20 Coronary heart disease / / 21347282 rs4775041 chr15 58674695 G C 4.65E-08 Cardiovascular disease risk factors / / 21943158 rs4775041 chr15 58674695 G C 1.23E-57 Metabolite levels / / 22286219 rs4775041 chr15 58674695 G C 2.69E-20 HDL cholesterol / / 22629316 rs4775041 chr15 58674695 G C 4.73E-15 Cholesterol,total / / 23063622 rs4775041 chr15 58674695 G C 5.09E-52 HDL cholesterol / / 23063622 rs4775041 chr15 58674695 G C 0.00033 Apolipoprotein B levels response after 40mg daily simvastatin treatment / / 23100282 rs4775041 chr15 58674695 G C 3.30E-04 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) / / 23103227 rs4775041 chr15 58674695 G C 1.47E-09 Metabolite levels / / 23281178 rs11858759 chr15 58676821 G A 1.12E-50 Metabolite levels / / 22286219 rs11071377 chr15 58677395 A T 7.70E-49 Metabolite levels / / 22286219 rs10468017 chr15 58678512 C T 7.40E-17 Lipid levels / / 18193043 rs10468017 chr15 58678512 C T 8.00E-23 HDL cholesterol / / 19060906 rs10468017 chr15 58678512 C T 1.63E-17 Triglycerides / / 19060911 rs10468017 chr15 58678512 C T 4.14E-04 Blood cell counts and other traits / / 20139978 rs10468017 chr15 58678512 C T 1.10E-08 Response to statin therapy / / 20339536 rs10468017 chr15 58678512 C T 1.00E-08 Age-related macular degeneration / / 20385826 rs10468017 chr15 58678512 C T 8.00E-23 Coronary heart disease / / 21347282 rs10468017 chr15 58678512 C T 6.00E-08 Metabolic syndrome (bivariate traits) / / 21386085 rs10468017 chr15 58678512 C T 2.57E-13 HDL cholesterol / / 21589926 rs10468017 chr15 58678512 C T 4.38E-06 HDL cholesterol / / 21589926 rs10468017 chr15 58678512 C T 3.00E-12 Age-related macular degeneration / / 21665990 rs10468017 chr15 58678512 C T 3.00E-12 Cardiovascular disease risk factors / / 21943158 rs10468017 chr15 58678512 C T 7.92E-12 Metabolite levels / / 22286219 rs10468017 chr15 58678512 C T 7.00E-43 Phospholipid levels (plasma) / / 22359512 rs10468017 chr15 58678512 C T 3.73E-10 HDL cholesterol / / 23063622 rs10468017 chr15 58678512 C T 0.00027 Apolipoprotein B levels response after 40mg daily simvastatin treatment / / 23100282 rs10468017 chr15 58678512 C T 2.70E-04 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) / / 23103227 rs10468017 chr15 58678512 C T 8.40E-07 Red blood cell traits / / 23222517 rs10468017 chr15 58678512 C T 9.94E-09 Metabolite levels / / 23281178 rs10468017 chr15 58678512 C T 3.00E-12 Blood metabolite levels / / 24816252 rs261290 chr15 58678720 T C 1.76E-65 Metabolite levels / / 22286219 rs56358871 chr15 58679387 G C 7.19E-53 Metabolite levels / / 22286219 rs7350789 chr15 58679668 G A 6.70E-12 Metabolite levels / / 22286219 rs261291 chr15 58680178 T C 2.33E-12 Metabolite levels / / 22286219 rs7177289 chr15 58680184 C T 3.53E-12 Metabolite levels / / 22286219 rs2414577 chr15 58680638 T C 4.58E-11 Metabolite levels / / 22286219 rs2414578 chr15 58680639 T C 4.58E-11 Metabolite levels / / 22286219 rs35853021 chr15 58680643 G T 7.00E-76 Lipid metabolism phenotypes / / 22286219 rs166358 chr15 58680805 G A 7.12E-09 Triglycerides / / 19060911 rs166358 chr15 58680805 G A 3.23E-19 Metabolite levels / / 22286219 rs166358 chr15 58680805 G A 3.97E-06 HDL particle features / / pha002900 rs2043085 chr15 58680954 T C 3.97E-11 Triglycerides / / 19060911 rs2043085 chr15 58680954 T C 2.40E-07 Response to statin therapy / / 20339536 rs2043085 chr15 58680954 T C 1.00E-08 Metabolic syndrome (bivariate traits) / / 21386085 rs2043085 chr15 58680954 T C 2.98E-72 Metabolite levels / / 22286219 rs2043085 chr15 58680954 T C 8.03E-08 Metabolite levels / / 23281178 rs2043085 chr15 58680954 T C 0.00051 Prostate cancer / / 23555315 rs2043085 chr15 58680954 T C 2.00E-08 Lipid traits / / 24386095 rs28698356 chr15 58681509 G C 1.05E-33 Metabolite levels / / 22286219 rs2043084 chr15 58682496 G C 6.25E-32 Metabolite levels / / 22286219 rs1825955 chr15 58682783 C A 1.58E-26 Metabolite levels / / 22286219 rs12185071 chr15 58683227 C T 2.81E-29 Metabolite levels / / 22286219 rs1532085 chr15 58683366 A G 2.00E-10 HDL cholesterol / / 19060910 rs1532085 chr15 58683366 A G 1.00E-35 HDL cholesterol / / 19060911 rs1532085 chr15 58683366 A G 4.00E-07 Cholesterol,total / / 19060911 rs1532085 chr15 58683366 A G 1.30E-10 Lipid levels / / 19802338 rs1532085 chr15 58683366 A G 9.00E-14 Lipid levels / / 19802338 rs1532085 chr15 58683366 A G 1.45E-19 Lipid levels / / 19936222 rs1532085 chr15 58683366 A G 3.70E-16 Lipid levels / / 19936222 rs1532085 chr15 58683366 A G 6.79E-17 Lipid levels / / 19936222 rs1532085 chr15 58683366 A G 8.92E-15 Lipid levels / / 19936222 rs1532085 chr15 58683366 A G 2.00E-07 Response to statin therapy / / 20339536 rs1532085 chr15 58683366 A G 2.00E-13 Triglycerides / / 20686565 rs1532085 chr15 58683366 A G 3.00E-96 HDL cholesterol / / 20686565 rs1532085 chr15 58683366 A G 9.00E-20 Cholesterol,total / / 20686565 rs1532085 chr15 58683366 A G 1.00E-35 Coronary heart disease / / 21347282 rs1532085 chr15 58683366 A G 1.58E-04 HDL cholesterol / / 21589926 rs1532085 chr15 58683366 A G 7.30E-12 HDL cholesterol / / 21589926 rs1532085 chr15 58683366 A G 1.85E-09 Cardiovascular disease risk factors / / 21943158 rs1532085 chr15 58683366 A G 6.13E-46 Metabolite levels / / 22286219 rs1532085 chr15 58683366 A G 5.00E-24 Metabolic syndrome / / 22399527 rs1532085 chr15 58683366 A G 9.00E-104 Metabolite levels (atherosclerosis) / / 22916037 rs1532085 chr15 58683366 A G 2.69E-08 HDL cholesterol / / 23063622 rs1532085 chr15 58683366 A G 9.80E-04 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) / / 23103227 rs1532085 chr15 58683366 A G 7.00E-11 Red blood cell traits / / 23222517 rs1532085 chr15 58683366 A G 5.80E-07 Lipid traits / / 24023260 rs1532085 chr15 58683366 A G 1.00E-188 HDL cholesterol / / 24097068 rs1532085 chr15 58683366 A G 2.00E-18 Triglycerides / / 24097068 rs1532085 chr15 58683366 A G 7.00E-47 Cholesterol,total / / 24097068 rs1532085 chr15 58683366 A G 1.20E-04 Lipid traits / / 24386095 rs1532085 chr15 58683366 A G 1.77E-10 HDL particle features / / pha002900 rs12185072 chr15 58683410 C T 1.47E-25 Metabolite levels / / 22286219 rs12905732 chr15 58683542 G C 7.90E-05 Response to statin therapy / / 20339536 rs12905732 chr15 58683542 G C 2.90E-23 Metabolite levels / / 22286219 rs28594460 chr15 58683585 A G 1.51E-26 Metabolite levels / / 22286219 rs16940167 chr15 58683697 T C 1.89E-25 Metabolite levels / / 22286219 rs11853674 chr15 58684057 A G 9.90E-05 Response to statin therapy / / 20339536 rs11853674 chr15 58684057 A G 6.95E-14 Metabolite levels / / 22286219 rs16940168 chr15 58684154 A T 9.14E-29 Metabolite levels / / 22286219 rs16940170 chr15 58684282 G A 5.41E-27 Metabolite levels / / 22286219 rs28495863 chr15 58684381 G A 2.54E-28 Metabolite levels / / 22286219 rs17821274 chr15 58684478 T C 1.49E-11 Metabolite levels / / 22286219 rs12185093 chr15 58684676 G A 4.10E-27 Metabolite levels / / 22286219 rs4775044 chr15 58684967 T G 1.84E-57 Metabolite levels / / 22286219 rs7497636 chr15 58685631 C T 5.67E-27 Metabolite levels / / 22286219 rs1444942 chr15 58685813 G C 5.93E-27 Metabolite levels / / 22286219 rs261298 chr15 58686157 C G 3.40E-40 Metabolite levels / / 22286219 rs261299 chr15 58686252 G A 1.17E-41 Metabolite levels / / 22286219 rs16940174 chr15 58686338 G A,C 3.73E-26 Metabolite levels / / 22286219 rs447794 chr15 58686638 G C 4.47E-22 Metabolite levels / / 22286219 rs7164909 chr15 58686754 C T 5.90E-06 Stroke (ischemic) / / 22384361 rs261301 chr15 58686939 T C 6.59E-20 Metabolite levels / / 22286219 rs17240832 chr15 58687370 A G 6.76E-21 Metabolite levels / / 22286219 rs16940181 chr15 58687524 A C 1.24E-26 Metabolite levels / / 22286219 rs7171102 chr15 58687530 G A 1.69E-15 Metabolite levels / / 22286219 rs174418 chr15 58687603 T C 5.18E-60 Metabolite levels / / 22286219 rs166359 chr15 58687609 G T 1.29E-26 Metabolite levels / / 22286219 rs495348 chr15 58687790 C G 8.78E-21 Metabolite levels / / 22286219 rs8032310 chr15 58687862 G A 4.91E-25 Metabolite levels / / 22286219 rs493258 chr15 58687880 T C 4.40E-05 Response to statin therapy / / 20339536 rs493258 chr15 58687880 T C 1.00E-07 Age-related macular degeneration / / 20385819 rs493258 chr15 58687880 T C 2.00E-08 Age-related macular degeneration / / 20385826 rs493258 chr15 58687880 T C 7.53E-47 Metabolite levels / / 22286219 rs493987 chr15 58687906 T C 5.41E-28 Metabolite levels / / 22286219 rs4238329 chr15 58688186 A C 7.60E-06 Stroke (ischemic) / / 22384361 rs920915 chr15 58688467 C G 5.50E-05 Response to statin therapy / / 20339536 rs920915 chr15 58688467 C G 8.01E-45 Metabolite levels / / 22286219 rs920915 chr15 58688467 C G 3.00E-11 Age-related macular degeneration / / 23455636 rs920916 chr15 58688477 G A 8.14E-45 Metabolite levels / / 22286219 rs920917 chr15 58688478 A C 1.99E-26 Metabolite levels / / 22286219 rs11855284 chr15 58689187 T C 3.92E-14 HDL cholesterol / / 21589926 rs11855284 chr15 58689187 T C 8.02E-07 HDL cholesterol / / 21589926 rs11855284 chr15 58689187 T C 5.44E-21 Metabolite levels / / 22286219 rs11858481 chr15 58689197 C T 2.52E-27 Metabolite levels / / 22286219 rs17821298 chr15 58690738 C A 8.01E-13 Metabolite levels / / 22286219 rs415799 chr15 58690754 G A 4.61E-27 Triglycerides / / 19060911 rs415799 chr15 58690754 G A 1.70E-08 Lipid levels / / 19802338 rs415799 chr15 58690754 G A 4.50E-11 Lipid levels / / 19802338 rs415799 chr15 58690754 G A 1.36E-07 HDL cholesterol / / 21589926 rs415799 chr15 58690754 G A 5.02E-39 Metabolite levels / / 22286219 rs415799 chr15 58690754 G A 1.66E-07 HDL particle features / / pha002900 rs490098 chr15 58691225 C A 1.10E-15 Metabolite levels / / 22286219 rs2082149 chr15 58691389 G A 2.31E-20 Metabolite levels / / 22286219 rs443401 chr15 58692095 C G 2.58E-42 Metabolite levels / / 22286219 rs397923 chr15 58692118 A T 2.55E-08 Triglycerides / / 19060911 rs397923 chr15 58692118 A T 1.20E-05 Response to statin therapy / / 20339536 rs397923 chr15 58692118 A T 1.60E-15 Metabolic syndrome phenotype / / 22022282 rs397923 chr15 58692118 A T 7.10E-18 Metabolic syndrome phenotype / / 22022282 rs397923 chr15 58692118 A T 4.79E-51 Metabolite levels / / 22286219 rs35128881 chr15 58692148 G T 5.14E-27 Metabolite levels / / 22286219 rs12708454 chr15 58692202 A C 1.21E-14 Metabolite levels / / 22286219 rs414671 chr15 58692479 C T 9.55E-11 Metabolite levels / / 22286219 rs12906722 chr15 58692715 C T 3.09E-13 Metabolite levels / / 22286219 rs16940204 chr15 58692936 C T 9.69E-17 Metabolite levels / / 22286219 rs487766 chr15 58693860 C T 4.58E-10 Triglycerides / / 19060911 rs487766 chr15 58693860 C T 2.36E-04 HDL cholesterol / / 21589926 rs487766 chr15 58693860 C T 5.08E-10 HDL cholesterol / / 21589926 rs487766 chr15 58693860 C T 1.49E-22 Metabolite levels / / 22286219 rs16940212 chr15 58694020 G T 1.00E-24 HDL cholesterol / / 21909109 rs16940212 chr15 58694020 G T 8.61E-13 Metabolite levels / / 22286219 rs16940213 chr15 58695337 C T 2.73E-20 Metabolite levels / / 22286219 rs16940213 chr15 58695337 C T 3.27E-05 HDL particle features / / pha002900 rs723967 chr15 58696300 T C 2.30E-05 Response to statin therapy / / 20339536 rs723967 chr15 58696300 T C 3.95E-45 Metabolite levels / / 22286219 rs28528324 chr15 58696971 T C 6.40E-13 Metabolite levels / / 22286219 rs16940223 chr15 58697072 T C 8.35E-13 Metabolite levels / / 22286219 rs12440032 chr15 58697834 C G 1.16E-21 Metabolite levels / / 22286219 rs28451440 chr15 58698113 T G 1.54E-14 Metabolite levels / / 22286219 rs62000864 chr15 58698243 T G 1.21E-46 Metabolite levels / / 22286219 rs12440217 chr15 58698357 G A 2.26E-11 Metabolite levels / / 22286219 rs11852978 chr15 58698755 T G 3.15E-19 Metabolite levels / / 22286219 rs11856159 chr15 58699010 C T 4.44E-12 Triglycerides / / 19060911 rs11856159 chr15 58699010 C T 1.34E-11 HDL cholesterol / / 21589926 rs11856159 chr15 58699010 C T 1.59E-06 HDL cholesterol / / 21589926 rs11856159 chr15 58699010 C T 4.12E-22 Metabolite levels / / 22286219 rs13329672 chr15 58699937 C T 1.81E-21 Metabolite levels / / 22286219 rs17240869 chr15 58700311 T C 8.50E-22 Metabolite levels / / 22286219 rs17240876 chr15 58701551 A G 9.15E-22 Metabolite levels / / 22286219 rs12438999 chr15 58702325 A G 4.56E-30 Metabolite levels / / 22286219 rs17821310 chr15 58702864 T C 2.49E-21 Metabolite levels / / 22286219 rs17821310 chr15 58702864 T C 6.25E-06 Obesity-related traits / / 23251661 rs17821316 chr15 58703069 A C 9.20E-05 Response to statin therapy / / 20339536 rs17821316 chr15 58703069 A C 5.87E-25 Metabolite levels / / 22286219 rs17821322 chr15 58703100 T C 7.04E-20 Metabolite levels / / 22286219 rs7183184 chr15 58703895 A G 5.68E-12 Metabolite levels / / 22286219 rs55993842 chr15 58704064 G T 7.57E-20 Metabolite levels / / 22286219 rs28442086 chr15 58705036 G A 2.70E-28 Metabolite levels / / 22286219 rs62000868 chr15 58705980 C G 1.12E-37 Metabolite levels / / 22286219 rs62000869 chr15 58706911 A G 5.53E-35 Metabolite levels / / 22286219 rs409668 chr15 58706926 T A 7.70E-05 Response to statin therapy / / 20339536 rs409668 chr15 58706926 T A 9.34E-42 Metabolite levels / / 22286219 rs60315394 chr15 58709181 C T 6.81E-11 Metabolite levels / / 22286219 rs422137 chr15 58709182 G A 1.90E-11 Metabolite levels / / 22286219 rs55696635 chr15 58709750 G A 2.57E-19 Metabolite levels / / 22286219 rs11071380 chr15 58710627 C A 3.10E-05 Response to statin therapy / / 20339536 rs11071380 chr15 58710627 C A 4.81E-37 Metabolite levels / / 22286219 rs62000870 chr15 58710736 T C 6.13E-18 Metabolite levels / / 22286219 rs8025065 chr15 58711206 G C 9.34E-12 Metabolite levels / / 22286219 rs11857380 chr15 58712203 T G 2.13E-23 Metabolite levels / / 22286219 rs11857380 chr15 58712203 T G 3.00E-06 Obesity-related traits / / 23251661 rs11854624 chr15 58712817 C G 1.96E-13 Metabolite levels / / 22286219 rs11854656 chr15 58712945 A C 6.59E-26 Metabolite levels / / 22286219 rs11858279 chr15 58712973 T C 1.53E-43 Metabolite levels / / 22286219 rs1373657 chr15 58717762 G T 6.26E-13 Metabolite levels / / 22286219 rs417344 chr15 58717919 T C 3.87E-13 Metabolite levels / / 22286219 rs495806 chr15 58718697 C A 2.95E-15 Metabolite levels / / 22286219 rs57476984 chr15 58718697 C CA 2.95E-15 Metabolite levels / / 22286219 rs7170361 chr15 58718998 T C 2.41E-50 Metabolite levels / / 22286219 rs11635491 chr15 58719741 G A 2.00E-07 Lipid levels / / 19913121 rs11635491 chr15 58719741 G A 2.40E-05 Lipid levels / / 19913121 rs11635491 chr15 58719741 G A 2.32E-45 Metabolite levels / / 22286219 rs11635491 chr15 58719741 G A 2.11E-08 Cholesterol,total / / 23063622 rs11635491 chr15 58719741 G A 3.77E-34 HDL cholesterol / / 23063622 rs35547826 chr15 58720405 G A 5.02E-12 Metabolite levels / / 22286219 rs4774297 chr15 58720431 C A 2.81E-12 Metabolite levels / / 22286219 rs4774297 chr15 58720431 C A 4.47E-16 HDL cholesterol / / 23063622 rs11857386 chr15 58721168 G C 3.57E-16 Metabolite levels / / 22286219 rs35684611 chr15 58721302 A G 5.74E-12 Metabolite levels / / 22286219 rs12912415 chr15 58721447 A G 1.17E-12 Metabolite levels / / 22286219 rs11071381 chr15 58721614 G A 1.50E-18 Metabolite levels / / 22286219 rs583662 chr15 58722276 G A 0.000000647 HDL cholesterol LIPC nearGene-5 23063622 rs1077835 chr15 58723426 A G 1.40E-05 Response to statin therapy LIPC nearGene-5 20339536 rs1077835 chr15 58723426 A G 1.10E-14 Metabolic syndrome phenotype LIPC nearGene-5 22022282 rs1077835 chr15 58723426 A G 5.60E-18 Metabolic syndrome phenotype LIPC nearGene-5 22022282 rs1077835 chr15 58723426 A G 1.49E-69 Metabolite levels LIPC nearGene-5 22286219 rs1077835 chr15 58723426 A G 2.00E-14 HDL cholesterol LIPC nearGene-5 23505323 rs1077834 chr15 58723479 T C 1.00E-14 Blood cell counts and other traits LIPC nearGene-5 20139978 rs1077834 chr15 58723479 T C 1.27E-14 Blood cell counts and other traits LIPC nearGene-5 20139978 rs1077834 chr15 58723479 T C 1.60E-05 Response to statin therapy LIPC nearGene-5 20339536 rs1077834 chr15 58723479 T C 4.03E-06 HDL cholesterol LIPC nearGene-5 21589926 rs1077834 chr15 58723479 T C 2.15E-16 Metabolite levels LIPC nearGene-5 22286219 rs1077834 chr15 58723479 T C 5.15E-05 HDL cholesterol LIPC nearGene-5 pha003074 rs1800588 chr15 58723675 C T 2.00E-32 HDL cholesterol LIPC nearGene-5 18193044 rs1800588 chr15 58723675 C T 1.20E-07 Lipid levels LIPC nearGene-5 19802338 rs1800588 chr15 58723675 C T 2.40E-12 Lipid levels LIPC nearGene-5 19802338 rs1800588 chr15 58723675 C T 3.85E-07 Lipid levels LIPC nearGene-5 19913121 rs1800588 chr15 58723675 C T 5.38E-10 Lipid levels LIPC nearGene-5 19913121 rs1800588 chr15 58723675 C T 1.20E-81 Lipid levels LIPC nearGene-5 19936222 rs1800588 chr15 58723675 C T 1.28E-13 Lipid levels LIPC nearGene-5 19936222 rs1800588 chr15 58723675 C T 1.49E-37 Lipid levels LIPC nearGene-5 19936222 rs1800588 chr15 58723675 C T 1.50E-09 Lipid levels LIPC nearGene-5 19936222 rs1800588 chr15 58723675 C T 1.50E-46 Lipid levels LIPC nearGene-5 19936222 rs1800588 chr15 58723675 C T 2.05E-24 Lipid levels LIPC nearGene-5 19936222 rs1800588 chr15 58723675 C T 3.30E-26 Lipid levels LIPC nearGene-5 19936222 rs1800588 chr15 58723675 C T 3.40E-10 Lipid levels LIPC nearGene-5 19936222 rs1800588 chr15 58723675 C T 3.50E-25 Lipid levels LIPC nearGene-5 19936222 rs1800588 chr15 58723675 C T 3.60E-23 Lipid levels LIPC nearGene-5 19936222 rs1800588 chr15 58723675 C T 3.86E-13 Lipid levels LIPC nearGene-5 19936222 rs1800588 chr15 58723675 C T 4.00E-54 Lipid levels LIPC nearGene-5 19936222 rs1800588 chr15 58723675 C T 7.40E-39 Lipid levels LIPC nearGene-5 19936222 rs1800588 chr15 58723675 C T 7.90E-42 Lipid levels LIPC nearGene-5 19936222 rs1800588 chr15 58723675 C T 8.00E-69 Lipid levels LIPC nearGene-5 19936222 rs1800588 chr15 58723675 C T 8.20E-37 Lipid levels LIPC nearGene-5 19936222 rs1800588 chr15 58723675 C T 9.37E-56 Lipid levels LIPC nearGene-5 19936222 rs1800588 chr15 58723675 C T 1.60E-05 Response to statin therapy LIPC nearGene-5 20339536 rs1800588 chr15 58723675 C T 2.00E-32 Coronary heart disease LIPC nearGene-5 21347282 rs1800588 chr15 58723675 C T 2.92E-62 Metabolite levels LIPC nearGene-5 22286219 rs1800588 chr15 58723675 C T 3.28E-14 Cholesterol,total LIPC nearGene-5 23063622 rs1800588 chr15 58723675 C T 5.52E-56 HDL cholesterol LIPC nearGene-5 23063622 rs1800588 chr15 58723675 C T 7.44E-14 Triglycerides LIPC nearGene-5 23063622 rs2070895 chr15 58723939 G A 2.38E-07 Lipid levels LIPC nearGene-5 19913121 rs2070895 chr15 58723939 G A 4.54E-10 Lipid levels LIPC nearGene-5 19913121 rs2070895 chr15 58723939 G A 1.10E-05 Response to statin therapy LIPC nearGene-5 20339536 rs2070895 chr15 58723939 G A 2.92E-62 Metabolite levels LIPC nearGene-5 22286219 rs2070895 chr15 58723939 G A 3.57E-15 HDL cholesterol (female) LIPC nearGene-5 22629316 rs2070895 chr15 58723939 G A 3.90E-24 HDL cholesterol LIPC nearGene-5 22629316 rs2070895 chr15 58723939 G A 8.28E-12 HDL cholesterol (male) LIPC nearGene-5 22629316 rs2070895 chr15 58723939 G A 2.27E-58 HDL cholesterol LIPC nearGene-5 23063622 rs2070895 chr15 58723939 G A 2.84E-14 Cholesterol,total LIPC nearGene-5 23063622 rs2070895 chr15 58723939 G A 5.21E-35 HDL cholesterol (female) LIPC nearGene-5 23063622 rs2070895 chr15 58723939 G A 6.29E-15 Triglycerides LIPC nearGene-5 23063622 rs2070895 chr15 58723939 G A 6.85E-22 HDL cholesterol (male) LIPC nearGene-5 23063622 rs2070895 chr15 58723939 G A 2.06E-08 HDL cholesterol LIPC nearGene-5 23236364 rs2070895 chr15 58723939 G A 1.00E-18 Blood metabolite levels LIPC nearGene-5 24816252 rs8192701 chr15 58724371 C T 5.52E-12 Metabolite levels LIPC intron 22286219 rs6494005 chr15 58724524 A G 9.92E-21 Metabolite levels LIPC intron 22286219 rs6494005 chr15 58724524 A G 0.000000644 Cholesterol,total LIPC intron 23063622 rs6494005 chr15 58724524 A G 7.04E-21 HDL cholesterol LIPC intron 23063622 rs11632618 chr15 58724706 G A 7.56E-14 Metabolite levels LIPC intron 22286219 rs11632618 chr15 58724706 G A 7.39E-18 HDL cholesterol LIPC intron 23063622 rs8034802 chr15 58724792 T A 1.50E-08 Lipid levels LIPC intron 19913121 rs8034802 chr15 58724792 T A 2.10E-05 Lipid levels LIPC intron 19913121 rs8034802 chr15 58724792 T A 5.00E-05 Response to statin therapy LIPC intron 20339536 rs8034802 chr15 58724792 T A 1.06E-53 Metabolite levels LIPC intron 22286219 rs8034802 chr15 58724792 T A 0.000000255 Triglycerides LIPC intron 23063622 rs8034802 chr15 58724792 T A 1.49E-10 Cholesterol,total LIPC intron 23063622 rs8034802 chr15 58724792 T A 2.29E-43 HDL cholesterol LIPC intron 23063622 rs8034802 chr15 58724792 T A 6.15E-09 HDL cholesterol LIPC intron 23236364 rs8033940 chr15 58724842 G A 1.02E-08 Lipid levels LIPC intron 19913121 rs8033940 chr15 58724842 G A 1.67E-05 Lipid levels LIPC intron 19913121 rs8033940 chr15 58724842 G A 4.70E-05 Response to statin therapy LIPC intron 20339536 rs8033940 chr15 58724842 G A 1.77E-49 Metabolite levels LIPC intron 22286219 rs8033940 chr15 58724842 G A 1.74E-44 HDL cholesterol LIPC intron 23063622 rs8033940 chr15 58724842 G A 2.70E-10 Cholesterol,total LIPC intron 23063622 rs8033940 chr15 58724842 G A 3.28E-08 Triglycerides LIPC intron 23063622 rs633695 chr15 58725839 A G 5.60E-05 Response to statin therapy LIPC intron 20339536 rs633695 chr15 58725839 A G 5.91E-52 Metabolite levels LIPC intron 22286219 rs17190510 chr15 58726463 G C 2.65E-12 Metabolite levels LIPC intron 22286219 rs261334 chr15 58726744 G C 2.90E-09 Lipid levels LIPC intron 18193043 rs261334 chr15 58726744 G C 1.40E-05 Response to statin therapy LIPC intron 20339536 rs261334 chr15 58726744 G C 5.00E-22 HDL cholesterol LIPC intron 20864672 rs261334 chr15 58726744 G C 2.00E-12 Metabolite levels LIPC intron 22286219 rs261334 chr15 58726744 G C 5.95E-08 Metabolite levels LIPC intron 23281178 rs261333 chr15 58727279 T C 1.40E-05 Response to statin therapy LIPC intron 20339536 rs261333 chr15 58727279 T C 4.50E-21 Metabolite levels LIPC intron 22286219 rs261332 chr15 58727325 A G 3.35E-05 Type 2 diabetes LIPC intron 17463246 rs261332 chr15 58727325 A G 5.02E-07 Cardiovascular disease LIPC intron 18179892 rs261332 chr15 58727325 A G 2.30E-15 Lipid levels LIPC intron 18193043 rs261332 chr15 58727325 A G 1.92E-07 Lipid levels LIPC intron 19913121 rs261332 chr15 58727325 A G 6.48E-10 Lipid levels LIPC intron 19913121 rs261332 chr15 58727325 A G 1.10E-05 Response to statin therapy LIPC intron 20339536 rs261332 chr15 58727325 A G 6.10E-09 HDL particle features LIPC intron 21283740 rs261332 chr15 58727325 A G 1.63E-13 Metabolite levels LIPC intron 22286219 rs261332 chr15 58727325 A G 1.51E-15 Cholesterol,total LIPC intron 23063622 rs261332 chr15 58727325 A G 3.15E-57 HDL cholesterol LIPC intron 23063622 rs261332 chr15 58727325 A G 4.53E-14 Triglycerides LIPC intron 23063622 rs62000939 chr15 58727687 T C 3.11E-12 Metabolite levels LIPC intron 22286219 rs17190517 chr15 58729144 C T 1.70E-05 Response to statin therapy LIPC intron 20339536 rs17190517 chr15 58729144 C T 6.58E-13 Metabolite levels LIPC intron 22286219 rs17190517 chr15 58729144 C T 5.24E-13 HDL cholesterol LIPC intron 23063622 rs588136 chr15 58730498 C T 7.02E-07 Lipid levels LIPC intron 19913121 rs588136 chr15 58730498 C T 9.75E-10 Lipid levels LIPC intron 19913121 rs588136 chr15 58730498 C T 1.50E-05 Response to statin therapy LIPC intron 20339536 rs588136 chr15 58730498 C T 2.38E-15 Metabolite levels LIPC intron 22286219 rs588136 chr15 58730498 C T 3.08E-13 Cholesterol,total LIPC intron 23063622 rs588136 chr15 58730498 C T 4.94E-55 HDL cholesterol LIPC intron 23063622 rs588136 chr15 58730498 C T 9.95E-14 Triglycerides LIPC intron 23063622 rs588136 chr15 58730498 C T 2.00E-12 Lipid traits LIPC intron 24023260 rs588136 chr15 58730498 C T 8.00E-12 Blood metabolite levels LIPC intron 24816252 rs17301739 chr15 58730639 C G 2.00E-06 Alzheimer's disease (cognitive decline) LIPC intron 23535033 rs12914035 chr15 58730889 A G 1.25E-11 Metabolite levels LIPC intron 22286219 rs261342 chr15 58731153 G C 2.12E-08 Lipid levels LIPC intron 19913121 rs261342 chr15 58731153 G C 7.93E-12 Lipid levels LIPC intron 19913121 rs261342 chr15 58731153 G C 1.50E-05 Response to statin therapy LIPC intron 20339536 rs261342 chr15 58731153 G C 1.13E-11 Metabolite levels LIPC intron 22286219 rs261342 chr15 58731153 G C 1.27E-13 Triglycerides LIPC intron 23063622 rs261342 chr15 58731153 G C 1.32E-14 Cholesterol,total LIPC intron 23063622 rs261342 chr15 58731153 G C 2.34E-54 HDL cholesterol LIPC intron 23063622 rs261342 chr15 58731153 G C 9.00E-13 Metabolite levels LIPC intron 23281178 rs12900622 chr15 58731455 T C 3.24E-12 Metabolite levels LIPC intron 22286219 rs261341 chr15 58731567 A G 4.05E-08 Lipid levels LIPC intron 19913121 rs261341 chr15 58731567 A G 4.89E-05 Lipid levels LIPC intron 19913121 rs261341 chr15 58731567 A G 5.40E-05 Response to statin therapy LIPC intron 20339536 rs261341 chr15 58731567 A G 8.46E-24 Metabolite levels LIPC intron 22286219 rs261341 chr15 58731567 A G 1.32E-34 HDL cholesterol LIPC intron 23063622 rs261341 chr15 58731567 A G 2.65E-09 Cholesterol,total LIPC intron 23063622 rs166362 chr15 58733512 G A 3.34E-04 Hearing function LIPC intron 17255346 rs166362 chr15 58733512 G A 7.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LIPC intron 23648065 rs261338 chr15 58735005 A G 1.73E-06 Lipid levels LIPC intron 19913121 rs261338 chr15 58735005 A G 1.98E-05 Lipid levels LIPC intron 19913121 rs261338 chr15 58735005 A G 8.20E-05 Response to statin therapy LIPC intron 20339536 rs261338 chr15 58735005 A G 1.38E-10 Metabolite levels LIPC intron 22286219 rs261338 chr15 58735005 A G 0.000000001 Triglycerides LIPC intron 23063622 rs261338 chr15 58735005 A G 1.47E-45 HDL cholesterol LIPC intron 23063622 rs261338 chr15 58735005 A G 2.03E-14 Cholesterol,total LIPC intron 23063622 rs261338 chr15 58735005 A G 0.000017 HDL cholesterol particle diameter LIPC intron 23263444 rs261337 chr15 58735449 T C 1.83E-04 Type 2 diabetes LIPC intron 17463246 rs12438071 chr15 58735823 A G 6.37E-06 Serum metabolites LIPC intron 19043545 rs4775046 chr15 58736778 C T 9.65E-18 Metabolite levels LIPC intron 22286219 rs4775046 chr15 58736778 C T 7.67E-16 HDL cholesterol LIPC intron 23063622 rs473224 chr15 58737341 T G 2.89E-11 Triglycerides LIPC intron 19060911 rs473224 chr15 58737341 T G 3.92E-12 Metabolite levels LIPC intron 22286219 rs473224 chr15 58737341 T G 1.04E-12 Cholesterol,total LIPC intron 23063622 rs473224 chr15 58737341 T G 4.29E-08 Triglycerides LIPC intron 23063622 rs473224 chr15 58737341 T G 6.82E-36 HDL cholesterol LIPC intron 23063622 rs473224 chr15 58737341 T G 0.000012 HDL cholesterol particle diameter LIPC intron 23263444 rs473224 chr15 58737341 T G 1.24E-05 HDL cholesterol LIPC intron pha003075 rs488490 chr15 58737661 C A 7.96E-11 Metabolite levels LIPC intron 22286219 rs488490 chr15 58737661 C A 0.0000126 HDL cholesterol particle diameter LIPC intron 23263444 rs12914626 chr15 58738423 C T 8.32E-33 Metabolite levels LIPC intron 22286219 rs17269264 chr15 58738760 G A 3.31E-16 Metabolite levels LIPC intron 22286219 rs17269264 chr15 58738760 G A 4.72E-14 HDL cholesterol LIPC intron 23063622 rs17269271 chr15 58739761 G C 3.68E-18 Metabolite levels LIPC intron 22286219 rs17269271 chr15 58739761 G C 9.03E-13 HDL cholesterol LIPC intron 23063622 rs573922 chr15 58740094 C T 2.10E-05 Response to statin therapy LIPC intron 20339536 rs573922 chr15 58740094 C T 1.04E-17 Metabolite levels LIPC intron 22286219 rs485671 chr15 58741134 A C 4.59E-04 Lipid levels LIPC intron 19913121 rs485671 chr15 58741134 A C 7.88E-06 Lipid levels LIPC intron 19913121 rs485671 chr15 58741134 A C 2.00E-05 Response to statin therapy LIPC intron 20339536 rs485671 chr15 58741134 A C 1.08E-43 Metabolite levels LIPC intron 22286219 rs485671 chr15 58741134 A C 0.000000629 Triglycerides LIPC intron 23063622 rs485671 chr15 58741134 A C 1.10E-36 HDL cholesterol LIPC intron 23063622 rs485671 chr15 58741134 A C 7.39E-10 Cholesterol,total LIPC intron 23063622 rs485538 chr15 58741177 C T 4.19E-04 Lipid levels LIPC intron 19913121 rs485538 chr15 58741177 C T 4.32E-06 Lipid levels LIPC intron 19913121 rs485538 chr15 58741177 C T 1.60E-05 Response to statin therapy LIPC intron 20339536 rs485538 chr15 58741177 C T 7.21E-43 Metabolite levels LIPC intron 22286219 rs485538 chr15 58741177 C T 0.000000734 Triglycerides LIPC intron 23063622 rs485538 chr15 58741177 C T 1.15E-37 HDL cholesterol LIPC intron 23063622 rs485538 chr15 58741177 C T 1.33E-09 Cholesterol,total LIPC intron 23063622 rs572410 chr15 58741384 C G 2.69E-06 Lipid levels LIPC intron 19913121 rs572410 chr15 58741384 C G 6.22E-05 Lipid levels LIPC intron 19913121 rs572410 chr15 58741384 C G 5.80E-05 Response to statin therapy LIPC intron 20339536 rs572410 chr15 58741384 C G 6.81E-17 Metabolite levels LIPC intron 22286219 rs572410 chr15 58741384 C G 3.90E-32 HDL cholesterol LIPC intron 23063622 rs572410 chr15 58741384 C G 8.46E-09 Cholesterol,total LIPC intron 23063622 rs686958 chr15 58741884 T A 4.13E-17 Metabolite levels LIPC intron 22286219 rs567746 chr15 58741891 A G 3.37E-24 Metabolite levels LIPC intron 22286219 rs261336 chr15 58742418 G A 9.09E-11 Triglycerides LIPC intron 19060911 rs261336 chr15 58742418 G A 2.64E-06 Lipid levels LIPC intron 19913121 rs261336 chr15 58742418 G A 4.31E-04 Lipid levels LIPC intron 19913121 rs261336 chr15 58742418 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) LIPC intron 20189245 rs261336 chr15 58742418 G A 5.20E-05 Response to statin therapy LIPC intron 20339536 rs261336 chr15 58742418 G A 5.25E-06 HDL cholesterol LIPC intron 21589926 rs261336 chr15 58742418 G A 6.23E-17 Metabolite levels LIPC intron 22286219 rs261336 chr15 58742418 G A 8.16E-10 Cholesterol,total LIPC intron 23063622 rs261336 chr15 58742418 G A 9.39E-36 HDL cholesterol LIPC intron 23063622 rs261336 chr15 58742418 G A 2.51E-05 Age-related macular degeneration LIPC intron pha002890 rs261336 chr15 58742418 G A 2.81E-05 HDL cholesterol LIPC intron pha003075 rs11858164 chr15 58742731 T G 7.00E-08 HDL cholesterol LIPC intron 18193046 rs11858164 chr15 58742731 T G 2.39E-05 Serum metabolites LIPC intron 19043545 rs11858164 chr15 58742731 T G 2.70E-23 Metabolite levels LIPC intron 22286219 rs8041059 chr15 58743709 C T 3.43E-05 Serum metabolites LIPC intron 19043545 rs8041059 chr15 58743709 C T 9.70E-20 Metabolite levels LIPC intron 22286219 rs8041059 chr15 58743709 C T 1.24E-12 HDL cholesterol LIPC intron 23063622 rs10152202 chr15 58744348 T G 2.73E-11 Metabolite levels LIPC intron 22286219 rs3825776 chr15 58746830 T C 9.00E-06 Amyotrophic lateral sclerosis LIPC intron 18084291 rs10518976 chr15 58751201 T A 7.87E-15 Metabolite levels LIPC intron 22286219 rs7172681 chr15 58754502 G C 0.00016 Coronary artery calcification LIPC intron 23727086 rs4775053 chr15 58769583 C T 6.64E-04 Iron levels LIPC intron pha002876 rs12593880 chr15 58779641 C A 1.78E-04 Iron levels LIPC intron pha002876 rs4561401 chr15 58784077 C T 4.33E-04 Multiple complex diseases LIPC intron 17554300 rs34101191 chr15 58793567 G A 2.90E-12 Metabolite levels LIPC intron 22286219 rs16940391 chr15 58799648 C G 0.000000245 LDL cholesterol LIPC intron 23063622 rs16940391 chr15 58799648 C G 4.29E-10 Triglycerides LIPC intron 23063622 rs10518982 chr15 58799754 A G 0.000000381 LDL cholesterol LIPC intron 23063622 rs10518982 chr15 58799754 A G 4.02E-11 Triglycerides LIPC intron 23063622 rs4774301 chr15 58801541 T C 1.50E-05 Urinary metabolites LIPC intron 21572414 rs12904012 chr15 58804663 T C 8.55E-04 Depression (quantitative trait) LIPC intron 20800221 rs10518983 chr15 58812777 C T 1.88E-08 Triglycerides LIPC intron 23063622 rs12324244 chr15 58812948 C T 0.00000136 LDL cholesterol LIPC intron 23063622 rs12324244 chr15 58812948 C T 4.83E-11 Triglycerides LIPC intron 23063622 rs10518984 chr15 58827870 A G 5.99E-05 Type 2 diabetes LIPC intron 17463246 rs690 chr15 58834741 G T 1.84E-04 Type 2 diabetes LIPC cds-synon 17463246 rs17190650 chr15 58837394 C T 8.35E-05 Insulin Resistance LIPC intron pha003062 rs11633043 chr15 58837722 G A 4.38E-15 Metabolite levels LIPC intron 22286219 rs6082 chr15 58837957 A G 3.84E-04 Alzheimer's disease LIPC cds-synon 22005930 rs2242065 chr15 58839298 C T 9.21E-05 Alzheimer's disease LIPC intron 22005930 rs7178362 chr15 58847263 T C 1.25E-10 Metabolite levels LIPC intron 22286219 rs3751542 chr15 58856033 T C 9.42E-05 Serum metabolites LIPC intron 19043545 rs3751542 chr15 58856033 T C 9.20E-07 Urinary metabolites LIPC intron 21572414 rs7175421 chr15 58858910 T C 9.30E-07 Urinary metabolites LIPC intron 21572414 rs4562992 chr15 58859594 C A 2.40E-06 Urinary metabolites LIPC intron 21572414 rs1365771 chr15 58860702 T A 6.45E-08 LDL cholesterol LIPC intron 23063622 rs11857411 chr15 58863526 C T 3.20E-04 Alzheimer's disease (late onset) / / 21379329 rs4774308 chr15 58866156 T C 9.94E-05 Cognitive performance / / 19734545 rs60439253 chr15 58874532 C A,T 1.09E-12 Metabolite levels / / 22286219 rs6494025 chr15 58876786 C T 1.84E-13 Metabolite levels / / 22286219 rs16940571 chr15 58882792 C T 3.03E-13 Metabolite levels / / 22286219 rs11638416 chr15 58891114 T A 1.78E-12 Metabolite levels ADAM10 intron 22286219 rs4775083 chr15 58892675 T C 3.97E-05 Insulin Resistance ADAM10 intron pha003062 rs16940602 chr15 58915035 G C 7.59E-04 Alzheimer's disease ADAM10 intron 17998437 rs17269425 chr15 58931340 A G 1.42E-12 Metabolite levels ADAM10 intron 22286219 rs16940651 chr15 58937475 A T 0.000835 Salmonella-induced pyroptosis ADAM10 intron 22837397 rs12912286 chr15 58938436 T C 0.000339 Salmonella-induced pyroptosis ADAM10 intron 22837397 rs6494030 chr15 58938939 T G 0.000646 Salmonella-induced pyroptosis ADAM10 intron 22837397 rs6494031 chr15 58939268 C T 0.000385 Salmonella-induced pyroptosis ADAM10 intron 22837397 rs12906705 chr15 58955036 C T 0.000391 Salmonella-induced pyroptosis ADAM10 intron 22837397 rs11853043 chr15 58992591 T C 1.00E-04 Epilepsy ADAM10 intron 22116939 rs793417 chr15 58995437 T C 1.44E-12 Metabolite levels ADAM10 intron 22286219 rs347118 chr15 59000623 G A 1.42E-12 Metabolite levels ADAM10 intron 22286219 rs602921 chr15 59003934 C T 1.40E-12 Metabolite levels ADAM10 intron 22286219 rs144893047 chr15 59009800 C T 1.30E-09 Breast cancer(er negative) ADAM10 missense 23555315 rs387005 chr15 59010065 T C 1.37E-12 Metabolite levels ADAM10 intron 22286219 rs424346 chr15 59010962 C T 1.18E-12 Metabolite levels ADAM10 intron 22286219 rs4238331 chr15 59012133 T G 9.99E-05 Diabetes Mellitus ADAM10 intron pha003059 rs4238331 chr15 59012133 T G 2.14E-05 Diabetes Mellitus ADAM10 intron pha003060 rs4238331 chr15 59012133 T G 3.60E-07 Insulin Resistance ADAM10 intron pha003062 rs4238331 chr15 59012133 T G 5.16E-06 Insulin-related traits ADAM10 intron pha003063 rs4775090 chr15 59012322 G A 0.00000219 HDL cholesterol ADAM10 intron 23063622 rs554022387 chr15 59020124 CAG C 0.000425 Salmonella-induced pyroptosis ADAM10 intron 22837397 rs6494038 chr15 59020124 C T 0.000425 Salmonella-induced pyroptosis ADAM10 intron 22837397 rs437549 chr15 59023559 T A 1.04E-13 Metabolite levels ADAM10 intron 22286219 rs347122 chr15 59039232 T C 1.20E-12 Metabolite levels ADAM10 intron 22286219 rs390390 chr15 59045393 A G 1.11E-12 Metabolite levels / / 22286219 rs347121 chr15 59059056 A G 1.14E-11 Metabolite levels / / 22286219 rs11639208 chr15 59065624 G A 5.23E-11 Metabolite levels FAM63B intron 22286219 rs650731 chr15 59065659 T C 1.06E-05 Diabetes Mellitus FAM63B intron pha003059 rs17236243 chr15 59067804 G A 4.00E-04 Cardiovascular heart disease in diabetics FAM63B intron 23982368 rs17190720 chr15 59069370 C G 3.85E-11 Metabolite levels FAM63B intron 22286219 rs387812 chr15 59074786 T C 3.29E-05 Insulin Resistance FAM63B intron pha003062 rs11631334 chr15 59076200 T A 1.02E-11 Metabolite levels FAM63B intron 22286219 rs384322 chr15 59080862 C A 1.07E-11 Metabolite levels FAM63B intron 22286219 rs11631244 chr15 59106110 T G 1.11E-11 Metabolite levels FAM63B intron 22286219 rs574683 chr15 59108316 T C 2.56E-04 Stroke FAM63B intron pha002887 rs16940810 chr15 59115159 C T 7.06E-12 Metabolite levels FAM63B intron 22286219 rs4775096 chr15 59140329 C T 2.99E-04 Multiple complex diseases FAM63B intron 17554300 rs4775096 chr15 59140329 C T 1.06E-05 Insulin Resistance FAM63B intron pha003062 rs4775096 chr15 59140329 C T 2.31E-05 Insulin-related traits FAM63B intron pha003063 rs173214 chr15 59160188 A G 4.00E-05 Asperger disorder / / 21182207 rs173214 chr15 59160188 A G 4.80E-05 Insulin Resistance / / pha003062 rs173214 chr15 59160188 A G 1.82E-05 Insulin-related traits / / pha003063 rs1078001 chr15 59167865 G A 5.00E-05 Asperger disorder / / 21182207 rs1078001 chr15 59167865 G A 2.50E-05 Insulin Resistance / / pha003062 rs1078001 chr15 59167865 G A 1.75E-05 Insulin-related traits / / pha003063 rs7179456 chr15 59174539 G T 7.00E-06 Asperger disorder SLTM intron 21182207 rs7496680 chr15 59189972 G A 1.74E-04 Multiple complex diseases SLTM intron 17554300 rs12595482 chr15 59195679 G A 3.00E-05 Asperger disorder SLTM intron 21182207 rs17302045 chr15 59199937 T G 7.00E-05 Asperger disorder SLTM intron 21182207 rs10518992 chr15 59203615 T C 5.00E-05 Asperger disorder SLTM intron 21182207 rs10518992 chr15 59203615 T C 8.85E-05 Insulin-related traits SLTM intron pha003063 rs3145 chr15 59212111 G A 4.00E-05 Asperger disorder SLTM intron 21182207 rs4775101 chr15 59218094 C T 1.00E-05 Asperger disorder SLTM intron 21182207 rs8028828 chr15 59236052 C A 1.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs12900291 chr15 59240419 T C 1.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs7167050 chr15 59240801 T G 1.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs8024549 chr15 59244357 C G 1.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs4600408 chr15 59246800 T C 1.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs4465553 chr15 59246820 G A 2.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs16940921 chr15 59246971 C G 5.51E-04 Multiple complex diseases / / 17554300 rs8037673 chr15 59249584 G A 8.00E-05 Asperger disorder / / 21182207 rs6494052 chr15 59295925 G A 1.93E-04 Multiple complex diseases RNF111 intron 17554300 rs10518995 chr15 59296076 C T 1.64E-04 Type 2 diabetes RNF111 intron 17463246 rs1446240 chr15 59296491 G T 1.90E-04 Asperger disorder RNF111 intron 21182207 rs16940987 chr15 59353863 C A 1.88E-11 Metabolite levels RNF111 intron 22286219 rs1044673 chr15 59389466 G A 4.14E-12 Metabolite levels / / 22286219 rs901478 chr15 59425158 G A 8.29E-04 Schizophrenia / / 19197363 rs4218 chr15 59428658 C G 1.00E-07 Social communication problems MYO1E UTR-3 24047820 rs2306791 chr15 59453384 T C 1.04E-11 Metabolite levels MYO1E cds-synon 22286219 rs17190785 chr15 59456637 G A 1.07E-05 Smoking cessation MYO1E intron 18519826 rs10519001 chr15 59458212 G T 6.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MYO1E intron 20877124 rs10519001 chr15 59458212 G T 1.55E-05 Parkinson's disease MYO1E intron 21738487 rs12442723 chr15 59458663 T C 2.32E-12 Metabolite levels MYO1E intron 22286219 rs2242321 chr15 59466217 T G 1.76E-04 Smoking cessation MYO1E intron 18519826 rs3816815 chr15 59466989 C G,T 8.04E-04 Obesity (extreme) MYO1E intron 21935397 rs3816815 chr15 59466989 C G,T 8.03E-13 Metabolite levels MYO1E intron 22286219 rs11854052 chr15 59467053 T C 4.52E-06 Smoking cessation MYO1E intron 18519826 rs12595602 chr15 59470217 T C 2.28E-04 Type 2 diabetes MYO1E intron 23300278 rs11632157 chr15 59476088 A C 3.28E-12 Metabolite levels MYO1E intron 22286219 rs11637519 chr15 59476316 T C 3.21E-12 Metabolite levels MYO1E intron 22286219 rs8036783 chr15 59476635 C T 5.62E-13 Metabolite levels MYO1E intron 22286219 rs12593888 chr15 59486738 T C 1.80E-12 Metabolite levels MYO1E intron 22286219 rs2306786 chr15 59487930 C G 1.00E-10 Metabolite levels (atherosclerosis) MYO1E intron 22916037 rs7165001 chr15 59505191 C T 7.41E-13 Metabolite levels MYO1E intron 22286219 rs2230155 chr15 59510189 G A,C,T 9.65E-04 Multiple complex diseases MYO1E cds-synon 17554300 rs17236509 chr15 59559968 C G 6.57E-04 Type 2 diabetes MYO1E intron 17463246 rs3743501 chr15 59591079 G T 1.65E-05 Blood Pressure MYO1E intron pha003040 rs3743501 chr15 59591079 G T 7.53E-05 Blood Pressure MYO1E intron pha003048 rs1484284 chr15 59594230 T C 9.06E-06 Blood Pressure MYO1E intron pha003040 rs17236557 chr15 59602998 C A 4.76E-05 Cognitive impairment induced by topiramate MYO1E intron 22091778 rs1017888 chr15 59603896 T G 2.00E-04 Cognitive impairment induced by topiramate MYO1E intron 22091778 rs10851648 chr15 59609753 T G 7.49E-04 Multiple complex diseases MYO1E intron 17554300 rs16941421 chr15 59697546 C T 8.20E-05 Response to methylphenidate treatment / / 21130132 rs10519005 chr15 59711691 C T 5.00E-06 Alcohol dependence (age at onset) / / 24962325 rs7164726 chr15 59715666 C T 5.30E-04 Alcohol dependence / / 20201924 rs7164726 chr15 59715666 C T 6.00E-04 Alcohol dependence / / 20201924 rs28890483 chr15 59719169 A G 9.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs4410020 chr15 59723253 G A 2.91E-04 Multiple complex diseases / / 17554300 rs4483799 chr15 59723265 T G 6.88E-05 Multiple complex diseases / / 17554300 rs4592597 chr15 59736724 C T 7.72E-04 Multiple complex diseases FAM81A intron 17554300 rs4592597 chr15 59736724 C T 6.81E-05 Bipolar disorder and schizophrenia FAM81A intron 20889312 rs4291860 chr15 59784334 C A 2.16E-04 Lymphocyte counts FAM81A intron 22286170 rs4238340 chr15 59823626 T C 5.88E-05 Cognitive test performance / / 20125193 rs17302400 chr15 59824987 C T 7.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs8035572 chr15 59891498 T C 1.64E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs8035572 chr15 59891498 T C 1.64E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs11637648 chr15 59895431 T C 5.38E-04 Smoking initiation / / 24665060 rs8038647 chr15 59895808 T C 6.45E-04 Smoking initiation / / 24665060 rs8041223 chr15 59936526 C G 0.00012 Salmonella-induced pyroptosis GTF2A2 intron 22837397 rs6151562 chr15 59961726 G A 1.69E-05 Alzheimer's disease (late onset) BNIP2 intron 21379329 rs12438078 chr15 59988472 G C 2.93E-04 Alcohol dependence / / 21314694 rs10851664 chr15 60000239 G C 7.59E-04 Alcohol dependence / / 21314694 rs11071474 chr15 60001060 T C 4.29E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs11630244 chr15 60021637 A G 8.62E-05 Coronary heart disease / / pha003032 rs17269775 chr15 60042722 T C 1.70E-05 Bone mineral density (BMD),in women / / 20164292 rs12900903 chr15 60138217 A G 9.35E-04 HIV-1 viral setpoint / / 17641165 rs12900903 chr15 60138217 A G 1.22E-04 HIV-1 viral setpoint / / 21490045 rs17191057 chr15 60140168 A G 7.14E-04 Multiple complex diseases / / 17554300 rs17269789 chr15 60140279 G T 7.48E-04 Multiple complex diseases / / 17554300 rs2917821 chr15 60144421 T G 4.29E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11633633 chr15 60159639 A G 8.62E-05 Serum metabolites / / 19043545 rs893277 chr15 60177040 A G 2.25E-04 Smoking initiation / / 24665060 rs2965341 chr15 60184014 C A 4.26E-05 Cognitive test performance / / 20125193 rs16941938 chr15 60214234 C G 2.70E-05 Intracerebral hemorrhage / / 24656865 rs67389830 chr15 60214343 G A 2.16E-05 Intracerebral hemorrhage / / 24656865 rs2970376 chr15 60236925 T C 0.00084 Salmonella-induced pyroptosis / / 22837397 rs1863393 chr15 60242626 T C 0.000851 Salmonella-induced pyroptosis / / 22837397 rs10519025 chr15 60259472 G C 8.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs12441267 chr15 60269235 C T 1.12E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs8025697 chr15 60283211 C A 7.63E-04 Type 2 diabetes / / 23300278 rs4775229 chr15 60293714 A C 4.50E-05 Asthma (bronchodilator response) / / 22792082 rs9920841 chr15 60302540 A G 5.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs4775230 chr15 60303749 T C 5.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs12595222 chr15 60306314 A G 4.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs12917568 chr15 60326157 A G 8.30E-04 Coronary Artery Disease / / 17634449 rs17269978 chr15 60374681 T C 5.35E-05 Partial epilepsies / / 20522523 rs7168491 chr15 60374873 T C 3.71E-04 Common variable immunodeficiency / / 21497890 rs10048054 chr15 60397836 C T 6.10E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1545873 chr15 60454402 A G 8.16E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2414660 chr15 60475342 C T 1.37E-05 Suicidal ideation / / 22030708 rs1630535 chr15 60510176 A G 1.30E-07 Suicidal ideation / / 22030708 rs10519012 chr15 60546166 A G 1.00E-04 Kidney function and endocine traits / / 17903292 rs7182332 chr15 60570622 G A 2.20E-05 Urinary metabolites / / 21572414 rs11635176 chr15 60580333 G A 4.83E-06 Asthma / / 21790008 rs16942401 chr15 60582457 A G 3.36E-06 Asthma / / 21790008 rs17191351 chr15 60631076 C T 4.44E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11629852 chr15 60650015 T G 4.00E-04 Gamma gluatamyl transferase levels (interaction with age) ANXA2 intron 22010049 rs6494194 chr15 60660750 A T 4.74E-05 Intracerebral hemorrhage ANXA2 intron 24656865 rs12595605 chr15 60668472 T G 1.12E-05 Intracerebral hemorrhage ANXA2 intron 24656865 rs12593075 chr15 60668587 A G 1.15E-05 Intracerebral hemorrhage ANXA2 intron 24656865 rs4774359 chr15 60669311 G A 8.98E-06 Intracerebral hemorrhage ANXA2 intron 24656865 rs3743268 chr15 60678160 G A 8.43E-04 Multiple complex diseases ANXA2 intron 17554300 rs936013 chr15 60718265 G C 3.92E-04 Type 2 diabetes /RG2 intron 17463246 rs4775272 chr15 60737761 C G 2.66E-04 Smoking cessation /RG2 intron 24665060 rs3743266 chr15 60781513 T C 1.09E-05 Bone mineral density RORA UTR-3 19181680 rs3743266 chr15 60781513 T C 8.00E-07 Menarche (age at onset) RORA UTR-3 21102462 rs2290430 chr15 60791954 A C 4.30E-04 Myasthenia gravis RORA intron 23055271 rs17270188 chr15 60799909 A G 4.49E-04 Smoking initiation RORA intron 24665060 rs16942660 chr15 60801066 C T 0.0009 post-traumatic stress disorder RORA intron 22869035 rs8036966 chr15 60856696 A C 2.34E-04 Smoking initiation RORA intron 24665060 rs2162069 chr15 60861075 A G 2.76E-04 Smoking initiation RORA intron 24665060 rs17237290 chr15 60871870 T C 0.00089 Rosuvastatin induced change in C-reactive protein (CRP) RORA intron 22230323 rs340005 chr15 60878030 G A 2.00E-08 Gamma gluatamyl transferase levels RORA intron 22010049 rs339969 chr15 60883281 C A 7.00E-20 Liver enzyme levels (gamma-glutamyl transferase) RORA intron 22001757 rs339969 chr15 60883281 C A 1.30E-06 Gamma gluatamyl transferase levels (interaction with age) RORA intron 22010049 rs340029 chr15 60894965 C T 4.00E-09 C-reactive protein RORA intron 21300955 rs340029 chr15 60894965 C T 2.10E-06 Gamma gluatamyl transferase levels (interaction with age) RORA intron 22010049 rs7172348 chr15 60895223 A G 5.09E-05 Socioeconomic Factors RORA intron pha003066 rs980000 chr15 60900963 C T 2.00E-06 Menarche (age at onset) RORA intron 23599027 rs980000 chr15 60900963 C T 3.41E-05 Menarche (age at onset) RORA intron 23599027 rs3784609 chr15 60910550 C T 3.00E-06 Total ventricular volume RORA intron 21116278 rs339978 chr15 60937402 C T 2.00E-06 Menarche (age at onset) RORA intron 23599027 rs339978 chr15 60937402 C T 3.60E-05 Menarche (age at onset) RORA intron 23599027 rs17237318 chr15 60945015 T C 9.63E-06 Total ventricular volume RORA intron 21116278 rs1657800 chr15 60965915 T C 1.50E-04 Type 2 diabetes and 6 quantitative traits RORA intron 17848626 rs10519058 chr15 60966927 A G 2.00E-04 Type 2 diabetes and 6 quantitative traits RORA intron 17848626 rs880626 chr15 60983429 G A 1.51E-04 Epilepsy RORA intron 22116939 rs16942951 chr15 60997297 A G 8.85E-10 Multiple complex diseases RORA intron 17554300 rs7180547 chr15 61001833 C T 0.00000158 Sasang constitution (Soeum) RORA intron 22394158 rs8027032 chr15 61002898 T C 2.56E-04 Suicide attempts in bipolar disorder RORA intron 21041247 rs8038077 chr15 61004647 T C 5.37E-04 Alzheimer's disease RORA intron 22005930 rs17303111 chr15 61009802 T C 1.73E-04 Suicide attempts in bipolar disorder RORA intron 21041247 rs2414680 chr15 61011271 A G 1.43E-04 Suicide attempts in bipolar disorder RORA intron 21041247 rs6494221 chr15 61016107 A C 1.50E-05 HIV-1 viral setpoint RORA intron 22174851 rs12909890 chr15 61017977 G A 3.90E-04 Multiple complex diseases RORA intron 17554300 rs16943012 chr15 61018808 C G 3.87E-04 Type 2 diabetes RORA intron 17463246 rs11635314 chr15 61028486 C T 5.49E-06 Hypertension (early onset hypertension) RORA intron 22479346 rs341415 chr15 61032054 T A 1.77E-04 Self-reported allergy RORA intron 23817569 rs12594992 chr15 61032335 T A 4.20E-04 Type 2 diabetes RORA intron 17463246 rs7178643 chr15 61033240 C G 5.17E-05 Multiple complex diseases RORA intron 17554300 rs9920962 chr15 61036550 A G 6.22E-05 IgE levels RORA intron 22075330 rs9920962 chr15 61036550 A G 5.28E-04 Self-reported allergy RORA intron 23817569 rs7172011 chr15 61039387 C T 6.42E-05 IgE levels RORA intron 22075330 rs7172011 chr15 61039387 C T 1.72E-04 Self-reported allergy RORA intron 23817569 rs11632684 chr15 61040591 T G 6.33E-05 IgE levels RORA intron 22075330 rs11632684 chr15 61040591 T G 1.64E-04 Self-reported allergy RORA intron 23817569 rs1351544 chr15 61042867 G T 8.63E-05 Self-reported allergy RORA intron 23817569 rs1817479 chr15 61043135 G C 8.61E-05 Self-reported allergy RORA intron 23817569 rs8025324 chr15 61043378 G A 6.10E-05 Self-reported allergy RORA intron 23817569 rs1318929 chr15 61045030 T C 4.60E-04 Taste perception RORA intron 22132133 rs16943064 chr15 61047144 G A 4.09E-05 Self-reported allergy RORA intron 23817569 rs11637301 chr15 61047898 A T 7.04E-05 Self-reported allergy RORA intron 23817569 rs9920592 chr15 61048200 C T 4.26E-05 Self-reported allergy RORA intron 23817569 rs9920593 chr15 61048213 C T 4.29E-05 Self-reported allergy RORA intron 23817569 rs1020730 chr15 61048578 C T 4.16E-05 Self-reported allergy RORA intron 23817569 rs922783 chr15 61053951 A G 4.01E-05 Self-reported allergy RORA intron 23817569 rs12900122 chr15 61055411 C T 2.13E-05 Self-reported allergy RORA intron 23817569 rs16943087 chr15 61056035 A G 4.73E-05 Self-reported allergy RORA intron 23817569 rs2279292 chr15 61057770 T C 1.08E-04 Self-reported allergy RORA intron 23817569 rs529034832 chr15 61059261 G GT 5.58E-05 Self-reported allergy RORA intron 23817569 rs8025689 chr15 61059261 G C 5.58E-05 Self-reported allergy RORA intron 23817569 rs9302215 chr15 61060367 T C 5.60E-04 Taste perception RORA intron 22132133 rs12591650 chr15 61060707 A G 7.00E-07 Subcutaneous adipose tissue RORA intron 22589738 rs11633029 chr15 61065553 T C 9.77E-05 Self-reported allergy RORA intron 23817569 rs11637671 chr15 61065607 A C,G,T 9.83E-05 Self-reported allergy RORA intron 23817569 rs11639084 chr15 61066516 C T 7.89E-05 Self-reported allergy RORA intron 23817569 rs7164773 chr15 61067948 C T 1.56E-04 Type 2 diabetes RORA intron 17846124 rs10519067 chr15 61068347 G A 4.43E-05 Self-reported allergy RORA intron 23817569 rs10519068 chr15 61068704 G A 6.37E-05 IgE levels RORA intron 22075330 rs10519068 chr15 61068704 G A 6.68E-05 Self-reported allergy RORA intron 23817569 rs11071557 chr15 61068954 T C 7.65E-05 Self-reported allergy RORA intron 23817569 rs11071558 chr15 61069421 A C,G 7.01E-05 Self-reported allergy RORA intron 23817569 rs11071559 chr15 61069988 C T 1.00E-07 Asthma RORA intron 20860503 rs11071559 chr15 61069988 C T 1.10E-07 Asthma RORA intron 21907864 rs11071559 chr15 61069988 C T 1.10E-07 Asthma RORA intron 22561531 rs11071559 chr15 61069988 C T 9.18E-05 Self-reported allergy RORA intron 23817569 rs922781 chr15 61070344 C G 5.62E-05 Attention deficit hyperactivity disorder RORA intron 18980221 rs12441037 chr15 61102657 T C 6.49E-05 Abdominal aortic aneurysm RORA intron 24046328 rs341366 chr15 61103590 A G 0.0000373 post-traumatic stress disorder RORA intron 22869035 rs341366 chr15 61103590 A G 3.73E-05 Schizophrenia RORA intron 22883433 rs341366 chr15 61103590 A G 6.41E-05 ldl cholesterol RORA intron pha003076 rs6494226 chr15 61105886 C T 5.59E-05 Abdominal aortic aneurysm RORA intron 24046328 rs2414681 chr15 61109318 C A 0.00005 post-traumatic stress disorder RORA intron 22869035 rs2414681 chr15 61109318 C A 5.00E-05 Schizophrenia RORA intron 22883433 rs10519074 chr15 61109873 C A 0.0000154 post-traumatic stress disorder RORA intron 22869035 rs10519074 chr15 61109873 C A 1.54E-05 Schizophrenia RORA intron 22883433 rs10519074 chr15 61109873 C A 7.09E-05 Cholesterol RORA intron pha003073 rs10519074 chr15 61109873 C A 9.46E-05 Cholesterol RORA intron pha003078 rs7169281 chr15 61114104 T C 0.0000295 post-traumatic stress disorder RORA intron 22869035 rs7169281 chr15 61114104 T C 2.95E-05 Schizophrenia RORA intron 22883433 rs12440095 chr15 61121217 G A 5.06E-04 White matter integrity RORA intron 22425255 rs8041061 chr15 61124838 G T 1.92E-04 Amyotrophic Lateral Sclerosis RORA intron 17362836 rs8041061 chr15 61124838 G T 0.00000016 post-traumatic stress disorder RORA intron 22869035 rs8041061 chr15 61124838 G T 1.64E-07 Schizophrenia RORA intron 22883433 rs8042149 chr15 61124953 T G 2.49E-08 post-traumatic stress disorder RORA intron 22869035 rs8042149 chr15 61124953 T G 2.49E-08 Schizophrenia RORA intron 22883433 rs4775301 chr15 61126859 T C 1.10E-04 Amyotrophic Lateral Sclerosis RORA intron 17362836 rs4775301 chr15 61126859 T C 0.000000459 post-traumatic stress disorder RORA intron 22869035 rs4775301 chr15 61126859 T C 4.59E-07 Schizophrenia RORA intron 22883433 rs8023252 chr15 61128781 G T 9.10E-04 Amyotrophic Lateral Sclerosis RORA intron 17362836 rs8024133 chr15 61130639 C T 0.000000877 post-traumatic stress disorder RORA intron 22869035 rs8024133 chr15 61130639 C T 8.77E-07 Schizophrenia RORA intron 22883433 rs11071561 chr15 61131683 T A 0.0000038 post-traumatic stress disorder RORA intron 22869035 rs11071561 chr15 61131683 T A 3.81E-06 Schizophrenia RORA intron 22883433 rs341401 chr15 61132845 G A 2.51E-04 Amyotrophic Lateral Sclerosis RORA intron 17362836 rs341401 chr15 61132845 G A 0.000062 post-traumatic stress disorder RORA intron 22869035 rs341401 chr15 61132845 G A 6.20E-05 Schizophrenia RORA intron 22883433 rs10519080 chr15 61138459 T C 5.79E-06 Hypertension (essential hypertension) RORA intron 22184326 rs341408 chr15 61141690 T C 1.02E-05 Major depressive disorder RORA intron 19107115 rs341408 chr15 61141690 T C 1.74E-06 Hypertension (essential hypertension) RORA intron 22184326 rs1902618 chr15 61164199 G A 2.00E-06 Pulmonary function decline RORA intron 22424883 rs729978 chr15 61187016 T C 6.60E-04 Suicide attempts in bipolar disorder RORA intron 21041247 rs729977 chr15 61187068 C T 6.72E-04 Suicide attempts in bipolar disorder RORA intron 21041247 rs12592999 chr15 61187821 G A 6.93E-04 Suicide attempts in bipolar disorder RORA intron 21041247 rs4775313 chr15 61188518 C G 5.76E-04 Type 2 diabetes RORA intron 17463246 rs4774376 chr15 61188681 G C 9.88E-04 Lymphocyte counts RORA intron 22286170 rs3803487 chr15 61189609 G A 7.59E-04 Suicide attempts in bipolar disorder RORA intron 21041247 rs17237465 chr15 61190011 T C 7.62E-04 Suicide attempts in bipolar disorder RORA intron 21041247 rs2899663 chr15 61194234 A G 6.59E-04 Type 2 diabetes RORA intron 17463246 rs2414686 chr15 61194350 A G 7.36E-04 Type 2 diabetes RORA intron 17463246 rs41346644 chr15 61195148 A G 5.67E-05 Multiple complex diseases RORA intron 17554300 rs8023563 chr15 61210255 T A 1.48E-05 Depression (quantitative trait) RORA intron 20800221 rs8028646 chr15 61211189 A T 7.17E-06 Depression (quantitative trait) RORA intron 20800221 rs8033151 chr15 61211462 A G 3.10E-05 Depression (quantitative trait) RORA intron 20800221 rs11071568 chr15 61211671 C T 4.96E-05 Depression (quantitative trait) RORA intron 20800221 rs2128166 chr15 61212262 G A 4.48E-05 Depression (quantitative trait) RORA intron 20800221 rs4264335 chr15 61212974 A G 5.00E-05 Depression (quantitative trait) RORA intron 20800221 rs2062095 chr15 61213082 G A 6.62E-04 Alzheimer's disease RORA intron 22005930 rs2062095 chr15 61213082 G A 1.48E-04 Smoking quantity RORA intron 24665060 rs2062092 chr15 61213225 C T 7.36E-04 Alzheimer's disease RORA intron 22005930 rs4775319 chr15 61213564 G A 6.11E-05 Depression (quantitative trait) RORA intron 20800221 rs4638513 chr15 61213617 G A 6.13E-05 Depression (quantitative trait) RORA intron 20800221 rs4547277 chr15 61213991 G A 6.16E-05 Depression (quantitative trait) RORA intron 20800221 rs1482051 chr15 61214954 T C 2.60E-04 Depression (quantitative trait) RORA intron 20800221 rs8029250 chr15 61218047 T C 5.35E-04 Alzheimer's disease RORA intron 22005930 rs12906588 chr15 61219596 T G 4.16E-04 Depression (quantitative trait) RORA intron 20800221 rs1482050 chr15 61223718 A C 9.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) RORA intron 23648065 rs1351545 chr15 61227793 T C 4.96E-05 Cognitive impairment induced by topiramate RORA intron 22091778 rs1351545 chr15 61227793 T C 6.75E-06 Cognitive impairment induced by topiramate RORA intron 22091778 rs1351545 chr15 61227793 T C 7.74E-05 Cognitive impairment induced by topiramate RORA intron 22091778 rs8034886 chr15 61228170 A G 2.40E-05 Urinary metabolites RORA intron 21572414 rs12594733 chr15 61244884 T C 3.41E-08 HDL cholesterol RORA intron 24886709 rs12912233 chr15 61267096 C T 6.00E-07 Depression (quantitative trait) RORA intron 20800221 rs12912233 chr15 61267096 C T 6.30E-07 Depression (quantitative trait) RORA intron 23290196 rs4775340 chr15 61267752 G A 6.27E-06 Depression (quantitative trait) RORA intron 20800221 rs17237521 chr15 61268282 T C 0.0002196 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RORA intron 23233654 rs17237521 chr15 61268282 T C 2.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) RORA intron 23233662 rs6494238 chr15 61269303 C T 5.29E-04 Response to cytadine analogues (cytosine arabinoside) RORA intron 24483146 rs8031801 chr15 61269447 G A 4.57E-04 Response to cytadine analogues (cytosine arabinoside) RORA intron 24483146 rs1589702 chr15 61272664 T C 6.61E-04 Coronary heart disease RORA intron 21971053 rs7168987 chr15 61274433 C T 1 Drug response to Etoposide RORA intron 17537913 rs7175830 chr15 61275513 G T 6.06E-04 Depression (quantitative trait) RORA intron 20800221 rs1949752 chr15 61277083 G A 7.82E-04 Depression (quantitative trait) RORA intron 20800221 rs11631179 chr15 61277476 T C 1 Drug response to Etoposide RORA intron 17537913 rs16943453 chr15 61286998 T G 4.88E-04 Smoking initiation RORA intron 24665060 rs10519096 chr15 61289944 G A 9.20E-05 Myasthenia gravis RORA intron 23055271 rs10519097 chr15 61290188 C T 4.70E-05 Myasthenia gravis RORA intron 23055271 rs11071581 chr15 61307380 C T 5.12E-05 Multiple complex diseases RORA intron 17554300 rs10162779 chr15 61317742 T C 8.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RORA intron 20877124 rs809736 chr15 61329788 A G 8.00E-06 Response to citalopram treatment RORA intron 19846067 rs809736 chr15 61329788 A G 3.31E-04 Alzheimer's disease RORA intron 22005930 rs809736 chr15 61329788 A G 8.19E-06 Vaspin levels RORA intron 22907691 rs7172342 chr15 61336442 C G 4.00E-06 Schizophrenia RORA intron 23212062 rs4774384 chr15 61336628 C T 4.42E-04 Schizophrenia RORA intron 24043878 rs782947 chr15 61339261 C T 9.05E-04 Alzheimer's disease RORA intron 22005930 rs782905 chr15 61373581 T A 8.03E-05 Biliary atresia RORA intron 20460270 rs11071586 chr15 61378086 C T 3.51E-05 Alzheimer's disease RORA intron 17998437 rs11071586 chr15 61378086 C T 6.96E-05 Serum metabolites RORA intron 19043545 rs782909 chr15 61381499 C T 1.40E-05 Diabetes Mellitus RORA intron pha003060 rs1437537 chr15 61385274 T C 0.000599 Salmonella-induced pyroptosis RORA intron 22837397 rs13329643 chr15 61397660 C T 5.59E-05 Diabetes Mellitus RORA intron pha003060 rs11071587 chr15 61433543 G A 8.71E-04 Alcohol dependence RORA intron 21314694 rs11071587 chr15 61433543 G A 0.00011 post-traumatic stress disorder RORA intron 22869035 rs11071588 chr15 61433578 T G 0.0000677 post-traumatic stress disorder RORA intron 22869035 rs1437547 chr15 61434581 A C,G,T 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes RORA intron 22628534 rs1816625 chr15 61437557 T C 3.47E-04 Smoking initiation RORA intron 24665060 rs12593790 chr15 61447643 A G 3.31E-05 Smoking initiation RORA intron 24665060 rs16943698 chr15 61450514 T C 4.21E-05 Smoking initiation RORA intron 24665060 rs1465811 chr15 61453791 T C 6.69E-05 Smoking initiation RORA intron 24665060 rs11071590 chr15 61462981 A G 1.90E-04 Multiple complex diseases RORA intron 17554300 rs11071591 chr15 61463031 T C 2.14E-04 Multiple complex diseases RORA intron 17554300 rs4774388 chr15 61466998 C T 4.73E-05 Smoking initiation RORA intron 24665060 rs1816624 chr15 61469322 C T 5.55E-04 Smoking initiation RORA intron 24665060 rs17204938 chr15 61473989 A C 4.65E-04 Lung function (forced expiratory volume in 1 second) RORA intron 24023788 rs1550226 chr15 61505679 T C 3.28E-04 Smoking initiation RORA intron 24665060 rs930358 chr15 61506685 G A 0.000545 Salmonella-induced pyroptosis RORA intron 22837397 rs8029174 chr15 61536422 C A 3.15E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4775378 chr15 61566215 A G 5.03E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs8026315 chr15 61569516 G T 7.90E-05 Hypothyroidism / / 22493691 rs4309342 chr15 61597447 T C 6.70E-05 Lymphocyte counts / / pha003094 rs3934516 chr15 61603979 G C 2.15E-05 Bipolar disorder / / 19488044 rs3934516 chr15 61603979 G C 5.53E-05 Bipolar Disorder / / pha002858 rs11633196 chr15 61617323 G A 5.92E-04 Multiple complex diseases / / 17554300 rs4297629 chr15 61688169 T C 1.80E-06 Urinary metabolites / / 21572414 rs4424867 chr15 61688191 A T 8.50E-06 Urinary metabolites / / 21572414 rs6494266 chr15 61700296 C T 7.55E-06 Response to amphetamines / / 22952603 rs6494267 chr15 61700342 C T 6.26E-06 Response to amphetamines / / 22952603 rs10851695 chr15 61700658 C G 8.08E-06 Response to amphetamines / / 22952603 rs7181076 chr15 61700916 C T 7.55E-06 Response to amphetamines / / 22952603 rs7181601 chr15 61701081 G A 6.84E-06 Response to amphetamines / / 22952603 rs4374104 chr15 61702153 G A 7.93E-06 Response to amphetamines / / 22952603 rs8031208 chr15 61702577 A G 9.49E-06 Response to amphetamines / / 22952603 rs3884558 chr15 61702779 A G 5.00E-06 Response to amphetamines / / 22952603 rs3884558 chr15 61702779 A G 4.00E-06 Breast cancer (prognosis) / / 23319801 rs11638616 chr15 61704119 A C 8.08E-06 Response to amphetamines / / 22952603 rs4270116 chr15 61704441 G A 6.91E-06 Response to amphetamines / / 22952603 rs4270117 chr15 61704543 G A 7.62E-06 Response to amphetamines / / 22952603 rs10851696 chr15 61704882 G C 7.51E-06 Response to amphetamines / / 22952603 rs12372930 chr15 61705263 A G 7.80E-06 Response to amphetamines / / 22952603 rs11071601 chr15 61705306 C T 5.84E-06 Response to amphetamines / / 22952603 rs8029558 chr15 61705620 T C 8.62E-06 Response to amphetamines / / 22952603 rs12905050 chr15 61705656 A G 8.25E-06 Response to amphetamines / / 22952603 rs7173611 chr15 61706561 C G 2.38E-04 Multiple complex diseases / / 17554300 rs7173611 chr15 61706561 C G 8.08E-06 Response to amphetamines / / 22952603 rs7175117 chr15 61706596 T C 8.08E-06 Response to amphetamines / / 22952603 rs7171652 chr15 61710312 C T 3.73E-05 Tuberculosis / / 24057671 rs7163165 chr15 61754358 T G 2.73E-05 Tuberculosis / / 24057671 rs8034331 chr15 61755995 C G 2.20E-05 Urinary metabolites / / 21572414 rs7170301 chr15 61781868 A T 7.97E-04 Type 2 diabetes / / 17463246 rs4609787 chr15 61796044 T A 6.67E-04 Multiple complex diseases / / 17554300 rs11631045 chr15 61806182 C T 2.13E-04 Smoking quantity / / 24665060 rs12595483 chr15 61826891 G C 3.07E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4775413 chr15 61840103 C T 2.00E-06 Schizophrenia / / 21926974 rs4775413 chr15 61840103 C T 1.79E-04 Schizophrenia / / 24043878 rs11636157 chr15 61842557 A C 6.40E-05 Suicide attempts in bipolar disorder / / 21423239 rs11636309 chr15 61842673 G A 7.33E-05 Suicide attempts in bipolar disorder / / 21423239 rs4774405 chr15 61849047 G A 7.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs4291862 chr15 61849582 T A 5.47E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs11071614 chr15 61851805 T C 3.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs11631683 chr15 61851859 G T 9.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs12592172 chr15 61852209 G T 8.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs8026487 chr15 61855047 A C 9.54E-04 Multiple complex diseases / / 17554300 rs2414718 chr15 61863133 G A 0.0000459 Schizophrenia / / 23637625 rs7497302 chr15 61870836 T C 7.79E-05 Orofacial clefts / / 22419666 rs12592967 chr15 61870943 C T 3.00E-07 Schizophrenia / / 22688191 rs3848121 chr15 61879564 C T 2.24E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs7179361 chr15 61895472 T G 2.21E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs16944395 chr15 61897801 T C 1.41E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs3848122 chr15 61900589 A G 2.21E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs7178929 chr15 61904451 A G 7.62E-06 Brachial circumference / / 22479309 rs11854700 chr15 61907481 C T 2.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs2414705 chr15 61909712 G T 2.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs2414726 chr15 61937482 C A 0.0000728 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2243431 chr15 61987998 T C 0.00012 Breast cancer / / 23555315 rs2414739 chr15 61994134 G A 9.46E-06 Parkinson's disease / / 21738487 rs11853885 chr15 61994614 G A 9.47E-05 Parkinson's disease / / 21738487 rs10519131 chr15 62001132 A C 6.65E-05 Parkinson's disease / / 21738487 rs10519131 chr15 62001132 A C 1.00E-06 Parkinson's disease / / 22451204 rs12916842 chr15 62011711 T C 7.33E-04 Multiple complex diseases / / 17554300 rs8028149 chr15 62017105 C T 6.24E-05 Major depressive disorder (broad) / / 20038947 rs2249910 chr15 62036078 G C 4.56E-04 Multiple complex diseases / / 17554300 rs12898793 chr15 62081161 T C 4.98E-04 Alzheimer's disease (late onset) / / 21379329 rs17303768 chr15 62091248 T A 4.93E-04 Multiple complex diseases / / 17554300 rs7178911 chr15 62093241 C T 4.54E-05 Serum metabolites / / 19043545 rs1425268 chr15 62101982 G A 1.90E-05 Urinary metabolites / / 21572414 rs2113931 chr15 62109469 G A 5.22E-05 Response to metformin / / 21186350 rs12907856 chr15 62110478 A G 5.84E-04 Taste perception / / 22132133 rs9920509 chr15 62123116 T C 0.0000617 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12437560 chr15 62124706 T G 2.90E-07 Primary biliary cirrhosis / / 23000144 rs12437560 chr15 62124706 T G 0.00000029 Facial morphology / / 23028347 rs2241492 chr15 62147207 T A 4.36E-06 Hearing function VPS13C intron 21493956 rs2241492 chr15 62147207 T A 4.45E-05 Type 2 diabetes VPS13C intron 22158537 rs8037603 chr15 62157537 C A 5.97E-04 Type 2 diabetes VPS13C UTR-3 22158537 rs12439719 chr15 62178695 A G 2.73E-04 Alzheimer's disease (late onset) VPS13C intron 21379329 rs11637606 chr15 62204714 A C 5.54E-05 Bipolar disorder and schizophrenia VPS13C intron 20889312 rs2303405 chr15 62253791 T C 3.51E-05 Bipolar disorder and schizophrenia VPS13C missense 20889312 rs17304010 chr15 62255172 A G 2.43E-04 Type 2 diabetes VPS13C intron 22158537 rs7168164 chr15 62301094 G A 3.92E-04 Type 2 diabetes VPS13C intron 22158537 rs4143844 chr15 62312840 A C 4.00E-06 Bipolar disorder and schizophrenia VPS13C intron 20889312 rs4143844 chr15 62312840 A C 4.93E-05 Schizophrenia VPS13C intron pha002857 rs17271305 chr15 62332980 A G 1.00E-07 Two-hour glucose challenge VPS13C intron 20081857 rs1436958 chr15 62338797 G T 3.87E-04 Multiple complex diseases VPS13C intron 17554300 rs1436958 chr15 62338797 G T 0.00000194 Fasting blood glucose VPS13C intron 22885924 rs1436958 chr15 62338797 G T 1.66E-09 2-hour glucose tolerance test VPS13C intron 22885924 rs1436958 chr15 62338797 G T 9.00E-06 IgG glycosylation VPS13C intron 23382691 rs11632441 chr15 62372238 A G 6.82E-04 Multiple complex diseases / / 17554300 rs4775458 chr15 62375036 T G 5.44E-04 Bipolar disorder / / 19259986 rs7178424 chr15 62380259 C T 6.00E-09 Height / / 20881960 rs12437833 chr15 62382733 A G 1.07E-06 Suicide attempts in bipolar disorder / / 21423239 rs4502156 chr15 62383155 T C 4.00E-20 Proinsulin levels / / 21873549 rs4502156 chr15 62383155 T C 0.000033 Type 2 diabetes (males) / / 22885922 rs4502156 chr15 62383155 T C 1.38E-25 Fasting blood glucose / / 22885924 rs4502156 chr15 62383155 T C 3.44E-13 2-hour glucose tolerance test / / 22885924 rs17304080 chr15 62386330 G T 5.42E-04 Type 2 diabetes / / 17463246 rs17304080 chr15 62386330 G T 1.80E-04 Multiple complex diseases / / 17554300 rs4775461 chr15 62387851 A G 4.31E-04 Type 2 diabetes / / 17463246 rs4775461 chr15 62387851 A G 6.41E-04 Multiple complex diseases / / 17554300 rs7163757 chr15 62391608 C T 7.40E-05 Type 2 diabetes / / 22158537 rs7163757 chr15 62391608 C T 4.00E-06 Type 2 diabetes / / 24509480 rs6494307 chr15 62394690 C G 4.27E-06 Type 2 diabetes / / 22158537 rs17271458 chr15 62395865 G A 6.46E-05 Suicide attempts in bipolar disorder / / 21423239 rs7167878 chr15 62396189 C A 7.09E-04 Type 2 diabetes / / 22158537 rs7172432 chr15 62396389 A G 9.00E-14 Type 2 diabetes / / 20818381 rs7172432 chr15 62396389 A G 2.86E-08 Type 2 diabetes / / 22158537 rs7172432 chr15 62396389 A G 7.40E-18 Insulin processing and secretion / / 23263489 rs7172432 chr15 62396389 A G 7.48E-08 Type 2 diabetes / / 23300278 rs7172432 chr15 62396389 A G 1.00E-06 Type 2 diabetes / / 23945395 rs7173964 chr15 62396942 G A 6.14E-07 Type 2 diabetes / / 22158537 rs7173964 chr15 62396942 G A 6.00E-12 Fasting glucose-related traits (interaction with BMI) / / 22581228 rs1370176 chr15 62397234 G A 9.74E-08 Type 2 diabetes / / 20818381 rs1370176 chr15 62397234 G A 8.70E-04 Alzheimer's disease / / 24755620 rs8030240 chr15 62399564 C T 6.61E-04 Multiple complex diseases / / 17554300 rs2083013 chr15 62401482 C T 8.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs1436955 chr15 62404382 C T 7.00E-07 Type 2 diabetes / / 20862305 rs17205498 chr15 62405255 G A 7.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs12911635 chr15 62406008 C T 2.77E-04 Multiple complex diseases / / 17554300 rs2414760 chr15 62407043 G C 5.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs9806383 chr15 62411514 A G 7.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs920179 chr15 62413339 A G 4.83E-04 Multiple complex diseases / / 17554300 rs920178 chr15 62413696 G A 3.63E-05 Type 2 diabetes / / 22158537 rs1436953 chr15 62414014 C T 5.03E-07 Type 2 diabetes / / 20818381 rs1436953 chr15 62414014 C T 8.00E-06 Type 2 diabetes / / 21799836 rs1436953 chr15 62414014 C T 1.42E-06 Type 2 diabetes / / 22158537 rs1436953 chr15 62414014 C T 0.000086 2-hour glucose tolerance test / / 22885924 rs6494309 chr15 62415728 T A 2.38E-04 Type 2 diabetes / / 22158537 rs6494310 chr15 62415736 G A 3.24E-04 Type 2 diabetes / / 22158537 rs4775470 chr15 62416585 C T 3.56E-05 Suicide attempts in bipolar disorder / / 21423239 rs17271493 chr15 62416959 C A 4.48E-04 Multiple complex diseases / / 17554300 rs17205526 chr15 62417134 A T 6.26E-05 Type 2 diabetes / / 22158537 rs11635791 chr15 62419882 G A 8.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs1579636 chr15 62420300 G A 3.57E-05 Suicide attempts in bipolar disorder / / 21423239 rs1469896 chr15 62420478 G C,T 7.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs2178207 chr15 62420805 G C 9.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs11854283 chr15 62421166 T A 1.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs4775471 chr15 62424649 C T 9.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs4775471 chr15 62424649 C T 9.73E-11 Fasting blood glucose / / 22885924 rs11071655 chr15 62427973 C T 7.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs11071655 chr15 62427973 C T 3.04E-05 Progressive supranuclear palsy / / 21685912 rs12909049 chr15 62429656 C T 4.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs8024230 chr15 62432081 C T 3.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs8024838 chr15 62432274 G A 3.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs11071657 chr15 62433962 A G 4.00E-08 Fasting glucose-related traits / / 20081858 rs11071657 chr15 62433962 A G 8.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs1881413 chr15 62434797 C G 9.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs12440695 chr15 62435156 T C 9.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs12440695 chr15 62435156 T C 0.000000296 Fasting blood glucose / / 22885924 rs12440695 chr15 62435156 T C 0.0000115 2-hour glucose tolerance test / / 22885924 rs17271521 chr15 62437363 T A 9.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs11635220 chr15 62439166 A G 7.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs11853937 chr15 62442196 C T 6.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs11858401 chr15 62452242 A G 1.50E-05 Urinary metabolites / / 21572414 rs12592154 chr15 62501627 G A 3.87E-04 Schizophrenia / / 20832056 rs1027844 chr15 62591326 G C,T 8.35E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17304157 chr15 62592006 A G 1.39E-05 Cognitive impairment induced by topiramate / / 22091778 rs17304157 chr15 62592006 A G 5.44E-04 Taste perception / / 22132133 rs10851713 chr15 62596220 A G 5.92E-04 Multiple complex diseases / / 17554300 rs11630493 chr15 62614802 T A 7.56E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs289107 chr15 62630615 A C 5.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs289123 chr15 62639641 A G 5.99E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs289123 chr15 62639641 A G 5.99E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs11071668 chr15 62658548 G C 7.75E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs289101 chr15 62676125 G A 2.86E-07 Schizophrenia / / 21926974 rs289102 chr15 62680426 C T 9.63E-06 Bilirubin levels / / 22085899 rs2456930 chr15 62687339 C T 1.50E-07 Temporal lobe volumes / / 20197096 rs289156 chr15 62702643 T C 8.20E-05 Tooth agenesis (mandibular third molar) / / 24172245 rs7171526 chr15 62709924 C G 7.57E-05 Multiple complex diseases / / 17554300 rs11631773 chr15 62716409 T C 6.30E-05 Response to statin therapy / / 20339536 rs2456467 chr15 62732330 G T 5.60E-05 Response to statin therapy / / 20339536 rs2456467 chr15 62732330 G T 2.47E-06 Elbow pain / / pha003008 rs8040704 chr15 62735529 A G 2.58E-05 Taste perception / / 22132133 rs17271730 chr15 62757722 A G 7.86E-04 Alzheimer's disease / / 22005930 rs11071671 chr15 62762595 G A 8.55E-04 Alzheimer's disease / / 22005930 rs12148147 chr15 62762968 T C 1.20E-04 Primary sclerosing cholangitis / / 19944697 rs370873 chr15 62764680 C T 4.25E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs1656146 chr15 62775608 C T 6.00E-04 Acute lung injury / / 22295056 rs2437131 chr15 62784203 C T 4.97E-04 Acute lung injury / / 22295056 rs1105998 chr15 62785451 C T 4.97E-04 Acute lung injury / / 22295056 rs16945148 chr15 62787160 T G 6.10E-05 Response to statin therapy / / 20339536 rs2456474 chr15 62790044 G T 7.86E-04 Multiple complex diseases / / 17554300 rs1661317 chr15 62791196 T C 4.25E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17271779 chr15 62792939 T C 8.50E-05 Response to statin therapy / / 20339536 rs2456462 chr15 62794256 G A 7.21E-04 Acute lung injury / / 22295056 rs2456462 chr15 62794256 G A 7.44E-05 Stroke / / pha002887 rs1194922 chr15 62795684 G A 7.52E-05 Schizophrenia / / 19571811 rs2439709 chr15 62797907 A G 7.48E-04 Acute lung injury / / 22295056 rs2471026 chr15 62797997 C T 6.64E-04 Acute lung injury / / 22295056 rs2471027 chr15 62800731 T G 6.52E-04 Acute lung injury / / 22295056 rs448458 chr15 62804488 T C 2.26E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs12443158 chr15 62808035 A C 8.84E-04 Acute lung injury / / 22295056 rs16945203 chr15 62808983 C T 8.88E-04 Acute lung injury / / 22295056 rs16945208 chr15 62812851 G A 8.21E-04 Acute lung injury / / 22295056 rs1372347 chr15 62816802 A G 8.36E-04 Parkinson's disease / / 17052657 rs11071673 chr15 62819584 G A 5.51E-04 Type 2 diabetes / / 17463246 rs11071673 chr15 62819584 G A 3.80E-04 Primary sclerosing cholangitis / / 19944697 rs8030359 chr15 62819996 T G 5.14E-04 Type 2 diabetes / / 17463246 rs8036087 chr15 62859521 T G 9.66E-04 Depression (quantitative trait) / / 20800221 rs12908576 chr15 62861409 C T 8.88E-04 Depression (quantitative trait) / / 20800221 rs12905414 chr15 62864130 G A 7.15E-04 Depression (quantitative trait) / / 20800221 rs11631593 chr15 62873305 A G 5.48E-05 Multiple complex diseases / / 17554300 rs12913538 chr15 62899160 G A 7.00E-06 Sleep depth / / 23728906 rs8042621 chr15 62919312 G A 3.14E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs938979 chr15 62939440 T C 2.26E-05 Alcoholism / / pha002893 rs12591037 chr15 62948909 C T 3.67E-05 Alcoholism TLN2 intron pha002893 rs16945618 chr15 63036072 A G 4.84E-04 Multiple complex diseases TLN2 intron 17554300 rs8033767 chr15 63047778 C T 6.36E-05 Femoral neck bone geometry TLN2 cds-synon 22087292 rs11637837 chr15 63048201 G A 8.13E-04 Type 2 diabetes TLN2 intron 17463246 rs4775542 chr15 63078377 T C 2.90E-05 Urinary metabolites TLN2 intron 21572414 rs4775542 chr15 63078377 T C 5.60E-05 Femoral neck bone geometry TLN2 intron 22087292 rs6494361 chr15 63082503 G A 2.24E-04 Multiple complex diseases TLN2 intron 17554300 rs4774453 chr15 63099535 G A 4.98E-10 Brain activation patterns in response to human facial expressions-for the negative faces task TLN2 intron 22828495 rs4774453 chr15 63099535 G A 2.95E-09 Airflow obstruction TLN2 intron 22837378 rs7178912 chr15 63100450 A G 3.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TLN2 intron 20877124 rs10851718 chr15 63100467 A G 1.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TLN2 intron 20877124 rs16945938 chr15 63139366 T C 4.45E-04 Multiple complex diseases / / 17554300 rs16945949 chr15 63145902 G A 5.12E-04 Alcohol dependence / / 20201924 rs8025643 chr15 63146810 C G 1.10E-06 Urinary metabolites / / 21572414 rs625901 chr15 63161831 A G 6.53E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs4775555 chr15 63167484 G A 7.57E-05 Orofacial clefts / / 22419666 rs489667 chr15 63171589 T G 4.59E-04 Type 2 diabetes / / 17463246 rs570763 chr15 63172467 G A 4.06E-04 Type 2 diabetes / / 17463246 rs11853643 chr15 63174047 G T 8.01E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs685201 chr15 63190224 T C 2.46E-04 Type 2 diabetes / / 17463246 rs729198 chr15 63191944 C A 3.00E-05 Prostate cancer / / 21743057 rs4274387 chr15 63192448 G C 1.00E-04 Prostate cancer / / 21743057 rs2171689 chr15 63192751 T C 6.00E-05 Prostate cancer / / 21743057 rs2899685 chr15 63192772 C G 6.00E-05 Prostate cancer / / 21743057 rs8042820 chr15 63194063 G A 3.00E-06 Prostate cancer / / 21743057 rs16946080 chr15 63195611 G A 4.43E-04 Type 2 diabetes / / 22238593 rs7172773 chr15 63195772 C T 3.00E-06 Prostate cancer / / 21743057 rs8030784 chr15 63198937 G A 3.00E-06 Prostate cancer / / 21743057 rs1602021 chr15 63207619 C G 1.83E-04 Smoking initiation / / 24665060 rs6494367 chr15 63215651 T C 8.44E-04 Multiple complex diseases / / 17554300 rs6494367 chr15 63215651 T C 1.91E-04 Bipolar disorder,schizoaffective / / 19567891 rs11634578 chr15 63222044 C T 7.05E-05 Relative hand skill / / 24068947 rs902025 chr15 63232401 A G 3.08E-04 Heart rate / / 23583979 rs8034321 chr15 63248945 C T 1.10E-05 Urinary metabolites / / 21572414 rs1489316 chr15 63281547 A T 6.64E-04 Type 2 diabetes / / 17463246 rs12437471 chr15 63288730 T C 2.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12595433 chr15 63290645 G A 5.00E-06 Obesity-related traits / / 23251661 rs11071709 chr15 63292048 T C 7.94E-04 Acute lung injury / / 22295056 rs1489315 chr15 63292446 C T 7.94E-04 Acute lung injury / / 22295056 rs1489315 chr15 63292446 C T 3.16E-04 Amyotrophic lateral sclerosis / / 23624525 rs1489314 chr15 63295972 A C 4.38E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs902031 chr15 63299362 T C 1.40E-04 Response to antidepressants / / 19736353 rs1906779 chr15 63303416 G A 9.12E-05 Orofacial clefts / / 20023658 rs8029221 chr15 63308583 C T 5.58E-05 Orofacial clefts / / 22863734 rs4774467 chr15 63311425 T C 3.20E-07 Orofacial clefts / / 22863734 rs4775599 chr15 63311495 A G 2.67E-07 Orofacial clefts / / 22863734 rs4774469 chr15 63311927 G A 6.46E-07 Orofacial clefts / / 22863734 rs4775600 chr15 63311940 A G 6.46E-07 Orofacial clefts / / 22863734 rs4775601 chr15 63311980 T C 8.86E-07 Orofacial clefts / / 22863734 rs4774470 chr15 63312119 G A 6.34E-07 Orofacial clefts / / 22863734 rs1873149 chr15 63312428 C A 5.83E-07 Orofacial clefts / / 22863734 rs1873147 chr15 63312632 G A 7.04E-07 Orofacial clefts / / 20023658 rs1873147 chr15 63312632 G A 8.00E-07 Orofacial clefts / / 22863734 rs7179658 chr15 63312695 T C 6.54E-07 Orofacial clefts / / 22863734 rs8040022 chr15 63313011 T C 5.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs12440411 chr15 63313581 T G 5.65E-07 Orofacial clefts / / 22863734 rs12443285 chr15 63313596 C T 5.65E-07 Orofacial clefts / / 22863734 rs12443295 chr15 63313666 C T 6.34E-07 Orofacial clefts / / 22863734 rs2130165 chr15 63314519 C T 5.83E-07 Orofacial clefts / / 22863734 rs7176277 chr15 63316183 G A 1.40E-04 Multiple complex diseases / / 17554300 rs6494383 chr15 63316212 G A 4.04E-05 Orofacial clefts / / 22863734 rs1489321 chr15 63318293 A G 5.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs12164904 chr15 63320534 C G 9.38E-04 Alcohol dependence / / 21314694 rs2899687 chr15 63325548 C T 2.46E-05 Orofacial clefts / / 22863734 rs11071718 chr15 63327533 C A 5.21E-04 Orofacial clefts / / 22863734 rs4775607 chr15 63328007 C T 8.35E-05 Blood Pressure / / pha003040 rs3809566 chr15 63333724 A G 4.00E-10 Platelet counts / / 22139419 rs3809566 chr15 63333724 A G 6.00E-04 Platelet counts / / 24026423 rs11071720 chr15 63341996 T C 2.00E-08 Mean platelet volume TPM1 intron 19820697 rs11071720 chr15 63341996 T C 1.90E-08 Mean platelet volume TPM1 intron 22423221 rs6494387 chr15 63345526 A G 2.32E-04 Type 2 diabetes TPM1 intron 22238593 rs1574311 chr15 63346320 G A 1.52E-04 Response to alcohol consumption (flushing response) TPM1 intron 24277619 rs7162932 chr15 63352651 A C 0.000000159 LDL cholesterol TPM1 intron 23063622 rs7162932 chr15 63352651 A C 0.000000592 Cholesterol,total TPM1 intron 23063622 rs11636105 chr15 63371220 G A 8.38E-04 Type 2 diabetes / / 17463246 rs11856845 chr15 63386833 T A 8.76E-04 Multiple complex diseases / / 17554300 rs2652836 chr15 63396301 C T 3.97E-05 Serum metabolites / / 19043545 rs2652834 chr15 63396867 A C,G,T 9.00E-09 HDL cholesterol / / 20686565 rs2652834 chr15 63396867 A C,G,T 4.00E-11 HDL cholesterol / / 24097068 rs2652822 chr15 63422772 T C 7.00E-27 Metabolic traits LACTB intron 21886157 rs1472631 chr15 63423739 A G 2.80E-05 Graves' disease LACTB intron 21841780 rs1472631 chr15 63423739 A G 2.00E-88 Blood metabolite levels LACTB intron 24816252 rs1126308 chr15 63429086 A C 8.00E-04 Acute lymphoblastic leukemia (childhood) LACTB intron 20189245 rs12899931 chr15 63435196 T C 6.79E-05 Graves' disease / / 21841780 rs2729812 chr15 63436628 A C 6.72E-05 Graves' disease / / 21841780 rs7162825 chr15 63439186 C T 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs953978 chr15 63445144 C T 9.22E-05 Graves' disease / / 21841780 rs2270948 chr15 63448780 C G 4.38E-04 Type 2 diabetes RPS27L intron 17463246 rs17828380 chr15 63467887 G C 2.73E-05 Bipolar disorder,affective / / 20528957 rs17828380 chr15 63467887 G C 5.00E-06 Social communication problems / / 24564958 rs8037296 chr15 63516759 A G 2.40E-05 Intelligence RAB8B intron 21826061 rs10519190 chr15 63549064 C T 2.18E-04 Alzheimer's disease RAB8B intron 17998437 rs1017546 chr15 63566702 A C 8.03E-05 Intelligence / / 21826061 rs1017546 chr15 63566702 A C 2.48E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs1017546 chr15 63566702 A C 8.53E-05 HDL cholesterol / / pha003075 rs3784672 chr15 63569017 G T 8.39E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs3784671 chr15 63569184 C A 1.47E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs959125 chr15 63583159 G C 9.56E-04 Suicide attempts in bipolar disorder APH1B intron 21423239 rs2068143 chr15 63588662 G A 7.50E-04 Suicide attempts in bipolar disorder APH1B intron 21423239 rs17762822 chr15 63601379 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1043239 chr15 63618110 A C 1.56E-05 Cognitive impairment induced by topiramate CA12 UTR-3 22091778 rs4984241 chr15 63623463 A G 1.67E-04 Cognitive impairment induced by topiramate CA12 intron 22091778 rs4984241 chr15 63623463 A G 6.18E-05 HDL cholesterol CA12 intron pha003075 rs2046484 chr15 63636878 C T 7.69E-04 Type 2 diabetes CA12 intron 17463246 rs8041909 chr15 63653479 T C 7.41E-04 Response to taxane treatment (placlitaxel) CA12 intron 23006423 rs16946916 chr15 63654787 A G 4.87E-04 Multiple complex diseases CA12 intron 17554300 rs16946922 chr15 63655725 G T 9.72E-04 Multiple complex diseases CA12 intron 17554300 rs6494402 chr15 63656735 A G 1.30E-05 Multiple complex diseases CA12 intron 17554300 rs7162383 chr15 63666420 C A 4.29E-04 Obesity (extreme) CA12 intron 21935397 rs901273 chr15 63677966 A G 6.86E-04 Stroke / / pha002886 rs1002175 chr15 63686327 G A 9.51E-04 Alzheimer's disease / / 24755620 rs2840098 chr15 63687200 A G 4.45E-04 Stroke / / pha002886 rs12911735 chr15 63691103 C T 8.95E-05 Suicide attempts in bipolar disorder / / 21423239 rs2036260 chr15 63691502 A G 6.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10519209 chr15 63713500 C G 7.67E-04 Multiple complex diseases / / 17554300 rs11071744 chr15 63731262 A G 9.30E-04 Multiple complex diseases / / 17554300 rs10519210 chr15 63737925 T G 1.00E-08 Heart failure / / 20445134 rs901271 chr15 63755420 G C 6.56E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4984246 chr15 63758428 G T 7.45E-04 Stroke / / pha002886 rs4984247 chr15 63758647 C T 3.72E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs4984247 chr15 63758647 C T 8.79E-04 Stroke / / pha002886 rs751940 chr15 63764505 T C 3.51E-04 Gallstones / / 17632509 rs17184382 chr15 63792486 A C 1.20E-05 Osteoarthritis (knee and hip) / / 21177295 rs17184382 chr15 63792486 A C 1.31E-05 Osteoarthritis (knee and hip) / / 21177295 rs17184382 chr15 63792486 A C 2.10E-04 Osteoarthritis (knee and hip) / / 21177295 rs12915297 chr15 63804555 T C 5.23E-06 Osteoarthritis USP3 intron 21871595 rs2414822 chr15 63812484 A T 2.47E-04 Multiple complex diseases USP3 intron 17554300 rs2058914 chr15 63831984 G A 5.44E-04 Aortic root size USP3 intron 21223598 rs8023466 chr15 63841675 G A 8.94E-05 Multiple complex diseases USP3 intron 17554300 rs3751043 chr15 63848805 C G 2.52E-04 Urate levels USP3 intron 23263486 rs7178762 chr15 63871292 C T 2.12E-04 Osteoarthritis (knee and hip) USP3 intron 21177295 rs7178762 chr15 63871292 C T 2.28E-04 Osteoarthritis (knee and hip) USP3 intron 21177295 rs7178762 chr15 63871292 C T 6.98E-05 Osteoarthritis (knee and hip) USP3 intron 21177295 rs12101373 chr15 63880752 C T 3.75E-06 Glycemic traits (pregnancy) USP3 intron 23903356 rs2649 chr15 63886593 C T 5.34E-04 Multiple complex diseases USP3 UTR-3 17554300 rs2649 chr15 63886593 C T 1.00E-04 Lymphocyte counts USP3 UTR-3 22286170 rs4247077 chr15 63890989 T C 9.29E-08 Metabolite levels FBXL22 intron 23281178 rs57017013 chr15 63891961 G A 2.00E-06 QRS duration in Tripanosoma cruzi seropositivity FBXL22 intron 24324551 rs8024070 chr15 63900519 T C 9.29E-08 Metabolite levels / / 23281178 rs4984252 chr15 63901646 G A 9.29E-08 Metabolite levels HERC1 intron 23281178 rs4283174 chr15 63905543 A G 9.29E-08 Metabolite levels HERC1 intron 23281178 rs4523879 chr15 63915379 G A 8.63E-08 Metabolite levels HERC1 intron 23281178 rs11630290 chr15 63915786 C T 1.00E-06 Iris characteristics HERC1 intron 21835309 rs17186555 chr15 63981327 C T 3.72E-04 Type 2 diabetes HERC1 intron 17463246 rs17186681 chr15 63988765 A T 5.27E-04 Type 2 diabetes HERC1 intron 17463246 rs10519220 chr15 64047120 T C 1.44E-04 Multiple complex diseases HERC1 intron 17554300 rs10519220 chr15 64047120 T C 7.10E-06 Urinary metabolites HERC1 intron 21572414 rs13379670 chr15 64068284 T C 8.29E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) HERC1 intron 24023788 rs11631544 chr15 64098557 T C 2.10E-05 Urinary metabolites HERC1 intron 21572414 rs17774993 chr15 64143361 C T 9.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs7180823 chr15 64150869 T G 1.51E-05 Osteoarthritis (knee and hip) / / 21177295 rs7180823 chr15 64150869 T G 3.72E-05 Osteoarthritis (knee and hip) / / 21177295 rs7180823 chr15 64150869 T G 9.32E-06 Osteoarthritis (knee and hip) / / 21177295 rs11071767 chr15 64154635 G A 6.56E-04 Multiple complex diseases / / 17554300 rs33942564 chr15 64167098 G GA,GT,GTA 5.56E-06 Osteoarthritis / / 21871595 rs34675318 chr15 64167098 G A 5.56E-06 Osteoarthritis / / 21871595 rs9806191 chr15 64238156 T C 3.00E-04 Multiple complex diseases DAPK2 intron 17554300 rs332289 chr15 64308369 C G 5.59E-04 Body mass index DAPK2 intron 21701565 rs184556 chr15 64313155 G C 4.47E-04 Multiple complex diseases DAPK2 intron 17554300 rs922177 chr15 64317620 C T 2.50E-04 Intelligence (childhood) DAPK2 intron 23358156 rs427789 chr15 64327492 T C 1.57E-04 Multiple complex diseases DAPK2 intron 17554300 rs395764 chr15 64330229 C T 2.12E-04 Multiple complex diseases DAPK2 intron 17554300 rs433902 chr15 64330541 T C 3.98E-04 Multiple complex diseases DAPK2 intron 17554300 rs11629676 chr15 64339939 C T 5.58E-04 Type 2 diabetes / / 17463246 rs7176404 chr15 64376238 C G 8.82E-04 Type 2 diabetes FAM96A intron 17463246 rs7164156 chr15 64439567 A G 9.49E-04 Type 2 diabetes / / 17463246 rs3743110 chr15 64462463 A G 3.45E-04 Multiple complex diseases CSNK1G1 UTR-3 17554300 rs16947844 chr15 64541781 C A 9.74E-04 Multiple complex diseases CSNK1G1 intron 17554300 rs3848147 chr15 64636754 G A 5.70E-05 HIV-1 control CSNK1G1 intron 20041166 rs10152936 chr15 64656242 T C 5.70E-05 HIV-1 control / / 20041166 rs7174731 chr15 64690772 A G 2.03E-04 Multiple complex diseases TRIP4 intron 17554300 rs74615166 chr15 64725490 T C 4.00E-07 Alzheimer's disease (late onset) TRIP4 intron 24162737 rs151216141 chr15 64792042 G T 0.000046 Breast cancer ZNF609 missense 23555315 rs2899699 chr15 64912919 G T 8.27E-05 Alcohol consumption ZNF609 intron 23953852 rs2414852 chr15 64936786 G C 6.74E-05 Multiple complex diseases ZNF609 intron 17554300 rs6494488 chr15 65024204 G A 0.00000196 Coronary artery disease / / 23202125 rs7176023 chr15 65101007 T C 2.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11631663 chr15 65117647 T C 8.80E-06 Urinary metabolites PIF1 intron 21572414 rs12595292 chr15 65153690 G A 9.00E-06 Coronary heart disease PLEKHO2 cds-synon 21347282 rs832891 chr15 65167333 A T 9.23E-27 Lymphocyte counts / / 22286170 rs1719271 chr15 65183801 A G 1.00E-11 Platelet counts / / 22139419 rs1719271 chr15 65183801 A G 1.00E-04 Platelet counts / / 24026423 rs8024697 chr15 65307488 G T 3.41E-05 Serum metabolites MTFMT intron 19043545 rs188718836 chr15 65321780 A T 0.00052 Prostate cancer MTFMT missense 23555315 rs2414869 chr15 65322866 T C 2.05E-04 Multiple complex diseases MTFMT nearGene-5 17554300 rs2946653 chr15 65331767 G T 2.35E-04 Multiple complex diseases / / 17554300 rs10851744 chr15 65340426 C T 6.60E-04 Multiple complex diseases OSTBETA intron 17554300 rs7178791 chr15 65354844 T C 4.47E-09 Multiple complex diseases RASL12 intron 17554300 rs7171610 chr15 65440092 T A 2.80E-05 Urinary metabolites / / 21572414 rs2679120 chr15 65497396 C G 4.03E-09 Narcolepsy CILP intron 19629137 rs8027881 chr15 65523681 C G 1.62E-25 Narcolepsy / / 19629137 rs79732200 chr15 65654908 G A 8.73E-08 Personality dimensions IGDCC3 intron 23658558 rs12442757 chr15 65689267 T C 6.40E-04 Birth weight IGDCC4 missense 17255346 rs736923 chr15 65695943 A G 4.61E-07 Red blood cell traits IGDCC4 intron 23222517 rs591980 chr15 65695983 G A 2.82E-07 Red blood cell traits IGDCC4 intron 23222517 rs3928450 chr15 65700445 C A 5.80E-07 Red blood cell traits IGDCC4 intron 23222517 rs7171289 chr15 65706569 C T 9.56E-07 Red blood cell traits IGDCC4 intron 23222517 rs2289045 chr15 65714746 G T 9.57E-07 Red blood cell traits IGDCC4 intron 23222517 rs652931 chr15 65718997 T C 1.38E-08 Red blood cell traits / / 23222517 rs662099 chr15 65726693 G A 1.18E-08 Red blood cell traits / / 23222517 rs12904090 chr15 65728008 A G 5.37E-07 Red blood cell traits / / 23222517 rs600193 chr15 65729409 C T 5.40E-05 Lymphocyte counts / / 22286170 rs688223 chr15 65731740 T C 6.77E-07 Red blood cell traits / / 23222517 rs11455 chr15 65737946 A G 2.76E-07 Red blood cell traits / / 23222517 rs8023716 chr15 65744861 G C 7.86E-08 Red blood cell traits DPP8 intron 23222517 rs352457 chr15 65777205 G A 1.82E-05 Breast cancer (survival) DPP8 intron 20332263 rs409987 chr15 65779783 G A 1.29E-04 Glycosylated haemoglobin levels DPP8 intron 17255346 rs3784448 chr15 65800856 C T 2.28E-07 Red blood cell traits DPP8 intron 23222517 rs352479 chr15 65803428 C A 4.72E-07 Red blood cell traits DPP8 intron 23222517 rs9635366 chr15 65804986 G A 2.14E-07 Red blood cell traits DPP8 intron 23222517 rs352476 chr15 65805389 T C 0.00000001 Mean corpuscular hemoglobin DPP8 intron 22560525 rs352476 chr15 65805389 T C 5.65E-07 Red blood cell traits DPP8 intron 23222517 rs2456015 chr15 65830518 C T 5.28E-05 Hypertension PTPLAD1 intron 22384028 rs2456009 chr15 65840082 C A 0.00000001 Mean corpuscular hemoglobin PTPLAD1 intron 22560525 rs12333 chr15 65869272 C T 4.98E-05 Hypertension PTPLAD1 UTR-3 22384028 rs11632310 chr15 65882326 G C,T 2.84E-08 Red blood cell traits C15orf44 intron 23222517 rs12906196 chr15 65884888 T C 2.97E-08 Red blood cell traits C15orf44 intron 23222517 rs6494529 chr15 65902922 G A 5.93E-08 Red blood cell traits C15orf44 intron 23222517 rs4366668 chr15 65903398 G A 5.34E-08 Red blood cell traits C15orf44 UTR-5 23222517 rs7178686 chr15 65911228 G C 5.33E-08 Red blood cell traits / / 23222517 rs870022 chr15 65914758 C T 4.76E-05 Height SLC24A1 intron 22021425 rs870022 chr15 65914758 C T 5.64E-07 Red blood cell traits SLC24A1 intron 23222517 rs3743171 chr15 65916527 A T 4.69E-05 Height SLC24A1 missense 22021425 rs3743171 chr15 65916527 A T 5.62E-07 Red blood cell traits SLC24A1 missense 23222517 rs8035639 chr15 65944548 C T 0.000000008 Mean corpuscular hemoglobin SLC24A1 intron 22560525 rs8030562 chr15 65958942 T C 3.77E-08 Red blood cell traits DENND4A intron 23222517 rs8029478 chr15 65973494 C T 3.70E-07 Red blood cell traits DENND4A intron 23222517 rs8028238 chr15 65980007 C T 6.89E-07 Red blood cell traits DENND4A intron 23222517 rs11071848 chr15 65989359 T C 7.90E-07 Red blood cell traits DENND4A intron 23222517 rs2899709 chr15 65991828 C T 7.23E-07 Red blood cell traits DENND4A intron 23222517 rs17810074 chr15 65994733 C T 2.21E-04 Response to cytadine analogues (cytosine arabinoside) DENND4A cds-synon 24483146 rs16948959 chr15 65995082 C G 7.13E-07 Red blood cell traits DENND4A intron 23222517 rs7176565 chr15 65998702 T C 7.60E-05 Electrocardiographic conduction measures DENND4A intron 19389651 rs7176565 chr15 65998702 T C 2.48E-07 Red blood cell traits DENND4A intron 23222517 rs7178242 chr15 66001431 C T 3.89E-07 Red blood cell traits DENND4A intron 23222517 rs2060454 chr15 66010379 C T 3.76E-07 Red blood cell traits DENND4A intron 23222517 rs12592786 chr15 66010917 C G 6.70E-07 Red blood cell traits DENND4A intron 23222517 rs7167740 chr15 66030800 A C 8.95E-07 Red blood cell traits DENND4A intron 23222517 rs4553574 chr15 66035672 T C 9.83E-07 Red blood cell traits DENND4A intron 23222517 rs7180542 chr15 66040030 C T 1.33E-07 Red blood cell traits DENND4A intron 23222517 rs10431806 chr15 66042655 C T 2.70E-07 Red blood cell traits DENND4A intron 23222517 rs10431765 chr15 66044551 G A 3.47E-07 Red blood cell traits DENND4A intron 23222517 rs8182006 chr15 66046111 T C 9.45E-07 Red blood cell traits DENND4A intron 23222517 rs12899850 chr15 66051299 C T 2.95E-07 Red blood cell traits DENND4A intron 23222517 rs6494537 chr15 66051345 C T 2.88E-09 Blood cell counts and other traits DENND4A intron 20139978 rs6494537 chr15 66051345 C T 3.00E-09 Blood cell counts and other traits DENND4A intron 20139978 rs6494537 chr15 66051345 C T 0.00000002 Mean corpuscular hemoglobin DENND4A intron 22560525 rs9920201 chr15 66055215 G A 9.63E-07 Red blood cell traits DENND4A intron 23222517 rs9920210 chr15 66055456 C G 3.61E-07 Red blood cell traits DENND4A intron 23222517 rs2727098 chr15 66062244 T C 4.39E-07 Red blood cell traits DENND4A intron 23222517 rs2572218 chr15 66063312 G A 9.03E-07 Red blood cell traits DENND4A intron 23222517 rs2727100 chr15 66063531 G A 8.70E-07 Red blood cell traits DENND4A intron 23222517 rs2033611 chr15 66066025 C T 2.60E-07 Red blood cell traits DENND4A intron 23222517 rs2572207 chr15 66070693 C T 3.00E-09 Red blood cell traits DENND4A intron 23222517 rs2572209 chr15 66073293 C T 9.88E-08 Red blood cell traits DENND4A intron 23222517 rs12916843 chr15 66078738 C T 6.16E-07 Red blood cell traits DENND4A intron 23222517 rs2660628 chr15 66108647 G A 4.53E-07 Red blood cell traits / / 23222517 rs2727089 chr15 66114855 T C 4.33E-07 Red blood cell traits / / 23222517 rs12594238 chr15 66159227 T C 3.00E-06 Asthma / / 24406073 rs333542 chr15 66205594 G A 1.30E-05 Body Mass Index MEGF11 intron pha003006 rs3803414 chr15 66206204 G A 3.40E-05 Major depression (suicidal thoughts and behavior) MEGF11 missense 21750702 rs16949145 chr15 66250525 A G 2.02E-04 Type 2 diabetes MEGF11 intron 17463246 rs333557 chr15 66263374 C T 4.27E-05 Alzheimer's disease MEGF11 intron 17998437 rs333562 chr15 66264207 T C 5.64E-04 Multiple complex diseases MEGF11 intron 17554300 rs11071854 chr15 66275951 A G 7.28E-04 Alzheimer's disease MEGF11 intron 17998437 rs11638943 chr15 66275967 G C 5.49E-04 Alzheimer's disease MEGF11 intron 17998437 rs2552176 chr15 66299460 G A 5.62E-04 Myocardial Infarction MEGF11 intron pha002873 rs12592821 chr15 66309124 G A 4.34E-05 Coronary heart disease MEGF11 intron pha003031 rs333583 chr15 66322702 G T 1.93E-05 Cognitive performance MEGF11 intron 19734545 rs3852627 chr15 66339349 C T 9.86E-04 Multiple complex diseases MEGF11 intron 17554300 rs9783681 chr15 66359486 T G 4.95E-05 Body Fat Distribution MEGF11 intron pha003017 rs16949434 chr15 66384354 T G 1.83E-05 Cholesterol MEGF11 intron pha003073 rs16949434 chr15 66384354 T G 3.00E-05 Cholesterol MEGF11 intron pha003078 rs6494552 chr15 66397022 A G 3.40E-04 Alzheimer's disease MEGF11 intron 17998437 rs1477795 chr15 66398302 A G 6.25E-05 Femoral neck bone geometry MEGF11 intron 22087292 rs4776735 chr15 66412230 T C 3.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MEGF11 intron 20877124 rs8039023 chr15 66420236 G T 9.29E-05 Alzheimer's disease MEGF11 intron 24755620 rs4776281 chr15 66432800 T C 1.43E-04 Myopia (pathological) MEGF11 intron 21095009 rs10518678 chr15 66432949 C T 3.89E-05 Myopia (pathological) MEGF11 intron 21095009 rs1477800 chr15 66446915 C T 4.90E-04 Iron levels MEGF11 intron pha002876 rs16949647 chr15 66488987 G T 1.20E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) MEGF11 intron 24023788 rs11634401 chr15 66498409 G A 2.60E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) MEGF11 intron 24023788 rs2086036 chr15 66498862 C A 3.70E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) MEGF11 intron 24023788 rs11635207 chr15 66504224 A G 6.30E-07 Urinary metabolites MEGF11 intron 21572414 rs4776292 chr15 66513813 T C 1.30E-04 Myasthenia gravis MEGF11 intron 23055271 rs16949724 chr15 66530732 G A 6.96E-05 Lymphocyte counts MEGF11 intron 22286170 rs7175451 chr15 66549703 A T 7.56E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6494560 chr15 66557277 A C 4.86E-05 Body Mass Index / / pha003007 rs6494560 chr15 66557277 A C 4.92E-06 Body Mass Index / / pha003015 rs6494560 chr15 66557277 A C 4.80E-05 Waist Circumference / / pha003025 rs7170930 chr15 66580853 C T 5.00E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6494562 chr15 66600629 C T 1.19E-04 HIV-1 viral setpoint DIS3L intron 21490045 rs6494562 chr15 66600629 C T 9.58E-05 Age-related macular degeneration DIS3L intron pha002890 rs11071884 chr15 66602054 C T 0.00009788 Sarcoidosis DIS3L intron 22952805 rs12906737 chr15 66612386 C T 0.00009679 Sarcoidosis DIS3L intron 22952805 rs72748369 chr15 66617180 C G 0.00008649 Sarcoidosis DIS3L intron 22952805 rs11632094 chr15 66620971 T C 0.00008705 Sarcoidosis DIS3L intron 22952805 rs35125899 chr15 66623230 C T 0.00008252 Sarcoidosis DIS3L intron 22952805 rs11071885 chr15 66625161 A G 2.08E-04 Smoking cessation DIS3L cds-synon 24665060 rs3759786 chr15 66629403 C A 0.00007214 Sarcoidosis TIPIN missense 22952805 rs4776779 chr15 66635669 C T 0.00007857 Sarcoidosis TIPIN intron 22952805 rs35387474 chr15 66638578 G A 0.00007857 Sarcoidosis TIPIN intron 22952805 rs11857363 chr15 66645939 C A 0.00007857 Sarcoidosis TIPIN intron 22952805 rs12914613 chr15 66647347 C T 0.00007857 Sarcoidosis TIPIN intron 22952805 rs12912375 chr15 66659184 C T 0.00008084 Sarcoidosis / / 22952805 rs4776783 chr15 66662107 A G 0.00007711 Sarcoidosis / / 22952805 rs17258785 chr15 66662359 T C 0.00007711 Sarcoidosis / / 22952805 rs8027432 chr15 66662696 C T 0.00007711 Sarcoidosis / / 22952805 rs141724971 chr15 66664087 C T 0.00007711 Sarcoidosis / / 22952805 rs8024529 chr15 66665860 A T 0.00008084 Sarcoidosis / / 22952805 rs34514523 chr15 66668607 C T 0.00008084 Sarcoidosis / / 22952805 rs139721172 chr15 66673364 T C 0.00008084 Sarcoidosis / / 22952805 rs67930309 chr15 66677332 A C 0.00007711 Sarcoidosis / / 22952805 rs11631295 chr15 66678991 A T 0.00008084 Sarcoidosis / / 22952805 rs11854215 chr15 66685295 C T 0.00007711 Sarcoidosis MAP2K1 intron 22952805 rs61027991 chr15 66688024 C T 0.00007711 Sarcoidosis MAP2K1 intron 22952805 rs34957511 chr15 66702266 C T 0.00007557 Sarcoidosis MAP2K1 intron 22952805 rs12909274 chr15 66706505 G A 0.00007922 Sarcoidosis MAP2K1 intron 22952805 rs11633875 chr15 66707134 T C 0.00007799 Sarcoidosis MAP2K1 intron 22952805 rs540311027 chr15 66707134 T TC 0.00007799 Sarcoidosis MAP2K1 intron 22952805 rs11636482 chr15 66721275 G A 0.00007557 Sarcoidosis MAP2K1 intron 22952805 rs11632225 chr15 66725345 G A 0.00007965 Sarcoidosis MAP2K1 intron 22952805 rs11852769 chr15 66736500 C T 0.00009913 Sarcoidosis MAP2K1 intron 22952805 rs17201047 chr15 66739670 A G 0.00009913 Sarcoidosis MAP2K1 intron 22952805 rs8684 chr15 66783610 G A 5.35E-05 Age-related macular degeneration MAP2K1 UTR-3 pha002890 rs7164579 chr15 66842009 G A 8.98E-04 Suicide attempts in bipolar disorder LCTL intron 21423239 rs8027997 chr15 66867547 C T 1.79E-05 Coronary restenosis / / 21878436 rs2439367 chr15 66875837 C T 1.40E-04 Multiple complex diseases / / 17554300 rs4776800 chr15 66882008 T C 4.58E-04 Multiple complex diseases / / 17554300 rs2439353 chr15 66890484 C G 2.06E-04 Alcohol dependence / / 21314694 rs893912 chr15 66928469 C T 3.50E-04 Type 2 diabetes / / 17846124 rs7359178 chr15 66981329 C T 2.27E-05 Prostate cancer / / 22923026 rs2053424 chr15 66990232 T G 1.50E-05 Graves' disease / / 21841780 rs17264185 chr15 66997087 A G 2.86E-05 Serum metabolites SMAD6 intron 19043545 rs2439397 chr15 67013821 G A 9.00E-06 Prostate cancer SMAD6 intron 21743057 rs2439391 chr15 67019313 A C 3.00E-05 Prostate cancer SMAD6 intron 21743057 rs2053423 chr15 67026217 C T 5.86E-05 Colorectal cancer SMAD6 intron 24737748 rs11858577 chr15 67066563 C T 9.00E-06 Subcutaneous adipose tissue SMAD6 intron 22589738 rs12441020 chr15 67089931 T G 9.45E-04 Depression (quantitative trait) / / 20800221 rs8026949 chr15 67129412 A T 5.48E-05 Serum metabolites / / 19043545 rs2414925 chr15 67129986 A G 2.80E-05 Urinary metabolites / / 21572414 rs16950284 chr15 67154184 C T 9.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4589502 chr15 67155069 C T 9.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4589502 chr15 67155069 C T 4.00E-06 Lung cancer (smoking interaction) / / 24658283 rs17273637 chr15 67193084 C T 0.0003013 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17273637 chr15 67193084 C T 3.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2169460 chr15 67197240 A G 4.00E-05 Response to statin therapy / / 20339536 rs2169460 chr15 67197240 A G 5.50E-06 Urinary metabolites / / 21572414 rs2708291 chr15 67197785 T C 6.64E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs266331 chr15 67198505 T C 1.35E-05 Multiple complex diseases / / 17554300 rs266362 chr15 67217815 A C 3.24E-04 Multiple complex diseases / / 17554300 rs1965269 chr15 67218945 A G 0.0003067 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1965269 chr15 67218945 A G 3.07E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17208967 chr15 67225594 T C 3.52E-06 Telomere length / / 23001564 rs7183187 chr15 67234340 G A 6.11E-06 Waist Circumference / / pha003023 rs266300 chr15 67241653 T C 6.25E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs7179528 chr15 67245807 C T 1.57E-06 Waist Circumference / / pha003023 rs266293 chr15 67247554 T C 7.70E-04 Multiple complex diseases / / 17554300 rs7169592 chr15 67247678 C A 5.58E-07 Waist Circumference / / pha003023 rs7169633 chr15 67247802 A C 6.12E-05 Waist Circumference / / pha003023 rs412689 chr15 67256027 A G 7.69E-05 Monocyte chemoattractant protein-1 / / pha003071 rs11071927 chr15 67261172 C A 1.00E-06 Smoking behavior / / 20418888 rs12906930 chr15 67299194 G A 4.97E-04 Alzheimer's disease (late onset) / / 21379329 rs4776870 chr15 67301687 G A 2.30E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7178347 chr15 67321386 T C 9.39E-04 Multiple complex diseases / / 17554300 rs266339 chr15 67326140 T C 1.26E-05 Osteoarthritis (knee and hip) / / 21177295 rs266339 chr15 67326140 T C 8.66E-05 Osteoarthritis (knee and hip) / / 21177295 rs266347 chr15 67331311 A G 5.70E-05 Cognitive impairment induced by topiramate / / 22091778 rs12911494 chr15 67341810 C T 9.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs266335 chr15 67344732 G A 2.40E-05 Urinary metabolites / / 21572414 rs4776338 chr15 67359883 T C 4.34E-04 Response to taxane treatment (placlitaxel) SMAD3 intron 23006423 rs7162912 chr15 67361308 T G 3.53E-04 Response to taxane treatment (placlitaxel) SMAD3 intron 23006423 rs12904944 chr15 67361774 G A 8.24E-04 Response to taxane treatment (placlitaxel) SMAD3 intron 23006423 rs10518705 chr15 67363283 T G 8.08E-04 Response to taxane treatment (placlitaxel) SMAD3 intron 23006423 rs10518707 chr15 67365622 A G 6.79E-04 Response to taxane treatment (placlitaxel) SMAD3 intron 23006423 rs12901499 chr15 67370445 G A 7.82E-04 Response to taxane treatment (placlitaxel) SMAD3 intron 23006423 rs2053295 chr15 67391739 G A 3.32E-05 Blood Pressure SMAD3 intron pha003040 rs6494632 chr15 67394294 A G 3.91E-04 Multiple complex diseases SMAD3 intron 17554300 rs12916733 chr15 67394384 C T 5.28E-05 Coronary Artery Disease SMAD3 intron 17634449 rs2053294 chr15 67399084 G A 4.68E-05 Blood Pressure SMAD3 intron pha003040 rs11637581 chr15 67412049 C T 7.21E-04 Multiple complex diseases SMAD3 intron 17554300 rs16950615 chr15 67416752 C G 7.27E-04 Obesity (extreme) SMAD3 intron 21935397 rs16950635 chr15 67418205 G A 7.68E-04 Obesity (extreme) SMAD3 UTR-5 21935397 rs12102171 chr15 67425033 C T 3.99E-05 Systemic sclerosis SMAD3 intron 21750679 rs4147358 chr15 67428014 C A 1.65E-05 Systemic sclerosis SMAD3 intron 21750679 rs10518714 chr15 67432161 A C 2.74E-04 Type 2 diabetes SMAD3 intron 17846124 rs17293443 chr15 67437863 T C 2.54E-05 Self-reported allergy SMAD3 intron 23817569 rs893473 chr15 67438091 A G 2.00E-04 Polycystic ovary syndrome SMAD3 intron 22178785 rs17227716 chr15 67438563 T G 8.48E-04 Multiple complex diseases SMAD3 intron 17554300 rs2289263 chr15 67439207 T G 7.84E-06 Heart Rate SMAD3 intron pha003053 rs2033785 chr15 67441866 C G 2.90E-04 Pulmonary function SMAD3 intron 23932459 rs1866316 chr15 67441997 T C 1.64E-07 Self-reported allergy SMAD3 intron 23817569 rs17293632 chr15 67442596 C T 3.00E-19 Crohn's disease SMAD3 intron 21102463 rs17293632 chr15 67442596 C T 6.00E-16 Inflammatory bowel disease SMAD3 intron 23128233 rs17293632 chr15 67442596 C T 1.49E-08 Self-reported allergy SMAD3 intron 23817569 rs10152544 chr15 67444747 C T 3.34E-06 Self-reported allergy SMAD3 intron 23817569 rs744910 chr15 67446785 G A 4.08E-06 Multiple complex diseases SMAD3 intron 17554300 rs744910 chr15 67446785 G A 4.05E-04 Coronary Artery Disease SMAD3 intron 17634449 rs744910 chr15 67446785 G A 4.00E-09 Asthma SMAD3 intron 20860503 rs744910 chr15 67446785 G A 3.90E-09 Asthma SMAD3 intron 21907864 rs744910 chr15 67446785 G A 5.22E-04 Taste perception SMAD3 intron 22132133 rs744910 chr15 67446785 G A 3.90E-09 Asthma SMAD3 intron 22561531 rs744910 chr15 67446785 G A 4.15E-06 Self-reported allergy SMAD3 intron 23817569 rs530339372 chr15 67446831 G GTA 1.57E-05 Height SMAD3 intron pha003011 rs530339372 chr15 67446831 G GTA 7.02E-05 Heart Rate SMAD3 intron pha003053 rs731874 chr15 67446831 G A 1.57E-05 Height SMAD3 intron pha003011 rs731874 chr15 67446831 G A 7.02E-05 Heart Rate SMAD3 intron pha003053 rs11634793 chr15 67447452 C T 3.99E-06 Self-reported allergy SMAD3 intron 23817569 rs8032739 chr15 67448899 A G 2.24E-07 Self-reported allergy SMAD3 intron 23817569 rs2033784 chr15 67449660 A G 1.66E-07 Self-reported allergy SMAD3 intron 23817569 rs17228058 chr15 67450305 A G 1.00E-08 Self-reported allergy SMAD3 intron 23817569 rs7173698 chr15 67450893 A G 3.01E-07 Self-reported allergy SMAD3 intron 23817569 rs1470004 chr15 67450909 A G 3.03E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SMAD3 intron 21844884 rs7174445 chr15 67451215 C G 5.98E-07 Self-reported allergy SMAD3 intron 23817569 rs35874463 chr15 67457698 A G 1.60E-08 Height SMAD3 missense 21194676 rs35874463 chr15 67457698 A G 1.70E-04 Height SMAD3 missense 21194676 rs35874463 chr15 67457698 A G 3.40E-13 Height SMAD3 missense 21194676 rs4562997 chr15 67458152 G A 3.32E-07 Self-reported allergy SMAD3 intron 23817569 rs17228212 chr15 67458639 T C 1.82E-06 Multiple complex diseases SMAD3 intron 17554300 rs17228212 chr15 67458639 T C 2.00E-07 Coronary heart disease SMAD3 intron 17634449 rs17228212 chr15 67458639 T C 2.00E-07 Coronary heart disease SMAD3 intron 21347282 rs7183244 chr15 67461311 T C 1.89E-05 Heart Rate SMAD3 intron pha003053 rs16950687 chr15 67464013 A G 7.65E-08 Self-reported allergy SMAD3 intron 23817569 rs4776344 chr15 67465363 G A 5.84E-05 Alzheimer's disease (late onset) SMAD3 intron 21379329 rs2278546 chr15 67466602 A G 1.39E-07 Self-reported allergy SMAD3 intron 23817569 rs12913547 chr15 67467507 T C 5.00E-10 Corneal structure SMAD3 intron 23291589 rs12708492 chr15 67467541 T C 8.12E-06 Asthma SMAD3 intron 20860503 rs12708492 chr15 67467541 T C 1.73E-05 Self-reported allergy SMAD3 intron 23817569 rs17294280 chr15 67468285 A G 3.58E-07 Self-reported allergy SMAD3 intron 23817569 rs17294280 chr15 67468285 A G 4.00E-09 Asthma and hay fever SMAD3 intron 24388013 rs7181556 chr15 67476768 C T 4.80E-07 Corneal structure SMAD3 intron 23291589 rs12900401 chr15 67486590 C T 5.34E-04 Multiple complex diseases SMAD3 UTR-3 17554300 rs7176940 chr15 67549850 G A 1.40E-05 Urinary metabolites IQCH intron 21572414 rs2414945 chr15 67567568 T C 1.40E-05 Urinary metabolites IQCH intron 21572414 rs7161879 chr15 67574440 C G 1.20E-05 Urinary metabolites IQCH intron 21572414 rs8038166 chr15 67603014 T C 1.10E-05 Urinary metabolites IQCH intron 21572414 rs12440869 chr15 67610951 A T 1.60E-05 Urinary metabolites IQCH intron 21572414 rs7163460 chr15 67611218 G A 1.40E-05 Urinary metabolites IQCH intron 21572414 rs7183186 chr15 67614092 T C 1.40E-05 Urinary metabolites IQCH intron 21572414 rs7178975 chr15 67617401 A C 1.40E-05 Urinary metabolites IQCH intron 21572414 rs8025186 chr15 67641554 G A 1.20E-05 Urinary metabolites IQCH intron 21572414 rs8030142 chr15 67649438 C G 1.40E-05 Urinary metabolites IQCH intron 21572414 rs8028934 chr15 67663284 A G 2.30E-05 Urinary metabolites IQCH intron 21572414 rs8040095 chr15 67695117 C T 4.06E-04 Multiple complex diseases IQCH intron 17554300 rs7359257 chr15 67702907 A C 2.00E-06 Menarche (age at onset) IQCH intron 21102462 rs10518723 chr15 67723614 T C 9.50E-04 Bipolar disorder IQCH intron 19259986 rs17232873 chr15 67769907 C G 3.11E-04 Type 2 diabetes IQCH intron 17463246 rs72747452 chr15 67809990 G A 0.000023 Menopause (age at onset) LOC100506686 intron 23424626 rs2414975 chr15 67971949 A T 1.34E-04 Multiple complex diseases MAP2K5 intron 17554300 rs2414976 chr15 67972988 T C 4.96E-04 Multiple complex diseases MAP2K5 intron 17554300 rs8042567 chr15 67975599 G A 9.52E-04 Response to cytidine analogues (gemcitabine) MAP2K5 intron 24483146 rs72751410 chr15 67988586 A G 0.000023 Menopause (age at onset) MAP2K5 intron 23424626 rs997295 chr15 68016343 G T 0.0000055 Body mass index (males) MAP2K5 intron 23001569 rs997295 chr15 68016343 G T 1.43E-08 Body mass index MAP2K5 intron 23001569 rs12593813 chr15 68036852 A G 1.00E-15 Restless legs syndrome MAP2K5 intron 17637780 rs12593813 chr15 68036852 A G 1.00E-22 Restless legs syndrome MAP2K5 intron 21779176 rs11635424 chr15 68037578 A G 3.65E-16 Restless legs syndrome MAP2K5 intron 17637780 rs8028313 chr15 68043057 C G 1.00E-11 Obesity MAP2K5 intron 23563607 rs8028313 chr15 68043057 C G 6.00E-13 Obesity MAP2K5 intron 23563607 rs884202 chr15 68054388 G A 1.17E-05 Restless legs syndrome MAP2K5 intron 17637780 rs868037 chr15 68054996 A G 2.11E-04 Type 2 diabetes MAP2K5 intron 17463246 rs11071959 chr15 68058903 A G 9.89E-06 F-cell distribution MAP2K5 intron 21326311 rs745213 chr15 68060389 T G 8.65E-05 Orofacial clefts MAP2K5 intron 20023658 rs4489954 chr15 68072075 T G 9.10E-04 Type 2 diabetes MAP2K5 intron 17463246 rs4489954 chr15 68072075 T G 2.68E-15 Restless legs syndrome MAP2K5 intron 17637780 rs3784709 chr15 68072275 C T 3.83E-04 Type 2 diabetes MAP2K5 intron 17463246 rs3784709 chr15 68072275 C T 4.06E-16 Restless legs syndrome MAP2K5 intron 17637780 rs12902904 chr15 68076533 G A 7.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP2K5 intron 20877124 rs4776970 chr15 68080886 A T 2.00E-09 Body mass index MAP2K5 intron 22344219 rs4776970 chr15 68080886 A T 3.00E-07 Body mass index MAP2K5 intron 24861553 rs2241423 chr15 68086838 G A 1.00E-18 Body mass index MAP2K5 intron 20935630 rs2241423 chr15 68086838 G A 6.02E-07 Body mass index MAP2K5 intron 22344219 rs2241423 chr15 68086838 G A 1.19E-18 Body mass index MAP2K5 intron 23001569 rs11856999 chr15 68090700 C T 6.34E-05 Orofacial clefts MAP2K5 intron 22419666 rs1026732 chr15 68095085 G A 3.77E-04 Type 2 diabetes MAP2K5 intron 17463246 rs1026732 chr15 68095085 G A 6.09E-17 Restless legs syndrome MAP2K5 intron 17637780 rs6494696 chr15 68103206 G C 4.70E-04 Type 2 diabetes / / 17463246 rs6494696 chr15 68103206 G C 2.00E-16 Restless legs syndrome / / 17637780 rs12898654 chr15 68128117 C G 5.93E-04 Type 2 diabetes / / 17463246 rs12898654 chr15 68128117 C G 4.37E-06 Diabetes (gestational) / / 22233651 rs16951344 chr15 68137843 T G 3.45E-05 Blood Pressure / / pha003045 rs16951344 chr15 68137843 T G 2.03E-05 Blood Pressure / / pha003047 rs4776991 chr15 68140162 G A 1.34E-05 Blood Pressure / / pha003045 rs4776991 chr15 68140162 G A 6.50E-06 Blood Pressure / / pha003047 rs4254278 chr15 68148862 T C 4.04E-05 Multiple complex diseases / / 17554300 rs28573814 chr15 68152198 G A 2.10E-05 Urinary metabolites / / 21572414 rs4776381 chr15 68155710 A G 1.54E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs4776381 chr15 68155710 A G 4.92E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs4306451 chr15 68157881 A G 4.90E-05 Cognitive test performance / / 20125193 rs11071966 chr15 68163774 G A 8.12E-05 Cognitive test performance / / 20125193 rs387325 chr15 68166930 T C 2.57E-05 Cognitive test performance / / 20125193 rs450466 chr15 68198523 C T 7.40E-06 Cognitive test performance / / 20125193 rs430610 chr15 68198622 G A 5.21E-06 Cognitive test performance / / 20125193 rs448720 chr15 68198911 C T 5.00E-06 Cognitive performance / / 20125193 rs338344 chr15 68270380 G A 6.61E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1532113 chr15 68294598 C T 4.15E-04 Lung function (forced vital capacity) / / 24023788 rs16951552 chr15 68302144 G A 1.83E-04 Multiple complex diseases / / 17554300 rs16951575 chr15 68317451 T C 2.54E-04 Multiple complex diseases / / 17554300 rs11071975 chr15 68329444 G T 8.28E-04 Recombination rate / / 21698098 rs1489595 chr15 68377126 T C 5.91E-04 Alzheimer's disease PIAS1 intron 24755620 rs10152713 chr15 68471891 C T 8.51E-05 Bipolar disorder and schizophrenia PIAS1 intron 20889312 rs16951653 chr15 68481390 A G 5.80E-04 Multiple complex diseases / / 17554300 rs8025947 chr15 68510770 A G 5.02E-04 Weight loss (gastric bypass surgery) CLN6 intron 23643386 rs1474032 chr15 68556512 G A 6.41E-04 Multiple complex diseases / / 17554300 rs7174755 chr15 68597127 T C 3.00E-07 Major depressive disorder ITGA11 intron 23377640 rs7174755 chr15 68597127 T C 9.00E-07 Major depressive disorder ITGA11 intron 23377640 rs17252387 chr15 68611489 G C 3.97E-05 Calcium intake levels and metabolic syndrome ITGA11 intron 22170361 rs3736495 chr15 68613490 G T 2.50E-04 Response to cytadine analogues (cytosine arabinoside) ITGA11 intron 24483146 rs7167822 chr15 68624175 C T 9.73E-05 Soluble levels of adhesion molecules ITGA11 intron pha003072 rs964691 chr15 68626542 T C 9.81E-05 Cognitive impairment induced by topiramate ITGA11 intron 22091778 rs6494736 chr15 68632687 T C 3.78E-06 Common variable immunodeficiency ITGA11 intron 21497890 rs2415005 chr15 68659958 T C 6.57E-04 Multiple complex diseases ITGA11 intron 17554300 rs7161791 chr15 68683575 C T 3.96E-07 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ITGA11 intron 20877124 rs11630897 chr15 68696621 A G 2.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ITGA11 intron 20877124 rs12050670 chr15 68697797 G T 5.10E-06 Urinary metabolites ITGA11 intron 21572414 rs9972560 chr15 68698138 G T 5.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ITGA11 intron 20877124 rs7164335 chr15 68715032 A G 1.00E-07 Attention deficit hyperactivity disorder ITGA11 intron 18839057 rs11072021 chr15 68717437 G A 8.95E-04 Myopia (pathological) ITGA11 intron 21095009 rs16952065 chr15 68718987 C T 1.00E-06 IgG glycosylation ITGA11 intron 23382691 rs16952065 chr15 68718987 C T 6.00E-06 IgG glycosylation ITGA11 intron 23382691 rs1445021 chr15 68735586 A G 9.00E-06 Coronary heart disease / / 21347282 rs7172197 chr15 68763881 A G 5.12E-04 Type 2 diabetes / / 17463246 rs2007265 chr15 68815034 G T 3.48E-04 Rheumatoid arthritis / / 21452313 rs11856323 chr15 68892989 C T 1.00E-07 Cognitive performance CORO2B intron 19734545 rs8028905 chr15 68905817 G T 9.40E-06 Urinary metabolites CORO2B intron 21572414 rs8026784 chr15 68967283 C T 5.70E-04 Aortic root size CORO2B intron 21223598 rs8033246 chr15 68976882 G A 8.07E-04 Response to taxane treatment (placlitaxel) CORO2B intron 23006423 rs12443134 chr15 69008251 A G 5.80E-04 Response to taxane treatment (placlitaxel) CORO2B intron 23006423 rs12915581 chr15 69008315 C T 6.67E-04 Response to taxane treatment (placlitaxel) CORO2B intron 23006423 rs17279860 chr15 69018959 A T 8.32E-04 Alcohol dependence CORO2B UTR-3 21314694 rs4467022 chr15 69024703 A G 4.00E-05 Cholesterol / / pha003073 rs4467022 chr15 69024703 A G 8.30E-05 Cholesterol / / pha003078 rs8030672 chr15 69059084 T A 1.00E-11 Esophageal cancer / / 21642993 rs2168010 chr15 69070536 C T 9.43E-04 Multiple complex diseases / / 17554300 rs2290428 chr15 69075474 G A 2.10E-04 Alzheimer's disease ANP32A intron 24755620 rs7162391 chr15 69080873 G A 5.38E-14 HDL cholesterol ANP32A intron 23063622 rs7164503 chr15 69081390 T C 6.40E-04 Alzheimer's disease ANP32A intron 24755620 rs6494774 chr15 69093943 A G 8.87E-05 Smoking initiation ANP32A intron 24665060 rs993048 chr15 69179625 T A,C,G 3.09E-04 Multiple complex diseases / / 17554300 rs4365239 chr15 69244680 C T 3.26E-06 Alcohol and nictotine co-dependence NOX5 intron 20158304 rs4777102 chr15 69278546 C T 1.67E-04 Alcohol dependence NOX5 intron 21314694 rs11072063 chr15 69291235 A G 9.38E-04 Type 2 diabetes NOX5 intron 17463246 rs2277554 chr15 69327998 C T 2.10E-06 Obesity-related traits NOX5 intron 23251661 rs3825853 chr15 69329591 C T 8.68E-06 Glycemic traits (pregnancy) NOX5 intron 23903356 rs10775200 chr15 69331758 G A 1.92E-06 Obesity-related traits NOX5 intron 23251661 rs311904 chr15 69346946 T C 2.00E-06 Obesity-related traits NOX5 intron 23251661 rs1392635 chr15 69398026 G A 2.00E-06 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy / / 23118302 rs12440912 chr15 69399556 T C 1.45E-04 Alzheimer's disease / / 17998437 rs1466867 chr15 69399667 C A 2.10E-05 Urinary metabolites / / 21572414 rs10162719 chr15 69408203 T C 2.46E-04 Type 2 diabetes / / 17463246 rs8026900 chr15 69424568 G A 6.46E-05 Magnesium levels / / pha003092 rs8031212 chr15 69437327 T C 2.10E-05 Urinary metabolites / / 21572414 rs7164986 chr15 69439784 G A 2.10E-05 Urinary metabolites / / 21572414 rs11072071 chr15 69444064 A C 6.90E-06 Urinary metabolites / / 21572414 rs7167499 chr15 69502443 G T 1.14E-05 Magnesium levels GLCE intron pha003092 rs2047823 chr15 69508167 G T 2.70E-05 Urinary metabolites GLCE intron 21572414 rs2899748 chr15 69524718 A G 2.43E-05 Magnesium levels GLCE intron pha003092 rs3865014 chr15 69561518 G A 9.70E-04 Coronary Artery Disease GLCE missense 17634449 rs1655 chr15 69609496 T C 9.50E-05 Serum metabolites PAQR5 intron 19043545 rs12905214 chr15 69625270 G A 3.35E-05 Schizophrenia PAQR5 intron 19571809 rs12905214 chr15 69625270 G A 0.0007714 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PAQR5 intron 23233654 rs12905214 chr15 69625270 G A 7.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) PAQR5 intron 23233662 rs12905214 chr15 69625270 G A 4.17E-05 Response to mTOR inhibitor (rapamycin) PAQR5 intron 24009623 rs11072089 chr15 69650053 C T 6.93E-04 Type 2 diabetes PAQR5 intron 17463246 rs11072089 chr15 69650053 C T 3.00E-06 Bipolar disorder and schizophrenia PAQR5 intron 20889312 rs1394415 chr15 69696249 T C 4.37E-04 Schizophrenia PAQR5 UTR-3 19197363 rs1504626 chr15 69699770 C G 2.58E-04 Multiple complex diseases PAQR5 UTR-3 17554300 rs8030051 chr15 69702705 T C 9.45E-04 Multiple complex diseases LOC145694 intron 17554300 rs2134926 chr15 69703848 T C 4.37E-04 Schizophrenia LOC145694 intron 19197363 rs3759825 chr15 69709686 G A 7.37E-04 Multiple complex diseases KIF23 intron 17554300 rs11072096 chr15 69717036 G A 5.18E-04 Schizophrenia KIF23 intron 19197363 rs3825858 chr15 69728949 A G 3.47E-04 Schizophrenia KIF23 cds-synon 19197363 rs8035404 chr15 69753230 G A 4.83E-04 Multiple complex diseases / / 17554300 rs4777144 chr15 69759667 C T 4.98E-05 Aortic root size / / 21223598 rs4777161 chr15 69861539 A G 2.13E-17 Mean platelet volume LOC145837 intron 22423221 rs1477592 chr15 69872886 C T 7.55E-04 Multiple complex diseases / / 17554300 rs4777168 chr15 69936082 A G 1.75E-04 Bronchopulmonary dysplasia / / 23897914 rs8025806 chr15 69938058 A G 1.42E-04 Alzheimer's disease (late onset) / / 21379329 rs4777170 chr15 69949516 T C 4.52E-05 Longevity / / 21612516 rs8043362 chr15 69985510 G A 5.90E-05 Immunoglobulin A / / 20694011 rs8026898 chr15 69991417 G A 6.03E-11 Rheumatoid arthritis / / 23143596 rs8026898 chr15 69991417 G A 6.52E-12 Rheumatoid arthritis (CCP positive) / / 23143596 rs8026898 chr15 69991417 G A 4.00E-19 Rheumatoid arthritis / / 24390342 rs8026898 chr15 69991417 G A 6.00E-18 Rheumatoid arthritis / / 24390342 rs12441341 chr15 69991614 A G 9.02E-05 Socioeconomic Factors / / pha003066 rs17374222 chr15 69995344 C A 2.00E-06 Rheumatoid arthritis / / 20453842 rs4776472 chr15 70006873 G A 8.00E-06 Atrial fibrillation / / 17903304 rs7176508 chr15 70018990 A G 5.00E-12 Chronic lymphocytic leukemia / / 18758461 rs7176508 chr15 70018990 A G 5.00E-12 Nasopharyngeal carcinoma / / 20512145 rs7176508 chr15 70018990 A G 3.00E-11 Chronic lymphocytic leukemia / / 22700719 rs7176508 chr15 70018990 A G 2.87E-11 Erectile dysfunction / / 22704111 rs7176508 chr15 70018990 A G 1.00E-17 Chronic lymphocytic leukemia / / 23770605 rs7176508 chr15 70018990 A G 8.00E-18 Chronic lymphocytic leukemia / / 24292274 rs10152591 chr15 70048157 A C 3.00E-10 Height / / 20881960 rs4410031 chr15 70078943 C T 8.73E-04 Parkinson's disease / / 17052657 rs881417 chr15 70083819 C T 9.31E-04 Multiple complex diseases / / 17554300 rs305055 chr15 70093064 T C 4.04E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17323663 chr15 70100189 T G 8.27E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11638405 chr15 70128555 G A 5.31E-04 Suicide attempts in bipolar disorder C15orf50 intron 21423239 rs304984 chr15 70134932 G A 3.86E-04 Multiple complex diseases / / 17554300 rs11638667 chr15 70146241 A T 6.61E-04 Type 2 diabetes / / 17463246 rs379468 chr15 70150451 T G 1.71E-04 Cognitive decline / / 23732972 rs12907468 chr15 70156785 T A 7.80E-06 Osteoarthritis / / 22566624 rs4777205 chr15 70164825 A C 2.08E-04 Multiple complex diseases / / 17554300 rs304963 chr15 70168077 A G 9.41E-05 Body Mass Index / / pha003007 rs12911453 chr15 70172048 A G 4.78E-05 Multiple complex diseases / / 17554300 rs7166273 chr15 70173964 T C 4.70E-04 Type 2 diabetes / / 17463246 rs304939 chr15 70181059 G C 6.25E-04 Multiple complex diseases / / 17554300 rs386825 chr15 70185411 C T 5.62E-04 Taste perception / / 22132133 rs3845197 chr15 70215474 C T 4.60E-04 Type 2 diabetes / / 17463246 rs16954052 chr15 70305237 G A 1.17E-05 Multiple complex diseases / / 17554300 rs17759112 chr15 70348304 C T 1.40E-05 Urinary metabolites TLE3 intron 21572414 rs16954106 chr15 70357918 G A 4.10E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TLE3 intron 20877124 rs16954106 chr15 70357918 G A 7.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TLE3 intron 20877124 rs7162712 chr15 70362560 C T 2.50E-05 Urinary metabolites TLE3 intron 21572414 rs2291985 chr15 70368540 C G 2.00E-04 Birth weight TLE3 intron 17255346 rs11630316 chr15 70369378 T C 9.00E-06 Cognitive function TLE3 intron 24684796 rs11636597 chr15 70421041 G A 1.50E-05 Pulmonary function / / 23932459 rs11856830 chr15 70424501 T C 5.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11856830 chr15 70424501 T C 2.41E-04 Pulmonary function / / 23932459 rs11856830 chr15 70424501 T C 3.20E-06 Pulmonary function / / 23932459 rs12907875 chr15 70430600 A T 4.60E-04 Pulmonary function / / 23932459 rs8036528 chr15 70431111 G T 3.32E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11855650 chr15 70431773 G T 5.35E-04 Type 2 diabetes / / 17463246 rs2937274 chr15 70438551 A G 4.59E-04 Type 2 diabetes / / 17463246 rs8040467 chr15 70452945 A C 4.28E-04 Alcohol dependence / / 21314694 rs2009403 chr15 70477904 A G 6.07E-04 Alcohol dependence / / 20201924 rs6494849 chr15 70480614 C A 2.81E-04 Multiple complex diseases / / 17554300 rs6494849 chr15 70480614 C A 7.00E-06 Bipolar disorder / / 19416921 rs745576 chr15 70481488 G A 1.28E-04 Multiple complex diseases / / 17554300 rs10162898 chr15 70490503 G A 6.63E-04 Alcohol dependence / / 20201924 rs16953714 chr15 70493804 G C 3.72E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs16954296 chr15 70517708 C T 4.60E-04 Alcohol dependence / / 20201924 rs16954296 chr15 70517708 C T 0.000051 Salmonella-induced pyroptosis / / 22837397 rs7175167 chr15 70525659 C T 3.10E-04 Alcohol dependence / / 20201924 rs7175167 chr15 70525659 C T 0.000641 Salmonella-induced pyroptosis / / 22837397 rs17767730 chr15 70530609 T C 1.80E-06 Urinary metabolites / / 21572414 rs1655217 chr15 70552303 G A 0.0000968 Carotid intima media thickness / / 23152477 rs1706717 chr15 70559428 A G 8.83E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs985226 chr15 70561180 C T 9.50E-05 Coffee consumption / / 21357676 rs11855389 chr15 70562208 C T 2.01E-04 Multiple complex diseases / / 17554300 rs1877422 chr15 70574680 C T 2.96E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1971791 chr15 70576138 G A 1.00E-06 Amyotrophic lateral sclerosis / / 22959728 rs9744287 chr15 70578782 A G 8.27E-04 Type 2 diabetes / / 17463246 rs2916179 chr15 70596974 C G 2.52E-04 Cognitive decline / / 23732972 rs2668606 chr15 70599743 G A 2.12E-04 Nonalcoholic fatty liver disease / / 21423719 rs11072158 chr15 70634709 A C,T 3.00E-06 Migraine with aura / / 23793025 rs2175569 chr15 70673456 G A 6.26E-04 Multiple complex diseases / / 17554300 rs12900871 chr15 70678849 G A 4.46E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs8023640 chr15 70702756 T C 1.70E-06 Urinary metabolites / / 21572414 rs8038866 chr15 70721394 T C 7.40E-06 Personality dimensions / / 21173776 rs8038308 chr15 70721586 G A 4.92E-05 Psoriasis / / 20953187 rs4777268 chr15 70721927 C T 2.12E-05 Psoriasis / / 20953187 rs8027878 chr15 70722604 G C 2.10E-06 Personality dimensions / / 21173776 rs8029033 chr15 70723498 C T 1.20E-06 Personality dimensions / / 21173776 rs4559866 chr15 70771201 A C 0.00004 Salmonella-induced pyroptosis / / 22837397 rs7161778 chr15 70775208 G A 0.000447 Salmonella-induced pyroptosis / / 22837397 rs11072189 chr15 70777612 G A 0.000378 Salmonella-induced pyroptosis / / 22837397 rs16954534 chr15 70782227 G A 3.76E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs8043413 chr15 70782544 C T 4.46E-05 Cognitive impairment induced by topiramate / / 22091778 rs3743313 chr15 70798142 C T 0.000727 Salmonella-induced pyroptosis / / 22837397 rs8034004 chr15 70798559 C T 6.00E-06 Self-reported allergy / / 23817569 rs4777292 chr15 70805717 A G 1.20E-04 Taste perception / / 22132133 rs12912411 chr15 70811164 C T 1.27E-06 Cognitive decline / / 23207651 rs16954559 chr15 70818228 G A 8.56E-05 Multiple complex diseases / / 17554300 rs2114719 chr15 70933338 A G 5.00E-04 Multiple complex diseases / / 17554300 rs2114719 chr15 70933338 A G 2.97E-05 Pulmonary function / / 23932459 rs2114719 chr15 70933338 A G 4.20E-07 Pulmonary function / / 23932459 rs2114719 chr15 70933338 A G 6.90E-04 Pulmonary function / / 23932459 rs2162555 chr15 70933572 T C 3.66E-04 Multiple complex diseases / / 17554300 rs2162555 chr15 70933572 T C 2.20E-04 Pulmonary function / / 23932459 rs2162555 chr15 70933572 T C 3.74E-05 Pulmonary function / / 23932459 rs2162555 chr15 70933572 T C 5.70E-07 Pulmonary function / / 23932459 rs6494886 chr15 70933731 A C 7.92E-04 Multiple complex diseases / / 17554300 rs6494886 chr15 70933731 A C 1.50E-05 Pulmonary function / / 23932459 rs6494886 chr15 70933731 A C 3.90E-07 Pulmonary function / / 23932459 rs2162556 chr15 70936438 T C 3.78E-04 Multiple complex diseases / / 17554300 rs2162556 chr15 70936438 T C 2.97E-05 Pulmonary function / / 23932459 rs2162556 chr15 70936438 T C 4.20E-07 Pulmonary function / / 23932459 rs2162556 chr15 70936438 T C 6.90E-04 Pulmonary function / / 23932459 rs2114722 chr15 70936564 C G 1.95E-04 Multiple complex diseases / / 17554300 rs1991088 chr15 71004450 T C 1.20E-06 Pulmonary function UACA intron 23932459 rs1991088 chr15 71004450 T C 1.72E-04 Pulmonary function UACA intron 23932459 rs1477439 chr15 71034580 C G 5.30E-06 Pulmonary function UACA intron 23932459 rs4777305 chr15 71045468 C T 1.50E-06 Pulmonary function UACA intron 23932459 rs4777305 chr15 71045468 C T 1.60E-04 Pulmonary function UACA intron 23932459 rs1549318 chr15 71109147 C T 2.00E-10 Proinsulin levels / / 21873549 rs1549317 chr15 71125204 A G 5.35E-05 Prion diseases LARP6 cds-synon 22210626 rs11072221 chr15 71132566 G C 9.30E-05 Response to statin therapy LARP6 intron 20339536 rs7175862 chr15 71144988 G A 8.80E-05 Response to statin therapy LARP6 intron 20339536 rs3809562 chr15 71148408 A G 7.70E-05 Response to statin therapy / / 20339536 rs3809562 chr15 71148408 A G 7.47E-05 Prion diseases / / 22210626 rs11855912 chr15 71152411 C T 6.20E-05 Response to statin therapy / / 20339536 rs4777316 chr15 71156131 C T 6.30E-05 Response to statin therapy / / 20339536 rs4777317 chr15 71156288 T C 6.20E-05 Response to statin therapy / / 20339536 rs4777319 chr15 71158278 T C 6.10E-05 Response to statin therapy / / 20339536 rs4542614 chr15 71158850 C A 5.70E-05 Response to statin therapy / / 20339536 rs11072232 chr15 71159425 G C 4.50E-05 Response to statin therapy / / 20339536 rs2178276 chr15 71160336 C G 5.80E-05 Response to statin therapy / / 20339536 rs4777321 chr15 71160364 T C 6.00E-05 Response to statin therapy / / 20339536 rs12441133 chr15 71164936 A G 5.50E-05 Response to statin therapy / / 20339536 rs12902589 chr15 71165088 A G 5.80E-05 Response to statin therapy / / 20339536 rs1112177 chr15 71166029 G T 6.50E-05 Response to statin therapy / / 20339536 rs4777325 chr15 71170003 G A 7.80E-05 Response to statin therapy / / 20339536 rs12595787 chr15 71172698 C T 1.27E-04 Prion diseases / / 22210626 rs12595787 chr15 71172698 C T 1.85E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs8033868 chr15 71172756 C G 4.80E-05 Response to statin therapy / / 20339536 rs2955035 chr15 71184495 A G 5.20E-05 Response to statin therapy THAP10 cds-synon 20339536 rs2955036 chr15 71185793 T C 5.20E-05 Response to statin therapy LRRC49 intron 20339536 rs2955036 chr15 71185793 T C 0.0000144 Colorectal adenoma (excluding hyperplasic) LRRC49 intron 23677573 rs2955036 chr15 71185793 T C 0.0000144 Colorectal adenoma LRRC49 intron 23677573 rs2955036 chr15 71185793 T C 0.0000144 Colorectal adenoma (including hyperplasic) LRRC49 intron 23677573 rs2955037 chr15 71185837 G A 5.40E-05 Response to statin therapy LRRC49 intron 20339536 rs1528827 chr15 71187784 G A 5.30E-05 Response to statin therapy LRRC49 intron 20339536 rs1528827 chr15 71187784 G A 0.00000571 Colorectal adenoma LRRC49 intron 23677573 rs1528827 chr15 71187784 G A 0.00000571 Colorectal adenoma (including hyperplasic) LRRC49 intron 23677573 rs1528827 chr15 71187784 G A 0.00000657 Colorectal adenoma (excluding hyperplasic) LRRC49 intron 23677573 rs2249595 chr15 71192576 T A 4.60E-05 Response to statin therapy LRRC49 intron 20339536 rs1406430 chr15 71196193 G A 4.20E-05 Response to statin therapy LRRC49 intron 20339536 rs1441252 chr15 71215378 A G 2.70E-05 Response to statin therapy LRRC49 intron 20339536 rs4777326 chr15 71226033 G A 4.40E-05 Response to statin therapy LRRC49 intron 20339536 rs920532 chr15 71231505 T C 4.00E-05 Response to statin therapy LRRC49 intron 20339536 rs150157186 chr15 71305225 G A 0.00086 Prostate cancer LRRC49 missense 23555315 rs986393 chr15 71349045 C T 4.11E-04 Bipolar disorder / / 19259986 rs12904863 chr15 71424009 T C 6.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1470266 chr15 71424632 C G 6.81E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs2292854 chr15 71435622 A G 7.21E-06 Thiazide-induced adverse metabolic effects in hypertensive patients THSD4 intron 23400010 rs16955200 chr15 71437555 A G 7.32E-06 Thiazide-induced adverse metabolic effects in hypertensive patients THSD4 intron 23400010 rs16955207 chr15 71437590 A G 7.31E-06 Thiazide-induced adverse metabolic effects in hypertensive patients THSD4 intron 23400010 rs12914813 chr15 71439712 T A 7.16E-06 Thiazide-induced adverse metabolic effects in hypertensive patients THSD4 intron 23400010 rs5024066 chr15 71449398 A G 7.43E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) THSD4 intron 23648065 rs4777336 chr15 71473310 G A 0.000839 Salmonella-induced pyroptosis THSD4 intron 22837397 rs17785209 chr15 71505337 G A 9.22E-06 Coronary Artery Disease THSD4 intron 17634449 rs4777345 chr15 71522857 C G 1.22E-05 Intracerebral hemorrhage THSD4 intron 24656865 rs4777345 chr15 71522857 C G 1.55E-05 Intracerebral hemorrhage THSD4 intron 24656865 rs10518942 chr15 71564140 A G 6.85E-04 Response to statin treatment (atorvastatin),change in cholesterol levels THSD4 intron 20031582 rs7174934 chr15 71571345 G A 6.79E-04 Multiple complex diseases THSD4 intron 17554300 rs2994 chr15 71572049 A G 4.00E-06 Height THSD4 intron 20400458 rs76917273 chr15 71572954 T A,C,G 5.00E-06 Serum dimethylarginine levels (symmetric) THSD4 intron 24159190 rs9806183 chr15 71574799 G A,C 2.00E-06 Periodontitis (PAL4Q3) THSD4 intron 24024966 rs9806183 chr15 71574799 G A,C 8.25E-06 Periodontitis (PAL4Q3) THSD4 intron 24024966 rs1442781 chr15 71576304 C G 5.86E-06 Periodontitis (PAL4Q3) THSD4 intron 24024966 rs1442779 chr15 71576755 A G 3.27E-06 Periodontitis (PAL4Q3) THSD4 intron 24024966 rs1442779 chr15 71576755 A G 7.00E-06 Periodontitis (Mean PAL) THSD4 intron 24024966 rs1442779 chr15 71576755 A G 7.00E-06 Periodontitis (PAL4Q3) THSD4 intron 24024966 rs12913078 chr15 71577615 G A 4.89E-06 Periodontitis (PAL4Q3) THSD4 intron 24024966 rs2063826 chr15 71583413 T C 5.70E-06 Periodontitis (PAL4Q3) THSD4 intron 24024966 rs11633212 chr15 71600251 G A 3.80E-06 Pulmonary function THSD4 intron 23932459 rs11633212 chr15 71600251 G A 5.33E-04 Pulmonary function THSD4 intron 23932459 rs11633212 chr15 71600251 G A 7.29E-05 Pulmonary function THSD4 intron 23932459 rs17786786 chr15 71608619 A C 1.28E-05 Pulmonary function THSD4 intron 23932459 rs17786786 chr15 71608619 A C 4.20E-08 Pulmonary function THSD4 intron 23932459 rs17786786 chr15 71608619 A C 7.28E-05 Pulmonary function THSD4 intron 23932459 rs17786786 chr15 71608619 A C 7.00E-06 Antibody status in Tripanosoma cruzi seropositivity THSD4 intron 24324551 rs6494904 chr15 71609522 G A 1.40E-08 Pulmonary function THSD4 intron 23932459 rs6494904 chr15 71609522 G A 1.57E-04 Pulmonary function THSD4 intron 23932459 rs6494904 chr15 71609522 G A 3.64E-06 Pulmonary function THSD4 intron 23932459 rs11855326 chr15 71610835 G A 1.57E-04 Pulmonary function THSD4 intron 23932459 rs11855326 chr15 71610835 G A 2.50E-08 Pulmonary function THSD4 intron 23932459 rs11855326 chr15 71610835 G A 6.12E-06 Pulmonary function THSD4 intron 23932459 rs1837762 chr15 71612303 G A 5.42E-06 Pulmonary function THSD4 intron 23932459 rs1837762 chr15 71612303 G A 5.70E-08 Pulmonary function THSD4 intron 23932459 rs11853359 chr15 71621524 G A 2.73E-05 Pulmonary function THSD4 intron 20010835 rs11858540 chr15 71622786 T G 3.00E-07 Pulmonary function THSD4 intron 23932459 rs11858540 chr15 71622786 T G 3.44E-05 Pulmonary function THSD4 intron 23932459 rs1441361 chr15 71625122 A G 2.80E-07 Pulmonary function THSD4 intron 23932459 rs1441361 chr15 71625122 A G 3.06E-05 Pulmonary function THSD4 intron 23932459 rs10518949 chr15 71628336 A G 1.56E-06 Lactate dehydrogenase levels THSD4 intron 20981236 rs10851839 chr15 71628370 T A 2.51E-05 Pulmonary function THSD4 intron 20010835 rs12899618 chr15 71645120 G A 7.00E-15 Pulmonary function THSD4 intron 20010834 rs12899618 chr15 71645120 G A 4.00E-21 Pulmonary function (interaction) THSD4 intron 23284291 rs16955491 chr15 71650112 C T 1.22E-05 Type 2 diabetes THSD4 intron 17463246 rs12102112 chr15 71655735 C T 6.43E-04 Alcohol dependence THSD4 intron 21314694 rs12102112 chr15 71655735 C T 3.54E-04 Pulmonary function THSD4 intron 23932459 rs2119568 chr15 71665824 T C 7.10E-05 Pulmonary function THSD4 intron 19300500 rs2119568 chr15 71665824 T C 5.05E-05 Pulmonary function THSD4 intron 20010835 rs1568010 chr15 71668512 T G 3.10E-04 Pulmonary function THSD4 intron 23932459 rs1568010 chr15 71668512 T G 7.60E-06 Pulmonary function THSD4 intron 23932459 rs11858454 chr15 71669115 A G 2.26E-04 Pulmonary function THSD4 intron 23932459 rs11858454 chr15 71669115 A G 5.30E-06 Pulmonary function THSD4 intron 23932459 rs12908092 chr15 71672753 T C 8.41E-05 Pulmonary function THSD4 intron 19300500 rs12908092 chr15 71672753 T C 6.69E-05 Pulmonary function THSD4 intron 20010835 rs2415116 chr15 71673185 C T 2.76E-05 Pulmonary function THSD4 intron 20010835 rs7167951 chr15 71678963 T G 2.30E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) THSD4 intron 25044411 rs16955520 chr15 71679186 C T 4.41E-04 Multiple complex diseases THSD4 intron 17554300 rs6494916 chr15 71679520 C G 1.07E-05 Type 2 diabetes THSD4 intron 17463246 rs2044029 chr15 71679959 A G 1.00E-07 Airflow obstruction THSD4 intron 22837378 rs8033889 chr15 71680080 G T 2.24E-05 Pulmonary function THSD4 intron 20010835 rs8033889 chr15 71680080 G T 2.30E-07 Pulmonary function THSD4 intron 23932459 rs8033889 chr15 71680080 G T 3.56E-05 Pulmonary function THSD4 intron 23932459 rs4531689 chr15 71688979 C T 3.87E-04 Pulmonary function THSD4 intron 23932459 rs4531689 chr15 71688979 C T 4.80E-06 Pulmonary function THSD4 intron 23932459 rs4288952 chr15 71690883 A G 9.40E-05 Serum metabolites THSD4 intron 19043545 rs4288952 chr15 71690883 A G 2.60E-04 Pulmonary function THSD4 intron 23932459 rs4288952 chr15 71690883 A G 4.60E-06 Pulmonary function THSD4 intron 23932459 rs10518959 chr15 71690941 T C 5.22E-05 Serum metabolites THSD4 intron 19043545 rs7165378 chr15 71691504 C T 6.40E-05 Longevity and age-related phenotypes THSD4 intron 17903295 rs7165378 chr15 71691504 C T 4.50E-04 Myopia (pathological) THSD4 intron 21095009 rs12441227 chr15 71696886 A G 2.79E-06 Pulmonary function THSD4 intron 23932459 rs12441227 chr15 71696886 A G 3.00E-09 Pulmonary function THSD4 intron 23932459 rs8037770 chr15 71742553 G T 4.71E-05 Relative hand skill THSD4 intron 24068947 rs16955642 chr15 71754225 T G 9.50E-05 Hypothyroidism THSD4 intron 22493691 rs16955676 chr15 71762384 T G 3.00E-05 Hypothyroidism THSD4 intron 22493691 rs1561710 chr15 71771585 A G 5.00E-05 Hypothyroidism THSD4 intron 22493691 rs7181587 chr15 71786905 C T 1.25E-04 Breast cancer THSD4 intron pha002853 rs8035401 chr15 71843649 A C 5.71E-06 Serum metabolites THSD4 intron 19043545 rs8037079 chr15 71843870 T C 1.83E-05 Serum metabolites THSD4 intron 19043545 rs3923493 chr15 71866632 C T 8.65E-05 Hemoglobin THSD4 intron pha003098 rs4606666 chr15 71901195 T C 1.19E-04 Multiple complex diseases THSD4 intron 17554300 rs11858418 chr15 71904835 A G 2.43E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) THSD4 intron 23648065 rs11858418 chr15 71904835 A G 6.47E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) THSD4 intron 23648065 rs13329645 chr15 71905049 G A 2.43E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) THSD4 intron 23648065 rs13329645 chr15 71905049 G A 6.47E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) THSD4 intron 23648065 rs2047689 chr15 71905556 C G 1.70E-06 Urinary metabolites THSD4 intron 21572414 rs8032794 chr15 71906850 G A 2.75E-04 Bipolar disorder,schizoaffective THSD4 intron 19567891 rs12910343 chr15 71910715 A G 1.80E-06 Urinary metabolites THSD4 intron 21572414 rs7182578 chr15 71911951 T C 9.60E-07 Urinary metabolites THSD4 intron 21572414 rs8026339 chr15 71916594 A C 4.96E-04 Multiple complex diseases THSD4 intron 17554300 rs950668 chr15 71921839 G A 2.32E-05 Lipoproteins THSD4 intron pha003079 rs1875415 chr15 71922208 T G 2.40E-06 Cognitive impairment induced by topiramate THSD4 intron 22091778 rs16955938 chr15 71939568 T C 2.17E-04 Multiple complex diseases THSD4 intron 17554300 rs1501419 chr15 71940311 C T 8.79E-06 Blood pressure (response to calcium channel blocker) THSD4 intron 24192120 rs7180092 chr15 71943580 G A 3.29E-07 Type 2 diabetes THSD4 intron 17463246 rs8033100 chr15 71977446 T C 5.98E-05 Parent of origin effect on language impairment (child trend) THSD4 intron 24571439 rs7180648 chr15 71982594 C T 3.84E-05 Parent of origin effect on language impairment (child trend) THSD4 intron 24571439 rs872476 chr15 71999067 A T 0.00013 Glaucoma (primary open-angle) THSD4 intron 23536807 rs4777450 chr15 72018469 G A 1.23E-05 Alopecia areata THSD4 intron 22027810 rs17737742 chr15 72022755 C T 6.52E-05 B cell non-Hodgkin lymphoma THSD4 intron 23749188 rs148016609 chr15 72057477 G A 0.000031 Prostate cancer THSD4 missense 23555315 rs8026085 chr15 72064381 C T 0.0004013 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) THSD4 intron 23233654 rs8026085 chr15 72064381 C T 4.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) THSD4 intron 23233662 rs8028659 chr15 72068344 A G 0.0003909 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) THSD4 intron 23233654 rs8028659 chr15 72068344 A G 3.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) THSD4 intron 23233662 rs7168147 chr15 72068448 C G 0.0003875 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) THSD4 intron 23233654 rs7168147 chr15 72068448 C G 3.88E-04 Methotrexate clearance (acute lymphoblastic leukemia) THSD4 intron 23233662 rs3825804 chr15 72070005 G A 0.0003868 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) THSD4 UTR-3 23233654 rs3825804 chr15 72070005 G A 3.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) THSD4 UTR-3 23233662 rs7402189 chr15 72070929 G A 4.54E-04 Tourette syndrome THSD4 UTR-3 22889924 rs1054260 chr15 72072557 C T 4.17E-04 Multiple complex diseases THSD4 UTR-3 17554300 rs1054260 chr15 72072557 C T 9.60E-05 Body mass (lean) THSD4 UTR-3 19268274 rs11634405 chr15 72084693 A G 2.50E-06 Duodenal ulcer / / 22387998 rs12898728 chr15 72112853 C T 6.00E-06 Metabolite levels (MHPG) / / 23319000 rs12898868 chr15 72112918 C T 3.73E-04 Aortic root size / / 21223598 rs12898868 chr15 72112918 C T 6.00E-06 Metabolite levels (MHPG) / / 23319000 rs8178 chr15 72114747 G A 4.20E-06 Metabolite levels (MHPG) / / 23319000 rs8557 chr15 72115733 T C 9.60E-06 Metabolite levels (MHPG) / / 23319000 rs2415121 chr15 72134018 C T 2.05E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs4777466 chr15 72136872 C T 2.05E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs4511483 chr15 72138590 G A 2.05E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs4526973 chr15 72138719 A G 5.03E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs6494973 chr15 72145728 A T 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs7496582 chr15 72147831 T G 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs7497104 chr15 72154000 C T 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs28650442 chr15 72155445 A T 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs12902421 chr15 72161403 T C 3.00E-08 Height MYO9A intron 20881960 rs12050794 chr15 72169466 G A 2.00E-06 Metabolite levels (HVA/MHPG ratio) MYO9A intron 23319000 rs2306576 chr15 72170686 T C 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs2415126 chr15 72171243 A G 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs9302260 chr15 72174611 T C 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs62023343 chr15 72174963 C A 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs8036307 chr15 72175120 A G 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs11633167 chr15 72179178 C A 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs16956369 chr15 72182813 C T 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs2128112 chr15 72186286 A T 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs7173626 chr15 72186926 C A 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs3784313 chr15 72187519 G T 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs7175373 chr15 72203517 C A 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs28717020 chr15 72216785 G A 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs2930069 chr15 72226977 G A 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs2929513 chr15 72229180 G A 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs2929511 chr15 72231682 C T 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs1552133 chr15 72232897 T A 5.65E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs1552134 chr15 72232898 T A 5.65E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs2929510 chr15 72233694 C G 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs2957728 chr15 72236432 G T 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs2929509 chr15 72239272 T C 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs1481862 chr15 72245648 G A 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs2929508 chr15 72246964 A T 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs2957724 chr15 72248474 A C 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs8040216 chr15 72255249 C T 3.20E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs11634608 chr15 72255718 A G 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs2957734 chr15 72261385 A G 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs2957735 chr15 72265173 T C 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs2957736 chr15 72265344 A G 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs748471 chr15 72266174 G A 7.07E-05 Multiple complex diseases MYO9A intron 17554300 rs2899775 chr15 72268354 C T 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs2899776 chr15 72268365 A T 3.49E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs2035379 chr15 72293202 C T 9.30E-04 Rheumatoid arthritis MYO9A intron 21452313 rs2200056 chr15 72302667 T C 7.74E-04 Rheumatoid arthritis MYO9A intron 21452313 rs111329014 chr15 72385979 A G 5.89E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs113484859 chr15 72385982 T C 5.89E-06 Metabolite levels (MHPG) MYO9A intron 23319000 rs7162299 chr15 72414065 A G 6.64E-06 Metabolite levels (MHPG) SENP8 intron 23319000 rs11072349 chr15 72464471 T C 8.94E-06 Metabolite levels (MHPG) GRAMD2 intron 23319000 rs11072350 chr15 72464609 T G 8.94E-06 Metabolite levels (MHPG) GRAMD2 intron 23319000 rs1037680 chr15 72514319 T C 5.71E-04 Rheumatoid arthritis PKM2 intron 21452313 rs4776589 chr15 72559060 G A 8.55E-04 Rheumatoid arthritis PARP6 intron 21452313 rs2959930 chr15 72598614 G A 8.91E-04 Alcohol dependence CELF6 UTR-5 21314694 rs2959930 chr15 72598614 G A 1.80E-04 Rheumatoid arthritis CELF6 UTR-5 21452313 rs730180 chr15 73007893 G A 3.78E-04 Schizophrenia (cytomegalovirus infection interaction) BBS4 intron 23358160 rs17826791 chr15 73011994 C G 7.72E-05 Response to citalopram treatment BBS4 intron 19846067 rs17826791 chr15 73011994 C G 3.63E-05 Bipolar disorder BBS4 intron 20451256 rs4777534 chr15 73050222 C T 6.61E-05 Body Fat Distribution ADPGK intron pha003016 rs4777534 chr15 73050222 C T 8.16E-05 Body Fat Distribution ADPGK intron pha003017 rs4777534 chr15 73050222 C T 4.17E-05 Body Fat Distribution ADPGK intron pha003018 rs8023358 chr15 73052845 A G 1.13E-05 Body Fat Distribution ADPGK cds-synon pha003016 rs8023358 chr15 73052845 A G 4.22E-05 Body Fat Distribution ADPGK cds-synon pha003017 rs8023358 chr15 73052845 A G 2.61E-05 Body Fat Distribution ADPGK cds-synon pha003018 rs10519024 chr15 73065871 T C 4.82E-05 Bipolar disorder ADPGK intron 20451256 rs11634630 chr15 73067234 T C 4.03E-04 Substance dependence ADPGK intron 21818250 rs4777542 chr15 73082366 C T 2.00E-07 Urate levels LOC100287559 intron 23263486 rs7178889 chr15 73111717 T C 3.16E-04 Multiple complex diseases / / 17554300 rs16957341 chr15 73130731 C T 1.18E-04 Multiple complex diseases / / 17554300 rs17755356 chr15 73143499 G A 3.99E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17755397 chr15 73143521 T C 8.99E-04 Multiple complex diseases / / 17554300 rs8034787 chr15 73148345 G T 6.99E-04 Parkinson's disease / / 17052657 rs8034787 chr15 73148345 G T 2.29E-04 Multiple complex diseases / / 17554300 rs17828399 chr15 73151979 C T 1.15E-04 Multiple complex diseases / / 17554300 rs895904 chr15 73157606 T C 0.000014 Mean arterial pressure / / 22510845 rs1947219 chr15 73186518 G T 4.21E-04 Type 2 diabetes / / 17463246 rs8034355 chr15 73231011 A G 1.88E-05 Multiple complex diseases / / 17554300 rs1900901 chr15 73257725 A G 8.31E-08 Metabolite levels / / 23281178 rs7183175 chr15 73258810 C T 1.53E-04 Coronary Artery Disease / / 17634449 rs2415209 chr15 73262691 G A 3.14E-04 Coronary Artery Disease / / 17634449 rs8025665 chr15 73263049 G A 7.03E-08 Metabolite levels / / 23281178 rs7171746 chr15 73273109 C T 8.47E-04 Insulin resistance / / 21901158 rs4522396 chr15 73276287 C T 9.32E-04 Coronary Artery Disease / / 17634449 rs4572358 chr15 73276349 G T 2.64E-04 Coronary Artery Disease / / 17634449 rs7164592 chr15 73276931 T G 5.21E-04 Coronary Artery Disease / / 17634449 rs9920771 chr15 73290655 C T 1.09E-04 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs4274405 chr15 73313691 A G 1.48E-04 Coronary Artery Disease / / 17634449 rs7173710 chr15 73331183 T G 3.85E-04 Coronary Artery Disease / / 17634449 rs4638547 chr15 73334993 C T 7.43E-04 Coronary Artery Disease / / 17634449 rs8031718 chr15 73390790 A G 1.00E-04 Cognitive impairment induced by topiramate NEO1 intron 22091778 rs7170328 chr15 73403389 G A 6.89E-05 Longevity NEO1 intron 20304771 rs16957640 chr15 73403694 C T 5.85E-05 Longevity NEO1 intron 20304771 rs7177629 chr15 73412761 T C 9.65E-05 Longevity NEO1 intron 20304771 rs6495056 chr15 73417565 A G 4.87E-05 Longevity NEO1 intron 20304771 rs7163504 chr15 73421553 A G 5.24E-05 Longevity NEO1 intron 20304771 rs7176908 chr15 73462401 C T 4.11E-04 Amyotrophic Lateral Sclerosis NEO1 intron 17362836 rs899480 chr15 73467336 A G 7.50E-04 Multiple complex diseases NEO1 intron 17554300 rs10518997 chr15 73556944 A G 9.35E-04 Type 2 diabetes NEO1 intron 17463246 rs2292915 chr15 73590579 C T 7.64E-05 Body Fat Distribution NEO1 intron pha003017 rs4777599 chr15 73629746 A G 1.97E-04 Acute lung injury HCN4 intron 22295056 rs3784806 chr15 73631578 G A 1.95E-04 Acute lung injury HCN4 intron 22295056 rs3784807 chr15 73631830 G A 1.91E-04 Acute lung injury HCN4 intron 22295056 rs4776632 chr15 73632376 G A 1.87E-04 Acute lung injury HCN4 intron 22295056 rs11857639 chr15 73637772 C T 8.00E-06 Waist circumference HCN4 intron 19557197 rs3826046 chr15 73650824 G A 5.26E-06 Stroke (ischemic) HCN4 intron 22941190 rs7164883 chr15 73652174 A G 3.00E-17 Atrial fibrillation HCN4 intron 22544366 rs12440104 chr15 73653009 G A 2.31E-04 Coronary heart disease HCN4 intron 21971053 rs12440104 chr15 73653009 G A 3.01E-04 Acute lung injury HCN4 intron 22295056 rs4489968 chr15 73665506 T G 1.85E-12 Atrial fibrillation / / 23583979 rs4489968 chr15 73665506 T G 4.00E-20 Heart rate / / 23583979 rs16957885 chr15 73717945 A G 7.33E-04 Multiple complex diseases / / 17554300 rs7177226 chr15 73747527 G A 5.23E-04 Bipolar disorder C15orf60 intron 19259986 rs11635553 chr15 73749608 G A 4.00E-06 IgG glycosylation C15orf60 intron 23382691 rs11635553 chr15 73749608 G A 6.00E-06 IgG glycosylation C15orf60 intron 23382691 rs11635553 chr15 73749608 G A 9.00E-06 IgG glycosylation C15orf60 intron 23382691 rs1481088 chr15 73842261 A G 4.11E-05 Parkinson's disease C15orf60 intron 19915575 rs922687 chr15 73848808 A C 1.42E-05 Parkinson's disease C15orf60 intron 19915575 rs7172407 chr15 73850401 T C 6.93E-04 Rheumatoid arthritis C15orf60 intron 21452313 rs7172407 chr15 73850401 T C 6.41E-04 Response to cytadine analogues (cytosine arabinoside) C15orf60 intron 24483146 rs2509 chr15 73859488 T A 3.69E-05 Multiple complex diseases NPTN intron 17554300 rs8028749 chr15 73884708 C T 9.69E-05 Waist-Hip Ratio NPTN intron pha003028 rs1564492 chr15 73933718 A G 1.06E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs8027445 chr15 73970618 C G 2.38E-05 Multiple complex diseases / / 17554300 rs8038465 chr15 73978337 C T 1.00E-09 Liver enzyme levels (gamma-glutamyl transferase) CD276 intron 22001757 rs11574484 chr15 73997988 T C 1.30E-05 Hypertension CD276 intron 22384028 rs1044581 chr15 74006691 T C 1.40E-05 Hypertension CD276 UTR-3 22384028 rs1044581 chr15 74006691 T C 3.91E-04 Myocardial Infarction CD276 UTR-3 pha002883 rs1038094 chr15 74012437 A G 4.95E-04 Multiple complex diseases / / 17554300 rs1038094 chr15 74012437 A G 9.00E-06 Bipolar disorder / / 21738484 rs2279154 chr15 74023017 G A 7.34E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2279155 chr15 74023137 C T 9.34E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12913205 chr15 74053739 C T 2.74E-04 Rheumatoid arthritis / / 21452313 rs16958237 chr15 74075608 G A 6.63E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7169729 chr15 74077167 A G 3.56E-06 Glaucoma (exfoliation) / / 24938310 rs17773784 chr15 74080674 T C 3.24E-10 Glaucoma (exfoliation) / / 24938310 rs1963477 chr15 74091872 G A 7.28E-06 Body Mass Index / / pha003006 rs1963477 chr15 74091872 G A 5.87E-06 Body Mass Index / / pha003014 rs8030494 chr15 74092777 C A 7.83E-05 Pulmonary function in asthmatics / / 23541324 rs874955 chr15 74106617 T C 8.21E-04 Multiple complex diseases / / 17554300 rs1471439 chr15 74106813 T A 2.52E-10 Glaucoma (exfoliation) / / 24938310 rs16958307 chr15 74107417 C A 7.80E-04 Multiple complex diseases / / 17554300 rs746655 chr15 74107677 A G 5.57E-04 Coronary Artery Disease / / 17634449 rs746655 chr15 74107677 A G 1.07E-11 Glaucoma (exfoliation) / / 24938310 rs4886416 chr15 74110996 T C 2.97E-21 Glaucoma (exfoliation) / / 24938310 rs921535 chr15 74111343 C T 2.87E-04 Multiple complex diseases / / 17554300 rs999743 chr15 74114969 A T 2.62E-13 Glaucoma (exfoliation) / / 24938310 rs999742 chr15 74115517 G A 2.21E-04 Multiple complex diseases / / 17554300 rs999742 chr15 74115517 G A 7.10E-04 Glaucoma / / 17690259 rs999742 chr15 74115517 G A 2.20E-21 Glaucoma (exfoliation) / / 24938310 rs1478558 chr15 74116224 G A 1.20E-05 Iris characteristics / / 21835309 rs4886425 chr15 74124543 A G 3.24E-04 Coronary Artery Disease / / 17634449 rs4886425 chr15 74124543 A G 7.62E-13 Glaucoma (exfoliation) / / 24938310 rs10519015 chr15 74125955 T C 4.56E-13 Glaucoma (exfoliation) / / 24938310 rs8030745 chr15 74133091 T C 5.39E-05 Prostate cancer / / pha002878 rs1452389 chr15 74138822 T C 5.97E-14 Glaucoma (exfoliation) / / 24938310 rs1452388 chr15 74139078 G A 5.68E-13 Glaucoma (exfoliation) / / 24938310 rs16958382 chr15 74139690 A G 8.90E-12 Glaucoma (exfoliation) / / 24938310 rs4886694 chr15 74143036 C T 6.41E-05 Multiple complex diseases / / 17554300 rs11637249 chr15 74147978 T C 7.72E-04 Type 2 diabetes / / 17463246 rs11637249 chr15 74147978 T C 9.77E-24 Glaucoma (exfoliation) / / 24938310 rs4338750 chr15 74149587 A G 8.01E-05 Multiple complex diseases / / 17554300 rs4338750 chr15 74149587 A G 5.03E-20 Glaucoma (exfoliation) / / 24938310 rs16958390 chr15 74153256 T C 5.04E-12 Glaucoma (exfoliation) / / 24938310 rs1869177 chr15 74160556 G A 9.03E-12 Glaucoma (exfoliation) / / 24938310 rs2290346 chr15 74163276 G A 8.42E-13 Glaucoma (exfoliation) / / 24938310 rs7163502 chr15 74164031 A T 8.72E-05 Multiple complex diseases / / 17554300 rs16958415 chr15 74168175 G A 5.02E-11 Glaucoma (exfoliation) TBC1D21 intron 24938310 rs4886725 chr15 74171006 G A 6.01E-25 Glaucoma (exfoliation) TBC1D21 intron 24938310 rs4445847 chr15 74172013 C T 3.74E-22 Glaucoma (exfoliation) TBC1D21 intron 24938310 rs16958445 chr15 74176557 G A 2.00E-16 Glaucoma (exfoliation) TBC1D21 missense 24938310 rs13638 chr15 74181538 A G 8.53E-04 Major depressive disorder TBC1D21 UTR-3 22472876 rs4558370 chr15 74204910 G T 1.73E-05 Glaucoma (exfoliation) / / 24938310 rs11634339 chr15 74205807 T C 5.20E-20 Glaucoma (exfoliation) / / 24938310 rs4461027 chr15 74211548 C T 1.20E-06 Glaucoma / / 17690259 rs1048661 chr15 74219546 G T 2.30E-12 Glaucoma LOXL1 missense 17690259 rs3825942 chr15 74219582 G A 3.00E-21 Glaucoma (exfoliation) LOXL1 missense 17690259 rs1550437 chr15 74221298 C T 8.20E-61 Glaucoma (exfoliation) LOXL1 intron 24938310 rs2165241 chr15 74222202 T C 1.00E-27 Glaucoma LOXL1 intron 17690259 rs2165241 chr15 74222202 T C 8.50E-08 Glaucoma (primary open-angle) LOXL1 intron 20835238 rs1992314 chr15 74223767 C G 3.90E-12 Glaucoma LOXL1 intron 17690259 rs1992314 chr15 74223767 C G 1.32E-83 Glaucoma (exfoliation) LOXL1 intron 24938310 rs8041685 chr15 74225193 G A 3.50E-06 Glaucoma LOXL1 intron 17690259 rs8041685 chr15 74225193 G A 7.60E-06 Glaucoma (primary open-angle) LOXL1 intron 20835238 rs2028386 chr15 74226708 C G 3.90E-28 Glaucoma LOXL1 intron 17690259 rs4337252 chr15 74226765 G C 5.70E-28 Glaucoma LOXL1 intron 17690259 rs4337252 chr15 74226765 G C 7.00E-09 Height LOXL1 intron 23563607 rs12594472 chr15 74227140 A T 6.49E-31 Glaucoma (exfoliation) LOXL1 intron 24938310 rs893816 chr15 74228464 C T 1.42E-83 Glaucoma (exfoliation) LOXL1 intron 24938310 rs4886782 chr15 74228810 G A 8.20E-13 Glaucoma LOXL1 intron 17690259 rs893817 chr15 74229065 G A 3.50E-10 Glaucoma LOXL1 intron 17690259 rs893817 chr15 74229065 G A 3.00E-06 Aortic root size LOXL1 intron 19584346 rs893818 chr15 74229195 G A 3.00E-84 Glaucoma (exfoliation) LOXL1 intron 24938310 rs16958494 chr15 74231349 C T 2.04E-30 Glaucoma (exfoliation) LOXL1 intron 24938310 rs12440667 chr15 74231439 C T 6.10E-26 Glaucoma LOXL1 intron 17690259 rs2304719 chr15 74235500 C T 2.20E-19 Glaucoma LOXL1 intron 17690259 rs2304719 chr15 74235500 C T 4.00E-05 Glaucoma (primary open-angle) LOXL1 intron 20835238 rs893821 chr15 74241235 T C 3.03E-45 Glaucoma (exfoliation) LOXL1 intron 24938310 rs750460 chr15 74241506 G A 4.50E-25 Glaucoma LOXL1 intron 17690259 rs750460 chr15 74241506 G A 4.00E-12 Height LOXL1 intron 20881960 rs4243042 chr15 74241624 A T 6.17E-04 Multiple complex diseases LOXL1 intron 17554300 rs4243042 chr15 74241624 A T 4.60E-25 Glaucoma LOXL1 intron 17690259 rs12441138 chr15 74243897 G A 1.94E-18 Glaucoma (exfoliation) LOXL1 intron 24938310 rs10152898 chr15 74255121 G T 5.10E-07 Glaucoma / / 17690259 rs3784562 chr15 74291023 G A 4.50E-13 Progranulin levels PML intron 21087763 rs3784562 chr15 74291023 G A 4.50E-13 Myocardial infarction PML intron 21211798 rs8039584 chr15 74305966 C T 5.00E-08 Myopia (pathological) PML intron 23049088 rs12592370 chr15 74311689 A G 4.50E-04 Pulmonary function PML intron 23932459 rs11072468 chr15 74312794 T C 4.96E-04 Lymphocyte counts PML intron 22286170 rs3825941 chr15 74317362 G A 2.37E-14 Glaucoma (exfoliation) PML intron 24938310 rs10851869 chr15 74331083 T C 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes PML intron 22628534 rs10851869 chr15 74331083 T C 2.66E-17 Glaucoma (exfoliation) PML intron 24938310 rs1550434 chr15 74331211 C T 2.00E-05 Pulmonary function PML intron 23932459 rs1550435 chr15 74331385 T C 4.28E-17 Glaucoma (exfoliation) PML intron 24938310 rs3784556 chr15 74332188 C A 1.22E-13 Glaucoma (exfoliation) PML intron 24938310 rs876383 chr15 74333413 G A 4.85E-05 Blood Pressure PML intron pha002903 rs5742915 chr15 74336633 T C 1.00E-15 Height PML missense 20881960 rs5742915 chr15 74336633 T C 2.00E-14 Paget's disease PML missense 21623375 rs5742915 chr15 74336633 T C 3.42E-04 Height PML missense 22216288 rs6772 chr15 74338939 C T 1.15E-04 Glaucoma (exfoliation) PML UTR-3 24938310 rs723434 chr15 74343330 A G 6.41E-04 Parkinson's disease / / 17052657 rs723434 chr15 74343330 A G 2.94E-11 Glaucoma (exfoliation) / / 24938310 rs8033129 chr15 74440419 C A 4.10E-04 Glaucoma / / 17690259 rs4886574 chr15 74461720 C T 8.40E-05 Coffee consumption / / 21357676 rs2899824 chr15 74470761 G A,C 5.96E-05 Multiple complex diseases / / 17554300 rs12915846 chr15 74500105 G A 7.24E-05 Body Mass Index STRA6 UTR-5 pha003020 rs16966903 chr15 74515306 G T 8.43E-04 Multiple complex diseases / / 17554300 rs3848163 chr15 74532036 G A 2.45E-04 Smoking cessation CCDC33 intron 24665060 rs11858661 chr15 74535158 C T 7.50E-04 Iris characteristics CCDC33 intron 21835309 rs9783698 chr15 74548773 G A 1.00E-06 Obesity-related traits CCDC33 intron 23251661 rs9783698 chr15 74548773 G A 3.00E-06 Obesity-related traits CCDC33 intron 23251661 rs735980 chr15 74552575 G A 1.70E-05 Endometriosis CCDC33 intron 21151130 rs901130 chr15 74573907 G C 1.24E-04 Multiple complex diseases CCDC33 intron 17554300 rs351203 chr15 74578045 A C 4.41E-04 Multiple complex diseases CCDC33 intron 17554300 rs2930291 chr15 74604834 G A 7.70E-06 Type 2 diabetes CCDC33 intron 17463249 rs2930291 chr15 74604834 G A 7.72E-06 Multiple complex diseases CCDC33 intron 17554300 rs2930313 chr15 74609378 A G 1.23E-04 Bulimia nervosa CCDC33 intron 23568457 rs2959011 chr15 74611781 A T 4.76E-04 Multiple complex diseases CCDC33 intron 17554300 rs11072478 chr15 74615507 C T 1.74E-04 Multiple complex diseases CCDC33 intron 17554300 rs2959008 chr15 74616577 A G 4.70E-04 Multiple complex diseases CCDC33 intron 17554300 rs2277603 chr15 74622533 A C,G,T 2.42E-05 Glucose levels CCDC33 missense pha003057 rs3803463 chr15 74667509 G A 6.16E-05 Glucose levels / / pha003057 rs7182869 chr15 74689649 T C 3.68E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1046146 chr15 74706943 G A 4.40E-05 Triglycerides SEMA7A cds-synon 19074352 rs11852686 chr15 74715205 T C 1.20E-07 Coffee consumption SEMA7A intron 21357676 rs11852686 chr15 74715205 T C 1.46E-05 Caffeine consumption SEMA7A intron 21490707 rs11856835 chr15 74716174 G A 1.10E-07 Coffee consumption SEMA7A intron 21357676 rs8036030 chr15 74716609 A G 1.50E-06 Coffee consumption SEMA7A intron 21357676 rs8036030 chr15 74716609 A G 8.00E-06 Airflow obstruction SEMA7A intron 22837378 rs1992145 chr15 74723644 G A 3.60E-05 Coffee consumption SEMA7A intron 21357676 rs7166701 chr15 74749015 A G 7.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) UBL7 intron 20877124 rs4544202 chr15 74760995 A G 7.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC440288 intron 20877124 rs8027459 chr15 74770334 G A 9.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) LOC440288 intron 23648065 rs10851872 chr15 74790183 A C 3.36E-05 Caffeine consumption / / 21490707 rs6495108 chr15 74794527 A G 9.32E-04 Multiple complex diseases / / 17554300 rs8028430 chr15 74845745 A G 8.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARID3B intron 20877124 rs11629946 chr15 74871891 C T 1.89E-04 Multiple complex diseases ARID3B intron 17554300 rs7497036 chr15 74873679 A G 2.35E-04 Multiple complex diseases ARID3B intron 17554300 rs12898794 chr15 74884447 C T 5.48E-05 Caffeine consumption ARID3B intron 21490707 rs9635320 chr15 74885091 A G 6.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARID3B intron 20877124 rs6495116 chr15 74885948 A G 6.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARID3B intron 20877124 rs11072494 chr15 74889163 C T 7.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARID3B UTR-3 20877124 rs11072495 chr15 74891131 G T 7.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4073149 chr15 74898419 G A 1.47E-04 Multiple complex diseases / / 17554300 rs6495117 chr15 74899500 T C 7.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6495118 chr15 74912012 T G 6.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CLK3 intron 20877124 rs2068982 chr15 74915888 C T 7.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CLK3 intron 20877124 rs11629749 chr15 74919593 C G 3.10E-04 Multiple complex diseases CLK3 intron 17554300 rs11072496 chr15 74920532 C T 2.93E-04 Multiple complex diseases CLK3 intron 17554300 rs7161903 chr15 74940270 A G 3.04E-04 Multiple complex diseases EDC3 intron 17554300 rs7497342 chr15 74948063 A G 7.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EDC3 intron 20877124 rs17861084 chr15 75012019 G T 0.000000121 Triglycerides CYP1A1 UTR-3 23063622 rs17861084 chr15 75012019 G T 6.14E-10 Cholesterol,total CYP1A1 UTR-3 23063622 rs4646421 chr15 75016192 G A,C,T 0.0000258 Transmission distortion CYP1A1 intron 22377632 rs2470893 chr15 75019449 C T 2.90E-09 Coffee consumption CYP1A1 nearGene-5 21357676 rs2470893 chr15 75019449 C T 5.00E-14 Caffeine consumption CYP1A1 nearGene-5 21490707 rs2470893 chr15 75019449 C T 2.00E-11 Coffee consumption CYP1A1 nearGene-5 21876539 rs2472297 chr15 75027880 C T 5.00E-14 Coffee consumption / / 21357676 rs2472297 chr15 75027880 C T 3.88E-07 Caffeine consumption / / 21490707 rs2472297 chr15 75027880 C T 4.50E-05 Coffee consumption / / 21876539 rs2472297 chr15 75027880 C T 2.47E-05 Urate levels / / 23263486 rs2472299 chr15 75033400 A G 3.00E-06 Coronary heart disease / / 21378988 rs2472299 chr15 75033400 A G 8.04E-05 Caffeine consumption / / 21490707 rs762551 chr15 75041917 C A 1 Drug response to Caffeine CYP1A2 intron 10233211 rs762551 chr15 75041917 C A 1 Drug response to Caffeine CYP1A2 intron 16522833 rs762551 chr15 75041917 C A 1 Drug response to Caffeine CYP1A2 intron 18089957 rs762551 chr15 75041917 C A 1 Drug response to Leflunomide CYP1A2 intron 18496682 rs762551 chr15 75041917 C A 1 Drug response to Olanzapine CYP1A2 intron 19636338 rs17861157 chr15 75043592 C A 0.00000028 Triglycerides CYP1A2 missense 23063622 rs17861157 chr15 75043592 C A 2.25E-14 Cholesterol,total CYP1A2 missense 23063622 rs2472304 chr15 75044238 G A 3.00E-07 Caffeine consumption CYP1A2 intron 21490707 rs72547516 chr15 75044578 A G,T 1 Drug response to Clozapine CYP1A2 missense 20125119 rs72547516 chr15 75044578 A G,T 1 Drug response to Phenacetin CYP1A2 missense 20125119 rs55889066 chr15 75045575 G A 1 Drug response to Phenacetin CYP1A2 missense 20125119 rs72547517 chr15 75047245 G A 1 Drug response to Clozapine CYP1A2 missense 20125119 rs72547517 chr15 75047245 G A 1 Drug response to Phenacetin CYP1A2 missense 20125119 rs11072508 chr15 75062397 C T 1.92E-05 Personality dimensions / / 22628180 rs1543927 chr15 75063573 T C 2.55E-05 Personality dimensions / / 22628180 rs1378942 chr15 75077367 C A 5.07E-04 Type 2 diabetes CSK intron 17463246 rs1378942 chr15 75077367 C A 1.00E-23 Diastolic blood pressure CSK intron 19430483 rs1378942 chr15 75077367 C A 1.00E-23 Coronary heart disease CSK intron 21347282 rs1378942 chr15 75077367 C A 1.00E-23 Blood pressure CSK intron 21378095 rs1378942 chr15 75077367 C A 1.56E-05 Caffeine consumption CSK intron 21490707 rs1378942 chr15 75077367 C A 1.80E-06 Blood pressure CSK intron 21572416 rs1378942 chr15 75077367 C A 2.00E-15 Blood pressure CSK intron 21909110 rs1378942 chr15 75077367 C A 3.00E-26 Diastolic blood pressure CSK intron 21909115 rs1378942 chr15 75077367 C A 6.00E-23 Systolic blood pressure CSK intron 21909115 rs2301249 chr15 75092384 T C 1.17E-05 Personality dimensions CSK intron 22628180 rs1378938 chr15 75096443 T C 7.80E-09 Celiac disease / / 22057235 rs1378938 chr15 75096443 T C 2.10E-06 Personality dimensions / / 22628180 rs7176022 chr15 75107880 A C 2.10E-06 Personality dimensions LMAN1L intron 22628180 rs7162232 chr15 75115895 G A 2.25E-06 Personality dimensions LMAN1L intron 22628180 rs11634474 chr15 75116184 C G 2.28E-06 Personality dimensions LMAN1L intron 22628180 rs6495122 chr15 75125645 A C 2.00E-10 Diastolic blood pressure / / 19430479 rs6495122 chr15 75125645 A C 2.00E-10 Coronary heart disease / / 21347282 rs6495122 chr15 75125645 A C 8.20E-05 Coffee consumption / / 21357676 rs6495122 chr15 75125645 A C 6.00E-07 Caffeine consumption / / 21490707 rs6495122 chr15 75125645 A C 7.00E-09 Coffee consumption / / 21876539 rs6495122 chr15 75125645 A C 1.42E-11 Blood pressure / / 21909110 rs9210 chr15 75128501 T C 1.18E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) ULK3 UTR-3 23648065 rs2290573 chr15 75129594 G A 1 Drug response to Imatinib ULK3 intron 15073101 rs2290573 chr15 75129594 G A 4.50E-05 Coffee consumption ULK3 intron 21357676 rs2290572 chr15 75130573 A G 2.52E-05 Personality dimensions ULK3 intron 22628180 rs4886615 chr15 75131661 A G 1.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) ULK3 cds-synon 23648065 rs936227 chr15 75131959 A G 9.77E-04 Type 2 diabetes ULK3 cds-synon 17463246 rs936227 chr15 75131959 A G 3.91E-05 Caffeine consumption ULK3 cds-synon 21490707 rs936227 chr15 75131959 A G 1.83E-05 Personality dimensions ULK3 cds-synon 22628180 rs936229 chr15 75132319 A G 9.97E-07 Personality dimensions ULK3 intron 22628180 rs936229 chr15 75132319 A G 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) ULK3 intron 23648065 rs12908814 chr15 75132490 C G 1.88E-05 Personality dimensions ULK3 intron 22628180 rs872263 chr15 75136444 C T 4.25E-07 Red blood cell traits / / 23222517 rs12487 chr15 75136694 T C 4.10E-05 Coffee consumption / / 21357676 rs3765066 chr15 75140854 G A 7.80E-06 Coffee consumption SCAMP2 intron 21357676 rs3765066 chr15 75140854 G A 8.93E-07 Personality dimensions SCAMP2 intron 22628180 rs3765066 chr15 75140854 G A 4.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) SCAMP2 intron 23648065 rs3765066 chr15 75140854 G A 8.90E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) SCAMP2 intron 23648065 rs936230 chr15 75145098 T C 1.17E-06 Personality dimensions SCAMP2 intron 22628180 rs1869959 chr15 75147332 A C 1.18E-06 Personality dimensions SCAMP2 intron 22628180 rs11630918 chr15 75155896 C T 1.70E-05 Coffee consumption SCAMP2 intron 21357676 rs11630918 chr15 75155896 C T 4.22E-07 Personality dimensions SCAMP2 intron 22628180 rs8037152 chr15 75156996 T A 1.21E-08 Red blood cell traits SCAMP2 intron 23222517 rs11072511 chr15 75159433 A G 7.60E-05 Coffee consumption SCAMP2 intron 21357676 rs11072511 chr15 75159433 A G 7.14E-07 Personality dimensions SCAMP2 intron 22628180 rs11072511 chr15 75159433 A G 8.80E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) SCAMP2 intron 23648065 rs8025170 chr15 75170983 G A 2.54E-07 Red blood cell traits / / 23222517 rs6495126 chr15 75175026 A G 1.08E-06 Personality dimensions / / 22628180 rs6495126 chr15 75175026 A G 8.00E-04 Pulmonary function / / 23932459 rs7497393 chr15 75175457 G C 7.40E-05 Coffee consumption / / 21357676 rs7497393 chr15 75175457 G C 7.21E-07 Personality dimensions / / 22628180 rs4886633 chr15 75178207 G A 1.06E-06 Personality dimensions / / 22628180 rs8031937 chr15 75181121 A G 1.06E-06 Personality dimensions MPI nearGene-5 22628180 rs7495739 chr15 75185670 A G 8.10E-05 Coffee consumption MPI intron 21357676 rs7495739 chr15 75185670 A G 8.47E-07 Personality dimensions MPI intron 22628180 rs1130741 chr15 75189930 A G 7.50E-05 Coffee consumption MPI cds-synon 21357676 rs1130741 chr15 75189930 A G 9.75E-07 Personality dimensions MPI cds-synon 22628180 rs1130741 chr15 75189930 A G 8.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) MPI cds-synon 23648065 rs7497201 chr15 75190690 A G 4.84E-06 Personality dimensions MPI nearGene-3 23658558 rs1127796 chr15 75193004 T C 7.90E-05 Coffee consumption FAM219B UTR-3 21357676 rs1127796 chr15 75193004 T C 9.59E-07 Personality dimensions FAM219B UTR-3 22628180 rs6495127 chr15 75194490 C T 1.53E-06 Personality dimensions FAM219B UTR-3 22628180 rs6495127 chr15 75194490 C T 6.48E-06 Personality dimensions FAM219B UTR-3 23658558 rs4886636 chr15 75196176 G A 7.20E-05 Coffee consumption FAM219B intron 21357676 rs4886636 chr15 75196176 G A 1.07E-06 Personality dimensions FAM219B intron 22628180 rs4886636 chr15 75196176 G A 8.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) FAM219B intron 23648065 rs11856413 chr15 75199892 A G 2.31E-06 Personality dimensions / / 22628180 rs11072512 chr15 75204026 C T 8.20E-05 Coffee consumption / / 21357676 rs11072512 chr15 75204026 C T 2.15E-06 Personality dimensions / / 22628180 rs1133323 chr15 75212225 C T 4.40E-05 Coffee consumption / / 21357676 rs1133323 chr15 75212225 C T 1.74E-06 Personality dimensions / / 22628180 rs1133322 chr15 75212357 A G 6.60E-05 Coffee consumption / / 21357676 rs1133322 chr15 75212357 A G 1.68E-06 Personality dimensions / / 22628180 rs11072513 chr15 75220968 C T 6.50E-05 Coffee consumption COX5A intron 21357676 rs11072513 chr15 75220968 C T 1.67E-06 Personality dimensions COX5A intron 22628180 rs11072514 chr15 75221865 T A 6.40E-05 Coffee consumption COX5A intron 21357676 rs11072514 chr15 75221865 T A 1.66E-06 Personality dimensions COX5A intron 22628180 rs8042694 chr15 75225415 G A 1.55E-06 Personality dimensions COX5A intron 22628180 rs8042694 chr15 75225415 G A 5.49E-06 Personality dimensions COX5A intron 23658558 rs11072518 chr15 75234610 T C 2.20E-05 Coffee consumption / / 21357676 rs11072518 chr15 75234610 T C 2.07E-06 Personality dimensions / / 22628180 rs2415251 chr15 75242155 T C 2.30E-05 Coffee consumption / / 21357676 rs2415251 chr15 75242155 T C 1.97E-05 Personality dimensions / / 22628180 rs6495132 chr15 75255322 C T 7.70E-05 Coffee consumption / / 21357676 rs6495132 chr15 75255322 C T 6.28E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs12050759 chr15 75265191 G A 5.90E-05 Coffee consumption / / 21357676 rs1867153 chr15 75271229 C T 7.70E-05 Coffee consumption / / 21357676 rs1867153 chr15 75271229 C T 3.91E-05 Parkinson's disease / / 21738487 rs1867153 chr15 75271229 C T 1.12E-05 Cognitive impairment induced by topiramate / / 22091778 rs3812945 chr15 75289722 T C 5.70E-05 Coffee consumption SCAMP5 intron 21357676 rs3812945 chr15 75289722 T C 5.72E-06 Caffeine consumption SCAMP5 intron 21490707 rs3812945 chr15 75289722 T C 5.64E-05 Parkinson's disease SCAMP5 intron 21738487 rs3812945 chr15 75289722 T C 4.60E-04 Myasthenia gravis SCAMP5 intron 23055271 rs8030089 chr15 75290377 C T 2.16E-08 Red blood cell traits SCAMP5 intron 23222517 rs12898551 chr15 75297907 C G 6.50E-06 Coffee consumption SCAMP5 intron 21357676 rs12906126 chr15 75301257 G T 4.84E-07 Red blood cell traits SCAMP5 intron 23222517 rs12900072 chr15 75307148 G A 6.30E-06 Coffee consumption SCAMP5 intron 21357676 rs4886414 chr15 75308650 C T 2.87E-08 Red blood cell traits SCAMP5 intron 23222517 rs4886648 chr15 75308837 G A 1.40E-05 Coffee consumption SCAMP5 intron 21357676 rs2289582 chr15 75310394 T C 1.34E-08 Red blood cell traits SCAMP5 intron 23222517 rs13056 chr15 75312187 A G 7.81E-08 Red blood cell traits SCAMP5 UTR-3 23222517 rs2304903 chr15 75315778 A G 2.20E-09 Red blood cell traits / / 23222517 rs8042558 chr15 75320433 G T 1.26E-08 Red blood cell traits PPCDC intron 23222517 rs8028632 chr15 75321262 T C 6.87E-10 Red blood cell traits PPCDC intron 23222517 rs5020842 chr15 75322310 T C 1.40E-08 Red blood cell traits PPCDC intron 23222517 rs4886649 chr15 75328595 T C 1.30E-06 Coffee consumption PPCDC intron 21357676 rs12917120 chr15 75329091 T C 1.98E-05 Cytomegalovirus antibody response PPCDC intron 21993531 rs4886417 chr15 75330159 T G 7.70E-06 Coffee consumption PPCDC intron 21357676 rs4886417 chr15 75330159 T G 4.09E-06 Caffeine consumption PPCDC intron 21490707 rs2120019 chr15 75334184 T C 2.10E-07 Red blood cell traits PPCDC intron 23222517 rs2120019 chr15 75334184 T C 2.00E-18 Blood trace element (Zn levels) PPCDC intron 23720494 rs8039755 chr15 75337426 T C 5.10E-05 Coffee consumption PPCDC intron 21357676 rs4886651 chr15 75344451 C T 5.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs7163636 chr15 75346760 T C 3.40E-05 Coffee consumption / / 21357676 rs7175720 chr15 75348962 G C 1.32E-07 Red blood cell traits / / 23222517 rs8042409 chr15 75350433 G A 1.73E-07 Red blood cell traits / / 23222517 rs8033837 chr15 75353975 A C 6.36E-07 Red blood cell traits / / 23222517 rs11854975 chr15 75363876 G A 7.80E-06 Coffee consumption / / 21357676 rs7162900 chr15 75368017 T C 1.41E-07 Red blood cell traits / / 23222517 rs7167285 chr15 75368769 A G 6.73E-07 Red blood cell traits / / 23222517 rs7173833 chr15 75369618 G A 1.71E-07 Red blood cell traits / / 23222517 rs8036197 chr15 75370232 T C 1.48E-07 Red blood cell traits / / 23222517 rs12148488 chr15 75382542 G T 7.80E-05 Coffee consumption / / 21357676 rs12148488 chr15 75382542 G T 6.00E-07 Caffeine consumption / / 21490707 rs12148488 chr15 75382542 G T 3.80E-04 Myasthenia gravis / / 23055271 rs8034281 chr15 75384227 C T 8.92E-04 Type 2 diabetes / / 17463246 rs8034281 chr15 75384227 C T 7.72E-04 Acute lung injury / / 22295056 rs4886655 chr15 75385568 G A 1.50E-05 Coffee consumption / / 21357676 rs7162941 chr15 75385622 C T 2.08E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs8040061 chr15 75393720 C A 0.00014 Prostate cancer / / 23555315 rs12148555 chr15 75395475 C T 1.10E-05 Coffee consumption / / 21357676 rs12148555 chr15 75395475 C T 3.40E-04 Acute lung injury / / 22295056 rs2029519 chr15 75415962 A G 1.07E-05 Alcohol dependence / / 23089632 rs3743212 chr15 75419543 C T 6.05E-05 Height / / pha003011 rs4479194 chr15 75422131 G A 0.00000527 Alcohol dependence / / 23089632 rs7172677 chr15 75424593 A C 0.00000715 Alcohol dependence / / 23089632 rs7172677 chr15 75424593 A C 0.000535 Alcohol dependence / / 23089632 rs7172677 chr15 75424593 A C 3.00E-08 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs902476 chr15 75431795 G A,C,T 5.71E-05 Cytomegalovirus antibody response / / 21993531 rs8029756 chr15 75435790 C T 4.51E-04 Acute lung injury / / 22295056 rs11072528 chr15 75436455 T C 7.80E-05 Coffee consumption / / 21357676 rs11072528 chr15 75436455 T C 6.92E-04 Acute lung injury / / 22295056 rs7178005 chr15 75437420 T C 9.30E-05 Coffee consumption / / 21357676 rs7178005 chr15 75437420 T C 6.87E-04 Acute lung injury / / 22295056 rs12910348 chr15 75437642 A G 9.30E-05 Coffee consumption / / 21357676 rs12910348 chr15 75437642 A G 7.90E-04 Acute lung injury / / 22295056 rs12914536 chr15 75437715 C T 9.30E-05 Coffee consumption / / 21357676 rs12914536 chr15 75437715 C T 7.71E-04 Acute lung injury / / 22295056 rs8033754 chr15 75439780 T C 3.62E-04 Type 2 diabetes / / 17463246 rs8033754 chr15 75439780 T C 8.80E-05 Coffee consumption / / 21357676 rs8033754 chr15 75439780 T C 6.98E-04 Acute lung injury / / 22295056 rs8025412 chr15 75444033 C T 7.60E-05 Coffee consumption / / 21357676 rs8025412 chr15 75444033 C T 8.31E-04 Acute lung injury / / 22295056 rs8027604 chr15 75447773 C T 7.90E-05 Coffee consumption / / 21357676 rs8027604 chr15 75447773 C T 9.90E-04 Acute lung injury / / 22295056 rs74979292 chr15 75447806 G A 0.0000929 Menopause (age at onset) / / 23424626 rs4886668 chr15 75448034 T C 8.10E-05 Coffee consumption / / 21357676 rs4886668 chr15 75448034 T C 9.90E-04 Acute lung injury / / 22295056 rs6495158 chr15 75448813 A G 8.50E-05 Coffee consumption / / 21357676 rs4886670 chr15 75449674 G T 1.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs4886670 chr15 75449674 G T 7.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs8040372 chr15 75450557 A G 7.78E-05 Caffeine consumption / / 21490707 rs6495163 chr15 75465051 G A 2.76E-04 Body mass index / / 17255346 rs16966785 chr15 75472094 A G 8.78E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs4886431 chr15 75506666 C T 9.34E-04 Multiple complex diseases / / 17554300 rs8028182 chr15 75718669 G T 3.00E-06 Sudden cardiac arrest SIN3A intron 21658281 rs4886707 chr15 75755467 C T 8.00E-08 Height / / 20189936 rs4886707 chr15 75755467 C T 1.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4886707 chr15 75755467 C T 3.51E-05 Sudden cardiac arrest / / 21658281 rs4886707 chr15 75755467 C T 5.54E-04 Lymphocyte counts / / 22286170 rs8034317 chr15 75764343 G A 2.95E-04 Amyotrophic lateral sclerosis (sporadic) PTPN9 intron 24529757 rs11636199 chr15 75825337 A G 9.44E-05 Calcium intake levels and metabolic syndrome PTPN9 intron 22170361 rs7163907 chr15 75845097 T C 4.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTPN9 intron 20877124 rs75393192 chr15 75870551 C T 2.00E-06 Antibody status in Tripanosoma cruzi seropositivity PTPN9 intron 24324551 rs11638663 chr15 75950163 G A 1.74E-04 Alzheimer's disease SNX33 UTR-3 24755620 rs8031394 chr15 75964226 T C 1.54E-04 Alzheimer's disease / / 24755620 rs8041033 chr15 75965752 G A 0.00000244 Common carotid artery thickness (near walls) / / 23487405 rs4886734 chr15 76010909 G A 0.00000244 Common carotid artery thickness (near walls) / / 23487405 rs2405781 chr15 76111016 G A 9.51E-06 Myocardial Infarction / / pha002883 rs12906546 chr15 76113936 C G 1.28E-04 Multiple complex diseases / / 17554300 rs17426432 chr15 76130390 A T 1.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs1394125 chr15 76158983 G A 3.00E-17 Chronic kidney disease UBE2Q2 intron 20383146 rs1394125 chr15 76158983 G A 7.42E-11 Chronic kidney disease UBE2Q2 intron 22479191 rs1394125 chr15 76158983 G A 3.00E-13 Urate levels UBE2Q2 intron 23263486 rs1976748 chr15 76160951 A G 9.65E-08 Red blood cell traits UBE2Q2 intron 23222517 rs1976748 chr15 76160951 A G 1.19E-10 Urate levels UBE2Q2 intron 23263486 rs335684 chr15 76194304 C T 9.75E-04 Multiple complex diseases / / 17554300 rs12437816 chr15 76194538 G C 5.87E-07 Red blood cell traits / / 23222517 rs12437816 chr15 76194538 G C 1.08E-08 Urate levels / / 23263486 rs2455895 chr15 76196674 T C 1.09E-04 Multiple complex diseases FBXO22 intron 17554300 rs1695372 chr15 76217098 T C 5.28E-05 Multiple complex diseases FBXO22 intron 17554300 rs2648436 chr15 76218414 T G 1.11E-04 Multiple complex diseases FBXO22 intron 17554300 rs10444856 chr15 76232422 T C 5.77E-07 Red blood cell traits / / 23222517 rs10444856 chr15 76232422 T C 7.68E-09 Urate levels / / 23263486 rs1874953 chr15 76236837 G C 4.24E-07 Red blood cell traits NRG4 intron 23222517 rs1874953 chr15 76236837 G C 6.93E-09 Urate levels NRG4 intron 23263486 rs11636220 chr15 76239068 A T 3.03E-07 Red blood cell traits NRG4 intron 23222517 rs2454472 chr15 76251848 A T 9.00E-04 Chronic kidney disease NRG4 intron 21931561 rs17428804 chr15 76260430 G T 1.70E-04 Coronary heart disease NRG4 intron 21966275 rs16967747 chr15 76260553 A G 7.55E-04 Multiple complex diseases NRG4 intron 17554300 rs11634028 chr15 76276150 T A 1.03E-08 Urate levels NRG4 intron 23263486 rs10851884 chr15 76290042 G A 7.93E-07 Red blood cell traits NRG4 intron 23222517 rs10851884 chr15 76290042 G A 3.59E-08 Urate levels NRG4 intron 23263486 rs11072566 chr15 76293971 A G 3.00E-10 Red blood cell traits NRG4 intron 23222517 rs11072566 chr15 76293971 A G 2.33E-08 Urate levels NRG4 intron 23263486 rs4886755 chr15 76298132 A G 3.78E-07 Red blood cell traits NRG4 intron 23222517 rs4886755 chr15 76298132 A G 6.15E-09 Urate levels NRG4 intron 23263486 rs10851885 chr15 76304503 A G 5.54E-10 Urate levels NRG4 intron 23263486 rs12440225 chr15 76313121 G A 2.29E-07 Red blood cell traits / / 23222517 rs12440225 chr15 76313121 G A 8.81E-09 Urate levels / / 23263486 rs7183492 chr15 76359055 C T 2.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C15orf27 intron 20877124 rs2959845 chr15 76363586 G C 8.40E-06 Multiple complex diseases C15orf27 intron 17554300 rs7172445 chr15 76373545 C G 1.39E-04 Multiple complex diseases C15orf27 intron 17554300 rs2959843 chr15 76378602 C A 6.89E-04 Alzheimer's disease C15orf27 intron 24755620 rs2221075 chr15 76395431 G A 2.86E-04 Alzheimer's disease C15orf27 intron 24755620 rs2959836 chr15 76395557 G A 1.31E-04 Alzheimer's disease C15orf27 intron 24755620 rs7181548 chr15 76409861 A C 0.0000196 Menopause (age at onset) C15orf27 intron 23424626 rs12324142 chr15 76414889 T G 1.03E-06 Phospholipid levels (plasma) C15orf27 intron 21829377 rs2935980 chr15 76422153 T G 1.13E-06 Phospholipid levels (plasma) C15orf27 intron 21829377 rs1391470 chr15 76429785 C T 3.82E-06 Phospholipid levels (plasma) C15orf27 intron 21829377 rs2959860 chr15 76454335 C T 1.14E-04 Fibrinogen C15orf27 intron 17255346 rs7163654 chr15 76456451 G A 3.17E-06 Phospholipid levels (plasma) C15orf27 intron 21829377 rs16967934 chr15 76456920 T G 2.91E-06 Phospholipid levels (plasma) C15orf27 intron 21829377 rs9920257 chr15 76469526 T C 7.44E-04 Multiple complex diseases C15orf27 intron 17554300 rs2456051 chr15 76477323 G A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes C15orf27 intron 22628534 rs4886485 chr15 76531520 A C 0.0000762 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ETFA intron 22628534 rs1914816 chr15 76546933 G A 7.00E-07 Response to tocilizumab in rheumatoid arthritis ETFA intron 22491018 rs17458234 chr15 76575021 C T 7.32E-04 Alzheimer's disease ETFA intron 24755620 rs17458234 chr15 76575021 C T 7.58E-05 Cholesterol ETFA intron pha003073 rs1801591 chr15 76578762 G A 9.74E-05 Cognitive performance ETFA missense 19734545 rs17362383 chr15 76650702 A G 4.53E-04 Multiple complex diseases SCAPER intron 17554300 rs4886798 chr15 76673226 C T 2.94E-04 Multiple complex diseases SCAPER intron 17554300 rs17460201 chr15 76673627 T C 3.47E-04 Multiple complex diseases SCAPER intron 17554300 rs12907805 chr15 76690606 G A 3.90E-04 Multiple complex diseases SCAPER intron 17554300 rs8030411 chr15 76699855 T C 1.82E-04 Multiple complex diseases SCAPER intron 17554300 rs4886495 chr15 76738959 T C 4.62E-04 Multiple complex diseases SCAPER intron 17554300 rs10519141 chr15 76739071 C T 1.12E-19 Varicose Veins SCAPER intron pha001412 rs4886805 chr15 76739384 C T 5.25E-04 Multiple complex diseases SCAPER intron 17554300 rs157776 chr15 76756703 T C 2.25E-04 Body mass index SCAPER intron 17255346 rs157776 chr15 76756703 T C 9.43E-05 Non-alcoholic fatty liver disease histology (other) SCAPER intron 20708005 rs17364076 chr15 76760891 C T 2.56E-04 Multiple complex diseases SCAPER intron 17554300 rs157764 chr15 76786788 C A 1.17E-04 Multiple complex diseases SCAPER intron 17554300 rs4886813 chr15 76838221 T C 1.18E-04 Multiple complex diseases SCAPER intron 17554300 rs2120108 chr15 76869929 A C 1.54E-04 Multiple complex diseases SCAPER intron 17554300 rs1867197 chr15 76910031 G A 9.32E-05 Multiple complex diseases SCAPER intron 17554300 rs12904417 chr15 76964152 G A 2.88E-04 Multiple complex diseases SCAPER intron 17554300 rs12440511 chr15 76993135 A G 4.83E-04 Multiple complex diseases SCAPER intron 17554300 rs2404602 chr15 77030792 A G 4.00E-13 Blood metabolite levels SCAPER intron 24816252 rs4641709 chr15 77047736 T C 2.41E-04 Multiple complex diseases SCAPER intron 17554300 rs11072625 chr15 77084984 G A 7.84E-04 Multiple complex diseases SCAPER intron 17554300 rs4886503 chr15 77108874 T C 1.25E-04 Multiple complex diseases SCAPER intron 17554300 rs3812908 chr15 77176158 T C 4.05E-04 Multiple complex diseases SCAPER missense 17554300 rs17464903 chr15 77195486 A G 1.94E-04 Multiple complex diseases / / 17554300 rs2469206 chr15 77247268 A G 4.66E-05 Brain structure / / 22504417 rs12148386 chr15 77254544 T C 4.56E-04 Smoking initiation / / 24665060 rs4420499 chr15 77314974 G T 3.60E-04 Myasthenia gravis PSTPIP1 intron 23055271 rs7402884 chr15 77381959 A G 8.96E-05 Cognitive impairment induced by topiramate / / 22091778 rs12899474 chr15 77391603 C T 0.00016 Schizophrenia / / 22440650 rs4886850 chr15 77404160 G C 3.10E-05 Type 2 diabetes PEAK1 UTR-3 21874001 rs1446312 chr15 77412189 G C 2.60E-05 Type 2 diabetes PEAK1 intron 21874001 rs12909704 chr15 77450964 C T 7.18E-05 Rheumatoid arthritis PEAK1 missense 19503088 rs4243045 chr15 77455914 A C 2.80E-05 Type 2 diabetes PEAK1 intron 21874001 rs11630770 chr15 77469643 G A 2.12E-04 Multiple complex diseases PEAK1 intron 17554300 rs11856513 chr15 77471105 C A 1.34E-05 Lymphocyte counts PEAK1 intron 22286170 rs7163503 chr15 77493505 C A 3.10E-05 Type 2 diabetes PEAK1 intron 21874001 rs12913233 chr15 77543297 C T 2.37E-05 Type 2 diabetes PEAK1 intron 22158537 rs2175941 chr15 77584498 T C 2.40E-05 Type 2 diabetes PEAK1 intron 21874001 rs11858641 chr15 77585820 C T 2.90E-05 Type 2 diabetes PEAK1 intron 21874001 rs11857294 chr15 77596725 C T 2.90E-05 Type 2 diabetes PEAK1 intron 21874001 rs11633318 chr15 77602698 T C 5.17E-04 Type 2 diabetes PEAK1 intron 22158537 rs11636554 chr15 77608747 G A 2.37E-05 Type 2 diabetes PEAK1 intron 22158537 rs1191196 chr15 77646504 C T 2.70E-05 Type 2 diabetes PEAK1 intron 21874001 rs1565757 chr15 77657682 C T 3.17E-05 Type 2 diabetes PEAK1 intron 22158537 rs7162362 chr15 77660093 G A 5.57E-06 Rheumatoid arthritis PEAK1 intron 19503088 rs7162362 chr15 77660093 G A 6.01E-04 Type 2 diabetes PEAK1 intron 22158537 rs12914345 chr15 77670401 A C 1.77E-05 Type 2 diabetes PEAK1 intron 22158537 rs11632729 chr15 77722006 G A 5.19E-04 Type 2 diabetes HMG20A intron 22158537 rs16968835 chr15 77734261 G A 5.77E-04 Type 2 diabetes HMG20A intron 22158537 rs7178572 chr15 77747190 A G 7.00E-11 Type 2 diabetes HMG20A intron 21874001 rs7178572 chr15 77747190 A G 1.00E-08 Type 2 diabetes HMG20A intron 22693455 rs7178572 chr15 77747190 A G 0.000000022 Type 2 diabetes HMG20A intron 22885922 rs7178572 chr15 77747190 A G 7.10E-11 Type 2 diabetes HMG20A intron 23300278 rs7178572 chr15 77747190 A G 2.00E-11 Type 2 diabetes HMG20A intron 24509480 rs937237 chr15 77747869 T C 6.12E-04 Response to taxane treatment (placlitaxel) HMG20A intron 23006423 rs12917143 chr15 77748016 A C 6.00E-04 Smoking initiation HMG20A intron 24665060 rs12906220 chr15 77759743 T C 2.33E-04 Smoking initiation HMG20A intron 24665060 rs7119 chr15 77777632 C T 5.00E-07 Type 2 diabetes / / 21490949 rs7119 chr15 77777632 C T 4.78E-04 Type 2 diabetes / / 22158537 rs7119 chr15 77777632 C T 4.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11857450 chr15 77802791 G C 3.10E-05 Type 2 diabetes / / 21874001 rs8040318 chr15 77803660 A C 5.00E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12902896 chr15 77809150 A C 7.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12917175 chr15 77818193 T C 4.93E-04 Type 2 diabetes / / 17463246 rs12901471 chr15 77818992 A G 5.76E-04 Type 2 diabetes / / 17463246 rs7177055 chr15 77832762 G A 0.0000018 Type 2 diabetes (males) / / 22885922 rs7177055 chr15 77832762 G A 0.0000038 Fasting blood glucose / / 22885922 rs7177055 chr15 77832762 G A 0.000013 Type 2 diabetes (females) / / 22885922 rs7177055 chr15 77832762 G A 4.60E-09 Type 2 diabetes / / 22885922 rs11630540 chr15 77833625 G A 5.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17394732 chr15 77835657 C T 2.05E-04 Type 2 diabetes / / 17463246 rs12909292 chr15 77837982 G T 9.12E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs907371 chr15 77844375 T C 5.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs907372 chr15 77844516 G T 7.30E-09 Type 2 diabetes / / 22885922 rs12902898 chr15 77849191 T C 5.31E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12917044 chr15 77850146 C T 4.40E-04 Type 2 diabetes / / 17463246 rs12917044 chr15 77850146 C T 2.35E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12917431 chr15 77850184 G C 3.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2137111 chr15 77851535 G A 7.00E-06 Anticoagulant levels / / 22216198 rs2667768 chr15 77875117 C A 2.87E-04 Multiple complex diseases / / 17554300 rs2682912 chr15 77875268 T G 5.28E-08 Narcolepsy / / 19629137 rs9806734 chr15 77887071 C G 4.82E-04 Multiple complex diseases / / 17554300 rs16968998 chr15 77897197 C T 3.73E-04 Myopia (pathological) / / 21095009 rs9652490 chr15 77963887 A G 1.00E-09 Essential tremor / / 19182806 rs7178761 chr15 77974460 G A 9.99E-05 Smoking initiation / / 24665060 rs4078063 chr15 77975762 C A 1.33E-04 Smoking initiation / / 24665060 rs9920633 chr15 77986268 T C 7.83E-04 Type 2 diabetes / / 17463246 rs11072662 chr15 77999436 A G 9.99E-04 Multiple complex diseases / / 17554300 rs11072662 chr15 77999436 A G 0.000359 Salmonella-induced pyroptosis / / 22837397 rs4886898 chr15 78004743 T C 0.000787 Salmonella-induced pyroptosis / / 22837397 rs6495246 chr15 78060547 C A 3.67E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs11857839 chr15 78091880 C G 3.50E-04 Multiple complex diseases / / 17554300 rs11857839 chr15 78091880 C G 5.92E-04 Alzheimer's disease / / 17998437 rs7164311 chr15 78096877 C G 6.06E-04 Type 2 diabetes / / 17463246 rs3936093 chr15 78101909 A G 8.01E-04 Multiple complex diseases / / 17554300 rs11852704 chr15 78106103 C A 4.59E-04 Alzheimer's disease / / 17998437 rs11857499 chr15 78131683 A T 2.57E-04 Type 2 diabetes / / 17463246 rs10468064 chr15 78158893 C T 1.18E-06 Waist-Hip Ratio / / pha003029 rs11857176 chr15 78164706 T C 8.00E-07 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs12904164 chr15 78207027 A G 4.27E-06 Insulin-related traits / / 22791750 rs7175950 chr15 78236353 A G 3.03E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LOC440292 intron 24023788 rs4617822 chr15 78263438 C T 6.70E-06 Urinary metabolites / / 21572414 rs12906542 chr15 78269472 A G 7.00E-07 Breast cancer / / 23354978 rs10519181 chr15 78288975 G C 1.04E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses TBC1D2B UTR-3 17903301 rs10519181 chr15 78288975 G C 1.70E-04 Statin-induced myopathy TBC1D2B UTR-3 21826682 rs4886554 chr15 78344922 G A 3.87E-05 Alcohol and nictotine co-dependence TBC1D2B intron 20158304 rs4886554 chr15 78344922 G A 8.86E-07 Schizophrenia TBC1D2B intron 21926974 rs12148365 chr15 78349350 G A 2.06E-05 Alcohol and nictotine co-dependence TBC1D2B intron 20158304 rs16969464 chr15 78362979 G A 7.37E-04 Smoking cessation TBC1D2B intron 24665060 rs11631180 chr15 78374581 T C 4.26E-06 Alcohol and nictotine co-dependence / / 20158304 rs16969482 chr15 78377610 T C 5.10E-06 Kawasaki disease / / 22446962 rs4473152 chr15 78381660 C G 8.15E-07 Interleukin levels (IL10,IL1Ra,IL6),in plasma / / 22205395 rs7182113 chr15 78392357 G A 2.48E-04 Endometrial cancer SH2D7 intron 24096698 rs2028548 chr15 78439120 C T 5.75E-05 Leukocyte Counts / / pha003091 rs8032618 chr15 78452003 C T 4.05E-04 Smoking quantity IDH3A intron 24665060 rs2304824 chr15 78466127 T C 2.46E-04 Smoking quantity ACSBG1 missense 24665060 rs8035724 chr15 78470542 G A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ACSBG1 intron 22628534 rs8033802 chr15 78499787 A C 4.74E-04 Lung function (forced expiratory volume in 1 second) ACSBG1 intron 24023788 rs4887017 chr15 78504662 A G 6.65E-04 Multiple complex diseases ACSBG1 intron 17554300 rs16969580 chr15 78506245 A G 5.65E-04 Multiple complex diseases ACSBG1 intron 17554300 rs11629576 chr15 78507316 G A 6.77E-05 Response to taxane treatment (placlitaxel) ACSBG1 intron 23006423 rs8037412 chr15 78509542 T A 9.15E-04 Response to taxane treatment (placlitaxel) ACSBG1 intron 23006423 rs11072744 chr15 78510819 G T 7.62E-05 Behcet's disease ACSBG1 intron pha002888 rs4886563 chr15 78527616 G T 6.72E-05 Body Mass Index / / pha003021 rs1533665 chr15 78530940 G A 7.00E-06 Personality dimensions / / 20691247 rs4887023 chr15 78535437 C G 1.68E-07 Red blood cell traits / / 23222517 rs12591810 chr15 78536209 A G 1.26E-07 Red blood cell traits / / 23222517 rs12904669 chr15 78536529 C T 8.16E-08 Red blood cell traits / / 23222517 rs12439144 chr15 78536924 G A 9.11E-07 Red blood cell traits / / 23222517 rs7166069 chr15 78539092 C A 2.19E-07 Red blood cell traits / / 23222517 rs12916463 chr15 78540267 A G 2.51E-04 Glycosylated haemoglobin levels / / 17255346 rs11633014 chr15 78546189 T C 9.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs41422846 chr15 78548078 T C 0.000841 Salmonella-induced pyroptosis / / 22837397 rs8039884 chr15 78550081 G T 1.15E-07 Red blood cell traits / / 23222517 rs17402006 chr15 78565188 T C 8.60E-05 Height D/JA4 intron pha003010 rs17402006 chr15 78565188 T C 2.90E-05 Height D/JA4 intron pha003011 rs11638991 chr15 78569950 A G 7.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) D/JA4 intron 20877124 rs1519820 chr15 78577207 G A 8.55E-05 Height WDR61 intron pha003011 rs7173851 chr15 78578659 T G 5.75E-04 Alcohol dependence WDR61 intron 24277619 rs2280366 chr15 78585898 T C 5.06E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WDR61 intron 20877124 rs2280366 chr15 78585898 T C 3.65E-07 Red blood cell traits WDR61 intron 23222517 rs2867932 chr15 78591037 A G 3.33E-09 Red blood cell traits WDR61 intron 23222517 rs4887029 chr15 78591510 C T 3.31E-07 Red blood cell traits WDR61 intron 23222517 rs16969711 chr15 78606913 A G 2.02E-05 Height / / pha003010 rs16969711 chr15 78606913 A G 1.63E-05 Height / / pha003011 rs8027394 chr15 78617913 T C 6.71E-05 Postoperative ventricular dysfunction / / 21980348 rs16969725 chr15 78637938 G A 5.38E-04 Fibrinogen CRABP1 intron 17255346 rs16969725 chr15 78637938 G A 7.14E-04 Suicide attempts in bipolar disorder CRABP1 intron 21423239 rs7168166 chr15 78644885 C T 7.93E-04 Multiple complex diseases / / 17554300 rs7168166 chr15 78644885 C T 7.51E-04 Lymphocyte counts / / 22286170 rs2037348 chr15 78653563 G A 5.85E-05 Relative hand skill in reading disability / / 24068947 rs3843956 chr15 78656319 A C 6.00E-05 IgE levels / / 17255346 rs3843956 chr15 78656319 A C 6.95E-05 Serum metabolites / / 19043545 rs2037349 chr15 78657720 G A 1.62E-04 IgE levels / / 17255346 rs2869036 chr15 78667572 G A 3.36E-06 Brain infarcts,covert MRI-defined / / 20044523 rs12900333 chr15 78678276 C T 0.0000062 Lumbar spine bone mineral density / / 22692763 rs12900333 chr15 78678276 C T 0.0000756 Lumbar spine bone mineral density (males) / / 22692763 rs4243082 chr15 78682076 C T 9.30E-04 Spine bone size / / 23207799 rs6495296 chr15 78696492 A G 3.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6495296 chr15 78696492 A G 4.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7163013 chr15 78698759 C T 9.00E-06 Obesity-related traits / / 23251661 rs2869030 chr15 78711803 G T 4.60E-24 Smoking behavior / / 20418888 rs2869030 chr15 78711803 G T 3.70E-08 Smoking behavior / / 20418890 rs4887053 chr15 78712699 A C,T 5.60E-10 Lung cancer / / 18978787 rs4887053 chr15 78712699 A C,T 5.94E-11 Lung cancer / / 19654303 rs4887053 chr15 78712699 A C,T 9.99E-16 Lung adenocarcinoma / / 19836008 rs4887053 chr15 78712699 A C,T 1.50E-32 Smoking behavior / / 20418888 rs4887053 chr15 78712699 A C,T 1.09E-07 Smoking behavior / / 20418890 rs4887053 chr15 78712699 A C,T 2.60E-20 Lung cancer / / 22899653 rs2869032 chr15 78714561 C T 2.60E-32 Smoking behavior / / 20418888 rs2869032 chr15 78714561 C T 1.29E-29 Smoking behavior / / 20418889 rs2869032 chr15 78714561 C T 1.14E-07 Smoking behavior / / 20418890 rs2869045 chr15 78718899 T C 1.10E-32 Smoking behavior / / 20418888 rs2869045 chr15 78718899 T C 1.10E-30 Smoking behavior / / 20418889 rs2869045 chr15 78718899 T C 1.15E-07 Smoking behavior / / 20418890 rs2568498 chr15 78721932 A T 2.46E-04 Multiple complex diseases / / 17554300 rs2568498 chr15 78721932 A T 2.50E-05 Smoking behavior / / 20418888 rs2568498 chr15 78721932 A T 1.06E-05 Smoking behavior / / 20418889 rs1394371 chr15 78724469 C T 4.30E-10 Lung cancer / / 18978787 rs1394371 chr15 78724469 C T 4.00E-08 Lung cancer / / 18978790 rs1394371 chr15 78724469 C T 1.27E-09 Lung cancer / / 19654303 rs1394371 chr15 78724469 C T 1.87E-22 Lung adenocarcinoma / / 19836008 rs1394371 chr15 78724469 C T 6.90E-36 Smoking behavior / / 20418888 rs1394371 chr15 78724469 C T 2.19E-33 Smoking behavior / / 20418889 rs1394371 chr15 78724469 C T 1.20E-28 Lung cancer / / 22899653 rs12903150 chr15 78724645 A G 3.22E-05 Lung adenocarcinoma / / 19836008 rs2568500 chr15 78726928 C T 3.60E-06 Smoking behavior / / 20418888 rs2568500 chr15 78726928 C T 2.90E-07 Smoking behavior / / 20418889 rs17483548 chr15 78730313 G A 6.55E-04 Nicotine dependence / / 17158188 rs17483548 chr15 78730313 G A 6.30E-50 Smoking behavior / / 20418888 rs17483548 chr15 78730313 G A 4.93E-48 Smoking behavior / / 20418889 rs17405217 chr15 78731149 C T 5.95E-04 Nicotine dependence IREB2 intron 17158188 rs17405217 chr15 78731149 C T 2.50E-50 Smoking behavior IREB2 intron 20418888 rs17405217 chr15 78731149 C T 2.09E-48 Smoking behavior IREB2 intron 20418889 rs924840 chr15 78731808 T A 4.00E-31 Smoking behavior IREB2 intron 20418888 rs924840 chr15 78731808 T A 4.62E-29 Smoking behavior IREB2 intron 20418889 rs924840 chr15 78731808 T A 1.11E-06 Smoking behavior IREB2 intron 20418890 rs2938671 chr15 78732754 A G 1.90E-31 Smoking behavior IREB2 intron 20418888 rs2938671 chr15 78732754 A G 1.84E-29 Smoking behavior IREB2 intron 20418889 rs2938671 chr15 78732754 A G 1.14E-06 Smoking behavior IREB2 intron 20418890 rs17483721 chr15 78733731 T C 9.10E-51 Smoking behavior IREB2 intron 20418888 rs17483721 chr15 78733731 T C 7.01E-49 Smoking behavior IREB2 intron 20418889 rs1847529 chr15 78735070 A C 7.00E-06 Smoking behavior IREB2 intron 20418888 rs1847529 chr15 78735070 A C 3.72E-06 Smoking behavior IREB2 intron 20418889 rs8041628 chr15 78735355 C G 6.00E-05 Smoking behavior IREB2 intron 20418888 rs8041628 chr15 78735355 C G 3.47E-06 Smoking behavior IREB2 intron 20418889 rs2568488 chr15 78736593 T A 3.70E-31 Smoking behavior IREB2 intron 20418888 rs2568488 chr15 78736593 T A 1.15E-28 Smoking behavior IREB2 intron 20418889 rs2568488 chr15 78736593 T A 4.62E-07 Smoking behavior IREB2 intron 20418890 rs2656052 chr15 78740932 A C 2.70E-51 Smoking behavior IREB2 intron 20418888 rs2656052 chr15 78740932 A C 5.57E-49 Smoking behavior IREB2 intron 20418889 rs2568494 chr15 78740964 G A 2.00E-51 Smoking behavior IREB2 intron 20418888 rs2568494 chr15 78740964 G A 1.61E-49 Smoking behavior IREB2 intron 20418889 rs7181486 chr15 78741618 T C 1.70E-51 Smoking behavior IREB2 intron 20418888 rs7181486 chr15 78741618 T C 1.48E-49 Smoking behavior IREB2 intron 20418889 rs2656073 chr15 78742276 T G 2.30E-31 Smoking behavior IREB2 intron 20418888 rs2656073 chr15 78742276 T G 2.74E-29 Smoking behavior IREB2 intron 20418889 rs2656073 chr15 78742276 T G 4.91E-07 Smoking behavior IREB2 intron 20418890 rs17483929 chr15 78742376 G A 6.00E-51 Smoking behavior IREB2 intron 20418888 rs17483929 chr15 78742376 G A 2.73E-49 Smoking behavior IREB2 intron 20418889 rs10519198 chr15 78742754 C A 3.18E-04 Multiple complex diseases IREB2 intron 17554300 rs10519198 chr15 78742754 C A 7.55E-07 Lung adenocarcinoma IREB2 intron 19836008 rs10519198 chr15 78742754 C A 3.40E-06 Smoking behavior IREB2 intron 20418888 rs10519198 chr15 78742754 C A 1.87E-06 Smoking behavior IREB2 intron 20418889 rs10519198 chr15 78742754 C A 2.60E-08 Lung cancer IREB2 intron 22899653 rs2958719 chr15 78743029 G A 2.50E-27 Smoking behavior IREB2 intron 20418888 rs2958719 chr15 78743029 G A 3.98E-06 Smoking behavior IREB2 intron 20418890 rs12909921 chr15 78743260 A G 4.20E-06 Smoking behavior IREB2 intron 20418888 rs12909921 chr15 78743260 A G 2.16E-06 Smoking behavior IREB2 intron 20418889 rs12910090 chr15 78743300 A C 4.30E-06 Smoking behavior IREB2 intron 20418888 rs12910090 chr15 78743300 A C 2.13E-06 Smoking behavior IREB2 intron 20418889 rs2656071 chr15 78745343 T A 3.50E-31 Smoking behavior IREB2 intron 20418888 rs2656071 chr15 78745343 T A 1.25E-29 Smoking behavior IREB2 intron 20418889 rs2656071 chr15 78745343 T A 5.23E-07 Smoking behavior IREB2 intron 20418890 rs2656069 chr15 78745707 C T 2.37E-14 Lung adenocarcinoma IREB2 intron 19836008 rs2656069 chr15 78745707 C T 1.10E-30 Smoking behavior IREB2 intron 20418888 rs2656069 chr15 78745707 C T 4.19E-29 Smoking behavior IREB2 intron 20418889 rs2656069 chr15 78745707 C T 5.18E-07 Smoking behavior IREB2 intron 20418890 rs2656069 chr15 78745707 C T 1.35E-06 chronic obstructive pulmonary disease IREB2 intron 21921092 rs2656069 chr15 78745707 C T 2.00E-08 Lung cancer IREB2 intron 22899653 rs2656065 chr15 78750549 G A 1.20E-52 Smoking behavior IREB2 intron 20418888 rs2656065 chr15 78750549 G A 1.04E-50 Smoking behavior IREB2 intron 20418889 rs2568483 chr15 78752343 G A 3.70E-31 Smoking behavior IREB2 intron 20418888 rs2568483 chr15 78752343 G A 1.32E-29 Smoking behavior IREB2 intron 20418889 rs2568483 chr15 78752343 G A 4.52E-07 Smoking behavior IREB2 intron 20418890 rs11639224 chr15 78753371 A G 2.40E-06 Smoking behavior IREB2 intron 20418888 rs11639224 chr15 78753371 A G 1.25E-06 Smoking behavior IREB2 intron 20418889 rs1964678 chr15 78754000 A G 2.50E-32 Smoking behavior IREB2 intron 20418888 rs1964678 chr15 78754000 A G 3.17E-29 Smoking behavior IREB2 intron 20418889 rs2009746 chr15 78754102 A G 2.70E-53 Smoking behavior IREB2 intron 20418888 rs2009746 chr15 78754102 A G 1.67E-51 Smoking behavior IREB2 intron 20418889 rs2938674 chr15 78757913 C A 3.30E-31 Smoking behavior IREB2 intron 20418888 rs2938674 chr15 78757913 C A 1.76E-29 Smoking behavior IREB2 intron 20418889 rs2938674 chr15 78757913 C A 4.42E-07 Smoking behavior IREB2 intron 20418890 rs17484235 chr15 78761414 C G 5.49E-04 Nicotine dependence IREB2 intron 17158188 rs17484235 chr15 78761414 C G 5.20E-41 Smoking behavior IREB2 intron 20418888 rs17484235 chr15 78761414 C G 4.38E-51 Smoking behavior IREB2 intron 20418889 rs4299116 chr15 78766194 T A 1.40E-32 Smoking behavior IREB2 intron 20418888 rs4299116 chr15 78766194 T A 1.80E-29 Smoking behavior IREB2 intron 20418889 rs1504550 chr15 78766250 A G 5.10E-54 Smoking behavior IREB2 intron 20418888 rs1504550 chr15 78766250 A G 3.28E-52 Smoking behavior IREB2 intron 20418889 rs12910910 chr15 78767850 C T 2.00E-32 Smoking behavior IREB2 intron 20418888 rs12910910 chr15 78767850 C T 3.03E-29 Smoking behavior IREB2 intron 20418889 rs8043227 chr15 78768871 C G 1.60E-13 Smoking behavior IREB2 intron 20418888 rs8043227 chr15 78768871 C G 3.89E-29 Smoking behavior IREB2 intron 20418889 rs11072766 chr15 78771546 C T 7.40E-32 Smoking behavior IREB2 intron 20418888 rs11072766 chr15 78771546 C T 4.90E-30 Smoking behavior IREB2 intron 20418889 rs11072766 chr15 78771546 C T 3.78E-07 Smoking behavior IREB2 intron 20418890 rs17484524 chr15 78772676 A G 2.00E-54 Smoking behavior IREB2 intron 20418888 rs17484524 chr15 78772676 A G 1.44E-52 Smoking behavior IREB2 intron 20418889 rs8042238 chr15 78774271 C T 1.10E-32 Smoking behavior IREB2 intron 20418888 rs8042238 chr15 78774271 C T 1.61E-29 Smoking behavior IREB2 intron 20418889 rs8042260 chr15 78774374 A G 1.60E-32 Smoking behavior IREB2 intron 20418888 rs8042260 chr15 78774374 A G 2.64E-29 Smoking behavior IREB2 intron 20418889 rs12903295 chr15 78778972 A G 5.00E-32 Smoking behavior IREB2 intron 20418888 rs12903295 chr15 78778972 A G 4.44E-29 Smoking behavior IREB2 intron 20418889 rs12904234 chr15 78779384 C T 4.70E-32 Smoking behavior IREB2 intron 20418888 rs12904234 chr15 78779384 C T 6.24E-29 Smoking behavior IREB2 intron 20418889 rs11858836 chr15 78783277 G A 1.00E-06 Chronic obstructive pulmonary disease IREB2 intron 22080838 rs965604 chr15 78789223 G A 2.30E-32 Smoking behavior IREB2 intron 20418888 rs965604 chr15 78789223 G A 1.59E-29 Smoking behavior IREB2 intron 20418889 rs13180 chr15 78789488 C T 6.00E-07 Lung cancer IREB2 cds-synon 18978790 rs13180 chr15 78789488 C T 7.12E-10 Lung cancer IREB2 cds-synon 19654303 rs13180 chr15 78789488 C T 1.45E-17 Lung adenocarcinoma IREB2 cds-synon 19836008 rs13180 chr15 78789488 C T 2.00E-08 Chronic obstructive pulmonary disease IREB2 cds-synon 20173748 rs13180 chr15 78789488 C T 4.20E-32 Smoking behavior IREB2 cds-synon 20418888 rs13180 chr15 78789488 C T 2.49E-29 Smoking behavior IREB2 cds-synon 20418889 rs13180 chr15 78789488 C T 9.93E-08 chronic obstructive pulmonary disease IREB2 cds-synon 21921092 rs13180 chr15 78789488 C T 9.30E-20 Lung cancer IREB2 cds-synon 22899653 rs1062980 chr15 78792527 T C 2.35E-10 Lung cancer IREB2 UTR-3 19654303 rs1062980 chr15 78792527 T C 9.05E-13 Lung adenocarcinoma IREB2 UTR-3 19836008 rs1062980 chr15 78792527 T C 3.42E-05 Chronic obstructive pulmonary disease IREB2 UTR-3 20173748 rs1062980 chr15 78792527 T C 8.70E-33 Smoking behavior IREB2 UTR-3 20418888 rs1062980 chr15 78792527 T C 1.32E-29 Smoking behavior IREB2 UTR-3 20418889 rs1062980 chr15 78792527 T C 9.53E-08 chronic obstructive pulmonary disease IREB2 UTR-3 21921092 rs1062980 chr15 78792527 T C 2.50E-04 Lung cancer IREB2 UTR-3 22899653 rs4362358 chr15 78796104 C T 1.50E-33 Smoking behavior / / 20418888 rs4362358 chr15 78796104 C T 1.38E-30 Smoking behavior / / 20418889 rs5019044 chr15 78796282 T A 9.40E-33 Smoking behavior / / 20418888 rs5019044 chr15 78796282 T A 5.62E-30 Smoking behavior / / 20418889 rs5019044 chr15 78796282 T A 1.47E-07 Smoking behavior / / 20418890 rs9788682 chr15 78802586 G A 1.20E-41 Smoking behavior AGPHD1 intron 20418888 rs9788682 chr15 78802586 G A 2.40E-39 Smoking behavior AGPHD1 intron 20418889 rs9788682 chr15 78802586 G A 1.06E-08 Smoking behavior AGPHD1 intron 20418890 rs9788721 chr15 78802869 C T 5.00E-68 Smoking behavior AGPHD1 intron 20418888 rs9788721 chr15 78802869 C T 2.97E-64 Smoking behavior AGPHD1 intron 20418889 rs200049096 chr15 78803057 C CCTT 1.80E-41 Smoking behavior AGPHD1 intron 20418888 rs200049096 chr15 78803057 C CCTT 1.39E-37 Smoking behavior AGPHD1 intron 20418889 rs200049096 chr15 78803057 C CCTT 1.25E-08 Smoking behavior AGPHD1 intron 20418890 rs7164594 chr15 78803057 C T 1.80E-41 Smoking behavior AGPHD1 intron 20418888 rs7164594 chr15 78803057 C T 1.39E-37 Smoking behavior AGPHD1 intron 20418889 rs7164594 chr15 78803057 C T 1.25E-08 Smoking behavior AGPHD1 intron 20418890 rs8034191 chr15 78806023 T C 3.00E-18 Lung cancer AGPHD1 intron 18385676 rs8034191 chr15 78806023 T C 5.00E-20 Lung cancer AGPHD1 intron 18385738 rs8034191 chr15 78806023 T C 1.00E-08 Lung cancer AGPHD1 intron 18780872 rs8034191 chr15 78806023 T C 4.03E-19 Lung cancer AGPHD1 intron 18978787 rs8034191 chr15 78806023 T C 3.00E-15 Lung cancer AGPHD1 intron 18978790 rs8034191 chr15 78806023 T C 1.00E-10 Chronic obstructive pulmonary disease AGPHD1 intron 19300482 rs8034191 chr15 78806023 T C 3.00E-26 Lung cancer AGPHD1 intron 19654303 rs8034191 chr15 78806023 T C 2.19E-46 Lung adenocarcinoma AGPHD1 intron 19836008 rs8034191 chr15 78806023 T C 5.31E-06 Chronic obstructive pulmonary disease AGPHD1 intron 20173748 rs8034191 chr15 78806023 T C 6.80E-68 Smoking behavior AGPHD1 intron 20418888 rs8034191 chr15 78806023 T C 1.04E-63 Smoking behavior AGPHD1 intron 20418889 rs8034191 chr15 78806023 T C 3.00E-26 Nasopharyngeal carcinoma AGPHD1 intron 20512145 rs8034191 chr15 78806023 T C 3.68E-06 F-cell distribution AGPHD1 intron 21326311 rs8034191 chr15 78806023 T C 1.06E-07 chronic obstructive pulmonary disease AGPHD1 intron 21921092 rs8034191 chr15 78806023 T C 9.50E-59 Lung cancer AGPHD1 intron 22899653 rs12591557 chr15 78811732 A G 3.90E-07 Smoking behavior AGPHD1 intron 20418888 rs12591557 chr15 78811732 A G 8.31E-08 Smoking behavior AGPHD1 intron 20418889 rs10519203 chr15 78814046 G A 3.10E-67 Smoking behavior AGPHD1 intron 20418888 rs10519203 chr15 78814046 G A 3.12E-63 Smoking behavior AGPHD1 intron 20418889 rs7163730 chr15 78814681 A G 6.10E-43 Smoking behavior AGPHD1 intron 20418888 rs7163730 chr15 78814681 A G 4.39E-40 Smoking behavior AGPHD1 intron 20418889 rs7163730 chr15 78814681 A G 1.22E-08 Smoking behavior AGPHD1 intron 20418890 rs8031948 chr15 78816057 G T 4.60E-68 Smoking behavior AGPHD1 intron 20418888 rs8031948 chr15 78816057 G T 1.62E-64 Smoking behavior AGPHD1 intron 20418889 rs8031948 chr15 78816057 G T 3.00E-09 Airflow obstruction AGPHD1 intron 22837378 rs4461039 chr15 78817447 A T 5.80E-44 Smoking behavior AGPHD1 intron 20418888 rs4461039 chr15 78817447 A T 5.81E-41 Smoking behavior AGPHD1 intron 20418889 rs4461039 chr15 78817447 A T 1.29E-08 Smoking behavior AGPHD1 intron 20418890 rs1504545 chr15 78818471 G C 9.33E-04 Multiple complex diseases AGPHD1 intron 17554300 rs952215 chr15 78819153 T C 4.42E-04 Multiple complex diseases AGPHD1 intron 17554300 rs12902493 chr15 78819275 C G 6.22E-04 Multiple complex diseases AGPHD1 intron 17554300 rs3885951 chr15 78825917 A G 6.19E-07 Lung adenocarcinoma AGPHD1 missense 19836008 rs3885951 chr15 78825917 A G 4.20E-16 Smoking behavior AGPHD1 missense 20418888 rs3885951 chr15 78825917 A G 2.20E-05 Lung cancer AGPHD1 missense 22899653 rs931794 chr15 78826180 G A 7.30E-69 Smoking behavior AGPHD1 intron 20418888 rs931794 chr15 78826180 G A 7.75E-66 Smoking behavior AGPHD1 intron 20418889 rs2036534 chr15 78826948 T C 9.81E-14 Lung cancer AGPHD1 intron 18978787 rs2036534 chr15 78826948 T C 5.00E-06 Lung cancer AGPHD1 intron 18978790 rs2036534 chr15 78826948 T C 2.23E-12 Lung cancer AGPHD1 intron 19654303 rs2036534 chr15 78826948 T C 5.29E-28 Lung adenocarcinoma AGPHD1 intron 19836008 rs2036534 chr15 78826948 T C 7.20E-43 Smoking behavior AGPHD1 intron 20418888 rs2036534 chr15 78826948 T C 3.99E-40 Smoking behavior AGPHD1 intron 20418889 rs2036534 chr15 78826948 T C 1.38E-08 Smoking behavior AGPHD1 intron 20418890 rs2036534 chr15 78826948 T C 1.38E-06 chronic obstructive pulmonary disease AGPHD1 intron 21921092 rs2036534 chr15 78826948 T C 3.30E-25 Lung cancer AGPHD1 intron 22899653 rs28675338 chr15 78827631 C T 1.00E-07 Chronic obstructive pulmonary disease AGPHD1 intron 21685187 rs58709975 chr15 78827631 C CT 1.00E-07 Chronic obstructive pulmonary disease AGPHD1 intron 21685187 rs12915366 chr15 78831753 G A 5.07E-05 Lung adenocarcinoma / / 19836008 rs3813571 chr15 78832792 G T 4.58E-04 Multiple complex diseases PSMA4 UTR-5 17554300 rs3813571 chr15 78832792 G T 7.20E-30 Progranulin levels PSMA4 UTR-5 21087763 rs3813571 chr15 78832792 G T 7.20E-30 Myocardial infarction PSMA4 UTR-5 21211798 rs3813570 chr15 78832832 T C 1.70E-41 Smoking behavior PSMA4 UTR-5 20418888 rs3813570 chr15 78832832 T C 3.06E-39 Smoking behavior PSMA4 UTR-5 20418889 rs3813570 chr15 78832832 T C 1.53E-08 Smoking behavior PSMA4 UTR-5 20418890 rs12901682 chr15 78833223 A C 4.00E-08 Response to tocilizumab in rheumatoid arthritis PSMA4 intron 22491018 rs4243083 chr15 78833830 C G 2.27E-08 Smoking behavior PSMA4 intron 20418889 rs2292117 chr15 78834689 A G 4.10E-04 Multiple complex diseases PSMA4 intron 17554300 rs2292117 chr15 78834689 A G 6.86E-05 Lung adenocarcinoma PSMA4 intron 19836008 rs4887063 chr15 78839715 C T 4.51E-04 Multiple complex diseases PSMA4 intron 17554300 rs4887063 chr15 78839715 C T 1.30E-07 Smoking behavior PSMA4 intron 20418888 rs4887063 chr15 78839715 C T 6.97E-08 Smoking behavior PSMA4 intron 20418889 rs1979907 chr15 78842239 T C 4.40E-09 Smoking behavior / / 20418888 rs1979907 chr15 78842239 T C 3.19E-09 Smoking behavior / / 20418889 rs1979906 chr15 78842289 C T 2.90E-04 Multiple complex diseases / / 17554300 rs1979905 chr15 78842374 A C 3.72E-04 Multiple complex diseases / / 17554300 rs1979905 chr15 78842374 A C 4.40E-09 Smoking behavior / / 20418888 rs1979905 chr15 78842374 A C 3.37E-09 Smoking behavior / / 20418889 rs4887064 chr15 78842847 G C 8.20E-07 Smoking behavior / / 20418888 rs4887064 chr15 78842847 G C 3.79E-09 Smoking behavior / / 20418889 rs12907966 chr15 78843051 C T 5.40E-09 Smoking behavior / / 20418888 rs12907966 chr15 78843051 C T 3.60E-09 Smoking behavior / / 20418889 rs880395 chr15 78844356 A G 6.50E-09 Smoking behavior / / 20418888 rs880395 chr15 78844356 A G 4.23E-09 Smoking behavior / / 20418889 rs905740 chr15 78844386 T C 6.40E-09 Smoking behavior / / 20418888 rs905740 chr15 78844386 T C 4.07E-09 Smoking behavior / / 20418889 rs7164030 chr15 78844661 G A 7.20E-09 Smoking behavior / / 20418888 rs7164030 chr15 78844661 G A 4.50E-09 Smoking behavior / / 20418889 rs4275821 chr15 78849541 C T 5.90E-11 Smoking behavior / / 20418888 rs4275821 chr15 78849541 C T 2.27E-10 Smoking behavior / / 20418889 rs7173512 chr15 78849914 C T 4.58E-06 Multiple complex diseases / / 17554300 rs7173512 chr15 78849914 C T 4.80E-11 Smoking behavior / / 20418888 rs7173512 chr15 78849914 C T 1.90E-10 Smoking behavior / / 20418889 rs2036527 chr15 78851615 G A 1.60E-67 Smoking behavior / / 20418888 rs2036527 chr15 78851615 G A 6.62E-65 Smoking behavior / / 20418889 rs2036527 chr15 78851615 G A 7.00E-07 Pulmonary function / / 21946350 rs2036527 chr15 78851615 G A 2.00E-08 Smoking behavior / / 22832964 rs684513 chr15 78858400 C G 2.60E-32 Smoking behavior CHR/5 intron 20418888 rs684513 chr15 78858400 C G 5.75E-39 Smoking behavior CHR/5 intron 20418889 rs684513 chr15 78858400 C G 6.30E-09 Smoking behavior CHR/5 intron 20418890 rs7166003 chr15 78861517 C T 5.71E-04 Multiple complex diseases CHR/5 intron 17554300 rs667282 chr15 78863472 T C 1.60E-42 Smoking behavior CHR/5 intron 20418888 rs667282 chr15 78863472 T C 1.07E-41 Smoking behavior CHR/5 intron 20418889 rs667282 chr15 78863472 T C 1.26E-08 Smoking behavior CHR/5 intron 20418890 rs667282 chr15 78863472 T C 2.00E-07 Smoking behavior CHR/5 intron 22832964 rs6495306 chr15 78865893 G A 8.43E-08 Lung adenocarcinoma CHR/5 intron 19836008 rs6495306 chr15 78865893 G A 1.80E-09 Lung cancer CHR/5 intron 22899653 rs17486278 chr15 78867482 A C 1.00E-66 Smoking behavior CHR/5 intron 20418888 rs17486278 chr15 78867482 A C 3.71E-64 Smoking behavior CHR/5 intron 20418889 rs17486278 chr15 78867482 A C 2.00E-07 Airflow obstruction CHR/5 intron 22837378 rs680244 chr15 78871288 T C 1 Drug response to Nicotine CHR/5 intron 18618000 rs680244 chr15 78871288 T C 6.31E-08 Lung adenocarcinoma CHR/5 intron 19836008 rs680244 chr15 78871288 T C 7.20E-10 Lung cancer CHR/5 intron 22899653 rs569207 chr15 78873119 C T 1 Drug response to Nicotine CHR/5 intron 18618000 rs569207 chr15 78873119 C T 3.70E-28 Smoking behavior CHR/5 intron 20418888 rs569207 chr15 78873119 C T 1.52E-24 Smoking behavior CHR/5 intron 20418889 rs569207 chr15 78873119 C T 2.35E-05 Smoking behavior CHR/5 intron 20418890 rs637137 chr15 78873976 T A 1.00E-42 Smoking behavior CHR/5 intron 20418888 rs637137 chr15 78873976 T A 1.07E-41 Smoking behavior CHR/5 intron 20418889 rs637137 chr15 78873976 T A 1.66E-08 Smoking behavior CHR/5 intron 20418890 rs7180002 chr15 78873993 A T 1.40E-66 Smoking behavior CHR/5 intron 20418888 rs7180002 chr15 78873993 A T 5.83E-64 Smoking behavior CHR/5 intron 20418889 rs481134 chr15 78877563 A G 4.41E-04 Multiple complex diseases CHR/5 intron 17554300 rs481134 chr15 78877563 A G 1.55E-04 Sudden cardiac arrest CHR/5 intron 21658281 rs951266 chr15 78878541 G A 6.00E-04 Nicotine dependence CHR/5 intron 18227835 rs951266 chr15 78878541 G A 1.40E-64 Smoking behavior CHR/5 intron 20418888 rs951266 chr15 78878541 G A 3.19E-61 Smoking behavior CHR/5 intron 20418889 rs16969968 chr15 78882925 G A 1 Drug response to Nicotine CHR/5 missense 18618000 rs16969968 chr15 78882925 G A 7.00E-68 Smoking behavior CHR/5 missense 20418888 rs16969968 chr15 78882925 G A 4.29E-65 Smoking behavior CHR/5 missense 20418889 rs16969968 chr15 78882925 G A 5.60E-72 Smoking behavior CHR/5 missense 22832964 rs518425 chr15 78883813 A G 1.50E-36 Smoking behavior CHR/5 intron 20418888 rs518425 chr15 78883813 A G 2.73E-36 Smoking behavior CHR/5 intron 20418889 rs514743 chr15 78884227 T A 3.18E-05 Multiple complex diseases CHR/5 intron 17554300 rs578776 chr15 78888400 G A 1 Drug response to Nicotine CHR/3 UTR-3 18618000 rs578776 chr15 78888400 G A 8.83E-11 Lung cancer CHR/3 UTR-3 19654303 rs578776 chr15 78888400 G A 8.93E-22 Lung adenocarcinoma CHR/3 UTR-3 19836008 rs578776 chr15 78888400 G A 1.30E-37 Smoking behavior CHR/3 UTR-3 20418888 rs578776 chr15 78888400 G A 6.93E-37 Smoking behavior CHR/3 UTR-3 20418889 rs578776 chr15 78888400 G A 1.90E-09 Lung cancer CHR/3 UTR-3 22899653 rs12910984 chr15 78891627 G A 1.71E-14 Lung cancer CHR/3 intron 19654303 rs12910984 chr15 78891627 G A 5.56E-25 Lung adenocarcinoma CHR/3 intron 19836008 rs12910984 chr15 78891627 G A 9.60E-43 Smoking behavior CHR/3 intron 20418888 rs12910984 chr15 78891627 G A 2.96E-42 Smoking behavior CHR/3 intron 20418889 rs12910984 chr15 78891627 G A 2.07E-08 Smoking behavior CHR/3 intron 20418890 rs12910984 chr15 78891627 G A 1.10E-16 Lung cancer CHR/3 intron 22899653 rs1051730 chr15 78894339 G A 1.33E-09 Lung cancer CHR/3 cds-synon 18385676 rs1051730 chr15 78894339 G A 5.40E-09 Lung cancer CHR/3 cds-synon 18385738 rs1051730 chr15 78894339 G A 6.00E-20 Nicotine dependence CHR/3 cds-synon 18385739 rs1051730 chr15 78894339 G A 1 Drug response to Nicotine CHR/3 cds-synon 18618000 rs1051730 chr15 78894339 G A 2.83E-19 Lung cancer CHR/3 cds-synon 18978787 rs1051730 chr15 78894339 G A 1.00E-15 Lung cancer CHR/3 cds-synon 18978790 rs1051730 chr15 78894339 G A 9.60E-14 Lung cancer CHR/3 cds-synon 19654303 rs1051730 chr15 78894339 G A 2.00E-51 Lung adenocarcinoma CHR/3 cds-synon 19836008 rs1051730 chr15 78894339 G A 2.14E-05 Chronic obstructive pulmonary disease CHR/3 cds-synon 20173748 rs1051730 chr15 78894339 G A 2.00E-69 Smoking behavior CHR/3 cds-synon 20418888 rs1051730 chr15 78894339 G A 2.00E-66 Smoking behavior CHR/3 cds-synon 20418889 rs1051730 chr15 78894339 G A 3.00E-73 Smoking behavior CHR/3 cds-synon 20418890 rs1051730 chr15 78894339 G A 2.00E-51 Nasopharyngeal carcinoma CHR/3 cds-synon 20512145 rs1051730 chr15 78894339 G A 6.00E-20 Coronary heart disease CHR/3 cds-synon 21347282 rs1051730 chr15 78894339 G A 5.54E-07 chronic obstructive pulmonary disease CHR/3 cds-synon 21921092 rs1051730 chr15 78894339 G A 2.80E-75 Smoking behavior CHR/3 cds-synon 22832964 rs1051730 chr15 78894339 G A 2.20E-63 Lung cancer CHR/3 cds-synon 22899653 rs1051730 chr15 78894339 G A 0.0008651 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CHR/3 cds-synon 23233654 rs1051730 chr15 78894339 G A 8.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) CHR/3 cds-synon 23233662 rs1051730 chr15 78894339 G A 8.65E-04 Response to antipsychotic treatment CHR/3 cds-synon 23241943 rs3743078 chr15 78894759 C G 6.80E-21 Smoking behavior CHR/3 intron 20418888 rs3743078 chr15 78894759 C G 4.62E-44 Smoking behavior CHR/3 intron 20418889 rs3743078 chr15 78894759 C G 2.25E-08 Smoking behavior CHR/3 intron 20418890 rs1317286 chr15 78896129 A G 2.60E-06 Nicotine dependence CHR/3 intron 18227835 rs1317286 chr15 78896129 A G 6.20E-68 Smoking behavior CHR/3 intron 20418888 rs1317286 chr15 78896129 A G 3.56E-65 Smoking behavior CHR/3 intron 20418889 rs938682 chr15 78896547 G A 7.11E-15 Lung cancer CHR/3 intron 19654303 rs938682 chr15 78896547 G A 1.74E-25 Lung adenocarcinoma CHR/3 intron 19836008 rs938682 chr15 78896547 G A 1.10E-43 Smoking behavior CHR/3 intron 20418888 rs938682 chr15 78896547 G A 3.29E-43 Smoking behavior CHR/3 intron 20418889 rs938682 chr15 78896547 G A 1.76E-08 Smoking behavior CHR/3 intron 20418890 rs938682 chr15 78896547 G A 1.00E-16 Lung cancer CHR/3 intron 22899653 rs12914385 chr15 78898723 C T 3.19E-16 Lung cancer CHR/3 intron 19654303 rs12914385 chr15 78898723 C T 2.75E-38 Lung adenocarcinoma CHR/3 intron 19836008 rs12914385 chr15 78898723 C T 6.70E-69 Smoking behavior CHR/3 intron 20418888 rs12914385 chr15 78898723 C T 7.83E-66 Smoking behavior CHR/3 intron 20418889 rs12914385 chr15 78898723 C T 2.81E-07 chronic obstructive pulmonary disease CHR/3 intron 21921092 rs12914385 chr15 78898723 C T 5.00E-07 Pulmonary function CHR/3 intron 21946350 rs12914385 chr15 78898723 C T 2.80E-28 Lung cancer CHR/3 intron 22899653 rs12914385 chr15 78898723 C T 6.00E-07 Serum albumin level CHR/3 intron 23022100 rs12914385 chr15 78898723 C T 0.0008534 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CHR/3 intron 23233654 rs12914385 chr15 78898723 C T 8.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) CHR/3 intron 23233662 rs12914385 chr15 78898723 C T 8.53E-04 Response to antipsychotic treatment CHR/3 intron 23241943 rs12914385 chr15 78898723 C T 3.00E-16 Chronic obstructive pulmonary disease (severe) CHR/3 intron 24621683 rs12914385 chr15 78898723 C T 6.00E-14 Chronic obstructive pulmonary disease (moderate to severe) CHR/3 intron 24621683 rs11637630 chr15 78899719 G A 1.60E-44 Smoking behavior CHR/3 intron 20418888 rs11637630 chr15 78899719 G A 3.76E-44 Smoking behavior CHR/3 intron 20418889 rs11637630 chr15 78899719 G A 1.59E-08 Smoking behavior CHR/3 intron 20418890 rs7177514 chr15 78907406 C G 6.60E-36 Smoking behavior CHR/3 intron 20418888 rs7177514 chr15 78907406 C G 2.92E-42 Smoking behavior CHR/3 intron 20418889 rs7177514 chr15 78907406 C G 1.43E-08 Smoking behavior CHR/3 intron 20418890 rs6495308 chr15 78907656 T C 6.90E-05 Nicotine dependence CHR/3 intron 18227835 rs6495308 chr15 78907656 T C 6.30E-44 Smoking behavior CHR/3 intron 20418888 rs6495308 chr15 78907656 T C 5.82E-44 Smoking behavior CHR/3 intron 20418889 rs6495308 chr15 78907656 T C 1.74E-08 Smoking behavior CHR/3 intron 20418890 rs12443170 chr15 78907736 G A 1.70E-23 Smoking behavior CHR/3 intron 20418888 rs12443170 chr15 78907736 G A 1.46E-25 Smoking behavior CHR/3 intron 20418889 rs12443170 chr15 78907736 G A 5.97E-06 Smoking behavior CHR/3 intron 20418890 rs8042059 chr15 78907859 A C 2.60E-44 Smoking behavior CHR/3 intron 20418888 rs8042059 chr15 78907859 A C 5.06E-44 Smoking behavior CHR/3 intron 20418889 rs8042059 chr15 78907859 A C 1.49E-08 Smoking behavior CHR/3 intron 20418890 rs8042374 chr15 78908032 A G 8.00E-12 Lung cancer CHR/3 intron 18978787 rs8042374 chr15 78908032 A G 2.70E-15 Lung cancer CHR/3 intron 19654303 rs8042374 chr15 78908032 A G 2.79E-25 Lung adenocarcinoma CHR/3 intron 19836008 rs8042374 chr15 78908032 A G 9.50E-43 Smoking behavior CHR/3 intron 20418888 rs8042374 chr15 78908032 A G 1.52E-42 Smoking behavior CHR/3 intron 20418889 rs8042374 chr15 78908032 A G 2.85E-08 Smoking behavior CHR/3 intron 20418890 rs8042374 chr15 78908032 A G 8.00E-12 Nasopharyngeal carcinoma CHR/3 intron 20512145 rs8042374 chr15 78908032 A G 1.10E-16 Lung cancer CHR/3 intron 22899653 rs4887069 chr15 78909070 A G 1.60E-39 Smoking behavior CHR/3 intron 20418888 rs4887069 chr15 78909070 A G 9.99E-39 Smoking behavior CHR/3 intron 20418889 rs4887069 chr15 78909070 A G 7.46E-08 Smoking behavior CHR/3 intron 20418890 rs3743075 chr15 78909452 T C 1.47E-05 Lung adenocarcinoma CHR/3 cds-synon 19836008 rs3743075 chr15 78909452 T C 6.70E-09 Smoking behavior CHR/3 cds-synon 20418888 rs3743075 chr15 78909452 T C 9.06E-05 Body Mass Index CHR/3 cds-synon pha003015 rs8040868 chr15 78911181 T C 5.80E-50 Smoking behavior CHR/3 cds-synon 20418888 rs8040868 chr15 78911181 T C 5.90E-44 Smoking behavior CHR/3 cds-synon 20418889 rs8040868 chr15 78911181 T C 6.00E-08 Obesity-related traits CHR/3 cds-synon 23251661 rs8040868 chr15 78911181 T C 7.00E-07 Pulmonary function (interaction) CHR/3 cds-synon 23284291 rs8040868 chr15 78911181 T C 9.00E-08 Pulmonary function (interaction) CHR/3 cds-synon 23284291 rs6495309 chr15 78915245 C T 1.85E-13 Lung cancer CHR/3 nearGene-5 18978787 rs6495309 chr15 78915245 C T 5.00E-06 Lung cancer CHR/3 nearGene-5 18978790 rs6495309 chr15 78915245 C T 1.93E-14 Lung cancer CHR/3 nearGene-5 19654303 rs6495309 chr15 78915245 C T 2.21E-29 Lung adenocarcinoma CHR/3 nearGene-5 19836008 rs6495309 chr15 78915245 C T 7.40E-41 Smoking behavior CHR/3 nearGene-5 20418888 rs6495309 chr15 78915245 C T 4.61E-40 Smoking behavior CHR/3 nearGene-5 20418889 rs6495309 chr15 78915245 C T 7.48E-08 Smoking behavior CHR/3 nearGene-5 20418890 rs6495309 chr15 78915245 C T 1.10E-32 Lung cancer CHR/3 nearGene-5 22899653 rs1948 chr15 78917399 A G 4.49E-06 Lung adenocarcinoma CHRNB4 cds-synon 19836008 rs17487223 chr15 78923987 C T 3.90E-61 Smoking behavior CHRNB4 intron 20418888 rs17487223 chr15 78923987 C T 3.18E-58 Smoking behavior CHRNB4 intron 20418889 rs950776 chr15 78926018 T C 1.28E-04 Multiple complex diseases CHRNB4 intron 17554300 rs950776 chr15 78926018 T C 1.80E-06 Lung adenocarcinoma CHRNB4 intron 19836008 rs950776 chr15 78926018 T C 4.00E-07 Sudden cardiac arrest CHRNB4 intron 21658281 rs950776 chr15 78926018 T C 7.00E-09 Lung cancer CHRNB4 intron 22899653 rs12440014 chr15 78926726 C G 1.10E-36 Smoking behavior CHRNB4 intron 20418888 rs12440014 chr15 78926726 C G 1.80E-41 Smoking behavior CHRNB4 intron 20418889 rs12441088 chr15 78928264 G T 2.60E-37 Smoking behavior CHRNB4 intron 20418888 rs12441088 chr15 78928264 G T 2.40E-34 Smoking behavior CHRNB4 intron 20418889 rs12441088 chr15 78928264 G T 4.21E-06 Smoking behavior CHRNB4 intron 20418890 rs11636605 chr15 78928878 A G 3.10E-28 Smoking behavior CHRNB4 intron 20418888 rs11636605 chr15 78928878 A G 9.08E-27 Smoking behavior CHRNB4 intron 20418889 rs11636605 chr15 78928878 A G 1.37E-05 Smoking behavior CHRNB4 intron 20418890 rs12441998 chr15 78929372 G A 2.06E-10 Lung cancer CHRNB4 intron 19654303 rs12441998 chr15 78929372 G A 1.58E-18 Lung adenocarcinoma CHRNB4 intron 19836008 rs12441998 chr15 78929372 G A 1.80E-28 Smoking behavior CHRNB4 intron 20418888 rs12441998 chr15 78929372 G A 7.02E-27 Smoking behavior CHRNB4 intron 20418889 rs12441998 chr15 78929372 G A 1.54E-05 Smoking behavior CHRNB4 intron 20418890 rs12441998 chr15 78929372 G A 2.60E-15 Lung cancer CHRNB4 intron 22899653 rs11072768 chr15 78929478 T G 3.50E-28 Smoking behavior CHRNB4 intron 20418888 rs11072768 chr15 78929478 T G 1.15E-26 Smoking behavior CHRNB4 intron 20418889 rs11072768 chr15 78929478 T G 1.44E-05 Smoking behavior CHRNB4 intron 20418890 rs1316971 chr15 78930510 A G 7.53E-10 Lung cancer CHRNB4 intron 19654303 rs1316971 chr15 78930510 A G 8.21E-18 Lung adenocarcinoma CHRNB4 intron 19836008 rs1316971 chr15 78930510 A G 5.50E-28 Smoking behavior CHRNB4 intron 20418888 rs1316971 chr15 78930510 A G 1.22E-26 Smoking behavior CHRNB4 intron 20418889 rs1316971 chr15 78930510 A G 1.54E-05 Smoking behavior CHRNB4 intron 20418890 rs1316971 chr15 78930510 A G 1.90E-14 Lung cancer CHRNB4 intron 22899653 rs9920506 chr15 78931057 A G 2.40E-19 Smoking behavior CHRNB4 intron 20418888 rs9920506 chr15 78931057 A G 4.98E-19 Smoking behavior CHRNB4 intron 20418889 rs9920506 chr15 78931057 A G 3.98E-05 Smoking behavior CHRNB4 intron 20418890 rs11637890 chr15 78935419 C G 2.25E-04 Sudden cardiac arrest / / 21658281 rs183951867 chr15 78940228 G A 0.0000562 Menopause (age at onset) / / 23424626 rs3971872 chr15 78942035 T C 9.99E-04 HIV-1 viral setpoint / / 17641165 rs11634351 chr15 78944718 G A 5.50E-46 Smoking behavior / / 20418888 rs11634351 chr15 78944718 G A 1.21E-43 Smoking behavior / / 20418889 rs8023822 chr15 78945040 C G 2.80E-05 Smoking behavior / / 20418888 rs8023822 chr15 78945040 C G 8.27E-14 Smoking behavior / / 20418889 rs12594247 chr15 78946633 C T 8.42E-07 Lung cancer / / 18978787 rs12594247 chr15 78946633 C T 1.47E-06 Lung cancer / / 19654303 rs12594247 chr15 78946633 C T 5.91E-13 Lung adenocarcinoma / / 19836008 rs12594247 chr15 78946633 C T 1.90E-18 Smoking behavior / / 20418888 rs12594247 chr15 78946633 C T 3.70E-18 Smoking behavior / / 20418889 rs12594247 chr15 78946633 C T 1.80E-14 Lung cancer / / 22899653 rs1021070 chr15 78946863 C G 2.60E-10 Smoking behavior / / 20418888 rs7181405 chr15 78948152 A G 6.00E-15 Smoking behavior / / 20418888 rs11638830 chr15 78948319 G C 5.00E-20 Smoking behavior / / 20418888 rs11638830 chr15 78948319 G C 2.13E-41 Smoking behavior / / 20418889 rs4887074 chr15 78952110 G C 1.90E-13 Smoking behavior / / 20418888 rs4887074 chr15 78952110 G C 4.17E-15 Smoking behavior / / 20418889 rs4887074 chr15 78952110 G C 9.51E-05 Smoking behavior / / 20418890 rs11072774 chr15 78952697 C T 3.00E-20 Smoking behavior / / 20418888 rs11072774 chr15 78952697 C T 6.71E-21 Smoking behavior / / 20418889 rs11072774 chr15 78952697 C T 3.88E-05 Smoking behavior / / 20418890 rs17487514 chr15 78953785 C T 1.48E-10 Lung adenocarcinoma / / 19836008 rs17487514 chr15 78953785 C T 8.40E-31 Smoking behavior / / 20418888 rs17487514 chr15 78953785 C T 1.52E-28 Smoking behavior / / 20418889 rs17487514 chr15 78953785 C T 1.90E-10 Lung cancer / / 22899653 rs12899135 chr15 78954379 A G 4.70E-42 Smoking behavior / / 20418888 rs12899135 chr15 78954379 A G 8.67E-41 Smoking behavior / / 20418889 rs12148319 chr15 78956192 A G 2.60E-14 Smoking behavior / / 20418888 rs12148319 chr15 78956192 A G 7.25E-15 Smoking behavior / / 20418889 rs12910237 chr15 78956338 C T 1.00E-13 Smoking behavior / / 20418888 rs1996371 chr15 78956806 T C 6.01E-09 Lung cancer / / 18978787 rs1996371 chr15 78956806 T C 6.00E-08 Lung cancer / / 18978790 rs1996371 chr15 78956806 T C 4.84E-08 Lung cancer / / 19654303 rs1996371 chr15 78956806 T C 1.40E-42 Smoking behavior / / 20418888 rs1996371 chr15 78956806 T C 8.10E-41 Smoking behavior / / 20418889 rs1996371 chr15 78956806 T C 1.10E-11 Lung cancer / / 22899653 rs12594550 chr15 78959037 C G 1.70E-12 Smoking behavior / / 20418888 rs12594550 chr15 78959037 C G 1.28E-15 Smoking behavior / / 20418889 rs6495314 chr15 78960529 A C 4.16E-09 Lung cancer / / 18978787 rs6495314 chr15 78960529 A C 8.00E-08 Lung cancer / / 18978790 rs6495314 chr15 78960529 A C 4.33E-08 Lung cancer / / 19654303 rs6495314 chr15 78960529 A C 1.03E-23 Lung adenocarcinoma / / 19836008 rs6495314 chr15 78960529 A C 2.10E-41 Smoking behavior / / 20418888 rs6495314 chr15 78960529 A C 5.02E-40 Smoking behavior / / 20418889 rs6495314 chr15 78960529 A C 2.20E-32 Lung cancer / / 22899653 rs922691 chr15 78963994 A G 1.77E-06 Lung adenocarcinoma / / 19836008 rs922691 chr15 78963994 A G 5.20E-12 Smoking behavior / / 20418888 rs12905641 chr15 78964362 C T 9.80E-13 Smoking behavior / / 20418888 rs11072784 chr15 78966058 T C 2.00E-06 Smoking behavior / / 20418888 rs28673058 chr15 78966422 C T 1.23E-04 Tuberculosis / / 22306650 rs11639372 chr15 78966655 C T 1.40E-41 Smoking behavior / / 20418888 rs11639372 chr15 78966655 C T 1.96E-40 Smoking behavior / / 20418889 rs12902602 chr15 78967401 A G 1.00E-41 Smoking behavior / / 20418888 rs12902602 chr15 78967401 A G 1.34E-40 Smoking behavior / / 20418889 rs1021071 chr15 78968179 G C 1.40E-19 Smoking behavior / / 20418888 rs1021071 chr15 78968179 G C 9.76E-41 Smoking behavior / / 20418889 rs11072785 chr15 78968229 C T 4.00E-41 Smoking behavior / / 20418888 rs11072785 chr15 78968229 C T 7.73E-40 Smoking behavior / / 20418889 rs11857532 chr15 78968268 T G 2.50E-31 Smoking behavior / / 20418888 rs11857532 chr15 78968268 T G 2.11E-31 Smoking behavior / / 20418889 rs4886580 chr15 78969385 T G 1.40E-41 Smoking behavior / / 20418888 rs4886580 chr15 78969385 T G 2.25E-40 Smoking behavior / / 20418889 rs16970006 chr15 78970259 T C 7.25E-07 Lung adenocarcinoma / / 19836008 rs16970006 chr15 78970259 T C 9.00E-11 Smoking behavior / / 20418888 rs8032552 chr15 78971136 T C 9.70E-13 Smoking behavior / / 20418888 rs11072787 chr15 78972977 T C 1.90E-13 Smoking behavior / / 20418888 rs11072787 chr15 78972977 T C 5.75E-13 Smoking behavior / / 20418889 rs8043123 chr15 78973393 C T 2.30E-12 Smoking behavior / / 20418888 rs8043123 chr15 78973393 C T 1.38E-12 Smoking behavior / / 20418889 rs8038920 chr15 78974545 A G 3.01E-09 Lung adenocarcinoma / / 19836008 rs8038920 chr15 78974545 A G 4.30E-13 Smoking behavior / / 20418888 rs8038920 chr15 78974545 A G 4.00E-12 Lung cancer / / 22899653 rs4887077 chr15 78978364 C T 2.07E-04 Multiple complex diseases / / 17554300 rs4887077 chr15 78978364 C T 7.89E-09 Lung cancer / / 18978787 rs4887077 chr15 78978364 C T 3.00E-07 Lung cancer / / 18978790 rs4887077 chr15 78978364 C T 6.85E-08 Lung cancer / / 19654303 rs4887077 chr15 78978364 C T 3.80E-40 Smoking behavior / / 20418888 rs4887077 chr15 78978364 C T 9.46E-39 Smoking behavior / / 20418889 rs4887077 chr15 78978364 C T 2.40E-17 Lung cancer / / 22899653 rs11638372 chr15 78983559 C T 1.48E-04 Multiple complex diseases / / 17554300 rs11638372 chr15 78983559 C T 7.23E-09 Lung cancer / / 18978787 rs11638372 chr15 78983559 C T 4.00E-07 Lung cancer / / 18978790 rs11638372 chr15 78983559 C T 5.93E-08 Lung cancer / / 19654303 rs11638372 chr15 78983559 C T 2.39E-22 Lung adenocarcinoma / / 19836008 rs11638372 chr15 78983559 C T 1.10E-39 Smoking behavior / / 20418888 rs11638372 chr15 78983559 C T 2.55E-38 Smoking behavior / / 20418889 rs11638372 chr15 78983559 C T 5.00E-31 Lung cancer / / 22899653 rs922692 chr15 78984214 C A 2.60E-40 Smoking behavior / / 20418888 rs922692 chr15 78984214 C A 6.60E-39 Smoking behavior / / 20418889 rs6495316 chr15 78986101 T A 1.44E-04 Multiple complex diseases / / 17554300 rs12910627 chr15 78994933 G C 7.70E-19 Smoking behavior / / 20418888 rs12910627 chr15 78994933 G C 2.38E-39 Smoking behavior / / 20418889 rs11072791 chr15 78997076 C A 1.30E-40 Smoking behavior / / 20418888 rs11072791 chr15 78997076 C A 2.26E-39 Smoking behavior / / 20418889 rs11072791 chr15 78997076 C A 5.75E-05 Cognitive impairment induced by topiramate / / 22091778 rs11633519 chr15 78999552 A G 2.40E-12 Smoking behavior / / 20418888 rs12899940 chr15 79001699 C T 2.60E-13 Smoking behavior / / 20418888 rs11634628 chr15 79005579 G A 1.60E-13 Smoking behavior / / 20418888 rs11072793 chr15 79006442 G A 7.67E-04 Type 2 diabetes / / 17463246 rs11072793 chr15 79006442 G A 1.20E-06 Lung adenocarcinoma / / 19836008 rs11072793 chr15 79006442 G A 1.30E-13 Smoking behavior / / 20418888 rs11072793 chr15 79006442 G A 7.80E-09 Lung cancer / / 22899653 rs11072794 chr15 79006582 T C 6.70E-04 Type 2 diabetes / / 17463246 rs11072794 chr15 79006582 T C 1.20E-13 Smoking behavior / / 20418888 rs11072794 chr15 79006582 T C 1.10E-12 Coronary artery disease / / 23202125 rs11638490 chr15 79007950 C T 1.10E-40 Smoking behavior / / 20418888 rs11638490 chr15 79007950 C T 7.11E-39 Smoking behavior / / 20418889 rs4887078 chr15 79011073 C T 9.50E-14 Smoking behavior / / 20418888 rs11629637 chr15 79019024 C T 1.40E-40 Smoking behavior / / 20418888 rs11629637 chr15 79019024 C T 8.09E-39 Smoking behavior / / 20418889 rs899997 chr15 79019578 G T 3.50E-12 Smoking behavior / / 20418888 rs899997 chr15 79019578 G T 2.00E-08 Coronary artery disease or large artery stroke / / 24262325 rs3813565 chr15 79019610 G T 1.40E-08 Lung cancer / / 19654303 rs3813565 chr15 79019610 G T 1.14E-17 Lung adenocarcinoma / / 19836008 rs3813565 chr15 79019610 G T 2.20E-41 Smoking behavior / / 20418888 rs3813565 chr15 79019610 G T 3.41E-40 Smoking behavior / / 20418889 rs3813565 chr15 79019610 G T 3.40E-17 Lung cancer / / 22899653 rs4887082 chr15 79025067 T C 1.10E-37 Smoking behavior / / 20418888 rs4887082 chr15 79025067 T C 7.27E-37 Smoking behavior / / 20418889 rs1383634 chr15 79029396 T C 1.50E-12 Smoking behavior / / 20418888 rs2219939 chr15 79029723 G A 4.60E-13 Smoking behavior / / 20418888 rs2219939 chr15 79029723 G A 2.00E-09 Coronary artery disease or ischemic stroke / / 24262325 rs4887091 chr15 79043580 T C 9.40E-12 Smoking behavior / / 20418888 rs7182567 chr15 79045054 A G 3.50E-12 Smoking behavior LOC646938 intron 20418888 rs3743068 chr15 79047285 G T 6.23E-04 Multiple complex diseases / / 17554300 rs12286 chr15 79051759 G A 2.90E-36 Smoking behavior ADAMTS7 UTR-3 20418888 rs12286 chr15 79051759 G A 1.18E-35 Smoking behavior ADAMTS7 UTR-3 20418889 rs1809420 chr15 79056769 T C 1.80E-31 Smoking behavior ADAMTS7 intron 20418888 rs1809420 chr15 79056769 T C 9.54E-31 Smoking behavior ADAMTS7 intron 20418889 rs7174367 chr15 79064667 A G 6.25E-05 Multiple complex diseases ADAMTS7 intron 17554300 rs7174367 chr15 79064667 A G 1.70E-34 Smoking behavior ADAMTS7 intron 20418888 rs7174367 chr15 79064667 A G 1.05E-33 Smoking behavior ADAMTS7 intron 20418889 rs7171916 chr15 79067951 G C 2.40E-21 Smoking behavior ADAMTS7 intron 20418888 rs7171916 chr15 79067951 G C 3.44E-28 Smoking behavior ADAMTS7 intron 20418889 rs1994016 chr15 79080234 C T 4.93E-07 Multiple complex diseases ADAMTS7 intron 17554300 rs1994016 chr15 79080234 C T 5.50E-23 Smoking behavior ADAMTS7 intron 20418888 rs1994016 chr15 79080234 C T 5.00E-13 Coronary heart disease ADAMTS7 intron 21239051 rs1994017 chr15 79080306 T C 6.70E-09 Smoking behavior ADAMTS7 intron 20418888 rs12905740 chr15 79082364 C T 1.20E-08 Smoking behavior ADAMTS7 intron 20418888 rs2277547 chr15 79082431 A G 4.11E-05 Lung adenocarcinoma ADAMTS7 intron 19836008 rs2277545 chr15 79083591 T C 3.10E-24 Smoking behavior ADAMTS7 intron 20418888 rs2277545 chr15 79083591 T C 1.05E-05 Cardiovascular disease risk factors ADAMTS7 intron 21239051 rs1564499 chr15 79084808 T C 3.49E-04 Type 2 diabetes ADAMTS7 intron 17463246 rs1564499 chr15 79084808 T C 6.19E-04 Multiple complex diseases ADAMTS7 intron 17554300 rs1564499 chr15 79084808 T C 1.30E-08 Smoking behavior ADAMTS7 intron 20418888 rs12903203 chr15 79084933 T C 1.70E-24 Smoking behavior ADAMTS7 intron 20418888 rs11631955 chr15 79085915 A G 2.15E-07 Multiple complex diseases ADAMTS7 intron 17554300 rs11631955 chr15 79085915 A G 1.80E-04 Coronary heart disease ADAMTS7 intron 21966275 rs2904228 chr15 79086099 G A 1.00E-08 Smoking behavior ADAMTS7 intron 20418888 rs3743057 chr15 79089007 T C 1.15E-06 Lung adenocarcinoma ADAMTS7 cds-synon 19836008 rs3743057 chr15 79089007 T C 3.90E-08 Smoking behavior ADAMTS7 cds-synon 20418888 rs3825807 chr15 79089111 A G 3.70E-24 Smoking behavior ADAMTS7 missense 20418888 rs3825807 chr15 79089111 A G 1.00E-12 Coronary heart disease ADAMTS7 missense 21378990 rs3825807 chr15 79089111 A G 1.07E-12 Pericardial fat ADAMTS7 missense 22589742 rs3825807 chr15 79089111 A G 7.00E-06 Coronary artery calcification ADAMTS7 missense 23561647 rs7177699 chr15 79089734 T C 7.80E-24 Smoking behavior ADAMTS7 intron 20418888 rs8038189 chr15 79099026 G C 1.80E-07 Smoking behavior ADAMTS7 intron 20418888 rs922693 chr15 79099538 G A 2.90E-10 Smoking behavior ADAMTS7 intron 20418888 rs11634042 chr15 79105350 C T 3.30E-18 Smoking behavior ADAMTS7 nearGene-5 20418888 rs11634042 chr15 79105350 C T 1.76E-16 Smoking behavior ADAMTS7 nearGene-5 20418889 rs1383636 chr15 79106220 G A 1.90E-10 Smoking behavior / / 20418888 rs4380028 chr15 79111093 C T 5.40E-07 Lung adenocarcinoma / / 19836008 rs4380028 chr15 79111093 C T 1.40E-11 Smoking behavior / / 20418888 rs4380028 chr15 79111093 C T 4.00E-09 Coronary heart disease / / 21378988 rs4380028 chr15 79111093 C T 6.20E-09 Lung cancer / / 22899653 rs6495335 chr15 79117133 G T 5.80E-12 Smoking behavior / / 20418888 rs7178051 chr15 79118296 C T 1.69E-06 Multiple complex diseases / / 17554300 rs7178051 chr15 79118296 C T 2.10E-12 Smoking behavior / / 20418888 rs7176187 chr15 79121373 T C 3.59E-06 Multiple complex diseases / / 17554300 rs7176187 chr15 79121373 T C 1.90E-12 Smoking behavior / / 20418888 rs11852830 chr15 79125429 A T 5.90E-17 Smoking behavior / / 20418888 rs8032771 chr15 79126059 A G 5.80E-17 Smoking behavior / / 20418888 rs4539564 chr15 79128499 G A 1.17E-06 Lung adenocarcinoma / / 19836008 rs4539564 chr15 79128499 G A 1.90E-16 Smoking behavior / / 20418888 rs4539564 chr15 79128499 G A 1.80E-09 Lung cancer / / 22899653 rs8035039 chr15 79129823 A G 3.70E-16 Smoking behavior / / 20418888 rs180807356 chr15 79130574 A G 0.0000752 Menopause (age at onset) / / 23424626 rs11072810 chr15 79132206 T C 5.90E-05 Multiple complex diseases / / 17554300 rs11072810 chr15 79132206 T C 2.70E-16 Smoking behavior / / 20418888 rs11072811 chr15 79132330 A C 1.83E-04 Multiple complex diseases / / 17554300 rs11072811 chr15 79132330 A C 2.50E-16 Smoking behavior / / 20418888 rs7403393 chr15 79135802 C G 1.40E-12 Smoking behavior / / 20418888 rs7173743 chr15 79141784 T C 2.30E-16 Smoking behavior / / 20418888 rs7173743 chr15 79141784 T C 0.00000196 Coronary artery disease (CAD) age <=50 / / 23202125 rs7173743 chr15 79141784 T C 0.0000223 Coronary artery disease (CAD) (females) / / 23202125 rs7173743 chr15 79141784 T C 1.57E-10 Coronary artery disease with myocardial infarction / / 23202125 rs7173743 chr15 79141784 T C 1.92E-09 Coronary artery disease (CAD) age >50 / / 23202125 rs7173743 chr15 79141784 T C 2.78E-08 Coronary artery disease (CAD) (males) / / 23202125 rs7173743 chr15 79141784 T C 3.21E-13 Coronary artery disease / / 23202125 rs7173743 chr15 79141784 T C 7.00E-08 Coronary artery disease / / 24262325 rs7181240 chr15 79145126 G A 0.00000179 Coronary artery disease / / 23202125 rs7164529 chr15 79145798 G A 9.72E-05 Bone mineral density / / 19181680 rs7164529 chr15 79145798 G A 5.10E-17 Smoking behavior / / 20418888 rs7164529 chr15 79145798 G A 5.00E-06 Age-related macular degeneration / / pha002869 rs7164529 chr15 79145798 G A 2.79E-06 Age-related macular degeneration / / pha002890 rs5029904 chr15 79152422 C G 1.00E-12 Smoking behavior / / 20418888 rs12595538 chr15 79154453 A T 1.60E-17 Smoking behavior / / 20418888 rs34872829 chr15 79154453 A ATT 1.60E-17 Smoking behavior / / 20418888 rs8029659 chr15 79167603 A G 3.58E-05 Lung adenocarcinoma MORF4L1 intron 19836008 rs8029659 chr15 79167603 A G 3.90E-11 Smoking behavior MORF4L1 intron 20418888 rs17243470 chr15 79172766 T G 7.20E-11 Smoking behavior MORF4L1 intron 20418888 rs17832351 chr15 79173005 A G 2.00E-11 Smoking behavior MORF4L1 intron 20418888 rs10519219 chr15 79190132 T C 8.44E-05 Heart Rate / / pha003051 rs894785 chr15 79214868 T G 4.04E-04 Smoking initiation CTSH intron 24665060 rs3784539 chr15 79219188 C T 0.00000309 Narcolepsy (non-HLA narcolepsy) CTSH intron 23459209 rs2289700 chr15 79224683 C T 9.00E-06 Bipolar disorder CTSH intron 21771265 rs16970287 chr15 79228257 A G 4.77E-06 Bipolar disorder CTSH intron 21771265 rs12148472 chr15 79231478 T C 2.37E-06 Type 1 diabetes CTSH intron 21980299 rs12148472 chr15 79231478 T C 0.00000388 Narcolepsy (non-HLA narcolepsy) CTSH intron 23459209 rs2870085 chr15 79234268 T C 1.48E-05 Response to Vitamin E supplementation CTSH intron 22437554 rs34843303 chr15 79234470 T C 2.79E-08 Narcolepsy (non-HLA narcolepsy) CTSH intron 23459209 rs34593439 chr15 79234957 G A 1.78E-08 Narcolepsy (non-HLA narcolepsy) CTSH intron 23459209 rs3825932 chr15 79235446 T C 6.55E-05 Multiple complex diseases CTSH intron 17554300 rs3825932 chr15 79235446 T C 3.00E-15 Type 1 diabetes CTSH intron 18978792 rs3825932 chr15 79235446 T C 8.00E-08 Type 1 diabetes CTSH intron 19430480 rs3825932 chr15 79235446 T C 3.00E-15 Multiple sclerosis CTSH intron 22190364 rs3825932 chr15 79235446 T C 5.24E-12 Lymphocyte counts CTSH intron 22286170 rs7183668 chr15 79256158 G T 2.34E-05 Heart Rate RASGRF1 intron pha003051 rs8039661 chr15 79259009 C T 0.0000531 Narcolepsy (non-HLA narcolepsy) RASGRF1 intron 23459209 rs57623551 chr15 79261077 A G 0.0000864 Narcolepsy (non-HLA narcolepsy) RASGRF1 intron 23459209 rs3743200 chr15 79274046 C T 5.66E-04 Type 2 diabetes RASGRF1 intron 17463246 rs3743200 chr15 79274046 C T 2.00E-06 RR interval (heart rate) RASGRF1 intron 20031603 rs3743201 chr15 79274253 T A 4.90E-04 Type 2 diabetes RASGRF1 intron 17463246 rs7168964 chr15 79274691 G A 2.96E-04 Type 2 diabetes RASGRF1 intron 17463246 rs116883402 chr15 79277486 C T 0.000056 Breast cancer (ER positive) RASGRF1 missense 23555315 rs7169735 chr15 79303453 T C 2.93E-04 Smoking initiation RASGRF1 intron 24665060 rs1373202 chr15 79321788 A C 5.62E-04 Response to cytadine analogues (cytosine arabinoside) RASGRF1 intron 24483146 rs1373201 chr15 79327168 G A 5.03E-04 Response to cytadine analogues (cytosine arabinoside) RASGRF1 intron 24483146 rs744059 chr15 79359505 C T 6.74E-04 Response to cytadine analogues (cytosine arabinoside) RASGRF1 intron 24483146 rs7174521 chr15 79362090 C A 8.88E-05 Cardiovascular disease RASGRF1 intron pha003065 rs4778879 chr15 79372875 A G 4.00E-11 Refractive error RASGRF1 intron 23396134 rs6495367 chr15 79375347 G A 3.86E-05 Refractive error RASGRF1 intron 20835236 rs6495367 chr15 79375347 G A 7.60E-06 Myopia (severe) RASGRF1 intron 23933737 rs28412916 chr15 79378167 A C 3.50E-11 Myopia (Age of onset) RASGRF1 intron 23468642 rs13380104 chr15 79378821 C T 4.42E-05 Refractive error RASGRF1 intron 20835236 rs1007365 chr15 79379492 T G 4.77E-05 Refractive error RASGRF1 intron 20835236 rs2049176 chr15 79392548 A C 2.54E-05 Refractive error / / 20835236 rs13379776 chr15 79394577 G T 1.32E-05 Myopia (severe) / / 23933737 rs7172107 chr15 79396743 G A 3.72E-04 Gallstones / / 17632509 rs2102999 chr15 79410710 T C 1.95E-05 Refractive error / / 20835236 rs8035606 chr15 79420245 C T 2.06E-05 Refractive error / / 20835236 rs1915726 chr15 79420620 C G 3.69E-07 Refractive error / / 20835236 rs1829673 chr15 79422503 T C 1.63E-05 Myopia (severe) / / 23933737 rs8031638 chr15 79422726 C T 4.48E-07 Refractive error / / 20835236 rs8024813 chr15 79427260 A G 3.93E-07 Refractive error / / 20835236 rs7166140 chr15 79430980 C T 9.40E-06 Urinary metabolites / / 21572414 rs939661 chr15 79431063 A G 2.73E-07 Refractive error / / 20835236 rs939661 chr15 79431063 A G 3.00E-05 Heart Rate / / pha003051 rs12595749 chr15 79432359 A G 6.39E-06 Refractive error / / 20835236 rs11634679 chr15 79432475 T C 3.83E-07 Refractive error / / 20835236 rs11635757 chr15 79432737 T C 3.83E-07 Refractive error / / 20835236 rs11630571 chr15 79432992 C A 3.82E-07 Refractive error / / 20835236 rs12902831 chr15 79433171 G A 3.82E-07 Refractive error / / 20835236 rs11638625 chr15 79434787 T G 3.96E-07 Refractive error / / 20835236 rs11634903 chr15 79436192 A G 3.94E-07 Refractive error / / 20835236 rs1402760 chr15 79439159 G A 4.36E-05 Myopia (severe) / / 23933737 rs4778924 chr15 79443363 T C 3.34E-07 Refractive error / / 20835236 rs11631411 chr15 79445816 C T 3.34E-07 Refractive error / / 20835236 rs4778651 chr15 79447810 G A 9.81E-07 Refractive error / / 20835236 rs2204069 chr15 79449335 A G 1.00E-06 Refractive error / / 20835236 rs12903747 chr15 79449627 A C 1.01E-06 Refractive error / / 20835236 rs939658 chr15 79451869 A G 2.00E-09 Refractive error / / 20835236 rs8033963 chr15 79455350 C T 1.59E-07 Refractive error / / 20835236 rs12439908 chr15 79456381 T C 1.69E-07 Refractive error / / 20835236 rs11629665 chr15 79457133 G A 1.69E-07 Refractive error / / 20835236 rs8031019 chr15 79458512 A G 1.69E-07 Refractive error / / 20835236 rs8031504 chr15 79458589 G T 1.69E-07 Refractive error / / 20835236 rs8027411 chr15 79461029 G T 7.91E-08 Refractive error / / 20835236 rs11072826 chr15 79461516 A G 1.38E-07 Refractive error / / 20835236 rs8038464 chr15 79463036 A T 6.35E-06 Refractive error / / 20835236 rs1474256 chr15 79463847 C T 2.77E-06 Refractive error / / 20835236 rs1474256 chr15 79463847 C T 6.00E-06 Bronchopulmonary dysplasia / / 23897914 rs1474256 chr15 79463847 C T 6.30E-06 Bronchopulmonary dysplasia / / 23897914 rs17175798 chr15 79463960 C T 1.38E-07 Refractive error / / 20835236 rs1434459 chr15 79465210 T C 2.49E-06 Refractive error / / 20835236 rs8024572 chr15 79465600 A G 2.67E-06 Refractive error / / 20835236 rs11634726 chr15 79465894 A G 2.21E-06 Refractive error / / 20835236 rs1560895 chr15 79468082 A G 4.52E-05 Refractive error / / 20835236 rs11072829 chr15 79470998 A G 2.49E-06 Refractive error / / 20835236 rs8028654 chr15 79484083 T G 3.60E-04 Alcohol dependence / / 20201924 rs9302287 chr15 79496350 A G 7.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC729911 intron 20877124 rs1001460 chr15 79504879 G A 9.51E-04 HIV-1 viral setpoint LOC729911 intron 17641165 rs16970717 chr15 79508010 A G 8.33E-05 Schizophrenia LOC729911 intron 19571809 rs1865360 chr15 79509424 A G 4.25E-05 Alzheimer's disease (late onset) LOC729911 intron 21379329 rs4779012 chr15 79510909 C A 8.00E-05 Glaucoma (primary open-angle) LOC729911 intron 20835238 rs4779031 chr15 79533372 C A 2.00E-06 IgG glycosylation LOC729911 intron 23382691 rs12903518 chr15 79537269 C T 0.00000543 Sasang constitution (Taeum) LOC729911 intron 22394158 rs7177417 chr15 79547515 G T 3.93E-04 Type 2 diabetes LOC729911 intron 17463246 rs8025118 chr15 79552379 G T 3.00E-06 Cognitive function LOC729911 intron 24684796 rs16970839 chr15 79609430 G A 2.64E-05 Type 2 diabetes TMED3 intron 22238593 rs12438018 chr15 79621516 G A 6.30E-08 Metabolite levels / / 23281178 rs6495392 chr15 79622321 A G 6.30E-08 Metabolite levels / / 23281178 rs6495393 chr15 79622356 G C 6.30E-08 Metabolite levels / / 23281178 rs6495394 chr15 79622387 C T 6.30E-08 Metabolite levels / / 23281178 rs6495395 chr15 79622404 T C 6.30E-08 Metabolite levels / / 23281178 rs4483826 chr15 79623743 A T 6.30E-08 Metabolite levels / / 23281178 rs4343261 chr15 79623941 C A 6.30E-08 Metabolite levels / / 23281178 rs4293356 chr15 79623985 G A 6.30E-08 Metabolite levels / / 23281178 rs4299130 chr15 79624481 G A 6.30E-08 Metabolite levels / / 23281178 rs4488417 chr15 79624559 A G 6.30E-08 Metabolite levels / / 23281178 rs17178444 chr15 79624911 A G 3.56E-04 Multiple complex diseases / / 17554300 rs17178444 chr15 79624911 A G 5.74E-08 Metabolite levels / / 23281178 rs16970860 chr15 79625582 T G 6.30E-08 Metabolite levels / / 23281178 rs8030533 chr15 79640953 G A 1.60E-05 Urinary metabolites / / 21572414 rs1018192 chr15 79692334 C A 1.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1395936 chr15 79696701 C T 6.99E-04 Type 2 diabetes / / 17463246 rs2055716 chr15 79697846 C T 2.63E-04 Type 2 diabetes / / 17463246 rs2865696 chr15 79698055 C T 6.83E-04 Type 2 diabetes / / 17463246 rs4779079 chr15 79699146 G A 6.02E-05 Lung function (forced vital capacity) / / 24023788 rs7169963 chr15 79741593 T G 6.33E-04 Substance dependence KIAA1024 intron 21818250 rs11634652 chr15 79749447 G T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes KIAA1024 missense 22628534 rs4778700 chr15 79787835 A G 9.66E-04 Alcohol dependence / / 21314694 rs8026171 chr15 79812987 G C 7.30E-04 Smoking quantity / / 24665060 rs11638410 chr15 79815143 G A 3.44E-04 Alcohol dependence / / 20201924 rs1415571 chr15 79819871 G T 8.11E-04 Alcohol dependence / / 20201924 rs1415571 chr15 79819871 G T 0.000016 Type 2 diabetes (females) / / 22885922 rs1685148 chr15 79835542 A T 8.01E-04 Aortic root size / / 21223598 rs1765248 chr15 79840124 G A 8.20E-06 Urinary metabolites / / 21572414 rs1685166 chr15 79840843 T C 8.20E-06 Urinary metabolites / / 21572414 rs1613454 chr15 79845759 T C 3.50E-06 Urinary metabolites / / 21572414 rs1685169 chr15 79846906 A G 4.70E-06 Urinary metabolites / / 21572414 rs1685157 chr15 79866993 T C 2.60E-05 Urinary metabolites / / 21572414 rs3904801 chr15 79867594 C G 2.21E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1765266 chr15 79869987 G A 7.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4779118 chr15 79884174 A T 1.94E-04 Multiple complex diseases / / 17554300 rs4778710 chr15 79884209 C T 2.38E-04 Multiple complex diseases / / 17554300 rs936894 chr15 79896166 C T 9.58E-04 Multiple complex diseases / / 17554300 rs11072865 chr15 79898351 T C 6.72E-04 Multiple complex diseases / / 17554300 rs2865199 chr15 79903372 T C 1.17E-11 Multiple complex diseases / / 17554300 rs7163832 chr15 79906344 A G 5.00E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs8031905 chr15 79907101 T A 8.32E-04 Multiple complex diseases / / 17554300 rs1872825 chr15 79907643 C T 9.52E-04 Multiple complex diseases / / 17554300 rs1872826 chr15 79907777 A G 9.29E-04 Multiple complex diseases / / 17554300 rs11854796 chr15 79924480 A G 3.17E-05 Post-operative nausea and vomiting / / 21694509 rs10519267 chr15 79924714 G A 0.000890177 Hypertension (early onset hypertension) / / 22479346 rs11857724 chr15 79950522 C A 1.32E-04 Type 2 diabetes / / 17463246 rs3913520 chr15 79953416 T G 6.84E-05 Type 2 diabetes / / 17463246 rs3913521 chr15 79953464 A G 6.60E-05 Type 2 diabetes / / 17463246 rs16954047 chr15 79954753 A G 1.74E-04 Type 2 diabetes / / 17463246 rs4779131 chr15 79955294 A G 6.69E-05 Type 2 diabetes / / 17463246 rs3913523 chr15 79956789 A T 6.84E-05 Type 2 diabetes / / 17463246 rs7171557 chr15 79974022 G T 3.62E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4778721 chr15 79975749 C T 8.16E-04 Substance dependence / / 21818250 rs16971243 chr15 79979443 A G 9.00E-04 Asthma (childhood onset) / / 21359210 rs2865181 chr15 79999217 A G 9.40E-05 Bipolar disorder / / 20451256 rs2865181 chr15 79999217 A G 2.74E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs2692194 chr15 80013422 T G 9.00E-06 IgG glycosylation / / 23382691 rs282796 chr15 80016070 G C 8.59E-04 Multiple complex diseases / / 17554300 rs282796 chr15 80016070 G C 7.46E-05 Serum metabolites / / 19043545 rs16971298 chr15 80031681 T C 4.50E-06 Urinary metabolites / / 21572414 rs429217 chr15 80033626 C T 1.18E-04 Progressive supranuclear palsy / / 21685912 rs443394 chr15 80033885 C T 4.66E-06 Alcohol dependence / / 23089632 rs1460177 chr15 80034345 C T 1.80E-06 Urinary metabolites / / 21572414 rs7176846 chr15 80061250 C T 3.43E-05 Intracerebral hemorrhage / / 24656865 rs1473406 chr15 80061726 C T 2.42E-05 Intracerebral hemorrhage / / 24656865 rs1473407 chr15 80062044 C T 3.35E-05 Intracerebral hemorrhage / / 24656865 rs11855092 chr15 80090238 G A 1.12E-05 Blood Pressure / / pha003050 rs4393531 chr15 80093132 G A 8.25E-05 Blood Pressure / / pha003049 rs1088036 chr15 80094341 C T 0.00041 Salmonella-induced pyroptosis / / 22837397 rs1081230 chr15 80095646 A G 6.20E-05 Cognitive function / / 24684796 rs1380642 chr15 80096871 C T 1.73E-05 Blood Pressure / / pha003050 rs16971368 chr15 80104175 A G 2.97E-11 Lymphocyte counts / / 22286170 rs642697 chr15 80121160 C T 9.00E-05 Response to statin therapy / / 20339536 rs584055 chr15 80126521 A T 9.20E-05 Response to statin therapy / / 20339536 rs622506 chr15 80139195 A C 9.30E-05 Response to statin therapy MTHFS intron 20339536 rs7177659 chr15 80158042 A C 4.70E-04 Multiple complex diseases MTHFS intron 17554300 rs7177659 chr15 80158042 A C 7.31E-05 Cognitive impairment induced by topiramate MTHFS intron 22091778 rs1113983 chr15 80166597 C A 1.30E-04 Anorexia nervosa MTHFS intron 23568457 rs12899781 chr15 80168282 T G 6.25E-04 Type 2 diabetes MTHFS intron 17463246 rs16971502 chr15 80181735 A G 9.91E-04 Multiple complex diseases MTHFS intron 17554300 rs12898642 chr15 80182050 T C 6.53E-04 Myocardial Infarction MTHFS intron pha002883 rs17286040 chr15 80184983 C T 3.50E-06 Urinary metabolites MTHFS intron 21572414 rs36035742 chr15 80192975 C T 4.00E-06 Periodontitis (Mean PAL) ST20 intron 24024966 rs113021818 chr15 80203640 G A 0.0000125 Nonsyndromic striae distensae (stretch marks) ST20 intron 23633020 rs75598935 chr15 80219593 G A 6.00E-06 Periodontitis (Mean PAL) / / 24024966 rs11636338 chr15 80245590 A C 3.46E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2865831 chr15 80247372 A T 0.000461 Salmonella-induced pyroptosis / / 22837397 rs2562754 chr15 80255209 C T 2.78E-05 Brain derived neurotrophic factor levels,in serum BCL2A1 intron 22047184 rs1138358 chr15 80263345 A C 2.70E-04 Type 2 diabetes BCL2A1 missense 23209189 rs1138357 chr15 80263406 C T 2.80E-04 Type 2 diabetes BCL2A1 missense 23209189 rs1987102 chr15 80265888 T C 9.80E-04 Type 2 diabetes / / 23209189 rs1879894 chr15 80268819 C T 2.80E-04 Type 2 diabetes / / 23209189 rs939971 chr15 80322269 C A 8.92E-04 Multiple complex diseases / / 17554300 rs7164805 chr15 80339456 G A 7.14E-04 Schizophrenia / / 19197363 rs6495474 chr15 80377452 G T 5.24E-05 Type 2 diabetes ZFAND6 intron 17463246 rs6495474 chr15 80377452 G T 1.11E-04 Multiple complex diseases ZFAND6 intron 17554300 rs10519280 chr15 80392689 A G 3.23E-04 Lung function (forced vital capacity) ZFAND6 intron 24023788 rs12438497 chr15 80401973 A T 1.15E-04 Multiple complex diseases ZFAND6 intron 17554300 rs2903265 chr15 80413384 A G 9.15E-05 Type 2 diabetes ZFAND6 intron 17463246 rs2903265 chr15 80413384 A G 9.60E-06 Type 2 diabetes ZFAND6 intron 17463249 rs2903265 chr15 80413384 A G 9.57E-06 Multiple complex diseases ZFAND6 intron 17554300 rs11635107 chr15 80414718 A C 8.92E-05 Cognitive performance ZFAND6 intron 19734545 rs11635107 chr15 80414718 A C 2.69E-04 Lung function (forced vital capacity) ZFAND6 intron 24023788 rs11634397 chr15 80432222 A G 2.00E-09 Type 2 diabetes / / 20581827 rs11634397 chr15 80432222 A G 2.00E-09 Type 2 diabetes / / 21647700 rs11634397 chr15 80432222 A G 0.000018 Type 2 diabetes / / 22885922 rs11634397 chr15 80432222 A G 1.40E-05 Type 2 diabetes / / 24509480 rs8026959 chr15 80443036 T C 2.88E-04 Lung function (forced vital capacity) / / 24023788 rs1370276 chr15 80450328 T C 8.39E-04 Body mass index FAH intron 21701565 rs8027913 chr15 80453730 G T 1.56E-04 Lung function (forced vital capacity) FAH intron 24023788 rs2114716 chr15 80454745 T C 3.97E-04 Multiple complex diseases FAH intron 17554300 rs2114716 chr15 80454745 T C 6.71E-04 Smoking cessation FAH intron 24665060 rs1545119 chr15 80460524 A G 8.20E-06 HDL cholesterol FAH intron pha003075 rs8033974 chr15 80462342 A G 8.43E-04 Body mass index FAH intron 21701565 rs7180031 chr15 80464669 A G 1.70E-05 Urinary metabolites FAH intron 21572414 rs3752692 chr15 80465920 G A 0.000706 Salmonella-induced pyroptosis FAH intron 22837397 rs8043254 chr15 80469025 C T 2.53E-05 Blood Pressure FAH intron pha003045 rs8043254 chr15 80469025 C T 3.97E-05 Blood Pressure FAH intron pha003047 rs2866592 chr15 80470834 C T 4.53E-04 Body mass index FAH intron 17255346 rs2866592 chr15 80470834 C T 6.41E-04 Body mass index FAH intron 21701565 rs2866593 chr15 80471491 A G 4.53E-04 Body mass index FAH intron 17255346 rs2866593 chr15 80471491 A G 0.000815 Salmonella-induced pyroptosis FAH intron 22837397 rs2043692 chr15 80472243 T C 6.34E-05 Personality dimensions FAH intron 18957941 rs2043692 chr15 80472243 T C 2.17E-04 Lung function (forced expiratory volume in 1 second) FAH intron 24023788 rs2043692 chr15 80472243 T C 5.42E-05 Lung function (forced vital capacity) FAH intron 24023788 rs12594576 chr15 80476575 A G 3.39E-06 Multiple complex diseases FAH intron 17554300 rs7177977 chr15 80476793 A G 0.000526 Salmonella-induced pyroptosis FAH intron 22837397 rs8039712 chr15 80477571 G A 1.76E-04 Smoking cessation FAH intron 24665060 rs1049194 chr15 80478645 T C 2.90E-05 Urinary metabolites FAH UTR-3 21572414 rs1020056 chr15 80484087 G T 6.74E-04 Body mass index / / 21701565 rs1865998 chr15 80484933 A G 6.08E-06 HDL cholesterol / / pha003075 rs713086 chr15 80488443 C A 1.40E-05 Urinary metabolites / / 21572414 rs11858089 chr15 80491062 T G 2.87E-04 Body mass index / / 17255346 rs1865997 chr15 80491453 T C 9.87E-04 Parkinson's disease / / 17052657 rs8026850 chr15 80495910 T C 6.18E-06 HDL cholesterol / / pha003075 rs8026850 chr15 80495910 T C 9.96E-05 Lipid levels / / pha003082 rs34939304 chr15 80500367 C G 2.89E-04 Insulin resistance / / 21901158 rs6495481 chr15 80500456 T C 6.97E-04 Body mass index / / 21701565 rs6495482 chr15 80501035 A G 6.85E-04 Body mass index / / 21701565 rs1020055 chr15 80505289 A C 2.46E-04 Lung function (forced vital capacity) / / 24023788 rs2903332 chr15 80553207 C T 0.0000031 Uterine leiomyomata / / 23040493 rs1347648 chr15 80558947 A G 3.02E-04 Coronary heart disease LOC283688 intron 21971053 rs11856226 chr15 80563203 G T 9.02E-05 Body mass index LOC283688 intron 17255346 rs11856226 chr15 80563203 G T 3.55E-05 Creatinine levels LOC283688 intron pha003069 rs7180711 chr15 80573702 T C 1.75E-04 Body mass index LOC283688 intron 17255346 rs16971923 chr15 80591752 T G 2.24E-04 Multiple complex diseases LOC283688 intron 17554300 rs12906720 chr15 80602727 A G 5.58E-05 Hearing function LOC283688 intron 17255346 rs17312725 chr15 80605911 A G 2.09E-04 Hearing function LOC283688 intron 17255346 rs17312955 chr15 80611629 A G 1.83E-04 Hearing function LOC283688 intron 17255346 rs7175683 chr15 80617236 G A 2.94E-04 Hearing function LOC283688 intron 17255346 rs3848199 chr15 80642794 C T 8.54E-05 Glucose levels / / pha003057 rs3848199 chr15 80642794 C T 1.52E-05 Diabetes Mellitus / / pha003060 rs1374214 chr15 80643626 A G 3.84E-04 Multiple complex diseases / / 17554300 rs12441931 chr15 80659655 A G 1.30E-06 Urinary metabolites / / 21572414 rs2278702 chr15 80694922 A T 3.22E-05 Multiple complex diseases / / 17554300 rs2278702 chr15 80694922 A T 6.00E-06 Bipolar disorder / / 18711365 rs1446337 chr15 80704761 A G 4.51E-05 Blood pressure ARNT2 intron 17255346 rs17315707 chr15 80718699 G A 8.02E-06 Stroke (ischemic) ARNT2 intron 21957438 rs3848170 chr15 80724489 A G 2.85E-05 Amyotrophic lateral sclerosis (sporadic) ARNT2 intron 24529757 rs4238517 chr15 80724564 G A 7.66E-04 Suicide attempts in bipolar disorder ARNT2 intron 21423239 rs4778799 chr15 80776699 G A 9.16E-04 Amyotrophic Lateral Sclerosis ARNT2 intron 17362836 rs4778800 chr15 80779758 T G 5.53E-04 Alcohol dependence ARNT2 intron 20201924 rs7178902 chr15 80790566 T C 7.76E-04 Myocardial Infarction ARNT2 intron pha002883 rs4238521 chr15 80796128 A G 7.87E-05 HIV-1 viral setpoint ARNT2 intron 17641165 rs4238521 chr15 80796128 A G 6.82E-04 Stroke ARNT2 intron 22306652 rs11072922 chr15 80806183 T C 1.00E-04 Information processing speed ARNT2 intron 21130836 rs11856676 chr15 80822547 C T 3.96E-04 Myocardial Infarction ARNT2 intron pha002883 rs6495506 chr15 80852918 G A 7.59E-06 Gallstones ARNT2 intron 17632509 rs4778818 chr15 80860100 G A 8.12E-04 Myocardial Infarction ARNT2 intron pha002873 rs4778823 chr15 80862745 A C 6.82E-04 Multiple complex diseases ARNT2 intron 17554300 rs12148329 chr15 81001278 T G 4.10E-04 Response to statin treatment (atorvastatin),change in cholesterol levels FAM108C1 intron 20031582 rs12148329 chr15 81001278 T G 9.00E-07 Immune response to smallpox vaccine (IL-6) FAM108C1 intron 22542470 rs2170881 chr15 81007264 A G 2.79E-05 Type 2 diabetes FAM108C1 intron 17463246 rs11072936 chr15 81014621 A C 8.22E-04 Type 2 diabetes FAM108C1 intron 17463246 rs967839 chr15 81019905 T C 1.33E-04 Alzheimer's disease (late onset) FAM108C1 intron 21379329 rs12900485 chr15 81022087 G A 3.33E-04 Body mass index FAM108C1 intron 17255346 rs12900485 chr15 81022087 G A 4.89E-04 Myopia (pathological) FAM108C1 intron 21095009 rs958091 chr15 81024367 T A 8.92E-04 Type 2 diabetes FAM108C1 intron 17463246 rs7171423 chr15 81029628 T C 0.000036 Colorectal cancer FAM108C1 intron 22532847 rs11630109 chr15 81030895 A G 8.60E-06 Gamma gluatamyl transferase levels (interaction with age) FAM108C1 intron 22010049 rs4778850 chr15 81034418 G A 2.67E-04 Blood pressure FAM108C1 intron 21909110 rs11630693 chr15 81056346 C T 8.80E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs12593088 chr15 81058640 G A 8.88E-05 Body mass index / / 17255346 rs3848177 chr15 81072088 C T 8.39E-04 Suicide attempts in bipolar disorder KIAA1199 intron 21423239 rs16972342 chr15 81075798 T A 4.95E-06 Recombination rate KIAA1199 intron 21698098 rs16972342 chr15 81075798 T A 6.96E-04 Response to cytidine analogues (gemcitabine) KIAA1199 intron 24483146 rs10519292 chr15 81077470 G A 5.64E-04 Suicide attempts in bipolar disorder KIAA1199 intron 21423239 rs906432 chr15 81081692 A G 7.69E-04 Smoking cessation KIAA1199 intron 24665060 rs11633017 chr15 81092977 G A 4.43E-04 Multiple complex diseases KIAA1199 intron 17554300 rs2055713 chr15 81109594 A G 5.61E-05 Cognitive performance KIAA1199 intron 19734545 rs2055713 chr15 81109594 A G 2.29E-04 Response to taxane treatment (placlitaxel) KIAA1199 intron 23006423 rs25431 chr15 81130887 G A 6.35E-04 Response to taxane treatment (placlitaxel) KIAA1199 intron 23006423 rs12372944 chr15 81135449 T C 4.17E-05 Alcohol consumption KIAA1199 intron 23743675 rs12591074 chr15 81137866 C T 7.40E-05 Alcohol consumption KIAA1199 intron 23743675 rs906428 chr15 81143074 G T 2.15E-04 Parkinson's disease KIAA1199 intron 17052657 rs2135881 chr15 81151809 T C 5.03E-04 Parkinson's disease KIAA1199 intron 17052657 rs4353448 chr15 81158072 G A 6.32E-06 Retinopathy in non-diabetics KIAA1199 intron 23393555 rs4145805 chr15 81160262 G A 8.11E-06 Retinopathy in non-diabetics KIAA1199 intron 23393555 rs7164719 chr15 81168503 G A 1.11E-04 Type 2 diabetes KIAA1199 intron 17463246 rs2271163 chr15 81217848 C T 3.70E-05 Nasopharyngeal carcinoma KIAA1199 intron 20512145 rs2903448 chr15 81226958 C T 3.88E-05 Blood Pressure KIAA1199 intron pha003048 rs8026419 chr15 81229910 G A 9.36E-05 Blood Pressure KIAA1199 intron pha003048 rs11856549 chr15 81265953 A G 5.04E-04 Myocardial Infarction / / pha002883 rs3743041 chr15 81270240 T C 3.42E-05 Blood Pressure MESDC2 UTR-3 pha003048 rs11072972 chr15 81304132 A G 1.19E-04 Myocardial Infarction / / pha002883 rs16972648 chr15 81308426 G A 1.00E-06 Prostate cancer / / 21743057 rs6495536 chr15 81314310 T A 4.00E-05 Prostate cancer / / 21743057 rs16972657 chr15 81318832 G A 1.97E-05 Blood Pressure / / pha003048 rs1320322 chr15 81339871 A G 4.46E-05 Type 2 diabetes / / 23300278 rs1509547 chr15 81352935 T C 8.26E-04 Alzheimer's disease / / 17998437 rs2663905 chr15 81359137 G A 5.00E-06 QT interval (interaction) / / 23459443 rs16972726 chr15 81367809 T C 3.49E-04 Alcohol dependence / / 21314694 rs2683260 chr15 81385552 T G 8.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs954969 chr15 81389238 T G 5.12E-05 Response to citalopram treatment / / 19846067 rs1509559 chr15 81391411 G A 5.71E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1509560 chr15 81391713 T G 5.71E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2048271 chr15 81427307 G A 3.00E-05 Psoriasis C15orf26 intron 20953189 rs4778881 chr15 81433836 T C 8.63E-04 Multiple complex diseases C15orf26 intron 17554300 rs12899903 chr15 81441599 A G 6.17E-04 Multiple complex diseases / / 17554300 rs17337055 chr15 81477672 T C 7.48E-04 Smoking quantity / / 24665060 rs7172689 chr15 81533695 C T 4.00E-06 Inattentive symptoms IL16 intron 18821565 rs4072111 chr15 81578139 C T 1.19E-05 Prostate cancer IL16 missense 18264096 rs7171517 chr15 81583481 G A 2.47E-05 Coronary heart disease IL16 intron pha003031 rs4778889 chr15 81588995 T C 5.80E-04 Smoking quantity IL16 intron 24665060 rs4778636 chr15 81591639 G A 2.66E-04 Lymphocyte counts IL16 intron 22286170 rs8034928 chr15 81594123 T C 5.34E-05 Alzheimer's disease (age of onset) IL16 intron 22005931 rs4778640 chr15 81604131 A G 6.62E-05 Pulmonary function IL16 UTR-3 19300500 rs3935740 chr15 81626725 G A 2.00E-07 Parkinson's disease TMC3 intron 23793441 rs9630440 chr15 81642064 A G 9.53E-05 Sudden cardiac arrest TMC3 intron 21658281 rs8042818 chr15 81642904 C T 1.10E-09 Health and aging,CVD and cancer age of onset TMC3 intron 22174011 rs8042818 chr15 81642904 C T 3.90E-10 Health and aging,CVD and cancer age of onset TMC3 intron 22174011 rs7178648 chr15 81651003 G A 3.17E-05 Dental caries TMC3 intron 21940522 rs8036147 chr15 81662840 G A 8.39E-06 Lymphocyte counts TMC3 intron 22286170 rs1871986 chr15 81802369 C T 7.31E-05 Blood Pressure / / pha003047 rs12441252 chr15 81843227 A T 8.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs4778907 chr15 81845060 T A 8.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs4778908 chr15 81845153 A G 9.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs969348 chr15 81847279 G A 1.73E-06 Suicide attempts in bipolar disorder / / 21423239 rs969347 chr15 81847377 T G 2.02E-06 Suicide attempts in bipolar disorder / / 21423239 rs2672088 chr15 81858178 G A 3.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs2624998 chr15 81858425 T G 4.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs2624999 chr15 81858503 A G 4.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs2672089 chr15 81860441 T C 4.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs1482929 chr15 81861009 T C 9.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs2625000 chr15 81863122 G C 5.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs922878 chr15 81865847 T C 7.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs1482934 chr15 81866658 T C 5.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs16973019 chr15 81867517 G A 4.45E-05 Suicide attempts in bipolar disorder / / 21423239 rs2449458 chr15 81872131 C G 7.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs2672093 chr15 81873237 G A 7.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs2624996 chr15 81881735 A G 8.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs2624996 chr15 81881735 A G 8.13E-04 Obesity (extreme) / / 21935397 rs1482943 chr15 81888336 A G 7.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs9783695 chr15 81889243 G T 8.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs6495599 chr15 81890611 A G 9.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs7178747 chr15 82083777 T A,G 1.95E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs8043322 chr15 82084934 A C 7.10E-05 Alcohol consumption (maxi-drinks) / / 24277619 rs7170175 chr15 82103939 C T 9.35E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4778652 chr15 82107103 T G 2.25E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs8032120 chr15 82117891 C T 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs9972517 chr15 82119151 C T 5.94E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs77963519 chr15 82193846 G A 4.00E-06 Post-traumatic stress disorder / / 24677629 rs4778944 chr15 82203675 T C 1.40E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1353122 chr15 82206430 T C 5.30E-05 Celiac disease / / 17558408 rs4778945 chr15 82209299 C T 9.54E-04 Multiple complex diseases / / 17554300 rs17258267 chr15 82217410 C A 7.03E-04 Multiple complex diseases / / 17554300 rs17258267 chr15 82217410 C A 4.02E-05 Myopia (severe) / / 23933737 rs4778656 chr15 82222597 T A 3.38E-04 Multiple complex diseases / / 17554300 rs12910333 chr15 82229940 A G 2.15E-05 Cognitive test performance / / 20125193 rs6495634 chr15 82233566 A T 1.27E-06 Height / / 20400458 rs6495634 chr15 82233566 A T 1.60E-06 Obesity,menopause / / 21424828 rs16973234 chr15 82234533 G C 1.61E-04 Multiple complex diseases / / 17554300 rs11630802 chr15 82241024 G A 4.88E-06 Alzheimer's disease / / 21059989 rs11630802 chr15 82241024 G A 7.06E-04 Alzheimer's disease / / 21059989 rs16973257 chr15 82247089 C T 7.63E-04 Type 2 diabetes / / 17463246 rs17350792 chr15 82248366 A G 9.06E-05 Multiple complex diseases / / 17554300 rs17350827 chr15 82250003 T C 1.58E-04 Multiple complex diseases / / 17554300 rs8031841 chr15 82252120 C A 1.57E-04 Type 2 diabetes / / 17463246 rs9806128 chr15 82264862 A G 4.70E-06 Urinary metabolites / / 21572414 rs12899742 chr15 82265489 A T 1.10E-05 Urinary metabolites / / 21572414 rs11856043 chr15 82274573 A G 1.20E-05 Urinary metabolites / / 21572414 rs1503064 chr15 82280275 A C 3.70E-06 Urinary metabolites / / 21572414 rs4563005 chr15 82283954 G A 3.40E-06 Urinary metabolites / / 21572414 rs12902481 chr15 82320148 C T 2.10E-05 Urinary metabolites / / 21572414 rs872332 chr15 82320166 A G 2.26E-04 White matter integrity / / 22425255 rs16973319 chr15 82333168 T G 6.18E-07 Schizophrenia / / 21926974 rs8029884 chr15 82344968 A G 1.10E-05 Urinary metabolites / / 21572414 rs4778663 chr15 82346498 G A 4.24E-06 Stroke (ischemic) / / 21957438 rs12324805 chr15 82352200 C A 7.00E-06 Body mass index / / 19079261 rs12324805 chr15 82352200 C A 6.90E-06 Smoking behavior / / 20418888 rs2665095 chr15 82370616 T C 3.86E-04 Schizophrenia / / 19197363 rs2665091 chr15 82377623 A T 4.57E-04 Multiple complex diseases / / 17554300 rs2654227 chr15 82378808 C T 4.44E-05 Otosclerosis / / 19230858 rs17699249 chr15 82409860 G A 1.70E-06 Aortic stiffness / / 22068335 rs2134514 chr15 82421126 G A 7.55E-04 Smoking initiation / / 24665060 rs2665103 chr15 82432715 T C 6.48E-05 Serum metabolites EFTUD1 intron 19043545 rs11636500 chr15 82451027 C A 0.0002 Migraine EFTUD1 intron 22678113 rs9972386 chr15 82454283 A G 5.77E-05 Vascular dementia EFTUD1 intron 22116812 rs1128431 chr15 82456227 T C 9.81E-04 Myocardial Infarction EFTUD1 missense pha002883 rs4778983 chr15 82503078 T C 3.90E-06 Aortic stiffness EFTUD1 intron 22068335 rs4778983 chr15 82503078 T C 9.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) EFTUD1 intron 23233662 rs7183805 chr15 82539431 A G 2.78E-04 Parkinson's disease EFTUD1 intron 17052657 rs11854289 chr15 82558802 T C 3.50E-04 Obesity (extreme) FAM154B intron 21935397 rs11854483 chr15 82559558 T C 3.50E-04 Obesity (extreme) FAM154B intron 21935397 rs17355437 chr15 82573255 C T 1.00E-04 Information processing speed FAM154B intron 21130836 rs1267658 chr15 83214154 C T 1.56E-04 Parkinson's disease CPEB1 intron 17052657 rs1267657 chr15 83215251 T C 4.06E-04 Parkinson's disease CPEB1 cds-synon 17052657 rs3850610 chr15 83221392 C A 1.37E-05 Serum metabolites CPEB1 intron 19043545 rs1145170 chr15 83225922 C T 2.88E-08 Metabolite levels CPEB1 intron 23281178 rs783540 chr15 83254708 A G 4.00E-06 Chronic lymphocytic leukemia CPEB1 intron 20062064 rs783540 chr15 83254708 A G 4.00E-06 Nasopharyngeal carcinoma CPEB1 intron 20512145 rs3970696 chr15 83263756 T A 0.0000914 Antisocial behavior CPEB1 intron 23077488 rs12908713 chr15 83342381 A T 7.08E-08 Metabolite levels AP3B2 intron 23281178 rs4779046 chr15 83342772 A G 5.35E-08 Metabolite levels AP3B2 intron 23281178 rs11638815 chr15 83352282 A C 1.00E-06 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy AP3B2 intron 23118302 rs8043401 chr15 83356259 A G 4.93E-04 Parkinson's disease AP3B2 intron 17052657 rs4779051 chr15 83370171 A C 6.45E-08 Metabolite levels AP3B2 intron 23281178 rs7182320 chr15 83387752 G A 9.24E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs7182320 chr15 83387752 G A 9.28E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs7163848 chr15 83398315 C T 7.00E-05 Chronic lymphocytic leukemia LOC283693 intron 24292274 rs12440776 chr15 83401541 T C 6.93E-04 Suicide attempts in bipolar disorder LOC283693 intron 21423239 rs12443184 chr15 83401757 G A 9.27E-04 Suicide attempts in bipolar disorder LOC283693 intron 21423239 rs13379712 chr15 83406702 A G 5.83E-04 Suicide attempts in bipolar disorder LOC283693 intron 21423239 rs8029423 chr15 83548978 A G 7.88E-04 Multiple complex diseases HOMER2 intron 17554300 rs8028925 chr15 83634125 A G 5.31E-05 IgE levels / / 22075330 rs2046070 chr15 83641784 A T 6.31E-04 Type 2 diabetes / / 17463246 rs2167602 chr15 83649292 A G 5.11E-05 Kawasaki disease / / 22446961 rs8027909 chr15 83661016 G A,C 5.36E-05 IgE levels C15orf40 intron 22075330 rs4842993 chr15 83713442 A C 1.01E-04 Aortic root size BTBD1 intron 21223598 rs1568657 chr15 83726179 A G 7.00E-06 Kawasaki disease BTBD1 intron 21326860 rs1568657 chr15 83726179 A G 3.67E-05 Kawasaki disease BTBD1 intron 22446961 rs1568657 chr15 83726179 A G 9.39E-07 HDL cholesterol BTBD1 intron pha003075 rs13379920 chr15 83756393 A G 4.58E-05 Kawasaki disease / / 22446961 rs1075619 chr15 83781474 T C 6.93E-05 Self-reported allergy TM6SF1 intron 23817569 rs2034618 chr15 83799632 C T 1.87E-05 Self-reported allergy TM6SF1 intron 23817569 rs17567151 chr15 83801716 C G 5.96E-05 Self-reported allergy TM6SF1 intron 23817569 rs41326445 chr15 83803546 G A 1.61E-04 Coronary Artery Disease TM6SF1 intron 17634449 rs12440386 chr15 83804861 C T 6.56E-05 Self-reported allergy TM6SF1 intron 23817569 rs8043224 chr15 83808103 T C 5.96E-05 Self-reported allergy HDGFRP3 intron 23817569 rs11858377 chr15 83808810 G A 7.06E-05 Self-reported allergy HDGFRP3 intron 23817569 rs10520576 chr15 83818272 G A 8.55E-05 Self-reported allergy HDGFRP3 intron 23817569 rs8027577 chr15 83819664 G A 9.01E-05 Self-reported allergy HDGFRP3 intron 23817569 rs11259965 chr15 83822244 T A 7.54E-05 Self-reported allergy HDGFRP3 intron 23817569 rs17567869 chr15 83824251 C G 8.97E-04 Coronary Artery Disease HDGFRP3 intron 17634449 rs17567869 chr15 83824251 C G 8.98E-05 Self-reported allergy HDGFRP3 intron 23817569 rs17508610 chr15 83824701 A G 2.15E-04 Coronary Artery Disease HDGFRP3 intron 17634449 rs17508610 chr15 83824701 A G 8.14E-05 Self-reported allergy HDGFRP3 intron 23817569 rs12440562 chr15 83832698 T G 8.26E-05 Self-reported allergy HDGFRP3 intron 23817569 rs965264 chr15 83833581 T C 7.60E-05 Self-reported allergy HDGFRP3 intron 23817569 rs965263 chr15 83833931 G T 7.80E-05 Self-reported allergy HDGFRP3 intron 23817569 rs7165978 chr15 83836372 A G 7.38E-05 Self-reported allergy HDGFRP3 intron 23817569 rs7164083 chr15 83837705 C T 8.42E-05 Self-reported allergy HDGFRP3 intron 23817569 rs1112404 chr15 83842480 A C 7.05E-05 Self-reported allergy HDGFRP3 intron 23817569 rs7165114 chr15 83843114 A C 8.62E-05 Self-reported allergy HDGFRP3 intron 23817569 rs12591855 chr15 83846150 G A 8.17E-05 Self-reported allergy HDGFRP3 intron 23817569 rs17568459 chr15 83850071 G A 8.58E-05 Self-reported allergy HDGFRP3 intron 23817569 rs11856164 chr15 83851743 A G 8.56E-05 Self-reported allergy HDGFRP3 intron 23817569 rs11852408 chr15 83852576 G A 8.31E-05 Self-reported allergy HDGFRP3 intron 23817569 rs17841157 chr15 83852620 C T 5.16E-04 Multiple sclerosis HDGFRP3 intron 17660530 rs17841157 chr15 83852620 C T 4.45E-05 Response to methylphenidate treatment HDGFRP3 intron 21130132 rs12595330 chr15 83854397 A G 8.45E-05 Self-reported allergy HDGFRP3 intron 23817569 rs17509233 chr15 83855156 A G 8.86E-05 Self-reported allergy HDGFRP3 intron 23817569 rs7495630 chr15 83874478 G C 8.50E-05 Self-reported allergy HDGFRP3 intron 23817569 rs7172384 chr15 83888938 C A 7.11E-05 Self-reported allergy / / 23817569 rs4550413 chr15 83889104 A T 6.92E-05 Self-reported allergy / / 23817569 rs8041329 chr15 83895853 G A 6.73E-05 Self-reported allergy / / 23817569 rs12438847 chr15 83900866 C T 6.84E-05 Self-reported allergy / / 23817569 rs11857428 chr15 83904786 G A 5.92E-05 Self-reported allergy / / 23817569 rs11856736 chr15 83911838 T C 4.86E-05 Self-reported allergy / / 23817569 rs4300612 chr15 83919472 A C 7.03E-05 Self-reported allergy / / 23817569 rs12441907 chr15 83922387 C A 4.95E-05 Self-reported allergy / / 23817569 rs4408505 chr15 83927791 G A 3.20E-05 Self-reported allergy BNC1 intron 23817569 rs11854520 chr15 83937081 C T 9.83E-04 Multiple complex diseases BNC1 intron 17554300 rs7172590 chr15 83940412 A G 5.06E-04 Multiple complex diseases BNC1 intron 17554300 rs7172590 chr15 83940412 A G 3.72E-05 Self-reported allergy BNC1 intron 23817569 rs11852287 chr15 83941734 G C 3.23E-05 Self-reported allergy BNC1 intron 23817569 rs4480763 chr15 83949470 C T 6.30E-05 Self-reported allergy BNC1 intron 23817569 rs11259905 chr15 83949751 A C 1.60E-04 Multiple complex diseases BNC1 intron 17554300 rs11259905 chr15 83949751 A C 8.85E-05 Coronary Artery Disease BNC1 intron 17634449 rs11259905 chr15 83949751 A C 6.33E-05 Self-reported allergy BNC1 intron 23817569 rs11259906 chr15 83949886 G A 4.78E-04 Multiple complex diseases BNC1 intron 17554300 rs7179675 chr15 83959100 C G 5.21E-05 Self-reported allergy / / 23817569 rs7180692 chr15 83959242 A G 4.67E-05 Self-reported allergy / / 23817569 rs1880532 chr15 83962307 A T 4.92E-05 Self-reported allergy / / 23817569 rs56081433 chr15 84011144 G A 0.00008112 Sarcoidosis / / 22952805 rs11259908 chr15 84012599 G A 1.76E-04 Multiple complex diseases / / 17554300 rs1510473 chr15 84019207 C T 2.15E-04 Multiple complex diseases / / 17554300 rs10520577 chr15 84027538 G T 6.20E-04 Coronary Artery Disease / / 17634449 rs17841201 chr15 84065381 A G 4.16E-04 Multiple complex diseases / / 17554300 rs301846 chr15 84091435 T G 2.65E-04 Smoking quantity / / 24665060 rs1723062 chr15 84097805 G A 8.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs301850 chr15 84098649 T C 8.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs427459 chr15 84103691 C A 5.21E-05 Multiple complex diseases / / 17554300 rs427459 chr15 84103691 C A 4.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs923968 chr15 84115520 C A 5.00E-04 Smoking quantity / / 24665060 rs6602977 chr15 84129515 A G 9.47E-05 Orofacial clefts SH3GL3 intron 22419666 rs9920377 chr15 84135138 G A 6.37E-04 Response to taxane treatment (placlitaxel) SH3GL3 intron 23006423 rs10906975 chr15 84173859 A G 3.59E-04 Body mass index SH3GL3 intron 21701565 rs10906975 chr15 84173859 A G 4.96E-04 Body mass index SH3GL3 intron 21701565 rs1491579 chr15 84178679 T C 1.47E-05 Alcohol consumption SH3GL3 intron 23743675 rs12905964 chr15 84179115 C T 8.63E-05 Alcohol consumption SH3GL3 intron 23743675 rs2732150 chr15 84201446 T C 4.86E-04 Coronary Artery Disease SH3GL3 intron 17634449 rs2642820 chr15 84203402 A G 6.10E-06 Urinary metabolites SH3GL3 intron 21572414 rs2201101 chr15 84205565 G T 8.73E-05 Blood Pressure SH3GL3 intron pha003048 rs17841192 chr15 84205679 C T 4.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SH3GL3 intron 20877124 rs2562769 chr15 84235930 G T 2.95E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SH3GL3 intron 20031582 rs2562769 chr15 84235930 G T 1.10E-05 Urinary metabolites SH3GL3 intron 21572414 rs12900490 chr15 84242585 T C 2.90E-05 Urinary metabolites SH3GL3 intron 21572414 rs7182482 chr15 84257351 G A 3.06E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SH3GL3 intron 20031582 rs2562764 chr15 84263750 C T 4.57E-04 Multiple complex diseases SH3GL3 intron 17554300 rs17158772 chr15 84273405 A G 4.40E-07 Urinary metabolites SH3GL3 intron 21572414 rs1896796 chr15 84274980 A G 0.000171 Schizophrenia SH3GL3 intron 22440650 rs2562784 chr15 84286492 A G 6.00E-08 Height SH3GL3 intron 18391950 rs17586847 chr15 84294132 A G 9.30E-06 Urinary metabolites / / 21572414 rs2554380 chr15 84315884 C T 9.00E-07 Height / / 18391951 rs17587205 chr15 84333412 C T 6.70E-04 Multiple complex diseases ADAMTSL3 intron 17554300 rs11639223 chr15 84372928 G A 1.20E-05 Urinary metabolites ADAMTSL3 intron 21572414 rs1896813 chr15 84379055 A G 8.26E-04 Response to alcohol consumption (flushing response) ADAMTSL3 intron 24277619 rs1383484 chr15 84522755 C T 9.00E-07 Height ADAMTSL3 intron 21998595 rs17158590 chr15 84539476 T C 2.68E-04 Multiple complex diseases ADAMTSL3 intron 17554300 rs4144691 chr15 84539619 C G 8.30E-06 Urinary metabolites ADAMTSL3 missense 21572414 rs190893945 chr15 84561984 T C 0.0000967 Menopause (age at onset) ADAMTSL3 intron 23424626 rs11259926 chr15 84566248 G A 2.20E-05 Urinary metabolites ADAMTSL3 intron 21572414 rs10906982 chr15 84568158 T A 2.00E-08 Height ADAMTSL3 intron 18391952 rs10906982 chr15 84568158 T A 5.00E-07 Height ADAMTSL3 intron 20397748 rs7175718 chr15 84569102 A C 3.43E-22 Narcolepsy ADAMTSL3 intron 19629137 rs7183263 chr15 84573041 T G 4.00E-07 Height ADAMTSL3 intron 20397748 rs11259933 chr15 84580156 G A 1.00E-19 Height ADAMTSL3 intron 23563607 rs11259936 chr15 84580582 A C 2.00E-35 Height ADAMTSL3 intron 20881960 rs4842838 chr15 84582124 G T 3.00E-08 Height ADAMTSL3 missense 19343178 rs4842838 chr15 84582124 G T 1.00E-07 Height ADAMTSL3 missense 20189936 rs2061999 chr15 84582740 C T 8.58E-05 Lactate dehydrogenase levels ADAMTSL3 intron 20981236 rs2135880 chr15 84589613 T G 9.12E-05 Lactate dehydrogenase levels ADAMTSL3 intron 20981236 rs8030379 chr15 84590910 G A 4.54E-05 Lactate dehydrogenase levels ADAMTSL3 intron 20981236 rs10520571 chr15 84616332 A G 8.86E-05 Major depressive disorder ADAMTSL3 intron 19107115 rs8028946 chr15 84617077 C T 8.86E-05 Major depressive disorder ADAMTSL3 intron 19107115 rs2011013 chr15 84625766 A T 4.23E-04 Body mass index ADAMTSL3 intron 17255346 rs2277849 chr15 84639350 C T 2.20E-04 Body mass index ADAMTSL3 missense 17255346 rs4359399 chr15 84645052 T A 3.09E-04 Body mass index ADAMTSL3 intron 17255346 rs713467 chr15 84646473 G A 4.40E-05 Information processing speed ADAMTSL3 intron 21130836 rs906427 chr15 84647207 T C 4.26E-04 Suicide attempts in bipolar disorder ADAMTSL3 intron 21423239 rs7176737 chr15 84651290 T C 4.37E-04 Suicide attempts in bipolar disorder ADAMTSL3 cds-synon 21423239 rs1531683 chr15 84679158 T C 3.00E-05 Prostate cancer ADAMTSL3 intron 21743057 rs2292188 chr15 84700783 A G 1.46E-04 Myocardial Infarction ADAMTSL3 intron pha002883 rs17299684 chr15 84704349 A G 3.25E-05 Breast cancer (survival) ADAMTSL3 intron 20332263 rs950169 chr15 84706461 C T 3.14E-07 Schizophrenia ADAMTSL3 missense 19197363 rs2135551 chr15 84707851 A G 1.35E-07 Schizophrenia ADAMTSL3 UTR-3 19197363 rs1818950 chr15 84722521 A G 7.73E-04 Type 2 diabetes / / 17463246 rs10520569 chr15 84729389 C T 4.24E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs7178655 chr15 84764241 T G 4.70E-05 Bipolar disorder LOC648809 intron 19488044 rs7178655 chr15 84764241 T G 7.22E-05 Bipolar Disorder LOC648809 intron pha002858 rs6603020 chr15 84784562 A G 1.12E-05 Bipolar disorder LOC648809 intron 19488044 rs6603020 chr15 84784562 A G 2.57E-05 Bipolar Disorder LOC648809 intron pha002858 rs1911155 chr15 84787635 A G 4.18E-06 Schizophrenia LOC648809 intron 19197363 rs11635160 chr15 84816785 G A 7.96E-08 Gender / / 22362730 rs17301021 chr15 84822076 C G 6.06E-15 Gender / / 22362730 rs12910334 chr15 84958318 G A 2.87E-06 Schizophrenia / / 19197363 rs3994533 chr15 85081827 C T 9.84E-26 Gender / / 22362730 rs3883011 chr15 85088394 G C 8.83E-17 Coronary Artery Disease UBE2Q2P1 intron 17634449 rs3883011 chr15 85088394 G C 1.37E-19 Gender UBE2Q2P1 intron 22362730 rs3883013 chr15 85088657 T C 8.69E-20 Gender UBE2Q2P1 intron 22362730 rs3883013 chr15 85088657 T C 2.04E-04 Celiac disease UBE2Q2P1 intron 23936387 rs3883013 chr15 85088657 T C 3.00E-07 Coronary heart disease UBE2Q2P1 intron 24778558 rs3883014 chr15 85088729 C G 1.53E-19 Gender UBE2Q2P1 intron 22362730 rs11635505 chr15 85097034 G T 4.84E-04 Multiple complex diseases UBE2Q2P1 intron 17554300 rs1849287 chr15 85103071 G C 9.09E-06 Hearing function UBE2Q2P1 intron 21493956 rs2020365 chr15 85119086 T C 9.74E-04 Rheumatoid arthritis LOC100506874 intron 21452313 rs11638554 chr15 85148231 T G 0.0008765 Sarcoidosis ZSCAN2 intron 22952805 rs2036949 chr15 85163605 T C 0.0005757 Sarcoidosis ZSCAN2 intron 22952805 rs11635597 chr15 85165699 C T 1.83E-04 Schizophrenia ZSCAN2 UTR-3 19197363 rs11635597 chr15 85165699 C T 0.00077 Sarcoidosis ZSCAN2 UTR-3 22952805 rs17598114 chr15 85171317 C T 0.0000607 Sarcoidosis / / 22952805 rs17532346 chr15 85171495 A C 9.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs11634320 chr15 85172183 C A 7.96E-04 Multiple complex diseases / / 17554300 rs4603535 chr15 85173872 C T 9.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs36126054 chr15 85177723 T G 0.0008897 Sarcoidosis SCAND2 intron 22952805 rs1061737 chr15 85183790 G C 0.0008831 Sarcoidosis / / 22952805 rs12914433 chr15 85184963 G A 0.0007306 Sarcoidosis / / 22952805 rs34069323 chr15 85187245 T C 2.00E-06 Periodontitis (CDC/AAP) WDR73 intron 24024966 rs2271431 chr15 85189464 T G 0.0001008 Sarcoidosis WDR73 cds-synon 22952805 rs12916712 chr15 85190780 T C 0.000688 Sarcoidosis WDR73 intron 22952805 rs62021197 chr15 85193869 T C 0.0001859 Sarcoidosis WDR73 intron 22952805 rs1051168 chr15 85200520 G T 0.0008442 Sarcoidosis NMB missense 22952805 rs1051168 chr15 85200520 G T 0.000127 Schizophrenia NMB missense 23637625 rs2292462 chr15 85200754 G T 7.35E-04 Schizophrenia NMB intron 19197363 rs11637728 chr15 85203392 A T 0.00006225 Sarcoidosis / / 22952805 rs12908161 chr15 85207825 A G 0.0003944 Sarcoidosis / / 22952805 rs12905057 chr15 85210765 A G 0.0002158 Sarcoidosis / / 22952805 rs56233902 chr15 85215577 C T 0.000124 Sarcoidosis SEC11A intron 22952805 rs34452033 chr15 85221993 A G 0.0003363 Sarcoidosis SEC11A intron 22952805 rs11638290 chr15 85227636 C T 0.000108 Sarcoidosis SEC11A intron 22952805 rs34028043 chr15 85231585 G A 0.0001284 Sarcoidosis SEC11A intron 22952805 rs34784022 chr15 85231906 T C 0.0001128 Sarcoidosis SEC11A intron 22952805 rs12911736 chr15 85240008 A G 0.00002556 Sarcoidosis SEC11A intron 22952805 rs12908699 chr15 85240403 G T 0.00009399 Sarcoidosis SEC11A intron 22952805 rs11636499 chr15 85243681 C T 0.00009342 Sarcoidosis SEC11A intron 22952805 rs35316992 chr15 85248133 A G 0.00009399 Sarcoidosis SEC11A intron 22952805 rs4643294 chr15 85250253 C T 0.00009399 Sarcoidosis SEC11A intron 22952805 rs62021219 chr15 85256159 C T 0.00009057 Sarcoidosis SEC11A intron 22952805 rs12907808 chr15 85256303 T C 0.00009057 Sarcoidosis SEC11A intron 22952805 rs34900908 chr15 85257599 G A 0.00009057 Sarcoidosis SEC11A intron 22952805 rs35524990 chr15 85258203 T C 4.06E-04 Major depressive disorder SEC11A intron 22472876 rs35524990 chr15 85258203 T C 0.00009057 Sarcoidosis SEC11A intron 22952805 rs62021226 chr15 85268036 T C 0.00008176 Sarcoidosis / / 22952805 rs12916867 chr15 85270275 T C 0.00008176 Sarcoidosis / / 22952805 rs16974510 chr15 85278404 T C 9.52E-04 Multiple complex diseases / / 17554300 rs35738019 chr15 85280210 T C 0.0001016 Sarcoidosis / / 22952805 rs34570071 chr15 85280212 T A 0.0001016 Sarcoidosis / / 22952805 rs60957376 chr15 85280792 T G 0.0001016 Sarcoidosis / / 22952805 rs10220733 chr15 85280864 G A 5.40E-04 Schizophrenia / / 19197363 rs10220733 chr15 85280864 G A 6.61E-05 Iron levels / / 19880490 rs10220733 chr15 85280864 G A 6.61E-05 Iron levels / / pha002876 rs11632465 chr15 85282045 A T 0.0001016 Sarcoidosis / / 22952805 rs17599989 chr15 85285536 T C 2.53E-04 Multiple complex diseases / / 17554300 rs17599989 chr15 85285536 T C 3.40E-04 Major depressive disorder / / 22472876 rs17599989 chr15 85285536 T C 0.0001145 Sarcoidosis / / 22952805 rs17534234 chr15 85285974 G A 4.56E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs62019463 chr15 85288087 G A 0.0001145 Sarcoidosis / / 22952805 rs62019464 chr15 85294469 T A 0.0002367 Sarcoidosis ZNF592 intron 22952805 rs11637142 chr15 85295927 A G 4.26E-04 Major depressive disorder ZNF592 intron 22472876 rs11637142 chr15 85295927 A G 0.0000355 Sarcoidosis ZNF592 intron 22952805 rs12910012 chr15 85298662 T C 3.81E-04 Major depressive disorder ZNF592 intron 22472876 rs12910012 chr15 85298662 T C 0.0002835 Sarcoidosis ZNF592 intron 22952805 rs12899981 chr15 85302373 G A 0.0002965 Sarcoidosis ZNF592 intron 22952805 rs34162609 chr15 85304446 C T 0.0002965 Sarcoidosis ZNF592 intron 22952805 rs11633450 chr15 85307287 C T 3.21E-04 Major depressive disorder ZNF592 intron 22472876 rs11633450 chr15 85307287 C T 0.0002965 Sarcoidosis ZNF592 intron 22952805 rs35758837 chr15 85311382 C T 0.0002965 Sarcoidosis ZNF592 intron 22952805 rs12443381 chr15 85314054 G A 5.00E-05 Alcoholism (heaviness of drinking) ZNF592 intron 21529783 rs17534709 chr15 85314397 G C 0.0004117 Sarcoidosis ZNF592 intron 22952805 rs11633377 chr15 85318065 A G 0.00006734 Sarcoidosis ZNF592 intron 22952805 rs11633413 chr15 85318159 A G 0.00006734 Sarcoidosis ZNF592 intron 22952805 rs17600551 chr15 85319258 A G 0.00006734 Sarcoidosis ZNF592 intron 22952805 rs9920528 chr15 85319570 T C 2.65E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ZNF592 intron 20031582 rs36033486 chr15 85319692 A G 0.0003752 Sarcoidosis ZNF592 intron 22952805 rs62019469 chr15 85321220 T C 0.00006734 Sarcoidosis ZNF592 intron 22952805 rs12908549 chr15 85322351 C G 0.0002665 Sarcoidosis ZNF592 intron 22952805 rs11633267 chr15 85324467 T C 0.0000444 Sarcoidosis ZNF592 intron 22952805 rs3748376 chr15 85328352 C T 5.64E-05 Schizophrenia ZNF592 intron 19197363 rs3748376 chr15 85328352 C T 5.19E-04 Major depressive disorder ZNF592 intron 22472876 rs3748376 chr15 85328352 C T 0.0001451 Sarcoidosis ZNF592 intron 22952805 rs12906348 chr15 85329421 A C 0.00002511 Sarcoidosis ZNF592 intron 22952805 rs10438428 chr15 85330745 C T 5.25E-04 Schizophrenia ZNF592 intron 19197363 rs10438428 chr15 85330745 C T 7.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZNF592 intron 20877124 rs10438428 chr15 85330745 C T 5.26E-04 Iron levels ZNF592 intron pha002876 rs34342559 chr15 85331271 A G 0.0001473 Sarcoidosis ZNF592 intron 22952805 rs62019472 chr15 85331493 A G 0.0001422 Sarcoidosis ZNF592 intron 22952805 rs35557864 chr15 85331629 A G 0.0001422 Sarcoidosis ZNF592 intron 22952805 rs12595786 chr15 85336670 T C 2.05E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ZNF592 intron 24023788 rs12595786 chr15 85336670 T C 1.05E-04 Iron levels ZNF592 intron pha002876 rs41492149 chr15 85336806 G A 2.48E-04 Multiple complex diseases ZNF592 intron 17554300 rs12903134 chr15 85337699 T A 0.0002712 Sarcoidosis ZNF592 intron 22952805 rs35726233 chr15 85337800 C T 0.0002712 Sarcoidosis ZNF592 intron 22952805 rs35960805 chr15 85343980 T G 0.0003504 Sarcoidosis ZNF592 intron 22952805 rs12912388 chr15 85344550 T A 0.0003504 Sarcoidosis ZNF592 intron 22952805 rs17601029 chr15 85347709 A G 0.0003106 Sarcoidosis ZNF592 UTR-3 22952805 rs35630683 chr15 85349231 T C 0.0004671 Sarcoidosis ZNF592 UTR-3 22952805 rs8037423 chr15 85355494 C T 6.16E-04 Iron levels / / pha002876 rs56864281 chr15 85357649 C A 0.0003246 Sarcoidosis / / 22952805 rs2879828 chr15 85361977 G T 3.69E-04 Iron levels ALPK3 intron pha002876 rs2340652 chr15 85374112 A G 0.0004826 Sarcoidosis ALPK3 intron 22952805 rs35473110 chr15 85374112 A ATG 0.0004826 Sarcoidosis ALPK3 intron 22952805 rs35808647 chr15 85377441 G A 0.0001514 Sarcoidosis ALPK3 intron 22952805 rs7164787 chr15 85379496 T C 4.27E-04 Iron levels ALPK3 intron pha002876 rs3803403 chr15 85383145 C G 0.0008539 Sarcoidosis ALPK3 missense 22952805 rs3803405 chr15 85383640 G A 0.0003947 Sarcoidosis ALPK3 missense 22952805 rs306206 chr15 85388653 A G 0.0004067 Sarcoidosis ALPK3 intron 22952805 rs182517 chr15 85389631 G A 0.0004533 Sarcoidosis ALPK3 intron 22952805 rs306208 chr15 85391306 T G 0.0002608 Sarcoidosis ALPK3 intron 22952805 rs16974567 chr15 85397374 G A 4.00E-05 Prostate cancer ALPK3 intron 21743057 rs306198 chr15 85405369 A G 6.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) ALPK3 intron 23648065 rs12900463 chr15 85415386 T C 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) ALPK3 UTR-3 23648065 rs4842994 chr15 85415799 C T 4.03E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) ALPK3 UTR-3 23648065 rs12917429 chr15 85425097 G T 2.35E-05 Alzheimer's disease (age of onset) / / 22005931 rs12909280 chr15 85429356 T G 1.07E-05 Alzheimer's disease (age of onset) SLC28A1 intron 22005931 rs3743161 chr15 85430838 G T 8.97E-06 Alzheimer's disease (age of onset) SLC28A1 intron 22005931 rs3743162 chr15 85430969 C T 9.00E-06 Alzheimer's disease (age of onset) SLC28A1 intron 22005931 rs12442557 chr15 85431144 G A 1.17E-05 Alzheimer's disease (age of onset) SLC28A1 intron 22005931 rs7182385 chr15 85435076 G A 8.72E-04 Suicide attempts in bipolar disorder SLC28A1 intron 21423239 rs3825876 chr15 85435868 G A 9.48E-04 Suicide attempts in bipolar disorder SLC28A1 intron 21423239 rs7342686 chr15 85435986 C T 8.86E-04 Suicide attempts in bipolar disorder SLC28A1 intron 21423239 rs11634491 chr15 85447060 A G 6.64E-04 Alcohol dependence SLC28A1 intron 20201924 rs2290272 chr15 85447431 G A 1 Drug response to Gemcitabine SLC28A1 missense 19940846 rs2290272 chr15 85447431 G A 2.93E-05 Bipolar disorder SLC28A1 missense 21771265 rs2290270 chr15 85448684 G C 4.24E-04 Suicide attempts in bipolar disorder SLC28A1 intron 21423239 rs2290269 chr15 85448906 C T 9.13E-04 Suicide attempts in bipolar disorder SLC28A1 intron 21423239 rs4076648 chr15 85449583 T C 3.57E-04 Suicide attempts in bipolar disorder SLC28A1 intron 21423239 rs17537076 chr15 85464498 G A 1.10E-04 Bone mineral density (BMD),in women SLC28A1 intron 20164292 rs2343675 chr15 85469227 G T 3.64E-05 Alzheimer's disease SLC28A1 intron 17998437 rs4980343 chr15 85471281 C T 5.00E-04 Alcohol dependence SLC28A1 intron 20201924 rs2242048 chr15 85478410 A G 1 Drug response to Gemcitabine / / 15224082 rs2242047 chr15 85478696 C T 1 Drug response to Gemcitabine SLC28A1 missense 15224082 rs2242046 chr15 85478729 G A 1 Drug response to Gemcitabine SLC28A1 missense 15224082 rs11073852 chr15 85511981 T A 1.30E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs7166894 chr15 85512205 G C 9.28E-05 Pulmonary function / / 20010835 rs2290273 chr15 85544050 C T 7.15E-04 Myocardial Infarction PDE8A intron pha002883 rs11856097 chr15 85544887 G A 8.90E-04 Atrial fibrillation PDE8A intron 21846873 rs7175477 chr15 85550656 C T 3.62E-04 Smoking quantity PDE8A intron 24665060 rs12900736 chr15 85558140 C T 7.19E-05 Body Mass Index PDE8A intron pha003009 rs289404 chr15 85566317 G T 0.000065 Primary sclerosing cholangitis PDE8A intron 22521342 rs289389 chr15 85575044 G A 8.38E-04 Myocardial Infarction PDE8A intron pha002883 rs289386 chr15 85581389 C T 6.20E-04 Crohn's disease PDE8A intron 17684544 rs289386 chr15 85581389 C T 1.40E-07 Height PDE8A intron 21194676 rs418676 chr15 85585157 G T 9.77E-04 Multiple complex diseases PDE8A intron 17554300 rs12909971 chr15 85588998 G C 7.07E-04 Multiple complex diseases PDE8A intron 17554300 rs12909971 chr15 85588998 G C 1.59E-05 Height PDE8A intron 22021425 rs11632658 chr15 85606213 A G 5.49E-04 Multiple complex diseases PDE8A intron 17554300 rs11632658 chr15 85606213 A G 5.69E-04 Coronary Artery Disease PDE8A intron 17634449 rs2304416 chr15 85618882 A G 2.31E-05 Multiple complex diseases PDE8A intron 17554300 rs2174218 chr15 85624656 G C 5.75E-05 Multiple complex diseases PDE8A intron 17554300 rs2174218 chr15 85624656 G C 5.67E-04 Coronary Artery Disease PDE8A intron 17634449 rs12904238 chr15 85639841 A T 3.48E-04 Multiple complex diseases PDE8A intron 17554300 rs4843019 chr15 85644459 T G 3.73E-04 Multiple complex diseases PDE8A intron 17554300 rs4843019 chr15 85644459 T G 2.19E-05 Height PDE8A intron 22021425 rs7167692 chr15 85660184 T C 2.60E-06 Glucose levels PDE8A intron pha003061 rs10520585 chr15 85661506 C G 6.72E-05 Coronary Artery Disease PDE8A intron 17634449 rs17541572 chr15 85665247 T C 4.25E-05 Multiple complex diseases PDE8A intron 17554300 rs17541572 chr15 85665247 T C 3.19E-04 Coronary Artery Disease PDE8A intron 17634449 rs4842868 chr15 85665622 T C 4.98E-05 HIV-1 control PDE8A intron 20041166 rs7177110 chr15 85671755 G A 3.16E-05 Multiple complex diseases PDE8A intron 17554300 rs3743157 chr15 85680532 C A 1.19E-04 Celiac disease PDE8A intron 23936387 rs3743157 chr15 85680532 C A 9.00E-04 Myocardial Infarction PDE8A intron pha002883 rs8040855 chr15 85699207 G C 3.00E-06 Bulimia nervosa / / 23568457 rs11073993 chr15 85717473 C T 7.13E-04 Multiple complex diseases / / 17554300 rs4643289 chr15 85726714 C T 1.80E-05 Urinary metabolites / / 21572414 rs1877198 chr15 85817218 A C 1.90E-06 Urinary metabolites / / 21572414 rs12438724 chr15 85825293 C T 4.09E-08 Interstitial lung disease / / 23583980 rs6496932 chr15 85825567 C A 3.50E-06 Central corneal thickness / / 20485516 rs6496932 chr15 85825567 C A 1.00E-08 Central corneal thickness / / 20719862 rs6496932 chr15 85825567 C A 7.00E-13 Corneal structure / / 23291589 rs11857574 chr15 85837960 A G 2.00E-06 Urinary metabolites / / 21572414 rs1828481 chr15 85840912 A C 9.85E-05 Cognitive impairment induced by topiramate / / 22091778 rs1828481 chr15 85840912 A C 1.11E-06 Interstitial lung disease / / 23583980 rs7172789 chr15 85843517 T C 1.12E-06 Interstitial lung disease / / 23583980 rs7169749 chr15 85845458 T C 5.20E-06 Urinary metabolites / / 21572414 rs8038164 chr15 85850040 T G 8.20E-06 Urinary metabolites / / 21572414 rs12591489 chr15 85870367 A G 1.80E-05 Urinary metabolites / / 21572414 rs10163187 chr15 85870518 C T 5.45E-10 Corneal structure / / 23291589 rs4843049 chr15 85874372 G A 4.50E-10 Corneal structure / / 23291589 rs11858744 chr15 85883064 C T 9.74E-07 Interstitial lung disease / / 23583980 rs4843050 chr15 85892181 C T 5.80E-06 Urinary metabolites / / 21572414 rs8029576 chr15 85894797 C T 1.00E-05 Urinary metabolites / / 21572414 rs2344080 chr15 85901589 C G 2.40E-06 Urinary metabolites / / 21572414 rs10520600 chr15 85908402 A G 2.68E-09 Corneal structure / / 23291589 rs10520600 chr15 85908402 A G 4.91E-05 Basophils / / pha003087 rs16977252 chr15 85926840 A G 3.36E-05 Interstitial lung disease AKAP13 intron 23583980 rs730439 chr15 85934531 G C 5.26E-04 Type 2 diabetes AKAP13 intron 17463246 rs730439 chr15 85934531 G C 6.91E-05 Multiple complex diseases AKAP13 intron 17554300 rs16977810 chr15 85938651 C A 8.54E-04 Alcohol dependence AKAP13 intron 20201924 rs16977813 chr15 85938850 C T 7.78E-04 Multiple complex diseases AKAP13 intron 17554300 rs7165772 chr15 85943775 A G 8.00E-04 Multiple complex diseases AKAP13 intron 17554300 rs7181604 chr15 85946265 C T 8.69E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines AKAP13 intron 21844884 rs13379803 chr15 85948709 C T 4.19E-04 Alcohol dependence AKAP13 intron 20201924 rs13379803 chr15 85948709 C T 6.87E-05 Potassium levels AKAP13 intron pha003086 rs11858860 chr15 85951446 T C 3.59E-04 Parkinson's disease AKAP13 intron 16252231 rs11858860 chr15 85951446 T C 1.39E-04 Alcohol dependence AKAP13 intron 20201924 rs12901648 chr15 85951718 T G 1.42E-06 Corneal structure AKAP13 intron 23291589 rs6497117 chr15 85956628 C T 8.10E-04 Type 2 diabetes AKAP13 intron 17463246 rs6497117 chr15 85956628 C T 3.28E-04 Multiple complex diseases AKAP13 intron 17554300 rs17552700 chr15 85959986 C T 1.40E-06 Urinary metabolites AKAP13 intron 21572414 rs17552971 chr15 85971935 C T 1.70E-06 Urinary metabolites AKAP13 intron 21572414 rs12443473 chr15 85998741 T C,G 9.50E-05 Potassium levels AKAP13 intron pha003086 rs4407021 chr15 86000503 C T 6.50E-04 Type 2 diabetes AKAP13 intron 17463246 rs4407021 chr15 86000503 C T 2.26E-04 Multiple complex diseases AKAP13 intron 17554300 rs7171364 chr15 86002027 G A 2.94E-04 Parkinson's disease AKAP13 intron 16252231 rs7171364 chr15 86002027 G A 3.40E-04 Pulmonary function AKAP13 intron 23932459 rs17553249 chr15 86006694 T C 5.80E-07 Urinary metabolites AKAP13 intron 21572414 rs17553734 chr15 86013059 G C 1.10E-07 Urinary metabolites AKAP13 intron 21572414 rs17553790 chr15 86013665 A G 1.40E-07 Urinary metabolites AKAP13 intron 21572414 rs12913754 chr15 86023538 A G 5.20E-06 Urinary metabolites AKAP13 intron 21572414 rs4526974 chr15 86024284 C T 9.44E-04 Myocardial Infarction AKAP13 intron pha002883 rs4632086 chr15 86028822 A G 1.14E-05 Cognitive impairment induced by topiramate AKAP13 intron 22091778 rs725686 chr15 86039564 T G 2.05E-06 Coronary Artery Disease AKAP13 intron 17634449 rs725686 chr15 86039564 T G 2.80E-06 Urinary metabolites AKAP13 intron 21572414 rs2880765 chr15 86056462 A T 0.0000102 Coronary artery disease AKAP13 intron 23202125 rs11637726 chr15 86059271 A G 2.10E-04 Coronary Artery Disease AKAP13 intron 17634449 rs6496044 chr15 86067306 G A 1.03E-05 Interstitial lung disease AKAP13 intron 23583980 rs6496044 chr15 86067306 G A 2.00E-06 Interstitial lung disease AKAP13 intron 23583980 rs12910789 chr15 86068022 C T 7.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) AKAP13 intron 23648065 rs7165300 chr15 86070069 G C 3.40E-05 Aging (time to event) AKAP13 intron 21782286 rs16940964 chr15 86070797 A G 6.99E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines AKAP13 intron 21844884 rs6496066 chr15 86075462 A C 8.16E-05 Psoriasis AKAP13 intron 20953190 rs4843067 chr15 86075747 G A 9.71E-05 Bipolar disorder and schizophrenia AKAP13 intron 20889312 rs2279167 chr15 86076584 A G 2.71E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines AKAP13 intron 21844884 rs2279168 chr15 86077189 A G 9.48E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines AKAP13 intron 21844884 rs11632326 chr15 86079834 A C 7.13E-05 Bipolar disorder AKAP13 intron 19488044 rs4503747 chr15 86085543 A G 7.96E-04 Tourette syndrome AKAP13 intron 22889924 rs4503747 chr15 86085543 A G 1.26E-04 Myocardial Infarction AKAP13 intron pha002873 rs2169876 chr15 86085776 T C 2.35E-14 Peripartum cardiomyopathy AKAP13 intron 21665988 rs2169876 chr15 86085776 T C 9.93E-05 Age-related macular degeneration AKAP13 intron 22125219 rs2169877 chr15 86085802 G A 8.06E-09 Interstitial lung disease AKAP13 intron 23583980 rs11634651 chr15 86093926 A C 5.66E-04 Coronary Artery Disease AKAP13 intron 17634449 rs17618909 chr15 86095462 T G 7.10E-04 Type 2 diabetes AKAP13 intron 17463246 rs16941432 chr15 86103176 A G 1.82E-08 Interstitial lung disease AKAP13 intron 23583980 rs8025492 chr15 86104914 C G 1.68E-04 Type 2 diabetes AKAP13 intron 17463246 rs7177107 chr15 86123364 G A 5.60E-04 Coronary heart disease AKAP13 missense 21966275 rs11635711 chr15 86126486 G C 6.49E-04 Type 2 diabetes AKAP13 intron 17463246 rs11635711 chr15 86126486 G C 2.14E-04 Coronary Artery Disease AKAP13 intron 17634449 rs6496109 chr15 86132008 C G 6.00E-04 Type 2 diabetes and 6 quantitative traits AKAP13 intron 17848626 rs11634177 chr15 86148390 C T 6.72E-04 Type 2 diabetes AKAP13 intron 17463246 rs11633893 chr15 86148438 G A 8.07E-04 Type 2 diabetes AKAP13 intron 17463246 rs11634707 chr15 86151867 A G 9.54E-04 Type 2 diabetes AKAP13 intron 17463246 rs12906580 chr15 86155287 A G 6.15E-04 Type 2 diabetes AKAP13 intron 17463246 rs11638762 chr15 86160441 A T 4.98E-04 Type 2 diabetes AKAP13 intron 17463246 rs11638762 chr15 86160441 A T 1.30E-05 Blood pressure AKAP13 intron 21228793 rs11638762 chr15 86160441 A T 6.30E-04 Blood pressure AKAP13 intron 21228793 rs6496137 chr15 86167386 A C 6.39E-05 IgE levels in asthmatics (D.f. specific) AKAP13 intron 23967269 rs10520597 chr15 86170255 G A 3.05E-05 Interstitial lung disease AKAP13 intron 23583980 rs17635450 chr15 86199049 C G 5.58E-04 Type 2 diabetes AKAP13 intron 17463246 rs17635450 chr15 86199049 C G 2.56E-04 Coronary Artery Disease AKAP13 intron 17634449 rs16942813 chr15 86201056 T C 1.06E-76 Multiple complex diseases AKAP13 intron 17554300 rs338544 chr15 86205189 A G 1.10E-04 IgE levels in asthmatics (D.f. specific) AKAP13 intron 23967269 rs11631660 chr15 86215412 A C 5.07E-04 Type 2 diabetes AKAP13 intron 17463246 rs338513 chr15 86220748 G A 5.64E-06 Body Mass Index AKAP13 intron pha003006 rs12594932 chr15 86230839 T C 8.31E-04 Myocardial Infarction AKAP13 intron pha002873 rs16943236 chr15 86233351 C T 7.68E-05 Chronic obstructive pulmonary disease AKAP13 intron 19300482 rs471073 chr15 86268672 C A 1.70E-05 Crohn's disease (time to surgery) AKAP13 intron 23665963 rs16943741 chr15 86278479 A G 1.66E-04 Type 2 diabetes AKAP13 intron 17463246 rs16943741 chr15 86278479 A G 4.14E-04 Coronary Artery Disease AKAP13 intron 17634449 rs11634311 chr15 86320952 C T 2.10E-04 Type 2 diabetes KLHL25 intron 17463246 rs2455561 chr15 86326348 T G 2.68E-06 Hearing function KLHL25 intron 21493956 rs4843098 chr15 86335218 C A 3.34E-05 Height KLHL25 intron pha003010 rs4842903 chr15 86360145 C A 9.96E-05 Crohn's disease / / 20570966 rs2344847 chr15 86361093 T C 1.83E-04 Alzheimer's disease (late onset) / / 21460841 rs2937947 chr15 86361416 T C 2.44E-04 Scoliosis / / 21216876 rs2946355 chr15 86364864 T C 8.05E-04 Multiple complex diseases / / 17554300 rs2937940 chr15 86367767 C T 1.90E-05 Lung adenocarcinoma / / 21242121 rs4420487 chr15 86369148 A G 5.55E-04 Multiple complex diseases / / 17554300 rs7176093 chr15 86369430 G A 7.00E-06 Aging traits / / 17903295 rs2344853 chr15 86383763 T C 3.96E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4262906 chr15 86462852 T C 3.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule) / / 24025145 rs4262906 chr15 86462852 T C 7.00E-07 Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel) / / 24025145 rs11858797 chr15 86465715 T C 8.74E-04 Alcohol dependence / / 20201924 rs12438110 chr15 86483678 G A 6.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs7170230 chr15 86522943 A G 5.33E-04 Coronary Artery Disease / / 17634449 rs4337270 chr15 86542912 T C 1.19E-04 Sudden cardiac arrest / / 21658281 rs6496300 chr15 86555629 T G 7.36E-05 Body mass index / / 17255346 rs6496300 chr15 86555629 T G 4.06E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2345265 chr15 86578025 A G 3.57E-04 Type 2 diabetes / / 17463246 rs2345265 chr15 86578025 A G 8.91E-04 Multiple complex diseases / / 17554300 rs2120640 chr15 86615378 T C 4.00E-04 Iron levels / / pha002876 rs16948444 chr15 86656985 C T 5.89E-06 Fasting insulin (interaction) / / 24204828 rs16948444 chr15 86656985 C T 6.49E-06 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs12914656 chr15 86660720 T C 2.00E-06 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs1822639 chr15 86676215 T C 6.91E-05 Body Fat Distribution / / pha003017 rs16948699 chr15 86688823 A G 3.66E-04 Multiple complex diseases AGBL1 intron 17554300 rs1867472 chr15 86700796 C T 0.0000848 Polycystic ovary syndrome AGBL1 intron 22951595 rs1867472 chr15 86700796 C T 8.48E-05 Intracranial aneurysm AGBL1 intron 22961961 rs10520611 chr15 86708338 C T 8.17E-05 Lipoproteins AGBL1 intron pha003079 rs8027839 chr15 86731697 A G 5.02E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines AGBL1 intron 21844884 rs4611420 chr15 86743222 G A 8.92E-04 Response to alcohol consumption (flushing response) AGBL1 intron 24277619 rs4887409 chr15 86745924 T G 7.73E-04 Depression (quantitative trait) AGBL1 intron 20800221 rs7174488 chr15 86760987 A G 9.14E-04 Response to TNF antagonist treatment AGBL1 intron 21061259 rs11073625 chr15 86766368 C T 9.72E-05 Erythrocyte counts AGBL1 intron pha003090 rs10520615 chr15 86769266 A G 7.78E-05 Blood Pressure AGBL1 intron pha002898 rs4887420 chr15 86784584 G A 2.59E-05 Smoking behavior AGBL1 intron 19188921 rs12911089 chr15 86803502 C G 6.87E-04 Type 2 diabetes AGBL1 intron 17463246 rs1566088 chr15 86806029 C T 0.00000483 Change in depression severity with Serotonin reuptake inhibitors (SRI) AGBL1 cds-synon 23091423 rs4887217 chr15 86806671 C G 7.14E-08 Metabolite levels AGBL1 intron 23281178 rs4887425 chr15 86806830 A T 6.28E-08 Metabolite levels AGBL1 intron 23281178 rs4887218 chr15 86807077 G A 8.39E-04 Multiple complex diseases AGBL1 intron 17554300 rs4887218 chr15 86807077 G A 0.0000044 Change in depression severity with Serotonin reuptake inhibitors (SRI) AGBL1 intron 23091423 rs10520617 chr15 86807542 C T 7.14E-08 Metabolite levels AGBL1 cds-synon 23281178 rs10520618 chr15 86807761 A G 6.51E-05 Erythrocyte counts AGBL1 cds-synon pha003101 rs11856833 chr15 86807884 A C 5.64E-08 Metabolite levels AGBL1 cds-synon 23281178 rs10520619 chr15 86808346 C G 2.77E-04 Multiple complex diseases AGBL1 intron 17554300 rs7181181 chr15 86809025 T C 0.00000417 Change in depression severity with Serotonin reuptake inhibitors (SRI) AGBL1 intron 23091423 rs8041327 chr15 86809807 C T 0.00000434 Change in depression severity with Serotonin reuptake inhibitors (SRI) AGBL1 intron 23091423 rs1159895 chr15 86817311 A G 6.61E-04 Suicide attempts in bipolar disorder AGBL1 intron 21041247 rs8026683 chr15 86825255 C A 3.50E-05 Psychosis (methamphetamine induced) AGBL1 intron 23594818 rs9630451 chr15 86838497 C T 2.09E-04 Multiple complex diseases AGBL1 cds-synon 17554300 rs33987779 chr15 86840844 A G 1.00E-05 Urinary metabolites AGBL1 intron 21572414 rs7167360 chr15 86847227 T G 5.34E-04 White matter integrity AGBL1 intron 22425255 rs10152333 chr15 86854359 T C 1.90E-07 Bronchopulmonary dysplasia AGBL1 intron 21836138 rs10152333 chr15 86854359 T C 2.72E-04 White matter integrity AGBL1 intron 22425255 rs10152333 chr15 86854359 T C 8.21E-05 Body Mass Index AGBL1 intron pha003006 rs10152811 chr15 86854590 A C 8.00E-07 Thiazide-induced adverse metabolic effects in hypertensive patients AGBL1 intron 23400010 rs12901001 chr15 86859476 A G 6.00E-06 Barrett's esophagus AGBL1 intron 22961001 rs12901001 chr15 86859476 A G 6.00E-06 Body mass index AGBL1 intron 22982992 rs1353577 chr15 86863911 G A 8.59E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) AGBL1 intron 24236485 rs12437556 chr15 86864635 C T 1.17E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) AGBL1 intron 24236485 rs12437556 chr15 86864635 C T 8.91E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) AGBL1 intron 24236485 rs12593149 chr15 86868108 G A 8.97E-05 Erythrocyte counts AGBL1 intron pha003101 rs4887432 chr15 86879332 G A 1.90E-05 Urinary metabolites AGBL1 intron 21572414 rs12901119 chr15 86881268 A T 2.20E-05 Urinary metabolites AGBL1 intron 21572414 rs4887435 chr15 86881661 T C 3.11E-04 Parkinson's disease AGBL1 intron 17052657 rs1496894 chr15 86888514 T A 1.50E-05 Urinary metabolites AGBL1 intron 21572414 rs41342449 chr15 86911313 G A 5.27E-04 Type 2 diabetes AGBL1 intron 17463246 rs41342449 chr15 86911313 G A 5.62E-04 Multiple complex diseases AGBL1 intron 17554300 rs1431234 chr15 86919703 A G 1.19E-05 Common variable immunodeficiency AGBL1 intron 21497890 rs10520624 chr15 86921095 C A,G,T 5.12E-04 Schizophrenia AGBL1 intron 21674006 rs16977195 chr15 86984240 A G 2.00E-06 Schizophrenia AGBL1 intron 18347602 rs16977195 chr15 86984240 A G 5.03E-08 Narcolepsy AGBL1 intron 19629137 rs6496336 chr15 86993211 A G 2.88E-04 Parkinson's disease AGBL1 intron 17052657 rs16977267 chr15 86993464 G T 1.60E-05 Psychosis (methamphetamine induced) AGBL1 intron 23594818 rs7171048 chr15 86993717 T C 1.69E-04 Multiple complex diseases AGBL1 intron 17554300 rs10520630 chr15 86995532 A G 4.79E-04 Parkinson's disease AGBL1 intron 17052657 rs10520631 chr15 86995713 C T 2.46E-04 Multiple complex diseases AGBL1 intron 17554300 rs4887466 chr15 86995749 C T 9.71E-04 Parkinson's disease AGBL1 intron 17052657 rs4243100 chr15 87037559 C T 7.53E-06 Cytomegalovirus antibody response AGBL1 intron 21993531 rs11632104 chr15 87049894 G A 3.23E-06 Cytomegalovirus antibody response AGBL1 intron 21993531 rs12443065 chr15 87050351 T C 9.75E-04 Type 2 diabetes AGBL1 intron 17463246 rs12443065 chr15 87050351 T C 3.39E-04 Multiple complex diseases AGBL1 intron 17554300 rs12439060 chr15 87050430 G A 3.88E-04 Multiple complex diseases AGBL1 intron 17554300 rs11633708 chr15 87050708 C T 6.60E-06 Cytomegalovirus antibody response AGBL1 intron 21993531 rs4435233 chr15 87050833 G A 4.75E-04 Multiple complex diseases AGBL1 intron 17554300 rs4493016 chr15 87050994 T C 4.28E-04 Multiple complex diseases AGBL1 intron 17554300 rs4887473 chr15 87053206 G T 3.86E-06 Cytomegalovirus antibody response AGBL1 intron 21993531 rs4887475 chr15 87053559 A T 7.01E-04 Multiple complex diseases AGBL1 intron 17554300 rs2011905 chr15 87053846 G T 2.00E-06 Cytomegalovirus antibody response AGBL1 intron 21993531 rs17618568 chr15 87061360 T G 9.77E-04 Insulin resistance AGBL1 intron 21901158 rs12591257 chr15 87064089 A C 4.00E-06 Psychosis (methamphetamine induced) AGBL1 intron 23594818 rs2346713 chr15 87078337 A C 5.60E-06 Psychosis (methamphetamine induced) AGBL1 intron 23594818 rs16977781 chr15 87081216 G A 3.68E-04 Body mass index AGBL1 intron 17255346 rs717552 chr15 87083122 T C 4.28E-04 Multiple complex diseases AGBL1 intron 17554300 rs11634524 chr15 87087110 G A 4.21E-04 Depression (quantitative trait) AGBL1 intron 20800221 rs9920342 chr15 87088234 C T 2.57E-04 Type 2 diabetes AGBL1 intron 17463246 rs9920348 chr15 87088306 C T 3.46E-04 Type 2 diabetes AGBL1 intron 17463246 rs2346724 chr15 87089806 C G 3.24E-04 Type 2 diabetes AGBL1 intron 17463246 rs4609816 chr15 87102625 T C 8.68E-04 Type 2 diabetes AGBL1 intron 17463246 rs4887487 chr15 87109504 T C 7.51E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines AGBL1 intron 21844884 rs4243102 chr15 87110728 A G 8.23E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines AGBL1 intron 21844884 rs8041191 chr15 87138722 A G 1.80E-04 Multiple complex diseases AGBL1 intron 17554300 rs4393536 chr15 87139933 T C 3.48E-04 Schizophrenia AGBL1 intron 20832056 rs8028834 chr15 87145741 G A 2.83E-04 Multiple complex diseases AGBL1 intron 17554300 rs2346733 chr15 87145842 A G 8.83E-05 Multiple complex diseases AGBL1 intron 17554300 rs2346733 chr15 87145842 A G 5.09E-05 Type 1 diabetes AGBL1 intron 18978792 rs2346734 chr15 87146081 A G 9.16E-05 Multiple complex diseases AGBL1 intron 17554300 rs2346734 chr15 87146081 A G 6.54E-05 Type 1 diabetes AGBL1 intron 18978792 rs2346735 chr15 87146118 G C 3.85E-05 Multiple complex diseases AGBL1 intron 17554300 rs2346735 chr15 87146118 G C 1.80E-05 Type 1 diabetes AGBL1 intron 18978792 rs16977877 chr15 87168732 G A 9.77E-04 Amyotrophic Lateral Sclerosis AGBL1 intron 17362836 rs16977877 chr15 87168732 G A 0.0000185 Panic disorder AGBL1 intron 23149450 rs16977877 chr15 87168732 G A 1.85E-05 Serum tamsulosin hydrochloride concentration AGBL1 intron 23151678 rs8040090 chr15 87169271 G A 0.0000185 Panic disorder AGBL1 intron 23149450 rs8040090 chr15 87169271 G A 1.85E-05 Serum tamsulosin hydrochloride concentration AGBL1 intron 23151678 rs16974087 chr15 87170697 T C 9.60E-04 Intelligence (childhood) AGBL1 intron 23358156 rs16974087 chr15 87170697 T C 5.15E-05 Receptive language ability AGBL1 intron 24687471 rs2469193 chr15 87171452 C T 2.45E-05 Serum metabolites AGBL1 intron 19043545 rs7183919 chr15 87180860 T C 4.79E-05 Postoperative ventricular dysfunction AGBL1 intron 21980348 rs2469184 chr15 87191977 A G 4.00E-08 Activated partial thromboplastin time AGBL1 intron 22703881 rs8035656 chr15 87201534 G A 1.20E-04 Multiple complex diseases AGBL1 intron 17554300 rs12595242 chr15 87225334 C T 4.63E-05 Waist Circumference AGBL1 intron pha003023 rs11631489 chr15 87241211 A G 7.76E-05 Multiple sclerosis (age of onset) AGBL1 intron 19010793 rs731597 chr15 87271959 T G 9.45E-04 Tourette syndrome AGBL1 intron 22889924 rs11631662 chr15 87318586 A G 7.93E-05 Information processing speed AGBL1 intron 21130836 rs16977977 chr15 87321057 A G 1.54E-04 Multiple complex diseases AGBL1 intron 17554300 rs28593062 chr15 87324764 G C 4.32E-04 Alzheimer's disease AGBL1 intron 24755620 rs16977995 chr15 87343750 T C 4.45E-04 Aortic root size AGBL1 intron 21223598 rs16977995 chr15 87343750 T C 7.70E-04 Alzheimer's disease AGBL1 intron 24755620 rs1377100 chr15 87344633 C G 6.50E-04 Aortic root size AGBL1 intron 21223598 rs1452455 chr15 87386841 C A 2.03E-04 Coronary heart disease AGBL1 intron 21606135 rs2347243 chr15 87389043 T C 4.31E-05 Multiple complex diseases AGBL1 intron 17554300 rs4887513 chr15 87390232 A C 8.61E-04 Alzheimer's disease AGBL1 intron 22005930 rs10520643 chr15 87402406 T G 3.63E-04 Multiple complex diseases AGBL1 intron 17554300 rs11073678 chr15 87405143 G A 2.96E-04 Birth weight AGBL1 intron 17255346 rs8026055 chr15 87405195 T C 5.79E-05 Acute lymphoblastic leukemia (childhood) AGBL1 intron 22076464 rs17646325 chr15 87415658 C G 4.21E-05 Intracerebral hemorrhage AGBL1 intron 24656865 rs11073681 chr15 87430684 C T 2.42E-04 Birth weight AGBL1 intron 17255346 rs4887515 chr15 87432014 G A 0.000195 Ovarian cancer AGBL1 intron 22794196 rs17647114 chr15 87436745 G A 4.00E-07 Response to antidepressant treatment AGBL1 intron 22041458 rs4375631 chr15 87438774 T C 4.31E-07 Facial morphology AGBL1 intron 22341974 rs7176964 chr15 87441734 T A 1.17E-05 Attention deficit hyperactivity disorder AGBL1 intron 20732625 rs4426325 chr15 87449130 A G 6.39E-04 Response to taxane treatment (placlitaxel) AGBL1 intron 23006423 rs7178641 chr15 87466031 C T 3.60E-04 Multiple complex diseases AGBL1 intron 17554300 rs6650533 chr15 87467262 T C 2.82E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) AGBL1 intron 24023788 rs16978094 chr15 87475446 A G 6.69E-04 Response to statin treatment (atorvastatin),change in cholesterol levels AGBL1 intron 20031582 rs1433449 chr15 87515339 G T 2.57E-04 Multiple complex diseases AGBL1 intron 17554300 rs6496376 chr15 87521903 C G 3.57E-04 Response to cytidine analogues (gemcitabine) AGBL1 intron 24483146 rs6496378 chr15 87522043 G A 4.46E-04 Response to cytidine analogues (gemcitabine) AGBL1 intron 24483146 rs4606685 chr15 87522343 A C 5.22E-04 Response to cytidine analogues (gemcitabine) AGBL1 intron 24483146 rs1010419 chr15 87536101 A G 7.70E-09 Bronchopulmonary dysplasia AGBL1 intron 21836138 rs2701405 chr15 87539918 C A 2.50E-08 Bronchopulmonary dysplasia AGBL1 intron 21836138 rs2881641 chr15 87542012 G A 4.43E-05 Cognitive test performance AGBL1 intron 20125193 rs2881641 chr15 87542012 G A 3.00E-04 Response to cytadine analogues (cytosine arabinoside) AGBL1 intron 24483146 rs4632097 chr15 87542058 G C 2.20E-06 Iron levels AGBL1 intron 21208937 rs1433446 chr15 87550870 T G 5.05E-05 Response to cytadine analogues (cytosine arabinoside) AGBL1 intron 24483146 rs2701419 chr15 87576793 A G 1.74E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2701422 chr15 87579826 T C 5.72E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2570135 chr15 87600986 T C 3.07E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17734241 chr15 87608414 G A 2.28E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10152646 chr15 87664390 C T 1.60E-04 Alcohol dependence / / 20201924 rs10152646 chr15 87664390 C T 7.20E-04 Alcohol dependence / / 20201924 rs16939915 chr15 87664653 C T 4.44E-05 Alzheimer's disease / / 22832961 rs11853091 chr15 87671163 T C,G 6.58E-05 Alzheimer's disease / / 22832961 rs10520650 chr15 87683530 G A 1.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs11636768 chr15 87695511 G A 5.00E-07 Migraine / / 21448238 rs8024343 chr15 87710066 A T 6.00E-06 Bulimia nervosa / / 23568457 rs16939987 chr15 87721668 A G 5.79E-04 Multiple complex diseases / / 17554300 rs12101402 chr15 87742098 A G 2.83E-07 Facial morphology / / 22341974 rs7176553 chr15 87748542 A T 2.81E-07 Facial morphology / / 22341974 rs3913351 chr15 87755594 G A 2.37E-07 Facial morphology / / 22341974 rs9920287 chr15 87768116 T C 1.60E-05 Urinary metabolites / / 21572414 rs2464605 chr15 87808158 C T 4.97E-05 Height / / 22021425 rs11632912 chr15 87846085 G A 8.25E-04 Type 2 diabetes / / 17463246 rs11630829 chr15 87847188 T C 2.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11630829 chr15 87847188 T C 8.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8030596 chr15 87848413 A G 6.75E-04 Type 2 diabetes / / 17463246 rs2348145 chr15 87878603 C T 8.60E-04 Type 2 diabetes / / 17463246 rs2122926 chr15 87879196 G A 2.69E-04 Type 2 diabetes / / 17463246 rs3910705 chr15 87896402 T C 5.61E-04 Smoking initiation / / 24665060 rs9284311 chr15 87928500 A C 8.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4887178 chr15 87932772 C T 4.71E-04 Type 2 diabetes / / 17463246 rs4887178 chr15 87932772 C T 2.22E-04 Multiple complex diseases / / 17554300 rs1442307 chr15 87939214 G A 2.17E-05 Iron status biomarkers / / 19084217 rs2679086 chr15 87962986 G A 5.89E-04 Multiple complex diseases / / 17554300 rs2261616 chr15 87976806 G C 1.35E-04 Multiple complex diseases / / 17554300 rs1442312 chr15 87977353 G C 3.40E-04 Type 2 diabetes / / 17463246 rs1442312 chr15 87977353 G C 1.34E-04 Multiple complex diseases / / 17554300 rs1442313 chr15 87977378 T C 3.30E-04 Type 2 diabetes / / 17463246 rs1442313 chr15 87977378 T C 1.03E-04 Multiple complex diseases / / 17554300 rs2679073 chr15 87977476 A G 4.00E-06 Coronary artery calcification / / 23870195 rs1036810 chr15 87987851 G C 2.68E-04 Multiple complex diseases / / 17554300 rs1036810 chr15 87987851 G C 3.22E-05 Serum metabolites / / 19043545 rs2606169 chr15 87996087 A G 2.30E-05 Urinary metabolites / / 21572414 rs41419445 chr15 88020975 A C 8.98E-04 Alzheimer's disease / / 17998437 rs16940448 chr15 88031388 A T 2.24E-04 Multiple complex diseases / / 17554300 rs17659104 chr15 88032736 G A 9.03E-04 Acute lung injury / / 22295056 rs2584162 chr15 88036774 G A 1.30E-06 Urinary metabolites / / 21572414 rs17812572 chr15 88037032 G T 6.60E-06 Urinary metabolites / / 21572414 rs17716031 chr15 88041919 T A 7.30E-06 Urinary metabolites / / 21572414 rs4887298 chr15 88088447 A G 3.99E-04 Multiple complex diseases / / 17554300 rs4534802 chr15 88112126 T G 1.39E-04 HIV-1 viral setpoint / / 17641165 rs10520658 chr15 88114672 A G 3.23E-04 Type 2 diabetes / / 17463246 rs10520658 chr15 88114672 A G 6.79E-05 Glucose levels / / pha003057 rs7178330 chr15 88128229 A G 3.50E-04 Type 2 diabetes / / 17463246 rs4887304 chr15 88131562 T C 4.38E-04 Sarcoidosis / / 19165924 rs4390560 chr15 88142015 A T 7.93E-04 Type 2 diabetes / / 17463246 rs10459693 chr15 88151833 C T 5.25E-04 Type 2 diabetes / / 17463246 rs17821658 chr15 88322412 C G 1.28E-04 Smoking initiation / / 24665060 rs16940789 chr15 88322461 G A 7.20E-05 Schizophrenia / / 19571809 rs1986826 chr15 88327131 T C 1.57E-05 Schizophrenia / / 19571809 rs4887326 chr15 88341400 A G 2.68E-05 Schizophrenia / / 19571809 rs4887327 chr15 88341662 T C 1.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs11073737 chr15 88342455 A G 1.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs7179067 chr15 88342686 G A 8.74E-05 Serum metabolites / / 19043545 rs717320 chr15 88344460 A G 6.15E-05 Suicide attempts in bipolar disorder / / 21423239 rs7166186 chr15 88345483 A T 5.34E-05 Schizophrenia / / 19571809 rs12324674 chr15 88355773 C A 7.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs8030747 chr15 88358250 T G 4.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs8030747 chr15 88358250 T G 2.66E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs11073742 chr15 88359293 T A 5.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs11073742 chr15 88359293 T A 1.25E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs11073745 chr15 88361399 G A 4.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs11073745 chr15 88361399 G A 2.06E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs4887329 chr15 88364430 G A 8.30E-05 Serum metabolites / / 19043545 rs4887330 chr15 88364527 T G 6.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs4243096 chr15 88366975 T C 3.89E-05 Schizophrenia / / 19571809 rs13313527 chr15 88370262 G A 5.00E-05 Memory performance / / 22105620 rs13313527 chr15 88370262 G A 9.62E-05 Relative hand skill / / 24068947 rs7164376 chr15 88396099 T C 7.67E-05 Progressive supranuclear palsy / / 21685912 rs1369416 chr15 88412825 G A 8.82E-04 Multiple complex diseases / / 17554300 rs11634388 chr15 88436617 G C 1.73E-04 Multiple complex diseases NTRK3 intron 17554300 rs1435403 chr15 88437069 A G 2.15E-04 Multiple complex diseases NTRK3 intron 17554300 rs16941002 chr15 88448293 T C 1.73E-04 Lung function (forced expiratory volume in 1 second) NTRK3 intron 24023788 rs7161806 chr15 88452595 G A 3.36E-04 Multiple complex diseases NTRK3 intron 17554300 rs1435397 chr15 88454826 A G 4.08E-04 Suicide attempts in bipolar disorder NTRK3 intron 21423239 rs1836592 chr15 88464802 T A 3.32E-04 Suicide attempts in bipolar disorder NTRK3 intron 21041247 rs1078163 chr15 88468931 T C 5.14E-06 Schizophrenia NTRK3 intron 21926974 rs1078163 chr15 88468931 T C 0.0000267 Schizophrenia NTRK3 intron 23637625 rs879131 chr15 88472170 A G 4.47E-04 Suicide attempts in bipolar disorder NTRK3 intron 21041247 rs8041239 chr15 88475356 A G 7.00E-04 Suicide attempts in bipolar disorder NTRK3 intron 21041247 rs1435399 chr15 88480537 T A 5.98E-04 Suicide attempts in bipolar disorder NTRK3 intron 21041247 rs8031871 chr15 88493008 C T 3.92E-04 Coronary heart disease NTRK3 intron 21971053 rs8031871 chr15 88493008 C T 6.37E-05 Brain derived neurotrophic factor levels,in serum NTRK3 intron 22047184 rs4887337 chr15 88493462 A C 2.44E-04 Suicide attempts in bipolar disorder NTRK3 intron 21041247 rs4887337 chr15 88493462 A C 7.10E-07 Urinary metabolites NTRK3 intron 21572414 rs7178071 chr15 88493894 A G 7.37E-04 Multiple complex diseases NTRK3 intron 17554300 rs7170215 chr15 88498141 A T 4.84E-05 Brain derived neurotrophic factor levels,in serum NTRK3 intron 22047184 rs11631508 chr15 88498466 A G 9.17E-04 Multiple complex diseases NTRK3 intron 17554300 rs13380271 chr15 88499185 C T 5.28E-05 Odorant perception NTRK3 intron 23910658 rs11630902 chr15 88513852 G T 9.35E-05 Lung function (forced vital capacity) NTRK3 intron pha003104 rs2018052 chr15 88519216 C T 7.56E-05 Lung function (forced vital capacity) NTRK3 intron pha003104 rs10520671 chr15 88546516 C G 6.20E-05 Volumetric brain MRI NTRK3 intron 17903297 rs1381112 chr15 88565851 G A 1.19E-04 Type 2 diabetes NTRK3 intron 17463246 rs1381112 chr15 88565851 G A 3.57E-04 Suicide attempts in bipolar disorder NTRK3 intron 21041247 rs1381112 chr15 88565851 G A 6.90E-05 Suicide attempts in bipolar disorder NTRK3 intron 21041247 rs4887348 chr15 88571534 A G 2.20E-05 Bone mineral density (BMD),in women NTRK3 intron 20164292 rs16941252 chr15 88638006 C T 2.16E-04 Lung function (forced expiratory volume in 1 second) NTRK3 intron 24023788 rs16941261 chr15 88655520 G C 8.10E-07 Schizophrenia NTRK3 intron 19571809 rs11631112 chr15 88659906 G T 1.04E-05 Schizophrenia NTRK3 intron 19571809 rs4887364 chr15 88660115 T C 3.95E-06 Schizophrenia NTRK3 intron 19571809 rs11630338 chr15 88661632 T C 7.60E-06 Schizophrenia NTRK3 intron 19571809 rs9806762 chr15 88661739 A G 7.65E-05 Cognitive test performance NTRK3 intron 20125193 rs9806762 chr15 88661739 A G 7.00E-06 Gaucher disease severity NTRK3 intron 22388998 rs991728 chr15 88662946 C G 5.07E-06 Schizophrenia NTRK3 intron 19571809 rs2114252 chr15 88664676 C A 1.61E-06 Schizophrenia NTRK3 intron 19571809 rs2114251 chr15 88664793 G A 3.37E-04 Tourette syndrome NTRK3 intron 22889924 rs994068 chr15 88666646 G C 1.29E-06 Schizophrenia NTRK3 intron 19571809 rs16941321 chr15 88670758 T G 2.22E-05 Gaucher disease severity NTRK3 intron 22388998 rs3784405 chr15 88688010 T C 6.97E-06 Schizophrenia NTRK3 intron 19571809 rs3784405 chr15 88688010 T C 7.38E-05 Bipolar disorder NTRK3 intron 20451256 rs11853913 chr15 88702841 G A 8.11E-04 Multiple complex diseases NTRK3 intron 17554300 rs17830422 chr15 88709057 T C 8.88E-06 Creutzfeldt-Jakob disease (variant) NTRK3 intron 22137330 rs16941371 chr15 88713525 T C 4.96E-04 Multiple complex diseases NTRK3 intron 17554300 rs16941392 chr15 88718356 T C 5.83E-04 Multiple complex diseases NTRK3 intron 17554300 rs1104918 chr15 88723712 T G 6.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) NTRK3 intron 23453885 rs6496469 chr15 88735310 A G 7.55E-06 Statin-induced myopathy NTRK3 intron 21826682 rs4887212 chr15 88756201 T C 8.17E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) NTRK3 intron 23648065 rs7169789 chr15 88760199 A G 7.95E-04 Multiple complex diseases NTRK3 intron 17554300 rs11073768 chr15 88765364 A G 7.72E-04 Multiple complex diseases NTRK3 intron 17554300 rs4887400 chr15 88794859 A C 4.16E-04 Amyotrophic Lateral Sclerosis NTRK3 intron 17362836 rs11073770 chr15 88820515 A C 4.54E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17184851 chr15 88821039 T C 2.25E-05 Bipolar disorder / / 17486107 rs894290 chr15 88824681 A G 3.03E-05 Alcohol dependence / / 20201924 rs894290 chr15 88824681 A G 3.03E-05 Alcoholism / / pha002891 rs16941652 chr15 88843187 A G 5.10E-04 Multiple complex diseases / / 17554300 rs894288 chr15 88848214 G A 2.80E-04 Multiple complex diseases / / 17554300 rs11631531 chr15 88864333 A C 6.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs962289 chr15 88887567 C T 7.43E-04 Myopia (pathological) / / 21095009 rs6496475 chr15 88898669 T C 4.28E-04 Alzheimer's disease (late onset) / / 21379329 rs6496475 chr15 88898669 T C 3.97E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2349981 chr15 88899631 A G 4.88E-05 Cognitive test performance / / 20125193 rs16941738 chr15 88915914 A T 7.44E-04 Multiple complex diseases / / 17554300 rs7166118 chr15 88985510 T C 4.56E-04 Obesity (extreme) / / 21935397 rs7182360 chr15 88991887 T C 6.27E-04 Obesity (extreme) / / 21935397 rs11855748 chr15 88994690 A G 8.80E-04 Obesity (extreme) / / 21935397 rs11858838 chr15 88994713 G A 8.73E-04 Obesity (extreme) / / 21935397 rs7167341 chr15 88995850 G A 9.92E-04 Obesity (extreme) / / 21935397 rs16941873 chr15 89003559 A T 8.42E-04 Obesity (extreme) MRPL46 intron 21935397 rs6496486 chr15 89005338 G T 8.42E-04 Obesity (extreme) MRPL46 intron 21935397 rs3809584 chr15 89009103 A G 8.45E-04 Obesity (extreme) MRPL46 intron 21935397 rs16941911 chr15 89011632 G A 8.49E-04 Obesity (extreme) MRPS11 intron 21935397 rs7176734 chr15 89015286 G T 8.49E-04 Obesity (extreme) MRPS11 intron 21935397 rs2289416 chr15 89015750 A C 8.44E-04 Obesity (extreme) MRPS11 intron 21935397 rs16941960 chr15 89022749 C T 8.44E-04 Obesity (extreme) / / 21935397 rs16941972 chr15 89024920 G T 8.41E-04 Obesity (extreme) / / 21935397 rs11858314 chr15 89026568 T C 8.41E-04 Obesity (extreme) / / 21935397 rs16941976 chr15 89028102 T C 8.40E-04 Obesity (extreme) / / 21935397 rs16941984 chr15 89028937 T C 8.39E-04 Obesity (extreme) / / 21935397 rs1000301 chr15 89029284 G A 8.39E-04 Obesity (extreme) / / 21935397 rs12101433 chr15 89032972 C A 8.37E-04 Obesity (extreme) / / 21935397 rs12101408 chr15 89033119 G A 8.38E-04 Obesity (extreme) / / 21935397 rs16941985 chr15 89033668 T C 8.83E-04 Obesity (extreme) / / 21935397 rs744886 chr15 89033719 C T 8.79E-04 Obesity (extreme) / / 21935397 rs17196732 chr15 89069299 G T 2.52E-04 Lung function (forced expiratory volume in 1 second) DET1 intron 17255346 rs17776563 chr15 89119104 G A 3.00E-10 Thyroid hormone levels / / 23408906 rs17776563 chr15 89119104 G A 6.00E-07 Thyroid hormone levels / / 23408906 rs11637983 chr15 89119421 C T 2.11E-05 Multiple complex diseases / / 17554300 rs2028389 chr15 89166761 T G 1.04E-04 Alzheimer's disease AEN intron 17998437 rs2028389 chr15 89166761 T G 2.41E-05 Alzheimer's disease AEN intron pha002879 rs147477549 chr15 89169738 G A 0.00021 Breast cancer AEN missense 23555315 rs2278598 chr15 89174748 G C 1.49E-04 Alzheimer's disease AEN UTR-3 17998437 rs4566136 chr15 89180521 C T 8.60E-04 Coronary heart disease / / 21966275 rs10152821 chr15 89180885 G A 2.61E-04 Multiple complex diseases / / 17554300 rs4932187 chr15 89192873 T C 9.83E-05 Creatinine levels ISG20 intron pha003069 rs8041687 chr15 89198560 A G 7.85E-07 Rheumatoid arthritis ISG20 intron 19503088 rs6496519 chr15 89238184 C T 3.52E-04 Multiple complex diseases / / 17554300 rs6496520 chr15 89238255 A C 4.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs4932194 chr15 89245239 A C 8.00E-07 Dupuytren's disease / / 21732829 rs8027587 chr15 89249139 A G 5.00E-06 Obesity-related traits / / 23251661 rs12902002 chr15 89252518 G A 5.38E-06 Obesity-related traits / / 23251661 rs7174169 chr15 89277150 G T 4.16E-05 Prostate cancer / / 22923026 rs4932411 chr15 89279339 T C 3.24E-04 Multiple complex diseases / / 17554300 rs4932199 chr15 89341050 A G 1.80E-07 Height / / 21998595 rs8026235 chr15 89349456 A C 2.43E-09 Cholesterol,total ACAN intron 23063622 rs12439075 chr15 89355911 C T 6.70E-05 Sickle cell anemia (severity) ACAN intron 20029952 rs8041863 chr15 89359689 T A 8.00E-08 Height ACAN intron 18391952 rs4932427 chr15 89361384 T A 6.50E-04 Multiple complex diseases ACAN intron 17554300 rs4932427 chr15 89361384 T A 2.50E-05 Urinary metabolites ACAN intron 21572414 rs8033375 chr15 89361859 T C 9.84E-04 Multiple complex diseases ACAN intron 17554300 rs4932431 chr15 89367015 A G 0.000075 Coronary artery calcification ACAN intron 23727086 rs11854545 chr15 89369104 G A 0.000000879 LDL cholesterol ACAN intron 23063622 rs12905452 chr15 89371423 A C 9.86E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ACAN intron 20877124 rs1464150 chr15 89376501 C G 0.0003882 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ACAN intron 23233654 rs1464150 chr15 89376501 C G 3.88E-04 Methotrexate clearance (acute lymphoblastic leukemia) ACAN intron 23233662 rs16942318 chr15 89382129 C A 0.00000176 Cholesterol,total ACAN missense 23063622 rs17789870 chr15 89382483 C T 0.0008214 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ACAN intron 23233654 rs17789870 chr15 89382483 C T 8.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) ACAN intron 23233662 rs16942333 chr15 89388264 A G 0.000000243 HDL cholesterol ACAN intron 23063622 rs16942333 chr15 89388264 A G 1.20E-09 Cholesterol,total ACAN intron 23063622 rs16942341 chr15 89388905 C T 4.00E-27 Height ACAN cds-synon 20881960 rs16942341 chr15 89388905 C T 1.60E-09 Height ACAN cds-synon 21194676 rs16942341 chr15 89388905 C T 2.30E-06 Height ACAN cds-synon 21194676 rs16942341 chr15 89388905 C T 9.60E-16 Height ACAN cds-synon 21194676 rs2280470 chr15 89395626 A G 1.00E-14 Height ACAN intron 20881960 rs2280470 chr15 89395626 A G 1.00E-15 Height ACAN intron 23563607 rs2351491 chr15 89398105 C T 2.00E-09 Height ACAN cds-synon 21998595 rs938609 chr15 89398631 T A 4.60E-09 Height ACAN missense 21194676 rs9630453 chr15 89403922 A G 5.16E-04 Nicotine dependence ACAN intron 17158188 rs9630453 chr15 89403922 A G 7.25E-04 Stroke ACAN intron pha002887 rs8042108 chr15 89404880 C T 2.14E-04 Nicotine dependence ACAN intron 17158188 rs4147339 chr15 89408231 C G 4.57E-06 Multiple complex diseases ACAN intron 17554300 rs16942398 chr15 89410482 T C 1.36E-09 Multiple complex diseases ACAN intron 17554300 rs2280465 chr15 89417629 G A 4.43E-06 Osteoarthritis (knee and hip) ACAN intron 21177295 rs2280465 chr15 89417629 G A 4.94E-05 Osteoarthritis (knee and hip) ACAN intron 21177295 rs2280465 chr15 89417629 G A 4.46E-05 Stroke ACAN intron pha002887 rs7179459 chr15 89425639 G A 1.70E-06 Urinary metabolites HAPLN3 intron 21572414 rs939590 chr15 89425779 G A 3.94E-05 Multiple complex diseases HAPLN3 intron 17554300 rs17791430 chr15 89426935 T C 4.57E-05 Multiple complex diseases HAPLN3 intron 17554300 rs4932444 chr15 89435129 T C 5.69E-04 Type 2 diabetes HAPLN3 intron 17463246 rs4932445 chr15 89435338 T A 7.50E-04 Type 2 diabetes HAPLN3 intron 17463246 rs3743392 chr15 89445651 A G 4.28E-05 Multiple complex diseases MFGE8 intron 17554300 rs12899529 chr15 89466182 T G 1.31E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs12443377 chr15 89479370 G A 1.00E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs12595660 chr15 89596925 G A 3.50E-04 Multiple complex diseases / / 17554300 rs12595660 chr15 89596925 G A 1.50E-05 Bipolar disorder,schizoaffective / / 19567891 rs11073831 chr15 89603728 G A 4.49E-04 Multiple complex diseases / / 17554300 rs11073831 chr15 89603728 G A 3.55E-06 Bipolar disorder,schizoaffective / / 19567891 rs11858077 chr15 89611557 A G 5.03E-04 Bipolar disorder,schizoaffective / / 19567891 rs16942644 chr15 89612736 G A 4.23E-04 Multiple complex diseases / / 17554300 rs16942644 chr15 89612736 G A 1.38E-06 Bipolar disorder,schizoaffective / / 19567891 rs420017 chr15 89617081 C T 7.00E-06 Height / / 21998595 rs420017 chr15 89617081 C T 8.00E-06 Obesity-related traits / / 23251661 rs7177792 chr15 89661039 C T 1 Drug response to Etoposide ABHD2 intron 17537913 rs16942755 chr15 89685197 T C 5.68E-04 Multiple complex diseases ABHD2 intron 17554300 rs2283436 chr15 89731776 T C 7.00E-07 Stroke (ischemic) ABHD2 intron 22384361 rs17228503 chr15 89763206 T C 7.55E-04 Suicide attempts in bipolar disorder RLBP1 intron 21423239 rs3759921 chr15 89764620 G A 4.80E-04 Suicide attempts in bipolar disorder RLBP1 intron 21423239 rs12324317 chr15 89766126 T C 3.16E-04 Suicide attempts in bipolar disorder RLBP1 nearGene-5 21423239 rs9806497 chr15 89768727 T C 4.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs11852866 chr15 89770786 T C 4.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs17228716 chr15 89773505 T C 5.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs12914337 chr15 89775555 C G 1.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs12903987 chr15 89780972 A C 8.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs12593363 chr15 89785116 A G 9.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs7178152 chr15 89787055 T G 7.66E-04 Suicide attempts in bipolar disorder FANCI nearGene-5 21423239 rs7184008 chr15 89789167 G A 8.23E-04 Myopia (pathological) FANCI intron 21095009 rs7184008 chr15 89789167 G A 5.02E-04 Suicide attempts in bipolar disorder FANCI intron 21423239 rs2108600 chr15 89791516 A G 4.81E-04 Suicide attempts in bipolar disorder FANCI intron 21423239 rs6496569 chr15 89795024 G A 3.54E-04 Suicide attempts in bipolar disorder FANCI intron 21423239 rs12898357 chr15 89801391 A G 8.66E-04 Suicide attempts in bipolar disorder FANCI intron 21423239 rs12900825 chr15 89801677 G C 8.43E-04 Suicide attempts in bipolar disorder FANCI intron 21423239 rs62020347 chr15 89803950 C T 0.00000018 Breast cancer FANCI missense 23555315 rs17803620 chr15 89804043 C T 8.19E-04 Suicide attempts in bipolar disorder FANCI missense 21423239 rs16942918 chr15 89804111 G A 8.27E-04 Suicide attempts in bipolar disorder FANCI intron 21423239 rs8040654 chr15 89805632 A G 6.38E-04 Suicide attempts in bipolar disorder FANCI intron 21423239 rs7167930 chr15 89810669 A C 6.16E-04 Suicide attempts in bipolar disorder FANCI intron 21423239 rs2159080 chr15 89813623 G A 8.61E-04 Suicide attempts in bipolar disorder FANCI intron 21423239 rs2882557 chr15 89820514 A G 8.73E-04 Suicide attempts in bipolar disorder FANCI intron 21423239 rs1599857 chr15 89821732 G A 9.17E-04 Suicide attempts in bipolar disorder FANCI intron 21423239 rs17804009 chr15 89823954 T C 9.78E-04 Suicide attempts in bipolar disorder FANCI intron 21423239 rs1990229 chr15 89824258 A C 9.61E-04 Suicide attempts in bipolar disorder FANCI intron 21423239 rs150544323 chr15 89837098 A G 0.0006 Prostate cancer FANCI missense 23555315 rs2283431 chr15 89838045 G A 9.34E-04 Suicide attempts in bipolar disorder FANCI intron 21423239 rs7170109 chr15 89841713 T C 5.46E-04 Suicide attempts in bipolar disorder FANCI intron 21423239 rs2238304 chr15 89843950 A T 6.17E-04 Suicide attempts in bipolar disorder FANCI intron 21423239 rs3087374 chr15 89859994 C A 2.58E-04 Coronary heart disease POLG missense 21606135 rs2246900 chr15 89862366 T C 9.14E-04 Suicide attempts in bipolar disorder POLG intron 21423239 rs2307449 chr15 89863928 T G 4.00E-13 Menopause (age at onset) POLG intron 22267201 rs16943057 chr15 89866360 T C 1.22E-04 Multiple complex diseases POLG intron 17554300 rs2351000 chr15 89869733 A G 4.30E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) POLG intron 24023788 rs2307444 chr15 89870623 G A 2.26E-04 Multiple complex diseases POLG intron 17554300 rs176641 chr15 89890182 A C 1.40E-05 Urinary metabolites / / 21572414 rs4932217 chr15 89902032 A C 8.00E-07 Height / / 18193045 rs176648 chr15 89939528 T G 3.41E-05 Coronary heart disease / / pha003031 rs7184034 chr15 89955161 T C 1.21E-04 Sudden cardiac arrest / / 21658281 rs12592645 chr15 89982879 C A 5.44E-06 Personality dimensions / / 23658558 rs1000471 chr15 89986583 C T 3.21E-04 Parkinson's disease / / 16252231 rs10162967 chr15 89996874 C T 2.94E-05 Meningococcal disease / / 20694013 rs1020145 chr15 90000871 G T 1.83E-05 Meningococcal disease / / 20694013 rs2075833 chr15 90016491 T C 7.14E-04 Multiple complex diseases RHCG intron 17554300 rs4932227 chr15 90064593 T C 4.12E-04 Amyotrophic lateral sclerosis (sporadic) LOC283761 intron 24529757 rs7165666 chr15 90065718 C G 1.50E-05 Urinary metabolites LOC283761 intron 21572414 rs8038108 chr15 90089276 C A 5.00E-09 Resting oxygen saturation in chronic obstructive pulmonary disease (pulse oxymetry) / / 24825563 rs7166317 chr15 90095777 A C 2.10E-05 Urinary metabolites / / 21572414 rs10775247 chr15 90126121 C T 3.00E-04 Otitis media (chronic/recurrent) C15orf42 missense 23974705 rs893724 chr15 90128799 T A 2.80E-05 Urinary metabolites C15orf42 intron 21572414 rs8032553 chr15 90137325 A G 3.00E-05 Lipid traits C15orf42 intron 17903299 rs894157 chr15 90168108 C T 9.00E-06 Obesity-related traits C15orf42 missense 23251661 rs1110060 chr15 90190048 A G 4.09E-05 Otitis media (chronic/recurrent) KIF7 intron 23974705 rs151155363 chr15 90190186 G A 0.0000184 Ratio of free to total prostate-specific antigen KIF7 missense 23555315 rs894160 chr15 90211823 C T 6.06E-04 Depression (quantitative trait) PLIN1 intron 20800221 rs8179043 chr15 90212144 T C 5.86E-04 Depression (quantitative trait) PLIN1 intron 20800221 rs11634708 chr15 90236210 C T 4.10E-05 Type 2 diabetes WDR93 intron 17463248 rs8035597 chr15 90237818 A C 3.35E-04 Smoking initiation WDR93 intron 24665060 rs12440918 chr15 90239455 T C 2.70E-06 Urinary metabolites WDR93 intron 21572414 rs11073886 chr15 90247017 G A 1.40E-05 Urinary metabolites WDR93 intron 21572414 rs11633274 chr15 90250479 A G 6.50E-06 Urinary metabolites WDR93 intron 21572414 rs11633980 chr15 90255555 T C 1.50E-05 Urinary metabolites WDR93 intron 21572414 rs2882677 chr15 90299514 C T 2.70E-05 Urinary metabolites / / 21572414 rs10584 chr15 90328551 G C 6.58E-04 Type 2 diabetes ANPEP UTR-3 17463246 rs6496603 chr15 90329192 A G 4.84E-04 Type 2 diabetes ANPEP intron 17463246 rs6496603 chr15 90329192 A G 1.26E-05 Major depressive disorder ANPEP intron pha002850 rs16974181 chr15 90332639 C G 6.20E-04 Iris characteristics ANPEP intron 21835309 rs25654 chr15 90334240 A G 1.40E-05 Urinary metabolites ANPEP cds-synon 21572414 rs25651 chr15 90335788 C T 1.40E-05 Urinary metabolites ANPEP missense 21572414 rs1439117 chr15 90338609 A C 2.00E-05 Urinary metabolites ANPEP intron 21572414 rs2007084 chr15 90345335 G A 2.00E-12 Blood metabolite levels ANPEP intron 24816252 rs2305443 chr15 90346861 C T 4.32E-04 Heart Failure ANPEP intron pha002885 rs8041622 chr15 90352069 G A 4.85E-05 Intracerebral hemorrhage ANPEP intron 24656865 rs9920421 chr15 90368067 G A 5.20E-05 Type 2 diabetes / / 21874001 rs9920775 chr15 90368273 T C 5.10E-05 Type 2 diabetes / / 21874001 rs11634658 chr15 90369148 T G 1.10E-04 Type 2 diabetes / / 21874001 rs4932143 chr15 90372067 G C 2.10E-05 Type 2 diabetes / / 21874001 rs2028299 chr15 90374257 C A 2.00E-11 Type 2 diabetes AP3S2 UTR-3 21874001 rs2028299 chr15 90374257 C A 1.90E-11 Type 2 diabetes AP3S2 UTR-3 23300278 rs2028299 chr15 90374257 C A 3.00E-06 Type 2 diabetes AP3S2 UTR-3 23945395 rs2028299 chr15 90374257 C A 5.00E-07 Type 2 diabetes AP3S2 UTR-3 24509480 rs12197 chr15 90376800 G A 5.60E-06 Urinary metabolites AP3S2 UTR-3 21572414 rs893617 chr15 90381278 C T 9.10E-05 Type 2 diabetes AP3S2 intron 21874001 rs2351706 chr15 90384115 A G 8.80E-05 Type 2 diabetes AP3S2 intron 21874001 rs16943645 chr15 90384861 T C 4.48E-05 Type 2 diabetes AP3S2 intron 17463246 rs16943645 chr15 90384861 T C 4.78E-05 Multiple complex diseases AP3S2 intron 17554300 rs12914541 chr15 90387346 G A 4.06E-04 Multiple complex diseases AP3S2 intron 17554300 rs12914541 chr15 90387346 G A 4.39E-05 Lipoprotein-associated phospholipase A2 activity and mass AP3S2 intron 20442857 rs16943651 chr15 90389463 G C 6.75E-04 Suicide attempts in bipolar disorder AP3S2 intron 21423239 rs10852122 chr15 90391921 A G 6.17E-04 Suicide attempts in bipolar disorder AP3S2 intron 21423239 rs11635652 chr15 90392153 G C 3.20E-05 Lipoprotein-associated phospholipase A2 activity and mass AP3S2 intron 20442857 rs11635652 chr15 90392153 G C 1.90E-05 Urinary metabolites AP3S2 intron 21572414 rs4932148 chr15 90394356 C T 6.60E-05 Type 2 diabetes AP3S2 intron 21874001 rs12912009 chr15 90429148 G A 1.00E-04 Type 2 diabetes AP3S2 intron 21874001 rs2043880 chr15 90432526 G A 1.10E-04 Type 2 diabetes AP3S2 intron 21874001 rs4932262 chr15 90439597 A C 7.15E-05 Type 2 diabetes C15orf38-AP3S2 intron 23945395 rs7178909 chr15 90447946 A G 5.00E-07 Common traits (Other) C15orf38 intron 20585627 rs1269077 chr15 90461129 C A 3.52E-05 Height / / 22021425 rs12594311 chr15 90488373 T G 4.71E-04 Multiple complex diseases / / 17554300 rs16943752 chr15 90501627 T C 1.21E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs16943752 chr15 90501627 T C 3.89E-05 Lung function (forced vital capacity) / / 24023788 rs12101723 chr15 90593947 T C 2.11E-05 Height ZNF710 intron 22021425 rs16943844 chr15 90595003 C G 3.50E-04 Type 2 diabetes ZNF710 intron 17463246 rs12592544 chr15 90599050 A G 4.34E-06 Height ZNF710 intron 22021425 rs2970358 chr15 90622504 C T 5.81E-04 Multiple complex diseases ZNF710 intron 17554300 rs9972327 chr15 90630892 C A 1.72E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) IDH2 intron 24023788 rs4553601 chr15 90647988 G T 9.42E-04 Lymphocyte counts / / 22286170 rs4932305 chr15 90764219 G A 1.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) SEMA4B missense 21239504 rs3751656 chr15 90771704 G A 0.00000244 Antisocial behavior SEMA4B cds-synon 23077488 rs3829490 chr15 90773059 C T 0.00000174 Antisocial behavior / / 23077488 rs9920862 chr15 90806140 G T 0.0000124 Antisocial behavior / / 23077488 rs11638027 chr15 90845500 G T 5.47E-12 Hepatitis B / / 24162738 rs7163019 chr15 90876669 C T 9.65E-04 Type 2 diabetes / / 17463246 rs7163411 chr15 90876808 C T 9.65E-04 Type 2 diabetes / / 17463246 rs16944212 chr15 90888049 C G 9.90E-04 Multiple complex diseases / / 17554300 rs3803539 chr15 90891982 A G 0.000000271 Stroke / / 23422753 rs6496667 chr15 90893668 C A 1.00E-06 Rheumatoid arthritis / / 22446963 rs16944283 chr15 90905553 A G 7.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8024110 chr15 90947453 C T 4.85E-04 Type 2 diabetes IQGAP1 intron 17463246 rs10520687 chr15 90967749 C G 1.20E-04 Type 2 diabetes and 6 quantitative traits IQGAP1 intron 17848626 rs2238320 chr15 90972441 G A 1.44E-04 Type 2 diabetes IQGAP1 intron 17463246 rs16944424 chr15 90983465 A G 1.87E-04 Type 2 diabetes IQGAP1 intron 17463246 rs8027211 chr15 90983706 T C 2.41E-04 Type 2 diabetes IQGAP1 intron 17463246 rs8025842 chr15 90995471 C T 9.86E-05 Non-alcoholic fatty liver disease histology (other) IQGAP1 intron 20708005 rs719473 chr15 90998064 A G 3.25E-04 Amyotrophic Lateral Sclerosis IQGAP1 intron 17362836 rs719473 chr15 90998064 A G 1.50E-04 Type 2 diabetes and 6 quantitative traits IQGAP1 intron 17848626 rs3213649 chr15 90999128 A C 2.40E-04 Amyotrophic Lateral Sclerosis IQGAP1 intron 17362836 rs8039288 chr15 91000445 T A 1.96E-04 Type 2 diabetes IQGAP1 intron 17463246 rs2238324 chr15 91006989 T C 9.20E-04 Amyotrophic Lateral Sclerosis IQGAP1 intron 17362836 rs16944500 chr15 91026973 A T 9.40E-05 Type 2 diabetes IQGAP1 intron 17463246 rs16944518 chr15 91035084 A C 4.37E-04 Amyotrophic Lateral Sclerosis IQGAP1 intron 17362836 rs16944518 chr15 91035084 A C 1.08E-04 Type 2 diabetes IQGAP1 intron 17463246 rs11073929 chr15 91038819 A G 3.96E-04 Lymphocyte counts IQGAP1 intron 22286170 rs3902286 chr15 91075375 C T 8.07E-04 Type 2 diabetes CRTC3 intron 17463246 rs12915189 chr15 91114376 A G 3.00E-06 Information processing speed CRTC3 intron 21130836 rs11635448 chr15 91125487 A G 9.39E-04 Tourette syndrome CRTC3 intron 22889924 rs7178220 chr15 91128189 G A 1.00E-04 Information processing speed CRTC3 intron 21130836 rs6496696 chr15 91129108 C T 7.20E-06 Information processing speed CRTC3 intron 21130836 rs10852136 chr15 91139798 T G 9.49E-05 Information processing speed CRTC3 intron 21130836 rs8028854 chr15 91140051 C T 7.15E-06 Information processing speed CRTC3 intron 21130836 rs8030781 chr15 91143072 T C 8.98E-06 Personality dimensions CRTC3 intron 22628180 rs8026682 chr15 91143253 A C 5.65E-05 Information processing speed CRTC3 intron 21130836 rs8026682 chr15 91143253 A C 8.10E-06 Personality dimensions CRTC3 intron 22628180 rs4932350 chr15 91143438 A G 8.26E-06 Personality dimensions CRTC3 intron 22628180 rs4932351 chr15 91143720 C G 8.52E-06 Personality dimensions CRTC3 intron 22628180 rs11631439 chr15 91143805 C A 5.11E-05 Information processing speed CRTC3 intron 21130836 rs11631439 chr15 91143805 C A 7.62E-06 Personality dimensions CRTC3 intron 22628180 rs6496703 chr15 91144903 G A 9.21E-06 Personality dimensions CRTC3 intron 22628180 rs8026218 chr15 91145265 G A 9.10E-06 Personality dimensions CRTC3 intron 22628180 rs4476150 chr15 91147214 G A 1.79E-05 Personality dimensions CRTC3 intron 22628180 rs1104880 chr15 91147512 A G 4.23E-04 Type 2 diabetes CRTC3 intron 17463246 rs7165429 chr15 91151881 C T 1.00E-04 Information processing speed CRTC3 intron 21130836 rs7165429 chr15 91151881 C T 2.26E-05 Personality dimensions CRTC3 intron 22628180 rs11636695 chr15 91152911 C G 2.24E-05 Personality dimensions CRTC3 intron 22628180 rs10520692 chr15 91154471 A G 2.09E-05 Personality dimensions CRTC3 intron 22628180 rs17180057 chr15 91155834 G A 2.28E-05 Personality dimensions CRTC3 intron 22628180 rs3743406 chr15 91161548 A G 2.26E-05 Personality dimensions CRTC3 intron 22628180 rs4932359 chr15 91172224 G A 7.99E-05 Information processing speed CRTC3 intron 21130836 rs7495132 chr15 91172901 C T 9.00E-11 Inflammatory bowel disease CRTC3 intron 23128233 rs7165170 chr15 91181489 A C 7.66E-05 Information processing speed CRTC3 intron 21130836 rs3743401 chr15 91185994 C T 7.10E-06 Information processing speed CRTC3 UTR-3 21130836 rs3743401 chr15 91185994 C T 0.000124 Salmonella-induced pyroptosis CRTC3 UTR-3 22837397 rs13379889 chr15 91195039 A G 7.66E-06 Information processing speed / / 21130836 rs13379889 chr15 91195039 A G 0.00059 Salmonella-induced pyroptosis / / 22837397 rs12915979 chr15 91199025 G A 4.83E-05 Information processing speed / / 21130836 rs12442284 chr15 91209433 T A,G 1.50E-05 Information processing speed / / 21130836 rs2518968 chr15 91307410 C G 2.48E-04 Multiple complex diseases BLM intron 17554300 rs17273206 chr15 91312313 G A 8.50E-05 Multiple complex diseases BLM intron 17554300 rs10468106 chr15 91325319 C T 0.000626 Salmonella-induced pyroptosis BLM intron 22837397 rs2227935 chr15 91326099 C T 0.000054 Breast cancer BLM missense 23555315 rs2380165 chr15 91340995 A G 5.60E-06 Osteoarthritis BLM intron 22566624 rs7167216 chr15 91354521 G A 0.000051 Breast cancer BLM missense 23555315 rs8041787 chr15 91365477 C T 8.04E-05 Hypertension / / 19609347 rs4932370 chr15 91404705 G A 0.000000103 Coronary artery disease (CAD) (males) / / 23202125 rs4932370 chr15 91404705 G A 0.0000281 Coronary artery disease with myocardial infarction / / 23202125 rs4932370 chr15 91404705 G A 0.000551 Coronary artery disease (CAD) (females) / / 23202125 rs4932370 chr15 91404705 G A 8.44E-08 Coronary artery disease (CAD) age >50 / / 23202125 rs4932178 chr15 91411656 C T 0.000526605 Hypertension (early onset hypertension) / / 22479346 rs4932178 chr15 91411656 C T 0.00043 Coronary artery calcification / / 23727086 rs17514846 chr15 91416550 C A 0.000389116 Hypertension (early onset hypertension) FURIN intron 22479346 rs17514846 chr15 91416550 C A 0.000000206 Coronary artery disease (CAD) (males) FURIN intron 23202125 rs17514846 chr15 91416550 C A 0.0000117 Systolic blood pressure FURIN intron 23202125 rs17514846 chr15 91416550 C A 0.000647 Coronary artery disease (CAD) (females) FURIN intron 23202125 rs17514846 chr15 91416550 C A 1.27E-08 Coronary artery disease (CAD) age >50 FURIN intron 23202125 rs17514846 chr15 91416550 C A 1.52E-09 Coronary artery disease with myocardial infarction FURIN intron 23202125 rs17514846 chr15 91416550 C A 9.33E-11 Coronary artery disease FURIN intron 23202125 rs17514846 chr15 91416550 C A 7.49E-05 Coronary artery disease FURIN intron 24262325 rs8032315 chr15 91418297 T A 2.30E-05 Urinary metabolites FURIN intron 21572414 rs4526996 chr15 91418591 A G 6.40E-04 Lymphocyte counts FURIN intron 22286170 rs2071410 chr15 91420940 C G 7.00E-06 Coronary heart disease FURIN intron 21966275 rs1573643 chr15 91420973 T C 1.32E-05 Attention deficit hyperactivity disorder FURIN intron 20732625 rs4702 chr15 91426560 G A 2.40E-05 Schizophrenia FURIN UTR-3 19571808 rs28510611 chr15 91428327 C A 0.000094 Breast cancer(er negative) FES missense 23555315 rs2521501 chr15 91437388 A T 3.00E-08 Blood pressure FES intron 21909110 rs2521501 chr15 91437388 A T 2.00E-15 Diastolic blood pressure FES intron 21909115 rs2521501 chr15 91437388 A T 5.00E-19 Systolic blood pressure FES intron 21909115 rs2521501 chr15 91437388 A T 7.00E-07 Hypertension FES intron 21909115 rs2521501 chr15 91437388 A T 1.31E-09 Coronary artery disease FES intron 23202125 rs2677744 chr15 91450441 G A 1.00E-06 Attention deficit hyperactivity disorder MAN2A2 intron 18839057 rs2106673 chr15 91452595 A G 5.05E-04 Blood pressure MAN2A2 missense 17255346 rs1266492 chr15 91456102 T C 2.23E-04 Blood pressure MAN2A2 intron 17255346 rs1266483 chr15 91462406 A G 8.73E-04 Multiple complex diseases MAN2A2 intron 17554300 rs12440774 chr15 91482935 G C 6.77E-06 Height UNC45A intron 22021425 rs7601 chr15 91509592 T C 3.23E-05 Lung adenocarcinoma PRC1 UTR-3 19836008 rs12910825 chr15 91511260 A G 4.31E-05 Height PRC1 intron 22021425 rs2290202 chr15 91512267 G T 4.90E-04 Type 2 diabetes PRC1 intron 22158537 rs8042680 chr15 91521337 C A 2.00E-10 Type 2 diabetes PRC1 intron 20581827 rs8042680 chr15 91521337 C A 2.00E-10 Type 2 diabetes PRC1 intron 21647700 rs8042680 chr15 91521337 C A 0.00000019 Type 2 diabetes PRC1 intron 22885922 rs8042680 chr15 91521337 C A 2.00E-10 Type 2 diabetes PRC1 intron 23300278 rs6496742 chr15 91523036 C T 6.40E-04 Volumetric brain MRI PRC1 intron 17903297 rs1867226 chr15 91523713 C G 5.80E-07 Blood pressure PRC1 intron 21378095 rs1867226 chr15 91523713 C G 7.60E-04 Type 2 diabetes PRC1 intron 22158537 rs142416384 chr15 91525048 C G 0.000021 Breast cancer PRC1 missense 23555315 rs12899811 chr15 91544076 A G 0.000000084 Type 2 diabetes (males) VPS33B intron 22885922 rs12899811 chr15 91544076 A G 6.30E-09 Type 2 diabetes VPS33B intron 22885922 rs12899811 chr15 91544076 A G 6.00E-07 Type 2 diabetes VPS33B intron 24509480 rs3743445 chr15 91561182 C T 3.60E-04 Alcohol dependence VPS33B intron 20201924 rs8026678 chr15 91562005 A G 6.20E-04 Alcohol dependence VPS33B intron 20201924 rs12913602 chr15 91575366 G T 2.70E-06 Urinary metabolites / / 21572414 rs11630140 chr15 91599958 T C 2.59E-04 Body mass index / / 21701565 rs11630140 chr15 91599958 T C 6.77E-04 Body mass index / / 21701565 rs10852143 chr15 91622281 C T 4.80E-06 Urinary metabolites / / 21572414 rs8024171 chr15 91671076 G A 1.40E-06 Urinary metabolites SV2B intron 21572414 rs16945255 chr15 91684287 A G 1.55E-04 Fibrinogen SV2B intron 17255346 rs17594278 chr15 91685519 T C 5.90E-05 Cytomegalovirus antibody response SV2B intron 21993531 rs17516032 chr15 91686453 A G 9.60E-05 Cytomegalovirus antibody response SV2B intron 21993531 rs10520697 chr15 91695901 T A 7.90E-05 Cytomegalovirus antibody response SV2B intron 21993531 rs11637698 chr15 91696344 G A 7.89E-05 Cytomegalovirus antibody response SV2B intron 21993531 rs12148251 chr15 91698922 G A 7.50E-05 Cytomegalovirus antibody response SV2B intron 21993531 rs6416561 chr15 91699075 G A 3.58E-04 Alzheimer's disease SV2B intron 17998437 rs12591682 chr15 91705959 T C 3.42E-04 Multiple complex diseases SV2B intron 17554300 rs756874 chr15 91717237 A G 8.67E-06 Serum metabolites SV2B intron 19043545 rs756873 chr15 91717328 C T 1.42E-07 Serum metabolites SV2B intron 19043545 rs886144 chr15 91717352 C T 2.00E-07 Metabolite levels SV2B intron 19043545 rs2012517 chr15 91717593 T C 7.84E-05 Serum metabolites SV2B intron 19043545 rs730616 chr15 91717996 C T 1.51E-06 Serum metabolites SV2B intron 19043545 rs2285529 chr15 91742578 A G 3.40E-04 Type 2 diabetes SV2B intron 17463246 rs2285529 chr15 91742578 A G 7.61E-04 Myopia (pathological) SV2B intron 21095009 rs2285528 chr15 91742669 C T 2.65E-05 Type 2 diabetes SV2B intron 17463246 rs2285528 chr15 91742669 C T 6.90E-04 Multiple complex diseases SV2B intron 17554300 rs2285528 chr15 91742669 C T 1.50E-05 Lipid levels SV2B intron 18193043 rs8039294 chr15 91743859 G T 6.29E-06 Blood pressure SV2B intron 21378095 rs2892184 chr15 91749626 A G 3.70E-05 Glucose levels SV2B intron pha002899 rs1002556 chr15 91774883 A C 4.30E-05 Coffee consumption SV2B intron 21357676 rs1005142 chr15 91784007 A G 2.01E-04 Body mass index SV2B intron 17255346 rs8042096 chr15 91792444 G A 6.14E-04 Myopia (pathological) SV2B intron 21095009 rs1076179 chr15 91800046 T C 6.25E-04 Myopia (pathological) SV2B intron 21095009 rs1075840 chr15 91801907 T G 5.49E-04 Myopia (pathological) SV2B intron 21095009 rs6496780 chr15 91812453 A G 4.84E-05 Major depressive disorder SV2B intron 21621269 rs11853779 chr15 91829283 C T 9.13E-04 Multiple complex diseases SV2B intron 17554300 rs1073167 chr15 91870233 T C 2.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17694187 chr15 91881260 C T 8.17E-04 Multiple complex diseases / / 17554300 rs1125976 chr15 91898943 T C 2.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs10520694 chr15 91900625 A G 2.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs12439990 chr15 91901038 G A 2.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs11634165 chr15 91909115 T G 7.99E-04 Coronary heart disease / / 21606135 rs8033124 chr15 91911474 C A 1.83E-04 Type 2 diabetes / / 21647700 rs11853306 chr15 91919792 A G 4.17E-04 Multiple complex diseases / / 17554300 rs4586406 chr15 91921234 T C 8.36E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6496799 chr15 91968540 A G 9.65E-05 Cognitive impairment induced by topiramate / / 22091778 rs4489981 chr15 91979779 T C 1.30E-05 AIDS / / 19754311 rs8043364 chr15 92013902 C T 1.95E-04 Stroke / / pha002887 rs8043364 chr15 92013902 C T 9.10E-05 Heart Rate / / pha003053 rs12917162 chr15 92028157 C G 1.89E-05 Aging (time to event) / / 21782286 rs8033394 chr15 92037101 G C 1.45E-04 Multiple complex diseases / / 17554300 rs6496812 chr15 92054139 T C 9.10E-06 Urinary metabolites / / 21572414 rs7496815 chr15 92061497 A G 0.0000586 Coronary artery disease / / 23202125 rs4395051 chr15 92087895 G C 6.61E-05 Serum metabolites / / 19043545 rs4509991 chr15 92088041 G A 5.24E-05 Serum metabolites / / 19043545 rs4932552 chr15 92091172 C T 1.84E-05 Gaucher disease severity / / 22388998 rs12594612 chr15 92097028 G A 5.75E-04 Multiple complex diseases / / 17554300 rs4932554 chr15 92097108 T C 9.32E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11637543 chr15 92099916 T C 1.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs4310831 chr15 92106380 G A 9.62E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6496832 chr15 92109095 A G 7.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs7174086 chr15 92114803 G C 7.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs4347602 chr15 92116107 C A 8.78E-06 Parkinson's disease / / 21248740 rs4932557 chr15 92118263 C A 7.93E-05 Parkinson's disease / / 21248740 rs4368146 chr15 92119390 A C 1.47E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12324460 chr15 92128412 T C 8.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs4932559 chr15 92133594 A G 3.90E-04 Alzheimer's disease / / 17998437 rs4383118 chr15 92139237 G A 0.00058 Prostate cancer / / 23555315 rs7495645 chr15 92139579 C T 1.05E-04 Multiple complex diseases / / 17554300 rs4420510 chr15 92146226 A G 1.75E-04 Suicide attempts in bipolar disorder / / 21041247 rs7495265 chr15 92150915 T C 1.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs7172774 chr15 92155000 G A 1.63E-04 Multiple complex diseases / / 17554300 rs7179520 chr15 92171900 G C 6.02E-04 Insulin resistance / / 21901158 rs7164176 chr15 92211774 G A 5.00E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs11852644 chr15 92225120 T A 5.19E-04 Suicide attempts in bipolar disorder / / 21041247 rs6496857 chr15 92249847 C T 6.10E-06 Endometriosis / / 21151130 rs6496858 chr15 92261849 A G 1.24E-05 Height / / 22021425 rs4074268 chr15 92277617 T G 5.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs4591122 chr15 92280440 A C 4.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs11631761 chr15 92301298 G A 0.0007 Breast cancer / / 23555315 rs4572364 chr15 92319918 G A 3.14E-04 Schizophrenia / / 19197363 rs4322641 chr15 92322122 C T 1.66E-04 Alcohol dependence / / 21314694 rs4356457 chr15 92326758 C G 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs8038779 chr15 92365436 A C 4.38E-04 White matter integrity / / 22425255 rs202195141 chr15 92394095 T TGA 2.06E-04 Nicotine smoking / / 19268276 rs7165398 chr15 92394095 T C 2.06E-04 Nicotine smoking / / 19268276 rs4075845 chr15 92398024 T C 4.13E-04 Nicotine smoking SLCO3A1 intron 19268276 rs12898512 chr15 92421288 G T 1.69E-04 Multiple complex diseases SLCO3A1 intron 17554300 rs12594215 chr15 92422340 G A 1.72E-05 Type 2 diabetes SLCO3A1 intron 17463246 rs4932583 chr15 92429089 A G 0.0000504 Amyotrophic lateral sclerosis SLCO3A1 intron 23587638 rs376603574 chr15 92430627 T TTGCC 0.0000639 Amyotrophic lateral sclerosis SLCO3A1 intron 23587638 rs7175096 chr15 92430627 T C 0.0000639 Amyotrophic lateral sclerosis SLCO3A1 intron 23587638 rs3924426 chr15 92445873 T C 2.00E-06 Response to iloperidone treatment (QT prolongation) SLCO3A1 intron 18521091 rs6496866 chr15 92446264 A T 6.18E-04 Type 2 diabetes SLCO3A1 intron 17463246 rs7175643 chr15 92472330 C T 5.53E-05 Erythrocyte counts SLCO3A1 intron pha003101 rs8027160 chr15 92505227 T G 2.99E-05 Serum metabolites SLCO3A1 intron 19043545 rs12905744 chr15 92518451 T C 7.42E-04 Suicide attempts in bipolar disorder SLCO3A1 intron 21423239 rs1568210 chr15 92522306 A G 5.61E-04 Suicide attempts in bipolar disorder SLCO3A1 intron 21423239 rs7163369 chr15 92533914 G A 0.00000327 Nicotine dependence (smoking) SLCO3A1 intron 22377092 rs12439738 chr15 92535551 C T 5.31E-04 Nicotine dependence SLCO3A1 intron 18227835 rs12439765 chr15 92535602 C G 6.25E-04 Nicotine dependence SLCO3A1 intron 18227835 rs4932597 chr15 92537617 A G 9.75E-04 Multiple complex diseases SLCO3A1 intron 17554300 rs4932597 chr15 92537617 A G 2.45E-04 Nicotine dependence SLCO3A1 intron 18227835 rs4932597 chr15 92537617 A G 8.65E-05 Biliary atresia SLCO3A1 intron 20460270 rs4932598 chr15 92537845 T C 1.92E-04 Nicotine dependence SLCO3A1 intron 18227835 rs7495052 chr15 92552029 T C 3.00E-06 Inattentive symptoms SLCO3A1 intron 18821565 rs7171137 chr15 92562627 C A 3.79E-05 Parkinson's disease SLCO3A1 intron 21812969 rs1568209 chr15 92581290 G A 9.55E-06 Type 2 diabetes SLCO3A1 intron 17463246 rs1568209 chr15 92581290 G A 2.80E-05 Body mass (lean) SLCO3A1 intron 19268274 rs7171275 chr15 92601966 G A 5.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLCO3A1 intron 20877124 rs8032656 chr15 92602314 G C 4.09E-06 Type 2 diabetes SLCO3A1 intron 17463246 rs8032656 chr15 92602314 G C 6.28E-04 Response to taxane treatment (placlitaxel) SLCO3A1 intron 23006423 rs7173864 chr15 92610467 T C 0.0000923 Nicotine dependence (smoking) SLCO3A1 intron 22377092 rs12910142 chr15 92623503 G A 0.000022 Nicotine dependence (smoking) SLCO3A1 intron 22377092 rs207968 chr15 92641430 G T 1.44E-04 Aortic root size SLCO3A1 intron 21223598 rs4984338 chr15 92645371 G A 3.00E-05 Response to statin therapy SLCO3A1 intron 20339536 rs4984338 chr15 92645371 G A 1.22E-05 Brain structure SLCO3A1 intron 22504417 rs4984338 chr15 92645371 G A 2.46E-04 Alzheimer's disease SLCO3A1 intron 24755620 rs1517618 chr15 92647645 G C 5.90E-05 Response to statin therapy SLCO3A1 missense 20339536 rs207964 chr15 92652173 T C 1.67E-05 Brain structure SLCO3A1 intron 22504417 rs207964 chr15 92652173 T C 1.70E-04 Smoking initiation SLCO3A1 intron 24665060 rs207964 chr15 92652173 T C 9.00E-05 Alzheimer's disease SLCO3A1 intron 24755620 rs207962 chr15 92652998 G C 8.85E-04 Alzheimer's disease SLCO3A1 intron 24755620 rs207961 chr15 92653604 C G 5.40E-04 Aortic root size SLCO3A1 intron 21223598 rs207959 chr15 92655262 T C 8.19E-04 Alzheimer's disease SLCO3A1 intron 24755620 rs169618 chr15 92657119 A G 7.40E-04 Alzheimer's disease SLCO3A1 intron 24755620 rs207954 chr15 92657373 T C 1.00E-06 Acute lymphoblastic leukemia (childhood) SLCO3A1 intron 22076464 rs185950 chr15 92658011 G T 1.80E-05 Response to statin therapy SLCO3A1 intron 20339536 rs185950 chr15 92658011 G T 1.51E-04 Alzheimer's disease SLCO3A1 intron 24755620 rs207952 chr15 92658041 G A 1.50E-05 Response to statin therapy SLCO3A1 intron 20339536 rs207952 chr15 92658041 G A 1.36E-04 Alzheimer's disease SLCO3A1 intron 24755620 rs16974268 chr15 92658852 C T 2.10E-05 Response to statin therapy SLCO3A1 intron 20339536 rs16974268 chr15 92658852 C T 6.17E-05 Alzheimer's disease SLCO3A1 intron 24755620 rs11631993 chr15 92659678 C G 1.80E-05 Response to statin therapy SLCO3A1 intron 20339536 rs7179547 chr15 92660618 A C 1.80E-05 Response to statin therapy SLCO3A1 intron 20339536 rs12439582 chr15 92660837 G A 2.90E-05 Response to statin therapy SLCO3A1 intron 20339536 rs12437502 chr15 92660866 T C 2.40E-05 Response to statin therapy SLCO3A1 intron 20339536 rs12437502 chr15 92660866 T C 2.08E-04 Stroke SLCO3A1 intron 22306652 rs12437502 chr15 92660866 T C 2.87E-05 Brain structure SLCO3A1 intron 22504417 rs11074041 chr15 92661004 C G 1.80E-05 Response to statin therapy SLCO3A1 intron 20339536 rs7175812 chr15 92663201 T C 1.80E-05 Response to statin therapy SLCO3A1 intron 20339536 rs7175812 chr15 92663201 T C 6.49E-05 Alzheimer's disease SLCO3A1 intron 24755620 rs2190748 chr15 92685078 G A 2.50E-05 Urinary metabolites SLCO3A1 intron 21572414 rs2190748 chr15 92685078 G A 6.34E-04 Smoking cessation SLCO3A1 intron 24665060 rs2238356 chr15 92685760 A C 8.63E-06 Obesity-related traits SLCO3A1 intron 23251661 rs2238355 chr15 92685778 T C 8.00E-06 Obesity-related traits SLCO3A1 intron 23251661 rs2283458 chr15 92689112 A G 1.21E-04 Smoking cessation SLCO3A1 intron 24665060 rs960440 chr15 92698643 G C 4.07E-04 Smoking cessation SLCO3A1 intron 24665060 rs768882 chr15 92698684 G A 1.00E-05 Calcium levels SLCO3A1 intron pha003085 rs10852168 chr15 92701994 G A 3.36E-04 Multiple complex diseases SLCO3A1 intron 17554300 rs10852169 chr15 92702401 A G 1.14E-04 Multiple complex diseases SLCO3A1 intron 17554300 rs2238341 chr15 92705031 A G 5.00E-06 Serum dimethylarginine levels (symmetric) SLCO3A1 intron 24159190 rs11631374 chr15 92709620 T G 5.69E-04 Smoking initiation SLCO3A1 intron 24665060 rs10520704 chr15 92720600 A G 8.00E-04 Crohn's disease / / 17684544 rs10852171 chr15 92725344 C T 2.03E-04 Smoking initiation / / 24665060 rs4778020 chr15 92726702 G A 2.48E-05 Calcium levels / / pha003085 rs16946511 chr15 92730538 T C 4.69E-04 Multiple complex diseases / / 17554300 rs17645358 chr15 92731319 G A 4.04E-04 Multiple complex diseases / / 17554300 rs4778032 chr15 92732085 T C 3.29E-04 Body mass index / / 17255346 rs12910687 chr15 92733330 G A 8.07E-05 Smoking initiation / / 24665060 rs1871437 chr15 92735915 T C 5.39E-06 Response to hepatitis C treatment / / 19684573 rs4778038 chr15 92739691 T C 5.71E-07 Smoking initiation / / 24665060 rs2079597 chr15 92745367 A C 3.18E-04 Smoking initiation / / 24665060 rs8043247 chr15 92745943 A T 8.89E-05 Smoking initiation / / 24665060 rs2387687 chr15 92758434 T G 2.70E-05 Urinary metabolites / / 21572414 rs4627288 chr15 92765469 A G 1.55E-04 Smoking initiation / / 24665060 rs4627290 chr15 92765570 A G 5.12E-05 Smoking initiation / / 24665060 rs11074052 chr15 92767772 G A 9.47E-07 Smoking initiation / / 24665060 rs7172232 chr15 92768642 A G 1.37E-04 Smoking initiation / / 24665060 rs1026759 chr15 92770579 C T 3.32E-04 Sarcoidosis / / 19165924 rs1479524 chr15 92775617 G A 1.90E-05 Urinary metabolites / / 21572414 rs8026156 chr15 92788817 A C 1.22E-04 Smoking initiation / / 24665060 rs4304977 chr15 92806291 G A 5.00E-06 DNA methylation (variation) / / 23725790 rs4777900 chr15 92814603 A G 1.24E-04 Smoking initiation / / 24665060 rs8027648 chr15 92822021 T C 1.42E-04 Smoking initiation / / 24665060 rs12901615 chr15 92847304 C A 2.21E-07 Smoking initiation / / 24665060 rs7163877 chr15 92853516 C T 5.78E-04 Smoking initiation / / 24665060 rs12912184 chr15 92858101 G A 9.00E-08 Smoking initiation / / 24665060 rs8025347 chr15 92859281 A G 1.61E-05 Caffeine consumption / / 21490707 rs8025347 chr15 92859281 A G 4.58E-04 Stroke / / pha002886 rs1871438 chr15 92859881 A G 8.00E-07 Colorectal cancer (diet interaction) / / 24743840 rs11074060 chr15 92860257 G A 9.57E-04 Type 2 diabetes / / 17463246 rs8036277 chr15 92860904 A G 6.38E-04 Type 2 diabetes / / 17463246 rs16946733 chr15 92863467 A G 5.69E-04 Myopia (pathological) / / 21095009 rs1386775 chr15 92867190 C T 9.88E-06 Smoking initiation / / 24665060 rs7170258 chr15 92868631 A G 3.75E-05 Smoking initiation / / 24665060 rs7171020 chr15 92869032 A C 8.54E-06 Smoking initiation / / 24665060 rs2892338 chr15 92870595 G A 7.13E-05 Smoking initiation / / 24665060 rs1986228 chr15 92876076 T C 3.02E-04 Smoking initiation / / 24665060 rs899525 chr15 92876467 G A 4.60E-04 Smoking initiation / / 24665060 rs12905014 chr15 92883840 T C 4.00E-07 Airflow obstruction / / 22837378 rs899529 chr15 92884421 C G 3.56E-04 Multiple complex diseases / / 17554300 rs8028666 chr15 92890028 G T 5.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs8028666 chr15 92890028 G T 5.31E-04 Tourette syndrome / / 22889924 rs7170557 chr15 92892688 T A 6.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs8037921 chr15 92909199 C T 9.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs936925 chr15 92918585 T C 1.38E-04 Blood pressure / / 17255346 rs4777708 chr15 92919771 A C 3.14E-04 Type 2 diabetes / / 17463246 rs2101436 chr15 92920921 C T 4.19E-04 Type 2 diabetes / / 17463246 rs17702901 chr15 92930411 G A 7.00E-08 Weight loss (gastric bypass surgery) / / 23643386 rs17646492 chr15 92933859 G A 8.83E-04 Multiple complex diseases / / 17554300 rs2035645 chr15 92946326 T G 3.42E-05 Heart Failure ST8SIA2 intron pha002884 rs2168351 chr15 92983722 A G 1.58E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ST8SIA2 intron 24023788 rs2168351 chr15 92983722 A G 7.60E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ST8SIA2 intron 24023788 rs11852344 chr15 93001521 G A 1.31E-05 Heart Rate ST8SIA2 intron pha003053 rs4777715 chr15 93002081 A G 1.73E-05 Erythrocyte counts ST8SIA2 intron pha003101 rs4777987 chr15 93002182 C T 7.40E-06 Erythrocyte counts ST8SIA2 intron pha003101 rs4777989 chr15 93006740 G A 6.10E-04 Coronary heart disease ST8SIA2 intron 21606135 rs2306842 chr15 93014670 A G 1.70E-05 Heart Rate / / pha003053 rs11629718 chr15 93014895 T G 2.30E-05 Urinary metabolites / / 21572414 rs1455773 chr15 93015427 G A 7.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) C15orf32 missense 21239504 rs8033301 chr15 93036741 G A 9.69E-04 Multiple complex diseases C15orf32 intron 17554300 rs1007523 chr15 93039730 C G 9.24E-04 Multiple complex diseases C15orf32 intron 17554300 rs8040009 chr15 93044339 T C 6.00E-06 Bipolar disorder C15orf32 UTR-3 20386566 rs8040009 chr15 93044339 T C 3.00E-07 Alcoholism (heaviness of drinking) C15orf32 UTR-3 21529783 rs1455782 chr15 93050966 A G 4.00E-06 Pulmonary function / / 17903307 rs8034095 chr15 93051659 T C 5.57E-05 Heart Rate / / pha003053 rs7169178 chr15 93074671 A G 7.17E-04 Amyotrophic lateral sclerosis / / 23624525 rs2168358 chr15 93074890 C A 4.49E-04 Amyotrophic lateral sclerosis / / 23624525 rs8034091 chr15 93075761 G A 3.52E-04 HIV-1 viral setpoint / / 17641165 rs17522931 chr15 93106417 G C 8.48E-04 Multiple complex diseases / / 17554300 rs11074079 chr15 93124949 A G 7.76E-05 Multiple sclerosis / / 17660530 rs4777724 chr15 93128456 G A 8.30E-04 HIV-1 viral setpoint / / 17641165 rs4777724 chr15 93128456 G A 4.88E-05 Socioeconomic Factors / / pha003066 rs2173063 chr15 93131632 G A 3.00E-06 Subcutaneous adipose tissue / / 22589738 rs1390786 chr15 93132768 T C 6.40E-05 HIV-1 viral setpoint / / 17641165 rs4777727 chr15 93135885 T G 8.43E-04 HIV-1 viral setpoint / / 17641165 rs4777727 chr15 93135885 T G 5.48E-05 Socioeconomic Factors / / pha003066 rs432364 chr15 93157519 T G 9.93E-05 Osteosarcoma / / 23727862 rs8032832 chr15 93158095 A G 0.0000726 Menopause (age at onset) / / 23424626 rs8043510 chr15 93159737 A G 4.73E-04 Osteosarcoma / / 23727862 rs285757 chr15 93179175 T C 7.00E-06 HIV-1 susceptibility FAM174B intron 21160409 rs1496725 chr15 93192523 G A 7.30E-04 Multiple complex diseases FAM174B intron 17554300 rs893379 chr15 93194688 T C 2.62E-04 Multiple complex diseases FAM174B intron 17554300 rs373481 chr15 93205454 T C 3.49E-04 Multiple complex diseases / / 17554300 rs401072 chr15 93211991 G A 9.55E-04 Multiple complex diseases / / 17554300 rs12898781 chr15 93214129 T G 9.56E-05 Schizophrenia(age at onset) / / 21688384 rs285753 chr15 93218077 G A 8.33E-05 Multiple complex diseases / / 17554300 rs10520712 chr15 93222071 G A 2.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11074094 chr15 93224690 T C 2.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs285729 chr15 93226337 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs285732 chr15 93226828 T C 8.12E-05 Multiple complex diseases / / 17554300 rs206351 chr15 93228961 A G 8.54E-04 Coronary Artery Disease / / 17634449 rs1018075 chr15 93235340 G A 2.52E-04 Multiple complex diseases / / 17554300 rs881268 chr15 93245099 C A 2.15E-04 Multiple complex diseases / / 17554300 rs1467972 chr15 93245286 G A 8.91E-04 Multiple complex diseases / / 17554300 rs6496981 chr15 93272939 A G 5.23E-04 Myopia (pathological) / / 21095009 rs7174203 chr15 93309613 A C 7.79E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6496996 chr15 93402496 G A 5.73E-05 Hypertension / / pha003042 rs10852181 chr15 93412778 C G 1.70E-04 Multiple complex diseases / / 17554300 rs4778052 chr15 93421244 C T 5.72E-04 Stroke / / pha002886 rs12916015 chr15 93464376 A G 2.10E-05 Personality dimensions CHD2 intron 18957941 rs12901950 chr15 93474177 C A 3.70E-05 Personality dimensions CHD2 intron 18957941 rs8035739 chr15 93479798 T C 4.49E-05 Serum metabolites CHD2 intron 19043545 rs2272462 chr15 93485300 T C 4.19E-04 Response to alcohol consumption (flushing response) CHD2 intron 24277619 rs8042395 chr15 93495973 A C 9.73E-07 Serum metabolites CHD2 intron 19043545 rs8032603 chr15 93505649 T G 5.64E-05 Hypertension CHD2 intron pha003042 rs17610312 chr15 93522759 T C 4.40E-05 Hypertension CHD2 intron pha003042 rs12592212 chr15 93528015 C T 5.56E-04 Myopia (pathological) CHD2 intron 21095009 rs7174740 chr15 93531714 C T 7.46E-05 Multiple complex diseases CHD2 intron 17554300 rs8042437 chr15 93547575 T C 4.73E-06 Hypertension CHD2 intron pha003042 rs1074513 chr15 93551547 C T 3.08E-05 Serum metabolites CHD2 intron 19043545 rs7164173 chr15 93561642 G T 5.62E-04 Type 2 diabetes CHD2 intron 17463246 rs7179432 chr15 93564972 T C 4.00E-06 IgG glycosylation CHD2 intron 23382691 rs7181095 chr15 93574819 C T 3.96E-05 Body mass index / / 19079261 rs7181095 chr15 93574819 C T 4.00E-05 Smoking behavior / / 20418888 rs1978877 chr15 93577383 T C 9.38E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11074130 chr15 93583742 T G 5.29E-04 Coronary Artery Disease / / 17634449 rs7164440 chr15 93584615 G A 3.24E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs8032755 chr15 93602056 G A 7.40E-06 Osteoarthritis RGMA intron 22763110 rs6497019 chr15 93627639 G A 9.50E-06 Urinary metabolites RGMA intron 21572414 rs6497019 chr15 93627639 G A 0.000804215 Hypertension (early onset hypertension) RGMA intron 22479346 rs10520720 chr15 93634724 G A 9.91E-04 Type 2 diabetes / / 17463246 rs7168353 chr15 93638401 G C 1.00E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4270125 chr15 93652234 T G 5.68E-04 Parkinson's disease / / 17052657 rs17705835 chr15 93662283 C T 3.82E-06 Hearing function / / 21493956 rs17705835 chr15 93662283 C T 3.81E-06 Blood Pressure / / pha003045 rs17705835 chr15 93662283 C T 3.20E-06 Blood Pressure / / pha003047 rs7180858 chr15 93678921 G T 2.75E-05 Basophils / / pha003087 rs10152527 chr15 93680942 G T 9.63E-04 Multiple complex diseases / / 17554300 rs10459680 chr15 93681470 T C 1.30E-05 Amyotrophic Lateral Sclerosis / / 17362836 rs10520714 chr15 93688462 C T 1.18E-04 Lipid levels / / 19016617 rs10520714 chr15 93688462 C T 8.45E-04 Lipid levels / / 19016617 rs7181117 chr15 93691220 A G 1.43E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4238464 chr15 93701227 A G 4.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4402508 chr15 93710324 A G 2.99E-04 Fibrinogen / / 17255346 rs6497031 chr15 93713666 G A 5.00E-06 Periodontitis (CDC/AAP) / / 24024966 rs17539990 chr15 93722795 C G 7.81E-04 Suicide attempts in bipolar disorder / / 21041247 rs4325505 chr15 93734982 C A 2.61E-04 Lung function (forced vital capacity) / / 24023788 rs6416581 chr15 93736874 T G 3.69E-04 Alzheimer's disease (late onset) / / 21379329 rs4777792 chr15 93742047 C T 3.30E-04 Breast cancer / / 19330027 rs12916315 chr15 93746004 G A 1.73E-04 Multiple complex diseases / / 17554300 rs12900484 chr15 93789196 G C 7.28E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12911343 chr15 93791087 G A 4.11E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9302365 chr15 93796278 C A 3.25E-05 Cognitive test performance / / 20125193 rs8032853 chr15 93798732 C T 4.23E-04 Lung function (forced vital capacity) / / 24023788 rs8031759 chr15 93798810 G T 3.90E-04 Type 2 diabetes / / 17463246 rs17540498 chr15 93800425 C T 5.16E-05 Serum metabolites / / 19043545 rs17612678 chr15 93815129 T C 5.00E-06 Obesity-related traits / / 23251661 rs17612678 chr15 93815129 T C 9.09E-04 Stroke / / pha002886 rs5016773 chr15 93826452 A G 2.45E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs5016773 chr15 93826452 A G 8.52E-05 Lung function (forced vital capacity) / / 24023788 rs11074159 chr15 93827272 C T 1.49E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs11074159 chr15 93827272 C T 3.80E-05 Lung function (forced vital capacity) / / 24023788 rs4777646 chr15 93843792 G C 6.27E-04 Multiple complex diseases / / 17554300 rs2388162 chr15 93853146 T C 2.25E-04 Multiple complex diseases / / 17554300 rs8028266 chr15 93863413 C T 5.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17541104 chr15 93863467 C T 4.48E-05 Vaspin levels / / 22907691 rs17541104 chr15 93863467 C T 0.0000448 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs7166968 chr15 93865146 G A 9.08E-05 Heart Rate / / pha003054 rs16947830 chr15 93877257 A G 7.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4777845 chr15 93877425 T C 9.00E-06 Adiponectin levels / / 22479202 rs17541406 chr15 93889459 C G 1.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs7164857 chr15 93892942 G T 6.53E-05 Hypertension / / 21082022 rs17441859 chr15 93894141 T C 5.36E-04 Stroke / / pha002886 rs1872049 chr15 93895831 G A 6.95E-04 Stroke / / pha002886 rs17541566 chr15 93896936 A G 7.49E-06 Hypertension / / 21082022 rs7176275 chr15 93899526 C G 1.70E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs4587928 chr15 93903068 C T 9.82E-05 Prostate cancer / / pha002877 rs10520722 chr15 93905833 T A 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs11636893 chr15 93908402 C A 8.95E-05 Colorectal cancer / / 19723657 rs4777855 chr15 93918962 A G 4.31E-04 Multiple complex diseases / / 17554300 rs11074185 chr15 93970412 A G 4.87E-04 Smoking quantity / / 24665060 rs8030979 chr15 93993781 C T 4.60E-07 Facial morphology / / 22341974 rs2087349 chr15 93997741 T C 6.70E-04 Multiple complex diseases / / 17554300 rs4777888 chr15 94004138 G C 1.45E-04 Type 2 diabetes / / 17463246 rs11074189 chr15 94005055 T C 4.99E-05 Serum metabolites / / 19043545 rs16948067 chr15 94006898 A G 2.67E-04 Type 2 diabetes / / 17463246 rs16974334 chr15 94006972 T C 7.05E-04 Type 2 diabetes / / 17463246 rs1542708 chr15 94020782 G A 0.000733 Salmonella-induced pyroptosis / / 22837397 rs2388299 chr15 94029616 A G 2.60E-04 Age-related macular degeneration / / 22125219 rs2388299 chr15 94029616 A G 0.0006953 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2388299 chr15 94029616 A G 6.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6497080 chr15 94033802 G A 1.38E-04 Age-related macular degeneration / / 22125219 rs7175404 chr15 94036688 A G 6.00E-07 Attention deficit hyperactivity disorder / / 18839057 rs11854956 chr15 94043784 T A 1.96E-04 Multiple complex diseases / / 17554300 rs7170834 chr15 94048638 G T 1.20E-04 IgE levels in asthmatics / / 23967269 rs7177584 chr15 94054751 A G 5.75E-04 Multiple complex diseases / / 17554300 rs10520733 chr15 94073065 C A 3.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12591541 chr15 94077313 T C 1.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11074199 chr15 94084984 C T 1.80E-05 Urinary metabolites / / 21572414 rs11638840 chr15 94085546 G A 7.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2220463 chr15 94086718 C T 2.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16948210 chr15 94088090 G C 2.41E-04 Type 2 diabetes / / 17463246 rs959891 chr15 94089021 G A 9.65E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4485303 chr15 94090035 G A 4.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4485303 chr15 94090035 G A 9.10E-05 Hypertension (essential hypertension) / / 22184326 rs17709163 chr15 94116764 A G 1.19E-07 Type 1 diabetes nephropathy / / 23028342 rs8032999 chr15 94116840 T G 5.62E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4777926 chr15 94141607 G C 9.10E-06 Urinary metabolites / / 21572414 rs12437854 chr15 94141833 T G 2.00E-09 Type 1 diabetes nephropathy / / 23028342 rs17626587 chr15 94153540 A G 8.83E-04 Type 2 diabetes / / 17463246 rs16948292 chr15 94158240 A G 8.82E-04 Multiple complex diseases / / 17554300 rs4777936 chr15 94179432 T C 8.80E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs4260001 chr15 94182862 C G 3.72E-05 Attention deficit hyperactivity disorder / / pha002875 rs12900133 chr15 94317376 C T 2.70E-05 Urinary metabolites / / 21572414 rs7498063 chr15 94334658 T C 8.18E-05 Blood Pressure / / pha003040 rs1578700 chr15 94359470 C T 9.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs1342522 chr15 94363885 C T 3.99E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7172139 chr15 94371122 C T 8.38E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs1891448 chr15 94393361 A G 3.95E-04 Type 2 diabetes / / 17463246 rs11857237 chr15 94409898 C A 1.30E-04 Type 2 diabetes / / 17463246 rs4335731 chr15 94432246 G A 3.61E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs10438448 chr15 94496299 T C 2.71E-05 Age-related macular degeneration / / 23577725 rs2054508 chr15 94574082 T C 1.31E-04 Type 2 diabetes / / 17463246 rs2054508 chr15 94574082 T C 2.64E-04 Smoking initiation / / 24665060 rs970374 chr15 94576079 G A 6.87E-05 Type 2 diabetes / / 17463246 rs1479821 chr15 94580353 T C 8.00E-04 Pancreatic cancer / / 23180869 rs16948671 chr15 94591307 T C 5.82E-04 Multiple complex diseases / / 17554300 rs8041151 chr15 94626455 C T 2.98E-04 Smoking initiation / / 24665060 rs2170055 chr15 94627555 T C 5.66E-04 Multiple complex diseases / / 17554300 rs1479831 chr15 94644230 C T 1.98E-04 Multiple complex diseases / / 17554300 rs10400909 chr15 94649121 G A 3.71E-04 Multiple complex diseases / / 17554300 rs2127470 chr15 94650054 G A 2.58E-04 Multiple complex diseases / / 17554300 rs1479833 chr15 94650643 G A 7.57E-04 Iron levels / / pha002876 rs6497173 chr15 94664199 T G 1.60E-05 Urinary metabolites / / 21572414 rs16948734 chr15 94664645 T C 5.10E-06 Urinary metabolites / / 21572414 rs7174567 chr15 94669167 G A 2.75E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs2219854 chr15 94679103 T C 6.71E-05 Iron levels / / 19880490 rs2219854 chr15 94679103 T C 6.71E-05 Iron levels / / pha002876 rs2388436 chr15 94689653 G A 6.00E-06 Hoarding / / 21302353 rs2713896 chr15 94700147 G T 8.44E-04 Type 2 diabetes / / 17463246 rs16948760 chr15 94701431 G A 3.96E-04 Iron levels / / pha002876 rs1350092 chr15 94704086 T C 4.18E-04 Type 2 diabetes / / 17463246 rs17660797 chr15 94738175 C T 1.13E-04 Smoking quantity / / 24665060 rs6497177 chr15 94741598 T G 1.27E-04 Schizophrenia / / 19197363 rs8036863 chr15 94742999 C A 5.63E-06 Uric acid levels / / 21294900 rs958692 chr15 94755158 G A 4.79E-05 Major depressive disorder / / 21621269 rs1378593 chr15 94763672 T C 4.10E-04 Glaucoma (primary open-angle) / / 22419738 rs1350090 chr15 94773470 G A 7.00E-05 Prostate cancer / / 21743057 rs10163015 chr15 94781904 C T 9.07E-05 Serum metabolites / / 19043545 rs1455764 chr15 94795658 T C 1.77E-04 White matter integrity / / 22425255 rs6497181 chr15 94797542 T G 1.28E-04 White matter integrity / / 22425255 rs1378591 chr15 94799751 C A 7.13E-04 White matter integrity / / 22425255 rs6497188 chr15 94804241 A G 2.93E-04 Gallstones / / 17632509 rs1563361 chr15 94829625 C T 6.25E-05 Aging (time to event) / / 21782286 rs4984344 chr15 94844430 G T 2.18E-04 Glycosylated haemoglobin levels MCTP2 intron 17255346 rs4984344 chr15 94844430 G T 4.25E-04 Multiple complex diseases MCTP2 intron 17554300 rs1347277 chr15 94845398 G A 3.62E-04 Multiple complex diseases MCTP2 intron 17554300 rs1368844 chr15 94845433 A G 9.72E-04 Multiple complex diseases MCTP2 intron 17554300 rs12899314 chr15 94849637 A G 6.70E-06 Bipolar disorder MCTP2 intron 20451256 rs10520745 chr15 94852556 T C 9.88E-04 Bipolar disorder MCTP2 intron 19259986 rs10520746 chr15 94852720 A G 9.88E-04 Bipolar disorder MCTP2 intron 19259986 rs13329421 chr15 94855550 G T 1.43E-06 Coronary heart disease MCTP2 intron pha003031 rs13329421 chr15 94855550 G T 4.33E-05 Left ventricular hypertrophy MCTP2 intron pha003052 rs294559 chr15 94855913 A G 7.01E-05 Serum metabolites MCTP2 intron 19043545 rs294548 chr15 94859821 C T 3.27E-04 Suicide attempts in bipolar disorder MCTP2 intron 21423239 rs7176196 chr15 94861302 G A 4.43E-04 Suicide attempts in bipolar disorder MCTP2 intron 21423239 rs7178199 chr15 94861317 A G 3.35E-04 Suicide attempts in bipolar disorder MCTP2 intron 21423239 rs4328383 chr15 94863837 T G 7.29E-04 Alcohol dependence MCTP2 intron 24277619 rs1433943 chr15 94866380 T C 4.15E-04 Coronary Artery Disease MCTP2 intron 17634449 rs16948939 chr15 94871918 G C 1.12E-04 Type 2 diabetes MCTP2 intron 17463246 rs11634520 chr15 94880171 G A 9.73E-04 Acute lung injury MCTP2 intron 22295056 rs3743307 chr15 94884980 G A 8.92E-04 Coronary Artery Disease MCTP2 intron 17634449 rs3743307 chr15 94884980 G A 4.28E-04 Alcohol dependence MCTP2 intron 24277619 rs11634659 chr15 94887670 T C 7.25E-04 Acute lung injury MCTP2 intron 22295056 rs11633938 chr15 94891927 G C 9.70E-05 Personality dimensions MCTP2 intron 18957941 rs12591731 chr15 94893149 A T 3.86E-04 Acute lung injury MCTP2 intron 22295056 rs17630600 chr15 94895754 G A 3.51E-04 Acute lung injury MCTP2 intron 22295056 rs17661962 chr15 94900367 A C 7.30E-05 Personality dimensions MCTP2 intron 18957941 rs11634430 chr15 94900506 A T 5.99E-04 Acute lung injury MCTP2 intron 22295056 rs7171661 chr15 94907062 T C 1.79E-05 Multiple sclerosis MCTP2 intron 20598377 rs7171661 chr15 94907062 T C 5.34E-05 Body Composition MCTP2 intron pha003012 rs7171661 chr15 94907062 T C 6.55E-05 Body Mass Index MCTP2 intron pha003021 rs16949031 chr15 94915413 T C 6.65E-04 Multiple complex diseases MCTP2 intron 17554300 rs4984390 chr15 94939508 G A 4.00E-06 Drug-induced liver injury (flucloxacillin) MCTP2 intron 19483685 rs16949089 chr15 94941136 G C 1.58E-04 Smoking initiation MCTP2 intron 24665060 rs10520754 chr15 94959409 C T 7.19E-04 Alcohol dependence MCTP2 intron 20201924 rs1368839 chr15 94960355 T G 4.98E-04 Alcohol dependence MCTP2 intron 20201924 rs17662596 chr15 94960651 A G 4.30E-06 Urinary metabolites MCTP2 intron 21572414 rs7176028 chr15 94961245 A G 2.90E-04 Type 2 diabetes and 6 quantitative traits MCTP2 intron 17848626 rs7176028 chr15 94961245 A G 8.40E-06 Urinary metabolites MCTP2 intron 21572414 rs17662635 chr15 94962892 A G 1.85E-04 Multiple complex diseases MCTP2 intron 17554300 rs17662665 chr15 94965953 C A 1.40E-05 Urinary metabolites MCTP2 intron 21572414 rs2289008 chr15 94983269 C T 3.95E-05 Coronary heart disease MCTP2 intron pha003056 rs293581 chr15 94989554 A G 3.57E-04 Multiple complex diseases MCTP2 intron 17554300 rs17730347 chr15 94996879 A G 2.00E-05 Urinary metabolites MCTP2 intron 21572414 rs1048048 chr15 95024760 T C 2.66E-04 Alcohol dependence MCTP2 UTR-3 20201924 rs4591082 chr15 95077137 G A 1.79E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs4984350 chr15 95093772 C T 6.48E-04 Alzheimer's disease / / 17998437 rs16949208 chr15 95114211 A C 8.85E-05 Blood Pressure / / pha003043 rs1863094 chr15 95115993 G A 2.80E-05 HDL cholesterol / / pha003075 rs2161936 chr15 95118265 C T 3.18E-04 Alzheimer's disease (late onset) / / 21379329 rs8035158 chr15 95160747 T C 8.99E-04 Multiple complex diseases / / 17554300 rs1014922 chr15 95165580 T G 3.00E-06 Sudden cardiac arrest / / 21658281 rs9920002 chr15 95168190 C T 1.06E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs1035649 chr15 95172968 T G 1.60E-06 Urinary metabolites / / 21572414 rs12442791 chr15 95197078 G A 5.43E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2199724 chr15 95235133 G T 2.59E-05 Behcet's disease / / pha002888 rs2046006 chr15 95237961 C A 9.03E-05 Behcet's disease / / pha002888 rs2169934 chr15 95241143 C T 9.37E-04 Obesity (extreme) / / 21935397 rs1026750 chr15 95242122 G T 8.51E-04 Obesity (extreme) / / 21935397 rs2199723 chr15 95247037 C A 1.57E-06 Scoliosis / / 21216876 rs6496036 chr15 95249902 A C 1.82E-04 Obesity (extreme) / / 21935397 rs899463 chr15 95252083 T C 7.67E-04 Obesity (extreme) / / 21935397 rs899464 chr15 95252529 T C 7.53E-04 Obesity (extreme) / / 21935397 rs2046003 chr15 95252667 T A 7.77E-04 Obesity (extreme) / / 21935397 rs2388778 chr15 95253577 A G 7.83E-04 Obesity (extreme) / / 21935397 rs736664 chr15 95254135 G T 7.99E-04 Obesity (extreme) / / 21935397 rs2388779 chr15 95257278 T C 6.40E-04 Obesity (extreme) / / 21935397 rs11637906 chr15 95258241 T C 8.77E-04 Obesity (extreme) / / 21935397 rs12901421 chr15 95259793 G A 2.09E-04 Obesity (extreme) / / 21935397 rs2199722 chr15 95259881 C A 5.96E-04 Obesity (extreme) / / 21935397 rs4984405 chr15 95260171 A G 4.42E-05 Multiple complex diseases / / 17554300 rs7168523 chr15 95263911 C T 5.91E-04 Obesity (extreme) / / 21935397 rs11073381 chr15 95265012 T G 1.01E-04 Obesity (extreme) / / 21935397 rs7170128 chr15 95265852 G A 1.01E-04 Obesity (extreme) / / 21935397 rs7170018 chr15 95265993 A T 5.81E-04 Obesity (extreme) / / 21935397 rs8036171 chr15 95266810 A C 5.73E-04 Obesity (extreme) / / 21935397 rs8037823 chr15 95266980 T C 5.36E-04 Obesity (extreme) / / 21935397 rs7181659 chr15 95267483 A G 9.17E-05 Obesity (extreme) / / 21935397 rs11634297 chr15 95267564 T A 8.89E-05 Obesity (extreme) / / 21935397 rs9302331 chr15 95268020 T C 7.87E-05 Obesity (extreme) / / 21935397 rs4984406 chr15 95268494 T C 7.20E-05 Obesity (extreme) / / 21935397 rs7173947 chr15 95270467 C T 3.00E-08 Blood cell counts and other traits / / 20139978 rs7173947 chr15 95270467 C T 3.23E-08 Blood cell counts and other traits / / 20139978 rs7173947 chr15 95270467 C T 3.23E-04 Obesity (extreme) / / 21935397 rs7178731 chr15 95270732 A G 3.20E-04 Obesity (extreme) / / 21935397 rs11633473 chr15 95270905 G A 3.21E-04 Obesity (extreme) / / 21935397 rs11638765 chr15 95271164 T A 3.22E-04 Obesity (extreme) / / 21935397 rs7179870 chr15 95271264 C G 3.22E-04 Obesity (extreme) / / 21935397 rs11633659 chr15 95271360 G C 3.24E-04 Obesity (extreme) / / 21935397 rs11633626 chr15 95271378 C A 3.28E-04 Obesity (extreme) / / 21935397 rs7181498 chr15 95271404 T C 3.31E-04 Obesity (extreme) / / 21935397 rs8025516 chr15 95271872 T G 3.33E-04 Obesity (extreme) / / 21935397 rs2046002 chr15 95272235 T C 7.14E-04 Obesity (extreme) / / 21935397 rs7169847 chr15 95272920 G T 5.44E-04 Obesity (extreme) / / 21935397 rs11073382 chr15 95274277 G A 2.02E-04 Obesity (extreme) / / 21935397 rs11073383 chr15 95274349 G A 2.03E-04 Obesity (extreme) / / 21935397 rs12440239 chr15 95313792 A G 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2199733 chr15 95316582 A G 3.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2061879 chr15 95316982 G A 2.54E-04 Multiple complex diseases / / 17554300 rs2061876 chr15 95317615 T A 3.13E-04 Multiple complex diseases / / 17554300 rs17664713 chr15 95318586 C T 1.55E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs17664713 chr15 95318586 C T 5.00E-06 Response to mTOR inhibitor (rapamycin) / / 24009623 rs16949516 chr15 95318767 T C 4.00E-06 Stearic acid (18:0) plasma levels / / 23362303 rs17732246 chr15 95319786 G A 4.63E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs17732246 chr15 95319786 G A 8.63E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs2388883 chr15 95321134 A G 5.21E-04 Multiple complex diseases / / 17554300 rs2199730 chr15 95322621 G T 0.000506 Salmonella-induced pyroptosis / / 22837397 rs7173525 chr15 95329708 T C 0.000639 Salmonella-induced pyroptosis / / 22837397 rs12442336 chr15 95333759 G A 2.12E-05 Coronary Artery Disease / / 17634449 rs10152812 chr15 95362466 T C 0.000539 Salmonella-induced pyroptosis / / 22837397 rs10520769 chr15 95382263 C T 8.04E-04 Schizophrenia / / 19197363 rs8024991 chr15 95411105 T C 7.89E-04 Multiple complex diseases / / 17554300 rs11639294 chr15 95416314 C T 0.000818 Schizophrenia / / 22440650 rs2892626 chr15 95419960 A G 6.80E-04 Multiple complex diseases / / 17554300 rs17665327 chr15 95445107 C G 2.75E-04 Multiple complex diseases / / 17554300 rs6496069 chr15 95471060 C T 3.54E-05 Pulmonary function in asthmatics / / 23541324 rs4281667 chr15 95473145 T G 1.62E-04 Epilepsy / / 22116939 rs2084470 chr15 95478913 A G 7.74E-04 Alzheimer's disease / / 24755620 rs8037155 chr15 95479659 T G 2.35E-04 Epilepsy / / 22116939 rs8037155 chr15 95479659 T G 1.84E-04 Smoking initiation / / 24665060 rs12437784 chr15 95487052 A G 1.01E-05 Pulmonary function in asthmatics / / 23541324 rs12050609 chr15 95496732 T G 2.01E-04 Alzheimer's disease / / 24755620 rs11073409 chr15 95499153 G T 8.07E-04 Alzheimer's disease / / 24755620 rs8029903 chr15 95500162 C T 2.50E-04 Alzheimer's disease / / 24755620 rs11637613 chr15 95500652 T G 4.33E-04 Type 2 diabetes / / 17463246 rs11637613 chr15 95500652 T G 2.59E-04 Alzheimer's disease / / 24755620 rs1031644 chr15 95509944 A C 5.11E-06 Cognitive test performance / / 20125193 rs7165620 chr15 95511473 C T 6.40E-06 Urinary metabolites / / 21572414 rs6496074 chr15 95511837 A G 3.00E-06 Cognitive performance / / 20125193 rs17635194 chr15 95513696 C T 1.60E-05 Urinary metabolites / / 21572414 rs7163584 chr15 95516476 A C 1.20E-05 Urinary metabolites / / 21572414 rs1457850 chr15 95531851 A G 1.37E-05 Type 2 diabetes and other traits / / 19734900 rs7170871 chr15 95533686 A G 4.18E-04 Multiple complex diseases / / 17554300 rs7170871 chr15 95533686 A G 1.40E-07 Urinary metabolites / / 21572414 rs11635863 chr15 95609121 A G 2.61E-04 Celiac disease / / 23936387 rs291030 chr15 95637149 A C 1.67E-04 Age-related macular degeneration / / 22125219 rs2894895 chr15 95642676 T G 1.85E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10852037 chr15 95678616 G C 5.05E-05 Serum metabolites / / 19043545 rs169712 chr15 95689069 G A 7.14E-05 Serum metabolites / / 19043545 rs169712 chr15 95689069 G A 2.80E-05 Urinary metabolites / / 21572414 rs1444852 chr15 95705175 A C,G 8.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs172350 chr15 95734340 T A 6.30E-04 Multiple complex diseases / / 17554300 rs290663 chr15 95734559 G C 6.69E-04 Multiple complex diseases / / 17554300 rs1444860 chr15 95806134 A G 4.53E-04 Multiple complex diseases / / 17554300 rs7173885 chr15 95807131 C G 3.88E-04 Multiple complex diseases / / 17554300 rs957703 chr15 95809130 A G 6.14E-05 Body Mass Index / / pha003019 rs957703 chr15 95809130 A G 5.70E-06 Body Mass Index / / pha003022 rs8030304 chr15 95814910 T C 1.71E-04 Myocardial Infarction / / pha002873 rs8030304 chr15 95814910 T C 1.11E-05 Body Mass Index / / pha003022 rs748095 chr15 95824428 G T 3.98E-06 Body Mass Index LOC400456 intron pha003022 rs10520775 chr15 95826797 T C 7.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC400456 intron 20877124 rs4482230 chr15 95827926 A G 3.20E-04 Response to antidepressants LOC400456 intron 19736353 rs12912439 chr15 95828705 C T 3.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC400456 intron 20877124 rs17637117 chr15 95904064 T G 3.43E-04 Type 2 diabetes / / 17463246 rs4614672 chr15 95905855 G A 7.89E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs8039182 chr15 95917000 G A 5.50E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10520778 chr15 95927728 C A 9.70E-04 Crohn's disease / / 17684544 rs10520779 chr15 95927822 C T 3.39E-04 Multiple complex diseases / / 17554300 rs17568712 chr15 95983079 A G 5.62E-04 Multiple complex diseases LOC145820 intron 17554300 rs10162686 chr15 96015083 A G 1.56E-04 Sarcoidosis LOC145820 intron 19165924 rs1834204 chr15 96028726 A G 8.40E-04 Response to alcohol consumption (flushing response) LOC145820 intron 24277619 rs8027583 chr15 96047157 C G 5.98E-05 Bipolar disorder and schizophrenia LOC145820 intron 20889312 rs933769 chr15 96052742 C T 7.00E-06 Alcoholism (alcohol dependence factor score) / / 21529783 rs16975304 chr15 96074814 A T 6.02E-04 Multiple complex diseases / / 17554300 rs7183500 chr15 96100923 A G 6.73E-04 Obesity (extreme) / / 21935397 rs7183672 chr15 96101018 A G 2.97E-04 Obesity (extreme) / / 21935397 rs6496121 chr15 96101497 C G 3.01E-04 Obesity (extreme) / / 21935397 rs10468114 chr15 96118957 G A 9.01E-04 Obesity (extreme) / / 21935397 rs16975363 chr15 96121835 G A 2.40E-05 HIV-1 control / / 20041166 rs10520788 chr15 96126414 T C 3.10E-06 Urinary metabolites / / 21572414 rs2397805 chr15 96126617 A G 1.34E-04 Coronary heart disease / / 21606135 rs8028726 chr15 96131960 G T 9.59E-04 Obesity (extreme) / / 21935397 rs2397811 chr15 96133494 C T 9.39E-04 Multiple complex diseases / / 17554300 rs8039954 chr15 96133934 C T 8.83E-04 Alzheimer's disease / / 17998437 rs4581667 chr15 96137908 T C 9.85E-05 Obesity (extreme) / / 21935397 rs2397806 chr15 96139140 G C 1.02E-04 Obesity (extreme) / / 21935397 rs10520789 chr15 96141867 G A 6.00E-07 Response to TNF-alpha inhibitors in rheumatoid arthritis / / 22569225 rs41374846 chr15 96143559 G A 4.18E-04 Multiple complex diseases / / 17554300 rs2397808 chr15 96150590 A G 6.17E-05 Serum metabolites / / 19043545 rs10520792 chr15 96151914 C T 9.47E-05 Serum metabolites / / 19043545 rs4321143 chr15 96156368 A G 7.00E-06 Conduct disorder (interaction) / / 18846501 rs4321143 chr15 96156368 A G 8.83E-05 Serum metabolites / / 19043545 rs7164160 chr15 96159374 T A 8.83E-05 Serum metabolites / / 19043545 rs12595580 chr15 96161716 T C 2.53E-04 Multiple complex diseases / / 17554300 rs12593084 chr15 96161743 G A 3.77E-04 Multiple complex diseases / / 17554300 rs2006950 chr15 96179390 G A 8.33E-05 Serum metabolites / / 19043545 rs4984595 chr15 96183699 T C 6.61E-04 Multiple complex diseases / / 17554300 rs7163576 chr15 96184014 A G 4.26E-04 Multiple complex diseases / / 17554300 rs11073443 chr15 96184927 A G 7.18E-04 Multiple complex diseases / / 17554300 rs17504636 chr15 96187805 C T 2.20E-05 Parkinson's disease (age of onset) / / 19772629 rs12232372 chr15 96188705 C T 3.52E-04 Smoking initiation / / 24665060 rs7180933 chr15 96200523 C A 4.77E-05 Suicidal ideation / / 20877300 rs16975518 chr15 96217126 A C 3.76E-04 Type 2 diabetes / / 17463246 rs17506333 chr15 96253243 A G 4.90E-05 Intelligence / / 21826061 rs16975550 chr15 96257703 C A 6.26E-05 Intelligence / / 21826061 rs2567446 chr15 96263982 A G 1.20E-07 Coronary heart disease / / 21971053 rs11856995 chr15 96325643 T C 7.41E-08 Common traits (Other) / / 20585627 rs12441195 chr15 96329105 C A 8.94E-05 Body mass (lean) / / 19268274 rs2567426 chr15 96332861 A G 3.00E-06 Information processing speed / / 21130836 rs16975679 chr15 96371724 C G 4.62E-04 Schizophrenia / / 20832056 rs744738 chr15 96372629 G A 6.00E-06 Obesity-related traits / / 23251661 rs1369943 chr15 96402314 G A 4.54E-05 stroke (ischemic) / / 17434096 rs2639187 chr15 96403310 G A 5.30E-05 Blood pressure / / 19114657 rs764761 chr15 96419244 A G 8.61E-04 Multiple complex diseases / / 17554300 rs4984460 chr15 96424399 T G 2.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs725213 chr15 96430634 T C 2.30E-05 Urinary metabolites / / 21572414 rs1450494 chr15 96439479 C A 2.08E-05 Serum metabolites / / 19043545 rs10520802 chr15 96474791 G T 8.00E-06 Urinary metabolites / / 21572414 rs16975924 chr15 96526342 A T 7.19E-05 Serum metabolites / / 19043545 rs12592953 chr15 96528345 C T 2.22E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs16975932 chr15 96530026 C T 5.69E-05 Coronary Artery Disease / / 17634449 rs16975933 chr15 96530880 G A 2.28E-05 Coronary Artery Disease / / 17634449 rs16975933 chr15 96530880 G A 2.50E-05 Urinary metabolites / / 21572414 rs17519963 chr15 96531370 T C 5.10E-06 Urinary metabolites / / 21572414 rs17592061 chr15 96543713 T G 2.88E-04 Multiple complex diseases / / 17554300 rs12441889 chr15 96545762 G A 0.0002939 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12441889 chr15 96545762 G A 2.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1450495 chr15 96552691 T G 8.27E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1450495 chr15 96552691 T G 6.57E-04 Premature ovarian failure / / 19508998 rs16976004 chr15 96582997 C G 0.000151 Breast cancer early age of onset / / 18463975 rs7163466 chr15 96594318 A G 3.84E-04 Multiple complex diseases / / 17554300 rs11852659 chr15 96595853 G C 6.42E-04 Multiple complex diseases / / 17554300 rs62009480 chr15 96600420 G A 0.0000742 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62009482 chr15 96600737 A G 0.0000736 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62009483 chr15 96600894 T C 0.0000733 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62009484 chr15 96600898 G A 0.0000728 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62009485 chr15 96601142 G T 0.0000413 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs59356661 chr15 96601301 A T 0.0000695 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs56121636 chr15 96601714 T C 0.0000698 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62009489 chr15 96602014 C A 0.0000606 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62009490 chr15 96602313 C T 0.0000692 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62009491 chr15 96602348 G A 0.000069 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62009492 chr15 96602509 C T 0.0000678 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62009493 chr15 96603020 C T 0.0000673 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62009494 chr15 96603043 C G,T 0.0000667 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs74032325 chr15 96603459 C T 0.0000639 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs74032326 chr15 96603474 G T 0.0000642 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs8030797 chr15 96603796 C A 0.0000678 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62009518 chr15 96604169 G A 0.0000674 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62009519 chr15 96604549 T G 0.0000666 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62009520 chr15 96605092 G A 0.0000615 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62009521 chr15 96605107 T A 0.0000615 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62009522 chr15 96605130 T C 0.0000613 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11636705 chr15 96605912 C T 5.39E-05 Nicotine smoking / / 19268276 rs16976042 chr15 96606332 T C 0.0000485 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs8033463 chr15 96606369 G A 9.94E-05 Triglycerides / / pha003080 rs62009523 chr15 96606395 G A 0.0000503 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs16976057 chr15 96612108 T C 8.60E-04 Multiple complex diseases / / 17554300 rs11854024 chr15 96613445 T G 2.36E-05 Triglycerides / / pha003080 rs16976072 chr15 96620238 T C 8.40E-08 Multiple complex diseases / / 17554300 rs7171368 chr15 96637443 T C 5.32E-04 Type 2 diabetes / / 17463246 rs7171368 chr15 96637443 T C 7.72E-04 Alcohol dependence / / 24277619 rs7174546 chr15 96637569 A G 3.56E-04 Type 2 diabetes / / 17463246 rs7166321 chr15 96640322 A C 7.89E-05 Serum metabolites / / 19043545 rs1036520 chr15 96645385 T C 1.80E-05 Serum metabolites / / 19043545 rs7170032 chr15 96645972 A G 1.22E-05 Serum metabolites / / 19043545 rs1036517 chr15 96646200 G A 8.10E-05 Alcohol dependence / / 24277619 rs10852043 chr15 96646751 T G 1.62E-05 Serum metabolites / / 19043545 rs4984499 chr15 96647793 T A 8.00E-06 Migraine / / 23793025 rs4984422 chr15 96655388 T C 8.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4984422 chr15 96655388 T C 1.65E-05 Coronary heart disease / / pha003035 rs7178874 chr15 96665128 A C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7178874 chr15 96665128 A C 2.23E-04 Vaspin levels / / 22907691 rs7178874 chr15 96665128 A C 0.0002227 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs7162174 chr15 96672859 G A 8.71E-04 Alzheimer's disease / / 17998437 rs1036521 chr15 96684549 C T 8.33E-04 Coronary Artery Disease / / 17634449 rs16976271 chr15 96684910 A G 2.78E-05 Coronary Artery Disease / / 17634449 rs4984505 chr15 96691651 T C 6.55E-05 Postoperative ventricular dysfunction / / 21980348 rs4984505 chr15 96691651 T C 2.46E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4984505 chr15 96691651 T C 4.66E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs8023580 chr15 96708291 T C 5.00E-06 Sex hormone-binding globulin levels / / 22829776 rs8023580 chr15 96708291 T C 8.00E-08 Sex hormone-binding globulin levels / / 22829776 rs8023580 chr15 96708291 T C 8.00E-12 Sex hormone-binding globulin levels / / 22829776 rs11073466 chr15 96728521 C T 3.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9806400 chr15 96741420 T C 2.00E-07 Immune response to measles-mumps-rubella vaccine / / 24811271 rs11073470 chr15 96779611 T A,C,G 1.20E-05 Urinary metabolites / / 21572414 rs2589250 chr15 96796760 G A 6.62E-04 Multiple complex diseases / / 17554300 rs4984530 chr15 96806416 T C 6.37E-05 Alcohol consumption / / 23743675 rs4984530 chr15 96806416 T C 5.93E-04 Smoking initiation / / 24665060 rs1437588 chr15 96809782 A G 4.77E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs1437588 chr15 96809782 A G 7.82E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs1437588 chr15 96809782 A G 3.00E-06 Migraine / / 23793025 rs2589238 chr15 96810867 C T 5.83E-05 Type 2 diabetes / / 17463246 rs2589238 chr15 96810867 C T 7.00E-05 Lipid levels / / 18193043 rs7180721 chr15 96816581 A G 4.77E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7182413 chr15 96817467 C A 7.82E-04 Multiple complex diseases / / 17554300 rs7182413 chr15 96817467 C A 6.53E-04 Smoking initiation / / 24665060 rs2398162 chr15 96830550 A G 6.00E-06 Hypertension LOC644192 intron 17554300 rs2398162 chr15 96830550 A G 6.00E-06 Coronary heart disease LOC644192 intron 21347282 rs11073474 chr15 96839069 G A 3.64E-04 Multiple complex diseases LOC644192 intron 17554300 rs7173576 chr15 96841524 C T 1.00E-04 Prostate cancer LOC644192 intron 21743057 rs7181753 chr15 96844727 C T 3.00E-06 Electroencephalographic traits in alcoholism LOC644192 intron 22554406 rs4310804 chr15 96858409 C G 9.34E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) LOC644192 intron 24236485 rs8031676 chr15 96910440 T C 0.000015 HDL cholesterol particle diameter / / 23263444 rs1437753 chr15 96928114 G T 7.50E-05 Personality dimensions / / 18957941 rs2008780 chr15 96932216 G A 8.71E-05 Blood Pressure / / pha003039 rs3812941 chr15 96936373 A G 4.62E-05 Height / / pha003011 rs7183636 chr15 96940113 T C 2.01E-04 Amyotrophic lateral sclerosis (sporadic) LOC100507325 intron 24529757 rs1437768 chr15 96948362 C A 9.53E-06 Height / / pha003011 rs12438258 chr15 96950375 C T 1.64E-05 Height / / pha003011 rs7170620 chr15 96954092 G A 2.95E-04 Smoking initiation / / 24665060 rs10162920 chr15 96971917 T C 6.83E-05 Body mass index / / 22446040 rs11637980 chr15 97002653 A G 2.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs934782 chr15 97016950 A G 9.41E-06 Response to amphetamines / / 22952603 rs7168357 chr15 97018475 T C 8.42E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs113154706 chr15 97018733 C T 7.00E-06 Response to amphetamines / / 22952603 rs12438146 chr15 97031142 T C 2.06E-04 Multiple complex diseases / / 17554300 rs4984549 chr15 97041535 G A 5.11E-06 Body Composition / / pha003012 rs4984549 chr15 97041535 G A 1.40E-05 Body Mass Index / / pha003021 rs1009132 chr15 97083924 A G 8.90E-05 Height / / pha003011 rs12593273 chr15 97170737 G A 2.38E-05 Multiple complex diseases / / 17554300 rs7179934 chr15 97205609 C T 5.50E-05 Major depressive disorder / / 21621269 rs12593006 chr15 97246385 G A 1.66E-04 Obesity (extreme) / / 21935397 rs4533251 chr15 97262427 T G 4.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs4321167 chr15 97272904 C A 5.90E-06 Primary sclerosing cholangitis / / 21151127 rs1948821 chr15 97277632 G A 8.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2654529 chr15 97283092 G T 1.20E-05 Urinary metabolites / / 21572414 rs2715792 chr15 97288811 A C 2.28E-05 Body mass (lean) / / 19268274 rs3812906 chr15 97325118 G A 4.80E-06 Post-operative nausea and vomiting LOC100652749 intron 21694509 rs1503340 chr15 97328053 C T 3.45E-05 Bipolar disorder SPATA8 intron 22925353 rs950615 chr15 97398377 G T 6.24E-04 Multiple complex diseases / / 17554300 rs11631447 chr15 97405121 C T 7.26E-04 Type 2 diabetes / / 17463246 rs7183318 chr15 97422907 C T 7.21E-04 Heart Failure / / pha002884 rs7161755 chr15 97450781 G A 1.20E-05 Bilirubin levels / / 19414484 rs7173819 chr15 97452678 A G,T 1.20E-05 Bilirubin levels / / 19414484 rs1990403 chr15 97467595 T A 1.30E-05 Bilirubin levels / / 19414484 rs2191557 chr15 97467902 G A 9.40E-05 Body Mass Index / / pha003015 rs2191554 chr15 97470986 G A 4.52E-05 Body Mass Index / / pha003015 rs2191553 chr15 97471021 G T 4.72E-05 Body Mass Index / / pha003015 rs2215467 chr15 97471803 C T 1.80E-05 Bilirubin levels / / 19414484 rs11073512 chr15 97511222 C G 1.50E-05 Urinary metabolites / / 21572414 rs12438054 chr15 97517316 C G 1.43E-05 Blood pressure / / 17255346 rs12438086 chr15 97517442 C T 4.42E-05 Blood pressure / / 17255346 rs1558391 chr15 97519268 C G 2.46E-04 Blood pressure / / 17255346 rs1558390 chr15 97519421 C T 2.54E-05 Blood pressure / / 17255346 rs11858597 chr15 97523081 A G 6.94E-05 Self-reported allergy / / 23817569 rs2535483 chr15 97556912 C T 5.63E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2670915 chr15 97556967 C G 2.20E-05 Urinary metabolites / / 21572414 rs2535469 chr15 97561344 A T 2.60E-05 Urinary metabolites / / 21572414 rs8023715 chr15 97607681 C A 1.00E-08 Systemic lupus erythematosus / / 24871463 rs8032658 chr15 97637472 T C 3.97E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1996142 chr15 97706598 G A 6.33E-05 Type 2 diabetes / / 17463246 rs2045325 chr15 97713766 G A 5.31E-06 Parkinson's disease / / 17052657 rs8035802 chr15 97728021 A C 9.79E-05 Cardiovascular disease / / pha003064 rs1513859 chr15 97750335 G A 7.00E-06 Obesity-related traits / / 23251661 rs2399653 chr15 97770558 C A 1.52E-04 Stroke / / pha002887 rs7169879 chr15 97792086 G A 3.27E-05 Platelet counts / / pha003100 rs12443114 chr15 97793688 A G 7.00E-07 Urinary metabolites / / 21572414 rs4965079 chr15 97798401 A G 9.14E-05 Hirschsprung's disease / / 19196962 rs11073531 chr15 97800606 C G 1.84E-05 Hirschsprung's disease / / 19196962 rs1017680 chr15 97806265 G A 9.95E-04 Rheumatoid arthritis / / 21452313 rs4965165 chr15 97807732 C T 9.86E-04 Rheumatoid arthritis / / 21452313 rs1869952 chr15 97808409 C A,T 9.27E-04 Rheumatoid arthritis / / 21452313 rs12900562 chr15 97808538 G A 9.20E-04 Rheumatoid arthritis / / 21452313 rs12900588 chr15 97808678 C T 9.79E-04 Rheumatoid arthritis / / 21452313 rs11073533 chr15 97815824 A G 8.49E-04 Rheumatoid arthritis / / 21452313 rs8038893 chr15 97869259 G A 0.0000313 Tuberculosis with early age of onset / / 22551897 rs4965177 chr15 97910353 A G 5.87E-04 Multiple complex diseases / / 17554300 rs4965180 chr15 97915636 G A 6.20E-05 Personality dimensions / / 18957941 rs9788634 chr15 97921075 T C 3.09E-05 Multiple sclerosis (age of onset) / / 19010793 rs7174368 chr15 97923437 C A 3.05E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs7174368 chr15 97923437 C A 1.34E-05 Serum albumin level / / pha003084 rs4555132 chr15 97939238 T C 3.10E-05 Alzheimer's disease (late onset) / / 20885792 rs4555132 chr15 97939238 T C 3.10E-05 Alzheimer's disease (late onset) / / 21460841 rs4076597 chr15 97940810 T C 4.11E-05 Vascular dementia / / 22116812 rs4128671 chr15 97970963 T C 8.01E-06 Prion diseases / / 22210626 rs7170916 chr15 97992682 A G 6.52E-04 Type 2 diabetes / / 17463246 rs4465589 chr15 98001082 T G 6.18E-04 Type 2 diabetes / / 17463246 rs1604172 chr15 98040555 A G 6.15E-04 Type 2 diabetes / / 17463246 rs12900806 chr15 98041177 T C 7.08E-05 Myocardial Infarction / / pha002883 rs11073559 chr15 98044496 G T 4.88E-04 Myocardial Infarction / / pha002883 rs1500642 chr15 98044868 A T 9.97E-06 Substance dependence / / 21818250 rs4523904 chr15 98047823 C A 2.03E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2399702 chr15 98048196 C T 3.95E-05 Serum alpha1-antitrypsin levels / / 23990791 rs2088783 chr15 98053084 C T 1.04E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs12912857 chr15 98082278 T C 7.08E-04 Type 2 diabetes / / 17463246 rs1500652 chr15 98093234 C T 4.82E-04 Alzheimer's disease (late onset) / / 21379329 rs6496232 chr15 98093994 C T 4.82E-04 Alzheimer's disease (late onset) / / 21379329 rs1500654 chr15 98096042 C A 3.30E-05 Alzheimer's disease (late onset) / / 21379329 rs12915016 chr15 98103736 A G 1.44E-05 Serum metabolites / / 19043545 rs12915016 chr15 98103736 A G 7.50E-06 Urinary metabolites / / 21572414 rs158286 chr15 98180905 A G 7.25E-04 Multiple complex diseases / / 17554300 rs289496 chr15 98189497 A G 8.76E-04 Insulin resistance / / 21901158 rs62025539 chr15 98189656 C T 0.0000725 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4965091 chr15 98195847 A G 2.81E-04 Alzheimer's disease (late onset) / / 21379329 rs616687 chr15 98198789 G A 1.30E-05 Response to statin therapy / / 20339536 rs503907 chr15 98200767 G T 1.20E-05 Response to statin therapy / / 20339536 rs62025541 chr15 98201654 T C 0.0000324 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs653747 chr15 98203108 C T 2.60E-05 Urinary metabolites / / 21572414 rs289471 chr15 98208220 T C 3.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7166706 chr15 98241949 T G 2.57E-04 Multiple complex diseases / / 17554300 rs920567 chr15 98248481 A T 3.97E-04 Multiple complex diseases / / 17554300 rs11633855 chr15 98253294 T C 9.68E-05 Interstitial lung disease / / 23583980 rs489927 chr15 98254111 C T 8.38E-04 Type 2 diabetes / / 17463246 rs1441479 chr15 98256302 T C 8.39E-05 Interstitial lung disease / / 23583980 rs11629532 chr15 98283553 C G 3.66E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs11629532 chr15 98283553 C G 7.24E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs7173988 chr15 98369781 T G 1.19E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LOC91948 intron 24023788 rs8030861 chr15 98373118 G A 2.91E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LOC91948 intron 24023788 rs1552675 chr15 98392886 T G 3.59E-04 Lung function (forced expiratory volume in 1 second) LOC91948 intron 24023788 rs1021393 chr15 98407997 T C 2.33E-06 Post-operative nausea and vomiting LOC91948 intron 21694509 rs1873502 chr15 98435452 A G 6.47E-04 Taste perception / / 22132133 rs6496267 chr15 98445797 G A 2.89E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs12443391 chr15 98494478 G T 2.04E-05 Schizophrenia / / 19571811 rs12441858 chr15 98500459 G T 2.60E-04 Birth weight / / 17255346 rs2087658 chr15 98500970 C T 3.69E-04 Type 2 diabetes / / 17463246 rs2087658 chr15 98500970 C T 5.73E-04 Multiple complex diseases / / 17554300 rs7174688 chr15 98505544 G C 9.27E-04 Acute lung injury ARRDC4 intron 22295056 rs4965121 chr15 98518792 C G 1.00E-06 Neuroticism / / 20634892 rs6496273 chr15 98520676 T C 3.39E-04 Multiple complex diseases / / 17554300 rs964672 chr15 98522038 G A 6.67E-04 Multiple complex diseases / / 17554300 rs923658 chr15 98535623 G T 1.65E-04 Multiple complex diseases / / 17554300 rs1491184 chr15 98536596 A G 2.37E-04 Multiple complex diseases / / 17554300 rs902625 chr15 98537979 T C 7.70E-04 Multiple complex diseases / / 17554300 rs1491187 chr15 98539489 C A 3.03E-05 Multiple complex diseases / / 17554300 rs4417535 chr15 98583104 A G 4.04E-04 Multiple complex diseases / / 17554300 rs7172170 chr15 98583617 C T 5.45E-04 Multiple complex diseases / / 17554300 rs1993976 chr15 98606313 G A 8.20E-07 Subcutaneous adipose tissue volume in HIV-infected men / / 21897333 rs12595523 chr15 98607816 A C 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs12148124 chr15 98608693 T C 3.76E-05 Alcohol and nictotine co-dependence / / 20158304 rs12148124 chr15 98608693 T C 3.32E-05 Cholesterol / / pha003083 rs1383149 chr15 98610131 A G 2.40E-05 Urinary metabolites / / 21572414 rs2086366 chr15 98617241 C T 4.77E-05 Cognitive decline / / 22054870 rs2086366 chr15 98617241 C T 5.51E-05 ldl cholesterol / / pha003077 rs2086366 chr15 98617241 C T 2.35E-05 Cholesterol / / pha003083 rs2170106 chr15 98630699 A G 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs984999 chr15 98662309 A C 8.31E-08 Acute lymphoblastic leukemia (B-cell precursor) / / 23996088 rs7171849 chr15 98672060 C A 8.44E-05 Bipolar disorder and schizophrenia / / 20889312 rs11634680 chr15 98676558 G T 1.78E-04 Prion diseases / / 22210626 rs8040985 chr15 98677156 C T 5.88E-04 Coronary heart disease / / 21971053 rs10902540 chr15 98681332 C T 2.03E-06 Retinopathy in non-diabetics / / 23393555 rs8025763 chr15 98688071 T C 2.00E-06 Ovarian response to FSH stimulation in IVF / / 21316307 rs7182895 chr15 98703328 C T 6.24E-04 Smoking initiation / / 24665060 rs6598258 chr15 98711639 A G 4.68E-04 Body mass index / / 17255346 rs1480090 chr15 98715661 C A 3.50E-05 Alzheimer's disease (late onset) / / 20885792 rs1480090 chr15 98715661 C A 3.50E-05 Alzheimer's disease (late onset) / / 21460841 rs1383139 chr15 98717677 G A 3.50E-05 Alzheimer's disease (late onset) / / 20885792 rs1383139 chr15 98717677 G A 3.50E-05 Alzheimer's disease (late onset) / / 21460841 rs922579 chr15 98722079 T G 3.87E-04 Multiple complex diseases / / 17554300 rs2620860 chr15 98744548 A G 6.54E-04 Bronchopulmonary dysplasia / / 23897914 rs11633447 chr15 98750737 C T 7.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1442809 chr15 98764804 C A 1.70E-05 Urinary metabolites / / 21572414 rs11247163 chr15 98774993 A G 3.33E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6598319 chr15 98783253 T G 8.17E-04 Tourette syndrome / / 22889924 rs7162271 chr15 98800468 C T 1.10E-05 Urinary metabolites / / 21572414 rs1837993 chr15 98801086 C T 8.00E-06 Urinary metabolites / / 21572414 rs1837993 chr15 98801086 C T 1.48E-04 Smoking cessation / / 24665060 rs11638366 chr15 98810226 T C 3.44E-06 Brachial circumference / / 22479309 rs4997560 chr15 98811241 T C 3.40E-06 Urinary metabolites / / 21572414 rs8025476 chr15 98814298 T G 9.49E-05 Alcohol consumption / / 23953852 rs970843 chr15 98876029 G C 5.00E-06 Obesity (extreme) / / 21935397 rs7180276 chr15 98882175 G A 7.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs12914601 chr15 98898025 G A 5.63E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2120021 chr15 98902172 T A 5.67E-04 Multiple complex diseases / / 17554300 rs12917426 chr15 98911989 A C 0.0007201 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12917426 chr15 98911989 A C 7.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12915580 chr15 98913175 C T 5.21E-05 Coronary heart disease / / pha003031 rs7181703 chr15 98924124 A G 2.12E-04 Lung function (forced vital capacity) / / 24023788 rs7181703 chr15 98924124 A G 4.98E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs4262929 chr15 98933320 C T 4.97E-04 Alzheimer's disease (late onset) / / 21379329 rs4965927 chr15 98935186 C T 1.94E-04 Multiple complex diseases / / 17554300 rs4076907 chr15 98937552 A C 1.18E-04 Multiple complex diseases / / 17554300 rs8041945 chr15 98938755 G C 6.87E-04 Multiple complex diseases / / 17554300 rs7183449 chr15 98957003 T C 3.37E-04 Multiple complex diseases / / 17554300 rs4965968 chr15 98959313 G A 8.13E-05 Smoking initiation / / 24665060 rs11632159 chr15 98975988 G A 1.20E-05 White matter hyperintensity burden / / 21681796 rs4129470 chr15 98982627 A G 0.000102 Salmonella-induced pyroptosis FAM169B UTR-3 22837397 rs9806766 chr15 99006894 A C 2.00E-06 Sleep duration FAM169B intron 22105623 rs9806781 chr15 99007060 A G 2.00E-06 Sleep duration FAM169B intron 22105623 rs12913020 chr15 99028246 G T 0.000103 Salmonella-induced pyroptosis FAM169B intron 22837397 rs12595471 chr15 99037854 C T 2.46E-05 Glaucoma (primary open-angle) FAM169B intron 22605921 rs7170126 chr15 99053813 C T 0.0000574 Panic disorder FAM169B intron 23149450 rs7170126 chr15 99053813 C T 5.74E-05 Serum tamsulosin hydrochloride concentration FAM169B intron 23151678 rs881096 chr15 99056657 C T 1.63E-04 Multiple complex diseases FAM169B intron 17554300 rs1863275 chr15 99056913 T A 2.00E-05 Urinary metabolites FAM169B intron 21572414 rs8034376 chr15 99064151 G T 7.33E-05 Body Mass Index / / pha003020 rs12914549 chr15 99065229 G A 3.85E-05 Body Mass Index / / pha003019 rs12914549 chr15 99065229 G A 4.40E-06 Body Mass Index / / pha003020 rs6598516 chr15 99069239 A G 2.41E-05 Body Mass Index / / pha003007 rs6598516 chr15 99069239 A G 2.32E-06 Body Mass Index / / pha003009 rs6598516 chr15 99069239 A G 4.69E-05 Body Mass Index / / pha003019 rs6598516 chr15 99069239 A G 9.93E-06 Body Mass Index / / pha003020 rs6598516 chr15 99069239 A G 2.78E-06 Waist Circumference / / pha003025 rs6598516 chr15 99069239 A G 2.23E-06 Weight / / pha003027 rs12719740 chr15 99072905 G A 3.44E-04 Alcohol dependence / / 20201924 rs12719740 chr15 99072905 G A 7.00E-07 Arthritis (juvenile idiopathic) / / 22354554 rs8043332 chr15 99073306 A G 3.39E-04 Alzheimer's disease (late onset) / / 21379329 rs8043332 chr15 99073306 A G 1.30E-04 Arthritis (juvenile idiopathic) / / 22354554 rs6598518 chr15 99073830 A C 0.00000379 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs933812 chr15 99082004 T C 3.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs933812 chr15 99082004 T C 1.00E-04 Information processing speed / / 21130836 rs4641724 chr15 99084760 C A 7.33E-04 Alcohol dependence / / 20201924 rs3803478 chr15 99090692 C A 2.42E-05 Amyotrophic lateral sclerosis / / 20801718 rs1319873 chr15 99112003 T C 1.05E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs11636483 chr15 99120152 G A 0.0000944 Uterine leiomyomata / / 23040493 rs11636483 chr15 99120152 G A 9.21E-04 Alzheimer's disease / / 24755620 rs1991210 chr15 99129962 T A 5.79E-04 Smoking initiation / / 24665060 rs7180993 chr15 99164370 A G 3.63E-04 Gallstones / / 17632509 rs7179187 chr15 99168770 T C 2.23E-04 Taste perception / / 22132133 rs12901358 chr15 99173481 T C 1.13E-05 Taste perception / / 22132133 rs11856426 chr15 99175000 A G 1.50E-05 Taste perception / / 22132133 rs4965425 chr15 99181663 C T 1.10E-04 Taste perception / / 22132133 rs6598537 chr15 99182531 C T 2.70E-05 Urinary metabolites / / 21572414 rs2871865 chr15 99194896 C G 3.00E-21 Height IGF1R intron 20881960 rs2871865 chr15 99194896 C G 3.50E-11 Height IGF1R intron 21194676 rs2871865 chr15 99194896 C G 6.10E-09 Height IGF1R intron 21194676 rs2871865 chr15 99194896 C G 7.90E-19 Height IGF1R intron 21194676 rs10902606 chr15 99216994 G C 6.54E-04 Type 2 diabetes IGF1R intron 17463246 rs11854132 chr15 99229330 G A 8.96E-05 Serum metabolites IGF1R intron 19043545 rs4966014 chr15 99248018 C T 1.68E-10 Urate levels IGF1R intron 23263486 rs11858316 chr15 99249029 C T 6.54E-12 Urate levels IGF1R intron 23263486 rs7174918 chr15 99251356 C T 6.48E-11 Urate levels IGF1R intron 23263486 rs8032477 chr15 99254554 C T 1.12E-11 Urate levels IGF1R intron 23263486 rs3803476 chr15 99256570 A G 3.20E-04 Alcohol dependence IGF1R intron 20201924 rs3803476 chr15 99256570 A G 8.48E-04 Response to taxane treatment (placlitaxel) IGF1R intron 23006423 rs3803476 chr15 99256570 A G 9.79E-12 Urate levels IGF1R intron 23263486 rs2018860 chr15 99258710 A T 1.20E-11 Urate levels IGF1R intron 23263486 rs11634241 chr15 99259016 G A 8.92E-13 Urate levels IGF1R intron 23263486 rs8038015 chr15 99263274 T C 2.55E-12 Urate levels IGF1R intron 23263486 rs11857366 chr15 99263801 A G 3.41E-05 Acute lymphoblastic leukemia (childhood) IGF1R intron 22076464 rs11857366 chr15 99263801 A G 2.79E-04 Response to taxane treatment (placlitaxel) IGF1R intron 23006423 rs11857366 chr15 99263801 A G 3.02E-12 Urate levels IGF1R intron 23263486 rs4966017 chr15 99267633 T G 6.40E-05 Alcohol dependence IGF1R intron 20201924 rs4966017 chr15 99267633 T G 7.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IGF1R intron 20877124 rs4966017 chr15 99267633 T G 6.40E-05 Alcoholism IGF1R intron pha002891 rs932071 chr15 99268030 G A 2.47E-10 Urate levels IGF1R intron 23263486 rs4616271 chr15 99268259 C T 3.39E-11 Urate levels IGF1R intron 23263486 rs4965430 chr15 99268850 C G 2.23E-12 Urate levels IGF1R intron 23263486 rs6598541 chr15 99271135 A G 5.00E-15 Urate levels IGF1R intron 23263486 rs875686 chr15 99272519 T A 5.17E-11 Urate levels IGF1R intron 23263486 rs11633717 chr15 99273032 T C 5.62E-11 Urate levels IGF1R intron 23263486 rs7166287 chr15 99273075 C T 1.41E-12 Urate levels IGF1R intron 23263486 rs4966019 chr15 99274326 C T 7.75E-12 Urate levels IGF1R intron 23263486 rs11633294 chr15 99275008 C A 1.07E-10 Urate levels IGF1R intron 23263486 rs907808 chr15 99280254 A G 1.46E-10 Urate levels IGF1R intron 23263486 rs2175800 chr15 99280981 A G 2.22E-04 Lung function (forced vital capacity) IGF1R intron 24023788 rs2175800 chr15 99280981 A G 3.50E-05 Lung function (forced expiratory volume in 1 second) IGF1R intron 24023788 rs1567811 chr15 99281833 C G 6.45E-10 Urate levels IGF1R intron 23263486 rs3743263 chr15 99282558 A G 5.27E-10 Urate levels IGF1R intron 23263486 rs3743264 chr15 99282587 G A 7.20E-10 Urate levels IGF1R intron 23263486 rs1007212 chr15 99283918 G A 8.12E-10 Urate levels IGF1R intron 23263486 rs2871974 chr15 99284074 C T 1.23E-11 Urate levels IGF1R intron 23263486 rs8037467 chr15 99284652 T G 3.31E-10 Urate levels IGF1R intron 23263486 rs4966020 chr15 99284680 G A 7.41E-10 Urate levels IGF1R intron 23263486 rs4966021 chr15 99285056 C T 1.08E-11 Urate levels IGF1R intron 23263486 rs4966022 chr15 99286284 A G 2.06E-10 Urate levels IGF1R intron 23263486 rs7176092 chr15 99286773 C G 2.81E-08 Triglycerides IGF1R intron 23063622 rs12908437 chr15 99287375 T C 5.18E-05 Response to taxane treatment (placlitaxel) IGF1R intron 23006423 rs12908437 chr15 99287375 T C 2.98E-12 Urate levels IGF1R intron 23263486 rs2137683 chr15 99289638 C G 3.20E-05 Response to taxane treatment (placlitaxel) IGF1R intron 23006423 rs2137683 chr15 99289638 C G 1.00E-11 Urate levels IGF1R intron 23263486 rs11632952 chr15 99290975 A G 2.21E-10 Urate levels IGF1R intron 23263486 rs7166999 chr15 99292805 A C 4.12E-04 Response to taxane treatment (placlitaxel) IGF1R intron 23006423 rs7166999 chr15 99292805 A C 3.14E-12 Urate levels IGF1R intron 23263486 rs6598542 chr15 99293056 G A 1.07E-04 Response to taxane treatment (placlitaxel) IGF1R intron 23006423 rs6598542 chr15 99293056 G A 9.34E-13 Urate levels IGF1R intron 23263486 rs6598543 chr15 99293552 A G 2.82E-12 Urate levels IGF1R intron 23263486 rs12898337 chr15 99294355 T C 2.08E-05 Response to taxane treatment (placlitaxel) IGF1R intron 23006423 rs12898337 chr15 99294355 T C 1.80E-12 Urate levels IGF1R intron 23263486 rs12898502 chr15 99294452 T C 3.82E-04 Response to taxane treatment (placlitaxel) IGF1R intron 23006423 rs12898502 chr15 99294452 T C 6.24E-11 Urate levels IGF1R intron 23263486 rs4966024 chr15 99295570 G A 1.59E-04 Response to taxane treatment (placlitaxel) IGF1R intron 23006423 rs4966024 chr15 99295570 G A 2.21E-12 Urate levels IGF1R intron 23263486 rs8041224 chr15 99297665 T C 2.43E-08 Urate levels IGF1R intron 23263486 rs10794486 chr15 99301535 G A 5.04E-05 Hypertension (early onset hypertension) IGF1R intron 22479346 rs2048640 chr15 99304975 G A 9.55E-04 Type 2 diabetes IGF1R intron 17463246 rs2048639 chr15 99305092 A T 9.55E-04 Type 2 diabetes IGF1R intron 17463246 rs7175052 chr15 99307950 C A 0.00024799 Hypertension (early onset hypertension) IGF1R intron 22479346 rs8031382 chr15 99313481 T C 5.61E-04 Weight loss (gastric bypass surgery) IGF1R intron 23633212 rs12439557 chr15 99314782 T C 3.99E-04 Weight loss (gastric bypass surgery) IGF1R intron 23633212 rs4267291 chr15 99340018 C T 7.99E-06 Lipid levels IGF1R intron 19913121 rs7182064 chr15 99356321 C T 0.00000169 Triglycerides IGF1R intron 23063622 rs2684777 chr15 99396694 T C 6.27E-04 Iron levels IGF1R intron pha002876 rs2715442 chr15 99412562 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) IGF1R intron 20708005 rs1357112 chr15 99433376 G A 2.80E-07 Urinary metabolites IGF1R intron 21572414 rs3743258 chr15 99443139 G A 9.59E-04 Suicide attempts in bipolar disorder IGF1R intron 21423239 rs8038056 chr15 99482928 A G 1.75E-04 Hemoglobin concentration IGF1R intron 20534544 rs2684796 chr15 99483392 T C 2.12E-04 Hemoglobin concentration IGF1R intron 20534544 rs7173377 chr15 99488728 C A 2.50E-05 Coronary heart disease IGF1R intron 21966275 rs17847195 chr15 99492061 G A 1.40E-04 Coronary heart disease IGF1R intron 21966275 rs2715423 chr15 99511873 G A 2.09E-05 Glucose levels PGPEP1L missense pha002899 rs2593052 chr15 99544732 T C 2.34E-04 Multiple complex diseases PGPEP1L intron 17554300 rs925234 chr15 99572216 C T 0.0000553 Panic disorder / / 23149450 rs925234 chr15 99572216 C T 5.53E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs2663101 chr15 99573395 T G 0.0000485 Panic disorder / / 23149450 rs2663101 chr15 99573395 T G 4.85E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs4288977 chr15 99588496 A T 8.99E-04 Multiple complex diseases / / 17554300 rs2593029 chr15 99596313 C T 4.83E-05 Cognitive test performance / / 20125193 rs1670262 chr15 99597353 A G 8.60E-05 Cognitive function / / 24684796 rs2654963 chr15 99599383 C T 1.30E-05 Urinary metabolites / / 21572414 rs2663134 chr15 99599607 G T 2.94E-04 Multiple complex diseases / / 17554300 rs1810092 chr15 99605041 A G 7.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs28504 chr15 99606243 A G 3.65E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4965211 chr15 99629577 C T 1.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4965211 chr15 99629577 C T 4.46E-05 Alzheimer's disease (late onset) / / 21379329 rs4965212 chr15 99629901 T G 1.51E-04 Height / / 17255346 rs937927 chr15 99632014 C A 8.88E-04 Type 2 diabetes / / 17463246 rs260090 chr15 99667524 G C 4.72E-04 Smoking initiation SYNM intron 24665060 rs4965447 chr15 99667726 C G 3.58E-04 Smoking initiation SYNM intron 24665060 rs1670227 chr15 99670518 T C 7.01E-05 Lung function (forced expiratory volume in 1 second) SYNM cds-synon 24023788 rs1670227 chr15 99670518 T C 7.13E-04 Smoking initiation SYNM cds-synon 24665060 rs260088 chr15 99677316 C A 3.54E-04 Smoking initiation TTC23 UTR-3 24665060 rs260089 chr15 99678145 G A 3.33E-04 Smoking initiation TTC23 UTR-3 24665060 rs181987 chr15 99679655 C A 2.69E-04 Smoking initiation TTC23 intron 24665060 rs260116 chr15 99682852 G A 4.41E-04 Smoking initiation TTC23 intron 24665060 rs7178187 chr15 99683251 A G 1.37E-05 Endometrial cancer TTC23 intron 24096698 rs7178187 chr15 99683251 A G 4.71E-05 Endometrial cancer TTC23 intron 24096698 rs7178187 chr15 99683251 A G 5.55E-05 Endometrial cancer TTC23 intron 24096698 rs260115 chr15 99683786 G A 2.51E-04 Lung function (forced expiratory volume in 1 second) TTC23 intron 24023788 rs8039637 chr15 99686951 C T 3.00E-04 Lung function (forced expiratory volume in 1 second) TTC23 intron 24023788 rs1703770 chr15 99694365 G A 4.99E-04 Lung function (forced expiratory volume in 1 second) TTC23 intron 24023788 rs2006920 chr15 99702723 G A 6.47E-05 Alzheimer's disease (late onset) TTC23 intron 21379329 rs2006920 chr15 99702723 G A 3.14E-05 Erythrocyte counts TTC23 intron pha003090 rs1530920 chr15 99710381 G C 4.75E-04 Schizophrenia(treatment response to risperidone) TTC23 intron 19850283 rs2292313 chr15 99796089 C T 2.37E-04 Fibrinogen LRRC28 intron 17255346 rs8039009 chr15 99834662 C T 1.00E-04 IgE levels in asthmatics (D.f. specific) LRRC28 intron 23967269 rs12592075 chr15 99836804 G A 6.63E-04 Response to taxane treatment (placlitaxel) LRRC28 intron 23006423 rs12913897 chr15 99838020 A G 7.80E-04 Response to taxane treatment (placlitaxel) LRRC28 intron 23006423 rs8041923 chr15 99839408 T C 7.58E-04 Response to taxane treatment (placlitaxel) LRRC28 intron 23006423 rs11858067 chr15 99904271 G A 8.99E-04 Multiple complex diseases LRRC28 intron 17554300 rs8041236 chr15 99910498 C A 3.50E-06 Coronary heart disease LRRC28 intron 21971053 rs4965475 chr15 99932366 C T 1.96E-04 Type 2 diabetes / / 17463246 rs4965475 chr15 99932366 C T 4.00E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4965476 chr15 99932797 T C 8.01E-04 Type 2 diabetes / / 17463246 rs4965476 chr15 99932797 T C 2.50E-05 Kawasaki disease / / 22446962 rs4965479 chr15 99939263 C A 1.40E-05 Kawasaki disease / / 22446962 rs4965479 chr15 99939263 C A 8.62E-04 Major depressive disorder / / 22472876 rs4965479 chr15 99939263 C A 6.89E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11247090 chr15 99945673 C G 6.55E-04 Major depressive disorder / / 22472876 rs11247090 chr15 99945673 C G 2.09E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4965480 chr15 99945881 A G 4.19E-04 Major depressive disorder / / 22472876 rs4965480 chr15 99945881 A G 6.56E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4965481 chr15 99946006 G A 2.57E-04 Major depressive disorder / / 22472876 rs4965481 chr15 99946006 G A 1.43E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11855683 chr15 99949289 C T 2.78E-05 Body mass index / / 17255346 rs4393551 chr15 99950772 T C 2.40E-05 Multiple sclerosis (age of onset) / / 19010793 rs6598242 chr15 99956954 A G 2.92E-04 Alzheimer's disease (late onset) / / 21379329 rs8042934 chr15 99984961 C T 4.48E-04 Alzheimer's disease (late onset) / / 21379329 rs7171291 chr15 100007996 G A 1.12E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4965245 chr15 100008392 C T 1.47E-04 Aortic root size / / 21223598 rs4965245 chr15 100008392 C T 5.62E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1561860 chr15 100009396 G C 6.50E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1561861 chr15 100009490 G T 5.46E-04 Multiple complex diseases / / 17554300 rs1561861 chr15 100009490 G T 4.71E-04 Aortic root size / / 21223598 rs1561861 chr15 100009490 G T 7.17E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs8026271 chr15 100014303 T C 8.00E-05 Prostate cancer / / 21743057 rs7167860 chr15 100016225 C T 3.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4965256 chr15 100032006 A G 4.70E-04 Aortic root size / / 21223598 rs11247105 chr15 100046294 T G 8.69E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1120716 chr15 100055308 T A 2.92E-04 Depression (quantitative trait) / / 20800221 rs756143 chr15 100057431 T A 9.63E-05 Depression (quantitative trait) / / 20800221 rs8030728 chr15 100086709 G A 5.86E-06 Coronary heart disease / / pha003035 rs4424892 chr15 100104385 C T 3.88E-04 Multiple complex diseases MEF2A nearGene-5 17554300 rs8036677 chr15 100148042 G A 1.76E-05 Coronary heart disease MEF2A intron pha003035 rs2581473 chr15 100196657 A G 0.000000238 Triglycerides MEF2A intron 23063622 rs2581473 chr15 100196657 A G 0.00000163 LDL cholesterol MEF2A intron 23063622 rs12913446 chr15 100218989 T C 4.45E-05 Coronary heart disease MEF2A intron pha003035 rs2290446 chr15 100246618 T C 1.90E-06 Urinary metabolites MEF2A intron 21572414 rs8029516 chr15 100252174 A C 5.17E-04 Multiple complex diseases MEF2A intron 17554300 rs200152842 chr15 100255814 AG A 2.94E-04 Multiple complex diseases MEF2A UTR-3 17554300 rs325381 chr15 100255814 A T 2.94E-04 Multiple complex diseases MEF2A UTR-3 17554300 rs325380 chr15 100256618 A C 2.90E-05 Cognitive function MEF2A UTR-3 24684796 rs7183836 chr15 100258034 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1993293 chr15 100297663 A G 4.00E-06 Coronary artery calcification / / 23870195 rs6598266 chr15 100299239 G A 3.00E-06 Major depressive disorder / / 23377640 rs8027079 chr15 100330051 T C 9.36E-05 Major depressive disorder (broad) / / 20038947 rs9920347 chr15 100339331 A G 1.90E-05 Urinary metabolites DNM1P46 intron 21572414 rs1823874 chr15 100357435 T C 3.00E-06 IgG glycosylation / / 23382691 rs12906587 chr15 100377319 T G 1.60E-05 Urinary metabolites / / 21572414 rs12905568 chr15 100389182 C T 1.55E-04 Acute lung injury / / 22295056 rs2017774 chr15 100397055 T C 2.33E-04 Lymphocyte counts / / 22286170 rs12914796 chr15 100441789 C T 2.95E-05 Reading and spelling / / 23738518 rs7163488 chr15 100445403 T C 4.57E-04 Tourette syndrome / / 22889924 rs2573674 chr15 100476683 C A 1.39E-07 Uric acid levels / / 21294900 rs2581360 chr15 100491882 C T 6.32E-07 Uric acid levels / / 21294900 rs1347477 chr15 100492706 A G 2.72E-06 Uric acid levels / / 21294900 rs2581354 chr15 100493194 T C 4.13E-04 Type 2 diabetes / / 17463246 rs2727217 chr15 100525941 A G 6.25E-04 Multiple complex diseases ADAMTS17 intron 17554300 rs2727217 chr15 100525941 A G 9.31E-06 Biliary atresia ADAMTS17 intron 20460270 rs2573668 chr15 100541776 T C 1.10E-05 Height ADAMTS17 intron 18391952 rs2573680 chr15 100559025 T C 8.54E-04 Nicotine smoking ADAMTS17 intron 19268276 rs1585933 chr15 100585715 A G 4.31E-04 Lung function (forced expiratory volume in 1 second) ADAMTS17 intron 24023788 rs1383547 chr15 100615805 T C 6.55E-05 Body mass index ADAMTS17 intron 17255346 rs729316 chr15 100623705 T G 3.63E-04 Type 2 diabetes ADAMTS17 intron 17463246 rs8041815 chr15 100646979 C A 4.83E-05 Serum metabolites ADAMTS17 intron 19043545 rs1552101 chr15 100677237 T C 8.30E-05 Coffee consumption ADAMTS17 intron 21357676 rs7183000 chr15 100691456 T C 5.60E-04 Alzheimer's disease ADAMTS17 intron 17998437 rs12441845 chr15 100702012 T C 6.93E-04 Smoking cessation ADAMTS17 intron 24665060 rs12441900 chr15 100702186 T C 7.86E-04 Smoking cessation ADAMTS17 intron 24665060 rs12437498 chr15 100704152 T C 6.37E-04 Smoking cessation ADAMTS17 intron 24665060 rs7498059 chr15 100707379 T C 2.78E-05 Smoking cessation ADAMTS17 intron 24665060 rs2086452 chr15 100728663 G A 1.00E-06 Osteosarcoma ADAMTS17 intron 23727862 rs1038235 chr15 100735967 T C 5.01E-04 Nicotine smoking ADAMTS17 intron 19268276 rs12148118 chr15 100739405 T C 1.63E-05 Age-related macular degeneration ADAMTS17 intron pha002856 rs4419043 chr15 100745680 A G 5.67E-05 Serum metabolites ADAMTS17 intron 19043545 rs4572372 chr15 100745994 C A 2.81E-04 Lung function (forced expiratory volume in 1 second) ADAMTS17 intron 24023788 rs4965593 chr15 100758385 C G 7.00E-10 Height ADAMTS17 intron 23563607 rs4965598 chr15 100759614 C T 4.00E-13 Height ADAMTS17 intron 20881960 rs4965599 chr15 100759884 C G 4.85E-05 Bipolar disorder and schizophrenia ADAMTS17 intron 20889312 rs4412959 chr15 100765138 T C 1.44E-04 Body mass index ADAMTS17 intron 17255346 rs11857875 chr15 100773215 T C 5.10E-05 Response to antidepressants ADAMTS17 intron 19736353 rs8024208 chr15 100774459 T C 1.81E-04 Lung function (forced vital capacity) ADAMTS17 intron 24023788 rs4533267 chr15 100786271 A G 3.00E-08 Height ADAMTS17 intron 18391951 rs4533267 chr15 100786271 A G 3.13E-04 Response to taxane treatment (placlitaxel) ADAMTS17 intron 23006423 rs7171129 chr15 100793347 T C 5.01E-04 Schizophrenia ADAMTS17 intron 20832056 rs2028592 chr15 100841019 T C 4.02E-04 Intracranial aneurysm ADAMTS17 intron 20613766 rs12437971 chr15 100844565 G A 1.70E-05 Bone mineral density (spine) ADAMTS17 intron 19079262 rs7176121 chr15 100845320 T C 0.000051 Glomerular filtration rate ADAMTS17 intron 22962313 rs12438347 chr15 100860385 G A 7.09E-04 Alzheimer's disease ADAMTS17 intron 24755620 rs2289584 chr15 100889496 T G 9.53E-05 Orofacial clefts FLJ42289 intron 20023658 rs2587799 chr15 100890608 G A 6.36E-05 Insulin-related traits / / pha003063 rs12915188 chr15 100912913 T C 3.46E-05 Orofacial clefts / / 20023658 rs2587748 chr15 100925708 A G 7.08E-05 Longevity / / 20304771 rs2585243 chr15 100934679 T C 2.24E-06 Alzheimer's disease (late onset) / / 21379329 rs2587736 chr15 100938446 T C 8.72E-05 Longevity / / 20304771 rs12914235 chr15 100942373 T C 5.95E-05 Longevity CERS3 UTR-3 20304771 rs1023782 chr15 100942843 G T 5.84E-05 Longevity CERS3 UTR-3 20304771 rs7180354 chr15 100946347 T C 5.82E-05 Longevity CERS3 intron 20304771 rs1000290 chr15 100949609 T C 6.15E-05 Longevity CERS3 intron 20304771 rs7164184 chr15 100953411 A G 4.60E-05 Longevity CERS3 intron 20304771 rs1393943 chr15 100971201 A T 4.65E-05 Longevity CERS3 intron 20304771 rs1966765 chr15 100974253 A T 1.10E-04 Type 2 diabetes and 6 quantitative traits CERS3 intron 17848626 rs1966764 chr15 100974315 T C 8.63E-05 Caffeine consumption CERS3 intron 21490707 rs2654602 chr15 100975635 C T 9.99E-05 Longevity CERS3 intron 20304771 rs2587803 chr15 100988814 T C 9.80E-05 Longevity CERS3 intron 20304771 rs12595207 chr15 100996038 C T 9.77E-04 Alzheimer's disease CERS3 intron 24755620 rs2654583 chr15 101002255 G A 4.66E-04 Alzheimer's disease (late onset) CERS3 intron 21379329 rs2654583 chr15 101002255 G A 9.88E-05 Serum albumin level CERS3 intron pha003084 rs1503474 chr15 101002738 G A 4.64E-06 Serum albumin level CERS3 intron pha003084 rs1988459 chr15 101005314 C T 3.82E-05 Longevity CERS3 intron 20304771 rs8028050 chr15 101006703 A G 9.66E-05 Longevity CERS3 intron 20304771 rs8029244 chr15 101008575 A G 1.17E-05 Longevity CERS3 intron 20304771 rs8028803 chr15 101008670 C T 1.22E-05 Longevity CERS3 intron 20304771 rs8028803 chr15 101008670 C T 4.31E-05 Serum albumin level CERS3 intron pha003084 rs12910887 chr15 101008947 T C 1.22E-05 Longevity CERS3 intron 20304771 rs12906592 chr15 101009249 C T 3.36E-05 Longevity CERS3 intron 20304771 rs1466931 chr15 101010351 A T 3.05E-05 Longevity CERS3 intron 20304771 rs1466930 chr15 101010710 C A,G 3.06E-05 Longevity CERS3 intron 20304771 rs11634135 chr15 101011031 G A 2.79E-05 Longevity CERS3 intron 20304771 rs1393942 chr15 101012497 C T 2.94E-05 Longevity CERS3 intron 20304771 rs2587766 chr15 101022884 G A 1.28E-04 Alzheimer's disease (late onset) CERS3 intron 21379329 rs2587766 chr15 101022884 G A 5.41E-05 Serum albumin level CERS3 intron pha003084 rs4643297 chr15 101023714 T C 1.61E-06 Serum albumin level CERS3 intron pha003084 rs2654637 chr15 101023788 T C 0.000195 Salmonella-induced pyroptosis CERS3 intron 22837397 rs1910410 chr15 101038847 G A 0.000896 Salmonella-induced pyroptosis CERS3 intron 22837397 rs1354332 chr15 101041896 T C 0.000499 Salmonella-induced pyroptosis CERS3 cds-synon 22837397 rs8030478 chr15 101042879 G A 0.000605 Salmonella-induced pyroptosis CERS3 intron 22837397 rs2587784 chr15 101045447 A C 1.16E-04 Alzheimer's disease (late onset) CERS3 intron 21379329 rs7173701 chr15 101048659 G A 3.69E-04 Acute lung injury CERS3 intron 22295056 rs7175210 chr15 101048705 C T 3.69E-04 Acute lung injury CERS3 intron 22295056 rs568509478 chr15 101048885 GTC G 5.12E-04 Acute lung injury CERS3 intron 22295056 rs7174243 chr15 101048885 G A 5.12E-04 Acute lung injury CERS3 intron 22295056 rs11247214 chr15 101055938 C T 7.17E-05 Serum albumin level CERS3 intron pha003084 rs1393945 chr15 101058935 G A 2.73E-06 Serum albumin level CERS3 intron pha003084 rs35737291 chr15 101061032 C CG 9.80E-04 Acute lung injury CERS3 intron 22295056 rs9806246 chr15 101061032 C A 9.80E-04 Acute lung injury CERS3 intron 22295056 rs4246316 chr15 101066561 C T 1.72E-05 Serum albumin level CERS3 intron pha003084 rs1566776 chr15 101070463 C T 3.11E-05 Sphingolipid levels CERS3 intron 19798445 rs12907869 chr15 101070929 G A 1.84E-05 Alzheimer's disease (late onset) CERS3 intron 21379329 rs11247219 chr15 101073157 T C 4.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CERS3 intron 20877124 rs11247219 chr15 101073157 T C 3.54E-05 Alzheimer's disease (late onset) CERS3 intron 21379329 rs4638553 chr15 101075626 A G 1.30E-05 Urinary metabolites CERS3 intron 21572414 rs4965668 chr15 101077349 T G 2.80E-07 Urinary metabolites CERS3 intron 21572414 rs1910412 chr15 101080212 A C 1.20E-05 Urinary metabolites CERS3 intron 21572414 rs12438080 chr15 101082063 A C 1.20E-05 Urinary metabolites CERS3 intron 21572414 rs9788652 chr15 101082169 G C 1.30E-05 Urinary metabolites CERS3 intron 21572414 rs7169732 chr15 101082724 A G 2.00E-05 Urinary metabolites CERS3 intron 21572414 rs4965315 chr15 101089269 C T 2.30E-06 Urinary metabolites / / 21572414 rs12915921 chr15 101089573 C T 2.98E-04 Alzheimer's disease (late onset) / / 21379329 rs12915921 chr15 101089573 C T 2.18E-05 Alzheimer's disease (late onset) / / 21460841 rs12915921 chr15 101089573 C T 3.54E-05 Orofacial clefts / / 22419666 rs12915921 chr15 101089573 C T 1.61E-04 Alzheimer's disease / / 24755620 rs4965316 chr15 101092226 T C 6.90E-06 Urinary metabolites / / 21572414 rs12442986 chr15 101092964 A T 2.49E-04 Alzheimer's disease / / 24755620 rs113791767 chr15 101094130 C CT 6.50E-04 Alcohol dependence / / 20201924 rs11634945 chr15 101094130 C T 6.50E-04 Alcohol dependence / / 20201924 rs883468 chr15 101102053 T C 3.01E-04 Alzheimer's disease / / 24755620 rs8451 chr15 101109677 C A 5.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) LINS missense 21239504 rs12157 chr15 101109794 C G 5.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) LINS missense 21239504 rs2411837 chr15 101110302 C G 5.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) LINS missense 21239504 rs1493652 chr15 101112342 T C 8.00E-04 Alcohol dependence LINS intron 20201924 rs7168920 chr15 101112719 C T 4.09E-04 Alzheimer's disease LINS intron 24755620 rs4965678 chr15 101115448 C A 7.15E-04 Alcohol dependence LINS intron 20201924 rs11247226 chr15 101120963 T C 5.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) LINS missense 21239504 rs3794503 chr15 101141896 C A 9.30E-05 Cognitive impairment induced by topiramate LINS intron 22091778 rs3794505 chr15 101142146 G A 7.60E-04 Alzheimer's disease LINS intron 24755620 rs6598368 chr15 101155726 T C 4.25E-05 Insulin Resistance ASB7 intron pha003062 rs6598368 chr15 101155726 T C 4.48E-05 Insulin-related traits ASB7 intron pha003063 rs1565750 chr15 101176687 A C 3.37E-04 Multiple complex diseases ASB7 intron 17554300 rs11247231 chr15 101199080 A C 9.95E-04 Lymphocyte counts / / 22286170 rs2956236 chr15 101200284 G A 2.04E-04 Vaspin levels / / 22907691 rs2956236 chr15 101200284 G A 0.0002037 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs304107 chr15 101222302 C G 2.20E-05 Urinary metabolites / / 21572414 rs1689954 chr15 101229784 C T 7.67E-05 Coronary heart disease / / pha003031 rs1002941 chr15 101242690 G A 4.70E-05 Lung cancer / / 18385738 rs1626645 chr15 101244572 T C 4.80E-45 Narcolepsy / / 19629137 rs184234 chr15 101251719 T C 1.00E-06 Response to taxane treatment (placlitaxel) / / 23006423 rs304115 chr15 101253557 G A 1.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11630690 chr15 101304166 C T 9.20E-05 Prion diseases / / 22210626 rs7178968 chr15 101311386 G C 3.28E-04 Multiple complex diseases / / 17554300 rs7173522 chr15 101318089 G A 6.61E-05 Monocyte chemoattractant protein-1 / / pha003071 rs7174629 chr15 101383589 T A 5.50E-05 Recombination rate / / 21698098 rs3825924 chr15 101445900 G A 1.73E-05 Response to acetaminophen (hepatotoxicity) ALDH1A3 intron 21177773 rs4246328 chr15 101446270 G A 3.69E-04 Alzheimer's disease (late onset) ALDH1A3 intron 21379329 rs4646685 chr15 101447757 T G 3.84E-04 Alzheimer's disease (late onset) ALDH1A3 intron 21379329 rs11854028 chr15 101447974 G T 4.31E-04 Alzheimer's disease (late onset) ALDH1A3 intron 21379329 rs3803428 chr15 101450910 C T 2.65E-04 Alzheimer's disease (late onset) ALDH1A3 intron 21379329 rs1130738 chr15 101455840 G A 3.99E-04 Alzheimer's disease (late onset) ALDH1A3 UTR-3 21379329 rs4646693 chr15 101458014 T C 2.06E-04 Alzheimer's disease (late onset) LOC100507452 intron 21379329 rs4075387 chr15 101480031 A C 1.06E-04 Amyotrophic lateral sclerosis (sporadic) LRRK1 intron 24529757 rs12911894 chr15 101493839 C A 3.00E-04 Alcohol dependence LRRK1 intron 20201924 rs8038607 chr15 101514629 T C 1.42E-04 Nicotine smoking LRRK1 intron 19268276 rs12442816 chr15 101520654 G A 7.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LRRK1 intron 20877124 rs7163635 chr15 101546195 T C 9.67E-05 Multiple sclerosis LRRK1 intron 17660530 rs11247251 chr15 101547631 C T 1.38E-04 Colorectal cancer LRRK1 intron 24737748 rs2034809 chr15 101555399 G A 2.73E-04 Age-related macular degeneration LRRK1 intron 22125219 rs2034809 chr15 101555399 G A 7.50E-05 Corneal structure LRRK1 intron 23291589 rs10751716 chr15 101558227 A G 3.80E-07 Urinary metabolites LRRK1 intron 21572414 rs930847 chr15 101558562 G T 6.00E-19 Corneal structure LRRK1 intron 23291589 rs936111 chr15 101559136 A G 2.10E-05 Volumetric brain MRI LRRK1 intron 17903297 rs1598492 chr15 101577534 G A 2.71E-04 Multiple complex diseases LRRK1 intron 17554300 rs2995904 chr15 101595898 G A 2.84E-04 Type 2 diabetes LRRK1 intron 17463246 rs2995904 chr15 101595898 G A 7.13E-04 Multiple complex diseases LRRK1 intron 17554300 rs3863405 chr15 101620336 C T 2.98E-04 Multiple complex diseases / / 17554300 rs2085161 chr15 101648029 T C 9.70E-04 Myopia (pathological) / / 21095009 rs11633369 chr15 101654432 C T 3.09E-04 Smoking initiation / / 24665060 rs1968734 chr15 101657719 G T 9.20E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1902131 chr15 101670586 T C 4.42E-04 Alzheimer's disease (late onset) / / 21379329 rs11635381 chr15 101671283 C T 6.43E-04 Alzheimer's disease / / 22005930 rs8034723 chr15 101676935 A G 4.49E-04 Multiple complex diseases / / 17554300 rs4965368 chr15 101680159 A G 3.90E-04 Alzheimer's disease / / 17998437 rs1809180 chr15 101697982 T C 5.81E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4965800 chr15 101702901 A G 7.15E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2005180 chr15 101718700 G A 1.00E-06 Urinary metabolites CHSY1 cds-synon 21572414 rs12593811 chr15 101721892 T C 7.00E-06 Corneal astigmatism CHSY1 intron 23322567 rs8043243 chr15 101771453 C T 9.33E-06 Corneal structure CHSY1 intron 23291589 rs8043243 chr15 101771453 C T 4.90E-04 Iron levels CHSY1 intron pha002876 rs7166401 chr15 101776118 A G 2.08E-13 Non-obstructive azoospermia CHSY1 intron 22197933 rs752092 chr15 101781934 A G 2.00E-09 Corneal structure CHSY1 intron 23291589 rs752092 chr15 101781934 A G 6.29E-04 Iron levels CHSY1 intron pha002876 rs4965373 chr15 101812395 A G 8.80E-04 Iron levels SELS UTR-3 pha002876 rs4965816 chr15 101823790 A C 6.98E-04 Suicide attempts in bipolar disorder SNRPA1 intron 21423239 rs12909636 chr15 101824271 C T 8.19E-04 Suicide attempts in bipolar disorder SNRPA1 intron 21423239 rs3825921 chr15 101862163 T C 2.23E-05 Relative hand skill in reading disability PCSK6 intron 24068947 rs1871978 chr15 101863289 T C 5.30E-06 Relative hand skill in reading disability PCSK6 intron 24068947 rs9806256 chr15 101863573 C T 6.36E-06 Relative hand skill in reading disability PCSK6 intron 24068947 rs4965830 chr15 101863989 T A 4.94E-07 Relative hand skill in reading disability PCSK6 intron 24068947 rs7182874 chr15 101865472 T C 9.00E-09 Relative hand skill in reading disability PCSK6 intron 24068947 rs752028 chr15 101869185 T C 5.09E-05 Sarcoidosis PCSK6 intron 19165924 rs752028 chr15 101869185 T C 9.12E-07 Relative hand skill in reading disability PCSK6 intron 24068947 rs752026 chr15 101869371 A G 9.66E-04 Depression (quantitative trait) PCSK6 intron 20800221 rs2239858 chr15 101872544 T C 9.37E-05 Relative hand skill in reading disability PCSK6 intron 24068947 rs11855415 chr15 101875123 A T 2.00E-08 Handedness in dyslexia PCSK6 intron 21051773 rs11855415 chr15 101875123 A T 7.28E-07 Relative hand skill in reading disability PCSK6 intron 24068947 rs2086678 chr15 101876416 C T 8.35E-05 Relative hand skill in reading disability PCSK6 intron 24068947 rs11854332 chr15 101882501 C T 2.59E-05 Prion diseases PCSK6 intron 22210626 rs11630183 chr15 101889555 A G 1.07E-05 Prion diseases PCSK6 intron 22210626 rs12593069 chr15 101895871 C T 3.77E-05 Cognitive performance PCSK6 intron 19734545 rs1531817 chr15 101906737 C A 0.00029 Coronary artery calcification PCSK6 intron 23727086 rs3784505 chr15 101907921 T C 0.00027 Coronary artery calcification PCSK6 intron 23727086 rs11858775 chr15 101923055 G T 2.23E-04 Blood pressure PCSK6 intron 17255346 rs3784481 chr15 101932164 G A 6.43E-04 Amyotrophic Lateral Sclerosis PCSK6 intron 17827064 rs4965843 chr15 101933226 G A 1.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PCSK6 intron 20877124 rs4965843 chr15 101933226 G A 0.0000265 LDL cholesterol PCSK6 intron 23063622 rs3784474 chr15 101936227 A T 2.00E-06 Urinary metabolites PCSK6 intron 21572414 rs4965847 chr15 101948365 C T 8.40E-06 Urinary metabolites PCSK6 intron 21572414 rs7168655 chr15 101964921 G A 0.0000076 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 PCSK6 intron 21873659 rs7169026 chr15 101965121 G A 2.76E-04 Insulin resistance PCSK6 intron 21901158 rs1006273 chr15 101965339 T A 0.00005 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=14 PCSK6 intron 21873659 rs2643358 chr15 101972035 G A 1.52E-05 Response to mTOR inhibitor (rapamycin) PCSK6 intron 24009623 rs12902244 chr15 101972055 T C 4.24E-05 Response to mTOR inhibitor (everolimus) PCSK6 intron 24009623 rs8024621 chr15 101972931 G A 1.22E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) PCSK6 intron 23648065 rs12101753 chr15 101987060 T C 1.83E-09 Cholesterol,total PCSK6 intron 23063622 rs4246336 chr15 101997586 A G 3.80E-04 Atrial fibrillation PCSK6 intron 21846873 rs7166898 chr15 102021048 C T 1.77E-05 Amyotrophic lateral sclerosis PCSK6 intron 20801718 rs2898887 chr15 102064176 G A 5.01E-04 Obesity (extreme) / / 21935397 rs2100045 chr15 102064634 G A 2.60E-04 Obesity (extreme) / / 21935397 rs7359236 chr15 102065335 G T 2.60E-04 Obesity (extreme) / / 21935397 rs7359250 chr15 102065598 C T 3.58E-04 Obesity (extreme) / / 21935397 rs2084148 chr15 102066461 C T 3.60E-04 Obesity (extreme) / / 21935397 rs2121212 chr15 102073092 T C 7.18E-05 Taste perception / / 22132133 rs4965898 chr15 102097626 G T 2.00E-05 Major depressive disorder / / 21042317 rs8038697 chr15 102101758 A G 1.40E-05 Major depressive disorder / / 21042317 rs9972548 chr15 102101941 G A 1.20E-05 Major depressive disorder / / 21042317 rs12148616 chr15 102108876 G C 3.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs11634684 chr15 102144955 C T 9.24E-05 Major depressive disorder (broad) / / 20038947 rs10152467 chr15 102146151 A G 7.59E-05 Major depressive disorder (broad) / / 20038947 rs1020394 chr15 102147426 T C 9.59E-05 Major depressive disorder (broad) / / 20038947 rs8036586 chr15 102152042 T C 4.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9635431 chr15 102165080 G A 1.00E-07 Urinary metabolites / / 21572414 rs9920596 chr15 102165803 A G 2.30E-07 Urinary metabolites / / 21572414 rs516667 chr15 102204031 G A 7.97E-04 Body mass index TARSL2 intron 21701565 rs8033312 chr15 102212577 T A 5.86E-05 Odorant perception TARSL2 intron 23910658 rs8024223 chr15 102215765 G A 4.56E-04 Alzheimer's disease TARSL2 intron 17998437 rs8035839 chr15 102247864 G A 4.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TARSL2 intron 20877124 rs8035859 chr15 102252852 A C 9.10E-05 Personality dimensions TARSL2 intron 18957941 rs8024180 chr15 102273500 G A 2.98E-04 Body mass index / / 21701565 rs352731 chr15 102289502 G C 5.51E-04 Body mass index / / 21701565 rs2456491 chr15 102305129 T C 5.25E-04 Body mass index / / 21701565 rs352743 chr15 102350597 G A 5.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs352744 chr15 102352429 T C 8.59E-04 Body mass index / / 21701565 rs7182334 chr15 102361139 A G 7.35E-04 Body mass index / / 21701565 rs7182651 chr15 102364833 G A 8.59E-05 Cognitive test performance / / 20125193 rs2203348 chr15 102366849 G A 5.23E-05 Cognitive impairment induced by topiramate / / 22091778 rs6598500 chr15 102381360 C T 8.38E-05 Iron levels / / 19880490 rs8029360 chr15 102395843 A G 3.61E-04 Body mass index / / 21701565 rs6600227 chr16 115072 A C 6.02E-08 Red blood cell traits RHBDF1 intron 23222517 rs743725 chr16 136888 T C 6.09E-12 Red blood cell traits NPRL3 intron 23222517 rs2562181 chr16 141659 C T 7.24E-07 Red blood cell traits NPRL3 intron 23222517 rs2541618 chr16 142825 T C 8.44E-08 Red blood cell traits NPRL3 intron 23222517 rs6600233 chr16 143503 C T 4.10E-15 Red blood cell traits NPRL3 intron 23222517 rs2562177 chr16 145282 C T 8.67E-07 Red blood cell traits NPRL3 intron 23222517 rs17525396 chr16 145884 A T 1.60E-41 Fetal hemoglobin levels NPRL3 intron 18245381 rs12927713 chr16 152220 G A 2.39E-09 Red blood cell traits NPRL3 intron 23222517 rs798613 chr16 154844 C T 7.99E-07 Red blood cell traits NPRL3 intron 23222517 rs2238367 chr16 155358 C T 2.78E-08 Type 2 diabetes NPRL3 intron 17463246 rs7199157 chr16 155966 C G 1.08E-15 Red blood cell traits NPRL3 intron 23222517 rs183350 chr16 161938 G A 3.23E-08 Red blood cell traits NPRL3 intron 23222517 rs11248850 chr16 163598 G A 6.00E-23 Red blood cell traits NPRL3 intron 23222517 rs11865131 chr16 163667 G A 5.73E-08 Red blood cell traits NPRL3 intron 23222517 rs216093 chr16 164935 T G 7.05E-07 Red blood cell traits NPRL3 intron 23222517 rs798604 chr16 168691 C G 2.26E-07 Red blood cell traits NPRL3 intron 23222517 rs2238368 chr16 170328 C T 4.93E-15 Red blood cell traits NPRL3 intron 23222517 rs2562164 chr16 176743 A G 1.01E-07 Red blood cell traits NPRL3 intron 23222517 rs7203560 chr16 184390 T G 1.00E-33 Mean corpuscular hemoglobin concentration NPRL3 intron 23263863 rs7203560 chr16 184390 T G 2.00E-08 Hematology traits NPRL3 intron 23263863 rs7203560 chr16 184390 T G 2.00E-23 Hematology traits NPRL3 intron 23263863 rs7203560 chr16 184390 T G 5.00E-62 Mean corpuscular hemoglobin NPRL3 intron 23263863 rs7203560 chr16 184390 T G 8.00E-43 Mean corpuscular volume NPRL3 intron 23263863 rs7203560 chr16 184390 T G 2.00E-09 Sickle cell anemia (haemolysis) NPRL3 intron 23406172 rs2857997 chr16 185102 G C 8.84E-09 Red blood cell traits NPRL3 intron 23222517 rs2857998 chr16 185123 A G 3.86E-15 Red blood cell traits NPRL3 intron 23222517 rs2562189 chr16 187429 C T 3.21E-14 Red blood cell traits NPRL3 intron 23222517 rs6600143 chr16 201389 C A 4.10E-07 Fetal hemoglobin levels HBZ nearGene-5 18245381 rs2541639 chr16 205035 G A 3.10E-21 Fetal hemoglobin levels / / 18245381 rs2858942 chr16 225653 A C 2.83E-09 Blood cell counts and other traits HBA1 nearGene-5 20139978 rs2858942 chr16 225653 A C 3.00E-09 Blood cell counts and other traits HBA1 nearGene-5 20139978 rs1211375 chr16 240280 A C 1.40E-33 Blood cell counts and traits,in red and white blood cells LUC7L intron 21153663 rs1211375 chr16 240280 A C 6.10E-08 Blood cell counts and traits,in red and white blood cells LUC7L intron 21153663 rs1211375 chr16 240280 A C 7.40E-13 Blood cell counts and traits,in red and white blood cells LUC7L intron 21153663 rs1211375 chr16 240280 A C 1.00E-16 Mean corpuscular volume LUC7L intron 23263863 rs1211375 chr16 240280 A C 3.00E-17 Mean corpuscular hemoglobin LUC7L intron 23263863 rs1211375 chr16 240280 A C 7.00E-14 Hematology traits LUC7L intron 23263863 rs1203957 chr16 241210 G T 2.10E-05 Urinary metabolites LUC7L intron 21572414 rs1203957 chr16 241210 G T 2.98E-07 Red blood cell traits LUC7L intron 23222517 rs1203981 chr16 265159 C T 1.93E-07 Platelet counts LUC7L intron 23263863 rs11248914 chr16 293562 T C 4.80E-06 Urinary metabolites ITFG3 intron 21572414 rs11248914 chr16 293562 T C 2.65E-21 Red blood cell traits ITFG3 intron 23222517 rs11248915 chr16 293915 G A 1.90E-05 Urinary metabolites ITFG3 intron 21572414 rs11248915 chr16 293915 G A 4.61E-08 Red blood cell traits ITFG3 intron 23222517 rs13339636 chr16 298588 A G 2.00E-34 Red blood cell traits ITFG3 intron 23446634 rs7189020 chr16 304803 A T 2.00E-12 Mean corpuscular volume ITFG3 intron 19862010 rs7189020 chr16 304803 A T 5.80E-05 Blood cell counts and other traits ITFG3 intron 20139978 rs7189020 chr16 304803 A T 5.74E-17 Red blood cell traits ITFG3 intron 23222517 rs1122794 chr16 309155 C A 3.00E-10 Mean corpuscular hemoglobin ITFG3 intron 19862010 rs1122794 chr16 309155 C A 9.12E-06 Blood cell counts and other traits ITFG3 intron 20139978 rs1122794 chr16 309155 C A 1.10E-05 Urinary metabolites ITFG3 intron 21572414 rs1122794 chr16 309155 C A 3.28E-09 Red blood cell traits ITFG3 intron 23222517 rs1122794 chr16 309155 C A 1.00E-08 Red blood cell traits ITFG3 intron 23446634 rs13335629 chr16 310380 G A 3.00E-23 Red blood cell traits ITFG3 intron 23446634 rs9924561 chr16 314780 G T 5.00E-29 Red blood cell traits ITFG3 intron 23696099 rs9924561 chr16 314780 G T 8.00E-36 Red blood cell traits ITFG3 intron 23696099 rs9924561 chr16 314780 G T 9.00E-17 Red blood cell traits ITFG3 intron 23696099 rs739999 chr16 319511 A G 8.66E-05 Personality dimensions RGS11 missense 18957941 rs739999 chr16 319511 A G 4.30E-05 Schizophrenia RGS11 missense 20185149 rs419949 chr16 334890 G A 8.39E-04 Bicuspid aortic valve PDIA2 missense 20098615 rs2685127 chr16 335373 C T 4.64E-04 Bicuspid aortic valve PDIA2 missense 20098615 rs117208012 chr16 347063 C T 0.000066 Prostate cancer (advanced) AXIN1 missense 23555315 rs214246 chr16 349293 A G 7.21E-05 Orofacial clefts AXIN1 intron 22419666 rs7200589 chr16 349331 G A 1.96E-05 Cognitive impairment induced by topiramate AXIN1 intron 22091778 rs1204042 chr16 352736 G A 1.60E-05 Urinary metabolites AXIN1 intron 21572414 rs1981492 chr16 356689 G A 8.90E-05 Alzheimer's disease (late onset) AXIN1 intron 21379329 rs11644916 chr16 359567 G A 2.07E-04 Alzheimer's disease (late onset) AXIN1 intron 21379329 rs11644916 chr16 359567 G A 6.24E-06 Parkinson's disease AXIN1 intron pha002868 rs3842949 chr16 360303 T C 8.11E-04 Response to alcohol consumption (flushing response) AXIN1 intron 24277619 rs7359414 chr16 362638 T G 9.36E-05 Alzheimer's disease (late onset) AXIN1 intron 21379329 rs9921222 chr16 375782 C T 3.79E-04 Bicuspid aortic valve AXIN1 intron 20098615 rs9921222 chr16 375782 C T 1.00E-16 Bone mineral density AXIN1 intron 22504420 rs9921222 chr16 375782 C T 1.13E-04 Bone mineral density (paediatric,total body less head) AXIN1 intron 24945404 rs9921222 chr16 375782 C T 7.95E-05 Bone mineral density (paediatric,skull) AXIN1 intron 24945404 rs7195617 chr16 376781 G A 2.15E-04 Type 2 diabetes AXIN1 intron 17463246 rs7195617 chr16 376781 G A 2.41E-04 Lymphocyte counts AXIN1 intron 22286170 rs11648673 chr16 377794 G A 4.77E-07 Parkinson's disease AXIN1 intron pha002868 rs12445857 chr16 386423 G A 6.80E-08 Urinary metabolites AXIN1 intron 21572414 rs9935993 chr16 401209 T C 1.10E-05 Urinary metabolites AXIN1 intron 21572414 rs7206329 chr16 407800 A G 2.00E-05 Urinary metabolites / / 21572414 rs4984666 chr16 446362 A C 7.67E-05 Type 2 diabetes / / 17463246 rs763151 chr16 449345 G C 5.08E-05 Lymphocyte counts NME4 intron 22286170 rs2266928 chr16 580124 C A 3.00E-11 Mean corpuscular hemoglobin concentration SOLH intron 23263863 rs1981483 chr16 630665 G A 4.00E-06 Disc degeneration (lumbar) PIGQ intron 22993228 rs1045274 chr16 630902 C G 3.00E-26 Progranulin levels PIGQ cds-synon 21087763 rs1045274 chr16 630902 C G 3.00E-26 Myocardial infarction PIGQ cds-synon 21211798 rs112194445 chr16 633354 G GCA 1.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIGQ missense 20877124 rs112194445 chr16 633354 G GCA 7.13E-05 Heart Rate PIGQ missense pha003053 rs710925 chr16 633354 G A 1.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIGQ missense 20877124 rs710925 chr16 633354 G A 7.13E-05 Heart Rate PIGQ missense pha003053 rs2017567 chr16 637212 T C 1.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2017567 chr16 637212 T C 9.00E-06 Disc degeneration (lumbar) / / 22993228 rs2017567 chr16 637212 T C 4.09E-05 Heart Rate / / pha003053 rs4984898 chr16 641164 G T 1.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RAB40C intron 20877124 rs4984898 chr16 641164 G T 6.98E-05 Heart Rate RAB40C intron pha003053 rs7205409 chr16 642610 T C 1.40E-04 Type 2 diabetes RAB40C intron 17463246 rs4144003 chr16 645968 C T 3.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RAB40C intron 20877124 rs4144003 chr16 645968 C T 9.44E-05 Heart Rate RAB40C intron pha003053 rs7190358 chr16 650788 G A 5.50E-06 Urinary metabolites RAB40C intron 21572414 rs7203694 chr16 652941 G A 5.70E-06 Urinary metabolites RAB40C intron 21572414 rs7204088 chr16 661142 T C 2.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RAB40C intron 20877124 rs7204439 chr16 661335 T C 4.00E-06 Disc degeneration (lumbar) RAB40C intron 22993228 rs4984677 chr16 671682 A G 3.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RAB40C intron 20877124 rs4984677 chr16 671682 A G 6.27E-05 Heart Rate RAB40C intron pha003053 rs763014 chr16 675680 T C 5.00E-06 Height RAB40C intron 18391950 rs3752496 chr16 710255 C T 1.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WDR90 intron 20877124 rs1045763 chr16 724084 C T 2.90E-05 Urinary metabolites RHOT2 UTR-3 21572414 rs1045763 chr16 724084 C T 4.63E-04 Coronary heart disease RHOT2 UTR-3 21606135 rs3830140 chr16 725335 G A 7.91E-04 Heart Failure RHBDL1 nearGene-5 pha002885 rs4984913 chr16 740466 A G 2.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs148595483 chr16 774193 G T 0.000000024 Prostate-specific antigen CCDC78 missense 23555315 rs11648796 chr16 792190 A G 1.00E-13 Height / / 20881960 rs12102635 chr16 800821 A G 3.00E-04 Stroke / / pha002887 rs12102635 chr16 800821 A G 1.33E-05 Glucose levels / / pha003058 rs77682584 chr16 839269 G A 0.00035 Breast cancer CHTF18 missense 23555315 rs59706474 chr16 840599 C T 0.0000071 Breast cancer CHTF18 missense 23555315 rs80165523 chr16 847033 C G 0.00014 Prostate cancer (advanced) CHTF18 missense 23555315 rs80165523 chr16 847033 C G 0.00029 Breast cancer CHTF18 missense 23555315 rs689439 chr16 875402 T C 7.39E-05 Pulmonary function in asthmatics / / 23541324 rs556179 chr16 885032 A G 5.43E-05 Pulmonary function in asthmatics / / 23541324 rs561553 chr16 895079 A C 7.11E-05 Pulmonary function in asthmatics / / 23541324 rs4984698 chr16 897566 G A 5.74E-05 Pulmonary function in asthmatics / / 23541324 rs4984698 chr16 897566 G A 8.33E-05 Pulmonary function in asthmatics / / 23541324 rs1001366 chr16 910950 T C 2.08E-04 Multiple complex diseases LMF1 intron 17554300 rs6600234 chr16 914426 C T 6.13E-05 Cognitive performance LMF1 intron 19734545 rs4984719 chr16 979006 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LMF1 intron 22628534 rs12595929 chr16 1007763 C T 5.30E-06 Biliary atresia LMF1 intron 20460270 rs591332 chr16 1045384 G A 4.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs4984627 chr16 1047780 C G 6.90E-05 Diabetic retinopathy / / 21441570 rs4984745 chr16 1049075 C T 1.82E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2744148 chr16 1073552 A G 3.03E-04 Alzheimer's disease (late onset) / / 21379329 rs2744148 chr16 1073552 A G 8.00E-08 Multiple sclerosis / / 21833088 rs453169 chr16 1081188 G A 5.46E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs611862 chr16 1092101 A G 1.16E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2467440 chr16 1109435 C T 3.22E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2056992 chr16 1109518 A C 1.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3751830 chr16 1128406 C T 1.42E-04 Amyotrophic Lateral Sclerosis SSTR5 intron 17827064 rs17135170 chr16 1135403 A G 3.63E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4566170 chr16 1192213 A G 0.000771 Height (Pygmy height) / / 22570615 rs11248859 chr16 1241997 G A 6.18E-05 Response to acetaminophen (hepatotoxicity) CAC/1H intron 21177773 rs3751664 chr16 1254369 C T 6.71E-08 Blood pressure CAC/1H missense 21378095 rs8063574 chr16 1260481 T C 0.00033 Prostate cancer CAC/1H cds-synon 23555315 rs4984639 chr16 1272865 G A 2.53E-04 Smoking cessation TPSG1 cds-synon 24665060 rs11641981 chr16 1313637 T C 4.31E-06 Major depressive disorder / / 22472876 rs8045299 chr16 1316225 A G 2.83E-06 Major depressive disorder / / 22472876 rs9937841 chr16 1320593 G A 1.59E-06 Major depressive disorder / / 22472876 rs35060045 chr16 1327322 G A 6.90E-18 Urinary metabolites / / 21572414 rs4984803 chr16 1349929 G A 6.10E-04 Multiple complex diseases / / 17554300 rs150730105 chr16 1391388 G A 0.0000143 Ratio of free to total prostate-specific antigen BAIAP3 missense 23555315 rs2745001 chr16 1517728 A G 8.04E-05 Multiple complex diseases CLCN7 intron 17554300 rs17808854 chr16 1528387 T C 3.79E-04 Alzheimer's disease / / 24755620 rs13336428 chr16 1532463 G A 1.00E-16 Bone mineral density / / 22504420 rs13336428 chr16 1532463 G A 2.34E-04 Bone mineral density (paediatric,total body less head) / / 24945404 rs13336428 chr16 1532463 G A 5.66E-05 Bone mineral density (paediatric,lower limb) / / 24945404 rs141845288 chr16 1536455 C T 0.00017 Breast cancer PTX4 missense 23555315 rs2248128 chr16 1555589 A G 4.99E-04 Birth weight TELO2 missense 17255346 rs3784819 chr16 1569202 C T 2.28E-04 Multiple complex diseases IFT140 intron 17554300 rs2235642 chr16 1584866 T C 6.59E-04 Parkinson's disease IFT140 intron 17052657 rs11648609 chr16 1616201 C T 9.98E-05 Cognitive test performance IFT140 missense 20125193 rs139619013 chr16 1634241 T C 0.000086 Breast cancer (ER positive) IFT140 missense 23555315 rs139619013 chr16 1634241 T C 0.00027 Breast cancer IFT140 missense 23555315 rs2667684 chr16 1650946 A G 6.13E-04 Suicide attempts in bipolar disorder IFT140 intron 21423239 rs1057983 chr16 1660274 A G 4.64E-04 Parkinson's disease IFT140 intron 17052657 rs6600158 chr16 1672602 T G 3.38E-04 Parkinson's disease CRAMP1L intron 17052657 rs8050447 chr16 1681769 C T 2.60E-04 Parkinson's disease CRAMP1L intron 17052657 rs3169425 chr16 1682281 A G 1.84E-04 Parkinson's disease CRAMP1L cds-synon 17052657 rs2072986 chr16 1691106 T C 4.12E-04 Parkinson's disease CRAMP1L intron 17052657 rs9940288 chr16 1692902 G A 4.79E-04 Type 2 diabetes CRAMP1L intron 17463246 rs3743511 chr16 1705081 A G 3.55E-04 Parkinson's disease CRAMP1L intron 17052657 rs3743511 chr16 1705081 A G 5.99E-04 Stroke CRAMP1L intron pha002886 rs200270407 chr16 1706275 C T 0.0003 Breast cancer (ER positive) CRAMP1L missense 23555315 rs200270407 chr16 1706275 C T 0.0003 Breast cancer CRAMP1L missense 23555315 rs2076416 chr16 1708110 G C 1.70E-04 Parkinson's disease CRAMP1L intron 17052657 rs2272893 chr16 1720844 A G 1.78E-04 Parkinson's disease CRAMP1L intron 17052657 rs2294444 chr16 1724693 G T 5.67E-04 Parkinson's disease CRAMP1L UTR-3 17052657 rs2235487 chr16 1730311 A G 9.82E-04 Obesity (extreme) HN1L intron 21935397 rs2235490 chr16 1743511 T C 3.55E-04 Parkinson's disease HN1L intron 17052657 rs6600162 chr16 1753332 T C 1.71E-04 Parkinson's disease / / 17052657 rs11860440 chr16 1757618 A G 9.69E-05 Parkinson's disease MAPK8IP3 intron 17052657 rs8059926 chr16 1761319 T G 8.85E-04 Suicide attempts in bipolar disorder MAPK8IP3 intron 21423239 rs2235649 chr16 1837406 C T 2.00E-11 Blood metabolite levels NUBP2 intron 24816252 rs1065656 chr16 1838836 C G 1.00E-11 Insulin-like growth factors NUBP2 UTR-3 21216879 rs1065656 chr16 1838836 C G 0.0002924 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NUBP2 UTR-3 23233654 rs1065656 chr16 1838836 C G 2.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) NUBP2 UTR-3 23233662 rs1742450 chr16 1854540 C T 3.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2575357 chr16 1863520 T C 1.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HAGH intron 20877124 rs8045169 chr16 1872459 C T 7.77E-05 Obesity (extreme) HAGH intron 21935397 rs104843 chr16 1873087 C A 5.04E-04 Alzheimer's disease HAGH intron 22005930 rs12325217 chr16 1887108 A T 1.50E-04 Alzheimer's disease FAHD1 intron 22005930 rs12325217 chr16 1887108 A T 0.0005892 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FAHD1 intron 23233654 rs12325217 chr16 1887108 A T 5.89E-04 Methotrexate clearance (acute lymphoblastic leukemia) FAHD1 intron 23233662 rs9806826 chr16 1894912 C T 7.15E-04 Alzheimer's disease C16orf73 cds-synon 22005930 rs9806826 chr16 1894912 C T 0.0005221 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) C16orf73 cds-synon 23233654 rs9806826 chr16 1894912 C T 5.22E-04 Methotrexate clearance (acute lymphoblastic leukemia) C16orf73 cds-synon 23233662 rs1742414 chr16 1898097 C T 8.83E-04 Alzheimer's disease C16orf73 intron 22005930 rs7200137 chr16 1901211 G T 8.49E-05 Cognitive impairment induced by topiramate C16orf73 intron 22091778 rs2492883 chr16 1902105 A G 7.04E-05 Alzheimer's disease C16orf73 intron 22005930 rs2492883 chr16 1902105 A G 0.0005882 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) C16orf73 intron 23233654 rs2492883 chr16 1902105 A G 5.88E-04 Methotrexate clearance (acute lymphoblastic leukemia) C16orf73 intron 23233662 rs10500322 chr16 1904239 T A 5.07E-04 Alzheimer's disease C16orf73 intron 22005930 rs2437745 chr16 1908431 G C 6.58E-05 Alzheimer's disease C16orf73 intron 22005930 rs2437745 chr16 1908431 G C 0.0007827 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) C16orf73 intron 23233654 rs2437745 chr16 1908431 G C 7.83E-04 Methotrexate clearance (acute lymphoblastic leukemia) C16orf73 intron 23233662 rs2437744 chr16 1908451 C T 6.44E-05 Alzheimer's disease C16orf73 intron 22005930 rs2437744 chr16 1908451 C T 0.0007856 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) C16orf73 intron 23233654 rs2437744 chr16 1908451 C T 7.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) C16orf73 intron 23233662 rs388928 chr16 1909657 G C 6.24E-05 Alzheimer's disease C16orf73 intron 22005930 rs388928 chr16 1909657 G C 0.0007971 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) C16orf73 intron 23233654 rs388928 chr16 1909657 G C 7.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) C16orf73 intron 23233662 rs1657095 chr16 1920678 A G 1.51E-04 Lymphocyte counts C16orf73 intron 22286170 rs4420529 chr16 1931056 T C 4.18E-04 Lymphocyte counts LINC00254 intron 22286170 rs911391 chr16 1947016 C A 7.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2429186 chr16 1969939 C T 2.86E-04 White matter integrity / / 22425255 rs2252523 chr16 1997614 A G 2.54E-04 Alcohol dependence RPL3L intron 21314694 rs2252523 chr16 1997614 A G 5.49E-05 Vaspin levels RPL3L intron 22907691 rs2252523 chr16 1997614 A G 0.0000549 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks RPL3L intron 22907730 rs2252523 chr16 1997614 A G 0.0002075 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit RPL3L intron 22907730 rs758335 chr16 2011126 A G 5.70E-04 Heart Failure NDUFB10 intron pha002884 rs1046495 chr16 2036048 T C 1.50E-07 Urinary metabolites GFER UTR-3 21572414 rs17135743 chr16 2036631 A G 1.50E-06 Urinary metabolites GFER UTR-3 21572414 rs9930956 chr16 2085295 C T 5.50E-08 Bicuspid aortic valve SLC9A3R2 intron 20098615 rs11876 chr16 2088312 C T 4.25E-05 Gaucher disease severity SLC9A3R2 UTR-3 22388998 rs2516739 chr16 2097158 G A 1.00E-06 Longevity NTHL1 intron 20834067 rs8059880 chr16 2101591 T C 0.000383 Salmonella-induced pyroptosis TSC2 intron 22837397 rs45502703 chr16 2107113 G C 5.00E-06 Obesity-related traits TSC2 missense 23251661 rs258281 chr16 2191734 A G 2.00E-09 Height / / 21194676 rs258281 chr16 2191734 A G 6.20E-07 Height / / 21194676 rs26868 chr16 2249376 T A 9.00E-17 Height / / 20881960 rs141206306 chr16 2296877 C T 0.00035 Prostate cancer ECI1 missense 23555315 rs141206306 chr16 2296877 C T 0.00046 Prostate cancer (non-advanced prostate cancer) ECI1 missense 23555315 rs155248 chr16 2312453 C T 5.00E-04 Multiple complex diseases RNPS1 intron 17554300 rs2014467 chr16 2336394 T C 7.63E-04 Parkinson's disease ABCA3 intron 21044948 rs17183533 chr16 2345388 T C 3.65E-04 Parkinson's disease ABCA3 intron 21044948 rs11867129 chr16 2365288 G T 9.21E-06 Intelligence ABCA3 intron 21826061 rs8057666 chr16 2415691 G A 2.23E-04 Multiple complex diseases / / 17554300 rs4627351 chr16 2429894 G C 8.45E-05 HIV-1 control ABCA17P intron 20041166 rs6600203 chr16 2445480 T G 1.68E-04 Cognitive decline ABCA17P intron 23732972 rs4497687 chr16 2446021 G A 1.68E-04 Cognitive decline ABCA17P intron 23732972 rs8052046 chr16 2484783 A C 3.61E-04 Cognitive decline CCNF intron 23732972 rs12926827 chr16 2488693 T C 1.32E-04 Cognitive decline CCNF intron 23732972 rs8060813 chr16 2499011 T C 2.68E-04 Cognitive decline CCNF intron 23732972 rs1136062 chr16 2502641 T C 2.45E-04 Cognitive decline CCNF intron 23732972 rs886953 chr16 2882267 G C 2.35E-04 Lymphocyte counts ZG16B UTR-3 22286170 rs732532 chr16 2906934 G A 5.75E-04 Smoking quantity PRSS22 intron 24665060 rs9926873 chr16 2939566 A T 2.25E-05 Intracerebral hemorrhage FLYWCH2 intron 24656865 rs9926873 chr16 2939566 A T 8.70E-06 Intracerebral hemorrhage FLYWCH2 intron 24656865 rs8056903 chr16 2942154 T C 2.31E-05 Intracerebral hemorrhage FLYWCH2 intron 24656865 rs8056903 chr16 2942154 T C 9.27E-06 Intracerebral hemorrhage FLYWCH2 intron 24656865 rs8048185 chr16 2942214 G A 1.14E-05 Intracerebral hemorrhage FLYWCH2 intron 24656865 rs8048185 chr16 2942214 G A 2.92E-05 Intracerebral hemorrhage FLYWCH2 intron 24656865 rs4786348 chr16 2943106 C T 2.30E-05 Intracerebral hemorrhage FLYWCH2 intron 24656865 rs4786348 chr16 2943106 C T 9.40E-06 Intracerebral hemorrhage FLYWCH2 intron 24656865 rs9673454 chr16 2944762 T A,G 1.05E-05 Intracerebral hemorrhage FLYWCH2 intron 24656865 rs9673454 chr16 2944762 T A,G 2.36E-05 Intracerebral hemorrhage FLYWCH2 intron 24656865 rs8044279 chr16 2944857 G A 1.86E-05 Intracerebral hemorrhage FLYWCH2 intron 24656865 rs8044279 chr16 2944857 G A 8.55E-06 Intracerebral hemorrhage FLYWCH2 intron 24656865 rs8048325 chr16 2944912 A T 1.03E-05 Intracerebral hemorrhage FLYWCH2 intron 24656865 rs8048325 chr16 2944912 A T 2.36E-05 Intracerebral hemorrhage FLYWCH2 intron 24656865 rs28715439 chr16 2945671 G A 1.08E-05 Intracerebral hemorrhage FLYWCH2 intron 24656865 rs28715439 chr16 2945671 G A 2.40E-05 Intracerebral hemorrhage FLYWCH2 intron 24656865 rs9935192 chr16 2969856 A C,G,T 0.000174351 Hypertension (early onset hypertension) FLYWCH1 intron 22479346 rs17603186 chr16 2974416 A G 2.65E-04 Lymphocyte counts FLYWCH1 intron 22286170 rs734138 chr16 2999218 C T 4.29E-04 Breast cancer FLYWCH1 UTR-3 20852631 rs8046063 chr16 3003697 C G 7.55E-04 Alzheimer's disease / / 17998437 rs886427 chr16 3023605 A G 6.00E-06 Metabolic syndrome PKMYT1 intron 20694148 rs1004792 chr16 3094261 G A 5.00E-04 Alcohol dependence / / 20201924 rs1004792 chr16 3094261 G A 6.90E-04 Alcohol dependence / / 20201924 rs7199221 chr16 3101639 G A 1.30E-06 Blood cell counts and traits,in red and white blood cells MMP25 intron 21153663 rs13335800 chr16 3112197 A T 9.88E-05 Multiple complex diseases / / 17554300 rs13335800 chr16 3112197 A T 1.19E-04 Gallstones / / 17632509 rs4349147 chr16 3124920 A G 8.00E-06 HIV-1 susceptibility / / 22174851 rs560947 chr16 3185737 T C 9.00E-06 Metabolite levels (X-11787) ZNF213 intron 23934736 rs224188 chr16 3203335 T C 2.00E-04 Crohn's disease / / 17447842 rs1816116 chr16 3214964 A G 4.24E-04 Multiple complex diseases / / 17554300 rs2741902 chr16 3216551 G C 2.54E-04 Multiple complex diseases / / 17554300 rs1002965 chr16 3230472 G C 8.85E-04 Coronary Artery Disease / / 17634449 rs1076573 chr16 3230888 T G 6.35E-04 Coronary Artery Disease / / 17634449 rs8044035 chr16 3251522 G A 7.60E-05 Cholesterol / / pha003073 rs2550401 chr16 3266071 A G,T 7.60E-05 Parkinson's disease (age of onset) / / 19772629 rs2741916 chr16 3266552 G A 2.30E-05 Parkinson's disease (age of onset) / / 19772629 rs2741919 chr16 3292896 C T 2.30E-05 Urinary metabolites MEFV UTR-3 21572414 rs11466018 chr16 3304739 A G 5.34E-09 HDL cholesterol MEFV missense 23063622 rs220376 chr16 3328518 G T 0.00082 Salmonella-induced pyroptosis / / 22837397 rs188761 chr16 3338343 G C 1.60E-05 Urinary metabolites ZNF263 intron 21572414 rs12325636 chr16 3364867 G C 1.10E-06 Urinary metabolites ZNF75A intron 21572414 rs17136316 chr16 3366141 A G 2.30E-05 Urinary metabolites ZNF75A intron 21572414 rs17136317 chr16 3366513 T A 1.20E-05 Urinary metabolites ZNF75A intron 21572414 rs17136317 chr16 3366513 T A 6.88E-04 Lymphocyte counts ZNF75A intron 22286170 rs17611827 chr16 3367061 G A 1.45E-05 Attention deficit hyperactivity disorder ZNF75A intron 20732625 rs17611827 chr16 3367061 G A 2.10E-05 Urinary metabolites ZNF75A intron 21572414 rs6501170 chr16 3377582 T C 7.13E-05 Cholesterol / / pha003073 rs6501170 chr16 3377582 T C 3.63E-06 ldl cholesterol / / pha003076 rs6501170 chr16 3377582 T C 2.59E-05 Cholesterol / / pha003078 rs1968055 chr16 3392053 T C 4.50E-04 Type 2 diabetes / / 17463246 rs11646593 chr16 3395190 T C 1.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs7200928 chr16 3397554 A T 1.80E-05 Urinary metabolites / / 21572414 rs1218762 chr16 3405986 G A 4.95E-05 IgE levels in asthmatics (D.f. specific) OR2C1 missense 23967269 rs7196196 chr16 3411855 C A 6.92E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs7196196 chr16 3411855 C A 1.83E-05 Blood Pressure / / pha003040 rs7188903 chr16 3412861 A G 5.01E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs11648996 chr16 3437268 G A 3.09E-04 Suicide attempts in bipolar disorder ZNF434 intron 21423239 rs2074366 chr16 3439676 G A 2.51E-05 Blood Pressure ZNF434 intron pha003040 rs7203180 chr16 3470827 C T 5.74E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs171634 chr16 3478866 G A 5.08E-07 Smoking cessation / / 18519826 rs37824 chr16 3486236 C T 4.98E-06 Smoking cessation ZNF597 UTR-3 18519826 rs12737 chr16 3486285 C A 2.86E-04 Multiple complex diseases / / 17554300 rs12737 chr16 3486285 C A 2.20E-06 Urinary metabolites / / 21572414 rs2270496 chr16 3491067 G C 2.01E-04 Multiple complex diseases ZNF597 intron 17554300 rs2270496 chr16 3491067 G C 1.50E-04 Insulin resistance ZNF597 intron 21901158 rs4786416 chr16 3498951 C T 1.55E-05 Blood Pressure /A60 intron pha003040 rs40363 chr16 3509056 G A 3.00E-06 Tuberculosis /A60 intron 24057671 rs2074524 chr16 3535028 G A 6.20E-06 Urinary metabolites /A60 UTR-3 21572414 rs11077346 chr16 3550147 C A 8.75E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs9790 chr16 3586230 C T 1.00E-05 Gamma gluatamyl transferase levels (interaction with age) CLUAP1 missense 22010049 rs12596890 chr16 3588068 A G 9.20E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs758747 chr16 3627358 C T 0.00065 Breast cancer NLRC3 UTR-5 23555315 rs3810813 chr16 3639827 G A 0.00035 Breast cancer SLX4 missense 23555315 rs714181 chr16 3640274 G A 6.76E-07 Paclitaxel sensitivity in NCI60 cancer cell lines SLX4 missense 21314952 rs146901714 chr16 3642817 C T 0.00006 Breast cancer SLX4 missense 23555315 rs9928274 chr16 3701824 T C 7.99E-13 Cholesterol,total D/SE1 nearGene-5 23063622 rs2074799 chr16 3705647 C T 0.00000119 Cholesterol,total D/SE1 intron 23063622 rs8176919 chr16 3706697 G A 4.32E-13 Cholesterol,total D/SE1 missense 23063622 rs8176938 chr16 3707091 C G 4.35E-04 Suicide attempts in bipolar disorder D/SE1 cds-synon 21423239 rs2791 chr16 3708170 C A,G,T 5.52E-04 Suicide attempts in bipolar disorder TRAP1 missense 21423239 rs2074805 chr16 3724857 A T 5.77E-04 Obesity (extreme) TRAP1 intron 21935397 rs2158962 chr16 3738027 A G 1.10E-05 Adverse response to lamotrigine and phenytoin TRAP1 intron 22379998 rs56240109 chr16 3769581 A G 5.00E-06 Metabolite levels (HVA/5-HIAA ratio) / / 23319000 rs3751845 chr16 3778337 G A 9.00E-06 Obesity-related traits CREBBP cds-synon 23251661 rs129963 chr16 3796147 T C 9.00E-06 QT interval (interaction) CREBBP intron 23459443 rs130021 chr16 3832471 A G 7.43E-04 Multiple complex diseases CREBBP intron 17554300 rs130021 chr16 3832471 A G 2.00E-04 Cognitive impairment induced by topiramate CREBBP intron 22091778 rs3789033 chr16 3839535 T C 2.48E-05 Cognitive test performance CREBBP intron 20125193 rs2239316 chr16 3913995 A G 8.94E-05 Cognitive test performance CREBBP intron 20125193 rs12446940 chr16 3962620 A G 4.47E-05 Cognitive performance / / 19734545 rs8049367 chr16 3980445 T C 1.20E-05 Hypertension / / 22384028 rs8049367 chr16 3980445 T C 8.74E-05 Orofacial clefts / / 22863734 rs11640300 chr16 3992783 C T 1.60E-05 Major depressive disorder / / 22472876 rs17256183 chr16 3994696 T C 2.02E-05 Major depressive disorder / / 22472876 rs7197403 chr16 3998630 T C 5.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7197403 chr16 3998630 T C 5.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2283491 chr16 3999584 T C 6.00E-04 Major depressive disorder / / 21042317 rs1978300 chr16 4002022 G A 6.21E-04 Type 2 diabetes / / 17463246 rs2531995 chr16 4013467 C T 4.00E-08 Obesity ADCY9 UTR-3 23563607 rs2531995 chr16 4013467 C T 7.00E-08 Body mass index ADCY9 UTR-3 24861553 rs11543317 chr16 4016049 G A 6.11E-05 Response to statin treatment (atorvastatin),change in cholesterol levels ADCY9 cds-synon 20031582 rs2238436 chr16 4025385 T G 1.04E-04 Obesity (extreme) ADCY9 intron 21935397 rs2072346 chr16 4027423 C A,G,T 5.22E-04 Obesity (extreme) ADCY9 intron 21935397 rs2240735 chr16 4027605 C T 1.03E-04 Obesity (extreme) ADCY9 cds-synon 21935397 rs2238439 chr16 4031348 A G 4.53E-04 Obesity (extreme) ADCY9 intron 21935397 rs2238439 chr16 4031348 A G 2.61E-04 Heart Failure ADCY9 intron pha002885 rs2531982 chr16 4033097 A G 1.64E-04 Obesity (extreme) ADCY9 intron 21935397 rs2230739 chr16 4033436 T C 6.25E-05 Pulmonary function in asthmatics ADCY9 missense 23541324 rs2444217 chr16 4038387 G A 9.00E-08 Body mass index ADCY9 intron 20935630 rs2072338 chr16 4056927 A G 6.01E-05 Cognitive test performance ADCY9 intron 20125193 rs12921697 chr16 4059746 C T 6.11E-05 Major depressive disorder ADCY9 intron 19107115 rs2239310 chr16 4060661 A G 9.30E-05 Lung function (forced vital capacity) ADCY9 intron pha003104 rs17136692 chr16 4068813 G A 9.57E-05 Postoperative ventricular dysfunction ADCY9 intron 21980348 rs10775349 chr16 4079823 G C 6.13E-04 Alcohol dependence ADCY9 intron 21314694 rs2601828 chr16 4103871 T C 1.00E-06 Partial epilepsies ADCY9 intron 20522523 rs2601828 chr16 4103871 T C 1.04E-06 Epilepsy ADCY9 intron 22116939 rs437115 chr16 4156423 T C 1.00E-04 Cognitive impairment induced by topiramate ADCY9 intron 22091778 rs9927767 chr16 4168170 T A 8.42E-04 Alcohol dependence ADCY9 nearGene-5 21314694 rs430537 chr16 4179531 G A 8.94E-04 Type 2 diabetes / / 17463246 rs231618 chr16 4184208 T C 8.49E-04 Type 2 diabetes / / 17463246 rs81647 chr16 4197370 G A 5.53E-05 Longevity / / 21612516 rs6500583 chr16 4206013 G A 9.28E-04 Insulin resistance / / 21901158 rs8051399 chr16 4242093 C T 3.51E-05 Diabetes Mellitus SRL UTR-3 pha003060 rs9922685 chr16 4250023 A G 1.80E-05 Urinary metabolites SRL intron 21572414 rs879151 chr16 4250915 C A 2.83E-04 Alcohol dependence SRL intron 21314694 rs879151 chr16 4250915 C A 1.30E-05 Urinary metabolites SRL intron 21572414 rs75825892 chr16 4257313 C T 5.00E-06 Obesity-related traits SRL intron 23251661 rs11646632 chr16 4258091 C T 7.95E-05 IgE levels SRL intron 22075330 rs4785955 chr16 4297651 G T 4.90E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LOC100507501 intron 22566498 rs374191922 chr16 4349110 CT C,CAA,CCC,CCCC 2.32E-04 Obesity (extreme) / / 21935397 rs561240673 chr16 4349110 C CA 2.32E-04 Obesity (extreme) / / 21935397 rs9928772 chr16 4349110 C A 2.32E-04 Obesity (extreme) / / 21935397 rs3848370 chr16 4360314 G C 3.99E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3747572 chr16 4385732 A G 0.000013 Pancreatic cancer and survival GLIS2 intron 22665904 rs611704 chr16 4395241 A G 5.96E-04 Aortic root size PAM16 intron 21223598 rs10974 chr16 4404620 C T 9.53E-05 Meningococcal disease CORO7 UTR-3 20694013 rs3747575 chr16 4415410 G T 9.46E-05 Coronary Artery Disease CORO7 intron 17634449 rs12103302 chr16 4440828 G A 0.000706 Height (Pygmy height) CORO7 intron 22570615 rs1139653 chr16 4484396 A T 1.41E-06 Waist-hip ratio D/JA3 missense 20935629 rs2304634 chr16 4500544 C T 0.000079 Schizophrenia D/JA3 intron 23637625 rs7188421 chr16 4507063 C G 4.97E-04 Multiple complex diseases D/JA3 nearGene-3 17554300 rs17137051 chr16 4521749 A G 1.87E-16 Lymphocyte counts NMRAL1 intron 22286170 rs1362626 chr16 4549226 C A,G 6.29E-05 Lymphocyte counts HMOX2 intron 22286170 rs3747600 chr16 4586222 A G 3.20E-06 Schizophrenia C16orf5 intron 21791550 rs3747600 chr16 4586222 A G 3.00E-05 Schizophrenia C16orf5 intron 21926974 rs3747600 chr16 4586222 A G 0.0000032 Psychosis C16orf5 intron 23164818 rs1486451 chr16 4607341 T G 5.69E-04 Multiple complex diseases C16orf96 intron 17554300 rs7199114 chr16 4638559 T A 6.21E-04 Suicide attempts in bipolar disorder C16orf96 intron 21423239 rs8050907 chr16 4646878 G A 7.00E-07 Obesity-related traits C16orf96 intron 23251661 rs7195763 chr16 4649300 C G 1.46E-06 Obesity-related traits C16orf96 missense 23251661 rs13335998 chr16 4651921 G T 1.67E-06 Obesity-related traits / / 23251661 rs1684609 chr16 4676595 A G 1.50E-04 Multiple complex diseases MGRN1 intron 17554300 rs6500627 chr16 4692113 G A 9.13E-04 Acute lung injury MGRN1 intron 22295056 rs1659495 chr16 4719981 G A 7.03E-05 Serum albumin level MGRN1 intron pha003084 rs715109 chr16 4721468 T C 1.07E-05 Serum albumin level MGRN1 intron pha003084 rs17137208 chr16 4766597 A C 6.00E-06 Asthma ANKS3 intron 21790008 rs4786548 chr16 4815425 T C 5.07E-05 Smoking initiation ZNF500 intron 24665060 rs11861487 chr16 4872760 C T 8.47E-05 Hemoglobin GLYR1 intron pha003098 rs11861487 chr16 4872760 C T 9.19E-06 Erythrocyte counts GLYR1 intron pha003099 rs2075467 chr16 4873242 C T 7.74E-04 Smoking initiation GLYR1 intron 24665060 rs2075467 chr16 4873242 C T 9.18E-05 Hemoglobin GLYR1 intron pha003098 rs2251666 chr16 4923091 G A 5.86E-06 Hemoglobin UBN1 intron pha003098 rs2251666 chr16 4923091 G A 2.19E-05 Erythrocyte counts UBN1 intron pha003099 rs17137364 chr16 4925291 T G 4.63E-04 Smoking initiation UBN1 cds-synon 24665060 rs1876359 chr16 4930100 C T 7.60E-06 Hemoglobin UBN1 cds-synon pha003098 rs1876359 chr16 4930100 C T 4.33E-05 Erythrocyte counts UBN1 cds-synon pha003099 rs17137389 chr16 4933907 T C 2.22E-04 Multiple complex diseases PPL cds-synon 17554300 rs1049206 chr16 4935146 C T 7.23E-05 Body Mass Index PPL cds-synon pha002896 rs1049206 chr16 4935146 C T 6.10E-06 Hemoglobin PPL cds-synon pha003098 rs1049206 chr16 4935146 C T 1.60E-05 Erythrocyte counts PPL cds-synon pha003099 rs741769 chr16 4936205 G T 3.56E-04 Multiple complex diseases PPL intron 17554300 rs9635542 chr16 5001380 A G 4.00E-06 Lung cancer-asbestos exposure interaction / / 22637743 rs9635542 chr16 5001380 A G 3.27E-07 Autism / / 22843504 rs34924084 chr16 5003074 C A 2.00E-06 Metabolite levels (HVA/MHPG ratio) / / 23319000 rs7191632 chr16 5026484 T C 4.33E-05 Body Mass Index SEC14L5 intron pha002896 rs2908646 chr16 5031844 A G 9.17E-06 Osteoarthritis SEC14L5 intron 22763110 rs7205279 chr16 5095599 C T 0.000616167 Hypertension (early onset hypertension) C16orf89 intron 22479346 rs11642475 chr16 5200515 A T 6.64E-04 Type 2 diabetes / / 17463246 rs2333967 chr16 5225061 C T 4.20E-04 Tourette syndrome / / 22889924 rs17137672 chr16 5238887 T A 7.89E-05 Multiple complex diseases / / 17554300 rs1881335 chr16 5266419 A C 5.99E-06 Parkinson's disease / / 21812969 rs9925078 chr16 5269253 T G 5.14E-05 Parkinson's disease / / 21812969 rs12600138 chr16 5275418 A G 2.05E-05 Aging (time to event) / / 21782286 rs12919132 chr16 5276231 G A 4.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs2178181 chr16 5281755 C G 5.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs9745912 chr16 5294727 T G 2.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs1881323 chr16 5305484 A C 7.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs4786022 chr16 5355667 T C 2.14E-04 Multiple complex diseases / / 17554300 rs2005316 chr16 5373940 C T 2.40E-04 Coronary heart disease / / 21606135 rs1358489 chr16 5409673 C T 1.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs490052 chr16 5415915 A G 5.49E-05 Bipolar disorder / / 19488044 rs9926610 chr16 5464801 T A 5.42E-05 Bipolar disorder / / 22925353 rs582567 chr16 5489632 A G 4.46E-05 Suicide attempts in bipolar disorder / / 21423239 rs547564 chr16 5507616 G C 1.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs8054024 chr16 5530617 A G 8.57E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4786694 chr16 5540441 G C 1.31E-05 Multiple complex diseases / / 17554300 rs6500691 chr16 5549429 A G 0.0002541 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6500691 chr16 5549429 A G 2.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12923969 chr16 5555136 A T 1.95E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12923969 chr16 5555136 A T 4.16E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs13337426 chr16 5559149 C T 5.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13337426 chr16 5559149 C T 2.34E-05 Body Mass Index / / pha003022 rs11639680 chr16 5560904 G A 3.32E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11639680 chr16 5560904 G A 5.92E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs8047061 chr16 5563621 T C 6.40E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4511535 chr16 5566392 G A 2.15E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4511535 chr16 5566392 G A 3.58E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2089406 chr16 5576745 G T 2.80E-05 Bone mineral density (spine) / / 19079262 rs11076922 chr16 5583318 G A 9.51E-04 Type 2 diabetes / / 17463246 rs870288 chr16 5585852 A G 1.00E-08 Phospholipid levels (plasma) / / 22359512 rs870288 chr16 5585852 A G 9.00E-06 Subcutaneous adipose tissue / / 22589738 rs3893314 chr16 5586594 T C 8.87E-04 Multiple complex diseases / / 17554300 rs8059013 chr16 5587408 T C 5.94E-04 Multiple complex diseases / / 17554300 rs1352149 chr16 5588083 A T 8.28E-04 Multiple complex diseases / / 17554300 rs2171226 chr16 5588451 C T 6.20E-04 Multiple complex diseases / / 17554300 rs11639793 chr16 5598466 G C 3.65E-04 Multiple complex diseases / / 17554300 rs3927119 chr16 5604602 A G 5.90E-05 Bone mineral density (spine) / / 19079262 rs1969139 chr16 5611121 C T 1.38E-04 Bone mineral traits,in men / / 21427758 rs1969139 chr16 5611121 C T 2.88E-05 Bone mineral traits,in men / / 21427758 rs1969139 chr16 5611121 C T 3.62E-04 Bone mineral traits,in men / / 21427758 rs6500698 chr16 5616334 G A 5.56E-04 Type 2 diabetes / / 17463246 rs8057236 chr16 5622467 T C 6.18E-05 Type 2 diabetes / / 17463246 rs11643962 chr16 5629357 C G 4.80E-04 Type 2 diabetes / / 17463246 rs1860304 chr16 5631166 A G 3.97E-04 Type 2 diabetes / / 17463246 rs17138116 chr16 5631226 G C 7.33E-05 Multiple complex diseases / / 17554300 rs4786729 chr16 5646708 G C 9.65E-04 Insulin resistance / / 21901158 rs1011490 chr16 5667482 A G 4.26E-04 Type 2 diabetes / / 17463246 rs7202041 chr16 5671792 T A 2.00E-04 Pancreatic cancer / / 23180869 rs12595932 chr16 5678886 C T 3.01E-04 Multiple complex diseases / / 17554300 rs878514 chr16 5688375 A G 0.000420588 Hypertension (early onset hypertension) / / 22479346 rs9924080 chr16 5704598 G A 1.33E-04 Multiple complex diseases / / 17554300 rs1860307 chr16 5720561 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7205413 chr16 5730176 G C 3.22E-04 Depression (quantitative trait) / / 20800221 rs4786751 chr16 5731945 C G 4.56E-04 Depression (quantitative trait) / / 20800221 rs17138366 chr16 5732416 C G 4.26E-04 Depression (quantitative trait) / / 20800221 rs17138369 chr16 5732466 C T 4.27E-04 Depression (quantitative trait) / / 20800221 rs9929433 chr16 5732697 A C 4.26E-04 Depression (quantitative trait) / / 20800221 rs8056887 chr16 5735074 T C 9.09E-04 Depression (quantitative trait) / / 20800221 rs8063894 chr16 5739204 G A 9.66E-04 Depression (quantitative trait) / / 20800221 rs4786754 chr16 5740007 G C 9.78E-04 Depression (quantitative trait) / / 20800221 rs766209 chr16 5751221 C T 6.29E-04 Prostate cancer mortality / / 20978177 rs4786060 chr16 5752636 C T 6.29E-04 Prostate cancer mortality / / 20978177 rs1558221 chr16 5753180 C T 6.29E-04 Prostate cancer mortality / / 20978177 rs17432899 chr16 5753958 A T 6.29E-04 Prostate cancer mortality / / 20978177 rs2041255 chr16 5755043 A G 9.00E-04 Prostate cancer mortality / / 20978177 rs12933690 chr16 5758532 G A 4.40E-04 Prostate cancer mortality / / 20978177 rs12922826 chr16 5758907 C G,T 3.79E-04 Prostate cancer mortality / / 20978177 rs12447242 chr16 5759019 C T 3.89E-04 Prostate cancer mortality / / 20978177 rs12447100 chr16 5759070 G A 5.31E-04 Prostate cancer mortality / / 20978177 rs7192139 chr16 5762949 G A 1.30E-04 Endometrial cancer / / 24096698 rs7192139 chr16 5762949 G A 5.77E-04 Endometrial cancer / / 24096698 rs9302806 chr16 5793163 G A 9.70E-04 Multiple complex diseases / / 17554300 rs9302806 chr16 5793163 G A 4.67E-04 Insulin resistance / / 21901158 rs8062586 chr16 5793684 T A 7.90E-04 Multiple complex diseases / / 17554300 rs9941024 chr16 5794312 T C 8.37E-04 Multiple complex diseases / / 17554300 rs17791105 chr16 5810130 G A 1.57E-04 Multiple complex diseases / / 17554300 rs8062590 chr16 5815912 C T 1.27E-04 Rheumatoid arthritis / / 21452313 rs8061354 chr16 5815953 G T 1.45E-04 Rheumatoid arthritis / / 21452313 rs1865814 chr16 5817372 A C 7.16E-05 Substance dependence / / 21818250 rs9933150 chr16 5831312 C T 1.36E-04 Rheumatoid arthritis / / 21452313 rs11861310 chr16 5835841 C T 7.93E-04 Multiple complex diseases / / 17554300 rs9926798 chr16 5835883 C T 8.38E-04 Multiple complex diseases / / 17554300 rs11076972 chr16 5837835 A T 4.34E-04 Multiple complex diseases / / 17554300 rs4349145 chr16 5842171 C G 6.35E-04 Multiple complex diseases / / 17554300 rs17138652 chr16 5843087 G A 6.33E-04 Multiple complex diseases / / 17554300 rs8059231 chr16 5850793 G T 1.41E-04 Multiple complex diseases / / 17554300 rs11642829 chr16 5853760 C A 5.44E-05 Insulin resistance / / 21901158 rs1865818 chr16 5856151 G A,C 4.35E-04 Schizophrenia / / 21674006 rs6500728 chr16 5900889 T C 7.15E-05 Pulmonary function in asthmatics / / 23541324 rs1436382 chr16 5908224 C T 7.39E-04 Type 2 diabetes / / 17463246 rs1816549 chr16 5909380 C T 4.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs1529917 chr16 5910763 C T 2.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs11076977 chr16 5910875 G A 1.15E-04 Type 2 diabetes / / 17463246 rs17138775 chr16 5918769 T C 7.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs17138775 chr16 5918769 T C 3.34E-04 Myocardial Infarction / / pha002873 rs2343338 chr16 5919051 A G 7.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs8053579 chr16 5920217 C G 4.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs11076983 chr16 5933559 T A 7.58E-04 Multiple complex diseases / / 17554300 rs2005820 chr16 5941964 C A 2.61E-04 Alzheimer's disease / / 24755620 rs9926429 chr16 5944583 A G 3.00E-04 Alzheimer's disease / / 24755620 rs12446993 chr16 5949350 C T 1.10E-04 Alzheimer's disease (late onset) / / 21379329 rs17138815 chr16 5951424 C T 4.49E-04 Alcohol dependence / / 20201924 rs3848386 chr16 5952157 A G 8.96E-04 Type 2 diabetes / / 17463246 rs1012259 chr16 5952909 G A 1.00E-04 Asthma (childhood onset) / / 21359210 rs9928116 chr16 5961030 A G 0.000573 Salmonella-induced pyroptosis / / 22837397 rs7187360 chr16 5984225 G C 0.000025 Salmonella-induced pyroptosis / / 22837397 rs7187360 chr16 5984225 G C 9.17E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10521082 chr16 5986703 A G 9.92E-04 Type 2 diabetes / / 17463246 rs7185467 chr16 5987351 C A 3.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8057201 chr16 5990871 C T 0.00003 Salmonella-induced pyroptosis / / 22837397 rs2343344 chr16 6019941 G A 4.24E-05 Suicide attempts in bipolar disorder / / 21423239 rs735919 chr16 6022280 G A 7.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs729533 chr16 6022750 T G 1.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs729533 chr16 6022750 T G 9.00E-06 Urinary metabolites / / 21572414 rs729532 chr16 6022768 C G 3.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs729532 chr16 6022768 C G 2.40E-06 Urinary metabolites / / 21572414 rs1076380 chr16 6023195 G A,C 1.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs2003545 chr16 6023520 C A 3.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs887265 chr16 6023892 T C 2.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs887268 chr16 6024123 A G 7.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs12931802 chr16 6024311 T C 1.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs4786795 chr16 6025124 A G 5.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs9930914 chr16 6025639 G T 4.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs11863516 chr16 6026219 C A 6.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs12919657 chr16 6026393 C T 4.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs17139042 chr16 6027738 C T 6.31E-04 Multiple complex diseases / / 17554300 rs2880608 chr16 6028451 G A 1.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs4640184 chr16 6029938 G C 9.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs8052848 chr16 6036560 C T 9.70E-04 Coronary Artery Disease / / 17634449 rs17139085 chr16 6050073 G A 1.50E-09 Biliary atresia / / 20460270 rs2059273 chr16 6051143 C T 4.90E-04 Breast cancer and prostate cancer / / 17903305 rs955905 chr16 6065358 A G 6.40E-06 Personality dimensions / / 21173776 rs4786804 chr16 6071498 G A 3.04E-04 Type 2 diabetes RBFOX1 intron 17463246 rs17139255 chr16 6107174 T G 3.45E-05 Interstitial lung disease RBFOX1 intron 23583980 rs1906060 chr16 6108430 C T 4.00E-06 Intraocular pressure RBFOX1 intron 24002674 rs8063300 chr16 6109577 A G 1.00E-04 Information processing speed RBFOX1 intron 21130836 rs1424118 chr16 6111073 C G 8.30E-04 Type 2 diabetes and 6 quantitative traits RBFOX1 intron 17848626 rs6500744 chr16 6113661 C T 3.00E-06 Conduct disorder (interaction) RBFOX1 intron 18846501 rs17139303 chr16 6115551 G A 1.04E-04 Smoking cessation RBFOX1 intron 18519826 rs17192650 chr16 6116396 G A 2.99E-04 Alcohol consumption (maxi-drinks) RBFOX1 intron 24277619 rs4786811 chr16 6132787 A G 3.71E-06 Bipolar disorder,schizoaffective RBFOX1 intron 19567891 rs4786815 chr16 6135185 C A 9.21E-04 Type 2 diabetes RBFOX1 intron 17463246 rs9936351 chr16 6141379 T C 6.50E-04 Response to cytidine analogues (gemcitabine) RBFOX1 intron 24483146 rs1906058 chr16 6144648 G T 1.91E-04 Alzheimer's disease (late onset) RBFOX1 intron 21379329 rs4786816 chr16 6148030 A G 2.00E-06 Obesity-related traits RBFOX1 intron 23251661 rs4786816 chr16 6148030 A G 6.05E-04 Smoking quantity RBFOX1 intron 24665060 rs7403856 chr16 6156326 A G 2.00E-06 Obesity-related traits RBFOX1 intron 23251661 rs7403856 chr16 6156326 A G 9.00E-06 Obesity-related traits RBFOX1 intron 23251661 rs7197461 chr16 6158261 A G 2.19E-04 Type 2 diabetes RBFOX1 intron 17463246 rs8052288 chr16 6160840 G A 8.98E-04 Myopia (pathological) RBFOX1 intron 21095009 rs2035593 chr16 6161995 G C 9.74E-05 Type 2 diabetes RBFOX1 intron 17463246 rs2035593 chr16 6161995 G C 1.94E-04 Multiple complex diseases RBFOX1 intron 17554300 rs2035593 chr16 6161995 G C 1.66E-04 Smoking cessation RBFOX1 intron 18519826 rs9921786 chr16 6163124 C T 3.31E-04 Type 2 diabetes RBFOX1 intron 17463246 rs11860225 chr16 6164301 G A 4.06E-04 Acute lung injury RBFOX1 intron 22295056 rs11866746 chr16 6165584 A G 2.81E-04 Acute lung injury RBFOX1 intron 22295056 rs747399 chr16 6166791 G A 3.88E-04 Insulin resistance RBFOX1 intron 21901158 rs8048198 chr16 6167331 C T 3.37E-04 Acute lung injury RBFOX1 intron 22295056 rs749467 chr16 6167496 C T 4.33E-04 Insulin resistance RBFOX1 intron 21901158 rs749467 chr16 6167496 C T 0.0002 Migraine RBFOX1 intron 22678113 rs8052721 chr16 6167649 C T 3.37E-04 Acute lung injury RBFOX1 intron 22295056 rs11643187 chr16 6168155 T A 3.37E-04 Acute lung injury RBFOX1 intron 22295056 rs9646295 chr16 6170093 G C 1.03E-04 Smoking cessation RBFOX1 intron 18519826 rs12932012 chr16 6170565 C T 2.53E-04 Acute lung injury RBFOX1 intron 22295056 rs4786821 chr16 6173543 A C,T 8.27E-04 Insulin resistance RBFOX1 intron 21901158 rs12924882 chr16 6180907 T C 1.85E-05 Common variable immunodeficiency RBFOX1 intron 21497890 rs12922855 chr16 6184390 T C 7.69E-04 Type 2 diabetes RBFOX1 intron 20818381 rs11865230 chr16 6191409 C T 8.06E-04 Type 2 diabetes RBFOX1 intron 20818381 rs12924838 chr16 6197835 G A 6.79E-05 Serum metabolites RBFOX1 intron 19043545 rs12449228 chr16 6205324 C T 1.37E-04 Lung function (forced expiratory volume in 1 second) RBFOX1 intron 24023788 rs12449228 chr16 6205324 C T 1.80E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) RBFOX1 intron 24023788 rs7191026 chr16 6206550 A C 1.94E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) RBFOX1 intron 24023788 rs12930756 chr16 6207842 G T 1.47E-04 Lung function (forced vital capacity) RBFOX1 intron 24023788 rs12930756 chr16 6207842 G T 8.00E-05 Lung function (forced expiratory volume in 1 second) RBFOX1 intron 24023788 rs17139483 chr16 6213749 C T 0.0001 Migraine RBFOX1 intron 22678113 rs17139483 chr16 6213749 C T 1.76E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) RBFOX1 intron 24023788 rs17139608 chr16 6281175 C T 3.02E-07 Multiple complex diseases RBFOX1 intron 17554300 rs17217621 chr16 6282073 C T 3.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBFOX1 intron 20877124 rs17817199 chr16 6283228 C T 2.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBFOX1 intron 20877124 rs17817199 chr16 6283228 C T 3.81E-04 Response to cytidine analogues (gemcitabine) RBFOX1 intron 24483146 rs11077017 chr16 6284887 G A 1.45E-04 Response to cytidine analogues (gemcitabine) RBFOX1 intron 24483146 rs4474682 chr16 6285091 T G 8.45E-04 Multiple complex diseases RBFOX1 intron 17554300 rs13336322 chr16 6291019 G A,C 7.60E-05 Bipolar disorder and schizophrenia RBFOX1 intron 20889312 rs13336322 chr16 6291019 G A,C 9.10E-05 Bipolar Disorder RBFOX1 intron pha002858 rs4786847 chr16 6310233 G A 9.00E-10 Smoking behavior RBFOX1 intron 20418888 rs7188257 chr16 6314935 C T 3.15E-05 Bipolar disorder RBFOX1 intron 19488044 rs7188257 chr16 6314935 C T 7.46E-05 Bipolar Disorder RBFOX1 intron pha002858 rs2880916 chr16 6336185 G C 1.00E-04 Multiple complex diseases RBFOX1 intron 17554300 rs716508 chr16 6336912 C T 6.40E-05 Osteoarthritis RBFOX1 intron 19508968 rs716508 chr16 6336912 C T 7.14E-06 Alzheimer's disease (late onset) RBFOX1 intron 21379329 rs4255787 chr16 6338221 T C 2.64E-04 Multiple complex diseases RBFOX1 intron 17554300 rs4255788 chr16 6338235 T C 2.65E-04 Multiple complex diseases RBFOX1 intron 17554300 rs17220445 chr16 6338473 G T 1.77E-04 Multiple complex diseases RBFOX1 intron 17554300 rs4786850 chr16 6345924 C A 5.30E-05 Bipolar disorder RBFOX1 intron 19488044 rs4786850 chr16 6345924 C A 8.39E-05 Osteoarthritis RBFOX1 intron 19508968 rs4786850 chr16 6345924 C A 4.20E-04 Alzheimer's disease (late onset) RBFOX1 intron 21379329 rs4786850 chr16 6345924 C A 3.70E-05 Bipolar Disorder RBFOX1 intron pha002858 rs1548842 chr16 6356187 T G 4.68E-05 HIV-1 control RBFOX1 intron 20041166 rs1548842 chr16 6356187 T G 5.88E-05 HIV-1 viral setpoint RBFOX1 intron 21490045 rs17139872 chr16 6372546 C T 1.16E-04 Multiple complex diseases RBFOX1 intron 17554300 rs1420029 chr16 6377499 A G 5.47E-04 Multiple complex diseases RBFOX1 intron 17554300 rs11077032 chr16 6413744 G T 1.90E-05 Information processing speed RBFOX1 intron 21130836 rs2795554 chr16 6417177 A G 4.43E-04 Multiple complex diseases RBFOX1 intron 17554300 rs12446308 chr16 6417933 A G 2.88E-08 Lung cancer RBFOX1 intron 19414679 rs9745932 chr16 6419123 C G 8.89E-04 Multiple complex diseases RBFOX1 intron 17554300 rs17140050 chr16 6428239 C T 3.65E-04 Multiple complex diseases RBFOX1 intron 17554300 rs12051005 chr16 6436716 C T 9.77E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBFOX1 intron 20877124 rs877254 chr16 6437672 T C 1.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBFOX1 intron 20877124 rs2109459 chr16 6440752 C A,G,T 5.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBFOX1 intron 20877124 rs17140100 chr16 6441560 A C 3.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBFOX1 intron 20877124 rs4786865 chr16 6442184 C T 2.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBFOX1 intron 20877124 rs9931078 chr16 6448291 A G 4.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBFOX1 intron 20877124 rs1003677 chr16 6456763 A G 8.61E-05 Orofacial clefts RBFOX1 intron 22863734 rs9938361 chr16 6505291 C T 4.46E-06 Acute lymphoblastic leukemia (childhood) RBFOX1 intron 22076464 rs17440477 chr16 6512733 T A 0.0000171 HDL cholesterol particle diameter RBFOX1 intron 23263444 rs1024697 chr16 6514039 T A 0.00000916 HDL cholesterol particle diameter RBFOX1 intron 23263444 rs8047986 chr16 6521006 C T 2.10E-05 Smoking behavior RBFOX1 intron 20418888 rs809704 chr16 6521768 A T 1.30E-05 Smoking behavior RBFOX1 intron 20418888 rs17140337 chr16 6522996 C G 0.000000604 Femoral neck bone mineral density (premenopausal) RBFOX1 intron 23074152 rs802698 chr16 6523482 C T 1.50E-05 Smoking behavior RBFOX1 intron 20418888 rs802698 chr16 6523482 C T 2.32E-05 Socioeconomic Factors RBFOX1 intron pha003067 rs1640968 chr16 6523671 A C 1.20E-05 Smoking behavior RBFOX1 intron 20418888 rs42347 chr16 6525591 T A 3.00E-05 Smoking behavior RBFOX1 intron 20418888 rs12932935 chr16 6525760 T G 3.53E-05 Cocaine dependence RBFOX1 intron 23958962 rs43142 chr16 6539775 G T 3.02E-05 Socioeconomic Factors RBFOX1 intron pha003067 rs9302822 chr16 6542925 G A 4.70E-04 Suicidal ideation RBFOX1 intron 22030708 rs813913 chr16 6554253 C A 7.58E-05 Socioeconomic Factors RBFOX1 intron pha003067 rs1639161 chr16 6561899 G A 1.10E-06 Serum metabolites RBFOX1 intron 19043545 rs2907823 chr16 6567747 T C 3.10E-05 Socioeconomic Factors RBFOX1 intron pha003067 rs1362334 chr16 6582314 C G 5.38E-04 Multiple complex diseases RBFOX1 intron 17554300 rs17822719 chr16 6583125 G A 7.75E-04 Alzheimer's disease RBFOX1 intron 17998437 rs17822719 chr16 6583125 G A 2.54E-05 Alzheimer's disease RBFOX1 intron pha002879 rs7195768 chr16 6586876 A G 5.79E-07 Monocyte counts RBFOX1 intron pha003089 rs17823421 chr16 6595898 G C 3.97E-04 Alzheimer's disease RBFOX1 intron 17998437 rs2052234 chr16 6602034 A T 5.18E-05 Multiple complex diseases RBFOX1 intron 17554300 rs11077049 chr16 6604090 G A 7.44E-04 Type 2 diabetes RBFOX1 intron 17463246 rs1548857 chr16 6636605 C A 9.21E-05 Interstitial lung disease RBFOX1 intron 23583980 rs1548860 chr16 6641118 C G 4.40E-05 Multiple complex diseases RBFOX1 intron 17554300 rs9925894 chr16 6646540 T G 7.71E-04 Multiple complex diseases RBFOX1 intron 17554300 rs9929156 chr16 6649735 C T 2.23E-04 Response to cytidine analogues (gemcitabine) RBFOX1 intron 24483146 rs9929156 chr16 6649735 C T 8.51E-04 Response to cytadine analogues (cytosine arabinoside) RBFOX1 intron 24483146 rs17193120 chr16 6650858 C T 7.98E-05 Response to cytidine analogues (gemcitabine) RBFOX1 intron 24483146 rs12596261 chr16 6651542 A G 1.64E-05 Lung function (forced expiratory volume in 1 second) RBFOX1 intron 24023788 rs12596261 chr16 6651542 A G 7.35E-05 Lung function (forced vital capacity) RBFOX1 intron 24023788 rs733411 chr16 6653206 C G 6.00E-04 Acute lymphoblastic leukemia (childhood) RBFOX1 intron 20189245 rs733410 chr16 6653568 C T 3.53E-05 Multiple sclerosis RBFOX1 intron 17660530 rs12933659 chr16 6653813 G C 9.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) RBFOX1 intron 23233662 rs11649176 chr16 6653899 G A 5.10E-04 Type 2 diabetes RBFOX1 intron 17463246 rs7200031 chr16 6666973 A C 2.31E-05 Type 2 diabetes RBFOX1 intron 17463246 rs17664315 chr16 6667295 T G 7.03E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21041247 rs8064016 chr16 6668417 C T 1.97E-04 Type 2 diabetes RBFOX1 intron 17463246 rs8064016 chr16 6668417 C T 3.46E-04 Multiple complex diseases RBFOX1 intron 17554300 rs8062885 chr16 6669626 G C 9.00E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21041247 rs6500805 chr16 6677777 A G 7.20E-04 Type 2 diabetes RBFOX1 intron 17463246 rs2041667 chr16 6678053 C G 9.26E-04 Type 2 diabetes RBFOX1 intron 17463246 rs17664932 chr16 6678340 A G 4.67E-05 Type 2 diabetes RBFOX1 intron 17463246 rs12596029 chr16 6678811 A G 1.00E-04 Cognitive impairment induced by topiramate RBFOX1 intron 22091778 rs12596029 chr16 6678811 A G 5.63E-05 White matter integrity RBFOX1 intron 22425255 rs1558564 chr16 6680426 T A 6.02E-05 Type 2 diabetes RBFOX1 intron 17463246 rs9944366 chr16 6680736 G C,T 2.93E-05 Aging (time to event) RBFOX1 intron 21782286 rs17665171 chr16 6681184 G A 1.60E-05 Urinary metabolites RBFOX1 intron 21572414 rs887856 chr16 6689092 A G 8.32E-04 White matter integrity RBFOX1 intron 22425255 rs11643447 chr16 6699261 A T 2.00E-07 Visceral adipose tissue adjusted for BMI RBFOX1 intron 22589738 rs17665477 chr16 6700889 T C 6.09E-05 Cognitive test performance RBFOX1 intron 20125193 rs2058527 chr16 6704749 T G 5.09E-04 White matter integrity RBFOX1 intron 22425255 rs9934375 chr16 6716876 C G 2.22E-05 Type 2 diabetes RBFOX1 intron 23300278 rs9938207 chr16 6729357 G A 9.28E-04 White matter integrity RBFOX1 intron 22425255 rs17667084 chr16 6735137 T C 1.83E-05 Cognitive impairment induced by topiramate RBFOX1 intron 22091778 rs7204582 chr16 6741579 A G 1.01E-11 Metabolite levels RBFOX1 intron 22286219 rs9806855 chr16 6749566 G A 9.09E-04 Rheumatoid arthritis RBFOX1 intron 21452313 rs4786924 chr16 6772948 A C 5.68E-04 HIV-1 viral setpoint RBFOX1 intron 17641165 rs4786112 chr16 6778612 C G 3.97E-04 Blood pressure RBFOX1 intron 17255346 rs9939317 chr16 6796804 T G 2.39E-04 Smoking cessation RBFOX1 intron 24665060 rs10492837 chr16 6801807 C A 5.00E-05 Eosinophil counts RBFOX1 intron pha003088 rs990608 chr16 6802378 T A 3.46E-04 Multiple complex diseases RBFOX1 intron 17554300 rs10775354 chr16 6807690 A C 2.58E-27 Narcolepsy RBFOX1 intron 19629137 rs17141359 chr16 6812292 A C 2.97E-04 Multiple complex diseases RBFOX1 intron 17554300 rs17141375 chr16 6813065 A G 1.72E-05 Multiple complex diseases RBFOX1 intron 17554300 rs9924021 chr16 6813671 G C 9.07E-04 Type 2 diabetes RBFOX1 intron 17463246 rs6500818 chr16 6817375 C T 2.00E-07 Dengue shock syndrome RBFOX1 intron 22001756 rs6500818 chr16 6817375 C T 6.77E-05 Coronary heart disease RBFOX1 intron pha003031 rs11864396 chr16 6835390 G C 2.70E-04 Multiple complex diseases RBFOX1 intron 17554300 rs7204283 chr16 6836312 T C 8.00E-05 Tooth agenesis (maxillary third molar) RBFOX1 intron 24172245 rs12921548 chr16 6846271 T C 1.07E-04 Response to taxane treatment (placlitaxel) RBFOX1 intron 23006423 rs11648981 chr16 6864819 G A 9.01E-05 Serum metabolites RBFOX1 intron 19043545 rs7190693 chr16 6875404 C T 3.91E-04 Response to taxane treatment (placlitaxel) RBFOX1 intron 23006423 rs11645781 chr16 6896128 A G 2.00E-07 Heart rate RBFOX1 intron 23583979 rs7201500 chr16 6897659 A G 9.69E-05 Parkinson's disease RBFOX1 intron 21812969 rs8054432 chr16 6898729 C T 1.76E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21041247 rs8054809 chr16 6898962 C G 1.77E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21041247 rs7500396 chr16 6903127 C T 3.30E-04 Blood pressure RBFOX1 intron 17255346 rs1492374 chr16 6909944 C G 1.97E-04 Blood pressure RBFOX1 intron 17255346 rs12921846 chr16 6910385 A G,T 9.00E-06 Attention deficit hyperactivity disorder and conduct disorder RBFOX1 intron 18951430 rs7187960 chr16 6919183 G T 5.56E-07 Hepatitis B RBFOX1 intron 24162738 rs17141598 chr16 6922578 C T 2.74E-04 Response to cytadine analogues (cytosine arabinoside) RBFOX1 intron 24483146 rs8044875 chr16 6943330 A C 1.60E-05 Iron levels RBFOX1 intron 21208937 rs4786947 chr16 6948633 G A 5.07E-05 Socioeconomic Factors RBFOX1 intron pha003067 rs11860643 chr16 6949791 G C 3.44E-05 Multiple complex diseases RBFOX1 intron 17554300 rs9939267 chr16 6958176 A G 4.40E-05 Serum metabolites RBFOX1 intron 19043545 rs12919552 chr16 6966553 G A 3.70E-05 Hemoglobin RBFOX1 intron pha003096 rs7197474 chr16 6967627 G A 3.02E-05 Hemoglobin RBFOX1 intron pha003096 rs7200151 chr16 6968926 T G 9.81E-05 Hemoglobin RBFOX1 intron pha003096 rs7195006 chr16 6999203 C A 1.83E-04 Tourette syndrome RBFOX1 intron 22889924 rs4290488 chr16 7032232 G A 6.05E-05 Cytomegalovirus antibody response RBFOX1 intron 21993531 rs5015420 chr16 7032454 G C 5.62E-05 Cytomegalovirus antibody response RBFOX1 intron 21993531 rs12149452 chr16 7037387 T G 3.05E-05 Cytomegalovirus antibody response RBFOX1 intron 21993531 rs1478727 chr16 7065508 G A 1.10E-06 Response to antidepressants RBFOX1 intron 19736353 rs2169853 chr16 7095570 G T 2.08E-04 Multiple complex diseases RBFOX1 intron 17554300 rs11647415 chr16 7107356 G A 4.37E-05 Multiple complex diseases RBFOX1 intron 17554300 rs11863148 chr16 7125901 T G 0.0000574 Carotid intima media thickness RBFOX1 intron 23152477 rs11866781 chr16 7139173 T C 5.00E-06 Periodontitis (PAL4Q3) RBFOX1 intron 24024966 rs4142923 chr16 7141210 G A 5.11E-04 Tuberculosis RBFOX1 intron 22239941 rs1551960 chr16 7142456 A G 4.67E-05 Amyotrophic Lateral Sclerosis RBFOX1 intron 18057069 rs4786964 chr16 7145567 A G 2.30E-05 Urinary metabolites RBFOX1 intron 21572414 rs1478702 chr16 7146477 A G 7.47E-04 Obesity (extreme) RBFOX1 intron 21935397 rs7194315 chr16 7148129 T C 6.99E-05 Coronary heart disease RBFOX1 intron pha003035 rs11639580 chr16 7149384 C T 1.20E-04 Blood pressure RBFOX1 intron 17255346 rs8061087 chr16 7151571 T C 3.26E-04 Multiple complex diseases RBFOX1 intron 17554300 rs1318703 chr16 7153692 C T 3.00E-05 Breast cancer RBFOX1 intron 17529967 rs35569480 chr16 7155448 A G 6.40E-05 Alcohol consumption RBFOX1 intron 23743675 rs1382477 chr16 7156753 A T 1.90E-05 Urinary metabolites RBFOX1 intron 21572414 rs1478693 chr16 7164219 T G 4.00E-06 Sleep time RBFOX1 intron 23728906 rs1478691 chr16 7168505 C T 2.77E-05 Serum metabolites RBFOX1 intron 19043545 rs11077139 chr16 7174874 C G 2.19E-05 Alcohol consumption RBFOX1 intron 23743675 rs9936520 chr16 7177220 C T 2.40E-05 Urinary metabolites RBFOX1 intron 21572414 rs1871256 chr16 7180064 A G 1.40E-05 Alcohol consumption RBFOX1 intron 23743675 rs10438594 chr16 7180899 C G 2.10E-05 Parkinson's disease (age of onset) RBFOX1 intron 19772629 rs7190550 chr16 7185152 C T 1.47E-04 Multiple complex diseases RBFOX1 intron 17554300 rs6500918 chr16 7186902 G T 1.33E-05 Alcohol consumption RBFOX1 intron 23743675 rs8052094 chr16 7188546 T C 2.72E-05 Alcohol consumption RBFOX1 intron 23743675 rs8047522 chr16 7189411 T C 2.87E-05 Alcohol consumption RBFOX1 intron 23743675 rs35269146 chr16 7189414 T A 2.89E-05 Alcohol consumption RBFOX1 intron 23743675 rs11863081 chr16 7189576 A C 3.00E-05 Alcohol consumption RBFOX1 intron 23743675 rs4444357 chr16 7190075 C T 1.90E-05 Alcohol consumption RBFOX1 intron 23743675 rs922471 chr16 7190897 G C 1.77E-05 Alcohol consumption RBFOX1 intron 23743675 rs922471 chr16 7190897 G C 9.82E-04 Response to cytidine analogues (gemcitabine) RBFOX1 intron 24483146 rs1904224 chr16 7191866 A T 2.33E-05 Alcohol consumption RBFOX1 intron 23743675 rs11641647 chr16 7194840 A G 5.67E-05 Alcohol consumption RBFOX1 intron 23743675 rs11641647 chr16 7194840 A G 7.47E-04 Response to cytidine analogues (gemcitabine) RBFOX1 intron 24483146 rs12447219 chr16 7199460 C T 8.66E-05 Height RBFOX1 intron pha003010 rs12447219 chr16 7199460 C T 3.40E-05 Height RBFOX1 intron pha003011 rs9929658 chr16 7210680 G A 1.28E-04 Prion diseases RBFOX1 intron 22210626 rs1471451 chr16 7211975 C T 4.16E-04 Response to cytidine analogues (gemcitabine) RBFOX1 intron 24483146 rs12597524 chr16 7213099 A G 1.50E-05 Urinary metabolites RBFOX1 intron 21572414 rs12597524 chr16 7213099 A G 4.35E-04 Response to cytidine analogues (gemcitabine) RBFOX1 intron 24483146 rs12599645 chr16 7213392 G A 4.35E-04 Response to cytidine analogues (gemcitabine) RBFOX1 intron 24483146 rs9302841 chr16 7227122 T A 2.00E-06 Response to antipsychotic therapy (extrapyramidal side effects) RBFOX1 intron 19875103 rs10500350 chr16 7230643 A G 5.20E-05 Cognitive performance RBFOX1 intron 19734545 rs13337511 chr16 7237955 C T 7.12E-04 Tourette syndrome RBFOX1 intron 22889924 rs17560841 chr16 7240801 G T 8.00E-04 Type 2 diabetes RBFOX1 intron 17463246 rs12325184 chr16 7243251 A G 6.44E-04 Tourette syndrome RBFOX1 intron 22889924 rs8053396 chr16 7251931 G A 8.20E-06 Urinary metabolites RBFOX1 intron 21572414 rs2881438 chr16 7272672 A T 4.46E-05 Serum metabolites RBFOX1 intron 19043545 rs7185684 chr16 7281941 G C 1.77E-08 Metabolite levels RBFOX1 intron 23281178 rs1922585 chr16 7286821 A G 1.50E-08 Metabolite levels RBFOX1 intron 23281178 rs11640060 chr16 7288608 A G 1.00E-05 Urinary metabolites RBFOX1 intron 21572414 rs11860241 chr16 7294639 A G 8.78E-06 Serum metabolites RBFOX1 intron 19043545 rs11860241 chr16 7294639 A G 6.00E-04 Primary sclerosing cholangitis RBFOX1 intron 19944697 rs11077162 chr16 7295103 G C 1.86E-05 Serum metabolites RBFOX1 intron 19043545 rs11077163 chr16 7295167 C T 3.74E-05 Serum metabolites RBFOX1 intron 19043545 rs11077164 chr16 7296884 G C 9.17E-04 Type 2 diabetes RBFOX1 intron 17463246 rs4635362 chr16 7298199 G C 3.91E-05 Serum metabolites RBFOX1 intron 19043545 rs4347647 chr16 7303445 C A 4.30E-06 Urinary metabolites RBFOX1 intron 21572414 rs8054413 chr16 7309161 A G 7.29E-05 Serum metabolites RBFOX1 intron 19043545 rs17143122 chr16 7309991 C T 6.12E-04 Multiple complex diseases RBFOX1 intron 17554300 rs1010884 chr16 7310508 C T 2.74E-05 Gaucher disease severity RBFOX1 intron 22388998 rs1922593 chr16 7313356 G A 5.50E-06 Urinary metabolites RBFOX1 intron 21572414 rs10852681 chr16 7314703 A G 4.20E-05 Bone mineral density (BMD),in women RBFOX1 intron 20164292 rs10852681 chr16 7314703 A G 1.00E-04 Cognitive impairment induced by topiramate RBFOX1 intron 22091778 rs8047052 chr16 7320496 A G 5.44E-05 Serum metabolites RBFOX1 intron 19043545 rs8051518 chr16 7320515 T C 7.42E-05 Serum metabolites RBFOX1 intron 19043545 rs12445831 chr16 7325578 T A 7.40E-06 Urinary metabolites RBFOX1 intron 21572414 rs12924980 chr16 7346098 G A 2.40E-05 Urinary metabolites RBFOX1 intron 21572414 rs4275868 chr16 7349777 T C 9.11E-04 HIV-1 viral setpoint RBFOX1 intron 17641165 rs4350587 chr16 7361523 G A 1.70E-05 Urinary metabolites RBFOX1 intron 21572414 rs8046401 chr16 7364523 G A 5.34E-04 Smoking initiation RBFOX1 intron 24665060 rs8046170 chr16 7369266 A G 3.42E-05 Multiple complex diseases RBFOX1 intron 17554300 rs11859000 chr16 7373049 C G 6.18E-05 Recombination rate RBFOX1 intron 21698098 rs17671597 chr16 7381106 C G 6.22E-05 Serum metabolites RBFOX1 intron 19043545 rs17671597 chr16 7381106 C G 0.000143 Salmonella-induced pyroptosis RBFOX1 intron 22837397 rs4257224 chr16 7395292 T G 2.76E-05 Major depressive disorder RBFOX1 intron 20516156 rs13330100 chr16 7398029 C T 2.30E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21041247 rs9934586 chr16 7398452 A G 7.59E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21041247 rs9936914 chr16 7398582 T A 7.59E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21041247 rs9924010 chr16 7398995 G A 1.15E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21041247 rs17143484 chr16 7399252 T C 1.14E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21041247 rs17842417 chr16 7400882 T C 1.10E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21041247 rs9933137 chr16 7402541 T G 1.07E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21041247 rs17146172 chr16 7403079 T C 1.07E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21041247 rs4787008 chr16 7415552 A G 6.00E-07 Diabetic retinopathy RBFOX1 intron 21441570 rs7206595 chr16 7420486 G A 4.26E-05 Leukocyte Counts RBFOX1 intron pha003091 rs7190881 chr16 7428423 C G 2.90E-04 Breast cancer and prostate cancer RBFOX1 intron 17903305 rs8057663 chr16 7431377 A G 6.01E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21041247 rs4627375 chr16 7433110 A G 6.66E-05 Leukocyte Counts RBFOX1 intron pha003091 rs7184072 chr16 7435087 T C 5.18E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21041247 rs7202052 chr16 7435150 A G 5.03E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21041247 rs7202208 chr16 7435165 A G 5.01E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21041247 rs7202219 chr16 7435183 A T 5.00E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21041247 rs12595866 chr16 7441344 A C 1.80E-06 Urinary metabolites RBFOX1 intron 21572414 rs17648389 chr16 7442494 C T 1.80E-06 Urinary metabolites RBFOX1 intron 21572414 rs11077175 chr16 7455755 G T 2.10E-05 Urinary metabolites RBFOX1 intron 21572414 rs8050761 chr16 7459039 C G 2.75E-05 Serum metabolites RBFOX1 intron 19043545 rs10500355 chr16 7459347 T A 4.91E-04 Insulin resistance RBFOX1 intron 21901158 rs10500355 chr16 7459347 T A 4.00E-09 Refractive error RBFOX1 intron 23474815 rs12149783 chr16 7459523 C T 5.56E-05 Serum metabolites RBFOX1 intron 19043545 rs10500356 chr16 7459614 T C 7.43E-05 Serum metabolites RBFOX1 intron 19043545 rs10500356 chr16 7459614 T C 7.21E-05 Orofacial clefts RBFOX1 intron 19270707 rs10500356 chr16 7459614 T C 7.14E-04 Amyotrophic lateral sclerosis RBFOX1 intron 23624525 rs17648524 chr16 7459683 G C 6.79E-05 Type 2 diabetes RBFOX1 intron 17463246 rs17648524 chr16 7459683 G C 2.14E-04 Insulin resistance RBFOX1 intron 21901158 rs17648524 chr16 7459683 G C 6.00E-10 Refractive error RBFOX1 intron 23396134 rs17648524 chr16 7459683 G C 1.30E-22 Myopia (Age of onset) RBFOX1 intron 23468642 rs4616298 chr16 7462074 A G 6.30E-06 Urinary metabolites RBFOX1 intron 21572414 rs6500961 chr16 7466553 A G 3.43E-04 Alzheimer's disease (late onset) RBFOX1 intron 21379329 rs6500963 chr16 7467489 T C 2.69E-06 Restless legs syndrome RBFOX1 intron 17637780 rs7190503 chr16 7468729 A G 9.67E-04 Response to taxane treatment (placlitaxel) RBFOX1 intron 23006423 rs7196364 chr16 7471667 G A 7.52E-04 Coronary Artery Disease RBFOX1 intron 17634449 rs4787016 chr16 7476725 C G 4.17E-05 Serum metabolites RBFOX1 intron 19043545 rs2109437 chr16 7493024 C T 0.000078 Primary sclerosing cholangitis RBFOX1 intron 23603763 rs2346943 chr16 7495186 T G 2.64E-06 Serum metabolites RBFOX1 intron 19043545 rs2346943 chr16 7495186 T G 5.34E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21041247 rs9933246 chr16 7497702 T C 1.83E-06 Serum metabolites RBFOX1 intron 19043545 rs9933246 chr16 7497702 T C 5.86E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21041247 rs7194484 chr16 7504546 A G 8.18E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21423239 rs9935875 chr16 7504596 A G 4.57E-07 Serum metabolites RBFOX1 intron 19043545 rs9935962 chr16 7504670 A C 3.93E-07 Serum metabolites RBFOX1 intron 19043545 rs9924951 chr16 7504854 G A 5.00E-07 Metabolite levels RBFOX1 intron 19043545 rs9936248 chr16 7505029 A C 4.70E-07 Serum metabolites RBFOX1 intron 19043545 rs10459843 chr16 7505082 G A 9.04E-04 Type 2 diabetes RBFOX1 intron 17463246 rs10459843 chr16 7505082 G A 1.40E-05 Serum metabolites RBFOX1 intron 19043545 rs9302851 chr16 7505379 G C 4.60E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21423239 rs11647085 chr16 7508433 G A 3.41E-04 Suicide attempts in bipolar disorder RBFOX1 intron 21423239 rs726476 chr16 7508784 C G 1.15E-06 Serum metabolites RBFOX1 intron 19043545 rs2191388 chr16 7530019 C T 5.93E-04 Common variable immunodeficiency RBFOX1 intron 21497890 rs17143781 chr16 7530601 A G 3.02E-05 Telomere length RBFOX1 intron 23001564 rs7198956 chr16 7534455 T A 1.60E-05 Urinary metabolites RBFOX1 intron 21572414 rs7194387 chr16 7534930 C G 3.88E-04 Multiple complex diseases RBFOX1 intron 17554300 rs10492754 chr16 7542356 T C 2.05E-04 Multiple complex diseases RBFOX1 intron 17554300 rs4787036 chr16 7552277 G A 3.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBFOX1 intron 20877124 rs1507015 chr16 7571292 C T 6.92E-05 Femoral neck bone geometry RBFOX1 intron 22087292 rs10459845 chr16 7585001 T G 7.16E-05 Orofacial clefts RBFOX1 intron 22419666 rs713115 chr16 7588038 G A 3.35E-06 Hearing function RBFOX1 intron 21493956 rs1507023 chr16 7588435 C T 7.50E-06 Vitamin D concentrations RBFOX1 intron 20600896 rs1507023 chr16 7588435 C T 7.50E-06 Vitamin D concentrations RBFOX1 intron 20600896 rs8060394 chr16 7589189 T C 1.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBFOX1 intron 20877124 rs11077197 chr16 7595920 G C 8.67E-06 Hearing function RBFOX1 intron 21493956 rs1507030 chr16 7611156 C G 3.76E-04 Nicotine smoking RBFOX1 intron 19268276 rs6500986 chr16 7613177 C G 5.48E-04 Diabetic retinopathy RBFOX1 intron 20871662 rs8051396 chr16 7613401 C G 5.10E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines RBFOX1 intron 21844884 rs8051396 chr16 7613401 C G 6.00E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines RBFOX1 intron 21844884 rs7500249 chr16 7615043 G A 2.08E-04 Multiple complex diseases RBFOX1 intron 17554300 rs7500249 chr16 7615043 G A 0.000614 Salmonella-induced pyroptosis RBFOX1 intron 22837397 rs17144183 chr16 7631319 A G 5.83E-05 Schizophrenia RBFOX1 intron 19571811 rs6500988 chr16 7633995 T C 4.31E-05 Creatinine levels RBFOX1 intron pha003069 rs1827980 chr16 7636371 T C 9.47E-04 Multiple complex diseases RBFOX1 intron 17554300 rs12596889 chr16 7659547 A G 8.22E-04 Response to statin treatment (atorvastatin),change in cholesterol levels RBFOX1 intron 20031582 rs9929993 chr16 7664875 C T 5.52E-04 Response to taxane treatment (placlitaxel) RBFOX1 intron 23006423 rs9941233 chr16 7682605 A G 7.90E-05 Coronary heart disease RBFOX1 intron pha003055 rs11648047 chr16 7690071 C T 0.000000985 Left atrial diameter RBFOX1 intron 23275298 rs1009693 chr16 7694924 C A 1.29E-04 Lung function (forced vital capacity) RBFOX1 intron 24023788 rs2109059 chr16 7709185 A G 2.50E-05 Urinary metabolites RBFOX1 intron 21572414 rs11077211 chr16 7730342 G C 1.40E-05 Body mass (lean) RBFOX1 intron 19268274 rs10492759 chr16 7735550 A C 8.90E-04 Taste perception RBFOX1 intron 22132133 rs8045076 chr16 7737836 A G 9.74E-04 Alzheimer's disease RBFOX1 intron 24755620 rs8055404 chr16 7745047 A G 5.35E-05 Bipolar disorder and schizophrenia RBFOX1 intron 20889312 rs12444931 chr16 7753704 G A 5.00E-06 Bipolar disorder and schizophrenia RBFOX1 intron 20889312 rs12448737 chr16 7753761 T A,C,G 5.42E-05 Bipolar disorder and schizophrenia RBFOX1 intron 20889312 rs2270128 chr16 7758638 A C 2.43E-04 Multiple complex diseases RBFOX1 intron 17554300 rs9927896 chr16 7764296 G C 9.42E-05 Serum metabolites / / 19043545 rs7197039 chr16 7766479 T C 7.14E-04 Multiple complex diseases / / 17554300 rs9927040 chr16 7766855 T G 2.89E-05 Nicotine smoking / / 19268276 rs4787067 chr16 7775397 A G 5.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs11648832 chr16 7781460 T C 0.00000219 Femoral neck bone mineral density (premenopausal) / / 23074152 rs1014124 chr16 7781828 T G 5.72E-05 Multiple complex diseases / / 17554300 rs7199396 chr16 7785836 G A 2.14E-04 Smoking initiation / / 24665060 rs17770916 chr16 7792912 C T 1.67E-04 Smoking initiation / / 24665060 rs7196984 chr16 7797128 C T 2.06E-04 Smoking initiation / / 24665060 rs2907363 chr16 7812932 A G 4.79E-04 Smoking initiation / / 24665060 rs12597817 chr16 7820618 T G 8.39E-05 Cognitive test performance / / 20125193 rs13380514 chr16 7823107 C G 9.97E-05 Suicide attempts in bipolar disorder / / 21423239 rs4787078 chr16 7824616 A G 9.70E-05 Cognitive test performance / / 20125193 rs9932500 chr16 7831084 G C 8.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs3111558 chr16 7831214 T C 3.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs3112740 chr16 7836297 C A 6.00E-06 Smoking behavior / / 19247474 rs4238884 chr16 7840181 C T 3.10E-04 Alzheimer's disease / / 17998437 rs3862445 chr16 7842522 T C 3.80E-04 Alcohol dependence / / 20201924 rs8061218 chr16 7842576 C G 1.89E-05 Sudden cardiac arrest / / 21658281 rs8060352 chr16 7842821 G C 7.08E-04 Multiple complex diseases / / 17554300 rs4374183 chr16 7847571 A G 7.70E-05 Primary sclerosing cholangitis / / 19944697 rs4273050 chr16 7847777 G C 8.84E-04 Alzheimer's disease / / 17998437 rs4273050 chr16 7847777 G C 9.96E-05 Serum metabolites / / 19043545 rs9302857 chr16 7848340 G A 2.90E-05 Primary sclerosing cholangitis / / 19944697 rs4456517 chr16 7849224 G A 4.10E-05 Primary sclerosing cholangitis / / 19944697 rs4787086 chr16 7851413 G A 3.55E-04 Smoking initiation / / 24665060 rs7194666 chr16 7853649 C T 4.61E-04 Alzheimer's disease (late onset) / / 21379329 rs9925150 chr16 7853712 G C 7.70E-05 Primary sclerosing cholangitis / / 19944697 rs8058542 chr16 7854984 G A 3.04E-05 Serum metabolites / / 19043545 rs8058542 chr16 7854984 G A 6.80E-04 Alcohol dependence / / 20201924 rs9944370 chr16 7885928 G T 2.30E-05 Urinary metabolites / / 21572414 rs12446289 chr16 7903609 T C 6.00E-06 Metabolite levels (MHPG) / / 23319000 rs9788925 chr16 7929654 A C 2.25E-06 Smooth-surface caries / / 24556642 rs9788927 chr16 7929828 A C 2.17E-06 Smooth-surface caries / / 24556642 rs4261521 chr16 7932047 G A 8.15E-04 Response to alcohol consumption (flushing response) / / 24277619 rs8053478 chr16 7935118 T C 2.18E-04 Alzheimer's disease / / 24755620 rs3922908 chr16 7951896 T C 9.12E-05 Alzheimer's disease / / 24755620 rs11649687 chr16 7952180 G A 7.85E-04 Alzheimer's disease / / 24755620 rs8052349 chr16 7956126 T C 6.02E-04 Alzheimer's disease / / 24755620 rs8044765 chr16 7958906 T C 2.75E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs11646592 chr16 7967110 C T 3.33E-04 Coronary heart disease / / 21971053 rs11646592 chr16 7967110 C T 2.23E-04 Alzheimer's disease / / 24755620 rs9939266 chr16 7979137 C T 1.40E-05 Urinary metabolites / / 21572414 rs6501039 chr16 7980532 G A 2.06E-05 Vaspin levels / / 22907691 rs6501039 chr16 7980532 G A 0.0000206 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs6501041 chr16 7986445 G A 1.15E-04 Vaspin levels / / 22907691 rs6501041 chr16 7986445 G A 0.0001154 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs1395594 chr16 7995283 G C 1.47E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs9939629 chr16 8009628 C A 6.81E-04 Response to alcohol consumption (flushing response) / / 24277619 rs7192993 chr16 8011215 A G 2.84E-08 Non-obstructive azoospermia / / 22197933 rs1395592 chr16 8014685 T C 9.61E-04 Alzheimer's disease / / 24755620 rs1395593 chr16 8019611 T G 5.91E-06 Prostate cancer / / pha002877 rs1395593 chr16 8019611 T G 6.99E-05 Prostate cancer / / pha002878 rs6501049 chr16 8024933 A G 2.15E-04 Vaspin levels / / 22907691 rs6501049 chr16 8024933 A G 0.0002147 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs4786201 chr16 8028614 G A 2.00E-04 Vaspin levels / / 22907691 rs4786201 chr16 8028614 G A 0.0001996 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs1354808 chr16 8038856 G A 7.85E-05 Insulin resistance / / 21901158 rs4787103 chr16 8042717 A G 2.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4787103 chr16 8042717 A G 2.51E-05 Socioeconomic Factors / / pha003066 rs9933906 chr16 8044973 C T 7.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs7197658 chr16 8060441 T G 4.99E-04 Hepatocellular carcinoma / / 22807686 rs7193013 chr16 8076008 T C 0.000087 Endometrial cancer / / 22426144 rs17672590 chr16 8089437 A G 4.58E-04 Smoking quantity / / 24665060 rs3112660 chr16 8090207 G A 9.14E-04 Multiple complex diseases / / 17554300 rs6501060 chr16 8091952 T C 9.67E-05 Blood Pressure / / pha003047 rs6501066 chr16 8098629 T C 8.12E-05 Serum metabolites / / 19043545 rs7197046 chr16 8098698 G A 6.15E-05 Serum metabolites / / 19043545 rs17672650 chr16 8099296 G T 3.69E-04 Smoking quantity / / 24665060 rs17740190 chr16 8100081 G A 8.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs1031367 chr16 8102290 A G 2.32E-04 Tourette syndrome / / 22889924 rs17672730 chr16 8102679 A G 6.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs17672782 chr16 8107004 C T 7.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs3112666 chr16 8111290 A G 3.09E-04 Stroke / / pha002887 rs17672815 chr16 8112564 A G 7.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs896398 chr16 8113853 C T 9.58E-04 Rheumatoid arthritis / / 21452313 rs12600095 chr16 8122183 C T 4.49E-04 Rheumatoid arthritis / / 21452313 rs4787125 chr16 8128058 A G 1.14E-05 Serum metabolites / / 19043545 rs1507037 chr16 8134615 A G 9.84E-04 Tourette syndrome / / 22889924 rs11077260 chr16 8143309 G T 9.83E-04 Tourette syndrome / / 22889924 rs11865277 chr16 8148808 T C 9.46E-04 Tourette syndrome / / 22889924 rs7199789 chr16 8155494 G C 2.97E-05 Serum metabolites / / 19043545 rs4786212 chr16 8160554 C T 3.85E-05 Serum metabolites / / 19043545 rs12929499 chr16 8170733 A G 5.31E-07 Serum metabolites / / 19043545 rs12929499 chr16 8170733 A G 9.38E-04 Rheumatoid arthritis / / 21452313 rs12929288 chr16 8174094 G C 7.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs7203840 chr16 8178507 C G 7.02E-06 Serum metabolites / / 19043545 rs1376657 chr16 8198871 C T 7.22E-04 Rheumatoid arthritis / / 21452313 rs4787150 chr16 8208094 A G 8.04E-04 Rheumatoid arthritis / / 21452313 rs17145380 chr16 8238988 G A 3.98E-04 Multiple complex diseases / / 17554300 rs12596707 chr16 8242146 G A 0.000254 Salmonella-induced pyroptosis / / 22837397 rs4787162 chr16 8290105 G A 6.93E-05 Serum metabolites / / 19043545 rs8055847 chr16 8304755 G C 1.98E-05 Serum metabolites / / 19043545 rs8062548 chr16 8305106 A C 3.52E-06 Serum metabolites / / 19043545 rs17145575 chr16 8308675 G A 3.50E-05 Major depressive disorder / / 22472876 rs2034588 chr16 8329327 T C 2.00E-06 Response to antidepressant treatment / / 22041458 rs2360851 chr16 8329678 T A 9.45E-04 Multiple complex diseases / / 17554300 rs17145664 chr16 8334711 C T 9.10E-04 Multiple complex diseases / / 17554300 rs1037369 chr16 8347843 C G 2.27E-05 Alzheimer's disease / / 22832961 rs40643 chr16 8374633 C A 1.89E-04 IgE levels / / 17255346 rs370603 chr16 8384475 T G 8.18E-04 Myopia (pathological) / / 21095009 rs29586 chr16 8396491 G A 6.25E-04 Multiple complex diseases / / 17554300 rs40460 chr16 8403593 C T 6.21E-04 Smoking cessation / / 24665060 rs4787185 chr16 8406960 T A 7.49E-04 Multiple complex diseases / / 17554300 rs41378944 chr16 8411336 A G 2.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs8044475 chr16 8411687 C G 1.82E-04 Type 2 diabetes / / 17463246 rs8044475 chr16 8411687 C G 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs29605 chr16 8415921 C T 7.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2361072 chr16 8426214 G A 7.32E-05 Receptive language ability / / 24687471 rs1542287 chr16 8426509 G A 8.78E-04 Myopia (pathological) / / 21095009 rs17199812 chr16 8430117 A G 6.47E-05 Diabetes Mellitus / / pha003060 rs2122913 chr16 8434830 T A 2.20E-05 Urinary metabolites / / 21572414 rs12598243 chr16 8441382 A T 4.27E-04 Multiple complex diseases / / 17554300 rs8051427 chr16 8445307 T C 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs7188412 chr16 8454413 C G 3.39E-04 Alzheimer's disease / / 24755620 rs12325385 chr16 8458215 C A 2.47E-04 Alzheimer's disease / / 24755620 rs4383128 chr16 8462873 A G 1.62E-04 Multiple complex diseases / / 17554300 rs4578629 chr16 8469447 A T 5.86E-04 Multiple complex diseases / / 17554300 rs12444380 chr16 8470217 C T 7.15E-04 Multiple complex diseases / / 17554300 rs6501126 chr16 8483921 A C 6.64E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9932531 chr16 8494294 A G 8.33E-05 Epilepsy (remission after treatment) / / 23962720 rs2361074 chr16 8495409 G T 6.75E-05 Epilepsy (remission after treatment) / / 23962720 rs7500401 chr16 8495998 T C 8.87E-05 Epilepsy (remission after treatment) / / 23962720 rs1006760 chr16 8501041 A G 7.04E-04 Multiple complex diseases / / 17554300 rs9939575 chr16 8501213 T C 5.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs8045405 chr16 8503222 G A 9.00E-06 QT interval / / 23534349 rs7501273 chr16 8506351 G C 8.32E-05 Epilepsy (remission after treatment) / / 23962720 rs12920876 chr16 8512660 G A 1.17E-05 Epilepsy (remission after treatment) / / 23962720 rs12596798 chr16 8513277 G A 3.85E-06 Epilepsy (remission after treatment) / / 23962720 rs12925764 chr16 8513552 G C 3.88E-06 Epilepsy (remission after treatment) / / 23962720 rs4290458 chr16 8514177 G A 3.93E-06 Epilepsy (remission after treatment) / / 23962720 rs12918289 chr16 8515137 C T 4.03E-06 Epilepsy (remission after treatment) / / 23962720 rs12919774 chr16 8515708 A G 5.28E-06 Epilepsy (remission after treatment) / / 23962720 rs11861312 chr16 8516188 T C 4.69E-05 Cognitive test performance / / 20125193 rs11077306 chr16 8516320 C G 4.08E-06 Epilepsy (remission after treatment) / / 23962720 rs11077307 chr16 8516408 C G 4.19E-06 Epilepsy (remission after treatment) / / 23962720 rs12923792 chr16 8517032 G A 4.99E-06 Epilepsy (remission after treatment) / / 23962720 rs11077308 chr16 8517507 G A 4.91E-04 Smoking quantity / / 24665060 rs11861787 chr16 8517745 A C 3.00E-06 Epilepsy (remission after treatment) / / 23962720 rs11865847 chr16 8518052 C T 4.57E-06 Epilepsy (remission after treatment) / / 23962720 rs55811665 chr16 8518301 G A 4.58E-06 Epilepsy (remission after treatment) / / 23962720 rs7203639 chr16 8518512 G T 3.09E-06 Epilepsy (remission after treatment) / / 23962720 rs7205383 chr16 8518715 C T 3.31E-06 Epilepsy (remission after treatment) / / 23962720 rs12934978 chr16 8520158 C T 5.96E-06 Epilepsy (remission after treatment) / / 23962720 rs12933981 chr16 8520246 G C 5.89E-06 Epilepsy (remission after treatment) / / 23962720 rs11077309 chr16 8520579 A G 5.87E-06 Epilepsy (remission after treatment) / / 23962720 rs6501139 chr16 8522458 T C 1.74E-05 Epilepsy (remission after treatment) / / 23962720 rs4286095 chr16 8523079 T A 1.74E-05 Epilepsy (remission after treatment) / / 23962720 rs4545800 chr16 8523107 T C 1.74E-05 Epilepsy (remission after treatment) / / 23962720 rs4414477 chr16 8523335 A C 1.68E-05 Epilepsy (remission after treatment) / / 23962720 rs7185317 chr16 8524466 G C 3.38E-04 Multiple complex diseases / / 17554300 rs7202633 chr16 8538433 T A 0.0000002 GLP-1-stimulated insulin secretion during hyperglycemic clamps / / 23674605 rs7202633 chr16 8538433 T A 0.00056 Arginine stimulated insulin secretion / / 23674605 rs12920180 chr16 8541061 T C 5.88E-05 Epilepsy (remission after treatment) / / 23962720 rs35856268 chr16 8543282 G C 1.12E-05 Epilepsy (remission after treatment) / / 23962720 rs12918041 chr16 8544516 T C 3.03E-05 Epilepsy (remission after treatment) / / 23962720 rs35284673 chr16 8559834 C T 7.43E-06 Epilepsy (remission after treatment) / / 23962720 rs13337192 chr16 8587688 G A 6.45E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7187274 chr16 8590448 T A 3.69E-05 Aging (time to event) / / 21782286 rs8061765 chr16 8590873 G A 1.60E-07 Gallstones / / 17632509 rs8061765 chr16 8590873 G A 8.12E-04 Alcohol dependence / / 21314694 rs9929530 chr16 8627136 C A 9.45E-05 Blood Pressure / / pha003040 rs3924628 chr16 8631063 G A 5.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs3924627 chr16 8631127 A G 6.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs2215927 chr16 8700111 A T 1.40E-05 Urinary metabolites / / 21572414 rs12446439 chr16 8708862 G A 3.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs17650602 chr16 8710021 A G 6.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs12597469 chr16 8722052 A G 8.90E-05 Serum albumin level METTL22 intron pha003084 rs6498521 chr16 8747827 C T 1.50E-05 Urinary metabolites / / 21572414 rs1345300 chr16 8764428 T C 1.83E-04 Alzheimer's disease / / 17998437 rs1731070 chr16 8800619 G A 4.08E-08 Metabolite levels ABAT intron 23281178 rs1731069 chr16 8800832 C A 4.08E-08 Metabolite levels ABAT intron 23281178 rs3095512 chr16 8802044 T A 4.08E-08 Metabolite levels ABAT intron 23281178 rs1731062 chr16 8802752 C T 3.54E-08 Metabolite levels ABAT intron 23281178 rs1731061 chr16 8803004 A G 9.48E-04 Type 2 diabetes ABAT intron 17463246 rs1731061 chr16 8803004 A G 6.75E-08 Metabolite levels ABAT intron 23281178 rs1640980 chr16 8803621 A C 4.08E-08 Metabolite levels ABAT intron 23281178 rs1273385 chr16 8806421 T C 4.95E-08 Metabolite levels ABAT intron 23281178 rs1420082 chr16 8809702 T C 2.10E-06 Urinary metabolites ABAT intron 21572414 rs1273396 chr16 8816812 C G 6.95E-04 Nicotine smoking ABAT intron 19268276 rs11645254 chr16 8821979 G C 6.38E-05 Serum metabolites ABAT intron 19043545 rs1273433 chr16 8853060 A T 2.49E-04 Response to taxane treatment (placlitaxel) ABAT intron 23006423 rs12448959 chr16 8859997 G C 1.62E-04 Breast cancer ABAT intron 21060860 rs8049072 chr16 8862212 C T 4.27E-04 Sudden cardiac arrest ABAT intron 21658281 rs8053509 chr16 8862271 G T 4.33E-05 Amyotrophic lateral sclerosis ABAT intron 20801717 rs8053509 chr16 8862271 G T 0.0000124 Amyotrophic lateral sclerosis ABAT intron 23587638 rs8053509 chr16 8862271 G T 0.000037 Amyotrophic lateral sclerosis ABAT intron 23587638 rs1299926 chr16 8871081 T A 1.28E-04 Lung function (forced expiratory volume in 1 second) ABAT intron 17255346 rs1299926 chr16 8871081 T A 2.46E-04 Type 2 diabetes ABAT intron 17463246 rs1299926 chr16 8871081 T A 8.00E-06 Anger ABAT intron 24489884 rs17674530 chr16 8876497 T C 3.84E-04 Multiple complex diseases ABAT UTR-3 17554300 rs12049 chr16 8889628 T C 2.77E-05 Cognitive test performance TMEM186 UTR-3 20125193 rs3826198 chr16 8906539 C A 3.57E-05 Orofacial clefts PMM2 intron 22419666 rs8057024 chr16 8908811 G A 9.75E-05 Cognitive test performance PMM2 intron 20125193 rs30778 chr16 8980952 G A 1.78E-04 Multiple complex diseases / / 17554300 rs201638486 chr16 9013464 T TTTATTTTG 8.06E-06 Multiple complex diseases USP7 intron 17554300 rs2126999 chr16 9013464 T C 8.06E-06 Multiple complex diseases USP7 intron 17554300 rs2437716 chr16 9031104 T C 7.90E-05 Multiple complex diseases USP7 intron 17554300 rs12929193 chr16 9044162 T C 6.79E-04 Multiple complex diseases USP7 intron 17554300 rs7192398 chr16 9077612 C A,G,T 3.39E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs9927946 chr16 9083367 T C 1.70E-05 Schizophrenia / / 19571809 rs4438302 chr16 9090615 T G 1.51E-05 Left ventricular hypertrophy / / pha003052 rs9923450 chr16 9102388 G A 5.97E-05 Myopia (pathological) / / 21640322 rs899258 chr16 9107554 G A 9.66E-04 Heart Failure / / pha002885 rs12598117 chr16 9118815 A G 1.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs7184991 chr16 9141051 C T 6.57E-04 Type 2 diabetes / / 17463246 rs9039 chr16 9205363 T C 5.03E-05 Body Fat Distribution C16orf72 intron pha003018 rs3743832 chr16 9213880 A C 4.00E-06 Non-substance related behavioral disinhibition / / 23942779 rs3743832 chr16 9213880 A C 9.00E-07 Behavioural disinhibition (generation interaction) / / 23942779 rs4386138 chr16 9216164 T G 2.40E-05 Urinary metabolites / / 21572414 rs9926522 chr16 9216948 A G 3.80E-06 Behavioural disinhibition (generation interaction) / / 23942779 rs9932566 chr16 9218701 T C 1.90E-05 Urinary metabolites / / 21572414 rs9932566 chr16 9218701 T C 4.11E-08 Lymphocyte counts / / 22286170 rs2941346 chr16 9259690 A G 3.01E-06 Type 2 diabetes / / 17463246 rs1114620 chr16 9263737 C T 2.98E-05 Type 2 diabetes / / 17463246 rs907025 chr16 9289238 C T 2.77E-04 Aortic root size / / 21223598 rs1510184 chr16 9290749 T G 6.80E-04 Smoking quantity / / 24665060 rs2965855 chr16 9298188 G C 1.17E-04 Multiple complex diseases / / 17554300 rs1510183 chr16 9299946 A T 4.83E-04 Multiple complex diseases / / 17554300 rs2965858 chr16 9300308 C G 1.94E-04 Multiple complex diseases / / 17554300 rs9788893 chr16 9301716 T G 4.78E-04 Multiple complex diseases / / 17554300 rs2965859 chr16 9302081 T A 5.03E-04 Multiple complex diseases / / 17554300 rs2941327 chr16 9302408 A T 4.27E-06 Multiple complex diseases / / 17554300 rs2965860 chr16 9302688 G A 8.49E-04 Multiple complex diseases / / 17554300 rs11647231 chr16 9303318 A G 7.24E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10500367 chr16 9306667 G A 1.33E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2941318 chr16 9312782 G A 7.08E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2965887 chr16 9321263 G A 4.59E-04 Multiple complex diseases / / 17554300 rs4782083 chr16 9322418 C T 2.30E-04 Multiple complex diseases / / 17554300 rs4782151 chr16 9325985 C T 1.20E-05 Urinary metabolites / / 21572414 rs4782151 chr16 9325985 C T 5.00E-06 Cervical cancer / / 24700089 rs4782152 chr16 9326011 A G 1.10E-05 Urinary metabolites / / 21572414 rs4782152 chr16 9326011 A G 5.32E-06 Cervical cancer / / 24700089 rs1876950 chr16 9332725 A G 7.73E-05 Cleft lip / / 20436469 rs8045112 chr16 9335318 A C 2.21E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2314293 chr16 9336618 A G 2.38E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs959228 chr16 9341096 G A 9.03E-05 Cleft lip / / 20436469 rs959228 chr16 9341096 G A 8.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1397142 chr16 9343347 G A 6.00E-06 Obesity-related traits / / 23251661 rs1876955 chr16 9349447 T C 6.80E-05 Type 2 diabetes / / 17463246 rs907021 chr16 9354756 C T 8.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7190139 chr16 9356311 T G 9.47E-05 Cleft lip / / 20436469 rs7190139 chr16 9356311 T G 8.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2965893 chr16 9371586 A T 5.46E-04 Type 2 diabetes / / 17463246 rs2099106 chr16 9380708 C T 1.70E-05 Type 2 diabetes / / 17463249 rs2099106 chr16 9380708 C T 8.08E-06 Multiple complex diseases / / 17554300 rs8061903 chr16 9382329 A G 5.00E-06 HIV-1 viral setpoint / / 22174851 rs7194178 chr16 9383682 T A 6.72E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs619140 chr16 9399292 C T 2.94E-04 Multiple complex diseases / / 17554300 rs619140 chr16 9399292 C T 2.82E-05 Brain structure / / 22504417 rs579193 chr16 9399711 C T 9.01E-04 Multiple complex diseases / / 17554300 rs631208 chr16 9399724 A G 2.00E-06 IgE grass sensitization / / 22036096 rs631208 chr16 9399724 A G 8.09E-06 Hypertension (essential hypertension) / / 22184326 rs40511 chr16 9405834 G A 3.27E-05 HIV-1 viral setpoint / / 22174851 rs2162948 chr16 9409310 A G 5.41E-05 HIV-1 viral setpoint / / 22174851 rs249292 chr16 9412804 C T 6.35E-06 HIV-1 viral setpoint / / 22174851 rs12596722 chr16 9417288 A C 2.40E-04 Multiple complex diseases / / 17554300 rs12596722 chr16 9417288 A C 1.23E-06 Osteoarthritis / / 22763110 rs17681592 chr16 9417495 T C 6.02E-04 Multiple complex diseases / / 17554300 rs12918413 chr16 9417781 C T 3.67E-04 Multiple complex diseases / / 17554300 rs249286 chr16 9425362 C A 9.16E-05 Hematocrit / / pha003097 rs837349 chr16 9426404 G A 9.16E-05 Hematocrit / / pha003097 rs1428809 chr16 9429916 A G 1.61E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs537966 chr16 9432732 A G 2.51E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs12597225 chr16 9447076 T C 5.89E-04 Smoking initiation / / 24665060 rs837359 chr16 9484028 T C 7.85E-04 Type 2 diabetes / / 17463246 rs12933414 chr16 9493967 C T 3.83E-05 Personality dimensions / / 18957941 rs694773 chr16 9512260 T C 2.21E-04 Obesity (extreme) / / 21935397 rs249279 chr16 9515678 T C 5.04E-05 Obesity (extreme) / / 21935397 rs249278 chr16 9515870 T A 5.11E-05 Obesity (extreme) / / 21935397 rs183657 chr16 9516090 T C 2.10E-04 Obesity (extreme) / / 21935397 rs8059436 chr16 9516315 T C 5.49E-05 Obesity (extreme) / / 21935397 rs249277 chr16 9516640 C T 5.58E-05 Obesity (extreme) / / 21935397 rs190345 chr16 9516647 C T 2.07E-04 Obesity (extreme) / / 21935397 rs249276 chr16 9516684 G T 5.75E-05 Obesity (extreme) / / 21935397 rs837351 chr16 9516992 A G 2.00E-04 Obesity (extreme) / / 21935397 rs837351 chr16 9516992 A G 8.32E-08 Metabolite levels / / 23281178 rs837353 chr16 9518493 T C 1.83E-04 Obesity (extreme) / / 21935397 rs17681985 chr16 9519225 A G 1.64E-04 Obesity (extreme) / / 21935397 rs837354 chr16 9519927 A T 1.37E-04 Obesity (extreme) / / 21935397 rs837354 chr16 9519927 A T 7.59E-08 Metabolite levels / / 23281178 rs930096 chr16 9522470 A G 4.32E-04 Obesity (extreme) / / 21935397 rs16965263 chr16 9532307 G A 2.23E-05 Obesity (extreme) / / 21935397 rs16965266 chr16 9532978 C T 2.19E-05 Obesity (extreme) / / 21935397 rs11075335 chr16 9534094 A T 6.03E-04 Obesity (extreme) / / 21935397 rs1019798 chr16 9534199 G A 5.99E-04 Obesity (extreme) / / 21935397 rs2304474 chr16 9535518 G T 1.15E-04 Obesity (extreme) / / 21935397 rs2304474 chr16 9535518 G T 2.73E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs1014568 chr16 9535715 C T 5.90E-04 Obesity (extreme) / / 21935397 rs9931240 chr16 9536471 G A 4.52E-04 Obesity (extreme) / / 21935397 rs11640563 chr16 9536631 A G 9.38E-05 Obesity (extreme) / / 21935397 rs1428795 chr16 9536847 G C 1.44E-05 Obesity (extreme) / / 21935397 rs9933849 chr16 9537880 T G 5.33E-04 Obesity (extreme) / / 21935397 rs2075152 chr16 9538061 C T 5.33E-04 Obesity (extreme) / / 21935397 rs2075153 chr16 9538259 T C 4.40E-04 Obesity (extreme) / / 21935397 rs1898230 chr16 9538685 G T 4.37E-04 Obesity (extreme) / / 21935397 rs759318 chr16 9539586 G A 7.32E-04 Obesity (extreme) / / 21935397 rs16965285 chr16 9543508 A T 2.56E-05 Obesity (extreme) / / 21935397 rs765081 chr16 9548663 A C 2.20E-04 Obesity (extreme) / / 21935397 rs1428801 chr16 9548959 C T 2.27E-04 Obesity (extreme) / / 21935397 rs1428803 chr16 9553827 G A 8.82E-04 Obesity (extreme) / / 21935397 rs1024784 chr16 9554345 A C 3.87E-05 Obesity (extreme) / / 21935397 rs7202570 chr16 9555369 T A 3.23E-05 Obesity (extreme) / / 21935397 rs7202570 chr16 9555369 T A 5.90E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs7188066 chr16 9555464 C T 3.23E-05 Obesity (extreme) / / 21935397 rs1428804 chr16 9555489 C T 3.24E-05 Obesity (extreme) / / 21935397 rs9930055 chr16 9556913 A C 4.34E-05 Obesity (extreme) / / 21935397 rs4780421 chr16 9561925 T C 2.42E-05 Obesity (extreme) / / 21935397 rs13336012 chr16 9562082 T C 7.62E-05 Response to methylphenidate treatment / / 21130132 rs887948 chr16 9562368 G A 1.77E-05 Obesity (extreme) / / 21935397 rs759321 chr16 9562745 T A 8.52E-04 Obesity (extreme) / / 21935397 rs720763 chr16 9566074 G A 1.55E-04 Multiple complex diseases / / 17554300 rs720763 chr16 9566074 G A 9.02E-04 Diabetic retinopathy / / 20871662 rs12935313 chr16 9566111 G C 2.40E-04 Multiple complex diseases / / 17554300 rs7201988 chr16 9608506 C G 3.00E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs1548849 chr16 9616423 G A 4.06E-05 Blood Pressure / / pha003045 rs8060304 chr16 9627486 T C 5.63E-05 Schizophrenia / / 24253340 rs12934132 chr16 9629106 G A 9.31E-05 Personality dimensions / / 23903073 rs917955 chr16 9653968 A C 1.90E-05 Urinary metabolites / / 21572414 rs1468769 chr16 9663655 C T 8.59E-05 Iron levels / / 19880490 rs1468769 chr16 9663655 C T 8.59E-05 Iron levels / / pha002876 rs7191552 chr16 9672917 A G 1.30E-05 Urinary metabolites / / 21572414 rs12325410 chr16 9675246 T G 1.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs9939858 chr16 9677897 C T 1.17E-06 Hypertension / / 21082022 rs721843 chr16 9692842 G C 1.58E-06 Response to statin therapy / / 22368281 rs8060684 chr16 9702917 G A 2.74E-07 Non-obstructive azoospermia / / 22197933 rs16965869 chr16 9722399 T G 8.31E-04 Multiple complex diseases / / 17554300 rs316374 chr16 9738961 C A 7.68E-04 Heart Failure / / pha002884 rs17550532 chr16 9744095 A G 2.00E-06 Sudden cardiac arrest / / 21658281 rs17550532 chr16 9744095 A G 2.50E-05 Orofacial clefts / / 22419666 rs170290 chr16 9748201 T C 1.50E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6416608 chr16 9754812 T C 2.54E-04 Multiple complex diseases / / 17554300 rs11646985 chr16 9755469 C G 7.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs17568440 chr16 9755481 G C 7.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs17653172 chr16 9759488 C T 2.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs4781605 chr16 9761770 C T 6.91E-05 Suicide attempts in bipolar disorder / / 21423239 rs12924780 chr16 9768940 C T 9.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs17653204 chr16 9771545 C G 1.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs11645816 chr16 9772106 C T 2.10E-05 Suicide attempts in bipolar disorder / / 21423239 rs3968869 chr16 9772633 A C 1.91E-05 Suicide attempts in bipolar disorder / / 21423239 rs11645132 chr16 9774775 T C 6.38E-05 Suicide attempts in bipolar disorder / / 21423239 rs17568614 chr16 9774788 A G 6.17E-05 Suicide attempts in bipolar disorder / / 21423239 rs7201482 chr16 9774871 C G 2.19E-05 Suicide attempts in bipolar disorder / / 21423239 rs1420046 chr16 9775196 C G 1.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs11645272 chr16 9775235 A G 1.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs11645272 chr16 9775235 A G 9.30E-05 Cholesterol / / pha003073 rs1362323 chr16 9781375 C T 5.73E-05 Multiple complex diseases / / 17554300 rs1362323 chr16 9781375 C T 1.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs1345290 chr16 9781846 G A 4.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs17568718 chr16 9782136 T A 7.27E-04 Multiple complex diseases / / 17554300 rs4063481 chr16 9783169 G C 8.56E-04 Multiple complex diseases / / 17554300 rs4063481 chr16 9783169 G C 4.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs4063482 chr16 9783290 A C 3.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs11640400 chr16 9784183 A G 3.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs11645442 chr16 9784445 C G 1.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs11645485 chr16 9784522 C T 1.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs2080270 chr16 9784803 G A 1.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs1345292 chr16 9784993 G C 3.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs2160168 chr16 9785099 A G 3.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs4781667 chr16 9785420 C T 1.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs8061088 chr16 9786170 T C 3.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs12923310 chr16 9787937 G T 4.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs12923310 chr16 9787937 G T 7.45E-08 Osteoarthritis / / 22763110 rs12925197 chr16 9788429 C G 1.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs8053582 chr16 9789066 G C 7.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs8061848 chr16 9790691 C T 2.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs4781670 chr16 9792542 C G 1.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs1476954 chr16 9793382 A G 1.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs1972577 chr16 9794960 G A 3.50E-05 Hirschsprung's disease / / 19196962 rs1972578 chr16 9795074 A G 9.07E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7203936 chr16 9798986 C G 1.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs7202531 chr16 9799012 G T 9.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs11648730 chr16 9807577 C T 6.06E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs8047193 chr16 9809395 G A 1.10E-05 Urinary metabolites / / 21572414 rs7206827 chr16 9812077 G C 3.20E-06 Urinary metabolites / / 21572414 rs8056965 chr16 9822300 T G 5.60E-06 Urinary metabolites / / 21572414 rs11866328 chr16 9862556 G T 2.00E-08 Hepatitis B GRIN2A intron 22004137 rs11866328 chr16 9862556 G T 1.60E-08 Hepatocellular carcinoma (hepatitis B virus related) GRIN2A intron 23242368 rs2267772 chr16 9867387 C G 7.03E-04 Type 2 diabetes GRIN2A intron 17463246 rs8060992 chr16 9873939 T A 6.54E-04 Bipolar disorder,schizoaffective GRIN2A intron 19567891 rs8058295 chr16 9911386 C A 7.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) GRIN2A intron 23453885 rs12920919 chr16 9937980 T C 1.00E-04 Nicotine smoking GRIN2A intron 19268276 rs11074502 chr16 10022719 C T 3.55E-05 Cognitive impairment induced by topiramate GRIN2A intron 22091778 rs4780717 chr16 10027281 C T 2.20E-05 Urinary metabolites GRIN2A intron 21572414 rs4780721 chr16 10030406 T A,G 2.60E-05 Urinary metabolites GRIN2A intron 21572414 rs4780721 chr16 10030406 T A,G 3.38E-05 Cognitive impairment induced by topiramate GRIN2A intron 22091778 rs13332245 chr16 10035065 C T 8.46E-04 Alzheimer's disease GRIN2A intron 17998437 rs12708644 chr16 10035240 A G 2.00E-04 Cognitive impairment induced by topiramate GRIN2A intron 22091778 rs1875209 chr16 10038054 C T 1.21E-05 Cognitive impairment induced by topiramate GRIN2A intron 22091778 rs57576479 chr16 10038322 C A 5.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9933069 chr16 10039337 A G 7.19E-05 Cognitive impairment induced by topiramate GRIN2A intron 22091778 rs59775432 chr16 10046693 G T 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7192121 chr16 10048583 T C 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs17670318 chr16 10049902 T G 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs16966731 chr16 10052440 T C 9.70E-06 Urinary metabolites GRIN2A intron 21572414 rs13330640 chr16 10054966 A G 6.33E-04 Aortic root size GRIN2A intron 21223598 rs9925439 chr16 10055461 T G 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs11642346 chr16 10058574 C T 7.80E-06 Urinary metabolites GRIN2A intron 21572414 rs1875206 chr16 10059007 A G 7.74E-05 Myocardial Infarction GRIN2A intron pha002873 rs17670396 chr16 10059322 T C 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs884918 chr16 10059826 T C 7.18E-04 Multiple complex diseases GRIN2A intron 17554300 rs7197048 chr16 10062615 C T 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs8045558 chr16 10064806 G A 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs57497843 chr16 10066411 G C 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs4780751 chr16 10067989 T A 1.00E-05 Urinary metabolites GRIN2A intron 21572414 rs4998386 chr16 10070545 C T 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7191736 chr16 10070578 C T 9.00E-07 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7190716 chr16 10070739 G T 9.00E-07 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs4254328 chr16 10071070 G A 9.00E-07 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs17569609 chr16 10071789 G A 8.00E-07 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs3897996 chr16 10072629 C T 7.00E-07 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9929020 chr16 10074142 T A 7.00E-07 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs17670509 chr16 10075994 T C 7.00E-07 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs11074517 chr16 10076656 G A 6.80E-08 Urinary metabolites GRIN2A intron 21572414 rs8044626 chr16 10078695 G T 7.00E-07 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7190619 chr16 10079124 G A 7.00E-07 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs17670544 chr16 10080032 A T 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs17569693 chr16 10080185 A G 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs61628643 chr16 10081285 A G 7.00E-07 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs59931374 chr16 10081287 G A 7.00E-07 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs11641062 chr16 10082751 G C 7.70E-06 Urinary metabolites GRIN2A intron 21572414 rs60547225 chr16 10088563 A G 9.00E-07 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs3105692 chr16 10094138 G C 2.30E-05 Urinary metabolites GRIN2A intron 21572414 rs7200719 chr16 10094546 C T 4.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs4107019 chr16 10095199 T C 1.15E-35 Narcolepsy GRIN2A intron 19629137 rs4107019 chr16 10095199 T C 5.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs8043728 chr16 10095503 C T 8.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7203512 chr16 10099086 T C 4.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7198528 chr16 10099095 A T 4.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs8060239 chr16 10112308 C T 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs17670766 chr16 10113425 T C 5.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs17569940 chr16 10114339 C G 4.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs1827197 chr16 10115364 C A 4.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7193123 chr16 10123047 C T 5.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs10500372 chr16 10125046 A G 1.21E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) GRIN2A intron 17982456 rs10500373 chr16 10125476 T C 7.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) GRIN2A intron 17982456 rs3743833 chr16 10127955 G A 3.71E-05 HIV-1 progression to AIDS and death GRIN2A intron 21811574 rs3743833 chr16 10127955 G A 5.56E-05 HIV-1 progression to AIDS and death GRIN2A intron 21811574 rs3743833 chr16 10127955 G A 6.41E-04 HIV-1 progression to AIDS and death GRIN2A intron 21811574 rs7193471 chr16 10137633 C T 4.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs13332501 chr16 10141139 G A 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs28528871 chr16 10142383 G A 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7190321 chr16 10144019 G C 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs28491487 chr16 10145196 T C 6.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs8056683 chr16 10145209 C T 4.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs8061963 chr16 10145287 T G 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs8062320 chr16 10145469 T C 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7203194 chr16 10145932 G C 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs8056514 chr16 10146992 G A 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7200649 chr16 10147476 C T 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7206296 chr16 10147478 T G 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs13335102 chr16 10148628 G A,C 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs58834898 chr16 10148777 G A 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs12102500 chr16 10149179 A G 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs12102636 chr16 10149228 T G 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9925707 chr16 10149767 A T 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9927914 chr16 10149853 T C 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9925801 chr16 10149892 A C 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9927926 chr16 10149904 T C 4.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs1463128 chr16 10150034 T C 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9937970 chr16 10150170 C T 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7194796 chr16 10153638 A T 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7198175 chr16 10154166 G A 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs17670977 chr16 10155271 T C 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7189360 chr16 10155995 C T 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7188122 chr16 10156045 G A 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9935354 chr16 10156791 C T 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs8043864 chr16 10156929 C A 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9922383 chr16 10157678 G A 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9922460 chr16 10157793 G T 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9935774 chr16 10158091 A G 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9938061 chr16 10158170 T C 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7197200 chr16 10158420 T C 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7192622 chr16 10158842 C G 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs1448261 chr16 10160824 G T 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs1448262 chr16 10160869 G T 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7188081 chr16 10160934 A G 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7188291 chr16 10161036 A G 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs17671033 chr16 10161226 G A 4.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9933478 chr16 10161252 G A 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs13331457 chr16 10161635 A C 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs28581562 chr16 10161841 G A 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs28465345 chr16 10161938 G A 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs28375797 chr16 10161996 C T 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs8057034 chr16 10162951 G A 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs8059513 chr16 10163228 A G 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs8059547 chr16 10163294 A G 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9930396 chr16 10163777 A G 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9933111 chr16 10164599 A G 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9922871 chr16 10164816 C A 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9922338 chr16 10164828 G A 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9302409 chr16 10165030 T C 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs17570290 chr16 10165146 T G 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs10518152 chr16 10165287 A G 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs10518151 chr16 10165319 T C 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs13332018 chr16 10165670 C T 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9938467 chr16 10165911 T C 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs8061018 chr16 10166402 T C 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9927648 chr16 10166501 G A 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs58797003 chr16 10166687 A C 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs59568026 chr16 10166777 A C 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs61224814 chr16 10167255 C T 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs60950183 chr16 10167298 A G 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs56666352 chr16 10167638 T C 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs12102832 chr16 10168132 T C 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs8062241 chr16 10168308 T C 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs8062624 chr16 10168497 T C 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9931653 chr16 10168692 T C 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs10518150 chr16 10168756 T G 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9933945 chr16 10168986 T A 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs10518149 chr16 10169062 A C 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs28634372 chr16 10169279 A G 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs60276136 chr16 10169590 A G 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs28540790 chr16 10169644 T G 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs28574279 chr16 10169671 G A 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs57587803 chr16 10169746 C T 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs60864732 chr16 10169756 T G 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs58861142 chr16 10169813 A G 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs16956843 chr16 10169965 G A 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs61686802 chr16 10170051 T C 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs13331030 chr16 10170191 G C 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs13331085 chr16 10170308 G C,T 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs13331088 chr16 10170318 G A 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs13331428 chr16 10170369 C A 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs13331461 chr16 10170447 C T 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs13331465 chr16 10170467 C T 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs13331168 chr16 10170497 G C 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs13331514 chr16 10170609 C A 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs13336632 chr16 10170654 A C 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs57737700 chr16 10170696 G T 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs13336710 chr16 10170828 A T 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs13332665 chr16 10171005 C G 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs13332699 chr16 10171087 C A 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs9940458 chr16 10171863 T G 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs2352741 chr16 10172705 T C 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs1375072 chr16 10173075 T C 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7191991 chr16 10173690 T C 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs1448268 chr16 10174677 C T 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs1448270 chr16 10175318 T G 5.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs1448271 chr16 10175471 T C 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs1111537 chr16 10175577 A G 4.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs1375075 chr16 10175729 G A 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs1375076 chr16 10175731 A C 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs4780784 chr16 10176088 G A 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs1448272 chr16 10176135 G C 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7199095 chr16 10177508 G C 6.00E-07 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7206094 chr16 10177510 T C 6.00E-07 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7206714 chr16 10177995 A C 1.69E-05 Alcohol dependence GRIN2A intron 21314694 rs7201627 chr16 10179958 T C 4.00E-07 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs4780792 chr16 10182349 T C 1.06E-04 Multiple complex diseases GRIN2A intron 17554300 rs1463132 chr16 10183087 T C 8.00E-06 HIV-1 control GRIN2A intron 20041166 rs17671178 chr16 10187207 A G 8.00E-08 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7203315 chr16 10188060 G T 4.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients GRIN2A intron 23400010 rs56275045 chr16 10201392 C A,G 5.00E-08 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs12445246 chr16 10206002 C A 8.89E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GRIN2A intron 22566498 rs11866570 chr16 10206175 T C 3.00E-05 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs7196139 chr16 10214398 T C 5.00E-07 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs1868289 chr16 10215813 G T 7.66E-05 Information processing speed GRIN2A intron 21130836 rs1375068 chr16 10216457 C A 1.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs4782266 chr16 10217990 A C 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs56135508 chr16 10218496 A G 2.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs1448253 chr16 10220866 C T 5.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs1448254 chr16 10220961 C A 1.11E-05 Tunica Media GRIN2A intron pha003034 rs9930364 chr16 10221483 A T 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs11645379 chr16 10221970 A G 3.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs6497716 chr16 10222808 C T 5.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs2197778 chr16 10223455 A C 5.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs1070479 chr16 10229372 G A 9.00E-06 Parkinson's disease (interaction with coffee consumption) GRIN2A intron 21876681 rs11074605 chr16 10230253 G T 7.17E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) GRIN2A intron 22566498 rs1070484 chr16 10231558 T C 2.54E-05 Eosinophil counts GRIN2A intron pha003088 rs1345424 chr16 10250659 T C 5.57E-06 Elbow pain GRIN2A intron pha003008 rs4780867 chr16 10271895 C G 8.30E-05 Response to statin therapy GRIN2A intron 20339536 rs1650396 chr16 10284156 C T 9.70E-05 Response to statin therapy / / 20339536 rs17671641 chr16 10284176 G A 8.80E-05 Response to statin therapy / / 20339536 rs1070495 chr16 10284216 G C 8.80E-05 Response to statin therapy / / 20339536 rs9930500 chr16 10288184 C T 8.20E-05 Response to statin therapy / / 20339536 rs9930833 chr16 10288573 C T 9.40E-05 Response to statin therapy / / 20339536 rs8046217 chr16 10288862 T A 7.90E-05 Response to statin therapy / / 20339536 rs4780896 chr16 10318531 C T 8.80E-05 HDL particle features / / pha002900 rs1097863 chr16 10327329 T G 3.20E-04 Alcohol dependence / / 20201924 rs13330098 chr16 10330277 T C 5.70E-04 Multiple complex diseases / / 17554300 rs1103909 chr16 10342518 G A 3.72E-04 Type 2 diabetes / / 17463246 rs1104039 chr16 10343038 C G 4.60E-05 Obesity,menopause / / 21424828 rs11074683 chr16 10349893 C T 9.58E-05 Waist-Hip Ratio / / pha003013 rs12449282 chr16 10357519 C A 0.000237846 Hypertension (early onset hypertension) / / 22479346 rs9939196 chr16 10425057 T C 6.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs7359456 chr16 10456135 A G 4.42E-04 Alzheimer's disease (late onset) / / 21379329 rs12597514 chr16 10482312 A G 4.66E-04 Alzheimer's disease (late onset) ATF7IP2 intron 21379329 rs13335336 chr16 10559263 A G 7.00E-07 Response to antipsychotic treatment ATF7IP2 intron 20195266 rs16957355 chr16 10589345 T G 2.45E-04 Blood pressure / / 17255346 rs184822539 chr16 10593203 T G 7.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs3790126 chr16 10624549 C T 1.79E-04 Blood pressure EMP2 UTR-3 17255346 rs6498068 chr16 10630777 C A 6.00E-06 Metabolite levels (MHPG) EMP2 intron 23319000 rs11074889 chr16 10633165 A G 2.13E-05 Attention deficit hyperactivity disorder EMP2 intron 20732625 rs11074889 chr16 10633165 A G 7.00E-07 Attention deficit hyperactivity disorder EMP2 intron 20732626 rs4780947 chr16 10659886 A G 5.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EMP2 intron 20877124 rs4780947 chr16 10659886 A G 6.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EMP2 intron 20877124 rs2354420 chr16 10663038 T C 2.31E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) EMP2 intron 24023788 rs2221433 chr16 10663627 T G 5.00E-06 Eating disorders EMP2 intron 23568457 rs1465349 chr16 10687290 G A 3.85E-04 Type 2 diabetes / / 17463246 rs4780959 chr16 10701056 A G 8.18E-05 Neuroblastoma / / pha002895 rs9925930 chr16 10734023 T G 5.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TEKT5 intron 20877124 rs2541530 chr16 10734474 A G 2.40E-05 Urinary metabolites TEKT5 intron 21572414 rs2719634 chr16 10735738 T A 4.73E-04 Response to cytadine analogues (cytosine arabinoside) TEKT5 intron 24483146 rs2541546 chr16 10742510 A G 6.02E-04 Multiple complex diseases TEKT5 intron 17554300 rs2719756 chr16 10742767 G C 6.47E-04 Multiple complex diseases TEKT5 intron 17554300 rs2719646 chr16 10748266 C T 0.0003976 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TEKT5 intron 23233654 rs2719646 chr16 10748266 C T 3.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) TEKT5 intron 23233662 rs2719646 chr16 10748266 C T 2.41E-04 Blood pressure (response to angiotensin II receptor blocker) TEKT5 intron 24192120 rs2541522 chr16 10750548 A G 0.0005176 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TEKT5 intron 23233654 rs2541522 chr16 10750548 A G 5.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) TEKT5 intron 23233662 rs2719710 chr16 10769958 T C 9.52E-05 Neutrophil count TEKT5 missense pha003095 rs2017417 chr16 10770907 A G 2.72E-13 Metabolite levels TEKT5 intron 22286219 rs2719715 chr16 10772824 A T 3.29E-04 Type 2 diabetes TEKT5 intron 17463246 rs16957526 chr16 10774378 G A 7.84E-05 Body mass index TEKT5 intron 17255346 rs2719726 chr16 10779741 A C 8.72E-04 Type 2 diabetes TEKT5 intron 17463246 rs2719726 chr16 10779741 A C 9.35E-05 Cholesterol TEKT5 intron pha003073 rs2719726 chr16 10779741 A C 9.01E-05 Cholesterol TEKT5 intron pha003078 rs2251984 chr16 10788106 A G 3.61E-05 Cholesterol TEKT5 intron pha003073 rs2251984 chr16 10788106 A G 2.70E-05 ldl cholesterol TEKT5 intron pha003076 rs2251984 chr16 10788106 A G 5.03E-05 Cholesterol TEKT5 intron pha003078 rs4780986 chr16 10815230 A G 9.42E-05 Alcohol dependence / / 20201924 rs4780986 chr16 10815230 A G 9.42E-05 Alcoholism / / pha002891 rs1092192 chr16 10822175 G A 8.48E-04 Type 2 diabetes / / 17463246 rs12935578 chr16 10829051 T C 3.64E-04 Type 2 diabetes / / 17463246 rs2697649 chr16 10835117 T C 2.18E-06 Carotenoid and tocopherol levels / / 19185284 rs4780323 chr16 10840847 C G 8.88E-05 Multiple complex diseases NUBP1 intron 17554300 rs1641788 chr16 10861110 C T 4.92E-05 Information processing speed FAM18A UTR-3 21130836 rs8055253 chr16 10871313 A C 6.52E-04 Amyotrophic lateral sclerosis (sporadic) FAM18A intron 24529757 rs11866645 chr16 10886823 T C 1.96E-05 Psoriasis FAM18A intron 20953187 rs9939578 chr16 10903108 A G 2.53E-04 Suicide attempts in bipolar disorder FAM18A intron 21423239 rs7196683 chr16 10924058 G A 1.22E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs4781002 chr16 10928112 A G 6.73E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6498114 chr16 10964118 G T 5.80E-10 Celiac disease / / 22057235 rs4781011 chr16 10975311 T G 3.00E-06 Ulcerative colitis CIITA intron 20228799 rs4781011 chr16 10975311 T G 5.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CIITA intron 20877124 rs7189406 chr16 10993488 G A 8.33E-05 Gallstones CIITA intron 17632509 rs6498124 chr16 10995850 G T 4.00E-05 Asthma (aspirin-intolerant) CIITA intron 21072201 rs7404615 chr16 10999673 C G 1.37E-04 Multiple complex diseases CIITA intron 17554300 rs7204799 chr16 11004549 C G 6.38E-04 Alzheimer's disease CIITA intron 17998437 rs7204799 chr16 11004549 C G 2.55E-04 Response to cytidine analogues (gemcitabine) CIITA intron 24483146 rs7404786 chr16 11012550 G C 1.90E-05 Urinary metabolites CIITA intron 21572414 rs8056269 chr16 11012567 G C 2.20E-05 Urinary metabolites CIITA intron 21572414 rs2229322 chr16 11016045 C T 7.67E-06 Acute lymphoblastic leukemia (childhood) CIITA cds-synon 22076464 rs4072864 chr16 11023868 A C 5.39E-05 Body mass (lean) DEXI intron 19268274 rs4072865 chr16 11024105 C T 2.25E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) DEXI intron 24023788 rs17802927 chr16 11037738 A G 3.78E-06 Self-reported allergy CLEC16A nearGene-5 23817569 rs3743976 chr16 11038824 C T 6.20E-06 Self-reported allergy CLEC16A intron 23817569 rs12931878 chr16 11042194 A G 2.90E-07 Type 1 diabetes CLEC16A intron 17632545 rs12931878 chr16 11042194 A G 1.10E-05 Alzheimer's disease (late onset) CLEC16A intron 21460841 rs8055533 chr16 11042239 G A 7.06E-06 Alzheimer's disease CLEC16A intron 19734903 rs8055533 chr16 11042239 G A 1.70E-06 Alzheimer's disease (late onset) CLEC16A intron 21460841 rs6498138 chr16 11045278 A T 1.60E-04 Multiple complex diseases CLEC16A intron 17554300 rs1035088 chr16 11048374 A G 1.66E-05 Self-reported allergy CLEC16A intron 23817569 rs1700820 chr16 11056618 A G 1.73E-04 Multiple complex diseases CLEC16A intron 17554300 rs4781028 chr16 11059363 C G 8.59E-06 Alzheimer's disease (late onset) CLEC16A intron 21460841 rs9302457 chr16 11059837 G A 2.20E-06 Alzheimer's disease CLEC16A intron 19734903 rs9302457 chr16 11059837 G A 7.50E-07 Alzheimer's disease (late onset) CLEC16A intron 21460841 rs16957843 chr16 11061205 C T 9.71E-05 Alzheimer's disease (late onset) CLEC16A intron 21460841 rs12923849 chr16 11061997 G A 3.43E-08 Type 1 diabetes CLEC16A intron 17632545 rs12923849 chr16 11061997 G A 1.93E-06 Self-reported allergy CLEC16A intron 23817569 rs17229044 chr16 11062936 C T 5.51E-06 Multiple complex diseases CLEC16A intron 17554300 rs17229044 chr16 11062936 C T 5.55E-08 Type 1 diabetes CLEC16A intron 17632545 rs17229044 chr16 11062936 C T 1.32E-06 Self-reported allergy CLEC16A intron 23817569 rs12921922 chr16 11064321 T C 5.17E-06 Self-reported allergy CLEC16A intron 23817569 rs16957849 chr16 11065307 T C 7.40E-06 Alzheimer's disease (late onset) CLEC16A intron 21460841 rs17803698 chr16 11070289 A G 7.55E-05 Multiple complex diseases CLEC16A intron 17554300 rs16957854 chr16 11070323 C T 3.28E-04 Multiple complex diseases CLEC16A intron 17554300 rs8055893 chr16 11071795 C T 1.50E-04 Multiple complex diseases CLEC16A intron 17554300 rs12708713 chr16 11072459 C T 5.66E-05 Multiple complex diseases CLEC16A intron 17554300 rs12708713 chr16 11072459 C T 1.34E-06 Self-reported allergy CLEC16A intron 23817569 rs7201845 chr16 11078338 G A 9.61E-06 Self-reported allergy CLEC16A intron 23817569 rs9652599 chr16 11079161 A G 9.48E-06 Self-reported allergy CLEC16A intron 23817569 rs6498142 chr16 11081249 C G 2.52E-05 Multiple complex diseases CLEC16A intron 17554300 rs6498142 chr16 11081249 C G 2.00E-07 Immunoglobulin A CLEC16A intron 20694011 rs8055968 chr16 11084703 A G 2.49E-05 Self-reported allergy CLEC16A intron 23817569 rs7403919 chr16 11085968 C T 1.20E-04 Self-reported allergy CLEC16A intron 23817569 rs13339285 chr16 11088694 C T 3.69E-06 Self-reported allergy CLEC16A intron 23817569 rs13330041 chr16 11088808 G A 6.80E-09 Type 1 diabetes CLEC16A intron 17632545 rs13330041 chr16 11088808 G A 8.82E-07 Self-reported allergy CLEC16A intron 23817569 rs8055544 chr16 11091561 G T 2.85E-05 Multiple complex diseases CLEC16A intron 17554300 rs8062322 chr16 11092319 C A 1.37E-05 Self-reported allergy CLEC16A intron 23817569 rs9926367 chr16 11093179 T C 4.37E-06 Self-reported allergy CLEC16A intron 23817569 rs9934231 chr16 11093321 C A,G 9.32E-05 Multiple complex diseases CLEC16A intron 17554300 rs13337334 chr16 11094418 G C 2.10E-05 Self-reported allergy CLEC16A intron 23817569 rs9925481 chr16 11097479 C T 4.10E-14 Progranulin levels CLEC16A intron 21087763 rs9925481 chr16 11097479 C T 4.10E-14 Myocardial infarction CLEC16A intron 21211798 rs723586 chr16 11098379 C G 2.85E-05 Self-reported allergy CLEC16A intron 23817569 rs7194305 chr16 11099707 A G 3.71E-05 Self-reported allergy CLEC16A intron 23817569 rs17804470 chr16 11099968 G C 2.22E-05 Self-reported allergy CLEC16A intron 23817569 rs12934193 chr16 11103725 T C 1.12E-06 Self-reported allergy CLEC16A intron 23817569 rs9935174 chr16 11111347 C T 1.11E-05 Self-reported allergy CLEC16A intron 23817569 rs2286975 chr16 11114006 G A 3.09E-05 Self-reported allergy CLEC16A intron 23817569 rs1003603 chr16 11114623 A C,G 6.51E-06 Self-reported allergy CLEC16A intron 23817569 rs1985372 chr16 11114839 C T 6.28E-06 Self-reported allergy CLEC16A intron 23817569 rs1861548 chr16 11118500 G C 4.89E-06 Self-reported allergy CLEC16A intron 23817569 rs8045749 chr16 11119653 A G 4.89E-06 Self-reported allergy CLEC16A intron 23817569 rs9923455 chr16 11131864 G C 2.80E-06 Self-reported allergy CLEC16A intron 23817569 rs9932114 chr16 11134903 G A 8.22E-04 Alzheimer's disease CLEC16A intron 17998437 rs7185202 chr16 11135064 C G 5.02E-04 Multiple complex diseases CLEC16A intron 17554300 rs8056098 chr16 11138812 G A 7.02E-06 Self-reported allergy CLEC16A intron 23817569 rs17230818 chr16 11142137 T A 8.46E-07 Self-reported allergy CLEC16A intron 23817569 rs3901386 chr16 11142720 T C 1.13E-07 Multiple complex diseases CLEC16A intron 17554300 rs3901386 chr16 11142720 T C 2.33E-06 Self-reported allergy CLEC16A intron 23817569 rs9302458 chr16 11144209 C G 2.90E-04 Multiple complex diseases CLEC16A intron 17554300 rs11863415 chr16 11147094 C G 5.96E-04 Multiple complex diseases CLEC16A intron 17554300 rs876476 chr16 11150248 G A 2.65E-05 Self-reported allergy CLEC16A intron 23817569 rs2286973 chr16 11154770 G A 1.74E-05 Self-reported allergy CLEC16A cds-synon 23817569 rs887864 chr16 11158885 G A 1.00E-06 Allergic rhinitis CLEC16A intron 22036096 rs887864 chr16 11158885 G A 1.36E-05 Self-reported allergy CLEC16A intron 23817569 rs741175 chr16 11159685 C T 3.53E-05 Self-reported allergy CLEC16A intron 23817569 rs741174 chr16 11159838 T C 4.62E-05 Self-reported allergy CLEC16A intron 23817569 rs741173 chr16 11159919 A C 3.49E-05 Self-reported allergy CLEC16A intron 23817569 rs8062923 chr16 11160966 A C 1.18E-05 Self-reported allergy CLEC16A intron 23817569 rs4781035 chr16 11161178 A G 1.02E-05 Self-reported allergy CLEC16A intron 23817569 rs7200940 chr16 11164567 G C 7.84E-06 Self-reported allergy CLEC16A intron 23817569 rs11860603 chr16 11165017 T C 3.04E-07 Multiple sclerosis CLEC16A intron 19525953 rs11860603 chr16 11165017 T C 2.99E-06 Self-reported allergy CLEC16A intron 23817569 rs11865121 chr16 11166688 C A 2.00E-07 Multiple sclerosis CLEC16A intron 19525953 rs11865121 chr16 11166688 C A 2.78E-06 Self-reported allergy CLEC16A intron 23817569 rs7198621 chr16 11167458 C G 2.77E-06 Self-reported allergy CLEC16A intron 23817569 rs7192790 chr16 11167914 C A 1.04E-06 Self-reported allergy CLEC16A intron 23817569 rs725613 chr16 11169683 T G 8.86E-11 Type 1 diabetes CLEC16A intron 17632545 rs725613 chr16 11169683 T G 3.13E-10 Primary biliary cirrhosis CLEC16A intron 21399635 rs725613 chr16 11169683 T G 1.93E-06 Self-reported allergy CLEC16A intron 23817569 rs12444495 chr16 11170455 T C 1.12E-06 Self-reported allergy CLEC16A intron 23817569 rs7184491 chr16 11170761 C T 2.31E-06 Self-reported allergy CLEC16A intron 23817569 rs12925642 chr16 11171602 A G 2.61E-12 Primary biliary cirrhosis CLEC16A intron 22961000 rs12925642 chr16 11171602 A G 3.31E-06 Self-reported allergy CLEC16A intron 23817569 rs2058531 chr16 11172109 T C 9.73E-13 Primary biliary cirrhosis CLEC16A intron 22961000 rs9652601 chr16 11174365 G A 2.35E-06 Self-reported allergy CLEC16A intron 23817569 rs9652582 chr16 11174564 G A 6.88E-13 Primary biliary cirrhosis CLEC16A intron 22961000 rs9652582 chr16 11174564 G A 1.56E-06 Self-reported allergy CLEC16A intron 23817569 rs2041670 chr16 11174652 G A 6.70E-10 Type 1 diabetes CLEC16A intron 17632545 rs2041670 chr16 11174652 G A 8.90E-05 Multiple sclerosis CLEC16A intron 20598377 rs2041670 chr16 11174652 G A 6.47E-13 Primary biliary cirrhosis CLEC16A intron 22961000 rs2041670 chr16 11174652 G A 1.52E-06 Self-reported allergy CLEC16A intron 23817569 rs7200786 chr16 11177801 A G 9.12E-07 Type 1 diabetes CLEC16A intron 17632545 rs7200786 chr16 11177801 A G 9.00E-17 Multiple sclerosis CLEC16A intron 21833088 rs7200786 chr16 11177801 A G 8.80E-05 Multiple sclerosis CLEC16A intron 24234648 rs12708715 chr16 11177824 C T 2.19E-13 Primary biliary cirrhosis CLEC16A intron 22961000 rs12932833 chr16 11178070 C G 1.11E-06 Self-reported allergy CLEC16A intron 23817569 rs9929994 chr16 11178245 A G 1.68E-06 Self-reported allergy CLEC16A intron 23817569 rs12708716 chr16 11179873 A G 3.00E-18 Type 1 diabetes CLEC16A intron 17554260 rs12708716 chr16 11179873 A G 5.00E-07 Type 1 diabetes CLEC16A intron 17554300 rs12708716 chr16 11179873 A G 7.00E-13 Type 1 diabetes CLEC16A intron 18978792 rs12708716 chr16 11179873 A G 2.00E-16 Type 1 diabetes CLEC16A intron 19430480 rs12708716 chr16 11179873 A G 1.49E-06 Multiple sclerosis CLEC16A intron 19525953 rs12708716 chr16 11179873 A G 5.00E-14 Type 1 diabetes autoantibodies CLEC16A intron 21829393 rs12708716 chr16 11179873 A G 1.10E-12 Multiple sclerosis CLEC16A intron 21833088 rs12708716 chr16 11179873 A G 1.08E-04 Multiple sclerosis CLEC16A intron 22190364 rs12708716 chr16 11179873 A G 9.70E-04 Hypothyroidism CLEC16A intron 22493691 rs12708716 chr16 11179873 A G 7.97E-13 Primary biliary cirrhosis CLEC16A intron 22961000 rs12708716 chr16 11179873 A G 2.50E-06 Self-reported allergy CLEC16A intron 23817569 rs9888908 chr16 11181244 C A 3.76E-06 Self-reported allergy CLEC16A intron 23817569 rs7203793 chr16 11182134 C G 4.37E-12 Primary biliary cirrhosis CLEC16A intron 22961000 rs11642009 chr16 11182893 T G 0.0000017 Asthma CLEC16A intron 23040885 rs11642009 chr16 11182893 T G 2.16E-06 Self-reported allergy CLEC16A intron 23817569 rs11861236 chr16 11183626 T C 2.26E-05 Self-reported allergy CLEC16A intron 23817569 rs17805769 chr16 11185873 A G 1.61E-05 Self-reported allergy CLEC16A intron 23817569 rs12924729 chr16 11187783 G A 6.33E-11 Multiple complex diseases CLEC16A intron 17554300 rs12924729 chr16 11187783 G A 1.46E-08 Type 1 diabetes CLEC16A intron 17632545 rs12924729 chr16 11187783 G A 3.00E-12 Primary biliary cirrhosis CLEC16A intron 21399635 rs12924729 chr16 11187783 G A 1.16E-12 Primary biliary cirrhosis CLEC16A intron 22961000 rs12924729 chr16 11187783 G A 6.77E-06 Self-reported allergy CLEC16A intron 23817569 rs12917656 chr16 11187862 T C 3.80E-05 Self-reported allergy CLEC16A intron 23817569 rs12919083 chr16 11188930 A C 0.00000305 Primary biliary cirrhosis CLEC16A intron 22936693 rs12919083 chr16 11188930 A C 5.38E-06 Self-reported allergy CLEC16A intron 23817569 rs12917716 chr16 11189148 G C 3.51E-05 Self-reported allergy CLEC16A intron 23817569 rs12599402 chr16 11189888 T C 3.19E-09 Type 1 diabetes CLEC16A intron 17632545 rs12599402 chr16 11189888 T C 5.00E-07 Systemic lupus erythematosus CLEC16A intron 23273568 rs12599402 chr16 11189888 T C 3.33E-05 Self-reported allergy CLEC16A intron 23817569 rs12928537 chr16 11191400 G A 4.65E-06 Self-reported allergy CLEC16A intron 23817569 rs17806056 chr16 11192499 T A 1.45E-06 Self-reported allergy CLEC16A intron 23817569 rs8061826 chr16 11192787 A G 1.68E-05 Self-reported allergy CLEC16A intron 23817569 rs3893661 chr16 11193880 C G 1.51E-05 Self-reported allergy CLEC16A intron 23817569 rs3893660 chr16 11193930 A G 8.04E-09 Multiple complex diseases CLEC16A intron 17554300 rs3893660 chr16 11193930 A G 1.41E-05 Self-reported allergy CLEC16A intron 23817569 rs3862468 chr16 11194018 G C 1.26E-05 Self-reported allergy CLEC16A intron 23817569 rs3862469 chr16 11194080 C T 5.81E-05 Self-reported allergy CLEC16A intron 23817569 rs12927355 chr16 11194771 C T 1.91E-16 Type 1 diabetes CLEC16A intron 21980299 rs12927355 chr16 11194771 C T 5.33E-13 Primary biliary cirrhosis CLEC16A intron 22961000 rs12927355 chr16 11194771 C T 2.85E-06 Self-reported allergy CLEC16A intron 23817569 rs9941107 chr16 11196041 G A 8.12E-09 Multiple complex diseases CLEC16A intron 17554300 rs9941107 chr16 11196041 G A 1.16E-05 Self-reported allergy CLEC16A intron 23817569 rs998592 chr16 11199678 C T 4.96E-09 Type 1 diabetes CLEC16A intron 17632545 rs998592 chr16 11199678 C T 1.38E-05 Self-reported allergy CLEC16A intron 23817569 rs998592 chr16 11199678 C T 1.38E-04 Breast cancer CLEC16A intron pha002853 rs17806299 chr16 11199980 G A 3.59E-06 Self-reported allergy CLEC16A intron 23817569 rs9933507 chr16 11201428 T C 2.66E-09 Type 1 diabetes CLEC16A intron 17632545 rs9933507 chr16 11201428 T C 2.40E-04 Systemic lupus erythematosus CLEC16A intron 23273568 rs9933507 chr16 11201428 T C 1.16E-05 Self-reported allergy CLEC16A intron 23817569 rs9926078 chr16 11203565 G C 1.11E-05 Self-reported allergy CLEC16A intron 23817569 rs12103174 chr16 11203730 A G 6.09E-06 Type 1 diabetes CLEC16A intron 17632545 rs12103174 chr16 11203730 A G 3.10E-04 Systemic lupus erythematosus CLEC16A intron 23273568 rs12103174 chr16 11203730 A G 9.14E-06 Self-reported allergy CLEC16A intron 23817569 rs767448 chr16 11204221 A G 1.20E-05 Self-reported allergy CLEC16A intron 23817569 rs7198004 chr16 11207617 A G 5.67E-08 Multiple complex diseases CLEC16A intron 17554300 rs7198004 chr16 11207617 A G 1.55E-05 Self-reported allergy CLEC16A intron 23817569 rs7203150 chr16 11207722 T C 3.56E-08 Multiple complex diseases CLEC16A intron 17554300 rs7203150 chr16 11207722 T C 1.72E-05 Self-reported allergy CLEC16A intron 23817569 rs9746695 chr16 11207894 T C 8.19E-09 Multiple complex diseases CLEC16A intron 17554300 rs9746695 chr16 11207894 T C 1.94E-12 Primary biliary cirrhosis CLEC16A intron 22961000 rs9746695 chr16 11207894 T C 9.56E-06 Self-reported allergy CLEC16A intron 23817569 rs12924985 chr16 11208322 G C 1.93E-05 Self-reported allergy CLEC16A intron 23817569 rs9923856 chr16 11210415 T C 6.00E-06 Atopic dermatitis CLEC16A intron 23042114 rs9923856 chr16 11210415 T C 4.37E-05 Self-reported allergy CLEC16A intron 23817569 rs12935413 chr16 11210447 G A 1.85E-10 Primary biliary cirrhosis CLEC16A intron 21399635 rs12935413 chr16 11210447 G A 2.05E-12 Primary biliary cirrhosis CLEC16A intron 22961000 rs12935413 chr16 11210447 G A 3.75E-06 Self-reported allergy CLEC16A intron 23817569 rs9927527 chr16 11212681 A G 6.88E-06 Self-reported allergy CLEC16A intron 23817569 rs12935657 chr16 11219041 G A 0.000005 Asthma CLEC16A intron 23040885 rs12935657 chr16 11219041 G A 5.19E-07 Self-reported allergy CLEC16A intron 23817569 rs78394940 chr16 11222238 C T 2.00E-06 Obesity-related traits CLEC16A intron 23251661 rs78394940 chr16 11222238 C T 9.00E-07 Obesity-related traits CLEC16A intron 23251661 rs2241099 chr16 11225064 C G 4.88E-07 Self-reported allergy CLEC16A intron 23817569 rs2867879 chr16 11226756 G A 2.69E-04 Multiple complex diseases CLEC16A intron 17554300 rs7184083 chr16 11227914 A G 5.94E-07 Multiple sclerosis CLEC16A intron 19525953 rs62026376 chr16 11228712 C T 1.00E-08 Asthma and hay fever CLEC16A intron 24388013 rs7203459 chr16 11230703 T C 2.00E-07 Self-reported allergy CLEC16A intron 23817569 rs2867880 chr16 11231857 G A 1.35E-06 Self-reported allergy CLEC16A intron 23817569 rs2903692 chr16 11238783 G A 7.00E-11 Type 1 diabetes CLEC16A intron 17632545 rs2903692 chr16 11238783 G A 0.0000064 Primary sclerosing cholangitis CLEC16A intron 22521342 rs2903692 chr16 11238783 G A 9.00E-05 Systemic lupus erythematosus CLEC16A intron 23273568 rs2903692 chr16 11238783 G A 1.09E-05 Self-reported allergy CLEC16A intron 23817569 rs12917893 chr16 11239978 A T 7.52E-06 Self-reported allergy CLEC16A intron 23817569 rs17673553 chr16 11241906 A G 2.74E-09 Type 1 diabetes CLEC16A intron 17632545 rs17673553 chr16 11241906 A G 0.0000017 Asthma CLEC16A intron 23040885 rs17673553 chr16 11241906 A G 1.70E-04 Systemic lupus erythematosus CLEC16A intron 23273568 rs17673553 chr16 11241906 A G 8.63E-07 Self-reported allergy CLEC16A intron 23817569 rs11864680 chr16 11244194 T G 2.02E-06 Self-reported allergy CLEC16A intron 23817569 rs6498169 chr16 11249329 G A 4.00E-06 Multiple sclerosis CLEC16A intron 17660530 rs28087 chr16 11252829 C T 9.81E-05 Serum metabolites CLEC16A intron 19043545 rs767019 chr16 11256936 G T 5.21E-04 Multiple complex diseases CLEC16A intron 17554300 rs794433 chr16 11288154 C T 4.30E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2052594 chr16 11291666 C T 5.84E-05 Platelet counts / / pha003100 rs11647724 chr16 11295248 G A 3.20E-04 Endometriosis / / 23104006 rs193772 chr16 11299077 T C 7.23E-05 Self-reported allergy / / 23817569 rs152306 chr16 11306636 C T 7.79E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2291657 chr16 11307024 C T 2.17E-06 Self-reported allergy / / 23817569 rs7199390 chr16 11313051 A T 2.00E-06 Social communication problems / / 24564958 rs1646067 chr16 11319045 G A 3.37E-04 Multiple complex diseases / / 17554300 rs1646067 chr16 11319045 G A 9.35E-05 Type 1 diabetes / / 18978792 rs11074956 chr16 11337721 G T 1.56E-05 Multiple complex diseases / / 17554300 rs149310 chr16 11345699 G C 5.52E-05 Multiple complex diseases / / 17554300 rs149310 chr16 11345699 G C 2.02E-05 Type 1 diabetes / / 18978792 rs4780355 chr16 11347858 T C 1.00E-13 Crohn's disease and psoriasis / / 22482804 rs4780355 chr16 11347858 T C 4.23E-13 Primary biliary cirrhosis / / 22961000 rs188754154 chr16 11349374 T A 0.000000392 Primary biliary cirrhosis SOCS1 UTR-5 22961000 rs243327 chr16 11353304 A G 4.38E-05 Multiple complex diseases / / 17554300 rs413024 chr16 11354091 A G 0.000000141 Primary biliary cirrhosis (anti-mitochondrial antibody positive) / / 22936693 rs413024 chr16 11354091 A G 0.0000107 Primary biliary cirrhosis in females / / 22936693 rs413024 chr16 11354091 A G 2.29E-08 Primary biliary cirrhosis / / 22936693 rs243325 chr16 11354497 T C 1.19E-04 Multiple complex diseases / / 17554300 rs243325 chr16 11354497 T C 0.000000156 Primary biliary cirrhosis / / 22936693 rs243325 chr16 11354497 T C 4.56E-13 Primary biliary cirrhosis / / 22961000 rs243317 chr16 11357331 A C 4.01E-14 Primary biliary cirrhosis / / 22961000 rs243318 chr16 11358018 G A 3.76E-14 Primary biliary cirrhosis / / 22961000 rs1646019 chr16 11359680 C T 6.72E-15 Primary biliary cirrhosis / / 22961000 rs243323 chr16 11361202 A G 6.60E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs243323 chr16 11361202 A G 2.50E-05 Celiac disease / / 22057235 rs243323 chr16 11361202 A G 9.07E-08 Primary biliary cirrhosis / / 22936693 rs243323 chr16 11361202 A G 2.23E-14 Primary biliary cirrhosis / / 22961000 rs11640138 chr16 11362729 G A 3.41E-05 Multiple sclerosis TNP2 missense 19525953 rs415595 chr16 11363692 A G 0.000000164 Primary sclerosing cholangitis / / 23603763 rs416603 chr16 11364079 A T 1.48E-04 Multiple complex diseases / / 17554300 rs416603 chr16 11364079 A T 3.00E-06 Type 1 diabetes / / 18978792 rs367569 chr16 11365500 C T 0.000000049 Psoriasis / / 23143594 rs393161 chr16 11366589 A G 5.39E-04 Tourette syndrome / / 22889924 rs529866 chr16 11373320 C T 2.00E-16 Inflammatory bowel disease / / 23128233 rs737008 chr16 11374866 G T 1.00E-06 Obesity-related traits PRM1 cds-synon 23251661 rs737008 chr16 11374866 G T 8.00E-07 Obesity-related traits PRM1 cds-synon 23251661 rs737008 chr16 11374866 G T 8.00E-07 Obesity-related traits PRM1 cds-synon 23251661 rs949429 chr16 11376029 C T 5.87E-06 Obesity-related traits / / 23251661 rs9673543 chr16 11384956 A G 2.00E-04 Celiac disease / / 22057235 rs117096873 chr16 11386960 C T 2.00E-06 Bulimia nervosa / / 23568457 rs17233387 chr16 11389048 C T 1.24E-06 Lymphocyte counts / / 22286170 rs11640295 chr16 11390728 G C 7.25E-36 Multiple complex diseases / / 17554300 rs1874021 chr16 11391190 G C 8.59E-04 Insulin resistance / / 21901158 rs7206320 chr16 11393685 A G 7.10E-04 Smoking quantity / / 24665060 rs4340345 chr16 11394128 A G 5.96E-04 Smoking quantity / / 24665060 rs1019553 chr16 11396350 C A 2.07E-05 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines / / 21483694 rs12928822 chr16 11403893 C T 3.00E-08 Celiac disease / / 20190752 rs12928822 chr16 11403893 C T 3.00E-08 Asthma / / 21150878 rs12928822 chr16 11403893 C T 3.12E-08 Celiac disease and Rheumatoid arthritis / / 21383967 rs12928822 chr16 11403893 C T 3.12E-08 Multiple sclerosis / / 22190364 rs12927773 chr16 11403963 G T 1.72E-04 Multiple complex diseases / / 17554300 rs7191700 chr16 11406803 C T 6.00E-07 Multiple sclerosis / / 22190364 rs1532303 chr16 11409841 C T 8.41E-05 Post-operative nausea and vomiting / / 21694509 rs12922090 chr16 11415117 C T 2.05E-04 Multiple complex diseases / / 17554300 rs12448960 chr16 11419378 C T 7.91E-04 Smoking quantity / / 24665060 rs4238604 chr16 11420769 C G 1.80E-05 Urinary metabolites / / 21572414 rs66718203 chr16 11428643 C G 0.000000446 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs66718203 chr16 11428643 C G 0.00000487 Oligoarticular juvenile idiopathic arthritis / / 23603761 rs7187741 chr16 11433103 G C 1.06E-04 Multiple complex diseases / / 17554300 rs7187741 chr16 11433103 G C 1.68E-05 Type 1 diabetes / / 18978792 rs6498184 chr16 11435990 T C 1.83E-04 Multiple complex diseases / / 17554300 rs2032933 chr16 11445040 G A 7.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs748244 chr16 11453261 G A 7.95E-04 Smoking quantity LOC388210 intron 24665060 rs7193871 chr16 11455606 G C 1.20E-04 Suicide attempts in bipolar disorder LOC388210 missense 21423239 rs2113260 chr16 11455993 T C 3.89E-04 Suicide attempts in bipolar disorder LOC388210 intron 21423239 rs731774 chr16 11456266 C T 1.84E-04 Suicide attempts in bipolar disorder LOC388210 intron 21423239 rs7205925 chr16 11462478 C T 5.44E-04 Type 2 diabetes LOC388210 intron 17463246 rs12596396 chr16 11468218 C A 4.51E-04 Suicide attempts in bipolar disorder LOC388210 intron 21423239 rs11074967 chr16 11471414 C G 0.00000024 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) LOC388210 intron 23603761 rs11649678 chr16 11474750 C T 7.70E-04 Suicide attempts in bipolar disorder LOC388210 intron 21423239 rs11864333 chr16 11475576 A G 3.60E-05 Multiple sclerosis LOC388210 intron 21833088 rs8056901 chr16 11476225 T C 7.81E-04 Suicide attempts in bipolar disorder LOC388210 intron 21423239 rs12931474 chr16 11476239 T C 7.67E-04 Suicide attempts in bipolar disorder LOC388210 intron 21423239 rs12448800 chr16 11477341 A G 2.86E-04 Lung function (forced vital capacity) LOC388210 intron 24023788 rs11646953 chr16 11500751 C T 4.57E-05 QT interval / / 19305409 rs9922089 chr16 11511725 A G 1.83E-05 Serum metabolites / / 19043545 rs11074988 chr16 11528551 T C 7.49E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4129933 chr16 11528893 C A 2.69E-07 Longevity,exceptional / / 20595579 rs8053650 chr16 11543445 C T 7.00E-04 Smoking cessation LOC400499 intron 24665060 rs12932782 chr16 11543870 C T 9.62E-06 Alcohol dependence LOC400499 intron 21703634 rs12932948 chr16 11544673 G A 1.17E-05 Alcohol dependence LOC400499 missense 21703634 rs4780376 chr16 11546711 T A 2.60E-05 Urinary metabolites LOC400499 intron 21572414 rs6498196 chr16 11548285 T G 2.10E-05 Urinary metabolites LOC400499 intron 21572414 rs7197119 chr16 11548790 G T 1.56E-05 Coronary heart disease LOC400499 intron pha003030 rs7206698 chr16 11553842 G C 3.46E-04 Blood pressure LOC400499 missense 17255346 rs8050530 chr16 11554867 C T 3.79E-04 Blood pressure LOC400499 missense 17255346 rs4513118 chr16 11556910 A G 2.00E-05 Urinary metabolites LOC400499 intron 21572414 rs7201423 chr16 11558706 C T 3.60E-06 Urinary metabolites LOC400499 intron 21572414 rs8051482 chr16 11564493 G C 2.10E-05 Urinary metabolites LOC400499 intron 21572414 rs4614743 chr16 11569240 A G 1.36E-04 Blood pressure LOC400499 intron 17255346 rs11646835 chr16 11613169 G A 9.55E-04 Alcohol dependence / / 21314694 rs12930396 chr16 11617658 A G 6.60E-05 Height / / pha003011 rs7203193 chr16 11641180 A G 3.00E-06 Coronary heart disease LITAF nearGene-3 21347282 rs4273053 chr16 11652119 G C,T 8.88E-04 Type 2 diabetes LITAF intron 17463246 rs8049607 chr16 11691753 T C 5.00E-15 QT interval / / 19305408 rs8049607 chr16 11691753 T C 6.00E-15 QT interval / / 19305409 rs8049607 chr16 11691753 T C 3.70E-05 Electrocardiographic traits / / 20062061 rs8049607 chr16 11691753 T C 7.00E-07 QT interval / / 23166209 rs735951 chr16 11693536 G A 1.60E-07 QT interval / / 19305409 rs735951 chr16 11693536 G A 5.55E-06 QT interval / / 23166209 rs13333308 chr16 11701649 T C 6.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) / / 24554482 rs11641991 chr16 11704816 G A 6.75E-06 QT interval / / 23166209 rs12446552 chr16 11720066 T C 6.70E-06 Urinary metabolites / / 21572414 rs12446552 chr16 11720066 T C 6.79E-04 Obesity (extreme) / / 21935397 rs872712 chr16 11724355 A G 7.85E-06 QT interval / / 23166209 rs7185522 chr16 11745847 A G 5.43E-04 Alzheimer's disease / / 22005930 rs7195296 chr16 11749774 A C 0.000415222 Primary sclerosing cholangitis / / 23603763 rs9934326 chr16 11750830 T C 7.34E-04 Alzheimer's disease / / 22005930 rs9927281 chr16 11753423 G A 4.13E-04 Orofacial clefts / / 22419666 rs2903973 chr16 11754409 C T 6.11E-04 Alzheimer's disease / / 22005930 rs7193441 chr16 11764821 C T 9.89E-04 Type 2 diabetes SNN intron 17463246 rs8191355 chr16 11774007 G T 6.04E-05 Alzheimer's disease (age of onset) TXNDC11 intron 22005931 rs12920377 chr16 11781582 A C 2.60E-06 Urinary metabolites TXNDC11 intron 21572414 rs11648550 chr16 11787714 G C 2.00E-05 Urinary metabolites TXNDC11 intron 21572414 rs7203803 chr16 11812291 C T 2.50E-05 Urinary metabolites TXNDC11 intron 21572414 rs16958604 chr16 11822148 A G 0.000022 Mean arterial pressure TXNDC11 intron 22510845 rs4439779 chr16 11826841 T C 2.60E-05 Urinary metabolites TXNDC11 intron 21572414 rs4780401 chr16 11839326 G T 4.00E-08 Rheumatoid arthritis / / 24390342 rs4780401 chr16 11839326 G T 9.00E-09 Rheumatoid arthritis / / 24390342 rs8043748 chr16 11846231 A G 0.0000684 Ovarian cancer ZC3H7A intron 22794196 rs8043748 chr16 11846231 A G 3.32E-05 Alcohol consumption ZC3H7A intron pha001401 rs8053435 chr16 11883518 C T 4.80E-04 Type 2 diabetes ZC3H7A intron 17463246 rs6498245 chr16 11886591 A G 2.15E-04 Type 2 diabetes ZC3H7A intron 17463246 rs154148 chr16 11956478 T C 7.97E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs40311 chr16 11963190 G C 7.11E-04 Multiple complex diseases GSPT1 UTR-3 17554300 rs17236053 chr16 11970882 T G 5.74E-05 Diabetes Mellitus GSPT1 intron pha003060 rs10852344 chr16 12016919 C T 1.00E-11 Menopause (age at onset) / / 22267201 rs10852344 chr16 12016919 C T 5.00E-08 Menopause (age at onset) / / 23307926 rs12922317 chr16 12077632 A G 9.00E-07 Schizophrenia SNX29 intron 23358160 rs8045739 chr16 12078259 T G 2.86E-04 Coronary Artery Disease SNX29 intron 17634449 rs8045739 chr16 12078259 T G 9.90E-04 Intelligence (childhood) SNX29 intron 23358156 rs8045634 chr16 12119251 A C 5.68E-04 Smoking quantity SNX29 intron 24665060 rs8045634 chr16 12119251 A C 9.64E-05 Cardiovascular disease SNX29 intron pha003065 rs8050827 chr16 12119676 T G 6.30E-04 Response to taxane treatment (placlitaxel) SNX29 intron 23006423 rs350216 chr16 12151140 A G 2.30E-06 Urinary metabolites SNX29 intron 21572414 rs9938283 chr16 12151437 G A 1.80E-05 Urinary metabolites SNX29 intron 21572414 rs350212 chr16 12154378 A G 2.75E-04 Alcohol dependence SNX29 intron 21314694 rs10500381 chr16 12157900 T C 5.24E-04 Response to alcohol consumption (flushing response) SNX29 intron 24277619 rs11648468 chr16 12181510 C T 7.33E-06 Homeostasis model assessment of insulin resistance (interaction) SNX29 intron 24204828 rs11648468 chr16 12181510 C T 7.63E-06 Fasting insulin (interaction) SNX29 intron 24204828 rs8048589 chr16 12185810 T C 4.00E-06 Homeostasis model assessment of insulin resistance (interaction) SNX29 intron 24204828 rs183008 chr16 12201691 T C 2.80E-05 Alcoholism (heaviness of drinking) SNX29 intron 21529783 rs350255 chr16 12205542 A G 1.60E-05 Alcoholism (heaviness of drinking) SNX29 intron 21529783 rs1704147 chr16 12234877 C T 6.36E-04 Type 2 diabetes SNX29 intron 17463246 rs350225 chr16 12241659 A G 8.76E-04 Multiple complex diseases SNX29 intron 17554300 rs7501241 chr16 12248857 C T 5.49E-04 Amyotrophic Lateral Sclerosis SNX29 intron 17362836 rs9788917 chr16 12268398 C T 9.97E-04 Multiple complex diseases SNX29 intron 17554300 rs1472979 chr16 12299234 C T 3.63E-04 Multiple complex diseases SNX29 intron 17554300 rs11644280 chr16 12301647 C T 2.83E-04 Multiple complex diseases SNX29 intron 17554300 rs830728 chr16 12311454 A G 6.60E-06 Urinary metabolites SNX29 intron 21572414 rs16959086 chr16 12342163 G T 1.88E-05 Multiple complex diseases SNX29 intron 17554300 rs7195058 chr16 12345184 T G 8.78E-04 Stroke SNX29 intron pha002887 rs905950 chr16 12358206 C T 9.07E-04 Stroke SNX29 intron pha002887 rs17697005 chr16 12361265 G A 1.11E-06 Multiple complex diseases SNX29 intron 17554300 rs158472 chr16 12426480 T C 1.75E-04 Aortic root size SNX29 intron 21223598 rs289673 chr16 12430870 A G 1.75E-05 Systolic blood pressure in sickle cell anemia SNX29 intron 24058526 rs16959252 chr16 12434674 A G 3.82E-04 Type 2 diabetes SNX29 intron 17463246 rs16959252 chr16 12434674 A G 8.62E-04 Depression (quantitative trait) SNX29 intron 20800221 rs12448282 chr16 12492011 C A,G,T 6.19E-04 Multiple complex diseases SNX29 intron 17554300 rs6498290 chr16 12492600 T G 5.20E-04 Multiple complex diseases SNX29 intron 17554300 rs6498293 chr16 12502757 C G 5.18E-08 Narcolepsy SNX29 intron 19629137 rs8047094 chr16 12533201 C T 5.55E-04 Multiple complex diseases SNX29 intron 17554300 rs1646304 chr16 12537631 C G 6.08E-04 Type 2 diabetes SNX29 intron 17463246 rs254115 chr16 12539673 C G 6.36E-05 Personality dimensions SNX29 intron 18957941 rs16959703 chr16 12550553 A C 1.18E-04 Multiple complex diseases SNX29 intron 17554300 rs6498308 chr16 12564663 A G 9.10E-06 Urinary metabolites SNX29 intron 21572414 rs7198595 chr16 12564907 G A 9.16E-05 Personality dimensions SNX29 intron 18957941 rs6498309 chr16 12564951 T C 8.20E-06 Urinary metabolites SNX29 intron 21572414 rs3803617 chr16 12581646 T C 7.06E-05 C-Reactive Protein SNX29 intron pha003070 rs34454587 chr16 12585703 A G 5.59E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SNX29 intron 24159190 rs7203242 chr16 12590137 T G 5.57E-04 Alzheimer's disease SNX29 intron 22005930 rs9806891 chr16 12590176 C T 2.30E-05 Substance dependence phenotypes SNX29 intron 24832863 rs9806891 chr16 12590176 C T 7.55E-06 Substance dependence phenotypes SNX29 intron 24832863 rs117147010 chr16 12596935 C T 1.00E-06 Serum dimethylarginine levels (symmetric) SNX29 intron 24159190 rs117147010 chr16 12596935 C T 3.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) SNX29 intron 24159190 rs9931578 chr16 12611773 A G 2.90E-05 Intelligence SNX29 intron 21826061 rs1641831 chr16 12613039 G A 4.20E-05 Blood Pressure SNX29 intron pha003039 rs169773 chr16 12625171 G T 1.72E-05 Chronic Hepatitis C infection SNX29 intron 21725309 rs1794304 chr16 12625395 G A 3.58E-06 Chronic Hepatitis C infection SNX29 intron 21725309 rs7189979 chr16 12630187 A C 0.000221 Salmonella-induced pyroptosis SNX29 intron 22837397 rs1641895 chr16 12641115 C T 5.00E-07 Visceral adipose tissue adjusted for BMI SNX29 intron 22589738 rs8052154 chr16 12642955 A G 1.54E-06 Lymphocyte counts SNX29 intron 22286170 rs12925894 chr16 12655233 A G 2.20E-05 Urinary metabolites SNX29 intron 21572414 rs17823157 chr16 12676529 G T 7.76E-04 Multiple complex diseases / / 17554300 rs17823157 chr16 12676529 G T 1.42E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs7198835 chr16 12697058 G C 8.16E-04 Multiple complex diseases / / 17554300 rs2217271 chr16 12704480 C A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11075123 chr16 12705135 C A 7.25E-06 Multiple complex diseases / / 17554300 rs11649101 chr16 12706689 G C 2.87E-04 Alzheimer's disease (late onset) / / 21460841 rs11075125 chr16 12706958 T A 5.39E-04 Alzheimer's disease / / 17998437 rs4780464 chr16 12707419 A G 4.31E-04 Alzheimer's disease (late onset) / / 21379329 rs4780464 chr16 12707419 A G 9.65E-04 Alzheimer's disease / / 24755620 rs1560104 chr16 12708208 C T 4.00E-06 Obesity-related traits / / 23251661 rs7188223 chr16 12709531 A G 2.55E-04 Alzheimer's disease (late onset) / / 21379329 rs12708762 chr16 12710965 C A 3.98E-04 Alzheimer's disease (late onset) / / 21379329 rs12708762 chr16 12710965 C A 5.78E-04 Cocaine dependence / / 23958962 rs12708762 chr16 12710965 C A 5.98E-04 Alzheimer's disease / / 24755620 rs17227296 chr16 12712199 A G 5.42E-04 Alzheimer's disease / / 17998437 rs735819 chr16 12712227 G A 6.82E-04 Alzheimer's disease / / 17998437 rs17227492 chr16 12714043 A G 6.57E-04 Alzheimer's disease / / 17998437 rs4780469 chr16 12714394 A C 9.24E-04 Alzheimer's disease / / 17998437 rs1713480 chr16 12758966 T C 5.54E-04 Smoking initiation CPPED1 missense 24665060 rs1713478 chr16 12760767 A G 4.38E-04 Response to taxane treatment (placlitaxel) CPPED1 intron 23006423 rs8049355 chr16 12776837 G A 3.92E-04 Suicide attempts in bipolar disorder CPPED1 intron 21423239 rs13330825 chr16 12795662 C T 2.17E-04 Type 2 diabetes CPPED1 intron 17463246 rs4781323 chr16 12795961 T C 5.34E-05 Type 2 diabetes CPPED1 intron 17463246 rs4781324 chr16 12797583 C T 8.09E-04 Type 2 diabetes CPPED1 intron 17463246 rs8050225 chr16 12810232 C T 6.09E-05 Multiple complex diseases CPPED1 intron 17554300 rs8057200 chr16 12836747 G A 2.42E-04 Type 2 diabetes LOC100652934 missense 17463246 rs8182207 chr16 12838346 A G 4.88E-05 Type 2 diabetes CPPED1 intron 17463246 rs8059402 chr16 12838430 C T 1.76E-04 Type 2 diabetes CPPED1 intron 17463246 rs938902 chr16 12851898 G T 7.13E-04 Multiple complex diseases CPPED1 intron 17554300 rs7187198 chr16 12852101 G C 2.30E-04 Multiple complex diseases CPPED1 intron 17554300 rs16960676 chr16 12880446 C T 8.70E-04 Multiple complex diseases CPPED1 intron 17554300 rs2865895 chr16 12891282 C G 8.71E-04 Insulin resistance CPPED1 intron 21901158 rs10852359 chr16 12892036 T C 4.53E-04 Insulin resistance CPPED1 intron 21901158 rs12708763 chr16 12892984 G A 7.15E-04 Insulin resistance CPPED1 intron 21901158 rs16960714 chr16 12893819 A G 3.31E-04 Insulin resistance CPPED1 intron 21901158 rs11866435 chr16 12894434 C T 7.31E-04 Insulin resistance CPPED1 intron 21901158 rs12598821 chr16 12894856 T C 5.81E-04 HIV(mother-to-child transmission) CPPED1 intron 20487506 rs12598821 chr16 12894856 T C 6.65E-05 HIV(mother-to-child transmission) CPPED1 intron 20487506 rs9941146 chr16 12900486 G A,C,T 4.52E-04 Type 2 diabetes / / 17463246 rs10500391 chr16 12961120 T G 8.30E-05 Celiac disease / / 17558408 rs10500391 chr16 12961120 T G 8.95E-04 Premature ovarian failure / / 19508998 rs1972403 chr16 12968578 A T 7.22E-04 Multiple complex diseases / / 17554300 rs1477377 chr16 12969056 G T 1.80E-06 Urinary metabolites / / 21572414 rs9938893 chr16 13012186 G A 5.16E-05 Type 2 diabetes SHISA9 intron 17463246 rs1433751 chr16 13018888 A T 2.19E-05 Type 2 diabetes SHISA9 intron 17463246 rs11075174 chr16 13020416 G A 6.54E-04 Type 2 diabetes SHISA9 intron 17463246 rs7189560 chr16 13043431 T C 4.89E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) SHISA9 intron 23648065 rs924546 chr16 13046720 A G 7.91E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) SHISA9 intron 23648065 rs4781357 chr16 13048150 C T 9.10E-04 Multiple complex diseases SHISA9 intron 17554300 rs7192086 chr16 13061611 T A 6.00E-06 Schizophrenia SHISA9 intron 18677311 rs7192086 chr16 13061611 T A 6.10E-06 Schizophrenia (treatment refractory) SHISA9 intron 22479419 rs1501304 chr16 13144688 T C 4.50E-04 Alcohol dependence SHISA9 intron 20201924 rs16961066 chr16 13152061 A G 7.16E-04 Multiple complex diseases SHISA9 intron 17554300 rs4465599 chr16 13154878 G A 4.00E-07 Palmitoleic acid (16:1n-7) plasma levels SHISA9 intron 23362303 rs276639 chr16 13179016 G A 4.69E-06 Paget's disease SHISA9 intron 20436471 rs251919 chr16 13198858 C T 2.41E-06 Paclitaxel sensitivity in NCI60 cancer cell lines SHISA9 intron 21314952 rs4781412 chr16 13203338 G C 5.91E-05 Type 2 diabetes SHISA9 intron 17463246 rs4781415 chr16 13217905 A G 8.00E-06 QRS duration in Tripanosoma cruzi seropositivity SHISA9 intron 24324551 rs153087 chr16 13219254 C T 1.08E-04 Response to cytidine analogues (gemcitabine) SHISA9 intron 24483146 rs16961199 chr16 13227088 A C 1.90E-05 Urinary metabolites SHISA9 intron 21572414 rs998803 chr16 13230868 G A 1.90E-05 Urinary metabolites SHISA9 intron 21572414 rs150063 chr16 13238897 T C 8.71E-06 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SHISA9 intron 24023788 rs150063 chr16 13238897 T C 9.00E-06 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SHISA9 intron 24023788 rs150064 chr16 13238954 G A 7.85E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SHISA9 intron 24023788 rs150064 chr16 13238954 G A 7.89E-05 Relative hand skill in reading disability SHISA9 intron 24068947 rs4781419 chr16 13243331 G A 2.00E-04 Acute lymphoblastic leukemia (childhood) SHISA9 intron 20189245 rs150071 chr16 13247355 T G 4.53E-04 Bipolar disorder SHISA9 intron 19259986 rs6498382 chr16 13253526 C T 8.43E-05 Pulmonary function SHISA9 intron 19300500 rs153091 chr16 13253956 G T 2.00E-06 Response to antipsychotic treatment SHISA9 intron 20195266 rs153091 chr16 13253956 G T 1.05E-05 Left ventricular hypertrophy SHISA9 intron pha003052 rs153089 chr16 13255874 A G 1.90E-06 Urinary metabolites SHISA9 intron 21572414 rs6498385 chr16 13259887 G A 9.03E-05 Pulmonary function SHISA9 intron 19300500 rs1898680 chr16 13272681 G T 4.14E-06 Bilirubin levels,in serum SHISA9 intron 19389676 rs10438542 chr16 13291654 A G 6.67E-05 Alzheimer's disease (late onset) SHISA9 intron 21379329 rs762780 chr16 13294127 T C 1.96E-04 Multiple complex diseases SHISA9 intron 17554300 rs149228 chr16 13304474 A C 1.49E-06 Type 2 diabetes SHISA9 intron 21647700 rs149228 chr16 13304474 A C 6.49E-05 Height SHISA9 intron pha003010 rs407146 chr16 13315655 C A 7.16E-05 Hypertension SHISA9 intron 21082022 rs415232 chr16 13316427 G A 5.23E-06 Cognitive impairment induced by topiramate SHISA9 intron 22091778 rs7204584 chr16 13319729 G A 9.85E-04 Obesity (extreme) SHISA9 intron 21935397 rs204029 chr16 13320154 A G 1.00E-04 Information processing speed SHISA9 intron 21130836 rs204030 chr16 13320781 G A 4.85E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) SHISA9 intron 17982456 rs204034 chr16 13323341 A G 1.20E-04 Celiac disease SHISA9 intron 23936387 rs17175665 chr16 13352182 C A 2.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs8058023 chr16 13352269 G C,T 9.54E-05 Serum metabolites / / 19043545 rs10492781 chr16 13356687 C T 6.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs9888948 chr16 13392581 C T 2.22E-04 Blood pressure / / 17255346 rs12923857 chr16 13401783 T C 7.88E-05 Blood pressure / / 17255346 rs6362 chr16 13416619 A G 1.62E-04 Blood pressure / / 17255346 rs12926625 chr16 13421017 C T 7.39E-05 Psoriasis / / 20953190 rs7200108 chr16 13438884 T C 0.0006 Breast cancer / / 22258532 rs2051738 chr16 13467705 T C 6.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs734826 chr16 13490380 A C 6.10E-04 Alcohol dependence / / 20201924 rs4781471 chr16 13521319 A G 1.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4781471 chr16 13521319 A G 2.35E-04 Insulin resistance / / 21901158 rs1858994 chr16 13532687 T C 1.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2188743 chr16 13549769 G A 5.27E-05 Major depressive disorder / / 19107115 rs10852366 chr16 13550540 C T 6.74E-05 Major depressive disorder / / 19107115 rs17266493 chr16 13553041 T C 3.43E-05 Height / / pha003011 rs6498415 chr16 13558439 T C 7.77E-04 Parkinson's disease / / 16252231 rs1013040 chr16 13564571 C A 4.96E-04 Parkinson's disease / / 16252231 rs7200899 chr16 13572974 T C 4.66E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs9922475 chr16 13575263 G A 1.24E-04 Alzheimer's disease / / 22005930 rs1013331 chr16 13584900 C A 5.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4309380 chr16 13615695 C T 8.67E-04 Coronary Artery Disease / / 17634449 rs4309380 chr16 13615695 C T 9.88E-04 Alzheimer's disease / / 22005930 rs10521095 chr16 13621435 G A 2.30E-05 Type 2 diabetes / / 17463248 rs6498423 chr16 13623880 G A 2.40E-05 Type 2 diabetes / / 17463248 rs12162088 chr16 13639892 A G 8.80E-05 Type 2 diabetes / / 17463248 rs16962270 chr16 13639925 A T 8.70E-05 Type 2 diabetes / / 17463248 rs8056716 chr16 13643974 G A 1.10E-04 White matter integrity / / 22425255 rs8056716 chr16 13643974 G A 8.90E-05 Creatinine levels / / pha003069 rs12930773 chr16 13648300 T C 1.00E-05 Urinary metabolites / / 21572414 rs2903308 chr16 13656885 A G 1.00E-05 Urinary metabolites / / 21572414 rs2903308 chr16 13656885 A G 2.00E-06 Response to citalopram treatment / / 22760553 rs6498433 chr16 13660870 T C 2.70E-05 Personality dimensions / / 18957941 rs6498433 chr16 13660870 T C 7.30E-07 Urinary metabolites / / 21572414 rs8055506 chr16 13661724 C T 6.10E-05 Personality dimensions / / 18957941 rs8055506 chr16 13661724 C T 1.00E-06 Urinary metabolites / / 21572414 rs12933124 chr16 13661998 G C 8.90E-07 Urinary metabolites / / 21572414 rs16962446 chr16 13694937 T C 2.00E-06 Urinary metabolites / / 21572414 rs1005410 chr16 13701374 C A 7.30E-05 Acute lung injury / / 22295056 rs4780529 chr16 13724482 C A 8.50E-07 Urinary metabolites / / 21572414 rs6498444 chr16 13726940 C T 8.39E-04 Multiple complex diseases / / 17554300 rs17199331 chr16 13747590 C T 5.20E-06 Urinary metabolites / / 21572414 rs7202384 chr16 13750724 C G 8.20E-05 Obesity-related traits / / 17903300 rs8053520 chr16 13756549 C A 1.60E-07 Urinary metabolites / / 21572414 rs16962588 chr16 13757367 A G 2.90E-06 Urinary metabolites / / 21572414 rs6498457 chr16 13764396 G T 3.45E-04 Multiple complex diseases / / 17554300 rs4997735 chr16 13764456 C A 3.52E-04 Multiple complex diseases / / 17554300 rs2097287 chr16 13764680 T C 2.84E-04 Multiple complex diseases / / 17554300 rs2097288 chr16 13764741 T C 4.52E-04 Multiple complex diseases / / 17554300 rs2105842 chr16 13764829 C T 3.34E-04 Multiple complex diseases / / 17554300 rs12927595 chr16 13765041 G T 3.79E-04 Multiple complex diseases / / 17554300 rs4781528 chr16 13766292 G A 4.15E-04 Multiple complex diseases / / 17554300 rs3916993 chr16 13767712 A G 5.93E-04 Multiple complex diseases / / 17554300 rs4781530 chr16 13770650 C T 3.69E-04 Multiple complex diseases / / 17554300 rs2051545 chr16 13772599 G T 5.60E-04 Obesity-related traits / / 17903300 rs10492769 chr16 13773829 C T 3.76E-04 Multiple complex diseases / / 17554300 rs12448623 chr16 13777395 T G 8.10E-04 Schizophrenia / / 19197363 rs12920954 chr16 13781228 A G 2.60E-05 Urinary metabolites / / 21572414 rs12930213 chr16 13782944 C G 1.99E-04 Multiple complex diseases / / 17554300 rs17794609 chr16 13791465 C G 1.20E-04 Multiple complex diseases / / 17554300 rs4238620 chr16 13795867 T C 7.27E-04 Schizophrenia / / 19197363 rs4238620 chr16 13795867 T C 2.80E-05 Urinary metabolites / / 21572414 rs12599140 chr16 13796521 G C 3.64E-04 Multiple complex diseases / / 17554300 rs10852368 chr16 13796539 C T 3.75E-04 Multiple complex diseases / / 17554300 rs12931772 chr16 13796834 A G 4.09E-04 Multiple complex diseases / / 17554300 rs12927885 chr16 13798132 C T 4.11E-04 Multiple complex diseases / / 17554300 rs12927885 chr16 13798132 C T 5.68E-04 Substance dependence / / 21818250 rs7195018 chr16 13798199 A G 4.08E-04 Multiple complex diseases / / 17554300 rs179619 chr16 13822359 C T 3.66E-05 Response to gemcitabine in pancreatic cancer / / 22142827 rs179620 chr16 13823027 T C 5.15E-04 Type 2 diabetes / / 17463246 rs1034392 chr16 13894417 C T 4.85E-04 Insulin resistance / / 21901158 rs6650560 chr16 13919178 A G 1.40E-04 Multiple complex diseases / / 17554300 rs7193298 chr16 13922331 T G 3.17E-04 Alzheimer's disease / / 17998437 rs17565143 chr16 13923020 G A 2.48E-05 Bipolar disorder / / 18317468 rs1794336 chr16 13950359 A C 8.06E-06 C-reactive protein / / 22492993 rs7190999 chr16 13956228 A G 6.45E-06 C-reactive protein / / 22492993 rs857164 chr16 13958817 T G 5.61E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs857164 chr16 13958817 T G 1.30E-05 C-reactive protein / / 22492993 rs231131 chr16 13959607 T C 6.66E-04 Multiple complex diseases / / 17554300 rs12934929 chr16 13960057 G A 7.22E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs231125 chr16 13966386 C T 1.70E-05 C-reactive protein / / 22492993 rs231124 chr16 13966418 T C 1.20E-05 C-reactive protein / / 22492993 rs2113334 chr16 13976356 T C 3.00E-06 Metabolic syndrome / / 20694148 rs2113334 chr16 13976356 T C 5.80E-06 Urinary metabolites / / 21572414 rs11644833 chr16 13978116 G A 9.80E-06 Urinary metabolites / / 21572414 rs1364363 chr16 13986727 C G 2.40E-04 Insulin resistance / / 21901158 rs6498482 chr16 13987719 T C 9.74E-04 Multiple complex diseases / / 17554300 rs6498482 chr16 13987719 T C 5.10E-04 Insulin resistance / / 21901158 rs112732710 chr16 14013898 T C 8.74E-06 Osteoarthritis ERCC4 nearGene-5 21871595 rs3136202 chr16 14038174 G A 6.00E-06 Conduct disorder (symptom count) ERCC4 intron 20585324 rs4781563 chr16 14045399 G A 2.00E-06 Bilirubin levels ERCC4 UTR-3 22085899 rs1794242 chr16 14102548 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1794242 chr16 14102548 G A 1.89E-04 Smoking quantity / / 24665060 rs1651189 chr16 14107366 T C 7.68E-05 Serum metabolites / / 19043545 rs1794236 chr16 14123737 C T 3.89E-04 Smoking quantity / / 24665060 rs1630373 chr16 14124066 G C 7.70E-05 Multiple complex diseases / / 17554300 rs9935021 chr16 14132484 G A 2.52E-05 Erythrocyte counts / / pha003101 rs7200856 chr16 14137090 A G 7.33E-05 Erythrocyte counts / / pha003101 rs12596849 chr16 14206749 G A 4.07E-04 Insulin resistance MKL2 intron 21901158 rs762769 chr16 14249996 C G 3.77E-04 Insulin resistance MKL2 intron 21901158 rs7204501 chr16 14276055 T C 2.91E-04 Insulin resistance MKL2 intron 21901158 rs2187664 chr16 14276878 C T 7.84E-04 Insulin resistance MKL2 intron 21901158 rs756472 chr16 14279481 G A 7.20E-05 Personality dimensions MKL2 intron 18957941 rs8049506 chr16 14329341 C T 8.32E-04 Amyotrophic Lateral Sclerosis MKL2 intron 17362836 rs30126 chr16 14355765 C T 4.69E-04 Insulin resistance MKL2 UTR-3 21901158 rs8049310 chr16 14359305 C G 4.92E-04 Multiple complex diseases MKL2 UTR-3 17554300 rs30245 chr16 14378042 C A 1.44E-04 Multiple complex diseases / / 17554300 rs1659127 chr16 14388305 G A 1.00E-11 Height / / 20881960 rs1659127 chr16 14388305 G A 4.00E-09 Menarche (age at onset) / / 21102462 rs246185 chr16 14395432 T C 5.00E-07 Puberty onset (genital enlargement) / / 24770850 rs246185 chr16 14395432 T C 9.00E-09 Puberty onset / / 24770850 rs12928353 chr16 14415800 C G 4.87E-04 Multiple complex diseases LOC100129781 intron 17554300 rs16963706 chr16 14464538 T C 3.96E-04 Alzheimer's disease (late onset) / / 21379329 rs11075236 chr16 14464656 C A 3.30E-05 Major depressive disorder / / 21042317 rs1533079 chr16 14471261 G A 2.46E-04 Myopia (pathological) / / 21095009 rs1533079 chr16 14471261 G A 4.77E-05 Prostate cancer / / pha002877 rs6498509 chr16 14475162 T C 1.01E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs6498513 chr16 14488130 A G 2.51E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs6498514 chr16 14488302 G C 2.79E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11075239 chr16 14500339 A C 1.56E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1810125 chr16 14507585 A G 1.50E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1810124 chr16 14507772 G C 1.09E-08 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs12325343 chr16 14520684 C A 1.43E-10 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs3923839 chr16 14577043 A G 3.50E-12 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs12445167 chr16 14578151 C T 3.86E-12 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs12445002 chr16 14578296 G A 4.86E-12 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs12446481 chr16 14586821 G A 7.21E-12 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs4395094 chr16 14609259 T C 4.20E-12 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs12448574 chr16 14618311 T G 8.26E-13 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs12444801 chr16 14618334 G C 2.64E-12 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs732459 chr16 14627694 C T 8.68E-04 Alcohol dependence PARN intron 20201924 rs732459 chr16 14627694 C T 1.12E-10 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs11645411 chr16 14629455 A T 3.35E-21 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs12446921 chr16 14629488 A G 8.68E-04 Alcohol dependence PARN intron 20201924 rs12446921 chr16 14629488 A G 8.21E-11 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs12386021 chr16 14632942 G A 5.24E-13 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs8052315 chr16 14633693 T C 2.69E-08 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs8061748 chr16 14648791 T C 3.40E-08 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs10500392 chr16 14654594 C A 5.45E-13 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs8062293 chr16 14657616 G A 5.13E-13 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs17201300 chr16 14665344 A G 2.30E-08 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs7200272 chr16 14665479 C T 6.23E-08 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs12447215 chr16 14671509 T C 7.00E-10 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs12447905 chr16 14672251 T C 2.66E-08 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs17260976 chr16 14679027 C G 2.96E-12 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs17261004 chr16 14697357 C T 5.02E-10 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs12928399 chr16 14705001 G C 7.96E-23 Plasma omega-6 polyunsaturated fatty acid levels PARN intron 24823311 rs8057053 chr16 15054865 C T 1.15E-10 Metabolite levels / / 22286219 rs4985167 chr16 15082865 C T 3.00E-07 Phospholipid levels (plasma) PDXDC1 intron 21829377 rs4985167 chr16 15082865 C T 1.26E-14 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 intron 24823311 rs4985167 chr16 15082865 C T 4.03E-11 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 intron 24823311 rs4985167 chr16 15082865 C T 4.60E-09 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 intron 24823311 rs4985167 chr16 15082865 C T 7.02E-64 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 intron 24823311 rs9888789 chr16 15118891 C A,G,T 1.40E-11 Metabolite levels PDXDC1 intron 22286219 rs8045034 chr16 15120914 A G 6.97E-14 Metabolite levels PDXDC1 intron 22286219 rs7192552 chr16 15122195 A G 1.36E-11 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 intron 24823311 rs7192552 chr16 15122195 A G 1.97E-08 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 intron 24823311 rs7192552 chr16 15122195 A G 2.11E-08 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 intron 24823311 rs7192552 chr16 15122195 A G 2.37E-49 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 intron 24823311 rs7404880 chr16 15123280 A G 1.22E-04 Bone mineral density PDXDC1 intron 24249740 rs4985124 chr16 15125441 T G 1.29E-06 Phospholipid levels (plasma) PDXDC1 intron 21829377 rs4985124 chr16 15125441 T G 1.00E-10 Metabolite levels PDXDC1 intron 22286219 rs4985124 chr16 15125441 T G 1.01E-09 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 intron 24823311 rs4985124 chr16 15125441 T G 1.23E-10 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 intron 24823311 rs4985124 chr16 15125441 T G 1.33E-14 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 intron 24823311 rs4985124 chr16 15125441 T G 3.11E-64 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 intron 24823311 rs4985124 chr16 15125441 T G 7.94E-05 Triglycerides PDXDC1 intron pha002904 rs12926897 chr16 15126890 C T 1.01E-06 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 intron 24823311 rs12926897 chr16 15126890 C T 1.45E-07 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 intron 24823311 rs12926897 chr16 15126890 C T 6.36E-09 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 intron 24823311 rs12926897 chr16 15126890 C T 6.81E-31 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 intron 24823311 rs35811052 chr16 15128416 A G 8.03E-11 Metabolite levels PDXDC1 intron 22286219 rs4985155 chr16 15129459 A G 2.35E-05 Triglycerides PDXDC1 intron 19074352 rs4985155 chr16 15129459 A G 2.35E-05 Polyunsaturated fatty acid levels,in plasma PDXDC1 intron 19148276 rs4985155 chr16 15129459 A G 2.05E-06 Phospholipid levels (plasma) PDXDC1 intron 21829377 rs4985155 chr16 15129459 A G 7.47E-11 Metabolite levels PDXDC1 intron 22286219 rs4985155 chr16 15129459 A G 2.00E-10 Bone mineral density PDXDC1 intron 22504420 rs4985155 chr16 15129459 A G 4.70E-04 Bone mineral density PDXDC1 intron 24249740 rs4985155 chr16 15129459 A G 2.00E-12 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 intron 24823311 rs4985155 chr16 15129459 A G 2.00E-67 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 intron 24823311 rs4985155 chr16 15129459 A G 2.85E-15 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 intron 24823311 rs4985155 chr16 15129459 A G 6.60E-09 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 intron 24823311 rs3198697 chr16 15129940 C T 2.61E-11 Metabolite levels PDXDC1 cds-synon 22286219 rs3198697 chr16 15129940 C T 2.00E-08 Triglycerides PDXDC1 cds-synon 24097068 rs3198697 chr16 15129940 C T 1.72E-56 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 cds-synon 24823311 rs3198697 chr16 15129940 C T 3.27E-15 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 cds-synon 24823311 rs3198697 chr16 15129940 C T 7.27E-11 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 cds-synon 24823311 rs7200543 chr16 15129970 A G 8.80E-07 Phospholipid levels (plasma) PDXDC1 cds-synon 21829377 rs7200543 chr16 15129970 A G 5.00E-16 Metabolic traits PDXDC1 cds-synon 21886157 rs7200543 chr16 15129970 A G 9.86E-11 Metabolite levels PDXDC1 cds-synon 22286219 rs7200543 chr16 15129970 A G 1.13E-64 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 cds-synon 24823311 rs7200543 chr16 15129970 A G 1.42E-15 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 cds-synon 24823311 rs7200543 chr16 15129970 A G 1.69E-10 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 cds-synon 24823311 rs7200543 chr16 15129970 A G 4.33E-11 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 cds-synon 24823311 rs1741 chr16 15130351 G C 1.17E-06 Phospholipid levels (plasma) PDXDC1 UTR-3 21829377 rs1741 chr16 15130351 G C 1.00E-15 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 UTR-3 24823311 rs1741 chr16 15130351 G C 2.00E-10 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 UTR-3 24823311 rs1741 chr16 15130351 G C 3.09E-11 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 UTR-3 24823311 rs1741 chr16 15130351 G C 5.17E-65 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 UTR-3 24823311 rs6498540 chr16 15130594 A G 1.18E-06 Phospholipid levels (plasma) PDXDC1 UTR-3 21829377 rs6498540 chr16 15130594 A G 9.83E-11 Metabolite levels PDXDC1 UTR-3 22286219 rs6498540 chr16 15130594 A G 3.00E-11 Blood metabolite levels PDXDC1 UTR-3 24816252 rs6498540 chr16 15130594 A G 1.70E-10 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 UTR-3 24823311 rs6498540 chr16 15130594 A G 3.03E-11 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 UTR-3 24823311 rs6498540 chr16 15130594 A G 5.47E-65 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 UTR-3 24823311 rs6498540 chr16 15130594 A G 9.97E-16 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 UTR-3 24823311 rs1121 chr16 15131076 G A 1.20E-06 Phospholipid levels (plasma) PDXDC1 UTR-3 21829377 rs1121 chr16 15131076 G A 1.02E-15 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 UTR-3 24823311 rs1121 chr16 15131076 G A 1.80E-10 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 UTR-3 24823311 rs1121 chr16 15131076 G A 3.00E-11 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 UTR-3 24823311 rs1121 chr16 15131076 G A 5.72E-65 Plasma omega-6 polyunsaturated fatty acid levels PDXDC1 UTR-3 24823311 rs4985154 chr16 15131642 G C 9.89E-11 Metabolite levels / / 22286219 rs1135999 chr16 15131962 A G 1.23E-06 Phospholipid levels (plasma) NTAN1 missense 21829377 rs1135999 chr16 15131962 A G 1.06E-15 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 missense 24823311 rs1135999 chr16 15131962 A G 2.06E-10 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 missense 24823311 rs1135999 chr16 15131962 A G 2.92E-11 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 missense 24823311 rs1135999 chr16 15131962 A G 3.48E-65 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 missense 24823311 rs1136001 chr16 15131974 G T 7.00E-06 Height NTAN1 missense 20189936 rs1136001 chr16 15131974 G T 1.27E-06 Phospholipid levels (plasma) NTAN1 missense 21829377 rs1136001 chr16 15131974 G T 7.99E-11 Metabolite levels NTAN1 missense 22286219 rs1136001 chr16 15131974 G T 1.00E-15 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 missense 24823311 rs1136001 chr16 15131974 G T 2.10E-10 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 missense 24823311 rs1136001 chr16 15131974 G T 2.88E-11 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 missense 24823311 rs1136001 chr16 15131974 G T 3.66E-65 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 missense 24823311 rs2740 chr16 15132108 A G 1.25E-06 Phospholipid levels (plasma) NTAN1 intron 21829377 rs2740 chr16 15132108 A G 9.92E-11 Metabolite levels NTAN1 intron 22286219 rs2740 chr16 15132108 A G 5.00E-32 Blood metabolite ratios NTAN1 intron 24816252 rs2740 chr16 15132108 A G 1.10E-15 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 intron 24823311 rs2740 chr16 15132108 A G 2.12E-10 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 intron 24823311 rs2740 chr16 15132108 A G 3.18E-11 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 intron 24823311 rs2740 chr16 15132108 A G 5.46E-65 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 intron 24823311 rs34614532 chr16 15132908 T C 1.02E-10 Metabolite levels NTAN1 intron 22286219 rs14347 chr16 15133889 T G 1.06E-10 Metabolite levels NTAN1 cds-synon 22286219 rs16966953 chr16 15135854 A G 1.13E-10 Metabolite levels NTAN1 intron 22286219 rs16966952 chr16 15135943 G A 1.29E-06 Phospholipid levels (plasma) NTAN1 intron 21829377 rs16966952 chr16 15135943 G A 1.23E-15 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 intron 24823311 rs16966952 chr16 15135943 G A 2.43E-10 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 intron 24823311 rs16966952 chr16 15135943 G A 5.05E-11 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 intron 24823311 rs16966952 chr16 15135943 G A 7.55E-65 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 intron 24823311 rs3803573 chr16 15138413 C T 1.46E-06 Phospholipid levels (plasma) NTAN1 intron 21829377 rs3803573 chr16 15138413 C T 1.39E-15 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 intron 24823311 rs3803573 chr16 15138413 C T 2.47E-10 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 intron 24823311 rs3803573 chr16 15138413 C T 5.00E-11 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 intron 24823311 rs3803573 chr16 15138413 C T 7.56E-65 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 intron 24823311 rs34955778 chr16 15139594 T C 2.34E-12 Metabolite levels NTAN1 intron 22286219 rs4500751 chr16 15140211 C T 1.58E-06 Phospholipid levels (plasma) NTAN1 intron 21829377 rs4500751 chr16 15140211 C T 6.00E-23 Phospholipid levels (plasma) NTAN1 intron 22359512 rs4500751 chr16 15140211 C T 1.47E-14 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 intron 24823311 rs4500751 chr16 15140211 C T 1.85E-09 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 intron 24823311 rs4500751 chr16 15140211 C T 2.16E-63 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 intron 24823311 rs4985148 chr16 15147788 A C 1.46E-06 Phospholipid levels (plasma) NTAN1 intron 21829377 rs4985148 chr16 15147788 A C 1.21E-14 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 intron 24823311 rs4985148 chr16 15147788 A C 1.49E-09 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 intron 24823311 rs4985148 chr16 15147788 A C 3.08E-63 Plasma omega-6 polyunsaturated fatty acid levels NTAN1 intron 24823311 rs11075253 chr16 15148646 C A 5.00E-15 Lipid metabolism phenotypes NTAN1 intron 22286219 rs12928099 chr16 15150505 C A 8.60E-15 Metabolite levels / / 22286219 rs2280018 chr16 15150833 A C 4.00E-14 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2280018 chr16 15150833 A C 5.00E-25 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs9927842 chr16 15153717 T C 2.70E-05 Urinary metabolites / / 21572414 rs3751877 chr16 15154898 T C 2.09E-24 Plasma omega-6 polyunsaturated fatty acid levels RRN3 UTR-3 24823311 rs3751877 chr16 15154898 T C 2.68E-06 Plasma omega-6 polyunsaturated fatty acid levels RRN3 UTR-3 24823311 rs4985147 chr16 15168760 T C 2.40E-04 Myasthenia gravis RRN3 intron 23055271 rs11644601 chr16 15172118 T C 7.56E-13 Metabolite levels RRN3 intron 22286219 rs4122352 chr16 15174571 G A 4.81E-12 Metabolite levels RRN3 intron 22286219 rs11075260 chr16 15285027 G T 4.31E-15 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1629212 chr16 15378697 A T 4.45E-20 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs692321 chr16 15506926 G T 6.87E-05 Blood Pressure / / pha003050 rs3844608 chr16 15512575 A G 8.12E-04 Type 2 diabetes / / 17463246 rs3844608 chr16 15512575 A G 3.17E-04 Gallstones / / 17632509 rs111671 chr16 15529311 G C 2.60E-14 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs153799 chr16 15535071 T C 9.25E-09 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs222135 chr16 15539327 C T 4.25E-14 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs153795 chr16 15540576 A T 9.49E-14 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs153793 chr16 15542199 G A 4.67E-14 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs222133 chr16 15545022 C T 7.17E-12 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs222130 chr16 15548310 G A 8.04E-14 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs153800 chr16 15549757 G A 6.66E-14 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs153801 chr16 15550012 C T 5.42E-14 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs153803 chr16 15552160 G A 4.51E-14 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs153804 chr16 15553054 A G 5.15E-14 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs153806 chr16 15556396 G A 1.08E-14 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs153807 chr16 15556503 C T 1.52E-24 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs1684546 chr16 15560425 G C 4.38E-25 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs2450356 chr16 15571344 C T 2.89E-14 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs219426 chr16 15583243 T G 4.19E-05 Monocyte chemoattractant protein-1 C16orf45 intron pha003071 rs219426 chr16 15583243 T G 5.87E-05 Lung function (forced expiratory volume in 1 second) C16orf45 intron pha003102 rs12148985 chr16 15586909 C T 2.20E-15 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs34792 chr16 15587497 C G 3.00E-06 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs34792 chr16 15587497 C G 3.07E-24 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs153785 chr16 15593292 G A 2.47E-09 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs153786 chr16 15593714 C T 2.11E-09 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs153787 chr16 15593773 A T 2.17E-09 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs153788 chr16 15594203 G A 2.53E-09 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs13339072 chr16 15597947 A G 3.31E-09 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs170168 chr16 15600995 C G 2.61E-09 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs153782 chr16 15601620 T C 2.35E-09 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs2445475 chr16 15602104 G A 6.00E-19 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs153783 chr16 15602366 G A 1.83E-09 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs12923446 chr16 15603580 C A 6.88E-07 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs1125972 chr16 15606987 A G 9.72E-07 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs1125972 chr16 15606987 A G 4.85E-05 Left ventricular hypertrophy C16orf45 intron pha003052 rs2067063 chr16 15608963 G A 7.79E-08 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs4597346 chr16 15623746 G C 8.61E-08 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs9922431 chr16 15658648 T C 8.03E-07 Plasma omega-6 polyunsaturated fatty acid levels C16orf45 intron 24823311 rs7185019 chr16 15683594 T C 1.06E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs1107142 chr16 15686345 T G 2.54E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs11866131 chr16 15686646 G T 2.78E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs2071330 chr16 15697795 C T 1.55E-06 Plasma omega-6 polyunsaturated fatty acid levels KIAA0430 intron 24823311 rs7191720 chr16 15707572 T C 4.08E-07 Plasma omega-6 polyunsaturated fatty acid levels KIAA0430 intron 24823311 rs11649126 chr16 15720247 G A 4.86E-12 Plasma omega-6 polyunsaturated fatty acid levels KIAA0430 intron 24823311 rs4781677 chr16 15730245 G A 3.58E-11 Plasma omega-6 polyunsaturated fatty acid levels KIAA0430 intron 24823311 rs4781678 chr16 15747112 C A 1.09E-06 Plasma omega-6 polyunsaturated fatty acid levels NDE1 intron 24823311 rs8061376 chr16 15754468 G T 7.41E-04 Response to taxane treatment (placlitaxel) NDE1 intron 23006423 rs7184854 chr16 15758906 T C 4.44E-04 Response to taxane treatment (placlitaxel) NDE1 intron 23006423 rs4781679 chr16 15761433 C G 4.73E-04 Response to taxane treatment (placlitaxel) NDE1 intron 23006423 rs3784859 chr16 15765403 T C 1.42E-04 Multiple complex diseases NDE1 intron 17554300 rs3784859 chr16 15765403 T C 2.66E-08 Plasma omega-6 polyunsaturated fatty acid levels NDE1 intron 24823311 rs11649278 chr16 15774782 G C 8.03E-09 Plasma omega-6 polyunsaturated fatty acid levels NDE1 intron 24823311 rs12934645 chr16 15780367 C T 1.08E-04 Multiple complex diseases NDE1 intron 17554300 rs11647544 chr16 15796568 C T 8.76E-09 Plasma omega-6 polyunsaturated fatty acid levels NDE1 intron 24823311 rs881803 chr16 15802334 C T 8.82E-09 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs10521101 chr16 15807677 T C 8.06E-11 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs1050163 chr16 15811023 C T 1.83E-09 Plasma omega-6 polyunsaturated fatty acid levels MYH11 cds-synon 24823311 rs1050162 chr16 15811062 C T 1.51E-04 Multiple complex diseases MYH11 cds-synon 17554300 rs1050162 chr16 15811062 C T 1.74E-09 Plasma omega-6 polyunsaturated fatty acid levels MYH11 cds-synon 24823311 rs2075512 chr16 15813945 C T 1.73E-06 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs2075511 chr16 15818141 A C 2.09E-05 Multiple complex diseases MYH11 cds-synon 17554300 rs2075511 chr16 15818141 A C 9.23E-08 Plasma omega-6 polyunsaturated fatty acid levels MYH11 cds-synon 24823311 rs16967494 chr16 15820863 C T 7.85E-07 Plasma omega-6 polyunsaturated fatty acid levels MYH11 missense 24823311 rs2272555 chr16 15831212 G A 6.81E-14 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs1050113 chr16 15839034 G A,C,T 1.23E-11 Plasma omega-6 polyunsaturated fatty acid levels MYH11 cds-synon 24823311 rs6498570 chr16 15843899 G A 9.31E-08 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs4781685 chr16 15845100 G C 1.75E-17 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs2272554 chr16 15850204 A G 1.52E-16 Plasma omega-6 polyunsaturated fatty acid levels MYH11 cds-synon 24823311 rs2280764 chr16 15853596 C G 2.72E-14 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs932233 chr16 15859279 C G 6.30E-04 Coronary heart disease MYH11 intron 21606135 rs16967478 chr16 15864284 G A 6.74E-05 Suicide attempts in bipolar disorder MYH11 intron 21423239 rs4781688 chr16 15865189 C A 1.80E-05 Response to Vitamin E supplementation MYH11 intron 22437554 rs12922040 chr16 15869466 C T 6.65E-04 Suicide attempts in bipolar disorder MYH11 intron 21423239 rs12922040 chr16 15869466 C T 4.25E-09 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs2075516 chr16 15869525 T C 5.04E-04 Suicide attempts in bipolar disorder MYH11 intron 21423239 rs2075516 chr16 15869525 T C 7.09E-04 Insulin resistance MYH11 intron 21901158 rs2075516 chr16 15869525 T C 5.78E-09 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs2072619 chr16 15869801 T C 6.81E-05 Insulin resistance MYH11 intron 21901158 rs11075280 chr16 15870487 G A 6.83E-10 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs4541094 chr16 15870735 C T 7.34E-10 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs1569300 chr16 15870748 G A 7.69E-10 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs4262965 chr16 15870758 G A 7.90E-10 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs4482303 chr16 15870877 C T 8.15E-10 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs10852376 chr16 15872073 G A 8.67E-10 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs2075515 chr16 15872319 G A 8.50E-10 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs2075514 chr16 15872609 A G 2.00E-06 Hypertension MYH11 intron 22384028 rs2075514 chr16 15872609 A G 1.06E-09 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs2075513 chr16 15876471 T C 4.69E-09 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs8060975 chr16 15877411 C T 2.19E-05 Serum metabolites MYH11 intron 19043545 rs8045778 chr16 15878252 C T 2.30E-09 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs6498573 chr16 15879373 C T 4.62E-05 Suicide attempts in bipolar disorder MYH11 intron 21423239 rs17213965 chr16 15881967 C T 9.00E-07 Waist-hip ratio MYH11 intron 23966867 rs17213965 chr16 15881967 C T 4.08E-06 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs3898632 chr16 15883241 G C 4.39E-06 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs17214007 chr16 15883490 T C 1.76E-12 Plasma omega-6 polyunsaturated fatty acid levels MYH11 intron 24823311 rs4781693 chr16 15886243 T C 2.47E-04 Amyotrophic lateral sclerosis MYH11 intron 23624525 rs13333967 chr16 15894368 G C 6.08E-04 Telomere length MYH11 intron 23900074 rs3915499 chr16 15910743 G A 2.81E-05 Heart rate MYH11 intron 23583979 rs215590 chr16 15927591 C A 0.000082 Nonsyndromic striae distensae (stretch marks) MYH11 intron 23633020 rs215587 chr16 15928307 C T 0.0000808 Nonsyndromic striae distensae (stretch marks) MYH11 intron 23633020 rs215584 chr16 15930250 G T 0.0000845 Nonsyndromic striae distensae (stretch marks) MYH11 intron 23633020 rs215583 chr16 15930535 G A 0.0000771 Nonsyndromic striae distensae (stretch marks) MYH11 intron 23633020 rs215581 chr16 15933174 T C 0.000432 Salmonella-induced pyroptosis MYH11 intron 22837397 rs7196606 chr16 15941025 A G 0.00042 Salmonella-induced pyroptosis MYH11 intron 22837397 rs9922682 chr16 15946778 C T 2.27E-04 Insulin resistance MYH11 intron 21901158 rs9922682 chr16 15946778 C T 2.24E-04 Lymphocyte counts MYH11 intron 22286170 rs9922682 chr16 15946778 C T 0.000378 Salmonella-induced pyroptosis MYH11 intron 22837397 rs9932695 chr16 15948539 G A 0.000321 Salmonella-induced pyroptosis MYH11 intron 22837397 rs9933417 chr16 15948632 C T 0.000322 Salmonella-induced pyroptosis MYH11 intron 22837397 rs3851702 chr16 15949562 T C 0.000422 Salmonella-induced pyroptosis MYH11 intron 22837397 rs3851704 chr16 15949775 A G 0.000389 Salmonella-induced pyroptosis MYH11 intron 22837397 rs3743518 chr16 15960226 T C 2.52E-05 Aging (time to event) / / 21782286 rs8052957 chr16 15991449 T G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs8052957 chr16 15991449 T G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs8052957 chr16 15991449 T G 0.000504 Salmonella-induced pyroptosis / / 22837397 rs169983 chr16 15996525 C T 1.06E-04 Type 2 diabetes / / 17463246 rs13335375 chr16 16018589 C T 0.0005 Prostate cancer / / 23555315 rs11075286 chr16 16027724 A C 3.93E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs11075286 chr16 16027724 A C 6.32E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs4148330 chr16 16041768 G A 2.27E-05 Response to mTOR inhibitor (rapamycin) ABCC1 nearGene-5 24009623 rs4148330 chr16 16041768 G A 9.80E-06 Response to mTOR inhibitor (everolimus) ABCC1 nearGene-5 24009623 rs119774 chr16 16086833 C T 1 Drug response to Montelukast ABCC1 intron 16293801 rs16967179 chr16 16091507 C T 0.000000669 Cholesterol,total ABCC1 intron 23063622 rs9635480 chr16 16094601 A G 2.90E-12 Progranulin levels ABCC1 intron 21087763 rs9635480 chr16 16094601 A G 2.90E-12 Myocardial infarction ABCC1 intron 21211798 rs8054156 chr16 16105482 G A 9.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) ABCC1 intron 23233662 rs16967145 chr16 16106970 G A 9.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) ABCC1 intron 23233662 rs3784862 chr16 16110891 G A 1 Drug response to Methotrexate ABCC1 intron 18256692 rs246214 chr16 16114892 C T 1.90E-04 Suicide attempts in bipolar disorder ABCC1 intron 21041247 rs246214 chr16 16114892 C T 7.30E-06 Urinary metabolites ABCC1 intron 21572414 rs246214 chr16 16114892 C T 6.80E-11 Brain activation patterns in response to human facial expressions-for the negative faces task ABCC1 intron 22828495 rs246214 chr16 16114892 C T 6.80E-11 Airflow obstruction ABCC1 intron 22837378 rs246240 chr16 16119024 A G 1 Drug response to Methotrexate ABCC1 intron 18256692 rs246240 chr16 16119024 A G 1.89E-04 Suicide attempts in bipolar disorder ABCC1 intron 21041247 rs246240 chr16 16119024 A G 2.10E-05 Urinary metabolites ABCC1 intron 21572414 rs924135 chr16 16123459 A T 2.00E-19 Blood metabolite levels ABCC1 intron 24816252 rs924136 chr16 16126475 G A 2.83E-04 Alcohol dependence ABCC1 intron 21314694 rs2062541 chr16 16127235 G A 1.00E-25 Blood metabolite ratios ABCC1 intron 24816252 rs2062541 chr16 16127235 G A 6.00E-13 Blood metabolite levels ABCC1 intron 24816252 rs246234 chr16 16128742 C G 3.00E-14 Blood metabolite levels ABCC1 intron 24816252 rs246230 chr16 16132880 C T 9.52E-04 Alzheimer's disease ABCC1 intron 17998437 rs35592 chr16 16141823 T C 1 Drug response to Methotrexate ABCC1 intron 18256692 rs35595 chr16 16149871 G A 2.95E-04 Cognitive impairment induced by topiramate ABCC1 intron 22091778 rs35597 chr16 16158034 G A 2.18E-04 Alzheimer's disease ABCC1 intron 17998437 rs35605 chr16 16162019 T C 1 Drug response to Irinotecan ABCC1 cds-synon 19940846 rs35605 chr16 16162019 T C 1 Drug response to SN-38 ABCC1 cds-synon 19940846 rs35610 chr16 16163273 A C 4.15E-04 Alzheimer's disease ABCC1 intron 17998437 rs35610 chr16 16163273 A C 9.48E-05 Hypertension ABCC1 intron pha003042 rs35613 chr16 16164065 A C 7.68E-04 Aortic root size ABCC1 intron 21223598 rs35621 chr16 16168608 C T 1.00E-04 Cognitive impairment induced by topiramate ABCC1 intron 22091778 rs35621 chr16 16168608 C T 7.79E-04 Cognitive impairment induced by topiramate ABCC1 intron 22091778 rs35626 chr16 16170615 G T 8.26E-04 Alcohol consumption (maxi-drinks) ABCC1 intron 24277619 rs45511401 chr16 16173232 G T 1 Drug response to Estradiol ABCC1 missense 11721885 rs45511401 chr16 16173232 G T 1 Drug response to Estrone ABCC1 missense 11721885 rs45511401 chr16 16173232 G T 1 Drug response to Atorvastatin ABCC1 missense 18851956 rs4148356 chr16 16177275 G A 1 Drug response to Methotrexate ABCC1 missense 16041243 rs2074086 chr16 16181142 T C 4.88E-04 Alcohol consumption (maxi-drinks) ABCC1 intron 24277619 rs4148358 chr16 16187175 C T 2.40E-05 Urinary metabolites ABCC1 intron 21572414 rs4148358 chr16 16187175 C T 4.89E-04 Alcohol consumption (maxi-drinks) ABCC1 intron 24277619 rs35529209 chr16 16205325 G A 1 Drug response to Estradiol ABCC1 missense 16041243 rs2238476 chr16 16213872 G A 1 Drug response to Methotrexate ABCC1 intron 18256692 rs28364006 chr16 16228249 A G 1 Drug response to Methotrexate ABCC1 missense 18256692 rs8056298 chr16 16236523 T G 9.11E-10 Cholesterol,total ABCC1 UTR-3 23063622 rs212093 chr16 16237754 A G 8.50E-05 Serum metabolites / / 19043545 rs2238472 chr16 16251599 C T 1 Drug response to Docetaxel ABCC6 missense 20038957 rs2238472 chr16 16251599 C T 1 Drug response to Thalidomide ABCC6 missense 20038957 rs2239329 chr16 16252168 G A 2.92E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ABCC6 intron 21844884 rs16967488 chr16 16252696 T C 3.40E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ABCC6 intron 21844884 rs2238470 chr16 16253570 C T 7.85E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ABCC6 intron 21844884 rs3213473 chr16 16256767 T A,G 7.00E-06 IgG glycosylation ABCC6 intron 23382691 rs8045279 chr16 16265561 C A 0.000487978 Hypertension (early onset hypertension) ABCC6 intron 22479346 rs2283508 chr16 16272508 G A 4.00E-05 Schizophrenia ABCC6 intron 19571808 rs3851722 chr16 16282307 G A 3.11E-04 Multiple complex diseases ABCC6 intron 17554300 rs3851722 chr16 16282307 G A 1.14E-04 Body mass index ABCC6 intron 21701565 rs3851722 chr16 16282307 G A 1.18E-04 Body mass index ABCC6 intron 21701565 rs3851722 chr16 16282307 G A 1.00E-04 Cognitive impairment induced by topiramate ABCC6 intron 22091778 rs2937148 chr16 16668904 A G 4.20E-06 Urinary metabolites / / 21572414 rs9937036 chr16 16730728 T G 8.00E-07 Obesity-related traits / / 23251661 rs1840186 chr16 16917137 A T 1.92E-05 Multiple complex diseases / / 17554300 rs17660389 chr16 16945225 A G 3.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs4622500 chr16 16946543 C T 4.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs10163255 chr16 16947106 A G 3.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs4503778 chr16 16949230 C T 3.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs1869393 chr16 16950771 A G 3.53E-05 Multiple complex diseases / / 17554300 rs1077811 chr16 16951990 T C 6.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs11644271 chr16 16954282 A G 7.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs7186128 chr16 16957915 G A 4.00E-07 non-small cell lung cancer / / 23478653 rs2100401 chr16 16959637 T G 8.22E-04 Obesity (extreme) / / 21935397 rs4344725 chr16 16965105 G A 9.47E-04 Obesity (extreme) / / 21935397 rs9936071 chr16 16965532 G A 8.73E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7206357 chr16 16968574 T C 7.14E-04 Obesity (extreme) / / 21935397 rs4238661 chr16 16972404 C G 5.04E-04 Fibrinogen / / 17255346 rs4238659 chr16 16974936 T C 6.54E-04 Obesity (extreme) / / 21935397 rs4782058 chr16 17004238 C T 1.85E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs1453512 chr16 17017899 C A 2.57E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs7190989 chr16 17028058 A G 3.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs9925934 chr16 17028247 A G 7.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs4782051 chr16 17028506 T C 5.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs7198795 chr16 17054910 G A 2.26E-04 Multiple complex diseases / / 17554300 rs7196141 chr16 17079923 T C 8.75E-06 Glycemic traits (pregnancy) / / 23903356 rs6498657 chr16 17092870 A C 3.46E-04 Multiple complex diseases / / 17554300 rs8064091 chr16 17093898 T A 4.05E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10852388 chr16 17127101 T C 2.18E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1391349 chr16 17168236 T G 2.99E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1391351 chr16 17177321 A G 8.93E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs4340319 chr16 17188875 G A 1.51E-16 Lymphocyte counts / / 22286170 rs12927816 chr16 17206303 C T 4.58E-05 Height XYLT1 intron pha003011 rs11641613 chr16 17210076 T G 1.55E-05 Height XYLT1 intron pha003011 rs9923657 chr16 17214305 G T 2.19E-05 Smoking cessation XYLT1 intron 18519826 rs9939115 chr16 17220559 T A 1.74E-04 Smoking cessation XYLT1 intron 18519826 rs9807009 chr16 17225850 C T 6.59E-05 Smoking cessation XYLT1 intron 18519826 rs4782031 chr16 17234040 C T 2.07E-05 Smoking cessation XYLT1 intron 18519826 rs2125190 chr16 17241128 C T 6.03E-04 Amyotrophic lateral sclerosis (sporadic) XYLT1 intron 24529757 rs2125191 chr16 17241182 T A,C,G 5.39E-04 Multiple complex diseases XYLT1 intron 17554300 rs1463462 chr16 17254059 G A 5.50E-07 Urinary metabolites XYLT1 intron 21572414 rs9940127 chr16 17255502 G T 6.30E-05 Myopia (pathological) XYLT1 intron 23049088 rs9933117 chr16 17255571 T C 2.86E-04 Taste perception XYLT1 intron 22132133 rs1542421 chr16 17270944 A G 5.43E-05 Tuberculosis XYLT1 intron 20694014 rs752482 chr16 17271327 T C 3.39E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) XYLT1 intron 23648065 rs752482 chr16 17271327 T C 6.97E-06 Body Mass Index XYLT1 intron pha002896 rs7190310 chr16 17271862 G A 7.61E-05 Tuberculosis XYLT1 intron 20694014 rs7195149 chr16 17271989 G A 5.54E-05 Tuberculosis XYLT1 intron 20694014 rs7197587 chr16 17272242 A G 4.95E-05 Tuberculosis XYLT1 intron 20694014 rs7197476 chr16 17272543 C T 4.46E-05 Tuberculosis XYLT1 intron 20694014 rs7197476 chr16 17272543 C T 1.72E-04 Myopia (pathological) XYLT1 intron 21095009 rs7198185 chr16 17272560 A G 5.05E-05 Tuberculosis XYLT1 intron 20694014 rs7198350 chr16 17272631 A T 4.64E-05 Tuberculosis XYLT1 intron 20694014 rs7205152 chr16 17276061 T C 2.33E-05 Tuberculosis XYLT1 intron 20694014 rs11863514 chr16 17277291 G A 5.10E-05 Tuberculosis XYLT1 intron 20694014 rs4782022 chr16 17303554 G A 6.24E-05 Post-operative nausea and vomiting XYLT1 intron 21694509 rs4782019 chr16 17325433 T C 1.02E-04 Aortic root size XYLT1 intron 21223598 rs10500398 chr16 17344723 C T 4.06E-05 Type 2 diabetes XYLT1 intron 17846125 rs11075345 chr16 17357457 C T 2.09E-05 Asthma XYLT1 intron 23181788 rs8062743 chr16 17379517 G A 1.09E-04 Alzheimer's disease (late onset) XYLT1 intron 21379329 rs6498673 chr16 17383298 T A 3.24E-05 Alzheimer's disease (late onset) XYLT1 intron 21460841 rs11861415 chr16 17384524 A G 7.86E-05 Alzheimer's disease (late onset) XYLT1 intron 21379329 rs11861415 chr16 17384524 A G 8.03E-05 Alzheimer's disease (late onset) XYLT1 intron 21460841 rs16968710 chr16 17387160 A G 1.60E-05 Urinary metabolites XYLT1 intron 21572414 rs7196829 chr16 17397988 T A 4.60E-07 Urinary metabolites XYLT1 intron 21572414 rs1457906 chr16 17406260 C T 8.42E-05 Soluble levels of adhesion molecules XYLT1 intron pha003072 rs4782010 chr16 17408872 C T 0.00055 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines XYLT1 intron 23204130 rs10468258 chr16 17409365 G A 5.45E-04 Insulin resistance XYLT1 intron 21901158 rs4782006 chr16 17411707 C G 8.39E-04 Multiple complex diseases XYLT1 intron 17554300 rs7498915 chr16 17519847 T C 1.60E-04 Rheumatoid arthritis XYLT1 intron 22446963 rs12446944 chr16 17532404 A G 5.62E-05 Serum metabolites XYLT1 intron 19043545 rs1465465 chr16 17547467 A G 7.94E-05 Response to cytadine analogues (cytosine arabinoside) XYLT1 intron 24483146 rs7197376 chr16 17573100 C T 5.57E-05 Orofacial clefts / / 22419666 rs6498719 chr16 17645929 T C 9.10E-05 Response to statin therapy / / 20339536 rs6498721 chr16 17646194 T C 7.30E-05 Acute lung injury / / 22295056 rs11075365 chr16 17659635 A G 7.06E-05 Colorectal cancer / / 19723657 rs8058505 chr16 17704188 G C 3.68E-04 Multiple complex diseases / / 17554300 rs12445126 chr16 17739692 G A 2.00E-06 Corneal astigmatism / / 23322567 rs7204462 chr16 17805123 C T 5.40E-04 Multiple complex diseases / / 17554300 rs1565774 chr16 17837836 G A 7.21E-05 Lung adenocarcinoma / / 19836008 rs4780677 chr16 17842758 A G 2.56E-04 Smoking initiation / / 24665060 rs1994895 chr16 17850249 G A 3.51E-04 Taste perception / / 22132133 rs7190404 chr16 17864721 A G 5.08E-04 Type 2 diabetes / / 17463246 rs12927088 chr16 17869061 T C 1.66E-04 Smoking initiation / / 24665060 rs1080507 chr16 17870613 A G 3.62E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1080507 chr16 17870613 A G 4.44E-04 Smoking initiation / / 24665060 rs9925075 chr16 17872721 A G 1.04E-04 Smoking initiation / / 24665060 rs10445008 chr16 17875911 A C,G,T 2.16E-04 Smoking initiation / / 24665060 rs1994893 chr16 17912586 T C 9.20E-04 Crohn's disease / / 17684544 rs8044171 chr16 17933820 G A 1.00E-04 Information processing speed / / 21130836 rs13331355 chr16 17942603 T C 2.00E-04 Information processing speed / / 21130836 rs1124011 chr16 17947127 A G 2.19E-10 Multiple complex diseases / / 17554300 rs7184894 chr16 17992833 T G 2.21E-04 Type 2 diabetes / / 17463246 rs7202822 chr16 17992847 A G 2.98E-04 Type 2 diabetes / / 17463246 rs9937528 chr16 17993230 A G 1.65E-04 Type 2 diabetes / / 17463246 rs8044394 chr16 17994157 G C 1.05E-04 Type 2 diabetes / / 17463246 rs2158231 chr16 17994640 G A 1.07E-04 Type 2 diabetes / / 17463246 rs2158231 chr16 17994640 G A 9.88E-05 Soluble levels of adhesion molecules / / pha003072 rs11075392 chr16 18007223 T C 3.43E-05 Odorant perception / / 23910658 rs1428103 chr16 18023977 C T 6.00E-06 Ulcerative colitis / / 19915572 rs9922516 chr16 18024850 A G 9.00E-06 Obesity-related traits / / 23251661 rs11642075 chr16 18043332 T C 1.41E-04 Type 2 diabetes / / 17463246 rs7194356 chr16 18062136 C T 7.00E-06 IgG glycosylation / / 23382691 rs10451103 chr16 18094687 A C 7.67E-05 Cognitive test performance / / 20125193 rs4781878 chr16 18135446 G A 0.0000191 LDL cholesterol particle diameter / / 23263444 rs12598040 chr16 18137266 C T 0.0000196 LDL cholesterol particle diameter / / 23263444 rs2471438 chr16 18162356 T C 5.83E-04 Aortic root size / / 21223598 rs6498767 chr16 18162969 C A 6.55E-04 Aortic root size / / 21223598 rs2641892 chr16 18799615 C A 4.94E-04 Tourette syndrome RPS15A intron 22889924 rs735173 chr16 18839788 G T 8.66E-04 Type 2 diabetes SMG1 intron 17463246 rs735173 chr16 18839788 G T 1.32E-10 Lymphocyte counts SMG1 intron 22286170 rs735173 chr16 18839788 G T 3.99E-04 Tourette syndrome SMG1 intron 22889924 rs2650618 chr16 18856299 T C 7.69E-09 Schizophrenia SMG1 intron 21926974 rs2650618 chr16 18856299 T C 9.72E-05 Bipolar disorder SMG1 intron 22925353 rs2650614 chr16 18861135 T G 4.89E-04 Tourette syndrome SMG1 intron 22889924 rs7205322 chr16 18957762 G A 2.00E-06 Glaucoma (primary open-angle) / / 20835238 rs7186386 chr16 18994925 C T 5.30E-05 Body mass (lean) / / 19268274 rs4444327 chr16 19016966 A G 8.43E-04 Response to cytadine analogues (cytosine arabinoside) TMC7 intron 24483146 rs12599856 chr16 19022448 A G 7.15E-04 Response to cytadine analogues (cytosine arabinoside) TMC7 intron 24483146 rs4265793 chr16 19028549 T C 6.00E-06 Response to angiotensin II receptor blocker therapy TMC7 intron 22566498 rs28583298 chr16 19041595 G A 0.00032 Prostate cancer TMC7 missense 23555315 rs7204704 chr16 19043541 T C 9.27E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) TMC7 intron 22566498 rs4258597 chr16 19045202 A C 9.42E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) TMC7 intron 22566498 rs4782198 chr16 19048222 A C 1.21E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) TMC7 intron 22566498 rs4782202 chr16 19083221 A G 1.95E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) COQ7 intron 22566498 rs6497323 chr16 19093440 T C 3.25E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7184530 chr16 19095085 A G 3.35E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs8051290 chr16 19097873 G A 1.03E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4496124 chr16 19098324 C T 1.03E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs10454701 chr16 19154690 A G 2.69E-05 Cocaine dependence / / 23958962 rs8062326 chr16 19156016 G A 4.00E-06 Alcohol dependence / / 21876473 rs9673444 chr16 19188256 C T 4.34E-04 Response to taxane treatment (placlitaxel) SYT17 intron 23006423 rs13336280 chr16 19191388 G A 1.32E-06 ldl cholesterol SYT17 intron pha003077 rs13336280 chr16 19191388 G A 6.37E-08 Cholesterol SYT17 intron pha003083 rs9932538 chr16 19208569 A G 5.66E-05 Parkinson's disease SYT17 intron 17052657 rs7188617 chr16 19210096 G A 9.64E-05 ldl cholesterol SYT17 intron pha003077 rs3785349 chr16 19229662 T G 7.10E-05 Electrocardiographic conduction measures SYT17 intron 19389651 rs9652587 chr16 19234089 G A 9.80E-05 Electrocardiographic conduction measures SYT17 intron 19389651 rs2269786 chr16 19242902 A C 9.24E-05 Glycosylated haemoglobin levels SYT17 intron 17255346 rs6497337 chr16 19244424 A G 6.48E-05 Parkinson's disease SYT17 intron 21738487 rs6497337 chr16 19244424 A G 7.25E-05 Orofacial clefts SYT17 intron 22419666 rs6497337 chr16 19244424 A G 2.12E-05 Breast cancer SYT17 intron pha002853 rs8054636 chr16 19246136 T C 4.21E-05 Parkinson's disease SYT17 intron 21738487 rs8054408 chr16 19246524 G A 9.12E-05 Parkinson's disease SYT17 intron 21738487 rs8054408 chr16 19246524 G A 5.30E-06 Orofacial clefts SYT17 intron 22419666 rs732999 chr16 19268837 C T 5.31E-05 Parkinson's disease SYT17 intron 21738487 rs732999 chr16 19268837 C T 1.96E-05 Orofacial clefts SYT17 intron 22419666 rs11343 chr16 19279464 T G 4.29E-05 Parkinson's disease / / 21738487 rs11074381 chr16 19299808 C G 5.50E-05 Pulmonary function CLEC19A intron 20010835 rs7202244 chr16 19300321 G A 6.75E-11 Multiple complex diseases CLEC19A intron 17554300 rs179228 chr16 19319697 T C 2.70E-05 Urinary metabolites CLEC19A intron 21572414 rs1023441 chr16 19331458 G A 5.56E-05 Meningococcal disease / / 20694013 rs7185896 chr16 19344852 C T 9.46E-04 Multiple complex diseases / / 17554300 rs9930053 chr16 19349990 C A 1.24E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1467895 chr16 19354451 G A 1.99E-04 IgE levels / / 17255346 rs1894382 chr16 19371087 G T 0.00067966 Hypertension (early onset hypertension) / / 22479346 rs12443654 chr16 19375297 T C 8.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs7188161 chr16 19377101 G A 0.0001856 Sarcoidosis / / 22952805 rs7194009 chr16 19377813 G A 7.33E-05 Waist Circumference / / pha003023 rs4457974 chr16 19393110 C T 7.60E-04 Taste perception / / 22132133 rs4457974 chr16 19393110 C T 0.000813008 Hypertension (early onset hypertension) / / 22479346 rs4780805 chr16 19404645 A G 5.10E-04 Multiple complex diseases / / 17554300 rs4780805 chr16 19404645 A G 8.00E-07 Sleep duration / / 23728906 rs16972025 chr16 19461882 G A 4.20E-05 Smoking initiation TMC5 intron 24665060 rs36019638 chr16 19471571 G A 0.00021 Breast cancer TMC5 missense 23555315 rs6497375 chr16 19471665 T C 8.65E-05 Triglycerides TMC5 intron pha003080 rs12708624 chr16 19512266 C T 8.32E-05 Lymphocyte counts / / 22286170 rs739639 chr16 19527777 C T 6.20E-05 Immunoglobulin A GDE1 intron 20694011 rs12447418 chr16 19539858 A G 2.02E-05 Triglycerides CCP110 intron pha003080 rs11074401 chr16 19546503 G A 3.53E-05 Triglycerides CCP110 intron pha003080 rs11866050 chr16 19590444 T C 3.65E-04 Smoking initiation C16orf62 cds-synon 24665060 rs6497385 chr16 19594051 T C 2.35E-06 Triglycerides C16orf62 intron pha003080 rs226859 chr16 19608795 A G 2.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C16orf62 intron 20877124 rs16972236 chr16 19617573 G A 2.27E-05 Triglycerides C16orf62 intron pha003080 rs226898 chr16 19620862 C T 4.13E-04 Multiple complex diseases C16orf62 intron 17554300 rs6497393 chr16 19644773 A G 0.000034 Asthma (exacerbation) C16orf62 intron 23706709 rs9934689 chr16 19670664 G A 5.52E-04 Myopia (pathological) C16orf62 intron 21095009 rs1544352 chr16 19713882 A G 1.94E-05 Obsessive-compulsive disorder / / 24821223 rs73541429 chr16 19719526 A G 2.09E-12 Metabolite levels C16orf88 intron 22286219 rs2354584 chr16 19778575 A G 8.98E-05 Multiple complex diseases IQCK intron 17554300 rs7191421 chr16 19852814 C A 3.60E-05 Response to statin therapy IQCK intron 20339536 rs757206 chr16 19855866 C T 3.70E-05 Response to statin therapy IQCK intron 20339536 rs227762 chr16 19859406 G A 1.50E-05 Response to statin therapy IQCK intron 20339536 rs227761 chr16 19861305 T C 1.10E-05 Response to statin therapy IQCK intron 20339536 rs4782291 chr16 19864558 G A 4.00E-05 Response to statin therapy IQCK intron 20339536 rs3748405 chr16 19870176 T C 5.40E-05 Response to statin therapy / / 20339536 rs227763 chr16 19872922 A G 1.60E-05 Response to statin therapy GPRC5B intron 20339536 rs9941245 chr16 19916895 T G 9.99E-05 Schizophrenia / / 20185149 rs9941245 chr16 19916895 T G 2.00E-06 Urinary metabolites / / 21572414 rs12444979 chr16 19933600 C T 3.00E-21 Body mass index / / 20935630 rs12444979 chr16 19933600 C T 2.91E-21 Body mass index / / 23001569 rs12446554 chr16 19935073 G T 4.00E-12 Obesity / / 23563607 rs12446632 chr16 19935389 G A 2.00E-10 Obesity / / 23563607 rs9926784 chr16 19941968 T C 2.20E-05 Urinary metabolites / / 21572414 rs7205054 chr16 19943026 C G 2.90E-05 Urinary metabolites / / 21572414 rs7205054 chr16 19943026 C G 4.31E-05 Body mass index / / 23669352 rs11639988 chr16 19944363 A G 4.00E-09 Obesity / / 23563607 rs4527026 chr16 19960320 C T 5.00E-06 Obesity-related traits / / 23251661 rs2764742 chr16 20030832 C T 6.80E-07 Ulcerative colitis / / 19915572 rs2764743 chr16 20031205 T A 8.00E-07 IgG glycosylation / / 23382691 rs868554 chr16 20050466 C G 5.72E-04 Fibrinogen GPR139 intron 17255346 rs2608173 chr16 20054359 C T 3.99E-04 Multiple complex diseases GPR139 intron 17554300 rs12596252 chr16 20056993 G A 3.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) GPR139 intron 23527680 rs12596252 chr16 20056993 G A 9.60E-06 Attention deficit hyperactivity disorder (combined symptoms) GPR139 intron 23527680 rs1902813 chr16 20057661 G C 3.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) GPR139 intron 23527680 rs1902813 chr16 20057661 G C 9.61E-06 Attention deficit hyperactivity disorder (combined symptoms) GPR139 intron 23527680 rs12926725 chr16 20059677 C T 3.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) GPR139 intron 23527680 rs12926725 chr16 20059677 C T 9.64E-06 Attention deficit hyperactivity disorder (combined symptoms) GPR139 intron 23527680 rs12931939 chr16 20060830 C T 6.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) GPR139 intron 23527680 rs11642361 chr16 20068714 G A 9.88E-05 HDL cholesterol GPR139 intron pha003074 rs1886712 chr16 20083693 C G 5.61E-04 Alcohol dependence GPR139 intron 21314694 rs10521114 chr16 20089754 G A 8.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs10521115 chr16 20090645 G A 8.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs7201408 chr16 20094054 A G 7.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs12924103 chr16 20094546 T C 7.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs7185264 chr16 20094886 G A 7.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs11647507 chr16 20095628 A C 7.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs12926729 chr16 20100370 G A 7.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs11642377 chr16 20109653 G A 7.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs2608200 chr16 20122290 A G 6.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs6497436 chr16 20123515 T C 6.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs12919130 chr16 20126974 A G 2.00E-06 Attention deficit hyperactivity disorder (inattention symptoms) / / 23527680 rs4426354 chr16 20134304 T C 7.90E-05 Parkinson's disease (age of onset) / / 19772629 rs9928153 chr16 20152650 A G 2.70E-04 Multiple complex diseases / / 17554300 rs4368165 chr16 20190635 C T 4.02E-05 Rheumatoid arthritis / / 21452313 rs6497445 chr16 20216617 T C 9.04E-05 Post-operative nausea and vomiting / / 21694509 rs9936241 chr16 20225644 G A 8.24E-05 Post-operative nausea and vomiting / / 21694509 rs10775267 chr16 20237977 C T 8.10E-04 Multiple complex diseases / / 17554300 rs7191955 chr16 20238586 T C 5.66E-05 Progressive supranuclear palsy / / 21685912 rs9935818 chr16 20239043 T C 2.00E-05 Urinary metabolites / / 21572414 rs9921767 chr16 20244780 A G 7.14E-04 Common variable immunodeficiency / / 21497890 rs4405562 chr16 20246025 C G 1.81E-04 Multiple complex diseases / / 17554300 rs12598578 chr16 20254476 G C 1.63E-04 Body mass index / / 22344219 rs11074446 chr16 20255123 T C 4.03E-04 Multiple complex diseases / / 17554300 rs11074446 chr16 20255123 T C 8.26E-04 Bipolar disorder,schizoaffective / / 19567891 rs12597579 chr16 20257867 C A,T 1.00E-08 Body mass index / / 22344219 rs12597579 chr16 20257867 C A,T 6.00E-07 Body mass index / / 24861553 rs4476181 chr16 20267075 G T 1.54E-05 Heart Rate / / pha003053 rs7191525 chr16 20276957 T G 7.33E-05 Schizophrenia / / 19571809 rs8050244 chr16 20277579 C T 7.44E-05 Type 2 diabetes / / 17463246 rs7189784 chr16 20283804 G A 7.44E-05 Type 2 diabetes / / 17463246 rs6497465 chr16 20288797 G A 2.71E-05 Schizophrenia / / 19571809 rs6497465 chr16 20288797 G A 5.82E-05 Schizophrenia / / pha002859 rs8054898 chr16 20290454 T C 3.02E-05 Schizophrenia / / 19571809 rs8054898 chr16 20290454 T C 5.82E-05 Schizophrenia / / pha002859 rs7184148 chr16 20291860 C A 5.76E-04 Multiple complex diseases / / 17554300 rs4558425 chr16 20309215 G A 2.83E-05 Alzheimer's disease (late onset) / / 21379329 rs4780877 chr16 20320669 C T 3.45E-05 Alzheimer's disease (late onset) / / 21379329 rs12444268 chr16 20342572 T A 2.00E-07 Type 1 diabetes / / 19430480 rs11859916 chr16 20351231 G A 2.00E-06 Femoral neck bone geometry UMOD intron 22087292 rs11647727 chr16 20356165 A G 2.43E-06 Hypertension UMOD intron 21082022 rs11647727 chr16 20356165 A G 1.72E-04 Blood pressure UMOD intron 22100073 rs4506906 chr16 20357398 G A 1.71E-04 Hypertension UMOD intron 21082022 rs4293393 chr16 20364588 A G 4.00E-10 Chronic kidney disease and serum Creatinine levels UMOD nearGene-5 20686651 rs4293393 chr16 20364588 A G 3.30E-07 Hypertension UMOD nearGene-5 21082022 rs13333226 chr16 20365654 A G 4.00E-11 Hypertension UMOD nearGene-5 21082022 rs13333226 chr16 20365654 A G 1.39E-04 Blood pressure UMOD nearGene-5 22100073 rs11862974 chr16 20366225 C A 4.38E-04 Taste perception / / 22132133 rs12922822 chr16 20367645 C T 6.48E-08 Chronic kidney disease / / 21931561 rs12917707 chr16 20367690 G T 2.00E-12 Renal function and chronic kidney disease / / 19430482 rs12917707 chr16 20367690 G T 5.00E-16 Renal function and chronic kidney disease / / 19430482 rs12917707 chr16 20367690 G T 1.00E-20 Chronic kidney disease / / 20383146 rs12917707 chr16 20367690 G T 2.16E-23 Chronic kidney disease / / 22479191 rs12917707 chr16 20367690 G T 1.90E-06 Glomerular filtration rate / / 23535967 rs12917707 chr16 20367690 G T 2.40E-06 Glomerular filtration rate / / 23535967 rs12917707 chr16 20367690 G T 4.40E-05 Glomerular filtration rate / / 23535967 rs12917707 chr16 20367690 G T 5.90E-04 Glomerular filtration rate / / 23535967 rs12917707 chr16 20367690 G T 6.50E-04 Glomerular filtration rate / / 23535967 rs12917707 chr16 20367690 G T 9.30E-07 Glomerular filtration rate / / 23535967 rs12917707 chr16 20367690 G T 9.80E-07 Glomerular filtration rate / / 23535967 rs12917707 chr16 20367690 G T 8.00E-73 Urinary uromodulin levels / / 24578125 rs4297685 chr16 20368564 T C 4.00E-04 Blood pressure / / 22100073 rs4494548 chr16 20371588 G A 4.00E-15 Urinary uromodulin levels PDILT intron 24578125 rs4496151 chr16 20373290 A G 1.01E-04 Hypertension PDILT intron 21082022 rs9922672 chr16 20391237 G T 8.15E-04 Multiple complex diseases PDILT intron 17554300 rs11860718 chr16 20392172 C T 3.27E-04 Multiple complex diseases PDILT intron 17554300 rs11864909 chr16 20400839 C T 1.00E-10 Renal function-related traits (sCR) PDILT intron 22797727 rs11864909 chr16 20400839 C T 4.00E-10 Renal function-related traits (eGRFcrea) PDILT intron 22797727 rs12446492 chr16 20408377 T A 6.00E-27 Urinary uromodulin levels PDILT intron 24578125 rs6416610 chr16 20418452 T C 8.22E-05 Psoriasis / / 18364390 rs11860025 chr16 20439568 A G 9.21E-04 White matter integrity ACSM5 intron 22425255 rs11647589 chr16 20449616 A G 3.00E-11 Blood metabolite levels ACSM5 intron 24816252 rs6497490 chr16 20477474 G T 5.00E-27 Blood metabolite levels ACSM2A intron 24816252 rs1394678 chr16 20491058 C T 2.00E-20 Blood metabolite levels ACSM2A intron 24816252 rs6497493 chr16 20512870 G A 1.62E-04 Amyotrophic lateral sclerosis / / 20801718 rs7499271 chr16 20555259 T A 6.00E-11 Metabolite levels ACSM2B intron 24625756 rs11643396 chr16 20599486 G A 1.30E-04 Atrial fibrillation / / 21846873 rs234993 chr16 20647644 T C 3.70E-04 Response to cytidine analogues (gemcitabine) ACSM1 intron 24483146 rs163235 chr16 20651378 C G 2.70E-05 Urinary metabolites ACSM1 intron 21572414 rs163273 chr16 20672628 T C 2.30E-07 Urinary metabolites ACSM1 intron 21572414 rs151222 chr16 20674492 G C 6.00E-06 Schizophrenia ACSM1 intron 18347602 rs151222 chr16 20674492 G C 2.62E-04 Response to cytidine analogues (gemcitabine) ACSM1 intron 24483146 rs163271 chr16 20675601 G A 5.00E-04 Pancreatic cancer ACSM1 intron 20484958 rs16970500 chr16 20680152 T G 6.10E-04 Atrial fibrillation ACSM1 intron 21846873 rs433598 chr16 20680206 C T 3.00E-06 Schizophrenia ACSM1 intron 20185149 rs433598 chr16 20680206 C T 2.20E-05 Urinary metabolites ACSM1 intron 21572414 rs433598 chr16 20680206 C T 3.30E-06 Schizophrenia (treatment refractory) ACSM1 intron 22479419 rs61745764 chr16 20681229 T A 0.00017 Breast cancer (ER positive) ACSM1 missense 23555315 rs61745764 chr16 20681229 T A 0.0001 Breast cancer ACSM1 missense 23555315 rs396508 chr16 20682354 A G 2.93E-05 Schizophrenia ACSM1 intron 20185149 rs396508 chr16 20682354 A G 2.50E-05 Urinary metabolites ACSM1 intron 21572414 rs395501 chr16 20683296 G A 1.10E-05 Urinary metabolites ACSM1 intron 21572414 rs163255 chr16 20689815 C T 3.40E-06 Urinary metabolites ACSM1 intron 21572414 rs3115441 chr16 20990976 T C 1.01E-04 Response to cytadine analogues (cytosine arabinoside) D/H3 intron 24483146 rs16970881 chr16 21113272 G A 1.00E-07 Immune reponse to smallpox (secreted IL-10) D/H3 intron 22610502 rs16970887 chr16 21115345 G C 7.25E-04 Multiple complex diseases D/H3 intron 17554300 rs7194423 chr16 21171873 A C 1.55E-05 Cognitive test performance TMEM159 intron 20125193 rs16971140 chr16 21187597 A G 6.40E-05 Response to statin therapy TMEM159 intron 20339536 rs9929374 chr16 21243950 A G 9.92E-06 IgE levels / / 22075330 rs17764140 chr16 21250033 G A 6.60E-04 Response to cytadine analogues (cytosine arabinoside) ANKS4B intron 24483146 rs7195761 chr16 21260162 G A 5.07E-04 Amyotrophic Lateral Sclerosis ANKS4B intron 17362836 rs8057454 chr16 21264441 G T 0.0002785 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8057454 chr16 21264441 G T 2.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7194883 chr16 21272365 T C 8.27E-04 Alzheimer's disease CRYM intron 17998437 rs14122 chr16 21272591 G C 3.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) CRYM cds-synon 23233662 rs14122 chr16 21272591 G C 0.0003442 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CRYM cds-synon 23233654 rs226039 chr16 21288101 A G 8.98E-06 Educational attainment CRYM intron 21694764 rs183170 chr16 21585792 C T 3.20E-05 Multiple complex diseases / / 17554300 rs4783414 chr16 21737414 T C 8.65E-05 Gallstones OTOA intron 17632509 rs8054407 chr16 21737626 G A 5.63E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OTOA intron 20877124 rs8058588 chr16 22178210 C T 1.76E-05 Bipolar disorder / / 19488044 rs8058588 chr16 22178210 C T 3.79E-05 Bipolar Disorder / / pha002863 rs6497576 chr16 22182493 G A 1.31E-04 Insulin resistance / / 21901158 rs9939477 chr16 22196483 A C 7.10E-05 Immunoglobulin A / / 20694011 rs754290 chr16 22223509 T C 5.25E-04 Multiple complex diseases EEF2K intron 17554300 rs6497580 chr16 22232426 G T 3.76E-04 Multiple complex diseases EEF2K intron 17554300 rs4783448 chr16 22241433 C T 7.50E-04 Alcohol dependence EEF2K intron 20201924 rs11639903 chr16 22257277 G A 6.76E-04 Multiple complex diseases EEF2K intron 17554300 rs11639903 chr16 22257277 G A 7.70E-04 Alzheimer's disease EEF2K intron 17998437 rs2873167 chr16 22261697 A T 6.30E-04 Multiple complex diseases EEF2K intron 17554300 rs7205095 chr16 22286573 C T 0.000879 Height (Pygmy height) EEF2K intron 22570615 rs11646610 chr16 22294923 C T 0.0000344 Height (Pygmy height) EEF2K intron 22570615 rs154553 chr16 22687564 A C 3.74E-08 Multiple complex diseases / / 17554300 rs724466 chr16 22797852 A G 3.80E-05 Type 2 diabetes / / 17460697 rs11074523 chr16 22826933 C G 5.91E-05 Serum metabolites HS3ST2 intron 19043545 rs460473 chr16 22833027 G A 1.03E-04 Schizophrenia(treatment response to risperidone) HS3ST2 intron 19850283 rs12932314 chr16 22836761 T C 9.10E-04 Acute lung injury HS3ST2 intron 22295056 rs169660 chr16 22840704 G A 4.20E-05 Pulmonary function in asthmatics HS3ST2 intron 23541324 rs2283524 chr16 22841492 T G 4.61E-10 Coronary heart disease (incident CHD) HS3ST2 intron 21829389 rs16973845 chr16 22874525 T C 1.36E-04 Type 2 diabetes HS3ST2 intron 17463246 rs7199670 chr16 22875238 G A 8.93E-04 Multiple complex diseases HS3ST2 intron 17554300 rs16973865 chr16 22875742 A G 6.09E-05 Type 2 diabetes HS3ST2 intron 17463246 rs2238486 chr16 22885421 G A 1.09E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) HS3ST2 intron 23648065 rs2519974 chr16 22889186 G A 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) HS3ST2 intron 23648065 rs916670 chr16 22891084 C T 9.96E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) HS3ST2 intron 23648065 rs9806846 chr16 22893745 G A 6.28E-04 Multiple complex diseases HS3ST2 intron 17554300 rs2239335 chr16 22897795 G A 6.89E-04 Multiple complex diseases HS3ST2 intron 17554300 rs2369690 chr16 22920852 C A 2.97E-04 Coronary Artery Disease HS3ST2 intron 17634449 rs1054028 chr16 22927214 T C 4.13E-05 Multiple complex diseases HS3ST2 UTR-3 17554300 rs12599188 chr16 22929129 T C 2.83E-05 Asthma / / 23181788 rs13331654 chr16 22935861 C A 7.00E-05 Cognitive impairment induced by topiramate / / 22091778 rs1476458 chr16 22938499 C G 7.12E-05 Asthma / / 23181788 rs11074528 chr16 22939240 T G 3.12E-04 Multiple complex diseases / / 17554300 rs999795 chr16 22950699 C A 9.07E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs74990 chr16 22978521 A C 8.71E-04 Insulin resistance / / 21901158 rs10459775 chr16 23009777 A C 0.000578004 Hypertension (early onset hypertension) / / 22479346 rs17728207 chr16 23036048 C T 7.47E-04 Alzheimer's disease / / 22005930 rs1011462 chr16 23050015 C T 2.55E-04 Multiple complex diseases / / 17554300 rs1011463 chr16 23050120 T A 2.53E-04 Multiple complex diseases / / 17554300 rs11647334 chr16 23050867 A G 2.55E-04 Multiple complex diseases / / 17554300 rs11647334 chr16 23050867 A G 6.45E-04 Smoking initiation / / 24665060 rs6497635 chr16 23052335 G A 2.94E-04 Multiple complex diseases / / 17554300 rs6497635 chr16 23052335 G A 7.42E-04 Smoking initiation / / 24665060 rs6497643 chr16 23062681 T C 4.18E-04 Multiple complex diseases / / 17554300 rs6497643 chr16 23062681 T C 2.75E-04 Schizophrenia / / 20832056 rs8049603 chr16 23067260 T G 1.00E-06 Multiple sclerosis / / 19525955 rs9929420 chr16 23073531 C G 1.42E-04 QT interval USP31 UTR-3 22726844 rs10492790 chr16 23076410 C T 3.57E-04 Smoking initiation USP31 UTR-3 24665060 rs10083789 chr16 23080634 C A 7.01E-04 Multiple complex diseases USP31 missense 17554300 rs10083789 chr16 23080634 C A 1.30E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) USP31 missense 24023788 rs886038 chr16 23092441 G A 3.41E-04 Smoking initiation USP31 intron 24665060 rs4967969 chr16 23111816 G A 3.41E-04 Smoking initiation USP31 intron 24665060 rs2369524 chr16 23114849 T C 1.88E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) USP31 intron 24023788 rs17797149 chr16 23135775 G A 1.87E-05 Orofacial clefts USP31 intron 20023658 rs4967976 chr16 23156362 C A 2.19E-04 Smoking initiation USP31 intron 24665060 rs4967978 chr16 23159827 C T 5.67E-04 Smoking initiation USP31 intron 24665060 rs9932339 chr16 23162432 C T 5.36E-04 Smoking initiation / / 24665060 rs4480807 chr16 23177766 A G 6.05E-04 Multiple complex diseases / / 17554300 rs4073291 chr16 23195993 A C 4.14E-04 Smoking initiation SCNN1G intron 24665060 rs11643777 chr16 23219272 C G 7.97E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SCNN1G intron 22566498 rs4499238 chr16 23221379 T C 7.45E-04 Type 2 diabetes SCNN1G intron 17463246 rs11649420 chr16 23222675 G A 9.41E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SCNN1G intron 22566498 rs7204325 chr16 23252506 T G 8.81E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs9888818 chr16 23299760 G A 3.40E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs34241435 chr16 23313185 G A 1 Drug response to Glibenclamide SCNN1B nearGene-5 18004211 rs34241435 chr16 23313185 G A 1 Drug response to Insulin-Glargine SCNN1B nearGene-5 18004211 rs239349 chr16 23352848 G A 3.09E-05 Chronic obstructive pulmonary disease SCNN1B intron 19300482 rs8044970 chr16 23361830 T G 6.61E-04 Smoking initiation SCNN1B intron 24665060 rs152745 chr16 23366422 G A 3.37E-04 HIV-1 viral setpoint SCNN1B intron 17641165 rs889299 chr16 23381914 G A 1 Drug response to Glibenclamide SCNN1B intron 18004211 rs889299 chr16 23381914 G A 1 Drug response to Insulin-Glargine SCNN1B intron 18004211 rs889299 chr16 23381914 G A 9.60E-04 Insulin resistance SCNN1B intron 21901158 rs13306628 chr16 23391981 G A 0.00000154 Cholesterol,total SCNN1B cds-synon 23063622 rs430208 chr16 23458485 T C 8.45E-04 Multiple complex diseases COG7 intron 17554300 rs4968008 chr16 23490353 T G 2.28E-04 Alzheimer's disease GGA2 intron 17998437 rs11074562 chr16 23499700 G A 2.16E-04 Alzheimer's disease GGA2 intron 17998437 rs4968014 chr16 23523875 C A 7.14E-04 Multiple complex diseases / / 17554300 rs4968014 chr16 23523875 C A 1.83E-04 Body mass index / / 21701565 rs11642434 chr16 23540237 T C 5.40E-04 Alzheimer's disease EARS2 intron 17998437 rs152454 chr16 23583111 T A,C,G 6.83E-04 Multiple complex diseases UBFD1 UTR-3 17554300 rs1016586 chr16 23588966 C T 8.69E-04 Body mass index / / 21701565 rs426745 chr16 23601535 C T 1.37E-06 Lymphocyte counts NDUFAB1 intron 22286170 rs120963 chr16 23608070 A G 6.61E-04 Multiple complex diseases / / 17554300 rs120963 chr16 23608070 A G 3.40E-04 Alzheimer's disease / / 17998437 rs420259 chr16 23634026 A G 6.00E-08 Bipolar disorder PALB2 intron 17554300 rs420259 chr16 23634026 A G 9.00E-09 Bipolar disorder PALB2 intron 21254220 rs249954 chr16 23640467 G A 2.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) PALB2 intron 23453885 rs35585 chr16 23677111 G A 1.74E-04 Multiple complex diseases DCTN5 intron 17554300 rs35585 chr16 23677111 G A 8.43E-12 Lymphocyte counts DCTN5 intron 22286170 rs35635 chr16 23693770 T G 1.49E-04 Multiple complex diseases PLK1 intron 17554300 rs8058610 chr16 23713395 C T 3.59E-05 Cognitive test performance ERN2 intron 20125193 rs9931275 chr16 23716577 G T 9.69E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ERN2 intron 21844884 rs4967959 chr16 23721601 T G 9.96E-04 Multiple complex diseases ERN2 intron 17554300 rs3809682 chr16 23724753 G A 8.73E-04 Type 2 diabetes ERN2 UTR-5 17463246 rs9745514 chr16 23731186 C A 1.70E-05 Urinary metabolites / / 21572414 rs192188 chr16 23739988 G A 5.20E-06 Urinary metabolites / / 21572414 rs13338358 chr16 23754198 G A 9.65E-04 Alcohol dependence / / 21314694 rs4968031 chr16 23765774 G A 1.00E-06 Platelet counts / / 21507922 rs7194152 chr16 23844455 C T 2.42E-04 Aortic root size / / 21223598 rs7404095 chr16 23864590 T C 1.00E-09 Inflammatory bowel disease PRKCB intron 23128233 rs7404095 chr16 23864590 T C 0.0000436 Primary sclerosing cholangitis PRKCB intron 23603763 rs7404005 chr16 23864724 A C 9.67E-04 Type 2 diabetes PRKCB intron 17463246 rs3826261 chr16 23877175 G A 2.36E-04 Glycemic traits (pregnancy) PRKCB intron 23903356 rs9806904 chr16 23877342 C A 3.41E-05 Serum metabolites PRKCB intron 19043545 rs8057472 chr16 23880697 G C 1.73E-04 Multiple complex diseases PRKCB intron 17554300 rs11645672 chr16 23885840 T G 7.60E-05 Orofacial clefts PRKCB intron 22419666 rs7404928 chr16 23888840 T C 4.00E-06 Rheumatoid arthritis PRKCB intron 22446963 rs732798 chr16 23903950 A C 9.47E-05 Non-alcoholic fatty liver disease histology (other) PRKCB intron 20708005 rs9922316 chr16 23909952 T G 0.00016 Alpha-2-adrenoceptor-mediated vasoconstriction PRKCB intron 23337848 rs3785392 chr16 23944483 A G 3.63E-05 Partial epilepsies PRKCB intron 20522523 rs1989647 chr16 23959420 G A 1.28E-05 Partial epilepsies PRKCB intron 20522523 rs1989647 chr16 23959420 G A 8.89E-06 Epilepsy PRKCB intron 22116939 rs11074594 chr16 23973371 G A 7.32E-04 Myocardial Infarction PRKCB intron pha002873 rs8051206 chr16 23983135 C T 8.21E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PRKCB intron 21844884 rs10492795 chr16 24016101 C A 5.44E-05 Height PRKCB intron pha003010 rs195993 chr16 24017961 C T 3.64E-04 Acute lung injury PRKCB intron 22295056 rs7199551 chr16 24033645 G T 6.70E-04 Obesity (extreme) PRKCB intron 21935397 rs7199551 chr16 24033645 G T 8.90E-05 Femoral neck bone geometry PRKCB intron 22087292 rs3785383 chr16 24046568 A G 8.05E-04 Suicide attempts in bipolar disorder PRKCB intron 21423239 rs1014632 chr16 24099744 T A 8.43E-04 Obesity (extreme) PRKCB intron 21935397 rs2636957 chr16 24101588 G A 9.86E-04 Obesity (extreme) PRKCB intron 21935397 rs2560406 chr16 24102562 T G 7.88E-04 Obesity (extreme) PRKCB intron 21935397 rs880824 chr16 24104328 A G 8.17E-04 Obesity (extreme) PRKCB intron 21935397 rs174828 chr16 24128365 A C 1.83E-04 Obesity (extreme) PRKCB intron 21935397 rs174828 chr16 24128365 A C 6.68E-05 Relative hand skill in reading disability PRKCB intron 24068947 rs198198 chr16 24128397 T A 9.59E-06 Social autistic-like traits PRKCB intron 24133439 rs169142 chr16 24131930 G A 4.25E-04 Obesity (extreme) PRKCB intron 21935397 rs182068 chr16 24134683 G C 3.03E-04 Obesity (extreme) PRKCB intron 21935397 rs198202 chr16 24149041 A G 6.30E-04 Insulin resistance PRKCB intron 21901158 rs2238493 chr16 24156946 T C 9.29E-04 Alcohol dependence PRKCB intron 21314694 rs16973330 chr16 24178207 C T 1.89E-04 Multiple complex diseases PRKCB intron 17554300 rs12445719 chr16 24213587 T C 3.14E-04 Nicotine smoking PRKCB intron 19268276 rs12445719 chr16 24213587 T C 3.53E-04 Insulin resistance PRKCB intron 21901158 rs10852263 chr16 24221758 C T 2.12E-04 Prostate cancer mortality PRKCB intron 20978177 rs8059889 chr16 24227433 G A 4.17E-10 Cholesterol,total PRKCB UTR-3 23063622 rs2239339 chr16 24229885 G C 9.11E-04 Prostate cancer mortality PRKCB UTR-3 20978177 rs424741 chr16 24231449 C T 1.62E-07 Pure-tone audiometry PRKCB UTR-3 pha001966 rs12149348 chr16 24261165 T C 3.36E-05 Orofacial clefts / / 22419666 rs9940796 chr16 24274391 A G 3.96E-04 Lung function (forced vital capacity) CACNG3 intron 24023788 rs12932555 chr16 24286232 A T 2.80E-06 Urinary metabolites CACNG3 intron 21572414 rs2247011 chr16 24292838 G A 2.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CACNG3 intron 20877124 rs2247011 chr16 24292838 G A 1.60E-07 Urinary metabolites CACNG3 intron 21572414 rs6497729 chr16 24296686 G A 3.90E-07 Urinary metabolites CACNG3 intron 21572414 rs2238507 chr16 24306105 G A 4.50E-07 Urinary metabolites CACNG3 intron 21572414 rs9652580 chr16 24308825 C T 6.13E-04 Premature ovarian failure CACNG3 intron 19508998 rs1557810 chr16 24309956 C T 0.00000289 Major depressive disorder age at onset<15 CACNG3 intron 22915352 rs9935334 chr16 24330301 G C 6.70E-06 Type 2 diabetes CACNG3 intron 17463246 rs9925729 chr16 24330389 T A 7.78E-06 Type 2 diabetes CACNG3 intron 17463246 rs11074616 chr16 24340691 A G 8.57E-04 Amyotrophic lateral sclerosis (sporadic) CACNG3 intron 24529757 rs12149602 chr16 24342531 C A 1.28E-04 Multiple complex diseases CACNG3 intron 17554300 rs12444564 chr16 24345761 C T 2.02E-04 Multiple complex diseases CACNG3 intron 17554300 rs2238521 chr16 24348591 G A 4.18E-04 Multiple complex diseases CACNG3 intron 17554300 rs11074618 chr16 24379983 C A 1.00E-05 Urinary metabolites / / 21572414 rs11074618 chr16 24379983 C A 1.03E-04 Arthritis (juvenile idiopathic) / / 22354554 rs9935277 chr16 24384711 A G 8.65E-05 Cognitive performance / / 19734545 rs9935277 chr16 24384711 A G 2.38E-04 Alcohol dependence / / 24277619 rs9936233 chr16 24385538 G A 1.35E-04 Arthritis (juvenile idiopathic) / / 22354554 rs11644596 chr16 24389861 T G 3.20E-05 Type 2 diabetes / / 17460697 rs7199880 chr16 24424387 T C 1.52E-05 HDL cholesterol / / pha003075 rs8054383 chr16 24456837 A G 5.47E-05 Neutrophil count / / pha003095 rs9930580 chr16 24462555 T C 1.30E-05 Leukocyte Counts / / pha003091 rs271011 chr16 24486366 C T 7.77E-05 Eosinophil counts / / pha003088 rs271011 chr16 24486366 C T 1.83E-05 Neutrophil count / / pha003095 rs271015 chr16 24488497 C T 2.50E-05 Eosinophil counts / / pha003088 rs271015 chr16 24488497 C T 7.54E-05 Lymphocyte counts / / pha003094 rs271015 chr16 24488497 C T 3.49E-07 Neutrophil count / / pha003095 rs890844 chr16 24507123 T A 3.48E-10 Multiple complex diseases / / 17554300 rs11643520 chr16 24531718 T C 6.00E-07 Brain structure / / 20171287 rs7195386 chr16 24578458 T C 9.00E-06 Obesity-related traits RBBP6 intron 23251661 rs7190684 chr16 24654908 C T 5.25E-04 Stroke / / pha002887 rs8045064 chr16 24675589 T C 4.00E-08 Alzheimer's disease (cognitive decline) FLJ45256 intron 23535033 rs16973907 chr16 24680439 A G 3.76E-05 Type 2 diabetes FLJ45256 intron 22158537 rs7198632 chr16 24695340 A G 4.63E-04 Smoking initiation / / 24665060 rs8049014 chr16 24698903 G A 2.90E-04 Multiple complex diseases / / 17554300 rs8049014 chr16 24698903 G A 5.67E-04 Smoking initiation / / 24665060 rs6497753 chr16 24710690 C T 1.56E-04 Stroke / / pha002886 rs9929676 chr16 24711964 G A 4.86E-04 Multiple complex diseases / / 17554300 rs11863729 chr16 24712999 G T 1.96E-04 Multiple complex diseases / / 17554300 rs9302427 chr16 24715653 C A 4.02E-04 Multiple complex diseases / / 17554300 rs9302427 chr16 24715653 C A 5.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs766181 chr16 24729771 C T 7.55E-05 Triglycerides / / pha002904 rs200541 chr16 24733141 A G 1.31E-04 Smoking initiation / / 24665060 rs189919 chr16 24737741 G A 1.32E-04 Smoking initiation / / 24665060 rs7202252 chr16 24741686 T C 1.04E-04 Smoking initiation TNRC6A intron 24665060 rs200536 chr16 24749203 G A 1.03E-04 Smoking initiation TNRC6A intron 24665060 rs16973968 chr16 24756538 C T 5.84E-04 Multiple complex diseases TNRC6A intron 17554300 rs16973968 chr16 24756538 C T 1.95E-04 Smoking cessation TNRC6A intron 18519826 rs200528 chr16 24759131 A G 1.78E-04 Smoking initiation TNRC6A intron 24665060 rs11862971 chr16 24767574 C A 1.90E-04 Smoking initiation TNRC6A intron 24665060 rs1465423 chr16 24772680 G C 1.35E-04 Smoking initiation TNRC6A intron 24665060 rs11639856 chr16 24788645 T A 2.38E-04 Smoking initiation TNRC6A missense 24665060 rs2343606 chr16 24793741 C T 1.36E-04 Smoking initiation TNRC6A intron 24665060 rs6497759 chr16 24801737 G A 1.29E-04 Smoking initiation TNRC6A missense 24665060 rs3803716 chr16 24802325 C T 9.68E-05 Smoking initiation TNRC6A missense 24665060 rs874484 chr16 24803242 T C 1.25E-04 Smoking initiation TNRC6A intron 24665060 rs17177078 chr16 24810681 C T 5.00E-06 Type 2 diabetes (dietary heme iron intake interaction) TNRC6A intron 23386860 rs2112783 chr16 24812512 G A 1.37E-04 Smoking initiation TNRC6A intron 24665060 rs2059134 chr16 24816492 A G 1.36E-04 Smoking initiation TNRC6A intron 24665060 rs16974070 chr16 24816830 A T 5.77E-04 Multiple complex diseases TNRC6A intron 17554300 rs12596320 chr16 24817505 C T 1.39E-06 Smoking cessation TNRC6A intron 18519826 rs11647120 chr16 24819806 A G 2.59E-04 Smoking initiation TNRC6A intron 24665060 rs2287783 chr16 24831727 C T 5.98E-04 Smoking initiation TNRC6A intron 24665060 rs2303083 chr16 24835168 G A 3.66E-04 Smoking initiation TNRC6A UTR-3 24665060 rs1862450 chr16 24856775 G A 2.32E-04 Smoking initiation / / 24665060 rs12926788 chr16 24879963 C G 5.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity SLC5A11 intron 24324551 rs274075 chr16 24889789 T A 1.77E-05 Cognitive test performance SLC5A11 intron 20125193 rs7186357 chr16 24894268 A G 2.02E-05 Cognitive test performance SLC5A11 intron 20125193 rs274068 chr16 24898972 C A 5.00E-07 Lupus nephritis in systemic lupus erythematosus SLC5A11 intron 24925725 rs274069 chr16 24899150 T C 8.50E-07 Lupus nephritis in systemic lupus erythematosus SLC5A11 intron 24925725 rs274094 chr16 24910477 G A 7.36E-04 Multiple complex diseases SLC5A11 intron 17554300 rs4788439 chr16 24931798 C T 7.00E-13 Blood metabolite levels ARHGAP17 intron 24816252 rs8062011 chr16 24959997 G C 1.93E-04 Type 2 diabetes ARHGAP17 intron 22158537 rs1035946 chr16 24974426 G A 6.43E-05 Multiple sclerosis ARHGAP17 intron 19525953 rs7205696 chr16 24984822 G A 2.80E-05 Urinary metabolites ARHGAP17 intron 21572414 rs4787294 chr16 25002350 A T 1.00E-20 Blood metabolite levels ARHGAP17 intron 24816252 rs8056443 chr16 25005208 A C 2.70E-05 Urinary metabolites ARHGAP17 intron 21572414 rs8061484 chr16 25011619 C T 8.92E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) ARHGAP17 intron 23648065 rs891842 chr16 25022311 A G 8.20E-06 Urinary metabolites ARHGAP17 intron 21572414 rs4993062 chr16 25035627 A G 2.17E-06 Type 2 diabetes / / 22158537 rs4787669 chr16 25047197 A G 3.52E-04 Type 2 diabetes / / 22158537 rs4787671 chr16 25049764 G A 2.15E-04 Type 2 diabetes / / 22158537 rs11642659 chr16 25121277 T C 3.57E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11642659 chr16 25121277 T C 1.18E-05 Panic disorder / / 19165232 rs17625090 chr16 25249257 A G 2.69E-04 Multiple complex diseases ZKSCAN2 UTR-3 17554300 rs61746620 chr16 25255366 G A 0.000013 Prostate cancer (non-advanced prostate cancer) ZKSCAN2 missense 23555315 rs61746620 chr16 25255366 G A 0.000089 Prostate cancer ZKSCAN2 missense 23555315 rs8062383 chr16 25261270 C G 3.87E-04 Multiple complex diseases ZKSCAN2 intron 17554300 rs2112811 chr16 25263278 G A 9.53E-05 Colorectal cancer (drug response in metastatic colorectal cancer) ZKSCAN2 missense 21239504 rs2112814 chr16 25278777 A G 7.07E-04 Prostate cancer mortality / / 20978177 rs9926115 chr16 25281220 T C 9.96E-04 Prostate cancer mortality / / 20978177 rs7197703 chr16 25281593 C T 5.64E-04 Prostate cancer mortality / / 20978177 rs918536 chr16 25281848 A G 5.07E-04 Prostate cancer mortality / / 20978177 rs7199745 chr16 25285100 C G 7.24E-04 Prostate cancer mortality / / 20978177 rs6497820 chr16 25286743 A G 5.31E-04 Prostate cancer mortality / / 20978177 rs7191284 chr16 25329195 T G 1.93E-05 Vascular dementia / / 22116812 rs972741 chr16 25468083 A G 7.26E-05 Body Mass Index / / pha003007 rs972741 chr16 25468083 A G 5.81E-06 Body Mass Index / / pha003009 rs972741 chr16 25468083 A G 5.00E-05 Waist Circumference / / pha003025 rs972741 chr16 25468083 A G 8.62E-06 Weight / / pha003027 rs8054701 chr16 25469105 T C 6.71E-06 Body Mass Index / / pha003009 rs8054701 chr16 25469105 T C 7.24E-05 Weight / / pha003026 rs8054701 chr16 25469105 T C 6.88E-05 Weight / / pha003027 rs7204641 chr16 25488449 G A 5.26E-05 Smoking initiation / / 24665060 rs7189168 chr16 25506954 C T 6.08E-05 Height / / pha003010 rs7189168 chr16 25506954 C T 5.33E-05 Coronary heart disease / / pha003032 rs7189942 chr16 25507438 A G 2.00E-05 Urinary metabolites / / 21572414 rs17199878 chr16 25509605 C G 1.90E-05 Urinary metabolites / / 21572414 rs11862679 chr16 25520007 C G 1.70E-05 Urinary metabolites / / 21572414 rs9934915 chr16 25534326 A G 6.93E-05 Height / / pha003010 rs12448073 chr16 25540482 A G 9.30E-06 Urinary metabolites / / 21572414 rs7197258 chr16 25543572 G T 6.81E-05 Height / / pha003010 rs11074699 chr16 25544451 G A 2.00E-05 Urinary metabolites / / 21572414 rs10852289 chr16 25544514 G T 9.20E-06 Urinary metabolites / / 21572414 rs1003341 chr16 25548973 C T 1.01E-05 Height / / pha003010 rs1003341 chr16 25548973 C T 6.15E-06 Height / / pha003011 rs16974978 chr16 25644834 C T 0.000022 Mean arterial pressure / / 22510845 rs4374178 chr16 25648452 C T 2.46E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs12932661 chr16 25658719 G A 5.11E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12932661 chr16 25658719 G A 7.06E-05 ldl cholesterol / / pha003076 rs12598109 chr16 25663013 G A 6.13E-04 Multiple complex diseases / / 17554300 rs17795251 chr16 25668649 C T 3.98E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17200180 chr16 25669550 T C 3.98E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12931909 chr16 25738441 G C 0.00088 Endometrial cancer HS3ST4 intron 22426144 rs4268750 chr16 25753251 T C 0.00031 Prostate cancer HS3ST4 intron 23555315 rs10431903 chr16 25756301 G A 5.13E-04 Nicotine smoking HS3ST4 intron 19268276 rs17774701 chr16 25757243 T C 9.43E-05 Lung adenocarcinoma HS3ST4 intron 19836008 rs7203781 chr16 25759028 T G 4.55E-04 Multiple complex diseases HS3ST4 intron 17554300 rs4129097 chr16 25767561 C G 4.51E-04 Multiple complex diseases HS3ST4 intron 17554300 rs11862584 chr16 25784598 T G 5.27E-04 Response to taxane treatment (placlitaxel) HS3ST4 intron 23006423 rs11074721 chr16 25784898 T C 7.05E-04 Response to taxane treatment (placlitaxel) HS3ST4 intron 23006423 rs12443577 chr16 25784920 C G 5.76E-04 Response to taxane treatment (placlitaxel) HS3ST4 intron 23006423 rs12443637 chr16 25785149 C T 3.49E-05 Triglycerides HS3ST4 intron pha003081 rs4787763 chr16 25806206 T C 1.28E-04 Amyotrophic Lateral Sclerosis HS3ST4 intron 17362836 rs4309396 chr16 25822482 C T 4.48E-04 Smoking initiation HS3ST4 intron 24665060 rs4511540 chr16 25849949 C T 7.18E-04 Aortic root size HS3ST4 intron 21223598 rs4787766 chr16 25851270 G A 7.75E-05 Bipolar disorder HS3ST4 intron 20451256 rs7203172 chr16 25854518 C T 5.74E-05 Multiple complex diseases HS3ST4 intron 17554300 rs4448943 chr16 25865578 G C 8.00E-05 Prostate cancer HS3ST4 intron 21743057 rs4305024 chr16 25870726 G A 9.19E-04 Multiple complex diseases HS3ST4 intron 17554300 rs4441276 chr16 25890305 G A 3.24E-04 Heart Failure HS3ST4 intron pha002884 rs4787777 chr16 25894989 T C 8.53E-04 Heart Failure HS3ST4 intron pha002884 rs3934987 chr16 25899657 A G 2.48E-04 Alzheimer's disease HS3ST4 intron 24755620 rs12446144 chr16 25909571 G A 7.34E-04 Amyotrophic Lateral Sclerosis HS3ST4 intron 17362836 rs11640710 chr16 25913837 A C 0.0000761 Nonsyndromic striae distensae (stretch marks) HS3ST4 intron 23633020 rs11074733 chr16 25942001 C A 1.97E-05 Amyotrophic lateral sclerosis (sporadic) HS3ST4 intron 24529757 rs117559033 chr16 25944544 C T 2.00E-06 Parasitemia in Tripanosoma cruzi seropositivity HS3ST4 intron 24324551 rs4303490 chr16 25944700 A G 3.40E-06 Urinary metabolites HS3ST4 intron 21572414 rs4303490 chr16 25944700 A G 1.10E-04 Alzheimer's disease HS3ST4 intron 24755620 rs8062993 chr16 25945785 G A 4.30E-06 Urinary metabolites HS3ST4 intron 21572414 rs12933515 chr16 25947714 G A 4.10E-06 Urinary metabolites HS3ST4 intron 21572414 rs9937695 chr16 25954471 G A 9.30E-05 Allergic sensitization HS3ST4 intron 23817571 rs9933692 chr16 25958240 G A 2.95E-04 Response to diuretic therapy in hypertension HS3ST4 intron 23753411 rs4074471 chr16 25959350 T G 2.94E-04 Response to diuretic therapy in hypertension HS3ST4 intron 23753411 rs12919731 chr16 25961377 G A 4.96E-04 Stroke HS3ST4 intron pha002886 rs12446064 chr16 25969633 C T 2.40E-06 Urinary metabolites HS3ST4 intron 21572414 rs8049738 chr16 25970032 T C 6.45E-05 Asthma HS3ST4 intron 11022011 rs12931133 chr16 25972596 G A 8.02E-04 Alzheimer's disease HS3ST4 intron 24755620 rs7199995 chr16 25975588 C T 6.20E-05 Depression (quantitative trait) HS3ST4 intron 23290196 rs7205464 chr16 25975935 G T 3.75E-05 Depression (quantitative trait) HS3ST4 intron 23290196 rs3922857 chr16 25977007 C T 5.36E-05 Depression (quantitative trait) HS3ST4 intron 23290196 rs4072224 chr16 25977514 A G 7.05E-05 Depression (quantitative trait) HS3ST4 intron 23290196 rs13339086 chr16 25977900 G A 6.99E-05 Depression (quantitative trait) HS3ST4 intron 23290196 rs4297682 chr16 25979718 A G 7.67E-05 Depression (quantitative trait) HS3ST4 intron 23290196 rs4564573 chr16 25980871 T C 9.13E-05 Serum metabolites HS3ST4 intron 19043545 rs4787792 chr16 25981445 C T 3.13E-05 Serum metabolites HS3ST4 intron 19043545 rs8063351 chr16 25989990 T C 3.13E-04 Smoking cessation HS3ST4 intron 24665060 rs4076875 chr16 25993628 C T 9.55E-04 Myopia (pathological) HS3ST4 intron 21095009 rs4073229 chr16 25995418 C T 9.02E-04 Myopia (pathological) HS3ST4 intron 21095009 rs11645216 chr16 25997672 G A 4.33E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) HS3ST4 intron 24023788 rs11645226 chr16 25997742 G A 3.39E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) HS3ST4 intron 24023788 rs7190163 chr16 26000346 G C 1.90E-05 Urinary metabolites HS3ST4 intron 21572414 rs7191801 chr16 26000673 T C 1.10E-05 Urinary metabolites HS3ST4 intron 21572414 rs6497910 chr16 26009660 C T 4.41E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) HS3ST4 intron 24023788 rs3923771 chr16 26019828 A T 1.55E-04 Multiple complex diseases HS3ST4 intron 17554300 rs12926546 chr16 26023883 A G 5.07E-04 Suicide attempts in bipolar disorder HS3ST4 intron 21423239 rs7200438 chr16 26042104 A T 6.08E-04 Type 2 diabetes HS3ST4 intron 17463246 rs3803712 chr16 26074500 C T 6.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HS3ST4 intron 20877124 rs7198646 chr16 26084476 C T 4.38E-05 Heart Rate HS3ST4 intron pha003054 rs4787348 chr16 26094599 G A 6.01E-05 Heart Rate HS3ST4 intron pha003053 rs12596791 chr16 26115562 G A 3.63E-04 Sudden cardiac arrest HS3ST4 intron 21658281 rs4129576 chr16 26129846 C T 6.93E-07 Odorant perception HS3ST4 intron 23910658 rs3809678 chr16 26133103 C T 2.20E-05 Urinary metabolites HS3ST4 intron 21572414 rs4544246 chr16 26141819 G A 7.25E-05 Psoriasis HS3ST4 intron 20953190 rs9933429 chr16 26170940 G A 2.40E-05 Urinary metabolites / / 21572414 rs9933429 chr16 26170940 G A 7.00E-06 Obesity-related traits / / 23251661 rs9938052 chr16 26177848 A G 8.00E-06 Urinary metabolites / / 21572414 rs9807002 chr16 26277419 T C 3.05E-05 Neuroticism / / 23229837 rs12925611 chr16 26290849 T C 6.34E-05 Suicide attempts in bipolar disorder / / 21041247 rs12925611 chr16 26290849 T C 6.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs12443717 chr16 26296959 A T 7.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs4787831 chr16 26339056 A C 7.18E-04 Smoking quantity / / 24665060 rs4787367 chr16 26347780 T G 9.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7202468 chr16 26352382 C T 5.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10492802 chr16 26381330 T C 6.23E-05 Iron status biomarkers / / 19084217 rs1989808 chr16 26391820 A T 1.40E-06 Memory performance / / 22105620 rs2214030 chr16 26397615 G T 4.82E-05 Type 2 diabetes / / 17463246 rs4419064 chr16 26407559 T C 6.30E-05 Memory performance / / 22105620 rs7196027 chr16 26446574 A G 6.20E-05 Memory performance / / 22105620 rs4787373 chr16 26451035 A G 3.40E-05 Memory performance / / 22105620 rs10492804 chr16 26454324 A G 3.90E-05 Memory performance / / 22105620 rs2023661 chr16 26454742 C T 3.20E-05 Memory performance / / 22105620 rs9922485 chr16 26459384 T C 1.39E-05 Post-operative nausea and vomiting / / 21694509 rs11074780 chr16 26459921 A G 7.30E-05 Memory performance / / 22105620 rs8064084 chr16 26474210 T G 4.00E-05 Memory performance / / 22105620 rs7350820 chr16 26474984 A G 4.00E-05 Memory performance / / 22105620 rs41382945 chr16 26502335 C G 2.67E-05 Type 2 diabetes / / 17463246 rs8051570 chr16 26502518 C T 1.30E-05 Memory performance / / 22105620 rs1012651 chr16 26511474 G A 3.27E-04 Stroke / / pha002886 rs12446827 chr16 26511874 A G 6.09E-05 Longevity / / 22279548 rs17505742 chr16 26514779 G T 4.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs386790051 chr16 26514779 GTGA GAGC 4.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs16975913 chr16 26515072 A T 7.01E-04 Multiple complex diseases / / 17554300 rs1363761 chr16 26527271 T C 0.0000541 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs9939729 chr16 26532143 G T 2.12E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs9927531 chr16 26534846 C A 2.50E-04 Lung adenocarcinoma / / 21242121 rs8057317 chr16 26552637 G A 8.11E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1895385 chr16 26561878 C T 1.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs237195 chr16 26563303 A G 8.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs237196 chr16 26563363 A G 5.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs237198 chr16 26566076 T A 6.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs237199 chr16 26566789 A C 5.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs183545 chr16 26567233 A T 4.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs171064 chr16 26567528 A G 9.32E-05 Suicide attempts in bipolar disorder / / 21423239 rs171064 chr16 26567528 A G 2.40E-05 Urinary metabolites / / 21572414 rs2520141 chr16 26571804 T A 1.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs2547416 chr16 26584816 C T 2.63E-06 Height / / pha003010 rs2547416 chr16 26584816 C T 2.35E-05 Height / / pha003011 rs2547416 chr16 26584816 C T 2.01E-05 Weight / / pha003026 rs11866811 chr16 26587493 A G 9.42E-04 Alzheimer's disease / / 17998437 rs237206 chr16 26595394 C T 7.10E-06 Height / / pha003010 rs237206 chr16 26595394 C T 5.37E-05 Erythrocyte counts / / pha003090 rs918553 chr16 26620935 G A 2.06E-04 Tourette syndrome / / 22889924 rs237131 chr16 26640406 G A 6.05E-06 Cognitive impairment induced by topiramate / / 22091778 rs237133 chr16 26641023 A T 2.74E-04 Multiple complex diseases / / 17554300 rs237142 chr16 26646032 G A 7.54E-05 Cognitive impairment induced by topiramate / / 22091778 rs237179 chr16 26662607 A G 8.28E-04 Multiple complex diseases / / 17554300 rs7200086 chr16 26678929 T C 4.95E-04 Alzheimer's disease / / 22005930 rs6497957 chr16 26681997 C T 5.90E-04 Alzheimer's disease / / 22005930 rs235807 chr16 26683422 G A 5.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs235806 chr16 26684008 T A 8.47E-05 Bipolar disorder / / 19259986 rs321441 chr16 26703677 G T 4.24E-04 Stroke / / pha002886 rs11647094 chr16 26714104 G A 6.59E-05 Suicide attempts in bipolar disorder / / 21423239 rs1811312 chr16 26731107 G A 5.97E-05 Body Mass Index / / pha003009 rs11074795 chr16 26731924 T C 5.97E-05 Body Mass Index / / pha003009 rs182678 chr16 26736920 G A 9.48E-04 Multiple complex diseases / / 17554300 rs716447 chr16 26741229 T C 7.29E-04 Major depressive disorder / / 22472876 rs321472 chr16 26745376 G A 8.04E-04 Coronary heart disease / / 21606135 rs186500 chr16 26746994 G A 1.40E-05 Urinary metabolites / / 21572414 rs5027319 chr16 26756471 A T 2.60E-05 Urinary metabolites / / 21572414 rs321428 chr16 26793580 C T 7.59E-04 Multiple complex diseases / / 17554300 rs12102836 chr16 26795341 A G 3.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8061566 chr16 26796643 G A 8.30E-05 Potassium levels / / pha003086 rs974474 chr16 26803575 G A 1.86E-04 Smoking quantity / / 24665060 rs4787389 chr16 26805784 G A 6.27E-04 Smoking initiation / / 24665060 rs4787389 chr16 26805784 G A 7.08E-05 Heart Rate / / pha003054 rs17185165 chr16 26812386 A G 1.05E-04 Multiple complex diseases / / 17554300 rs10400960 chr16 26830618 C T 2.57E-04 Lung function (forced vital capacity) / / 24023788 rs121196 chr16 26866149 T C 5.05E-04 Multiple complex diseases / / 17554300 rs12446049 chr16 26866855 G C 2.50E-05 Urinary metabolites / / 21572414 rs2188776 chr16 26869677 T C 9.71E-05 Multiple complex diseases / / 17554300 rs6497965 chr16 26872744 A G 5.75E-05 Bipolar disorder and schizophrenia / / 20889312 rs7201756 chr16 26938116 T A 7.39E-07 Multiple complex diseases / / 17554300 rs17705438 chr16 26948830 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6497978 chr16 26984365 G A 3.72E-04 Multiple complex diseases / / 17554300 rs7204336 chr16 27030491 A T 1.60E-05 Urinary metabolites / / 21572414 rs7206078 chr16 27048236 C T 4.10E-04 Response to antidepressants / / 19736353 rs12927663 chr16 27054161 G A 3.17E-05 HDL cholesterol / / pha003074 rs12927663 chr16 27054161 G A 2.45E-05 HDL cholesterol / / pha003075 rs2203512 chr16 27056455 G A 3.00E-07 Cognitive performance / / 19734545 rs11648276 chr16 27075755 C T 4.36E-05 Cervical cancer / / 24700089 rs8061733 chr16 27075902 G A 9.00E-05 Body Mass Index / / pha003007 rs11074843 chr16 27090311 T C 0.0000553 Amyotrophic lateral sclerosis / / 23587638 rs7201146 chr16 27102315 A G 3.30E-04 Body mass index / / 17255346 rs17638585 chr16 27109136 A C 9.63E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs10521142 chr16 27130155 A G 5.75E-05 Tunica Media / / pha003037 rs9921605 chr16 27134987 C T 9.83E-04 Major depressive disorder / / 22472876 rs1913895 chr16 27147284 C T 4.14E-05 Psoriasis / / 20953190 rs2090297 chr16 27157612 T C 5.26E-05 Tunica Media / / pha003037 rs2090296 chr16 27157795 T C 5.33E-05 Tunica Media / / pha003037 rs12444461 chr16 27158872 C T 5.32E-05 Tunica Media / / pha003037 rs4258620 chr16 27179325 A G 6.44E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs12051243 chr16 27214458 G T 7.42E-05 Monocyte counts / / pha003089 rs16976587 chr16 27214984 G A 9.00E-06 Obesity-related traits JMJD5 intron 23251661 rs2958 chr16 27236403 G A 6.77E-04 Suicide attempts in bipolar disorder NSMCE1 UTR-3 21423239 rs12928394 chr16 27238737 G A 7.70E-04 Suicide attempts in bipolar disorder NSMCE1 intron 21423239 rs7186985 chr16 27249243 T C 1.56E-04 Suicide attempts in bipolar disorder NSMCE1 intron 21423239 rs7186151 chr16 27249381 G A 1.50E-04 Suicide attempts in bipolar disorder NSMCE1 intron 21423239 rs12446162 chr16 27256129 C T 4.90E-05 Suicide attempts in bipolar disorder NSMCE1 intron 21423239 rs7359403 chr16 27259555 T C 1.64E-04 Multiple complex diseases NSMCE1 intron 17554300 rs4787417 chr16 27266817 G A 1.75E-04 Multiple complex diseases NSMCE1 intron 17554300 rs7189192 chr16 27267309 C T 1.11E-04 Suicide attempts in bipolar disorder NSMCE1 intron 21423239 rs7195194 chr16 27268779 G C 5.43E-04 Multiple complex diseases NSMCE1 missense 17554300 rs4787418 chr16 27271072 A G 1.64E-04 Suicide attempts in bipolar disorder NSMCE1 intron 21423239 rs4399540 chr16 27276463 G A 1.60E-04 Suicide attempts in bipolar disorder NSMCE1 intron 21423239 rs7195219 chr16 27277056 G A 1.60E-04 Suicide attempts in bipolar disorder NSMCE1 intron 21423239 rs8046004 chr16 27288407 G A 1.19E-04 Suicide attempts in bipolar disorder FLJ21408 intron 21423239 rs4523933 chr16 27316283 T C 9.95E-05 Aortic root size / / 21223598 rs4547336 chr16 27316401 A C 3.17E-05 Aortic root size / / 21223598 rs8057585 chr16 27320369 G C 1.10E-04 Aortic root size / / 21223598 rs6498012 chr16 27331974 C G 7.56E-05 Serum metabolites IL4R intron 19043545 rs4787948 chr16 27341059 A G 2.09E-05 Self-reported allergy IL4R intron 23817569 rs3024530 chr16 27350687 A G 3.77E-04 Suicide attempts in bipolar disorder IL4R intron 21423239 rs3024547 chr16 27354361 C T 4.54E-04 Gallstones IL4R intron 17632509 rs3024676 chr16 27373558 C A 1.07E-05 IgE levels IL4R intron 22075330 rs1805011 chr16 27373872 A C 2.39E-06 IgE levels IL4R missense 22075330 rs1805011 chr16 27373872 A C 0.00061 Asthma (exacerbation) IL4R missense 23706709 rs2234898 chr16 27373915 G T 2.37E-06 IgE levels IL4R cds-synon 22075330 rs1805012 chr16 27373964 T C 1.87E-06 IgE levels IL4R missense 22075330 rs2234900 chr16 27373972 T C 1.81E-06 IgE levels IL4R cds-synon 22075330 rs1805015 chr16 27374180 T C 6.70E-06 IgE levels IL4R missense 22075330 rs1805015 chr16 27374180 T C 3.08E-05 Coronary heart disease IL4R missense pha003030 rs1801275 chr16 27374400 A G 1.00E-07 IgE levels IL4R missense 22075330 rs4787426 chr16 27384731 T G 2.40E-05 Urinary metabolites / / 21572414 rs6498015 chr16 27391624 A G 5.35E-05 Self-reported allergy / / 23817569 rs6498016 chr16 27391788 G A 1.94E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs6498017 chr16 27394858 A G 5.49E-06 Self-reported allergy / / 23817569 rs722517 chr16 27396595 T C 4.65E-04 IgE levels / / 17255346 rs722517 chr16 27396595 T C 2.85E-06 Self-reported allergy / / 23817569 rs11074854 chr16 27397539 G C 2.28E-06 Self-reported allergy / / 23817569 rs1859308 chr16 27397998 A G 2.28E-06 Self-reported allergy / / 23817569 rs7199163 chr16 27399100 T G 1.96E-06 Self-reported allergy / / 23817569 rs2107357 chr16 27410829 A G 3.00E-07 Self-reported allergy / / 23817569 rs2189521 chr16 27413566 C T 8.75E-05 Creatinine levels IL21R UTR-5 pha003069 rs179771 chr16 27417744 G C 2.31E-05 Self-reported allergy IL21R intron 23817569 rs7199138 chr16 27434533 G C 1.41E-05 Bone mineral density IL21R intron 19874204 rs8057551 chr16 27434927 A G 2.00E-06 Bone mineral density IL21R intron 19874204 rs8061992 chr16 27435038 C A 8.62E-06 Bone mineral density IL21R intron 19874204 rs3093317 chr16 27444078 C T 6.76E-04 Multiple complex diseases IL21R intron 17554300 rs3093330 chr16 27446054 C T 2.49E-05 Blood Pressure IL21R intron pha003049 rs3093406 chr16 27452700 C T 1.26E-04 White matter integrity IL21R intron 22425255 rs9934589 chr16 27769894 G A 8.40E-04 Type 2 diabetes KIAA0556 intron 17463246 rs9944296 chr16 27772891 C T 0.00000939 Ratio of free to total prostate-specific antigen KIAA0556 cds-synon 23555315 rs12447401 chr16 27805133 C A 0.00033 Endometrial cancer GSG1L intron 22426144 rs705914 chr16 27813483 G A 3.71E-04 Multiple complex diseases GSG1L intron 17554300 rs6498038 chr16 27824831 A C 0.000281978 Hypertension (early onset hypertension) GSG1L intron 22479346 rs1363749 chr16 27827381 G A 1.01E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) GSG1L intron 24023788 rs1363749 chr16 27827381 G A 3.81E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) GSG1L intron 24023788 rs2384812 chr16 27853219 G A 4.77E-05 Parkinson's disease GSG1L intron 17052657 rs772958 chr16 27855639 T C 7.02E-04 Multiple complex diseases GSG1L intron 17554300 rs1615164 chr16 27860811 T G 7.22E-05 Serum metabolites GSG1L intron 19043545 rs933664 chr16 27936267 A C 2.13E-04 Longevity GSG1L intron 22279548 rs1549268 chr16 27947454 A G 5.92E-05 Type 2 diabetes GSG1L intron 17463246 rs1549269 chr16 27947672 C T 2.71E-04 Type 2 diabetes GSG1L intron 17463246 rs9923466 chr16 27949208 G T 5.73E-05 Type 2 diabetes GSG1L intron 17463246 rs12920707 chr16 27969978 G A 8.25E-04 Type 2 diabetes GSG1L intron 17463246 rs4788017 chr16 27976829 A G 2.83E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GSG1L intron 20031582 rs2898879 chr16 27977483 C T 1.35E-05 Chronic obstructive pulmonary disease GSG1L intron 19300482 rs2898879 chr16 27977483 C T 1.35E-05 Response to statin treatment (atorvastatin),change in cholesterol levels GSG1L intron 20031582 rs763763 chr16 27978219 T C 1.36E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GSG1L intron 20031582 rs8054996 chr16 27992628 C T 2.82E-04 Lung function (forced vital capacity) GSG1L intron 24023788 rs4788025 chr16 28003221 G A 2.00E-04 Response to platinum-based chemotherapy in small-cell lung cancer GSG1L intron 20463552 rs205391 chr16 28052963 T C 7.00E-06 Obesity-related traits GSG1L intron 23251661 rs17516321 chr16 28054732 C T 2.83E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) GSG1L intron 24023788 rs8051871 chr16 28097915 A G 1.14E-04 Alzheimer's disease / / pha002879 rs9930464 chr16 28143489 C T 9.60E-06 Cognitive performance XPO6 intron 19734545 rs2726034 chr16 28336882 T C 0.0000309 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs151178 chr16 28483061 A T 0.0000076 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs149299 chr16 28485141 T C 0.00000717 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs151179 chr16 28487056 A G 0.00000646 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs181195 chr16 28488369 A T 0.00000716 Nonsyndromic striae distensae (stretch marks) CLN3 nearGene-3 23633020 rs34839 chr16 28489346 T C 0.00000816 Nonsyndromic striae distensae (stretch marks) CLN3 intron 23633020 rs151181 chr16 28490517 T C 2.00E-11 Crohn's disease CLN3 intron 21102463 rs151181 chr16 28490517 T C 2.48E-07 Esophageal cancer (squamous cell) CLN3 intron 22960999 rs151181 chr16 28490517 T C 0.00000792 Nonsyndromic striae distensae (stretch marks) CLN3 intron 23633020 rs151303 chr16 28492510 C A 0.00000648 Nonsyndromic striae distensae (stretch marks) CLN3 intron 23633020 rs34838 chr16 28494350 A G 0.00000643 Nonsyndromic striae distensae (stretch marks) CLN3 intron 23633020 rs42861 chr16 28494421 A G 0.00000653 Nonsyndromic striae distensae (stretch marks) CLN3 intron 23633020 rs34836 chr16 28494823 A G 0.000006 Nonsyndromic striae distensae (stretch marks) CLN3 intron 23633020 rs151182 chr16 28495752 C T 0.00000415 Nonsyndromic striae distensae (stretch marks) CLN3 intron 23633020 rs151301 chr16 28497059 T A 0.0000042 Nonsyndromic striae distensae (stretch marks) CLN3 intron 23633020 rs34835 chr16 28499291 A G 0.00000207 Nonsyndromic striae distensae (stretch marks) CLN3 intron 23633020 rs27741 chr16 28504181 G A 0.00000143 Nonsyndromic striae distensae (stretch marks) CLN3 nearGene-5 23633020 rs149271 chr16 28506872 A G 0.00000276 Nonsyndromic striae distensae (stretch marks) APOBR cds-synon 23633020 rs180743 chr16 28507644 C G 0.00000411 Nonsyndromic striae distensae (stretch marks) APOBR missense 23633020 rs180744 chr16 28508048 A G 0.00000292 Nonsyndromic striae distensae (stretch marks) APOBR cds-synon 23633020 rs151174 chr16 28508069 C T 0.00000286 Nonsyndromic striae distensae (stretch marks) APOBR cds-synon 23633020 rs40831 chr16 28508447 A G 0.00000521 Nonsyndromic striae distensae (stretch marks) APOBR cds-synon 23633020 rs200288763 chr16 28508506 C T 0.0001 Breast cancer (ER positive) APOBR missense 23555315 rs40834 chr16 28510393 C T 0.000032 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs40836 chr16 28510537 A G 0.000039 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs40837 chr16 28510845 A G 0.0000261 Nonsyndromic striae distensae (stretch marks) IL27 UTR-3 23633020 rs181203 chr16 28512371 A C 0.0000102 Nonsyndromic striae distensae (stretch marks) IL27 intron 23633020 rs181206 chr16 28513403 A G 0.00001 Nonsyndromic striae distensae (stretch marks) IL27 missense 23633020 rs181207 chr16 28513530 C T 0.00000944 Nonsyndromic striae distensae (stretch marks) IL27 intron 23633020 rs181209 chr16 28514854 G T 0.00000886 Nonsyndromic striae distensae (stretch marks) IL27 intron 23633020 rs26528 chr16 28517709 T C 1.00E-21 Inflammatory bowel disease IL27 intron 23128233 rs26528 chr16 28517709 T C 0.0000224 Nonsyndromic striae distensae (stretch marks) IL27 intron 23633020 rs153109 chr16 28519096 T C 0.0000214 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs56354901 chr16 28523144 T C 0.00000465 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs240707 chr16 28524612 C G 0.0000296 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs153111 chr16 28524723 C T 0.0000295 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs153106 chr16 28526897 T C 0.00000098 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62034318 chr16 28527221 C T 0.00000344 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs79046494 chr16 28527326 G A 0.00000358 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs28449958 chr16 28528781 G A 0.00000327 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs240705 chr16 28529716 C T 0.000000911 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs240704 chr16 28529949 T C 0.000000909 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4787458 chr16 28531287 A G 0.000000648 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs240702 chr16 28531353 C T 0.000000919 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62034319 chr16 28532188 T G 0.000000919 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs28698667 chr16 28533071 C T 0.000000862 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62034321 chr16 28534038 C T 0.000000871 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4788085 chr16 28535003 A G 0.000000862 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs28772958 chr16 28535305 A G 0.000000862 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62034322 chr16 28535834 G A 0.00000047 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62034323 chr16 28536473 C T 0.000000861 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62034324 chr16 28536762 T C 0.00000052 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2106480 chr16 28537971 T C 0.000000869 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62034325 chr16 28538640 A G 0.000000635 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62034326 chr16 28539293 A G 0.000000669 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4788084 chr16 28539848 C T 3.00E-13 Type 1 diabetes / / 19430480 rs4788084 chr16 28539848 C T 1.00E-08 Type 1 diabetes autoantibodies / / 21829393 rs4788084 chr16 28539848 C T 2.60E-13 Multiple sclerosis / / 22190364 rs4788084 chr16 28539848 C T 0.000000911 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs8046271 chr16 28541394 T C 0.000000934 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4788083 chr16 28545449 A G 0.0000011 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs75932386 chr16 28546865 C T 0.0000023 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs151227 chr16 28549508 G A 2.62E-04 Multiple complex diseases NUPR1 cds-synon 17554300 rs151227 chr16 28549508 G A 3.20E-06 Diabetic retinopathy NUPR1 cds-synon 21441570 rs3785354 chr16 28550667 C T 0.00000208 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1074631 chr16 28554108 G A 6.37E-04 Response to TNF antagonist treatment / / 21061259 rs1074631 chr16 28554108 G A 0.00000201 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4787457 chr16 28555400 A G 0.00000188 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9926245 chr16 28555706 T A 0.00000141 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4788081 chr16 28556147 T C 0.00000158 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4788080 chr16 28558081 C T 0.0000016 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4787456 chr16 28559573 C T 0.00000156 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4788078 chr16 28559981 G A 0.00000155 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs112366001 chr16 28561785 T A 0.00000152 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs13331170 chr16 28561982 T C 0.00000154 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62034350 chr16 28562256 A G 0.00000152 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62034351 chr16 28565489 G A 0.000000762 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs7191618 chr16 28565667 C G 0.00000183 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs7187604 chr16 28565953 A G 0.000000742 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs3859172 chr16 28566158 G T 0.00000172 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs151320 chr16 28568678 C T 7.59E-05 Type 1 diabetes CCDC101 intron 18978792 rs151320 chr16 28568678 C T 3.10E-06 Diabetic retinopathy CCDC101 intron 21441570 rs4788077 chr16 28569764 G C 0.000000709 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs4788076 chr16 28570005 C T 4.49E-04 Response to TNF antagonist treatment CCDC101 intron 21061259 rs4788076 chr16 28570005 C T 0.000000733 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs140001625 chr16 28575917 C T 0.00000169 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs538810479 chr16 28575917 C CAT 0.00000169 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs56272201 chr16 28580685 A G 0.000000909 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs56396270 chr16 28580829 C T 0.000000958 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs62034355 chr16 28581038 G C 0.00000108 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs12447461 chr16 28582941 C A 0.0000011 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs151230 chr16 28583215 G A 3.20E-06 Diabetic retinopathy CCDC101 intron 21441570 rs112191041 chr16 28583362 A G 0.0000011 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs11074911 chr16 28583865 C T 0.0000011 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs151229 chr16 28584937 G A 3.20E-06 Diabetic retinopathy CCDC101 intron 21441570 rs56209193 chr16 28585636 C T 0.00000111 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs7193402 chr16 28586127 T C 9.04E-05 Type 1 diabetes CCDC101 intron 18978792 rs7193402 chr16 28586127 T C 3.45E-04 Response to TNF antagonist treatment CCDC101 intron 21061259 rs7193402 chr16 28586127 T C 0.00000112 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs7186573 chr16 28587389 T C 0.00000134 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs62034358 chr16 28587597 G T 0.00000134 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs12445823 chr16 28588049 A C 0.00000139 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs12445744 chr16 28588395 A C 0.00000145 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs12448429 chr16 28588443 C T 0.00000173 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs4787455 chr16 28589455 G A 0.0000015 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs11641853 chr16 28589719 A G 3.40E-06 Diabetic retinopathy CCDC101 intron 21441570 rs7190771 chr16 28590030 G A 0.00000156 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs112047757 chr16 28590862 C T 0.00000186 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs112831778 chr16 28590989 C T 0.00000194 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs9924471 chr16 28591530 G A 3.22E-22 Multiple complex diseases CCDC101 intron 17554300 rs9924471 chr16 28591530 G A 1.21E-11 Type 1 diabetes CCDC101 intron 21980299 rs17707300 chr16 28593347 T C 5.28E-04 Response to TNF antagonist treatment CCDC101 intron 21061259 rs17707300 chr16 28593347 T C 0.00000213 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs4788074 chr16 28593597 G A 3.45E-04 Response to TNF antagonist treatment CCDC101 intron 21061259 rs4788074 chr16 28593597 G A 5.44E-07 Esophageal cancer (squamous cell) CCDC101 intron 22960999 rs4788074 chr16 28593597 G A 0.00000198 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs4788073 chr16 28594549 A G 0.00000187 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs17640009 chr16 28595700 A G 0.00000172 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs75539558 chr16 28595810 C G 0.00000153 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs10521145 chr16 28596884 G A 8.38E-04 Multiple complex diseases CCDC101 intron 17554300 rs10521145 chr16 28596884 G A 3.40E-06 Diabetic retinopathy CCDC101 intron 21441570 rs55792032 chr16 28599411 A G 0.00000162 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs62034359 chr16 28600091 C T 0.00000203 Nonsyndromic striae distensae (stretch marks) CCDC101 intron 23633020 rs2077031 chr16 28603168 T A 0.00000142 Nonsyndromic striae distensae (stretch marks) SULT1A2 nearGene-3 23633020 rs762634 chr16 28603335 T C 0.00000194 Nonsyndromic striae distensae (stretch marks) SULT1A2 UTR-3 23633020 rs710410 chr16 28603342 A G 0.00000191 Nonsyndromic striae distensae (stretch marks) SULT1A2 UTR-3 23633020 rs1059491 chr16 28603655 T G 0.00000139 Nonsyndromic striae distensae (stretch marks) SULT1A2 missense 23633020 rs62031560 chr16 28605915 T A 0.00000141 Nonsyndromic striae distensae (stretch marks) SULT1A2 intron 23633020 rs113208333 chr16 28606160 G T 0.00000154 Nonsyndromic striae distensae (stretch marks) SULT1A2 intron 23633020 rs11647881 chr16 28606173 C A 8.60E-06 Diabetic retinopathy SULT1A2 intron 21441570 rs4149406 chr16 28607070 A G 0.00000146 Nonsyndromic striae distensae (stretch marks) SULT1A2 intron 23633020 rs4115668 chr16 28607532 G A 0.00000142 Nonsyndromic striae distensae (stretch marks) SULT1A2 UTR-5 23633020 rs743590 chr16 28608230 G A 0.00000138 Nonsyndromic striae distensae (stretch marks) SULT1A2 intron 23633020 rs762633 chr16 28608341 T C 0.00000139 Nonsyndromic striae distensae (stretch marks) SULT1A2 UTR-5 23633020 rs35175818 chr16 28608746 A C 0.00000139 Nonsyndromic striae distensae (stretch marks) SULT1A2 nearGene-5 23633020 rs4149398 chr16 28608938 C G 0.00000143 Nonsyndromic striae distensae (stretch marks) SULT1A2 nearGene-5 23633020 rs62031562 chr16 28609329 A T 0.00000148 Nonsyndromic striae distensae (stretch marks) SULT1A2 nearGene-5 23633020 rs11074907 chr16 28613965 A G 0.00000354 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7192601 chr16 28614488 C T 0.0000027 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7191548 chr16 28614734 T C 0.00000339 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11074904 chr16 28615708 G A 7.80E-06 Diabetic retinopathy / / 21441570 rs1968752 chr16 28631585 T G 1.20E-06 Esophageal cancer (squamous cell) SULT1A1 intron 22960999 rs62036613 chr16 28823097 A G 0.00000166 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62036614 chr16 28824685 T C 0.00000165 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs113029997 chr16 28825100 T C 0.00000168 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11860513 chr16 28825420 C T 0.0000015 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2008514 chr16 28825605 G A 9.66E-04 Obesity (extreme) / / 21935397 rs2008514 chr16 28825605 G A 0.00000167 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1987472 chr16 28825777 C T 0.00000167 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1987471 chr16 28825866 T G 0.00000171 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs56186137 chr16 28825953 A G 0.00000152 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62036616 chr16 28826307 A G 0.00000169 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62036617 chr16 28827498 T C 0.00000182 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62036618 chr16 28828834 A C 0.00000199 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4788095 chr16 28831359 T C 0.00000203 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs72793809 chr16 28832382 C T 0.00000205 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62036620 chr16 28833097 A G 0.00000171 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62036621 chr16 28833299 C A 0.00000191 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4451951 chr16 28836205 T C 0.00000224 Nonsyndromic striae distensae (stretch marks) ATXN2L intron 23633020 rs62036622 chr16 28837203 T G 0.00000228 Nonsyndromic striae distensae (stretch marks) ATXN2L intron 23633020 rs8049439 chr16 28837515 T C 2.00E-09 Inflammatory bowel disease (early onset) ATXN2L intron 19915574 rs8049439 chr16 28837515 T C 6.00E-06 Smoking behavior ATXN2L intron 20418888 rs8049439 chr16 28837515 T C 2.00E-09 Multiple sclerosis ATXN2L intron 22190364 rs8049439 chr16 28837515 T C 0.0000045 Nonsyndromic striae distensae (stretch marks) ATXN2L intron 23633020 rs8049439 chr16 28837515 T C 1.00E-07 Educational attainment ATXN2L intron 23722424 rs8049439 chr16 28837515 T C 2.20E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ATXN2L intron 24023788 rs8062405 chr16 28837906 A G 9.66E-04 Obesity (extreme) ATXN2L intron 21935397 rs8062405 chr16 28837906 A G 3.70E-06 Lymphocyte counts ATXN2L intron 22286170 rs8062405 chr16 28837906 A G 0.00000252 Nonsyndromic striae distensae (stretch marks) ATXN2L intron 23633020 rs72793811 chr16 28839392 G A 0.0000027 Nonsyndromic striae distensae (stretch marks) ATXN2L intron 23633020 rs78613234 chr16 28839425 T C 0.0000027 Nonsyndromic striae distensae (stretch marks) ATXN2L intron 23633020 rs62036623 chr16 28839735 C G 0.0000026 Nonsyndromic striae distensae (stretch marks) ATXN2L intron 23633020 rs62036624 chr16 28839930 G T 0.00000254 Nonsyndromic striae distensae (stretch marks) ATXN2L intron 23633020 rs72793812 chr16 28840381 A G 0.00000234 Nonsyndromic striae distensae (stretch marks) ATXN2L intron 23633020 rs12443881 chr16 28841777 C T 9.67E-04 Obesity (extreme) ATXN2L intron 21935397 rs12443881 chr16 28841777 C T 2.45E-06 Esophageal cancer (squamous cell) ATXN2L intron 22960999 rs12443881 chr16 28841777 C T 0.0000027 Nonsyndromic striae distensae (stretch marks) ATXN2L intron 23633020 rs55991577 chr16 28843025 C T 0.00000282 Nonsyndromic striae distensae (stretch marks) ATXN2L intron 23633020 rs56358680 chr16 28843118 A G 0.00000269 Nonsyndromic striae distensae (stretch marks) ATXN2L intron 23633020 rs62036626 chr16 28844284 A G 0.00000256 Nonsyndromic striae distensae (stretch marks) ATXN2L intron 23633020 rs62036657 chr16 28844365 G A 0.00000269 Nonsyndromic striae distensae (stretch marks) ATXN2L intron 23633020 rs12444171 chr16 28845251 G A 0.00000269 Nonsyndromic striae distensae (stretch marks) ATXN2L intron 23633020 rs56404918 chr16 28846840 T G 0.00000234 Nonsyndromic striae distensae (stretch marks) ATXN2L intron 23633020 rs55719896 chr16 28846866 G A 0.00000243 Nonsyndromic striae distensae (stretch marks) ATXN2L intron 23633020 rs55830740 chr16 28847149 G C 0.00000272 Nonsyndromic striae distensae (stretch marks) ATXN2L intron 23633020 rs12928404 chr16 28847246 T C 0.00000526 Nonsyndromic striae distensae (stretch marks) ATXN2L intron 23633020 rs12325113 chr16 28848668 T C 9.69E-04 Obesity (extreme) / / 21935397 rs12325113 chr16 28848668 T C 0.00000269 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12325278 chr16 28848818 A G 9.68E-04 Obesity (extreme) / / 21935397 rs12325278 chr16 28848818 A G 0.0000027 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62036658 chr16 28850371 T G 0.00000258 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs3088215 chr16 28853996 A C 0.0000026 Nonsyndromic striae distensae (stretch marks) TUFM UTR-3 23633020 rs28403629 chr16 28854769 A G 0.00000256 Nonsyndromic striae distensae (stretch marks) TUFM intron 23633020 rs61737565 chr16 28855522 G C 0.00000254 Nonsyndromic striae distensae (stretch marks) TUFM intron 23633020 rs4788099 chr16 28855727 A G 9.68E-04 Obesity (extreme) TUFM intron 21935397 rs4788099 chr16 28855727 A G 0.000000188 Body mass index (females) TUFM intron 23001569 rs4788099 chr16 28855727 A G 6.49E-10 Body mass index TUFM intron 23001569 rs4788099 chr16 28855727 A G 0.00000245 Nonsyndromic striae distensae (stretch marks) TUFM intron 23633020 rs9972693 chr16 28859802 A G 0.00000244 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs113079736 chr16 28860183 G A 0.00000241 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12325014 chr16 28860237 C G 0.00000242 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9972768 chr16 28861734 A C 0.0000021 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs56040780 chr16 28861881 C T 0.00000228 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs80275162 chr16 28863517 T A 0.00000206 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs56163509 chr16 28864471 A G 0.00000277 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4788100 chr16 28864673 T C 9.68E-04 Obesity (extreme) / / 21935397 rs4788100 chr16 28864673 T C 0.00000222 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62037363 chr16 28865042 T C 0.00000209 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7205323 chr16 28865892 C T 9.68E-04 Obesity (extreme) / / 21935397 rs7205323 chr16 28865892 C T 0.00000138 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7187333 chr16 28865916 G A 9.68E-04 Obesity (extreme) / / 21935397 rs7187333 chr16 28865916 G A 0.00000138 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs147684209 chr16 28867061 T C 0.00000213 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs149601295 chr16 28867159 G A 0.00000257 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4788101 chr16 28867804 C T 0.00000209 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62037364 chr16 28868695 G A 0.00000215 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62037365 chr16 28868962 C G 0.00000215 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11150609 chr16 28870596 A G 0.00000216 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12446589 chr16 28870962 G A 0.00000224 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs62037366 chr16 28871657 C A 0.00000218 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11859512 chr16 28871853 C T 0.00000181 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11861132 chr16 28871860 A G 0.00000171 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11861174 chr16 28871989 A G 0.00000226 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7499337 chr16 28872354 G C 0.000002 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6565229 chr16 28872598 T C 0.00000237 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4788102 chr16 28873398 G A 3.50E-06 Smoking behavior SH2B1 nearGene-5 20418888 rs4788102 chr16 28873398 G A 9.68E-04 Obesity (extreme) SH2B1 nearGene-5 21935397 rs4788102 chr16 28873398 G A 0.00000228 Nonsyndromic striae distensae (stretch marks) SH2B1 nearGene-5 23633020 rs62037367 chr16 28874547 C G 0.00000155 Nonsyndromic striae distensae (stretch marks) SH2B1 nearGene-5 23633020 rs7198606 chr16 28875122 T G 0.00000219 Nonsyndromic striae distensae (stretch marks) SH2B1 UTR-5 23633020 rs11864750 chr16 28875204 A T 0.00000205 Nonsyndromic striae distensae (stretch marks) SH2B1 UTR-5 23633020 rs7193733 chr16 28875482 A G 0.00000207 Nonsyndromic striae distensae (stretch marks) SH2B1 UTR-5 23633020 rs11863370 chr16 28879484 A G 0.00000206 Nonsyndromic striae distensae (stretch marks) SH2B1 intron 23633020 rs8055982 chr16 28881202 A C 9.76E-04 Obesity (extreme) SH2B1 intron 21935397 rs8055982 chr16 28881202 A C 0.00000202 Nonsyndromic striae distensae (stretch marks) SH2B1 intron 23633020 rs7498603 chr16 28882424 T C 0.00000309 Nonsyndromic striae distensae (stretch marks) SH2B1 intron 23633020 rs7498665 chr16 28883241 A G 1.00E-09 Weight SH2B1 missense 19079260 rs7498665 chr16 28883241 A G 3.00E-10 Body mass index SH2B1 missense 19079260 rs7498665 chr16 28883241 A G 5.00E-11 Body mass index SH2B1 missense 19079261 rs7498665 chr16 28883241 A G 5.10E-11 Smoking behavior SH2B1 missense 20418888 rs7498665 chr16 28883241 A G 3.00E-13 Obesity SH2B1 missense 23563607 rs7498665 chr16 28883241 A G 5.00E-12 Obesity SH2B1 missense 23563607 rs7498665 chr16 28883241 A G 0.00000199 Nonsyndromic striae distensae (stretch marks) SH2B1 missense 23633020 rs62037369 chr16 28883841 C T 0.00000186 Nonsyndromic striae distensae (stretch marks) SH2B1 intron 23633020 rs7359397 chr16 28885659 C T 2.00E-20 Body mass index SH2B1 nearGene-3 20935630 rs7359397 chr16 28885659 C T 1.88E-20 Body mass index SH2B1 nearGene-3 23001569 rs7359397 chr16 28885659 C T 0.00000079 Nonsyndromic striae distensae (stretch marks) SH2B1 nearGene-3 23633020 rs11864107 chr16 28885931 T C 0.00000176 Nonsyndromic striae distensae (stretch marks) SH2B1 nearGene-3 23633020 rs3888190 chr16 28889486 C A 0.00000179 Nonsyndromic striae distensae (stretch marks) ATP2A1 nearGene-5 23633020 rs62037371 chr16 28890131 C A 0.0000018 Nonsyndromic striae distensae (stretch marks) ATP2A1 intron 23633020 rs8055138 chr16 28891465 C T 0.00000195 Nonsyndromic striae distensae (stretch marks) ATP2A1 intron 23633020 rs11645143 chr16 28893409 T C 0.00000187 Nonsyndromic striae distensae (stretch marks) ATP2A1 intron 23633020 rs11641216 chr16 28893532 A G 0.00000189 Nonsyndromic striae distensae (stretch marks) ATP2A1 intron 23633020 rs7498555 chr16 28893571 T C 0.00000194 Nonsyndromic striae distensae (stretch marks) ATP2A1 intron 23633020 rs8061590 chr16 28895130 A G 0.00000201 Nonsyndromic striae distensae (stretch marks) ATP2A1 intron 23633020 rs11642449 chr16 28896015 C T 0.0000347 Nonsyndromic striae distensae (stretch marks) ATP2A1 intron 23633020 rs8056890 chr16 28897452 G A 0.0000349 Nonsyndromic striae distensae (stretch marks) ATP2A1 intron 23633020 rs6565259 chr16 28898793 T C 0.000029 Nonsyndromic striae distensae (stretch marks) ATP2A1 cds-synon 23633020 rs9931989 chr16 28906084 G C 5.06E-11 Body mass index ATP2A1 intron 19079261 rs9931989 chr16 28906084 G C 4.90E-11 Smoking behavior ATP2A1 intron 20418888 rs9931989 chr16 28906084 G C 0.0000477 Nonsyndromic striae distensae (stretch marks) ATP2A1 intron 23633020 rs7189927 chr16 28913787 T C 0.0000784 Nonsyndromic striae distensae (stretch marks) ATP2A1 intron 23633020 rs8046545 chr16 28915217 G A 0.0000655 Nonsyndromic striae distensae (stretch marks) ATP2A1 intron 23633020 rs10499 chr16 28915527 G A 0.0000654 Nonsyndromic striae distensae (stretch marks) ATP2A1 UTR-3 23633020 rs7188071 chr16 28917644 T C 0.0000691 Nonsyndromic striae distensae (stretch marks) RABEP2 intron 23633020 rs7184597 chr16 28921809 T C 7.00E-09 Obesity RABEP2 intron 23563607 rs7184597 chr16 28921809 T C 0.000094 Nonsyndromic striae distensae (stretch marks) RABEP2 intron 23633020 rs11646653 chr16 28922149 C T 0.0000898 Nonsyndromic striae distensae (stretch marks) RABEP2 intron 23633020 rs9708958 chr16 28922743 A G 0.0000747 Nonsyndromic striae distensae (stretch marks) RABEP2 intron 23633020 rs7185232 chr16 28933468 C T 0.000088 Nonsyndromic striae distensae (stretch marks) RABEP2 intron 23633020 rs7185232 chr16 28933468 C T 1.38E-07 Parkinson's disease RABEP2 intron 24842889 rs2904880 chr16 28944396 C G 1.47E-08 Body mass index CD19 missense 23001569 rs6565300 chr16 28993049 A C 2.85E-06 Esophageal cancer (squamous cell) SPNS1 intron 22960999 rs4077347 chr16 29036915 G A 5.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs252272 chr16 29101402 C A 1.68E-04 Response to taxane treatment (placlitaxel) RRN3P2 intron 23006423 rs12922496 chr16 29130999 C T 4.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1642006 chr16 29136331 G C 5.43E-04 Depression (quantitative trait) / / 20800221 rs1646128 chr16 29141436 G A 8.49E-04 Depression (quantitative trait) / / 20800221 rs1642025 chr16 29147718 C G 6.03E-04 Depression (quantitative trait) / / 20800221 rs1646112 chr16 29154049 C T 1.53E-04 Depression (quantitative trait) / / 20800221 rs11646140 chr16 29155480 G A 6.27E-05 Post-operative nausea and vomiting / / 21694509 rs166152 chr16 29156005 A G 1.27E-04 Depression (quantitative trait) / / 20800221 rs252283 chr16 29164026 C A 9.02E-05 Depression (quantitative trait) / / 20800221 rs1364270 chr16 29168052 A G 1.61E-04 Depression (quantitative trait) / / 20800221 rs252289 chr16 29168094 G T 1.64E-04 Depression (quantitative trait) / / 20800221 rs252358 chr16 29177452 G C 4.25E-04 Depression (quantitative trait) / / 20800221 rs252353 chr16 29182179 G A 7.72E-04 Depression (quantitative trait) / / 20800221 rs12933229 chr16 29182190 T C 9.50E-06 Urinary metabolites / / 21572414 rs252345 chr16 29184698 T C 1.99E-04 Depression (quantitative trait) / / 20800221 rs252330 chr16 29192870 C T 1.09E-04 Depression (quantitative trait) / / 20800221 rs153219 chr16 29215298 G C 1.56E-04 Depression (quantitative trait) / / 20800221 rs252304 chr16 29224442 G A 9.83E-05 Depression (quantitative trait) / / 20800221 rs252246 chr16 29241389 A G 8.90E-05 Depression (quantitative trait) / / 20800221 rs252247 chr16 29242488 G C 9.86E-05 Depression (quantitative trait) / / 20800221 rs194045 chr16 29246102 C T 2.09E-04 Depression (quantitative trait) / / 20800221 rs2111259 chr16 29246341 T G 9.34E-05 Serum metabolites / / 19043545 rs8050132 chr16 29265186 C G 1.01E-04 Depression (quantitative trait) / / 20800221 rs11646318 chr16 29265508 C A 1.44E-04 Depression (quantitative trait) / / 20800221 rs1364182 chr16 29656093 C A 4.58E-04 Obesity (extreme) / / 21935397 rs1364184 chr16 29656210 A G 4.45E-04 Obesity (extreme) / / 21935397 rs4788172 chr16 29668253 G A 8.56E-04 Obesity (extreme) / / 21935397 rs3764275 chr16 29672982 A C 8.06E-04 Obesity (extreme) / / 21935397 rs3764276 chr16 29673203 T C 5.31E-04 Obesity (extreme) / / 21935397 rs3759987 chr16 29673903 G T 8.03E-04 Obesity (extreme) / / 21935397 rs11574550 chr16 29673970 C G 8.03E-04 Obesity (extreme) / / 21935397 rs11574552 chr16 29674033 T C 5.23E-04 Obesity (extreme) / / 21935397 rs2071420 chr16 29674823 A G 5.19E-04 Obesity (extreme) SPN intron 21935397 rs1050881 chr16 29675928 C T 7.43E-04 Obesity (extreme) SPN cds-synon 21935397 rs9933310 chr16 29690904 A G 3.30E-05 Anorexia nervosa QPRT intron 23568457 rs12596308 chr16 29691196 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes QPRT intron 22628534 rs9922666 chr16 29698625 G T 0.0000012 LDL cholesterol particle diameter QPRT intron 23263444 rs9923341 chr16 29698710 C T 0.0000041 LDL cholesterol particle diameter QPRT intron 23263444 rs1057452 chr16 29833714 G A 3.20E-04 Response to taxane treatment (placlitaxel) C16orf53 UTR-3 23006423 rs12917823 chr16 29877301 G T 8.27E-05 Response to taxane treatment (placlitaxel) LOC440356 intron 23006423 rs12917712 chr16 29882490 C T 7.00E-06 Systemic lupus erythematosus SEZ6L2 UTR-3 23273568 rs4787483 chr16 29885447 A G 2.00E-06 Anthropometric traits SEZ6L2 intron 19260139 rs4787483 chr16 29885447 A G 4.72E-06 Response to taxane treatment (placlitaxel) SEZ6L2 intron 23006423 rs4787484 chr16 29906546 C T 1.00E-06 Response to taxane treatment (placlitaxel) SEZ6L2 intron 23006423 rs7498372 chr16 29910725 A G 8.18E-05 Response to taxane treatment (placlitaxel) SEZ6L2 nearGene-5 23006423 rs7189550 chr16 29911260 G A 4.61E-05 Response to taxane treatment (placlitaxel) SEZ6L2 nearGene-5 23006423 rs11647753 chr16 29928115 A G 4.12E-07 Red blood cell traits KCTD13 intron 23222517 rs4788196 chr16 29967434 A G 8.71E-04 Suicide attempts in bipolar disorder / / 21041247 rs4788196 chr16 29967434 A G 9.00E-11 Pubertal anthropometrics / / 23449627 rs7204797 chr16 29968015 C T 8.10E-04 Multiple complex diseases / / 17554300 rs7204797 chr16 29968015 C T 3.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs6565173 chr16 29974167 G A 3.47E-04 Suicide attempts in bipolar disorder TMEM219 intron 21041247 rs4787486 chr16 29977562 A T 3.44E-04 Suicide attempts in bipolar disorder TMEM219 intron 21041247 rs11901 chr16 29984070 C G 3.41E-04 Suicide attempts in bipolar disorder TMEM219 intron 21041247 rs4318227 chr16 29984839 C G 3.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs11150577 chr16 29986525 G A 9.39E-04 Multiple complex diseases TAOK2 intron 17554300 rs11150577 chr16 29986525 G A 3.05E-04 Suicide attempts in bipolar disorder TAOK2 intron 21041247 rs4283241 chr16 29988349 G A 5.00E-04 Multiple complex diseases TAOK2 intron 17554300 rs4283241 chr16 29988349 G A 2.91E-04 Suicide attempts in bipolar disorder TAOK2 intron 21041247 rs4583255 chr16 29988941 A G 2.90E-04 Suicide attempts in bipolar disorder TAOK2 intron 21041247 rs4583255 chr16 29988941 A G 1.90E-06 Schizophrenia TAOK2 intron 21791550 rs4583255 chr16 29988941 A G 0.00026 Bipolar disorder TAOK2 intron 23164818 rs4583255 chr16 29988941 A G 0.00047 Body mass index TAOK2 intron 23164818 rs4583255 chr16 29988941 A G 6.60E-11 Psychosis TAOK2 intron 23164818 rs9925915 chr16 29993686 G C 2.89E-04 Suicide attempts in bipolar disorder TAOK2 intron 21041247 rs3814884 chr16 29994736 T A 4.32E-04 Suicide attempts in bipolar disorder TAOK2 intron 21041247 rs3814883 chr16 29994922 C T 1.39E-04 Suicide attempts in bipolar disorder TAOK2 cds-synon 21041247 rs4788204 chr16 29995218 G A 2.88E-04 Suicide attempts in bipolar disorder TAOK2 intron 21041247 rs4787489 chr16 29995880 G A 2.86E-04 Suicide attempts in bipolar disorder TAOK2 intron 21041247 rs3814881 chr16 30000901 G A 3.45E-04 Multiple complex diseases TAOK2 intron 17554300 rs3814881 chr16 30000901 G A 2.38E-04 Suicide attempts in bipolar disorder TAOK2 intron 21041247 rs9924686 chr16 30003076 G A 2.35E-04 Suicide attempts in bipolar disorder TAOK2 UTR-3 21041247 rs146278367 chr16 30004603 T C,G 0.000017 Prostate cancer (advanced) HIRIP3 missense 23555315 rs4788209 chr16 30013266 C T 2.99E-04 Suicide attempts in bipolar disorder INO80E intron 21041247 rs11150580 chr16 30014564 C T 3.33E-04 Suicide attempts in bipolar disorder INO80E intron 21041247 rs3814880 chr16 30017895 T C 2.14E-04 Suicide attempts in bipolar disorder DOC2A intron 21041247 rs3935873 chr16 30018500 C T 6.15E-04 Multiple complex diseases DOC2A cds-synon 17554300 rs3935873 chr16 30018500 C T 2.12E-04 Suicide attempts in bipolar disorder DOC2A cds-synon 21041247 rs11642612 chr16 30030195 A C 1.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs11150581 chr16 30030699 T C 1.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs11150581 chr16 30030699 T C 4.26E-05 Information processing speed / / 21130836 rs12325539 chr16 30033633 T C 1.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs12325539 chr16 30033633 T C 4.26E-05 Information processing speed / / 21130836 rs4788212 chr16 30034469 T G 3.45E-07 Red blood cell traits / / 23222517 rs4788213 chr16 30034524 T C 6.16E-05 Cleft lip / / 20436469 rs8054507 chr16 30046042 G A 2.00E-04 Information processing speed / / 21130836 rs11642740 chr16 30060655 A G 4.80E-05 Information processing speed / / 21130836 rs11642740 chr16 30060655 A G 5.39E-04 Heart rate / / 23583979 rs9928448 chr16 30072530 T C 2.00E-04 Information processing speed ALDOA intron 21130836 rs2278557 chr16 30093779 C G 6.88E-04 Heart rate PPP4C intron 23583979 rs6565174 chr16 30111904 A C 8.89E-05 Coronary heart disease LOC100506914 intron pha003030 rs9924308 chr16 30154740 A G 1.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7204270 chr16 30156963 C T 8.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7202714 chr16 30177807 C T 5.63E-04 Multiple complex diseases / / 17554300 rs4471699 chr16 30320307 G T 9.86E-56 Multiple complex diseases LOC595101 intron 17554300 rs188305385 chr16 30353264 T A 1.56E-04 Acne (severe) / / 24927181 rs4787642 chr16 30359408 T C 5.79E-06 Glycemic traits (pregnancy) / / 23903356 rs11862806 chr16 30364071 A G 1.62E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CD2BP2 UTR-3 20031582 rs11862806 chr16 30364071 A G 3.12E-06 Glycemic traits (pregnancy) CD2BP2 UTR-3 23903356 rs8049108 chr16 30376486 T C 3.64E-06 Glycemic traits (pregnancy) TBC1D10B cds-synon 23903356 rs8050812 chr16 30385837 T C 6.81E-05 Coronary heart disease / / pha003031 rs11150589 chr16 30482494 T C 6.00E-10 Ulcerative colitis / / 23128233 rs1064524 chr16 30492823 C T 2.00E-07 Smooth-surface caries ITGAL missense 24556642 rs1064524 chr16 30492823 C T 2.07E-07 Smooth-surface caries ITGAL missense 24556642 rs12448354 chr16 30493630 G A 0.00031 Coronary artery calcification ITGAL intron 23727086 rs11150590 chr16 30493881 T C 0.00027 Coronary artery calcification ITGAL intron 23727086 rs2285459 chr16 30495412 T C 3.38E-06 Parkinson's disease ITGAL intron pha002868 rs3087438 chr16 30500761 G A 2.77E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ITGAL intron 23648065 rs6565189 chr16 30507265 T G 3.39E-04 Type 2 diabetes ITGAL intron 17463246 rs1557672 chr16 30510571 C T 0.0000199 Paraoxonase activity ITGAL intron 23160181 rs17790434 chr16 30520856 C T 9.21E-11 Acenocoumarol maintenance dosage ITGAL intron 19578179 rs11574947 chr16 30524676 C T 7.51E-11 Warfarin responsiveness (phenprocoumon) ITGAL intron 21063236 rs61735343 chr16 30536916 T C 5.17E-05 Acne (severe) ZNF768 missense 24927181 rs11645241 chr16 30539097 C T 3.07E-16 Acenocoumarol maintenance dosage / / 19578179 rs6565191 chr16 30546488 G A 7.22E-04 Multiple complex diseases / / 17554300 rs6565191 chr16 30546488 G A 8.96E-28 Acenocoumarol maintenance dosage / / 19578179 rs17790906 chr16 30569659 T G 0.0000373 Alcohol craving with or without dependence / / 22481050 rs7186852 chr16 30635659 A G 3.00E-07 Systemic lupus erythematosus / / 19838193 rs7197475 chr16 30642867 C T 9.32E-20 Acenocoumarol maintenance dosage / / 19578179 rs7197475 chr16 30642867 C T 3.00E-08 Systemic lupus erythematosus / / 19838193 rs3747481 chr16 30666367 C T 1.42E-11 Acenocoumarol maintenance dosage PRR14 missense 19578179 rs8058578 chr16 30726248 C T 3.93E-12 Acenocoumarol maintenance dosage SRCAP intron 19578179 rs11642466 chr16 30781942 A G 5.60E-14 Acenocoumarol maintenance dosage RNF40 intron 19578179 rs199766404 chr16 30795481 C G 0.000013 Breast cancer ZNF629 missense 23555315 rs8058961 chr16 30809063 G A 9.03E-14 Acenocoumarol maintenance dosage / / 19578179 rs4889490 chr16 30823047 G T 2.33E-63 Acenocoumarol maintenance dosage / / 19578179 rs4889490 chr16 30823047 G T 4.95E-15 Warfarin responsiveness (phenprocoumon) / / 21063236 rs8046001 chr16 30833321 C T 7.40E-33 Acenocoumarol maintenance dosage / / 19578179 rs6565209 chr16 30837096 C T 7.96E-05 Multiple complex diseases / / 17554300 rs11864054 chr16 30846134 G A 5.57E-15 Warfarin responsiveness (phenprocoumon) / / 21063236 rs11150596 chr16 30850242 C T 1.81E-35 Acenocoumarol maintenance dosage / / 19578179 rs11150596 chr16 30850242 C T 2.18E-08 Warfarin responsiveness (phenprocoumon) / / 21063236 rs4889630 chr16 30877544 T C 3.90E-05 Psoriasis / / 19169255 rs9933843 chr16 30903679 C T 7.70E-06 Psoriasis BCL7C intron 19169255 rs9933843 chr16 30903679 C T 2.58E-47 Acenocoumarol maintenance dosage BCL7C intron 19578179 rs1046276 chr16 30914626 T C 5.35E-07 Red blood cell traits CTF1 UTR-3 23222517 rs11649653 chr16 30918487 C G 3.00E-08 Triglycerides / / 20686565 rs11649653 chr16 30918487 C G 8.46E-10 Warfarin responsiveness (phenprocoumon) / / 21063236 rs11649653 chr16 30918487 C G 0.00043 Coronary artery calcification / / 23727086 rs11649653 chr16 30918487 C G 2.00E-07 Triglycerides / / 24097068 rs12924903 chr16 30928970 A G 2.50E-40 Acenocoumarol maintenance dosage / / 19578179 rs3813020 chr16 30934075 G A 8.65E-07 Red blood cell traits / / 23222517 rs10782001 chr16 30942625 G A 9.00E-10 Psoriasis FBXL19 intron 20953189 rs10782001 chr16 30942625 G A 2.60E-07 Red blood cell traits FBXL19 intron 23222517 rs10782002 chr16 30946506 A G 1.11E-07 Red blood cell traits FBXL19 intron 23222517 rs7200879 chr16 30947572 A G 5.00E-19 Acenocoumarol maintenance dosage FBXL19 intron 19578179 rs1458202 chr16 30953202 G A 5.73E-08 Red blood cell traits FBXL19 intron 23222517 rs4889599 chr16 30968589 C T 6.09E-08 Red blood cell traits / / 23222517 rs2305884 chr16 30970741 G A 1.40E-05 Psoriasis SETD1A intron 19169255 rs2305884 chr16 30970741 G A 2.47E-42 Acenocoumarol maintenance dosage SETD1A intron 19578179 rs2305884 chr16 30970741 G A 4.70E-07 Red blood cell traits SETD1A intron 23222517 rs1870293 chr16 30970941 T C 2.13E-07 Red blood cell traits SETD1A intron 23222517 rs2054213 chr16 30971810 A G 4.37E-08 Red blood cell traits SETD1A intron 23222517 rs11150601 chr16 30977799 G A 2.21E-07 Red blood cell traits SETD1A intron 23222517 rs897986 chr16 30980902 T C 1.40E-05 Psoriasis SETD1A intron 19169255 rs897986 chr16 30980902 T C 1.43E-43 Acenocoumarol maintenance dosage SETD1A intron 19578179 rs897986 chr16 30980902 T C 4.71E-07 Red blood cell traits SETD1A intron 23222517 rs4889603 chr16 30982225 A G 6.75E-16 Warfarin responsiveness (phenprocoumon) SETD1A intron 21063236 rs4889603 chr16 30982225 A G 4.13E-05 Parkinson's disease SETD1A intron 22451204 rs4889525 chr16 30989858 T C 1.50E-07 Red blood cell traits SETD1A intron 23222517 rs6950 chr16 30995669 T A,C,G 4.28E-08 Red blood cell traits SETD1A UTR-3 23222517 rs2305880 chr16 30999462 T C 1.05E-07 Red blood cell traits HSD3B7 cds-synon 23222517 rs13708 chr16 31000809 G A,C,T 2.22E-08 Red blood cell traits STX1B UTR-3 23222517 rs8062719 chr16 31002664 A G 2.67E-07 Red blood cell traits STX1B UTR-3 23222517 rs8060857 chr16 31002720 G A 1.23E-07 Red blood cell traits STX1B UTR-3 23222517 rs17855121 chr16 31004169 T C 0.0000221 Alcohol craving with or without dependence STX1B cds-synon 22481050 rs12445568 chr16 31004812 T C 3.53E-47 Acenocoumarol maintenance dosage STX1B intron 19578179 rs12445568 chr16 31004812 T C 1.20E-16 Psoriasis STX1B intron 23143594 rs9788865 chr16 31009588 C T 8.38E-04 Type 2 diabetes STX1B intron 17463246 rs4889606 chr16 31011183 A G 1.60E-18 Warfarin responsiveness (phenprocoumon) STX1B intron 21063236 rs9926533 chr16 31014179 C T 1.60E-18 Warfarin responsiveness (phenprocoumon) STX1B intron 21063236 rs11150604 chr16 31037020 A T 2.10E-22 Warfarin responsiveness (phenprocoumon) / / 21063236 rs10871454 chr16 31048079 C T 5.00E-34 Warfarin maintenance dose STX4 intron 18535201 rs10871454 chr16 31048079 C T 2.00E-123 Acenocoumarol maintenance dosage STX4 intron 19578179 rs10871454 chr16 31048079 C T 2.10E-22 Warfarin responsiveness (phenprocoumon) STX4 intron 21063236 rs10871454 chr16 31048079 C T 0.00022 Coronary artery calcification STX4 intron 23727086 rs9939417 chr16 31053467 C T 1.65E-18 Warfarin responsiveness (phenprocoumon) / / 21063236 rs17839567 chr16 31057945 A G 3.45E-05 Lymphocyte counts / / 22286170 rs2303223 chr16 31075175 G A 2.08E-18 Warfarin responsiveness (phenprocoumon) ZNF668 cds-synon 21063236 rs881929 chr16 31079371 G T 2.85E-18 Warfarin responsiveness (phenprocoumon) ZNF668 intron 21063236 rs6565217 chr16 31083324 G A 9.93E-04 Type 2 diabetes ZNF668 intron 17463246 rs6565217 chr16 31083324 G A 6.16E-05 Lymphocyte counts ZNF668 intron 22286170 rs2303222 chr16 31085470 T C 3.86E-18 Warfarin responsiveness (phenprocoumon) ZNF668 UTR-5 21063236 rs749671 chr16 31088347 G A 4.45E-18 Warfarin responsiveness (phenprocoumon) ZNF646 cds-synon 21063236 rs749670 chr16 31088625 A G 5.18E-18 Warfarin responsiveness (phenprocoumon) ZNF646 missense 21063236 rs11865038 chr16 31095171 C T 4.00E-07 Parkinson's disease PRSS53 intron 22451204 rs7294 chr16 31102321 C T 1.40E-45 Acenocoumarol maintenance dosage VKORC1 UTR-3 19578179 rs7200749 chr16 31102589 G A 1 Drug response to Warfarin VKORC1 missense 16270629 rs2359612 chr16 31103796 A G 1 Drug response to Warfarin VKORC1 intron 16270629 rs2359612 chr16 31103796 A G 8.63E-18 Warfarin responsiveness (phenprocoumon) VKORC1 intron 21063236 rs8050894 chr16 31104509 C G 1 Drug response to Warfarin VKORC1 intron 16270629 rs8050894 chr16 31104509 C G 8.60E-18 Warfarin responsiveness (phenprocoumon) VKORC1 intron 21063236 rs9934438 chr16 31104878 G A 1 Drug response to Acenocoumarol VKORC1 intron 19270263 rs17708472 chr16 31105353 G A 1 Drug response to Warfarin VKORC1 intron 16270629 rs9923231 chr16 31107689 C A,G,T 1 Drug response to Warfarin VKORC1 nearGene-5 10073515 rs9923231 chr16 31107689 C A,G,T 1 Drug response to Warfarin VKORC1 nearGene-5 15001971 rs9923231 chr16 31107689 C A,G,T 1 Drug response to Warfarin VKORC1 nearGene-5 15284536 rs9923231 chr16 31107689 C A,G,T 1 Drug response to Warfarin VKORC1 nearGene-5 15888487 rs9923231 chr16 31107689 C A,G,T 1 Drug response to Warfarin VKORC1 nearGene-5 15930419 rs9923231 chr16 31107689 C A,G,T 1 Drug response to Warfarin VKORC1 nearGene-5 1597090 rs9923231 chr16 31107689 C A,G,T 1 Drug response to Warfarin VKORC1 nearGene-5 16580898 rs9923231 chr16 31107689 C A,G,T 1 Drug response to Warfarin VKORC1 nearGene-5 17510308 rs9923231 chr16 31107689 C A,G,T 1 Drug response to Warfarin VKORC1 nearGene-5 17635701 rs9923231 chr16 31107689 C A,G,T 1 Drug response to Warfarin VKORC1 nearGene-5 17846394 rs9923231 chr16 31107689 C A,G,T 1 Drug response to Warfarin VKORC1 nearGene-5 17906972 rs9923231 chr16 31107689 C A,G,T 1 Drug response to Warfarin VKORC1 nearGene-5 18056659 rs9923231 chr16 31107689 C A,G,T 1 Drug response to Warfarin VKORC1 nearGene-5 18250228 rs9923231 chr16 31107689 C A,G,T 1 Drug response to Warfarin VKORC1 nearGene-5 18252229 rs9923231 chr16 31107689 C A,G,T 1 Drug response to Warfarin VKORC1 nearGene-5 18281915 rs9923231 chr16 31107689 C A,G,T 1 Drug response to Warfarin VKORC1 nearGene-5 18305455 rs9923231 chr16 31107689 C A,G,T 1 Drug response to Warfarin VKORC1 nearGene-5 18855533 rs9923231 chr16 31107689 C A,G,T 1 Drug response to Warfarin VKORC1 nearGene-5 19228618 rs9923231 chr16 31107689 C A,G,T 3.00E-181 Warfarin maintenance dose VKORC1 nearGene-5 19300499 rs9923231 chr16 31107689 C A,G,T 1 Drug response to Warfarin VKORC1 nearGene-5 19794411 rs9923231 chr16 31107689 C A,G,T 9.00E-31 Warfarin maintenance dose VKORC1 nearGene-5 20833655 rs2032915 chr16 31117413 C T 6.99E-18 Warfarin responsiveness (phenprocoumon) / / 21063236 rs14235 chr16 31121793 G A 7.36E-18 Warfarin responsiveness (phenprocoumon) BCKDK cds-synon 21063236 rs889555 chr16 31122571 C T 6.56E-17 Acenocoumarol maintenance dosage BCKDK intron 19578179 rs749767 chr16 31124407 A G 3.08E-103 Acenocoumarol maintenance dosage / / 19578179 rs749767 chr16 31124407 A G 2.79E-17 Warfarin responsiveness (phenprocoumon) / / 21063236 rs9925964 chr16 31129895 A G 2.79E-17 Warfarin responsiveness (phenprocoumon) KAT8 intron 21063236 rs1978487 chr16 31129942 C T 7.82E-104 Acenocoumarol maintenance dosage KAT8 intron 19578179 rs1978487 chr16 31129942 C T 2.79E-17 Warfarin responsiveness (phenprocoumon) KAT8 intron 21063236 rs4527034 chr16 31131614 A G 6.82E-18 Warfarin responsiveness (phenprocoumon) KAT8 intron 21063236 rs11865499 chr16 31132250 A G 1.44E-17 Acenocoumarol maintenance dosage KAT8 intron 19578179 rs889548 chr16 31137712 C T 5.61E-106 Acenocoumarol maintenance dosage KAT8 intron 19578179 rs889548 chr16 31137712 C T 4.47E-18 Warfarin responsiveness (phenprocoumon) KAT8 intron 21063236 rs1549293 chr16 31141993 C T 4.37E-18 Warfarin responsiveness (phenprocoumon) KAT8 intron 21063236 rs12597511 chr16 31145219 C T 4.36E-18 Warfarin responsiveness (phenprocoumon) PRSS8 intron 21063236 rs2855475 chr16 31147548 G A 4.34E-18 Warfarin responsiveness (phenprocoumon) / / 21063236 rs17708638 chr16 31171174 C T 2.16E-08 Warfarin responsiveness (phenprocoumon) / / 21063236 rs57348955 chr16 31185882 G A 3.76E-08 Graves' disease / / 22922229 rs57348955 chr16 31185882 G A 5.13E-08 Graves' disease and Hashimoto's thyroiditis / / 22922229 rs741810 chr16 31193942 C A 4.68E-19 Acenocoumarol maintenance dosage FUS cds-synon 19578179 rs1052352 chr16 31195279 C T 7.20E-11 Warfarin responsiveness (phenprocoumon) FUS cds-synon 21063236 rs4889537 chr16 31203529 G C 3.65E-04 Type 2 diabetes FUS UTR-3 17463246 rs8056505 chr16 31214898 C T 2.49E-19 Acenocoumarol maintenance dosage PYCARD nearGene-5 19578179 rs2288005 chr16 31227908 C T 7.35E-11 Warfarin responsiveness (phenprocoumon) PYDC1 intron 21063236 rs1808430 chr16 31258993 G A 1.42E-04 Alzheimer's disease (late onset) / / 21460841 rs4561481 chr16 31259553 G A 1.06E-04 Alzheimer's disease (late onset) / / 21460841 rs889551 chr16 31260422 A G 1.35E-04 Alzheimer's disease (late onset) / / 21460841 rs4889640 chr16 31264267 C A 1.10E-04 Type 2 diabetes / / 17463246 rs4889640 chr16 31264267 C A 3.33E-17 Acenocoumarol maintenance dosage / / 19578179 rs4889640 chr16 31264267 C A 1.09E-04 Alzheimer's disease (late onset) / / 21460841 rs7193943 chr16 31271063 G A 3.95E-04 Type 2 diabetes ITGAM nearGene-5 17463246 rs1143679 chr16 31276811 G A 1.70E-17 Systemic lupus erythematosus ITGAM missense 19286673 rs1143679 chr16 31276811 G A 7.30E-04 Systemic lupus erythematosus ITGAM missense 19286673 rs1143679 chr16 31276811 G A 0.0000952 LDL cholesterol ITGAM missense 23063622 rs8048583 chr16 31279536 T C 6.26E-17 Acenocoumarol maintenance dosage ITGAM intron 19578179 rs2359661 chr16 31281147 A G 1.01E-07 Systemic lupus erythematosus and Systemic sclerosis ITGAM intron 23740937 rs1143680 chr16 31289396 T C 1.01E-08 Acenocoumarol maintenance dosage ITGAM missense 19578179 rs9937837 chr16 31298939 T G 7.70E-04 Systemic lupus erythematosus ITGAM intron 19286673 rs9937837 chr16 31298939 T G 7.90E-10 Systemic lupus erythematosus ITGAM intron 21408207 rs9937837 chr16 31298939 T G 7.00E-06 Systemic lupus erythematosus ITGAM intron 23273568 rs7190018 chr16 31301478 G A 3.44E-11 Systemic lupus erythematosus and Systemic sclerosis ITGAM intron 23740937 rs12928810 chr16 31311715 G A 0.00000406 LDL cholesterol ITGAM intron 23063622 rs9888739 chr16 31313253 C T 2.00E-23 Systemic lupus erythematosus ITGAM intron 18204446 rs9888739 chr16 31313253 C T 1.61E-23 Systemic lupus erythematosus ITGAM intron 19286673 rs9888739 chr16 31313253 C T 1.00E-15 Systemic lupus erythematosus ITGAM intron 21408207 rs9888739 chr16 31313253 C T 7.30E-05 Systemic lupus erythematosus ITGAM intron 23273568 rs9888739 chr16 31313253 C T 4.00E-11 Systemic lupus erythematosus ITGAM intron 24871463 rs11860650 chr16 31326706 C T 1.90E-20 Multiple sclerosis ITGAM intron 22190364 rs11860650 chr16 31326706 C T 1.00E-10 Systemic lupus erythematosus and Systemic sclerosis ITGAM intron 23740937 rs1143681 chr16 31332890 C T 4.31E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ITGAM cds-synon 21844884 rs11150610 chr16 31334236 C A 2.00E-06 Systemic lupus erythematosus ITGAM intron 19165918 rs11150610 chr16 31334236 C A 3.72E-28 Acenocoumarol maintenance dosage ITGAM intron 19578179 rs11150610 chr16 31334236 C A 1.89E-09 Warfarin responsiveness (phenprocoumon) ITGAM intron 21063236 rs7206295 chr16 31336519 T C 9.90E-05 Alzheimer's disease (late onset) ITGAM intron 21460841 rs1143683 chr16 31336888 C T 1.70E-04 Systemic lupus erythematosus ITGAM missense 19286673 rs1143683 chr16 31336888 C T 6.03E-08 Systemic lupus erythematosus ITGAM missense 19286673 rs1143683 chr16 31336888 C T 7.00E-04 Systemic lupus erythematosus ITGAM missense 19286673 rs1143683 chr16 31336888 C T 8.60E-05 Systemic lupus erythematosus ITGAM missense 23273568 rs7193268 chr16 31340997 C T 6.40E-04 Systemic lupus erythematosus ITGAM intron 19286673 rs7193268 chr16 31340997 C T 5.70E-10 Systemic lupus erythematosus ITGAM intron 21408207 rs7193268 chr16 31340997 C T 8.70E-05 Systemic lupus erythematosus ITGAM intron 23273568 rs1143678 chr16 31343005 C T 3.70E-16 Systemic lupus erythematosus ITGAM missense 18204446 rs1143678 chr16 31343005 C T 8.50E-14 Systemic lupus erythematosus ITGAM missense 19286673 rs1143678 chr16 31343005 C T 1.10E-09 Systemic lupus erythematosus ITGAM missense 21408207 rs1143678 chr16 31343005 C T 8.70E-05 Systemic lupus erythematosus ITGAM missense 23273568 rs9673519 chr16 31347557 T C 1.26E-04 Alzheimer's disease (late onset) / / 21460841 rs3925075 chr16 31347748 A G 1.68E-12 Acenocoumarol maintenance dosage / / 19578179 rs3925075 chr16 31347748 A G 5.00E-06 IgA nephropathy / / 22197929 rs11150612 chr16 31357760 G A 8.19E-24 Acenocoumarol maintenance dosage / / 19578179 rs4522435 chr16 31361923 T C 1.82E-04 Tourette syndrome / / 22889924 rs11574631 chr16 31363977 C T 2.55E-15 Acenocoumarol maintenance dosage / / 19578179 rs4548893 chr16 31364493 C T 2.36E-12 Systemic lupus erythematosus / / 18204446 rs4548893 chr16 31364493 C T 7.90E-10 Systemic lupus erythematosus / / 21408207 rs4548893 chr16 31364493 C T 0.000011 Major depressive disorder / / 22915352 rs11150614 chr16 31366016 A G 6.92E-15 Acenocoumarol maintenance dosage ITGAX nearGene-5 19578179 rs11574637 chr16 31368874 T C 3.00E-11 Systemic lupus erythematosus ITGAX intron 18204098 rs11574637 chr16 31368874 T C 4.23E-05 Body Mass Index ITGAX intron pha003007 rs8052139 chr16 31386862 C A 0.00000032 Asthma ITGAX intron 23040885 rs59889488 chr16 31391887 C T 0.0006 Prostate cancer ITGAX missense 23555315 rs2454908 chr16 31411185 C T 0.00000183 Alcohol craving with or without dependence ITGAD intron 22481050 rs2454908 chr16 31411185 C T 0.0000404 Alcohol dependence ITGAD intron 22481050 rs3116150 chr16 31498021 G A 0.000645 Salmonella-induced pyroptosis SLC5A2 intron 22837397 rs11865835 chr16 31509816 T C 0.000681 Height (Pygmy height) C16orf58 intron 22570615 rs7187900 chr16 31523113 A G 7.53E-04 Bulimia nervosa / / 23568457 rs7206531 chr16 31542415 T C 6.16E-05 C-Reactive Protein / / pha003070 rs4889548 chr16 31580530 A C 2.70E-04 Multiple complex diseases / / 17554300 rs8046892 chr16 31615193 G A 2.71E-04 Age-related macular degeneration / / 22125219 rs7204877 chr16 31665305 A G 3.61E-04 Alzheimer's disease (late onset) / / 21379329 rs1881318 chr16 31689102 G A 3.95E-04 Alzheimer's disease (late onset) / / 21379329 rs4632148 chr16 31707257 C T 4.01E-04 Alzheimer's disease (late onset) / / 21379329 rs1468158 chr16 31715931 T C 3.49E-04 Alzheimer's disease (late onset) KIAA0664L3 intron 21379329 rs17839518 chr16 31722285 G A 4.94E-04 Alzheimer's disease / / 17998437 rs929209 chr16 31743663 T C 3.27E-04 Alzheimer's disease (late onset) ZNF720 intron 21379329 rs8048741 chr16 31758245 G A 4.28E-04 Alzheimer's disease (late onset) ZNF720 intron 21379329 rs929207 chr16 31827215 C T 1.01E-04 Alcohol dependence / / 24277619 rs12927233 chr16 32137965 T C 5.21E-05 Orofacial clefts / / 22863734 rs13380637 chr16 32480924 C A 5.00E-06 Response to amphetamines / / 22952603 rs9939624 chr16 34202673 C A 6.35E-04 Multiple complex diseases / / 17554300 rs11149544 chr16 34228466 A G 8.50E-04 Multiple complex diseases / / 17554300 rs281594 chr16 34283775 A C 6.43E-04 Multiple complex diseases / / 17554300 rs281593 chr16 34286360 A G 6.52E-04 Multiple complex diseases / / 17554300 rs4581708 chr16 34321463 C A 4.02E-04 Type 2 diabetes / / 17463246 rs17841582 chr16 34530586 G T 1.87E-04 Multiple complex diseases / / 17554300 rs8055603 chr16 34568667 G A 1.85E-04 Multiple complex diseases / / 17554300 rs9926177 chr16 34592035 C G 4.55E-04 Multiple complex diseases / / 17554300 rs9939309 chr16 34609804 G A 5.03E-05 Multiple complex diseases LOC283914 intron 17554300 rs1540541 chr16 34663747 G A 5.49E-04 Multiple complex diseases / / 17554300 rs171123 chr16 34670858 G A 7.50E-04 Multiple complex diseases / / 17554300 rs17841571 chr16 34679678 T C 8.31E-04 Multiple complex diseases / / 17554300 rs62057608 chr16 34682193 C T 4.00E-06 Obesity-related traits / / 23251661 rs171125 chr16 34760967 C T 8.10E-06 Glioma / / 19578367 rs11860567 chr16 34790371 A G 5.49E-04 Multiple complex diseases / / 17554300 rs11863988 chr16 34790434 G A 1.48E-04 Multiple complex diseases / / 17554300 rs2306743 chr16 34791791 G C 5.86E-04 Type 2 diabetes / / 17463246 rs7198892 chr16 34813361 T G 1.76E-04 Multiple complex diseases / / 17554300 rs8054993 chr16 34822371 C A 3.79E-04 Multiple complex diseases / / 17554300 rs8057388 chr16 34850921 T C 5.92E-04 Multiple complex diseases / / 17554300 rs17841551 chr16 34877723 C T 4.29E-04 Multiple complex diseases / / 17554300 rs8058675 chr16 34923039 G A 4.18E-04 Multiple complex diseases / / 17554300 rs7194464 chr16 34962691 T C 7.97E-04 Multiple complex diseases / / 17554300 rs1393007 chr16 34964475 C G 4.02E-04 Type 2 diabetes / / 17463246 rs12599426 chr16 35088131 T C 3.00E-06 Palmitoleic acid (16:1n-7) plasma levels / / 23362303 rs2134083 chr16 35090200 G C 4.28E-04 Multiple complex diseases / / 17554300 rs11860826 chr16 35122095 A G 4.32E-04 Multiple complex diseases / / 17554300 rs7197337 chr16 46507944 T G 5.10E-04 Multiple complex diseases ANKRD26P1 intron 17554300 rs9935841 chr16 46539392 G A 5.62E-04 Suicide attempts in bipolar disorder ANKRD26P1 intron 21041247 rs1054722 chr16 46615362 T C 6.93E-05 Alzheimer's disease SHCBP1 UTR-3 17998437 rs35313904 chr16 46644903 G A 3.40E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) SHCBP1 intron 23648065 rs2075157 chr16 46764374 C T 4.67E-04 Suicide attempts in bipolar disorder MYLK3 intron 21041247 rs11247495 chr16 46804464 C T 3.60E-04 Suicide attempts in bipolar disorder / / 21041247 rs4967594 chr16 46916594 C A,T 5.82E-04 Multiple complex diseases / / 17554300 rs2034598 chr16 47001626 G A 1.14E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) D/JA2 intron 24023788 rs933511 chr16 47094850 A G 9.69E-04 Multiple complex diseases / / 17554300 rs11644557 chr16 47194051 T C 9.82E-06 Podoconiosis ITFG1 intron 22455414 rs16953067 chr16 47200165 A G 7.24E-04 Multiple complex diseases ITFG1 intron 17554300 rs3095627 chr16 47276820 G T 7.12E-04 Taste perception ITFG1 intron 22132133 rs2111227 chr16 47486817 C T 1.91E-04 Prion diseases ITFG1 intron 22210626 rs16945387 chr16 47544697 A G 1.50E-05 Urinary metabolites PHKB intron 21572414 rs7202866 chr16 47735030 G A 8.36E-04 Multiple complex diseases PHKB UTR-3 17554300 rs9929891 chr16 47912764 C T 1.55E-04 Multiple complex diseases LOC100507534 intron 17554300 rs9926879 chr16 47922185 T C 3.85E-04 Multiple complex diseases / / 17554300 rs8048189 chr16 47928844 G A 1.13E-04 Multiple complex diseases / / 17554300 rs16945894 chr16 48180110 C T 9.00E-06 Amyotrophic lateral sclerosis (sporadic) ABCC12 intron 24529757 rs16945916 chr16 48201432 T C 1.00E-04 Prostate cancer ABCC11 missense 21743057 rs11861031 chr16 48213167 T C 8.00E-05 Prostate cancer ABCC11 intron 21743057 rs7203695 chr16 48232536 A G 4.33E-05 Amyotrophic lateral sclerosis (sporadic) ABCC11 intron 24529757 rs8050120 chr16 48235577 C G 7.69E-04 Parkinson's disease ABCC11 intron 16252231 rs13335504 chr16 48252973 C T 3.37E-04 Multiple complex diseases ABCC11 intron 17554300 rs9941123 chr16 48255539 C T 4.60E-04 Multiple complex diseases ABCC11 intron 17554300 rs16946039 chr16 48294571 G A 4.36E-04 Parkinson's disease LONP2 intron 16252231 rs11076561 chr16 48308087 A G 5.56E-04 Parkinson's disease LONP2 intron 16252231 rs9302757 chr16 48336497 A G 5.38E-04 Parkinson's disease LONP2 intron 16252231 rs9933211 chr16 48352138 A G 3.93E-04 Parkinson's disease LONP2 intron 16252231 rs13338978 chr16 48368490 C G 3.84E-04 Parkinson's disease LONP2 intron 16252231 rs16946122 chr16 48377901 C T 5.58E-04 Multiple complex diseases LONP2 intron 17554300 rs8055028 chr16 48378114 A C 3.85E-04 Parkinson's disease LONP2 intron 16252231 rs11076564 chr16 48380165 A T 5.50E-04 Multiple complex diseases LONP2 intron 17554300 rs8051441 chr16 48384344 C A 8.93E-06 Odorant perception LONP2 intron 23910658 rs8055764 chr16 48384370 G A 9.55E-04 Alzheimer's disease LONP2 intron 17998437 rs9938490 chr16 48448086 T C 3.85E-04 Parkinson's disease / / 16252231 rs7197521 chr16 48474262 T C 7.76E-04 Stroke / / pha002886 rs7184700 chr16 48488527 A G 1.21E-04 Taste perception / / 22132133 rs2173715 chr16 48504364 G T 2.66E-04 Taste perception / / 22132133 rs1566467 chr16 48512981 T C 3.07E-04 Taste perception / / 22132133 rs8063059 chr16 48523443 C T 8.20E-04 Taste perception / / 22132133 rs41334049 chr16 48528824 G C 0.000706 Salmonella-induced pyroptosis / / 22837397 rs2062553 chr16 48531171 G T 1.87E-05 Taste perception / / 22132133 rs4785521 chr16 48532560 A G 3.97E-04 Taste perception / / 22132133 rs11076569 chr16 48532746 G A 4.13E-05 Taste perception / / 22132133 rs1001872 chr16 48538811 G A 4.65E-05 Taste perception / / 22132133 rs9925138 chr16 48554249 G T 2.34E-04 Taste perception / / 22132133 rs1224 chr16 48572817 G A 7.50E-05 Temporomandibular joint disorders N4BP1 UTR-3 23746317 rs3743779 chr16 48574040 T G 7.50E-05 Temporomandibular joint disorders N4BP1 UTR-3 23746317 rs1039340 chr16 48574637 A C 7.50E-05 Temporomandibular joint disorders N4BP1 UTR-3 23746317 rs1039341 chr16 48574869 C T 7.50E-05 Temporomandibular joint disorders N4BP1 UTR-3 23746317 rs12443883 chr16 48602733 C T 3.90E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) N4BP1 intron 23648065 rs6500394 chr16 48606657 T C 2.95E-04 Multiple complex diseases N4BP1 intron 17554300 rs4785524 chr16 48619941 G A 8.19E-04 Response to cytidine analogues (gemcitabine) N4BP1 intron 24483146 rs6500395 chr16 48621402 T C 6.00E-07 Response to tocilizumab in rheumatoid arthritis N4BP1 intron 22491018 rs1872656 chr16 48654075 A G 2.43E-04 Multiple complex diseases / / 17554300 rs7199206 chr16 48702538 T C 9.05E-06 Lymphocyte counts / / 22286170 rs2111243 chr16 48724897 C T 8.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4785251 chr16 48749050 T G 4.68E-04 Alzheimer's disease / / 22005930 rs1420722 chr16 48749535 A C 7.54E-04 Alzheimer's disease / / 22005930 rs6500407 chr16 48750797 C T 4.41E-04 Alzheimer's disease / / 22005930 rs1420721 chr16 48753664 T C 4.46E-04 Alzheimer's disease / / 22005930 rs1345436 chr16 48759641 T C 1.78E-04 Alzheimer's disease / / 22005930 rs7404238 chr16 48763325 G T 2.02E-04 Alzheimer's disease / / 22005930 rs9936686 chr16 48764023 G A 8.10E-05 Alzheimer's disease / / 22005930 rs12599325 chr16 48785822 C A 5.02E-04 Alzheimer's disease / / 22005930 rs8063922 chr16 48818856 C T 1.87E-05 Alzheimer's disease / / 22005930 rs1420702 chr16 48834325 G A 5.82E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12149083 chr16 48861920 T C 1.66E-04 Alzheimer's disease / / 22005930 rs11643759 chr16 48866421 C T 2.27E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1872694 chr16 48877631 A G 1.12E-05 Prostate cancer / / pha002878 rs933546 chr16 48881144 G T 5.20E-08 Metabolite levels / / 23281178 rs12598215 chr16 48890475 A C 5.73E-08 Metabolite levels / / 23281178 rs7404239 chr16 48891102 A G 1.00E-04 Prostate cancer / / 21743057 rs9934172 chr16 48891213 A G 1.00E-04 Prostate cancer / / 21743057 rs3095652 chr16 48891621 G A 1.00E-04 Prostate cancer / / 21743057 rs8055353 chr16 48892246 T C 1.00E-04 Prostate cancer / / 21743057 rs1362586 chr16 48892858 T C 1.00E-04 Prostate cancer / / 21743057 rs1362587 chr16 48893109 C T 1.00E-04 Prostate cancer / / 21743057 rs41481745 chr16 48893266 T A 7.02E-04 Multiple complex diseases / / 17554300 rs3103020 chr16 48896563 T A 1.00E-04 Prostate cancer / / 21743057 rs874880 chr16 48899937 A G 3.24E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1345399 chr16 48907300 C G 8.30E-04 Multiple complex diseases / / 17554300 rs1420585 chr16 48995896 C T 6.76E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs1548928 chr16 49016770 A G 7.41E-05 Response to hepatitis C treatment / / 19684573 rs1972586 chr16 49019194 A G 6.10E-06 Serum metabolites / / 19043545 rs4785157 chr16 49023060 G A 8.14E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs16946750 chr16 49031941 T C 8.25E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1075875 chr16 49038220 T C 4.80E-04 Amyotrophic lateral sclerosis / / 23624525 rs13332755 chr16 49047944 G T 5.91E-04 HIV-1 viral setpoint / / 17641165 rs2908866 chr16 49051381 T C 1.41E-05 Colorectal cancer / / 21242260 rs2967303 chr16 49101879 C G 5.96E-04 Suicide attempts in bipolar disorder / / 21041247 rs2967260 chr16 49103092 T A 6.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs7205094 chr16 49103564 G T 3.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs2967255 chr16 49111515 A C 7.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs2967254 chr16 49112140 T C 7.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs11859884 chr16 49113163 A G 2.67E-06 Social autistic-like traits / / 24133439 rs1009302 chr16 49113335 C T 2.68E-06 Social autistic-like traits / / 24133439 rs1009301 chr16 49113477 T G 2.68E-06 Social autistic-like traits / / 24133439 rs9972834 chr16 49115007 G A 3.92E-04 Smoking cessation / / 24665060 rs1420612 chr16 49115353 G T 2.72E-06 Social autistic-like traits / / 24133439 rs2967249 chr16 49115636 T C 4.70E-05 Serum metabolites / / 19043545 rs10521175 chr16 49115962 C A 2.75E-06 Social autistic-like traits / / 24133439 rs2908915 chr16 49117050 C T 6.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs9635530 chr16 49117411 A C 2.54E-06 Social autistic-like traits / / 24133439 rs9635530 chr16 49117411 A C 9.22E-04 Response to alcohol consumption (flushing response) / / 24277619 rs16946876 chr16 49118099 T C 2.54E-06 Social autistic-like traits / / 24133439 rs16946880 chr16 49119449 C T 2.53E-06 Social autistic-like traits / / 24133439 rs16946881 chr16 49119787 C T 2.53E-06 Social autistic-like traits / / 24133439 rs4785276 chr16 49121379 A G 8.46E-06 Social autistic-like traits / / 24133439 rs11860027 chr16 49122315 C T 2.52E-06 Social autistic-like traits / / 24133439 rs7499215 chr16 49122930 G T 2.51E-06 Social autistic-like traits / / 24133439 rs1345408 chr16 49123174 C G 4.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs1345407 chr16 49123518 C T 8.90E-06 Urinary metabolites / / 21572414 rs1345406 chr16 49124038 A C 2.69E-06 Social autistic-like traits / / 24133439 rs1345405 chr16 49124128 A G 2.69E-06 Social autistic-like traits / / 24133439 rs1345404 chr16 49124169 A G 2.69E-06 Social autistic-like traits / / 24133439 rs1362594 chr16 49125344 C G 4.09E-06 Social autistic-like traits / / 24133439 rs1861572 chr16 49126988 T A 2.67E-06 Social autistic-like traits / / 24133439 rs753858 chr16 49127550 T C 2.66E-06 Social autistic-like traits / / 24133439 rs4785161 chr16 49129088 C A 2.66E-06 Social autistic-like traits / / 24133439 rs1558757 chr16 49134293 C A 5.70E-04 Smoking cessation / / 24665060 rs2883805 chr16 49136065 G T 2.59E-06 Social autistic-like traits / / 24133439 rs16946931 chr16 49142506 T C 2.00E-06 Social autistic-like traits / / 24133439 rs1397590 chr16 49160042 A G 8.25E-04 Response to alcohol consumption (flushing response) / / 24277619 rs11866376 chr16 49241775 A G 1.44E-04 Multiple complex diseases / / 17554300 rs729517 chr16 49251979 T C 2.15E-04 Type 2 diabetes / / 17463246 rs1510989 chr16 49295607 T C 1.85E-05 Esophageal cancer (squamous cell) / / 22960999 rs17775330 chr16 49331140 T C 1.87E-04 Multiple complex diseases / / 17554300 rs8052939 chr16 49344719 A G 2.00E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs8052686 chr16 49344886 C T 1.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7195955 chr16 49347749 T C 3.99E-05 Obesity (extreme) / / 21935397 rs2883894 chr16 49350689 T A 6.04E-05 Obesity (extreme) / / 21935397 rs1894975 chr16 49350745 G T 6.04E-05 Obesity (extreme) / / 21935397 rs12923050 chr16 49351341 C T 6.07E-05 Obesity (extreme) / / 21935397 rs2216263 chr16 49353504 A T 6.08E-05 Obesity (extreme) / / 21935397 rs152710 chr16 49354794 C T 6.09E-05 Obesity (extreme) / / 21935397 rs152709 chr16 49358701 T C 9.09E-04 Obesity (extreme) / / 21935397 rs152708 chr16 49358944 A G 3.03E-04 Obesity (extreme) / / 21935397 rs152707 chr16 49359121 A G 4.62E-05 Obesity (extreme) / / 21935397 rs152712 chr16 49360358 C T 4.93E-05 Obesity (extreme) / / 21935397 rs152713 chr16 49361181 C T 4.94E-05 Obesity (extreme) / / 21935397 rs27788 chr16 49363512 T C 8.72E-04 Obesity (extreme) / / 21935397 rs27789 chr16 49363837 C T 8.32E-04 Obesity (extreme) / / 21935397 rs27790 chr16 49364144 C T 8.36E-04 Obesity (extreme) / / 21935397 rs27791 chr16 49364516 A G 4.76E-05 Obesity (extreme) / / 21935397 rs27920 chr16 49365121 T A 6.77E-05 Obesity (extreme) / / 21935397 rs27793 chr16 49365661 A G 5.23E-05 Obesity (extreme) / / 21935397 rs12931576 chr16 49366706 C T 3.81E-04 Alzheimer's disease (late onset) / / 21379329 rs36507 chr16 49368188 A G 7.41E-05 Obesity (extreme) / / 21935397 rs8057939 chr16 49394276 T C 5.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs27813 chr16 49412531 A G 4.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C16orf78 intron 20877124 rs27783 chr16 49412608 G A 7.93E-05 Cognitive impairment induced by topiramate C16orf78 intron 22091778 rs27807 chr16 49438040 A G 9.53E-04 Alzheimer's disease / / 22005930 rs152654 chr16 49444746 A G 1.60E-16 Narcolepsy / / 19629137 rs9928068 chr16 49444763 T C 4.33E-04 Acute lung injury / / 22295056 rs7186041 chr16 49493503 C T 5.04E-04 Multiple complex diseases / / 17554300 rs4785310 chr16 49504166 A C 6.07E-05 Lung cancer / / 18978787 rs7201926 chr16 49537339 T C 5.75E-05 Fibrinogen ZNF423 intron pha003068 rs1861659 chr16 49565261 A C 7.89E-04 Amyotrophic Lateral Sclerosis ZNF423 intron 17362836 rs2080637 chr16 49570013 C T 2.61E-04 Amyotrophic Lateral Sclerosis ZNF423 intron 17362836 rs6500232 chr16 49588606 G T 9.57E-05 Multiple complex diseases ZNF423 intron 17554300 rs12933502 chr16 49589395 C T 5.41E-05 Cognitive impairment induced by topiramate ZNF423 intron 22091778 rs746158 chr16 49593526 T C 2.20E-05 Erythrocyte counts ZNF423 intron pha003101 rs9932213 chr16 49616858 T C 1.80E-05 Personality dimensions ZNF423 intron 18957941 rs9934292 chr16 49630102 T C 9.90E-04 Type 2 diabetes ZNF423 intron 17463246 rs16947676 chr16 49632029 A G 5.67E-04 Smoking quantity ZNF423 intron 24665060 rs2098421 chr16 49639815 G A 8.85E-05 Height ZNF423 intron 17255346 rs2080501 chr16 49643566 G A 8.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZNF423 intron 20877124 rs2080501 chr16 49643566 G A 4.00E-06 IgG glycosylation ZNF423 intron 23382691 rs2080501 chr16 49643566 G A 5.00E-06 IgG glycosylation ZNF423 intron 23382691 rs7203818 chr16 49644298 G A 4.03E-04 Tourette syndrome ZNF423 intron 22889924 rs13333217 chr16 49649940 C T 4.00E-04 Smoking initiation ZNF423 intron 24665060 rs11076489 chr16 49650937 T G 5.32E-04 Smoking initiation ZNF423 intron 24665060 rs16944158 chr16 49652779 T G 4.00E-06 IgG glycosylation ZNF423 intron 23382691 rs1861339 chr16 49683938 C T 8.72E-04 Type 2 diabetes ZNF423 intron 17463246 rs2540736 chr16 49684321 T C 8.11E-04 Type 2 diabetes ZNF423 intron 17463246 rs12444011 chr16 49686558 A C,G,T 2.20E-05 Urinary metabolites ZNF423 intron 21572414 rs12444011 chr16 49686558 A C,G,T 7.71E-04 Smoking quantity ZNF423 intron 24665060 rs9938109 chr16 49688918 G A 7.64E-04 Type 2 diabetes ZNF423 intron 17463246 rs9302740 chr16 49688949 T C 3.64E-04 Type 2 diabetes ZNF423 intron 17463246 rs1990629 chr16 49717571 G A 9.00E-04 Endometriosis ZNF423 intron 21151130 rs1990629 chr16 49717571 G A 7.56E-05 Systemic sclerosis ZNF423 intron 21750679 rs1477020 chr16 49720240 T C 2.49E-05 Systemic sclerosis ZNF423 intron 21750679 rs1861341 chr16 49723520 C G 2.60E-05 Parkinson's disease (age of onset) ZNF423 intron 19772629 rs766985 chr16 49739038 T G 7.34E-04 Smoking initiation ZNF423 intron 24665060 rs8055357 chr16 49743137 A G 3.85E-04 Smoking initiation ZNF423 intron 24665060 rs9927179 chr16 49743339 G A 7.21E-04 Smoking initiation ZNF423 intron 24665060 rs17281813 chr16 49750790 T C 3.00E-06 Inattentive symptoms ZNF423 intron 18821565 rs1477025 chr16 49811433 T C 8.00E-04 Acute lymphoblastic leukemia (childhood) ZNF423 intron 20189245 rs17210965 chr16 49820164 G A 1.67E-04 Alzheimer's disease ZNF423 intron 22005930 rs4785193 chr16 49820598 C T 1.63E-04 Alzheimer's disease ZNF423 intron 22005930 rs11076499 chr16 49828405 G A 9.71E-05 Soluble levels of adhesion molecules ZNF423 intron pha003072 rs8060157 chr16 49830204 A G 8.29E-05 Soluble levels of adhesion molecules ZNF423 intron pha003072 rs11649602 chr16 49835709 G A 3.43E-04 Smoking cessation ZNF423 intron 24665060 rs750589 chr16 49836271 A G 2.60E-05 Coronary heart disease ZNF423 intron 21971053 rs750589 chr16 49836271 A G 8.31E-04 Alzheimer's disease ZNF423 intron 22005930 rs750589 chr16 49836271 A G 9.86E-06 Soluble levels of adhesion molecules ZNF423 intron pha003072 rs4785358 chr16 49839782 G A 4.14E-05 Asthma ZNF423 intron pha003128 rs4074849 chr16 49844664 C T 0.000537842 Hypertension (early onset hypertension) ZNF423 intron 22479346 rs12443775 chr16 49861119 G C 9.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs16948031 chr16 49863504 G A 7.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs16948031 chr16 49863504 G A 7.52E-04 Smoking initiation / / 24665060 rs933558 chr16 49866005 G A 2.04E-04 Coronary heart disease / / 21971053 rs2160565 chr16 49877102 A G 4.52E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs8058644 chr16 49896680 C T 1.95E-06 Postoperative ventricular dysfunction / / 21980348 rs12709072 chr16 49911620 G A 4.81E-05 Warfarin maintenance dose / / 19300499 rs4785195 chr16 49932806 T G 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10521193 chr16 49941230 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs17212761 chr16 49946893 C T 8.44E-04 Type 2 diabetes / / 17463246 rs4785367 chr16 49956194 T C 8.30E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4785367 chr16 49956194 T C 9.02E-06 Response to gemcitabine in pancreatic cancer / / 22142827 rs2058809 chr16 49958723 T C 8.33E-05 Bipolar disorder and schizophrenia / / 20889312 rs4785371 chr16 49980751 C T 2.65E-04 Cholesterol / / 17255346 rs4785371 chr16 49980751 C T 6.83E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7191565 chr16 49982174 C T 4.20E-06 Urinary metabolites / / 21572414 rs7204868 chr16 49984353 C A,T 1.71E-04 Myocardial Infarction / / pha002883 rs6500271 chr16 49997941 G T 1.48E-04 Epilepsy / / 22116939 rs7204293 chr16 50028105 G A 1.42E-05 Testicular germ cell tumor / / 23666239 rs9934218 chr16 50028605 C T 0.000585 Salmonella-induced pyroptosis / / 22837397 rs1187411 chr16 50034680 G A 8.09E-04 Type 2 diabetes / / 17463246 rs7204814 chr16 50048951 A G 6.62E-04 Schizophrenia / / 19197363 rs17213285 chr16 50062313 G A 9.36E-04 Type 2 diabetes CNEP1R1 intron 17463246 rs7201173 chr16 50062611 G A 9.36E-06 Carotenoid and tocopherol levels CNEP1R1 intron 19185284 rs9941089 chr16 50072298 G A 0.000353 Salmonella-induced pyroptosis / / 22837397 rs4785201 chr16 50089192 A G 4.53E-06 Alcohol dependence / / 19581569 rs11649294 chr16 50091335 C T 5.13E-04 Multiple complex diseases / / 17554300 rs4785204 chr16 50103734 C T 2.00E-20 Esophageal cancer (squamous cell) HEATR3 intron 22960999 rs8051216 chr16 50113773 C T 5.33E-04 Type 2 diabetes HEATR3 intron 17463246 rs8051216 chr16 50113773 C T 5.73E-04 Schizophrenia HEATR3 intron 19197363 rs7191639 chr16 50114098 G A 3.82E-04 Multiple complex diseases HEATR3 intron 17554300 rs877639 chr16 50118245 G A 7.21E-04 Schizophrenia HEATR3 intron 19197363 rs8046148 chr16 50142944 A G 3.00E-06 Testicular germ cell tumor LOC100505488 intron 23666239 rs8046148 chr16 50142944 A G 4.00E-09 Testicular germ cell tumor LOC100505488 intron 23666240 rs8046148 chr16 50142944 A G 4.18E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) LOC100505488 intron 24023788 rs7206735 chr16 50148508 T C 3.49E-07 Esophageal cancer (squamous cell) LOC100505488 intron 22960999 rs1477126 chr16 50237330 C T 5.26E-05 Multiple complex diseases PAPD5 intron 17554300 rs4785393 chr16 50259483 A G 2.53E-04 Longevity PAPD5 intron 22279548 rs7184802 chr16 50355996 G A 1.92E-05 Adipocyte fatty acid-binding protein concentration,in serum BRD7 intron 21863005 rs1990684 chr16 50427554 C T 4.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs11648136 chr16 50436523 C T 7.62E-04 Type 2 diabetes / / 17463246 rs9941219 chr16 50437528 C T 4.00E-06 Liver enzyme levels (alanine transaminase) / / 24124411 rs731660 chr16 50441208 C A 4.06E-06 Liver enzyme levels (alanine transaminase) / / 24124411 rs4369662 chr16 50443200 T C 4.90E-06 Crohn's disease / / 17804789 rs4598913 chr16 50443407 C T 3.43E-04 Taste perception / / 22132133 rs7192726 chr16 50444891 C T 4.21E-04 Taste perception / / 22132133 rs4483840 chr16 50445412 G T 4.70E-06 Crohn's disease / / 17804789 rs7204069 chr16 50451650 A G 4.21E-04 Taste perception / / 22132133 rs4785419 chr16 50461051 G T 2.50E-05 Urinary metabolites / / 21572414 rs1861543 chr16 50464110 C T 5.11E-06 Crohn's disease / / 17804789 rs1592538 chr16 50502844 A G 3.33E-04 Multiple complex diseases / / 17554300 rs6500315 chr16 50508101 A G 3.98E-07 Multiple complex diseases / / 17554300 rs6500315 chr16 50508101 A G 1.04E-06 Crohn's disease / / 17804789 rs8044151 chr16 50523194 G A 4.47E-04 Type 2 diabetes / / 17463246 rs8044151 chr16 50523194 G A 5.14E-05 Schizophrenia / / 19571809 rs1592473 chr16 50525105 T G 3.85E-05 Crohn's disease / / 17804789 rs12149258 chr16 50536826 A G 7.73E-05 Crohn's disease / / 17804789 rs1990623 chr16 50565970 A G 3.16E-06 Crohn's disease / / 17804789 rs11642187 chr16 50578449 A C 6.69E-04 Coronary Artery Disease / / 17634449 rs4785433 chr16 50586941 C G 9.38E-04 Coronary Artery Disease NKD1 intron 17634449 rs4785220 chr16 50627378 T C 2.31E-08 Crohn's disease NKD1 intron 17804789 rs8046845 chr16 50660764 G A 4.33E-07 Crohn's disease NKD1 intron 17804789 rs8047222 chr16 50660962 G A 2.40E-04 Multiple complex diseases NKD1 intron 17554300 rs1558663 chr16 50662844 G A 1.00E-07 Crohn's disease NKD1 intron 17804789 rs11640716 chr16 50665089 T G 4.97E-07 Crohn's disease NKD1 intron 17804789 rs7198686 chr16 50666566 T C 7.00E-07 Crohn's disease NKD1 intron 17804789 rs12913 chr16 50668426 T C 4.00E-07 Crohn's disease NKD1 UTR-3 17804789 rs745230 chr16 50670182 G C 4.30E-07 Crohn's disease NKD1 UTR-3 17804789 rs12924696 chr16 50671721 G A 1.97E-08 Crohn's disease NKD1 UTR-3 17804789 rs749985 chr16 50673651 T C 1.42E-06 Crohn's disease NKD1 UTR-3 17804789 rs7199150 chr16 50676514 G A 9.05E-04 Multiple complex diseases / / 17554300 rs9926095 chr16 50679315 A C 6.00E-07 Crohn's disease / / 17804789 rs7186163 chr16 50686557 A C 2.65E-07 Multiple complex diseases / / 17554300 rs7186163 chr16 50686557 A C 3.00E-07 Crohn's disease / / 17804789 rs2066849 chr16 50687015 C T 6.24E-07 Multiple complex diseases / / 17554300 rs8050932 chr16 50687673 C T 1.25E-05 Multiple complex diseases / / 17554300 rs8050932 chr16 50687673 C T 1.58E-07 Crohn's disease / / 17804789 rs1109863 chr16 50692364 G A 3.16E-08 Crohn's disease / / 17804789 rs6596 chr16 50709723 G A 4.71E-29 Crohn's disease SNX20 cds-synon 17804789 rs7202124 chr16 50714029 G A 2.38E-05 Crohn's disease SNX20 intron 17804789 rs2066848 chr16 50715185 G A 1.51E-09 Crohn's disease SNX20 UTR-5 17804789 rs8062727 chr16 50718041 G A 7.67E-05 Crohn's disease / / 17804789 rs9302752 chr16 50719103 T C 4.00E-40 Leprosy / / 20018961 rs9302752 chr16 50719103 T C 4.24E-18 Leprosy / / 22019778 rs9302752 chr16 50719103 T C 1.45E-12 Leprosy / / pha002872 rs1420685 chr16 50719674 T C 7.05E-05 Crohn's disease / / 17804789 rs2004804 chr16 50720917 G A 5.11E-05 Crohn's disease / / 17804789 rs1981760 chr16 50723074 C T 6.12E-05 Crohn's disease / / 17804789 rs9933594 chr16 50724087 G C 9.28E-04 Multiple complex diseases / / 17554300 rs7194886 chr16 50725193 C T 2.93E-05 Crohn's disease / / 17804789 rs7194886 chr16 50725193 C T 1.77E-30 Leprosy / / 20018961 rs7194886 chr16 50725193 C T 2.42E-07 Leprosy / / pha002872 rs4785224 chr16 50730446 G A 1.01E-06 Crohn's disease NOD2 nearGene-5 17804789 rs2076753 chr16 50733374 G T 8.63E-23 Crohn's disease NOD2 intron 17804789 rs2111235 chr16 50733969 A G 4.16E-06 Crohn's disease NOD2 intron 17804789 rs8057341 chr16 50737980 A G 2.14E-09 Crohn's disease NOD2 intron 17804789 rs8057341 chr16 50737980 A G 5.53E-05 Leprosy NOD2 intron 20018961 rs17221417 chr16 50739582 C G 4.00E-11 Crohn's disease NOD2 intron 17554300 rs17221417 chr16 50739582 C G 4.11E-25 Crohn's disease NOD2 intron 17804789 rs17312836 chr16 50741462 A C 8.90E-07 Multiple complex diseases NOD2 intron 17554300 rs17312836 chr16 50741462 A C 4.00E-07 Crohn's disease NOD2 intron 17804789 rs11647841 chr16 50743331 G A 1.55E-06 Crohn's disease NOD2 intron 17804789 rs2066842 chr16 50744624 C T 3.49E-07 Crohn's disease NOD2 missense 17804789 rs2066843 chr16 50745199 C T 2.86E-09 Crohn's disease NOD2 cds-synon 17068223 rs2066843 chr16 50745199 C T 8.00E-04 Type 2 diabetes NOD2 cds-synon 17463246 rs2066843 chr16 50745199 C T 1.16E-12 Multiple complex diseases NOD2 cds-synon 17554300 rs1861759 chr16 50745583 T G 7.62E-07 Multiple complex diseases NOD2 cds-synon 17554300 rs2066844 chr16 50745926 C T 1.29E-18 Crohn's disease NOD2 missense 17684544 rs2066844 chr16 50745926 C T 2.61E-10 Crohn's disease NOD2 missense 17804789 rs17313265 chr16 50747704 C T 7.31E-29 Crohn's disease NOD2 intron 17804789 rs751271 chr16 50751175 T G 2.92E-04 Multiple complex diseases NOD2 intron 17554300 rs751271 chr16 50751175 T G 5.26E-11 Crohn's disease NOD2 intron 17804789 rs748855 chr16 50751398 A G 2.63E-07 Multiple complex diseases NOD2 intron 17554300 rs1861758 chr16 50751787 G A 5.31E-07 Multiple complex diseases NOD2 intron 17554300 rs7203691 chr16 50753424 G A 1.37E-06 Crohn's disease NOD2 intron 17804789 rs10521209 chr16 50755709 T G 8.65E-05 Crohn's disease NOD2 intron 17684544 rs2066845 chr16 50756540 G C,T 7.44E-10 Crohn's disease NOD2 missense 17684544 rs2066845 chr16 50756540 G C,T 1.00E-45 Crohn's disease NOD2 missense 17804789 rs2066845 chr16 50756540 G C,T 4.62E-08 Crohn's disease NOD2 missense 18587394 rs5743289 chr16 50756774 C G,T 1.00E-06 Crohn's disease NOD2 intron 17447842 rs5743289 chr16 50756774 C G,T 6.00E-17 Crohn's disease NOD2 intron 17804789 rs5743289 chr16 50756774 C G,T 4.00E-10 Inflammatory bowel disease NOD2 intron 18758464 rs2076756 chr16 50756881 A G 5.00E-10 Inflammatory bowel disease NOD2 intron 17068223 rs2076756 chr16 50756881 A G 7.00E-14 Crohn's disease NOD2 intron 17435756 rs2076756 chr16 50756881 A G 4.60E-04 Multiple complex diseases NOD2 intron 17554300 rs2076756 chr16 50756881 A G 1.00E-21 Crohn's disease NOD2 intron 17684544 rs2076756 chr16 50756881 A G 1.00E-09 Crohn's disease NOD2 intron 17804789 rs2076756 chr16 50756881 A G 4.00E-69 Crohn's disease NOD2 intron 21102463 rs2076756 chr16 50756881 A G 1.00E-37 Crohn's disease NOD2 intron 22412388 rs2076756 chr16 50756881 A G 3.00E-10 Crohn's disease NOD2 intron 22936669 rs5743291 chr16 50757276 G A 1.00E-20 Crohn's disease NOD2 missense 17804789 rs749910 chr16 50758849 G A 1.84E-31 Crohn's disease NOD2 intron 17804789 rs1077861 chr16 50759547 A T 9.00E-04 Gamma gluatamyl transferase levels (interaction with age) NOD2 intron 22010049 rs199883290 chr16 50763778 G C 2.51E-49 Crohn's disease NOD2 frameshift 17684544 rs199883290 chr16 50763778 G C 3.00E-24 Crohn's disease NOD2 frameshift 18587394 rs199883290 chr16 50763778 G C 2.00E-15 Crohn's disease NOD2 frameshift 20570966 rs199883290 chr16 50763778 G C 3.00E-24 Asthma NOD2 frameshift 21150878 rs199883290 chr16 50763778 G C 6.00E-209 Crohn's disease NOD2 frameshift 23128233 rs2066847 chr16 50763778 G GC 2.51E-49 Crohn's disease NOD2 frameshift 17684544 rs2066847 chr16 50763778 G GC 3.00E-24 Crohn's disease NOD2 frameshift 18587394 rs2066847 chr16 50763778 G GC 2.00E-15 Crohn's disease NOD2 frameshift 20570966 rs2066847 chr16 50763778 G GC 3.00E-24 Asthma NOD2 frameshift 21150878 rs2066847 chr16 50763778 G GC 6.00E-209 Crohn's disease NOD2 frameshift 23128233 rs540973741 chr16 50763778 G GC 2.51E-49 Crohn's disease NOD2 frameshift 17684544 rs540973741 chr16 50763778 G GC 3.00E-24 Crohn's disease NOD2 frameshift 18587394 rs540973741 chr16 50763778 G GC 2.00E-15 Crohn's disease NOD2 frameshift 20570966 rs540973741 chr16 50763778 G GC 3.00E-24 Asthma NOD2 frameshift 21150878 rs540973741 chr16 50763778 G GC 6.00E-209 Crohn's disease NOD2 frameshift 23128233 rs5743293 chr16 50763778 G GC 2.51E-49 Crohn's disease NOD2 frameshift 17684544 rs5743293 chr16 50763778 G GC 3.00E-24 Crohn's disease NOD2 frameshift 18587394 rs5743293 chr16 50763778 G GC 2.00E-15 Crohn's disease NOD2 frameshift 20570966 rs5743293 chr16 50763778 G GC 3.00E-24 Asthma NOD2 frameshift 21150878 rs5743293 chr16 50763778 G GC 6.00E-209 Crohn's disease NOD2 frameshift 23128233 rs3135499 chr16 50766127 A C 1.11E-08 Multiple complex diseases NOD2 UTR-3 17554300 rs3135499 chr16 50766127 A C 1.62E-08 Crohn's disease NOD2 UTR-3 17804789 rs8056611 chr16 50767647 A G 6.68E-07 Crohn's disease / / 17804789 rs751919 chr16 50775745 T G 2.00E-07 Crohn's disease CYLD nearGene-5 17804789 rs8060598 chr16 50781802 T C 4.14E-08 Multiple complex diseases CYLD intron 17554300 rs8060598 chr16 50781802 T C 3.16E-08 Crohn's disease CYLD intron 17804789 rs3785142 chr16 50787147 G A 1.77E-07 Multiple complex diseases CYLD intron 17554300 rs7342715 chr16 50787483 A G 6.03E-09 Multiple complex diseases CYLD intron 17554300 rs7342715 chr16 50787483 A G 1.26E-07 Crohn's disease CYLD intron 17804789 rs3135503 chr16 50791250 T G 4.24E-08 Multiple complex diseases CYLD intron 17554300 rs3135503 chr16 50791250 T G 3.16E-08 Crohn's disease CYLD intron 17804789 rs4785450 chr16 50792268 C T 3.72E-07 Multiple complex diseases CYLD intron 17554300 rs9925070 chr16 50800647 T G 2.66E-08 Multiple complex diseases CYLD intron 17554300 rs11859674 chr16 50802715 G A 9.94E-05 Potassium levels CYLD intron pha003086 rs1420873 chr16 50803756 G C 2.50E-05 Urinary metabolites CYLD intron 21572414 rs6500331 chr16 50808726 G A 1.89E-07 Crohn's disease CYLD intron 17804789 rs16948813 chr16 50811964 G A 1.04E-05 Orofacial clefts CYLD intron 22419666 rs8062540 chr16 50817932 A G 9.73E-07 Crohn's disease CYLD intron 17804789 rs2111435 chr16 50819910 C T 2.60E-05 Crohn's disease CYLD intron 17804789 rs4785226 chr16 50822964 A C 7.50E-06 Crohn's disease CYLD intron 17804789 rs2066852 chr16 50827518 C T 2.69E-05 Potassium levels CYLD cds-synon pha003086 rs2302759 chr16 50827601 A G 7.00E-07 Crohn's disease CYLD intron 17804789 rs2160683 chr16 50829853 A T 2.27E-06 Crohn's disease CYLD intron 17804789 rs17223592 chr16 50837947 G A 2.69E-05 Potassium levels / / pha003086 rs1861762 chr16 50839648 T C 2.27E-06 Crohn's disease / / 17804789 rs4785452 chr16 50842077 T C 1.79E-05 Crohn's disease / / 17804789 rs12922698 chr16 50848973 C T 4.26E-09 Crohn's disease / / 17804789 rs17224078 chr16 50851829 C T 5.61E-04 Type 2 diabetes / / 17463246 rs16948876 chr16 50854418 G A 2.00E-10 Leprosy / / 22019778 rs1548992 chr16 50859055 T C 5.32E-04 Tourette syndrome / / 22889924 rs6500336 chr16 50865549 T G 4.83E-04 Multiple complex diseases / / 17554300 rs11643967 chr16 50882811 C T 2.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1496647 chr16 50905010 A C 4.93E-04 Schizophrenia / / 19197363 rs16948994 chr16 50911946 T C 5.23E-04 Multiple complex diseases / / 17554300 rs2029923 chr16 50916464 C A 3.63E-05 Crohn's disease / / 17804789 rs2357934 chr16 50917845 G A 5.95E-05 Rheumatoid arthritis / / 17804836 rs1948558 chr16 50928855 G A 4.97E-04 Alzheimer's disease / / 24755620 rs8061762 chr16 50932584 G A 4.92E-04 Alzheimer's disease / / 24755620 rs1507047 chr16 50932779 C T 3.83E-05 Type 2 diabetes / / 17463246 rs1507048 chr16 50932797 A G 7.36E-05 Type 2 diabetes / / 17463246 rs9929432 chr16 50935442 G A 1.80E-05 Urinary metabolites / / 21572414 rs1507051 chr16 50939067 G A 1.40E-05 Urinary metabolites / / 21572414 rs17226979 chr16 50949161 A G 2.48E-04 Multiple complex diseases / / 17554300 rs17226979 chr16 50949161 A G 6.18E-06 Crohn's disease / / 17804789 rs9935378 chr16 50973078 C T 1.18E-05 Crohn's disease / / 17804789 rs4785482 chr16 50974725 C T 1.09E-05 Crohn's disease / / 17804789 rs17325379 chr16 50976307 A T 7.57E-04 Multiple complex diseases / / 17554300 rs17325379 chr16 50976307 A T 2.13E-05 Crohn's disease / / 17804789 rs1872679 chr16 50978048 T G 8.49E-06 Crohn's disease / / 17804789 rs4785483 chr16 50979745 G C 9.86E-06 Crohn's disease / / 17804789 rs6500350 chr16 50984731 C G 3.66E-05 Crohn's disease / / 17804789 rs1564981 chr16 50986308 G A 2.00E-10 Bone mineral density / / 22504420 rs4785484 chr16 50988142 G C 2.02E-05 Crohn's disease / / 17804789 rs17228232 chr16 50988750 G A 3.21E-05 Post-operative nausea and vomiting / / 21694509 rs2129247 chr16 50990540 C T 3.44E-05 Crohn's disease / / 17804789 rs1528602 chr16 50999201 T C 1.82E-05 Crohn's disease / / 17804789 rs2129250 chr16 51007618 G A 5.70E-05 Crohn's disease / / 17804789 rs16949179 chr16 51009198 T C 7.36E-05 Crohn's disease / / 17804789 rs8046199 chr16 51012547 G A 4.62E-05 Post-operative nausea and vomiting / / 21694509 rs1566045 chr16 51021803 T C 2.00E-22 Bone mineral density / / 22504420 rs1566045 chr16 51021803 T C 0.000000257 Femoral neck bone mineral density (premenopausal) / / 23074152 rs4785231 chr16 51047959 C T 0.00007138 Sarcoidosis / / 22952805 rs9797107 chr16 51048046 T A 0.00001775 Sarcoidosis / / 22952805 rs9796882 chr16 51048047 C A 0.00001752 Sarcoidosis / / 22952805 rs16949212 chr16 51049988 G T 3.58E-04 Type 2 diabetes / / 17463246 rs16949212 chr16 51049988 G T 4.84E-04 Multiple complex diseases / / 17554300 rs10521219 chr16 51063914 T C 4.86E-04 Multiple complex diseases / / 17554300 rs4785235 chr16 51064083 T C 2.70E-04 Bone mineral density / / 24249740 rs7191446 chr16 51068059 A G 5.78E-05 Crohn's disease / / 17804789 rs978556 chr16 51075461 T G 9.72E-04 Type 2 diabetes / / 17463246 rs1354809 chr16 51078756 C G 5.04E-04 Type 2 diabetes / / 17463246 rs1567152 chr16 51079160 C T 7.38E-04 Type 2 diabetes / / 17463246 rs4002339 chr16 51083162 G T 4.70E-06 Coronary heart disease / / pha003030 rs8060595 chr16 51083636 A G 2.13E-05 Crohn's disease / / 17804789 rs924131 chr16 51097687 T G 0.000460314 Hypertension (early onset hypertension) / / 22479346 rs10852612 chr16 51124309 G A 3.50E-06 Urinary metabolites / / 21572414 rs10521221 chr16 51130159 C T 9.51E-04 Alcohol dependence / / 24277619 rs17329124 chr16 51130564 T A 8.67E-04 Self-reported allergy / / 23817569 rs8059264 chr16 51131382 C A 6.97E-04 Self-reported allergy / / 23817569 rs747432 chr16 51133202 C A 2.20E-05 Urinary metabolites / / 21572414 rs747431 chr16 51133268 G A 7.58E-04 Self-reported allergy / / 23817569 rs8061957 chr16 51136552 C T 2.10E-05 Urinary metabolites / / 21572414 rs11646341 chr16 51138255 C T 7.54E-04 Self-reported allergy / / 23817569 rs1826824 chr16 51139345 G A 3.19E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1852740 chr16 51140364 G T 7.44E-04 Self-reported allergy / / 23817569 rs4238821 chr16 51144335 T C 9.51E-04 Alcohol dependence / / 24277619 rs10521222 chr16 51158710 C T 9.00E-13 C-reactive protein / / 21300955 rs10852613 chr16 51201830 C T 1.00E-04 Prostate cancer / / 21743057 rs7185923 chr16 51245487 T C 9.86E-05 Cognitive test performance / / 20125193 rs7185923 chr16 51245487 T C 4.00E-06 Weight loss (gastric bypass surgery) / / 23643386 rs7500931 chr16 51279824 T C 9.89E-04 Alcohol dependence / / 21314694 rs7185437 chr16 51289593 T G 5.15E-04 Multiple complex diseases / / 17554300 rs7185437 chr16 51289593 T G 9.03E-05 Serum metabolites / / 19043545 rs4131099 chr16 51330531 G A 4.00E-06 Personality dimensions / / 20691247 rs10521242 chr16 51357210 A G 1.00E-04 Information processing speed / / 21130836 rs10521240 chr16 51357322 C A 6.18E-04 Rheumatoid arthritis / / 21452313 rs11076452 chr16 51374733 C T 1.70E-05 Urinary metabolites / / 21572414 rs7206160 chr16 51385984 A C 2.30E-05 Personality dimensions / / 18957941 rs1420997 chr16 51422518 G A 7.61E-05 Information processing speed / / 21130836 rs17616633 chr16 51451683 T C 7.40E-05 White matter hyperintensity burden / / 21681796 rs1362756 chr16 51458290 C G 5.00E-09 Optic disc parameters / / 20548946 rs11649384 chr16 51468005 T G 3.99E-04 Blood pressure / / 17255346 rs7193789 chr16 51469209 T A 3.30E-04 Blood pressure / / 17255346 rs7193789 chr16 51469209 T A 5.00E-04 Type 2 diabetes / / 17463246 rs17532886 chr16 51469346 A G 3.30E-04 Blood pressure / / 17255346 rs17532886 chr16 51469346 A G 5.00E-04 Type 2 diabetes / / 17463246 rs17532886 chr16 51469346 A G 9.02E-06 Paget's disease / / 20436471 rs1110488 chr16 51495009 G T 0.00001973 Sarcoidosis / / 22952805 rs13338826 chr16 51497459 C G 6.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs1109739 chr16 51499207 G A 0.0000413 Central corneal thickness in patients with an IOP <= 21mmHg and no history of IOP>= 21mmHg / / 22661486 rs2379054 chr16 51499412 G T 9.98E-06 Waist Circumference / / pha003023 rs1080791 chr16 51500120 A G 9.98E-06 Waist Circumference / / pha003023 rs1391729 chr16 51545245 G A 3.22E-05 Coronary heart disease / / pha003032 rs10521238 chr16 51562530 G A 4.45E-05 Tourette syndrome / / 22889924 rs8053972 chr16 51565812 A G 7.42E-04 Tourette syndrome / / 22889924 rs10521237 chr16 51567231 T G 1.33E-05 Coronary heart disease / / pha003032 rs4783832 chr16 51589991 G A 2.30E-05 Urinary metabolites / / 21572414 rs16949983 chr16 51590758 C T 3.95E-04 Smoking cessation / / 24665060 rs1072858 chr16 51593364 C T 4.50E-06 Urinary metabolites / / 21572414 rs8062350 chr16 51597037 A G 7.00E-06 Urinary metabolites / / 21572414 rs2173454 chr16 51598869 G A 7.00E-06 Urinary metabolites / / 21572414 rs2380107 chr16 51599260 T G 7.76E-04 Multiple complex diseases / / 17554300 rs16950026 chr16 51604634 C T 5.53E-04 Rheumatoid arthritis / / 21452313 rs1909338 chr16 51605142 A G 4.30E-06 Urinary metabolites / / 21572414 rs1353788 chr16 51606021 A G 4.99E-04 Rheumatoid arthritis / / 21452313 rs2030114 chr16 51609947 G A 2.00E-06 Blood pressure measurement (high sodium and potassium intervention) / / 24165912 rs2030114 chr16 51609947 G A 7.00E-13 Blood pressure measurement (high sodium and potassium intervention) / / 24165912 rs16950037 chr16 51610561 G A 2.86E-04 Multiple complex diseases / / 17554300 rs1498780 chr16 51611098 G C 6.70E-06 Urinary metabolites / / 21572414 rs2647967 chr16 51658435 C T 4.04E-04 Premature ovarian failure / / 19508998 rs2647967 chr16 51658435 C T 8.44E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs2647969 chr16 51666146 T G 9.36E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs2647970 chr16 51666246 A G 9.44E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs2647971 chr16 51667865 T C 4.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs2647972 chr16 51668195 T C 4.21E-04 Suicide attempts in bipolar disorder / / 21041247 rs7204626 chr16 51678263 T C 1.19E-04 Suicide attempts in bipolar disorder / / 21041247 rs4254326 chr16 51678773 G A 1.83E-04 Cholesterol / / 17255346 rs7190369 chr16 51685714 C T 9.40E-06 Urinary metabolites / / 21572414 rs4275850 chr16 51693036 C A 1.69E-05 Odorant perception / / 23910658 rs4587972 chr16 51700026 T C 3.22E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16950188 chr16 51705337 C T 3.00E-05 Prostate cancer / / 21743057 rs1381451 chr16 51715875 G A 1.00E-05 Prostate cancer / / 21743057 rs1381451 chr16 51715875 G A 6.90E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1461928 chr16 51722029 C T 6.17E-04 Premature ovarian failure / / 19508998 rs12595945 chr16 51734008 T C 9.89E-04 Obesity (extreme) / / 21935397 rs17342711 chr16 51765573 A G 2.37E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10521246 chr16 51766077 A T 1.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1564002 chr16 51767734 G A 7.21E-04 Premature ovarian failure / / 19508998 rs8045957 chr16 51771624 C T 6.00E-04 Premature ovarian failure / / 19508998 rs17258888 chr16 51788698 A G 7.40E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2169430 chr16 51813861 T C 3.16E-05 Premature ovarian failure / / 19508998 rs2169430 chr16 51813861 T C 3.16E-05 Other erythrocyte phenotypes / / 19862010 rs16944951 chr16 51820998 C T 4.23E-06 Asthma (childhood onset) / / 23829686 rs2126337 chr16 51822621 C T 3.50E-05 Premature ovarian failure / / 19508998 rs2126337 chr16 51822621 C T 3.50E-05 Other erythrocyte phenotypes / / 19862010 rs2892063 chr16 51855425 G A 9.90E-04 Multiple complex diseases / / 17554300 rs10521044 chr16 51878423 G A 4.15E-05 Cognitive test performance / / 20125193 rs3912519 chr16 51883388 G A 7.09E-05 Cognitive test performance / / 20125193 rs12599301 chr16 51892130 C T 2.01E-05 Eosinophil counts / / pha003088 rs11076194 chr16 51903470 A G 4.66E-05 Colorectal cancer / / 19723657 rs4784958 chr16 52021630 C T 7.81E-05 Coronary heart disease / / pha003031 rs256596 chr16 52062912 C A 9.70E-05 Alcohol dependence LOC388276 intron 24277619 rs1592477 chr16 52083691 C T 5.60E-05 Alcohol dependence LOC388276 intron 24277619 rs28493173 chr16 52084917 A G 9.72E-04 Multiple complex diseases LOC388276 intron 17554300 rs33364 chr16 52089135 G T 2.61E-04 Alcohol dependence LOC388276 intron 24277619 rs12931290 chr16 52102937 C T 5.00E-06 Asthma LOC388276 intron 21790008 rs42771 chr16 52104747 G A 6.27E-04 Alcohol dependence LOC388276 intron 24277619 rs4785102 chr16 52186729 T C 0.000821563 Hypertension (early onset hypertension) / / 22479346 rs1894899 chr16 52198041 C T 4.38E-04 Multiple complex diseases / / 17554300 rs2540765 chr16 52207132 A C 0.000821563 Hypertension (early onset hypertension) / / 22479346 rs2540759 chr16 52212011 G A 0.000821563 Hypertension (early onset hypertension) / / 22479346 rs8061839 chr16 52213504 T G 0.000892 Salmonella-induced pyroptosis / / 22837397 rs17353227 chr16 52219763 A G 9.13E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1641354 chr16 52221210 G A 0.000176273 Hypertension (early onset hypertension) / / 22479346 rs1362382 chr16 52224990 G T 0.000386214 Hypertension (early onset hypertension) / / 22479346 rs1641365 chr16 52240559 G T 9.58E-05 Hypertension (early onset hypertension) / / 22479346 rs7189391 chr16 52246621 T A 1.99E-04 Glycosylated haemoglobin levels / / 17255346 rs2540742 chr16 52251307 G A 0.000722697 Hypertension (early onset hypertension) / / 22479346 rs1076081 chr16 52262091 T C 0.000340289 Hypertension (early onset hypertension) / / 22479346 rs3095543 chr16 52272607 T C 0.000416595 Hypertension (early onset hypertension) / / 22479346 rs1420210 chr16 52279119 G A 7.00E-05 Hypertension (early onset hypertension) / / 22479346 rs1362376 chr16 52291939 T C 1.18E-04 Smoking cessation / / 24665060 rs1362377 chr16 52300064 T C 6.11E-04 Multiple complex diseases / / 17554300 rs10521261 chr16 52300255 T G 1.35E-04 Smoking cessation / / 24665060 rs1345311 chr16 52301052 C T 4.98E-04 Multiple complex diseases / / 17554300 rs1861315 chr16 52301822 A C 7.67E-05 Hypertension (early onset hypertension) / / 22479346 rs6498798 chr16 52310527 G A 4.39E-04 Smoking initiation / / 24665060 rs10521263 chr16 52312632 T C 6.11E-05 Myopia (pathological) / / 21095009 rs10521263 chr16 52312632 T C 0.000800877 Hypertension (early onset hypertension) / / 22479346 rs10521263 chr16 52312632 T C 2.30E-04 Smoking initiation / / 24665060 rs1477013 chr16 52314396 T A 6.37E-05 Serum metabolites / / 19043545 rs16951015 chr16 52317810 G A 2.01E-04 Myopia (pathological) / / 21095009 rs12597387 chr16 52318510 T A 5.43E-05 Serum metabolites / / 19043545 rs11075433 chr16 52320342 T C 6.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16951021 chr16 52321976 T C 3.00E-07 Methotrexate phramacokinetics (acute lymphoblastic leukemia) / / 19901119 rs1420198 chr16 52323195 A G 1.65E-04 HIV-1 viral setpoint / / 17641165 rs1420198 chr16 52323195 A G 4.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1420198 chr16 52323195 A G 6.28E-04 Smoking initiation / / 24665060 rs4784165 chr16 52347819 T G 4.00E-11 Polycystic ovary syndrome / / 22885925 rs12927194 chr16 52366446 C T 0.0000838 Polycystic ovary syndrome / / 22951595 rs12927194 chr16 52366446 C T 8.38E-05 Intracranial aneurysm / / 22961961 rs1079926 chr16 52386456 A G 4.31E-04 Parkinson's disease / / 17052657 rs7202238 chr16 52389818 T C 4.60E-05 Bone mineral density (BMD),in women / / 20164292 rs11648686 chr16 52393396 A G 1.78E-05 HIV-1 progression / / 20064070 rs12932054 chr16 52402916 G A 5.70E-06 Urinary metabolites / / 21572414 rs9302550 chr16 52405521 C T 2.53E-05 Serum metabolites / / 19043545 rs1420528 chr16 52417241 C G 2.20E-05 Serum metabolites / / 19043545 rs1125832 chr16 52421140 T A 3.38E-04 Alcohol dependence / / 21314694 rs2193104 chr16 52445871 G C 2.60E-05 Urinary metabolites / / 21572414 rs1420537 chr16 52453567 A C 3.68E-04 Alzheimer's disease / / 24755620 rs1420540 chr16 52466181 C A 4.45E-04 Body mass index / / 21701565 rs1420546 chr16 52488707 C T 8.68E-04 Alzheimer's disease TOX3 intron 22005930 rs8051542 chr16 52534167 T C 1.00E-12 Breast cancer TOX3 intron 17529967 rs4784220 chr16 52535810 T C 1.52E-12 Breast cancer (early onset) TOX3 intron 24493630 rs4784221 chr16 52537526 A G 2.77E-04 Depression (quantitative trait) TOX3 intron 20800221 rs4784221 chr16 52537526 A G 2.19E-04 Obesity (extreme) TOX3 intron 21935397 rs9933638 chr16 52539597 A G 6.85E-10 Breast cancer (early onset) TOX3 intron 24493630 rs12443621 chr16 52548037 A G 2.00E-19 Breast cancer TOX3 intron 17529967 rs8046979 chr16 52555742 A G 2.30E-05 Alcohol and nictotine co-dependence TOX3 intron 20158304 rs8046979 chr16 52555742 A G 2.68E-10 Breast cancer (early onset) TOX3 intron 24493630 rs1420531 chr16 52558834 G A 3.04E-04 Depression (quantitative trait) TOX3 intron 20800221 rs1420531 chr16 52558834 G A 2.53E-04 Obesity (extreme) TOX3 intron 21935397 rs1420533 chr16 52563626 G A 9.23E-10 Breast cancer (early onset) TOX3 intron 24493630 rs2193094 chr16 52566454 T G 9.09E-10 Breast cancer (early onset) TOX3 intron 24493630 rs11648477 chr16 52570969 T C 3.06E-04 Depression (quantitative trait) TOX3 intron 20800221 rs11648477 chr16 52570969 T C 2.54E-04 Obesity (extreme) TOX3 intron 21935397 rs9931232 chr16 52572832 G A 1.21E-09 Breast cancer (early onset) TOX3 intron 24493630 rs4784223 chr16 52575907 A G 6.00E-21 Breast cancer (early onset) TOX3 intron 24493630 rs3803662 chr16 52586341 A G 1.00E-36 Breast cancer / / 17529967 rs3803662 chr16 52586341 A G 6.00E-19 Breast cancer / / 17529974 rs3803662 chr16 52586341 A G 1.00E-09 Breast cancer / / 19330030 rs3803662 chr16 52586341 A G 3.00E-15 Breast cancer / / 20453838 rs3803662 chr16 52586341 A G 1.00E-36 Nasopharyngeal carcinoma / / 20512145 rs3803662 chr16 52586341 A G 4.00E-07 Breast cancer / / 20872241 rs3803662 chr16 52586341 A G 3.40E-05 Breast cancer / / 22452962 rs3803662 chr16 52586341 A G 4.00E-15 Breast cancer (male) / / 23001122 rs3803662 chr16 52586341 A G 2.00E-114 Breast cancer / / 23535729 rs3803662 chr16 52586341 A G 6.00E-13 Breast cancer / / 23535733 rs3803662 chr16 52586341 A G 3.00E-11 Breast cancer / / 24143190 rs4594251 chr16 52597844 C T 5.54E-04 Depression (quantitative trait) LOC643714 intron 20800221 rs4594251 chr16 52597844 C T 3.21E-04 Obesity (extreme) LOC643714 intron 21935397 rs4784227 chr16 52599188 C T 1.00E-28 Breast cancer LOC643714 intron 20585626 rs4784227 chr16 52599188 C T 3.90E-09 Breast cancer (ER positive) LOC643714 intron 23555315 rs4784227 chr16 52599188 C T 6.00E-11 Breast cancer LOC643714 intron 23555315 rs4784228 chr16 52600618 A G 3.31E-04 Obesity (extreme) LOC643714 intron 21935397 rs3104751 chr16 52603028 C T 1.71E-04 Depression (quantitative trait) LOC643714 intron 20800221 rs3104751 chr16 52603028 C T 3.59E-04 Obesity (extreme) LOC643714 intron 21935397 rs3104753 chr16 52603911 C T 1.75E-04 Depression (quantitative trait) LOC643714 intron 20800221 rs3104753 chr16 52603911 C T 3.72E-04 Obesity (extreme) LOC643714 intron 21935397 rs3481 chr16 52605096 A G 1.76E-04 Depression (quantitative trait) LOC643714 intron 20800221 rs3481 chr16 52605096 A G 3.75E-04 Obesity (extreme) LOC643714 intron 21935397 rs16951281 chr16 52605300 C T 5.93E-04 Multiple complex diseases LOC643714 intron 17554300 rs3104755 chr16 52606237 A G 1.76E-04 Depression (quantitative trait) LOC643714 intron 20800221 rs3104755 chr16 52606237 A G 3.75E-04 Obesity (extreme) LOC643714 intron 21935397 rs3112562 chr16 52608263 C G 1.73E-04 Depression (quantitative trait) LOC643714 intron 20800221 rs3112562 chr16 52608263 C G 3.68E-04 Obesity (extreme) LOC643714 intron 21935397 rs10521267 chr16 52608672 G T 1.83E-06 Multiple complex diseases LOC643714 intron 17554300 rs3104758 chr16 52609033 C A 1.01E-04 Telomere length LOC643714 intron 21573004 rs1109951 chr16 52612044 C T 2.31E-04 Depression (quantitative trait) LOC643714 intron 20800221 rs1109951 chr16 52612044 C T 2.82E-04 Obesity (extreme) LOC643714 intron 21935397 rs3112638 chr16 52612619 C T 2.00E-04 Depression (quantitative trait) LOC643714 intron 20800221 rs3112638 chr16 52612619 C T 2.82E-04 Obesity (extreme) LOC643714 intron 21935397 rs12935019 chr16 52613037 G A 1.73E-04 Depression (quantitative trait) LOC643714 intron 20800221 rs12935019 chr16 52613037 G A 2.81E-04 Obesity (extreme) LOC643714 intron 21935397 rs3104763 chr16 52613581 A G 1.71E-04 Depression (quantitative trait) LOC643714 intron 20800221 rs3104763 chr16 52613581 A G 2.81E-04 Obesity (extreme) LOC643714 intron 21935397 rs4784230 chr16 52618113 T C 1.70E-04 Depression (quantitative trait) LOC643714 intron 20800221 rs4784230 chr16 52618113 T C 2.81E-04 Obesity (extreme) LOC643714 intron 21935397 rs11645620 chr16 52618953 C T 1.62E-04 Depression (quantitative trait) LOC643714 intron 20800221 rs11645620 chr16 52618953 C T 2.25E-04 Obesity (extreme) LOC643714 intron 21935397 rs3112633 chr16 52620577 C T 1.59E-04 Depression (quantitative trait) LOC643714 intron 20800221 rs3112633 chr16 52620577 C T 1.68E-04 Obesity (extreme) LOC643714 intron 21935397 rs11640537 chr16 52622112 G A 1.57E-04 Depression (quantitative trait) LOC643714 intron 20800221 rs11640537 chr16 52622112 G A 1.67E-04 Obesity (extreme) LOC643714 intron 21935397 rs6498960 chr16 52623637 C T 5.60E-04 Depression (quantitative trait) LOC643714 intron 20800221 rs6498960 chr16 52623637 C T 2.91E-04 Obesity (extreme) LOC643714 intron 21935397 rs4262942 chr16 52623836 T G 5.60E-04 Depression (quantitative trait) LOC643714 intron 20800221 rs4262942 chr16 52623836 T G 2.89E-04 Obesity (extreme) LOC643714 intron 21935397 rs2335 chr16 52624446 T G 3.98E-04 Depression (quantitative trait) LOC643714 intron 20800221 rs2335 chr16 52624446 T G 2.88E-04 Obesity (extreme) LOC643714 intron 21935397 rs3104767 chr16 52624738 G T 9.00E-19 Restless legs syndrome LOC643714 intron 21779176 rs12922061 chr16 52635000 C T 4.00E-10 Breast cancer LOC643714 intron 24143190 rs3112612 chr16 52635164 G A 4.00E-10 Breast cancer LOC643714 intron 21263130 rs3104800 chr16 52646376 G A 7.72E-04 Multiple complex diseases / / 17554300 rs3112609 chr16 52648731 C G 5.99E-04 Multiple complex diseases / / 17554300 rs3104824 chr16 52679093 A C 8.62E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs16951516 chr16 52690704 C T 1.56E-04 Amyotrophic lateral sclerosis / / 20801718 rs4500723 chr16 52702013 C T 4.08E-05 Response to metformin / / 21186350 rs4386133 chr16 52706844 G A 8.04E-05 Response to metformin / / 21186350 rs12932515 chr16 52712547 G T 8.91E-05 Response to metformin / / 21186350 rs1420247 chr16 52748342 C A,G,T 8.99E-05 Multiple complex diseases / / 17554300 rs1420247 chr16 52748342 C A,G,T 2.10E-05 Urinary metabolites / / 21572414 rs11642888 chr16 52802136 T C 5.96E-05 Response to metformin / / 21186350 rs7196680 chr16 52802181 T C 7.78E-05 Response to metformin / / 21186350 rs2387818 chr16 52803247 T G 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4377151 chr16 52803515 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs9923965 chr16 52806057 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1894898 chr16 52817511 G A 6.07E-04 Multiple complex diseases / / 17554300 rs1420258 chr16 52821637 A G 3.52E-06 Tetralogy of Fallot / / 23297363 rs7190231 chr16 52823984 G A 5.98E-04 Multiple complex diseases / / 17554300 rs8044632 chr16 52830966 T C 8.89E-04 Multiple complex diseases / / 17554300 rs6499100 chr16 52831462 T C 1.00E-06 Tetralogy of Fallot / / 23297363 rs1579237 chr16 52833422 T C 2.16E-04 Alcohol dependence / / 20201924 rs1579237 chr16 52833422 T C 1.53E-06 Tetralogy of Fallot / / 23297363 rs1420239 chr16 52876611 T C 4.47E-05 Multiple complex diseases / / 17554300 rs11640993 chr16 52886605 G A 3.41E-06 Multiple complex diseases / / 17554300 rs7188309 chr16 52886767 G A 4.09E-05 Multiple complex diseases / / 17554300 rs2387823 chr16 52888119 C G 2.89E-06 Multiple complex diseases / / 17554300 rs10521275 chr16 52907039 C T 3.63E-05 Multiple complex diseases / / 17554300 rs4461066 chr16 52911609 C T 3.10E-05 Subclinical atherosclerosis / / 17903303 rs1344484 chr16 52912299 T C 1.64E-06 Multiple complex diseases / / 17554300 rs1344484 chr16 52912299 T C 2.00E-06 Bipolar disorder / / 21254220 rs1344485 chr16 52912332 A G 1.78E-06 Multiple complex diseases / / 17554300 rs8056052 chr16 52912738 C G 4.22E-06 Multiple complex diseases / / 17554300 rs8061856 chr16 52913327 A G 9.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2192859 chr16 52914749 C T 1.88E-06 Multiple complex diseases / / 17554300 rs11647459 chr16 52915751 C T 2.92E-06 Multiple complex diseases / / 17554300 rs12930501 chr16 52921779 G A 6.00E-04 Alcohol dependence / / 20201924 rs12919591 chr16 52923038 A G 1.20E-06 Urinary metabolites / / 21572414 rs1362441 chr16 52928126 T G 8.39E-04 Multiple complex diseases / / 17554300 rs6499142 chr16 52929034 T G 2.95E-04 Type 2 diabetes / / 17463246 rs9934468 chr16 52932090 C T 0.00076 Salmonella-induced pyroptosis / / 22837397 rs11075661 chr16 52937499 T A 9.28E-04 Type 2 diabetes / / 17463246 rs12149387 chr16 52939464 A C 9.87E-04 Type 2 diabetes / / 17463246 rs1345339 chr16 52945609 G A 1.74E-04 Telomere length / / 23900074 rs13353184 chr16 52960945 A G 7.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9922822 chr16 52976666 T G 4.75E-04 Smoking initiation / / 24665060 rs9930106 chr16 52997498 A G 6.77E-05 Arthritis (juvenile idiopathic) / / 22354554 rs13335763 chr16 53002558 G A 1.65E-05 Telomere length / / 23900074 rs4784281 chr16 53004508 A T 8.73E-04 Alcohol dependence / / 21314694 rs7203946 chr16 53010486 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7201711 chr16 53036298 C T 3.03E-16 Multiple complex diseases / / 17554300 rs6499205 chr16 53037529 T C 1.15E-04 Body mass index / / 21701565 rs6499205 chr16 53037529 T C 2.72E-04 Body mass index / / 21701565 rs1420316 chr16 53045141 A G 8.72E-04 Body mass index / / 21701565 rs8051957 chr16 53054410 A G 7.23E-05 Blood Pressure / / pha002898 rs4002283 chr16 53072119 C T 1.50E-05 Triglycerides / / pha003080 rs10852453 chr16 53073788 T A 1.00E-06 IgG glycosylation / / 23382691 rs10852454 chr16 53073854 A G 1.48E-06 Triglycerides / / pha003080 rs7198530 chr16 53083566 G T 1.70E-05 Urinary metabolites / / 21572414 rs9937509 chr16 53100136 A G 2.80E-05 Urinary metabolites CHD9 intron 21572414 rs8050947 chr16 53126338 C T 2.90E-05 Urinary metabolites CHD9 intron 21572414 rs7199440 chr16 53135032 C T 3.00E-05 Prostate cancer CHD9 intron 21743057 rs7204230 chr16 53192331 T C 1.00E-10 Fibrinogen CHD9 intron 23969696 rs1073454 chr16 53196042 A G 5.88E-05 Bilirubin levels,in serum CHD9 intron 19389676 rs1421069 chr16 53197934 A G 1.33E-04 Lung function (forced expiratory volume in 1 second) CHD9 intron 24023788 rs2388011 chr16 53213419 A G 1.06E-04 Lung function (forced expiratory volume in 1 second) CHD9 intron 24023788 rs58474046 chr16 53253710 T C 2.84E-04 Crohn's disease CHD9 intron 23850713 rs6499548 chr16 53341748 T G 9.65E-04 Birth weight CHD9 missense 17255346 rs6499548 chr16 53341748 T G 1.02E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CHD9 missense 24023788 rs6499548 chr16 53341748 T G 6.22E-05 Lung function (forced expiratory volume in 1 second) CHD9 missense 24023788 rs2908792 chr16 53412419 T C 7.83E-04 Lymphocyte counts / / 22286170 rs2908796 chr16 53422359 T G 2.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs7203132 chr16 53429775 G A 9.38E-04 Multiple complex diseases / / 17554300 rs1074182 chr16 53471357 T G 3.17E-05 Tuberculosis RBL2 intron 24057671 rs16952252 chr16 53483980 C A 1.71E-04 Multiple complex diseases RBL2 intron 17554300 rs9929873 chr16 53490676 C T 1.49E-04 Multiple complex diseases RBL2 intron 17554300 rs7204496 chr16 53496598 G A 1.48E-04 Multiple complex diseases RBL2 intron 17554300 rs8061388 chr16 53503440 G T 3.59E-04 Multiple complex diseases RBL2 intron 17554300 rs8043918 chr16 53513033 C T 9.96E-05 Multiple complex diseases RBL2 intron 17554300 rs8049033 chr16 53513055 T C 2.28E-04 Multiple complex diseases RBL2 intron 17554300 rs17801498 chr16 53513452 C G 1.95E-04 Multiple complex diseases RBL2 intron 17554300 rs7189819 chr16 53536345 C T 4.17E-04 Amyotrophic lateral sclerosis (sporadic) AKTIP intron 24529757 rs11863156 chr16 53556090 C T 0.0000786 Bipolar disorder / / 23637625 rs10521294 chr16 53562595 G A 3.15E-05 Cognitive test performance / / 20125193 rs10521296 chr16 53563244 G A 6.46E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs8060020 chr16 53588064 G A 5.41E-04 Type 2 diabetes / / 17463246 rs12597881 chr16 53596366 G A 8.13E-04 Obesity (extreme) / / 21935397 rs12928335 chr16 53614746 C T 3.18E-04 Obesity (extreme) / / 21935397 rs12444460 chr16 53637054 C T 9.62E-04 Obesity (extreme) RPGRIP1L intron 21935397 rs3213758 chr16 53639438 C T 1.36E-04 Schizophrenia RPGRIP1L missense 19197363 rs3213758 chr16 53639438 C T 4.11E-04 Alzheimer's disease (late onset) RPGRIP1L missense 21379329 rs3213758 chr16 53639438 C T 9.66E-04 Obesity (extreme) RPGRIP1L missense 21935397 rs3213758 chr16 53639438 C T 6.00E-11 Vitiligo (non-segmental) RPGRIP1L missense 23678272 rs3213758 chr16 53639438 C T 6.00E-13 Vitiligo (segmental) RPGRIP1L missense 23678272 rs17803830 chr16 53642860 T C 7.96E-04 Type 2 diabetes RPGRIP1L intron 17463246 rs9922369 chr16 53648482 G A 7.53E-04 Multiple complex diseases RPGRIP1L intron 17554300 rs9922369 chr16 53648482 G A 3.36E-06 Creutzfeldt-Jakob disease (variant) RPGRIP1L intron 22137330 rs2111119 chr16 53671754 C T 8.57E-04 Obesity (extreme) RPGRIP1L missense 21935397 rs2302677 chr16 53682949 C T 4.70E-05 Bone mineral density (spine) RPGRIP1L missense 19079262 rs17215517 chr16 53683585 C T 1.69E-04 Multiple complex diseases RPGRIP1L intron 17554300 rs12598253 chr16 53730602 A G 8.55E-05 Schizophrenia RPGRIP1L intron 19197363 rs12598253 chr16 53730602 A G 2.44E-04 Alzheimer's disease (late onset) RPGRIP1L intron 21379329 rs12447481 chr16 53748969 T G 5.14E-05 Schizophrenia FTO intron 19197363 rs12445162 chr16 53750137 G A 7.17E-04 Obesity (extreme) FTO intron 21935397 rs7205986 chr16 53755146 A G 6.92E-06 Waist circumference FTO intron 19557197 rs7206010 chr16 53755177 A G 1.38E-06 Waist circumference FTO intron 19557197 rs7206010 chr16 53755177 A G 5.54E-04 Obesity (extreme) FTO intron 21935397 rs1421084 chr16 53757740 A G 3.00E-06 Subcutaneous adipose tissue FTO intron 22589738 rs4386132 chr16 53759123 C T 4.32E-04 Obesity (extreme) FTO intron 21935397 rs4386132 chr16 53759123 C T 2.78E-05 Potassium levels FTO intron pha003086 rs4280233 chr16 53764849 G T 4.14E-04 Obesity (extreme) FTO intron 21935397 rs7203521 chr16 53769293 G A 1.83E-06 Waist circumference FTO intron 19557197 rs7203521 chr16 53769293 G A 5.34E-04 Obesity (extreme) FTO intron 21935397 rs6499640 chr16 53769677 G A 8.32E-04 Amyotrophic Lateral Sclerosis FTO intron 17362836 rs6499640 chr16 53769677 G A 4.00E-13 Body mass index FTO intron 19079260 rs6499640 chr16 53769677 G A 6.00E-14 Weight FTO intron 19079260 rs6499640 chr16 53769677 G A 2.36E-06 Waist circumference FTO intron 19557197 rs6499640 chr16 53769677 G A 6.00E-08 Smoking behavior FTO intron 20418888 rs6499640 chr16 53769677 G A 5.24E-04 Obesity (extreme) FTO intron 21935397 rs8059991 chr16 53772346 A G 9.89E-06 Waist circumference FTO intron 19557197 rs8059991 chr16 53772346 A G 7.08E-04 Obesity (extreme) FTO intron 21935397 rs6499641 chr16 53772626 T A 9.57E-06 Waist circumference FTO intron 19557197 rs6499641 chr16 53772626 T A 6.75E-04 Obesity (extreme) FTO intron 21935397 rs4396532 chr16 53773047 G A 2.99E-04 Obesity (extreme) FTO intron 21935397 rs13333228 chr16 53793798 T C 5.77E-13 Obesity FTO intron 23563607 rs13333228 chr16 53793798 T C 0.0000954 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs17525605 chr16 53794469 G C 0.0000891 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs4784323 chr16 53797565 A G 9.20E-06 Body mass index FTO intron 19557197 rs4784323 chr16 53797565 A G 8.09E-07 Obesity (extreme) FTO intron 21935397 rs7206790 chr16 53797908 C G 9.32E-12 Waist circumference FTO intron 19557197 rs7206790 chr16 53797908 C G 8.92E-10 Obesity (extreme) FTO intron 21935397 rs28429148 chr16 53798319 G A 0.0000433 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs8047395 chr16 53798523 G A 1.52E-11 Waist circumference FTO intron 19557197 rs8047395 chr16 53798523 G A 5.06E-10 Obesity (extreme) FTO intron 21935397 rs8047395 chr16 53798523 G A 0.00000505 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs8047587 chr16 53798622 G T 0.0000245 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9937521 chr16 53799296 C T 0.000067 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs28562191 chr16 53799303 C T 0.0000975 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9937053 chr16 53799507 G A 9.00E-04 Obesity-related traits FTO intron 17658951 rs9937053 chr16 53799507 G A 5.31E-18 Waist circumference FTO intron 19557197 rs9937053 chr16 53799507 G A 1.05E-13 Obesity (extreme) FTO intron 21935397 rs9937053 chr16 53799507 G A 0.0000181 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9937354 chr16 53799847 G A 0.0000173 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9928094 chr16 53799905 A G 5.47E-18 Waist circumference FTO intron 19557197 rs9928094 chr16 53799905 A G 1.06E-13 Obesity (extreme) FTO intron 21935397 rs9928094 chr16 53799905 A G 0.0000173 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9930333 chr16 53799977 T A,C,G 5.85E-18 Waist circumference FTO intron 19557197 rs9930333 chr16 53799977 T A,C,G 1.06E-13 Obesity (extreme) FTO intron 21935397 rs9930333 chr16 53799977 T A,C,G 0.0000173 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9930397 chr16 53799985 T A 0.0000174 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9940278 chr16 53800200 C T 0.0000161 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9932600 chr16 53800272 T C 0.0000513 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs12446228 chr16 53800387 A G 1.90E-07 Waist circumference FTO intron 19557197 rs12446228 chr16 53800387 A G 7.87E-08 Obesity (extreme) FTO intron 21935397 rs9939973 chr16 53800568 G A 8.62E-10 Multiple complex diseases FTO intron 17554300 rs9939973 chr16 53800568 G A 8.50E-08 Obesity-related traits FTO intron 17658951 rs9939973 chr16 53800568 G A 2.11E-07 Obesity (early onset extreme) FTO intron 18159244 rs9939973 chr16 53800568 G A 3.58E-18 Waist circumference FTO intron 19557197 rs9939973 chr16 53800568 G A 1.12E-05 Body mass index FTO intron 19584900 rs9939973 chr16 53800568 G A 1.05E-13 Obesity (extreme) FTO intron 21935397 rs9939973 chr16 53800568 G A 0.0000181 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9940646 chr16 53800629 C G 4.48E-18 Waist circumference FTO intron 19557197 rs9940646 chr16 53800629 C G 7.51E-14 Obesity (extreme) FTO intron 21935397 rs9940646 chr16 53800629 C G 0.0000175 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9940128 chr16 53800754 G A 8.50E-10 Multiple complex diseases FTO intron 17554300 rs9940128 chr16 53800754 G A 8.50E-08 Obesity-related traits FTO intron 17658951 rs9940128 chr16 53800754 G A 7.72E-07 Obesity (early onset extreme) FTO intron 18159244 rs9940128 chr16 53800754 G A 3.48E-18 Waist circumference FTO intron 19557197 rs9940128 chr16 53800754 G A 1.42E-05 Body mass index FTO intron 19584900 rs9940128 chr16 53800754 G A 7.86E-07 Obesity FTO intron 21544081 rs9940128 chr16 53800754 G A 1.04E-13 Obesity (extreme) FTO intron 21935397 rs9940128 chr16 53800754 G A 2.00E-09 Metabolic syndrome FTO intron 22399527 rs9940128 chr16 53800754 G A 0.0000173 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9940128 chr16 53800754 G A 4.00E-23 Body mass index FTO intron 23669352 rs1421085 chr16 53800954 T C 2.00E-04 Obesity-related traits FTO intron 17658951 rs1421085 chr16 53800954 T C 4.31E-51 Body mass index FTO intron 19079261 rs1421085 chr16 53800954 T C 1.00E-28 Obesity FTO intron 19151714 rs1421085 chr16 53800954 T C 1.65E-10 Waist circumference FTO intron 19557197 rs1421085 chr16 53800954 T C 9.50E-52 Smoking behavior FTO intron 20418888 rs1421085 chr16 53800954 T C 5.00E-14 Obesity (extreme) FTO intron 21935397 rs1421085 chr16 53800954 T C 0.00065 Fasting blood glucose FTO intron 22885924 rs1421085 chr16 53800954 T C 1.87E-15 Fasting insulin-related traits FTO intron 22885924 rs1421085 chr16 53800954 T C 1.26E-73 Body mass index FTO intron 23001569 rs1421085 chr16 53800954 T C 1.46E-26 Body mass index (males) FTO intron 23001569 rs1421085 chr16 53800954 T C 2.60E-24 Body mass index (females) FTO intron 23001569 rs1421085 chr16 53800954 T C 2.33E-08 HDL cholesterol FTO intron 23063622 rs1421085 chr16 53800954 T C 3.67E-12 Body mass index FTO intron 23555315 rs1421085 chr16 53800954 T C 6.00E-39 Obesity FTO intron 23563607 rs1421085 chr16 53800954 T C 3.00E-28 Obesity (early onset extreme) FTO intron 23563609 rs1421085 chr16 53800954 T C 0.0000111 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs1421085 chr16 53800954 T C 1.00E-09 Dietary macronutrient intake FTO intron 23636237 rs1421085 chr16 53800954 T C 1.67E-10 Body mass index FTO intron 24064335 rs1421085 chr16 53800954 T C 2.75E-04 Fat body mass FTO intron 24064335 rs1421085 chr16 53800954 T C 3.45E-06 Body mass index FTO intron 24348519 rs1421086 chr16 53801343 C A 0.0000186 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9923147 chr16 53801549 C T 3.61E-18 Waist circumference FTO intron 19557197 rs9923147 chr16 53801549 C T 7.81E-07 Obesity FTO intron 21544081 rs9923147 chr16 53801549 C T 1.03E-13 Obesity (extreme) FTO intron 21935397 rs9923147 chr16 53801549 C T 3.69E-04 Type 2 diabetes FTO intron 22158537 rs9923147 chr16 53801549 C T 0.0000206 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9923544 chr16 53801985 C T 3.96E-18 Waist circumference FTO intron 19557197 rs9923544 chr16 53801985 C T 7.79E-07 Obesity FTO intron 21544081 rs9923544 chr16 53801985 C T 1.02E-13 Obesity (extreme) FTO intron 21935397 rs9923544 chr16 53801985 C T 4.28E-04 Type 2 diabetes FTO intron 22158537 rs9923544 chr16 53801985 C T 0.0000161 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs11642015 chr16 53802494 C T 0.0000112 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs8055197 chr16 53803156 G A 2.56E-12 Waist circumference FTO intron 19557197 rs8055197 chr16 53803156 G A 5.53E-10 Obesity (extreme) FTO intron 21935397 rs8055197 chr16 53803156 G A 0.00000216 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs1558901 chr16 53803187 A T 0.0000189 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs62048402 chr16 53803223 G A 0.0000111 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs1558902 chr16 53803574 T A 5.00E-19 Waist circumference FTO intron 19557197 rs1558902 chr16 53803574 T A 5.00E-19 Obesity (early onset extreme) FTO intron 20421936 rs1558902 chr16 53803574 T A 7.00E-13 Obesity (extreme) FTO intron 20421936 rs1558902 chr16 53803574 T A 5.00E-120 Body mass index FTO intron 20935630 rs1558902 chr16 53803574 T A 1.00E-07 Obesity FTO intron 21544081 rs1558902 chr16 53803574 T A 4.86E-14 Obesity (extreme) FTO intron 21935397 rs1558902 chr16 53803574 T A 1.01E-05 Type 2 diabetes FTO intron 22158537 rs1558902 chr16 53803574 T A 4.80E-120 Body mass index FTO intron 23001569 rs1558902 chr16 53803574 T A 4.96E-12 Body mass index FTO intron 23555315 rs1558902 chr16 53803574 T A 2.00E-81 Obesity FTO intron 23563607 rs1558902 chr16 53803574 T A 0.0000089 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs1558902 chr16 53803574 T A 1.56E-10 Body mass index FTO intron 24064335 rs1558902 chr16 53803574 T A 2.77E-04 Fat body mass FTO intron 24064335 rs1558902 chr16 53803574 T A 7.00E-27 Body mass index FTO intron 24861553 rs1861866 chr16 53804340 C T 2.54E-12 Waist circumference FTO intron 19557197 rs1861866 chr16 53804340 C T 5.51E-10 Obesity (extreme) FTO intron 21935397 rs1861866 chr16 53804340 C T 0.00000203 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs10852521 chr16 53804965 T C 2.41E-12 Waist circumference FTO intron 19557197 rs10852521 chr16 53804965 T C 5.41E-10 Obesity (extreme) FTO intron 21935397 rs10852521 chr16 53804965 T C 0.00000189 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs11075985 chr16 53805207 C A 3.47E-18 Waist circumference FTO intron 19557197 rs11075985 chr16 53805207 C A 7.95E-07 Obesity FTO intron 21544081 rs11075985 chr16 53805207 C A 1.00E-13 Obesity (extreme) FTO intron 21935397 rs11075985 chr16 53805207 C A 2.11E-04 Type 2 diabetes FTO intron 22158537 rs11075985 chr16 53805207 C A 0.0000165 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs11075986 chr16 53805344 C G 3.54E-09 Obesity FTO intron 23563607 rs2058908 chr16 53806145 T C 2.96E-07 Waist circumference FTO intron 19557197 rs2058908 chr16 53806145 T C 4.46E-07 Obesity (extreme) FTO intron 21935397 rs9922047 chr16 53806280 C G 8.51E-08 Multiple complex diseases FTO intron 17554300 rs9922047 chr16 53806280 C G 2.20E-12 Waist circumference FTO intron 19557197 rs9922047 chr16 53806280 C G 1.00E-04 Body mass index FTO intron 19584900 rs9922047 chr16 53806280 C G 5.77E-10 Obesity (extreme) FTO intron 21935397 rs9922047 chr16 53806280 C G 0.00000176 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs56094641 chr16 53806453 A G 0.00000934 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs16952522 chr16 53807498 C G 8.99E-04 Type 2 diabetes FTO intron 17463246 rs17817288 chr16 53807764 A G 5.26E-09 Multiple complex diseases FTO intron 17554300 rs17817288 chr16 53807764 A G 3.19E-13 Waist circumference FTO intron 19557197 rs17817288 chr16 53807764 A G 4.94E-05 Body mass index FTO intron 19584900 rs17817288 chr16 53807764 A G 3.76E-10 Obesity (extreme) FTO intron 21935397 rs17817288 chr16 53807764 A G 0.00000125 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs1477196 chr16 53808258 A G 8.66E-08 Waist circumference FTO intron 19557197 rs1477196 chr16 53808258 A G 8.32E-08 Obesity (extreme) FTO intron 21935397 rs55872725 chr16 53809123 C T 0.00000737 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs1121980 chr16 53809247 G A 8.78E-10 Multiple complex diseases FTO intron 17554300 rs1121980 chr16 53809247 G A 8.80E-08 Obesity-related traits FTO intron 17658951 rs1121980 chr16 53809247 G A 1.00E-07 Obesity (early onset extreme) FTO intron 18159244 rs1121980 chr16 53809247 G A 4.00E-08 Body mass index FTO intron 18454148 rs1121980 chr16 53809247 G A 9.61E-18 Waist circumference FTO intron 19557197 rs1121980 chr16 53809247 G A 9.97E-06 Body mass index FTO intron 19584900 rs1121980 chr16 53809247 G A 7.85E-07 Obesity FTO intron 21544081 rs1121980 chr16 53809247 G A 1.11E-13 Obesity (extreme) FTO intron 21935397 rs1121980 chr16 53809247 G A 8.20E-18 Type 2 diabetes FTO intron 22885922 rs1121980 chr16 53809247 G A 0.0000185 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs1121980 chr16 53809247 G A 3.00E-08 Triglycerides FTO intron 24097068 rs1121980 chr16 53809247 G A 7.00E-09 HDL cholesterol FTO intron 24097068 rs7187250 chr16 53810546 C A 0.0000154 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs7193144 chr16 53810686 T C 9.60E-14 Type 2 diabetes FTO intron 17463249 rs7193144 chr16 53810686 T C 1.44E-08 Multiple complex diseases FTO intron 17554300 rs7193144 chr16 53810686 T C 1.00E-07 Obesity-related traits FTO intron 17658951 rs7193144 chr16 53810686 T C 7.65E-07 Obesity (early onset extreme) FTO intron 18159244 rs7193144 chr16 53810686 T C 1.21E-17 Waist circumference FTO intron 19557197 rs7193144 chr16 53810686 T C 1.05E-05 Body mass index FTO intron 19584900 rs7193144 chr16 53810686 T C 1.78E-07 Obesity FTO intron 21544081 rs7193144 chr16 53810686 T C 2.35E-13 Obesity (extreme) FTO intron 21935397 rs7193144 chr16 53810686 T C 4.23E-06 Type 2 diabetes FTO intron 22158537 rs7193144 chr16 53810686 T C 0.0000153 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs62033399 chr16 53810943 C T 0.0000151 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs62033400 chr16 53811788 A G 0.0000201 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs62033400 chr16 53811788 A G 2.00E-14 Body mass index FTO intron 24064335 rs8063057 chr16 53812433 T C 0.000014 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs8057044 chr16 53812614 G A 1.03E-11 Waist circumference FTO intron 19557197 rs8057044 chr16 53812614 G A 1.68E-09 Obesity (extreme) FTO intron 21935397 rs8057044 chr16 53812614 G A 0.000015 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs17817449 chr16 53813367 T G 1.00E-17 Waist circumference FTO intron 19557197 rs17817449 chr16 53813367 T G 2.00E-12 Obesity FTO intron 21552555 rs17817449 chr16 53813367 T G 3.08E-13 Obesity (extreme) FTO intron 21935397 rs17817449 chr16 53813367 T G 1.22E-06 Type 2 diabetes FTO intron 22158537 rs17817449 chr16 53813367 T G 4.60E-27 Body mass index FTO intron 22344219 rs17817449 chr16 53813367 T G 6.00E-14 Breast cancer FTO intron 23535729 rs17817449 chr16 53813367 T G 6.00E-07 Breast cancer FTO intron 23535733 rs17817449 chr16 53813367 T G 1.68E-08 Body mass index FTO intron 23555315 rs17817449 chr16 53813367 T G 0.0000137 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs17817449 chr16 53813367 T G 1.04E-06 Body mass index FTO intron 24064335 rs17817449 chr16 53813367 T G 1.14E-04 Fat body mass FTO intron 24064335 rs17817449 chr16 53813367 T G 5.56E-07 Body mass index FTO intron 24348519 rs8043757 chr16 53813450 A T 2.00E-04 Obesity-related traits FTO intron 17658951 rs8043757 chr16 53813450 A T 1.02E-17 Waist circumference FTO intron 19557197 rs8043757 chr16 53813450 A T 1.96E-07 Obesity FTO intron 21544081 rs8043757 chr16 53813450 A T 3.16E-13 Obesity (extreme) FTO intron 21935397 rs8043757 chr16 53813450 A T 1.30E-08 Type 2 diabetes FTO intron 22158537 rs8043757 chr16 53813450 A T 5.00E-110 Obesity FTO intron 23563607 rs8043757 chr16 53813450 A T 0.0000141 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs11075987 chr16 53815161 T G 4.51E-11 Waist circumference FTO intron 19557197 rs11075987 chr16 53815161 T G 3.40E-09 Obesity (extreme) FTO intron 21935397 rs11075987 chr16 53815161 T G 0.00000376 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs17817497 chr16 53815435 T C 0.0000139 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs8050136 chr16 53816275 C A 1.00E-12 Type 2 diabetes FTO intron 17463248 rs8050136 chr16 53816275 C A 7.00E-14 Type 2 diabetes FTO intron 17463249 rs8050136 chr16 53816275 C A 6.46E-11 Multiple complex diseases FTO intron 17554300 rs8050136 chr16 53816275 C A 6.80E-08 Obesity-related traits FTO intron 17658951 rs8050136 chr16 53816275 C A 9.76E-07 Obesity (early onset extreme) FTO intron 18159244 rs8050136 chr16 53816275 C A 7.00E-06 Type 2 diabetes FTO intron 18372903 rs8050136 chr16 53816275 C A 2.00E-17 Type 2 diabetes FTO intron 19056611 rs8050136 chr16 53816275 C A 1.00E-47 Body mass index FTO intron 19079260 rs8050136 chr16 53816275 C A 5.00E-36 Weight FTO intron 19079260 rs8050136 chr16 53816275 C A 9.48E-18 Waist circumference FTO intron 19557197 rs8050136 chr16 53816275 C A 8.72E-06 Body mass index FTO intron 19584900 rs8050136 chr16 53816275 C A 4.40E-24 Smoking behavior FTO intron 20418888 rs8050136 chr16 53816275 C A 1.50E-05 Psoriasis FTO intron 20953189 rs8050136 chr16 53816275 C A 4.00E-08 Body mass in chronic obstructive pulmonary disease FTO intron 21037115 rs8050136 chr16 53816275 C A 2.00E-17 Coronary heart disease FTO intron 21347282 rs8050136 chr16 53816275 C A 3.00E-26 Adiposity FTO intron 21706003 rs8050136 chr16 53816275 C A 3.49E-13 Obesity (extreme) FTO intron 21935397 rs8050136 chr16 53816275 C A 1.00E-08 Type 2 diabetes FTO intron 22158537 rs8050136 chr16 53816275 C A 6.00E-06 Type 2 diabetes FTO intron 23209189 rs8050136 chr16 53816275 C A 1.30E-12 Type 2 diabetes FTO intron 23300278 rs8050136 chr16 53816275 C A 0.000000053 Body mass index FTO intron 23555315 rs8050136 chr16 53816275 C A 0.0000123 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs8050136 chr16 53816275 C A 1.72E-06 Body mass index FTO intron 24064335 rs8050136 chr16 53816275 C A 6.60E-05 Fat body mass FTO intron 24064335 rs8050136 chr16 53816275 C A 1.00E-07 Body mass index FTO intron 24348519 rs4783819 chr16 53816647 G C 1.50E-07 Waist circumference FTO intron 19557197 rs4783819 chr16 53816647 G C 1.21E-07 Obesity (extreme) FTO intron 21935397 rs4783819 chr16 53816647 G C 0.0000948 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs8051591 chr16 53816752 A G 1.09E-17 Waist circumference FTO intron 19557197 rs8051591 chr16 53816752 A G 2.24E-07 Obesity FTO intron 21544081 rs8051591 chr16 53816752 A G 3.57E-13 Obesity (extreme) FTO intron 21935397 rs8051591 chr16 53816752 A G 1.44E-08 Type 2 diabetes FTO intron 22158537 rs8051591 chr16 53816752 A G 0.0000116 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9935401 chr16 53816838 G A 1.09E-17 Waist circumference FTO intron 19557197 rs9935401 chr16 53816838 G A 4.06E-09 Obesity (early onset extreme) FTO intron 20421936 rs9935401 chr16 53816838 G A 2.22E-07 Obesity FTO intron 21544081 rs9935401 chr16 53816838 G A 3.71E-13 Obesity (extreme) FTO intron 21935397 rs9935401 chr16 53816838 G A 1.38E-08 Type 2 diabetes FTO intron 22158537 rs9935401 chr16 53816838 G A 0.0000114 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9933509 chr16 53818167 T C 0.0000264 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs3751812 chr16 53818460 G T 4.00E-04 Obesity-related traits FTO intron 17658951 rs3751812 chr16 53818460 G T 1.38E-17 Waist circumference FTO intron 19557197 rs3751812 chr16 53818460 G T 3.30E-24 Smoking behavior FTO intron 20418888 rs3751812 chr16 53818460 G T 3.79E-13 Obesity (extreme) FTO intron 21935397 rs3751812 chr16 53818460 G T 8.97E-09 Type 2 diabetes FTO intron 22158537 rs3751812 chr16 53818460 G T 0.00089614 Hypertension (early onset hypertension) FTO intron 22479346 rs3751812 chr16 53818460 G T 0.0000103 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs3751813 chr16 53818708 G T 4.91E-12 Waist circumference FTO intron 19557197 rs3751813 chr16 53818708 G T 1.45E-10 Obesity (extreme) FTO intron 21935397 rs3751814 chr16 53818724 G A 0.0000109 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9931900 chr16 53818813 A G 0.0000281 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs56313538 chr16 53818834 A G 0.0000123 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9936385 chr16 53819169 T C 6.83E-18 Waist circumference FTO intron 19557197 rs9936385 chr16 53819169 T C 1.42E-13 Obesity (extreme) FTO intron 21935397 rs9936385 chr16 53819169 T C 1.04E-06 Type 2 diabetes FTO intron 22158537 rs9936385 chr16 53819169 T C 0.000081 Fasting insulin-related traits FTO intron 22885922 rs9936385 chr16 53819169 T C 0.00033 HOMA-IR FTO intron 22885922 rs9936385 chr16 53819169 T C 2.60E-23 Type 2 diabetes FTO intron 22885922 rs9936385 chr16 53819169 T C 3.20E-18 Type 2 diabetes (males) FTO intron 22885922 rs9936385 chr16 53819169 T C 6.40E-11 Type 2 diabetes (females) FTO intron 22885922 rs9936385 chr16 53819169 T C 0.0000168 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9936385 chr16 53819169 T C 1.00E-12 Type 2 diabetes FTO intron 24509480 rs9923233 chr16 53819198 G C 1.40E-04 Obesity-related traits FTO intron 17658951 rs9923233 chr16 53819198 G C 1.19E-17 Waist circumference FTO intron 19557197 rs9923233 chr16 53819198 G C 4.15E-13 Obesity (extreme) FTO intron 21935397 rs9923233 chr16 53819198 G C 1.70E-12 Metabolic syndrome phenotype FTO intron 22022282 rs9923233 chr16 53819198 G C 4.30E-05 Metabolic syndrome phenotype FTO intron 22022282 rs9923233 chr16 53819198 G C 4.90E-10 Metabolic syndrome phenotype FTO intron 22022282 rs9923233 chr16 53819198 G C 0.0000121 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9923312 chr16 53819367 G A 0.0000123 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs11075988 chr16 53819771 G A 0.0000123 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs11075989 chr16 53819877 C T 1.03E-17 Waist circumference FTO intron 19557197 rs11075989 chr16 53819877 C T 3.79E-13 Obesity (extreme) FTO intron 21935397 rs11075989 chr16 53819877 C T 1.28E-08 Type 2 diabetes FTO intron 22158537 rs11075989 chr16 53819877 C T 0.0000114 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs11075990 chr16 53819893 A G 1.11E-17 Waist circumference FTO intron 19557197 rs11075990 chr16 53819893 A G 1.64E-07 Obesity FTO intron 21544081 rs11075990 chr16 53819893 A G 3.79E-13 Obesity (extreme) FTO intron 21935397 rs11075990 chr16 53819893 A G 8.40E-07 Type 2 diabetes FTO intron 22158537 rs11075990 chr16 53819893 A G 2.00E-51 Body mass index FTO intron 23563607 rs11075990 chr16 53819893 A G 0.0000117 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs11075991 chr16 53819937 A T 0.0000124 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs11075992 chr16 53820066 T C 0.000014 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9926289 chr16 53820503 G A 1.64E-09 Multiple complex diseases FTO intron 17554300 rs9926289 chr16 53820503 G A 1.40E-07 Obesity-related traits FTO intron 17658951 rs9926289 chr16 53820503 G A 2.25E-07 Type 2 diabetes FTO intron 22158537 rs9926289 chr16 53820503 G A 0.0000127 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9939609 chr16 53820527 T A 2.00E-20 Body mass index FTO intron 17434869 rs9939609 chr16 53820527 T A 9.00E-12 Type 2 diabetes FTO intron 17463249 rs9939609 chr16 53820527 T A 2.00E-07 Type 2 diabetes FTO intron 17554300 rs9939609 chr16 53820527 T A 1.30E-07 Obesity-related traits FTO intron 17658951 rs9939609 chr16 53820527 T A 1.94E-06 Obesity (early onset extreme) FTO intron 18159244 rs9939609 chr16 53820527 T A 4.00E-51 Body mass index FTO intron 19079261 rs9939609 chr16 53820527 T A 2.00E-07 Biomedical quantitative traits FTO intron 19396169 rs9939609 chr16 53820527 T A 1.06E-17 Waist circumference FTO intron 19557197 rs9939609 chr16 53820527 T A 4.30E-51 Smoking behavior FTO intron 20418888 rs9939609 chr16 53820527 T A 3.00E-08 Menarche (age at onset) FTO intron 21102462 rs9939609 chr16 53820527 T A 3.30E-11 Menarche (age at onset) FTO intron 21102462 rs9939609 chr16 53820527 T A 2.00E-07 Coronary heart disease FTO intron 21347282 rs9939609 chr16 53820527 T A 1.66E-07 Obesity FTO intron 21544081 rs9939609 chr16 53820527 T A 2.00E-07 Type 2 diabetes FTO intron 21647700 rs9939609 chr16 53820527 T A 3.79E-13 Obesity (extreme) FTO intron 21935397 rs9939609 chr16 53820527 T A 5.26E-07 Type 2 diabetes FTO intron 22158537 rs9939609 chr16 53820527 T A 1.00E-20 Type 2 diabetes FTO intron 22693455 rs9939609 chr16 53820527 T A 5.50E-08 Type 2 diabetes FTO intron 23300278 rs9939609 chr16 53820527 T A 5.25E-08 Body mass index FTO intron 23555315 rs9939609 chr16 53820527 T A 0.0000127 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9939609 chr16 53820527 T A 6.07E-07 Body mass index FTO intron 24348519 rs9937709 chr16 53820813 A G 0.0000309 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9927317 chr16 53820996 C A,G 0.0000123 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs17817712 chr16 53821125 A G 6.02E-05 Type 2 diabetes FTO intron 22158537 rs17817712 chr16 53821125 A G 0.0000167 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs7206410 chr16 53821297 T C 0.0000117 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs12597786 chr16 53821307 C T 3.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FTO intron 20877124 rs7206629 chr16 53821413 T C 0.0000293 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs7202116 chr16 53821615 A G 2.27E-09 Waist circumference FTO intron 19557197 rs7202116 chr16 53821615 A G 3.76E-13 Obesity (extreme) FTO intron 21935397 rs7202116 chr16 53821615 A G 5.79E-07 Type 2 diabetes FTO intron 22158537 rs7202116 chr16 53821615 A G 2.00E-10 Body mass index FTO intron 22982992 rs7202116 chr16 53821615 A G 0.0000115 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs7202296 chr16 53821690 A G 0.0000113 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs7201850 chr16 53821862 C T 1.58E-16 Waist circumference FTO intron 19557197 rs7201850 chr16 53821862 C T 7.39E-13 Obesity (extreme) FTO intron 21935397 rs7201850 chr16 53821862 C T 0.0000279 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs66908032 chr16 53822142 C A 0.0000113 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs72803697 chr16 53822183 C T 0.0000112 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs62033403 chr16 53822237 A G 0.0000115 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs62033404 chr16 53822239 A G 0.0000115 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs62033405 chr16 53822387 C T 0.0000159 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs7206122 chr16 53822440 G A 0.0000111 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs7190396 chr16 53822502 T G 0.0000105 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs7185735 chr16 53822651 A G 1.57E-17 Waist circumference FTO intron 19557197 rs7185735 chr16 53822651 A G 1.16E-07 Obesity FTO intron 21544081 rs7185735 chr16 53822651 A G 3.77E-13 Obesity (extreme) FTO intron 21935397 rs7185735 chr16 53822651 A G 1.01E-07 Type 2 diabetes FTO intron 22158537 rs7185735 chr16 53822651 A G 1.00E-79 Obesity FTO intron 23563607 rs7185735 chr16 53822651 A G 0.0000108 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs2042031 chr16 53823718 G A 0.0000284 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs79994966 chr16 53823727 T C 0.0000144 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs62033406 chr16 53824226 A G 0.00000437 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9941349 chr16 53825488 C T 6.00E-12 Obesity (extreme) FTO intron 19553259 rs9941349 chr16 53825488 C T 1.75E-16 Waist circumference FTO intron 19557197 rs9941349 chr16 53825488 C T 7.42E-13 Obesity (extreme) FTO intron 21935397 rs9941349 chr16 53825488 C T 3.87E-05 Type 2 diabetes FTO intron 22158537 rs9941349 chr16 53825488 C T 1.99E-14 Obesity FTO intron 22484627 rs9941349 chr16 53825488 C T 4.97E-09 Body mass index FTO intron 23555315 rs9941349 chr16 53825488 C T 0.0000352 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9941349 chr16 53825488 C T 4.73E-10 Body mass index FTO intron 24064335 rs9941349 chr16 53825488 C T 7.86E-04 Fat body mass FTO intron 24064335 rs56137030 chr16 53825905 G A 0.0000376 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs28567725 chr16 53826028 T C 0.0000414 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs9931494 chr16 53827179 C G 1.70E-16 Waist circumference FTO intron 19557197 rs9931494 chr16 53827179 C G 5.66E-07 Obesity FTO intron 21544081 rs9931494 chr16 53827179 C G 7.80E-13 Obesity (extreme) FTO intron 21935397 rs9931494 chr16 53827179 C G 3.21E-05 Type 2 diabetes FTO intron 22158537 rs9931494 chr16 53827179 C G 0.0000462 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs10468280 chr16 53827479 A G 0.00002 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs62033408 chr16 53827962 A G 0.0000199 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs17817964 chr16 53828066 C T 1.62E-17 Waist circumference FTO intron 19557197 rs17817964 chr16 53828066 C T 2.37E-07 Obesity FTO intron 21544081 rs17817964 chr16 53828066 C T 4.32E-13 Obesity (extreme) FTO intron 21935397 rs17817964 chr16 53828066 C T 1.98E-07 Type 2 diabetes FTO intron 22158537 rs17817964 chr16 53828066 C T 1.00E-10 Body mass index FTO intron 23583978 rs17817964 chr16 53828066 C T 0.0000212 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs7190492 chr16 53828752 A G 2.12E-07 Waist circumference FTO intron 19557197 rs7190492 chr16 53828752 A G 2.00E-12 Smoking behavior FTO intron 20418888 rs7190492 chr16 53828752 A G 1.37E-07 Obesity (extreme) FTO intron 21935397 rs9930501 chr16 53830452 A G 1.04E-16 Waist circumference FTO intron 19557197 rs9930501 chr16 53830452 A G 5.44E-12 Obesity (extreme) FTO intron 21935397 rs9930501 chr16 53830452 A G 1.96E-06 Type 2 diabetes FTO intron 22158537 rs9930506 chr16 53830465 A G 2.80E-08 Multiple complex diseases FTO intron 17554300 rs9930506 chr16 53830465 A G 3.00E-08 Obesity-related traits FTO intron 17658951 rs9930506 chr16 53830465 A G 9.00E-07 Obesity-related traits FTO intron 17658951 rs9930506 chr16 53830465 A G 9.00E-07 Obesity-related traits FTO intron 17658951 rs9930506 chr16 53830465 A G 1.08E-16 Waist circumference FTO intron 19557197 rs9930506 chr16 53830465 A G 5.55E-05 Body mass index FTO intron 19584900 rs9930506 chr16 53830465 A G 5.98E-12 Obesity (extreme) FTO intron 21935397 rs9930506 chr16 53830465 A G 3.93E-06 Type 2 diabetes FTO intron 22158537 rs9930506 chr16 53830465 A G 5.56E-09 Body mass index FTO intron 24064335 rs9932754 chr16 53830491 T C 1.06E-16 Waist circumference FTO intron 19557197 rs9932754 chr16 53830491 T C 6.02E-12 Obesity (extreme) FTO intron 21935397 rs9922708 chr16 53831146 C T 1.10E-16 Waist circumference FTO intron 19557197 rs9922708 chr16 53831146 C T 6.11E-12 Obesity (extreme) FTO intron 21935397 rs9922708 chr16 53831146 C T 7.58E-05 Type 2 diabetes FTO intron 22158537 rs9922619 chr16 53831771 G T 1.22E-16 Waist circumference FTO intron 19557197 rs9922619 chr16 53831771 G T 6.28E-12 Obesity (extreme) FTO intron 21935397 rs9922619 chr16 53831771 G T 6.00E-08 Subcutaneous adipose tissue FTO intron 22589738 rs8044769 chr16 53839135 T C 4.31E-11 Waist circumference FTO intron 19557197 rs8044769 chr16 53839135 T C 7.90E-16 Smoking behavior FTO intron 20418888 rs8044769 chr16 53839135 T C 1.14E-08 Obesity (extreme) FTO intron 21935397 rs8044769 chr16 53839135 T C 4.00E-06 Osteoarthritis FTO intron 22763110 rs8044769 chr16 53839135 T C 4.00E-06 Cortical thickness FTO intron 22792071 rs8044769 chr16 53839135 T C 0.0000596 Nonsyndromic striae distensae (stretch marks) FTO intron 23633020 rs12149832 chr16 53842908 G A 9.31E-18 Waist circumference FTO intron 19557197 rs12149832 chr16 53842908 G A 3.76E-12 Obesity (extreme) FTO intron 21935397 rs12149832 chr16 53842908 G A 4.25E-06 Type 2 diabetes FTO intron 22158537 rs12149832 chr16 53842908 G A 5.00E-22 Body mass index FTO intron 22344221 rs12149832 chr16 53842908 G A 2.00E-04 Menarche (age at onset) FTO intron 23599027 rs6499646 chr16 53843533 T C 4.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FTO intron 20877124 rs1115005 chr16 53844294 C T 1.18E-04 Multiple complex diseases FTO intron 17554300 rs11642841 chr16 53845487 C A 4.07E-18 Waist circumference FTO intron 19557197 rs11642841 chr16 53845487 C A 3.00E-08 Type 2 diabetes FTO intron 20581827 rs11642841 chr16 53845487 C A 6.66E-12 Obesity (extreme) FTO intron 21935397 rs11642841 chr16 53845487 C A 0.000178 Type 2 diabetes FTO intron 22325160 rs11642841 chr16 53845487 C A 1.10E-19 Type 2 diabetes FTO intron 22885922 rs11642841 chr16 53845487 C A 3.40E-08 Type 2 diabetes FTO intron 23300278 rs11642841 chr16 53845487 C A 2.96E-04 Type 2 diabetes FTO intron 24390345 rs1861867 chr16 53848561 A G 2.27E-06 Waist circumference FTO intron 19557197 rs1861867 chr16 53848561 A G 6.84E-09 Obesity (extreme) FTO intron 21935397 rs9972717 chr16 53851304 G A 2.98E-04 Multiple complex diseases FTO intron 17554300 rs11075995 chr16 53855291 A T 4.00E-08 Breast cancer FTO intron 23535733 rs10521308 chr16 53865126 G A 3.82E-04 Nicotine smoking FTO intron 19268276 rs9302652 chr16 53865975 C T 1.16E-09 Obesity FTO intron 23563607 rs9302652 chr16 53865975 C T 3.89E-09 Obesity FTO intron 23563607 rs17818902 chr16 53871806 T G 5.00E-04 Body mass index FTO intron 19584900 rs17818902 chr16 53871806 T G 6.00E-04 Body mass index FTO intron 19584900 rs17818920 chr16 53871903 A C 7.00E-04 Body mass index FTO intron 19584900 rs8044353 chr16 53905156 G A 3.77E-04 Response to statin treatment (atorvastatin),change in cholesterol levels FTO intron 20031582 rs1362571 chr16 53911770 G T 7.62E-04 Alcohol dependence FTO intron 21314694 rs16952619 chr16 53918647 A G 1.83E-18 Triglycerides FTO intron 23063622 rs12149433 chr16 53928079 G C 0.00055 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 FTO intron 21873659 rs9926180 chr16 53928607 T A 0.0005 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 FTO intron 21873659 rs7500562 chr16 53930890 C G 0.00053 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 FTO intron 21873659 rs13335343 chr16 53931440 A G 0.00061 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 FTO intron 21873659 rs1861551 chr16 53948194 A T 7.20E-06 Urinary metabolites FTO intron 21572414 rs12925189 chr16 53985273 G A 8.20E-06 Urinary metabolites FTO intron 21572414 rs11644943 chr16 53995584 T A 0.000161 Breast cancer early age of onset FTO intron 18463975 rs12446047 chr16 53997302 C T 8.65E-05 Coronary heart disease FTO intron pha003056 rs17823199 chr16 53998930 C T 8.60E-06 Urinary metabolites FTO intron 21572414 rs1111483 chr16 54000907 C A 2.30E-05 Urinary metabolites FTO intron 21572414 rs8053888 chr16 54003805 C T 2.70E-05 Urinary metabolites FTO intron 21572414 rs7185783 chr16 54007822 G T 0.00013 Coronary artery calcification FTO intron 23727086 rs9302654 chr16 54009545 C T 0.00023 Coronary artery calcification FTO intron 23727086 rs4784335 chr16 54009688 G T 0.00033 Coronary artery calcification FTO intron 23727086 rs16952728 chr16 54014643 C G 7.61E-04 Type 2 diabetes FTO intron 17463246 rs13337356 chr16 54017310 C G 0.0000036 Coronary artery calcification FTO intron 23727086 rs12324955 chr16 54019686 G A 0.000019 Coronary artery calcification FTO intron 23727086 rs8049235 chr16 54021009 G A 8.97E-06 Serum metabolites FTO intron 19043545 rs12596210 chr16 54027971 T C 9.00E-06 Sex hormone-binding globulin levels FTO intron 22675492 rs35873641 chr16 54027971 T TG 9.00E-06 Sex hormone-binding globulin levels FTO intron 22675492 rs11864881 chr16 54029304 C A 5.98E-05 Serum metabolites FTO intron 19043545 rs7205987 chr16 54034145 T C 6.82E-04 Type 2 diabetes FTO intron 17463246 rs7200972 chr16 54036352 G A 2.88E-05 Serum metabolites FTO intron 19043545 rs7199363 chr16 54039014 T C 0.00000737 Paraoxonase activity FTO intron 23160181 rs12600130 chr16 54043323 C G 2.20E-05 Urinary metabolites FTO intron 21572414 rs17825567 chr16 54057771 C A 4.00E-04 Multiple complex diseases FTO intron 17554300 rs17825567 chr16 54057771 C A 2.04E-05 Major depressive disorder (broad) FTO intron 20038947 rs1136002 chr16 54061141 T C 0.0000177 Paraoxonase activity FTO intron 23160181 rs1477094 chr16 54063618 T A 0.00045 Coronary artery calcification FTO intron 23727086 rs13331869 chr16 54065994 T A 3.34E-04 Nicotine dependence FTO intron 17158188 rs2302673 chr16 54068121 T C 8.85E-05 Nicotine dependence FTO intron 17158188 rs2192872 chr16 54074627 T C 0.0000644 Paraoxonase activity FTO intron 23160181 rs4784351 chr16 54075698 A G 0.0000563 Paraoxonase activity FTO intron 23160181 rs16952906 chr16 54083167 T C 9.79E-04 Nicotine dependence FTO intron 17158188 rs1078013 chr16 54085694 T A 0.00018 Coronary artery calcification FTO intron 23727086 rs1076467 chr16 54085925 G A 0.00039 Coronary artery calcification FTO intron 23727086 rs940214 chr16 54091078 A C 0.00039 Coronary artery calcification FTO intron 23727086 rs8049933 chr16 54094130 C T 0.00018 Coronary artery calcification FTO intron 23727086 rs2689247 chr16 54097159 C T 7.37E-05 Schizophrenia FTO intron 19571809 rs2003583 chr16 54100006 C T 0.0000148 Paraoxonase activity FTO intron 23160181 rs1108086 chr16 54100369 T C 0.00029 Coronary artery calcification FTO intron 23727086 rs2540786 chr16 54100401 G A 9.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) FTO intron 23233662 rs2540766 chr16 54105971 G A 0.0004948 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FTO intron 23233654 rs2540766 chr16 54105971 G A 4.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) FTO intron 23233662 rs7206012 chr16 54113564 T C 7.82E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) FTO intron 22566498 rs16953002 chr16 54114824 G A 4.00E-12 Melanoma FTO intron 23455637 rs16953047 chr16 54130170 G T 4.00E-04 Alcohol dependence FTO intron 21314694 rs10163409 chr16 54138880 A T 7.40E-09 Dietary macronutrient intake FTO intron 23372041 rs708278 chr16 54144925 A G 9.09E-04 Oral cancers (chewing tobacco related) FTO intron 22503698 rs8053279 chr16 54151179 A G 1.42E-04 Myopia (pathological) / / 21095009 rs2075205 chr16 54153099 A T 7.83E-05 Alzheimer's disease / / 17998437 rs2542674 chr16 54206026 C T 5.07E-04 Sarcoidosis / / 19165924 rs7190251 chr16 54211135 T A 8.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs836994 chr16 54213541 C T 2.78E-05 Bipolar disorder and schizophrenia / / 20889312 rs836994 chr16 54213541 C T 3.26E-04 Smoking initiation / / 24665060 rs10153048 chr16 54238008 G A 1.99E-05 Soluble levels of adhesion molecules / / pha003072 rs836986 chr16 54239701 A G 4.26E-05 Multiple complex diseases / / 17554300 rs2665278 chr16 54242664 T C 8.48E-04 Multiple complex diseases / / 17554300 rs7188172 chr16 54244920 T C 7.04E-04 Multiple complex diseases / / 17554300 rs16953218 chr16 54252833 G A 2.11E-05 Soluble levels of adhesion molecules / / pha003072 rs8060235 chr16 54265765 G A 5.80E-05 Alcoholism (heaviness of drinking) / / 21529783 rs3751723 chr16 54320197 G T 2.72E-04 Alzheimer's disease IRX3 UTR-5 22005930 rs1562797 chr16 54343069 C T 8.45E-05 Serum metabolites / / 19043545 rs1530787 chr16 54345270 G A 1.75E-05 Adverse response to lamotrigine and phenytoin / / 22379998 rs4783833 chr16 54354480 A T 2.55E-04 Body mass index / / 21701565 rs4783833 chr16 54354480 A T 5.38E-04 Body mass index / / 21701565 rs8056104 chr16 54355601 T G 7.96E-04 Schizophrenia / / 19197363 rs8056104 chr16 54355601 T G 2.62E-04 Body mass index / / 21701565 rs8056104 chr16 54355601 T G 6.11E-04 Body mass index / / 21701565 rs9933367 chr16 54368954 A T 6.95E-04 Multiple complex diseases / / 17554300 rs4784376 chr16 54414284 C T 8.04E-04 Multiple complex diseases / / 17554300 rs8045954 chr16 54442483 A C 6.55E-04 Celiac disease / / 23936387 rs4784379 chr16 54453976 A G 9.90E-05 Inflammation / / pha002897 rs10521310 chr16 54460342 C T 9.00E-06 Urinary metabolites / / 21572414 rs17199152 chr16 54461785 G A 1.20E-05 Urinary metabolites / / 21572414 rs12149455 chr16 54478230 A G 2.30E-05 Urinary metabolites / / 21572414 rs9929651 chr16 54481592 C T 4.69E-07 Basophils / / pha003087 rs4784391 chr16 54485959 G A 0.00051681 Hypertension (early onset hypertension) / / 22479346 rs2388639 chr16 54489793 C A 9.00E-09 Asthma (corticosteroid response) / / 24486069 rs1861352 chr16 54490303 G A 1.02E-05 Creatinine levels / / pha003069 rs12447674 chr16 54492183 A G 4.10E-05 Creatinine levels / / pha003069 rs9921518 chr16 54494424 A G 9.00E-06 Dialysis-related mortality / / 21546767 rs17200147 chr16 54504420 C T 9.28E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12929998 chr16 54514123 A C 2.77E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs933518 chr16 54522121 C T 8.00E-04 Epithelial ovarian cancer / / 24190013 rs1420290 chr16 54524225 G A 7.85E-04 Iron levels / / pha002876 rs12051408 chr16 54527296 T C 8.16E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs1362435 chr16 54532641 A C 7.75E-04 Alzheimer's disease / / 22005930 rs751214 chr16 54542033 A C 8.42E-05 Monocyte counts / / pha003089 rs6499697 chr16 54561496 C A 9.56E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs16953625 chr16 54563823 C T 4.58E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16953659 chr16 54587432 A G 1.33E-06 Alcohol and nictotine co-dependence / / 20158304 rs16953659 chr16 54587432 A G 1.82E-04 Celiac disease / / 23936387 rs12444320 chr16 54627595 C T 7.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12444320 chr16 54627595 C T 5.40E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs7193843 chr16 54677292 A G 3.20E-06 Urinary metabolites / / 21572414 rs7193843 chr16 54677292 A G 2.86E-04 Stroke / / pha002886 rs16953850 chr16 54712304 T A 4.89E-05 Bipolar disorder / / 20451256 rs9924623 chr16 54725496 T C 3.93E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17205999 chr16 54727937 G A 6.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs9925202 chr16 54728661 G T 1.56E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1493902 chr16 54729686 C T 2.70E-06 Response to lithium treatment in bipolar disorder / / 19448189 rs7206354 chr16 54730864 A C 5.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs11647205 chr16 54732235 G A 5.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs1420562 chr16 54733746 T C 8.27E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs8044591 chr16 54734507 C A 5.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs9928941 chr16 54745268 A G 2.40E-04 Asperger disorder / / 21182207 rs4440156 chr16 54794101 G A 7.00E-06 Asthma / / 21790008 rs4440156 chr16 54794101 G A 1.84E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4784428 chr16 54838767 C T 7.93E-04 Smoking cessation / / 24665060 rs11647804 chr16 54842074 A G 6.87E-04 Multiple complex diseases / / 17554300 rs11076059 chr16 54850716 G A 1.22E-04 Multiple complex diseases / / 17554300 rs4410070 chr16 54851741 A C 7.11E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs4435250 chr16 54856671 C T 1.64E-04 Orofacial clefts / / 22863734 rs4784429 chr16 54859732 G T 9.13E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4131946 chr16 54862474 T A 3.10E-06 Primary tooth development (number of teeth) / / 23704328 rs4555155 chr16 54887921 A C 2.23E-04 Multiple complex diseases / / 17554300 rs4587973 chr16 55023394 C T 7.86E-04 HIV-1 viral setpoint / / 17641165 rs4622507 chr16 55043667 T C 2.00E-06 Social communication problems / / 24564958 rs12708948 chr16 55078245 C T 1.40E-06 Primary tooth development (time to first tooth eruption) / / 23704328 rs7184407 chr16 55107147 C T 4.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs13333707 chr16 55118798 C T 5.80E-04 Alcohol dependence / / 20201924 rs13333707 chr16 55118798 C T 8.87E-05 Major depressive disorder / / 21621269 rs8045342 chr16 55138038 C T 2.84E-06 Carotenoid and tocopherol levels / / 19185284 rs6499748 chr16 55139434 C G 2.65E-28 Narcolepsy / / 19629137 rs4783874 chr16 55142853 C T 6.84E-06 Carotenoid and tocopherol levels / / 19185284 rs4784481 chr16 55142949 C T 6.84E-06 Carotenoid and tocopherol levels / / 19185284 rs4784489 chr16 55151351 A C 6.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4783880 chr16 55156650 A T 1.60E-05 Obesity,menopause / / 21424828 rs901447 chr16 55158697 A G 2.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17210989 chr16 55173094 G A 1.49E-05 Neuroblastoma / / pha002895 rs12932067 chr16 55176106 A G 1.03E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs728571 chr16 55214093 C T 3.25E-04 Schizophrenia / / 19197363 rs2589001 chr16 55218862 T C 7.70E-06 Type 2 diabetes / / 17293876 rs2589001 chr16 55218862 T C 7.70E-06 Type 2 diabetes / / 19184112 rs2589010 chr16 55223146 A G 3.65E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2631522 chr16 55225083 T C 2.00E-05 Urinary metabolites / / 21572414 rs12926302 chr16 55233680 A G 4.78E-06 Information processing speed / / 21130836 rs2171262 chr16 55239232 G A 4.36E-05 Information processing speed / / 21130836 rs17291845 chr16 55245037 G A 5.00E-06 Information processing speed / / 21130836 rs4290468 chr16 55246255 G A 5.43E-04 Type 2 diabetes / / 17463246 rs12918335 chr16 55246303 G A 7.90E-06 Information processing speed / / 21130836 rs2397376 chr16 55253790 C T 4.08E-05 Anxiety in major depressive disorder / / 24047446 rs2001970 chr16 55255191 T C 9.00E-06 Visceral fat / / 22589738 rs11076087 chr16 55266507 A C 8.35E-04 Bipolar disorder,schizoaffective / / 19567891 rs4784508 chr16 55282571 C T 8.41E-05 Multiple complex diseases / / 17554300 rs16954609 chr16 55291144 T C 1.98E-06 Multiple complex diseases / / 17554300 rs4567706 chr16 55302271 G A 1.55E-05 Multiple complex diseases / / 17554300 rs8043627 chr16 55312072 A G 6.20E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs30924 chr16 55316678 T C 2.92E-05 Hypertension / / pha003042 rs30941 chr16 55324767 T C 3.59E-05 Hypertension / / pha003042 rs31042 chr16 55329601 A G 9.73E-04 Obesity (extreme) / / 21935397 rs31042 chr16 55329601 A G 6.71E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9302665 chr16 55340567 C G 2.44E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs31075 chr16 55357238 T C 7.37E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs16954836 chr16 55369323 A G 8.00E-04 Smoking quantity / / 24665060 rs258586 chr16 55389523 C T 2.77E-05 Obesity (extreme) / / 21935397 rs365760 chr16 55391632 A T 3.07E-05 Obesity (extreme) / / 21935397 rs16954899 chr16 55401096 G A 5.97E-04 Rheumatoid arthritis / / 21452313 rs360774 chr16 55401333 T C 7.20E-04 Rheumatoid arthritis / / 21452313 rs17232065 chr16 55425383 C T 2.10E-04 Fibrinogen / / 17255346 rs41140 chr16 55426131 G C 4.69E-04 Multiple complex diseases / / 17554300 rs9933802 chr16 55429134 T G 2.23E-04 Fibrinogen / / 17255346 rs11640811 chr16 55442880 C T 2.23E-04 Fibrinogen / / 17255346 rs2576561 chr16 55470974 T C 2.98E-05 Multiple complex diseases / / 17554300 rs2397449 chr16 55472928 T C 2.22E-04 Multiple complex diseases / / 17554300 rs1558670 chr16 55478046 C T 8.74E-04 Rheumatoid arthritis / / 21452313 rs2576543 chr16 55479818 T A 1.21E-04 Multiple complex diseases / / 17554300 rs2540726 chr16 55481111 G A 2.71E-05 Multiple complex diseases / / 17554300 rs10521323 chr16 55481221 G A 4.37E-05 Serum metabolites / / 19043545 rs1437245 chr16 55481549 A C 8.10E-04 Rheumatoid arthritis / / 21452313 rs1816594 chr16 55489908 C T 3.02E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11643163 chr16 55498659 A G 3.78E-04 Alzheimer's disease (late onset) / / 21379329 rs11859163 chr16 55502376 T G 5.80E-06 Height / / pha003010 rs11859163 chr16 55502376 T G 8.03E-06 Height / / pha003011 rs1005913 chr16 55504521 T G 8.50E-05 HIV-1 control / / 20041166 rs243842 chr16 55527422 T C 3.38E-04 Oral cancers (chewing tobacco related) MMP2 intron 22503698 rs6499766 chr16 55604128 A T 1.00E-06 Thyroid hormone levels LPCAT2 intron 23408906 rs6499766 chr16 55604128 A T 5.00E-08 Thyroid hormone levels LPCAT2 intron 23408906 rs17841329 chr16 55703011 G A 5.00E-04 Multiple complex diseases SLC6A2 intron 17554300 rs1566652 chr16 55731575 G T 9.01E-05 Blood Pressure SLC6A2 intron pha003043 rs11864456 chr16 55766754 A G 3.52E-04 Multiple complex diseases CES1P2 intron 17554300 rs9938863 chr16 55767078 C T 3.98E-04 Gallstones CES1P2 intron 17632509 rs9937399 chr16 55781434 T C 1.10E-04 Multiple complex diseases CES1P2 intron 17554300 rs1974708 chr16 55793837 T C 8.69E-05 Glucose levels / / pha003057 rs7199731 chr16 55794301 A G 2.07E-05 Coronary heart disease / / pha003031 rs2244613 chr16 55844609 G T 5.00E-07 Response to dabigatran etexilate treatment CES1 intron 23467860 rs2244614 chr16 55844617 G A 9.51E-07 Meningococcal disease CES1 intron 20694013 rs1814268 chr16 55853059 A G 0.000446 Salmonella-induced pyroptosis CES1 intron 22837397 rs8192935 chr16 55861794 A G 1.00E-06 Response to dabigatran etexilate treatment CES1 intron 23467860 rs7184362 chr16 55879620 A G 3.00E-06 QRS duration in Tripanosoma cruzi seropositivity CES5A nearGene-3 24324551 rs7186875 chr16 55883761 A C 8.08E-04 Type 2 diabetes CES5A intron 17463246 rs11076128 chr16 55899703 T C 7.20E-04 Multiple complex diseases CES5A intron 17554300 rs7187404 chr16 55900367 G T 4.20E-04 Multiple complex diseases CES5A intron 17554300 rs57161061 chr16 55909702 A T 0.0000251 Nonsyndromic striae distensae (stretch marks) CES5A intron 23633020 rs2253986 chr16 55911022 C A,G,T 2.84E-05 Serum metabolites CES5A intron 19043545 rs6499799 chr16 55922341 A G 1.88E-05 Serum metabolites CES5A intron 19043545 rs4784604 chr16 55922429 A G 1.53E-05 Serum metabolites CES5A intron 19043545 rs9940636 chr16 55928921 G C 7.73E-06 Uric acid levels CES5A intron 21294900 rs8053467 chr16 55932021 G T 7.32E-05 Serum metabolites CES5A intron 19043545 rs7205550 chr16 55938138 C T 6.59E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CES5A intron 20031582 rs6499806 chr16 55971982 G A 8.54E-05 Serum metabolites CES5A intron 19043545 rs6499811 chr16 55982743 T C 8.20E-05 Serum metabolites CES5A intron 19043545 rs7195911 chr16 55985580 G A 7.24E-05 Serum metabolites CES5A intron 19043545 rs8057875 chr16 56003175 T C 1.63E-05 Multiple complex diseases / / 17554300 rs1588414 chr16 56006958 A G 3.82E-05 Serum metabolites / / 19043545 rs8053433 chr16 56029565 G A 5.29E-05 Cognitive test performance / / 20125193 rs1397151 chr16 56039310 T C 4.70E-04 Multiple complex diseases / / 17554300 rs4783923 chr16 56041190 G A 5.29E-05 Cognitive test performance / / 20125193 rs4783925 chr16 56044545 T C 5.29E-05 Cognitive test performance / / 20125193 rs9925963 chr16 56088957 C G 9.97E-04 Insulin resistance / / 21901158 rs4784651 chr16 56311774 G A 3.41E-04 Type 2 diabetes G/O1 intron 17463246 rs899239 chr16 56321119 A G 2.88E-04 Premature ovarian failure G/O1 intron 19508998 rs9937815 chr16 56330832 A G 8.75E-06 Osteoarthritis G/O1 intron 22763110 rs922445 chr16 56342059 G A 3.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) G/O1 intron 20877124 rs922445 chr16 56342059 G A 0.0003201 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) G/O1 intron 23233654 rs922445 chr16 56342059 G A 3.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) G/O1 intron 23233662 rs899236 chr16 56352905 G A 6.64E-05 Tunica Media G/O1 intron pha003034 rs4784652 chr16 56356830 C G 2.30E-05 Urinary metabolites G/O1 intron 21572414 rs4784655 chr16 56364030 G C 2.40E-05 Urinary metabolites G/O1 intron 21572414 rs13338253 chr16 56372461 T C 1.85E-04 Lung function (forced expiratory volume in 1 second) G/O1 intron 24023788 rs13338253 chr16 56372461 T C 2.95E-04 Lung function (forced vital capacity) G/O1 intron 24023788 rs2617841 chr16 56373222 G A 8.95E-05 Postoperative ventricular dysfunction G/O1 intron 21980348 rs4783935 chr16 56375496 C T 5.27E-05 Type 2 diabetes G/O1 intron 17463246 rs4924 chr16 56396486 C T 2.00E-05 Rheumatoid arthritis AMFR UTR-3 17804836 rs1382359 chr16 56399514 G A 8.65E-04 Alzheimer's disease AMFR intron 24755620 rs2617848 chr16 56399835 T C 8.65E-04 Alzheimer's disease AMFR intron 24755620 rs2241956 chr16 56400847 T C 8.65E-04 Alzheimer's disease AMFR intron 24755620 rs2241957 chr16 56401294 T C 8.65E-04 Alzheimer's disease AMFR intron 24755620 rs2587866 chr16 56403899 C T 8.57E-04 Alzheimer's disease AMFR intron 24755620 rs2587869 chr16 56406926 G A 8.57E-04 Alzheimer's disease AMFR intron 24755620 rs2587871 chr16 56412526 T C 9.05E-05 Serum metabolites AMFR intron 19043545 rs2587871 chr16 56412526 T C 8.57E-04 Alzheimer's disease AMFR intron 24755620 rs2587873 chr16 56412734 C G 8.32E-04 Alzheimer's disease AMFR intron 24755620 rs2440467 chr16 56417047 T C 8.32E-04 Alzheimer's disease AMFR intron 24755620 rs2440468 chr16 56420594 G A 2.00E-05 Rheumatoid arthritis AMFR intron 17804836 rs2432538 chr16 56421427 A G 7.49E-04 Alzheimer's disease AMFR intron 24755620 rs2550309 chr16 56434742 G A 7.49E-04 Alzheimer's disease AMFR intron 24755620 rs2966206 chr16 56441253 G A 7.49E-04 Alzheimer's disease AMFR intron 24755620 rs7203090 chr16 56444439 C T 7.49E-04 Alzheimer's disease AMFR intron 24755620 rs7187883 chr16 56445999 C A 7.06E-04 Alzheimer's disease AMFR intron 24755620 rs2966205 chr16 56446612 C T 7.06E-04 Alzheimer's disease AMFR intron 24755620 rs6499837 chr16 56453981 T C 6.79E-04 Alzheimer's disease AMFR intron 24755620 rs4784667 chr16 56462000 G A 7.20E-04 Alzheimer's disease / / 24755620 rs7192780 chr16 56467566 A G 7.79E-04 Alzheimer's disease NUDT21 intron 24755620 rs8056687 chr16 56468561 C T 7.87E-04 Alzheimer's disease NUDT21 intron 24755620 rs4784669 chr16 56481282 G A 1.26E-05 Type 2 diabetes NUDT21 intron 17463246 rs8060037 chr16 56484820 C T 1.52E-04 Lung function (forced expiratory volume in 1 second) NUDT21 intron 24023788 rs11640819 chr16 56486248 A G 5.94E-04 Alzheimer's disease OGFOD1 intron 24755620 rs34793257 chr16 56494071 C T 5.56E-04 Alzheimer's disease OGFOD1 intron 24755620 rs14306 chr16 56510299 A C 6.30E-04 Alzheimer's disease OGFOD1 UTR-3 24755620 rs7198524 chr16 56510601 C T 6.48E-04 Alzheimer's disease OGFOD1 UTR-3 24755620 rs4783941 chr16 56511736 T C 7.46E-04 Alzheimer's disease / / 24755620 rs1559452 chr16 56537193 A G 2.64E-04 Myopia (pathological) BBS2 intron 21095009 rs9937444 chr16 56543558 A G 9.46E-15 Lymphocyte counts BBS2 intron 22286170 rs2288058 chr16 56548777 C T 2.44E-04 Myopia (pathological) BBS2 intron 21095009 rs282234 chr16 56597941 T C 1.60E-05 Urinary metabolites / / 21572414 rs11643815 chr16 56602798 G A 2.47E-04 Alzheimer's disease / / 24755620 rs4784684 chr16 56604330 G A 2.74E-04 Alzheimer's disease / / 24755620 rs1909749 chr16 56612702 C T 8.25E-04 Alcohol dependence / / 21314694 rs381706 chr16 56613116 T A 1.20E-05 Urinary metabolites / / 21572414 rs8055724 chr16 56649637 C T 3.70E-04 Lymphocyte counts / / 22286170 rs8049883 chr16 56673410 G A 2.90E-05 Urinary metabolites MT1A intron 21572414 rs8049883 chr16 56673410 G A 2.08E-07 Nasopharyngeal carcinoma MT1A intron 23209447 rs1001362 chr16 56674858 T C 5.31E-04 Alzheimer's disease / / 24755620 rs7189840 chr16 56683626 G A 4.90E-05 Immunoglobulin A / / 20694011 rs12447986 chr16 56695546 T C 1.38E-04 Multiple complex diseases / / 17554300 rs11647796 chr16 56696551 A G 4.23E-04 Multiple complex diseases / / 17554300 rs7194895 chr16 56697091 G T 4.15E-05 Parkinson's disease / / 17052657 rs2062545 chr16 56704125 G A 7.70E-04 Response to taxane treatment (placlitaxel) MT1H intron 23006423 rs2011186 chr16 56705869 T C 1.85E-05 Brain structure / / 22504417 rs12598600 chr16 56721870 C T 4.06E-04 Type 2 diabetes / / 17463246 rs8064100 chr16 56725173 A G 3.00E-06 Gambling / / 22780124 rs7187278 chr16 56730518 A T 3.50E-04 Smoking initiation / / 24665060 rs4784718 chr16 56732125 G A 7.94E-05 Tunica Media / / pha003036 rs13332276 chr16 56732211 G T 7.94E-05 Tunica Media / / pha003036 rs4783955 chr16 56757816 A G 4.85E-05 Bipolar disorder / / 17486107 rs8048885 chr16 56800333 T A 4.69E-04 Smoking cessation NUP93 intron 24665060 rs13329802 chr16 56812300 C T 6.34E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) NUP93 intron 23648065 rs10852553 chr16 56825666 G A 9.10E-05 HDL cholesterol NUP93 intron pha003075 rs16962399 chr16 56846804 C T 5.10E-05 Triglycerides NUP93 intron 19074352 rs1529929 chr16 56849496 G A 3.54E-05 Coronary restenosis NUP93 intron 21878436 rs2895432 chr16 56856955 G A 1.20E-06 Metabolic syndrome phenotype NUP93 intron 22022282 rs2895432 chr16 56856955 G A 1.20E-66 Metabolic syndrome phenotype NUP93 intron 22022282 rs2895432 chr16 56856955 G A 1.60E-66 Metabolic syndrome phenotype NUP93 intron 22022282 rs2241770 chr16 56866196 T C 1.40E-08 Triglycerides NUP93 intron 19060911 rs1347591 chr16 56868700 A G 7.06E-04 Rheumatoid arthritis NUP93 intron 21452313 rs16962767 chr16 56873789 T C 4.82E-08 Triglycerides NUP93 intron 19060911 rs16962767 chr16 56873789 T C 7.50E-05 Triglycerides NUP93 intron 19074352 rs8044753 chr16 56883438 G A 5.00E-05 Prostate cancer / / 21743057 rs735144 chr16 56883924 A G 3.83E-05 Coronary restenosis / / 21878436 rs1436424 chr16 56895034 G T 2.37E-14 HDL cholesterol / / 23063622 rs13306673 chr16 56900931 C T 6.66E-11 HDL cholesterol SLC12A3 intron 23063622 rs12596776 chr16 56919348 C G 1.10E-04 Type 2 diabetes SLC12A3 intron 17463246 rs12596776 chr16 56919348 C G 2.80E-08 Lipid levels SLC12A3 intron 18193043 rs13306677 chr16 56926195 G A 1.20E-07 Lipid levels SLC12A3 intron 18193043 rs13306677 chr16 56926195 G A 1.32E-10 HDL cholesterol SLC12A3 intron 23063622 rs8056954 chr16 56930229 G T 1.75E-12 HDL cholesterol (female) SLC12A3 intron 23063622 rs8056954 chr16 56930229 G T 2.22E-13 HDL cholesterol SLC12A3 intron 23063622 rs11643718 chr16 56933519 G A 2.00E-05 Type 2 diabetes SLC12A3 missense 14578305 rs11643718 chr16 56933519 G A 1.43E-05 Systolic blood pressure SLC12A3 missense 21909115 rs11643718 chr16 56933519 G A 6.96E-09 HDL cholesterol SLC12A3 missense 23063622 rs12447287 chr16 56937998 T C 2.84E-04 Type 2 diabetes SLC12A3 intron 17463246 rs12446689 chr16 56938016 A G 1.70E-04 HDL particle features SLC12A3 intron 21283740 rs12446689 chr16 56938016 A G 1.73E-13 HDL cholesterol SLC12A3 intron 23063622 rs2289114 chr16 56938522 C T 3.00E-05 Lipid levels SLC12A3 intron 18193043 rs2289114 chr16 56938522 C T 1.19E-05 Body mass (lean) SLC12A3 intron 19268274 rs11640308 chr16 56939969 A G 4.08E-04 Multiple complex diseases SLC12A3 intron 17554300 rs3794650 chr16 56940513 T C 6.45E-05 Body mass (lean) SLC12A3 intron 19268274 rs1138429 chr16 56942921 A T 5.07E-19 HDL cholesterol SLC12A3 intron 23063622 rs2217332 chr16 56969148 G A 8.60E-06 HDL cholesterol HERPUD1 missense 18193046 rs2217332 chr16 56969148 G A 6.77E-10 Triglycerides HERPUD1 missense 19060911 rs2217332 chr16 56969148 G A 3.00E-06 Metabolic syndrome HERPUD1 missense 20694148 rs247615 chr16 56984763 A G 1.81E-10 Triglycerides / / 19060911 rs247615 chr16 56984763 A G 1.63E-27 HDL cholesterol / / 23063622 rs9989419 chr16 56985139 A G 1.62E-09 Type 2 diabetes / / 17463246 rs9989419 chr16 56985139 A G 1.03E-10 Cardiovascular disease / / 18179892 rs9989419 chr16 56985139 A G 3.00E-31 HDL cholesterol / / 18193043 rs9989419 chr16 56985139 A G 3.07E-48 Triglycerides / / 19060911 rs9989419 chr16 56985139 A G 9.20E-19 Lipid levels / / 19802338 rs9989419 chr16 56985139 A G 9.60E-14 Lipid levels / / 19802338 rs9989419 chr16 56985139 A G 2.59E-12 Lipid levels / / 19913121 rs9989419 chr16 56985139 A G 4.39E-04 Lipid levels / / 19913121 rs9989419 chr16 56985139 A G 9.76E-21 Lipid levels / / 19913121 rs9989419 chr16 56985139 A G 9.00E-27 HDL cholesterol / / 20031538 rs9989419 chr16 56985139 A G 2.60E-14 Response to statin therapy / / 20339536 rs9989419 chr16 56985139 A G 5.96E-14 Lipid levels / / 20370913 rs9989419 chr16 56985139 A G 1.00E-32 HDL cholesterol / / 20864672 rs9989419 chr16 56985139 A G 3.00E-31 Coronary heart disease / / 21347282 rs9989419 chr16 56985139 A G 2.47E-07 HDL cholesterol / / 21589926 rs9989419 chr16 56985139 A G 2.89E-12 HDL cholesterol / / 21589926 rs9989419 chr16 56985139 A G 2.24E-18 Cardiovascular disease risk factors / / 21943158 rs9989419 chr16 56985139 A G 1.52E-57 HDL cholesterol (female) / / 23063622 rs9989419 chr16 56985139 A G 2.16E-108 HDL cholesterol / / 23063622 rs9989419 chr16 56985139 A G 5.13E-46 HDL cholesterol (male) / / 23063622 rs9989419 chr16 56985139 A G 5.00E-11 Lipid traits / / 24023261 rs9989419 chr16 56985139 A G 2.71E-09 HDL cholesterol / / 24886709 rs9989419 chr16 56985139 A G 2.21E-09 HDL particle features / / pha002900 rs9989419 chr16 56985139 A G 7.27E-05 HDL cholesterol / / pha003075 rs12448528 chr16 56985555 A G 1.94E-09 Triglycerides / / 19060911 rs12448528 chr16 56985555 A G 1.30E-14 Response to statin therapy / / 20339536 rs7203286 chr16 56986762 G T 1.97E-17 Metabolite levels / / 22286219 rs12446515 chr16 56987015 C T 2.40E-24 Metabolite levels / / 22286219 rs56156922 chr16 56987369 T C 9.98E-25 Metabolite levels / / 22286219 rs56228609 chr16 56987765 C T 9.46E-25 Metabolite levels / / 22286219 rs173539 chr16 56988044 C T 4.00E-75 HDL cholesterol / / 19060906 rs173539 chr16 56988044 C T 9.20E-32 Response to statin therapy / / 20339536 rs173539 chr16 56988044 C T 4.00E-75 Coronary heart disease / / 21347282 rs173539 chr16 56988044 C T 1.00E-16 Metabolic syndrome (bivariate traits) / / 21386085 rs173539 chr16 56988044 C T 5.00E-16 HDL Cholesterol - Triglycerides (HDLC-TG) / / 21386085 rs173539 chr16 56988044 C T 9.00E-09 Metabolic syndrome / / 21386085 rs173539 chr16 56988044 C T 4.00E-75 HDL cholesterol / / 21589926 rs173539 chr16 56988044 C T 3.00E-65 Cardiovascular disease risk factors / / 21943158 rs173539 chr16 56988044 C T 2.70E-08 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs173539 chr16 56988044 C T 1.64E-27 Metabolite levels / / 22286219 rs173539 chr16 56988044 C T 8.50E-17 Sphingolipid levels / / 22359512 rs173539 chr16 56988044 C T 3.00E-70 Metabolite levels (atherosclerosis) / / 22916037 rs247616 chr16 56989590 C T 2.80E-16 Triglycerides / / 19060911 rs247616 chr16 56989590 C T 2.50E-32 Response to statin therapy / / 20339536 rs247616 chr16 56989590 C T 1.00E-23 Cardiovascular disease risk factors / / 20838585 rs247616 chr16 56989590 C T 3.00E-08 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs247616 chr16 56989590 C T 5.00E-61 Metabolic syndrome phenotype / / 22022282 rs247616 chr16 56989590 C T 7.10E-06 Metabolic syndrome phenotype / / 22022282 rs247616 chr16 56989590 C T 8.30E-72 Metabolic syndrome phenotype / / 22022282 rs247616 chr16 56989590 C T 2.34E-27 Metabolite levels / / 22286219 rs247616 chr16 56989590 C T 7.80E-17 Sphingolipid levels / / 22359512 rs247616 chr16 56989590 C T 1.00E-11 Blood metabolite levels / / 24816252 rs12923459 chr16 56989830 G A 1.77E-22 Metabolite levels / / 22286219 rs247617 chr16 56990716 C A 1.17E-27 Metabolite levels / / 22286219 rs247617 chr16 56990716 C A 9.00E-60 Metabolic syndrome / / 22399527 rs247617 chr16 56990716 C A 1.00E-44 HDL cholesterol / / 23726366 rs247617 chr16 56990716 C A 3.00E-16 HDL cholesterol / / 23726366 rs183130 chr16 56991363 C T 1.02E-28 Metabolite levels / / 22286219 rs6499861 chr16 56991495 C G 2.59E-22 HDL cholesterol / / 23063622 rs28888131 chr16 56991624 G A 1.78E-13 Metabolite levels / / 22286219 rs6499863 chr16 56992017 G A 9.44E-25 HDL cholesterol / / 23063622 rs6499863 chr16 56992017 G A 1.76E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs12920974 chr16 56993025 G T 1.26E-12 Metabolite levels / / 22286219 rs12149545 chr16 56993161 G A 3.05E-27 Metabolite levels / / 22286219 rs12708967 chr16 56993211 T C 1.60E-13 Lipid levels / / 19913121 rs12708967 chr16 56993211 T C 6.76E-04 Lipid levels / / 19913121 rs12708967 chr16 56993211 T C 8.79E-23 Lipid levels / / 19913121 rs12708967 chr16 56993211 T C 3.80E-14 Response to statin therapy / / 20339536 rs12708967 chr16 56993211 T C 3.16E-18 Cardiovascular disease risk factors / / 21943158 rs12708967 chr16 56993211 T C 1.93E-14 Metabolite levels / / 22286219 rs12708967 chr16 56993211 T C 8.00E-11 Sphingolipid levels / / 22359512 rs12708967 chr16 56993211 T C 2.69E-105 HDL cholesterol / / 23063622 rs3764261 chr16 56993324 C A 2.00E-57 HDL cholesterol / / 18193043 rs3764261 chr16 56993324 C A 1.00E-27 Waist circumference and related phenotypes / / 18454146 rs3764261 chr16 56993324 C A 7.00E-29 HDL cholesterol / / 19060910 rs3764261 chr16 56993324 C A 2.59E-89 Triglycerides / / 19060911 rs3764261 chr16 56993324 C A 3.00E-12 HDL cholesterol / / 19359809 rs3764261 chr16 56993324 C A 1.00E-41 Lipid levels / / 19802338 rs3764261 chr16 56993324 C A 1.10E-34 Lipid levels / / 19802338 rs3764261 chr16 56993324 C A 1.06E-06 Lipid levels / / 19913121 rs3764261 chr16 56993324 C A 1.12E-06 Lipid levels / / 19913121 rs3764261 chr16 56993324 C A 6.19E-19 Lipid levels / / 19913121 rs3764261 chr16 56993324 C A 6.80E-36 Lipid levels / / 19913121 rs3764261 chr16 56993324 C A 4.84E-29 Blood cell counts and other traits / / 20139978 rs3764261 chr16 56993324 C A 5.00E-29 Blood cell counts and other traits / / 20139978 rs3764261 chr16 56993324 C A 2.10E-31 Response to statin therapy / / 20339536 rs3764261 chr16 56993324 C A 7.00E-07 Age-related macular degeneration / / 20385819 rs3764261 chr16 56993324 C A 1.87E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs3764261 chr16 56993324 C A 1.00E-12 Triglycerides / / 20686565 rs3764261 chr16 56993324 C A 7.00E-14 Cholesterol,total / / 20686565 rs3764261 chr16 56993324 C A 7E-380 HDL cholesterol / / 20686565 rs3764261 chr16 56993324 C A 9.00E-13 LDL cholesterol / / 20686565 rs3764261 chr16 56993324 C A 1.00E-48 Metabolic syndrome / / 20694148 rs3764261 chr16 56993324 C A 2.20E-10 HDL particle features / / 21283740 rs3764261 chr16 56993324 C A 5.60E-15 HDL particle features / / 21283740 rs3764261 chr16 56993324 C A 3.00E-12 Coronary heart disease / / 21347282 rs3764261 chr16 56993324 C A 3.00E-13 Metabolic syndrome (bivariate traits) / / 21386085 rs3764261 chr16 56993324 C A 1.22E-25 HDL cholesterol / / 21589926 rs3764261 chr16 56993324 C A 2.63E-13 HDL cholesterol / / 21589926 rs3764261 chr16 56993324 C A 6.40E-43 HDL cholesterol / / 21589926 rs3764261 chr16 56993324 C A 7.00E-09 Age-related macular degeneration / / 21665990 rs3764261 chr16 56993324 C A 1.69E-40 Cardiovascular disease risk factors / / 21943158 rs3764261 chr16 56993324 C A 1.00E-36 Lipid metabolism phenotypes / / 22286219 rs3764261 chr16 56993324 C A 6.90E-17 Sphingolipid levels / / 22359512 rs3764261 chr16 56993324 C A 0.000000211 LDL cholesterol / / 23063622 rs3764261 chr16 56993324 C A 0.000000743 Triglycerides / / 23063622 rs3764261 chr16 56993324 C A 1.66E-08 Triglycerides / / 23063622 rs3764261 chr16 56993324 C A 6.14E-10 Cholesterol,total / / 23063622 rs3764261 chr16 56993324 C A 8.67E-275 HDL cholesterol / / 23063622 rs3764261 chr16 56993324 C A 0.0000028 Apolipoprotein B levels / / 23100282 rs3764261 chr16 56993324 C A 0.000027 Apolipoprotein B levels response after 40mg daily simvastatin treatment / / 23100282 rs3764261 chr16 56993324 C A 2.80E-06 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) / / 23103227 rs3764261 chr16 56993324 C A 7.00E-21 Lipoprotein-associated phospholipase A2 activity and mass / / 23118302 rs3764261 chr16 56993324 C A 4.53E-12 HDL cholesterol / / 23236364 rs3764261 chr16 56993324 C A 1E-769 HDL cholesterol / / 24097068 rs3764261 chr16 56993324 C A 2.00E-25 Triglycerides / / 24097068 rs3764261 chr16 56993324 C A 2.00E-34 LDL cholesterol / / 24097068 rs3764261 chr16 56993324 C A 4.00E-31 Cholesterol,total / / 24097068 rs3764261 chr16 56993324 C A 2.00E-25 Lipid traits / / 24386095 rs3764261 chr16 56993324 C A 6.97E-29 HDL particle features / / pha002900 rs3764261 chr16 56993324 C A 8.17E-05 HDL cholesterol / / pha003074 rs3764261 chr16 56993324 C A 1.89E-07 HDL cholesterol / / pha003075 rs12447839 chr16 56993935 C T 4.68E-14 HDL cholesterol CETP nearGene-5 23063622 rs12447924 chr16 56994192 C T 1.11E-16 HDL cholesterol CETP nearGene-5 23063622 rs12720918 chr16 56994212 T C 1.00E-15 Lipid levels CETP nearGene-5 19913121 rs12720918 chr16 56994212 T C 1.15E-08 Lipid levels CETP nearGene-5 19913121 rs12720918 chr16 56994212 T C 2.35E-05 Lipid levels CETP nearGene-5 19913121 rs12720918 chr16 56994212 T C 3.07E-04 Lipid levels CETP nearGene-5 19913121 rs12720918 chr16 56994212 T C 1.81E-12 Metabolite levels CETP nearGene-5 22286219 rs12720918 chr16 56994212 T C 0.00000484 LDL cholesterol CETP nearGene-5 23063622 rs12720918 chr16 56994212 T C 0.0000568 Triglycerides CETP nearGene-5 23063622 rs12720918 chr16 56994212 T C 4.78E-87 HDL cholesterol CETP nearGene-5 23063622 rs17231506 chr16 56994528 C T 1.36E-06 Lipid levels CETP nearGene-5 19913121 rs17231506 chr16 56994528 C T 1.41E-19 Lipid levels CETP nearGene-5 19913121 rs17231506 chr16 56994528 C T 2.21E-36 Lipid levels CETP nearGene-5 19913121 rs17231506 chr16 56994528 C T 4.63E-07 Lipid levels CETP nearGene-5 19913121 rs17231506 chr16 56994528 C T 3.90E-12 Response to statin therapy CETP nearGene-5 20339536 rs17231506 chr16 56994528 C T 1.90E-10 HDL particle features CETP nearGene-5 21283740 rs17231506 chr16 56994528 C T 5.90E-15 HDL particle features CETP nearGene-5 21283740 rs17231506 chr16 56994528 C T 9.09E-28 Metabolite levels CETP nearGene-5 22286219 rs17231506 chr16 56994528 C T 1.13E-60 HDL cholesterol (male) CETP nearGene-5 22629316 rs17231506 chr16 56994528 C T 1.20E-120 HDL cholesterol CETP nearGene-5 22629316 rs17231506 chr16 56994528 C T 6.83E-68 HDL cholesterol (female) CETP nearGene-5 22629316 rs17231506 chr16 56994528 C T 0.000000777 Triglycerides CETP nearGene-5 23063622 rs17231506 chr16 56994528 C T 1.28E-273 HDL cholesterol CETP nearGene-5 23063622 rs17231506 chr16 56994528 C T 9.31E-10 Cholesterol,total CETP nearGene-5 23063622 rs4783961 chr16 56994894 G A 1.90E-08 Response to statin therapy CETP nearGene-5 20339536 rs4783961 chr16 56994894 G A 1.81E-06 HDL cholesterol CETP nearGene-5 21589926 rs4783961 chr16 56994894 G A 3.80E-11 Metabolite levels CETP nearGene-5 22286219 rs4783961 chr16 56994894 G A 1.17E-43 HDL cholesterol CETP nearGene-5 22629316 rs4783961 chr16 56994894 G A 9.11E-52 HDL cholesterol CETP nearGene-5 23063622 rs4783961 chr16 56994894 G A 6.08E-40 HDL cholesterol CETP nearGene-5 23236364 rs4783962 chr16 56995038 T C 4.02E-04 Type 2 diabetes CETP nearGene-5 17463246 rs4783962 chr16 56995038 T C 1.13E-16 HDL cholesterol CETP nearGene-5 23063622 rs1799851 chr16 56995234 CCC CA,CC 2.70E-09 HDL cholesterol CETP nearGene-5 23063622 rs1800776 chr16 56995234 C A 2.70E-09 HDL cholesterol CETP nearGene-5 23063622 rs1800775 chr16 56995236 C A 3.00E-06 Triglycerides CETP nearGene-5 17463246 rs1800775 chr16 56995236 C A 3.00E-13 Triglycerides CETP nearGene-5 17463246 rs1800775 chr16 56995236 C A 1.00E-73 HDL cholesterol CETP nearGene-5 18193044 rs1800775 chr16 56995236 C A 2.25E-23 Triglycerides CETP nearGene-5 19060911 rs1800775 chr16 56995236 C A 2.70E-37 Lipid levels CETP nearGene-5 19802338 rs1800775 chr16 56995236 C A 7.00E-27 Lipid levels CETP nearGene-5 19802338 rs1800775 chr16 56995236 C A 2.63E-29 Lipid levels CETP nearGene-5 19913121 rs1800775 chr16 56995236 C A 8.75E-16 Lipid levels CETP nearGene-5 19913121 rs1800775 chr16 56995236 C A 1.00E-38 Lipid levels CETP nearGene-5 19936222 rs1800775 chr16 56995236 C A 1.10E-53 Lipid levels CETP nearGene-5 19936222 rs1800775 chr16 56995236 C A 1.20E-18 Lipid levels CETP nearGene-5 19936222 rs1800775 chr16 56995236 C A 1.35E-59 Lipid levels CETP nearGene-5 19936222 rs1800775 chr16 56995236 C A 1.37E-81 Lipid levels CETP nearGene-5 19936222 rs1800775 chr16 56995236 C A 1.86E-59 Lipid levels CETP nearGene-5 19936222 rs1800775 chr16 56995236 C A 2.79E-19 Lipid levels CETP nearGene-5 19936222 rs1800775 chr16 56995236 C A 2.90E-09 Lipid levels CETP nearGene-5 19936222 rs1800775 chr16 56995236 C A 3.28E-93 Lipid levels CETP nearGene-5 19936222 rs1800775 chr16 56995236 C A 4.27E-08 Lipid levels CETP nearGene-5 19936222 rs1800775 chr16 56995236 C A 4.30E-51 Lipid levels CETP nearGene-5 19936222 rs1800775 chr16 56995236 C A 4.50E-16 Lipid levels CETP nearGene-5 19936222 rs1800775 chr16 56995236 C A 4.50E-42 Lipid levels CETP nearGene-5 19936222 rs1800775 chr16 56995236 C A 4.56E-14 Lipid levels CETP nearGene-5 19936222 rs1800775 chr16 56995236 C A 4.70E-20 Lipid levels CETP nearGene-5 19936222 rs1800775 chr16 56995236 C A 4.96E-87 Lipid levels CETP nearGene-5 19936222 rs1800775 chr16 56995236 C A 7.95E-78 Lipid levels CETP nearGene-5 19936222 rs1800775 chr16 56995236 C A 8.80E-15 Lipid levels CETP nearGene-5 19936222 rs1800775 chr16 56995236 C A 9.36E-31 Lipid levels CETP nearGene-5 19936222 rs1800775 chr16 56995236 C A 4.00E-93 HDL cholesterol CETP nearGene-5 20031564 rs1800775 chr16 56995236 C A 1.66E-07 Blood cell counts and other traits CETP nearGene-5 20139978 rs1800775 chr16 56995236 C A 1.90E-20 Response to statin therapy CETP nearGene-5 20339536 rs1800775 chr16 56995236 C A 8.61E-34 Lipid levels CETP nearGene-5 20370913 rs1800775 chr16 56995236 C A 1.00E-73 Coronary heart disease CETP nearGene-5 21347282 rs1800775 chr16 56995236 C A 1.00E-73 HDL cholesterol CETP nearGene-5 21589926 rs1800775 chr16 56995236 C A 1.17E-12 HDL cholesterol CETP nearGene-5 21589926 rs1800775 chr16 56995236 C A 5.55E-25 HDL cholesterol CETP nearGene-5 21589926 rs1800775 chr16 56995236 C A 6.72E-32 Cardiovascular disease risk factors CETP nearGene-5 21943158 rs1800775 chr16 56995236 C A 2.66E-18 Metabolite levels CETP nearGene-5 22286219 rs1800775 chr16 56995236 C A 9.20E-17 Sphingolipid levels CETP nearGene-5 22359512 rs1800775 chr16 56995236 C A 5.20E-196 HDL cholesterol CETP nearGene-5 23063622 rs1800775 chr16 56995236 C A 8.38E-11 Cholesterol,total CETP nearGene-5 23063622 rs1800775 chr16 56995236 C A 8.01E-13 HDL cholesterol CETP nearGene-5 23696881 rs1800775 chr16 56995236 C A 3.00E-09 Lipid traits CETP nearGene-5 24023260 rs1800775 chr16 56995236 C A 1.00E-11 Blood metabolite levels CETP nearGene-5 24816252 rs17231520 chr16 56995827 G A 4.21E-31 HDL cholesterol (female) CETP nearGene-5 22629316 rs17231520 chr16 56995827 G A 6.54E-32 HDL cholesterol (male) CETP nearGene-5 22629316 rs17231520 chr16 56995827 G A 7.65E-58 HDL cholesterol CETP nearGene-5 22629316 rs17231520 chr16 56995827 G A 1.70E-62 HDL cholesterol CETP nearGene-5 23236364 rs35088638 chr16 56996158 T TG 4.59E-20 Metabolite levels CETP intron 22286219 rs3816117 chr16 56996158 T C 4.59E-20 Metabolite levels CETP intron 22286219 rs711752 chr16 56996211 G A 7.90E-41 HDL cholesterol CETP intron 18193046 rs711752 chr16 56996211 G A 3.12E-15 Triglycerides CETP intron 19060911 rs711752 chr16 56996211 G A 2.19E-18 Lipid levels CETP intron 19913121 rs711752 chr16 56996211 G A 6.48E-32 Lipid levels CETP intron 19913121 rs711752 chr16 56996211 G A 8.60E-18 Response to statin therapy CETP intron 20339536 rs711752 chr16 56996211 G A 2.96E-34 Cardiovascular disease risk factors CETP intron 21943158 rs711752 chr16 56996211 G A 4.51E-21 Metabolite levels CETP intron 22286219 rs711752 chr16 56996211 G A 6.50E-19 Sphingolipid levels CETP intron 22359512 rs711752 chr16 56996211 G A 1.55E-196 HDL cholesterol CETP intron 23063622 rs711752 chr16 56996211 G A 6.73E-10 Cholesterol,total CETP intron 23063622 rs711752 chr16 56996211 G A 4.77E-13 HDL cholesterol CETP intron 23696881 rs708272 chr16 56996288 G A 2.60E-38 Lipid levels CETP intron 19802338 rs708272 chr16 56996288 G A 3.60E-28 Lipid levels CETP intron 19802338 rs708272 chr16 56996288 G A 1.02E-18 Lipid levels CETP intron 19913121 rs708272 chr16 56996288 G A 1.87E-32 Lipid levels CETP intron 19913121 rs708272 chr16 56996288 G A 1.87E-26 Lipid levels CETP intron 19936222 rs708272 chr16 56996288 G A 1.30E-08 Response to statin therapy CETP intron 20339536 rs708272 chr16 56996288 G A 2.60E-12 HDL cholesterol CETP intron 21589926 rs708272 chr16 56996288 G A 9.79E-22 HDL cholesterol CETP intron 21589926 rs708272 chr16 56996288 G A 1.18E-20 Metabolite levels CETP intron 22286219 rs708272 chr16 56996288 G A 5.93E-197 HDL cholesterol CETP intron 23063622 rs708272 chr16 56996288 G A 6.39E-10 Cholesterol,total CETP intron 23063622 rs708272 chr16 56996288 G A 0.000043 Apolipoprotein B levels CETP intron 23100282 rs708272 chr16 56996288 G A 0.00005 Apolipoprotein B levels response after 40mg daily simvastatin treatment CETP intron 23100282 rs708272 chr16 56996288 G A 5.00E-05 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) CETP intron 23103227 rs34620476 chr16 56996649 C A 5.00E-21 Metabolite levels CETP intron 22286219 rs1864163 chr16 56997233 G A 7.00E-39 HDL cholesterol CETP intron 18193043 rs1864163 chr16 56997233 G A 4.16E-17 Triglycerides CETP intron 19060911 rs1864163 chr16 56997233 G A 1.00E-18 Lipid levels CETP intron 19802338 rs1864163 chr16 56997233 G A 6.90E-26 Lipid levels CETP intron 19802338 rs1864163 chr16 56997233 G A 2.80E-27 Lipid levels CETP intron 19913121 rs1864163 chr16 56997233 G A 8.48E-16 Lipid levels CETP intron 19913121 rs1864163 chr16 56997233 G A 3.30E-25 Lipid levels CETP intron 19936222 rs1864163 chr16 56997233 G A 7.40E-22 Lipid levels CETP intron 19936222 rs1864163 chr16 56997233 G A 1.50E-17 Response to statin therapy CETP intron 20339536 rs1864163 chr16 56997233 G A 7.00E-39 Coronary heart disease CETP intron 21347282 rs1864163 chr16 56997233 G A 7.19E-09 HDL cholesterol CETP intron 21589926 rs1864163 chr16 56997233 G A 9.78E-21 HDL cholesterol CETP intron 21589926 rs1864163 chr16 56997233 G A 2.42E-18 Cardiovascular disease risk factors CETP intron 21943158 rs1864163 chr16 56997233 G A 7.95E-17 Metabolite levels CETP intron 22286219 rs1864163 chr16 56997233 G A 1.70E-12 Sphingolipid levels CETP intron 22359512 rs1864163 chr16 56997233 G A 9.18E-05 Stroke (ischemic) CETP intron 22941190 rs1864163 chr16 56997233 G A 2.24E-08 Cholesterol,total CETP intron 23063622 rs1864163 chr16 56997233 G A 4.22E-190 HDL cholesterol CETP intron 23063622 rs1864163 chr16 56997233 G A 7.00E-16 Age-related macular degeneration CETP intron 23455636 rs1864163 chr16 56997233 G A 1.07E-05 HDL cholesterol CETP intron pha003074 rs4587963 chr16 56997369 A T 2.33E-16 HDL cholesterol CETP intron 23063622 rs9929488 chr16 56998572 G C 2.00E-14 Response to statin therapy CETP intron 20339536 rs9929488 chr16 56998572 G C 1.01E-16 Metabolite levels CETP intron 22286219 rs9929488 chr16 56998572 G C 1.20E-11 Sphingolipid levels CETP intron 22359512 rs12720926 chr16 56998918 A G 1.32E-20 Metabolite levels CETP intron 22286219 rs7203984 chr16 56999258 A C 2.67E-10 Triglycerides CETP intron 19060911 rs7203984 chr16 56999258 A C 1.08E-20 Lipid levels CETP intron 19913121 rs7203984 chr16 56999258 A C 1.19E-12 Lipid levels CETP intron 19913121 rs7203984 chr16 56999258 A C 9.10E-15 Response to statin therapy CETP intron 20339536 rs7203984 chr16 56999258 A C 2.12E-17 Cardiovascular disease risk factors CETP intron 21943158 rs7203984 chr16 56999258 A C 2.75E-16 Metabolite levels CETP intron 22286219 rs7203984 chr16 56999258 A C 3.70E-08 Sphingolipid levels CETP intron 22359512 rs7203984 chr16 56999258 A C 1.04E-08 Cholesterol,total CETP intron 23063622 rs7203984 chr16 56999258 A C 2.87E-168 HDL cholesterol CETP intron 23063622 rs11508026 chr16 56999328 C T 7.52E-18 Lipid levels CETP intron 19913121 rs11508026 chr16 56999328 C T 9.92E-30 Lipid levels CETP intron 19913121 rs11508026 chr16 56999328 C T 2.00E-17 Response to statin therapy CETP intron 20339536 rs11508026 chr16 56999328 C T 9.22E-35 Cardiovascular disease risk factors CETP intron 21943158 rs11508026 chr16 56999328 C T 4.33E-20 Metabolite levels CETP intron 22286219 rs11508026 chr16 56999328 C T 2.40E-19 Sphingolipid levels CETP intron 22359512 rs11508026 chr16 56999328 C T 1.18E-186 HDL cholesterol CETP intron 23063622 rs11508026 chr16 56999328 C T 9.26E-09 Cholesterol,total CETP intron 23063622 rs708273 chr16 56999949 A G 1.00E-06 Lipid levels CETP intron 19913121 rs708273 chr16 56999949 A G 3.64E-04 Lipid levels CETP intron 19913121 rs708273 chr16 56999949 A G 5.57E-27 HDL cholesterol CETP intron 23063622 rs820299 chr16 57000284 G A 3.03E-14 HDL cholesterol CETP intron 23063622 rs8045855 chr16 57000696 T A 3.89E-19 Metabolite levels CETP intron 22286219 rs12720922 chr16 57000885 G A 1.34E-21 Lipid levels CETP intron 19913121 rs12720922 chr16 57000885 G A 8.69E-13 Lipid levels CETP intron 19913121 rs12720922 chr16 57000885 G A 2.38E-18 Metabolite levels CETP intron 22286219 rs12720922 chr16 57000885 G A 1.34E-191 HDL cholesterol CETP intron 23063622 rs12720922 chr16 57000885 G A 3.82E-10 Cholesterol,total CETP intron 23063622 rs118146573 chr16 57000938 G A 4.00E-10 Cholesterol,total CETP intron 24886709 rs4784741 chr16 57001216 C T 6.77E-21 Metabolite levels CETP intron 22286219 rs12444012 chr16 57001438 G A 6.89E-21 Metabolite levels CETP intron 22286219 rs12597002 chr16 57002404 C A 1.70E-08 Lipid levels CETP intron 19802338 rs12597002 chr16 57002404 C A 1.31E-06 Lipid levels CETP intron 19913121 rs12597002 chr16 57002404 C A 6.02E-04 Lipid levels CETP intron 19913121 rs12597002 chr16 57002404 C A 5.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CETP intron 20877124 rs12597002 chr16 57002404 C A 7.02E-27 HDL cholesterol CETP intron 23063622 rs9926440 chr16 57002663 C G 1.10E-14 Response to statin therapy CETP intron 20339536 rs9926440 chr16 57002663 C G 5.48E-14 Metabolite levels CETP intron 22286219 rs9926440 chr16 57002663 C G 1.80E-12 Sphingolipid levels CETP intron 22359512 rs9939224 chr16 57002732 T G 5.63E-14 Lipid levels CETP intron 19913121 rs9939224 chr16 57002732 T G 5.81E-23 Lipid levels CETP intron 19913121 rs9939224 chr16 57002732 T G 5.90E-15 Response to statin therapy CETP intron 20339536 rs9939224 chr16 57002732 T G 7.00E-12 Metabolic syndrome (bivariate traits) CETP intron 21386085 rs9939224 chr16 57002732 T G 1.28E-19 Cardiovascular disease risk factors CETP intron 21943158 rs9939224 chr16 57002732 T G 1.65E-14 Metabolite levels CETP intron 22286219 rs9939224 chr16 57002732 T G 7.30E-09 Sphingolipid levels CETP intron 22359512 rs9939224 chr16 57002732 T G 3.26E-09 Cholesterol,total CETP intron 23063622 rs9939224 chr16 57002732 T G 6.01E-181 HDL cholesterol CETP intron 23063622 rs11076174 chr16 57003146 T C 1.50E-05 Response to statin therapy CETP intron 20339536 rs11076174 chr16 57003146 T C 1.81E-06 HDL cholesterol CETP intron 21589926 rs11076174 chr16 57003146 T C 1.74E-29 HDL cholesterol CETP intron 23063622 rs891141 chr16 57003723 G T 1.10E-09 Cholesterol,total CETP intron 23063622 rs891142 chr16 57003977 T C 0.000000397 Cholesterol,total CETP intron 23063622 rs7205804 chr16 57004889 G A 4.70E-47 HDL cholesterol CETP intron 18193046 rs7205804 chr16 57004889 G A 7.69E-17 Triglycerides CETP intron 19060911 rs7205804 chr16 57004889 G A 2.30E-16 Response to statin therapy CETP intron 20339536 rs7205804 chr16 57004889 G A 5.33E-23 Metabolite levels CETP intron 22286219 rs7205804 chr16 57004889 G A 8.50E-20 Sphingolipid levels CETP intron 22359512 rs1532625 chr16 57005301 C T 2.61E-18 Lipid levels CETP intron 19913121 rs1532625 chr16 57005301 C T 2.91E-31 Lipid levels CETP intron 19913121 rs1532625 chr16 57005301 C T 6.46E-04 Lipid levels CETP intron 19913121 rs1532625 chr16 57005301 C T 1.32E-22 Metabolite levels CETP intron 22286219 rs1532625 chr16 57005301 C T 1.41E-188 HDL cholesterol CETP intron 23063622 rs1532625 chr16 57005301 C T 2.37E-08 Cholesterol,total CETP intron 23063622 rs1532624 chr16 57005479 C A 9.00E-94 HDL cholesterol CETP intron 19060911 rs1532624 chr16 57005479 C A 1.10E-27 Lipid levels CETP intron 19802338 rs1532624 chr16 57005479 C A 1.30E-37 Lipid levels CETP intron 19802338 rs1532624 chr16 57005479 C A 4.69E-18 Lipid levels CETP intron 19913121 rs1532624 chr16 57005479 C A 4.96E-31 Lipid levels CETP intron 19913121 rs1532624 chr16 57005479 C A 7.26E-04 Lipid levels CETP intron 19913121 rs1532624 chr16 57005479 C A 1.10E-39 Lipid levels CETP intron 19936222 rs1532624 chr16 57005479 C A 1.30E-66 Lipid levels CETP intron 19936222 rs1532624 chr16 57005479 C A 2.98E-55 Lipid levels CETP intron 19936222 rs1532624 chr16 57005479 C A 3.00E-20 Cholesterol CETP intron 20066028 rs1532624 chr16 57005479 C A 2.70E-16 Response to statin therapy CETP intron 20339536 rs1532624 chr16 57005479 C A 9.00E-94 Coronary heart disease CETP intron 21347282 rs1532624 chr16 57005479 C A 2.64E-04 Rheumatoid arthritis CETP intron 21452313 rs1532624 chr16 57005479 C A 3.00E-23 HDL cholesterol CETP intron 21589926 rs1532624 chr16 57005479 C A 3.33E-13 HDL cholesterol CETP intron 21589926 rs1532624 chr16 57005479 C A 9.40E-94 HDL cholesterol CETP intron 21589926 rs1532624 chr16 57005479 C A 8.39E-36 Cardiovascular disease risk factors CETP intron 21943158 rs1532624 chr16 57005479 C A 9.07E-23 Metabolite levels CETP intron 22286219 rs1532624 chr16 57005479 C A 8.60E-20 Sphingolipid levels CETP intron 22359512 rs1532624 chr16 57005479 C A 2.47E-09 Cholesterol,total CETP intron 23063622 rs1532624 chr16 57005479 C A 2.74E-198 HDL cholesterol CETP intron 23063622 rs1532624 chr16 57005479 C A 1.00E-24 HDL cholesterol CETP intron 23505323 rs1532624 chr16 57005479 C A 2.97E-22 HDL particle features CETP intron pha002900 rs12720873 chr16 57006072 G A 2.86E-10 HDL cholesterol CETP intron 23063622 rs11076175 chr16 57006378 A G 5.58E-23 Lipid levels CETP intron 19913121 rs11076175 chr16 57006378 A G 5.66E-13 Lipid levels CETP intron 19913121 rs11076175 chr16 57006378 A G 1.50E-15 Response to statin therapy CETP intron 20339536 rs11076175 chr16 57006378 A G 1.28E-19 Cardiovascular disease risk factors CETP intron 21943158 rs11076175 chr16 57006378 A G 1.25E-18 Metabolite levels CETP intron 22286219 rs11076175 chr16 57006378 A G 1.10E-08 Sphingolipid levels CETP intron 22359512 rs11076175 chr16 57006378 A G 6.53E-193 HDL cholesterol CETP intron 23063622 rs11076175 chr16 57006378 A G 7.79E-10 Cholesterol,total CETP intron 23063622 rs7499892 chr16 57006590 C T 1.69E-54 Triglycerides CETP intron 19060911 rs7499892 chr16 57006590 C T 9.00E-06 Biochemical measures CETP intron 19260141 rs7499892 chr16 57006590 C T 1.80E-24 Lipid levels CETP intron 19802338 rs7499892 chr16 57006590 C T 3.80E-20 Lipid levels CETP intron 19802338 rs7499892 chr16 57006590 C T 1.27E-13 Lipid levels CETP intron 19913121 rs7499892 chr16 57006590 C T 7.14E-24 Lipid levels CETP intron 19913121 rs7499892 chr16 57006590 C T 1.40E-20 Lipid levels CETP intron 19936222 rs7499892 chr16 57006590 C T 1.66E-14 Lipid levels CETP intron 19936222 rs7499892 chr16 57006590 C T 3.50E-15 Response to statin therapy CETP intron 20339536 rs7499892 chr16 57006590 C T 3.40E-13 Lipid levels CETP intron 21448234 rs7499892 chr16 57006590 C T 1.61E-23 HDL cholesterol CETP intron 21589926 rs7499892 chr16 57006590 C T 2.94E-11 HDL cholesterol CETP intron 21589926 rs7499892 chr16 57006590 C T 1.28E-19 Cardiovascular disease risk factors CETP intron 21943158 rs7499892 chr16 57006590 C T 1.67E-18 Metabolite levels CETP intron 22286219 rs7499892 chr16 57006590 C T 1.20E-08 Sphingolipid levels CETP intron 22359512 rs7499892 chr16 57006590 C T 4.20E-78 HDL cholesterol CETP intron 22629316 rs7499892 chr16 57006590 C T 2.85E-91 HDL cholesterol (female) CETP intron 23063622 rs7499892 chr16 57006590 C T 4.40E-89 HDL cholesterol (male) CETP intron 23063622 rs7499892 chr16 57006590 C T 5.16E-10 Cholesterol,total CETP intron 23063622 rs7499892 chr16 57006590 C T 9.58E-195 HDL cholesterol CETP intron 23063622 rs7499892 chr16 57006590 C T 7.27E-24 HDL cholesterol CETP intron 23236364 rs7499892 chr16 57006590 C T 3.50E-12 Lipid traits CETP intron 24023260 rs7499892 chr16 57006590 C T 2.29E-16 HDL particle features CETP intron pha002900 rs7499892 chr16 57006590 C T 4.22E-06 HDL cholesterol CETP intron pha003074 rs289713 chr16 57006829 T A 6.96E-14 Metabolite levels CETP intron 22286219 rs9930761 chr16 57007192 T C 1.60E-10 HDL cholesterol CETP intron 23063622 rs5883 chr16 57007353 C T 2.46E-15 Lipid levels CETP cds-synon 19913121 rs5883 chr16 57007353 C T 4.85E-05 Lipid levels CETP cds-synon 19913121 rs5883 chr16 57007353 C T 1.72E-12 HDL cholesterol CETP cds-synon 22629316 rs5883 chr16 57007353 C T 1.20E-23 HDL cholesterol CETP cds-synon 23063622 rs11076176 chr16 57007446 T G 2.07E-07 Lipid levels CETP intron 19913121 rs11076176 chr16 57007446 T G 4.62E-12 Lipid levels CETP intron 19913121 rs11076176 chr16 57007446 T G 5.71E-15 Metabolite levels CETP intron 22286219 rs11076176 chr16 57007446 T G 8.88E-67 HDL cholesterol CETP intron 22629316 rs11076176 chr16 57007446 T G 2.47E-12 Cholesterol,total CETP intron 23063622 rs11076176 chr16 57007446 T G 3.07E-123 HDL cholesterol CETP intron 23063622 rs289714 chr16 57007451 G A 1.14E-06 Lipid levels CETP intron 19913121 rs289714 chr16 57007451 G A 2.56E-10 Lipid levels CETP intron 19913121 rs289714 chr16 57007451 G A 3.30E-10 Response to statin therapy CETP intron 20339536 rs289714 chr16 57007451 G A 1.07E-09 Cardiovascular disease risk factors CETP intron 21943158 rs289714 chr16 57007451 G A 1.30E-57 Metabolic syndrome phenotype CETP intron 22022282 rs289714 chr16 57007451 G A 3.10E-58 Metabolic syndrome phenotype CETP intron 22022282 rs289714 chr16 57007451 G A 7.20E-06 Metabolic syndrome phenotype CETP intron 22022282 rs289714 chr16 57007451 G A 7.00E-11 Metabolite levels CETP intron 22286219 rs289714 chr16 57007451 G A 2.89E-106 HDL cholesterol CETP intron 23063622 rs289714 chr16 57007451 G A 7.74E-13 Cholesterol,total CETP intron 23063622 rs158477 chr16 57007610 G A 1.44E-11 HDL cholesterol CETP intron 23063622 rs158480 chr16 57008227 G A 3.05E-12 HDL cholesterol CETP intron 23063622 rs289715 chr16 57008508 A T 7.00E-08 Response to statin therapy CETP intron 20339536 rs289715 chr16 57008508 A T 3.82E-33 HDL cholesterol CETP intron 23063622 rs289716 chr16 57009376 T A 1.06E-08 Lipid levels CETP intron 19913121 rs289716 chr16 57009376 T A 1.22E-09 Lipid levels CETP intron 19913121 rs289716 chr16 57009376 T A 0.0000012 Cholesterol,total CETP intron 23063622 rs289716 chr16 57009376 T A 1.04E-53 HDL cholesterol CETP intron 23063622 rs289717 chr16 57009388 G A 1.65E-07 Lipid levels CETP intron 19913121 rs289717 chr16 57009388 G A 6.89E-10 Lipid levels CETP intron 19913121 rs289717 chr16 57009388 G A 8.80E-05 Response to statin therapy CETP intron 20339536 rs289717 chr16 57009388 G A 1.13E-35 HDL cholesterol CETP intron 23063622 rs736274 chr16 57009769 T A 1.98E-37 HDL cholesterol CETP intron 23063622 rs289718 chr16 57009932 C T 2.45E-09 Lipid levels CETP intron 19913121 rs289718 chr16 57009932 C T 2.55E-10 Lipid levels CETP intron 19913121 rs289718 chr16 57009932 C T 0.000001 Cholesterol,total CETP intron 23063622 rs289718 chr16 57009932 C T 1.73E-54 HDL cholesterol CETP intron 23063622 rs289719 chr16 57009941 T C 1.01E-08 Lipid levels CETP intron 19913121 rs289719 chr16 57009941 T C 1.27E-09 Lipid levels CETP intron 19913121 rs289719 chr16 57009941 T C 0.000001 Cholesterol,total CETP intron 23063622 rs289719 chr16 57009941 T C 1.13E-53 HDL cholesterol CETP intron 23063622 rs2033254 chr16 57009985 T C 4.00E-05 Type 2 diabetes CETP intron 17463248 rs4784744 chr16 57011185 G A 6.66E-23 Triglycerides CETP intron 19060911 rs4784744 chr16 57011185 G A 2.17E-07 Lipid levels CETP intron 19913121 rs4784744 chr16 57011185 G A 5.37E-10 Lipid levels CETP intron 19913121 rs4784744 chr16 57011185 G A 2.19E-04 Rheumatoid arthritis CETP intron 21452313 rs4784744 chr16 57011185 G A 2.32E-07 HDL cholesterol CETP intron 21589926 rs4784744 chr16 57011185 G A 5.23E-04 HDL cholesterol CETP intron 21589926 rs4784744 chr16 57011185 G A 3.34E-35 HDL cholesterol CETP intron 23063622 rs4784744 chr16 57011185 G A 7.15E-05 Coronary heart disease CETP intron pha003035 rs12720900 chr16 57011297 T C 0.000000718 LDL cholesterol CETP intron 23063622 rs12720900 chr16 57011297 T C 8.48E-12 Cholesterol,total CETP intron 23063622 rs291044 chr16 57011452 G A 2.62E-07 Lipid levels CETP intron 19913121 rs291044 chr16 57011452 G A 9.67E-10 Lipid levels CETP intron 19913121 rs291044 chr16 57011452 G A 2.23E-35 HDL cholesterol CETP intron 23063622 rs891144 chr16 57011936 C T 0.000000195 HDL cholesterol CETP intron 23063622 rs12708979 chr16 57012354 C T 6.97E-08 LDL cholesterol CETP intron 23063622 rs12708979 chr16 57012354 C T 7.68E-13 Triglycerides CETP intron 23063622 rs12708980 chr16 57012379 T G 4.40E-05 Type 2 diabetes CETP intron 17463248 rs12708980 chr16 57012379 T G 2.00E-28 HDL cholesterol CETP intron 21909109 rs12720889 chr16 57012563 A T 1.33E-09 Lipid levels CETP intron 19913121 rs12720889 chr16 57012563 A T 3.91E-09 Lipid levels CETP intron 19913121 rs12720889 chr16 57012563 A T 2.27E-50 HDL cholesterol CETP intron 23063622 rs4784745 chr16 57014875 A G 4.07E-07 Lipid levels CETP intron 19913121 rs4784745 chr16 57014875 A G 5.13E-09 Lipid levels CETP intron 19913121 rs4784745 chr16 57014875 A G 5.00E-05 Response to statin therapy CETP intron 20339536 rs4784745 chr16 57014875 A G 1.14E-34 HDL cholesterol CETP intron 23063622 rs5880 chr16 57015091 G C 3.10E-21 HDL cholesterol CETP missense 18193046 rs5880 chr16 57015091 G C 4.00E-10 Lipid levels CETP missense 19802338 rs5880 chr16 57015091 G C 6.81E-08 Lipid levels CETP missense 19913121 rs5880 chr16 57015091 G C 6.90E-12 Lipid levels CETP missense 19913121 rs5880 chr16 57015091 G C 1.30E-07 Response to statin therapy CETP missense 20339536 rs5880 chr16 57015091 G C 7.28E-33 HDL cholesterol CETP missense 22629316 rs5880 chr16 57015091 G C 7.66E-73 HDL cholesterol CETP missense 23063622 rs5880 chr16 57015091 G C 2.00E-16 HDL cholesterol CETP missense 24886709 rs1800774 chr16 57015545 C T 7.30E-06 Type 2 diabetes CETP intron 17463248 rs5882 chr16 57016092 G A 7.80E-09 HDL cholesterol CETP missense 18193046 rs5882 chr16 57016092 G A 6.37E-15 Triglycerides CETP missense 19060911 rs5882 chr16 57016092 G A 4.50E-08 Lipid levels CETP missense 19802338 rs5882 chr16 57016092 G A 2.78E-07 Lipid levels CETP missense 19913121 rs5882 chr16 57016092 G A 5.42E-07 Lipid levels CETP missense 19913121 rs5882 chr16 57016092 G A 4.10E-07 HDL cholesterol CETP missense 21589926 rs5882 chr16 57016092 G A 1.07E-41 HDL cholesterol CETP missense 23063622 rs9923854 chr16 57017002 T G 6.44E-13 HDL cholesterol CETP intron 23063622 rs2303790 chr16 57017292 A G 0.00000111 HDL cholesterol CETP missense 23063622 rs2303790 chr16 57017292 A G 1.09E-21 LDL cholesterol CETP missense 23063622 rs2303790 chr16 57017292 A G 1.39E-13 Triglycerides CETP missense 23063622 rs2303790 chr16 57017292 A G 1.48E-17 Triglycerides CETP missense 23063622 rs1800777 chr16 57017319 G A 2.80E-18 HDL cholesterol CETP missense 18193046 rs1800777 chr16 57017319 G A 2.50E-09 Lipid levels CETP missense 19802338 rs1800777 chr16 57017319 G A 1.79E-07 Lipid levels CETP missense 19913121 rs1800777 chr16 57017319 G A 8.46E-11 Lipid levels CETP missense 19913121 rs1800777 chr16 57017319 G A 2.20E-63 HDL cholesterol CETP missense 23063622 rs289741 chr16 57017474 G A 1.00E-06 Metabolic syndrome phenotype CETP intron 22022282 rs289741 chr16 57017474 G A 1.10E-64 Metabolic syndrome phenotype CETP intron 22022282 rs289741 chr16 57017474 G A 1.60E-66 Metabolic syndrome phenotype CETP intron 22022282 rs1801706 chr16 57017662 G A 1.20E-06 Lipid levels CETP UTR-3 19913121 rs1801706 chr16 57017662 G A 5.45E-05 Lipid levels CETP UTR-3 19913121 rs1801706 chr16 57017662 G A 5.32E-04 Rheumatoid arthritis CETP UTR-3 21452313 rs1801706 chr16 57017662 G A 1.14E-10 HDL cholesterol CETP UTR-3 23063622 rs289742 chr16 57017762 C G 3.00E-07 Response to statin therapy CETP nearGene-3 20339536 rs289742 chr16 57017762 C G 2.15E-39 HDL cholesterol CETP nearGene-3 23063622 rs289743 chr16 57017796 G A 1.54E-08 Lipid levels CETP nearGene-3 19913121 rs289743 chr16 57017796 G A 8.62E-09 Lipid levels CETP nearGene-3 19913121 rs289743 chr16 57017796 G A 2.68E-49 HDL cholesterol CETP nearGene-3 23063622 rs289744 chr16 57018102 G T 2.70E-08 Lipid levels CETP nearGene-3 19802338 rs289744 chr16 57018102 G T 8.31E-05 Major depressive disorder (broad) CETP nearGene-3 20038947 rs289744 chr16 57018102 G T 8.32E-05 Rheumatoid arthritis CETP nearGene-3 21452313 rs289744 chr16 57018102 G T 2.27E-08 HDL cholesterol CETP nearGene-3 21589926 rs289744 chr16 57018102 G T 3.36E-04 HDL cholesterol CETP nearGene-3 21589926 rs12720917 chr16 57019392 T C 5.68E-13 HDL cholesterol / / 23063622 rs12720917 chr16 57019392 T C 7.99E-04 Iron levels / / pha002876 rs17290922 chr16 57024317 G C 8.00E-06 Schizophrenia NLRC5 intron 23212062 rs1566439 chr16 57024662 T C 3.30E-08 Lipid levels NLRC5 intron 18193043 rs17369468 chr16 57027765 A T 9.52E-04 Obesity (extreme) NLRC5 intron 21935397 rs289735 chr16 57029562 C T 5.24E-04 Smoking cessation NLRC5 intron 24665060 rs289736 chr16 57031210 T C 5.86E-04 Acute lung injury NLRC5 intron 22295056 rs17369578 chr16 57031811 G A 3.26E-04 Multiple complex diseases NLRC5 intron 17554300 rs289708 chr16 57038162 A G 3.93E-04 Lymphocyte counts NLRC5 intron 22286170 rs16965039 chr16 57047299 T C 6.00E-07 Coronary heart disease NLRC5 intron 21347282 rs821470 chr16 57058582 A G 3.00E-06 Bipolar disorder and schizophrenia NLRC5 intron 22688191 rs289726 chr16 57074451 T C 6.74E-06 Erythrocyte counts NLRC5 intron pha003101 rs1011130 chr16 57108821 G A 1.12E-05 Post-operative nausea and vomiting NLRC5 intron 21694509 rs11639875 chr16 57113864 C T 6.60E-04 Alcohol dependence NLRC5 intron 20201924 rs2305699 chr16 57149645 C A 4.18E-04 Response to taxane treatment (placlitaxel) CPNE2 intron 23006423 rs4784772 chr16 57159402 A G 1.20E-05 Serum metabolites CPNE2 intron 19043545 rs4784779 chr16 57183725 T C 1.80E-05 Urinary metabolites / / 21572414 rs767505 chr16 57212650 A G 0.0000236 Alcohol craving with or without dependence FAM192A intron 22481050 rs767505 chr16 57212650 A G 0.00031 Alcohol dependence FAM192A intron 22481050 rs715040 chr16 57248479 G T 1.69E-04 Lymphocyte counts RSPRY1 intron 22286170 rs8046668 chr16 57297464 C T 3.76E-05 Dental caries PLLP intron 21940522 rs11640439 chr16 57303194 G A 3.00E-06 Sleep duration PLLP intron 23728906 rs8044834 chr16 57324070 C T 8.68E-05 Alzheimer's disease / / pha002879 rs1787781 chr16 57341148 A G 6.75E-04 Multiple complex diseases / / 17554300 rs1645893 chr16 57341599 A G 9.50E-06 Renal cell carcinoma / / 24220910 rs1787785 chr16 57342381 T A 3.74E-04 Multiple complex diseases / / 17554300 rs1645890 chr16 57353934 G A 2.29E-04 Alzheimer's disease / / 17998437 rs654974 chr16 57380956 A G 1.12E-04 Alzheimer's disease / / 17998437 rs4151117 chr16 57417134 G T 3.37E-04 Hepatocellular carcinoma / / 22807686 rs2239354 chr16 57418987 G A 3.80E-06 Stroke (ischemic) / / 22384361 rs4784805 chr16 57441407 C A 4.73E-04 Multiple complex diseases CCL17 intron 17554300 rs886434 chr16 57444709 C T 0.000765 Salmonella-induced pyroptosis CCL17 intron 22837397 rs16957051 chr16 57468408 T C 2.50E-05 Malaria CIAPIN1 intron 19465909 rs11557674 chr16 57474687 G C 0.0000668 Salmonella-induced pyroptosis CIAPIN1 missense 22837397 rs2239355 chr16 57502926 C T 6.61E-04 Multiple complex diseases POLR2C intron 17554300 rs2161647 chr16 57503330 C A 4.10E-05 Malaria POLR2C intron 19465909 rs604965 chr16 57521274 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10775336 chr16 57545736 C G 3.25E-04 Multiple complex diseases / / 17554300 rs12917875 chr16 57562220 T C 2.45E-04 Intracranial aneurysm CCDC102A intron 20613766 rs8052123 chr16 57563671 T C 5.00E-06 Cataracts in type 2 diabetes CCDC102A intron 23137000 rs1004911 chr16 57575397 A G 5.90E-05 Response to statin therapy / / 20339536 rs8050345 chr16 57575812 T C 6.00E-05 Response to statin therapy / / 20339536 rs4784824 chr16 57577910 C A,G 6.00E-05 Response to statin therapy GPR114 intron 20339536 rs4140664 chr16 57578644 G T 6.30E-05 Response to statin therapy GPR114 intron 20339536 rs4784827 chr16 57583211 C T 6.70E-05 Response to statin therapy GPR114 intron 20339536 rs7185200 chr16 57586235 C T 5.40E-05 Response to statin therapy GPR114 intron 20339536 rs8060347 chr16 57587634 T C 5.00E-05 Response to statin therapy GPR114 intron 20339536 rs4783998 chr16 57587934 A G 7.70E-05 Response to statin therapy GPR114 intron 20339536 rs7187785 chr16 57591916 G A 9.10E-05 Response to lithium treatment in bipolar disorder GPR114 intron 19448189 rs9937918 chr16 57601792 C T 3.30E-05 Vitamin D concentrations GPR114 cds-synon 20600896 rs9937918 chr16 57601792 C T 3.30E-05 Vitamin D concentrations GPR114 cds-synon 20600896 rs1450353 chr16 57628571 G A 2.00E-06 Fasting plasma glucose / / 19060907 rs1349335 chr16 57628827 G A 0.0001 Migraine / / 22678113 rs7204900 chr16 57645507 G A 5.41E-04 Rheumatoid arthritis / / 21452313 rs8047279 chr16 57660708 G A 1.30E-05 Urinary metabolites GPR56 intron 21572414 rs12103178 chr16 57668728 C T 8.69E-04 Tourette syndrome GPR56 intron 22889924 rs1466134 chr16 57670947 G A 8.05E-06 Alzheimer's disease (late onset) GPR56 intron 21379329 rs2404691 chr16 57677099 C T 5.55E-05 Alzheimer's disease (late onset) GPR56 intron 21379329 rs3785326 chr16 57677573 G A 4.09E-04 Alzheimer's disease (late onset) GPR56 intron 21379329 rs16958674 chr16 57693055 C T 2.57E-04 Multiple complex diseases GPR56 intron 17554300 rs9935751 chr16 57713679 C A 5.65E-04 Response to alcohol consumption (flushing response) GPR97 intron 24277619 rs9939524 chr16 57723752 A G 4.45E-04 Stroke / / pha002887 rs2967154 chr16 57780156 T C 6.49E-05 Multiple complex diseases KATNB1 intron 17554300 rs12922275 chr16 57787027 C T 1.96E-05 Basophils KATNB1 cds-synon pha003087 rs12445947 chr16 57799648 G A 9.92E-05 Melanoma KIFC3 intron 21926416 rs2965787 chr16 57807066 T G 1.21E-04 Multiple complex diseases KIFC3 intron 17554300 rs4784010 chr16 57810318 C T 7.46E-04 Multiple complex diseases KIFC3 intron 17554300 rs8061387 chr16 57832503 T C 0.000611 Salmonella-induced pyroptosis KIFC3 intron 22837397 rs1477404 chr16 57850141 C G 2.90E-05 Urinary metabolites / / 21572414 rs1582594 chr16 57851574 G T 6.20E-06 Urinary metabolites / / 21572414 rs1582594 chr16 57851574 G T 3.00E-06 Longevity / / 21612516 rs1002456 chr16 57852819 G A 1.10E-05 Urinary metabolites / / 21572414 rs874505 chr16 57852955 G C 1.80E-05 Urinary metabolites / / 21572414 rs7499947 chr16 57853658 C T 0.0000575 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6499913 chr16 57853992 T C 0.0000321 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2967140 chr16 57855668 T C 0.0000352 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1541703 chr16 57855680 T G 0.0000351 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1971070 chr16 57855848 C T 0.0000347 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2967139 chr16 57856108 G A 0.0000332 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9924215 chr16 57856132 A G 0.0000343 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs9928652 chr16 57856398 T C 0.0000378 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2967173 chr16 57856895 T C 0.0000327 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2911348 chr16 57857559 C T 0.0000308 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2967137 chr16 57861723 T C 8.00E-06 Longevity / / 21612516 rs2967137 chr16 57861723 T C 0.0000192 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2967138 chr16 57862087 A C 0.0000276 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2967134 chr16 57869092 A G 4.80E-06 Urinary metabolites / / 21572414 rs247040 chr16 57877310 C T 9.50E-05 Diabetic retinopathy / / 21441570 rs247062 chr16 57888792 A C 2.10E-05 Urinary metabolites / / 21572414 rs193612 chr16 57890606 T C 0.00000117 HDL cholesterol particle diameter / / 23263444 rs1017241 chr16 57893561 G A 4.50E-06 Cardiovascular disease / / pha003064 rs247067 chr16 57895062 T C 0.0000012 HDL cholesterol particle diameter / / 23263444 rs247068 chr16 57897626 C T 2.32E-04 White matter integrity / / 22425255 rs247068 chr16 57897626 C T 0.00000263 HDL cholesterol particle diameter / / 23263444 rs17411006 chr16 57902615 C T 6.84E-06 Cardiovascular disease / / pha003064 rs366589 chr16 57905176 G A 0.0000015 HDL cholesterol particle diameter / / 23263444 rs16959429 chr16 57909654 G A 2.58E-04 IgE levels / / 17255346 rs17240973 chr16 57933066 G A 8.60E-04 Multiple complex diseases CNGB1 intron 17554300 rs17821412 chr16 57938755 A G 8.54E-04 Type 2 diabetes CNGB1 cds-synon 17463246 rs376270 chr16 57950057 G A,C,T 3.10E-04 Parkinson's disease CNGB1 missense 16252231 rs166000 chr16 57954268 A G 6.97E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CNGB1 intron 20877124 rs247052 chr16 57967218 T C 1.80E-04 Asthma CNGB1 intron 20698975 rs247052 chr16 57967218 T C 2.59E-06 Lung function (forced expiratory volume in 1 second) CNGB1 intron pha003103 rs2303779 chr16 57973989 G A 3.88E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CNGB1 intron 22566498 rs8052097 chr16 57975215 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) CNGB1 intron 20708005 rs8052097 chr16 57975215 G A 2.69E-04 Alzheimer's disease (late onset) CNGB1 intron 21379329 rs4436767 chr16 57982644 A G 8.11E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CNGB1 intron 22566498 rs11645062 chr16 58003743 T C 6.30E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CNGB1 intron 22566498 rs16959626 chr16 58027465 G A 2.70E-06 Urinary metabolites / / 21572414 rs3743553 chr16 58030053 T C 9.55E-05 Pulmonary function / / 20010835 rs3759953 chr16 58057345 A C 5.40E-06 Urinary metabolites / / 21572414 rs11648508 chr16 58063513 G T 2.55E-05 Pulmonary function MMP15 intron 20010835 rs4784887 chr16 58065624 G A 9.96E-05 Pulmonary function MMP15 intron 20010835 rs2304488 chr16 58074210 A G 1.29E-05 Pulmonary function MMP15 intron 19300500 rs2304488 chr16 58074210 A G 2.40E-05 Pulmonary function MMP15 intron 20010835 rs12447804 chr16 58075282 C T 1.50E-05 Pulmonary function MMP15 intron 19300500 rs12447804 chr16 58075282 C T 7.58E-05 Pulmonary function MMP15 intron 20010835 rs12447804 chr16 58075282 C T 4.00E-08 Pulmonary function MMP15 intron 21946350 rs12447804 chr16 58075282 C T 4.00E-08 Pulmonary function (interaction) MMP15 intron 23284291 rs2118018 chr16 58076422 A G 1.22E-05 Pulmonary function MMP15 intron 19300500 rs2118018 chr16 58076422 A G 2.09E-05 Pulmonary function MMP15 intron 20010835 rs3743563 chr16 58079165 G A 1.48E-05 Pulmonary function MMP15 missense 19300500 rs3743563 chr16 58079165 G A 3.61E-06 Pulmonary function MMP15 missense 20010835 rs1050779 chr16 58080215 G C 1.46E-05 Pulmonary function MMP15 UTR-3 19300500 rs1050779 chr16 58080215 G C 3.54E-06 Pulmonary function MMP15 UTR-3 20010835 rs2241773 chr16 58080910 C T 3.45E-05 Pulmonary function / / 19300500 rs2241773 chr16 58080910 C T 1.26E-05 Pulmonary function / / 20010835 rs9926547 chr16 58081794 C T 9.14E-06 Pulmonary function / / 19300500 rs9926547 chr16 58081794 C T 5.77E-05 Pulmonary function / / 20010835 rs12447440 chr16 58085170 G T 1.14E-05 Pulmonary function / / 19300500 rs12447440 chr16 58085170 G T 5.40E-06 Pulmonary function / / 20010835 rs12929002 chr16 58085882 G A 3.40E-05 Pulmonary function / / 19300500 rs12929002 chr16 58085882 G A 1.30E-05 Pulmonary function / / 20010835 rs12924451 chr16 58093669 G T 3.34E-05 Pulmonary function / / 19300500 rs12924451 chr16 58093669 G T 1.41E-05 Pulmonary function / / 20010835 rs9926693 chr16 58097357 A G 2.74E-05 Pulmonary function / / 19300500 rs9926693 chr16 58097357 A G 8.84E-05 Pulmonary function / / 20010835 rs12597233 chr16 58100208 G A 5.31E-05 Pulmonary function / / 19300500 rs12597233 chr16 58100208 G A 2.22E-05 Pulmonary function / / 20010835 rs6499933 chr16 58105677 T C 3.76E-04 Heart Failure / / pha002884 rs9937047 chr16 58145585 G A 2.06E-04 Sleep duration / / 23728906 rs1006438 chr16 58172603 T C,G 7.81E-04 Alcohol dependence / / 21314694 rs6499937 chr16 58196161 A G 2.62E-04 Type 2 diabetes CSNK2A2 intron 17463246 rs6499937 chr16 58196161 A G 4.53E-09 Multiple complex diseases CSNK2A2 intron 17554300 rs7185886 chr16 58196736 C T 7.73E-04 Type 2 diabetes CSNK2A2 intron 17463246 rs2242445 chr16 58199203 G T 0.0000243 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity CSNK2A2 intron 22945461 rs1875525 chr16 58201849 C T 3.45E-04 Alzheimer's disease (late onset) CSNK2A2 intron 21379329 rs1875522 chr16 58202107 C T 3.94E-04 Alzheimer's disease (late onset) CSNK2A2 intron 21379329 rs1393203 chr16 58207203 A C 4.48E-04 Alzheimer's disease (late onset) CSNK2A2 intron 21379329 rs74019828 chr16 58209274 G A 5.00E-08 Telomere length CSNK2A2 intron 24795349 rs2550360 chr16 58224290 T C 3.52E-05 Paget's disease CSNK2A2 intron 20436471 rs2550363 chr16 58227983 C T 5.55E-05 Paget's disease CSNK2A2 intron 20436471 rs8056660 chr16 58229348 T C 2.61E-04 Type 2 diabetes CSNK2A2 intron 17463246 rs7196068 chr16 58234135 G A 1.04E-05 Lymphocyte counts / / 22286170 rs1974876 chr16 58285203 C T 8.34E-04 Suicide attempts in bipolar disorder CCDC113 intron 21041247 rs11076229 chr16 58288959 G A 8.28E-04 Suicide attempts in bipolar disorder CCDC113 intron 21041247 rs11076230 chr16 58288985 T G 8.24E-04 Suicide attempts in bipolar disorder CCDC113 intron 21041247 rs12596498 chr16 58289177 C T 8.17E-04 Suicide attempts in bipolar disorder CCDC113 intron 21041247 rs16959980 chr16 58289807 T C 8.07E-04 Suicide attempts in bipolar disorder CCDC113 intron 21041247 rs9937285 chr16 58298743 C A 9.83E-04 Aortic root size CCDC113 intron 21223598 rs1834018 chr16 58307242 A G 1.59E-06 Brain infarcts,covert MRI-defined CCDC113 intron 20044523 rs2288014 chr16 58327774 A G 1.88E-04 Aortic root size PRSS54 intron 21223598 rs7200570 chr16 58365078 A G 5.08E-13 Multiple complex diseases / / 17554300 rs7203177 chr16 58404712 T C 3.91E-04 Alzheimer's disease / / 22005930 rs1424072 chr16 58411617 T C 3.20E-05 Waist-Hip Ratio / / pha003013 rs1424072 chr16 58411617 T C 3.31E-05 Waist-Hip Ratio / / pha003028 rs41515846 chr16 58456643 C G 2.90E-04 Multiple complex diseases / / 17554300 rs6499956 chr16 58458445 T C 3.67E-05 Intracerebral hemorrhage / / 24656865 rs1895522 chr16 58459038 G A 5.92E-06 Intracerebral hemorrhage / / 24656865 rs4784935 chr16 58460342 A G 2.66E-05 Intracerebral hemorrhage / / 24656865 rs9928581 chr16 58461365 G A 2.66E-05 Intracerebral hemorrhage / / 24656865 rs1424077 chr16 58462627 G A 3.16E-05 Intracerebral hemorrhage / / 24656865 rs2042401 chr16 58464075 T C 2.99E-05 Intracerebral hemorrhage / / 24656865 rs9931547 chr16 58466107 A G 2.78E-05 Intracerebral hemorrhage / / 24656865 rs4784938 chr16 58467853 G A 3.09E-05 Intracerebral hemorrhage / / 24656865 rs56139189 chr16 58468090 G A 2.66E-05 Intracerebral hemorrhage / / 24656865 rs3890512 chr16 58470046 C G 1.54E-05 Intracerebral hemorrhage / / 24656865 rs8057901 chr16 58470427 G A 4.45E-05 Intracerebral hemorrhage / / 24656865 rs246192 chr16 58544295 G C 0.0000625 Menopause (age at onset) NDRG4 intron 23424626 rs1058132 chr16 58546297 C T 5.50E-04 Lymphocyte counts NDRG4 UTR-3 22286170 rs11644694 chr16 58557342 G A 2.52E-04 Glycosylated haemoglobin levels CNOT1 cds-synon 17255346 rs37060 chr16 58566304 G A 1.00E-07 QT interval CNOT1 intron 22726844 rs37062 chr16 58567238 A G 3.00E-25 QT interval CNOT1 intron 19305408 rs37062 chr16 58567238 A G 1.00E-06 Electrocardiographic traits CNOT1 intron 20062063 rs1549607 chr16 58583975 A G 2.03E-12 QT interval CNOT1 intron 19305409 rs7188697 chr16 58622178 G A 7.00E-25 QT interval CNOT1 intron 19305409 rs7188697 chr16 58622178 G A 4.00E-05 QT interval CNOT1 intron 23166209 rs37037 chr16 58664602 A G 5.31E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12149056 chr16 58690964 T A 0.0000771 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs60979655 chr16 58695139 C T 0.000093 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs8061077 chr16 58697786 C T 1.80E-05 Major depression (suicidal thoughts and behavior) / / 21750702 rs9806843 chr16 58704861 A G 1.99E-05 Bone mineral traits,in men SLC38A7 intron 21427758 rs9806843 chr16 58704861 A G 5.91E-04 Bone mineral traits,in men SLC38A7 intron 21427758 rs9806843 chr16 58704861 A G 8.55E-05 Bone mineral traits,in men SLC38A7 intron 21427758 rs11639682 chr16 58707132 C A 0.0000787 Nonsyndromic striae distensae (stretch marks) SLC38A7 intron 23633020 rs59234479 chr16 58707628 G A 0.0000883 Nonsyndromic striae distensae (stretch marks) SLC38A7 intron 23633020 rs2280399 chr16 58711532 G T 2.56E-05 Glycosylated haemoglobin levels SLC38A7 intron 17255346 rs11647748 chr16 58731884 A G 0.0000883 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11643617 chr16 58732855 G C 0.0000714 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs73549255 chr16 58735673 G A 0.0000911 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11076256 chr16 58752466 C T 1.19E-04 Suicide attempts in bipolar disorder GOT2 missense 21423239 rs12600277 chr16 58759332 C G 3.00E-06 Aortic root size GOT2 intron 21223598 rs4784054 chr16 58776314 G A 2.00E-21 Blood metabolite levels / / 24816252 rs12709013 chr16 58829790 T C 3.00E-24 Blood metabolite ratios / / 24816252 rs9932019 chr16 58886531 G A 4.08E-05 Hepatitis B / / 21750111 rs970169 chr16 58893589 T G 0.000743978 Hypertension (early onset hypertension) / / 22479346 rs11076276 chr16 58918381 T C 2.80E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs3859046 chr16 58925426 C A 7.40E-04 Alzheimer's disease / / 22005930 rs12933209 chr16 58937209 C A 4.29E-04 Aortic root size / / 21223598 rs16960640 chr16 58973180 C T 1.29E-04 Multiple complex diseases / / 17554300 rs9921589 chr16 58973237 C T 4.24E-04 Multiple complex diseases / / 17554300 rs12927800 chr16 58973967 T G 6.21E-04 Multiple complex diseases / / 17554300 rs12927800 chr16 58973967 T G 8.21E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1992113 chr16 58974871 A G 6.75E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1865968 chr16 58978250 G T 1.72E-05 Bone mass and geometry / / 17903296 rs16960677 chr16 58992492 T C 6.07E-04 Multiple complex diseases / / 17554300 rs7194392 chr16 59003011 G A 8.93E-04 Type 2 diabetes / / 17463246 rs9927197 chr16 59010778 T C 3.08E-04 Multiple complex diseases / / 17554300 rs9927197 chr16 59010778 T C 1.98E-04 Smoking initiation / / 24665060 rs9925004 chr16 59049590 C T 1.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12928605 chr16 59150174 T C 8.74E-04 Alzheimer's disease / / 22005930 rs12924603 chr16 59152349 T G 9.16E-04 Alzheimer's disease / / 22005930 rs12930086 chr16 59166991 A C 8.08E-04 Alzheimer's disease / / 22005930 rs8049612 chr16 59168376 T C 8.26E-04 Alzheimer's disease / / 22005930 rs8044839 chr16 59168520 C T 9.43E-04 Alzheimer's disease / / 22005930 rs4584810 chr16 59177803 A T 8.65E-04 Alzheimer's disease / / 22005930 rs12918173 chr16 59184245 G C 1.30E-04 Multiple complex diseases / / 17554300 rs12918173 chr16 59184245 G C 8.16E-04 Alzheimer's disease / / 22005930 rs12927771 chr16 59185767 G C 3.82E-04 Alzheimer's disease / / 22005930 rs16960887 chr16 59187668 A G 7.58E-04 Alzheimer's disease / / 22005930 rs12927383 chr16 59189245 A T 7.45E-04 Alzheimer's disease / / 22005930 rs12927245 chr16 59190337 A G 5.91E-04 Alzheimer's disease / / 22005930 rs16960890 chr16 59190716 A G 7.81E-04 Alzheimer's disease / / 22005930 rs16960891 chr16 59190813 T A 6.79E-04 Alzheimer's disease / / 22005930 rs12928667 chr16 59191275 A G 6.88E-04 Alzheimer's disease / / 22005930 rs12928599 chr16 59194707 G C 9.38E-04 Alzheimer's disease / / 22005930 rs9934713 chr16 59201368 T G 3.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9934713 chr16 59201368 T G 0.000639 Salmonella-induced pyroptosis / / 22837397 rs9939720 chr16 59207770 C T 0.000284 Salmonella-induced pyroptosis / / 22837397 rs4544229 chr16 59228592 T C 1.26E-04 Lung function (forced vital capacity) / / 24023788 rs6500030 chr16 59310742 T G 6.86E-07 Major depressive disorder / / 19107115 rs1117306 chr16 59321826 A G 2.67E-06 Major depressive disorder / / 19107115 rs1117306 chr16 59321826 A G 5.63E-04 Amyotrophic lateral sclerosis / / 23624525 rs10521054 chr16 59334041 A G 1.60E-05 Urinary metabolites / / 21572414 rs925338 chr16 59349532 T C 5.28E-05 Major depressive disorder / / 19107115 rs17186051 chr16 59403054 G A 4.09E-06 Major depressive disorder / / 19107115 rs6500035 chr16 59433491 A G 1.39E-05 Creatinine levels / / pha003069 rs8051036 chr16 59434042 C T 1.39E-05 Creatinine levels / / pha003069 rs2048320 chr16 59464031 C T 5.77E-05 Creatinine levels / / pha003069 rs9922896 chr16 59489143 A G 7.15E-04 Type 2 diabetes / / 17463246 rs12598492 chr16 59529665 G A 6.65E-04 Multiple complex diseases / / 17554300 rs954303 chr16 59581776 A G 8.76E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs8054523 chr16 59668463 C A 2.30E-04 Multiple complex diseases / / 17554300 rs41070 chr16 59668949 T C 1.95E-04 Alzheimer's disease / / 17998437 rs423114 chr16 59675887 C T 6.95E-05 Socioeconomic Factors / / pha003066 rs8054794 chr16 59727039 G A 7.83E-06 Fibrinogen / / pha003068 rs12921587 chr16 59733833 A G 1.50E-05 Fibrinogen / / pha003068 rs7189924 chr16 59738150 A G 1.02E-05 Fibrinogen / / pha003068 rs11076334 chr16 59739473 T C 1.50E-05 Fibrinogen / / pha003068 rs1566435 chr16 59745602 A G 3.40E-04 Multiple complex diseases / / 17554300 rs1500289 chr16 59750695 A G 4.22E-05 Fibrinogen / / pha003068 rs1604117 chr16 59756567 C T 7.84E-05 Fibrinogen / / pha003068 rs965916 chr16 59761692 A G 6.21E-05 Cognitive impairment induced by topiramate / / 22091778 rs965916 chr16 59761692 A G 7.54E-06 Cognitive impairment induced by topiramate / / 22091778 rs4785061 chr16 59791249 A G 3.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1445455 chr16 59835426 A G 5.51E-04 Smoking initiation / / 24665060 rs4785071 chr16 59858992 G T 5.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1445458 chr16 59878048 C T 8.68E-04 Heart Failure / / pha002884 rs8056650 chr16 59890698 G A 1.47E-06 Temporal lobe volumes / / 20197096 rs10500413 chr16 59911613 C T 1.09E-05 Cholesterol / / 17255346 rs10500413 chr16 59911613 C T 9.44E-04 Type 2 diabetes / / 17463246 rs11864428 chr16 59914350 G A 1.21E-04 Cholesterol / / 17255346 rs2121005 chr16 59921605 A T 2.40E-05 Urinary metabolites / / 21572414 rs7198976 chr16 59929526 G C 6.11E-04 Multiple complex diseases / / 17554300 rs16961543 chr16 59940188 T G 6.00E-06 Obesity-related traits / / 23251661 rs1873942 chr16 59995851 T C 7.22E-04 Sarcoidosis / / 21540310 rs1035538 chr16 60079162 T C 3.64E-05 Triglycerides / / pha003080 rs2582597 chr16 60125785 G A 7.46E-04 Parkinson's disease / / 17052657 rs1423946 chr16 60136254 G A 1.58E-05 Asthma / / 11022011 rs11649159 chr16 60159522 T A 9.66E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11640445 chr16 60195615 T A 2.10E-05 Urinary metabolites / / 21572414 rs8044976 chr16 60209303 C T 1.80E-05 Urinary metabolites / / 21572414 rs7192941 chr16 60221141 G A 2.40E-05 Urinary metabolites / / 21572414 rs10500429 chr16 60248142 C T 5.94E-05 Insulin Resistance / / pha003062 rs10500429 chr16 60248142 C T 6.15E-05 Insulin-related traits / / pha003063 rs1545208 chr16 60271139 T C 6.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs8056087 chr16 60271850 T C 5.71E-05 Insulin Resistance / / pha003062 rs8056087 chr16 60271850 T C 7.66E-05 Insulin-related traits / / pha003063 rs9939722 chr16 60304680 C T 4.75E-05 Insulin Resistance / / pha003062 rs9939722 chr16 60304680 C T 4.62E-05 Insulin-related traits / / pha003063 rs1376049 chr16 60304887 G A 9.93E-05 Body Fat Distribution / / pha003017 rs1376049 chr16 60304887 G A 7.01E-05 Body Fat Distribution / / pha003018 rs9932186 chr16 60314656 G T 3.00E-08 Phospholipid levels (plasma) / / 22359512 rs12445643 chr16 60322346 A G 8.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs999488 chr16 60327936 A G 5.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs1376046 chr16 60332481 T G 5.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs9889057 chr16 60333374 G T 1.81E-28 Multiple complex diseases / / 17554300 rs993647 chr16 60335984 T C 5.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs1465892 chr16 60350846 C T 6.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs993388 chr16 60353087 T C 4.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs7197884 chr16 60355828 G A 1.65E-05 Hemoglobin / / pha003098 rs7197884 chr16 60355828 G A 4.99E-05 Erythrocyte counts / / pha003099 rs9302722 chr16 60358564 C T 8.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs9302723 chr16 60361045 A G 8.53E-04 Alzheimer's disease / / 24755620 rs9302723 chr16 60361045 A G 2.90E-05 Hemoglobin / / pha003098 rs9302723 chr16 60361045 A G 5.43E-05 Erythrocyte counts / / pha003099 rs1155406 chr16 60376163 G A 3.49E-05 Brain structure / / 22504417 rs75749637 chr16 60395316 C G 4.64E-05 Intracerebral hemorrhage / / 24656865 rs8050990 chr16 60395347 C T 5.00E-04 Alcohol dependence / / 20201924 rs8050990 chr16 60395347 C T 5.90E-04 Alcohol dependence / / 20201924 rs73568432 chr16 60395552 G A 4.73E-05 Intracerebral hemorrhage / / 24656865 rs1947261 chr16 60406574 G A 5.02E-05 Major depressive disorder / / 20516156 rs1364149 chr16 60444135 A G 6.29E-05 Erythrocyte counts / / pha003099 rs2407318 chr16 60447170 A G 1 Drug response to Etoposide / / 17537913 rs1423901 chr16 60448452 G A 1 Drug response to Etoposide / / 17537913 rs7187742 chr16 60450246 T C 1 Drug response to Etoposide / / 17537913 rs7188601 chr16 60451202 C T 7.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs12446837 chr16 60453462 T A 7.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs4784108 chr16 60454275 G A 7.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs1559364 chr16 60455069 C T 5.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs1423902 chr16 60460365 T C 7.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs1895507 chr16 60462696 A G 1 Drug response to Etoposide / / 17537913 rs1423904 chr16 60466359 T C 8.92E-05 Hemoglobin / / pha003098 rs8062487 chr16 60473776 T C 1 Drug response to Etoposide / / 17537913 rs11076384 chr16 60513067 C T 9.37E-05 Erythrocyte counts / / pha003099 rs9932943 chr16 60535704 T C 4.16E-04 Smoking cessation / / 24665060 rs1530795 chr16 60577200 T C 6.37E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs9746438 chr16 60598610 C T 1.58E-04 Alzheimer's disease (late onset) / / 21379329 rs11649643 chr16 60649079 G A 2.13E-04 Alzheimer's disease (late onset) / / 21379329 rs11076397 chr16 60653220 T A 4.33E-05 Serum metabolites / / 19043545 rs8050802 chr16 60660846 A G 1.36E-05 Suicidal ideation / / 20877300 rs9922955 chr16 60675619 A T 5.33E-04 Multiple complex diseases / / 17554300 rs17822114 chr16 60733603 C T 3.00E-18 Myopia (pathological) / / 23049088 rs6500144 chr16 60764767 A G 0.00035 Salmonella-induced pyroptosis / / 22837397 rs768275 chr16 60843488 C G 6.91E-04 Bipolar disorder / / 19259986 rs1424206 chr16 60845484 C T 5.33E-04 Myocardial Infarction / / pha002883 rs10500434 chr16 60855125 G A 7.75E-04 Bipolar disorder / / 19259986 rs8052823 chr16 60870593 C T 3.05E-06 Cognitive decline / / 22054870 rs8055281 chr16 60902823 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs16962797 chr16 60980867 C A 2.39E-06 Odorant perception / / 23910658 rs9930641 chr16 61028827 G T 0.0003027 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9930641 chr16 61028827 G T 3.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1909766 chr16 61061390 T C 9.90E-05 Alcohol dependence / / 20201924 rs1909766 chr16 61061390 T C 9.93E-05 Alcoholism / / pha002892 rs1500358 chr16 61065607 A C 2.76E-04 Multiple complex diseases / / 17554300 rs11863847 chr16 61070430 C T 7.96E-05 Cognitive performance / / 19734545 rs12448305 chr16 61090505 A G 6.54E-05 Body Composition / / pha003012 rs8062408 chr16 61108029 A T 7.81E-04 Smoking cessation / / 24665060 rs12923268 chr16 61109024 A G 7.82E-04 Multiple complex diseases / / 17554300 rs2133804 chr16 61117433 G T 9.27E-04 Multiple complex diseases / / 17554300 rs2639889 chr16 61123147 C T 9.00E-07 Morbidity-free survival / / 17903295 rs1386348 chr16 61134913 A G 4.83E-05 Cognitive test performance / / 20125193 rs12930069 chr16 61225355 G A 9.42E-04 Depression (quantitative trait) / / 20800221 rs1423742 chr16 61319206 T C 6.90E-04 Heart Failure / / pha002885 rs9922966 chr16 61340362 G C 4.41E-04 Multiple complex diseases / / 17554300 rs7204275 chr16 61436948 G A 4.29E-04 Multiple complex diseases / / 17554300 rs4784117 chr16 61455329 G C 2.70E-04 Multiple complex diseases / / 17554300 rs11644632 chr16 61461212 A G 8.00E-06 Hypertension / / 22384028 rs7184230 chr16 61463955 A G 8.18E-05 Multiple complex diseases / / 17554300 rs12930401 chr16 61467147 A G 5.12E-05 Multiple complex diseases / / 17554300 rs12930697 chr16 61475502 G A 5.00E-06 Hypertension / / 22384028 rs1037109 chr16 61479014 A G 1.00E-05 Hypertension / / 22384028 rs1550823 chr16 61482816 T C 8.00E-06 Hypertension / / 22384028 rs17822582 chr16 61551277 C T 2.77E-05 Alzheimer's disease / / 17998437 rs2078539 chr16 61584238 A G 7.74E-04 Sarcoidosis / / 21540310 rs4410067 chr16 61598713 A G 8.84E-06 Alzheimer's disease / / 17998437 rs1319109 chr16 61598734 A G 7.62E-06 Alzheimer's disease / / 17998437 rs2897803 chr16 61601594 G A 7.81E-06 Alzheimer's disease / / 17998437 rs16963614 chr16 61610131 C A 6.30E-05 Alzheimer's disease / / 17998437 rs7204375 chr16 61612843 C T 5.85E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs11646955 chr16 61620660 A G 5.63E-05 Alzheimer's disease / / 17998437 rs16963653 chr16 61635511 C T 2.25E-04 Alzheimer's disease / / 17998437 rs12595958 chr16 61673780 T G 0.0008078 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12595958 chr16 61673780 T G 8.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs16963728 chr16 61674103 G A 0.0008294 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16963728 chr16 61674103 G A 8.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4357937 chr16 61684448 G T 2.81E-04 Height / / 17255346 rs4427786 chr16 61685130 G A 2.64E-04 Height / / 17255346 rs5002375 chr16 61686281 T C 2.30E-04 Height CDH8 UTR-3 17255346 rs5002375 chr16 61686281 T C 9.52E-04 Alzheimer's disease CDH8 UTR-3 17998437 rs4360928 chr16 61694178 A G 2.27E-04 Height CDH8 intron 17255346 rs4438299 chr16 61702337 C T 2.07E-04 Multiple complex diseases CDH8 intron 17554300 rs4438299 chr16 61702337 C T 4.90E-05 Alzheimer's disease CDH8 intron 17998437 rs11641508 chr16 61712411 C A 8.87E-05 Height CDH8 intron 17255346 rs11862752 chr16 61713781 C A 1.60E-04 Alzheimer's disease CDH8 intron 17998437 rs10500450 chr16 61716382 T C 3.83E-04 Multiple complex diseases CDH8 intron 17554300 rs10500450 chr16 61716382 T C 6.19E-05 Alzheimer's disease CDH8 intron 17998437 rs17248877 chr16 61721709 C T 0.0007396 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH8 intron 23233654 rs17248877 chr16 61721709 C T 7.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs8052159 chr16 61744821 T C 7.83E-04 Type 2 diabetes CDH8 intron 17463246 rs4784155 chr16 61748905 T C 5.61E-04 Multiple complex diseases CDH8 intron 17554300 rs8052121 chr16 61753968 C G 0.0001308 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH8 intron 23233654 rs8052121 chr16 61753968 C G 1.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs16963887 chr16 61763541 A C 3.11E-04 Height CDH8 intron 17255346 rs16963887 chr16 61763541 A C 6.70E-04 Type 2 diabetes CDH8 intron 17463246 rs10500453 chr16 61771571 A G 0.0001069 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH8 intron 23233654 rs10500453 chr16 61771571 A G 1.07E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs8048207 chr16 61778095 C T 8.00E-06 Non-small cell lung cancer CDH8 intron 23144319 rs10500454 chr16 61782253 C T 0.0006468 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH8 intron 23233654 rs10500454 chr16 61782253 C T 6.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs17822810 chr16 61784248 T G 6.91E-04 Multiple complex diseases CDH8 intron 17554300 rs17248968 chr16 61785019 G A 0.0006525 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH8 intron 23233654 rs17248968 chr16 61785019 G A 6.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs17248975 chr16 61785080 G A 0.0006541 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH8 intron 23233654 rs17248975 chr16 61785080 G A 6.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs17248982 chr16 61786825 C A 2.24E-04 Myocardial Infarction CDH8 intron pha002883 rs11639560 chr16 61788469 C T 0.00032 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH8 intron 23233654 rs11639560 chr16 61788469 C T 3.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs7498254 chr16 61792854 C T 0.0006741 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH8 intron 23233654 rs7498254 chr16 61792854 C T 6.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs1582999 chr16 61795979 G A 0.0007051 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH8 intron 23233654 rs1582999 chr16 61795979 G A 7.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs1583000 chr16 61796144 G T 0.0007082 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH8 intron 23233654 rs1583000 chr16 61796144 G T 7.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs17822834 chr16 61798899 G C 0.0005171 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH8 intron 23233654 rs17822834 chr16 61798899 G C 5.17E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs11642874 chr16 61808465 A G 0.0007325 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH8 intron 23233654 rs11642874 chr16 61808465 A G 7.33E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs11648416 chr16 61834706 A G 9.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs17822852 chr16 61848568 A T 9.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs11646171 chr16 61858089 G A 0.0008984 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH8 intron 23233654 rs11646171 chr16 61858089 G A 8.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs11640872 chr16 61863026 T C 0.000899 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH8 intron 23233654 rs11640872 chr16 61863026 T C 8.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs11645881 chr16 61863430 G A,C 0.0008993 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH8 intron 23233654 rs11645881 chr16 61863430 G A,C 8.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs1436377 chr16 61863765 C A 0.0008993 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH8 intron 23233654 rs1436377 chr16 61863765 C A 8.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs1369923 chr16 61878581 C T 5.70E-06 Response to antidepressants CDH8 intron 19736353 rs1369923 chr16 61878581 C T 2.78E-05 Non-word repetition CDH8 intron 23738518 rs11075440 chr16 61883401 A C 9.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs17249073 chr16 61911016 C T 9.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs17379848 chr16 61947630 C T 9.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH8 intron 23233662 rs12599168 chr16 61951709 C G 3.96E-04 Sudden cardiac arrest CDH8 intron 21658281 rs3784847 chr16 61977449 A G 1.81E-08 Parkinson's disease CDH8 intron 21812969 rs3784847 chr16 61977449 A G 1.66E-09 Parkinson's disease CDH8 intron pha002868 rs11075447 chr16 62002956 A G 8.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDH8 intron 20877124 rs8058174 chr16 62017413 A G 1.53E-04 Birth weight CDH8 intron 17255346 rs11863646 chr16 62020880 A G 1.58E-04 Birth weight CDH8 intron 17255346 rs1304648 chr16 62025800 T C 2.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDH8 intron 20877124 rs4784170 chr16 62038912 C T 5.60E-06 Urinary metabolites CDH8 intron 21572414 rs16964164 chr16 62039969 T C 6.10E-06 Urinary metabolites CDH8 intron 21572414 rs16964168 chr16 62041227 G A 4.65E-04 Depression (quantitative trait) CDH8 intron 20800221 rs10735131 chr16 62056928 C T 1.50E-05 Urinary metabolites CDH8 intron 21572414 rs11641766 chr16 62060970 A G 1.30E-05 Urinary metabolites CDH8 intron 21572414 rs12927313 chr16 62068339 T G 2.20E-05 Urinary metabolites CDH8 intron 21572414 rs9302540 chr16 62071523 C G 2.20E-05 Urinary metabolites / / 21572414 rs7498886 chr16 62079202 A G 2.00E-05 Urinary metabolites / / 21572414 rs8050940 chr16 62100211 T C 1.00E-26 Myopia (pathological) / / 23049088 rs9925201 chr16 62122294 T G 2.30E-05 Urinary metabolites / / 21572414 rs9938191 chr16 62131626 T C 1.40E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs9924310 chr16 62137472 G A 5.16E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs16964413 chr16 62285364 C T 5.57E-05 Orofacial clefts / / 20023658 rs7188209 chr16 62328519 A G 0.0000671 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10500464 chr16 62336454 C T 9.62E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs7192220 chr16 62347227 G A 3.56E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs13339104 chr16 62360468 G A 0.00065 Salmonella-induced pyroptosis / / 22837397 rs11645366 chr16 62377153 C T 7.00E-06 Cystic fibrosis severity / / 21602797 rs16964597 chr16 62397489 G A 3.96E-04 Alzheimer's disease / / 22005930 rs17423077 chr16 62439746 T C 5.14E-08 Metabolite levels / / 23281178 rs17423477 chr16 62459308 T C 2.13E-08 Metabolite levels / / 23281178 rs1394551 chr16 62535243 A G 4.65E-05 Orofacial clefts / / 20023658 rs2938719 chr16 62574466 A G 8.10E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2911292 chr16 62580946 C T 2.34E-05 Nicotine smoking / / 19268276 rs2911293 chr16 62585662 G T 6.82E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs16964828 chr16 62596314 T C 5.45E-04 Multiple complex diseases / / 17554300 rs4265819 chr16 62617217 A G 7.03E-06 Multiple complex diseases / / 17554300 rs4261554 chr16 62622120 A G 1.10E-04 Multiple complex diseases / / 17554300 rs2911301 chr16 62624382 G A 5.08E-05 Multiple complex diseases / / 17554300 rs1364229 chr16 62628775 T C 7.92E-05 Multiple complex diseases / / 17554300 rs2938729 chr16 62631318 T G 4.52E-04 Multiple complex diseases / / 17554300 rs7192064 chr16 62632273 G A 9.63E-04 Multiple complex diseases / / 17554300 rs2131402 chr16 62633196 C T 4.39E-05 Multiple complex diseases / / 17554300 rs3011247 chr16 62635954 C G 3.10E-04 Multiple complex diseases / / 17554300 rs6498863 chr16 62636472 T C 4.94E-04 Multiple complex diseases / / 17554300 rs1424031 chr16 62638025 A C 2.33E-04 Multiple complex diseases / / 17554300 rs288604 chr16 62672612 G A 2.98E-07 Autism / / 22843504 rs16965001 chr16 62674375 G A 6.07E-04 Insulin resistance / / 21901158 rs2162952 chr16 62777408 A T 8.21E-05 Relative hand skill in reading disability / / 24068947 rs919371 chr16 62777635 A G 2.09E-05 Relative hand skill in reading disability / / 24068947 rs2962438 chr16 62778599 A C 6.47E-05 Relative hand skill in reading disability / / 24068947 rs1428824 chr16 62779885 C G 6.46E-05 Relative hand skill in reading disability / / 24068947 rs2962431 chr16 62782444 T C 6.44E-05 Relative hand skill in reading disability / / 24068947 rs2408351 chr16 62783997 G T 9.42E-05 Relative hand skill in reading disability / / 24068947 rs1428822 chr16 62785778 T C 6.43E-05 Relative hand skill in reading disability / / 24068947 rs2408348 chr16 62785930 G A 6.43E-05 Relative hand skill in reading disability / / 24068947 rs1428821 chr16 62786015 G C 6.43E-05 Relative hand skill in reading disability / / 24068947 rs1428820 chr16 62786064 A G 6.43E-05 Relative hand skill in reading disability / / 24068947 rs1428819 chr16 62786238 C T 6.42E-05 Relative hand skill in reading disability / / 24068947 rs1428818 chr16 62786282 A G 7.10E-05 Relative hand skill in reading disability / / 24068947 rs2052871 chr16 62794811 G C 1.02E-05 Relative hand skill in reading disability / / 24068947 rs2962461 chr16 62796921 A C 9.34E-06 Relative hand skill in reading disability / / 24068947 rs2962462 chr16 62798852 G T 2.00E-06 Relative hand skill in reading disability / / 24068947 rs974873 chr16 62802151 G A 2.16E-05 Relative hand skill in reading disability / / 24068947 rs6498872 chr16 62805243 A C 1.20E-05 Relative hand skill in reading disability / / 24068947 rs2115414 chr16 62805728 C T 8.44E-06 Relative hand skill in reading disability / / 24068947 rs2962469 chr16 62815924 T C 1.19E-05 Relative hand skill in reading disability / / 24068947 rs2962470 chr16 62816545 C G 2.18E-05 Relative hand skill in reading disability / / 24068947 rs2408330 chr16 62840744 A T 9.91E-06 Relative hand skill in reading disability / / 24068947 rs2962457 chr16 62849577 C G 1.05E-05 Relative hand skill in reading disability / / 24068947 rs2962459 chr16 62854585 G A 3.41E-05 Prion diseases / / 22210626 rs11861369 chr16 62858607 G C 3.18E-04 Multiple complex diseases / / 17554300 rs2962447 chr16 62858858 G A 9.53E-04 Multiple complex diseases / / 17554300 rs1366538 chr16 62873057 A G 5.63E-04 Multiple complex diseases / / 17554300 rs1364242 chr16 62885276 T C 2.78E-05 Relative hand skill in reading disability / / 24068947 rs1366539 chr16 62886440 C T 2.84E-05 Relative hand skill in reading disability / / 24068947 rs7192837 chr16 62948686 T G 1.15E-04 Multiple complex diseases / / 17554300 rs16965450 chr16 63052798 T C 8.72E-04 Multiple complex diseases / / 17554300 rs16965450 chr16 63052798 T C 1.51E-06 Height / / 22021425 rs1848824 chr16 63072942 A T 5.60E-06 Height / / 22021425 rs2055848 chr16 63094277 G C 4.62E-05 Height / / 22021425 rs8051889 chr16 63103583 C T 3.66E-04 Multiple complex diseases / / 17554300 rs2158355 chr16 63198773 A G 2.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8060756 chr16 63202385 G A 6.75E-04 Multiple complex diseases / / 17554300 rs11641803 chr16 63310490 C T 5.08E-04 Smoking initiation / / 24665060 rs219607 chr16 63363717 T C 4.00E-05 Prostate cancer / / 21743057 rs219605 chr16 63364524 C A 4.00E-05 Prostate cancer / / 21743057 rs178141 chr16 63367138 T A 4.00E-05 Prostate cancer / / 21743057 rs1347579 chr16 63396006 G A 1.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1008220 chr16 63436308 T C 7.64E-04 Aortic root size / / 21223598 rs150745 chr16 63448670 T C 8.32E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs16966070 chr16 63533620 A T 1.07E-05 Bipolar disorder / / 18317468 rs7185153 chr16 63533915 T C 6.54E-04 Type 2 diabetes / / 17463246 rs2113213 chr16 63545556 C T 7.49E-04 Multiple complex diseases / / 17554300 rs4949127 chr16 63558061 C G 5.24E-04 Multiple complex diseases / / 17554300 rs9932227 chr16 63573514 C T 1.30E-05 Alcohol dependence / / 20201924 rs9932227 chr16 63573514 C T 1.50E-04 Alcohol dependence / / 20201924 rs9932227 chr16 63573514 C T 1.31E-05 Alcoholism / / pha002893 rs11865197 chr16 63588542 T C 3.76E-04 Fibrinogen / / 17255346 rs11865197 chr16 63588542 T C 3.40E-04 Alcohol dependence / / 20201924 rs11865197 chr16 63588542 T C 8.80E-04 Alcohol dependence / / 20201924 rs2911181 chr16 63597260 A G 3.00E-04 Alcohol dependence / / 20201924 rs2911181 chr16 63597260 A G 9.00E-04 Alcohol dependence / / 20201924 rs918705 chr16 63604091 G T 8.75E-04 Multiple complex diseases / / 17554300 rs1559374 chr16 63607148 T C 8.14E-05 Cholesterol / / 17255346 rs9930983 chr16 63609845 T C 5.06E-04 Multiple complex diseases / / 17554300 rs1862751 chr16 63627883 T A 6.07E-04 Substance dependence / / 21818250 rs2911174 chr16 63657290 C T 6.60E-05 Elbow pain / / pha003008 rs7190898 chr16 63718049 G T 1.71E-04 Hearing function / / 17255346 rs4949141 chr16 63754165 T C 7.99E-05 Cognitive test performance / / 20125193 rs9926921 chr16 63754804 G T 8.23E-05 Cognitive test performance / / 20125193 rs1451759 chr16 63755083 G A 8.80E-05 Major depressive disorder / / 21042317 rs4949146 chr16 63770084 G A 3.62E-04 Hearing function / / 17255346 rs4949147 chr16 63770443 G A 3.62E-04 Hearing function / / 17255346 rs722730 chr16 63776887 A C 1.91E-04 Hearing function / / 17255346 rs1975673 chr16 63785319 A G 1.56E-04 Smoking cessation / / 24665060 rs4949081 chr16 63803493 T C 6.62E-06 Hearing function / / 17255346 rs4949150 chr16 63806613 T C 1.52E-05 Hearing function / / 17255346 rs258159 chr16 63813773 G A 2.54E-05 Hearing function / / 17255346 rs258160 chr16 63814814 T C 1.09E-05 Hearing function / / 17255346 rs35575 chr16 63822079 T C 2.00E-05 Hearing function / / 17255346 rs35574 chr16 63823678 T C 2.11E-06 Hearing function / / 17255346 rs35572 chr16 63827540 T C 9.79E-06 Hearing function / / 17255346 rs190484 chr16 63827608 A T 1.92E-05 Hearing function / / 17255346 rs413201 chr16 63843369 A G 7.60E-04 Spine bone size / / 23207799 rs1381102 chr16 63955447 G A 6.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs9927100 chr16 63986686 T C 9.00E-05 Prostate cancer / / 21743057 rs9989402 chr16 63993912 T C 9.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs9989364 chr16 63994180 C T 9.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs879153 chr16 64014002 A C 2.71E-05 Panic disorder / / 19165232 rs9928626 chr16 64044440 G A 4.79E-05 Cognitive test performance / / 20125193 rs16966881 chr16 64066955 T C 3.47E-04 Multiple complex diseases / / 17554300 rs1836868 chr16 64067989 T G 2.00E-04 Spine bone size / / 21947420 rs12444627 chr16 64072858 C T 3.57E-04 Multiple complex diseases / / 17554300 rs7205114 chr16 64156503 C T 5.84E-04 Multiple complex diseases / / 17554300 rs16967137 chr16 64215084 C T 1.77E-04 Multiple complex diseases / / 17554300 rs9931309 chr16 64221018 C A 4.08E-06 Cardiovascular disease / / pha003064 rs9931309 chr16 64221018 C A 2.59E-05 Triglycerides / / pha003080 rs9931309 chr16 64221018 C A 1.50E-05 Leukocyte Counts / / pha003091 rs2917688 chr16 64297174 G A 4.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs72781120 chr16 64299648 T C 0.00001313 Sarcoidosis / / 22952805 rs112725204 chr16 64300390 C A 0.00001056 Sarcoidosis / / 22952805 rs2917702 chr16 64302397 C T 4.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10500497 chr16 64307911 G T 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs62039824 chr16 64377637 G A 0.00004323 Sarcoidosis / / 22952805 rs62039825 chr16 64377670 C T 0.0000132 Sarcoidosis / / 22952805 rs12448599 chr16 64378910 G A 0.00004323 Sarcoidosis / / 22952805 rs12448650 chr16 64379076 G A 0.00004323 Sarcoidosis / / 22952805 rs12448632 chr16 64379183 C T 0.0000132 Sarcoidosis / / 22952805 rs62039826 chr16 64382056 A T 0.00004264 Sarcoidosis / / 22952805 rs16967364 chr16 64382321 G T 0.000013 Sarcoidosis / / 22952805 rs16967367 chr16 64382817 A G 3.81E-04 Bipolar disorder,schizoaffective / / 19567891 rs16967367 chr16 64382817 A G 0.00004264 Sarcoidosis / / 22952805 rs62039829 chr16 64384575 A G 0.00001273 Sarcoidosis / / 22952805 rs62039830 chr16 64384860 A G 0.00001256 Sarcoidosis / / 22952805 rs62039841 chr16 64386078 A G 0.00004129 Sarcoidosis / / 22952805 rs62039842 chr16 64386450 T G 0.00004129 Sarcoidosis / / 22952805 rs62039843 chr16 64386670 A G 0.00001256 Sarcoidosis / / 22952805 rs16967378 chr16 64388427 A G 0.00004129 Sarcoidosis / / 22952805 rs16967379 chr16 64388636 T C 0.00001256 Sarcoidosis / / 22952805 rs1816585 chr16 64392468 T A 0.00001311 Sarcoidosis / / 22952805 rs1816584 chr16 64392519 G A 0.00001311 Sarcoidosis / / 22952805 rs12448245 chr16 64394219 G A 0.00001943 Sarcoidosis / / 22952805 rs1437163 chr16 64395652 C A 5.43E-05 Triglycerides / / pha003081 rs1437163 chr16 64395652 C A 3.52E-05 Lipid levels / / pha003082 rs716078 chr16 64397397 C A 0.00001795 Sarcoidosis / / 22952805 rs8047755 chr16 64399027 C T 0.00001658 Sarcoidosis / / 22952805 rs16967412 chr16 64399684 A G 0.00001658 Sarcoidosis / / 22952805 rs16967421 chr16 64401484 T C 0.00001606 Sarcoidosis / / 22952805 rs9888979 chr16 64403920 C T 0.00001941 Sarcoidosis / / 22952805 rs62039852 chr16 64404555 A G 0.00004646 Sarcoidosis / / 22952805 rs28625512 chr16 64405260 C A 0.00001728 Sarcoidosis / / 22952805 rs9888869 chr16 64405659 T C 0.00001682 Sarcoidosis / / 22952805 rs16967425 chr16 64406159 T C 0.00001563 Sarcoidosis / / 22952805 rs9889111 chr16 64406173 A C 0.00001682 Sarcoidosis / / 22952805 rs1437161 chr16 64407463 G T 0.00001295 Sarcoidosis / / 22952805 rs8049973 chr16 64407997 T C 0.000009222 Sarcoidosis / / 22952805 rs16967437 chr16 64409161 G A 0.000008158 Sarcoidosis / / 22952805 rs12446787 chr16 64409893 A G 0.000006607 Sarcoidosis / / 22952805 rs28866501 chr16 64410722 C T 0.000004259 Sarcoidosis / / 22952805 rs59969311 chr16 64416253 G A 0.000043 Sarcoidosis / / 22952805 rs72782925 chr16 64420930 T C 0.00004338 Sarcoidosis / / 22952805 rs35125673 chr16 64421474 C T 0.00004338 Sarcoidosis / / 22952805 rs9931897 chr16 64422393 C A 0.0002 Endometrial cancer / / 22426144 rs62041568 chr16 64424570 C T 0.00004258 Sarcoidosis / / 22952805 rs72782933 chr16 64424992 C T 0.00004258 Sarcoidosis / / 22952805 rs2161691 chr16 64434375 C T 2.30E-05 Urinary metabolites / / 21572414 rs1437138 chr16 64459581 G A 2.20E-05 Urinary metabolites / / 21572414 rs9932560 chr16 64505098 A G 3.70E-05 Coffee consumption / / 21357676 rs9923551 chr16 64508623 G A 2.40E-05 Urinary metabolites / / 21572414 rs16967543 chr16 64517488 A G 7.16E-05 Post-operative nausea and vomiting / / 21694509 rs17405026 chr16 64519086 A G 1.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs17405026 chr16 64519086 A G 9.43E-04 Alzheimer's disease / / 22005930 rs41362348 chr16 64632253 T A 1.58E-04 Type 2 diabetes / / 17463246 rs16967753 chr16 64635403 C T 1.00E-06 Metabolite levels (Pyroglutamine) / / 23934736 rs7184774 chr16 64730789 T G 1.50E-05 Urinary metabolites / / 21572414 rs1423987 chr16 64748241 T C 8.65E-05 Multiple complex diseases / / 17554300 rs1423987 chr16 64748241 T C 7.90E-06 Urinary metabolites / / 21572414 rs1423988 chr16 64748469 T C 9.90E-05 Multiple complex diseases / / 17554300 rs1423988 chr16 64748469 T C 7.90E-06 Urinary metabolites / / 21572414 rs231050 chr16 64760537 T C 1.80E-05 Urinary metabolites / / 21572414 rs231051 chr16 64760796 C A 7.50E-06 Urinary metabolites / / 21572414 rs10852418 chr16 64760841 C T 1.80E-04 Multiple complex diseases / / 17554300 rs10852418 chr16 64760841 C T 2.00E-06 Urinary metabolites / / 21572414 rs231070 chr16 64769024 T A 1.80E-05 Urinary metabolites / / 21572414 rs231082 chr16 64775069 G A 1.80E-05 Urinary metabolites / / 21572414 rs231087 chr16 64777229 T A 2.20E-05 Urinary metabolites / / 21572414 rs231088 chr16 64777278 C G 1.80E-05 Urinary metabolites / / 21572414 rs2320127 chr16 64782613 G C 1.90E-05 Urinary metabolites / / 21572414 rs231108 chr16 64791944 C T 1.80E-05 Urinary metabolites / / 21572414 rs231109 chr16 64796139 C T 1.80E-05 Urinary metabolites / / 21572414 rs231115 chr16 64800167 A C 1.60E-05 Urinary metabolites / / 21572414 rs17487665 chr16 64807455 C T 4.30E-06 Urinary metabolites / / 21572414 rs17487769 chr16 64813858 T C 9.60E-06 Urinary metabolites / / 21572414 rs17494512 chr16 64821254 A G 4.30E-06 Urinary metabolites / / 21572414 rs1364219 chr16 64823664 G A 8.93E-04 Cognition,early reading ability / / 17684495 rs1862769 chr16 64825733 C T 8.60E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17410049 chr16 64825766 T C 3.90E-06 Urinary metabolites / / 21572414 rs1424003 chr16 64827484 T G 0.0000554 Bipolar disorder / / 23637625 rs12446421 chr16 64847668 C G 3.00E-06 Urinary metabolites / / 21572414 rs12446430 chr16 64847786 A G 1.90E-06 Urinary metabolites / / 21572414 rs9924680 chr16 64857840 G A 4.60E-06 Urinary metabolites / / 21572414 rs2874150 chr16 64871527 C T 6.80E-06 Urinary metabolites / / 21572414 rs16967999 chr16 64929024 G A 1.04E-05 Corneal structure / / 22003120 rs17498325 chr16 64941887 G A 9.10E-06 Bipolar disorder / / 19416921 rs6498964 chr16 64944972 T C 0.00000007 Brain microstructure and intellectual performance / / 22723713 rs1390641 chr16 64955205 G A 6.90E-06 Urinary metabolites / / 21572414 rs436044 chr16 64962648 C T 6.97E-05 Inflammation / / pha002897 rs436044 chr16 64962648 C T 8.85E-05 Potassium levels / / pha003086 rs185394 chr16 64970343 T C 2.10E-04 Corneal structure / / 22003120 rs17500088 chr16 64977853 C T 1.60E-05 Urinary metabolites / / 21572414 rs1402020 chr16 64990187 A G 5.43E-04 Type 2 diabetes CDH11 intron 17463246 rs4967866 chr16 65002591 C T 8.00E-05 Parkinson's disease (age of onset) CDH11 intron 19772629 rs35213 chr16 65016087 A C,G,T 8.84E-05 Eosinophil counts CDH11 missense pha003088 rs35201 chr16 65021157 T C 6.54E-05 Eosinophil counts CDH11 intron pha003088 rs35198 chr16 65023581 G T 6.62E-04 Insulin resistance CDH11 intron 21901158 rs35195 chr16 65025718 G A 6.44E-04 Corneal structure CDH11 missense 22003120 rs1554401 chr16 65031338 C T 7.76E-04 Type 2 diabetes CDH11 intron 17463246 rs1607697 chr16 65051121 C T 1.30E-07 Urinary metabolites CDH11 intron 21572414 rs878359 chr16 65060817 A G 5.79E-05 Insulin resistance CDH11 intron 21901158 rs1079008 chr16 65070923 T C 1.10E-05 Parkinson's disease (age of onset) CDH11 intron 19772629 rs12598268 chr16 65088804 C T 3.14E-05 IgE levels CDH11 intron 22075330 rs12232421 chr16 65137094 G A 1.53E-04 Multiple sclerosis CDH11 intron 17660530 rs11861237 chr16 65140495 C T 9.40E-05 Triglycerides CDH11 intron 19074352 rs16968505 chr16 65143526 G A 3.61E-04 Multiple complex diseases CDH11 intron 17554300 rs3890768 chr16 65170890 C A 7.38E-06 Cognitive impairment induced by topiramate / / 22091778 rs3890768 chr16 65170890 C A 2.38E-04 Epilepsy / / 22116939 rs1030248 chr16 65203416 G T 5.21E-05 Recombination rate / / 21698098 rs7204297 chr16 65209168 T C 8.30E-05 Age-related macular degeneration / / 20861866 rs7204297 chr16 65209168 T C 1.86E-05 Age-related macular degeneration / / pha000002 rs10500512 chr16 65209539 A G 4.59E-05 Aging (time to event) / / 21782286 rs16968653 chr16 65214467 T C 6.18E-04 Type 2 diabetes / / 17463246 rs10500510 chr16 65223036 T G 1.41E-04 Multiple sclerosis / / 17660530 rs1154572 chr16 65244342 A G 9.27E-05 Cognitive impairment induced by topiramate / / 22091778 rs7195314 chr16 65259345 C T 8.30E-06 Carotid intima media thickness / / 21909108 rs11864736 chr16 65261411 C A 8.00E-06 Carotid intima media thickness / / 21909108 rs1508212 chr16 65279386 A G 8.41E-05 Inflammation / / pha002897 rs1423798 chr16 65289733 A C,T 6.25E-04 Alzheimer's disease / / 17998437 rs8056267 chr16 65292982 A G 9.71E-04 Alzheimer's disease / / 17998437 rs1423773 chr16 65306262 G A 6.57E-05 Systemic sclerosis / / 21750679 rs9302570 chr16 65306450 C T 6.30E-07 Urinary metabolites / / 21572414 rs1423772 chr16 65308021 A C 2.56E-05 Cognitive performance / / 19734545 rs16968811 chr16 65316386 A C 3.72E-05 Bipolar disorder,affective / / 20528957 rs1494759 chr16 65336600 A G 5.26E-05 Information processing speed LOC283867 intron 21130836 rs2216746 chr16 65339864 C T 8.85E-05 Cognitive performance LOC283867 intron 19734545 rs1423796 chr16 65351301 C G 7.23E-04 Type 2 diabetes LOC283867 intron 17463246 rs9939071 chr16 65389574 C T 9.06E-04 Myocardial Infarction LOC283867 intron pha002873 rs9939071 chr16 65389574 C T 5.62E-04 Heart Failure LOC283867 intron pha002884 rs818380 chr16 65428134 A G 8.79E-04 Stroke LOC283867 intron pha002886 rs17439904 chr16 65462858 C T 2.23E-06 Multiple complex diseases LOC283867 intron 17554300 rs818406 chr16 65477189 A C 9.94E-05 Multiple complex diseases LOC283867 intron 17554300 rs818406 chr16 65477189 A C 1.09E-04 Bipolar disorder,affective LOC283867 intron 20528957 rs8055646 chr16 65504388 C T 3.91E-04 Bipolar disorder,affective LOC283867 intron 20528957 rs7198937 chr16 65505251 C T 1.61E-04 Bipolar disorder,affective LOC283867 intron 20528957 rs10163315 chr16 65512119 C G 6.84E-04 Multiple complex diseases LOC283867 intron 17554300 rs10163315 chr16 65512119 C G 3.79E-05 Bipolar disorder,affective LOC283867 intron 20528957 rs8048931 chr16 65516113 C T 1.68E-04 Multiple complex diseases LOC283867 intron 17554300 rs8048931 chr16 65516113 C T 1.66E-05 Bipolar disorder,affective LOC283867 intron 20528957 rs8058455 chr16 65522923 A G 1.32E-05 Bipolar disorder,affective LOC283867 intron 20528957 rs8063546 chr16 65523486 A G 1.63E-04 Multiple complex diseases LOC283867 intron 17554300 rs6499002 chr16 65523599 A G 1.78E-05 Bipolar disorder,affective LOC283867 intron 20528957 rs1559344 chr16 65531502 A T 2.60E-06 Multiple complex diseases LOC283867 intron 17554300 rs1559344 chr16 65531502 A T 1.07E-04 Bipolar disorder,affective LOC283867 intron 20528957 rs9927630 chr16 65541068 A G 6.36E-04 Suicide attempts in bipolar disorder LOC283867 intron 21423239 rs9927847 chr16 65541081 G A 6.84E-04 Suicide attempts in bipolar disorder LOC283867 intron 21423239 rs9938662 chr16 65541202 T C 6.74E-04 Suicide attempts in bipolar disorder LOC283867 intron 21423239 rs9930041 chr16 65541488 A T 6.90E-04 Suicide attempts in bipolar disorder LOC283867 intron 21423239 rs11859091 chr16 65542293 T G 2.69E-04 Suicide attempts in bipolar disorder LOC283867 intron 21423239 rs9931914 chr16 65554495 C G 6.24E-04 Suicide attempts in bipolar disorder LOC283867 intron 21423239 rs1862725 chr16 65562465 A G 4.19E-04 Suicide attempts in bipolar disorder LOC283867 intron 21423239 rs7186484 chr16 65562916 T C 3.93E-04 Suicide attempts in bipolar disorder LOC283867 intron 21423239 rs6499006 chr16 65570271 T C 2.40E-05 Urinary metabolites LOC283867 intron 21572414 rs3096276 chr16 65577365 C T 4.86E-05 Triglycerides LOC283867 intron pha003080 rs12447283 chr16 65595639 G A 4.69E-04 Alzheimer's disease LOC283867 intron 17998437 rs6499011 chr16 65635402 A G 7.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs11639514 chr16 65669114 C G 1.40E-05 Urinary metabolites / / 21572414 rs1327486 chr16 65692481 A G 1.80E-05 Urinary metabolites / / 21572414 rs2045925 chr16 65719331 A G 4.17E-04 Substance dependence / / 21818250 rs17443522 chr16 65721618 G A 6.89E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17606970 chr16 65733467 G A 8.36E-04 Multiple complex diseases / / 17554300 rs2279 chr16 65743383 A G 4.63E-04 Multiple complex diseases / / 17554300 rs17675333 chr16 65750752 A G 2.39E-04 Multiple complex diseases / / 17554300 rs17675333 chr16 65750752 A G 3.87E-05 Type 1 diabetes / / 18978792 rs17675333 chr16 65750752 A G 8.60E-06 Urinary metabolites / / 21572414 rs4267307 chr16 65775170 T C 2.75E-05 Stroke (ischemic) / / 22941190 rs9930311 chr16 65782478 A G 3.82E-04 Parkinson's disease / / 16252231 rs6499034 chr16 65782941 A C 2.40E-05 Coronary heart disease / / pha003031 rs7195999 chr16 65802075 C T 8.19E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs410941 chr16 65804052 T G 3.67E-04 Multiple complex diseases / / 17554300 rs461785 chr16 65809044 G A 7.29E-04 Multiple complex diseases / / 17554300 rs12598089 chr16 65813302 A C 3.90E-04 Multiple complex diseases / / 17554300 rs374970 chr16 65813570 G A 7.36E-04 Multiple complex diseases / / 17554300 rs466221 chr16 65814356 G C 1.82E-04 Multiple complex diseases / / 17554300 rs185278 chr16 65840460 G A 9.29E-05 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs8055944 chr16 65849933 C A 7.97E-04 Multiple complex diseases / / 17554300 rs8055944 chr16 65849933 C A 5.29E-04 Alzheimer's disease / / 17998437 rs1110528 chr16 65879447 G A 2.31E-04 Multiple complex diseases / / 17554300 rs1110528 chr16 65879447 G A 2.44E-04 Alzheimer's disease / / 17998437 rs6499044 chr16 65887358 C G 7.66E-05 Sarcoidosis / / 19165924 rs8060933 chr16 65891108 G T 4.09E-06 Leprosy / / 22019778 rs1969527 chr16 65892754 T C 4.33E-06 Molar-incisor hypomineralization / / 23918034 rs1126179 chr16 65895364 A G 3.00E-06 Molar-incisor hypomineralization / / 23918034 rs153676 chr16 65896839 T C 3.01E-06 Mammographic density / / 22532574 rs149194 chr16 65897016 T C 9.74E-05 Mammographic density / / 22532574 rs17697705 chr16 65902950 G A 1.14E-05 Colorectal cancer / / 21242260 rs12930287 chr16 65938406 G A 4.80E-06 Asthma / / 20698975 rs37162 chr16 65946497 C A 2.35E-05 Cognitive performance / / 19734545 rs1094928 chr16 65954472 T G 2.00E-04 Information processing speed / / 21130836 rs4785878 chr16 65955116 A G 3.23E-04 Multiple complex diseases / / 17554300 rs432824 chr16 65958720 C T 2.00E-04 Information processing speed / / 21130836 rs254348 chr16 65980789 A G 8.06E-05 Information processing speed / / 21130836 rs254348 chr16 65980789 A G 1.15E-04 Barrett's esophagus / / 24121790 rs254348 chr16 65980789 A G 1.40E-05 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs17765606 chr16 65983447 A G 9.35E-05 Multiple sclerosis / / 19525953 rs254363 chr16 65985376 G A 3.79E-04 Type 2 diabetes / / 17463246 rs7186427 chr16 65986967 G A 8.27E-05 Diabetes Mellitus / / pha003059 rs16969589 chr16 65988234 C T 3.66E-04 Type 2 diabetes / / 17463246 rs16969590 chr16 65988372 C G 2.90E-04 Type 2 diabetes / / 17463246 rs2343882 chr16 65992307 A G 6.79E-04 Body mass index / / 21701565 rs1110522 chr16 66032737 C T 2.45E-04 Multiple complex diseases / / 17554300 rs11643876 chr16 66061013 C A,T 7.03E-04 Body mass index / / 21701565 rs10083774 chr16 66061440 G C 2.90E-05 Urinary metabolites / / 21572414 rs10083774 chr16 66061440 G C 0.0008566 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10083774 chr16 66061440 G C 8.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6499059 chr16 66067421 A G 2.80E-05 Urinary metabolites / / 21572414 rs41356047 chr16 66083787 A C 1.01E-05 Multiple complex diseases / / 17554300 rs11864855 chr16 66090427 G A 5.31E-05 Body Mass Index / / pha003014 rs17616367 chr16 66105036 A G 1.52E-05 Magnesium levels / / pha003092 rs4628974 chr16 66105763 A G 8.52E-04 Parkinson's disease / / 17052657 rs12931996 chr16 66121933 T C 2.76E-05 Coronary heart disease / / pha003031 rs7191006 chr16 66126856 C T 3.74E-05 Coronary heart disease / / pha003031 rs8050896 chr16 66158736 A T 4.00E-08 Response to antipsychotic treatment / / 23241943 rs16969837 chr16 66168320 C T 5.12E-04 Type 2 diabetes / / 17463246 rs235125 chr16 66270632 A G 0.000555052 Hypertension (early onset hypertension) / / 22479346 rs233507 chr16 66277504 A T 8.60E-05 Serum metabolites / / 19043545 rs233509 chr16 66278773 G T 8.96E-05 Serum metabolites / / 19043545 rs233520 chr16 66282156 T C 9.39E-05 Serum metabolites / / 19043545 rs1437198 chr16 66366554 G A 8.70E-04 Multiple complex diseases / / 17554300 rs1437200 chr16 66371756 G A 6.04E-04 Type 2 diabetes / / 17463246 rs7197577 chr16 66373115 A G 4.14E-05 Body Mass Index / / pha003006 rs7197577 chr16 66373115 A G 6.33E-05 Body Mass Index / / pha003014 rs11863931 chr16 66378752 A G 4.64E-04 Alcohol dependence / / 21314694 rs6499075 chr16 66387396 C T 4.69E-04 Multiple complex diseases / / 17554300 rs9940044 chr16 66398933 A G 5.00E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1076020 chr16 66407893 G C 1.50E-05 Urinary metabolites CDH5 intron 21572414 rs1076019 chr16 66408031 G A 9.17E-05 Vaspin levels CDH5 intron 22907691 rs1076019 chr16 66408031 G A 0.0000917 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit CDH5 intron 22907730 rs7404629 chr16 66412729 G A 7.23E-06 Osteoarthritis CDH5 intron 22763110 rs1049970 chr16 66432423 T C 0.000463 Rate of forced expiratory volume in 1 second (FEV1) decline (young adult women) CDH5 missense 23527081 rs8050957 chr16 66451217 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs3855650 chr16 66458859 T C 3.15E-04 Smoking initiation / / 24665060 rs6499083 chr16 66464880 C A 4.60E-05 Hypertension BEAN1 intron 19609347 rs7198295 chr16 66476944 C T 1.11E-05 Schizophrenia BEAN1 intron 19571811 rs11646672 chr16 66487206 A C 4.89E-04 Depression (quantitative trait) BEAN1 intron 20800221 rs8056099 chr16 66510153 G A 2.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BEAN1 intron 20877124 rs8056099 chr16 66510153 G A 2.05E-04 Scoliosis BEAN1 intron 21216876 rs40191 chr16 66517326 C T 7.04E-04 Smoking initiation BEAN1 intron 24665060 rs16956585 chr16 66527859 C T 2.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16956585 chr16 66527859 C T 6.67E-05 Bipolar disorder and schizophrenia / / 20889312 rs3743711 chr16 66542957 G A 7.30E-04 Smoking initiation TK2 UTR-3 24665060 rs16956732 chr16 66599791 G A 5.80E-07 Schizophrenia CKLF cds-synon 21926974 rs896086 chr16 66607188 A G 4.64E-04 Lung function (forced vital capacity) CMTM1 intron 24023788 rs355950 chr16 66659024 C T 3.21E-04 Multiple complex diseases CMTM4 intron 17554300 rs17767429 chr16 66668869 G A 7.92E-04 Response to alcohol consumption (flushing response) CMTM4 intron 24277619 rs363184 chr16 66803097 G A 6.70E-04 Multiple complex diseases CCDC79 intron 17554300 rs363170 chr16 66843363 A G 7.79E-04 Heart rate /E1 intron 23583979 rs363175 chr16 66855647 C T 7.10E-05 Alcoholism (heaviness of drinking) /E1 intron 21529783 rs422945 chr16 66866633 T G 7.00E-05 Alcoholism (heaviness of drinking) / / 21529783 rs12446736 chr16 66992693 C T 1.63E-05 Aging (time to event) / / 21782286 rs11860308 chr16 67035519 T C 6.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CES4A intron 20877124 rs11860308 chr16 67035519 T C 2.20E-06 Primary tooth development (time to first tooth eruption) CES4A intron 23704328 rs61744399 chr16 67037054 A C 0.00076 Breast cancer CES4A missense 23555315 rs7185839 chr16 67052047 T G 4.31E-07 HDL particle features / / pha002900 rs1106304 chr16 67197138 C T 1.93E-09 Triglycerides FBXL8 cds-synon 23063622 rs2233455 chr16 67207933 C A,G,T 0.000000142 HDL cholesterol NOL3 UTR-5 23236364 rs2233455 chr16 67207933 C A,G,T 1.72E-07 HDL particle features NOL3 UTR-5 pha002900 rs868213 chr16 67220457 A G 1.64E-07 HDL particle features EXOC3L1 intron pha002900 rs3729639 chr16 67225501 C T 2.00E-11 Coronary heart disease / / 21347282 rs11700 chr16 67232684 A G 1.61E-07 HDL particle features E2F4 UTR-3 pha002900 rs7196989 chr16 67259663 C T 1.51E-07 HDL particle features LRRC29 intron pha002900 rs3852700 chr16 67271858 T C 3.70E-05 Major depressive disorder FHOD1 intron 21042317 rs3852700 chr16 67271858 T C 9.71E-08 HDL particle features FHOD1 intron pha002900 rs7186310 chr16 67305513 A C 2.86E-05 HDL particle features SLC9A5 UTR-3 pha002900 rs11860295 chr16 67316234 C T 1.23E-05 HDL particle features PLEKHG4 missense pha002900 rs11860295 chr16 67316234 C T 5.38E-05 Glucose levels PLEKHG4 missense pha003061 rs8044843 chr16 67318242 A G 3.48E-05 HDL particle features PLEKHG4 missense pha002900 rs8044843 chr16 67318242 A G 6.77E-05 Glucose levels PLEKHG4 missense pha003061 rs3868142 chr16 67320223 G A 2.17E-05 HDL particle features PLEKHG4 missense pha002900 rs3868142 chr16 67320223 G A 5.38E-05 Glucose levels PLEKHG4 missense pha003061 rs3868143 chr16 67328453 T C 2.73E-05 HDL particle features KCTD19 intron pha002900 rs3868143 chr16 67328453 T C 5.38E-05 Glucose levels KCTD19 intron pha003061 rs11859352 chr16 67390448 A G 3.76E-05 HDL particle features LRRC36 intron pha002900 rs11859352 chr16 67390448 A G 7.81E-05 Glucose levels LRRC36 intron pha003061 rs8055190 chr16 67391618 C T 2.98E-05 Multiple complex diseases LRRC36 intron 17554300 rs8047080 chr16 67402588 A G 3.13E-05 HDL particle features LRRC36 intron pha002900 rs8047080 chr16 67402588 A G 6.47E-05 Glucose levels LRRC36 intron pha003061 rs2279023 chr16 67478251 G A 5.11E-04 Coronary Artery Disease ATP6V0D1 intron 17634449 rs16957447 chr16 67489857 T G 5.20E-05 Multiple complex diseases ATP6V0D1 intron 17554300 rs9933102 chr16 67538910 T C 5.70E-04 Multiple complex diseases / / 17554300 rs7191281 chr16 67655133 T C 7.72E-06 HDL particle features CTCF intron pha002900 rs6499137 chr16 67671804 T G 1.47E-10 Triglycerides CTCF UTR-3 19060911 rs6499137 chr16 67671804 T G 2.20E-08 HDL particle features CTCF UTR-3 pha002900 rs7204371 chr16 67693797 G A 4.00E-06 Obesity-related traits ACD intron 23251661 rs7187476 chr16 67699948 T C 3.80E-07 Red blood cell traits C16orf48 intron 23222517 rs7187476 chr16 67699948 T C 8.84E-08 HDL particle features C16orf48 intron pha002900 rs12449157 chr16 67708897 A G 2.00E-07 HDL cholesterol GFOD2 UTR-3 20864672 rs12449157 chr16 67708897 A G 2.67E-07 Red blood cell traits GFOD2 UTR-3 23222517 rs8051587 chr16 67796315 A C 7.92E-09 Red blood cell traits RANBP10 intron 23222517 rs7191129 chr16 67801391 A G 5.69E-08 Red blood cell traits RANBP10 intron 23222517 rs7199443 chr16 67841129 T G 1.20E-07 Red blood cell traits TS/XIP1 UTR-5 23222517 rs2008173 chr16 67856240 A G 4.26E-09 Red blood cell traits TS/XIP1 intron 23222517 rs7198357 chr16 67884619 C T 1.43E-09 Red blood cell traits NUTF2 intron 23222517 rs12930280 chr16 67891074 A C 0.0000579 Coronary artery calcification NUTF2 intron 23394302 rs1124324 chr16 67897487 C T 5.22E-07 Red blood cell traits NUTF2 intron 23222517 rs1124324 chr16 67897487 C T 2.16E-04 Smoking initiation NUTF2 intron 24665060 rs2271293 chr16 67902070 G A 9.00E-13 HDL cholesterol NUTF2 intron 19060906 rs2271293 chr16 67902070 G A 8.00E-16 HDL cholesterol NUTF2 intron 19060911 rs2271293 chr16 67902070 G A 1.50E-07 Lipid levels NUTF2 intron 19936222 rs2271293 chr16 67902070 G A 1.90E-05 Lipid levels NUTF2 intron 19936222 rs2271293 chr16 67902070 G A 7.10E-05 Lipid levels NUTF2 intron 19936222 rs2271293 chr16 67902070 G A 7.40E-07 Lipid levels NUTF2 intron 19936222 rs2271293 chr16 67902070 G A 8.00E-16 Coronary heart disease NUTF2 intron 21347282 rs2271293 chr16 67902070 G A 2.82E-05 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) NUTF2 intron 21541012 rs2271293 chr16 67902070 G A 4.66E-08 HDL particle features NUTF2 intron pha002900 rs2271294 chr16 67902326 A T 1.12E-09 Red blood cell traits NUTF2 intron 23222517 rs11553287 chr16 67905407 A G 1.51E-09 Red blood cell traits / / 23222517 rs8060686 chr16 67911517 T C 8.00E-06 Coronary heart disease EDC4 cds-synon 21347282 rs8060686 chr16 67911517 T C 2.00E-10 Metabolic syndrome EDC4 cds-synon 22399527 rs8060686 chr16 67911517 T C 3.30E-08 Red blood cell traits EDC4 cds-synon 23222517 rs139776238 chr16 67919696 G A 0.00024 Prostate cancer NRN1L missense 23555315 rs10468274 chr16 67922342 G A 2.64E-11 Triglycerides / / 19060911 rs10468274 chr16 67922342 G A 1.73E-07 Red blood cell traits / / 23222517 rs10468274 chr16 67922342 G A 3.56E-07 HDL particle features / / pha002900 rs7196789 chr16 67927124 C T 4.41E-09 Red blood cell traits / / 23222517 rs34298659 chr16 67927697 C T 0.0000506 Coronary artery calcification PSKH1 intron 23394302 rs16942887 chr16 67928042 G A 8.00E-33 HDL cholesterol PSKH1 intron 20686565 rs16942887 chr16 67928042 G A 2.29E-08 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) PSKH1 intron 21541012 rs16942887 chr16 67928042 G A 8.00E-54 HDL cholesterol PSKH1 intron 24097068 rs16957590 chr16 67934725 A G 3.19E-06 Multiple complex diseases PSKH1 intron 17554300 rs7187289 chr16 67967878 A C 3.23E-09 Red blood cell traits / / 23222517 rs11075663 chr16 67969790 T G 9.55E-08 LDL cholesterol PSMB10 intron 23063622 rs20549 chr16 67969930 A G 2.61E-14 HDL cholesterol PSMB10 missense 23063622 rs20549 chr16 67969930 A G 3.90E-09 Red blood cell traits PSMB10 missense 23222517 rs11574514 chr16 67971380 C T 2.00E-07 Crohn's disease / / 22412388 rs4986970 chr16 67976320 A T 8.60E-04 Lipid levels LCAT missense 19936222 rs4986970 chr16 67976320 A T 3.14E-08 HDL cholesterol LCAT missense 23063622 rs17240378 chr16 67976693 G T 1.00E-47 Cholesterol,total LCAT intron 23063622 rs17240378 chr16 67976693 G T 1.48E-35 LDL cholesterol LCAT intron 23063622 rs17240378 chr16 67976693 G T 3.10E-18 Triglycerides LCAT intron 23063622 rs17240378 chr16 67976693 G T 3.13E-47 HDL cholesterol LCAT intron 23063622 rs35673026 chr16 67976851 C T 0.00000154 HDL cholesterol LCAT missense 22629316 rs35673026 chr16 67976851 C T 0.0000024 HDL cholesterol LCAT missense 23236364 rs1109166 chr16 67977382 T C 1.40E-04 Lipid levels SLC12A4 UTR-3 19936222 rs1109166 chr16 67977382 T C 1.40E-06 Lipid levels SLC12A4 UTR-3 19936222 rs1109166 chr16 67977382 T C 1.50E-04 Lipid levels SLC12A4 UTR-3 19936222 rs1109166 chr16 67977382 T C 1.60E-06 Lipid levels SLC12A4 UTR-3 19936222 rs1109166 chr16 67977382 T C 5.10E-04 Lipid levels SLC12A4 UTR-3 19936222 rs1109166 chr16 67977382 T C 8.20E-06 Lipid levels SLC12A4 UTR-3 19936222 rs1109166 chr16 67977382 T C 8.30E-04 Lipid levels SLC12A4 UTR-3 19936222 rs1109166 chr16 67977382 T C 1.31E-15 HDL cholesterol SLC12A4 UTR-3 23063622 rs1109166 chr16 67977382 T C 1.98E-08 Red blood cell traits SLC12A4 UTR-3 23222517 rs2292318 chr16 67985706 C T 0.0000794 HDL cholesterol (male) SLC12A4 intron 23063622 rs2292318 chr16 67985706 C T 1.00E-13 HDL cholesterol (female) SLC12A4 intron 23063622 rs2292318 chr16 67985706 C T 1.23E-16 HDL cholesterol SLC12A4 intron 23063622 rs3785098 chr16 67993643 T C 8.64E-09 Red blood cell traits SLC12A4 intron 23222517 rs255049 chr16 68013471 T C 3.00E-08 HDL cholesterol DPEP3 intron 19060910 rs255049 chr16 68013471 T C 3.78E-05 Cognitive test performance DPEP3 intron 20125193 rs255049 chr16 68013471 T C 3.00E-08 Coronary heart disease DPEP3 intron 21347282 rs255049 chr16 68013471 T C 3.06E-08 HDL particle features DPEP3 intron pha002900 rs1107767 chr16 68020063 G C 2.12E-04 Multiple complex diseases / / 17554300 rs255052 chr16 68024995 G A 1.00E-07 HDL cholesterol DPEP2 intron 18193043 rs255052 chr16 68024995 G A 2.80E-04 Lipid levels DPEP2 intron 19802338 rs255052 chr16 68024995 G A 1.00E-07 Coronary heart disease DPEP2 intron 21347282 rs255052 chr16 68024995 G A 7.24E-08 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) DPEP2 intron 21541012 rs255052 chr16 68024995 G A 0.0000129 HDL cholesterol (female) DPEP2 intron 22629316 rs255052 chr16 68024995 G A 0.0000532 HDL cholesterol (male) DPEP2 intron 22629316 rs255052 chr16 68024995 G A 5.02E-09 HDL cholesterol DPEP2 intron 22629316 rs255052 chr16 68024995 G A 9.25E-19 HDL cholesterol DPEP2 intron 23063622 rs255052 chr16 68024995 G A 2.36E-07 HDL particle features DPEP2 intron pha002900 rs8059305 chr16 68036666 A C 5.89E-07 Red blood cell traits / / 23222517 rs7204192 chr16 68039309 A G 7.41E-07 Red blood cell traits / / 23222517 rs7204208 chr16 68069416 A G 9.45E-08 Red blood cell traits DUS2L intron 23222517 rs7201591 chr16 68086105 A G 3.57E-08 Red blood cell traits DUS2L intron 23222517 rs2301814 chr16 68105171 C A,G 3.23E-08 Red blood cell traits DUS2L intron 23222517 rs6499157 chr16 68105474 A C 3.12E-09 Red blood cell traits DUS2L intron 23222517 rs2107369 chr16 68116018 T G 0.00000926 HDL cholesterol (female) / / 22629316 rs2107369 chr16 68116018 T G 9.23E-08 HDL cholesterol / / 22629316 rs2107369 chr16 68116018 T G 4.47E-20 HDL cholesterol / / 23063622 rs1859311 chr16 68125917 G T 6.60E-09 HDL cholesterol NFATC3 intron 23063622 rs9932251 chr16 68131732 G A 1.40E-11 Triglycerides NFATC3 intron 19060911 rs9932251 chr16 68131732 G A 7.49E-07 HDL particle features NFATC3 intron pha002900 rs7205935 chr16 68152157 A G 4.44E-08 Red blood cell traits NFATC3 intron 23222517 rs2418736 chr16 68154862 G A 1.57E-09 Triglycerides NFATC3 intron 19060911 rs2418736 chr16 68154862 G A 3.96E-14 HDL cholesterol NFATC3 intron 23063622 rs2418736 chr16 68154862 G A 3.19E-08 Red blood cell traits NFATC3 intron 23222517 rs2418736 chr16 68154862 G A 8.20E-07 HDL particle features NFATC3 intron pha002900 rs7195601 chr16 68175424 G A 0.00000129 LDL cholesterol NFATC3 intron 23063622 rs7193701 chr16 68185160 G A 4.02E-07 Red blood cell traits NFATC3 intron 23222517 rs7193701 chr16 68185160 G A 3.87E-07 HDL particle features NFATC3 intron pha002900 rs8044995 chr16 68189340 G A 4.11E-08 Red blood cell traits NFATC3 intron 23222517 rs4359427 chr16 68202747 C T 1.38E-11 Triglycerides NFATC3 intron 19060911 rs4359427 chr16 68202747 C T 5.13E-20 HDL cholesterol NFATC3 intron 23063622 rs4359427 chr16 68202747 C T 8.21E-07 HDL particle features NFATC3 intron pha002900 rs8046355 chr16 68205214 T A 4.23E-08 Red blood cell traits NFATC3 intron 23222517 rs8048034 chr16 68210604 A G 1.12E-14 HDL cholesterol NFATC3 intron 23063622 rs8048034 chr16 68210604 A G 3.94E-08 Red blood cell traits NFATC3 intron 23222517 rs9932414 chr16 68219969 A G 6.95E-04 Response to taxane treatment (placlitaxel) NFATC3 intron 23006423 rs9932414 chr16 68219969 A G 1.82E-08 Red blood cell traits NFATC3 intron 23222517 rs6499163 chr16 68243486 G T 4.59E-09 Red blood cell traits NFATC3 intron 23222517 rs9938020 chr16 68251784 C G 8.43E-08 Red blood cell traits NFATC3 intron 23222517 rs7187202 chr16 68273895 T C 1.42E-12 HDL cholesterol / / 23063622 rs7187202 chr16 68273895 T C 3.47E-08 Red blood cell traits / / 23222517 rs7197756 chr16 68275516 A C 1.40E-08 Red blood cell traits / / 23222517 rs1975802 chr16 68285847 A G 2.28E-08 Triglycerides PLA2G15 intron 19060911 rs1975802 chr16 68285847 A G 2.46E-07 Red blood cell traits PLA2G15 intron 23222517 rs1975802 chr16 68285847 A G 1.95E-07 HDL particle features PLA2G15 intron pha002900 rs16957784 chr16 68287974 A T 0.000000215 LDL cholesterol PLA2G15 intron 23063622 rs2290700 chr16 68288983 T G 5.31E-08 Red blood cell traits PLA2G15 intron 23222517 rs2290699 chr16 68289059 C T 1.41E-07 Red blood cell traits PLA2G15 intron 23222517 rs3743739 chr16 68293320 T C 4.24E-12 HDL cholesterol PLA2G15 cds-synon 23063622 rs3743739 chr16 68293320 T C 8.42E-08 Red blood cell traits PLA2G15 cds-synon 23222517 rs9933029 chr16 68303410 A G 3.96E-05 Cervical cancer SLC7A6 intron 24700089 rs8056893 chr16 68304392 C A 2.00E-30 Blood metabolite levels SLC7A6 intron 24816252 rs8056893 chr16 68304392 C A 3.00E-39 Blood metabolite ratios SLC7A6 intron 24816252 rs9935025 chr16 68307447 T C 4.60E-05 Cervical cancer SLC7A6 intron 24700089 rs4783552 chr16 68310312 T C 5.43E-05 Cervical cancer SLC7A6 intron 24700089 rs6499165 chr16 68326200 A C 1.00E-18 Metabolic traits SLC7A6 intron 21886157 rs6499166 chr16 68326917 G A 0.00000038 Glomerular filtration rate SLC7A6 intron 22962313 rs2863979 chr16 68331890 G A 1.00E-17 Blood metabolite levels SLC7A6 UTR-3 24816252 rs41363946 chr16 68334430 T C 2.61E-05 Multiple complex diseases SLC7A6 UTR-3 17554300 rs7190070 chr16 68353983 C T 6.50E-04 Response to taxane treatment (placlitaxel) PRMT7 intron 23006423 rs1111571 chr16 68363181 G A 9.50E-04 Alcohol dependence PRMT7 intron 21314694 rs1111571 chr16 68363181 G A 3.60E-05 Duodenal ulcer PRMT7 intron 22387998 rs8058517 chr16 68379860 C T 6.92E-10 Triglycerides PRMT7 intron 19060911 rs8058517 chr16 68379860 C T 8.82E-05 Schizophrenia PRMT7 intron pha002859 rs8058517 chr16 68379860 C T 4.37E-08 HDL particle features PRMT7 intron pha002900 rs7190134 chr16 68381516 G A 9.62E-04 Response to taxane treatment (placlitaxel) PRMT7 intron 23006423 rs7197653 chr16 68383047 G A,C 2.00E-06 Magnesium levels PRMT7 intron 20700443 rs4783554 chr16 68384010 A G 3.77E-05 Duodenal ulcer PRMT7 intron 22387998 rs1465467 chr16 68398432 C T 1.11E-04 Lymphocyte counts SMPD3 intron 22286170 rs2863973 chr16 68409435 A C 0.000000007 HDL cholesterol SMPD3 intron 23063622 rs8050499 chr16 68428326 A G 3.85E-05 HDL particle features SMPD3 intron pha002900 rs11649335 chr16 68436154 C T 2.21E-04 Blood pressure SMPD3 intron 17255346 rs11649335 chr16 68436154 C T 7.62E-04 Coronary heart disease SMPD3 intron 21606135 rs16958011 chr16 68520446 G A 4.94E-04 Multiple complex diseases / / 17554300 rs8048966 chr16 68566787 G A 2.15E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1182968 chr16 68573945 C T 5.66E-04 Ulcerative colitis,refractory ZFP90 intron 20848476 rs12149608 chr16 68586504 G C 0.00000317 Primary sclerosing cholangitis ZFP90 intron 23603763 rs1728785 chr16 68591230 A C 3.00E-08 Ulcerative colitis ZFP90 intron 19915572 rs1728785 chr16 68591230 A C 3.00E-08 Multiple sclerosis ZFP90 intron 22190364 rs1728785 chr16 68591230 A C 4.00E-08 Ulcerative colitis ZFP90 intron 23128233 rs17689437 chr16 68600351 C T 1.00E-06 Response to antipsychotic treatment in schizophrenia (reasoning) ZFP90 UTR-3 21107309 rs17689437 chr16 68600351 C T 6.00E-06 HIV-1 viral setpoint ZFP90 UTR-3 22174851 rs16958163 chr16 68608275 G T 4.85E-04 Multiple complex diseases / / 17554300 rs6499188 chr16 68674788 G A 4.00E-08 Ulcerative colitis / / 21297633 rs3118228 chr16 68710737 T G 2.27E-07 Red blood cell traits CDH3 intron 23222517 rs117432663 chr16 68734249 G A 1.35E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs192253604 chr16 68757769 G A 8.00E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs9929218 chr16 68820946 G A 1.00E-08 Colorectal cancer CDH1 intron 19011631 rs9929218 chr16 68820946 G A 1.00E-08 Nasopharyngeal carcinoma CDH1 intron 20512145 rs1862748 chr16 68832943 C T 2.60E-06 Colorectal cancer CDH1 intron 19011631 rs10431923 chr16 68839263 G T 1.47E-05 Serum metabolites CDH1 intron 19043545 rs3785076 chr16 68850783 A G 3.87E-06 Corneal structure CDH1 intron 22003120 rs10500546 chr16 68956625 A G 5.51E-04 Amyotrophic Lateral Sclerosis TMCO7 intron 17362836 rs10500547 chr16 68960982 T C 5.50E-06 Urinary metabolites TMCO7 intron 21572414 rs13330043 chr16 69026253 G A 6.04E-04 Type 2 diabetes TMCO7 intron 17463246 rs251100 chr16 69055675 C A 2.10E-04 Iris characteristics TMCO7 intron 21835309 rs9934572 chr16 69058613 A G 4.17E-05 Fibrinogen TMCO7 intron 17255346 rs12325454 chr16 69102989 T C 9.50E-04 Iris characteristics TMCO7 intron 21835309 rs143939627 chr16 69104267 G A 2.61E-05 Colorectal cancer TMCO7 intron 24737748 rs8047014 chr16 69135049 C A 4.00E-06 Attention deficit hyperactivity disorder / / 18821565 rs2232228 chr16 69143577 A G 7.15E-06 HDL particle features HAS3 cds-synon pha002900 rs3785079 chr16 69145476 A C 2.09E-05 Body Mass Index HAS3 intron pha003006 rs3785079 chr16 69145476 A C 7.76E-05 Waist Circumference HAS3 intron pha003024 rs8049057 chr16 69210661 G T 5.15E-05 Cervical cancer / / 24700089 rs246129 chr16 69341781 A G 4.06E-05 HDL particle features SNTB2 UTR-3 pha002900 rs153050 chr16 69349738 T C 6.09E-06 HDL particle features VPS4A intron pha002900 rs11647864 chr16 69355506 C T 3.92E-04 Alcohol dependence VPS4A intron 21314694 rs16958762 chr16 69374946 A G 4.97E-04 Multiple complex diseases NIP7 intron 17554300 rs7187262 chr16 69494279 A C 3.80E-25 Narcolepsy CYB5B intron 19629137 rs4783708 chr16 69495181 C T 5.67E-04 Multiple sclerosis CYB5B intron 17660530 rs744972 chr16 69542376 A C 9.00E-06 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs732021 chr16 69542478 C G 2.55E-08 Urate levels / / 23263486 rs4783718 chr16 69547741 T C 0.00045 Prostate cancer / / 23555315 rs7200764 chr16 69548788 T C 3.69E-06 Left ventricular mass / / 21212386 rs4783720 chr16 69559696 C T 8.85E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs13330951 chr16 69563842 A G 0.000076 Major depressive disorder / / 23149448 rs7193778 chr16 69563890 C T 8.00E-10 Urate levels / / 23263486 rs17296283 chr16 69586228 C T 8.46E-05 Type 2 diabetes and other traits / / 19734900 rs17230557 chr16 69587121 T C 8.50E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs1364063 chr16 69588572 T C 2.00E-08 Menarche (age at onset) / / 21102462 rs12599391 chr16 69605349 T C 4.19E-04 Multiple complex diseases NFAT5 intron 17554300 rs6499235 chr16 69622516 A G 0.00000101 Triglycerides NFAT5 intron 23063622 rs33063 chr16 69640217 A G 8.83E-04 Acute lung injury NFAT5 intron 22295056 rs39999 chr16 69653696 C G 8.15E-04 Acute lung injury NFAT5 intron 22295056 rs244415 chr16 69666683 G A 3.92E-04 Multiple complex diseases NFAT5 intron 17554300 rs10500553 chr16 69685014 A G 3.42E-10 Alcohol consumption NFAT5 intron pha001398 rs9889219 chr16 69721415 G A 2.39E-05 Aging (time to event) NFAT5 intron 21782286 rs145602190 chr16 69727480 A G 0.00000017 Breast cancer(er negative) NFAT5 missense 23555315 rs1437134 chr16 69730426 A G 3.36E-04 Multiple complex diseases NFAT5 UTR-3 17554300 rs1800566 chr16 69745145 G A 1 Drug response to Epirubicin NQO1 missense 18511948 rs1800566 chr16 69745145 G A 9.55E-05 Brain lesion load NQO1 missense 19010793 rs1131341 chr16 69748869 G A,C,T 1.40E-04 Coronary heart disease NQO1 missense 21966275 rs8053497 chr16 69755900 A G 9.92E-08 Triglycerides NQO1 intron 23063622 rs689460 chr16 69760286 C G 0.00000106 Triglycerides NQO1 intron 23063622 rs6499255 chr16 69830328 A G 1.00E-06 IgE levels WWP2 intron 23146381 rs904810 chr16 69950656 T C 2.80E-04 Telomere length WWP2 intron 23900074 rs904809 chr16 69951291 A G 4.30E-05 Bulimia nervosa WWP2 intron 23568457 rs904809 chr16 69951291 A G 3.26E-04 Telomere length WWP2 intron 23900074 rs2270842 chr16 69970000 T G 4.60E-04 Amyotrophic Lateral Sclerosis WWP2 intron 17362836 rs1983016 chr16 69970329 A G 2.96E-04 Amyotrophic Lateral Sclerosis WWP2 cds-synon 17362836 rs3762177 chr16 69971965 A G 2.36E-04 Amyotrophic Lateral Sclerosis WWP2 intron 17362836 rs3748386 chr16 69974659 G A 9.29E-04 Myocardial Infarction WWP2 UTR-3 pha002883 rs1052429 chr16 69975360 G A 3.93E-04 Amyotrophic Lateral Sclerosis WWP2 UTR-3 17362836 rs1052429 chr16 69975360 G A 1.40E-04 Bone mineral density WWP2 UTR-3 21927923 rs1055255 chr16 70191421 C T 3.11E-04 Acute lung injury PDPR UTR-3 22295056 rs4081753 chr16 70287177 A G 3.80E-07 Urinary metabolites AARS cds-synon 21572414 rs7205918 chr16 70288732 T C 1.70E-05 Obesity,menopause AARS intron 21424828 rs12149660 chr16 70309237 G A 8.12E-04 Response to cytidine analogues (gemcitabine) AARS intron 24483146 rs4985525 chr16 70383238 C A 2.60E-05 Urinary metabolites DDX19A intron 21572414 rs34109485 chr16 70450739 C T 8.00E-05 HIV-1 control ST3GAL2 intron 20041166 rs13335135 chr16 70490521 A C 3.83E-29 Multiple complex diseases FUK intron 17554300 rs11861805 chr16 70505359 T A 6.00E-06 Obesity-related traits FUK intron 23251661 rs11861805 chr16 70505359 T A 8.00E-06 Obesity-related traits FUK intron 23251661 rs2303791 chr16 70531754 T G 3.00E-04 Alzheimer's disease COG4 intron 17998437 rs4985534 chr16 70603220 T C 2.51E-04 Alzheimer's disease SF3B3 intron 17998437 rs16970331 chr16 70611562 A G 7.31E-04 Multiple complex diseases SF3B3 UTR-3 17554300 rs8049475 chr16 70630309 C T 9.04E-05 Multiple complex diseases IL34 intron 17554300 rs11075773 chr16 70642437 C T 6.05E-04 Response to statin treatment (atorvastatin),change in cholesterol levels IL34 intron 20031582 rs16970406 chr16 70669292 T C 4.88E-04 Alzheimer's disease IL34 intron 24755620 rs9925191 chr16 70676679 T C 4.19E-04 Alzheimer's disease IL34 intron 24755620 rs6499330 chr16 70677785 G A 6.90E-05 Personality dimensions IL34 intron 18957941 rs3813905 chr16 70680850 C G 3.35E-05 Type 2 diabetes IL34 UTR-5 21647700 rs2168608 chr16 70682694 G A 4.10E-05 Personality dimensions IL34 intron 18957941 rs8046424 chr16 70690989 G C 1.49E-04 Response to statin treatment (atorvastatin),change in cholesterol levels IL34 missense 20031582 rs8046424 chr16 70690989 G C 4.41E-05 Response to statin treatment (atorvastatin),change in cholesterol levels IL34 missense 20031582 rs4985556 chr16 70694000 C A 1.92E-05 Alzheimer's disease (late onset) IL34 STOP-GAIN 21460841 rs2271047 chr16 70818759 A G 4.80E-04 Myasthenia gravis VAC14 intron 23055271 rs34544582 chr16 70818759 A AG 4.80E-04 Myasthenia gravis VAC14 intron 23055271 rs8060947 chr16 70823633 A G 8.69E-04 Type 2 diabetes VAC14 intron 17463246 rs8063716 chr16 70833405 G A 1.66E-05 Height VAC14 intron pha003010 rs12149070 chr16 70913984 C T 8.00E-06 Chronic obstructive pulmonary disease-related biomarkers HYDIN intron 23144326 rs12149070 chr16 70913984 C T 1.02E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) HYDIN intron 24023788 rs12149261 chr16 70998145 C A 3.50E-75 White blood cell count HYDIN intron 21738479 rs2795674 chr16 71022190 G C 5.04E-11 Multiple complex diseases HYDIN intron 17554300 rs195656 chr16 71047484 G A 7.00E-06 Celiac disease HYDIN intron 23936387 rs6416707 chr16 71048781 C T 6.44E-04 Multiple complex diseases HYDIN intron 17554300 rs6499386 chr16 71049391 C T 1.86E-04 Multiple complex diseases HYDIN intron 17554300 rs11075838 chr16 71067798 T C 0.000768 Salmonella-induced pyroptosis HYDIN intron 22837397 rs9935325 chr16 71093625 C T 4.24E-05 Multiple complex diseases HYDIN intron 17554300 rs9939485 chr16 71207879 G C 3.55E-05 Diabetes (gestational) HYDIN intron 22233651 rs757106 chr16 71223208 C T 7.16E-04 Taste perception HYDIN intron 22132133 rs235989 chr16 71230079 A T 5.96E-04 Type 2 diabetes HYDIN intron 17463246 rs2042423 chr16 71234989 C T 8.84E-04 Alcohol dependence HYDIN intron 21314694 rs764600 chr16 71237702 C T 7.16E-04 Taste perception HYDIN intron 22132133 rs236009 chr16 71251795 T C 6.29E-04 Type 2 diabetes HYDIN intron 17463246 rs236008 chr16 71254941 C T 2.48E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy HYDIN intron 23834954 rs12933427 chr16 71268123 T C 7.16E-04 Taste perception / / 22132133 rs235997 chr16 71284193 A G 8.50E-04 Type 2 diabetes / / 17463246 rs889704 chr16 71392062 C A 1.33E-04 Attention deficit hyperactivity disorder / / 22420046 rs6499513 chr16 71404780 C T 7.53E-04 Smoking initiation CALB2 intron 24665060 rs12444419 chr16 71408475 T G 7.93E-05 Longevity CALB2 intron 20304771 rs8046337 chr16 71408527 A G 7.55E-05 Longevity CALB2 intron 20304771 rs6499515 chr16 71408940 G A 3.90E-04 Type 2 diabetes CALB2 intron 17463246 rs11641122 chr16 71410120 G T 5.64E-05 Longevity CALB2 intron 20304771 rs13338215 chr16 71436032 T C 8.88E-04 Multiple complex diseases / / 17554300 rs8060811 chr16 71436154 C A 4.78E-04 Multiple complex diseases / / 17554300 rs12102284 chr16 71439049 G A 1.09E-04 Common variable immunodeficiency / / 21497890 rs1030483 chr16 71442416 A G 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7188475 chr16 71446358 G A 5.32E-06 Type 2 diabetes / / 17463246 rs12922830 chr16 71447270 C T 1.59E-05 Type 2 diabetes / / 17463246 rs4363868 chr16 71458299 G A 5.01E-04 Taste perception / / 22132133 rs12918320 chr16 71463602 A G 1.57E-05 Type 2 diabetes / / 17463246 rs16972808 chr16 71478717 T C 1.38E-04 Type 2 diabetes / / 17463246 rs2070832 chr16 71487206 T C 1.49E-04 Stroke ZNF23 missense pha002886 rs2052873 chr16 71505303 C T 1.47E-04 Type 2 diabetes / / 17463246 rs75731908 chr16 71509207 A C 0.000019 Prostate cancer (advanced) ZNF19 missense 23555315 rs12935091 chr16 71525208 A G 2.00E-05 Longevity / / 20304771 rs16973260 chr16 71534853 C T 2.14E-04 Type 2 diabetes / / 17463246 rs4149497 chr16 71558970 G A 2.02E-05 Longevity CHST4 nearGene-5 20304771 rs4149497 chr16 71558970 G A 1.67E-04 Attention deficit hyperactivity disorder CHST4 nearGene-5 22420046 rs12919417 chr16 71579711 C T 2.48E-05 Alzheimer's disease / / 17998437 rs12919417 chr16 71579711 C T 3.20E-04 Pulmonary function / / 23932459 rs12447033 chr16 71583655 C A 6.15E-04 Alzheimer's disease / / 17998437 rs2432524 chr16 71584333 G T 5.06E-13 Metabolite levels / / 22286219 rs2432524 chr16 71584333 G T 4.73E-04 Stroke / / pha002886 rs310331 chr16 71589376 A T 4.17E-11 Metabolite levels / / 22286219 rs172649 chr16 71596005 G T 9.26E-12 Metabolite levels / / 22286219 rs1477386 chr16 71600477 C G 7.96E-13 Metabolite levels LOC100132529 intron 22286219 rs172650 chr16 71603912 C A 7.76E-13 Metabolite levels TAT intron 22286219 rs2432520 chr16 71607384 T G 5.62E-13 Metabolite levels TAT intron 22286219 rs3829537 chr16 71612346 C A 5.97E-14 Metabolite levels TAT nearGene-5 22286219 rs11862798 chr16 71612569 C A 6.22E-14 Metabolite levels TAT nearGene-5 22286219 rs9930543 chr16 71612631 G A 2.15E-14 Metabolite levels TAT nearGene-5 22286219 rs11075889 chr16 71612889 A G 2.95E-14 Metabolite levels TAT nearGene-5 22286219 rs4788808 chr16 71615613 C T 1.17E-11 Metabolite levels / / 22286219 rs4788809 chr16 71615820 G A 6.05E-14 Metabolite levels / / 22286219 rs4788810 chr16 71621637 T C 5.54E-04 Type 2 diabetes / / 17463246 rs16973352 chr16 71624835 T C 4.97E-04 Multiple complex diseases / / 17554300 rs4788812 chr16 71625467 A G 4.56E-14 Metabolite levels / / 22286219 rs11648240 chr16 71628274 A G 5.84E-14 Metabolite levels / / 22286219 rs4788546 chr16 71629820 T C 2.45E-13 Metabolite levels / / 22286219 rs4788547 chr16 71634544 G A 5.47E-14 Metabolite levels / / 22286219 rs4788814 chr16 71634604 A T 5.13E-14 Metabolite levels / / 22286219 rs4788815 chr16 71634811 A T 2.00E-17 Metabolite levels / / 22286219 rs4788815 chr16 71634811 A T 4.00E-13 Metabolite levels (atherosclerosis) / / 22916037 rs11641811 chr16 71635836 C A 6.24E-11 Metabolite levels / / 22286219 rs9932415 chr16 71639601 T C 1.87E-14 Metabolite levels / / 22286219 rs11075891 chr16 71639649 C T 2.76E-14 Metabolite levels / / 22286219 rs4788817 chr16 71641395 T C 7.91E-14 Metabolite levels / / 22286219 rs11075892 chr16 71641690 T C 3.34E-14 Metabolite levels / / 22286219 rs11643690 chr16 71645638 T C 1.19E-13 Metabolite levels / / 22286219 rs7206039 chr16 71645914 C A 1.11E-13 Metabolite levels / / 22286219 rs2334880 chr16 71653637 A G 2.00E-06 Malaria / / 22895189 rs34764568 chr16 71657605 G T 2.12E-13 Metabolite levels / / 22286219 rs4788821 chr16 71660310 G A 1.30E-13 Metabolite levels MARVELD3 missense 22286219 rs12444484 chr16 71661536 T A 2.37E-13 Metabolite levels MARVELD3 intron 22286219 rs12932850 chr16 71668634 T G 1.70E-13 Metabolite levels MARVELD3 cds-synon 22286219 rs2303225 chr16 71674882 C G 2.06E-13 Metabolite levels MARVELD3 cds-synon 22286219 rs8058188 chr16 71675136 G A 9.95E-11 Metabolite levels MARVELD3 UTR-3 22286219 rs3752681 chr16 71678663 T C 1.94E-13 Metabolite levels / / 22286219 rs8203 chr16 71678932 T C 1.88E-13 Metabolite levels PHLPP2 UTR-3 22286219 rs1058747 chr16 71679204 C T 2.52E-13 Metabolite levels PHLPP2 UTR-3 22286219 rs61733125 chr16 71682796 T C 9.54E-13 Metabolite levels PHLPP2 cds-synon 22286219 rs61733124 chr16 71682830 C T 2.55E-11 Metabolite levels PHLPP2 missense 22286219 rs1582589 chr16 71686054 A G 2.02E-13 Metabolite levels PHLPP2 intron 22286219 rs2303224 chr16 71692443 A G 2.75E-12 Metabolite levels PHLPP2 intron 22286219 rs10500559 chr16 71693093 T C 2.25E-13 Metabolite levels PHLPP2 intron 22286219 rs62053107 chr16 71694211 T C 2.41E-13 Metabolite levels PHLPP2 intron 22286219 rs62053108 chr16 71696020 C T 1.31E-13 Metabolite levels PHLPP2 intron 22286219 rs1035545 chr16 71697752 T C 1.36E-13 Metabolite levels PHLPP2 intron 22286219 rs2032918 chr16 71703436 T G 6.24E-05 Cognitive test performance PHLPP2 intron 20125193 rs11648674 chr16 71703729 A G 7.01E-14 Metabolite levels PHLPP2 intron 22286219 rs3925658 chr16 71709167 A G 5.21E-14 Metabolite levels PHLPP2 intron 22286219 rs9927336 chr16 71712321 G A 9.94E-14 Metabolite levels PHLPP2 intron 22286219 rs9927437 chr16 71712462 G A 1.12E-13 Metabolite levels PHLPP2 intron 22286219 rs4788549 chr16 71714119 C G 2.52E-13 Metabolite levels PHLPP2 intron 22286219 rs7186890 chr16 71716524 A G 3.39E-11 Metabolite levels PHLPP2 intron 22286219 rs17355804 chr16 71717214 A G 7.80E-06 Alzheimer's disease PHLPP2 intron 17998437 rs8048057 chr16 71717384 G A 1.31E-13 Metabolite levels PHLPP2 intron 22286219 rs8048210 chr16 71717405 G A,C 1.32E-12 Metabolite levels PHLPP2 intron 22286219 rs4788826 chr16 71721020 T C 3.06E-13 Metabolite levels PHLPP2 intron 22286219 rs4788827 chr16 71721032 G T 1.89E-13 Metabolite levels PHLPP2 intron 22286219 rs9940217 chr16 71721513 G A 1.88E-13 Metabolite levels PHLPP2 intron 22286219 rs28582831 chr16 71726741 A T 1.15E-12 Metabolite levels PHLPP2 intron 22286219 rs9936903 chr16 71727571 A T 1.22E-13 Metabolite levels PHLPP2 intron 22286219 rs9937280 chr16 71727862 C T 3.12E-13 Metabolite levels PHLPP2 intron 22286219 rs12926987 chr16 71732795 C G 1.86E-13 Metabolite levels PHLPP2 intron 22286219 rs60881203 chr16 71737659 T G 1.86E-13 Metabolite levels PHLPP2 intron 22286219 rs12597065 chr16 71741624 C T 3.20E-13 Metabolite levels PHLPP2 intron 22286219 rs35131351 chr16 71747848 CT C 2.43E-13 Metabolite levels PHLPP2 intron 22286219 rs9923679 chr16 71747848 C T 2.43E-13 Metabolite levels PHLPP2 intron 22286219 rs6499533 chr16 71755098 A C 9.30E-11 Metabolite levels / / 22286219 rs34734042 chr16 71755672 A C 1.04E-13 Metabolite levels / / 22286219 rs9925228 chr16 71759364 C T 1.17E-13 Metabolite levels / / 22286219 rs918721 chr16 71760611 G A 1.14E-13 Metabolite levels / / 22286219 rs1392487 chr16 71760988 C A 1.14E-13 Metabolite levels / / 22286219 rs9921270 chr16 71761061 T C 1.05E-13 Metabolite levels / / 22286219 rs3751817 chr16 71764834 C T 1.13E-13 Metabolite levels AP1G1 UTR-3 22286219 rs11539980 chr16 71765416 G T 1.43E-13 Metabolite levels AP1G1 UTR-3 22286219 rs4788551 chr16 71767661 C T 1.15E-13 Metabolite levels AP1G1 intron 22286219 rs4788552 chr16 71767836 G A 1.12E-13 Metabolite levels AP1G1 intron 22286219 rs2278031 chr16 71768500 T C 1.13E-13 Metabolite levels AP1G1 intron 22286219 rs8052999 chr16 71770836 G A 2.31E-12 Metabolite levels AP1G1 intron 22286219 rs904763 chr16 71773190 G T 1.95E-11 Metabolite levels AP1G1 missense 22286219 rs11645467 chr16 71774390 G A 1.10E-13 Metabolite levels AP1G1 intron 22286219 rs11646635 chr16 71774697 G T 1.06E-13 Metabolite levels AP1G1 intron 22286219 rs11641873 chr16 71774896 T G 1.06E-13 Metabolite levels AP1G1 intron 22286219 rs11646748 chr16 71775080 C T 1.66E-13 Metabolite levels AP1G1 intron 22286219 rs951453 chr16 71776144 C T 5.89E-13 Metabolite levels AP1G1 intron 22286219 rs4788442 chr16 71777448 G C 1.10E-13 Metabolite levels AP1G1 intron 22286219 rs35173463 chr16 71778640 G A 1.06E-13 Metabolite levels AP1G1 intron 22286219 rs2270832 chr16 71780485 G A 1.08E-13 Metabolite levels AP1G1 intron 22286219 rs2270831 chr16 71780599 T C 1.05E-13 Metabolite levels AP1G1 intron 22286219 rs11859903 chr16 71781102 C T 4.72E-11 Metabolite levels AP1G1 intron 22286219 rs2270830 chr16 71782444 A G 1.04E-13 Metabolite levels AP1G1 intron 22286219 rs11075900 chr16 71783373 T A 1.17E-13 Metabolite levels AP1G1 intron 22286219 rs4788554 chr16 71785817 A C 1.20E-13 Metabolite levels AP1G1 intron 22286219 rs2036338 chr16 71788830 G C 6.16E-14 Metabolite levels AP1G1 intron 22286219 rs12447856 chr16 71790673 C T 1.09E-13 Metabolite levels AP1G1 intron 22286219 rs9939455 chr16 71791798 C T 3.93E-14 Metabolite levels AP1G1 intron 22286219 rs11866559 chr16 71792190 G A 2.31E-12 Metabolite levels AP1G1 intron 22286219 rs7185997 chr16 71792208 T C 1.19E-13 Metabolite levels AP1G1 intron 22286219 rs7194858 chr16 71798821 C G 4.29E-11 Metabolite levels AP1G1 intron 22286219 rs7195701 chr16 71799100 G A 4.29E-11 Metabolite levels AP1G1 intron 22286219 rs8060867 chr16 71800036 T C 1.28E-13 Metabolite levels AP1G1 intron 22286219 rs12930206 chr16 71800384 T A 1.56E-13 Metabolite levels AP1G1 intron 22286219 rs12920243 chr16 71801594 G C 1.29E-13 Metabolite levels AP1G1 intron 22286219 rs8062441 chr16 71803914 G T 7.00E-14 Metabolite levels AP1G1 intron 22286219 rs8062477 chr16 71803974 G A 1.07E-13 Metabolite levels AP1G1 intron 22286219 rs11075902 chr16 71809088 C T 1.35E-13 Metabolite levels AP1G1 intron 22286219 rs951939 chr16 71809534 C T 1.35E-13 Metabolite levels AP1G1 intron 22286219 rs9922054 chr16 71813751 T C 2.11E-13 Metabolite levels AP1G1 intron 22286219 rs11075904 chr16 71816899 G A 3.27E-05 Cognitive test performance AP1G1 intron 20125193 rs4788558 chr16 71821377 C T 1.05E-13 Metabolite levels AP1G1 intron 22286219 rs1392483 chr16 71822231 C T 2.31E-13 Metabolite levels AP1G1 intron 22286219 rs9925069 chr16 71824171 C T 2.55E-13 Metabolite levels AP1G1 intron 22286219 rs28704189 chr16 71825998 G A 2.60E-13 Metabolite levels AP1G1 intron 22286219 rs11861285 chr16 71827792 T C 7.50E-11 Metabolite levels AP1G1 intron 22286219 rs9940990 chr16 71831343 T A 2.82E-13 Metabolite levels AP1G1 intron 22286219 rs10459804 chr16 71833831 A T 5.03E-13 Metabolite levels AP1G1 intron 22286219 rs7203231 chr16 71837477 T G 0.000063 Follicular lymphoma AP1G1 intron 23025665 rs3848389 chr16 71839915 T C 5.40E-13 Metabolite levels AP1G1 intron 22286219 rs12598902 chr16 71845186 C T 9.76E-12 Metabolite levels / / 22286219 rs12597418 chr16 71855220 G A 3.86E-13 Metabolite levels / / 22286219 rs56309616 chr16 71862448 A G 1.65E-12 Metabolite levels / / 22286219 rs60740701 chr16 71875515 G A 1.60E-12 Metabolite levels / / 22286219 rs12600163 chr16 71877201 G C 1.19E-12 Metabolite levels / / 22286219 rs4788563 chr16 71879868 A C 5.04E-12 Metabolite levels / / 22286219 rs61747555 chr16 71885423 A G 1.09E-10 Metabolite levels ATXN1L missense 22286219 rs6499545 chr16 71889173 C A,G,T 6.55E-11 Metabolite levels ATXN1L UTR-3 22286219 rs2291947 chr16 71890489 C G 2.07E-12 Metabolite levels ATXN1L UTR-3 22286219 rs4788567 chr16 71893498 G A 2.05E-12 Metabolite levels ATXN1L intron 22286219 rs9936965 chr16 71900064 T C 2.14E-12 Metabolite levels ZNF821 intron 22286219 rs4538017 chr16 71900907 C T 2.01E-12 Metabolite levels ZNF821 intron 22286219 rs9937626 chr16 71903750 G A 2.18E-12 Metabolite levels ZNF821 intron 22286219 rs2335712 chr16 71906597 C T 4.32E-05 Cognitive test performance ZNF821 intron 20125193 rs2335711 chr16 71907559 T A 9.78E-11 Metabolite levels ZNF821 intron 22286219 rs55702379 chr16 71907561 T A 2.21E-12 Metabolite levels ZNF821 intron 22286219 rs13332113 chr16 71920559 T C 2.22E-12 Metabolite levels / / 22286219 rs4788572 chr16 71921783 A G 2.22E-12 Metabolite levels / / 22286219 rs4788448 chr16 71921979 C A 2.22E-12 Metabolite levels / / 22286219 rs13332180 chr16 71929859 C T 2.49E-12 Metabolite levels IST1 intron 22286219 rs4788449 chr16 71931219 G A 1.67E-05 Cognitive test performance IST1 intron 20125193 rs4788578 chr16 71938372 C G 2.49E-12 Metabolite levels IST1 intron 22286219 rs1834033 chr16 71943781 C G 2.98E-12 Metabolite levels IST1 intron 22286219 rs34111614 chr16 71949163 C T 3.26E-12 Metabolite levels IST1 intron 22286219 rs7350856 chr16 71951094 G T 2.98E-12 Metabolite levels IST1 intron 22286219 rs2335708 chr16 71956596 A G 1.27E-12 Metabolite levels IST1 intron 22286219 rs9925684 chr16 71957753 T C 2.85E-12 Metabolite levels IST1 intron 22286219 rs7197486 chr16 71958052 A G 1.62E-04 Iron levels IST1 intron pha002876 rs3751820 chr16 71961906 A G 2.21E-04 Iron levels IST1 UTR-3 pha002876 rs16973500 chr16 71965196 C T 7.00E-06 Attention deficit hyperactivity disorder and conduct disorder PKD1L3 intron 18951430 rs952160 chr16 71965725 T C 1.46E-12 Metabolite levels PKD1L3 intron 22286219 rs952159 chr16 71965915 G A 3.38E-12 Metabolite levels PKD1L3 intron 22286219 rs17286411 chr16 71968701 C G 5.83E-11 Metabolite levels PKD1L3 intron 22286219 rs12926041 chr16 71978645 G C 3.91E-13 Metabolite levels PKD1L3 intron 22286219 rs12926300 chr16 71978997 C T 9.18E-12 Metabolite levels PKD1L3 intron 22286219 rs12599192 chr16 71979097 G A 9.17E-12 Metabolite levels PKD1L3 intron 22286219 rs1035543 chr16 71983772 G C 1.11E-12 Metabolite levels PKD1L3 missense 22286219 rs1035543 chr16 71983772 G C 0.00000087 Stroke PKD1L3 missense 23422753 rs9889100 chr16 71986073 C T 1.15E-12 Metabolite levels PKD1L3 intron 22286219 rs11648353 chr16 71986764 G A 7.77E-11 Metabolite levels PKD1L3 intron 22286219 rs7204708 chr16 71986946 A G 7.07E-11 Metabolite levels PKD1L3 cds-synon 22286219 rs12935795 chr16 71987452 G C 7.46E-11 Metabolite levels PKD1L3 intron 22286219 rs9888748 chr16 71987851 G A 9.36E-11 Metabolite levels PKD1L3 intron 22286219 rs9921412 chr16 71988106 C T 1.99E-14 Metabolite levels PKD1L3 missense 22286219 rs9921705 chr16 71988220 G A 6.53E-11 Metabolite levels PKD1L3 intron 22286219 rs11075911 chr16 71988505 T C 1.24E-10 Metabolite levels PKD1L3 intron 22286219 rs2303220 chr16 71988728 T G 7.39E-11 Metabolite levels PKD1L3 intron 22286219 rs62053803 chr16 71989413 G A 6.67E-11 Metabolite levels PKD1L3 intron 22286219 rs8054175 chr16 71990424 G A,C 6.36E-11 Metabolite levels PKD1L3 intron 22286219 rs8054111 chr16 71990651 A G 6.30E-11 Metabolite levels PKD1L3 intron 22286219 rs12447423 chr16 71990781 C T 6.50E-11 Metabolite levels PKD1L3 intron 22286219 rs4788584 chr16 71993386 A T 5.55E-11 Metabolite levels PKD1L3 intron 22286219 rs4788585 chr16 71993638 A G 9.42E-05 Cognitive test performance PKD1L3 intron 20125193 rs4788585 chr16 71993638 A G 5.34E-11 Metabolite levels PKD1L3 intron 22286219 rs8052028 chr16 71993957 G A 6.60E-11 Metabolite levels PKD1L3 intron 22286219 rs2878406 chr16 71995038 G C 7.47E-11 Metabolite levels PKD1L3 intron 22286219 rs4462592 chr16 71995558 C T 8.16E-11 Metabolite levels PKD1L3 intron 22286219 rs8053891 chr16 71997789 A C 7.91E-11 Metabolite levels PKD1L3 intron 22286219 rs7197967 chr16 72007232 G A 8.64E-04 Suicide attempts in bipolar disorder PKD1L3 cds-synon 21041247 rs7205297 chr16 72025531 G A 5.79E-07 Left ventricular mass PKD1L3 intron 21212386 rs17664900 chr16 72027611 G A 0.0000454 Circulating PCSK9 levels PKD1L3 intron 22460556 rs2228437 chr16 72040499 C A 1.37E-04 Aortic root size / / 21223598 rs3213422 chr16 72042682 A C 1 Drug response to Leflunomide DHODH missense 19207032 rs8057016 chr16 72046211 G T 5.02E-23 Narcolepsy DHODH intron 19629137 rs8045316 chr16 72052625 G A 9.69E-06 White blood cell count DHODH intron 21738479 rs12924886 chr16 72075593 A T 4.92E-12 Metabolite levels / / 22286219 rs1424241 chr16 72078907 G A 5.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs1424241 chr16 72078907 G A 1.88E-06 White blood cell count / / 21738479 rs7197453 chr16 72079127 G C 9.86E-04 Obesity (extreme) / / 21935397 rs7197869 chr16 72079352 G C 9.75E-04 Obesity (extreme) / / 21935397 rs16973640 chr16 72084134 T G 6.64E-10 Cholesterol,total / / 23063622 rs7191270 chr16 72084995 T C 6.52E-10 Cholesterol,total / / 23063622 rs8062041 chr16 72088964 C T 9.22E-04 Obesity (extreme) HP intron 21935397 rs3794695 chr16 72097827 C T 8.65E-14 Metabolite levels HPR intron 22286219 rs34042070 chr16 72101525 C G 8.30E-14 Metabolite levels HPR intron 22286219 rs2000999 chr16 72108093 G A 2.00E-22 LDL cholesterol HPR intron 20686565 rs2000999 chr16 72108093 G A 3.00E-24 Cholesterol,total HPR intron 20686565 rs2000999 chr16 72108093 G A 8.00E-06 Coronary heart disease HPR intron 21966275 rs2000999 chr16 72108093 G A 1.47E-13 Metabolite levels HPR intron 22286219 rs2000999 chr16 72108093 G A 8.00E-59 Haptoglobin levels HPR intron 22403646 rs2000999 chr16 72108093 G A 0.00000163 LDL cholesterol (male) HPR intron 22629316 rs2000999 chr16 72108093 G A 0.000491 LDL cholesterol (female) HPR intron 22629316 rs2000999 chr16 72108093 G A 2.39E-08 LDL cholesterol HPR intron 22629316 rs2000999 chr16 72108093 G A 1.72E-13 Cholesterol,total HPR intron 23063622 rs2000999 chr16 72108093 G A 3.33E-09 LDL cholesterol HPR intron 23063622 rs2000999 chr16 72108093 G A 2.79E-10 Alpha-2 globulin (%) HPR intron 23696881 rs2000999 chr16 72108093 G A 4.00E-41 LDL cholesterol HPR intron 24097068 rs2000999 chr16 72108093 G A 7.00E-41 Cholesterol,total HPR intron 24097068 rs200255876 chr16 72108192 T G 0.0003 Breast cancer HPR missense 23555315 rs2550038 chr16 72112013 T C 8.43E-04 Obesity (extreme) / / 21935397 rs2550035 chr16 72113416 C G 8.36E-04 Obesity (extreme) / / 21935397 rs217181 chr16 72114002 C T 2.33E-17 Metabolite levels / / 22286219 rs217181 chr16 72114002 C T 1.00E-36 Metabolite levels (atherosclerosis) / / 22916037 rs217181 chr16 72114002 C T 5.95E-10 Cholesterol,total / / 23063622 rs10492813 chr16 72122463 C T 8.03E-04 Obesity (extreme) TXNL4B intron 21935397 rs3852781 chr16 72123556 T A,G 7.97E-04 Obesity (extreme) TXNL4B intron 21935397 rs7191127 chr16 72123992 G T 6.53E-04 Obesity (extreme) TXNL4B intron 21935397 rs7190995 chr16 72124157 A G 6.51E-04 Obesity (extreme) TXNL4B intron 21935397 rs2303285 chr16 72124495 A C 7.76E-04 Obesity (extreme) TXNL4B intron 21935397 rs3764311 chr16 72125617 C G 7.70E-04 Obesity (extreme) TXNL4B intron 21935397 rs3764312 chr16 72125733 A C 6.33E-04 Obesity (extreme) TXNL4B intron 21935397 rs10492814 chr16 72126514 G A 7.22E-04 Obesity (extreme) TXNL4B intron 21935397 rs12924413 chr16 72129745 T C 6.99E-04 Obesity (extreme) DHX38 intron 21935397 rs35794819 chr16 72130103 C G 0.00000549 Alcohol consumption DHX38 missense 23555315 rs1050361 chr16 72130203 C G 7.49E-04 Obesity (extreme) DHX38 cds-synon 21935397 rs1050362 chr16 72130815 C A 4.62E-04 Obesity (extreme) DHX38 cds-synon 21935397 rs2072142 chr16 72132713 C T 6.21E-04 Obesity (extreme) DHX38 intron 21935397 rs2072141 chr16 72133211 G A 7.89E-04 Obesity (extreme) DHX38 intron 21935397 rs12708928 chr16 72137227 C A 6.44E-04 Obesity (extreme) DHX38 intron 21935397 rs2240243 chr16 72137561 G A 6.51E-04 Obesity (extreme) DHX38 cds-synon 21935397 rs12325142 chr16 72138112 G T 7.33E-04 Obesity (extreme) DHX38 intron 21935397 rs2074626 chr16 72139184 C A 7.37E-04 Obesity (extreme) DHX38 cds-synon 21935397 rs2287997 chr16 72140553 G A 1.17E-13 Metabolite levels DHX38 intron 22286219 rs2287997 chr16 72140553 G A 1.01E-10 Alpha-2 globulin (%) DHX38 intron 23696881 rs8051882 chr16 72142072 C T 7.08E-04 Obesity (extreme) DHX38 intron 21935397 rs9926156 chr16 72142895 G C 7.79E-04 Obesity (extreme) DHX38 intron 21935397 rs2241412 chr16 72144284 A G 8.26E-04 Obesity (extreme) DHX38 intron 21935397 rs6680 chr16 72146570 T C 8.66E-04 Obesity (extreme) DHX38 UTR-3 21935397 rs6499560 chr16 72147666 A C 9.03E-04 Obesity (extreme) / / 21935397 rs8047377 chr16 72148339 T C 9.19E-04 Obesity (extreme) / / 21935397 rs6499561 chr16 72148404 A G 7.88E-04 Obesity (extreme) / / 21935397 rs4788460 chr16 72154509 C T 2.77E-12 Metabolite levels PMFBP1 intron 22286219 rs4788605 chr16 72154682 G T 5.61E-11 Metabolite levels PMFBP1 intron 22286219 rs11647069 chr16 72155237 T C 3.47E-12 Metabolite levels PMFBP1 intron 22286219 rs11641721 chr16 72155241 G A 5.16E-11 Metabolite levels PMFBP1 intron 22286219 rs8052408 chr16 72158077 C T 2.60E-05 Urinary metabolites PMFBP1 intron 21572414 rs34832584 chr16 72162966 G T 3.61E-13 Metabolite levels PMFBP1 missense 22286219 rs10492815 chr16 72163694 A G 5.27E-05 Suicide attempts in bipolar disorder PMFBP1 intron 21423239 rs17603936 chr16 72169002 C A 4.97E-11 Metabolite levels PMFBP1 intron 22286219 rs4788611 chr16 72175256 A G 4.24E-11 Metabolite levels PMFBP1 intron 22286219 rs35370634 chr16 72184566 C T 5.63E-11 Metabolite levels PMFBP1 missense 22286219 rs3812985 chr16 72187957 A T 9.39E-11 Metabolite levels PMFBP1 intron 22286219 rs4788614 chr16 72188828 T C 1.13E-10 Metabolite levels PMFBP1 intron 22286219 rs4788615 chr16 72192372 G A 8.46E-11 Metabolite levels PMFBP1 intron 22286219 rs11648622 chr16 72193036 G A 9.93E-13 Metabolite levels PMFBP1 intron 22286219 rs8047881 chr16 72193906 A G 9.81E-11 Metabolite levels PMFBP1 intron 22286219 rs28419077 chr16 72196776 A G 1.20E-10 Metabolite levels PMFBP1 intron 22286219 rs217176 chr16 72203192 T C 2.09E-14 Metabolite levels PMFBP1 intron 22286219 rs7202323 chr16 72217113 T G 4.91E-04 Parkinson's disease / / 17052657 rs7186908 chr16 72220373 G C 5.00E-09 Liver enzyme levels (alkaline phosphatase) / / 22001757 rs3852789 chr16 72228506 A C 3.00E-05 Breast cancer / / 17529967 rs11645898 chr16 72229532 T C 1.05E-10 Metabolite levels / / 22286219 rs2023929 chr16 72236956 G A 5.84E-05 Lung adenocarcinoma / / 19836008 rs2023929 chr16 72236956 G A 2.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs8060484 chr16 72249130 G T 1.30E-04 Lymphocyte counts / / 22286170 rs17668704 chr16 72257699 A T 9.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs11646048 chr16 72291732 A G 4.24E-05 Type 2 diabetes / / 17463246 rs17605951 chr16 72297642 A C 7.03E-04 Obesity (extreme) / / 21935397 rs9940976 chr16 72311826 A C 3.64E-04 Type 2 diabetes / / 17463246 rs13333771 chr16 72314620 G T 3.98E-04 Type 2 diabetes / / 17463246 rs10492819 chr16 72329956 A G 6.05E-04 Type 2 diabetes / / 17463246 rs16971039 chr16 72603988 C A 8.79E-04 Multiple complex diseases / / 17554300 rs9302640 chr16 72694760 T C 3.13E-04 Multiple complex diseases / / 17554300 rs10500569 chr16 72756101 G T 7.00E-12 Metabolite levels (atherosclerosis) / / 22916037 rs292932 chr16 72782824 A G 5.79E-04 Schizophrenia / / 21674006 rs292935 chr16 72784822 T C 9.10E-04 Multiple complex diseases / / 17554300 rs8044476 chr16 72800567 A G 7.21E-05 Prion diseases / / 22210626 rs16971312 chr16 72855844 A G 9.43E-04 Multiple complex diseases ZFHX3 intron 17554300 rs7185166 chr16 72887183 C T 8.12E-04 Type 2 diabetes ZFHX3 intron 17463246 rs9937452 chr16 72894840 C A 4.81E-04 Aortic root size ZFHX3 intron 21223598 rs9889054 chr16 72898864 C T 7.33E-06 Cognitive impairment induced by topiramate ZFHX3 intron 22091778 rs2157787 chr16 72928928 A C 5.91E-04 Parkinson's disease ZFHX3 intron 17052657 rs16971384 chr16 72931085 A G 5.00E-06 Coronary heart disease ZFHX3 intron 21347282 rs12708935 chr16 72959027 G A 1.34E-05 Amyotrophic lateral sclerosis (sporadic) ZFHX3 intron 24529757 rs12599412 chr16 72979063 T C 1.94E-04 Taste perception ZFHX3 intron 22132133 rs13336412 chr16 72981949 C A 5.02E-04 Multiple complex diseases ZFHX3 intron 17554300 rs12149946 chr16 72984340 G A 1.27E-05 Brain derived neurotrophic factor levels,in serum ZFHX3 intron 22047184 rs4788683 chr16 72997747 G T 2.19E-04 Vaspin levels ZFHX3 intron 22907691 rs4788683 chr16 72997747 G T 0.000219 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit ZFHX3 intron 22907730 rs16971447 chr16 73007970 T C 8.90E-05 Parkinson's disease (familial) ZFHX3 intron 18985386 rs7199343 chr16 73009024 A T 1.25E-05 Serum metabolites ZFHX3 intron 19043545 rs7199343 chr16 73009024 A T 2.00E-06 Kawasaki disease ZFHX3 intron 19132087 rs10852516 chr16 73009698 T C 4.65E-05 Serum metabolites ZFHX3 intron 19043545 rs11075954 chr16 73012164 T C 1.48E-05 Orofacial clefts ZFHX3 intron 22419666 rs1858800 chr16 73024276 C T 0.0000348 Tuberculosis with late age of onset ZFHX3 intron 22551897 rs2068360 chr16 73028249 C T 0.0000468 Tuberculosis with late age of onset ZFHX3 intron 22551897 rs7193343 chr16 73029160 T C 1.00E-10 Atrial fibrillation ZFHX3 intron 19597491 rs4556810 chr16 73033473 C A 0.00000749 Tuberculosis with late age of onset ZFHX3 intron 22551897 rs4556810 chr16 73033473 C A 6.27E-05 Waist Circumference ZFHX3 intron pha003025 rs8056528 chr16 73036633 T C 1.80E-04 Common variable immunodeficiency ZFHX3 intron 21497890 rs2106261 chr16 73051620 C T 2.00E-15 Atrial fibrillation ZFHX3 intron 19597492 rs2106261 chr16 73051620 C T 3.00E-16 Atrial fibrillation ZFHX3 intron 22544366 rs1548374 chr16 73059729 A G 3.03E-05 Body Mass Index ZFHX3 intron pha003007 rs1548374 chr16 73059729 A G 2.89E-05 Body Mass Index ZFHX3 intron pha003015 rs1548374 chr16 73059729 A G 7.87E-06 Waist Circumference ZFHX3 intron pha003025 rs4788692 chr16 73065656 T C 7.16E-04 Suicide attempts in bipolar disorder ZFHX3 intron 21423239 rs4788692 chr16 73065656 T C 1.02E-04 Response to taxane treatment (placlitaxel) ZFHX3 intron 23006423 rs879324 chr16 73068678 G A 1.60E-05 Urinary metabolites ZFHX3 intron 21572414 rs879324 chr16 73068678 G A 2.00E-08 Stroke (ischemic) ZFHX3 intron 23041239 rs12932445 chr16 73069888 T C 5.78E-06 Stroke ZFHX3 intron 22306652 rs9940520 chr16 73074012 G C 1.30E-05 Telomere length ZFHX3 intron 23900074 rs9926271 chr16 73125231 T C 2.73E-04 Barrett's esophagus / / 24121790 rs9926271 chr16 73125231 T C 3.56E-04 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs17693924 chr16 73136458 T C 1.45E-05 Serum metabolites / / 19043545 rs7187519 chr16 73149607 A G 1.35E-05 ldl cholesterol / / pha003077 rs13329908 chr16 73150369 A G 2.21E-07 ldl cholesterol / / pha003077 rs13329908 chr16 73150369 A G 2.75E-05 Cholesterol / / pha003083 rs7190071 chr16 73185078 T C 0.0000069 Primary sclerosing cholangitis C16orf47 intron 22521342 rs6564251 chr16 73309204 C T 8.40E-05 Diabetes Mellitus / / pha003060 rs7189557 chr16 73320309 C T 1.00E-04 Information processing speed / / 21130836 rs7195261 chr16 73325849 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6564865 chr16 73368572 G A 1.71E-04 HIV-1 viral setpoint / / 17641165 rs11866632 chr16 73373632 T G 3.30E-05 Bilirubin levels / / 19414484 rs3900250 chr16 73375322 C T 5.92E-04 HIV-1 viral setpoint / / 17641165 rs3900250 chr16 73375322 C T 3.10E-05 Bilirubin levels / / 19414484 rs4346228 chr16 73375719 A G 2.20E-05 Bilirubin levels / / 19414484 rs12923103 chr16 73378934 A G 1.40E-05 Bilirubin levels / / 19414484 rs11150483 chr16 73382150 A G 3.50E-05 Bilirubin levels / / 19414484 rs4889197 chr16 73394615 A G 9.72E-04 Coronary heart disease / / 21971053 rs5000749 chr16 73403769 T G 3.93E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7189531 chr16 73406302 G A 1.32E-04 Multiple complex diseases / / 17554300 rs7186409 chr16 73410254 T C 3.46E-04 Taste perception / / 22132133 rs7203059 chr16 73418430 A G 9.21E-04 Multiple complex diseases / / 17554300 rs1477403 chr16 73423202 G A 6.18E-05 Periodontitis (Chronic) LOC100506172 intron 25008200 rs9934948 chr16 73439355 C T 6.00E-06 Breast cancer (survival) LOC100506172 intron 22232737 rs34046694 chr16 73440152 G A 9.25E-04 Multiple complex diseases LOC100506172 intron 17554300 rs1055164 chr16 73454872 T G 2.00E-06 Urinary metabolites / / 21572414 rs1055165 chr16 73455018 G A 2.70E-05 Urinary metabolites / / 21572414 rs1423727 chr16 73467733 C T 7.28E-04 Myopia (pathological) / / 21095009 rs12446956 chr16 73501536 T C 1.00E-06 Major depressive disorder / / 21042317 rs12446956 chr16 73501536 T C 1.10E-06 Depression (quantitative trait) / / 23290196 rs825842 chr16 73525237 G A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs825842 chr16 73525237 G A 7.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs825840 chr16 73525427 C G 1.20E-05 Urinary metabolites / / 21572414 rs825851 chr16 73536221 G T 3.75E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11648088 chr16 73539381 A G 1.77E-05 Neuroblastoma / / pha002895 rs825836 chr16 73542760 G A 4.93E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2432544 chr16 73552643 C T 5.05E-05 Soluble levels of adhesion molecules / / pha003072 rs8058620 chr16 73552951 G C 4.01E-04 Type 2 diabetes / / 17463246 rs825857 chr16 73557062 A C 7.42E-05 Soluble levels of adhesion molecules / / pha003072 rs4888447 chr16 73560998 T C 5.17E-04 Alzheimer's disease / / 17998437 rs2459557 chr16 73567549 C A 6.06E-04 Multiple complex diseases / / 17554300 rs7191888 chr16 73581058 A G 6.00E-06 Multiple sclerosis (severity) / / 19010793 rs8054782 chr16 73637631 A G 4.10E-06 Urinary metabolites / / 21572414 rs4887870 chr16 73650853 A G 1.26E-04 Stroke / / pha002887 rs4888588 chr16 73696079 C T 6.80E-06 Word reading / / 23738518 rs3956052 chr16 73698112 C A 4.66E-06 Word reading / / 23738518 rs8056327 chr16 73702024 G C 5.94E-04 Multiple complex diseases / / 17554300 rs8056327 chr16 73702024 G C 4.66E-06 Word reading / / 23738518 rs1480566 chr16 73704271 A C 2.96E-04 Multiple complex diseases / / 17554300 rs1480566 chr16 73704271 A C 4.66E-06 Word reading / / 23738518 rs17377346 chr16 73704462 A C 3.18E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs8048857 chr16 73705051 C T 3.97E-06 Word reading / / 23738518 rs4243136 chr16 73705780 T C 2.06E-06 Word reading / / 23738518 rs4243137 chr16 73705912 A T 2.06E-06 Word reading / / 23738518 rs990258 chr16 73708098 A G 1.05E-06 Word reading / / 23738518 rs716271 chr16 73708524 A G 7.81E-04 Multiple complex diseases / / 17554300 rs716271 chr16 73708524 A G 8.83E-07 Word reading / / 23738518 rs716270 chr16 73708889 G A 8.83E-07 Word reading / / 23738518 rs8059199 chr16 73712234 C A 2.16E-07 Word reading / / 23738518 rs764255 chr16 73713683 C T 2.00E-07 Word reading / / 23738518 rs8054209 chr16 73731111 A C 6.56E-05 Lipoproteins / / pha003079 rs2127740 chr16 73732309 G A 5.20E-05 Age-related macular degeneration / / 20385819 rs16972369 chr16 73752982 A G 2.70E-05 Bone mineral density (BMD),in women / / 20164292 rs7206578 chr16 73753033 T C 4.53E-04 Multiple complex diseases / / 17554300 rs7206578 chr16 73753033 T C 5.00E-06 Urinary metabolites / / 21572414 rs7192200 chr16 73753179 C G 7.39E-04 Multiple complex diseases / / 17554300 rs7192200 chr16 73753179 C G 5.00E-06 Urinary metabolites / / 21572414 rs7205922 chr16 73753290 A T 7.35E-04 Multiple complex diseases / / 17554300 rs7205922 chr16 73753290 A T 5.10E-06 Urinary metabolites / / 21572414 rs12443917 chr16 73758522 T C 9.74E-04 White matter integrity / / 22425255 rs179184 chr16 73769676 A C 2.81E-04 Multiple complex diseases / / 17554300 rs9933173 chr16 73774855 T C 5.17E-04 Type 2 diabetes / / 17463246 rs454357 chr16 73776418 A G 5.92E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs328338 chr16 73785861 C T 6.78E-05 Major depressive disorder / / 19107115 rs1388900 chr16 73800629 C T 5.65E-05 Telomere length / / 21573004 rs16972539 chr16 73804701 C T 1.56E-05 Major depression (suicidal thoughts and behavior) / / 21750702 rs1849240 chr16 73811879 T C 6.30E-05 Colorectal cancer / / 24448986 rs744350 chr16 73816322 T C 5.69E-05 Blood Pressure / / pha003047 rs427576 chr16 73829270 A C 8.32E-05 Age-related macular degeneration / / 22125219 rs427576 chr16 73829270 A C 4.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs379401 chr16 73830364 C G 5.56E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs417278 chr16 73830476 T C 5.30E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs565955 chr16 73831516 C T 4.37E-04 Age-related macular degeneration / / 22125219 rs328345 chr16 73851342 T C 7.38E-04 Taste perception / / 22132133 rs753808 chr16 73855723 C T 1.78E-04 Taste perception / / 22132133 rs328310 chr16 73889299 A G 3.88E-04 Multiple complex diseases / / 17554300 rs2892190 chr16 73899352 T C 1.17E-04 Multiple complex diseases / / 17554300 rs9922664 chr16 73909507 G A 8.66E-04 Multiple complex diseases / / 17554300 rs17391167 chr16 73914812 T C 3.96E-04 Multiple complex diseases / / 17554300 rs17332447 chr16 73932916 A G 2.40E-06 Urinary metabolites / / 21572414 rs10500580 chr16 73950557 C G 2.10E-07 Urinary metabolites / / 21572414 rs12596410 chr16 73964938 G C 2.10E-05 Urinary metabolites / / 21572414 rs4402595 chr16 73976130 A G 1.80E-05 Urinary metabolites / / 21572414 rs2663145 chr16 74005024 C T 2.30E-05 Urinary metabolites / / 21572414 rs9932434 chr16 74010302 C T 6.06E-05 Hypertension / / pha003041 rs2526057 chr16 74058446 C A 8.34E-04 Alzheimer's disease / / 22005930 rs11642698 chr16 74073632 T C 0.0002 Migraine / / 22678113 rs2716601 chr16 74076252 A G 1.00E-06 Treatment response for severe sepsis / / 22310353 rs766410 chr16 74088473 A G 6.50E-05 Longevity / / 20304771 rs2716605 chr16 74098007 T G 6.08E-04 Stroke / / pha002886 rs12149894 chr16 74107201 A G 8.99E-05 Multiple complex diseases / / 17554300 rs7205584 chr16 74107877 G C 1.15E-04 Multiple complex diseases / / 17554300 rs9673539 chr16 74301477 G A 2.85E-05 Psoriasis / / 20953187 rs1195631 chr16 74341902 A C 6.80E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LOC100506201 intron 20031582 rs4888213 chr16 74360929 G A 8.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10871290 chr16 74472696 C T 9.79E-04 Type 2 diabetes / / 17463246 rs10871290 chr16 74472696 C T 0.000015 Breast cancer early age of onset / / 18463975 rs6564117 chr16 74501856 C G 9.01E-04 Type 2 diabetes GLG1 intron 17463246 rs8059315 chr16 74506447 G C 0.0000416 Breast cancer early age of onset GLG1 intron 18463975 rs8059869 chr16 74506765 G C 7.87E-04 Type 2 diabetes GLG1 intron 17463246 rs9938426 chr16 74523739 G C 0.0000334 Breast cancer early age of onset GLG1 intron 18463975 rs7189123 chr16 74540097 C A 7.74E-04 Tourette syndrome GLG1 intron 22889924 rs13380609 chr16 74553501 T A 3.00E-04 Type 2 diabetes GLG1 intron 17463246 rs8053084 chr16 74620007 C T 1.16E-04 Type 2 diabetes GLG1 intron 17463246 rs8058034 chr16 74627711 C T 3.65E-04 Type 2 diabetes GLG1 intron 17463246 rs4887778 chr16 74638159 T C 8.74E-04 Type 2 diabetes GLG1 intron 17463246 rs4887779 chr16 74647795 C T 3.13E-04 Type 2 diabetes / / 17463246 rs11149759 chr16 74662597 C T 2.81E-04 Suicide attempts in bipolar disorder RFWD3 intron 21423239 rs4888262 chr16 74670458 C T 5.00E-12 Testicular germ cell tumor RFWD3 cds-synon 23666239 rs9938833 chr16 74672201 G A 3.39E-04 Type 2 diabetes RFWD3 intron 17463246 rs8047350 chr16 74679244 C A 6.12E-04 Type 2 diabetes RFWD3 intron 17463246 rs8058922 chr16 74695079 G T 2.72E-04 Type 2 diabetes RFWD3 missense 17463246 rs4448975 chr16 74702254 G A 3.60E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4395097 chr16 74702430 C T 4.38E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9929483 chr16 74707037 A G 9.20E-05 Type 2 diabetes MLKL intron 17463246 rs6564159 chr16 74713054 A G 8.22E-04 Type 2 diabetes MLKL intron 17463246 rs4887784 chr16 74713331 C G 9.28E-04 Type 2 diabetes MLKL intron 17463246 rs2240245 chr16 74758984 A G 8.43E-05 Psoriasis FA2H intron 20953190 rs2240245 chr16 74758984 A G 4.34E-06 Post-operative nausea and vomiting FA2H intron 21694509 rs2240252 chr16 74770705 T G 2.23E-04 Multiple complex diseases FA2H intron 17554300 rs11863417 chr16 74784319 T A 1.95E-05 Femoral neck bone geometry FA2H intron 22087292 rs8048578 chr16 74796334 A T 1.05E-04 Type 2 diabetes FA2H intron 17463246 rs241371 chr16 74820071 C A 4.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs8045562 chr16 74843903 A T 5.42E-05 Serum metabolites / / 19043545 rs8054840 chr16 74850912 C A 7.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs6564173 chr16 74861095 A G 5.41E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs11648451 chr16 74868518 A C 3.50E-05 Serum metabolites / / 19043545 rs11648451 chr16 74868518 A C 1.00E-05 Urinary metabolites / / 21572414 rs725710 chr16 74873513 C A 3.30E-05 Schizophrenia / / 19197363 rs725709 chr16 74873574 G A 5.76E-04 Stroke / / pha002887 rs7190905 chr16 74873927 T C 8.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs16948255 chr16 74881820 C T 1.00E-06 HIV-1 control / / 20041166 rs6564177 chr16 74884070 C T 5.28E-05 Serum metabolites / / 19043545 rs2869846 chr16 74884658 A G 5.28E-05 Serum metabolites / / 19043545 rs10514389 chr16 74934279 T C 9.87E-04 Type 2 diabetes WDR59 intron 17463246 rs7342703 chr16 74935232 T C 4.67E-04 Lymphocyte counts WDR59 intron 22286170 rs16950325 chr16 74953140 T C 5.20E-04 Multiple complex diseases WDR59 intron 17554300 rs2042415 chr16 74978618 G A 3.00E-06 Obesity-related traits WDR59 intron 23251661 rs2042415 chr16 74978618 G A 5.00E-06 Obesity-related traits WDR59 intron 23251661 rs2042415 chr16 74978618 G A 8.00E-06 Obesity-related traits WDR59 intron 23251661 rs2042415 chr16 74978618 G A 8.00E-06 Obesity-related traits WDR59 intron 23251661 rs9646309 chr16 75012457 G A 2.60E-05 Urinary metabolites WDR59 intron 21572414 rs17604707 chr16 75019777 A G 2.37E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs17684886 chr16 75086875 A T 6.80E-06 Diabetic retinopathy ZNRF1 intron 21441570 rs6564199 chr16 75090134 A T 8.42E-04 Suicide attempts in bipolar disorder ZNRF1 intron 21423239 rs16953919 chr16 75091897 G T 9.02E-04 Suicide attempts in bipolar disorder ZNRF1 intron 21423239 rs9936747 chr16 75102952 T C 3.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZNRF1 intron 20877124 rs9936747 chr16 75102952 T C 1.80E-05 Diabetic retinopathy ZNRF1 intron 21441570 rs8049357 chr16 75106409 C G 8.54E-04 Suicide attempts in bipolar disorder ZNRF1 intron 21423239 rs13337868 chr16 75107716 G C 2.00E-05 Diabetic retinopathy ZNRF1 intron 21441570 rs11641489 chr16 75108287 G A 9.48E-04 Suicide attempts in bipolar disorder ZNRF1 intron 21423239 rs4447456 chr16 75123994 G T 9.22E-05 Cognitive impairment induced by topiramate ZNRF1 intron 22091778 rs62059203 chr16 75132865 G C 1.31E-04 Cocaine dependence ZNRF1 intron 23958962 rs62059203 chr16 75132865 G C 4.92E-04 Cocaine dependence ZNRF1 intron 23958962 rs989925 chr16 75141060 A G 3.98E-04 Suicide attempts in bipolar disorder ZNRF1 intron 21423239 rs1043509 chr16 75144408 A T 1.35E-04 Prostate cancer mortality ZNRF1 UTR-3 20978177 rs1833980 chr16 75160366 A G 2.28E-05 Serum metabolites / / 19043545 rs7195303 chr16 75167579 G A 9.00E-06 Crohn's disease (time to surgery) / / 23665963 rs9927029 chr16 75172340 A G 5.22E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs1579332 chr16 75172457 C G 2.30E-05 Urinary metabolites / / 21572414 rs4479268 chr16 75224733 A C 6.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6564221 chr16 75224971 C T 3.40E-04 Alzheimer's disease (late onset) / / 21379329 rs1019537 chr16 75230638 T C 6.56E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1019539 chr16 75230739 T C 6.56E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10514392 chr16 75232286 G A 7.40E-05 Cognitive impairment induced by topiramate / / 22091778 rs7202877 chr16 75247245 T G 3.00E-15 Type 1 diabetes / / 19430480 rs7202877 chr16 75247245 T G 3.10E-15 Multiple sclerosis / / 22190364 rs7202877 chr16 75247245 T G 0.00000007 Type 2 diabetes (males) / / 22885922 rs7202877 chr16 75247245 T G 2.00E-70 Type 2 diabetes / / 22885922 rs7202877 chr16 75247245 T G 0.00000088 GLP-1-stimulated insulin secretion during hyperglycemic clamps / / 23674605 rs7202877 chr16 75247245 T G 5.70E-04 Type 2 diabetes / / 24509480 rs7202877 chr16 75247245 T G 3.59E-05 Pancreatic cancer / / pha002889 rs8056814 chr16 75252327 G A 4.16E-05 Age-related macular degeneration / / 21197116 rs8056814 chr16 75252327 G A 1.13E-07 Type 1 diabetes / / 21980299 rs8056814 chr16 75252327 G A 4.82E-06 Age-related macular degeneration / / pha000001 rs8056814 chr16 75252327 G A 2.82E-05 Age-related macular degeneration / / pha002856 rs8048956 chr16 75254966 G C 9.78E-04 Response to taxane treatment (placlitaxel) CTRB1 intron 23006423 rs11864719 chr16 75255129 G T 4.95E-04 Alzheimer's disease CTRB1 intron 24755620 rs13331385 chr16 75259218 T A 6.10E-74 Type 2 diabetes / / 22885922 rs16957552 chr16 75269124 T C 1.38E-08 LDL cholesterol BCAR1 missense 23063622 rs16957552 chr16 75269124 T C 1.95E-08 Cholesterol,total BCAR1 missense 23063622 rs16957552 chr16 75269124 T C 5.13E-09 Triglycerides BCAR1 missense 23063622 rs36097424 chr16 75275231 G A 1.64E-04 Alzheimer's disease (late onset) BCAR1 intron 21379329 rs1035540 chr16 75278795 A G 0.00000062 Amygdala reactivity BCAR1 intron 22856363 rs1862737 chr16 75281964 A C 7.50E-05 Cognitive performance BCAR1 UTR-5 19734545 rs4888367 chr16 75292120 G A 2.40E-05 Alzheimer's disease (late onset) BCAR1 intron 21379329 rs4261573 chr16 75294211 T C 1.77E-04 Multiple complex diseases BCAR1 intron 17554300 rs13337397 chr16 75295639 C A 6.65E-06 Pancreatic cancer BCAR1 intron pha002889 rs8052310 chr16 75296247 G A 4.48E-04 Alzheimer's disease (late onset) BCAR1 intron 21379329 rs1001861 chr16 75306455 G A 0.00000716 Carotid intima media thickness / / 23152477 rs6564245 chr16 75308899 C T 9.50E-04 Multiple complex diseases / / 17554300 rs6564245 chr16 75308899 C T 5.26E-06 Type 1 diabetes / / 18978792 rs4888378 chr16 75332041 A G 0.000000675 Carotid intima media thickness CFDP1 intron 23152477 rs4888378 chr16 75332041 A G 0.00000653 Coronary artery disease CFDP1 intron 23152477 rs4888378 chr16 75332041 A G 0.0000291 Myocardial infarction CFDP1 intron 23152477 rs10871308 chr16 75342846 C T 7.65E-04 Multiple complex diseases CFDP1 intron 17554300 rs4536500 chr16 75343197 G C 2.61E-04 Multiple complex diseases CFDP1 intron 17554300 rs4536500 chr16 75343197 G C 1.84E-05 Type 1 diabetes CFDP1 intron 18978792 rs2865531 chr16 75390316 T A 2.00E-11 Pulmonary function CFDP1 intron 21946350 rs2865531 chr16 75390316 T A 2.00E-08 Pulmonary function (interaction) CFDP1 intron 23284291 rs9934007 chr16 75390532 T C 9.40E-04 Multiple complex diseases CFDP1 intron 17554300 rs9934007 chr16 75390532 T C 3.31E-05 Type 1 diabetes CFDP1 intron 18978792 rs4993971 chr16 75411634 G C 4.10E-04 Multiple complex diseases CFDP1 intron 17554300 rs4993971 chr16 75411634 G C 1.79E-05 Type 1 diabetes CFDP1 intron 18978792 rs766522 chr16 75424110 T C 1.90E-06 Aortic stiffness CFDP1 intron 22068335 rs247438 chr16 75432649 G C 7.28E-04 Multiple complex diseases CFDP1 intron 17554300 rs247438 chr16 75432649 G C 6.54E-06 Type 1 diabetes CFDP1 intron 18978792 rs4888416 chr16 75449176 C G 9.30E-07 Aortic stiffness CFDP1 intron 22068335 rs8046416 chr16 75487758 T C 4.98E-05 Type 1 diabetes TMEM170A intron 18978792 rs2550893 chr16 75539436 C T 1.36E-04 Smoking initiation / / 24665060 rs7197382 chr16 75549885 A C 6.37E-05 Aging (time to event) / / 21782286 rs2242406 chr16 75574030 C T 0.0000946 Ankle-brachial index TMEM231 cds-synon 22361517 rs12595883 chr16 75583499 T C 5.07E-04 Alzheimer's disease TMEM231 intron 24755620 rs11149841 chr16 75602797 G T 1.93E-04 Multiple complex diseases GABARAPL2 intron 17554300 rs11149841 chr16 75602797 G T 3.15E-07 Lymphocyte counts GABARAPL2 intron 22286170 rs12598094 chr16 75608586 A G 5.97E-04 Alzheimer's disease GABARAPL2 intron 24755620 rs3743599 chr16 75646576 G T 5.60E-04 Alzheimer's disease ADAT1 missense 24755620 rs11149843 chr16 75649275 A C 2.50E-05 Urinary metabolites ADAT1 intron 21572414 rs11648478 chr16 75654031 A T 1.69E-04 Multiple complex diseases ADAT1 intron 17554300 rs16940961 chr16 75654926 C T 4.49E-04 Multiple complex diseases ADAT1 intron 17554300 rs963820 chr16 75659849 T G 3.00E-06 Urinary metabolites / / 21572414 rs3784929 chr16 75677027 A G 4.20E-04 Alzheimer's disease KARS intron 24755620 rs17697324 chr16 75728368 A G 7.37E-04 Type 2 diabetes / / 17463246 rs4887835 chr16 75731047 C G 8.04E-04 Type 2 diabetes / / 17463246 rs16943189 chr16 75787129 G C,T 4.33E-04 Multiple complex diseases / / 17554300 rs12597128 chr16 75871898 G T 5.72E-04 Type 2 diabetes / / 17463246 rs4887840 chr16 75882059 A G 2.26E-06 Magnesium levels / / pha003092 rs16943694 chr16 75966770 T G 6.83E-04 Alcohol dependence / / 20201924 rs1948632 chr16 75991446 G A 8.00E-06 Tuberculosis / / 20694014 rs7196289 chr16 75994499 A G 9.17E-06 Tuberculosis / / 20694014 rs17676550 chr16 76009781 A C 4.20E-04 Blood pressure / / 17255346 rs17676550 chr16 76009781 A C 7.34E-04 Multiple complex diseases / / 17554300 rs904264 chr16 76011887 C T 1.14E-05 Tuberculosis / / 20694014 rs904263 chr16 76012189 A G 5.43E-05 Tuberculosis / / 20694014 rs1353690 chr16 76018855 A C 1.83E-05 Tuberculosis / / 20694014 rs7191424 chr16 76019450 T G 1.14E-05 Tuberculosis / / 20694014 rs7184868 chr16 76019587 G C 1.14E-05 Tuberculosis / / 20694014 rs16943756 chr16 76028137 C G 9.26E-06 Type 2 diabetes / / 17463246 rs35763384 chr16 76028673 G A 1.52E-04 Type 2 diabetes / / 17463246 rs16943759 chr16 76028759 C G 8.73E-06 Type 2 diabetes / / 17463246 rs16943764 chr16 76028864 C T 1.14E-05 Type 2 diabetes / / 17463246 rs11647358 chr16 76029172 T C 1.80E-05 Type 2 diabetes / / 17463246 rs7199697 chr16 76043201 A G 9.59E-06 Preeclampsia / / 23551011 rs160960 chr16 76079617 C A 8.26E-06 Serum metabolites / / 19043545 rs160952 chr16 76084543 G A 2.05E-05 Serum metabolites / / 19043545 rs2432614 chr16 76096084 T C 8.61E-05 Serum metabolites / / 19043545 rs2432614 chr16 76096084 T C 2.60E-05 Urinary metabolites / / 21572414 rs432885 chr16 76099459 T C 1.40E-05 Urinary metabolites / / 21572414 rs419958 chr16 76105172 T G 7.90E-08 Urinary metabolites / / 21572414 rs6564307 chr16 76111734 C T 9.70E-04 Multiple complex diseases / / 17554300 rs977045 chr16 76116063 C A 2.98E-05 Cognitive impairment induced by topiramate / / 22091778 rs1423858 chr16 76130755 C T 4.80E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2432608 chr16 76140126 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs16943879 chr16 76156421 C A 6.67E-04 Multiple complex diseases / / 17554300 rs724246 chr16 76169443 C A 5.94E-04 Multiple complex diseases / / 17554300 rs2288060 chr16 76169867 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs257827 chr16 76203282 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs257827 chr16 76203282 A G 5.85E-05 Cognitive impairment induced by topiramate / / 22091778 rs194453 chr16 76213497 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2068766 chr16 76214774 C A 3.33E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs16943958 chr16 76215159 C T 8.05E-04 Alzheimer's disease / / 17998437 rs41503154 chr16 76227484 G T 8.09E-06 Alzheimer's disease / / 17998437 rs2194295 chr16 76241475 C A,G,T 1.00E-04 Prostate cancer / / 21743057 rs2866619 chr16 76252142 G A 2.38E-05 Alcohol and nictotine co-dependence / / 20158304 rs41531747 chr16 76261161 G T 3.08E-05 Alzheimer's disease / / 17998437 rs16944012 chr16 76261207 G A 2.63E-05 Alzheimer's disease / / 17998437 rs16944012 chr16 76261207 G A 1.30E-05 Serum metabolites / / 19043545 rs9940792 chr16 76290087 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7193230 chr16 76318542 G C 5.00E-06 Response to amphetamines CNT/P4 intron 22952603 rs9923061 chr16 76324361 G A 2.80E-04 Alzheimer's disease CNT/P4 intron 17998437 rs929853 chr16 76334673 G A 5.80E-04 Alcohol dependence CNT/P4 intron 21314694 rs1428759 chr16 76336609 G A 0.0000153 Central corneal thickness in patients with an IOP <= 21mmHg and no history of IOP>= 21mmHg CNT/P4 intron 22661486 rs1428759 chr16 76336609 G A 1.53E-05 Testosterone levels CNT/P4 intron 22675492 rs9939043 chr16 76340905 G A 0.0000027 Central corneal thickness in patients with an IOP <= 21mmHg and no history of IOP>= 21mmHg CNT/P4 intron 22661486 rs9939043 chr16 76340905 G A 2.70E-06 Testosterone levels CNT/P4 intron 22675492 rs1428758 chr16 76341506 A G 0.0000174 Central corneal thickness in patients with an IOP <= 21mmHg and no history of IOP>= 21mmHg CNT/P4 intron 22661486 rs1428758 chr16 76341506 A G 1.74E-05 Testosterone levels CNT/P4 intron 22675492 rs2052866 chr16 76348997 C T 0.0000327 Central corneal thickness in patients with an IOP <= 21mmHg and no history of IOP>= 21mmHg CNT/P4 intron 22661486 rs2866710 chr16 76350805 A G 0.0000117 Central corneal thickness in patients with an IOP <= 21mmHg and no history of IOP>= 21mmHg CNT/P4 intron 22661486 rs2866710 chr16 76350805 A G 1.17E-05 Testosterone levels CNT/P4 intron 22675492 rs4888492 chr16 76354827 A C 1.71E-05 Personality dimensions CNT/P4 intron 22628180 rs6564323 chr16 76362013 C T 4.23E-04 Lung function (forced vital capacity) CNT/P4 intron 24023788 rs8053796 chr16 76364177 T C 1.70E-05 Age-related macular degeneration CNT/P4 intron 21665990 rs8058722 chr16 76365831 G A 0.00071 Salmonella-induced pyroptosis CNT/P4 intron 22837397 rs12325022 chr16 76372629 G A 4.43E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CNT/P4 intron 20031582 rs13339408 chr16 76374438 A G 1.71E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CNT/P4 intron 20031582 rs9319495 chr16 76375008 C G 5.10E-04 Type 2 diabetes and 6 quantitative traits CNT/P4 intron 17848626 rs17698989 chr16 76380991 G A 5.26E-04 Suicide attempts in bipolar disorder CNT/P4 intron 21041247 rs1346557 chr16 76383537 G A 5.71E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CNT/P4 intron 20031582 rs2016901 chr16 76387435 T C 2.82E-05 Personality dimensions CNT/P4 intron 22628180 rs17766740 chr16 76389134 G T 8.51E-05 Response to statin treatment (atorvastatin),change in cholesterol levels CNT/P4 intron 20031582 rs17766740 chr16 76389134 G T 8.61E-04 Response to taxane treatment (placlitaxel) CNT/P4 intron 23006423 rs2866714 chr16 76390571 T C 0.000717 Salmonella-induced pyroptosis CNT/P4 intron 22837397 rs4595825 chr16 76391243 T C 0.000518 Salmonella-induced pyroptosis CNT/P4 intron 22837397 rs4528602 chr16 76391292 A G 3.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) CNT/P4 intron 17982456 rs17699214 chr16 76393741 T C 4.34E-04 Response to taxane treatment (placlitaxel) CNT/P4 intron 23006423 rs1428753 chr16 76404057 G A 8.05E-04 Multiple complex diseases CNT/P4 intron 17554300 rs7193350 chr16 76404556 C T 8.28E-04 Response to taxane treatment (placlitaxel) CNT/P4 intron 23006423 rs17766945 chr16 76409032 G A 8.74E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CNT/P4 intron 20031582 rs6564329 chr16 76438646 G T 8.86E-06 Height CNT/P4 intron 20400458 rs6564329 chr16 76438646 G T 8.90E-06 Obesity,menopause CNT/P4 intron 21424828 rs12925884 chr16 76439799 C T 3.37E-05 Post-operative nausea and vomiting CNT/P4 intron 21694509 rs4427835 chr16 76465146 G T 1.60E-05 Urinary metabolites CNT/P4 intron 21572414 rs4433831 chr16 76466570 G A 8.17E-04 Multiple complex diseases CNT/P4 intron 17554300 rs4888508 chr16 76472683 C T 1.20E-05 Urinary metabolites CNT/P4 intron 21572414 rs4888508 chr16 76472683 C T 6.06E-05 Cognitive impairment induced by topiramate CNT/P4 intron 22091778 rs9888934 chr16 76474707 G A 3.65E-04 Insulin resistance CNT/P4 intron 21901158 rs7186058 chr16 76476160 A G 9.39E-04 Alzheimer's disease CNT/P4 intron 22005930 rs7186058 chr16 76476160 A G 1.00E-04 Cognitive impairment induced by topiramate CNT/P4 intron 22091778 rs13331860 chr16 76476469 A G 7.67E-04 Alzheimer's disease CNT/P4 intron 22005930 rs4887863 chr16 76476856 T C 7.68E-04 Alzheimer's disease CNT/P4 intron 22005930 rs17699551 chr16 76477747 A T 6.49E-04 Alzheimer's disease CNT/P4 intron 22005930 rs6564343 chr16 76501304 G C 3.84E-04 Multiple complex diseases CNT/P4 missense 17554300 rs4888517 chr16 76526428 A G 2.88E-04 Lung function (forced expiratory volume in 1 second) CNT/P4 intron 24023788 rs4533311 chr16 76530137 T C 1.80E-04 Lung function (forced expiratory volume in 1 second) CNT/P4 intron 24023788 rs4393596 chr16 76565917 C T 9.55E-05 Multiple complex diseases CNT/P4 intron 17554300 rs4485401 chr16 76566157 A G 4.69E-05 Serum metabolites CNT/P4 intron 19043545 rs4485401 chr16 76566157 A G 2.00E-08 Sphingolipid levels CNT/P4 intron 22359512 rs4359472 chr16 76573095 G C 6.37E-04 Parkinson's disease CNT/P4 intron 17052657 rs12449188 chr16 76621240 A G 6.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4888525 chr16 76621805 A T 7.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs8062497 chr16 76624463 A G 3.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8050735 chr16 76710087 T C 5.06E-05 Type 2 diabetes / / 17463246 rs8047051 chr16 76722500 G A 5.20E-05 Type 2 diabetes / / 17463246 rs8050006 chr16 76723053 A C 4.98E-05 Type 2 diabetes / / 17463246 rs8057477 chr16 76750120 T C 3.85E-05 Type 2 diabetes / / 17463246 rs4888535 chr16 76761656 T A 5.91E-05 Type 2 diabetes / / 17463246 rs4337315 chr16 76774918 G T 2.54E-05 Type 2 diabetes / / 17463246 rs4888543 chr16 76798472 A C 7.88E-06 Type 2 diabetes / / 17463246 rs3924497 chr16 76818163 C T 1.01E-04 Type 2 diabetes / / 17463246 rs8049365 chr16 76819318 C T 1.50E-05 Type 2 diabetes / / 17463246 rs113716969 chr16 76846266 T C 2.00E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs147886789 chr16 76852538 G A 8.19E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs8054642 chr16 76866601 G A 3.56E-04 Multiple complex diseases / / 17554300 rs13330107 chr16 76878862 G A 9.00E-06 Inattentive symptoms / / 18821565 rs17679567 chr16 76890126 T C 9.00E-06 Response to TNF-alpha inhibitors in rheumatoid arthritis / / 22569225 rs4513114 chr16 76900428 A G 1.90E-05 Response to statin therapy / / 20339536 rs41437646 chr16 76925161 C G 7.03E-04 Multiple complex diseases / / 17554300 rs41486948 chr16 76925258 A G 1.51E-04 Multiple complex diseases / / 17554300 rs1496961 chr16 76935150 T G 5.48E-04 Multiple complex diseases / / 17554300 rs1496961 chr16 76935150 T G 3.50E-05 Creutzfeldt-Jakob disease (variant) / / 22137330 rs1580765 chr16 76949414 G A 7.53E-04 Multiple complex diseases / / 17554300 rs1580765 chr16 76949414 G A 2.36E-05 Creutzfeldt-Jakob disease (variant) / / 22137330 rs1390895 chr16 76951700 C G 8.70E-04 Type 2 diabetes / / 17846124 rs1874536 chr16 76954287 G A 9.69E-04 Multiple complex diseases / / 17554300 rs1874536 chr16 76954287 G A 2.61E-05 Creutzfeldt-Jakob disease (variant) / / 22137330 rs4519342 chr16 76955287 A T 3.39E-05 Creutzfeldt-Jakob disease (variant) / / 22137330 rs3736338 chr16 76961847 G A 6.88E-05 Blood Pressure / / pha002898 rs1982955 chr16 76969598 T C 4.00E-07 Immune response to measles-mumps-rubella vaccine / / 24811271 rs9938941 chr16 76972558 G A,C,T 9.00E-05 HIV-1 control / / 20041166 rs12598288 chr16 76978695 A G 5.55E-05 Creutzfeldt-Jakob disease (variant) / / 22137330 rs1604532 chr16 77011245 A T 8.71E-04 Multiple complex diseases / / 17554300 rs283984 chr16 77013046 C T 1.52E-04 Multiple complex diseases / / 17554300 rs10431977 chr16 77016280 C T 4.49E-05 Elbow pain / / pha003008 rs16945072 chr16 77031378 T C 1.36E-05 Multiple complex diseases / / 17554300 rs7184877 chr16 77031505 A G 4.78E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs9319501 chr16 77043337 T A 6.81E-04 Type 2 diabetes / / 17463246 rs10514407 chr16 77043478 C T 5.94E-05 Diabetes Mellitus / / pha003060 rs7206200 chr16 77047416 G A 3.28E-04 Type 2 diabetes / / 17463246 rs2220233 chr16 77050294 T C 8.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs1875582 chr16 77063147 C T 7.06E-04 Multiple complex diseases / / 17554300 rs284939 chr16 77111576 G A 8.29E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs284939 chr16 77111576 G A 1.12E-05 Nasopharyngeal carcinoma / / 23209447 rs284939 chr16 77111576 G A 1.12E-05 Schizophrenia / / 23212062 rs285001 chr16 77112564 T G 2.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs285001 chr16 77112564 T G 1.11E-05 Nasopharyngeal carcinoma / / 23209447 rs285001 chr16 77112564 T G 1.11E-05 Schizophrenia / / 23212062 rs9929566 chr16 77125102 T C 3.00E-05 Coronary heart disease / / pha003056 rs284989 chr16 77132938 G A 3.51E-04 Smoking initiation / / 24665060 rs4243134 chr16 77177128 C T 2.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4555168 chr16 77177737 C A 1.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6564396 chr16 77190073 C A 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11640619 chr16 77233168 G A 8.86E-04 Alcohol dependence MON1B UTR-3 21314694 rs2278044 chr16 77254863 C G 4.99E-04 Coronary heart disease / / 21606135 rs17769245 chr16 77263717 A G 1.27E-07 Rheumatoid arthritis / / 21452313 rs7198006 chr16 77269832 C A 7.29E-05 Alzheimer's disease / / 22832961 rs7198588 chr16 77270144 C A 4.78E-05 Alzheimer's disease / / 22832961 rs4411511 chr16 77309963 G A 9.55E-06 Leprosy / / 22019778 rs7201773 chr16 77310808 A G 7.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs4888616 chr16 77313765 G T 9.23E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17712826 chr16 77313881 C T 9.61E-05 White matter integrity / / 22425255 rs889706 chr16 77317591 T C 4.23E-06 White matter integrity ADAMTS18 UTR-3 22425255 rs12934894 chr16 77319899 A G 8.33E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ADAMTS18 intron 23648065 rs12921392 chr16 77320605 A G 4.86E-05 White matter integrity ADAMTS18 intron 22425255 rs17712956 chr16 77322254 A G 3.14E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ADAMTS18 intron 23648065 rs16945464 chr16 77326724 C T 1.72E-04 White matter integrity ADAMTS18 intron 22425255 rs551979191 chr16 77326724 C CT 1.72E-04 White matter integrity ADAMTS18 intron 22425255 rs12935229 chr16 77328895 C T 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ADAMTS18 cds-synon 23648065 rs12935394 chr16 77328990 C A 4.40E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ADAMTS18 missense 23648065 rs7192208 chr16 77329641 T G 2.73E-04 Alzheimer's disease (late onset) ADAMTS18 intron 21379329 rs7192208 chr16 77329641 T G 2.00E-06 White matter integrity ADAMTS18 intron 22425255 rs8053462 chr16 77340081 C T 7.87E-04 Multiple complex diseases ADAMTS18 intron 17554300 rs274537 chr16 77344970 A G 7.67E-04 Multiple complex diseases ADAMTS18 intron 17554300 rs274520 chr16 77355291 A G 1.90E-04 Multiple complex diseases ADAMTS18 intron 17554300 rs11643269 chr16 77377567 G A 4.10E-04 Alcohol dependence ADAMTS18 intron 20201924 rs8058333 chr16 77389762 C T 6.38E-04 White matter integrity ADAMTS18 intron 22425255 rs2650907 chr16 77393207 G C 5.00E-04 Sudden cardiac arrest ADAMTS18 intron 21738491 rs8044972 chr16 77400082 C T 2.90E-05 Bone mineral density ADAMTS18 intron 19249006 rs8044972 chr16 77400082 C T 6.67E-04 White matter integrity ADAMTS18 intron 22425255 rs7205945 chr16 77406731 G A 9.88E-04 White matter integrity ADAMTS18 intron 22425255 rs17620748 chr16 77421336 G C 2.30E-06 Urinary metabolites ADAMTS18 intron 21572414 rs11864477 chr16 77427769 T C 2.00E-08 Bone mineral density ADAMTS18 intron 19249006 rs11149983 chr16 77429605 C T 6.90E-06 Urinary metabolites ADAMTS18 intron 21572414 rs12596244 chr16 77429804 A G 6.68E-04 Type 2 diabetes ADAMTS18 intron 17463246 rs12596244 chr16 77429804 A G 5.35E-05 Multiple complex diseases ADAMTS18 intron 17554300 rs17620846 chr16 77430576 A G 2.70E-05 Urinary metabolites ADAMTS18 intron 21572414 rs1346563 chr16 77436283 G A 9.00E-06 Urinary metabolites ADAMTS18 intron 21572414 rs4888626 chr16 77436921 A G 8.13E-05 Serum metabolites ADAMTS18 intron 19043545 rs12446196 chr16 77444872 A T 5.66E-05 Multiple complex diseases ADAMTS18 intron 17554300 rs1428840 chr16 77449432 C T 4.43E-05 Serum metabolites ADAMTS18 intron 19043545 rs17688543 chr16 77455721 T C 2.63E-04 Multiple complex diseases ADAMTS18 intron 17554300 rs1366547 chr16 77462381 A C 6.13E-04 Multiple complex diseases ADAMTS18 intron 17554300 rs4888633 chr16 77481339 G A 3.80E-04 Multiple complex diseases / / 17554300 rs12448442 chr16 77483271 A G 9.90E-05 Triglycerides / / pha003081 rs7185964 chr16 77484585 C A 5.62E-04 Multiple complex diseases / / 17554300 rs1565781 chr16 77488112 T C 1.31E-07 Statin-induced myopathy / / 21826682 rs10514417 chr16 77492493 G T 8.58E-05 Triglycerides / / pha003080 rs1826601 chr16 77502186 T C 1.00E-05 Bone mineral density (BMD),in women / / 20164292 rs1385321 chr16 77521092 G A 9.93E-04 Multiple complex diseases / / 17554300 rs12449256 chr16 77521178 G C 5.82E-04 Multiple complex diseases / / 17554300 rs2343704 chr16 77533076 T C 2.46E-04 Multiple complex diseases / / 17554300 rs7194124 chr16 77537701 T C 2.28E-04 Multiple complex diseases / / 17554300 rs1385320 chr16 77542423 G T 1.10E-04 Bone mineral density (BMD),in women / / 20164292 rs1493892 chr16 77545082 T G 5.76E-04 Multiple complex diseases / / 17554300 rs8057501 chr16 77558677 A G 7.50E-05 Bone mineral density (BMD),in women / / 20164292 rs8057501 chr16 77558677 A G 4.03E-05 Waist-Hip Ratio / / pha003029 rs1826598 chr16 77572955 C A 5.40E-07 Intraocular pressure / / 22570627 rs9925028 chr16 77577240 C G 1.30E-05 Urinary metabolites / / 21572414 rs282988 chr16 77590129 G A 2.06E-04 Type 2 diabetes / / 17463246 rs9937892 chr16 77597116 C G 2.06E-04 Type 2 diabetes / / 17463246 rs157318 chr16 77597357 T C 1.10E-05 Urinary metabolites / / 21572414 rs7203041 chr16 77608572 G C 1.70E-04 Type 2 diabetes / / 17463246 rs16946004 chr16 77612950 T C 1.28E-05 Multiple complex diseases / / 17554300 rs389977 chr16 77615731 T G 3.54E-04 Height / / 17255346 rs7188063 chr16 77616289 T G 7.71E-04 Type 2 diabetes / / 17463246 rs9927133 chr16 77618873 T G 8.91E-04 Type 2 diabetes / / 17463246 rs10514420 chr16 77619256 C T 8.33E-04 Type 2 diabetes / / 17463246 rs12928238 chr16 77625747 T A 6.80E-06 Urinary metabolites / / 21572414 rs157469 chr16 77628285 G A 2.32E-04 Height / / 17255346 rs166826 chr16 77638665 C G,T 8.72E-04 Depression (quantitative trait) / / 20800221 rs13336488 chr16 77640232 A G 3.70E-05 Bone mineral density (BMD),in women / / 20164292 rs7193915 chr16 77647073 T C 2.57E-05 Brain structure / / 22504417 rs1839259 chr16 77650847 C G 4.50E-05 Brain structure / / 22504417 rs1117412 chr16 77651113 G C 8.42E-04 Type 2 diabetes / / 17463246 rs1117412 chr16 77651113 G C 2.40E-05 Brain structure / / 22504417 rs1449202 chr16 77663037 G A 4.11E-33 Narcolepsy / / 19629137 rs17690853 chr16 77663201 G C 2.23E-04 Height / / 17255346 rs3891920 chr16 77668184 T C 8.81E-04 Depression (quantitative trait) / / 20800221 rs280846 chr16 77673597 C T 2.24E-04 Parkinson's disease / / 17052657 rs280849 chr16 77675163 T C 3.56E-04 Multiple complex diseases / / 17554300 rs2220160 chr16 77682895 C A 1.96E-04 Acute lung injury / / 22295056 rs2880777 chr16 77683264 A G 3.75E-04 Acute lung injury / / 22295056 rs1449208 chr16 77683645 C T 1.75E-04 Acute lung injury / / 22295056 rs7203274 chr16 77684529 G A 1.58E-04 Acute lung injury / / 22295056 rs6564461 chr16 77685338 G C 3.59E-04 Acute lung injury / / 22295056 rs8044908 chr16 77688406 G C 5.14E-04 Acute lung injury / / 22295056 rs8046934 chr16 77688451 A C 1.72E-04 Acute lung injury / / 22295056 rs1868465 chr16 77688760 C T 2.44E-04 Acute lung injury / / 22295056 rs8051539 chr16 77710724 C T 4.80E-05 Electrocardiographic conduction measures / / 19389651 rs12596600 chr16 77713197 T C 2.60E-05 Urinary metabolites / / 21572414 rs11150011 chr16 77714098 G T 2.24E-04 Multiple complex diseases / / 17554300 rs11150012 chr16 77714205 G A 1.94E-04 Multiple complex diseases / / 17554300 rs11150012 chr16 77714205 G A 2.18E-05 Type 1 diabetes / / 18978792 rs11150013 chr16 77720183 T C 5.80E-04 Multiple complex diseases / / 17554300 rs8045081 chr16 77738990 T C 2.78E-05 Coronary heart disease / / pha003031 rs10871341 chr16 77743177 A G 8.17E-04 Alcohol dependence / / 24277619 rs10871341 chr16 77743177 A G 6.64E-05 Magnesium levels / / pha003092 rs9939604 chr16 77745595 G A 8.59E-05 Magnesium levels / / pha003092 rs8053932 chr16 77753888 G A 3.53E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9931184 chr16 77763255 T G 2.19E-05 Cognitive impairment induced by topiramate NUDT7 intron 22091778 rs4888666 chr16 77766284 A G 1.71E-04 Multiple complex diseases NUDT7 intron 17554300 rs4888671 chr16 77783580 G A 7.00E-06 Obesity-related traits / / 23251661 rs2966033 chr16 77787309 T C 2.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs9989393 chr16 77787348 T A 5.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs4888683 chr16 77816028 T C 4.83E-04 Smoking initiation / / 24665060 rs61737715 chr16 77822722 C T 0.00019 Breast cancer (ER positive) VAT1L missense 23555315 rs11648930 chr16 77837251 A C 3.16E-05 Magnesium levels VAT1L intron pha003092 rs2966061 chr16 77841712 A G 5.40E-06 Urinary metabolites VAT1L intron 21572414 rs2914446 chr16 77843210 A G 1.64E-04 Type 2 diabetes VAT1L intron 17463246 rs8048150 chr16 77846663 T C 2.01E-04 Alcohol consumption VAT1L intron 23743675 rs2966055 chr16 77847613 A G 6.30E-06 Urinary metabolites VAT1L intron 21572414 rs2966053 chr16 77850966 T C 8.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VAT1L intron 20877124 rs2966040 chr16 77863802 T C 3.60E-06 Urinary metabolites VAT1L intron 21572414 rs9934540 chr16 77876763 T C 4.00E-07 Alzheimer's disease (cognitive decline) VAT1L intron 23535033 rs254772 chr16 77876875 G A 4.19E-04 Response to statin treatment (atorvastatin),change in cholesterol levels VAT1L intron 20031582 rs254772 chr16 77876875 G A 3.89E-04 Suicide attempts in bipolar disorder VAT1L intron 21423239 rs254770 chr16 77877571 A T 6.39E-05 Suicide attempts in bipolar disorder VAT1L intron 21423239 rs173855 chr16 77879657 A G 4.30E-06 Urinary metabolites VAT1L intron 21572414 rs407055 chr16 77880917 A T 6.40E-06 Urinary metabolites VAT1L intron 21572414 rs9925458 chr16 77890206 A G 7.98E-04 Multiple complex diseases VAT1L intron 17554300 rs1080941 chr16 77890685 A C 7.33E-04 Multiple complex diseases VAT1L intron 17554300 rs435746 chr16 77916191 T A 3.00E-06 Bipolar disorder and schizophrenia VAT1L intron 20889312 rs442307 chr16 77923069 T C 3.24E-05 Bipolar disorder and schizophrenia VAT1L intron 20889312 rs440488 chr16 77926130 A G 7.98E-05 Bipolar disorder and schizophrenia VAT1L intron 20889312 rs397404 chr16 77926189 C A 2.10E-04 Type 2 diabetes VAT1L intron 17463246 rs379930 chr16 77927974 C G 2.19E-04 Type 2 diabetes VAT1L intron 17463246 rs369727 chr16 77928032 T C 2.18E-04 Type 2 diabetes VAT1L intron 17463246 rs423974 chr16 77930524 C T 3.46E-04 Type 2 diabetes VAT1L intron 17463246 rs17718275 chr16 77936040 A G 1.13E-04 Type 2 diabetes VAT1L intron 17463246 rs8062644 chr16 77939493 A G 2.23E-04 Alzheimer's disease VAT1L intron 17998437 rs437626 chr16 77944653 C T 4.87E-04 Alzheimer's disease VAT1L intron 17998437 rs17718408 chr16 77945983 A G 1.40E-04 Multiple complex diseases VAT1L intron 17554300 rs1125694 chr16 77955062 A T 2.55E-04 Multiple complex diseases VAT1L intron 17554300 rs370063 chr16 77978061 A T 4.43E-29 Narcolepsy VAT1L intron 19629137 rs17775590 chr16 78015442 G T 5.31E-04 Type 2 diabetes / / 17463246 rs11861089 chr16 78019687 T C 7.99E-07 Inflammatory biomarkers / / 22291609 rs11642709 chr16 78037250 C T 3.60E-06 Response to amphetamines / / 22952603 rs11639887 chr16 78037410 T C 2.53E-06 Response to amphetamines / / 22952603 rs11643805 chr16 78037560 C A 1.89E-06 Response to amphetamines / / 22952603 rs11649224 chr16 78037778 A T 2.43E-06 Response to amphetamines / / 22952603 rs11150032 chr16 78037893 C A 2.36E-06 Response to amphetamines / / 22952603 rs56058344 chr16 78038362 T C 4.70E-06 Response to amphetamines / / 22952603 rs56085948 chr16 78038506 T C 8.89E-06 Response to amphetamines / / 22952603 rs72798888 chr16 78038888 A G 1.86E-06 Response to amphetamines / / 22952603 rs72798889 chr16 78038974 T C 1.96E-06 Response to amphetamines / / 22952603 rs11648060 chr16 78039064 C T 1.96E-06 Response to amphetamines / / 22952603 rs11649083 chr16 78039641 G A 2.30E-06 Response to amphetamines / / 22952603 rs11649412 chr16 78039797 C T 4.56E-06 Response to amphetamines / / 22952603 rs11645587 chr16 78039977 T C 2.32E-06 Response to amphetamines / / 22952603 rs11640136 chr16 78040384 G T 1.03E-06 Response to amphetamines / / 22952603 rs11640475 chr16 78040438 C T 7.34E-06 Response to amphetamines / / 22952603 rs11646856 chr16 78040443 T C 7.88E-06 Response to amphetamines / / 22952603 rs11640182 chr16 78040451 G T 7.90E-06 Response to amphetamines / / 22952603 rs72798891 chr16 78040679 T C 8.60E-07 Response to amphetamines / / 22952603 rs72798892 chr16 78040860 G A 9.71E-07 Response to amphetamines / / 22952603 rs72798894 chr16 78040951 C T 1.13E-06 Response to amphetamines / / 22952603 rs72798895 chr16 78040974 G C 9.72E-07 Response to amphetamines / / 22952603 rs7186088 chr16 78041269 G C 1.36E-06 Response to amphetamines / / 22952603 rs7197676 chr16 78041385 T G 3.19E-06 Response to amphetamines / / 22952603 rs7190919 chr16 78041439 G C 4.10E-06 Response to amphetamines / / 22952603 rs7198037 chr16 78041538 T C 1.05E-06 Response to amphetamines / / 22952603 rs7192699 chr16 78041618 C T 9.84E-07 Response to amphetamines / / 22952603 rs7193378 chr16 78041661 A G 1.04E-06 Response to amphetamines / / 22952603 rs72798901 chr16 78042630 T G 9.34E-06 Response to amphetamines / / 22952603 rs11863259 chr16 78044034 G T 1.77E-06 Response to amphetamines / / 22952603 rs11859527 chr16 78044163 A T 1.29E-06 Response to amphetamines / / 22952603 rs1882596 chr16 78045800 G T 7.61E-04 Acute lung injury / / 22295056 rs17776016 chr16 78047817 C T 2.77E-05 Kawasaki disease / / 22446961 rs2735413 chr16 78053643 A T 9.00E-07 Systolic blood pressure (alcohol consumption interaction) / / 24376456 rs2735401 chr16 78057103 G T 4.54E-05 Kawasaki disease CLEC3A intron 22446961 rs2262658 chr16 78060267 A G 2.26E-06 Kawasaki disease CLEC3A intron 22446961 rs7192416 chr16 78063143 C T 1.73E-05 Kawasaki disease CLEC3A intron 22446961 rs2293776 chr16 78064351 C G 5.52E-05 Longevity CLEC3A cds-synon 20304771 rs4494555 chr16 78068601 C G 7.04E-05 Longevity / / 20304771 rs1955389 chr16 78068964 C T 7.16E-05 Longevity / / 20304771 rs1955390 chr16 78069034 T C 7.29E-05 Longevity / / 20304771 rs2344495 chr16 78070000 G A 7.67E-05 Longevity / / 20304771 rs11642341 chr16 78074394 T G 7.21E-05 Longevity / / 20304771 rs11642677 chr16 78075409 A G 7.54E-05 Longevity / / 20304771 rs2344922 chr16 78085408 C G 8.12E-05 Longevity / / 20304771 rs8045479 chr16 78086361 C G 6.55E-05 Longevity / / 20304771 rs8044195 chr16 78086396 G A 8.53E-05 Longevity / / 20304771 rs4369682 chr16 78087561 C G 8.40E-04 Multiple complex diseases / / 17554300 rs4369682 chr16 78087561 C G 8.62E-05 Longevity / / 20304771 rs11150040 chr16 78090982 C G 8.35E-04 Multiple complex diseases / / 17554300 rs11150040 chr16 78090982 C G 9.82E-05 Longevity / / 20304771 rs4324138 chr16 78101372 T G 6.21E-05 Kawasaki disease / / 22446961 rs1922617 chr16 78112263 G A 5.30E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs1922617 chr16 78112263 G A 5.30E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs4887934 chr16 78114956 G A 2.80E-05 Urinary metabolites / / 21572414 rs11641213 chr16 78115195 A G 4.45E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs11641213 chr16 78115195 A G 4.45E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs16947095 chr16 78115623 G A 3.74E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs16947095 chr16 78115623 G A 3.74E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs11649069 chr16 78140002 C T 5.00E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy WWOX intron 24578207 rs11649069 chr16 78140002 C T 5.00E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy WWOX intron 24578207 rs16947129 chr16 78151746 T C 2.39E-06 Osteoarthritis WWOX intron 22763110 rs13338697 chr16 78167906 A G 2.92E-05 Blood pressure (response to angiotensin II receptor blocker) WWOX intron 24192120 rs13333314 chr16 78167930 G A 2.94E-05 Blood pressure (response to angiotensin II receptor blocker) WWOX intron 24192120 rs1079572 chr16 78187138 G A 1.00E-08 Lung function (forced vital capacity) WWOX intron 24929828 rs12716850 chr16 78187903 A G 1.00E-07 Pulmonary function (interaction) WWOX intron 23284291 rs8056446 chr16 78188496 G A 8.00E-08 Pulmonary function (interaction) WWOX intron 23284291 rs12716852 chr16 78188738 G A 2.00E-07 Pulmonary function WWOX intron 21946350 rs146895972 chr16 78188878 C T 0.0000411 Nonsyndromic striae distensae (stretch marks) WWOX intron 23633020 rs11862871 chr16 78214218 C G 7.64E-04 Suicide attempts in bipolar disorder WWOX intron 21423239 rs4887942 chr16 78214952 A G 0.000249703 Hypertension (early onset hypertension) WWOX intron 22479346 rs4888761 chr16 78222989 G A 0.00000417 Stroke WWOX intron 23422753 rs17652533 chr16 78251616 A G 4.75E-04 Parkinson's disease WWOX intron 17052657 rs2059238 chr16 78258810 A C 3.00E-06 Cardiac structure and function WWOX intron 19584346 rs16947307 chr16 78270078 C T 2.88E-05 Tunica Media WWOX intron pha003034 rs12923794 chr16 78302399 T C 0.000041 Salmonella-induced pyroptosis WWOX intron 22837397 rs4508428 chr16 78303266 T C 1.02E-05 Nicotine smoking WWOX intron 19268276 rs4508428 chr16 78303266 T C 3.82E-04 Nicotine smoking WWOX intron 19268276 rs4508428 chr16 78303266 T C 0.000257 Salmonella-induced pyroptosis WWOX intron 22837397 rs4243149 chr16 78311773 A G 2.17E-06 Tunica Media WWOX intron pha003036 rs11150053 chr16 78316266 A G 8.06E-04 Amyotrophic Lateral Sclerosis WWOX intron 17362836 rs4888775 chr16 78324964 G A 2.17E-05 Tunica Media WWOX intron pha003036 rs4267317 chr16 78326209 G A 5.80E-05 Tunica Media WWOX intron pha003036 rs78867184 chr16 78335044 A G 9.00E-06 Metabolite levels (5-HIAA) WWOX intron 23319000 rs7199623 chr16 78347738 G A 9.41E-06 Tunica Media WWOX intron pha003036 rs11641760 chr16 78350669 T C 1.16E-06 Insulin-related traits WWOX intron 22791750 rs11866209 chr16 78352757 C T 8.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WWOX intron 20877124 rs11866209 chr16 78352757 C T 2.92E-06 Cognitive impairment induced by topiramate WWOX intron 22091778 rs9922483 chr16 78356662 T G 5.85E-05 Tunica Media WWOX intron pha003036 rs7192196 chr16 78360663 G A 7.29E-05 Tunica Media WWOX intron pha003036 rs8057779 chr16 78383140 C G 2.67E-07 Esophageal cancer (squamous cell) WWOX intron 22960999 rs8044888 chr16 78391217 C T 7.16E-05 Multiple complex diseases WWOX intron 17554300 rs11648339 chr16 78393122 C T 1.21E-05 Personality dimensions WWOX intron 22628180 rs4888786 chr16 78394040 A G 5.52E-06 Personality dimensions WWOX intron 22628180 rs12917864 chr16 78402002 T G 9.15E-06 Personality dimensions WWOX intron 22628180 rs12918436 chr16 78402867 C T 9.30E-06 Personality dimensions WWOX intron 22628180 rs12932569 chr16 78404518 T C 2.93E-05 Personality dimensions WWOX intron 22628180 rs4412982 chr16 78405049 A T 7.11E-06 Personality dimensions WWOX intron 22628180 rs11639904 chr16 78406523 G A 1.10E-05 Personality dimensions WWOX intron 22628180 rs11150069 chr16 78407063 A C 9.43E-06 Prostate cancer(aggressive) WWOX intron 21467234 rs13338044 chr16 78407567 T C 1.34E-05 Personality dimensions WWOX intron 22628180 rs11645844 chr16 78408972 C T 2.98E-05 Personality dimensions WWOX intron 22628180 rs4888798 chr16 78410634 C T 4.75E-05 Personality dimensions WWOX intron 22628180 rs4887962 chr16 78412716 C T 3.41E-05 Personality dimensions WWOX intron 22628180 rs4888800 chr16 78412843 C T 2.87E-05 Personality dimensions WWOX intron 22628180 rs8055871 chr16 78417710 G A 2.18E-04 Multiple complex diseases WWOX intron 17554300 rs11643855 chr16 78419958 C T 4.79E-04 Multiple complex diseases WWOX intron 17554300 rs8057749 chr16 78458471 G C 9.40E-06 Type 2 diabetes WWOX intron 21647700 rs4130513 chr16 78458750 G A 9.30E-04 Obesity (extreme) WWOX intron 21935397 rs9921967 chr16 78459534 G A 2.53E-04 Type 2 diabetes WWOX intron 17463246 rs11150078 chr16 78466704 C A 3.91E-04 Type 2 diabetes WWOX intron 17463246 rs11150078 chr16 78466704 C A 2.00E-06 Bipolar disorder (body mass index interaction) WWOX intron 24322204 rs3764342 chr16 78466758 A C 4.98E-04 Multiple complex diseases WWOX intron 17554300 rs8043887 chr16 78467308 G C 3.42E-04 Type 2 diabetes WWOX intron 17463246 rs2738652 chr16 78494356 T A 3.45E-04 Nicotine dependence WWOX intron 17158188 rs9933282 chr16 78503548 C T 2.07E-04 Response to cytadine analogues (cytosine arabinoside) WWOX intron 24483146 rs2738679 chr16 78504998 T C 8.69E-04 Longevity WWOX intron 22279548 rs2667552 chr16 78505906 C T 1.74E-04 Oral cancers (chewing tobacco related) WWOX intron 22503698 rs9937755 chr16 78508301 T C 6.14E-04 Response to cytadine analogues (cytosine arabinoside) WWOX intron 24483146 rs9931636 chr16 78512088 A C 3.60E-05 Intracerebral hemorrhage WWOX intron 24656865 rs2667557 chr16 78513191 C T 4.82E-05 Intracerebral hemorrhage WWOX intron 24656865 rs2667558 chr16 78514068 A G 9.69E-04 Multiple complex diseases WWOX intron 17554300 rs2738690 chr16 78517027 G T 4.17E-04 Multiple complex diseases WWOX intron 17554300 rs8064066 chr16 78539115 G C 7.96E-04 Coronary heart disease WWOX intron 21606135 rs16947902 chr16 78552049 C G 1.34E-04 Multiple complex diseases WWOX intron 17554300 rs2941948 chr16 78559840 C G 2.30E-05 Urinary metabolites WWOX intron 21572414 rs2978632 chr16 78559880 T C 7.25E-05 Obesity (extreme) WWOX intron 21935397 rs16947980 chr16 78560058 G A 8.57E-04 Multiple complex diseases WWOX intron 17554300 rs11150084 chr16 78561820 C G 2.37E-04 Obesity (extreme) WWOX intron 21935397 rs11645676 chr16 78563832 C T 5.51E-05 Prostate cancer mortality WWOX intron 20978177 rs2738499 chr16 78568416 A G 3.30E-04 Obesity (extreme) WWOX intron 21935397 rs2667627 chr16 78568430 C T 2.98E-04 Obesity (extreme) WWOX intron 21935397 rs17706989 chr16 78569957 C G 1.00E-06 Response to antipsychotic treatment in schizophrenia (reasoning) WWOX intron 21107309 rs2738502 chr16 78570541 G C 1.86E-04 Obesity (extreme) WWOX intron 21935397 rs1106217 chr16 78572242 C T 3.96E-04 Obesity (extreme) WWOX intron 21935397 rs1317575 chr16 78572255 G C 2.87E-04 Obesity (extreme) WWOX intron 21935397 rs9635580 chr16 78572354 C T 2.48E-05 Post-operative nausea and vomiting WWOX intron 21694509 rs1105314 chr16 78572542 A G 3.02E-04 Obesity (extreme) WWOX intron 21935397 rs2667634 chr16 78573628 C G 2.35E-04 Obesity (extreme) WWOX intron 21935397 rs9989362 chr16 78574676 T C 4.61E-05 Prostate cancer mortality WWOX intron 20978177 rs2667646 chr16 78577582 C T 8.12E-04 Premature ovarian failure WWOX intron 19508998 rs2667648 chr16 78581138 T C 3.90E-05 Parkinson's disease (age of onset) WWOX intron 19772629 rs17640190 chr16 78593907 G A 7.85E-04 Nicotine smoking WWOX intron 19268276 rs11642089 chr16 78601706 G A 0.000859905 Hypertension (early onset hypertension) WWOX intron 22479346 rs11150090 chr16 78621373 A G 6.17E-04 Multiple complex diseases WWOX intron 17554300 rs16948137 chr16 78622688 A G 9.24E-04 Alzheimer's disease WWOX intron 17998437 rs1912804 chr16 78626583 C G 9.44E-04 Suicide attempts in bipolar disorder WWOX intron 21423239 rs2738545 chr16 78629320 G A 7.67E-04 Multiple complex diseases WWOX intron 17554300 rs2859631 chr16 78631794 G A 1.00E-06 Radiation response WWOX intron 20923822 rs2548876 chr16 78654819 C T 6.23E-05 Multiple complex diseases WWOX intron 17554300 rs2738571 chr16 78657827 G A 1.60E-06 Left ventricular hypertrophy WWOX intron pha003052 rs4622523 chr16 78664742 G C 2.15E-04 Alzheimer's disease (late onset) WWOX intron 21460841 rs2550626 chr16 78678727 C T 9.66E-04 Multiple complex diseases WWOX intron 17554300 rs2738586 chr16 78679045 G A 5.88E-04 Type 2 diabetes WWOX intron 17463246 rs2738587 chr16 78679533 A C 5.98E-04 Type 2 diabetes WWOX intron 17463246 rs2161620 chr16 78681118 G A 5.97E-05 Cognitive test performance WWOX intron 20125193 rs10514440 chr16 78681303 C T 5.40E-04 Lung adenocarcinoma WWOX intron 21242121 rs2113120 chr16 78688144 T C 2.55E-05 F-cell distribution WWOX intron 21326311 rs4499247 chr16 78701811 C T 6.06E-04 Suicide attempts in bipolar disorder WWOX intron 21423239 rs9925569 chr16 78756328 G A 2.29E-04 Glycosylated haemoglobin levels WWOX intron 17255346 rs9925569 chr16 78756328 G A 2.70E-05 Urinary metabolites WWOX intron 21572414 rs8047442 chr16 78764097 T C 2.91E-05 Bipolar disorder WWOX intron 19488044 rs8047442 chr16 78764097 T C 2.97E-05 Bipolar Disorder WWOX intron pha002863 rs1364290 chr16 78772582 A G 9.21E-04 Common variable immunodeficiency WWOX intron 21497890 rs16948419 chr16 78773274 G T 9.46E-04 Multiple complex diseases WWOX intron 17554300 rs7196702 chr16 78784233 G A 7.78E-04 Response to statin treatment (atorvastatin),change in cholesterol levels WWOX intron 20031582 rs10514443 chr16 78795885 G A 9.30E-04 Breast cancer and prostate cancer WWOX intron 17903305 rs4887981 chr16 78802116 T C 8.80E-05 Response to cytidine analogues (gemcitabine) WWOX intron 24483146 rs4888846 chr16 78805763 A T 2.27E-05 Schizophrenia WWOX intron 20832056 rs17709200 chr16 78807770 A G 4.86E-05 Schizophrenia WWOX intron 20832056 rs9929519 chr16 78808383 C A 1.90E-04 Schizophrenia WWOX intron 20832056 rs17642004 chr16 78809124 G A 3.73E-05 Schizophrenia WWOX intron 20832056 rs16948449 chr16 78810901 G A 5.73E-04 Multiple complex diseases WWOX intron 17554300 rs10514445 chr16 78812865 A T 5.82E-04 Multiple complex diseases WWOX intron 17554300 rs7194007 chr16 78814566 C T 9.76E-04 Suicide attempts in bipolar disorder WWOX intron 21423239 rs12926134 chr16 78818933 T C 5.45E-05 Bipolar disorder,affective WWOX intron 20528957 rs2550593 chr16 78822569 G T 3.05E-04 Birth weight WWOX intron 17255346 rs1110559 chr16 78827865 A G 5.18E-04 Amyotrophic Lateral Sclerosis WWOX intron 17362836 rs2293902 chr16 78837772 C T 1.10E-04 Lung function (forced vital capacity) WWOX intron 24023788 rs2293902 chr16 78837772 C T 9.72E-05 Lung function (forced expiratory volume in 1 second) WWOX intron 24023788 rs7499973 chr16 78842183 G C 9.42E-04 Type 2 diabetes WWOX intron 17463246 rs7499973 chr16 78842183 G C 9.90E-07 Urinary metabolites WWOX intron 21572414 rs3946180 chr16 78843984 G A 2.37E-04 Lung function (forced expiratory volume in 1 second) WWOX intron 24023788 rs3946180 chr16 78843984 G A 3.38E-04 Lung function (forced vital capacity) WWOX intron 24023788 rs12445110 chr16 78852682 T C 2.09E-05 Lung function (forced expiratory volume in 1 second) WWOX intron 24023788 rs12445110 chr16 78852682 T C 5.13E-05 Lung function (forced vital capacity) WWOX intron 24023788 rs7196220 chr16 78854228 C A 4.33E-05 Cognitive performance WWOX intron 19734545 rs7201888 chr16 78854487 A G 8.10E-04 Multiple complex diseases WWOX intron 17554300 rs7193003 chr16 78858560 C A 8.70E-04 Multiple complex diseases WWOX intron 17554300 rs7184580 chr16 78860946 A C 0.000114 5-fluorouracil induced haematologic in response to colorectal cancer treatment WWOX intron 22310351 rs7185014 chr16 78869972 C T 6.68E-04 Response to cytidine analogues (gemcitabine) WWOX intron 24483146 rs11649397 chr16 78872859 G A 4.02E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) WWOX intron 23648065 rs4888865 chr16 78877418 C A 3.66E-04 Type 2 diabetes WWOX intron 17463246 rs13335801 chr16 78882440 G C 2.00E-05 Urinary metabolites WWOX intron 21572414 rs8054190 chr16 78897381 C T 0.000680127 Hypertension (early onset hypertension) WWOX intron 22479346 rs7197238 chr16 78897742 A G 0.000337106 Hypertension (early onset hypertension) WWOX intron 22479346 rs2178952 chr16 78901723 A G 8.59E-04 Parkinson's disease WWOX intron 17052657 rs6564613 chr16 78901769 G A 2.50E-05 Urinary metabolites WWOX intron 21572414 rs11647676 chr16 78926616 T A 9.30E-05 Malaria WWOX intron 19465909 rs2292124 chr16 78930216 G C 3.10E-05 Malaria WWOX intron 19465909 rs11861377 chr16 78940747 T C 5.51E-04 Aortic root size WWOX intron 21223598 rs11861377 chr16 78940747 T C 4.00E-06 Urinary metabolites WWOX intron 21572414 rs9923451 chr16 78952439 A G 8.00E-07 Obesity WWOX intron 21552555 rs8059300 chr16 78955240 A C 4.26E-05 Self-reported allergy WWOX intron 23817569 rs8047671 chr16 78969981 T A,C,G 3.96E-04 Multiple complex diseases WWOX intron 17554300 rs8047671 chr16 78969981 T A,C,G 3.16E-04 Sarcoidosis WWOX intron 19165924 rs8047671 chr16 78969981 T A,C,G 7.09E-05 Acute lymphoblastic leukemia (childhood) WWOX intron 19684603 rs8047671 chr16 78969981 T A,C,G 7.66E-05 Suicide attempts in bipolar disorder WWOX intron 21423239 rs1349 chr16 78970460 G C 2.70E-04 Suicide attempts in bipolar disorder WWOX intron 21423239 rs2062897 chr16 78972002 A T 3.88E-04 Suicide attempts in bipolar disorder WWOX intron 21423239 rs12598030 chr16 78973088 A G 6.21E-05 Suicide attempts in bipolar disorder WWOX intron 21423239 rs7203590 chr16 78973247 A G 4.23E-04 Suicide attempts in bipolar disorder WWOX intron 21423239 rs12596126 chr16 78973829 G A 4.84E-04 Suicide attempts in bipolar disorder WWOX intron 21423239 rs12596284 chr16 78973967 C G 3.58E-04 Suicide attempts in bipolar disorder WWOX intron 21423239 rs7195069 chr16 78978277 T C 7.85E-04 Multiple complex diseases WWOX intron 17554300 rs9935088 chr16 78979515 A G 7.88E-04 Alcohol dependence WWOX intron 21314694 rs7185469 chr16 78982911 G A 2.43E-04 Smoking initiation WWOX intron 24665060 rs16949021 chr16 78983479 C G 2.34E-18 Multiple complex diseases WWOX intron 17554300 rs11860206 chr16 79004797 T C 4.27E-04 Multiple complex diseases WWOX intron 17554300 rs7197569 chr16 79008996 C G 1.64E-04 Cognition,early reading ability WWOX intron 17684495 rs16949152 chr16 79019253 A G 6.37E-05 Weight WWOX intron pha003026 rs4888901 chr16 79020532 T G 1.00E-04 Adverse response to radiation therapy WWOX intron 23719583 rs4888910 chr16 79027129 G A 8.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WWOX intron 20877124 rs4888910 chr16 79027129 G A 9.45E-05 Cholesterol WWOX intron pha003078 rs11644322 chr16 79039600 C T 3.15E-05 Response to gemcitabine in pancreatic cancer WWOX intron 22142827 rs9935794 chr16 79041567 G A 7.48E-04 Myocardial Infarction WWOX intron pha002883 rs2550731 chr16 79044649 G T 8.38E-04 Response to gemcitabine in pancreatic cancer WWOX intron 22142827 rs9921664 chr16 79049280 C A 2.72E-04 Smoking initiation WWOX intron 24665060 rs16949222 chr16 79050116 C T 4.64E-04 Insulin resistance WWOX intron 21901158 rs2550698 chr16 79063156 T G 4.10E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) WWOX intron 23648065 rs2656641 chr16 79067690 C T 3.02E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) WWOX intron 23648065 rs17713676 chr16 79073421 C T 8.00E-06 Response to amphetamines WWOX intron 22952603 rs117868651 chr16 79074336 A T 7.91E-06 Response to amphetamines WWOX intron 22952603 rs79612874 chr16 79074868 T A 8.24E-06 Response to amphetamines WWOX intron 22952603 rs17646139 chr16 79075620 T G 8.70E-06 Response to amphetamines WWOX intron 22952603 rs74549820 chr16 79076110 C A 8.50E-06 Response to amphetamines WWOX intron 22952603 rs8046508 chr16 79078175 C T 9.64E-05 Cognitive impairment induced by topiramate WWOX intron 22091778 rs2550685 chr16 79085489 A C 9.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) WWOX intron 23233662 rs9922235 chr16 79096417 G C 5.80E-06 Sleep latency WWOX intron 23728906 rs7194361 chr16 79108354 C T 4.81E-05 Celiac disease WWOX intron 23936387 rs1080511 chr16 79114484 A C 4.60E-04 Smoking cessation WWOX intron 24665060 rs4888920 chr16 79115931 A G 2.00E-04 Coronary heart disease WWOX intron 21606135 rs13339155 chr16 79119069 G A 8.92E-04 Multiple complex diseases WWOX intron 17554300 rs13339155 chr16 79119069 G A 5.10E-04 Alzheimer's disease WWOX intron 17998437 rs13339155 chr16 79119069 G A 7.94E-04 Coronary heart disease WWOX intron 21606135 rs4888924 chr16 79126550 A G 5.86E-04 Type 2 diabetes WWOX intron 17463246 rs4888925 chr16 79126670 G A 5.88E-04 Alzheimer's disease WWOX intron 17998437 rs8048899 chr16 79131913 T C 9.71E-05 Coronary heart disease WWOX intron pha003031 rs2005036 chr16 79156222 C T 3.42E-04 Alzheimer's disease (late onset) WWOX intron 21379329 rs7498200 chr16 79161842 A G 9.26E-05 Orofacial clefts WWOX intron 22419666 rs11866970 chr16 79164452 A G 7.90E-06 Urinary metabolites WWOX intron 21572414 rs9646322 chr16 79164851 G A 5.97E-04 Multiple complex diseases WWOX intron 17554300 rs1424112 chr16 79171956 A G 6.33E-04 Rheumatoid arthritis WWOX intron 21452313 rs11647886 chr16 79172681 G T 4.05E-06 Acne (severe teenage) WWOX intron 24114350 rs7193539 chr16 79175411 C A 6.51E-05 Information processing speed WWOX intron 21130836 rs7200634 chr16 79176337 A C 4.15E-05 Schizophrenia WWOX intron 19571809 rs7200634 chr16 79176337 A C 7.11E-05 Schizophrenia WWOX intron pha002859 rs11859942 chr16 79180259 C G 7.42E-04 Response to statin treatment (atorvastatin),change in cholesterol levels WWOX intron 20031582 rs8053895 chr16 79184460 A G 9.20E-04 Multiple complex diseases WWOX intron 17554300 rs4459555 chr16 79185196 T C 4.33E-04 Lung function (forced expiratory volume in 1 second) WWOX intron 24023788 rs16949716 chr16 79185824 G A 2.25E-04 Multiple complex diseases WWOX intron 17554300 rs8050187 chr16 79186886 T C 7.00E-06 Anorexia nervosa WWOX intron 23568457 rs12919104 chr16 79188548 T C 6.30E-04 Multiple complex diseases WWOX intron 17554300 rs12919104 chr16 79188548 T C 2.00E-05 Urinary metabolites WWOX intron 21572414 rs11859414 chr16 79189453 C G 6.59E-04 Multiple complex diseases WWOX intron 17554300 rs6564651 chr16 79194138 T C 9.03E-05 Coronary heart disease WWOX intron pha003056 rs11150140 chr16 79200414 G A 0.00000764 Asthma WWOX intron 22694930 rs17656178 chr16 79201179 A G 0.00000179 Asthma WWOX intron 22694930 rs8055765 chr16 79206951 T C 1.20E-05 Urinary metabolites WWOX intron 21572414 rs12716871 chr16 79213239 C G 9.62E-04 Multiple complex diseases WWOX intron 17554300 rs3751832 chr16 79214272 A G 9.00E-04 Breast cancer and prostate cancer WWOX intron 17903305 rs1834037 chr16 79215085 C T 5.57E-04 Lymphocyte counts WWOX intron 22286170 rs4888014 chr16 79216221 G A 4.38E-04 Alzheimer's disease WWOX intron 17998437 rs415738 chr16 79227420 A G 7.36E-04 Myocardial Infarction WWOX intron pha002873 rs415738 chr16 79227420 A G 4.50E-05 Diabetes Mellitus WWOX intron pha003059 rs414723 chr16 79228250 C T 2.34E-05 Diabetes Mellitus WWOX intron pha003059 rs12445467 chr16 79229465 T C 4.08E-04 Lung function (forced expiratory volume in 1 second) WWOX intron 24023788 rs12445467 chr16 79229465 T C 4.82E-04 Lung function (forced vital capacity) WWOX intron 24023788 rs383673 chr16 79232446 A C 8.37E-04 Parkinson's disease WWOX intron 17052657 rs417711 chr16 79239372 A G 0.000543 Salmonella-induced pyroptosis WWOX intron 22837397 rs9922579 chr16 79280298 C T 5.02E-05 LDL lipoproteins / / pha002902 rs437620 chr16 79291806 G A 1.24E-04 Myocardial Infarction / / pha002873 rs270443 chr16 79293082 G A 9.42E-04 Multiple complex diseases / / 17554300 rs10514449 chr16 79297197 A C 6.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4392087 chr16 79307762 T C 9.39E-04 Depression (quantitative trait) / / 20800221 rs8046680 chr16 79308415 G A 8.89E-04 Depression (quantitative trait) / / 20800221 rs12596576 chr16 79308531 C T 2.42E-04 Depression (quantitative trait) / / 20800221 rs12924284 chr16 79308897 C T 8.02E-04 Depression (quantitative trait) / / 20800221 rs9806921 chr16 79312083 C T 2.34E-04 Depression (quantitative trait) / / 20800221 rs7194743 chr16 79315897 T C 3.98E-04 Depression (quantitative trait) / / 20800221 rs10871360 chr16 79316298 A G 8.40E-04 Depression (quantitative trait) / / 20800221 rs7193219 chr16 79316318 G A 5.30E-04 Depression (quantitative trait) / / 20800221 rs4888945 chr16 79316533 A G 5.17E-04 Depression (quantitative trait) / / 20800221 rs8054578 chr16 79316815 A G 2.89E-04 Depression (quantitative trait) / / 20800221 rs4888946 chr16 79317430 T A 4.08E-04 Depression (quantitative trait) / / 20800221 rs2347572 chr16 79318712 G C 2.65E-04 Depression (quantitative trait) / / 20800221 rs2881664 chr16 79318983 T C 4.26E-04 Depression (quantitative trait) / / 20800221 rs8056789 chr16 79319300 A T 1.28E-04 Depression (quantitative trait) / / 20800221 rs4888947 chr16 79319687 C A 4.22E-04 Depression (quantitative trait) / / 20800221 rs16950148 chr16 79325890 C G 6.36E-08 LDL cholesterol particle diameter / / 23263444 rs12934695 chr16 79328608 G A 0.000000167 LDL cholesterol particle diameter / / 23263444 rs1396702 chr16 79336647 T C 2.55E-04 Depression (quantitative trait) / / 20800221 rs1396702 chr16 79336647 T C 6.06E-05 Major depressive disorder / / pha002850 rs8054083 chr16 79339797 C T 0.000004 LDL cholesterol particle diameter / / 23263444 rs17710897 chr16 79346682 C T 6.71E-04 Depression (quantitative trait) / / 20800221 rs4888950 chr16 79347229 A G 0.00000138 LDL cholesterol particle diameter / / 23263444 rs17654551 chr16 79348840 G C 3.60E-06 Personality dimensions / / 21173776 rs17654551 chr16 79348840 G C 0.00000766 LDL cholesterol particle diameter / / 23263444 rs17724508 chr16 79350204 T C 5.36E-04 Multiple complex diseases / / 17554300 rs17724508 chr16 79350204 T C 1.50E-05 Urinary metabolites / / 21572414 rs8063785 chr16 79353312 T C 2.53E-06 Brachial circumference / / 22479309 rs16950229 chr16 79353333 C T 2.34E-06 Brachial circumference / / 22479309 rs6564659 chr16 79353419 C T 1.29E-04 Alzheimer's disease / / 24755620 rs8043805 chr16 79353899 A G 2.33E-06 Brachial circumference / / 22479309 rs7186445 chr16 79357795 C T 1.40E-06 Personality dimensions / / 21173776 rs7186445 chr16 79357795 C T 0.00000842 LDL cholesterol particle diameter / / 23263444 rs9927057 chr16 79360803 A G 8.83E-05 Tunica Media / / pha003038 rs1876763 chr16 79361201 C T 3.98E-04 Depression (quantitative trait) / / 20800221 rs9939416 chr16 79361953 G T 8.06E-04 Depression (quantitative trait) / / 20800221 rs2221705 chr16 79362411 C T 2.10E-06 Personality dimensions / / 21173776 rs2221705 chr16 79362411 C T 0.00000921 LDL cholesterol particle diameter / / 23263444 rs1121985 chr16 79363079 A C 6.85E-06 Obesity-related traits / / 23251661 rs7191820 chr16 79363814 A G 6.00E-06 Obesity-related traits / / 23251661 rs1553722 chr16 79375151 C G 9.03E-05 Type 2 diabetes / / 22158537 rs10514454 chr16 79379018 A G 5.72E-05 Type 2 diabetes / / 22158537 rs16950314 chr16 79379182 T C 4.43E-05 Type 2 diabetes / / 22158537 rs17724843 chr16 79381110 C G 1.05E-04 Type 2 diabetes / / 22158537 rs13333724 chr16 79382911 C G 6.08E-05 Type 2 diabetes / / 22158537 rs13334407 chr16 79386530 A T 3.05E-05 Type 2 diabetes / / 22158537 rs17724884 chr16 79389470 T C 9.41E-06 Type 2 diabetes / / 22158537 rs7198543 chr16 79392691 A G 8.86E-04 Type 2 diabetes / / 17463246 rs2068174 chr16 79393107 C T 8.27E-04 Type 2 diabetes / / 17463246 rs4888957 chr16 79398547 G A 9.31E-04 HIV-1 viral setpoint / / 17641165 rs12446038 chr16 79406034 G C 8.70E-04 Type 2 diabetes / / 17463246 rs17797882 chr16 79406918 C T 9.00E-07 Type 2 diabetes / / 22158537 rs17797882 chr16 79406918 C T 9.49E-07 Type 2 diabetes / / 23300278 rs3812994 chr16 79408669 T A 1.52E-05 Type 2 diabetes / / 22158537 rs3812993 chr16 79408826 G C 2.82E-05 Type 2 diabetes / / 22158537 rs11150157 chr16 79413110 C T 3.26E-04 Smoking initiation / / 24665060 rs4390610 chr16 79413669 C T 2.11E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7192960 chr16 79416563 C T 9.93E-04 Type 2 diabetes / / 17463246 rs7192960 chr16 79416563 C T 8.21E-04 Alzheimer's disease / / 24755620 rs4888966 chr16 79431853 G C 5.00E-06 Dental caries / / 23259602 rs4533297 chr16 79437045 A T 2.22E-05 IgE levels / / 22075330 rs16950383 chr16 79448778 G T 7.82E-04 Alzheimer's disease / / 24755620 rs11859724 chr16 79451166 C T 8.58E-05 Cognitive decline / / 22054870 rs11864863 chr16 79451202 T C 4.15E-05 Cognitive decline / / 22054870 rs7191732 chr16 79467703 C T 4.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7191732 chr16 79467703 C T 6.89E-05 Blood Pressure / / pha003047 rs7206380 chr16 79471714 C T 1.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4888984 chr16 79509334 T C 3.00E-06 Parkinson's disease / / 17052657 rs1423812 chr16 79512541 T G 5.60E-05 Personality dimensions / / 18957941 rs7199071 chr16 79519633 C T 4.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4888033 chr16 79520476 A C 4.40E-04 Stroke / / pha002886 rs11150170 chr16 79522673 T C 0.000896 Salmonella-induced pyroptosis / / 22837397 rs2549513 chr16 79550727 C A 9.65E-06 Cardiovascular disease / / 17903304 rs4558431 chr16 79560537 C G,T 1.80E-04 Type 2 diabetes / / 17463246 rs10514459 chr16 79562141 C T 8.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10514459 chr16 79562141 C T 4.96E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1345849 chr16 79565943 A G 2.72E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1364095 chr16 79566150 G C,T 7.78E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2347948 chr16 79566854 G A 1.77E-04 Taste perception / / 22132133 rs821233 chr16 79570069 T C 7.45E-05 Taste perception / / 22132133 rs821232 chr16 79570138 A C 2.07E-04 Cognitive decline / / 23732972 rs7498403 chr16 79585021 C T 5.00E-06 Height / / 20668459 rs12598123 chr16 79586741 T C 5.37E-05 Multiple sclerosis / / 17660530 rs16950694 chr16 79600776 A G 6.00E-04 Tourette syndrome / / 22889924 rs1541692 chr16 79608692 C T 8.59E-05 Serum metabolites / / 19043545 rs30408 chr16 79627282 C T 2.85E-04 Type 2 diabetes MAF nearGene-3 17463246 rs12597382 chr16 79641309 C A 5.42E-05 Self-reported allergy / / 23817569 rs8059614 chr16 79641363 C T 1.91E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs8045611 chr16 79642849 C T 1.55E-04 Fibrinogen / / 17255346 rs8045611 chr16 79642849 C T 6.15E-05 Self-reported allergy / / 23817569 rs889472 chr16 79645989 C A 1.00E-09 Renal function-related traits (urea) / / 22797727 rs17686166 chr16 79646953 C T 2.83E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs386965 chr16 79652541 C T 4.00E-06 Multiple sclerosis / / 21833088 rs9922527 chr16 79671625 T C 5.84E-04 Multiple complex diseases / / 17554300 rs1424233 chr16 79682751 T C 4.00E-13 Obesity / / 19151714 rs1424233 chr16 79682751 T C 1.00E-05 Smoking behavior / / 20418888 rs889791 chr16 79687003 G T 4.20E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7184694 chr16 79691318 C T 5.60E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7184694 chr16 79691318 C T 4.21E-04 Multiple complex diseases / / 17554300 rs1364339 chr16 79699967 G A 7.86E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4889009 chr16 79700447 G C 3.00E-07 Thyroid peroxidase antibody positivity / / 24586183 rs4888041 chr16 79702573 T A 7.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs8048539 chr16 79704152 T C 0.000095 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs11150187 chr16 79704412 C T 3.08E-04 Type 2 diabetes / / 17463246 rs11150187 chr16 79704412 C T 4.30E-05 Parkinson's disease (familial) / / 18985386 rs8047723 chr16 79704915 G T 1.82E-04 Type 2 diabetes / / 17463246 rs8047723 chr16 79704915 G T 5.60E-05 Parkinson's disease (familial) / / 18985386 rs7500666 chr16 79706406 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7188445 chr16 79734987 G A 2.00E-09 Urate levels / / 23263486 rs7190187 chr16 79735178 C T 1.18E-04 Thyroid stimulating hormone / / 24852370 rs8052812 chr16 79735653 G A 7.20E-07 Urinary metabolites / / 21572414 rs9941206 chr16 79738795 C G 2.00E-05 Urinary metabolites / / 21572414 rs12923295 chr16 79740249 C T 2.50E-06 Urinary metabolites / / 21572414 rs11150192 chr16 79741569 C T 2.80E-05 Serum metabolites / / 19043545 rs17767281 chr16 79742441 T C 6.05E-04 Type 2 diabetes / / 17463246 rs11150193 chr16 79742862 T C 7.20E-07 Urinary metabolites / / 21572414 rs16951117 chr16 79743350 C T 2.80E-05 Multiple complex diseases / / 17554300 rs17767383 chr16 79744401 G A 7.64E-04 Myopia (pathological) / / 21095009 rs17767383 chr16 79744401 G A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs17767419 chr16 79744548 C T 3.91E-04 Type 2 diabetes / / 17463246 rs17767419 chr16 79744548 C T 6.30E-05 Parkinson's disease (familial) / / 18985386 rs17767419 chr16 79744548 C T 9.00E-15 Thyroid volume / / 21565293 rs17767491 chr16 79745487 A G 2.37E-04 Type 2 diabetes / / 17463246 rs17767491 chr16 79745487 A G 7.30E-05 Parkinson's disease (familial) / / 18985386 rs7203756 chr16 79745606 A T 2.37E-04 Type 2 diabetes / / 17463246 rs7203756 chr16 79745606 A T 7.30E-05 Parkinson's disease (familial) / / 18985386 rs17767742 chr16 79749005 C G 5.24E-04 Type 2 diabetes / / 17463246 rs17767742 chr16 79749005 C G 6.60E-05 Parkinson's disease (familial) / / 18985386 rs3813579 chr16 79749276 G A 4.00E-10 Thyroid volume / / 21565293 rs3813582 chr16 79749353 T C 2.76E-04 Type 2 diabetes / / 17463246 rs3813582 chr16 79749353 T C 2.90E-05 Urinary metabolites / / 21572414 rs3813582 chr16 79749353 T C 6.00E-10 Thyroid function / / 22494929 rs3813582 chr16 79749353 T C 6.00E-17 Thyroid hormone levels / / 23408906 rs3813582 chr16 79749353 T C 8.00E-18 Thyroid hormone levels / / 23408906 rs17767904 chr16 79749975 G A 4.32E-04 Myopia (pathological) / / 21095009 rs4575545 chr16 79755446 G A 2.00E-06 Thyroid stimulating hormone / / 24852370 rs4334315 chr16 79756197 A T 6.65E-08 Thyroid function / / 22494929 rs17690030 chr16 79782150 C T 9.28E-04 Type 2 diabetes / / 17463246 rs4243182 chr16 79816247 G A 3.79E-04 Lung function (forced vital capacity) / / 24023788 rs11649168 chr16 79845969 C T 7.70E-06 Urinary metabolites / / 21572414 rs8043824 chr16 79847142 G A 5.48E-04 Diabetic nephropathy / / 21150874 rs3924889 chr16 79868499 A C 1.25E-05 Suicidal ideation / / 20877300 rs8061789 chr16 79871920 T C 9.16E-05 Waist-Hip Ratio / / pha003028 rs7184534 chr16 79882250 A C 5.53E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs7184534 chr16 79882250 A C 5.53E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs4329930 chr16 79896825 T C 2.69E-04 Myocardial Infarction / / pha002873 rs4267316 chr16 79902218 T C 9.47E-05 Myocardial Infarction / / pha002873 rs13336562 chr16 79904347 T G 2.94E-05 Serum metabolites / / 19043545 rs13338370 chr16 79906206 T C 6.80E-06 Serum metabolites / / 19043545 rs13337624 chr16 79910465 T C 8.18E-06 Serum metabolites / / 19043545 rs7188674 chr16 79923310 C T 1.68E-05 Serum metabolites / / 19043545 rs4274451 chr16 79936791 A G 2.08E-05 Serum metabolites / / 19043545 rs10514476 chr16 80023841 A G 2.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11645885 chr16 80032104 C A 6.33E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs9929759 chr16 80042989 C G 3.03E-04 Type 2 diabetes / / 17463246 rs11642717 chr16 80050661 A G 3.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11642717 chr16 80050661 A G 5.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs12449111 chr16 80052304 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12444808 chr16 80053766 C A 2.40E-05 Tooth agenesis (mandibular third molar) / / 24172245 rs11648597 chr16 80054863 A G 7.67E-05 Serum albumin level / / pha003084 rs4889067 chr16 80058041 C G 1.33E-04 Multiple complex diseases / / 17554300 rs4402582 chr16 80063069 A G 1.02E-04 Multiple complex diseases / / 17554300 rs12716881 chr16 80063680 C A 1.52E-04 Multiple complex diseases / / 17554300 rs8046585 chr16 80065370 G T 7.77E-06 Rheumatoid arthritis / / 19503088 rs28499095 chr16 80085406 G A 4.63E-04 Alzheimer's disease (late onset) / / 21379329 rs6564728 chr16 80096832 C T 7.16E-04 Multiple complex diseases / / 17554300 rs10514480 chr16 80131517 C T 8.48E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7201995 chr16 80138134 A G 9.88E-05 Serum metabolites / / 19043545 rs1110763 chr16 80157024 C T 7.54E-04 Type 2 diabetes / / 17463246 rs1110763 chr16 80157024 C T 3.40E-06 Urinary metabolites / / 21572414 rs16952477 chr16 80159704 A G 3.90E-06 Urinary metabolites / / 21572414 rs11862421 chr16 80181833 A T 2.69E-04 Cholesterol / / 17255346 rs8049125 chr16 80189487 T C 3.50E-04 Intelligence (childhood) / / 23358156 rs8060581 chr16 80192605 G C 1.00E-06 Presence of antiphospholipid antibodies / / 23509613 rs17796160 chr16 80220495 C T 9.36E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10083792 chr16 80233141 C T 9.13E-04 Type 2 diabetes / / 17463246 rs10514489 chr16 80235649 G C 9.79E-04 Type 2 diabetes / / 17463246 rs1564220 chr16 80237726 C A,T 5.01E-04 Type 2 diabetes / / 17463246 rs11150256 chr16 80303130 G A 2.90E-04 Schizophrenia / / 19197363 rs11150256 chr16 80303130 G A 2.65E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11859036 chr16 80305551 C A 7.00E-06 Corneal astigmatism / / 23761726 rs1518605 chr16 80313843 C G 7.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs11150269 chr16 80335253 C T 2.60E-05 Urinary metabolites / / 21572414 rs1401197 chr16 80337633 G A 9.80E-05 Blood Pressure / / pha003050 rs10514492 chr16 80360226 T G 7.15E-04 Type 2 diabetes / / 17463246 rs16952935 chr16 80362303 G A 3.78E-04 Multiple complex diseases / / 17554300 rs16952992 chr16 80367005 G C 3.52E-04 Multiple complex diseases / / 17554300 rs2679301 chr16 80367434 T C 7.75E-05 Intracranial aneurysm / / 22286173 rs11646667 chr16 80369307 C T 4.46E-04 Type 2 diabetes / / 17463246 rs2654467 chr16 80376022 T G 9.30E-04 Diabetic nephropathy / / 21150874 rs2626643 chr16 80378003 T A,G 1.73E-04 Intracranial aneurysm / / 22286173 rs11644170 chr16 80386315 C T 8.74E-05 Multiple complex diseases / / 17554300 rs6564756 chr16 80392158 T A 3.63E-04 Sudden cardiac arrest / / 21658281 rs16953111 chr16 80396925 G A 0.0000983 Uterine leiomyomata / / 23040493 rs9931203 chr16 80398965 A G 6.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9933411 chr16 80398966 T C 7.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13330837 chr16 80399555 C T 8.50E-06 Urinary metabolites / / 21572414 rs12716888 chr16 80399660 A T 2.60E-05 Urinary metabolites / / 21572414 rs12716889 chr16 80399712 T A 2.30E-05 Urinary metabolites / / 21572414 rs1484032 chr16 80415890 G T 8.96E-05 Multiple complex diseases / / 17554300 rs12924746 chr16 80427501 T A 5.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs2170823 chr16 80434491 G T 4.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs4889146 chr16 80436449 C A 8.09E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1110789 chr16 80440301 T C 7.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs1126264 chr16 80441136 T C 2.35E-04 Alzheimer's disease (late onset) / / 21379329 rs1125733 chr16 80452240 A G 4.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs35588118 chr16 80452240 AT A 4.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs11150282 chr16 80493705 C T 8.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs11150282 chr16 80493705 C T 5.88E-05 Telomere length / / 21573004 rs4581712 chr16 80497601 C A 3.00E-09 Liver enzyme levels (gamma-glutamyl transferase) / / 22001757 rs10871386 chr16 80519879 G A 5.34E-05 Serum metabolites / / 19043545 rs4491514 chr16 80526470 G A 4.93E-06 Socioeconomic Factors / / pha003066 rs4468638 chr16 80531515 G A 4.58E-05 Socioeconomic Factors / / pha003066 rs4533300 chr16 80549158 C T 2.86E-05 Socioeconomic Factors / / pha003066 rs4522433 chr16 80549258 G A 8.63E-05 Multiple complex diseases / / 17554300 rs8048886 chr16 80559659 T A 7.03E-05 Cytomegalovirus antibody response / / 21993531 rs4577099 chr16 80568573 C T 2.76E-05 Cytomegalovirus antibody response / / 21993531 rs4577099 chr16 80568573 C T 3.50E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs9928594 chr16 80570241 T C 2.78E-05 Cytomegalovirus antibody response / / 21993531 rs9938023 chr16 80570574 G A 2.80E-05 Cytomegalovirus antibody response / / 21993531 rs7204803 chr16 80614415 T C 5.83E-04 Sarcoidosis / / 19165924 rs12927176 chr16 80622841 G C 2.70E-05 Urinary metabolites / / 21572414 rs16953630 chr16 80623032 A G 5.83E-04 Multiple complex diseases / / 17554300 rs4613079 chr16 80643957 G A 5.06E-07 Blood pressure CDYL2 intron 21378095 rs4613079 chr16 80643957 G A 5.40E-10 Interleukin levels (IL10,IL1Ra,IL6),in plasma CDYL2 intron 22205395 rs13329835 chr16 80650805 A G 2.00E-16 Breast cancer CDYL2 intron 23535729 rs881083 chr16 80652783 A C 5.87E-04 Alzheimer's disease CDYL2 intron 22005930 rs12448290 chr16 80655883 T G 4.30E-04 Alcohol dependence CDYL2 intron 20201924 rs12448290 chr16 80655883 T G 8.80E-07 Urinary metabolites CDYL2 intron 21572414 rs12448290 chr16 80655883 T G 6.69E-04 Substance dependence CDYL2 intron 21818250 rs9927571 chr16 80656966 G T 2.60E-04 Alcohol dependence CDYL2 intron 20201924 rs4889171 chr16 80657544 G A 6.71E-05 Type 2 diabetes CDYL2 intron 17463246 rs2123279 chr16 80658749 G A 1.50E-04 Type 2 diabetes and 6 quantitative traits CDYL2 intron 17848626 rs11150298 chr16 80698896 C G 0.000621 Salmonella-induced pyroptosis CDYL2 intron 22837397 rs11863297 chr16 80703757 G A 8.57E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CDYL2 intron 20031582 rs8049284 chr16 80718879 A G 0.000009 Salmonella-induced pyroptosis CDYL2 cds-synon 22837397 rs8047798 chr16 80719086 G C 0.0000513 Salmonella-induced pyroptosis CDYL2 intron 22837397 rs896630 chr16 80723610 C T 0.0000859 Salmonella-induced pyroptosis CDYL2 intron 22837397 rs7202548 chr16 80727754 A G 0.0000709 Salmonella-induced pyroptosis CDYL2 intron 22837397 rs41472047 chr16 80745775 G A 8.00E-06 Smoking initiation CDYL2 intron 24665060 rs8047401 chr16 80747013 C T 2.34E-04 Taste perception CDYL2 intron 22132133 rs4580175 chr16 80754387 A G 7.75E-04 Smoking initiation CDYL2 intron 24665060 rs11644898 chr16 80754757 A C 4.92E-04 Endometrial cancer CDYL2 intron 24096698 rs11644898 chr16 80754757 A C 9.34E-04 Endometrial cancer CDYL2 intron 24096698 rs4513113 chr16 80760582 T C 6.53E-04 Smoking initiation CDYL2 intron 24665060 rs2316576 chr16 80770289 A T 9.13E-05 Schizophrenia CDYL2 intron 19571811 rs11150312 chr16 80796394 C T 3.90E-04 Type 2 diabetes CDYL2 intron 17463246 rs8055721 chr16 80803117 G T 4.38E-04 Type 2 diabetes CDYL2 intron 17463246 rs11643320 chr16 80810943 T G 2.18E-05 Personality dimensions CDYL2 intron 22628180 rs17761499 chr16 80818676 T C 8.50E-05 Multiple complex diseases CDYL2 intron 17554300 rs17761499 chr16 80818676 T C 8.89E-05 Otosclerosis CDYL2 intron 19230858 rs17761499 chr16 80818676 T C 2.56E-05 Personality dimensions CDYL2 intron 22628180 rs7204972 chr16 80821565 G T 1.80E-04 Multiple complex diseases CDYL2 intron 17554300 rs16954023 chr16 80821706 C G 1.23E-04 Multiple complex diseases CDYL2 intron 17554300 rs3114385 chr16 80824154 A G 2.03E-04 Taste perception CDYL2 intron 22132133 rs11645677 chr16 80834612 G A 8.53E-04 Taste perception CDYL2 intron 22132133 rs8053834 chr16 80844348 A G 2.75E-04 Taste perception / / 22132133 rs12448585 chr16 80849567 T C 6.21E-05 Hemoglobin / / pha003098 rs12448585 chr16 80849567 T C 9.05E-06 Erythrocyte counts / / pha003099 rs2580317 chr16 80855640 T C 4.23E-05 Erythrocyte counts / / pha003099 rs2432414 chr16 80892483 C T 1.64E-04 Arthritis (juvenile idiopathic) / / 22354554 rs2549904 chr16 80910193 A G 3.09E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9923415 chr16 80934859 A G 7.19E-05 Amyotrophic lateral sclerosis / / 20801717 rs1981868 chr16 80947996 G A 5.24E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7199467 chr16 80951145 A C 8.86E-04 Multiple complex diseases / / 17554300 rs9319558 chr16 80952299 A T 3.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7187344 chr16 80953051 G A 5.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12446053 chr16 80964131 G A 2.10E-04 Asperger disorder / / 21182207 rs2549841 chr16 81023572 G A 2.70E-05 Urinary metabolites CMC2 intron 21572414 rs2549854 chr16 81026639 A G 2.80E-05 Urinary metabolites CMC2 intron 21572414 rs2549855 chr16 81026852 C G 2.60E-05 Urinary metabolites CMC2 intron 21572414 rs2911150 chr16 81028799 T C 2.70E-05 Urinary metabolites CMC2 intron 21572414 rs1048194 chr16 81064702 G A 7.39E-12 Multiple complex diseases CENPN UTR-3 17554300 rs2602431 chr16 81070697 A G 6.60E-04 Asperger disorder ATMIN intron 21182207 rs2257378 chr16 81077915 T C 8.29E-05 Cognitive impairment induced by topiramate ATMIN cds-synon 22091778 rs145595395 chr16 81095485 G A 0.00028 Breast cancer C16orf46 STOP-GAIN 23555315 rs804889 chr16 81096539 T G 7.32E-04 Obesity (extreme) C16orf46 intron 21935397 rs10514513 chr16 81114183 C T 5.64E-05 HDL cholesterol / / pha003075 rs2123624 chr16 81147114 T C 5.17E-04 Multiple complex diseases PKD1L2 intron 17554300 rs8045357 chr16 81148438 T C 4.56E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PKD1L2 intron 20877124 rs8047530 chr16 81149871 A G 6.19E-05 Serum metabolites PKD1L2 intron 19043545 rs11640624 chr16 81149980 G A,C 7.28E-04 Coronary Artery Disease PKD1L2 intron 17634449 rs12933918 chr16 81154448 T C 1.70E-05 Urinary metabolites PKD1L2 intron 21572414 rs4889240 chr16 81156522 T C 7.00E-06 Attention deficit hyperactivity disorder and conduct disorder PKD1L2 intron 18951430 rs35008336 chr16 81159685 A T 1.80E-06 Coronary heart disease PKD1L2 intron 22319020 rs8059530 chr16 81160492 A G 7.38E-04 Coronary Artery Disease PKD1L2 intron 17634449 rs3826050 chr16 81167314 G A 6.54E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PKD1L2 intron 20877124 rs7204299 chr16 81170299 A G 2.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PKD1L2 intron 20877124 rs4889244 chr16 81173193 C T 4.45E-05 Cognitive test performance PKD1L2 missense 20125193 rs7190949 chr16 81189583 T C 0.0003966 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PKD1L2 intron 23233654 rs7190949 chr16 81189583 T C 3.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) PKD1L2 intron 23233662 rs74029003 chr16 81198254 T C 0.00026 Prostate cancer PKD1L2 missense 23555315 rs1901818 chr16 81204125 C G 1.69E-04 Parkinson's disease PKD1L2 UTR-3 17052657 rs1377464 chr16 81206701 T G 4.92E-04 Parkinson's disease PKD1L2 intron 17052657 rs745207 chr16 81207408 G C 6.53E-04 Parkinson's disease PKD1L2 intron 17052657 rs935933 chr16 81209234 C T 2.10E-04 Celiac disease PKD1L2 cds-synon 23936387 rs9319563 chr16 81219329 G T 1.61E-04 Multiple complex diseases PKD1L2 intron 17554300 rs9931907 chr16 81223296 C T 1.18E-04 Diabetic nephropathy PKD1L2 intron pha002866 rs7205673 chr16 81232275 G A 0.00056 Stroke PKD1L2 missense 23422753 rs10438611 chr16 81233418 T A 4.96E-04 Multiple complex diseases PKD1L2 intron 17554300 rs6420424 chr16 81242102 G A 9.21E-04 Type 2 diabetes PKD1L2 missense 17463246 rs6420424 chr16 81242102 G A 1.89E-09 Carotenoid and tocopherol levels PKD1L2 missense 19185284 rs8044334 chr16 81248935 T G 9.59E-10 Carotenoid and tocopherol levels PKD1L2 intron 19185284 rs8044334 chr16 81248935 T G 8.90E-05 Alcoholism (heaviness of drinking) PKD1L2 intron 21529783 rs11645428 chr16 81258896 G A 8.09E-04 Type 2 diabetes / / 17463246 rs11645428 chr16 81258896 G A 5.98E-13 Carotenoid and tocopherol levels / / 19185284 rs11645428 chr16 81258896 G A 5.96E-14 Lutein / / 23696881 rs12926540 chr16 81258987 T C 4.73E-11 Beta carotene / / 23696881 rs9708919 chr16 81260786 C T 4.03E-14 Lutein / / 23696881 rs6564851 chr16 81264597 T G 2.00E-24 Carotenoid and tocopherol levels / / 19185284 rs6564851 chr16 81264597 T G 1.26E-10 Beta carotene / / 23696881 rs4889293 chr16 81292730 C G 8.36E-05 Serum metabolites BCMO1 intron 19043545 rs4889294 chr16 81303759 T C 5.00E-07 Protein quantitative trait loci BCMO1 intron 18464913 rs4889294 chr16 81303759 T C 2.03E-04 Alcohol consumption (maxi-drinks) BCMO1 intron 24277619 rs9937350 chr16 81307584 C T 5.44E-06 Serum metabolites BCMO1 intron 19043545 rs3803651 chr16 81318882 A G 0.00065814 Hypertension (early onset hypertension) BCMO1 intron 22479346 rs11647597 chr16 81321298 T G 0.000653396 Hypertension (early onset hypertension) BCMO1 intron 22479346 rs918775 chr16 81333568 T C 9.22E-05 Multiple complex diseases / / 17554300 rs918776 chr16 81333636 T C 6.10E-05 Multiple complex diseases / / 17554300 rs11639552 chr16 81334796 T C 5.75E-05 Multiple complex diseases / / 17554300 rs17186765 chr16 81335081 C T 4.53E-04 Type 2 diabetes / / 17463246 rs17186765 chr16 81335081 C T 7.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs11859133 chr16 81335103 T C 1.07E-04 Multiple complex diseases / / 17554300 rs889747 chr16 81338874 C G 9.24E-05 Multiple complex diseases / / 17554300 rs9889027 chr16 81341363 G A 3.20E-05 Multiple complex diseases / / 17554300 rs2216768 chr16 81359825 G A 1.08E-04 Response to taxane treatment (placlitaxel) GAN intron 23006423 rs1820260 chr16 81374504 G C 1.68E-04 Multiple complex diseases GAN intron 17554300 rs12448813 chr16 81396574 G C 2.67E-04 Multiple complex diseases GAN intron 17554300 rs2161728 chr16 81400177 A G 5.23E-04 Multiple complex diseases GAN intron 17554300 rs16955238 chr16 81415691 T C 2.41E-04 Type 2 diabetes / / 17463246 rs16955238 chr16 81415691 T C 5.64E-118 Multiple complex diseases / / 17554300 rs16955255 chr16 81420131 G C 2.41E-04 Type 2 diabetes / / 17463246 rs310020 chr16 81421075 A G 3.48E-04 Multiple complex diseases / / 17554300 rs310020 chr16 81421075 A G 4.45E-05 Aging (time to event) / / 21782286 rs11643220 chr16 81422926 G A 5.03E-05 Cognitive performance / / 19734545 rs11643220 chr16 81422926 G A 7.35E-05 Waist Circumference / / pha003023 rs12149466 chr16 81429258 C G 7.61E-04 Multiple complex diseases / / 17554300 rs12924670 chr16 81433070 T C 2.96E-04 Cholesterol / / 17255346 rs8044853 chr16 81457659 C T 5.81E-04 Type 2 diabetes / / 22158537 rs8051009 chr16 81459415 T G 6.39E-04 Type 2 diabetes / / 22158537 rs310008 chr16 81473649 C G 4.00E-06 Menarche (age at onset) / / 23667675 rs1563655 chr16 81475932 G A 3.77E-06 Hearing function / / 21493956 rs1563655 chr16 81475932 G A 8.61E-06 Hearing function / / 21493956 rs16955379 chr16 81489373 C T 3.00E-07 Type 2 diabetes CMIP intron 22158537 rs9930117 chr16 81489957 A C 8.54E-06 Type 2 diabetes CMIP intron 22158537 rs12596103 chr16 81490553 C T 5.69E-07 Type 2 diabetes CMIP intron 22158537 rs12596138 chr16 81490749 C T 2.47E-06 Type 2 diabetes CMIP intron 22158537 rs12599890 chr16 81496902 G A,C,T 1.93E-06 Type 2 diabetes CMIP intron 22158537 rs12596548 chr16 81503877 C T 4.19E-05 Type 2 diabetes CMIP intron 22158537 rs2927324 chr16 81512821 C T 9.41E-04 Response to taxane treatment (placlitaxel) CMIP intron 23006423 rs16955433 chr16 81517119 C T 5.39E-04 Tourette syndrome CMIP intron 22889924 rs2926003 chr16 81522281 C T 1.80E-05 Parkinson's disease (age of onset) CMIP intron 19772629 rs2926003 chr16 81522281 C T 2.98E-05 Tunica Media CMIP intron pha003038 rs7193307 chr16 81526302 G A 1.38E-04 Suicide attempts in bipolar disorder CMIP intron 21423239 rs12932649 chr16 81526836 C T 4.65E-05 Suicide attempts in bipolar disorder CMIP intron 21423239 rs2927311 chr16 81531230 C G 6.36E-05 Suicide attempts in bipolar disorder CMIP intron 21423239 rs4889326 chr16 81533662 C T 3.15E-05 Suicide attempts in bipolar disorder CMIP intron 21423239 rs2925979 chr16 81534790 T C 2.00E-11 HDL cholesterol CMIP intron 20686565 rs2925979 chr16 81534790 T C 3.00E-21 Adiponectin levels CMIP intron 22479202 rs2925979 chr16 81534790 T C 1.00E-19 HDL cholesterol CMIP intron 24097068 rs2925979 chr16 81534790 T C 2.00E-10 Adiponectin levels CMIP intron 24105470 rs4889327 chr16 81536652 C T 8.73E-05 Suicide attempts in bipolar disorder CMIP intron 21423239 rs12920728 chr16 81538842 G A 5.09E-05 Suicide attempts in bipolar disorder CMIP intron 21423239 rs16955460 chr16 81541681 C T 1.75E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CMIP intron 20031582 rs8182218 chr16 81547687 T G 5.07E-05 Suicide attempts in bipolar disorder CMIP intron 21423239 rs2925991 chr16 81555951 A C 0.00007409 Sarcoidosis CMIP intron 22952805 rs7196069 chr16 81561456 G C 1.53E-04 Multiple complex diseases CMIP intron 17554300 rs12933858 chr16 81566121 C T 3.62E-06 Hearing function CMIP intron 21493956 rs4889334 chr16 81566182 C G 3.65E-06 Hearing function CMIP intron 21493956 rs898967 chr16 81566780 C T 3.07E-06 Hearing function CMIP intron 21493956 rs898967 chr16 81566780 C T 9.64E-07 Hearing function CMIP intron 21493956 rs13333159 chr16 81568064 T G 2.99E-04 Multiple complex diseases CMIP intron 17554300 rs16955523 chr16 81569273 G A 3.41E-04 Multiple complex diseases CMIP intron 17554300 rs1870924 chr16 81571979 T G 5.70E-06 Urinary metabolites CMIP intron 21572414 rs12932885 chr16 81579923 C T 0.000483 Salmonella-induced pyroptosis CMIP intron 22837397 rs2911276 chr16 81595186 G A 6.91E-05 Cardiovascular disease CMIP intron pha003064 rs2966121 chr16 81596370 A G 4.60E-06 Urinary metabolites CMIP intron 21572414 rs12929474 chr16 81617327 C A 5.46E-04 Obesity (extreme) CMIP intron 21935397 rs4889348 chr16 81633117 G A 0.0000324 Primary sclerosing cholangitis CMIP intron 23603763 rs9927231 chr16 81644289 A G 6.73E-04 Amyotrophic lateral sclerosis (sporadic) CMIP intron 24529757 rs11150394 chr16 81649454 A G 9.76E-04 Suicide attempts in bipolar disorder CMIP intron 21423239 rs3924153 chr16 81659267 A G 9.76E-05 Myocardial Infarction CMIP intron pha002873 rs7205166 chr16 81675733 G A 4.54E-04 Tourette syndrome CMIP intron 22889924 rs16955713 chr16 81678049 T G 5.80E-04 Insulin resistance CMIP intron 21901158 rs11644382 chr16 81707252 G A 8.90E-06 Urinary metabolites CMIP intron 21572414 rs11647444 chr16 81716880 T C 8.30E-07 Urinary metabolites CMIP intron 21572414 rs753108 chr16 81728981 A G 8.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CMIP intron 20877124 rs3751859 chr16 81735012 G A 8.83E-05 Information processing speed CMIP intron 21130836 rs1128432 chr16 81745097 T C 4.16E-05 Height CMIP UTR-3 pha003011 rs4889373 chr16 81747602 A G 2.90E-05 Height / / pha003011 rs12446319 chr16 81774798 T C 9.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs12931598 chr16 81802714 C G 2.79E-05 Bipolar disorder / / 20451256 rs11864983 chr16 81822707 A G 6.68E-04 Multiple complex diseases PLCG2 intron 17554300 rs12598194 chr16 81825054 C T 1.74E-05 Bipolar disorder and schizophrenia PLCG2 intron 20889312 rs4293371 chr16 81826853 G C 6.65E-04 Suicide attempts in bipolar disorder PLCG2 intron 21423239 rs4889409 chr16 81866586 G C 1.40E-05 Urinary metabolites PLCG2 intron 21572414 rs12445050 chr16 81870969 C T 7.80E-06 Urinary metabolites PLCG2 intron 21572414 rs13334419 chr16 81875483 A G 1.42E-04 Multiple complex diseases PLCG2 intron 17554300 rs4497678 chr16 81884513 C G 8.22E-05 Type 2 diabetes PLCG2 intron 17463246 rs4072683 chr16 81887541 T C 4.26E-04 Myocardial Infarction PLCG2 intron pha002883 rs7189843 chr16 81902139 G C 6.00E-05 Height PLCG2 intron 19396169 rs4888184 chr16 81907481 G A 5.63E-04 Multiple complex diseases PLCG2 intron 17554300 rs4888184 chr16 81907481 G A 2.10E-05 Urinary metabolites PLCG2 intron 21572414 rs8055576 chr16 81920530 G T 9.39E-05 Response to hepatitis C treatment PLCG2 intron 19684573 rs4889428 chr16 81924994 C T 7.82E-04 Stroke PLCG2 intron pha002887 rs1143689 chr16 81941319 C T 6.06E-05 Left ventricular hypertrophy PLCG2 cds-synon pha003052 rs3922849 chr16 81955177 C T 4.27E-05 Parkinson's disease PLCG2 intron 17052657 rs13331678 chr16 81955298 T C 5.31E-05 Coronary heart disease PLCG2 intron pha003035 rs7192724 chr16 81958298 C G 3.00E-06 Breast cancer (menopausal hormone therapy interaction) PLCG2 intron 24080446 rs17202296 chr16 81959191 G C 2.80E-05 Breast cancer (menopausal hormone therapy interaction) PLCG2 intron 24080446 rs7201045 chr16 81959952 A G 9.02E-05 Ulcerative colitis PLCG2 intron 19915573 rs8063604 chr16 81960200 A G 2.77E-05 Ulcerative colitis PLCG2 intron 19915573 rs12446596 chr16 81960365 C T 2.45E-05 Ulcerative colitis PLCG2 intron 19915573 rs3813009 chr16 81960958 G C 4.00E-06 IgG glycosylation PLCG2 intron 23382691 rs3813009 chr16 81960958 G C 4.00E-07 IgG glycosylation PLCG2 intron 23382691 rs4888190 chr16 81963618 G T 4.50E-05 Breast cancer (menopausal hormone therapy interaction) PLCG2 intron 24080446 rs4284633 chr16 81980740 A G 2.24E-05 Cognitive impairment induced by topiramate PLCG2 intron 22091778 rs4312298 chr16 81981176 T G 7.00E-06 Alcohol dependence PLCG2 intron 21956439 rs4889447 chr16 81982491 T C 1.33E-04 Type 2 diabetes PLCG2 intron 17463246 rs12444401 chr16 81982624 C G 4.76E-04 Multiple complex diseases PLCG2 intron 17554300 rs4888197 chr16 81984437 A G 1.32E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) PLCG2 intron 23648065 rs4889448 chr16 81985595 C T 3.95E-05 Parkinson's disease (motor and cognition) PLCG2 intron 22658654 rs4889448 chr16 81985595 C T 3.95E-05 Immune response to anthrax vaccine PLCG2 intron 22658931 rs4888199 chr16 81989382 G C 2.09E-04 Suicide attempts in bipolar disorder PLCG2 intron 21423239 rs4243226 chr16 81993974 A G 2.50E-05 Urinary metabolites / / 21572414 rs9938764 chr16 81999406 A G 1.32E-05 Cognitive test performance / / 20125193 rs4580155 chr16 82002104 T C 8.00E-06 Alcohol dependence / / 21956439 rs12716930 chr16 82007607 G A 2.63E-25 Narcolepsy / / 19629137 rs11443 chr16 82031448 T C 2.53E-04 Alzheimer's disease SDR42E1 UTR-3 17998437 rs41526051 chr16 82045890 G C 3.90E-04 Alzheimer's disease / / 17998437 rs41526051 chr16 82045890 G C 1.64E-04 Alzheimer's disease / / 24755620 rs11648233 chr16 82075317 C A 0.000091 Erectile dysfunction after radiotherapy for prostate cancer HSD17B2 intron 23021708 rs8046533 chr16 82082978 C G 5.72E-17 Multiple complex diseases HSD17B2 intron 17554300 rs2042429 chr16 82113471 C T 2.37E-05 Multiple sclerosis (brain glutamate levels) HSD17B2 intron 20802204 rs10514523 chr16 82117764 G A 4.83E-04 Insulin resistance HSD17B2 intron 21901158 rs10514529 chr16 82143687 A G 8.53E-04 Obesity (extreme) / / 21935397 rs11639926 chr16 82152710 G T 4.80E-05 Type 2 diabetes / / 17463246 rs9940865 chr16 82168019 A G 4.36E-04 Alzheimer's disease / / 17998437 rs11647519 chr16 82168234 G T 4.58E-04 Alzheimer's disease / / 17998437 rs8050864 chr16 82170431 T G 3.27E-04 Multiple complex diseases / / 17554300 rs7192444 chr16 82180338 G C 2.46E-06 Type 2 diabetes / / 17463246 rs11647563 chr16 82193496 T C 4.22E-04 Alzheimer's disease MPHOSPH6 intron 17998437 rs2967355 chr16 82200103 A C 9.07E-06 Type 2 diabetes MPHOSPH6 intron 17463246 rs12597171 chr16 82200119 C T 1.35E-04 Type 2 diabetes MPHOSPH6 intron 17463246 rs12597534 chr16 82200276 G T 1.44E-04 Type 2 diabetes MPHOSPH6 intron 17463246 rs10514532 chr16 82200337 T C 1.35E-04 Type 2 diabetes MPHOSPH6 intron 17463246 rs7205534 chr16 82201618 G A 1.46E-04 Type 2 diabetes MPHOSPH6 intron 17463246 rs10514533 chr16 82202376 C G,T 3.33E-04 Alzheimer's disease MPHOSPH6 intron 17998437 rs3829552 chr16 82206486 C A 2.30E-04 Alzheimer's disease / / 17998437 rs1862820 chr16 82208282 G C 5.58E-05 Lymphocyte counts / / 22286170 rs2967374 chr16 82209861 A G 2.70E-07 Telomere length / / 23535734 rs2967379 chr16 82213311 A G 4.30E-04 Type 2 diabetes / / 23209189 rs918763 chr16 82219643 C G 5.55E-04 Multiple complex diseases / / 17554300 rs7206226 chr16 82222920 C A 1.55E-04 Multiple complex diseases / / 17554300 rs1424153 chr16 82223485 A C 6.85E-04 Alzheimer's disease / / 17998437 rs1424153 chr16 82223485 A C 7.60E-05 Personality dimensions / / 18957941 rs1364288 chr16 82226717 C T 7.36E-04 Alzheimer's disease / / 17998437 rs2967391 chr16 82230392 T G 7.82E-05 Alzheimer's disease / / 17998437 rs2967391 chr16 82230392 T G 1.72E-05 Alcohol consumption / / 23743675 rs2967391 chr16 82230392 T G 1.52E-04 Alzheimer's disease / / pha002879 rs2911411 chr16 82231125 G A 1.75E-05 Alcohol consumption / / 23743675 rs2967393 chr16 82231669 T C 1.26E-04 Alzheimer's disease / / 17998437 rs2967393 chr16 82231669 T C 2.32E-05 Alcohol consumption / / 23743675 rs2967394 chr16 82231805 C T 2.29E-05 Alcohol consumption / / 23743675 rs929892 chr16 82232444 G A 1.82E-05 Alcohol consumption / / 23743675 rs2967395 chr16 82233063 G C 1.93E-05 Alcohol consumption / / 23743675 rs9944350 chr16 82247882 A T 1.72E-05 Alcohol consumption / / 23743675 rs1967095 chr16 82252003 T C 5.58E-05 Alzheimer's disease / / 17998437 rs2967407 chr16 82252059 G C 1.16E-04 Alzheimer's disease / / 17998437 rs2967408 chr16 82252681 G A 6.51E-05 Alzheimer's disease / / 17998437 rs11862388 chr16 82255428 G A 2.14E-04 Alzheimer's disease / / 17998437 rs1979649 chr16 82256742 T C 6.10E-04 Alzheimer's disease / / 17998437 rs2932814 chr16 82257367 C T 1.64E-04 Alzheimer's disease / / 17998437 rs2967340 chr16 82257551 G A 1.42E-04 Alzheimer's disease / / 17998437 rs2967340 chr16 82257551 G A 2.14E-04 Alzheimer's disease / / pha002879 rs2967339 chr16 82257594 A G 2.91E-04 Alzheimer's disease / / 17998437 rs902542 chr16 82259866 A G 2.77E-04 Alzheimer's disease / / 17998437 rs2967337 chr16 82262556 G A 1.31E-05 Alzheimer's disease / / 17998437 rs7187181 chr16 82274265 C T 3.12E-05 Magnesium levels / / pha003092 rs12102745 chr16 82282017 A G 6.04E-05 Alcohol consumption / / 23743675 rs12599930 chr16 82282091 C A 9.98E-05 Type 2 diabetes / / 17463246 rs4782727 chr16 82301047 A C 3.22E-04 Alcohol dependence / / 20201924 rs2967319 chr16 82303735 C T 6.60E-04 Depression (quantitative trait) / / 20800221 rs2932821 chr16 82306343 G A 8.87E-04 Type 2 diabetes / / 17463246 rs10514535 chr16 82318045 C T 2.30E-05 Urinary metabolites / / 21572414 rs11863065 chr16 82326805 G A 1.00E-06 Obesity-related traits / / 23251661 rs11863065 chr16 82326805 G A 1.00E-07 Obesity-related traits / / 23251661 rs11863065 chr16 82326805 G A 3.00E-06 Obesity-related traits / / 23251661 rs11863065 chr16 82326805 G A 4.00E-07 Obesity-related traits / / 23251661 rs11863065 chr16 82326805 G A 5.00E-06 Obesity-related traits / / 23251661 rs11863065 chr16 82326805 G A 9.00E-06 Obesity-related traits / / 23251661 rs11863065 chr16 82326805 G A 9.00E-07 Obesity-related traits / / 23251661 rs4087296 chr16 82377781 T C 3.00E-07 Bone mineral density / / 17903296 rs4082514 chr16 82379953 G T 3.00E-06 Cognitive performance / / 19734545 rs4476170 chr16 82408873 C A 6.80E-05 Information processing speed / / 21130836 rs9932820 chr16 82420374 G A 5.27E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs8051567 chr16 82422015 G T 1.70E-05 Non-word repetition / / 23738518 rs7195081 chr16 82422113 A G 5.84E-04 Multiple complex diseases / / 17554300 rs4782872 chr16 82429066 A G 9.99E-04 Multiple complex diseases / / 17554300 rs4782872 chr16 82429066 A G 4.99E-05 Serum metabolites / / 19043545 rs1019959 chr16 82431694 C A 6.56E-04 Rheumatoid arthritis / / 21452313 rs3901526 chr16 82446005 G T 8.92E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs3909533 chr16 82447491 A G 9.08E-07 Non-word repetition / / 23738518 rs7202694 chr16 82447854 A G 6.33E-06 Prostate cancer / / 22923026 rs7202694 chr16 82447854 A G 5.69E-07 Non-word repetition / / 23738518 rs7202575 chr16 82448109 C T 2.92E-06 Prostate cancer / / 22923026 rs7202575 chr16 82448109 C T 9.08E-07 Non-word repetition / / 23738518 rs7196091 chr16 82448358 C T 1.21E-07 Non-word repetition / / 23738518 rs956315 chr16 82448987 G A 1.21E-07 Non-word repetition / / 23738518 rs2161694 chr16 82450206 G T 1.31E-07 Non-word repetition / / 23738518 rs1025066 chr16 82450318 G T 1.74E-07 Non-word repetition / / 23738518 rs1025065 chr16 82451159 T G 2.01E-06 Rheumatoid arthritis / / 21452313 rs1025065 chr16 82451159 T G 3.10E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs6565017 chr16 82454231 G T 1.61E-07 Non-word repetition / / 23738518 rs11649273 chr16 82455819 T C 1.38E-04 Rheumatoid arthritis / / 21452313 rs1424049 chr16 82457618 G T 1.32E-07 Non-word repetition / / 23738518 rs7187223 chr16 82457733 A G 5.21E-05 Attention deficit hyperactivity disorder / / 18980221 rs7187223 chr16 82457733 A G 1.00E-07 Non-word repetition / / 23738518 rs8047238 chr16 82459672 C A 1.28E-04 Rheumatoid arthritis / / 21452313 rs8053728 chr16 82485251 C T 6.00E-06 Response to fenofibrate (adiponectin levels) / / 23149075 rs16957495 chr16 82513058 T G 2.10E-04 Type 2 diabetes / / 17463246 rs1862798 chr16 82516361 G C 1.96E-04 Type 2 diabetes / / 17463246 rs1991867 chr16 82519228 C T 4.00E-06 D-dimer levels / / 21502573 rs1991867 chr16 82519228 C T 2.00E-09 White matter microstructure (global fractional anisotropy) / / 24736177 rs17241197 chr16 82527281 A G 5.35E-05 Type 2 diabetes / / 17463246 rs964745 chr16 82540806 C G 1.72E-04 Type 2 diabetes / / 17463246 rs3859079 chr16 82548434 C G 1.80E-05 Parkinson's disease (familial) / / 18985386 rs10514541 chr16 82552789 G T 0.000771 Salmonella-induced pyroptosis / / 22837397 rs10514542 chr16 82557684 G C 6.98E-06 Cardiovascular disease / / 18179892 rs7198864 chr16 82561702 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs17242561 chr16 82562346 T C 2.94E-04 Taste perception / / 22132133 rs7201898 chr16 82592769 T C 9.67E-05 Femoral neck bone geometry / / 22087292 rs4783227 chr16 82594383 T C 4.00E-07 Response to antipsychotic treatment / / 20195266 rs7184080 chr16 82608735 G C 3.67E-05 Multiple complex diseases / / 17554300 rs16957747 chr16 82609532 A G 9.10E-06 Urinary metabolites / / 21572414 rs11646213 chr16 82642651 A T 8.00E-06 Hypertension / / 19304780 rs11646213 chr16 82642651 A T 8.00E-06 Coronary heart disease / / 21347282 rs4783238 chr16 82644583 T G 1.12E-06 Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel) / / 24025145 rs3852724 chr16 82646094 A C 3.21E-05 Adiponectin levels / / 20887962 rs12596316 chr16 82646152 A G 1.93E-10 Adiponectin levels / / 20887962 rs3844412 chr16 82646333 A G 4.00E-07 Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel) / / 24025145 rs3865185 chr16 82646462 T A 3.21E-05 Adiponectin levels / / 20887962 rs3865186 chr16 82646972 G A 3.09E-05 Adiponectin levels / / 20887962 rs3865186 chr16 82646972 G A 3.19E-04 Adiponectin levels / / 22065538 rs3865188 chr16 82650717 A T 4.00E-30 Adiponectin levels / / 20876611 rs3865188 chr16 82650717 A T 3.00E-83 Adiponectin levels / / 20887962 rs7193788 chr16 82656160 A G 1.07E-06 Adiponectin levels / / 20887962 rs7193788 chr16 82656160 A G 3.51E-07 Adiponectin levels / / 22065538 rs6565051 chr16 82658728 G A 1.14E-09 Adiponectin levels / / 20887962 rs7204454 chr16 82659194 G C 5.15E-09 Adiponectin levels / / 20887962 rs4783244 chr16 82662268 G T 6.00E-17 Adiponectin levels CDH13 intron 21771975 rs4783244 chr16 82662268 G T 5.06E-10 Adiponectin levels CDH13 intron 22065538 rs4783244 chr16 82662268 G T 7.00E-165 Adiponectin levels CDH13 intron 24105470 rs12051272 chr16 82663288 G T 5.00E-40 Adiponectin levels CDH13 intron 22065538 rs12051272 chr16 82663288 G T 1.00E-14 Adiponectin levels CDH13 intron 22479202 rs12051272 chr16 82663288 G T 6.00E-48 Adiponectin levels CDH13 intron 22479202 rs139419280 chr16 82664833 G A 8.00E-06 Serum dimethylarginine levels (symmetric) CDH13 intron 24159190 rs8047711 chr16 82667671 G A 3.96E-06 Adiponectin levels CDH13 intron 22065538 rs16957913 chr16 82670249 T C 1.38E-11 Adiponectin levels CDH13 intron 20887962 rs12599599 chr16 82670539 G A 3.83E-12 Adiponectin levels CDH13 intron 20887962 rs12597537 chr16 82670636 A G 6.70E-12 Adiponectin levels CDH13 intron 20887962 rs8057927 chr16 82692812 T C 1.00E-06 Schizophrenia CDH13 intron 23358160 rs8050316 chr16 82696136 C A 1.40E-05 Urinary metabolites CDH13 intron 21572414 rs4782726 chr16 82701333 A G 2.50E-05 Prostate cancer CDH13 intron 18264096 rs11640875 chr16 82721424 A G 2.01E-05 Alcohol dependence CDH13 intron 19581569 rs11640875 chr16 82721424 A G 2.10E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CDH13 intron 24023788 rs11640875 chr16 82721424 A G 5.54E-04 Myocardial Infarction CDH13 intron pha002873 rs11646411 chr16 82746937 C G 7.00E-06 Attention deficit hyperactivity disorder CDH13 intron 18839057 rs12598803 chr16 82776312 C T 0.0007127 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH13 intron 23233654 rs12598803 chr16 82776312 C T 7.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH13 intron 23233662 rs12600161 chr16 82779603 T C 0.0006813 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH13 intron 23233654 rs12600161 chr16 82779603 T C 6.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH13 intron 23233662 rs41345948 chr16 82784440 T C 4.58E-05 Multiple complex diseases CDH13 intron 17554300 rs4395067 chr16 82786040 G A 9.57E-05 Psoriasis CDH13 intron 20953190 rs8056064 chr16 82787053 A G 2.00E-06 Multiple myeloma (IgH translocation) CDH13 intron 23502783 rs8043851 chr16 82812366 A G 6.26E-04 Tourette syndrome CDH13 intron 22889924 rs17276586 chr16 82812773 T C 4.52E-04 Multiple complex diseases CDH13 intron 17554300 rs12920400 chr16 82812959 C A 4.70E-05 Psoriasis CDH13 intron 19169255 rs11646849 chr16 82817251 G A 1.60E-05 Personality dimensions CDH13 intron 18957941 rs11642248 chr16 82817263 A G 2.62E-04 Tourette syndrome CDH13 intron 22889924 rs12386026 chr16 82817591 C T 2.00E-06 Tuberculosis CDH13 intron 20694014 rs7185386 chr16 82821672 C G 9.99E-04 Type 2 diabetes CDH13 intron 17463246 rs7186123 chr16 82821752 A C 2.99E-04 Type 2 diabetes CDH13 intron 17463246 rs7184426 chr16 82821908 G A 5.50E-04 Diabetic retinopathy CDH13 intron 20871662 rs12447750 chr16 82823027 C A 2.60E-05 Urinary metabolites CDH13 intron 21572414 rs8056579 chr16 82823424 A G 2.53E-05 Personality dimensions CDH13 intron 18957941 rs8056579 chr16 82823424 A G 2.50E-05 Personality dimensions CDH13 intron 21173776 rs8057014 chr16 82831914 T G 1.69E-04 Birth weight CDH13 intron 17255346 rs9930305 chr16 82851107 C G 0.0006462 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH13 intron 23233654 rs9930305 chr16 82851107 C G 6.46E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH13 intron 23233662 rs4782733 chr16 82852296 C A 4.19E-05 Alzheimer's disease CDH13 intron 17998437 rs2549147 chr16 82855349 A G 0.0005949 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH13 intron 23233654 rs2549147 chr16 82855349 A G 5.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH13 intron 23233662 rs2549146 chr16 82858144 G A 0.0001951 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH13 intron 23233654 rs2549146 chr16 82858144 G A 1.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH13 intron 23233662 rs2549151 chr16 82860249 G T 1.01E-04 Vaspin levels CDH13 intron 22907691 rs2549151 chr16 82860249 G T 0.0000521 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit CDH13 intron 22907730 rs2549151 chr16 82860249 G T 0.0001008 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks CDH13 intron 22907730 rs11647270 chr16 82861704 A G 0.0003435 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH13 intron 23233654 rs11647270 chr16 82861704 A G 3.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH13 intron 23233662 rs10492859 chr16 82861814 A G 2.42E-05 Lipid levels CDH13 intron 19016617 rs10492859 chr16 82861814 A G 2.77E-04 Lipid levels CDH13 intron 19016617 rs10492859 chr16 82861814 A G 9.45E-04 Major depressive disorder CDH13 intron 22472876 rs2549153 chr16 82861932 G A 0.0006355 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH13 intron 23233654 rs2549153 chr16 82861932 G A 6.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH13 intron 23233662 rs1903623 chr16 82863283 G A 9.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH13 intron 23233662 rs2156 chr16 82864466 A C 7.85E-05 Bipolar disorder and schizophrenia CDH13 intron 20889312 rs1982608 chr16 82864780 A G 0.0008769 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH13 intron 23233654 rs1982608 chr16 82864780 A G 8.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH13 intron 23233662 rs17673191 chr16 82892426 G A 1.42E-04 Alzheimer's disease CDH13 intron 22005930 rs17673376 chr16 82895800 A G 3.75E-04 Alzheimer's disease CDH13 intron 22005930 rs11647182 chr16 82896398 A G 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer CDH13 intron 21245432 rs16958782 chr16 82896849 G A 3.74E-05 Bipolar disorder and schizophrenia CDH13 intron 20889312 rs11150506 chr16 82902451 A C 8.76E-05 Major depressive disorder CDH13 intron 21621269 rs7201088 chr16 82907020 C G 6.60E-06 Urinary metabolites CDH13 intron 21572414 rs2059230 chr16 82916682 T C 1.40E-05 Urinary metabolites CDH13 intron 21572414 rs4783293 chr16 82919690 C T 8.90E-06 Urinary metabolites CDH13 intron 21572414 rs12928678 chr16 82922580 T G 4.31E-05 Basophils CDH13 intron pha003087 rs12933472 chr16 82924685 G A 5.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDH13 intron 20877124 rs2216739 chr16 82926244 G A 9.23E-05 Serum metabolites CDH13 intron 19043545 rs11150517 chr16 82929611 T G 2.80E-05 Urinary metabolites CDH13 intron 21572414 rs11150518 chr16 82929728 G A 1.01E-04 Nicotine smoking CDH13 intron 19268276 rs17674675 chr16 82935671 A G 0.000365183 Hypertension (early onset hypertension) CDH13 intron 22479346 rs9319578 chr16 82936043 A G 5.41E-05 Substance dependence CDH13 intron 21818250 rs17675094 chr16 82949088 G C 1.35E-04 Multiple complex diseases CDH13 intron 17554300 rs17675602 chr16 82962763 A T 5.00E-06 Migraine - clinic-based CDH13 intron 23793025 rs11639621 chr16 82987872 T G 2.36E-04 Multiple complex diseases CDH13 intron 17554300 rs11648843 chr16 82988025 A C 1.42E-04 Multiple complex diseases CDH13 intron 17554300 rs12597778 chr16 82994130 T C 8.51E-04 Myocardial Infarction CDH13 intron pha002873 rs7404645 chr16 83020528 G A 2.78E-05 Coronary heart disease CDH13 intron pha003030 rs10492871 chr16 83020829 G A 5.26E-05 Personality dimensions CDH13 intron 18957941 rs6565099 chr16 83038982 T C 9.76E-04 Response to TNF antagonist treatment CDH13 intron 21061259 rs8057458 chr16 83060151 C G 8.80E-06 Personality dimensions CDH13 intron 21173776 rs7498488 chr16 83061411 G T 2.14E-04 Alzheimer's disease (late onset) CDH13 intron 21379329 rs9888896 chr16 83065403 T C 2.59E-05 Coronary heart disease CDH13 intron pha003030 rs12934355 chr16 83067325 G A 4.23E-04 Insulin resistance CDH13 intron 21901158 rs11150533 chr16 83071146 T G 7.36E-04 Insulin resistance CDH13 intron 21901158 rs11642883 chr16 83071614 A G 3.97E-04 Alzheimer's disease (late onset) CDH13 intron 21379329 rs11642883 chr16 83071614 A G 1.88E-04 Ankylosing spondylitis CDH13 intron 22138694 rs4783307 chr16 83076634 G T 1.70E-05 Personality dimensions CDH13 intron 18957941 rs4783307 chr16 83076634 G T 1.70E-05 Personality dimensions CDH13 intron 21173776 rs4519324 chr16 83078464 A G 0.0000968 Polycystic ovary syndrome CDH13 intron 22951595 rs4519324 chr16 83078464 A G 9.68E-05 Intracranial aneurysm CDH13 intron 22961961 rs6565107 chr16 83084290 A G 3.85E-04 Alzheimer's disease CDH13 intron 17998437 rs6565108 chr16 83084384 A T 2.60E-05 Urinary metabolites CDH13 intron 21572414 rs4783311 chr16 83084723 A G 1.90E-05 Urinary metabolites CDH13 intron 21572414 rs4783313 chr16 83088513 G A 8.84E-04 Multiple complex diseases CDH13 intron 17554300 rs7196826 chr16 83099707 C A 6.40E-04 Multiple complex diseases CDH13 intron 17554300 rs12446149 chr16 83109259 G A 1.43E-04 Multiple complex diseases CDH13 intron 17554300 rs7192356 chr16 83111317 G T 1.77E-04 Parkinson's disease CDH13 intron 17052657 rs7187677 chr16 83117361 A G 1.64E-04 Smoking cessation CDH13 intron 18519826 rs9930517 chr16 83122125 C A 1.10E-05 Urinary metabolites CDH13 intron 21572414 rs10438638 chr16 83123517 G C 4.40E-06 Urinary metabolites CDH13 intron 21572414 rs12929690 chr16 83136478 A G 5.30E-05 Parkinson's disease CDH13 intron 17052657 rs16959291 chr16 83142696 G A 2.10E-05 Urinary metabolites CDH13 intron 21572414 rs4128843 chr16 83151726 C G 4.95E-05 Bipolar disorder CDH13 intron 22925353 rs28507852 chr16 83155325 T A 5.05E-05 Alcohol consumption CDH13 intron 23743675 rs11150542 chr16 83157119 G A 2.21E-05 Alcohol consumption CDH13 intron 23743675 rs11641255 chr16 83157143 C G 4.82E-05 Alcohol consumption CDH13 intron 23743675 rs8056019 chr16 83168776 C T 7.03E-04 Type 2 diabetes CDH13 intron 17463246 rs9922449 chr16 83173892 C G 2.03E-04 Aortic root size CDH13 intron 21223598 rs9932942 chr16 83173960 A G 3.34E-04 Aortic root size CDH13 intron 21223598 rs12597394 chr16 83175687 C T 1.64E-04 Aortic root size CDH13 intron 21223598 rs13339002 chr16 83180857 T C 1.34E-04 Smoking cessation CDH13 intron 18519826 rs8058701 chr16 83181174 C G 5.76E-04 Type 2 diabetes CDH13 intron 17463246 rs8064200 chr16 83181462 T A 8.43E-04 Type 2 diabetes CDH13 intron 17463246 rs7203576 chr16 83188272 A G 5.40E-05 Pericardial fat CDH13 intron 22589742 rs12598771 chr16 83189742 A T 5.15E-04 Multiple complex diseases CDH13 intron 17554300 rs8045844 chr16 83196225 A T 1.27E-04 Multiple complex diseases CDH13 intron 17554300 rs4341727 chr16 83196443 G T 1.56E-04 Multiple complex diseases CDH13 intron 17554300 rs12103103 chr16 83196870 T C 1.56E-04 Multiple complex diseases CDH13 intron 17554300 rs7187443 chr16 83197057 C G 1.62E-04 Multiple complex diseases CDH13 intron 17554300 rs7188275 chr16 83197075 A G 2.60E-04 Multiple complex diseases CDH13 intron 17554300 rs6565145 chr16 83197501 G A 1.47E-04 Multiple complex diseases CDH13 intron 17554300 rs8050581 chr16 83197659 G A 1.16E-04 Multiple complex diseases CDH13 intron 17554300 rs8055236 chr16 83212398 G T 6.00E-06 Coronary heart disease CDH13 intron 17554300 rs8055236 chr16 83212398 G T 9.73E-06 Coronary Artery Disease CDH13 intron 17634449 rs8055236 chr16 83212398 G T 6.00E-06 Coronary heart disease CDH13 intron 21347282 rs8054283 chr16 83215640 A C 8.93E-06 Liver disease in chronic hepatitis B virus infection CDH13 intron 24065354 rs8058964 chr16 83215662 T C 7.21E-07 Multiple complex diseases CDH13 intron 17554300 rs12716963 chr16 83226300 A G 3.50E-05 Multiple complex diseases CDH13 intron 17554300 rs8045006 chr16 83256273 C A 1.58E-04 Attention deficit hyperactivity disorder CDH13 intron 20732625 rs8045006 chr16 83256273 C A 2.28E-05 Attention deficit hyperactivity disorder CDH13 intron 20732627 rs10514587 chr16 83256377 T C,G 3.59E-05 Bilirubin levels,in serum CDH13 intron 19389676 rs889730 chr16 83257305 C T 6.76E-05 Smoking cessation CDH13 intron 18519826 rs7198414 chr16 83257733 T G 3.90E-05 Multiple complex diseases CDH13 intron 17554300 rs17749270 chr16 83258890 G T 6.09E-04 Heart Failure CDH13 intron pha002884 rs889723 chr16 83260056 A G 7.60E-05 Lung function (forced expiratory volume in 1 second) CDH13 intron pha003102 rs8045365 chr16 83262098 A G 5.28E-05 Attention deficit hyperactivity disorder CDH13 intron 20732625 rs12917991 chr16 83265112 C A 1.29E-04 Attention deficit hyperactivity disorder CDH13 intron 20732625 rs11150555 chr16 83270249 G A 1.70E-04 Attention deficit hyperactivity disorder CDH13 intron pha002875 rs11150557 chr16 83271211 G A 2.35E-04 Amyotrophic lateral sclerosis CDH13 intron 23624525 rs4421965 chr16 83280091 A G 2.62E-04 Fibrinogen CDH13 intron 17255346 rs2194341 chr16 83280444 A C 2.73E-05 Tunica Media CDH13 intron pha003036 rs10514585 chr16 83284338 G A 5.00E-06 Depression (quantitative trait) CDH13 intron 20800221 rs10514585 chr16 83284338 G A 4.90E-06 Depression (quantitative trait) CDH13 intron 23290196 rs4782525 chr16 83284554 T C 3.69E-05 Depression (quantitative trait) CDH13 intron 20800221 rs12596191 chr16 83286768 G T 2.65E-05 Depression (quantitative trait) CDH13 intron 20800221 rs889724 chr16 83287432 G A 4.58E-04 Depression (quantitative trait) CDH13 intron 20800221 rs889724 chr16 83287432 G A 1.80E-06 Urinary metabolites CDH13 intron 21572414 rs748645 chr16 83288453 C A 3.36E-04 Depression (quantitative trait) CDH13 intron 20800221 rs717840 chr16 83288987 G A 2.43E-05 Depression (quantitative trait) CDH13 intron 20800221 rs1477418 chr16 83290560 G C 2.22E-04 Depression (quantitative trait) CDH13 intron 20800221 rs1477418 chr16 83290560 G C 3.20E-06 Urinary metabolites CDH13 intron 21572414 rs12921178 chr16 83293114 T C 2.75E-04 Depression (quantitative trait) CDH13 intron 20800221 rs8046875 chr16 83295486 T G 3.67E-04 Depression (quantitative trait) CDH13 intron 20800221 rs7188467 chr16 83295869 T C,G 2.21E-04 Depression (quantitative trait) CDH13 intron 20800221 rs17679225 chr16 83304743 G A 5.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDH13 intron 20877124 rs9937227 chr16 83306442 T A,C,G 1.70E-05 Urinary metabolites CDH13 intron 21572414 rs11643859 chr16 83307764 G C 5.14E-06 Type 2 diabetes CDH13 intron 17463246 rs17679617 chr16 83308001 C T 1.77E-04 Bipolar disorder,schizoaffective CDH13 intron 19567891 rs1559439 chr16 83310923 G C 7.33E-04 Alzheimer's disease CDH13 intron 17998437 rs11866427 chr16 83312850 T A 4.20E-06 Urinary metabolites CDH13 intron 21572414 rs17195894 chr16 83319882 G A 3.47E-04 Depression (quantitative trait) CDH13 intron 20800221 rs17195894 chr16 83319882 G A 6.38E-05 Height CDH13 intron pha003010 rs8056050 chr16 83323717 T C 1.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDH13 intron 20877124 rs8056050 chr16 83323717 T C 1.37E-04 Amyotrophic lateral sclerosis CDH13 intron 23624525 rs11644424 chr16 83326059 C A 5.02E-04 Amyotrophic Lateral Sclerosis CDH13 intron 17362836 rs11644424 chr16 83326059 C A 8.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) CDH13 intron 24025145 rs1125244 chr16 83327014 C T 2.60E-05 Urinary metabolites CDH13 intron 21572414 rs2875784 chr16 83328162 A G 3.65E-04 Coronary heart disease CDH13 intron 21606135 rs7201419 chr16 83329979 A C 3.90E-05 Amyotrophic Lateral Sclerosis CDH13 intron 17362836 rs11860092 chr16 83335839 C T 9.66E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) CDH13 intron 24025145 rs723919 chr16 83342234 G A 1.10E-04 IgE levels in asthmatics (D.f. specific) CDH13 intron 23967269 rs763727 chr16 83342301 G A 7.15E-05 IgE levels in asthmatics (D.f. specific) CDH13 intron 23967269 rs763727 chr16 83342301 G A 7.61E-05 IgE levels in asthmatics (D.p. specific) CDH13 intron 23967269 rs747674 chr16 83346679 T C 6.01E-05 Schizophrenia CDH13 intron 20185149 rs6563892 chr16 83348255 A G 9.10E-04 Depression (quantitative trait) CDH13 intron 20800221 rs1035569 chr16 83348824 A G 6.64E-04 Depression (quantitative trait) CDH13 intron 20800221 rs1035569 chr16 83348824 A G 2.20E-06 Malaria CDH13 intron 23717212 rs1035569 chr16 83348824 A G 7.34E-05 IgE levels in asthmatics (D.f. specific) CDH13 intron 23967269 rs7194029 chr16 83349398 T C 8.67E-04 Depression (quantitative trait) CDH13 intron 20800221 rs7194029 chr16 83349398 T C 3.67E-06 Malaria CDH13 intron 23717212 rs7194029 chr16 83349398 T C 6.25E-05 IgE levels in asthmatics (D.f. specific) CDH13 intron 23967269 rs7194029 chr16 83349398 T C 9.19E-05 IgE levels in asthmatics (D.p. specific) CDH13 intron 23967269 rs13336933 chr16 83357284 C T 8.84E-04 Depression (quantitative trait) CDH13 intron 20800221 rs6563897 chr16 83358288 A G 1.10E-04 IgE levels in asthmatics (D.f. specific) CDH13 intron 23967269 rs6563898 chr16 83358776 A G 9.50E-04 Depression (quantitative trait) CDH13 intron 20800221 rs6563898 chr16 83358776 A G 3.60E-05 IgE levels in asthmatics (D.p. specific) CDH13 intron 23967269 rs6563898 chr16 83358776 A G 8.00E-06 IgE levels in asthmatics (D.f. specific) CDH13 intron 23967269 rs6563898 chr16 83358776 A G 3.83E-05 Height CDH13 intron pha003011 rs10514579 chr16 83359653 C G 5.40E-05 Personality dimensions CDH13 intron 18957941 rs10514579 chr16 83359653 C G 9.28E-04 Depression (quantitative trait) CDH13 intron 20800221 rs9940464 chr16 83360775 T C 5.00E-07 Malaria CDH13 intron 23717212 rs13332362 chr16 83366609 A G 2.23E-04 Depression (quantitative trait) CDH13 intron 20800221 rs10514577 chr16 83368400 G C 1.06E-06 Malaria CDH13 intron 23717212 rs918771 chr16 83371484 C T 2.34E-04 Depression (quantitative trait) CDH13 intron 20800221 rs918767 chr16 83372034 C G 1.78E-04 Depression (quantitative trait) CDH13 intron 20800221 rs16960253 chr16 83373514 A T 1.77E-04 Type 2 diabetes CDH13 intron 17463246 rs10514574 chr16 83373963 A C 7.20E-06 Schizophrenia CDH13 intron 20185149 rs17211336 chr16 83375258 A G 6.28E-06 Schizophrenia CDH13 intron 20185149 rs1895534 chr16 83377916 C A 1.43E-04 Type 2 diabetes CDH13 intron 17463246 rs9932999 chr16 83379264 A G 7.20E-05 Personality dimensions CDH13 intron 18957941 rs9938206 chr16 83391288 C T 7.94E-04 Insulin resistance CDH13 intron 21901158 rs9938320 chr16 83391480 A G 1.15E-04 Insulin resistance CDH13 intron 21901158 rs1424169 chr16 83393302 G A 8.42E-05 IgE levels in asthmatics (D.f. specific) CDH13 intron 23967269 rs16960303 chr16 83396737 A G 9.31E-04 Depression (quantitative trait) CDH13 intron 20800221 rs16960303 chr16 83396737 A G 6.82E-06 Insulin resistance CDH13 intron 21901158 rs16960306 chr16 83398107 C G 4.71E-04 Insulin resistance CDH13 intron 21901158 rs1013465 chr16 83412113 T G 6.50E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) CDH13 intron 23648065 rs12050931 chr16 83417673 A C 8.84E-04 Insulin resistance CDH13 intron 21901158 rs12050931 chr16 83417673 A C 2.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) CDH13 intron 23648065 rs889712 chr16 83418974 G A 9.80E-05 Major depressive disorder CDH13 intron 21621269 rs16960334 chr16 83423397 G T 4.22E-04 Smoking initiation CDH13 intron 24665060 rs6563903 chr16 83423650 C T 2.20E-05 Urinary metabolites CDH13 intron 21572414 rs6563903 chr16 83423650 C T 7.27E-05 Blood pressure CDH13 intron 24001895 rs17285278 chr16 83423827 C G,T 1.23E-04 Multiple complex diseases CDH13 intron 17554300 rs17285299 chr16 83424024 C G 7.48E-05 Multiple complex diseases CDH13 intron 17554300 rs12924439 chr16 83424040 T A 3.31E-04 Insulin resistance CDH13 intron 21901158 rs918764 chr16 83427282 T C 1.90E-05 Urinary metabolites CDH13 intron 21572414 rs59337790 chr16 83431679 G GCTTGAGTGTACAGCAGAATCCCATTTATTCAATTACTCCAGACCAGTGTATCCGAAA 2.26E-04 Type 2 diabetes CDH13 intron 17463246 rs9931770 chr16 83431679 G A 2.26E-04 Type 2 diabetes CDH13 intron 17463246 rs12924031 chr16 83432200 T C 1.40E-05 Urinary metabolites CDH13 intron 21572414 rs16960354 chr16 83432498 T C 9.78E-05 Type 2 diabetes CDH13 intron 17463246 rs11647148 chr16 83438394 C T 6.51E-05 Response to taxane treatment (placlitaxel) CDH13 intron 23006423 rs12929342 chr16 83442302 G T 2.50E-05 Urinary metabolites CDH13 intron 21572414 rs17286565 chr16 83446304 A G 2.82E-04 Response to taxane treatment (placlitaxel) CDH13 intron 23006423 rs12919362 chr16 83447930 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CDH13 intron 22628534 rs1364309 chr16 83451039 G A 0.00000419 Common carotid artery thickness (far walls) CDH13 intron 23487405 rs10514573 chr16 83453851 A G 6.55E-04 Response to taxane treatment (placlitaxel) CDH13 intron 23006423 rs10514572 chr16 83455332 G C 5.27E-07 Paclitaxel sensitivity in NCI60 cancer cell lines CDH13 intron 21314952 rs9925521 chr16 83457455 T G 5.75E-06 Asthma (childhood onset) CDH13 intron 23829686 rs8054845 chr16 83487316 G A 3.32E-04 Suicide,with and without major depression CDH13 intron 22059935 rs8054845 chr16 83487316 G A 4.42E-04 Suicide,with and without major depression CDH13 intron 22059935 rs17216786 chr16 83487471 C A 1.00E-06 Response to antipsychotic treatment CDH13 intron 20195266 rs11646484 chr16 83490774 G A 5.60E-05 Post-operative nausea and vomiting CDH13 intron 21694509 rs4782796 chr16 83491379 C T 3.93E-05 Post-operative nausea and vomiting CDH13 intron 21694509 rs1387381 chr16 83492734 T C 1.15E-04 Suicide,with and without major depression CDH13 intron 22059935 rs1387381 chr16 83492734 T C 5.38E-04 Suicide,with and without major depression CDH13 intron 22059935 rs16960577 chr16 83505325 C G 7.00E-04 Multiple complex diseases CDH13 intron 17554300 rs1489310 chr16 83511242 G A 7.33E-06 Post-operative nausea and vomiting CDH13 intron 21694509 rs12919255 chr16 83535543 G A 5.87E-05 Potassium levels CDH13 intron pha003086 rs4782805 chr16 83538170 C T 1.63E-04 Smoking cessation CDH13 intron 18519826 rs4291893 chr16 83553581 A G 6.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CDH13 intron 20877124 rs4074375 chr16 83555113 T G 1.14E-05 Alcohol and nictotine co-dependence CDH13 intron 20158304 rs4074375 chr16 83555113 T G 2.05E-05 Amyotrophic lateral sclerosis (sporadic) CDH13 intron 24529757 rs4074373 chr16 83555525 A G 8.51E-05 Smoking cessation CDH13 intron 18519826 rs4074373 chr16 83555525 A G 7.00E-06 Homeostasis model assessment of beta-cell function (interaction) CDH13 intron 24204828 rs4284623 chr16 83556281 A C 7.29E-06 Stroke (ischemic) CDH13 intron 21957438 rs7187172 chr16 83561866 C A 3.90E-06 Stroke (ischemic) CDH13 intron 21957438 rs11640777 chr16 83562213 T C 7.49E-06 Stroke (ischemic) CDH13 intron 21957438 rs4782812 chr16 83563611 G T 2.34E-05 Sudden cardiac arrest CDH13 intron 21658281 rs7206005 chr16 83564742 A G 1.29E-04 Amyotrophic Lateral Sclerosis CDH13 intron 17827064 rs10871275 chr16 83568605 T C 1.34E-04 B cell non-Hodgkin lymphoma CDH13 intron 23749188 rs4782814 chr16 83569787 G T 6.03E-05 Smoking cessation CDH13 intron 18519826 rs4238691 chr16 83569881 G A 8.95E-05 Schizophrenia CDH13 intron 19571809 rs4238691 chr16 83569881 G A 5.55E-05 Schizophrenia CDH13 intron pha002859 rs9930750 chr16 83589489 C T 3.27E-05 Schizophrenia CDH13 intron 19571809 rs9930750 chr16 83589489 C T 3.14E-05 Schizophrenia CDH13 intron pha002859 rs4357934 chr16 83591217 C G 2.95E-05 Schizophrenia CDH13 intron 19571809 rs4357934 chr16 83591217 C G 2.19E-05 Schizophrenia CDH13 intron pha002859 rs4477688 chr16 83614472 T C 1.33E-04 Aortic root size CDH13 intron 21223598 rs7499397 chr16 83620469 C T 1.98E-05 Systolic blood pressure in sickle cell anemia CDH13 intron 24058526 rs8053315 chr16 83621093 G T 6.83E-04 Multiple complex diseases CDH13 intron 17554300 rs16960938 chr16 83626088 G A 3.60E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) CDH13 intron 23648065 rs8055119 chr16 83638982 G A 2.76E-04 Smoking initiation CDH13 intron 24665060 rs7201413 chr16 83639199 C A 4.03E-04 Smoking initiation CDH13 intron 24665060 rs6563943 chr16 83639335 G A 6.00E-06 Height CDH13 intron 20189936 rs6563943 chr16 83639335 G A 4.69E-05 Body Mass Index CDH13 intron pha003006 rs6563943 chr16 83639335 G A 5.41E-05 Waist Circumference CDH13 intron pha003024 rs16961037 chr16 83650950 A G 8.73E-04 Type 2 diabetes CDH13 intron 17463246 rs16961043 chr16 83651685 T C 7.33E-04 Insulin resistance CDH13 intron 21901158 rs9939760 chr16 83652902 G A 9.00E-06 Smoking initiation CDH13 intron 24665060 rs17688077 chr16 83656264 C T 2.31E-04 Nicotine smoking CDH13 intron 19268276 rs16961072 chr16 83662293 C T 6.94E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) CDH13 intron 23648065 rs722939 chr16 83664226 A G 7.83E-05 Glaucoma (primary open-angle) CDH13 intron 22605921 rs1833963 chr16 83681806 G A 5.68E-04 Parkinson's disease CDH13 intron 17052657 rs13337331 chr16 83681953 A T 5.98E-05 Serum metabolites CDH13 intron 19043545 rs28499084 chr16 83692881 G T 2.34E-06 Response to amphetamines CDH13 intron 22952603 rs10781971 chr16 83695697 A G 7.65E-05 Personality dimensions CDH13 intron 18957941 rs9940706 chr16 83698706 C A 3.48E-04 Type 2 diabetes CDH13 intron 17463246 rs9940706 chr16 83698706 C A 1.45E-05 Personality dimensions CDH13 intron 18957941 rs9940706 chr16 83698706 C A 1.50E-05 Personality dimensions CDH13 intron 21173776 rs8058532 chr16 83709666 C T 2.00E-06 Response to amphetamines CDH13 intron 22952603 rs3784943 chr16 83712435 A G 5.00E-08 Response to amphetamines CDH13 intron 22952603 rs8052167 chr16 83715549 G C 3.38E-05 Femoral neck bone geometry CDH13 intron 22087292 rs1423846 chr16 83721952 A G 1.92E-04 White matter integrity CDH13 intron 22425255 rs7200481 chr16 83725371 C T 9.16E-04 Response to taxane treatment (placlitaxel) CDH13 intron 23006423 rs8059763 chr16 83725910 G A 5.14E-05 Coronary heart disease CDH13 intron pha003031 rs12446894 chr16 83727833 G T 6.41E-05 Coronary heart disease CDH13 intron pha003031 rs11861962 chr16 83735130 T C 4.44E-06 Coronary heart disease CDH13 intron pha003031 rs7198252 chr16 83737342 G A 8.97E-05 Coronary heart disease CDH13 intron pha003031 rs7200376 chr16 83746972 C T 2.96E-05 Cognitive test performance CDH13 intron 20125193 rs12927653 chr16 83755481 A G 6.39E-05 Cognitive test performance CDH13 intron 20125193 rs254315 chr16 83756412 T C 7.10E-04 Breast cancer and prostate cancer CDH13 intron 17903305 rs9929930 chr16 83756988 C G 2.10E-05 Urinary metabolites CDH13 intron 21572414 rs3784962 chr16 83757328 A G 3.00E-06 Cognitive performance CDH13 intron 20125193 rs3784962 chr16 83757328 A G 6.00E-06 Cognitive performance CDH13 intron 20125193 rs419382 chr16 83759089 T C 1.03E-04 Nicotine smoking CDH13 intron 19268276 rs7206133 chr16 83762106 A G 6.94E-04 Nicotine smoking CDH13 intron 19268276 rs7206133 chr16 83762106 A G 1.80E-05 Urinary metabolites CDH13 intron 21572414 rs3096277 chr16 83764204 T C 1.00E-09 Blood pressure CDH13 intron 17903302 rs403473 chr16 83767219 G C 9.37E-04 Multiple complex diseases CDH13 intron 17554300 rs401443 chr16 83770853 C T 9.17E-04 Rheumatoid arthritis CDH13 intron 21452313 rs444881 chr16 83771496 G C 4.00E-06 IgG glycosylation CDH13 intron 23382691 rs9932947 chr16 83771943 T C 5.91E-04 Heart Failure CDH13 intron pha002884 rs443832 chr16 83779644 G C 2.44E-04 Type 2 diabetes CDH13 intron 17463246 rs3743616 chr16 83781995 A C 3.47E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CDH13 intron 21844884 rs735675 chr16 83782517 C T 4.30E-05 Coronary heart disease CDH13 intron 21606135 rs254346 chr16 83782950 G T 2.81E-04 Multiple complex diseases CDH13 intron 17554300 rs254347 chr16 83783115 G A 3.48E-04 Multiple complex diseases CDH13 intron 17554300 rs1645841 chr16 83783247 A G 3.73E-04 Multiple complex diseases CDH13 intron 17554300 rs183717 chr16 83783267 G A 4.35E-04 Multiple complex diseases CDH13 intron 17554300 rs16961677 chr16 83783405 T C 6.04E-04 Multiple complex diseases CDH13 intron 17554300 rs1645844 chr16 83783490 G A 4.80E-04 Multiple complex diseases CDH13 intron 17554300 rs149740259 chr16 83783828 G A 9.00E-06 Periodontitis (Mean PAL) CDH13 intron 24024966 rs3784992 chr16 83785065 A G 7.87E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CDH13 intron 21844884 rs11641114 chr16 83785148 C T 8.33E-05 Coronary heart disease CDH13 intron 21606135 rs11641114 chr16 83785148 C T 7.86E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CDH13 intron 21844884 rs11864540 chr16 83791265 G A 1.30E-04 Aortic root size CDH13 intron 21223598 rs11864540 chr16 83791265 G A 5.50E-05 Coronary heart disease CDH13 intron 21606135 rs889491 chr16 83799822 T A 7.75E-04 Type 2 diabetes CDH13 intron 17463246 rs707236 chr16 83803160 T A 1.12E-04 Multiple complex diseases CDH13 intron 17554300 rs707236 chr16 83803160 T A 6.30E-04 Pulmonary function CDH13 intron 23932459 rs707235 chr16 83803382 C T 5.30E-06 Urinary metabolites CDH13 intron 21572414 rs17700757 chr16 83805890 G A 1.60E-05 Urinary metabolites CDH13 intron 21572414 rs9938761 chr16 83810691 C G 2.10E-07 Urinary metabolites CDH13 intron 21572414 rs247402 chr16 83811203 T G 0.0004315 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH13 intron 23233654 rs247402 chr16 83811203 T G 4.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH13 intron 23233662 rs247401 chr16 83811223 A T 2.60E-08 Urinary metabolites CDH13 intron 21572414 rs247400 chr16 83811640 A G 0.0004064 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH13 intron 23233654 rs247400 chr16 83811640 A G 4.06E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH13 intron 23233662 rs185051 chr16 83812347 T C 1.70E-06 Urinary metabolites CDH13 intron 21572414 rs1981860 chr16 83813294 T C 9.12E-05 Information processing speed CDH13 intron 21130836 rs2113148 chr16 83815587 G A 9.26E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH13 intron 23233662 rs16961753 chr16 83816524 G C 0.0008116 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CDH13 intron 23233654 rs16961753 chr16 83816524 G C 8.12E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH13 intron 23233662 rs1061492 chr16 83817495 A G 3.95E-05 Information processing speed CDH13 intron 21130836 rs462407 chr16 83822604 C T 7.29E-05 Myopia (pathological) CDH13 intron 21640322 rs463480 chr16 83824498 T A 1.40E-05 Urinary metabolites CDH13 intron 21572414 rs8058334 chr16 83825634 T C 5.18E-05 Coronary heart disease CDH13 intron 21606135 rs690836 chr16 83826766 C G 8.07E-04 Type 2 diabetes CDH13 intron 17463246 rs2326025 chr16 83827801 G C 4.08E-04 Body mass index CDH13 intron 21701565 rs2326025 chr16 83827801 G C 9.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH13 intron 23233662 rs464557 chr16 83828453 A G 4.60E-06 Urinary metabolites CDH13 intron 21572414 rs3743617 chr16 83828544 C G 3.91E-04 Body mass index CDH13 intron 21701565 rs3743617 chr16 83828544 C G 9.04E-04 Methotrexate clearance (acute lymphoblastic leukemia) CDH13 intron 23233662 rs460796 chr16 83830299 T G 1.90E-05 Urinary metabolites / / 21572414 rs7197423 chr16 83830689 G A 3.56E-05 Coronary heart disease / / 21606135 rs7197423 chr16 83830689 G A 5.99E-04 Smoking cessation / / 24665060 rs467392 chr16 83832206 C G 9.67E-04 Type 2 diabetes / / 17463246 rs467392 chr16 83832206 C G 2.00E-05 Urinary metabolites / / 21572414 rs8047406 chr16 83832493 T A 0.0007028 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8047406 chr16 83832493 T A 7.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8049546 chr16 83836732 G A 4.32E-04 Type 2 diabetes / / 17463246 rs33125 chr16 83851073 T C 6.45E-04 Type 2 diabetes / / 17463246 rs8056675 chr16 83860783 T C 9.96E-05 Information processing speed / / 21130836 rs8056675 chr16 83860783 T C 0.000277724 Hypertension (early onset hypertension) / / 22479346 rs11862993 chr16 83862636 G A 2.60E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs9933995 chr16 83863934 G T 1.90E-05 Urinary metabolites / / 21572414 rs40004 chr16 83864458 A G 2.70E-05 Urinary metabolites / / 21572414 rs412116 chr16 83885265 C G 5.88E-05 Serum metabolites / / 19043545 rs1469112 chr16 83886924 C T 2.93E-05 Type 2 diabetes / / 17463246 rs7188807 chr16 83887679 C G 9.98E-05 Type 2 diabetes / / 17463246 rs7189126 chr16 83887696 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs426694 chr16 83892343 A C 6.36E-04 Multiple complex diseases / / 17554300 rs425807 chr16 83892507 G A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs3809622 chr16 83931538 C T 8.51E-04 Alcohol dependence MLYCD nearGene-5 20201924 rs2278037 chr16 83941726 C T 6.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MLYCD intron 20877124 rs11149609 chr16 83970840 C G 7.60E-06 Urinary metabolites / / 21572414 rs12599670 chr16 83971109 G C 2.40E-05 Urinary metabolites / / 21572414 rs16962277 chr16 83971242 G A 7.90E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10163267 chr16 83973918 G C 5.47E-07 Nasopharyngeal carcinoma / / 23209447 rs8058168 chr16 83974066 G A 5.14E-05 IgE levels / / 17255346 rs253136 chr16 83979601 G T 6.70E-04 Coronary Artery Disease / / 17634449 rs111901175 chr16 83979819 T G 3.60E-11 Metabolite levels / / 22286219 rs4782863 chr16 83982460 A G 7.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs824400 chr16 83989936 C G 8.68E-04 Coronary Artery Disease OSGIN1 intron 17634449 rs824400 chr16 83989936 C G 2.00E-18 Progranulin levels OSGIN1 intron 21087763 rs824400 chr16 83989936 C G 2.00E-18 Myocardial infarction OSGIN1 intron 21211798 rs2247470 chr16 84009402 T C 6.73E-05 IgE levels in asthmatics (D.p. specific) NECAB2 intron 23967269 rs68004739 chr16 84020685 G T 0.00028 Prostate cancer NECAB2 intron 23555315 rs9926939 chr16 84026540 G C 6.17E-04 Multiple complex diseases NECAB2 intron 17554300 rs2292324 chr16 84028014 C G 5.33E-04 Fibrinogen NECAB2 missense 17255346 rs9927612 chr16 84035216 T A,G 5.03E-04 Multiple complex diseases NECAB2 intron 17554300 rs17724230 chr16 84041658 T G 4.62E-05 Multiple complex diseases / / 17554300 rs11864146 chr16 84046715 A G 2.00E-06 Non-alcoholic fatty liver disease histology (other) SLC38A8 intron 23213074 rs9783761 chr16 84056956 C T 2.80E-05 Urinary metabolites SLC38A8 intron 21572414 rs8057907 chr16 84061798 G A 4.09E-05 Heart Rate SLC38A8 intron pha003053 rs12919122 chr16 84063715 G A 3.59E-04 Smoking quantity SLC38A8 intron 24665060 rs4782885 chr16 84081796 C T 1.30E-05 Urinary metabolites / / 21572414 rs4782886 chr16 84082463 C T 9.00E-06 Urinary metabolites / / 21572414 rs8056413 chr16 84082650 G T 1 Drug response to Etoposide / / 17537913 rs999781 chr16 84095254 G C 4.00E-06 Urinary metabolites MBTPS1 intron 21572414 rs2875855 chr16 84108651 G A 1.70E-05 Urinary metabolites MBTPS1 intron 21572414 rs2136665 chr16 84122206 T A 1.87E-05 Odorant perception MBTPS1 intron 23910658 rs8049209 chr16 84130286 C G 5.20E-06 Plasminogen activator inhibitor-1 (PAI1) levels,in plasma MBTPS1 intron 20558613 rs3785028 chr16 84136622 C T 1.87E-04 Age-related macular degeneration MBTPS1 intron 22125219 rs4082806 chr16 84165620 C T 1.88E-04 Type 2 diabetes HSDL1 intron 17463246 rs9932838 chr16 84169624 C T 9.55E-06 Multiple sclerosis (brain glutamate levels) HSDL1 intron 20802204 rs7184373 chr16 84175227 G A 7.66E-04 Smoking quantity HSDL1 intron 24665060 rs16962897 chr16 84209080 G A 0.0001641 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) D/AF1 intron 23233654 rs16962897 chr16 84209080 G A 1.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) D/AF1 intron 23233662 rs1056616 chr16 84211718 C T 0.000124 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TAF1C UTR-3 23233654 rs1056616 chr16 84211718 C T 1.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) TAF1C UTR-3 23233662 rs2288025 chr16 84211735 A C 0.0001238 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TAF1C UTR-3 23233654 rs2288025 chr16 84211735 A C 1.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) TAF1C UTR-3 23233662 rs1056612 chr16 84211788 G C 0.0001627 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TAF1C UTR-3 23233654 rs1056612 chr16 84211788 G C 1.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) TAF1C UTR-3 23233662 rs150717903 chr16 84212647 T C 0.0000083 Prostate cancer (advanced) TAF1C missense 23555315 rs3743642 chr16 84212928 G A 0.0001615 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TAF1C cds-synon 23233654 rs3743642 chr16 84212928 G A 1.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) TAF1C cds-synon 23233662 rs4150167 chr16 84213684 C T 3.00E-07 Autism TAF1C missense 22843504 rs4150162 chr16 84214214 A T 0.0001632 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TAF1C intron 23233654 rs4150162 chr16 84214214 A T 1.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) TAF1C intron 23233662 rs3785032 chr16 84216257 A G 0.0001501 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TAF1C intron 23233654 rs3785032 chr16 84216257 A G 1.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) TAF1C intron 23233662 rs2288026 chr16 84220344 C G 0.0001895 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TAF1C intron 23233654 rs2288026 chr16 84220344 C G 1.90E-04 Methotrexate clearance (acute lymphoblastic leukemia) TAF1C intron 23233662 rs3759977 chr16 84221170 T A 0.0000709 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs3759977 chr16 84221170 T A 7.09E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7185078 chr16 84233348 G A 6.13E-04 Type 2 diabetes / / 17463246 rs7185137 chr16 84233536 C T 8.09E-07 Type 2 diabetes / / 17463246 rs7185137 chr16 84233536 C T 4.29E-04 Multiple complex diseases / / 17554300 rs7185137 chr16 84233536 C T 7.00E-06 Asthma / / 21790008 rs244887 chr16 84240104 A G 6.28E-04 Alzheimer's disease / / 17998437 rs8062778 chr16 84245295 C G 8.31E-04 Multiple complex diseases / / 17554300 rs40254 chr16 84248757 A G 2.97E-05 Crohn's disease and Celiac disease / / 21298027 rs40254 chr16 84248757 A G 8.94E-04 Iron levels / / pha002876 rs39555 chr16 84253029 C A 1.37E-04 Bipolar disorder,affective / / 20528957 rs39554 chr16 84253767 G C 8.50E-05 Bipolar disorder,affective / / 20528957 rs16963061 chr16 84254187 G A 1.81E-04 Type 2 diabetes / / 17463246 rs39553 chr16 84254287 A G 2.05E-04 Bipolar disorder,affective / / 20528957 rs39552 chr16 84254384 G A 3.12E-04 Bipolar disorder,affective / / 20528957 rs39551 chr16 84254811 G A 7.94E-05 Bipolar disorder,affective KCNG4 UTR-3 20528957 rs39550 chr16 84254846 C T 7.94E-05 Bipolar disorder,affective KCNG4 UTR-3 20528957 rs12447573 chr16 84258153 A G 8.75E-04 Multiple complex diseases KCNG4 intron 17554300 rs517731 chr16 84260153 C T 4.80E-05 Bipolar disorder,affective KCNG4 intron 20528957 rs7196274 chr16 84262109 G A 1.30E-06 Asthma KCNG4 intron 21907864 rs11646443 chr16 84270476 G A 0.00057 Prostate cancer KCNG4 missense 23555315 rs35075881 chr16 84270890 T C 0.000025 Breast cancer(er negative) KCNG4 missense 23555315 rs746080 chr16 84274405 T G 6.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs7190491 chr16 84292635 A G 1.60E-05 HIV-1 viral setpoint / / 17641165 rs437218 chr16 84294167 T G 1.18E-04 HIV-1 viral setpoint / / 17641165 rs244844 chr16 84304674 T C 7.14E-05 Chronic Hepatitis C infection / / 21725309 rs244844 chr16 84304674 T C 6.64E-05 Lymphocyte counts / / pha003094 rs244844 chr16 84304674 T C 1.30E-05 Neutrophil count / / pha003095 rs12598746 chr16 84305216 G A 6.13E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs138642423 chr16 84310399 C G 7.00E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs11644041 chr16 84316281 G A 5.09E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs39547 chr16 84319789 A G 1.58E-04 Smoking cessation / / 18519826 rs11862438 chr16 84321653 C G 7.42E-04 Alcohol dependence / / 21314694 rs6564009 chr16 84333760 C T 1.19E-04 Multiple complex diseases WFDC1 intron 17554300 rs16963349 chr16 84338234 T C 1.00E-07 Systolic blood pressure (alcohol consumption interaction) WFDC1 intron 24376456 rs8051764 chr16 84340896 A C 1.64E-04 Smoking cessation WFDC1 intron 18519826 rs8051764 chr16 84340896 A C 4.08E-04 Smoking cessation WFDC1 intron 18519826 rs364836 chr16 84343341 G C 9.50E-05 Type 2 diabetes WFDC1 intron 17463246 rs4782606 chr16 84351789 G A 5.76E-04 Multiple complex diseases WFDC1 intron 17554300 rs16963454 chr16 84363263 C T 7.04E-05 Multiple complex diseases WFDC1 UTR-3 17554300 rs7206131 chr16 84381553 A G 2.89E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs958577 chr16 84411856 C T 5.13E-06 Hepatitis B vaccine response ATP2C2 intron 21764829 rs12933433 chr16 84418245 G A 7.27E-04 Amyotrophic Lateral Sclerosis ATP2C2 intron 17362836 rs11863271 chr16 84422815 C T 2.47E-05 Hepatitis B vaccine response ATP2C2 intron 21764829 rs8048576 chr16 84423034 G A 9.00E-13 Chronic obstructive pulmonary disease-related biomarkers ATP2C2 intron 23144326 rs7189221 chr16 84423060 A G 2.20E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ATP2C2 intron 24023788 rs9929758 chr16 84430781 T C 3.15E-04 Attention deficit hyperactivity disorder ATP2C2 intron 22012869 rs922450 chr16 84433034 C T 7.80E-04 Parkinson's disease ATP2C2 intron 17052657 rs10514604 chr16 84446384 C G 1.22E-04 Multiple complex diseases ATP2C2 intron 17554300 rs10514604 chr16 84446384 C G 8.00E-07 Attention deficit hyperactivity disorder ATP2C2 intron 18839057 rs17741422 chr16 84448418 T C 3.31E-05 Epilepsy ATP2C2 intron 22116939 rs17741422 chr16 84448418 T C 0.000603732 Hypertension (early onset hypertension) ATP2C2 intron 22479346 rs247808 chr16 84450224 T G 3.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ATP2C2 intron 20877124 rs247808 chr16 84450224 T G 7.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ATP2C2 intron 20877124 rs12149164 chr16 84451091 G A 2.71E-04 Smoking initiation ATP2C2 intron 24665060 rs11641662 chr16 84457646 C T 6.76E-04 Suicide attempts in bipolar disorder ATP2C2 intron 21423239 rs7205320 chr16 84460493 A G 3.60E-04 Suicide attempts in bipolar disorder ATP2C2 intron 21423239 rs8059665 chr16 84463189 G T 9.56E-05 Amyotrophic lateral sclerosis ATP2C2 intron 19193627 rs962877 chr16 84463525 A G 5.90E-04 Multiple complex diseases ATP2C2 intron 17554300 rs962878 chr16 84463853 G A 8.76E-04 Multiple complex diseases ATP2C2 intron 17554300 rs4782626 chr16 84473985 G A 1.92E-04 Multiple complex diseases ATP2C2 intron 17554300 rs4782966 chr16 84474137 C T 8.02E-04 Amyotrophic Lateral Sclerosis ATP2C2 intron 17362836 rs4782966 chr16 84474137 C T 2.12E-05 Cognitive impairment induced by topiramate ATP2C2 intron 22091778 rs16973814 chr16 84479620 G T 7.40E-04 Alcohol dependence ATP2C2 intron 20201924 rs16973814 chr16 84479620 G T 9.23E-04 Tourette syndrome ATP2C2 intron 22889924 rs17815700 chr16 84489033 T C 6.80E-04 Alcohol dependence ATP2C2 intron 20201924 rs17815700 chr16 84489033 T C 7.10E-04 Alcohol dependence ATP2C2 intron 20201924 rs368047 chr16 84509368 C G 8.45E-04 Insulin resistance / / 21901158 rs9936257 chr16 84524469 G C 4.93E-04 Multiple complex diseases KIAA1609 intron 17554300 rs9926674 chr16 84524669 T A 8.36E-04 Multiple complex diseases KIAA1609 intron 17554300 rs12923086 chr16 84533101 A G 3.88E-05 Acute lung injury KIAA1609 intron 22295056 rs12923106 chr16 84533145 A C 3.88E-05 Acute lung injury KIAA1609 intron 22295056 rs6564046 chr16 84533697 T C 5.87E-04 Multiple complex diseases KIAA1609 intron 17554300 rs6564046 chr16 84533697 T C 1.89E-05 Acute lung injury KIAA1609 intron 22295056 rs368681 chr16 84534252 G C 6.21E-04 Acute lung injury KIAA1609 intron 22295056 rs567637 chr16 84534366 G A 1.58E-04 Acute lung injury KIAA1609 intron 22295056 rs11643825 chr16 84534796 G T 1.16E-04 Acute lung injury KIAA1609 intron 22295056 rs12933519 chr16 84535030 G C 6.93E-05 Acute lung injury KIAA1609 intron 22295056 rs4782983 chr16 84535355 A G 6.70E-04 Acute lung injury KIAA1609 intron 22295056 rs692081 chr16 84535790 C G 8.00E-04 Suicide attempts in bipolar disorder KIAA1609 intron 21423239 rs6564047 chr16 84536066 C T 1.48E-04 Acute lung injury KIAA1609 intron 22295056 rs247849 chr16 84546087 C A 1.69E-05 Cognitive test performance / / 20125193 rs1465594 chr16 84547841 G A 5.02E-05 Cognitive test performance / / 20125193 rs4782996 chr16 84553206 C T 6.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11641157 chr16 84557317 G A 8.95E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs417190 chr16 84569101 C T 9.50E-04 Obesity (extreme) / / 21935397 rs13336385 chr16 84572028 G C 3.75E-05 Non-word repetition / / 23738518 rs371915 chr16 84578241 A G 2.00E-08 Eosinophilic esophagitis (pediatric) / / 20208534 rs11859410 chr16 84580078 C A 1.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs247872 chr16 84597896 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4783026 chr16 84625830 G A 8.02E-05 Post-operative nausea and vomiting COTL1 intron 21694509 rs2967874 chr16 84635724 C T 9.80E-06 Urinary metabolites COTL1 intron 21572414 rs3111577 chr16 84635785 T C 8.60E-06 Urinary metabolites COTL1 intron 21572414 rs1808568 chr16 84638029 T G 7.83E-04 Obesity (extreme) COTL1 intron 21935397 rs17827507 chr16 84645486 T C 1.37E-05 Melanoma COTL1 intron 21926416 rs16974279 chr16 84645679 C T 1.95E-05 Multiple complex diseases COTL1 intron 17554300 rs2925055 chr16 84654935 A G 1.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs17827984 chr16 84668807 C G 3.95E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11647936 chr16 84685509 A T 4.00E-06 Waist circumference KLHL36 intron 20966902 rs16974367 chr16 84698110 C T 4.62E-04 Multiple complex diseases / / 17554300 rs9936719 chr16 84730830 G A 4.88E-04 Parkinson's disease / / 17052657 rs8045120 chr16 84741149 G T 1.30E-04 Type 2 diabetes USP10 intron 17463246 rs3764286 chr16 84741343 C T 8.79E-04 Parkinson's disease USP10 intron 17052657 rs1862794 chr16 84750595 C T 8.34E-04 Type 2 diabetes USP10 intron 17463246 rs1862794 chr16 84750595 C T 2.87E-04 Multiple complex diseases USP10 intron 17554300 rs41422347 chr16 84750816 T C 1.19E-04 Multiple complex diseases USP10 intron 17554300 rs12149617 chr16 84754898 G A 1.48E-04 Multiple complex diseases USP10 intron 17554300 rs12149617 chr16 84754898 G A 3.91E-04 Coronary Artery Disease USP10 intron 17634449 rs41386649 chr16 84769024 C T 2.64E-04 Multiple complex diseases USP10 intron 17554300 rs17763304 chr16 84771176 C T 7.13E-04 Type 2 diabetes USP10 intron 17463246 rs17763304 chr16 84771176 C T 3.42E-04 Multiple complex diseases USP10 intron 17554300 rs17763304 chr16 84771176 C T 7.82E-04 Coronary Artery Disease USP10 intron 17634449 rs4510001 chr16 84774120 T C 5.71E-04 Type 2 diabetes USP10 intron 17463246 rs4510001 chr16 84774120 T C 1.70E-04 Multiple complex diseases USP10 intron 17554300 rs744839 chr16 84774436 C T 9.72E-04 Type 2 diabetes USP10 intron 17463246 rs11149680 chr16 84780907 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes USP10 intron 22628534 rs8051512 chr16 84781101 C G 2.31E-04 Parkinson's disease USP10 intron 17052657 rs16974538 chr16 84783658 T G 3.10E-05 Cognitive performance USP10 intron 19734545 rs17831494 chr16 84785378 G A 8.06E-04 Type 2 diabetes USP10 intron 17463246 rs17831494 chr16 84785378 G A 9.03E-05 Multiple complex diseases USP10 intron 17554300 rs4783057 chr16 84785672 G A 3.74E-04 Response to taxane treatment (placlitaxel) USP10 intron 23006423 rs4783057 chr16 84785672 G A 4.30E-04 Response to cytidine analogues (gemcitabine) USP10 intron 24483146 rs6564074 chr16 84786250 C A 1.93E-04 Response to taxane treatment (placlitaxel) USP10 intron 23006423 rs6564074 chr16 84786250 C A 1.48E-04 Response to cytidine analogues (gemcitabine) USP10 intron 24483146 rs7186789 chr16 84786855 T G 6.13E-04 Depression (quantitative trait) USP10 intron 20800221 rs7205632 chr16 84796402 A T 5.85E-04 Type 2 diabetes USP10 intron 17463246 rs7205632 chr16 84796402 A T 4.14E-04 Multiple complex diseases USP10 intron 17554300 rs7205632 chr16 84796402 A T 4.88E-04 Response to cytidine analogues (gemcitabine) USP10 intron 24483146 rs12932018 chr16 84796603 A G 6.00E-06 Response to mTOR inhibitor (everolimus) USP10 cds-synon 24009623 rs2641688 chr16 84801751 G A 6.53E-04 Response to cytidine analogues (gemcitabine) USP10 intron 24483146 rs2641692 chr16 84833921 G A 5.21E-04 Multiple complex diseases / / 17554300 rs8057431 chr16 84839954 C A 1.20E-05 Asthma / / 22561531 rs10735709 chr16 84845518 G C 7.44E-04 Type 2 diabetes / / 17463246 rs5022975 chr16 84846982 A T 4.52E-04 Type 2 diabetes / / 17463246 rs9939197 chr16 84856532 G A 0.0000362 Nonsyndromic striae distensae (stretch marks) CRISPLD2 intron 23633020 rs4783079 chr16 84856889 C A 0.0000408 Nonsyndromic striae distensae (stretch marks) CRISPLD2 intron 23633020 rs4782661 chr16 84856930 T C 0.0000698 Nonsyndromic striae distensae (stretch marks) CRISPLD2 intron 23633020 rs17111 chr16 84857244 A G 0.0000609 Nonsyndromic striae distensae (stretch marks) CRISPLD2 intron 23633020 rs2131754 chr16 84857345 A G 0.0000685 Nonsyndromic striae distensae (stretch marks) CRISPLD2 intron 23633020 rs8048917 chr16 84857679 G A 8.81E-04 Type 2 diabetes CRISPLD2 intron 17463246 rs8048917 chr16 84857679 G A 4.07E-04 Multiple complex diseases CRISPLD2 intron 17554300 rs9932059 chr16 84866420 A G 0.000258 Breast cancer early age of onset CRISPLD2 intron 18463975 rs6564083 chr16 84889936 G A 9.00E-07 Urinary metabolites CRISPLD2 intron 21572414 rs1587272 chr16 84894281 A G 4.29E-05 Multiple complex diseases CRISPLD2 intron 17554300 rs16974931 chr16 84952943 C T 1.48E-04 Multiple complex diseases / / 17554300 rs12599043 chr16 84955551 C A 6.61E-05 Serum metabolites / / 19043545 rs2641678 chr16 84958952 T A 3.31E-05 Personality dimensions / / 22628180 rs11863338 chr16 84959707 C G 9.63E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11863425 chr16 84959942 C A 7.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13334795 chr16 84966561 C T 6.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16974980 chr16 84972563 A G 5.38E-05 Alzheimer's disease (late onset) / / 20885792 rs4783101 chr16 84977997 G A 2.86E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4783102 chr16 84978048 T C 1.40E-04 Pulmonary function / / 23932459 rs2326458 chr16 84987679 C A 8.00E-07 Height / / 18391951 rs7192876 chr16 85012669 T G 2.53E-04 Alzheimer's disease (late onset) ZDHHC7 intron 21379329 rs1566458 chr16 85018931 T C 1.20E-04 Insulin response ZDHHC7 intron 19430760 rs7192417 chr16 85034117 T G 6.31E-04 Coronary heart disease ZDHHC7 intron 21971053 rs7499539 chr16 85038065 G A 2.12E-04 Response to cholinesterase inhibitors in Alzheimer's disease ZDHHC7 intron 23374588 rs1875247 chr16 85044207 T C 2.04E-04 Type 2 diabetes ZDHHC7 intron 17463246 rs1875247 chr16 85044207 T C 0.0008644 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ZDHHC7 intron 23233654 rs1875247 chr16 85044207 T C 8.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) ZDHHC7 intron 23233662 rs11867115 chr16 85045693 A G 0.0008294 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11867115 chr16 85045693 A G 8.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9936836 chr16 85056156 A G 6.66E-05 Cognitive impairment induced by topiramate / / 22091778 rs8056742 chr16 85092748 T C 5.00E-07 Amyotrophic lateral sclerosis KIAA0513 intron 22959728 rs8050910 chr16 85139173 G T 9.55E-06 Crohn's disease FAM92B intron 17435756 rs2062550 chr16 85164601 T C 1.76E-05 Waist Circumference / / pha003024 rs2062550 chr16 85164601 T C 6.48E-07 Waist-Hip Ratio / / pha003029 rs882718 chr16 85179677 C A 8.54E-04 Alzheimer's disease LOC400548 intron 24755620 rs3104834 chr16 85181875 C T 1.27E-04 Alzheimer's disease LOC100506467 intron 24755620 rs9933007 chr16 85181955 T C 4.08E-05 Alzheimer's disease LOC100506467 intron 24755620 rs3104836 chr16 85182087 G A,C,T 7.59E-04 Alzheimer's disease LOC100506467 intron 24755620 rs7196417 chr16 85182630 C T 1.20E-05 Urinary metabolites LOC100506467 intron 21572414 rs2937137 chr16 85182899 T G 4.55E-04 Alzheimer's disease LOC100506467 intron 24755620 rs2966849 chr16 85183682 A G 1.90E-05 Urinary metabolites LOC100506467 intron 21572414 rs4783136 chr16 85184014 G A 2.50E-05 Urinary metabolites LOC100506467 intron 21572414 rs12922458 chr16 85185908 G A 4.40E-04 Alzheimer's disease LOC100506467 intron 24755620 rs1472541 chr16 85186264 T C 1.33E-05 Alzheimer's disease LOC100506467 intron 24755620 rs9935396 chr16 85189217 A G 2.47E-04 Alzheimer's disease LOC100506467 intron 24755620 rs17791545 chr16 85189262 G C 6.76E-05 Alzheimer's disease LOC100506467 intron 24755620 rs8056715 chr16 85189550 G C 2.19E-06 Alzheimer's disease LOC100506467 intron 24755620 rs2937143 chr16 85189891 G A 4.55E-05 Alzheimer's disease LOC100506467 intron 24755620 rs2937145 chr16 85190230 C A 2.02E-06 Alzheimer's disease LOC100506467 intron 24755620 rs2966852 chr16 85190466 C T 2.79E-04 Alzheimer's disease LOC100506467 intron 24755620 rs6564107 chr16 85197980 A G 4.45E-04 Alzheimer's disease LOC100506467 intron 24755620 rs4636894 chr16 85201970 C T 2.71E-05 Alzheimer's disease LOC100506467 intron 24755620 rs4783146 chr16 85227748 A G 0.000602212 Hypertension (early onset hypertension) / / 22479346 rs12444866 chr16 85228341 C T 0.00067854 Hypertension (early onset hypertension) / / 22479346 rs12449263 chr16 85242209 T A 2.39E-04 Lymphocyte counts / / 22286170 rs4782695 chr16 85270410 G A 4.97E-04 Multiple complex diseases / / 17554300 rs16944651 chr16 85336503 G A 6.38E-04 Multiple complex diseases / / 17554300 rs2966870 chr16 85340979 T C 4.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8047149 chr16 85364315 C T 8.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7192631 chr16 85396820 C G 6.68E-05 Body mass index / / 17255346 rs4783192 chr16 85420064 T G 5.43E-04 Multiple complex diseases / / 17554300 rs900764 chr16 85473118 A G 3.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs900766 chr16 85480882 C G 1.50E-05 Urinary metabolites / / 21572414 rs876056 chr16 85504682 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6540278 chr16 85620902 C T 2.90E-04 Myasthenia gravis / / 23055271 rs4240810 chr16 85625127 G T 7.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs451871 chr16 85736429 C T 5.01E-05 Serum metabolites / / 19043545 rs408988 chr16 85769720 G A 9.93E-04 Parkinson's disease C16orf74 intron 17052657 rs301164 chr16 85813880 T C 1.10E-14 Progranulin levels COX4NB intron 21087763 rs301164 chr16 85813880 T C 1.10E-14 Myocardial infarction COX4NB intron 21211798 rs11860152 chr16 85817324 G A 0.0000106 Antisocial behavior COX4NB intron 23077488 rs11866179 chr16 85818418 A C 0.0000107 Antisocial behavior COX4NB intron 23077488 rs896253 chr16 85820202 G A 0.0000112 Antisocial behavior COX4NB intron 23077488 rs10514609 chr16 85824073 T C 8.18E-04 Type 2 diabetes COX4NB intron 17463246 rs10514609 chr16 85824073 T C 3.92E-06 Serum metabolites COX4NB intron 19043545 rs11648858 chr16 85832292 C G 2.68E-04 Blood pressure COX4NB intron 17255346 rs11648858 chr16 85832292 C G 7.50E-05 Multiple complex diseases COX4NB intron 17554300 rs11648858 chr16 85832292 C G 3.55E-08 Lymphocyte counts COX4NB intron 22286170 rs2733954 chr16 85836256 T C 3.23E-04 Type 2 diabetes COX4I1 intron 17463246 rs2733954 chr16 85836256 T C 5.26E-04 Multiple complex diseases COX4I1 intron 17554300 rs2733955 chr16 85836291 C G 8.23E-04 Type 2 diabetes COX4I1 intron 17463246 rs2733955 chr16 85836291 C G 3.07E-04 Multiple complex diseases COX4I1 intron 17554300 rs2075531 chr16 85838916 A G 3.86E-05 Type 2 diabetes COX4I1 intron 17463246 rs2075531 chr16 85838916 A G 9.89E-04 Multiple complex diseases COX4I1 intron 17554300 rs2075553 chr16 85839977 G C 5.24E-04 Type 2 diabetes COX4I1 intron 17463246 rs2075553 chr16 85839977 G C 2.57E-04 Multiple complex diseases COX4I1 intron 17554300 rs17806623 chr16 85874817 A G 7.46E-04 Type 2 diabetes / / 17463246 rs4843852 chr16 85897418 T G 8.20E-06 Urinary metabolites / / 21572414 rs11861580 chr16 85898547 C G 7.31E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs11648716 chr16 85906616 A G 7.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs391023 chr16 85927814 C T 5.00E-17 Chronic lymphocytic leukemia / / 23770605 rs391525 chr16 85944439 A G 6.21E-05 stroke (ischemic) IRF8 intron 17434096 rs391525 chr16 85944439 A G 3.00E-09 Chronic lymphocytic leukemia IRF8 intron 21131588 rs391525 chr16 85944439 A G 5.40E-07 Chronic lymphocytic leukemia IRF8 intron 22700719 rs391525 chr16 85944439 A G 5.40E-07 Erectile dysfunction IRF8 intron 22704111 rs2292982 chr16 85944823 T G 4.76E-17 Chronic lymphocytic leukemia IRF8 intron 23770605 rs147968 chr16 85945839 T C 4.46E-05 Kawasaki disease IRF8 intron 22446961 rs424971 chr16 85946450 T C 2.11E-05 Kawasaki disease IRF8 intron 22446961 rs424971 chr16 85946450 T C 3.00E-16 Monocyte counts IRF8 intron 23314186 rs2280378 chr16 85952745 A G 3.44E-05 Kawasaki disease IRF8 intron 22446961 rs7185022 chr16 85952929 A C 1.17E-07 Kawasaki disease IRF8 intron 22446961 rs16940005 chr16 85953682 G C 6.06E-04 Insulin resistance IRF8 intron 21901158 rs10514611 chr16 85955242 C T 4.18E-04 Bipolar disorder IRF8 UTR-3 19259986 rs1044873 chr16 85955671 C T 4.70E-05 Immunoglobulin A IRF8 UTR-3 20694011 rs1044873 chr16 85955671 C T 1.00E-09 Chronic lymphocytic leukemia IRF8 UTR-3 24292274 rs17444745 chr16 85961562 G A 7.00E-06 QRS duration / / 23534349 rs11644034 chr16 85972612 G A 8.97E-04 Multiple complex diseases / / 17554300 rs12711490 chr16 85973028 T C 3.00E-10 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs305061 chr16 85975659 C T 4.00E-07 Chronic lymphocytic leukemia / / 20062064 rs305061 chr16 85975659 C T 4.00E-07 Nasopharyngeal carcinoma / / 20512145 rs305061 chr16 85975659 C T 9.00E-08 Chronic lymphocytic leukemia / / 22700719 rs305061 chr16 85975659 C T 9.42E-08 Erectile dysfunction / / 22704111 rs305061 chr16 85975659 C T 8.76E-06 Chronic lymphocytic leukemia / / 23770605 rs16940101 chr16 85978125 A G 5.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs10863202 chr16 85987998 A G 6.53E-04 Multiple complex diseases / / 17554300 rs10863202 chr16 85987998 A G 1.40E-05 Crohn's disease / / 18587394 rs10863202 chr16 85987998 A G 2.70E-05 Anger / / 24489884 rs11642873 chr16 85991705 A C 2.00E-12 Systemic sclerosis / / 21779181 rs10863203 chr16 85993580 T C 3.29E-04 Multiple complex diseases / / 17554300 rs908983 chr16 85994520 C T 6.91E-04 Multiple complex diseases / / 17554300 rs12446139 chr16 85995584 G A 1.55E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs908979 chr16 85999992 A G 1.15E-04 Type 2 diabetes / / 17846125 rs4843880 chr16 86008641 T C 1.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4843880 chr16 86008641 T C 1.42E-05 Tunica Media / / pha003038 rs9308366 chr16 86009519 G A 4.25E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs16940186 chr16 86009740 T C 4.00E-10 Ulcerative colitis / / 23511034 rs13333054 chr16 86011033 C T 1.00E-08 Multiple sclerosis / / 21833088 rs10521318 chr16 86011337 C T 1.00E-09 Inflammatory bowel disease / / 23128233 rs1401884 chr16 86013551 G C 6.83E-07 Multiple sclerosis / / 19525953 rs16940202 chr16 86014241 T C 6.00E-19 Ulcerative colitis / / 21297633 rs16940202 chr16 86014241 T C 3.00E-09 Ulcerative colitis / / 23511034 rs17445836 chr16 86017663 G A 4.00E-09 Multiple sclerosis / / 19525953 rs17445836 chr16 86017663 G A 2.40E-06 Multiple sclerosis / / 21833088 rs2280381 chr16 86018633 C T 2.00E-06 Rheumatoid arthritis / / 22446963 rs6540239 chr16 86018861 T C 6.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13330176 chr16 86019087 T A 0.00000004 Rheumatoid arthritis / / 23143596 rs13330176 chr16 86019087 T A 5.30E-09 Rheumatoid arthritis (CCP positive) / / 23143596 rs13330176 chr16 86019087 T A 1.00E-12 Rheumatoid arthritis / / 24390342 rs13330176 chr16 86019087 T A 2.80E-05 Rheumatoid arthritis / / 24390342 rs13330176 chr16 86019087 T A 9.00E-09 Rheumatoid arthritis / / 24390342 rs11117432 chr16 86019271 G A 5.00E-11 Primary biliary cirrhosis / / 21399635 rs11117433 chr16 86019516 G C 1.41E-09 Primary biliary cirrhosis / / 22961000 rs35703946 chr16 86021505 G A 0.00061 Primary biliary cirrhosis / / 22936693 rs12599351 chr16 86024616 T C 3.09E-04 Gallstones / / 17632509 rs1568387 chr16 86024879 G A 1.98E-04 Primary biliary cirrhosis / / 21399635 rs11640000 chr16 86049947 A C 1.10E-08 Urinary metabolites / / 21572414 rs11117436 chr16 86050359 C G 4.60E-06 Urinary metabolites / / 21572414 rs6540246 chr16 86053834 C A 2.13E-04 IgE levels / / 17255346 rs13330844 chr16 86054886 C G 1.96E-04 IgE levels / / 17255346 rs2030361 chr16 86068522 A G 4.30E-06 Urinary metabolites / / 21572414 rs2361742 chr16 86078516 G A 9.86E-06 Cognitive decline / / 23207651 rs17239938 chr16 86079098 C T 3.88E-04 Aortic root size / / 21223598 rs4843897 chr16 86093721 A G 1.99E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs6540248 chr16 86094005 A G 7.23E-04 Multiple complex diseases / / 17554300 rs6540248 chr16 86094005 A G 8.60E-06 Urinary metabolites / / 21572414 rs16940375 chr16 86096628 C T 2.09E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs16940375 chr16 86096628 C T 1.06E-05 Coronary heart disease / / pha003031 rs8050326 chr16 86104142 G A 3.00E-07 Major depressive disorder / / 23857890 rs2352937 chr16 86130876 G A 1.05E-04 Multiple complex diseases / / 17554300 rs4843349 chr16 86131064 G A 7.99E-05 Partial epilepsies / / 20522523 rs904204 chr16 86136699 C G 9.48E-04 Alzheimer's disease / / 17998437 rs16940464 chr16 86139608 C T 6.85E-05 Multiple complex diseases / / 17554300 rs4843910 chr16 86153427 A G 4.67E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs11117450 chr16 86158321 G A 8.20E-04 Acute lung injury / / 22295056 rs1466805 chr16 86158574 T G 9.05E-05 Triglycerides / / pha003080 rs11648147 chr16 86159370 A G 1.65E-05 Cocaine dependence / / 23958962 rs75021996 chr16 86167653 C G 0.00006412 Sarcoidosis / / 22952805 rs113570485 chr16 86167732 G C 0.00007447 Sarcoidosis / / 22952805 rs28703194 chr16 86167884 C T 0.00009027 Sarcoidosis / / 22952805 rs76500044 chr16 86168154 C T 0.00002468 Sarcoidosis / / 22952805 rs12447057 chr16 86168727 T C 1.70E-05 Urinary metabolites / / 21572414 rs8056862 chr16 86169419 C T 2.10E-05 Urinary metabolites / / 21572414 rs11863347 chr16 86169595 A T 5.40E-06 Urinary metabolites / / 21572414 rs79338758 chr16 86170816 A C 0.000068 Sarcoidosis / / 22952805 rs73269404 chr16 86173301 T A 0.00004147 Sarcoidosis / / 22952805 rs138480408 chr16 86174225 G C 0.00005138 Sarcoidosis / / 22952805 rs79231811 chr16 86175354 G T 0.00005138 Sarcoidosis / / 22952805 rs76636619 chr16 86176660 A G 0.00005638 Sarcoidosis / / 22952805 rs11117457 chr16 86180385 A T 2.64E-04 Multiple complex diseases / / 17554300 rs1809844 chr16 86188011 C T 7.45E-04 Taste perception / / 22132133 rs1497732 chr16 86191464 C T 6.78E-04 Taste perception / / 22132133 rs768080 chr16 86192565 G T 3.48E-04 Taste perception / / 22132133 rs276987 chr16 86196770 G C 2.53E-04 Multiple complex diseases / / 17554300 rs276983 chr16 86200926 T C 3.07E-04 Age-related macular degeneration / / 22125219 rs9933359 chr16 86201589 C T 9.04E-05 Coronary Artery Disease / / 17634449 rs276968 chr16 86232176 T G 5.14E-05 Type 2 diabetes and other traits LOC100506542 intron 19734900 rs276968 chr16 86232176 T G 2.78E-04 Hemoglobin concentration LOC100506542 intron 20534544 rs904201 chr16 86248387 G A 6.41E-04 Smoking initiation / / 24665060 rs12102705 chr16 86250157 G C 4.76E-04 Multiple complex diseases / / 17554300 rs1693947 chr16 86261733 A G 4.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17833272 chr16 86264048 T C 1.09E-04 Alzheimer's disease (late onset) / / 21379329 rs4843359 chr16 86277441 G A 2.77E-04 Alzheimer's disease / / 21059989 rs4843359 chr16 86277441 G A 5.81E-06 Alzheimer's disease / / 21059989 rs1693962 chr16 86280112 G A 1.92E-04 Multiple complex diseases / / 17554300 rs13333251 chr16 86290512 G A 6.88E-05 Serum metabolites / / 19043545 rs4843924 chr16 86292215 T A 9.20E-05 Memory performance / / 22105620 rs11645915 chr16 86292293 G C 1.90E-05 Sudden cardiac arrest / / 21658281 rs11117472 chr16 86301948 G A 6.02E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9926735 chr16 86302032 G T 1.50E-05 Urinary metabolites / / 21572414 rs7205575 chr16 86304244 C T 1.77E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7191751 chr16 86304261 A G 1.69E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs987052 chr16 86322459 T C 4.58E-05 Parkinson's disease LOC146513 intron 17052657 rs987052 chr16 86322459 T C 1.00E-07 Smoking behavior LOC146513 intron 20418888 rs987052 chr16 86322459 T C 7.00E-07 Obesity-related traits LOC146513 intron 23251661 rs2696851 chr16 86324375 C G 2.04E-05 Response to mTOR inhibitor (rapamycin) LOC146513 intron 24009623 rs2581269 chr16 86331869 G C 8.65E-04 Parkinson's disease / / 17052657 rs2665322 chr16 86361271 G A 2.70E-05 Urinary metabolites / / 21572414 rs2696835 chr16 86365571 C G 3.00E-06 Diabetic retinopathy / / 21441570 rs2289430 chr16 86367189 G A 5.95E-04 Multiple complex diseases LOC732275 intron 17554300 rs2289430 chr16 86367189 G A 7.00E-04 Acute lymphoblastic leukemia (childhood) LOC732275 intron 20189245 rs4083242 chr16 86368526 G A 1.00E-07 Obesity-related traits LOC732275 intron 23251661 rs11643741 chr16 86368599 T G 4.47E-07 Obesity-related traits LOC732275 intron 23251661 rs3828516 chr16 86369306 C A 1.89E-07 Obesity-related traits LOC732275 intron 23251661 rs3762873 chr16 86369360 G A 1.10E-05 Body Mass Index LOC732275 intron pha003014 rs11641231 chr16 86381184 C G 8.00E-06 Response to statin therapy / / 20339536 rs1728369 chr16 86386213 A C 0.0002 Migraine / / 22678113 rs1728417 chr16 86392392 C T 3.53E-05 Multiple complex diseases / / 17554300 rs41362847 chr16 86395647 A G 6.91E-05 Coronary Artery Disease / / 17634449 rs16940965 chr16 86399261 C G 3.84E-04 Multiple complex diseases / / 17554300 rs3111601 chr16 86400081 C T 5.41E-04 White matter integrity / / 22425255 rs3111601 chr16 86400081 C T 1.56E-05 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs3111601 chr16 86400081 C T 4.24E-04 Barrett's esophagus / / 24121790 rs3111601 chr16 86400081 C T 8.49E-05 Esophageal adenocarcinoma / / 24121790 rs9936833 chr16 86403118 C T 3.00E-10 Barrett's esophagus / / 22961001 rs9936833 chr16 86403118 C T 3.00E-10 Body mass index / / 22982992 rs1532167 chr16 86404204 T G 1.25E-04 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs1532167 chr16 86404204 T G 8.53E-04 Esophageal adenocarcinoma / / 24121790 rs716364 chr16 86405993 G A 3.90E-04 Type 2 diabetes / / 17463246 rs716364 chr16 86405993 G A 7.91E-04 Multiple complex diseases / / 17554300 rs1728397 chr16 86408213 A G 4.50E-06 Diabetic retinopathy / / 21441570 rs4843366 chr16 86409801 A C 3.81E-04 Multiple complex diseases / / 17554300 rs4843366 chr16 86409801 A C 3.21E-05 Type 1 diabetes / / 18978792 rs13334640 chr16 86411952 A G 7.36E-04 Type 2 diabetes / / 17463246 rs4843368 chr16 86418076 C T 6.52E-05 Iron levels / / 19880490 rs4843368 chr16 86418076 C T 6.52E-05 Iron levels / / pha002876 rs12921058 chr16 86422686 C T 7.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1629159 chr16 86433447 T A 6.50E-04 Multiple complex diseases / / 17554300 rs1728400 chr16 86434446 C A 2.07E-06 Iron levels / / 19880490 rs1728400 chr16 86434446 C A 2.07E-06 Iron levels / / pha002876 rs8054124 chr16 86434553 T C 1.06E-05 Iron levels / / 19880490 rs8054124 chr16 86434553 T C 1.06E-05 Iron levels / / pha002876 rs8060246 chr16 86436817 T C 2.50E-05 Job-related exhaustion / / 23620144 rs8045253 chr16 86437767 T C 9.10E-04 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs8045253 chr16 86437767 T C 6.00E-04 Iron levels / / pha002876 rs8055977 chr16 86442105 C T 7.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16941203 chr16 86445586 G C 6.35E-16 Multiple complex diseases / / 17554300 rs9646304 chr16 86446585 G A 1.20E-05 Urinary metabolites / / 21572414 rs2103284 chr16 86447184 G A 7.35E-04 Alcohol dependence / / 20201924 rs9923190 chr16 86456633 C T 3.62E-04 Alcohol dependence / / 20201924 rs2178146 chr16 86463695 T C 1.00E-06 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs2178146 chr16 86463695 T C 4.00E-06 Esophageal adenocarcinoma / / 24121790 rs2178146 chr16 86463695 T C 6.24E-04 Barrett's esophagus / / 24121790 rs9929553 chr16 86464336 A C 0.00000179 Major depressive disorder age at onset>25 / / 22915352 rs4843376 chr16 86470082 A G 2.12E-04 Esophageal adenocarcinoma / / 24121790 rs4843376 chr16 86470082 A G 4.61E-04 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs12446146 chr16 86482021 A G 3.25E-05 Smoking initiation / / 24665060 rs11644988 chr16 86485131 G A 2.00E-06 Corneal astigmatism / / 23322567 rs11865483 chr16 86494979 A T 2.26E-04 Multiple complex diseases / / 17554300 rs4843963 chr16 86508283 T A 1.70E-04 Multiple complex diseases / / 17554300 rs7203834 chr16 86508972 G C 1.82E-04 Multiple complex diseases / / 17554300 rs7203834 chr16 86508972 G C 3.85E-05 Serum metabolites / / 19043545 rs7199903 chr16 86509444 C T 1.52E-05 Multiple complex diseases / / 17554300 rs889594 chr16 86511484 G C 1.61E-04 Multiple complex diseases LOC400550 intron 17554300 rs7187365 chr16 86511915 T C 6.00E-06 Obesity (early onset extreme) LOC400550 intron 23563609 rs889595 chr16 86512080 T A 8.60E-06 Multiple complex diseases LOC400550 intron 17554300 rs889595 chr16 86512080 T A 1.13E-05 Coronary Artery Disease LOC400550 intron 17634449 rs1580602 chr16 86512874 A G 7.72E-05 HIV-1 viral setpoint LOC400550 intron 22174851 rs9926237 chr16 86522437 T G 3.35E-04 Multiple complex diseases LOC400550 intron 17554300 rs7186668 chr16 86522899 C G 3.74E-04 Multiple complex diseases LOC400550 intron 17554300 rs2306967 chr16 86525478 T C 6.39E-04 Multiple complex diseases LOC400550 intron 17554300 rs39536 chr16 86532032 T C 1.95E-06 Platelet counts LOC400550 intron pha003100 rs7187428 chr16 86540059 G T 7.36E-05 Fibrinogen LOC400550 intron pha003068 rs7187428 chr16 86540059 G T 3.85E-05 Platelet counts LOC400550 intron pha003100 rs3751806 chr16 86546145 C T 7.00E-05 Memory performance FOXF1 intron 22105620 rs4843977 chr16 86555873 C G 9.10E-08 Urinary metabolites / / 21572414 rs3751797 chr16 86567492 A T 8.74E-05 Type 2 diabetes MTHFSD intron 17846126 rs11646114 chr16 86583774 T A 8.90E-05 Type 2 diabetes MTHFSD intron 17463248 rs2354022 chr16 86588655 G C 8.41E-04 Suicide attempts in bipolar disorder MTHFSD intron 21423239 rs918727 chr16 86590080 A G 5.32E-04 Alzheimer's disease / / 24755620 rs1035550 chr16 86602707 A G 7.66E-04 Acute lung injury FOXC2 nearGene-3 22295056 rs7199466 chr16 86608609 T G 5.88E-04 Multiple complex diseases / / 17554300 rs7204395 chr16 86608786 T C 4.30E-06 Urinary metabolites / / 21572414 rs4843177 chr16 86629376 A G 4.00E-05 Schizophrenia / / 19571811 rs12448905 chr16 86630866 C A 1.45E-04 Type 2 diabetes / / 20818381 rs1862783 chr16 86631479 G A,C 3.00E-06 Urinary metabolites / / 21572414 rs2068142 chr16 86632309 G A 7.85E-05 Dengue shock syndrome / / 22001756 rs16941642 chr16 86640105 A G 1.16E-04 Acute lung injury / / 22295056 rs12711459 chr16 86640835 A G 2.13E-05 Recombination rate / / 21698098 rs12448691 chr16 86643092 C T 8.73E-04 Acute lung injury / / 22295056 rs539692775 chr16 86643092 CGTT C 8.73E-04 Acute lung injury / / 22295056 rs1992623 chr16 86645780 G T 7.08E-05 Recombination rate / / 21698098 rs12325417 chr16 86665459 T C 2.14E-04 Multiple complex diseases / / 17554300 rs9925302 chr16 86666303 C T 3.60E-04 Myasthenia gravis / / 23055271 rs2354025 chr16 86667409 C T 7.60E-05 Bone mineral density (BMD),in women / / 20164292 rs16941722 chr16 86668566 A C 4.97E-04 Substance dependence / / 21818250 rs7193748 chr16 86673554 C T 8.53E-04 Aortic root size / / 21223598 rs1562108 chr16 86680465 G A 3.33E-05 Cognitive decline / / 22054870 rs300032 chr16 86680996 G A 3.00E-07 IgG glycosylation / / 23382691 rs300032 chr16 86680996 G A 9.00E-08 IgG glycosylation / / 23382691 rs1867485 chr16 86681031 G A 5.40E-04 Multiple complex diseases / / 17554300 rs1867485 chr16 86681031 G A 3.00E-06 Obesity-related traits / / 23251661 rs12922111 chr16 86699023 C T 9.20E-04 Alzheimer's disease / / 24755620 rs11866010 chr16 86704396 A C 2.90E-04 Hemoglobin concentration / / 20534544 rs7188801 chr16 86707769 G A 8.00E-06 Bone properties (heel) / / 24430505 rs388466 chr16 86708741 G A 8.20E-05 Response to statin therapy / / 20339536 rs12932673 chr16 86709731 C G 1.90E-08 Bone mineral density (spine) / / 19801982 rs12932673 chr16 86709731 C G 7.41E-05 Relative hand skill in reading disability / / 24068947 rs10048146 chr16 86710660 A G 2.00E-07 Bone mineral density (hip) / / 19801982 rs10048146 chr16 86710660 A G 2.00E-08 Bone mineral density (spine) / / 19801982 rs10048146 chr16 86710660 A G 1.00E-14 Bone mineral density / / 22504420 rs10048146 chr16 86710660 A G 1.44E-05 Bone mineral density / / 24249740 rs10048146 chr16 86710660 A G 5.60E-07 Bone mineral density / / 24249740 rs10048146 chr16 86710660 A G 7.61E-09 Bone mineral density / / 24249740 rs71390846 chr16 86714715 G C 2.00E-06 Bone mineral density / / 24249740 rs71390846 chr16 86714715 G C 2.00E-10 Bone mineral density / / 24249740 rs9888814 chr16 86726006 G T 1.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs11866031 chr16 86727299 A G 8.31E-04 Iron levels / / pha002876 rs7189606 chr16 86729101 C A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs8052487 chr16 86729693 G A 9.12E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11865476 chr16 86732778 T C 2.78E-04 Type 2 diabetes / / 17463246 rs11117202 chr16 86739957 C T 7.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs11117203 chr16 86739975 G A 5.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs8046054 chr16 86740340 T C 4.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs9924445 chr16 86746818 A G 2.46E-05 Multiple sclerosis / / 19525953 rs300004 chr16 86747384 G A 9.92E-04 Multiple complex diseases / / 17554300 rs299995 chr16 86751195 A G 2.21E-04 Schizophrenia / / 19197363 rs299977 chr16 86761699 T C 5.16E-04 Schizophrenia / / 19197363 rs1899881 chr16 86774688 G A 2.37E-05 Post-operative nausea and vomiting / / 21694509 rs299936 chr16 86781454 T G 9.80E-06 Urinary metabolites / / 21572414 rs2059285 chr16 86781497 G A 7.39E-04 Schizophrenia / / 19197363 rs7405302 chr16 86783646 T G 3.16E-05 Post-operative nausea and vomiting / / 21694509 rs11642036 chr16 86786925 T G 9.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11642036 chr16 86786925 T G 1.17E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs8052199 chr16 86790996 A G 3.53E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs16942100 chr16 86802880 G A 6.86E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs299967 chr16 86804847 G A 3.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11643847 chr16 86805799 T A 9.70E-06 Urinary metabolites / / 21572414 rs7403863 chr16 86810343 T C 4.93E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7199746 chr16 86822348 C A 5.89E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4843460 chr16 86825472 C T 9.50E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11640979 chr16 86825963 C T 8.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs13337840 chr16 86827339 A G 9.00E-07 Ulcerative colitis / / 19915572 rs13337840 chr16 86827339 A G 4.38E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs8055182 chr16 86827528 G A 1.71E-04 Multiple complex diseases / / 17554300 rs2059287 chr16 86828158 C A 4.06E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs9922728 chr16 86838435 G A 7.30E-06 Urinary metabolites / / 21572414 rs9922728 chr16 86838435 G A 9.77E-05 Body Mass Index / / pha003021 rs12932360 chr16 86840294 A T 7.59E-05 Pulmonary function / / 20010835 rs11644604 chr16 86841346 G C 3.69E-05 Pulmonary function / / 20010835 rs11645771 chr16 86841732 G A 6.27E-05 Pulmonary function / / 20010835 rs4843465 chr16 86842116 G A 5.91E-05 Pulmonary function / / 20010835 rs3922878 chr16 86854704 A C 2.50E-05 Anger / / 24489884 rs13380717 chr16 86904135 A G 2.95E-04 Type 2 diabetes / / 17463246 rs11642990 chr16 86910194 C T 7.30E-05 Lipoproteins / / pha003079 rs4843189 chr16 86910392 T C 3.98E-05 Cognitive impairment induced by topiramate / / 22091778 rs3934493 chr16 86928408 G A 4.30E-04 Multiple complex diseases / / 17554300 rs11642315 chr16 86935809 A G 4.21E-05 Multiple complex diseases / / 17554300 rs4075391 chr16 86944900 T C 7.57E-05 Cognitive impairment induced by topiramate / / 22091778 rs6539984 chr16 86958876 C T 5.30E-06 Urinary metabolites / / 21572414 rs8060973 chr16 86993458 A G 0.0007536 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8060973 chr16 86993458 A G 7.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9931220 chr16 87037459 T C 0.0003897 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9931220 chr16 87037459 T C 3.90E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12445562 chr16 87045923 G A 3.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4552032 chr16 87047185 T C 5.16E-05 Depression (quantitative trait) / / 20800221 rs8054887 chr16 87048842 G A 3.65E-05 Depression (quantitative trait) / / 20800221 rs8056525 chr16 87049055 C T 9.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17290774 chr16 87054437 C A 4.83E-04 Response to alcohol consumption (flushing response) / / 24277619 rs16942559 chr16 87062221 C G,T 4.97E-04 Multiple complex diseases / / 17554300 rs12445424 chr16 87063374 G A 2.99E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs3893739 chr16 87069462 T C 0.0002735 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs3893739 chr16 87069462 T C 2.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs721544 chr16 87073635 G A 8.81E-04 Coronary heart disease / / 21971053 rs11647733 chr16 87077299 G A 1.08E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs3849233 chr16 87081190 A G 7.92E-04 Iron levels / / pha002876 rs1965172 chr16 87085366 G A 4.48E-05 Body Mass Index / / pha003006 rs1965172 chr16 87085366 G A 2.93E-05 Waist Circumference / / pha003024 rs745289 chr16 87101185 A G 4.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17697480 chr16 87101424 G C 7.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs17770146 chr16 87101452 T A 7.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs16942624 chr16 87106123 C T 9.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs9937239 chr16 87107120 G A 0.00000002 Mean corpuscular hemoglobin concentration / / 22560525 rs12933233 chr16 87111630 A G 8.00E-06 Alzheimer's disease (age of onset) / / 22005931 rs6540003 chr16 87115287 A G 1.84E-05 Alzheimer's disease (age of onset) / / 22005931 rs3909499 chr16 87142809 G C 3.29E-10 Multiple complex diseases / / 17554300 rs4843530 chr16 87151514 A G 3.42E-05 Glucose levels / / pha003057 rs4843530 chr16 87151514 A G 4.99E-05 Glucose levels / / pha003058 rs8052172 chr16 87180078 C T 6.50E-05 Schizophrenia(age at onset) / / 21688384 rs6540013 chr16 87181941 T C 8.99E-05 HIV(mother-to-child transmission) / / 20487506 rs12597955 chr16 87182096 G T 9.65E-05 Schizophrenia(age at onset) / / 21688384 rs17836231 chr16 87187454 C G 7.53E-05 Schizophrenia(age at onset) / / 21688384 rs8052505 chr16 87188106 T C 6.62E-06 Schizophrenia(age at onset) / / 21688384 rs12598263 chr16 87190924 A G 9.90E-04 Alzheimer's disease / / 24755620 rs8044338 chr16 87199038 T C 8.34E-04 Alzheimer's disease / / 24755620 rs12711472 chr16 87224132 A C 4.60E-05 White matter hyperintensity burden / / 21681796 rs12711472 chr16 87224132 A C 2.43E-04 White matter integrity / / 22425255 rs9308344 chr16 87224930 C G 7.20E-05 White matter hyperintensity burden / / 21681796 rs4843559 chr16 87225431 G A 5.17E-04 Type 2 diabetes / / 17463246 rs4843559 chr16 87225431 G A 4.20E-05 White matter hyperintensity burden / / 21681796 rs4843558 chr16 87225473 G A 5.17E-04 Type 2 diabetes / / 17463246 rs4843558 chr16 87225473 G A 4.10E-05 White matter hyperintensity burden / / 21681796 rs12921347 chr16 87226843 C G 8.80E-05 White matter hyperintensity burden / / 21681796 rs6540016 chr16 87229435 C T 9.39E-04 Type 2 diabetes / / 17463246 rs7185688 chr16 87229739 A G 7.65E-04 Type 2 diabetes / / 17463246 rs1108048 chr16 87245731 G A 7.10E-05 White matter hyperintensity burden / / 21681796 rs4843230 chr16 87248963 G T 3.88E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1110338 chr16 87250227 C T 4.56E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1110338 chr16 87250227 C T 8.56E-05 C-Reactive Protein / / pha003070 rs11640181 chr16 87258088 A G 3.56E-04 White matter integrity / / 22425255 rs12599613 chr16 87259939 C T 3.46E-04 Type 2 diabetes / / 17463246 rs11646937 chr16 87261838 T C 3.84E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs7195221 chr16 87262231 T C 3.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10220973 chr16 87288428 T C 9.18E-05 Multiple complex diseases / / 17554300 rs7203346 chr16 87305069 G T 8.18E-05 Cognitive test performance LOC100506559 intron 20125193 rs6540029 chr16 87311820 G T 4.92E-06 Multiple complex diseases LOC100506559 intron 17554300 rs8050099 chr16 87319096 G T 7.63E-04 Type 2 diabetes LOC100506559 intron 17463246 rs12918175 chr16 87357910 A G 0.0000441 Polycystic ovary syndrome / / 22951595 rs12918175 chr16 87357910 A G 4.41E-05 Intracranial aneurysm / / 22961961 rs3748395 chr16 87360627 G A 6.96E-05 Lymphocyte counts / / 22286170 rs1062746 chr16 87364650 T C 2.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy) FBXO31 UTR-3 24554482 rs11117267 chr16 87386375 T C 0.0006915 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FBXO31 intron 23233654 rs11117267 chr16 87386375 T C 6.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) FBXO31 intron 23233662 rs10779242 chr16 87386517 A G 0.000623 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FBXO31 intron 23233654 rs10779242 chr16 87386517 A G 6.23E-04 Methotrexate clearance (acute lymphoblastic leukemia) FBXO31 intron 23233662 rs10779243 chr16 87386754 A G 0.00068 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FBXO31 intron 23233654 rs10779243 chr16 87386754 A G 6.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) FBXO31 intron 23233662 rs8043667 chr16 87387765 A T 0.0008387 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FBXO31 intron 23233654 rs8043667 chr16 87387765 A T 8.39E-04 Methotrexate clearance (acute lymphoblastic leukemia) FBXO31 intron 23233662 rs11646004 chr16 87389001 C T 0.0007415 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FBXO31 intron 23233654 rs11646004 chr16 87389001 C T 7.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) FBXO31 intron 23233662 rs1834022 chr16 87394386 A G 0.00044 Prostate cancer FBXO31 intron 23555315 rs11645617 chr16 87409266 T C 0.0008598 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FBXO31 intron 23233654 rs11645617 chr16 87409266 T C 8.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) FBXO31 intron 23233662 rs11649260 chr16 87409288 G A 0.0008565 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FBXO31 intron 23233654 rs11649260 chr16 87409288 G A 8.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) FBXO31 intron 23233662 rs8054103 chr16 87420182 G A 9.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) FBXO31 intron 23233662 rs750956 chr16 87420769 G A 9.24E-05 Multiple complex diseases FBXO31 intron 17554300 rs7204722 chr16 87430239 C T 7.86E-04 Suicide attempts in bipolar disorder MAP1LC3B intron 21423239 rs8051218 chr16 87436463 T C 7.69E-04 Alzheimer's disease MAP1LC3B intron 24755620 rs1050863 chr16 87440895 G A 9.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) ZCCHC14 UTR-3 23233662 rs2241617 chr16 87441048 T C 0.000000106 Nicotine dependence (smoking) ZCCHC14 UTR-3 22377092 rs34068017 chr16 87441048 T TC 0.000000106 Nicotine dependence (smoking) ZCCHC14 UTR-3 22377092 rs3748400 chr16 87445839 C T 4.00E-05 Insulin response ZCCHC14 missense 19430760 rs3748400 chr16 87445839 C T 6.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZCCHC14 missense 20877124 rs3748400 chr16 87445839 C T 0.0000104 Nicotine dependence (smoking) ZCCHC14 missense 22377092 rs7191969 chr16 87455383 T C 9.18E-04 Alzheimer's disease ZCCHC14 intron 24755620 rs9646303 chr16 87461969 G A 5.00E-06 Major depressive disorder ZCCHC14 intron 22472876 rs9646303 chr16 87461969 G A 6.42E-06 Schizophrenia (treatment refractory) ZCCHC14 intron 22479419 rs9646303 chr16 87461969 G A 1.15E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) ZCCHC14 intron 24236485 rs12925472 chr16 87481032 C T 0.00025 Nicotine dependence (smoking) ZCCHC14 intron 22377092 rs12925472 chr16 87481032 C T 9.65E-05 Major depressive disorder ZCCHC14 intron 22472876 rs11644573 chr16 87483121 C T 6.65E-04 Insulin resistance ZCCHC14 intron 21901158 rs13334632 chr16 87490819 T C 0.0000128 Nicotine dependence (smoking) ZCCHC14 intron 22377092 rs11648852 chr16 87493737 T C 0.0000106 Nicotine dependence (smoking) ZCCHC14 missense 22377092 rs7192628 chr16 87494858 C T 0.00000583 Nicotine dependence (smoking) ZCCHC14 intron 22377092 rs9936994 chr16 87502815 G A 0.0000691 Nicotine dependence (smoking) ZCCHC14 intron 22377092 rs12051182 chr16 87518044 C T 2.56E-04 Insulin resistance ZCCHC14 intron 21901158 rs11645728 chr16 87556088 A G 9.90E-05 Major depressive disorder / / 22472876 rs11645728 chr16 87556088 A G 8.12E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11641868 chr16 87557621 G A 5.62E-04 Coronary Artery Disease / / 17634449 rs4488454 chr16 87569135 C G 4.97E-06 Attention deficit hyperactivity disorder / / 20732627 rs4488454 chr16 87569135 C G 7.30E-05 Diabetic retinopathy / / 21441570 rs9922687 chr16 87570851 T C 5.22E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11117283 chr16 87571161 C T 1.15E-05 Attention deficit hyperactivity disorder / / 20732627 rs11117283 chr16 87571161 C T 9.30E-05 Diabetic retinopathy / / 21441570 rs2334207 chr16 87581198 T G 4.60E-05 Longevity / / 22279548 rs2334207 chr16 87581198 T G 9.68E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2334208 chr16 87589190 T C 7.19E-05 Body Mass Index / / pha003007 rs2334208 chr16 87589190 T C 7.45E-05 Waist Circumference / / pha003024 rs2334208 chr16 87589190 T C 2.86E-05 Weight / / pha003026 rs2334208 chr16 87589190 T C 4.23E-05 Weight / / pha003027 rs3909525 chr16 87603645 G A 8.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2562059 chr16 87638855 C G 4.40E-22 Progranulin levels JPH3 intron 21087763 rs2562059 chr16 87638855 C G 4.40E-22 Myocardial infarction JPH3 intron 21211798 rs1864150 chr16 87641912 C T 6.74E-05 Serum metabolites JPH3 intron 19043545 rs1864152 chr16 87642073 A C 4.14E-04 Response to taxane treatment (placlitaxel) JPH3 intron 23006423 rs1864152 chr16 87642073 A C 1.50E-05 Magnesium levels JPH3 intron pha003092 rs918368 chr16 87678144 T C 6.86E-04 Amyotrophic Lateral Sclerosis JPH3 cds-synon 17362836 rs9934222 chr16 87678249 G A 0.0000228 Menopause (age at onset) JPH3 cds-synon 23424626 rs34975147 chr16 87678576 C T 5.00E-06 Bipolar disorder (body mass index interaction) JPH3 cds-synon 24322204 rs12443771 chr16 87680576 G A 1.13E-05 Brain derived neurotrophic factor levels,in serum JPH3 intron 22047184 rs4843650 chr16 87683486 A G 8.65E-05 Interstitial lung disease JPH3 intron 23583980 rs4843650 chr16 87683486 A G 9.70E-06 Behavioural disinhibition (generation interaction) JPH3 intron 23942779 rs7200927 chr16 87688524 A G 8.14E-04 Multiple complex diseases JPH3 intron 17554300 rs7203610 chr16 87688568 G A 1.07E-04 Smoking initiation JPH3 intron 24665060 rs1129212 chr16 87731878 G A 9.03E-04 Amyotrophic Lateral Sclerosis LOC100652950 intron 17362836 rs12447906 chr16 87756858 T C 9.30E-05 Cognitive function KLHDC4 intron 24684796 rs4354949 chr16 87784383 C T 7.38E-05 C-Reactive Protein KLHDC4 intron pha003070 rs4417557 chr16 87792392 T C 3.93E-04 Multiple complex diseases KLHDC4 intron 17554300 rs4843269 chr16 87802311 G A 2.80E-05 Urinary metabolites / / 21572414 rs7199224 chr16 87842914 A C 9.48E-04 Multiple complex diseases / / 17554300 rs8051149 chr16 87878822 G A 9.00E-26 Blood metabolite levels SLC7A5 intron 24816252 rs7499404 chr16 87957458 T C 8.88E-05 Diabetes (gestational) CA5A intron 22233651 rs8055231 chr16 87976349 A T 9.58E-04 Lymphocyte counts / / 22286170 rs6540118 chr16 87980759 T C 8.57E-05 Aging (time to event) / / 21782286 rs4843747 chr16 87991051 A C 2.00E-07 Menopause (age at onset) BANP intron 19448619 rs4843291 chr16 88013385 A G 1.17E-06 Systemic lupus erythematosus and Systemic sclerosis BANP intron 23740937 rs12102841 chr16 88072574 C G 5.34E-04 Response to taxane treatment (placlitaxel) BANP intron 23006423 rs8045521 chr16 88074533 C T 7.58E-04 Alzheimer's disease BANP intron 24755620 rs8044965 chr16 88074927 G C 7.58E-04 Alzheimer's disease BANP intron 24755620 rs4843779 chr16 88077317 C T 9.20E-04 Alzheimer's disease BANP intron 24755620 rs11641065 chr16 88079144 A G 9.36E-04 Alzheimer's disease BANP intron 24755620 rs7403837 chr16 88081639 G C 5.51E-04 Multiple complex diseases BANP intron 17554300 rs9930033 chr16 88090168 C T 8.15E-04 Alzheimer's disease BANP intron 24755620 rs11117354 chr16 88092092 T C 9.16E-04 Alzheimer's disease BANP intron 24755620 rs7499959 chr16 88110422 C G 2.95E-04 Response to taxane treatment (placlitaxel) BANP UTR-3 23006423 rs4843792 chr16 88116130 A G 7.25E-04 Alzheimer's disease / / 24755620 rs9940475 chr16 88157383 G T 8.28E-05 Coronary heart disease / / 21606135 rs8046487 chr16 88161416 A G 5.44E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9936927 chr16 88162882 G A 1.78E-04 Coronary heart disease / / 21606135 rs7206210 chr16 88165210 T C,G 5.60E-04 Stroke / / pha002886 rs6540190 chr16 88198278 G A 7.13E-04 Stroke / / pha002886 rs11117382 chr16 88199279 C G 1.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs7196712 chr16 88213794 C T 5.70E-06 Kawasaki disease / / 22446962 rs12925118 chr16 88283703 G A 5.09E-05 Fibrinogen / / pha003068 rs12447690 chr16 88298124 C T 9.00E-11 Central corneal thickness / / 20485516 rs12447690 chr16 88298124 C T 6.00E-22 Central corneal thickness / / 20719862 rs12447690 chr16 88298124 C T 9.23E-34 Central corneal thickness / / 21098505 rs12447690 chr16 88298124 C T 3.62E-12 Central corneal thickness / / 22814818 rs12447690 chr16 88298124 C T 8.42E-37 Corneal structure / / 23291589 rs12447690 chr16 88298124 C T 4.46E-06 Axial length / / 24144296 rs7500824 chr16 88299491 A G 1.14E-11 Central corneal thickness / / 20719862 rs7500824 chr16 88299491 A G 7.08E-39 Corneal structure / / 23291589 rs7500824 chr16 88299491 A G 9.45E-07 Axial length / / 24144296 rs4352077 chr16 88300429 C T 5.56E-07 Axial length / / 24144296 rs7405095 chr16 88307825 A G 1.18E-11 Central corneal thickness / / 20719862 rs8059024 chr16 88314163 T C 4.60E-06 Central corneal thickness / / 20719862 rs8059024 chr16 88314163 T C 2.46E-07 Axial length / / 24144296 rs6540220 chr16 88315515 G C 1.23E-11 Central corneal thickness / / 20719862 rs7501109 chr16 88320862 G C 1.24E-11 Central corneal thickness / / 20719862 rs7501109 chr16 88320862 G C 4.36E-07 Axial length / / 24144296 rs7501402 chr16 88320911 A T 1.68E-11 Central corneal thickness / / 20719862 rs7501402 chr16 88320911 A T 1.03E-06 Axial length / / 24144296 rs6540223 chr16 88321436 C T 1.40E-11 Central corneal thickness / / 20719862 rs6540223 chr16 88321436 C T 1.27E-39 Corneal structure / / 23291589 rs6540223 chr16 88321436 C T 7.00E-08 Axial length / / 24144296 rs12448211 chr16 88330513 G A 2.59E-38 Corneal structure / / 23291589 rs12448211 chr16 88330513 G A 9.27E-06 Axial length / / 24144296 rs9938149 chr16 88331640 C A 5.20E-07 Central corneal thickness / / 20485516 rs9938149 chr16 88331640 C A 1.63E-16 Central corneal thickness / / 21098505 rs9938149 chr16 88331640 C A 1.00E-12 Central corneal thickness / / 22814818 rs9938149 chr16 88331640 C A 2.00E-49 Corneal structure / / 23291589 rs9938149 chr16 88331640 C A 6.38E-07 Axial length / / 24144296 rs8059298 chr16 88332479 T C 1.20E-06 Axial length / / 24144296 rs9925231 chr16 88338107 T C 6.42E-12 Central corneal thickness / / 21098505 rs7204132 chr16 88344517 T G 8.30E-06 Central corneal thickness / / 20485516 rs7204132 chr16 88344517 T G 2.69E-07 Central corneal thickness / / 20719862 rs7204132 chr16 88344517 T G 9.45E-11 Central corneal thickness / / 21098505 rs9927272 chr16 88346709 G A 1.21E-08 Central corneal thickness / / 21098505 rs12597574 chr16 88356427 G T 3.98E-04 Sudden cardiac arrest / / 21658281 rs6603052 chr16 88358227 C T 6.46E-06 Longevity,exceptional / / 20595579 rs9930225 chr16 88370667 A G 5.76E-05 Serum metabolites / / 19043545 rs7204523 chr16 88376441 G A 7.91E-05 Serum metabolites / / 19043545 rs904790 chr16 88528780 T C 8.00E-06 Follicle stimulating hormone ZFPM1 intron 24049095 rs868874 chr16 88570383 T C 1.28E-05 Alcohol dependence ZFPM1 intron 23089632 rs3965782 chr16 88576794 G A 7.40E-04 Alcohol dependence ZFPM1 intron 24277619 rs9935402 chr16 88639749 G A 8.47E-04 Multiple complex diseases ZC3H18 intron 17554300 rs9932685 chr16 88675177 A G 2.54E-04 Fibrinogen ZC3H18 intron 17255346 rs11642855 chr16 88682317 G A 5.84E-04 Smoking initiation ZC3H18 intron 24665060 rs8047318 chr16 88683946 A G 2.85E-05 Bipolar disorder ZC3H18 intron 19259986 rs1111434 chr16 88688435 G T 1.90E-04 Fibrinogen ZC3H18 intron 17255346 rs8062466 chr16 88696309 C T 3.13E-04 Multiple complex diseases ZC3H18 intron 17554300 rs899729 chr16 88701780 C A 2.73E-05 Fibrinogen / / 17255346 rs3794624 chr16 88717074 G A 8.54E-05 Soluble levels of adhesion molecules CYBA intron pha003072 rs6500487 chr16 88727733 C T 8.20E-07 Urinary metabolites MVD intron 21572414 rs1056707 chr16 88741504 G C 7.70E-06 Urinary metabolites MGC23284 intron 21572414 rs4287555 chr16 88755325 G C 9.20E-06 Urinary metabolites / / 21572414 rs7186861 chr16 88761282 G A 0.00086536 Hypertension (early onset hypertension) / / 22479346 rs881633 chr16 88773738 C T 2.10E-05 Follicular lymphoma CTU2 intron 21533074 rs8052560 chr16 88777242 C A 3.00E-08 Height CTU2 intron 20881960 rs2290904 chr16 88780090 G A 1.28E-04 Suicide attempts in bipolar disorder CTU2 cds-synon 21423239 rs2290902 chr16 88782676 A G 3.27E-06 Bicuspid aortic valve PIEZO1 cds-synon 20098615 rs2290901 chr16 88783233 C T 1.10E-16 Health and aging,CVD and cancer age of onset PIEZO1 missense 22174011 rs2290901 chr16 88783233 C T 7.20E-20 Health and aging,CVD and cancer age of onset PIEZO1 missense 22174011 rs750740 chr16 88807338 T C 4.63E-04 Stroke (ischemic) PIEZO1 intron 21940970 rs750739 chr16 88807608 A G 2.09E-08 Red blood cell traits PIEZO1 intron 23222517 rs6500497 chr16 88810587 T A 1.60E-04 Suicidal ideation PIEZO1 intron 22030708 rs6500498 chr16 88810645 G C 3.00E-04 Suicidal ideation PIEZO1 intron 22030708 rs9788969 chr16 88812250 T C 1 Drug response to Etoposide PIEZO1 intron 17537913 rs750124 chr16 88813114 G A 1 Drug response to Etoposide PIEZO1 intron 17537913 rs2341002 chr16 88835579 C T 7.71E-05 Coronary heart disease PIEZO1 intron pha003035 rs10445033 chr16 88840462 G A 2.00E-22 Red blood cell traits PIEZO1 intron 23222517 rs889761 chr16 88842215 G C 9.51E-14 Red blood cell traits PIEZO1 intron 23222517 rs2932690 chr16 88842953 G A 5.82E-08 Red blood cell traits PIEZO1 intron 23222517 rs9933309 chr16 88844932 T C 8.96E-12 Red blood cell traits PIEZO1 intron 23222517 rs9933309 chr16 88844932 T C 1.00E-08 Glycated hemoglobin levels PIEZO1 intron 24647736 rs9932423 chr16 88846849 C A 2.80E-07 Red blood cell traits PIEZO1 intron 23222517 rs475596 chr16 88846951 G C 3.03E-08 Red blood cell traits PIEZO1 intron 23222517 rs2608604 chr16 88849421 A G 3.96E-08 Red blood cell traits PIEZO1 intron 23222517 rs2608604 chr16 88849421 A G 9.17E-05 Platelet counts PIEZO1 intron 23263863 rs837763 chr16 88853729 C T 3.55E-13 Blood cell counts and other traits / / 20139978 rs837763 chr16 88853729 C T 4.00E-13 Blood cell counts and other traits / / 20139978 rs837763 chr16 88853729 C T 5.00E-10 Mean corpuscular hemoglobin concentration / / 22560525 rs837763 chr16 88853729 C T 7.13E-11 Red blood cell traits / / 23222517 rs837763 chr16 88853729 C T 4.08E-04 Red blood cell traits / / 23935956 rs860762 chr16 88856370 C T 1.50E-08 Red blood cell traits / / 23222517 rs8191478 chr16 88877429 G A 3.45E-04 Lung function (forced expiratory volume in 1 second) APRT intron 24023788 rs550269 chr16 88881635 T C 2.00E-05 Brain structure GALNS intron 22504417 rs7205379 chr16 88904800 A G 1.34E-05 Hemoglobin GALNS intron pha003096 rs7205379 chr16 88904800 A G 7.74E-05 Hematocrit GALNS intron pha003097 rs12447646 chr16 88910824 G A 4.90E-04 Alzheimer's disease GALNS intron 22005930 rs11076726 chr16 88912899 G T 6.96E-04 Multiple complex diseases GALNS intron 17554300 rs729795 chr16 88952904 G A 1.54E-04 Multiple complex diseases CBFA2T3 intron 17554300 rs533581 chr16 88967437 T C 8.00E-06 Social autistic-like traits CBFA2T3 intron 24133439 rs488251 chr16 88972554 G A 3.90E-05 Glucose levels CBFA2T3 intron pha003058 rs1808448 chr16 88993580 C T 3.84E-04 Response to taxane treatment (placlitaxel) CBFA2T3 intron 23006423 rs9922120 chr16 89010291 C T 3.85E-05 Cognitive test performance CBFA2T3 intron 20125193 rs7188793 chr16 89042861 A G 9.18E-05 Pulmonary function CBFA2T3 intron 20010835 rs9932354 chr16 89052565 C A 6.00E-08 Skin sensitivity to sun / / 18488028 rs11076747 chr16 89057025 G A 2.70E-08 Hair,eye and skin pigmentation / / 17952075 rs11076747 chr16 89057025 G A 5.50E-11 Skin sensitivity to sun / / 18488028 rs7193497 chr16 89064019 T C 5.97E-06 Biliary atresia / / 20460270 rs7186136 chr16 89122739 T C 2.55E-04 Multiple complex diseases / / 17554300 rs7184784 chr16 89170171 T C 8.77E-04 Graves' disease ACSF3 intron 21841780 rs4782328 chr16 89182218 A G 1.09E-05 Femoral neck bone geometry ACSF3 intron 22087292 rs4530136 chr16 89201805 A G 6.07E-04 Graves' disease ACSF3 intron 21841780 rs12599126 chr16 89206483 T C 8.30E-08 Skin sensitivity to sun ACSF3 intron 18488028 rs4310853 chr16 89229984 G A 2.02E-05 Femoral neck bone geometry / / 22087292 rs729201 chr16 89240783 A G 7.85E-07 Heart Failure CDH15 intron pha002884 rs1112463 chr16 89270661 A T 9.78E-05 Femoral neck bone geometry / / 22087292 rs9921361 chr16 89294439 G T 4.40E-09 Hair,eye and skin pigmentation ZNF778 missense 17952075 rs9921361 chr16 89294439 G T 2.30E-11 Skin sensitivity to sun ZNF778 missense 18488028 rs9921361 chr16 89294439 G T 9.96E-04 Suicide attempts in bipolar disorder ZNF778 missense 21423239 rs4785637 chr16 89316412 C T 3.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs4785644 chr16 89321238 T C 7.90E-05 Adiposity / / 19461586 rs4785644 chr16 89321238 T C 5.27E-07 Blood Pressure / / pha003044 rs4785648 chr16 89328477 A G 4.90E-08 Skin sensitivity to sun / / 18488028 rs2306632 chr16 89337143 C A,G,T 1.00E-04 Information processing speed ANKRD11 intron 21130836 rs1466540 chr16 89344477 C T 1.20E-07 Hair,eye and skin pigmentation ANKRD11 intron 17952075 rs1466540 chr16 89344477 C T 9.80E-09 Skin sensitivity to sun ANKRD11 intron 18488028 rs2279349 chr16 89350178 G A 3.07E-04 Heart Failure ANKRD11 cds-synon pha002884 rs2353028 chr16 89352678 G A 4.40E-10 Hair,eye and skin pigmentation ANKRD11 intron 17952075 rs2353028 chr16 89352678 G A 1.70E-13 Skin sensitivity to sun ANKRD11 intron 18488028 rs2353028 chr16 89352678 G A 1.65E-05 Blood Pressure ANKRD11 intron pha003044 rs2306633 chr16 89355278 A G 5.30E-12 Hair,eye and skin pigmentation ANKRD11 intron 17952075 rs2306633 chr16 89355278 A G 2.20E-16 Skin sensitivity to sun ANKRD11 intron 18488028 rs2306633 chr16 89355278 A G 5.95E-05 Blood Pressure ANKRD11 intron pha003044 rs3114916 chr16 89361613 G C 7.06E-04 Type 2 diabetes ANKRD11 intron 17463246 rs2277908 chr16 89371839 G A 3.47E-05 Schizophrenia ANKRD11 intron pha002859 rs3096304 chr16 89373707 C T 3.20E-09 Skin sensitivity to sun ANKRD11 intron 18488028 rs3114908 chr16 89383725 T C 6.09E-04 Type 2 diabetes ANKRD11 intron 17463246 rs2353033 chr16 89385561 C T 1.90E-17 Hair,eye and skin pigmentation ANKRD11 intron 17952075 rs2353033 chr16 89385561 C T 7.98E-08 Black vs. red hair color ANKRD11 intron 18483556 rs2353033 chr16 89385561 C T 2.30E-26 Skin sensitivity to sun ANKRD11 intron 18488028 rs2353033 chr16 89385561 C T 3.32E-07 Melanoma ANKRD11 intron 21706340 rs889574 chr16 89386808 A G 4.40E-08 Hair,eye and skin pigmentation ANKRD11 intron 17952075 rs889574 chr16 89386808 A G 1.50E-09 Skin sensitivity to sun ANKRD11 intron 18488028 rs3096322 chr16 89441123 G A 1.10E-05 Urinary metabolites ANKRD11 intron 21572414 rs3096299 chr16 89448663 G A 4.00E-06 Multiple myeloma (IgH translocation) ANKRD11 intron 23502783 rs2086824 chr16 89471246 A C 2.00E-06 Multiple myeloma (IgH translocation) ANKRD11 intron 23502783 rs2965946 chr16 89516612 T C 3.90E-08 Skin sensitivity to sun ANKRD11 intron 18488028 rs4347628 chr16 89570635 T C 2.10E-12 Hair,eye and skin pigmentation / / 17952075 rs4347628 chr16 89570635 T C 1.70E-13 Skin sensitivity to sun / / 18488028 rs4347628 chr16 89570635 T C 3.80E-09 Common traits (Other) / / 20585627 rs12924776 chr16 89586592 A T 9.93E-06 Coronary heart disease SPG7 intron 21378990 rs3803677 chr16 89595723 G A 1.70E-04 Multiple complex diseases SPG7 intron 17554300 rs3803676 chr16 89596106 C T 9.38E-05 Multiple complex diseases SPG7 intron 17554300 rs2460456 chr16 89601893 C T 7.13E-04 Multiple complex diseases SPG7 intron 17554300 rs11640186 chr16 89602006 C G 3.29E-04 Multiple complex diseases SPG7 intron 17554300 rs382745 chr16 89603586 A G 5.08E-05 Multiple complex diseases SPG7 UTR-3 17554300 rs382745 chr16 89603586 A G 4.50E-13 Hair,eye and skin pigmentation SPG7 UTR-3 17952075 rs382745 chr16 89603586 A G 3.90E-18 Skin sensitivity to sun SPG7 UTR-3 18488028 rs382745 chr16 89603586 A G 4.42E-08 Lymphocyte counts SPG7 UTR-3 22286170 rs2056309 chr16 89607414 G A 4.76E-04 Multiple complex diseases SPG7 intron 17554300 rs2292954 chr16 89613123 A G 1 Drug response to Docetaxel SPG7 missense 20038957 rs2292954 chr16 89613123 A G 1 Drug response to Thalidomide SPG7 missense 20038957 rs12960 chr16 89620328 G A 1 Drug response to Docetaxel SPG7 missense 20038957 rs12960 chr16 89620328 G A 1 Drug response to Thalidomide SPG7 missense 20038957 rs16965827 chr16 89626894 G A 5.75E-04 Multiple complex diseases / / 17554300 rs12709089 chr16 89630311 G A 8.82E-04 Multiple complex diseases RPL13 UTR-3 17554300 rs455527 chr16 89644001 T C 6.10E-09 Skin sensitivity to sun CPNE7 missense 18488028 rs455527 chr16 89644001 T C 4.15E-05 Heart Failure CPNE7 missense pha002884 rs352935 chr16 89648580 C T 2.20E-10 Hair,eye and skin pigmentation CPNE7 intron 17952075 rs352935 chr16 89648580 C T 9.10E-19 Skin sensitivity to sun CPNE7 intron 18488028 rs352935 chr16 89648580 C T 1.00E-05 Tanning CPNE7 intron 19340012 rs352935 chr16 89648580 C T 5.78E-06 Melanoma CPNE7 intron 21706340 rs352935 chr16 89648580 C T 6.61E-05 Melanoma CPNE7 intron 21926416 rs464349 chr16 89656251 T C 1.20E-13 Hair,eye and skin pigmentation CPNE7 intron 17952075 rs464349 chr16 89656251 T C 1.30E-20 Skin sensitivity to sun CPNE7 intron 18488028 rs464349 chr16 89656251 T C 5.60E-07 Tanning CPNE7 intron 19340012 rs154659 chr16 89667337 T C 7.00E-08 Tanning / / 19340012 rs154659 chr16 89667337 T C 2.40E-09 Common traits (Other) / / 20585627 rs154659 chr16 89667337 T C 7.56E-05 Pancreatic cancer / / pha002874 rs8059821 chr16 89675068 T G 1.96E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16965867 chr16 89680868 C T 1 Drug response to Etoposide DPEP1 intron 17537913 rs164741 chr16 89692298 A G 9.00E-39 Hair,eye and skin pigmentation DPEP1 intron 17952075 rs164741 chr16 89692298 A G 1.05E-10 Black vs. red hair color DPEP1 intron 18483556 rs164741 chr16 89692298 A G 1.50E-61 Skin sensitivity to sun DPEP1 intron 18488028 rs164741 chr16 89692298 A G 1.50E-06 Melanoma DPEP1 intron 21706340 rs164741 chr16 89692298 A G 2.43E-06 Melanoma DPEP1 intron 21926416 rs445537 chr16 89703424 A G 4.00E-04 Response to antidepressants DPEP1 intron 19736353 rs445537 chr16 89703424 A G 9.77E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) DPEP1 intron 23648065 rs154657 chr16 89708096 G A 2.30E-06 Urinary metabolites / / 21572414 rs154657 chr16 89708096 G A 2.00E-43 Homocysteine levels / / 23824729 rs164749 chr16 89708224 T G 3.10E-06 Urinary metabolites / / 21572414 rs164746 chr16 89709019 G A 6.00E-06 Urinary metabolites / / 21572414 rs460879 chr16 89712889 C T 2.00E-22 Hair,eye and skin pigmentation CHMP1A intron 17952075 rs460879 chr16 89712889 C T 2.70E-38 Skin sensitivity to sun CHMP1A intron 18488028 rs460879 chr16 89712889 C T 1.70E-12 Common traits (Other) CHMP1A intron 20585627 rs258336 chr16 89720831 T G 1.20E-05 Urinary metabolites CHMP1A intron 21572414 rs11647958 chr16 89720909 T A 8.20E-06 Urinary metabolites CHMP1A intron 21572414 rs154663 chr16 89726035 T C 9.00E-07 Height C16orf55 intron 23456168 rs7188458 chr16 89726484 G A 5.43E-04 Type 2 diabetes C16orf55 intron 17463246 rs7188458 chr16 89726484 G A 1.60E-37 Hair,eye and skin pigmentation C16orf55 intron 17952075 rs7188458 chr16 89726484 G A 6.85E-09 Black vs. red hair color C16orf55 intron 18483556 rs7188458 chr16 89726484 G A 1.10E-58 Skin sensitivity to sun C16orf55 intron 18488028 rs7188458 chr16 89726484 G A 7.99E-11 Melanoma C16orf55 intron 21706340 rs459920 chr16 89730827 T C 9.50E-20 Hair,eye and skin pigmentation C16orf55 intron 17952075 rs459920 chr16 89730827 T C 5.70E-34 Skin sensitivity to sun C16orf55 intron 18488028 rs459920 chr16 89730827 T C 1.70E-11 Common traits (Other) C16orf55 intron 20585627 rs459920 chr16 89730827 T C 5.41E-06 Melanoma C16orf55 intron 21706340 rs447735 chr16 89734349 T C 1.41E-10 Common traits (Other) C16orf55 intron 20585627 rs467035 chr16 89740285 C G 5.00E-06 Urinary metabolites / / 21572414 rs2115401 chr16 89740609 T C 6.10E-06 Urinary metabolites / / 21572414 rs12443954 chr16 89741496 A G 8.00E-14 Hair,eye and skin pigmentation / / 17952075 rs12443954 chr16 89741496 A G 3.80E-24 Skin sensitivity to sun / / 18488028 rs12443954 chr16 89741496 A G 6.92E-07 Common traits (Other) / / 20585627 rs12443954 chr16 89741496 A G 1.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs3751700 chr16 89752194 G A 2.30E-09 Skin sensitivity to sun / / 18488028 rs3751700 chr16 89752194 G A 6.37E-05 Major depressive disorder / / 22472876 rs3751700 chr16 89752194 G A 6.06E-04 Heart Failure / / pha002884 rs258324 chr16 89754255 T G 1.70E-09 Hair,eye and skin pigmentation CDK10 intron 17952075 rs258324 chr16 89754255 T G 2.10E-11 Skin sensitivity to sun CDK10 intron 18488028 rs258324 chr16 89754255 T G 9.87E-05 Major depressive disorder CDK10 intron 22472876 rs258322 chr16 89755903 A G 5.60E-27 Hair,eye and skin pigmentation CDK10 intron 17952075 rs258322 chr16 89755903 A G 2.00E-23 Black vs. red hair color CDK10 intron 18483556 rs258322 chr16 89755903 A G 4.20E-41 Skin sensitivity to sun CDK10 intron 18488028 rs258322 chr16 89755903 A G 6.61E-04 Bipolar disorder,schizoaffective CDK10 intron 19567891 rs258322 chr16 89755903 A G 3.00E-27 Melanoma CDK10 intron 19578364 rs258322 chr16 89755903 A G 3.00E-27 Nasopharyngeal carcinoma CDK10 intron 20512145 rs258322 chr16 89755903 A G 7.54E-17 Melanoma CDK10 intron 21706340 rs258322 chr16 89755903 A G 9.63E-07 Melanoma CDK10 intron 21926416 rs258322 chr16 89755903 A G 3.00E-27 Melanoma CDK10 intron 21983787 rs258322 chr16 89755903 A G 1.33E-66 Hair color (red) CDK10 intron 22140526 rs258322 chr16 89755903 A G 2.00E-09 Melanoma CDK10 intron 24980573 rs1946482 chr16 89762410 T C 1.80E-09 Skin sensitivity to sun CDK10 UTR-3 18488028 rs3751695 chr16 89764549 G A 6.00E-14 Hair,eye and skin pigmentation SPATA2L cds-synon 17952075 rs3751695 chr16 89764549 G A 3.80E-13 Skin sensitivity to sun SPATA2L cds-synon 18488028 rs3751695 chr16 89764549 G A 8.87E-05 Bone mineral density SPATA2L cds-synon 19181680 rs4785587 chr16 89772619 G A 4.78E-06 Vitiligo / / 22561518 rs1110331 chr16 89774396 G A 9.90E-06 Urinary metabolites C16orf7 intron 21572414 rs3809646 chr16 89786855 C T 0.000576 Bipolar disorder C16orf7 intron 23637625 rs6500437 chr16 89789898 T C 2.20E-08 Skin sensitivity to sun ZNF276 missense 18488028 rs6500437 chr16 89789898 T C 2.63E-09 Common traits (Other) ZNF276 missense 20585627 rs7204478 chr16 89795485 C T 1.40E-39 Hair,eye and skin pigmentation ZNF276 intron 17952075 rs7204478 chr16 89795485 C T 2.38E-06 Black vs. red hair color ZNF276 intron 18483556 rs7204478 chr16 89795485 C T 1.30E-62 Skin sensitivity to sun ZNF276 intron 18488028 rs7189734 chr16 89800550 G A 4.07E-08 Common traits (Other) ZNF276 intron 20585627 rs1800359 chr16 89805261 A G 3.50E-22 Hair,eye and skin pigmentation ZNF276 UTR-3 17952075 rs1800359 chr16 89805261 A G 4.50E-34 Skin sensitivity to sun ZNF276 UTR-3 18488028 rs1800359 chr16 89805261 A G 1.41E-06 Melanoma ZNF276 UTR-3 21706340 rs1061646 chr16 89805977 G A 9.12E-09 Common traits (Other) ZNF276 UTR-3 20585627 rs8058895 chr16 89814807 T C 1.50E-19 Hair,eye and skin pigmentation FANCA intron 17952075 rs8058895 chr16 89814807 T C 2.30E-31 Skin sensitivity to sun FANCA intron 18488028 rs2011877 chr16 89814818 T A,G 5.20E-08 Skin sensitivity to sun FANCA intron 18488028 rs2011877 chr16 89814818 T A,G 6.80E-07 Hair color (red) FANCA intron 22140526 rs1800345 chr16 89815217 C T 4.57E-08 Common traits (Other) FANCA intron 20585627 rs9926296 chr16 89818089 A G 2.00E-13 Vitiligo FANCA intron 22561518 rs12931267 chr16 89818732 C G 3.00E-10 Hair color FANCA intron 20585627 rs12931267 chr16 89818732 C G 5.00E-87 Hair color FANCA intron 20585627 rs12931267 chr16 89818732 C G 8.00E-62 Freckling FANCA intron 20585627 rs3890534 chr16 89835289 C T 1.05E-05 Caffeine consumption FANCA intron 21490707 rs3890534 chr16 89835289 C T 6.30E-05 Blood pressure (response to angiotensin II receptor blocker) FANCA intron 24192120 rs7195066 chr16 89836323 C T 4.30E-26 Hair,eye and skin pigmentation FANCA missense 17952075 rs7195066 chr16 89836323 C T 2.50E-43 Skin sensitivity to sun FANCA missense 18488028 rs3785275 chr16 89842029 C G 1.35E-08 Common traits (Other) FANCA intron 20585627 rs2016571 chr16 89844276 G C 6.31E-09 Common traits (Other) FANCA intron 20585627 rs8058179 chr16 89846987 A G 1.70E-04 Multiple complex diseases FANCA intron 17554300 rs8058179 chr16 89846987 A G 9.40E-06 Urinary metabolites FANCA intron 21572414 rs2239359 chr16 89849480 C T 4.50E-10 Skin sensitivity to sun FANCA missense 18488028 rs2239360 chr16 89849583 C T 3.98E-07 Common traits (Other) FANCA intron 20585627 rs16966142 chr16 89851033 C T 1.10E-09 Hair,eye and skin pigmentation FANCA intron 17952075 rs16966142 chr16 89851033 C T 4.90E-13 Skin sensitivity to sun FANCA intron 18488028 rs16966142 chr16 89851033 C T 1.41E-08 Common traits (Other) FANCA intron 20585627 rs16966142 chr16 89851033 C T 6.00E-06 Caffeine consumption FANCA intron 21490707 rs6500450 chr16 89858024 A G 5.10E-05 Lymphocyte counts FANCA intron 22286170 rs6500452 chr16 89858505 T C 9.55E-08 Common traits (Other) FANCA intron 20585627 rs12921383 chr16 89859753 T C 8.00E-11 Homocysteine levels FANCA intron 23824729 rs1800286 chr16 89869761 T C 2.50E-23 Hair,eye and skin pigmentation FANCA intron 17952075 rs1800286 chr16 89869761 T C 8.80E-36 Skin sensitivity to sun FANCA intron 18488028 rs11861084 chr16 89875710 A C 2.20E-24 Hair,eye and skin pigmentation FANCA intron 17952075 rs11861084 chr16 89875710 A C 6.00E-37 Skin sensitivity to sun FANCA intron 18488028 rs11861084 chr16 89875710 A C 6.20E-07 Urinary metabolites FANCA intron 21572414 rs11861084 chr16 89875710 A C 1.64E-06 Melanoma FANCA intron 21706340 rs8047581 chr16 89884502 C T 8.20E-07 Urinary metabolites FANCA nearGene-5 21572414 rs2079672 chr16 89884917 G A 3.38E-04 Multiple complex diseases FANCA nearGene-5 17554300 rs2079672 chr16 89884917 G A 1.40E-06 Urinary metabolites FANCA nearGene-5 21572414 rs2293585 chr16 89888853 C T 1.01E-05 Alcohol consumption / / 23953852 rs6500457 chr16 89898764 G C 2.83E-04 Multiple complex diseases SPIRE2 intron 17554300 rs6500457 chr16 89898764 G C 2.20E-06 Urinary metabolites SPIRE2 intron 21572414 rs6500457 chr16 89898764 G C 0.000719 Salmonella-induced pyroptosis SPIRE2 intron 22837397 rs12599531 chr16 89909401 T C 2.90E-07 Urinary metabolites SPIRE2 intron 21572414 rs8060934 chr16 89920025 C T 1.70E-30 Hair,eye and skin pigmentation SPIRE2 intron 17952075 rs8060934 chr16 89920025 C T 3.50E-49 Skin sensitivity to sun SPIRE2 intron 18488028 rs3803688 chr16 89934886 A G 5.40E-08 Skin sensitivity to sun SPIRE2 intron 18488028 rs2270461 chr16 89972345 T C 2.50E-18 Progranulin levels TCF25 intron 21087763 rs2270461 chr16 89972345 T C 2.50E-18 Myocardial infarction TCF25 intron 21211798 rs2270460 chr16 89972416 C A 6.40E-10 Skin sensitivity to sun TCF25 intron 18488028 rs8045560 chr16 89979494 T C 1.71E-04 Parkinson's disease / / 17052657 rs3212345 chr16 89982272 T C 2.00E-04 Parkinson's disease / / 17052657 rs3212346 chr16 89982358 G A 4.70E-09 Skin sensitivity to sun MC1R nearGene-5 18488028 rs1805006 chr16 89985918 C A 9.55E-07 Common traits (Other) MC1R missense 20585627 rs2228479 chr16 89985940 G A 6.80E-04 Skin pigmentation MC1R missense 17999355 rs11547464 chr16 89986091 G A 1.41E-13 Common traits (Other) MC1R missense 20585627 rs1805007 chr16 89986117 C T 1.00E-96 Freckles MC1R missense 17952075 rs1805007 chr16 89986117 C T 2.00E-13 Blond vs. brown hair color MC1R missense 17952075 rs1805007 chr16 89986117 C T 2.00E-142 Red vs non-red hair color MC1R missense 17952075 rs1805007 chr16 89986117 C T 2.00E-55 Skin sensitivity to sun MC1R missense 17952075 rs1805007 chr16 89986117 C T 4.00E-17 Basal cell carcinoma MC1R missense 21700618 rs1805007 chr16 89986117 C T 3.20E-139 Hair color (red) MC1R missense 22140526 rs1805007 chr16 89986117 C T 1.00E-65 Tanning MC1R missense 23548203 rs1805007 chr16 89986117 C T 2.00E-19 Sunburns MC1R missense 23548203 rs1805007 chr16 89986117 C T 3.00E-09 Hair color MC1R missense 23548203 rs1805007 chr16 89986117 C T 3.00E-10 Non-melanoma skin cancer MC1R missense 23548203 rs1805008 chr16 89986144 C T 4.20E-95 Hair,eye and skin pigmentation MC1R missense 17952075 rs1805008 chr16 89986144 C T 3.40E-50 Hair color (red) MC1R missense 22140526 rs1805008 chr16 89986144 C T 1.30E-13 Tanning MC1R missense 23548203 rs1805008 chr16 89986144 C T 4.80E-05 Sunburns MC1R missense 23548203 rs1805008 chr16 89986144 C T 7.20E-05 Hair color MC1R missense 23548203 rs885479 chr16 89986154 G A 2.10E-09 Skin sensitivity to sun MC1R missense 18488028 rs885479 chr16 89986154 G A 2.12E-05 Information processing speed MC1R missense 21130836 rs885479 chr16 89986154 G A 1.42E-05 Heart Failure MC1R missense pha002884 rs3212369 chr16 89986760 A G 3.78E-04 Alcohol dependence MC1R UTR-3 20201924 rs2302898 chr16 89998794 G A 8.90E-12 Hair color (red) TUBB3 intron 22140526 rs7195043 chr16 90020861 C T 5.18E-09 Melanoma DEF8 intron 21926416 rs8049897 chr16 90024202 G A 9.52E-22 Black vs. red hair color DEF8 intron 18483556 rs8049897 chr16 90024202 G A 7.07E-04 Major depressive disorder DEF8 intron 22472876 rs8051733 chr16 90024206 A G 3.80E-09 Melanoma DEF8 intron 21926416 rs17784583 chr16 90026979 T C 2.52E-05 Caffeine consumption DEF8 intron 21490707 rs8063761 chr16 90027626 A T 7.47E-05 Type 2 diabetes DEF8 intron 17463246 rs8063761 chr16 90027626 A T 6.03E-04 Alzheimer's disease DEF8 intron 17998437 rs4785751 chr16 90029417 G A 1.13E-10 Melanoma DEF8 intron 21926416 rs4785752 chr16 90035141 A G 5.66E-08 Melanoma / / 21926416 rs4785755 chr16 90037828 G A 1.40E-08 Hair,eye and skin pigmentation CENPBD1 missense 17952075 rs4785755 chr16 90037828 G A 1.90E-14 Skin sensitivity to sun CENPBD1 missense 18488028 rs4785755 chr16 90037828 G A 5.13E-07 Common traits (Other) CENPBD1 missense 20585627 rs4408545 chr16 90044028 C T 2.20E-44 Hair,eye and skin pigmentation AFG3L1P intron 17952075 rs4408545 chr16 90044028 C T 1.22E-12 Black vs. red hair color AFG3L1P intron 18483556 rs4408545 chr16 90044028 C T 7.60E-72 Skin sensitivity to sun AFG3L1P intron 18488028 rs4408545 chr16 90044028 C T 1.29E-06 Melanoma AFG3L1P intron 21706340 rs4408545 chr16 90044028 C T 4.43E-10 Melanoma AFG3L1P intron 21926416 rs11648898 chr16 90045986 A G 1.62E-08 Melanoma AFG3L1P intron 21926416 rs4238833 chr16 90050689 G T 3.90E-55 Hair,eye and skin pigmentation AFG3L1P intron 17952075 rs4238833 chr16 90050689 G T 1.46E-14 Black vs. red hair color AFG3L1P intron 18483556 rs4238833 chr16 90050689 G T 3.40E-84 Skin sensitivity to sun AFG3L1P intron 18488028 rs4238833 chr16 90050689 G T 1.04E-09 Melanoma AFG3L1P intron 21706340 rs4238833 chr16 90050689 G T 5.78E-07 Melanoma AFG3L1P intron 21926416 rs4785759 chr16 90050880 A C 4.42E-08 Melanoma AFG3L1P intron 21926416 rs9939542 chr16 90053048 A C 4.32E-06 Melanoma AFG3L1P intron 21926416 rs7201721 chr16 90058746 G A 4.40E-10 Hair,eye and skin pigmentation AFG3L1P intron 17952075 rs7201721 chr16 90058746 G A 8.70E-15 Skin sensitivity to sun AFG3L1P intron 18488028 rs4785763 chr16 90066936 A C 3.20E-56 Hair,eye and skin pigmentation / / 17952075 rs4785763 chr16 90066936 A C 4.31E-17 Black vs. red hair color / / 18483556 rs4785763 chr16 90066936 A C 3.00E-86 Skin sensitivity to sun / / 18488028 rs4785763 chr16 90066936 A C 6.00E-22 Melanoma / / 19578364 rs4785763 chr16 90066936 A C 6.00E-22 Nasopharyngeal carcinoma / / 20512145 rs4785763 chr16 90066936 A C 1.80E-06 Melanoma / / 21926416 rs11076650 chr16 90067941 G A 2.02E-09 Melanoma / / 21926416 rs9936896 chr16 90069059 T C 1.50E-12 Hair,eye and skin pigmentation / / 17952075 rs9936896 chr16 90069059 T C 4.60E-24 Skin sensitivity to sun / / 18488028 rs2241084 chr16 90075412 T C 6.55E-04 Obesity (extreme) DBNDD1 intron 21935397 rs8059973 chr16 90079534 A G 2.90E-09 Skin sensitivity to sun DBNDD1 intron 18488028 rs8059973 chr16 90079534 A G 6.81E-07 Melanoma DBNDD1 intron 21706340 rs10852628 chr16 90079927 C T 6.96E-08 Melanoma DBNDD1 intron 21926416 rs9936215 chr16 90081660 A G 2.45E-07 Common traits (Other) DBNDD1 intron 20585627 rs11648785 chr16 90084561 C T 1.40E-19 Hair,eye and skin pigmentation DBNDD1 intron 17952075 rs11648785 chr16 90084561 C T 3.70E-27 Skin sensitivity to sun DBNDD1 intron 18488028 rs11648785 chr16 90084561 C T 3.00E-09 Tanning DBNDD1 intron 19340012 rs2241039 chr16 90088437 G A 6.40E-24 Hair,eye and skin pigmentation / / 17952075 rs2241039 chr16 90088437 G A 3.20E-08 Black vs. red hair color / / 18483556 rs2241039 chr16 90088437 G A 3.20E-33 Skin sensitivity to sun / / 18488028 rs17178299 chr16 90103659 G A 7.75E-04 Multiple complex diseases GAS8 missense 17554300 rs3785181 chr16 90105333 C T 9.50E-11 Skin sensitivity to sun GAS8 intron 18488028 rs3785181 chr16 90105333 C T 4.89E-04 Heart Failure GAS8 intron pha002884 rs9928084 chr16 90105726 G A 1.80E-05 Urinary metabolites GAS8 intron 21572414 rs2241032 chr16 90109519 G A 3.09E-07 Common traits (Other) GAS8 intron 20585627 rs2241032 chr16 90109519 G A 3.53E-06 Heart Failure GAS8 intron pha002884 rs3743824 chr16 90110027 G A 4.88E-04 Fibrinogen GAS8 UTR-3 17255346 rs1048149 chr16 90110950 C T 5.70E-10 Hair,eye and skin pigmentation GAS8 UTR-3 17952075 rs1048149 chr16 90110950 C T 1.40E-15 Skin sensitivity to sun GAS8 UTR-3 18488028 rs4628973 chr16 90112226 A G 4.62E-07 Prostate cancer(aggressive) LOC100130015 intron 21467234 rs4785612 chr16 90113107 C A 1.20E-12 Skin sensitivity to sun LOC100130015 intron 18488028 rs12446573 chr16 90122202 A G 5.25E-04 Smoking quantity / / 24665060 rs2078478 chr16 90130136 C T 7.40E-08 Hair,eye and skin pigmentation PRDM7 missense 17952075 rs2078478 chr16 90130136 C T 6.20E-09 Skin sensitivity to sun PRDM7 missense 18488028 rs2078478 chr16 90130136 C T 6.58E-04 Heart Failure PRDM7 missense pha002884 rs7196459 chr16 90141477 T G 2.20E-20 Hair,eye and skin pigmentation PRDM7 intron 17952075 rs7196459 chr16 90141477 T G 1.00E-05 Black vs. red hair color PRDM7 intron 18483556 rs7196459 chr16 90141477 T G 1.60E-34 Skin sensitivity to sun PRDM7 intron 18488028 rs9922277 chr16 90158838 T C 3.00E-05 Prostate cancer / / 21743057 rs7498369 chr16 90160064 A G 3.00E-05 Prostate cancer / / 21743057 rs2396789 chr17 8547 T C 0.000025 Asthma (exacerbation) / / 23706709 rs6565705 chr17 13905 G A 7.13E-04 Taste perception / / 22132133 rs7223862 chr17 14417 G A 7.13E-04 Taste perception / / 22132133 rs8064924 chr17 18901 G A 1.84E-04 Celiac disease / / 23936387 rs2294074 chr17 22211 G A 0.0000003 Asthma (exacerbation) / / 23706709 rs7224313 chr17 38761 C G 3.36E-04 Body mass index LOC100506371 nearGene-5 17255346 rs7217319 chr17 38924 T C 4.00E-06 AIDS progression LOC100506371 nearGene-5 21502085 rs4890199 chr17 43474 T C 2.15E-04 Body mass index / / 17255346 rs1609550 chr17 53206 G A 4.88E-04 Multiple complex diseases / / 17554300 rs11654695 chr17 58980 C T 6.78E-05 Nicotine smoking / / 19268276 rs11150884 chr17 62526 T C 3.16E-04 Nicotine smoking RPH3AL UTR-3 19268276 rs7226358 chr17 65351 C T 2.71E-05 Cognitive performance RPH3AL intron 19734545 rs12450789 chr17 69854 C T 3.73E-04 Alcohol consumption (maxi-drinks) RPH3AL intron 24277619 rs4890197 chr17 83173 T G 1.30E-05 Urinary metabolites RPH3AL intron 21572414 rs10454094 chr17 111223 T A 6.00E-04 Multiple complex diseases RPH3AL intron 17554300 rs7207517 chr17 125892 C T 3.05E-07 Autism RPH3AL intron 22843504 rs4354994 chr17 152362 C T 2.40E-05 Calcium levels RPH3AL intron pha003085 rs11869174 chr17 198698 T C 1.23E-04 Breast cancer RPH3AL intron pha002853 rs4366776 chr17 216763 C T 4.52E-06 Ankle-brachial index / / 22199011 rs9899894 chr17 217829 G A 2.92E-05 Glycosylated haemoglobin levels / / 17255346 rs4341804 chr17 218145 C A 3.89E-05 Glycosylated haemoglobin levels / / 17255346 rs7222730 chr17 221278 T C 9.10E-06 Personality dimensions / / 21173776 rs9319629 chr17 222982 G A 8.80E-04 Alcohol dependence / / 21314694 rs12945271 chr17 228677 C T 3.90E-06 Personality dimensions / / 21173776 rs4247113 chr17 228978 C T 2.62E-05 Parkinson's disease / / pha002868 rs4130140 chr17 257557 G A 2.30E-05 Asthma / / 11022011 rs9895447 chr17 258914 G A 0.0000112 post-traumatic stress disorder C17orf97 nearGene-5 22869035 rs9895447 chr17 258914 G A 1.12E-05 Schizophrenia C17orf97 nearGene-5 22883433 rs71355256 chr17 259248 C T 0.00000428 post-traumatic stress disorder C17orf97 nearGene-5 22869035 rs71355256 chr17 259248 C T 4.28E-06 Schizophrenia C17orf97 nearGene-5 22883433 rs67288608 chr17 266655 G C 0.0000116 post-traumatic stress disorder / / 22869035 rs67288608 chr17 266655 G C 1.16E-05 Schizophrenia / / 22883433 rs6565727 chr17 273298 G A 0.0000132 post-traumatic stress disorder / / 22869035 rs6565727 chr17 273298 G A 1.32E-05 Schizophrenia / / 22883433 rs4286157 chr17 402843 A G 7.17E-05 Pulmonary function / / 20010835 rs9895280 chr17 411369 A G 1.77E-06 Pulmonary function / / 20010835 rs8069445 chr17 430245 G T 2.22E-06 Pulmonary function VPS53 intron 20010835 rs9908345 chr17 432471 T C 2.26E-06 Pulmonary function VPS53 intron 20010835 rs9897065 chr17 446011 G A 2.43E-06 Pulmonary function VPS53 intron 20010835 rs3744734 chr17 452898 T C 2.73E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VPS53 intron 20877124 rs12450330 chr17 531729 T C 9.39E-04 Type 2 diabetes VPS53 intron 17463246 rs17609440 chr17 533588 G A 2.05E-04 Lung function (forced vital capacity) VPS53 intron 24023788 rs16954363 chr17 575504 G A 8.56E-04 Type 2 diabetes VPS53 intron 17463246 rs16954363 chr17 575504 G A 1.98E-04 Multiple complex diseases VPS53 intron 17554300 rs7207469 chr17 585475 T G 2.10E-05 Urinary metabolites VPS53 intron 21572414 rs684232 chr17 618965 T C 5.00E-15 Prostate cancer / / 23535732 rs2740354 chr17 632905 T C 7.85E-05 Body mass (lean) / / 19268274 rs2740351 chr17 643426 G A 7.50E-04 Response to TNF antagonist treatment FAM57A intron 21061259 rs1064245 chr17 644986 A C 9.10E-15 Leukemia(T-cell recognition in patients) FAM57A UTR-3 21062987 rs1045491 chr17 647988 C T 9.10E-15 Leukemia(T-cell recognition in patients) GEMIN4 UTR-3 21062987 rs1045481 chr17 648157 G A 9.10E-15 Leukemia(T-cell recognition in patients) GEMIN4 cds-synon 21062987 rs1062923 chr17 649067 A G 3.79E-05 Insulin resistance GEMIN4 missense 21901158 rs2291778 chr17 653818 G T 8.66E-04 Multiple complex diseases GEMIN4 intron 17554300 rs2750012 chr17 684261 G A 7.25E-05 Alzheimer's disease GLOD4 intron 21098978 rs11658079 chr17 692520 C T 4.93E-05 Alzheimer's disease RNMTL1 intron 21098978 rs9915388 chr17 698176 A G 4.47E-05 Alzheimer's disease / / 21098978 rs9915388 chr17 698176 A G 4.20E-04 Smoking quantity / / 24665060 rs7215435 chr17 698664 T C 3.43E-05 Alzheimer's disease / / 21098978 rs623323 chr17 700020 T C 4.00E-06 Type 2 diabetes / / 23300278 rs11650995 chr17 745387 A C 5.98E-04 Suicide attempts in bipolar disorder NXN intron 21423239 rs12939291 chr17 745738 C T 5.11E-04 Suicide attempts in bipolar disorder NXN intron 21423239 rs12939329 chr17 745774 C T 5.75E-04 Suicide attempts in bipolar disorder NXN intron 21423239 rs12950217 chr17 755326 G A 6.00E-04 Suicide attempts in bipolar disorder NXN intron 21423239 rs747685 chr17 775051 T A 6.00E-07 Blood pressure NXN intron 24954895 rs747687 chr17 775334 G C 2.00E-07 Blood pressure NXN intron 24954895 rs561811 chr17 781407 C T 8.66E-05 Alzheimer's disease (late onset) NXN intron 21379329 rs72812014 chr17 782116 G A 5.03E-06 Personality dimensions NXN intron 23658558 rs12601692 chr17 782416 A G 1.68E-04 Alzheimer's disease (late onset) NXN intron 21379329 rs7222487 chr17 782899 G T 1.14E-05 Alzheimer's disease (late onset) NXN intron 21379329 rs2663319 chr17 790803 G A 2.95E-04 Lung function (forced vital capacity) NXN intron 24023788 rs8066894 chr17 793117 G A 9.05E-04 Alzheimer's disease NXN intron 22005930 rs8067018 chr17 793147 G T 8.33E-04 Alzheimer's disease NXN intron 22005930 rs8081618 chr17 793207 C T 8.30E-04 Alzheimer's disease NXN intron 22005930 rs548176 chr17 796372 T C 2.95E-04 Lung function (forced vital capacity) NXN intron 24023788 rs2467248 chr17 799933 A G 6.34E-04 HIV-1 viral setpoint NXN intron 17641165 rs12603526 chr17 800593 T C 3.00E-08 Colorectal cancer NXN intron 24836286 rs11247565 chr17 831109 C T 1.31E-05 Multiple sclerosis NXN intron 20598377 rs2360111 chr17 831667 C T 3.00E-04 Bipolar disorder NXN intron 17486107 rs2360111 chr17 831667 C T 3.00E-06 Economic and political preferences NXN intron 22566634 rs8078764 chr17 838175 C T 9.87E-05 Attention deficit hyperactivity disorder NXN intron 22420046 rs7222776 chr17 840805 G T 1.43E-04 Suicide attempts in bipolar disorder NXN intron 21041247 rs4968132 chr17 850226 G A 2.41E-04 Age-related macular degeneration NXN intron 22125219 rs2048241 chr17 853632 G A 6.60E-05 Lipoprotein-associated phospholipase A2 activity and mass NXN intron 20442857 rs2586238 chr17 902322 A G 2.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TIMM22 intron 20877124 rs11247571 chr17 908502 A G 1.41E-05 Lymphocyte counts ABR UTR-3 22286170 rs9910794 chr17 936851 A G 2.50E-06 Urinary metabolites ABR intron 21572414 rs2304961 chr17 961900 G A 7.58E-05 Major depressive disorder ABR intron 22472876 rs7406978 chr17 1037159 T C 4.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ABR intron 20877124 rs9916862 chr17 1038188 A G 6.64E-05 Rheumatoid arthritis ABR intron 21452313 rs4473259 chr17 1100469 G A 7.44E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9890233 chr17 1119873 T C 9.57E-04 Multiple complex diseases / / 17554300 rs11867310 chr17 1120797 A G 8.77E-04 Premature ovarian failure / / 19508998 rs28655569 chr17 1145506 G T 3.33E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs28603687 chr17 1151592 T C 5.19E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4790867 chr17 1182166 C T 1.30E-04 Amyotrophic lateral sclerosis / / 20801718 rs7208333 chr17 1220321 G T 4.79E-04 Depression (quantitative trait) / / 20800221 rs2361573 chr17 1225940 T G 1.03E-04 Nicotine dependence / / 17158188 rs7209096 chr17 1229222 G A 1.09E-04 Nicotine dependence / / 17158188 rs902967 chr17 1233615 G A 3.98E-05 Type 2 diabetes / / 17463246 rs902966 chr17 1233635 T C 9.81E-07 Lymphocyte counts / / 22286170 rs12937460 chr17 1235037 G A 6.47E-04 Depression (quantitative trait) / / 20800221 rs8076453 chr17 1235317 A T 3.63E-04 Depression (quantitative trait) / / 20800221 rs8076453 chr17 1235317 A T 9.20E-04 Insulin resistance / / 21901158 rs11650217 chr17 1235727 G A 6.59E-04 Depression (quantitative trait) / / 20800221 rs8078073 chr17 1268683 T C 0.000163 Height (Pygmy height) YWHAE intron 22570615 rs9914542 chr17 1272899 T C 0.000899 Height (Pygmy height) YWHAE intron 22570615 rs10521111 chr17 1281864 A G 5.42E-04 Depression (quantitative trait) YWHAE intron 20800221 rs12938116 chr17 1289749 C G 7.61E-04 Depression (quantitative trait) YWHAE intron 20800221 rs16945811 chr17 1294614 G A 2.21E-04 Multiple complex diseases YWHAE intron 17554300 rs11651209 chr17 1364896 A C 8.44E-04 Multiple complex diseases / / 17554300 rs8071435 chr17 1365747 G A 0.0002 Migraine / / 22678113 rs11652315 chr17 1414590 C G 1.44E-04 Fibrinogen INPP5K intron 17255346 rs939563 chr17 1415910 T A 6.90E-05 Serum metabolites INPP5K intron 19043545 rs16948748 chr17 1457839 T G 1.95E-06 Paclitaxel-induced neuropathy PITP/ intron 23776197 rs4790713 chr17 1522877 G A 7.65E-05 Alcohol dependence SLC43A2 intron 21314694 rs8072430 chr17 1538561 G A 1.65E-11 LDL cholesterol SCARF1 missense 23063622 rs200942821 chr17 1553040 C T 0.000085 Prostate cancer (advanced) RILP missense 23555315 rs28620466 chr17 1560525 G A 2.33E-04 Response to cytadine analogues (cytosine arabinoside) PRPF8 intron 24483146 rs34853504 chr17 1616093 G A 1.15E-04 Smoking initiation MIR22HG intron 24665060 rs11078597 chr17 1618363 T C 2.70E-06 Calcium levels MIR22HG intron 20705733 rs11078597 chr17 1618363 T C 1.00E-14 Serum albumin level MIR22HG intron 23022100 rs11078597 chr17 1618363 T C 7.00E-13 Serum albumin level MIR22HG intron 23022100 rs7221974 chr17 1630584 A G 1.28E-06 HDL cholesterol WDR81 cds-synon pha003075 rs9912287 chr17 1630992 G A 3.70E-06 Calcium levels WDR81 cds-synon 20705733 rs12150338 chr17 1634104 C T 7.00E-07 Calcium levels WDR81 cds-synon 20705733 rs12150338 chr17 1634104 C T 2.00E-06 Calcium levels WDR81 cds-synon 24068962 rs8065251 chr17 1637458 G A 3.30E-06 Calcium levels WDR81 cds-synon 20705733 rs8077638 chr17 1640793 C T 3.20E-06 Calcium levels WDR81 cds-synon 20705733 rs2287322 chr17 1641035 A G 3.20E-06 Calcium levels WDR81 UTR-3 20705733 rs2070863 chr17 1648502 C T 4.10E-06 Calcium levels SERPINF2 missense 20705733 rs2070863 chr17 1648502 C T 0.0000241 Triglycerides SERPINF2 missense 23063622 rs2070863 chr17 1648502 C T 0.0000373 Triglycerides SERPINF2 missense 23063622 rs4790285 chr17 1651697 T C 4.20E-06 Calcium levels SERPINF2 intron 20705733 rs2277695 chr17 1651780 A G 4.20E-05 Iron levels SERPINF2 intron 21208937 rs3976 chr17 1653091 G A 4.30E-06 Calcium levels SERPINF2 intron 20705733 rs4790821 chr17 1654048 A G 8.10E-06 Calcium levels SERPINF2 intron 20705733 rs8074026 chr17 1657073 T C 2.00E-10 Creutzfeldt-Jakob disease (variant) SERPINF2 intron 22137330 rs1057335 chr17 1657653 G A 6.10E-05 Diabetic retinopathy SERPINF2 missense 21441570 rs1057335 chr17 1657653 G A 0.0000588 Triglycerides SERPINF2 missense 23063622 rs1136287 chr17 1673276 C T 8.70E-04 Coronary heart disease SERPINF1 missense 21966275 rs12603825 chr17 1673405 G A 5.16E-04 Response to cytidine analogues (gemcitabine) SERPINF1 intron 24483146 rs2071021 chr17 1679793 A G 6.50E-04 Coronary heart disease SERPINF1 intron 21966275 rs11062 chr17 1683012 G A 5.19E-05 Coronary heart disease SMYD4 UTR-3 pha003031 rs17821469 chr17 1690427 G A 9.44E-04 Type 2 diabetes SMYD4 intron 17463246 rs9914094 chr17 1721613 T A 4.12E-05 Multiple complex diseases SMYD4 intron 17554300 rs4790825 chr17 1745850 A G 9.90E-04 Alcohol dependence RPA1 intron 21314694 rs4790830 chr17 1754380 A T 9.50E-06 Urinary metabolites RPA1 intron 21572414 rs11656253 chr17 1761446 G A 9.21E-05 Relative hand skill RPA1 intron 24068947 rs8067195 chr17 1778272 G A 2.74E-05 Lung function (forced expiratory volume in 1 second) RPA1 intron pha003102 rs2270411 chr17 1778566 A G 2.74E-05 Lung function (forced expiratory volume in 1 second) RPA1 intron pha003102 rs8077346 chr17 1786133 C T 4.83E-05 Relative hand skill RPA1 intron 24068947 rs2270412 chr17 1792174 G A 8.30E-06 Personality dimensions RPA1 intron 21173776 rs2270412 chr17 1792174 G A 4.10E-04 Stroke RPA1 intron pha002887 rs7503021 chr17 1797890 G A 9.50E-05 Coronary heart disease RPA1 intron pha003056 rs4525524 chr17 1844871 T C 7.83E-04 Alcohol consumption (maxi-drinks) RTN4RL1 intron 24277619 rs4516268 chr17 1846831 C A 0.000541 Salmonella-induced pyroptosis RTN4RL1 intron 22837397 rs11654521 chr17 1855991 A T 1.70E-05 Urinary metabolites RTN4RL1 intron 21572414 rs6503101 chr17 1860638 T C 2.35E-04 Lung function (forced expiratory volume in 1 second) RTN4RL1 intron 24023788 rs4525525 chr17 1866892 G T 4.64E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) RTN4RL1 intron 23648065 rs4790850 chr17 1870515 T C 1.63E-04 Response to cytidine analogues (gemcitabine) RTN4RL1 intron 24483146 rs4239061 chr17 1871472 T G 1.01E-04 Response to cytidine analogues (gemcitabine) RTN4RL1 intron 24483146 rs3752962 chr17 1939543 T C 6.40E-05 Cognitive performance DPH1 intron 19734545 rs12451788 chr17 1941048 A G 1.39E-04 Multiple complex diseases DPH1 intron 17554300 rs8065878 chr17 1952079 C T 8.07E-04 Type 2 diabetes / / 17463246 rs8065878 chr17 1952079 C T 8.27E-04 Multiple complex diseases / / 17554300 rs6503222 chr17 1977862 G A 6.54E-04 Smoking cessation SMG6 intron 24665060 rs4790312 chr17 1981480 T C 2.53E-04 Smoking cessation SMG6 intron 24665060 rs3900333 chr17 1994011 G C 1.76E-07 Multiple complex diseases SMG6 intron 17554300 rs4790877 chr17 1995254 G A 7.94E-05 Bone mineral density SMG6 intron 24249740 rs11654642 chr17 2008938 G A 2.17E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SMG6 intron 24023788 rs8082647 chr17 2010597 T C 8.22E-06 White blood cell count SMG6 intron 21738479 rs2984942 chr17 2030155 T C 8.88E-05 Femoral neck bone geometry SMG6 intron 22087292 rs4790881 chr17 2068932 C A 1.00E-18 Bone mineral density SMG6 intron 22504420 rs4790881 chr17 2068932 C A 4.72E-04 Bone mineral density SMG6 intron 24249740 rs4790881 chr17 2068932 C A 9.78E-04 Bone mineral density (paediatric,upper limb) SMG6 intron 24945404 rs112415631 chr17 2072074 G C 0.0000832 Nonsyndromic striae distensae (stretch marks) SMG6 intron 23633020 rs11871926 chr17 2084712 C T 7.01E-06 Lipid traits SMG6 intron 21777205 rs7219557 chr17 2086200 G A 8.09E-04 Taste perception SMG6 intron 22132133 rs11078855 chr17 2091308 C T 4.10E-04 Taste perception SMG6 intron 22132133 rs16952025 chr17 2116798 A G 3.31E-06 Lymphocyte counts SMG6 intron 22286170 rs2281727 chr17 2117945 A G 0.000000263 Coronary artery disease with myocardial infarction SMG6 intron 23202125 rs2281727 chr17 2117945 A G 0.0000133 Coronary artery disease (CAD) (males) SMG6 intron 23202125 rs2281727 chr17 2117945 A G 0.0000646 Coronary artery disease (CAD) age >50 SMG6 intron 23202125 rs2281727 chr17 2117945 A G 2.94E-10 Coronary artery disease (CAD) age <=50 SMG6 intron 23202125 rs2281727 chr17 2117945 A G 1.00E-07 Coronary artery disease SMG6 intron 24262325 rs1231206 chr17 2125605 G A 9.00E-10 Coronary heart disease SMG6 intron 21378990 rs216172 chr17 2126504 G C 1.00E-09 Coronary heart disease SMG6 intron 21378990 rs216172 chr17 2126504 G C 1.15E-09 Pericardial fat SMG6 intron 22589742 rs216215 chr17 2140668 T C 2.30E-05 Urinary metabolites SMG6 intron 21572414 rs10852932 chr17 2143460 G T 2.00E-11 Aortic root size SMG6 intron 19584346 rs11078884 chr17 2145193 T C 3.00E-06 Metabolite levels (5-HIAA) SMG6 intron 23319000 rs34166400 chr17 2146392 G C 8.41E-06 Lipid traits SMG6 intron 21777205 rs170040 chr17 2165714 C T 1.72E-04 Multiple complex diseases SMG6 intron 17554300 rs17761864 chr17 2171637 C A 2.00E-11 Esophageal cancer (squamous cell) SMG6 intron 22960999 rs216193 chr17 2203453 A G 8.45E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SMG6 cds-synon 22566498 rs4523957 chr17 2208899 G T 6.00E-08 Schizophrenia SRR intron 23974872 rs391300 chr17 2216258 T C 3.00E-09 Type 2 diabetes SRR intron 20174558 rs391300 chr17 2216258 T C 3.00E-09 Type 2 diabetes SRR intron 21647700 rs391300 chr17 2216258 T C 5.26E-04 Taste perception SRR intron 22132133 rs391300 chr17 2216258 T C 3.00E-09 Type 2 diabetes SRR intron 23300278 rs12451892 chr17 2247982 T C 7.50E-05 Diabetic retinopathy SGSM2 intron 21441570 rs7213791 chr17 2251059 G A 5.47E-05 Orofacial clefts SGSM2 intron 22419666 rs9915206 chr17 2254137 T C 5.15E-04 Acute lung injury SGSM2 intron 22295056 rs4790333 chr17 2262703 C T 3.00E-09 Proinsulin levels SGSM2 intron 21873549 rs16952099 chr17 2264023 C T 2.14E-04 Acute lung injury SGSM2 intron 22295056 rs3213714 chr17 2276085 G T 4.57E-04 Acute lung injury SGSM2 intron 22295056 rs2429917 chr17 2280934 T C 7.01E-06 Lipid traits SGSM2 intron 21777205 rs61741902 chr17 2282779 G A 4.80E-10 Insulin processing and secretion SGSM2 missense 23263489 rs3826335 chr17 2310130 G A 5.20E-05 Multiple complex diseases / / 17554300 rs9303064 chr17 2316938 T C 2.00E-04 Suicide attempts in bipolar disorder LOC284009 intron 21423239 rs4790336 chr17 2326480 C T 2.17E-04 Suicide attempts in bipolar disorder METTL16 intron 21423239 rs9894088 chr17 2336370 T C 1.98E-04 Coronary Artery Disease METTL16 intron 17634449 rs11871981 chr17 2355517 A C 2.40E-04 Stroke METTL16 intron pha002887 rs4268798 chr17 2366585 T C 5.11E-05 Age-related macular degeneration METTL16 intron 21197116 rs4268798 chr17 2366585 T C 6.05E-06 Age-related macular degeneration METTL16 intron pha000001 rs4268798 chr17 2366585 T C 6.70E-06 Age-related macular degeneration METTL16 intron pha002856 rs16952167 chr17 2394796 T C 0.000323 Salmonella-induced pyroptosis METTL16 intron 22837397 rs7214877 chr17 2414208 G A 3.06E-05 HDL particle features METTL16 intron pha002900 rs935134 chr17 2414549 T C 2.03E-05 HDL particle features METTL16 intron pha002900 rs12450119 chr17 2420934 C T 8.35E-07 HDL particle features / / pha002900 rs9891572 chr17 2428508 C T 2.00E-07 HDL cholesterol / / 19060910 rs9891572 chr17 2428508 C T 2.00E-07 Coronary heart disease / / 21347282 rs9891572 chr17 2428508 C T 2.33E-07 HDL particle features / / pha002900 rs11655295 chr17 2434024 G T 4.19E-05 Alcohol and nictotine co-dependence / / 20158304 rs11078231 chr17 2446024 C T 2.39E-06 Lipid traits / / 21777205 rs8080511 chr17 2468169 A C 2.86E-04 Alzheimer's disease (late onset) / / 21379329 rs7209945 chr17 2474929 A G 9.94E-06 Serum metabolites / / 19043545 rs12952976 chr17 2490600 T C 5.86E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs8077351 chr17 2545473 A G 9.90E-06 Urinary metabolites PAFAH1B1 intron 21572414 rs2317297 chr17 2577091 C T 1.10E-05 Urinary metabolites PAFAH1B1 intron 21572414 rs4790353 chr17 2578648 G T 6.84E-05 Tunica Media PAFAH1B1 intron pha003034 rs7216704 chr17 2589022 C T 9.29E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) PAFAH1B1 nearGene-3 23648065 rs2277663 chr17 2597969 C T 4.76E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) KIAA0664 intron 24023788 rs7222829 chr17 2707991 A G 0.000877672 Hypertension (early onset hypertension) RAP1GAP2 intron 22479346 rs4790365 chr17 2714251 A G 1.17E-04 Arthritis (juvenile idiopathic) RAP1GAP2 intron 22354554 rs8075081 chr17 2719530 G T 6.93E-04 Parkinson's disease RAP1GAP2 intron 17052657 rs9895147 chr17 2725555 T C 6.87E-04 Type 2 diabetes RAP1GAP2 intron 17463246 rs6502555 chr17 2729652 T C 3.11E-05 Response to acetaminophen (hepatotoxicity) RAP1GAP2 intron 21177773 rs9909561 chr17 2740799 C T 1.57E-04 Alzheimer's disease RAP1GAP2 intron 22005930 rs2317457 chr17 2753213 G A 8.98E-04 Nicotine smoking RAP1GAP2 intron 19268276 rs6502574 chr17 2757600 C G 9.31E-04 Suicide attempts in bipolar disorder RAP1GAP2 intron 21423239 rs8069788 chr17 2758657 C T 8.85E-04 Suicide attempts in bipolar disorder RAP1GAP2 intron 21423239 rs12603284 chr17 2771512 C T 1.30E-05 Urinary metabolites RAP1GAP2 intron 21572414 rs12603284 chr17 2771512 C T 3.00E-06 Sudden cardiac arrest RAP1GAP2 intron 21658281 rs59403466 chr17 2785895 T G 6.00E-07 PR interval in Tripanosoma cruzi seropositivity RAP1GAP2 intron 24324551 rs17835089 chr17 2810672 G C 4.18E-04 Alzheimer's disease RAP1GAP2 intron 17998437 rs17835089 chr17 2810672 G C 4.98E-04 Alcohol dependence RAP1GAP2 intron 21314694 rs17822227 chr17 2869541 A G 9.25E-04 Amyotrophic Lateral Sclerosis RAP1GAP2 intron 17362836 rs6502656 chr17 2881291 A G 7.60E-04 Stroke RAP1GAP2 intron pha002887 rs2004738 chr17 2885808 C T 8.19E-05 Hypertension RAP1GAP2 intron pha003042 rs12051711 chr17 2887139 G A 6.90E-05 Hypertension RAP1GAP2 intron pha003042 rs8076504 chr17 2890191 G C 1.53E-04 Alzheimer's disease RAP1GAP2 intron 17998437 rs12936442 chr17 2933109 C T 9.27E-05 Blood Pressure RAP1GAP2 intron pha003045 rs12936442 chr17 2933109 C T 6.52E-05 Blood Pressure RAP1GAP2 intron pha003047 rs9895098 chr17 2938533 T C 3.00E-07 Asthma (sex interaction) RAP1GAP2 UTR-3 24824216 rs7208097 chr17 2944778 C T 2.48E-05 Bone mineral density / / 19181680 rs7208097 chr17 2944778 C T 4.86E-04 Myocardial Infarction / / pha002873 rs4300683 chr17 2995572 G A 6.44E-04 White matter integrity OR1D2 missense 22425255 rs6502689 chr17 3019246 A G 2.00E-05 Urinary metabolites / / 21572414 rs6502691 chr17 3019625 T C 7.27E-04 White matter integrity / / 22425255 rs6502692 chr17 3019725 T C 1.50E-05 Urinary metabolites / / 21572414 rs6502692 chr17 3019725 T C 7.56E-04 White matter integrity / / 22425255 rs12947365 chr17 3022970 T C 9.81E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs6502697 chr17 3029420 A G 8.07E-04 White matter integrity / / 22425255 rs12449465 chr17 3029554 T C 1.00E-06 Endometriosis / / 23472165 rs11868610 chr17 3037207 A C 9.29E-05 White matter integrity / / 22425255 rs4790441 chr17 3049680 T C 4.42E-05 White matter integrity LOC100288728 intron 22425255 rs1081100 chr17 3057413 T C 1.04E-04 White matter integrity LOC100288728 intron 22425255 rs7220042 chr17 3057511 G T 1.01E-04 White matter integrity LOC100288728 intron 22425255 rs7213893 chr17 3059871 A C 1.31E-04 White matter integrity LOC100288728 intron 22425255 rs12601685 chr17 3099416 C G 1.26E-05 Personality dimensions / / 23903073 rs11867349 chr17 3100699 A G 4.74E-04 Multiple complex diseases / / 17554300 rs17222299 chr17 3162307 A G 1.26E-14 Multiple complex diseases / / 17554300 rs2469795 chr17 3164801 G A 6.16E-06 Bipolar disorder / / 17486107 rs2005290 chr17 3188012 C G 2.00E-06 Cocaine dependence / / 23958962 rs2005290 chr17 3188012 C G 4.00E-07 Cocaine dependence / / 23958962 rs7218125 chr17 3195603 T A 2.07E-04 Multiple complex diseases OR3A1 STOP-GAIN 17554300 rs9303170 chr17 3210368 A C 9.41E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9906179 chr17 3213962 A G 4.72E-04 Multiple complex diseases / / 17554300 rs9911226 chr17 3214106 C A 9.59E-04 Multiple complex diseases / / 17554300 rs769430 chr17 3214969 A G 8.36E-04 Multiple complex diseases / / 17554300 rs329629 chr17 3238989 C A 9.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs392510 chr17 3247426 T C 2.30E-05 Urinary metabolites / / 21572414 rs7222579 chr17 3247652 T C 5.09E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7222594 chr17 3247683 T C 9.41E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs230404 chr17 3281464 T A 9.35E-04 Type 2 diabetes / / 17463246 rs7220312 chr17 3287175 T C 5.88E-04 Multiple complex diseases / / 17554300 rs10491218 chr17 3293338 C T 4.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10491218 chr17 3293338 C T 9.81E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11652855 chr17 3313063 T G 7.41E-04 Alzheimer's disease / / 17998437 rs11656466 chr17 3313127 C T 3.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs16953011 chr17 3313354 C A 2.61E-04 Alzheimer's disease / / 17998437 rs10491216 chr17 3320406 C T 1.74E-06 Statin-induced myopathy / / 21826682 rs227787 chr17 3324810 A G 3.90E-06 Urinary metabolites OR3A3 missense 21572414 rs769431 chr17 3337057 A G 2.72E-04 Amyotrophic Lateral Sclerosis OR1E2 missense 17362836 rs227800 chr17 3340445 C T 1.81E-05 Blood Pressure / / pha003040 rs9303174 chr17 3342002 A C 1.00E-05 Urinary metabolites / / 21572414 rs9303174 chr17 3342002 A C 7.50E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs16953050 chr17 3347706 C T 5.84E-04 Multiple complex diseases SPATA22 intron 17554300 rs4790142 chr17 3371501 G A 7.84E-06 Nasopharyngeal carcinoma SPATA22 intron 23209447 rs7209613 chr17 3372179 A G 7.23E-04 Amyotrophic Lateral Sclerosis SPATA22 intron 17827064 rs7221929 chr17 3376188 A G 6.10E-06 Antibody status in Tripanosoma cruzi seropositivity ASPA nearGene-5 24324551 rs12940665 chr17 3376519 T G 4.96E-06 Antibody status in Tripanosoma cruzi seropositivity ASPA nearGene-5 24324551 rs7220982 chr17 3376682 G A 5.13E-06 Antibody status in Tripanosoma cruzi seropositivity ASPA nearGene-5 24324551 rs7207788 chr17 3376885 T C 6.76E-06 Antibody status in Tripanosoma cruzi seropositivity ASPA nearGene-5 24324551 rs11078450 chr17 3377396 C G 4.92E-06 Antibody status in Tripanosoma cruzi seropositivity ASPA nearGene-5 24324551 rs11078451 chr17 3377743 G A 4.64E-06 Antibody status in Tripanosoma cruzi seropositivity ASPA intron 24324551 rs3829957 chr17 3378876 C T 9.00E-04 Acute lymphoblastic leukemia (childhood) ASPA intron 20189245 rs1493282 chr17 3382331 T C 9.96E-04 Amyotrophic Lateral Sclerosis ASPA intron 17362836 rs1493282 chr17 3382331 T C 8.57E-05 Cognitive test performance ASPA intron 20125193 rs11651636 chr17 3383527 A G 2.04E-06 Antibody status in Tripanosoma cruzi seropositivity ASPA intron 24324551 rs11656291 chr17 3383573 C T 2.04E-06 Antibody status in Tripanosoma cruzi seropositivity ASPA intron 24324551 rs1488688 chr17 3385249 A C 9.26E-05 Cholesterol ASPA intron pha003078 rs62071297 chr17 3389006 T A 3.20E-06 Antibody status in Tripanosoma cruzi seropositivity ASPA intron 24324551 rs4790495 chr17 3390008 G T 6.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ASPA intron 20877124 rs4790495 chr17 3390008 G T 6.36E-05 Blood Pressure ASPA intron pha003040 rs923375 chr17 3393068 T C 4.00E-16 Myopia (pathological) ASPA intron 23049088 rs923376 chr17 3393086 T C 2.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ASPA intron 20877124 rs923376 chr17 3393086 T C 2.70E-04 Blood pressure ASPA intron 21572416 rs16953074 chr17 3394215 A G 9.00E-05 Prostate cancer ASPA intron 21743057 rs2035939 chr17 3396397 T C 8.32E-05 Brain lesion load ASPA intron 19010793 rs10521121 chr17 3409888 A C 2.79E-04 Parkinson's disease / / 17052657 rs7219780 chr17 3418554 C T 5.26E-04 Multiple complex diseases TRPV3 intron 17554300 rs9909424 chr17 3418598 G A 5.44E-04 Lymphocyte counts TRPV3 intron 22286170 rs11655540 chr17 3473945 T G 1.12E-04 HIV-1 viral setpoint TRPV1 intron 21490045 rs161364 chr17 3477812 C T 2.81E-04 Suicide attempts in bipolar disorder TRPV1 intron 21423239 rs9902581 chr17 3482299 C T 0.00008 Coronary artery calcification TRPV1 intron 23727086 rs17633288 chr17 3483785 T C 9.47E-04 Multiple complex diseases TRPV1 missense 17554300 rs224536 chr17 3487180 A G 8.72E-04 Multiple complex diseases TRPV1 intron 17554300 rs222747 chr17 3493200 C G 6.97E-04 Response to statin treatment (atorvastatin),change in cholesterol levels TRPV1 missense 20031582 rs16953301 chr17 3513347 C T 5.40E-04 Coronary heart disease SHPK UTR-3 21966275 rs465563 chr17 3513719 G A 3.70E-05 Carotid intima media thickness SHPK UTR-3 19679847 rs222790 chr17 3531490 G A 8.45E-04 Body mass index SHPK intron 21701565 rs150858 chr17 3532670 C T 7.43E-04 Body mass index SHPK intron 21701565 rs150858 chr17 3532670 C T 2.18E-04 Insulin resistance SHPK intron 21901158 rs400113 chr17 3542455 T C 5.41E-04 Parkinson's disease CTNS intron 17052657 rs558639 chr17 3546231 T C 2.98E-04 Multiple complex diseases CTNS intron 17554300 rs224500 chr17 3548447 A G 8.83E-05 Multiple complex diseases CTNS intron 17554300 rs222778 chr17 3552038 G A 2.35E-04 Parkinson's disease CTNS intron 17052657 rs4790530 chr17 3555424 G A 5.47E-04 Body mass index CTNS intron 21701565 rs222757 chr17 3569913 G T 6.48E-04 Response to taxane treatment (placlitaxel) TAX1BP3 intron 23006423 rs2567869 chr17 3604400 G A 1.81E-04 Age-related macular degeneration / / 22125219 rs2567869 chr17 3604400 G A 5.45E-04 Lymphocyte counts / / 22286170 rs2567846 chr17 3606192 G A 7.72E-05 Lymphocyte counts / / 22286170 rs1107400 chr17 3615496 A G 2.73E-04 Age-related macular degeneration / / 22125219 rs1367950 chr17 3618298 C T 3.74E-04 Age-related macular degeneration ITGAE intron 22125219 rs220470 chr17 3664975 A G 1.00E-07 Attention deficit hyperactivity disorder ITGAE intron 18839057 rs6502743 chr17 3670883 T G 3.69E-04 Response to cytadine analogues (cytosine arabinoside) ITGAE intron 24483146 rs9916609 chr17 3672514 C A 0.0000603 Nicotine dependence (smoking) ITGAE intron 22377092 rs9916609 chr17 3672514 C A 4.19E-04 Response to cytadine analogues (cytosine arabinoside) ITGAE intron 24483146 rs17175691 chr17 3695981 G A 2.10E-05 Urinary metabolites ITGAE intron 21572414 rs3809805 chr17 3704483 G A 1.10E-05 Urinary metabolites ITGAE UTR-5 21572414 rs2891 chr17 3705526 C T 7.27E-05 Body Mass Index / / pha002896 rs2302299 chr17 3725899 A C 7.78E-05 Postoperative ventricular dysfunction C17orf85 intron 21980348 rs1558294 chr17 3763574 C T 2.18E-04 Birth weight / / 17255346 rs2240807 chr17 3763841 A G 4.42E-04 Multiple complex diseases CAMKK1 UTR-3 17554300 rs2288684 chr17 3764630 G A 1.00E-04 Cognitive impairment induced by topiramate CAMKK1 UTR-3 22091778 rs2915546 chr17 3765268 T G 1.78E-05 Cytomegalovirus antibody response CAMKK1 UTR-3 21993531 rs218705 chr17 3766380 G A 6.64E-05 Cytomegalovirus antibody response CAMKK1 intron 21993531 rs2532947 chr17 3768679 A G 6.82E-05 Cytomegalovirus antibody response CAMKK1 UTR-3 21993531 rs2532945 chr17 3769508 A G 7.39E-05 Cytomegalovirus antibody response CAMKK1 intron 21993531 rs758642 chr17 3786907 G A 7.00E-06 Smoking behavior CAMKK1 intron 19247474 rs758642 chr17 3786907 G A 4.47E-04 Response to taxane treatment (placlitaxel) CAMKK1 intron 23006423 rs887389 chr17 3793303 A G 6.33E-05 Lung function (forced vital capacity) CAMKK1 intron pha003104 rs8076916 chr17 3822637 T C 4.91E-04 Tourette syndrome / / 22889924 rs2074991 chr17 3838626 T C 3.36E-04 Stroke ATP2A3 intron pha002887 rs1062683 chr17 3839685 G A,C,T 4.95E-05 Recombination rate ATP2A3 missense 21698098 rs8064630 chr17 3842491 G A 8.98E-04 Alzheimer's disease ATP2A3 intron 17998437 rs8064630 chr17 3842491 G A 3.04E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers ATP2A3 intron 21775533 rs9915261 chr17 3868738 T C 0.000545511 Hypertension (early onset hypertension) ATP2A3 nearGene-5 22479346 rs6502762 chr17 3872264 C T 4.54E-05 Insulin-related traits / / pha002901 rs7215084 chr17 3880148 C T 0.00000598 HDL cholesterol particle diameter / / 23263444 rs16942524 chr17 3880353 G A 9.90E-04 Multiple complex diseases / / 17554300 rs9891113 chr17 3881130 T C 0.00000623 HDL cholesterol particle diameter / / 23263444 rs8082036 chr17 3882613 G C 0.00000636 HDL cholesterol particle diameter / / 23263444 rs7207552 chr17 3896807 A G 9.59E-05 Magnesium levels / / pha003092 rs9914203 chr17 3899643 G A 2.96E-04 Eating disorders / / 23568457 rs6502764 chr17 3901502 T G 7.73E-04 Multiple complex diseases / / 17554300 rs6502764 chr17 3901502 T G 6.08E-05 Serum metabolites / / 19043545 rs2176324 chr17 3943543 G A 7.73E-04 Multiple complex diseases ZZEF1 intron 17554300 rs9895032 chr17 3951946 C T 6.32E-04 Multiple complex diseases ZZEF1 intron 17554300 rs7221595 chr17 4007594 T C 5.00E-06 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia ZZEF1 intron 24039173 rs17176322 chr17 4056376 G A 1.32E-04 Multiple complex diseases CYB5D2 intron 17554300 rs7222860 chr17 4066223 A G 1.52E-04 Lymphocyte counts / / 22286170 rs16953766 chr17 4072707 G A 3.52E-05 Multiple complex diseases ANKFY1 intron 17554300 rs1982176 chr17 4074395 A C 3.90E-04 Alcohol dependence ANKFY1 intron 20201924 rs2278524 chr17 4081975 G A 8.14E-05 Multiple complex diseases ANKFY1 intron 17554300 rs2278524 chr17 4081975 G A 2.50E-05 Urinary metabolites ANKFY1 intron 21572414 rs9903228 chr17 4089883 A G 4.94E-04 Multiple complex diseases ANKFY1 intron 17554300 rs4790587 chr17 4090060 G A 2.16E-04 Multiple complex diseases ANKFY1 intron 17554300 rs2053256 chr17 4108648 A G 7.43E-05 HIV-1 viral setpoint ANKFY1 intron 22174851 rs10521130 chr17 4110024 C T 2.46E-04 Multiple complex diseases ANKFY1 intron 17554300 rs7222603 chr17 4112922 G C 3.32E-04 Multiple complex diseases ANKFY1 intron 17554300 rs1982177 chr17 4119994 G A 2.36E-04 Multiple complex diseases ANKFY1 intron 17554300 rs9907369 chr17 4120494 G C 4.94E-04 Multiple complex diseases ANKFY1 intron 17554300 rs1821860 chr17 4134119 T C 2.36E-04 Multiple complex diseases ANKFY1 intron 17554300 rs9915670 chr17 4143290 T C 2.33E-04 Multiple complex diseases ANKFY1 intron 17554300 rs12601993 chr17 4151421 G A 3.47E-04 Multiple complex diseases ANKFY1 intron 17554300 rs9913077 chr17 4153807 T C 1.06E-04 Multiple complex diseases ANKFY1 intron 17554300 rs4790598 chr17 4156620 G T 3.33E-04 Parkinson's disease ANKFY1 intron 17052657 rs733622 chr17 4181122 G A 9.19E-05 Type 1 diabetes UBE2G1 intron 18978792 rs4508454 chr17 4198650 A G 8.19E-04 Multiple complex diseases UBE2G1 intron 17554300 rs4508454 chr17 4198650 A G 7.48E-05 Serum metabolites UBE2G1 intron 19043545 rs2325988 chr17 4199284 A G 5.16E-05 Type 1 diabetes UBE2G1 intron 18978792 rs7216130 chr17 4207243 T A 8.86E-05 Type 1 diabetes UBE2G1 intron 18978792 rs17764251 chr17 4214005 G A 7.20E-07 Urinary metabolites UBE2G1 intron 21572414 rs17764251 chr17 4214005 G A 1.80E-04 Response to taxane treatment (placlitaxel) UBE2G1 intron 23006423 rs2053255 chr17 4221236 A G 8.39E-05 Type 1 diabetes UBE2G1 intron 18978792 rs8074770 chr17 4242178 G A 5.80E-05 Type 1 diabetes UBE2G1 intron 18978792 rs7207359 chr17 4310639 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs9889598 chr17 4336687 C A 4.24E-04 Taste perception / / 22132133 rs3809853 chr17 4337412 C G 2.89E-04 Taste perception SPNS3 cds-synon 22132133 rs7211542 chr17 4374569 C T 7.99E-05 Type 2 diabetes SPNS3 intron 17463246 rs8078744 chr17 4377095 G A 4.64E-04 Suicide attempts in bipolar disorder SPNS3 intron 21423239 rs4790196 chr17 4377593 T C 9.99E-04 Suicide attempts in bipolar disorder SPNS3 intron 21423239 rs4790198 chr17 4377979 G A 9.78E-04 Suicide attempts in bipolar disorder SPNS3 intron 21423239 rs7214170 chr17 4378082 T A 7.94E-04 Suicide attempts in bipolar disorder SPNS3 intron 21423239 rs8070786 chr17 4379067 G A 6.16E-04 Suicide attempts in bipolar disorder SPNS3 intron 21423239 rs333133 chr17 4379847 G A 6.19E-04 Suicide attempts in bipolar disorder SPNS3 intron 21423239 rs8073958 chr17 4384778 G A 6.98E-04 Suicide attempts in bipolar disorder SPNS3 intron 21423239 rs333119 chr17 4393498 C T 6.00E-06 Obesity-related traits / / 23251661 rs12602297 chr17 4394890 A G 9.00E-05 Eosinophil counts / / pha003088 rs11078512 chr17 4398442 A G 5.95E-04 Type 2 diabetes / / 17463246 rs899444 chr17 4420052 A G 5.73E-05 Triglycerides SPNS2 intron pha003081 rs899444 chr17 4420052 A G 7.56E-05 Lipid levels SPNS2 intron pha003082 rs10521140 chr17 4441309 C A 6.10E-04 HIV-1 viral setpoint SPNS2 UTR-3 17641165 rs7217556 chr17 4478836 T C 1.32E-04 Multiple complex diseases / / 17554300 rs11654457 chr17 4488884 T C 8.48E-05 Multiple complex diseases SMTNL2 intron 17554300 rs4597375 chr17 4494815 T C 4.85E-05 Cognitive performance SMTNL2 intron 19734545 rs899446 chr17 4496662 G A 1.92E-04 Obesity (extreme) SMTNL2 intron 21935397 rs899445 chr17 4496747 T G 3.59E-04 Obesity (extreme) SMTNL2 intron 21935397 rs9908079 chr17 4497084 G T 6.66E-04 Obesity (extreme) SMTNL2 intron 21935397 rs2035262 chr17 4499121 A G 3.50E-05 Tooth agenesis (maxillary third molar) SMTNL2 intron 24172245 rs4790207 chr17 4502310 T G 4.62E-04 Obesity (extreme) SMTNL2 intron 21935397 rs4790657 chr17 4508276 T G 1.57E-05 Colorectal cancer SMTNL2 intron 21242260 rs8070464 chr17 4512492 G A 5.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11078523 chr17 4523167 T C 4.41E-04 Alcohol dependence / / 20201924 rs7217186 chr17 4539392 C T 1.41E-04 Osteoarthritis ALOX15 intron 19508968 rs8071990 chr17 4579638 G A 1.00E-04 Prostate cancer PELP1 intron 21743057 rs7221588 chr17 4580539 C A 7.83E-06 Multiple complex diseases PELP1 intron 17554300 rs7214568 chr17 4584098 T C 4.92E-04 Multiple complex diseases PELP1 intron 17554300 rs9899501 chr17 4587342 A G 2.14E-04 Multiple complex diseases PELP1 intron 17554300 rs906453 chr17 4594965 C T 2.01E-05 Alcohol dependence PELP1 intron 20201924 rs906453 chr17 4594965 C T 2.01E-05 Alcoholism PELP1 intron pha002891 rs7214635 chr17 4601020 G A 0.000181984 Primary sclerosing cholangitis PELP1 intron 23603763 rs7214635 chr17 4601020 G A 3.63E-04 Lung function (forced expiratory volume in 1 second) PELP1 intron 24023788 rs12451741 chr17 4604030 G T 7.88E-04 Alcohol dependence PELP1 intron 20201924 rs4790687 chr17 4604634 A G 4.31E-04 Alcohol dependence PELP1 intron 20201924 rs4790688 chr17 4605068 C T 4.27E-04 Alcohol dependence PELP1 intron 20201924 rs4790689 chr17 4605200 A C 4.27E-04 Alcohol dependence PELP1 intron 20201924 rs7225717 chr17 4608052 A G 4.14E-04 Alcohol dependence / / 20201924 rs7215300 chr17 4608622 T C 5.88E-04 Alcohol dependence / / 20201924 rs3786047 chr17 4615098 A G 1.01E-04 Alcohol dependence ARRB2 intron 20201924 rs1045280 chr17 4622638 C T 6.56E-04 Alcohol dependence ARRB2 cds-synon 20201924 rs1051007 chr17 4636813 A G 6.55E-05 Glucose levels MED11 UTR-3 pha003058 rs1051009 chr17 4637886 G A 6.47E-04 Response to cytidine analogues (gemcitabine) CXCL16 UTR-3 24483146 rs4790224 chr17 4646064 A G 1.82E-04 Multiple complex diseases ZMYND15 intron 17554300 rs12451720 chr17 4646480 C T 9.33E-04 Multiple complex diseases ZMYND15 intron 17554300 rs2271165 chr17 4649378 T C 2.16E-05 Response to mTOR inhibitor (everolimus) ZMYND15 UTR-3 24009623 rs7223183 chr17 4649785 A G 4.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs754814 chr17 4657034 C T 4.17E-05 Multiple complex diseases / / 17554300 rs754814 chr17 4657034 C T 2.01E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs733099 chr17 4658971 G A 4.69E-05 Cognitive impairment induced by topiramate / / 22091778 rs4790700 chr17 4662359 C T 3.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4790700 chr17 4662359 C T 1.25E-04 HIV-1 viral setpoint / / 21490045 rs4790700 chr17 4662359 C T 5.28E-04 Alzheimer's disease / / 22005930 rs12051548 chr17 4683035 G C 1.00E-09 Sphingolipid levels TM4SF5 intron 22359512 rs12051548 chr17 4683035 G C 1.00E-11 Metabolite levels (atherosclerosis) TM4SF5 intron 22916037 rs3764900 chr17 4722133 C T 2.46E-04 Major depressive disorder PLD2 intron 22472876 rs11651691 chr17 4744823 T A,C,G 7.71E-05 Orofacial clefts MINK1 intron 22419666 rs12602901 chr17 4824625 G C 9.82E-04 Type 2 diabetes / / 17463246 rs12602901 chr17 4824625 G C 1.00E-26 Blood metabolite levels / / 24816252 rs2243093 chr17 4835895 T C 0.0000594 Ankle-brachial index GP1BA UTR-5 22361517 rs6065 chr17 4836381 C T 2.00E-12 Blood cell counts and other traits GP1BA missense 20139978 rs6065 chr17 4836381 C T 2.13E-12 Blood cell counts and other traits GP1BA missense 20139978 rs6065 chr17 4836381 C T 2.13E-12 Hepatitis B GP1BA missense 21750111 rs6065 chr17 4836381 C T 3.00E-11 Platelet counts GP1BA missense 22139419 rs6065 chr17 4836381 C T 2.13E-17 Mean platelet volume GP1BA missense 22423221 rs2243100 chr17 4839033 C T 0.00005 Ankle-brachial index / / 22361517 rs2243102 chr17 4839149 C T 2.55E-05 Type 2 diabetes / / 17463246 rs2243102 chr17 4839149 C T 3.10E-04 Primary sclerosing cholangitis / / 19944697 rs400688 chr17 4839930 A G 2.00E-06 Primary tooth development (number of teeth) / / 23704328 rs238238 chr17 4856376 A G 1.71E-04 Type 2 diabetes ENO3 missense 17463246 rs238228 chr17 4878960 G A 3.87E-05 Lymphocyte counts CAMTA2 intron 22286170 rs11658587 chr17 4901982 C T 6.00E-06 Obesity-related traits KIF1C intron 23251661 rs238237 chr17 4902958 G A 3.83E-04 Type 2 diabetes KIF1C intron 17463246 rs389855 chr17 4952934 A G 2.30E-05 Urinary metabolites / / 21572414 rs8072032 chr17 4955206 G T 8.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs4790246 chr17 4971655 A G 5.30E-06 Parkinson's disease / / 20711177 rs4790741 chr17 4989326 A G 3.34E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) ZFP3 intron 23648065 rs11657827 chr17 5008957 G A 2.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs9912347 chr17 5017772 A G 2.00E-04 Asthma and hay fever ZNF232 intron 24388013 rs2304449 chr17 5044794 G A 4.10E-17 Health and aging,CVD and cancer age of onset USP6 missense 22174011 rs2304449 chr17 5044794 G A 5.70E-11 Health and aging,CVD and cancer age of onset USP6 missense 22174011 rs1819114 chr17 5047479 C T 1.06E-04 Multiple complex diseases USP6 intron 17554300 rs8081019 chr17 5090308 C T 2.40E-05 Urinary metabolites ZNF594 intron 21572414 rs2439945 chr17 5124462 C T 5.45E-04 Insulin resistance SCIMP intron 21901158 rs7225151 chr17 5137047 G A 4.00E-07 Alzheimer's disease (late onset) SCIMP intron 24162737 rs2585284 chr17 5138513 A C 5.78E-04 Insulin resistance / / 21901158 rs2439938 chr17 5141800 A G 9.86E-05 Post-operative nausea and vomiting / / 21694509 rs2439933 chr17 5147504 G T 6.57E-04 Insulin resistance / / 21901158 rs9903704 chr17 5266343 A G 3.84E-05 Cognitive performance RABEP1 intron 19734545 rs72634030 chr17 5272580 C A 2.00E-09 Rheumatoid arthritis RABEP1 intron 24390342 rs72634030 chr17 5272580 C A 2.90E-05 Rheumatoid arthritis RABEP1 intron 24390342 rs72634030 chr17 5272580 C A 9.60E-06 Rheumatoid arthritis RABEP1 intron 24390342 rs3026108 chr17 5283909 C T 5.60E-06 Urinary metabolites RABEP1 intron 21572414 rs1065483 chr17 5284770 G A 1.63E-13 Lymphocyte counts RABEP1 cds-synon 22286170 rs11209 chr17 5289580 A G 8.02E-04 Body mass index NUP88 cds-synon 21701565 rs1806269 chr17 5323228 C A 6.37E-04 Type 2 diabetes RPAIN UTR-5 17463246 rs8070740 chr17 5331896 A G 0.000033 Coronary artery calcification RPAIN UTR-3 23727086 rs12603094 chr17 5347956 A T 2.03E-04 Type 2 diabetes DHX33 intron 17463246 rs3744714 chr17 5354077 C T 4.24E-06 Magnesium levels DHX33 intron pha003092 rs16954697 chr17 5356913 C T 3.05E-04 Sudden cardiac arrest DHX33 cds-synon 21658281 rs11867311 chr17 5358671 C T 7.58E-04 Major depressive disorder DHX33 intron 22472876 rs3865353 chr17 5361075 G T 1.05E-04 Major depressive disorder DHX33 intron 22472876 rs55935197 chr17 5361225 A G 0.00009454 Sarcoidosis DHX33 intron 22952805 rs16954705 chr17 5361613 C T 5.82E-04 Multiple complex diseases DHX33 intron 17554300 rs8070008 chr17 5366650 C G 9.40E-04 Major depressive disorder DHX33 intron 22472876 rs8069315 chr17 5366947 G A 0.00007635 Sarcoidosis DHX33 missense 22952805 rs3865350 chr17 5381867 C T 1.17E-04 Major depressive disorder DERL2 intron 22472876 rs3865351 chr17 5382031 C T 3.50E-04 Major depressive disorder DERL2 intron 22472876 rs1805456 chr17 5386025 A G 4.97E-04 Multiple complex diseases DERL2 intron 17554300 rs2309399 chr17 5391690 G A 1.88E-04 Major depressive disorder MIS12 UTR-5 22472876 rs9902174 chr17 5396813 A G 7.18E-04 Major depressive disorder / / 22472876 rs5862 chr17 5402957 A G 7.07E-05 Amyotrophic lateral sclerosis LOC728392 UTR-3 20801717 rs9900356 chr17 5419278 C T 0.00018 Coronary artery calcification NLRP1 intron 23727086 rs11651270 chr17 5425077 T C 6.59E-04 Myocardial Infarction NLRP1 missense pha002873 rs11868655 chr17 5426193 T C 1.55E-10 LDL cholesterol NLRP1 intron 23063622 rs11868655 chr17 5426193 T C 3.30E-09 Cholesterol,total NLRP1 intron 23063622 rs12952208 chr17 5442588 A G 3.82E-04 Multiple complex diseases NLRP1 intron 17554300 rs9889625 chr17 5446616 G A 3.65E-04 Multiple complex diseases NLRP1 intron 17554300 rs11652907 chr17 5449665 T C 1.30E-04 Stroke NLRP1 intron pha002886 rs925596 chr17 5488099 G A 1.00E-04 Blood pressure NLRP1 nearGene-5 21060006 rs925596 chr17 5488099 G A 5.20E-05 Blood pressure NLRP1 nearGene-5 21060006 rs9892702 chr17 5571881 G C 6.61E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6502872 chr17 5573766 C T 5.02E-05 Multiple complex diseases / / 17554300 rs6502873 chr17 5576885 C T 2.67E-07 Height / / pha003010 rs6502873 chr17 5576885 C T 2.65E-07 Height / / pha003011 rs7223088 chr17 5579859 C T 1.48E-06 Height / / pha003010 rs7223088 chr17 5579859 C T 1.61E-06 Height / / pha003011 rs4985678 chr17 5598568 T C 3.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4985678 chr17 5598568 T C 6.85E-05 Coronary heart disease / / pha003055 rs2535584 chr17 5633982 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs734319 chr17 5670410 G A 1.59E-04 Tourette syndrome / / 22889924 rs917686 chr17 5687717 A G 0.000033 Salmonella-induced pyroptosis LOC339166 intron 22837397 rs9901001 chr17 5689712 T C 8.05E-04 Multiple complex diseases LOC339166 intron 17554300 rs17645516 chr17 5689785 C A 3.24E-24 Narcolepsy LOC339166 intron 19629137 rs11655838 chr17 5723206 A G 3.47E-05 Cognitive impairment induced by topiramate LOC339166 intron 22091778 rs11655838 chr17 5723206 A G 9.68E-07 Venous thromboembolism LOC339166 intron 22672568 rs2042005 chr17 5733558 G A 2.97E-05 Blood pressure (response to angiotensin II receptor blocker) LOC339166 intron 24192120 rs2042004 chr17 5733863 G C 7.97E-06 Blood pressure (response to angiotensin II receptor blocker) LOC339166 intron 24192120 rs7222168 chr17 5734283 A G 1.22E-05 Blood pressure (response to angiotensin II receptor blocker) LOC339166 intron 24192120 rs8065927 chr17 5763071 T C 8.24E-08 Metabolite levels LOC339166 intron 23281178 rs888326 chr17 5765353 A G 6.76E-05 Prostate cancer LOC339166 intron 22923026 rs12949500 chr17 5768789 T C 1.51E-04 Response to cytadine analogues (cytosine arabinoside) LOC339166 intron 24483146 rs7218232 chr17 5770670 C T 5.03E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) LOC339166 intron 23648065 rs79967188 chr17 5785093 C T 4.76E-05 Intracerebral hemorrhage LOC339166 intron 24656865 rs189869876 chr17 5788346 G T 7.07E-05 Acne (severe) LOC339166 intron 24927181 rs76770958 chr17 5794250 C T 4.27E-05 Intracerebral hemorrhage LOC339166 intron 24656865 rs7214232 chr17 5812251 G A 2.50E-05 Urinary metabolites LOC339166 intron 21572414 rs723656 chr17 5865515 G A 1.47E-16 Varicose Veins / / pha001416 rs7225604 chr17 5892651 T C 6.17E-04 Schizophrenia / / 19197363 rs9303196 chr17 5907443 A T 8.00E-06 Non-small cell lung cancer / / 20876614 rs16955393 chr17 5945975 G A 5.07E-06 Glucose levels / / pha003058 rs1972498 chr17 5951088 G A 9.71E-05 Cognitive test performance / / 20125193 rs7210943 chr17 5982293 G A 2.60E-04 Response to taxane treatment (placlitaxel) WSCD1 intron 23006423 rs8069520 chr17 5998915 G A 1.50E-06 Urinary metabolites WSCD1 intron 21572414 rs4254372 chr17 6023338 G A 1.35E-04 Celiac disease WSCD1 intron 23936387 rs8069938 chr17 6028184 A G 4.50E-05 Diabetic nephropathy / / pha002866 rs7213574 chr17 6037373 C T 8.40E-06 Urinary metabolites / / 21572414 rs8075301 chr17 6038769 G A 3.98E-05 Aortic root size / / 21223598 rs6502919 chr17 6039624 A T 6.39E-04 Multiple complex diseases / / 17554300 rs7213706 chr17 6051906 C T 9.54E-04 Obesity (extreme) / / 21935397 rs7211276 chr17 6058341 G C,T 3.96E-32 Narcolepsy / / 19629137 rs3744728 chr17 6093951 T C 3.00E-06 Bipolar disorder (mood-incongruent) / / 23092984 rs17201619 chr17 6114005 G A 1.17E-06 Multiple complex diseases / / 17554300 rs2159271 chr17 6132447 C T 7.87E-04 Multiple complex diseases / / 17554300 rs4796444 chr17 6135803 T C 6.74E-04 Multiple complex diseases / / 17554300 rs7503953 chr17 6141677 A C 2.70E-12 Pancreatic cancer / / 21849791 rs7503953 chr17 6141677 A C 2.42E-04 Coronary heart disease / / 21971053 rs7503953 chr17 6141677 A C 2.00E-07 Wegener's granulomatosis / / 23740775 rs3888640 chr17 6153134 G A 5.79E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs3888640 chr17 6153134 G A 0.00074 Salmonella-induced pyroptosis / / 22837397 rs2871274 chr17 6158885 A G 2.70E-05 Urinary metabolites / / 21572414 rs12950017 chr17 6159654 T C 2.10E-05 Urinary metabolites / / 21572414 rs12453984 chr17 6160970 A C 2.00E-05 Urinary metabolites / / 21572414 rs12452055 chr17 6161918 G A 1.20E-05 Urinary metabolites / / 21572414 rs1872235 chr17 6163555 A T 9.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1872236 chr17 6163894 A C 7.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9284355 chr17 6165834 G A 6.93E-06 White blood cell count / / 21738479 rs35756657 chr17 6169426 G A 4.00E-04 Urinary metabolites / / 21572414 rs8078518 chr17 6175260 T C 7.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1077009 chr17 6179929 T C 9.30E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9894371 chr17 6212579 A G 3.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs2309567 chr17 6237099 C G 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs2309569 chr17 6238686 T A 3.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs8067250 chr17 6239453 C T 3.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs7221011 chr17 6241432 C T 1.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs12449441 chr17 6300035 G A 3.18E-04 Bipolar disorder,schizoaffective / / 19567891 rs1533313 chr17 6305922 T C,G 9.73E-05 Smoking cessation / / 24665060 rs11657269 chr17 6319784 A G 2.46E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs907946 chr17 6320519 G A 7.21E-04 Parkinson's disease / / 17052657 rs7212734 chr17 6340460 G A 8.49E-09 Free thyroxine (FT4) AIPL1 nearGene-5 23696881 rs58926603 chr17 6341870 A G 4.39E-09 Free thyroxine (FT4) / / 23696881 rs58926603 chr17 6341870 A G 5.62E-09 Free thyroxine (FT4)* / / 23696881 rs10852882 chr17 6362733 T C 2.30E-05 Urinary metabolites PITPNM3 intron 21572414 rs11653722 chr17 6373244 G A 0.00039 Personality disorders (PD) - Cluster C PITPNM3 intron 22981920 rs12949662 chr17 6379747 T C 2.80E-05 Urinary metabolites PITPNM3 intron 21572414 rs12601618 chr17 6390007 C T 0.000709156 Hypertension (early onset hypertension) PITPNM3 intron 22479346 rs9916344 chr17 6398213 C T 3.54E-04 Longevity PITPNM3 intron 22279548 rs9916344 chr17 6398213 C T 7.27E-05 Response to mTOR inhibitor (rapamycin) PITPNM3 intron 24009623 rs8064810 chr17 6404727 G A 6.20E-06 Urinary metabolites PITPNM3 intron 21572414 rs8074746 chr17 6406333 G A 0.000391 Salmonella-induced pyroptosis PITPNM3 intron 22837397 rs3809835 chr17 6406883 C T 7.73E-05 Response to mTOR inhibitor (rapamycin) PITPNM3 missense 24009623 rs6502960 chr17 6431123 A G 0.0000081 Asthma (exacerbation) PITPNM3 intron 23706709 rs356041 chr17 6453406 C G 8.67E-04 Multiple complex diseases PITPNM3 intron 17554300 rs1470297 chr17 6508829 C G 1.72E-04 Alzheimer's disease KIAA0753 intron 17998437 rs2304977 chr17 6513329 G A 0.000073 Carotid intima media thickness KIAA0753 missense 23152477 rs11657031 chr17 6548278 C T 3.20E-04 Multiple complex diseases MED31 intron 17554300 rs7214691 chr17 6548730 G A 9.90E-05 Personality dimensions MED31 intron 18957941 rs7211519 chr17 6549589 C G 7.25E-04 Alzheimer's disease MED31 intron 17998437 rs2040847 chr17 6558011 G A 9.40E-05 Personality dimensions / / 18957941 rs680625 chr17 6584878 A G 1.32E-07 Multiple complex diseases / / 17554300 rs170149 chr17 6595930 G A 1.00E-13 Blood metabolite levels SLC13A5 intron 24816252 rs2269922 chr17 6600547 G A 3.98E-05 Calcium levels SLC13A5 intron pha003085 rs218676 chr17 6607018 G A 5.00E-06 Economic and political preferences (time) SLC13A5 intron 22566634 rs16956197 chr17 6613827 T C 2.60E-05 Lung adenocarcinoma SLC13A5 intron 22797724 rs11078645 chr17 6625144 A G 3.04E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11654002 chr17 6630436 A T 8.30E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6502980 chr17 6680293 A G 2.57E-04 Multiple complex diseases FBXO39 intron 17554300 rs1509123 chr17 6683878 C T 3.78E-04 Multiple complex diseases FBXO39 missense 17554300 rs1509123 chr17 6683878 C T 5.00E-09 Blood metabolite levels FBXO39 missense 24816252 rs8081984 chr17 6686566 T G 7.46E-05 Response to acetaminophen (hepatotoxicity) FBXO39 intron 21177773 rs10852886 chr17 6692841 T A 7.50E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs12602795 chr17 6693745 C T 9.65E-06 Political ideology / / 24569950 rs4299197 chr17 6696191 G A 2.60E-04 Alzheimer's disease (late onset) / / 21379329 rs17804647 chr17 6704071 G A 2.97E-04 Multiple complex diseases TEKT1 cds-synon 17554300 rs12103647 chr17 6721327 C A 1.31E-04 Multiple complex diseases TEKT1 intron 17554300 rs9901847 chr17 6729550 G A 5.74E-04 Multiple complex diseases TEKT1 intron 17554300 rs58630086 chr17 6781413 G A 6.00E-07 Bipolar disorder (body mass index interaction) ALOX12P2 intron 24322204 rs2271315 chr17 6802289 C T 2.19E-04 Multiple complex diseases ALOX12P2 intron 17554300 rs11656451 chr17 6814546 T C 4.31E-05 Anxiety in major depressive disorder / / 24047446 rs2135845 chr17 6847073 A G 0.000181952 Hypertension (early onset hypertension) / / 22479346 rs9630722 chr17 6850461 G A 0.000867571 Hypertension (early onset hypertension) / / 22479346 rs11571365 chr17 6913855 C T 0.0000593 Paraoxonase activity ALOX12 UTR-3 23160181 rs2271316 chr17 6915401 C G 2.00E-23 Blood metabolite levels LOC100506713 intron 24816252 rs2077976 chr17 6931769 G A 1.80E-12 Metabolite levels BCL6B UTR-3 23281178 rs312457 chr17 6940393 G A 8.00E-13 Type 2 diabetes SLC16A13 intron 23945395 rs75493593 chr17 6945087 G T 5.00E-15 Type 2 diabetes SLC16A11 missense 24390345 rs4796366 chr17 6962511 T G 6.40E-06 Urinary metabolites / / 21572414 rs4796366 chr17 6962511 T G 9.49E-04 Lymphocyte counts / / 22286170 rs17805145 chr17 6974980 T C 7.49E-05 HIV-1 viral setpoint / / 21490045 rs314239 chr17 7013365 G A 2.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ASGR2 intron 20877124 rs2062737 chr17 7031638 A G 5.80E-07 Urinary metabolites / / 21572414 rs2062737 chr17 7031638 A G 5.09E-05 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs12453853 chr17 7044746 G A 8.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs4464125 chr17 7051275 G A 1.28E-04 Multiple complex diseases / / 17554300 rs34870220 chr17 7084911 C T 0.0000126 Alcohol craving with or without dependence / / 22481050 rs11650232 chr17 7088923 A G 8.71E-05 HIV-1 viral setpoint / / 21490045 rs12947697 chr17 7089617 C T 0.0000319 Alcohol craving with or without dependence / / 22481050 rs314253 chr17 7091650 T C 1.02E-04 HIV-1 viral setpoint / / 21490045 rs314253 chr17 7091650 T C 8.00E-12 Liver enzyme levels (alkaline phosphatase) / / 22001757 rs314253 chr17 7091650 T C 3.00E-10 LDL cholesterol / / 24097068 rs408315 chr17 7106475 A G 2.58E-12 Metabolite levels DLG4 intron 22286219 rs507506 chr17 7118322 A G 2.00E-06 Adiponectin levels DLG4 intron 22479202 rs41283399 chr17 7121539 C T 1.57E-11 Metabolite levels DLG4 intron 22286219 rs41283401 chr17 7122340 G A 1.54E-11 Metabolite levels DLG4 UTR-5 22286219 rs41283403 chr17 7122828 C T 1.54E-11 Metabolite levels DLG4 UTR-5 22286219 rs148584617 chr17 7128292 G A 0.0005 Prostate cancer ACADVL missense 23555315 rs2074216 chr17 7133609 G A 1.07E-04 Suicide attempts in bipolar disorder DVL2 cds-synon 21423239 rs117616209 chr17 7142851 C T 3.00E-14 Metabolite levels / / 22286219 rs11544290 chr17 7162533 C T 1.22E-11 Metabolite levels C17orf81 UTR-3 22286219 rs2073476 chr17 7183985 G A 0.000000309 Triglycerides SLC2A4 nearGene-5 23063622 rs5415 chr17 7184481 T C 5.00E-06 Birth weight SLC2A4 nearGene-5 23202124 rs16956647 chr17 7186022 C T 0.000195 Salmonella-induced pyroptosis SLC2A4 intron 22837397 rs5436 chr17 7187793 C T 3.16E-05 Atrial fibrillation SLC2A4 intron 21846873 rs3809816 chr17 7233011 C A 4.04E-04 Parkinson's disease / / 17052657 rs2292067 chr17 7252148 G T 1.99E-09 Lymphocyte counts ACAP1 intron 22286170 rs2269762 chr17 7285831 C T 3.30E-05 Cognitive function TNK1 intron 24684796 rs1554948 chr17 7286326 T A 6.30E-05 Alzheimer's disease (late onset) TNK1 cds-synon 21460841 rs7208523 chr17 7288228 C T 4.56E-04 Suicide attempts in bipolar disorder TNK1 intron 21423239 rs7220814 chr17 7290695 A G 0.00002 Breast cancer TNK1 splice-3 23555315 rs2075760 chr17 7292726 C T 1.30E-05 Urinary metabolites TNK1 UTR-3 21572414 rs4613118 chr17 7297452 A G 8.86E-05 Neuroblastoma PLSCR3 UTR-5 pha002895 rs17882626 chr17 7306727 A G 9.10E-04 Response to cytadine analogues (cytosine arabinoside) C17orf61 intron 24483146 rs11078674 chr17 7310473 A C 8.70E-05 Type 2 diabetes / / 17293876 rs11078674 chr17 7310473 A C 8.70E-05 Type 2 diabetes / / 19184112 rs2302762 chr17 7358861 T C 7.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CHRNB1 intron 20877124 rs4491591 chr17 7386055 C T 9.36E-05 Multiple complex diseases SLC35G6 missense 17554300 rs11658168 chr17 7406134 A G 7.39E-04 Multiple complex diseases POLR2A intron 17554300 rs8071847 chr17 7407327 A G 4.40E-06 Height POLR2A intron 21194676 rs8071847 chr17 7407327 A G 5.00E-09 Height POLR2A intron 21194676 rs6761 chr17 7417663 C T 3.00E-07 Protein quantitative trait loci POLR2A UTR-3 18464913 rs6761 chr17 7417663 C T 5.50E-05 Triglycerides POLR2A UTR-3 pha003081 rs9899183 chr17 7452977 C T 9.75E-06 Hearing function TNFSF12 intron 21493956 rs4511593 chr17 7455536 C T 1.50E-06 Urinary metabolites TNFSF12 intron 21572414 rs4968210 chr17 7457352 G A 7.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TNFSF12 intron 20877124 rs11552708 chr17 7462555 G A 3.81E-09 Non-albumin protein levels TNFSF13 missense 22558069 rs11552708 chr17 7462555 G A 4.00E-09 IgM levels TNFSF13 missense 23118916 rs3803800 chr17 7462969 A G 9.00E-11 IgA nephropathy TNFSF13 missense 22197929 rs3803800 chr17 7462969 A G 7.00E-15 Non-albumin protein levels TNFSF13 missense 22558069 rs3803800 chr17 7462969 A G 3.00E-07 IgA levels TNFSF13 missense 22864923 rs3803800 chr17 7462969 A G 9.28E-06 IgM levels TNFSF13 missense 23118916 rs4968212 chr17 7468216 T C 0.00009817 Sarcoidosis SENP3 intron 22952805 rs11078697 chr17 7469229 C T 4.00E-07 IgM levels SENP3 intron 23118916 rs11078697 chr17 7469229 C T 6.27E-19 Follicle stimulating hormone SENP3 intron 24049095 rs4602096 chr17 7473457 C A 6.20E-05 Hematology traits SENP3 intron 23303382 rs4968214 chr17 7477477 A G 0.00007538 Sarcoidosis EIF4A1 intron 22952805 rs9901675 chr17 7484812 G A 2.69E-07 Non-albumin protein levels CD68 missense 22558069 rs9901675 chr17 7484812 G A 1.00E-07 Sex hormone-binding globulin levels CD68 missense 22829776 rs2075230 chr17 7487108 A G 1.00E-08 Follicle stimulating hormone MPDU1 UTR-5 24049095 rs2075230 chr17 7487108 A G 5.00E-19 Follicle stimulating hormone MPDU1 UTR-5 24049095 rs4227 chr17 7491177 G T 4.00E-10 IgA nephropathy MPDU1 UTR-3 22197929 rs73242239 chr17 7501905 G C 0.0000267 Sarcoidosis FXR2 intron 22952805 rs12452603 chr17 7504977 T C 0.00004833 Sarcoidosis FXR2 intron 22952805 rs11653545 chr17 7512074 G A 2.00E-07 IgM levels FXR2 intron 23118916 rs12150660 chr17 7521915 G T 1.00E-41 Testosterone levels SHBG intron 21998597 rs12150660 chr17 7521915 G T 2.00E-106 Sex hormone-binding globulin levels SHBG intron 22829776 rs12150660 chr17 7521915 G T 2.00E-55 Sex hormone-binding globulin levels SHBG intron 22829776 rs12150660 chr17 7521915 G T 4.00E-80 Sex hormone-binding globulin levels SHBG intron 22829776 rs12150660 chr17 7521915 G T 6.00E-30 Sex hormone-binding globulin levels SHBG intron 22829776 rs1799941 chr17 7533423 G A 7.80E-04 Response to cytadine analogues (cytosine arabinoside) SHBG intron 24483146 rs6258 chr17 7534678 C T 2.00E-22 Testosterone levels SHBG missense 21998597 rs6258 chr17 7534678 C T 3.00E-46 Sex hormone-binding globulin levels SHBG missense 22829776 rs6259 chr17 7536527 G A 1.06E-04 Colorectal cancer SHBG missense 24836286 rs727428 chr17 7537792 T C 2.00E-16 Sex hormone-binding globulin levels / / 22675492 rs727428 chr17 7537792 T C 1.00E-11 Androgen levels / / 22936694 rs727428 chr17 7537792 T C 1.00E-12 Androgen levels / / 22936694 rs2955617 chr17 7538785 C A 8.37E-04 Heart rate / / 23583979 rs1641544 chr17 7539866 T C 6.49E-04 Schizophrenia / / 19197363 rs1641537 chr17 7545721 T C 1.00E-24 Sex hormone-binding globulin levels / / 22829776 rs1641537 chr17 7545721 T C 4.34E-04 Colorectal cancer / / 24836286 rs1641523 chr17 7549681 C T 1.10E-09 Urinary metabolites / / 21572414 rs72829446 chr17 7552123 C T 6.00E-08 Androgen levels / / 22936694 rs72829446 chr17 7552123 C T 9.00E-10 Androgen levels / / 22936694 rs1642763 chr17 7557419 A G 1.61E-04 Pancreatic cancer / / pha002874 rs1641510 chr17 7561496 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs8073498 chr17 7569698 A C 2.09E-04 Vaspin levels / / 22907691 rs8073498 chr17 7569698 A C 0.0002086 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs78378222 chr17 7571752 T G 1.00E-05 Skin cancer (cutaneous basal cell carcinoma) TP53 UTR-3 21946351 rs78378222 chr17 7571752 T G 1.60E-04 Skin cancer (cutaneous basal cell carcinoma) TP53 UTR-3 21946351 rs78378222 chr17 7571752 T G 2.20E-20 Skin cancer (cutaneous basal cell carcinoma) TP53 UTR-3 21946351 rs78378222 chr17 7571752 T G 2.40E-06 Skin cancer (cutaneous basal cell carcinoma) TP53 UTR-3 21946351 rs78378222 chr17 7571752 T G 4.00E-22 Basal cell carcinoma TP53 UTR-3 24403052 rs12951053 chr17 7577407 A C 5.30E-05 Hematology traits TP53 intron 23303382 rs1625895 chr17 7578115 T C 2.00E-21 Sex hormone-binding globulin levels TP53 intron 22829776 rs1042522 chr17 7579472 G C 1 Drug response to Fluorouracil TP53 missense 18357466 rs1042522 chr17 7579472 G C 1 Drug response to Cisplatin TP53 missense 19786980 rs1042522 chr17 7579472 G C 1 Drug response to Cyclophosphamide TP53 missense 19786980 rs8078476 chr17 7581228 G A 0.000000294 HDL cholesterol TP53 intron 23063622 rs11651917 chr17 7618604 G A 2.96E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs16956936 chr17 7633692 C T 2.34E-04 Multiple complex diseases D/H2 intron 17554300 rs16956936 chr17 7633692 C T 5.08E-05 Type 1 diabetes D/H2 intron 18978792 rs16956936 chr17 7633692 C T 5.00E-07 Type 1 diabetes D/H2 intron 19430480 rs12453814 chr17 7665293 A G 4.81E-04 Alcohol dependence D/H2 intron 21314694 rs139308934 chr17 7671294 G A 0.00033 Breast cancer D/H2 missense 23555315 rs8066124 chr17 7676703 T C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes D/H2 intron 22628534 rs9905906 chr17 7685748 C T 0.000374339 Hypertension (early onset hypertension) D/H2 intron 22479346 rs872346 chr17 7721030 G A 1.37E-04 Amyotrophic lateral sclerosis (sporadic) D/H2 intron 24529757 rs9916791 chr17 7721231 T C 4.93E-05 Cholesterol D/H2 intron pha003073 rs9916791 chr17 7721231 T C 6.14E-05 Cholesterol D/H2 intron pha003078 rs4130668 chr17 7739664 T C 6.85E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs4130668 chr17 7739664 T C 8.60E-07 Primary tooth development (number of teeth) / / 23704328 rs11078711 chr17 7777214 G T 2.95E-05 Multiple complex diseases / / 17554300 rs11078712 chr17 7785977 A G 6.63E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4239111 chr17 7811998 T C 3.66E-05 Information processing speed CHD3 intron 21130836 rs9891006 chr17 7825574 T G 8.29E-04 Type 2 diabetes / / 17463246 rs35421969 chr17 7846713 G A 0.00032 Prostate cancer CNTROB missense 23555315 rs7218733 chr17 7888971 A C 4.50E-05 Response to statin therapy / / 20339536 rs12449814 chr17 7911709 G T 2.60E-05 Response to statin therapy GUCY2D intron 20339536 rs12449814 chr17 7911709 G T 2.76E-04 Stroke GUCY2D intron pha002887 rs7503918 chr17 7922025 C T 6.15E-05 Alcohol dependence GUCY2D intron 21703634 rs4130511 chr17 7930799 T A 8.96E-04 Type 2 diabetes / / 17463246 rs4383207 chr17 7936282 A G 8.14E-04 Type 2 diabetes / / 17463246 rs4247362 chr17 7944542 T C 3.02E-05 Cognitive test performance ALOX15B intron 20125193 rs9911427 chr17 7971640 G A 8.35E-05 Cognitive test performance / / 20125193 rs12943817 chr17 7974834 C T 5.43E-04 Alcohol dependence / / 20201924 rs12943817 chr17 7974834 C T 3.65E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs3027300 chr17 7988993 A C 8.04E-05 Body Composition ALOX12B intron pha003012 rs3027300 chr17 7988993 A C 2.98E-05 Body Mass Index ALOX12B intron pha003021 rs894506 chr17 8004121 C T 8.04E-04 Type 2 diabetes ALOXE3 intron 17463246 rs3027290 chr17 8008120 C G 6.36E-11 Triglycerides ALOXE3 intron 23063622 rs9892383 chr17 8010228 T C 6.66E-05 Cognitive test performance ALOXE3 intron 20125193 rs3027209 chr17 8014416 A G 5.99E-04 Alzheimer's disease ALOXE3 intron 24755620 rs3027213 chr17 8016013 A C 2.74E-04 Response to taxane treatment (placlitaxel) ALOXE3 intron 23006423 rs3027213 chr17 8016013 A C 5.63E-04 Alzheimer's disease ALOXE3 intron 24755620 rs3027232 chr17 8022065 G A 5.51E-04 Type 2 diabetes ALOXE3 missense 17463246 rs9889775 chr17 8032068 G T 9.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12937495 chr17 8046147 C T 0.000082 Breast cancer(er negative) PER1 missense 23555315 rs2304911 chr17 8050979 A G 2.01E-04 Lung function (forced expiratory volume in 1 second) PER1 intron 24023788 rs6503090 chr17 8080409 A G 0.000381 Salmonella-induced pyroptosis / / 22837397 rs8531 chr17 8092694 T G 1.91E-04 Breast cancer C17orf59 cds-synon pha002853 rs9891949 chr17 8099183 G A 4.47E-04 Asthma / / 21804549 rs9891949 chr17 8099183 G A 0.000000058 Asthma / / 23040885 rs3027247 chr17 8130867 A C 9.00E-06 Parkinson's disease (motor and cognition) CTC1 UTR-3 22658654 rs3027234 chr17 8136092 C T 2.00E-08 Telomere length CTC1 intron 23001564 rs1861954 chr17 8198504 G T 3.30E-05 Response to Vitamin E supplementation / / 22437554 rs4792734 chr17 8208155 A G 5.45E-04 Multiple complex diseases / / 17554300 rs2270445 chr17 8219478 A G 1.00E-04 Cognitive impairment induced by topiramate ARHGEF15 intron 22091778 rs2270445 chr17 8219478 A G 1.02E-10 Lymphocyte counts ARHGEF15 intron 22286170 rs12600950 chr17 8233085 T G 6.10E-06 Urinary metabolites / / 21572414 rs12952489 chr17 8241891 A G 6.13E-07 Lymphocyte counts / / 22286170 rs2313148 chr17 8251845 T C 5.00E-06 Parkinson's disease (motor and cognition) / / 22658654 rs8070926 chr17 8254369 G C 9.45E-04 Type 2 diabetes / / 17463246 rs4792792 chr17 8265776 A G 2.60E-05 Urinary metabolites / / 21572414 rs78738842 chr17 8273026 G A 0.00000027 Breast cancer(er negative) KRBA2 missense 23555315 rs111570631 chr17 8383838 G A 0.00019 Breast cancer (ER positive) MYH10 missense 23555315 rs904417 chr17 8384875 T G 7.04E-04 Multiple complex diseases MYH10 intron 17554300 rs7208821 chr17 8476743 C T 7.41E-04 Alcohol dependence MYH10 intron 21314694 rs9897780 chr17 8559766 G A 8.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6503137 chr17 8565356 T C 8.24E-05 Behcet's disease / / pha002888 rs7213402 chr17 8595094 C T 2.09E-05 Leukocyte Counts / / pha003091 rs2101938 chr17 8620629 C T 2.35E-04 Height / / 17255346 rs1529606 chr17 8622190 T G 2.74E-05 Height / / 17255346 rs1971773 chr17 8633310 C T 5.48E-05 Behcet's disease CCDC42 UTR-3 pha002888 rs9906231 chr17 8636265 C G 3.92E-04 Height CCDC42 intron 17255346 rs196449 chr17 8708327 G A,C 4.12E-04 Multiple complex diseases PIK3R6 intron 17554300 rs12944785 chr17 8735090 A G 9.91E-05 Coronary restenosis PIK3R6 intron 21878436 rs17206162 chr17 8745897 G A 3.38E-04 Multiple complex diseases PIK3R6 intron 17554300 rs373495 chr17 8785996 C A 5.00E-05 Diabetic retinopathy PIK3R5 intron 21441570 rs400439 chr17 8786038 A C 4.90E-05 Diabetic retinopathy PIK3R5 intron 21441570 rs374864 chr17 8786924 T C 5.00E-05 Diabetic retinopathy PIK3R5 intron 21441570 rs374864 chr17 8786924 T C 3.58E-04 Taste perception PIK3R5 intron 22132133 rs443532 chr17 8787495 G A 5.20E-05 Diabetic retinopathy PIK3R5 intron 21441570 rs436193 chr17 8787847 G C 5.10E-05 Diabetic retinopathy PIK3R5 intron 21441570 rs454347 chr17 8788154 C A 5.40E-05 Diabetic retinopathy PIK3R5 intron 21441570 rs381309 chr17 8792029 A G 6.59E-04 Smoking cessation PIK3R5 cds-synon 24665060 rs413310 chr17 8794527 G A 5.40E-05 Diabetic retinopathy PIK3R5 intron 21441570 rs427554 chr17 8802655 G A 4.43E-05 Taste perception PIK3R5 intron 22132133 rs10491087 chr17 8850988 C A,G,T 9.67E-05 Non-alcoholic fatty liver disease histology (other) PIK3R5 intron 20708005 rs11078772 chr17 8871542 C A 3.23E-05 Orofacial clefts / / 22863734 rs16957797 chr17 8899137 T G 6.70E-06 Major depressive disorder / / 20516156 rs11078773 chr17 8904563 T C 9.70E-04 Smoking behavior / / 20418888 rs7219148 chr17 8905016 T G 0.0000506 post-traumatic stress disorder / / 22869035 rs7219148 chr17 8905016 T G 5.06E-05 Schizophrenia / / 22883433 rs2872615 chr17 8914693 T C 2.33E-06 Cleft lip / / 20436469 rs2872615 chr17 8914693 T C 4.73E-07 Orofacial clefts / / 22863734 rs9788972 chr17 8919630 G A 6.00E-09 Cleft lip / / 20436469 rs9788972 chr17 8919630 G A 2.49E-07 Orofacial clefts / / 22863734 rs4791330 chr17 8920599 T C 6.81E-08 Cleft lip / / 20436469 rs940853 chr17 8927174 G A 7.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NTN1 intron 20877124 rs1880646 chr17 8929845 A G 1.82E-05 Cleft lip NTN1 intron 20436469 rs1880646 chr17 8929845 A G 3.96E-06 Orofacial clefts NTN1 intron 22863734 rs6503167 chr17 8931499 T C 4.30E-06 Type 2 diabetes NTN1 intron 17463246 rs4791331 chr17 8932082 C T 6.41E-06 Cleft lip NTN1 intron 20436469 rs7223172 chr17 8932888 A C 6.82E-06 Type 2 diabetes NTN1 intron 17463246 rs8076457 chr17 8943929 T C 2.00E-07 Orofacial clefts NTN1 intron 22863734 rs9915089 chr17 8952894 C T 6.90E-07 Cleft lip NTN1 intron 20436469 rs8069536 chr17 8956285 G T 4.41E-08 Cleft lip NTN1 intron 20436469 rs8069536 chr17 8956285 G T 1.28E-06 Orofacial clefts NTN1 intron 22863734 rs8081823 chr17 8965551 G A 2.49E-06 Cleft lip NTN1 intron 20436469 rs8081823 chr17 8965551 G A 7.49E-05 Orofacial clefts NTN1 intron 22863734 rs9899718 chr17 9002267 T C 5.99E-04 Response to taxane treatment (placlitaxel) NTN1 intron 23006423 rs4791779 chr17 9005393 A G 5.73E-05 Orofacial clefts NTN1 intron 22419666 rs4791794 chr17 9026810 T C 6.63E-05 Serum metabolites NTN1 intron 19043545 rs16957962 chr17 9060026 A G 2.85E-05 Melanoma NTN1 intron 21926416 rs16942842 chr17 9062487 G A 7.89E-04 Multiple complex diseases NTN1 intron 17554300 rs16942842 chr17 9062487 G A 2.78E-05 Odorant perception NTN1 intron 23910658 rs7214739 chr17 9065935 T C 4.94E-05 Diabetic nephropathy NTN1 intron pha002864 rs9897106 chr17 9073303 G A 3.88E-04 Multiple complex diseases NTN1 intron 17554300 rs9897106 chr17 9073303 G A 6.31E-04 Sarcoidosis NTN1 intron 19165924 rs8067387 chr17 9087421 A G 3.42E-05 Sodium levels NTN1 intron pha003093 rs3785982 chr17 9090224 C T 8.00E-06 Breast cancer (prognosis) NTN1 intron 23319801 rs6503186 chr17 9092261 C T 3.79E-05 Sodium levels NTN1 intron pha003093 rs16958060 chr17 9114358 A G 0.000636 Salmonella-induced pyroptosis NTN1 intron 22837397 rs12939263 chr17 9127010 C T 5.21E-05 Post-operative nausea and vomiting NTN1 intron 21694509 rs9909240 chr17 9140091 G A 9.32E-07 Rheumatoid arthritis NTN1 intron 19503088 rs9909240 chr17 9140091 G A 3.53E-04 Tourette syndrome NTN1 intron 22889924 rs2302198 chr17 9148060 A G 7.40E-04 Depression (quantitative trait) / / 20800221 rs7219119 chr17 9154655 C T 6.71E-05 Major depressive disorder STX8 intron 22472876 rs9897485 chr17 9169367 T C 2.50E-05 Urinary metabolites STX8 intron 21572414 rs17808595 chr17 9178382 T G 7.89E-05 Multiple complex diseases STX8 intron 17554300 rs4534894 chr17 9196295 A G 1.26E-04 Coronary heart disease STX8 intron 21606135 rs7220761 chr17 9240240 T C 3.63E-04 Type 2 diabetes STX8 intron 17463246 rs4239104 chr17 9268502 T C 4.79E-05 Attention deficit hyperactivity disorder STX8 intron pha002875 rs8078384 chr17 9308347 G C 9.43E-04 Suicide attempts in bipolar disorder STX8 intron 21423239 rs8068962 chr17 9314141 T C 3.32E-05 Neuroticism STX8 intron 23229837 rs12452001 chr17 9337661 G C 9.94E-04 Coronary Artery Disease STX8 intron 17634449 rs12452001 chr17 9337661 G C 7.45E-05 Serum metabolites STX8 intron 19043545 rs7216753 chr17 9349826 A C 5.46E-05 Alcohol dependence STX8 intron 21703634 rs8071640 chr17 9354504 A G 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes STX8 intron 22628534 rs9895062 chr17 9370623 A G 2.11E-04 Multiple complex diseases STX8 intron 17554300 rs6503206 chr17 9375419 A G 1.69E-04 White matter integrity STX8 intron 22425255 rs10521158 chr17 9383203 T C 9.80E-05 C-Reactive Protein STX8 intron pha003070 rs4791841 chr17 9384095 T C 3.24E-05 Multiple sclerosis (age of onset) STX8 intron 19010793 rs6503211 chr17 9392700 T A,C,G 2.19E-05 Information processing speed STX8 intron 21130836 rs1133295 chr17 9471711 T G 2.40E-05 Urinary metabolites STX8 cds-synon 21572414 rs4791853 chr17 9477141 C G 7.10E-06 Urinary metabolites STX8 intron 21572414 rs422819 chr17 9555377 G A 9.62E-04 Response to alcohol consumption (flushing response) USP43 intron 24277619 rs274907 chr17 9564861 T G 2.42E-05 F-cell distribution USP43 intron 21326311 rs6503238 chr17 9582214 T C 1.72E-04 Response to taxane treatment (placlitaxel) USP43 intron 23006423 rs7220651 chr17 9590319 T G 4.37E-04 Response to taxane treatment (placlitaxel) USP43 intron 23006423 rs16958589 chr17 9590409 T C 7.79E-04 Response to taxane treatment (placlitaxel) USP43 intron 23006423 rs8078327 chr17 9601871 G A 5.21E-04 Response to taxane treatment (placlitaxel) USP43 intron 23006423 rs407454 chr17 9606330 T C 3.90E-04 Schizophrenia USP43 intron 19197363 rs12450515 chr17 9632247 A G 5.64E-04 Type 2 diabetes USP43 cds-synon 17463246 rs185677 chr17 9639304 C T 4.56E-05 Body Fat Distribution / / pha003017 rs185677 chr17 9639304 C T 3.16E-05 Body Fat Distribution / / pha003018 rs424508 chr17 9652868 T C 8.77E-04 Alcohol dependence / / 21314694 rs8067933 chr17 9658245 C A 2.70E-05 Body Mass Index / / pha003019 rs8067933 chr17 9658245 C A 6.87E-05 Body Mass Index / / pha003020 rs17810028 chr17 9680203 C G 1.80E-05 Urinary metabolites DHRS7C intron 21572414 rs11655196 chr17 9686465 T G 2.20E-05 Urinary metabolites DHRS7C intron 21572414 rs4791866 chr17 9696883 C T 2.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4791866 chr17 9696883 C T 6.24E-06 F-cell distribution / / 21326311 rs4791868 chr17 9698244 G C 4.30E-04 Prostate cancer mortality / / 20978177 rs12103880 chr17 9698342 G A 3.41E-08 F-cell distribution / / 21326311 rs4791872 chr17 9703225 A G 8.04E-05 Multiple complex diseases / / 17554300 rs17207745 chr17 9703299 G A 2.56E-04 Prostate cancer mortality / / 20978177 rs3848437 chr17 9711104 G A 8.49E-04 Multiple complex diseases / / 17554300 rs17207766 chr17 9711808 C T 3.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4791360 chr17 9713505 G A 3.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17810130 chr17 9716564 T C 5.93E-04 Multiple complex diseases / / 17554300 rs1402654 chr17 9728210 C G 4.87E-04 Multiple complex diseases / / 17554300 rs2047664 chr17 9728611 C G 4.73E-04 Multiple complex diseases / / 17554300 rs2047664 chr17 9728611 C G 1.75E-04 Smoking cessation / / 18519826 rs17207885 chr17 9730764 T C 2.74E-04 Multiple complex diseases GLP2R intron 17554300 rs17207885 chr17 9730764 T C 5.87E-04 Insulin resistance GLP2R intron 21901158 rs3786122 chr17 9741938 T G 4.40E-04 Tourette syndrome GLP2R intron 22889924 rs1607987 chr17 9761666 T C 2.02E-05 Recombination rate GLP2R intron 21698098 rs7222383 chr17 9767222 A G 4.04E-04 Type 2 diabetes GLP2R intron 17463246 rs756222 chr17 9768866 G A 2.55E-04 Type 2 diabetes GLP2R intron 17463246 rs756222 chr17 9768866 G A 7.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) GLP2R intron 20877124 rs6503256 chr17 9771775 G A 2.62E-04 Type 2 diabetes GLP2R intron 17463246 rs17810423 chr17 9775918 T A 2.23E-04 Type 2 diabetes GLP2R intron 17463246 rs12936268 chr17 9776277 A T 9.00E-04 Suicide attempts in bipolar disorder GLP2R intron 21041247 rs12953287 chr17 9776471 C T 8.71E-04 Suicide attempts in bipolar disorder GLP2R intron 21041247 rs4791901 chr17 9781954 A G 1.40E-04 Multiple complex diseases GLP2R intron 17554300 rs4791901 chr17 9781954 A G 1.47E-04 Smoking cessation GLP2R intron 18519826 rs7219033 chr17 9787958 G A 0.0000263 Triglycerides GLP2R intron 23063622 rs2240737 chr17 9791159 G A 1.04E-04 Type 2 diabetes GLP2R intron 17463246 rs2240737 chr17 9791159 G A 2.03E-04 Smoking cessation GLP2R intron 18519826 rs4791905 chr17 9795420 C G 6.00E-05 Prostate cancer / / 21743057 rs4791906 chr17 9795452 C T 4.90E-05 Diabetic retinopathy / / 21441570 rs4791906 chr17 9795452 C T 0.0000565 Carotid intima media thickness / / 23152477 rs874307 chr17 9798074 G C 2.90E-05 Urinary metabolites / / 21572414 rs6503264 chr17 9804493 C T 2.29E-04 Type 2 diabetes RCVRN intron 17463246 rs2286531 chr17 9808571 T G 0.0002 Migraine RCVRN UTR-5 22678113 rs2286531 chr17 9808571 T G 9.67E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) RCVRN UTR-5 23648065 rs17683107 chr17 9824402 G A 8.50E-07 Primary sclerosing cholangitis GAS7 intron 21151127 rs16959082 chr17 9861011 T C 8.58E-04 Multiple complex diseases GAS7 intron 17554300 rs16959082 chr17 9861011 T C 1.24E-04 Smoking cessation GAS7 intron 18519826 rs11650718 chr17 9871184 T A 5.79E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GAS7 intron 20031582 rs3826529 chr17 9874145 G A 8.01E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) GAS7 intron 23648065 rs16959128 chr17 9874387 A G 5.57E-04 Multiple complex diseases GAS7 intron 17554300 rs3786094 chr17 9875205 T C 6.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) GAS7 intron 23648065 rs16959192 chr17 9890142 G A 5.66E-05 Smoking cessation GAS7 intron 18519826 rs8069470 chr17 9901677 G A 9.68E-05 Height GAS7 intron pha003011 rs7210903 chr17 9904482 A G 9.94E-05 Height GAS7 intron pha003011 rs3786083 chr17 9905073 G A 0.00029 Coronary artery calcification GAS7 intron 23727086 rs1016134 chr17 9927081 A G 4.57E-04 Response to cytidine analogues (gemcitabine) GAS7 intron 24483146 rs3760501 chr17 9932122 T C 5.11E-04 Response to cytidine analogues (gemcitabine) GAS7 intron 24483146 rs7222232 chr17 9936802 A C 0.000000461 HDL cholesterol GAS7 intron 23063622 rs7216104 chr17 9943679 T C 2.30E-05 Serum metabolites GAS7 intron 19043545 rs11656239 chr17 9950667 C T 0.00015 Coronary artery calcification GAS7 intron 23727086 rs8071787 chr17 9962136 T C 0.00000039 Triglycerides GAS7 intron 23063622 rs8071787 chr17 9962136 T C 5.26E-12 HDL cholesterol GAS7 intron 23063622 rs8071787 chr17 9962136 T C 6.20E-12 LDL cholesterol GAS7 intron 23063622 rs3865253 chr17 9969493 A G 1.10E-05 Urinary metabolites GAS7 intron 21572414 rs3967769 chr17 9981026 A C 5.80E-04 Multiple complex diseases GAS7 intron 17554300 rs734844 chr17 10004782 G A 8.13E-04 Response to statin treatment (atorvastatin),change in cholesterol levels GAS7 intron 20031582 rs16959323 chr17 10006097 C T 9.40E-06 HIV-1 control GAS7 intron 20041166 rs1476439 chr17 10010287 G A 2.31E-05 Cognitive test performance GAS7 intron 20125193 rs7225744 chr17 10016398 C T 1.84E-05 Height GAS7 intron pha003011 rs17760174 chr17 10017615 C A 8.95E-05 Height GAS7 intron pha003011 rs1076145 chr17 10020214 A G 6.90E-04 Suicide attempts in bipolar disorder GAS7 intron 21423239 rs739351 chr17 10020876 G A 7.02E-04 Suicide attempts in bipolar disorder GAS7 intron 21423239 rs739350 chr17 10021041 G C 7.15E-04 Suicide attempts in bipolar disorder GAS7 intron 21423239 rs12449525 chr17 10023722 G A 6.27E-04 Suicide attempts in bipolar disorder GAS7 intron 21423239 rs3764429 chr17 10025298 G A 7.06E-05 Height GAS7 intron pha003010 rs3764429 chr17 10025298 G A 8.72E-06 Height GAS7 intron pha003011 rs2157697 chr17 10027566 A C 1.89E-05 Suicide attempts in bipolar disorder GAS7 intron 21423239 rs12150284 chr17 10031090 C T 1.99E-04 Suicide attempts in bipolar disorder GAS7 intron 21423239 rs12150284 chr17 10031090 C T 1.00E-04 Cognitive impairment induced by topiramate GAS7 intron 22091778 rs12150284 chr17 10031090 C T 2.50E-08 Intraocular pressure GAS7 intron 22570627 rs12150284 chr17 10031090 C T 2.00E-06 Intraocular pressure GAS7 intron 24002674 rs9913911 chr17 10031183 A G 2.11E-04 Suicide attempts in bipolar disorder GAS7 intron 21423239 rs9913911 chr17 10031183 A G 2.40E-08 Intraocular pressure GAS7 intron 22570627 rs11656696 chr17 10033679 C A 1.00E-08 Intraocular pressure GAS7 intron 22570627 rs9889528 chr17 10035337 C T 2.10E-08 Intraocular pressure GAS7 intron 22570627 rs4572442 chr17 10036796 A G 5.30E-04 Coronary heart disease GAS7 intron 21966275 rs6503288 chr17 10044288 A G 2.02E-04 Type 2 diabetes GAS7 intron 17463246 rs2051668 chr17 10051143 A G 1.47E-04 Smoking quantity GAS7 intron 24665060 rs9891299 chr17 10081297 G A 3.87E-05 Prion diseases GAS7 intron 22210626 rs4128645 chr17 10082169 C T 5.60E-04 Atrial fibrillation GAS7 intron 21846873 rs7503418 chr17 10082249 C T 0.0000653 LDL cholesterol GAS7 intron 23063622 rs12950553 chr17 10089563 C T 2.87E-05 Intracerebral hemorrhage GAS7 intron 24656865 rs12948698 chr17 10089663 G A 3.28E-05 Intracerebral hemorrhage GAS7 intron 24656865 rs7503909 chr17 10090019 G A 3.39E-05 Intracerebral hemorrhage GAS7 intron 24656865 rs7225158 chr17 10095453 C T 1.31E-04 Progressive supranuclear palsy GAS7 intron 21685912 rs34723702 chr17 10096877 C T 2.55E-05 Intracerebral hemorrhage GAS7 intron 24656865 rs8073468 chr17 10106513 G A 1.88E-06 Post-operative nausea and vomiting / / 21694509 rs8073468 chr17 10106513 G A 3.29E-04 Iron levels / / pha002876 rs4791943 chr17 10115947 A G 5.21E-04 Iron levels / / pha002876 rs9674875 chr17 10130845 G A 2.48E-05 Iron levels / / 19880490 rs9674875 chr17 10130845 G A 2.48E-05 Iron levels / / pha002876 rs4791959 chr17 10163569 A G 1.08E-05 Orofacial clefts / / 22419666 rs12450499 chr17 10168316 T C 1.40E-04 Vaspin levels / / 22907691 rs12450499 chr17 10168316 T C 0.0000336 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs12450499 chr17 10168316 T C 0.0001404 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs4791962 chr17 10168780 A G 9.39E-05 Orofacial clefts / / 22419666 rs12940268 chr17 10177844 T C 8.07E-04 White matter integrity / / 22425255 rs4451986 chr17 10179427 T G 6.25E-05 Heart Rate / / pha003054 rs2051987 chr17 10180193 C T 8.31E-05 Alzheimer's disease (late onset) / / 21379329 rs999339 chr17 10198931 G A 6.16E-04 Nicotine smoking / / 19268276 rs9896736 chr17 10205996 T C 4.11E-05 IgE levels MYH13 intron 22075330 rs2074877 chr17 10223714 T C 7.20E-04 Alzheimer's disease (late onset) MYH13 missense 21460841 rs1859999 chr17 10228815 A G 1.05E-04 Response to statin treatment (atorvastatin),change in cholesterol levels MYH13 intron 20031582 rs2277644 chr17 10231417 C T 1.18E-05 Formal thought disorder in schizophrenia MYH13 cds-synon 22648509 rs2277645 chr17 10231498 A C,T 6.59E-04 Suicide attempts in bipolar disorder MYH13 intron 21423239 rs17208457 chr17 10234591 C T 5.70E-05 Formal thought disorder in schizophrenia MYH13 intron 22648509 rs3760423 chr17 10243717 G A 6.91E-04 Suicide attempts in bipolar disorder MYH13 cds-synon 21423239 rs9303255 chr17 10244863 G A 7.87E-04 Suicide attempts in bipolar disorder MYH13 intron 21423239 rs4791979 chr17 10245864 G A 6.47E-04 Suicide attempts in bipolar disorder MYH13 intron 21423239 rs2024075 chr17 10264552 A G 7.43E-04 Myopia (pathological) MYH13 intron 21095009 rs9303257 chr17 10266369 G A 9.02E-04 Suicide attempts in bipolar disorder MYH13 intron 21423239 rs12951092 chr17 10266970 T C 9.42E-05 Arthritis (juvenile idiopathic) MYH13 intron 22354554 rs12950258 chr17 10267204 C T 5.93E-05 Arthritis (juvenile idiopathic) MYH13 intron 22354554 rs11658869 chr17 10267231 A G 6.88E-04 Suicide attempts in bipolar disorder MYH13 intron 21423239 rs4791981 chr17 10267610 C T 8.15E-04 Suicide attempts in bipolar disorder MYH13 intron 21423239 rs11658620 chr17 10272636 A G 7.80E-05 Arthritis (juvenile idiopathic) MYH13 intron 22354554 rs11653603 chr17 10272891 G A 2.12E-05 Arthritis (juvenile idiopathic) MYH13 intron 22354554 rs7207507 chr17 10283950 C T 8.51E-05 Serum metabolites / / 19043545 rs12451599 chr17 10285967 G A 3.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs2024076 chr17 10309962 C T 6.28E-04 Suicide attempts in bipolar disorder MYH8 intron 21423239 rs2058101 chr17 10354974 T C 9.93E-04 Suicide attempts in bipolar disorder MYH4 intron 21423239 rs2108606 chr17 10362269 C T 3.37E-05 IgE levels in asthmatics (D.p. specific) MYH4 intron 23967269 rs2108606 chr17 10362269 C T 6.18E-05 IgE levels in asthmatics (D.f. specific) MYH4 intron 23967269 rs187438258 chr17 10429123 G A 0.00011 Prostate cancer (advanced) MYH2 missense 23555315 rs12952334 chr17 10431275 A G 1.40E-05 IgE levels in asthmatics (D.p. specific) MYH2 intron 23967269 rs12952334 chr17 10431275 A G 3.29E-05 IgE levels in asthmatics (D.f. specific) MYH2 intron 23967269 rs201597 chr17 10528368 A G 6.55E-04 Acne (severe) / / 24927181 rs16943577 chr17 10538446 G C 3.14E-10 Cholesterol,total MYH3 intron 23063622 rs2097657 chr17 10552488 G A 3.31E-04 Multiple complex diseases MYH3 intron 17554300 rs62060696 chr17 10553769 C T 4.20E-05 Acne (severe) MYH3 intron 24927181 rs2239930 chr17 10558733 G A 2.61E-04 Multiple complex diseases MYH3 intron 17554300 rs169313 chr17 10567483 A C 8.00E-06 Relative hand skill in reading disability / / 24068947 rs6503319 chr17 10574159 C T 7.00E-07 Malaria / / 19465909 rs9904211 chr17 10578792 T C 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2662959 chr17 10583589 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SCO1 nearGene-3 22628534 rs2520188 chr17 10588435 T C 2.53E-04 Multiple complex diseases SCO1 intron 17554300 rs2175039 chr17 10598011 C T 4.94E-04 Multiple complex diseases SCO1 intron 17554300 rs2520166 chr17 10601990 T C 7.45E-04 Multiple complex diseases C17orf48 intron 17554300 rs2520166 chr17 10601990 T C 4.86E-10 Triglycerides C17orf48 intron 23063622 rs9898817 chr17 10610213 A G 8.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C17orf48 intron 20877124 rs9898817 chr17 10610213 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes C17orf48 intron 22628534 rs406446 chr17 10614442 A G 4.98E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) C17orf48 missense 24023788 rs440655 chr17 10617803 G T 3.35E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) TMEM220 UTR-3 24023788 rs421541 chr17 10632499 G A 7.80E-04 Type 2 diabetes TMEM220 intron 17463246 rs421541 chr17 10632499 G A 3.38E-04 Lymphocyte counts TMEM220 intron 22286170 rs4791422 chr17 10664579 C T 2.47E-04 Multiple complex diseases / / 17554300 rs7217562 chr17 10678813 C T 2.58E-04 White matter integrity / / 22425255 rs8080671 chr17 10681423 A G 7.90E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs930525 chr17 10695255 T C 8.04E-04 White matter integrity / / 22425255 rs1550656 chr17 10707285 C T 9.90E-04 Myocardial Infarction / / pha002873 rs17817050 chr17 10709753 A G 1.10E-05 Colorectal cancer / / 24836286 rs4792037 chr17 10711059 C G 5.35E-04 Smoking quantity / / 24665060 rs4792038 chr17 10711174 C A 4.13E-04 Smoking quantity / / 24665060 rs9903961 chr17 10732872 A G 2.75E-05 Educational attainment PIRT intron 21694764 rs8073328 chr17 10737764 T G 2.00E-05 Smoking initiation PIRT intron 24665060 rs8073358 chr17 10737856 T G 1.38E-05 Smoking initiation PIRT intron 24665060 rs12600692 chr17 10759270 C T 6.43E-04 Multiple complex diseases / / 17554300 rs11654958 chr17 10762993 C T 1.20E-04 Response to TNF antagonist treatment / / 21061259 rs16943802 chr17 10768198 A C 7.29E-04 Multiple complex diseases / / 17554300 rs11867377 chr17 10771810 G A 4.96E-04 Lung function (forced vital capacity) / / 24023788 rs753566 chr17 10775814 C G 3.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2304965 chr17 10783871 C T 5.81E-04 Longevity / / 22279548 rs2304966 chr17 10784088 G A 6.36E-04 Type 2 diabetes / / 17463246 rs11653389 chr17 10791443 C A 4.02E-04 Response to TNF antagonist treatment / / 21061259 rs8081802 chr17 10817993 T C 6.48E-04 Multiple complex diseases / / 17554300 rs2692352 chr17 10864011 T C 4.43E-06 Serum metabolites / / 19043545 rs9303266 chr17 10892650 G T 7.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs11655160 chr17 10893070 G A 3.16E-04 Serum selenium levels / / 23698163 rs11650930 chr17 10893094 A G 3.38E-04 Serum selenium levels / / 23698163 rs1544501 chr17 10906609 T C 2.11E-05 Suicide attempts in bipolar disorder / / 21423239 rs8076865 chr17 10918749 C T 6.87E-05 Suicide attempts in bipolar disorder / / 21423239 rs11652800 chr17 10921807 G C 5.76E-05 Suicide attempts in bipolar disorder / / 21423239 rs4792087 chr17 10923029 A T 3.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs7218005 chr17 10923372 C T 4.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs7218705 chr17 10923827 C G 4.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs7208694 chr17 10924291 T A,G 3.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs7222379 chr17 10924376 G A 7.66E-04 Coronary Artery Disease / / 17634449 rs7222379 chr17 10924376 G A 3.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs7209571 chr17 10924833 T A 4.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs11656814 chr17 10924848 G A 3.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs11653555 chr17 10924905 T C 2.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs6503345 chr17 10924995 G A 1.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs4791448 chr17 10925534 G A 1.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs6503347 chr17 10929027 T C 0.000891 Salmonella-induced pyroptosis / / 22837397 rs1468482 chr17 10943386 C T 1.99E-04 Type 2 diabetes / / 17463246 rs16944173 chr17 10958907 G A 0.000872 Salmonella-induced pyroptosis / / 22837397 rs2079572 chr17 10964501 G A 7.05E-04 Aortic root size / / 21223598 rs9906456 chr17 11051636 A C 0.000867351 Hypertension (early onset hypertension) / / 22479346 rs12453205 chr17 11055149 C T 0.000082 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12453224 chr17 11055263 C A 0.0000852 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11871233 chr17 11055657 G T 0.0000772 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7223370 chr17 11057357 T C 0.0000816 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs114608829 chr17 11057955 C T 0.000082 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs74481227 chr17 11058797 T G 0.0000833 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs149812470 chr17 11059040 A G 0.0000766 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs79016815 chr17 11059271 T A 0.0000721 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs139947696 chr17 11061116 A T 0.0000704 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12450301 chr17 11061447 G A 0.0000729 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs112772069 chr17 11062464 A G 0.0000605 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs80243831 chr17 11062894 C A 0.000069 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10438729 chr17 11063221 G A 0.000094 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10438746 chr17 11063279 T C 0.0000736 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs140995996 chr17 11069011 A G 0.0000781 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs8068143 chr17 11071547 A G 0.0000731 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12451358 chr17 11071747 A G 0.0000812 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12453058 chr17 11073129 T A 0.0000805 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12453145 chr17 11073445 T G 0.0000795 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs8068486 chr17 11073971 T A 0.0000765 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6503357 chr17 11074570 A G 0.0000712 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs147170133 chr17 11076150 A G 0.0000522 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs61166387 chr17 11076168 A G 0.0000494 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs60004698 chr17 11076223 C T 0.0000752 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs8079505 chr17 11076402 T C 0.0000612 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs8080866 chr17 11077803 C T 0.0000728 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs8079732 chr17 11077813 G T 0.0000717 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs8066473 chr17 11078077 C G 0.0000836 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs8076220 chr17 11100665 T C 2.00E-06 Obesity-related traits / / 23251661 rs11078885 chr17 11105794 A G 4.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2024134 chr17 11114132 T G 6.31E-05 Bone mass and geometry / / 17903296 rs1468524 chr17 11126125 C T 7.13E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4792113 chr17 11154439 T C 1.30E-05 Urinary metabolites SHISA6 intron 21572414 rs11078890 chr17 11154608 A G 1.40E-05 Urinary metabolites SHISA6 intron 21572414 rs112380460 chr17 11166786 G A 0.00013 Breast cancer SHISA6 missense 23555315 rs12941011 chr17 11169452 G A 1.90E-05 Urinary metabolites SHISA6 intron 21572414 rs985686 chr17 11171790 G C 5.10E-06 Urinary metabolites SHISA6 intron 21572414 rs1003883 chr17 11171813 T C 2.20E-05 Urinary metabolites SHISA6 intron 21572414 rs12603687 chr17 11173089 T G 1.70E-05 Urinary metabolites SHISA6 intron 21572414 rs9892139 chr17 11183519 C A 3.30E-04 Type 2 diabetes SHISA6 intron 17463246 rs12943640 chr17 11224534 G A 9.37E-05 Major depressive disorder SHISA6 intron 22472876 rs719251 chr17 11228108 G A 1.73E-05 Prion diseases SHISA6 intron 22210626 rs7219748 chr17 11234619 A C 2.15E-05 Prion diseases SHISA6 intron 22210626 rs12602611 chr17 11240422 G A 5.71E-04 Aortic root size SHISA6 intron 21223598 rs8076431 chr17 11250219 C A 2.00E-06 IgG glycosylation SHISA6 intron 23382691 rs12325711 chr17 11259037 G C 7.70E-04 Smoking initiation SHISA6 intron 24665060 rs1034899 chr17 11306660 T C 9.94E-05 Serum metabolites SHISA6 intron 19043545 rs205023 chr17 11316401 A G 3.23E-04 Iron levels SHISA6 intron pha002876 rs205020 chr17 11319696 T G 9.10E-04 Suicide attempts in bipolar disorder SHISA6 intron 21423239 rs205043 chr17 11323957 A G 1.45E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SHISA6 intron 24023788 rs11650466 chr17 11326270 C T 2.50E-05 Urinary metabolites SHISA6 intron 21572414 rs205047 chr17 11328428 C T 5.55E-04 Suicide attempts in bipolar disorder SHISA6 intron 21423239 rs1877644 chr17 11342608 G A 2.00E-06 Obesity-related traits SHISA6 intron 23251661 rs2969184 chr17 11344615 T G 6.17E-04 White matter integrity SHISA6 intron 22425255 rs1513740 chr17 11366688 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) SHISA6 intron 20708005 rs1513741 chr17 11366905 T C 5.96E-04 Amyotrophic lateral sclerosis (sporadic) SHISA6 intron 24529757 rs2969222 chr17 11380107 T C 8.76E-05 Non-alcoholic fatty liver disease histology (other) SHISA6 intron 20708005 rs4792143 chr17 11385890 C T 5.00E-06 Stroke (ischemic) SHISA6 intron 24262325 rs2068746 chr17 11389480 T C 2.78E-06 Height SHISA6 intron pha003010 rs2068746 chr17 11389480 T C 1.44E-05 Height SHISA6 intron pha003011 rs2908972 chr17 11407259 T A 4.50E-13 Myopia (Age of onset) SHISA6 intron 23468642 rs2969180 chr17 11407901 G A 7.00E-11 Refractive error SHISA6 intron 23396134 rs16944965 chr17 11436487 T C 4.63E-04 Alzheimer's disease (late onset) SHISA6 intron 21379329 rs1861573 chr17 11445022 T C 1.43E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SHISA6 intron 24023788 rs2874641 chr17 11460264 A G 5.80E-04 Response to taxane treatment (placlitaxel) SHISA6 intron 23006423 rs11652896 chr17 11477247 T C 6.58E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs8072888 chr17 11490257 T C 5.39E-04 Type 2 diabetes / / 17463246 rs929466 chr17 11510689 C T 1.04E-04 Alzheimer's disease (late onset) D/H9 intron 21379329 rs16945089 chr17 11527013 C G 3.66E-05 Body mass (lean) D/H9 intron 19268274 rs16945089 chr17 11527013 C G 1.94E-04 Suicide attempts in bipolar disorder D/H9 intron 21041247 rs16945089 chr17 11527013 C G 7.39E-04 Suicide attempts in bipolar disorder D/H9 intron 21041247 rs11655911 chr17 11536049 G A 4.90E-06 Urinary metabolites D/H9 intron 21572414 rs11870030 chr17 11553873 A G 4.43E-04 Response to cytadine analogues (cytosine arabinoside) D/H9 intron 24483146 rs736626 chr17 11573583 A G 9.22E-05 Response to cytadine analogues (cytosine arabinoside) D/H9 intron 24483146 rs12946617 chr17 11576903 G A 7.10E-05 Potassium levels D/H9 intron pha003086 rs7223160 chr17 11581255 T C 4.91E-04 Response to cytadine analogues (cytosine arabinoside) D/H9 intron 24483146 rs2191078 chr17 11586923 G A 3.00E-05 Response to lithium treatment in bipolar disorder D/H9 intron 19448189 rs2191078 chr17 11586923 G A 9.22E-05 Response to cytadine analogues (cytosine arabinoside) D/H9 intron 24483146 rs7207282 chr17 11588869 G A 9.06E-04 Response to cytadine analogues (cytosine arabinoside) D/H9 intron 24483146 rs7220893 chr17 11593821 C A 9.06E-04 Response to cytadine analogues (cytosine arabinoside) D/H9 intron 24483146 rs9904264 chr17 11646283 A G 3.82E-05 Melanoma D/H9 intron 21926416 rs3744578 chr17 11648332 C T 7.77E-05 Melanoma D/H9 cds-synon 21926416 rs4792166 chr17 11649778 A T 3.86E-05 Type 2 diabetes D/H9 intron 17463246 rs12449476 chr17 11653008 T C 5.49E-05 Melanoma D/H9 intron 21926416 rs12449476 chr17 11653008 T C 4.34E-05 White matter integrity D/H9 intron 22425255 rs9909956 chr17 11671437 C T 9.48E-05 Multiple complex diseases D/H9 intron 17554300 rs7215021 chr17 11687521 G T 2.46E-04 Multiple complex diseases D/H9 intron 17554300 rs4792176 chr17 11692316 G T 4.61E-04 Myopia (pathological) D/H9 intron 21095009 rs7218761 chr17 11693587 C A 1.00E-07 Immune response to measles-mumps-rubella vaccine D/H9 intron 24811271 rs2010253 chr17 11694706 C T 1.98E-04 Myopia (pathological) D/H9 intron 21095009 rs2322052 chr17 11704128 A G 5.33E-04 Myopia (pathological) D/H9 intron 21095009 rs9894590 chr17 11706186 T C 2.75E-04 Myopia (pathological) D/H9 intron 21095009 rs12949783 chr17 11707051 A G 7.19E-04 Myopia (pathological) D/H9 intron 21095009 rs4792181 chr17 11712491 T G 2.20E-04 Myopia (pathological) D/H9 intron 21095009 rs4329950 chr17 11734346 A G 1.36E-04 Height D/H9 intron 17255346 rs9905250 chr17 11734395 C T 1.08E-04 Height D/H9 intron 17255346 rs4792189 chr17 11773760 C T 7.68E-05 Bipolar disorder D/H9 intron 19488044 rs9902986 chr17 11774305 C T 7.99E-05 Serum metabolites D/H9 intron 19043545 rs4791481 chr17 11796642 G A 8.72E-04 Alzheimer's disease D/H9 intron 17998437 rs4792192 chr17 11803461 C T 3.00E-06 Myopia (pathological) D/H9 intron 23049088 rs10852800 chr17 11884516 C T 2.00E-05 Tanning ZNF18 intron 19340012 rs6502173 chr17 11899613 C T 1.56E-04 Amyotrophic lateral sclerosis (sporadic) ZNF18 intron 24529757 rs7223378 chr17 11907061 C G 2.60E-05 Urinary metabolites / / 21572414 rs7216812 chr17 11941483 C T 1.00E-04 Information processing speed MAP2K4 intron 21130836 rs8069300 chr17 11984232 G C 8.90E-06 Urinary metabolites MAP2K4 intron 21572414 rs9788973 chr17 11985574 T C 2.58E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer MAP2K4 intron 21483023 rs10432016 chr17 11990679 A G 8.90E-06 Urinary metabolites MAP2K4 intron 21572414 rs1870584 chr17 12047544 A G 5.00E-06 Response to amphetamines / / 22952603 rs4791490 chr17 12048344 C A 2.50E-05 Urinary metabolites / / 21572414 rs9903561 chr17 12049035 A T 6.40E-04 Coronary heart disease / / 21966275 rs9892185 chr17 12077779 A G 5.34E-04 Smoking initiation / / 24665060 rs11078060 chr17 12119479 A C 5.04E-04 Multiple complex diseases / / 17554300 rs10468473 chr17 12127676 T C 2.09E-05 Coronary heart disease / / pha003031 rs9899504 chr17 12159990 A G 1.50E-04 Insulin resistance / / 21901158 rs8068445 chr17 12160645 G A 1.10E-05 Neuroblastoma / / pha002895 rs714422 chr17 12163132 G A 2.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs12150546 chr17 12167635 A G 3.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs16945798 chr17 12169804 A G 3.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs12103753 chr17 12171195 G T 2.20E-05 Urinary metabolites / / 21572414 rs12103753 chr17 12171195 G T 7.61E-04 Insulin resistance / / 21901158 rs2322376 chr17 12178317 G A 2.41E-04 White matter integrity / / 22425255 rs17627328 chr17 12188305 G A 4.18E-04 Nicotine dependence / / 17158188 rs12453693 chr17 12191339 C T 3.40E-04 Fibrinogen / / 17255346 rs2529690 chr17 12239004 G A 1.90E-05 Urinary metabolites / / 21572414 rs8066012 chr17 12318243 T C 6.30E-05 Major depressive disorder / / 22472876 rs16945992 chr17 12328305 G C 1.36E-04 Multiple complex diseases / / 17554300 rs1350703 chr17 12372220 G A 7.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16946068 chr17 12375660 G A 2.19E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs8069430 chr17 12382463 A G 9.02E-04 Common variable immunodeficiency / / 21497890 rs237293 chr17 12401752 A G 2.16E-04 Stroke / / pha002886 rs237366 chr17 12408522 C T 0.0002556 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs237366 chr17 12408522 C T 2.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs237348 chr17 12426753 T C 2.40E-05 Urinary metabolites / / 21572414 rs173160 chr17 12428335 G T 1.80E-05 Urinary metabolites / / 21572414 rs4791503 chr17 12473309 T C 7.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FLJ34690 intron 20877124 rs9897731 chr17 12490108 A G 2.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FLJ34690 intron 20877124 rs1233861 chr17 12514811 T C 4.79E-04 Multiple complex diseases FLJ34690 intron 17554300 rs6502198 chr17 12537978 T C 9.47E-04 Stroke FLJ34690 intron pha002887 rs12150632 chr17 12580010 A C 4.06E-04 Multiple complex diseases MYOCD intron 17554300 rs2030303 chr17 12585990 A G 1.68E-04 Multiple complex diseases MYOCD intron 17554300 rs12185281 chr17 12610402 G A 8.28E-05 Alzheimer's disease MYOCD intron 22832961 rs7210857 chr17 12615971 G T 8.36E-04 Response to taxane treatment (placlitaxel) MYOCD intron 23006423 rs1233856 chr17 12618066 A G 2.47E-04 Type 2 diabetes MYOCD intron 17463246 rs16946506 chr17 12621121 A G 6.41E-04 Alzheimer's disease MYOCD intron 17998437 rs12452107 chr17 12627170 G T 6.46E-04 Alzheimer's disease MYOCD intron 17998437 rs2322592 chr17 12634150 T C 8.92E-04 Type 2 diabetes MYOCD intron 17463246 rs758185 chr17 12635215 C G 4.70E-04 Atrial fibrillation MYOCD intron 21846873 rs12944722 chr17 12636154 G C 6.73E-05 Testosterone levels MYOCD intron 22675492 rs200893721 chr17 12636735 T TAC 5.78E-05 Testosterone levels MYOCD intron 22675492 rs7225709 chr17 12636735 T C 5.78E-05 Testosterone levels MYOCD intron 22675492 rs9905820 chr17 12637371 T G 4.00E-06 Testosterone levels MYOCD intron 22675492 rs12603345 chr17 12637602 T C 6.11E-05 Testosterone levels MYOCD intron 22675492 rs9913758 chr17 12666721 C G 6.11E-08 LDL cholesterol MYOCD cds-synon 23063622 rs9913758 chr17 12666721 C G 8.47E-12 HDL cholesterol MYOCD cds-synon 23063622 rs16946601 chr17 12695750 G A 6.56E-05 Multiple complex diseases ARHGAP44 intron 17554300 rs4569331 chr17 12702961 T A 1.35E-04 Multiple complex diseases ARHGAP44 intron 17554300 rs7212932 chr17 12713750 C G 2.60E-04 Height ARHGAP44 intron 21998595 rs7223656 chr17 12715517 C T 9.17E-05 Alzheimer's disease ARHGAP44 intron 17998437 rs3785731 chr17 12732925 A G 4.70E-04 Rheumatoid arthritis ARHGAP44 intron 21452313 rs12600697 chr17 12736766 C T 4.24E-05 Celiac disease ARHGAP44 intron 23936387 rs9900388 chr17 12742770 C A 7.35E-04 Alzheimer's disease ARHGAP44 intron 17998437 rs4792287 chr17 12744186 C T 5.24E-04 Alzheimer's disease ARHGAP44 intron 17998437 rs16946685 chr17 12745298 G A 4.47E-04 Coronary heart disease ARHGAP44 intron 21606135 rs12946355 chr17 12764883 T C 3.41E-04 Response to cytidine analogues (gemcitabine) ARHGAP44 intron 24483146 rs7218950 chr17 12772584 G A 1.77E-04 Alzheimer's disease ARHGAP44 intron 24755620 rs7223372 chr17 12772901 G A 1.56E-05 Smoking cessation ARHGAP44 intron 18519826 rs11651483 chr17 12777402 A G 3.00E-07 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ARHGAP44 intron 23648065 rs6502208 chr17 12781955 G C 7.30E-04 Depression (quantitative trait) ARHGAP44 intron 20800221 rs7209847 chr17 12804550 A G 5.32E-05 Smoking cessation ARHGAP44 intron 18519826 rs7209847 chr17 12804550 A G 9.00E-06 Economic and political preferences ARHGAP44 intron 22566634 rs6502214 chr17 12809239 G A 1.91E-04 Smoking cessation ARHGAP44 intron 18519826 rs11078096 chr17 12857896 C T 4.12E-04 Multiple complex diseases ARHGAP44 intron 17554300 rs11078097 chr17 12858230 G T 2.90E-06 Parkinson's disease (age of onset) ARHGAP44 intron 19772629 rs9904572 chr17 12862359 G A 7.20E-07 Parkinson's disease (age of onset) ARHGAP44 intron 19772629 rs10521204 chr17 12868660 C A 3.00E-04 Type 2 diabetes ARHGAP44 intron 17846126 rs10521205 chr17 12869142 T C 3.00E-04 Type 2 diabetes ARHGAP44 intron 17846126 rs2240570 chr17 12882789 A G 4.68E-05 stroke (ischemic) ARHGAP44 intron 17434096 rs2240570 chr17 12882789 A G 5.91E-05 Cognitive performance ARHGAP44 intron 19734545 rs2240569 chr17 12882816 T C 4.68E-05 stroke (ischemic) ARHGAP44 intron 17434096 rs8069856 chr17 12887379 T C 0.00011 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines ARHGAP44 intron 23204130 rs2523 chr17 12895815 C T 2.05E-04 Suicide attempts in bipolar disorder ELAC2 UTR-3 21423239 rs1044569 chr17 12895929 G A 2.05E-04 Suicide attempts in bipolar disorder ELAC2 UTR-3 21423239 rs1044564 chr17 12895984 G C 1.78E-04 Suicide attempts in bipolar disorder ELAC2 UTR-3 21423239 rs7218504 chr17 12927654 G C 0.000038 Salmonella-induced pyroptosis / / 22837397 rs9906017 chr17 12931749 C T 6.50E-05 Iron levels / / 21208937 rs1859972 chr17 12982299 A C 9.82E-04 Multiple complex diseases / / 17554300 rs9894068 chr17 13007258 A G 4.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2322787 chr17 13021484 A G 1.18E-04 Multiple complex diseases / / 17554300 rs16947205 chr17 13027868 T G 5.98E-05 Bipolar disorder and schizophrenia / / 20889312 rs16947205 chr17 13027868 T G 1.00E-05 White blood cell count / / 21738479 rs16947215 chr17 13028293 A C 2.32E-05 Bipolar disorder and schizophrenia / / 20889312 rs9900808 chr17 13062795 G A 7.95E-04 Multiple complex diseases / / 17554300 rs9900808 chr17 13062795 G A 2.00E-06 Cannabis use (initiation) / / 22823124 rs17562313 chr17 13083406 T G 5.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs17562474 chr17 13087647 T C 5.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs17642767 chr17 13089744 T A 6.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs12940069 chr17 13091212 T C 6.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs17562828 chr17 13093053 G A 9.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs12325725 chr17 13095576 G A 9.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs2521892 chr17 13097490 T C 8.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs1120385 chr17 13099968 T C 7.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs16947339 chr17 13103518 C G 8.06E-04 Multiple complex diseases / / 17554300 rs2674952 chr17 13109450 C T 4.01E-05 stroke (ischemic) / / 17434096 rs2674959 chr17 13115254 G T 8.16E-04 Alcohol dependence / / 20201924 rs10521211 chr17 13129143 C T 2.00E-05 LDL lipoproteins / / pha002902 rs8064833 chr17 13130956 T C 7.40E-05 Orofacial clefts / / 22419666 rs17564279 chr17 13138644 A G 7.78E-05 Insulin-related traits / / pha003063 rs17564356 chr17 13140225 A G 0.000802805 Hypertension (early onset hypertension) / / 22479346 rs2322858 chr17 13144762 T G 4.20E-07 Urinary metabolites / / 21572414 rs11651762 chr17 13156053 A G 6.62E-05 Glucose levels / / pha003058 rs16947459 chr17 13156979 A G 1.68E-05 IgE levels / / 17255346 rs4141326 chr17 13158144 T G 8.61E-05 Eosinophil counts / / pha003088 rs10521213 chr17 13169858 G A 7.23E-05 Arthritis (juvenile idiopathic) / / 22354554 rs2079019 chr17 13191247 C A 3.34E-05 Cognitive test performance / / 20125193 rs8076501 chr17 13195189 G A 2.20E-04 Alcohol dependence / / 20201924 rs8076501 chr17 13195189 G A 7.00E-04 Alcohol dependence / / 20201924 rs8080564 chr17 13201543 G A 8.37E-05 Cognitive test performance / / 20125193 rs8080564 chr17 13201543 G A 3.31E-04 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs10521215 chr17 13208676 G C 8.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11078146 chr17 13234015 C T 3.19E-04 Multiple complex diseases / / 17554300 rs6650595 chr17 13234130 C T 5.58E-04 Multiple complex diseases / / 17554300 rs2188889 chr17 13237647 G A 1.77E-04 Multiple complex diseases / / 17554300 rs2188889 chr17 13237647 G A 1.90E-05 Urinary metabolites / / 21572414 rs9900695 chr17 13244447 A G 2.58E-04 Multiple complex diseases / / 17554300 rs11653964 chr17 13251289 G T 5.71E-04 Multiple complex diseases / / 17554300 rs11653964 chr17 13251289 G T 7.85E-05 Personality dimensions / / 18957941 rs12452203 chr17 13287845 G A 8.74E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs16947819 chr17 13306534 A G 7.81E-05 Type 2 diabetes / / 17463246 rs9898623 chr17 13314401 C A 6.63E-04 Type 2 diabetes / / 17463246 rs9891849 chr17 13322330 C T 9.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs17744560 chr17 13324861 C A 2.20E-05 Coffee consumption / / 21357676 rs8068216 chr17 13364290 G A 2.70E-05 Urinary metabolites / / 21572414 rs758204 chr17 13376188 T G 5.60E-06 Urinary metabolites / / 21572414 rs11078160 chr17 13377293 G A 7.40E-06 Urinary metabolites / / 21572414 rs7209938 chr17 13393882 A G 7.55E-04 Insulin resistance / / 21901158 rs9892731 chr17 13410561 C T 9.78E-06 Odorant perception HS3ST3A1 intron 23910658 rs9903786 chr17 13429665 G A 3.11E-05 Serum metabolites HS3ST3A1 intron 19043545 rs10521226 chr17 13451829 T C 1.08E-05 Chronic Hepatitis C infection HS3ST3A1 intron 21725309 rs3785690 chr17 13495749 C T 1.60E-05 Urinary metabolites HS3ST3A1 intron 21572414 rs726800 chr17 13500604 A G 3.24E-05 Schizophrenia HS3ST3A1 intron 19571809 rs726800 chr17 13500604 A G 4.58E-05 Schizophrenia HS3ST3A1 intron pha002859 rs1013122 chr17 13524917 C T 4.85E-05 Parkinson's disease (motor and cognition) / / 22658654 rs2079627 chr17 13539228 T C 7.64E-05 Height / / pha003010 rs10521232 chr17 13539804 T C 4.00E-06 Tonometry / / 17903302 rs10521232 chr17 13539804 T C 6.91E-05 Lactate dehydrogenase levels / / 20981236 rs1013120 chr17 13545219 C A 2.20E-04 Suicidal ideation / / 22030708 rs1013120 chr17 13545219 C A 1.32E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs11654550 chr17 13559045 T C 4.68E-04 Sudden cardiac arrest / / 21658281 rs10521233 chr17 13559080 A G 2.40E-05 Urinary metabolites / / 21572414 rs10521233 chr17 13559080 A G 3.00E-06 Asthma (childhood onset) / / 22560479 rs10521233 chr17 13559080 A G 2.24E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs765475 chr17 13570448 T C 6.28E-05 Erythrocyte counts / / pha003090 rs11654855 chr17 13619946 T C 3.58E-05 Calcium levels / / pha003085 rs4054823 chr17 13625024 T C 2.10E-06 Prostate cancer(aggressive) / / 21467234 rs9903180 chr17 13628180 C T 1.63E-05 Word reading / / 23738518 rs4792390 chr17 13628787 C A 1.63E-05 Word reading / / 23738518 rs4792391 chr17 13628869 C T 1.12E-05 Word reading / / 23738518 rs4792392 chr17 13628946 A G 1.12E-05 Word reading / / 23738518 rs8072794 chr17 13629661 G C 1.12E-05 Word reading / / 23738518 rs8073786 chr17 13629760 T C 1.12E-05 Word reading / / 23738518 rs12938791 chr17 13630121 G A 1.12E-05 Word reading / / 23738518 rs6502296 chr17 13633640 G A 1.63E-05 Word reading / / 23738518 rs17665827 chr17 13633974 G A 3.87E-04 Major depressive disorder / / 22472876 rs7222583 chr17 13676016 C T 2.40E-06 Urinary metabolites / / 21572414 rs4792394 chr17 13684917 C A 9.00E-06 Conduct disorder (symptom count) LOC100506974 intron 20585324 rs9915220 chr17 13689978 A G 6.11E-04 Type 2 diabetes LOC100506974 intron 17846126 rs8080388 chr17 13706283 T G 3.00E-04 Schizophrenia / / 19197363 rs7215286 chr17 13708861 C G 3.00E-06 IgG glycosylation / / 23382691 rs11868579 chr17 13709499 G A 4.02E-04 Body mass index / / 21701565 rs6502302 chr17 13731768 G T 0.0003925 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6502302 chr17 13731768 G T 3.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12949531 chr17 13733806 C T 8.00E-06 Systemic lupus erythematosus / / 19165918 rs12150192 chr17 13734612 C T 1.00E-04 Schizophrenia / / 19197363 rs2215150 chr17 13735596 A G 3.84E-04 Multiple complex diseases / / 17554300 rs11649927 chr17 13767150 A G 5.80E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7213494 chr17 13787160 C A 0.0000932 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7213494 chr17 13787160 C A 9.32E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8076755 chr17 13788655 G A 0.0000984 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8076755 chr17 13788655 G A 9.84E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4792411 chr17 13797101 C A 6.97E-05 Lipoproteins / / pha003079 rs720712 chr17 13798629 A G 8.64E-04 Bipolar disorder / / 19259986 rs8075048 chr17 13800220 T C 0.0002754 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8075048 chr17 13800220 T C 2.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs933373 chr17 13801297 T C 6.97E-05 Lipoproteins / / pha003079 rs933374 chr17 13801481 C T 3.49E-05 Glucose levels / / pha003058 rs4792419 chr17 13841519 G A 8.30E-04 Multiple complex diseases / / 17554300 rs12950365 chr17 13844814 C T 5.50E-06 Urinary metabolites / / 21572414 rs12949849 chr17 13849931 T C 2.20E-08 Urinary metabolites / / 21572414 rs8069913 chr17 13871442 T G 6.70E-04 Lipid traits / / 17903299 rs9303098 chr17 13892279 T A 2.59E-04 Multiple complex diseases / / 17554300 rs6502323 chr17 13900090 T A 9.53E-04 Multiple complex diseases / / 17554300 rs17608059 chr17 13910549 C T 3.00E-07 Temperament / / 22832960 rs9914753 chr17 13941088 G A 8.64E-05 Bipolar disorder / / 17486107 rs2159132 chr17 14005439 G A 2.40E-05 Serum metabolites COX10 cds-synon 19043545 rs12150130 chr17 14117282 C T 6.00E-06 Conotruncal heart defects / / 24800985 rs7207687 chr17 14152804 G C 1.60E-05 Serum metabolites / / 19043545 rs11654370 chr17 14154851 G A 1.37E-05 Serum metabolites / / 19043545 rs960296 chr17 14164815 T G 7.18E-05 Parkinson's disease / / 17052657 rs960296 chr17 14164815 T G 3.65E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17680211 chr17 14171686 G A 7.51E-05 Amyotrophic lateral sclerosis / / 20801717 rs755730 chr17 14197451 A G 7.78E-05 Coronary heart disease / / pha003033 rs2190626 chr17 14203118 G A 4.12E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11870163 chr17 14213880 G A,T 2.88E-04 Response to cytidine analogues (gemcitabine) HS3ST3B1 intron 24483146 rs4791571 chr17 14215076 A G 5.70E-05 Parkinson's disease (age of onset) HS3ST3B1 intron 19772629 rs1005322 chr17 14221383 G A 2.89E-04 Type 2 diabetes HS3ST3B1 intron 17463246 rs1005321 chr17 14221501 G A 3.38E-04 Longevity HS3ST3B1 intron 22279548 rs7225272 chr17 14256285 A G 4.02E-04 Birth weight / / 17255346 rs9903604 chr17 14266997 A G 7.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2170371 chr17 14269687 G T 1.26E-04 Multiple complex diseases / / 17554300 rs3848445 chr17 14294021 C T 8.00E-09 Protein quantitative trait loci / / 18464913 rs2127994 chr17 14298594 C T 6.18E-05 Femoral neck bone geometry / / 22087292 rs8082455 chr17 14299892 G A 3.20E-05 Type 2 diabetes / / 22158537 rs4316797 chr17 14308398 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4054673 chr17 14308820 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9896612 chr17 14319001 G T 5.41E-04 Nonalcoholic fatty liver disease / / 21423719 rs2022240 chr17 14342334 G A 6.35E-04 Multiple complex diseases / / 17554300 rs10221222 chr17 14349703 T C 5.09E-05 Multiple complex diseases / / 17554300 rs1005395 chr17 14355233 G A 3.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs7215419 chr17 14358445 C G 8.64E-08 Metabolite levels / / 23281178 rs9912653 chr17 14358778 C G 3.20E-04 Schizophrenia / / 20832056 rs9912653 chr17 14358778 C G 3.81E-05 Formal thought disorder in schizophrenia / / 22648509 rs10521271 chr17 14363666 C T 1.09E-11 Pure-tone audiometry / / pha001966 rs4791580 chr17 14366938 G C 1.09E-11 Pure-tone audiometry / / pha001966 rs2080115 chr17 14404666 T C 5.20E-05 Bone mineral density (BMD),in women / / 20164292 rs598240 chr17 14409662 A C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2323284 chr17 14410166 C T 4.30E-05 Bone mineral density (BMD),in women / / 20164292 rs11651617 chr17 14411208 A G 4.30E-05 Bone mineral density (BMD),in women / / 20164292 rs2875006 chr17 14420822 A G 4.50E-05 Glaucoma (primary open-angle) / / 20835238 rs2022247 chr17 14429747 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9890008 chr17 14471693 A G 0.00000221 Composite episodic memory score / / 22865056 rs17697297 chr17 14471825 C T 3.00E-05 Memory performance / / 22105620 rs7210988 chr17 14473571 A G 9.61E-04 Multiple complex diseases / / 17554300 rs12601539 chr17 14473595 T A 2.80E-05 Memory performance / / 22105620 rs9789000 chr17 14481009 G A 2.73E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2079794 chr17 14508792 A G 3.04E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9891025 chr17 14510614 A G 7.54E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4541114 chr17 14512399 A G 2.45E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2109174 chr17 14513310 T C 5.12E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12600394 chr17 14517467 C T 1.58E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs16949981 chr17 14519818 T G 4.30E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12937378 chr17 14522841 T C 0.000121979 Hypertension (early onset hypertension) / / 22479346 rs10521277 chr17 14522951 G A 9.50E-05 Hypertension (early onset hypertension) / / 22479346 rs1465265 chr17 14527186 A G 6.16E-05 Hypertension (early onset hypertension) / / 22479346 rs2191194 chr17 14534400 G A 2.75E-05 Hypertension (early onset hypertension) / / 22479346 rs7503362 chr17 14535081 C T 3.01E-05 Hypertension (early onset hypertension) / / 22479346 rs2191195 chr17 14539202 G T 1.09E-05 Hypertension (early onset hypertension) / / 22479346 rs11652573 chr17 14542140 G A 2.73E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs16950131 chr17 14549642 C T 4.68E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs2323457 chr17 14554190 C A 4.63E-06 Central corneal thickness / / 20719862 rs2323457 chr17 14554190 C A 4.68E-08 Corneal structure / / 23291589 rs2323457 chr17 14554190 C A 5.04E-04 Smoking cessation / / 24665060 rs2323458 chr17 14554236 G A 5.29E-04 Smoking cessation / / 24665060 rs12936630 chr17 14559373 C T 4.65E-06 Central corneal thickness / / 20719862 rs12602267 chr17 14559930 A G 4.66E-06 Central corneal thickness / / 20719862 rs12602281 chr17 14559960 C T 4.67E-06 Central corneal thickness / / 20719862 rs12946988 chr17 14560522 C T 4.68E-06 Central corneal thickness / / 20719862 rs12949542 chr17 14560666 T G 4.69E-06 Central corneal thickness / / 20719862 rs12947853 chr17 14560679 G C 4.69E-06 Central corneal thickness / / 20719862 rs12950397 chr17 14560898 T A 4.06E-06 Central corneal thickness / / 20719862 rs148128182 chr17 14560898 T TTCAGGATCTGTTAGGGATGGAATCAGGTCAGAGCCACA 4.06E-06 Central corneal thickness / / 20719862 rs367757489 chr17 14560898 T TTTAGGATCTGTTAGGGATGGAATCAGGTCAGAGCCACA 4.06E-06 Central corneal thickness / / 20719862 rs59455216 chr17 14560898 T TTCAGGATCTGTTAGGGATGGAATCAGGTCAGAGCCACA 4.06E-06 Central corneal thickness / / 20719862 rs12940030 chr17 14561016 T C 4.71E-06 Central corneal thickness / / 20719862 rs12940030 chr17 14561016 T C 7.00E-10 Corneal structure / / 23291589 rs12940030 chr17 14561016 T C 4.96E-04 Smoking cessation / / 24665060 rs12940335 chr17 14561146 T C 1.49E-06 Central corneal thickness / / 20719862 rs12938222 chr17 14561213 A G 4.73E-06 Central corneal thickness / / 20719862 rs8069803 chr17 14561743 T C 4.76E-06 Central corneal thickness / / 20719862 rs5020064 chr17 14561779 G A 4.76E-06 Central corneal thickness / / 20719862 rs5020066 chr17 14561848 A C 4.77E-06 Central corneal thickness / / 20719862 rs5020067 chr17 14561921 G A 4.77E-06 Central corneal thickness / / 20719862 rs5020068 chr17 14561934 T A 4.78E-06 Central corneal thickness / / 20719862 rs5020069 chr17 14562111 C T 4.79E-06 Central corneal thickness / / 20719862 rs9914478 chr17 14562148 T C 4.80E-06 Central corneal thickness / / 20719862 rs9914512 chr17 14562190 T C 4.82E-06 Central corneal thickness / / 20719862 rs1558271 chr17 14562624 T C 4.84E-06 Central corneal thickness / / 20719862 rs1558272 chr17 14562643 G T 4.87E-06 Central corneal thickness / / 20719862 rs9914639 chr17 14562766 G A 0.000696557 Hypertension (early onset hypertension) / / 22479346 rs9914639 chr17 14562766 G A 5.84E-04 Smoking cessation / / 24665060 rs12950593 chr17 14562911 C G 4.91E-06 Central corneal thickness / / 20719862 rs12951138 chr17 14562936 G C 4.92E-06 Central corneal thickness / / 20719862 rs12951163 chr17 14562973 G A 4.93E-06 Central corneal thickness / / 20719862 rs12449673 chr17 14563434 A G 4.94E-06 Central corneal thickness / / 20719862 rs4605202 chr17 14564070 G C 4.99E-06 Central corneal thickness / / 20719862 rs9900619 chr17 14564117 A G 5.01E-06 Central corneal thickness / / 20719862 rs4792533 chr17 14564689 A T 5.75E-04 Smoking cessation / / 24665060 rs4792534 chr17 14564849 A G 5.05E-06 Central corneal thickness / / 20719862 rs4792534 chr17 14564849 A G 9.60E-08 Corneal structure / / 23291589 rs4792534 chr17 14564849 A G 5.39E-04 Smoking cessation / / 24665060 rs4792535 chr17 14565130 C T 5.06E-06 Central corneal thickness / / 20719862 rs4792535 chr17 14565130 C T 7.22E-08 Corneal structure / / 23291589 rs9898082 chr17 14566999 T C 5.26E-06 Central corneal thickness / / 20719862 rs8080998 chr17 14567551 A C 5.27E-06 Central corneal thickness / / 20719862 rs8080998 chr17 14567551 A C 4.72E-04 Smoking cessation / / 24665060 rs12950233 chr17 14569886 G A 8.92E-05 Serum metabolites / / 19043545 rs12950233 chr17 14569886 G A 5.15E-04 Smoking cessation / / 24665060 rs727031 chr17 14572401 G A 5.41E-04 Smoking cessation / / 24665060 rs1558274 chr17 14576452 T C 3.89E-04 Smoking cessation / / 24665060 rs7209320 chr17 14580120 T C 6.53E-06 Central corneal thickness / / 20719862 rs4792539 chr17 14580998 T C 3.14E-04 Multiple complex diseases / / 17554300 rs4792540 chr17 14581084 C T 7.71E-04 Multiple complex diseases / / 17554300 rs11078264 chr17 14583850 T C 8.02E-04 Multiple complex diseases / / 17554300 rs12451822 chr17 14584316 C T 0.0000878 Migraine / / 22678113 rs12451822 chr17 14584316 C T 8.78E-05 Migraine / / 22683712 rs11653737 chr17 14604769 T C 3.19E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9904813 chr17 14628506 C T 3.34E-04 Birth weight / / 17255346 rs9899891 chr17 14629746 G A 4.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs10521280 chr17 14645902 A G 3.10E-04 Parkinson's disease / / 17052657 rs7211689 chr17 14646168 A C 1.30E-04 IgE levels in asthmatics / / 23967269 rs12943503 chr17 14655730 A G 2.03E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6502391 chr17 14672691 G A 5.41E-04 Multiple complex diseases / / 17554300 rs7209265 chr17 14676871 G A 9.66E-05 Non-alcoholic fatty liver disease histology (other) FLJ45831 intron 20708005 rs7209265 chr17 14676871 G A 8.26E-04 Myopia (pathological) FLJ45831 intron 21095009 rs1558264 chr17 14678265 T C 5.05E-04 Taste perception FLJ45831 intron 22132133 rs7207483 chr17 14680642 G A 3.85E-04 Myopia (pathological) FLJ45831 intron 21095009 rs8067850 chr17 14716551 C T 6.84E-04 Alzheimer's disease / / 22005930 rs7207732 chr17 14742348 C G 2.64E-04 Alzheimer's disease / / 22005930 rs7219207 chr17 14743915 T C 2.69E-04 Alzheimer's disease / / 22005930 rs10521283 chr17 14744641 C T 7.21E-04 Alzheimer's disease / / 22005930 rs2191180 chr17 14748935 A C 3.16E-04 Smoking cessation / / 24665060 rs2191179 chr17 14749174 G C 4.98E-04 Multiple complex diseases / / 17554300 rs7211522 chr17 14755471 C T 1.54E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs9916612 chr17 14763564 C T 6.60E-04 Alcohol dependence / / 20201924 rs2215298 chr17 14825498 T A 7.62E-05 Type 2 diabetes / / 17463246 rs12939631 chr17 14862478 C T 2.53E-05 Odorant perception / / 23910658 rs16950732 chr17 14865655 A G 6.77E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2191123 chr17 14865806 G C 5.22E-05 Serum metabolites / / 19043545 rs4792564 chr17 14875713 C G 4.77E-04 Multiple complex diseases / / 17554300 rs4792564 chr17 14875713 C G 1.23E-05 Serum metabolites / / 19043545 rs8082421 chr17 14885887 G A 3.65E-05 Blood Pressure / / pha002898 rs8080728 chr17 14889643 G A 2.40E-04 Longevity / / 22279548 rs8066099 chr17 14889925 C T 2.00E-06 Obesity-related traits / / 23251661 rs8075436 chr17 14911566 A G 8.66E-04 Multiple complex diseases / / 17554300 rs4239131 chr17 14918324 T C 4.39E-04 Tourette syndrome / / 22889924 rs9890618 chr17 14936231 G A 2.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16950911 chr17 14952924 C T 8.26E-06 Height / / pha003011 rs12603925 chr17 14988987 A G 4.56E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs16950952 chr17 14989659 T C 8.67E-04 Alzheimer's disease / / 17998437 rs11078278 chr17 14994001 T C 5.50E-04 Alcohol dependence / / 20201924 rs16830 chr17 14997297 T C 8.73E-04 Alzheimer's disease / / 22005930 rs8068817 chr17 15008806 T C 1.83E-04 Type 2 diabetes / / 17463246 rs8071619 chr17 15009032 A T 1.83E-04 Type 2 diabetes / / 17463246 rs16951011 chr17 15010250 A G 1.09E-04 Type 2 diabetes / / 17463246 rs9906223 chr17 15010653 A G 1.79E-04 Type 2 diabetes / / 17463246 rs9908356 chr17 15010752 T C 1.75E-04 Type 2 diabetes / / 17463246 rs763614 chr17 15022096 C T 6.11E-04 Multiple complex diseases / / 17554300 rs11654880 chr17 15024028 T C 6.26E-04 Multiple complex diseases / / 17554300 rs2191116 chr17 15026800 T C 2.59E-04 Multiple complex diseases / / 17554300 rs917538 chr17 15034841 C A 0.0000461 Uterine leiomyomata / / 23040493 rs8080588 chr17 15037855 A T 6.07E-06 Multiple complex diseases / / 17554300 rs8081435 chr17 15065191 T C 8.53E-05 Cognitive test performance / / 20125193 rs4792581 chr17 15066696 T C 6.53E-04 Alcohol dependence / / 21314694 rs9906227 chr17 15075605 A G 5.29E-05 Orofacial clefts / / 22419666 rs9899379 chr17 15083481 A G 7.29E-05 Cognitive test performance / / 20125193 rs4356515 chr17 15088293 T C 1.29E-05 Sudden cardiac arrest / / 21658281 rs9916167 chr17 15094180 G A 8.79E-04 Rheumatoid arthritis / / 21452313 rs9916167 chr17 15094180 G A 6.78E-04 Body mass index / / 21701565 rs2215236 chr17 15098319 G A 4.70E-05 Cognitive function / / 24684796 rs16951193 chr17 15098982 T C 9.59E-04 Multiple complex diseases / / 17554300 rs12951674 chr17 15099857 G T 9.08E-04 Type 2 diabetes / / 17463246 rs9889622 chr17 15115707 T C 0.0000119 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs230922 chr17 15116760 A G 2.08E-05 Arthritis (juvenile idiopathic) / / 22354554 rs230915 chr17 15148256 T C 1.19E-04 Arthritis (juvenile idiopathic) PMP22 intron 22354554 rs16951263 chr17 15161172 G C 2.83E-04 Multiple complex diseases PMP22 intron 17554300 rs10852830 chr17 15181526 C T 7.26E-04 Multiple complex diseases / / 17554300 rs7502492 chr17 15185485 A G 5.74E-06 QT interval / / 23166209 rs2323653 chr17 15186049 A G 3.06E-06 QT interval / / 23166209 rs1079974 chr17 15186337 G T 2.96E-06 QT interval / / 23166209 rs1380181 chr17 15193056 A G 3.00E-07 QT interval / / 23166209 rs8073642 chr17 15194475 T A 7.15E-04 Alzheimer's disease / / 17998437 rs1380179 chr17 15196137 G A 6.12E-06 QT interval / / 23166209 rs170745 chr17 15206021 A G 8.92E-06 QT interval / / 23166209 rs16951377 chr17 15229971 A T 4.63E-04 Smoking quantity TEKT3 intron 24665060 rs8066838 chr17 15288433 A C 6.90E-05 Hypothyroidism / / 22493691 rs16951470 chr17 15322594 T C 3.93E-05 Alzheimer's disease / / 21098978 rs2906966 chr17 15331517 T G 8.00E-06 Pulmonary function / / 17903307 rs2906966 chr17 15331517 T G 9.31E-07 Podoconiosis / / 22455414 rs12947999 chr17 15335579 C T 6.47E-04 Coronary heart disease / / 21971053 rs2906985 chr17 15348077 T C 7.41E-04 Multiple complex diseases CDRT4 intron 17554300 rs729355 chr17 15349114 G A 9.70E-04 Coronary Artery Disease CDRT4 intron 17634449 rs728854 chr17 15358666 A G 4.92E-04 Multiple complex diseases CDRT4 intron 17554300 rs728854 chr17 15358666 A G 9.43E-04 Coronary Artery Disease CDRT4 intron 17634449 rs7212614 chr17 15373196 A G 4.15E-04 Amyotrophic Lateral Sclerosis FAM18B2-CDRT4 intron 17362836 rs7219850 chr17 15383670 A G 5.20E-06 Urinary metabolites FAM18B2-CDRT4 intron 21572414 rs9674557 chr17 15387225 A G 7.50E-06 Urinary metabolites FAM18B2-CDRT4 intron 21572414 rs7219580 chr17 15389982 T C 5.40E-06 Urinary metabolites FAM18B2-CDRT4 intron 21572414 rs8071399 chr17 15390952 G T 1.69E-05 Diabetes Mellitus FAM18B2-CDRT4 intron pha003059 rs2052022 chr17 15404987 G A 7.50E-04 Type 2 diabetes FAM18B2-CDRT4 intron 17463246 rs8071082 chr17 15419589 G T 7.53E-04 Parkinson's disease FAM18B2 intron 17052657 rs12948266 chr17 15421535 T C 6.00E-06 Major depression (suicidal thoughts and behavior) FAM18B2 intron 21750702 rs2938158 chr17 15447364 T C 7.38E-04 Rheumatoid arthritis FAM18B2 intron 21452313 rs2938171 chr17 15449627 A G 4.30E-04 Amyotrophic Lateral Sclerosis FAM18B2 intron 17827064 rs2938171 chr17 15449627 A G 9.54E-04 Rheumatoid arthritis FAM18B2 intron 21452313 rs2240593 chr17 15647723 C T 6.56E-04 Taste perception TBC1D26 UTR-3 22132133 rs2240593 chr17 15647723 C T 1.25E-05 Duodenal ulcer TBC1D26 UTR-3 22387998 rs859267 chr17 15826021 A C 3.00E-07 Immune reponse to smallpox (secreted IL-12p40) / / 22610502 rs1076423 chr17 15873150 T G 3.00E-04 Coronary heart disease ADORA2B intron 21971053 rs7213125 chr17 15908772 G A 8.84E-04 Type 2 diabetes TTC19 intron 17463246 rs7213125 chr17 15908772 G A 6.38E-04 Coronary heart disease TTC19 intron 21971053 rs8070719 chr17 15917718 C G 4.62E-04 Type 2 diabetes TTC19 intron 17463246 rs8074888 chr17 15917905 G A 4.33E-04 Coronary heart disease TTC19 intron 21971053 rs3744328 chr17 15930882 T C 7.79E-05 Type 2 diabetes TTC19 UTR-3 17463246 rs7224403 chr17 15940525 T C 4.38E-04 Type 2 diabetes NCOR1 intron 17463246 rs8067494 chr17 15950751 A G 4.73E-04 Type 2 diabetes NCOR1 intron 17463246 rs8079698 chr17 15954812 G A 7.79E-05 Type 2 diabetes NCOR1 intron 17463246 rs3760296 chr17 15959279 A G 2.50E-04 Type 2 diabetes NCOR1 intron 17463246 rs1073093 chr17 15963063 C T 7.79E-05 Type 2 diabetes NCOR1 intron 17463246 rs1073094 chr17 15963449 T C 4.62E-04 Type 2 diabetes NCOR1 intron 17463246 rs1073095 chr17 15963465 T G 7.79E-05 Type 2 diabetes NCOR1 intron 17463246 rs3760295 chr17 15978663 T C 4.38E-04 Type 2 diabetes NCOR1 intron 17463246 rs7218945 chr17 16036594 A G 0.000000615 LDL cholesterol NCOR1 intron 23063622 rs7218945 chr17 16036594 A G 1.71E-09 HDL cholesterol NCOR1 intron 23063622 rs16959544 chr17 16058348 A G 1.39E-04 Type 2 diabetes NCOR1 intron 17463246 rs16959547 chr17 16059208 C G 7.02E-05 Type 2 diabetes NCOR1 intron 17463246 rs7225813 chr17 16074287 G C 4.73E-04 Type 2 diabetes NCOR1 intron 17463246 rs7220699 chr17 16080210 T C 4.73E-04 Type 2 diabetes NCOR1 intron 17463246 rs7212874 chr17 16114457 G C 2.29E-04 Type 2 diabetes NCOR1 intron 17463246 rs7210990 chr17 16170764 C A 1.99E-04 Type 2 diabetes PIGL intron 22158537 rs2014604 chr17 16176883 T C 4.36E-05 Type 2 diabetes PIGL intron 22158537 rs7219687 chr17 16177387 C G 9.42E-04 Multiple complex diseases PIGL intron 17554300 rs7219687 chr17 16177387 C G 3.02E-05 Type 2 diabetes PIGL intron 22158537 rs12948244 chr17 16178100 T C 7.77E-04 Type 2 diabetes PIGL intron 22158537 rs2109262 chr17 16184629 T G 2.19E-04 Type 2 diabetes PIGL intron 22158537 rs3785626 chr17 16185248 T G 2.05E-04 Type 2 diabetes PIGL intron 22158537 rs11651578 chr17 16187592 G A 2.66E-04 Type 2 diabetes PIGL intron 22158537 rs3785625 chr17 16190418 G C 2.82E-04 Type 2 diabetes PIGL intron 22158537 rs4791665 chr17 16196056 A G 5.89E-05 Type 2 diabetes PIGL intron 22158537 rs11868284 chr17 16196275 T C 5.63E-04 Type 2 diabetes PIGL intron 22158537 rs4792731 chr17 16201941 T C 2.02E-04 Type 2 diabetes PIGL intron 22158537 rs9944524 chr17 16212650 A G 2.68E-05 Amyotrophic lateral sclerosis PIGL intron 20801717 rs9944524 chr17 16212650 A G 1.80E-04 Stroke (pediatric) PIGL intron 22990015 rs6502499 chr17 16216205 A G 7.24E-05 Type 2 diabetes PIGL intron 22158537 rs3785621 chr17 16218846 T C 1.75E-04 Type 2 diabetes PIGL intron 22158537 rs1005380 chr17 16219792 C T 7.13E-04 Type 2 diabetes PIGL intron 17463246 rs1476810 chr17 16233217 C T 9.36E-05 HDL cholesterol / / pha003074 rs7477 chr17 16246016 A C 3.00E-07 Amyotrophic lateral sclerosis CENPV UTR-3 22959728 rs7217735 chr17 16315919 A G 3.05E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs3813769 chr17 16318932 T C 3.53E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) TRPV2 UTR-5 23648065 rs4792739 chr17 16322676 T C 0.00013 Prostate cancer TRPV2 intron 23555315 rs4792739 chr17 16322676 T C 0.00019 Prostate cancer (non-advanced prostate cancer) TRPV2 intron 23555315 rs8079010 chr17 16328955 T C 8.25E-05 Suicide attempts in bipolar disorder TRPV2 intron 21423239 rs12602006 chr17 16337288 G A 7.02E-05 Suicide attempts in bipolar disorder TRPV2 intron 21423239 rs1141283 chr17 16346757 A C 3.71E-04 Suicide attempts in bipolar disorder FAM211A UTR-3 21423239 rs185998385 chr17 16347245 C T 0.00058 Breast cancer FAM211A missense 23555315 rs4430787 chr17 16348071 A G 3.92E-04 Suicide attempts in bipolar disorder C17orf76-AS1 intron 21423239 rs2882581 chr17 16350239 A G 4.59E-04 Suicide attempts in bipolar disorder C17orf76-AS1 intron 21423239 rs11871929 chr17 16351856 C T 9.33E-06 White blood cell count C17orf76-AS1 intron 21738479 rs11078342 chr17 16353617 T C,G 7.94E-06 White blood cell count C17orf76-AS1 intron 21738479 rs11869614 chr17 16355043 C T 9.20E-04 Suicide attempts in bipolar disorder C17orf76-AS1 intron 21423239 rs8082268 chr17 16356319 T C 3.77E-04 Suicide attempts in bipolar disorder C17orf76-AS1 intron 21423239 rs12951804 chr17 16358661 T A 1.55E-04 Suicide attempts in bipolar disorder C17orf76-AS1 intron 21423239 rs4792750 chr17 16359014 T C 3.21E-04 Suicide attempts in bipolar disorder C17orf76-AS1 intron 21423239 rs12603277 chr17 16360919 A G 4.44E-04 Suicide attempts in bipolar disorder C17orf76-AS1 intron 21423239 rs11078344 chr17 16362978 C T 7.08E-04 Suicide attempts in bipolar disorder C17orf76-AS1 intron 21423239 rs11654069 chr17 16365086 A G 8.19E-04 Suicide attempts in bipolar disorder C17orf76-AS1 intron 21423239 rs3744281 chr17 16367282 A T 7.18E-04 Suicide attempts in bipolar disorder C17orf76-AS1 intron 21423239 rs7215641 chr17 16368752 A G 6.32E-04 Suicide attempts in bipolar disorder C17orf76-AS1 intron 21423239 rs4792752 chr17 16375112 A C 2.49E-04 Alzheimer's disease FAM211A intron 17998437 rs673760 chr17 16401682 A G 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs673824 chr17 16401728 G C 1.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs12602910 chr17 16402114 A G 1.10E-06 Urinary metabolites / / 21572414 rs1017095 chr17 16419756 T C 2.91E-04 Multiple complex diseases / / 17554300 rs7214679 chr17 16442464 G T 9.02E-05 Lung adenocarcinoma / / 19836008 rs7224723 chr17 16456614 T G 9.55E-05 Lung adenocarcinoma ZNF287 missense 19836008 rs546844 chr17 16473277 G A 2.10E-06 Serum metabolites / / 19043545 rs2351390 chr17 16479171 C T 1.10E-05 Lung adenocarcinoma / / 19836008 rs2970059 chr17 16501495 C T 3.40E-04 White matter integrity / / 22425255 rs3874888 chr17 16740270 C A 5.74E-04 Body mass index / / 21701565 rs9890677 chr17 16763440 G T 1.23E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1964555 chr17 16763555 T C 1.74E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7210837 chr17 16764978 G A 5.75E-07 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9900143 chr17 16782270 A G 1.07E-04 Aortic root size / / 21223598 rs9899666 chr17 16803471 G A 3.10E-05 White matter hyperintensity burden / / 21681796 rs9907451 chr17 16804606 C T 2.70E-05 White matter hyperintensity burden / / 21681796 rs4792793 chr17 16816543 C G 4.00E-06 Metabolite levels (Pyroglutamine) / / 23934736 rs11654076 chr17 16819909 A G 6.02E-04 Iron levels / / pha002876 rs16961828 chr17 16820224 G C 7.41E-09 Non-albumin protein levels / / 22558069 rs4239138 chr17 16821625 G A 8.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4792795 chr17 16826016 A G 2.24E-08 Non-albumin protein levels / / 22558069 rs4792795 chr17 16826016 A G 1.10E-08 Hematology traits / / 23303382 rs3752005 chr17 16828713 A T 2.32E-08 Non-albumin protein levels / / 22558069 rs3751991 chr17 16835286 C A 2.32E-08 Non-albumin protein levels / / 22558069 rs4792800 chr17 16845167 A G 5.38E-12 Non-albumin protein levels TNFRSF13B intron 22558069 rs4792800 chr17 16845167 A G 1.00E-12 IgG levels TNFRSF13B intron 22673310 rs4792800 chr17 16845167 A G 2.00E-06 Multiple myeloma TNFRSF13B intron 23955597 rs4561508 chr17 16848750 C T 6.28E-12 Non-albumin protein levels TNFRSF13B intron 22558069 rs4561508 chr17 16848750 C T 1.00E-09 Serum total protein level TNFRSF13B intron 23022100 rs4561508 chr17 16848750 C T 2.00E-11 Serum total protein level TNFRSF13B intron 23022100 rs4561508 chr17 16848750 C T 2.00E-18 Serum total protein level TNFRSF13B intron 23022100 rs4561508 chr17 16848750 C T 8.00E-24 Hematology traits TNFRSF13B intron 23303382 rs4273077 chr17 16849139 A G 3.00E-10 Blood cell counts and other traits TNFRSF13B intron 20139978 rs4273077 chr17 16849139 A G 3.15E-10 Blood cell counts and other traits TNFRSF13B intron 20139978 rs4273077 chr17 16849139 A G 4.34E-10 Non-albumin protein levels TNFRSF13B intron 22558069 rs4273077 chr17 16849139 A G 8.00E-09 Multiple myeloma TNFRSF13B intron 23955597 rs11654088 chr17 16849813 G C 9.93E-08 Non-albumin protein levels TNFRSF13B intron 22558069 rs3818716 chr17 16851834 C T 6.28E-05 Age-related macular degeneration TNFRSF13B intron 22125219 rs3818716 chr17 16851834 C T 5.63E-07 Non-albumin protein levels TNFRSF13B intron 22558069 rs2274892 chr17 16852027 T G 5.61E-07 Non-albumin protein levels TNFRSF13B intron 22558069 rs8072293 chr17 16855878 C T 3.55E-04 Age-related macular degeneration TNFRSF13B cds-synon 22125219 rs7216399 chr17 16856578 A G 6.00E-04 Pulmonary function TNFRSF13B intron 23932459 rs4985694 chr17 16861332 G A 8.23E-04 Alzheimer's disease TNFRSF13B intron 22005930 rs4985726 chr17 16863638 C G 1.00E-14 Non-albumin protein levels TNFRSF13B intron 22558069 rs4985726 chr17 16863638 C G 7.00E-24 Non-albumin protein levels TNFRSF13B intron 22558069 rs4985700 chr17 16866075 C A 4.73E-07 Non-albumin protein levels TNFRSF13B intron 22558069 rs7226097 chr17 16868561 C T 3.98E-10 Non-albumin protein levels TNFRSF13B intron 22558069 rs6502546 chr17 16878488 A G 2.07E-04 Sudden cardiac arrest / / 21658281 rs8074984 chr17 16879070 G A 1.56E-04 Lung function (forced vital capacity) / / 24023788 rs8079130 chr17 16884960 T C 1.07E-04 Body mass index / / 17255346 rs9907308 chr17 16892265 G A 9.55E-05 Iron levels / / 19880490 rs9907308 chr17 16892265 G A 9.55E-05 Iron levels / / pha002876 rs9630717 chr17 16899313 G T 1.19E-07 Orofacial clefts / / 22419666 rs11867934 chr17 16933404 T C 7.00E-06 Diabetic retinopathy / / 21441570 rs6502557 chr17 16960978 G A 6.00E-06 IgG glycosylation MPRIP intron 23382691 rs4078062 chr17 16978834 G A 9.41E-06 Osteoarthritis MPRIP intron 22763110 rs12603417 chr17 17001291 T C 4.40E-05 Bipolar disorder and schizophrenia MPRIP intron 20889312 rs41319048 chr17 17059792 T C 3.67E-05 Multiple complex diseases MPRIP intron 17554300 rs61744862 chr17 17068182 G A 7.00E-08 Obesity-related traits MPRIP intron 23251661 rs7218781 chr17 17085409 C A 8.38E-05 Bipolar disorder and schizophrenia MPRIP intron 20889312 rs4985741 chr17 17087880 T G 6.60E-05 Subclinical atherosclerosis MPRIP intron 17903303 rs16961406 chr17 17091905 G A 2.49E-05 Type 2 diabetes MPRIP UTR-3 17463246 rs2292527 chr17 17126041 G A 4.81E-04 Multiple complex diseases FLCN intron 17554300 rs2292527 chr17 17126041 G A 1.50E-07 Asthma (childhood onset) FLCN intron 23829686 rs12600635 chr17 17142896 A G 2.00E-07 IgG glycosylation / / 23382691 rs12600635 chr17 17142896 A G 4.00E-07 IgG glycosylation / / 23382691 rs9899615 chr17 17201576 C T 8.62E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12452946 chr17 17253288 G A 1.80E-05 Urinary metabolites / / 21572414 rs11871699 chr17 17254274 A T 2.20E-06 Urinary metabolites / / 21572414 rs17648393 chr17 17254392 T C 4.80E-06 Urinary metabolites / / 21572414 rs9910779 chr17 17285174 T C 3.83E-04 White matter integrity / / 22425255 rs1569040 chr17 17306087 A G 1.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs8079827 chr17 17307972 G A 1.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs8080681 chr17 17308009 T C 1.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs35590625 chr17 17326363 G A 5.61E-16 Multiple complex diseases SMCR9 missense 17554300 rs12949948 chr17 17328111 G A 8.30E-06 Urinary metabolites / / 21572414 rs4315391 chr17 17329728 G A 1.60E-05 Urinary metabolites / / 21572414 rs4315391 chr17 17329728 G A 1.43E-04 Stroke / / pha002887 rs9893203 chr17 17334887 A G 9.90E-04 Multiple complex diseases / / 17554300 rs1242492 chr17 17374391 T C 1.58E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs17723136 chr17 17379580 C T 8.60E-04 Multiple complex diseases / / 17554300 rs7946 chr17 17409560 C T 5.64E-05 Myopia (pathological) PEMT missense 21640322 rs4646404 chr17 17420199 G A 3.07E-06 Waist-hip ratio PEMT intron 20935629 rs4646399 chr17 17431527 C T 8.16E-05 Alzheimer's disease (age of onset) PEMT intron 22005931 rs4646388 chr17 17444369 G A 9.88E-05 Psoriasis PEMT intron 20953190 rs3744118 chr17 17448589 C T 1.00E-04 Cognitive impairment induced by topiramate PEMT intron 22091778 rs4646383 chr17 17454883 C T 7.02E-05 Cognitive impairment induced by topiramate PEMT intron 22091778 rs2278952 chr17 17485584 G A 3.01E-05 Cognitive impairment induced by topiramate PEMT UTR-5 22091778 rs12453139 chr17 17515891 T G 7.21E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12936587 chr17 17543722 G A 4.00E-10 Coronary heart disease / / 21378990 rs12936587 chr17 17543722 G A 4.45E-10 Pericardial fat / / 22589742 rs12936587 chr17 17543722 G A 0.000000055 Coronary artery disease with myocardial infarction / / 23202125 rs12936587 chr17 17543722 G A 0.00000227 Coronary artery disease (CAD) age >50 / / 23202125 rs12936587 chr17 17543722 G A 0.0000134 Coronary artery disease (CAD) age <=50 / / 23202125 rs12936587 chr17 17543722 G A 0.0000286 Waist-hip ratio / / 23202125 rs12936587 chr17 17543722 G A 1.24E-09 Coronary artery disease / / 23202125 rs12936587 chr17 17543722 G A 5.97E-08 Coronary artery disease (CAD) (males) / / 23202125 rs12936587 chr17 17543722 G A 2.00E-07 Coronary artery disease / / 24262325 rs12936587 chr17 17543722 G A 2.00E-10 Coronary artery disease or large artery stroke / / 24262325 rs12936587 chr17 17543722 G A 2.70E-05 Large artery stroke / / 24262325 rs12449964 chr17 17544704 C T 8.43E-09 Coronary heart disease / / 21378990 rs12449964 chr17 17544704 C T 2.00E-08 Coronary artery disease or ischemic stroke / / 24262325 rs4925094 chr17 17569012 G A 2.45E-04 Lymphocyte counts / / 22286170 rs11654526 chr17 17617309 C T 9.53E-05 Response to mTOR inhibitor (everolimus) RAI1 intron 24009623 rs11649804 chr17 17696755 C A 1.52E-06 Parkinson's disease RAI1 missense 21738487 rs8081943 chr17 17706684 A G 1.60E-37 Health and aging,CVD and cancer age of onset RAI1 intron 22174011 rs8081943 chr17 17706684 A G 3.80E-16 Health and aging,CVD and cancer age of onset RAI1 intron 22174011 rs8081943 chr17 17706684 A G 6.70E-48 Health and aging,CVD and cancer age of onset RAI1 intron 22174011 rs8081943 chr17 17706684 A G 8.10E-10 Health and aging,CVD and cancer age of onset RAI1 intron 22174011 rs3818717 chr17 17707105 T C 7.40E-06 Parkinson's disease RAI1 cds-synon 21738487 rs1889019 chr17 17707240 C G 3.80E-11 Health and aging,CVD and cancer age of onset RAI1 intron 22174011 rs1889019 chr17 17707240 C G 4.70E-28 Health and aging,CVD and cancer age of onset RAI1 intron 22174011 rs1889019 chr17 17707240 C G 6.60E-39 Health and aging,CVD and cancer age of onset RAI1 intron 22174011 rs1889019 chr17 17707240 C G 7.60E-14 Health and aging,CVD and cancer age of onset RAI1 intron 22174011 rs4925114 chr17 17711270 A G 6.75E-07 Parkinson's disease RAI1 intron 21738487 rs11868035 chr17 17715101 G A 6.00E-08 Parkinson's disease SREBF1 UTR-3 21738487 rs4925115 chr17 17721457 A G 0.000000204 Type 2 diabetes SREBF1 intron 22325160 rs9902941 chr17 17733760 C T 1.07E-06 Parkinson's disease SREBF1 intron 21738487 rs4925119 chr17 17742904 A G 1.55E-06 Parkinson's disease / / 21738487 rs3183702 chr17 17747289 A G 5.48E-06 Parkinson's disease TOM1L2 UTR-3 21738487 rs7501812 chr17 17750907 G A 1.72E-05 Parkinson's disease TOM1L2 UTR-3 21738487 rs12951376 chr17 17752809 T C 7.75E-05 Parkinson's disease TOM1L2 intron 21738487 rs8065563 chr17 17782404 G A 9.68E-05 Parkinson's disease TOM1L2 intron 21738487 rs4925125 chr17 17794444 T C 4.12E-05 Parkinson's disease TOM1L2 intron 21738487 rs7222480 chr17 17818817 G T 2.64E-05 Parkinson's disease TOM1L2 intron 21738487 rs6502622 chr17 17834691 A G 2.39E-05 Parkinson's disease TOM1L2 intron 21738487 rs6502629 chr17 17869642 A G 5.11E-05 Parkinson's disease TOM1L2 intron 21738487 rs4299203 chr17 17878159 T G 0.000000156 Coronary artery disease LRRC48 intron 23202125 rs7219320 chr17 17880877 A G 0.000000177 Coronary artery disease LRRC48 intron 23202125 rs4072739 chr17 17884660 G A 9.96E-05 Parkinson's disease LRRC48 intron 21738487 rs4459604 chr17 17888549 T C 3.60E-05 Serum metabolites LRRC48 intron 19043545 rs4368210 chr17 17896090 C T 3.77E-05 Serum metabolites LRRC48 cds-synon 19043545 rs4584886 chr17 17896205 C T 4.02E-05 Serum metabolites LRRC48 missense 19043545 rs4924832 chr17 17897739 T C 4.02E-05 Serum metabolites LRRC48 intron 19043545 rs6502632 chr17 17913057 T C 2.93E-04 Gallstones LRRC48 intron 17632509 rs6502632 chr17 17913057 T C 4.02E-05 Serum metabolites LRRC48 intron 19043545 rs9896837 chr17 17924868 A G 4.02E-05 Serum metabolites ATPAF2 intron 19043545 rs2955384 chr17 17939573 G A 2.99E-05 Serum metabolites ATPAF2 intron 19043545 rs149036879 chr17 17942293 C T 0.00029 Prostate cancer ATPAF2 missense 23555315 rs2955359 chr17 17946730 T C 3.21E-05 Parkinson's disease C17orf39 intron 21738487 rs2955355 chr17 17948475 G A 4.49E-05 Parkinson's disease C17orf39 cds-synon 21738487 rs4643387 chr17 17972973 T C 5.94E-05 Serum metabolites / / 19043545 rs4426402 chr17 17977926 T C 6.98E-05 Serum metabolites / / 19043545 rs7211714 chr17 17986955 A G 1.50E-05 Parkinson's disease / / 21738487 rs4925138 chr17 17992793 T G 9.22E-06 Parkinson's disease DRG2 intron 21738487 rs854813 chr17 18003845 C T 1.38E-05 Parkinson's disease DRG2 intron 21738487 rs854762 chr17 18009102 G A 7.98E-05 Parkinson's disease DRG2 intron 21738487 rs854764 chr17 18011750 T C 2.65E-05 Serum metabolites / / 19043545 rs854767 chr17 18018263 C A 7.82E-05 Serum metabolites MYO15A intron 19043545 rs854791 chr17 18029857 C T 2.57E-05 Parkinson's disease MYO15A intron 21738487 rs854787 chr17 18035019 G A 7.75E-05 Parkinson's disease MYO15A intron 21738487 rs712274 chr17 18064195 T C 8.77E-06 Hepatitis C induced liver cirrhosis MYO15A intron 23321320 rs8077577 chr17 18064730 C T 4.00E-06 Obesity-related traits MYO15A cds-synon 23251661 rs2015336 chr17 18073610 A G 4.10E-06 Obesity-related traits MYO15A intron 23251661 rs11078411 chr17 18088094 C T 8.63E-06 Obesity-related traits ALKBH5 cds-synon 23251661 rs11078412 chr17 18100618 A G 7.17E-06 Obesity-related traits ALKBH5 intron 23251661 rs11655588 chr17 18107451 A G 7.17E-06 Obesity-related traits ALKBH5 intron 23251661 rs1563371 chr17 18111793 C T 7.17E-06 Obesity-related traits ALKBH5 UTR-3 23251661 rs13284 chr17 18112130 C T 6.31E-06 Obesity-related traits ALKBH5 UTR-3 23251661 rs3088233 chr17 18112675 C T 7.17E-06 Obesity-related traits ALKBH5 UTR-3 23251661 rs2746028 chr17 18139896 G T 1.14E-05 Osteoarthritis (knee and hip) LLGL1 intron 21177295 rs2746028 chr17 18139896 G T 1.59E-04 Osteoarthritis (knee and hip) LLGL1 intron 21177295 rs2746028 chr17 18139896 G T 7.07E-04 Osteoarthritis (knee and hip) LLGL1 intron 21177295 rs3088175 chr17 18177578 T G 6.29E-04 Multiple complex diseases TOP3A UTR-3 17554300 rs17806489 chr17 18249611 G A 7.16E-04 Type 2 diabetes SHMT1 intron 17463246 rs16942994 chr17 18571345 G C 6.64E-04 Multiple complex diseases ZNF286B intron 17554300 rs11871508 chr17 18704031 G A 4.80E-06 Diabetic retinopathy FAM18B1 intron 21441570 rs4924935 chr17 18753870 C T 8.00E-06 Pancreatic cancer / / 20686608 rs1037036 chr17 18764077 G A 4.34E-04 Lymphocyte counts PRPSAP2 intron 22286170 rs8080032 chr17 18827793 C A 3.40E-06 Iron levels PRPSAP2 intron 21208937 rs11656953 chr17 18828703 G A 7.04E-04 Taste perception PRPSAP2 intron 22132133 rs11657284 chr17 18830123 T G 3.22E-04 Alzheimer's disease (late onset) PRPSAP2 intron 21379329 rs1859083 chr17 18843306 G A 1.70E-05 Odorant perception / / 23910658 rs1634418 chr17 18853178 A G 2.00E-05 Urinary metabolites / / 21572414 rs959071 chr17 19142226 C T 5.37E-04 Smoking initiation EPN2 intron 24665060 rs3785784 chr17 19195431 G A 6.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EPN2 intron 20877124 rs2233074 chr17 19284071 G C 0.000000114 Cholesterol,total MAPK7 cds-synon 23063622 rs6587082 chr17 19287476 T G 0.0000918 Trichophyton tonsurans susceptibility MFAP4 UTR-3 22704677 rs16960104 chr17 19310683 A T 4.69E-04 Acute lung injury / / 22295056 rs1110466 chr17 19313997 C T 1.34E-05 Age-related macular degeneration / / pha000001 rs2386314 chr17 19314296 T C 2.38E-05 Brain structure / / 22504417 rs7211239 chr17 19320495 A G 5.40E-04 Multiple complex diseases RNF112 UTR-3 17554300 rs7208015 chr17 19320879 C G 1.72E-05 Brain structure / / 22504417 rs2386315 chr17 19326702 G A 2.75E-05 Brain structure / / 22504417 rs763751 chr17 19326857 T C 3.31E-05 Brain structure / / 22504417 rs2428588 chr17 19377559 A G 1.70E-04 Height / / 21998595 rs2453580 chr17 19438321 T C 5.16E-08 Chronic kidney disease SLC47A1 intron 22479191 rs2018675 chr17 19441531 C T 5.70E-05 Serum metabolites SLC47A1 intron 19043545 rs2440154 chr17 19444987 A G 3.85E-05 Post-operative nausea and vomiting SLC47A1 intron 21694509 rs2453568 chr17 19457509 T C 7.93E-07 Post-operative nausea and vomiting SLC47A1 intron 21694509 rs35790011 chr17 19463591 G A 1 Drug response to Metformin SLC47A1 missense 19940846 rs2453594 chr17 19484951 T C 8.87E-04 Tourette syndrome / / 22889924 rs2165894 chr17 19489796 A G 8.19E-04 Tourette syndrome / / 22889924 rs9903027 chr17 19534434 A G 9.24E-05 Blood Pressure / / pha002898 rs962801 chr17 19559095 C T 1.67E-05 Lymphocyte counts ALDH3A2 intron 22286170 rs2386142 chr17 19594008 A G 6.40E-04 Iris characteristics SLC47A2 intron 21835309 rs16960360 chr17 19613601 A C 5.39E-05 Bipolar disorder SLC47A2 intron 17486107 rs2072327 chr17 19651482 T G 1.22E-04 Type 2 diabetes ALDH3A1 intron 17463246 rs17794370 chr17 19697976 G A 4.46E-05 Serum metabolites ULK2 intron 19043545 rs157406 chr17 19710651 A G 4.77E-05 Lung adenocarcinoma ULK2 intron 19836008 rs157395 chr17 19724155 C T 8.35E-05 Lung adenocarcinoma ULK2 intron 19836008 rs281357 chr17 19742514 T C 4.00E-06 Parkinson's disease ULK2 intron 17052657 rs9899357 chr17 19800549 T C 4.31E-07 Red blood cell traits / / 23222517 rs4925054 chr17 19801417 C G 4.49E-10 Red blood cell traits / / 23222517 rs427033 chr17 19803244 C T 1.12E-09 Red blood cell traits / / 23222517 rs397969 chr17 19804247 T C 2.00E-09 Platelet counts / / 22139419 rs6813 chr17 19808445 T C 7.71E-10 Red blood cell traits AKAP10 UTR-3 23222517 rs203467 chr17 19809749 C T 4.86E-05 Vascular dementia AKAP10 intron 22116812 rs203467 chr17 19809749 C T 2.06E-08 Red blood cell traits AKAP10 intron 23222517 rs203466 chr17 19809953 C G 4.02E-05 Multiple complex diseases AKAP10 intron 17554300 rs203457 chr17 19818338 C A 6.58E-05 Multiple complex diseases AKAP10 intron 17554300 rs119672 chr17 19818601 A G 3.90E-05 Multiple complex diseases AKAP10 intron 17554300 rs203480 chr17 19828959 G A 1.49E-08 Red blood cell traits AKAP10 intron 23222517 rs203478 chr17 19829842 G C 3.53E-10 Red blood cell traits AKAP10 intron 23222517 rs850622 chr17 19837536 C T 6.36E-04 Type 2 diabetes AKAP10 intron 17463246 rs850622 chr17 19837536 C T 7.39E-10 Red blood cell traits AKAP10 intron 23222517 rs1638528 chr17 19837929 A G 1.01E-09 Red blood cell traits AKAP10 intron 23222517 rs1638527 chr17 19845393 G A 5.44E-10 Red blood cell traits AKAP10 intron 23222517 rs1638526 chr17 19848450 T C 1.03E-09 Red blood cell traits AKAP10 intron 23222517 rs2108978 chr17 19861458 C T 3.62E-05 Multiple complex diseases AKAP10 missense 17554300 rs17604987 chr17 19867331 T A 5.38E-04 Type 2 diabetes AKAP10 intron 17463246 rs17604987 chr17 19867331 T A 1.08E-09 Red blood cell traits AKAP10 intron 23222517 rs8079923 chr17 19869544 C T 5.27E-10 Red blood cell traits AKAP10 intron 23222517 rs7222403 chr17 19879164 T C 7.34E-07 Red blood cell traits AKAP10 intron 23222517 rs7209653 chr17 19882084 T C 3.50E-10 Red blood cell traits AKAP10 nearGene-5 23222517 rs9901294 chr17 19888501 G A 4.39E-10 Red blood cell traits / / 23222517 rs12453720 chr17 19895202 G A 2.24E-10 Red blood cell traits / / 23222517 rs12450857 chr17 19895248 C T 8.05E-12 Red blood cell traits / / 23222517 rs9916675 chr17 19900168 A G 2.26E-07 Red blood cell traits / / 23222517 rs1860302 chr17 19914399 T A 1.03E-12 Red blood cell traits SPECC1 intron 23222517 rs4925065 chr17 19914546 C T 1.11E-12 Red blood cell traits SPECC1 intron 23222517 rs4925067 chr17 19921222 C G 1.51E-12 Red blood cell traits SPECC1 intron 23222517 rs7211535 chr17 19922364 A G 8.24E-14 Red blood cell traits SPECC1 intron 23222517 rs7218708 chr17 19926836 A G 2.55E-14 Red blood cell traits SPECC1 intron 23222517 rs1034904 chr17 19927699 C T 3.07E-14 Red blood cell traits SPECC1 intron 23222517 rs12946508 chr17 19952059 A T 5.97E-12 Red blood cell traits SPECC1 intron 23222517 rs4925072 chr17 19956899 A G 3.00E-12 Red blood cell traits SPECC1 intron 23222517 rs3862151 chr17 19957289 A G 3.77E-09 Red blood cell traits SPECC1 intron 23222517 rs3862152 chr17 19959693 C T 1.69E-16 Red blood cell traits SPECC1 intron 23222517 rs17759041 chr17 19959966 A G 5.10E-12 Red blood cell traits SPECC1 intron 23222517 rs17759083 chr17 19963605 T A 2.87E-19 Red blood cell traits SPECC1 intron 23222517 rs9915758 chr17 19964775 A G 9.09E-15 Red blood cell traits SPECC1 intron 23222517 rs9897246 chr17 19965702 T G 1.73E-14 Red blood cell traits SPECC1 intron 23222517 rs7209752 chr17 19969397 A G 1.06E-05 Celiac disease SPECC1 intron 23936387 rs4925075 chr17 19969735 G A 1.50E-12 Red blood cell traits SPECC1 intron 23222517 rs12947713 chr17 19974002 G C 7.54E-14 Red blood cell traits SPECC1 intron 23222517 rs8075343 chr17 19975487 T C 2.09E-13 Red blood cell traits SPECC1 intron 23222517 rs8068484 chr17 19976394 C T 9.43E-12 Red blood cell traits SPECC1 intron 23222517 rs4341795 chr17 19977228 C T 5.47E-11 Red blood cell traits SPECC1 intron 23222517 rs12937327 chr17 19978984 C T 5.25E-12 Red blood cell traits SPECC1 intron 23222517 rs4925078 chr17 19982473 G A 1.79E-12 Red blood cell traits SPECC1 intron 23222517 rs888424 chr17 19985427 G A 5.35E-20 Red blood cell traits SPECC1 intron 23222517 rs4924803 chr17 19991806 C T 2.38E-04 Multiple complex diseases SPECC1 intron 17554300 rs4924803 chr17 19991806 C T 3.94E-16 Red blood cell traits SPECC1 intron 23222517 rs4925081 chr17 19991993 G A 2.71E-04 Multiple complex diseases SPECC1 intron 17554300 rs4925081 chr17 19991993 G A 2.69E-15 Red blood cell traits SPECC1 intron 23222517 rs17759609 chr17 19992514 G C 2.82E-13 Red blood cell traits SPECC1 intron 23222517 rs11867585 chr17 19992607 A G 7.50E-15 Red blood cell traits SPECC1 intron 23222517 rs4925082 chr17 19994673 T C 7.75E-20 Red blood cell traits SPECC1 intron 23222517 rs11204422 chr17 19996429 A T 8.58E-04 Type 2 diabetes SPECC1 intron 17463246 rs11204422 chr17 19996429 A T 2.19E-17 Red blood cell traits SPECC1 intron 23222517 rs7208025 chr17 19997870 T C 8.68E-14 Red blood cell traits SPECC1 intron 23222517 rs7208365 chr17 19998017 T G 1.40E-15 Red blood cell traits SPECC1 intron 23222517 rs4925084 chr17 19998958 C T 2.24E-10 Red blood cell traits SPECC1 intron 23222517 rs888423 chr17 19999409 G A 5.62E-16 Red blood cell traits SPECC1 intron 23222517 rs12942179 chr17 19999781 G A 3.42E-14 Red blood cell traits SPECC1 intron 23222517 rs918227 chr17 20002164 A G 9.14E-14 Red blood cell traits SPECC1 intron 23222517 rs12451841 chr17 20004875 G A 5.84E-20 Red blood cell traits SPECC1 intron 23222517 rs7216599 chr17 20015600 G C 9.31E-14 Red blood cell traits SPECC1 intron 23222517 rs2042046 chr17 20018841 T C 6.72E-04 Multiple complex diseases SPECC1 intron 17554300 rs2042046 chr17 20018841 T C 8.86E-14 Red blood cell traits SPECC1 intron 23222517 rs17686622 chr17 20020364 C G 1.23E-09 Red blood cell traits SPECC1 intron 23222517 rs12949485 chr17 20021661 A G 1.52E-09 Red blood cell traits SPECC1 intron 23222517 rs17759923 chr17 20022035 G A 1.58E-12 Red blood cell traits SPECC1 intron 23222517 rs2013441 chr17 20023099 G A 1.20E-15 Red blood cell traits SPECC1 intron 23222517 rs2013441 chr17 20023099 G A 9.00E-06 Obesity-related traits SPECC1 intron 23251661 rs2013443 chr17 20023109 G C 4.42E-15 Red blood cell traits SPECC1 intron 23222517 rs17759959 chr17 20024095 A G 2.55E-17 Red blood cell traits SPECC1 intron 23222517 rs4925087 chr17 20024582 A C 3.04E-15 Red blood cell traits SPECC1 intron 23222517 rs4924808 chr17 20026548 A G 1.97E-16 Red blood cell traits SPECC1 intron 23222517 rs4924808 chr17 20026548 A G 9.78E-06 Obesity-related traits SPECC1 intron 23251661 rs16960697 chr17 20027718 A G 2.34E-15 Red blood cell traits SPECC1 intron 23222517 rs17686798 chr17 20029170 G T 3.18E-17 Red blood cell traits SPECC1 intron 23222517 rs11868116 chr17 20029593 T C 4.60E-15 Red blood cell traits SPECC1 intron 23222517 rs4588033 chr17 20029901 C G 1.60E-15 Red blood cell traits SPECC1 intron 23222517 rs1812934 chr17 20030960 A T 2.91E-16 Red blood cell traits SPECC1 intron 23222517 rs9893832 chr17 20038273 A G 2.53E-15 Red blood cell traits SPECC1 intron 23222517 rs17686839 chr17 20039171 A G 2.95E-17 Red blood cell traits SPECC1 intron 23222517 rs8078716 chr17 20044291 G A 3.80E-15 Red blood cell traits SPECC1 intron 23222517 rs4924809 chr17 20044673 C T 7.74E-17 Red blood cell traits SPECC1 intron 23222517 rs12947950 chr17 20045176 C T 1.55E-09 Red blood cell traits SPECC1 intron 23222517 rs8066143 chr17 20048355 A C 2.69E-12 Red blood cell traits SPECC1 intron 23222517 rs4925088 chr17 20049344 A G 3.33E-13 Red blood cell traits SPECC1 intron 23222517 rs10438824 chr17 20058510 C T 2.44E-09 Red blood cell traits SPECC1 intron 23222517 rs1009082 chr17 20062959 G A 1.55E-11 Red blood cell traits SPECC1 intron 23222517 rs9901336 chr17 20064190 G A 1.69E-10 Red blood cell traits SPECC1 intron 23222517 rs4925090 chr17 20066631 C T 2.78E-13 Red blood cell traits SPECC1 intron 23222517 rs8080649 chr17 20069677 G C 2.66E-13 Red blood cell traits SPECC1 intron 23222517 rs4924810 chr17 20071819 T C 2.68E-11 Red blood cell traits SPECC1 intron 23222517 rs2703794 chr17 20073338 T C 6.23E-16 Red blood cell traits SPECC1 intron 23222517 rs1859407 chr17 20078137 T C 2.58E-13 Red blood cell traits SPECC1 intron 23222517 rs2189710 chr17 20078964 C A 4.13E-16 Red blood cell traits SPECC1 intron 23222517 rs2526462 chr17 20079460 A T 5.83E-16 Red blood cell traits SPECC1 intron 23222517 rs2189709 chr17 20083226 T A 3.27E-13 Red blood cell traits SPECC1 intron 23222517 rs2703799 chr17 20085768 G T 3.20E-16 Red blood cell traits SPECC1 intron 23222517 rs2526460 chr17 20086352 G A 2.74E-16 Red blood cell traits SPECC1 intron 23222517 rs2703800 chr17 20086562 A G 4.68E-04 Multiple complex diseases SPECC1 intron 17554300 rs2703800 chr17 20086562 A G 3.22E-12 Red blood cell traits SPECC1 intron 23222517 rs2107565 chr17 20088492 C T 3.06E-14 Red blood cell traits SPECC1 intron 23222517 rs2386485 chr17 20095246 G A 2.44E-16 Red blood cell traits SPECC1 intron 23222517 rs2526491 chr17 20097462 A G 2.54E-07 Red blood cell traits SPECC1 intron 23222517 rs2703802 chr17 20101039 T C 5.77E-07 Red blood cell traits SPECC1 intron 23222517 rs2107566 chr17 20103252 G A 1.56E-16 Red blood cell traits SPECC1 intron 23222517 rs2526484 chr17 20103760 A G 3.05E-12 Red blood cell traits SPECC1 intron 23222517 rs2703803 chr17 20107069 G T 1.61E-13 Red blood cell traits SPECC1 intron 23222517 rs2703804 chr17 20107195 T C 1.84E-12 Red blood cell traits SPECC1 intron 23222517 rs2703805 chr17 20107773 T C 3.57E-15 Red blood cell traits SPECC1 cds-synon 23222517 rs2703806 chr17 20108239 A T 5.27E-17 Red blood cell traits SPECC1 missense 23222517 rs2703806 chr17 20108239 A T 8.81E-06 Obesity-related traits SPECC1 missense 23251661 rs2703807 chr17 20109189 C T 2.66E-14 Red blood cell traits SPECC1 cds-synon 23222517 rs1544421 chr17 20114217 T C 2.56E-17 Red blood cell traits SPECC1 intron 23222517 rs2703813 chr17 20115315 T C 2.36E-05 Type 2 diabetes SPECC1 intron 17846126 rs2703813 chr17 20115315 T C 9.12E-10 Red blood cell traits SPECC1 intron 23222517 rs2703814 chr17 20117151 T C 2.92E-15 Red blood cell traits SPECC1 intron 23222517 rs2703815 chr17 20118499 T C 3.15E-16 Red blood cell traits SPECC1 intron 23222517 rs2703816 chr17 20118887 A G 4.38E-17 Red blood cell traits SPECC1 intron 23222517 rs2703817 chr17 20119677 T G 4.12E-16 Red blood cell traits SPECC1 intron 23222517 rs2703818 chr17 20119976 T A 1.79E-12 Red blood cell traits SPECC1 intron 23222517 rs2703821 chr17 20121526 C T 4.26E-17 Red blood cell traits SPECC1 intron 23222517 rs2526481 chr17 20127018 T C 6.00E-14 Red blood cell traits SPECC1 intron 23222517 rs2263175 chr17 20128029 C G 7.93E-12 Red blood cell traits SPECC1 intron 23222517 rs2526480 chr17 20130074 C T 4.26E-16 Red blood cell traits SPECC1 intron 23222517 rs2703771 chr17 20130154 C G 6.66E-04 Multiple complex diseases SPECC1 intron 17554300 rs2703771 chr17 20130154 C G 1.53E-14 Red blood cell traits SPECC1 intron 23222517 rs2526478 chr17 20130452 C T 6.75E-04 Multiple complex diseases SPECC1 intron 17554300 rs2526478 chr17 20130452 C T 6.97E-14 Red blood cell traits SPECC1 intron 23222517 rs2526477 chr17 20131193 A G 5.85E-12 Red blood cell traits SPECC1 intron 23222517 rs2703772 chr17 20131453 C A 1.91E-12 Red blood cell traits SPECC1 intron 23222517 rs2703773 chr17 20131814 T C 1.23E-09 Red blood cell traits SPECC1 intron 23222517 rs2703774 chr17 20133538 G A 3.22E-16 Red blood cell traits SPECC1 intron 23222517 rs2526476 chr17 20134289 C T 4.56E-04 Multiple complex diseases SPECC1 intron 17554300 rs2526476 chr17 20134289 C T 9.32E-14 Red blood cell traits SPECC1 intron 23222517 rs2526475 chr17 20136216 T C 2.49E-15 Red blood cell traits SPECC1 intron 23222517 rs2526475 chr17 20136216 T C 8.81E-06 Obesity-related traits SPECC1 intron 23251661 rs2158473 chr17 20139090 T C 3.00E-05 Type 2 diabetes SPECC1 intron 17846126 rs2158473 chr17 20139090 T C 2.34E-17 Red blood cell traits SPECC1 intron 23222517 rs2703781 chr17 20144714 A G 1.55E-15 Red blood cell traits SPECC1 intron 23222517 rs2703782 chr17 20144799 A G 1.29E-17 Red blood cell traits SPECC1 intron 23222517 rs757495 chr17 20150018 A C 2.51E-15 Red blood cell traits SPECC1 intron 23222517 rs2526471 chr17 20151673 G A 1.44E-09 Red blood cell traits SPECC1 intron 23222517 rs733794 chr17 20157957 T C 3.21E-15 Red blood cell traits SPECC1 intron 23222517 rs2526469 chr17 20162748 C T 1.54E-11 Red blood cell traits SPECC1 intron 23222517 rs2526468 chr17 20163072 C G 2.03E-11 Red blood cell traits SPECC1 intron 23222517 rs2703790 chr17 20163209 G A 2.37E-12 Red blood cell traits SPECC1 intron 23222517 rs2703791 chr17 20163529 A G 2.86E-17 Red blood cell traits SPECC1 cds-synon 23222517 rs2526466 chr17 20165251 C T 2.55E-15 Red blood cell traits SPECC1 intron 23222517 rs2703792 chr17 20166950 G A 2.51E-17 Red blood cell traits SPECC1 intron 23222517 rs2158472 chr17 20171524 C T 4.83E-15 Red blood cell traits SPECC1 intron 23222517 rs9897328 chr17 20174852 G A 5.68E-12 Red blood cell traits SPECC1 intron 23222517 rs9896221 chr17 20180337 G A 1.81E-16 Red blood cell traits SPECC1 intron 23222517 rs9904928 chr17 20180536 T C 3.16E-17 Red blood cell traits SPECC1 intron 23222517 rs9896709 chr17 20180550 G A 3.02E-17 Red blood cell traits SPECC1 intron 23222517 rs12603372 chr17 20181566 A G 6.54E-04 Multiple complex diseases SPECC1 intron 17554300 rs12603372 chr17 20181566 A G 1.03E-13 Red blood cell traits SPECC1 intron 23222517 rs3850780 chr17 20181902 A C 4.77E-15 Red blood cell traits SPECC1 intron 23222517 rs3850783 chr17 20184501 A G 3.96E-15 Red blood cell traits SPECC1 intron 23222517 rs3850784 chr17 20185030 A G 4.92E-17 Red blood cell traits SPECC1 intron 23222517 rs3850785 chr17 20185248 A G 6.14E-17 Red blood cell traits SPECC1 intron 23222517 rs10491107 chr17 20188174 T C 8.13E-04 Multiple complex diseases SPECC1 intron 17554300 rs10491107 chr17 20188174 T C 1.27E-13 Red blood cell traits SPECC1 intron 23222517 rs9905493 chr17 20188581 C G 3.48E-15 Red blood cell traits SPECC1 intron 23222517 rs1561974 chr17 20196144 G A 3.87E-17 Red blood cell traits SPECC1 intron 23222517 rs2034109 chr17 20196633 C T 4.63E-12 Red blood cell traits SPECC1 intron 23222517 rs9325894 chr17 20197101 T C 3.34E-17 Red blood cell traits SPECC1 intron 23222517 rs11654025 chr17 20198160 A T 4.12E-16 Red blood cell traits SPECC1 intron 23222517 rs7207611 chr17 20204516 A G 7.41E-16 Red blood cell traits SPECC1 intron 23222517 rs1373147 chr17 20206645 T A 5.26E-06 Type 2 diabetes SPECC1 intron 17846126 rs1373147 chr17 20206645 T A 4.30E-17 Red blood cell traits SPECC1 intron 23222517 rs6587064 chr17 20207884 G A 2.04E-09 Red blood cell traits SPECC1 intron 23222517 rs2120282 chr17 20209474 C T 5.29E-16 Red blood cell traits SPECC1 intron 23222517 rs2165897 chr17 20209721 T C 2.35E-16 Red blood cell traits SPECC1 intron 23222517 rs8071665 chr17 20209943 T C 2.55E-16 Red blood cell traits SPECC1 intron 23222517 rs8068720 chr17 20214171 G T 4.86E-16 Red blood cell traits SPECC1 intron 23222517 rs8070401 chr17 20214492 C T 2.23E-11 Red blood cell traits SPECC1 intron 23222517 rs7223476 chr17 20215352 T G 9.08E-04 Multiple complex diseases SPECC1 intron 17554300 rs7223476 chr17 20215352 T G 6.02E-12 Red blood cell traits SPECC1 intron 23222517 rs11871827 chr17 20215905 G C 1.94E-16 Red blood cell traits SPECC1 intron 23222517 rs11870147 chr17 20216095 T C 1.71E-16 Red blood cell traits SPECC1 intron 23222517 rs8079701 chr17 20216565 G A 3.19E-12 Red blood cell traits SPECC1 intron 23222517 rs8071274 chr17 20216928 T C 3.46E-12 Red blood cell traits SPECC1 intron 23222517 rs1992562 chr17 20218793 T G 4.81E-16 Red blood cell traits / / 23222517 rs1992562 chr17 20218793 T G 8.81E-06 Obesity-related traits / / 23251661 rs2058971 chr17 20219508 T A 2.54E-16 Red blood cell traits / / 23222517 rs7207817 chr17 20221328 T C 9.30E-10 Red blood cell traits / / 23222517 rs11204303 chr17 20244948 A C 2.28E-13 Red blood cell traits CCDC144C intron 23222517 rs2694201 chr17 20334398 G A 3.61E-16 Red blood cell traits / / 23222517 rs1815569 chr17 20640777 A G 2.60E-05 Cognitive impairment induced by topiramate / / 22091778 rs7208434 chr17 20646527 G A 1.87E-07 Type 2 diabetes / / 21799836 rs2993352 chr17 20719239 C T 0.000190759 Hypertension (early onset hypertension) / / 22479346 rs2993369 chr17 20735097 C T 0.000489529 Hypertension (early onset hypertension) / / 22479346 rs2993369 chr17 20735097 C T 2.66E-05 Tunica Media / / pha003034 rs2993369 chr17 20735097 C T 4.93E-05 Tunica Media / / pha003036 rs2993367 chr17 20737867 T C 0.000269212 Hypertension (early onset hypertension) / / 22479346 rs2993367 chr17 20737867 T C 4.88E-05 Tunica Media / / pha003034 rs2993367 chr17 20737867 T C 7.40E-05 Tunica Media / / pha003036 rs17763869 chr17 20789105 A G 1.80E-06 Urinary metabolites CCDC144NL intron 21572414 rs12450680 chr17 20813326 C T 9.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs11204326 chr17 20852310 C T 4.58E-04 Body mass index / / 21701565 rs7215006 chr17 20853295 C T 2.26E-04 Body mass index / / 21701565 rs4381653 chr17 20865013 A G 3.32E-04 Body mass index / / 21701565 rs1044414 chr17 20904451 A G 6.88E-04 Heart Failure USP22 UTR-3 pha002884 rs9914758 chr17 20910424 T C 7.27E-04 Body mass index USP22 intron 21701565 rs9909279 chr17 20914156 G A 4.74E-04 Body mass index USP22 intron 21701565 rs7226229 chr17 20924077 C T 1.00E-06 Blood trace element (Se levels) USP22 intron 23720494 rs2127096 chr17 20934127 C T 2.28E-04 Body mass index USP22 intron 21701565 rs1993901 chr17 20938791 A G 6.04E-04 Heart Failure USP22 intron pha002884 rs899343 chr17 20979794 C T 2.90E-04 Heart Failure / / pha002884 rs17771193 chr17 21005471 C T 2.01E-04 Smoking quantity / / 24665060 rs8064815 chr17 21019308 A G 3.06E-04 Type 2 diabetes / / 17463246 rs9891647 chr17 21121136 C T 5.89E-05 Blood Pressure / / pha003040 rs9911465 chr17 21127058 A G 8.76E-05 Blood Pressure / / pha003040 rs11204346 chr17 21141614 T C 2.90E-05 Urinary metabolites / / 21572414 rs6587128 chr17 21157703 G T 9.10E-05 Post-operative nausea and vomiting / / 21694509 rs6587128 chr17 21157703 G T 9.74E-06 Potassium levels / / pha003086 rs7217373 chr17 21160030 C G 4.86E-05 Body mass index / / 21701565 rs7217373 chr17 21160030 C G 5.66E-05 Body mass index / / 21701565 rs7217403 chr17 21160085 C T 6.13E-05 Body mass index / / 21701565 rs7217403 chr17 21160085 C T 6.95E-05 Body mass index / / 21701565 rs11652094 chr17 21172289 G C 2.21E-05 Body mass index / / 21701565 rs11652094 chr17 21172289 G C 3.22E-05 Body mass index / / 21701565 rs3760201 chr17 21193618 G A 3.29E-05 Attention deficit hyperactivity disorder MAP2K3 intron 22012869 rs9901404 chr17 21213782 A G 1.07E-04 Body mass index MAP2K3 intron 21701565 rs9901404 chr17 21213782 A G 8.02E-05 Body mass index MAP2K3 intron 21701565 rs6587138 chr17 21214253 G A 4.45E-04 Type 2 diabetes MAP2K3 intron 17463246 rs9906072 chr17 21245687 T C 1.98E-04 Body mass index / / 21701565 rs9906072 chr17 21245687 T C 8.78E-04 Body mass index / / 21701565 rs7213608 chr17 21279289 C T 1.10E-04 Height KCNJ12 nearGene-5 21998595 rs4640244 chr17 21284223 A G 2.00E-08 Height KCNJ12 intron 20881960 rs1878958 chr17 21374579 A G 2.16E-04 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs7503709 chr17 21428752 C T 1.57E-04 Parkinson's disease / / 17052657 rs1975974 chr17 21707060 A G 1.00E-07 Psoriasis / / 20953189 rs17052344 chr17 21717543 G A 3.80E-04 Psoriasis / / 20953189 rs4889730 chr17 21717727 T G 2.83E-11 Parkinson's disease / / pha002868 rs17052370 chr17 21736353 C T 6.10E-06 Type 2 diabetes / / 21874001 rs6565378 chr17 21831307 A G 9.30E-04 Type 2 diabetes / / 17463246 rs17052396 chr17 21835272 A G 6.95E-05 Femoral neck bone geometry / / 22087292 rs7225244 chr17 21843894 G T 7.13E-05 Femoral neck bone geometry / / 22087292 rs17808708 chr17 21986851 G A 3.80E-04 Body mass index / / 17255346 rs8072903 chr17 21991614 A C 1.78E-04 Body mass index / / 17255346 rs8072903 chr17 21991614 A C 3.61E-04 Multiple complex diseases / / 17554300 rs7406339 chr17 22002556 A G 8.85E-04 Multiple complex diseases / / 17554300 rs11654492 chr17 22008649 A C 1.07E-04 Bipolar disorder / / 17486107 rs4889705 chr17 22026080 T C 1.19E-04 Fibrinogen / / 17255346 rs7207298 chr17 22095127 T C 1.48E-04 Lipid traits / / 22028671 rs1915048 chr17 22097293 C T 9.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs1818691 chr17 22103925 T C 2.33E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7213544 chr17 22110184 G A 2.87E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2203931 chr17 22138445 G A 9.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs1606914 chr17 22159899 C T 1.10E-06 Urinary metabolites / / 21572414 rs1973661 chr17 22201035 A G 3.74E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs73317122 chr17 25320889 G T 4.00E-06 Response to amphetamines / / 22952603 rs1975980 chr17 25395691 C G 9.34E-05 Response to methylphenidate treatment / / 21130132 rs1402726 chr17 25395770 C T 4.47E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs11080056 chr17 25404049 C T 6.08E-05 Response to methylphenidate treatment / / 21130132 rs4795519 chr17 25541278 A C 1.00E-12 Chronic myeloid leukemia / / 21540461 rs7220921 chr17 25551283 A T 4.78E-05 Alzheimer's disease / / 22832961 rs3762811 chr17 25564760 C T 5.10E-05 Alzheimer's disease / / 22832961 rs17776355 chr17 25565155 G A 5.35E-05 Alzheimer's disease / / 22832961 rs12602978 chr17 25567080 C T 7.00E-07 Dental caries LOC100506418 intron 23064961 rs2270759 chr17 25568598 G A 5.17E-05 Alzheimer's disease LOC100506418 intron 22832961 rs2270758 chr17 25568707 G A 5.12E-05 Alzheimer's disease / / 22832961 rs2270757 chr17 25568923 G A 5.53E-05 Alzheimer's disease / / 22832961 rs17703271 chr17 25571166 T C 4.61E-07 Triglycerides / / 19074352 rs17703271 chr17 25571166 T C 4.61E-07 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs16965654 chr17 25607692 G A,C,T 4.15E-08 Osteoporosis / / 20548944 rs6505182 chr17 25607721 C G 4.11E-05 Multiple complex diseases / / 17554300 rs12306 chr17 25622111 G T 2.02E-05 HIV(mother-to-child transmission) WSB1 intron 20487506 rs12306 chr17 25622111 G T 4.68E-05 Height WSB1 intron pha003011 rs11080131 chr17 25636954 T G 6.84E-04 Alcohol dependence WSB1 intron 21314694 rs1060618 chr17 25640081 A G 8.99E-05 Height WSB1 UTR-3 pha003010 rs1060618 chr17 25640081 A G 9.46E-05 Height WSB1 UTR-3 pha003011 rs374285747 chr17 25640081 A AG 8.99E-05 Height WSB1 UTR-3 pha003010 rs374285747 chr17 25640081 A AG 9.46E-05 Height WSB1 UTR-3 pha003011 rs4795567 chr17 25650739 T C 9.42E-06 Height / / pha003010 rs4795567 chr17 25650739 T C 5.91E-06 Height / / pha003011 rs2015836 chr17 25751342 A G 7.71E-04 Suicide attempts in bipolar disorder TBC1D3P5 intron 21423239 rs1554523 chr17 25751831 G A 9.08E-04 Suicide attempts in bipolar disorder TBC1D3P5 intron 21423239 rs1879921 chr17 25753521 A G 7.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs4795677 chr17 25776662 T C 6.31E-04 Smoking initiation / / 24665060 rs2945412 chr17 25843643 G A 9.00E-17 Crohn's disease KSR1 intron 23128233 rs17778162 chr17 25850509 G A 1.77E-04 Alcohol dependence KSR1 intron 21314694 rs2948529 chr17 25870542 C T 6.57E-05 Crohn's disease KSR1 intron 17804789 rs2948527 chr17 25872185 T C 5.85E-04 Crohn's disease KSR1 intron 17804789 rs2948527 chr17 25872185 T C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes KSR1 intron 22628534 rs940013 chr17 25885431 G T 3.12E-04 Smoking quantity KSR1 intron 24665060 rs2948525 chr17 25888671 T C 1.87E-04 Smoking quantity KSR1 intron 24665060 rs2945398 chr17 25888702 T G 3.44E-04 Smoking quantity KSR1 intron 24665060 rs2945401 chr17 25900488 T C 9.47E-04 Multiple complex diseases KSR1 intron 17554300 rs940009 chr17 25900783 T C 6.15E-04 Smoking quantity KSR1 intron 24665060 rs2948514 chr17 25907052 G C 4.15E-04 Smoking quantity KSR1 intron 24665060 rs2140225 chr17 25923170 A G 9.16E-05 Multiple complex diseases KSR1 intron 17554300 rs2140225 chr17 25923170 A G 1.22E-04 Smoking quantity KSR1 intron 24665060 rs16966333 chr17 25924596 C T 1.88E-04 Smoking quantity KSR1 intron 24665060 rs4239242 chr17 25974258 T C 4.52E-04 White matter integrity LGALS9 intron 22425255 rs4794986 chr17 25983153 G A 6.92E-07 Crohn's disease / / 17804789 rs12450575 chr17 25995731 C T 1.26E-04 Lymphocyte counts / / 22286170 rs9891469 chr17 26008052 A G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4239246 chr17 26012188 G A 0.0000965 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10438809 chr17 26031625 G A,C 5.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs4595846 chr17 26051702 G T 0.000063 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs4595846 chr17 26051702 G T 0.00025 Prostate cancer / / 23555315 rs9901734 chr17 26081029 C G 1.23E-04 Arthritis (juvenile idiopathic) / / 22354554 rs11653716 chr17 26084532 C G 1.40E-04 Alzheimer's disease (late onset) NOS2 intron 21460841 rs944722 chr17 26092037 C T 1.00E-09 Fractional exhaled nitric oxide (childhood) NOS2 intron 24315451 rs944722 chr17 26092037 C T 3.00E-07 Fractional exhaled nitric oxide (childhood) NOS2 intron 24315451 rs2297515 chr17 26093333 A C 2.13E-06 Asthma NOS2 intron 11022011 rs2297518 chr17 26096597 G A 1.94E-04 Multiple complex diseases NOS2 missense 17554300 rs9797244 chr17 26097131 T C 6.68E-04 Multiple complex diseases NOS2 intron 17554300 rs8070472 chr17 26101188 G A 2.35E-08 HDL cholesterol NOS2 intron 23063622 rs4796052 chr17 26103034 C T 7.34E-04 Crohn's disease NOS2 intron 17804789 rs4795067 chr17 26106675 A G 4.00E-11 Psoriasis NOS2 intron 20953189 rs4795067 chr17 26106675 A G 9.94E-05 Leukocyte Counts NOS2 intron pha003091 rs28998802 chr17 26124908 G A 3.30E-16 Psoriasis NOS2 intron 23143594 rs28998800 chr17 26126086 T C 0.000000236 Cholesterol,total NOS2 intron 23063622 rs10459953 chr17 26127518 C G 1.27E-04 Schizophrenia(treatment response to risperidone) NOS2 UTR-5 19850283 rs11080358 chr17 26130596 G A 4.98E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2779251 chr17 26131326 G A 1.49E-08 Autism / / 22935194 rs16966598 chr17 26138122 G C 1.78E-04 Type 2 diabetes / / 17463246 rs12602762 chr17 26194880 G A 1.02E-04 Alzheimer's disease / / 22005930 rs3751972 chr17 26206414 C A 2.00E-10 Fractional exhaled nitric oxide (childhood) C17orf108 UTR-3 24315451 rs3751972 chr17 26206414 C A 7.00E-09 Fractional exhaled nitric oxide (childhood) C17orf108 UTR-3 24315451 rs7224724 chr17 26216090 T C 6.89E-04 Body mass index C17orf108 intron 21701565 rs2079714 chr17 26222520 G A 3.14E-04 Body mass index / / 21701565 rs2079714 chr17 26222520 G A 6.54E-04 Body mass index / / 21701565 rs4796228 chr17 26222810 G A 6.91E-04 Body mass index / / 21701565 rs8078361 chr17 26230480 C T 8.64E-04 Multiple complex diseases / / 17554300 rs11653617 chr17 26247888 G A 4.84E-05 Asthma / / pha003128 rs8079838 chr17 26266432 G C 2.60E-05 Urinary metabolites / / 21572414 rs4483903 chr17 26305867 A T 3.45E-04 Type 2 diabetes / / 17463246 rs4239214 chr17 26327892 G A 8.29E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7502703 chr17 26337703 G A 2.31E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11653873 chr17 26338912 G A 2.02E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12452097 chr17 26545488 C A 1.10E-04 Crohn's disease / / 17804789 rs4435306 chr17 26549716 T G 5.15E-05 Crohn's disease / / 17804789 rs2292633 chr17 26575380 G A 2.82E-07 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs35462237 chr17 26580220 C A 7.72E-07 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs16964203 chr17 26582710 A C 2.55E-07 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs17792915 chr17 26584687 G A 6.39E-07 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs9914405 chr17 26588359 G A 5.82E-07 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs12937920 chr17 26590657 C T 1.24E-07 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs9892047 chr17 26592357 C G 5.65E-07 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs9890374 chr17 26592362 G A 5.65E-07 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs9900311 chr17 26595407 G A 4.58E-07 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs9909055 chr17 26596128 C T 2.30E-05 Amyotrophic lateral sclerosis / / 20801717 rs9909055 chr17 26596128 C T 1.98E-07 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs9909055 chr17 26596128 C T 3.86E-06 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs12947213 chr17 26598674 C T 5.74E-07 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs2006933 chr17 26601133 T G 9.00E-07 Amyotrophic lateral sclerosis / / 22959728 rs2006933 chr17 26601133 T G 8.69E-07 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs9894481 chr17 26610220 C T 5.37E-07 Amyotrophic lateral sclerosis (sporadic) KRT18P55 intron 24256812 rs34517613 chr17 26610252 C T 1.11E-08 Amyotrophic lateral sclerosis (sporadic) KRT18P55 intron 24256812 rs34517613 chr17 26610252 C T 9.00E-09 Amyotrophic lateral sclerosis (sporadic) KRT18P55 intron 24256812 rs171360 chr17 26643989 A C 6.06E-04 Smoking quantity / / 24665060 rs11080055 chr17 26649724 A C 1.11E-04 Ankylosing spondylitis TMEM97 intron 22138694 rs3093720 chr17 26665768 C A 8.81E-04 Stroke TNFAIP1 intron pha002887 rs2234116 chr17 26667226 C T 2.00E-04 Gamma gluatamyl transferase levels (interaction with age) TNFAIP1 intron 22010049 rs17802736 chr17 26686445 A G 0.0000968 post-traumatic stress disorder TMEM199 intron 22869035 rs17802736 chr17 26686445 A G 9.68E-05 Schizophrenia TMEM199 intron 22883433 rs2071379 chr17 26695832 A G 3.24E-04 Amyotrophic lateral sclerosis (sporadic) VTN intron 24529757 rs35714695 chr17 26719788 G A 3.21E-07 Amyotrophic lateral sclerosis (sporadic) SARM1 intron 24256812 rs739439 chr17 26723822 C T 3.97E-07 Amyotrophic lateral sclerosis (sporadic) SARM1 UTR-3 24256812 rs2239908 chr17 26725265 G A 6.80E-05 Ankylosing spondylitis SARM1 UTR-3 22138694 rs11080058 chr17 26742060 G A 2.67E-04 Blood pressure / / 17255346 rs11080058 chr17 26742060 G A 0.000222 Oxaliplatin induced neuropathy in response to colorectal cancer treatment / / 22310351 rs598858 chr17 26852685 A G 9.74E-06 Rheumatoid arthritis (ACPA-negative) FOXN1 intron 24532677 rs618791 chr17 26899502 T C 2.70E-05 Urinary metabolites / / 21572414 rs140829639 chr17 26940561 A G 0.00027 Breast cancer (ER positive) SGK494 missense 23555315 rs12602520 chr17 26955330 A C 8.14E-06 Coronary heart disease KIAA0100 missense pha003032 rs12601110 chr17 27035335 A G 8.64E-06 Coronary heart disease PROCA1 intron pha003032 rs3809797 chr17 27065211 T C 3.26E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) NEK8 cds-synon 24192120 rs4795456 chr17 27072463 G A 8.50E-04 Iris characteristics TRAF4 intron 21835309 rs4795456 chr17 27072463 G A 5.04E-13 Red blood cell traits TRAF4 intron 23222517 rs2070265 chr17 27075423 C T 7.00E-04 Gamma gluatamyl transferase levels (interaction with age) TRAF4 cds-synon 22010049 rs2070265 chr17 27075423 C T 5.08E-14 Red blood cell traits TRAF4 cds-synon 23222517 rs3181215 chr17 27077331 A G 7.58E-13 Red blood cell traits TRAF4 UTR-3 23222517 rs12325788 chr17 27080049 G A 3.83E-10 Red blood cell traits / / 23222517 rs568700395 chr17 27080049 G GA 3.83E-10 Red blood cell traits / / 23222517 rs58565441 chr17 27080049 G GA 3.83E-10 Red blood cell traits / / 23222517 rs4794836 chr17 27082710 C G 2.23E-13 Red blood cell traits / / 23222517 rs2043031 chr17 27085564 A G 2.64E-12 Red blood cell traits C17orf63 cds-synon 23222517 rs2043031 chr17 27085564 A G 3.65E-06 LDL lipoproteins C17orf63 cds-synon pha002902 rs4795457 chr17 27087929 C T 3.91E-11 Red blood cell traits C17orf63 intron 23222517 rs4795457 chr17 27087929 C T 3.28E-06 LDL lipoproteins C17orf63 intron pha002902 rs7215000 chr17 27088436 C T 1.20E-12 Red blood cell traits C17orf63 intron 23222517 rs7215310 chr17 27088626 C A 2.24E-13 Red blood cell traits C17orf63 intron 23222517 rs9905510 chr17 27092325 G A 2.40E-13 Red blood cell traits C17orf63 intron 23222517 rs9906213 chr17 27097589 A T 2.68E-12 Red blood cell traits C17orf63 intron 23222517 rs9908881 chr17 27100924 T A 9.17E-13 Red blood cell traits C17orf63 intron 23222517 rs9891925 chr17 27104540 A T 5.94E-12 Red blood cell traits C17orf63 intron 23222517 rs4795459 chr17 27113726 G C 3.72E-13 Red blood cell traits C17orf63 intron 23222517 rs12453504 chr17 27119524 C A 6.90E-04 Iris characteristics C17orf63 intron 21835309 rs12453504 chr17 27119524 C A 3.37E-13 Red blood cell traits C17orf63 intron 23222517 rs9890155 chr17 27125467 A G 1.03E-11 Red blood cell traits C17orf63 intron 23222517 rs4262997 chr17 27129562 A G 3.32E-12 Red blood cell traits C17orf63 intron 23222517 rs11658884 chr17 27132742 G A 3.29E-13 Red blood cell traits C17orf63 intron 23222517 rs2043032 chr17 27136692 A G 1.11E-12 Red blood cell traits C17orf63 intron 23222517 rs2046759 chr17 27138817 T C 6.92E-13 Red blood cell traits C17orf63 intron 23222517 rs1035989 chr17 27143810 T G 7.39E-13 Red blood cell traits C17orf63 intron 23222517 rs8078402 chr17 27145124 T A 7.43E-13 Red blood cell traits C17orf63 intron 23222517 rs4795463 chr17 27146389 G C 7.49E-13 Red blood cell traits C17orf63 intron 23222517 rs4795464 chr17 27146497 G C 7.32E-13 Red blood cell traits C17orf63 intron 23222517 rs9898892 chr17 27150750 T C 7.52E-13 Red blood cell traits C17orf63 intron 23222517 rs4795465 chr17 27151498 C T 2.80E-12 Red blood cell traits C17orf63 intron 23222517 rs9303621 chr17 27161138 A G 1.09E-10 Red blood cell traits C17orf63 intron 23222517 rs9303621 chr17 27161138 A G 2.84E-06 LDL lipoproteins C17orf63 intron pha002902 rs17721223 chr17 27166706 A T 1.14E-07 Red blood cell traits C17orf63 intron 23222517 rs11652272 chr17 27167973 C G 8.31E-12 Red blood cell traits C17orf63 intron 23222517 rs9892942 chr17 27178761 C T 3.89E-12 Red blood cell traits / / 23222517 rs9895443 chr17 27182944 G A 1.37E-12 Red blood cell traits ERAL1 intron 23222517 rs9914988 chr17 27183104 G A 4.00E-12 Red blood cell traits ERAL1 intron 23222517 rs2242345 chr17 27185827 C T 4.00E-04 Iris characteristics ERAL1 cds-synon 21835309 rs2242345 chr17 27185827 C T 2.14E-13 Red blood cell traits ERAL1 cds-synon 23222517 rs6803 chr17 27187789 C T 4.61E-13 Red blood cell traits ERAL1 UTR-3 23222517 rs901975 chr17 27189774 A G 5.44E-13 Red blood cell traits / / 23222517 rs968726 chr17 27194634 C T 3.77E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7221773 chr17 27202888 G A 0.000787 Salmonella-induced pyroptosis / / 22837397 rs7221773 chr17 27202888 G A 2.55E-12 Red blood cell traits / / 23222517 rs4795474 chr17 27228198 G A 1.42E-08 Red blood cell traits DHRS13 cds-synon 23222517 rs2277665 chr17 27238075 G A 1.07E-05 Acne (severe teenage) PHF12 intron 24114350 rs4795475 chr17 27239376 G C 3.51E-09 Red blood cell traits PHF12 UTR-3 23222517 rs8066347 chr17 27244473 G A 9.64E-12 Red blood cell traits PHF12 intron 23222517 rs11652544 chr17 27252989 C T 1.51E-10 Red blood cell traits PHF12 intron 23222517 rs11655019 chr17 27255191 T C 1.40E-11 Red blood cell traits PHF12 intron 23222517 rs4795476 chr17 27257478 G C 1.27E-05 Acne (severe teenage) PHF12 intron 24114350 rs17794628 chr17 27260145 C T 8.97E-07 Red blood cell traits PHF12 intron 23222517 rs6505098 chr17 27260656 C A 4.00E-08 Red blood cell traits PHF12 intron 23222517 rs1806982 chr17 27266143 G A 1.11E-08 Red blood cell traits PHF12 intron 23222517 rs731970 chr17 27266440 C T 6.50E-08 Red blood cell traits PHF12 intron 23222517 rs12948391 chr17 27275621 T C 1.35E-08 Red blood cell traits PHF12 intron 23222517 rs12941884 chr17 27284443 A G 6.34E-08 Red blood cell traits SEZ6 missense 23222517 rs2277664 chr17 27286662 C G 9.56E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SEZ6 intron 21844884 rs2277664 chr17 27286662 C G 9.97E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SEZ6 intron 21844884 rs2277664 chr17 27286662 C G 3.47E-08 Red blood cell traits SEZ6 intron 23222517 rs4794842 chr17 27290751 G T 4.28E-07 Red blood cell traits SEZ6 intron 23222517 rs12453166 chr17 27298709 A G 2.87E-07 Red blood cell traits SEZ6 intron 23222517 rs1873477 chr17 27311532 A G 2.14E-07 Red blood cell traits SEZ6 intron 23222517 rs12451955 chr17 27314224 A G 1.99E-08 Red blood cell traits SEZ6 intron 23222517 rs9898529 chr17 27318861 A T 3.17E-08 Red blood cell traits SEZ6 intron 23222517 rs11080075 chr17 27322441 G T 4.88E-08 Red blood cell traits SEZ6 intron 23222517 rs12943420 chr17 27397974 G A 3.86E-04 Multiple complex diseases / / 17554300 rs4795495 chr17 27413908 C G 7.38E-04 Suicide attempts in bipolar disorder MYO18A intron 21041247 rs115455253 chr17 27417925 C T 0.000093 Breast cancer(er negative) MYO18A missense 23555315 rs4965417 chr17 27418106 C T 7.42E-04 Suicide attempts in bipolar disorder MYO18A intron 21041247 rs7212295 chr17 27431425 A G 1.11E-04 Multiple complex diseases MYO18A intron 17554300 rs7212295 chr17 27431425 A G 9.42E-06 Alcohol dependence MYO18A intron 23089632 rs12601535 chr17 27441077 C G 1.89E-05 Multiple complex diseases MYO18A cds-synon 17554300 rs882729 chr17 27449976 T C 6.34E-04 Suicide attempts in bipolar disorder MYO18A intron 21041247 rs7219630 chr17 27450429 A G 6.30E-04 Suicide attempts in bipolar disorder MYO18A intron 21041247 rs9896721 chr17 27463464 T C 4.29E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MYO18A intron 22566498 rs1388175 chr17 27464016 A C 5.60E-04 Suicide attempts in bipolar disorder MYO18A intron 21041247 rs8067041 chr17 27471953 G A 3.30E-04 Smoking cessation MYO18A intron 24665060 rs12452739 chr17 27472243 G A 6.28E-04 Suicide attempts in bipolar disorder MYO18A intron 21041247 rs12949480 chr17 27477038 G A 8.24E-04 Smoking cessation MYO18A intron 24665060 rs902580 chr17 27486259 C A 2.98E-04 Suicide attempts in bipolar disorder MYO18A intron 21041247 rs11650603 chr17 27492042 C T 7.98E-05 Type 2 diabetes MYO18A intron 17463246 rs6505114 chr17 27499140 G A 6.74E-04 Multiple complex diseases MYO18A intron 17554300 rs6505114 chr17 27499140 G A 3.14E-04 Suicide attempts in bipolar disorder MYO18A intron 21041247 rs9906043 chr17 27504921 G A 5.38E-05 Smoking cessation MYO18A intron 24665060 rs8080958 chr17 27508704 T A 3.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs16963476 chr17 27521476 C T 1.99E-04 Type 2 diabetes / / 17463246 rs4965978 chr17 27524242 T C 2.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs9897342 chr17 27524501 C A 1.59E-04 Smoking cessation / / 24665060 rs7213514 chr17 27537242 C T 1.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs727999 chr17 27546630 A G 3.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs9900880 chr17 27549806 A G 3.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs9303624 chr17 27562990 T C 5.32E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs16964930 chr17 27568512 C T 7.36E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11653144 chr17 27675226 C T 8.54E-05 Caffeine consumption / / 21490707 rs11653144 chr17 27675226 C T 4.00E-08 Mean platelet volume / / 22423221 rs2138852 chr17 27703349 C T 7.00E-28 Mean platelet volume / / 19110211 rs2138852 chr17 27703349 C T 1.00E-22 Mean platelet volume / / 19820697 rs2138852 chr17 27703349 C T 1.40E-22 Mean platelet volume / / 22423221 rs8076739 chr17 27714587 C T 5.00E-38 Mean platelet volume / / 22139419 rs8076739 chr17 27714587 C T 1.00E-10 Mean platelet volume / / 24026423 rs7213208 chr17 27732869 A G 1.30E-07 Mean platelet volume TAOK1 intron 22423221 rs7208363 chr17 27733408 A T 5.31E-07 Mean platelet volume TAOK1 intron 22423221 rs883828 chr17 27753846 C A 2.61E-05 Caffeine consumption TAOK1 intron 21490707 rs11655000 chr17 27767343 T C 6.33E-06 Mean platelet volume TAOK1 intron 22423221 rs9900280 chr17 27769598 G A 1.37E-06 Mean platelet volume TAOK1 intron 22423221 rs9900280 chr17 27769598 G A 1.00E-10 Mean platelet volume TAOK1 intron 24026423 rs7217677 chr17 27775667 C A 2.53E-05 Caffeine consumption TAOK1 intron 21490707 rs559972 chr17 27814496 C T 3.00E-18 Platelet counts TAOK1 intron 22139419 rs12943131 chr17 27863706 A G 1.04E-06 Mean platelet volume TAOK1 intron 22423221 rs3110496 chr17 27917771 A G 6.85E-04 Bipolar disorder,schizoaffective / / 19567891 rs3110496 chr17 27917771 A G 7.00E-09 Height / / 20881960 rs3809789 chr17 27955761 G A 7.38E-04 Type 2 diabetes SSH2 UTR-3 17463246 rs3809789 chr17 27955761 G A 6.76E-05 Multiple complex diseases SSH2 UTR-3 17554300 rs140696098 chr17 27959223 C G 0.00001 Breast cancer(er negative) SSH2 missense 23555315 rs4794859 chr17 27962393 T G 2.25E-04 Multiple complex diseases SSH2 intron 17554300 rs4794859 chr17 27962393 T G 5.97E-05 Cognitive impairment induced by topiramate SSH2 intron 22091778 rs3098949 chr17 27978694 C T 8.47E-04 Multiple complex diseases SSH2 intron 17554300 rs2617875 chr17 28090024 T G 4.83E-04 Multiple complex diseases SSH2 intron 17554300 rs185083507 chr17 28295809 A G 0.00021 Breast cancer (ER positive) EFCAB5 missense 23555315 rs9897794 chr17 28296327 T G 1.66E-05 Psoriasis EFCAB5 missense 20953190 rs9902453 chr17 28349095 G A 9.78E-05 Serum metabolites EFCAB5 intron 19043545 rs12941382 chr17 28410124 T C 2.19E-05 Psoriasis EFCAB5 intron 20953190 rs12948898 chr17 28410324 G A 1.93E-05 Psoriasis EFCAB5 intron 20953190 rs4470197 chr17 28464474 T C 8.10E-06 Bone mineral density NSRP1 intron 21927923 rs11544945 chr17 28505174 A C 3.26E-04 Hearing function NSRP1 missense 17255346 rs529910751 chr17 28548588 A C 1 Drug response to Fluoxetine / / 10481059 rs529910751 chr17 28548588 A C 1 Drug response to Fluvoxamine / / 10481059 rs529910751 chr17 28548588 A C 1 Drug response to Paroxetine / / 10481059 rs529910751 chr17 28548588 A C 1 Drug response to Fluoxetine / / 10611371 rs529910751 chr17 28548588 A C 1 Drug response to Fluvoxamine / / 10611371 rs529910751 chr17 28548588 A C 1 Drug response to Paroxetine / / 10611371 rs529910751 chr17 28548588 A C 1 Drug response to Fluoxetine / / 10683861 rs529910751 chr17 28548588 A C 1 Drug response to Fluvoxamine / / 10683861 rs529910751 chr17 28548588 A C 1 Drug response to Paroxetine / / 10683861 rs529910751 chr17 28548588 A C 1 Drug response to Fluoxetine / / 12374640 rs529910751 chr17 28548588 A C 1 Drug response to Fluvoxamine / / 12374640 rs529910751 chr17 28548588 A C 1 Drug response to Paroxetine / / 12374640 rs529910751 chr17 28548588 A C 1 Drug response to Fluoxetine / / 18253134 rs529910751 chr17 28548588 A C 1 Drug response to Fluvoxamine / / 18253134 rs529910751 chr17 28548588 A C 1 Drug response to Paroxetine / / 18253134 rs7212502 chr17 28549202 A G 0.000000148 Triglycerides SLC6A4 intron 23063622 rs7212502 chr17 28549202 A G 1.33E-08 HDL cholesterol SLC6A4 intron 23063622 rs16965623 chr17 28552986 A G 1.75E-05 Multiple complex diseases SLC6A4 intron 17554300 rs25531 chr17 28564346 T C 1 Drug response to Citalopram SLC6A4 nearGene-5 18618621 rs4795541 chr17 28564359 G GA,GG 1 Drug response to Escitalopram SLC6A4 nearGene-5 19272758 rs1050565 chr17 28576076 T C 1 Drug response to Bleomycin BLMH missense 18398146 rs16965645 chr17 28579270 A G 1.53E-22 Narcolepsy BLMH intron 19629137 rs3110093 chr17 28661392 A G 0.0000009 Asthma (exacerbation) / / 23706709 rs8071110 chr17 28672885 A G 7.90E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs917631 chr17 28699529 C T 2.66E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9913111 chr17 28709886 G A 2.66E-04 Response to cytadine analogues (cytosine arabinoside) CPD intron 24483146 rs11080125 chr17 28713726 T G 4.12E-04 Response to cytadine analogues (cytosine arabinoside) CPD intron 24483146 rs3794794 chr17 28720741 A C 3.61E-05 Response to cytadine analogues (cytosine arabinoside) CPD intron 24483146 rs12453652 chr17 28730860 C T 2.66E-04 Response to cytadine analogues (cytosine arabinoside) CPD intron 24483146 rs17731038 chr17 28756149 T G 5.29E-04 Response to cytadine analogues (cytosine arabinoside) CPD intron 24483146 rs2191351 chr17 28759035 T C 8.80E-04 Response to cytadine analogues (cytosine arabinoside) CPD intron 24483146 rs9916242 chr17 28764151 G A 2.83E-04 Response to cytadine analogues (cytosine arabinoside) CPD intron 24483146 rs9911455 chr17 28788586 G A 2.66E-04 Response to cytadine analogues (cytosine arabinoside) CPD intron 24483146 rs11651814 chr17 28798645 T C 2.66E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs917629 chr17 28800352 G A 1.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9303633 chr17 28807450 A G 3.16E-04 Response to cytadine analogues (cytosine arabinoside) GOSR1 intron 24483146 rs10512432 chr17 28812120 G A 4.19E-04 Rheumatoid arthritis GOSR1 intron 21452313 rs4795555 chr17 28824495 C T 2.82E-05 Response to cytadine analogues (cytosine arabinoside) GOSR1 intron 24483146 rs4795556 chr17 28836574 G T 4.06E-05 Response to cytadine analogues (cytosine arabinoside) GOSR1 intron 24483146 rs3829594 chr17 28842538 C A 3.82E-04 Response to cytadine analogues (cytosine arabinoside) GOSR1 intron 24483146 rs216463 chr17 28853530 A C 4.32E-05 Response to cytadine analogues (cytosine arabinoside) GOSR1 UTR-3 24483146 rs216465 chr17 28856675 T G 2.76E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs141108 chr17 28862034 G A,C,T 8.98E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs216468 chr17 28862408 T C 5.66E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs216469 chr17 28862979 T C 6.94E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs216478 chr17 28867035 A G 5.43E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs216481 chr17 28869069 G A 1.30E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs216483 chr17 28870727 C T 7.59E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs216485 chr17 28872625 T A 4.66E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs216451 chr17 28879935 G A 8.08E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17606460 chr17 28899024 C T 7.52E-04 Multiple complex diseases / / 17554300 rs7209032 chr17 29019731 T C 8.95E-05 Major depressive disorder / / 19107115 rs7503542 chr17 29073830 A C 2.00E-04 Information processing speed SUZ12P intron 21130836 rs11658027 chr17 29094882 G A 4.25E-04 Type 2 diabetes SUZ12P intron 17463246 rs11656419 chr17 29096821 A G 2.00E-04 Information processing speed SUZ12P intron 21130836 rs9895785 chr17 29107708 T C 2.00E-04 Information processing speed / / 21130836 rs1061342 chr17 29114463 G A 2.00E-04 Information processing speed CRLF3 intron 21130836 rs9915139 chr17 29158515 A G 5.94E-04 Type 2 diabetes / / 17463246 rs3816780 chr17 29161358 C T 2.10E-05 Urinary metabolites ATAD5 missense 21572414 rs3764419 chr17 29164023 C A 2.00E-21 Height ATAD5 intron 20881960 rs3764419 chr17 29164023 C A 9.00E-14 Height ATAD5 intron 23563607 rs3760318 chr17 29247715 G A 2.00E-09 Height / / 18391951 rs3760318 chr17 29247715 G A 3.49E-05 Height / / 19570815 rs7225461 chr17 29259899 G A 5.53E-04 Multiple complex diseases ADAP2 intron 17554300 rs17826255 chr17 29333516 T C 8.00E-09 Myopia (pathological) LOC646021 intron 23049088 rs8067737 chr17 29349688 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC400590 intron 22628534 rs9892839 chr17 29618990 A G 6.80E-05 Blood Pressure NF1 intron pha003039 rs7503922 chr17 29641935 C A 1.61E-04 Parkinson's disease NF1 intron 17052657 rs9894648 chr17 29653293 T C 3.74E-04 Parkinson's disease NF1 intron 17052657 rs3815154 chr17 29654974 G A 2.55E-04 Parkinson's disease NF1 intron 17052657 rs2854308 chr17 29666539 A G 2.10E-04 Parkinson's disease NF1 intron 17052657 rs2525569 chr17 29675971 T A 1.72E-04 Parkinson's disease NF1 intron 17052657 rs2525570 chr17 29681245 A G 4.26E-04 Parkinson's disease NF1 intron 17052657 rs2525570 chr17 29681245 A G 0.0000115 Migraine NF1 intron 22678113 rs2525570 chr17 29681245 A G 1.15E-05 Migraine NF1 intron 22683712 rs7350943 chr17 29684553 C T 2.04E-04 Parkinson's disease NF1 intron 17052657 rs1048317 chr17 29704002 T C 2.98E-04 Parkinson's disease NF1 UTR-3 17052657 rs2525574 chr17 29705947 T C 2.16E-04 Parkinson's disease / / 17052657 rs2525574 chr17 29705947 T C 0.0001 Migraine / / 22678113 rs8065496 chr17 29720140 T C 2.23E-04 Parkinson's disease RAB11FIP4 intron 17052657 rs178858 chr17 29773751 G A 7.54E-05 Relative hand skill RAB11FIP4 intron 24068947 rs178862 chr17 29775014 G A 4.30E-05 Relative hand skill RAB11FIP4 intron 24068947 rs11868735 chr17 29796197 A G 1.24E-04 IgE levels RAB11FIP4 intron 17255346 rs178889 chr17 29796314 C T 8.31E-04 Suicide attempts in bipolar disorder RAB11FIP4 intron 21423239 rs178890 chr17 29796804 G A 4.96E-04 Suicide attempts in bipolar disorder RAB11FIP4 intron 21423239 rs12453770 chr17 29797211 C A 2.11E-04 IgE levels RAB11FIP4 intron 17255346 rs178892 chr17 29797333 C A 4.22E-04 Suicide attempts in bipolar disorder RAB11FIP4 intron 21423239 rs178893 chr17 29797674 C G 2.44E-04 Suicide attempts in bipolar disorder RAB11FIP4 intron 21423239 rs11649754 chr17 29823165 T A 5.51E-04 Suicide attempts in bipolar disorder RAB11FIP4 intron 21423239 rs882544 chr17 29838277 A G 9.29E-04 Suicide attempts in bipolar disorder RAB11FIP4 intron 21423239 rs2343165 chr17 29870883 A G 2.13E-04 Taste perception / / 22132133 rs9908294 chr17 29884773 C T 9.83E-05 Waist Circumference / / pha003023 rs223128 chr17 29909428 G T 9.58E-05 Taste perception / / 22132133 rs3901745 chr17 29912081 A G 2.52E-05 Hypertension / / pha003041 rs315437 chr17 29983833 G C 1.71E-04 Attention deficit hyperactivity disorder / / pha002875 rs364465 chr17 30019279 A G 6.18E-05 Postoperative ventricular dysfunction / / 21980348 rs16966835 chr17 30036578 C T 1.60E-05 Urinary metabolites / / 21572414 rs9914500 chr17 30067427 T G 8.60E-04 Multiple complex diseases / / 17554300 rs7212433 chr17 30083687 T C 2.07E-07 Hearing function / / 21493956 rs9910565 chr17 30085200 A T 7.89E-04 Alcohol dependence / / 21314694 rs220457 chr17 30102635 C T 3.80E-04 Subclinical atherosclerosis / / 17903303 rs8082305 chr17 30106587 G A 7.77E-05 Nicotine smoking / / 19268276 rs9303646 chr17 30114207 C T 0.0008406 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9303646 chr17 30114207 C T 8.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9303646 chr17 30114207 C T 0.000279982 Primary sclerosing cholangitis / / 23603763 rs9903176 chr17 30114467 A C 0.0008466 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9903176 chr17 30114467 A C 8.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12325969 chr17 30115169 G A 0.0004676 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12325969 chr17 30115169 G A 4.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs16966942 chr17 30120664 C T 8.54E-04 Coronary Artery Disease / / 17634449 rs1468263 chr17 30147884 A G 5.21E-05 Fibrinogen / / pha003068 rs6505265 chr17 30172580 G A 2.20E-05 Fibrinogen / / pha003068 rs2051810 chr17 30195841 C T 1.92E-05 Fibrinogen UTP6 intron pha003068 rs11658318 chr17 30206059 T C 1.94E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) UTP6 intron 23648065 rs17780086 chr17 30343282 G A 3.00E-08 Height / / 20881960 rs16972641 chr17 30344511 T C 2.53E-04 Multiple complex diseases / / 17554300 rs6505282 chr17 30480180 A G 3.30E-04 Multiple complex diseases RHOT1 intron 17554300 rs8076276 chr17 30502955 G A 4.01E-05 HIV-1 viral setpoint RHOT1 intron 22174851 rs6505290 chr17 30531097 C G 6.35E-04 Multiple complex diseases RHOT1 intron 17554300 rs17780304 chr17 30535856 G A 6.00E-06 Obesity-related traits RHOT1 intron 23251661 rs894723 chr17 30584017 T C 7.82E-05 HDL cholesterol / / pha003074 rs116861917 chr17 30596472 C T 0.00007637 Sarcoidosis RHBDL3 intron 22952805 rs12950671 chr17 30612520 A G 0.00029119 Hypertension (early onset hypertension) RHBDL3 intron 22479346 rs8073013 chr17 30635730 A G 1.57E-05 Gallstones RHBDL3 intron 17632509 rs8069673 chr17 30661250 A G 2.30E-05 Urinary metabolites C17orf75 intron 21572414 rs9901737 chr17 30681354 G C 7.33E-11 Lymphocyte counts ZNF207 intron 22286170 rs11080180 chr17 30682998 G A 6.42E-04 Smoking initiation ZNF207 intron 24665060 rs3795244 chr17 30692396 G T 0.000003 Pancreatic cancer and survival ZNF207 missense 22665904 rs11653160 chr17 30717222 A G 7.19E-04 Smoking initiation / / 24665060 rs11656289 chr17 30761160 T C 4.88E-04 Smoking initiation / / 24665060 rs8078837 chr17 30763537 A G 4.60E-04 Smoking initiation / / 24665060 rs9916114 chr17 30766950 T C 8.20E-05 Parkinson's disease (age of onset) / / 19772629 rs9910731 chr17 30784034 A G 9.78E-05 Serum metabolites PSMD11 intron 19043545 rs4132610 chr17 30801441 C T 6.10E-05 Coronary heart disease PSMD11 intron 21966275 rs4523973 chr17 30809455 G A 5.32E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs756785 chr17 30812845 T C 5.41E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs2285428 chr17 30820176 T C 9.58E-05 Serum metabolites / / 19043545 rs2285428 chr17 30820176 T C 5.41E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs4287613 chr17 30827688 C T 2.01E-04 Smoking initiation MYO1D intron 24665060 rs1018866 chr17 30829664 T G 7.60E-05 Lymphocyte counts MYO1D intron 22286170 rs1018866 chr17 30829664 T G 3.33E-04 Smoking initiation MYO1D intron 24665060 rs1989805 chr17 30873862 T C 9.80E-05 Sarcoidosis MYO1D intron 19165924 rs225190 chr17 30877658 C T 6.00E-06 Pancreatic cancer MYO1D intron 20686608 rs225188 chr17 30878170 G A 2.33E-04 Sarcoidosis MYO1D intron 19165924 rs225184 chr17 30882127 T C 4.26E-04 Amyotrophic Lateral Sclerosis MYO1D intron 17827064 rs11657700 chr17 30893571 G A 5.48E-06 Tuberculosis MYO1D intron 22306650 rs225206 chr17 30894372 T G 1.38E-04 Sarcoidosis MYO1D intron 19165924 rs225206 chr17 30894372 T G 2.99E-05 Pulmonary function MYO1D intron 19300500 rs225207 chr17 30894724 T A 4.90E-05 Pulmonary function MYO1D intron 23932459 rs225212 chr17 30896455 C T 5.00E-06 Hypertension risk in short sleep duration MYO1D intron 22322875 rs7225669 chr17 30906715 C T 1.40E-05 Urinary metabolites MYO1D intron 21572414 rs2157841 chr17 30915202 T C 7.10E-05 Height MYO1D intron pha003010 rs2052413 chr17 30936838 A G 5.16E-05 Magnesium levels MYO1D intron pha003092 rs17780520 chr17 30938991 T C 2.09E-04 Coronary Artery Disease MYO1D intron 17634449 rs35262048 chr17 30939145 G T 1.76E-04 Coronary Artery Disease MYO1D intron 17634449 rs7215958 chr17 30986166 C T 3.82E-04 Multiple complex diseases MYO1D missense 17554300 rs2729352 chr17 31013088 C T 4.31E-04 Type 2 diabetes MYO1D intron 17463246 rs17183295 chr17 31078272 C T 1.00E-10 Refractive error MYO1D intron 23396134 rs7216206 chr17 31170399 C T 0.0000058 Mean arterial pressure MYO1D intron 22510845 rs2470209 chr17 31239329 G A 1.90E-04 Subclinical atherosclerosis / / 17903303 rs10512441 chr17 31239645 C T 0.00000077 Myopia (Age of onset) / / 23468642 rs9904938 chr17 31301478 C T 3.40E-05 Bipolar disorder / / 19488044 rs9904938 chr17 31301478 C T 7.03E-05 Bipolar Disorder / / pha002863 rs16967818 chr17 31317698 A G 4.91E-04 Taste perception / / 22132133 rs16967818 chr17 31317698 A G 2.02E-04 Lymphocyte counts / / 22286170 rs1859078 chr17 31318492 A C 7.05E-05 Body mass index / / 17255346 rs34889454 chr17 31318547 TA T 1.67E-05 Body mass index / / 17255346 rs34889454 chr17 31318547 TA T 2.36E-05 Multiple sclerosis / / 17660530 rs5820007 chr17 31318547 T C 1.67E-05 Body mass index / / 17255346 rs5820007 chr17 31318547 T C 2.36E-05 Multiple sclerosis / / 17660530 rs4999077 chr17 31318829 C T 5.91E-05 Body mass index / / 17255346 rs4999077 chr17 31318829 C T 7.98E-05 Multiple sclerosis / / 17660530 rs2188953 chr17 31319024 A C 3.35E-04 Taste perception SPACA3 intron 22132133 rs2188952 chr17 31319092 T G 4.22E-05 Taste perception SPACA3 intron 22132133 rs28964 chr17 31322254 A G 6.82E-05 Potassium levels SPACA3 intron pha003086 rs16963742 chr17 31328812 G A 1.80E-04 Height / / 17255346 rs7226216 chr17 31329911 G A 3.88E-04 Sudden cardiac arrest / / 21658281 rs28929 chr17 31342949 A G 0.000046 Mean arterial pressure ASIC2 intron 22510845 rs8074010 chr17 31358083 A G 5.35E-04 Schizophrenia ASIC2 intron 19197363 rs16561 chr17 31365752 C T 6.68E-05 HIV-1 viral setpoint ASIC2 intron 22174851 rs4795735 chr17 31371868 G A 3.54E-06 Obesity-related traits ASIC2 intron 23251661 rs11654976 chr17 31375354 C T 6.65E-06 Obesity-related traits ASIC2 intron 23251661 rs17808461 chr17 31393702 C T 4.00E-06 Obesity-related traits ASIC2 intron 23251661 rs7224279 chr17 31450715 C T 3.51E-04 Alzheimer's disease (late onset) ASIC2 intron 21379329 rs7207422 chr17 31454388 A G 2.06E-04 Longevity ASIC2 intron 22279548 rs4794940 chr17 31459920 T C 0.00043 Erectile dysfunction after radiotherapy for prostate cancer ASIC2 intron 23021708 rs11656076 chr17 31464270 G A 7.06E-04 Amyotrophic Lateral Sclerosis ASIC2 intron 17362836 rs7218135 chr17 31493343 G T 6.36E-04 Nicotine smoking ASIC2 intron 19268276 rs11652702 chr17 31516331 C T 1.25E-05 Body Mass Index ASIC2 intron pha003014 rs9899129 chr17 31536813 A G 7.80E-05 Diabetic retinopathy ASIC2 intron 21441570 rs2173191 chr17 31537651 G A 1.10E-05 Urinary metabolites ASIC2 intron 21572414 rs12952455 chr17 31558579 G A 1.87E-05 Longevity ASIC2 intron 20304771 rs9972933 chr17 31565268 C T 1.10E-05 Longevity ASIC2 intron 20304771 rs9972931 chr17 31565776 G A 1.25E-05 Longevity ASIC2 intron 20304771 rs319750 chr17 31571877 C T 1.90E-05 Urinary metabolites ASIC2 intron 21572414 rs4795754 chr17 31575175 A G 0.000300933 Hypertension (early onset hypertension) ASIC2 intron 22479346 rs1995100 chr17 31582721 G A 3.31E-05 Aging (time to event) ASIC2 intron 21782286 rs880305 chr17 31587907 G A 1.37E-04 HIV-1 viral setpoint ASIC2 intron 17641165 rs12952139 chr17 31590833 T C 4.80E-05 Serum metabolites ASIC2 intron 19043545 rs1532457 chr17 31607870 G A 2.19E-04 Alzheimer's disease ASIC2 intron 17998437 rs9891803 chr17 31609815 C T 8.38E-04 Response to taxane treatment (placlitaxel) ASIC2 intron 23006423 rs9915774 chr17 31623326 G A 1.49E-04 Response to taxane treatment (placlitaxel) ASIC2 intron 23006423 rs2346689 chr17 31626855 G A 1.30E-05 Urinary metabolites ASIC2 intron 21572414 rs2346689 chr17 31626855 G A 8.09E-04 Response to taxane treatment (placlitaxel) ASIC2 intron 23006423 rs9303662 chr17 31633201 C T 3.11E-04 Response to taxane treatment (placlitaxel) ASIC2 intron 23006423 rs10432046 chr17 31636912 G T 5.98E-04 Response to taxane treatment (placlitaxel) ASIC2 intron 23006423 rs1391077 chr17 31639502 C T 5.82E-04 Response to taxane treatment (placlitaxel) ASIC2 intron 23006423 rs12449358 chr17 31647041 T A 8.81E-04 Response to taxane treatment (placlitaxel) ASIC2 intron 23006423 rs12449358 chr17 31647041 T A 6.65E-04 Smoking quantity ASIC2 intron 24665060 rs320629 chr17 31654683 C T 8.37E-04 Response to taxane treatment (placlitaxel) ASIC2 intron 23006423 rs1504575 chr17 31656804 A G 6.89E-04 Response to taxane treatment (placlitaxel) ASIC2 intron 23006423 rs63953 chr17 31657608 G A 8.50E-04 Suicide,with and without major depression ASIC2 intron 22059935 rs76604546 chr17 31659032 T A 0.0000718 post-traumatic stress disorder ASIC2 intron 22869035 rs76604546 chr17 31659032 T A 7.18E-05 Schizophrenia ASIC2 intron 22883433 rs320637 chr17 31665328 C T 9.24E-04 Response to taxane treatment (placlitaxel) ASIC2 intron 23006423 rs320637 chr17 31665328 C T 4.00E-06 Amyotrophic lateral sclerosis (sporadic) ASIC2 intron 24529757 rs2036537 chr17 31671470 A G 3.37E-05 Parent of origin effect on language impairment (paternal) ASIC2 intron 24571439 rs439783 chr17 31677160 T C 2.52E-05 Response to citalopram treatment ASIC2 intron 19846067 rs439783 chr17 31677160 T C 1.62E-05 Vaspin levels ASIC2 intron 22907691 rs7213724 chr17 31689057 T G 9.56E-05 Parent of origin effect on language impairment (paternal) ASIC2 intron 24571439 rs1007033 chr17 31695774 C T 3.00E-06 Soluble leptin receptor levels ASIC2 intron 20167575 rs7215745 chr17 31702422 G A 8.76E-04 Amyotrophic Lateral Sclerosis ASIC2 intron 17827064 rs8074678 chr17 31702697 A C 2.40E-05 Urinary metabolites ASIC2 intron 21572414 rs2347154 chr17 31703323 T C 2.50E-04 Alzheimer's disease ASIC2 intron 17998437 rs17184873 chr17 31706825 G A 6.68E-04 Amyotrophic Lateral Sclerosis ASIC2 intron 17827064 rs7207801 chr17 31709666 A G 2.86E-04 Type 2 diabetes ASIC2 intron 17463246 rs1021891 chr17 31710972 C T 8.94E-05 IgE levels in asthmatics (D.f. specific) ASIC2 intron 23967269 rs4353517 chr17 31724017 C A 3.16E-05 Bipolar disorder ASIC2 intron 19488044 rs4794947 chr17 31726011 C G 6.47E-06 Serum metabolites ASIC2 intron 19043545 rs16968296 chr17 31737034 A G 3.56E-04 Type 2 diabetes ASIC2 intron 17463246 rs1354492 chr17 31737421 T C 2.00E-06 vWF and FVIII levels ASIC2 intron 21810271 rs4795780 chr17 31744471 C T 1.03E-04 Telomere length ASIC2 intron 21573004 rs2036535 chr17 31751013 G A 4.07E-04 Nicotine smoking ASIC2 intron 19268276 rs1553497 chr17 31756983 T G 8.76E-04 Type 2 diabetes ASIC2 intron 17463246 rs1546350 chr17 31757511 G A,C,T 3.70E-05 Pericardial fat ASIC2 intron 22589742 rs7221119 chr17 31773278 A G 4.10E-05 Pericardial fat ASIC2 intron 22589742 rs1394384 chr17 31789043 T C 3.31E-04 Alzheimer's disease ASIC2 intron 22005930 rs952540 chr17 31789102 T C 1.74E-04 Substance dependence ASIC2 intron 21818250 rs7222281 chr17 31797152 C G 1.57E-04 Alzheimer's disease ASIC2 intron 22005930 rs1039577 chr17 31798725 C T 1.47E-04 Alzheimer's disease ASIC2 intron 22005930 rs4795795 chr17 31801544 C G 1.37E-04 Alzheimer's disease ASIC2 intron 22005930 rs4795797 chr17 31801767 T C 1.39E-04 Alzheimer's disease ASIC2 intron 22005930 rs883251 chr17 31806375 T A 1.50E-04 Alzheimer's disease ASIC2 intron 22005930 rs7218475 chr17 31807587 T C 1.52E-04 Alzheimer's disease ASIC2 intron 22005930 rs12453548 chr17 31809526 G A 5.67E-04 Stroke ASIC2 intron pha002887 rs12452051 chr17 31810323 A G 1.91E-04 Alzheimer's disease ASIC2 intron 22005930 rs11657396 chr17 31816537 T C 5.16E-05 Blood Pressure ASIC2 intron pha003048 rs4305127 chr17 31817874 C T 6.16E-05 Body Mass Index ASIC2 intron pha003006 rs4305127 chr17 31817874 C T 3.68E-05 Body Mass Index ASIC2 intron pha003014 rs4305127 chr17 31817874 C T 9.19E-05 Weight ASIC2 intron pha003026 rs9915613 chr17 31818362 A G 8.98E-04 Multiple complex diseases ASIC2 intron 17554300 rs7210939 chr17 31825761 T C 8.58E-05 HDL cholesterol ASIC2 intron pha003074 rs12942506 chr17 31826041 A C 6.51E-05 HDL cholesterol ASIC2 intron pha003074 rs1434586 chr17 31860912 A G 5.08E-05 C-Reactive Protein ASIC2 intron pha003070 rs9903859 chr17 31866067 G A 3.82E-05 Depression (quantitative trait) ASIC2 intron 23290196 rs8079016 chr17 31870759 C T 4.40E-05 Depression (quantitative trait) ASIC2 intron 23290196 rs6505350 chr17 31872753 C T 8.50E-04 Multiple complex diseases ASIC2 intron 17554300 rs4387635 chr17 31879841 C T 2.13E-04 Multiple complex diseases ASIC2 intron 17554300 rs9898999 chr17 31881235 C T 8.80E-05 Depression (quantitative trait) ASIC2 intron 23290196 rs12452350 chr17 31886384 A G 8.41E-05 Depression (quantitative trait) ASIC2 intron 23290196 rs2043475 chr17 31887161 C T 6.14E-05 Depression (quantitative trait) ASIC2 intron 23290196 rs6505358 chr17 31892814 C T 9.59E-04 Myopia (pathological) ASIC2 intron 21095009 rs4795810 chr17 31895361 A G 9.40E-04 Myopia (pathological) ASIC2 intron 21095009 rs12453488 chr17 31897097 G A 2.02E-05 Depression (quantitative trait) ASIC2 intron 23290196 rs12451111 chr17 31900951 C T 7.72E-06 Depression (quantitative trait) ASIC2 intron 23290196 rs12451588 chr17 31901142 C G 8.98E-06 Depression (quantitative trait) ASIC2 intron 23290196 rs12450179 chr17 31902993 A G 1.89E-04 Gallstones ASIC2 intron 17632509 rs12452510 chr17 31903957 T A 1.07E-05 Depression (quantitative trait) ASIC2 intron 23290196 rs12449501 chr17 31904005 G A 1.24E-05 Depression (quantitative trait) ASIC2 intron 23290196 rs12936007 chr17 31906785 A G 9.06E-04 Myopia (pathological) ASIC2 intron 21095009 rs12452091 chr17 31907134 C G 7.07E-06 Depression (quantitative trait) ASIC2 intron 23290196 rs2347548 chr17 31907726 G T 9.06E-04 Myopia (pathological) ASIC2 intron 21095009 rs8072065 chr17 31911597 A G 6.10E-06 Depression (quantitative trait) ASIC2 intron 23290196 rs10512448 chr17 31918339 T C 3.69E-11 Gout ASIC2 intron pha001406 rs9900677 chr17 31920154 A G 7.94E-06 Depression (quantitative trait) ASIC2 intron 23290196 rs7225564 chr17 31936471 C T 5.41E-04 Suicide attempts in bipolar disorder ASIC2 intron 21423239 rs12943567 chr17 31938138 T C 5.62E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) ASIC2 intron 23648065 rs1369108 chr17 31941707 C T 9.08E-04 Multiple complex diseases ASIC2 intron 17554300 rs1369108 chr17 31941707 C T 5.34E-04 Suicide attempts in bipolar disorder ASIC2 intron 21423239 rs1369106 chr17 31941957 G A 7.94E-04 Suicide attempts in bipolar disorder ASIC2 intron 21423239 rs12185231 chr17 31944004 A G 3.97E-04 Suicide attempts in bipolar disorder ASIC2 intron 21423239 rs12185267 chr17 31944022 G A 8.00E-04 Suicide attempts in bipolar disorder ASIC2 intron 21423239 rs4794966 chr17 31944898 G A 5.20E-04 Suicide attempts in bipolar disorder ASIC2 intron 21423239 rs977296 chr17 31944974 G A 9.37E-04 Suicide attempts in bipolar disorder ASIC2 intron 21423239 rs977295 chr17 31945074 A C 5.20E-04 Suicide attempts in bipolar disorder ASIC2 intron 21423239 rs874895 chr17 31945718 T C 5.41E-04 Suicide attempts in bipolar disorder ASIC2 intron 21423239 rs874894 chr17 31946328 C T 5.54E-04 Suicide attempts in bipolar disorder ASIC2 intron 21423239 rs9911526 chr17 31953738 A T 8.44E-04 Insulin resistance ASIC2 intron 21901158 rs17836884 chr17 31957151 T G 9.52E-05 Multiple complex diseases ASIC2 intron 17554300 rs7221246 chr17 31960248 C T 6.55E-04 Cognitive impairment induced by topiramate ASIC2 intron 22091778 rs9916566 chr17 31961191 C A 1.11E-04 Multiple complex diseases ASIC2 intron 17554300 rs9889413 chr17 31961386 C G 6.84E-05 Multiple complex diseases ASIC2 intron 17554300 rs1984634 chr17 31967460 C T 5.73E-05 Obesity (extreme) ASIC2 intron 21935397 rs1984634 chr17 31967460 C T 0.0000725 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ASIC2 intron 22628534 rs280039 chr17 31989230 C T 0.0000397 Panic disorder ASIC2 intron 23149450 rs280039 chr17 31989230 C T 3.97E-05 Serum tamsulosin hydrochloride concentration ASIC2 intron 23151678 rs8080289 chr17 32013645 C T 6.32E-04 Type 2 diabetes ASIC2 intron 17463246 rs10512451 chr17 32014117 G A 7.39E-04 Type 2 diabetes ASIC2 intron 17463246 rs7209819 chr17 32044278 A C 1.91E-05 Intracranial aneurysm ASIC2 intron 20613766 rs8067181 chr17 32058858 A G 5.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ASIC2 intron 20877124 rs17783280 chr17 32065023 A C 1.65E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) ASIC2 intron 22566498 rs8079764 chr17 32065055 C T 1.28E-04 Multiple complex diseases ASIC2 intron 17554300 rs10512453 chr17 32066000 G A 6.53E-04 Response to cytadine analogues (cytosine arabinoside) ASIC2 intron 24483146 rs9915369 chr17 32067142 T C 1.79E-06 Multiple complex diseases ASIC2 intron 17554300 rs748993 chr17 32101668 G T 9.80E-05 Cognitive function ASIC2 intron 24684796 rs12452755 chr17 32105243 A G 5.68E-04 Type 2 diabetes ASIC2 intron 17463246 rs9902172 chr17 32105308 C A 4.01E-04 Type 2 diabetes ASIC2 intron 17463246 rs11080234 chr17 32105321 A G 4.66E-04 Type 2 diabetes ASIC2 intron 17463246 rs9909514 chr17 32106107 C G 4.01E-04 Type 2 diabetes ASIC2 intron 17463246 rs1844739 chr17 32116396 C G 2.10E-05 Cognitive function ASIC2 intron 24684796 rs6505380 chr17 32134294 G A 4.00E-05 Cognitive function ASIC2 intron 24684796 rs8076171 chr17 32134418 G A 4.76E-06 Personality dimensions ASIC2 intron 23658558 rs7210618 chr17 32141417 C T 9.10E-05 Cognitive function ASIC2 intron 24684796 rs2881781 chr17 32157023 A G 6.92E-06 Personality dimensions ASIC2 intron 23658558 rs2881782 chr17 32159519 A C 0.000345725 Hypertension (early onset hypertension) ASIC2 intron 22479346 rs2881782 chr17 32159519 A C 9.96E-05 Leukocyte Counts ASIC2 intron pha003091 rs17783478 chr17 32160611 A G 7.60E-05 Serum metabolites ASIC2 intron 19043545 rs317326 chr17 32161502 C A 1.55E-04 Multiple complex diseases ASIC2 intron 17554300 rs183412 chr17 32164169 T C 5.28E-05 Orofacial clefts ASIC2 intron 22419666 rs317415 chr17 32181176 T C 8.85E-05 Aging (time to event) ASIC2 intron 21782286 rs317342 chr17 32186049 G A 3.78E-04 Cognitive impairment induced by topiramate ASIC2 intron 22091778 rs1548301 chr17 32191359 G A 1.00E-05 Urinary metabolites ASIC2 intron 21572414 rs17783671 chr17 32193700 C T 1.48E-05 Weight ASIC2 intron pha003026 rs7501817 chr17 32229537 G T 2.47E-05 Response to hepatitis C treatment ASIC2 intron 19684573 rs7501817 chr17 32229537 G T 8.29E-04 Oral cancers (chewing tobacco related) ASIC2 intron 22503698 rs4795837 chr17 32232555 C T 9.93E-04 Type 2 diabetes ASIC2 intron 17463246 rs444953 chr17 32236051 T C 8.26E-04 Cognitive impairment induced by topiramate ASIC2 intron 22091778 rs11869615 chr17 32245868 T C 0.000344 Common carotid artery thickness (average of near and far wall measures) ASIC2 intron 23487405 rs902557 chr17 32250107 C T 0.000237 Common carotid artery thickness (average of near and far wall measures) ASIC2 intron 23487405 rs17783797 chr17 32272785 A G 3.06E-04 Multiple complex diseases ASIC2 intron 17554300 rs1467841 chr17 32278930 T C 9.55E-04 Alzheimer's disease ASIC2 intron 22005930 rs4795840 chr17 32281724 T C 2.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ASIC2 intron 20877124 rs4795840 chr17 32281724 T C 9.95E-04 Alzheimer's disease ASIC2 intron 22005930 rs11650066 chr17 32287449 G A 6.00E-06 Coronary heart disease ASIC2 intron 21378988 rs9907580 chr17 32288468 T C 2.80E-04 Schizophrenia ASIC2 intron 19197363 rs9907580 chr17 32288468 T C 1.71E-10 Narcolepsy ASIC2 intron 19629137 rs902558 chr17 32300618 T C 4.28E-05 Type 2 diabetes ASIC2 intron 17463246 rs317331 chr17 32306252 C T 3.09E-04 Stroke ASIC2 intron pha002887 rs117364231 chr17 32306423 C T 1.00E-07 PR interval in Tripanosoma cruzi seropositivity ASIC2 intron 24324551 rs2785061 chr17 32307532 A C 5.60E-05 Type 2 diabetes ASIC2 intron 17463246 rs16969071 chr17 32312132 T C 7.70E-05 Bipolar disorder and schizophrenia ASIC2 intron 20889312 rs9912758 chr17 32315968 T A 7.66E-05 Bipolar disorder and schizophrenia ASIC2 intron 20889312 rs11869731 chr17 32338871 G C 4.72E-15 Response to lithium treatment in bipolar disorder ASIC2 intron 21961650 rs11869731 chr17 32338871 G C 6.00E-14 Response to lithium treatment in bipolar disorder ASIC2 intron 21961650 rs4451997 chr17 32353020 A G 3.28E-04 Cognitive impairment induced by topiramate ASIC2 intron 22091778 rs6505393 chr17 32375998 T C 7.79E-04 Multiple complex diseases ASIC2 intron 17554300 rs4795851 chr17 32384051 A G 9.78E-04 Suicide attempts in bipolar disorder ASIC2 intron 21423239 rs886358 chr17 32416459 G A 2.66E-04 Cognitive impairment induced by topiramate ASIC2 intron 22091778 rs116908816 chr17 32422699 G T 9.00E-06 QT interval in Tripanosoma cruzi seropositivity ASIC2 intron 24324551 rs2023867 chr17 32424019 A C 2.00E-04 Cognitive impairment induced by topiramate ASIC2 intron 22091778 rs9303674 chr17 32458849 C T 8.00E-06 Hypothyroidism ASIC2 intron 22493691 rs9901756 chr17 32464154 A C 7.00E-06 Hypothyroidism ASIC2 intron 22493691 rs8064367 chr17 32472860 T C 9.10E-04 Pulmonary function ASIC2 intron 23932459 rs2368697 chr17 32498200 G A 9.86E-05 Serum metabolites / / 19043545 rs2003533 chr17 32501774 G A 1.20E-05 Urinary metabolites / / 21572414 rs731971 chr17 32504904 T A 1.20E-05 Urinary metabolites / / 21572414 rs4794990 chr17 32505189 C T 7.70E-06 Urinary metabolites / / 21572414 rs7218501 chr17 32505722 C T 1.90E-05 Urinary metabolites / / 21572414 rs4328493 chr17 32509708 A G 0.000250098 Hypertension (early onset hypertension) / / 22479346 rs4794992 chr17 32518991 A G 4.09E-04 Tourette syndrome / / 22889924 rs8065802 chr17 32520761 T A 1.80E-05 Urinary metabolites / / 21572414 rs7207653 chr17 32526693 C A 1.40E-05 Urinary metabolites / / 21572414 rs1024612 chr17 32549356 A G 7.00E-04 Volumetric brain MRI / / 17903297 rs6505400 chr17 32556614 G A 1.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6505400 chr17 32556614 G A 2.34E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4795893 chr17 32574448 G A 7.10E-04 Alzheimer's disease / / 22005930 rs1860190 chr17 32576573 T A 6.75E-04 Multiple complex diseases / / 17554300 rs3917894 chr17 32585961 G A 8.25E-14 Multiple complex diseases / / 17554300 rs2530797 chr17 32586094 C T 1.75E-04 Multiple complex diseases / / 17554300 rs991804 chr17 32587725 C T 5.34E-07 Crohn's disease / / 18587394 rs3091315 chr17 32593665 A G 2.00E-13 Crohn's disease / / 21102463 rs3091316 chr17 32593974 G A 4.00E-08 Crohn's disease / / 22412388 rs3091316 chr17 32593974 G A 1.00E-26 Inflammatory bowel disease / / 23128233 rs8073784 chr17 32628336 A G 6.85E-05 Bipolar disorder / / 19259986 rs8073784 chr17 32628336 A G 2.39E-04 Coronary heart disease / / 21971053 rs8075846 chr17 32632483 C A,G,T 1.26E-04 Coronary heart disease / / 21971053 rs1431991 chr17 32682506 G A 1.97E-05 Serum metabolites / / 19043545 rs2072070 chr17 32686006 T C 6.01E-05 Serum metabolites / / 19043545 rs159316 chr17 32686210 T G 9.50E-04 Type 2 diabetes / / 23209189 rs138527286 chr17 32688826 T C 0.000041 Prostate cancer (non-advanced prostate cancer) CCL1 missense 23555315 rs138527286 chr17 32688826 T C 0.00016 Prostate cancer CCL1 missense 23555315 rs867132 chr17 32692533 T A 1.28E-04 Multiple complex diseases / / 17554300 rs12603353 chr17 32699625 G T 9.88E-04 Multiple complex diseases / / 17554300 rs9902407 chr17 32707556 A G 5.00E-04 Multiple complex diseases / / 17554300 rs212453 chr17 32715148 A G 5.48E-05 Rheumatoid arthritis / / 17804836 rs159258 chr17 32717213 C T 6.16E-05 Rheumatoid arthritis / / 17804836 rs212470 chr17 32724793 C T 1.13E-05 Rheumatoid arthritis / / 17804836 rs7207094 chr17 32725669 G A 2.72E-06 Phospholipid levels (plasma) / / 21829377 rs210837 chr17 32735169 A G 5.80E-05 Tooth agenesis (third molar) / / 24172245 rs886161 chr17 32747064 T C 1.82E-04 Birth weight / / 17255346 rs17661147 chr17 32753128 G A 2.13E-04 Birth weight / / 17255346 rs1367955 chr17 32797925 G T 1.69E-05 Lymphocyte counts / / pha003094 rs1367955 chr17 32797925 G T 5.19E-07 Neutrophil count / / pha003095 rs891754 chr17 32810443 A C 7.35E-05 Neutrophil count / / pha003095 rs295104 chr17 32814666 T C 7.42E-04 Multiple complex diseases / / 17554300 rs2436093 chr17 32817130 A G 8.51E-04 Aortic root size / / 21223598 rs213135 chr17 32822032 G A 7.88E-05 Cognitive impairment induced by topiramate / / 22091778 rs9889895 chr17 32822378 G A 7.08E-05 Insulin resistance / / 21901158 rs9889895 chr17 32822378 G A 7.51E-07 Blood pressure / / 21996601 rs16969946 chr17 32825261 C A 9.48E-04 Multiple complex diseases / / 17554300 rs2215229 chr17 32840110 T C 9.14E-04 Multiple complex diseases / / 17554300 rs1014023 chr17 32849529 G A 8.95E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11656710 chr17 32859091 G A 2.70E-06 Urinary metabolites / / 21572414 rs1860275 chr17 32860649 G A 7.21E-04 Alcohol dependence / / 24277619 rs17662217 chr17 32862190 T C 7.90E-07 Urinary metabolites / / 21572414 rs16970009 chr17 32862601 G A 1.50E-07 Urinary metabolites / / 21572414 rs990510 chr17 32869951 C A 2.84E-04 Alcohol dependence / / 24277619 rs12600895 chr17 32872853 G A 5.54E-05 Cognitive test performance / / 20125193 rs758411 chr17 32876946 A G 2.42E-04 Alcohol dependence / / 24277619 rs988199 chr17 32883256 G A 2.30E-05 Personality dimensions / / 18957941 rs988199 chr17 32883256 G A 7.06E-04 Alcohol dependence / / 24277619 rs7214380 chr17 32886639 A G 2.29E-05 Basophils / / pha003087 rs12944367 chr17 32893550 G T 0.0000138 Tuberculosis with late age of onset / / 22551897 rs17662779 chr17 32894147 G A 6.40E-05 Serum metabolites / / 19043545 rs7217712 chr17 32894641 G A 0.0000115 Tuberculosis with late age of onset / / 22551897 rs4795936 chr17 32903538 A G 4.65E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) C17orf102 UTR-3 24023788 rs11080287 chr17 32923347 G A 9.53E-05 Multiple complex diseases TMEM132E intron 17554300 rs1558207 chr17 32967784 A G 7.55E-05 Serum albumin level / / pha003084 rs16970117 chr17 32970842 T C 8.72E-05 Serum albumin level / / pha003084 rs4990638 chr17 32972729 T C 2.00E-06 Personality dimensions / / 23903073 rs4341789 chr17 32976304 T C 7.35E-05 Coronary heart disease / / pha003035 rs11650365 chr17 32977717 G A 4.71E-05 Orofacial clefts / / 22419666 rs11654964 chr17 32989538 A C 3.00E-06 Lobular breast cancer (menopausal hormone therapy interaction) / / 24080446 rs16970162 chr17 32989786 G C 8.60E-06 Lobular breast cancer (menopausal hormone therapy interaction) / / 24080446 rs11080292 chr17 32998577 C T 9.30E-06 Lobular breast cancer (menopausal hormone therapy interaction) / / 24080446 rs7502462 chr17 32999635 G A 5.58E-05 Cholesterol / / 17255346 rs7502462 chr17 32999635 G A 4.77E-05 Coronary heart disease / / pha003056 rs10491113 chr17 33004133 C T 9.90E-06 Bipolar disorder / / 18317468 rs4795972 chr17 33014996 A G 1.47E-04 Stroke / / pha002887 rs4795032 chr17 33026691 C T 2.93E-05 Systemic sclerosis / / 21750679 rs4795032 chr17 33026691 C T 1.90E-04 Stroke / / pha002886 rs1990264 chr17 33029570 A G 0.000439406 Hypertension (early onset hypertension) / / 22479346 rs1990264 chr17 33029570 A G 4.32E-04 Stroke / / pha002886 rs16970282 chr17 33032098 A C 3.35E-04 Alcohol dependence / / 21314694 rs16970311 chr17 33065601 C T 4.88E-04 Multiple complex diseases / / 17554300 rs8082524 chr17 33068380 G A 2.55E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs887081 chr17 33078110 T G 5.17E-05 Systemic sclerosis / / 21750679 rs730547 chr17 33112106 C T 1.00E-07 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2009052 chr17 33112848 A G 7.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16970398 chr17 33131734 G A 2.03E-05 Smoking behavior / / 19188921 rs17544975 chr17 33139508 G A 9.19E-05 Bipolar disorder / / 19488044 rs17544975 chr17 33139508 G A 3.93E-05 Bipolar disorder and schizophrenia / / 20889312 rs9675202 chr17 33161067 C T 5.74E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs192656758 chr17 33250888 C A 0.0000586 Menopause (age at onset) / / 23424626 rs35071763 chr17 33313129 C CG 0.000089 Prostate cancer (advanced) LIG3 missense 23555315 rs3744356 chr17 33313129 C T 0.000089 Prostate cancer (advanced) LIG3 missense 23555315 rs3135998 chr17 33322322 A G 2.14E-04 Lung function (forced vital capacity) LIG3 intron 24023788 rs2074518 chr17 33324382 C T 6.00E-12 QT interval LIG3 intron 19305408 rs2074517 chr17 33324678 T C 7.35E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) LIG3 intron 24192120 rs3744357 chr17 33334112 C T 5.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12940238 chr17 33365835 T C 1.55E-04 Multiple complex diseases RFFL intron 17554300 rs1634800 chr17 33383030 C T 3.94E-04 Tourette syndrome RFFL intron 22889924 rs797989 chr17 33414758 C A 1.08E-04 Tourette syndrome RFFL intron 22889924 rs4796032 chr17 33431561 C T 4.91E-04 Multiple complex diseases RAD51D intron 17554300 rs3816754 chr17 33433849 G T 8.36E-04 Longevity RAD51D intron 22279548 rs8075760 chr17 33440166 T C 1.41E-04 Multiple complex diseases RAD51D intron 17554300 rs17629188 chr17 33457028 G A 3.70E-04 Alcohol dependence FNDC8 intron 20201924 rs17629188 chr17 33457028 G A 9.08E-05 Cytomegalovirus antibody response FNDC8 intron 21993531 rs9893791 chr17 33470320 C G 0.000351 Salmonella-induced pyroptosis / / 22837397 rs4795065 chr17 33504809 C T 3.12E-04 Multiple complex diseases UNC45B intron 17554300 rs8076291 chr17 33507928 G A 6.68E-04 Multiple complex diseases UNC45B intron 17554300 rs9303683 chr17 33536170 G A 6.38E-05 Response to metformin / / 21186350 rs1383541 chr17 33539825 T C 8.67E-06 Response to metformin / / 21186350 rs7225419 chr17 33546469 T C 6.31E-05 Alzheimer's disease / / 17998437 rs17629798 chr17 33546932 T C 6.67E-04 Nicotine dependence / / 17158188 rs17629798 chr17 33546932 T C 5.99E-04 Multiple complex diseases / / 17554300 rs11080325 chr17 33563709 G A 7.66E-05 Response to metformin / / 21186350 rs11653010 chr17 33565349 A G 8.52E-05 Response to metformin / / 21186350 rs12601614 chr17 33574253 C T 2.23E-06 Lymphocyte counts SLFN5 intron 22286170 rs7222370 chr17 33584234 T G 8.10E-06 Urinary metabolites SLFN5 intron 21572414 rs899940 chr17 33586840 T G 8.60E-04 Alcohol dependence SLFN5 intron 20201924 rs2622524 chr17 33595842 T G 3.47E-05 Brain structure / / 22504417 rs9893542 chr17 33596090 T G 1.55E-04 Age-related macular degeneration / / 22125219 rs4795069 chr17 33609247 C A 2.60E-04 Suicidal ideation / / 22030708 rs11869751 chr17 33718177 C T 5.82E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2681072 chr17 33734417 C T 1.77E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12950933 chr17 33736590 T C 8.66E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1849733 chr17 33749919 A C 8.37E-05 Response to statin treatment (atorvastatin),change in cholesterol levels SLFN12 missense 20031582 rs7216096 chr17 33772954 G A 6.96E-04 Type 2 diabetes SLFN13 intron 17463246 rs7216096 chr17 33772954 G A 9.02E-05 Major depressive disorder SLFN13 intron 21621269 rs8069504 chr17 33774265 T C 2.78E-05 Postoperative ventricular dysfunction SLFN13 intron 21980348 rs11655913 chr17 33797665 T C 7.41E-04 Lymphocyte counts / / 22286170 rs17549947 chr17 33817688 C T 3.72E-04 Multiple complex diseases / / 17554300 rs8077695 chr17 33832591 T G 3.97E-04 Depression (quantitative trait) / / 20800221 rs8068906 chr17 33840265 A G 5.60E-04 Depression (quantitative trait) / / 20800221 rs8068353 chr17 33840295 C G 3.44E-06 Depression (quantitative trait) / / 20800221 rs8067329 chr17 33840328 G A 4.53E-04 Depression (quantitative trait) / / 20800221 rs6505478 chr17 33841044 C A 5.99E-04 Depression (quantitative trait) / / 20800221 rs12450474 chr17 33841737 C A 2.30E-04 Depression (quantitative trait) / / 20800221 rs34006651 chr17 33841737 CT C 2.30E-04 Depression (quantitative trait) / / 20800221 rs8070473 chr17 33843512 T G 2.00E-06 Depression (quantitative trait) LOC100652927 intron 20800221 rs8070473 chr17 33843512 T G 1.50E-06 Depression (quantitative trait) LOC100652927 intron 23290196 rs8066424 chr17 33843917 C T 1.81E-05 Depression (quantitative trait) LOC100652927 intron 20800221 rs4796093 chr17 33846604 G A 1.16E-05 Depression (quantitative trait) LOC100652927 intron 20800221 rs2376179 chr17 33847026 G A 7.38E-04 Depression (quantitative trait) LOC100652927 intron 20800221 rs7221507 chr17 33847808 C T 9.04E-04 Depression (quantitative trait) LOC100652927 intron 20800221 rs10512472 chr17 33884804 T C 2.00E-14 Platelet counts SLFN14 missense 22139419 rs2840044 chr17 33892068 A G 6.57E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs2840044 chr17 33892068 A G 7.90E-06 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs2840044 chr17 33892068 A G 8.00E-06 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs16971217 chr17 33944055 C G 4.00E-12 Mean platelet volume AP2B1 intron 22139419 rs9303690 chr17 34005513 C T 4.76E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) AP2B1 intron 24023788 rs1014161 chr17 34065695 C A,G,T 2.58E-04 Myocardial Infarction RASL10B intron pha002883 rs4251704 chr17 34135251 T C 2.90E-05 Urinary metabolites TAF15 nearGene-5 21572414 rs7209512 chr17 34144460 A G 9.30E-06 Iron levels TAF15 intron 21208937 rs4251737 chr17 34146818 C A 8.33E-05 Waist-Hip Ratio TAF15 intron pha003029 rs4239252 chr17 34163565 G A 2.46E-05 Glaucoma (primary open-angle) TAF15 intron 22605921 rs141245415 chr17 34191290 C T 0.000069 Breast cancer(er negative) C17orf66 missense 23555315 rs16971600 chr17 34196878 T C 7.57E-04 Type 2 diabetes / / 17463246 rs16971600 chr17 34196878 T C 2.10E-05 Iron levels / / 21208937 rs16971600 chr17 34196878 T C 0.00032 Coronary artery calcification / / 23727086 rs11653051 chr17 34236170 C T 8.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11653282 chr17 34236746 C T 6.69E-05 Cervical cancer / / 24700089 rs2526325 chr17 34247218 G A 3.82E-04 Aortic root size RDM1 cds-synon 21223598 rs865922 chr17 34291588 A C 1.99E-04 Myocardial Infarction / / pha002883 rs1635281 chr17 34296012 A G 3.41E-04 Myocardial Infarction / / pha002883 rs854683 chr17 34314007 G C 7.99E-04 Parkinson's disease CCL14-CCL15 intron 16252231 rs2293788 chr17 34328542 G A 2.94E-04 Suicide attempts in bipolar disorder CCL15 UTR-5 21423239 rs854664 chr17 34355778 A G 7.92E-04 Type 2 diabetes / / 17463246 rs712046 chr17 34358297 T C 3.00E-07 Pulmonary function / / 23932459 rs712046 chr17 34358297 T C 7.23E-05 Pulmonary function / / 23932459 rs854679 chr17 34358839 T G 3.40E-07 Pulmonary function / / 23932459 rs854679 chr17 34358839 T G 5.66E-05 Pulmonary function / / 23932459 rs854674 chr17 34359972 C T 6.80E-07 Pulmonary function / / 23932459 rs854674 chr17 34359972 C T 9.55E-05 Pulmonary function / / 23932459 rs9893947 chr17 34366549 C T 4.46E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs854636 chr17 34372818 G T 5.21E-04 Type 2 diabetes / / 17463246 rs1967293 chr17 34391274 A T 1.11E-04 Multiple complex diseases / / 17554300 rs2015070 chr17 34391783 C T 9.38E-05 Multiple complex diseases CCL18 intron 17554300 rs712043 chr17 34396667 C T 9.55E-04 Multiple complex diseases CCL18 intron 17554300 rs712044 chr17 34396784 A G 2.21E-04 Multiple complex diseases CCL18 intron 17554300 rs10491121 chr17 34430336 G A 3.20E-05 C-Reactive Protein / / pha003070 rs4796153 chr17 34443800 A C 8.14E-04 Type 2 diabetes / / 17463246 rs12945586 chr17 34446915 G A 7.37E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12939695 chr17 34447402 A G 1.60E-04 Type 2 diabetes / / 17463246 rs4500794 chr17 34464949 G A 4.89E-04 Weight loss (gastric bypass surgery) / / 23643386 rs4500794 chr17 34464949 G A 3.27E-05 Tunica Media / / pha003034 rs1015673 chr17 34477386 C T 1.37E-23 Macrophage inflammatory protein-1b / / 23696881 rs4796217 chr17 34819191 C T 4.00E-21 Protein quantitative trait loci / / 18464913 rs4796217 chr17 34819191 C T 1.09E-21 Macrophage inflammatory protein-1b / / 23696881 rs9906158 chr17 34824604 C T 1.32E-25 Narcolepsy / / 19629137 rs9900762 chr17 34824702 G T 5.99E-05 Multiple complex diseases / / 17554300 rs12601485 chr17 34824845 C T 6.00E-05 Parkinson's disease (age of onset) / / 19772629 rs1982737 chr17 34837642 G A 1.17E-04 Multiple complex diseases / / 17554300 rs8081787 chr17 34863110 T C 1.67E-04 Glycosylated haemoglobin levels MYO19 intron 17255346 rs11650008 chr17 34892731 C A 8.70E-04 Taste perception PIGW intron 22132133 rs1076184 chr17 34942750 T A 6.70E-04 Multiple complex diseases GGNBP2 intron 17554300 rs17619821 chr17 34944593 G A 3.77E-04 Lymphocyte counts GGNBP2 intron 22286170 rs875213 chr17 34955034 A G 1.35E-06 Diabetes Mellitus DHRS11 intron pha003059 rs17138323 chr17 34969300 C T 1.73E-04 Glycosylated haemoglobin levels / / 17255346 rs8071407 chr17 34975760 G C 1.17E-04 Coronary Artery Disease / / 17634449 rs17138297 chr17 34979921 G A 1.64E-04 IgE levels / / 17255346 rs757011 chr17 34985353 G T 6.85E-05 Type 2 diabetes / / 17463246 rs975577 chr17 34986640 A G 4.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10491120 chr17 34988444 A G 3.83E-04 Fibrinogen / / 17255346 rs10491120 chr17 34988444 A G 8.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10491120 chr17 34988444 A G 2.70E-05 Urinary metabolites / / 21572414 rs9889382 chr17 35018201 G A 0.0001 Migraine / / 22678113 rs4795139 chr17 35021190 A G 1.11E-04 Lung function (forced vital capacity) / / 24023788 rs4795139 chr17 35021190 A G 1.31E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs12600420 chr17 35048367 T C 4.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1899651 chr17 35055773 T C 6.51E-04 Type 2 diabetes / / 17463246 rs11650542 chr17 35056470 C T 4.40E-04 Type 2 diabetes / / 17463246 rs8079759 chr17 35057303 A C 7.47E-05 Panic disorder / / 19165232 rs6607337 chr17 35057373 T C 8.72E-04 Type 2 diabetes / / 17463246 rs2411182 chr17 35059718 G A 8.72E-04 Type 2 diabetes / / 17463246 rs2411180 chr17 35059989 A T 7.93E-04 Type 2 diabetes / / 17463246 rs8075696 chr17 35088930 T C 1.76E-04 Type 2 diabetes / / 17463246 rs1899655 chr17 35114791 A C 2.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs975683 chr17 35122227 T A 1.30E-04 Type 2 diabetes / / 17463246 rs1391008 chr17 35123256 C T 5.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs295886 chr17 35128715 C T 1.21E-06 Soluble levels of adhesion molecules / / pha003072 rs11652953 chr17 35130985 G A 4.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs11651588 chr17 35132006 T C 4.28E-04 Suicide attempts in bipolar disorder / / 21423239 rs11654377 chr17 35132347 G A 3.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs9902080 chr17 35132771 T G 3.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs11263794 chr17 35133475 G A 1.81E-04 Type 2 diabetes / / 17463246 rs11263794 chr17 35133475 G A 4.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs11263795 chr17 35133578 G A 2.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs9902774 chr17 35133721 A G 4.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs7359578 chr17 35134725 C T 1.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs12452614 chr17 35136530 C T 4.05E-04 Type 2 diabetes / / 17463246 rs12452614 chr17 35136530 C T 4.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs12452628 chr17 35136578 C G 9.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs11652880 chr17 35136847 G A 4.09E-04 Type 2 diabetes / / 17463246 rs11652880 chr17 35136847 G A 3.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs11263797 chr17 35137106 G C 6.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs295883 chr17 35137362 A C 9.85E-05 Serum metabolites / / 19043545 rs11868056 chr17 35137651 T C 8.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs12451962 chr17 35139899 T C 2.87E-05 Serum metabolites / / 19043545 rs8081743 chr17 35140439 A G 4.78E-05 Serum metabolites / / 19043545 rs8081743 chr17 35140439 A G 5.15E-05 Myopia (pathological) / / 23049088 rs8078886 chr17 35140892 C T 4.65E-05 Serum metabolites / / 19043545 rs9889984 chr17 35141150 G A 3.48E-05 Serum metabolites / / 19043545 rs9912522 chr17 35141462 C T 4.53E-05 Serum metabolites / / 19043545 rs12451831 chr17 35142244 C A 4.07E-05 Serum metabolites / / 19043545 rs7209658 chr17 35144946 G A 4.07E-05 Serum metabolites / / 19043545 rs295869 chr17 35147345 T C 6.86E-05 ldl cholesterol / / pha003076 rs8070114 chr17 35174912 A G 3.28E-05 Cognitive test performance / / 20125193 rs17138064 chr17 35189091 G A 8.80E-06 Central corneal thickness / / 20485516 rs17138064 chr17 35189091 G A 5.00E-07 Orofacial clefts / / 22419666 rs9889432 chr17 35214519 C A 9.15E-05 Schizophrenia / / 24253340 rs17565060 chr17 35227061 G T 1.73E-05 Height / / pha003011 rs11263804 chr17 35227612 G C 4.55E-05 Serum metabolites / / 19043545 rs7217173 chr17 35227901 C G 4.38E-04 Alzheimer's disease / / 24755620 rs10512480 chr17 35237981 A G 8.81E-04 Taste perception / / 22132133 rs13380844 chr17 35243142 C T 2.80E-05 Urinary metabolites / / 21572414 rs11655926 chr17 35243370 C T 3.28E-05 Height / / pha003011 rs12452370 chr17 35246564 T C 7.73E-05 Height / / pha003011 rs883286 chr17 35246805 G T 6.13E-05 Height / / pha003011 rs4795164 chr17 35249496 G C 8.23E-04 Lymphocyte counts / / 22286170 rs10512479 chr17 35249517 A C 9.32E-05 stroke (ischemic) / / 17434096 rs8082436 chr17 35250149 G A 4.41E-05 stroke (ischemic) / / 17434096 rs4795165 chr17 35259685 T C 6.14E-05 Blood Pressure / / pha003044 rs9901344 chr17 35281135 A G 1.97E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2306658 chr17 35306312 G C,T 2.00E-06 Obesity-related traits AATF UTR-5 23251661 rs2306658 chr17 35306312 G C,T 9.00E-06 Obesity-related traits AATF UTR-5 23251661 rs8077789 chr17 35309726 G C 2.73E-05 Height AATF intron 22021425 rs17651665 chr17 35345145 G A 8.43E-05 Neuroticism AATF intron 23229837 rs2301685 chr17 35378121 G A 4.94E-05 Neuroticism AATF intron 23229837 rs1266186 chr17 35425598 A G 2.76E-05 Height / / 22021425 rs1266180 chr17 35447268 T C 2.55E-04 Alzheimer's disease ACACA intron 24755620 rs1266182 chr17 35451367 T A 1.16E-04 Alzheimer's disease ACACA intron 24755620 rs1266175 chr17 35468050 A G 2.47E-04 Alzheimer's disease ACACA intron 24755620 rs12450937 chr17 35494511 T C 1.81E-04 Alzheimer's disease ACACA intron 24755620 rs7221404 chr17 35536842 T C 5.92E-04 Alzheimer's disease ACACA intron 24755620 rs2305098 chr17 35550416 A C,G,T 8.00E-07 Urinary metabolites ACACA intron 21572414 rs2590728 chr17 35592617 T A 1.10E-05 Urinary metabolites ACACA intron 21572414 rs17841479 chr17 35693858 G C 1.30E-06 Urinary metabolites ACACA intron 21572414 rs8081319 chr17 35731081 A G 8.00E-07 Celiac disease ACACA intron 24999842 rs8082190 chr17 35748867 C T 5.16E-05 Tuberculosis C17orf78 UTR-3 20694014 rs878520 chr17 35762107 G C 7.68E-05 Lymphocyte counts ACACA intron 22286170 rs7211875 chr17 35771468 C T 4.19E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TADA2A missense 24023788 rs2158239 chr17 35808558 G T 7.26E-04 Multiple complex diseases TADA2A intron 17554300 rs12938215 chr17 35813380 G A 6.24E-04 Coronary heart disease TADA2A intron 21606135 rs853231 chr17 35814383 G A 3.13E-05 Elbow pain TADA2A intron pha003008 rs853207 chr17 35825367 C T 9.40E-04 Multiple complex diseases TADA2A intron 17554300 rs2074412 chr17 35839066 C T 3.24E-05 Elbow pain / / pha003008 rs712039 chr17 35850553 C T 3.00E-06 Tuberculosis DUSP14 intron 20694014 rs712039 chr17 35850553 C T 1.25E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) DUSP14 intron 22566498 rs8064314 chr17 35858392 A G 6.69E-05 HIV-1 viral setpoint DUSP14 intron 22174851 rs12946892 chr17 35860991 A G 8.50E-05 Intelligence (childhood) DUSP14 intron 23358156 rs4794755 chr17 35866985 T C 1.66E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) DUSP14 intron 24023788 rs1016679 chr17 35874330 T A 8.95E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11868673 chr17 35877662 T A 4.05E-06 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNRG UTR-3 22566498 rs1045013 chr17 35878893 G A 6.70E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNRG UTR-3 22566498 rs12453417 chr17 35882154 A G 1.10E-05 Urinary metabolites SYNRG intron 21572414 rs1416 chr17 35894811 T C 2.02E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNRG intron 22566498 rs3110626 chr17 35896402 C T 2.00E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNRG intron 22566498 rs2074409 chr17 35898342 G T 2.00E-06 Response to angiotensin II receptor blocker therapy SYNRG intron 22566498 rs12942520 chr17 35947226 G T 8.41E-04 Depression (quantitative trait) SYNRG intron 20800221 rs8079671 chr17 35966977 G T 8.89E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) SYNRG intron 22566498 rs4795208 chr17 35970749 C T 8.45E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11651621 chr17 35999118 G A 5.53E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) DDX52 intron 22566498 rs11263754 chr17 36026022 T A 9.72E-04 Multiple complex diseases / / 17554300 rs6607284 chr17 36026335 C T 7.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs7211602 chr17 36026401 C A 7.92E-05 Bipolar disorder and schizophrenia / / 20889312 rs7211602 chr17 36026401 C A 5.50E-05 Lung adenocarcinoma / / 22797724 rs3110647 chr17 36034423 A G 6.44E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs3110647 chr17 36034423 A G 1.29E-05 Cholesterol / / pha003073 rs3110647 chr17 36034423 A G 1.88E-05 ldl cholesterol / / pha003076 rs3110647 chr17 36034423 A G 8.98E-06 Cholesterol / / pha003078 rs3094513 chr17 36048523 G A 8.05E-05 Femoral neck bone geometry HNF1B intron 22087292 rs3110640 chr17 36048823 A G 4.37E-04 Lung function (forced expiratory volume in 1 second) HNF1B intron 17255346 rs3110640 chr17 36048823 A G 2.35E-05 Podoconiosis HNF1B intron 22455414 rs3094509 chr17 36062299 A G 5.17E-04 Amyotrophic Lateral Sclerosis HNF1B intron 17362836 rs2107133 chr17 36064897 A G 8.77E-05 Attention deficit hyperactivity disorder HNF1B intron pha002875 rs3110648 chr17 36071034 T G 2.80E-05 Height HNF1B intron pha003010 rs3110648 chr17 36071034 T G 1.07E-05 Height HNF1B intron pha003011 rs11649743 chr17 36074979 G A 5.60E-05 Prostate cancer HNF1B intron 18264096 rs7209295 chr17 36075196 A G 0.000000443 HDL cholesterol HNF1B intron 23063622 rs2107131 chr17 36086689 A G 7.69E-05 Serum metabolites HNF1B intron 19043545 rs3744763 chr17 36090885 G A 2.00E-07 Prostate cancer HNF1B intron 18264097 rs3744763 chr17 36090885 G A 6.50E-08 Prostate-specific antigen levels HNF1B intron 21160077 rs3744763 chr17 36090885 G A 6.00E-07 Type 2 diabetes HNF1B intron 21874001 rs7405776 chr17 36093022 A G 6.07E-07 Endometrial cancer HNF1B intron 21499250 rs2005705 chr17 36096300 A G 2.35E-07 Endometrial cancer HNF1B intron 21499250 rs2005705 chr17 36096300 A G 1.00E-06 Prostate cancer (early onset) HNF1B intron 24740154 rs757211 chr17 36096478 C T 9.31E-07 Endometrial cancer HNF1B intron 21499250 rs757210 chr17 36096515 T A,C,G 1.27E-06 Endometrial cancer HNF1B intron 21499250 rs757210 chr17 36096515 T A,C,G 5.00E-04 Gamma gluatamyl transferase levels (interaction with age) HNF1B intron 22010049 rs757210 chr17 36096515 T A,C,G 3.90E-06 Ovarian cancer HNF1B intron 23535730 rs757210 chr17 36096515 T A,C,G 8.00E-10 Ovarian cancer HNF1B intron 23535730 rs757210 chr17 36096515 T A,C,G 9.00E-04 Ovarian cancer HNF1B intron 23535730 rs4430796 chr17 36098040 G A 1.00E-11 Prostate cancer and type 2 diabetes HNF1B intron 17603485 rs4430796 chr17 36098040 G A 1.00E-09 Prostate cancer HNF1B intron 18264096 rs4430796 chr17 36098040 G A 8.30E-12 Prostate cancer HNF1B intron 18264097 rs4430796 chr17 36098040 G A 8.00E-06 Prostate cancer HNF1B intron 19767754 rs4430796 chr17 36098040 G A 1.00E-11 Nasopharyngeal carcinoma HNF1B intron 20512145 rs4430796 chr17 36098040 G A 2.00E-06 Type 2 diabetes HNF1B intron 20581827 rs4430796 chr17 36098040 G A 6.00E-11 Prostate-specific antigen levels HNF1B intron 21160077 rs4430796 chr17 36098040 G A 7.00E-10 Endometrial cancer HNF1B intron 21499250 rs4430796 chr17 36098040 G A 2.00E-06 Type 2 diabetes HNF1B intron 21647700 rs4430796 chr17 36098040 G A 3.80E-04 Coronary heart disease HNF1B intron 21966275 rs4430796 chr17 36098040 G A 0.000000248 Type 2 diabetes HNF1B intron 22325160 rs4430796 chr17 36098040 G A 0.0000024 Type 2 diabetes HNF1B intron 22885922 rs4430796 chr17 36098040 G A 2.00E-11 Type 2 diabetes HNF1B intron 22961080 rs4430796 chr17 36098040 G A 0.000016 Prostate cancer (non-advanced prostate cancer) HNF1B intron 23555315 rs4430796 chr17 36098040 G A 0.00009 Prostate cancer HNF1B intron 23555315 rs4430796 chr17 36098040 G A 4.00E-06 Type 2 diabetes HNF1B intron 23945395 rs4430796 chr17 36098040 G A 9.00E-10 Type 2 diabetes HNF1B intron 24509480 rs4430796 chr17 36098040 G A 2.50E-06 Prostate cancer (early onset) HNF1B intron 24740154 rs4239217 chr17 36098987 G A 1.19E-08 Endometrial cancer HNF1B intron 21499250 rs11651755 chr17 36099840 C T 1.82E-07 Endometrial cancer HNF1B intron 21499250 rs11651755 chr17 36099840 C T 2.00E-11 Type 2 diabetes HNF1B intron 22885922 rs10908278 chr17 36099952 T A 2.25E-07 Endometrial cancer HNF1B intron 21499250 rs11657964 chr17 36100767 A G 9.67E-07 Endometrial cancer HNF1B intron 21499250 rs7501939 chr17 36101156 T C 4.70E-09 Prostate cancer and type 2 diabetes HNF1B intron 17603485 rs7501939 chr17 36101156 T C 8.88E-09 Prostate cancer HNF1B intron 18264096 rs7501939 chr17 36101156 T C 9.00E-12 Prostate cancer HNF1B intron 18264097 rs7501939 chr17 36101156 T C 3.00E-18 Prostate cancer HNF1B intron 19767753 rs7501939 chr17 36101156 T C 3.00E-18 Nasopharyngeal carcinoma HNF1B intron 20512145 rs7501939 chr17 36101156 T C 1.00E-12 Prostate cancer HNF1B intron 20676098 rs7501939 chr17 36101156 T C 5.30E-07 Prostate-specific antigen levels HNF1B intron 21160077 rs7501939 chr17 36101156 T C 5.35E-08 Endometrial cancer HNF1B intron 21499250 rs7501939 chr17 36101156 T C 2.00E-06 Prostate cancer HNF1B intron 21743057 rs7501939 chr17 36101156 T C 0.000053 Prostate cancer (non-advanced prostate cancer) HNF1B intron 23555315 rs7501939 chr17 36101156 T C 0.000086 Prostate cancer HNF1B intron 23555315 rs7501939 chr17 36101156 T C 7.04E-05 Body Mass Index HNF1B intron pha003009 rs8064454 chr17 36101586 A C 4.72E-07 Endometrial cancer HNF1B intron 21499250 rs12601991 chr17 36101633 G T 1.38E-06 Endometrial cancer HNF1B intron 21499250 rs11263762 chr17 36101926 G A 1.22E-06 Endometrial cancer HNF1B intron 21499250 rs7405696 chr17 36102035 G C 1.22E-06 Endometrial cancer HNF1B intron 21499250 rs11651052 chr17 36102381 A G 4.63E-07 Endometrial cancer HNF1B intron 21499250 rs11651052 chr17 36102381 A G 0.0000066 Type 2 diabetes (males) HNF1B intron 22885922 rs11651052 chr17 36102381 A G 1.80E-12 Type 2 diabetes HNF1B intron 22885922 rs11651052 chr17 36102381 A G 2.70E-09 Type 2 diabetes (females) HNF1B intron 22885922 rs757209 chr17 36102833 G A 6.15E-07 Endometrial cancer HNF1B intron 21499250 rs9901746 chr17 36103149 G A 1.69E-06 Endometrial cancer HNF1B intron 21499250 rs11263763 chr17 36103565 G A 3.71E-07 Endometrial cancer HNF1B intron 21499250 rs11263763 chr17 36103565 G A 1.80E-11 Type 2 diabetes HNF1B intron 22885922 rs11658063 chr17 36103872 C G 8.59E-07 Endometrial cancer HNF1B intron 21499250 rs12453443 chr17 36104121 C G 3.49E-06 Endometrial cancer HNF1B intron 21499250 rs3760511 chr17 36106313 T G 1.40E-06 Prostate cancer and type 2 diabetes HNF1B nearGene-5 17603485 rs3760511 chr17 36106313 T G 3.60E-08 Prostate cancer HNF1B nearGene-5 18264097 rs17138335 chr17 36118135 A G 6.11E-04 Multiple complex diseases / / 17554300 rs8067696 chr17 36122952 A G 1.20E-05 Urinary metabolites / / 21572414 rs17705445 chr17 36131437 C T 2.21E-04 Prostate cancer mortality / / 20978177 rs7209835 chr17 36133614 C A,T 2.01E-05 Basophils / / pha003087 rs9900825 chr17 36152099 G A 3.23E-05 Personality dimensions / / 18957941 rs3942352 chr17 36173595 C T 1.37E-05 Basophils / / pha003087 rs1533494 chr17 36173994 C T 9.76E-04 Depression (quantitative trait) / / 20800221 rs9890585 chr17 36183891 A G 6.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs7217787 chr17 36185038 T C 5.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs7214181 chr17 36186865 C T 5.52E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7220682 chr17 36188471 C T 1.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs7221878 chr17 36191133 T C 6.75E-05 Suicide attempts in bipolar disorder / / 21423239 rs7208963 chr17 36207702 C T 4.94E-05 Suicide attempts in bipolar disorder LOC284100 intron 21423239 rs6607306 chr17 36213829 C G 1.92E-04 Suicide attempts in bipolar disorder LOC284100 intron 21423239 rs10512474 chr17 36223325 A G 1.85E-04 Suicide attempts in bipolar disorder LOC284100 intron 21423239 rs3874961 chr17 36224026 G A 1.87E-04 Suicide attempts in bipolar disorder LOC284100 intron 21423239 rs3874962 chr17 36224277 G A 1.45E-04 Suicide attempts in bipolar disorder LOC284100 intron 21423239 rs9907381 chr17 36228819 C T 1.66E-04 Suicide attempts in bipolar disorder LOC284100 intron 21423239 rs3953882 chr17 36231965 C T 1.32E-04 Suicide attempts in bipolar disorder LOC284100 intron 21423239 rs9896972 chr17 36233906 C T 3.08E-05 Suicide attempts in bipolar disorder / / 21423239 rs16965350 chr17 36614563 C T 1.50E-05 Urinary metabolites ARHGAP23 intron 21572414 rs16965356 chr17 36615582 T C 2.80E-05 Urinary metabolites ARHGAP23 intron 21572414 rs12938080 chr17 36616865 T C 6.74E-04 Alzheimer's disease ARHGAP23 intron 22005930 rs8069283 chr17 36620920 G C 6.19E-04 Alzheimer's disease ARHGAP23 intron 22005930 rs6503637 chr17 36621556 T C 5.53E-04 Alzheimer's disease ARHGAP23 intron 22005930 rs3892952 chr17 36753832 A G 1.19E-05 Systemic lupus erythematosus SRCIN1 intron pha002867 rs2075052 chr17 36776981 G T 8.45E-04 Stroke / / pha002887 rs7224160 chr17 36784786 G C 4.92E-05 Lymphocyte counts / / 22286170 rs7211741 chr17 36795136 G A 1.18E-04 Acute lung injury / / 22295056 rs2080025 chr17 36836115 T A 6.21E-04 Type 2 diabetes / / 17463246 rs720528 chr17 36845826 T C 8.07E-04 Multiple complex diseases / / 17554300 rs720528 chr17 36845826 T C 7.03E-05 Serum metabolites / / 19043545 rs1043515 chr17 36922196 A G 3.00E-10 Height PIP4K2B UTR-3 20881960 rs228285 chr17 36922510 G A 8.17E-05 Attention deficit hyperactivity disorder PIP4K2B UTR-3 22420046 rs11653487 chr17 36942631 C T 0.00043469 Hypertension (early onset hypertension) PIP4K2B intron 22479346 rs11653086 chr17 37037718 G T 7.80E-06 Urinary metabolites LASP1 intron 21572414 rs3785461 chr17 37042006 G A 2.56E-04 Hearing function LASP1 intron 17255346 rs11659022 chr17 37062847 A G 6.27E-04 Multiple complex diseases LASP1 intron 17554300 rs82977 chr17 37064348 G A 8.39E-04 Amyotrophic Lateral Sclerosis LASP1 intron 17362836 rs82977 chr17 37064348 G A 1.19E-05 Alcohol and nictotine co-dependence LASP1 intron 20158304 rs660413 chr17 37075506 G A 3.82E-04 Suicide attempts in bipolar disorder LASP1 UTR-3 21423239 rs9906595 chr17 37101380 T C 4.00E-06 Obesity-related traits FBXO47 missense 23251661 rs7213323 chr17 37119920 C T 7.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FBXO47 intron 20877124 rs4795343 chr17 37219325 C T 8.08E-05 Coronary restenosis LOC100131347 intron 21878436 rs4795344 chr17 37219361 G A 6.19E-04 Parkinson's disease LOC100131347 intron 17052657 rs12453592 chr17 37222473 C T 4.23E-05 Coronary restenosis PLXDC1 UTR-3 21878436 rs12453656 chr17 37226399 A G 2.80E-05 Urinary metabolites PLXDC1 intron 21572414 rs2091763 chr17 37230242 T C 4.46E-05 Coronary restenosis PLXDC1 intron 21878436 rs3744077 chr17 37235193 G A 5.22E-05 Coronary restenosis PLXDC1 intron 21878436 rs16526 chr17 37321672 A C 4.06E-04 Smoking initiation ARL5C intron 24665060 rs523516 chr17 37331345 A T 4.00E-06 IgG glycosylation CACNB1 UTR-3 23382691 rs626657 chr17 37332963 C A 2.00E-06 IgG glycosylation CACNB1 intron 23382691 rs2301775 chr17 37341235 A G 3.08E-06 Meningococcal disease CACNB1 intron 20694013 rs2301775 chr17 37341235 A G 1.80E-04 Alzheimer's disease (late onset) CACNB1 intron 21379329 rs636027 chr17 37363793 T C 7.54E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs486512 chr17 37365699 C T 1.70E-13 Asthma (childhood onset) / / 17611496 rs16968682 chr17 37386899 C T 6.87E-04 Alzheimer's disease / / 17998437 rs11078893 chr17 37396679 T C 9.57E-07 Red blood cell traits / / 23222517 rs2879258 chr17 37399379 G T 2.79E-07 Primary biliary cirrhosis / / 21399635 rs8076462 chr17 37400025 G C 7.08E-07 Red blood cell traits / / 23222517 rs11655972 chr17 37407072 C T 3.80E-07 Primary biliary cirrhosis / / 21399635 rs755500 chr17 37409865 G A 1.70E-05 Urinary metabolites FBXL20 UTR-3 21572414 rs755500 chr17 37409865 G A 9.18E-07 Red blood cell traits FBXL20 UTR-3 23222517 rs2338755 chr17 37419317 T C 1.50E-05 Urinary metabolites FBXL20 intron 21572414 rs2338755 chr17 37419317 T C 8.35E-07 Red blood cell traits FBXL20 intron 23222517 rs8073907 chr17 37424149 C T 3.50E-07 Primary biliary cirrhosis FBXL20 intron 21399635 rs8073907 chr17 37424149 C T 2.40E-07 Red blood cell traits FBXL20 intron 23222517 rs634365 chr17 37436966 C T 1.40E-05 Urinary metabolites FBXL20 intron 21572414 rs602688 chr17 37439496 T C 1.20E-05 Urinary metabolites FBXL20 intron 21572414 rs602688 chr17 37439496 T C 9.89E-07 Red blood cell traits FBXL20 intron 23222517 rs801426 chr17 37441109 G A 1.50E-05 Urinary metabolites FBXL20 intron 21572414 rs801426 chr17 37441109 G A 8.93E-07 Red blood cell traits FBXL20 intron 23222517 rs585961 chr17 37444036 G A 3.56E-04 Alcohol dependence FBXL20 intron 20201924 rs590051 chr17 37446571 T C 3.50E-07 Primary biliary cirrhosis FBXL20 intron 21399635 rs632202 chr17 37453294 C A 3.13E-07 Red blood cell traits FBXL20 intron 23222517 rs2302073 chr17 37457342 A G 2.40E-07 Primary biliary cirrhosis FBXL20 intron 21399635 rs8066704 chr17 37477218 C T 9.94E-07 Red blood cell traits FBXL20 intron 23222517 rs8070695 chr17 37478062 G A 1.50E-05 Urinary metabolites FBXL20 intron 21572414 rs8070695 chr17 37478062 G A 5.79E-07 Red blood cell traits FBXL20 intron 23222517 rs9944411 chr17 37483599 T C 8.37E-07 Chronic kidney disease FBXL20 intron 21931561 rs9944411 chr17 37483599 T C 8.00E-07 Red blood cell traits FBXL20 intron 23222517 rs7220650 chr17 37487168 T C 5.72E-04 Alcohol dependence FBXL20 intron 20201924 rs7220650 chr17 37487168 T C 1.40E-05 Urinary metabolites FBXL20 intron 21572414 rs7220650 chr17 37487168 T C 3.20E-07 Red blood cell traits FBXL20 intron 23222517 rs2338800 chr17 37498149 G C 3.45E-04 Multiple complex diseases FBXL20 intron 17554300 rs2338800 chr17 37498149 G C 1.90E-05 Urinary metabolites FBXL20 intron 21572414 rs2338800 chr17 37498149 G C 3.66E-07 Red blood cell traits FBXL20 intron 23222517 rs9916302 chr17 37499949 T C 5.42E-07 Red blood cell traits FBXL20 intron 23222517 rs8069451 chr17 37504933 T C 8.20E-04 Alcohol dependence FBXL20 intron 20201924 rs8069451 chr17 37504933 T C 1.60E-05 Urinary metabolites FBXL20 intron 21572414 rs8069451 chr17 37504933 T C 2.70E-07 Red blood cell traits FBXL20 intron 23222517 rs8076494 chr17 37516722 T C 1.60E-05 Urinary metabolites FBXL20 intron 21572414 rs8076494 chr17 37516722 T C 6.97E-07 Red blood cell traits FBXL20 intron 23222517 rs9908131 chr17 37520449 T C 2.40E-07 Primary biliary cirrhosis FBXL20 intron 21399635 rs4511574 chr17 37532916 C T 4.64E-04 Alcohol dependence FBXL20 intron 20201924 rs7221875 chr17 37543328 G A 9.32E-07 Red blood cell traits FBXL20 intron 23222517 rs7208487 chr17 37543449 T G 8.00E-07 Primary biliary cirrhosis FBXL20 intron 21399635 rs7208487 chr17 37543449 T G 5.60E-09 Glomerular filtration rate FBXL20 intron 22962313 rs9906612 chr17 37547631 A C 2.40E-07 Primary biliary cirrhosis FBXL20 intron 21399635 rs8076546 chr17 37555403 G A 2.63E-07 Red blood cell traits FBXL20 intron 23222517 rs9904919 chr17 37556431 G C 2.57E-07 Red blood cell traits FBXL20 intron 23222517 rs6503513 chr17 37561613 A G 2.30E-08 Primary biliary cirrhosis MED1 UTR-3 21399635 rs12452509 chr17 37574722 G A 5.92E-04 Alcohol dependence MED1 intron 20201924 rs7501488 chr17 37576417 T G 5.92E-04 Alcohol dependence MED1 intron 20201924 rs9646419 chr17 37597185 A G 1.20E-07 Primary biliary cirrhosis MED1 intron 21399635 rs11655550 chr17 37610123 T C 7.59E-04 Asthma (childhood onset) / / 17611496 rs11655550 chr17 37610123 T C 1.42E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs11655550 chr17 37610123 T C 7.00E-07 Systemic lupus erythematosus / / 24871463 rs11078902 chr17 37631883 C G 9.32E-07 Red blood cell traits CDK12 intron 23222517 rs11078903 chr17 37631924 G A 3.07E-09 Chronic kidney disease CDK12 intron 22479191 rs11078903 chr17 37631924 G A 3.55E-07 Red blood cell traits CDK12 intron 23222517 rs12449852 chr17 37632088 A G 2.20E-07 Primary biliary cirrhosis CDK12 intron 21399635 rs12936996 chr17 37665554 G A 1.30E-05 Urinary metabolites CDK12 intron 21572414 rs12936996 chr17 37665554 G A 2.46E-07 Red blood cell traits CDK12 intron 23222517 rs7503705 chr17 37669704 A G 6.71E-04 Alcohol dependence CDK12 intron 20201924 rs7503705 chr17 37669704 A G 6.88E-07 Red blood cell traits CDK12 intron 23222517 rs11078912 chr17 37671490 A G 8.80E-06 Urinary metabolites CDK12 intron 21572414 rs11078913 chr17 37671714 G T 6.77E-07 Red blood cell traits CDK12 intron 23222517 rs11658678 chr17 37680096 C T 6.33E-07 Red blood cell traits CDK12 intron 23222517 rs8065963 chr17 37681332 C T 6.94E-07 Red blood cell traits CDK12 intron 23222517 rs8069074 chr17 37685401 A G 1.10E-07 Primary biliary cirrhosis CDK12 intron 21399635 rs8069074 chr17 37685401 A G 5.60E-07 Red blood cell traits CDK12 intron 23222517 rs4239222 chr17 37696235 G T 1.20E-05 Urinary metabolites / / 21572414 rs4239222 chr17 37696235 G T 5.34E-07 Red blood cell traits / / 23222517 rs7503069 chr17 37697128 C G 8.12E-07 Red blood cell traits / / 23222517 rs11657153 chr17 37699729 A G 1.33E-07 Red blood cell traits / / 23222517 rs11654018 chr17 37703740 T C 9.30E-06 Urinary metabolites / / 21572414 rs2303316 chr17 37704217 A G 1.20E-05 Urinary metabolites / / 21572414 rs2303316 chr17 37704217 A G 7.29E-07 Red blood cell traits / / 23222517 rs7503377 chr17 37708841 T C 1.90E-07 Primary biliary cirrhosis / / 21399635 rs7503377 chr17 37708841 T C 8.90E-07 Red blood cell traits / / 23222517 rs7216086 chr17 37709422 G A 4.95E-07 Red blood cell traits / / 23222517 rs11078915 chr17 37715426 T C 5.34E-07 Red blood cell traits / / 23222517 rs6503521 chr17 37715551 G T 3.64E-07 Red blood cell traits / / 23222517 rs4795384 chr17 37716771 C G 5.16E-07 Red blood cell traits / / 23222517 rs4488484 chr17 37717377 T A 7.56E-07 Red blood cell traits / / 23222517 rs8182252 chr17 37727950 T C 5.91E-09 Red blood cell traits / / 23222517 rs1619021 chr17 37739274 G A 1.69E-04 Alcohol dependence / / 20201924 rs1877030 chr17 37740161 T C 1.30E-05 Rheumatoid arthritis / / 24390342 rs1877030 chr17 37740161 T C 2.00E-08 Rheumatoid arthritis / / 24390342 rs1877030 chr17 37740161 T C 3.20E-04 Rheumatoid arthritis / / 24390342 rs2271309 chr17 37784990 G A 6.79E-07 Red blood cell traits PPP1R1B intron 23222517 rs12601930 chr17 37789432 C T 4.18E-11 Triglycerides PPP1R1B intron 23063622 rs907094 chr17 37790371 G A 5.80E-07 Red blood cell traits PPP1R1B intron 23222517 rs9972882 chr17 37807698 A C 8.10E-07 Red blood cell traits STARD3 intron 23222517 rs11869286 chr17 37813856 G C 4.50E-04 Multiple complex diseases STARD3 intron 17554300 rs11869286 chr17 37813856 G C 3.00E-14 HDL cholesterol STARD3 intron 20686565 rs11869286 chr17 37813856 G C 1.30E-05 Urinary metabolites STARD3 intron 21572414 rs11869286 chr17 37813856 G C 0.0000208 HDL cholesterol STARD3 intron 23063622 rs11869286 chr17 37813856 G C 3.00E-17 HDL cholesterol STARD3 intron 24097068 rs1877031 chr17 37814080 G A 2.76E-07 Asthma STARD3 missense 20860503 rs1877031 chr17 37814080 G A 3.00E-04 Myasthenia gravis STARD3 missense 23055271 rs2271308 chr17 37817482 T C 4.78E-07 Asthma STARD3 intron 20860503 rs2271308 chr17 37817482 T C 1.70E-10 Asthma STARD3 intron 21907864 rs2271308 chr17 37817482 T C 2.90E-04 Myasthenia gravis STARD3 intron 23055271 rs113612868 chr17 37821435 G GT 2.73E-07 Asthma TCAP nearGene-5 20860503 rs113612868 chr17 37821435 G GT 4.90E-04 Myasthenia gravis TCAP nearGene-5 23055271 rs931992 chr17 37821435 G T 2.73E-07 Asthma TCAP nearGene-5 20860503 rs931992 chr17 37821435 G T 4.90E-04 Myasthenia gravis TCAP nearGene-5 23055271 rs1053651 chr17 37822311 A C 3.78E-08 Red blood cell traits TCAP cds-synon 23222517 rs3764351 chr17 37824339 G A 1.21E-06 Asthma PNMT nearGene-5 20860503 rs2941503 chr17 37828745 A G 8.52E-09 Asthma PGAP3 UTR-3 20860503 rs2247862 chr17 37829129 A G 8.90E-06 Urinary metabolites PGAP3 intron 21572414 rs2941504 chr17 37830900 A G 1.14E-05 Multiple complex diseases PGAP3 cds-synon 17554300 rs2941504 chr17 37830900 A G 8.30E-09 Asthma PGAP3 cds-synon 20860503 rs2941504 chr17 37830900 A G 1.48E-06 Asthma PGAP3 cds-synon 22188591 rs1565922 chr17 37831035 A G 1.10E-08 Asthma PGAP3 intron 20860503 rs907089 chr17 37833600 G A 4.10E-04 Multiple complex diseases PGAP3 intron 17554300 rs12150298 chr17 37834541 T C 6.57E-08 Asthma PGAP3 intron 20860503 rs2517955 chr17 37843681 C T 2.19E-07 Asthma PGAP3 intron 21804549 rs2934971 chr17 37854507 G T 1.70E-05 Urinary metabolites ERBB2 intron 21572414 rs2952155 chr17 37861718 T C 3.63E-07 Asthma ERBB2 intron 21804549 rs1810132 chr17 37866005 C T 1.16E-07 Asthma ERBB2 intron 20860503 rs1810132 chr17 37866005 C T 2.31E-07 Asthma ERBB2 intron 21804549 rs4252627 chr17 37868715 C T 1.01E-05 Asthma ERBB2 intron 20860503 rs1136201 chr17 37879588 A C,G,T 1 Drug response to Trastuzumab ERBB2 missense 17693647 rs1136201 chr17 37879588 A C,G,T 2.00E-05 Tooth agenesis (mandibular third molar) ERBB2 missense 24172245 rs1058808 chr17 37884037 C G 8.33E-07 Asthma ERBB2 frameshift 21804549 rs1058808 chr17 37884037 C G 7.81E-04 Asthma ERBB2 frameshift 22188591 rs2941522 chr17 37910368 C T 0.00000244 Primary biliary cirrhosis / / 22936693 rs12946510 chr17 37912377 C T 4.00E-38 Inflammatory bowel disease / / 23128233 rs907091 chr17 37921742 C T 5.01E-06 Asthma (childhood onset) IKZF3 UTR-3 17611496 rs907091 chr17 37921742 C T 2.60E-05 Urinary metabolites IKZF3 UTR-3 21572414 rs907091 chr17 37921742 C T 0.000000284 Primary biliary cirrhosis in females IKZF3 UTR-3 22936693 rs907091 chr17 37921742 C T 3.43E-09 Primary biliary cirrhosis IKZF3 UTR-3 22936693 rs907091 chr17 37921742 C T 5.47E-10 Primary biliary cirrhosis (anti-mitochondrial antibody positive) IKZF3 UTR-3 22936693 rs907091 chr17 37921742 C T 3.38E-07 Esophageal cancer (squamous cell) IKZF3 UTR-3 22960999 rs907091 chr17 37921742 C T 1.04E-13 Primary biliary cirrhosis IKZF3 UTR-3 22961000 rs907091 chr17 37921742 C T 5.61E-07 Self-reported allergy IKZF3 UTR-3 23817569 rs907092 chr17 37922259 G A 3.19E-04 Multiple complex diseases IKZF3 cds-synon 17554300 rs907092 chr17 37922259 G A 1.20E-09 Asthma (childhood onset) IKZF3 cds-synon 17611496 rs907092 chr17 37922259 G A 8.00E-06 Primary biliary cirrhosis IKZF3 cds-synon 19458352 rs907092 chr17 37922259 G A 8.53E-14 Asthma IKZF3 cds-synon 20860503 rs907092 chr17 37922259 G A 3.24E-12 Asthma IKZF3 cds-synon 21804549 rs907092 chr17 37922259 G A 4.40E-04 Myasthenia gravis IKZF3 cds-synon 23055271 rs907092 chr17 37922259 G A 2.87E-07 Self-reported allergy IKZF3 cds-synon 23817569 rs907092 chr17 37922259 G A 5.70E-13 Asthma IKZF3 cds-synon 24406073 rs2313430 chr17 37929816 T C 1.94E-11 Asthma IKZF3 intron 21804549 rs2313430 chr17 37929816 T C 1.36E-13 Primary biliary cirrhosis IKZF3 intron 22961000 rs10445308 chr17 37938047 C T 1.10E-04 Asthma (childhood onset) IKZF3 intron 17611496 rs10445308 chr17 37938047 C T 8.39E-13 Asthma IKZF3 intron 21804549 rs10445308 chr17 37938047 C T 1.98E-11 Primary biliary cirrhosis IKZF3 intron 22961000 rs10445308 chr17 37938047 C T 6.83E-07 Self-reported allergy IKZF3 intron 23817569 rs9911688 chr17 37943801 C T 1.90E-05 Systemic lupus erythematosus IKZF3 intron 24871463 rs17676191 chr17 37949924 A G 4.70E-05 Lipid traits IKZF3 intron 22028671 rs9909593 chr17 37970149 A G 5.23E-13 Asthma IKZF3 intron 21804549 rs9909593 chr17 37970149 A G 2.24E-11 Primary biliary cirrhosis IKZF3 intron 22961000 rs9909593 chr17 37970149 A G 6.15E-07 Self-reported allergy IKZF3 intron 23817569 rs12450323 chr17 37972708 G T 4.00E-07 Asthma and hay fever IKZF3 intron 24388013 rs9303277 chr17 37976469 C T 5.05E-04 Multiple complex diseases IKZF3 intron 17554300 rs9303277 chr17 37976469 C T 1.26E-22 Asthma (childhood onset) IKZF3 intron 17611496 rs9303277 chr17 37976469 C T 2.00E-09 Primary biliary cirrhosis IKZF3 intron 20639880 rs9303277 chr17 37976469 C T 2.52E-15 Asthma IKZF3 intron 20860503 rs9303277 chr17 37976469 C T 1.01E-11 Asthma IKZF3 intron 21804549 rs9303277 chr17 37976469 C T 9.56E-14 Primary biliary cirrhosis IKZF3 intron 22961000 rs9303277 chr17 37976469 C T 4.00E-09 Primary biliary cirrhosis IKZF3 intron 23000144 rs9303277 chr17 37976469 C T 1.50E-05 Myasthenia gravis IKZF3 intron 23055271 rs9303277 chr17 37976469 C T 7.00E-06 Systemic lupus erythematosus and Systemic sclerosis IKZF3 intron 23740937 rs9303277 chr17 37976469 C T 5.05E-07 Self-reported allergy IKZF3 intron 23817569 rs3816470 chr17 37985801 A G 8.22E-12 Asthma IKZF3 intron 21804549 rs3816470 chr17 37985801 A G 1.42E-12 Primary biliary cirrhosis IKZF3 intron 22961000 rs3816470 chr17 37985801 A G 2.63E-08 Self-reported allergy IKZF3 intron 23817569 rs9635726 chr17 38020141 C T 3.85E-05 Self-reported allergy IKZF3 intron 23817569 rs1453559 chr17 38020419 T C 0.00000271 Primary biliary cirrhosis IKZF3 UTR-5 22936693 rs4795397 chr17 38023745 A G 2.75E-11 Primary biliary cirrhosis ZPBP2 nearGene-5 22961000 rs4795397 chr17 38023745 A G 0.00004 Primary sclerosing cholangitis ZPBP2 nearGene-5 23603763 rs4795397 chr17 38023745 A G 4.89E-08 Self-reported allergy ZPBP2 nearGene-5 23817569 rs11557466 chr17 38024626 C T 6.02E-13 Asthma ZPBP2 cds-synon 21804549 rs11557466 chr17 38024626 C T 7.30E-12 Primary biliary cirrhosis ZPBP2 cds-synon 22961000 rs11557466 chr17 38024626 C T 8.68E-08 Self-reported allergy ZPBP2 cds-synon 23817569 rs11078925 chr17 38025208 T C 1.86E-12 Asthma ZPBP2 intron 21804549 rs11078925 chr17 38025208 T C 6.96E-12 Primary biliary cirrhosis ZPBP2 intron 22961000 rs11078925 chr17 38025208 T C 8.11E-08 Self-reported allergy ZPBP2 intron 23817569 rs12150079 chr17 38025417 G A 7.23E-05 Multiple complex diseases ZPBP2 intron 17554300 rs12150079 chr17 38025417 G A 5.02E-09 Asthma ZPBP2 intron 20860503 rs12150079 chr17 38025417 G A 1.98E-07 Asthma ZPBP2 intron 21804549 rs12150079 chr17 38025417 G A 3.98E-04 Type 1 diabetes ZPBP2 intron 21980299 rs12150079 chr17 38025417 G A 3.21E-05 Self-reported allergy ZPBP2 intron 23817569 rs11650661 chr17 38026286 A T 1.80E-13 Primary biliary cirrhosis ZPBP2 intron 22961000 rs12709365 chr17 38027400 A G 7.68E-12 Primary biliary cirrhosis ZPBP2 intron 22961000 rs13380815 chr17 38027583 A G 6.65E-12 Primary biliary cirrhosis ZPBP2 intron 22961000 rs11557467 chr17 38028634 G T 3.16E-23 Asthma (childhood onset) ZPBP2 missense 17611496 rs11557467 chr17 38028634 G T 4.82E-15 Asthma ZPBP2 missense 20860503 rs11557467 chr17 38028634 G T 0.000000114 Primary biliary cirrhosis ZPBP2 missense 22936693 rs11557467 chr17 38028634 G T 2.56E-13 Primary biliary cirrhosis ZPBP2 missense 22961000 rs11557467 chr17 38028634 G T 6.00E-05 Myasthenia gravis ZPBP2 missense 23055271 rs11557467 chr17 38028634 G T 8.02E-08 Self-reported allergy ZPBP2 missense 23817569 rs12936231 chr17 38029120 C G 2.40E-04 Multiple complex diseases ZPBP2 intron 17554300 rs12936231 chr17 38029120 C G 1.95E-10 Asthma ZPBP2 intron 21804549 rs12936231 chr17 38029120 C G 6.73E-09 Primary biliary cirrhosis ZPBP2 intron 22936693 rs12936231 chr17 38029120 C G 1.88E-13 Primary biliary cirrhosis ZPBP2 intron 22961000 rs12936231 chr17 38029120 C G 2.80E-07 Self-reported allergy ZPBP2 intron 23817569 rs11870965 chr17 38030205 T A 4.04E-10 Asthma ZPBP2 intron 21804549 rs11870965 chr17 38030205 T A 6.26E-12 Primary biliary cirrhosis ZPBP2 intron 22961000 rs11870965 chr17 38030205 T A 1.04E-07 Self-reported allergy ZPBP2 intron 23817569 rs9903250 chr17 38031030 G A 7.13E-08 Primary biliary cirrhosis ZPBP2 intron 22936693 rs10852935 chr17 38031674 C T 5.35E-12 Primary biliary cirrhosis ZPBP2 cds-synon 22961000 rs10852936 chr17 38031714 C T 2.40E-04 Asthma (childhood onset) ZPBP2 intron 17611496 rs10852936 chr17 38031714 C T 6.26E-12 Primary biliary cirrhosis ZPBP2 intron 22961000 rs10852936 chr17 38031714 C T 5.66E-08 Self-reported allergy ZPBP2 intron 23817569 rs9891174 chr17 38031802 T A 4.30E-12 Primary biliary cirrhosis ZPBP2 intron 22961000 rs36095411 chr17 38031865 T G 6.98E-12 Primary biliary cirrhosis ZPBP2 intron 22961000 rs34189114 chr17 38032460 C T 5.98E-12 Primary biliary cirrhosis ZPBP2 intron 22961000 rs35736272 chr17 38032680 T C 6.96E-12 Primary biliary cirrhosis ZPBP2 intron 22961000 rs1054609 chr17 38033277 A C 3.31E-04 Asthma (childhood onset) ZPBP2 UTR-3 17611496 rs1054609 chr17 38033277 A C 2.23E-10 Asthma ZPBP2 UTR-3 21804549 rs1054609 chr17 38033277 A C 6.97E-12 Primary biliary cirrhosis ZPBP2 UTR-3 22961000 rs9907088 chr17 38035116 G A 3.16E-12 Asthma / / 21804549 rs9907088 chr17 38035116 G A 6.26E-12 Primary biliary cirrhosis / / 22961000 rs9907088 chr17 38035116 G A 1.05E-07 Self-reported allergy / / 23817569 rs36038753 chr17 38035370 G T 6.23E-12 Primary biliary cirrhosis / / 22961000 rs35569035 chr17 38035624 C T 6.20E-12 Primary biliary cirrhosis / / 22961000 rs9910826 chr17 38035648 A G 6.24E-12 Primary biliary cirrhosis / / 22961000 rs9904624 chr17 38036586 A G 1.63E-12 Asthma / / 21804549 rs9904624 chr17 38036586 A G 6.25E-12 Primary biliary cirrhosis / / 22961000 rs12939565 chr17 38038389 A T 3.35E-13 Primary biliary cirrhosis / / 22961000 rs12232497 chr17 38040119 T C 1.21E-13 Asthma / / 21804549 rs12232497 chr17 38040119 T C 6.57E-12 Primary biliary cirrhosis / / 22961000 rs12232497 chr17 38040119 T C 1.09E-07 Self-reported allergy / / 23817569 rs12941333 chr17 38040534 C T 6.72E-12 Primary biliary cirrhosis / / 22961000 rs2872507 chr17 38040763 G A 1.12E-04 Multiple complex diseases / / 17554300 rs2872507 chr17 38040763 G A 5.00E-09 Crohn's disease / / 18587394 rs2872507 chr17 38040763 G A 9.00E-07 Rheumatoid arthritis / / 20453842 rs2872507 chr17 38040763 G A 5.52E-14 Asthma / / 20860503 rs2872507 chr17 38040763 G A 2.00E-09 Crohn's disease / / 21102463 rs2872507 chr17 38040763 G A 5.00E-09 Asthma / / 21150878 rs2872507 chr17 38040763 G A 5.00E-11 Ulcerative colitis / / 21297633 rs2872507 chr17 38040763 G A 2.70E-05 Urinary metabolites / / 21572414 rs2872507 chr17 38040763 G A 6.84E-12 Asthma / / 21804549 rs2872507 chr17 38040763 G A 2.00E-06 Type 1 diabetes autoantibodies / / 21829393 rs2872507 chr17 38040763 G A 5.00E-09 Multiple sclerosis / / 22190364 rs2872507 chr17 38040763 G A 8.21E-12 Primary biliary cirrhosis / / 22961000 rs2872507 chr17 38040763 G A 2.79E-09 Rheumatoid arthritis (CCP positive) / / 23143596 rs2872507 chr17 38040763 G A 2.80E-09 Rheumatoid arthritis / / 23143596 rs2872507 chr17 38040763 G A 6.04E-04 Ulcerative colitis / / 23511034 rs2872507 chr17 38040763 G A 1.09E-07 Self-reported allergy / / 23817569 rs9901146 chr17 38043343 G A 5.57E-12 Asthma / / 21804549 rs9901146 chr17 38043343 G A 3.12E-13 Primary biliary cirrhosis / / 22961000 rs9901146 chr17 38043343 G A 6.08E-08 Self-reported allergy / / 23817569 rs12936409 chr17 38043649 C T 7.01E-12 Primary biliary cirrhosis / / 22961000 rs12936409 chr17 38043649 C T 0.000000372 Rheumatoid arthritis / / 23143596 rs12936409 chr17 38043649 C T 0.00000069 Rheumatoid arthritis (CCP positive) / / 23143596 rs12103884 chr17 38045725 C T 2.41E-13 Primary biliary cirrhosis / / 22961000 rs12950209 chr17 38049102 T C 1.18E-13 Primary biliary cirrhosis / / 22961000 rs12950743 chr17 38049233 T C 5.30E-12 Asthma / / 21804549 rs12950743 chr17 38049233 T C 2.16E-13 Primary biliary cirrhosis / / 22961000 rs12950743 chr17 38049233 T C 5.74E-08 Self-reported allergy / / 23817569 rs7359623 chr17 38049589 C T 4.64E-12 Asthma / / 21804549 rs7359623 chr17 38049589 C T 7.94E-13 Primary biliary cirrhosis / / 22961000 rs7359623 chr17 38049589 C T 7.81E-08 Self-reported allergy / / 23817569 rs8067378 chr17 38051348 A G 2.00E-23 Asthma (childhood onset) / / 17611496 rs8067378 chr17 38051348 A G 1.00E-07 Ulcerative colitis / / 20228799 rs8067378 chr17 38051348 A G 1.61E-15 Asthma / / 20860503 rs8067378 chr17 38051348 A G 6.43E-11 Asthma / / 21804549 rs8067378 chr17 38051348 A G 5.09E-09 Primary biliary cirrhosis / / 22936693 rs8067378 chr17 38051348 A G 6.05E-14 Primary biliary cirrhosis / / 22961000 rs8067378 chr17 38051348 A G 2.70E-05 Myasthenia gravis / / 23055271 rs8067378 chr17 38051348 A G 1.98E-07 Self-reported allergy / / 23817569 rs8067378 chr17 38051348 A G 9.00E-10 Cervical cancer / / 23817570 rs12453507 chr17 38053207 C G 5.81E-13 Primary biliary cirrhosis / / 22961000 rs2123685 chr17 38053889 T C 2.14E-06 Asthma (childhood onset) / / 17611496 rs8069176 chr17 38057197 G A 3.80E-10 Asthma (childhood onset) / / 17611496 rs8069176 chr17 38057197 G A 5.66E-12 Asthma / / 21804549 rs8069176 chr17 38057197 G A 5.19E-08 Self-reported allergy / / 23817569 rs8069176 chr17 38057197 G A 2.00E-08 Fractional exhaled nitric oxide (childhood) / / 24315451 rs8069176 chr17 38057197 G A 5.00E-06 Fractional exhaled nitric oxide (childhood) / / 24315451 rs2305480 chr17 38062196 G A 3.00E-09 Asthma (childhood onset) GSDMB missense 17611496 rs2305480 chr17 38062196 G A 5.45E-05 Crohn's disease GSDMB missense 18587394 rs2305480 chr17 38062196 G A 3.00E-08 Ulcerative colitis GSDMB missense 20228799 rs2305480 chr17 38062196 G A 1.00E-07 Asthma GSDMB missense 20860503 rs2305480 chr17 38062196 G A 1.31E-13 Asthma GSDMB missense 21804549 rs2305480 chr17 38062196 G A 9.60E-08 Asthma GSDMB missense 21907864 rs2305480 chr17 38062196 G A 3.00E-08 Multiple sclerosis GSDMB missense 22190364 rs2305480 chr17 38062196 G A 9.60E-08 Asthma GSDMB missense 22561531 rs2305480 chr17 38062196 G A 0.000000382 Primary biliary cirrhosis GSDMB missense 22936693 rs2305480 chr17 38062196 G A 3.58E-11 Primary biliary cirrhosis GSDMB missense 22961000 rs2305480 chr17 38062196 G A 4.20E-09 Rheumatoid arthritis GSDMB missense 23143596 rs2305480 chr17 38062196 G A 4.38E-08 Self-reported allergy GSDMB missense 23817569 rs2305480 chr17 38062196 G A 5.79E-05 Atopic dermatitis GSDMB missense 23886662 rs2305480 chr17 38062196 G A 6.00E-23 Asthma (childhood,severe) GSDMB missense 24241537 rs2305479 chr17 38062217 C T 8.91E-12 Asthma (childhood onset) GSDMB missense 17611496 rs2305479 chr17 38062217 C T 1.30E-05 Urinary metabolites GSDMB missense 21572414 rs2305479 chr17 38062217 C T 1.21E-12 Asthma GSDMB missense 21804549 rs2305479 chr17 38062217 C T 3.82E-08 Primary biliary cirrhosis GSDMB missense 22936693 rs2305479 chr17 38062217 C T 1.50E-12 Primary biliary cirrhosis GSDMB missense 22961000 rs2305479 chr17 38062217 C T 2.13E-08 Self-reported allergy GSDMB missense 23817569 rs11078926 chr17 38062976 G A 4.37E-04 Asthma (childhood onset) GSDMB intron 17611496 rs11078926 chr17 38062976 G A 4.31E-08 Self-reported allergy GSDMB intron 23817569 rs62067034 chr17 38063738 C T 1.66E-12 Primary biliary cirrhosis GSDMB intron 22961000 rs11078927 chr17 38064405 C T 2.95E-04 Multiple complex diseases GSDMB intron 17554300 rs11078927 chr17 38064405 C T 1.50E-05 Urinary metabolites GSDMB intron 21572414 rs11078927 chr17 38064405 C T 2.00E-16 Asthma GSDMB intron 21804549 rs11078927 chr17 38064405 C T 8.73E-06 Lymphocyte counts GSDMB intron 22286170 rs11078927 chr17 38064405 C T 3.95E-08 Self-reported allergy GSDMB intron 23817569 rs11078927 chr17 38064405 C T 5.44E-05 Atopic dermatitis GSDMB intron 23886662 rs11078927 chr17 38064405 C T 2.40E-10 Asthma GSDMB intron 24406073 rs11078928 chr17 38064469 T C 4.16E-11 Primary biliary cirrhosis GSDMB splice-5 22961000 rs2290400 chr17 38066240 T C 3.98E-23 Asthma (childhood onset) GSDMB intron 17611496 rs2290400 chr17 38066240 T C 6.00E-13 Type 1 diabetes GSDMB intron 19430480 rs2290400 chr17 38066240 T C 9.09E-16 Asthma GSDMB intron 20860503 rs2290400 chr17 38066240 T C 3.75E-11 Asthma GSDMB intron 21804549 rs2290400 chr17 38066240 T C 5.50E-13 Multiple sclerosis GSDMB intron 22190364 rs2290400 chr17 38066240 T C 2.30E-04 Rheumatoid arthritis GSDMB intron 22446963 rs2290400 chr17 38066240 T C 2.68E-12 Primary biliary cirrhosis GSDMB intron 22961000 rs2290400 chr17 38066240 T C 3.80E-05 Myasthenia gravis GSDMB intron 23055271 rs2290400 chr17 38066240 T C 6.26E-08 Self-reported allergy GSDMB intron 23817569 rs2290400 chr17 38066240 T C 9.77E-05 Asthma GSDMB intron pha003127 rs1008723 chr17 38066267 G T 2.24E-05 Asthma (childhood onset) GSDMB intron 17611496 rs1008723 chr17 38066267 G T 7.96E-13 Asthma GSDMB intron 21804549 rs1008723 chr17 38066267 G T 3.87E-12 Primary biliary cirrhosis GSDMB intron 22961000 rs1008723 chr17 38066267 G T 4.39E-08 Self-reported allergy GSDMB intron 23817569 rs1008723 chr17 38066267 G T 9.77E-05 Asthma GSDMB intron pha003127 rs56380902 chr17 38066372 T C 2.95E-12 Primary biliary cirrhosis GSDMB intron 22961000 rs4795400 chr17 38067020 C T 3.84E-04 Multiple complex diseases GSDMB intron 17554300 rs4795400 chr17 38067020 C T 2.51E-08 Asthma (childhood onset) GSDMB intron 17611496 rs4795400 chr17 38067020 C T 1.38E-13 Asthma GSDMB intron 21804549 rs4795400 chr17 38067020 C T 2.37E-08 Self-reported allergy GSDMB intron 23817569 rs869402 chr17 38068043 T C 9.34E-04 Multiple complex diseases GSDMB intron 17554300 rs869402 chr17 38068043 T C 2.00E-05 Urinary metabolites GSDMB intron 21572414 rs869402 chr17 38068043 T C 3.46E-14 Asthma GSDMB intron 21804549 rs869402 chr17 38068043 T C 7.31E-11 Primary biliary cirrhosis GSDMB intron 22961000 rs869402 chr17 38068043 T C 0.000125 Asthma GSDMB intron 23666277 rs869402 chr17 38068043 T C 2.42E-08 Self-reported allergy GSDMB intron 23817569 rs1011082 chr17 38068514 T C 1.19E-10 Primary biliary cirrhosis GSDMB intron 22961000 rs12450091 chr17 38068621 T C 0.0002 Breast cancer GSDMB missense 23555315 rs921650 chr17 38069076 G A 8.67E-11 Primary biliary cirrhosis GSDMB intron 22961000 rs6503524 chr17 38069809 C G,T 8.03E-11 Primary biliary cirrhosis GSDMB intron 22961000 rs7216389 chr17 38069949 C T 9.00E-11 Asthma GSDMB intron 17611496 rs7216389 chr17 38069949 C T 1.29E-15 Asthma GSDMB intron 20860503 rs7216389 chr17 38069949 C T 4.99E-12 Asthma GSDMB intron 21804549 rs7216389 chr17 38069949 C T 9.01E-11 Primary biliary cirrhosis GSDMB intron 22961000 rs7216389 chr17 38069949 C T 1.20E-04 Myasthenia gravis GSDMB intron 23055271 rs7216389 chr17 38069949 C T 3.17E-08 Self-reported allergy GSDMB intron 23817569 rs7216389 chr17 38069949 C T 9.30E-09 Asthma GSDMB intron 24406073 rs7216558 chr17 38070071 C T 3.91E-11 Primary biliary cirrhosis GSDMB intron 22961000 rs1031458 chr17 38072173 G T 8.16E-11 Primary biliary cirrhosis GSDMB intron 22961000 rs9303280 chr17 38074031 T C 4.09E-13 Asthma GSDMB intron 21804549 rs9303280 chr17 38074031 T C 9.00E-09 Self-reported allergy GSDMB intron 23817569 rs9303281 chr17 38074046 G A 1.82E-12 Asthma (childhood onset) GSDMB intron 17611496 rs9303281 chr17 38074046 G A 3.67E-12 Asthma GSDMB intron 21804549 rs9303281 chr17 38074046 G A 4.17E-11 Primary biliary cirrhosis GSDMB intron 22961000 rs9303281 chr17 38074046 G A 8.73E-08 Self-reported allergy GSDMB intron 23817569 rs7219923 chr17 38074518 C T 1.66E-12 Asthma (childhood onset) GSDMB intron 17611496 rs7219923 chr17 38074518 C T 3.25E-11 Asthma GSDMB intron 21804549 rs7219923 chr17 38074518 C T 3.84E-11 Primary biliary cirrhosis GSDMB intron 22961000 rs7219923 chr17 38074518 C T 8.84E-08 Self-reported allergy GSDMB intron 23817569 rs3902920 chr17 38075016 T C 5.20E-10 Primary biliary cirrhosis GSDMB nearGene-5 22961000 rs7224129 chr17 38075426 G A 1.16E-11 Asthma GSDMB nearGene-5 21804549 rs7224129 chr17 38075426 G A 4.45E-11 Primary biliary cirrhosis GSDMB nearGene-5 22961000 rs7224129 chr17 38075426 G A 9.71E-08 Self-reported allergy GSDMB nearGene-5 23817569 rs4065275 chr17 38080865 A G,T 1.26E-11 Asthma (childhood onset) ORMDL3 intron 17611496 rs4065275 chr17 38080865 A G,T 3.27E-11 Primary biliary cirrhosis ORMDL3 intron 22961000 rs8076131 chr17 38080912 G A 1.91E-10 Asthma (childhood onset) ORMDL3 intron 17611496 rs8076131 chr17 38080912 G A 8.62E-14 Asthma ORMDL3 intron 21804549 rs8076131 chr17 38080912 G A 3.60E-08 Self-reported allergy ORMDL3 intron 23817569 rs12603332 chr17 38082807 T C 4.93E-11 Asthma ORMDL3 intron 21804549 rs12603332 chr17 38082807 T C 6.64E-11 Primary biliary cirrhosis ORMDL3 intron 22961000 rs12603332 chr17 38082807 T C 1.69E-08 Self-reported allergy ORMDL3 intron 23817569 rs3744246 chr17 38084350 T C 6.00E-04 Asthma / / 20860503 rs4795402 chr17 38085385 A C 6.03E-04 Asthma (childhood onset) / / 17611496 rs4795403 chr17 38085722 T C 5.58E-07 Asthma / / 21804549 rs4795405 chr17 38088417 T C 2.51E-15 Asthma (childhood onset) / / 17611496 rs4795405 chr17 38088417 T C 1.01E-13 Asthma / / 20860503 rs4795405 chr17 38088417 T C 1.49E-10 Asthma / / 21804549 rs4795405 chr17 38088417 T C 1.66E-08 Self-reported allergy / / 23817569 rs4794820 chr17 38089344 A G 1.35E-09 Asthma (childhood onset) / / 17611496 rs4794820 chr17 38089344 A G 2.38E-09 Asthma / / 21804549 rs4794820 chr17 38089344 A G 1.00E-08 Asthma / / 22561531 rs4794820 chr17 38089344 A G 1.02E-08 Self-reported allergy / / 23817569 rs7207600 chr17 38091660 G A 4.17E-06 Asthma (childhood onset) / / 17611496 rs7207600 chr17 38091660 G A 9.31E-07 Self-reported allergy / / 23817569 rs8079416 chr17 38092713 T C 1.26E-11 Asthma (childhood onset) / / 17611496 rs8079416 chr17 38092713 T C 3.53E-14 Asthma / / 20860503 rs8079416 chr17 38092713 T C 1.11E-05 Systemic sclerosis / / 21750679 rs8079416 chr17 38092713 T C 2.42E-07 Asthma / / 21804549 rs8079416 chr17 38092713 T C 2.40E-22 Asthma / / 21907864 rs8079416 chr17 38092713 T C 3.87E-06 Self-reported allergy / / 23817569 rs6503525 chr17 38095174 G C 5.50E-10 Asthma (childhood onset) / / 17611496 rs6503525 chr17 38095174 G C 5.00E-07 Asthma / / 21150878 rs6503525 chr17 38095174 G C 2.88E-07 Asthma / / 21804549 rs6503525 chr17 38095174 G C 5.95E-06 Self-reported allergy / / 23817569 rs8065126 chr17 38099035 T C 5.89E-07 Asthma (childhood onset) LRRC3C intron 17611496 rs8065126 chr17 38099035 T C 8.90E-04 Depression (quantitative trait) LRRC3C intron 20800221 rs8065126 chr17 38099035 T C 7.50E-07 Self-reported allergy LRRC3C intron 23817569 rs4065985 chr17 38101932 G C 3.32E-07 Asthma / / 21804549 rs4065985 chr17 38101932 G C 8.86E-06 Self-reported allergy / / 23817569 rs3893044 chr17 38103016 T C 3.39E-08 Asthma (childhood onset) / / 17611496 rs3893044 chr17 38103016 T C 1.80E-05 Urinary metabolites / / 21572414 rs8071050 chr17 38106599 A G 6.30E-10 Asthma / / 21907864 rs4795408 chr17 38107627 G A 5.01E-11 Asthma (childhood onset) / / 17611496 rs4795408 chr17 38107627 G A 5.55E-07 Asthma / / 21804549 rs4795408 chr17 38107627 G A 1.26E-05 Self-reported allergy / / 23817569 rs9895948 chr17 38108363 T C 1.81E-06 Self-reported allergy / / 23817569 rs7209742 chr17 38108708 A G 4.37E-07 Asthma (childhood onset) / / 17611496 rs17609240 chr17 38110689 T G 9.00E-09 Hematological parameters / / 19820697 rs17609240 chr17 38110689 T G 2.77E-06 Self-reported allergy / / 23817569 rs8076474 chr17 38111234 G C 3.72E-07 Asthma (childhood onset) / / 17611496 rs8076474 chr17 38111234 G C 2.81E-06 Self-reported allergy / / 23817569 rs1007654 chr17 38111354 A G 2.24E-06 Asthma (childhood onset) / / 17611496 rs1007654 chr17 38111354 A G 3.66E-09 Asthma / / 20860503 rs1007654 chr17 38111354 A G 2.99E-06 Self-reported allergy / / 23817569 rs1007655 chr17 38111419 G A 1.26E-06 Asthma (childhood onset) / / 17611496 rs1007655 chr17 38111419 G A 9.36E-04 Depression (quantitative trait) / / 20800221 rs1007655 chr17 38111419 G A 3.38E-06 Self-reported allergy / / 23817569 rs2313640 chr17 38111845 C T 8.13E-07 Asthma (childhood onset) / / 17611496 rs2313640 chr17 38111845 C T 9.67E-04 Depression (quantitative trait) / / 20800221 rs2313640 chr17 38111845 C T 3.00E-06 Self-reported allergy / / 23817569 rs7218742 chr17 38114361 A G 6.03E-07 Asthma (childhood onset) / / 17611496 rs7218742 chr17 38114361 A G 3.46E-06 Self-reported allergy / / 23817569 rs7218321 chr17 38114469 C T 2.19E-06 Asthma (childhood onset) / / 17611496 rs7218321 chr17 38114469 C T 3.46E-06 Self-reported allergy / / 23817569 rs7219080 chr17 38114516 A C 2.51E-06 Asthma (childhood onset) / / 17611496 rs7219080 chr17 38114516 A C 3.33E-09 Asthma / / 20860503 rs7219080 chr17 38114516 A C 3.56E-06 Self-reported allergy / / 23817569 rs6503526 chr17 38114598 C T 1.05E-09 Asthma (childhood onset) / / 17611496 rs6503526 chr17 38114598 C T 6.63E-07 Asthma / / 21804549 rs6503526 chr17 38114598 C T 1.70E-05 Self-reported allergy / / 23817569 rs6503527 chr17 38114719 G A 1.78E-06 Asthma (childhood onset) / / 17611496 rs6503527 chr17 38114719 G A 3.56E-06 Self-reported allergy / / 23817569 rs3902025 chr17 38119254 G T 8.71E-08 Asthma (childhood onset) GSDMA UTR-5 17611496 rs3902025 chr17 38119254 G T 9.62E-11 Asthma GSDMA UTR-5 20860503 rs3902025 chr17 38119254 G T 7.84E-06 Self-reported allergy GSDMA UTR-5 23817569 rs3894194 chr17 38121993 G A 1.00E-11 Asthma (childhood onset) GSDMA missense 17611496 rs3894194 chr17 38121993 G A 5.00E-09 Asthma GSDMA missense 20860503 rs3894194 chr17 38121993 G A 1.92E-07 Asthma GSDMA missense 21804549 rs3894194 chr17 38121993 G A 4.60E-09 Asthma GSDMA missense 21907864 rs3894194 chr17 38121993 G A 4.60E-09 Asthma GSDMA missense 22561531 rs3894194 chr17 38121993 G A 7.85E-06 Self-reported allergy GSDMA missense 23817569 rs3894194 chr17 38121993 G A 9.60E-05 Atopic dermatitis GSDMA missense 23886662 rs3894194 chr17 38121993 G A 3.00E-21 Asthma (childhood,severe) GSDMA missense 24241537 rs3894194 chr17 38121993 G A 4.60E-06 Asthma GSDMA missense 24406073 rs7212938 chr17 38122680 G T 7.76E-04 Asthma (childhood onset) GSDMA missense 17611496 rs7212938 chr17 38122680 G T 5.68E-07 Asthma GSDMA missense 21804549 rs7212938 chr17 38122680 G T 1.51E-06 Self-reported allergy GSDMA missense 23817569 rs7212938 chr17 38122680 G T 4.00E-10 Asthma and hay fever GSDMA missense 24388013 rs3859192 chr17 38128648 C T 7.10E-13 Asthma (childhood onset) GSDMA intron 17611496 rs3859192 chr17 38128648 C T 2.20E-11 Asthma GSDMA intron 20860503 rs3859192 chr17 38128648 C T 7.83E-06 Post-operative nausea and vomiting GSDMA intron 21694509 rs3859192 chr17 38128648 C T 2.00E-12 White blood cell count GSDMA intron 22037903 rs8075668 chr17 38137623 C T 4.95E-09 Asthma PSMD3 intron 20860503 rs11078929 chr17 38140234 C G,T 0.00000043 Primary biliary cirrhosis PSMD3 intron 22936693 rs4065321 chr17 38143548 C T 2.94E-14 Blood cell counts and other traits PSMD3 intron 20139978 rs4065321 chr17 38143548 C T 3.00E-14 Blood cell counts and other traits PSMD3 intron 20139978 rs12453334 chr17 38153473 C T 2.63E-07 Asthma PSMD3 intron 20860503 rs12453334 chr17 38153473 C T 7.99E-05 Soluble levels of adhesion molecules PSMD3 intron pha003072 rs4794822 chr17 38156712 C T 6.00E-10 Neutrophil count / / 20172861 rs4794822 chr17 38156712 C T 4.00E-16 White blood cell types / / 21738478 rs4794822 chr17 38156712 C T 9.00E-35 White blood cell count / / 21738480 rs8070454 chr17 38160754 C T 1.99E-06 Asthma / / 20860503 rs8070454 chr17 38160754 C T 2.16E-05 Post-operative nausea and vomiting / / 21694509 rs8078723 chr17 38166879 T C 2.00E-31 White blood cell count / / 21738480 rs8078723 chr17 38166879 T C 1.19E-04 Lymphocyte counts / / 22286170 rs8078723 chr17 38166879 T C 3.00E-09 C-reactive protein and white blood cell count / / 22788528 rs9894543 chr17 38167993 T C 7.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs7224260 chr17 38168613 C T 7.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs2302776 chr17 38178149 A G 6.46E-05 Asthma (childhood onset) MED24 intron 17611496 rs2302777 chr17 38179492 A G 8.00E-07 Multiple myeloma (hyperdiploidy) MED24 cds-synon 23502783 rs9916158 chr17 38182229 G T 5.75E-08 Asthma MED24 intron 20860503 rs9916158 chr17 38182229 G T 8.73E-05 Platelet counts MED24 intron 23263863 rs7502514 chr17 38188844 A G 1.80E-05 Self-reported allergy MED24 intron 23817569 rs11078936 chr17 38197914 T C 4.17E-05 Asthma (childhood onset) MED24 intron 17611496 rs11078936 chr17 38197914 T C 1.67E-08 Asthma MED24 intron 20860503 rs8065443 chr17 38208940 A G 4.04E-05 Self-reported allergy MED24 intron 23817569 rs868150 chr17 38213359 A G 4.57E-05 Self-reported allergy / / 23817569 rs7502966 chr17 38216522 C T 2.41E-05 Self-reported allergy THRA nearGene-5 23817569 rs2071427 chr17 38254492 C T 4.60E-05 Asthma NR1D1 intron pha003128 rs75041531 chr17 38393151 A C 9.00E-07 PR interval in Tripanosoma cruzi seropositivity WIPF2 intron 24324551 rs141184179 chr17 38418816 C T 0.0003 Breast cancer WIPF2 missense 23555315 rs1130199 chr17 38447569 T C 1.15E-05 Birth weight CDC6 cds-synon 17255346 rs11650680 chr17 38579236 C T 5.60E-12 Asthma (childhood onset) / / 17611496 rs584438 chr17 38599172 C A,G,T 5.00E-12 Height LOC100287562 intron 23563607 rs1009728 chr17 38609207 T C 4.75E-05 Triglycerides IGFBP4 intron pha003080 rs8078319 chr17 38629215 C T 5.78E-05 Multiple complex diseases / / 17554300 rs17557153 chr17 38636825 C A 3.50E-06 Soluble leptin receptor levels TNS4 intron 20167575 rs4890115 chr17 38640605 C T 3.63E-05 Tunica Media TNS4 intron pha003038 rs2290207 chr17 38640744 C T 2.50E-05 Urinary metabolites TNS4 missense 21572414 rs2290206 chr17 38640992 A G 2.50E-05 Urinary metabolites TNS4 intron 21572414 rs896136 chr17 38651447 G A 9.01E-05 Multiple complex diseases TNS4 intron 17554300 rs6503543 chr17 38652844 A G 1.58E-04 Multiple complex diseases TNS4 intron 17554300 rs7217539 chr17 38661566 C T 5.47E-05 Cognitive test performance / / 20125193 rs4092050 chr17 38662753 C T 8.42E-05 Cognitive test performance / / 20125193 rs630643 chr17 38729588 A G 9.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs803119 chr17 38750296 G C 8.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs1358174 chr17 38757759 G A 1.24E-05 Multiple complex diseases / / 17554300 rs1358174 chr17 38757759 G A 1.67E-04 Type 1 diabetes / / 21980299 rs7221109 chr17 38770286 T C 2.00E-07 Multiple complex diseases / / 17554300 rs7221109 chr17 38770286 T C 2.46E-05 Type 1 diabetes / / 18978792 rs7221109 chr17 38770286 T C 1.00E-09 Type 1 diabetes / / 19430480 rs7221109 chr17 38770286 T C 1.30E-09 Multiple sclerosis / / 22190364 rs7221109 chr17 38770286 T C 0.00022 Breast cancer / / 23555315 rs8074179 chr17 38770965 C G 7.15E-05 Multiple complex diseases / / 17554300 rs4890093 chr17 38795943 T C 2.96E-05 Multiple complex diseases SMARCE1 intron 17554300 rs1048572 chr17 38797242 A G 1.90E-05 Multiple complex diseases SMARCE1 intron 17554300 rs917593 chr17 38816526 A G 2.96E-05 Multiple complex diseases KRT222 intron 17554300 rs2429552 chr17 38868480 T C 5.53E-04 Lymphocyte counts / / 22286170 rs16966168 chr17 38881219 G A 1.77E-04 Obesity (extreme) / / 21935397 rs16966168 chr17 38881219 G A 1.31E-05 Depression (quantitative trait) / / 23290196 rs7226123 chr17 38885366 T C 9.03E-04 Multiple complex diseases / / 17554300 rs1073839 chr17 38890734 T G 2.39E-04 Obesity (extreme) / / 21935397 rs1073839 chr17 38890734 T G 2.96E-05 Depression (quantitative trait) / / 23290196 rs9303295 chr17 38891163 A G 2.48E-04 Obesity (extreme) / / 21935397 rs9303295 chr17 38891163 A G 4.09E-05 Depression (quantitative trait) / / 23290196 rs758632 chr17 38892689 C T 3.92E-05 Asthma / / pha003128 rs9915172 chr17 38925032 C T 4.14E-05 Myopia (pathological) KRT26 intron 23049088 rs2315504 chr17 39046881 C A 8.00E-06 Height / / 19893584 rs12603998 chr17 39066651 T C 6.18E-05 Cardiovascular disease / / pha003064 rs2315603 chr17 39091943 A G 3.83E-05 Serum metabolites KRT23 intron 19043545 rs9908900 chr17 39116072 C T 9.49E-04 Multiple complex diseases KRT39 intron 17554300 rs8075776 chr17 39154663 C T 9.80E-04 Subclinical atherosclerosis / / 17903303 rs2315607 chr17 39158377 C T 4.66E-04 Multiple complex diseases / / 17554300 rs7222585 chr17 39217597 T G 6.40E-04 Type 2 diabetes / / 17463246 rs7223549 chr17 39218714 C T 8.32E-04 Type 2 diabetes / / 17463246 rs7209155 chr17 39218970 T A,C,G 2.29E-05 Multiple complex diseases / / 17554300 rs17490885 chr17 39221312 G T 6.79E-05 Multiple complex diseases / / 17554300 rs8080054 chr17 39225742 A C 1.03E-05 Bipolar disorder and schizophrenia / / 20889312 rs6503586 chr17 39228142 C T 6.59E-06 Bipolar disorder and schizophrenia / / 20889312 rs3914090 chr17 39230058 T A 2.25E-05 Bipolar disorder and schizophrenia / / 20889312 rs2173202 chr17 39235235 T C 3.47E-05 Bipolar disorder and schizophrenia / / 20889312 rs6416909 chr17 39235389 G A 1.39E-05 Bipolar disorder and schizophrenia / / 20889312 rs6503588 chr17 39235453 A G 1.77E-05 Bipolar disorder and schizophrenia / / 20889312 rs1848812 chr17 39235917 C T 7.77E-06 Bipolar disorder and schizophrenia / / 20889312 rs1848811 chr17 39235963 A G 8.79E-06 Bipolar disorder and schizophrenia / / 20889312 rs1510075 chr17 39236452 G A 6.22E-06 Bipolar disorder and schizophrenia / / 20889312 rs2874201 chr17 39238382 C T 1.08E-05 Bipolar disorder and schizophrenia / / 20889312 rs439075 chr17 39239467 T G 8.75E-06 Bipolar disorder and schizophrenia / / 20889312 rs9895828 chr17 39241489 C G 4.36E-06 Bipolar disorder and schizophrenia / / 20889312 rs4006360 chr17 39250639 C T 4.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs2320221 chr17 39251266 G T 1.46E-05 Bipolar disorder and schizophrenia / / 20889312 rs1874607 chr17 39287791 G A 2.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs917635 chr17 39302683 G A 8.84E-06 Bipolar disorder and schizophrenia / / 20889312 rs975251 chr17 39407341 G T 8.50E-05 Alzheimer's disease / / 17998437 rs12451126 chr17 39444101 C T 8.95E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs12451126 chr17 39444101 C T 0.0000089 Asthma (exacerbation) / / 23706709 rs12449502 chr17 39453510 C T 9.05E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs12449502 chr17 39453510 C T 0.0000089 Asthma (exacerbation) / / 23706709 rs8074471 chr17 39456179 G A 0.000008 Asthma (exacerbation) / / 23706709 rs8074471 chr17 39456179 G A 1.88E-05 Erythrocyte counts / / pha003090 rs1001191 chr17 39458476 A T 5.19E-04 Multiple complex diseases / / 17554300 rs758741 chr17 39458893 G A 7.28E-04 Multiple complex diseases / / 17554300 rs758741 chr17 39458893 G A 1.88E-05 Erythrocyte counts / / pha003090 rs4243258 chr17 39460315 C A 4.60E-06 Urinary metabolites / / 21572414 rs4890167 chr17 39460454 G A 7.71E-04 Multiple complex diseases / / 17554300 rs4890167 chr17 39460454 G A 3.77E-04 Alzheimer's disease / / 17998437 rs8067910 chr17 39466888 C T 2.49E-04 Birth weight KRTAP16-1 nearGene-5 17255346 rs9900308 chr17 39469326 C T 2.24E-04 Birth weight / / 17255346 rs10512485 chr17 39470631 T C 4.37E-05 Erythrocyte counts / / pha003090 rs12449671 chr17 39471929 G A 3.59E-04 Multiple complex diseases KRTAP17-1 UTR-5 17554300 rs12449683 chr17 39472018 G A 3.13E-04 Multiple complex diseases KRTAP17-1 nearGene-5 17554300 rs9901096 chr17 39472842 G A 4.37E-05 Erythrocyte counts KRTAP17-1 nearGene-5 pha003090 rs12451938 chr17 39481320 T C 5.22E-04 Multiple complex diseases / / 17554300 rs9895247 chr17 39484621 T C 3.44E-04 Multiple complex diseases / / 17554300 rs9895247 chr17 39484621 T C 8.00E-07 Urinary metabolites / / 21572414 rs16966690 chr17 39486159 G C 6.05E-04 Alzheimer's disease / / 17998437 rs6503623 chr17 39503659 A G 4.00E-04 Chronic fatigue syndrome KRT33A intron 21912186 rs150620728 chr17 39520119 C T 0.00000058 Prostate cancer (advanced) KRT33B missense 23555315 rs16966738 chr17 39521015 T C 2.26E-04 Birth weight KRT33B intron 17255346 rs757102 chr17 39534946 C T 1.80E-05 Urinary metabolites KRT34 intron 21572414 rs7214766 chr17 39569918 G A 6.94E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17494081 chr17 39589083 T G 1.49E-05 Alzheimer's disease / / 21627779 rs17494418 chr17 39595835 T C 6.18E-04 Alzheimer's disease KRT38 intron 17998437 rs4796643 chr17 39595875 G C 3.47E-04 Multiple complex diseases KRT38 intron 17554300 rs9902039 chr17 39601255 C A 1.39E-04 Multiple complex diseases / / 17554300 rs12452065 chr17 39608863 C T 6.15E-06 Erythrocyte counts / / pha003090 rs11655712 chr17 39625032 A C 8.69E-04 Type 2 diabetes KRT32 nearGene-5 17463246 rs2011243 chr17 39636044 G A 1.22E-04 Birth weight KRT35 intron 17255346 rs12451976 chr17 39638548 C T 6.80E-05 Erythrocyte counts KRT35 nearGene-5 pha003090 rs9303309 chr17 39638907 C T 8.12E-04 Schizophrenia KRT35 nearGene-5 21674006 rs16967000 chr17 39641073 C A 6.95E-05 Erythrocyte counts / / pha003090 rs3760521 chr17 39648257 G A 0.000744506 Hypertension (early onset hypertension) / / 22479346 rs721411 chr17 39648944 C T 0.000480496 Hypertension (early onset hypertension) / / 22479346 rs8081580 chr17 39656981 T C 1.51E-04 Amyotrophic lateral sclerosis (sporadic) KRT13 nearGene-3 24529757 rs903 chr17 39657337 C A 8.46E-05 Sudden cardiac arrest KRT13 UTR-3 21658281 rs4796606 chr17 39664087 G A 4.83E-05 Alzheimer's disease (late onset) / / 21379329 rs768027 chr17 39666529 A G 4.62E-05 Alzheimer's disease (late onset) / / 21379329 rs8082575 chr17 39666594 C G 2.30E-26 Narcolepsy / / 19629137 rs3744784 chr17 39674540 A G 9.98E-05 Cognitive test performance KRT15 intron 20125193 rs1050784 chr17 39674641 T C 9.98E-05 Cognitive test performance KRT15 missense 20125193 rs3760519 chr17 39675594 A G 6.15E-04 Type 2 diabetes KRT15 nearGene-5 17463246 rs3760519 chr17 39675594 A G 3.60E-05 Personality dimensions KRT15 nearGene-5 18957941 rs4796780 chr17 39680935 A G 3.70E-05 Personality dimensions KRT19 intron 18957941 rs16967085 chr17 39687632 C G 3.30E-05 Personality dimensions / / 18957941 rs7406917 chr17 39691099 C T 6.96E-05 Fibrinogen / / 17255346 rs7406917 chr17 39691099 C T 8.18E-05 Cognitive test performance / / 20125193 rs62066569 chr17 39712739 G A 0.00002677 Sarcoidosis / / 22952805 rs4372746 chr17 39765714 T C 1.60E-05 Urinary metabolites KRT16 nearGene-3 21572414 rs7219249 chr17 39832676 G A 0.0000058 Stroke / / 23422753 rs12453963 chr17 39838104 T C 3.20E-04 Atrial fibrillation / / 21846873 rs12453963 chr17 39838104 T C 5.81E-05 Insulin Resistance / / pha003062 rs12453963 chr17 39838104 T C 4.69E-05 Insulin-related traits / / pha003063 rs7217461 chr17 39865756 C T 3.60E-06 Urinary metabolites / / 21572414 rs9908890 chr17 39866295 A G 2.72E-09 HDL cholesterol / / 23063622 rs9906561 chr17 39866336 G A 3.60E-06 Urinary metabolites / / 21572414 rs7213435 chr17 39874075 C A 6.70E-06 Urinary metabolites / / 21572414 rs11079009 chr17 39881730 C A 4.70E-06 Urinary metabolites HAP1 intron 21572414 rs4523977 chr17 39883350 G A 1.50E-05 Urinary metabolites HAP1 missense 21572414 rs7406082 chr17 39896062 T C 7.64E-04 Type 2 diabetes / / 17463246 rs4502275 chr17 39896843 A G 2.39E-04 Type 2 diabetes / / 17463246 rs6503659 chr17 39897264 A T 2.96E-04 Type 2 diabetes / / 17463246 rs6503659 chr17 39897264 A T 3.00E-16 Esophageal cancer (squamous cell) / / 22960999 rs7406717 chr17 39908770 C T 3.49E-04 Birth weight / / 17255346 rs11650969 chr17 39934077 T G 3.58E-04 Schizophrenia JUP intron 19197363 rs191392302 chr17 39953961 T G 3.00E-08 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs117897485 chr17 39974440 C T 0.00065 Breast cancer FKBP10 missense 23555315 rs17498875 chr17 40009955 C T 6.00E-04 Alcohol dependence KLHL11 UTR-3 21314694 rs8071234 chr17 40028568 C G 1.35E-08 Lymphocyte counts ACLY intron 22286170 rs4239268 chr17 40154777 G A 9.90E-06 Left ventricular hypertrophy D/JC7 intron 21828061 rs4277396 chr17 40186128 C A 6.53E-04 Suicide attempts in bipolar disorder ZNF385C intron 21423239 rs1076188 chr17 40219433 T G 3.61E-05 Epilepsy / / 22116939 rs4796768 chr17 40224118 C T 1.21E-04 Epilepsy / / 22116939 rs2074158 chr17 40257163 T C 2.34E-04 Multiple complex diseases DHX58 missense 17554300 rs2074158 chr17 40257163 T C 8.80E-05 Pulmonary function DHX58 missense 23932459 rs4796770 chr17 40264896 C A 4.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs1122326 chr17 40274873 A C 0.0007 Stroke HSPB9 missense 23422753 rs739637 chr17 40280944 G C 6.15E-08 Metabolite levels RAB5C intron 23281178 rs739636 chr17 40281063 T G 4.99E-08 Metabolite levels RAB5C intron 23281178 rs2240009 chr17 40283142 C G 6.15E-08 Metabolite levels RAB5C intron 23281178 rs9915255 chr17 40284191 C T 6.15E-08 Metabolite levels RAB5C intron 23281178 rs8070446 chr17 40285879 G A 6.15E-08 Metabolite levels RAB5C intron 23281178 rs8074708 chr17 40286354 G A 6.15E-08 Metabolite levels RAB5C intron 23281178 rs9903204 chr17 40288062 G A 6.15E-08 Metabolite levels RAB5C intron 23281178 rs11079034 chr17 40288890 G A 6.15E-08 Metabolite levels RAB5C intron 23281178 rs11079035 chr17 40289012 G A 7.85E-08 Metabolite levels RAB5C intron 23281178 rs7224737 chr17 40289364 G A 7.13E-13 Lymphocyte counts RAB5C intron 22286170 rs7224737 chr17 40289364 G A 1.26E-08 Metabolite levels RAB5C intron 23281178 rs12603327 chr17 40290552 T C 6.15E-08 Metabolite levels RAB5C intron 23281178 rs12603330 chr17 40290589 T A 6.15E-08 Metabolite levels RAB5C intron 23281178 rs7214921 chr17 40294025 T C 6.15E-08 Metabolite levels RAB5C intron 23281178 rs9912576 chr17 40318734 A G 2.50E-05 Urinary metabolites KCNH4 intron 21572414 rs17500235 chr17 40356360 T G 1.20E-04 Coronary heart disease STAT5B intron 21966275 rs6503691 chr17 40394090 C T 9.46E-05 Post-operative nausea and vomiting STAT5B intron 21694509 rs16967637 chr17 40446422 C A 5.86E-04 Aortic root size STAT5A intron 21223598 rs3809758 chr17 40471980 C T 7.23E-05 Sudden cardiac arrest STAT3 intron 21658281 rs2293152 chr17 40481529 G C 4.00E-08 Multiple sclerosis STAT3 intron 22190364 rs8069645 chr17 40494902 A G 1.53E-04 Multiple complex diseases STAT3 intron 17554300 rs8069645 chr17 40494902 A G 2.49E-05 Crohn's disease STAT3 intron 23266558 rs3816769 chr17 40498273 T C 3.10E-05 Multiple complex diseases STAT3 intron 17554300 rs3816769 chr17 40498273 T C 5.70E-06 Urinary metabolites STAT3 intron 21572414 rs6503695 chr17 40499533 T C 2.49E-05 Crohn's disease STAT3 intron 23266558 rs9891119 chr17 40507980 A C 2.00E-10 Multiple sclerosis STAT3 intron 21833088 rs9891119 chr17 40507980 A C 2.00E-15 Crohn's disease STAT3 intron 23266558 rs9891119 chr17 40507980 A C 1.60E-04 Multiple sclerosis STAT3 intron 24234648 rs744166 chr17 40514201 A G 7.19E-06 Multiple complex diseases STAT3 intron 17554300 rs744166 chr17 40514201 A G 7.00E-12 Crohn's disease STAT3 intron 18587394 rs744166 chr17 40514201 A G 3.00E-10 Multiple sclerosis STAT3 intron 20159113 rs744166 chr17 40514201 A G 7.00E-12 Asthma STAT3 intron 21150878 rs744166 chr17 40514201 A G 9.10E-06 Urinary metabolites STAT3 intron 21572414 rs744166 chr17 40514201 A G 1.20E-06 Multiple sclerosis STAT3 intron 21833088 rs744166 chr17 40514201 A G 6.14E-05 Multiple sclerosis STAT3 intron 22190364 rs744166 chr17 40514201 A G 1.69E-05 Crohn's disease STAT3 intron 23266558 rs3785898 chr17 40515120 C A 1.26E-04 Multiple complex diseases STAT3 intron 17554300 rs3785898 chr17 40515120 C A 1.40E-05 Urinary metabolites STAT3 intron 21572414 rs12942547 chr17 40527544 A G 6.00E-22 Inflammatory bowel disease STAT3 intron 23128233 rs1026916 chr17 40529835 A G 2.03E-05 Multiple complex diseases STAT3 intron 17554300 rs1026916 chr17 40529835 A G 3.00E-06 Urinary metabolites STAT3 intron 21572414 rs7211777 chr17 40534075 G A 2.19E-05 Multiple complex diseases STAT3 intron 17554300 rs7211777 chr17 40534075 G A 3.80E-06 Urinary metabolites STAT3 intron 21572414 rs7211777 chr17 40534075 G A 5.77E-04 Insulin resistance STAT3 intron 21901158 rs4796793 chr17 40542210 G C 1 Drug response to Interferon Alfacon-1 STAT3 nearGene-5 17602083 rs4796793 chr17 40542210 G C 5.26E-04 Amyotrophic lateral sclerosis (sporadic) STAT3 nearGene-5 24529757 rs16967738 chr17 40546267 T C 1.66E-04 Multiple complex diseases / / 17554300 rs2883456 chr17 40552794 C T 1.42E-04 Crohn's disease / / 23266558 rs963986 chr17 40561579 G C 5.30E-09 Psoriasis PTRF intron 23143594 rs1968866 chr17 40566240 T C 6.96E-04 Crohn's disease PTRF intron 23266558 rs12948909 chr17 40570602 A C 6.13E-05 Multiple complex diseases PTRF intron 17554300 rs12948909 chr17 40570602 A C 7.10E-07 Crohn's disease PTRF intron 18587394 rs11871801 chr17 40570772 A C 2.34E-04 Multiple complex diseases PTRF intron 17554300 rs11871801 chr17 40570772 A C 3.00E-08 Crohn's disease PTRF intron 21102463 rs1905339 chr17 40582296 T C 3.59E-04 Crohn's disease / / 23266558 rs9897702 chr17 40609405 A G 5.00E-05 Parkinson's disease / / 21738487 rs1032070 chr17 40618251 C T 3.72E-04 Type 2 diabetes ATP6V0A1 intron 17463246 rs665268 chr17 40722029 A G 7.09E-04 Glycosylated haemoglobin levels MLX missense 17255346 rs9903251 chr17 40735077 C G 7.60E-04 Type 2 diabetes FAM134C intron 17463246 rs4792992 chr17 40737117 G A 4.98E-04 Type 2 diabetes FAM134C intron 17463246 rs4793039 chr17 40760234 A G 6.46E-05 Parkinson's disease FAM134C intron 21738487 rs7220074 chr17 40767786 G A 1.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4792930 chr17 40805844 T G 1.30E-05 Body mass index (non-asthmatics) / / 23517042 rs9897724 chr17 40846914 C T 7.44E-04 Coronary Artery Disease CNT/P1 intron 17634449 rs7215553 chr17 40896077 T C 2.00E-04 Personality dimensions EZH1 intron 23903073 rs9892506 chr17 40904492 A G 1.91E-09 Triglycerides / / 23063622 rs873084 chr17 40930095 A G 4.63E-04 Depression (quantitative trait) VPS25 intron 20800221 rs9910698 chr17 40971770 C T 1.25E-04 Depression (quantitative trait) BECN1 intron 20800221 rs33986943 chr17 41004637 G A 9.65E-04 Stroke (pediatric) AOC3 missense 22990015 rs2670854 chr17 41085683 A G 6.03E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs528854 chr17 41098108 G A 1.60E-04 Height / / 17255346 rs528854 chr17 41098108 G A 6.70E-04 Taste perception / / 22132133 rs7218454 chr17 41106085 T C 7.41E-06 Taste perception / / 22132133 rs146878083 chr17 41106983 T C 0.0001 Breast cancer(er negative) / / 23555315 rs188757965 chr17 41119569 T G 9.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs6503721 chr17 41127448 A G 1.12E-05 Taste perception / / 22132133 rs2667945 chr17 41134412 T G 2.78E-05 Height RUNDC1 intron 17255346 rs2667945 chr17 41134412 T G 8.25E-04 Taste perception RUNDC1 intron 22132133 rs12944462 chr17 41137501 C A 2.47E-06 Taste perception RUNDC1 intron 22132133 rs10852953 chr17 41140267 T G 1.12E-05 Taste perception RUNDC1 intron 22132133 rs323496 chr17 41141971 T C 6.59E-04 Type 2 diabetes RUNDC1 intron 17463246 rs1043284 chr17 41145527 C T 1.66E-05 Height RUNDC1 UTR-3 17255346 rs2271539 chr17 41150949 G A 4.82E-04 Taste perception RPL27 intron 22132133 rs1108287 chr17 41157105 T G 2.98E-05 Taste perception / / 22132133 rs443759 chr17 41165734 C T 6.26E-04 Type 2 diabetes IFI35 intron 17463246 rs443759 chr17 41165734 C T 4.60E-04 Taste perception IFI35 intron 22132133 rs455055 chr17 41167957 C A 5.54E-06 Taste perception VAT1 UTR-3 22132133 rs429464 chr17 41170898 T C 2.45E-05 Alcohol consumption VAT1 intron 23953852 rs382571 chr17 41171481 G A 2.90E-05 Alcohol consumption VAT1 intron 23953852 rs2298862 chr17 41176688 T C 6.99E-04 Depression (quantitative trait) RND2 nearGene-5 20800221 rs2298862 chr17 41176688 T C 6.11E-04 Taste perception RND2 nearGene-5 22132133 rs2298861 chr17 41176831 G A 6.11E-04 Taste perception RND2 nearGene-5 22132133 rs915945 chr17 41179864 C T 8.53E-04 Depression (quantitative trait) RND2 intron 20800221 rs12944458 chr17 41180772 C T 8.25E-04 Taste perception RND2 UTR-3 22132133 rs9911630 chr17 41188342 A G 8.43E-04 Depression (quantitative trait) / / 20800221 rs9911630 chr17 41188342 A G 3.10E-05 Taste perception / / 22132133 rs11657053 chr17 41191129 G T 7.88E-04 Depression (quantitative trait) / / 20800221 rs11657053 chr17 41191129 G T 6.11E-04 Taste perception / / 22132133 rs7223952 chr17 41194885 T C 2.05E-05 Taste perception / / 22132133 rs11659028 chr17 41195025 T A 6.11E-04 Taste perception / / 22132133 rs8176323 chr17 41195711 G C 7.94E-04 Depression (quantitative trait) / / 20800221 rs8176322 chr17 41195773 A G 7.63E-04 Depression (quantitative trait) / / 20800221 rs12516 chr17 41196408 G A 5.16E-04 Taste perception BRCA1 UTR-3 22132133 rs8176318 chr17 41197274 C A 7.66E-04 Depression (quantitative trait) BRCA1 UTR-3 20800221 rs4793190 chr17 41200109 T C 8.33E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs3092988 chr17 41201702 C T 7.80E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs8070179 chr17 41202688 G A 7.74E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs8176297 chr17 41203325 T A 7.85E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs4793191 chr17 41204377 A G 7.93E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs8176289 chr17 41206056 T C 8.00E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs8176273 chr17 41211653 A G 8.09E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs8176265 chr17 41213996 C T 7.68E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs3092994 chr17 41215825 C T 7.74E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs8176242 chr17 41217874 C T 9.89E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs4793194 chr17 41218333 G A 9.89E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs1799966 chr17 41223094 T A,C,G 9.92E-04 Depression (quantitative trait) BRCA1 missense 20800221 rs397509198 chr17 41223094 T TC 9.92E-04 Depression (quantitative trait) BRCA1 missense 20800221 rs8176202 chr17 41230228 G A 9.95E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs8176194 chr17 41231221 A C 9.96E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs8176193 chr17 41231516 C T 9.96E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs4793197 chr17 41231902 G A 9.96E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs1060915 chr17 41234470 A C,G,T 9.95E-04 Depression (quantitative trait) BRCA1 cds-synon 20800221 rs8067269 chr17 41235799 G A 9.82E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs3950989 chr17 41237953 G A 9.66E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs2070834 chr17 41242285 T G 9.63E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs799916 chr17 41243190 T G 9.71E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs16942 chr17 41244000 T C 9.60E-04 Depression (quantitative trait) BRCA1 missense 20800221 rs16941 chr17 41244435 T A,C,G 9.58E-04 Depression (quantitative trait) BRCA1 missense 20800221 rs80357920 chr17 41244435 TCTTTAA T 9.58E-04 Depression (quantitative trait) BRCA1 missense 20800221 rs799917 chr17 41244936 G A,C,T 9.67E-04 Depression (quantitative trait) BRCA1 missense 20800221 rs799917 chr17 41244936 G A,C,T 5.21E-05 Taste perception BRCA1 missense 22132133 rs16940 chr17 41245237 A G 9.40E-04 Depression (quantitative trait) BRCA1 cds-synon 20800221 rs397508955 chr17 41245237 A AG,ATGAAATACTGCTACTCTCT 9.40E-04 Depression (quantitative trait) BRCA1 cds-synon 20800221 rs1799949 chr17 41245466 G A 9.36E-04 Depression (quantitative trait) BRCA1 cds-synon 20800221 rs397763555 chr17 41247122 A ACCT 7.81E-04 Taste perception BRCA1 intron 22132133 rs5820483 chr17 41247122 A ACCT 7.81E-04 Taste perception BRCA1 intron 22132133 rs71228776 chr17 41247122 A ACCT 7.81E-04 Taste perception BRCA1 intron 22132133 rs8176140 chr17 41251646 T A 8.98E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs799912 chr17 41257134 T C 9.18E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs799912 chr17 41257134 T C 5.59E-05 Taste perception BRCA1 intron 22132133 rs8176126 chr17 41259049 C T 9.29E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs8176126 chr17 41259049 C T 7.01E-13 Lymphocyte counts BRCA1 intron 22286170 rs3765640 chr17 41276247 A G 9.07E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs799905 chr17 41277187 G C 9.04E-04 Depression (quantitative trait) BRCA1 intron 20800221 rs799906 chr17 41278116 T C 9.04E-04 Depression (quantitative trait) NBR2 intron 20800221 rs799906 chr17 41278116 T C 1.47E-04 Taste perception NBR2 intron 22132133 rs11653069 chr17 41283377 C T 8.99E-04 Depression (quantitative trait) NBR2 intron 20800221 rs2175957 chr17 41286822 T G 8.94E-04 Depression (quantitative trait) NBR2 intron 20800221 rs11656097 chr17 41290613 G T 8.91E-04 Depression (quantitative trait) NBR2 intron 20800221 rs2292595 chr17 41290674 G C 8.89E-04 Depression (quantitative trait) / / 20800221 rs11658754 chr17 41292739 G A 8.86E-04 Depression (quantitative trait) NBR2 intron 20800221 rs7223062 chr17 41297652 A C 8.82E-04 Depression (quantitative trait) / / 20800221 rs11079056 chr17 41300799 C A 8.77E-04 Depression (quantitative trait) / / 20800221 rs1973646 chr17 41310495 T C 8.55E-04 Depression (quantitative trait) LOC100505899 intron 20800221 rs2271573 chr17 41327621 A G 7.90E-04 Depression (quantitative trait) NBR1 intron 20800221 rs2271574 chr17 41327648 T C 7.89E-04 Depression (quantitative trait) NBR1 intron 20800221 rs4239149 chr17 41328095 A G 7.84E-04 Depression (quantitative trait) NBR1 intron 20800221 rs4239149 chr17 41328095 A G 1.62E-04 Taste perception NBR1 intron 22132133 rs2171461 chr17 41403711 C A,G,T 0.000103 Height (Pygmy height) / / 22570615 rs9646416 chr17 41424101 C A 7.72E-04 Depression (quantitative trait) / / 20800221 rs8078799 chr17 41426948 G A 2.10E-04 Multiple complex diseases / / 17554300 rs4793230 chr17 41427403 A C 2.38E-04 Taste perception / / 22132133 rs4474733 chr17 41433660 G T 6.22E-04 Depression (quantitative trait) / / 20800221 rs11657004 chr17 41442751 A G 7.48E-04 Depression (quantitative trait) / / 20800221 rs11654307 chr17 41444436 C G 7.69E-04 Depression (quantitative trait) / / 20800221 rs9912203 chr17 41445145 G A 7.12E-04 Depression (quantitative trait) / / 20800221 rs7215223 chr17 41501295 C T 5.75E-05 Hepatocellular carcinoma / / 22807686 rs1984518 chr17 41521666 T G 1.41E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7224969 chr17 41573527 C T 5.71E-04 Multiple complex diseases DHX8 intron 17554300 rs1971 chr17 41602518 G A 2.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs11650719 chr17 41651885 G A 7.10E-06 Suicide attempts in bipolar disorder / / 21423239 rs11650719 chr17 41651885 G A 7.90E-06 Urinary metabolites / / 21572414 rs12941944 chr17 41653440 T G 1.27E-05 Suicide attempts in bipolar disorder / / 21423239 rs12373151 chr17 41672346 G A 3.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs1728171 chr17 41673329 G A 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs4793011 chr17 41726325 A G 2.12E-05 Height MEOX1 intron pha003010 rs4793011 chr17 41726325 A G 4.90E-05 Height MEOX1 intron pha003011 rs16940095 chr17 41757926 A G 3.36E-05 Alcohol consumption / / 23953852 rs6503468 chr17 41772813 T C 9.63E-05 Lung adenocarcinoma / / 19836008 rs1107748 chr17 41773814 T C 1.00E-07 Bone mineral density (spine) / / 19079262 rs4793017 chr17 41780980 A G 4.25E-05 Suicidal ideation / / 20877300 rs7220711 chr17 41789965 A G 2.20E-08 Bone mineral density (spine) / / 19079262 rs4792909 chr17 41798824 G T 2.00E-11 Bone mineral density / / 22504420 rs1513670 chr17 41807331 T C 2.00E-08 Bone mineral density (hip) / / 19079262 rs865429 chr17 41835215 G A 2.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SOST intron 20877124 rs865429 chr17 41835215 G A 3.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SOST intron 20877124 rs16940199 chr17 41844538 G A 3.51E-04 Multiple complex diseases DUSP3 UTR-3 17554300 rs8077889 chr17 41878166 A C 1.00E-08 Triglycerides / / 24097068 rs231519 chr17 41961051 T C 8.96E-06 Cognitive function MPP2 intron 24684796 rs231518 chr17 41961451 T C 1.10E-05 Cognitive function MPP2 intron 24684796 rs231513 chr17 41965200 C G 8.00E-06 Cognitive function MPP2 intron 24684796 rs231506 chr17 41970191 T C 8.02E-06 Cognitive function MPP2 intron 24684796 rs231500 chr17 41973374 T C 2.50E-05 Cognitive function MPP2 intron 24684796 rs231499 chr17 41973507 A G 9.34E-06 Cognitive function MPP2 intron 24684796 rs231498 chr17 41975251 C G 1.90E-05 Cognitive function MPP2 intron 24684796 rs231480 chr17 41983498 G A 9.04E-05 Crohn's disease MPP2 intron 17804789 rs179586 chr17 41999094 T C 2.30E-05 Cognitive function / / 24684796 rs1731901 chr17 41999156 T A 5.99E-05 Multiple complex diseases / / 17554300 rs1731906 chr17 42005741 T C 1.47E-04 Multiple complex diseases / / 17554300 rs1731893 chr17 42012926 C T 4.17E-05 Cognitive test performance / / 20125193 rs1731893 chr17 42012926 C T 1.60E-05 Height / / 22021425 rs231471 chr17 42019494 C T 2.95E-05 Cognitive test performance PPY intron 20125193 rs231461 chr17 42033043 G A 2.50E-05 Type 2 diabetes PYY intron 17293876 rs231461 chr17 42033043 G A 2.50E-05 Type 2 diabetes PYY intron 19184112 rs1642598 chr17 42045212 G A 4.04E-04 Lymphocyte counts PYY intron 22286170 rs9895585 chr17 42064987 A C 9.00E-06 Response to taxane treatment (placlitaxel) PYY intron 23006423 rs228768 chr17 42191893 G T 4.36E-04 Multiple complex diseases HDAC5 intron 17554300 rs228769 chr17 42193185 G C 2.00E-08 Bone mineral density (hip) HDAC5 intron 19801982 rs228769 chr17 42193185 G C 4.00E-06 Bone mineral density (spine) HDAC5 intron 19801982 rs453789 chr17 42196015 A C 1.48E-08 Triglycerides HDAC5 intron 23063622 rs79605584 chr17 42199676 G A 1.49E-04 Cocaine dependence HDAC5 intron 23958962 rs12603404 chr17 42223914 G A 4.52E-05 Glycated hemoglobin levels C17orf53 intron 24244560 rs12601855 chr17 42224023 A G 2.92E-05 Glycated hemoglobin levels C17orf53 intron 24244560 rs16940539 chr17 42224581 C G 3.24E-05 Glycated hemoglobin levels C17orf53 intron 24244560 rs227584 chr17 42225547 A C 9.00E-07 Bone mineral density (hip) C17orf53 missense 19079262 rs227584 chr17 42225547 A C 3.00E-24 Bone mineral density C17orf53 missense 22504420 rs2285954 chr17 42232938 T G 2.82E-05 Glycated hemoglobin levels C17orf53 intron 24244560 rs12602486 chr17 42241929 T G 1.00E-24 Glycated hemoglobin levels / / 24244560 rs12602486 chr17 42241929 T G 2.96E-05 Glycated hemoglobin levels / / 24244560 rs11652516 chr17 42272586 G A 3.19E-09 Metabolite levels ATXN7L3 intron 23281178 rs2071167 chr17 42287519 C T 0.0000813 Coronary artery disease UBTF cds-synon 23202125 rs2269906 chr17 42294337 A C 4.84E-04 Multiple complex diseases UBTF intron 17554300 rs2269906 chr17 42294337 A C 1.95E-11 Red blood cell traits UBTF intron 23222517 rs2269906 chr17 42294337 A C 4.49E-04 Self-reported allergy UBTF intron 23817569 rs2269905 chr17 42294462 A G 8.87E-11 Red blood cell traits UBTF intron 23222517 rs2269905 chr17 42294462 A G 4.24E-04 Self-reported allergy UBTF intron 23817569 rs11652651 chr17 42302907 G A 5.22E-04 Multiple complex diseases / / 17554300 rs11652651 chr17 42302907 G A 3.28E-11 Red blood cell traits / / 23222517 rs7222349 chr17 42304644 G A 4.50E-04 Multiple complex diseases / / 17554300 rs7222349 chr17 42304644 G A 7.90E-11 Red blood cell traits / / 23222517 rs9901595 chr17 42305699 G A 1.87E-08 Red blood cell traits / / 23222517 rs9901595 chr17 42305699 G A 7.29E-04 Self-reported allergy / / 23817569 rs7209801 chr17 42323376 G A 4.03E-08 Red blood cell traits / / 23222517 rs7209801 chr17 42323376 G A 2.78E-04 Self-reported allergy / / 23817569 rs2072081 chr17 42327493 G T 3.19E-08 Red blood cell traits SLC4A1 UTR-3 23222517 rs2857078 chr17 42330171 A C 3.43E-09 Red blood cell traits SLC4A1 intron 23222517 rs5023 chr17 42330729 T C 1.00E-06 Obesity-related traits SLC4A1 missense 23251661 rs5020 chr17 42332587 A G 0.000000028 LDL cholesterol SLC4A1 cds-synon 23063622 rs5020 chr17 42332587 A G 1.49E-11 Triglycerides SLC4A1 cds-synon 23063622 rs28931583 chr17 42335888 G C 0.000014 Breast cancer(er negative) SLC4A1 missense 23555315 rs2074108 chr17 42336149 C T 1.87E-05 Blood Pressure SLC4A1 intron pha003045 rs2074108 chr17 42336149 C T 8.93E-06 Blood Pressure SLC4A1 intron pha003047 rs5036 chr17 42338945 T C 6.64E-07 Glycated hemoglobin levels SLC4A1 missense 24244560 rs9913813 chr17 42354693 G A 2.29E-19 HDL cholesterol / / 23063622 rs9913813 chr17 42354693 G A 9.81E-09 LDL cholesterol / / 23063622 rs7216307 chr17 42413481 C T 0.00022 Coronary artery calcification / / 23727086 rs11655476 chr17 42415772 C T 0.00042 Coronary artery calcification / / 23727086 rs3760365 chr17 42420676 C T 0.000088 Coronary artery calcification GRN nearGene-5 23727086 rs4792938 chr17 42424599 G C 0.0005 Coronary artery calcification GRN intron 23727086 rs708384 chr17 42437682 C A 7.41E-05 Parkinson's disease FAM171A2 intron 21738487 rs708382 chr17 42442344 T C 2.81E-05 Parkinson's disease / / 21738487 rs708382 chr17 42442344 T C 2.00E-08 Platelet counts / / 22139419 rs850737 chr17 42443784 T C 3.01E-05 Parkinson's disease / / 21738487 rs8070273 chr17 42467570 G C 0.000000048 Cholesterol,total ITGA2B nearGene-5 23063622 rs8070273 chr17 42467570 G C 1.40E-09 LDL cholesterol ITGA2B nearGene-5 23063622 rs2037958 chr17 42472045 T G 0.000893 Salmonella-induced pyroptosis / / 22837397 rs1018358 chr17 42472588 C T 0.000629 Salmonella-induced pyroptosis / / 22837397 rs9902493 chr17 42497737 G A 0.000773 Salmonella-induced pyroptosis GPATCH8 intron 22837397 rs4793103 chr17 42511682 A G 0.000865 Salmonella-induced pyroptosis GPATCH8 intron 22837397 rs7223926 chr17 42578882 G A 0.000774 Salmonella-induced pyroptosis GPATCH8 intron 22837397 rs4792948 chr17 42637488 C T 1.94E-05 Job-related exhaustion FZD2 UTR-3 23620144 rs7501777 chr17 42638677 T G 6.22E-05 Post-operative nausea and vomiting / / 21694509 rs9944407 chr17 42661960 C T 2.89E-05 Major depressive disorder / / 20516156 rs9944407 chr17 42661960 C T 0.00000331 Major depressive disorder age at onset<30 / / 22915352 rs8065132 chr17 42662099 C T 5.43E-04 Multiple complex diseases / / 17554300 rs11656687 chr17 42662966 C T 0.000694 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11656687 chr17 42662966 C T 6.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12450493 chr17 42672190 C T 0.000452 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12450493 chr17 42672190 C T 4.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11655190 chr17 42679220 G A 3.49E-10 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs8079488 chr17 42746144 C T 6.30E-11 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain C17orf104 intron 20154673 rs3897489 chr17 42753873 A G 7.00E-11 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs3744477 chr17 42827673 G A 3.78E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain DBF4B intron 20154673 rs4426386 chr17 42835495 A G 2.16E-09 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs4043263 chr17 42860326 G A 2.69E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs4043263 chr17 42860326 G A 6.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8064954 chr17 42867443 A C 4.79E-09 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs8064669 chr17 42874870 C T 3.04E-07 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs17544947 chr17 42918966 T G 1.31E-05 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs17544947 chr17 42918966 T G 5.67E-05 Breast Cancer in BRCA1 mutation carriers / / 23544013 rs8069296 chr17 42935059 T C 4.60E-05 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain EFTUD2 intron 20154673 rs9910260 chr17 42939170 G A 8.44E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain EFTUD2 intron 20154673 rs8077272 chr17 42941468 T C 7.93E-05 Type 2 diabetes EFTUD2 intron 17463246 rs9914884 chr17 42955589 T C 6.99E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain EFTUD2 intron 20154673 rs7210042 chr17 42967295 T C 1.21E-04 Type 2 diabetes EFTUD2 intron 17463246 rs9908594 chr17 42973313 G A 7.92E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain EFTUD2 intron 20154673 rs7222312 chr17 42978554 T C 1.21E-04 Type 2 diabetes CCDC103 intron 17463246 rs12937256 chr17 42981499 C T 6.03E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs3826425 chr17 42981654 A G 5.13E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs3744473 chr17 42982288 A G 1.03E-04 Type 2 diabetes / / 17463246 rs3744473 chr17 42982288 A G 7.33E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs17629022 chr17 42992049 T C 5.70E-05 Coffee consumption GFAP intron 21357676 rs2070935 chr17 42993118 G T 8.93E-05 Height GFAP nearGene-5 pha003010 rs2070935 chr17 42993118 G T 8.73E-05 Height GFAP nearGene-5 pha003011 rs3760379 chr17 42993855 A G 3.14E-04 Glaucoma (primary open-angle) GFAP nearGene-5 22419738 rs9908100 chr17 43007951 T C 1.70E-05 Parkinson's disease (age of onset) KIF18B intron 19772629 rs17546822 chr17 43008970 T C 1.13E-05 Asthma KIF18B missense 23181788 rs12941574 chr17 43030679 T C 1.20E-06 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs4793166 chr17 43035377 G A 1.82E-04 Frontotemporal lobar degeneration with TDP-43 inclusions,in brain / / 20154673 rs7225162 chr17 43036260 C T 3.50E-04 Iris characteristics / / 21835309 rs1007190 chr17 43038209 C T 2.00E-06 DNA methylation (variation) C1QL1 intron 23725790 rs4792963 chr17 43071612 A G 5.63E-04 Stroke / / pha002887 rs11652163 chr17 43081974 A G 9.55E-05 Brain lesion load / / 19010793 rs2337437 chr17 43096229 G T 8.29E-04 Schizophrenia / / 19197363 rs9900173 chr17 43111688 G A 3.39E-05 Brain lesion load DCAKD cds-synon 19010793 rs9898793 chr17 43116313 C T 3.55E-05 Brain lesion load DCAKD intron 19010793 rs9898793 chr17 43116313 C T 8.50E-05 Bone mineral density (spine) DCAKD intron 19079262 rs8078303 chr17 43117813 T C 1.62E-06 Multiple complex diseases DCAKD intron 17554300 rs2157839 chr17 43151400 T C 7.70E-05 Bone mineral density (spine) NMT1 intron 19079262 rs7213273 chr17 43155914 G A 7.33E-07 Blood pressure NMT1 intron 21909110 rs6503422 chr17 43163851 T C 8.13E-05 Brain lesion load NMT1 intron 19010793 rs1005136 chr17 43164246 G T 4.48E-04 Multiple complex diseases NMT1 intron 17554300 rs1005136 chr17 43164246 G T 2.61E-04 Lymphocyte counts NMT1 intron 22286170 rs2301597 chr17 43173273 T C 8.74E-04 Alcohol consumption (maxi-drinks) NMT1 intron 24277619 rs2239922 chr17 43175906 C T 6.51E-04 Multiple complex diseases NMT1 cds-synon 17554300 rs2269746 chr17 43185023 C A 6.64E-05 Lung function (forced vital capacity) NMT1 UTR-3 24023788 rs739454 chr17 43195205 C T 2.75E-04 Birth weight PLCD3 intron 17255346 rs3744758 chr17 43195663 A G 8.10E-04 Type 2 diabetes PLCD3 cds-synon 17463246 rs3744760 chr17 43195981 T C 2.59E-05 Serum metabolites PLCD3 intron 19043545 rs3744760 chr17 43195981 T C 6.09E-04 Smoking initiation PLCD3 intron 24665060 rs2129732 chr17 43197593 G A 5.87E-04 Multiple complex diseases PLCD3 intron 17554300 rs7207047 chr17 43198998 G A 1.60E-04 Coronary heart disease PLCD3 intron 21966275 rs9303454 chr17 43200918 A G 5.50E-04 Coronary heart disease PLCD3 intron 21966275 rs12946454 chr17 43208121 A T 1.00E-08 Systolic blood pressure PLCD3 intron 19430483 rs12946454 chr17 43208121 A T 1.00E-08 Coronary heart disease PLCD3 intron 21347282 rs12946454 chr17 43208121 A T 1.00E-08 Blood pressure PLCD3 intron 21378095 rs12946454 chr17 43208121 A T 4.35E-08 Systolic blood pressure PLCD3 intron 21909115 rs2291447 chr17 43212963 G T 2.00E-06 Economic and political preferences ACBD4 UTR-5 22566634 rs4986172 chr17 43216281 C T 2.00E-16 Height ACBD4 intron 20881960 rs116523982 chr17 43223170 G A 0.0000251 Menopause (age at onset) / / 23424626 rs3744412 chr17 43225422 G C 0.0000252 Menopause (age at onset) HEXIM1 UTR-5 23424626 rs59622946 chr17 43237648 G T 0.00000493 Menopause (age at onset) / / 23424626 rs16939893 chr17 43240081 C T 0.0000273 Menopause (age at onset) HEXIM2 intron 23424626 rs200017941 chr17 43247151 G A 0.000054 Breast cancer(er negative) HEXIM2 missense 23555315 rs4792819 chr17 43247957 A C 3.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100505972 intron 20877124 rs1552458 chr17 43298388 A G 8.54E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7215764 chr17 43338941 G C 8.29E-04 Multiple complex diseases TEX34 intron 17554300 rs1047841 chr17 43340631 C T 5.25E-04 Type 2 diabetes MAP3K14 UTR-3 17463246 rs4792809 chr17 43346980 G T 6.51E-04 Multiple complex diseases MAP3K14 intron 17554300 rs11574831 chr17 43347610 C T 4.77E-04 Coronary heart disease MAP3K14 intron 21606135 rs9908330 chr17 43383100 A G 9.90E-06 Urinary metabolites MAP3K14 intron 21572414 rs12449740 chr17 43385349 G A 2.40E-06 Urinary metabolites MAP3K14 intron 21572414 rs16939961 chr17 43401748 C T 9.10E-05 HIV-1 control / / 20041166 rs4792814 chr17 43403005 T C 3.30E-06 Urinary metabolites / / 21572414 rs4792814 chr17 43403005 T C 3.00E-06 Multiple sclerosis / / 21833088 rs34993366 chr17 43404148 T C 6.64E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs1000354 chr17 43413451 A G 1.90E-05 Urinary metabolites / / 21572414 rs12947718 chr17 43493101 G A 7.46E-05 Multiple complex diseases ARHGAP27 intron 17554300 rs12947718 chr17 43493101 G A 3.84E-05 Brain structure ARHGAP27 intron 22504417 rs12947718 chr17 43493101 G A 8.94E-08 Red blood cell traits ARHGAP27 intron 23222517 rs12942666 chr17 43499839 A G 4.54E-05 Brain structure ARHGAP27 intron 22504417 rs12942666 chr17 43499839 A G 2.65E-08 Red blood cell traits ARHGAP27 intron 23222517 rs7222389 chr17 43501442 T C 3.53E-08 Red blood cell traits ARHGAP27 intron 23222517 rs34018943 chr17 43508303 A G 3.87E-05 Brain structure ARHGAP27 intron 22504417 rs11012 chr17 43513441 C T 8.04E-11 Parkinson's disease PLEKHM1 UTR-3 19915575 rs11012 chr17 43513441 C T 6.00E-08 Parkinson's disease PLEKHM1 UTR-3 20070850 rs11012 chr17 43513441 C T 7.74E-11 Parkinson's disease PLEKHM1 UTR-3 21738487 rs11012 chr17 43513441 C T 9.36E-13 Parkinson's disease PLEKHM1 UTR-3 22438815 rs11012 chr17 43513441 C T 2.17E-05 Brain structure PLEKHM1 UTR-3 22504417 rs11012 chr17 43513441 C T 1.24E-07 Red blood cell traits PLEKHM1 UTR-3 23222517 rs11012 chr17 43513441 C T 8.77E-05 Parkinson's disease PLEKHM1 UTR-3 pha002865 rs11012 chr17 43513441 C T 2.85E-06 Parkinson's disease PLEKHM1 UTR-3 pha002868 rs9730 chr17 43513551 C G 1.05E-07 Red blood cell traits PLEKHM1 UTR-3 23222517 rs17631303 chr17 43516402 A G 5.38E-05 Multiple complex diseases PLEKHM1 intron 17554300 rs17631303 chr17 43516402 A G 1.80E-08 Red blood cell traits PLEKHM1 intron 23222517 rs17631303 chr17 43516402 A G 1.00E-08 Ovarian cancer in BRCA1 mutation carriers PLEKHM1 intron 23544013 rs17631303 chr17 43516402 A G 1.41E-08 Ovarian cancer in BRCA1 mutation carriers PLEKHM1 intron 23544013 rs17631303 chr17 43516402 A G 2.80E-10 Ovarian cancer in BRCA1 mutation carriers PLEKHM1 intron 23544013 rs2077606 chr17 43529293 G A 7.92E-08 Red blood cell traits PLEKHM1 intron 23222517 rs2077606 chr17 43529293 G A 1.27E-09 Ovarian cancer in BRCA1 mutation carriers PLEKHM1 intron 23544013 rs3946526 chr17 43541656 C T 9.00E-05 Multiple complex diseases PLEKHM1 intron 17554300 rs3946526 chr17 43541656 C T 2.74E-09 Red blood cell traits PLEKHM1 intron 23222517 rs17631676 chr17 43549526 A G 3.16E-05 Brain structure PLEKHM1 intron 22504417 rs561571325 chr17 43575228 T C 1.39E-07 Red blood cell traits / / 23222517 rs527989506 chr17 43656895 G A 1.40E-09 Red blood cell traits / / 23222517 rs2668680 chr17 43659975 T C 9.08E-09 Red blood cell traits / / 23222517 rs543659018 chr17 43659975 T C 9.08E-09 Red blood cell traits / / 23222517 rs57213017 chr17 43666906 G C 9.26E-05 Multiple complex diseases / / 17554300 rs57213017 chr17 43666906 G C 2.50E-07 Red blood cell traits / / 23222517 rs1724411 chr17 43669931 T C 1.63E-07 Red blood cell traits / / 23222517 rs566002249 chr17 43669931 T C 1.63E-07 Red blood cell traits / / 23222517 rs549463181 chr17 43679121 G A 4.82E-09 Primary biliary cirrhosis LOC100653029 missense 22961000 rs440778 chr17 43686420 A C,G,T 8.42E-04 Obesity (extreme) / / 21935397 rs541886938 chr17 43693538 G T 1.23E-04 Multiple complex diseases / / 17554300 rs541886938 chr17 43693538 G T 2.49E-07 Red blood cell traits / / 23222517 rs383241 chr17 43705356 G A 1.22E-09 Red blood cell traits CRHR1 intron 23222517 rs436667 chr17 43709415 C T 7.29E-07 Red blood cell traits CRHR1 intron 23222517 rs2942169 chr17 43711539 G C 4.65E-07 Red blood cell traits CRHR1 intron 23222517 rs241044 chr17 43712464 G A 4.03E-07 Red blood cell traits CRHR1 intron 23222517 rs241041 chr17 43713925 A C,G,T 5.80E-06 Parkinson's disease CRHR1 intron 20711177 rs241041 chr17 43713925 A C,G,T 2.06E-09 Parkinson's disease CRHR1 intron 22438815 rs241041 chr17 43713925 A C,G,T 4.59E-09 Primary biliary cirrhosis CRHR1 intron 22961000 rs241041 chr17 43713925 A C,G,T 4.31E-07 Red blood cell traits CRHR1 intron 23222517 rs241039 chr17 43714673 A T 6.30E-06 Parkinson's disease CRHR1 intron 20711177 rs241039 chr17 43714673 A T 2.23E-09 Parkinson's disease CRHR1 intron 22438815 rs241039 chr17 43714673 A T 4.17E-07 Red blood cell traits CRHR1 intron 23222517 rs2942168 chr17 43714850 G A,C,T 5.30E-06 Parkinson's disease CRHR1 intron 20711177 rs2942168 chr17 43714850 G A,C,T 1.00E-28 Parkinson's disease CRHR1 intron 21292315 rs2942168 chr17 43714850 G A,C,T 2.27E-46 Parkinson's disease CRHR1 intron 22438815 rs2942168 chr17 43714850 G A,C,T 1.62E-18 Parkinson's disease CRHR1 intron 22451204 rs2942168 chr17 43714850 G A,C,T 4.59E-09 Primary biliary cirrhosis CRHR1 intron 22961000 rs2942168 chr17 43714850 G A,C,T 9.69E-07 Red blood cell traits CRHR1 intron 23222517 rs2942168 chr17 43714850 G A,C,T 2.00E-05 Parkinson's disease CRHR1 intron 24511991 rs2942168 chr17 43714850 G A,C,T 3.00E-04 Parkinson's disease CRHR1 intron 24511991 rs2942168 chr17 43714850 G A,C,T 5.00E-06 Parkinson's disease CRHR1 intron 24511991 rs2942168 chr17 43714850 G A,C,T 4.18E-06 Parkinson's disease CRHR1 intron 24842889 rs2942167 chr17 43715018 T C 5.80E-06 Parkinson's disease CRHR1 intron 20711177 rs2942167 chr17 43715018 T C 1.44E-09 Primary biliary cirrhosis CRHR1 intron 22961000 rs2942167 chr17 43715018 T C 3.33E-07 Red blood cell traits CRHR1 intron 23222517 rs413778 chr17 43716885 A G 1.44E-04 Multiple complex diseases CRHR1 intron 17554300 rs413778 chr17 43716885 A G 5.59E-05 Brain structure CRHR1 intron 22504417 rs413778 chr17 43716885 A G 1.70E-09 Primary biliary cirrhosis CRHR1 intron 22961000 rs413778 chr17 43716885 A G 1.08E-07 Red blood cell traits CRHR1 intron 23222517 rs389217 chr17 43717131 C T 5.33E-05 Brain structure CRHR1 intron 22504417 rs389217 chr17 43717131 C T 1.41E-09 Primary biliary cirrhosis CRHR1 intron 22961000 rs389217 chr17 43717131 C T 5.00E-07 Red blood cell traits CRHR1 intron 23222517 rs439558 chr17 43717803 T C 1.20E-04 Brain structure CRHR1 intron 22504417 rs439558 chr17 43717803 T C 1.47E-09 Primary biliary cirrhosis CRHR1 intron 22961000 rs439558 chr17 43717803 T C 1.49E-09 Red blood cell traits CRHR1 intron 23222517 rs393152 chr17 43719143 A G 2.00E-16 Parkinson's disease CRHR1 intron 19915575 rs393152 chr17 43719143 A G 9.22E-14 Parkinson's disease CRHR1 intron 21738487 rs393152 chr17 43719143 A G 1.95E-16 Prion diseases CRHR1 intron 22210626 rs393152 chr17 43719143 A G 2.40E-22 Parkinson's disease CRHR1 intron 22438815 rs393152 chr17 43719143 A G 1.31E-04 Brain structure CRHR1 intron 22504417 rs393152 chr17 43719143 A G 4.91E-09 Primary biliary cirrhosis CRHR1 intron 22961000 rs393152 chr17 43719143 A G 2.87E-07 Red blood cell traits CRHR1 intron 23222517 rs393152 chr17 43719143 A G 9.26E-08 Interstitial lung disease CRHR1 intron 23583980 rs393152 chr17 43719143 A G 1.42E-07 Parkinson's disease CRHR1 intron pha002868 rs2942164 chr17 43721283 G C 2.17E-07 Red blood cell traits CRHR1 intron 23222517 rs413917 chr17 43723189 G A 2.12E-07 Red blood cell traits CRHR1 intron 23222517 rs3418 chr17 43723462 C T 4.51E-07 Red blood cell traits CRHR1 intron 23222517 rs449501 chr17 43724555 G A 3.38E-07 Red blood cell traits CRHR1 intron 23222517 rs448830 chr17 43725212 G A 0.000000003 Primary biliary cirrhosis CRHR1 intron 22961000 rs448830 chr17 43725212 G A 9.24E-07 Red blood cell traits CRHR1 intron 23222517 rs142742547 chr17 43725684 GT G 9.31E-07 Red blood cell traits CRHR1 intron 23222517 rs434428 chr17 43725684 G A 9.31E-07 Red blood cell traits CRHR1 intron 23222517 rs385691 chr17 43726125 A C 4.87E-07 Red blood cell traits CRHR1 intron 23222517 rs455028 chr17 43726574 T C 9.89E-07 Red blood cell traits CRHR1 intron 23222517 rs366858 chr17 43726588 C T 4.94E-07 Red blood cell traits CRHR1 intron 23222517 rs439945 chr17 43726659 A C 2.65E-07 Red blood cell traits CRHR1 intron 23222517 rs453997 chr17 43727061 C T 1.33E-04 Multiple complex diseases CRHR1 intron 17554300 rs453997 chr17 43727061 C T 7.29E-05 Brain structure CRHR1 intron 22504417 rs453997 chr17 43727061 C T 1.26E-07 Red blood cell traits CRHR1 intron 23222517 rs424243 chr17 43727887 A T 4.74E-07 Red blood cell traits CRHR1 intron 23222517 rs422112 chr17 43728137 G A 1.61E-04 Multiple complex diseases CRHR1 intron 17554300 rs422112 chr17 43728137 G A 6.63E-11 Lymphocyte counts CRHR1 intron 22286170 rs422112 chr17 43728137 G A 3.88E-09 Primary biliary cirrhosis CRHR1 intron 22961000 rs422112 chr17 43728137 G A 1.73E-07 Red blood cell traits CRHR1 intron 23222517 rs417968 chr17 43728376 G A 5.50E-11 Parkinson's disease CRHR1 intron 19915575 rs417968 chr17 43728376 G A 4.40E-11 Parkinson's disease CRHR1 intron 21044948 rs417968 chr17 43728376 G A 7.74E-11 Parkinson's disease CRHR1 intron 21738487 rs417968 chr17 43728376 G A 8.21E-22 Parkinson's disease CRHR1 intron 22438815 rs417968 chr17 43728376 G A 3.79E-04 Brain structure CRHR1 intron 22504417 rs417968 chr17 43728376 G A 6.65E-10 Red blood cell traits CRHR1 intron 23222517 rs417968 chr17 43728376 G A 1.57E-05 Interstitial lung disease CRHR1 intron 23583980 rs417968 chr17 43728376 G A 5.08E-09 Parkinson's disease CRHR1 intron 24842889 rs413844 chr17 43729384 G A 9.95E-04 Obesity (extreme) CRHR1 intron 21935397 rs413844 chr17 43729384 G A 6.15E-07 Red blood cell traits CRHR1 intron 23222517 rs647483 chr17 43729432 C T 7.93E-08 Red blood cell traits CRHR1 intron 23222517 rs241036 chr17 43731719 A C 4.53E-07 Red blood cell traits CRHR1 intron 23222517 rs241035 chr17 43731896 C T 4.88E-07 Red blood cell traits CRHR1 intron 23222517 rs1706719 chr17 43733264 C T 8.57E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) CRHR1 intron 23648065 rs241033 chr17 43733983 G A 1.31E-04 Multiple complex diseases CRHR1 missense 17554300 rs241033 chr17 43733983 G A 5.33E-08 Red blood cell traits CRHR1 missense 23222517 rs241032 chr17 43734145 T C 1.36E-04 Multiple complex diseases CRHR1 intron 17554300 rs241031 chr17 43734304 T C 1.43E-04 Multiple complex diseases CRHR1 missense 17554300 rs241031 chr17 43734304 T C 3.43E-08 Red blood cell traits CRHR1 missense 23222517 rs241030 chr17 43734503 A G 9.83E-04 Obesity (extreme) CRHR1 intron 21935397 rs241030 chr17 43734503 A G 2.10E-07 Red blood cell traits CRHR1 intron 23222517 rs241027 chr17 43735478 A G 5.23E-07 Red blood cell traits CRHR1 UTR-3 23222517 rs241026 chr17 43735555 G A 2.43E-07 Red blood cell traits CRHR1 UTR-3 23222517 rs241023 chr17 43737040 G A 2.36E-07 Red blood cell traits CRHR1 intron 23222517 rs241022 chr17 43737730 T C 7.49E-07 Red blood cell traits CRHR1 intron 23222517 rs241021 chr17 43738627 T G 2.27E-07 Red blood cell traits CRHR1 intron 23222517 rs241020 chr17 43738676 C A 2.54E-07 Red blood cell traits CRHR1 intron 23222517 rs1724409 chr17 43740565 G T 9.94E-07 Red blood cell traits CRHR1 intron 23222517 rs17760577 chr17 43741452 C T 9.64E-05 Multiple complex diseases CRHR1 intron 17554300 rs17760577 chr17 43741452 C T 5.98E-08 Red blood cell traits CRHR1 intron 23222517 rs17760631 chr17 43743045 T C 2.20E-07 Red blood cell traits CRHR1 intron 23222517 rs1635298 chr17 43744344 T A 6.37E-07 Red blood cell traits CRHR1 intron 23222517 rs17687462 chr17 43744990 C T 5.68E-07 Red blood cell traits CRHR1 intron 23222517 rs17760733 chr17 43746276 G T 1.84E-04 Multiple complex diseases CRHR1 intron 17554300 rs17760733 chr17 43746276 G T 5.25E-07 Red blood cell traits CRHR1 intron 23222517 rs17687504 chr17 43746721 A G 5.11E-07 Red blood cell traits CRHR1 intron 23222517 rs17687534 chr17 43749579 T C 5.56E-07 Red blood cell traits CRHR1 intron 23222517 rs1631850 chr17 43749942 A G 0.000000193 Primary biliary cirrhosis CRHR1 intron 22961000 rs17687571 chr17 43750010 G A 9.25E-05 Multiple complex diseases CRHR1 intron 17554300 rs17687571 chr17 43750010 G A 1.41E-07 Red blood cell traits CRHR1 intron 23222517 rs1630095 chr17 43750172 G A 5.94E-07 Red blood cell traits CRHR1 intron 23222517 rs17687625 chr17 43750238 A G 5.85E-07 Red blood cell traits CRHR1 intron 23222517 rs1635291 chr17 43751913 G A 5.96E-12 Parkinson's disease CRHR1 intron 21738487 rs1635291 chr17 43751913 G A 3.41E-07 Red blood cell traits CRHR1 intron 23222517 rs1635291 chr17 43751913 G A 1.49E-06 Interstitial lung disease CRHR1 intron 23583980 rs1635291 chr17 43751913 G A 2.27E-05 Parkinson's disease CRHR1 intron pha002868 rs17687667 chr17 43754099 G A 9.23E-05 Multiple complex diseases CRHR1 intron 17554300 rs17687667 chr17 43754099 G A 6.33E-08 Red blood cell traits CRHR1 intron 23222517 rs1724401 chr17 43755857 C A 8.90E-07 Red blood cell traits CRHR1 intron 23222517 rs1724400 chr17 43755871 A C 1.80E-07 Red blood cell traits CRHR1 intron 23222517 rs17687740 chr17 43756376 G C 5.63E-07 Red blood cell traits CRHR1 intron 23222517 rs757502 chr17 43756506 C T 5.99E-07 Red blood cell traits CRHR1 intron 23222517 rs757501 chr17 43756685 A G 5.57E-07 Red blood cell traits CRHR1 intron 23222517 rs757500 chr17 43756833 C A 2.16E-07 Red blood cell traits CRHR1 intron 23222517 rs1635288 chr17 43756969 A G 2.00E-05 Multiple complex diseases CRHR1 intron 17554300 rs17761046 chr17 43758382 T C 7.69E-08 Red blood cell traits CRHR1 intron 23222517 rs17687838 chr17 43759048 T C 1.90E-07 Red blood cell traits CRHR1 intron 23222517 rs17687849 chr17 43759719 A G 2.79E-04 Multiple complex diseases CRHR1 intron 17554300 rs17687849 chr17 43759719 A G 1.10E-07 Red blood cell traits CRHR1 intron 23222517 rs17761100 chr17 43760389 A G 5.75E-07 Red blood cell traits CRHR1 intron 23222517 rs17761124 chr17 43760516 A T 3.38E-07 Red blood cell traits CRHR1 intron 23222517 rs16941035 chr17 43761519 T G 1.23E-07 Red blood cell traits CRHR1 intron 23222517 rs16941038 chr17 43761565 T C 2.21E-07 Red blood cell traits CRHR1 intron 23222517 rs2049515 chr17 43761856 C T 5.45E-07 Red blood cell traits CRHR1 intron 23222517 rs2158474 chr17 43761939 G C 2.36E-07 Red blood cell traits CRHR1 intron 23222517 rs17761207 chr17 43762255 T C 1.27E-04 Multiple complex diseases CRHR1 intron 17554300 rs17761207 chr17 43762255 T C 6.84E-08 Red blood cell traits CRHR1 intron 23222517 rs17688002 chr17 43762594 A T 1.33E-04 Multiple complex diseases CRHR1 intron 17554300 rs17688002 chr17 43762594 A T 1.62E-07 Red blood cell traits CRHR1 intron 23222517 rs2040846 chr17 43762846 A G 5.67E-07 Red blood cell traits CRHR1 intron 23222517 rs4486953 chr17 43763007 T C 2.15E-07 Red blood cell traits CRHR1 intron 23222517 rs17688032 chr17 43763202 G A 2.19E-07 Red blood cell traits CRHR1 intron 23222517 rs17688056 chr17 43763241 C T 1.34E-04 Multiple complex diseases CRHR1 intron 17554300 rs17688056 chr17 43763241 C T 8.90E-08 Red blood cell traits CRHR1 intron 23222517 rs17688068 chr17 43763935 A G 1.31E-04 Multiple complex diseases CRHR1 intron 17554300 rs17688068 chr17 43763935 A G 6.27E-08 Red blood cell traits CRHR1 intron 23222517 rs17688090 chr17 43764987 G A 2.33E-07 Red blood cell traits CRHR1 intron 23222517 rs17761387 chr17 43765450 G A 5.89E-07 Red blood cell traits CRHR1 intron 23222517 rs6503443 chr17 43765881 T C 1.04E-07 Red blood cell traits CRHR1 intron 23222517 rs17688205 chr17 43766352 G C 2.56E-07 Red blood cell traits CRHR1 intron 23222517 rs2040845 chr17 43767188 G C 7.76E-07 Red blood cell traits CRHR1 intron 23222517 rs7215239 chr17 43767773 T C 2.02E-11 Parkinson's disease CRHR1 intron 21044948 rs7215239 chr17 43767773 T C 1.42E-11 Parkinson's disease CRHR1 intron 21738487 rs7215239 chr17 43767773 T C 7.70E-17 Parkinson's disease CRHR1 intron 22438815 rs7215239 chr17 43767773 T C 1.04E-07 Red blood cell traits CRHR1 intron 23222517 rs7215239 chr17 43767773 T C 9.18E-07 Interstitial lung disease CRHR1 intron 23583980 rs7215239 chr17 43767773 T C 5.08E-09 Parkinson's disease CRHR1 intron 24842889 rs7215239 chr17 43767773 T C 3.43E-05 Parkinson's disease CRHR1 intron pha002868 rs17688296 chr17 43767815 C T 7.02E-07 Red blood cell traits CRHR1 intron 23222517 rs7207373 chr17 43770712 C T 1.65E-07 Red blood cell traits CRHR1 intron 23222517 rs17688391 chr17 43772109 C A 1.37E-04 Multiple complex diseases CRHR1 intron 17554300 rs17688391 chr17 43772109 C A 5.19E-08 Red blood cell traits CRHR1 intron 23222517 rs17688410 chr17 43772251 C T 7.27E-07 Red blood cell traits CRHR1 intron 23222517 rs17688434 chr17 43772540 G A 3.02E-04 Multiple complex diseases CRHR1 intron 17554300 rs17688434 chr17 43772540 G A 2.74E-07 Red blood cell traits CRHR1 intron 23222517 rs17688452 chr17 43773085 G A 3.43E-07 Red blood cell traits CRHR1 intron 23222517 rs10491144 chr17 43773124 A C 8.70E-07 Red blood cell traits CRHR1 intron 23222517 rs10491143 chr17 43773248 A T 8.57E-07 Red blood cell traits CRHR1 intron 23222517 rs17688534 chr17 43773877 A T 8.51E-07 Red blood cell traits CRHR1 intron 23222517 rs17761838 chr17 43774959 T C 3.70E-07 Red blood cell traits CRHR1 intron 23222517 rs12150141 chr17 43775145 G A 3.55E-07 Red blood cell traits CRHR1 intron 23222517 rs12150610 chr17 43775479 T C 4.07E-04 Multiple complex diseases CRHR1 intron 17554300 rs12150610 chr17 43775479 T C 4.09E-08 Red blood cell traits CRHR1 intron 23222517 rs12150547 chr17 43775546 A G 2.06E-04 Multiple complex diseases CRHR1 intron 17554300 rs12150547 chr17 43775546 A G 3.34E-07 Red blood cell traits CRHR1 intron 23222517 rs17688682 chr17 43775929 C G 9.16E-07 Red blood cell traits CRHR1 intron 23222517 rs12150454 chr17 43776061 C T 9.28E-07 Red blood cell traits CRHR1 intron 23222517 rs12150464 chr17 43776371 C T 1.88E-09 Red blood cell traits CRHR1 intron 23222517 rs17761985 chr17 43776787 C T 2.09E-07 Red blood cell traits CRHR1 intron 23222517 rs17688767 chr17 43777542 A G 4.49E-07 Red blood cell traits CRHR1 intron 23222517 rs17688773 chr17 43777710 T C 1.71E-04 Multiple complex diseases CRHR1 intron 17554300 rs17688773 chr17 43777710 T C 4.28E-08 Red blood cell traits CRHR1 intron 23222517 rs17762073 chr17 43777745 C A,T 3.24E-07 Red blood cell traits CRHR1 intron 23222517 rs17688875 chr17 43778406 A G 4.62E-07 Red blood cell traits CRHR1 intron 23222517 rs17762165 chr17 43778602 C T 9.63E-05 Multiple complex diseases CRHR1 intron 17554300 rs17762165 chr17 43778602 C T 1.05E-07 Red blood cell traits CRHR1 intron 23222517 rs17688916 chr17 43778680 T A 1.81E-08 Red blood cell traits CRHR1 intron 23222517 rs17688922 chr17 43779351 G A 1.05E-04 Multiple complex diseases CRHR1 intron 17554300 rs17688922 chr17 43779351 G A 1.10E-07 Red blood cell traits CRHR1 intron 23222517 rs17688944 chr17 43779419 T A 1.15E-04 Multiple complex diseases CRHR1 intron 17554300 rs17688944 chr17 43779419 T A 8.93E-08 Red blood cell traits CRHR1 intron 23222517 rs1526128 chr17 43779624 C T 1.48E-08 Red blood cell traits CRHR1 intron 23222517 rs1526129 chr17 43779657 T C 8.18E-08 Red blood cell traits CRHR1 intron 23222517 rs17762308 chr17 43780948 T C 4.25E-07 Red blood cell traits CRHR1 intron 23222517 rs968028 chr17 43781105 A G 1.87E-04 Multiple complex diseases CRHR1 intron 17554300 rs968028 chr17 43781105 A G 4.70E-09 Red blood cell traits CRHR1 intron 23222517 rs968027 chr17 43781250 C T 8.66E-05 Multiple complex diseases CRHR1 intron 17554300 rs968027 chr17 43781250 C T 1.19E-07 Red blood cell traits CRHR1 intron 23222517 rs1724425 chr17 43781747 C T 8.40E-07 Urinary metabolites CRHR1 intron 21572414 rs1724425 chr17 43781747 C T 7.77E-05 Parkinson's disease CRHR1 intron pha002865 rs17762361 chr17 43781778 A G 5.62E-07 Red blood cell traits CRHR1 intron 23222517 rs17689104 chr17 43782492 A G 5.93E-07 Red blood cell traits CRHR1 intron 23222517 rs17689116 chr17 43782558 T C 4.22E-07 Red blood cell traits CRHR1 intron 23222517 rs1526123 chr17 43783340 T C 1.28E-07 Parkinson's disease CRHR1 intron 19915575 rs1526123 chr17 43783340 T C 2.40E-08 Parkinson's disease CRHR1 intron 22438815 rs17689182 chr17 43783573 C T 5.89E-07 Red blood cell traits CRHR1 intron 23222517 rs17689218 chr17 43785808 T C 7.52E-07 Red blood cell traits CRHR1 intron 23222517 rs17762535 chr17 43787130 T C 8.03E-07 Red blood cell traits CRHR1 intron 23222517 rs1105571 chr17 43793200 A T 6.77E-07 Red blood cell traits CRHR1 intron 23222517 rs1105569 chr17 43793388 C T 2.29E-04 Obesity (extreme) CRHR1 intron 21935397 rs1105569 chr17 43793388 C T 7.91E-07 Red blood cell traits CRHR1 intron 23222517 rs11655470 chr17 43795433 C T 4.00E-06 Head circumference (infant) CRHR1 intron 22504419 rs1880750 chr17 43796541 T A 1.51E-07 Red blood cell traits CRHR1 intron 23222517 rs17563433 chr17 43800351 A C 5.64E-07 Red blood cell traits CRHR1 intron 23222517 rs17649019 chr17 43801593 G A 8.71E-08 Red blood cell traits CRHR1 intron 23222517 rs17563501 chr17 43801695 C T 1.13E-04 Multiple complex diseases CRHR1 intron 17554300 rs17563501 chr17 43801695 C T 9.08E-08 Red blood cell traits CRHR1 intron 23222517 rs10514879 chr17 43802971 C T 3.35E-07 Red blood cell traits CRHR1 intron 23222517 rs1358071 chr17 43803189 C A 9.86E-04 Obesity (extreme) CRHR1 intron 21935397 rs1358071 chr17 43803189 C A 6.52E-08 Red blood cell traits CRHR1 intron 23222517 rs9303521 chr17 43805194 T G 1.00E-08 Bone mineral density (spine) CRHR1 intron 19801982 rs9303521 chr17 43805194 T G 4.00E-06 Bone mineral density (hip) CRHR1 intron 19801982 rs9303521 chr17 43805194 T G 2.41E-05 Parkinson's disease CRHR1 intron 21738487 rs4401083 chr17 43806015 G A 7.63E-08 Red blood cell traits CRHR1 intron 23222517 rs1880752 chr17 43806264 C T 4.49E-07 Red blood cell traits CRHR1 intron 23222517 rs4617909 chr17 43806451 C T 4.71E-07 Red blood cell traits CRHR1 intron 23222517 rs2902662 chr17 43806925 G A 1.40E-04 Multiple complex diseases CRHR1 intron 17554300 rs2902662 chr17 43806925 G A 7.58E-08 Red blood cell traits CRHR1 intron 23222517 rs2864087 chr17 43807063 C T 4.66E-07 Red blood cell traits CRHR1 intron 23222517 rs4471726 chr17 43807134 T C 7.63E-08 Red blood cell traits CRHR1 intron 23222517 rs17563599 chr17 43807955 A C 3.82E-07 Red blood cell traits CRHR1 intron 23222517 rs17649138 chr17 43808067 G A 2.39E-08 Red blood cell traits CRHR1 intron 23222517 rs4390635 chr17 43809016 C T 4.89E-07 Red blood cell traits CRHR1 intron 23222517 rs17649162 chr17 43810371 G C 1.01E-07 Red blood cell traits CRHR1 intron 23222517 rs17563683 chr17 43811072 A G 6.33E-07 Red blood cell traits CRHR1 intron 23222517 rs1880753 chr17 43811260 G A 1.63E-05 Parkinson's disease CRHR1 intron 21738487 rs1880753 chr17 43811260 G A 1.70E-05 Obesity (extreme) CRHR1 intron 21935397 rs17563718 chr17 43811673 C T 6.83E-07 Red blood cell traits CRHR1 intron 23222517 rs1526125 chr17 43812177 C T 7.22E-07 Red blood cell traits CRHR1 intron 23222517 rs1526126 chr17 43812218 C T 7.56E-07 Red blood cell traits CRHR1 intron 23222517 rs12938476 chr17 43812897 T C 3.25E-05 Serum metabolites CRHR1 intron 19043545 rs12938476 chr17 43812897 T C 6.57E-07 Parkinson's disease CRHR1 intron 21738487 rs12938476 chr17 43812897 T C 4.27E-05 Obesity (extreme) CRHR1 intron 21935397 rs12944235 chr17 43813221 G A 1.66E-05 Obesity (extreme) CRHR1 intron 21935397 rs17563787 chr17 43813252 C G 1.30E-04 Multiple complex diseases CRHR1 intron 17554300 rs17563787 chr17 43813252 C G 2.20E-07 Red blood cell traits CRHR1 intron 23222517 rs17563800 chr17 43817459 C T 1.16E-04 Multiple complex diseases CRHR1 intron 17554300 rs17563800 chr17 43817459 C T 3.45E-07 Red blood cell traits CRHR1 intron 23222517 rs17563827 chr17 43818222 C A 1.01E-04 Multiple complex diseases CRHR1 intron 17554300 rs17563827 chr17 43818222 C A 4.18E-08 Red blood cell traits CRHR1 intron 23222517 rs17563861 chr17 43818906 A G 8.38E-07 Red blood cell traits CRHR1 intron 23222517 rs17563889 chr17 43818946 A T 8.66E-07 Red blood cell traits CRHR1 intron 23222517 rs17563923 chr17 43819450 G A 8.38E-07 Red blood cell traits CRHR1 intron 23222517 rs12150683 chr17 43824848 A G 7.00E-07 Red blood cell traits CRHR1 intron 23222517 rs17334797 chr17 43825912 A G 6.60E-06 Parkinson's disease CRHR1 intron 20711177 rs17334797 chr17 43825912 A G 1.56E-09 Parkinson's disease CRHR1 intron 22438815 rs17334797 chr17 43825912 A G 8.86E-07 Red blood cell traits CRHR1 intron 23222517 rs12150658 chr17 43826305 G A 1.14E-07 Red blood cell traits CRHR1 intron 23222517 rs12150672 chr17 43826637 G A 1.74E-04 Multiple complex diseases CRHR1 intron 17554300 rs12150672 chr17 43826637 G A 8.22E-09 Red blood cell traits CRHR1 intron 23222517 rs17334894 chr17 43827209 G A 6.34E-08 Red blood cell traits CRHR1 intron 23222517 rs12150451 chr17 43827431 A G 4.71E-07 Red blood cell traits CRHR1 intron 23222517 rs12150048 chr17 43827471 G C 2.84E-07 Red blood cell traits CRHR1 intron 23222517 rs12150455 chr17 43827508 A G 1.61E-07 Red blood cell traits CRHR1 intron 23222517 rs12150604 chr17 43828221 T A 5.81E-07 Red blood cell traits CRHR1 intron 23222517 rs17334944 chr17 43828617 G A 7.54E-07 Red blood cell traits CRHR1 intron 23222517 rs17426064 chr17 43828698 C T 5.70E-06 Parkinson's disease CRHR1 intron 20711177 rs17426064 chr17 43828698 C T 1.60E-09 Parkinson's disease CRHR1 intron 22438815 rs17426064 chr17 43828698 C T 4.04E-07 Red blood cell traits CRHR1 intron 23222517 rs17426106 chr17 43828935 G C 2.05E-04 Multiple complex diseases CRHR1 intron 17554300 rs17426106 chr17 43828935 G C 4.87E-09 Red blood cell traits CRHR1 intron 23222517 rs17426174 chr17 43830938 G C 4.46E-08 Red blood cell traits CRHR1 intron 23222517 rs17426195 chr17 43832367 G A 8.92E-05 Multiple complex diseases CRHR1 intron 17554300 rs17426195 chr17 43832367 G A 1.25E-08 Red blood cell traits CRHR1 intron 23222517 rs11079716 chr17 43834873 G A 3.81E-07 Red blood cell traits CRHR1 intron 23222517 rs529814250 chr17 43834873 G A 3.81E-07 Red blood cell traits CRHR1 intron 23222517 rs11079717 chr17 43835351 T C 4.45E-08 Red blood cell traits CRHR1 intron 23222517 rs11079718 chr17 43839951 A T 2.42E-10 Red blood cell traits CRHR1 intron 23222517 rs11079719 chr17 43840006 T G 9.32E-08 Red blood cell traits CRHR1 intron 23222517 rs11079720 chr17 43840016 G A 5.82E-07 Red blood cell traits CRHR1 intron 23222517 rs11079721 chr17 43840107 C A 5.97E-08 Red blood cell traits CRHR1 intron 23222517 rs11079723 chr17 43841729 T C 1.16E-08 Red blood cell traits CRHR1 intron 23222517 rs11079724 chr17 43841912 C T 1.73E-07 Red blood cell traits CRHR1 intron 23222517 rs4074462 chr17 43855228 G T 8.48E-05 Multiple complex diseases CRHR1 intron 17554300 rs4074462 chr17 43855228 G T 1.46E-07 Red blood cell traits CRHR1 intron 23222517 rs242941 chr17 43892520 A C 1.69E-06 Parkinson's disease CRHR1 intron 21738487 rs17689471 chr17 43892973 T C 7.62E-05 Multiple complex diseases CRHR1 intron 17554300 rs17689471 chr17 43892973 T C 3.63E-08 Red blood cell traits CRHR1 intron 23222517 rs17762769 chr17 43893403 G A 9.87E-05 Multiple complex diseases CRHR1 intron 17554300 rs17762769 chr17 43893403 G A 3.41E-07 Red blood cell traits CRHR1 intron 23222517 rs8072451 chr17 43893716 C T 3.57E-05 Multiple complex diseases CRHR1 intron 17554300 rs8072451 chr17 43893716 C T 1.20E-07 Red blood cell traits CRHR1 intron 23222517 rs4277389 chr17 43895653 A G 1.07E-04 Multiple complex diseases CRHR1 intron 17554300 rs4277389 chr17 43895653 A G 1.16E-07 Red blood cell traits CRHR1 intron 23222517 rs4566211 chr17 43895696 G A 1.50E-08 Red blood cell traits CRHR1 intron 23222517 rs12150390 chr17 43896228 T C 6.60E-06 Parkinson's disease CRHR1 intron 20711177 rs12150390 chr17 43896228 T C 9.74E-09 Parkinson's disease CRHR1 intron 22438815 rs17689653 chr17 43898963 A T 3.93E-07 Red blood cell traits CRHR1 intron 23222517 rs242936 chr17 43899209 A G 8.06E-04 Smoking quantity CRHR1 intron 24665060 rs17762954 chr17 43899786 C T 4.87E-08 Male-pattern baldness CRHR1 intron 22693459 rs17762954 chr17 43899786 C T 7.41E-07 2-hour glucose tolerance test CRHR1 intron 22885924 rs17762954 chr17 43899786 C T 5.66E-08 Red blood cell traits CRHR1 intron 23222517 rs173365 chr17 43901074 A G 9.46E-05 Parkinson's disease CRHR1 intron 21738487 rs1912151 chr17 43902944 C T 7.30E-06 Parkinson's disease CRHR1 intron 20711177 rs1912151 chr17 43902944 C T 7.16E-09 Parkinson's disease CRHR1 intron 22438815 rs1912151 chr17 43902944 C T 2.82E-07 Red blood cell traits CRHR1 intron 23222517 rs1396862 chr17 43902997 G A 6.80E-06 Parkinson's disease CRHR1 intron 20711177 rs1396862 chr17 43902997 G A 7.98E-09 Parkinson's disease CRHR1 intron 22438815 rs1396862 chr17 43902997 G A 3.20E-07 Red blood cell traits CRHR1 intron 23222517 rs17689824 chr17 43904397 C T 1.26E-04 Multiple complex diseases CRHR1 intron 17554300 rs17689824 chr17 43904397 C T 1.44E-07 Red blood cell traits CRHR1 intron 23222517 rs17763086 chr17 43905481 T G 8.83E-05 Multiple complex diseases CRHR1 intron 17554300 rs17763086 chr17 43905481 T G 7.20E-06 Parkinson's disease CRHR1 intron 20711177 rs17763086 chr17 43905481 T G 8.52E-09 Parkinson's disease CRHR1 intron 22438815 rs17763086 chr17 43905481 T G 1.91E-07 Red blood cell traits CRHR1 intron 23222517 rs17425752 chr17 43906726 A C 1.22E-13 Parkinson's disease CRHR1 intron 21738487 rs17689882 chr17 43906828 G A 6.87E-05 Multiple complex diseases CRHR1 intron 17554300 rs17689882 chr17 43906828 G A 1.05E-07 Red blood cell traits CRHR1 intron 23222517 rs1876831 chr17 43907745 C T 3.36E-07 Red blood cell traits CRHR1 intron 23222517 rs16940665 chr17 43907896 T C 6.00E-06 Parkinson's disease CRHR1 cds-synon 20711177 rs16940665 chr17 43907896 T C 1.05E-13 Parkinson's disease CRHR1 cds-synon 21738487 rs16940665 chr17 43907896 T C 1.38E-08 Parkinson's disease CRHR1 cds-synon 22438815 rs16940665 chr17 43907896 T C 3.53E-07 Red blood cell traits CRHR1 cds-synon 23222517 rs16940668 chr17 43907966 G A 5.12E-13 Parkinson's disease CRHR1 intron 21738487 rs17689918 chr17 43910088 G A 3.04E-07 Red blood cell traits CRHR1 intron 23222517 rs17689966 chr17 43910455 G A 3.91E-05 Parkinson's disease CRHR1 intron 21738487 rs16940674 chr17 43910507 C T 1.62E-13 Parkinson's disease CRHR1 STOP-GAIN 21738487 rs16940674 chr17 43910507 C T 1.28E-07 Red blood cell traits CRHR1 STOP-GAIN 23222517 rs16940676 chr17 43911036 G A 6.40E-14 Parkinson's disease CRHR1 intron 21738487 rs1876830 chr17 43911352 C T 6.57E-14 Parkinson's disease CRHR1 intron 21738487 rs1876829 chr17 43911443 T C 3.90E-13 Parkinson's disease CRHR1 intron 21738487 rs1876829 chr17 43911443 T C 2.04E-07 Red blood cell traits CRHR1 intron 23222517 rs1876828 chr17 43911525 C T 7.60E-06 Parkinson's disease CRHR1 intron 20711177 rs1876828 chr17 43911525 C T 1.14E-14 Parkinson's disease CRHR1 intron 21738487 rs1876828 chr17 43911525 C T 6.89E-09 Parkinson's disease CRHR1 intron 22438815 rs16940677 chr17 43911898 C T 7.60E-08 Parkinson's disease CRHR1 intron 24842889 rs2316765 chr17 43912454 T C 2.59E-14 Parkinson's disease CRHR1 UTR-3 21738487 rs878886 chr17 43912490 C G 7.60E-06 Parkinson's disease CRHR1 UTR-3 20711177 rs878886 chr17 43912490 C G 6.82E-09 Parkinson's disease CRHR1 UTR-3 22438815 rs878886 chr17 43912490 C G 3.69E-07 Red blood cell traits CRHR1 UTR-3 23222517 rs878887 chr17 43912582 C T 6.90E-06 Parkinson's disease CRHR1 UTR-3 20711177 rs878887 chr17 43912582 C T 9.65E-14 Parkinson's disease CRHR1 UTR-3 21738487 rs878887 chr17 43912582 C T 8.18E-09 Parkinson's disease CRHR1 UTR-3 22438815 rs878887 chr17 43912582 C T 4.47E-07 Red blood cell traits CRHR1 UTR-3 23222517 rs878888 chr17 43912635 A G 7.10E-06 Parkinson's disease CRHR1 UTR-3 20711177 rs878888 chr17 43912635 A G 1.01E-13 Parkinson's disease CRHR1 UTR-3 21738487 rs878888 chr17 43912635 A G 6.38E-09 Parkinson's disease CRHR1 UTR-3 22438815 rs4525537 chr17 43912723 T C 6.60E-06 Parkinson's disease CRHR1 UTR-3 20711177 rs4525537 chr17 43912723 T C 4.62E-14 Parkinson's disease CRHR1 UTR-3 21738487 rs4525537 chr17 43912723 T C 5.94E-09 Parkinson's disease CRHR1 UTR-3 22438815 rs4640231 chr17 43912786 G C 8.34E-05 Multiple complex diseases CRHR1 UTR-3 17554300 rs4640231 chr17 43912786 G C 6.40E-06 Parkinson's disease CRHR1 UTR-3 20711177 rs4640231 chr17 43912786 G C 5.75E-09 Parkinson's disease CRHR1 UTR-3 22438815 rs4640231 chr17 43912786 G C 1.76E-07 Red blood cell traits CRHR1 UTR-3 23222517 rs4482334 chr17 43912830 T C 7.26E-14 Parkinson's disease CRHR1 UTR-3 21738487 rs10445364 chr17 43916356 G A 6.90E-06 Parkinson's disease / / 20711177 rs10445364 chr17 43916356 G A 6.36E-09 Parkinson's disease / / 22438815 rs10445364 chr17 43916356 G A 7.04E-07 Red blood cell traits / / 23222517 rs17763515 chr17 43917818 G A 3.67E-09 Primary biliary cirrhosis / / 22961000 rs17763533 chr17 43918190 T C 9.79E-05 Multiple complex diseases / / 17554300 rs17763533 chr17 43918190 T C 4.03E-09 Primary biliary cirrhosis / / 22961000 rs17763533 chr17 43918190 T C 6.66E-08 Red blood cell traits / / 23222517 rs56150806 chr17 43919301 T C 3.70E-09 Primary biliary cirrhosis / / 22961000 rs17690314 chr17 43919884 T G 8.23E-07 Red blood cell traits / / 23222517 rs17690326 chr17 43920974 T C 8.52E-07 Red blood cell traits SPPL2C nearGene-5 23222517 rs17763596 chr17 43921210 G T 7.40E-06 Parkinson's disease SPPL2C nearGene-5 20711177 rs17763596 chr17 43921210 G T 9.12E-09 Parkinson's disease SPPL2C nearGene-5 22438815 rs17763596 chr17 43921210 G T 4.42E-09 Primary biliary cirrhosis SPPL2C nearGene-5 22961000 rs17763596 chr17 43921210 G T 9.14E-07 Red blood cell traits SPPL2C nearGene-5 23222517 rs17763634 chr17 43921754 T C 1.48E-09 Red blood cell traits MAPT-AS1 intron 23222517 rs62621252 chr17 43922942 T C 3.39E-09 Primary biliary cirrhosis SPPL2C missense 22961000 rs242944 chr17 43923180 G A 5.75E-05 Parkinson's disease SPPL2C missense 21738487 rs12185233 chr17 43923654 G C 7.00E-06 Parkinson's disease SPPL2C missense 20711177 rs12185233 chr17 43923654 G C 5.60E-09 Parkinson's disease SPPL2C missense 22438815 rs12185233 chr17 43923654 G C 3.58E-08 Male-pattern baldness SPPL2C missense 22693459 rs12185233 chr17 43923654 G C 5.63E-09 Primary biliary cirrhosis SPPL2C missense 22961000 rs12185233 chr17 43923654 G C 1.47E-09 Red blood cell traits SPPL2C missense 23222517 rs12185268 chr17 43923683 A G 6.70E-06 Parkinson's disease SPPL2C missense 20711177 rs12185268 chr17 43923683 A G 3.00E-14 Parkinson's disease SPPL2C missense 21738487 rs12185268 chr17 43923683 A G 5.53E-25 Parkinson's disease SPPL2C missense 22438815 rs12185268 chr17 43923683 A G 5.47E-09 Primary biliary cirrhosis SPPL2C missense 22961000 rs12185268 chr17 43923683 A G 4.97E-08 Red blood cell traits SPPL2C missense 23222517 rs12185268 chr17 43923683 A G 4.58E-09 Parkinson's disease SPPL2C missense 24842889 rs12185268 chr17 43923683 A G 1.90E-07 Parkinson's disease SPPL2C missense pha002868 rs12185235 chr17 43923703 C T 5.90E-06 Parkinson's disease SPPL2C cds-synon 20711177 rs12185235 chr17 43923703 C T 1.56E-08 Parkinson's disease SPPL2C cds-synon 22438815 rs12185235 chr17 43923703 C T 2.83E-08 Male-pattern baldness SPPL2C cds-synon 22693459 rs12185235 chr17 43923703 C T 8.94E-07 Red blood cell traits SPPL2C cds-synon 23222517 rs11079725 chr17 43923934 T C 2.66E-08 Male-pattern baldness SPPL2C missense 22693459 rs11079725 chr17 43923934 T C 6.49E-09 Primary biliary cirrhosis SPPL2C missense 22961000 rs11079725 chr17 43923934 T C 1.60E-09 Red blood cell traits SPPL2C missense 23222517 rs12373123 chr17 43924073 T C 5.60E-06 Parkinson's disease SPPL2C missense 20711177 rs12373123 chr17 43924073 T C 5.23E-09 Parkinson's disease SPPL2C missense 22438815 rs12373123 chr17 43924073 T C 2.58E-08 Male-pattern baldness SPPL2C missense 22693459 rs12373123 chr17 43924073 T C 5.97E-09 Primary biliary cirrhosis SPPL2C missense 22961000 rs12373123 chr17 43924073 T C 7.40E-07 Red blood cell traits SPPL2C missense 23222517 rs12373139 chr17 43924130 G A 4.56E-09 Primary biliary cirrhosis SPPL2C missense 22961000 rs12373139 chr17 43924130 G A 7.75E-14 Parkinson's disease SPPL2C missense 19915575 rs12373139 chr17 43924130 G A 3.08E-14 Parkinson's disease SPPL2C missense 21738487 rs12373139 chr17 43924130 G A 8.25E-27 Parkinson's disease SPPL2C missense 22438815 rs12373139 chr17 43924130 G A 2.37E-07 Red blood cell traits SPPL2C missense 23222517 rs12373139 chr17 43924130 G A 7.07E-08 Interstitial lung disease SPPL2C missense 23583980 rs12373139 chr17 43924130 G A 4.91E-07 Parkinson's disease SPPL2C missense pha002868 rs12373142 chr17 43924200 C G 5.50E-06 Parkinson's disease SPPL2C missense 20711177 rs12373142 chr17 43924200 C G 4.54E-09 Parkinson's disease SPPL2C missense 22438815 rs12373142 chr17 43924200 C G 2.46E-08 Male-pattern baldness SPPL2C missense 22693459 rs12373142 chr17 43924200 C G 4.32E-09 Primary biliary cirrhosis SPPL2C missense 22961000 rs12373142 chr17 43924200 C G 5.97E-07 Red blood cell traits SPPL2C missense 23222517 rs12373124 chr17 43924219 T C 5.00E-10 Male-pattern baldness SPPL2C missense 22693459 rs12373124 chr17 43924219 T C 4.32E-09 Primary biliary cirrhosis SPPL2C missense 22961000 rs12373124 chr17 43924219 T C 5.10E-07 Red blood cell traits SPPL2C missense 23222517 rs12373140 chr17 43924231 G A 4.75E-09 Primary biliary cirrhosis SPPL2C missense 22961000 rs12373168 chr17 43924337 A C 2.38E-08 Male-pattern baldness SPPL2C UTR-3 22693459 rs12373168 chr17 43924337 A C 6.95E-07 Red blood cell traits SPPL2C UTR-3 23222517 rs17690661 chr17 43924521 G A 2.12E-08 Male-pattern baldness MAPT-AS1 intron 22693459 rs17690661 chr17 43924521 G A 1.11E-09 Red blood cell traits MAPT-AS1 intron 23222517 rs55943825 chr17 43924776 C T 9.61E-09 Primary biliary cirrhosis MAPT-AS1 intron 22961000 rs17690679 chr17 43924803 A G 2.02E-08 Male-pattern baldness MAPT-AS1 intron 22693459 rs17690679 chr17 43924803 A G 8.81E-09 Primary biliary cirrhosis MAPT-AS1 intron 22961000 rs17690679 chr17 43924803 A G 9.03E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs17690703 chr17 43925297 C T 2.07E-04 Multiple complex diseases MAPT-AS1 intron 17554300 rs17690703 chr17 43925297 C T 9.45E-13 Parkinson's disease MAPT-AS1 intron 19915575 rs17690703 chr17 43925297 C T 2.50E-05 Urinary metabolites MAPT-AS1 intron 21572414 rs17690703 chr17 43925297 C T 8.05E-10 Parkinson's disease MAPT-AS1 intron 21738487 rs17690703 chr17 43925297 C T 1.48E-18 Parkinson's disease MAPT-AS1 intron 22438815 rs17690703 chr17 43925297 C T 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes MAPT-AS1 intron 22628534 rs17690703 chr17 43925297 C T 0.000000383 Primary biliary cirrhosis MAPT-AS1 intron 22961000 rs17690703 chr17 43925297 C T 5.48E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs17690703 chr17 43925297 C T 3.42E-05 Interstitial lung disease MAPT-AS1 intron 23583980 rs17690703 chr17 43925297 C T 6.00E-09 Idiopathic pulmonary fibrosis MAPT-AS1 intron 24429156 rs17769490 chr17 43925605 G A 8.19E-05 Multiple complex diseases MAPT-AS1 intron 17554300 rs17769490 chr17 43925605 G A 1.84E-08 Male-pattern baldness MAPT-AS1 intron 22693459 rs17769490 chr17 43925605 G A 1.56E-08 Primary biliary cirrhosis MAPT-AS1 intron 22961000 rs17769490 chr17 43925605 G A 5.24E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs62054820 chr17 43926755 A G 0.00000002 Primary biliary cirrhosis MAPT-AS1 intron 22961000 rs56385754 chr17 43927255 G T 2.55E-08 Primary biliary cirrhosis MAPT-AS1 intron 22961000 rs17769552 chr17 43927290 G A 1.81E-08 Primary biliary cirrhosis MAPT-AS1 intron 22961000 rs17769552 chr17 43927290 G A 2.46E-04 Multiple complex diseases MAPT-AS1 intron 17554300 rs17769552 chr17 43927290 G A 1.32E-08 Male-pattern baldness MAPT-AS1 intron 22693459 rs17769552 chr17 43927290 G A 2.15E-10 Red blood cell traits MAPT-AS1 intron 23222517 rs62054822 chr17 43927708 A G 1.72E-08 Primary biliary cirrhosis MAPT-AS1 intron 22961000 rs885639 chr17 43928614 T G 1.58E-08 Male-pattern baldness MAPT-AS1 intron 22693459 rs885639 chr17 43928614 T G 1.02E-09 Red blood cell traits MAPT-AS1 intron 23222517 rs62054824 chr17 43929992 C T 4.60E-09 Primary biliary cirrhosis MAPT-AS1 intron 22961000 rs62054825 chr17 43930033 G A 4.88E-09 Primary biliary cirrhosis MAPT-AS1 intron 22961000 rs79589869 chr17 43930238 C A 4.17E-09 Primary biliary cirrhosis MAPT-AS1 intron 22961000 rs2873269 chr17 43931122 C T 1.68E-08 Male-pattern baldness MAPT-AS1 intron 22693459 rs2873269 chr17 43931122 C T 2.07E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs10445368 chr17 43933171 C T 2.05E-08 Male-pattern baldness MAPT-AS1 intron 22693459 rs10445368 chr17 43933171 C T 1.65E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs10445335 chr17 43934896 T A 3.71E-08 Red blood cell traits MAPT-AS1 intron 23222517 rs10445370 chr17 43935118 G A 2.11E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs962885 chr17 43935631 T C 7.04E-08 Narcolepsy MAPT-AS1 intron 19629137 rs12150516 chr17 43944519 C T 7.38E-08 Red blood cell traits MAPT-AS1 intron 23222517 rs1078830 chr17 43946112 T C 2.49E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs34097347 chr17 43949448 C A 9.34E-05 Multiple complex diseases MAPT-AS1 intron 17554300 rs2106784 chr17 43949892 C T 1.38E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs2158072 chr17 43950195 T C 1.97E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs10491140 chr17 43950976 G A,T 1.08E-09 Red blood cell traits MAPT-AS1 intron 23222517 rs62055491 chr17 43951120 T C 2.43E-09 Primary biliary cirrhosis MAPT-AS1 intron 22961000 rs34416056 chr17 43951220 T G 2.43E-09 Primary biliary cirrhosis MAPT-AS1 intron 22961000 rs62055492 chr17 43951345 C A 2.43E-09 Primary biliary cirrhosis MAPT-AS1 intron 22961000 rs2055794 chr17 43951717 G A 7.82E-09 Red blood cell traits MAPT-AS1 intron 23222517 rs916793 chr17 43954686 G A 8.28E-05 Multiple complex diseases MAPT-AS1 intron 17554300 rs916793 chr17 43954686 G A 2.94E-09 Primary biliary cirrhosis MAPT-AS1 intron 22961000 rs916793 chr17 43954686 G A 3.97E-08 Red blood cell traits MAPT-AS1 intron 23222517 rs4441322 chr17 43955030 A G 5.14E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs17691328 chr17 43955487 C T 5.92E-05 Multiple complex diseases MAPT-AS1 intron 17554300 rs17691328 chr17 43955487 C T 2.14E-08 Red blood cell traits MAPT-AS1 intron 23222517 rs2019822 chr17 43959918 T A 1.49E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs17770108 chr17 43961292 G T 6.13E-08 Red blood cell traits MAPT-AS1 intron 23222517 rs17770120 chr17 43963943 C A 1.45E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs17770150 chr17 43964163 G A 1.44E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs17770186 chr17 43964191 C A 1.48E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs17691449 chr17 43964283 G C 1.45E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs17691466 chr17 43968219 A G 3.66E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs17691508 chr17 43968463 C G 3.61E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs17770296 chr17 43969136 C T 3.53E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs17691556 chr17 43969168 T A 1.57E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs17770337 chr17 43969779 G T 3.61E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs17770343 chr17 43970154 T C 8.80E-06 Parkinson's disease MAPT-AS1 intron 20711177 rs17770343 chr17 43970154 T C 5.91E-08 Parkinson's disease MAPT-AS1 intron 22438815 rs17770343 chr17 43970154 T C 1.65E-07 Red blood cell traits MAPT-AS1 intron 23222517 rs17691610 chr17 43970662 G T 8.40E-06 Parkinson's disease MAPT-AS1 intron 20711177 rs17691610 chr17 43970662 G T 4.72E-08 Parkinson's disease MAPT-AS1 intron 22438815 rs17691610 chr17 43970662 G T 3.62E-09 Red blood cell traits MAPT-AS1 intron 23222517 rs76594404 chr17 43971457 G C 3.39E-09 Primary biliary cirrhosis MAPT-AS1 intron 22961000 rs80233201 chr17 43971481 T C 3.29E-09 Primary biliary cirrhosis MAPT-AS1 intron 22961000 rs62056778 chr17 43971604 C G 3.29E-09 Primary biliary cirrhosis MAPT-AS1 intron 22961000 rs11575895 chr17 43971785 A G 3.54E-09 Primary biliary cirrhosis MAPT UTR-5 22961000 rs62056779 chr17 43971937 C A 3.19E-09 Primary biliary cirrhosis MAPT UTR-5 22961000 rs11575896 chr17 43972142 G A 3.10E-09 Primary biliary cirrhosis MAPT intron 22961000 rs74457229 chr17 43972581 C T 3.10E-09 Primary biliary cirrhosis MAPT intron 22961000 rs74548327 chr17 43973080 A G 3.63E-09 Primary biliary cirrhosis MAPT intron 22961000 rs111972148 chr17 43973121 G C 3.63E-09 Primary biliary cirrhosis MAPT intron 22961000 rs76324150 chr17 43973233 C T 3.99E-09 Primary biliary cirrhosis MAPT intron 22961000 rs113347741 chr17 43973408 C T 3.76E-09 Primary biliary cirrhosis MAPT intron 22961000 rs78720789 chr17 43973413 A G 1.76E-09 Primary biliary cirrhosis MAPT intron 22961000 rs4792891 chr17 43973498 T G 6.63E-07 Parkinson's disease MAPT intron 21738487 rs62056780 chr17 43973652 C T 4.01E-09 Primary biliary cirrhosis MAPT intron 22961000 rs62056781 chr17 43973899 T C 3.89E-09 Primary biliary cirrhosis LOC100653027 missense 22961000 rs74496580 chr17 43974065 C A 3.66E-09 Primary biliary cirrhosis LOC100653027 missense 22961000 rs62056782 chr17 43974230 C T 3.24E-09 Primary biliary cirrhosis MAPT intron 22961000 rs113161176 chr17 43974354 G A 3.05E-09 Primary biliary cirrhosis MAPT intron 22961000 rs80346216 chr17 43974476 G T 3.05E-09 Primary biliary cirrhosis MAPT intron 22961000 rs76632685 chr17 43974477 A T 3.05E-09 Primary biliary cirrhosis MAPT intron 22961000 rs62056783 chr17 43974549 G C 3.05E-09 Primary biliary cirrhosis MAPT intron 22961000 rs62056784 chr17 43974889 C G 2.53E-09 Primary biliary cirrhosis MAPT intron 22961000 rs11079727 chr17 43976813 C A 0.0000098 HDL cholesterol particle diameter MAPT intron 23263444 rs1864325 chr17 43977827 C T 2.78E-05 Multiple complex diseases MAPT intron 17554300 rs1864325 chr17 43977827 C T 7.13E-14 Parkinson's disease MAPT intron 21738487 rs1864325 chr17 43977827 C T 5.00E-11 Bone mineral density MAPT intron 22504420 rs1864325 chr17 43977827 C T 4.96E-08 Male-pattern baldness MAPT intron 22693459 rs1864325 chr17 43977827 C T 2.34E-09 Primary biliary cirrhosis MAPT intron 22961000 rs1864325 chr17 43977827 C T 5.51E-07 Red blood cell traits MAPT intron 23222517 rs1864325 chr17 43977827 C T 9.03E-04 Bone mineral density (paediatric,lower limb) MAPT intron 24945404 rs1560310 chr17 43978534 G A 1.73E-07 Red blood cell traits MAPT intron 23222517 rs2099151 chr17 43979822 A T 2.00E-07 Red blood cell traits MAPT intron 23222517 rs2082068 chr17 43979971 C T 4.26E-08 Red blood cell traits MAPT intron 23222517 rs1984937 chr17 43980530 A C 1.98E-07 Red blood cell traits MAPT intron 23222517 rs17563965 chr17 43990919 A G 1.98E-07 Red blood cell traits MAPT intron 23222517 rs17563986 chr17 43991272 A G 1.67E-14 Parkinson's disease MAPT intron 19915575 rs17563986 chr17 43991272 A G 4.85E-14 Parkinson's disease MAPT intron 21738487 rs17563986 chr17 43991272 A G 3.81E-21 Parkinson's disease MAPT intron 22438815 rs17563986 chr17 43991272 A G 2.74E-07 Red blood cell traits MAPT intron 23222517 rs17563986 chr17 43991272 A G 3.39E-08 Interstitial lung disease MAPT intron 23583980 rs17563986 chr17 43991272 A G 3.04E-09 Parkinson's disease MAPT intron 24842889 rs17563986 chr17 43991272 A G 3.44E-07 Parkinson's disease MAPT intron pha002868 rs17564020 chr17 43991781 G T 1.86E-07 Red blood cell traits MAPT intron 23222517 rs17649518 chr17 43994386 C A 1.45E-07 Red blood cell traits MAPT intron 23222517 rs17649553 chr17 43994648 C T 3.13E-09 Primary biliary cirrhosis MAPT intron 22961000 rs17649553 chr17 43994648 C T 4.39E-07 Red blood cell traits MAPT intron 23222517 rs17649571 chr17 43994952 A G 1.88E-07 Red blood cell traits MAPT intron 23222517 rs17564153 chr17 43995098 G A 1.64E-07 Red blood cell traits MAPT intron 23222517 rs17649641 chr17 43997372 T C 7.46E-05 Multiple complex diseases MAPT intron 17554300 rs17649641 chr17 43997372 T C 3.89E-09 Primary biliary cirrhosis MAPT intron 22961000 rs17649641 chr17 43997372 T C 7.35E-08 Red blood cell traits MAPT intron 23222517 rs17564223 chr17 43997520 C T 3.78E-05 Multiple complex diseases MAPT intron 17554300 rs17564223 chr17 43997520 C T 2.16E-07 Red blood cell traits MAPT intron 23222517 rs17649700 chr17 43997901 G C 6.28E-05 Multiple complex diseases MAPT intron 17554300 rs17649700 chr17 43997901 G C 1.03E-07 Red blood cell traits MAPT intron 23222517 rs1467969 chr17 43998328 C T 6.90E-05 Multiple complex diseases MAPT intron 17554300 rs1467969 chr17 43998328 C T 8.53E-08 Red blood cell traits MAPT intron 23222517 rs1467970 chr17 43998574 T G 1.73E-07 Red blood cell traits MAPT intron 23222517 rs767058 chr17 43998767 T C 3.51E-09 Primary biliary cirrhosis MAPT intron 22961000 rs767058 chr17 43998767 T C 1.71E-07 Red blood cell traits MAPT intron 23222517 rs767057 chr17 43998822 A G 5.02E-14 Parkinson's disease MAPT intron 21738487 rs767057 chr17 43998822 A G 3.41E-09 Primary biliary cirrhosis MAPT intron 22961000 rs767057 chr17 43998822 A G 2.01E-07 Red blood cell traits MAPT intron 23222517 rs767056 chr17 43998910 C T 1.89E-07 Red blood cell traits MAPT intron 23222517 rs767059 chr17 43999100 G C,T 1.62E-07 Red blood cell traits MAPT intron 23222517 rs4792894 chr17 43999203 G A 2.80E-06 Urinary metabolites MAPT intron 21572414 rs8079501 chr17 44000234 A T 6.18E-08 Red blood cell traits MAPT intron 23222517 rs8078495 chr17 44000610 G A,T 1.10E-07 Red blood cell traits MAPT intron 23222517 rs17649866 chr17 44000914 T C 1.60E-07 Red blood cell traits MAPT intron 23222517 rs17564493 chr17 44001379 C T 5.95E-05 Multiple complex diseases MAPT intron 17554300 rs17564493 chr17 44001379 C T 3.72E-08 Red blood cell traits MAPT intron 23222517 rs17649918 chr17 44001621 A G 1.91E-07 Red blood cell traits MAPT intron 23222517 rs17649954 chr17 44001661 A G 6.28E-05 Multiple complex diseases MAPT intron 17554300 rs17649954 chr17 44001661 A G 4.90E-08 Red blood cell traits MAPT intron 23222517 rs17564619 chr17 44002138 A G 5.15E-05 Multiple complex diseases MAPT intron 17554300 rs17564619 chr17 44002138 A G 2.33E-08 Red blood cell traits MAPT intron 23222517 rs17650063 chr17 44002555 A G 6.68E-05 Multiple complex diseases MAPT intron 17554300 rs17650063 chr17 44002555 A G 3.78E-09 Primary biliary cirrhosis MAPT intron 22961000 rs17650063 chr17 44002555 A G 4.66E-08 Red blood cell traits MAPT intron 23222517 rs16940742 chr17 44004924 A G 5.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAPT intron 20877124 rs17564780 chr17 44005413 A G 8.16E-05 Multiple complex diseases MAPT intron 17554300 rs17564780 chr17 44005413 A G 8.46E-08 Red blood cell traits MAPT intron 23222517 rs17564829 chr17 44006601 T C 6.05E-14 Primary biliary cirrhosis MAPT intron 22961000 rs8078967 chr17 44008101 T C 9.16E-05 Parkinson's disease MAPT intron 21738487 rs7501759 chr17 44009921 A G 2.07E-07 Red blood cell traits MAPT intron 23222517 rs2316782 chr17 44010040 A G 2.03E-07 Red blood cell traits MAPT intron 23222517 rs2316783 chr17 44010118 G C 5.46E-07 Red blood cell traits MAPT intron 23222517 rs17564871 chr17 44011018 A G 1.74E-07 Red blood cell traits MAPT intron 23222517 rs17564948 chr17 44011749 A G 4.86E-08 Red blood cell traits MAPT intron 23222517 rs17564983 chr17 44011825 A C 5.91E-14 Parkinson's disease MAPT intron 21738487 rs17564983 chr17 44011825 A C 3.52E-08 Red blood cell traits MAPT intron 23222517 rs17650335 chr17 44012343 G A 1.01E-07 Red blood cell traits MAPT intron 23222517 rs17565025 chr17 44012463 T C 4.11E-08 Red blood cell traits MAPT intron 23222517 rs17650381 chr17 44013024 T C 6.54E-05 Multiple complex diseases MAPT intron 17554300 rs17650381 chr17 44013024 T C 5.79E-08 Red blood cell traits MAPT intron 23222517 rs17650417 chr17 44013103 G T 3.56E-08 Red blood cell traits MAPT intron 23222517 rs12150111 chr17 44013938 A G 7.81E-05 Multiple complex diseases MAPT intron 17554300 rs12150111 chr17 44013938 A G 3.12E-09 Primary biliary cirrhosis MAPT intron 22961000 rs12150111 chr17 44013938 A G 4.85E-08 Red blood cell traits MAPT intron 23222517 rs12150460 chr17 44014137 G T 4.59E-08 Red blood cell traits MAPT intron 23222517 rs12150195 chr17 44014263 T C 4.44E-08 Red blood cell traits MAPT intron 23222517 rs12150229 chr17 44015446 A G 6.16E-08 Red blood cell traits MAPT intron 23222517 rs12150230 chr17 44015464 A G 5.25E-08 Red blood cell traits MAPT intron 23222517 rs12150576 chr17 44015624 G A 4.49E-08 Red blood cell traits MAPT intron 23222517 rs12150235 chr17 44015745 A G 5.74E-08 Red blood cell traits MAPT intron 23222517 rs12150242 chr17 44015816 A G 6.19E-08 Red blood cell traits MAPT intron 23222517 rs12150104 chr17 44015929 G A 5.84E-08 Red blood cell traits MAPT intron 23222517 rs242557 chr17 44019712 G A 9.00E-18 Progressive supranuclear palsy MAPT intron 21685912 rs2316784 chr17 44021699 G T 1.84E-07 Red blood cell traits MAPT intron 23222517 rs4327091 chr17 44021717 G A 4.96E-05 Brain structure MAPT intron 22504417 rs4327091 chr17 44021717 G A 1.62E-07 Red blood cell traits MAPT intron 23222517 rs62062784 chr17 44024552 C G 4.54E-09 Primary biliary cirrhosis MAPT intron 22961000 rs62062785 chr17 44024562 G T 4.54E-09 Primary biliary cirrhosis MAPT intron 22961000 rs242559 chr17 44025888 C A 6.31E-04 Multiple complex diseases MAPT intron 17554300 rs242559 chr17 44025888 C A 4.11E-05 Brain structure MAPT intron 22504417 rs242559 chr17 44025888 C A 3.53E-08 Male-pattern baldness MAPT intron 22693459 rs242559 chr17 44025888 C A 0.000000829 2-hour glucose tolerance test MAPT intron 22885924 rs242559 chr17 44025888 C A 9.75E-08 Red blood cell traits MAPT intron 23222517 rs62062793 chr17 44026321 T C 4.27E-09 Primary biliary cirrhosis MAPT intron 22961000 rs62062794 chr17 44026394 A G 4.27E-09 Primary biliary cirrhosis MAPT intron 22961000 rs78556223 chr17 44026478 A G 4.27E-09 Primary biliary cirrhosis MAPT intron 22961000 rs77266933 chr17 44026490 A C 4.27E-09 Primary biliary cirrhosis MAPT intron 22961000 rs74531363 chr17 44026495 A G 4.27E-09 Primary biliary cirrhosis MAPT intron 22961000 rs242561 chr17 44026548 T C 6.25E-09 Primary biliary cirrhosis MAPT intron 22961000 rs62062795 chr17 44027090 C T 4.03E-09 Primary biliary cirrhosis MAPT intron 22961000 rs62062796 chr17 44027316 G A 4.03E-09 Primary biliary cirrhosis MAPT intron 22961000 rs62062797 chr17 44027366 T G 4.03E-09 Primary biliary cirrhosis MAPT intron 22961000 rs62062798 chr17 44027383 A G 4.03E-09 Primary biliary cirrhosis MAPT intron 22961000 rs17650579 chr17 44030115 C T 1.22E-07 Red blood cell traits MAPT intron 23222517 rs17650597 chr17 44030195 A T 1.30E-07 Red blood cell traits MAPT intron 23222517 rs17650633 chr17 44030231 T C 1.28E-07 Red blood cell traits MAPT intron 23222517 rs17650651 chr17 44030311 T G 1.29E-07 Red blood cell traits MAPT intron 23222517 rs17571718 chr17 44032768 T C 6.96E-05 Multiple complex diseases MAPT intron 17554300 rs17571718 chr17 44032768 T C 4.17E-05 Brain structure MAPT intron 22504417 rs17571718 chr17 44032768 T C 4.51E-08 Male-pattern baldness MAPT intron 22693459 rs17571718 chr17 44032768 T C 1.12E-07 Red blood cell traits MAPT intron 23222517 rs17571739 chr17 44032915 T A,C,G 8.78E-05 Multiple complex diseases MAPT intron 17554300 rs17571739 chr17 44032915 T A,C,G 3.95E-05 Brain structure MAPT intron 22504417 rs17571739 chr17 44032915 T A,C,G 4.15E-08 Male-pattern baldness MAPT intron 22693459 rs17571739 chr17 44032915 T A,C,G 4.68E-09 Primary biliary cirrhosis MAPT intron 22961000 rs17571739 chr17 44032915 T A,C,G 1.28E-07 Red blood cell traits MAPT intron 23222517 rs17571781 chr17 44033802 T C 3.98E-08 Male-pattern baldness MAPT intron 22693459 rs17571781 chr17 44033802 T C 1.44E-07 Red blood cell traits MAPT intron 23222517 rs17571809 chr17 44034859 A G 3.93E-08 Male-pattern baldness MAPT intron 22693459 rs17571809 chr17 44034859 A G 2.95E-09 Primary biliary cirrhosis MAPT intron 22961000 rs17571809 chr17 44034859 A G 1.30E-07 Red blood cell traits MAPT intron 23222517 rs17650771 chr17 44035367 A G 4.53E-08 Male-pattern baldness MAPT intron 22693459 rs17650771 chr17 44035367 A G 6.31E-08 Red blood cell traits MAPT intron 23222517 rs17571857 chr17 44035706 A G 4.24E-05 Brain structure MAPT intron 22504417 rs17571857 chr17 44035706 A G 3.08E-08 Male-pattern baldness MAPT intron 22693459 rs17571857 chr17 44035706 A G 1.34E-07 Red blood cell traits MAPT intron 23222517 rs17650818 chr17 44036787 T C 2.96E-08 Male-pattern baldness MAPT intron 22693459 rs17650818 chr17 44036787 T C 1.28E-07 Red blood cell traits MAPT intron 23222517 rs17650842 chr17 44037491 A G 2.82E-08 Male-pattern baldness MAPT intron 22693459 rs17650842 chr17 44037491 A G 1.41E-07 Red blood cell traits MAPT intron 23222517 rs17650860 chr17 44039008 G A 4.12E-05 Brain structure MAPT intron 22504417 rs17650860 chr17 44039008 G A 2.77E-08 Male-pattern baldness MAPT intron 22693459 rs17650860 chr17 44039008 G A 1.30E-07 Red blood cell traits MAPT intron 23222517 rs17650872 chr17 44039516 G T 1.10E-04 Multiple complex diseases MAPT intron 17554300 rs17650872 chr17 44039516 G T 4.26E-05 Brain structure MAPT intron 22504417 rs17650872 chr17 44039516 G T 2.55E-08 Male-pattern baldness MAPT intron 22693459 rs17650872 chr17 44039516 G T 7.40E-08 Red blood cell traits MAPT intron 23222517 rs17650901 chr17 44039691 A G 5.60E-06 Parkinson's disease MAPT UTR-5 20711177 rs17650901 chr17 44039691 A G 7.85E-09 Parkinson's disease MAPT UTR-5 22438815 rs17650901 chr17 44039691 A G 2.75E-08 Male-pattern baldness MAPT UTR-5 22693459 rs17650901 chr17 44039691 A G 1.46E-07 Red blood cell traits MAPT UTR-5 23222517 rs17650973 chr17 44044220 A T 2.71E-08 Male-pattern baldness MAPT intron 22693459 rs17650973 chr17 44044220 A T 1.44E-07 Red blood cell traits MAPT intron 23222517 rs17650991 chr17 44044508 A C 4.76E-05 Obesity (extreme) MAPT intron 21935397 rs17650991 chr17 44044508 A C 6.85E-09 Male-pattern baldness MAPT intron 22693459 rs17650991 chr17 44044508 A C 5.54E-08 Red blood cell traits MAPT intron 23222517 rs17572147 chr17 44044985 A G 2.71E-08 Male-pattern baldness MAPT intron 22693459 rs17572147 chr17 44044985 A G 6.67E-07 Red blood cell traits MAPT intron 23222517 rs17572169 chr17 44045974 C T 1.10E-04 Multiple complex diseases MAPT intron 17554300 rs17572169 chr17 44045974 C T 4.18E-05 Brain structure MAPT intron 22504417 rs17572169 chr17 44045974 C T 2.71E-08 Male-pattern baldness MAPT intron 22693459 rs17572169 chr17 44045974 C T 3.94E-09 Primary biliary cirrhosis MAPT intron 22961000 rs17572169 chr17 44045974 C T 1.24E-07 Red blood cell traits MAPT intron 23222517 rs75242405 chr17 44049329 C T 3.39E-09 Primary biliary cirrhosis MAPT intron 22961000 rs17651093 chr17 44049550 G A 2.65E-08 Male-pattern baldness MAPT intron 22693459 rs17651093 chr17 44049550 G A 5.72E-07 Red blood cell traits MAPT intron 23222517 rs17572248 chr17 44049867 A G 2.69E-08 Male-pattern baldness MAPT intron 22693459 rs17572248 chr17 44049867 A G 5.59E-07 Red blood cell traits MAPT intron 23222517 rs17651134 chr17 44050340 G A 2.77E-08 Male-pattern baldness MAPT intron 22693459 rs17651134 chr17 44050340 G A 5.43E-07 Red blood cell traits MAPT intron 23222517 rs1800547 chr17 44051846 A G 6.80E-06 Parkinson's disease MAPT intron 20711177 rs1800547 chr17 44051846 A G 5.72E-14 Parkinson's disease MAPT intron 21738487 rs1800547 chr17 44051846 A G 9.59E-12 Parkinson's disease MAPT intron 22438815 rs1800547 chr17 44051846 A G 4.92E-05 Brain structure MAPT intron 22504417 rs1800547 chr17 44051846 A G 2.85E-08 Male-pattern baldness MAPT intron 22693459 rs1800547 chr17 44051846 A G 5.58E-07 Red blood cell traits MAPT intron 23222517 rs17651213 chr17 44051924 G A 1.42E-04 Multiple complex diseases MAPT intron 17554300 rs17651213 chr17 44051924 G A 3.30E-05 Brain structure MAPT intron 22504417 rs17651213 chr17 44051924 G A 3.35E-08 Male-pattern baldness MAPT intron 22693459 rs17651213 chr17 44051924 G A 4.08E-09 Primary biliary cirrhosis MAPT intron 22961000 rs17651213 chr17 44051924 G A 5.42E-08 Red blood cell traits MAPT intron 23222517 rs17572361 chr17 44052009 T C 9.97E-05 Multiple complex diseases MAPT intron 17554300 rs17572361 chr17 44052009 T C 4.48E-05 Brain structure MAPT intron 22504417 rs17572361 chr17 44052009 T C 2.84E-08 Male-pattern baldness MAPT intron 22693459 rs17572361 chr17 44052009 T C 4.08E-09 Primary biliary cirrhosis MAPT intron 22961000 rs17572361 chr17 44052009 T C 6.64E-08 Red blood cell traits MAPT intron 23222517 rs17651243 chr17 44052284 G A 2.81E-08 Male-pattern baldness MAPT intron 22693459 rs17651243 chr17 44052284 G A 5.26E-07 Red blood cell traits MAPT intron 23222517 rs78104015 chr17 44052733 A G 4.08E-09 Primary biliary cirrhosis MAPT intron 22961000 rs62063777 chr17 44053171 A G 4.08E-09 Primary biliary cirrhosis MAPT intron 22961000 rs2217394 chr17 44053448 A G 2.78E-08 Male-pattern baldness MAPT intron 22693459 rs2217394 chr17 44053448 A G 5.58E-07 Red blood cell traits MAPT intron 23222517 rs17651285 chr17 44054237 G A 2.78E-08 Male-pattern baldness MAPT intron 22693459 rs17651285 chr17 44054237 G A 4.97E-07 Red blood cell traits MAPT intron 23222517 rs17572467 chr17 44054388 T C 2.77E-08 Male-pattern baldness MAPT intron 22693459 rs17572467 chr17 44054388 T C 5.37E-07 Red blood cell traits MAPT intron 23222517 rs17572495 chr17 44054596 T G 2.77E-08 Male-pattern baldness MAPT intron 22693459 rs17572495 chr17 44054596 T G 5.52E-07 Red blood cell traits MAPT intron 23222517 rs754593 chr17 44054696 G A 7.47E-05 Parkinson's disease MAPT intron 21738487 rs754593 chr17 44054696 G A 1.12E-08 Red blood cell traits MAPT intron 23222517 rs754512 chr17 44055647 A T 2.77E-08 Male-pattern baldness MAPT intron 22693459 rs754512 chr17 44055647 A T 5.24E-07 Red blood cell traits MAPT intron 23222517 rs1981997 chr17 44056767 G A 3.55E-14 Parkinson's disease MAPT intron 19915575 rs1981997 chr17 44056767 G A 5.69E-14 Parkinson's disease MAPT intron 21738487 rs1981997 chr17 44056767 G A 8.03E-21 Parkinson's disease MAPT intron 22438815 rs1981997 chr17 44056767 G A 4.83E-05 Brain structure MAPT intron 22504417 rs1981997 chr17 44056767 G A 1.02E-07 Red blood cell traits MAPT intron 23222517 rs1981997 chr17 44056767 G A 2.52E-08 Interstitial lung disease MAPT intron 23583980 rs1981997 chr17 44056767 G A 9.00E-14 Interstitial lung disease MAPT intron 23583980 rs1981997 chr17 44056767 G A 2.02E-07 Parkinson's disease MAPT intron pha002868 rs1981998 chr17 44056833 G A 2.34E-08 Male-pattern baldness MAPT intron 22693459 rs1981998 chr17 44056833 G A 5.31E-07 Red blood cell traits MAPT intron 23222517 rs17572613 chr17 44058004 A G 2.33E-08 Male-pattern baldness MAPT intron 22693459 rs17572613 chr17 44058004 A G 5.41E-07 Red blood cell traits MAPT intron 23222517 rs17572627 chr17 44058629 T A 2.31E-08 Male-pattern baldness MAPT intron 22693459 rs17572627 chr17 44058629 T A 1.25E-07 Red blood cell traits MAPT intron 23222517 rs17651483 chr17 44058861 C A 2.30E-08 Male-pattern baldness MAPT intron 22693459 rs17651483 chr17 44058861 C A 6.10E-07 Red blood cell traits MAPT intron 23222517 rs63750417 chr17 44060775 C T 3.93E-09 Primary biliary cirrhosis MAPT missense 22961000 rs62063786 chr17 44061023 G A 3.93E-09 Primary biliary cirrhosis MAPT missense 22961000 rs62063787 chr17 44061036 T C 3.93E-09 Primary biliary cirrhosis MAPT missense 22961000 rs17651549 chr17 44061278 C T 4.80E-06 Parkinson's disease MAPT missense 20711177 rs17651549 chr17 44061278 C T 3.54E-08 Parkinson's disease MAPT missense 22438815 rs17651549 chr17 44061278 C T 4.88E-05 Brain structure MAPT missense 22504417 rs17651549 chr17 44061278 C T 2.28E-08 Male-pattern baldness MAPT missense 22693459 rs17651549 chr17 44061278 C T 3.93E-09 Primary biliary cirrhosis MAPT missense 22961000 rs17651549 chr17 44061278 C T 6.17E-07 Red blood cell traits MAPT missense 23222517 rs554819069 chr17 44061898 T C 4.80E-09 Primary biliary cirrhosis MAPT intron 22961000 rs530157802 chr17 44062993 A G 5.24E-09 Primary biliary cirrhosis MAPT intron 22961000 rs1529534 chr17 44063140 A G 2.24E-08 Male-pattern baldness MAPT intron 22693459 rs1529534 chr17 44063140 A G 6.50E-07 Red blood cell traits MAPT intron 23222517 rs541986174 chr17 44063140 A G 2.24E-08 Male-pattern baldness MAPT intron 22693459 rs541986174 chr17 44063140 A G 6.50E-07 Red blood cell traits MAPT intron 23222517 rs2435211 chr17 44063244 C T 3.02E-04 Type 2 diabetes MAPT intron 17463246 rs2435211 chr17 44063244 C T 2.20E-05 Brain structure MAPT intron 22504417 rs17572795 chr17 44063393 G A 2.20E-08 Male-pattern baldness MAPT intron 22693459 rs17572795 chr17 44063393 G A 6.40E-07 Red blood cell traits MAPT intron 23222517 rs531217003 chr17 44063393 G A 2.20E-08 Male-pattern baldness MAPT intron 22693459 rs531217003 chr17 44063393 G A 6.40E-07 Red blood cell traits MAPT intron 23222517 rs17572823 chr17 44063563 T C 2.21E-08 Male-pattern baldness MAPT intron 22693459 rs17572823 chr17 44063563 T C 6.53E-07 Red blood cell traits MAPT intron 23222517 rs571131167 chr17 44063563 T C 2.21E-08 Male-pattern baldness MAPT intron 22693459 rs571131167 chr17 44063563 T C 6.53E-07 Red blood cell traits MAPT intron 23222517 rs531963580 chr17 44063723 A C,G 4.80E-09 Primary biliary cirrhosis MAPT intron 22961000 rs9901937 chr17 44063723 A C,G 4.80E-09 Primary biliary cirrhosis MAPT intron 22961000 rs547435395 chr17 44063766 A G 1.18E-04 Multiple complex diseases MAPT intron 17554300 rs547435395 chr17 44063766 A G 4.37E-05 Brain structure MAPT intron 22504417 rs547435395 chr17 44063766 A G 2.21E-08 Male-pattern baldness MAPT intron 22693459 rs547435395 chr17 44063766 A G 1.65E-07 Red blood cell traits MAPT intron 23222517 rs565744479 chr17 44063787 A G 4.80E-09 Primary biliary cirrhosis MAPT intron 22961000 rs17572893 chr17 44064208 G A 9.98E-05 Multiple complex diseases MAPT intron 17554300 rs17572893 chr17 44064208 G A 4.31E-05 Brain structure MAPT intron 22504417 rs17572893 chr17 44064208 G A 2.22E-08 Male-pattern baldness MAPT intron 22693459 rs17572893 chr17 44064208 G A 1.25E-07 Red blood cell traits MAPT intron 23222517 rs537342897 chr17 44064208 G A 9.98E-05 Multiple complex diseases MAPT intron 17554300 rs537342897 chr17 44064208 G A 4.31E-05 Brain structure MAPT intron 22504417 rs537342897 chr17 44064208 G A 2.22E-08 Male-pattern baldness MAPT intron 22693459 rs537342897 chr17 44064208 G A 1.25E-07 Red blood cell traits MAPT intron 23222517 rs552965964 chr17 44064759 A C 2.22E-08 Male-pattern baldness MAPT intron 22693459 rs552965964 chr17 44064759 A C 7.42E-09 Red blood cell traits MAPT intron 23222517 rs10445371 chr17 44065410 G A 2.42E-08 Male-pattern baldness MAPT intron 22693459 rs10445371 chr17 44065410 G A 3.22E-09 Primary biliary cirrhosis MAPT intron 22961000 rs10445371 chr17 44065410 G A 6.64E-07 Red blood cell traits MAPT intron 23222517 rs919461 chr17 44065669 A T 3.22E-09 Primary biliary cirrhosis MAPT intron 22961000 rs919461 chr17 44065669 A T 7.67E-07 Red blood cell traits MAPT intron 23222517 rs919462 chr17 44065740 C T 3.22E-09 Primary biliary cirrhosis MAPT intron 22961000 rs919464 chr17 44065901 C T 3.48E-09 Primary biliary cirrhosis MAPT intron 22961000 rs919464 chr17 44065901 C T 6.79E-07 Red blood cell traits MAPT intron 23222517 rs17651700 chr17 44066634 C G 6.79E-07 Red blood cell traits MAPT intron 23222517 rs10445337 chr17 44067400 T C 5.90E-06 Parkinson's disease MAPT missense 20711177 rs10445337 chr17 44067400 T C 1.35E-08 Parkinson's disease MAPT missense 22438815 rs10445337 chr17 44067400 T C 1.05E-08 Red blood cell traits MAPT missense 23222517 rs10445337 chr17 44067400 T C 2.49E-09 Primary biliary cirrhosis MAPT missense 22961000 rs17651754 chr17 44067546 T C 6.96E-07 Red blood cell traits MAPT intron 23222517 rs10445338 chr17 44067682 G A 6.80E-06 Parkinson's disease MAPT intron 20711177 rs10445338 chr17 44067682 G A 1.49E-08 Parkinson's disease MAPT intron 22438815 rs10445338 chr17 44067682 G A 6.95E-07 Red blood cell traits MAPT intron 23222517 rs62063796 chr17 44068289 G A 3.22E-09 Primary biliary cirrhosis MAPT intron 22961000 rs62063797 chr17 44068294 G C 3.22E-09 Primary biliary cirrhosis MAPT intron 22961000 rs11656151 chr17 44068492 A G 4.70E-05 Alzheimer's disease (late onset) MAPT intron 22027014 rs1052551 chr17 44068924 G A,T 6.00E-06 Parkinson's disease MAPT cds-synon 20711177 rs1052551 chr17 44068924 G A,T 5.79E-08 Parkinson's disease MAPT cds-synon 22438815 rs1052551 chr17 44068924 G A,T 4.64E-05 Brain structure MAPT cds-synon 22504417 rs17573175 chr17 44071089 C G 8.63E-05 Multiple complex diseases MAPT intron 17554300 rs17573175 chr17 44071089 C G 6.60E-06 Parkinson's disease MAPT intron 20711177 rs17573175 chr17 44071089 C G 8.16E-09 Parkinson's disease MAPT intron 22438815 rs17573175 chr17 44071089 C G 4.03E-05 Brain structure MAPT intron 22504417 rs17573175 chr17 44071089 C G 1.72E-07 Red blood cell traits MAPT intron 23222517 rs2435200 chr17 44071851 G A 3.14E-05 Parkinson's disease MAPT intron 21738487 rs2435200 chr17 44071851 G A 5.86E-07 Red blood cell traits MAPT intron 23222517 rs17652036 chr17 44073027 G A 8.51E-07 Red blood cell traits MAPT intron 23222517 rs17652066 chr17 44073145 G C 3.26E-09 Primary biliary cirrhosis MAPT intron 22961000 rs1052553 chr17 44073889 A G 6.70E-06 Parkinson's disease MAPT cds-synon 20711177 rs1052553 chr17 44073889 A G 1.05E-15 Parkinson's disease MAPT cds-synon 22438815 rs1052553 chr17 44073889 A G 4.44E-05 Brain structure MAPT cds-synon 22504417 rs1052553 chr17 44073889 A G 5.66E-07 Red blood cell traits MAPT cds-synon 23222517 rs17652121 chr17 44073973 T C 6.80E-06 Parkinson's disease MAPT cds-synon 20711177 rs17652121 chr17 44073973 T C 2.17E-08 Parkinson's disease MAPT cds-synon 22438815 rs17652121 chr17 44073973 T C 4.10E-09 Primary biliary cirrhosis MAPT cds-synon 22961000 rs17652121 chr17 44073973 T C 8.54E-07 Red blood cell traits MAPT cds-synon 23222517 rs62063851 chr17 44074435 C G 3.37E-09 Primary biliary cirrhosis MAPT intron 22961000 rs62063852 chr17 44074581 A G 3.80E-09 Primary biliary cirrhosis MAPT intron 22961000 rs62063853 chr17 44074613 A G 3.37E-09 Primary biliary cirrhosis MAPT intron 22961000 rs62063854 chr17 44074619 G A 3.37E-09 Primary biliary cirrhosis MAPT intron 22961000 rs1078268 chr17 44075901 A G 1.40E-04 Multiple complex diseases MAPT intron 17554300 rs1078268 chr17 44075901 A G 6.40E-06 Parkinson's disease MAPT intron 20711177 rs1078268 chr17 44075901 A G 8.50E-09 Parkinson's disease MAPT intron 22438815 rs1078268 chr17 44075901 A G 4.14E-05 Brain structure MAPT intron 22504417 rs1078268 chr17 44075901 A G 3.65E-09 Primary biliary cirrhosis MAPT intron 22961000 rs1078268 chr17 44075901 A G 4.24E-08 Red blood cell traits MAPT intron 23222517 rs62063857 chr17 44076665 A G 2.11E-12 Parkinson's disease STH missense 22438815 rs62063857 chr17 44076665 A G 3.03E-09 Primary biliary cirrhosis STH missense 22961000 rs62064662 chr17 44079721 A G 6.76E-09 Primary biliary cirrhosis MAPT intron 22961000 rs138957038 chr17 44080039 T TG 6.12E-09 Primary biliary cirrhosis MAPT intron 22961000 rs62064663 chr17 44080039 T G 6.12E-09 Primary biliary cirrhosis MAPT intron 22961000 rs8070723 chr17 44081064 A G 3.52E-05 Multiple complex diseases MAPT intron 17554300 rs8070723 chr17 44081064 A G 9.64E-14 Parkinson's disease MAPT intron 19915575 rs8070723 chr17 44081064 A G 7.00E-12 Parkinson's disease MAPT intron 21044948 rs8070723 chr17 44081064 A G 5.96E-06 Primary biliary cirrhosis MAPT intron 21399635 rs8070723 chr17 44081064 A G 2.00E-118 Progressive supranuclear palsy MAPT intron 21685912 rs8070723 chr17 44081064 A G 7.65E-14 Parkinson's disease MAPT intron 21738487 rs8070723 chr17 44081064 A G 5.01E-20 Parkinson's disease MAPT intron 22438815 rs8070723 chr17 44081064 A G 4.07E-05 Brain structure MAPT intron 22504417 rs8070723 chr17 44081064 A G 3.23E-09 Primary biliary cirrhosis MAPT intron 22961000 rs8070723 chr17 44081064 A G 2.24E-07 Red blood cell traits MAPT intron 23222517 rs8070723 chr17 44081064 A G 3.87E-08 Interstitial lung disease MAPT intron 23583980 rs8070723 chr17 44081064 A G 2.41E-09 Parkinson's disease MAPT intron 24842889 rs8070723 chr17 44081064 A G 3.36E-07 Parkinson's disease MAPT intron pha002868 rs17573509 chr17 44081224 G A 6.00E-06 Parkinson's disease MAPT intron 20711177 rs17573593 chr17 44082603 A C 4.67E-07 Red blood cell traits MAPT intron 23222517 rs17573607 chr17 44083081 G A 3.62E-07 Red blood cell traits MAPT intron 23222517 rs17652337 chr17 44083323 C T 5.81E-08 Red blood cell traits MAPT intron 23222517 rs1991556 chr17 44083402 G A 6.18E-13 Parkinson's disease MAPT intron 21738487 rs1991556 chr17 44083402 G A 2.21E-07 Red blood cell traits MAPT intron 23222517 rs8067056 chr17 44083948 T C 2.69E-06 Parkinson's disease MAPT intron 21738487 rs8067056 chr17 44083948 T C 4.33E-05 Obesity (extreme) MAPT intron 21935397 rs8067056 chr17 44083948 T C 2.02E-08 Red blood cell traits MAPT intron 23222517 rs17652449 chr17 44088937 G C 1.46E-04 Multiple complex diseases MAPT intron 17554300 rs17652449 chr17 44088937 G C 3.85E-05 Brain structure MAPT intron 22504417 rs17652449 chr17 44088937 G C 5.86E-09 Primary biliary cirrhosis MAPT intron 22961000 rs17652449 chr17 44088937 G C 1.20E-07 Red blood cell traits MAPT intron 23222517 rs733966 chr17 44089563 C T 5.34E-07 Red blood cell traits MAPT intron 23222517 rs75666751 chr17 44090148 A C 6.06E-09 Primary biliary cirrhosis MAPT intron 22961000 rs551853349 chr17 44090536 G A 3.69E-05 Brain structure MAPT intron 22504417 rs551853349 chr17 44090536 G A 1.53E-08 Red blood cell traits MAPT intron 23222517 rs12150170 chr17 44090646 A G 6.16E-07 Red blood cell traits MAPT intron 23222517 rs12150515 chr17 44090685 G T 5.32E-07 Red blood cell traits MAPT intron 23222517 rs17573858 chr17 44090796 T C 5.98E-07 Red blood cell traits MAPT intron 23222517 rs17652502 chr17 44094471 G A 1.06E-04 Multiple complex diseases MAPT intron 17554300 rs17652502 chr17 44094471 G A 3.92E-05 Brain structure MAPT intron 22504417 rs17652502 chr17 44094471 G A 5.01E-09 Primary biliary cirrhosis MAPT intron 22961000 rs17652502 chr17 44094471 G A 5.33E-08 Red blood cell traits MAPT intron 23222517 rs9468 chr17 44101563 T C 5.20E-04 Alzheimer's disease (late onset) MAPT UTR-3 22027014 rs9468 chr17 44101563 T C 3.20E-06 Parkinson's disease MAPT UTR-3 22438815 rs9468 chr17 44101563 T C 6.67E-07 Red blood cell traits MAPT UTR-3 23222517 rs1052587 chr17 44102604 T C 5.40E-06 Parkinson's disease MAPT UTR-3 20711177 rs1052587 chr17 44102604 T C 2.62E-09 Parkinson's disease MAPT UTR-3 22438815 rs1052587 chr17 44102604 T C 4.04E-05 Brain structure MAPT UTR-3 22504417 rs1052587 chr17 44102604 T C 4.82E-09 Primary biliary cirrhosis MAPT UTR-3 22961000 rs1052587 chr17 44102604 T C 6.13E-07 Red blood cell traits MAPT UTR-3 23222517 rs1052590 chr17 44102638 A G 4.82E-09 Primary biliary cirrhosis MAPT UTR-3 22961000 rs1052594 chr17 44102689 G C 4.82E-09 Primary biliary cirrhosis MAPT UTR-3 22961000 rs1052594 chr17 44102689 G C 6.38E-07 Red blood cell traits MAPT UTR-3 23222517 rs17574040 chr17 44102865 A C 7.00E-06 Parkinson's disease MAPT UTR-3 20711177 rs17574040 chr17 44102865 A C 4.82E-09 Primary biliary cirrhosis MAPT UTR-3 22961000 rs17574040 chr17 44102865 A C 5.03E-07 Red blood cell traits MAPT UTR-3 23222517 rs16940799 chr17 44102933 T C 7.80E-06 Parkinson's disease MAPT UTR-3 20711177 rs16940799 chr17 44102933 T C 4.82E-09 Primary biliary cirrhosis MAPT UTR-3 22961000 rs16940799 chr17 44102933 T C 5.04E-07 Red blood cell traits MAPT UTR-3 23222517 rs7687 chr17 44103296 T C 4.82E-09 Primary biliary cirrhosis MAPT UTR-3 22961000 rs7687 chr17 44103296 T C 5.03E-07 Red blood cell traits MAPT UTR-3 23222517 rs17652748 chr17 44103616 C T 4.82E-09 Primary biliary cirrhosis MAPT UTR-3 22961000 rs17652748 chr17 44103616 C T 4.79E-07 Red blood cell traits MAPT UTR-3 23222517 rs75010486 chr17 44103825 T C 4.82E-09 Primary biliary cirrhosis MAPT UTR-3 22961000 rs16940806 chr17 44103826 G A,C,T 4.82E-09 Primary biliary cirrhosis MAPT UTR-3 22961000 rs2158257 chr17 44104343 A C 6.80E-06 Parkinson's disease MAPT UTR-3 20711177 rs2158257 chr17 44104343 A C 4.82E-09 Primary biliary cirrhosis MAPT UTR-3 22961000 rs2158257 chr17 44104343 A C 6.61E-07 Red blood cell traits MAPT UTR-3 23222517 rs17574228 chr17 44104509 T C 1.25E-04 Multiple complex diseases MAPT UTR-3 17554300 rs17574228 chr17 44104509 T C 6.80E-06 Parkinson's disease MAPT UTR-3 20711177 rs17574228 chr17 44104509 T C 3.27E-09 Parkinson's disease MAPT UTR-3 22438815 rs17574228 chr17 44104509 T C 4.82E-09 Primary biliary cirrhosis MAPT UTR-3 22961000 rs17574228 chr17 44104509 T C 1.09E-07 Red blood cell traits MAPT UTR-3 23222517 rs7521 chr17 44105395 A G 2.66E-05 Parkinson's disease MAPT UTR-3 21738487 rs7521 chr17 44105395 A G 5.24E-07 Red blood cell traits MAPT UTR-3 23222517 rs7350928 chr17 44108100 C T 7.30E-06 Parkinson's disease KANSL1 UTR-3 20711177 rs7350928 chr17 44108100 C T 3.87E-05 Brain structure KANSL1 UTR-3 22504417 rs7350928 chr17 44108100 C T 9.22E-07 Red blood cell traits KANSL1 UTR-3 23222517 rs17574361 chr17 44108202 A G 7.20E-06 Parkinson's disease KANSL1 UTR-3 20711177 rs17574361 chr17 44108202 A G 3.43E-09 Parkinson's disease KANSL1 UTR-3 22438815 rs17574361 chr17 44108202 A G 3.91E-05 Brain structure KANSL1 UTR-3 22504417 rs17574361 chr17 44108202 A G 4.69E-07 Red blood cell traits KANSL1 UTR-3 23222517 rs17652961 chr17 44108355 G A 3.81E-05 Brain structure KANSL1 UTR-3 22504417 rs17652961 chr17 44108355 G A 5.27E-07 Red blood cell traits KANSL1 UTR-3 23222517 rs34579536 chr17 44108906 A G 3.89E-09 Primary biliary cirrhosis KANSL1 missense 22961000 rs17574425 chr17 44109188 C G 5.15E-07 Red blood cell traits KANSL1 intron 23222517 rs1076222 chr17 44109769 C G 1.12E-04 Multiple complex diseases KANSL1 intron 17554300 rs1076222 chr17 44109769 C G 3.39E-05 Brain structure KANSL1 intron 22504417 rs1076222 chr17 44109769 C G 5.29E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs1076222 chr17 44109769 C G 2.90E-08 Red blood cell traits KANSL1 intron 23222517 rs7350980 chr17 44110271 G A 9.25E-05 Multiple complex diseases KANSL1 intron 17554300 rs7350980 chr17 44110271 G A 2.01E-07 Red blood cell traits KANSL1 intron 23222517 rs36076725 chr17 44110532 G A,C,T 6.50E-06 Parkinson's disease KANSL1 missense 20711177 rs36076725 chr17 44110532 G A,C,T 3.27E-09 Primary biliary cirrhosis KANSL1 missense 22961000 rs35833914 chr17 44110541 G A,C,T 7.70E-06 Parkinson's disease KANSL1 missense 20711177 rs35833914 chr17 44110541 G A,C,T 3.27E-09 Primary biliary cirrhosis KANSL1 missense 22961000 rs4597358 chr17 44110670 C G 1.28E-04 Multiple complex diseases KANSL1 intron 17554300 rs4597358 chr17 44110670 C G 8.88E-07 Red blood cell traits KANSL1 intron 23222517 rs17574604 chr17 44111613 A G 7.20E-06 Parkinson's disease KANSL1 missense 20711177 rs17574604 chr17 44111613 A G 7.00E-09 Parkinson's disease KANSL1 missense 22438815 rs17574604 chr17 44111613 A G 3.75E-05 Brain structure KANSL1 missense 22504417 rs17574604 chr17 44111613 A G 3.27E-09 Primary biliary cirrhosis KANSL1 missense 22961000 rs17574604 chr17 44111613 A G 8.34E-07 Red blood cell traits KANSL1 missense 23222517 rs17653162 chr17 44111827 C A 1.09E-04 Multiple complex diseases KANSL1 intron 17554300 rs17653162 chr17 44111827 C A 3.87E-05 Brain structure KANSL1 intron 22504417 rs17653162 chr17 44111827 C A 2.01E-07 Red blood cell traits KANSL1 intron 23222517 rs62062322 chr17 44112385 A G 5.31E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs17653193 chr17 44112441 G A 5.31E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs17653193 chr17 44112441 G A 4.15E-07 Red blood cell traits KANSL1 intron 23222517 rs17653211 chr17 44112638 T C 5.31E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs17653211 chr17 44112638 T C 8.91E-07 Red blood cell traits KANSL1 intron 23222517 rs17653255 chr17 44112743 C A 5.31E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs17653255 chr17 44112743 C A 5.58E-07 Red blood cell traits KANSL1 intron 23222517 rs62062323 chr17 44113224 C T 5.31E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs4608377 chr17 44113359 T C 5.08E-07 Red blood cell traits KANSL1 intron 23222517 rs12185225 chr17 44113491 T C 5.31E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs17574796 chr17 44115074 T C 5.70E-07 Red blood cell traits KANSL1 intron 23222517 rs17574824 chr17 44115107 C T 1.56E-04 Multiple complex diseases KANSL1 intron 17554300 rs17574824 chr17 44115107 C T 3.47E-05 Brain structure KANSL1 intron 22504417 rs17574824 chr17 44115107 C T 5.31E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs17574824 chr17 44115107 C T 2.49E-08 Red blood cell traits KANSL1 intron 23222517 rs12185243 chr17 44115351 T C 9.37E-10 Red blood cell traits KANSL1 intron 23222517 rs8077487 chr17 44115440 T C 7.67E-07 Red blood cell traits KANSL1 intron 23222517 rs11079729 chr17 44115569 C A 4.19E-05 Multiple complex diseases KANSL1 intron 17554300 rs11079729 chr17 44115569 C A 3.70E-05 Brain structure KANSL1 intron 22504417 rs11079729 chr17 44115569 C A 5.31E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs11079729 chr17 44115569 C A 9.40E-08 Red blood cell traits KANSL1 intron 23222517 rs12150542 chr17 44115730 G A 5.05E-07 Red blood cell traits KANSL1 intron 23222517 rs12150090 chr17 44115886 C T 7.96E-05 Multiple complex diseases KANSL1 intron 17554300 rs12150090 chr17 44115886 C T 3.92E-05 Brain structure KANSL1 intron 22504417 rs12150090 chr17 44115886 C T 5.31E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs12150090 chr17 44115886 C T 1.30E-07 Red blood cell traits KANSL1 intron 23222517 rs41437445 chr17 44116238 G A 1.21E-04 Multiple complex diseases KANSL1 intron 17554300 rs7221390 chr17 44116950 T G 9.78E-05 Multiple complex diseases KANSL1 intron 17554300 rs7221390 chr17 44116950 T G 9.66E-08 Red blood cell traits KANSL1 intron 23222517 rs34043286 chr17 44117119 A G 3.27E-09 Primary biliary cirrhosis KANSL1 missense 22961000 rs10514897 chr17 44117397 A G 3.88E-07 Red blood cell traits KANSL1 intron 23222517 rs41382552 chr17 44118999 A G 1.00E-04 Multiple complex diseases KANSL1 intron 17554300 rs10514898 chr17 44119636 A C 3.92E-07 Red blood cell traits KANSL1 intron 23222517 rs41374248 chr17 44120442 A G 1.46E-04 Multiple complex diseases KANSL1 intron 17554300 rs41399444 chr17 44121469 C T 8.41E-05 Multiple complex diseases KANSL1 intron 17554300 rs569670697 chr17 44121469 C T 8.41E-05 Multiple complex diseases KANSL1 intron 17554300 rs575200428 chr17 44121917 C T 5.01E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs7218319 chr17 44126365 C T 6.82E-07 Red blood cell traits KANSL1 intron 23222517 rs12150447 chr17 44128125 A C 4.16E-05 Brain structure KANSL1 intron 22504417 rs12150447 chr17 44128125 A C 6.67E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs12150447 chr17 44128125 A C 2.67E-07 Red blood cell traits KANSL1 intron 23222517 rs12150064 chr17 44128407 C A 2.60E-07 Red blood cell traits KANSL1 intron 23222517 rs17653836 chr17 44128876 T A 2.57E-07 Red blood cell traits KANSL1 intron 23222517 rs17575423 chr17 44129253 T C 2.57E-07 Red blood cell traits KANSL1 intron 23222517 rs4792827 chr17 44131305 T C 3.13E-05 Parkinson's disease KANSL1 intron 21738487 rs4792827 chr17 44131305 T C 6.56E-08 Red blood cell traits KANSL1 intron 23222517 rs17575437 chr17 44133031 T A 2.54E-07 Red blood cell traits KANSL1 intron 23222517 rs17653889 chr17 44133070 A T 2.56E-07 Red blood cell traits KANSL1 intron 23222517 rs17653906 chr17 44133142 G A 2.47E-07 Red blood cell traits KANSL1 intron 23222517 rs17575507 chr17 44134095 A G 2.54E-07 Red blood cell traits KANSL1 intron 23222517 rs876944 chr17 44134391 G T 2.48E-07 Red blood cell traits KANSL1 intron 23222517 rs1107820 chr17 44135359 T C 2.47E-07 Red blood cell traits KANSL1 intron 23222517 rs17575556 chr17 44135827 G A 1.11E-04 Multiple complex diseases KANSL1 intron 17554300 rs17575556 chr17 44135827 G A 3.71E-05 Brain structure KANSL1 intron 22504417 rs17575556 chr17 44135827 G A 6.72E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs17575556 chr17 44135827 G A 5.79E-08 Red blood cell traits KANSL1 intron 23222517 rs17653998 chr17 44135985 A G 2.61E-07 Red blood cell traits KANSL1 intron 23222517 rs41384744 chr17 44137070 A G 3.50E-04 Multiple complex diseases KANSL1 intron 17554300 rs17654016 chr17 44137925 T C 7.60E-07 Red blood cell traits KANSL1 intron 23222517 rs2316951 chr17 44139083 G C 2.32E-07 Red blood cell traits KANSL1 intron 23222517 rs17575683 chr17 44139662 C A,G,T 1.28E-04 Multiple complex diseases KANSL1 intron 17554300 rs17575683 chr17 44139662 C A,G,T 1.38E-07 Red blood cell traits KANSL1 intron 23222517 rs6503455 chr17 44140748 C T 4.32E-08 Red blood cell traits KANSL1 intron 23222517 rs2838 chr17 44141347 A G 2.83E-07 Red blood cell traits KANSL1 intron 23222517 rs12150127 chr17 44141732 G A 6.53E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs62060792 chr17 44141955 T A 6.53E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs17575850 chr17 44144387 C A 1.97E-04 Multiple complex diseases KANSL1 intron 17554300 rs17575850 chr17 44144387 C A 3.41E-05 Brain structure KANSL1 intron 22504417 rs17575850 chr17 44144387 C A 6.34E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs17575850 chr17 44144387 C A 7.50E-08 Red blood cell traits KANSL1 intron 23222517 rs17659731 chr17 44144634 G A 2.52E-07 Red blood cell traits KANSL1 intron 23222517 rs1117253 chr17 44149297 A C 4.03E-05 Brain structure KANSL1 intron 22504417 rs1117253 chr17 44149297 A C 2.36E-07 Red blood cell traits KANSL1 intron 23222517 rs974293 chr17 44150233 G A 2.43E-07 Red blood cell traits KANSL1 intron 23222517 rs2066899 chr17 44155732 C T 6.31E-07 Red blood cell traits KANSL1 intron 23222517 rs2316954 chr17 44156167 G A 2.29E-07 Red blood cell traits KANSL1 intron 23222517 rs17659881 chr17 44157597 A G 1.30E-04 Multiple complex diseases KANSL1 intron 17554300 rs17659881 chr17 44157597 A G 3.84E-05 Brain structure KANSL1 intron 22504417 rs17659881 chr17 44157597 A G 6.42E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs17659881 chr17 44157597 A G 6.69E-08 Red blood cell traits KANSL1 intron 23222517 rs1476554 chr17 44159102 C T 2.54E-07 Red blood cell traits KANSL1 intron 23222517 rs17659953 chr17 44159725 C A,G,T 4.08E-05 Brain structure KANSL1 intron 22504417 rs17659953 chr17 44159725 C A,G,T 2.59E-07 Red blood cell traits KANSL1 intron 23222517 rs17576165 chr17 44159849 T C 7.10E-06 Parkinson's disease KANSL1 cds-synon 20711177 rs17660017 chr17 44160674 G C 2.60E-07 Red blood cell traits KANSL1 intron 23222517 rs17660065 chr17 44162284 T C 9.26E-05 Multiple complex diseases KANSL1 intron 17554300 rs17660065 chr17 44162284 T C 3.88E-05 Brain structure KANSL1 intron 22504417 rs17660065 chr17 44162284 T C 4.63E-08 Red blood cell traits KANSL1 intron 23222517 rs8080583 chr17 44162597 C A 1.12E-04 Multiple complex diseases KANSL1 intron 17554300 rs8080583 chr17 44162597 C A 5.82E-08 Red blood cell traits KANSL1 intron 23222517 rs3912061 chr17 44165098 C T 2.38E-07 Red blood cell traits KANSL1 intron 23222517 rs17660132 chr17 44165803 T C 1.23E-04 Multiple complex diseases KANSL1 intron 17554300 rs17660132 chr17 44165803 T C 3.96E-05 Brain structure KANSL1 intron 22504417 rs17660132 chr17 44165803 T C 7.09E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs17660132 chr17 44165803 T C 2.97E-08 Red blood cell traits KANSL1 intron 23222517 rs17660167 chr17 44166311 C T 1.84E-07 Red blood cell traits KANSL1 intron 23222517 rs17660228 chr17 44166500 G A 2.89E-07 Red blood cell traits KANSL1 intron 23222517 rs17660251 chr17 44166646 C T 2.31E-07 Red blood cell traits KANSL1 intron 23222517 rs17660294 chr17 44167101 T C 1.01E-08 Primary biliary cirrhosis KANSL1 intron 22961000 rs17660294 chr17 44167101 T C 2.10E-07 Red blood cell traits KANSL1 intron 23222517 rs79923630 chr17 44167661 G T 7.78E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs62061767 chr17 44167729 A G 1.01E-08 Primary biliary cirrhosis KANSL1 intron 22961000 rs17660337 chr17 44169605 T C 2.09E-07 Red blood cell traits KANSL1 intron 23222517 rs17576631 chr17 44170018 G C 2.55E-07 Red blood cell traits KANSL1 intron 23222517 rs17660398 chr17 44170612 C T 2.46E-07 Red blood cell traits KANSL1 intron 23222517 rs17576695 chr17 44172327 T A 2.77E-07 Red blood cell traits KANSL1 intron 23222517 rs17576709 chr17 44173356 C G 2.75E-07 Red blood cell traits KANSL1 intron 23222517 rs17660464 chr17 44177993 C A 7.50E-06 Parkinson's disease KANSL1 intron 20711177 rs17660464 chr17 44177993 C A 4.74E-05 Brain structure KANSL1 intron 22504417 rs17660464 chr17 44177993 C A 2.60E-08 Male-pattern baldness KANSL1 intron 22693459 rs17660464 chr17 44177993 C A 1.06E-07 Red blood cell traits KANSL1 intron 23222517 rs17576779 chr17 44178272 C T 3.16E-07 Red blood cell traits KANSL1 intron 23222517 rs17660488 chr17 44178337 T C 2.80E-07 Red blood cell traits KANSL1 intron 23222517 rs17576842 chr17 44179992 A G 3.04E-07 Red blood cell traits KANSL1 intron 23222517 rs17576870 chr17 44180442 A G 9.44E-09 Red blood cell traits KANSL1 intron 23222517 rs17660595 chr17 44180954 A G 1.03E-04 Multiple complex diseases KANSL1 intron 17554300 rs17660595 chr17 44180954 A G 6.95E-05 Type 1 diabetes KANSL1 intron 18978792 rs17660595 chr17 44180954 A G 2.78E-07 Red blood cell traits KANSL1 intron 23222517 rs17576954 chr17 44181933 T C 2.41E-07 Red blood cell traits KANSL1 intron 23222517 rs17576989 chr17 44183616 C A 2.96E-07 Red blood cell traits KANSL1 intron 23222517 rs8070420 chr17 44185479 G T 1.06E-07 Red blood cell traits KANSL1 intron 23222517 rs17577024 chr17 44186252 G A 2.34E-07 Red blood cell traits KANSL1 intron 23222517 rs17577052 chr17 44186301 T C 1.98E-07 Red blood cell traits KANSL1 intron 23222517 rs9904766 chr17 44186952 T C 2.78E-07 Red blood cell traits KANSL1 intron 23222517 rs9303525 chr17 44187257 A G 8.00E-15 Intracranial volume KANSL1 intron 22504418 rs9303525 chr17 44187257 A G 3.53E-07 Red blood cell traits KANSL1 intron 23222517 rs17577094 chr17 44187492 A G 8.86E-05 Multiple complex diseases KANSL1 intron 17554300 rs17577094 chr17 44187492 A G 4.33E-05 Brain structure KANSL1 intron 22504417 rs17577094 chr17 44187492 A G 6.41E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs17577094 chr17 44187492 A G 4.63E-08 Red blood cell traits KANSL1 intron 23222517 rs17577094 chr17 44187492 A G 8.00E-09 Parkinson's disease KANSL1 intron 24842889 rs17577159 chr17 44188477 T G 2.47E-07 Red blood cell traits KANSL1 intron 23222517 rs7225002 chr17 44189067 A G 8.40E-08 Parkinson's disease KANSL1 intron 19915575 rs7225002 chr17 44189067 A G 2.21E-09 Parkinson's disease KANSL1 intron 21738487 rs7225002 chr17 44189067 A G 1.43E-09 Parkinson's disease KANSL1 intron 22438815 rs7225002 chr17 44189067 A G 6.60E-07 Red blood cell traits KANSL1 intron 23222517 rs7225002 chr17 44189067 A G 7.60E-06 Interstitial lung disease KANSL1 intron 23583980 rs7225002 chr17 44189067 A G 0.000659554 Primary sclerosing cholangitis KANSL1 intron 23603763 rs17660847 chr17 44189373 C T 2.34E-08 Male-pattern baldness KANSL1 intron 22693459 rs17660847 chr17 44189373 C T 1.96E-07 Red blood cell traits KANSL1 intron 23222517 rs17660865 chr17 44189408 T C 3.34E-07 Red blood cell traits KANSL1 intron 23222517 rs17660907 chr17 44191085 G A 8.75E-05 Multiple complex diseases KANSL1 intron 17554300 rs17660907 chr17 44191085 G A 2.27E-07 Red blood cell traits KANSL1 intron 23222517 rs17660936 chr17 44191159 C T 2.48E-07 Red blood cell traits KANSL1 intron 23222517 rs17577313 chr17 44191835 A G 2.36E-07 Red blood cell traits KANSL1 intron 23222517 rs4548919 chr17 44192395 G T 2.44E-07 Red blood cell traits KANSL1 intron 23222517 rs4630591 chr17 44192568 C T 3.47E-08 Male-pattern baldness KANSL1 intron 22693459 rs4630591 chr17 44192568 C T 2.01E-07 Red blood cell traits KANSL1 intron 23222517 rs17577369 chr17 44192923 A G 2.47E-07 Red blood cell traits KANSL1 intron 23222517 rs17661015 chr17 44192957 T C 2.76E-07 Red blood cell traits KANSL1 intron 23222517 rs17661027 chr17 44193097 C A 2.27E-07 Red blood cell traits KANSL1 intron 23222517 rs17661045 chr17 44194152 T A 2.21E-07 Red blood cell traits KANSL1 intron 23222517 rs17577447 chr17 44194381 T A 2.47E-07 Red blood cell traits KANSL1 intron 23222517 rs10514901 chr17 44194735 G T 2.24E-07 Red blood cell traits KANSL1 intron 23222517 rs17577496 chr17 44194835 T C 2.60E-07 Red blood cell traits KANSL1 intron 23222517 rs17661141 chr17 44196015 C G 2.67E-07 Red blood cell traits KANSL1 intron 23222517 rs1468241 chr17 44196153 A G 4.71E-05 Brain structure KANSL1 intron 22504417 rs1468241 chr17 44196153 A G 2.39E-07 Red blood cell traits KANSL1 intron 23222517 rs4383188 chr17 44197603 T C 4.62E-05 Multiple complex diseases KANSL1 intron 17554300 rs4383188 chr17 44197603 T C 6.40E-08 Red blood cell traits KANSL1 intron 23222517 rs3087534 chr17 44198806 T C 4.07E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs62061855 chr17 44199670 G A 4.07E-09 Primary biliary cirrhosis KANSL1 intron 22961000 rs17577650 chr17 44205500 A G 4.55E-07 Red blood cell traits KANSL1 intron 23222517 rs4471723 chr17 44205690 C T 7.87E-08 Red blood cell traits KANSL1 intron 23222517 rs1122381 chr17 44205839 A G 3.69E-07 Red blood cell traits KANSL1 intron 23222517 rs1122380 chr17 44206079 C T 4.02E-07 Red blood cell traits KANSL1 intron 23222517 rs10514903 chr17 44206646 C G 6.73E-09 Red blood cell traits KANSL1 intron 23222517 rs17661348 chr17 44207066 A G 5.40E-07 Red blood cell traits KANSL1 intron 23222517 rs17661385 chr17 44207778 A G 5.80E-07 Red blood cell traits KANSL1 intron 23222517 rs10514904 chr17 44207887 C T 1.12E-07 Red blood cell traits KANSL1 intron 23222517 rs17661428 chr17 44208144 C G 1.01E-04 Multiple complex diseases KANSL1 intron 17554300 rs17661428 chr17 44208144 C G 6.46E-05 Type 1 diabetes KANSL1 intron 18978792 rs17661428 chr17 44208144 C G 2.51E-07 Red blood cell traits KANSL1 intron 23222517 rs17577877 chr17 44208218 A G 5.79E-07 Red blood cell traits KANSL1 intron 23222517 rs6503457 chr17 44208312 G T 6.16E-07 Red blood cell traits KANSL1 intron 23222517 rs8070942 chr17 44208674 G T 9.09E-05 Multiple complex diseases KANSL1 intron 17554300 rs8070942 chr17 44208674 G T 1.98E-08 Primary biliary cirrhosis KANSL1 intron 22961000 rs8070942 chr17 44208674 G T 4.57E-07 Red blood cell traits KANSL1 intron 23222517 rs17577954 chr17 44209628 T C 5.29E-07 Red blood cell traits KANSL1 intron 23222517 rs17577975 chr17 44210442 C T 5.18E-07 Red blood cell traits KANSL1 intron 23222517 rs7207582 chr17 44210933 A G 7.13E-07 Red blood cell traits KANSL1 intron 23222517 rs12150087 chr17 44210988 C G 6.03E-07 Red blood cell traits KANSL1 intron 23222517 rs10221243 chr17 44212310 G A 9.30E-07 Red blood cell traits KANSL1 intron 23222517 rs9915547 chr17 44212782 T C 8.17E-07 Red blood cell traits KANSL1 intron 23222517 rs542524111 chr17 44213204 C T 1.19E-04 Multiple complex diseases KANSL1 intron 17554300 rs542524111 chr17 44213204 C T 3.88E-05 Type 1 diabetes KANSL1 intron 18978792 rs542524111 chr17 44213204 C T 1.91E-07 Red blood cell traits KANSL1 intron 23222517 rs564905548 chr17 44213712 G A 7.66E-05 Multiple complex diseases KANSL1 intron 17554300 rs564905548 chr17 44213712 G A 4.73E-05 Brain structure KANSL1 intron 22504417 rs564905548 chr17 44213712 G A 6.39E-07 Red blood cell traits KANSL1 intron 23222517 rs532044959 chr17 44213921 A C 5.85E-07 Red blood cell traits KANSL1 intron 23222517 rs547112461 chr17 44213934 G A 6.40E-07 Red blood cell traits KANSL1 intron 23222517 rs536077496 chr17 44214094 A G 9.22E-09 Red blood cell traits KANSL1 intron 23222517 rs575074983 chr17 44214888 T C 1.29E-07 Red blood cell traits KANSL1 intron 23222517 rs568519571 chr17 44215896 C T 6.33E-07 Red blood cell traits KANSL1 intron 23222517 rs557239232 chr17 44216158 T C 6.94E-07 Red blood cell traits KANSL1 intron 23222517 rs575816835 chr17 44216226 A G 1.17E-04 Multiple complex diseases KANSL1 intron 17554300 rs575816835 chr17 44216226 A G 3.66E-07 Red blood cell traits KANSL1 intron 23222517 rs563314190 chr17 44217112 G T 7.03E-07 Red blood cell traits KANSL1 intron 23222517 rs528392906 chr17 44217293 G A 7.20E-07 Red blood cell traits KANSL1 intron 23222517 rs558031693 chr17 44218044 A T 1.32E-07 Red blood cell traits KANSL1 intron 23222517 rs573245541 chr17 44218138 C T 1.39E-09 Red blood cell traits KANSL1 intron 23222517 rs534210380 chr17 44218242 C T 1.09E-09 Red blood cell traits KANSL1 intron 23222517 rs564301026 chr17 44220454 T G 7.28E-07 Red blood cell traits KANSL1 intron 23222517 rs2532307 chr17 44221350 G A 7.31E-07 Red blood cell traits KANSL1 intron 23222517 rs527841438 chr17 44221476 A T 1.01E-08 Red blood cell traits KANSL1 intron 23222517 rs538148047 chr17 44221602 G C 2.61E-08 Male-pattern baldness KANSL1 intron 22693459 rs538148047 chr17 44221602 G C 6.13E-07 Red blood cell traits KANSL1 intron 23222517 rs386477606 chr17 44222019 G T 1.58E-09 Red blood cell traits KANSL1 intron 23222517 rs573082572 chr17 44222067 T G 7.64E-07 Red blood cell traits KANSL1 intron 23222517 rs544161107 chr17 44222335 G A 3.54E-14 Parkinson's disease KANSL1 intron 21738487 rs544161107 chr17 44222335 G A 5.74E-07 Red blood cell traits KANSL1 intron 23222517 rs2696588 chr17 44222424 G C 2.28E-08 Red blood cell traits KANSL1 intron 23222517 rs533125554 chr17 44222460 T G 5.68E-07 Red blood cell traits KANSL1 intron 23222517 rs527778993 chr17 44223060 G A 5.75E-07 Red blood cell traits KANSL1 intron 23222517 rs567744882 chr17 44223243 G A 6.50E-07 Red blood cell traits KANSL1 intron 23222517 rs9674888 chr17 44224272 G A 4.99E-07 Red blood cell traits KANSL1 intron 23222517 rs538530693 chr17 44225886 G A 2.36E-07 Red blood cell traits KANSL1 intron 23222517 rs537938065 chr17 44227186 G A 6.75E-07 Red blood cell traits KANSL1 intron 23222517 rs538569832 chr17 44227510 A T 1.12E-07 Red blood cell traits KANSL1 intron 23222517 rs553616014 chr17 44227531 T C 7.24E-07 Red blood cell traits KANSL1 intron 23222517 rs554944034 chr17 44227882 C G 1.63E-08 Red blood cell traits KANSL1 intron 23222517 rs576500756 chr17 44228169 C T 2.43E-08 Male-pattern baldness KANSL1 intron 22693459 rs576500756 chr17 44228169 C T 2.96E-07 Red blood cell traits KANSL1 intron 23222517 rs577482939 chr17 44228529 G A 2.62E-08 Male-pattern baldness KANSL1 intron 22693459 rs577482939 chr17 44228529 G A 9.55E-07 Red blood cell traits KANSL1 intron 23222517 rs541759959 chr17 44228609 C G 2.62E-08 Male-pattern baldness KANSL1 intron 22693459 rs541759959 chr17 44228609 C G 1.84E-07 Red blood cell traits KANSL1 intron 23222517 rs560044525 chr17 44228619 C T 2.62E-08 Male-pattern baldness KANSL1 intron 22693459 rs560044525 chr17 44228619 C T 1.90E-07 Red blood cell traits KANSL1 intron 23222517 rs542300723 chr17 44228770 A G 2.63E-08 Male-pattern baldness KANSL1 intron 22693459 rs542300723 chr17 44228770 A G 2.04E-07 Red blood cell traits KANSL1 intron 23222517 rs560926498 chr17 44228824 A G 2.63E-08 Male-pattern baldness KANSL1 intron 22693459 rs560926498 chr17 44228824 A G 2.27E-07 Red blood cell traits KANSL1 intron 23222517 rs547291419 chr17 44229364 T C 2.63E-08 Male-pattern baldness KANSL1 intron 22693459 rs547291419 chr17 44229364 T C 4.36E-09 Red blood cell traits KANSL1 intron 23222517 rs565882203 chr17 44229415 T C 2.63E-08 Male-pattern baldness KANSL1 intron 22693459 rs565882203 chr17 44229415 T C 3.93E-09 Red blood cell traits KANSL1 intron 23222517 rs541694781 chr17 44230097 C T 2.49E-08 Male-pattern baldness KANSL1 intron 22693459 rs541694781 chr17 44230097 C T 1.47E-08 Red blood cell traits KANSL1 intron 23222517 rs564591344 chr17 44230647 C T 2.66E-08 Male-pattern baldness KANSL1 intron 22693459 rs564591344 chr17 44230647 C T 2.08E-07 Red blood cell traits KANSL1 intron 23222517 rs569963579 chr17 44231295 G A 9.21E-05 Multiple complex diseases KANSL1 intron 17554300 rs569963579 chr17 44231295 G A 2.65E-08 Male-pattern baldness KANSL1 intron 22693459 rs569963579 chr17 44231295 G A 1.83E-07 Red blood cell traits KANSL1 intron 23222517 rs537399285 chr17 44231326 G A 4.05E-05 Multiple complex diseases KANSL1 intron 17554300 rs537399285 chr17 44231326 G A 2.65E-08 Male-pattern baldness KANSL1 intron 22693459 rs537399285 chr17 44231326 G A 1.05E-07 Red blood cell traits KANSL1 intron 23222517 rs553321776 chr17 44231617 A T 2.66E-08 Male-pattern baldness KANSL1 intron 22693459 rs553321776 chr17 44231617 A T 1.99E-07 Red blood cell traits KANSL1 intron 23222517 rs574949827 chr17 44231827 T C 2.66E-08 Male-pattern baldness KANSL1 intron 22693459 rs574949827 chr17 44231827 T C 3.40E-09 Red blood cell traits KANSL1 intron 23222517 rs530819145 chr17 44232959 G A 2.66E-08 Male-pattern baldness KANSL1 intron 22693459 rs530819145 chr17 44232959 G A 9.32E-07 Red blood cell traits KANSL1 intron 23222517 rs570839197 chr17 44232990 T C 2.45E-08 Male-pattern baldness KANSL1 intron 22693459 rs570839197 chr17 44232990 T C 1.59E-08 Red blood cell traits KANSL1 intron 23222517 rs576400151 chr17 44233776 T C 1.43E-04 Multiple complex diseases KANSL1 intron 17554300 rs576400151 chr17 44233776 T C 2.66E-08 Male-pattern baldness KANSL1 intron 22693459 rs576400151 chr17 44233776 T C 1.19E-07 Red blood cell traits KANSL1 intron 23222517 rs540782647 chr17 44233811 C T 2.67E-08 Male-pattern baldness KANSL1 intron 22693459 rs540782647 chr17 44233811 C T 7.90E-07 Red blood cell traits KANSL1 intron 23222517 rs542050069 chr17 44234060 A G 2.46E-08 Male-pattern baldness KANSL1 intron 22693459 rs542050069 chr17 44234060 A G 2.48E-08 Red blood cell traits KANSL1 intron 23222517 rs552475563 chr17 44234526 C T 1.24E-04 Multiple complex diseases KANSL1 intron 17554300 rs552475563 chr17 44234526 C T 2.68E-08 Male-pattern baldness KANSL1 intron 22693459 rs552475563 chr17 44234526 C T 1.99E-07 Red blood cell traits KANSL1 intron 23222517 rs564325593 chr17 44236725 C A 5.07E-05 Multiple complex diseases KANSL1 intron 17554300 rs564325593 chr17 44236725 C A 2.98E-08 Male-pattern baldness KANSL1 intron 22693459 rs564325593 chr17 44236725 C A 3.45E-07 Red blood cell traits KANSL1 intron 23222517 rs540664392 chr17 44237068 A T 1.22E-04 Multiple complex diseases KANSL1 intron 17554300 rs540664392 chr17 44237068 A T 2.69E-08 Male-pattern baldness KANSL1 intron 22693459 rs540664392 chr17 44237068 A T 1.87E-07 Red blood cell traits KANSL1 intron 23222517 rs533307115 chr17 44237372 G C 2.71E-08 Male-pattern baldness KANSL1 intron 22693459 rs533307115 chr17 44237372 G C 7.83E-09 Red blood cell traits KANSL1 intron 23222517 rs562593126 chr17 44238424 G A 2.75E-08 Male-pattern baldness KANSL1 intron 22693459 rs562593126 chr17 44238424 G A 5.84E-09 Red blood cell traits KANSL1 intron 23222517 rs533246868 chr17 44238490 G A 2.76E-08 Male-pattern baldness KANSL1 intron 22693459 rs533246868 chr17 44238490 G A 9.05E-07 Red blood cell traits KANSL1 intron 23222517 rs568059837 chr17 44238938 T C 2.76E-08 Male-pattern baldness KANSL1 intron 22693459 rs568059837 chr17 44238938 T C 6.08E-07 Red blood cell traits KANSL1 intron 23222517 rs535060999 chr17 44238966 T C 2.77E-08 Male-pattern baldness KANSL1 intron 22693459 rs535060999 chr17 44238966 T C 5.98E-07 Red blood cell traits KANSL1 intron 23222517 rs544243747 chr17 44239958 C T 2.78E-08 Male-pattern baldness KANSL1 intron 22693459 rs544243747 chr17 44239958 C T 7.67E-07 Red blood cell traits KANSL1 intron 23222517 rs562531663 chr17 44240107 T C 2.79E-08 Male-pattern baldness KANSL1 intron 22693459 rs562531663 chr17 44240107 T C 7.75E-09 Red blood cell traits KANSL1 intron 23222517 rs386558525 chr17 44240986 C A 5.89E-05 Multiple complex diseases KANSL1 intron 17554300 rs386558525 chr17 44240986 C A 3.45E-05 Brain structure KANSL1 intron 22504417 rs386558525 chr17 44240986 C A 2.79E-08 Male-pattern baldness KANSL1 intron 22693459 rs386558525 chr17 44240986 C A 9.42E-08 Red blood cell traits KANSL1 intron 23222517 rs539559479 chr17 44241304 C G 2.79E-08 Male-pattern baldness KANSL1 intron 22693459 rs539559479 chr17 44241304 C G 8.59E-07 Red blood cell traits KANSL1 intron 23222517 rs533699804 chr17 44241664 T C 1.49E-04 Multiple complex diseases KANSL1 intron 17554300 rs533699804 chr17 44241664 T C 2.80E-08 Male-pattern baldness KANSL1 intron 22693459 rs533699804 chr17 44241664 T C 1.23E-07 Red blood cell traits KANSL1 intron 23222517 rs567428298 chr17 44243179 A G 2.80E-08 Male-pattern baldness KANSL1 intron 22693459 rs567428298 chr17 44243179 A G 5.94E-07 Red blood cell traits KANSL1 intron 23222517 rs543087623 chr17 44243979 C T 2.80E-08 Male-pattern baldness KANSL1 intron 22693459 rs543087623 chr17 44243979 C T 7.65E-07 Red blood cell traits KANSL1 intron 23222517 rs565531740 chr17 44244397 G A 2.80E-08 Male-pattern baldness KANSL1 intron 22693459 rs565531740 chr17 44244397 G A 3.56E-07 Red blood cell traits KANSL1 intron 23222517 rs544717127 chr17 44244581 T C 2.82E-08 Male-pattern baldness KANSL1 intron 22693459 rs544717127 chr17 44244581 T C 5.19E-07 Red blood cell traits KANSL1 intron 23222517 rs549030526 chr17 44244896 C G 2.62E-08 Male-pattern baldness KANSL1 intron 22693459 rs549030526 chr17 44244896 C G 2.41E-10 Red blood cell traits KANSL1 intron 23222517 rs531360085 chr17 44244926 T G 2.86E-08 Male-pattern baldness KANSL1 intron 22693459 rs531360085 chr17 44244926 T G 3.04E-07 Red blood cell traits KANSL1 intron 23222517 rs386477048 chr17 44245171 G T 2.62E-08 Male-pattern baldness KANSL1 intron 22693459 rs386477048 chr17 44245171 G T 1.08E-10 Red blood cell traits KANSL1 intron 23222517 rs538910132 chr17 44245359 G A 2.64E-08 Male-pattern baldness KANSL1 intron 22693459 rs538910132 chr17 44245359 G A 7.27E-09 Red blood cell traits KANSL1 intron 23222517 rs555006557 chr17 44246211 A G 2.89E-08 Male-pattern baldness KANSL1 intron 22693459 rs555006557 chr17 44246211 A G 8.82E-07 Red blood cell traits KANSL1 intron 23222517 rs544076796 chr17 44246405 C A 2.89E-08 Male-pattern baldness KANSL1 intron 22693459 rs544076796 chr17 44246405 C A 2.68E-07 Red blood cell traits KANSL1 intron 23222517 rs2532277 chr17 44246527 T C 2.63E-08 Male-pattern baldness KANSL1 intron 22693459 rs2532277 chr17 44246527 T C 9.47E-07 Red blood cell traits KANSL1 intron 23222517 rs2532276 chr17 44246624 C A 8.86E-05 Multiple complex diseases KANSL1 intron 17554300 rs2532276 chr17 44246624 C A 2.78E-08 Male-pattern baldness KANSL1 intron 22693459 rs2532276 chr17 44246624 C A 1.35E-07 Red blood cell traits KANSL1 intron 23222517 rs542364049 chr17 44246997 G A 1.24E-04 Multiple complex diseases KANSL1 intron 17554300 rs542364049 chr17 44246997 G A 2.88E-08 Male-pattern baldness KANSL1 intron 22693459 rs542364049 chr17 44246997 G A 5.76E-08 Red blood cell traits KANSL1 intron 23222517 rs560699746 chr17 44247017 C A 3.60E-07 Red blood cell traits KANSL1 intron 23222517 rs549599956 chr17 44247164 A G 8.24E-11 Parkinson's disease KANSL1 intron 19915575 rs549599956 chr17 44247164 A G 6.90E-06 Parkinson's disease KANSL1 intron 20711177 rs549599956 chr17 44247164 A G 3.63E-13 Parkinson's disease KANSL1 intron 21738487 rs549599956 chr17 44247164 A G 1.26E-05 Attention deficit hyperactivity disorder KANSL1 intron 22012869 rs549599956 chr17 44247164 A G 3.89E-15 Parkinson's disease KANSL1 intron 22438815 rs549599956 chr17 44247164 A G 2.44E-08 Male-pattern baldness KANSL1 intron 22693459 rs549599956 chr17 44247164 A G 9.74E-07 Red blood cell traits KANSL1 intron 23222517 rs549599956 chr17 44247164 A G 1.29E-07 Interstitial lung disease KANSL1 intron 23583980 rs549599956 chr17 44247164 A G 2.22E-07 Parkinson's disease KANSL1 intron pha002868 rs564717292 chr17 44247314 C T 2.88E-08 Male-pattern baldness KANSL1 intron 22693459 rs564717292 chr17 44247314 C T 3.91E-07 Red blood cell traits KANSL1 intron 23222517 rs570200944 chr17 44248042 G A 2.90E-08 Male-pattern baldness KANSL1 intron 22693459 rs570200944 chr17 44248042 G A 2.26E-07 Red blood cell traits KANSL1 intron 23222517 rs566672630 chr17 44248769 T C 2.89E-08 Male-pattern baldness KANSL1 missense 22693459 rs566672630 chr17 44248769 T C 4.87E-09 Primary biliary cirrhosis KANSL1 missense 22961000 rs566672630 chr17 44248769 T C 2.31E-07 Red blood cell traits KANSL1 missense 23222517 rs535019273 chr17 44248814 G A 8.40E-06 Parkinson's disease KANSL1 cds-synon 20711177 rs535019273 chr17 44248814 G A 3.45E-05 Brain structure KANSL1 cds-synon 22504417 rs535019273 chr17 44248814 G A 2.90E-08 Male-pattern baldness KANSL1 cds-synon 22693459 rs535019273 chr17 44248814 G A 2.39E-07 Red blood cell traits KANSL1 cds-synon 23222517 rs571568457 chr17 44249096 A C 2.06E-08 Male-pattern baldness KANSL1 cds-synon 22693459 rs571568457 chr17 44249096 A C 2.27E-10 Red blood cell traits KANSL1 cds-synon 23222517 rs543087095 chr17 44249199 T G 7.01E-07 Red blood cell traits KANSL1 missense 23222517 rs564755460 chr17 44249621 A G 1.92E-07 Red blood cell traits KANSL1 intron 23222517 rs532291518 chr17 44249800 G A 3.85E-05 Brain structure KANSL1 intron 22504417 rs532291518 chr17 44249800 G A 1.58E-08 Red blood cell traits KANSL1 intron 23222517 rs546433642 chr17 44250108 T C 5.62E-13 Parkinson's disease KANSL1 intron 19915575 rs546433642 chr17 44250108 T C 8.76E-14 Parkinson's disease KANSL1 intron 21738487 rs546433642 chr17 44250108 T C 7.89E-19 Parkinson's disease KANSL1 intron 22438815 rs546433642 chr17 44250108 T C 3.56E-05 Brain structure KANSL1 intron 22504417 rs546433642 chr17 44250108 T C 2.73E-08 Male-pattern baldness KANSL1 intron 22693459 rs546433642 chr17 44250108 T C 5.18E-08 Red blood cell traits KANSL1 intron 23222517 rs546433642 chr17 44250108 T C 9.61E-08 Interstitial lung disease KANSL1 intron 23583980 rs546433642 chr17 44250108 T C 2.70E-07 Parkinson's disease KANSL1 intron pha002868 rs553285076 chr17 44250473 G C 2.60E-08 Male-pattern baldness KANSL1 intron 22693459 rs553285076 chr17 44250473 G C 3.80E-08 Red blood cell traits KANSL1 intron 23222517 rs535725934 chr17 44250616 G A 2.30E-08 Red blood cell traits KANSL1 intron 23222517 rs541260793 chr17 44251230 T C 3.84E-07 Red blood cell traits KANSL1 intron 23222517 rs528564917 chr17 44251907 C T 3.88E-07 Red blood cell traits KANSL1 intron 23222517 rs547200563 chr17 44251972 G A 2.06E-08 Red blood cell traits KANSL1 intron 23222517 rs536694159 chr17 44252416 G C 2.07E-08 Red blood cell traits KANSL1 intron 23222517 rs563621837 chr17 44253364 G A 9.64E-05 Multiple complex diseases KANSL1 intron 17554300 rs563621837 chr17 44253364 G A 7.50E-07 Red blood cell traits KANSL1 intron 23222517 rs529398497 chr17 44254291 C T 2.98E-07 Red blood cell traits KANSL1 intron 23222517 rs550757212 chr17 44254379 C T 1.08E-04 Multiple complex diseases KANSL1 intron 17554300 rs550757212 chr17 44254379 C T 2.17E-07 Red blood cell traits KANSL1 intron 23222517 rs569247938 chr17 44254413 A G 4.18E-04 Multiple complex diseases KANSL1 intron 17554300 rs569247938 chr17 44254413 A G 4.41E-07 Red blood cell traits KANSL1 intron 23222517 rs570324382 chr17 44254494 T C 3.15E-04 Multiple complex diseases KANSL1 intron 17554300 rs570324382 chr17 44254494 T C 6.44E-07 Red blood cell traits KANSL1 intron 23222517 rs575638762 chr17 44255017 T C 2.69E-08 Red blood cell traits KANSL1 intron 23222517 rs533467502 chr17 44255532 T C 2.62E-08 Red blood cell traits KANSL1 intron 23222517 rs534369494 chr17 44255777 G A 2.62E-08 Red blood cell traits KANSL1 intron 23222517 rs575478168 chr17 44256296 G A 2.64E-08 Male-pattern baldness KANSL1 intron 22693459 rs575478168 chr17 44256296 G A 3.74E-08 Red blood cell traits KANSL1 intron 23222517 rs573087564 chr17 44256655 G A 2.54E-08 Red blood cell traits KANSL1 intron 23222517 rs544272461 chr17 44257473 T C 2.05E-08 Red blood cell traits KANSL1 intron 23222517 rs557923371 chr17 44258354 G C 1.99E-08 Red blood cell traits KANSL1 intron 23222517 rs573087816 chr17 44258422 G T 4.47E-07 Red blood cell traits KANSL1 intron 23222517 rs534069237 chr17 44258446 A G 5.66E-07 Red blood cell traits KANSL1 intron 23222517 rs551312659 chr17 44259519 A G 7.23E-07 Red blood cell traits KANSL1 intron 23222517 rs566628150 chr17 44259539 A C 2.71E-08 Male-pattern baldness KANSL1 intron 22693459 rs566628150 chr17 44259539 A C 5.99E-07 Red blood cell traits KANSL1 intron 23222517 rs567324860 chr17 44259792 G A 2.76E-08 Male-pattern baldness KANSL1 intron 22693459 rs567324860 chr17 44259792 G A 8.69E-10 Red blood cell traits KANSL1 intron 23222517 rs537893623 chr17 44259919 A G 4.08E-07 Red blood cell traits KANSL1 intron 23222517 rs578055951 chr17 44260416 T C 4.55E-07 Red blood cell traits KANSL1 intron 23222517 rs548762783 chr17 44261753 T C 4.51E-07 Red blood cell traits KANSL1 intron 23222517 rs571583943 chr17 44262418 G A 4.22E-07 Red blood cell traits KANSL1 intron 23222517 rs2732588 chr17 44262950 G A 1.85E-07 Red blood cell traits KANSL1 intron 23222517 rs544780187 chr17 44263923 T C 1.87E-08 Red blood cell traits KANSL1 intron 23222517 rs539179202 chr17 44264045 T C 4.62E-07 Red blood cell traits KANSL1 intron 23222517 rs539073154 chr17 44264717 A C 3.33E-07 Red blood cell traits KANSL1 intron 23222517 rs566214080 chr17 44264943 T C 4.48E-07 Red blood cell traits KANSL1 intron 23222517 rs559157320 chr17 44265477 G C 2.82E-08 Male-pattern baldness KANSL1 intron 22693459 rs559157320 chr17 44265477 G C 4.68E-07 Red blood cell traits KANSL1 intron 23222517 rs549710507 chr17 44266022 A G 7.01E-05 Multiple complex diseases KANSL1 intron 17554300 rs549710507 chr17 44266022 A G 1.62E-07 Red blood cell traits KANSL1 intron 23222517 rs559790424 chr17 44267617 A G 9.82E-05 Multiple complex diseases KANSL1 intron 17554300 rs559790424 chr17 44267617 A G 2.93E-07 Red blood cell traits KANSL1 intron 23222517 rs570203120 chr17 44267863 G A 8.50E-05 Multiple complex diseases KANSL1 intron 17554300 rs570203120 chr17 44267863 G A 1.01E-07 Red blood cell traits KANSL1 intron 23222517 rs547806751 chr17 44269546 C T 3.95E-05 Multiple complex diseases KANSL1 intron 17554300 rs547806751 chr17 44269546 C T 2.51E-07 Red blood cell traits KANSL1 intron 23222517 rs2696633 chr17 44270059 A T 1.05E-08 Primary biliary cirrhosis KANSL1 UTR-5 22961000 rs546821167 chr17 44271152 G A 1.02E-08 Primary biliary cirrhosis KANSL1 intron 22961000 rs529556708 chr17 44271430 A G 1.02E-08 Primary biliary cirrhosis KANSL1 intron 22961000 rs569635106 chr17 44272000 G A 3.50E-04 Multiple complex diseases KANSL1 intron 17554300 rs569635106 chr17 44272000 G A 2.89E-07 Red blood cell traits KANSL1 intron 23222517 rs570486150 chr17 44272266 A G 3.71E-05 Brain structure KANSL1 intron 22504417 rs570486150 chr17 44272266 A G 5.13E-07 Red blood cell traits KANSL1 intron 23222517 rs553226241 chr17 44272552 C T 4.91E-07 Red blood cell traits KANSL1 intron 23222517 rs574644730 chr17 44272679 G C 3.10E-07 Red blood cell traits KANSL1 intron 23222517 rs535751452 chr17 44272928 C A 3.03E-07 Red blood cell traits KANSL1 intron 23222517 rs544396824 chr17 44273889 C T 9.31E-09 Red blood cell traits KANSL1 intron 23222517 rs563076603 chr17 44273919 A G 7.99E-07 Red blood cell traits KANSL1 intron 23222517 rs570399582 chr17 44274560 T C 5.87E-07 Red blood cell traits KANSL1 intron 23222517 rs568196639 chr17 44276578 T C 3.88E-07 Red blood cell traits KANSL1 intron 23222517 rs528977056 chr17 44276618 A G 4.02E-07 Red blood cell traits KANSL1 intron 23222517 rs539364020 chr17 44276821 G A 4.16E-07 Red blood cell traits KANSL1 intron 23222517 rs2532229 chr17 44277265 A C 4.31E-09 Red blood cell traits KANSL1 intron 23222517 rs556496186 chr17 44277691 T C 3.63E-07 Red blood cell traits KANSL1 intron 23222517 rs545270044 chr17 44277818 A G 1.41E-08 Red blood cell traits KANSL1 intron 23222517 rs533813183 chr17 44278661 G A 3.46E-08 Male-pattern baldness KANSL1 intron 22693459 rs533813183 chr17 44278661 G A 6.21E-07 Red blood cell traits KANSL1 intron 23222517 rs17664048 chr17 44278742 A G 3.12E-07 Red blood cell traits KANSL1 intron 23222517 rs573536609 chr17 44279760 G A 3.10E-07 Red blood cell traits KANSL1 intron 23222517 rs562641029 chr17 44279803 T G 6.41E-08 Red blood cell traits KANSL1 intron 23222517 rs551188913 chr17 44280188 T A 1.03E-04 Multiple complex diseases KANSL1 intron 17554300 rs551188913 chr17 44280188 T A 7.02E-08 Red blood cell traits KANSL1 intron 23222517 rs571742017 chr17 44280697 T C 5.32E-08 Red blood cell traits KANSL1 intron 23222517 rs555346866 chr17 44281452 A G 4.50E-07 Red blood cell traits KANSL1 intron 23222517 rs547806241 chr17 44283571 C T 9.93E-07 Red blood cell traits KANSL1 intron 23222517 rs559754274 chr17 44285531 G A 3.93E-05 Brain structure KANSL1 intron 22504417 rs2668653 chr17 44288156 T C 2.13E-07 Red blood cell traits KANSL1 intron 23222517 rs2532419 chr17 44288281 C T 5.53E-07 Red blood cell traits KANSL1 intron 23222517 rs2732628 chr17 44288284 G A 9.17E-10 Red blood cell traits KANSL1 intron 23222517 rs2532418 chr17 44288579 T C 2.51E-04 Multiple complex diseases KANSL1 intron 17554300 rs2532418 chr17 44288579 T C 1.27E-07 Red blood cell traits KANSL1 intron 23222517 rs2668645 chr17 44288640 A G 3.66E-07 Red blood cell traits KANSL1 intron 23222517 rs2732629 chr17 44289101 A G 3.64E-07 Red blood cell traits KANSL1 intron 23222517 rs2732630 chr17 44289150 A C 5.51E-07 Red blood cell traits KANSL1 intron 23222517 rs2532417 chr17 44289220 C T 4.70E-07 Red blood cell traits KANSL1 intron 23222517 rs2732631 chr17 44289232 G T 4.78E-07 Red blood cell traits KANSL1 intron 23222517 rs2532416 chr17 44289291 A C 5.08E-07 Red blood cell traits KANSL1 intron 23222517 rs2668665 chr17 44290047 G A 6.18E-07 Red blood cell traits KANSL1 intron 23222517 rs2732606 chr17 44291365 C T 5.53E-07 Red blood cell traits KANSL1 intron 23222517 rs2732605 chr17 44291381 A G 6.64E-07 Red blood cell traits KANSL1 intron 23222517 rs2668695 chr17 44292126 T C 8.67E-05 Multiple complex diseases KANSL1 intron 17554300 rs2668695 chr17 44292126 T C 1.34E-07 Red blood cell traits KANSL1 intron 23222517 rs2668692 chr17 44293020 G A 7.87E-14 Parkinson's disease KANSL1 intron 19915575 rs2668692 chr17 44293020 G A 1.27E-13 Parkinson's disease KANSL1 intron 21738487 rs2668692 chr17 44293020 G A 8.88E-20 Parkinson's disease KANSL1 intron 22438815 rs2668692 chr17 44293020 G A 4.20E-05 Brain structure KANSL1 intron 22504417 rs2668692 chr17 44293020 G A 4.54E-07 Red blood cell traits KANSL1 intron 23222517 rs2668692 chr17 44293020 G A 1.04E-07 Interstitial lung disease KANSL1 intron 23583980 rs2668692 chr17 44293020 G A 3.94E-07 Parkinson's disease KANSL1 intron pha002868 rs2668691 chr17 44293546 C T 5.84E-08 Red blood cell traits KANSL1 intron 23222517 rs560050580 chr17 44297148 G A 4.28E-07 Red blood cell traits KANSL1 intron 23222517 rs555719522 chr17 44302881 C T 7.97E-09 Primary biliary cirrhosis / / 22961000 rs552419936 chr17 44313757 G A 7.78E-09 Primary biliary cirrhosis / / 22961000 rs2732715 chr17 44321527 C T 5.85E-09 Primary biliary cirrhosis / / 22961000 rs554899842 chr17 44331214 T C 9.70E-06 Parkinson's disease / / 20711177 rs564614982 chr17 44334288 C G 1.12E-08 Primary biliary cirrhosis / / 22961000 rs527420934 chr17 44337429 G C 4.43E-09 Primary biliary cirrhosis / / 22961000 rs561504284 chr17 44340253 A G 2.49E-10 Ovarian cancer in BRCA1 mutation carriers / / 23544013 rs2532345 chr17 44343902 G A 2.22E-04 Brain structure / / 22504417 rs111413387 chr17 44344409 A C 2.24E-09 Primary biliary cirrhosis / / 22961000 rs2732649 chr17 44344810 T G 2.24E-09 Primary biliary cirrhosis / / 22961000 rs2732651 chr17 44345063 C T 4.65E-07 Red blood cell traits / / 23222517 rs2696565 chr17 44345080 C T 3.51E-07 Red blood cell traits / / 23222517 rs2668719 chr17 44345090 C A 4.62E-07 Red blood cell traits / / 23222517 rs2732653 chr17 44345519 G A 2.21E-07 Red blood cell traits / / 23222517 rs565005382 chr17 44345519 G A 2.21E-07 Red blood cell traits / / 23222517 rs570571928 chr17 44346039 A G 1.17E-08 Red blood cell traits / / 23222517 rs2696561 chr17 44346393 C G 6.31E-09 Red blood cell traits / / 23222517 rs2696558 chr17 44346951 T A 5.69E-05 Obesity (extreme) / / 21935397 rs2696558 chr17 44346951 T A 7.01E-08 Red blood cell traits / / 23222517 rs2458216 chr17 44346962 C T 5.49E-07 Red blood cell traits / / 23222517 rs529941744 chr17 44347097 A G 5.27E-07 Red blood cell traits / / 23222517 rs569948327 chr17 44347165 T C 3.67E-07 Red blood cell traits / / 23222517 rs2696557 chr17 44347218 C A 1.91E-07 Red blood cell traits / / 23222517 rs530676870 chr17 44347218 C A 1.91E-07 Red blood cell traits / / 23222517 rs2532332 chr17 44347727 A T 3.47E-07 Red blood cell traits / / 23222517 rs568197156 chr17 44347727 A T 3.47E-07 Red blood cell traits / / 23222517 rs2950694 chr17 44348298 A G 4.96E-07 Red blood cell traits / / 23222517 rs2532331 chr17 44348326 G A 1.31E-07 Red blood cell traits / / 23222517 rs2950693 chr17 44348356 T A 3.38E-07 Red blood cell traits / / 23222517 rs2696555 chr17 44348370 A G 3.80E-08 Red blood cell traits / / 23222517 rs2950692 chr17 44348387 A C,G,T 3.81E-07 Red blood cell traits / / 23222517 rs2732711 chr17 44350293 A G 3.72E-05 Brain structure / / 22504417 rs2732711 chr17 44350293 A G 6.98E-07 Red blood cell traits / / 23222517 rs557129713 chr17 44351087 T C 1.50E-07 Red blood cell traits / / 23222517 rs562855425 chr17 44351285 A G 3.01E-05 Multiple complex diseases / / 17554300 rs562855425 chr17 44351285 A G 1.14E-07 Red blood cell traits / / 23222517 rs2732707 chr17 44351600 C T 4.33E-07 Red blood cell traits / / 23222517 rs2732706 chr17 44351686 C T 2.65E-05 Multiple complex diseases / / 17554300 rs2732706 chr17 44351686 C T 8.76E-07 Red blood cell traits / / 23222517 rs2696541 chr17 44351743 G A 1.05E-07 Red blood cell traits / / 23222517 rs2732705 chr17 44351929 T G 2.73E-05 Multiple complex diseases / / 17554300 rs2732705 chr17 44351929 T G 8.51E-08 Red blood cell traits / / 23222517 rs2668622 chr17 44352131 G T 7.94E-05 Multiple complex diseases / / 17554300 rs2668622 chr17 44352131 G T 5.12E-05 Recombination rate / / 21698098 rs549572472 chr17 44352621 A G 6.36E-07 Red blood cell traits / / 23222517 rs2668624 chr17 44352872 A G 2.66E-05 Multiple complex diseases / / 17554300 rs2668624 chr17 44352872 A G 3.07E-07 Red blood cell traits / / 23222517 rs568873066 chr17 44352872 A G 2.66E-05 Multiple complex diseases / / 17554300 rs568873066 chr17 44352872 A G 3.07E-07 Red blood cell traits / / 23222517 rs539045125 chr17 44352970 C A 3.21E-07 Red blood cell traits / / 23222517 rs2668626 chr17 44353175 T C 6.72E-08 Red blood cell traits / / 23222517 rs2668627 chr17 44353693 T C 7.83E-07 Red blood cell traits / / 23222517 rs2732702 chr17 44353728 T G 4.17E-08 Red blood cell traits / / 23222517 rs561488872 chr17 44353728 T G 4.17E-08 Red blood cell traits / / 23222517 rs111198951 chr17 44353885 G A 1.07E-04 Multiple complex diseases / / 17554300 rs111198951 chr17 44353885 G A 4.39E-08 Red blood cell traits / / 23222517 rs565415067 chr17 44354103 A G 4.19E-08 Red blood cell traits / / 23222517 rs566238830 chr17 44354549 C G 1.04E-07 Red blood cell traits / / 23222517 rs2696531 chr17 44355634 C G,T 3.81E-09 Red blood cell traits / / 23222517 rs2696530 chr17 44355714 A C,G,T 3.34E-07 Red blood cell traits / / 23222517 rs2696525 chr17 44356637 C A,G,T 1.54E-08 Red blood cell traits / / 23222517 rs570136507 chr17 44357297 G T 1.08E-07 Red blood cell traits / / 23222517 rs17665188 chr17 44357351 T A,C,G 6.71E-08 Red blood cell traits / / 23222517 rs530576715 chr17 44363885 G T 7.41E-07 Red blood cell traits / / 23222517 rs2732615 chr17 44364056 T C 3.45E-07 Red blood cell traits / / 23222517 rs2732613 chr17 44364829 A C 4.67E-08 Red blood cell traits / / 23222517 rs532193457 chr17 44368404 C T 4.10E-08 Red blood cell traits / / 23222517 rs538628 chr17 44787313 G C 5.11E-08 Red blood cell traits NSF intron 23222517 rs183211 chr17 44788310 G A 7.62E-11 Parkinson's disease NSF intron 19915575 rs183211 chr17 44788310 G A 9.38E-09 Parkinson's disease NSF intron 21738487 rs183211 chr17 44788310 G A 3.00E-07 Parkinson's disease NSF intron 21812969 rs183211 chr17 44788310 G A 4.06E-12 Parkinson's disease NSF intron 22438815 rs183211 chr17 44788310 G A 8.11E-05 Prostate cancer NSF intron 22923026 rs183211 chr17 44788310 G A 6.19E-07 Red blood cell traits NSF intron 23222517 rs183211 chr17 44788310 G A 2.00E-09 Ovarian cancer in BRCA1 mutation carriers NSF intron 23544013 rs183211 chr17 44788310 G A 3.00E-08 Ovarian cancer in BRCA1 mutation carriers NSF intron 23544013 rs183211 chr17 44788310 G A 3.13E-08 Ovarian cancer in BRCA1 mutation carriers NSF intron 23544013 rs183211 chr17 44788310 G A 6.95E-06 Interstitial lung disease NSF intron 23583980 rs183211 chr17 44788310 G A 1.05E-05 Parkinson's disease NSF intron pha002868 rs199436 chr17 44789285 A G 3.11E-07 Red blood cell traits NSF intron 23222517 rs169201 chr17 44790203 A G 4.39E-14 Parkinson's disease NSF intron 19915575 rs169201 chr17 44790203 A G 5.60E-13 Parkinson's disease NSF intron 21738487 rs169201 chr17 44790203 A G 2.00E-15 Parkinson's disease NSF intron 22438815 rs169201 chr17 44790203 A G 6.00E-11 Ovarian cancer in BRCA1 mutation carriers NSF intron 23544013 rs169201 chr17 44790203 A G 2.33E-07 Interstitial lung disease NSF intron 23583980 rs169201 chr17 44790203 A G 1.25E-07 Parkinson's disease NSF intron pha002868 rs199438 chr17 44791643 G A 2.28E-07 Red blood cell traits NSF intron 23222517 rs199439 chr17 44793503 A G 1.46E-07 Red blood cell traits NSF intron 23222517 rs142167 chr17 44795234 A G 7.55E-04 Multiple complex diseases NSF intron 17554300 rs142167 chr17 44795234 A G 8.90E-08 Red blood cell traits NSF intron 23222517 rs199456 chr17 44797919 C T 1.50E-07 Red blood cell traits NSF intron 23222517 rs199455 chr17 44799216 C T 1.29E-07 Red blood cell traits NSF intron 23222517 rs7224296 chr17 44800046 G A 1.32E-08 Parkinson's disease NSF intron 19915575 rs7224296 chr17 44800046 G A 1.89E-07 Parkinson's disease NSF intron 21738487 rs7224296 chr17 44800046 G A 1.45E-10 Parkinson's disease NSF intron 22438815 rs7224296 chr17 44800046 G A 9.41E-05 Prostate cancer NSF intron 22923026 rs7224296 chr17 44800046 G A 6.34E-07 Red blood cell traits NSF intron 23222517 rs7224296 chr17 44800046 G A 3.48E-05 Interstitial lung disease NSF intron 23583980 rs199454 chr17 44800110 G A 8.00E-06 Parkinson's disease NSF intron 20711177 rs199452 chr17 44801340 C T 9.27E-08 Red blood cell traits NSF intron 23222517 rs199449 chr17 44808902 G A 3.16E-04 Multiple complex diseases NSF intron 17554300 rs199448 chr17 44809001 A G 6.64E-05 Multiple complex diseases NSF intron 17554300 rs199448 chr17 44809001 A G 3.82E-08 Primary biliary cirrhosis NSF intron 22961000 rs199448 chr17 44809001 A G 3.30E-07 Red blood cell traits NSF intron 23222517 rs16941389 chr17 44811098 C T 9.65E-05 Multiple complex diseases NSF intron 17554300 rs7226263 chr17 44814884 T C 4.31E-05 Prostate cancer NSF intron 22923026 rs12325819 chr17 44816132 G T 3.93E-05 Prostate cancer NSF intron 22923026 rs199445 chr17 44817408 C T 1.94E-07 Red blood cell traits NSF intron 23222517 rs199443 chr17 44819565 C T 9.00E-11 Ovarian cancer in BRCA1 mutation carriers NSF intron 23544013 rs199442 chr17 44820122 G A 2.80E-07 Red blood cell traits NSF intron 23222517 rs199535 chr17 44822662 A G 7.37E-05 Multiple complex diseases NSF intron 17554300 rs199535 chr17 44822662 A G 1.04E-07 Red blood cell traits NSF intron 23222517 rs199534 chr17 44824213 T G 6.78E-08 Red blood cell traits NSF intron 23222517 rs199534 chr17 44824213 T G 9.00E-11 Ovarian cancer in BRCA1 mutation carriers NSF intron 23544013 rs9896243 chr17 44826056 C G 6.80E-05 Multiple complex diseases NSF intron 17554300 rs199533 chr17 44828931 G A 1.00E-14 Parkinson's disease NSF cds-synon 19915575 rs199533 chr17 44828931 G A 1.00E-06 Parkinson's disease NSF cds-synon 20711177 rs199533 chr17 44828931 G A 1.90E-13 Parkinson's disease NSF cds-synon 21738487 rs199533 chr17 44828931 G A 8.85E-26 Parkinson's disease NSF cds-synon 22438815 rs199533 chr17 44828931 G A 1.22E-08 Primary biliary cirrhosis NSF cds-synon 22961000 rs199533 chr17 44828931 G A 6.36E-07 Red blood cell traits NSF cds-synon 23222517 rs199533 chr17 44828931 G A 5.19E-07 Interstitial lung disease NSF cds-synon 23583980 rs199533 chr17 44828931 G A 9.09E-06 Parkinson's disease NSF cds-synon 24842889 rs199533 chr17 44828931 G A 5.05E-08 Parkinson's disease NSF cds-synon pha002868 rs199530 chr17 44836653 G A 1.30E-04 Multiple complex diseases / / 17554300 rs199530 chr17 44836653 G A 5.66E-07 Red blood cell traits / / 23222517 rs199529 chr17 44837217 A C 4.20E-07 Red blood cell traits / / 23222517 rs199528 chr17 44843136 C T 1.40E-06 Parkinson's disease WNT3 intron 20711177 rs199528 chr17 44843136 C T 2.92E-07 Red blood cell traits WNT3 intron 23222517 rs199525 chr17 44847834 T G 8.03E-09 Primary biliary cirrhosis WNT3 intron 22961000 rs199520 chr17 44853872 G A 3.73E-07 Red blood cell traits WNT3 intron 23222517 rs199515 chr17 44856641 G C 3.68E-05 Multiple complex diseases WNT3 intron 17554300 rs199515 chr17 44856641 G C 3.99E-04 Lymphocyte counts WNT3 intron 22286170 rs199515 chr17 44856641 G C 3.00E-17 Parkinson's disease WNT3 intron 22451204 rs199515 chr17 44856641 G C 4.21E-08 Primary biliary cirrhosis WNT3 intron 22961000 rs199515 chr17 44856641 G C 1.78E-07 Red blood cell traits WNT3 intron 23222517 rs199514 chr17 44856881 G A 1.26E-08 Primary biliary cirrhosis WNT3 intron 22961000 rs199514 chr17 44856881 G A 2.63E-07 Red blood cell traits WNT3 intron 23222517 rs199509 chr17 44858728 G A 5.41E-07 Red blood cell traits WNT3 intron 23222517 rs199507 chr17 44858855 A G 6.36E-07 Red blood cell traits WNT3 intron 23222517 rs199506 chr17 44859031 A G 6.43E-07 Red blood cell traits WNT3 intron 23222517 rs415430 chr17 44859144 C T 2.70E-06 Parkinson's disease WNT3 intron 20711177 rs415430 chr17 44859144 C T 1.71E-13 Parkinson's disease WNT3 intron 21738487 rs415430 chr17 44859144 C T 7.00E-07 Parkinson's disease WNT3 intron 21812969 rs415430 chr17 44859144 C T 7.63E-07 Red blood cell traits WNT3 intron 23222517 rs415430 chr17 44859144 C T 7.86E-07 Interstitial lung disease WNT3 intron 23583980 rs415430 chr17 44859144 C T 4.50E-08 Parkinson's disease WNT3 intron pha002868 rs199505 chr17 44859410 A G 1.57E-08 Primary biliary cirrhosis WNT3 intron 22961000 rs199505 chr17 44859410 A G 7.30E-07 Red blood cell traits WNT3 intron 23222517 rs70602 chr17 44859715 T C 1.66E-08 Primary biliary cirrhosis WNT3 intron 22961000 rs70602 chr17 44859715 T C 5.94E-07 Red blood cell traits WNT3 intron 23222517 rs70600 chr17 44860021 C T 9.24E-09 Primary biliary cirrhosis WNT3 intron 22961000 rs199501 chr17 44862613 A G 3.62E-07 Red blood cell traits WNT3 intron 23222517 rs916888 chr17 44863133 T C 4.53E-07 Red blood cell traits WNT3 intron 23222517 rs2074404 chr17 44865439 T G 1.00E-06 Celiac disease WNT3 intron 20190752 rs2074404 chr17 44865439 T G 9.43E-10 Parkinson's disease WNT3 intron 21738487 rs2074404 chr17 44865439 T G 3.52E-07 Red blood cell traits WNT3 intron 23222517 rs2074404 chr17 44865439 T G 9.79E-04 Myocardial Infarction WNT3 intron pha002883 rs199498 chr17 44865603 T C 2.00E-04 Parkinson's disease WNT3 intron 24511991 rs199498 chr17 44865603 T C 2.00E-06 Parkinson's disease WNT3 intron 24511991 rs199498 chr17 44865603 T C 8.00E-07 Parkinson's disease WNT3 intron 24511991 rs11658976 chr17 44866805 G A 6.20E-05 Smoking cessation WNT3 intron 24665060 rs12452064 chr17 44868187 G A 9.10E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) WNT3 intron 23648065 rs11650531 chr17 44873995 T C 4.33E-05 Hemoglobin WNT3 intron pha003098 rs11650531 chr17 44873995 T C 1.12E-05 Erythrocyte counts WNT3 intron pha003099 rs3851781 chr17 44891301 C T 5.07E-05 Response to cytidine analogues (gemcitabine) WNT3 intron 24483146 rs11079738 chr17 44904049 A G 5.72E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs8069437 chr17 44906949 T C 2.45E-11 Blood pressure / / 21909110 rs1373089 chr17 44915265 G A 4.00E-05 Multiple sclerosis / / 21833088 rs2083798 chr17 44921897 A G 7.32E-06 Multiple complex diseases / / 17554300 rs2083797 chr17 44921929 T C 7.89E-06 Multiple complex diseases / / 17554300 rs8082211 chr17 44941035 G A 3.19E-04 Multiple complex diseases WNT9B intron 17554300 rs11079740 chr17 44949100 G C 9.00E-06 Antineutrophil cytoplasmic antibody-associated vasculitis WNT9B intron 22808956 rs197932 chr17 44974347 T C 0.00049 Breast cancer / / 23555315 rs1662594 chr17 44992737 G A 8.68E-04 Multiple complex diseases / / 17554300 rs1662594 chr17 44992737 G A 9.38E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs1867237 chr17 45003829 G A 5.40E-04 Multiple complex diseases GOSR2 intron 17554300 rs17608766 chr17 45013271 T C 5.00E-10 Ventricular conduction GOSR2 UTR-3 21076409 rs17608766 chr17 45013271 T C 2.00E-07 Blood pressure GOSR2 UTR-3 21909110 rs17608766 chr17 45013271 T C 6.00E-15 Blood pressure GOSR2 UTR-3 21909110 rs17608766 chr17 45013271 T C 1.00E-10 Systolic blood pressure GOSR2 UTR-3 21909115 rs1052586 chr17 45018463 T C 4.08E-05 Acute lymphoblastic leukemia (childhood) GOSR2 UTR-3 19684603 rs6504622 chr17 45019731 T C 4.90E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs11079742 chr17 45020128 C T 2.24E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs9911967 chr17 45026911 C T 7.28E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs9303532 chr17 45034002 T C 1.94E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs16941404 chr17 45054180 C G 2.43E-04 Nicotine dependence / / 17158188 rs8081157 chr17 45058442 A G 1.57E-04 Multiple complex diseases / / 17554300 rs2317996 chr17 45063349 T C 3.38E-05 Bilirubin levels,in serum / / 19389676 rs17616652 chr17 45080757 A G 4.64E-05 Multiple complex diseases / / 17554300 rs3883305 chr17 45095678 G A 3.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs3883305 chr17 45095678 G A 2.06E-05 Bilirubin levels,in serum / / 19389676 rs2007723 chr17 45146789 C T 9.55E-04 Multiple complex diseases LOC100506214 intron 17554300 rs2873131 chr17 45166056 T C 5.70E-04 Type 2 diabetes and 6 quantitative traits LOC100506214 intron 17848626 rs10514915 chr17 45166126 G A 7.92E-04 Multiple complex diseases LOC100506214 intron 17554300 rs10514915 chr17 45166126 G A 3.80E-04 Type 2 diabetes and 6 quantitative traits LOC100506214 intron 17848626 rs1989858 chr17 45179324 G A 6.76E-04 Multiple complex diseases / / 17554300 rs11570441 chr17 45267985 G C 1.65E-04 Multiple complex diseases / / 17554300 rs17605038 chr17 45302098 G A 5.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs9895150 chr17 45307928 A G 5.51E-04 Multiple complex diseases / / 17554300 rs11079764 chr17 45309693 A G 5.00E-06 IgG glycosylation / / 23382691 rs11079764 chr17 45309693 A G 4.73E-04 Smoking initiation / / 24665060 rs4968255 chr17 45312813 C T 6.24E-04 Smoking initiation / / 24665060 rs16969966 chr17 45318452 C A 5.33E-05 Waist-Hip Ratio / / pha003013 rs16969966 chr17 45318452 C A 7.91E-05 Waist-Hip Ratio / / pha003028 rs12452359 chr17 45319912 T G 7.62E-04 Multiple complex diseases / / 17554300 rs7223003 chr17 45324293 G A 5.73E-05 Waist-Hip Ratio / / pha003013 rs7223003 chr17 45324293 G A 7.28E-05 Waist-Hip Ratio / / pha003028 rs7223003 chr17 45324293 G A 1.45E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs2317385 chr17 45329682 G A 7.97E-05 Waist-Hip Ratio ITGB3 nearGene-5 pha003013 rs2317385 chr17 45329682 G A 5.84E-05 Lung function (forced expiratory volume in 1 second) ITGB3 nearGene-5 pha003103 rs10514919 chr17 45342129 G T 4.26E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ITGB3 intron 24023788 rs10514919 chr17 45342129 G T 4.22E-04 Response to alcohol consumption (flushing response) ITGB3 intron 24277619 rs11657517 chr17 45343713 C T 3.66E-04 Multiple complex diseases ITGB3 intron 17554300 rs3851806 chr17 45350919 G C 0.000087 Coronary artery calcification ITGB3 intron 23727086 rs7209700 chr17 45351118 A G 7.46E-05 Type 2 diabetes ITGB3 intron 17463246 rs7209700 chr17 45351118 A G 4.00E-07 IgG glycosylation ITGB3 intron 23382691 rs2292867 chr17 45357489 C T 2.98E-05 Waist-Hip Ratio ITGB3 intron pha003013 rs2292867 chr17 45357489 C T 4.86E-05 Waist-Hip Ratio ITGB3 intron pha003028 rs5918 chr17 45360730 T C 1 Drug response to Pravastatin ITGB3 missense 11545752 rs5918 chr17 45360730 T C 1 Drug response to Aspirin ITGB3 missense 11723016 rs2292700 chr17 45362423 A G 5.19E-05 Hypertension ITGB3 intron pha003041 rs8064853 chr17 45363178 A G 1.66E-09 LDL cholesterol ITGB3 intron 23063622 rs9912177 chr17 45363217 A T 2.14E-17 Triglycerides ITGB3 intron 23063622 rs9912177 chr17 45363217 A T 2.37E-23 LDL cholesterol ITGB3 intron 23063622 rs12603582 chr17 45377577 G T 0.0000553 Cholesterol,total ITGB3 intron 23063622 rs3760372 chr17 45380002 T C 7.20E-04 Parkinson's disease ITGB3 intron 17052657 rs11869835 chr17 45381823 G T 4.30E-06 Hypertension ITGB3 intron pha003041 rs11869835 chr17 45381823 G T 5.12E-05 Hypertension ITGB3 intron pha003042 rs7214993 chr17 45386797 G C 6.21E-05 Serum metabolites ITGB3 intron 19043545 rs11867160 chr17 45406167 A G 9.25E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) C17orf57 intron 23648065 rs12051795 chr17 45413384 G A 7.99E-04 Multiple complex diseases C17orf57 intron 17554300 rs11871031 chr17 45416538 T A 3.25E-04 Multiple complex diseases C17orf57 intron 17554300 rs7206971 chr17 45425115 G A,T 1.00E-08 Cholesterol,total C17orf57 intron 20686565 rs7206971 chr17 45425115 G A,T 4.00E-09 LDL cholesterol C17orf57 intron 20686565 rs7206971 chr17 45425115 G A,T 1.00E-07 Cholesterol,total C17orf57 intron 24097068 rs7206971 chr17 45425115 G A,T 3.00E-07 LDL cholesterol C17orf57 intron 24097068 rs6504872 chr17 45438952 C T 2.48E-04 Smoking initiation C17orf57 intron 24665060 rs10514925 chr17 45444868 G C 8.70E-04 Alzheimer's disease C17orf57 intron 17998437 rs12452315 chr17 45479446 A C 9.09E-04 Multiple complex diseases C17orf57 intron 17554300 rs3883318 chr17 45490251 C T 9.25E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) C17orf57 cds-synon 23648065 rs9901869 chr17 45575206 G A 8.72E-06 Multiple sclerosis / / 19525953 rs9901869 chr17 45575206 G A 9.62E-07 Multiple sclerosis / / 22190364 rs2935183 chr17 45607572 T G 5.00E-07 Multiple sclerosis or amyotrophic lateral sclerosis / / 24234648 rs11869926 chr17 45683125 G T 7.53E-04 Multiple complex diseases NPEPPS intron 17554300 rs11079784 chr17 45702280 T C 1.57E-04 Age-related macular degeneration / / 22125219 rs4239162 chr17 45755810 G A 6.93E-06 Multiple sclerosis KPNB1 intron 19525953 rs7223246 chr17 45759767 C T 6.31E-05 Smoking initiation KPNB1 intron 24665060 rs16958421 chr17 45762119 G T 2.30E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4794048 chr17 45763073 A C 2.30E-04 Multiple complex diseases / / 17554300 rs16942128 chr17 45764235 G A 9.12E-04 Type 2 diabetes / / 17463246 rs16942128 chr17 45764235 G A 9.58E-04 Multiple complex diseases / / 17554300 rs16942128 chr17 45764235 G A 2.39E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6503796 chr17 45765249 T C 4.44E-04 Age-related macular degeneration / / 22125219 rs8070463 chr17 45768836 T C 5.00E-08 Ankylosing spondylitis / / 21743469 rs8070463 chr17 45768836 T C 1.00E-07 Multiple sclerosis / / 22190364 rs4794067 chr17 45808828 T C 2.22E-04 Osteoarthritis TBX21 nearGene-5 19508968 rs2240017 chr17 45810919 C G 1 Drug response to Budesonide TBX21 missense 15604153 rs2240017 chr17 45810919 C G 1 Drug response to Nedocromil TBX21 missense 15604153 rs17244587 chr17 45823035 G A 1 Drug response to Desipramine TBX21 UTR-3 18504423 rs17244587 chr17 45823035 G A 1 Drug response to Fluoxetine TBX21 UTR-3 18504423 rs12950390 chr17 45830948 T C 3.00E-06 IgG glycosylation / / 23382691 rs11651000 chr17 45835278 G A 8.00E-06 IgG glycosylation / / 23382691 rs11651000 chr17 45835278 G A 9.00E-06 IgG glycosylation / / 23382691 rs4793658 chr17 45878733 A C 1.40E-04 Multiple complex diseases / / 17554300 rs4793658 chr17 45878733 A C 1.47E-04 Myopia (pathological) / / 21095009 rs9904503 chr17 45884372 T C 2.40E-05 Height / / 21998595 rs9896712 chr17 45884543 G A 4.10E-05 Height / / 21998595 rs991108 chr17 45887142 G A 7.93E-06 Tunica Media OSBPL7 intron pha003034 rs12602461 chr17 45889349 G A 2.78E-04 Depression (quantitative trait) OSBPL7 intron 20800221 rs201063776 chr17 45891202 T G 0.0003 Breast cancer OSBPL7 splice-5 23555315 rs4794202 chr17 45930539 G T 8.00E-08 Alzheimer's disease (cognitive decline) SP6 intron 23535033 rs9944405 chr17 45953033 T A 7.39E-05 Type 2 diabetes / / 17463246 rs9944405 chr17 45953033 T A 2.25E-04 Depression (quantitative trait) / / 20800221 rs11079799 chr17 45956073 A G 1.51E-04 Height / / 17255346 rs4794225 chr17 45957591 T G 1.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4450442 chr17 45965943 T G 2.17E-04 Depression (quantitative trait) / / 20800221 rs1133221 chr17 45976389 T G 2.26E-04 Depression (quantitative trait) SP2 intron 20800221 rs16949270 chr17 45982473 C T 6.29E-04 Type 2 diabetes SP2 intron 17463246 rs16949270 chr17 45982473 C T 2.26E-04 Depression (quantitative trait) SP2 intron 20800221 rs16949296 chr17 45984949 A G 2.28E-04 Depression (quantitative trait) SP2 intron 20800221 rs7207225 chr17 45985414 A G 8.12E-04 Schizophrenia SP2 intron 21674006 rs16949418 chr17 45991240 C T 8.16E-05 Bipolar disorder SP2 intron 18317468 rs2229358 chr17 45994154 G A 2.00E-04 Information processing speed SP2 cds-synon 21130836 rs2597169 chr17 46034091 A G 2.00E-04 Information processing speed PRR15L intron 21130836 rs2525105 chr17 46039543 G T 4.66E-04 Depression (quantitative trait) / / 20800221 rs17616799 chr17 46039553 A G 3.97E-04 Depression (quantitative trait) / / 20800221 rs2525109 chr17 46042327 C T 4.54E-05 Height / / 17255346 rs4794333 chr17 46045495 T C 3.00E-04 Nicotine smoking / / 19268276 rs2597167 chr17 46047656 T C 6.00E-06 Metabolite levels (Pyroglutamine) / / 23934736 rs2285860 chr17 46048412 G T 4.86E-04 Depression (quantitative trait) / / 20800221 rs2597164 chr17 46069980 C T 1.80E-05 Urinary metabolites / / 21572414 rs2240119 chr17 46111172 T C 3.62E-04 Type 2 diabetes COPZ2 intron 17463246 rs2240119 chr17 46111172 T C 4.14E-04 Depression (quantitative trait) COPZ2 intron 20800221 rs8076163 chr17 46120325 T C 3.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1317850 chr17 46121839 T C 3.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs757353 chr17 46122270 A G 4.56E-04 Depression (quantitative trait) / / 20800221 rs72823592 chr17 46123004 G A 9.00E-09 Epilepsy (generalized) / / 22949513 rs3764400 chr17 46123932 T C 4.00E-07 Body mass index / / 20935630 rs2023885 chr17 46126373 G A 3.49E-04 Depression (quantitative trait) NFE2L1 intron 20800221 rs9899461 chr17 46129353 C T 2.09E-04 Height NFE2L1 intron 17255346 rs2229369 chr17 46136133 G C 3.32E-04 Depression (quantitative trait) NFE2L1 cds-synon 20800221 rs2240120 chr17 46142144 C T 3.31E-04 Depression (quantitative trait) / / 20800221 rs11079806 chr17 46142680 G A 1.85E-04 Height / / 17255346 rs11079806 chr17 46142680 G A 7.73E-04 Type 2 diabetes / / 17463246 rs11651097 chr17 46147039 T C 7.04E-05 Height / / 17255346 rs6847 chr17 46147807 T A 2.09E-04 Height CBX1 UTR-3 17255346 rs9747665 chr17 46149252 G T 3.40E-04 Multiple complex diseases CBX1 intron 17554300 rs16951519 chr17 46152291 G A 3.31E-04 Depression (quantitative trait) CBX1 intron 20800221 rs2240121 chr17 46152322 T C 3.31E-04 Depression (quantitative trait) CBX1 intron 20800221 rs2240122 chr17 46152559 C A 2.19E-04 Height CBX1 intron 17255346 rs35354810 chr17 46152559 C CT 2.19E-04 Height CBX1 intron 17255346 rs7220520 chr17 46167942 T C 2.51E-04 Height CBX1 intron 17255346 rs2109984 chr17 46171099 T G 1.59E-04 Height CBX1 intron 17255346 rs978263 chr17 46180664 A G 3.31E-04 Depression (quantitative trait) / / 20800221 rs8080662 chr17 46190819 G A 1.73E-04 Height SNX11 intron 17255346 rs8071199 chr17 46195335 T A 4.56E-04 Type 2 diabetes SNX11 intron 17463246 rs8071199 chr17 46195335 T A 3.31E-04 Depression (quantitative trait) SNX11 intron 20800221 rs7224461 chr17 46203430 C G 3.30E-04 Depression (quantitative trait) / / 20800221 rs2109983 chr17 46207148 A G 9.72E-04 Depression (quantitative trait) / / 20800221 rs3815472 chr17 46210773 C T 3.32E-04 Depression (quantitative trait) / / 20800221 rs8071879 chr17 46217457 G A 3.22E-04 Depression (quantitative trait) SKAP1 intron 20800221 rs2325804 chr17 46218545 G A 3.21E-04 Depression (quantitative trait) SKAP1 intron 20800221 rs208009 chr17 46229691 C T 3.07E-04 Depression (quantitative trait) SKAP1 intron 20800221 rs208008 chr17 46230838 C T 5.30E-04 Depression (quantitative trait) SKAP1 intron 20800221 rs208005 chr17 46239985 A G 3.05E-04 Depression (quantitative trait) SKAP1 intron 20800221 rs3805366 chr17 46246894 C T 7.09E-04 Suicide attempts in bipolar disorder SKAP1 intron 21423239 rs12603115 chr17 46248994 C T 4.18E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SKAP1 intron 24023788 rs3805368 chr17 46253263 G A 2.23E-04 Suicide attempts in bipolar disorder SKAP1 intron 21423239 rs12948653 chr17 46259254 C A 1.41E-04 Smoking cessation SKAP1 intron 18519826 rs10514935 chr17 46260674 T C 1.51E-04 Smoking cessation SKAP1 intron 18519826 rs10514935 chr17 46260674 T C 1.52E-04 Smoking cessation SKAP1 intron 18519826 rs1452663 chr17 46293386 C G 5.65E-04 Type 2 diabetes SKAP1 intron 17463246 rs1452663 chr17 46293386 C G 2.44E-04 Depression (quantitative trait) SKAP1 intron 20800221 rs16953941 chr17 46296204 C A 5.65E-04 Type 2 diabetes SKAP1 intron 17463246 rs16953941 chr17 46296204 C A 2.43E-04 Depression (quantitative trait) SKAP1 intron 20800221 rs1979897 chr17 46309546 C T 2.30E-04 Depression (quantitative trait) SKAP1 intron 20800221 rs16954268 chr17 46319546 G A 2.25E-04 Depression (quantitative trait) SKAP1 intron 20800221 rs2938484 chr17 46319852 C T 4.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SKAP1 intron 20877124 rs16954324 chr17 46324584 C T 4.83E-04 Depression (quantitative trait) SKAP1 intron 20800221 rs17620866 chr17 46328398 C G 2.19E-04 Depression (quantitative trait) SKAP1 intron 20800221 rs8081754 chr17 46328667 G A 0.0000117 LDL cholesterol SKAP1 intron 23063622 rs17694092 chr17 46334294 A G 2.33E-04 Depression (quantitative trait) SKAP1 intron 20800221 rs979746 chr17 46336112 A C 9.96E-04 Alzheimer's disease SKAP1 intron 17998437 rs17694404 chr17 46348354 G A 2.53E-04 Depression (quantitative trait) SKAP1 intron 20800221 rs9905961 chr17 46356364 T A 4.62E-05 Smoking cessation SKAP1 intron 18519826 rs9905961 chr17 46356364 T A 4.82E-04 Smoking cessation SKAP1 intron 18519826 rs2084881 chr17 46357120 G A 2.00E-06 Ovarian cancer SKAP1 intron 20852632 rs17621689 chr17 46358952 T G 5.13E-04 Depression (quantitative trait) SKAP1 intron 20800221 rs7221510 chr17 46373671 C T 8.59E-05 Acute lymphoblastic leukemia (childhood) SKAP1 intron 19684603 rs7218167 chr17 46394050 G A 2.00E-05 Asperger disorder SKAP1 intron 21182207 rs10514944 chr17 46398352 G A 4.30E-04 Type 2 diabetes SKAP1 intron 17463246 rs10514944 chr17 46398352 G A 5.21E-04 Depression (quantitative trait) SKAP1 intron 20800221 rs9303542 chr17 46411500 A G 1.00E-06 Ovarian cancer SKAP1 intron 20852632 rs9303542 chr17 46411500 A G 3.00E-10 Ovarian cancer SKAP1 intron 23535730 rs9303542 chr17 46411500 A G 6.00E-09 Ovarian cancer SKAP1 intron 23535730 rs17623416 chr17 46430565 A C 5.17E-04 Depression (quantitative trait) SKAP1 intron 20800221 rs17623518 chr17 46438150 G A 1.72E-04 Type 2 diabetes SKAP1 intron 17463246 rs17623518 chr17 46438150 G A 5.55E-04 Depression (quantitative trait) SKAP1 intron 20800221 rs16955960 chr17 46445993 T G 1.61E-04 Type 2 diabetes SKAP1 intron 17463246 rs16955960 chr17 46445993 T G 5.40E-04 Depression (quantitative trait) SKAP1 intron 20800221 rs16956501 chr17 46497274 G C 3.23E-04 Type 2 diabetes SKAP1 intron 17463246 rs16956501 chr17 46497274 G C 6.23E-04 Depression (quantitative trait) SKAP1 intron 20800221 rs16957085 chr17 46532956 G A 1.69E-04 Type 2 diabetes / / 17463246 rs16957085 chr17 46532956 G A 4.87E-04 Depression (quantitative trait) / / 20800221 rs9907565 chr17 46535345 A G 1.69E-04 Type 2 diabetes / / 17463246 rs9907565 chr17 46535345 A G 5.07E-04 Depression (quantitative trait) / / 20800221 rs9899997 chr17 46542719 T G 1.37E-04 Type 2 diabetes / / 17463246 rs16957299 chr17 46550362 G A 6.64E-04 Depression (quantitative trait) / / 20800221 rs1553754 chr17 46563707 G T 2.81E-06 Body mass index / / 19557197 rs2325948 chr17 46574491 C T 8.73E-05 Attention deficit hyperactivity disorder / / 22420046 rs12450225 chr17 46592413 A G 8.14E-05 Attention deficit hyperactivity disorder / / 22420046 rs10853100 chr17 46602432 T C 7.66E-05 Attention deficit hyperactivity disorder / / 22420046 rs11079828 chr17 46609103 T C 6.54E-06 Attention deficit hyperactivity disorder / / 22420046 rs6504339 chr17 46616244 G A 3.66E-04 Multiple complex diseases / / 17554300 rs6504340 chr17 46617019 A G 6.00E-07 Primary tooth development (number of teeth) / / 20195514 rs999493 chr17 46625519 G A 2.19E-04 Acute lung injury / / 22295056 rs4793927 chr17 46635019 C T 9.11E-06 Body mass index HOXB3 intron 19557197 rs2555111 chr17 46648899 C T 7.17E-04 Acute lung injury HOXB3 intron 22295056 rs3809782 chr17 46657927 G A 8.07E-04 Acute lung injury / / 22295056 rs2288278 chr17 46661292 G A 9.59E-06 Body mass index / / 19557197 rs2288278 chr17 46661292 G A 9.62E-04 Acute lung injury / / 22295056 rs9299 chr17 46669430 C T 4.00E-09 Obesity HOXB5 UTR-3 22484627 rs9299 chr17 46669430 C T 7.27E-05 Body mass index HOXB5 UTR-3 24861553 rs2303487 chr17 46704536 G T 6.36E-05 Cognitive performance / / 19734545 rs890435 chr17 46719399 C T 1.24E-05 Cognitive performance / / 19734545 rs2326017 chr17 46720565 C T 3.00E-07 Cognitive performance / / 19734545 rs2326017 chr17 46720565 C T 2.00E-06 Body mass index (non-asthmatics) / / 23517042 rs9890514 chr17 46738883 C A 0.0000036 Platelet thrombus as measured by PFA-100ColA closure time upon shear stress / / 22550155 rs8074700 chr17 46749791 A C 1.00E-06 Body mass index (non-asthmatics) / / 23517042 rs3096648 chr17 46753824 A G 7.98E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9909854 chr17 46756891 C T 3.29E-04 Alcohol dependence / / 21314694 rs3096644 chr17 46757575 G T 9.91E-04 Acute lung injury / / 22295056 rs3096644 chr17 46757575 G T 6.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) / / 23934736 rs7208024 chr17 46768854 G C 9.13E-04 Obesity (extreme) / / 21935397 rs7213972 chr17 46768899 T G 9.28E-04 Obesity (extreme) / / 21935397 rs8081391 chr17 46772200 G A 9.56E-04 Obesity (extreme) / / 21935397 rs7222822 chr17 46774872 C T 9.81E-04 Obesity (extreme) / / 21935397 rs2280351 chr17 46830299 G A 6.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs7219021 chr17 46840541 T G 1.22E-04 Suicide attempts in bipolar disorder TTLL6 intron 21423239 rs7219021 chr17 46840541 T G 6.20E-05 Hypothyroidism TTLL6 intron 22493691 rs7219021 chr17 46840541 T G 1.00E-07 Bipolar disorder and schizophrenia TTLL6 intron 24280982 rs953259 chr17 46841894 T C 2.65E-04 Myocardial Infarction TTLL6 intron pha002873 rs11657371 chr17 46843873 T C 8.93E-05 Suicide attempts in bipolar disorder TTLL6 intron 21423239 rs7217007 chr17 46844697 C T 4.37E-05 Suicide attempts in bipolar disorder TTLL6 intron 21423239 rs11652858 chr17 46844996 C T 1.71E-04 Suicide attempts in bipolar disorder TTLL6 intron 21423239 rs2032844 chr17 46847364 C A 9.24E-05 Suicide attempts in bipolar disorder TTLL6 missense 21423239 rs7217983 chr17 46853345 A G 3.03E-04 Suicide attempts in bipolar disorder TTLL6 intron 21423239 rs9915337 chr17 46857421 T A 2.61E-04 Suicide attempts in bipolar disorder TTLL6 intron 21423239 rs10468517 chr17 46862114 C T 2.45E-04 Suicide attempts in bipolar disorder TTLL6 intron 21423239 rs7209108 chr17 46863898 C T 1.59E-04 Suicide attempts in bipolar disorder TTLL6 intron 21423239 rs3901705 chr17 46865760 T C 2.94E-04 Suicide attempts in bipolar disorder TTLL6 intron 21423239 rs3848457 chr17 46866026 C T 5.45E-04 Suicide attempts in bipolar disorder TTLL6 intron 21423239 rs3887854 chr17 46868710 C T 5.64E-04 Multiple complex diseases TTLL6 intron 17554300 rs9901447 chr17 46872346 C T 2.44E-04 Suicide attempts in bipolar disorder TTLL6 intron 21423239 rs632824 chr17 46877882 G T 2.00E-05 Urinary metabolites TTLL6 intron 21572414 rs17634167 chr17 46878625 A G 0.0000162 Menopause (age at onset) TTLL6 cds-synon 23424626 rs8073596 chr17 46883045 C T 7.62E-05 Neuroblastoma TTLL6 intron pha002895 rs7214800 chr17 46886614 C G 7.61E-04 Obesity (extreme) TTLL6 intron 21935397 rs3959442 chr17 46894377 A C,G,T 0.00023 Prostate cancer TTLL6 missense 23555315 rs606911 chr17 46908228 G A 1.61E-04 Heart rate / / 23583979 rs563916 chr17 46930907 G A 4.11E-06 Neuroblastoma CALCOCO2 intron pha002895 rs10278 chr17 46939658 C G 0.00054 Prostate cancer CALCOCO2 missense 23555315 rs999475 chr17 46988044 G A 9.04E-04 Suicide attempts in bipolar disorder UBE2Z intron 21423239 rs46522 chr17 46988597 C T 8.13E-04 Type 2 diabetes UBE2Z intron 17463246 rs46522 chr17 46988597 C T 7.27E-04 Multiple complex diseases UBE2Z intron 17554300 rs46522 chr17 46988597 C T 2.00E-08 Coronary heart disease UBE2Z intron 21378990 rs46522 chr17 46988597 C T 1.81E-08 Pericardial fat UBE2Z intron 22589742 rs9894220 chr17 46989154 A G 4.10E-06 Coronary heart disease UBE2Z intron 22319020 rs1058018 chr17 47000251 C T 3.68E-04 Type 2 diabetes UBE2Z cds-synon 17463246 rs145067756 chr17 47000993 A AAGAAAGAATGTCAC 7.02E-07 Stroke (ischemic) UBE2Z intron 21957438 rs77149783 chr17 47000993 A C 7.02E-07 Stroke (ischemic) UBE2Z intron 21957438 rs11079842 chr17 47002762 G A 8.59E-04 Suicide attempts in bipolar disorder UBE2Z intron 21423239 rs2088138 chr17 47004723 G A 1.50E-04 Suicidal ideation UBE2Z UTR-3 22030708 rs15563 chr17 47005193 A G 9.90E-04 Type 2 diabetes UBE2Z UTR-3 17463246 rs15563 chr17 47005193 A G 0.0000582 Coronary artery disease (CAD) (males) UBE2Z UTR-3 23202125 rs15563 chr17 47005193 A G 0.000386 Coronary artery disease (CAD) age <=50 UBE2Z UTR-3 23202125 rs15563 chr17 47005193 A G 1.81E-05 Coronary artery disease UBE2Z UTR-3 24262325 rs12941604 chr17 47007013 G A 3.88E-05 Neuroblastoma / / pha002895 rs2270576 chr17 47007963 C T 9.11E-04 Suicide attempts in bipolar disorder SNF8 cds-synon 21423239 rs4793992 chr17 47008207 A G 7.72E-04 Type 2 diabetes SNF8 intron 17463246 rs4793993 chr17 47008546 C T 2.59E-05 Lymphocyte counts SNF8 intron 22286170 rs1994970 chr17 47014127 T C 8.57E-04 Type 2 diabetes SNF8 intron 17463246 rs9904288 chr17 47031973 T C 9.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs3848460 chr17 47047114 A G 2.31E-04 Type 2 diabetes / / 17463246 rs9899404 chr17 47053828 T C 4.47E-07 Longevity,exceptional / / 20595579 rs9899404 chr17 47053828 T C 1.09E-05 Longevity / / 22279548 rs2411759 chr17 47071074 C T 1.82E-06 Longevity,exceptional / / 20595579 rs1994969 chr17 47080431 G T 7.00E-16 Primary tooth development (number of teeth) IGF2BP1 intron 23704328 rs9674544 chr17 47084711 G A 2.00E-08 Primary tooth development (number of teeth) IGF2BP1 intron 20195514 rs9674544 chr17 47084711 G A 8.00E-07 Primary tooth development (time to first tooth eruption) IGF2BP1 intron 20195514 rs9899580 chr17 47106878 T G 7.50E-05 Hypothyroidism IGF2BP1 intron 22493691 rs11655950 chr17 47129121 G A 8.40E-05 Hypothyroidism IGF2BP1 UTR-3 22493691 rs6504595 chr17 47187056 T G 3.60E-06 Urinary metabolites / / 21572414 rs9902755 chr17 47220726 C T 0.00000083 Myopia (Age of onset) B4GALNT2 intron 23468642 rs627386 chr17 47290795 T G 4.00E-06 IgG glycosylation ABI3 intron 23382691 rs11650494 chr17 47345186 G A 2.00E-09 Prostate cancer / / 23535732 rs4794037 chr17 47369302 A G 8.39E-04 Amyotrophic Lateral Sclerosis ZNF652 UTR-3 17362836 rs12452264 chr17 47370077 G A 4.62E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ZNF652 UTR-3 21844884 rs9892264 chr17 47372944 G A 6.62E-04 Multiple complex diseases ZNF652 UTR-3 17554300 rs2240300 chr17 47377521 A G 1.00E-04 Cognitive impairment induced by topiramate ZNF652 intron 22091778 rs2072153 chr17 47390014 G C 4.00E-08 Height ZNF652 intron 20881960 rs12940887 chr17 47402807 C T 2.00E-07 Blood pressure ZNF652 intron 21909110 rs12940887 chr17 47402807 C T 2.29E-14 Systolic blood pressure ZNF652 intron 21909115 rs9910777 chr17 47407481 G A 7.39E-04 Multiple complex diseases ZNF652 intron 17554300 rs11652146 chr17 47422363 G A 2.25E-05 Cognitive impairment induced by topiramate ZNF652 intron 22091778 rs2411979 chr17 47427243 G A 6.43E-04 Amyotrophic Lateral Sclerosis ZNF652 intron 17362836 rs2411979 chr17 47427243 G A 5.26E-05 Hemoglobin concentration ZNF652 intron 20534544 rs2411980 chr17 47430223 C G 9.95E-04 Multiple complex diseases ZNF652 intron 17554300 rs7210100 chr17 47436749 G A 3.00E-13 Prostate cancer ZNF652 intron 21602798 rs7210100 chr17 47436749 G A 0.00017 Prostate cancer (non-advanced prostate cancer) ZNF652 intron 23555315 rs7210100 chr17 47436749 G A 0.00037 Prostate cancer ZNF652 intron 23555315 rs1867087 chr17 47440420 A G 4.00E-06 Hypertension / / 22384028 rs16948048 chr17 47440466 A G 5.00E-09 Diastolic blood pressure / / 19430483 rs16948048 chr17 47440466 A G 5.00E-09 Coronary heart disease / / 21347282 rs16948048 chr17 47440466 A G 5.00E-09 Blood pressure / / 21378095 rs16948048 chr17 47440466 A G 2.88E-07 Blood pressure / / 21909110 rs16948048 chr17 47440466 A G 0.000146 Coronary artery disease / / 23202125 rs16948048 chr17 47440466 A G 0.000033 Primary sclerosing cholangitis / / 23603763 rs200932358 chr17 47445751 GATAA G 2.00E-10 Sex hormone-binding globulin levels / / 22829776 rs200932358 chr17 47445751 GATAA G 4.00E-14 Sex hormone-binding globulin levels / / 22829776 rs2411984 chr17 47445751 G A 2.00E-10 Sex hormone-binding globulin levels / / 22829776 rs2411984 chr17 47445751 G A 4.00E-14 Sex hormone-binding globulin levels / / 22829776 rs371768722 chr17 47445751 G GATAA 2.00E-10 Sex hormone-binding globulin levels / / 22829776 rs371768722 chr17 47445751 G GATAA 4.00E-14 Sex hormone-binding globulin levels / / 22829776 rs11655704 chr17 47448172 T C 7.54E-06 Hemoglobin concentration / / 20534544 rs16948058 chr17 47449499 C T 2.37E-05 Alcohol dependence / / 20201924 rs16948058 chr17 47449499 C T 2.37E-05 Alcoholism / / pha002891 rs7209400 chr17 47450057 C T 4.50E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17637472 chr17 47461433 G A 1.06E-06 Esophageal cancer (squamous cell) / / 22960999 rs4987082 chr17 47481374 T C 8.00E-06 Hypertension PHB nearGene-3 22384028 rs35919134 chr17 47501933 T TC 1.26E-08 Primary biliary cirrhosis / / 22961000 rs2584681 chr17 47529746 A G 0.0000266 Carotid intima media thickness / / 23152477 rs1317636 chr17 47551127 T C 3.86E-04 Multiple complex diseases / / 17554300 rs1035050 chr17 47564012 T C 9.00E-06 Bipolar disorder / / 19416921 rs16948200 chr17 47566312 G A 2.00E-08 Immune reponse to smallpox (secreted IL-2) / / 22610502 rs2671683 chr17 47566411 C T 7.94E-04 Parkinson's disease / / 17052657 rs2537710 chr17 47566586 C A 1.85E-04 Multiple complex diseases / / 17554300 rs603769 chr17 47570085 A G 1.76E-04 Body mass index / / 21701565 rs603769 chr17 47570085 A G 4.61E-05 Body mass index / / 21701565 rs2584665 chr17 47570182 A C 2.34E-04 Multiple complex diseases / / 17554300 rs2584665 chr17 47570182 A C 1.04E-04 Body mass index / / 21701565 rs2584665 chr17 47570182 A C 3.21E-04 Body mass index / / 21701565 rs565042 chr17 47577839 A G 1.09E-07 Height NGFR intron 22021425 rs734194 chr17 47591609 T G 7.24E-05 Lymphocyte counts NGFR UTR-3 pha003094 rs734194 chr17 47591609 T G 6.28E-05 Neutrophil count NGFR UTR-3 pha003095 rs2671641 chr17 47597727 G C 5.87E-04 Obesity (extreme) LOC100288866 intron 21935397 rs2671650 chr17 47603516 C A 7.89E-05 Cognitive test performance LOC100288866 intron 20125193 rs1061431 chr17 47676982 G A 5.18E-04 Taste perception SPOP UTR-3 22132133 rs11870428 chr17 47759376 G A 8.72E-05 Cognitive performance / / 19734545 rs11870428 chr17 47759376 G A 4.82E-06 Heart Failure / / pha002885 rs8064701 chr17 47789865 G C 4.80E-06 Prostate cancer (early onset) FAM117A intron 24740154 rs7225566 chr17 47798725 A G 8.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FAM117A intron 20877124 rs4793621 chr17 47863368 T C 4.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7218139 chr17 47940769 T C 7.90E-04 Multiple complex diseases / / 17554300 rs8079058 chr17 47942375 G A 8.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs271674 chr17 47978986 C A,G,T 6.00E-06 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs271674 chr17 47978986 C A,G,T 6.27E-06 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs271674 chr17 47978986 C A,G,T 6.27E-06 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs11651236 chr17 47980813 G C 2.03E-04 Type 2 diabetes / / 17463246 rs271645 chr17 47999993 A G 4.58E-05 Brain structure / / 22504417 rs271646 chr17 48000146 G T 2.19E-05 Brain structure / / 22504417 rs271653 chr17 48005880 C T 2.87E-05 Brain structure / / 22504417 rs169217 chr17 48013188 A T 6.73E-04 Obesity (extreme) / / 21935397 rs182109 chr17 48016501 T C 3.19E-04 Body mass index / / 17255346 rs271661 chr17 48018335 T A 7.07E-04 Type 2 diabetes / / 17463246 rs271661 chr17 48018335 T A 1.95E-05 Serum metabolites / / 19043545 rs6504626 chr17 48019891 T C 3.46E-04 Alcohol dependence / / 20201924 rs4794077 chr17 48023082 C T 8.61E-04 Type 2 diabetes / / 17463246 rs4793622 chr17 48023393 C A 2.26E-05 Orofacial clefts / / 19270707 rs17638215 chr17 48042609 A G 1.10E-05 Diabetic retinopathy / / 21441570 rs151180891 chr17 48068913 C T 0.00019 Prostate cancer DLX3 missense 23555315 rs12942470 chr17 48121417 A G 7.08E-04 Multiple complex diseases / / 17554300 rs199146 chr17 48122961 T C 9.16E-04 Tourette syndrome / / 22889924 rs199140 chr17 48130079 G C 2.78E-05 Personality dimensions LOC284080 intron 18957941 rs9895410 chr17 48131195 T C 2.95E-04 Suicide attempts in bipolar disorder LOC284080 intron 21041247 rs9890077 chr17 48131460 A G 8.89E-04 Suicide attempts in bipolar disorder LOC284080 intron 21041247 rs4794094 chr17 48132643 T C 8.83E-04 Suicide attempts in bipolar disorder LOC284080 intron 21041247 rs4793636 chr17 48139500 G A 1.08E-33 Narcolepsy ITGA3 intron 19629137 rs9906470 chr17 48145784 G A 9.55E-04 Multiple complex diseases ITGA3 intron 17554300 rs531650995 chr17 48195818 CACAG C 2.27E-04 Epilepsy SAMD14 intron 22116939 rs739500 chr17 48195818 C T 2.27E-04 Epilepsy SAMD14 intron 22116939 rs12453363 chr17 48221920 G A 6.31E-04 Heart Failure PPP1R9B intron pha002884 rs1046329 chr17 48248906 C G 1.37E-05 Neuroticism SGCA intron 23229837 rs2075555 chr17 48274291 T G 8.00E-08 Breast cancer COL1A1 intron 17903305 rs2075555 chr17 48274291 T G 8.00E-08 Nasopharyngeal carcinoma COL1A1 intron 20512145 rs1800012 chr17 48277749 C A 1 Drug response to Etidronic Acid COL1A1 intron 11547828 rs1800012 chr17 48277749 C A 1 Drug response to Etidronic Acid COL1A1 intron 11907712 rs1800012 chr17 48277749 C A 1 Drug response to Etidronic Acid COL1A1 intron 12810179 rs1800012 chr17 48277749 C A 1 Drug response to Etidronic Acid COL1A1 intron 16475872 rs1800012 chr17 48277749 C A 1 Drug response to Etidronic Acid COL1A1 intron 8841196 rs1800012 chr17 48277749 C A 1 Drug response to Etidronic Acid COL1A1 intron 9738510 rs2586502 chr17 48289070 C A 1.00E-06 Response to taxane treatment (docetaxel) / / 23006423 rs1881140 chr17 48316872 A G 2.53E-05 Major depression (suicidal thoughts and behavior) / / 21750702 rs9893817 chr17 48327844 T A 9.78E-04 Type 2 diabetes / / 17463246 rs4793645 chr17 48347817 C A 3.40E-05 Type 2 diabetes / / 23209189 rs2696259 chr17 48349450 G A 9.05E-04 Parkinson's disease TMEM92 intron 17052657 rs2696259 chr17 48349450 G A 2.19E-05 Lipoproteins TMEM92 intron pha003079 rs2253804 chr17 48355560 T C 1.58E-04 Response to cytidine analogues (gemcitabine) TMEM92 intron 24483146 rs1918733 chr17 48364231 C T 1.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1008509 chr17 48406251 T C 0.00000564 Nicotine dependence (smoking) / / 23542338 rs2097844 chr17 48430694 G A 6.29E-05 Tunica Media XYLT2 intron pha003036 rs4794136 chr17 48433958 T C 9.82E-05 Tunica Media XYLT2 cds-synon pha003036 rs17714829 chr17 48452481 T C 4.71E-05 Body Mass Index EME1 intron pha003009 rs8070068 chr17 48521203 G A 3.28E-05 Cognitive test performance ACSF2 intron 20125193 rs4389179 chr17 48528151 C T 6.95E-05 Cognitive test performance ACSF2 intron 20125193 rs2290862 chr17 48557326 G A 0.000033 Stroke RSAD1 missense 23422753 rs6504663 chr17 48591209 A G 9.00E-06 Visceral fat MYCBPAP intron 22589738 rs146276624 chr17 48600427 C A,T 0.00013 Breast cancer MYCBPAP missense 23555315 rs145595403 chr17 48618243 C G 0.00009 Prostate cancer (advanced) EPN3 missense 23555315 rs62621401 chr17 48628160 A G 0.00089 Prostate cancer SPATA20 missense 23555315 rs117964204 chr17 48692082 C T 1.00E-09 Alzheimer's disease (cognitive decline) CAC/1G intron 23535033 rs4148409 chr17 48718531 T C,G 4.27E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) ABCC3 intron 23648065 rs4794174 chr17 48725604 G T 7.75E-05 Socioeconomic Factors ABCC3 intron pha003066 rs17562516 chr17 48729781 T A 9.67E-10 Lymphocyte counts ABCC3 intron 22286170 rs1978153 chr17 48737861 C G 2.70E-05 Urinary metabolites ABCC3 intron 21572414 rs11568607 chr17 48745787 G A 1.90E-09 Triglycerides ABCC3 intron 23063622 rs11568607 chr17 48745787 G A 6.39E-14 LDL cholesterol ABCC3 intron 23063622 rs11568607 chr17 48745787 G A 7.82E-18 Cholesterol,total ABCC3 intron 23063622 rs11867565 chr17 48827106 A G 2.59E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LUC7L3 intron 24023788 rs2159432 chr17 48836052 T C 8.77E-05 Non-alcoholic fatty liver disease histology (other) LINC00483 intron 20708005 rs1984555 chr17 48836197 C T 8.99E-05 Glucose levels LINC00483 intron pha002899 rs3760401 chr17 48846615 G A 3.40E-05 Brain structure / / 22504417 rs1860444 chr17 48868181 C T 4.30E-04 Lung adenocarcinoma / / 21242121 rs16949303 chr17 48877899 G A,C 2.64E-05 Panic disorder / / 19165232 rs9905480 chr17 48936065 C T 2.24E-05 Waist-Hip Ratio / / pha003029 rs9303568 chr17 48939527 C T 1.62E-05 Waist-Hip Ratio / / pha003013 rs9303568 chr17 48939527 C T 6.20E-05 Waist Circumference / / pha003024 rs9303568 chr17 48939527 C T 4.04E-05 Waist-Hip Ratio / / pha003028 rs9303568 chr17 48939527 C T 3.36E-05 Waist-Hip Ratio / / pha003029 rs9910467 chr17 48955759 G A 0.000407 Salmonella-induced pyroptosis / / 22837397 rs8073538 chr17 48967375 A G 9.89E-05 Waist-Hip Ratio / / pha003013 rs8073538 chr17 48967375 A G 1.14E-05 Body Fat Distribution / / pha003016 rs8073538 chr17 48967375 A G 4.64E-05 Body Fat Distribution / / pha003017 rs8073538 chr17 48967375 A G 5.47E-05 Body Fat Distribution / / pha003018 rs12452766 chr17 48969375 G C 8.54E-06 Serum metabolites / / 19043545 rs10445383 chr17 48985443 G A 6.41E-04 Multiple complex diseases / / 17554300 rs1860443 chr17 49009532 C G 2.10E-04 Iris characteristics / / 21835309 rs11657251 chr17 49082330 G A 9.15E-05 Body Fat Distribution SPAG9 intron pha003016 rs1558253 chr17 49210820 G T 6.90E-04 Coronary Artery Disease / / 17634449 rs2215290 chr17 49224221 C T 7.58E-05 Cortisol secretion,in saliva / / 21316860 rs3760469 chr17 49230552 T G 9.84E-05 Tunica Media NME1 nearGene-5 pha003037 rs11868380 chr17 49233447 C G 5.55E-05 Multiple complex diseases NME1 intron 17554300 rs4605213 chr17 49244747 G C 3.00E-08 Height NME2 intron 20881960 rs7213331 chr17 49350341 A G 9.39E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers UTP18 intron 21775533 rs4794220 chr17 49363547 A G 5.70E-04 Lymphocyte counts UTP18 intron 22286170 rs175391 chr17 49398048 T G 1.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs175391 chr17 49398048 T G 8.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17575864 chr17 49399669 C A 1.20E-05 Urinary metabolites / / 21572414 rs7213536 chr17 49438652 C T 8.50E-06 Urinary metabolites / / 21572414 rs6504709 chr17 49441059 A G 5.99E-04 Multiple complex diseases / / 17554300 rs6504709 chr17 49441059 A G 2.70E-05 Urinary metabolites / / 21572414 rs9904836 chr17 49480042 G A 8.60E-04 Multiple complex diseases / / 17554300 rs8068533 chr17 49505579 G A 1.78E-04 Amyotrophic lateral sclerosis / / 23624525 rs7213039 chr17 49511272 T A 6.53E-04 Multiple complex diseases / / 17554300 rs12603901 chr17 49555095 G A 3.75E-05 Triglycerides / / pha003080 rs11655733 chr17 49565547 G A 5.13E-05 Bipolar disorder / / 22925353 rs9635758 chr17 49612200 G A 1.60E-05 Menarche (age at onset) / / 19448622 rs9635759 chr17 49613785 G A 7.00E-13 Menarche (age at onset) / / 21102462 rs7226040 chr17 49620450 G A 8.42E-04 Multiple complex diseases / / 17554300 rs16950093 chr17 49640184 C T 5.60E-04 Pulmonary function / / 23932459 rs4794268 chr17 49662910 C G 4.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs4262990 chr17 49666388 T A 4.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs4794274 chr17 49674987 A G 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs4488496 chr17 49675762 G A 4.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs4476216 chr17 49675878 T G 4.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs4399573 chr17 49678916 C A 1.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs6504736 chr17 49689592 A G 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs12601545 chr17 49693437 C T 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs8076197 chr17 49737583 G A 2.18E-04 Alzheimer's disease CA10 intron 17998437 rs8076496 chr17 49737739 G A 9.56E-04 Alzheimer's disease CA10 intron 17998437 rs9303590 chr17 49741141 C T 6.65E-04 Multiple complex diseases CA10 intron 17554300 rs8064617 chr17 49742142 G A 9.61E-05 Alzheimer's disease CA10 intron 17998437 rs5022059 chr17 49742553 T G 3.79E-04 Multiple complex diseases CA10 intron 17554300 rs5022059 chr17 49742553 T G 3.23E-05 Acute lymphoblastic leukemia (childhood) CA10 intron 19684603 rs2873938 chr17 49755374 G A 7.15E-04 Coronary heart disease CA10 intron 21606135 rs9906298 chr17 49780250 T C 4.10E-10 Gallstones CA10 intron 17632509 rs9906298 chr17 49780250 T C 7.46E-05 Cognitive impairment induced by topiramate CA10 intron 22091778 rs1263970 chr17 49784791 T C 3.30E-05 Lung adenocarcinoma CA10 intron 22797724 rs4794300 chr17 49807207 T C 8.56E-05 Serum metabolites CA10 intron 19043545 rs11869209 chr17 49808242 A C 8.17E-04 Alzheimer's disease CA10 intron 17998437 rs1263978 chr17 49816472 G A 4.49E-04 Alzheimer's disease CA10 intron 17998437 rs1263984 chr17 49828330 G T 5.00E-04 Alzheimer's disease CA10 intron 17998437 rs1268418 chr17 49832407 A G 2.71E-04 Alzheimer's disease CA10 intron 17998437 rs4794304 chr17 49849208 A G 2.01E-04 Cholesterol CA10 intron 17255346 rs2319453 chr17 49853021 T C 4.18E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) CA10 intron 23648065 rs2319517 chr17 49874734 G A 1.35E-04 Myocardial Infarction CA10 intron pha002873 rs1501255 chr17 49886052 C T 8.48E-05 Creatinine levels CA10 intron pha003069 rs767326 chr17 49905696 A C 1.01E-05 Heart Rate CA10 intron pha003051 rs981577 chr17 49907913 G C 1.48E-04 Smoking cessation CA10 intron 18519826 rs981578 chr17 49908261 A G 5.11E-05 Heart Rate CA10 intron pha003051 rs202132 chr17 49916168 C T 5.31E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CA10 intron 20877124 rs9890222 chr17 49933891 C T 4.67E-04 Aortic root size CA10 intron 21223598 rs8076116 chr17 49934897 T G 4.89E-04 Suicide attempts in bipolar disorder CA10 intron 21041247 rs7215201 chr17 49949240 A G 6.85E-07 Smoking cessation CA10 intron 18519826 rs8073930 chr17 49952858 A G 5.96E-26 Narcolepsy CA10 intron 19629137 rs967676 chr17 49960309 T C 3.18E-05 Asthma CA10 intron 20159242 rs967676 chr17 49960309 T C 4.69E-04 Tourette syndrome CA10 intron 22889924 rs967676 chr17 49960309 T C 3.58E-04 Myocardial Infarction CA10 intron pha002873 rs9674802 chr17 49979895 T C 2.40E-05 Urinary metabolites CA10 intron 21572414 rs16950751 chr17 49986458 C G 3.26E-04 Multiple complex diseases CA10 intron 17554300 rs202121 chr17 49991180 G C 1.10E-05 Multiple complex diseases CA10 intron 17554300 rs202120 chr17 49991378 T C 1.27E-05 Multiple complex diseases CA10 intron 17554300 rs203076 chr17 49999485 C A 4.07E-06 Multiple complex diseases CA10 intron 17554300 rs203090 chr17 50009548 C T 1.97E-05 Multiple complex diseases CA10 intron 17554300 rs203092 chr17 50009994 C A 2.06E-05 Multiple complex diseases CA10 intron 17554300 rs203093 chr17 50010372 C A,G,T 1.25E-05 Multiple complex diseases CA10 intron 17554300 rs203097 chr17 50013277 G T 1.01E-05 Multiple complex diseases CA10 intron 17554300 rs203098 chr17 50013434 G A 1.86E-05 Multiple complex diseases CA10 intron 17554300 rs11871528 chr17 50015787 G T 9.32E-04 Obesity (extreme) CA10 intron 21935397 rs203010 chr17 50027994 T C 1.33E-04 Multiple complex diseases CA10 intron 17554300 rs203018 chr17 50035504 A G 1.41E-04 Smoking cessation CA10 intron 18519826 rs6504754 chr17 50043613 G A 8.17E-04 Multiple complex diseases CA10 intron 17554300 rs9900811 chr17 50067848 T G 4.85E-04 Multiple complex diseases CA10 intron 17554300 rs203042 chr17 50072245 G A 4.23E-04 Multiple complex diseases CA10 intron 17554300 rs996379 chr17 50077613 G T 9.37E-04 Multiple complex diseases CA10 intron 17554300 rs4794315 chr17 50079849 A G 8.67E-04 Multiple complex diseases CA10 intron 17554300 rs1501253 chr17 50080143 A G 6.74E-04 Multiple complex diseases CA10 intron 17554300 rs203050 chr17 50080751 T C 5.25E-04 Multiple complex diseases CA10 intron 17554300 rs8076286 chr17 50096756 C A 2.94E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CA10 intron 24023788 rs16950939 chr17 50128124 A G 3.61E-04 Type 2 diabetes CA10 intron 17463246 rs4641792 chr17 50160421 T C 8.06E-04 Suicide attempts in bipolar disorder CA10 intron 21423239 rs1393735 chr17 50173184 C T 3.25E-04 Response to alcohol consumption (flushing response) CA10 intron 24277619 rs2938139 chr17 50179416 G A 8.24E-05 Type 2 diabetes CA10 intron 17463246 rs1503058 chr17 50211856 C T 7.34E-04 Suicide attempts in bipolar disorder CA10 intron 21423239 rs10853121 chr17 50215698 T C 1.05E-04 Suicide attempts in bipolar disorder CA10 intron 21423239 rs16951028 chr17 50216689 G A 6.37E-04 Suicide attempts in bipolar disorder CA10 intron 21423239 rs11079992 chr17 50217537 G A 9.24E-05 Asthma CA10 intron 20159242 rs11079992 chr17 50217537 G A 6.99E-04 Stroke CA10 intron pha002887 rs8066895 chr17 50228529 G T 6.57E-14 Multiple complex diseases CA10 intron 17554300 rs12939066 chr17 50270268 C T 5.09E-04 Tourette syndrome / / 22889924 rs17609255 chr17 50274170 C T 8.84E-04 Tourette syndrome / / 22889924 rs4605214 chr17 50282834 C T 5.84E-04 Tourette syndrome / / 22889924 rs16951120 chr17 50293638 C T 6.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs11867974 chr17 50294398 G A 6.19E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs1875674 chr17 50306841 T C 6.55E-05 Major depressive disorder / / 21621269 rs1393734 chr17 50310245 T C 1.04E-04 Multiple complex diseases / / 17554300 rs1393734 chr17 50310245 T C 7.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10515001 chr17 50328457 C T 9.84E-04 Type 2 diabetes / / 17463246 rs12604022 chr17 50334924 C T 3.78E-04 Tourette syndrome / / 22889924 rs6504764 chr17 50342112 T A 8.74E-04 Multiple complex diseases / / 17554300 rs2769577 chr17 50358178 T A 1.00E-04 Prostate cancer / / 21743057 rs7216377 chr17 50523806 T A 1.80E-05 Urinary metabolites / / 21572414 rs8072879 chr17 50524821 G C 1.50E-05 Urinary metabolites / / 21572414 rs1559467 chr17 50526188 T C 1.70E-05 Urinary metabolites / / 21572414 rs9893354 chr17 50538567 A G 7.10E-06 Urinary metabolites / / 21572414 rs12601816 chr17 50572240 C T 6.80E-05 Type 1 diabetes / / 18978792 rs16951546 chr17 50585822 T C 9.04E-05 Type 1 diabetes / / 18978792 rs2874120 chr17 50628256 C T 3.30E-05 Bipolar disorder and schizophrenia / / 20889312 rs952258 chr17 50628985 G C 2.11E-05 Bipolar disorder and schizophrenia / / 20889312 rs349947 chr17 50653210 T C 4.79E-05 Bipolar disorder and schizophrenia / / 20889312 rs349929 chr17 50663355 A G 7.78E-04 Parkinson's disease / / 17052657 rs349921 chr17 50665821 C G 4.96E-04 Multiple complex diseases / / 17554300 rs349914 chr17 50671032 C A 5.75E-05 Bipolar disorder and schizophrenia / / 20889312 rs2452232 chr17 50713602 A G 6.78E-04 Parkinson's disease / / 17052657 rs1492215 chr17 50725970 G A 7.78E-04 Parkinson's disease / / 17052657 rs1492219 chr17 50728873 A G 7.78E-04 Parkinson's disease / / 17052657 rs1492219 chr17 50728873 A G 8.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4329953 chr17 50810147 T C 3.31E-04 Type 2 diabetes / / 17463246 rs4794382 chr17 50810615 G C 3.30E-04 Type 2 diabetes / / 17463246 rs9916411 chr17 50812211 A G 9.75E-04 Type 2 diabetes / / 17463246 rs2331499 chr17 50814093 A T 4.45E-04 Type 2 diabetes / / 17463246 rs4794387 chr17 50814615 C G 5.47E-04 Type 2 diabetes / / 17463246 rs35161953 chr17 50835537 G GC 2.63E-04 Bipolar disorder / / 18317468 rs35161953 chr17 50835537 G GC 7.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9303605 chr17 50835537 G T 2.63E-04 Bipolar disorder / / 18317468 rs9303605 chr17 50835537 G T 7.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2331503 chr17 50836995 A G 2.85E-04 Type 2 diabetes / / 17463246 rs4451995 chr17 50837022 C T 1.65E-04 Bipolar disorder / / 18317468 rs11871098 chr17 50841286 G T 1.49E-04 Bipolar disorder / / 18317468 rs16952209 chr17 50866238 A G 1.70E-06 Urinary metabolites / / 21572414 rs16952224 chr17 50868924 T C 6.51E-04 Multiple complex diseases / / 17554300 rs10515029 chr17 50888949 G A 5.00E-05 Type 2 diabetes and 6 quantitative traits / / 17848626 rs8080294 chr17 50908543 A G 1.31E-05 C-Reactive Protein / / pha003070 rs6504793 chr17 50909244 C T 9.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs12450274 chr17 50937029 C T 2.44E-04 Multiple complex diseases / / 17554300 rs12950422 chr17 50937590 G C 2.20E-04 Multiple complex diseases / / 17554300 rs12942636 chr17 50937854 C T 3.28E-04 Multiple complex diseases / / 17554300 rs7223463 chr17 50938666 C T 1.81E-04 Multiple complex diseases / / 17554300 rs12940567 chr17 50953593 A G 4.38E-05 Bipolar disorder / / 20451256 rs12940567 chr17 50953593 A G 9.20E-04 Acute lung injury / / 22295056 rs12603777 chr17 50960591 T G 3.42E-05 Aging (time to event) / / 21782286 rs12603777 chr17 50960591 T G 3.86E-04 Acute lung injury / / 22295056 rs9905326 chr17 50969647 G A 6.18E-04 Multiple complex diseases / / 17554300 rs12945035 chr17 51004890 C T 3.26E-04 Multiple complex diseases / / 17554300 rs10515031 chr17 51007180 C T 8.78E-04 Multiple complex diseases / / 17554300 rs2137477 chr17 51052648 C G 6.90E-04 Multiple complex diseases / / 17554300 rs1512856 chr17 51069669 G A 8.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1512856 chr17 51069669 G A 8.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2877398 chr17 51112697 C T 2.59E-04 Amyotrophic lateral sclerosis / / 23624525 rs9898180 chr17 51114649 A G 9.56E-05 Aging (time to event) / / 21782286 rs8073783 chr17 51237941 C T 8.00E-06 Conduct disorder (interaction) / / 18846501 rs8073783 chr17 51237941 C T 8.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs807095 chr17 51292173 C A 3.75E-04 Multiple complex diseases / / 17554300 rs806942 chr17 51359859 G T 3.14E-04 Multiple complex diseases / / 17554300 rs806941 chr17 51360314 G T 2.50E-04 Multiple complex diseases / / 17554300 rs806933 chr17 51363191 C A 4.23E-04 Multiple complex diseases / / 17554300 rs10515040 chr17 51504320 G T 1.29E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs10852956 chr17 51529741 G A 8.91E-06 Podoconiosis / / 22455414 rs12453135 chr17 51544897 C T 7.71E-04 Type 2 diabetes / / 17463246 rs1910205 chr17 51550324 A T 4.72E-04 Type 2 diabetes / / 17463246 rs2055474 chr17 51559761 C T 2.57E-04 Type 2 diabetes / / 17463246 rs8076424 chr17 51578654 A G 2.36E-06 Podoconiosis / / 22455414 rs7215331 chr17 51630448 C G 1.96E-04 Multiple complex diseases / / 17554300 rs9904281 chr17 51648075 G A 9.61E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4384641 chr17 51690806 T C 2.56E-04 Multiple complex diseases / / 17554300 rs9910928 chr17 51700482 C T 5.91E-05 Information processing speed / / 21130836 rs3105827 chr17 51711517 T A 1.90E-05 Urinary metabolites / / 21572414 rs9890370 chr17 51750457 C G 1.31E-05 Body mass index / / 17255346 rs8076616 chr17 51752802 G A 1.72E-05 Body mass index / / 17255346 rs7222923 chr17 51753517 A G 1.79E-04 Body mass index / / 17255346 rs12946220 chr17 51781250 C T 1.45E-04 Body mass index / / 17255346 rs7223345 chr17 51800597 T A 2.48E-04 Body mass index / / 17255346 rs4483901 chr17 51862028 A G 1.90E-04 Breast cancer / / 21060860 rs17648423 chr17 51896003 A G 6.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17648423 chr17 51896003 A G 8.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3803825 chr17 51901084 A G 5.57E-04 Coronary Artery Disease KIF2B cds-synon 17634449 rs3803825 chr17 51901084 A G 1.52E-04 Breast cancer KIF2B cds-synon 21060860 rs4561519 chr17 51901703 C G 4.76E-04 Coronary Artery Disease KIF2B missense 17634449 rs4794469 chr17 51909049 C A 1.06E-04 Breast cancer / / 21060860 rs2331798 chr17 51909152 T C 2.88E-05 Monocyte counts / / pha003089 rs2331864 chr17 51914886 T C 7.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12953016 chr17 52000308 A G 4.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17728713 chr17 52000506 A G 4.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1457364 chr17 52064725 T C 0.000372692 Hypertension (early onset hypertension) / / 22479346 rs1350324 chr17 52066854 G A 0.000591316 Hypertension (early onset hypertension) / / 22479346 rs4793764 chr17 52070999 T C 0.000600088 Hypertension (early onset hypertension) / / 22479346 rs7209841 chr17 52081040 T G 0.000548415 Hypertension (early onset hypertension) / / 22479346 rs11079107 chr17 52089407 T C 0.000671701 Hypertension (early onset hypertension) / / 22479346 rs9890710 chr17 52120211 A G 5.10E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs9303345 chr17 52156544 T A 7.87E-20 Alcohol consumption / / pha001402 rs1379395 chr17 52161007 C T 3.26E-04 Lung function (forced vital capacity) / / 24023788 rs2157768 chr17 52227893 T C 3.56E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1508002 chr17 52244986 A T 9.83E-06 QT interval / / 23166209 rs9897174 chr17 52256225 G T 8.07E-04 Type 2 diabetes / / 17463246 rs11079110 chr17 52263741 G A 1.79E-04 Stroke / / pha002887 rs1508019 chr17 52295016 T G 1.74E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11079111 chr17 52297620 T C 4.33E-06 Major depressive disorder / / 19107115 rs1828096 chr17 52313270 A C 6.47E-04 Bipolar disorder / / 19259986 rs12451623 chr17 52315711 G A 6.32E-05 Major depressive disorder / / 19107115 rs7221007 chr17 52315948 C T 6.99E-04 Bipolar disorder / / 19259986 rs1567226 chr17 52317557 A C 6.01E-04 Bipolar disorder / / 19259986 rs17738435 chr17 52350956 T C 1.93E-04 Smoking initiation / / 24665060 rs2019089 chr17 52437493 A G 7.28E-05 Alcohol withdrawal symptoms / / 22072270 rs8066010 chr17 52453585 G A 2.77E-06 Major depressive disorder / / 20516156 rs8067196 chr17 52467631 A C 2.26E-06 Major depressive disorder / / 20516156 rs8067196 chr17 52467631 A C 0.00000325 Major depressive disorder age at onset<35 / / 22915352 rs8067196 chr17 52467631 A C 0.00000376 Major depressive disorder age at onset<30 / / 22915352 rs4794497 chr17 52485877 T C 3.97E-05 Serum metabolites / / 19043545 rs6504909 chr17 52548125 A G 3.00E-06 Obesity-related traits / / 23251661 rs4239186 chr17 52577219 T C 2.45E-04 Fibrinogen / / 17255346 rs12150099 chr17 52584614 C T 2.29E-05 Fibrinogen / / 17255346 rs12150099 chr17 52584614 C T 9.72E-05 Hemoglobin / / pha003098 rs12150099 chr17 52584614 C T 2.91E-05 Erythrocyte counts / / pha003099 rs11654616 chr17 52604380 G A 3.52E-04 Fibrinogen / / 17255346 rs7207449 chr17 52619915 G A 1.46E-04 Pancreatic cancer / / pha002874 rs2115663 chr17 52621498 C T 5.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2115663 chr17 52621498 C T 7.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8079935 chr17 52634878 A G 7.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9913683 chr17 52645863 G A 7.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9913683 chr17 52645863 G A 7.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4793773 chr17 52646414 T C 8.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7225084 chr17 52652493 T G 7.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7225084 chr17 52652493 T G 7.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6504930 chr17 52770992 C T 9.20E-04 Common variable immunodeficiency / / 21497890 rs10468542 chr17 52772651 A G 8.40E-05 Response to antidepressants / / 19736353 rs10468542 chr17 52772651 A G 2.15E-04 Myocardial Infarction / / pha002873 rs10468512 chr17 52780711 C T 6.60E-05 Response to antidepressants / / 19736353 rs6504934 chr17 52830106 A G 5.70E-06 Urinary metabolites / / 21572414 rs9909390 chr17 52839122 A T 6.34E-04 Type 2 diabetes / / 17463246 rs9907974 chr17 52842531 T C 3.65E-04 Type 2 diabetes / / 17463246 rs2958908 chr17 52846363 C T 9.04E-05 Body mass index / / 22446040 rs2907636 chr17 52879449 A G 5.90E-04 Taste perception / / 22132133 rs2159441 chr17 52880077 A G 7.58E-04 Alzheimer's disease / / 22005930 rs2907641 chr17 52883339 C T 2.56E-04 Taste perception / / 22132133 rs11079130 chr17 52889930 T C 4.72E-05 Non-word repetition / / 23738518 rs4794538 chr17 52925502 T C 3.47E-05 Anxiety in major depressive disorder / / 24047446 rs4794538 chr17 52925502 T C 8.65E-05 Body Mass Index / / pha003014 rs16955216 chr17 52929254 C A 4.04E-05 Non-word repetition / / 23738518 rs8066213 chr17 52930323 C A 4.04E-05 Non-word repetition / / 23738518 rs2934890 chr17 52931473 T C 2.57E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2934890 chr17 52931473 T C 3.57E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12150025 chr17 52932154 A T 6.94E-08 Multiple complex diseases / / 17554300 rs12150025 chr17 52932154 A T 1.60E-05 Urinary metabolites / / 21572414 rs16955225 chr17 52933320 A C 4.04E-05 Non-word repetition / / 23738518 rs11079136 chr17 52934145 T G 1.60E-05 Urinary metabolites / / 21572414 rs2860466 chr17 52934349 G A 3.50E-04 Multiple complex diseases / / 17554300 rs9303359 chr17 52934629 A G 7.81E-04 Response to TNF antagonist treatment / / 21061259 rs2934894 chr17 52940581 G T 2.05E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2934894 chr17 52940581 G T 9.94E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7207731 chr17 52942722 C T 3.70E-06 Urinary metabolites / / 21572414 rs11658131 chr17 52943398 A G 2.30E-05 Urinary metabolites / / 21572414 rs2958933 chr17 52953030 C T 7.72E-04 Coronary heart disease / / 21606135 rs17683844 chr17 52965694 T C 8.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8079105 chr17 52966403 C T 2.36E-04 Multiple complex diseases / / 17554300 rs8069447 chr17 53008873 T G 1.87E-05 Bipolar disorder TOM1L1 intron 22925353 rs6504950 chr17 53056471 G A 1.40E-05 Breast cancer STXBP4 intron 19330027 rs6504950 chr17 53056471 G A 1.40E-08 Breast cancer STXBP4 intron 19330027 rs6504950 chr17 53056471 G A 2.00E-13 Breast cancer STXBP4 intron 23535729 rs17817382 chr17 53062180 A G 0.0000386 Narcolepsy (non-HLA narcolepsy) STXBP4 intron 23459209 rs2787501 chr17 53093965 G C 1.15E-04 Type 2 diabetes STXBP4 intron 17463246 rs2628305 chr17 53140427 A C 2.51E-04 Type 2 diabetes STXBP4 intron 17463246 rs2628302 chr17 53158361 G A 7.14E-05 Cortisol secretion,in saliva STXBP4 intron 21316860 rs1484769 chr17 53166651 G A 4.14E-04 Type 2 diabetes STXBP4 intron 17463246 rs244363 chr17 53188893 G A 7.99E-05 Cognitive performance STXBP4 intron 19734545 rs244340 chr17 53199345 G A 6.98E-05 Cognitive performance STXBP4 intron 19734545 rs2628316 chr17 53219837 A C,G,T 7.69E-04 Type 2 diabetes STXBP4 intron 17463246 rs171512 chr17 53273593 G T 9.58E-04 Multiple complex diseases / / 17554300 rs4627424 chr17 53332044 G A 8.57E-04 Body mass index / / 21701565 rs12450116 chr17 53333925 C T 3.26E-04 Multiple complex diseases / / 17554300 rs8071484 chr17 53350098 C T 4.96E-04 Coronary heart disease HLF intron 21606135 rs4617927 chr17 53356126 G T 5.80E-09 Urate levels HLF intron 23263486 rs4617927 chr17 53356126 G T 4.22E-06 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) HLF intron 24236485 rs3829577 chr17 53360264 A G 3.35E-08 Urate levels HLF intron 23263486 rs1477141 chr17 53361838 T G 2.53E-08 Urate levels HLF intron 23263486 rs1477141 chr17 53361838 T G 5.79E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) HLF intron 24236485 rs7224610 chr17 53364788 C A 5.00E-17 Urate levels HLF intron 23263486 rs7224610 chr17 53364788 C A 3.54E-04 Stroke HLF intron pha002887 rs3794748 chr17 53365172 A G 5.73E-09 Urate levels HLF intron 23263486 rs955734 chr17 53367223 G A 6.78E-04 Type 2 diabetes HLF intron 17463246 rs10852974 chr17 53372566 G C 1.19E-09 Urate levels HLF intron 23263486 rs3829578 chr17 53381510 T C 3.61E-08 Urate levels HLF intron 23263486 rs4793788 chr17 53381796 C A 2.40E-08 Urate levels HLF intron 23263486 rs12453442 chr17 53390421 G A 0.0000239 Carotid intima media thickness HLF intron 23152477 rs4147525 chr17 53427776 T C 5.01E-05 Cognitive impairment induced by topiramate / / 22091778 rs9911896 chr17 53445130 C T 1.61E-05 Cognitive performance / / 19734545 rs9899143 chr17 53450163 G T 8.60E-04 Multiple complex diseases / / 17554300 rs933577 chr17 53452335 C T 6.20E-04 Type 2 diabetes / / 17463246 rs4583311 chr17 53453103 A G 5.06E-04 Smoking initiation / / 24665060 rs12941878 chr17 53460305 A G 1 Drug response to Etoposide / / 17537913 rs7223336 chr17 53464623 A T 4.53E-05 Multiple complex diseases / / 17554300 rs888206 chr17 53468213 C T 3.11E-04 Alcohol dependence / / 20201924 rs11079171 chr17 53484056 G A 3.96E-04 Multiple complex diseases MMD intron 17554300 rs4794583 chr17 53488036 C T 5.97E-04 Multiple complex diseases MMD intron 17554300 rs4630612 chr17 53497765 A G 4.47E-05 Alcohol dependence MMD intron 20201924 rs4630612 chr17 53497765 A G 4.47E-05 Alcoholism MMD intron pha002891 rs3760275 chr17 53500659 A G 8.58E-04 Type 2 diabetes / / 20818381 rs7226279 chr17 53513821 C A 6.88E-06 Obesity-related traits / / 23251661 rs4794588 chr17 53519171 T C 3.75E-04 Type 2 diabetes / / 17463246 rs11653011 chr17 53519844 T C 3.00E-06 Obesity-related traits / / 23251661 rs4794591 chr17 53521546 G C 1.10E-05 Urinary metabolites / / 21572414 rs9303369 chr17 53533743 C A 6.66E-06 Odorant perception / / 23910658 rs12150374 chr17 53558699 C T 5.88E-04 Multiple complex diseases / / 17554300 rs8070676 chr17 53559703 A G 8.80E-06 Urinary metabolites / / 21572414 rs7208128 chr17 53567523 C A 2.08E-04 Multiple complex diseases / / 17554300 rs17819224 chr17 53568698 A G 7.82E-05 Hypertension (essential hypertension) / / 22184326 rs12603425 chr17 53576069 T C 9.30E-04 Multiple complex diseases / / 17554300 rs11079178 chr17 53587818 G A 8.57E-04 Multiple complex diseases / / 17554300 rs7212458 chr17 53596398 A C 2.44E-04 Multiple complex diseases / / 17554300 rs1396215 chr17 53608767 C T 3.25E-04 Multiple complex diseases / / 17554300 rs17757577 chr17 53609406 C T 3.24E-04 Type 2 diabetes / / 17463246 rs17757577 chr17 53609406 C T 5.44E-04 Multiple complex diseases / / 17554300 rs878601 chr17 53640442 G A 3.01E-04 Multiple complex diseases / / 17554300 rs17819558 chr17 53646240 T C 3.36E-04 Stroke / / pha002887 rs8077387 chr17 53712887 T C 6.49E-05 Body Fat Distribution / / pha003017 rs8064998 chr17 53720626 A G 5.24E-05 Body Fat Distribution / / pha003016 rs8064998 chr17 53720626 A G 3.03E-05 Body Fat Distribution / / pha003017 rs8064998 chr17 53720626 A G 5.13E-05 Body Fat Distribution / / pha003018 rs8072303 chr17 53734176 C T 2.20E-05 Height / / 22021425 rs8071849 chr17 53734584 G A 1.33E-05 Height / / 22021425 rs9895813 chr17 53743722 C G 4.45E-05 Brain structure / / 22504417 rs9303372 chr17 53745944 G A 2.24E-04 Smoking initiation / / 24665060 rs1549519 chr17 53757787 T C 6.00E-09 Height / / 22021425 rs1426745 chr17 53776495 A G 2.09E-06 Height / / 22021425 rs17758328 chr17 53808795 C A 2.16E-05 Angioedema in response to angiotensin-converting enzyme inhibitor TMEM100 intron 23838604 rs17819140 chr17 53811360 T C 6.33E-05 Glucose levels / / pha003061 rs2960088 chr17 53819087 C A 3.20E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2114443 chr17 53827252 G A 1.57E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2960081 chr17 53827982 T G 2.35E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11867309 chr17 53840149 G A 0.000000835 Cholesterol,total PCTP intron 23063622 rs11867309 chr17 53840149 G A 6.04E-09 LDL cholesterol PCTP intron 23063622 rs12051898 chr17 53880022 C T 3.87E-04 Alzheimer's disease (late onset) / / 21379329 rs8079136 chr17 53907805 G A 6.10E-05 Type 2 diabetes / / 17463246 rs8079136 chr17 53907805 G A 1.14E-04 Amyotrophic lateral sclerosis / / 20801718 rs11649803 chr17 53910659 G A 5.78E-05 Type 2 diabetes / / 17463246 rs9910335 chr17 53918388 G T 5.00E-05 Prostate cancer / / 21743057 rs2332565 chr17 53964223 G A 7.23E-04 Type 2 diabetes / / 17846125 rs879768 chr17 53974012 T A 5.60E-04 Multiple complex diseases / / 17554300 rs11079203 chr17 53982098 C T 4.62E-04 Alzheimer's disease (late onset) / / 21379329 rs16956486 chr17 54005586 A G 2.72E-04 Alzheimer's disease (late onset) / / 21379329 rs17758963 chr17 54111606 A G 3.42E-04 Alzheimer's disease (late onset) / / 21379329 rs9303380 chr17 54117492 G A 1.72E-04 Alzheimer's disease (late onset) / / 21379329 rs8066419 chr17 54120957 T G 0.00000138 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment / / 23392654 rs8066419 chr17 54120957 T G 1.38E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs767644 chr17 54121348 T A 3.60E-05 Self-reported allergy / / 23817569 rs9807083 chr17 54122133 G A 0.00000158 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment / / 23392654 rs9807083 chr17 54122133 G A 1.58E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs7210295 chr17 54122740 G A 0.00000103 Collagen-Stimulated platelet aggregation after aspirin and clopidogrel treatment / / 23392654 rs7210295 chr17 54122740 G A 1.03E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs2060070 chr17 54123973 G A 2.00E-06 IgG glycosylation / / 23382691 rs2060070 chr17 54123973 G A 2.00E-06 IgG glycosylation / / 23382691 rs2060070 chr17 54123973 G A 9.00E-07 IgG glycosylation / / 23382691 rs4794614 chr17 54126588 T A 3.75E-04 Insulin resistance / / 21901158 rs4794617 chr17 54130470 G A 0.000315 Salmonella-induced pyroptosis / / 22837397 rs7214018 chr17 54149669 C G 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs16956631 chr17 54150254 A G 4.60E-05 Response to statin therapy / / 20339536 rs1431314 chr17 54151214 A G 1.40E-05 Response to statin therapy / / 20339536 rs1431315 chr17 54151295 T G 1.20E-05 Response to statin therapy / / 20339536 rs1431316 chr17 54151310 C T 1.50E-05 Response to statin therapy / / 20339536 rs6505037 chr17 54156243 G T 3.30E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6505038 chr17 54156938 C T 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs9895591 chr17 54157359 G A 5.74E-04 Multiple complex diseases / / 17554300 rs4793803 chr17 54163047 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs8070386 chr17 54164361 T A 3.34E-04 Multiple complex diseases / / 17554300 rs4794623 chr17 54164464 T C 7.59E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9912513 chr17 54167853 T C 7.90E-04 Obesity,menopause / / 21424828 rs17759200 chr17 54172277 G A 3.97E-06 Nasopharyngeal carcinoma / / 23209447 rs1431318 chr17 54192523 A G 9.00E-07 Cannabis dependence / / 21668797 rs8065311 chr17 54203360 G T 2.00E-06 Cannabis dependence / / 21668797 rs7213834 chr17 54204487 G A 2.59E-05 Body Composition / / pha003012 rs10491196 chr17 54215810 A C 1.18E-05 Body Composition / / pha003012 rs10491197 chr17 54221679 A G 1.18E-05 Body Composition / / pha003012 rs4794626 chr17 54256139 G C 6.40E-04 Type 2 diabetes ANKFN1 intron 17463246 rs6505044 chr17 54258240 A C 2.90E-05 Urinary metabolites ANKFN1 intron 21572414 rs9911043 chr17 54262845 G A 7.90E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) ANKFN1 intron 23648065 rs1019238 chr17 54278715 G A 6.00E-07 Cannabis dependence ANKFN1 intron 21668797 rs11871341 chr17 54335266 G A 1.10E-05 Urinary metabolites ANKFN1 intron 21572414 rs1154928 chr17 54351233 A C 8.34E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21423239 rs9903956 chr17 54388824 T C 2.04E-04 Aortic root size ANKFN1 intron 21223598 rs62075284 chr17 54393314 C T 1.82E-04 Telomere length ANKFN1 intron 24478790 rs12944196 chr17 54396835 C T 2.40E-06 Urinary metabolites ANKFN1 intron 21572414 rs12950466 chr17 54401490 A C 2.30E-06 Urinary metabolites ANKFN1 intron 21572414 rs12450830 chr17 54401990 G C 4.97E-04 Multiple complex diseases ANKFN1 intron 17554300 rs12939082 chr17 54407001 G A 9.30E-06 Urinary metabolites ANKFN1 intron 21572414 rs759107 chr17 54409471 A G 2.64E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs759107 chr17 54409471 A G 4.43E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs8082579 chr17 54416639 T G 1.11E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs8082579 chr17 54416639 T G 7.72E-05 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs2110200 chr17 54420702 G T 2.62E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs2110200 chr17 54420702 G T 3.30E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs1547966 chr17 54424871 C T 2.70E-05 Major depressive disorder ANKFN1 intron 20516156 rs1547966 chr17 54424871 C T 1.05E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs1547966 chr17 54424871 C T 1.11E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs12449568 chr17 54430155 C T 2.00E-06 Height ANKFN1 intron 18391950 rs9915451 chr17 54433211 A G 1.02E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs9915451 chr17 54433211 A G 1.25E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs8069322 chr17 54450134 G A 3.00E-05 Prostate cancer ANKFN1 cds-synon 21743057 rs7210515 chr17 54453119 C T 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer ANKFN1 intron 21245432 rs4794639 chr17 54470311 G A 2.26E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs4794639 chr17 54470311 G A 3.37E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs9899359 chr17 54495896 C G 3.38E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs9899359 chr17 54495896 C G 3.79E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs2215759 chr17 54501205 A G 2.77E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs2215759 chr17 54501205 A G 2.82E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs7213627 chr17 54507431 T G 2.66E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs7213627 chr17 54507431 T G 3.82E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs980080 chr17 54509069 T C 2.57E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs980080 chr17 54509069 T C 4.08E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs10852984 chr17 54509306 A G 2.58E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs10852984 chr17 54509306 A G 4.12E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs4793818 chr17 54513566 G T 2.15E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs4793818 chr17 54513566 G T 2.56E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs7220133 chr17 54518069 C T 2.38E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs7220133 chr17 54518069 C T 3.20E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs7224952 chr17 54525346 T C 8.26E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs7218500 chr17 54529771 T C 2.82E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs7218500 chr17 54529771 T C 5.65E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs9913702 chr17 54538702 T C 3.00E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs9913702 chr17 54538702 T C 4.74E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs1548809 chr17 54539035 C T 3.01E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs1548809 chr17 54539035 C T 4.77E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs12945850 chr17 54545514 C T 3.10E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs12945850 chr17 54545514 C T 4.31E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs1442831 chr17 54552581 A T 3.98E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs1442831 chr17 54552581 A T 8.16E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs8070836 chr17 54553312 T C 3.99E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs8070836 chr17 54553312 T C 8.41E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs11653462 chr17 54556803 T G 4.00E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs11653462 chr17 54556803 T G 8.72E-04 Suicide attempts in bipolar disorder ANKFN1 intron 21041247 rs5027751 chr17 54557543 G A 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer ANKFN1 intron 21245432 rs2165759 chr17 54557591 T C 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer ANKFN1 intron 21245432 rs139388119 chr17 54559801 G A 0.000032 Prostate cancer (advanced) ANKFN1 missense 23555315 rs4794643 chr17 54598597 G A 4.79E-04 Acute lung injury / / 22295056 rs17760268 chr17 54611291 C T 4.00E-06 Celiac disease / / 23936387 rs4239203 chr17 54612393 C T 4.20E-06 Urinary metabolites / / 21572414 rs10515131 chr17 54612445 T C 6.85E-05 Panic disorder / / 19165232 rs17760296 chr17 54615617 T G 7.00E-06 Orofacial clefts / / 20023658 rs17760296 chr17 54615617 T G 2.80E-05 Urinary metabolites / / 21572414 rs17760296 chr17 54615617 T G 2.65E-04 Orofacial clefts / / 22863734 rs11871132 chr17 54628980 C A 9.97E-04 Type 2 diabetes / / 17463246 rs11870369 chr17 54634768 C G 2.68E-04 Type 2 diabetes / / 17463246 rs12150511 chr17 54651360 G A 2.92E-04 Multiple complex diseases / / 17554300 rs1992505 chr17 54676993 A C 6.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs7213501 chr17 54677251 A G 6.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs1561902 chr17 54679700 A C 2.88E-06 Type 2 diabetes / / 17463246 rs12603626 chr17 54682331 A C 3.40E-05 Blood pressure / / 21060006 rs12603626 chr17 54682331 A C 8.80E-04 Blood pressure / / 21060006 rs11079246 chr17 54683338 T C 6.42E-05 Type 2 diabetes / / 17463246 rs1003395 chr17 54696232 G A 7.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs16957492 chr17 54705189 T A 7.68E-04 Multiple complex diseases / / 17554300 rs12325830 chr17 54709644 C T 1.99E-07 Type 2 diabetes / / 17463246 rs17713947 chr17 54710308 T C 1.86E-04 Type 2 diabetes / / 17463246 rs11079249 chr17 54716686 A G 6.83E-05 Type 2 diabetes / / 17463246 rs2108831 chr17 54717904 G C 1.70E-06 Cocaine dependence / / 23958962 rs2108831 chr17 54717904 G C 5.67E-05 Cocaine dependence / / 23958962 rs6503752 chr17 54733715 C T 3.04E-04 Type 2 diabetes / / 17463246 rs12936596 chr17 54743099 G T 6.56E-04 Orofacial clefts / / 22863734 rs12451251 chr17 54749558 C T 5.62E-04 Orofacial clefts / / 22863734 rs8182331 chr17 54752926 T A 9.72E-08 Metabolite levels / / 23281178 rs12951993 chr17 54760614 A G 3.94E-07 Orofacial clefts / / 22863734 rs1029723 chr17 54767548 G A 1.44E-05 Orofacial clefts / / 22863734 rs227731 chr17 54773238 T G 1.00E-08 Orofacial clefts / / 20023658 rs227731 chr17 54773238 T G 4.67E-05 Cleft lip / / 20436469 rs227731 chr17 54773238 T G 2.00E-08 Orofacial clefts / / 22863734 rs227731 chr17 54773238 T G 0.0000796 Facial morphology / / 23028347 rs227730 chr17 54773951 T C 4.83E-05 Orofacial clefts / / 20023658 rs227730 chr17 54773951 T C 6.27E-06 Orofacial clefts / / 22863734 rs227724 chr17 54778817 A T 7.00E-15 Height / / 20881960 rs227723 chr17 54778904 C T 2.44E-05 Cognitive performance / / 19734545 rs227723 chr17 54778904 C T 6.54E-05 Orofacial clefts / / 20023658 rs227723 chr17 54778904 C T 2.88E-06 Orofacial clefts / / 22863734 rs3914806 chr17 54804377 T C 3.88E-05 Height / / 22021425 rs1914986 chr17 54807709 C T 2.70E-06 Height / / 22021425 rs227665 chr17 54813751 A C 3.24E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs7219027 chr17 54823170 A G 2.29E-05 Serum albumin level / / pha003084 rs16957765 chr17 54824122 C T 2.58E-04 Type 2 diabetes / / 17463246 rs12150403 chr17 54828295 C A 7.22E-05 Orofacial clefts / / 22419666 rs2049063 chr17 54833348 C A 4.63E-06 Gallstones / / 17632509 rs1401796 chr17 54839759 C A 2.00E-08 Height / / 20881960 rs8182274 chr17 54843281 G A 6.39E-04 Smoking quantity / / 24665060 rs4794665 chr17 54850329 A G 1.00E-07 Height / / 18391951 rs10515134 chr17 54863448 G A 4.62E-04 Obesity (extreme) / / 21935397 rs7224488 chr17 54868625 A C 2.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6503765 chr17 54880572 G A 1.34E-04 Alzheimer's disease C17orf67 intron 17998437 rs1052227 chr17 54906137 T C 7.99E-05 Alzheimer's disease C17orf67 intron 17998437 rs7225724 chr17 54912737 A G 2.42E-04 Lymphocyte counts DGKE intron 22286170 rs6503772 chr17 54916689 A C 4.35E-04 Obesity (extreme) DGKE intron 21935397 rs6503774 chr17 54918840 C G 4.80E-04 Type 2 diabetes DGKE intron 17463246 rs11651692 chr17 54938015 G A 8.21E-05 Obesity (extreme) DGKE intron 21935397 rs9911560 chr17 54939715 T C 4.80E-04 Type 2 diabetes DGKE intron 17463246 rs3826295 chr17 54939737 T A 4.80E-04 Type 2 diabetes DGKE intron 17463246 rs7209070 chr17 54946194 T C 6.60E-04 Type 2 diabetes / / 17463246 rs11651323 chr17 54947969 C G 1.29E-04 Obesity (extreme) / / 21935397 rs2525998 chr17 54967528 A G 4.29E-04 Smoking initiation TRIM25 UTR-3 24665060 rs205499 chr17 54972401 G A 4.24E-04 Longevity TRIM25 intron 22279548 rs2525994 chr17 54976922 C A 7.72E-04 Alcohol dependence TRIM25 intron 21314694 rs2525994 chr17 54976922 C A 2.82E-04 Smoking initiation TRIM25 intron 24665060 rs2525993 chr17 54977780 C T 1.54E-04 Smoking initiation TRIM25 intron 24665060 rs205497 chr17 54979128 G A 2.12E-04 Smoking initiation TRIM25 intron 24665060 rs12453004 chr17 55065530 A G 5.96E-05 Smoking initiation SCPEP1 intron 24665060 rs4794679 chr17 55086808 T C 1.17E-05 Age-related macular degeneration / / 22125219 rs6503782 chr17 55108734 A T 2.00E-06 Age-related macular degeneration / / 23577725 rs8078110 chr17 55112092 G A 2.67E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs8078110 chr17 55112092 G A 3.39E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs8073390 chr17 55119994 C T 7.00E-06 Response to amphetamines / / 22952603 rs3095505 chr17 55197914 G C 7.36E-04 Response to taxane treatment (placlitaxel) AKAP1 UTR-3 23006423 rs15944 chr17 55198248 A T 5.84E-05 Bipolar disorder and schizophrenia AKAP1 UTR-3 20889312 rs15944 chr17 55198248 A T 4.40E-04 Smoking initiation AKAP1 UTR-3 24665060 rs6967 chr17 55198420 C T 3.04E-05 Dengue shock syndrome AKAP1 UTR-3 22001756 rs1016987 chr17 55226477 C G 3.28E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9652853 chr17 55281591 T C 2.61E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9901454 chr17 55287871 T C 5.96E-04 Multiple complex diseases / / 17554300 rs9905713 chr17 55301369 A G 7.84E-05 HIV-1 viral setpoint / / 22174851 rs9913816 chr17 55307680 T G 7.91E-04 Type 2 diabetes / / 17463246 rs8071182 chr17 55336155 G A 9.94E-05 Type 2 diabetes MSI2 intron 17463246 rs8071182 chr17 55336155 G A 0.00008403 Sarcoidosis MSI2 intron 22952805 rs9893359 chr17 55338514 T C 8.87E-05 Cytomegalovirus antibody response MSI2 intron 21993531 rs9895389 chr17 55342518 C T 7.56E-04 Obesity (extreme) MSI2 intron 21935397 rs16958149 chr17 55345474 G A 5.34E-04 Multiple complex diseases MSI2 intron 17554300 rs16958160 chr17 55350167 C T 3.31E-04 Multiple complex diseases MSI2 intron 17554300 rs16958184 chr17 55356446 C T 8.99E-04 Multiple complex diseases MSI2 intron 17554300 rs8071867 chr17 55368090 C T 2.60E-05 Urinary metabolites MSI2 intron 21572414 rs6503808 chr17 55386638 T C 4.66E-04 Smoking quantity MSI2 intron 24665060 rs2332903 chr17 55398644 G A 4.96E-04 Multiple complex diseases MSI2 intron 17554300 rs12951074 chr17 55401227 C A 5.30E-06 Urinary metabolites MSI2 intron 21572414 rs9890811 chr17 55412461 A G 1.83E-05 Alcohol and nictotine co-dependence MSI2 intron 20158304 rs792379 chr17 55435013 C T 9.62E-04 Multiple complex diseases MSI2 intron 17554300 rs703859 chr17 55437411 C T 5.92E-04 Type 2 diabetes MSI2 intron 17463246 rs12949781 chr17 55437990 G C 2.39E-04 Type 2 diabetes MSI2 intron 17463246 rs792376 chr17 55438556 A G 4.86E-04 Type 2 diabetes MSI2 intron 17463246 rs1982272 chr17 55453351 G A 4.80E-04 Type 2 diabetes MSI2 intron 17463246 rs1982270 chr17 55453609 A C 8.34E-04 Type 2 diabetes MSI2 intron 17463246 rs1982269 chr17 55453675 G A 7.64E-04 Type 2 diabetes MSI2 intron 17463246 rs792364 chr17 55454008 G A 3.83E-04 Multiple complex diseases MSI2 intron 17554300 rs8066677 chr17 55462245 C G 2.00E-06 Urinary metabolites MSI2 intron 21572414 rs9904197 chr17 55477138 C T 4.60E-04 Depression (quantitative trait) MSI2 intron 20800221 rs11871646 chr17 55485466 A G 2.39E-04 Depression (quantitative trait) MSI2 intron 20800221 rs12603207 chr17 55507199 G A 1.46E-05 Schizophrenia(age at onset) MSI2 intron 21688384 rs12949258 chr17 55522685 T G 6.15E-05 IgE levels MSI2 intron 22075330 rs11657292 chr17 55522855 T C 1.00E-04 Schizophrenia MSI2 intron 22037552 rs11657292 chr17 55522855 T C 1.62E-05 IgE levels MSI2 intron 22075330 rs2877824 chr17 55523223 C T 3.16E-05 IgE levels MSI2 intron 22075330 rs920747 chr17 55523434 G A 4.54E-05 IgE levels MSI2 intron 22075330 rs12601123 chr17 55525926 T C 8.49E-05 Alzheimer's disease MSI2 intron 17998437 rs277069 chr17 55557779 T G 3.20E-04 Alzheimer's disease MSI2 intron 17998437 rs16958490 chr17 55559817 C T 5.06E-04 Insulin resistance MSI2 intron 21901158 rs277067 chr17 55565676 A G 6.79E-05 HIV-1 viral setpoint MSI2 intron 22174851 rs8082249 chr17 55582932 G A 3.16E-05 Serum metabolites MSI2 intron 19043545 rs1024819 chr17 55607271 C T 8.48E-05 Serum metabolites MSI2 intron 19043545 rs1024820 chr17 55607591 T C 5.98E-04 Multiple complex diseases MSI2 intron 17554300 rs17761855 chr17 55612447 A G 5.65E-05 Tunica Media MSI2 intron pha003037 rs4793867 chr17 55615576 A C 5.31E-05 Tunica Media MSI2 intron pha003037 rs17834557 chr17 55618697 T C 4.58E-05 Tunica Media MSI2 intron pha003037 rs1861471 chr17 55619498 G A 2.49E-04 Lung function (forced expiratory volume in 1 second) MSI2 intron 24023788 rs1861471 chr17 55619498 G A 2.77E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) MSI2 intron 24023788 rs9912125 chr17 55633468 C T 8.19E-05 Cognitive test performance MSI2 intron 20125193 rs17834633 chr17 55647906 C T 2.30E-05 Urinary metabolites MSI2 intron 21572414 rs12450714 chr17 55676536 G A 3.78E-05 Potassium levels MSI2 intron pha003086 rs8065120 chr17 55738649 G A 2.97E-04 Alzheimer's disease (late onset) MSI2 intron 21379329 rs13341026 chr17 55743710 T A 7.70E-06 Urinary metabolites MSI2 intron 21572414 rs11079321 chr17 55747416 G A 8.00E-06 Coronary artery calcification MSI2 intron 23870195 rs2286359 chr17 55754573 G A 9.32E-05 Coronary heart disease MSI2 intron pha003035 rs4793894 chr17 55764260 T A 5.93E-04 Aortic root size / / 21223598 rs8077599 chr17 55767444 A G 9.12E-05 Multiple complex diseases / / 17554300 rs4793563 chr17 55790675 A T 4.65E-04 Type 2 diabetes / / 17463246 rs2190759 chr17 55794699 T C 2.21E-04 Multiple complex diseases / / 17554300 rs8067261 chr17 55802620 G A 9.90E-06 Urinary metabolites / / 21572414 rs886926 chr17 55817413 C T 8.23E-06 Birth weight / / 17255346 rs12449409 chr17 55822467 G A 2.29E-05 Birth weight / / 17255346 rs8077059 chr17 55823552 C T 5.00E-06 Sex hormone-binding globulin levels / / 22675492 rs12949028 chr17 55825470 A C 8.90E-06 Birth weight / / 17255346 rs12949688 chr17 55825701 A G 2.10E-05 Birth weight / / 17255346 rs9892194 chr17 55825825 A G 2.92E-06 Birth weight / / 17255346 rs9892194 chr17 55825825 A G 1.89E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4793573 chr17 55834533 G A 1.48E-05 Height / / 22021425 rs10083839 chr17 55835623 G A 2.76E-05 Height / / 22021425 rs203265 chr17 55851160 T G 3.89E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs203264 chr17 55851419 T A,C,G 1.84E-04 Birth weight / / 17255346 rs203257 chr17 55854388 T C 2.82E-04 Birth weight / / 17255346 rs10515149 chr17 55856050 C G,T 5.86E-04 Coronary heart disease / / 21606135 rs12938916 chr17 55866287 G A 8.12E-07 Multiple complex diseases / / 17554300 rs12938916 chr17 55866287 G A 5.00E-07 Bipolar disorder / / 21254220 rs9911992 chr17 55917919 T G 9.70E-06 HIV-1 control MRPS23 intron 20041166 rs17835022 chr17 55940770 T C 3.50E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CUEDC1 intron 20877124 rs2304943 chr17 55950300 T C 4.12E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CUEDC1 intron 20877124 rs17762330 chr17 55950363 G A 4.65E-04 Multiple complex diseases CUEDC1 intron 17554300 rs8080016 chr17 55954403 A G 5.27E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CUEDC1 intron 20877124 rs2586046 chr17 55956425 C T 8.91E-04 Body mass index CUEDC1 intron 21701565 rs4793576 chr17 55960648 G T 2.36E-04 Body mass index CUEDC1 intron 21701565 rs4793576 chr17 55960648 G T 6.34E-04 Body mass index CUEDC1 intron 21701565 rs2685506 chr17 55963529 G C 7.51E-04 Body mass index CUEDC1 intron 21701565 rs9913983 chr17 56001319 C T 6.89E-06 White blood cell count / / 21738479 rs16942528 chr17 56005604 G A 1.87E-04 Cholesterol / / 17255346 rs8074980 chr17 56010960 G A 2.00E-06 Multiple sclerosis (brain glutamate levels) / / 20802204 rs10445323 chr17 56102953 A G 4.86E-04 Stroke / / pha002887 rs7207440 chr17 56134453 C T 7.63E-04 Multiple complex diseases / / 17554300 rs2585842 chr17 56142411 C A 3.80E-04 Gallstones / / 17632509 rs11079337 chr17 56162496 C A 5.10E-04 Response to taxane treatment (placlitaxel) DYNLL2 intron 23006423 rs181224 chr17 56191008 A G 2.15E-05 Bone mass and geometry / / 17903296 rs181224 chr17 56191008 A G 5.85E-05 Bilirubin levels,in serum / / 19389676 rs181247 chr17 56207731 A G 3.20E-04 Breast cancer and prostate cancer / / 17903305 rs17740678 chr17 56226845 A T 3.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1075009 chr17 56230863 A G 4.00E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1075009 chr17 56230863 A G 8.54E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs8071251 chr17 56232315 G A 2.18E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs8071251 chr17 56232315 G A 3.67E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2052085 chr17 56242230 C T 5.62E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9904720 chr17 56253587 C A 3.95E-04 Alzheimer's disease / / 24755620 rs3826300 chr17 56290334 T C 1.61E-04 Parkinson's disease MKS1 intron 17052657 rs3744105 chr17 56290556 A G 2.15E-04 Parkinson's disease MKS1 intron 17052657 rs8067912 chr17 56313904 T C 1.00E-06 IgG glycosylation / / 23382691 rs8067912 chr17 56313904 T C 5.00E-07 IgG glycosylation / / 23382691 rs7209537 chr17 56328214 C T 5.00E-04 Tourette syndrome LPO intron 22889924 rs2301870 chr17 56332327 G A 3.78E-04 Tourette syndrome LPO missense 22889924 rs8178375 chr17 56338778 T C 2.87E-05 Major depressive disorder LPO intron 19107115 rs8178375 chr17 56338778 T C 5.13E-04 Tourette syndrome LPO intron 22889924 rs35897051 chr17 56348226 T G 3.32E-08 Circulating myeloperoxidase levels (serum) MPO splice-5 23620142 rs2071409 chr17 56348230 T G 1.31E-05 Major depressive disorder MPO intron 19107115 rs2071409 chr17 56348230 T G 4.13E-04 Tourette syndrome MPO intron 22889924 rs28730837 chr17 56355397 G A 5.21E-12 Circulating myeloperoxidase levels (serum) MPO missense 23620142 rs12452417 chr17 56367202 G A 2.18E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs12940923 chr17 56369849 A T 1.69E-21 Circulating myeloperoxidase levels (plasma) / / 23620142 rs12940923 chr17 56369849 A T 4.00E-09 Circulating myeloperoxidase levels (plasma) / / 23620142 rs12940923 chr17 56369849 A T 8.49E-35 Circulating myeloperoxidase levels (plasma) / / 23620142 rs6503858 chr17 56380471 T C 8.72E-04 Multiple complex diseases BZRAP1 intron 17554300 rs6503858 chr17 56380471 T C 0.000559 fMRI brain tests in schizophrenia BZRAP1 intron 22440650 rs144106922 chr17 56389516 C T 0.000071 Breast cancer BZRAP1 missense 23555315 rs2074630 chr17 56393714 G A 8.26E-04 White matter integrity BZRAP1 intron 22425255 rs2680691 chr17 56405858 T C 2.16E-04 Lung function (forced expiratory volume in 1 second) BZRAP1 UTR-5 17255346 rs1985749 chr17 56417002 A G 7.97E-04 Alzheimer's disease LOC100506779 intron 24755620 rs2014835 chr17 56417287 T C 1.30E-04 Vaspin levels LOC100506779 intron 22907691 rs2014835 chr17 56417287 T C 0.0001296 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit LOC100506779 intron 22907730 rs1859401 chr17 56421706 G A 2.40E-04 Vaspin levels LOC100506779 intron 22907691 rs1859401 chr17 56421706 G A 0.00024 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks LOC100506779 intron 22907730 rs2070107 chr17 56423201 G C 9.60E-06 Urinary metabolites SUPT4H1 UTR-3 21572414 rs13414 chr17 56431453 A G 9.80E-06 Urinary metabolites RNF43 UTR-3 21572414 rs13414 chr17 56431453 A G 7.88E-04 Acute lung injury RNF43 UTR-3 22295056 rs2877877 chr17 56431530 A G 7.88E-04 Acute lung injury RNF43 UTR-3 22295056 rs2680702 chr17 56431549 A G 1.10E-05 Urinary metabolites RNF43 UTR-3 21572414 rs2158460 chr17 56432362 C G 7.88E-04 Acute lung injury RNF43 intron 22295056 rs10515157 chr17 56433448 G A 7.88E-04 Acute lung injury RNF43 intron 22295056 rs2680701 chr17 56438301 G A 4.84E-28 Circulating myeloperoxidase levels (plasma) RNF43 missense 23620142 rs2680701 chr17 56438301 G A 4.98E-10 Circulating myeloperoxidase levels (plasma) RNF43 missense 23620142 rs11079348 chr17 56438624 G T 5.77E-04 Acute lung injury RNF43 intron 22295056 rs2680700 chr17 56440542 G T 5.60E-08 Primary tooth development (number of teeth) RNF43 intron 23704328 rs2680700 chr17 56440542 G T 4.73E-06 Lipoproteins RNF43 intron pha003079 rs2257205 chr17 56448297 C T 8.00E-06 Pancreatic cancer RNF43 missense 20686608 rs113212925 chr17 56450454 C G,T 4.02E-06 Cocaine dependence RNF43 intron 23958962 rs113212925 chr17 56450454 C G,T 6.97E-04 Cocaine dependence RNF43 intron 23958962 rs3785493 chr17 56472119 T G 1.70E-06 Urinary metabolites RNF43 intron 21572414 rs8078280 chr17 56473132 A G 7.70E-06 Urinary metabolites RNF43 intron 21572414 rs9889419 chr17 56473259 T C 3.43E-04 Response to taxane treatment (placlitaxel) RNF43 intron 23006423 rs10515155 chr17 56481944 A G 3.60E-04 Volumetric brain MRI RNF43 intron 17903297 rs10515155 chr17 56481944 A G 3.90E-06 Urinary metabolites RNF43 intron 21572414 rs10515155 chr17 56481944 A G 1.01E-04 Lymphocyte counts RNF43 intron 22286170 rs1476596 chr17 56485358 A G 8.77E-05 Response to taxane treatment (placlitaxel) RNF43 intron 23006423 rs3785492 chr17 56488063 T C 9.14E-04 Suicide attempts in bipolar disorder RNF43 intron 21423239 rs114469297 chr17 56488380 A G 7.07E-04 Cocaine dependence RNF43 intron 23958962 rs3744093 chr17 56492800 T C 2.28E-05 Dental caries RNF43 missense 21940522 rs3744093 chr17 56492800 T C 3.45E-04 Response to taxane treatment (placlitaxel) RNF43 missense 23006423 rs3744093 chr17 56492800 T C 3.84E-05 Anxiety and major depressive disorder RNF43 missense 24047446 rs2429369 chr17 56501420 A G 8.53E-04 Response to taxane treatment (placlitaxel) HSF5 intron 23006423 rs2429369 chr17 56501420 A G 1.40E-07 Primary tooth development (time to first tooth eruption) HSF5 intron 23704328 rs3803753 chr17 56540110 G A 1.21E-04 Suicide attempts in bipolar disorder HSF5 intron 21423239 rs3803752 chr17 56540267 C T 1.37E-04 Suicide attempts in bipolar disorder HSF5 missense 21423239 rs3803752 chr17 56540267 C T 2.93E-04 Dental caries HSF5 missense 21940522 rs114903983 chr17 56560860 T C 1.56E-04 Cocaine dependence HSF5 intron 23958962 rs3087762 chr17 56568680 C T 1.39E-04 Suicide attempts in bipolar disorder MTMR4 UTR-3 21423239 rs12603808 chr17 56578508 T G 1.17E-04 Suicide attempts in bipolar disorder MTMR4 intron 21423239 rs2240719 chr17 56582477 G C 1.18E-04 Suicide attempts in bipolar disorder MTMR4 intron 21423239 rs2302189 chr17 56584205 A C 8.00E-06 Dental caries MTMR4 missense 21940522 rs2302189 chr17 56584205 A C 4.37E-05 Anxiety and major depressive disorder MTMR4 missense 24047446 rs116087723 chr17 56585006 C T 2.92E-04 Cocaine dependence MTMR4 intron 23958962 rs3744108 chr17 56585872 G C 4.69E-04 Response to taxane treatment (placlitaxel) MTMR4 missense 23006423 rs2007993 chr17 56590643 T C 3.24E-04 Suicide attempts in bipolar disorder MTMR4 intron 21423239 rs8182262 chr17 56608401 G T 2.13E-04 Multiple complex diseases SEPT4 intron 17554300 rs4793952 chr17 56608465 C T 1.00E-06 Obesity,menopause SEPT4 intron 21424828 rs4793952 chr17 56608465 C T 2.56E-04 Response to taxane treatment (placlitaxel) SEPT4 intron 23006423 rs17822735 chr17 56620167 C T 2.52E-04 Suicide attempts in bipolar disorder C17orf47 missense 21423239 rs714959 chr17 56628601 T C 3.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs9905704 chr17 56632543 G T 4.00E-13 Testicular germ cell tumor / / 23666239 rs9905704 chr17 56632543 G T 3.00E-09 Testicular germ cell tumor / / 23666240 rs34818467 chr17 56643109 A G 3.19E-04 Suicide attempts in bipolar disorder TEX14 cds-synon 21423239 rs12944693 chr17 56644816 T C 7.62E-04 Acute lung injury TEX14 intron 22295056 rs1267543 chr17 56656624 A G 5.05E-07 Testicular germ cell tumor TEX14 intron 23666239 rs6503870 chr17 56659018 C T 5.43E-06 Dental caries TEX14 missense 21940522 rs8071916 chr17 56660279 A G 9.45E-04 Response to taxane treatment (placlitaxel) TEX14 intron 23006423 rs9907940 chr17 56663842 A G 6.45E-04 Response to taxane treatment (placlitaxel) TEX14 intron 23006423 rs7210432 chr17 56668170 C T 3.27E-04 Suicide attempts in bipolar disorder TEX14 intron 21423239 rs9303399 chr17 56672309 G A 3.90E-04 Suicide attempts in bipolar disorder TEX14 intron 21423239 rs302848 chr17 56686454 G A 4.30E-04 Obesity,menopause TEX14 intron 21424828 rs1864754 chr17 56688789 T G 3.29E-04 Suicide attempts in bipolar disorder TEX14 intron 21423239 rs368243 chr17 56708979 T C 6.86E-06 Dental caries TEX14 intron 21940522 rs412000 chr17 56709058 G C 1.60E-05 Primary tooth development (number of teeth) TEX14 intron 23704328 rs412000 chr17 56709058 G C 2.00E-09 Primary tooth development (time to first tooth eruption) TEX14 intron 23704328 rs1631237 chr17 56734695 A G 5.95E-04 Response to taxane treatment (placlitaxel) TEX14 intron 23006423 rs17822837 chr17 56737838 G A 3.29E-04 Suicide attempts in bipolar disorder TEX14 intron 21423239 rs12946522 chr17 56768103 T G 9.51E-04 Tourette syndrome TEX14 intron 22889924 rs17222691 chr17 56771096 C T 3.67E-04 Suicide attempts in bipolar disorder RAD51C intron 21423239 rs17822908 chr17 56801778 T C 3.86E-04 Suicide attempts in bipolar disorder RAD51C intron 21423239 rs304270 chr17 56802141 C T 7.51E-06 Dental caries RAD51C intron 21940522 rs10515159 chr17 56802693 G C 3.10E-04 Volumetric brain MRI RAD51C intron 17903297 rs10515159 chr17 56802693 G C 4.11E-04 Suicide attempts in bipolar disorder RAD51C intron 21423239 rs8074016 chr17 56840587 A G 3.29E-04 Suicide attempts in bipolar disorder PPM1E intron 21423239 rs9303401 chr17 56847945 C T 5.00E-06 Cognitive test performance PPM1E intron 17903297 rs9303401 chr17 56847945 C T 8.81E-04 Tourette syndrome PPM1E intron 22889924 rs7224276 chr17 56897827 C T 2.82E-04 Suicide attempts in bipolar disorder PPM1E intron 21423239 rs12944948 chr17 56951474 A G 9.49E-04 Response to taxane treatment (placlitaxel) PPM1E intron 23006423 rs9911578 chr17 56953147 C T 7.47E-06 Dental caries PPM1E intron 21940522 rs9911753 chr17 56983174 G A 1.51E-09 Circulating myeloperoxidase levels (plasma) PPM1E intron 23620142 rs9911753 chr17 56983174 G A 1.92E-39 Circulating myeloperoxidase levels (plasma) PPM1E intron 23620142 rs9911753 chr17 56983174 G A 7.43E-07 Circulating myeloperoxidase levels (plasma) PPM1E intron 23620142 rs1588322 chr17 56990099 T C 6.32E-04 Response to taxane treatment (placlitaxel) PPM1E intron 23006423 rs7221274 chr17 57008128 A G 4.04E-09 Testicular germ cell tumor PPM1E intron 23666239 rs8071280 chr17 57010225 T C 9.49E-04 Response to taxane treatment (placlitaxel) PPM1E intron 23006423 rs7207693 chr17 57016525 C T 1.11E-05 Dental caries PPM1E intron 21940522 rs16943326 chr17 57050365 C T 5.23E-04 Suicide attempts in bipolar disorder PPM1E intron 21423239 rs16943326 chr17 57050365 C T 9.76E-04 Tourette syndrome PPM1E intron 22889924 rs16943326 chr17 57050365 C T 4.30E-05 Breast cancer PPM1E intron pha002853 rs12600349 chr17 57054245 C T 7.12E-04 Suicide attempts in bipolar disorder PPM1E intron 21423239 rs3809724 chr17 57061238 G A 8.03E-04 Suicide attempts in bipolar disorder PPM1E UTR-3 21423239 rs3809724 chr17 57061238 G A 9.48E-05 Breast cancer PPM1E UTR-3 pha002853 rs6503890 chr17 57064167 A G 9.16E-04 Response to taxane treatment (placlitaxel) TRIM37 intron 23006423 rs8081967 chr17 57072701 T C 1.67E-14 Circulating myeloperoxidase levels (serum) TRIM37 intron 23620142 rs8081967 chr17 57072701 T C 2.13E-06 Circulating myeloperoxidase levels (serum) TRIM37 intron 23620142 rs2333409 chr17 57139134 G A 7.35E-05 Dental caries TRIM37 intron 21940522 rs7502947 chr17 57229716 G A 1.10E-07 Primary tooth development (time to first tooth eruption) SKA2 intron 23704328 rs9892425 chr17 57241938 G A 9.48E-04 Depression (quantitative trait) PRR11 intron 20800221 rs735023 chr17 57260359 A C 8.78E-04 Acute lung injury PRR11 intron 22295056 rs2291193 chr17 57272079 G A 7.44E-06 Triglycerides PRR11 intron 19074352 rs2291193 chr17 57272079 G A 7.44E-06 Polyunsaturated fatty acid levels,in plasma PRR11 intron 19148276 rs6503905 chr17 57287454 A G 3.00E-12 Circulating myeloperoxidase levels (plasma) SMG8 cds-synon 23620142 rs7224035 chr17 57373098 G A 2.28E-04 Type 2 diabetes / / 17463246 rs6503915 chr17 57384199 A G 0.000559 Salmonella-induced pyroptosis / / 22837397 rs930709 chr17 57422568 G A 7.25E-05 Lung function (forced expiratory volume in 1 second) YPEL2 intron pha003103 rs16943469 chr17 57445176 T A 1.18E-04 Multiple complex diseases YPEL2 intron 17554300 rs2290266 chr17 57466917 A G 3.32E-05 Magnesium levels YPEL2 intron pha003092 rs4968360 chr17 57497792 A G 1.54E-08 Metabolite levels / / 23281178 rs4968361 chr17 57502828 A G 4.09E-04 Lipid levels / / 19016617 rs4968361 chr17 57502828 A G 5.02E-04 Lipid levels / / 19016617 rs764424 chr17 57505604 G A 0.00009415 Sarcoidosis / / 22952805 rs4968363 chr17 57511073 T C 0.0000282 Tuberculosis with late age of onset / / 22551897 rs7207863 chr17 57537775 A G 5.96E-05 Response to hepatitis C treatment / / 19684573 rs7210298 chr17 57541627 A G 1.58E-05 Multiple complex diseases / / 17554300 rs7210298 chr17 57541627 A G 6.05E-05 Coronary heart disease / / pha003032 rs16943620 chr17 57565932 T A 8.10E-06 Urinary metabolites / / 21572414 rs17494053 chr17 57567551 C T 4.62E-05 Triglycerides / / pha003080 rs6503923 chr17 57642075 C T 2.83E-04 Multiple complex diseases / / 17554300 rs9911334 chr17 57752778 G A 5.81E-04 Multiple complex diseases CLTC intron 17554300 rs16943799 chr17 57775463 T C 9.85E-05 Panic disorder PTRH2 intron 19165232 rs9899611 chr17 57832190 A G 5.90E-05 Hypothyroidism VMP1 intron 22493691 rs2777899 chr17 57832391 T G 6.10E-06 Asthma VMP1 intron 20698975 rs11650106 chr17 57850251 C T 3.00E-09 Lipoprotein-associated phospholipase A2 activity and mass VMP1 intron 23118302 rs2665404 chr17 57875396 C T 5.00E-04 Acute lymphoblastic leukemia (childhood) VMP1 intron 20189245 rs2645492 chr17 57875554 G A 8.50E-05 Hypothyroidism VMP1 intron 22493691 rs2063353 chr17 57889192 T G 9.30E-04 Type 2 diabetes and 6 quantitative traits VMP1 intron 17848626 rs1295927 chr17 57929535 A G 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs1292043 chr17 57934169 A G 3.25E-06 Obesity-related traits / / 23251661 rs2645482 chr17 57943115 T G 5.57E-04 Crohn's disease TUBD1 intron 17804789 rs1295923 chr17 57960436 A G 3.62E-06 Obesity-related traits TUBD1 intron 23251661 rs1292053 chr17 57963537 A G 7.11E-04 Crohn's disease TUBD1 missense 17804789 rs1292053 chr17 57963537 A G 5.89E-04 Alzheimer's disease TUBD1 missense 17998437 rs1292053 chr17 57963537 A G 5.00E-04 Acute lymphoblastic leukemia (childhood) TUBD1 missense 20189245 rs1292053 chr17 57963537 A G 9.00E-13 Inflammatory bowel disease TUBD1 missense 23128233 rs1296279 chr17 57965731 G A 6.92E-04 Multiple complex diseases TUBD1 intron 17554300 rs1296279 chr17 57965731 G A 7.10E-05 Coronary heart disease TUBD1 intron 21966275 rs2526354 chr17 57976658 T C 2.56E-04 Multiple complex diseases RPS6KB1 intron 17554300 rs2526354 chr17 57976658 T C 1.01E-04 Arthritis (juvenile idiopathic) RPS6KB1 intron 22354554 rs2531899 chr17 58007193 G A 4.78E-06 Obesity-related traits RPS6KB1 intron 23251661 rs180515 chr17 58024275 A G 9.00E-08 Multiple sclerosis RPS6KB1 UTR-3 21833088 rs1051424 chr17 58024324 A G 3.00E-06 Obesity-related traits RPS6KB1 UTR-3 23251661 rs12600680 chr17 58037374 T C 4.80E-06 Obesity-related traits RNFT1 intron 23251661 rs1024637 chr17 58038893 C T 6.10E-06 Lipid levels RNFT1 intron 18193043 rs4632189 chr17 58048915 A C 2.55E-05 Osteosarcoma / / 23727862 rs237220 chr17 58112377 T C 2.78E-04 Insulin resistance / / 21901158 rs12951337 chr17 58154207 C T 7.29E-04 Multiple complex diseases HEATR6 intron 17554300 rs10515177 chr17 58167485 A G 7.42E-04 Multiple complex diseases / / 17554300 rs2333656 chr17 58184540 T C 3.50E-04 Insulin resistance / / 21901158 rs1843137 chr17 58185636 A T 3.94E-04 Insulin resistance / / 21901158 rs2627907 chr17 58218881 A C 7.54E-05 Cognitive test performance / / 20125193 rs185658468 chr17 58235051 A T 0.00000051 Prostate cancer (advanced) CA4 missense 23555315 rs8071181 chr17 58508582 G A 1.44E-05 Age-related macular degeneration C17orf64 cds-synon pha000001 rs16944359 chr17 58522495 T A 2.61E-04 Multiple complex diseases APPBP2 UTR-3 17554300 rs17500797 chr17 58528705 T C 4.06E-04 Birth weight APPBP2 intron 17255346 rs6503977 chr17 58592033 C T 9.73E-04 Heart Failure APPBP2 intron pha002884 rs16944483 chr17 58604461 A G 5.19E-04 Multiple complex diseases / / 17554300 rs8077600 chr17 58613330 T C 4.03E-04 Coronary heart disease / / 21606135 rs1206599 chr17 58614662 T A 1.05E-04 Multiple complex diseases / / 17554300 rs2643108 chr17 58626244 C T 3.14E-05 Multiple complex diseases / / 17554300 rs931563 chr17 58631572 C G 2.82E-04 Multiple complex diseases / / 17554300 rs1197069 chr17 58634884 G A 3.16E-05 Multiple complex diseases / / 17554300 rs1197062 chr17 58641118 T G 6.38E-04 Coronary heart disease / / 21606135 rs11655927 chr17 58828402 G A 1.26E-05 Height BCAS3 intron 22021425 rs11655927 chr17 58828402 G A 7.47E-04 Response to taxane treatment (placlitaxel) BCAS3 intron 23006423 rs8076615 chr17 58828449 C A,G,T 8.90E-04 Response to taxane treatment (placlitaxel) BCAS3 intron 23006423 rs8077981 chr17 58828624 T C 5.13E-07 Crohn's disease BCAS3 intron 17804789 rs7501556 chr17 58833214 A G 1.47E-05 Height BCAS3 intron 22021425 rs8078216 chr17 58837937 C T 6.67E-04 Response to taxane treatment (placlitaxel) BCAS3 intron 23006423 rs7211703 chr17 58846364 A G 1.53E-05 Height BCAS3 intron 22021425 rs9899338 chr17 58907917 T G 4.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) BCAS3 intron 23648065 rs4456565 chr17 58921974 T C 4.92E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) BCAS3 intron 23648065 rs7224438 chr17 58966538 T C 4.00E-07 Immune reponse to smallpox (secreted IL-2) BCAS3 intron 22610502 rs17594273 chr17 58982593 A G 6.79E-05 Body Mass Index BCAS3 intron pha002896 rs6504006 chr17 58998658 C T 5.14E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) BCAS3 intron 23648065 rs7213603 chr17 59003189 T C 9.79E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) BCAS3 intron 23648065 rs8080784 chr17 59017025 T C 9.79E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) BCAS3 intron 23648065 rs9914370 chr17 59022395 A G 9.79E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) BCAS3 intron 23648065 rs8070812 chr17 59061568 G C 3.99E-04 Multiple complex diseases BCAS3 intron 17554300 rs9652858 chr17 59087808 G A 6.44E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) BCAS3 intron 23648065 rs6504016 chr17 59158243 G A 3.99E-05 Crohn's disease BCAS3 intron 17804789 rs11868441 chr17 59239221 A G 2.00E-09 Renal function-related traits (BUN) BCAS3 intron 22797727 rs4968535 chr17 59245274 T C 4.50E-04 Crohn's disease BCAS3 intron 17684544 rs8068952 chr17 59286644 G C 3.00E-08 Vertical cup-disc ratio BCAS3 intron 20548946 rs1860373 chr17 59288896 G A 3.14E-05 Follicular lymphoma BCAS3 intron 21533074 rs72832584 chr17 59292436 A C 1.00E-11 Alzheimer's disease (cognitive decline) BCAS3 intron 23535033 rs3785864 chr17 59304612 C T 2.33E-05 Platelet counts BCAS3 intron pha003100 rs7223401 chr17 59306037 A G 6.98E-07 Platelet counts BCAS3 intron pha003100 rs17513268 chr17 59323043 A G 7.00E-06 Obesity-related traits BCAS3 intron 23251661 rs7212729 chr17 59323221 G A 6.10E-06 Personality dimensions BCAS3 intron 21173776 rs7212729 chr17 59323221 G A 1.18E-05 Stroke BCAS3 intron pha002887 rs3785862 chr17 59329968 A G 8.00E-06 Personality dimensions BCAS3 intron 21173776 rs3867607 chr17 59339541 T C 6.06E-04 Myopia (pathological) BCAS3 intron 21095009 rs732350 chr17 59340859 A G 9.33E-04 Myopia (pathological) BCAS3 intron 21095009 rs9906465 chr17 59343880 A G 1.08E-04 Type 2 diabetes BCAS3 intron 17463246 rs8082635 chr17 59352163 G A 3.54E-04 Multiple complex diseases BCAS3 intron 17554300 rs8082635 chr17 59352163 G A 1.82E-04 Alzheimer's disease (late onset) BCAS3 intron 21379329 rs4968548 chr17 59359667 G A 6.93E-04 Response to cytadine analogues (cytosine arabinoside) BCAS3 intron 24483146 rs7215706 chr17 59366049 G A 1.64E-04 Alzheimer's disease (late onset) BCAS3 intron 21379329 rs3902107 chr17 59388010 G A 8.62E-04 Response to statin treatment (atorvastatin),change in cholesterol levels BCAS3 intron 20031582 rs3902107 chr17 59388010 G A 5.10E-04 Asperger disorder BCAS3 intron 21182207 rs1034911 chr17 59389420 A G 1.50E-04 Asperger disorder BCAS3 intron 21182207 rs34578071 chr17 59391379 A AT 8.00E-06 Breast cancer BCAS3 intron 23468962 rs3785856 chr17 59391379 A G 8.00E-06 Breast cancer BCAS3 intron 23468962 rs3843245 chr17 59416467 A G 3.37E-04 Multiple complex diseases BCAS3 intron 17554300 rs1990292 chr17 59444758 G A 2.25E-05 Nephrolithiasis BCAS3 intron 22396660 rs11653176 chr17 59447369 T C 2.48E-05 Diabetes Mellitus BCAS3 intron pha003060 rs11650989 chr17 59449636 G A 9.21E-04 Multiple complex diseases BCAS3 intron 17554300 rs11650989 chr17 59449636 G A 5.80E-04 Chronic kidney disease BCAS3 intron 21931561 rs11650989 chr17 59449636 G A 2.48E-08 Urate levels BCAS3 intron 23263486 rs9905274 chr17 59450441 T C 2.81E-05 Nephrolithiasis BCAS3 intron 22396660 rs9905274 chr17 59450441 T C 3.69E-08 Urate levels BCAS3 intron 23263486 rs9895661 chr17 59456589 C T 1.00E-15 Chronic kidney disease BCAS3 intron 20383146 rs9895661 chr17 59456589 C T 4.85E-08 Chronic kidney disease BCAS3 intron 22479191 rs9895661 chr17 59456589 C T 5.00E-11 Renal function-related traits (eGRFcrea) BCAS3 intron 22797727 rs9895661 chr17 59456589 C T 7.00E-11 Renal function-related traits (sCR) BCAS3 intron 22797727 rs9895661 chr17 59456589 C T 1.41E-08 Urate levels BCAS3 intron 23263486 rs2079742 chr17 59465697 T C 1.00E-08 Urate levels BCAS3 intron 23263486 rs11079428 chr17 59466701 T A 1.47E-08 Urate levels BCAS3 intron 23263486 rs2286527 chr17 59471686 A G 1.56E-04 Telomere length LOC645722 intron 24478790 rs8068318 chr17 59483766 C T 3.00E-10 Creatinine levels TBX2 intron 20383145 rs9892365 chr17 59491384 A G 1.40E-17 Height / / 21194676 rs9892365 chr17 59491384 A G 2.20E-06 Height / / 21194676 rs9892365 chr17 59491384 A G 2.90E-13 Height / / 21194676 rs2079795 chr17 59496649 T C 2.90E-06 Height / / 19396169 rs2079795 chr17 59496649 T C 3.00E-06 Height / / 19893584 rs2079795 chr17 59496649 T C 2.00E-24 Height / / 20881960 rs2079795 chr17 59496649 T C 1.00E-18 Height / / 23563607 rs740754 chr17 59496860 T A 3.46E-04 Smoking initiation / / 24665060 rs740753 chr17 59496927 T C 6.59E-04 Smoking initiation / / 24665060 rs757608 chr17 59497277 A G 6.00E-08 Height / / 18391951 rs757608 chr17 59497277 A G 2.89E-06 Height / / 19893584 rs7214760 chr17 59508731 C T 3.12E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3785833 chr17 59538663 C T 3.72E-05 Serum metabolites TBX4 intron 19043545 rs873363 chr17 59545329 C A 7.76E-04 Type 2 diabetes TBX4 intron 17463246 rs873363 chr17 59545329 C A 8.63E-05 Serum metabolites TBX4 intron 19043545 rs744651 chr17 59563248 C T 4.48E-05 Serum metabolites / / 19043545 rs16945325 chr17 59567791 C T 7.06E-05 Cognitive performance / / 19734545 rs10853034 chr17 59584565 T C 1.60E-05 Kawasaki disease / / 22446962 rs11079433 chr17 59584889 G A 3.45E-05 Alcohol consumption / / 23953852 rs12451827 chr17 59600468 G A 4.02E-06 Height / / 22021425 rs17610181 chr17 59667953 G A 8.00E-06 Osteoarthritis (hip) /CA2 STOP-GAIN 23989986 rs2040609 chr17 59694638 T C 6.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1541346 chr17 59694919 C T 2.41E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7222964 chr17 59726936 T C 4.76E-04 Taste perception / / 22132133 rs4986765 chr17 59763465 T C 4.00E-04 Alcohol consumption (maxi-drinks) BRIP1 cds-synon 24277619 rs717962 chr17 59804310 G A 2.10E-04 Type 2 diabetes and 6 quantitative traits BRIP1 intron 17848626 rs9906313 chr17 59855281 T C 4.82E-05 Insulin resistance BRIP1 intron 21901158 rs9904292 chr17 59877984 C T 5.69E-05 Insulin resistance BRIP1 intron 21901158 rs34289250 chr17 59880646 T C 5.70E-13 Ovarian cancer BRIP1 intron 21964575 rs12453935 chr17 59897455 G A 9.00E-06 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) BRIP1 intron 24023788 rs8076727 chr17 59914681 G A 3.99E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) BRIP1 intron 24023788 rs12937080 chr17 59929737 A G 8.30E-09 Ovarian cancer BRIP1 intron 21964575 rs12938171 chr17 59980355 G A 2.10E-12 Ovarian cancer INTS2 intron 21964575 rs12451939 chr17 60047642 A G 7.10E-09 Ovarian cancer MED13 intron 21964575 rs4422036 chr17 60136168 G A 1.65E-04 Parkinson's disease MED13 intron 21044948 rs8081812 chr17 60181783 C T 1.99E-04 Parkinson's disease / / 21044948 rs8081812 chr17 60181783 C T 3.16E-05 Prion diseases / / 22210626 rs4522464 chr17 60199130 T G 3.45E-05 Parkinson's disease / / 21044948 rs12451501 chr17 60247727 A G 2.22E-04 Type 2 diabetes / / 17463246 rs12451501 chr17 60247727 A G 1.40E-05 Lipid levels / / 18193043 rs4968415 chr17 60264240 G T 9.70E-06 Urinary metabolites / / 21572414 rs11654358 chr17 60271972 C A 8.18E-04 Major depressive disorder / / 22472876 rs12936559 chr17 60325222 G A 9.13E-05 Attention deficit hyperactivity disorder / / 22420046 rs1913072 chr17 60383604 C T 4.95E-04 Depression (quantitative trait) / / 20800221 rs1512444 chr17 60389302 C A 9.61E-04 Depression (quantitative trait) / / 20800221 rs12940211 chr17 60410565 A G 8.12E-04 Depression (quantitative trait) / / 20800221 rs2080696 chr17 60411708 T C 8.54E-04 Depression (quantitative trait) / / 20800221 rs12953094 chr17 60413826 A G 6.48E-04 Depression (quantitative trait) / / 20800221 rs9889346 chr17 60421914 G A 7.09E-04 Parkinson's disease / / 16252231 rs954563 chr17 60429710 T C 3.42E-04 Depression (quantitative trait) / / 20800221 rs9895067 chr17 60443830 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9898027 chr17 60498069 C T 1.51E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9899640 chr17 60498807 A G 2.27E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11543000 chr17 60501409 A G 1.89E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines METTL2A intron 21844884 rs2429391 chr17 60740964 G A 1.26E-04 Alzheimer's disease (late onset) MRC2 intron 21379329 rs2460300 chr17 60759347 A G 1.40E-05 Temporomandibular joint disorders MRC2 intron 23746317 rs2460300 chr17 60759347 A G 2.87E-05 Amyotrophic lateral sclerosis (sporadic) MRC2 intron 24529757 rs2429387 chr17 60767015 G A 2.90E-05 Temporomandibular joint disorders MRC2 missense 23746317 rs2251393 chr17 60778932 G A 1.20E-14 Progranulin levels MARCH10 UTR-3 21087763 rs2251393 chr17 60778932 G A 1.20E-14 Myocardial infarction MARCH10 UTR-3 21211798 rs2251393 chr17 60778932 G A 4.00E-07 Sudden cardiac arrest MARCH10 UTR-3 21658281 rs9889540 chr17 60789059 G C 4.52E-05 Depression (quantitative trait) MARCH10 intron 20800221 rs9890213 chr17 60789316 G C 3.66E-04 Depression (quantitative trait) MARCH10 intron 20800221 rs9891713 chr17 60789405 T C 5.17E-04 Depression (quantitative trait) MARCH10 intron 20800221 rs1024653 chr17 60791818 A C 3.57E-04 Type 2 diabetes MARCH10 intron 17463246 rs17683483 chr17 60802483 C A 1.07E-05 Alzheimer's disease (late onset) MARCH10 intron 21379329 rs17683483 chr17 60802483 C A 5.69E-04 Alzheimer's disease MARCH10 intron 24755620 rs17684593 chr17 60841251 C T 7.27E-05 Hypertension MARCH10 intron pha003041 rs9908887 chr17 60904812 A G 7.35E-05 Serum metabolites / / 19043545 rs11868614 chr17 60909196 G A 5.44E-04 Obesity (extreme) / / 21935397 rs11871421 chr17 60913443 C T 5.42E-04 Obesity (extreme) / / 21935397 rs12051594 chr17 60927603 G A 7.72E-04 Obesity (extreme) / / 21935397 rs9892593 chr17 60981969 A G 2.90E-06 Schizophrenia / / 21747397 rs7216013 chr17 60992533 C A 2.67E-04 Obesity (extreme) / / 21935397 rs241062 chr17 61029952 A T 7.63E-04 Alzheimer's disease / / 22005930 rs241059 chr17 61040644 T C 8.26E-04 Alzheimer's disease / / 22005930 rs12150107 chr17 61109044 G A 4.42E-05 Brain structure TANC2 intron 22504417 rs239368 chr17 61129121 C T 4.57E-05 Brain structure TANC2 intron 22504417 rs8071332 chr17 61141953 A G 5.30E-05 Orofacial clefts TANC2 intron 22863734 rs8072580 chr17 61150419 T C 6.46E-25 Narcolepsy TANC2 intron 19629137 rs7210972 chr17 61232478 A G 4.01E-05 Brain structure TANC2 intron 22504417 rs9913027 chr17 61241107 C T 1.78E-05 Brain structure TANC2 intron 22504417 rs12150068 chr17 61351398 A G 4.63E-04 Smoking initiation TANC2 intron 24665060 rs2907465 chr17 61384439 G A 4.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TANC2 intron 20877124 rs2429427 chr17 61393816 G A 5.98E-05 Serum metabolites TANC2 intron 19043545 rs2429427 chr17 61393816 G A 2.75E-05 Blood pressure (response to calcium channel blocker) TANC2 intron 24192120 rs2429431 chr17 61411538 C G 4.49E-04 Alzheimer's disease TANC2 intron 22005930 rs17760362 chr17 61418667 T A 1.56E-05 Longevity (85 years and older) TANC2 intron 24688116 rs3809721 chr17 61431754 G T 7.61E-04 Alzheimer's disease TANC2 intron 22005930 rs4968765 chr17 61432774 A G 7.20E-04 Alzheimer's disease TANC2 intron 22005930 rs4968767 chr17 61443944 C A 3.26E-04 Alzheimer's disease TANC2 intron 22005930 rs4968767 chr17 61443944 C A 3.59E-05 Brain structure TANC2 intron 22504417 rs9902439 chr17 61445365 T A 9.63E-06 Kawasaki disease TANC2 intron 21221998 rs9902439 chr17 61445365 T A 2.63E-04 Alzheimer's disease TANC2 intron 22005930 rs4968768 chr17 61445920 A G 7.00E-04 Alzheimer's disease TANC2 intron 22005930 rs8078255 chr17 61447321 C T 2.63E-04 Alzheimer's disease TANC2 intron 22005930 rs8065950 chr17 61457217 G C 7.19E-04 Alzheimer's disease TANC2 intron 22005930 rs1029764 chr17 61459067 C A 2.62E-04 Alzheimer's disease TANC2 intron 22005930 rs1029765 chr17 61459284 A G 3.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TANC2 intron 20877124 rs1029765 chr17 61459284 A G 2.75E-05 Blood pressure (response to calcium channel blocker) TANC2 intron 24192120 rs9893857 chr17 61463748 G T 7.07E-04 Alzheimer's disease TANC2 intron 22005930 rs7219930 chr17 61464730 T C 2.56E-04 Alzheimer's disease TANC2 intron 22005930 rs4968644 chr17 61468052 G C 7.00E-04 Alzheimer's disease TANC2 intron 22005930 rs2270133 chr17 61473325 C A 2.79E-06 Kawasaki disease TANC2 intron 21221998 rs2270133 chr17 61473325 C A 2.44E-04 Alzheimer's disease TANC2 intron 22005930 rs4968772 chr17 61481619 A G 3.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TANC2 intron 20877124 rs7224147 chr17 61488308 G T 5.19E-04 Alzheimer's disease TANC2 intron 22005930 rs3760257 chr17 61496471 C T 7.92E-05 Taste perception TANC2 intron 22132133 rs3087776 chr17 61510278 C T 4.11E-05 Brain structure CYB561 UTR-3 22504417 rs4968777 chr17 61530211 T C 4.58E-05 Brain structure / / 22504417 rs9896864 chr17 61536308 A G 4.32E-05 Multiple complex diseases / / 17554300 rs28730839 chr17 61560501 C G 2.82E-09 LDL cholesterol ACE missense 23063622 rs4311 chr17 61560763 T C 2.45E-04 Smoking quantity ACE intron 24665060 rs4329 chr17 61563458 A G 8.00E-20 Metabolic traits ACE intron 21886157 rs1799752 chr17 61565890 T TATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC 1 Drug response to Sildenafil (Viagra) ACE intron 12837457 rs4343 chr17 61566031 G A 3.00E-25 Angiotensin-converting enzyme activity ACE cds-synon 20066004 rs4343 chr17 61566031 G A 4.50E-06 Asthma ACE cds-synon 23181788 rs4343 chr17 61566031 G A 1.00E-18 Metabolite levels ACE cds-synon 24625756 rs4343 chr17 61566031 G A 8.00E-14 Metabolite levels ACE cds-synon 24625756 rs4343 chr17 61566031 G A 9.00E-25 Metabolite levels ACE cds-synon 24625756 rs4343 chr17 61566031 G A 1.00E-37 Blood metabolite ratios ACE cds-synon 24816252 rs4351 chr17 61569732 G A 4.76E-04 Gallstones ACE intron 17632509 rs4351 chr17 61569732 G A 9.00E-13 Metabolite levels ACE intron 23281178 rs4351 chr17 61569732 G A 1.00E-14 Blood metabolite levels ACE intron 24816252 rs4351 chr17 61569732 G A 1.00E-19 Blood metabolite levels ACE intron 24816252 rs4351 chr17 61569732 G A 3.00E-17 Blood metabolite levels ACE intron 24816252 rs4351 chr17 61569732 G A 4.00E-22 Blood metabolite levels ACE intron 24816252 rs4362 chr17 61573761 T C 1.00E-21 Blood metabolite levels ACE cds-synon 24816252 rs4459610 chr17 61584720 A T 8.01E-04 Glycosylated haemoglobin levels / / 17255346 rs8066114 chr17 61589840 C G 8.54E-04 Coronary Artery Disease / / 17634449 rs4968656 chr17 61616959 A G 4.07E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) KCNH6 intron 23648065 rs4968656 chr17 61616959 A G 1.07E-04 Telomere length KCNH6 intron 24478790 rs12949197 chr17 61619379 C T 4.07E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) KCNH6 intron 23648065 rs12949197 chr17 61619379 C T 1.79E-04 Telomere length KCNH6 intron 24478790 rs12601211 chr17 61637421 G A 3.86E-04 Telomere length DCAF7 intron 24478790 rs7209435 chr17 61712964 T C 7.00E-07 Height MAP3K3 intron 18391951 rs9903897 chr17 61716705 T A 2.50E-09 Height MAP3K3 intron 21998595 rs8081612 chr17 61724695 C T 1.30E-22 Height MAP3K3 intron 21194676 rs8081612 chr17 61724695 C T 1.60E-12 Height MAP3K3 intron 21194676 rs8081612 chr17 61724695 C T 2.60E-09 Height MAP3K3 intron 21194676 rs8081612 chr17 61724695 C T 3.74E-05 Height MAP3K3 intron 22021425 rs8075273 chr17 61728881 C A 6.32E-05 Lymphocyte counts MAP3K3 intron 22286170 rs11658329 chr17 61763031 G C 6.00E-10 Height MAP3K3 intron 21998595 rs11658329 chr17 61763031 G C 5.00E-10 Height MAP3K3 intron 22021425 rs9901507 chr17 61765524 G A 6.50E-05 Amyotrophic lateral sclerosis (sporadic) MAP3K3 intron 24529757 rs15637 chr17 61772050 C G 1.10E-09 Height MAP3K3 UTR-3 21998595 rs4968661 chr17 61796306 T C 9.15E-05 Hypertension STRADA intron 19609347 rs6504177 chr17 61812655 G A 8.65E-04 Multiple complex diseases STRADA intron 17554300 rs16947073 chr17 61833318 G A 5.40E-05 Triglycerides CCDC47 intron 19074352 rs11654841 chr17 61838259 G A 8.99E-04 Multiple complex diseases CCDC47 intron 17554300 rs2044125 chr17 61863184 G T 8.31E-04 Multiple complex diseases DDX42 intron 17554300 rs2044125 chr17 61863184 G T 8.50E-05 Hypertension DDX42 intron 19609347 rs115348708 chr17 61897716 C G 0.000017 Breast cancer(er negative) FTSJ3 missense 23555315 rs2584624 chr17 61904546 A G 2.73E-05 Cognitive test performance FTSJ3 UTR-5 20125193 rs2584624 chr17 61904546 A G 9.46E-04 White matter integrity FTSJ3 UTR-5 22425255 rs2665833 chr17 61906846 T C 7.46E-05 Cognitive test performance PSMC5 intron 20125193 rs2665833 chr17 61906846 T C 9.46E-04 White matter integrity PSMC5 intron 22425255 rs968719 chr17 61908271 C T 7.32E-04 Multiple complex diseases PSMC5 cds-synon 17554300 rs968719 chr17 61908271 C T 9.25E-05 Hypertension PSMC5 cds-synon 19609347 rs6919 chr17 61909485 T A 5.32E-05 Hypertension SMARCD2 UTR-3 19609347 rs2584622 chr17 61910167 G A 7.92E-05 Major depressive disorder SMARCD2 UTR-3 21621269 rs2665831 chr17 61912392 C T 7.30E-04 Multiple complex diseases SMARCD2 intron 17554300 rs2665831 chr17 61912392 C T 6.46E-05 Hypertension SMARCD2 intron 19609347 rs2665797 chr17 61922485 G C 8.88E-04 Multiple complex diseases / / 17554300 rs2665797 chr17 61922485 G C 1.73E-05 Hypertension / / 19609347 rs2665795 chr17 61925272 C T 6.62E-05 Hypertension / / 19609347 rs2727330 chr17 61925498 G A 4.37E-05 Hypertension / / 19609347 rs2584608 chr17 61936710 T C 9.11E-04 Multiple complex diseases / / 17554300 rs2584608 chr17 61936710 T C 4.38E-05 Hypertension / / 19609347 rs2854214 chr17 61945449 G C 4.23E-05 Hypertension / / 19609347 rs2665850 chr17 61954112 T C 5.44E-05 Hypertension / / 19609347 rs2008018 chr17 61954471 G A 5.95E-05 Serum metabolites / / 19043545 rs2665838 chr17 61966465 C G 5.00E-25 Height / / 20881960 rs2665808 chr17 61970009 T C 3.39E-04 Multiple complex diseases / / 17554300 rs2854160 chr17 61977248 T C 5.00E-08 Height / / 21998595 rs2941551 chr17 61978548 A G 3.00E-14 Height / / 23563607 rs12450683 chr17 61984299 C G 1.01E-04 Multiple complex diseases / / 17554300 rs2854152 chr17 61986027 A G 4.20E-07 Height / / 21998595 rs2665846 chr17 61988923 C A,G,T 1.94E-04 Multiple complex diseases / / 17554300 rs2001344 chr17 61996007 C G 0.00000104 Triglycerides GH1 intron 23063622 rs7921 chr17 62006259 G A 1.40E-09 Height CD79B UTR-3 21194676 rs7921 chr17 62006259 G A 3.00E-21 Height CD79B UTR-3 21194676 rs7921 chr17 62006259 G A 3.40E-12 Height CD79B UTR-3 21194676 rs2070776 chr17 62007498 A G 9.00E-09 Height CD79B cds-synon 20881960 rs2227906 chr17 62018164 A C 1.16E-06 Age-related macular degeneration SCN4A cds-synon pha000001 rs2070720 chr17 62018773 T C 3.88E-04 Alzheimer's disease SCN4A cds-synon 17998437 rs6504191 chr17 62041068 T C 2.78E-04 Alzheimer's disease SCN4A missense 22005930 rs917557 chr17 62041558 G T 3.54E-04 Alzheimer's disease SCN4A intron 22005930 rs2877373 chr17 62042078 T C 2.00E-04 Alzheimer's disease SCN4A intron 22005930 rs9891362 chr17 62042705 G A 2.21E-04 Alzheimer's disease SCN4A intron 22005930 rs11079516 chr17 62042841 A G 9.60E-04 Alzheimer's disease SCN4A intron 22005930 rs2009051 chr17 62043357 C G,T 2.20E-04 Alzheimer's disease SCN4A intron 22005930 rs4968677 chr17 62044195 T C 2.30E-04 Alzheimer's disease SCN4A intron 22005930 rs4968678 chr17 62044208 A G 7.99E-04 Alzheimer's disease SCN4A intron 22005930 rs4968678 chr17 62044208 A G 6.35E-08 Schizophrenia SCN4A intron 22440650 rs758517 chr17 62044567 T C 2.34E-04 Alzheimer's disease SCN4A intron 22005930 rs9907593 chr17 62072637 G C 4.43E-05 Serum metabolites / / 19043545 rs2021746 chr17 62133488 T A 1.38E-04 Coronary Artery Disease ERN1 intron 17634449 rs196933 chr17 62134056 G A 4.68E-04 Smoking initiation ERN1 intron 24665060 rs16947438 chr17 62146498 G T 9.37E-04 Multiple complex diseases ERN1 intron 17554300 rs16947446 chr17 62146804 G A 6.82E-04 Multiple complex diseases ERN1 intron 17554300 rs8076809 chr17 62181308 A C 6.62E-04 Stroke ERN1 intron pha002887 rs1874087 chr17 62185764 C T 5.97E-04 Alzheimer's disease ERN1 intron 22005930 rs2291676 chr17 62204629 A T 1.40E-06 Urinary metabolites ERN1 intron 21572414 rs8069038 chr17 62211164 A G 1.66E-05 Rheumatoid arthritis / / 17804836 rs923912 chr17 62242678 A G 3.63E-04 Multiple complex diseases TEX2 intron 17554300 rs9890520 chr17 62246959 G A 3.40E-04 Multiple complex diseases TEX2 intron 17554300 rs903285 chr17 62251795 A G 4.62E-04 Multiple complex diseases TEX2 intron 17554300 rs9896542 chr17 62259376 A G 8.09E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) TEX2 intron 23648065 rs9896542 chr17 62259376 A G 6.04E-04 Response to cytadine analogues (cytosine arabinoside) TEX2 intron 24483146 rs9913400 chr17 62261122 T C 5.91E-04 Response to cytadine analogues (cytosine arabinoside) TEX2 intron 24483146 rs4968701 chr17 62266253 C T 2.03E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) TEX2 intron 23648065 rs1010940 chr17 62268147 A G 4.93E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) TEX2 intron 23648065 rs11079531 chr17 62268535 G A 4.93E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) TEX2 intron 23648065 rs1880590 chr17 62289347 C T 1.72E-04 Telomere length TEX2 intron 24478790 rs9915054 chr17 62317999 A G 4.93E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) TEX2 intron 23648065 rs7359586 chr17 62354992 C T 1.20E-04 Telomere length / / 24478790 rs4968712 chr17 62356108 A T 7.34E-04 Multiple complex diseases / / 17554300 rs17564034 chr17 62358301 T G 6.40E-05 Telomere length / / 24478790 rs1122800 chr17 62391365 C G 8.13E-04 Insulin resistance / / 21901158 rs2070783 chr17 62406971 A G 0.0000011 Coronary artery disease PECAM1 intron 23202125 rs5005692 chr17 62407139 C T 3.53E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) PECAM1 intron 24023788 rs6504218 chr17 62408299 A G 1.00E-06 Coronary heart disease PECAM1 intron 21378988 rs8068311 chr17 62468927 T C 4.43E-07 Height / / 22021425 rs61733782 chr17 62476429 G A 4.74E-04 Telomere length POLG2 cds-synon 24478790 rs3744409 chr17 62492413 A G 5.39E-07 Height POLG2 intron 22021425 rs1427463 chr17 62492582 C T 5.41E-07 Height POLG2 missense 22021425 rs9905016 chr17 62493343 T C 8.22E-07 Height POLG2 nearGene-5 22021425 rs2075552 chr17 62500753 C T 1.07E-06 Height DDX5 intron 22021425 rs6504237 chr17 62501006 C T 1.02E-06 Height DDX5 intron 22021425 rs16947824 chr17 62501505 G A 1.43E-05 Alcohol and nictotine co-dependence DDX5 intron 20158304 rs16947824 chr17 62501505 G A 7.93E-06 Alcohol and nictotine co-dependence DDX5 intron 20158304 rs16947824 chr17 62501505 G A 2.20E-04 Telomere length DDX5 intron 24478790 rs375616822 chr17 62506280 T TC 3.00E-06 PR interval in Tripanosoma cruzi seropositivity CEP95 intron 24324551 rs57166100 chr17 62506280 T C 3.00E-06 PR interval in Tripanosoma cruzi seropositivity CEP95 intron 24324551 rs16947838 chr17 62509960 A G 1.39E-04 Telomere length CEP95 intron 24478790 rs9906228 chr17 62510182 C T 4.62E-04 Telomere length CEP95 intron 24478790 rs78267724 chr17 62512279 C T 1.06E-04 Telomere length CEP95 intron 24478790 rs77203371 chr17 62515094 C T 9.80E-05 Telomere length CEP95 intron 24478790 rs16947846 chr17 62516241 T G 1.44E-04 Telomere length CEP95 intron 24478790 rs9897203 chr17 62530143 G A 0.0002 Migraine CEP95 intron 22678113 rs111573840 chr17 62543431 T C 8.70E-05 Telomere length SMURF2 intron 24478790 rs74375784 chr17 62545042 C T 8.70E-05 Telomere length SMURF2 intron 24478790 rs76097728 chr17 62547526 A G 8.90E-05 Telomere length SMURF2 intron 24478790 rs16947868 chr17 62549265 T C 2.87E-04 Telomere length SMURF2 intron 24478790 rs77582577 chr17 62556420 T G 7.40E-05 Telomere length SMURF2 intron 24478790 rs8070258 chr17 62574813 T C 9.20E-05 Telomere length SMURF2 intron 24478790 rs17401012 chr17 62592059 C A 8.70E-05 Telomere length SMURF2 intron 24478790 rs8074368 chr17 62596796 T C 0.0002 Migraine SMURF2 intron 22678113 rs111854052 chr17 62600935 A T 9.00E-06 Periodontitis (Mean PAL) SMURF2 intron 24024966 rs80319692 chr17 62635137 C A 1.80E-04 Telomere length SMURF2 intron 24478790 rs74575465 chr17 62645212 T C 8.90E-05 Telomere length SMURF2 intron 24478790 rs78148049 chr17 62651290 C T 4.60E-05 Telomere length SMURF2 intron 24478790 rs9908143 chr17 62754586 T C 5.04E-05 Orofacial clefts LOC146880 intron 20023658 rs9908143 chr17 62754586 T C 5.07E-05 Orofacial clefts LOC146880 intron 22863734 rs2007530 chr17 62764047 C T 2.67E-05 Orofacial clefts LOC146880 intron 20023658 rs2007530 chr17 62764047 C T 4.46E-06 Orofacial clefts LOC146880 intron 22863734 rs1808191 chr17 62784028 A C 2.81E-05 Orofacial clefts PLEKHM1P intron 20023658 rs1808191 chr17 62784028 A C 4.56E-06 Orofacial clefts PLEKHM1P intron 22863734 rs6504266 chr17 62968339 A G 1.40E-05 White matter hyperintensity burden AMZ2P1 intron 21681796 rs7212449 chr17 62973023 C T 2.30E-05 White matter hyperintensity burden / / 21681796 rs17685439 chr17 62981333 A C 5.60E-05 White matter hyperintensity burden / / 21681796 rs4791250 chr17 62983145 T G 5.70E-05 White matter hyperintensity burden / / 21681796 rs2044178 chr17 62985837 A G 4.90E-05 White matter hyperintensity burden / / 21681796 rs12938589 chr17 62986362 A C 5.00E-05 White matter hyperintensity burden / / 21681796 rs11652805 chr17 62987151 C T 1.46E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11652805 chr17 62987151 C T 3.29E-04 Stroke / / pha002887 rs12953318 chr17 62990240 A G 4.50E-05 White matter hyperintensity burden / / 21681796 rs9910274 chr17 62990757 G A 4.50E-05 White matter hyperintensity burden / / 21681796 rs4791246 chr17 62993996 C T 3.30E-05 White matter hyperintensity burden / / 21681796 rs10853057 chr17 62998023 C T 1.50E-05 White matter hyperintensity burden / / 21681796 rs10853057 chr17 62998023 C T 3.00E-10 White matter microstructure (global fractional anisotropy) / / 24736177 rs7501452 chr17 63001552 T C 4.90E-05 White matter hyperintensity burden / / 21681796 rs4239089 chr17 63001982 T C 5.40E-05 White matter hyperintensity burden / / 21681796 rs12939956 chr17 63002382 C T 5.30E-05 White matter hyperintensity burden / / 21681796 rs3972219 chr17 63018533 A G 7.11E-06 Asthma G/13 intron 19910028 rs12944877 chr17 63035254 G A 5.80E-05 White matter hyperintensity burden G/13 intron 21681796 rs7207420 chr17 63036590 T C 8.36E-04 Multiple complex diseases G/13 intron 17554300 rs2011307 chr17 63039997 C T 6.20E-05 White matter hyperintensity burden G/13 intron 21681796 rs6504271 chr17 63045737 C T 6.80E-05 White matter hyperintensity burden G/13 intron 21681796 rs11656396 chr17 63046076 T C 9.40E-05 White matter hyperintensity burden G/13 intron 21681796 rs8076716 chr17 63048009 T C 7.30E-05 White matter hyperintensity burden G/13 intron 21681796 rs1838080 chr17 63056780 A G 1.10E-05 White matter hyperintensity burden / / 21681796 rs4791242 chr17 63057651 T C 1.00E-05 White matter hyperintensity burden / / 21681796 rs16959655 chr17 63083938 T C 4.37E-05 Alzheimer's disease (age of onset) / / 22005931 rs16959655 chr17 63083938 T C 5.53E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1808918 chr17 63099682 C T 3.47E-06 Waist Circumference LOC100507002 intron pha003023 rs1808918 chr17 63099682 C T 3.35E-05 Leukocyte Counts LOC100507002 intron pha003091 rs413223 chr17 63103057 C T 1.01E-05 Personality dimensions LOC100507002 intron 22628180 rs444394 chr17 63106571 C A 1.80E-05 Urinary metabolites LOC100507002 intron 21572414 rs299826 chr17 63108458 G A 8.01E-05 Waist Circumference / / pha003023 rs11869786 chr17 63111452 A G 9.43E-05 Waist Circumference / / pha003023 rs12603232 chr17 63155764 C T 3.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RGS9 intron 20877124 rs8070837 chr17 63238699 A G 6.24E-04 Multiple complex diseases / / 17554300 rs8076584 chr17 63253687 T C 4.29E-26 Narcolepsy / / 19629137 rs17763241 chr17 63257153 C T 3.15E-04 Hearing function / / 17255346 rs9903077 chr17 63264391 G A 3.96E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7208337 chr17 63288648 T C 5.46E-06 Gallstones / / 17632509 rs740856 chr17 63297121 C T 4.39E-06 White blood cell count / / 21738479 rs17763899 chr17 63301537 A G 3.02E-04 Hearing function / / 17255346 rs9910773 chr17 63302475 A G 2.52E-04 Hearing function / / 17255346 rs9904001 chr17 63309198 A G 5.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8069306 chr17 63311048 C T 2.45E-04 Insulin resistance / / 21901158 rs2869832 chr17 63323581 T C 7.90E-04 Myocardial Infarction / / pha002883 rs7225315 chr17 63351440 G A 0.000593 Salmonella-induced pyroptosis / / 22837397 rs16962156 chr17 63363117 C T 2.47E-04 Type 2 diabetes / / 17463246 rs7226054 chr17 63380264 T C 1.80E-06 Urinary metabolites / / 21572414 rs6504303 chr17 63393207 C T 4.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6504303 chr17 63393207 C T 1.47E-05 Magnesium levels / / pha003092 rs9893772 chr17 63408152 C T 9.10E-06 Urinary metabolites / / 21572414 rs41462445 chr17 63410815 G C 9.10E-06 Urinary metabolites / / 21572414 rs4630583 chr17 63411857 C T 1.00E-05 Urinary metabolites / / 21572414 rs887489 chr17 63412511 T C 1.40E-05 Urinary metabolites / / 21572414 rs2041396 chr17 63420016 C T 1.50E-05 Urinary metabolites / / 21572414 rs7222705 chr17 63434189 C A 1.68E-05 Stroke / / pha002887 rs9912807 chr17 63486180 C G 4.17E-04 Sarcoidosis / / 19165924 rs12451970 chr17 63495754 G T 7.04E-05 Iron levels / / 19880490 rs12451970 chr17 63495754 G T 7.04E-05 Iron levels / / pha002876 rs6416942 chr17 63505670 G A 1.01E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3923086 chr17 63549488 A C 1.66E-04 Renal cell carcinoma AXIN2 intron 22010048 rs757558 chr17 63561592 G T 2.59E-05 Coronary heart disease / / 21606135 rs7215016 chr17 63570303 C A 3.60E-04 Age-related macular degeneration / / 22125219 rs8072268 chr17 63601772 C G 3.58E-04 Type 2 diabetes / / 17463246 rs7221315 chr17 63610319 C A 2.85E-04 Type 2 diabetes / / 17463246 rs4791150 chr17 63631310 T C 7.20E-06 Urinary metabolites / / 21572414 rs2107654 chr17 63633073 T C 1.80E-06 Endometriosis CEP112 intron 21151130 rs7222221 chr17 63634368 G A 6.40E-05 Personality dimensions CEP112 intron 18957941 rs8068462 chr17 63639892 C A 8.60E-05 Personality dimensions CEP112 intron 18957941 rs2079301 chr17 63641770 T C 1.50E-05 Personality dimensions CEP112 intron 18957941 rs8074751 chr17 63642542 G A 1.00E-06 Attention deficit hyperactivity disorder CEP112 intron 20732626 rs9899991 chr17 63644331 C T 4.70E-05 Personality dimensions CEP112 intron 18957941 rs9899991 chr17 63644331 C T 6.00E-06 Urinary metabolites CEP112 intron 21572414 rs1034764 chr17 63726773 C T 6.69E-05 Prostate cancer CEP112 intron 22923026 rs181929163 chr17 63740545 T C 1.57E-08 Alpha-2 globulin (%) CEP112 intron 23696881 rs11653120 chr17 63790224 C T 6.13E-04 Smoking quantity CEP112 intron 24665060 rs9894277 chr17 63856501 T G 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CEP112 intron 22628534 rs9910009 chr17 63859144 G T 8.60E-07 Urinary metabolites CEP112 intron 21572414 rs6504367 chr17 63867881 T C 7.40E-07 Urinary metabolites CEP112 intron 21572414 rs2024272 chr17 63869115 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CEP112 intron 22628534 rs2024272 chr17 63869115 C T 1.64E-04 Myocardial Infarction CEP112 intron pha002883 rs10512507 chr17 63870376 T C 9.55E-04 Parkinson's disease CEP112 intron 16252231 rs1420803 chr17 63888906 T C 0.0000451 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CEP112 intron 22628534 rs2241008 chr17 63898157 C T 8.86E-05 Cognitive test performance CEP112 intron 20125193 rs997652 chr17 63914365 G T 3.22E-05 Cardiovascular disease CEP112 intron 17903304 rs997651 chr17 63914383 G A 2.28E-05 Cardiovascular disease CEP112 intron 17903304 rs8069984 chr17 63950126 C T 2.70E-05 Urinary metabolites CEP112 intron 21572414 rs11870588 chr17 63976774 T A 2.70E-05 Urinary metabolites CEP112 intron 21572414 rs7219574 chr17 63990157 G A 5.50E-06 Urinary metabolites CEP112 intron 21572414 rs1443285 chr17 64018137 G A 6.60E-06 Urinary metabolites CEP112 intron 21572414 rs9912085 chr17 64022699 A T 6.10E-06 Urinary metabolites CEP112 intron 21572414 rs6504392 chr17 64031719 C T 7.50E-06 Urinary metabolites CEP112 intron 21572414 rs6504393 chr17 64031773 G T 6.60E-06 Urinary metabolites CEP112 intron 21572414 rs1443290 chr17 64032308 A G 6.60E-06 Urinary metabolites CEP112 intron 21572414 rs1443291 chr17 64032552 C T 0.00000224 alzheimer's disease (late onset) CEP112 intron 22785395 rs8081876 chr17 64048670 T C 3.47E-04 Multiple complex diseases CEP112 intron 17554300 rs2319125 chr17 64098545 T C 1.00E-06 beta2-Glycoprotein I (beta2-GPI) plasma levels CEP112 intron 23279374 rs7209395 chr17 64133726 T C 3.00E-06 Weight CEP112 intron 19851299 rs7209395 chr17 64133726 T C 7.00E-07 beta2-Glycoprotein I (beta2-GPI) plasma levels CEP112 intron 23279374 rs2159556 chr17 64158655 C T 1.35E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CEP112 intron 20031582 rs16958921 chr17 64172189 G A 1.79E-22 Narcolepsy CEP112 intron 19629137 rs7225197 chr17 64197259 A G 8.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11651658 chr17 64198640 T C 1.49E-04 Smoking initiation / / 24665060 rs8178944 chr17 64209378 C T 0.00000207 Cholesterol,total APOH intron 23063622 rs8178944 chr17 64209378 C T 8.28E-12 LDL cholesterol APOH intron 23063622 rs1801689 chr17 64210580 A C 0.00000492 Cholesterol,total APOH missense 23063622 rs1801689 chr17 64210580 A C 9.41E-14 LDL cholesterol APOH missense 23063622 rs1801689 chr17 64210580 A C 0.000000305 LDL cholesterol APOH missense 23236364 rs1801689 chr17 64210580 A C 1.00E-11 LDL cholesterol APOH missense 24097068 rs8178855 chr17 64214104 A C 1.46E-04 Myopia (pathological) APOH intron 21095009 rs8178926 chr17 64216591 C T 0.00000206 Cholesterol,total APOH intron 23063622 rs8178926 chr17 64216591 C T 8.21E-12 LDL cholesterol APOH intron 23063622 rs1801692 chr17 64222164 C T 1.58E-04 Blood pressure measurement (high sodium and potassium intervention) APOH missense 24165912 rs1801692 chr17 64222164 C T 4.10E-07 Blood pressure measurement (high sodium and potassium intervention) APOH missense 24165912 rs1801692 chr17 64222164 C T 5.76E-07 Blood pressure measurement (high sodium and potassium intervention) APOH missense 24165912 rs7213041 chr17 64224616 C T 5.03E-04 Smoking initiation APOH intron 24665060 rs11867410 chr17 64227363 T C 3.00E-07 Blood pressure measurement (high sodium and potassium intervention) APOH nearGene-5 24165912 rs11867410 chr17 64227363 T C 3.00E-07 Blood pressure measurement (high sodium and potassium intervention) APOH nearGene-5 24165912 rs11867410 chr17 64227363 T C 8.41E-05 Blood pressure measurement (high sodium and potassium intervention) APOH nearGene-5 24165912 rs76773033 chr17 64234461 G A,C 0.0000924 Carotid intima media thickness / / 23152477 rs10048158 chr17 64236318 T C 1.00E-06 beta2-Glycoprotein I (beta2-GPI) plasma levels / / 23279374 rs4791075 chr17 64238065 G A 2.80E-04 Myopia (pathological) / / 21095009 rs9910778 chr17 64261974 T G 1.86E-05 C-Reactive Protein / / pha003070 rs11658474 chr17 64281458 C T 3.59E-05 C-Reactive Protein / / pha003070 rs8081614 chr17 64284384 T G 9.30E-05 Alcohol dependence / / 22096494 rs11867898 chr17 64295321 A G 2.12E-05 C-Reactive Protein / / pha003070 rs9912468 chr17 64318357 G C 1.00E-08 Ventricular conduction PRKCA intron 21076409 rs17634425 chr17 64384076 A G 1.45E-04 Pancreatic cancer PRKCA intron pha002874 rs4417581 chr17 64400808 T G 2.54E-05 Cortisol secretion,in saliva PRKCA intron 21316860 rs4790911 chr17 64410915 T C 8.27E-05 Meningococcal disease PRKCA intron 20694013 rs4790911 chr17 64410915 T C 1.80E-05 Cortisol secretion,in saliva PRKCA intron 21316860 rs16959238 chr17 64419349 G A 6.54E-04 Amyotrophic Lateral Sclerosis PRKCA intron 17362836 rs16959238 chr17 64419349 G A 6.00E-04 Acute lymphoblastic leukemia (childhood) PRKCA intron 20189245 rs16959238 chr17 64419349 G A 6.51E-05 Biliary atresia PRKCA intron 20460270 rs973753 chr17 64428682 C T 4.73E-05 Alcohol dependence PRKCA intron 20201924 rs973753 chr17 64428682 C T 1.42E-05 Cortisol secretion,in saliva PRKCA intron 21316860 rs973753 chr17 64428682 C T 4.73E-05 Alcoholism PRKCA intron pha002891 rs7405806 chr17 64431594 C A 6.67E-04 Parkinson's disease PRKCA intron 17052657 rs7405806 chr17 64431594 C A 5.87E-04 Amyotrophic Lateral Sclerosis PRKCA intron 17362836 rs11079657 chr17 64432066 A G 5.72E-04 Alcohol dependence PRKCA intron 20201924 rs7207499 chr17 64447165 G A 5.00E-06 Post-traumatic stress disorder (asjusted for relatedness) PRKCA intron 23726511 rs11653643 chr17 64515731 C A 3.16E-06 Coronary artery calcification PRKCA intron 23870195 rs11651708 chr17 64517313 T A 3.00E-06 Coronary artery calcification PRKCA intron 23870195 rs6504441 chr17 64529642 C T 1.06E-06 Longevity PRKCA intron 21612516 rs9303509 chr17 64530887 C A 8.91E-06 Coronary artery calcification PRKCA intron 23870195 rs11656279 chr17 64538464 T C 1.12E-05 Sudden cardiac arrest PRKCA intron 21658281 rs1533344 chr17 64545563 C T 7.20E-07 Urinary metabolites PRKCA intron 21572414 rs8069859 chr17 64574582 C G 4.40E-04 Alzheimer's disease PRKCA intron 17998437 rs8069859 chr17 64574582 C G 2.52E-04 Blood pressure (response to calcium channel blocker) PRKCA intron 24192120 rs41493450 chr17 64578937 G C 3.79E-05 Blood pressure (response to calcium channel blocker) PRKCA intron 24192120 rs8072741 chr17 64578951 A C 2.00E-05 Urinary metabolites PRKCA intron 21572414 rs9646428 chr17 64582011 A G 2.50E-05 Urinary metabolites PRKCA intron 21572414 rs9897094 chr17 64601791 A G 1.90E-05 Urinary metabolites PRKCA intron 21572414 rs10451280 chr17 64621079 G C 1.60E-06 Urinary metabolites PRKCA intron 21572414 rs9915719 chr17 64650126 T C 6.87E-04 Alzheimer's disease PRKCA intron 17998437 rs9911259 chr17 64654915 C A 4.40E-05 Type 2 diabetes PRKCA intron 17463248 rs16959880 chr17 64655066 A G 4.30E-05 Type 2 diabetes PRKCA intron 17463248 rs8077110 chr17 64656587 A G 4.30E-05 Type 2 diabetes PRKCA intron 17463248 rs1024740 chr17 64657690 C G 4.30E-05 Type 2 diabetes PRKCA intron 17463248 rs7207345 chr17 64663285 T C 7.50E-05 Type 2 diabetes PRKCA intron 17463248 rs7207345 chr17 64663285 T C 2.43E-04 Alzheimer's disease PRKCA intron 17998437 rs16960077 chr17 64701909 A G 4.46E-04 Alzheimer's disease PRKCA intron 17998437 rs10491200 chr17 64703877 C T 8.36E-05 Biliary atresia PRKCA intron 20460270 rs9894916 chr17 64708396 T C 2.15E-05 Cholesterol PRKCA intron pha003073 rs9894916 chr17 64708396 T C 3.69E-05 ldl cholesterol PRKCA intron pha003076 rs9894916 chr17 64708396 T C 2.55E-05 Cholesterol PRKCA intron pha003078 rs8081512 chr17 64708866 A G 3.07E-04 Osteoarthritis PRKCA intron 19508968 rs7501721 chr17 64714579 C T 6.97E-05 Epilepsy (remission after treatment) PRKCA intron 23962720 rs16960114 chr17 64716626 T C 8.43E-04 Type 2 diabetes PRKCA intron 17463246 rs9303511 chr17 64727631 C T 7.90E-04 Volumetric brain MRI PRKCA intron 17903297 rs9911416 chr17 64734203 G T 7.07E-04 Multiple complex diseases PRKCA intron 17554300 rs3803820 chr17 64738297 A G 0.000236 Colorectal cancer PRKCA intron 22532847 rs4644888 chr17 64745690 C T 1.80E-05 Urinary metabolites PRKCA intron 21572414 rs4644888 chr17 64745690 C T 2.25E-05 Tunica Media PRKCA intron pha003038 rs4381631 chr17 64766443 T G 5.80E-09 Urinary metabolites PRKCA intron 21572414 rs3889237 chr17 64779430 G T 3.00E-08 Height PRKCA intron 22021425 rs4791040 chr17 64787573 T C 6.19E-08 Response to diuretic therapy in hypertension PRKCA intron 23753411 rs16960228 chr17 64788827 G A 6.03E-08 Response to diuretic therapy in hypertension PRKCA intron 23753411 rs4254365 chr17 64793333 T G 4.67E-06 Height PRKCA intron 22021425 rs4791034 chr17 64809835 T G 8.05E-04 Multiple complex diseases / / 17554300 rs4791034 chr17 64809835 T G 8.37E-05 Serum metabolites / / 19043545 rs4791032 chr17 64816465 A G 1.40E-04 Alcohol dependence / / 20201924 rs11870024 chr17 64818008 G A 4.50E-04 Alcohol dependence / / 20201924 rs1476813 chr17 64834068 T C 3.10E-04 Lung function (forced vital capacity) / / 24023788 rs12603665 chr17 64837577 C T 2.50E-04 Multiple complex diseases / / 17554300 rs6504466 chr17 64852309 A G 7.51E-04 Multiple complex diseases / / 17554300 rs8071471 chr17 64852349 G A 7.28E-04 Multiple complex diseases / / 17554300 rs3848413 chr17 64857460 G A 7.39E-04 Type 2 diabetes / / 17846124 rs11868854 chr17 64858371 A G 3.96E-04 Multiple complex diseases / / 17554300 rs1120577 chr17 64866456 A G 2.93E-04 Multiple complex diseases / / 17554300 rs1120577 chr17 64866456 A G 3.18E-04 Cognitive decline / / 23732972 rs758664 chr17 64871272 G A 1.42E-05 Multiple complex diseases / / 17554300 rs7222943 chr17 64887689 G T 7.40E-04 Multiple complex diseases / / 17554300 rs12602753 chr17 64902332 T C 7.53E-05 Bipolar disorder / / 17486107 rs2109266 chr17 64908600 C T 2.90E-06 Narcolepsy / / 20711174 rs35259735 chr17 64913220 A AG 1.07E-04 Response to alcohol consumption (flushing response) / / 24277619 rs6504471 chr17 64913220 A G 1.07E-04 Response to alcohol consumption (flushing response) / / 24277619 rs17645023 chr17 64917033 A T 5.72E-04 Alzheimer's disease / / 17998437 rs17645023 chr17 64917033 A T 6.00E-07 Bipolar disorder and schizophrenia / / 21057379 rs17645023 chr17 64917033 A T 0.000067 Prostate cancer / / 23555315 rs9907335 chr17 64928628 G A 1.61E-07 Facial morphology / / 22341974 rs6504477 chr17 64945929 G A 1.38E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs740559 chr17 64971249 G A 3.46E-04 Alzheimer's disease (late onset) CACNG4 intron 21379329 rs719935 chr17 65000219 C A 2.23E-04 Multiple complex diseases CACNG4 intron 17554300 rs2159211 chr17 65022159 T C 0.0000479 Panic disorder CACNG4 intron 23149450 rs2159211 chr17 65022159 T C 4.79E-05 Serum tamsulosin hydrochloride concentration CACNG4 intron 23151678 rs3803815 chr17 65029264 C T 3.76E-06 Rheumatoid arthritis CACNG4 UTR-3 19503088 rs726586 chr17 65037905 T A 5.13E-04 Multiple complex diseases / / 17554300 rs3785579 chr17 65042501 G C 1.30E-117 Multiple complex diseases CACNG1 intron 17554300 rs4790992 chr17 65043944 A T 5.69E-04 Suicide attempts in bipolar disorder CACNG1 intron 21423239 rs11651301 chr17 65045326 A G 3.79E-04 Suicide attempts in bipolar disorder CACNG1 intron 21423239 rs2363843 chr17 65045786 T C 2.94E-04 Suicide attempts in bipolar disorder CACNG1 intron 21423239 rs2270084 chr17 65050305 T C 9.90E-04 Suicide attempts in bipolar disorder CACNG1 intron 21423239 rs763333 chr17 65087308 G C 7.43E-04 Suicide attempts in bipolar disorder HELZ intron 21423239 rs7214803 chr17 65095681 G T 7.97E-04 Suicide attempts in bipolar disorder HELZ intron 21423239 rs11657929 chr17 65104666 T G 8.05E-04 Suicide attempts in bipolar disorder HELZ cds-synon 21423239 rs7218840 chr17 65108522 T C 7.98E-04 Suicide attempts in bipolar disorder HELZ intron 21423239 rs9914426 chr17 65126641 G C 9.68E-04 Suicide attempts in bipolar disorder HELZ intron 21423239 rs1035176 chr17 65156919 G C 7.25E-04 Suicide attempts in bipolar disorder HELZ intron 21423239 rs9898703 chr17 65181097 G C 5.01E-04 Type 2 diabetes HELZ intron 17463246 rs12942297 chr17 65192484 G A 7.05E-04 Suicide attempts in bipolar disorder HELZ intron 21423239 rs10512514 chr17 65211876 A C 8.19E-05 Serum metabolites HELZ intron 19043545 rs8080100 chr17 65212042 C T 5.50E-04 Type 2 diabetes and 6 quantitative traits HELZ missense 17848626 rs8078002 chr17 65230991 G A 4.33E-04 Type 2 diabetes HELZ intron 17463246 rs9911952 chr17 65256894 C G 2.68E-04 Type 2 diabetes / / 17463246 rs16960774 chr17 65309815 A G 4.34E-06 Height / / 22021425 rs11867328 chr17 65346116 C T 1.75E-08 Height PSMD12 intron 22021425 rs17648225 chr17 65363813 T G 1.34E-04 Premature ovarian failure / / 19508998 rs17648225 chr17 65363813 T G 4.29E-05 Height / / 22021425 rs8072471 chr17 65367062 C T 5.37E-06 Post-operative nausea and vomiting / / 21694509 rs11654663 chr17 65389305 A C 1.47E-07 Post-operative nausea and vomiting PITPNC1 intron 21694509 rs9902423 chr17 65400254 G T 1.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PITPNC1 intron 20877124 rs7207677 chr17 65407766 G A 1.86E-04 Multiple complex diseases PITPNC1 intron 17554300 rs7224000 chr17 65410934 A G 3.00E-06 Response to protease inhibitor treatment in hepatitis c (peak serum total bilirubin levels) PITPNC1 intron 24503447 rs2017854 chr17 65488021 G C 2.93E-05 Multiple complex diseases PITPNC1 intron 17554300 rs2017854 chr17 65488021 G C 3.00E-06 Pulmonary function PITPNC1 intron 23932459 rs2017854 chr17 65488021 G C 3.87E-05 Pulmonary function PITPNC1 intron 23932459 rs2017854 chr17 65488021 G C 8.50E-04 Pulmonary function PITPNC1 intron 23932459 rs11079694 chr17 65497106 A C 2.90E-04 Alzheimer's disease (late onset) PITPNC1 intron 21379329 rs9908834 chr17 65503123 A C 6.50E-05 Alzheimer's disease (late onset) PITPNC1 intron 21379329 rs9908926 chr17 65511550 C T 6.53E-05 HIV-1 viral setpoint PITPNC1 intron 22174851 rs4791286 chr17 65512709 C T 1.73E-04 Alzheimer's disease (late onset) PITPNC1 intron 21379329 rs4791284 chr17 65516649 T G 3.02E-04 Alzheimer's disease (late onset) PITPNC1 intron 21379329 rs2009679 chr17 65539872 A G 2.97E-05 Alzheimer's disease (late onset) PITPNC1 intron 21379329 rs11656439 chr17 65553003 T C 3.53E-05 Alzheimer's disease (late onset) PITPNC1 intron 21379329 rs3760216 chr17 65565503 T C 1.70E-05 Alzheimer's disease (late onset) PITPNC1 intron 21379329 rs2570054 chr17 65580271 T C 2.35E-04 Stroke PITPNC1 intron pha002887 rs4791278 chr17 65631670 A C 0.0007482 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PITPNC1 intron 23233654 rs4791278 chr17 65631670 A C 7.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) PITPNC1 intron 23233662 rs2537828 chr17 65643086 T C 8.13E-06 Alzheimer's disease PITPNC1 intron 17998437 rs2537828 chr17 65643086 T C 3.82E-06 Alzheimer's disease PITPNC1 intron pha002879 rs2625566 chr17 65688288 T C 2.27E-04 Alzheimer's disease PITPNC1 intron 17998437 rs4791241 chr17 65696637 C A 2.26E-04 Alzheimer's disease LOC100507049 intron 17998437 rs4496196 chr17 65706748 C G 1.81E-04 Type 2 diabetes LOC100507049 intron 17463246 rs12453460 chr17 65710869 G T 4.44E-05 Gallbladder cancer LOC100507049 intron 22318345 rs3760220 chr17 65713350 G T 9.93E-04 Multiple complex diseases LOC100507049 intron 17554300 rs2291284 chr17 65717525 T C 0.000014 Breast cancer NOL11 missense 23555315 rs4791114 chr17 65778573 G A 4.37E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs8072947 chr17 65781026 C T 6.32E-05 Suicide attempts in bipolar disorder / / 21423239 rs8079078 chr17 65821166 C A 1.10E-05 White blood cell types / / 21738478 rs1976053 chr17 65833002 C G 9.21E-06 Esophageal cancer (squamous cell) BPTF intron 22960999 rs11079707 chr17 65835617 G A 4.04E-04 Amyotrophic lateral sclerosis (sporadic) BPTF intron 24529757 rs2128792 chr17 65857177 C T 2.97E-04 Amyotrophic lateral sclerosis (sporadic) BPTF intron 24529757 rs9899296 chr17 65872403 T G 9.20E-08 Multiple complex diseases BPTF intron 17554300 rs60856912 chr17 65892343 G T 1.07E-05 Lung adenocarcinoma BPTF intron 22797724 rs61676547 chr17 65892507 G C 1.05E-05 Lung adenocarcinoma BPTF intron 22797724 rs56148300 chr17 65892752 T C 9.98E-06 Lung adenocarcinoma BPTF intron 22797724 rs56404791 chr17 65893019 T G 9.98E-06 Lung adenocarcinoma BPTF intron 22797724 rs6504550 chr17 65894542 A G 7.40E-04 Iris characteristics BPTF intron 21835309 rs7216064 chr17 65898809 G A 7.00E-11 Lung adenocarcinoma BPTF intron 22797724 rs7216064 chr17 65898809 G A 7.00E-06 Lung cancer BPTF intron 23143601 rs8065906 chr17 65902645 G A 9.92E-06 Lung adenocarcinoma BPTF intron 22797724 rs12602655 chr17 65909442 A G 9.57E-06 Lung adenocarcinoma BPTF intron 22797724 rs8072225 chr17 65912960 A G 8.63E-06 Lung adenocarcinoma BPTF intron 22797724 rs55896768 chr17 65913358 T C 8.63E-06 Lung adenocarcinoma BPTF intron 22797724 rs12600941 chr17 65918807 A G 9.06E-06 Lung adenocarcinoma BPTF intron 22797724 rs62085991 chr17 65920508 G A 9.44E-06 Lung adenocarcinoma BPTF intron 22797724 rs4790981 chr17 65921834 A G 1.03E-05 Lung adenocarcinoma BPTF intron 22797724 rs62085992 chr17 65923083 T A 9.82E-06 Lung adenocarcinoma BPTF intron 22797724 rs62085993 chr17 65923152 T C 1.07E-05 Lung adenocarcinoma BPTF intron 22797724 rs73338706 chr17 65926604 T C 1.07E-05 Lung adenocarcinoma BPTF intron 22797724 rs4271626 chr17 65930133 G A 1.07E-05 Lung adenocarcinoma BPTF intron 22797724 rs4791300 chr17 65930772 A G 1.03E-05 Lung adenocarcinoma BPTF intron 22797724 rs4791299 chr17 65930937 A G 1.03E-05 Lung adenocarcinoma BPTF intron 22797724 rs56393562 chr17 65933918 C T 1.07E-05 Lung adenocarcinoma BPTF intron 22797724 rs8071463 chr17 65938655 G A 9.07E-04 Multiple complex diseases BPTF intron 17554300 rs8071463 chr17 65938655 G A 8.93E-05 Alcohol dependence BPTF intron 21703634 rs8071463 chr17 65938655 G A 1.07E-05 Lung adenocarcinoma BPTF intron 22797724 rs12451721 chr17 65939075 G A 9.82E-06 Lung adenocarcinoma BPTF intron 22797724 rs11870068 chr17 65944515 A C 7.67E-06 Alcohol dependence BPTF intron 20202923 rs11870068 chr17 65944515 A C 8.09E-05 Alcohol dependence BPTF intron 21703634 rs11870068 chr17 65944515 A C 3.60E-04 Alcohol dependence BPTF intron 21956439 rs7223357 chr17 65945536 C G 1.07E-05 Lung adenocarcinoma BPTF intron 22797724 rs11867401 chr17 65947970 G A 1.03E-05 Lung adenocarcinoma BPTF intron 22797724 rs9907491 chr17 65949993 G A 1.03E-05 Lung adenocarcinoma BPTF intron 22797724 rs4790974 chr17 65951107 A T 1.03E-05 Lung adenocarcinoma BPTF intron 22797724 rs9899520 chr17 65957568 A G 1.07E-05 Lung adenocarcinoma BPTF intron 22797724 rs59956089 chr17 65960854 T C 5.51E-06 Lung adenocarcinoma BPTF intron 22797724 rs10445361 chr17 65962238 T G 1.07E-05 Lung adenocarcinoma BPTF intron 22797724 rs62086043 chr17 65968003 A G 1.07E-05 Lung adenocarcinoma BPTF intron 22797724 rs62086044 chr17 65970837 G T 1.07E-05 Lung adenocarcinoma BPTF intron 22797724 rs6416958 chr17 65971611 T C 5.73E-05 Multiple complex diseases BPTF intron 17554300 rs62086045 chr17 65973731 G A 1.07E-05 Lung adenocarcinoma BPTF intron 22797724 rs7210027 chr17 65977053 C T 1.07E-05 Lung adenocarcinoma BPTF intron 22797724 rs4790941 chr17 65977132 G A 1.07E-05 Lung adenocarcinoma BPTF intron 22797724 rs11656743 chr17 65980289 G A 1.07E-05 Lung adenocarcinoma BPTF UTR-3 22797724 rs8076442 chr17 66022660 G C 1.59E-04 Multiple complex diseases / / 17554300 rs8064704 chr17 66123432 T G 1.29E-04 Multiple complex diseases / / 17554300 rs6501426 chr17 66136320 G C 8.82E-04 Multiple complex diseases / / 17554300 rs41322951 chr17 66152910 T C 2.10E-19 Multiple complex diseases / / 17554300 rs12943154 chr17 66161018 A C 2.30E-05 Urinary metabolites / / 21572414 rs4968855 chr17 66234938 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs3213690 chr17 66246416 A G 7.31E-05 Cognitive impairment induced by topiramate AMZ2 missense 22091778 rs7210814 chr17 66256956 G T 3.89E-05 Serum metabolites ARSG intron 19043545 rs7222013 chr17 66267691 A T 5.72E-04 Multiple complex diseases SLC16A6 missense 17554300 rs35397826 chr17 66270082 A G 0.000059 Breast cancer SLC16A6 missense 23555315 rs8080714 chr17 66272177 T C 1.65E-04 Blood pressure SLC16A6 intron 17255346 rs17774757 chr17 66319900 A G 1.70E-05 Urinary metabolites ARSG intron 21572414 rs1558878 chr17 66364804 T C 3.50E-05 Amyotrophic Lateral Sclerosis ARSG missense 18057069 rs1558878 chr17 66364804 T C 8.53E-05 Periodontitis (Chronic) ARSG missense 25008200 rs16972915 chr17 66377808 C T 4.31E-04 Alzheimer's disease (late onset) ARSG intron 21379329 rs11655081 chr17 66382209 T C 4.00E-09 Musician's dystonia ARSG intron 24375517 rs11655081 chr17 66382209 T C 5.18E-05 Schizophrenia ARSG intron pha002857 rs6501422 chr17 66389646 T C 6.50E-05 Alcoholism (heaviness of drinking) ARSG intron 21529783 rs7342975 chr17 66391232 A G 1.31E-04 Multiple complex diseases ARSG cds-synon 17554300 rs9972951 chr17 66391276 G A 4.11E-04 Multiple complex diseases ARSG missense 17554300 rs9972951 chr17 66391276 G A 3.45E-04 Coronary heart disease ARSG missense 21971053 rs2160725 chr17 66395726 A C 3.89E-04 Heart Failure ARSG intron pha002884 rs12943181 chr17 66424341 G C 4.63E-05 Response to methylphenidate treatment WIPI1 intron 21130132 rs1002446 chr17 66424923 C T 8.24E-05 Type 2 diabetes WIPI1 intron 17463246 rs1002446 chr17 66424923 C T 9.04E-04 Alzheimer's disease WIPI1 intron 17998437 rs1002446 chr17 66424923 C T 2.05E-05 Response to methylphenidate treatment WIPI1 intron 21130132 rs2909207 chr17 66439605 T C 1.70E-09 Lipid levels WIPI1 intron 19936222 rs883541 chr17 66449122 G A 3.94E-04 Smoking quantity WIPI1 missense 24665060 rs1108683 chr17 66455904 T A 5.30E-05 Iris characteristics / / 21835309 rs12943658 chr17 66469190 C T 2.40E-05 Urinary metabolites / / 21572414 rs2041980 chr17 66478018 G A 4.36E-05 Lactate dehydrogenase levels / / 20981236 rs7350947 chr17 66483524 C T 2.50E-06 Lipid levels / / 18193043 rs16972996 chr17 66512084 G A 9.46E-04 Multiple complex diseases PRKAR1A intron 17554300 rs2302234 chr17 66538239 G T 7.82E-20 Lymphocyte counts FAM20A missense 22286170 rs7213247 chr17 66546130 G A 8.87E-05 Glucose levels FAM20A intron pha003058 rs1017094 chr17 66608900 C G 0.0002277 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1017094 chr17 66608900 C G 2.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs77325336 chr17 66625794 C T 4.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs16973170 chr17 66639907 T C 7.75E-05 Height / / pha003011 rs11653150 chr17 66640075 A G 0.000133 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11653150 chr17 66640075 A G 1.33E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12051776 chr17 66641339 T C 0.0001327 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12051776 chr17 66641339 T C 1.33E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs887281 chr17 66654051 C T 0.0001306 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs887281 chr17 66654051 C T 1.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9899388 chr17 66659285 T C 0.0001234 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9899388 chr17 66659285 T C 1.23E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12150054 chr17 66660827 G A 3.37E-04 Multiple complex diseases / / 17554300 rs12150054 chr17 66660827 G A 6.43E-05 Height / / pha003010 rs12150054 chr17 66660827 G A 1.99E-05 Height / / pha003011 rs8073015 chr17 66661001 G A 1.43E-04 Aortic root size / / 21223598 rs11657722 chr17 66661438 A G 3.38E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs9911500 chr17 66662561 G C 0.0001035 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9911500 chr17 66662561 G C 1.04E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12937017 chr17 66684624 G A 8.74E-04 Type 2 diabetes / / 17463246 rs7213314 chr17 66685847 C T 0.000000168 Left ventricular internal diastolic diameter / / 23275298 rs9895790 chr17 66690586 G A 8.96E-04 Type 2 diabetes / / 17463246 rs17742017 chr17 66696251 C A 9.36E-05 Multiple complex diseases / / 17554300 rs8075075 chr17 66700965 C T 2.14E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs8075075 chr17 66700965 C T 4.44E-04 Lung function (forced vital capacity) / / 24023788 rs872387 chr17 66702344 C A 2.14E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs872387 chr17 66702344 C A 3.36E-04 Lung function (forced vital capacity) / / 24023788 rs872387 chr17 66702344 C A 4.32E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs17674853 chr17 66752022 A G 2.46E-05 Alcohol withdrawal symptoms / / 22072270 rs55982272 chr17 66791892 G C 0.00004995 Sarcoidosis / / 22952805 rs4968953 chr17 66792240 G A 0.00005909 Sarcoidosis / / 22952805 rs9901473 chr17 66794431 A G 1.19E-04 Endometrial cancer / / 24096698 rs9901473 chr17 66794431 A G 5.11E-04 Endometrial cancer / / 24096698 rs4968957 chr17 66799953 T C 0.00009854 Sarcoidosis / / 22952805 rs9891717 chr17 66805787 A G 4.37E-06 Multiple complex diseases / / 17554300 rs4254382 chr17 66812495 T C 4.62E-06 Psoriasis / / 20953187 rs9897551 chr17 66817866 A G 2.29E-05 Coronary heart disease / / pha003031 rs8071366 chr17 66825940 G A 8.68E-04 Alcohol dependence / / 20201924 rs9893368 chr17 66833954 G A 8.16E-05 Serum metabolites / / 19043545 rs4148008 chr17 66875294 C G 2.00E-10 HDL cholesterol ABCA8 intron 20686565 rs4148008 chr17 66875294 C G 1.00E-12 HDL cholesterol ABCA8 intron 24097068 rs4968967 chr17 66877664 C G 1.14E-05 Type 2 diabetes ABCA8 intron 23300278 rs4147994 chr17 66903236 G A 3.41E-04 Response to taxane treatment (placlitaxel) ABCA8 intron 23006423 rs3744498 chr17 66928815 C T 3.56E-04 Depression (quantitative trait) ABCA8 intron 20800221 rs3744499 chr17 66928830 T C 3.83E-04 Depression (quantitative trait) ABCA8 intron 20800221 rs4147970 chr17 66928920 C G 3.04E-04 Depression (quantitative trait) ABCA8 intron 20800221 rs4147968 chr17 66929828 G A 2.57E-04 Depression (quantitative trait) ABCA8 intron 20800221 rs10512521 chr17 66933801 A G 6.83E-04 Multiple complex diseases ABCA8 intron 17554300 rs4147953 chr17 66943640 G A 8.14E-04 Depression (quantitative trait) ABCA8 intron 20800221 rs4147951 chr17 66943738 A G 8.17E-04 Depression (quantitative trait) ABCA8 intron 20800221 rs11077858 chr17 66971575 G C 6.29E-05 Serum metabolites ABCA9 UTR-3 19043545 rs11077859 chr17 66971879 T C 5.63E-05 Serum metabolites ABCA9 UTR-3 19043545 rs4968828 chr17 67001568 A G 9.64E-05 Stroke ABCA9 intron pha002887 rs11871766 chr17 67022135 C A 3.98E-04 Amyotrophic Lateral Sclerosis ABCA9 intron 17362836 rs7215642 chr17 67027870 A G 8.81E-04 Amyotrophic Lateral Sclerosis ABCA9 intron 17362836 rs7215642 chr17 67027870 A G 2.30E-05 Urinary metabolites ABCA9 intron 21572414 rs11650025 chr17 67043636 G C 1.34E-04 Multiple complex diseases ABCA9 intron 17554300 rs2302290 chr17 67075072 G A 9.08E-04 Depression (quantitative trait) ABCA6 UTR-3 20800221 rs740517 chr17 67083139 A C 9.74E-04 Depression (quantitative trait) ABCA6 intron 20800221 rs2098034 chr17 67089038 C T 6.82E-04 Depression (quantitative trait) ABCA6 intron 20800221 rs2364315 chr17 67099129 A G 5.42E-04 Depression (quantitative trait) ABCA6 intron 20800221 rs11659091 chr17 67109662 G A 6.75E-04 Depression (quantitative trait) ABCA6 intron 20800221 rs12103556 chr17 67153374 G C 5.22E-04 Multiple complex diseases ABCA10 intron 17554300 rs4968852 chr17 67184837 C T 5.00E-06 Urinary metabolites ABCA10 intron 21572414 rs41496448 chr17 67191149 A C 4.50E-04 Multiple complex diseases ABCA10 intron 17554300 rs35991088 chr17 67195813 C A 3.11E-04 Multiple complex diseases ABCA10 intron 17554300 rs12941264 chr17 67215712 C T 2.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) ABCA10 cds-synon 23648065 rs1558169 chr17 67236736 A G 3.43E-05 Multiple complex diseases ABCA10 intron 17554300 rs9895649 chr17 67258233 G A 7.97E-05 LDL lipoproteins ABCA5 intron pha002902 rs558076 chr17 67335782 C T 2.53E-05 Parkinson's disease / / pha002868 rs817097 chr17 67378062 T G 6.22E-06 Parkinson's disease / / pha002868 rs817575 chr17 67400254 T C 7.43E-06 Type 2 diabetes / / 23300278 rs817565 chr17 67432385 T G 3.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy) MAP2K6 intron 24554482 rs8078890 chr17 67482314 C A 2.75E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) MAP2K6 intron 17982456 rs8065100 chr17 67483655 G A 3.63E-08 HDL cholesterol MAP2K6 intron 23063622 rs16974082 chr17 67495271 C G 0.000000135 HDL cholesterol MAP2K6 intron 23063622 rs16974193 chr17 67542747 C T 1.40E-04 Multiple complex diseases / / 17554300 rs11658750 chr17 67591596 A G 4.61E-04 Taste perception / / 22132133 rs9913573 chr17 67656119 A G 9.98E-05 Socioeconomic Factors / / pha003067 rs6501341 chr17 67665781 A G 7.03E-04 Depression (quantitative trait) / / 20800221 rs11870477 chr17 67802352 A C 3.00E-06 Response to TNF-alpha inhibitors in rheumatoid arthritis / / 22569225 rs16974415 chr17 67824776 C T 5.32E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2366017 chr17 67850901 G A 3.00E-07 Palmitoleic acid (16:1n-7) plasma levels / / 23362303 rs9898891 chr17 67925574 C T 4.10E-04 Multiple complex diseases / / 17554300 rs8071899 chr17 67930946 A G 0.00000512 Lumbar spine bone mineral density (premenopausal) / / 23074152 rs7217192 chr17 67988824 G C 2.95E-04 Multiple complex diseases / / 17554300 rs1978147 chr17 67994958 C T 9.71E-04 Type 2 diabetes / / 17463246 rs6364 chr17 68027063 C T 3.88E-05 Serum metabolites / / 19043545 rs180172 chr17 68037314 A G 6.48E-04 Alcohol dependence / / 21314694 rs180181 chr17 68039434 C A 6.69E-05 Heart Rate / / pha003054 rs2215006 chr17 68049793 G T 6.69E-05 Heart Rate / / pha003054 rs11867479 chr17 68090207 C T 2.00E-10 Height KCNJ16 intron 20881960 rs9302911 chr17 68094230 C T 9.05E-04 Type 2 diabetes KCNJ16 intron 17463246 rs12936361 chr17 68108417 T C 5.00E-06 Periodontitis (DPAL) KCNJ16 intron 24024966 rs6788 chr17 68131526 C T 4.86E-04 Parkinson's disease KCNJ16 UTR-3 17052657 rs7217293 chr17 68135294 T C 8.86E-05 Prion diseases / / 22210626 rs1468472 chr17 68170749 C T 9.50E-05 HDL particle features KCNJ2 intron 21283740 rs4328485 chr17 68177765 C A 6.43E-05 Information processing speed / / 21130836 rs8080944 chr17 68185586 G A 2.00E-19 Primary tooth development (number of teeth) / / 23704328 rs8080944 chr17 68185586 G A 8.00E-34 Primary tooth development (time to first tooth eruption) / / 23704328 rs8079702 chr17 68190826 G A 1.00E-14 Primary tooth development (number of teeth) / / 20195514 rs8079702 chr17 68190826 G A 4.00E-22 Primary tooth development (time to first tooth eruption) / / 20195514 rs3744486 chr17 68194043 G A 1.30E-05 Urinary metabolites / / 21572414 rs8068407 chr17 68194184 T C 2.20E-05 Urinary metabolites / / 21572414 rs9914814 chr17 68218115 G A,C 9.30E-04 Multiple complex diseases / / 17554300 rs17703427 chr17 68232008 A G 1.49E-05 Stroke / / pha002887 rs236565 chr17 68237589 T C 8.17E-04 Type 2 diabetes / / 17463246 rs236567 chr17 68242546 A G 5.00E-04 Type 2 diabetes / / 17463246 rs992072 chr17 68258208 G T 2.11E-07 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs623011 chr17 68259446 A G 4.00E-12 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs9913349 chr17 68260070 C T 3.90E-07 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs11077484 chr17 68260716 G A 6.79E-04 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs236511 chr17 68264096 G C 2.98E-07 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs4968887 chr17 68264545 C T 1.15E-04 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs2529681 chr17 68264797 T G 2.98E-07 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs236500 chr17 68267024 T A 8.30E-07 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs12453584 chr17 68267733 G A 2.25E-04 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs376627483 chr17 68269712 CAAAATACATAATTTAAGATTT C 1.85E-07 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs7223705 chr17 68269712 C A 1.85E-07 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs1399185 chr17 68270955 G T 8.30E-07 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs1355915 chr17 68271045 G C 8.30E-07 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs8075271 chr17 68272060 G A 3.03E-04 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs8076950 chr17 68272078 A C 3.03E-04 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs17714860 chr17 68272354 G A 4.76E-05 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs11650230 chr17 68273753 C T 3.03E-04 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs723498 chr17 68275532 C A 3.25E-05 Asthma / / 20159242 rs8074548 chr17 68275724 C T 2.75E-04 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs2215027 chr17 68279437 G A 8.67E-04 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs8068647 chr17 68282166 T A 2.25E-04 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs4968890 chr17 68286268 C T 3.03E-04 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs11077488 chr17 68290082 C T 1.68E-05 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs11077488 chr17 68290082 C T 1.20E-05 Breast cancer / / 22452962 rs6501384 chr17 68291133 C T 6.00E-06 Eosinophilic esophagitis (pediatric) / / 20208534 rs7222503 chr17 68299785 G T 6.35E-04 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs7225313 chr17 68303286 C A 5.24E-04 Substance dependence / / 21818250 rs7225313 chr17 68303286 C A 6.35E-04 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs17715938 chr17 68315648 T C 5.18E-04 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs16975551 chr17 68316459 C T 2.00E-04 Substance dependence / / 21818250 rs16975551 chr17 68316459 C T 2.75E-04 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs11653587 chr17 68316678 G A 2.75E-04 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs17716091 chr17 68319533 G A 5.00E-06 Asthma (childhood onset) / / 23829686 rs10775360 chr17 68325868 C T 1.00E-04 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs312691 chr17 68326338 T C 8.00E-14 Thyrotoxic hypokalemic periodic paralysis / / 22863731 rs17175892 chr17 68335659 A C 4.71E-04 Multiple complex diseases / / 17554300 rs10512574 chr17 68337964 T C 2.21E-04 Thyrotoxic hypokalemic periodic paralysis / / 22399142 rs16975645 chr17 68352021 G T 1.29E-04 Multiple complex diseases / / 17554300 rs17715597 chr17 68387220 G A 5.16E-04 Multiple complex diseases / / 17554300 rs1860454 chr17 68395219 G A 1.30E-05 Psoriasis / / 19169255 rs17715796 chr17 68398237 C T 1.80E-05 Urinary metabolites / / 21572414 rs11077494 chr17 68416552 G T 3.58E-04 Multiple complex diseases / / 17554300 rs1396515 chr17 68430993 G C 6.05E-04 Type 2 diabetes / / 17846125 rs1396514 chr17 68431026 C T 5.46E-04 Type 2 diabetes / / 17846125 rs75394140 chr17 68469737 A G 0.00000648 Menopause (age at onset) / / 23424626 rs981106 chr17 68472639 A G 5.45E-06 Body mass index / / 19557197 rs76988592 chr17 68474265 T C 0.00000724 Menopause (age at onset) / / 23424626 rs17779747 chr17 68494992 G T 6.00E-12 QT interval / / 19305409 rs7216598 chr17 68502076 A G 9.57E-05 Multiple complex diseases / / 17554300 rs7218368 chr17 68506682 G A 3.81E-08 QT interval / / 19305409 rs8073016 chr17 68516092 G T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7219669 chr17 68521861 G T 6.00E-14 Cardiac repolarization / / 22342860 rs11651554 chr17 68533019 G A 2.50E-04 Rheumatoid arthritis / / 21452313 rs16913 chr17 68537347 C T 2.59E-04 Rheumatoid arthritis / / 21452313 rs1817630 chr17 68539112 G A 7.67E-05 Formal thought disorder in schizophrenia / / 22648509 rs41450951 chr17 68540319 T C 7.40E-04 Multiple complex diseases / / 17554300 rs17780198 chr17 68540687 A G 4.50E-06 Urinary metabolites / / 21572414 rs10512540 chr17 68540752 C T 1.35E-04 Rheumatoid arthritis / / 21452313 rs1991680 chr17 68557203 C G 1.20E-05 Urinary metabolites / / 21572414 rs1860316 chr17 68606316 G A 3.20E-08 Type 2 diabetes / / 17460697 rs41408048 chr17 68608397 A G 9.23E-04 Multiple complex diseases / / 17554300 rs41408048 chr17 68608397 A G 1.80E-05 Urinary metabolites / / 21572414 rs41459950 chr17 68609232 T C 2.60E-05 Urinary metabolites / / 21572414 rs1981647 chr17 68621193 T C 6.50E-06 Type 2 diabetes / / 17460697 rs16975985 chr17 68634065 A G 5.00E-06 Obesity-related traits / / 23251661 rs1843622 chr17 68637507 G A 4.30E-06 Type 2 diabetes / / 17460697 rs4584866 chr17 68638264 C A 1.35E-04 Rheumatoid arthritis / / 21452313 rs17718586 chr17 68644189 G T 2.00E-08 Sudden cardiac arrest / / 21658281 rs2191113 chr17 68647821 G A 9.50E-08 Type 2 diabetes / / 17460697 rs9890889 chr17 68661880 C A 3.20E-05 Type 2 diabetes / / 17460697 rs2367005 chr17 68666455 T G 9.80E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs2367005 chr17 68666455 T G 6.29E-04 Smoking cessation / / 24665060 rs4793501 chr17 68718734 C T 3.00E-08 Refractive error / / 23396134 rs929474 chr17 68724036 G A 6.03E-06 Personality dimensions / / 18957941 rs16976206 chr17 68732090 T C 2.15E-05 Tuberculosis / / 20694014 rs17223370 chr17 68786758 C G 1.16E-04 Alzheimer's disease / / 17998437 rs17823496 chr17 68803253 G A 1.50E-04 Alzheimer's disease / / 17998437 rs1990193 chr17 68828089 C A 9.00E-06 Obesity-related traits / / 23251661 rs12449436 chr17 68828557 T C 7.95E-05 Alzheimer's disease / / 17998437 rs9895016 chr17 68833326 C T 0.0000491 Panic disorder / / 23149450 rs9895016 chr17 68833326 C T 4.91E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs2190551 chr17 68840462 A T 0.0000306 Panic disorder / / 23149450 rs2190551 chr17 68840462 A T 3.06E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs978708 chr17 68845035 C A 0.0000494 Panic disorder / / 23149450 rs978708 chr17 68845035 C A 4.94E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs2041058 chr17 68860294 C T 2.72E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1015657 chr17 68878487 A G 2.00E-06 Formal thought disorder in schizophrenia / / 22648509 rs33962851 chr17 68908290 C G 2.07E-05 Bipolar disorder and schizophrenia / / 20889312 rs11077530 chr17 68921040 C T 6.00E-06 Menarche (age at onset) / / 19282985 rs7208728 chr17 68921833 G A 5.17E-06 Menarche (age at onset) / / 19282985 rs8081439 chr17 68923526 T C 6.97E-06 Blood Pressure / / pha003040 rs12952980 chr17 68954153 G A 1.70E-05 Panic disorder / / 19165232 rs1073572 chr17 68956061 G A 1.48E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4793517 chr17 68968634 A G 9.40E-06 Urinary metabolites / / 21572414 rs11655471 chr17 68975034 T C 6.03E-06 Blood Pressure / / pha003040 rs6501431 chr17 68976415 C T 3.00E-09 Lung function (forced vital capacity) / / 24929828 rs8073559 chr17 68977484 A G 3.76E-04 Longevity / / 22279548 rs8073477 chr17 68977785 C T 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs9908572 chr17 68983141 G A 4.19E-05 Personality dimensions / / 22628180 rs7223685 chr17 68988741 T A 5.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs1005316 chr17 68990369 G A 1.40E-05 Type 2 diabetes / / 17293876 rs1005316 chr17 68990369 G A 1.40E-05 Type 2 diabetes / / 19184112 rs1005316 chr17 68990369 G A 6.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs9906837 chr17 68994954 C T 2.88E-05 Personality dimensions / / 22628180 rs8080412 chr17 68996451 A C 3.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs9893736 chr17 68997181 G C 3.55E-05 Personality dimensions / / 22628180 rs2886872 chr17 68998517 G C 3.44E-05 Personality dimensions / / 22628180 rs11656020 chr17 68999246 A T 1.52E-05 Personality dimensions / / 22628180 rs11651188 chr17 68999392 C A 3.08E-05 Personality dimensions / / 22628180 rs17824029 chr17 68999856 G A 2.75E-05 Personality dimensions / / 22628180 rs4793521 chr17 69004522 G A 2.37E-05 Personality dimensions / / 22628180 rs10163516 chr17 69008134 G A 2.70E-05 IgE levels / / 22075330 rs7224019 chr17 69008416 A G 4.18E-05 Insulin resistance / / 21901158 rs7215208 chr17 69018993 C T 7.77E-04 Type 2 diabetes / / 17463246 rs7210863 chr17 69034000 A T 2.81E-04 Type 2 diabetes / / 17463246 rs6501434 chr17 69035852 A C 1.81E-06 Stroke (ischemic) / / 22941190 rs17765111 chr17 69038138 G A 1.99E-06 Stroke (ischemic) / / 22941190 rs2193345 chr17 69039164 A G 5.69E-04 Type 2 diabetes / / 17463246 rs17765129 chr17 69039331 A G 2.82E-06 Stroke (ischemic) / / 22941190 rs2193346 chr17 69040230 T C 5.08E-04 Type 2 diabetes / / 17463246 rs17177691 chr17 69040840 T C 3.16E-06 Stroke (ischemic) / / 22941190 rs17177705 chr17 69041010 G A 3.35E-06 Stroke (ischemic) / / 22941190 rs8068158 chr17 69042388 T C 3.45E-06 Stroke (ischemic) / / 22941190 rs1990730 chr17 69043850 T C 9.43E-04 Type 2 diabetes / / 17463246 rs1990730 chr17 69043850 T C 3.98E-06 Stroke (ischemic) / / 22941190 rs2058844 chr17 69050570 T C 4.49E-04 White matter integrity / / 22425255 rs2058846 chr17 69051200 C G 8.28E-04 Type 2 diabetes / / 17463246 rs9890860 chr17 69063761 C T 8.68E-04 Multiple complex diseases / / 17554300 rs4793331 chr17 69075359 G A 2.26E-04 Multiple complex diseases / / 17554300 rs6501435 chr17 69076164 G A 8.17E-05 Multiple complex diseases / / 17554300 rs12449659 chr17 69096808 T C 7.92E-04 Lung function (forced vital capacity) / / 24929828 rs9302931 chr17 69098801 C T 4.49E-05 Age-related macular degeneration / / 22125219 rs2190693 chr17 69103758 G A 2.69E-04 Insulin resistance / / 21901158 rs16976411 chr17 69105350 T C 0.0004293 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16976411 chr17 69105350 T C 4.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs991528 chr17 69105584 A G 0.000408 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs991528 chr17 69105584 A G 4.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1859962 chr17 69108753 G T 3.00E-10 Prostate cancer and type 2 diabetes / / 17603485 rs1859962 chr17 69108753 G T 1.00E-06 Prostate cancer / / 18264097 rs1859962 chr17 69108753 G T 2.00E-16 Prostate cancer / / 19767753 rs1859962 chr17 69108753 G T 2.00E-16 Nasopharyngeal carcinoma / / 20512145 rs1859962 chr17 69108753 G T 3.00E-11 Prostate cancer / / 21743057 rs1859962 chr17 69108753 G T 0.00042 Prostate cancer / / 22532847 rs1859962 chr17 69108753 G T 0.000067 Prostate cancer / / 23555315 rs1859962 chr17 69108753 G T 2.60E-04 Prostate cancer (early onset) / / 24740154 rs11650165 chr17 69109618 C T 5.16E-05 Pulmonary function / / 20010835 rs4793528 chr17 69110773 A G 4.73E-05 Pulmonary function / / 20010835 rs9674957 chr17 69111098 G A 2.29E-10 Narcolepsy / / 19629137 rs9674957 chr17 69111098 G A 4.50E-05 Pulmonary function / / 20010835 rs9889335 chr17 69115146 T G 5.70E-07 Prostate cancer / / 18264097 rs4328484 chr17 69116230 G A 5.91E-05 Pulmonary function / / 20010835 rs4793529 chr17 69118636 T C 2.00E-13 Prostate cancer / / 24753544 rs11654749 chr17 69125606 G T 1.00E-08 Pulmonary function (interaction) / / 23284291 rs11654749 chr17 69125606 G T 7.00E-08 Pulmonary function (interaction) / / 23284291 rs6501445 chr17 69138843 A C 4.79E-04 Multiple complex diseases / / 17554300 rs8065751 chr17 69142778 T A 0.0006336 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8065751 chr17 69142778 T A 6.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8080251 chr17 69142807 A T 0.0006457 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8080251 chr17 69142807 A T 6.46E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2041114 chr17 69144617 A G 9.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs11657298 chr17 69147636 T C 4.85E-05 Heart Rate / / pha003053 rs9916274 chr17 69151533 C T 0.0001948 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9916274 chr17 69151533 C T 1.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7209594 chr17 69151780 T A 0.0000959 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7209594 chr17 69151780 T A 9.59E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9747823 chr17 69157577 C T 0.0001995 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9747823 chr17 69157577 C T 2.00E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2108536 chr17 69169776 G A 0.0001178 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2108536 chr17 69169776 G A 1.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7216882 chr17 69170970 A G 0.0001184 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7216882 chr17 69170970 A G 1.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7206969 chr17 69173149 G A 0.0001248 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7206969 chr17 69173149 G A 1.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1859966 chr17 69175743 C T 0.0002861 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1859966 chr17 69175743 C T 2.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7211425 chr17 69179478 G A 0.0001313 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7211425 chr17 69179478 G A 1.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17224938 chr17 69182743 T C 0.0001398 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17224938 chr17 69182743 T C 1.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1011729 chr17 69187587 C T 0.0003325 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1011729 chr17 69187587 C T 3.33E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1011730 chr17 69187745 A G 0.0005211 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1011730 chr17 69187745 A G 5.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7214479 chr17 69190949 T C 8.10E-08 Prostate cancer and type 2 diabetes / / 17603485 rs2367265 chr17 69191367 C T 0.0003285 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2367265 chr17 69191367 C T 3.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs16976458 chr17 69196263 C T 4.59E-06 Asthma (childhood onset) / / 23829686 rs16976460 chr17 69197424 G A 4.33E-04 Multiple complex diseases / / 17554300 rs17225050 chr17 69197489 T C 0.0001863 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17225050 chr17 69197489 T C 1.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6501455 chr17 69201811 A G 6.90E-06 Prostate cancer and type 2 diabetes / / 17603485 rs8067671 chr17 69207164 C G 0.00021 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8067671 chr17 69207164 C G 2.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs983085 chr17 69212061 A G 2.00E-04 Prostate cancer and type 2 diabetes / / 17603485 rs7215164 chr17 69220321 G A 0.0003621 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7215164 chr17 69220321 G A 3.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8075481 chr17 69224196 C G 4.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs8080004 chr17 69224299 T G 0.000616 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8080004 chr17 69224299 T G 6.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8067695 chr17 69234311 T C 0.0008806 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8067695 chr17 69234311 T C 8.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12946942 chr17 69236998 G T 6.00E-12 adolescent idiopathic scoliosis / / 24023777 rs10512561 chr17 69244797 C T 1.10E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2058005 chr17 69245735 T C 4.69E-06 Prostate cancer / / pha002878 rs9916641 chr17 69246354 A G 9.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs9914454 chr17 69246529 G A 9.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs9895737 chr17 69246667 T C 9.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs1859827 chr17 69248193 A C 7.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs713158 chr17 69257574 A G 4.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs2158906 chr17 69257833 G A 1.37E-05 Prostate cancer / / pha002878 rs11077552 chr17 69259211 A G 1.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs17178711 chr17 69259505 A T 9.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs12950327 chr17 69259647 T C 1.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs4500786 chr17 69264913 T C 1.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs757991 chr17 69266982 A G 2.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs2214949 chr17 69273969 T C 1.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs11077554 chr17 69286681 T G 2.80E-06 Prostate cancer / / pha002878 rs4468671 chr17 69290669 C T 7.07E-06 Prostate cancer / / pha002878 rs2190465 chr17 69292335 T C 2.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs11658880 chr17 69293854 G T 3.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs6501473 chr17 69312222 C T 2.10E-05 Urinary metabolites / / 21572414 rs1859825 chr17 69312709 G A 3.09E-05 Serum metabolites / / 19043545 rs12947455 chr17 69322500 T C 2.20E-05 Urinary metabolites / / 21572414 rs2367385 chr17 69342850 C T 4.11E-05 Serum metabolites / / 19043545 rs17178928 chr17 69364682 G A 3.91E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7221046 chr17 69367311 A C 3.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4239152 chr17 69371040 T C 2.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4239153 chr17 69371095 G T 4.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2190707 chr17 69372864 T G 7.63E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10512565 chr17 69379760 A G 5.61E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs8066684 chr17 69379799 C G 4.87E-04 Multiple complex diseases / / 17554300 rs10512566 chr17 69380081 C A 5.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11653363 chr17 69380886 A G 2.63E-05 Body Composition / / pha003012 rs11653363 chr17 69380886 A G 2.24E-05 Body Mass Index / / pha003021 rs11653363 chr17 69380886 A G 5.16E-05 Diabetes Mellitus / / pha003059 rs11077561 chr17 69380906 C T 6.40E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs8080955 chr17 69382599 G C 9.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11653885 chr17 69385117 C G,T 2.20E-05 Urinary metabolites / / 21572414 rs11653885 chr17 69385117 C G,T 3.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs8064579 chr17 69386424 G A 4.74E-04 Alzheimer's disease (late onset) / / 21379329 rs17225632 chr17 69386667 A C 1.46E-05 Body Mass Index / / pha003019 rs17225632 chr17 69386667 A C 1.70E-05 Body Mass Index / / pha003020 rs7207973 chr17 69419672 C T 1.02E-05 Multiple complex diseases / / 17554300 rs2215060 chr17 69436277 T C 4.88E-04 Schizophrenia / / 19197363 rs12602732 chr17 69462277 C G 9.57E-04 Multiple complex diseases / / 17554300 rs11869872 chr17 69464163 T C 9.88E-04 Multiple complex diseases / / 17554300 rs9907236 chr17 69490073 G A 2.00E-06 Coronary artery calcification / / 23870195 rs7219970 chr17 69494090 G T 8.76E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11871027 chr17 69520930 C A 7.27E-05 Age-related macular degeneration / / 22125219 rs4793360 chr17 69543626 G A 2.40E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2340500 chr17 69756520 G A 9.33E-05 Hemoglobin / / pha003098 rs713122 chr17 69768587 A C 4.58E-06 Psoriasis / / 18364390 rs713122 chr17 69768587 A C 6.76E-05 Hemoglobin / / pha003098 rs8080960 chr17 69786943 G A 5.75E-06 Osteoarthritis / / 22763110 rs7216707 chr17 69794556 C T 2.31E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs11654836 chr17 69794912 T C 3.86E-05 Serum metabolites / / 19043545 rs9914334 chr17 69795669 C G 3.07E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2190470 chr17 69811488 G T 8.44E-04 Multiple complex diseases / / 17554300 rs733383 chr17 69824561 G T 2.53E-05 Orofacial clefts / / 22419666 rs7218313 chr17 69831308 A C 5.80E-05 Varicose Veins / / pha001411 rs7217914 chr17 69831434 C T 5.94E-05 Varicose Veins / / pha001411 rs7223546 chr17 69832043 A G 4.93E-05 Varicose Veins / / pha001411 rs34001630 chr17 69856464 A C 2.63E-04 Body mass index / / 21701565 rs2058010 chr17 69861376 G A 3.16E-05 Pulmonary function / / 20010835 rs1029607 chr17 69866254 A C 8.24E-04 Body mass index / / 21701565 rs9891805 chr17 69874400 T C 4.10E-05 Pulmonary function / / 20010835 rs9910003 chr17 69878684 T C 1.22E-04 Body mass index / / 21701565 rs9910003 chr17 69878684 T C 7.66E-04 Body mass index / / 21701565 rs16976977 chr17 69882495 G A 5.12E-05 Pulmonary function / / 20010835 rs9901105 chr17 69885029 C T 6.36E-05 Pulmonary function / / 20010835 rs8066333 chr17 69893058 A G 2.95E-04 Body mass index / / 21701565 rs8066333 chr17 69893058 A G 5.13E-05 Body mass index / / 21701565 rs8081332 chr17 69897934 G A 1.40E-04 Body mass index / / 21701565 rs8081332 chr17 69897934 G A 6.00E-04 Body mass index / / 21701565 rs7211707 chr17 69899334 G A 2.33E-04 Body mass index / / 21701565 rs1990188 chr17 69903797 C A 4.01E-04 Body mass index / / 21701565 rs1990186 chr17 69903833 A G 4.10E-04 Body mass index / / 21701565 rs9912803 chr17 69904186 A G 1.93E-04 Body mass index / / 21701565 rs12951391 chr17 69911582 C T 5.86E-05 Pulmonary function / / 20010835 rs16977002 chr17 69915333 T C 4.11E-07 Primary biliary cirrhosis / / 23000144 rs16977002 chr17 69915333 T C 0.000000411 Facial morphology / / 23028347 rs2341313 chr17 69915632 T C 6.69E-05 Pulmonary function / / 20010835 rs16977008 chr17 69916480 T C 3.40E-07 Primary biliary cirrhosis / / 23000144 rs16977008 chr17 69916480 T C 0.00000034 Facial morphology / / 23028347 rs16977009 chr17 69916524 C T 3.00E-07 Primary biliary cirrhosis / / 23000144 rs16977009 chr17 69916524 C T 0.0000003 Facial morphology / / 23028347 rs16977012 chr17 69916891 G A 7.36E-05 Pulmonary function / / 20010835 rs4793389 chr17 69917917 C A 3.00E-07 Primary biliary cirrhosis / / 23000144 rs4793389 chr17 69917917 C A 0.0000003 Facial morphology / / 23028347 rs8079498 chr17 69919452 T C 2.86E-07 Primary biliary cirrhosis / / 23000144 rs8079498 chr17 69919452 T C 0.000000286 Facial morphology / / 23028347 rs7214306 chr17 69921271 T C 2.86E-07 Primary biliary cirrhosis / / 23000144 rs7214306 chr17 69921271 T C 0.000000286 Facial morphology / / 23028347 rs9897139 chr17 69929555 T C 8.20E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7213040 chr17 69934311 C T 7.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12944813 chr17 69944958 T A 8.28E-05 Pulmonary function / / 20010835 rs7217932 chr17 69949016 A G 2.00E-11 Bone mineral density / / 22504420 rs7209111 chr17 69959015 T C 1.06E-05 Pulmonary function / / 20010835 rs7214582 chr17 69959963 T C 3.94E-05 Waist Circumference / / pha003024 rs11652803 chr17 69979807 G A 3.40E-06 Urinary metabolites / / 21572414 rs2190492 chr17 69980044 G T 1.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs10512580 chr17 69986412 C A 2.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs12944831 chr17 69995725 A G 2.26E-05 Pulmonary function / / 20010835 rs3803833 chr17 70018911 T G 4.93E-04 Longevity / / 22279548 rs12451606 chr17 70023827 T C 7.20E-05 Bipolar disorder and schizophrenia / / 20889312 rs2193055 chr17 70025713 T G 8.70E-05 Bipolar disorder / / 19488044 rs2193055 chr17 70025713 T G 2.60E-05 Bipolar disorder and schizophrenia / / 20889312 rs2193055 chr17 70025713 T G 7.14E-05 Bipolar Disorder / / pha002858 rs2058742 chr17 70040547 G T 2.81E-05 Response to hepatitis C treatment / / 19684573 rs17767924 chr17 70043418 G A 4.67E-04 Body mass index / / 21701565 rs11077594 chr17 70048025 T C 9.53E-05 Serum metabolites / / 19043545 rs11868184 chr17 70051551 T G 2.63E-04 Body mass index / / 21701565 rs10438697 chr17 70055734 G A 8.99E-05 Serum metabolites / / 19043545 rs10438697 chr17 70055734 G A 4.16E-04 Body mass index / / 21701565 rs10438697 chr17 70055734 G A 6.33E-04 Body mass index / / 21701565 rs10438697 chr17 70055734 G A 8.02E-04 Body mass index / / 21701565 rs9892101 chr17 70065847 T C 1.89E-04 Body mass index / / 21701565 rs8077585 chr17 70066312 G A 4.85E-04 Coronary Artery Disease / / 17634449 rs1558748 chr17 70066502 T C 4.80E-05 Cognitive impairment induced by topiramate / / 22091778 rs1558748 chr17 70066502 T C 4.22E-06 Cognitive decline / / 23207651 rs1558748 chr17 70066502 T C 5.35E-05 Behcet's disease / / pha002888 rs2241171 chr17 70070791 C T 1.31E-04 Body mass index / / 21701565 rs2241171 chr17 70070791 C T 5.26E-04 Body mass index / / 21701565 rs12452541 chr17 70073175 A T 1.80E-04 Body mass index FLJ37644 intron 21701565 rs12452541 chr17 70073175 A T 5.85E-04 Body mass index FLJ37644 intron 21701565 rs12452541 chr17 70073175 A T 5.99E-04 Body mass index FLJ37644 intron 21701565 rs7207745 chr17 70090575 G A 1.33E-04 Body mass index FLJ37644 intron 21701565 rs7207745 chr17 70090575 G A 2.96E-04 Body mass index FLJ37644 intron 21701565 rs9903394 chr17 70091433 A G 8.47E-05 Pulmonary function in asthmatics FLJ37644 intron 23541324 rs9903394 chr17 70091433 A G 4.99E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) FLJ37644 intron 23648065 rs9890304 chr17 70093315 C T 1.03E-04 Body mass index FLJ37644 intron 21701565 rs9890304 chr17 70093315 C T 6.83E-04 Body mass index FLJ37644 intron 21701565 rs9890304 chr17 70093315 C T 7.18E-06 Body mass index FLJ37644 intron 21701565 rs12451717 chr17 70093483 C T 1.02E-04 Body mass index FLJ37644 intron 21701565 rs12451717 chr17 70093483 C T 2.78E-04 Body mass index FLJ37644 intron 21701565 rs9913711 chr17 70098161 G C 1.00E-09 Liver enzyme levels (gamma-glutamyl transferase) FLJ37644 intron 22001757 rs17246021 chr17 70104439 T C 1.55E-04 Body mass index FLJ37644 intron 21701565 rs17246021 chr17 70104439 T C 7.52E-05 Body mass index FLJ37644 intron 21701565 rs9893662 chr17 70111871 T C 1.35E-04 Body mass index FLJ37644 intron 21701565 rs9893662 chr17 70111871 T C 4.68E-05 Body mass index FLJ37644 intron 21701565 rs9915657 chr17 70127536 T C 1.00E-07 Thyroid hormone levels / / 23408906 rs9915657 chr17 70127536 T C 2.00E-07 Thyroid hormone levels / / 23408906 rs9915657 chr17 70127536 T C 8.00E-13 Thyroid hormone levels / / 23408906 rs1024826 chr17 70147581 T C 2.65E-04 Alcohol dependence / / 20201924 rs7210251 chr17 70152363 C T 6.59E-04 Spine bone size / / 23207799 rs2880328 chr17 70164961 C T 7.00E-04 Multiple complex diseases / / 17554300 rs741348 chr17 70171052 T C 5.23E-04 Spine bone size / / 23207799 rs16977135 chr17 70193355 A C 7.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs16977140 chr17 70197291 T C 5.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs16977143 chr17 70199286 G T 6.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs11870459 chr17 70200678 G A 8.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs1122200 chr17 70202189 A G 4.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs8079881 chr17 70202393 A G 1.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs2880562 chr17 70230735 C T 7.43E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs9898438 chr17 70243963 G A 7.19E-05 Weight / / pha003026 rs4793418 chr17 70256076 C A 1.43E-04 Multiple complex diseases / / 17554300 rs11871183 chr17 70259804 G T 1.36E-04 Heart Failure / / pha002885 rs11077598 chr17 70274865 G A 2.58E-04 Multiple complex diseases / / 17554300 rs11077598 chr17 70274865 G A 1.42E-05 Psoriasis / / 20953190 rs12936248 chr17 70287131 G A 1.92E-04 Multiple complex diseases / / 17554300 rs4793422 chr17 70289225 C T 2.39E-05 Psoriasis / / 20953190 rs1967304 chr17 70291156 C A 3.01E-04 Multiple complex diseases / / 17554300 rs1029645 chr17 70295760 G A 8.87E-04 Multiple complex diseases / / 17554300 rs4793426 chr17 70299817 A C 4.01E-05 Psoriasis / / 20953190 rs17181550 chr17 70299958 T G 9.33E-05 Psoriasis / / 20953190 rs9916144 chr17 70306378 C T 2.12E-04 Multiple complex diseases / / 17554300 rs16977176 chr17 70321327 G A 8.81E-04 Acute lung injury / / 22295056 rs7216312 chr17 70324178 G C 1.00E-05 Urinary metabolites / / 21572414 rs4793431 chr17 70331665 G C 2.00E-05 Urinary metabolites / / 21572414 rs6501536 chr17 70360095 C G 5.30E-06 Urinary metabolites / / 21572414 rs12941150 chr17 70363395 G A 7.00E-06 Pulmonary function decline / / 22424883 rs759563 chr17 70370888 C T 2.70E-05 Diabetic retinopathy / / 21441570 rs7222185 chr17 70385567 G A 1.64E-05 Alcohol dependence / / 21703634 rs7207536 chr17 70386151 G A 4.54E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4140875 chr17 70388518 C A 3.29E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9906315 chr17 70393080 G A 1.10E-05 Urinary metabolites / / 21572414 rs3744311 chr17 70407856 C T 3.43E-06 Response to gemcitabine in pancreatic cancer LOC100499467 intron 22142827 rs12941567 chr17 70426599 C T 4.09E-04 Amyotrophic Lateral Sclerosis LOC100499467 intron 17362836 rs6501543 chr17 70430643 G A 8.92E-05 Rheumatoid arthritis LOC100499467 intron 17804836 rs12452364 chr17 70431496 T C 8.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100499467 intron 20877124 rs12452519 chr17 70441333 C T 1.00E-04 Lipid levels LOC100499467 intron pha003082 rs4264435 chr17 70457870 C G 7.00E-04 Acute lymphoblastic leukemia (childhood) LOC100499467 intron 20189245 rs1035076 chr17 70462845 A G 7.70E-04 Type 2 diabetes and 6 quantitative traits LOC100499467 intron 17848626 rs8078277 chr17 70463457 T C 4.00E-04 Acute lymphoblastic leukemia (childhood) LOC100499467 intron 20189245 rs1177982 chr17 70472337 T C 4.45E-04 Response to cytadine analogues (cytosine arabinoside) LOC100499467 intron 24483146 rs2041631 chr17 70479684 C A 6.36E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines LOC100499467 intron 21844884 rs887802 chr17 70491063 T C 7.67E-05 Serum metabolites LOC100499467 intron 19043545 rs56868433 chr17 70544315 C T 1.07E-11 Metabolite levels LOC100499467 intron 22286219 rs857510 chr17 70563083 C T 3.93E-05 Bone mineral density LOC100499467 intron 19181680 rs13341155 chr17 70577660 T C 5.14E-04 Multiple complex diseases LOC100499467 intron 17554300 rs718073 chr17 70584265 C T 5.00E-06 Relative hand skill in reading disability LOC100499467 intron 24068947 rs718072 chr17 70584327 G A 8.77E-05 Relative hand skill in reading disability LOC100499467 intron 24068947 rs11077614 chr17 70594629 G A 3.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs4793461 chr17 70620643 G A 6.68E-04 Multiple complex diseases LINC00511 intron 17554300 rs9906859 chr17 70624280 T C 9.43E-05 Non-alcoholic fatty liver disease histology (other) LINC00511 intron 20708005 rs7210086 chr17 70641698 A C 2.00E-09 Ulcerative colitis / / 23128233 rs3924958 chr17 70645446 A G 2.78E-05 Rheumatoid arthritis SLC39A11 intron 17804836 rs12939126 chr17 70660427 C T 1.94E-04 Obesity (extreme) SLC39A11 intron 21935397 rs4793297 chr17 70660902 A G 5.65E-04 Multiple complex diseases SLC39A11 intron 17554300 rs4793297 chr17 70660902 A G 8.01E-06 Gallstones SLC39A11 intron 17632509 rs7208934 chr17 70680637 G A 2.46E-04 Myopia (pathological) SLC39A11 intron 21095009 rs8077681 chr17 70682612 C G 2.23E-06 Height SLC39A11 intron 20400458 rs8077681 chr17 70682612 C G 2.20E-06 Obesity,menopause SLC39A11 intron 21424828 rs2567513 chr17 70692740 C T 6.66E-05 Response to acetaminophen (hepatotoxicity) SLC39A11 intron 21177773 rs8066857 chr17 70696103 C T 8.00E-06 Amyotrophic lateral sclerosis SLC39A11 intron 19451621 rs891684 chr17 70713539 G A 4.00E-07 Serum selenium levels SLC39A11 intron 23698163 rs2567507 chr17 70716929 A C,G,T 6.80E-06 Urinary metabolites SLC39A11 intron 21572414 rs8071840 chr17 70721707 A G 5.19E-05 Biliary atresia SLC39A11 intron 20460270 rs8071840 chr17 70721707 A G 8.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) SLC39A11 intron 23648065 rs9944510 chr17 70735225 G T 8.72E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) SLC39A11 intron 23648065 rs10775361 chr17 70744901 T G 5.07E-04 Multiple complex diseases SLC39A11 intron 17554300 rs2713980 chr17 70760161 C T 9.00E-04 Acute lymphoblastic leukemia (childhood) SLC39A11 intron 20189245 rs2567537 chr17 70767734 A G 3.00E-04 Acute lymphoblastic leukemia (childhood) SLC39A11 intron 20189245 rs2567533 chr17 70771727 A G 1.34E-04 Smoking initiation SLC39A11 intron 24665060 rs1077768 chr17 70772843 G C 7.40E-06 Urinary metabolites SLC39A11 intron 21572414 rs1077768 chr17 70772843 G C 6.20E-04 Smoking initiation SLC39A11 intron 24665060 rs2713969 chr17 70773785 T C 7.72E-05 Smoking initiation SLC39A11 intron 24665060 rs12942980 chr17 70775607 G A 2.87E-05 Smoking initiation SLC39A11 intron 24665060 rs12450445 chr17 70776154 C A 3.45E-05 Smoking initiation SLC39A11 intron 24665060 rs2567524 chr17 70779765 C T 6.90E-05 Smoking initiation SLC39A11 intron 24665060 rs2060097 chr17 70781905 A G 7.56E-04 Multiple complex diseases SLC39A11 intron 17554300 rs4793310 chr17 70783318 T C 7.67E-07 Smoking initiation SLC39A11 intron 24665060 rs2714011 chr17 70783734 C T 3.91E-05 Multiple complex diseases SLC39A11 intron 17554300 rs2714011 chr17 70783734 C T 4.43E-06 Smoking initiation SLC39A11 intron 24665060 rs7406107 chr17 70784427 T C 4.32E-07 Smoking initiation SLC39A11 intron 24665060 rs12948247 chr17 70787004 T A 1.10E-05 Hypertension SLC39A11 intron 22384028 rs2567519 chr17 70788406 G A 1.00E-07 Smoking initiation SLC39A11 intron 24665060 rs2714016 chr17 70788639 C A 1.40E-05 Hypertension SLC39A11 intron 22384028 rs2714016 chr17 70788639 C A 5.06E-07 Smoking initiation SLC39A11 intron 24665060 rs2714017 chr17 70788741 C T 9.00E-06 Hypertension SLC39A11 intron 22384028 rs2714017 chr17 70788741 C T 1.34E-07 Smoking initiation SLC39A11 intron 24665060 rs2714018 chr17 70788857 G A 7.49E-07 Smoking initiation SLC39A11 intron 24665060 rs2714019 chr17 70789650 C T 2.08E-05 Smoking initiation SLC39A11 intron 24665060 rs2713989 chr17 70801534 A G 9.00E-06 Hypertension SLC39A11 intron 22384028 rs12943829 chr17 70826404 G C 2.00E-06 Visceral adipose tissue adjusted for BMI SLC39A11 intron 22589738 rs11077637 chr17 70846830 G A 1.71E-04 HIV-1 viral setpoint SLC39A11 intron 17641165 rs4793316 chr17 70847518 T C 1.18E-04 HIV-1 viral setpoint SLC39A11 intron 17641165 rs9910192 chr17 70849563 G A 7.80E-05 HIV-1 viral setpoint SLC39A11 intron 17641165 rs4575596 chr17 70877779 T C 5.94E-04 Suicide attempts in bipolar disorder SLC39A11 intron 21041247 rs10512591 chr17 70879560 A G 8.98E-05 Lymphocyte counts SLC39A11 intron 22286170 rs4476236 chr17 70879913 G A 6.08E-04 Suicide attempts in bipolar disorder SLC39A11 intron 21041247 rs4494615 chr17 70880912 C T 6.10E-04 Suicide attempts in bipolar disorder SLC39A11 intron 21041247 rs4969119 chr17 70881404 C T 6.09E-04 Suicide attempts in bipolar disorder SLC39A11 intron 21041247 rs4969120 chr17 70881435 C T 6.13E-04 Suicide attempts in bipolar disorder SLC39A11 intron 21041247 rs4969122 chr17 70882238 A C 6.15E-04 Suicide attempts in bipolar disorder SLC39A11 intron 21041247 rs4969123 chr17 70882358 A G 6.16E-04 Suicide attempts in bipolar disorder SLC39A11 intron 21041247 rs4969124 chr17 70882370 T C 6.18E-04 Suicide attempts in bipolar disorder SLC39A11 intron 21041247 rs8078564 chr17 70882964 C G 6.19E-04 Suicide attempts in bipolar disorder SLC39A11 intron 21041247 rs8078727 chr17 70883044 C T 6.19E-04 Suicide attempts in bipolar disorder SLC39A11 intron 21041247 rs4570929 chr17 70883266 C A 6.19E-04 Suicide attempts in bipolar disorder SLC39A11 intron 21041247 rs4503863 chr17 70883493 C T 6.21E-04 Suicide attempts in bipolar disorder SLC39A11 intron 21041247 rs7223107 chr17 70883558 C T 6.23E-04 Suicide attempts in bipolar disorder SLC39A11 intron 21041247 rs6501572 chr17 70884262 T G 6.26E-04 Suicide attempts in bipolar disorder SLC39A11 intron 21041247 rs16977420 chr17 70884720 G A 6.06E-05 Bipolar disorder SLC39A11 intron 20451256 rs8069336 chr17 70884882 G A 6.27E-04 Suicide attempts in bipolar disorder SLC39A11 intron 21041247 rs7502006 chr17 70902716 C T 4.50E-04 Myasthenia gravis SLC39A11 intron 23055271 rs17248007 chr17 70914249 T C 2.47E-04 Multiple complex diseases SLC39A11 intron 17554300 rs6501581 chr17 70915599 G A 3.10E-04 Myasthenia gravis SLC39A11 intron 23055271 rs8069126 chr17 70916464 C G 1.00E-05 Urinary metabolites SLC39A11 intron 21572414 rs41335744 chr17 70918396 A G 8.39E-04 Multiple complex diseases SLC39A11 intron 17554300 rs951284 chr17 70927317 A T 2.43E-04 Alzheimer's disease (late onset) SLC39A11 intron 21379329 rs4969040 chr17 70947492 A G 5.00E-05 Adverse response to radiation therapy SLC39A11 intron 23719583 rs2466511 chr17 70962463 C T 6.57E-05 Amyotrophic Lateral Sclerosis SLC39A11 intron 17827064 rs6501587 chr17 70989701 C T 8.74E-04 Amyotrophic Lateral Sclerosis SLC39A11 intron 17827064 rs4969049 chr17 71000940 T C 1.00E-06 Body mass index (interaction) SLC39A11 intron 23192594 rs9891292 chr17 71010985 T G 2.22E-09 Metabolite levels SLC39A11 intron 23281178 rs1552846 chr17 71035613 T A 6.19E-04 Response to taxane treatment (placlitaxel) SLC39A11 intron 23006423 rs17183634 chr17 71035850 G T 2.00E-04 Information processing speed SLC39A11 intron 21130836 rs8081534 chr17 71042081 G A 7.60E-06 Urinary metabolites SLC39A11 intron 21572414 rs903107 chr17 71061934 T C 6.00E-06 Liver enzyme levels (alanine transaminase) SLC39A11 intron 24124411 rs9302952 chr17 71064226 A C 4.04E-07 Autism SLC39A11 intron 22843504 rs12449970 chr17 71069491 C T 3.27E-04 Alzheimer's disease SLC39A11 intron 24755620 rs9944433 chr17 71081952 G A 3.50E-05 Bone mineral density (BMD),in women SLC39A11 intron 20164292 rs8068198 chr17 71085624 C T 0.00001 Endoxifen sentivity (5 uM) SLC39A11 intron 23508821 rs17248371 chr17 71090300 G A 3.52E-04 Multiple complex diseases / / 17554300 rs4969065 chr17 71110350 T C 7.50E-06 Fasting plasma glucose / / 19060907 rs11655490 chr17 71113564 G A 8.50E-05 Parkinson's disease (age of onset) / / 19772629 rs11655490 chr17 71113564 G A 0.0000476 Amyotrophic lateral sclerosis / / 23587638 rs4969069 chr17 71130573 C T 4.70E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4969069 chr17 71130573 C T 8.93E-04 Alcohol dependence / / 21314694 rs2044720 chr17 71139411 A G 1.57E-04 Multiple complex diseases / / 17554300 rs10852744 chr17 71143527 T G 5.15E-04 Type 2 diabetes / / 17463246 rs12326039 chr17 71151463 G T 6.55E-08 Triglycerides / / 23063622 rs1037260 chr17 71157265 G T 6.50E-05 Alcohol dependence / / 20201924 rs1037260 chr17 71157265 G T 6.50E-05 Alcoholism / / pha002892 rs728291 chr17 71163788 C A 1.74E-05 Serum metabolites SSTR2 intron 19043545 rs728291 chr17 71163788 C A 7.70E-04 Bipolar disorder,schizoaffective SSTR2 intron 19567891 rs1037261 chr17 71164376 G A 5.92E-05 Serum metabolites SSTR2 intron 19043545 rs1037261 chr17 71164376 G A 1.69E-04 Bipolar disorder,schizoaffective SSTR2 intron 19567891 rs1466113 chr17 71165318 C G 2.70E-05 Obesity-related traits SSTR2 intron 17903300 rs1466113 chr17 71165318 C G 6.85E-05 Serum metabolites SSTR2 intron 19043545 rs1466113 chr17 71165318 C G 2.82E-04 Bipolar disorder,schizoaffective SSTR2 intron 19567891 rs9890798 chr17 71239598 C T 5.17E-04 Alzheimer's disease C17orf80 intron 22005930 rs12950128 chr17 71288029 A G 7.86E-05 Cognitive impairment induced by topiramate CDC42EP4 intron 22091778 rs9302960 chr17 71298458 C G 1.00E-06 Urinary metabolites CDC42EP4 intron 21572414 rs3816995 chr17 71335260 G A 2.00E-07 Panic disorder SDK2 intron 19165232 rs3816995 chr17 71335260 G A 0.0000443 Panic disorder SDK2 intron 23149450 rs3816995 chr17 71335260 G A 4.43E-05 Serum tamsulosin hydrochloride concentration SDK2 intron 23151678 rs937447 chr17 71395907 T C 5.52E-05 Type 2 diabetes SDK2 intron 17463246 rs11654556 chr17 71402939 C G 1.50E-05 Urinary metabolites SDK2 intron 21572414 rs1872083 chr17 71467391 C T 7.24E-04 Multiple complex diseases SDK2 intron 17554300 rs12452761 chr17 71468267 G A 6.30E-06 Urinary metabolites SDK2 cds-synon 21572414 rs11653635 chr17 71490803 C T 2.79E-05 Paget's disease SDK2 intron 20436471 rs17185043 chr17 71492728 C T 4.85E-04 Multiple complex diseases SDK2 intron 17554300 rs1872080 chr17 71511336 G A 6.75E-05 Cervical cancer SDK2 intron 24700089 rs7217454 chr17 71515907 G C 6.55E-04 Type 2 diabetes SDK2 intron 17463246 rs1078439 chr17 71544306 T C 3.48E-06 Glucose levels SDK2 intron pha003058 rs1078439 chr17 71544306 T C 2.03E-05 Glucose levels SDK2 intron pha003061 rs12941308 chr17 71566957 C T 3.07E-05 Serum metabolites SDK2 intron 19043545 rs16977684 chr17 71582875 C A 3.52E-04 Multiple complex diseases SDK2 intron 17554300 rs790092 chr17 71600245 T C 8.40E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) SDK2 intron 23648065 rs715778 chr17 71603446 A G 1.92E-04 Type 2 diabetes SDK2 intron 17463246 rs8078884 chr17 71617626 G A 7.67E-04 Multiple complex diseases SDK2 intron 17554300 rs9895288 chr17 71620113 G A 2.56E-05 HIV-1 viral setpoint SDK2 intron 21490045 rs9895288 chr17 71620113 G A 3.40E-04 Lung function (forced vital capacity) SDK2 intron 24023788 rs1858030 chr17 71622669 G A 8.96E-04 Nicotine dependence SDK2 intron 17158188 rs11077694 chr17 71623842 A G 9.33E-04 Multiple complex diseases SDK2 intron 17554300 rs12449935 chr17 71649662 T C 5.79E-04 Alzheimer's disease / / 24755620 rs3898631 chr17 71671916 A G 3.48E-04 Smoking quantity / / 24665060 rs17249600 chr17 71681427 T C 8.11E-04 Insulin resistance / / 21901158 rs12452401 chr17 71689125 A G 4.23E-05 Iron levels / / 19880490 rs12452401 chr17 71689125 A G 4.23E-05 Iron levels / / pha002876 rs9906186 chr17 71690356 C T 8.14E-05 Cardiovascular disease / / pha003065 rs2683191 chr17 71700963 A G 3.14E-04 Multiple complex diseases / / 17554300 rs2619995 chr17 71703533 C A 2.45E-04 Tourette syndrome / / 22889924 rs2619996 chr17 71703758 C T 9.07E-05 Diabetes Mellitus / / pha003060 rs899596 chr17 71735485 A G 2.09E-04 Tourette syndrome LOC100134391 intron 22889924 rs9909176 chr17 71736843 T C 6.34E-04 Multiple complex diseases LOC100134391 intron 17554300 rs1552013 chr17 71737076 G A 2.19E-04 Multiple complex diseases LOC100134391 intron 17554300 rs11659005 chr17 71753161 G A 0.0006544 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LINC00469 intron 23233654 rs11659005 chr17 71753161 G A 6.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) LINC00469 intron 23233662 rs12451840 chr17 71807713 T C 3.00E-06 IgG glycosylation LINC00469 intron 23382691 rs2586841 chr17 71815050 T C 0.000596203 Hypertension (early onset hypertension) LINC00469 intron 22479346 rs1585804 chr17 71834001 A C 4.05E-05 Serum metabolites / / 19043545 rs1585804 chr17 71834001 A C 4.57E-05 Insulin-related traits / / pha002901 rs12452084 chr17 71838219 C T 5.36E-04 Smoking quantity / / 24665060 rs4789538 chr17 71839902 A G 2.10E-05 Urinary metabolites / / 21572414 rs922560 chr17 71850430 A G 1.02E-05 Elbow pain / / pha003008 rs4789600 chr17 71856764 G A 2.74E-04 Multiple complex diseases / / 17554300 rs12944809 chr17 71885862 C G 7.10E-04 Multiple complex diseases / / 17554300 rs7502667 chr17 71894357 C A 4.46E-04 Multiple complex diseases / / 17554300 rs7502667 chr17 71894357 C A 5.96E-04 Smoking cessation / / 24665060 rs8065308 chr17 71898105 C T 1.30E-06 Sickle cell anemia (severity) / / 20029952 rs7359571 chr17 71916715 A G 3.71E-04 Multiple complex diseases / / 17554300 rs7223619 chr17 71926893 C T 2.60E-05 Urinary metabolites / / 21572414 rs4789609 chr17 71933039 T C 6.01E-04 Response to alcohol consumption (flushing response) / / 24277619 rs4789036 chr17 71939036 A G 4.20E-05 Response to alcohol consumption (flushing response) / / 24277619 rs8075246 chr17 71940218 A G 4.00E-06 Urinary metabolites / / 21572414 rs12103453 chr17 71945011 A G 4.79E-29 Multiple complex diseases / / 17554300 rs9902475 chr17 71963953 A C 5.12E-04 Rheumatoid arthritis / / 21452313 rs7216729 chr17 71970337 G T 8.14E-05 Multiple complex diseases / / 17554300 rs868929 chr17 71973275 C T 8.39E-05 Postoperative ventricular dysfunction / / 21980348 rs8081998 chr17 71974611 T C 4.52E-05 Postoperative ventricular dysfunction / / 21980348 rs11657439 chr17 71984938 T A,C,G 2.41E-04 Multiple complex diseases / / 17554300 rs432342 chr17 71995213 T C 0.00007686 Sarcoidosis / / 22952805 rs440919 chr17 71997239 T C 9.94E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11656163 chr17 71998971 C A 7.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs11077721 chr17 72042737 G A 1.47E-06 Schizophrenia / / 22037552 rs6501685 chr17 72048075 C T 6.12E-06 Schizophrenia / / 19571811 rs2219402 chr17 72053767 C T 9.80E-05 Multiple sclerosis / / 17660530 rs6501689 chr17 72055172 C T 8.56E-04 Multiple complex diseases / / 17554300 rs6501691 chr17 72063345 G A 8.32E-04 Smoking cessation / / 24665060 rs9906003 chr17 72065264 G A 5.53E-05 Celiac disease / / 23936387 rs12942418 chr17 72074718 G A 5.71E-05 Celiac disease / / 23936387 rs8080915 chr17 72083792 T C 2.85E-04 Gallstones / / 17632509 rs12449868 chr17 72164175 A G 3.99E-05 Type 2 diabetes and other traits / / 19734900 rs4789626 chr17 72167585 C T 4.29E-05 Type 2 diabetes and other traits / / 19734900 rs12602594 chr17 72178448 A C 8.93E-04 Taste perception / / 22132133 rs4789632 chr17 72190551 C T 6.40E-04 Parkinson's disease / / 17052657 rs4435291 chr17 72193793 G C 6.53E-05 Bipolar disorder / / 19488044 rs7219464 chr17 72196391 C A 1.67E-05 Pancreatic cancer / / pha002874 rs8077790 chr17 72197032 A G 7.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3809714 chr17 72198375 G A 8.45E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs3826321 chr17 72198496 T C 8.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4789636 chr17 72198839 T C 2.22E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11658026 chr17 72214863 A C 7.20E-05 Brain derived neurotrophic factor levels,in serum TTYH2 intron 22047184 rs8081928 chr17 72248947 G C 1.67E-04 Multiple sclerosis TTYH2 intron 17660530 rs11650353 chr17 72263924 A G 5.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7219585 chr17 72268208 A G 1.00E-06 Information processing speed / / 21130836 rs12940226 chr17 72271426 C T 6.12E-04 Tourette syndrome D/I2 intron 22889924 rs11652975 chr17 72288399 T C 3.15E-04 Lung function (forced expiratory volume in 1 second) D/I2 intron 17255346 rs11654138 chr17 72316831 G A 3.10E-07 Urinary metabolites / / 21572414 rs150121973 chr17 72366770 G A 0.000046 Breast cancer(er negative) GPR142 missense 23555315 rs16978020 chr17 72382917 C A 1.08E-05 Brain structure / / 22504417 rs4789658 chr17 72389526 A T 4.82E-05 Brain structure / / 22504417 rs9897184 chr17 72414761 G A 1.88E-04 Alcohol dependence / / 24277619 rs16978038 chr17 72422081 T C 8.90E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs2251065 chr17 72447700 C T 3.18E-05 Lymphocyte counts / / 22286170 rs2670827 chr17 72463021 C T 2.38E-05 Multiple sclerosis (brain glutamate levels) CD300A intron 20802204 rs9915892 chr17 72481980 G A 9.44E-05 Bladder cancer / / 19648920 rs783258 chr17 72496035 T C 1.09E-04 Type 2 diabetes / / 17463246 rs1171208 chr17 72503355 G A 1.03E-04 Celiac disease / / 23936387 rs1107704 chr17 72508425 A G 2.54E-04 Celiac disease / / 23936387 rs1171196 chr17 72512881 A G 2.84E-04 Myocardial Infarction / / pha002883 rs10512596 chr17 72523224 T C 4.73E-04 Suicide,with and without major depression CD300LB intron 22059935 rs7221379 chr17 72548847 C G 4.68E-06 Gallstones / / 17632509 rs11650378 chr17 72570776 A G 9.29E-05 Body mass (lean) / / 19268274 rs11650378 chr17 72570776 A G 2.44E-05 Personality dimensions / / 22628180 rs12453454 chr17 72592955 T C 9.14E-05 Body mass (lean) / / 19268274 rs492256 chr17 72604176 T A 9.20E-06 Height / / 20400458 rs563530 chr17 72604717 C T 2.34E-05 Serum metabolites / / 19043545 rs144682080 chr17 72613389 C T 0.00019 Breast cancer (ER positive) CD300E missense 23555315 rs581157 chr17 72613589 T G 6.26E-04 Cholesterol CD300E missense 17255346 rs11657349 chr17 72620811 T G 8.36E-04 Tourette syndrome / / 22889924 rs491192 chr17 72623855 T G 3.18E-04 Cholesterol / / 17255346 rs550333 chr17 72626824 G A 9.12E-04 Tourette syndrome / / 22889924 rs783018 chr17 72633162 C T 2.09E-04 Tourette syndrome / / 22889924 rs11657185 chr17 72633815 A G 7.35E-05 HIV-1 viral setpoint / / 21490045 rs562170 chr17 72637593 A G 6.68E-05 Relative hand skill / / 24068947 rs16978166 chr17 72673549 G A 2.54E-04 Alcohol consumption (maxi-drinks) RAB37 intron 24277619 rs10512597 chr17 72699833 T C 8.00E-11 Fibrinogen CD300LF intron 20031577 rs10512597 chr17 72699833 T C 1.00E-08 Fibrinogen CD300LF intron 23969696 rs1054131 chr17 72743202 G A 3.99E-04 Parkinson's disease RAB37 UTR-3 17052657 rs9904111 chr17 72751663 C T 5.23E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) SLC9A3R1 intron 23648065 rs41282065 chr17 72758167 G A 0.00015 Prostate cancer SLC9A3R1 missense 23555315 rs41282065 chr17 72758167 G A 0.00063 Prostate cancer (non-advanced prostate cancer) SLC9A3R1 missense 23555315 rs734232 chr17 72765731 G A 3.58E-04 Coronary heart disease SLC9A3R1 nearGene-3 21606135 rs2305213 chr17 72769739 A G 6.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) /T9 missense 23648065 rs2305213 chr17 72769739 A G 8.93E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) /T9 missense 23648065 rs6501737 chr17 72780830 T C 6.70E-07 Urinary metabolites TMEM104 intron 21572414 rs4789097 chr17 72781208 A G 4.80E-07 Urinary metabolites TMEM104 intron 21572414 rs2384957 chr17 72784630 A G 8.90E-07 Urinary metabolites TMEM104 intron 21572414 rs11077764 chr17 72787684 T C 3.05E-04 Lipid traits TMEM104 intron 22028671 rs16978197 chr17 72808647 C T 2.00E-04 Alcohol dependence TMEM104 intron 20201924 rs2385067 chr17 72810070 G A 3.70E-04 Type 2 diabetes TMEM104 intron 17463246 rs1568447 chr17 72837012 C T 7.10E-04 Alcohol dependence / / 20201924 rs1568447 chr17 72837012 C T 8.40E-06 Urinary metabolites / / 21572414 rs1568447 chr17 72837012 C T 0.00000408 Alcohol dependence / / 23691058 rs9901283 chr17 72837832 G A 7.90E-04 Alcohol dependence / / 20201924 rs9901283 chr17 72837832 G A 9.43E-05 Alcohol dependence / / 21703634 rs9901283 chr17 72837832 G A 0.00000931 Alcohol dependence / / 23691058 rs11652088 chr17 72839832 G A 4.40E-04 Alcohol dependence GRIN2C intron 20201924 rs11652088 chr17 72839832 G A 7.08E-05 Alcohol dependence GRIN2C intron 21703634 rs11652088 chr17 72839832 G A 0.0000035 Alcohol dependence GRIN2C intron 23691058 rs690533 chr17 72850173 A G 8.50E-04 Alcohol dependence GRIN2C intron 20201924 rs690578 chr17 72853450 G A 6.50E-04 Alcohol dependence GRIN2C intron 20201924 rs2683267 chr17 72854983 T C 3.20E-04 Alcohol dependence GRIN2C intron 20201924 rs690371 chr17 72859078 A G 5.60E-04 Alcohol dependence FDXR intron 20201924 rs690307 chr17 72859709 C A 3.90E-04 Alcohol dependence FDXR intron 20201924 rs199975806 chr17 72875670 C A 0.00035 Breast cancer (ER positive) FADS6 missense 23555315 rs7503366 chr17 72895244 C A 2.98E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs483557 chr17 72896128 C T 2.92E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs141455683 chr17 72926682 G A 0.0003 Breast cancer OTOP2 missense 23555315 rs4789112 chr17 72943929 C T 1.29E-05 Cognitive impairment induced by topiramate OTOP3 intron 22091778 rs1994720 chr17 72946078 A G 1.83E-04 Multiple complex diseases / / 17554300 rs4789114 chr17 72950927 T C 2.42E-04 Multiple complex diseases C17orf28 intron 17554300 rs3744198 chr17 72956124 G A 3.40E-05 Response to acetaminophen (hepatotoxicity) C17orf28 cds-synon 21177773 rs11650024 chr17 72968154 G T 2.20E-04 Alzheimer's disease (late onset) C17orf28 intron 21379329 rs4789121 chr17 72989698 T C 2.50E-05 Cognitive test performance CDR2L intron 20125193 rs1873598 chr17 72993046 G A 7.51E-09 Multiple complex diseases CDR2L intron 17554300 rs10512598 chr17 73038132 G A 5.90E-05 Information processing speed ATP5H intron 21130836 rs11077773 chr17 73060073 T C 8.00E-06 Information processing speed KCTD2 UTR-3 21130836 rs6501755 chr17 73070405 T C 1.30E-05 Urinary metabolites / / 21572414 rs4789128 chr17 73070788 T C 1.30E-05 Urinary metabolites / / 21572414 rs4788863 chr17 73089852 T C 1.00E-05 Urinary metabolites / / 21572414 rs750844 chr17 73120928 G A 4.58E-05 Schizophrenia ARMC7 intron 19571811 rs11657106 chr17 73204137 C T 9.22E-05 Waist Circumference NUP85 intron pha003024 rs1871269 chr17 73220999 C T 9.22E-05 Waist Circumference NUP85 intron pha003024 rs3760203 chr17 73256347 C G 1.03E-04 Multiple complex diseases GGA3 intron 17554300 rs10512603 chr17 73256445 A G 1.03E-04 Multiple complex diseases GGA3 intron 17554300 rs8073890 chr17 73256533 T C 9.61E-05 Warfarin maintenance dose GGA3 intron 19300499 rs4788883 chr17 73285954 A G 7.00E-04 Gamma gluatamyl transferase levels (interaction with age) SLC25A19 nearGene-5 22010049 rs12603538 chr17 73298067 G A 4.74E-04 Multiple complex diseases / / 17554300 rs9892996 chr17 73303217 G A 6.84E-04 Multiple complex diseases / / 17554300 rs12936583 chr17 73304710 C A 0.00006179 Sarcoidosis / / 22952805 rs11658023 chr17 73308722 C T 0.00008721 Sarcoidosis / / 22952805 rs4559942 chr17 73309269 G A 0.00008517 Sarcoidosis / / 22952805 rs7219 chr17 73315368 C T 0.00007295 Sarcoidosis GRB2 UTR-3 22952805 rs12946365 chr17 73317644 C T 4.57E-06 Systemic lupus erythematosus and Systemic sclerosis GRB2 intron 23740937 rs12938183 chr17 73320433 G C 0.00007719 Sarcoidosis GRB2 intron 22952805 rs2164244 chr17 73325244 C T 0.00005819 Sarcoidosis GRB2 intron 22952805 rs12600908 chr17 73328374 G A 1.32E-05 Aging (time to event) GRB2 intron 21782286 rs16967789 chr17 73328989 G A 2.44E-04 Multiple complex diseases GRB2 intron 17554300 rs16967789 chr17 73328989 G A 7.48E-04 Response to taxane treatment (placlitaxel) GRB2 intron 23006423 rs1966663 chr17 73333871 T C 0.00009433 Sarcoidosis GRB2 intron 22952805 rs12940188 chr17 73342702 T C 0.00009931 Sarcoidosis GRB2 intron 22952805 rs11077787 chr17 73343344 G C 3.45E-04 Multiple complex diseases GRB2 intron 17554300 rs9900586 chr17 73343927 A C 4.31E-04 Multiple complex diseases GRB2 intron 17554300 rs12950752 chr17 73344079 A G 0.00005831 Sarcoidosis GRB2 intron 22952805 rs1076094 chr17 73344711 T C 2.74E-04 Multiple complex diseases GRB2 intron 17554300 rs959260 chr17 73369422 C T 2.10E-06 Height GRB2 intron 21194676 rs959260 chr17 73369422 C T 2.70E-04 Height GRB2 intron 21194676 rs4789182 chr17 73374945 G A 8.75E-04 Multiple complex diseases GRB2 intron 17554300 rs4789182 chr17 73374945 G A 8.50E-07 Systemic lupus erythematosus and Systemic sclerosis GRB2 intron 23740937 rs16967866 chr17 73407381 T G 1.46E-04 Type 2 diabetes / / 17463246 rs16967866 chr17 73407381 T G 5.65E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7223674 chr17 73413449 G A 3.63E-04 Multiple complex diseases / / 17554300 rs9913538 chr17 73416814 G T 7.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9896052 chr17 73418862 A C 1.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6501798 chr17 73444647 C T 2.20E-05 Response to Vitamin E supplementation / / 22437554 rs7501644 chr17 73507866 A C 6.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CASKIN2 intron 20877124 rs8064529 chr17 73519413 C T 5.28E-05 Psoriasis TSEN54 missense 20953190 rs1671035 chr17 73553928 T C 3.14E-04 Height LLGL2 intron 17255346 rs1671021 chr17 73565171 T C 4.00E-04 Stroke (ischemic) LLGL2 missense 19403135 rs820259 chr17 73593574 C T 7.62E-04 Aortic root size MYO15B intron 21223598 rs820144 chr17 73611823 T C 4.08E-05 Brain structure / / 22504417 rs820205 chr17 73641052 T A 1.20E-05 Urinary metabolites RECQL5 intron 21572414 rs8066082 chr17 73677546 T G 3.97E-04 Multiple complex diseases SAP30BP intron 17554300 rs820215 chr17 73693810 C T 2.00E-05 Urinary metabolites SAP30BP intron 21572414 rs820215 chr17 73693810 C T 3.00E-04 Cognitive impairment induced by topiramate SAP30BP intron 22091778 rs2305529 chr17 73702253 G A 4.78E-05 Orofacial clefts SAP30BP intron 22863734 rs820229 chr17 73702402 T C 3.73E-04 Multiple complex diseases SAP30BP intron 17554300 rs3744000 chr17 73704333 C T 5.48E-05 Orofacial clefts / / 22863734 rs9897994 chr17 73704865 G A 3.60E-06 Urinary metabolites / / 21572414 rs820164 chr17 73715524 C T 0.000000236 HDL cholesterol ITGB4 nearGene-5 23063622 rs2290769 chr17 73826406 G C 8.10E-06 White matter hyperintensity burden UNC13D intron 21681796 rs2290769 chr17 73826406 G C 0.000222 white matter hyperintensity burden UNC13D intron 23674528 rs17581728 chr17 73830996 C T 6.10E-06 White matter hyperintensity burden UNC13D intron 21681796 rs17581728 chr17 73830996 C T 0.0000497 white matter hyperintensity burden UNC13D intron 23674528 rs7217432 chr17 73834604 A G 5.80E-06 White matter hyperintensity burden UNC13D intron 21681796 rs7217432 chr17 73834604 A G 0.000523 white matter hyperintensity burden UNC13D intron 23674528 rs7221792 chr17 73834690 T G 5.50E-06 White matter hyperintensity burden UNC13D intron 21681796 rs7221792 chr17 73834690 T G 0.000199 white matter hyperintensity burden UNC13D intron 23674528 rs7223416 chr17 73836162 C G 5.40E-06 White matter hyperintensity burden UNC13D cds-synon 21681796 rs7223416 chr17 73836162 C G 0.000204 white matter hyperintensity burden UNC13D cds-synon 23674528 rs8067076 chr17 73837142 A C 9.13E-04 Multiple complex diseases UNC13D intron 17554300 rs8067076 chr17 73837142 A C 5.20E-06 White matter hyperintensity burden UNC13D intron 21681796 rs8067076 chr17 73837142 A C 0.00012 white matter hyperintensity burden UNC13D intron 23674528 rs2290771 chr17 73844748 A G 4.50E-07 White matter hyperintensity burden WBP2 intron 21681796 rs2290771 chr17 73844748 A G 0.00000102 white matter hyperintensity burden WBP2 intron 23674528 rs936393 chr17 73847613 A G 6.80E-09 White matter hyperintensity burden WBP2 intron 21681796 rs936393 chr17 73847613 A G 4.81E-09 white matter hyperintensity burden WBP2 intron 23674528 rs1463485 chr17 73851791 C G 8.30E-08 White matter hyperintensity burden / / 21681796 rs1463485 chr17 73851791 C G 7.94E-09 white matter hyperintensity burden / / 23674528 rs11869977 chr17 73857382 C G 5.70E-09 White matter hyperintensity burden / / 21681796 rs11869977 chr17 73857382 C G 1.10E-09 white matter hyperintensity burden / / 23674528 rs11870121 chr17 73858938 A G 6.80E-08 White matter hyperintensity burden / / 21681796 rs9894383 chr17 73865657 T G 5.30E-09 White matter hyperintensity burden / / 21681796 rs9894383 chr17 73865657 T G 8.71E-10 white matter hyperintensity burden / / 23674528 rs3744017 chr17 73871467 G A 7.30E-09 White matter hyperintensity burden TRIM47 intron 21681796 rs3744017 chr17 73871467 G A 8.49E-09 white matter hyperintensity burden TRIM47 intron 23674528 rs1055129 chr17 73872948 A G 3.00E-11 White matter hyperintensity burden TRIM47 intron 21681796 rs1055129 chr17 73872948 A G 3.58E-08 white matter hyperintensity burden TRIM47 intron 23674528 rs1551619 chr17 73885805 C T 2.00E-07 White matter hyperintensity burden TRIM65 UTR-3 21681796 rs1551619 chr17 73885805 C T 0.000000553 white matter hyperintensity burden TRIM65 UTR-3 23674528 rs3760128 chr17 73886888 A G 8.00E-07 White matter hyperintensity burden TRIM65 missense 21681796 rs3760128 chr17 73886888 A G 0.00000313 white matter hyperintensity burden TRIM65 missense 23674528 rs3744028 chr17 73888672 T C 4.00E-15 White matter hyperintensity burden TRIM65 intron 21681796 rs3744028 chr17 73888672 T C 6.39E-09 white matter hyperintensity burden TRIM65 intron 23674528 rs7370 chr17 73894804 G A 3.30E-05 White matter hyperintensity burden MRPL38 UTR-3 21681796 rs1046446 chr17 73896299 C T 4.20E-06 White matter hyperintensity burden MRPL38 intron 21681796 rs1046446 chr17 73896299 C T 0.0000137 white matter hyperintensity burden MRPL38 intron 23674528 rs3785437 chr17 73906222 G T 2.90E-07 White matter hyperintensity burden / / 21681796 rs3785437 chr17 73906222 G T 6.15E-08 white matter hyperintensity burden / / 23674528 rs9302994 chr17 73906934 G A 3.00E-06 White matter hyperintensity burden FBF1 intron 21681796 rs9302994 chr17 73906934 G A 0.0000144 white matter hyperintensity burden FBF1 intron 23674528 rs9895947 chr17 73908566 A C 2.80E-06 White matter hyperintensity burden FBF1 intron 21681796 rs9895947 chr17 73908566 A C 0.0000101 white matter hyperintensity burden FBF1 intron 23674528 rs9891076 chr17 73911715 C T 1.20E-05 White matter hyperintensity burden FBF1 intron 21681796 rs6501841 chr17 73924086 G A 4.94E-04 Multiple complex diseases FBF1 intron 17554300 rs1135889 chr17 73926121 C A 5.60E-06 White matter hyperintensity burden FBF1 missense 21681796 rs1135889 chr17 73926121 C A 0.0000152 white matter hyperintensity burden FBF1 missense 23674528 rs7218498 chr17 73931847 C G 1.20E-05 White matter hyperintensity burden FBF1 intron 21681796 rs2608882 chr17 73934130 G A 7.30E-06 White matter hyperintensity burden FBF1 intron 21681796 rs2608882 chr17 73934130 G A 0.0000293 white matter hyperintensity burden FBF1 intron 23674528 rs2608881 chr17 73936653 G C 8.03E-05 Multiple complex diseases FBF1 intron 17554300 rs12430 chr17 73941955 G A 8.88E-06 Alopecia areata ACOX1 UTR-3 22027810 rs3682 chr17 73942150 A G 1.10E-05 White matter hyperintensity burden ACOX1 UTR-3 21681796 rs1135640 chr17 73949540 G C 1.20E-05 White matter hyperintensity burden ACOX1 missense 21681796 rs6501843 chr17 73949918 G A 1.20E-05 White matter hyperintensity burden ACOX1 intron 21681796 rs8065144 chr17 73959857 A G 5.68E-04 Multiple complex diseases ACOX1 intron 17554300 rs8065144 chr17 73959857 A G 2.53E-05 Insulin-related traits ACOX1 intron pha003063 rs7342883 chr17 74003846 G A 1.44E-05 Schizophrenia (cytomegalovirus infection interaction) EVPL missense 23358160 rs12951303 chr17 74036112 G A 6.77E-06 Glycemic traits (pregnancy) SRP68 intron 23903356 rs4789241 chr17 74063523 G A 1.16E-05 Cognitive impairment induced by topiramate SRP68 intron 22091778 rs16968495 chr17 74066476 T C 1.94E-11 Triglycerides SRP68 cds-synon 23063622 rs2598414 chr17 74067099 C T 1.21E-05 Cognitive impairment induced by topiramate SRP68 intron 22091778 rs2257020 chr17 74076415 G A 1.05E-05 Cognitive impairment induced by topiramate ZACN missense 22091778 rs2257020 chr17 74076415 G A 0.00082 Prostate cancer ZACN missense 23555315 rs2305347 chr17 74080443 C T 8.19E-05 Cognitive impairment induced by topiramate EXOC7 intron 22091778 rs2665981 chr17 74089311 A G 2.00E-05 Urinary metabolites EXOC7 intron 21572414 rs2666011 chr17 74095893 G A 1.60E-05 Urinary metabolites EXOC7 intron 21572414 rs2585746 chr17 74115882 C T 6.10E-06 Urinary metabolites / / 21572414 rs2665969 chr17 74122209 C T 3.50E-08 Non-obstructive azoospermia / / 22541561 rs2598425 chr17 74142891 C T 2.06E-04 Body mass index RNF157 intron 17255346 rs1868821 chr17 74149689 C T 4.10E-04 Atrial fibrillation RNF157 intron 21846873 rs8068137 chr17 74165189 C T 9.33E-06 Sleep duration RNF157 intron 22105623 rs9911832 chr17 74189525 G A 8.72E-06 Sleep duration RNF157 intron 22105623 rs8077453 chr17 74190033 G T 0.000182257 Hypertension (early onset hypertension) RNF157 intron 22479346 rs9302997 chr17 74211844 T A 5.10E-06 Subclinical atherosclerosis RNF157 intron 17903303 rs10512605 chr17 74212382 C T 7.85E-04 Iron levels RNF157 intron pha002876 rs8068689 chr17 74239621 T C 8.30E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs8079062 chr17 74255029 A G 3.56E-04 Iron levels / / pha002876 rs347675 chr17 74275160 C T 5.58E-05 Body Mass Index QRICH2 cds-synon pha003006 rs4789267 chr17 74279445 T C 1.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) QRICH2 intron 20877124 rs4789267 chr17 74279445 T C 8.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) QRICH2 intron 20877124 rs164009 chr17 74283669 A G 7.57E-04 Type 2 diabetes QRICH2 intron 17463246 rs164009 chr17 74283669 A G 7.87E-04 Coronary Artery Disease QRICH2 intron 17634449 rs164009 chr17 74283669 A G 5.00E-04 Obesity,menopause QRICH2 intron 21424828 rs164009 chr17 74283669 A G 2.00E-07 Urate levels QRICH2 intron 23263486 rs2279056 chr17 74309474 A G 7.01E-04 Coronary Artery Disease PRPSAP1 intron 17634449 rs2279055 chr17 74309561 C G 2.02E-04 Cognitive decline PRPSAP1 intron 23732972 rs9892909 chr17 74373075 C T 2.00E-04 Blood pressure / / 21060006 rs9892909 chr17 74373075 C T 4.00E-04 Blood pressure / / 21060006 rs9892909 chr17 74373075 C T 5.30E-06 Blood pressure / / 21060006 rs9892909 chr17 74373075 C T 9.00E-04 Blood pressure / / 21060006 rs9989481 chr17 74374619 T C 3.60E-06 Urinary metabolites / / 21572414 rs1550767 chr17 74428363 T C 1.51E-04 Multiple complex diseases UBE2O intron 17554300 rs4788926 chr17 74487735 T C 9.92E-04 Suicide attempts in bipolar disorder RHBDF2 intron 21423239 rs12950648 chr17 74499333 C T 5.66E-04 Acute lung injury / / 22295056 rs12948783 chr17 74499400 G A 8.10E-09 Pain relief with opioid treatment / / 21622719 rs12950972 chr17 74519300 T C 2.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs895156 chr17 74541883 A C 6.60E-05 Blood Pressure PRCD nearGene-3 pha003039 rs752049 chr17 74546939 C T 6.39E-05 Blood Pressure / / pha003039 rs9911606 chr17 74548000 G T 5.55E-05 Blood Pressure / / pha003039 rs16967307 chr17 74573532 T C 9.11E-08 Metabolite levels ST6GAL/C2 intron 23281178 rs11655698 chr17 74574062 A G 9.11E-08 Metabolite levels ST6GAL/C2 intron 23281178 rs10512610 chr17 74574132 C G 9.11E-08 Metabolite levels ST6GAL/C2 intron 23281178 rs3809700 chr17 74583226 G T 7.22E-05 Body mass index / / 24827717 rs11077846 chr17 74607747 A G 4.70E-05 Parkinson's disease (age of onset) / / 19772629 rs12951774 chr17 74615229 C T 5.03E-04 Alzheimer's disease / / 22005930 rs12937733 chr17 74618243 T C 6.37E-04 Alzheimer's disease / / 22005930 rs2410993 chr17 74618871 T C 2.90E-06 Urinary metabolites / / 21572414 rs8073763 chr17 74621298 C T 8.22E-04 Alzheimer's disease ST6GAL/C1 UTR-3 22005930 rs115756441 chr17 74625633 C T 0.0000024 Breast cancer (ER positive) ST6GAL/C1 missense 23555315 rs9910052 chr17 74668801 T G 6.34E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7211963 chr17 74696446 C T 8.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MXRA7 intron 20877124 rs1005645 chr17 74696760 T C 2.18E-05 Creatinine levels MXRA7 intron pha003069 rs887309 chr17 74707834 C T 2.29E-04 Multiple complex diseases / / 17554300 rs201999820 chr17 74725812 C T 0.00051 Prostate cancer METTL23 missense 23555315 rs147321492 chr17 74729764 T C 0.0000042 Prostate cancer (advanced) METTL23 missense 23555315 rs3744061 chr17 74733403 G A 2.00E-10 Retinal arteriolar caliber SRSF2 UTR-5 23776548 rs8081711 chr17 74735676 A G 3.49E-05 Multiple complex diseases MFSD11 intron 17554300 rs9916811 chr17 74749273 C T 1.77E-05 Retinal arteriolar caliber MFSD11 intron 23776548 rs2411036 chr17 74815685 T C 3.86E-10 Narcolepsy / / 19629137 rs12452461 chr17 74824709 C T 2.85E-04 Alzheimer's disease / / 22005930 rs12452874 chr17 74825247 G A 7.24E-04 Alzheimer's disease / / 22005930 rs644871 chr17 74858608 T C 6.02E-06 Erythrocyte counts / / pha003101 rs11077873 chr17 74872905 C T 6.52E-04 Multiple complex diseases MGAT5B intron 17554300 rs1036987 chr17 74892171 A T 3.45E-06 Hearing function MGAT5B intron 21493956 rs532753 chr17 74892854 A C 3.41E-04 Suicide attempts in bipolar disorder MGAT5B intron 21423239 rs9916886 chr17 74895786 A C 2.00E-04 Information processing speed MGAT5B intron 21130836 rs8064352 chr17 74896345 G T 2.00E-04 Information processing speed MGAT5B intron 21130836 rs8065442 chr17 74896359 C T 2.00E-04 Information processing speed MGAT5B intron 21130836 rs569234 chr17 74899123 C T 8.67E-04 Suicide attempts in bipolar disorder MGAT5B intron 21423239 rs567207 chr17 74899373 C T 7.66E-04 Suicide attempts in bipolar disorder MGAT5B intron 21423239 rs642058 chr17 74899615 A G 7.66E-04 Suicide attempts in bipolar disorder MGAT5B intron 21423239 rs641233 chr17 74899797 A G 7.70E-04 Suicide attempts in bipolar disorder MGAT5B intron 21423239 rs76936 chr17 74899963 G A 7.54E-04 Suicide attempts in bipolar disorder MGAT5B intron 21423239 rs535136 chr17 74900585 C A 7.50E-04 Suicide attempts in bipolar disorder MGAT5B intron 21423239 rs1025934 chr17 74905595 T G 6.44E-05 Information processing speed MGAT5B intron 21130836 rs4789374 chr17 74912360 G A 1.26E-04 Alzheimer's disease (late onset) MGAT5B intron 21379329 rs2411042 chr17 74913937 G T 3.42E-04 Alcohol dependence MGAT5B intron 21314694 rs16969506 chr17 74914941 A G 4.19E-04 Type 2 diabetes MGAT5B intron 17463246 rs16969506 chr17 74914941 A G 1.00E-04 Adverse response to radiation therapy MGAT5B intron 23719583 rs4789378 chr17 74930366 T C 1.89E-04 Oral cancers (chewing tobacco related) MGAT5B intron 22503698 rs11656656 chr17 74945891 A G 2.79E-04 Scoliosis MGAT5B UTR-3 21216876 rs7221059 chr17 74988444 C A 3.00E-08 Pulmonary emphysema / / 24383474 rs3848391 chr17 74988840 C T 6.27E-06 Substance dependence phenotypes / / 24832863 rs11655206 chr17 74989576 C T 5.60E-05 Male-pattern baldness / / 18849994 rs4789398 chr17 74995894 C T 6.61E-06 Substance dependence phenotypes / / 24832863 rs4789400 chr17 74997897 A G 5.00E-06 Cannabis use (initiation) / / 22823124 rs11653989 chr17 75004213 A T 3.00E-06 Cardiac repolarization / / 22683750 rs6501930 chr17 75009071 G A 9.80E-05 LDL lipoproteins / / pha002902 rs3915813 chr17 75010493 C T 8.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs8066206 chr17 75025229 A T 7.00E-05 Response to statin therapy / / 20339536 rs12939845 chr17 75038316 C T 3.35E-05 Alzheimer's disease (age of onset) / / 22005931 rs12948945 chr17 75038439 T G 2.93E-05 Alzheimer's disease (age of onset) / / 22005931 rs679210 chr17 75045983 A C 1.10E-06 Alcoholism (heaviness of drinking) / / 21529783 rs894573 chr17 75070799 T G 5.45E-04 Premature ovarian failure / / 19508998 rs2053568 chr17 75109300 T C 3.17E-04 Alcohol dependence SEC14L1 intron 21314694 rs11652039 chr17 75110626 G A 5.15E-04 Obesity (extreme) SEC14L1 intron 21935397 rs569908 chr17 75125632 C T 1.70E-05 Urinary metabolites SEC14L1 intron 21572414 rs542539 chr17 75126270 C T 1.90E-05 Urinary metabolites SEC14L1 intron 21572414 rs16969682 chr17 75127012 A C 2.93E-04 Obesity (extreme) SEC14L1 intron 21935397 rs16969683 chr17 75128195 C T 1.20E-05 Urinary metabolites SEC14L1 intron 21572414 rs16967342 chr17 75141643 T C 3.82E-04 Obesity (extreme) SEC14L1 intron 21935397 rs2176757 chr17 75146266 T C 3.65E-04 Obesity (extreme) SEC14L1 intron 21935397 rs2411070 chr17 75148813 A G 3.70E-04 Obesity (extreme) SEC14L1 intron 21935397 rs2008417 chr17 75155776 T C 1.29E-05 Obesity (extreme) SEC14L1 intron 21935397 rs17612259 chr17 75157866 T A 1.28E-05 Obesity (extreme) SEC14L1 intron 21935397 rs17612441 chr17 75182811 T C 3.53E-04 Obesity (extreme) SEC14L1 intron 21935397 rs6501941 chr17 75184381 T C 3.37E-04 Obesity (extreme) SEC14L1 intron 21935397 rs7222475 chr17 75184643 G A 3.25E-04 Obesity (extreme) SEC14L1 intron 21935397 rs17540424 chr17 75190112 C T 2.98E-04 Obesity (extreme) SEC14L1 intron 21935397 rs16969749 chr17 75192907 G A 4.02E-04 Alzheimer's disease SEC14L1 intron 24755620 rs2271792 chr17 75201529 G C 2.96E-04 Obesity (extreme) SEC14L1 intron 21935397 rs17540750 chr17 75205145 A G 2.97E-04 Obesity (extreme) SEC14L1 intron 21935397 rs2280270 chr17 75205562 C T 3.03E-04 Obesity (extreme) SEC14L1 intron 21935397 rs3744064 chr17 75211208 C T 7.00E-07 Cognitive performance SEC14L1 UTR-3 19734545 rs7215278 chr17 75215103 G T 2.97E-05 Obesity (extreme) / / 21935397 rs16969774 chr17 75218568 T G 1.14E-05 Obesity (extreme) / / 21935397 rs17613220 chr17 75236950 G C 1.50E-05 Urinary metabolites / / 21572414 rs2174919 chr17 75247279 G A 1.65E-05 Colorectal cancer / / 21242260 rs647861 chr17 75255961 T C 1.85E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9898775 chr17 75270088 G T 7.75E-05 Glucose levels / / pha003061 rs11077898 chr17 75306521 G A 8.08E-05 Lipoproteins SEPT9 intron pha003079 rs11654929 chr17 75309351 A G 0.000686134 Hypertension (early onset hypertension) SEPT9 intron 22479346 rs4788985 chr17 75313335 A G 1.80E-04 Nicotine use SEPT9 intron 23942779 rs4788985 chr17 75313335 A G 7.80E-04 Alcohol consumption SEPT9 intron 23942779 rs4788985 chr17 75313335 A G 9.00E-06 Illicit drug use SEPT9 intron 23942779 rs1347545 chr17 75320440 C T 9.32E-05 Sudden cardiac arrest SEPT9 intron 21658281 rs892964 chr17 75326517 A C 0.000707397 Hypertension (early onset hypertension) SEPT9 intron 22479346 rs2411109 chr17 75332456 G A 2.69E-04 Alcohol dependence SEPT9 intron 21314694 rs2898645 chr17 75332699 T C 0.000577862 Hypertension (early onset hypertension) SEPT9 intron 22479346 rs2117925 chr17 75344736 T C 5.20E-04 Amyotrophic Lateral Sclerosis SEPT9 intron 17362836 rs7221079 chr17 75345027 T C 6.48E-05 Hypertension (essential hypertension) SEPT9 intron 22184326 rs11655079 chr17 75348675 C T 6.65E-05 Hypertension (essential hypertension) SEPT9 intron 22184326 rs367539 chr17 75350872 C T 5.70E-08 Progranulin levels SEPT9 intron 21087763 rs367539 chr17 75350872 C T 5.70E-08 Myocardial infarction SEPT9 intron 21211798 rs7209417 chr17 75365508 G A 2.42E-05 Hypertension (essential hypertension) SEPT9 intron 22184326 rs12451315 chr17 75372126 C G 8.84E-05 Sudden cardiac arrest SEPT9 intron 21658281 rs892961 chr17 75400100 T A 9.00E-06 Airflow obstruction SEPT9 intron 22837378 rs312813 chr17 75508893 T G 1.80E-05 Urinary metabolites / / 21572414 rs4462668 chr17 75528870 T G 8.76E-05 Body Mass Index / / pha003022 rs8070652 chr17 75539619 G A 7.39E-04 Alzheimer's disease / / 17998437 rs12947286 chr17 75545954 C T 0.0000068 Autism spectrum disorders LOC100507351 intron 22412387 rs8072007 chr17 75562087 T G 4.96E-04 Multiple complex diseases / / 17554300 rs2411129 chr17 75576843 G A 7.67E-05 Body Fat Distribution / / pha003016 rs11077917 chr17 75590582 C T 1.03E-04 Multiple complex diseases / / 17554300 rs7214455 chr17 75599604 C T 8.60E-05 Cognitive impairment induced by topiramate / / 22091778 rs1108759 chr17 75600682 C A 1.87E-04 Amyotrophic lateral sclerosis / / 23624525 rs1077759 chr17 75608685 C T 4.23E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs2077252 chr17 75609112 G A 8.74E-04 Schizophrenia / / 19197363 rs7350912 chr17 75623026 T A 3.66E-04 Type 2 diabetes / / 17463246 rs17546529 chr17 75624399 G T 6.50E-05 Personality dimensions / / 18957941 rs2077613 chr17 75639967 G A 8.99E-04 Type 2 diabetes / / 17463246 rs4789482 chr17 75658977 A G 6.08E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs9908508 chr17 75690021 C T 2.09E-04 Coronary heart disease / / 21606135 rs9891526 chr17 75695351 G A 7.10E-05 Diabetic retinopathy / / 21441570 rs9894103 chr17 75695409 A G 4.50E-05 Diabetic retinopathy / / 21441570 rs7214916 chr17 75695647 T C 3.70E-05 Diabetic retinopathy / / 21441570 rs9901599 chr17 75696248 A C 2.77E-04 Coronary heart disease / / 21606135 rs9902073 chr17 75696443 A C 2.49E-04 Coronary heart disease / / 21606135 rs9907643 chr17 75697579 G A 3.60E-05 Diabetic retinopathy / / 21441570 rs7212215 chr17 75699320 C T 3.80E-05 Diabetic retinopathy / / 21441570 rs9897643 chr17 75701576 G C 1.65E-04 Coronary heart disease / / 21606135 rs9906155 chr17 75701697 T C 9.00E-06 Body mass index / / 20966902 rs9906155 chr17 75701697 T C 4.40E-05 Diabetic retinopathy / / 21441570 rs9914269 chr17 75702800 T C 4.50E-05 Diabetic retinopathy / / 21441570 rs1529964 chr17 75706339 T C 2.01E-04 Osteoarthritis / / 19508968 rs6501985 chr17 75712159 G A 5.39E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9909030 chr17 75718552 G A 7.50E-05 Diabetic retinopathy / / 21441570 rs9905062 chr17 75721715 G T 3.68E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1965780 chr17 75734511 G A 2.63E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9907505 chr17 75738914 C T 6.22E-04 Taste perception / / 22132133 rs8080918 chr17 75738935 G A 7.74E-04 Multiple complex diseases / / 17554300 rs7501958 chr17 75761003 C T 1.01E-04 Obesity (extreme) / / 21935397 rs6501989 chr17 75774691 A G 8.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16970548 chr17 75807631 G A 7.17E-05 Cognitive impairment induced by topiramate / / 22091778 rs7405515 chr17 75815125 G A 1.79E-05 Height / / pha003010 rs7405515 chr17 75815125 G A 3.07E-05 Height / / pha003011 rs16970570 chr17 75822847 G A 3.00E-06 Body mass index / / 20818722 rs11870565 chr17 75824095 A G 4.15E-05 Tunica Media / / pha003036 rs9910282 chr17 75834770 A G 2.57E-04 Multiple complex diseases / / 17554300 rs4789504 chr17 75835645 C T 1.53E-05 Body Mass Index / / pha003014 rs4789505 chr17 75835968 C T 1.40E-04 Multiple complex diseases / / 17554300 rs8080480 chr17 75839026 C T 5.01E-04 Multiple complex diseases / / 17554300 rs8080480 chr17 75839026 C T 1.97E-05 Body Mass Index / / pha003014 rs7222222 chr17 75889612 C T 6.13E-04 Myocardial Infarction / / pha002883 rs9902857 chr17 75916160 C T 6.41E-05 Blood Pressure / / pha002898 rs4789517 chr17 75929330 G C 6.53E-04 Multiple complex diseases / / 17554300 rs4789009 chr17 75938016 G C 4.83E-04 Alzheimer's disease / / 22005930 rs4239002 chr17 75938886 T A 2.26E-04 Alzheimer's disease / / 22005930 rs4789519 chr17 75939120 A C 1.98E-04 Alzheimer's disease / / 22005930 rs12051866 chr17 75940605 C T 6.20E-04 Alzheimer's disease / / 22005930 rs12051871 chr17 75940724 C A 3.12E-04 Alzheimer's disease / / 22005930 rs11867214 chr17 75941268 G T 1.56E-04 Alzheimer's disease / / 22005930 rs16970672 chr17 75944650 G A 6.00E-06 Personality dimensions / / 21173776 rs16970672 chr17 75944650 G A 2.00E-06 Alzheimer's disease / / 22005930 rs4789522 chr17 75959825 A C 3.33E-04 Alzheimer's disease / / 22005930 rs8080086 chr17 75977988 A G 3.72E-04 Alzheimer's disease / / 22005930 rs16970721 chr17 75982181 G A 9.59E-05 Alzheimer's disease / / 22005930 rs9904097 chr17 75984984 A G 1.09E-05 Alzheimer's disease / / 22005930 rs1001168 chr17 75991816 C G 5.64E-06 Personality dimensions / / 21173776 rs1001168 chr17 75991816 C G 2.16E-04 Alzheimer's disease / / 22005930 rs1007754 chr17 75995073 A G 1.02E-04 Alzheimer's disease / / 22005930 rs8074332 chr17 76000573 T C 4.16E-04 Alzheimer's disease TNRC6C intron 22005930 rs4789523 chr17 76012854 C T 6.95E-05 Multiple complex diseases TNRC6C intron 17554300 rs4789523 chr17 76012854 C T 1.66E-05 Alzheimer's disease TNRC6C intron 22005930 rs9889827 chr17 76026671 T C 8.74E-05 Alzheimer's disease TNRC6C intron 22005930 rs16970755 chr17 76030028 G A 2.33E-06 Personality dimensions TNRC6C intron 21173776 rs16970755 chr17 76030028 G A 1.77E-04 Alzheimer's disease TNRC6C intron 22005930 rs4362447 chr17 76033562 C T 6.46E-06 Multiple complex diseases TNRC6C intron 17554300 rs4362447 chr17 76033562 C T 3.36E-04 Alzheimer's disease TNRC6C intron 22005930 rs16970766 chr17 76039419 G C 1.50E-04 Alzheimer's disease TNRC6C intron 22005930 rs2311443 chr17 76054749 C G 1.30E-04 Alzheimer's disease TNRC6C intron 22005930 rs16970774 chr17 76055547 G A 1.30E-04 Alzheimer's disease TNRC6C intron 22005930 rs9916037 chr17 76056144 T C 1.26E-04 Alzheimer's disease TNRC6C intron 22005930 rs2311442 chr17 76057354 A G 1.28E-04 Alzheimer's disease TNRC6C intron 22005930 rs2871765 chr17 76057435 A C 1.29E-04 Alzheimer's disease TNRC6C intron 22005930 rs16970784 chr17 76058682 A T 2.16E-04 Multiple complex diseases TNRC6C intron 17554300 rs9893684 chr17 76059782 A G 1.43E-04 Alzheimer's disease TNRC6C intron 22005930 rs4789012 chr17 76061566 C A 5.87E-05 Multiple complex diseases TNRC6C intron 17554300 rs4789012 chr17 76061566 C A 3.15E-04 Alzheimer's disease TNRC6C intron 22005930 rs9909805 chr17 76077700 A G 1.07E-04 Alzheimer's disease TNRC6C intron 22005930 rs2311001 chr17 76092553 G C 1.05E-04 Alzheimer's disease TNRC6C intron 22005930 rs2311001 chr17 76092553 G C 3.14E-04 Schizophrenia TNRC6C intron 24043878 rs2613514 chr17 76110518 A G 3.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients TMC6 intron 23400010 rs8073715 chr17 76151386 A G 2.60E-05 IgE levels C17orf99 intron 17255346 rs8073715 chr17 76151386 A G 4.14E-05 Prion diseases C17orf99 intron 22210626 rs9909570 chr17 76158527 G A 2.68E-04 Multiple complex diseases C17orf99 intron 17554300 rs2292235 chr17 76160881 C A 3.73E-04 Coronary heart disease C17orf99 intron 21971053 rs12232476 chr17 76169771 G A 2.65E-04 IgE levels / / 17255346 rs2854702 chr17 76171330 C T 1.05E-04 IgE levels TK1 intron 17255346 rs2854702 chr17 76171330 C T 2.67E-05 Heart Rate TK1 intron pha003051 rs1811086 chr17 76173022 G A 5.65E-04 Multiple complex diseases TK1 intron 17554300 rs16970909 chr17 76190494 G T 7.36E-05 Height AFMID intron 19570815 rs12947167 chr17 76217983 T C 1.49E-04 Lymphocyte counts BIRC5 intron 22286170 rs2071214 chr17 76219591 G A 1.77E-04 Alcohol dependence BIRC5 missense 21314694 rs2071214 chr17 76219591 G A 8.00E-06 Behavioural disinhibition (generation interaction) BIRC5 missense 23942779 rs17879146 chr17 76219945 T G 1.00E-06 Periodontitis (Mean PAL) BIRC5 UTR-3 24024966 rs9907137 chr17 76228630 C T 1.13E-05 Elbow pain TMEM235 intron pha003008 rs7211218 chr17 76236954 A C 1.26E-04 Smoking initiation TMEM235 UTR-3 24665060 rs11658812 chr17 76237874 G A 2.72E-05 Myopia (pathological) / / 23049088 rs11656102 chr17 76243058 C T 4.91E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7217176 chr17 76276483 G A 2.18E-05 Coronary heart disease / / 21606135 rs8081523 chr17 76304510 C G 5.00E-06 Blood trace element (Se levels) / / 23720494 rs4789580 chr17 76311991 T G 9.00E-06 IgG glycosylation / / 23382691 rs4447485 chr17 76338687 C T 4.65E-04 Stroke / / pha002886 rs4082919 chr17 76377482 T G 0.000000891 Cholesterol,total PGS1 intron 23063622 rs4082919 chr17 76377482 T G 0.0000233 LDL cholesterol PGS1 intron 23063622 rs4082919 chr17 76377482 T G 4.42E-07 Red blood cell traits PGS1 intron 23222517 rs4366775 chr17 76382079 C T 4.23E-08 Red blood cell traits PGS1 intron 23222517 rs4969178 chr17 76388202 A G 8.89E-07 Red blood cell traits PGS1 intron 23222517 rs17561950 chr17 76392144 G A 5.56E-08 Red blood cell traits PGS1 intron 23222517 rs4969182 chr17 76393030 T C 8.59E-09 Red blood cell traits PGS1 intron 23222517 rs4969183 chr17 76393372 A G 1.98E-08 Red blood cell traits PGS1 intron 23222517 rs4969184 chr17 76393413 G A 7.02E-09 Red blood cell traits PGS1 intron 23222517 rs3817295 chr17 76394526 T A 8.82E-07 Red blood cell traits PGS1 intron 23222517 rs6501208 chr17 76395038 A T 8.24E-07 Red blood cell traits PGS1 intron 23222517 rs17845783 chr17 76395430 C CC,CT 8.78E-07 Red blood cell traits PGS1 cds-synon 23222517 rs2292642 chr17 76395430 C T 8.78E-07 Red blood cell traits PGS1 cds-synon 23222517 rs4129767 chr17 76403984 G A 5.00E-09 HDL cholesterol PGS1 intron 20686565 rs4129767 chr17 76403984 G A 1.00E-08 Red blood cell traits PGS1 intron 23222517 rs4129767 chr17 76403984 G A 2.00E-11 HDL cholesterol PGS1 intron 24097068 rs72925845 chr17 76439361 G A 1.07E-05 Triglycerides D/H17 intron 24886709 rs7211232 chr17 76442641 C T 9.17E-05 Major depressive disorder (broad) D/H17 intron 20038947 rs4969189 chr17 76444858 C T 3.73E-04 Lymphocyte counts D/H17 intron 22286170 rs8081163 chr17 76478878 A G 7.71E-04 Multiple complex diseases D/H17 intron 17554300 rs9900319 chr17 76479367 G A 3.95E-04 Response to taxane treatment (placlitaxel) D/H17 intron 23006423 rs11654661 chr17 76484948 C T 1.80E-04 Suicide attempts in bipolar disorder D/H17 intron 21423239 rs11077375 chr17 76491194 G A 3.11E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) D/H17 intron 20877124 rs11077375 chr17 76491194 G A 4.49E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) D/H17 intron 20877124 rs17655474 chr17 76495486 C G 3.35E-04 Insulin resistance D/H17 intron 21901158 rs671899 chr17 76497778 T C 7.70E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) D/H17 intron 20877124 rs671899 chr17 76497778 T C 8.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) D/H17 intron 20877124 rs139273056 chr17 76497940 C T 0.000085 Prostate cancer (advanced) D/H17 missense 23555315 rs139273056 chr17 76497940 C T 0.00083 Prostate cancer D/H17 missense 23555315 rs12103535 chr17 76500652 C T 5.94E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) D/H17 intron 20877124 rs2120660 chr17 76504512 G A 6.16E-04 Multiple complex diseases D/H17 intron 17554300 rs642612 chr17 76521526 T C 7.83E-05 Intelligence D/H17 intron 21826061 rs4969201 chr17 76543242 T C 2.30E-05 Urinary metabolites D/H17 intron 21572414 rs8071885 chr17 76543590 C G 2.84E-05 Acute lymphoblastic leukemia (childhood) D/H17 intron 19684603 rs8080186 chr17 76549152 C G 2.70E-06 Urinary metabolites D/H17 intron 21572414 rs144524797 chr17 76565555 C T 0.00016 Breast cancer D/H17 missense 23555315 rs4969204 chr17 76597976 C T 2.10E-04 Multiple complex diseases / / 17554300 rs6501232 chr17 76608673 A G 4.95E-04 Parkinson's disease / / 17052657 rs4796808 chr17 76613675 G T 9.24E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs4796796 chr17 76614120 C T 3.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs7502312 chr17 76620933 A G 2.43E-04 Multiple complex diseases / / 17554300 rs9908993 chr17 76633585 G A 4.63E-04 Lymphocyte counts / / 22286170 rs4796827 chr17 76633965 A G 2.00E-06 Anxiety and major depressive disorder / / 24047446 rs7210405 chr17 76646503 G A 1.30E-04 Telomere length / / 21573004 rs10512617 chr17 76693551 C G 1.65E-05 Statin-induced myopathy CYTH1 intron 21826682 rs6501243 chr17 76744555 C A 7.88E-04 Alzheimer's disease CYTH1 intron 22005930 rs2010806 chr17 76781936 A T 3.56E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs8182269 chr17 76789991 A T 6.07E-11 Lymphocyte counts / / 22286170 rs1044486 chr17 76792179 G A 7.95E-04 Alzheimer's disease / / 22005930 rs7218605 chr17 76811803 C T 4.42E-06 Parkinson's disease USP36 intron 17052657 rs3744793 chr17 76817090 C T 7.24E-04 Type 2 diabetes USP36 missense 17463246 rs3744792 chr17 76823227 T G 6.58E-04 Type 2 diabetes USP36 intron 22158537 rs7213204 chr17 76831800 T C 9.87E-04 HIV-1 viral setpoint USP36 intron 17641165 rs16971783 chr17 76856653 T A 0.00049 Coronary artery calcification TIMP2 intron 23727086 rs11077399 chr17 76864175 A G 7.59E-05 Serum metabolites TIMP2 intron 19043545 rs9900972 chr17 76868614 A G 8.00E-06 Obesity-related traits TIMP2 intron 23251661 rs2009196 chr17 76870581 C G 2.00E-06 Periodontitis (CDC/AAP) TIMP2 intron 24024966 rs9916773 chr17 76870618 C A 3.59E-04 Response to taxane treatment (placlitaxel) TIMP2 intron 23006423 rs7502935 chr17 76878629 G A 1.91E-05 Alzheimer's disease (late onset) TIMP2 intron 21379329 rs4789939 chr17 76881703 T C 6.00E-07 Dupuytren's disease TIMP2 intron 21732829 rs4789939 chr17 76881703 T C 1.49E-04 Myocardial Infarction TIMP2 intron pha002883 rs2376999 chr17 76890864 A G 5.70E-04 Myocardial Infarction TIMP2 intron pha002883 rs4789937 chr17 76894680 A G 1.06E-16 Adiponectin levels TIMP2 intron 20887962 rs4789936 chr17 76897974 C T 7.12E-04 Tourette syndrome LOC100653515 UTR-5 22889924 rs4789933 chr17 76923426 C T 8.71E-05 Brain lesion load / / 19010793 rs4789932 chr17 76924275 G A 0.000045 Coronary artery calcification / / 23727086 rs4789855 chr17 76931042 G A 5.05E-04 Multiple complex diseases / / 17554300 rs3785529 chr17 76972960 C T 6.32E-04 Coronary heart disease LGALS3BP intron 21971053 rs3826312 chr17 77073327 T C 2.07E-04 Amyotrophic lateral sclerosis (sporadic) ENGASE intron 24529757 rs8073225 chr17 77087782 T C 6.75E-05 Intelligence RBFOX3 intron 21826061 rs7218918 chr17 77100721 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) RBFOX3 intron 20708005 rs11868833 chr17 77110044 T C 4.38E-04 Smoking cessation RBFOX3 intron 24665060 rs2612773 chr17 77115387 C T 1.20E-05 Urinary metabolites RBFOX3 intron 21572414 rs2612773 chr17 77115387 C T 0.00038 Salmonella-induced pyroptosis RBFOX3 intron 22837397 rs2612781 chr17 77116029 A G 2.43E-05 Cognitive test performance RBFOX3 intron 20125193 rs898528 chr17 77166803 T C 4.94E-05 Parkinson's disease RBFOX3 intron pha002865 rs9907316 chr17 77169930 T C 6.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBFOX3 intron 20877124 rs2703534 chr17 77172776 G A 6.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBFOX3 intron 20877124 rs2045660 chr17 77176351 T C 2.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBFOX3 intron 20877124 rs922171 chr17 77202502 G C 4.20E-04 Multiple complex diseases RBFOX3 intron 17554300 rs17674253 chr17 77220594 C A 7.97E-05 Information processing speed RBFOX3 intron 21130836 rs12603684 chr17 77223799 G T 0.0000402 Alcohol craving with or without dependence RBFOX3 intron 22481050 rs2889619 chr17 77228898 T A 7.20E-04 Multiple complex diseases RBFOX3 intron 17554300 rs4789960 chr17 77229462 A G 9.72E-04 Response to cytadine analogues (cytosine arabinoside) RBFOX3 intron 24483146 rs1869934 chr17 77234671 A G 9.70E-04 Amyotrophic Lateral Sclerosis RBFOX3 intron 17827064 rs7217721 chr17 77246390 G C 5.24E-29 Multiple complex diseases RBFOX3 intron 17554300 rs4789878 chr17 77266394 G C 8.18E-04 Prostate cancer mortality RBFOX3 intron 20978177 rs4274472 chr17 77268173 G A 6.94E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) RBFOX3 intron 23648065 rs12449931 chr17 77276078 T C 4.93E-05 Orofacial clefts RBFOX3 intron 22419666 rs4789996 chr17 77283230 T G 2.00E-04 Cognitive impairment induced by topiramate RBFOX3 intron 22091778 rs4789996 chr17 77283230 T G 2.74E-05 Cognitive impairment induced by topiramate RBFOX3 intron 22091778 rs7223756 chr17 77283251 T C 3.89E-05 Hypertension (essential hypertension) RBFOX3 intron 22184326 rs12449949 chr17 77285304 C T 1.86E-05 Triglycerides RBFOX3 intron pha003080 rs12449949 chr17 77285304 C T 1.18E-05 Triglycerides RBFOX3 intron pha003081 rs12449949 chr17 77285304 C T 3.57E-06 Lipid levels RBFOX3 intron pha003082 rs9898469 chr17 77285677 G A 7.90E-04 Response to taxane treatment (placlitaxel) RBFOX3 intron 23006423 rs4789997 chr17 77287586 A G 4.87E-05 Hypertension (essential hypertension) RBFOX3 intron 22184326 rs9906023 chr17 77287993 C T 4.66E-05 Lipid levels RBFOX3 intron pha003082 rs9894139 chr17 77290082 A G 0.000897991 Hypertension (early onset hypertension) RBFOX3 intron 22479346 rs1563447 chr17 77293430 C T 4.13E-05 Hypertension (essential hypertension) RBFOX3 intron 22184326 rs4789885 chr17 77310495 C T 1.21E-04 Birth weight RBFOX3 intron 17255346 rs7214890 chr17 77328374 T G 3.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBFOX3 intron 20877124 rs4541108 chr17 77328609 G A 3.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBFOX3 intron 20877124 rs8081466 chr17 77330461 G A 2.34E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBFOX3 intron 20877124 rs2377402 chr17 77331446 A C 2.34E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBFOX3 intron 20877124 rs8076595 chr17 77335040 T C 5.35E-04 Multiple complex diseases RBFOX3 intron 17554300 rs4789890 chr17 77344082 T G 1.89E-04 Lung function (forced vital capacity) RBFOX3 intron 24023788 rs8075376 chr17 77350658 C T 1.37E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RBFOX3 intron 20877124 rs4790018 chr17 77365079 C T 1.17E-06 Parent of origin effect on language impairment (child trend) RBFOX3 intron 24571439 rs12949424 chr17 77368153 G A 7.66E-05 Alzheimer's disease RBFOX3 intron 17998437 rs11656673 chr17 77400623 C T 2.68E-05 Celiac disease RBFOX3 intron 23936387 rs1316453 chr17 77410859 T C 7.00E-06 Self-reported allergy RBFOX3 intron 23817569 rs4790035 chr17 77418628 C T 7.57E-05 Tourette syndrome RBFOX3 intron 22889924 rs377535442 chr17 77473800 G C 1.07E-04 Insulin resistance RBFOX3 intron 21901158 rs4790051 chr17 77480325 A G 6.59E-04 Type 2 diabetes LOC100287250 intron 17463246 rs4073995 chr17 77545109 T G 5.68E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs8076446 chr17 77723584 A G 5.84E-04 Type 2 diabetes / / 17463246 rs3751954 chr17 77753485 A G 4.59E-06 Schizophrenia CBX2 intron 19571809 rs3751954 chr17 77753485 A G 9.51E-06 Schizophrenia CBX2 intron pha002859 rs8066940 chr17 77766621 G A 0.0007255 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8066940 chr17 77766621 G A 7.26E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8066940 chr17 77766621 G A 7.43E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs8066940 chr17 77766621 G A 2.79E-05 Periodontitis (Chronic) / / 25008200 rs870681 chr17 77773876 A C 9.05E-04 Myocardial Infarction / / pha002883 rs745571 chr17 77781387 T C 9.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs745570 chr17 77781725 A G 9.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9747992 chr17 77804840 C T 2.00E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs9747031 chr17 77804936 G C 6.13E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs8072921 chr17 77833017 G A 9.20E-06 Urinary metabolites / / 21572414 rs12936913 chr17 77833916 C T 9.90E-06 Urinary metabolites / / 21572414 rs8078624 chr17 77844799 T G 5.00E-05 Prostate cancer / / 21743057 rs1696761 chr17 77846012 T C 6.34E-06 Heart Rate / / pha003051 rs1285264 chr17 77849496 G C 9.34E-04 Multiple complex diseases / / 17554300 rs1285264 chr17 77849496 G C 6.14E-04 Type 2 diabetes / / 22238593 rs2587493 chr17 77852795 C G 0.000336 Breast cancer early age of onset / / 18463975 rs2587493 chr17 77852795 C G 6.05E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2362396 chr17 77854454 T C 4.39E-06 Heart Rate / / pha003051 rs4889796 chr17 77856638 T C 5.83E-05 Depression (quantitative trait) / / 23290196 rs1663183 chr17 77886060 A G 7.76E-04 Type 2 diabetes / / 17463246 rs3169601 chr17 77909438 T C 7.04E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs7210391 chr17 77933071 C A 2.79E-05 Blood Pressure TBC1D16 intron pha003043 rs4441315 chr17 77953453 C T 6.57E-04 Stroke TBC1D16 intron pha002886 rs7209428 chr17 77970941 G A 6.76E-05 HIV-1 viral setpoint TBC1D16 intron 22174851 rs187993089 chr17 78032753 C T 0.00074 Breast cancer CCDC40 missense 23555315 rs2289534 chr17 78039619 G A 6.24E-05 Tourette syndrome CCDC40 intron 22889924 rs8082554 chr17 78039867 C T 9.22E-04 White matter integrity CCDC40 intron 22425255 rs9319623 chr17 78054606 C G 4.70E-06 Urinary metabolites CCDC40 intron 21572414 rs200815406 chr17 78055521 A G 0.000023 Breast cancer (ER positive) CCDC40 missense 23555315 rs715041 chr17 78058432 G A 2.01E-04 Multiple complex diseases CCDC40 intron 17554300 rs1467979 chr17 78060743 C T 2.00E-06 IgG glycosylation CCDC40 intron 23382691 rs1467979 chr17 78060743 C T 3.00E-06 IgG glycosylation CCDC40 intron 23382691 rs2361701 chr17 78066617 G A 4.00E-06 IgG glycosylation CCDC40 intron 23382691 rs12600845 chr17 78077714 C T 2.72E-04 Alzheimer's disease GAA intron 17998437 rs8077849 chr17 78104137 C T 7.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2304855 chr17 78118266 T A 4.31E-05 Parkinson's disease (motor and cognition) EIF4A3 intron 22658654 rs8065486 chr17 78138196 G A 7.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4889990 chr17 78157995 G A 2.46E-05 IgE levels CARD14 cds-synon 17255346 rs2044102 chr17 78159360 A C 2.70E-05 Urinary metabolites CARD14 intron 21572414 rs3829611 chr17 78161815 C T 2.04E-04 IgE levels CARD14 intron 17255346 rs11652075 chr17 78178893 C T 0.000000034 Psoriasis CARD14 missense 23143594 rs2071148 chr17 78183936 G A 2.40E-04 Cardiovascular disease adverse events in renal patients treated with calcineurin inhibitors SGSH UTR-3 16155738 rs9894254 chr17 78184679 C T 8.51E-04 Suicide attempts in bipolar disorder SGSH missense 21423239 rs9894254 chr17 78184679 C T 8.65E-04 Longevity SGSH missense 22279548 rs4889841 chr17 78193831 T C 7.53E-05 Potassium levels SGSH intron pha003086 rs12452028 chr17 78212231 G C 7.49E-07 Interleukin levels (IL10,IL1Ra,IL6),in plasma SLC26A11 intron 22205395 rs8079641 chr17 78212420 G A,C,T 8.71E-04 Alzheimer's disease SLC26A11 intron 17998437 rs9891691 chr17 78268999 C G 4.26E-04 Multiple complex diseases RNF213 intron 17554300 rs9905727 chr17 78272814 A G 6.72E-04 Multiple complex diseases RNF213 intron 17554300 rs8081176 chr17 78283987 T C 1.50E-05 Multiple sclerosis RNF213 intron 21833088 rs9674807 chr17 78286177 C T 0.00061488 Hypertension (early onset hypertension) RNF213 intron 22479346 rs7225029 chr17 78297779 G A 6.74E-04 Celiac disease RNF213 intron 23936387 rs12051723 chr17 78324259 G T 3.00E-06 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy RNF213 intron 23118302 rs36103733 chr17 78337893 C T 0.000224 Sarcoidosis RNF213 intron 22952805 rs6565681 chr17 78348494 A G 2.00E-08 Moyamoya disease RNF213 intron 21048783 rs7223701 chr17 78362651 T G 6.24E-04 Multiple complex diseases RNF213 intron 17554300 rs9913006 chr17 78390931 T G 5.40E-05 Receptive language ability ENDOV intron 24687471 rs8067574 chr17 78392391 C T 8.88E-04 Multiple complex diseases ENDOV intron 17554300 rs8067574 chr17 78392391 C T 3.28E-05 Receptive language ability ENDOV intron 24687471 rs12943620 chr17 78444658 T G 4.47E-05 Smoking initiation NPTX1 cds-synon 24665060 rs7224941 chr17 78516908 A G 6.68E-04 Insulin resistance / / 21901158 rs5003528 chr17 78524130 C T 6.74E-04 Insulin resistance RPTOR intron 21901158 rs4627412 chr17 78524244 G A 0.0000463 Otitis media (children 3 years old or younger) RPTOR intron 23133572 rs9911978 chr17 78524407 G A 0.0000463 Otitis media (children 3 years old or younger) RPTOR intron 23133572 rs4396581 chr17 78549734 T C 5.84E-05 Multiple complex diseases RPTOR intron 17554300 rs4075782 chr17 78556325 C T 4.72E-05 Lymphocyte counts RPTOR intron 22286170 rs9913181 chr17 78573872 T G 5.29E-04 Prostate cancer mortality RPTOR intron 20978177 rs7503807 chr17 78591111 A C 2.00E-08 Obesity RPTOR intron 23563607 rs8075393 chr17 78594754 C T 2.90E-05 Urinary metabolites RPTOR intron 21572414 rs901064 chr17 78596040 A G 1.16E-04 Multiple complex diseases RPTOR intron 17554300 rs12952285 chr17 78596158 C G 7.97E-04 Prostate cancer mortality RPTOR intron 20978177 rs12939076 chr17 78634810 C A 0.0002 Migraine RPTOR intron 22678113 rs7218924 chr17 78641361 T C 0.0003651 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RPTOR intron 23233654 rs7218924 chr17 78641361 T C 3.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) RPTOR intron 23233662 rs8068064 chr17 78683460 G A 0.0003148 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RPTOR intron 23233654 rs8068064 chr17 78683460 G A 3.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) RPTOR intron 23233662 rs1564868 chr17 78685176 C T 0.0003147 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RPTOR intron 23233654 rs1564868 chr17 78685176 C T 3.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) RPTOR intron 23233662 rs7503911 chr17 78694997 C T 0.0003164 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RPTOR intron 23233654 rs7503911 chr17 78694997 C T 3.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) RPTOR intron 23233662 rs2315921 chr17 78706517 A T 8.83E-04 Type 2 diabetes RPTOR intron 17463246 rs9915378 chr17 78708418 A G 0.000853283 Hypertension (early onset hypertension) RPTOR intron 22479346 rs6565479 chr17 78712423 A G 0.0003255 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RPTOR intron 23233654 rs6565479 chr17 78712423 A G 3.26E-04 Methotrexate clearance (acute lymphoblastic leukemia) RPTOR intron 23233662 rs4969230 chr17 78726261 T C 1.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPTOR intron 20877124 rs4969230 chr17 78726261 T C 0.000590874 Hypertension (early onset hypertension) RPTOR intron 22479346 rs4969230 chr17 78726261 T C 0.0006811 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RPTOR intron 23233654 rs4969230 chr17 78726261 T C 6.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) RPTOR intron 23233662 rs3898096 chr17 78726575 G A 0.00021 Salmonella-induced pyroptosis RPTOR intron 22837397 rs4969235 chr17 78732673 A T 0.0006856 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RPTOR intron 23233654 rs4969235 chr17 78732673 A T 6.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) RPTOR intron 23233662 rs7215564 chr17 78737287 C T 6.06E-05 Cognitive performance RPTOR intron 19734545 rs7215564 chr17 78737287 C T 2.00E-06 Myopia (pathological) RPTOR intron 23049088 rs4969404 chr17 78746363 C T 0.0006956 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RPTOR intron 23233654 rs4969404 chr17 78746363 C T 6.96E-04 Methotrexate clearance (acute lymphoblastic leukemia) RPTOR intron 23233662 rs4969277 chr17 78779981 C T 0.0000159 Panic disorder RPTOR intron 23149450 rs4969277 chr17 78779981 C T 1.59E-05 Serum tamsulosin hydrochloride concentration RPTOR intron 23151678 rs9915426 chr17 78784312 A G 4.00E-06 Urinary metabolites RPTOR intron 21572414 rs2333990 chr17 78784925 G A 9.31E-04 Oral cancers (chewing tobacco related) RPTOR intron 22503698 rs6565481 chr17 78798154 C T 3.68E-04 Multiple complex diseases RPTOR intron 17554300 rs7216306 chr17 78803575 A G 6.80E-06 Urinary metabolites RPTOR intron 21572414 rs7219745 chr17 78816908 C A 5.61E-04 Response to cytidine analogues (gemcitabine) RPTOR intron 24483146 rs2589155 chr17 78822217 G A 4.98E-04 Multiple complex diseases RPTOR intron 17554300 rs2672893 chr17 78827863 A G 1.57E-04 Parkinson's disease RPTOR intron 17052657 rs2672893 chr17 78827863 A G 2.63E-04 Alzheimer's disease (late onset) RPTOR intron 21379329 rs908241 chr17 78835678 G A 7.83E-04 Nicotine smoking RPTOR intron 19268276 rs12232521 chr17 78872953 A G 3.76E-04 Prostate cancer mortality RPTOR intron 20978177 rs868432 chr17 78877735 G A 3.93E-04 Nicotine smoking RPTOR intron 19268276 rs7220348 chr17 78885858 C A 5.95E-05 Cervical cancer RPTOR intron 24700089 rs9908270 chr17 78895889 C A 7.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPTOR intron 20877124 rs9908270 chr17 78895889 C A 9.41E-05 Blood Pressure RPTOR intron pha003039 rs9908270 chr17 78895889 C A 8.94E-05 Blood Pressure RPTOR intron pha003045 rs11653325 chr17 78910629 T C 4.57E-04 Nicotine smoking RPTOR intron 19268276 rs7219318 chr17 78912354 T C 8.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPTOR intron 20877124 rs7219318 chr17 78912354 T C 7.90E-05 Blood Pressure RPTOR intron pha003045 rs6420480 chr17 78914748 G A 6.19E-04 Depression (quantitative trait) RPTOR intron 20800221 rs1468033 chr17 78916953 G A 1.15E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPTOR intron 20877124 rs1468033 chr17 78916953 G A 6.22E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPTOR intron 20877124 rs1468033 chr17 78916953 G A 3.05E-05 Blood Pressure RPTOR intron pha003039 rs1468033 chr17 78916953 G A 1.28E-05 Blood Pressure RPTOR intron pha003045 rs1468033 chr17 78916953 G A 7.00E-05 Blood Pressure RPTOR intron pha003047 rs2271612 chr17 78919920 C T 6.50E-05 Diabetic retinopathy RPTOR intron 21441570 rs8074171 chr17 78925649 G A 0.0000083 Mean arterial pressure RPTOR intron 22510845 rs6420481 chr17 78925950 T C 2.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPTOR intron 20877124 rs6420481 chr17 78925950 T C 7.24E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPTOR intron 20877124 rs7225525 chr17 78928792 C T 3.52E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPTOR intron 20877124 rs7225525 chr17 78928792 C T 8.38E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPTOR intron 20877124 rs7224748 chr17 78929020 G A 3.52E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPTOR intron 20877124 rs7224748 chr17 78929020 G A 8.38E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RPTOR intron 20877124 rs1399571 chr17 78952470 T C 8.48E-05 Blood Pressure / / pha003039 rs144716331 chr17 78972930 G T 0.00015 Breast cancer CHMP6 missense 23555315 rs8078438 chr17 78976595 T C 6.58E-05 Odorant perception / / 23910658 rs8072124 chr17 79001300 G A 2.98E-04 Alzheimer's disease (late onset) / / 21379329 rs8067235 chr17 79024637 G A 6.00E-08 Memory performance BAIAP2 intron 24392092 rs8080525 chr17 79029016 C T 7.99E-05 Lipoprotein-associated phospholipase A2 activity and mass BAIAP2 intron 20442857 rs8066330 chr17 79058278 C T 1.79E-05 B cell non-Hodgkin lymphoma BAIAP2 intron 23749188 rs9900420 chr17 79111395 C A 9.17E-04 Heart Failure AATK intron pha002885 rs7220048 chr17 79118573 T C 9.00E-06 Obesity-related traits AATK intron 23251661 rs2659046 chr17 79145891 A G 6.03E-05 Post-operative nausea and vomiting AATK-AS1 intron 21694509 rs8069265 chr17 79159425 T C 5.09E-05 Response to hepatitis C treatment / / 19684573 rs8069265 chr17 79159425 T C 0.0008848 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8069265 chr17 79159425 T C 8.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2279913 chr17 79168268 A C 4.00E-07 IgG glycosylation AZI1 intron 23382691 rs2659029 chr17 79190562 A G 2.70E-05 Urinary metabolites AZI1 intron 21572414 rs9896850 chr17 79191726 C T 3.12E-04 Multiple complex diseases AZI1 intron 17554300 rs2659005 chr17 79218714 C T 2.00E-06 IgG glycosylation / / 23382691 rs2659005 chr17 79218714 C T 3.00E-07 IgG glycosylation / / 23382691 rs2659005 chr17 79218714 C T 4.00E-07 IgG glycosylation / / 23382691 rs2659005 chr17 79218714 C T 9.00E-06 IgG glycosylation / / 23382691 rs7224668 chr17 79235788 T C 3.00E-08 IgG glycosylation SLC38A10 intron 23382691 rs7211465 chr17 79239655 G A 7.27E-04 Suicide attempts in bipolar disorder SLC38A10 intron 21423239 rs2271090 chr17 79246605 A G 3.09E-04 Multiple complex diseases SLC38A10 intron 17554300 rs7212762 chr17 79254903 T C 5.71E-04 Response to taxane treatment (placlitaxel) SLC38A10 intron 23006423 rs10445407 chr17 79261809 C A 6.75E-04 Multiple complex diseases SLC38A10 intron 17554300 rs10445407 chr17 79261809 C A 1.00E-06 Longevity SLC38A10 intron 20834067 rs8076302 chr17 79265701 C T 5.73E-05 Bipolar disorder and schizophrenia SLC38A10 intron 20889312 rs7212109 chr17 79284614 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6565550 chr17 79285991 T C 2.66E-04 Stroke TMEM105 UTR-3 pha002886 rs8079022 chr17 79299484 G A 8.80E-04 Alzheimer's disease TMEM105 intron 17998437 rs1701 chr17 79375998 C A 4.16E-04 Premature ovarian failure BAHCC1 intron 19508998 rs1139405 chr17 79478019 G A 2.75E-05 Parkinson's disease (motor and cognition) ACTG1 cds-synon 22658654 rs1139405 chr17 79478019 G A 2.75E-05 Immune response to anthrax vaccine ACTG1 cds-synon 22658931 rs7405450 chr17 79540449 C T 5.45E-04 Amyotrophic Lateral Sclerosis NPLOC4 intron 17362836 rs9911383 chr17 79541116 G A 8.68E-04 Multiple complex diseases NPLOC4 intron 17554300 rs8075102 chr17 79558976 T G 8.18E-04 Parkinson's disease NPLOC4 intron 17052657 rs1122424 chr17 79560494 C T 4.68E-04 Multiple complex diseases NPLOC4 intron 17554300 rs11652797 chr17 79574124 G A 1.80E-04 Multiple complex diseases NPLOC4 intron 17554300 rs75078292 chr17 79585492 A G 0.00000098 Myopia (Age of onset) NPLOC4 intron 23468642 rs9894429 chr17 79596811 C T 9.00E-14 Eye color NPLOC4 cds-synon 20463881 rs6565612 chr17 79602820 T C 2.71E-04 Multiple complex diseases NPLOC4 intron 17554300 rs9905639 chr17 79614154 A G 5.19E-04 Multiple complex diseases TSPAN10 intron 17554300 rs9906358 chr17 79614481 A G 2.14E-06 Lymphocyte counts TSPAN10 intron 22286170 rs7406828 chr17 79619226 C T 5.73E-04 Multiple complex diseases PDE6G intron 17554300 rs6565619 chr17 79645896 G A 1.64E-05 Lymphocyte counts / / 22286170 rs3204270 chr17 79682051 C A,G,T 5.00E-06 Dental caries SLC25A10 cds-synon 23259602 rs9903371 chr17 79993064 C G 7.09E-06 Menarche (age at onset) / / 19282985 rs4502283 chr17 80044726 G A,C 0.0003 Coronary artery calcification FASN intron 23727086 rs6502057 chr17 80082060 A G 0.00000306 Uterine leiomyomata CCDC57 intron 23040493 rs11077969 chr17 80085633 A G 0.00000391 Uterine leiomyomata CCDC57 missense 23040493 rs7213172 chr17 80085703 G C,T 0.00000423 Uterine leiomyomata CCDC57 missense 23040493 rs7406163 chr17 80086389 C T 0.00000446 Uterine leiomyomata CCDC57 missense 23040493 rs4625783 chr17 80086395 T C 4.00E-13 Blood metabolite levels CCDC57 missense 24816252 rs7221544 chr17 80087337 C T 0.00000626 Uterine leiomyomata CCDC57 intron 23040493 rs4789753 chr17 80092131 T C 1.65E-04 Multiple complex diseases CCDC57 intron 17554300 rs8080423 chr17 80102279 A G 0.00000436 Uterine leiomyomata CCDC57 intron 23040493 rs3935402 chr17 80114252 C T 8.49E-04 Multiple complex diseases CCDC57 intron 17554300 rs7502078 chr17 80131879 C A 0.00000404 Uterine leiomyomata CCDC57 intron 23040493 rs140732712 chr17 80137043 C G 0.00029 Breast cancer (ER positive) CCDC57 missense 23555315 rs4247357 chr17 80166989 G T 0.000000745 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.000000842 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.00000186 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.00000219 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.00000649 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.00000688 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.00000725 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.00000796 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.00000849 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.0000116 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.0000117 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.0000146 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.0000147 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.0000155 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.0000171 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.0000182 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.0000183 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.0000207 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.0000215 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.0000236 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.0000238 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.0000245 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.0000265 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 0.0000278 Uterine leiomyomata CCDC57 intron 23040493 rs4247357 chr17 80166989 G T 3.05E-08 Uterine leiomyomata CCDC57 intron 23040493 rs9896932 chr17 80255037 A G 0.0000191 Antithrombin / / 23705025 rs11575033 chr17 80278956 C T 4.49E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SECTM1 UTR-3 21844884 rs7207095 chr17 80339729 A G 3.64E-05 Personality dimensions / / 18957941 rs3751913 chr17 80405552 T C 0.0000506 Height (Pygmy height) C17orf62 intron 22570615 rs9303029 chr17 80408815 C T 4.00E-07 Protein quantitative trait loci / / 18464913 rs3829567 chr17 80442722 T C 0.000634 Salmonella-induced pyroptosis /RF cds-synon 22837397 rs6502114 chr17 80449676 G A 3.75E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11658011 chr17 80524358 A G 1.38E-04 Tourette syndrome FOXK2 intron 22889924 rs12453001 chr17 80535141 T A 1.30E-05 Urinary metabolites FOXK2 intron 21572414 rs9905533 chr17 80539114 C T 2.42E-04 Tourette syndrome FOXK2 intron 22889924 rs6502124 chr17 80545156 A G 8.15E-06 Parkinson's disease (motor and cognition) FOXK2 intron 22658654 rs4789817 chr17 80607989 A G 4.93E-05 Orofacial clefts / / 22863734 rs2279395 chr17 80617552 G A 5.15E-04 Amyotrophic Lateral Sclerosis RAB40B intron 17362836 rs1046875 chr17 80685426 A G 4.00E-17 Glycated hemoglobin levels FN3KRP UTR-3 24647736 rs1046896 chr17 80685533 C T 2.00E-26 Glycated Hemoglobin levels FN3KRP UTR-3 20858683 rs1046896 chr17 80685533 C T 1.58E-26 Glycated hemoglobin levels FN3KRP UTR-3 22885924 rs1046896 chr17 80685533 C T 2.00E-07 Glycated hemoglobin levels FN3KRP UTR-3 24244560 rs2264574 chr17 80703380 C T 1.52E-04 Type 2 diabetes FN3K intron 17463246 rs2451214 chr17 80715054 T C 1.55E-04 Type 2 diabetes TBCD intron 17463246 rs11650019 chr17 80750690 C T 7.86E-05 Type 2 diabetes TBCD intron 17463246 rs610516 chr17 80762839 T C 4.53E-05 Type 2 diabetes TBCD intron 17463246 rs668990 chr17 80765322 C A 2.17E-05 Type 2 diabetes TBCD intron 17463246 rs11658083 chr17 80779610 C T 7.01E-05 Formal thought disorder in schizophrenia TBCD intron 22648509 rs3744165 chr17 80790442 T G 1.00E-04 Schizophrenia ZNF750 UTR-5 22037552 rs8069699 chr17 80796671 C T 9.01E-05 Height TBCD intron pha003011 rs4986122 chr17 80825500 G A 9.87E-05 Lymphocyte counts TBCD intron 22286170 rs3744159 chr17 80842251 G A 5.10E-04 Iris characteristics TBCD intron 21835309 rs4986131 chr17 80853796 A G 7.78E-04 Multiple complex diseases TBCD intron 17554300 rs729124 chr17 80887206 A G 3.56E-05 Bipolar disorder and schizophrenia TBCD intron 20889312 rs1127986 chr17 80887244 T C 2.85E-04 Suicide attempts in bipolar disorder TBCD cds-synon 21423239 rs6502015 chr17 80888164 A G 8.71E-04 Suicide attempts in bipolar disorder TBCD intron 21423239 rs11077949 chr17 80896115 C T 1.96E-04 Suicide attempts in bipolar disorder TBCD intron 21423239 rs3744156 chr17 80897215 C T 4.00E-04 Suicide attempts in bipolar disorder TBCD intron 21423239 rs8073471 chr17 80897492 A G 1.00E-04 Schizophrenia TBCD intron 22037552 rs3603 chr17 80901002 C T 2.38E-04 Suicide attempts in bipolar disorder TBCD UTR-3 21423239 rs11077950 chr17 80901750 C T 3.11E-04 Suicide attempts in bipolar disorder B3GNTL1 UTR-3 21423239 rs12940475 chr17 80902411 G T 7.54E-04 Suicide attempts in bipolar disorder B3GNTL1 intron 21423239 rs7225887 chr17 80904844 C T 3.42E-04 Suicide attempts in bipolar disorder B3GNTL1 missense 21423239 rs9909026 chr17 80925205 A C 4.87E-05 Epilepsy (remission after treatment) B3GNTL1 intron 23962720 rs59574779 chr17 80925401 A G 4.94E-05 Epilepsy (remission after treatment) B3GNTL1 intron 23962720 rs9898649 chr17 80937305 T C 6.41E-04 Response to taxane treatment (placlitaxel) B3GNTL1 intron 23006423 rs9891371 chr17 80937828 G A 6.74E-04 Coronary heart disease B3GNTL1 intron 21606135 rs12603456 chr17 80939160 A T 7.35E-06 Height B3GNTL1 intron 20400458 rs12939139 chr17 80967489 C T 8.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) B3GNTL1 intron 20877124 rs898099 chr17 80980068 T C 9.63E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) B3GNTL1 intron 22566498 rs7224733 chr17 81004770 A G 3.58E-04 Multiple complex diseases B3GNTL1 intron 17554300 rs1143006 chr17 81006387 G A 9.94E-04 Multiple complex diseases B3GNTL1 cds-synon 17554300 rs1143006 chr17 81006387 G A 6.12E-04 Alcohol dependence B3GNTL1 cds-synon 24277619 rs7406119 chr17 81006629 C T 7.04E-04 Multiple complex diseases B3GNTL1 cds-synon 17554300 rs7502145 chr17 81048659 G C 1.80E-05 Urinary metabolites METRNL intron 21572414 rs74778902 chr18 100134 C T 7.24E-06 Periodontitis (Mean PAL) / / 24024966 rs9284390 chr18 112535 G A 9.78E-04 Myopia (pathological) ROCK1P1 intron 21095009 rs9284390 chr18 112535 G A 2.00E-04 Cognitive impairment induced by topiramate ROCK1P1 intron 22091778 rs57440971 chr18 120296 C T 4.00E-06 Periodontitis (Mean PAL) ROCK1P1 intron 24024966 rs4797876 chr18 155566 C T 7.64E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs655781 chr18 196829 G A 1.56E-04 Epilepsy USP14 intron 22116939 rs585578 chr18 204232 G A 1.40E-04 Epilepsy USP14 intron 22116939 rs481077 chr18 218695 T C 1.82E-04 Epilepsy THOC1 intron 22116939 rs8094221 chr18 220341 C A 3.64E-04 Multiple complex diseases THOC1 intron 17554300 rs672856 chr18 220658 G A 1.57E-04 Epilepsy THOC1 intron 22116939 rs7227515 chr18 225051 C T 1.00E-04 Multiple complex diseases THOC1 intron 17554300 rs577454 chr18 250047 T C 1.76E-04 Epilepsy THOC1 intron 22116939 rs11080970 chr18 272535 G T 8.52E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs8096537 chr18 273216 T C 1.58E-05 Multiple complex diseases / / 17554300 rs12457331 chr18 277763 C T 4.78E-05 Body Mass Index / / pha003020 rs7226677 chr18 278796 A G 7.00E-06 Bipolar disorder / / 18711365 rs7226677 chr18 278796 A G 4.00E-06 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs620837 chr18 286971 C A 7.83E-04 Epilepsy / / 22116939 rs16941940 chr18 287648 T G 7.06E-04 Epilepsy / / 22116939 rs8088001 chr18 287705 T G 6.76E-04 Multiple complex diseases / / 17554300 rs8083730 chr18 293519 G A 9.03E-04 Coronary heart disease / / 21971053 rs8083730 chr18 293519 G A 0.0000566 Panic disorder / / 23149450 rs8083730 chr18 293519 G A 5.66E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs599019 chr18 294495 C A 3.40E-05 Birth weight / / 17255346 rs599019 chr18 294495 C A 3.64E-05 Diabetic retinopathy / / 20871662 rs654581 chr18 311393 C G 8.02E-04 Smoking initiation / / 24665060 rs554821 chr18 322183 G A 2.62E-04 Epilepsy COLEC12 intron 22116939 rs621636 chr18 322522 C T 2.59E-04 Epilepsy COLEC12 intron 22116939 rs621636 chr18 322522 C T 3.00E-06 Obesity-related traits COLEC12 intron 23251661 rs16942962 chr18 344459 G A 2.99E-05 Multiple complex diseases COLEC12 intron 17554300 rs694372 chr18 351114 C A 1.95E-04 Insulin resistance COLEC12 intron 21901158 rs17548840 chr18 352577 A G 7.95E-05 Multiple complex diseases COLEC12 intron 17554300 rs644435 chr18 355944 A G 4.00E-06 Obesity-related traits COLEC12 intron 23251661 rs565151 chr18 356095 G T 6.51E-05 Insulin resistance COLEC12 intron 21901158 rs666599 chr18 356374 A G 5.71E-06 Obesity-related traits COLEC12 intron 23251661 rs3810040 chr18 357247 G A 6.30E-04 Multiple complex diseases COLEC12 intron 17554300 rs618671 chr18 362199 A G 7.04E-06 Primary biliary cirrhosis COLEC12 intron 21399635 rs8082746 chr18 365815 T C 4.03E-05 Serum metabolites COLEC12 intron 19043545 rs4798111 chr18 377746 T G 9.35E-04 Suicide attempts in bipolar disorder COLEC12 intron 21423239 rs11662068 chr18 381997 C G 1.90E-06 Urinary metabolites COLEC12 intron 21572414 rs7240217 chr18 395661 A G 3.44E-05 Multiple complex diseases COLEC12 intron 17554300 rs9966524 chr18 400706 T C 0.000871 Salmonella-induced pyroptosis COLEC12 intron 22837397 rs7243583 chr18 400766 T C 6.23E-04 Smoking initiation COLEC12 intron 24665060 rs1539790 chr18 401573 G A 0.000456 Salmonella-induced pyroptosis COLEC12 intron 22837397 rs12605749 chr18 401869 G A 2.00E-04 Cognitive impairment induced by topiramate COLEC12 intron 22091778 rs9303946 chr18 420105 C T 6.50E-06 Urinary metabolites COLEC12 intron 21572414 rs2621180 chr18 421278 A G 1.10E-05 Urinary metabolites COLEC12 intron 21572414 rs2846651 chr18 421334 A G 1.10E-05 Urinary metabolites COLEC12 intron 21572414 rs2846650 chr18 421524 A G 1.60E-05 Urinary metabolites COLEC12 intron 21572414 rs16944356 chr18 424065 G C 2.98E-04 Body mass index COLEC12 intron 21701565 rs12962668 chr18 444687 G A 2.68E-04 Type 2 diabetes COLEC12 intron 17463246 rs1383227 chr18 445039 T C 3.46E-04 Obesity (extreme) COLEC12 intron 21935397 rs1893134 chr18 450102 G A 3.01E-04 Obesity (extreme) COLEC12 intron 21935397 rs9947737 chr18 455128 A G 4.02E-04 Type 2 diabetes COLEC12 intron 17463246 rs9303954 chr18 457853 T G 5.44E-04 Body mass index COLEC12 intron 21701565 rs9303955 chr18 457867 G A 1.92E-04 Type 2 diabetes COLEC12 intron 17463246 rs2621167 chr18 458662 T C 7.32E-05 Taste perception COLEC12 intron 22132133 rs2621176 chr18 463418 A C 4.20E-04 Taste perception COLEC12 intron 22132133 rs4797173 chr18 466351 C T 4.67E-04 Major depressive disorder COLEC12 intron 22472876 rs9941423 chr18 489385 C T 7.33E-04 Amyotrophic Lateral Sclerosis COLEC12 intron 17362836 rs7235159 chr18 497729 T C 8.69E-06 Scoliosis COLEC12 intron 21216876 rs9967577 chr18 516584 G A 7.16E-04 Parkinson's disease / / 17052657 rs11081187 chr18 544739 T C 1.70E-04 Multiple complex diseases / / 17554300 rs508969 chr18 565414 A G 6.80E-04 Lipid traits / / 17903299 rs13339701 chr18 566272 T A 7.05E-04 Type 2 diabetes / / 17463246 rs12955326 chr18 566905 T C 6.03E-04 Multiple complex diseases / / 17554300 rs578026 chr18 597751 T G 5.28E-04 Suicide attempts in bipolar disorder CLUL1 intron 21423239 rs9973159 chr18 597950 C T 4.40E-05 Age-related macular degeneration CLUL1 intron 20385819 rs1542397 chr18 605530 G A 9.98E-04 Suicide attempts in bipolar disorder CLUL1 intron 21423239 rs16947340 chr18 608018 G A 7.86E-04 Suicide attempts in bipolar disorder CLUL1 intron 21423239 rs12958499 chr18 608179 C G 9.39E-04 Suicide attempts in bipolar disorder CLUL1 intron 21423239 rs16947351 chr18 608342 A G 6.31E-05 Type 2 diabetes CLUL1 intron 17463246 rs16947351 chr18 608342 A G 7.75E-04 Suicide attempts in bipolar disorder CLUL1 intron 21423239 rs16947356 chr18 608468 A C 9.55E-04 Suicide attempts in bipolar disorder CLUL1 intron 21423239 rs483655 chr18 616653 C T 7.23E-05 Cognitive performance CLUL1 intron 19734545 rs10502288 chr18 631435 G A 2.50E-04 Crohn's disease CLUL1 intron 17684544 rs10468763 chr18 632239 T C 5.81E-04 Multiple complex diseases CLUL1 intron 17554300 rs2853741 chr18 657352 T C 5.44E-04 Parkinson's disease C18orf56 intron 17052657 rs502396 chr18 659236 C T 7.97E-04 Alcohol dependence TYMS intron 20201924 rs2853539 chr18 659829 A G 1 Drug response to Methotrexate TYMS intron 19902562 rs2244500 chr18 661005 A G 6.61E-04 Parkinson's disease TYMS intron 17052657 rs2847153 chr18 661647 G A 9.06E-07 Lymphocyte counts TYMS intron 22286170 rs11873890 chr18 662135 A G 0.000000142 Triglycerides TYMS intron 23063622 rs11873890 chr18 662135 A G 0.00000097 Cholesterol,total TYMS intron 23063622 rs11873890 chr18 662135 A G 1.63E-16 HDL cholesterol TYMS intron 23063622 rs3744962 chr18 674320 A G 7.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ENOSF1 cds-synon 20877124 rs2741173 chr18 698312 A G 3.44E-05 Telomere length ENOSF1 intron 23001564 rs2847325 chr18 703442 G A 7.74E-04 Amyotrophic Lateral Sclerosis ENOSF1 intron 17362836 rs9635864 chr18 733474 C T 1.81E-04 Alzheimer's disease YES1 intron 17998437 rs3786347 chr18 743226 A G 9.71E-04 Myocardial Infarction YES1 intron pha002883 rs6506537 chr18 794273 T C 2.15E-05 Lymphocyte counts YES1 intron 22286170 rs11664027 chr18 807368 T G 3.00E-07 PR interval in Tripanosoma cruzi seropositivity YES1 intron 24324551 rs11081364 chr18 831094 T C 7.88E-05 Serum metabolites / / 19043545 rs7240865 chr18 847251 C T 9.47E-04 Multiple complex diseases / / 17554300 rs1291183 chr18 849178 A C 4.00E-06 Pulmonary function in asthmatics / / 23541324 rs1291183 chr18 849178 A C 5.47E-05 Pulmonary function in asthmatics / / 23541324 rs2846766 chr18 865028 C A 8.74E-05 Bipolar disorder / / 18317468 rs8093310 chr18 894891 C T 8.11E-04 Multiple complex diseases / / 17554300 rs4797328 chr18 894965 C T 1.93E-05 Multiple sclerosis / / 17660530 rs1893154 chr18 905125 A G 2.97E-04 Response to taxane treatment (placlitaxel) ADCYAP1 intron 23006423 rs1893154 chr18 905125 A G 3.00E-06 Obesity-related traits ADCYAP1 intron 23251661 rs1893154 chr18 905125 A G 1.93E-04 Amyotrophic lateral sclerosis (sporadic) ADCYAP1 intron 24529757 rs4798773 chr18 932503 G C 5.73E-04 Multiple complex diseases / / 17554300 rs16953183 chr18 944533 C T 5.64E-05 Serum metabolites / / 19043545 rs1940292 chr18 951623 T C 7.95E-04 Type 2 diabetes / / 17463246 rs1610274 chr18 954465 G A 2.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs8090931 chr18 958056 G A 1.09E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs1523397 chr18 963538 A G 2.69E-05 Intracerebral hemorrhage / / 24656865 rs1085998 chr18 983188 G A 1.90E-05 Fasting plasma glucose / / 19060907 rs789071 chr18 1008339 G A 5.65E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs789071 chr18 1008339 G A 8.58E-04 Alcohol dependence / / 24277619 rs789072 chr18 1008417 C T 5.65E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs1720464 chr18 1013959 C T 5.65E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs16954588 chr18 1014560 C T 8.58E-04 Alcohol dependence / / 24277619 rs7232873 chr18 1017323 A G 6.14E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs789040 chr18 1017587 G A 6.92E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs789046 chr18 1020820 A G 2.18E-04 Sudden cardiac arrest / / 21658281 rs789046 chr18 1020820 A G 8.53E-04 Alcohol dependence / / 24277619 rs789026 chr18 1046527 A G 9.90E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs789027 chr18 1046560 C T 8.27E-04 Type 2 diabetes / / 17463246 rs4796899 chr18 1086189 G T 4.65E-04 Parkinson's disease / / 17052657 rs304397 chr18 1096439 G A 1.34E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs304409 chr18 1106342 C T 4.60E-05 Subclinical atherosclerosis / / 17903303 rs6505623 chr18 1125057 C T 1.60E-04 Lipid traits / / 17903299 rs9954959 chr18 1197145 G A 7.99E-05 Lung function (forced vital capacity) / / pha003104 rs1826508 chr18 1206984 C T 4.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) / / 23934736 rs1472194 chr18 1210675 G A 2.25E-04 Myocardial Infarction / / pha002873 rs987611 chr18 1306068 C T 7.76E-05 Coronary heart disease LINC00470 intron 21971053 rs2099468 chr18 1318650 T G 3.16E-04 Multiple complex diseases LINC00470 intron 17554300 rs9950729 chr18 1344120 T C 1.60E-04 Alcohol dependence LINC00470 intron 20201924 rs9950729 chr18 1344120 T C 2.90E-04 Alcohol dependence LINC00470 intron 20201924 rs1836648 chr18 1350253 C T 8.28E-04 Multiple complex diseases LINC00470 intron 17554300 rs12232668 chr18 1356839 G A 8.08E-04 Multiple complex diseases LINC00470 intron 17554300 rs2344674 chr18 1359325 T C 2.29E-04 Multiple complex diseases LINC00470 intron 17554300 rs1146075 chr18 1366301 C T 5.00E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs1146069 chr18 1414472 A C 3.85E-04 Multiple complex diseases / / 17554300 rs1605504 chr18 1452986 G A 2.40E-04 Coronary heart disease / / 21971053 rs9635809 chr18 1466512 T C 3.01E-05 Calcium levels / / pha003085 rs218526 chr18 1484945 T C 2.14E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs218526 chr18 1484945 T C 3.75E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs218526 chr18 1484945 T C 5.28E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs218526 chr18 1484945 T C 5.37E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs6505933 chr18 1505590 C T 2.10E-05 Personality dimensions / / 18957941 rs16941632 chr18 1538602 T C 4.65E-04 Multiple complex diseases / / 17554300 rs8083659 chr18 1539695 G A 2.45E-08 Metabolite levels / / 23281178 rs1941661 chr18 1540230 T C 4.57E-08 Metabolite levels / / 23281178 rs1941655 chr18 1543756 G C 4.57E-08 Metabolite levels / / 23281178 rs1941657 chr18 1546802 C G 1.06E-08 Metabolite levels / / 23281178 rs1941659 chr18 1547449 T C 4.57E-08 Metabolite levels / / 23281178 rs1115486 chr18 1549380 G A 4.57E-08 Metabolite levels / / 23281178 rs2080742 chr18 1549563 C G 4.57E-08 Metabolite levels / / 23281178 rs8090793 chr18 1549994 C T 4.57E-08 Metabolite levels / / 23281178 rs8089941 chr18 1550046 T C 4.57E-08 Metabolite levels / / 23281178 rs8085502 chr18 1550566 G C 4.57E-08 Metabolite levels / / 23281178 rs9954957 chr18 1559481 A G 4.77E-08 Metabolite levels / / 23281178 rs9958246 chr18 1562025 C T 6.28E-08 Metabolite levels / / 23281178 rs9944906 chr18 1565606 G A 6.28E-08 Metabolite levels / / 23281178 rs17384005 chr18 1575020 A G 1.10E-05 Type 2 diabetes / / 17463248 rs17384697 chr18 1583687 A G 2.47E-04 Type 2 diabetes / / 17463246 rs8097348 chr18 1595021 G A 7.00E-06 Exercise (leisure time) / / 19727025 rs6505951 chr18 1678746 C T 1.53E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6505951 chr18 1678746 C T 4.57E-04 Multiple complex diseases / / 17554300 rs1563187 chr18 1681442 C T 3.70E-07 Urinary metabolites / / 21572414 rs4797052 chr18 1699830 T C 4.14E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs9966172 chr18 1700239 C A 3.48E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs7241494 chr18 1713347 T C 2.20E-07 Urinary metabolites / / 21572414 rs11661077 chr18 1725758 C A 6.20E-04 Multiple complex diseases / / 17554300 rs1563188 chr18 1738361 A G 3.48E-04 Alcohol dependence / / 20201924 rs12326912 chr18 1757523 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1371267 chr18 1758001 A C 4.47E-04 Smoking initiation / / 24665060 rs16942039 chr18 1768512 A G 3.14E-04 Smoking initiation / / 24665060 rs1371264 chr18 1775084 A G 3.03E-04 Multiple complex diseases / / 17554300 rs2712735 chr18 1775175 G C 4.48E-04 Multiple complex diseases / / 17554300 rs16942081 chr18 1796710 A T 8.65E-04 Type 2 diabetes / / 17463246 rs16942082 chr18 1799889 A G 4.49E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs8093266 chr18 1800338 G A 7.52E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs8091249 chr18 1802443 T G 7.31E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs7241970 chr18 1803913 T C 7.53E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs7227078 chr18 1804120 T C 7.52E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs7227080 chr18 1804124 T G 7.51E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs62079387 chr18 1805200 T C 7.15E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs11660591 chr18 1805225 T C 8.16E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs9964595 chr18 1807674 G A 4.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs2712751 chr18 1815516 T C 2.50E-05 Urinary metabolites / / 21572414 rs2345595 chr18 1818385 A C 4.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs754905 chr18 1824510 A G 8.57E-04 Multiple complex diseases / / 17554300 rs2712767 chr18 1825170 C T 9.45E-04 Type 2 diabetes / / 17463246 rs9953530 chr18 1870787 A T 1.10E-05 Urinary metabolites / / 21572414 rs11661394 chr18 1877044 A G 3.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12970397 chr18 1908848 G A 4.89E-04 Smoking quantity / / 24665060 rs1605930 chr18 1923978 C T 3.20E-04 Depression (quantitative trait) / / 20800221 rs16942254 chr18 1924923 G A 7.04E-05 Depression (quantitative trait) / / 20800221 rs2345869 chr18 1944400 C T 4.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs9966123 chr18 1961967 T C 3.51E-05 Bipolar disorder / / 17486107 rs7504717 chr18 1967518 A G 1.60E-05 Urinary metabolites / / 21572414 rs6505987 chr18 1977713 G T 3.00E-08 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs1940646 chr18 2002665 A G 9.06E-05 Systemic sclerosis / / 21750679 rs16942454 chr18 2029166 C T 7.59E-04 Multiple complex diseases / / 17554300 rs9959376 chr18 2034580 C T 1.22E-04 Parkinson's disease / / 16252231 rs12967693 chr18 2105249 G A 8.66E-04 Obesity (extreme) / / 21935397 rs11877976 chr18 2187489 T C 2.30E-05 Urinary metabolites / / 21572414 rs11080927 chr18 2240220 C T 1.58E-04 Fibrinogen / / 17255346 rs7236153 chr18 2274078 T G 2.09E-04 Vaspin levels / / 22907691 rs7236153 chr18 2274078 T G 0.0002089 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs7228281 chr18 2276242 T C 6.12E-04 Smoking initiation / / 24665060 rs7240747 chr18 2302770 C T 2.46E-04 Multiple complex diseases / / 17554300 rs7240747 chr18 2302770 C T 2.87E-05 Caffeine consumption / / 21490707 rs1365240 chr18 2309943 C T 4.09E-04 Multiple complex diseases / / 17554300 rs1365241 chr18 2310134 A G 3.58E-04 Multiple complex diseases / / 17554300 rs9303898 chr18 2312881 C T 5.05E-04 Multiple complex diseases / / 17554300 rs9303900 chr18 2323411 G A 9.04E-04 Multiple complex diseases / / 17554300 rs7231168 chr18 2329839 T C 6.77E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3942404 chr18 2330828 C G 3.49E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs8086975 chr18 2332259 G A 8.23E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs16943088 chr18 2341382 G A 1.22E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs7227539 chr18 2377088 A G 9.54E-04 Multiple complex diseases / / 17554300 rs7227539 chr18 2377088 A G 1.58E-05 Lung Function (Forced Expiratory Volume in 1 second) / / 25044411 rs4287646 chr18 2404812 G C 1.12E-04 Multiple complex diseases / / 17554300 rs16943205 chr18 2412278 A G 1.13E-04 Prion diseases / / 22210626 rs3914856 chr18 2413983 G A,C 5.79E-04 Multiple complex diseases / / 17554300 rs8084727 chr18 2452129 T A 5.79E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs3914785 chr18 2452177 A G 2.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs16943313 chr18 2481917 G A 2.61E-04 Schizophrenia(age at onset) / / 21688384 rs1879352 chr18 2498054 T C 5.96E-04 Coronary Artery Disease / / 17634449 rs1879352 chr18 2498054 T C 9.00E-06 Acute lymphoblastic leukemia (childhood) / / 19684603 rs1879352 chr18 2498054 T C 9.00E-06 Nasopharyngeal carcinoma / / 20512145 rs1878555 chr18 2502688 G A 0.000583 Salmonella-induced pyroptosis / / 22837397 rs17617822 chr18 2504483 A C 7.48E-05 Rheumatoid arthritis / / 21452313 rs2677867 chr18 2511076 A G 2.21E-04 Rheumatoid arthritis / / 21452313 rs12455468 chr18 2521689 G A 6.17E-04 Coronary Artery Disease / / 17634449 rs770224 chr18 2533130 T C 2.12E-05 Alcoholism / / pha002893 rs2644171 chr18 2540198 A G 5.02E-05 Alcoholism METTL4 intron pha002893 rs2677879 chr18 2547500 G T 4.72E-05 Sensory disturbances after bilateral sagittal split ramus osteotomy METTL4 missense 23834954 rs2677894 chr18 2572056 C G 2.60E-04 Lymphocyte counts NDC80 intron 22286170 rs13381300 chr18 2572095 T G 1.30E-06 Urinary metabolites NDC80 intron 21572414 rs9955172 chr18 2603821 A C 2.80E-06 Urinary metabolites NDC80 intron 21572414 rs182046301 chr18 2614475 A G 2.00E-06 PR interval in Tripanosoma cruzi seropositivity NDC80 intron 24324551 rs9303909 chr18 2634848 T G 6.30E-04 Rheumatoid arthritis / / 21452313 rs2044107 chr18 2635263 A G 5.24E-04 Atopy / / 21625490 rs4533365 chr18 2645746 A G 3.18E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs12605423 chr18 2725198 A G 3.50E-04 Multiple complex diseases SMCHD1 intron 17554300 rs11080985 chr18 2725432 G A 2.12E-04 Multiple complex diseases SMCHD1 intron 17554300 rs11664217 chr18 2725597 G A 2.89E-04 Multiple complex diseases SMCHD1 intron 17554300 rs8092725 chr18 2738259 G A 8.74E-04 Iron levels SMCHD1 intron pha002876 rs11872184 chr18 2739733 G A 4.00E-06 Conotruncal heart defects SMCHD1 intron 24800985 rs11080987 chr18 2748323 T C 1.31E-04 Multiple complex diseases SMCHD1 intron 17554300 rs4798023 chr18 2753247 T C 3.49E-04 Multiple complex diseases SMCHD1 intron 17554300 rs12959881 chr18 2763210 A C 2.26E-04 Multiple complex diseases SMCHD1 intron 17554300 rs17552605 chr18 2791071 A C 9.15E-04 Suicide attempts in bipolar disorder SMCHD1 intron 21423239 rs596701 chr18 2828699 C T 4.55E-04 Alzheimer's disease (late onset) / / 21379329 rs894761 chr18 2856482 C A 4.07E-05 Blood Pressure EMILIN2 intron pha003050 rs28877609 chr18 2865505 G A 3.00E-06 PR interval in Tripanosoma cruzi seropositivity EMILIN2 intron 24324551 rs8086883 chr18 2866490 T C 8.03E-04 Response to taxane treatment (placlitaxel) EMILIN2 intron 23006423 rs583523 chr18 2874156 G A 1.61E-04 Type 2 diabetes EMILIN2 intron 17463246 rs583523 chr18 2874156 G A 4.60E-04 Alzheimer's disease EMILIN2 intron 17998437 rs583523 chr18 2874156 G A 8.47E-04 Response to taxane treatment (placlitaxel) EMILIN2 intron 23006423 rs11080995 chr18 2900028 C T 2.99E-04 Alzheimer's disease (late onset) EMILIN2 intron 21379329 rs11080995 chr18 2900028 C T 5.96E-05 Pancreatic cancer EMILIN2 intron pha002874 rs1790994 chr18 2913431 T C 6.92E-06 Rheumatoid arthritis EMILIN2 UTR-3 19503088 rs2282635 chr18 2921444 T C 8.01E-05 Gallstones LPIN2 intron 17632509 rs2282636 chr18 2921777 T C 5.94E-06 Pancreatic cancer LPIN2 intron pha002874 rs16944053 chr18 2922900 G A 6.23E-04 Multiple complex diseases LPIN2 intron 17554300 rs3819090 chr18 2926402 G T 2.10E-05 Pancreatic cancer LPIN2 intron pha002874 rs3826637 chr18 2937646 A G 7.25E-06 Pancreatic cancer LPIN2 intron pha002874 rs643507 chr18 2946291 C T 8.00E-09 Body mass index (asthmatics) LPIN2 intron 23517042 rs641287 chr18 2946833 T A 2.58E-05 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines LPIN2 intron 21483694 rs10460009 chr18 2948029 C T 9.00E-06 Type 2 diabetes LPIN2 intron 21490949 rs8087073 chr18 2967845 A C 1.00E-09 PR interval in Tripanosoma cruzi seropositivity LPIN2 intron 24324551 rs16944160 chr18 2995308 T C 7.90E-04 Multiple complex diseases LPIN2 intron 17554300 rs678156 chr18 3002436 C T 0.00000006 Brain microstructure and intellectual performance LPIN2 intron 22723713 rs77228315 chr18 3038308 A G 7.82E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs76382868 chr18 3040520 A G 7.87E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs78192384 chr18 3041397 G A 7.00E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs9956108 chr18 3042416 G T 4.49E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs115445970 chr18 3056424 T A 9.96E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs4798062 chr18 3071242 T A,C,G 1.04E-05 Height MYOM1 intron pha003011 rs10502311 chr18 3077397 T C 2.98E-05 Height MYOM1 intron pha003011 rs3765623 chr18 3086065 C T 3.83E-05 Nephrolithiasis MYOM1 missense 22396660 rs4413045 chr18 3088903 T C 4.93E-06 Elbow pain MYOM1 intron pha003008 rs4413045 chr18 3088903 T C 2.40E-05 Height MYOM1 intron pha003010 rs4413045 chr18 3088903 T C 6.28E-06 Height MYOM1 intron pha003011 rs8089599 chr18 3129131 T C 2.90E-05 Cholesterol MYOM1 intron pha003073 rs8089599 chr18 3129131 T C 9.00E-05 Cholesterol MYOM1 intron pha003078 rs7506674 chr18 3133302 A G 4.93E-04 Smoking initiation MYOM1 intron 24665060 rs4797100 chr18 3138553 A G 5.66E-04 Parkinson's disease MYOM1 intron 17052657 rs8087321 chr18 3168616 A G 4.16E-04 Insulin resistance MYOM1 intron 21901158 rs8087329 chr18 3168637 A G 1.58E-04 Insulin resistance MYOM1 intron 21901158 rs9951849 chr18 3171473 G T 1.48E-04 Suicide attempts in bipolar disorder MYOM1 intron 21423239 rs10153321 chr18 3176377 G A 8.73E-07 Alcohol and nictotine co-dependence MYOM1 intron 20158304 rs10853291 chr18 3183354 T C 9.83E-06 Autism MYOM1 intron 24189344 rs976655 chr18 3213337 G T 8.90E-04 Type 2 diabetes and 6 quantitative traits MYOM1 intron 17848626 rs79794368 chr18 3249129 C T 1.48E-05 Cocaine dependence MYL12A intron 23958962 rs6506088 chr18 3250689 G C 4.13E-04 Blood pressure MYL12A intron 17255346 rs6506088 chr18 3250689 G C 7.95E-04 Multiple complex diseases MYL12A intron 17554300 rs13381416 chr18 3251833 A G 1.06E-05 Cocaine dependence MYL12A intron 23958962 rs61751192 chr18 3253942 C T 1.73E-05 Cocaine dependence MYL12A cds-synon 23958962 rs3786458 chr18 3254460 T A 3.66E-04 Blood pressure MYL12A intron 17255346 rs9947947 chr18 3268699 A G 3.44E-04 Multiple complex diseases MYL12B intron 17554300 rs1791111 chr18 3282219 G A 7.01E-04 Schizophrenia / / 19197363 rs8086134 chr18 3291714 A G 3.90E-06 Urinary metabolites / / 21572414 rs1791124 chr18 3316176 T G 1.85E-05 Alcohol dependence / / 19581569 rs1791124 chr18 3316176 T G 6.93E-05 Major depressive disorder / / 22472876 rs1791124 chr18 3316176 T G 7.33E-05 Diabetes Mellitus / / pha003059 rs1791124 chr18 3316176 T G 4.22E-05 Cholesterol / / pha003073 rs1791124 chr18 3316176 T G 2.94E-05 Cholesterol / / pha003078 rs1662813 chr18 3319915 C T 4.61E-04 Schizophrenia / / 19197363 rs1662813 chr18 3319915 C T 8.65E-05 Cholesterol / / pha003078 rs949306 chr18 3327801 G A 1.31E-05 Triglycerides / / 19074352 rs949306 chr18 3327801 G A 1.31E-05 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs949306 chr18 3327801 G A 3.48E-05 Lipoproteins / / pha003079 rs894733 chr18 3327868 C T 9.40E-04 Rheumatoid arthritis / / 21452313 rs1623523 chr18 3328746 T C 3.00E-06 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs1626048 chr18 3343266 T A 5.53E-05 Response to metformin / / 21186350 rs1662830 chr18 3345173 A G 4.76E-05 Response to metformin / / 21186350 rs9954608 chr18 3388779 A G 5.69E-05 Response to methotrexate in juvenile idiopathic arthritis / / 24709693 rs6506122 chr18 3394449 T C 5.00E-06 Response to methotrexate in juvenile idiopathic arthritis / / 24709693 rs11874742 chr18 3397434 C T 5.33E-05 Post-operative nausea and vomiting / / 21694509 rs7229555 chr18 3414023 A G 8.76E-04 Multiple complex diseases TGIF1 intron 17554300 rs11081045 chr18 3415763 T G 5.21E-06 Periodontitis (DPAL) TGIF1 intron 24024966 rs12457997 chr18 3415831 C T 5.00E-06 Periodontitis (DPAL) TGIF1 intron 24024966 rs11664784 chr18 3419463 A G 1.77E-04 Multiple complex diseases TGIF1 intron 17554300 rs7234567 chr18 3420806 A G 5.16E-04 Amyotrophic Lateral Sclerosis TGIF1 intron 17362836 rs1020301 chr18 3426724 G A 7.35E-05 Waist Circumference TGIF1 intron pha003024 rs1962914 chr18 3426898 G T 3.20E-04 Type 2 diabetes TGIF1 intron 17463246 rs1962914 chr18 3426898 G T 7.13E-04 Multiple complex diseases TGIF1 intron 17554300 rs7235674 chr18 3433425 G A 1.19E-05 ldl cholesterol TGIF1 intron pha003077 rs2238536 chr18 3452978 C T 6.26E-05 AIDS TGIF1 intron 19754311 rs58882377 chr18 3465132 A G 8.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs431220 chr18 3467413 C T 5.88E-05 Alcohol dependence LOC100505592 intron 20201924 rs431220 chr18 3467413 C T 5.88E-05 Alcoholism LOC100505592 intron pha002891 rs17724172 chr18 3512216 T C 9.00E-06 Cardiac Troponin-T levels DLGAP1 intron 23247143 rs642466 chr18 3518761 G T 5.17E-04 Smoking initiation DLGAP1 intron 24665060 rs12964965 chr18 3520555 T C 1.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DLGAP1 intron 20877124 rs8083633 chr18 3522006 T C 1.00E-06 Economic and political preferences (time) DLGAP1 intron 22566634 rs641299 chr18 3544662 T A 3.15E-27 Narcolepsy DLGAP1 intron 19629137 rs7232859 chr18 3566945 C A 7.27E-06 Body Fat Distribution DLGAP1 intron pha003016 rs7232859 chr18 3566945 C A 6.57E-05 Body Fat Distribution DLGAP1 intron pha003017 rs7232859 chr18 3566945 C A 6.38E-05 Body Fat Distribution DLGAP1 intron pha003018 rs475528 chr18 3580742 A C,G,T 3.01E-07 Body Fat Distribution DLGAP1 intron pha003016 rs475528 chr18 3580742 A C,G,T 3.27E-07 Body Fat Distribution DLGAP1 intron pha003017 rs475528 chr18 3580742 A C,G,T 3.86E-07 Body Fat Distribution DLGAP1 intron pha003018 rs2240899 chr18 3595011 G C 2.80E-06 Primary tooth development (number of teeth) DLGAP1 intron 23704328 rs17647607 chr18 3595765 A G 1.40E-05 Response to citalopram treatment DLGAP1 intron 19846067 rs474122 chr18 3603112 A G 5.28E-04 White matter integrity DLGAP1 intron 22425255 rs1791379 chr18 3611838 A G 1.28E-04 Tourette syndrome DLGAP1 intron 22889924 rs17725070 chr18 3612720 T C 4.98E-05 Iron levels DLGAP1 intron 19880490 rs17725070 chr18 3612720 T C 4.98E-05 Iron levels DLGAP1 intron pha002876 rs1639365 chr18 3649896 T C 1.15E-04 Myopia (pathological) DLGAP1 intron 21095009 rs767887 chr18 3653422 T C 2.70E-04 Myopia (pathological) DLGAP1 intron 21095009 rs1077850 chr18 3665135 A G 4.24E-05 Multiple complex diseases DLGAP1 intron 17554300 rs1675244 chr18 3670649 A G 8.96E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) DLGAP1 intron 23648065 rs1116345 chr18 3671652 T C 9.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) DLGAP1 intron 23648065 rs342484 chr18 3701841 G C 1.11E-04 Prostate cancer mortality DLGAP1 intron 20978177 rs439890 chr18 3720081 C T 6.14E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DLGAP1 intron 20877124 rs1133851 chr18 3722038 G A 6.48E-04 Response to cytadine analogues (cytosine arabinoside) DLGAP1 intron 24483146 rs7359820 chr18 3723036 C T 4.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DLGAP1 intron 20877124 rs6506135 chr18 3790757 T C 8.92E-06 Job-related exhaustion DLGAP1 intron 23620144 rs9960018 chr18 3793080 C T 5.00E-05 Tanning DLGAP1 intron 19340012 rs4797124 chr18 3793921 T C 6.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DLGAP1 intron 20877124 rs3786431 chr18 3814148 C G 2.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity DLGAP1 cds-synon 24324551 rs17649611 chr18 3824077 T G 2.78E-04 Aortic root size DLGAP1 intron 21223598 rs11873667 chr18 3825114 C T 7.08E-06 Hepatitis B DLGAP1 intron 21750111 rs7232492 chr18 3830245 C T 5.36E-06 Hepatitis B DLGAP1 intron 21750111 rs10502314 chr18 3840072 G A 6.18E-04 Heart Failure DLGAP1 intron pha002885 rs3915772 chr18 3848826 T C 8.43E-05 Neuroblastoma DLGAP1 intron pha002895 rs3760605 chr18 3870771 T C 5.13E-04 Multiple complex diseases DLGAP1 intron 17554300 rs3910707 chr18 3873447 A C 4.40E-05 Alcohol consumption (maxi-drinks) DLGAP1 intron 24277619 rs76205593 chr18 3879739 C G 7.00E-06 Obesity-related traits DLGAP1 missense 23251661 rs9946373 chr18 3962377 T C 7.34E-04 Depression (quantitative trait) DLGAP1 intron 20800221 rs41399245 chr18 3964699 A T 5.20E-04 Alzheimer's disease DLGAP1 intron 17998437 rs4541164 chr18 3991340 G C 8.78E-04 Acute lung injury DLGAP1 intron 22295056 rs4420626 chr18 3991413 C A 8.24E-04 Acute lung injury DLGAP1 intron 22295056 rs10853309 chr18 4001419 G A 8.73E-04 Insulin resistance DLGAP1 intron 21901158 rs9789192 chr18 4001972 T C 4.66E-04 Multiple complex diseases DLGAP1 intron 17554300 rs1442385 chr18 4025719 G A 2.91E-05 Leukocyte Counts DLGAP1 intron pha003091 rs1372631 chr18 4026587 T G 4.13E-05 Alcohol and nictotine co-dependence DLGAP1 intron 20158304 rs2137 chr18 4026741 T C 9.45E-04 Multiple complex diseases DLGAP1 intron 17554300 rs10502317 chr18 4031134 A T 4.70E-05 Parkinson's disease (age of onset) DLGAP1 intron 19772629 rs2119846 chr18 4048189 T C 5.21E-05 Coronary heart disease DLGAP1 intron pha003031 rs7504269 chr18 4072948 A G 7.19E-04 Type 2 diabetes DLGAP1 intron 17463246 rs7240625 chr18 4074007 T G 6.22E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) DLGAP1 intron 23648065 rs8083052 chr18 4079845 A G 3.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DLGAP1 intron 20877124 rs8083052 chr18 4079845 A G 3.60E-05 Body Mass Index DLGAP1 intron pha003009 rs8094832 chr18 4080734 G A 1.75E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DLGAP1 intron 20877124 rs11661443 chr18 4083102 A G 4.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DLGAP1 intron 20877124 rs11663122 chr18 4084386 T G 2.14E-04 Response to taxane treatment (placlitaxel) DLGAP1 intron 23006423 rs7505930 chr18 4092001 C T 6.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DLGAP1 intron 20877124 rs4798175 chr18 4126456 C A 3.64E-05 Body Mass Index DLGAP1 intron pha003015 rs2049161 chr18 4127583 A C 5.90E-05 Electrocardiographic traits and heart rate variability DLGAP1 intron 17903306 rs16946066 chr18 4132371 G A 1.98E-05 Multiple complex diseases DLGAP1 intron 17554300 rs1402627 chr18 4133739 T C 4.40E-05 Alzheimer's disease (late onset) DLGAP1 intron 20885792 rs1402627 chr18 4133739 T C 4.40E-05 Alzheimer's disease (late onset) DLGAP1 intron 21460841 rs12607175 chr18 4147483 C T 9.10E-06 Asthma (childhood onset) DLGAP1 intron 23829686 rs4798185 chr18 4150017 G A 9.81E-04 Suicide attempts in bipolar disorder DLGAP1 intron 21423239 rs8095654 chr18 4154024 C T 8.78E-04 Suicide attempts in bipolar disorder DLGAP1 intron 21423239 rs7232189 chr18 4161831 C T 4.74E-04 Response to taxane treatment (placlitaxel) DLGAP1 intron 23006423 rs11081097 chr18 4172963 C T 4.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DLGAP1 intron 20877124 rs6506187 chr18 4176633 G T 5.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DLGAP1 intron 20877124 rs9959484 chr18 4182758 G A 1.73E-06 Post-operative nausea and vomiting DLGAP1 intron 21694509 rs2177008 chr18 4200866 C T 2.60E-05 Urinary metabolites DLGAP1 intron 21572414 rs973449 chr18 4208439 A G 8.77E-05 Non-alcoholic fatty liver disease histology (other) DLGAP1 intron 20708005 rs1402631 chr18 4211925 G T 2.11E-05 Femoral neck bone geometry DLGAP1 intron 22087292 rs641205 chr18 4242200 G A 4.13E-05 Duodenal ulcer DLGAP1 intron 22387998 rs541039 chr18 4275455 T C 5.11E-05 Bone mineral density DLGAP1 intron 19181680 rs523436 chr18 4295384 C T 1.80E-05 Tooth agenesis (maxillary third molar) DLGAP1 intron 24172245 rs4798212 chr18 4310797 C T 9.20E-04 Multiple complex diseases DLGAP1 intron 17554300 rs722606 chr18 4360028 G A 7.65E-04 Multiple complex diseases DLGAP1 intron 17554300 rs10084008 chr18 4390081 T G 2.50E-05 HIV-1 control DLGAP1 intron 20041166 rs7244876 chr18 4394577 A G 3.91E-04 Response to taxane treatment (placlitaxel) DLGAP1 intron 23006423 rs9303950 chr18 4412153 C T 7.73E-05 Coronary heart disease DLGAP1 intron pha003033 rs3850796 chr18 4415283 G T 2.60E-04 Multiple complex diseases DLGAP1 intron 17554300 rs11081118 chr18 4444996 T C 1.43E-05 Body mass (lean) DLGAP1 intron 19268274 rs280976 chr18 4446528 A G 3.76E-04 Alzheimer's disease (late onset) DLGAP1 intron 21379329 rs280987 chr18 4448941 C A 5.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) DLGAP1 intron 17982456 rs280987 chr18 4448941 C A 6.57E-04 Depression (quantitative trait) DLGAP1 intron 20800221 rs280986 chr18 4449084 G A 6.60E-04 Depression (quantitative trait) DLGAP1 intron 20800221 rs16946854 chr18 4450775 A G 5.47E-05 Cholesterol DLGAP1 intron pha003073 rs6506203 chr18 4453640 C A 2.02E-04 Alzheimer's disease DLGAP1 intron 17998437 rs2135414 chr18 4458600 C A 9.10E-06 Urinary metabolites / / 21572414 rs12454329 chr18 4510629 A G 1.63E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7228133 chr18 4539085 G T 2.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs2847108 chr18 4592823 T C 5.18E-04 Schizophrenia / / 19197363 rs1785061 chr18 4601573 T G 6.27E-05 Serum metabolites / / 19043545 rs1107066 chr18 4632110 G A 8.38E-05 Monocyte chemoattractant protein-1 / / pha003071 rs12969362 chr18 4652432 C T 2.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12969362 chr18 4652432 C T 2.40E-06 Coronary heart disease / / pha003031 rs1940860 chr18 4664610 G T 9.25E-04 Type 2 diabetes / / 17463246 rs11660971 chr18 4672296 A T 4.93E-04 Type 2 diabetes / / 17463246 rs1557305 chr18 4721359 C T 1.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1557305 chr18 4721359 C T 5.00E-06 Eating disorders / / 22911880 rs1557305 chr18 4721359 C T 2.33E-08 Coronary heart disease / / pha003031 rs9964615 chr18 4728340 T C 2.56E-04 Blood pressure / / 24001895 rs12970492 chr18 4735745 G C 1.06E-04 Type 2 diabetes / / 17463246 rs6506242 chr18 4749982 T C 9.89E-04 Type 2 diabetes / / 17463246 rs12961355 chr18 4763493 A G 7.56E-05 Monocyte chemoattractant protein-1 / / pha003071 rs12960989 chr18 4772751 G C 1.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs7237848 chr18 4773110 C T 4.75E-05 Suicide attempts in bipolar disorder / / 21423239 rs7237848 chr18 4773110 C T 2.00E-07 White blood cell types / / 21738478 rs7505612 chr18 4776396 A C 2.87E-04 Longevity / / 22279548 rs7505612 chr18 4776396 A C 7.18E-04 Tourette syndrome / / 22889924 rs7504165 chr18 4777539 T C 5.50E-06 Longevity,exceptional / / 20595579 rs11081150 chr18 4786165 T C 3.03E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1501045 chr18 4951575 T G 5.22E-06 Height / / 17255346 rs1501045 chr18 4951575 T G 8.89E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs2321278 chr18 4969964 C G 1.27E-04 Height / / 17255346 rs1466882 chr18 4970506 A C 3.92E-04 Height / / 17255346 rs7234590 chr18 4989683 G A 4.00E-04 Aortic root size / / 21223598 rs13381899 chr18 5050455 G A 3.47E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1501056 chr18 5051085 C A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12966500 chr18 5061254 T C 3.87E-04 Lung function (forced vital capacity) / / 24023788 rs188357 chr18 5071785 T C 9.13E-05 Breast cancer / / pha002853 rs291648 chr18 5078653 T C 1.23E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10853325 chr18 5112203 C A 1.55E-04 Height / / 17255346 rs11659710 chr18 5137679 A G 5.89E-04 Insulin resistance / / 21901158 rs7236094 chr18 5153864 G C 1.91E-04 Suicide attempts in bipolar disorder C18orf42 intron 21423239 rs9961211 chr18 5156547 G A 4.44E-05 Acute lung injury C18orf42 intron 22295056 rs12457539 chr18 5161461 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes C18orf42 intron 22628534 rs11081175 chr18 5188604 C T 6.05E-04 Multiple complex diseases C18orf42 intron 17554300 rs1154999 chr18 5193260 A G 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes C18orf42 intron 22628534 rs8090209 chr18 5204070 C T 3.16E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4798311 chr18 5215978 C T 3.01E-04 Multiple complex diseases / / 17554300 rs4797197 chr18 5215992 T A 4.11E-04 Multiple complex diseases / / 17554300 rs1395065 chr18 5217594 G A 2.31E-05 Elbow pain / / pha003008 rs8094621 chr18 5224663 G A 3.60E-04 Multiple complex diseases / / 17554300 rs924960 chr18 5241007 G A 8.08E-04 Amyotrophic lateral sclerosis (sporadic) LOC339290 intron 24529757 rs3184460 chr18 5244261 A G 8.16E-05 Elbow pain / / pha003008 rs2174541 chr18 5249982 T C 1.90E-05 Urinary metabolites / / 21572414 rs8092448 chr18 5250817 G T 3.17E-04 Depression (quantitative trait) / / 20800221 rs4798330 chr18 5251192 T G 2.86E-04 Depression (quantitative trait) / / 20800221 rs1109434 chr18 5286076 A G 1.75E-04 Depression (quantitative trait) / / 20800221 rs8094633 chr18 5349100 C T 3.57E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs4798341 chr18 5352986 G A 9.45E-04 Multiple complex diseases / / 17554300 rs7236529 chr18 5366458 C T 9.28E-05 Creatinine levels / / pha003069 rs3926157 chr18 5379249 C T 1.43E-05 Body mass index / / 17255346 rs11661371 chr18 5396976 C T 6.22E-04 Suicide attempts in bipolar disorder EPB41L3 intron 21423239 rs11661371 chr18 5396976 C T 2.21E-05 Vascular dementia EPB41L3 intron 22116812 rs9965501 chr18 5408814 T G 3.02E-04 Body mass index EPB41L3 intron 17255346 rs12605370 chr18 5408997 C A 1.22E-04 Body mass index EPB41L3 intron 17255346 rs12605370 chr18 5408997 C A 7.02E-04 Suicide attempts in bipolar disorder EPB41L3 intron 21423239 rs3817466 chr18 5410574 A G 7.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs6506299 chr18 5411968 G A,C 6.71E-04 Suicide attempts in bipolar disorder EPB41L3 intron 21423239 rs16948141 chr18 5413815 T C 6.72E-04 Suicide attempts in bipolar disorder EPB41L3 intron 21423239 rs16948141 chr18 5413815 T C 7.24E-04 Insulin resistance EPB41L3 intron 21901158 rs8082898 chr18 5416160 T C 5.61E-05 Body mass index EPB41L3 missense 17255346 rs17466502 chr18 5417183 A C 1.00E-04 Personality dimensions EPB41L3 intron 23903073 rs17466502 chr18 5417183 A C 1.81E-04 Iron levels EPB41L3 intron pha002876 rs16948164 chr18 5418636 A G 8.82E-04 Suicide attempts in bipolar disorder EPB41L3 intron 21423239 rs1610066 chr18 5433011 G A 8.91E-04 Suicide attempts in bipolar disorder EPB41L3 intron 21423239 rs9950450 chr18 5471765 C T 4.85E-04 Suicide attempts in bipolar disorder EPB41L3 intron 21423239 rs9952940 chr18 5472021 C T 4.68E-04 Suicide attempts in bipolar disorder EPB41L3 intron 21423239 rs11664867 chr18 5472048 A G 5.71E-04 Suicide attempts in bipolar disorder EPB41L3 intron 21423239 rs4798366 chr18 5475271 G T 5.03E-04 Suicide attempts in bipolar disorder EPB41L3 intron 21423239 rs12965156 chr18 5519322 C T 6.88E-05 Major depressive disorder (broad) EPB41L3 intron 20038947 rs1719953 chr18 5525037 C T 0.0000035 Sasang constitution (Taeum) EPB41L3 intron 22394158 rs1539809 chr18 5529675 C T 2.00E-06 Social communication problems EPB41L3 intron 24564958 rs1941000 chr18 5555731 C T 9.49E-05 Major depressive disorder (broad) / / 20038947 rs12955291 chr18 5556111 C T 6.90E-05 Major depressive disorder (broad) / / 20038947 rs12954752 chr18 5556492 G C 7.75E-05 Major depressive disorder (broad) / / 20038947 rs1785393 chr18 5559690 C T 1.80E-04 Multiple complex diseases / / 17554300 rs1785394 chr18 5560258 T C,G 4.62E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs8090286 chr18 5562155 T G 2.00E-06 Urinary metabolites / / 21572414 rs1785427 chr18 5579427 A G 5.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs1719933 chr18 5580911 T C 5.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs1719934 chr18 5585158 A G 7.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs1785378 chr18 5587094 G A 7.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs1719937 chr18 5587607 A G 7.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs1785380 chr18 5589629 A C 8.79E-04 Suicide attempts in bipolar disorder / / 21041247 rs1785381 chr18 5589721 C T 7.35E-04 Suicide attempts in bipolar disorder / / 21041247 rs1785382 chr18 5590926 C T 5.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs1719939 chr18 5592779 T C 4.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs1785407 chr18 5594350 A G 4.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs1785408 chr18 5594648 A G 4.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs1719943 chr18 5594667 C T 4.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs1785409 chr18 5594739 T C 4.81E-04 Suicide attempts in bipolar disorder / / 21041247 rs1785410 chr18 5594917 C T 4.81E-04 Suicide attempts in bipolar disorder / / 21041247 rs1539811 chr18 5595958 C T 4.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs1539812 chr18 5596091 T C 4.82E-04 Suicide attempts in bipolar disorder / / 21041247 rs1719944 chr18 5596603 T C 4.82E-04 Suicide attempts in bipolar disorder / / 21041247 rs1719983 chr18 5596822 C T 4.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs1785413 chr18 5596929 A G 4.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs1785414 chr18 5597676 T G 5.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs1719985 chr18 5598554 C T 3.62E-04 Type 2 diabetes / / 17463246 rs1719985 chr18 5598554 C T 5.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs1785415 chr18 5598976 G A 4.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs1785416 chr18 5599104 T C 4.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs1785418 chr18 5601403 G A 5.43E-04 Suicide attempts in bipolar disorder / / 21041247 rs4798376 chr18 5604240 T C 7.57E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs4798376 chr18 5604240 T C 4.03E-05 Serum alpha1-antitrypsin levels / / 23990791 rs10221410 chr18 5605989 C T 5.20E-04 Alcohol dependence / / 20201924 rs1785423 chr18 5610882 A G 1.99E-05 Parkinson's disease (motor and cognition) / / 22658654 rs4290555 chr18 5617122 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1941011 chr18 5659096 A T 4.96E-05 Type 2 diabetes / / 17846124 rs1941011 chr18 5659096 A T 5.00E-05 Type 2 diabetes / / 21647700 rs8083933 chr18 5718931 G A 7.25E-04 Body mass index / / 21701565 rs11874707 chr18 5731840 G T 7.40E-05 Alcohol consumption (maxi-drinks) / / 24277619 rs9948473 chr18 5745074 A G 6.34E-04 Alzheimer's disease / / 17998437 rs1917917 chr18 5753004 C T 1.37E-04 Celiac disease LOC645355 intron 23936387 rs1917917 chr18 5753004 C T 1.29E-05 Blood Pressure LOC645355 intron pha002903 rs11662748 chr18 5762618 G A 1.00E-06 Obesity-related traits LOC645355 intron 23251661 rs16948784 chr18 5765682 A T 9.00E-06 Prostate cancer LOC645355 intron 21743057 rs4798411 chr18 5812657 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11081216 chr18 5840255 A G 5.57E-04 Alzheimer's disease / / 17998437 rs11662763 chr18 5857091 C T 5.00E-06 Immunoglobulin A / / 20694011 rs9947332 chr18 5866947 C T 1.88E-05 Coronary heart disease / / pha003030 rs9948128 chr18 5892517 T C 4.03E-05 Parkinson's disease / / 21738487 rs2212522 chr18 5900773 C T 6.45E-04 Multiple complex diseases / / 17554300 rs11876129 chr18 5908566 T C 5.68E-06 Parent of origin effect on language impairment (child trend) / / 24571439 rs1940604 chr18 5913606 C T 9.63E-05 Hypertension (essential hypertension) / / 22184326 rs1940613 chr18 5923280 G A 1.66E-25 Narcolepsy / / 19629137 rs4798416 chr18 5930979 A C 1.35E-04 Coronary heart disease / / 21971053 rs635546 chr18 5937732 A G 8.60E-04 Suicidal ideation / / 22030708 rs499074 chr18 5940165 A G 7.43E-04 Tourette syndrome / / 22889924 rs8094014 chr18 5940341 A G 4.21E-04 Smoking cessation / / 24665060 rs11661935 chr18 5944834 G A 5.30E-06 Urinary metabolites / / 21572414 rs1893192 chr18 5947874 G A 8.42E-04 Multiple complex diseases / / 17554300 rs6506346 chr18 5948060 T C 4.99E-04 Tourette syndrome / / 22889924 rs564950 chr18 5948817 G A 7.76E-04 Tourette syndrome / / 22889924 rs9957452 chr18 5975760 G A 4.53E-04 Smoking cessation L3MBTL4 intron 24665060 rs16949147 chr18 5978258 A G 2.15E-04 Smoking cessation L3MBTL4 intron 24665060 rs1539808 chr18 5978931 C T 4.00E-06 Sleep time L3MBTL4 intron 23728906 rs515938 chr18 5991586 G C 3.60E-04 Type 2 diabetes L3MBTL4 intron 17463246 rs12967420 chr18 6000607 A C 6.81E-04 Amyotrophic lateral sclerosis (sporadic) L3MBTL4 intron 24529757 rs9953663 chr18 6007921 A T 1.80E-05 Urinary metabolites L3MBTL4 intron 21572414 rs9967429 chr18 6008207 C A 8.16E-05 ldl cholesterol L3MBTL4 intron pha003077 rs4798426 chr18 6008583 A C 1.50E-05 Urinary metabolites L3MBTL4 intron 21572414 rs9959352 chr18 6008961 T C 7.80E-05 ldl cholesterol L3MBTL4 intron pha003077 rs4798428 chr18 6022319 C T 2.53E-05 ldl cholesterol L3MBTL4 intron pha003077 rs570964 chr18 6022521 C T 7.00E-06 Urinary metabolites L3MBTL4 intron 21572414 rs1632611 chr18 6022693 A C 1.23E-04 Smoking cessation L3MBTL4 intron 24665060 rs672036 chr18 6023632 A G 1.46E-04 Smoking cessation L3MBTL4 intron 24665060 rs8084935 chr18 6030259 C A 6.56E-04 Suicide attempts in bipolar disorder L3MBTL4 intron 21423239 rs11661481 chr18 6044407 C A 6.79E-05 Intelligence L3MBTL4 intron 21826061 rs7243663 chr18 6083616 T C 4.49E-04 Type 2 diabetes L3MBTL4 intron 17463246 rs7238172 chr18 6083812 G T 5.54E-04 Type 2 diabetes L3MBTL4 intron 17463246 rs7245021 chr18 6092906 T C 1.85E-04 Celiac disease L3MBTL4 intron 23936387 rs12457649 chr18 6097485 T C 6.36E-04 Stroke L3MBTL4 intron pha002887 rs9630755 chr18 6104755 T G 7.30E-05 Response to statin therapy L3MBTL4 intron 20339536 rs16949431 chr18 6105967 G C 6.50E-05 Response to statin therapy L3MBTL4 intron 20339536 rs1818871 chr18 6117637 C A 9.61E-04 Stroke L3MBTL4 intron pha002886 rs8083296 chr18 6158716 A C 5.31E-09 Gallstones L3MBTL4 intron 17632509 rs664356 chr18 6159280 G C 8.47E-05 Type 2 diabetes L3MBTL4 intron 17463246 rs8099156 chr18 6190247 G A 9.38E-07 Multiple complex diseases L3MBTL4 intron 17554300 rs636589 chr18 6274885 A C 5.89E-05 Pancreatic cancer L3MBTL4 intron pha002874 rs3898848 chr18 6294119 G A 0.000315 Salmonella-induced pyroptosis L3MBTL4 intron 22837397 rs7235294 chr18 6310558 T C 0.000636 Salmonella-induced pyroptosis L3MBTL4 intron 22837397 rs397966 chr18 6312205 T C 0.000611 Salmonella-induced pyroptosis L3MBTL4 intron 22837397 rs341184 chr18 6365614 A G 4.74E-04 Bipolar disorder L3MBTL4 intron 19259986 rs1436907 chr18 6384431 C T 2.84E-04 Alzheimer's disease (late onset) L3MBTL4 intron 21379329 rs341237 chr18 6401283 T C 7.36E-05 Alzheimer's disease (late onset) L3MBTL4 intron 21379329 rs9965853 chr18 6402126 C T 3.73E-04 Suicide attempts in bipolar disorder L3MBTL4 intron 21041247 rs9965853 chr18 6402126 C T 3.60E-05 Alzheimer's disease (late onset) L3MBTL4 intron 21379329 rs12969887 chr18 6402671 A C 2.49E-04 Suicide attempts in bipolar disorder L3MBTL4 intron 21041247 rs2123311 chr18 6403285 A G 1.77E-04 Alzheimer's disease (late onset) L3MBTL4 intron 21379329 rs12961587 chr18 6404347 A G 1.90E-04 Suicide attempts in bipolar disorder L3MBTL4 intron 21041247 rs4797242 chr18 6407483 C A 3.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) L3MBTL4 intron 20877124 rs4797242 chr18 6407483 C A 1.55E-04 Suicide attempts in bipolar disorder L3MBTL4 intron 21041247 rs1020045 chr18 6410927 T C 5.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) L3MBTL4 intron 20877124 rs1964500 chr18 6412196 C G 2.15E-04 Multiple complex diseases L3MBTL4 intron 17554300 rs1834586 chr18 6412607 G C 1.24E-04 Type 2 diabetes L3MBTL4 intron 17463246 rs12456924 chr18 6447840 G T 1.60E-05 Urinary metabolites / / 21572414 rs1105794 chr18 6451334 G A 8.47E-04 Alzheimer's disease / / 22005930 rs4479336 chr18 6451515 C T 7.68E-04 Alzheimer's disease / / 22005930 rs9952528 chr18 6453861 T C 6.45E-04 Alzheimer's disease / / 22005930 rs4570962 chr18 6455370 C T 7.80E-04 Alzheimer's disease / / 22005930 rs12455109 chr18 6457227 G T 6.35E-04 Insulin resistance / / 21901158 rs8083385 chr18 6459659 A G 0.0001 Endometrial cancer / / 22426144 rs6506389 chr18 6467156 C T 5.60E-05 Alcohol dependence / / 20201924 rs6506389 chr18 6467156 C T 5.62E-05 Alcoholism / / pha002892 rs7226975 chr18 6470228 G A 1.61E-05 Cognitive test performance / / 20125193 rs7235209 chr18 6471939 A G 6.27E-05 Post-operative nausea and vomiting / / 21694509 rs6506395 chr18 6474590 A G 6.47E-05 Type 2 diabetes / / 23300278 rs6506396 chr18 6474641 T C 7.50E-06 Urinary metabolites / / 21572414 rs9963268 chr18 6480844 A C 5.61E-05 Cognitive test performance / / 20125193 rs12458804 chr18 6490913 C T 9.20E-05 HIV-1 control / / 20041166 rs12458804 chr18 6490913 C T 2.79E-04 Tourette syndrome / / 22889924 rs12456901 chr18 6507212 C T 5.12E-05 Smoking quantity / / 24665060 rs11081245 chr18 6524247 T A,C,G 2.49E-04 Multiple complex diseases LOC100130480 intron 17554300 rs9966928 chr18 6543564 G A 6.93E-04 Obesity (extreme) LOC100130480 intron 21935397 rs2155836 chr18 6545591 A T 0.0005935 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100130480 intron 23233654 rs2155836 chr18 6545591 A T 5.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100130480 intron 23233662 rs8086391 chr18 6547010 T C 5.80E-04 Type 2 diabetes and 6 quantitative traits LOC100130480 intron 17848626 rs8087580 chr18 6548096 A T 0.0006055 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100130480 intron 23233654 rs8087580 chr18 6548096 A T 6.06E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100130480 intron 23233662 rs8087708 chr18 6548120 A C 0.0006153 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100130480 intron 23233654 rs8087708 chr18 6548120 A C 6.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100130480 intron 23233662 rs1941495 chr18 6549667 C A 0.0005983 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100130480 intron 23233654 rs1941495 chr18 6549667 C A 5.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100130480 intron 23233662 rs1941494 chr18 6549764 G A 7.93E-04 Obesity (extreme) LOC100130480 intron 21935397 rs4411591 chr18 6550117 C T 0.00004835 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100130480 intron 23233654 rs4411591 chr18 6550117 C T 7.33E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100130480 intron 23233662 rs1954849 chr18 6551424 C A 0.0006102 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100130480 intron 23233654 rs1954849 chr18 6551424 C A 6.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100130480 intron 23233662 rs948426 chr18 6567182 A G 1.00E-06 Hypothyroidism LOC100130480 intron 22493691 rs11664790 chr18 6567538 G T 3.14E-04 Height LOC100130480 intron 17255346 rs8085932 chr18 6574570 A G 5.62E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LOC100130480 intron 22566498 rs17506582 chr18 6579216 T C 8.00E-06 Hypothyroidism LOC100130480 intron 22493691 rs2155835 chr18 6581793 G A 8.70E-05 Hypothyroidism LOC100130480 intron 22493691 rs1941496 chr18 6582104 G A 8.70E-06 Hypothyroidism LOC100130480 intron 22493691 rs8092631 chr18 6587541 T C 2.30E-05 Hypothyroidism LOC100130480 intron 22493691 rs1941491 chr18 6603954 C T 1.80E-05 Hypothyroidism / / 22493691 rs7241053 chr18 6638009 G A 5.20E-04 Primary sclerosing cholangitis / / 19944697 rs6506416 chr18 6638382 A C 0.0000471 Sarcoidosis / / 22952805 rs7231551 chr18 6641708 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7239022 chr18 6646853 C T 5.60E-06 Urinary metabolites / / 21572414 rs948428 chr18 6661437 C A 1.90E-05 Urinary metabolites / / 21572414 rs7505079 chr18 6666417 A G 1.40E-05 Urinary metabolites / / 21572414 rs7505079 chr18 6666417 A G 1.97E-04 Cognitive decline / / 23732972 rs9973079 chr18 6667746 T A 7.11E-04 Multiple complex diseases / / 17554300 rs11662297 chr18 6668050 A G 4.00E-06 Obesity-related traits / / 23251661 rs7506974 chr18 6726843 A G 9.61E-05 Lipoproteins / / pha003079 rs9959071 chr18 6732846 A G 1.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7505383 chr18 6741974 T C 2.50E-05 Urinary metabolites / / 21572414 rs4077790 chr18 6762055 G C 3.89E-04 Type 2 diabetes / / 17463246 rs8092311 chr18 6764297 G A 4.16E-04 Type 2 diabetes / / 17463246 rs8092311 chr18 6764297 G A 6.74E-05 Glucose levels / / pha003057 rs9965330 chr18 6764633 A C 9.50E-06 Urinary metabolites / / 21572414 rs1583178 chr18 6766273 A G 6.69E-04 Type 2 diabetes / / 17463246 rs11081271 chr18 6776036 G A 2.26E-04 Gallstones / / 17632509 rs1431381 chr18 6812509 G T 7.80E-05 Bone mineral density (BMD),in women / / 20164292 rs4798497 chr18 6853195 A G 8.44E-04 Suicide attempts in bipolar disorder ARHGAP28 intron 21423239 rs2567261 chr18 6868925 T C 1.21E-05 Alcohol dependence ARHGAP28 intron 23089632 rs2567261 chr18 6868925 T C 3.18E-04 Substance dependence phenotypes ARHGAP28 intron 24832863 rs2567261 chr18 6868925 T C 3.76E-08 Substance dependence phenotypes ARHGAP28 intron 24832863 rs17515951 chr18 6878965 C T 2.72E-04 Cholesterol ARHGAP28 intron 17255346 rs12454415 chr18 6908726 A G 0.000176 Asthma ARHGAP28 intron 22502797 rs4486988 chr18 6913420 T C 8.50E-04 Response to cytidine analogues (gemcitabine) ARHGAP28 UTR-3 24483146 rs766992 chr18 6916952 C T 7.06E-05 Coronary heart disease / / pha003031 rs2847197 chr18 6919628 T C 7.71E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2567259 chr18 6919785 C T 1.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9952054 chr18 6922019 C A 4.63E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1272845 chr18 6922924 G A 6.26E-05 Cholesterol / / 17255346 rs645313 chr18 6923733 A C 5.53E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1835654 chr18 6926688 G T 0.000878539 Hypertension (early onset hypertension) / / 22479346 rs4797265 chr18 6928180 G T 5.41E-04 Alcohol dependence / / 20201924 rs4797271 chr18 6932938 A C 1.45E-08 Metabolite levels / / 23281178 rs4797272 chr18 6933057 C T 1.45E-08 Metabolite levels / / 23281178 rs2105657 chr18 6937974 A G 1.45E-08 Metabolite levels / / 23281178 rs1261716 chr18 6939477 C A 3.17E-09 Metabolite levels / / 23281178 rs597503 chr18 6939947 G A 2.00E-08 Sudden cardiac arrest / / 21658281 rs597503 chr18 6939947 G A 3.17E-09 Metabolite levels / / 23281178 rs7244553 chr18 6939965 A G 3.17E-09 Metabolite levels / / 23281178 rs584440 chr18 6940522 A G 3.17E-09 Metabolite levels / / 23281178 rs4398173 chr18 6941108 A G 4.00E-06 Response to citalopram treatment / / 22760553 rs4398173 chr18 6941108 A G 2.77E-05 Odorant perception / / 23910658 rs3810046 chr18 6941662 G T 5.00E-07 Response to citalopram treatment / / 22760553 rs2016639 chr18 6943264 G A 1.10E-06 Urinary metabolites LAMA1 cds-synon 21572414 rs8084092 chr18 6945448 C T 2.80E-09 Metabolite levels LAMA1 intron 23281178 rs16950868 chr18 6956238 C A 1.80E-05 Urinary metabolites LAMA1 intron 21572414 rs658121 chr18 6977044 G T 6.48E-04 Myopia (pathological) LAMA1 intron 21095009 rs671871 chr18 6977844 A G 3.50E-04 Myopia (pathological) LAMA1 missense 21095009 rs541770 chr18 6978770 T C 3.50E-04 Myopia (pathological) LAMA1 intron 21095009 rs538815 chr18 6982443 C T 7.77E-06 Left ventricular mass LAMA1 intron 21212386 rs6650624 chr18 6983564 G A 1.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LAMA1 intron 20877124 rs552219 chr18 6984699 A G 4.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LAMA1 intron 20877124 rs11664063 chr18 6985270 C T 7.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LAMA1 missense 20877124 rs11662579 chr18 6986611 T C 1.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LAMA1 intron 20877124 rs492522 chr18 6986638 T C 1.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LAMA1 intron 20877124 rs17519184 chr18 6986714 G A 1.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LAMA1 intron 20877124 rs7228564 chr18 6992249 T C 5.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LAMA1 intron 20877124 rs7228564 chr18 6992249 T C 3.72E-05 Height LAMA1 intron pha003010 rs7228564 chr18 6992249 T C 2.26E-05 Height LAMA1 intron pha003011 rs601304 chr18 6992327 C T 4.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LAMA1 intron 20877124 rs692849 chr18 6996232 G T 3.45E-05 Triglycerides LAMA1 intron pha002904 rs625106 chr18 6999628 T C 3.38E-06 Narcolepsy LAMA1 cds-synon 20711174 rs2016274 chr18 7002596 C A 7.09E-04 Multiple complex diseases LAMA1 intron 17554300 rs12965358 chr18 7003718 A C 3.60E-04 Multiple complex diseases LAMA1 intron 17554300 rs662471 chr18 7008591 T C 4.48E-05 Heart Rate LAMA1 missense pha003054 rs952428 chr18 7008901 T C 7.56E-04 Multiple complex diseases LAMA1 intron 17554300 rs11661841 chr18 7023705 C T 2.96E-04 Multiple complex diseases LAMA1 intron 17554300 rs658209 chr18 7023733 G C 9.46E-04 Multiple complex diseases LAMA1 intron 17554300 rs658188 chr18 7023748 C A 8.55E-04 Multiple complex diseases LAMA1 intron 17554300 rs7227276 chr18 7028454 G A 6.48E-05 Asthma LAMA1 intron 11022011 rs600695 chr18 7034946 G A 3.58E-07 Autism LAMA1 intron 22843504 rs677136 chr18 7035915 A C 3.95E-04 Myopia (pathological) LAMA1 intron 21095009 rs660098 chr18 7037428 G A 6.82E-04 Multiple complex diseases LAMA1 intron 17554300 rs143997842 chr18 7037641 G A 0.000031 Breast cancer LAMA1 missense 23555315 rs522402 chr18 7038462 C T 1.90E-05 Orofacial clefts LAMA1 intron 22863734 rs16951095 chr18 7042911 C T 7.00E-06 Non-small cell lung cancer LAMA1 intron 20876614 rs11663956 chr18 7043455 C A 3.50E-04 Acute lung injury LAMA1 intron 22295056 rs11659412 chr18 7063532 G A 4.46E-06 Arthritis (juvenile idiopathic) LAMA1 intron 22354554 rs8090011 chr18 7068462 C A,G 8.00E-09 Type 2 diabetes LAMA1 intron 22693455 rs7228959 chr18 7076464 G A 2.00E-04 Cognitive impairment induced by topiramate LAMA1 intron 22091778 rs16951201 chr18 7081724 G A 6.66E-05 Orofacial clefts LAMA1 intron 22419666 rs16951252 chr18 7111033 C G 6.40E-04 Alzheimer's disease LAMA1 intron 17998437 rs10502353 chr18 7147079 T G 3.72E-05 Coronary heart disease / / pha003030 rs10502353 chr18 7147079 T G 1.57E-05 Coronary heart disease / / pha003031 rs450015 chr18 7164754 A G 2.08E-04 Multiple complex diseases / / 17554300 rs450015 chr18 7164754 A G 4.84E-05 Lung adenocarcinoma / / 19836008 rs383624 chr18 7169275 T C 7.03E-04 Multiple complex diseases / / 17554300 rs383624 chr18 7169275 T C 2.40E-05 Urinary metabolites / / 21572414 rs7237852 chr18 7171101 G A 3.53E-04 Multiple complex diseases / / 17554300 rs367057 chr18 7174228 A G 3.59E-04 Obesity (extreme) / / 21935397 rs454719 chr18 7174604 G T 3.61E-04 Obesity (extreme) / / 21935397 rs333100 chr18 7176547 C G 7.92E-04 Obesity (extreme) / / 21935397 rs333099 chr18 7176761 T G 7.97E-04 Obesity (extreme) / / 21935397 rs333097 chr18 7177383 G T 7.91E-04 Obesity (extreme) / / 21935397 rs144753731 chr18 7231881 A G 0.00017 Prostate cancer LRRC30 missense 23555315 rs144753731 chr18 7231881 A G 0.00039 Prostate cancer (non-advanced prostate cancer) LRRC30 missense 23555315 rs8087367 chr18 7238619 C A 3.99E-04 Multiple complex diseases / / 17554300 rs4797283 chr18 7249740 C T 8.00E-04 Alcohol dependence / / 20201924 rs8088371 chr18 7255661 T A 2.82E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1018250 chr18 7255921 T C 2.82E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9958292 chr18 7303201 G T 4.57E-11 Non-obstructive azoospermia / / 22197933 rs569629 chr18 7329035 C T 5.89E-04 Premature ovarian failure / / 19508998 rs569629 chr18 7329035 C T 7.90E-05 Erythrocyte counts / / pha003090 rs12966566 chr18 7375924 G A 6.98E-04 White matter integrity / / 22425255 rs11081324 chr18 7382442 A C 2.06E-04 Type 2 diabetes / / 17463246 rs4359528 chr18 7383469 A G 6.90E-04 Major depressive disorder / / 21042317 rs8091331 chr18 7392667 A G 2.04E-07 Schizophrenia / / 21926974 rs12608027 chr18 7421273 G A 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs8098365 chr18 7433519 T G 7.43E-04 Type 2 diabetes / / 17463246 rs12373291 chr18 7436339 C T 7.21E-04 Taste perception / / 22132133 rs12607083 chr18 7444318 C T 8.63E-04 Obesity (extreme) / / 21935397 rs16951791 chr18 7448196 G A 2.97E-05 Anxiety in major depressive disorder / / 24047446 rs16951807 chr18 7462429 A C 7.33E-05 Type 2 diabetes / / 17463246 rs567338 chr18 7488970 G A 3.70E-05 Alcohol and nictotine co-dependence / / 20158304 rs533682 chr18 7491478 T C 4.24E-05 Alcohol and nictotine co-dependence / / 20158304 rs692996 chr18 7493288 A G 2.22E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs543759 chr18 7508561 A G 2.63E-05 Multiple complex diseases / / 17554300 rs41377444 chr18 7512046 A T 4.48E-04 Multiple complex diseases / / 17554300 rs576192 chr18 7519001 T G 3.06E-05 Alcohol and nictotine co-dependence / / 20158304 rs503716 chr18 7533566 C T 4.31E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs982723 chr18 7547607 A G 2.31E-04 Iron levels / / pha002876 rs489659 chr18 7557909 T C 6.20E-05 Bone mineral density (BMD),in women / / 20164292 rs539975 chr18 7562317 C T 4.35E-05 Intelligence / / 21826061 rs539975 chr18 7562317 C T 1.59E-04 Iron levels / / pha002876 rs1941137 chr18 7592888 C T 7.37E-05 Major depressive disorder PTPRM intron 21621269 rs1941136 chr18 7594890 A G 8.12E-04 Coronary heart disease PTPRM intron 21971053 rs7243600 chr18 7597104 T C 6.57E-04 Smoking initiation PTPRM intron 24665060 rs16952222 chr18 7608051 C T 3.91E-04 Type 2 diabetes PTPRM intron 17463246 rs1893224 chr18 7608911 A G 1.11E-04 Response to cholinesterase inhibitors in Alzheimer's disease PTPRM intron 23374588 rs7228736 chr18 7622514 T G 5.62E-04 Coronary heart disease PTPRM intron 21971053 rs6506520 chr18 7627956 G A 5.68E-04 Coronary heart disease PTPRM intron 21971053 rs16952248 chr18 7628955 C T 3.95E-04 Type 2 diabetes PTPRM intron 17463246 rs948337 chr18 7629802 A G 6.08E-04 Type 2 diabetes PTPRM intron 17463246 rs11874043 chr18 7650146 T G 6.28E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PTPRM intron 21844884 rs661059 chr18 7688140 A G 3.66E-04 Aortic root size PTPRM intron 21223598 rs4121619 chr18 7689201 T G 2.77E-04 Type 2 diabetes PTPRM intron 17463246 rs4121619 chr18 7689201 T G 3.83E-05 Serum metabolites PTPRM intron 19043545 rs582683 chr18 7717565 A T 1.57E-04 Obesity (extreme) PTPRM intron 21935397 rs644399 chr18 7734016 G A 1.97E-05 Type 2 diabetes PTPRM intron 17463246 rs664592 chr18 7740473 A G 2.39E-04 Type 2 diabetes PTPRM intron 17463246 rs664592 chr18 7740473 A G 5.88E-05 Serum metabolites PTPRM intron 19043545 rs616019 chr18 7743140 A G 1.28E-04 Type 2 diabetes PTPRM intron 17463246 rs616019 chr18 7743140 A G 3.42E-05 Serum metabolites PTPRM intron 19043545 rs7243299 chr18 7755771 T C 8.00E-06 Dialysis-related mortality PTPRM intron 21546767 rs8091188 chr18 7760652 G A 3.86E-04 Multiple complex diseases PTPRM intron 17554300 rs594771 chr18 7763363 G A 9.87E-04 Obesity (extreme) PTPRM intron 21935397 rs1446083 chr18 7770950 A G 2.40E-05 Multiple complex diseases PTPRM intron 17554300 rs875530 chr18 7774104 T C 1.30E-05 Serum uric acid levels PTPRM intron 17997608 rs9946476 chr18 7774724 A C 8.57E-05 Multiple complex diseases PTPRM intron 17554300 rs9949027 chr18 7774830 T C 1.00E-04 Cognitive impairment induced by topiramate PTPRM intron 22091778 rs7232348 chr18 7775837 C T 8.92E-04 White matter integrity PTPRM intron 22425255 rs7233842 chr18 7784872 A G 3.44E-04 Multiple complex diseases PTPRM intron 17554300 rs7232461 chr18 7792267 T C 4.34E-07 Multiple complex diseases PTPRM intron 17554300 rs422656 chr18 7793429 C A 6.23E-04 Obesity (extreme) PTPRM intron 21935397 rs624519 chr18 7795543 T A 5.70E-04 Obesity (extreme) PTPRM intron 21935397 rs789451 chr18 7795723 G A 9.21E-04 Obesity (extreme) PTPRM intron 21935397 rs638251 chr18 7796393 C T 5.96E-04 Obesity (extreme) PTPRM intron 21935397 rs17557502 chr18 7810110 C T 2.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTPRM intron 20877124 rs17557502 chr18 7810110 C T 1.80E-05 Word reading PTPRM intron 23738518 rs16952559 chr18 7821152 C T 0.0004969 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PTPRM intron 23233654 rs16952559 chr18 7821152 C T 4.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) PTPRM intron 23233662 rs12963758 chr18 7824091 T C 4.44E-05 Vaspin levels PTPRM intron 22907691 rs12963758 chr18 7824091 T C 0.0000256 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit PTPRM intron 22907730 rs12963758 chr18 7824091 T C 0.0000444 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks PTPRM intron 22907730 rs894760 chr18 7851754 A G 0.0005752 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PTPRM intron 23233654 rs894760 chr18 7851754 A G 5.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) PTPRM intron 23233662 rs9304004 chr18 7877629 G A 9.79E-04 Prostate cancer mortality PTPRM intron 20978177 rs1441002 chr18 7887531 G A 1.20E-05 Cognitive impairment induced by topiramate PTPRM intron 22091778 rs17565758 chr18 7897307 A C 6.84E-04 Multiple complex diseases PTPRM intron 17554300 rs1866854 chr18 7902147 T C 1.08E-04 Type 2 diabetes PTPRM intron 17463246 rs10502365 chr18 7909131 G T 1.89E-05 Type 2 diabetes PTPRM intron 17463246 rs2165412 chr18 7922931 G A 6.25E-06 Type 2 diabetes PTPRM intron 17463246 rs7228385 chr18 7936914 C A 2.39E-04 Sarcoidosis PTPRM intron 19165924 rs12957993 chr18 7945923 C T 1.35E-04 Glycosylated haemoglobin levels PTPRM intron 17255346 rs12957388 chr18 7953419 T C 1.94E-04 Glycosylated haemoglobin levels PTPRM intron 17255346 rs8096083 chr18 7959012 T C 2.28E-04 Glycosylated haemoglobin levels PTPRM intron 17255346 rs7505939 chr18 7997833 T C 5.29E-05 Iron levels PTPRM intron 19880490 rs7505939 chr18 7997833 T C 5.29E-05 Iron levels PTPRM intron pha002876 rs6506544 chr18 8013716 C T 2.03E-04 Iron levels PTPRM intron pha002876 rs12957856 chr18 8030442 G C 6.40E-04 Alzheimer's disease PTPRM intron 24755620 rs511993 chr18 8096100 T G 8.74E-04 Response to cytadine analogues (cytosine arabinoside) PTPRM intron 24483146 rs11660158 chr18 8116625 A G 9.08E-05 Smoking initiation PTPRM intron 24665060 rs11660158 chr18 8116625 A G 4.81E-04 Iron levels PTPRM intron pha002876 rs8098064 chr18 8209269 G A 4.00E-06 Dialysis-related mortality PTPRM intron 21546767 rs12457777 chr18 8210878 C G 4.99E-04 Smoking cessation PTPRM intron 24665060 rs12965261 chr18 8218296 G A 9.93E-05 Orofacial clefts PTPRM intron 19270707 rs976168 chr18 8220827 T C 3.87E-05 Orofacial clefts PTPRM intron 19270707 rs4399595 chr18 8227344 G A 8.50E-05 Orofacial clefts PTPRM intron 19270707 rs12954626 chr18 8227954 T C 8.30E-05 Orofacial clefts PTPRM intron 19270707 rs12954626 chr18 8227954 T C 2.20E-04 Smoking cessation PTPRM intron 24665060 rs7243209 chr18 8233278 A G 6.71E-05 Scoliosis PTPRM intron 21216876 rs7244913 chr18 8251524 C A 5.82E-04 Multiple complex diseases PTPRM intron 17554300 rs7505928 chr18 8271135 C A 1.57E-05 Cognitive performance PTPRM intron 19734545 rs7505928 chr18 8271135 C A 1.20E-06 Esophageal cancer (squamous cell) PTPRM intron 22960999 rs6506569 chr18 8275857 T C 7.00E-06 Response to methotrexate in rheumatoid arthritis PTPRM intron 24583629 rs16953201 chr18 8298073 G C 7.58E-05 Sudden cardiac arrest PTPRM intron 21658281 rs679561 chr18 8303370 G A 2.44E-05 Reading and spelling PTPRM intron 23738518 rs603596 chr18 8306509 C T 1.62E-04 Multiple complex diseases PTPRM intron 17554300 rs624640 chr18 8331825 C T 1.79E-05 Gaucher disease severity PTPRM intron 22388998 rs7226445 chr18 8355048 A C 8.77E-04 Response to taxane treatment (placlitaxel) PTPRM intron 23006423 rs8087223 chr18 8356825 G A 6.46E-04 Response to taxane treatment (placlitaxel) PTPRM intron 23006423 rs1466342 chr18 8357434 G A 7.91E-04 Type 2 diabetes PTPRM intron 17463246 rs2169014 chr18 8364598 T C 5.66E-04 Schizophrenia PTPRM intron 19197363 rs656068 chr18 8391829 A G 8.36E-04 Schizophrenia PTPRM intron 19197363 rs656068 chr18 8391829 A G 5.64E-05 Prostate cancer PTPRM intron pha002878 rs635269 chr18 8408431 G A 8.96E-04 Schizophrenia / / 19197363 rs8096865 chr18 8430248 C T 3.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs654958 chr18 8430955 G A 5.00E-05 Multiple complex diseases / / 17554300 rs16953541 chr18 8450713 A G 4.25E-04 Multiple complex diseases / / 17554300 rs16953553 chr18 8453792 C T 5.60E-07 Urinary metabolites / / 21572414 rs16953556 chr18 8454044 A C 1.40E-06 Urinary metabolites / / 21572414 rs10502370 chr18 8454501 T C 5.60E-07 Urinary metabolites / / 21572414 rs16953559 chr18 8454599 G A 5.60E-07 Urinary metabolites / / 21572414 rs651568 chr18 8454984 C T 4.12E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7243929 chr18 8455102 A G 2.86E-05 Multiple complex diseases / / 17554300 rs10502367 chr18 8467834 A G 5.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs17494870 chr18 8471372 C T 2.20E-06 Systemic lupus erythematosus(serologic and cytokine profiles in serum) / / 20659327 rs4798647 chr18 8478169 C T 8.72E-04 Type 2 diabetes / / 17463246 rs12185468 chr18 8479685 C T 4.62E-04 Sudden cardiac arrest / / 21658281 rs12185468 chr18 8479685 C T 3.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs10502372 chr18 8480755 C T 3.13E-05 Coronary heart disease / / pha003031 rs9807797 chr18 8485433 G A 8.31E-06 White blood cell count / / 21738479 rs9807483 chr18 8485638 A G,T 7.95E-06 White blood cell count / / 21738479 rs8086902 chr18 8495190 A G 7.01E-04 Multiple complex diseases / / 17554300 rs726688 chr18 8503530 T C 6.71E-05 Odorant perception / / 23910658 rs7237326 chr18 8505193 A G 3.23E-04 Esophageal adenocarcinoma / / 24121790 rs7233905 chr18 8511382 A G 5.52E-04 Multiple complex diseases / / 17554300 rs8083753 chr18 8531733 C T 7.98E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs16953694 chr18 8538494 C T 7.40E-04 Multiple complex diseases / / 17554300 rs10502374 chr18 8540639 G C 3.60E-05 Multiple complex diseases / / 17554300 rs9950641 chr18 8541500 A G 1.70E-05 Coffee consumption / / 21357676 rs17581972 chr18 8546673 T A 1.47E-04 Type 2 diabetes / / 17463246 rs7242980 chr18 8549458 T C 6.83E-05 Potassium levels / / pha003086 rs6506598 chr18 8563622 A G 1.11E-05 Hypertension / / pha003041 rs17582975 chr18 8572792 T C 9.32E-04 Multiple complex diseases / / 17554300 rs7233164 chr18 8592726 A G 5.06E-04 Smoking initiation / / 24665060 rs1442686 chr18 8599797 C G 1.33E-05 Iron status biomarkers / / 19084217 rs321655 chr18 8624151 A G 8.67E-04 Type 2 diabetes RAB12 intron 17463246 rs9304017 chr18 8627595 A G 8.40E-04 Crohn's disease RAB12 intron 17684544 rs321665 chr18 8632807 C T 8.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RAB12 intron 20877124 rs9949325 chr18 8641331 A G 2.14E-04 Type 2 diabetes / / 17463246 rs11659548 chr18 8656226 C T 1.30E-05 Urinary metabolites / / 21572414 rs17479191 chr18 8662567 G A 6.16E-08 Metabolite levels / / 23281178 rs4798668 chr18 8662961 G A 5.16E-08 Metabolite levels / / 23281178 rs529984 chr18 8671302 A G 8.18E-09 Metabolite levels / / 23281178 rs670454 chr18 8692920 T C 0.0007 5-fluorouracil induced mucositis in response to colorectal cancer treatment / / 22310351 rs4798677 chr18 8699988 A G 5.08E-04 Type 2 diabetes LOC100287082 intron 17463246 rs1249489 chr18 8711942 G A 5.91E-04 Tourette syndrome / / 22889924 rs1249489 chr18 8711942 G A 3.67E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs2111836 chr18 8716321 G A 7.49E-04 Tourette syndrome / / 22889924 rs2017162 chr18 8730240 A T 6.99E-06 Personality dimensions SOGA2 intron 22628180 rs4798680 chr18 8730726 G A 5.39E-06 Personality dimensions SOGA2 intron 22628180 rs4239334 chr18 8730751 C T 7.14E-06 Personality dimensions SOGA2 intron 22628180 rs8094051 chr18 8734682 G C 2.97E-05 Personality dimensions SOGA2 intron 22628180 rs8095514 chr18 8734995 C T 9.02E-05 Response to hepatitis C treatment SOGA2 intron 19684573 rs1035300 chr18 8735545 A G 8.31E-04 Suicide attempts in bipolar disorder SOGA2 intron 21423239 rs7235989 chr18 8736346 T G 2.96E-05 Personality dimensions SOGA2 intron 22628180 rs688573 chr18 8740330 G A 1.90E-05 Urinary metabolites SOGA2 intron 21572414 rs558297 chr18 8743340 T C 5.30E-06 Urinary metabolites SOGA2 intron 21572414 rs497084 chr18 8770517 C T 3.69E-04 Obesity (extreme) SOGA2 intron 21935397 rs9966269 chr18 8789077 A G 6.18E-05 Epilepsy (remission after treatment) SOGA2 intron 23962720 rs16954160 chr18 8789233 G A 9.43E-05 Epilepsy (remission after treatment) SOGA2 intron 23962720 rs16954178 chr18 8794092 T G 9.99E-04 Type 2 diabetes SOGA2 intron 17463246 rs566890 chr18 8797189 G T 0.000121 Common carotid artery thickness (average of near and far wall measures) SOGA2 intron 23487405 rs561737 chr18 8799111 C T 3.70E-05 Immunoglobulin A SOGA2 intron 20694011 rs7243361 chr18 8814459 G C 6.25E-05 Multiple complex diseases SOGA2 intron 17554300 rs3810053 chr18 8820886 C T 3.62E-04 Multiple complex diseases SOGA2 intron 17554300 rs612012 chr18 8823119 T C 5.39E-06 Elbow pain SOGA2 intron pha003008 rs16954325 chr18 8823577 C T 6.70E-04 Response to taxane treatment (placlitaxel) SOGA2 intron 23006423 rs12960677 chr18 8824239 A C 9.83E-04 Response to taxane treatment (placlitaxel) SOGA2 intron 23006423 rs595802 chr18 8827648 G A 2.54E-05 Cytomegalovirus antibody response SOGA2 intron 21993531 rs627543 chr18 8830080 C T 9.20E-04 Myopia (pathological) SOGA2 intron 21095009 rs3744975 chr18 8832268 C T 8.33E-04 Myopia (pathological) SOGA2 UTR-3 21095009 rs670578 chr18 8851159 C T 2.28E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs625719 chr18 8858086 G A 4.78E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs673730 chr18 8866616 C T 6.08E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1383597 chr18 8867520 G T 8.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs7236228 chr18 8876666 C T 6.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs675935 chr18 8894369 C T 5.45E-04 Stroke / / pha002887 rs690200 chr18 8908980 A C 9.32E-04 Iron levels / / pha002876 rs2377929 chr18 8910868 A C 3.62E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2377929 chr18 8910868 A C 6.36E-05 Height / / pha003010 rs1545814 chr18 8922412 T C 5.59E-04 Heart Failure / / pha002884 rs9952946 chr18 8922950 G C 0.000011 Panic disorder / / 23149450 rs9952946 chr18 8922950 G C 1.10E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs7244245 chr18 8931652 T C 1.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy) / / 24554482 rs10164229 chr18 8944005 G C 9.00E-05 Type 2 diabetes / / 17463246 rs11081443 chr18 8944208 T C 9.97E-05 Type 2 diabetes / / 17463246 rs11081443 chr18 8944208 T C 1.72E-04 Heart Failure / / pha002884 rs1573320 chr18 8959613 C T 9.46E-04 Prostate cancer mortality / / 20978177 rs10502386 chr18 8966144 G T 1.00E-06 Obesity-related traits / / 23251661 rs10502386 chr18 8966144 G T 5.00E-06 Obesity-related traits / / 23251661 rs10502386 chr18 8966144 G T 6.00E-06 Obesity-related traits / / 23251661 rs10502386 chr18 8966144 G T 7.00E-06 Obesity-related traits / / 23251661 rs11081444 chr18 8970358 G A 1.02E-04 Multiple complex diseases / / 17554300 rs4798732 chr18 8975827 G A 7.18E-04 Stroke / / pha002886 rs1893146 chr18 8987427 G A 8.13E-05 Multiple complex diseases / / 17554300 rs12953380 chr18 8999085 C T 2.35E-08 Metabolite levels / / 23281178 rs9956719 chr18 8999352 A T 4.19E-05 Bipolar disorder / / 20451256 rs11081453 chr18 9000246 T C 7.70E-05 Thyroid peroxidase antibody positivity / / 24586183 rs10468792 chr18 9046854 C A 1.10E-05 Urinary metabolites / / 21572414 rs7228816 chr18 9057540 T C 1.20E-06 Urinary metabolites / / 21572414 rs11665492 chr18 9062964 C T 4.90E-06 Urinary metabolites / / 21572414 rs12953401 chr18 9095600 T C 6.76E-05 Age-related macular degeneration / / 22125219 rs12956041 chr18 9179471 A G 3.28E-04 Age-related macular degeneration ANKRD12 intron 22125219 rs10502391 chr18 9240413 C T 2.81E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) ANKRD12 intron 17982456 rs1443597 chr18 9244546 G A 5.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) ANKRD12 intron 17982456 rs6506648 chr18 9246896 G A 8.42E-04 Schizophrenia ANKRD12 intron 19197363 rs1893198 chr18 9248150 T C 9.51E-05 Schizophrenia ANKRD12 intron 19197363 rs8092135 chr18 9274636 A G 6.77E-04 Schizophrenia ANKRD12 intron 19197363 rs1114591 chr18 9285824 T C 3.23E-05 Pancreatic cancer ANKRD12 UTR-3 pha002889 rs2864527 chr18 9288456 T G 4.00E-06 Dental caries / / 23064961 rs7243448 chr18 9321276 C A 7.46E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs8082834 chr18 9324483 T C 5.17E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1107146 chr18 9326852 T C 4.73E-04 Multiple complex diseases / / 17554300 rs1107147 chr18 9326897 A C 6.24E-05 Multiple complex diseases / / 17554300 rs2902838 chr18 9328065 T G 7.60E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7234762 chr18 9352569 T G 2.10E-05 Urinary metabolites TWSG1 intron 21572414 rs3786173 chr18 9353430 A G 2.10E-05 Urinary metabolites TWSG1 intron 21572414 rs4798804 chr18 9395383 T C 7.46E-04 Type 2 diabetes TWSG1 intron 17463246 rs8091539 chr18 9408889 G C 3.31E-05 Multiple complex diseases / / 17554300 rs8094970 chr18 9412451 G A 1.08E-04 Alzheimer's disease (late onset) / / 21379329 rs4798812 chr18 9420504 G A 8.52E-05 Scoliosis / / 21216876 rs4797374 chr18 9427006 T G 8.42E-04 Lymphocyte counts / / 22286170 rs751355 chr18 9428420 C T 9.75E-05 Multiple complex diseases / / 17554300 rs751355 chr18 9428420 C T 2.99E-04 Scoliosis / / 21216876 rs1979368 chr18 9454478 G A 4.19E-05 Bipolar disorder / / 21771265 rs7241781 chr18 9488704 C T 1.50E-05 Urinary metabolites RALBP1 intron 21572414 rs329017 chr18 9492196 T C 4.73E-05 Bipolar disorder RALBP1 intron 21771265 rs1813100 chr18 9512985 G A 5.48E-06 Bipolar disorder RALBP1 intron 21771265 rs329007 chr18 9522606 G A 8.71E-05 Brain lesion load RALBP1 intron 19010793 rs1942150 chr18 9538533 A G 7.91E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1942150 chr18 9538533 A G 1.60E-05 Urinary metabolites / / 21572414 rs2840354 chr18 9545961 C T 5.75E-05 Socioeconomic Factors / / pha003066 rs329020 chr18 9558525 C T 6.13E-04 Depression (quantitative trait) PPP4R1 intron 20800221 rs329034 chr18 9583891 C T 6.63E-04 Depression (quantitative trait) PPP4R1 intron 20800221 rs1275666 chr18 9594877 G A 6.88E-04 Depression (quantitative trait) PPP4R1 intron 20800221 rs666536 chr18 9630578 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs666536 chr18 9630578 A G 6.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17508949 chr18 9637626 A G 4.04E-05 Left ventricular hypertrophy / / pha003052 rs7244365 chr18 9640213 G A 1.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs633907 chr18 9642637 G A 5.18E-04 Type 2 diabetes / / 17463246 rs683278 chr18 9643749 G A 4.90E-06 Lipid levels / / 18193043 rs16955385 chr18 9646198 A G 1.46E-04 Type 2 diabetes / / 17463246 rs16955385 chr18 9646198 A G 6.30E-07 Lipid levels / / 18193043 rs4384658 chr18 9653171 A G 6.68E-05 Migraine / / 23793025 rs620726 chr18 9687038 A C 9.70E-05 Cholesterol / / pha003073 rs1378528 chr18 9709481 G T 5.61E-04 Type 2 diabetes RAB31 intron 17463246 rs1455587 chr18 9710554 G T 1.99E-08 Lymphocyte counts RAB31 intron 22286170 rs2045228 chr18 9725787 G A 7.59E-04 Parkinson's disease RAB31 intron 17052657 rs11081496 chr18 9726631 C T 3.42E-04 Parkinson's disease RAB31 intron 17052657 rs7228240 chr18 9729894 T C 3.00E-04 Acute lymphoblastic leukemia (childhood) RAB31 intron 20189245 rs6506683 chr18 9730723 A G 3.00E-04 Acute lymphoblastic leukemia (childhood) RAB31 intron 20189245 rs921835 chr18 9744353 A G 2.41E-04 Multiple complex diseases RAB31 intron 17554300 rs7237162 chr18 9746439 G A 7.27E-04 Multiple complex diseases RAB31 intron 17554300 rs16955559 chr18 9763009 C T 2.68E-04 Type 2 diabetes RAB31 intron 17463246 rs10502393 chr18 9765612 C T 9.47E-05 Non-alcoholic fatty liver disease histology (other) RAB31 intron 20708005 rs6506697 chr18 9775372 A G 3.11E-04 Multiple complex diseases RAB31 intron 17554300 rs6506698 chr18 9775411 A G 2.38E-04 Multiple complex diseases RAB31 intron 17554300 rs6506699 chr18 9775566 G A 2.00E-04 Multiple complex diseases RAB31 intron 17554300 rs7233332 chr18 9784914 G A 6.00E-06 Blood pressure (age interaction) RAB31 intron 24954895 rs9945476 chr18 9786265 A G 9.47E-05 Soluble levels of adhesion molecules RAB31 intron pha003072 rs11872226 chr18 9835419 C A 9.69E-04 Response to cytadine analogues (cytosine arabinoside) RAB31 intron 24483146 rs2903677 chr18 9837639 C A 2.09E-04 Lymphocyte counts RAB31 intron 22286170 rs555935 chr18 9845307 T C 3.30E-06 Urinary metabolites RAB31 intron 21572414 rs575420 chr18 9848371 A C 3.70E-06 Urinary metabolites RAB31 intron 21572414 rs688248 chr18 9848613 C T 5.89E-05 Serum metabolites RAB31 intron 19043545 rs508816 chr18 9849620 T C 1.20E-05 Urinary metabolites RAB31 intron 21572414 rs625014 chr18 9855114 G A 1.20E-06 Urinary metabolites RAB31 intron 21572414 rs557706 chr18 9861155 G C 1.40E-05 Urinary metabolites RAB31 UTR-3 21572414 rs7228636 chr18 9871426 C T 1.90E-05 Urinary metabolites / / 21572414 rs513186 chr18 9882587 T C 4.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs601874 chr18 9886890 A G 6.11E-04 Alzheimer's disease TXNDC2 cds-synon 22005930 rs11664080 chr18 9888027 C T 6.19E-05 Alcohol dependence TXNDC2 cds-synon 19581569 rs1784554 chr18 9889669 G A 3.65E-04 Alzheimer's disease / / 22005930 rs9957463 chr18 9892595 G A 2.69E-06 Cognitive impairment induced by topiramate / / 22091778 rs29162 chr18 9931497 C T 3.63E-04 Response to statin treatment (atorvastatin),change in cholesterol levels VAPA intron 20031582 rs4491597 chr18 9946405 G C 4.65E-04 Alzheimer's disease VAPA intron 24755620 rs29128 chr18 9948041 C T 6.88E-04 Alzheimer's disease VAPA intron 24755620 rs9945403 chr18 9991724 T C 2.46E-05 Acne (severe teenage) / / 24114350 rs29023 chr18 9996159 C T 3.28E-05 Serum metabolites / / 19043545 rs4797393 chr18 10010426 T C 1.41E-04 Acute lung injury / / 22295056 rs7229522 chr18 10010733 A G 1.41E-04 Acute lung injury / / 22295056 rs9944814 chr18 10010833 G A 1.41E-04 Acute lung injury / / 22295056 rs7229707 chr18 10010882 A G 1.57E-04 Acute lung injury / / 22295056 rs4797394 chr18 10011572 G T 5.85E-04 Acute lung injury / / 22295056 rs4797396 chr18 10011664 C T 5.85E-04 Acute lung injury / / 22295056 rs8087436 chr18 10014552 A G 5.09E-04 Acute lung injury / / 22295056 rs9949747 chr18 10015490 T C 6.56E-04 Multiple complex diseases / / 17554300 rs7245342 chr18 10052043 C T 1.60E-07 Urinary metabolites / / 21572414 rs670362 chr18 10066414 C T 3.87E-05 Type 2 diabetes / / 17463246 rs16956227 chr18 10070208 T C 7.51E-04 Type 2 diabetes / / 17463246 rs17436294 chr18 10072823 A G 2.81E-04 Type 2 diabetes / / 17463246 rs8089099 chr18 10078071 G A 3.00E-07 Pulmonary function (interaction) / / 23284291 rs8089099 chr18 10078071 G A 4.00E-07 Pulmonary function (interaction) / / 23284291 rs2041718 chr18 10112756 A C 9.19E-04 Multiple complex diseases / / 17554300 rs522276 chr18 10112896 C G 8.70E-07 Urinary metabolites / / 21572414 rs659259 chr18 10126122 G T 2.00E-04 Information processing speed / / 21130836 rs11080390 chr18 10136596 T C 2.61E-04 Spine bone size / / 23207799 rs532241 chr18 10140629 T G 7.20E-04 Alcohol dependence / / 20201924 rs7232833 chr18 10187407 A G 6.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs9950062 chr18 10202897 G A 8.24E-04 Age-related macular degeneration / / 22125219 rs16974035 chr18 10279356 A G 5.00E-05 Postoperative ventricular dysfunction / / 21980348 rs11877964 chr18 10283139 C T 2.63E-05 Body Mass Index / / pha003006 rs4797425 chr18 10285090 C T 8.15E-07 Coronary heart disease / / pha003030 rs12967528 chr18 10286339 A G 3.88E-05 Body Mass Index / / pha003006 rs12967528 chr18 10286339 A G 9.58E-05 Waist Circumference / / pha003024 rs2002050 chr18 10296129 G A 3.12E-05 Body Mass Index / / pha003006 rs2077706 chr18 10301440 A G 2.00E-05 Urinary metabolites / / 21572414 rs189981 chr18 10302491 T C 8.71E-04 Type 2 diabetes / / 17463246 rs206420 chr18 10311032 G A 0.000435127 Hypertension (early onset hypertension) / / 22479346 rs206418 chr18 10314566 C T 2.10E-07 Urinary metabolites / / 21572414 rs206626 chr18 10321347 A G 2.00E-06 Metabolite levels (Pyroglutamine) / / 23934736 rs35121014 chr18 10340807 T C 6.40E-06 Urinary metabolites / / 21572414 rs2002072 chr18 10353179 C A 2.40E-05 Urinary metabolites / / 21572414 rs206580 chr18 10370771 A C,G,T 8.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs17541270 chr18 10371035 A G 1.55E-04 Depression (quantitative trait) / / 20800221 rs206578 chr18 10375034 A G 3.88E-04 Type 2 diabetes / / 17463246 rs206548 chr18 10382883 C T 9.00E-07 Serum protein levels (sST2) / / 23999434 rs206541 chr18 10384136 T C 2.42E-04 Type 2 diabetes / / 17463246 rs206539 chr18 10384729 A G 5.60E-05 Type 2 diabetes / / 17463246 rs206536 chr18 10385342 T C 9.56E-04 Depression (quantitative trait) / / 20800221 rs206536 chr18 10385342 T C 5.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs11080410 chr18 10385479 T C 1.60E-04 Depression (quantitative trait) / / 20800221 rs11873516 chr18 10385632 G A 1.65E-04 Depression (quantitative trait) / / 20800221 rs11664110 chr18 10385767 T C 1.67E-04 Depression (quantitative trait) / / 20800221 rs11661404 chr18 10386324 A C 1.98E-04 Depression (quantitative trait) / / 20800221 rs11661411 chr18 10386381 A G 1.89E-04 Depression (quantitative trait) / / 20800221 rs11661552 chr18 10386714 C T 2.57E-04 Depression (quantitative trait) / / 20800221 rs11661552 chr18 10386714 C T 8.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs12966487 chr18 10386781 A G 5.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs399211 chr18 10395219 C T 6.05E-04 Type 2 diabetes / / 17463246 rs367024 chr18 10398673 C T 6.21E-05 Prion diseases / / 22210626 rs367024 chr18 10398673 C T 8.30E-05 Interstitial lung disease / / 23583980 rs7228576 chr18 10408492 C T 7.58E-04 Obesity (extreme) / / 21935397 rs7228576 chr18 10408492 C T 9.13E-07 Alopecia areata / / 22027810 rs206514 chr18 10411194 C T 2.00E-05 Urinary metabolites / / 21572414 rs206514 chr18 10411194 C T 0.000000266 Joint damage severity in rheumatoid arthritis / / 23696630 rs12954196 chr18 10424214 A G 8.17E-04 Alzheimer's disease / / 17998437 rs12957179 chr18 10428454 G A 4.72E-05 Blood Pressure / / pha003043 rs11663409 chr18 10430126 T C 6.59E-04 Obesity (extreme) / / 21935397 rs11660127 chr18 10430734 C T 6.52E-04 Obesity (extreme) / / 21935397 rs11080418 chr18 10431749 C T 6.40E-04 Obesity (extreme) / / 21935397 rs12955584 chr18 10433382 G A 9.64E-04 Obesity (extreme) / / 21935397 rs12966945 chr18 10435574 T C 9.12E-04 Obesity (extreme) / / 21935397 rs10468615 chr18 10435868 A T 8.85E-04 Obesity (extreme) / / 21935397 rs2115706 chr18 10436288 A G 5.48E-05 Obesity (extreme) / / 21935397 rs206439 chr18 10444655 C T 4.68E-05 Obesity (extreme) / / 21935397 rs2847351 chr18 10447041 A G 9.90E-05 Bone mineral density (spine) / / 19079262 rs12606657 chr18 10458256 C A 9.83E-04 Coronary heart disease APCDD1 intron 21606135 rs564991 chr18 10465054 A C 8.57E-04 Obesity (extreme) APCDD1 intron 21935397 rs564991 chr18 10465054 A C 9.14E-05 Blood pressure (response to calcium channel blocker) APCDD1 intron 24192120 rs11665347 chr18 10478812 G A 5.73E-05 Osteoarthritis (knee and hip) APCDD1 intron 21177295 rs11665347 chr18 10478812 G A 7.97E-06 Osteoarthritis APCDD1 intron 22763110 rs114154601 chr18 10487749 C T 0.00061 Breast cancer APCDD1 missense 23555315 rs10502395 chr18 10492023 C A 9.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10502395 chr18 10492023 C A 2.80E-05 Urinary metabolites / / 21572414 rs487755 chr18 10511148 C A 3.22E-05 Response to methylphenidate treatment / / 21130132 rs16974688 chr18 10515739 T G 2.40E-05 Urinary metabolites / / 21572414 rs9947634 chr18 10555576 C A 4.55E-04 Multiple complex diseases / / 17554300 rs11660660 chr18 10656460 G T 6.65E-06 Stroke (ischemic) / / 22941190 rs487186 chr18 10665135 C T 2.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs485476 chr18 10665278 A T 1.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs480802 chr18 10665770 C T 2.37E-05 Suicide attempts in bipolar disorder / / 21423239 rs17550441 chr18 10667125 A C 8.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs8095590 chr18 10674815 C T 3.67E-04 Suicide attempts in bipolar disorder PIEZO2 intron 21041247 rs510529 chr18 10676564 C T 5.97E-04 Suicide attempts in bipolar disorder PIEZO2 intron 21041247 rs600419 chr18 10677979 T C 5.95E-04 Suicide attempts in bipolar disorder PIEZO2 intron 21041247 rs600433 chr18 10677992 G T 9.00E-05 Type 2 diabetes and 6 quantitative traits PIEZO2 intron 17848626 rs3748423 chr18 10691192 T G 3.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIEZO2 intron 20877124 rs10502404 chr18 10698511 A G 5.56E-04 Schizophrenia PIEZO2 intron 21674006 rs4796900 chr18 10701798 A C 3.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIEZO2 intron 20877124 rs12458196 chr18 10708501 C T 8.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIEZO2 intron 20877124 rs17565338 chr18 10716552 G A 8.17E-04 Suicide attempts in bipolar disorder PIEZO2 intron 21423239 rs5024299 chr18 10741011 G A 8.94E-04 Multiple complex diseases PIEZO2 intron 17554300 rs7241380 chr18 10762962 G A 8.02E-04 Multiple complex diseases PIEZO2 cds-synon 17554300 rs1881088 chr18 10765792 C G 8.59E-04 Multiple complex diseases PIEZO2 intron 17554300 rs2865126 chr18 10766425 A G 8.00E-06 Metabolite levels (5-HIAA/ MHPG Ratio) PIEZO2 intron 23319000 rs1881092 chr18 10769837 T C 1.82E-05 Heart Rate PIEZO2 intron pha003051 rs1918680 chr18 10774861 A G 1.82E-05 Heart Rate PIEZO2 intron pha003051 rs8097202 chr18 10778785 T G 5.84E-04 Insulin resistance PIEZO2 intron 21901158 rs2293517 chr18 10784331 C T 2.10E-05 Heart Rate PIEZO2 intron pha003051 rs7237226 chr18 10807962 T A 1.05E-05 Type 2 diabetes PIEZO2 intron 17463246 rs1918672 chr18 10808723 C T 8.00E-06 Type 2 diabetes PIEZO2 intron 17463246 rs1918672 chr18 10808723 C T 1.67E-05 Suicidal ideation PIEZO2 intron 20877300 rs9961777 chr18 10811094 A G 9.77E-04 Type 2 diabetes PIEZO2 intron 17463246 rs8095854 chr18 10811476 T C 2.94E-05 Type 2 diabetes PIEZO2 intron 17463246 rs264212 chr18 10884845 T G 9.47E-05 Non-alcoholic fatty liver disease histology (other) PIEZO2 intron 20708005 rs11080466 chr18 10899028 A G 1.00E-06 Non-small cell lung cancer PIEZO2 intron 21866343 rs11663246 chr18 10900614 G A 1.74E-05 Non-small cell lung cancer PIEZO2 intron 21866343 rs264272 chr18 10923808 G T 3.00E-06 Major depressive disorder PIEZO2 intron 23377640 rs264272 chr18 10923808 G T 4.00E-06 Major depressive disorder PIEZO2 intron 23377640 rs155320 chr18 10959495 G A 8.28E-04 Response to cytadine analogues (cytosine arabinoside) PIEZO2 intron 24483146 rs264193 chr18 10960761 C G 9.45E-04 Response to cytadine analogues (cytosine arabinoside) PIEZO2 intron 24483146 rs264202 chr18 10966525 T C 8.05E-04 Response to cytadine analogues (cytosine arabinoside) PIEZO2 intron 24483146 rs264246 chr18 10969377 A G 8.22E-04 Response to cytadine analogues (cytosine arabinoside) PIEZO2 intron 24483146 rs264234 chr18 10974448 T C 4.50E-04 Response to cytadine analogues (cytosine arabinoside) PIEZO2 intron 24483146 rs264233 chr18 10974487 G A 7.22E-04 Response to cytadine analogues (cytosine arabinoside) PIEZO2 intron 24483146 rs2660283 chr18 10997117 C T 6.02E-04 Response to cytadine analogues (cytosine arabinoside) PIEZO2 intron 24483146 rs7244357 chr18 11002565 T G 8.55E-04 Response to cytadine analogues (cytosine arabinoside) PIEZO2 intron 24483146 rs2660280 chr18 11008835 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) PIEZO2 intron 20708005 rs1032061 chr18 11013533 G A 3.94E-05 Alzheimer's disease PIEZO2 intron 17998437 rs1032061 chr18 11013533 G A 1.55E-04 Alzheimer's disease PIEZO2 intron pha002879 rs1471671 chr18 11013889 G C 4.99E-04 Type 2 diabetes PIEZO2 intron 17463246 rs983176 chr18 11015588 C T 5.54E-04 Type 2 diabetes PIEZO2 intron 17463246 rs983177 chr18 11015718 C T 9.47E-05 Non-alcoholic fatty liver disease histology (other) PIEZO2 intron 20708005 rs2625358 chr18 11020599 C T 3.61E-04 Type 2 diabetes PIEZO2 intron 17463246 rs2870109 chr18 11063562 T A 4.51E-06 Thiazide-induced adverse metabolic effects in hypertensive patients PIEZO2 intron 23400010 rs2870108 chr18 11063871 G A 4.44E-06 Thiazide-induced adverse metabolic effects in hypertensive patients PIEZO2 intron 23400010 rs12455924 chr18 11064409 C T 3.00E-07 Thiazide-induced adverse metabolic effects in hypertensive patients PIEZO2 intron 23400010 rs12455924 chr18 11064409 C T 3.49E-05 Response to cytadine analogues (cytosine arabinoside) PIEZO2 intron 24483146 rs6505611 chr18 11064752 A G 4.39E-06 Thiazide-induced adverse metabolic effects in hypertensive patients PIEZO2 intron 23400010 rs8086223 chr18 11065122 A G 8.64E-07 Thiazide-induced adverse metabolic effects in hypertensive patients PIEZO2 intron 23400010 rs7231609 chr18 11065993 A G 3.89E-06 Thiazide-induced adverse metabolic effects in hypertensive patients PIEZO2 intron 23400010 rs7228002 chr18 11068227 G A 5.01E-07 Thiazide-induced adverse metabolic effects in hypertensive patients PIEZO2 intron 23400010 rs6505614 chr18 11069659 G A 8.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients PIEZO2 intron 23400010 rs8089847 chr18 11069798 G T 7.97E-06 Thiazide-induced adverse metabolic effects in hypertensive patients PIEZO2 intron 23400010 rs8085263 chr18 11070338 C T 7.98E-06 Thiazide-induced adverse metabolic effects in hypertensive patients PIEZO2 intron 23400010 rs8085688 chr18 11070641 C T 7.09E-06 Thiazide-induced adverse metabolic effects in hypertensive patients PIEZO2 intron 23400010 rs8090641 chr18 11071006 T C 1.49E-06 Thiazide-induced adverse metabolic effects in hypertensive patients PIEZO2 intron 23400010 rs8090641 chr18 11071006 T C 6.79E-04 Response to cytadine analogues (cytosine arabinoside) PIEZO2 intron 24483146 rs8090019 chr18 11071197 G A 7.97E-06 Thiazide-induced adverse metabolic effects in hypertensive patients PIEZO2 intron 23400010 rs8090173 chr18 11071287 G A 7.92E-06 Thiazide-induced adverse metabolic effects in hypertensive patients PIEZO2 intron 23400010 rs17106 chr18 11074577 C T 2.08E-04 Celiac disease PIEZO2 intron 23936387 rs3975417 chr18 11086602 T C 2.09E-06 Paclitaxel sensitivity in NCI60 cancer cell lines PIEZO2 intron 21314952 rs9954162 chr18 11089213 A G 2.00E-05 Urinary metabolites PIEZO2 intron 21572414 rs7359786 chr18 11109213 G A 2.34E-04 Multiple complex diseases PIEZO2 intron 17554300 rs7359782 chr18 11109237 C T 2.42E-04 Multiple complex diseases PIEZO2 intron 17554300 rs16755 chr18 11118427 A G 6.71E-04 Myopia (pathological) PIEZO2 intron 21095009 rs16755 chr18 11118427 A G 1.24E-05 Job-related exhaustion PIEZO2 intron 23620144 rs6505620 chr18 11127492 G A 3.24E-04 Myopia (pathological) PIEZO2 intron 21095009 rs4629032 chr18 11168361 T G 5.37E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1542836 chr18 11176068 T G 1.20E-04 Smoking quantity / / 24665060 rs13381578 chr18 11215064 T C 0.0000868 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4797509 chr18 11249982 A G 4.87E-04 Myocardial Infarction / / pha002873 rs1566198 chr18 11259831 G T 5.80E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs7230244 chr18 11262321 C T 9.92E-04 Myocardial Infarction / / pha002873 rs7243066 chr18 11282319 G A 9.00E-06 Dental caries / / 23259602 rs11874128 chr18 11377139 A G 3.22E-04 Type 2 diabetes / / 17463246 rs11877517 chr18 11377890 T C 7.07E-04 Type 2 diabetes / / 17463246 rs11874322 chr18 11377923 A G 6.60E-04 Type 2 diabetes / / 17463246 rs35650447 chr18 11409580 A G 4.96E-04 Multiple complex diseases / / 17554300 rs8083731 chr18 11423536 T G 1.36E-05 Lung adenocarcinoma / / 19836008 rs10502408 chr18 11423603 G A 9.56E-04 Multiple complex diseases / / 17554300 rs8084551 chr18 11471820 A C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs8091421 chr18 11485132 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1455244 chr18 11494199 T C 3.00E-06 Schizophrenia / / 23212062 rs472174 chr18 11564905 C T 9.08E-05 Hypertension (essential hypertension) / / 22184326 rs11875811 chr18 11655887 A G 7.11E-04 Smoking quantity / / 24665060 rs34913163 chr18 11655887 A AG 7.11E-04 Smoking quantity / / 24665060 rs12960691 chr18 11668861 C T 8.08E-04 Multiple complex diseases / / 17554300 rs8099016 chr18 11696064 G T 5.88E-04 Stroke (pediatric) G/L intron 22990015 rs1013459 chr18 11700534 A G 6.31E-04 HIV-1 viral setpoint G/L intron 17641165 rs7227117 chr18 11733374 A G 5.89E-06 White blood cell count G/L intron 21738479 rs9947295 chr18 11759432 C T 8.00E-06 QT interval (interaction) G/L intron 23459443 rs9947295 chr18 11759432 C T 6.25E-05 Leukocyte Counts G/L intron pha003091 rs8087789 chr18 11760915 T C 8.42E-04 Type 2 diabetes G/L intron 17463246 rs2903236 chr18 11762047 T C 1.39E-04 Coronary Artery Disease G/L intron 17634449 rs9962277 chr18 11799182 C T 8.50E-05 Soluble levels of adhesion molecules G/L intron pha003072 rs675581 chr18 11887234 C T 2.11E-05 Insulin resistance MPPE1 intron 21901158 rs4797589 chr18 11917410 G A 3.10E-05 Potassium levels / / pha003086 rs663749 chr18 11957685 G C 3.80E-04 Alcohol dependence / / 20201924 rs619671 chr18 11961189 C T 8.90E-04 Alcohol dependence / / 20201924 rs694039 chr18 11962813 T C 9.88E-04 Alzheimer's disease / / 22005930 rs610541 chr18 11970809 C T 8.58E-04 Alzheimer's disease / / 22005930 rs2586219 chr18 11970973 G A 8.59E-04 Alzheimer's disease / / 22005930 rs1787984 chr18 11972439 A G 2.10E-04 Alcohol dependence / / 20201924 rs7506045 chr18 11987272 C T 7.00E-07 Stroke IMPA2 intron 17434096 rs635013 chr18 11991132 G A 5.78E-04 Multiple complex diseases IMPA2 intron 17554300 rs684680 chr18 11992265 C T 5.37E-05 Potassium levels IMPA2 intron pha003086 rs605047 chr18 11993959 T C 9.66E-04 Self-reported allergy IMPA2 intron 23817569 rs2002212 chr18 12006035 G A 9.60E-05 Sudden cardiac arrest IMPA2 intron 21658281 rs7235476 chr18 12011478 A G 5.43E-04 Response to statin treatment (atorvastatin),change in cholesterol levels IMPA2 intron 20031582 rs1060510 chr18 12016989 C G 5.80E-04 Body mass index IMPA2 intron 21701565 rs7236715 chr18 12057923 C T 5.95E-05 Hearing impairment / / 19047183 rs7243090 chr18 12273032 T A 5.06E-05 Breast cancer CIDEA intron 21060860 rs7230480 chr18 12274697 T C 8.89E-05 Orofacial clefts CIDEA intron 22419666 rs7229921 chr18 12283547 A G 9.87E-06 Cardiovascular disease / / 18179892 rs7229921 chr18 12283547 A G 7.21E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs9807444 chr18 12300936 T C 0.000304 Salmonella-induced pyroptosis / / 22837397 rs9303768 chr18 12301322 T C 1.94E-07 Lymphocyte counts / / 22286170 rs9303768 chr18 12301322 T C 0.000577 Salmonella-induced pyroptosis / / 22837397 rs16977167 chr18 12393970 T C 2.35E-05 Multiple complex diseases / / 17554300 rs11662125 chr18 12395904 T C 2.07E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs7243316 chr18 12400284 C G 6.17E-04 Multiple complex diseases / / 17554300 rs16977185 chr18 12414848 G C 1.17E-04 Lung function (forced expiratory volume in 1 second) SLMO1 intron 17255346 rs1019839 chr18 12504685 A G 1.20E-06 Urinary metabolites SPIRE1 intron 21572414 rs11663391 chr18 12516768 C A 6.92E-06 Longevity,exceptional SPIRE1 intron 20595579 rs17615991 chr18 12548970 T C 1.37E-04 Fibrinogen SPIRE1 intron 17255346 rs723836 chr18 12549850 T C 6.92E-04 Type 2 diabetes SPIRE1 intron 17463246 rs1940973 chr18 12550747 T C 8.00E-07 Immune response to smallpox vaccine (IL-6) SPIRE1 intron 22542470 rs7243917 chr18 12599042 G A 5.50E-06 Urinary metabolites SPIRE1 intron 21572414 rs9959145 chr18 12606463 G T 3.00E-08 Immune response to smallpox vaccine (IL-6) SPIRE1 intron 22542470 rs9963809 chr18 12644344 T C 9.52E-05 Type 2 diabetes SPIRE1 intron 17463246 rs9955985 chr18 12712112 T C 7.44E-04 Lymphocyte counts PSMG2 intron 22286170 rs1893213 chr18 12736556 G A 7.31E-05 Schizophrenia / / 19197363 rs10460003 chr18 12747012 C T 6.97E-07 Celiac disease and Rheumatoid arthritis / / 21383967 rs9960807 chr18 12770851 A G 2.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs2847266 chr18 12773338 C T 5.00E-05 Lung adenocarcinoma / / 22797724 rs2847277 chr18 12778032 G T 0.00023 Rosuvastatin induced percent change in C-reactive protein (CRP) / / 22230323 rs2542151 chr18 12779947 G T 1.00E-14 Type 1 diabetes / / 17554260 rs2542151 chr18 12779947 G T 3.00E-08 Crohn's disease / / 17554261 rs2542151 chr18 12779947 G T 2.00E-07 Crohn's disease / / 17554300 rs2542151 chr18 12779947 G T 5.00E-17 Crohn's disease / / 18587394 rs2542151 chr18 12779947 G T 9.00E-08 Type 1 diabetes / / 18978792 rs2542151 chr18 12779947 G T 5.00E-17 Asthma / / 21150878 rs2542151 chr18 12779947 G T 1.19E-11 Crohn's disease and Celiac disease / / 21298027 rs2542151 chr18 12779947 G T 4.00E-13 Type 1 diabetes autoantibodies / / 21829393 rs2542151 chr18 12779947 G T 5.10E-17 Multiple sclerosis / / 22190364 rs2542151 chr18 12779947 G T 2.50E-07 Arthritis (juvenile idiopathic) / / 22354554 rs2847293 chr18 12782448 A T 0.00000112 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis / / 23603761 rs2847293 chr18 12782448 A T 1.44E-12 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs2847293 chr18 12782448 A T 7.17E-09 Oligoarticular juvenile idiopathic arthritis / / 23603761 rs2542152 chr18 12782761 T C 2.10E-05 Multiple complex diseases / / 17554300 rs6505765 chr18 12782849 C G 0.00038 Rosuvastatin induced change in C-reactive protein (CRP) / / 22230323 rs2542160 chr18 12789246 G C 2.68E-04 Multiple complex diseases PTPN2 intron 17554300 rs2542160 chr18 12789246 G C 1.79E-04 Arthritis (juvenile idiopathic) PTPN2 intron 22354554 rs2847297 chr18 12797694 A G 3.80E-06 Multiple complex diseases PTPN2 intron 17554300 rs2847297 chr18 12797694 A G 4.79E-04 Rheumatoid arthritis PTPN2 intron 21452313 rs2847297 chr18 12797694 A G 3.06E-06 Arthritis (juvenile idiopathic) PTPN2 intron 22354554 rs2847297 chr18 12797694 A G 2.00E-08 Rheumatoid arthritis PTPN2 intron 22446963 rs2847297 chr18 12797694 A G 0.0000115 Primary sclerosing cholangitis PTPN2 intron 23603763 rs1893217 chr18 12809340 A G 7.05E-16 Crohn's disease PTPN2 intron 18587394 rs1893217 chr18 12809340 A G 4.00E-15 Type 1 diabetes PTPN2 intron 19430480 rs1893217 chr18 12809340 A G 3.00E-10 Celiac disease PTPN2 intron 20190752 rs1893217 chr18 12809340 A G 1.00E-14 Crohn's disease PTPN2 intron 21102463 rs1893217 chr18 12809340 A G 3.00E-10 Asthma PTPN2 intron 21150878 rs1893217 chr18 12809340 A G 6.54E-11 Crohn's disease and Celiac disease PTPN2 intron 21298027 rs1893217 chr18 12809340 A G 5.00E-12 Celiac disease and Rheumatoid arthritis PTPN2 intron 21383967 rs1893217 chr18 12809340 A G 1.63E-08 Type 1 diabetes PTPN2 intron 21980299 rs1893217 chr18 12809340 A G 2.52E-10 Multiple sclerosis PTPN2 intron 22190364 rs1893217 chr18 12809340 A G 3.00E-26 Inflammatory bowel disease PTPN2 intron 23128233 rs1893217 chr18 12809340 A G 3.72E-05 Magnesium levels PTPN2 intron pha003092 rs2847289 chr18 12812167 A C 9.44E-04 Parkinson's disease PTPN2 intron 17052657 rs2847281 chr18 12821593 A G 2.00E-08 C-reactive protein PTPN2 intron 21300955 rs2847281 chr18 12821593 A G 0.00074 Rosuvastatin induced percent change in C-reactive protein (CRP) PTPN2 intron 22230323 rs2847281 chr18 12821593 A G 4.20E-06 Arthritis (juvenile idiopathic) PTPN2 intron 22354554 rs2847281 chr18 12821593 A G 2.00E-11 Esophageal cancer (squamous cell) PTPN2 intron 22960999 rs16939895 chr18 12821903 G A 1.83E-08 Multiple complex diseases PTPN2 intron 17554300 rs16939895 chr18 12821903 G A 5.52E-08 Arthritis (juvenile idiopathic) PTPN2 intron 22354554 rs8087237 chr18 12834359 C A 7.97E-05 Multiple complex diseases PTPN2 intron 17554300 rs8087237 chr18 12834359 C A 2.24E-06 Arthritis (juvenile idiopathic) PTPN2 intron 22354554 rs478582 chr18 12835976 T C 7.46E-06 Celiac disease and Rheumatoid arthritis PTPN2 intron 21383967 rs11875687 chr18 12843137 T C 1.90E-10 Celiac disease PTPN2 intron 22057235 rs11875687 chr18 12843137 T C 1.90E-10 Celiac disease PTPN2 intron 23143596 rs657555 chr18 12847136 C T 3.02E-09 Crohn's disease and Celiac disease PTPN2 intron 21298027 rs657555 chr18 12847136 C T 2.20E-07 Celiac disease and Rheumatoid arthritis PTPN2 intron 21383967 rs657555 chr18 12847136 C T 3.31E-04 Rheumatoid arthritis PTPN2 intron 21452313 rs62097857 chr18 12857758 G A 5.20E-05 Celiac disease PTPN2 intron 22057235 rs62097857 chr18 12857758 G A 0.00000446 Rheumatoid arthritis PTPN2 intron 23143596 rs62097857 chr18 12857758 G A 0.000052 Celiac disease PTPN2 intron 23143596 rs62097857 chr18 12857758 G A 0.000088 Rheumatoid arthritis (CCP positive) PTPN2 intron 23143596 rs62097857 chr18 12857758 G A 0.000114 Rheumatoid arthritis (CCP negative) PTPN2 intron 23143596 rs669822 chr18 12863142 C T 2.33E-04 Type 2 diabetes PTPN2 intron 17463246 rs7234029 chr18 12877060 A G 2.66E-09 Multiple complex diseases PTPN2 intron 17554300 rs7234029 chr18 12877060 A G 1.65E-08 Arthritis (juvenile idiopathic) PTPN2 intron 22354554 rs8083786 chr18 12881361 A G 2.00E-11 Rheumatoid arthritis PTPN2 intron 24390342 rs8083786 chr18 12881361 A G 6.00E-18 Rheumatoid arthritis PTPN2 intron 24390342 rs8083786 chr18 12881361 A G 8.00E-09 Rheumatoid arthritis PTPN2 intron 24390342 rs2222138 chr18 12889217 G T 1.30E-04 Multiple complex diseases / / 17554300 rs2222138 chr18 12889217 G T 3.05E-04 Lymphocyte counts / / 22286170 rs8090365 chr18 12910932 G A 1.60E-06 Amyotrophic Lateral Sclerosis / / 17362836 rs11080612 chr18 12921361 C T 8.91E-05 Prion diseases / / 22210626 rs12326918 chr18 12922549 G A 3.33E-05 Anxiety and major depressive disorder / / 24047446 rs8090471 chr18 12926924 A G 3.87E-05 Brain structure / / 22504417 rs8088313 chr18 12977206 A C 2.62E-04 Type 2 diabetes SEH1L intron 17463246 rs12605081 chr18 12999964 A G 9.60E-04 Iris characteristics CEP192 intron 21835309 rs116020861 chr18 13029986 G A 0.00029 Prostate cancer CEP192 missense 23555315 rs61740922 chr18 13057655 C T 0.00054 Prostate cancer CEP192 missense 23555315 rs6505780 chr18 13069782 C T 4.43E-04 Alzheimer's disease CEP192 missense 17998437 rs576963 chr18 13145264 G A 4.50E-04 Alzheimer's disease / / 17998437 rs17604778 chr18 13174963 C T 6.60E-04 Iris characteristics / / 21835309 rs2155869 chr18 13199302 T C 5.36E-06 Creatinine levels / / pha003069 rs4797739 chr18 13207252 A G 1.67E-05 Creatinine levels / / pha003069 rs4797752 chr18 13247482 C T 9.29E-04 Depression (quantitative trait) C18orf1 intron 20800221 rs4797753 chr18 13247880 T C 9.43E-04 Depression (quantitative trait) C18orf1 intron 20800221 rs9963094 chr18 13255156 G T 9.24E-04 Depression (quantitative trait) C18orf1 intron 20800221 rs11080639 chr18 13260027 C T 1.16E-04 Multiple complex diseases C18orf1 intron 17554300 rs9951177 chr18 13260163 T C 2.07E-04 Multiple complex diseases C18orf1 intron 17554300 rs7232054 chr18 13271319 A G 8.87E-04 Multiple complex diseases C18orf1 intron 17554300 rs1893979 chr18 13289270 A G 2.90E-05 Urinary metabolites C18orf1 intron 21572414 rs1893978 chr18 13289602 C T 2.90E-05 Urinary metabolites C18orf1 intron 21572414 rs11659895 chr18 13301705 T C 9.40E-06 Urinary metabolites C18orf1 intron 21572414 rs9960998 chr18 13302602 A G 1.30E-06 Urinary metabolites C18orf1 intron 21572414 rs9960998 chr18 13302602 A G 2.85E-04 Amyotrophic lateral sclerosis (sporadic) C18orf1 intron 24529757 rs6505798 chr18 13308950 G A 5.27E-05 Parkinson's disease C18orf1 intron 17052657 rs16940343 chr18 13309150 C T 8.70E-06 Urinary metabolites C18orf1 intron 21572414 rs1869497 chr18 13310057 A G 2.90E-05 Urinary metabolites C18orf1 intron 21572414 rs4570935 chr18 13312264 G A 3.97E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) C18orf1 intron 22566498 rs2867874 chr18 13312511 C T 3.96E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) C18orf1 intron 22566498 rs16940349 chr18 13312896 A G 3.95E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) C18orf1 intron 22566498 rs7241109 chr18 13313114 A G 3.95E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) C18orf1 intron 22566498 rs7241410 chr18 13313263 C G 3.95E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) C18orf1 intron 22566498 rs7241438 chr18 13313351 A G 3.95E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) C18orf1 intron 22566498 rs9963572 chr18 13313509 C T 9.46E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) C18orf1 intron 22566498 rs4797761 chr18 13313994 G A 3.36E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) C18orf1 intron 22566498 rs930797 chr18 13316513 G A 4.23E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) C18orf1 intron 22566498 rs9953274 chr18 13317297 C T 2.70E-05 Urinary metabolites C18orf1 intron 21572414 rs930798 chr18 13319167 C T 4.23E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) C18orf1 intron 22566498 rs930799 chr18 13319232 C T 5.25E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) C18orf1 intron 22566498 rs8087505 chr18 13320303 C T 4.23E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) C18orf1 intron 22566498 rs7234501 chr18 13324511 C T 5.32E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) C18orf1 intron 22566498 rs7236152 chr18 13324832 T A 5.77E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) C18orf1 intron 22566498 rs2187502 chr18 13325561 T C 4.24E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) C18orf1 intron 22566498 rs949259 chr18 13325650 C T 4.24E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) C18orf1 intron 22566498 rs2085050 chr18 13326241 G A 4.24E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) C18orf1 intron 22566498 rs2085049 chr18 13326477 G A 6.09E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) C18orf1 intron 22566498 rs7226901 chr18 13326749 G A 4.26E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) C18orf1 intron 22566498 rs10084046 chr18 13330368 A G 3.00E-04 Pancreatic cancer C18orf1 intron 23180869 rs8094197 chr18 13330830 G A 6.00E-04 Pancreatic cancer C18orf1 intron 23180869 rs7231366 chr18 13332691 T C 1.93E-04 Parkinson's disease C18orf1 intron 17052657 rs7231366 chr18 13332691 T C 6.44E-05 Pancreatic cancer C18orf1 intron 23180869 rs9954359 chr18 13335351 C G 9.22E-06 Pancreatic cancer C18orf1 intron 23180869 rs2276392 chr18 13336841 C A 2.42E-04 Parkinson's disease C18orf1 intron 17052657 rs2276392 chr18 13336841 C A 9.22E-06 Pancreatic cancer C18orf1 intron 23180869 rs4797764 chr18 13342265 G T 9.36E-05 Body Fat Distribution C18orf1 intron pha003017 rs981621 chr18 13357200 A G 7.57E-05 Pancreatic cancer C18orf1 intron 23180869 rs9948620 chr18 13358206 C T 2.00E-04 Pancreatic cancer C18orf1 intron 23180869 rs7237577 chr18 13360231 A G 6.59E-05 Pancreatic cancer C18orf1 intron 23180869 rs17681406 chr18 13361130 C T 2.00E-04 Pancreatic cancer C18orf1 intron 23180869 rs1107340 chr18 13362403 C T 1.00E-04 Pancreatic cancer C18orf1 intron 23180869 rs897035 chr18 13363931 C G 5.00E-04 Pancreatic cancer C18orf1 intron 23180869 rs11080646 chr18 13365259 A C 7.87E-05 Pancreatic cancer C18orf1 intron 23180869 rs7227361 chr18 13365592 G T 2.00E-04 Pancreatic cancer C18orf1 intron 23180869 rs9946524 chr18 13366148 T C 3.20E-05 Pancreatic cancer C18orf1 intron 23180869 rs12456874 chr18 13366862 A G 6.00E-07 Pancreatic cancer C18orf1 intron 23180869 rs12456874 chr18 13366862 A G 1.03E-05 Body Mass Index C18orf1 intron pha003006 rs12456874 chr18 13366862 A G 8.95E-05 Body Mass Index C18orf1 intron pha003007 rs12456874 chr18 13366862 A G 8.64E-06 Waist Circumference C18orf1 intron pha003024 rs12456874 chr18 13366862 A G 4.69E-06 Weight C18orf1 intron pha003026 rs12456874 chr18 13366862 A G 3.23E-05 Weight C18orf1 intron pha003027 rs11663785 chr18 13367216 G C 3.90E-06 Pancreatic cancer C18orf1 intron 23180869 rs872906 chr18 13377699 G A 5.90E-04 Suicide attempts in bipolar disorder C18orf1 intron 21423239 rs8099604 chr18 13400350 T C 1.97E-05 Sudden cardiac arrest C18orf1 intron 21658281 rs9807144 chr18 13401662 T C 8.51E-05 Sudden cardiac arrest C18orf1 intron 21658281 rs6505813 chr18 13422042 T C 1.70E-05 Urinary metabolites C18orf1 intron 21572414 rs11663519 chr18 13430168 C T 9.87E-05 C-Reactive Protein C18orf1 intron pha003070 rs11663520 chr18 13430212 A C 6.24E-04 Coronary heart disease C18orf1 intron 21606135 rs16940502 chr18 13430308 A G 5.50E-09 Platelet aggregation(pre- and post-aspirin) C18orf1 intron 20529293 rs12965816 chr18 13431322 T C 9.56E-05 Alzheimer's disease C18orf1 intron 24755620 rs12458775 chr18 13432341 C T 2.53E-04 Coronary heart disease C18orf1 intron 21606135 rs9960403 chr18 13437993 A G 6.95E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C18orf1 intron 20877124 rs12959057 chr18 13442528 T G 6.52E-06 C-Reactive Protein C18orf1 intron pha003070 rs528895583 chr18 13442528 TG T 6.52E-06 C-Reactive Protein C18orf1 intron pha003070 rs10502421 chr18 13464437 C T 5.07E-05 Bilirubin levels,in serum C18orf1 intron 19389676 rs12960530 chr18 13485172 C T 6.22E-04 HIV-1 viral setpoint C18orf1 intron 17641165 rs7229093 chr18 13487287 A G 4.67E-05 Tunica Media C18orf1 intron pha003038 rs1559865 chr18 13503887 G T 1.00E-04 Crohn's disease C18orf1 intron 17684544 rs12604898 chr18 13506495 C T 7.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C18orf1 intron 20877124 rs1284412 chr18 13552887 T C 7.83E-04 Cognition,early reading ability C18orf1 intron 17684495 rs1284419 chr18 13556732 A G 5.12E-04 Multiple complex diseases C18orf1 intron 17554300 rs1284436 chr18 13562149 C T 6.95E-04 Multiple complex diseases C18orf1 intron 17554300 rs4797788 chr18 13590752 A G 2.54E-05 Receptive language ability C18orf1 intron 24687471 rs1785182 chr18 13623536 G A 6.84E-04 Amyotrophic Lateral Sclerosis C18orf1 intron 17827064 rs8094791 chr18 13626101 G A 4.43E-04 Multiple complex diseases C18orf1 intron 17554300 rs4797793 chr18 13638962 G A 5.34E-04 Alcohol dependence C18orf1 intron 21314694 rs12326169 chr18 13642721 T C 6.82E-04 Response to taxane treatment (placlitaxel) C18orf1 intron 23006423 rs4796995 chr18 13708574 A G 5.00E-08 Bone mineral density FAM210A intron 22504420 rs8098141 chr18 13739861 T C 7.64E-04 Multiple complex diseases RNMT intron 17554300 rs17694459 chr18 13745055 G A 6.44E-04 Acute lung injury RNMT intron 22295056 rs1942670 chr18 13757116 C A 6.59E-04 Multiple complex diseases RNMT intron 17554300 rs9965741 chr18 13775569 C T 4.49E-04 Multiple complex diseases / / 17554300 rs2155668 chr18 13799456 C T 5.58E-06 Asthma (childhood onset) / / 23829686 rs9949908 chr18 13800956 G T 0.0000157 LDL cholesterol particle diameter / / 23263444 rs1785081 chr18 13801209 C T 0.0000115 LDL cholesterol particle diameter / / 23263444 rs1284074 chr18 13801306 G A 0.0000115 LDL cholesterol particle diameter / / 23263444 rs948271 chr18 13803024 T C 0.0000152 LDL cholesterol particle diameter / / 23263444 rs2105655 chr18 13804755 G A 1.52E-04 Multiple complex diseases / / 17554300 rs1284065 chr18 13815680 T C 0.000232236 Hypertension (early onset hypertension) / / 22479346 rs9955902 chr18 13828444 T G 1.00E-04 IgE levels in asthmatics / / 23967269 rs1298527 chr18 13830371 G A 2.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1787861 chr18 13833487 A G 7.90E-05 Iron levels / / 21208937 rs16941231 chr18 13833835 C T 2.55E-04 Multiple complex diseases / / 17554300 rs1541279 chr18 13844057 C T 1.59E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6505851 chr18 13849325 A C 6.02E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs877128 chr18 13911628 C T 4.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MC2R intron 20877124 rs4797840 chr18 13929121 C G 9.52E-04 Multiple complex diseases / / 17554300 rs7233911 chr18 13931827 C T 7.19E-04 Multiple complex diseases / / 17554300 rs7233911 chr18 13931827 C T 2.04E-05 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines / / 21483694 rs4486974 chr18 13941504 T C 2.66E-04 Alzheimer's disease (late onset) / / 21379329 rs12958056 chr18 13961709 T C 2.24E-04 Alzheimer's disease (late onset) / / 21379329 rs12454351 chr18 13982662 C T 3.17E-04 Blood pressure / / 17255346 rs11664081 chr18 13987011 C A 4.44E-04 Alzheimer's disease (late onset) / / 21379329 rs12962755 chr18 13987292 C T 4.22E-04 Alzheimer's disease (late onset) / / 21379329 rs12457555 chr18 13992052 C G 3.33E-04 Gallstones / / 17632509 rs2159942 chr18 14062349 A C 3.96E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs17619135 chr18 14071464 G A 1.58E-04 Multiple complex diseases / / 17554300 rs3927214 chr18 14352092 A G 5.16E-05 Glucose levels / / pha003058 rs11660136 chr18 14412624 A G 2.47E-05 Body mass index / / 21701565 rs11660136 chr18 14412624 A G 5.61E-04 Body mass index / / 21701565 rs2132916 chr18 14710502 A G 1.90E-06 Urinary metabolites / / 21572414 rs4105209 chr18 14710842 G A 5.25E-04 Aortic root size / / 21223598 rs4086824 chr18 14715283 T C 4.90E-06 Urinary metabolites / / 21572414 rs12964673 chr18 14774429 T G 6.69E-04 Myopia (pathological) ANKRD30B intron 21095009 rs786038 chr18 14938839 T C 8.32E-05 Serum metabolites / / 19043545 rs2945660 chr18 14961870 A G 2.42E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs288982 chr18 18601148 A G 0.000000082 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) ROCK1 intron 23080225 rs4800112 chr18 18641822 T C 0.000000089 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) ROCK1 intron 23080225 rs8085504 chr18 18671098 G A 5.70E-04 Iris characteristics ROCK1 intron 21835309 rs920743 chr18 18948750 G A 9.81E-04 Parkinson's disease GREB1L intron 17052657 rs291783 chr18 19020950 G A 5.10E-04 Multiple complex diseases GREB1L intron 17554300 rs16942790 chr18 19115131 T C 6.42E-04 Multiple complex diseases ESCO1 intron 17554300 rs2850565 chr18 19256146 A G 9.24E-05 Multiple complex diseases ABHD3 intron 17554300 rs11662721 chr18 19261413 C T 1.00E-08 Phospholipid levels (plasma) ABHD3 intron 22359512 rs2959510 chr18 19325482 G A 6.28E-04 Multiple complex diseases MIB1 intron 17554300 rs1893384 chr18 19351344 A C 2.33E-04 Parkinson's disease MIB1 intron 17052657 rs3017041 chr18 19355507 C T 3.37E-04 Parkinson's disease MIB1 intron 17052657 rs2959521 chr18 19379421 T C 0.00000013 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) MIB1 intron 23080225 rs12458857 chr18 19428028 A T 3.58E-04 Lymphocyte counts MIB1 intron 22286170 rs10163732 chr18 19540467 G A 3.74E-04 Multiple complex diseases / / 17554300 rs8084283 chr18 19568146 A G 6.84E-04 Multiple complex diseases / / 17554300 rs8084283 chr18 19568146 A G 4.35E-04 Alzheimer's disease / / 24755620 rs16961918 chr18 19578054 A C 4.49E-04 Multiple complex diseases / / 17554300 rs16961918 chr18 19578054 A C 6.02E-04 Alzheimer's disease / / 24755620 rs8094271 chr18 19600460 A T 2.02E-04 Multiple complex diseases / / 17554300 rs7231221 chr18 19623097 A G 7.30E-06 Urinary metabolites / / 21572414 rs7238607 chr18 19627529 T C 5.60E-06 Urinary metabolites / / 21572414 rs16962606 chr18 19629239 C T 6.10E-06 Urinary metabolites / / 21572414 rs2170080 chr18 19637703 G A 2.14E-04 Multiple complex diseases / / 17554300 rs2170080 chr18 19637703 G A 7.90E-06 Urinary metabolites / / 21572414 rs2046058 chr18 19637794 G A 1.71E-04 Multiple complex diseases / / 17554300 rs2046058 chr18 19637794 G A 1.10E-05 Urinary metabolites / / 21572414 rs9951526 chr18 19641474 T G 3.73E-04 Multiple complex diseases / / 17554300 rs9951526 chr18 19641474 T G 1.00E-05 Urinary metabolites / / 21572414 rs4800353 chr18 19654137 A G 1.13E-05 Esophageal adenocarcinoma / / 24121790 rs4800353 chr18 19654137 A G 1.64E-04 Barrett's esophagus / / 24121790 rs4800353 chr18 19654137 A G 3.00E-07 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs9953528 chr18 19664098 G A 4.57E-04 Multiple complex diseases / / 17554300 rs9953528 chr18 19664098 G A 1.30E-05 Urinary metabolites / / 21572414 rs9954367 chr18 19672259 T G 2.29E-04 Parkinson's disease / / 17052657 rs8098673 chr18 19673331 A C 1.44E-05 Crohn's disease / / 18587394 rs1426018 chr18 19678118 G A 5.41E-04 Multiple complex diseases / / 17554300 rs9950004 chr18 19696670 A T 5.29E-06 Asthma / / 11022011 rs9950004 chr18 19696670 A T 2.27E-04 Multiple complex diseases / / 17554300 rs11663716 chr18 19704036 T C 5.66E-05 Cognitive test performance / / 20125193 rs2061935 chr18 19708348 G A 9.82E-04 Multiple complex diseases / / 17554300 rs2061935 chr18 19708348 G A 3.24E-05 Cognitive test performance / / 20125193 rs17729993 chr18 19723939 T A 7.90E-04 Multiple complex diseases / / 17554300 rs7240020 chr18 19778928 T C 3.38E-04 Stroke GATA6 intron pha002886 rs34779667 chr18 19783526 T G 1.40E-04 Urinary metabolites / / 21572414 rs4800369 chr18 19786854 C T 5.67E-04 Stroke / / pha002886 rs4800370 chr18 19787006 T A 8.92E-05 Diabetic nephropathy / / pha002864 rs1426022 chr18 19788303 T G 5.03E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11081823 chr18 19790812 T A 7.44E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11873362 chr18 19790884 T C 8.89E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7343048 chr18 19794295 A G 5.70E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11664999 chr18 19803221 C T 9.70E-05 Diabetic nephropathy / / pha002864 rs16964883 chr18 19806814 G A 1.60E-06 Urinary metabolites / / 21572414 rs11081839 chr18 19823874 A G 1.60E-06 Urinary metabolites / / 21572414 rs16965051 chr18 19828623 G C 1.20E-05 Urinary metabolites / / 21572414 rs7240774 chr18 19829244 C T 7.20E-06 Urinary metabolites / / 21572414 rs7242238 chr18 19856195 G C 7.86E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10438939 chr18 19857079 A G 1.98E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11876487 chr18 19867362 G A 1.98E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11664830 chr18 19888904 A G 2.61E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7231539 chr18 19940145 C T 1.40E-04 Sarcoidosis / / 19165924 rs4800398 chr18 19955631 C A 8.29E-05 Height / / pha003011 rs34069471 chr18 19982454 A C 3.72E-04 Type 2 diabetes / / 17463246 rs1893251 chr18 19991432 C T 5.74E-04 Type 2 diabetes / / 17463246 rs10468923 chr18 19991567 T C 6.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs1893252 chr18 19991591 T C 2.60E-04 Multiple complex diseases / / 17554300 rs8093101 chr18 19994344 A C 8.36E-04 Suicide attempts in bipolar disorder CTAGE1 UTR-3 21423239 rs12458941 chr18 19999151 C T 6.53E-05 Myopia (pathological) / / 21095009 rs10502431 chr18 20015975 G C 5.67E-04 Multiple complex diseases / / 17554300 rs4410190 chr18 20020200 C T 3.17E-04 Multiple complex diseases / / 17554300 rs4410190 chr18 20020200 C T 0.00012 Coronary artery disease / / 23202125 rs518897 chr18 20040225 A T 6.99E-05 Pulmonary function / / 20010835 rs581252 chr18 20042465 T C 5.51E-05 Multiple complex diseases / / 17554300 rs509640 chr18 20052870 C T 1.98E-04 Multiple complex diseases / / 17554300 rs509640 chr18 20052870 C T 7.90E-06 Urinary metabolites / / 21572414 rs472819 chr18 20054211 C A 8.79E-05 Pulmonary function / / 20010835 rs472819 chr18 20054211 C A 3.70E-06 Urinary metabolites / / 21572414 rs2159930 chr18 20058108 A C 4.31E-04 Multiple complex diseases / / 17554300 rs177994 chr18 20064591 G A 6.91E-04 Multiple complex diseases / / 17554300 rs177995 chr18 20065480 G A 6.49E-04 Multiple complex diseases / / 17554300 rs929581 chr18 20069699 T C 2.38E-04 Multiple complex diseases / / 17554300 rs16967814 chr18 20070591 C T 3.58E-04 Multiple complex diseases / / 17554300 rs473518 chr18 20084674 T G 9.00E-06 Migraine - clinic-based / / 23793025 rs12958298 chr18 20097414 G A 3.52E-05 Pulmonary function / / 20010835 rs764359 chr18 20097909 A C 3.38E-05 Pulmonary function / / 20010835 rs764358 chr18 20097957 A G,T 7.28E-05 Pulmonary function / / 20010835 rs2110136 chr18 20101666 A G 3.13E-05 Pulmonary function / / 20010835 rs178013 chr18 20107522 G C 9.72E-04 Multiple complex diseases / / 17554300 rs577725 chr18 20121384 A G 5.42E-05 Pulmonary function / / 20010835 rs9960559 chr18 20125691 C T 7.02E-05 Pulmonary function / / 20010835 rs515674 chr18 20125850 C T 1.07E-05 Pulmonary function / / 20010835 rs518217 chr18 20126082 C T 4.12E-05 Pulmonary function / / 20010835 rs542228 chr18 20126434 G T 1.09E-05 Pulmonary function / / 20010835 rs4800418 chr18 20146740 A C 1.70E-11 Intracranial aneurysm / / 20364137 rs35687920 chr18 20154558 G A 1.97E-06 Tuberculosis / / 22306650 rs11662668 chr18 20179381 G A 1.40E-12 Intracranial aneurysm / / 20364137 rs4331426 chr18 20190795 G A 7.00E-09 Tuberculosis / / 20694014 rs4331426 chr18 20190795 G A 2.00E-08 Tuberculosis / / 24057671 rs11874936 chr18 20203953 T C 1.61E-05 Tuberculosis / / 20694014 rs11876485 chr18 20216247 T C 0.00000896 Adenoma (male) / / 22532847 rs11082043 chr18 20222985 G C 9.58E-04 Type 2 diabetes / / 17463246 rs11661542 chr18 20223695 C A 1.00E-12 Intracranial aneurysm / / 20364137 rs299238 chr18 20307051 T G 4.67E-05 Parkinson's disease / / 23793441 rs11659279 chr18 20308684 T A 2.90E-05 Urinary metabolites / / 21572414 rs1521920 chr18 20311555 C A 2.90E-05 Urinary metabolites / / 21572414 rs909048 chr18 20315693 A C 2.90E-05 Urinary metabolites / / 21572414 rs10502429 chr18 20505280 C A 3.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs9954649 chr18 20613270 G A 1.69E-05 Alopecia areata / / 22027810 rs9807753 chr18 20664430 G A 1.04E-05 Nephrolithiasis / / 22396660 rs8098316 chr18 20672555 T G 4.77E-06 Nephrolithiasis / / 22396660 rs6507498 chr18 20683093 T C 4.55E-05 Nephrolithiasis / / 22396660 rs4292018 chr18 20702129 C G 1.70E-05 Waist-hip ratio / / 23966867 rs8093542 chr18 20709123 A C 3.21E-06 Nephrolithiasis / / 22396660 rs4800451 chr18 20716805 C T 2.62E-04 Cholesterol CABLES1 intron 17255346 rs4800451 chr18 20716805 C T 3.30E-06 Nephrolithiasis CABLES1 intron 22396660 rs9962540 chr18 20718818 T A 9.11E-05 Type 2 diabetes CABLES1 intron 17463246 rs9962540 chr18 20718818 T A 2.60E-04 Multiple complex diseases CABLES1 intron 17554300 rs11082304 chr18 20720973 G T 6.00E-06 Smoking behavior CABLES1 intron 19247474 rs11082304 chr18 20720973 G T 7.66E-05 Cognitive test performance CABLES1 intron 20125193 rs11082304 chr18 20720973 G T 5.00E-11 Platelet counts CABLES1 intron 22139419 rs11082304 chr18 20720973 G T 5.00E-15 Height CABLES1 intron 23563607 rs11082304 chr18 20720973 G T 5.00E-06 Platelet counts CABLES1 intron 24026423 rs4800148 chr18 20724328 G A 4.00E-09 Height CABLES1 intron 18391951 rs4800148 chr18 20724328 G A 5.91E-06 Height CABLES1 intron 19570815 rs4800148 chr18 20724328 G A 3.60E-05 Height CABLES1 intron 19893584 rs4800148 chr18 20724328 G A 6.35E-06 Nephrolithiasis CABLES1 intron 22396660 rs7235010 chr18 20724810 G A 7.59E-05 Nephrolithiasis CABLES1 intron 22396660 rs4800452 chr18 20727611 C T 4.00E-30 Height CABLES1 intron 20881960 rs4800452 chr18 20727611 C T 7.74E-05 Nephrolithiasis CABLES1 intron 22396660 rs4239436 chr18 20731930 A G 4.97E-05 Nephrolithiasis CABLES1 intron 22396660 rs4369779 chr18 20735408 T C 3.00E-06 Height CABLES1 intron 20189936 rs4369779 chr18 20735408 T C 6.86E-04 Stroke CABLES1 intron pha002886 rs8094261 chr18 20746728 G C 3.60E-05 Height CABLES1 intron 19893584 rs7232992 chr18 20861916 T A 4.81E-04 Multiple complex diseases / / 17554300 rs7232992 chr18 20861916 T A 5.30E-05 Parkinson's disease (familial) / / 18985386 rs2337024 chr18 20875793 A G 4.30E-04 Multiple complex diseases / / 17554300 rs9949617 chr18 20879217 C T 2.00E-08 Hypertriglyceridemia TMEM241 intron 23505323 rs12326518 chr18 20885128 C T 5.62E-04 Stroke TMEM241 intron pha002887 rs6507580 chr18 20885221 T C 8.53E-05 Neutrophil count TMEM241 intron pha003095 rs4800465 chr18 20890954 G C 1.86E-04 Multiple complex diseases TMEM241 intron 17554300 rs4800465 chr18 20890954 G C 1.11E-04 Lymphocyte counts TMEM241 intron 22286170 rs4800466 chr18 20891027 T C 3.47E-04 Multiple complex diseases TMEM241 intron 17554300 rs7233508 chr18 20911592 T C 7.34E-05 Major depressive disorder TMEM241 intron 22472876 rs7238618 chr18 20913598 G A 4.16E-04 Prostate cancer mortality TMEM241 intron 20978177 rs6507592 chr18 20913883 A G 7.75E-04 Multiple complex diseases TMEM241 intron 17554300 rs6507592 chr18 20913883 A G 6.26E-05 Major depressive disorder TMEM241 intron 22472876 rs1276324 chr18 20918419 C G 6.38E-04 Multiple complex diseases TMEM241 intron 17554300 rs1276324 chr18 20918419 C G 3.49E-05 Major depressive disorder TMEM241 intron 22472876 rs1276321 chr18 20921272 T C 8.92E-04 Multiple complex diseases TMEM241 intron 17554300 rs1276321 chr18 20921272 T C 4.45E-05 Major depressive disorder TMEM241 intron 22472876 rs1276321 chr18 20921272 T C 0.000011 Major depressive disorder TMEM241 intron 22915352 rs11082423 chr18 20929994 T C 7.71E-04 Type 2 diabetes TMEM241 intron 17463246 rs11082423 chr18 20929994 T C 3.35E-05 Multiple complex diseases TMEM241 intron 17554300 rs11082423 chr18 20929994 T C 5.74E-06 Major depressive disorder TMEM241 intron 22472876 rs7230499 chr18 20930130 T C 6.56E-04 Multiple complex diseases TMEM241 intron 17554300 rs7230499 chr18 20930130 T C 6.31E-05 Major depressive disorder TMEM241 intron 22472876 rs12456691 chr18 20932722 C T 8.64E-06 Major depressive disorder TMEM241 intron 22472876 rs1501411 chr18 20932878 G C 4.94E-04 Suicide attempts in bipolar disorder TMEM241 intron 21423239 rs17259202 chr18 20935833 G T 8.80E-05 Major depressive disorder TMEM241 intron 22472876 rs12607475 chr18 20946796 C T 6.13E-05 Major depressive disorder TMEM241 intron 22472876 rs12607475 chr18 20946796 C T 0.00001 Major depressive disorder TMEM241 intron 22915352 rs8086974 chr18 20953951 C T 6.31E-04 Suicide attempts in bipolar disorder TMEM241 intron 21423239 rs7239133 chr18 20959079 C T 5.63E-04 Suicide attempts in bipolar disorder TMEM241 intron 21423239 rs17187071 chr18 21043689 A G 8.48E-04 Multiple complex diseases RIOK3 intron 17554300 rs2291993 chr18 21044607 G A 4.27E-04 Amyotrophic lateral sclerosis (sporadic) RIOK3 intron 24529757 rs11663607 chr18 21066921 A G 2.72E-04 IgE levels / / 17255346 rs8086463 chr18 21112002 A G 0.000000358 Triglycerides NPC1 UTR-3 23063622 rs8086463 chr18 21112002 A G 1.32E-08 HDL cholesterol NPC1 UTR-3 23063622 rs2510344 chr18 21113285 T C 7.44E-05 Serum metabolites NPC1 intron 19043545 rs2282558 chr18 21118980 G A 2.21E-04 Multiple complex diseases NPC1 intron 17554300 rs1805081 chr18 21140432 T C 3.00E-07 Obesity NPC1 missense 19151714 rs1805081 chr18 21140432 T C 2.00E-06 Smoking behavior NPC1 missense 20418888 rs12605771 chr18 21159533 T C 3.44E-05 Multiple complex diseases NPC1 intron 17554300 rs1629335 chr18 21221139 C G 1.00E-07 Amyotrophic lateral sclerosis (sporadic) ANKRD29 intron 24256812 rs1652373 chr18 21228647 G T 4.64E-05 Amyotrophic lateral sclerosis ANKRD29 intron 20801717 rs1652373 chr18 21228647 G T 1.35E-05 Amyotrophic lateral sclerosis (sporadic) ANKRD29 intron 24256812 rs1652373 chr18 21228647 G T 2.66E-07 Amyotrophic lateral sclerosis (sporadic) ANKRD29 intron 24256812 rs9949997 chr18 21230924 C T 4.17E-09 Multiple complex diseases ANKRD29 intron 17554300 rs12957850 chr18 21233960 G T 2.64E-07 Amyotrophic lateral sclerosis (sporadic) ANKRD29 intron 24256812 rs62093304 chr18 21235970 T C 2.09E-07 Amyotrophic lateral sclerosis (sporadic) ANKRD29 intron 24256812 rs12966755 chr18 21239841 G T 4.37E-07 Amyotrophic lateral sclerosis (sporadic) ANKRD29 intron 24256812 rs12970798 chr18 21240144 G A 4.37E-07 Amyotrophic lateral sclerosis (sporadic) ANKRD29 intron 24256812 rs1788776 chr18 21244037 G A 7.67E-08 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs1788776 chr18 21244037 G A 8.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs1711468 chr18 21244539 C A 4.16E-07 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs12606211 chr18 21245480 C T 3.29E-07 Amyotrophic lateral sclerosis (sporadic) / / 24256812 rs17259361 chr18 21250072 C T 6.30E-04 Multiple complex diseases / / 17554300 rs12955607 chr18 21257635 T C 2.16E-06 Pancreatic cancer / / 22158540 rs2878906 chr18 21364642 A G 8.99E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs11082762 chr18 21365853 A G 7.00E-07 Amyotrophic lateral sclerosis LAMA3 intron 22959728 rs938602 chr18 21392678 G A 6.89E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs2155841 chr18 21395358 G C 8.02E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs1941521 chr18 21404334 A G 1.86E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs1941520 chr18 21404696 C T 2.19E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs8098244 chr18 21405553 A G 2.70E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs8099617 chr18 21408779 T C 7.28E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs8099763 chr18 21409064 A G 7.81E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs1941515 chr18 21411932 T C 7.90E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs4800517 chr18 21417868 G C 6.26E-04 Multiple complex diseases LAMA3 intron 17554300 rs8099017 chr18 21419314 A G 7.14E-04 Type 2 diabetes LAMA3 intron 17463246 rs8099017 chr18 21419314 A G 8.86E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs12373237 chr18 21425936 G A 3.04E-04 Type 2 diabetes LAMA3 intron 17463246 rs12373237 chr18 21425936 G A 4.30E-12 Progranulin levels LAMA3 intron 21087763 rs12373237 chr18 21425936 G A 4.30E-12 Myocardial infarction LAMA3 intron 21211798 rs8086359 chr18 21429571 G A 6.20E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs12955083 chr18 21432966 T A 2.72E-04 Type 2 diabetes LAMA3 intron 17463246 rs948433 chr18 21435456 G A 7.85E-04 Multiple complex diseases LAMA3 intron 17554300 rs11878083 chr18 21437468 G A 3.70E-07 Smoking cessation LAMA3 intron 18519826 rs8092476 chr18 21438632 T C 6.67E-07 Smoking cessation LAMA3 intron 18519826 rs8093042 chr18 21441484 G A 8.43E-04 Multiple complex diseases LAMA3 intron 17554300 rs8093042 chr18 21441484 G A 8.26E-05 Smoking cessation LAMA3 intron 18519826 rs1893290 chr18 21442621 C T 7.13E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs1941524 chr18 21445263 G T 2.13E-04 Type 2 diabetes LAMA3 intron 17463246 rs7243993 chr18 21449402 C T 6.79E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs7229663 chr18 21449444 T A 6.54E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs11662907 chr18 21455559 A G 7.10E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs9961718 chr18 21473767 T C 6.63E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs1262341 chr18 21475559 T G 7.47E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs8087837 chr18 21477582 G T 6.22E-06 Smoking cessation LAMA3 intron 18519826 rs1154226 chr18 21481233 C G 7.55E-04 Suicide attempts in bipolar disorder LAMA3 cds-synon 21423239 rs729814 chr18 21483206 G A 6.97E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs1893289 chr18 21488947 G A 8.15E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs2082047 chr18 21489886 T C 8.97E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs1560281 chr18 21493675 A G 7.98E-04 Type 2 diabetes LAMA3 intron 17463246 rs17203003 chr18 21493890 G A 8.17E-04 Suicide attempts in bipolar disorder LAMA3 intron 21423239 rs3786412 chr18 21502064 G A 4.00E-04 Response to antidepressants LAMA3 intron 19736353 rs10502441 chr18 21503171 A G 4.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) LAMA3 intron 17982456 rs1154238 chr18 21515391 G A 6.30E-04 Multiple complex diseases LAMA3 intron 17554300 rs1154238 chr18 21515391 G A 3.56E-06 Smoking cessation LAMA3 intron 18519826 rs1154238 chr18 21515391 G A 5.30E-05 Creutzfeldt-Jakob disease (variant) LAMA3 intron 22137330 rs1786045 chr18 21537962 C T 3.02E-05 Smoking cessation / / 18519826 rs8085689 chr18 21656634 C G 5.20E-06 Educational attainment TTC39C intron 21694764 rs2305024 chr18 21662816 A C 2.05E-05 Alcohol and nictotine co-dependence TTC39C intron 20158304 rs2120570 chr18 21666835 A G 1.20E-05 Urinary metabolites TTC39C intron 21572414 rs4043684 chr18 21668064 T C 5.10E-06 Urinary metabolites TTC39C intron 21572414 rs4476256 chr18 21690868 G A 2.90E-04 Multiple complex diseases TTC39C intron 17554300 rs4476256 chr18 21690868 G A 4.15E-06 Cognitive test performance TTC39C intron 20125193 rs4595868 chr18 21693892 C T 6.64E-06 Cognitive test performance TTC39C intron 20125193 rs11874765 chr18 21694002 C T 2.39E-05 Blood pressure TTC39C intron 24001895 rs11874765 chr18 21694002 C T 3.00E-04 Blood pressure TTC39C intron 24001895 rs8085837 chr18 21694921 A G 9.37E-04 Tourette syndrome TTC39C intron 22889924 rs2029238 chr18 21702106 G A 2.63E-05 Educational attainment TTC39C intron 21694764 rs3816822 chr18 21708999 G A 1.95E-05 Cognitive test performance TTC39C intron 20125193 rs2278663 chr18 21718805 T A 8.26E-05 Blood pressure / / 24001895 rs3786418 chr18 21740878 C T 3.03E-05 Aortic root size CABYR intron 21223598 rs9635963 chr18 21749615 G A 2.00E-07 Protein quantitative trait loci OSBPL1A intron 18464913 rs11083004 chr18 21766111 G A 6.63E-05 Cognitive test performance OSBPL1A intron 20125193 rs7242469 chr18 21773097 C T 9.44E-04 Response to taxane treatment (placlitaxel) OSBPL1A intron 23006423 rs6508259 chr18 21788296 G A 9.73E-04 Amyotrophic Lateral Sclerosis OSBPL1A intron 17362836 rs6508259 chr18 21788296 G A 1.52E-05 Serum metabolites OSBPL1A intron 19043545 rs4800181 chr18 21788747 G A 0.000000033 Mean arterial pressure OSBPL1A intron 22510845 rs7244139 chr18 21789727 C T 4.11E-04 Amyotrophic Lateral Sclerosis OSBPL1A intron 17362836 rs17203129 chr18 21792650 G A 5.70E-05 Alcohol dependence OSBPL1A intron 24277619 rs11083021 chr18 21798850 G A 4.90E-08 Primary nonsyndromic vesicoureteric reflex OSBPL1A intron 19959718 rs4281802 chr18 21806700 T C 5.27E-04 Alcohol dependence OSBPL1A intron 21314694 rs901618 chr18 21818666 G A 1.26E-05 Post-operative nausea and vomiting OSBPL1A intron 21694509 rs9964923 chr18 21828099 T A 1.00E-04 Prostate cancer OSBPL1A intron 21743057 rs275853 chr18 21835688 A G 4.95E-04 Multiple complex diseases OSBPL1A intron 17554300 rs2730015 chr18 21894943 G A 4.90E-04 Multiple complex diseases OSBPL1A intron 17554300 rs7236369 chr18 21925144 G A 6.90E-04 Alzheimer's disease OSBPL1A intron 22005930 rs1532010 chr18 21928041 G T 7.00E-04 Nicotine dependence OSBPL1A intron 17407593 rs1532010 chr18 21928041 G T 3.49E-06 Schizophrenia OSBPL1A intron 24253340 rs2160810 chr18 21936838 G C 6.87E-04 Alzheimer's disease OSBPL1A intron 22005930 rs7227401 chr18 21938658 T G 4.00E-07 Osteoporosis OSBPL1A intron 20548944 rs677213 chr18 22026988 C T 7.00E-04 Nicotine dependence IMPACT intron 17407593 rs16940765 chr18 22048547 T C 2.18E-06 Triglycerides HRH4 intron 19074352 rs16940765 chr18 22048547 T C 2.18E-06 Polyunsaturated fatty acid levels,in plasma HRH4 intron 19148276 rs17187619 chr18 22049580 T C 3.77E-04 Response to cytadine analogues (cytosine arabinoside) HRH4 intron 24483146 rs4800573 chr18 22059670 G A 7.48E-04 Multiple complex diseases HRH4 UTR-3 17554300 rs581302 chr18 22067402 C T 8.87E-08 Metabolite levels / / 23281178 rs17187646 chr18 22080507 G A 5.36E-05 Personality dimensions / / 23903073 rs537069 chr18 22089244 G A 9.10E-05 Alcohol consumption (maxi-drinks) / / 24277619 rs12969960 chr18 22098925 C T 9.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs499468 chr18 22099649 C T 1.71E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs7235440 chr18 22106776 C T 7.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs7235440 chr18 22106776 C T 6.00E-06 Obesity-related traits / / 23251661 rs1006609 chr18 22114057 A G 1.39E-04 Cholesterol / / 17255346 rs1006609 chr18 22114057 A G 4.42E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs17798101 chr18 22120936 T C 2.72E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs1622239 chr18 22132507 C T 7.13E-04 Multiple complex diseases / / 17554300 rs1791261 chr18 22135044 G T 1.90E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs1791510 chr18 22135116 C T 5.64E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs12954803 chr18 22136569 A G 8.00E-06 Response to taxane treatment (docetaxel) / / 23006423 rs7226750 chr18 22136830 G A 4.93E-05 Hepatocellular carcinoma / / 22807686 rs1945150 chr18 22137454 G T 9.35E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11659943 chr18 22142090 A G 3.15E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12185417 chr18 22155018 C A 7.60E-04 Suicide attempts in bipolar disorder / / 21041247 rs17203601 chr18 22157554 G A 1.65E-04 Alcohol dependence / / 21314694 rs1894019 chr18 22170630 G A 8.30E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs8085514 chr18 22193236 C T 0.00009 Carotid intima media thickness / / 23152477 rs746622 chr18 22194408 G A 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs339869 chr18 22207589 A G 8.28E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs339866 chr18 22208601 G A 8.76E-05 Non-alcoholic fatty liver disease histology (other) LOC729950 intron 20708005 rs339863 chr18 22209444 C T 1.00E-04 Cognitive impairment induced by topiramate LOC729950 intron 22091778 rs7240925 chr18 22230579 C A 8.01E-05 Monocyte counts LOC729950 intron pha003089 rs339882 chr18 22253632 G A 2.86E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9950831 chr18 22285057 T C 7.60E-05 Multiple complex diseases / / 17554300 rs9952222 chr18 22330488 C A 1.30E-06 Response to citalopram in major depressive disorder / / 20619826 rs11873656 chr18 22331765 A C 1.28E-05 Response to citalopram treatment / / 19846067 rs11873656 chr18 22331765 A C 1.90E-06 Response to citalopram in major depressive disorder / / 20619826 rs11872385 chr18 22336276 T G 8.31E-05 Response to citalopram treatment / / 19846067 rs7229673 chr18 22346141 C T 4.03E-05 Response to citalopram treatment / / 19846067 rs7229673 chr18 22346141 C T 6.70E-06 Response to citalopram in major depressive disorder / / 20619826 rs1451296 chr18 22362861 T C 7.57E-06 Response to citalopram treatment / / 19846067 rs6508329 chr18 22365168 G A 3.20E-06 Response to citalopram treatment / / 19846067 rs17203928 chr18 22372891 G C 9.15E-05 Response to citalopram treatment / / 19846067 rs10502457 chr18 22375671 C T 2.23E-05 Response to citalopram treatment / / 19846067 rs9959791 chr18 22388399 T A 1.70E-05 Urinary metabolites / / 21572414 rs1451290 chr18 22390049 G A 1.70E-05 Urinary metabolites / / 21572414 rs896295 chr18 22391283 T G 5.80E-06 Urinary metabolites / / 21572414 rs17203977 chr18 22399548 C G 9.88E-05 Response to citalopram treatment / / 19846067 rs6508331 chr18 22401907 A G 1.30E-05 Urinary metabolites / / 21572414 rs17260226 chr18 22411007 A T 8.90E-05 Personality dimensions / / 18957941 rs7227701 chr18 22437586 C T 6.80E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1901299 chr18 22442179 A C 2.59E-05 Lung adenocarcinoma / / 19836008 rs10853647 chr18 22443542 G A 2.86E-04 Taste perception / / 22132133 rs17798556 chr18 22445772 A G 3.30E-06 Urinary metabolites / / 21572414 rs12608210 chr18 22493884 G A 9.02E-04 Type 2 diabetes / / 17463246 rs12608210 chr18 22493884 G A 8.62E-05 Serum metabolites / / 19043545 rs11083104 chr18 22554311 T G 6.41E-05 Type 2 diabetes / / 17463246 rs10502463 chr18 22561753 G A 3.50E-04 Type 2 diabetes / / 17463246 rs10502464 chr18 22567258 G A 1.03E-05 Bilirubin levels,in serum / / 19389676 rs1941611 chr18 22576025 A G 7.32E-04 Schizophrenia / / 19197363 rs4800613 chr18 22607723 G A 2.51E-04 Schizophrenia / / 19197363 rs9963409 chr18 22632927 C T 1.93E-04 Cholesterol / / 17255346 rs9963409 chr18 22632927 C T 4.91E-04 Schizophrenia / / 19197363 rs5022348 chr18 22639237 C T 3.33E-04 Schizophrenia / / 19197363 rs4800623 chr18 22696065 T G 1.01E-04 Insulin resistance ZNF521 intron 21901158 rs7228750 chr18 22714149 G A 3.53E-04 Epilepsy ZNF521 intron 22116939 rs12962215 chr18 22730645 T C 6.22E-06 Adverse response to lamotrigine and phenytoin ZNF521 intron 22379998 rs8083432 chr18 22731360 A C 6.00E-06 Adverse response to lamotrigine and phenytoin ZNF521 intron 22379998 rs9951749 chr18 22757449 T C 6.75E-05 Waist-Hip Ratio ZNF521 intron pha003013 rs9951749 chr18 22757449 T C 6.87E-05 Waist-Hip Ratio ZNF521 intron pha003028 rs9944695 chr18 22785015 T C 2.01E-04 Type 2 diabetes ZNF521 intron 17463246 rs7226622 chr18 22791558 C T 6.74E-04 Alcohol dependence ZNF521 intron 21314694 rs6508355 chr18 22825993 A G 5.56E-04 Major depressive disorder ZNF521 intron 22472876 rs12456829 chr18 22918008 A G 5.45E-04 Smoking cessation ZNF521 intron 24665060 rs4265900 chr18 22935146 C G 7.09E-04 Smoking initiation / / 24665060 rs4800631 chr18 22955681 T G 7.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7407490 chr18 22971962 A G 6.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7407524 chr18 22972215 A G 6.08E-05 Smoking initiation / / 24665060 rs7239145 chr18 23020578 A G 6.17E-06 White blood cell count / / 21738479 rs12964450 chr18 23020923 T G 5.13E-06 White blood cell count / / 21738479 rs888285 chr18 23039616 G A 1.05E-05 Duodenal ulcer / / 22387998 rs4800217 chr18 23045937 G A 4.25E-05 Duodenal ulcer / / 22387998 rs16941509 chr18 23054030 G A 1.00E-04 Prostate cancer / / 21743057 rs6508378 chr18 23057712 C T 1.20E-05 Urinary metabolites / / 21572414 rs16941583 chr18 23112424 T C 5.70E-04 Multiple complex diseases / / 17554300 rs16941631 chr18 23193585 G A 4.77E-05 Receptive language ability / / 24687471 rs274231 chr18 23204703 G A 4.59E-04 Alzheimer's disease / / 17998437 rs11083145 chr18 23248111 T C 2.00E-05 Urinary metabolites / / 21572414 rs1840440 chr18 23257186 T C 3.00E-07 Weight / / 19851299 rs1840440 chr18 23257186 T C 2.00E-05 Urinary metabolites / / 21572414 rs965178 chr18 23261220 T C 2.70E-07 Weight / / 19851299 rs9950714 chr18 23291100 C T 4.82E-04 Coronary heart disease / / 21606135 rs16941764 chr18 23306660 G A 6.49E-04 Coronary heart disease / / 21606135 rs17799256 chr18 23328744 C T 2.01E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1971613 chr18 23335325 T C 2.60E-06 Urinary metabolites / / 21572414 rs1785710 chr18 23358827 G C 5.10E-05 Type 2 diabetes / / 17463248 rs7231041 chr18 23393104 T C 2.00E-06 Obesity-related traits / / 23251661 rs7231041 chr18 23393104 T C 3.00E-06 Obesity-related traits / / 23251661 rs7231041 chr18 23393104 T C 5.00E-06 Obesity-related traits / / 23251661 rs12607678 chr18 23397979 T C 8.02E-06 Hearing function / / 21493956 rs12608438 chr18 23399979 A G 8.74E-06 Hearing function / / 21493956 rs12608228 chr18 23404581 T C 7.39E-06 Hearing function / / 21493956 rs9966832 chr18 23405188 A G 5.00E-06 Periodontitis (Mean PAL) / / 24024966 rs7234534 chr18 23407436 G T 5.24E-06 Hearing function / / 21493956 rs997243 chr18 23408170 C A 7.16E-06 Hearing function / / 21493956 rs5007492 chr18 23408553 C A 6.68E-06 Hearing function / / 21493956 rs11083150 chr18 23422661 G A 2.31E-05 Multiple complex diseases / / 17554300 rs1626332 chr18 23439250 A T 8.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs8098773 chr18 23441159 T C 8.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs4800674 chr18 23441662 C G 1.68E-04 Multiple complex diseases / / 17554300 rs4800675 chr18 23441695 A G 1.75E-04 Multiple complex diseases / / 17554300 rs10502469 chr18 23446542 T C 5.47E-04 Insulin resistance / / 21901158 rs764783 chr18 23451734 G A 2.09E-04 Alzheimer's disease (late onset) / / 21379329 rs11664356 chr18 23453098 C T 3.87E-04 Alzheimer's disease (late onset) / / 21379329 rs6508397 chr18 23458416 G A 4.07E-04 Alzheimer's disease (late onset) / / 21379329 rs4800678 chr18 23462535 G T 3.96E-04 Alzheimer's disease (late onset) / / 21379329 rs9953857 chr18 23490176 T C 2.75E-04 Alzheimer's disease (late onset) / / 21379329 rs7242725 chr18 23500473 G A 4.78E-04 Alzheimer's disease (late onset) / / 21379329 rs4800691 chr18 23504760 T G 4.07E-04 Alzheimer's disease (late onset) / / 21379329 rs559814 chr18 23551606 A G 2.23E-04 Parkinson's disease / / 17052657 rs559814 chr18 23551606 A G 3.89E-04 Height / / 17255346 rs9952224 chr18 23583173 T G 8.68E-05 Orofacial clefts / / 19270707 rs12960119 chr18 23614703 A G 2.00E-06 Rhegmatogenous retinal detachment SS18 intron 23585552 rs7228783 chr18 23684907 T G 1.00E-04 Prostate cancer / / 21743057 rs11877878 chr18 23764235 A G 8.76E-04 Tourette syndrome PSMA8 intron 22889924 rs11877878 chr18 23764235 A G 5.00E-06 Periodontitis (Mean PAL) PSMA8 intron 24024966 rs11877878 chr18 23764235 A G 6.24E-06 Periodontitis (Mean PAL) PSMA8 intron 24024966 rs11877878 chr18 23764235 A G 9.44E-06 Periodontitis (Mean PAL) PSMA8 intron 24024966 rs11873475 chr18 23766056 A C 7.67E-06 Periodontitis (Mean PAL) PSMA8 intron 24024966 rs28688822 chr18 23767448 A G 6.95E-06 Periodontitis (Mean PAL) PSMA8 intron 24024966 rs59077772 chr18 23767545 T A 6.96E-06 Periodontitis (Mean PAL) PSMA8 intron 24024966 rs2121561 chr18 23768769 A G 6.33E-06 Periodontitis (Mean PAL) PSMA8 intron 24024966 rs4800725 chr18 23776274 T A 5.59E-06 Periodontitis (Mean PAL) / / 24024966 rs9956182 chr18 23777560 G A 7.32E-06 Periodontitis (Mean PAL) / / 24024966 rs13381091 chr18 23778553 A G 5.35E-06 Periodontitis (Mean PAL) / / 24024966 rs13381092 chr18 23778571 A T 5.35E-06 Periodontitis (Mean PAL) / / 24024966 rs8091826 chr18 23778939 G A 5.33E-06 Periodontitis (Mean PAL) / / 24024966 rs59129887 chr18 23781301 G A 5.23E-06 Periodontitis (Mean PAL) / / 24024966 rs4800728 chr18 23782140 G A 5.32E-06 Periodontitis (Mean PAL) / / 24024966 rs8097810 chr18 23785648 A G 4.00E-06 Periodontitis (Mean PAL) / / 24024966 rs8097810 chr18 23785648 A G 6.47E-06 Periodontitis (Mean PAL) / / 24024966 rs1791780 chr18 23892672 G A 4.00E-07 Visceral adipose tissue adjusted for BMI TAF4B intron 22589738 rs1785581 chr18 23997267 T C 0.00000298 Ovarian follicle number and menopause / / 22696150 rs16942307 chr18 24009886 C T 2.74E-04 Hearing function / / 17255346 rs1599910 chr18 24017924 C G 1.09E-05 Serum metabolites / / 19043545 rs1599910 chr18 24017924 C G 8.80E-06 Urinary metabolites / / 21572414 rs12969033 chr18 24020065 T C 2.32E-05 Serum metabolites / / 19043545 rs12969033 chr18 24020065 T C 8.80E-06 Urinary metabolites / / 21572414 rs7241214 chr18 24047874 G A 3.00E-04 Body mass index KCTD1 intron 17255346 rs6508445 chr18 24059256 A G 7.37E-05 Attention deficit hyperactivity disorder KCTD1 intron pha002875 rs9304496 chr18 24108797 C T 9.89E-04 Longevity KCTD1 intron 22279548 rs17799909 chr18 24110159 C T 9.83E-04 Multiple complex diseases KCTD1 intron 17554300 rs16942421 chr18 24156425 G A,C,T 8.00E-10 Sudden cardiac arrest KCTD1 intron 21658281 rs2021421 chr18 24180297 T C 2.97E-04 Response to cytidine analogues (gemcitabine) KCTD1 intron 24483146 rs533813 chr18 24182253 T C 2.25E-04 Response to cytidine analogues (gemcitabine) KCTD1 intron 24483146 rs1616725 chr18 24184806 T A,C 2.88E-04 Response to cytidine analogues (gemcitabine) KCTD1 intron 24483146 rs573698 chr18 24188204 T C 7.19E-04 Response to cytidine analogues (gemcitabine) KCTD1 intron 24483146 rs693535 chr18 24194484 T C 3.57E-04 Response to cytidine analogues (gemcitabine) KCTD1 intron 24483146 rs2438416 chr18 24194776 T C 7.40E-04 Response to cytidine analogues (gemcitabine) KCTD1 intron 24483146 rs573845 chr18 24196930 T C 7.44E-04 Response to cytidine analogues (gemcitabine) KCTD1 intron 24483146 rs1370911 chr18 24207693 C T 4.49E-05 Amyotrophic lateral sclerosis (sporadic) KCTD1 intron 24529757 rs920308 chr18 24217223 G A 7.88E-04 HIV-1 viral setpoint KCTD1 intron 17641165 rs11083175 chr18 24217557 G A 3.26E-04 Smoking initiation KCTD1 intron 24665060 rs9807159 chr18 24233441 C T 2.41E-05 Body Mass Index KCTD1 intron pha003015 rs9653034 chr18 24239754 G A 3.06E-05 Neuroblastoma / / pha002895 rs4800755 chr18 24243610 A G 5.46E-05 Serum metabolites / / 19043545 rs4800756 chr18 24247450 G A 5.83E-05 Serum metabolites / / 19043545 rs12960395 chr18 24250211 G A 5.80E-05 Malaria / / 19465909 rs8083994 chr18 24261921 T G 2.35E-05 Neuroblastoma / / pha002895 rs1349217 chr18 24305809 G A 1.66E-08 Metabolite levels / / 23281178 rs647852 chr18 24314507 A G 7.98E-05 Alcohol consumption / / 23953852 rs1667550 chr18 24332476 A G 1.30E-04 Alzheimer's disease (late onset) / / 21379329 rs1667550 chr18 24332476 A G 1.19E-05 Magnesium levels / / pha003092 rs527616 chr18 24337424 C G 2.00E-10 Breast cancer / / 23535729 rs16942640 chr18 24349178 T C 5.25E-07 Multiple complex diseases / / 17554300 rs11872394 chr18 24358519 G A 7.69E-05 Socioeconomic Factors / / pha003067 rs2040215 chr18 24370868 G T 9.24E-05 Prion diseases / / 22210626 rs4800269 chr18 24371645 A C 3.43E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs566381 chr18 24382693 C A 9.66E-05 Type 2 diabetes / / 17463246 rs2339219 chr18 24383919 A G 2.31E-04 Multiple complex diseases / / 17554300 rs2339219 chr18 24383919 A G 1.70E-05 Urinary metabolites / / 21572414 rs16942835 chr18 24419908 A T 7.01E-06 Lipid traits / / 21777205 rs8094228 chr18 24453731 C T 0.0003 Migraine CHST9-AS1 intron 22678113 rs163061 chr18 24473742 G C 9.70E-07 Type 1 diabetes CHST9-AS1 intron 19875614 rs163061 chr18 24473742 G C 1.19E-04 Body mass index CHST9-AS1 intron 21701565 rs163061 chr18 24473742 G C 4.04E-04 Body mass index CHST9-AS1 intron 21701565 rs10502479 chr18 24489222 A C 7.40E-06 White blood cell count CHST9-AS1 intron 21738479 rs16943045 chr18 24533824 T C 8.00E-04 Gamma gluatamyl transferase levels (interaction with age) CHST9 intron 22010049 rs1436904 chr18 24570667 T G 3.00E-08 Breast cancer CHST9 intron 23535729 rs1154210 chr18 24577220 A G 4.22E-04 Multiple complex diseases CHST9 intron 17554300 rs1941113 chr18 24580909 C T 2.05E-04 Type 2 diabetes CHST9 intron 22158537 rs1352033 chr18 24635490 C T 3.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CHST9 intron 20877124 rs8096922 chr18 24637020 C T 6.48E-04 Aortic root size CHST9 intron 21223598 rs9961915 chr18 24687324 C T 5.00E-06 Dental caries CHST9 intron 23259602 rs7240658 chr18 24687347 T A 7.35E-05 Schizophrenia CHST9 intron 19571809 rs7240658 chr18 24687347 T A 5.80E-05 Iron levels CHST9 intron 21208937 rs9953270 chr18 24687371 T C 3.00E-06 Bronchopulmonary dysplasia CHST9 intron 23897914 rs919140 chr18 24689706 G C 8.31E-05 Schizophrenia CHST9 intron 19571809 rs11660925 chr18 24792075 T C 4.08E-05 Hemoglobin / / pha003098 rs11660925 chr18 24792075 T C 6.56E-05 Erythrocyte counts / / pha003099 rs11661183 chr18 24793163 A G 4.08E-05 Hemoglobin / / pha003098 rs11661183 chr18 24793163 A G 6.56E-05 Erythrocyte counts / / pha003099 rs11660384 chr18 24801301 C T 2.16E-04 Type 2 diabetes / / 17463246 rs11660384 chr18 24801301 C T 2.80E-04 Cognitive decline / / 23732972 rs17712675 chr18 24806736 G C 2.80E-04 Cognitive decline / / 23732972 rs7228535 chr18 24807371 A T 1.95E-04 Cognitive decline / / 23732972 rs11659338 chr18 24817857 C T 4.30E-05 Hemoglobin / / pha003098 rs11659338 chr18 24817857 C T 6.88E-05 Erythrocyte counts / / pha003099 rs2247559 chr18 24827956 C T 2.85E-05 Hemoglobin / / pha003098 rs11663112 chr18 24830305 A G 4.08E-05 Hemoglobin / / pha003098 rs11663112 chr18 24830305 A G 7.42E-05 Erythrocyte counts / / pha003099 rs17713248 chr18 24833531 A C 7.73E-05 Hemoglobin / / pha003098 rs16943440 chr18 24858335 T C 2.67E-04 Type 2 diabetes / / 17463246 rs1519134 chr18 24896199 G A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs17642841 chr18 24960051 G A 2.30E-05 Urinary metabolites / / 21572414 rs7241931 chr18 24973816 C T 6.38E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs10164209 chr18 24982471 C T 6.44E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs8091214 chr18 24988023 C T 6.44E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs8091551 chr18 24988282 C T 6.45E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs1105237 chr18 24994052 G T 2.10E-05 Urinary metabolites / / 21572414 rs1105237 chr18 24994052 G T 7.23E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16943614 chr18 25001111 C T 2.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16943627 chr18 25007624 C T 4.25E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11083215 chr18 25009332 T G 6.79E-05 Smoking initiation / / 24665060 rs4800279 chr18 25070355 G T 5.00E-06 White matter integrity / / 23218918 rs654668 chr18 25125958 T C 7.63E-04 Type 2 diabetes / / 17463246 rs1420956 chr18 25167945 T C 5.00E-06 Obesity-related traits / / 23251661 rs13381702 chr18 25194240 G A 2.30E-05 Urinary metabolites / / 21572414 rs17665021 chr18 25222211 T G 6.11E-05 Nicotine smoking / / 19268276 rs10502496 chr18 25232267 C T 6.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7236484 chr18 25237011 T A 1.61E-06 Testicular cancer / / 19483682 rs16943957 chr18 25251682 C T 5.35E-05 Schizophrenia / / 19571809 rs4638670 chr18 25281147 A C,G 1.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4638670 chr18 25281147 A C,G 9.89E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12606601 chr18 25287953 G A 9.30E-05 Pericardial fat / / 22589742 rs16944011 chr18 25292363 C G 9.74E-05 Nicotine smoking / / 19268276 rs16944011 chr18 25292363 C G 3.30E-05 Pericardial fat / / 22589742 rs2851762 chr18 25292830 T G 2.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2714384 chr18 25302948 C T 5.09E-05 Heart Rate / / pha003053 rs2851757 chr18 25313101 C T 5.65E-05 Taste perception / / 22132133 rs2851758 chr18 25316814 A G 7.30E-06 Taste perception / / 22132133 rs7229884 chr18 25337548 G A 1.98E-05 Taste perception / / 22132133 rs12373190 chr18 25342045 G A 8.52E-06 Taste perception / / 22132133 rs4800820 chr18 25376473 C T 2.20E-05 HIV-1 progression / / 20064070 rs9957708 chr18 25379390 A G 2.71E-05 HIV-1 progression / / 20064070 rs7227215 chr18 25392902 C A 1.80E-05 Urinary metabolites / / 21572414 rs12954176 chr18 25408173 T C 1.98E-05 Multiple complex diseases / / 17554300 rs10502503 chr18 25413104 T C 5.78E-04 Heart Failure / / pha002885 rs4525572 chr18 25416245 A G 1.63E-04 Cocaine dependence / / 23958962 rs4525572 chr18 25416245 A G 6.42E-05 Cocaine dependence / / 23958962 rs9944711 chr18 25426974 T C 3.15E-04 Cocaine dependence / / 23958962 rs9944711 chr18 25426974 T C 6.42E-05 Cocaine dependence / / 23958962 rs8098920 chr18 25502001 G A 6.57E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7232372 chr18 25502791 T C 0.0001174 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7232372 chr18 25502791 T C 1.17E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9807662 chr18 25503620 T C 7.50E-05 Type 2 diabetes / / 17463246 rs12709794 chr18 25507049 C T 3.02E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs17462546 chr18 25511301 C T 2.14E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17445462 chr18 25517786 G A 0.0001091 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17445462 chr18 25517786 G A 1.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1348388 chr18 25528530 T C 3.05E-05 Smoking initiation / / 24665060 rs11564422 chr18 25532080 G A 2.28E-04 Multiple complex diseases CDH2 UTR-3 17554300 rs2289664 chr18 25532304 T C 0.00012 Breast cancer CDH2 missense 23555315 rs9963326 chr18 25532723 A G 3.21E-06 Glaucoma (primary open-angle) CDH2 intron 22605921 rs9945664 chr18 25533472 T C 3.06E-05 Multiple complex diseases CDH2 intron 17554300 rs11083241 chr18 25551961 G A 1 Drug response to Etoposide CDH2 intron 17537913 rs2298574 chr18 25569058 A G 6.00E-06 vWF and FVIII levels CDH2 intron 21810271 rs17446008 chr18 25621366 C A 1.10E-06 Chronic kidney disease CDH2 intron 22479191 rs11564394 chr18 25670974 C T 1.53E-04 Heart Failure CDH2 intron pha002884 rs528438 chr18 25673875 C T 7.85E-04 Schizophrenia CDH2 intron 19197363 rs1662735 chr18 25674859 A G 6.92E-04 Myocardial Infarction CDH2 intron pha002883 rs1220025 chr18 25682035 C T 6.76E-04 Myocardial Infarction CDH2 intron pha002883 rs11564386 chr18 25700791 T C 8.00E-06 Obesity-related traits CDH2 intron 23251661 rs2155765 chr18 25705139 T C 7.48E-06 Obesity-related traits CDH2 intron 23251661 rs11564338 chr18 25718176 C T 2.40E-05 Urinary metabolites CDH2 intron 21572414 rs11083252 chr18 25726723 G A 3.16E-06 Lung adenocarcinoma CDH2 intron 19836008 rs11083252 chr18 25726723 G A 8.20E-05 Asthma (bronchodilator response) CDH2 intron 22792082 rs12458418 chr18 25728219 A G 8.14E-05 Eosinophil counts CDH2 intron pha003088 rs17446875 chr18 25728693 G A 4.43E-05 Lung adenocarcinoma CDH2 intron 19836008 rs8088570 chr18 25741053 G A 4.75E-04 Multiple complex diseases CDH2 intron 17554300 rs11564299 chr18 25760028 A G 6.07E-06 Lung adenocarcinoma / / 19836008 rs11564299 chr18 25760028 A G 4.80E-05 Asthma (bronchodilator response) / / 22792082 rs7241236 chr18 25766962 A G 3.19E-06 Response to amphetamines / / 22952603 rs995519 chr18 25771992 A G 4.18E-06 Response to amphetamines / / 22952603 rs4800843 chr18 25773016 C T 3.00E-06 Response to amphetamines / / 22952603 rs7230988 chr18 25774084 C T 3.65E-06 Response to amphetamines / / 22952603 rs9807278 chr18 25778857 A G 3.43E-06 Response to amphetamines / / 22952603 rs1990415 chr18 25779542 G A 3.43E-06 Response to amphetamines / / 22952603 rs11659841 chr18 25786880 C T 9.00E-06 Periodontal disease-related phenotypes / / 24347629 rs721526 chr18 25795214 G A 1.90E-05 HIV-1 control / / 20041166 rs4800293 chr18 25813277 A G 1.90E-05 HIV-1 control / / 20041166 rs2109630 chr18 25818973 C T 3.80E-05 HIV-1 control / / 20041166 rs11564346 chr18 25826962 C T 7.44E-04 Alcohol dependence / / 20201924 rs8099301 chr18 25838851 G T 2.30E-05 HIV-1 control / / 20041166 rs17470203 chr18 25856581 C A 5.91E-04 Obesity (extreme) / / 21935397 rs17448275 chr18 25911858 T G 8.32E-04 Obesity (extreme) / / 21935397 rs11083271 chr18 25926059 C T 8.00E-06 Non-alcoholic fatty liver disease histology (lobular) / / 20708005 rs9956258 chr18 25986410 A G 9.66E-05 Multiple complex diseases / / 17554300 rs2311719 chr18 26013388 G A 3.95E-04 Tourette syndrome / / 22889924 rs2311719 chr18 26013388 G A 2.89E-05 Erythrocyte counts / / pha003099 rs12966353 chr18 26043003 A C 2.00E-04 Schizophrenia / / 19197363 rs4131805 chr18 26059112 T C 2.00E-06 Hip geometry / / 17903296 rs8099735 chr18 26059307 T G 3.31E-04 Premature ovarian failure / / 19508998 rs4800309 chr18 26085085 A C 3.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4800309 chr18 26085085 A C 7.02E-05 Lung function (forced vital capacity) / / 24023788 rs9953932 chr18 26090998 A G 2.00E-04 Schizophrenia / / 19197363 rs11876069 chr18 26092129 T C 5.83E-04 Premature ovarian failure / / 19508998 rs11083286 chr18 26094407 A G 3.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11083286 chr18 26094407 A G 1.10E-04 Lung function (forced vital capacity) / / 24023788 rs17749815 chr18 26120683 C T 2.52E-04 Premature ovarian failure / / 19508998 rs17749815 chr18 26120683 C T 1.30E-04 Vaspin levels / / 22907691 rs17749815 chr18 26120683 C T 0.0001297 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs17749815 chr18 26120683 C T 0.0002221 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs1566819 chr18 26120737 T G 6.52E-06 Lung function (forced vital capacity) / / 24023788 rs879500 chr18 26124688 C A 5.00E-06 Lung function (forced vital capacity) / / 24023788 rs1857705 chr18 26131117 C T 1.50E-05 Lung function (forced vital capacity) / / 24023788 rs16944936 chr18 26148544 T C 9.10E-04 Coronary Artery Disease / / 17634449 rs11873775 chr18 26163921 C T 1.30E-04 Vaspin levels / / 22907691 rs11873775 chr18 26163921 C T 0.0001265 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs11873775 chr18 26163921 C T 0.0001297 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs11873775 chr18 26163921 C T 7.84E-04 Smoking cessation / / 24665060 rs8095062 chr18 26176918 C A 4.91E-04 Premature ovarian failure / / 19508998 rs8095062 chr18 26176918 C A 1.30E-04 Vaspin levels / / 22907691 rs8095062 chr18 26176918 C A 0.0001265 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs8095062 chr18 26176918 C A 0.0001297 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs16945051 chr18 26194483 T C 1.30E-04 Vaspin levels / / 22907691 rs16945051 chr18 26194483 T C 0.0001265 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs16945051 chr18 26194483 T C 0.0001297 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs7230370 chr18 26196851 A G 1.30E-04 Vaspin levels / / 22907691 rs7230370 chr18 26196851 A G 0.0001265 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs7230370 chr18 26196851 A G 0.0001297 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs1504133 chr18 26212187 T C 3.54E-05 Lung function (forced vital capacity) / / 24023788 rs2847407 chr18 26215299 G A 3.13E-05 Lung function (forced vital capacity) / / 24023788 rs10502510 chr18 26225616 T C 7.17E-05 Parkinson's disease / / 21248740 rs948390 chr18 26261406 C T 2.72E-05 Hemoglobin / / pha003096 rs948390 chr18 26261406 C T 2.36E-05 Hematocrit / / pha003097 rs356926 chr18 26329054 G A 8.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs1692491 chr18 26344393 C T 2.47E-05 Hemoglobin / / pha003096 rs1692491 chr18 26344393 C T 1.72E-05 Hematocrit / / pha003097 rs1692491 chr18 26344393 C T 7.45E-05 Erythrocyte counts / / pha003101 rs11083301 chr18 26353724 A G 6.35E-05 Insulin-related traits / / pha002901 rs356894 chr18 26367661 G A 3.22E-04 Smoking cessation / / 24665060 rs1518589 chr18 26404772 C T 4.68E-05 Insulin-related traits / / pha002901 rs16945515 chr18 26436302 C T 5.72E-04 Smoking cessation / / 24665060 rs485916 chr18 26438855 A G 4.89E-05 Insulin-related traits / / pha002901 rs2171324 chr18 26445040 C T 3.25E-05 Insulin-related traits / / pha002901 rs1401191 chr18 26457167 C T 6.08E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1464217 chr18 26465206 A G 7.02E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4800889 chr18 26467370 G A 5.00E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs495401 chr18 26499413 T C 7.49E-04 Taste perception / / 22132133 rs11877588 chr18 26563494 G T 7.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2155771 chr18 26564127 A C 7.30E-04 Taste perception / / 22132133 rs9964679 chr18 26569901 G A 5.32E-05 Blood Pressure / / pha002898 rs1941200 chr18 26589667 C T 7.90E-05 Temperament (bipolar disorder) / / 22365631 rs11083314 chr18 26590846 C T 9.80E-05 Temperament (bipolar disorder) / / 22365631 rs7239312 chr18 26595555 T G 9.70E-05 Temperament (bipolar disorder) / / 22365631 rs1941890 chr18 26596627 C T 1.80E-05 Temperament (bipolar disorder) / / 22365631 rs9965312 chr18 26599922 C T 7.00E-05 Temperament (bipolar disorder) / / 22365631 rs9953307 chr18 26605068 A G 4.90E-05 Temperament (bipolar disorder) / / 22365631 rs2155929 chr18 26606647 G A 5.00E-06 Temperament (bipolar disorder) / / 22365631 rs9956727 chr18 26664005 A T 5.70E-06 Urinary metabolites / / 21572414 rs10502525 chr18 26665670 G A 3.29E-05 Lactate dehydrogenase levels / / 20981236 rs10502524 chr18 26665868 A G 7.09E-04 Smoking quantity / / 24665060 rs16946138 chr18 26667697 A G 5.30E-04 Smoking quantity / / 24665060 rs16946140 chr18 26669160 C A 7.98E-04 Smoking quantity / / 24665060 rs11083321 chr18 26669899 G A 4.05E-04 Type 2 diabetes / / 17463246 rs11083321 chr18 26669899 G A 1.40E-05 Urinary metabolites / / 21572414 rs16946152 chr18 26671962 T C 2.27E-04 Taste perception / / 22132133 rs2032727 chr18 26675679 A G 2.20E-06 Urinary metabolites / / 21572414 rs4145170 chr18 26676672 G A 3.00E-06 Cognitive performance / / 20125193 rs1833433 chr18 26711467 T C 1.90E-06 Urinary metabolites / / 21572414 rs9807781 chr18 26716668 C G 4.98E-04 Type 2 diabetes / / 17463246 rs8091445 chr18 26727523 C A 5.10E-04 Type 2 diabetes / / 17463246 rs2032725 chr18 26730357 G A 2.00E-05 Urinary metabolites / / 21572414 rs8094993 chr18 26733646 C T 2.00E-05 Urinary metabolites / / 21572414 rs1549050 chr18 26768186 C A 6.02E-05 Iron levels / / 19880490 rs1549050 chr18 26768186 C A 6.02E-05 Iron levels / / pha002876 rs10502520 chr18 26801474 A G 8.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4629057 chr18 26805185 C G 2.18E-04 Type 2 diabetes / / 17463246 rs16946458 chr18 26830742 T C 5.82E-04 Multiple complex diseases / / 17554300 rs10502518 chr18 26832895 G A,C,T 7.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2056096 chr18 26846197 G A 0.000073 Pancreatic cancer and survival / / 22665904 rs9973037 chr18 26919393 C T 1.00E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9973037 chr18 26919393 C T 2.24E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9973037 chr18 26919393 C T 3.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1406435 chr18 26926197 A T 8.74E-04 Type 2 diabetes / / 17463246 rs1406435 chr18 26926197 A T 5.05E-04 Multiple complex diseases / / 17554300 rs9950880 chr18 26966941 G A 7.53E-05 Common variable immunodeficiency / / 21497890 rs9950880 chr18 26966941 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11083330 chr18 26977073 T A 2.15E-05 Recombination rate / / 21698098 rs4456590 chr18 27064710 T C 8.77E-04 Parkinson's disease / / 17052657 rs4513182 chr18 27068769 C T 8.77E-04 Parkinson's disease / / 17052657 rs11878034 chr18 27095855 G A 2.61E-04 Parkinson's disease / / 17052657 rs1492801 chr18 27205055 G A 9.62E-04 Multiple complex diseases / / 17554300 rs16947033 chr18 27209396 T C 2.08E-04 Multiple complex diseases / / 17554300 rs1492806 chr18 27210028 G A 5.77E-04 Aortic root size / / 21223598 rs16947039 chr18 27211242 C T 1.85E-04 Multiple complex diseases / / 17554300 rs1118493 chr18 27217322 C T 5.78E-04 Aortic root size / / 21223598 rs8097651 chr18 27232011 G A,C,T 1.71E-04 Multiple complex diseases / / 17554300 rs8097651 chr18 27232011 G A,C,T 4.09E-04 Coronary Artery Disease / / 17634449 rs12605002 chr18 27237820 C T 1.31E-06 Body mass index / / 22446040 rs4534931 chr18 27251606 A G 2.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs1121898 chr18 27253083 G C 3.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs12965872 chr18 27261357 A T 6.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs12051914 chr18 27266289 C T 6.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs1389023 chr18 27269147 T A 3.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs8085322 chr18 27270300 G A 3.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs8083202 chr18 27271360 A C 3.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs9960031 chr18 27272740 A C 3.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs1552788 chr18 27274039 G T 2.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs1552789 chr18 27274359 C T 5.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs4480877 chr18 27274599 T C 4.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs10502528 chr18 27280703 C T 4.97E-05 Coronary heart disease / / pha003033 rs9965898 chr18 27297990 T C 1.99E-05 Multiple complex diseases / / 17554300 rs9952206 chr18 27298696 C T 4.16E-04 Alzheimer's disease (late onset) / / 21379329 rs2863190 chr18 27298745 T C 6.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs9967310 chr18 27299591 A G 6.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs9967445 chr18 27301274 C A 6.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs9967346 chr18 27301857 G C 7.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs8085905 chr18 27305768 A G 6.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs9954968 chr18 27307082 T C 8.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs9955682 chr18 27307823 T C 8.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs9955880 chr18 27308218 A G 8.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs8090751 chr18 27309006 T A 7.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs8085699 chr18 27309115 G A 7.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs8085712 chr18 27309152 G A 4.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs8087706 chr18 27309485 A G 9.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs9962306 chr18 27310041 A G 8.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs1492815 chr18 27319352 C T 8.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs7235960 chr18 27321930 C T 8.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs7234807 chr18 27321947 G A 9.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs12962495 chr18 27322034 C G 9.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs4629048 chr18 27326288 C A 7.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs12454547 chr18 27327987 A G 3.95E-04 Alzheimer's disease (late onset) / / 21379329 rs11661822 chr18 27353168 A G 1.59E-05 Sodium levels / / pha003093 rs11877136 chr18 27365512 G A 4.52E-06 Multiple complex diseases / / 17554300 rs9951431 chr18 27368785 C T 1.71E-04 Alzheimer's disease (late onset) / / 21379329 rs12454815 chr18 27376270 A T 4.00E-05 Prostate cancer / / 21743057 rs12457327 chr18 27376503 C G 4.00E-05 Prostate cancer / / 21743057 rs1371978 chr18 27423375 C A 1.96E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs9960307 chr18 27442503 T C 4.11E-04 Multiple complex diseases / / 17554300 rs2863740 chr18 27454427 T A 1.88E-04 Multiple complex diseases / / 17554300 rs1595963 chr18 27460348 G C 8.46E-177 Multiple complex diseases / / 17554300 rs12607637 chr18 27503493 T C 4.67E-04 Obesity (extreme) / / 21935397 rs2015085 chr18 27506062 A C 2.91E-04 Obesity (extreme) / / 21935397 rs12965207 chr18 27532832 C T 2.39E-04 Obesity (extreme) / / 21935397 rs9966721 chr18 27542045 C T 2.33E-04 Obesity (extreme) / / 21935397 rs7243787 chr18 27572034 C T 8.35E-05 Obesity (extreme) / / 21935397 rs12967036 chr18 27575754 G A 7.89E-05 Obesity (extreme) / / 21935397 rs7244533 chr18 27580903 C T 6.31E-04 Obesity (extreme) / / 21935397 rs7234178 chr18 27629208 T A 4.16E-04 Obesity (extreme) / / 21935397 rs12604702 chr18 27631785 C A 1.76E-04 Obesity (extreme) / / 21935397 rs4490071 chr18 27639100 A G 5.00E-05 Serum metabolites / / 19043545 rs4799767 chr18 27647313 A G 9.05E-04 Multiple complex diseases / / 17554300 rs12970785 chr18 27651772 A C 1.75E-04 Obesity (extreme) / / 21935397 rs1357809 chr18 27656199 T C 3.10E-04 Alzheimer's disease / / 17998437 rs8091342 chr18 27662134 C T 5.02E-04 Multiple complex diseases / / 17554300 rs1534063 chr18 27672649 G A 4.82E-04 Obesity (extreme) / / 21935397 rs1534064 chr18 27674060 G A 4.81E-04 Obesity (extreme) / / 21935397 rs4455042 chr18 27675667 G A 2.90E-05 Alzheimer's disease / / 17998437 rs1997021 chr18 27676662 G A 5.04E-05 Alzheimer's disease / / 17998437 rs9959395 chr18 27677669 C T 4.70E-04 Obesity (extreme) / / 21935397 rs2418453 chr18 27678287 C T 3.16E-04 Iron levels / / pha002876 rs12968899 chr18 27680980 C T 4.63E-04 Obesity (extreme) / / 21935397 rs9961904 chr18 27691745 T C 4.60E-04 Obesity (extreme) / / 21935397 rs9960213 chr18 27714231 A C 4.26E-04 Obesity (extreme) / / 21935397 rs12969614 chr18 27715769 T G 4.21E-04 Obesity (extreme) / / 21935397 rs9959805 chr18 27723311 G A 4.17E-04 Obesity (extreme) / / 21935397 rs9956642 chr18 27729671 G C 3.95E-04 Obesity (extreme) / / 21935397 rs1554649 chr18 27734905 T C 3.93E-04 Obesity (extreme) / / 21935397 rs9959731 chr18 27735777 C A 3.91E-04 Obesity (extreme) / / 21935397 rs4799794 chr18 27737649 G A 3.90E-04 Obesity (extreme) / / 21935397 rs7243894 chr18 27740097 T A 7.71E-04 Multiple complex diseases / / 17554300 rs12605594 chr18 27740247 C T 3.84E-04 Obesity (extreme) / / 21935397 rs1547567 chr18 27744424 G A 3.83E-04 Obesity (extreme) / / 21935397 rs1547568 chr18 27746539 T C 3.77E-04 Obesity (extreme) / / 21935397 rs1357807 chr18 27748055 T C 9.46E-04 Multiple complex diseases / / 17554300 rs9962557 chr18 27757577 A G 3.08E-04 Obesity (extreme) / / 21935397 rs9304552 chr18 27773905 G A 2.55E-04 Obesity (extreme) / / 21935397 rs7229599 chr18 27785170 T C 1.11E-05 Response to tamoxifen in breast cancer / / 22180457 rs2949528 chr18 27787263 G A 6.52E-04 Iron levels / / pha002876 rs7232093 chr18 27790493 G T 9.30E-04 Obesity (extreme) / / 21935397 rs4393646 chr18 27790932 T G 9.35E-04 Obesity (extreme) / / 21935397 rs4527093 chr18 27791085 T C 9.45E-04 Obesity (extreme) / / 21935397 rs2960028 chr18 27792675 T A 8.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs7240797 chr18 27793630 A G 6.33E-04 Iron levels / / pha002876 rs16960876 chr18 27793777 T C 5.55E-04 Obesity (extreme) / / 21935397 rs4452027 chr18 27825441 T C 1.10E-05 Urinary metabolites / / 21572414 rs9960874 chr18 27826653 T C 8.81E-05 Cognitive performance / / 19734545 rs12961416 chr18 27827586 C T 1.28E-04 Birth weight / / 17255346 rs9304554 chr18 27845177 A C 1.05E-06 Bilirubin levels,in serum / / 19389676 rs1317088 chr18 27852624 T C 5.42E-04 Smoking initiation / / 24665060 rs2960051 chr18 27856134 C T 1.24E-08 Birth weight / / 17255346 rs2960051 chr18 27856134 C T 6.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2949535 chr18 27857785 A G 2.00E-05 Subclinical atherosclerosis / / 17903303 rs2949535 chr18 27857785 A G 2.40E-05 Orofacial clefts / / 22419666 rs16947786 chr18 27858581 A G 6.08E-04 Alzheimer's disease / / 17998437 rs2949518 chr18 27862545 A G 8.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4564656 chr18 27881033 G A 2.58E-09 Birth weight / / 17255346 rs6508654 chr18 27882564 T C 7.01E-07 Birth weight / / 17255346 rs4499314 chr18 27911115 C T 8.11E-05 Panic disorder / / 19165232 rs4499314 chr18 27911115 C T 1.88E-06 Phospholipid levels (plasma) / / 21829377 rs11664615 chr18 27915220 T G 6.21E-04 Obesity (extreme) / / 21935397 rs8087548 chr18 27918230 C T 1.07E-05 Bilirubin levels,in serum / / 19389676 rs3107997 chr18 27920244 C T 1.65E-07 Birth weight / / 17255346 rs1344050 chr18 27923561 G A 7.55E-05 Serum metabolites / / 19043545 rs1344050 chr18 27923561 G A 2.87E-05 HIV-1 viral setpoint / / 22174851 rs2419037 chr18 27926577 T C 3.47E-05 Birth weight / / 17255346 rs2419037 chr18 27926577 T C 2.55E-04 Insulin resistance / / 21901158 rs2419037 chr18 27926577 T C 4.68E-04 Obesity (extreme) / / 21935397 rs3107987 chr18 27935931 T C 2.39E-05 Birth weight / / 17255346 rs3107987 chr18 27935931 T C 3.97E-04 Obesity (extreme) / / 21935397 rs6508673 chr18 27956443 C T 3.00E-06 Obesity-related traits / / 23251661 rs4799945 chr18 27959102 G A 1.01E-05 Calcium levels / / pha003085 rs1443005 chr18 27983046 G A 2.85E-06 Calcium levels / / pha003085 rs2083752 chr18 28005959 A C 8.70E-05 Birth weight / / 17255346 rs16948053 chr18 28011290 C T 2.98E-04 Birth weight / / 17255346 rs16948059 chr18 28013655 T C 9.01E-05 Birth weight / / 17255346 rs9635996 chr18 28013940 C T 9.20E-05 Birth weight / / 17255346 rs1007779 chr18 28015411 C T 1.65E-05 Birth weight / / 17255346 rs1372940 chr18 28017919 C T 5.74E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs2585711 chr18 28095458 C T 2.53E-05 Cognitive performance / / 19734545 rs1867185 chr18 28096650 T C 8.77E-04 Cardiovascular disease risk factors / / 21239051 rs2585710 chr18 28097927 C T 1.90E-05 Urinary metabolites / / 21572414 rs972697 chr18 28110019 G A 5.47E-05 Paget's disease / / 20436471 rs972697 chr18 28110019 G A 9.00E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs8085261 chr18 28111186 A C 3.15E-06 Alcohol and nictotine co-dependence / / 20158304 rs16948253 chr18 28130162 T A 7.88E-04 Multiple complex diseases / / 17554300 rs2542749 chr18 28131125 A G 4.45E-06 Phospholipid levels (plasma) / / 21829377 rs2729409 chr18 28141688 G A 3.00E-06 Protein quantitative trait loci / / 18464913 rs1035270 chr18 28142775 A G 1.69E-05 Intelligence / / 21826061 rs1035270 chr18 28142775 A G 2.64E-05 Hemoglobin / / pha003096 rs1035270 chr18 28142775 A G 8.03E-05 Hematocrit / / pha003097 rs2542729 chr18 28148384 T C 1.16E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs2927774 chr18 28154437 G T 4.12E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs1478542 chr18 28161212 G A 0.0004174 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1478542 chr18 28161212 G A 4.17E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17797075 chr18 28176688 G A 8.02E-04 Multiple complex diseases / / 17554300 rs17797075 chr18 28176688 G A 0.0001256 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17797075 chr18 28176688 G A 1.26E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2678787 chr18 28182328 C T 6.36E-05 Attention deficit hyperactivity disorder / / 18980221 rs2542754 chr18 28197518 A G 5.77E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs1788979 chr18 28237663 T C 1.34E-05 Multiple complex diseases / / 17554300 rs17710831 chr18 28262459 A G 8.05E-04 Parkinson's disease / / 17052657 rs12970656 chr18 28268890 T C 3.73E-04 Multiple complex diseases / / 17554300 rs1547872 chr18 28269124 A G 6.13E-04 Smoking quantity / / 24665060 rs2850280 chr18 28281972 G A 8.40E-04 Multiple complex diseases / / 17554300 rs2678798 chr18 28286552 G T 7.92E-04 Multiple complex diseases / / 17554300 rs2733129 chr18 28289616 T C 6.67E-04 Multiple complex diseases / / 17554300 rs2733128 chr18 28291546 A G 2.99E-04 Multiple complex diseases / / 17554300 rs948869 chr18 28294341 G T 1.90E-04 Multiple complex diseases / / 17554300 rs2733126 chr18 28294595 A G 4.77E-04 Multiple complex diseases / / 17554300 rs2591119 chr18 28367748 G A 3.19E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2591118 chr18 28367893 C T 2.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1943536 chr18 28368036 G A 5.42E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2591117 chr18 28370223 T A 1.96E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2591116 chr18 28370584 T A 1.96E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9959280 chr18 28374995 T A 1.70E-05 Urinary metabolites / / 21572414 rs2850266 chr18 28377315 A T 1.47E-04 Multiple complex diseases / / 17554300 rs1954971 chr18 28379243 T C 1.00E-05 Blood Phenotypes / / 17903294 rs4547414 chr18 28384725 G A 7.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2733119 chr18 28391012 T A 1.65E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9966361 chr18 28392489 C A,G 3.06E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2733156 chr18 28394375 C T 1.52E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2591108 chr18 28404303 G C 4.75E-04 Multiple complex diseases / / 17554300 rs2099454 chr18 28513207 T G 2.57E-04 Birth weight / / 17255346 rs3910338 chr18 28522973 T C 3.30E-04 Birth weight / / 17255346 rs7238072 chr18 28536055 G A 5.63E-05 Birth weight / / 17255346 rs7238072 chr18 28536055 G A 9.68E-04 Type 2 diabetes / / 17463246 rs16960984 chr18 28539901 G A 2.02E-04 Smoking quantity / / 24665060 rs16961011 chr18 28549959 T C 2.52E-04 Smoking quantity / / 24665060 rs16961031 chr18 28559904 C G 5.96E-05 Bipolar disorder / / 19488044 rs9961958 chr18 28560707 T G 7.55E-05 Suicide attempts in bipolar disorder / / 21423239 rs12373365 chr18 28580411 G T 7.74E-04 Alzheimer's disease DSC3 intron 17998437 rs12373365 chr18 28580411 G T 7.91E-04 Alzheimer's disease DSC3 intron 22005930 rs11081674 chr18 28580490 C T 5.58E-04 Alzheimer's disease DSC3 intron 17998437 rs11081674 chr18 28580490 C T 4.05E-04 Alzheimer's disease DSC3 intron 22005930 rs11081675 chr18 28580677 G A 5.01E-05 Vitiligo DSC3 intron 19890347 rs1313586 chr18 28586964 A G 9.71E-04 Alzheimer's disease DSC3 cds-synon 17998437 rs1313595 chr18 28602768 C A 1.39E-04 Alzheimer's disease DSC3 intron 24755620 rs166724 chr18 28605492 T A 5.31E-05 Serum metabolites DSC3 intron 19043545 rs276926 chr18 28621278 G A 3.08E-04 Alzheimer's disease DSC3 intron 24755620 rs10502557 chr18 28628256 T G 5.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1790695 chr18 28638832 G A 4.25E-05 Suicide,with and without major depression / / 22059935 rs1790695 chr18 28638832 G A 5.13E-04 Suicide,with and without major depression / / 22059935 rs1126214 chr18 28639548 T C 6.50E-06 Bronchopulmonary dysplasia / / 23897914 rs1126214 chr18 28639548 T C 7.00E-06 Bronchopulmonary dysplasia / / 23897914 rs1893963 chr18 28649042 T C 9.44E-04 Height DSC2 missense 17255346 rs1789063 chr18 28673913 T A 2.20E-05 Urinary metabolites DSC2 intron 21572414 rs1790706 chr18 28683238 A G 3.32E-04 Multiple complex diseases DSC2 nearGene-5 17554300 rs8086137 chr18 28707415 T C 2.35E-11 Parkinson's disease / / 21812969 rs1789072 chr18 28711519 C T 7.40E-04 Multiple complex diseases DSC1 intron 17554300 rs28620831 chr18 28713994 A C,G 0.0001 Breast cancer DSC1 missense 23555315 rs1658108 chr18 28719444 T A 1.23E-04 Alzheimer's disease DSC1 intron 17998437 rs11877142 chr18 28728281 A T 4.33E-04 Blood pressure (response to angiotensin II receptor blocker) DSC1 intron 24192120 rs9948648 chr18 28732160 T C 3.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DSC1 intron 20877124 rs9944577 chr18 28752661 C T 8.20E-05 Type 2 diabetes / / 17463246 rs6506895 chr18 28771843 A C 1.34E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2919999 chr18 28784342 T C 6.41E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2920001 chr18 28789725 T C 1.00E-06 Multiple sclerosis / / 23412934 rs2920005 chr18 28820997 G A 9.31E-04 Type 2 diabetes / / 17463246 rs7233386 chr18 28827377 T C 6.30E-06 Lipid traits / / 17903299 rs7231460 chr18 28832187 T C 3.70E-07 Lipid traits / / 17903299 rs966376 chr18 28832838 T C 4.50E-07 Lipid traits / / 17903299 rs16961553 chr18 28836704 T C 5.49E-04 Multiple complex diseases / / 17554300 rs16961583 chr18 28848094 T C 1.54E-04 Multiple complex diseases / / 17554300 rs17801274 chr18 28858921 G A 4.03E-04 Alzheimer's disease (late onset) / / 21379329 rs7235354 chr18 28900328 C T 9.72E-05 Type 2 diabetes DSG1 intron 17463246 rs12962355 chr18 28900577 G A 1.48E-04 Type 2 diabetes DSG1 intron 17463246 rs12963302 chr18 28900634 T C 1.85E-04 Type 2 diabetes DSG1 intron 17463246 rs12607370 chr18 28900664 G A 1.50E-04 Type 2 diabetes DSG1 intron 17463246 rs7236477 chr18 28902322 A G 7.00E-06 Eosinophilic esophagitis (pediatric) DSG1 intron 20208534 rs9950622 chr18 28912874 C T 6.68E-04 Type 2 diabetes DSG1 intron 17463246 rs2114269 chr18 28915605 C T 6.55E-04 Type 2 diabetes DSG1 intron 17463246 rs11081691 chr18 28918942 G A 5.41E-04 Type 2 diabetes DSG1 intron 17463246 rs17715980 chr18 28938047 A C 4.21E-04 Type 2 diabetes / / 17463246 rs11876192 chr18 28940034 A C 2.82E-05 Type 2 diabetes / / 17463246 rs11081692 chr18 28943792 A G 2.51E-04 Type 2 diabetes / / 17463246 rs11081692 chr18 28943792 A G 5.11E-05 Serum metabolites / / 19043545 rs1991289 chr18 28946104 G T 1.21E-04 Longevity / / 22279548 rs9950246 chr18 28949852 C T 4.47E-04 Type 2 diabetes / / 17463246 rs1031732 chr18 28955160 T C 1.45E-04 Type 2 diabetes DSG4 nearGene-5 17463246 rs12458294 chr18 28955504 T A 2.09E-04 Type 2 diabetes DSG4 nearGene-5 17463246 rs1941190 chr18 28961414 T C 2.35E-05 Type 2 diabetes DSG4 intron 17463246 rs3859361 chr18 28964634 G A 3.44E-04 Type 2 diabetes DSG4 intron 17463246 rs1813419 chr18 28964860 T C 2.46E-05 Type 2 diabetes DSG4 intron 17463246 rs7233718 chr18 28970147 G C 5.37E-05 Type 2 diabetes DSG4 intron 17463246 rs10775448 chr18 28976882 C T 1.74E-05 Type 2 diabetes DSG4 intron 17463246 rs4799570 chr18 28986333 A C 2.02E-05 Type 2 diabetes DSG4 missense 17463246 rs12709651 chr18 28988468 A C 3.68E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) DSG4 intron 24192120 rs2125987 chr18 28988724 C T 1.60E-05 Type 2 diabetes DSG4 intron 17463246 rs12966815 chr18 28989216 A G 3.68E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) DSG4 intron 24192120 rs8099248 chr18 29030080 G T 9.60E-06 Type 2 diabetes DSG3 intron 17463246 rs1941184 chr18 29038123 A C 4.00E-06 Parkinson's disease (age of onset) DSG3 intron 19772629 rs16961975 chr18 29046606 G A 2.63E-04 Barrett's esophagus DSG3 missense 24121790 rs16961975 chr18 29046606 G A 2.96E-04 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) DSG3 missense 24121790 rs11660216 chr18 29049018 C T 5.67E-04 Type 2 diabetes DSG3 intron 17463246 rs7236328 chr18 29055093 A C 2.70E-05 Urinary metabolites DSG3 intron 21572414 rs8093731 chr18 29088958 C T 1.00E-04 Alzheimer's disease (late onset) DSG2 intron 24162737 rs7243604 chr18 29130605 A G 7.36E-05 Myopia (severe) LOC100652770 intron 23933737 rs1616887 chr18 29160752 A G 3.95E-06 Cleft lip / / 20436469 rs723744 chr18 29172476 G T 4.84E-06 Cleft lip TTR intron 20436469 rs1791227 chr18 29177831 T C 0.000000637 Cholesterol,total TTR intron 23063622 rs1667254 chr18 29186128 C T 2.41E-05 Cleft lip / / 20436469 rs1667255 chr18 29187279 A C 6.00E-14 Retinol levels / / 21878437 rs4799585 chr18 29190174 C T 8.81E-06 Cleft lip / / 20436469 rs1667280 chr18 29219172 C T 3.09E-04 Type 2 diabetes B4GALT6 intron 17463246 rs1667284 chr18 29226208 A G 1.90E-04 Type 2 diabetes B4GALT6 intron 17463246 rs1551006 chr18 29233245 A G 1.49E-04 Type 2 diabetes B4GALT6 intron 17463246 rs1551006 chr18 29233245 A G 5.77E-05 Serum metabolites B4GALT6 intron 19043545 rs2595372 chr18 29238357 C A 5.07E-05 Vaspin levels B4GALT6 intron 22907691 rs2595372 chr18 29238357 C A 0.0000507 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks B4GALT6 intron 22907730 rs2595372 chr18 29238357 C A 0.0002128 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit B4GALT6 intron 22907730 rs1791183 chr18 29238686 C T 2.70E-05 Urinary metabolites B4GALT6 intron 21572414 rs1791204 chr18 29259819 C G 2.30E-05 Urinary metabolites B4GALT6 intron 21572414 rs1449082 chr18 29264028 C T 9.53E-04 Parkinson's disease B4GALT6 intron 17052657 rs10438933 chr18 29273129 A G 1.34E-04 Parkinson's disease / / 17052657 rs10438933 chr18 29273129 A G 1.00E-06 Amyotrophic lateral sclerosis / / 19451621 rs6506940 chr18 29333635 G A 1.20E-05 Lobular breast cancer (menopausal hormone therapy interaction) / / 24080446 rs10502575 chr18 29336591 A G 1.00E-07 Coronary artery calcification / / 23870195 rs8089491 chr18 29343254 G A 8.91E-07 Coronary artery calcification / / 23870195 rs594334 chr18 29364523 C T 3.40E-05 Lobular breast cancer (menopausal hormone therapy interaction) / / 24080446 rs616082 chr18 29367640 C A,T 5.01E-07 Coronary artery calcification / / 23870195 rs12326399 chr18 29398246 C T 3.26E-04 Taste perception / / 22132133 rs639595 chr18 29407057 G A 8.20E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs17741796 chr18 29409319 C T 1.35E-05 Erythrocyte counts TRAPPC8 UTR-3 pha003101 rs11873080 chr18 29410068 C T 1.49E-05 HDL cholesterol TRAPPC8 UTR-3 pha003075 rs9966530 chr18 29424289 A G 6.04E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) TRAPPC8 intron 23648065 rs11665424 chr18 29484640 C T 2.66E-05 Erythrocyte counts TRAPPC8 intron pha003101 rs11081729 chr18 29511785 A G 2.66E-05 Erythrocyte counts TRAPPC8 intron pha003101 rs8097835 chr18 29542707 A G 4.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2042745 chr18 29549567 T C 6.63E-04 Telomere length / / 23900074 rs4799612 chr18 29554761 A G 3.65E-04 Tourette syndrome / / 22889924 rs4799615 chr18 29561668 C A 9.79E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs12607151 chr18 29565776 G A 2.40E-05 Urinary metabolites / / 21572414 rs8083251 chr18 29593903 A G 6.04E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7226543 chr18 29606623 G C 4.30E-05 Age-related macular degeneration RNF125 intron pha002856 rs8093813 chr18 29614986 T A 1.40E-06 Urinary metabolites RNF125 intron 21572414 rs336277 chr18 29640430 T C 7.52E-05 Myopia (severe) RNF125 intron 23933737 rs336281 chr18 29647415 G T 4.48E-04 Smoking initiation RNF125 intron 24665060 rs8086733 chr18 29647869 G A 1.06E-05 Hypertension RNF125 intron 22384028 rs9955978 chr18 29664416 C T 4.26E-05 Lymphocyte counts / / 22286170 rs1808891 chr18 29715218 G A 2.12E-04 Lymphocyte counts / / 22286170 rs12373195 chr18 29729603 T G 2.55E-04 Multiple complex diseases / / 17554300 rs12373195 chr18 29729603 T G 2.74E-04 Obesity (extreme) / / 21935397 rs4799636 chr18 29739230 A G 2.09E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4799636 chr18 29739230 A G 2.20E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs8092245 chr18 29745782 C A 9.81E-06 Hearing function / / 21493956 rs10502583 chr18 29757133 T G 1.10E-05 Blood Phenotypes / / 17903294 rs5009126 chr18 29769749 A T 7.37E-06 Hearing function / / 21493956 rs9960741 chr18 29771464 G A 9.56E-04 Parkinson's disease MEP1B intron 17052657 rs16962818 chr18 29779094 G C 1.90E-05 Urinary metabolites MEP1B intron 21572414 rs8095196 chr18 29781337 G A 6.23E-04 Smoking quantity MEP1B intron 24665060 rs17663067 chr18 29784370 C T 3.28E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) MEP1B intron 24023788 rs2241891 chr18 29790378 C T 5.93E-05 Amyotrophic lateral sclerosis (sporadic) MEP1B intron 24529757 rs335518 chr18 29793526 C T 5.64E-05 Bipolar disorder MEP1B intron 22925353 rs680321 chr18 29797958 T C 6.22E-05 Bipolar disorder MEP1B intron 22925353 rs670059 chr18 29817015 C T 2.50E-05 Urinary metabolites / / 21572414 rs16963135 chr18 29918072 T C 8.03E-04 Multiple complex diseases FAM59A intron 17554300 rs10502587 chr18 29920430 C T 1.90E-06 Job-related exhaustion FAM59A intron 23620144 rs10502589 chr18 29924170 A T 5.20E-04 Multiple complex diseases FAM59A intron 17554300 rs16963205 chr18 29930576 T C 6.14E-04 Taste perception FAM59A intron 22132133 rs16963279 chr18 29950624 C T 3.13E-06 Primary nonsyndromic vesicoureteric reflex FAM59A intron 19959718 rs41535045 chr18 29951847 A G 4.01E-04 Type 2 diabetes FAM59A intron 17463246 rs17743799 chr18 29963113 A G 6.20E-04 Type 2 diabetes FAM59A intron 17463246 rs13381088 chr18 29969986 C T 3.64E-05 Job-related exhaustion FAM59A intron 23620144 rs3826611 chr18 29972565 T C 4.72E-05 Job-related exhaustion FAM59A intron 23620144 rs3786310 chr18 29972724 A G 4.05E-05 Job-related exhaustion FAM59A intron 23620144 rs13381344 chr18 29973731 T C 9.27E-04 Multiple complex diseases FAM59A intron 17554300 rs2055060 chr18 30018417 C T 2.13E-04 Multiple complex diseases FAM59A intron 17554300 rs1350552 chr18 30028088 C T 5.64E-04 Smoking quantity FAM59A intron 24665060 rs10502600 chr18 30030522 T C 0.000513 Salmonella-induced pyroptosis FAM59A intron 22837397 rs9947062 chr18 30045069 A C 6.78E-04 Taste perception FAM59A intron 22132133 rs9953890 chr18 30091078 T C 6.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16963478 chr18 30099132 G A 5.64E-04 Multiple complex diseases / / 17554300 rs17744605 chr18 30118768 C T 3.60E-05 Temporomandibular joint disorders / / 23746317 rs1648663 chr18 30123568 G A 1.61E-05 HDL particle features / / pha002900 rs4799649 chr18 30126466 T C 9.30E-06 Urinary metabolites / / 21572414 rs9964350 chr18 30129645 T C 1.00E-05 Urinary metabolites / / 21572414 rs330987 chr18 30130249 C G 4.40E-07 Urinary metabolites / / 21572414 rs1426723 chr18 30140024 G A 2.80E-05 Urinary metabolites / / 21572414 rs1426723 chr18 30140024 G A 9.26E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs9954988 chr18 30301116 C A 1.09E-04 Multiple complex diseases KLHL14 intron 17554300 rs12606529 chr18 30340360 T C 4.91E-04 Iron levels KLHL14 intron pha002876 rs9675424 chr18 30388308 A C 2.54E-04 Multiple complex diseases / / 17554300 rs41446249 chr18 30392068 C T 6.36E-04 Multiple complex diseases / / 17554300 rs8084688 chr18 30393854 C A 5.01E-05 Response to hepatitis C treatment / / 19684573 rs2032182 chr18 30395373 A G 1.50E-06 Response to hepatitis C treatment / / 19684573 rs4799668 chr18 30416900 A G 2.25E-07 Body mass index / / 19584900 rs4799668 chr18 30416900 A G 4.70E-07 Body mass index / / 19584900 rs9956150 chr18 30479190 G A 5.48E-05 Age-related macular degeneration / / pha000002 rs17739703 chr18 30523288 T C 6.69E-05 Nicotine smoking C18orf34 intron 19268276 rs4556865 chr18 30640189 A G 8.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C18orf34 intron 20877124 rs271490 chr18 30741491 C T 4.12E-04 Alzheimer's disease C18orf34 intron 17998437 rs271491 chr18 30741563 C T 4.43E-04 Alzheimer's disease C18orf34 intron 17998437 rs271453 chr18 30769521 A G 4.68E-04 Alzheimer's disease C18orf34 intron 17998437 rs17667691 chr18 30778086 G A 7.69E-06 Alcohol and nictotine co-dependence C18orf34 intron 20158304 rs271430 chr18 30801190 A G 4.46E-04 Alzheimer's disease C18orf34 intron 17998437 rs6507016 chr18 30927775 C T 9.10E-04 Multiple complex diseases C18orf34 intron 17554300 rs6507016 chr18 30927775 C T 4.00E-06 Prostate cancer (gene x gene interaction) C18orf34 intron 22219177 rs6507022 chr18 30998131 G C 9.00E-06 Metabolite levels (X-11787) C18orf34 intron 23934736 rs6417062 chr18 31023452 T C 4.24E-04 Multiple complex diseases / / 17554300 rs6417062 chr18 31023452 T C 5.90E-04 Alzheimer's disease / / 17998437 rs11081809 chr18 31023946 G C 5.79E-04 Multiple complex diseases / / 17554300 rs11081809 chr18 31023946 G C 7.61E-05 Alzheimer's disease / / 17998437 rs9948697 chr18 31024610 C A,G 4.89E-04 Multiple complex diseases / / 17554300 rs9948697 chr18 31024610 C A,G 1.79E-04 Alzheimer's disease / / 17998437 rs1119034 chr18 31026538 T G 7.34E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6507040 chr18 31031280 A G 7.65E-04 Multiple complex diseases / / 17554300 rs6507040 chr18 31031280 A G 3.15E-04 Alzheimer's disease / / 17998437 rs9949772 chr18 31042633 A G 4.25E-04 Multiple complex diseases / / 17554300 rs1824248 chr18 31073822 A C 5.26E-04 Multiple complex diseases / / 17554300 rs11081813 chr18 31075341 A G 4.43E-04 HIV-1 viral setpoint / / 17641165 rs1457869 chr18 31079618 G T 6.55E-04 HIV-1 viral setpoint / / 17641165 rs726145 chr18 31187910 C A 8.68E-05 Lipoproteins ASXL3 intron pha003079 rs55916387 chr18 31246244 A G 8.00E-06 Antibody status in Tripanosoma cruzi seropositivity ASXL3 intron 24324551 rs8098239 chr18 31253638 G A 5.47E-05 Pulmonary function ASXL3 intron 19300500 rs4799708 chr18 31255829 T C,G 5.23E-05 Pulmonary function ASXL3 intron 19300500 rs4799709 chr18 31255871 T C 4.92E-05 Pulmonary function ASXL3 intron 19300500 rs8090361 chr18 31263992 C G 5.03E-05 Pulmonary function ASXL3 intron 19300500 rs17733794 chr18 31265469 G T 5.08E-05 Pulmonary function ASXL3 intron 19300500 rs7227148 chr18 31266295 C G 5.12E-05 Pulmonary function ASXL3 intron 19300500 rs4799710 chr18 31266741 A C,G,T 6.40E-04 Pulmonary function ASXL3 intron 23932459 rs4799710 chr18 31266741 A C,G,T 7.00E-06 Pulmonary function ASXL3 intron 23932459 rs4799712 chr18 31273471 G A 2.54E-05 Aging (time to event) ASXL3 intron 21782286 rs16964887 chr18 31324056 T G 4.98E-04 Multiple complex diseases ASXL3 missense 17554300 rs12957087 chr18 31328519 C T 0.00068 Prostate cancer / / 23555315 rs41347951 chr18 31328643 C T 9.02E-05 Multiple complex diseases / / 17554300 rs8091611 chr18 31338016 G A 5.70E-05 Potassium levels / / pha003086 rs10502621 chr18 31383571 G A 2.70E-05 Urinary metabolites / / 21572414 rs1013696 chr18 31420010 T C 4.00E-06 Response to antidepressants / / 20360315 rs12458173 chr18 31430167 G A 4.08E-04 Taste perception / / 22132133 rs1452646 chr18 31449793 A G 9.19E-05 Taste perception NOL4 intron 22132133 rs958127 chr18 31497346 T G 2.18E-04 Taste perception NOL4 intron 22132133 rs1377186 chr18 31523975 T C 5.37E-05 Taste perception NOL4 intron 22132133 rs1470828 chr18 31524969 A G 2.00E-05 Urinary metabolites NOL4 intron 21572414 rs17816647 chr18 31592138 G A 8.71E-04 Taste perception NOL4 intron 22132133 rs4799738 chr18 31607748 A G 7.31E-05 Epilepsy (remission after treatment) NOL4 intron 23962720 rs1941355 chr18 31612425 C A,G,T 4.91E-04 Stroke NOL4 intron pha002886 rs9952815 chr18 31615885 A G 3.57E-04 Taste perception NOL4 intron 22132133 rs7240888 chr18 31624868 A C 5.47E-04 Taste perception NOL4 intron 22132133 rs8097877 chr18 31627955 T C 7.08E-04 Taste perception NOL4 intron 22132133 rs9961162 chr18 31630420 G A 1.42E-04 Stroke NOL4 intron pha002886 rs4273120 chr18 31633083 G A 1.15E-04 Taste perception NOL4 intron 22132133 rs7241999 chr18 31640468 T C 2.78E-05 Taste perception NOL4 intron 22132133 rs7239368 chr18 31645379 G A 9.00E-06 Response to citalopram treatment NOL4 intron 19846067 rs7239368 chr18 31645379 G A 6.12E-05 Vaspin levels NOL4 intron 22907691 rs12971068 chr18 31646755 C G 5.60E-06 Urinary metabolites NOL4 intron 21572414 rs11878100 chr18 31655157 A G 1.16E-04 Taste perception NOL4 intron 22132133 rs4239384 chr18 31656349 G A 8.27E-04 Stroke NOL4 intron pha002886 rs9957617 chr18 31659206 G A 5.61E-05 Taste perception NOL4 intron 22132133 rs4419128 chr18 31663695 A G 6.50E-06 Urinary metabolites NOL4 intron 21572414 rs4435332 chr18 31666868 A G 9.00E-06 Urinary metabolites NOL4 intron 21572414 rs4552083 chr18 31667019 C T 4.52E-04 Taste perception NOL4 intron 22132133 rs4239387 chr18 31668351 T G 6.58E-04 Stroke NOL4 intron pha002886 rs11081843 chr18 31683596 T C 2.56E-23 Narcolepsy NOL4 intron 19629137 rs11661450 chr18 31763811 A G 5.80E-04 Taste perception NOL4 intron 22132133 rs12964456 chr18 31769918 C A 6.00E-04 Taste perception NOL4 intron 22132133 rs4239389 chr18 31788027 C T 8.05E-04 Multiple complex diseases NOL4 intron 17554300 rs4486982 chr18 31857656 C T 8.82E-04 Acute lung injury / / 22295056 rs4423495 chr18 31859381 C A 8.49E-04 HIV-1 viral setpoint / / 17641165 rs16965248 chr18 31940611 A G 2.60E-05 HIV-1 control / / 20041166 rs12961053 chr18 31945534 G T 3.80E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs17666499 chr18 32019372 A G 8.00E-05 Parkinson's disease (age of onset) / / 19772629 rs9961251 chr18 32072308 C T 2.69E-05 Magnesium levels DT/ nearGene-5 pha003092 rs2849492 chr18 32156187 T G 2.41E-04 Vaspin levels DT/ intron 22907691 rs2849492 chr18 32156187 T G 0.0002407 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit DT/ intron 22907730 rs16965579 chr18 32170407 A G 2.95E-04 Multiple complex diseases DT/ intron 17554300 rs6507096 chr18 32175025 G A 4.79E-04 Depression (quantitative trait) DT/ intron 20800221 rs12051912 chr18 32190827 T C 2.16E-04 Multiple complex diseases DT/ intron 17554300 rs17642885 chr18 32229940 T C 9.90E-04 Multiple complex diseases DT/ intron 17554300 rs17556495 chr18 32233242 C T 5.84E-04 Type 2 diabetes DT/ intron 17463246 rs11659908 chr18 32233356 A G 3.06E-05 Coronary Artery Disease DT/ intron 17634449 rs16965739 chr18 32235100 A G 9.37E-04 Type 2 diabetes DT/ intron 17463246 rs10502626 chr18 32238866 T C 9.91E-04 Depression (quantitative trait) DT/ intron 20800221 rs12956631 chr18 32240008 C T 3.56E-05 Bipolar disorder and schizophrenia DT/ intron 20889312 rs7227497 chr18 32241897 G A 7.20E-04 Type 2 diabetes DT/ intron 17463246 rs7227497 chr18 32241897 G A 8.58E-04 Depression (quantitative trait) DT/ intron 20800221 rs3910171 chr18 32263213 T A 7.05E-04 Type 2 diabetes DT/ intron 17463246 rs16965776 chr18 32277764 C G 5.40E-04 Multiple complex diseases DT/ intron 17554300 rs12963825 chr18 32289448 A G 5.85E-04 Depression (quantitative trait) DT/ intron 20800221 rs995164 chr18 32304323 C A 3.49E-04 Type 2 diabetes DT/ intron 17463246 rs995164 chr18 32304323 C A 1.12E-05 Bipolar disorder and schizophrenia DT/ intron 20889312 rs899828 chr18 32312652 T G 8.09E-04 Response to taxane treatment (placlitaxel) DT/ intron 23006423 rs16965841 chr18 32324360 T C 7.20E-04 Type 2 diabetes DT/ intron 17463246 rs10502635 chr18 32325314 A G 9.05E-04 Type 2 diabetes DT/ intron 17463246 rs4799781 chr18 32362647 T A 8.23E-05 Multiple complex diseases DT/ intron 17554300 rs1383290 chr18 32373736 A C 6.17E-05 Panic disorder DT/ intron 19165232 rs9989533 chr18 32373873 T C 3.79E-04 Amyotrophic Lateral Sclerosis DT/ intron 17362836 rs949217 chr18 32421916 C A 2.20E-05 Urinary metabolites DT/ intron 21572414 rs496728 chr18 32452848 C A 7.81E-04 Multiple complex diseases DT/ intron 17554300 rs511638 chr18 32456354 T C 1.80E-06 Urinary metabolites DT/ intron 21572414 rs17558116 chr18 32462683 T C 1.00E-05 Urinary metabolites DT/ intron 21572414 rs1424455 chr18 32484984 G C 5.40E-06 Urinary metabolites / / 21572414 rs10502639 chr18 32512650 C T 2.20E-06 Esophageal cancer (squamous cell) / / 22960999 rs11660848 chr18 32574010 T C 6.86E-04 Depression (quantitative trait) MAPRE2 intron 20800221 rs7240845 chr18 32574960 G C 8.58E-04 Depression (quantitative trait) MAPRE2 intron 20800221 rs531558 chr18 32575286 T A 9.70E-04 Depression (quantitative trait) MAPRE2 intron 20800221 rs11081882 chr18 32623599 G T 7.17E-04 Myopia (pathological) MAPRE2 intron 21095009 rs595086 chr18 32624667 A G 1.92E-04 Parkinson's disease MAPRE2 intron 17052657 rs7228414 chr18 32634634 A G 6.21E-04 Alcohol dependence MAPRE2 intron 20201924 rs2957291 chr18 32647363 C T 8.19E-04 Taste perception MAPRE2 intron 22132133 rs515106 chr18 32656935 T C 8.18E-04 Taste perception MAPRE2 intron 22132133 rs604578 chr18 32669440 T A 9.50E-05 Longevity and age-related phenotypes MAPRE2 intron 17903295 rs668747 chr18 32674433 A G 8.18E-04 Taste perception MAPRE2 intron 22132133 rs3786322 chr18 32675822 G A 9.51E-05 Taste perception MAPRE2 intron 22132133 rs16966451 chr18 32684202 T A 1.70E-05 Urinary metabolites MAPRE2 intron 21572414 rs539716 chr18 32701540 C T 9.52E-05 Taste perception MAPRE2 intron 22132133 rs1271784 chr18 32718597 T A 1.12E-04 Diabetic nephropathy MAPRE2 intron 21150874 rs1271784 chr18 32718597 T A 3.59E-04 Type 2 diabetes MAPRE2 intron 22238593 rs550139 chr18 32724324 T C 3.30E-05 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia / / 24039173 rs746172 chr18 32751792 G A 1.65E-04 Taste perception / / 22132133 rs626777 chr18 32760054 G A 2.70E-05 Urinary metabolites / / 21572414 rs8093346 chr18 32805796 A G 1.50E-06 Post-operative nausea and vomiting / / 21694509 rs3810022 chr18 32861362 C T 3.03E-04 Amyotrophic Lateral Sclerosis ZSCAN30 intron 17362836 rs8089948 chr18 32871882 C T 1.85E-04 Amyotrophic Lateral Sclerosis ZNF271 intron 17362836 rs4401110 chr18 32935610 C T 2.98E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs116303449 chr18 32956931 A G 6.00E-07 Parasitemia in Tripanosoma cruzi seropositivity ZNF396 intron 24324551 rs355315 chr18 33019706 T C 1.23E-05 Coronary heart disease / / pha003030 rs9964280 chr18 33055145 T C 6.30E-05 HIV-1 control INO80C intron 20041166 rs355331 chr18 33074220 T C 7.28E-05 Cognitive test performance INO80C intron 20125193 rs355338 chr18 33079212 T C 7.28E-05 Cognitive test performance / / 20125193 rs9962397 chr18 33079612 T C 1.99E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9953852 chr18 33097960 C T 3.00E-06 Capecitabine sensitivity / / 22864933 rs17647094 chr18 33116178 G A 1.16E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1241347 chr18 33182828 A G 2.96E-05 Heart Rate / / pha003053 rs12965398 chr18 33222414 G T 2.70E-05 Urinary metabolites / / 21572414 rs635462 chr18 33251159 G T 9.00E-05 Prostate cancer GALNT1 intron 21743057 rs508284 chr18 33260373 C T 2.00E-05 Prostate cancer GALNT1 intron 21743057 rs549804 chr18 33264057 G A 2.00E-05 Prostate cancer GALNT1 intron 21743057 rs496841 chr18 33273553 T A 2.00E-05 Prostate cancer GALNT1 intron 21743057 rs475231 chr18 33276380 G A 2.00E-05 Prostate cancer GALNT1 intron 21743057 rs644489 chr18 33281464 C T 2.00E-05 Prostate cancer GALNT1 intron 21743057 rs17562324 chr18 33290114 G A 9.11E-05 Multiple complex diseases GALNT1 UTR-3 17554300 rs1628083 chr18 33304652 A T 2.00E-05 Prostate cancer / / 21743057 rs9948792 chr18 33351824 T C 5.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs767531 chr18 33357868 T G 7.10E-06 Drug-induced torsades de pointes / / 24223155 rs4799816 chr18 33384924 T C 6.73E-06 Monocyte counts / / pha003089 rs1942240 chr18 33387429 T C 1.58E-05 Monocyte counts / / pha003089 rs4799817 chr18 33416275 T C 5.09E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9960370 chr18 33494636 C T 6.00E-06 Drug-induced torsades de pointes / / 24223155 rs1789536 chr18 33524398 A G 7.40E-06 Drug-induced torsades de pointes / / 24223155 rs1789532 chr18 33532322 G A 7.90E-06 Drug-induced torsades de pointes / / 24223155 rs1786224 chr18 33536145 C T 9.49E-04 HIV-1 viral setpoint / / 17641165 rs2276314 chr18 33557466 A G 4.00E-07 Drug-induced torsades de pointes C18orf21 missense 24223155 rs4799838 chr18 33597530 T C 9.40E-07 Drug-induced torsades de pointes RPRD1A intron 24223155 rs1789529 chr18 33671697 C T 1.20E-04 HIV-1 viral setpoint / / 17641165 rs1789529 chr18 33671697 C T 8.73E-04 Myopia (pathological) / / 21095009 rs7235371 chr18 33674808 A G 2.84E-04 Myopia (pathological) / / 21095009 rs1944323 chr18 33679581 G C 9.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4799847 chr18 33686203 A G 5.96E-04 HIV-1 viral setpoint / / 17641165 rs1789516 chr18 33691688 T A 7.78E-06 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs1785919 chr18 33691964 G A 7.78E-06 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs1785919 chr18 33691964 G A 1.55E-04 Amyotrophic lateral sclerosis (sporadic) SLC39A6 intron 24529757 rs1789514 chr18 33692654 T C 7.78E-06 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs34972108 chr18 33693065 T A 7.78E-06 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs1785918 chr18 33693198 C T 7.78E-06 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs1050631 chr18 33694120 G A 4.00E-08 Esophageal squamous cell cancer (length of survival) SLC39A6 cds-synon 23644492 rs1789512 chr18 33694542 T C 1.00E-05 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs1789509 chr18 33695400 G A 7.78E-06 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs1539822 chr18 33695943 C T 7.78E-06 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs1785916 chr18 33696156 A G 7.78E-06 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs1789504 chr18 33696772 A C 7.78E-06 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs1789503 chr18 33696865 T G 7.78E-06 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs1785915 chr18 33697761 G C 4.57E-05 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs719147 chr18 33698192 T G 7.78E-06 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs1789550 chr18 33699553 T C 7.78E-06 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs1785914 chr18 33700796 G A 7.78E-06 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs3110564 chr18 33701589 T C 7.78E-06 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs2155827 chr18 33703874 T C 7.78E-06 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs2236718 chr18 33705135 T G 7.78E-06 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs11081934 chr18 33705304 G A 7.78E-06 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs1107840 chr18 33707164 A C 7.78E-06 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs11873168 chr18 33707581 T C 7.78E-06 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs948419 chr18 33707884 T C 2.88E-05 Esophageal squamous cell cancer (length of survival) SLC39A6 intron 23644492 rs7242481 chr18 33709217 G A 2.60E-07 Esophageal squamous cell cancer (length of survival) SLC39A6 UTR-5 23644492 rs1631346 chr18 33709664 T G 6.00E-04 Esophageal squamous cell cancer (length of survival) / / 23644492 rs1632169 chr18 33709762 G C 4.00E-04 Esophageal squamous cell cancer (length of survival) / / 23644492 rs1785900 chr18 33710170 C T 6.00E-04 Esophageal squamous cell cancer (length of survival) ELP2 intron 23644492 rs9958282 chr18 33710440 T A 6.00E-04 Esophageal squamous cell cancer (length of survival) ELP2 intron 23644492 rs1010955 chr18 33710610 T C 6.00E-04 Esophageal squamous cell cancer (length of survival) ELP2 intron 23644492 rs948417 chr18 33711274 A G 4.00E-04 Esophageal squamous cell cancer (length of survival) ELP2 intron 23644492 rs3737473 chr18 33719044 A G 6.04E-05 HIV-1 viral setpoint ELP2 intron 17641165 rs3819174 chr18 33721325 C T 2.99E-04 Multiple complex diseases ELP2 intron 17554300 rs3819174 chr18 33721325 C T 6.40E-06 Age-related macular degeneration ELP2 intron 20861866 rs2032206 chr18 33752823 A G 6.40E-06 Age-related macular degeneration ELP2 intron 20861866 rs3826608 chr18 33766982 G A 3.53E-04 HIV-1 viral setpoint / / 17641165 rs4267398 chr18 33767749 G A 2.84E-04 Amyotrophic lateral sclerosis (sporadic) MOCOS intron 24529757 rs17740112 chr18 33791013 A G 5.98E-04 Multiple complex diseases MOCOS intron 17554300 rs17672620 chr18 33791120 A T 4.12E-04 Multiple complex diseases MOCOS intron 17554300 rs16967576 chr18 33794596 T C 1.51E-04 Lung function (forced expiratory volume in 1 second) MOCOS intron 17255346 rs3786276 chr18 33837495 T C 8.30E-06 Coffee consumption MOCOS intron 21357676 rs11873182 chr18 33839565 A G 1.05E-04 Response to statin treatment (atorvastatin),change in cholesterol levels MOCOS intron 20031582 rs529342 chr18 33849868 G T 3.74E-05 Iron levels / / 19880490 rs529342 chr18 33849868 G T 3.74E-05 Iron levels / / pha002876 rs12604338 chr18 33852617 T G 3.21E-05 Body Mass Index / / pha003022 rs4799863 chr18 33873415 A G 5.00E-06 Upper aerodigestive tract cancers / / 21437268 rs9956546 chr18 33882448 G A 2.90E-06 Breast cancer FHOD3 intron 17529974 rs7240720 chr18 33888895 A G 0.000370714 Hypertension (early onset hypertension) FHOD3 intron 22479346 rs507163 chr18 33907628 C T 1.40E-04 Multiple complex diseases FHOD3 intron 17554300 rs12966207 chr18 33936966 T G 7.96E-04 HIV-1 viral setpoint FHOD3 intron 17641165 rs16967791 chr18 33937076 A G 6.96E-04 Multiple complex diseases FHOD3 intron 17554300 rs7244352 chr18 33938060 A G 4.85E-06 HDL cholesterol FHOD3 intron 21589926 rs9963440 chr18 33940734 T C 9.75E-04 Multiple complex diseases FHOD3 intron 17554300 rs17746090 chr18 33941944 A G 3.28E-04 Multiple complex diseases FHOD3 intron 17554300 rs8088004 chr18 34001343 C T 5.13E-27 Narcolepsy FHOD3 intron 19629137 rs11081949 chr18 34003948 T C 9.72E-04 Multiple complex diseases FHOD3 intron 17554300 rs11081949 chr18 34003948 T C 1.18E-04 Amyotrophic lateral sclerosis (sporadic) FHOD3 intron 24529757 rs3848482 chr18 34018577 C T 3.99E-04 Birth weight FHOD3 intron 17255346 rs878913 chr18 34034731 C G 1.51E-04 Cocaine dependence FHOD3 intron 23958962 rs878913 chr18 34034731 C G 3.12E-05 Cocaine dependence FHOD3 intron 23958962 rs1554009 chr18 34046177 G A 3.84E-05 Multiple complex diseases FHOD3 intron 17554300 rs1790644 chr18 34046384 A C 4.10E-06 Endometriosis FHOD3 intron 21151130 rs1109787 chr18 34048108 G T 9.80E-05 White matter hyperintensity burden FHOD3 intron 21681796 rs1708700 chr18 34049074 G C 7.10E-05 White matter hyperintensity burden FHOD3 intron 21681796 rs9950563 chr18 34058015 A C 6.43E-05 Bipolar disorder and schizophrenia FHOD3 intron 20889312 rs1708708 chr18 34077685 A T 4.28E-05 Relative hand skill in reading disability FHOD3 intron 24068947 rs17565834 chr18 34081849 A G 4.77E-04 Multiple complex diseases FHOD3 intron 17554300 rs12955215 chr18 34083239 A G 7.29E-04 Response to cytadine analogues (cytosine arabinoside) FHOD3 intron 24483146 rs12607135 chr18 34084319 C T 5.95E-04 Tourette syndrome FHOD3 intron 22889924 rs7242523 chr18 34090960 A G 4.02E-04 Response to cytadine analogues (cytosine arabinoside) FHOD3 intron 24483146 rs12458763 chr18 34091618 C A 9.57E-04 Alzheimer's disease FHOD3 intron 22005930 rs903736 chr18 34101676 G T 1.47E-04 Amyotrophic Lateral Sclerosis FHOD3 intron 17362836 rs903736 chr18 34101676 G T 2.31E-05 Orofacial clefts FHOD3 intron 22863734 rs9635886 chr18 34106087 T C 7.55E-04 Multiple complex diseases FHOD3 intron 17554300 rs17651157 chr18 34107452 T C 1.00E-07 Response to antipsychotic treatment FHOD3 intron 20195266 rs12963484 chr18 34116301 C T 1 Drug response to Etoposide FHOD3 intron 17537913 rs12963694 chr18 34116553 A C 9.54E-06 Bipolar disorder and schizophrenia FHOD3 intron 20889312 rs1390431 chr18 34119428 C T 9.71E-05 Major depressive disorder (broad) FHOD3 intron 20038947 rs1390431 chr18 34119428 C T 2.81E-05 Bipolar disorder and schizophrenia FHOD3 intron 20889312 rs2172946 chr18 34125987 A G 5.52E-04 Amyotrophic Lateral Sclerosis FHOD3 intron 17362836 rs3947413 chr18 34127234 C T 1 Drug response to Etoposide FHOD3 intron 17537913 rs9951261 chr18 34146384 G T 7.67E-04 Response to cytadine analogues (cytosine arabinoside) FHOD3 intron 24483146 rs4799870 chr18 34164941 C G 3.59E-04 Alzheimer's disease FHOD3 intron 22005930 rs953224 chr18 34169060 A G 7.22E-04 Parkinson's disease FHOD3 intron 17052657 rs4799425 chr18 34170114 C T 3.72E-04 Alzheimer's disease FHOD3 intron 22005930 rs4799872 chr18 34171514 C T 8.29E-04 Alzheimer's disease FHOD3 intron 22005930 rs7229111 chr18 34178483 G A 4.28E-04 Alzheimer's disease FHOD3 intron 22005930 rs12605734 chr18 34182266 G A 7.55E-04 Alzheimer's disease FHOD3 intron 17998437 rs7228898 chr18 34199429 T C 4.86E-05 Bipolar disorder FHOD3 intron 19488044 rs1076993 chr18 34204260 T G 6.04E-04 Multiple complex diseases FHOD3 intron 17554300 rs17680225 chr18 34221270 G A 1.36E-05 Type 2 diabetes FHOD3 intron 17463246 rs12965274 chr18 34243130 T G 6.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FHOD3 intron 20877124 rs8094794 chr18 34252749 C T 6.00E-06 Periodontal disease-related phenotypes FHOD3 intron 24347629 rs516514 chr18 34261048 C T 0.000000125 Hypertrophic cardiomyopathy FHOD3 intron 23255317 rs10502665 chr18 34276582 C T 9.04E-04 Multiple complex diseases FHOD3 intron 17554300 rs4799887 chr18 34319157 C T 0.0000364 Primary sclerosing cholangitis FHOD3 intron 23603763 rs572244 chr18 34363534 G A 6.14E-06 Obesity-related traits / / 23251661 rs7226408 chr18 34371861 C T 5.00E-06 Obesity-related traits / / 23251661 rs16968339 chr18 34423710 G C 0.000273 Salmonella-induced pyroptosis KIAA1328 intron 22837397 rs1365511 chr18 34425998 C A 6.18E-17 Lymphocyte counts KIAA1328 intron 22286170 rs16968475 chr18 34575677 G T 0.000392 Salmonella-induced pyroptosis KIAA1328 intron 22837397 rs8095910 chr18 34587096 T C 0.000395 Salmonella-induced pyroptosis KIAA1328 intron 22837397 rs13313604 chr18 34622865 C T 0.000374 Salmonella-induced pyroptosis KIAA1328 intron 22837397 rs2046471 chr18 34635606 G A 5.02E-04 Multiple complex diseases KIAA1328 intron 17554300 rs9965261 chr18 34645639 G T 1.03E-04 Smoking cessation KIAA1328 intron 24665060 rs323285 chr18 34735899 T C 0.00051 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines KIAA1328 intron 23204130 rs16968601 chr18 34755544 C T 0.000154 Salmonella-induced pyroptosis KIAA1328 intron 22837397 rs894775 chr18 34870751 T C 9.28E-05 Bipolar disorder and schizophrenia CELF4 intron 20889312 rs17653286 chr18 34872204 C T 8.79E-04 Multiple complex diseases CELF4 intron 17554300 rs7241842 chr18 34872741 T C 1.98E-05 Schizophrenia CELF4 intron 19571809 rs4799910 chr18 34875735 C G 3.19E-05 Bipolar disorder and schizophrenia CELF4 intron 20889312 rs1893455 chr18 34876792 G A 2.78E-05 Bipolar disorder and schizophrenia CELF4 intron 20889312 rs12607920 chr18 34902125 T G 3.60E-04 Intelligence (childhood) CELF4 intron 23358156 rs11082000 chr18 34917023 G A 8.87E-04 Schizophrenia CELF4 intron 19197363 rs554346 chr18 34923786 A G 7.62E-04 Suicide attempts in bipolar disorder CELF4 intron 21423239 rs687775 chr18 34926060 T G 6.80E-04 Suicide attempts in bipolar disorder CELF4 intron 21423239 rs605828 chr18 34926178 G C 2.10E-04 Suicide attempts in bipolar disorder CELF4 intron 21423239 rs4799915 chr18 34928639 C T 3.00E-06 Response to iloperidone treatment (QT prolongation) CELF4 intron 18521091 rs4799915 chr18 34928639 C T 6.86E-04 Obesity (extreme) CELF4 intron 21935397 rs521409 chr18 34929099 A G 0.000563546 Hypertension (early onset hypertension) CELF4 intron 22479346 rs3865392 chr18 34929464 C A 8.89E-04 Obesity (extreme) CELF4 intron 21935397 rs3895875 chr18 34936882 T C 9.63E-04 Obesity (extreme) CELF4 intron 21935397 rs3865393 chr18 34937109 A C 9.78E-04 Obesity (extreme) CELF4 intron 21935397 rs1247920 chr18 34956763 G A 4.50E-04 Amyotrophic Lateral Sclerosis CELF4 intron 17362836 rs488797 chr18 34970627 C T 6.35E-04 Amyotrophic Lateral Sclerosis CELF4 intron 17362836 rs8094149 chr18 34979873 G T 1.00E-04 Cognitive impairment induced by topiramate CELF4 intron 22091778 rs11660785 chr18 34984125 C A 3.84E-05 Monocyte counts CELF4 intron pha003089 rs11659173 chr18 35017618 G A 9.71E-05 Monocyte counts CELF4 intron pha003089 rs12605960 chr18 35034502 T C 5.72E-04 Obesity (extreme) CELF4 intron 21935397 rs9675529 chr18 35036213 C T 4.77E-04 Obesity (extreme) CELF4 intron 21935397 rs948535 chr18 35037003 G T 7.17E-04 Obesity (extreme) CELF4 intron 21935397 rs17750143 chr18 35038483 T C 7.27E-04 Obesity (extreme) CELF4 intron 21935397 rs17682727 chr18 35049456 G A 6.39E-04 Obesity (extreme) CELF4 intron 21935397 rs7228860 chr18 35052972 C A 1.48E-04 Obesity (extreme) CELF4 intron 21935397 rs11659709 chr18 35053449 C T 9.07E-04 Suicide attempts in bipolar disorder CELF4 intron 21423239 rs11874426 chr18 35055756 C T 1.22E-04 Obesity (extreme) CELF4 intron 21935397 rs9304173 chr18 35061197 A G 6.18E-04 Obesity (extreme) CELF4 intron 21935397 rs1893371 chr18 35067127 G A 0.0002143 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CELF4 intron 23233654 rs1893371 chr18 35067127 G A 2.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) CELF4 intron 23233662 rs1539849 chr18 35074002 A C 7.76E-04 Amyotrophic Lateral Sclerosis CELF4 intron 17827064 rs17750321 chr18 35078682 C A 5.00E-06 Social communication problems CELF4 intron 24564958 rs17750345 chr18 35079222 C A 6.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CELF4 intron 20877124 rs1786800 chr18 35080103 T C 3.61E-05 Cognitive impairment induced by topiramate CELF4 intron 22091778 rs1786811 chr18 35086774 T C 7.91E-05 Response to citalopram treatment CELF4 intron 19846067 rs10502674 chr18 35087383 C T 6.52E-04 Alcohol dependence CELF4 intron 21314694 rs1786776 chr18 35087457 G A 9.13E-05 Response to citalopram treatment CELF4 intron 19846067 rs1786776 chr18 35087457 G A 4.30E-05 Recombination rate CELF4 intron 21698098 rs4799934 chr18 35103667 A C 1.46E-134 Multiple complex diseases CELF4 intron 17554300 rs6507202 chr18 35110152 A G 1.04E-06 Multiple complex diseases CELF4 intron 17554300 rs7506371 chr18 35179960 T C 2.47E-05 Dengue shock syndrome / / 22001756 rs4799461 chr18 35185858 A G 2.69E-04 Alzheimer's disease / / 17998437 rs10502675 chr18 35198296 C T 9.32E-05 Dengue shock syndrome / / 22001756 rs10502675 chr18 35198296 C T 3.00E-06 Response to amphetamines / / 22952603 rs11663050 chr18 35201153 T G 1.40E-05 Urinary metabolites / / 21572414 rs17570458 chr18 35209656 G C 7.96E-05 Male fertility / / 22633400 rs2162440 chr18 35214006 A G 3.00E-06 Telomere length / / 19359265 rs2162440 chr18 35214006 A G 4.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7235755 chr18 35216261 A G 4.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1863645 chr18 35224278 G T 3.90E-04 Type 2 diabetes / / 17463246 rs17683199 chr18 35238850 G A 7.05E-04 Multiple complex diseases / / 17554300 rs11664658 chr18 35259529 C T 7.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1212167 chr18 35333334 A G 2.06E-04 Heart Failure / / pha002884 rs138479572 chr18 35333334 AT A 2.06E-04 Heart Failure / / pha002884 rs1346282 chr18 35336508 C T 5.60E-04 Schizophrenia / / 21674006 rs1187229 chr18 35355012 T C 2.75E-04 Type 2 diabetes / / 17463246 rs1187229 chr18 35355012 T C 7.31E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1787068 chr18 35363713 G A 4.19E-04 Type 2 diabetes / / 17463246 rs12961969 chr18 35364098 A C 9.45E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs8096603 chr18 35365441 G A 3.26E-04 Type 2 diabetes / / 17463246 rs1787053 chr18 35367850 C G 2.26E-04 Type 2 diabetes / / 17463246 rs1786971 chr18 35371600 G A 8.79E-05 IgE levels / / 17255346 rs1786971 chr18 35371600 G A 5.55E-05 Hemoglobin / / pha003098 rs3017109 chr18 35372224 T A 2.60E-04 Type 2 diabetes / / 17463246 rs12958383 chr18 35372588 C G 2.26E-04 Type 2 diabetes / / 17463246 rs1786939 chr18 35376658 C T 1.65E-04 Type 2 diabetes / / 17463246 rs948582 chr18 35378141 G A 1.99E-04 Type 2 diabetes / / 17463246 rs1787087 chr18 35378540 C T 8.26E-05 IgE levels / / 17255346 rs1787087 chr18 35378540 C T 5.55E-05 Hemoglobin / / pha003098 rs1632205 chr18 35390292 C T 2.26E-04 Type 2 diabetes / / 17463246 rs1632205 chr18 35390292 C T 6.78E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1630769 chr18 35393017 A G 7.00E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1786962 chr18 35393278 T C 2.35E-04 Type 2 diabetes / / 17463246 rs4493136 chr18 35444008 G C 1.50E-05 Urinary metabolites / / 21572414 rs4291982 chr18 35445641 A G 2.50E-05 Urinary metabolites / / 21572414 rs4291982 chr18 35445641 A G 2.04E-05 Hemoglobin / / pha003098 rs4291982 chr18 35445641 A G 4.55E-05 Erythrocyte counts / / pha003099 rs4438375 chr18 35464488 G A 4.36E-04 Type 2 diabetes / / 17463246 rs4799978 chr18 35494832 C T 5.39E-04 Rheumatoid arthritis / / 21452313 rs4799982 chr18 35508284 T G 2.04E-04 Rheumatoid arthritis / / 21452313 rs12969251 chr18 35515421 A G 3.66E-08 Sickle cell anemia (severity) / / 20029952 rs12957518 chr18 35525733 A G 2.94E-04 Sudden cardiac arrest / / 21658281 rs4129469 chr18 35534040 C T 1.73E-04 Rheumatoid arthritis / / 21452313 rs12607533 chr18 35535686 G A 2.81E-04 Rheumatoid arthritis / / 21452313 rs4799989 chr18 35542361 G T 1.73E-04 Rheumatoid arthritis / / 21452313 rs8095525 chr18 35578714 C T 7.74E-04 Parkinson's disease / / 17052657 rs6507234 chr18 35584240 A G 8.53E-04 Multiple complex diseases / / 17554300 rs8097488 chr18 35645568 T C 0.000771 Salmonella-induced pyroptosis / / 22837397 rs8096901 chr18 35645843 C T 3.11E-04 Multiple complex diseases / / 17554300 rs8096901 chr18 35645843 C T 5.06E-05 Hirschsprung's disease / / 19196962 rs16969649 chr18 35657401 C T 3.33E-04 Multiple complex diseases / / 17554300 rs8091939 chr18 35660513 A T 3.78E-04 Multiple complex diseases / / 17554300 rs17536346 chr18 35667915 A G 6.00E-04 Alcohol dependence / / 20201924 rs9966896 chr18 35672416 C A 2.52E-04 Multiple complex diseases / / 17554300 rs12150709 chr18 35673542 G C 7.17E-04 Multiple complex diseases / / 17554300 rs10502685 chr18 35678711 C A 6.00E-04 Alcohol dependence / / 20201924 rs9952844 chr18 35687896 C A 9.58E-04 Multiple complex diseases / / 17554300 rs8088879 chr18 35691290 T C 3.23E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4799475 chr18 35699438 C T 5.28E-04 Multiple complex diseases / / 17554300 rs1484092 chr18 35702827 A G 1.30E-04 Multiple complex diseases / / 17554300 rs1484095 chr18 35717578 A G 5.37E-05 Male fertility / / 22633400 rs1385033 chr18 35738208 A G 3.03E-04 Hemoglobin concentration / / 20534544 rs9950759 chr18 35739781 C T 4.38E-04 Multiple complex diseases / / 17554300 rs716530 chr18 35749971 A T 7.53E-04 Multiple complex diseases / / 17554300 rs17551764 chr18 35755761 C T 3.03E-04 Hemoglobin concentration / / 20534544 rs9950528 chr18 35762461 A G 7.69E-05 Multiple complex diseases / / 17554300 rs4800012 chr18 35798338 A C 6.08E-04 Multiple complex diseases / / 17554300 rs4589635 chr18 35802324 T C 6.45E-04 Multiple complex diseases / / 17554300 rs8094895 chr18 35818998 A G 7.92E-04 Multiple complex diseases / / 17554300 rs1849242 chr18 35835745 A T 2.51E-04 Multiple complex diseases / / 17554300 rs9948279 chr18 35844220 G A 3.08E-05 Type 1 diabetes / / 18978792 rs1858378 chr18 35857438 G A 2.72E-05 Age-related macular degeneration / / pha002890 rs1858378 chr18 35857438 G A 4.66E-05 Waist-Hip Ratio / / pha003029 rs12608059 chr18 35867296 A C 6.83E-04 Taste perception / / 22132133 rs11082066 chr18 35868007 A C 6.75E-05 Waist-Hip Ratio / / pha003029 rs17628762 chr18 35871719 C A 2.40E-05 Age-related macular degeneration / / 20385819 rs16969987 chr18 35872504 T C 7.31E-04 Multiple complex diseases / / 17554300 rs4800019 chr18 35876335 G A 5.49E-05 Serum metabolites / / 19043545 rs949092 chr18 35877182 A G 4.08E-05 Serum metabolites / / 19043545 rs870391 chr18 35885805 C T 5.67E-05 Age-related macular degeneration / / pha002890 rs7228861 chr18 35891422 A G 0.000338 Salmonella-induced pyroptosis / / 22837397 rs1543073 chr18 35895358 A G 1.57E-05 Systolic blood pressure in sickle cell anemia / / 24058526 rs1145552 chr18 35937299 G A 2.00E-04 Information processing speed / / 21130836 rs1196943 chr18 35948299 G C 4.00E-04 Obesity (extreme) / / 21935397 rs1196943 chr18 35948299 G C 2.13E-04 Alzheimer's disease / / 24755620 rs1196945 chr18 35948380 G A 4.02E-04 Obesity (extreme) / / 21935397 rs1145555 chr18 35948655 T C 3.55E-04 Obesity (extreme) / / 21935397 rs1789783 chr18 35949457 C T 3.70E-04 Obesity (extreme) / / 21935397 rs1789783 chr18 35949457 C T 4.21E-04 Alzheimer's disease / / 24755620 rs977767 chr18 35950723 C T 3.73E-04 Obesity (extreme) / / 21935397 rs1212408 chr18 35951792 T G 4.24E-04 Obesity (extreme) / / 21935397 rs1145557 chr18 35953570 A C 3.74E-04 Obesity (extreme) / / 21935397 rs1145557 chr18 35953570 A C 4.38E-04 Alzheimer's disease / / 24755620 rs1145559 chr18 35954028 T G 4.26E-04 Obesity (extreme) / / 21935397 rs1145560 chr18 35954175 C T 3.69E-04 Obesity (extreme) / / 21935397 rs1511944 chr18 35955726 C T 3.69E-04 Obesity (extreme) / / 21935397 rs1511942 chr18 35956009 G A 3.69E-04 Obesity (extreme) / / 21935397 rs1511941 chr18 35956046 A G 3.70E-04 Obesity (extreme) / / 21935397 rs1789611 chr18 35957827 C T 3.70E-04 Obesity (extreme) / / 21935397 rs1606249 chr18 35959528 T C 3.70E-04 Obesity (extreme) / / 21935397 rs1196942 chr18 35959826 A C 3.72E-04 Obesity (extreme) / / 21935397 rs1196941 chr18 35959839 A C 3.78E-04 Obesity (extreme) / / 21935397 rs1145562 chr18 35960366 T A 3.84E-04 Obesity (extreme) / / 21935397 rs1145562 chr18 35960366 T A 4.58E-04 Alzheimer's disease / / 24755620 rs958801 chr18 35960926 C T 3.87E-04 Obesity (extreme) / / 21935397 rs1145567 chr18 35964819 G T 3.87E-04 Obesity (extreme) / / 21935397 rs1196939 chr18 35965413 A G 2.00E-04 Information processing speed / / 21130836 rs1511938 chr18 35967920 A G 2.04E-05 Obesity (extreme) / / 21935397 rs1511938 chr18 35967920 A G 5.01E-04 Alzheimer's disease / / 24755620 rs1145569 chr18 35968000 T C 6.06E-04 Obesity (extreme) / / 21935397 rs1196937 chr18 35969244 C T 6.43E-04 Obesity (extreme) / / 21935397 rs1196598 chr18 35972469 C T 6.65E-04 Obesity (extreme) / / 21935397 rs1209307 chr18 35975454 C T 7.51E-04 Obesity (extreme) / / 21935397 rs1196604 chr18 35976560 T C 7.65E-04 Obesity (extreme) / / 21935397 rs1196606 chr18 35977068 G T 7.80E-04 Obesity (extreme) / / 21935397 rs1196607 chr18 35977100 T C 7.84E-04 Obesity (extreme) / / 21935397 rs1196608 chr18 35977139 A C 7.84E-04 Obesity (extreme) / / 21935397 rs1789782 chr18 35977568 G A 7.85E-04 Obesity (extreme) / / 21935397 rs981531 chr18 35978516 C T 3.95E-04 Obesity (extreme) / / 21935397 rs1621192 chr18 35979297 T A 7.94E-04 Obesity (extreme) / / 21935397 rs2861744 chr18 35980164 G A 7.93E-04 Obesity (extreme) / / 21935397 rs1706317 chr18 35980528 C T 7.95E-04 Obesity (extreme) / / 21935397 rs1546523 chr18 35980808 A G 2.56E-05 Obesity (extreme) / / 21935397 rs1398075 chr18 35981431 C G 1.51E-05 Cognitive decline / / 22054870 rs1196577 chr18 35982628 G A 7.85E-04 Obesity (extreme) / / 21935397 rs977153 chr18 35982918 C T 7.79E-04 Obesity (extreme) / / 21935397 rs1196579 chr18 35984129 A G 7.86E-04 Obesity (extreme) / / 21935397 rs1196582 chr18 35985759 G A 7.79E-04 Obesity (extreme) / / 21935397 rs1196583 chr18 35986312 G A 7.76E-04 Obesity (extreme) / / 21935397 rs1196584 chr18 35986559 C T 7.64E-04 Obesity (extreme) / / 21935397 rs11659348 chr18 35991476 G A 2.27E-04 Obesity (extreme) / / 21935397 rs11661910 chr18 35994031 A T 2.40E-04 Obesity (extreme) / / 21935397 rs1511937 chr18 35994996 T C 7.30E-05 Tooth agenesis (maxillary third molar) / / 24172245 rs4476251 chr18 35995173 C T 2.31E-04 Obesity (extreme) / / 21935397 rs885033 chr18 36001458 A G 4.20E-05 Tooth agenesis (maxillary third molar) / / 24172245 rs885034 chr18 36001573 A C 2.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs932026 chr18 36005511 G A 1.47E-07 Autism / / 22843504 rs1944800 chr18 36007413 A G 4.87E-04 Obesity (extreme) / / 21935397 rs11082073 chr18 36010871 T C 9.75E-04 Multiple complex diseases / / 17554300 rs11082073 chr18 36010871 T C 2.73E-04 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs11082075 chr18 36011779 G A 2.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11082076 chr18 36012486 C T 4.30E-05 Tooth agenesis (maxillary third molar) / / 24172245 rs16970186 chr18 36015043 T C 1.40E-05 Urinary metabolites / / 21572414 rs1944395 chr18 36017573 G A 0.000083 Pancreatic cancer and survival / / 22665904 rs8092129 chr18 36019017 G C 2.90E-06 Urinary metabolites / / 21572414 rs1944390 chr18 36024983 A G 4.90E-06 Urinary metabolites / / 21572414 rs867750 chr18 36036190 T C 7.10E-06 Urinary metabolites / / 21572414 rs1944386 chr18 36037621 T C 4.06E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10502692 chr18 36040352 C T 4.46E-06 Post-traumatic stress disorder / / 24080187 rs9284421 chr18 36060187 A G 5.68E-05 Cognitive performance / / 19734545 rs9954217 chr18 36064615 G A 3.45E-04 Stroke / / pha002886 rs16970440 chr18 36074828 G A 7.46E-04 Alzheimer's disease / / 17998437 rs11874847 chr18 36082516 A G 2.85E-05 IgE levels / / 22075330 rs1426679 chr18 36085089 T C 0.00010644 Hypertension (early onset hypertension) / / 22479346 rs17640975 chr18 36100304 C T 1.40E-04 Intelligence (childhood) / / 23358156 rs1426687 chr18 36118581 A G 2.50E-05 Parkinson's disease (familial) / / 18985386 rs12968649 chr18 36121933 T G 1.40E-05 Urinary metabolites / / 21572414 rs2033106 chr18 36122026 T C 7.81E-04 Multiple complex diseases / / 17554300 rs9807249 chr18 36132929 G C 1.40E-05 Parkinson's disease (familial) / / 18985386 rs16970664 chr18 36162582 G A 2.97E-04 Multiple complex diseases / / 17554300 rs10853457 chr18 36165617 C T 7.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4800037 chr18 36197047 G A 9.60E-06 Smooth-surface caries / / 24556642 rs11082098 chr18 36198732 C A 1.68E-06 Smooth-surface caries / / 24556642 rs11082098 chr18 36198732 C A 2.00E-06 Smooth-surface caries / / 24556642 rs11082098 chr18 36198732 C A 2.63E-07 Smooth-surface caries / / 24556642 rs1011394 chr18 36203982 T C 1.55E-05 Elbow pain / / pha003008 rs9951903 chr18 36206783 C T 6.96E-06 Smooth-surface caries / / 24556642 rs6507261 chr18 36209048 C A 9.31E-05 Acute lung injury / / 22295056 rs7240129 chr18 36210292 C T 7.00E-06 Smooth-surface caries / / 24556642 rs7240338 chr18 36210489 A G 9.31E-05 Acute lung injury / / 22295056 rs11662414 chr18 36223289 C T 8.05E-05 Acute lung injury / / 22295056 rs10502706 chr18 36224215 A T 8.05E-05 Acute lung injury / / 22295056 rs8086448 chr18 36227459 T C 8.20E-05 Acute lung injury / / 22295056 rs7242236 chr18 36231245 T C 7.80E-04 Parkinson's disease / / 17052657 rs3744906 chr18 36235593 C T 6.96E-06 Smooth-surface caries / / 24556642 rs1943413 chr18 36237678 C A 6.70E-05 Acute lung injury / / 22295056 rs17652147 chr18 36334583 A G 6.68E-04 Multiple complex diseases / / 17554300 rs1439494 chr18 36341319 G A 9.23E-04 Parkinson's disease / / 17052657 rs4128463 chr18 36431536 C A 5.79E-04 Type 2 diabetes / / 17846125 rs17596183 chr18 36476257 C T 4.10E-05 Anger / / 24489884 rs12961726 chr18 36494542 G A 5.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16971165 chr18 36504999 G A 3.69E-06 Lipid traits / / 21777205 rs8092033 chr18 36526657 A G 7.12E-04 Intracranial aneurysm / / 20613766 rs4327120 chr18 36532976 T C 5.91E-04 Rheumatoid arthritis / / 21452313 rs7242296 chr18 36536103 C T 7.85E-04 Rheumatoid arthritis / / 21452313 rs2953409 chr18 36579088 G A 6.78E-04 Rheumatoid arthritis / / 21452313 rs2958599 chr18 36581023 T C 8.70E-04 Multiple complex diseases / / 17554300 rs2958599 chr18 36581023 T C 9.17E-05 Response to citalopram treatment / / 19846067 rs9961264 chr18 36598772 G A 5.17E-05 Multiple complex diseases / / 17554300 rs12965440 chr18 36604476 T G 7.11E-05 Caffeine consumption / / 21490707 rs2175063 chr18 36627347 G T 4.98E-05 Bipolar disorder / / 17486107 rs17602961 chr18 36627629 C A 9.84E-05 Telomere length / / 21573004 rs8088189 chr18 36682717 C T 3.18E-04 Rheumatoid arthritis / / 21452313 rs1396654 chr18 36742905 T C 8.09E-05 Cytomegalovirus antibody response / / 21993531 rs4287637 chr18 36744896 T C 8.09E-05 Cytomegalovirus antibody response / / 21993531 rs4511605 chr18 36744974 T C 8.09E-05 Cytomegalovirus antibody response / / 21993531 rs7227272 chr18 36746623 G A 8.36E-04 Multiple complex diseases / / 17554300 rs4581776 chr18 36747024 G C 8.09E-05 Cytomegalovirus antibody response / / 21993531 rs4799502 chr18 36747779 A T 8.09E-05 Cytomegalovirus antibody response / / 21993531 rs4416086 chr18 36748710 C T 8.09E-05 Cytomegalovirus antibody response / / 21993531 rs11873983 chr18 36748849 A G 8.09E-05 Cytomegalovirus antibody response / / 21993531 rs4427876 chr18 36751298 C T 8.11E-05 Cytomegalovirus antibody response / / 21993531 rs4427876 chr18 36751298 C T 8.05E-07 Insulin-related traits / / 22791750 rs4239422 chr18 36756879 G A 4.16E-06 Insulin-related traits / / 22791750 rs7236101 chr18 36762074 C T 8.13E-05 Cytomegalovirus antibody response / / 21993531 rs7236101 chr18 36762074 C T 1.04E-06 Insulin-related traits / / 22791750 rs9955832 chr18 36767759 C T 4.83E-06 Insulin-related traits / / 22791750 rs9955842 chr18 36767856 A T 8.18E-05 Cytomegalovirus antibody response / / 21993531 rs8093427 chr18 36771124 T C 7.54E-07 Insulin-related traits / / 22791750 rs16971699 chr18 36814582 T C 6.10E-05 Hypothyroidism LOC647946 intron 22493691 rs1573427 chr18 36817942 A C 9.44E-05 Coronary heart disease LOC647946 intron pha003032 rs1431704 chr18 36853734 T C 5.00E-11 Alopecia areata LOC647946 intron 22027810 rs7233056 chr18 36874502 A G 5.12E-05 Asthma LOC647946 intron 11022011 rs1346964 chr18 36883108 A G 9.93E-04 Rheumatoid arthritis LOC647946 intron 21452313 rs2032268 chr18 36884204 T C 8.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LOC647946 intron 23648065 rs10502722 chr18 36886378 T G 6.73E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LOC647946 intron 23648065 rs12962762 chr18 36901805 C T 3.29E-05 Cognitive impairment induced by topiramate LOC647946 intron 22091778 rs2276209 chr18 36942457 A C 3.25E-04 Cholesterol LOC647946 intron 17255346 rs2043186 chr18 36946528 G A 8.25E-04 Bipolar disorder LOC647946 intron 19259986 rs7350983 chr18 36968817 C T 3.60E-04 Allergic sensitization LOC647946 intron 23817571 rs11082138 chr18 36998210 T C 4.01E-04 Type 2 diabetes LOC647946 intron 17463246 rs4800099 chr18 37058056 T G 2.53E-05 Height LOC647946 intron 22021425 rs17684043 chr18 37070215 C T 5.40E-06 Height LOC647946 intron 22021425 rs7226835 chr18 37165305 C A 8.00E-06 Obesity-related traits LOC647946 intron 23251661 rs11082143 chr18 37177734 A C 9.85E-04 Obesity (extreme) LOC647946 intron 21935397 rs11659955 chr18 37192581 T C 7.75E-06 Obesity-related traits LOC647946 intron 23251661 rs2852331 chr18 37230551 G A 4.09E-04 Smoking cessation LOC647946 intron 24665060 rs2852335 chr18 37233393 C T 4.26E-04 Smoking cessation LOC647946 intron 24665060 rs1444394 chr18 37238603 C T 4.16E-04 Smoking cessation LOC647946 intron 24665060 rs16972146 chr18 37241438 C T 2.00E-05 Urinary metabolites LOC647946 intron 21572414 rs491566 chr18 37249145 A T 6.37E-04 Multiple complex diseases LOC647946 intron 17554300 rs625586 chr18 37261527 G A 6.34E-04 Smoking cessation LOC647946 intron 24665060 rs650998 chr18 37262629 A C 2.10E-05 Height LOC647946 intron 22021425 rs525985 chr18 37277024 C T 1.56E-05 Smoking cessation LOC647946 intron 24665060 rs628005 chr18 37280942 T A 2.47E-04 Smoking cessation LOC647946 intron 24665060 rs630228 chr18 37281414 T G 6.94E-04 Smoking cessation LOC647946 intron 24665060 rs1444393 chr18 37286372 A G 1.59E-04 Smoking cessation LOC647946 intron 24665060 rs7229654 chr18 37295986 A G 8.00E-05 Type 2 diabetes LOC647946 intron 17463248 rs1596583 chr18 37296895 G A 7.30E-05 Type 2 diabetes LOC647946 intron 17463248 rs2588844 chr18 37303198 T C 1.53E-04 Smoking cessation LOC647946 intron 24665060 rs1398899 chr18 37315686 T G 6.61E-04 Smoking cessation LOC647946 intron 24665060 rs9675995 chr18 37320909 G A 8.30E-05 Type 2 diabetes LOC647946 intron 17463248 rs2848800 chr18 37321974 T C 9.82E-05 Serum metabolites LOC647946 intron 19043545 rs2726223 chr18 37322098 T C 2.83E-05 Smoking cessation LOC647946 intron 24665060 rs10853467 chr18 37328330 A G 8.20E-05 Type 2 diabetes LOC647946 intron 17463248 rs2588849 chr18 37332613 G A 4.62E-04 Smoking cessation / / 24665060 rs1513679 chr18 37346404 G A 8.05E-04 Smoking cessation / / 24665060 rs16972414 chr18 37455922 A G 1.96E-05 Longevity / / 20304771 rs12967168 chr18 37474050 A T 3.01E-05 Longevity / / 20304771 rs11082159 chr18 37478658 C T 2.60E-05 Longevity / / 20304771 rs2862294 chr18 37530560 A G 3.40E-04 Alzheimer's disease / / 17998437 rs307090 chr18 37535064 A C 6.45E-04 Smoking cessation / / 24665060 rs17632270 chr18 37555430 T C 4.98E-04 Alzheimer's disease / / 17998437 rs2568472 chr18 37559238 T C 1.99E-04 Alzheimer's disease / / 17998437 rs394365 chr18 37574039 G A 2.03E-04 Alzheimer's disease / / 17998437 rs17634225 chr18 37602515 G A 3.01E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs307125 chr18 37630731 G A 1.40E-05 Urinary metabolites / / 21572414 rs11660705 chr18 37656504 G T 7.24E-04 Multiple complex diseases / / 17554300 rs752216 chr18 37682827 T C 1.98E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6507326 chr18 37685038 C T 1.00E-05 Urinary metabolites / / 21572414 rs4799526 chr18 37686747 T C 3.51E-04 Type 2 diabetes / / 17463246 rs17715143 chr18 37686796 A G 3.70E-04 Type 2 diabetes / / 17463246 rs9955685 chr18 37693873 C T 3.88E-05 Fibrinogen / / pha003068 rs2032185 chr18 37702482 C T 8.85E-04 Multiple complex diseases / / 17554300 rs12457251 chr18 37717146 C A 4.25E-04 Alzheimer's disease / / 17998437 rs10502730 chr18 37718186 A G 4.74E-04 Alzheimer's disease / / 17998437 rs2017653 chr18 37729761 T G 9.46E-04 Type 2 diabetes / / 17463246 rs4424971 chr18 37776163 G T 1.42E-04 Response to TNF antagonist treatment / / 21061259 rs11876920 chr18 37778232 G T 8.19E-05 Lipid levels / / pha003082 rs9947293 chr18 37789034 T C 3.20E-04 Smoking initiation / / 24665060 rs1943611 chr18 37808206 G A 4.89E-04 Lung function (forced vital capacity) / / 24023788 rs12327116 chr18 37882901 G A 2.75E-05 Creatinine levels / / pha003069 rs13381637 chr18 37889917 A C 2.05E-04 Alzheimer's disease (late onset) / / 21379329 rs1975204 chr18 37894077 C T 4.01E-04 Alzheimer's disease (late onset) / / 21379329 rs1368774 chr18 37899795 A G 5.15E-04 Longevity / / 22279548 rs10163673 chr18 37917964 T A 7.19E-05 IgE levels / / 22075330 rs1433862 chr18 37920879 T C 5.21E-05 Hypertension / / pha003041 rs9963583 chr18 37924645 A C 1.20E-05 Acute lung injury / / 22295056 rs7239895 chr18 37924667 T C 1.35E-04 Multiple complex diseases / / 17554300 rs16973135 chr18 37930012 T A 1.07E-04 Multiple complex diseases / / 17554300 rs10853472 chr18 37971735 A C 5.18E-05 Cardiovascular disease / / pha003065 rs12966097 chr18 37988095 A C 5.44E-04 Type 2 diabetes / / 17463246 rs10460060 chr18 37996055 A C 8.83E-05 Insulin Resistance / / pha003062 rs10460060 chr18 37996055 A C 8.88E-06 Insulin-related traits / / pha003063 rs7234952 chr18 37999748 T G 8.16E-05 Insulin Resistance / / pha003062 rs7234952 chr18 37999748 T G 8.16E-06 Insulin-related traits / / pha003063 rs16973295 chr18 38002731 A G 2.61E-04 Body mass index / / 17255346 rs16973295 chr18 38002731 A G 4.61E-05 Bipolar disorder / / 20451256 rs12963423 chr18 38005433 C T 2.52E-04 Type 2 diabetes / / 17463246 rs12963423 chr18 38005433 C T 7.65E-04 Multiple complex diseases / / 17554300 rs9304222 chr18 38011865 T G 2.90E-04 Type 2 diabetes / / 17463246 rs16973345 chr18 38015530 A G 1.96E-04 Body mass index / / 17255346 rs16973345 chr18 38015530 A G 3.15E-05 Prostate cancer / / 22923026 rs16973410 chr18 38029873 C T 1.94E-05 Response to lithium treatment in bipolar disorder / / 21961650 rs16973410 chr18 38029873 C T 3.42E-04 Response to lithium treatment in bipolar disorder / / 21961650 rs203150 chr18 38037221 A G 5.88E-05 Hypertension / / pha003042 rs7233091 chr18 38108623 G A 3.92E-04 Multiple complex diseases / / 17554300 rs4577168 chr18 38123271 A G 4.91E-04 Multiple complex diseases / / 17554300 rs7506165 chr18 38146351 C T 4.52E-04 Alzheimer's disease (late onset) / / 21379329 rs7504171 chr18 38156482 C T 4.52E-04 Alzheimer's disease (late onset) / / 21379329 rs3884664 chr18 38156644 C T 8.95E-04 Multiple complex diseases / / 17554300 rs10502739 chr18 38220099 C T 8.00E-06 Metabolite levels (X-11787) / / 23934736 rs2469875 chr18 38227098 A G 8.69E-05 Schizophrenia / / 19571809 rs2469875 chr18 38227098 A G 6.95E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs41472645 chr18 38268024 T G 5.48E-04 Body mass index / / 21701565 rs1436997 chr18 38288514 T C 8.87E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs16973693 chr18 38288556 C T 9.01E-04 Acute lung injury / / 22295056 rs226663 chr18 38292951 T C 7.85E-05 Socioeconomic Factors / / pha003067 rs16973702 chr18 38295620 T C 8.70E-04 Acute lung injury / / 22295056 rs8182398 chr18 38300181 C T 3.49E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs9950139 chr18 38302138 T A 2.57E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs17749027 chr18 38310763 G C,T 9.30E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs7241403 chr18 38317230 G A 8.70E-04 Acute lung injury / / 22295056 rs10502742 chr18 38317410 G A 6.55E-04 Acute lung injury / / 22295056 rs10502743 chr18 38321702 T C 5.39E-04 Acute lung injury / / 22295056 rs10502743 chr18 38321702 T C 7.62E-04 Smoking initiation / / 24665060 rs16973710 chr18 38323249 C T 5.01E-04 Acute lung injury / / 22295056 rs9959057 chr18 38324308 A G 7.53E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs8085392 chr18 38327610 G A 5.01E-04 Acute lung injury / / 22295056 rs9963340 chr18 38333985 T G 4.03E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs325360 chr18 38338281 A G 7.63E-05 Cognitive decline / / 22054870 rs16973713 chr18 38340207 G C 7.93E-04 Acute lung injury / / 22295056 rs12959903 chr18 38342272 G A 7.61E-04 Smoking initiation / / 24665060 rs1346703 chr18 38346383 G A 3.52E-04 Multiple complex diseases / / 17554300 rs1346703 chr18 38346383 G A 7.99E-04 Acute lung injury / / 22295056 rs8085429 chr18 38357795 G A 8.38E-04 Type 2 diabetes / / 22158537 rs16973745 chr18 38360625 A G 0.000182 Transmission distortion / / 22377632 rs2043152 chr18 38389284 G A 9.71E-04 Type 2 diabetes / / 22158537 rs1367685 chr18 38391824 A C 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1367683 chr18 38396134 A G 6.85E-04 Type 2 diabetes / / 22158537 rs17678242 chr18 38397623 C T 6.21E-04 Type 2 diabetes / / 22158537 rs1896950 chr18 38398156 G A 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs9946083 chr18 38401483 T G 6.61E-04 Type 2 diabetes / / 22158537 rs2195573 chr18 38403343 G A 6.85E-04 Type 2 diabetes / / 22158537 rs1896949 chr18 38410663 G A 7.92E-04 Type 2 diabetes / / 22158537 rs8099502 chr18 38418391 C T 7.80E-04 Type 2 diabetes / / 22158537 rs7236385 chr18 38420145 C A 8.39E-04 Type 2 diabetes / / 22158537 rs12458209 chr18 38422495 T A 3.02E-04 Type 2 diabetes / / 22158537 rs2567171 chr18 38441179 T C 9.24E-04 Type 2 diabetes / / 22158537 rs323598 chr18 38478813 C T 1.37E-04 Progressive supranuclear palsy / / 21685912 rs7229865 chr18 38517038 G A 3.37E-04 Height / / 17255346 rs1869282 chr18 38524259 C A 8.50E-05 Electrocardiographic conduction measures / / 19389651 rs1453029 chr18 38580171 T C 2.42E-07 Esophageal cancer (squamous cell) / / 22960999 rs4530229 chr18 38613586 A C 5.46E-04 Smoking initiation / / 24665060 rs2123473 chr18 38619600 A G 2.70E-05 Urinary metabolites / / 21572414 rs11665535 chr18 38628951 C A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7238667 chr18 38640705 C T 1.20E-05 Urinary metabolites / / 21572414 rs4486998 chr18 38669890 G T 2.72E-05 Bipolar disorder / / 18317468 rs4890286 chr18 38672977 G A 1.84E-05 Blood Pressure / / pha002903 rs16974057 chr18 38673320 G A 3.62E-04 Multiple complex diseases / / 17554300 rs4371242 chr18 38724649 T G 2.40E-06 Urinary metabolites / / 21572414 rs4609938 chr18 38724921 T C 2.75E-04 Smoking cessation / / 24665060 rs10502751 chr18 38725434 A T 6.80E-07 Urinary metabolites / / 21572414 rs5005414 chr18 38728795 G A 4.55E-05 Serum albumin level / / pha003084 rs17769226 chr18 38731837 T C 5.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17769226 chr18 38731837 T C 4.03E-05 Serum albumin level / / pha003084 rs10502752 chr18 38733962 G T 2.22E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17769347 chr18 38735059 A G 1.78E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17769347 chr18 38735059 A G 4.03E-05 Serum albumin level / / pha003084 rs16974138 chr18 38735952 G C 2.25E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17696757 chr18 38736742 T C 7.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17696757 chr18 38736742 T C 3.22E-05 Serum albumin level / / pha003084 rs16974139 chr18 38739067 C A 3.62E-05 Serum albumin level / / pha003084 rs2552493 chr18 38751659 T C 4.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2552489 chr18 38758207 T A 4.10E-06 Urinary metabolites / / 21572414 rs17697518 chr18 38765659 C T 7.00E-07 Obesity / / 22484627 rs12971263 chr18 38768209 T C 1.90E-04 Cognitive decline / / 23732972 rs8087566 chr18 38792674 G A 2.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1941590 chr18 38800431 C T 3.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8091768 chr18 38812558 C A 3.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4890708 chr18 38828458 A G 5.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1557324 chr18 38837001 G A 4.48E-05 Telomere length / / 23001564 rs4890712 chr18 38903507 C A 4.80E-04 Alcohol dependence / / 24277619 rs16974430 chr18 38938714 T G 5.84E-04 Multiple complex diseases / / 17554300 rs7245323 chr18 38965524 T C 8.33E-04 Alcohol dependence / / 24277619 rs2703167 chr18 39036343 A C 8.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs11874148 chr18 39038165 C T 3.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs4318293 chr18 39039714 C A 3.69E-04 Suicide attempts in bipolar disorder / / 21041247 rs17710973 chr18 39049013 T C 7.73E-04 Depression (quantitative trait) / / 20800221 rs2703175 chr18 39049087 A G 8.62E-04 Suicide attempts in bipolar disorder / / 21041247 rs7239339 chr18 39068238 G A 9.68E-04 Depression (quantitative trait) KC6 intron 20800221 rs12456335 chr18 39069132 C T 5.03E-04 Depression (quantitative trait) KC6 intron 20800221 rs12607607 chr18 39082090 C T 4.30E-04 Depression (quantitative trait) KC6 intron 20800221 rs12605092 chr18 39084977 A T 4.38E-04 Depression (quantitative trait) KC6 intron 20800221 rs2587642 chr18 39089205 C T 2.01E-04 Suicide attempts in bipolar disorder KC6 intron 21041247 rs12606140 chr18 39099218 C T 4.40E-04 Depression (quantitative trait) KC6 intron 20800221 rs11082237 chr18 39102899 A T 6.59E-04 Depression (quantitative trait) / / 20800221 rs17712291 chr18 39104470 T C 7.42E-04 Depression (quantitative trait) / / 20800221 rs2848760 chr18 39106472 G A 8.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs2703183 chr18 39108874 T A 8.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs2703176 chr18 39109040 C T 8.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs2612353 chr18 39109144 C T 3.26E-10 Multiple complex diseases / / 17554300 rs2587615 chr18 39110635 C T 8.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs2612344 chr18 39111022 C T 8.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs2612343 chr18 39111056 T C 8.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs2848766 chr18 39112394 A G 8.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs2848767 chr18 39112648 C T 8.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs2848768 chr18 39113436 T C 8.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs2612339 chr18 39114110 A G 7.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs2848770 chr18 39114857 A G 7.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs2587634 chr18 39119311 C T 7.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs2587632 chr18 39120180 C T 7.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs12606897 chr18 39121474 G A 4.89E-04 Depression (quantitative trait) / / 20800221 rs2612326 chr18 39140018 A G 7.62E-04 Multiple complex diseases / / 17554300 rs2587613 chr18 39164485 G A 9.33E-04 Multiple complex diseases / / 17554300 rs9954713 chr18 39183202 T A 2.30E-05 Multiple complex diseases / / 17554300 rs16975050 chr18 39187170 T G 5.00E-07 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4404160 chr18 39187890 G A 8.40E-04 Alzheimer's disease / / 22005930 rs11082240 chr18 39195969 G A 9.11E-05 Multiple complex diseases / / 17554300 rs9958032 chr18 39228310 C T 3.00E-06 Blood trace element (Zn levels) / / 23720494 rs1433928 chr18 39244966 T C 5.68E-04 Multiple complex diseases / / 17554300 rs1865288 chr18 39257639 C T 1.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4890354 chr18 39260616 T C 1.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8097884 chr18 39271041 T C 4.14E-05 Telomere length / / 23001564 rs1991891 chr18 39278375 T C 5.66E-06 Telomere length / / 23001564 rs9304251 chr18 39280378 G A,C,T 1.70E-05 Urinary metabolites / / 21572414 rs16975220 chr18 39292132 A G 3.63E-05 Multiple complex diseases / / 17554300 rs16975252 chr18 39325813 G A 9.36E-05 Bipolar disorder and schizophrenia / / 20889312 rs1433937 chr18 39363386 C G 0.000498 Salmonella-induced pyroptosis / / 22837397 rs17657594 chr18 39370967 C T 8.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9961679 chr18 39377518 G A 1.22E-04 Hearing function / / 17255346 rs1025443 chr18 39379699 G A 2.80E-05 Urinary metabolites / / 21572414 rs768343 chr18 39432678 C T 6.60E-05 Male fertility / / 22633400 rs9944879 chr18 39437187 C T 8.71E-05 Male fertility / / 22633400 rs9304257 chr18 39442352 A G 8.71E-05 Male fertility / / 22633400 rs1432145 chr18 39444514 C T 8.63E-04 Alzheimer's disease / / 22005930 rs987379 chr18 39448075 T G 8.71E-05 Male fertility / / 22633400 rs2878293 chr18 39464104 A G 1.02E-04 Aortic root size / / 21223598 rs7241193 chr18 39505006 G A 3.72E-04 Alzheimer's disease / / 17998437 rs1897396 chr18 39506254 A T 2.49E-04 Alzheimer's disease / / 17998437 rs1432138 chr18 39507776 T A 9.13E-04 Alzheimer's disease / / 17998437 rs12961563 chr18 39530811 G A 8.13E-04 Prostate cancer mortality / / 20978177 rs3813065 chr18 39534825 C T 5.00E-04 Systemic lupus erythematosus / / 20671926 rs52911 chr18 39554939 G A,C,T 3.19E-04 Alzheimer's disease PIK3C3 intron 17998437 rs10775471 chr18 39583699 G A 3.05E-04 Alzheimer's disease PIK3C3 intron 17998437 rs12455083 chr18 39627244 C T 1.69E-04 Alzheimer's disease PIK3C3 intron 17998437 rs948873 chr18 39673209 T A 1.12E-04 Alzheimer's disease / / 17998437 rs1557418 chr18 39676044 T C 2.78E-04 Alzheimer's disease / / 17998437 rs536139 chr18 39678486 A T 9.38E-04 Type 2 diabetes / / 17463246 rs12455611 chr18 39721225 C T 3.10E-05 Diabetes Mellitus / / pha003060 rs870833 chr18 39736681 G A 3.10E-05 Diabetes Mellitus / / pha003060 rs574957 chr18 39744969 G A 2.26E-05 Serum metabolites / / 19043545 rs483295 chr18 39747502 C T 4.95E-04 Multiple complex diseases / / 17554300 rs1941531 chr18 39768746 A G 7.27E-05 Diabetes Mellitus LOC284260 intron pha003060 rs1381342 chr18 39791233 G A 1.92E-04 Coronary heart disease LOC284260 intron 21971053 rs10084013 chr18 39823817 A G 3.36E-06 Hearing function LOC284260 intron 21493956 rs2219638 chr18 39843623 A T 4.61E-04 Multiple complex diseases LOC284260 intron 17554300 rs1381345 chr18 39872265 T G 3.84E-04 Multiple complex diseases LOC284260 intron 17554300 rs10502782 chr18 39885799 G A 1.28E-11 Gout LOC284260 intron pha001406 rs17610383 chr18 39892281 G A 1.72E-05 Duodenal ulcer LOC284260 intron 22387998 rs8095186 chr18 39913180 G A 9.80E-04 Suicidal ideation LOC284260 intron 22030708 rs9304270 chr18 39937509 C T 2.00E-06 Obesity-related traits LOC284260 intron 23251661 rs10502786 chr18 39938014 G A 2.23E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LOC284260 intron 24023788 rs346452 chr18 39940966 G A 2.00E-06 Periodontitis (PAL4Q3) LOC284260 intron 24024966 rs346449 chr18 39942308 C T 6.22E-06 Periodontitis (PAL4Q3) LOC284260 intron 24024966 rs346445 chr18 39943164 G A 3.84E-06 Periodontitis (PAL4Q3) LOC284260 intron 24024966 rs1442650 chr18 39970159 G C 4.85E-11 Multiple complex diseases LOC284260 intron 17554300 rs346221 chr18 40023306 G A 4.00E-06 Periodontitis (PAL4Q3) LOC284260 intron 24024966 rs12606301 chr18 40023782 G A 5.00E-06 Economic and political preferences (immigration/crime) LOC284260 intron 22566634 rs346195 chr18 40037779 G A 6.34E-06 Periodontitis (PAL4Q3) LOC284260 intron 24024966 rs11082277 chr18 40050363 G A 8.37E-05 Nicotine smoking LOC284260 intron 19268276 rs346230 chr18 40052746 C T 9.23E-06 Periodontitis (PAL4Q3) LOC284260 intron 24024966 rs7235528 chr18 40058882 T C 4.00E-06 Economic and political preferences (immigration/crime) LOC284260 intron 22566634 rs16976171 chr18 40059621 G T 4.00E-06 Coronary artery calcification LOC284260 intron 23870195 rs8090196 chr18 40075956 C T 3.00E-06 Economic and political preferences (immigration/crime) LOC284260 intron 22566634 rs1346987 chr18 40102641 C A 2.00E-06 Economic and political preferences (immigration/crime) LOC284260 intron 22566634 rs6507478 chr18 40105465 T A,G 3.67E-05 HDL cholesterol LOC284260 intron pha003075 rs7231412 chr18 40105657 T C 6.00E-06 Economic and political preferences (immigration/crime) LOC284260 intron 22566634 rs7239883 chr18 40147671 G A 2.20E-05 Urinary metabolites LOC284260 intron 21572414 rs7239883 chr18 40147671 G A 9.88E-04 Myocardial Infarction LOC284260 intron pha002883 rs9964460 chr18 40156291 G A 8.12E-05 Major depressive disorder (broad) LOC284260 intron 20038947 rs7238529 chr18 40161451 A G 7.90E-05 Major depressive disorder (broad) LOC284260 intron 20038947 rs7228101 chr18 40166871 A G 7.34E-05 Major depressive disorder (broad) LOC284260 intron 20038947 rs17694970 chr18 40182606 A G 1.00E-06 Asthma LOC284260 intron 21790008 rs17694970 chr18 40182606 A G 2.00E-06 Asthma LOC284260 intron 21790008 rs17694970 chr18 40182606 A G 2.00E-06 Asthma LOC284260 intron 21790008 rs2878722 chr18 40183618 G A 7.51E-05 Celiac disease LOC284260 intron 23936387 rs8085520 chr18 40184499 C T 6.04E-04 Multiple complex diseases LOC284260 intron 17554300 rs613691 chr18 40196798 A C 1.70E-05 Urinary metabolites LOC284260 intron 21572414 rs12959352 chr18 40225279 A G 7.09E-05 Obesity (extreme) LOC284260 intron 21935397 rs8085804 chr18 40288293 C T 8.00E-06 Cognitive performance / / 19734545 rs618236 chr18 40334100 T G 6.34E-05 Colorectal cancer RIT2 intron 19723657 rs17634039 chr18 40390563 A G 8.82E-04 Alzheimer's disease RIT2 intron 22005930 rs16976979 chr18 40404217 A G 4.58E-04 Alzheimer's disease RIT2 intron 22005930 rs17634573 chr18 40405282 G C 4.20E-04 Alzheimer's disease RIT2 intron 22005930 rs17712687 chr18 40407149 A G 4.19E-04 Alzheimer's disease RIT2 intron 22005930 rs17634648 chr18 40407175 T C 4.20E-04 Alzheimer's disease RIT2 intron 22005930 rs16976993 chr18 40408370 A C 4.16E-04 Alzheimer's disease RIT2 intron 22005930 rs10502802 chr18 40409146 A G 4.50E-04 Alzheimer's disease RIT2 intron 22005930 rs16977004 chr18 40409602 T G 4.15E-04 Alzheimer's disease RIT2 intron 22005930 rs17712831 chr18 40410219 A C 4.18E-04 Alzheimer's disease RIT2 intron 22005930 rs7231491 chr18 40413225 C T 4.16E-04 Alzheimer's disease RIT2 intron 22005930 rs17713111 chr18 40413991 T C 4.14E-04 Alzheimer's disease RIT2 intron 22005930 rs1943946 chr18 40414893 A C 6.12E-04 Alzheimer's disease RIT2 intron 22005930 rs632168 chr18 40416651 A C 7.70E-04 Alzheimer's disease RIT2 intron 22005930 rs630915 chr18 40416933 A C 7.68E-04 Alzheimer's disease RIT2 intron 22005930 rs482472 chr18 40417473 T A 3.66E-04 Alzheimer's disease RIT2 intron 22005930 rs17635398 chr18 40417845 A G 3.54E-04 Alzheimer's disease RIT2 intron 22005930 rs473976 chr18 40418431 C T 5.03E-04 Alzheimer's disease RIT2 intron 22005930 rs8088908 chr18 40420814 T C 3.67E-04 Alzheimer's disease RIT2 intron 22005930 rs8087737 chr18 40421936 C T 3.65E-04 Alzheimer's disease RIT2 intron 22005930 rs17713637 chr18 40423030 T C 3.66E-04 Alzheimer's disease RIT2 intron 22005930 rs649056 chr18 40423146 T C 5.02E-04 Alzheimer's disease RIT2 intron 22005930 rs17635641 chr18 40423700 G C 2.31E-04 Alzheimer's disease RIT2 intron 22005930 rs679891 chr18 40427497 G T 4.97E-04 Alzheimer's disease RIT2 intron 22005930 rs17713884 chr18 40430468 G A 3.66E-04 Alzheimer's disease RIT2 intron 22005930 rs17635858 chr18 40431879 T C 5.45E-04 Alzheimer's disease RIT2 intron 22005930 rs16977065 chr18 40437651 C T 1.00E-07 Response to tocilizumab in rheumatoid arthritis RIT2 intron 22491018 rs684446 chr18 40438444 T G 4.23E-04 Alzheimer's disease RIT2 intron 22005930 rs4890241 chr18 40442972 G C 3.40E-04 Alzheimer's disease RIT2 intron 22005930 rs17714417 chr18 40448275 A G 3.51E-04 Alzheimer's disease RIT2 intron 22005930 rs8093756 chr18 40453147 T C 3.46E-04 Alzheimer's disease RIT2 intron 22005930 rs1944413 chr18 40454451 A G 3.42E-04 Alzheimer's disease RIT2 intron 22005930 rs488136 chr18 40458873 T C 6.34E-04 Alzheimer's disease RIT2 intron 22005930 rs551291 chr18 40461143 A C 7.33E-04 Alzheimer's disease RIT2 intron 22005930 rs8093580 chr18 40462255 A T 3.15E-04 Alzheimer's disease RIT2 intron 22005930 rs4890413 chr18 40462441 T C 5.01E-04 Alzheimer's disease RIT2 intron 22005930 rs16977074 chr18 40464570 T C 5.39E-04 Alzheimer's disease RIT2 intron 22005930 rs17714864 chr18 40465044 T C 3.08E-04 Alzheimer's disease RIT2 intron 22005930 rs8091643 chr18 40465696 A G 1.98E-04 Alzheimer's disease RIT2 intron 22005930 rs4890414 chr18 40466178 A T 3.08E-04 Alzheimer's disease RIT2 intron 22005930 rs4890416 chr18 40466265 G A 3.08E-04 Alzheimer's disease RIT2 intron 22005930 rs4890417 chr18 40466457 C A 4.24E-04 Alzheimer's disease RIT2 intron 22005930 rs8084102 chr18 40467505 C T 3.01E-04 Alzheimer's disease RIT2 intron 22005930 rs8085172 chr18 40467577 T C 2.97E-04 Alzheimer's disease RIT2 intron 22005930 rs8088192 chr18 40468053 C T 2.83E-04 Alzheimer's disease RIT2 intron 22005930 rs8089316 chr18 40468883 A G 2.54E-04 Alzheimer's disease RIT2 intron 22005930 rs8094360 chr18 40470953 G A 1.54E-04 Alzheimer's disease RIT2 intron 22005930 rs540570 chr18 40473343 T C 0.0005294 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RIT2 intron 23233654 rs540570 chr18 40473343 T C 5.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) RIT2 intron 23233662 rs489718 chr18 40475219 C T 5.02E-05 Body Mass Index RIT2 intron pha003014 rs472591 chr18 40483622 A G 9.63E-05 Body Mass Index RIT2 intron pha003014 rs565924 chr18 40509304 C T 8.73E-04 Multiple complex diseases RIT2 intron 17554300 rs16977161 chr18 40545122 A G 7.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RIT2 intron 20877124 rs10502807 chr18 40548004 C T 9.81E-05 Smoking initiation RIT2 intron 24665060 rs1945004 chr18 40554893 C T 1.20E-05 Urinary metabolites RIT2 intron 21572414 rs1945004 chr18 40554893 C T 6.76E-05 Parkinson's disease RIT2 intron 21738487 rs879215 chr18 40557661 T C 1.00E-04 Cognitive impairment induced by topiramate RIT2 intron 22091778 rs7407708 chr18 40565905 G A 9.51E-05 Parkinson's disease RIT2 intron 21738487 rs9958208 chr18 40591084 G A,C,T 5.00E-06 Acute lymphoblastic leukemia (childhood) RIT2 intron 23007406 rs9958002 chr18 40591103 A T 6.51E-04 Multiple complex diseases RIT2 intron 17554300 rs9962882 chr18 40601298 T C 8.21E-05 Parkinson's disease RIT2 intron 21738487 rs4341830 chr18 40619706 G A 8.36E-04 Type 2 diabetes RIT2 intron 17463246 rs11663460 chr18 40635415 T C 9.75E-04 Multiple complex diseases RIT2 intron 17554300 rs11663460 chr18 40635415 T C 2.70E-05 Urinary metabolites RIT2 intron 21572414 rs7244651 chr18 40655156 T C 1.58E-27 Narcolepsy RIT2 intron 19629137 rs4441358 chr18 40657643 G A 2.10E-05 Urinary metabolites RIT2 intron 21572414 rs4890426 chr18 40672418 T G 1.99E-05 Parkinson's disease RIT2 intron 21738487 rs12456492 chr18 40673380 A G 2.00E-10 Parkinson's disease RIT2 intron 22451204 rs4130047 chr18 40678235 T C 2.00E-07 Parkinson's disease RIT2 intron 21738487 rs7241952 chr18 40681125 T C 4.36E-05 Multiple complex diseases RIT2 intron 17554300 rs8096948 chr18 40681293 T C 3.13E-05 Parkinson's disease RIT2 intron 21738487 rs17645716 chr18 40722791 A T 1.68E-04 Type 2 diabetes / / 17463246 rs1076971 chr18 40765236 C A 8.63E-05 Type 2 diabetes / / 17463246 rs1076971 chr18 40765236 C A 8.01E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs12605134 chr18 40766524 G T 8.33E-04 Depression (quantitative trait) / / 20800221 rs17664267 chr18 40808798 G T 7.00E-06 Conduct disorder (interaction) / / 18846501 rs17664267 chr18 40808798 G T 3.85E-28 Narcolepsy / / 19629137 rs9955650 chr18 40831637 C T 7.54E-05 Major depressive disorder / / 22472876 rs16977454 chr18 40862247 C A 2.26E-05 Major depressive disorder / / 22472876 rs583338 chr18 40872233 T C 3.00E-05 Suicidal ideation / / 22030708 rs12457996 chr18 40872273 T C 6.00E-06 Major depressive disorder / / 21042317 rs12457996 chr18 40872273 T C 1.21E-05 Major depressive disorder / / 22472876 rs12457996 chr18 40872273 T C 5.70E-06 Depression (quantitative trait) / / 23290196 rs633595 chr18 41012629 C T 2.40E-04 Multiple complex diseases / / 17554300 rs642666 chr18 41021213 G A 8.26E-04 Multiple complex diseases / / 17554300 rs1527436 chr18 41113801 T G 9.33E-05 Multiple sclerosis (age of onset) / / 19010793 rs4393648 chr18 41168311 A G 2.36E-04 Smoking initiation / / 24665060 rs9950114 chr18 41176419 T A 4.15E-04 Smoking initiation / / 24665060 rs4890257 chr18 41192213 G A 1.18E-04 Aortic root size / / 21223598 rs9953470 chr18 41207659 T C 1.38E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9967274 chr18 41208306 C T 3.82E-04 Smoking initiation / / 24665060 rs2884665 chr18 41218025 T C 4.10E-06 Coronary spasm / / 18075462 rs920459 chr18 41251229 G A 2.33E-04 Multiple complex diseases / / 17554300 rs1967349 chr18 41253982 T C 3.37E-04 Multiple complex diseases / / 17554300 rs9966787 chr18 41308774 G A 7.44E-04 Parkinson's disease / / 16252231 rs12327091 chr18 41422451 C A 9.80E-04 Iron levels / / pha002876 rs1460521 chr18 41440151 C T 5.91E-05 Left ventricular hypertrophy / / pha003052 rs9675420 chr18 41467746 G A 6.63E-05 Multiple complex diseases / / 17554300 rs2169195 chr18 41474764 A T 5.13E-04 Type 2 diabetes / / 17463246 rs1380836 chr18 41480527 C T 2.00E-06 Obesity-related traits / / 23251661 rs2169197 chr18 41482252 A G 2.51E-04 Type 2 diabetes / / 17463246 rs2169197 chr18 41482252 A G 8.98E-04 Multiple complex diseases / / 17554300 rs8096705 chr18 41515845 T C 9.30E-05 Neuroticism / / 23229837 rs9954495 chr18 41558218 A G 7.72E-04 Type 2 diabetes / / 17463246 rs7229537 chr18 41559142 G A 6.47E-04 Type 2 diabetes / / 17463246 rs7230555 chr18 41559268 T G 8.98E-04 Type 2 diabetes / / 17463246 rs7229587 chr18 41559321 C G 2.08E-04 Type 2 diabetes / / 17463246 rs2359590 chr18 41579197 T C 3.41E-04 Type 2 diabetes / / 17463246 rs1015735 chr18 41623323 T C 9.68E-05 Follicular lymphoma / / 21533074 rs4340393 chr18 41630054 C T 9.05E-05 Follicular lymphoma / / 21533074 rs8099736 chr18 41685818 G T 7.50E-05 Otosclerosis / / 19230858 rs12957481 chr18 41691798 T C 2.13E-04 Parkinson's disease / / 17052657 rs623922 chr18 41728933 G C 6.43E-04 Alzheimer's disease / / 17998437 rs1878315 chr18 41728970 A G 8.87E-05 Body mass (lean) / / 19268274 rs17767634 chr18 41796551 C T 7.35E-04 Prostate cancer mortality / / 20978177 rs17767808 chr18 41797982 T G 7.86E-04 Prostate cancer mortality / / 20978177 rs717139 chr18 41819425 C T 6.12E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9675482 chr18 41823537 T C 5.06E-04 Alzheimer's disease / / 17998437 rs11082375 chr18 41837838 T A 4.35E-04 Alzheimer's disease / / 17998437 rs1456611 chr18 41843006 A C 7.80E-05 Alzheimer's disease / / 17998437 rs1456610 chr18 41843945 A G 2.53E-04 Alzheimer's disease / / 17998437 rs8099490 chr18 41846902 G A 1.50E-04 Alzheimer's disease / / 17998437 rs3951468 chr18 41873027 C T 5.22E-04 Coronary Artery Disease / / 17634449 rs12968853 chr18 41903433 C T 8.71E-05 Arthritis (juvenile idiopathic) / / 22354554 rs9304309 chr18 41981339 A G 6.90E-06 Bilirubin levels / / 19414484 rs8087876 chr18 42015661 G T 8.80E-06 Urinary metabolites / / 21572414 rs10502827 chr18 42034018 C T 6.68E-04 Bipolar disorder / / 19259986 rs9961416 chr18 42037193 A G 1.60E-05 Urinary metabolites / / 21572414 rs9951264 chr18 42037678 T G 3.50E-05 Bilirubin levels / / 19414484 rs10853517 chr18 42039010 G A 3.10E-05 Bilirubin levels / / 19414484 rs9967515 chr18 42044589 C T 3.00E-05 Bilirubin levels / / 19414484 rs7230479 chr18 42044962 A C 1.60E-05 Urinary metabolites / / 21572414 rs9957037 chr18 42048214 A C 6.51E-06 Hirschsprung's disease / / 19196962 rs9957037 chr18 42048214 A C 8.00E-06 Urinary metabolites / / 21572414 rs9957243 chr18 42048495 A G 3.30E-05 Bilirubin levels / / 19414484 rs1511764 chr18 42051776 T A 3.00E-05 Bilirubin levels / / 19414484 rs1511765 chr18 42052201 C T 2.70E-05 Bilirubin levels / / 19414484 rs2359894 chr18 42055272 C A 1.10E-04 Sleep and circadian phenotypes / / 17903308 rs2359894 chr18 42055272 C A 8.00E-06 Urinary metabolites / / 21572414 rs2221838 chr18 42055478 A G 2.00E-05 Bilirubin levels / / 19414484 rs1397987 chr18 42055874 A G 2.00E-05 Bilirubin levels / / 19414484 rs1511767 chr18 42057696 C G 1.90E-05 Bilirubin levels / / 19414484 rs1828532 chr18 42059132 G A 1.90E-05 Bilirubin levels / / 19414484 rs4410172 chr18 42061728 G C 1.90E-05 Bilirubin levels / / 19414484 rs12605825 chr18 42068006 T C 9.10E-06 Bilirubin levels / / 19414484 rs12605825 chr18 42068006 T C 7.90E-06 Urinary metabolites / / 21572414 rs16978026 chr18 42068053 A G 9.10E-06 Bilirubin levels / / 19414484 rs16978026 chr18 42068053 A G 9.40E-06 Urinary metabolites / / 21572414 rs12604201 chr18 42069477 C A 9.30E-06 Bilirubin levels / / 19414484 rs9956825 chr18 42078046 C A 1.40E-05 Urinary metabolites / / 21572414 rs2048485 chr18 42090667 C T 8.00E-06 Schizophrenia / / 22885689 rs4321282 chr18 42091035 A G 1.10E-05 Urinary metabolites / / 21572414 rs8083820 chr18 42098942 T G 2.30E-05 Urinary metabolites / / 21572414 rs1983249 chr18 42134447 A G 5.41E-05 HIV-1 control / / 20041166 rs1983249 chr18 42134447 A G 6.72E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs4467169 chr18 42152467 A G 1.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4467169 chr18 42152467 A G 2.67E-04 Celiac disease / / 23936387 rs10164078 chr18 42155773 G A 1.59E-04 Celiac disease / / 23936387 rs1563992 chr18 42245766 C T 1.10E-05 Urinary metabolites / / 21572414 rs12958322 chr18 42309786 T C 5.14E-05 Multiple complex diseases SETBP1 intron 17554300 rs17782904 chr18 42313710 G A 9.04E-05 IgE levels SETBP1 intron 22075330 rs17710169 chr18 42314009 C G 8.77E-05 IgE levels SETBP1 intron 22075330 rs11082403 chr18 42317790 T G 2.00E-06 Triglycerides SETBP1 intron 19074352 rs11082403 chr18 42317790 T G 2.00E-06 Polyunsaturated fatty acid levels,in plasma SETBP1 intron 19148276 rs11082403 chr18 42317790 T G 8.25E-05 IgE levels SETBP1 intron 22075330 rs17710446 chr18 42318188 C T 8.06E-04 Type 2 diabetes SETBP1 intron 17463246 rs17783459 chr18 42329076 C A 0.00000334 Platelet thrombus as measured by PFA-100ColA closure time upon shear stress SETBP1 intron 22550155 rs16978185 chr18 42404038 A G 4.84E-04 Multiple complex diseases SETBP1 intron 17554300 rs6507588 chr18 42419103 C T 1.10E-05 Diabetes Mellitus SETBP1 intron pha003060 rs9956543 chr18 42419575 A T 1.55E-04 Multiple complex diseases SETBP1 intron 17554300 rs12965289 chr18 42423162 G T 3.10E-05 White matter hyperintensity burden SETBP1 intron 21681796 rs665997 chr18 42427597 T C 3.00E-05 White matter hyperintensity burden SETBP1 intron 21681796 rs622759 chr18 42429091 G C 5.90E-05 White matter hyperintensity burden SETBP1 intron 21681796 rs991014 chr18 42439886 C T 6.00E-10 Ventricular conduction SETBP1 intron 21076409 rs678726 chr18 42440229 C T 7.60E-05 White matter hyperintensity burden SETBP1 intron 21681796 rs654269 chr18 42444241 G A 2.80E-05 White matter hyperintensity burden SETBP1 intron 21681796 rs11660213 chr18 42481985 A G 2.04E-04 Prion diseases SETBP1 intron 22210626 rs616444 chr18 42485524 A C 9.00E-05 Type 2 diabetes SETBP1 intron 17463248 rs3744825 chr18 42532606 G A 9.56E-04 White matter integrity SETBP1 missense 22425255 rs9783858 chr18 42534584 C T 1.50E-05 Urinary metabolites SETBP1 intron 21572414 rs17726928 chr18 42538724 G A 7.80E-06 Urinary metabolites SETBP1 intron 21572414 rs9962988 chr18 42557018 A G 4.93E-04 Multiple complex diseases SETBP1 intron 17554300 rs11082417 chr18 42566287 C T 5.40E-05 Serum metabolites SETBP1 intron 19043545 rs716152 chr18 42605872 C A 5.30E-05 Lung adenocarcinoma SETBP1 intron 22797724 rs9967367 chr18 42606091 C T 4.90E-05 Lung adenocarcinoma SETBP1 intron 22797724 rs10502849 chr18 42612091 C T 6.53E-05 Alzheimer's disease (late onset) SETBP1 intron 21379329 rs10502849 chr18 42612091 C T 9.41E-05 Sensory disturbances after bilateral sagittal split ramus osteotomy SETBP1 intron 23834954 rs7228266 chr18 42620533 G A 1.21E-05 Sensory disturbances after bilateral sagittal split ramus osteotomy SETBP1 intron 23834954 rs1893486 chr18 42689285 C T 4.26E-05 Type 2 diabetes / / 17463246 rs4890526 chr18 42720724 A G 4.58E-04 White matter integrity / / 22425255 rs1942574 chr18 42725529 G A 7.94E-22 Breast cancer (Postmenopausal women) / / 23423446 rs998124 chr18 42725662 A G 5.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs8089498 chr18 42748365 A G 9.37E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs8083006 chr18 42789492 C T 3.25E-09 Male-pattern baldness / / 22693459 rs10502860 chr18 42799809 A G 2.80E-05 Type 2 diabetes SLC14A2 intron 17460697 rs10502861 chr18 42800148 C T 5.30E-04 Crohn's disease SLC14A2 intron 17684544 rs10502861 chr18 42800148 C T 3.00E-09 Male-pattern baldness SLC14A2 intron 22693459 rs1381556 chr18 42803331 T C 3.70E-09 Male-pattern baldness SLC14A2 intron 22693459 rs1350905 chr18 42804140 A G 3.74E-09 Male-pattern baldness SLC14A2 intron 22693459 rs1350904 chr18 42804399 G A 3.74E-09 Male-pattern baldness SLC14A2 intron 22693459 rs12606816 chr18 42804525 A G 3.85E-09 Male-pattern baldness SLC14A2 intron 22693459 rs12959797 chr18 42807933 G A 3.40E-09 Male-pattern baldness SLC14A2 intron 22693459 rs8098865 chr18 42810387 A G 3.85E-09 Male-pattern baldness SLC14A2 intron 22693459 rs1903647 chr18 42812895 A G 9.84E-09 Male-pattern baldness SLC14A2 intron 22693459 rs1903646 chr18 42812979 T A 9.40E-09 Male-pattern baldness SLC14A2 intron 22693459 rs8085664 chr18 42814156 C A 1.07E-08 Male-pattern baldness SLC14A2 intron 22693459 rs7230186 chr18 42814492 C G 9.14E-09 Male-pattern baldness SLC14A2 intron 22693459 rs11082435 chr18 42818527 T C 8.27E-09 Male-pattern baldness SLC14A2 intron 22693459 rs11664621 chr18 42821457 C T 9.36E-09 Male-pattern baldness SLC14A2 intron 22693459 rs7240906 chr18 42821700 T C 8.69E-09 Male-pattern baldness SLC14A2 intron 22693459 rs6507604 chr18 42821965 T C 6.06E-09 Male-pattern baldness SLC14A2 intron 22693459 rs11659892 chr18 42823267 A C 3.46E-04 Multiple complex diseases SLC14A2 intron 17554300 rs16978310 chr18 42823514 A G 5.74E-04 Multiple complex diseases SLC14A2 intron 17554300 rs7235910 chr18 42823994 G C 5.42E-04 Multiple complex diseases SLC14A2 intron 17554300 rs7235815 chr18 42824095 C T 0.000554 Asthma SLC14A2 intron 22502797 rs7237237 chr18 42902001 C T 8.10E-05 Temperament (bipolar disorder) SLC14A2 intron 22365631 rs12326278 chr18 42908391 C T 7.39E-04 Multiple complex diseases SLC14A2 intron 17554300 rs16978345 chr18 42924995 A G 6.20E-05 Temperament (bipolar disorder) SLC14A2 intron 22365631 rs12607452 chr18 42928169 C T 5.00E-05 Temperament (bipolar disorder) SLC14A2 intron 22365631 rs2243803 chr18 42956672 T A 3.00E-07 Menarche (age at onset) SLC14A2 intron 21102462 rs2014869 chr18 42966587 C T 7.07E-04 Multiple complex diseases SLC14A2 intron 17554300 rs2014869 chr18 42966587 C T 3.89E-04 Smoking initiation SLC14A2 intron 24665060 rs9807288 chr18 42972154 C G 2.86E-04 Response to taxane treatment (placlitaxel) SLC14A2 intron 23006423 rs1421201 chr18 42972289 A G 6.72E-05 Non-alcoholic fatty liver disease histology (other) SLC14A2 intron 20708005 rs1362838 chr18 42974182 A G 6.73E-04 Response to taxane treatment (placlitaxel) SLC14A2 intron 23006423 rs2612561 chr18 42982959 C T 5.07E-04 Response to taxane treatment (placlitaxel) SLC14A2 intron 23006423 rs17823562 chr18 42988088 C A 1.01E-04 Response to taxane treatment (placlitaxel) SLC14A2 intron 23006423 rs17750770 chr18 42988330 T A 5.00E-05 Serum metabolites SLC14A2 intron 19043545 rs17750770 chr18 42988330 T A 1.03E-04 Response to taxane treatment (placlitaxel) SLC14A2 intron 23006423 rs888433 chr18 42989212 T G 9.28E-04 Suicide attempts in bipolar disorder SLC14A2 intron 21423239 rs7230301 chr18 42990753 T G 1.36E-04 Response to taxane treatment (placlitaxel) SLC14A2 intron 23006423 rs2885618 chr18 42990841 G A 4.80E-05 Kidney function and endocine traits SLC14A2 intron 17903292 rs7242620 chr18 42990931 A G 5.32E-04 Response to taxane treatment (placlitaxel) SLC14A2 intron 23006423 rs4622609 chr18 42998976 A G 7.10E-04 Response to taxane treatment (placlitaxel) SLC14A2 intron 23006423 rs11877050 chr18 43006308 C A 6.13E-04 Type 2 diabetes SLC14A2 intron 17463246 rs6507618 chr18 43032283 C A 7.92E-05 Age-related macular degeneration SLC14A2 intron pha000002 rs2612545 chr18 43033662 G A 9.33E-05 Waist Circumference SLC14A2 intron pha003025 rs10502863 chr18 43038800 G A 9.93E-05 Body mass index SLC14A2 intron 22446040 rs2542995 chr18 43044432 T G 4.00E-05 Type 2 diabetes and 6 quantitative traits SLC14A2 intron 17848626 rs2543007 chr18 43051699 T C 6.53E-08 Tuberculosis SLC14A2 intron 22306650 rs2052370 chr18 43070051 C T 2.73E-05 Body Mass Index SLC14A2 intron pha003009 rs1833418 chr18 43094069 G C 5.90E-06 Urinary metabolites SLC14A2 intron 21572414 rs7236548 chr18 43097750 C A 1.60E-05 Urinary metabolites SLC14A2 intron 21572414 rs2543029 chr18 43098275 C A 2.60E-05 Urinary metabolites SLC14A2 intron 21572414 rs11875613 chr18 43100966 T G 1.60E-06 Urinary metabolites SLC14A2 intron 21572414 rs8099211 chr18 43103958 G A 8.01E-04 Alcohol dependence SLC14A2 intron 20201924 rs8099273 chr18 43104212 A G 6.66E-05 Alcohol dependence SLC14A2 intron 20201924 rs8099273 chr18 43104212 A G 6.66E-05 Alcoholism SLC14A2 intron pha002891 rs2543025 chr18 43149976 T C 2.84E-04 Premature ovarian failure SLC14A2 intron 19508998 rs10502868 chr18 43153949 T C 7.00E-06 Biochemical measures SLC14A2 intron 19260141 rs1815956 chr18 43160411 T A 7.89E-05 Response to statin treatment (atorvastatin),change in cholesterol levels SLC14A2 intron 20031582 rs10775478 chr18 43162894 T G 3.99E-04 Premature ovarian failure SLC14A2 intron 19508998 rs4890552 chr18 43167421 A C 8.00E-04 Premature ovarian failure SLC14A2 intron 19508998 rs7227483 chr18 43187130 A G 7.00E-18 Renal function-related traits (BUN) SLC14A2 intron 22797727 rs1385340 chr18 43190600 G A 7.70E-06 Urinary metabolites SLC14A2 intron 21572414 rs7232775 chr18 43202404 C T 8.00E-14 Metabolite levels SLC14A2 intron 21909109 rs1484873 chr18 43206985 A G 1.08E-05 Body Mass Index SLC14A2 missense pha003009 rs1484875 chr18 43213473 C T 9.40E-06 Urinary metabolites SLC14A2 intron 21572414 rs4890568 chr18 43231622 G A 2.00E-10 Blood cell counts and other traits SLC14A2 intron 20139978 rs4890568 chr18 43231622 G A 2.02E-10 Blood cell counts and other traits SLC14A2 intron 20139978 rs7243707 chr18 43232274 A C 6.10E-04 Alcohol dependence SLC14A2 intron 20201924 rs16978435 chr18 43233400 T C 7.89E-23 Narcolepsy SLC14A2 intron 19629137 rs949022 chr18 43234904 G A 3.30E-05 Cognitive impairment induced by topiramate SLC14A2 intron 22091778 rs900973 chr18 43235882 T G 1.46E-05 Cognitive impairment induced by topiramate SLC14A2 intron 22091778 rs12454702 chr18 43236930 A G 3.98E-04 Type 2 diabetes SLC14A2 intron 17463246 rs8087798 chr18 43242836 C T 3.99E-04 Multiple complex diseases SLC14A2 intron 17554300 rs1123617 chr18 43252883 G A 1 Drug response to Nifedipine SLC14A2 missense 17344938 rs871465 chr18 43257345 G A 3.66E-04 Multiple complex diseases SLC14A2 intron 17554300 rs16978444 chr18 43258364 G A 7.25E-04 Type 2 diabetes SLC14A2 intron 17463246 rs3745009 chr18 43262359 G A 1 Drug response to Nifedipine SLC14A2 missense 17344938 rs16978453 chr18 43268318 C T 7.36E-04 Type 2 diabetes / / 17463246 rs3760578 chr18 43302976 C T 2.96E-04 Blood pressure SLC14A1 nearGene-5 17255346 rs10460032 chr18 43303089 A G 9.41E-05 Vaspin levels SLC14A1 nearGene-5 22907691 rs10460032 chr18 43303089 A G 0.0000941 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks SLC14A1 nearGene-5 22907730 rs10460032 chr18 43303089 A G 0.0002378 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit SLC14A1 nearGene-5 22907730 rs11877062 chr18 43307246 C T 0.00085 Prostate cancer SLC14A1 missense 23555315 rs17674580 chr18 43309911 C T 8.00E-11 Bladder cancer SLC14A1 intron 21750109 rs17674580 chr18 43309911 C T 4.00E-05 Urinary bladder cancer SLC14A1 intron 24861552 rs7238033 chr18 43316966 T C 9.00E-09 Bladder cancer SLC14A1 intron 21824976 rs7238033 chr18 43316966 T C 8.40E-05 Urinary bladder cancer SLC14A1 intron 24861552 rs16978475 chr18 43317005 T C 2.30E-05 Urinary metabolites SLC14A1 intron 21572414 rs10775480 chr18 43317282 T C 8.90E-09 Bladder cancer SLC14A1 intron 21824976 rs10775480 chr18 43317282 T C 6.00E-08 Bladder cancer SLC14A1 intron 24163127 rs10853535 chr18 43317547 C T 4.40E-06 Bladder cancer SLC14A1 intron 21824976 rs11082469 chr18 43321269 A G 1.80E-05 Bladder cancer SLC14A1 intron 21824976 rs11082469 chr18 43321269 A G 1.60E-22 Kidd system Jka antigen SLC14A1 intron 22611595 rs16978485 chr18 43335922 G A 4.10E-06 Urinary metabolites / / 21572414 rs477397 chr18 43411190 C A 3.31E-04 Response to taxane treatment (placlitaxel) SIGLEC15 intron 23006423 rs518464 chr18 43436221 T C 1.72E-05 Schizophrenia(age at onset) EPG5 intron 21688384 rs616345 chr18 43554371 T G 8.77E-04 Taste perception / / 22132133 rs920296 chr18 43562851 G T 2.57E-04 Smoking quantity / / 24665060 rs920295 chr18 43563022 C T 1.85E-04 Smoking cessation / / 24665060 rs688547 chr18 43591273 A G 5.34E-04 Smoking quantity PSTPIP2 intron 24665060 rs4890614 chr18 43593870 A G 6.88E-05 Schizophrenia PSTPIP2 intron pha002859 rs4890617 chr18 43622800 T C 5.04E-04 Smoking quantity PSTPIP2 intron 24665060 rs4890619 chr18 43631759 T C 6.16E-06 Aortic root size PSTPIP2 intron 21223598 rs4890620 chr18 43631858 G A 2.23E-05 Aortic root size PSTPIP2 intron 21223598 rs4890620 chr18 43631858 G A 9.07E-04 Insulin resistance PSTPIP2 intron 21901158 rs16978521 chr18 43640364 G A 3.86E-04 Multiple complex diseases PSTPIP2 intron 17554300 rs9807399 chr18 43640714 A C 1.06E-04 HIV-1 viral setpoint PSTPIP2 intron 17641165 rs9807399 chr18 43640714 A C 7.12E-05 HIV-1 viral setpoint PSTPIP2 intron 21490045 rs12955201 chr18 43643435 A C 1.14E-04 HIV-1 viral setpoint PSTPIP2 intron 17641165 rs12955201 chr18 43643435 A C 6.17E-05 HIV-1 viral setpoint PSTPIP2 intron 21490045 rs9950234 chr18 43653200 T C 1.59E-07 Red blood cell traits / / 23222517 rs9955008 chr18 43658888 G A 2.82E-07 Red blood cell traits / / 23222517 rs3745004 chr18 43660400 C A 4.63E-04 Multiple complex diseases / / 17554300 rs3745004 chr18 43660400 C A 7.20E-05 Myasthenia gravis / / 23055271 rs3745004 chr18 43660400 C A 4.05E-04 Iron levels / / pha002876 rs8088881 chr18 43664970 T C 7.41E-05 Height ATP5A1 intron pha003011 rs7244921 chr18 43667528 T C 6.96E-04 HIV-1 viral setpoint ATP5A1 intron 17641165 rs7244921 chr18 43667528 T C 6.16E-05 Height ATP5A1 intron pha003011 rs13381709 chr18 43670988 C T 7.86E-04 HIV-1 viral setpoint ATP5A1 intron 17641165 rs13381709 chr18 43670988 C T 6.15E-05 Height ATP5A1 intron pha003011 rs8089150 chr18 43674300 A G 6.96E-04 HIV-1 viral setpoint ATP5A1 intron 17641165 rs8089150 chr18 43674300 A G 5.81E-05 Height ATP5A1 intron pha003011 rs11874712 chr18 43688576 C A 2.00E-07 Migraine - clinic-based HAUS1 intron 23793025 rs8083916 chr18 43694676 C A 8.54E-04 Suicide attempts in bipolar disorder HAUS1 intron 21041247 rs1866321 chr18 43698309 C T 4.51E-07 Red blood cell traits HAUS1 intron 23222517 rs12607480 chr18 43701587 G A 7.33E-04 Suicide attempts in bipolar disorder HAUS1 intron 21041247 rs9965812 chr18 43702733 C T 4.34E-04 HIV-1 viral setpoint HAUS1 intron 17641165 rs12954742 chr18 43703223 C G 3.18E-07 Red blood cell traits HAUS1 intron 23222517 rs4243278 chr18 43707880 A G 7.13E-04 Suicide attempts in bipolar disorder HAUS1 intron 21041247 rs12456616 chr18 43713064 T G 1.92E-07 Red blood cell traits / / 23222517 rs8083454 chr18 43713650 A G 6.26E-06 Left ventricular mass / / 21212386 rs1791403 chr18 43715506 A G 7.65E-05 HIV-1 viral setpoint / / 17641165 rs1791403 chr18 43715506 A G 2.56E-13 Red blood cell traits / / 23222517 rs12967694 chr18 43719536 T C 1.36E-16 Red blood cell traits / / 23222517 rs11082512 chr18 43719682 G A 1.17E-16 Red blood cell traits / / 23222517 rs7242375 chr18 43736903 T C 4.69E-15 Red blood cell traits / / 23222517 rs7241527 chr18 43736932 G A 4.97E-16 Red blood cell traits / / 23222517 rs7245091 chr18 43743081 A G 3.24E-04 HIV-1 viral setpoint / / 17641165 rs7245091 chr18 43743081 A G 2.28E-17 Red blood cell traits / / 23222517 rs4453596 chr18 43749826 T C 7.15E-17 Red blood cell traits / / 23222517 rs8084309 chr18 43751993 T C 7.34E-15 Red blood cell traits / / 23222517 rs7234695 chr18 43762182 T A 3.59E-19 Red blood cell traits C18orf25 intron 23222517 rs8094706 chr18 43770146 T C 3.59E-21 Red blood cell traits C18orf25 intron 23222517 rs4890317 chr18 43770510 T C 1.36E-21 Red blood cell traits C18orf25 intron 23222517 rs8086956 chr18 43773903 A G 2.67E-18 Red blood cell traits C18orf25 intron 23222517 rs9947316 chr18 43777831 T G 4.04E-13 Red blood cell traits C18orf25 intron 23222517 rs9956574 chr18 43782203 C T 2.21E-19 Red blood cell traits C18orf25 intron 23222517 rs9945783 chr18 43782260 T C 8.25E-22 Red blood cell traits C18orf25 intron 23222517 rs4890626 chr18 43784498 G C,T 1.06E-19 Red blood cell traits C18orf25 intron 23222517 rs4890628 chr18 43788045 T C 1.04E-21 Red blood cell traits C18orf25 intron 23222517 rs8095374 chr18 43793488 T C 8.59E-14 Red blood cell traits C18orf25 intron 23222517 rs4890629 chr18 43797564 A G 5.85E-18 Red blood cell traits C18orf25 intron 23222517 rs9675387 chr18 43798023 G A 2.73E-19 Red blood cell traits C18orf25 intron 23222517 rs4574015 chr18 43802126 T C 7.59E-22 Red blood cell traits C18orf25 intron 23222517 rs4542747 chr18 43802169 C T 7.37E-19 Red blood cell traits C18orf25 intron 23222517 rs12607898 chr18 43802778 A G 1.25E-18 Red blood cell traits C18orf25 intron 23222517 rs12969147 chr18 43806524 G A 8.66E-22 Red blood cell traits C18orf25 intron 23222517 rs9959905 chr18 43811050 A G 1.48E-18 Red blood cell traits C18orf25 intron 23222517 rs9949494 chr18 43811300 T C 9.59E-23 Red blood cell traits C18orf25 intron 23222517 rs9952469 chr18 43812010 T C 9.98E-23 Red blood cell traits C18orf25 intron 23222517 rs4890319 chr18 43812644 T A 1.27E-22 Red blood cell traits C18orf25 intron 23222517 rs12962307 chr18 43815420 A T 9.83E-20 Red blood cell traits C18orf25 intron 23222517 rs7228365 chr18 43817832 A G 2.38E-04 Parkinson's disease C18orf25 intron 16252231 rs7228365 chr18 43817832 A G 4.23E-19 Red blood cell traits C18orf25 intron 23222517 rs7231820 chr18 43823431 G A 9.61E-18 Red blood cell traits C18orf25 intron 23222517 rs7231430 chr18 43823472 A G 1.22E-19 Red blood cell traits C18orf25 intron 23222517 rs4890632 chr18 43826293 G A 1.48E-22 Red blood cell traits C18orf25 intron 23222517 rs6507693 chr18 43829137 G A 1.08E-18 Red blood cell traits C18orf25 intron 23222517 rs9955853 chr18 43829655 C T 5.94E-13 Red blood cell traits C18orf25 intron 23222517 rs9944767 chr18 43831057 G A 2.87E-21 Red blood cell traits C18orf25 intron 23222517 rs9944836 chr18 43831380 A G 1.24E-18 Red blood cell traits C18orf25 intron 23222517 rs4890633 chr18 43833278 G A 1.89E-23 Red blood cell traits C18orf25 intron 23222517 rs12605945 chr18 43834118 A G 7.41E-15 Red blood cell traits C18orf25 intron 23222517 rs8099202 chr18 43834634 T G 2.80E-23 Red blood cell traits C18orf25 intron 23222517 rs7230154 chr18 43835793 C T 4.72E-19 Red blood cell traits C18orf25 intron 23222517 rs11664743 chr18 43837255 C A 1.23E-04 HIV-1 viral setpoint C18orf25 intron 17641165 rs9963153 chr18 43840064 T C 5.15E-22 Red blood cell traits C18orf25 intron 23222517 rs9959813 chr18 43841082 A G 3.57E-18 Red blood cell traits C18orf25 intron 23222517 rs11082518 chr18 43842032 G A 1.29E-22 Red blood cell traits C18orf25 intron 23222517 rs200351105 chr18 43842618 C CAA 2.13E-19 Red blood cell traits C18orf25 intron 23222517 rs9963843 chr18 43842618 C A 2.13E-19 Red blood cell traits C18orf25 intron 23222517 rs3744858 chr18 43845269 C T 1.26E-19 Red blood cell traits C18orf25 UTR-3 23222517 rs8093407 chr18 43849464 A G 3.39E-18 Red blood cell traits / / 23222517 rs8098751 chr18 43850587 G A 1.38E-22 Red blood cell traits / / 23222517 rs7239351 chr18 43851338 A T 8.78E-18 Red blood cell traits / / 23222517 rs718513 chr18 43856267 C G 7.18E-18 Red blood cell traits / / 23222517 rs718515 chr18 43856297 G A 1.37E-13 Red blood cell traits / / 23222517 rs718514 chr18 43856354 A C 5.31E-19 Red blood cell traits / / 23222517 rs17758799 chr18 43859288 G A 1.04E-08 Red blood cell traits / / 23222517 rs11082519 chr18 43860477 G A 5.56E-16 Red blood cell traits / / 23222517 rs4890635 chr18 43861336 T C 6.40E-16 Red blood cell traits / / 23222517 rs726131 chr18 43864568 C T 2.22E-04 HIV-1 viral setpoint / / 17641165 rs726131 chr18 43864568 C T 5.34E-08 Red blood cell traits / / 23222517 rs4243279 chr18 43865298 C T 3.71E-04 HIV-1 viral setpoint / / 17641165 rs4243279 chr18 43865298 C T 9.00E-11 Red blood cell traits / / 23222517 rs11873572 chr18 43866158 T G 8.96E-04 Depression (quantitative trait) / / 20800221 rs11877350 chr18 43867311 G A 6.22E-10 Red blood cell traits / / 23222517 rs8088306 chr18 43869179 T C 4.37E-14 Red blood cell traits / / 23222517 rs8087419 chr18 43869236 C T 3.41E-11 Red blood cell traits / / 23222517 rs17686457 chr18 43870742 G A 4.20E-09 Red blood cell traits / / 23222517 rs4890636 chr18 43871959 T C 3.09E-10 Red blood cell traits / / 23222517 rs2044222 chr18 43872899 T C 1.84E-10 Red blood cell traits / / 23222517 rs4433901 chr18 43876309 T C 4.82E-08 Red blood cell traits / / 23222517 rs4890637 chr18 43880955 C T 7.69E-04 HIV-1 viral setpoint / / 17641165 rs948597 chr18 43893561 A G 2.79E-04 Smoking initiation / / 24665060 rs9964221 chr18 43897107 G T 7.80E-06 Urinary metabolites / / 21572414 rs9947826 chr18 43899499 A G 1.53E-04 Smoking initiation / / 24665060 rs8086538 chr18 43904534 G A 1.40E-05 Urinary metabolites / / 21572414 rs11082521 chr18 43911448 T C 8.89E-04 Multiple complex diseases / / 17554300 rs11663834 chr18 43945004 T G 6.39E-06 Carotenoid and tocopherol levels RNF165 intron 19185284 rs11874989 chr18 43947216 C T 8.43E-05 Lung adenocarcinoma RNF165 intron 19836008 rs11874989 chr18 43947216 C T 8.06E-04 Response to cytadine analogues (cytosine arabinoside) RNF165 intron 24483146 rs6507699 chr18 43948347 C T 1.24E-04 Response to cytadine analogues (cytosine arabinoside) RNF165 intron 24483146 rs3894151 chr18 43959703 C T 5.56E-04 White matter integrity RNF165 intron 22425255 rs6507701 chr18 43962917 T C 8.60E-04 Endometriosis RNF165 intron 21151130 rs7238416 chr18 43981647 G A 3.38E-04 Multiple complex diseases RNF165 intron 17554300 rs12607419 chr18 44002268 C A 4.33E-04 Smoking cessation RNF165 intron 24665060 rs9944943 chr18 44065343 T C 0.000193 Height (Pygmy height) LOXHD1 intron 22570615 rs4614822 chr18 44106331 G T 6.47E-04 Response to alcohol consumption (flushing response) LOXHD1 intron 24277619 rs10502872 chr18 44110581 C T 3.04E-04 Coronary Artery Disease LOXHD1 intron 17634449 rs4890668 chr18 44111608 A G 2.39E-05 Post-operative nausea and vomiting LOXHD1 intron 21694509 rs11661096 chr18 44125167 T C 9.23E-05 Response to mTOR inhibitor (rapamycin) LOXHD1 intron 24009623 rs4890673 chr18 44134616 G A 0.000307 Height (Pygmy height) LOXHD1 intron 22570615 rs328168 chr18 44157420 T G 4.56E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328166 chr18 44157506 G T 2.39E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328165 chr18 44158631 C G 3.97E-04 Obesity (extreme) LOXHD1 intron 21935397 rs167872 chr18 44160478 G A 3.90E-04 Obesity (extreme) LOXHD1 intron 21935397 rs1818567 chr18 44161676 A G 7.13E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328161 chr18 44162850 A T 3.79E-04 Obesity (extreme) LOXHD1 intron 21935397 rs655140 chr18 44164430 A T 7.06E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328159 chr18 44164697 C T 3.79E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328158 chr18 44167695 C A 3.69E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328157 chr18 44167842 T C 3.69E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328155 chr18 44168944 C T 3.67E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328154 chr18 44169144 G A 3.67E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328153 chr18 44170208 C T 3.57E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328152 chr18 44170285 C G 3.57E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328151 chr18 44170346 G A 3.57E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328150 chr18 44170385 C T 3.56E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328149 chr18 44170471 G A 3.35E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328147 chr18 44171464 G A 3.30E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328145 chr18 44173449 A C 3.17E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328144 chr18 44174553 C T 2.48E-04 Obesity (extreme) LOXHD1 intron 21935397 rs16939690 chr18 44174696 G A 1.14E-04 Multiple complex diseases LOXHD1 intron 17554300 rs328143 chr18 44174924 T C 2.29E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328142 chr18 44176303 A G 2.23E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328141 chr18 44176837 T C 2.70E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328140 chr18 44177141 C T 2.78E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328138 chr18 44178169 T G 2.81E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328137 chr18 44178596 G A 2.85E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328136 chr18 44178626 T A 2.90E-04 Obesity (extreme) LOXHD1 intron 21935397 rs328135 chr18 44179708 C A 3.08E-04 Obesity (extreme) LOXHD1 intron 21935397 rs660618 chr18 44180695 C T 9.44E-04 Obesity (extreme) LOXHD1 intron 21935397 rs16939800 chr18 44199487 C T 2.12E-04 Lung function (forced expiratory volume in 1 second) LOXHD1 intron 24023788 rs11662257 chr18 44204073 T C 6.47E-04 Premature ovarian failure LOXHD1 intron 19508998 rs544049 chr18 44204713 G A 3.39E-04 Alcohol dependence LOXHD1 intron 21314694 rs544049 chr18 44204713 G A 7.15E-05 C-Reactive Protein LOXHD1 intron pha003070 rs328182 chr18 44233349 G A 6.84E-04 Suicide attempts in bipolar disorder LOXHD1 intron 21423239 rs328183 chr18 44235014 T C 8.33E-04 Suicide attempts in bipolar disorder LOXHD1 intron 21423239 rs435202 chr18 44240526 C T 3.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs10502875 chr18 44241478 G A 2.97E-05 Tuberculosis / / 22239941 rs10502876 chr18 44257422 G A 7.01E-04 Coronary heart disease / / 21606135 rs9952976 chr18 44307719 G A 2.09E-06 Alopecia areata ST8SIA5 intron 22027810 rs7237483 chr18 44317081 A G 4.39E-05 Tunica Media ST8SIA5 intron pha003036 rs17707032 chr18 44335147 G A 5.66E-04 Sarcoidosis ST8SIA5 intron 19165924 rs557661 chr18 44365657 A G 7.50E-07 Personality dimensions / / 21173776 rs538221 chr18 44375111 G A 4.80E-07 Personality dimensions / / 21173776 rs2510444 chr18 44376849 G T 4.80E-07 Personality dimensions / / 21173776 rs487386 chr18 44377004 T C 1.10E-04 Multiple complex diseases / / 17554300 rs509647 chr18 44383675 G T 4.70E-07 Personality dimensions / / 21173776 rs642897 chr18 44396917 T G 5.00E-07 Personality dimensions PIAS2 UTR-3 21173776 rs649076 chr18 44414614 A G 6.30E-07 Personality dimensions PIAS2 intron 21173776 rs607780 chr18 44417456 C T 5.80E-07 Personality dimensions PIAS2 intron 21173776 rs695001 chr18 44422333 A C 5.40E-07 Personality dimensions PIAS2 intron 21173776 rs7236403 chr18 44422661 T C 8.60E-06 Central corneal thickness PIAS2 intron 20485516 rs626217 chr18 44429182 T G 5.30E-07 Personality dimensions PIAS2 intron 21173776 rs658756 chr18 44431832 T C 2.55E-04 Multiple complex diseases PIAS2 intron 17554300 rs658756 chr18 44431832 T C 4.90E-07 Personality dimensions PIAS2 intron 21173776 rs2032215 chr18 44439011 A C 4.70E-07 Personality dimensions PIAS2 intron 21173776 rs577200 chr18 44442402 T G 1.30E-06 Personality dimensions PIAS2 intron 21173776 rs605487 chr18 44444778 G C 5.20E-07 Personality dimensions PIAS2 intron 21173776 rs2156050 chr18 44455873 A G 5.30E-07 Personality dimensions PIAS2 intron 21173776 rs7240239 chr18 44460037 T C 5.30E-07 Personality dimensions PIAS2 intron 21173776 rs4890341 chr18 44467368 T C,G 7.10E-07 Personality dimensions PIAS2 intron 21173776 rs8086286 chr18 44467515 G A 3.33E-05 Multiple complex diseases PIAS2 intron 17554300 rs10853545 chr18 44475220 A T 1.73E-04 Multiple complex diseases PIAS2 intron 17554300 rs10853545 chr18 44475220 A T 5.40E-07 Personality dimensions PIAS2 intron 21173776 rs2051292 chr18 44484372 C G 1.40E-06 Personality dimensions PIAS2 intron 21173776 rs4890707 chr18 44497724 C G 3.80E-07 Personality dimensions PIAS2 nearGene-5 21173776 rs11875795 chr18 44513071 G A 8.20E-06 Central corneal thickness / / 20485516 rs8096263 chr18 44515216 C T 7.62E-05 Multiple complex diseases / / 17554300 rs1539878 chr18 44523004 T C 3.30E-07 Personality dimensions / / 21173776 rs9304340 chr18 44526582 G A 2.80E-07 Personality dimensions / / 21173776 rs11660085 chr18 44529603 C T 2.97E-05 Multiple complex diseases KAT/L2 intron 17554300 rs7232114 chr18 44529818 C G 1.37E-04 Type 2 diabetes KAT/L2 intron 17463246 rs10853547 chr18 44530548 A C 1.38E-04 Multiple complex diseases KAT/L2 intron 17554300 rs10853547 chr18 44530548 A C 1.80E-06 Personality dimensions KAT/L2 intron 21173776 rs7227700 chr18 44537102 T G 1.70E-06 Personality dimensions KAT/L2 intron 21173776 rs4890699 chr18 44541029 T C 1.70E-06 Personality dimensions KAT/L2 intron 21173776 rs7244778 chr18 44541915 T C 1.80E-06 Personality dimensions KAT/L2 intron 21173776 rs2010834 chr18 44560875 C A 2.00E-06 Personality dimensions TCEB3B missense 21173776 rs998818 chr18 44564162 T C 5.72E-05 Response to cytidine analogues (gemcitabine) KAT/L2 intron 24483146 rs2571030 chr18 44573854 G A 2.90E-06 Personality dimensions KAT/L2 intron 21173776 rs2060416 chr18 44576240 G C 6.30E-06 Personality dimensions KAT/L2 intron 21173776 rs2246877 chr18 44577005 A G 1.40E-07 Personality dimensions KAT/L2 intron 21173776 rs2571031 chr18 44577063 T C 2.70E-06 Personality dimensions KAT/L2 intron 21173776 rs2571032 chr18 44578250 T A 3.00E-06 Personality dimensions KAT/L2 intron 21173776 rs2571034 chr18 44578565 A G 3.53E-05 Multiple complex diseases KAT/L2 intron 17554300 rs2571034 chr18 44578565 A G 1.10E-07 Personality dimensions KAT/L2 intron 21173776 rs2247021 chr18 44578794 G T 3.10E-06 Personality dimensions KAT/L2 intron 21173776 rs2247221 chr18 44580082 C T 3.60E-06 Personality dimensions KAT/L2 intron 21173776 rs6507719 chr18 44581310 A T 2.80E-06 Personality dimensions KAT/L2 intron 21173776 rs2576040 chr18 44582027 T C 6.39E-05 Multiple complex diseases KAT/L2 intron 17554300 rs2576038 chr18 44582200 C G 7.60E-06 Personality dimensions KAT/L2 intron 21173776 rs2571021 chr18 44583498 T C 1.30E-05 Multiple complex diseases KAT/L2 intron 17554300 rs2571021 chr18 44583498 T C 1.60E-06 Personality dimensions KAT/L2 intron 21173776 rs2571020 chr18 44584189 A T 2.90E-06 Personality dimensions KAT/L2 intron 21173776 rs2576037 chr18 44585420 C T 1.00E-07 Personality dimensions KAT/L2 intron 21173776 rs7233515 chr18 44585955 G A 7.90E-08 Personality dimensions KAT/L2 missense 21173776 rs2576036 chr18 44587102 A C 2.03E-05 Multiple complex diseases KAT/L2 intron 17554300 rs2576036 chr18 44587102 A C 1.80E-06 Personality dimensions KAT/L2 intron 21173776 rs7236545 chr18 44590473 C T 1.92E-04 Amyotrophic lateral sclerosis (sporadic) KAT/L2 intron 24529757 rs4986228 chr18 44595259 G A 7.70E-07 Personality dimensions KAT/L2 intron 21173776 rs2289133 chr18 44602249 T C 2.70E-06 Personality dimensions KAT/L2 intron 21173776 rs9961383 chr18 44604001 C T 1.50E-06 Personality dimensions KAT/L2 intron 21173776 rs16954921 chr18 44610526 C A 3.00E-06 Personality dimensions KAT/L2 intron 21173776 rs2317324 chr18 44628687 T C 2.50E-06 Personality dimensions / / 21173776 rs7242978 chr18 44633424 T G 1.44E-04 Multiple complex diseases / / 17554300 rs7239323 chr18 44636506 G C 2.40E-06 Personality dimensions HDHD2 intron 21173776 rs2571014 chr18 44640330 A G 3.00E-06 Personality dimensions HDHD2 intron 21173776 rs2571007 chr18 44645610 G A 3.00E-06 Personality dimensions HDHD2 intron 21173776 rs2635052 chr18 44650607 C G 2.30E-06 Personality dimensions HDHD2 intron 21173776 rs2571010 chr18 44652130 A G 2.30E-06 Personality dimensions HDHD2 intron 21173776 rs2635054 chr18 44653028 T C 2.30E-06 Personality dimensions HDHD2 intron 21173776 rs13381713 chr18 44669499 C T 1.50E-06 Personality dimensions HDHD2 intron 21173776 rs2668761 chr18 44673049 C T 3.40E-06 Personality dimensions HDHD2 intron 21173776 rs2635049 chr18 44687303 T C 0.0000912 alzheimer's disease (late onset) IER3IP1 intron 22785395 rs2576052 chr18 44690107 T C 2.00E-06 Personality dimensions IER3IP1 intron 21173776 rs2571004 chr18 44710302 T A 1.40E-06 Personality dimensions / / 21173776 rs2684819 chr18 44710691 C T 1.50E-06 Personality dimensions / / 21173776 rs2571005 chr18 44714365 G A 2.50E-06 Personality dimensions / / 21173776 rs2571006 chr18 44718515 G T 1.50E-06 Personality dimensions / / 21173776 rs2684833 chr18 44719428 C G 1.90E-06 Personality dimensions / / 21173776 rs9304343 chr18 44720664 C T 2.40E-06 Personality dimensions / / 21173776 rs1434529 chr18 44730142 C T 1.60E-06 Personality dimensions SKOR2 intron 21173776 rs1836259 chr18 44732389 C G 1.50E-06 Personality dimensions SKOR2 intron 21173776 rs2247578 chr18 44745056 A G 1.10E-07 Personality dimensions SKOR2 intron 21173776 rs2668778 chr18 44745185 A C 1.10E-07 Personality dimensions SKOR2 intron 21173776 rs2247777 chr18 44746739 C G 1.40E-07 Personality dimensions SKOR2 intron 21173776 rs2684838 chr18 44748079 T G 6.20E-06 Personality dimensions SKOR2 intron 21173776 rs2137287 chr18 44751856 A G 7.90E-06 Personality dimensions SKOR2 intron 21173776 rs2137288 chr18 44752041 A G 8.90E-06 Personality dimensions SKOR2 intron 21173776 rs2137289 chr18 44752125 G A,C 8.50E-06 Personality dimensions SKOR2 intron 21173776 rs1398217 chr18 44752238 G C,T 2.00E-13 Menarche (age at onset) SKOR2 intron 21102462 rs1398217 chr18 44752238 G C,T 6.40E-06 Personality dimensions SKOR2 intron 21173776 rs2684814 chr18 44754103 T C 6.40E-07 Personality dimensions SKOR2 intron 21173776 rs17785419 chr18 44765469 G A 7.95E-04 Multiple complex diseases SKOR2 intron 17554300 rs2668772 chr18 44770621 T G 2.70E-06 Personality dimensions SKOR2 intron 21173776 rs2668771 chr18 44775897 G A 1.20E-06 Personality dimensions / / 21173776 rs1512235 chr18 44781569 A G 3.40E-06 Personality dimensions / / 21173776 rs2668767 chr18 44785302 T C 3.70E-06 Personality dimensions / / 21173776 rs2668764 chr18 44790218 C T 3.70E-06 Personality dimensions / / 21173776 rs2684853 chr18 44793532 G A 3.70E-06 Personality dimensions / / 21173776 rs9947662 chr18 44860264 G A 3.00E-06 Migraine / / 23793025 rs9947662 chr18 44860264 G A 8.44E-04 Migraine with aura / / 23793025 rs7239153 chr18 44870580 T C 7.60E-07 Urinary metabolites / / 21572414 rs1893784 chr18 44919327 T C 6.85E-04 Lung cancer / / 19414679 rs892579 chr18 44938671 G A 7.60E-06 Digit length ratio / / 20303062 rs9951221 chr18 44979575 C A,T 1.60E-04 Multiple complex diseases / / 17554300 rs7359758 chr18 45042516 C T 2.36E-04 Insulin resistance / / 21901158 rs4939841 chr18 45047670 C T 9.17E-05 Insulin resistance / / 21901158 rs4939841 chr18 45047670 C T 7.68E-04 Coronary heart disease / / 21971053 rs10853554 chr18 45053586 C G 4.88E-04 Bipolar disorder,schizoaffective / / 19567891 rs12604167 chr18 45059898 A G 8.25E-05 Cognitive performance / / 19734545 rs17797866 chr18 45064799 T G 4.98E-04 Bipolar disorder,schizoaffective / / 19567891 rs1105471 chr18 45086502 T G 3.95E-04 Coronary heart disease / / 21971053 rs1876926 chr18 45090166 T C 4.53E-04 Multiple complex diseases / / 17554300 rs8092886 chr18 45097865 A G 5.13E-04 Coronary heart disease / / 21971053 rs10163681 chr18 45102280 C T 3.54E-04 Coronary heart disease / / 21971053 rs10502884 chr18 45104375 T C 3.54E-04 Coronary heart disease / / 21971053 rs17798773 chr18 45107905 G A,C,T 2.53E-05 Cervical cancer / / 24700089 rs17736813 chr18 45107986 G C 4.24E-05 Cervical cancer / / 24700089 rs11661572 chr18 45128988 T C 8.40E-06 Urinary metabolites / / 21572414 rs11665292 chr18 45131800 T C 3.18E-04 Type 2 diabetes / / 17463246 rs11082611 chr18 45134328 A G 6.10E-06 Urinary metabolites / / 21572414 rs7240934 chr18 45138173 G A 6.93E-04 Insulin resistance / / 21901158 rs984360 chr18 45155234 A G 2.10E-06 Urinary metabolites / / 21572414 rs10502885 chr18 45155501 G A 2.00E-06 Urinary metabolites / / 21572414 rs1995415 chr18 45175402 G A 1.20E-06 Urinary metabolites / / 21572414 rs10502887 chr18 45179883 A G 2.79E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs10502887 chr18 45179883 A G 5.02E-05 Statin-induced myopathy / / 21826682 rs16956487 chr18 45183896 G C 1.13E-07 Type 2 diabetes / / 17463246 rs1604557 chr18 45200811 A G 6.89E-05 Hypertension / / pha003041 rs9945213 chr18 45218683 G C 2.40E-05 Urinary metabolites / / 21572414 rs4939877 chr18 45238757 C T 1.30E-07 Urinary metabolites / / 21572414 rs12958368 chr18 45242061 C G 1.90E-07 Urinary metabolites / / 21572414 rs12959467 chr18 45242092 T A 1.40E-07 Urinary metabolites / / 21572414 rs885216 chr18 45242393 T A 5.00E-06 Urinary metabolites / / 21572414 rs905310 chr18 45243999 G A 1.90E-07 Urinary metabolites / / 21572414 rs905311 chr18 45244296 C A 4.90E-07 Urinary metabolites / / 21572414 rs12969463 chr18 45244578 C T 3.60E-07 Urinary metabolites / / 21572414 rs2852950 chr18 45298230 G A 1.86E-05 Atopy / / 21625490 rs2852945 chr18 45319554 C T 4.15E-05 Cleft lip / / 20436469 rs2852945 chr18 45319554 C T 5.77E-05 Orofacial clefts / / 22863734 rs2852945 chr18 45319554 C T 3.14E-05 Left ventricular hypertrophy / / pha003052 rs2852945 chr18 45319554 C T 8.51E-05 Heart Rate / / pha003053 rs8085335 chr18 45363289 A G 3.52E-04 Atopy SMAD2 UTR-3 21625490 rs9954448 chr18 45508229 T C 8.77E-04 Multiple complex diseases / / 17554300 rs7243734 chr18 45563098 G A 4.97E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZBTB7C intron 20877124 rs4072059 chr18 45564962 G C 4.43E-04 Response to taxane treatment (placlitaxel) ZBTB7C intron 23006423 rs8089034 chr18 45577201 C T 9.42E-04 Response to taxane treatment (placlitaxel) ZBTB7C intron 23006423 rs7244057 chr18 45579276 A C 9.78E-04 Response to taxane treatment (placlitaxel) ZBTB7C intron 23006423 rs3935039 chr18 45591325 C T 7.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZBTB7C intron 20877124 rs3935039 chr18 45591325 C T 7.03E-04 Response to taxane treatment (placlitaxel) ZBTB7C intron 23006423 rs4445959 chr18 45614429 C T 3.29E-06 Cognitive impairment induced by topiramate ZBTB7C intron 22091778 rs12604363 chr18 45620052 C A 0.0000848 Panic disorder ZBTB7C intron 23149450 rs12604363 chr18 45620052 C A 8.48E-05 Serum tamsulosin hydrochloride concentration ZBTB7C intron 23151678 rs9945594 chr18 45625421 G A 3.00E-06 Urinary metabolites ZBTB7C intron 21572414 rs7228349 chr18 45625572 G A 2.60E-06 Urinary metabolites ZBTB7C intron 21572414 rs9947627 chr18 45631389 C T 9.50E-06 Urinary metabolites ZBTB7C intron 21572414 rs9946730 chr18 45634519 T C 6.29E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ZBTB7C intron 21844884 rs4940257 chr18 45635154 C A 9.16E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ZBTB7C intron 21844884 rs4939731 chr18 45635331 T C 4.56E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ZBTB7C intron 21844884 rs6417101 chr18 45672819 T C 2.15E-04 Multiple complex diseases / / 17554300 rs4939747 chr18 45688841 C T 7.50E-04 Alcohol dependence / / 20201924 rs6507820 chr18 45694281 C T 5.41E-04 Alcohol dependence / / 20201924 rs12957159 chr18 45710712 T C 5.63E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11661829 chr18 45720993 G A 2.80E-05 Urinary metabolites / / 21572414 rs8087577 chr18 45726496 G A 8.33E-04 Taste perception / / 22132133 rs16948892 chr18 45728158 C T 2.10E-05 Urinary metabolites / / 21572414 rs1944576 chr18 45735067 G A 8.89E-05 Coronary heart disease / / pha003035 rs4940340 chr18 45755247 T C 2.98E-04 Multiple complex diseases / / 17554300 rs12967400 chr18 45779667 A G 3.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1944586 chr18 45786206 A G 3.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17744700 chr18 45794555 C T 6.61E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1944582 chr18 45815417 A G 4.00E-06 Response to taxane treatment (docetaxel) / / 23006423 rs9957779 chr18 45817748 A G 1.90E-04 Alcohol dependence / / 20201924 rs9957779 chr18 45817748 A G 5.80E-04 Alcohol dependence / / 20201924 rs9946041 chr18 45831814 C T 6.39E-05 Coronary heart disease / / pha003030 rs6507838 chr18 45835987 T C 8.15E-07 Coronary heart disease / / pha003030 rs6507838 chr18 45835987 T C 5.46E-05 Coronary heart disease / / pha003031 rs7235739 chr18 45836094 G T 6.12E-05 Coronary heart disease / / pha003030 rs4940352 chr18 45841003 A C 5.22E-04 Smoking cessation / / 24665060 rs17751276 chr18 45844500 T C 2.65E-05 Coronary heart disease / / pha003030 rs7226782 chr18 45852077 G A 3.52E-05 Height / / pha003010 rs7226782 chr18 45852077 G A 9.88E-05 Height / / pha003011 rs871082 chr18 45860275 T C 5.00E-06 Coronary heart disease / / pha003030 rs17824587 chr18 45861939 C T 2.92E-06 Coronary heart disease / / pha003030 rs11082671 chr18 45865597 A G 2.00E-08 Height / / 23456168 rs2187430 chr18 45866936 G A 3.04E-04 Height / / 17255346 rs1893838 chr18 45878148 C T 4.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs9953229 chr18 45881487 C T 8.80E-04 Schizophrenia / / 19197363 rs9953229 chr18 45881487 C T 5.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs9945706 chr18 45882529 T C 5.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs17824737 chr18 45886517 C T 9.21E-04 Multiple complex diseases / / 17554300 rs6507842 chr18 45887992 C A 6.58E-05 Cortisol secretion,in saliva / / 21316860 rs1873126 chr18 45902342 T C 1.97E-04 Schizophrenia / / 19197363 rs4258691 chr18 45907944 G A 3.46E-04 Schizophrenia / / 19197363 rs4258691 chr18 45907944 G A 7.55E-05 Height / / pha003010 rs7243063 chr18 45913068 C T 9.24E-05 Personality dimensions / / 23903073 rs4940366 chr18 45914752 G T 3.85E-06 Gaucher disease severity / / 22388998 rs4940366 chr18 45914752 G T 0.0000726 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs8087061 chr18 45923445 G T 3.94E-04 Schizophrenia / / 19197363 rs1011076 chr18 45937817 C T 5.41E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1873128 chr18 45941307 C A 7.24E-04 Multiple complex diseases / / 17554300 rs16949181 chr18 45945536 C T 9.35E-05 Serum metabolites / / 19043545 rs4940375 chr18 45951263 G T 8.34E-05 Serum metabolites / / 19043545 rs8082814 chr18 45977075 G A 7.56E-04 Alcohol dependence / / 21314694 rs16949218 chr18 45979900 G A 4.51E-04 Alzheimer's disease / / 17998437 rs16949218 chr18 45979900 G A 1.20E-04 Asthma / / 23181788 rs4940382 chr18 45989199 T C 2.50E-05 Urinary metabolites / / 21572414 rs9956450 chr18 45998519 T C 6.83E-04 Multiple complex diseases / / 17554300 rs1588616 chr18 46008209 T C 5.20E-04 Multiple complex diseases / / 17554300 rs12607412 chr18 46072320 G A 4.12E-04 Alzheimer's disease CTIF intron 22005930 rs6507852 chr18 46075049 G A 2.52E-04 Alzheimer's disease CTIF intron 22005930 rs907547 chr18 46076096 G T 2.57E-04 Alzheimer's disease CTIF intron 22005930 rs907546 chr18 46076290 G A 2.60E-04 Alzheimer's disease CTIF intron 22005930 rs9952398 chr18 46076778 C A 2.55E-04 Alzheimer's disease CTIF intron 22005930 rs12456253 chr18 46076974 G T 8.19E-04 Alzheimer's disease CTIF intron 22005930 rs12606093 chr18 46077295 C A 9.36E-04 Alzheimer's disease CTIF intron 22005930 rs2175565 chr18 46079852 G A 2.87E-04 Alzheimer's disease CTIF intron 22005930 rs1028010 chr18 46085830 T A 2.16E-04 Alzheimer's disease CTIF intron 22005930 rs11082685 chr18 46093177 A G 4.45E-04 Alzheimer's disease CTIF intron 22005930 rs4349219 chr18 46094971 A G 2.70E-04 Fibrinogen CTIF intron 17255346 rs3744827 chr18 46095943 A G 3.88E-04 Alzheimer's disease CTIF intron 22005930 rs9948328 chr18 46095984 T C 1.25E-04 Alzheimer's disease CTIF intron 22005930 rs17829490 chr18 46109074 T C 0.000257737 Hypertension (early onset hypertension) CTIF intron 22479346 rs7240702 chr18 46137899 A G 1.10E-04 Multiple complex diseases CTIF intron 17554300 rs299713 chr18 46156087 G C 2.18E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CTIF intron 20031582 rs9948061 chr18 46166626 T C 6.42E-05 Serum metabolites CTIF intron 19043545 rs11082688 chr18 46168576 T G 5.33E-04 Endometrial cancer CTIF intron 24096698 rs7240607 chr18 46173896 C G 7.70E-04 Type 2 diabetes CTIF intron 17463246 rs299738 chr18 46201052 A G 7.12E-04 Amyotrophic Lateral Sclerosis CTIF intron 17827064 rs8091345 chr18 46216413 G A 1.38E-04 Pancreatic cancer CTIF intron pha002874 rs8083681 chr18 46218584 A G 8.31E-04 Multiple complex diseases CTIF intron 17554300 rs7233521 chr18 46219733 G A 6.80E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CTIF intron 20031582 rs8089264 chr18 46221152 C T 5.81E-05 Bipolar disorder and schizophrenia CTIF intron 20889312 rs16949825 chr18 46227444 C G 3.00E-06 IgG glycosylation CTIF intron 23382691 rs16949825 chr18 46227444 C G 7.00E-06 IgG glycosylation CTIF intron 23382691 rs9967059 chr18 46238976 A G 4.08E-04 Smoking initiation CTIF intron 24665060 rs9947954 chr18 46240711 A C 8.00E-06 IgG glycosylation CTIF intron 23382691 rs900246 chr18 46242131 G A 3.20E-07 Rheumatoid arthritis CTIF intron 19503088 rs9952724 chr18 46252815 A C 1.50E-09 Parkinson's disease CTIF intron 17052657 rs12604748 chr18 46263316 G A 3.70E-04 Multiple complex diseases CTIF intron 17554300 rs4939800 chr18 46266174 A G 9.48E-04 Alzheimer's disease CTIF intron 24755620 rs16949934 chr18 46277226 G A 0.00002 Mean arterial pressure CTIF intron 22510845 rs16949934 chr18 46277226 G A 7.11E-04 Alzheimer's disease CTIF intron 24755620 rs11082701 chr18 46282917 C A 1.40E-05 Urinary metabolites CTIF intron 21572414 rs4939559 chr18 46283864 G C 6.38E-04 Alzheimer's disease CTIF intron 17998437 rs1542593 chr18 46283912 G A 6.77E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) CTIF intron 23648065 rs4939560 chr18 46285145 A G 3.16E-06 Retinopathy in non-diabetics CTIF intron 23393555 rs11877669 chr18 46314384 G T 1.02E-04 Birth weight CTIF intron 17255346 rs11877669 chr18 46314384 G T 8.71E-05 Iron levels CTIF intron 19880490 rs11877669 chr18 46314384 G T 8.71E-05 Iron levels CTIF intron pha002876 rs12455557 chr18 46317088 C T 1.82E-05 Rheumatoid arthritis CTIF intron 21452313 rs12455557 chr18 46317088 C T 0.00058525 Hypertension (early onset hypertension) CTIF intron 22479346 rs12455557 chr18 46317088 C T 3.87E-04 Lung function (forced expiratory volume in 1 second) CTIF intron 24023788 rs12455557 chr18 46317088 C T 6.00E-06 Lung function (forced vital capacity) CTIF intron 24023788 rs4583322 chr18 46319685 G A 1.81E-05 Rheumatoid arthritis CTIF intron 21452313 rs4583322 chr18 46319685 G A 0.000689331 Hypertension (early onset hypertension) CTIF intron 22479346 rs4939813 chr18 46325109 T G 5.46E-04 Rheumatoid arthritis CTIF intron 21452313 rs4500815 chr18 46332908 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CTIF intron 22628534 rs7227892 chr18 46336702 A T 2.00E-06 Migraine with aura CTIF intron 23793025 rs7227892 chr18 46336702 A T 5.87E-04 Migraine - clinic-based CTIF intron 23793025 rs9951895 chr18 46343818 T C 1.00E-04 Prostate cancer CTIF intron 21743057 rs12458062 chr18 46368541 C T 5.18E-05 Myopia (pathological) CTIF intron 23049088 rs4939821 chr18 46371993 C T 5.56E-08 Schizophrenia CTIF intron 21926974 rs8096534 chr18 46374167 G A 8.65E-04 Multiple complex diseases CTIF intron 17554300 rs12455029 chr18 46376821 G A 5.77E-08 Metabolite levels CTIF intron 23281178 rs1317355 chr18 46379626 C T 5.22E-08 Metabolite levels CTIF intron 23281178 rs1317625 chr18 46380182 G A 6.84E-05 Cognitive performance CTIF intron 19734545 rs1317625 chr18 46380182 G A 0.000213748 Hypertension (early onset hypertension) CTIF intron 22479346 rs7240004 chr18 46395022 A G 1.00E-09 Inflammatory bowel disease / / 23128233 rs7229639 chr18 46450976 A G 3.00E-11 Colorectal cancer SMAD7 intron 24448986 rs7229639 chr18 46450976 A G 2.00E-08 Colorectal cancer SMAD7 intron 24836286 rs4939827 chr18 46453463 T C 1.00E-12 Colorectal cancer SMAD7 intron 17934461 rs4939827 chr18 46453463 T C 8.00E-28 Colorectal cancer SMAD7 intron 18372901 rs4939827 chr18 46453463 T C 2.00E-06 Colorectal cancer SMAD7 intron 18372905 rs4939827 chr18 46453463 T C 2.20E-11 Colorectal cancer SMAD7 intron 19011631 rs4939827 chr18 46453463 T C 8.00E-28 Nasopharyngeal carcinoma SMAD7 intron 20512145 rs4939827 chr18 46453463 T C 1.00E-07 Colorectal cancer SMAD7 intron 21761138 rs4939827 chr18 46453463 T C 0.0000196 Adenoma (female) SMAD7 intron 22532847 rs4939827 chr18 46453463 T C 0.000198 Adenoma SMAD7 intron 22532847 rs4939827 chr18 46453463 T C 2.00E-10 Colorectal cancer SMAD7 intron 23266556 rs4939827 chr18 46453463 T C 1.53E-08 Colorectal cancer SMAD7 intron 24836286 rs4939827 chr18 46453463 T C 4.87E-05 Monocyte chemoattractant protein-1 SMAD7 intron pha003071 rs12953717 chr18 46453929 C T 9.10E-12 Colorectal cancer SMAD7 intron 17934461 rs12953717 chr18 46453929 C T 4.70E-12 Colorectal cancer SMAD7 intron 19011631 rs12953717 chr18 46453929 C T 3.21E-04 Tourette syndrome SMAD7 intron 22889924 rs12953717 chr18 46453929 C T 7.04E-05 Alcohol consumption SMAD7 intron 23953852 rs4464148 chr18 46459032 T C 3.94E-08 Colorectal cancer SMAD7 intron 17934461 rs2337104 chr18 46462952 T C 9.02E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SMAD7 intron 21844884 rs8089910 chr18 46510376 G C 6.30E-04 Multiple complex diseases / / 17554300 rs8089910 chr18 46510376 G C 2.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs12962825 chr18 46513913 A G 2.75E-04 Suicide attempts in bipolar disorder / / 21041247 rs2635509 chr18 46514192 G A 6.37E-05 Suicide attempts in bipolar disorder / / 21041247 rs698611 chr18 46528270 C A 2.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs357906 chr18 46553265 G A 2.91E-04 Multiple complex diseases / / 17554300 rs833520 chr18 46564559 T C 3.40E-06 Post-operative nausea and vomiting / / 21694509 rs833520 chr18 46564559 T C 6.88E-06 Height / / 22021425 rs833523 chr18 46573551 G A 7.13E-05 Multiple complex diseases DYM intron 17554300 rs357894 chr18 46579970 C T 4.00E-06 Dental caries DYM intron 23064961 rs357897 chr18 46584184 C T 2.02E-04 Multiple complex diseases DYM intron 17554300 rs357897 chr18 46584184 C T 2.30E-09 Height DYM intron 21998595 rs357897 chr18 46584184 C T 1.69E-05 Height DYM intron 22021425 rs1787200 chr18 46587654 G A 1.00E-10 Height DYM intron 21998595 rs1787200 chr18 46587654 G A 7.00E-10 Height DYM intron 22021425 rs7239949 chr18 46618828 T G 1.62E-07 Height DYM intron 22021425 rs9284426 chr18 46627041 G A 1.29E-04 Multiple complex diseases DYM intron 17554300 rs8085780 chr18 46634754 C T 3.26E-06 Multiple complex diseases DYM intron 17554300 rs833501 chr18 46636783 G A 2.60E-06 Urinary metabolites DYM intron 21572414 rs10502897 chr18 46645818 T C 3.51E-04 Myocardial Infarction DYM intron pha002883 rs7236575 chr18 46653380 G A 9.42E-04 Multiple complex diseases DYM intron 17554300 rs948789 chr18 46700696 G A 4.21E-04 Multiple complex diseases DYM intron 17554300 rs4939846 chr18 46716085 G A 3.88E-04 Multiple complex diseases DYM intron 17554300 rs1943009 chr18 46736325 A G 3.84E-04 Response to statin treatment (atorvastatin),change in cholesterol levels DYM intron 20031582 rs1788119 chr18 46797797 C T 1.34E-04 Multiple complex diseases DYM intron 17554300 rs549201 chr18 46806107 C T 9.20E-04 Alzheimer's disease DYM intron 22005930 rs552086 chr18 46806432 G C 9.87E-04 Alzheimer's disease DYM intron 22005930 rs523373 chr18 46817697 C A 9.26E-04 Alzheimer's disease DYM intron 22005930 rs484892 chr18 46824517 A T 8.91E-04 Alzheimer's disease DYM intron 22005930 rs494752 chr18 46853270 G C 7.37E-04 Alzheimer's disease DYM intron 22005930 rs9635952 chr18 46861612 T C 2.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DYM intron 20877124 rs556230 chr18 46863805 T C 2.77E-04 Alzheimer's disease DYM intron 22005930 rs2658743 chr18 46867039 T A 2.75E-04 Alzheimer's disease DYM intron 22005930 rs6507898 chr18 46872032 G A 2.81E-04 Alzheimer's disease DYM intron 22005930 rs7506861 chr18 46885443 A G 8.68E-04 Alzheimer's disease DYM intron 22005930 rs4939863 chr18 46885674 A G 4.50E-06 Urinary metabolites DYM intron 21572414 rs2001801 chr18 46886704 A T 8.94E-04 Alzheimer's disease DYM intron 22005930 rs3809924 chr18 46889938 A G 7.32E-04 Alzheimer's disease DYM intron 22005930 rs10775493 chr18 46904769 G C 9.12E-04 Alzheimer's disease DYM intron 22005930 rs4939866 chr18 46917287 A T 2.53E-04 Alzheimer's disease DYM intron 22005930 rs4939867 chr18 46917573 C A 8.79E-04 Alzheimer's disease DYM intron 22005930 rs4939579 chr18 46920611 T G 9.16E-04 Alzheimer's disease DYM intron 22005930 rs6507908 chr18 46935790 G C 1.70E-05 Urinary metabolites DYM intron 21572414 rs7505245 chr18 46939616 T C 2.56E-04 Alzheimer's disease DYM intron 22005930 rs9967417 chr18 46959500 G C 9.00E-25 Height DYM intron 20881960 rs9967417 chr18 46959500 G C 5.00E-09 Height DYM intron 23563607 rs11082752 chr18 46968603 C T 4.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DYM intron 20877124 rs8099594 chr18 46991160 A C,G,T 6.83E-04 Multiple complex diseases / / 17554300 rs8099594 chr18 46991160 A C,G,T 3.00E-07 Height / / 18391952 rs12955787 chr18 47030252 C T 8.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7238552 chr18 47037399 C T 6.87E-05 Alcohol dependence / / 21314694 rs6507928 chr18 47054073 G C 1.50E-06 Urinary metabolites / / 21572414 rs12966382 chr18 47085440 C T 1.63E-13 HDL cholesterol / / 23063622 rs17798877 chr18 47086955 C T 0.0000566 Body mass index / / 23001569 rs4245232 chr18 47086998 A C 0.00000085 HDL cholesterol / / 23063622 rs874565 chr18 47088690 C A 0.000000304 Cholesterol,total LIPG cds-synon 23063622 rs874565 chr18 47088690 C A 4.91E-09 HDL cholesterol LIPG cds-synon 23063622 rs2000813 chr18 47093864 C T 2.62E-07 Autism LIPG missense 22843504 rs8093249 chr18 47097398 A G 0.000000479 HDL cholesterol LIPG intron 23063622 rs3786249 chr18 47097489 C T 5.48E-04 Insulin resistance LIPG intron 21901158 rs11875600 chr18 47099186 A G 8.08E-11 HDL cholesterol LIPG intron 23063622 rs9951026 chr18 47109693 G A 5.00E-06 Testicular germ cell tumor LIPG intron 23666239 rs17798991 chr18 47121316 G T 6.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs17798991 chr18 47121316 G T 7.00E-06 Obesity-related traits / / 23251661 rs11664186 chr18 47121698 A G 2.57E-04 Myopia (pathological) / / 21095009 rs8099385 chr18 47126885 C G 3.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs17656498 chr18 47128176 T C 7.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs16950701 chr18 47128325 G A 1.30E-05 Urinary metabolites / / 21572414 rs12954469 chr18 47130228 G A 4.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs17712928 chr18 47130342 G A 6.53E-04 Coronary Artery Disease / / 17634449 rs17726094 chr18 47131238 T A 1.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs8098775 chr18 47131716 T C 7.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs9954848 chr18 47131781 G A 7.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs8090363 chr18 47133828 A G 1.96E-08 Lipid levels / / 19936222 rs11664741 chr18 47134465 G T 2.13E-06 Glaucoma (primary open-angle) / / 22605921 rs7231795 chr18 47135972 T C 4.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs11872886 chr18 47136392 C T 5.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs6507932 chr18 47137027 T C 6.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs6507933 chr18 47137318 C A 5.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs7241596 chr18 47138066 C T 4.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs12955001 chr18 47138999 G A 6.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs9958768 chr18 47141313 T A 0.0000156 Placental abruption / / 23205182 rs4939587 chr18 47142173 T G 0.0000756 Placental abruption / / 23205182 rs4939879 chr18 47145983 A G 0.00000188 Placental abruption / / 23205182 rs7240405 chr18 47159090 A G 5.00E-10 HDL cholesterol / / 20031538 rs7240405 chr18 47159090 A G 1.58E-08 Lipid levels / / 20370913 rs7228085 chr18 47160814 A G 7.00E-11 Lipid metabolism phenotypes / / 22286219 rs7241918 chr18 47160953 G T 2.00E-19 Cholesterol,total / / 20686565 rs7241918 chr18 47160953 G T 3.00E-49 HDL cholesterol / / 20686565 rs7241918 chr18 47160953 G T 1.00E-44 HDL cholesterol / / 24097068 rs7241918 chr18 47160953 G T 4.00E-18 Cholesterol,total / / 24097068 rs4939883 chr18 47167214 T C 1.40E-07 Lipid levels / / 18193043 rs4939883 chr18 47167214 T C 7.00E-15 HDL cholesterol / / 19060906 rs4939883 chr18 47167214 T C 2.00E-11 HDL cholesterol / / 19060911 rs4939883 chr18 47167214 T C 1.90E-05 Lipid levels / / 19802338 rs4939883 chr18 47167214 T C 1.23E-10 Lipid levels / / 19936222 rs4939883 chr18 47167214 T C 1.27E-09 Lipid levels / / 19936222 rs4939883 chr18 47167214 T C 1.28E-10 Lipid levels / / 19936222 rs4939883 chr18 47167214 T C 1.85E-09 Lipid levels / / 19936222 rs4939883 chr18 47167214 T C 1.87E-08 Lipid levels / / 19936222 rs4939883 chr18 47167214 T C 2.40E-11 Lipid levels / / 19936222 rs4939883 chr18 47167214 T C 2.60E-09 Lipid levels / / 19936222 rs4939883 chr18 47167214 T C 2.70E-09 Lipid levels / / 19936222 rs4939883 chr18 47167214 T C 4.00E-10 Lipid levels / / 19936222 rs4939883 chr18 47167214 T C 5.28E-13 Lipid levels / / 19936222 rs4939883 chr18 47167214 T C 5.58E-14 Lipid levels / / 19936222 rs4939883 chr18 47167214 T C 6.10E-09 Lipid levels / / 19936222 rs4939883 chr18 47167214 T C 7.37E-16 Lipid levels / / 19936222 rs4939883 chr18 47167214 T C 1.85E-08 Lipid levels / / 20370913 rs4939883 chr18 47167214 T C 7.00E-15 Coronary heart disease / / 21347282 rs1943981 chr18 47169815 A T 2.50E-08 Lipid levels / / 20370913 rs1943981 chr18 47169815 A T 0.00000229 HDL cholesterol (male) / / 22629316 rs1943981 chr18 47169815 A T 1.81E-09 HDL cholesterol (female) / / 22629316 rs1943981 chr18 47169815 A T 1.83E-13 HDL cholesterol / / 22629316 rs1943981 chr18 47169815 A T 3.63E-11 Cholesterol,total / / 23063622 rs1943981 chr18 47169815 A T 6.99E-25 HDL cholesterol / / 23063622 rs2187375 chr18 47172283 A G 3.00E-17 Blood metabolite levels / / 24816252 rs4939887 chr18 47176911 A G 3.50E-04 Lipid levels / / 19802338 rs948937 chr18 47179901 A T 2.15E-04 Coronary Artery Disease / / 17634449 rs2156552 chr18 47181668 A T 6.00E-12 HDL cholesterol / / 18193043 rs2156552 chr18 47181668 A T 2.00E-07 HDL cholesterol / / 18193044 rs2156552 chr18 47181668 A T 1.14E-08 Lipid levels / / 20370913 rs2156552 chr18 47181668 A T 2.00E-12 HDL cholesterol / / 20864672 rs2156552 chr18 47181668 A T 6.00E-12 Coronary heart disease / / 21347282 rs2156552 chr18 47181668 A T 1.33E-10 Cholesterol,total / / 23063622 rs2156552 chr18 47181668 A T 1.67E-09 HDL cholesterol (male) / / 23063622 rs2156552 chr18 47181668 A T 1.85E-24 HDL cholesterol / / 23063622 rs2156552 chr18 47181668 A T 2.86E-12 HDL cholesterol (female) / / 23063622 rs1540037 chr18 47182664 A G 2.95E-17 HDL cholesterol / / 23063622 rs1540037 chr18 47182664 A G 3.13E-08 Cholesterol,total / / 23063622 rs12970803 chr18 47195574 A T 6.69E-05 Serum metabolites / / 19043545 rs12970803 chr18 47195574 A T 1.33E-04 Arthritis (juvenile idiopathic) / / 22354554 rs17799355 chr18 47198147 G A 1.58E-04 Coronary heart disease / / 21971053 rs17726403 chr18 47199408 G A 5.98E-04 Multiple complex diseases / / 17554300 rs6507945 chr18 47243912 A C 6.91E-09 Lipid levels / / 20370913 rs869013 chr18 47261355 T C 2.50E-04 Multiple complex diseases / / 17554300 rs4939891 chr18 47266045 A C 5.94E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7241641 chr18 47277757 A G 8.66E-05 Arthritis (juvenile idiopathic) / / 22354554 rs6507952 chr18 47278147 C T 4.29E-05 Arthritis (juvenile idiopathic) / / 22354554 rs617619 chr18 47328029 C T 4.91E-04 Multiple complex diseases ACAA2 intron 17554300 rs9964783 chr18 47365005 A C 8.18E-05 Attention deficit hyperactivity disorder MYO5B intron 22420046 rs17713794 chr18 47372610 T C 9.72E-05 Cognitive test performance MYO5B intron 20125193 rs17713794 chr18 47372610 T C 6.84E-05 Diabetes Mellitus MYO5B intron pha003059 rs485835 chr18 47375552 A C 4.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MYO5B intron 20877124 rs657424 chr18 47402280 A C 1.70E-05 Amyotrophic lateral sclerosis (sporadic) MYO5B intron 24529757 rs1787613 chr18 47416413 G A 2.32E-05 Statin-induced myopathy MYO5B intron 21826682 rs11876567 chr18 47419990 T C 2.00E-04 Insulin resistance MYO5B intron 21901158 rs2298628 chr18 47455923 C T 4.82E-05 Telomere length MYO5B cds-synon 20139977 rs4939921 chr18 47462328 T C 2.04E-08 Bipolar disorder MYO5B intron 18317468 rs1787603 chr18 47467489 G T 5.66E-04 Multiple complex diseases MYO5B intron 17554300 rs1787603 chr18 47467489 G T 2.70E-05 Urinary metabolites MYO5B intron 21572414 rs1787294 chr18 47471504 A G 8.17E-04 Multiple complex diseases MYO5B intron 17554300 rs1787294 chr18 47471504 A G 1.60E-05 Urinary metabolites MYO5B intron 21572414 rs3915600 chr18 47487666 G A 2.90E-05 Urinary metabolites MYO5B intron 21572414 rs4939924 chr18 47503579 C T 1.19E-05 Schizophrenia MYO5B intron 22037552 rs9963530 chr18 47523322 A T 1.99E-04 Response to cytadine analogues (cytosine arabinoside) MYO5B intron 24483146 rs9950823 chr18 47526880 A G 4.55E-04 Type 2 diabetes MYO5B intron 17463246 rs16951384 chr18 47527117 T C 8.86E-05 Type 2 diabetes MYO5B intron 17463246 rs9304393 chr18 47532215 T C 4.16E-04 Response to cytadine analogues (cytosine arabinoside) MYO5B intron 24483146 rs7243216 chr18 47536822 G A 5.91E-05 Lung function (forced expiratory volume in 1 second) MYO5B intron pha003103 rs2721091 chr18 47577456 C T 8.41E-04 Multiple complex diseases MYO5B intron 17554300 rs2852095 chr18 47580051 G A 5.87E-04 Type 2 diabetes MYO5B intron 17463246 rs2852095 chr18 47580051 G A 9.00E-04 Crohn's disease MYO5B intron 17684544 rs17801957 chr18 47581964 A G 9.04E-04 Type 2 diabetes MYO5B intron 17463246 rs1511153 chr18 47610455 G A 5.21E-05 Multiple complex diseases MYO5B intron 17554300 rs9954152 chr18 47640008 A C 2.24E-05 Height MYO5B intron 17255346 rs9954152 chr18 47640008 A C 1.60E-04 Asperger disorder MYO5B intron 21182207 rs2457965 chr18 47643188 C A 7.65E-06 Height MYO5B intron 17255346 rs2457965 chr18 47643188 C A 9.00E-05 Asperger disorder MYO5B intron 21182207 rs1705533 chr18 47650193 G A 7.00E-06 Urinary metabolites MYO5B intron 21572414 rs1705533 chr18 47650193 G A 6.07E-05 Diabetic nephropathy MYO5B intron pha002852 rs2469479 chr18 47651376 A C 3.22E-04 Height MYO5B intron 17255346 rs2469478 chr18 47651537 C T 2.50E-04 Height MYO5B intron 17255346 rs2457975 chr18 47653137 A T 3.10E-06 Urinary metabolites MYO5B intron 21572414 rs1790412 chr18 47658365 T C 5.36E-05 Height MYO5B intron 17255346 rs12150790 chr18 47667220 T C 7.57E-06 White blood cell count MYO5B intron 21738479 rs973655 chr18 47670024 T C 1.03E-04 Dental caries MYO5B intron 21940522 rs17802396 chr18 47670213 T C 7.58E-06 White blood cell count MYO5B intron 21738479 rs17802456 chr18 47681265 A T 3.20E-06 White blood cell count MYO5B intron 21738479 rs17660456 chr18 47685580 C G 5.00E-06 Urinary metabolites MYO5B intron 21572414 rs2469480 chr18 47711963 C T 2.58E-05 Height MYO5B intron 17255346 rs1511155 chr18 47717242 T A 1.97E-05 Height MYO5B intron 17255346 rs951388 chr18 47717815 A C 6.37E-05 Height MYO5B intron 17255346 rs1397677 chr18 47725047 C T 2.27E-04 Height / / 17255346 rs1397677 chr18 47725047 C T 3.15E-05 F-cell distribution / / 21326311 rs736162 chr18 47726830 T G 1.25E-04 Birth weight / / 17255346 rs1662892 chr18 47731764 C A 2.00E-04 Height / / 17255346 rs1662903 chr18 47763331 G A 1.27E-04 Type 2 diabetes CCDC11 intron 17463246 rs768360 chr18 47764073 A G 9.44E-04 Multiple complex diseases CCDC11 intron 17554300 rs9965706 chr18 47779351 G A 2.21E-04 Multiple complex diseases CCDC11 intron 17554300 rs8085254 chr18 47782149 A C 1.70E-05 Type 2 diabetes CCDC11 intron 17463246 rs140689 chr18 47800421 A T 9.71E-04 Type 2 diabetes MBD1 intron 17463246 rs999199 chr18 47805294 A C 2.16E-04 Type 2 diabetes MBD1 intron 17463246 rs999199 chr18 47805294 A C 9.90E-06 Urinary metabolites MBD1 intron 21572414 rs17660776 chr18 47811374 G A 4.74E-04 Multiple complex diseases CXXC1 cds-synon 17554300 rs9961704 chr18 47818688 C T 3.54E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs9304395 chr18 47835784 G T 2.04E-05 F-cell distribution / / 21326311 rs12970172 chr18 47837796 T C 5.06E-04 Chronic lymphocytic leukemia / / 23770605 rs4939626 chr18 47840555 T C 5.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1036935 chr18 47843534 A G 2.00E-06 Chronic lymphocytic leukemia / / 20062064 rs1036935 chr18 47843534 A G 2.00E-06 Nasopharyngeal carcinoma / / 20512145 rs9947393 chr18 47877641 T C 5.40E-06 Urinary metabolites / / 21572414 rs7243020 chr18 47906458 A G 4.73E-04 Multiple complex diseases SKA1 intron 17554300 rs17661298 chr18 47911998 C T 8.34E-06 Age-related macular degeneration SKA1 intron 22125219 rs4939970 chr18 47941714 T C 5.35E-04 HIV-1 viral setpoint / / 17641165 rs2969988 chr18 47960553 A G 2.95E-04 Type 2 diabetes / / 17463246 rs2119547 chr18 47963964 C T 3.65E-06 Asthma / / 11022011 rs2028456 chr18 47965828 C T 1.53E-04 Scoliosis / / 21216876 rs9964613 chr18 47967166 G A 2.61E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1372195 chr18 47983914 T C 7.65E-04 Type 2 diabetes / / 17463246 rs11082824 chr18 47990198 A C 4.11E-04 Type 2 diabetes / / 17463246 rs1441288 chr18 47993122 T C 2.40E-05 Urinary metabolites / / 21572414 rs9960150 chr18 48008440 C T 4.88E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4542754 chr18 48017822 G A 5.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4452041 chr18 48018953 T C 4.60E-05 Cognitive function / / 24684796 rs17662089 chr18 48052631 A G 1.55E-05 Type 2 diabetes / / 17463246 rs6508005 chr18 48073981 C A 1.99E-04 Smoking cessation / / 24665060 rs8084774 chr18 48074147 C T 2.73E-04 Smoking cessation / / 24665060 rs4939987 chr18 48081138 C G 5.63E-04 Prostate cancer mortality / / 20978177 rs8089517 chr18 48096752 C G 7.48E-04 Prostate cancer mortality MAPK4 intron 20978177 rs4322755 chr18 48118360 G A 9.63E-04 Prostate cancer mortality MAPK4 intron 20978177 rs4322755 chr18 48118360 G A 2.10E-04 Intelligence (childhood) MAPK4 intron 23358156 rs992595 chr18 48124715 A G 7.48E-04 Prostate cancer mortality MAPK4 intron 20978177 rs2053248 chr18 48148195 C T 3.33E-05 Information processing speed MAPK4 intron 21130836 rs17718895 chr18 48159563 T C 2.86E-04 Response to platinum-based chemotherapy in small-cell lung cancer MAPK4 intron 20463552 rs2118370 chr18 48161544 G A 2.56E-04 Response to platinum-based chemotherapy in small-cell lung cancer MAPK4 intron 20463552 rs893316 chr18 48166556 C T 1.17E-04 Prion diseases MAPK4 intron 22210626 rs3813086 chr18 48188792 A G 2.29E-04 Blood pressure MAPK4 intron 17255346 rs3813086 chr18 48188792 A G 2.47E-04 Type 2 diabetes MAPK4 intron 17463246 rs9955932 chr18 48195259 G A 1.86E-04 Blood pressure MAPK4 intron 17255346 rs9956244 chr18 48195558 G A 9.94E-04 Endometrial cancer MAPK4 intron 24096698 rs1893489 chr18 48195661 C T 9.45E-05 Blood pressure MAPK4 intron 17255346 rs7240429 chr18 48243318 T C 1.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) MAPK4 intron 23648065 rs2586777 chr18 48330625 T C 4.79E-04 Prostate cancer mortality MRO intron 20978177 rs2849233 chr18 48331553 T C 3.63E-04 Prostate cancer mortality MRO missense 20978177 rs2849233 chr18 48331553 T C 5.59E-04 Response to taxane treatment (placlitaxel) MRO missense 23006423 rs2586775 chr18 48336154 A G 6.46E-04 Alzheimer's disease MRO intron 24755620 rs2586772 chr18 48340687 T C 6.08E-04 Alzheimer's disease MRO intron 24755620 rs2586771 chr18 48342476 G C 9.40E-04 Insulin resistance MRO intron 21901158 rs2586770 chr18 48343650 G A 3.34E-05 Cognitive performance MRO intron 19734545 rs2586770 chr18 48343650 G A 8.97E-04 Alzheimer's disease MRO intron 24755620 rs17663462 chr18 48358340 G A 9.07E-05 Cognitive performance / / 19734545 rs2847579 chr18 48362664 C A 6.34E-05 Hypertension (essential hypertension) / / 22184326 rs12954691 chr18 48371394 T C 8.21E-05 Height / / pha003010 rs12954691 chr18 48371394 T C 1.27E-05 Height / / pha003011 rs732528 chr18 48378234 T C 7.00E-06 Entorhinal cortical thickness / / 21116278 rs2850542 chr18 48403560 G T 3.85E-05 Bone mineral density ME2 nearGene-5 19181680 rs1033060 chr18 48426317 A G 4.18E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ME2 intron 20877124 rs1033060 chr18 48426317 A G 9.05E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ME2 intron 20877124 rs1033060 chr18 48426317 A G 4.86E-04 Suicide attempts in bipolar disorder ME2 intron 21423239 rs642633 chr18 48429604 T A 2.62E-04 Lymphocyte counts ME2 intron 22286170 rs9807334 chr18 48524161 G A 2.00E-07 Immune reponse to smallpox (secreted IFN-alpha) / / 22610502 rs11875522 chr18 48591762 G A 1.27E-10 HDL cholesterol SMAD4 intron 23063622 rs4940047 chr18 48677125 T G 4.25E-05 Personality dimensions / / 18957941 rs4940047 chr18 48677125 T G 7.40E-06 Urinary metabolites / / 21572414 rs7230711 chr18 48690619 A G 1.22E-06 Parkinson's disease (motor and cognition) / / 22658654 rs7230711 chr18 48690619 A G 1.00E-06 Immune response to anthrax vaccine / / 22658931 rs7229495 chr18 48695807 A G 3.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1539857 chr18 48697936 T C 2.49E-06 Parkinson's disease (motor and cognition) / / 22658654 rs1539857 chr18 48697936 T C 2.49E-06 Immune response to anthrax vaccine / / 22658931 rs8096445 chr18 48713040 C T 9.00E-09 Immune response to smallpox vaccine (IL-6) MEX3C intron 22610502 rs16952919 chr18 48735827 G T 7.28E-06 Parkinson's disease (motor and cognition) / / 22658654 rs16952919 chr18 48735827 G T 7.28E-06 Immune response to anthrax vaccine / / 22658931 rs10502916 chr18 48745119 G A 5.12E-05 Bone mineral density / / 19181680 rs16952953 chr18 48745852 T C 1.93E-06 Parkinson's disease (motor and cognition) / / 22658654 rs16952953 chr18 48745852 T C 1.93E-06 Immune response to anthrax vaccine / / 22658931 rs7238856 chr18 48746230 C T 2.38E-06 Parkinson's disease (motor and cognition) / / 22658654 rs7238856 chr18 48746230 C T 2.38E-06 Immune response to anthrax vaccine / / 22658931 rs7241194 chr18 48750133 C G 4.51E-06 Parkinson's disease (motor and cognition) / / 22658654 rs7241194 chr18 48750133 C G 4.51E-06 Immune response to anthrax vaccine / / 22658931 rs16953153 chr18 48840388 G A 2.90E-05 Cognitive test performance / / 20125193 rs11661595 chr18 48873826 A G 6.52E-05 Magnesium levels / / pha003092 rs2442968 chr18 48885419 A G 7.23E-04 Myocardial Infarction / / pha002883 rs6508069 chr18 48924702 G T 6.82E-05 Kawasaki disease LOC100287225 intron 22081228 rs16953405 chr18 48966202 G A 9.88E-05 Multiple complex diseases LOC100287225 intron 17554300 rs16953406 chr18 48968144 A G 1.71E-04 Multiple complex diseases LOC100287225 intron 17554300 rs7231829 chr18 49000596 C A 2.00E-06 Urinary metabolites LOC100287225 intron 21572414 rs1869843 chr18 49002679 C A 1.50E-05 Urinary metabolites LOC100287225 intron 21572414 rs1369765 chr18 49014317 T C 9.69E-04 Suicide attempts in bipolar disorder LOC100287225 intron 21423239 rs11082877 chr18 49014615 G A 8.11E-04 Endometrial cancer LOC100287225 intron 24096698 rs2082347 chr18 49038111 G C 0.00047 Personality disorders (PD) - Cluster C LOC100287225 intron 22981920 rs7231303 chr18 49063271 T C 1.20E-04 Vaspin levels LOC100287225 intron 22907691 rs7231303 chr18 49063271 T C 0.0001201 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks LOC100287225 intron 22907730 rs9959607 chr18 49081262 G A 8.08E-04 Alzheimer's disease LOC100287225 intron 17998437 rs1025450 chr18 49109894 T C 2.02E-06 Multiple complex diseases / / 17554300 rs16953567 chr18 49121467 T C 9.42E-04 Type 2 diabetes / / 17463246 rs2615561 chr18 49135742 A G 2.13E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs322551 chr18 49135938 G T 3.12E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs322550 chr18 49136645 G T 2.13E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2568456 chr18 49147416 A G 1.84E-04 Intracranial aneurysm / / 20613766 rs2615550 chr18 49162580 T C 9.59E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs16953666 chr18 49166331 G T 6.15E-04 Multiple complex diseases / / 17554300 rs322529 chr18 49175440 T A 9.53E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17751934 chr18 49201814 C T 0.00000916 Bisphosphonate-induced osteonecrosis of the jaw / / 22267851 rs1827645 chr18 49218800 A G 9.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs1676114 chr18 49225177 C A 7.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs1699913 chr18 49226367 C G 9.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs1699924 chr18 49235774 T C 7.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs1462453 chr18 49238293 G A 8.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs323084 chr18 49239047 T C 8.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs172829 chr18 49239209 C T 8.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs323083 chr18 49239749 C T 8.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs717527 chr18 49241464 G A 9.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs10502926 chr18 49242723 C A 9.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs2615547 chr18 49242852 C T 8.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs323081 chr18 49243635 C T 9.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs323080 chr18 49244058 A G 7.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs8099749 chr18 49245390 T G 9.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs7230792 chr18 49246537 C A 9.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs16953853 chr18 49247617 C G 6.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs9957731 chr18 49251309 G C 8.54E-05 Type 2 diabetes / / 17463246 rs16953869 chr18 49257610 G A 8.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs1394360 chr18 49265902 T A 7.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs323099 chr18 49266934 T C 9.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs323105 chr18 49276222 C G 2.17E-05 Depression (quantitative trait) / / 23290196 rs12955929 chr18 49279737 T G 3.28E-05 Depression (quantitative trait) / / 23290196 rs12955292 chr18 49281080 G A 4.44E-05 Depression (quantitative trait) / / 23290196 rs323097 chr18 49287112 A C 6.33E-05 Depression (quantitative trait) / / 23290196 rs9949310 chr18 49288934 T C 1.23E-04 Fibrinogen / / 17255346 rs9949310 chr18 49288934 T C 7.02E-05 Depression (quantitative trait) / / 23290196 rs323087 chr18 49290764 G A 2.09E-04 Multiple complex diseases / / 17554300 rs323092 chr18 49291961 A G 3.50E-04 Myasthenia gravis / / 23055271 rs7230877 chr18 49297654 T C 9.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs9949657 chr18 49298415 C T 6.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs16954006 chr18 49299819 C T 2.70E-06 Type 2 diabetes / / 17463246 rs16954006 chr18 49299819 C T 1.09E-25 Narcolepsy / / 19629137 rs8083614 chr18 49302211 A G 5.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs975733 chr18 49304611 T C 4.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs1504508 chr18 49313585 T C 5.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs822072 chr18 49322478 A T 7.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs1504512 chr18 49327350 C T 2.58E-04 Type 2 diabetes / / 17463246 rs12457252 chr18 49350277 T A 9.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs1383525 chr18 49351749 A G 4.27E-05 Serum metabolites / / 19043545 rs1383525 chr18 49351749 A G 8.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs1351435 chr18 49404964 T G 5.00E-06 Obesity-related traits / / 23251661 rs10520815 chr18 49434774 G A 5.22E-04 Stroke / / pha002887 rs2953261 chr18 49469467 G A 6.03E-05 Serum metabolites / / 19043545 rs5003334 chr18 49517190 G C 0.0000104 LDL cholesterol particle diameter / / 23263444 rs11662620 chr18 49529356 G T 1.31E-04 Multiple complex diseases / / 17554300 rs8094211 chr18 49545574 T C 0.0000165 LDL cholesterol particle diameter / / 23263444 rs9956761 chr18 49552032 G A 7.68E-05 Heart Rate / / pha003053 rs4075498 chr18 49572750 A G 8.86E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4075498 chr18 49572750 A G 4.09E-05 Heart Rate / / pha003053 rs4625815 chr18 49578533 G A 1.02E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7227964 chr18 49582382 G A 2.56E-04 Multiple complex diseases / / 17554300 rs12456701 chr18 49582708 A T 2.68E-04 Multiple complex diseases / / 17554300 rs4369770 chr18 49586080 G A 0.000465 Salmonella-induced pyroptosis / / 22837397 rs9966763 chr18 49643056 G C 2.58E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4401133 chr18 49653903 C A 5.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12326228 chr18 49665498 T C 5.17E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7243527 chr18 49680361 A C 2.70E-05 Urinary metabolites / / 21572414 rs7234019 chr18 49715124 C A 8.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2044350 chr18 49720023 C G 6.73E-04 Obesity (extreme) / / 21935397 rs4939693 chr18 49720850 T C 6.93E-04 Obesity (extreme) / / 21935397 rs7232159 chr18 49727080 G A 2.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12326784 chr18 49738276 T C 5.60E-06 Urinary metabolites / / 21572414 rs1445102 chr18 49740360 T C 3.15E-04 Smoking initiation / / 24665060 rs1373765 chr18 49746600 T C 6.40E-04 Type 2 diabetes / / 17463246 rs16954504 chr18 49750952 C T 4.89E-04 Multiple complex diseases / / 17554300 rs1373762 chr18 49754077 T C 5.38E-05 Heart Rate / / pha003054 rs1373755 chr18 49786402 A T 9.27E-04 Type 2 diabetes / / 17463246 rs352135 chr18 49832132 A G 1.71E-05 Personality dimensions / / 22628180 rs8089554 chr18 49840378 A G 1.50E-05 Personality dimensions / / 22628180 rs8096242 chr18 49843566 G A 3.94E-04 Alzheimer's disease (late onset) / / 21379329 rs191604 chr18 49847072 C G 1.52E-05 Personality dimensions / / 22628180 rs352138 chr18 49851496 C T 2.87E-05 Personality dimensions / / 22628180 rs919634 chr18 49857598 A G 2.97E-05 Personality dimensions / / 22628180 rs10853617 chr18 49858801 T A 3.00E-05 Personality dimensions / / 22628180 rs4940174 chr18 49859963 A T 2.75E-05 Personality dimensions / / 22628180 rs4940175 chr18 49860336 A G 2.77E-05 Personality dimensions / / 22628180 rs1443573 chr18 49874596 T C 1.46E-05 Personality dimensions DCC intron 22628180 rs1443570 chr18 49878620 G A 6.13E-06 Personality dimensions DCC intron 22628180 rs959655 chr18 49878864 G C 6.13E-06 Personality dimensions DCC intron 22628180 rs768207 chr18 49878970 C A 1.35E-04 Bone mass and geometry DCC intron 17903296 rs1443568 chr18 49880242 A G 2.59E-04 Multiple complex diseases DCC intron 17554300 rs17754086 chr18 49880909 G A 9.36E-04 Multiple complex diseases DCC intron 17554300 rs10502943 chr18 49901001 A C 9.50E-04 Type 2 diabetes and 6 quantitative traits DCC intron 17848626 rs7230231 chr18 49901714 A G 7.55E-04 Multiple complex diseases DCC intron 17554300 rs11660123 chr18 49905353 A G 7.60E-05 Suicide attempts in bipolar disorder DCC intron 21423239 rs8093706 chr18 49913071 A C 7.47E-04 Suicide attempts in bipolar disorder DCC intron 21423239 rs7231326 chr18 49915410 G A 2.06E-04 Suicide attempts in bipolar disorder DCC intron 21423239 rs12969035 chr18 49926669 A T 4.63E-05 Suicide attempts in bipolar disorder DCC intron 21423239 rs12970400 chr18 49926787 T C 2.40E-04 Suicide attempts in bipolar disorder DCC intron 21423239 rs3915401 chr18 49934606 C A 1.34E-04 Suicide attempts in bipolar disorder DCC intron 21423239 rs16954942 chr18 49947799 C T 1.40E-05 Multiple complex diseases DCC intron 17554300 rs2960617 chr18 49948735 A C 2.00E-04 Cognitive impairment induced by topiramate DCC intron 22091778 rs17827880 chr18 49969561 T C 4.00E-04 Response to alcohol consumption (flushing response) DCC intron 24277619 rs2168159 chr18 50026915 C T 2.89E-04 Myocardial Infarction DCC intron pha002883 rs1144049 chr18 50030912 T C 4.52E-05 Coronary heart disease DCC intron pha003032 rs1031062 chr18 50038122 T G 5.46E-04 Suicide attempts in bipolar disorder DCC intron 21041247 rs1671253 chr18 50040561 G A 7.04E-05 Obsessive-compulsive disorder DCC intron 24821223 rs1671253 chr18 50040561 G A 7.04E-05 Obsessive-compulsive disorder DCC intron 24821223 rs12964400 chr18 50052362 A G 3.75E-04 Suicide attempts in bipolar disorder DCC intron 21041247 rs1349930 chr18 50052729 C G 4.80E-04 Suicide attempts in bipolar disorder DCC intron 21041247 rs1349929 chr18 50064926 G A 9.10E-06 Urinary metabolites DCC intron 21572414 rs2165649 chr18 50074384 A G 4.82E-04 Suicide attempts in bipolar disorder DCC intron 21423239 rs1550567 chr18 50089518 G A 7.97E-04 Suicide attempts in bipolar disorder DCC intron 21041247 rs11665228 chr18 50095540 T C 3.70E-04 Suicide attempts in bipolar disorder DCC intron 21041247 rs12961437 chr18 50106099 T C,G 3.68E-04 Suicide attempts in bipolar disorder DCC intron 21041247 rs4940191 chr18 50108230 G A 7.80E-04 Suicide attempts in bipolar disorder DCC intron 21041247 rs12456699 chr18 50124246 A G 7.29E-04 Suicide attempts in bipolar disorder DCC intron 21423239 rs1145300 chr18 50126359 T A 9.26E-04 Type 2 diabetes DCC intron 17463246 rs1145300 chr18 50126359 T A 2.24E-04 Suicide attempts in bipolar disorder DCC intron 21423239 rs1144101 chr18 50128294 A C 2.31E-04 Suicide attempts in bipolar disorder DCC intron 21423239 rs16955291 chr18 50129323 G A 5.19E-04 Coronary heart disease DCC intron 21606135 rs9304426 chr18 50130153 G A 2.58E-04 Suicide attempts in bipolar disorder DCC intron 21423239 rs1221872 chr18 50130337 A G 2.48E-04 Suicide attempts in bipolar disorder DCC intron 21423239 rs1221872 chr18 50130337 A G 5.80E-05 Alcoholism (heaviness of drinking) DCC intron 21529783 rs1221874 chr18 50131110 A G 2.19E-04 Suicide attempts in bipolar disorder DCC intron 21423239 rs1221874 chr18 50131110 A G 6.40E-05 Alcoholism (heaviness of drinking) DCC intron 21529783 rs1221876 chr18 50132161 A T 3.97E-04 Suicide attempts in bipolar disorder DCC intron 21423239 rs995831 chr18 50132645 G C 3.70E-04 Suicide attempts in bipolar disorder DCC intron 21423239 rs1221877 chr18 50133826 A G 3.88E-04 Suicide attempts in bipolar disorder DCC intron 21423239 rs1221877 chr18 50133826 A G 5.70E-05 Alcoholism (heaviness of drinking) DCC intron 21529783 rs1221881 chr18 50134261 A T 3.54E-04 Suicide attempts in bipolar disorder DCC intron 21423239 rs1221883 chr18 50135265 C T 5.22E-04 Suicide attempts in bipolar disorder DCC intron 21423239 rs1221884 chr18 50135346 A G 5.06E-04 Suicide attempts in bipolar disorder DCC intron 21423239 rs1221884 chr18 50135346 A G 7.10E-05 Alcoholism (heaviness of drinking) DCC intron 21529783 rs1675217 chr18 50137957 T G 7.75E-04 Aortic root size DCC intron 21223598 rs1221864 chr18 50144533 A G 9.71E-04 Alzheimer's disease DCC intron 17998437 rs7231528 chr18 50158120 T C 6.44E-05 Schizophrenia DCC intron 19571809 rs12606713 chr18 50179844 A G 1.74E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) DCC intron 24023788 rs11082932 chr18 50180139 C A 6.03E-04 Alzheimer's disease DCC intron 24755620 rs17749090 chr18 50185457 T C 4.75E-05 Alzheimer's disease DCC intron 24755620 rs7242423 chr18 50192001 G A 9.79E-07 Multiple complex diseases DCC intron 17554300 rs7242423 chr18 50192001 G A 0.00008 Major depressive disorder DCC intron 23149448 rs4940203 chr18 50192396 C T 5.00E-07 Obesity-related traits DCC intron 23251661 rs9966348 chr18 50192702 C A 3.47E-04 Age-related macular degeneration DCC intron 22125219 rs8086577 chr18 50209369 T A,C 3.06E-05 Response to mTOR inhibitor (everolimus) DCC intron 24009623 rs1460196 chr18 50215412 C T 9.00E-06 Response to mTOR inhibitor (everolimus) DCC intron 24009623 rs9959862 chr18 50225570 G C 2.49E-05 Alzheimer's disease DCC intron 17998437 rs9952236 chr18 50235853 A G 2.39E-05 Behcet's disease DCC intron 23291587 rs6508153 chr18 50262963 C A 4.46E-05 Brain structure DCC intron 22504417 rs16955448 chr18 50269252 A T 6.53E-04 Type 2 diabetes DCC intron 17463246 rs10083941 chr18 50282122 C T 1.20E-05 Alcoholism (heaviness of drinking) DCC intron 21529783 rs768048 chr18 50285398 C T 8.00E-06 Alcoholism (alcohol use disorder factor score) DCC intron 21529783 rs6508159 chr18 50288020 C A 1.20E-05 Alcoholism (heaviness of drinking) DCC intron 21529783 rs10515956 chr18 50308432 G A 4.90E-05 Alcoholism (heaviness of drinking) DCC intron 21529783 rs9960581 chr18 50310772 C T 4.66E-04 Type 2 diabetes DCC intron 17463246 rs9953246 chr18 50311486 A T 3.28E-04 Type 2 diabetes DCC intron 17463246 rs9941444 chr18 50315007 G A 4.07E-04 Type 2 diabetes DCC intron 17463246 rs10469016 chr18 50326885 G A 2.70E-05 Alcoholism (heaviness of drinking) DCC intron 21529783 rs1893572 chr18 50346997 G C 4.76E-05 Serum metabolites DCC intron 19043545 rs16955601 chr18 50353638 C G 5.81E-04 Multiple complex diseases DCC intron 17554300 rs9948007 chr18 50355807 T C 5.88E-04 Type 2 diabetes DCC intron 17463246 rs4998815 chr18 50367700 T G 7.10E-06 Urinary metabolites DCC intron 21572414 rs1573410 chr18 50368768 A G 5.80E-06 Urinary metabolites DCC intron 21572414 rs1573409 chr18 50368797 G A 2.90E-06 Urinary metabolites DCC intron 21572414 rs6508168 chr18 50376909 C G 3.40E-06 Urinary metabolites DCC intron 21572414 rs17387869 chr18 50404757 T C 2.90E-05 Urinary metabolites DCC intron 21572414 rs2156283 chr18 50430275 G A 6.20E-04 Multiple complex diseases DCC intron 17554300 rs12455748 chr18 50435971 G C 6.02E-04 Type 2 diabetes DCC intron 17463246 rs16955848 chr18 50448235 C T 4.69E-05 Multiple complex diseases DCC intron 17554300 rs1943132 chr18 50466897 G A 3.60E-05 Gallbladder cancer DCC intron 22318345 rs950279 chr18 50467474 G A 9.45E-05 Diabetes Mellitus DCC intron pha003060 rs7504990 chr18 50517776 T C 7.00E-08 Gallbladder cancer DCC intron 22318345 rs7506663 chr18 50519527 T C 3.67E-07 Gallbladder cancer DCC intron 22318345 rs9957080 chr18 50520733 G T 7.46E-08 Gallbladder cancer DCC intron 22318345 rs9304437 chr18 50521566 T G 7.46E-08 Gallbladder cancer DCC intron 22318345 rs7507060 chr18 50525557 C T 7.46E-08 Gallbladder cancer DCC intron 22318345 rs11082960 chr18 50525840 G T 7.46E-08 Gallbladder cancer DCC intron 22318345 rs7504512 chr18 50529637 G A 4.21E-08 Gallbladder cancer DCC intron 22318345 rs7506454 chr18 50533671 G A 3.15E-07 Gallbladder cancer DCC intron 22318345 rs9944713 chr18 50534412 C A 3.15E-07 Gallbladder cancer DCC intron 22318345 rs7233818 chr18 50535809 T C 3.15E-07 Gallbladder cancer DCC intron 22318345 rs9951405 chr18 50536604 A G 1.45E-04 Gallbladder cancer DCC intron 22318345 rs4940234 chr18 50538552 C A 3.15E-07 Gallbladder cancer DCC intron 22318345 rs4077283 chr18 50546319 G A 3.15E-07 Gallbladder cancer DCC intron 22318345 rs4078289 chr18 50547105 A G 3.15E-07 Gallbladder cancer DCC intron 22318345 rs4078288 chr18 50547251 G A 3.19E-07 Gallbladder cancer DCC intron 22318345 rs7504750 chr18 50547640 C A 3.15E-07 Gallbladder cancer DCC intron 22318345 rs11874663 chr18 50567129 G A 1.20E-05 Urinary metabolites DCC intron 21572414 rs4129439 chr18 50589083 T C 5.72E-04 Amyotrophic Lateral Sclerosis DCC intron 17362836 rs4995148 chr18 50597529 T A 1.10E-06 Urinary metabolites DCC intron 21572414 rs9945776 chr18 50617497 A G 9.47E-04 Type 2 diabetes DCC intron 17463246 rs9945776 chr18 50617497 A G 1.49E-04 Multiple complex diseases DCC intron 17554300 rs16956114 chr18 50623189 G A 3.10E-06 Urinary metabolites DCC intron 21572414 rs4321259 chr18 50623640 G A 1.28E-05 Platelet counts DCC intron 21507922 rs11082969 chr18 50680524 C G 9.03E-04 Type 2 diabetes DCC intron 17463246 rs4614799 chr18 50694304 G A 8.18E-04 Type 2 diabetes DCC intron 17463246 rs4277413 chr18 50698926 G A 1.28E-05 Platelet counts DCC intron 21507922 rs4939728 chr18 50793071 A G 9.68E-04 Type 2 diabetes DCC intron 17463246 rs9966618 chr18 50810506 T C 1.16E-04 Smoking initiation DCC intron 24665060 rs12963046 chr18 50836912 A G 7.57E-04 Smoking initiation DCC intron 24665060 rs965943 chr18 50857430 A G 8.37E-05 Age-related macular degeneration DCC intron pha000002 rs9950970 chr18 50863808 T C 2.87E-05 Age-related macular degeneration DCC intron 21197116 rs1367634 chr18 50864668 T G 4.87E-05 Age-related macular degeneration DCC intron 21197116 rs12954274 chr18 50865874 C T 3.46E-05 Age-related macular degeneration DCC intron 21197116 rs11874922 chr18 50886168 A G 7.85E-04 Oral cancers (chewing tobacco related) DCC intron 22503698 rs17504372 chr18 50903050 C T 5.99E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) DCC intron 23648065 rs1394466 chr18 50905206 A G 4.19E-04 Alzheimer's disease DCC intron 17998437 rs17504520 chr18 50905357 G T 7.37E-04 Alzheimer's disease DCC intron 17998437 rs11876941 chr18 50906031 G A 5.00E-06 Body mass index (interaction) DCC intron 23192594 rs12604940 chr18 50972215 A G 4.58E-04 Oral cancers (chewing tobacco related) DCC intron 22503698 rs200386788 chr18 50994295 G A 0.00035 Breast cancer DCC missense 23555315 rs4280318 chr18 50998348 G C 7.31E-04 Alzheimer's disease DCC intron 17998437 rs4940260 chr18 51001129 T C 7.85E-04 Alzheimer's disease DCC intron 17998437 rs1393337 chr18 51005241 G A 3.57E-04 Type 2 diabetes DCC intron 17463246 rs8082807 chr18 51010902 A C 7.78E-04 Response to taxane treatment (placlitaxel) DCC intron 23006423 rs8088048 chr18 51054765 T C 7.50E-04 Type 2 diabetes DCC intron 17463246 rs2270954 chr18 51057298 A C 3.67E-04 Multiple complex diseases DCC UTR-3 17554300 rs2270954 chr18 51057298 A C 1.57E-04 Oral cancers (chewing tobacco related) DCC UTR-3 22503698 rs4245262 chr18 51063841 T C 3.36E-05 Type 2 diabetes / / 17463246 rs7233241 chr18 51093875 T C 7.76E-05 Chronic obstructive pulmonary disease / / 19300482 rs1899384 chr18 51103889 T C 7.19E-05 Cognitive impairment induced by topiramate / / 22091778 rs7236483 chr18 51113479 C A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12604310 chr18 51124040 A G 5.47E-04 Type 2 diabetes / / 17463246 rs894274 chr18 51129489 A G 3.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4347699 chr18 51183679 G A 4.82E-05 Bipolar disorder and schizophrenia / / 20889312 rs1442080 chr18 51184594 G A 2.86E-05 F-cell distribution / / 21326311 rs6508244 chr18 51186543 T C 3.02E-04 Height / / 17255346 rs17519016 chr18 51190090 T A 3.32E-05 Body mass (lean) / / 19268274 rs1811441 chr18 51192592 A G 2.24E-05 Schizophrenia / / 19571811 rs7240087 chr18 51195083 G A 1.24E-05 Body mass (lean) / / 19268274 rs1364461 chr18 51248682 C G 8.97E-04 Multiple complex diseases / / 17554300 rs9946329 chr18 51263487 T C 8.83E-04 Multiple complex diseases / / 17554300 rs10502983 chr18 51266566 T C 1.23E-05 Body mass (lean) / / 19268274 rs12457654 chr18 51280499 T C 7.43E-04 Type 2 diabetes / / 17463246 rs8087095 chr18 51297743 G A 9.40E-04 Type 2 diabetes / / 17463246 rs8087095 chr18 51297743 G A 3.54E-06 Serum metabolites / / 19043545 rs7504347 chr18 51402644 G A 6.23E-04 Multiple complex diseases / / 17554300 rs16957445 chr18 51403368 C T 8.16E-06 Schizophrenia / / 21926974 rs1498164 chr18 51432215 A T 7.12E-04 Multiple complex diseases / / 17554300 rs904276 chr18 51434340 T C 0.0005 Breast cancer / / 22258532 rs904276 chr18 51434340 T C 0.000325 Salmonella-induced pyroptosis / / 22837397 rs4569360 chr18 51449053 T C 0.000746 Salmonella-induced pyroptosis / / 22837397 rs9956700 chr18 51451700 G T 7.48E-06 Lipoproteins / / pha003079 rs1498134 chr18 51465208 G A 7.39E-04 Type 2 diabetes / / 17463246 rs11659290 chr18 51467234 G A 4.06E-05 Lipoproteins / / pha003079 rs4131468 chr18 51473193 A T 8.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17533756 chr18 51473853 C T 7.01E-06 Periodontitis (Mean PAL) / / 24024966 rs1498139 chr18 51478026 A C 3.36E-05 Monocyte chemoattractant protein-1 / / pha003071 rs11660673 chr18 51486832 G A 4.64E-05 Lipoproteins / / pha003079 rs7236513 chr18 51490042 G T 6.09E-06 Periodontitis (Mean PAL) / / 24024966 rs9951511 chr18 51490284 T C 4.11E-05 Lipoproteins / / pha003079 rs8088499 chr18 51506899 G T 3.16E-05 Lipoproteins / / pha003079 rs9947105 chr18 51510546 C T 3.16E-05 Lipoproteins / / pha003079 rs67283606 chr18 51510571 T C 8.70E-06 Periodontitis (Mean PAL) / / 24024966 rs9951640 chr18 51511640 T C 2.92E-05 Lipoproteins / / pha003079 rs4129335 chr18 51517355 G C 7.37E-06 Periodontitis (Mean PAL) / / 24024966 rs67463530 chr18 51519051 G C 7.71E-06 Periodontitis (Mean PAL) / / 24024966 rs9304456 chr18 51520620 G A 3.72E-05 Lipoproteins / / pha003079 rs1995138 chr18 51526568 G A 4.00E-06 Periodontitis (Mean PAL) / / 24024966 rs1826972 chr18 51532725 T C 6.76E-06 Periodontitis (Mean PAL) / / 24024966 rs1259806 chr18 51551983 G A 1.07E-04 Type 2 diabetes / / 17463246 rs1259808 chr18 51553172 A G 8.88E-04 Type 2 diabetes / / 17463246 rs117215340 chr18 51569087 C T 0.0000702 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11083040 chr18 51596681 G A 2.30E-05 Urinary metabolites / / 21572414 rs117693452 chr18 51669866 A G 0.0000573 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7614 chr18 51681244 T C 0.0006 Breast cancer MBD2 UTR-3 22258532 rs4041245 chr18 51685525 T C 0.0009 Breast cancer MBD2 intron 22258532 rs8094493 chr18 51700391 T G 2.30E-05 Urinary metabolites MBD2 intron 21572414 rs8094493 chr18 51700391 T G 0.0009 Breast cancer MBD2 intron 22258532 rs4940321 chr18 51776460 G A 6.59E-06 Telomere length / / 23001564 rs666027 chr18 51797231 A G 8.68E-04 Multiple complex diseases POLI intron 17554300 rs3730723 chr18 51803898 A T 8.70E-04 Multiple complex diseases POLI intron 17554300 rs3730729 chr18 51804702 C T 4.40E-05 Asthma POLI intron 11022011 rs686881 chr18 51813534 A G 4.00E-33 Narcolepsy POLI intron 19629137 rs545979 chr18 51819750 C T 3.50E-10 Psoriasis POLI intron 23143594 rs1618800 chr18 51886850 A G 2.12E-04 Smoking initiation C18orf54 intron 24665060 rs145808382 chr18 51888070 C G 0.00022 Breast cancer C18orf54 missense 23555315 rs11872614 chr18 51899514 A G 2.18E-04 Multiple complex diseases C18orf54 intron 17554300 rs2118288 chr18 51910314 A G 7.49E-04 Multiple complex diseases / / 17554300 rs3936759 chr18 51962431 T C 3.66E-04 Stroke / / pha002887 rs6508304 chr18 51976000 T C 1.00E-04 Response to TNF antagonist treatment / / 21061259 rs8092229 chr18 51976374 A G 1.00E-04 Prostate cancer / / 21743057 rs7238584 chr18 51976578 T C 1.00E-04 Prostate cancer / / 21743057 rs6508305 chr18 51976885 T C 1.00E-04 Prostate cancer / / 21743057 rs7243226 chr18 51977617 G A 5.16E-04 Response to TNF antagonist treatment / / 21061259 rs16958339 chr18 51978349 A G 1.00E-04 Prostate cancer / / 21743057 rs10502991 chr18 51989289 G A 1.00E-05 Volumetric brain MRI / / 17903297 rs1608516 chr18 52003106 A T 1.00E-04 Prostate cancer / / 21743057 rs9630796 chr18 52027179 C A 6.53E-04 Smoking quantity / / 24665060 rs1866037 chr18 52033152 T C 3.58E-04 Response to TNF antagonist treatment / / 21061259 rs940312 chr18 52035521 C T 1.00E-04 Prostate cancer / / 21743057 rs1370362 chr18 52035679 A G 1.38E-04 Response to TNF antagonist treatment / / 21061259 rs1403885 chr18 52040247 G A 2.45E-04 Response to TNF antagonist treatment / / 21061259 rs16960608 chr18 52044425 G A 7.00E-06 Prostate cancer / / 21743057 rs8090228 chr18 52220942 C T 0.0000021 Mean arterial pressure / / 22510845 rs1155789 chr18 52296359 G A 3.04E-05 Multiple complex diseases / / 17554300 rs8088716 chr18 52325144 A G 5.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1451940 chr18 52325804 G A 8.90E-05 Serum metabolites / / 19043545 rs723940 chr18 52328815 C A 8.90E-05 Serum metabolites / / 19043545 rs7229280 chr18 52393744 A G 1.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs9958683 chr18 52407917 C A 1.06E-04 Smoking initiation / / 24665060 rs7238548 chr18 52411452 G C 3.22E-04 Smoking initiation / / 24665060 rs9319913 chr18 52474765 C T 5.83E-04 Multiple complex diseases / / 17554300 rs2311120 chr18 52477123 A G 1.22E-05 Attention deficit hyperactivity disorder / / 18980221 rs2311120 chr18 52477123 A G 2.14E-05 Attention deficit hyperactivity disorder / / pha002875 rs2008315 chr18 52484889 G A 6.72E-05 Sudden cardiac arrest / / 21658281 rs2006776 chr18 52504498 A G 1.30E-04 Type 2 diabetes and 6 quantitative traits RAB27B intron 17848626 rs4801103 chr18 52530018 G A 1.40E-05 Urinary metabolites RAB27B intron 21572414 rs11152031 chr18 52533038 C T 9.90E-06 Urinary metabolites RAB27B intron 21572414 rs11152033 chr18 52535785 T C 1.60E-05 Urinary metabolites RAB27B intron 21572414 rs2018709 chr18 52536724 A G 1.70E-05 Urinary metabolites RAB27B intron 21572414 rs33976189 chr18 52548995 A C 7.74E-04 Type 2 diabetes RAB27B intron 17463246 rs1978357 chr18 52550061 C T 1.72E-04 Type 2 diabetes RAB27B intron 17463246 rs3737477 chr18 52551716 C T 8.46E-04 Type 2 diabetes RAB27B intron 17463246 rs4801109 chr18 52571434 T C 3.03E-34 Narcolepsy CCDC68 UTR-3 19629137 rs6566950 chr18 52575269 G C 3.21E-09 Multiple complex diseases CCDC68 intron 17554300 rs11665320 chr18 52581893 G A 8.31E-05 Cognitive test performance CCDC68 intron 20125193 rs11665320 chr18 52581893 G A 8.03E-05 Coronary heart disease CCDC68 intron pha003030 rs9963419 chr18 52648055 T C 8.71E-05 Serum metabolites / / 19043545 rs9955009 chr18 52715175 T C 7.76E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4309482 chr18 52750469 A G 6.45E-04 Schizophrenia / / 19197363 rs4309482 chr18 52750469 A G 9.68E-07 Schizophrenia / / 21747397 rs4309482 chr18 52750469 A G 7.80E-09 Schizophrenia / / 21791550 rs4309482 chr18 52750469 A G 0.0000003 Psychosis / / 23164818 rs4309482 chr18 52750469 A G 0.000017 Schizophrenia / / 23164818 rs12966547 chr18 52752017 G A 3.00E-08 Schizophrenia / / 21926974 rs12966547 chr18 52752017 G A 3.00E-10 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs12966547 chr18 52752017 G A 0.00000623 Schizophrenia / / 23637625 rs4801131 chr18 52752700 C T 1.00E-08 Schizophrenia / / 23974872 rs9958798 chr18 52769637 T C 7.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4510110 chr18 52780909 A G 5.60E-05 Major depressive disorder / / 21042317 rs4801135 chr18 52783138 T C 2.56E-04 Alzheimer's disease / / 24755620 rs10502995 chr18 52805876 G A 6.88E-07 Esophageal cancer (squamous cell) / / 22960999 rs4800982 chr18 52809403 G A 2.70E-05 Major depressive disorder / / 21042317 rs4800982 chr18 52809403 G A 1.17E-06 Vascular dementia / / 22116812 rs729053 chr18 52809681 G C 3.41E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs8099483 chr18 52812241 T A 9.58E-04 Multiple complex diseases / / 17554300 rs8099483 chr18 52812241 T A 2.50E-05 Major depressive disorder / / 21042317 rs1942263 chr18 52817175 A G 4.62E-04 Alzheimer's disease / / 24755620 rs9951150 chr18 52821124 A G 2.60E-05 Major depressive disorder / / 21042317 rs9951150 chr18 52821124 A G 6.00E-07 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs4800985 chr18 52829535 C T 1.15E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12607567 chr18 52858659 G A 3.50E-06 Diabetic retinopathy / / 21441570 rs1970671 chr18 52863108 C G 3.00E-06 Diabetic retinopathy / / 21441570 rs1261078 chr18 52866791 A G 3.64E-04 Insulin resistance / / 21901158 rs1261097 chr18 52868977 T G 6.10E-06 Diabetic retinopathy / / 21441570 rs9953026 chr18 52877266 C T 2.30E-05 Urinary metabolites / / 21572414 rs11665032 chr18 52886611 C T 1.98E-04 Type 2 diabetes / / 17463246 rs2276195 chr18 52896509 G A 9.24E-04 Type 2 diabetes TCF4 intron 17463246 rs41339445 chr18 52896630 G T 2.60E-05 Urinary metabolites TCF4 intron 21572414 rs10515969 chr18 52903814 T C 4.14E-04 Alzheimer's disease (late onset) TCF4 intron 21379329 rs1261073 chr18 52907820 A C 8.74E-04 Type 2 diabetes TCF4 intron 17463246 rs1942265 chr18 52915567 G C 2.19E-04 Type 2 diabetes TCF4 intron 17463246 rs4800988 chr18 52919906 A T 2.14E-04 Type 2 diabetes TCF4 intron 17463246 rs1261093 chr18 52920950 C T 5.04E-04 Suicide attempts in bipolar disorder TCF4 intron 21423239 rs1539951 chr18 52921673 T C 2.08E-04 Type 2 diabetes TCF4 intron 17463246 rs41437147 chr18 52926576 T C 2.10E-05 Urinary metabolites TCF4 intron 21572414 rs35969244 chr18 52927400 T C 2.10E-05 Urinary metabolites TCF4 intron 21572414 rs1788027 chr18 52942827 G A 7.37E-04 Suicide attempts in bipolar disorder TCF4 intron 21423239 rs1261117 chr18 52949657 T C 3.00E-10 Schizophrenia TCF4 intron 23894747 rs10502998 chr18 52984980 T A 1.54E-04 Multiple complex diseases TCF4 intron 17554300 rs1788026 chr18 53011114 G A 5.65E-04 Smoking initiation TCF4 intron 24665060 rs1631486 chr18 53026357 G A 4.00E-06 Obesity (early onset extreme) TCF4 intron 23563609 rs9646596 chr18 53049212 G A 2.60E-07 Schizophrenia (treatment refractory) TCF4 intron 22479419 rs17594526 chr18 53058238 C T 1.00E-07 Schizophrenia TCF4 intron 19571811 rs17594526 chr18 53058238 C T 1.30E-07 Schizophrenia (treatment refractory) TCF4 intron 22479419 rs12607679 chr18 53059748 T C 3.23E-04 Body mass index TCF4 intron 21701565 rs17594665 chr18 53063719 G A 1.60E-07 Schizophrenia (treatment refractory) TCF4 intron 22479419 rs17594721 chr18 53065892 A G 3.70E-07 Schizophrenia (treatment refractory) TCF4 intron 22479419 rs1020169 chr18 53066079 T A 7.32E-04 Body mass index TCF4 intron 21701565 rs11152369 chr18 53066328 A C 2.00E-07 Schizophrenia (treatment refractory) TCF4 intron 22479419 rs11152369 chr18 53066328 A C 2.00E-07 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) TCF4 intron 23453885 rs17509991 chr18 53067184 G A 2.90E-07 Schizophrenia (treatment refractory) TCF4 intron 22479419 rs17510124 chr18 53068680 T C 3.80E-07 Schizophrenia (treatment refractory) TCF4 intron 22479419 rs7228846 chr18 53074618 A G 2.80E-07 Schizophrenia (treatment refractory) TCF4 intron 22479419 rs8089309 chr18 53075292 A C 3.80E-07 Schizophrenia (treatment refractory) TCF4 intron 22479419 rs2958186 chr18 53077795 C T 1.77E-04 Body mass index TCF4 intron 21701565 rs1371832 chr18 53082236 C T 4.00E-07 Schizophrenia (treatment refractory) TCF4 intron 22479419 rs2919451 chr18 53084300 C T 2.40E-05 Urinary metabolites TCF4 intron 21572414 rs7231748 chr18 53109035 A G 6.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) TCF4 intron 17982456 rs1452788 chr18 53117304 A G 9.30E-04 Neuroticism TCF4 intron 17667963 rs2924328 chr18 53133740 T C 4.49E-04 Major depressive disorder TCF4 intron 22472876 rs2924329 chr18 53135894 G A 9.37E-05 Partial epilepsies TCF4 intron 20522523 rs17511755 chr18 53149722 G C 8.43E-06 Multiple complex diseases TCF4 intron 17554300 rs17511755 chr18 53149722 G C 0.0000132 LDL cholesterol particle diameter TCF4 intron 23263444 rs2958183 chr18 53150076 A G 9.39E-04 Type 2 diabetes TCF4 intron 17463246 rs9960767 chr18 53155002 A C 4.00E-09 Schizophrenia TCF4 intron 19571808 rs9960767 chr18 53155002 A C 4.20E-09 Schizophrenia TCF4 intron 21791550 rs9960767 chr18 53155002 A C 4.10E-09 Schizophrenia (treatment refractory) TCF4 intron 22479419 rs9960767 chr18 53155002 A C 0.0000018 Psychosis TCF4 intron 23164818 rs9960767 chr18 53155002 A C 0.00057 Schizophrenia TCF4 intron 23164818 rs9960767 chr18 53155002 A C 0.00000586 LDL cholesterol particle diameter TCF4 intron 23263444 rs12327270 chr18 53168073 A G 0.00000599 LDL cholesterol particle diameter TCF4 intron 23263444 rs12956276 chr18 53175966 G A 5.87E-05 Post-operative nausea and vomiting TCF4 intron 21694509 rs17512836 chr18 53194961 T C 1.00E-06 Schizophrenia TCF4 intron 21926974 rs1452787 chr18 53207207 A G 3.00E-08 Sclerosing cholangitis and ulcerative colitis (combined) TCF4 intron 22821403 rs613872 chr18 53210302 G T 8.93E-05 Psoriasis TCF4 intron 18364390 rs613872 chr18 53210302 G T 1.00E-18 Fuchs's corneal dystrophy TCF4 intron 20825314 rs613872 chr18 53210302 G T 1.76E-04 Lung function (forced vital capacity) TCF4 intron 24023788 rs41396445 chr18 53242137 C A 1.51E-04 Type 2 diabetes TCF4 intron 17463246 rs17061809 chr18 53267742 C G 4.29E-05 Creutzfeldt-Jakob disease (variant) TCF4 intron 22137330 rs635538 chr18 53273614 G A 1.22E-04 Alzheimer's disease (late onset) TCF4 intron 21379329 rs635538 chr18 53273614 G A 9.60E-04 Major depressive disorder TCF4 intron 22472876 rs9951280 chr18 53276523 G A 5.64E-04 Type 2 diabetes TCF4 intron 17463246 rs10871582 chr18 53276589 G T 5.80E-04 Type 2 diabetes TCF4 intron 17463246 rs7236100 chr18 53302321 A G 5.38E-04 Acute lung injury TCF4 intron 22295056 rs12458015 chr18 53305735 T C 7.30E-06 Primary sclerosing cholangitis / / 21151127 rs34888346 chr18 53361131 A C 4.40E-04 Urinary metabolites / / 21572414 rs4800995 chr18 53415377 G A 2.14E-04 Alzheimer's disease (late onset) / / 21379329 rs9947593 chr18 53448395 T C 6.26E-04 Smoking initiation / / 24665060 rs12455398 chr18 53455923 A G 1.45E-04 Height / / 17255346 rs1031830 chr18 53464767 G A 5.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1531519 chr18 53480206 T C 5.64E-05 Schizophrenia / / 19197363 rs9966697 chr18 53527330 G A 1.58E-04 Multiple complex diseases / / 17554300 rs8092776 chr18 53531732 G A 2.43E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17602354 chr18 53565287 T C 2.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs9963616 chr18 53583104 A G 2.60E-05 Smoking cessation / / 24665060 rs9950331 chr18 53586052 A G 2.18E-05 Smoking cessation / / 24665060 rs1506633 chr18 53586671 T C 8.50E-04 Tourette syndrome / / 22889924 rs2588478 chr18 53625296 G T 3.60E-04 Type 2 diabetes / / 17463246 rs12327025 chr18 53628999 A G 3.32E-05 Smoking cessation / / 24665060 rs2588476 chr18 53630757 A G 1.30E-05 Intracerebral hemorrhage / / 24656865 rs1985049 chr18 53633786 T C 2.05E-04 Osteoarthritis / / 19508968 rs17603324 chr18 53636776 G A 0.000776 fMRI brain tests in schizophrenia / / 22440650 rs1424401 chr18 53640779 G A 0.00086 Prostate cancer / / 23555315 rs1424401 chr18 53640779 G A 4.68E-05 Triglycerides / / pha002904 rs2902193 chr18 53650309 A G 8.59E-05 Triglycerides / / pha002904 rs1978503 chr18 53664282 A G 1.00E-06 Breast cancer / / 17903305 rs1978503 chr18 53664282 A G 1.00E-06 Nasopharyngeal carcinoma / / 20512145 rs1978503 chr18 53664282 A G 1.03E-04 Intracranial aneurysm / / 20613766 rs8095403 chr18 53674492 A G 5.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1364417 chr18 53693949 C A 5.91E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs2161800 chr18 53694600 C T 3.18E-05 HIV-1 viral setpoint / / 21490045 rs2862260 chr18 53708692 A G 5.69E-05 HIV-1 viral setpoint / / 21490045 rs2535724 chr18 53727502 T C 1.88E-05 Type 2 diabetes / / 17463246 rs2535729 chr18 53736180 G A 7.45E-04 Type 2 diabetes / / 17463246 rs1945737 chr18 53744545 T C 9.15E-04 Type 2 diabetes / / 17463246 rs2588482 chr18 53747425 G A 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2187543 chr18 53753106 C T 1.00E-04 Cognitive impairment induced by topiramate LOC100505474 intron 22091778 rs8086702 chr18 53763260 T G 8.89E-05 Body Fat Distribution LOC100505474 intron pha003017 rs1792695 chr18 53782900 T G 8.29E-04 Multiple complex diseases LOC100505474 intron 17554300 rs12953613 chr18 53801555 T C 4.09E-04 Multiple complex diseases LOC100505474 intron 17554300 rs12953613 chr18 53801555 T C 5.49E-04 Body mass index LOC100505474 intron 21701565 rs1792745 chr18 53804993 T C 1.22E-05 Reading disability and language impairment / / 24024963 rs11151596 chr18 53810122 C A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs41362144 chr18 53815135 T C 1.75E-04 Multiple complex diseases / / 17554300 rs1792738 chr18 53845164 G A 4.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1792738 chr18 53845164 G A 3.57E-04 Response to alcohol consumption (flushing response) / / 24277619 rs12963861 chr18 53853489 C T 1.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12963861 chr18 53853489 C T 2.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12604483 chr18 53855525 A T 7.00E-06 HIV-1 susceptibility / / 21160409 rs1792728 chr18 53856680 G A 8.58E-04 Multiple complex diseases / / 17554300 rs11151630 chr18 53857981 C A 6.84E-04 Substance dependence / / 21818250 rs917712 chr18 53875290 A G 3.87E-04 Multiple complex diseases / / 17554300 rs1625778 chr18 53881022 G A 6.14E-05 Basophils / / pha003087 rs2006936 chr18 53907779 A G 7.50E-05 Alzheimer's disease (age of onset) / / 22005931 rs2538026 chr18 53928641 A G 8.91E-07 Asthma / / 11022011 rs1229598 chr18 53934787 A G 7.83E-07 Asthma / / 11022011 rs1229598 chr18 53934787 A G 5.29E-04 Type 2 diabetes / / 17463246 rs9959800 chr18 53964140 T A 1.70E-04 Neuroticism / / 17667963 rs17090137 chr18 53967581 C T 2.10E-04 Multiple complex diseases / / 17554300 rs10048254 chr18 54053578 G A 3.00E-06 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs12606566 chr18 54069099 G T 5.03E-04 Multiple complex diseases / / 17554300 rs302047 chr18 54109588 G A 8.85E-05 Pure-tone audiometry / / pha001963 rs17090195 chr18 54162135 A G 9.93E-04 Multiple complex diseases / / 17554300 rs6566784 chr18 54164713 C T 4.96E-04 Multiple complex diseases / / 17554300 rs663220 chr18 54200266 T C 2.30E-05 Urinary metabolites / / 21572414 rs655980 chr18 54211902 A T 2.82E-05 Type 2 diabetes / / 17463246 rs620024 chr18 54216469 A T 3.42E-05 Type 2 diabetes / / 17463246 rs683366 chr18 54219977 A G 1.20E-05 Subclinical atherosclerosis / / 17903303 rs602339 chr18 54242024 A G 4.42E-04 Type 2 diabetes / / 17463246 rs602339 chr18 54242024 A G 7.10E-06 Urinary metabolites / / 21572414 rs10513897 chr18 54283938 C T 2.77E-04 Alzheimer's disease TXNL1 intron 24755620 rs2234343 chr18 54305949 C T 4.69E-04 Alzheimer's disease / / 24755620 rs1005419 chr18 54308996 C T 8.24E-04 Multiple complex diseases / / 17554300 rs559998 chr18 54317023 G T 7.93E-04 Coronary heart disease / / 21606135 rs477415 chr18 54319099 A T 6.26E-04 Coronary heart disease WDR7 intron 21606135 rs633235 chr18 54341968 G A 4.90E-04 Multiple complex diseases WDR7 intron 17554300 rs12953387 chr18 54365965 C T 1.91E-04 Coronary heart disease WDR7 intron 21606135 rs11664579 chr18 54385713 A G 4.84E-04 Type 2 diabetes WDR7 intron 17463246 rs2080681 chr18 54388902 T G 2.43E-04 Coronary heart disease WDR7 intron 21606135 rs17750015 chr18 54397622 T C 8.00E-06 Depression and alcohol dependence WDR7 intron 22064162 rs9946253 chr18 54480479 A C 4.74E-04 Parkinson's disease WDR7 intron 17052657 rs1542006 chr18 54555423 C G 3.73E-04 Multiple complex diseases WDR7 intron 17554300 rs6566839 chr18 54557209 C G 1.45E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) WDR7 intron 17982456 rs2083020 chr18 54567759 A G 1.40E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) WDR7 intron 17982456 rs2043686 chr18 54581904 A G 3.32E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) WDR7 intron 17982456 rs8094838 chr18 54591871 A G 7.32E-04 Alzheimer's disease WDR7 intron 17998437 rs1657415 chr18 54649711 G A 8.66E-04 Type 2 diabetes WDR7 intron 17463246 rs1657421 chr18 54658824 C T 1.71E-05 Hemoglobin WDR7 intron pha003096 rs1657421 chr18 54658824 C T 7.99E-05 Hematocrit WDR7 intron pha003097 rs1787463 chr18 54659855 A G 8.19E-05 Hemoglobin WDR7 intron pha003096 rs1787479 chr18 54663205 C G 6.52E-04 Type 2 diabetes WDR7 intron 17463246 rs17830589 chr18 54675357 G T 4.73E-05 Serum albumin level WDR7 intron pha003084 rs2278495 chr18 54687813 G A 7.94E-04 Type 2 diabetes WDR7 intron 17463246 rs722091 chr18 54690271 G A 2.62E-04 Type 2 diabetes WDR7 intron 17463246 rs722090 chr18 54690287 C T 2.40E-04 Type 2 diabetes WDR7 intron 17463246 rs1657396 chr18 54696407 T C 9.54E-04 Multiple complex diseases WDR7 UTR-3 17554300 rs893168 chr18 54700894 G A 8.10E-05 Hemoglobin / / pha003096 rs4800956 chr18 54703529 T C 7.00E-04 Coronary heart disease / / 21606135 rs2027704 chr18 54705706 C T 3.37E-05 Hemoglobin / / pha003096 rs1630260 chr18 54711185 T C 2.27E-04 Smoking initiation / / 24665060 rs11661212 chr18 54714164 C T 2.19E-05 Multiple sclerosis (age of onset) / / 19010793 rs948654 chr18 54744144 G A 8.62E-04 Multiple complex diseases / / 17554300 rs1557351 chr18 54752314 T C 4.00E-06 Multiple sclerosis (age of onset) / / 19010793 rs948651 chr18 54754936 C T 1.58E-05 Multiple sclerosis (age of onset) / / 19010793 rs6566855 chr18 54761682 T C 9.32E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs948655 chr18 54773343 C T 5.39E-04 Response to TNF antagonist treatment / / 21061259 rs9319912 chr18 54784587 A T 3.34E-04 Response to TNF antagonist treatment / / 21061259 rs10439019 chr18 54799044 G A 3.35E-04 Response to TNF antagonist treatment / / 21061259 rs4801083 chr18 54804232 C A 1.47E-04 Multiple complex diseases / / 17554300 rs4801083 chr18 54804232 C A 9.27E-05 Attention deficit hyperactivity disorder / / 22420046 rs7506169 chr18 54804883 C T 5.49E-04 Multiple complex diseases / / 17554300 rs7235814 chr18 54807220 A G 3.35E-04 Response to TNF antagonist treatment / / 21061259 rs12605509 chr18 54847305 T A,G 8.12E-05 Insulin resistance / / 21901158 rs9952148 chr18 54847451 T C 5.61E-04 Insulin resistance / / 21901158 rs1943402 chr18 54854050 A G 6.69E-04 Insulin resistance / / 21901158 rs6566869 chr18 54856147 T C 3.23E-04 Insulin resistance / / 21901158 rs10163683 chr18 54856602 C T 6.04E-04 Insulin resistance / / 21901158 rs4800966 chr18 54872338 T C 4.19E-04 Insulin resistance / / 21901158 rs17063226 chr18 54873640 T C 9.19E-04 Type 2 diabetes / / 17463246 rs77512994 chr18 54886093 T C 1.51E-04 Acne (severe) / / 24927181 rs17063257 chr18 54889929 A T 7.31E-04 Type 2 diabetes / / 17463246 rs1943404 chr18 54926042 A T 7.11E-04 Type 2 diabetes / / 17463246 rs9955714 chr18 54946418 G C 8.25E-04 Type 2 diabetes / / 17463246 rs1120787 chr18 54983554 G T 7.00E-06 HIV-1 control / / 20041166 rs1943406 chr18 54986641 G A 4.39E-04 Alzheimer's disease / / 17998437 rs1943406 chr18 54986641 G A 2.20E-05 Coronary heart disease / / pha003030 rs1235694 chr18 54998867 G A 9.70E-05 HIV-1 control / / 20041166 rs1788828 chr18 55003293 C T 3.09E-04 Alzheimer's disease / / 17998437 rs641676 chr18 55013074 G A 7.05E-04 Alzheimer's disease / / 17998437 rs478765 chr18 55013866 A G 7.45E-04 Alzheimer's disease / / 17998437 rs625661 chr18 55014423 A T 6.47E-04 Alzheimer's disease / / 17998437 rs1230704 chr18 55016718 G A 9.40E-06 HIV-1 control / / 20041166 rs9951414 chr18 55018872 A C 2.40E-05 HIV-1 control / / 20041166 rs3745060 chr18 55021725 A C 4.89E-06 Coronary heart disease ST8SIA3 missense pha003030 rs1153626 chr18 55027334 G A,T 2.55E-06 Coronary heart disease ST8SIA3 cds-synon pha003030 rs1153623 chr18 55028651 A G 8.79E-06 Coronary heart disease ST8SIA3 UTR-3 pha003030 rs1942965 chr18 55032486 T C 6.06E-04 Type 2 diabetes ST8SIA3 UTR-3 17463246 rs608955 chr18 55043782 C T 6.58E-05 Coronary heart disease / / pha003030 rs2849460 chr18 55052923 C T 3.47E-05 Coronary heart disease / / pha003030 rs121318 chr18 55055455 T C 3.63E-05 Coronary heart disease / / pha003030 rs121317 chr18 55055482 T C 4.40E-05 Coronary heart disease / / pha003030 rs221852 chr18 55055647 T C 3.63E-05 Coronary heart disease / / pha003030 rs221877 chr18 55066546 A G 9.66E-06 Coronary heart disease / / pha003030 rs1217573 chr18 55074660 T C 3.33E-06 Coronary heart disease / / pha003030 rs1234635 chr18 55077122 G T 3.79E-05 Coronary heart disease / / pha003030 rs1217566 chr18 55089606 T C 3.76E-06 Coronary heart disease / / pha003030 rs652506 chr18 55138556 C T 6.72E-04 Multiple complex diseases ONECUT2 intron 17554300 rs570046 chr18 55144432 C T 9.99E-05 Response to mTOR inhibitor (rapamycin) ONECUT2 UTR-3 24009623 rs12456161 chr18 55160689 A G 1.31E-05 Sudden cardiac arrest / / 21658281 rs12454101 chr18 55161469 G A,C,T 3.39E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs644016 chr18 55164547 G A 6.13E-04 Acute lung injury / / 22295056 rs4940864 chr18 55183035 A T 4.70E-05 Multiple complex diseases / / 17554300 rs7242048 chr18 55197807 C T 4.72E-04 Depression (quantitative trait) / / 20800221 rs643693 chr18 55201053 A C 2.99E-05 Eosinophil counts / / pha003088 rs754789 chr18 55201461 T C 7.81E-04 Type 2 diabetes / / 17463246 rs597741 chr18 55204476 C T 6.66E-05 Major depressive disorder / / 21621269 rs1531348 chr18 55209401 G A 2.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12957678 chr18 55218139 C T 0.0002 Migraine FECH intron 22678113 rs533952 chr18 55236342 T G 7.92E-04 Multiple complex diseases FECH intron 17554300 rs317806 chr18 55250264 T C 3.27E-04 Response to cytadine analogues (cytosine arabinoside) FECH intron 24483146 rs11663509 chr18 55280209 A G 4.64E-05 Height /RS intron pha003011 rs1968274 chr18 55314211 T C 7.68E-06 Height ATP8B1 UTR-3 pha003010 rs1968274 chr18 55314211 T C 4.49E-05 Height ATP8B1 UTR-3 pha003011 rs7226404 chr18 55319472 A C 3.17E-05 Height ATP8B1 intron pha003010 rs12968116 chr18 55322502 C T 9.00E-10 Liver enzyme levels (gamma-glutamyl transferase) ATP8B1 missense 22001757 rs12968116 chr18 55322502 C T 1.06E-05 Height ATP8B1 missense pha003010 rs12968116 chr18 55322502 C T 4.55E-05 Height ATP8B1 missense pha003011 rs17832328 chr18 55325199 G A 1.59E-06 Cognitive impairment induced by topiramate ATP8B1 intron 22091778 rs1893673 chr18 55327300 T C 7.75E-05 Pancreatic cancer ATP8B1 intron pha002889 rs317838 chr18 55338656 G A 2.20E-06 Stroke (ischemic) ATP8B1 intron 22384361 rs317838 chr18 55338656 G A 4.17E-04 Lung function (forced expiratory volume in 1 second) ATP8B1 intron 24023788 rs317835 chr18 55339811 C A 2.20E-06 Stroke (ischemic) ATP8B1 intron 22384361 rs317809 chr18 55358917 G A 3.04E-04 Lung function (forced expiratory volume in 1 second) ATP8B1 intron 24023788 rs11873034 chr18 55359314 A G 5.05E-04 Multiple complex diseases ATP8B1 intron 17554300 rs319449 chr18 55360092 T C 3.76E-04 Multiple complex diseases ATP8B1 intron 17554300 rs17686300 chr18 55368747 G A 6.86E-05 Coronary heart disease ATP8B1 intron pha003056 rs319407 chr18 55376554 T G 1.83E-05 Serum metabolites ATP8B1 intron 19043545 rs17064003 chr18 55410511 G A 3.40E-05 Response to statin therapy ATP8B1 intron 20339536 rs7237436 chr18 55425144 A G 2.64E-05 Brain structure ATP8B1 intron 22504417 rs7236632 chr18 55434202 G A 6.00E-06 Attention deficit hyperactivity disorder and conduct disorder ATP8B1 intron 18951430 rs10503019 chr18 55454377 G A 3.00E-06 Vitiligo ATP8B1 intron 19890347 rs2571236 chr18 55456674 G A 5.32E-06 Breast cancer (survival) ATP8B1 intron 20332263 rs2571225 chr18 55461863 T C 7.96E-05 Body Mass Index ATP8B1 intron pha003009 rs41479544 chr18 55472316 G A 1.29E-06 Asthma (childhood onset) ATP8B1 nearGene-5 23829686 rs2663839 chr18 55485514 C T 3.92E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs62094879 chr18 55496305 C T 6.00E-06 Metabolite levels (MHPG) / / 23319000 rs671127 chr18 55508418 C T 1.40E-05 Urinary metabolites / / 21572414 rs565567 chr18 55508463 G T 2.40E-05 Urinary metabolites / / 21572414 rs17692241 chr18 55510452 G A 4.86E-04 Alzheimer's disease (late onset) / / 21379329 rs6566904 chr18 55511115 A T 3.56E-05 Serum metabolites / / 19043545 rs4346276 chr18 55517372 T G 4.38E-04 Psoriasis / / 20953187 rs3859406 chr18 55532556 A G 6.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs583639 chr18 55546006 T C 1.30E-05 Urinary metabolites / / 21572414 rs7243538 chr18 55562464 G A 4.54E-05 HIV-1 viral setpoint / / 22174851 rs1942526 chr18 55618877 A G 8.20E-05 Hypertension / / 21082022 rs1893469 chr18 55625499 T G 2.38E-05 Hypertension / / 21082022 rs11875185 chr18 55627840 A G 7.00E-06 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs12457254 chr18 55637712 C A 4.58E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4941229 chr18 55645543 C T 5.60E-05 Hypertension / / 22384028 rs9955776 chr18 55659654 G A 4.98E-05 Hypertension / / 22384028 rs9319924 chr18 55687065 A G 4.10E-04 Aortic root size / / 21223598 rs8097619 chr18 55720220 C T 6.33E-04 Insulin resistance NEDD4L intron 21901158 rs9989622 chr18 55721004 C G 9.89E-04 Multiple complex diseases NEDD4L intron 17554300 rs9989622 chr18 55721004 C G 6.89E-04 Insulin resistance NEDD4L intron 21901158 rs1787777 chr18 55775343 T C 6.11E-04 Type 2 diabetes NEDD4L intron 17463246 rs529445 chr18 55783497 C A 3.00E-06 Amyotrophic lateral sclerosis (sporadic) NEDD4L intron 24529757 rs554192 chr18 55784763 A G 2.24E-04 Premature ovarian failure NEDD4L intron 19508998 rs549476 chr18 55810733 A G 3.00E-06 Response to amphetamines NEDD4L intron 22952603 rs878396 chr18 55811058 G A 3.85E-05 Atopy NEDD4L intron 21625490 rs8088164 chr18 55828612 T C 5.33E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NEDD4L intron 20877124 rs158865 chr18 55903021 C T 1.97E-05 Crohn's disease NEDD4L intron 18587394 rs158862 chr18 55903721 C T 5.71E-04 Multiple complex diseases NEDD4L intron 17554300 rs17064520 chr18 55909630 C T 3.22E-07 Asthma NEDD4L intron 11022011 rs158856 chr18 55910523 C T 7.00E-06 Insomnia (caffeine-induced) NEDD4L intron 22754043 rs646509 chr18 55912732 A C 1.20E-16 Health and aging,CVD and cancer age of onset NEDD4L missense 22174011 rs646509 chr18 55912732 A C 2.50E-34 Health and aging,CVD and cancer age of onset NEDD4L missense 22174011 rs646509 chr18 55912732 A C 2.60E-07 Health and aging,CVD and cancer age of onset NEDD4L missense 22174011 rs646509 chr18 55912732 A C 2.70E-47 Health and aging,CVD and cancer age of onset NEDD4L missense 22174011 rs2288772 chr18 55915325 G A 1.00E-04 Cognitive impairment induced by topiramate NEDD4L intron 22091778 rs1453082 chr18 55936104 G T 2.03E-05 Endometrial cancer NEDD4L intron 24096698 rs1453082 chr18 55936104 G T 6.61E-05 Endometrial cancer NEDD4L intron 24096698 rs1453082 chr18 55936104 G T 8.91E-05 Endometrial cancer NEDD4L intron 24096698 rs12604734 chr18 55937757 T C 3.50E-05 Diabetic retinopathy NEDD4L intron 21441570 rs4941373 chr18 55941906 G C 8.50E-06 Digit length ratio NEDD4L intron 20303062 rs4058295 chr18 55957987 C A 8.30E-06 Digit length ratio NEDD4L intron 20303062 rs9952789 chr18 55959751 G C 9.00E-05 Diabetic retinopathy NEDD4L intron 21441570 rs2288775 chr18 55983364 A G 5.50E-06 Digit length ratio NEDD4L intron 20303062 rs7243164 chr18 55988294 G A 1.65E-04 Type 2 diabetes NEDD4L intron 17463246 rs10503022 chr18 55991546 T C 6.10E-05 Diabetic retinopathy NEDD4L intron 21441570 rs4058287 chr18 55995721 A G 9.29E-06 Nephrolithiasis NEDD4L intron 22396660 rs12454023 chr18 56009604 C T 8.00E-07 Migraine with aura NEDD4L intron 23793025 rs12454023 chr18 56009604 C T 8.66E-04 Migraine - clinic-based NEDD4L intron 23793025 rs7242150 chr18 56041732 T G 8.10E-04 Response to statin treatment (atorvastatin),change in cholesterol levels NEDD4L intron 20031582 rs8098336 chr18 56051135 T C 7.13E-05 Cognitive test performance NEDD4L intron 20125193 rs6566965 chr18 56063153 C T 3.34E-05 Cognitive test performance NEDD4L intron 20125193 rs4503880 chr18 56084054 T C 3.00E-12 Liver enzyme levels (gamma-glutamyl transferase) / / 22001757 rs4503880 chr18 56084054 T C 4.90E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs12373325 chr18 56087648 T C 8.40E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs4998040 chr18 56093999 G A 8.40E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs10871755 chr18 56094783 C G 8.40E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs7227231 chr18 56094885 G C,T 8.40E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs4245267 chr18 56096214 C A 8.40E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs8099014 chr18 56109859 C A 6.00E-06 Platelet counts / / 21507922 rs7235137 chr18 56141977 G C 6.27E-05 Multiple complex diseases / / 17554300 rs2001517 chr18 56142312 G A 8.43E-04 Alzheimer's disease / / 24755620 rs2003157 chr18 56142391 C T 5.73E-05 Multiple complex diseases / / 17554300 rs7240666 chr18 56149099 T C 6.21E-05 Alcohol dependence ALPK2 missense 19581569 rs2277720 chr18 56165164 G A 4.41E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) ALPK2 intron 23648065 rs7236716 chr18 56167136 G A 8.71E-04 Alzheimer's disease ALPK2 intron 22005930 rs4940721 chr18 56169886 G A 3.62E-04 Alzheimer's disease ALPK2 intron 22005930 rs3809985 chr18 56184107 C T 7.32E-06 Hearing function ALPK2 intron 21493956 rs3809983 chr18 56202768 C A 3.70E-06 Celiac disease ALPK2 missense 17558408 rs3809982 chr18 56203074 G A 7.00E-06 Celiac disease ALPK2 missense 17558408 rs3809973 chr18 56204932 T G 7.07E-04 Multiple complex diseases ALPK2 missense 17554300 rs3809973 chr18 56204932 T G 6.60E-05 Celiac disease ALPK2 missense 17558408 rs3809970 chr18 56204991 C T 9.20E-05 Celiac disease ALPK2 missense 17558408 rs12103986 chr18 56205262 A C,G 7.80E-05 Celiac disease ALPK2 missense 17558408 rs9965985 chr18 56206955 G T 4.39E-04 Taste perception ALPK2 intron 22132133 rs12456021 chr18 56213390 G A 4.00E-06 Multiple sclerosis ALPK2 intron 21833088 rs8094276 chr18 56229592 T G 4.49E-05 Blood Pressure ALPK2 intron pha003048 rs8086790 chr18 56245042 A G 3.92E-08 Multiple complex diseases ALPK2 intron 17554300 rs11659233 chr18 56261723 A G 2.71E-04 Smoking cessation ALPK2 intron 24665060 rs4940732 chr18 56285051 G A 1.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ALPK2 intron 20877124 rs4940732 chr18 56285051 G A 5.36E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ALPK2 intron 20877124 rs4940734 chr18 56297220 A G 1.53E-04 Cholesterol / / 17255346 rs6420554 chr18 56327492 T C 4.35E-04 Multiple complex diseases / / 17554300 rs12455229 chr18 56363908 A C 6.35E-04 Response to taxane treatment (placlitaxel) MALT1 intron 23006423 rs4293479 chr18 56376936 A G 1.23E-05 Multiple complex diseases MALT1 intron 17554300 rs7238078 chr18 56384192 T G 3.00E-09 Multiple sclerosis MALT1 intron 21833088 rs7238078 chr18 56384192 T G 7.50E-04 Multiple sclerosis MALT1 intron 24234648 rs7506022 chr18 56410129 C G 9.43E-04 Suicide attempts in bipolar disorder MALT1 intron 21423239 rs2319974 chr18 56416469 A G 1.17E-06 Alcohol and nictotine co-dependence MALT1 UTR-3 20158304 rs11663212 chr18 56445257 C A 0.0003 Endometrial cancer / / 22426144 rs6567010 chr18 56461373 G C 8.42E-04 Multiple complex diseases / / 17554300 rs8086176 chr18 56467120 G A 6.39E-04 Coronary Artery Disease / / 17634449 rs8092519 chr18 56468061 A G 7.40E-04 Multiple complex diseases / / 17554300 rs8095914 chr18 56476313 T C 4.94E-04 Coronary Artery Disease / / 17634449 rs7507051 chr18 56518513 G A 0.000623652 Hypertension (early onset hypertension) / / 22479346 rs9957614 chr18 56520865 C T 4.76E-04 Insulin resistance / / 21901158 rs6567030 chr18 56528896 C T 8.52E-06 Body Mass Index / / pha002896 rs7226876 chr18 56532820 C T 3.10E-06 Urinary metabolites ZNF532 intron 21572414 rs7226876 chr18 56532820 C T 9.45E-05 Major depressive disorder ZNF532 intron 22472876 rs937815 chr18 56567906 G T 3.25E-05 Crohn's disease ZNF532 intron 17435756 rs17761525 chr18 56578953 C T 7.00E-05 Alcohol dependence ZNF532 intron 20201924 rs17761525 chr18 56578953 C T 0.000842773 Hypertension (early onset hypertension) ZNF532 intron 22479346 rs17761525 chr18 56578953 C T 7.05E-05 Alcoholism ZNF532 intron pha002892 rs7237384 chr18 56604022 G A 4.21E-04 Body mass index ZNF532 intron 21701565 rs4496254 chr18 56616346 G A 1.00E-04 Tetralogy of Fallot ZNF532 intron 23297363 rs6567036 chr18 56620022 T C 1.47E-04 Multiple complex diseases ZNF532 intron 17554300 rs7245090 chr18 56635323 T G 1.30E-04 Alcohol dependence ZNF532 intron 20201924 rs6567038 chr18 56637843 G A 9.87E-04 Multiple complex diseases ZNF532 intron 17554300 rs6567041 chr18 56642783 A G 1.58E-12 Blood pressure ZNF532 intron 21909110 rs17695069 chr18 56650936 C G 4.54E-06 Brain infarcts,covert MRI-defined ZNF532 intron 20044523 rs11152112 chr18 56662048 G A 2.20E-06 Non-obstructive azoospermia / / 22541561 rs11664729 chr18 56665804 G A 6.10E-06 Urinary metabolites / / 21572414 rs7236560 chr18 56668510 G A 8.81E-04 Body mass index / / 21701565 rs7236560 chr18 56668510 G A 2.70E-05 Major depressive disorder / / 22472876 rs8091043 chr18 56672598 T C 6.14E-04 Alzheimer's disease / / 24755620 rs9952079 chr18 56679499 G A 5.10E-05 Information processing speed / / 21130836 rs17695139 chr18 56687109 T G 7.03E-05 Glycosylated haemoglobin levels / / 17255346 rs17756931 chr18 56688375 A T 6.25E-04 Alzheimer's disease / / 17998437 rs17756937 chr18 56688434 C T 5.33E-04 Multiple complex diseases / / 17554300 rs7226455 chr18 56701867 A G 7.08E-06 Post-operative nausea and vomiting / / 21694509 rs17761829 chr18 56709282 T C 2.70E-05 Urinary metabolites / / 21572414 rs4940441 chr18 56715755 G C 6.47E-04 Body mass index / / 21701565 rs17065415 chr18 56730717 C T 5.77E-04 Rheumatoid arthritis / / 21452313 rs4940807 chr18 56735130 A C 1.00E-04 Prostate cancer / / 21743057 rs17695297 chr18 56735852 T A 5.88E-05 Cytomegalovirus antibody response / / 21993531 rs4940811 chr18 56742904 A G 3.67E-04 Type 2 diabetes / / 17463246 rs4940812 chr18 56742965 G A 2.35E-04 Type 2 diabetes / / 17463246 rs10871764 chr18 56751029 G A 6.46E-05 Body Fat Distribution / / pha003017 rs1037757 chr18 56752054 G A,C 8.00E-06 Alzheimer's disease (age of onset) / / 22005931 rs1037756 chr18 56752290 A G 9.79E-06 Alzheimer's disease (age of onset) / / 22005931 rs4940444 chr18 56752500 T C 8.92E-04 Alcohol dependence / / 21314694 rs17065432 chr18 56752706 G A 2.10E-05 Alzheimer's disease (age of onset) / / 22005931 rs1033071 chr18 56752927 G C 3.24E-05 Alzheimer's disease (age of onset) / / 22005931 rs8095175 chr18 56753763 G A 1.92E-05 Alzheimer's disease (age of onset) / / 22005931 rs17835250 chr18 56758929 A G 6.10E-05 Type 2 diabetes / / 17463246 rs1380100 chr18 56778710 C A 4.00E-06 Smoking behavior / / 20418888 rs12963675 chr18 56813295 T G 2.67E-04 Coronary heart disease SEC11C intron 21971053 rs10503023 chr18 56832775 G A 7.13E-04 Type 2 diabetes / / 17463246 rs11152133 chr18 56852926 G C 1.74E-04 Glycosylated haemoglobin levels / / 17255346 rs8098067 chr18 56859448 A G 5.00E-04 Schizophrenia / / 19197363 rs17065615 chr18 56876517 T C 2.33E-04 Multiple complex diseases / / 17554300 rs9961404 chr18 56877537 C T 4.48E-05 Multiple complex diseases / / 17554300 rs9961404 chr18 56877537 C T 2.78E-05 Cognitive performance / / 19734545 rs9961404 chr18 56877537 C T 1.02E-05 Pancreatic cancer / / pha002889 rs9961822 chr18 56877916 C T 3.05E-05 Multiple complex diseases / / 17554300 rs1517037 chr18 56878274 C T 6.81E-06 Pancreatic cancer / / pha002889 rs1517036 chr18 56878362 G A 1.18E-05 Multiple complex diseases / / 17554300 rs9319943 chr18 56879827 T C 3.34E-06 Pancreatic cancer / / pha002889 rs8094537 chr18 56920558 G A 4.01E-04 Type 2 diabetes / / 17463246 rs9947104 chr18 56934358 A G 1.57E-04 Type 2 diabetes RAX UTR-3 17463246 rs3744893 chr18 56935860 G A 3.05E-05 Coronary heart disease RAX UTR-3 21971053 rs17696441 chr18 56948020 A C 4.30E-04 Breast cancer (survival) / / 22232737 rs9973180 chr18 56954214 C T 9.04E-05 Attention deficit hyperactivity disorder / / pha002875 rs4940456 chr18 56963742 C T 3.74E-04 Lymphocyte counts CPLX4 UTR-3 22286170 rs17769193 chr18 56963767 C G 3.33E-04 Multiple complex diseases CPLX4 UTR-3 17554300 rs12232751 chr18 56966260 G A 1.20E-04 Attention deficit hyperactivity disorder CPLX4 intron pha002875 rs473567 chr18 56969992 C T 3.79E-04 Type 2 diabetes CPLX4 intron 17463246 rs1043334 chr18 56996526 T G 1.60E-04 Gallstones LMAN1 UTR-3 17632509 rs10515978 chr18 57005655 T C 0.000316 Rate of forced expiratory volume in 1 second (FEV1) decline (young adult women) LMAN1 intron 23527081 rs12963340 chr18 57018922 G A 0.000055 Coronary artery calcification LMAN1 intron 23727086 rs7239759 chr18 57044710 T C 1.82E-04 Aortic root size / / 21223598 rs8087926 chr18 57056766 G T 6.39E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10503027 chr18 57070378 C T 5.92E-05 Body Mass Index / / pha003021 rs12965304 chr18 57088063 C T 8.70E-07 Schizophrenia / / 21926974 rs1444489 chr18 57090172 G A 1.20E-05 Urinary metabolites / / 21572414 rs7229758 chr18 57109258 T C 5.14E-05 Personality dimensions CCBE1 intron 18957941 rs895005 chr18 57115789 C G,T 2.69E-04 Multiple complex diseases CCBE1 intron 17554300 rs7241697 chr18 57128956 G A 2.90E-05 Body Mass Index CCBE1 intron pha003021 rs4998986 chr18 57131733 G A 1.57E-04 Response to cytadine analogues (cytosine arabinoside) CCBE1 intron 24483146 rs4998985 chr18 57131794 G T 1.50E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CCBE1 intron 24023788 rs4998984 chr18 57131948 G A 8.57E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CCBE1 intron 24023788 rs8094515 chr18 57133556 G A 4.93E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CCBE1 intron 24023788 rs600795 chr18 57134297 C A 2.71E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CCBE1 intron 24023788 rs7234617 chr18 57170237 T A 2.89E-04 Multiple complex diseases CCBE1 intron 17554300 rs6567092 chr18 57171796 T C 2.73E-04 Multiple complex diseases CCBE1 intron 17554300 rs4940465 chr18 57173844 T C 4.53E-05 Blood Pressure CCBE1 intron pha002903 rs12606330 chr18 57182339 G A 7.45E-05 Receptive language ability CCBE1 intron 24687471 rs17065909 chr18 57182908 C T 2.54E-04 Type 2 diabetes CCBE1 intron 17463246 rs4552110 chr18 57183948 A T 4.20E-06 Type 2 diabetes CCBE1 intron 17463246 rs1013320 chr18 57201696 A G 2.30E-05 Urinary metabolites CCBE1 intron 21572414 rs992025 chr18 57231286 A G 5.97E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CCBE1 intron 20031582 rs1944980 chr18 57284133 C T 1.40E-04 Alcohol dependence CCBE1 intron 20201924 rs1944980 chr18 57284133 C T 5.80E-05 Alcohol dependence CCBE1 intron 20201924 rs1944980 chr18 57284133 C T 5.75E-05 Alcoholism CCBE1 intron pha002893 rs1864309 chr18 57309059 T G 1.60E-06 Recombination rate CCBE1 intron 21698098 rs17698267 chr18 57311775 T G 9.54E-05 Blood Pressure CCBE1 intron pha003043 rs11152166 chr18 57314807 C T 3.00E-06 Major depressive disorder CCBE1 intron 23857890 rs11152166 chr18 57314807 C T 4.46E-05 Body Mass Index CCBE1 intron pha003020 rs6567111 chr18 57323790 A G 4.28E-05 Postoperative ventricular dysfunction CCBE1 intron 21980348 rs1652065 chr18 57343666 T G 5.22E-05 Postoperative ventricular dysfunction CCBE1 intron 21980348 rs11152170 chr18 57349900 A C 2.10E-05 Urinary metabolites CCBE1 intron 21572414 rs2852356 chr18 57360133 G A 4.07E-04 Nicotine smoking CCBE1 intron 19268276 rs17066173 chr18 57362014 C T 8.41E-04 Multiple complex diseases CCBE1 intron 17554300 rs12606371 chr18 57365624 C A 8.55E-05 Insulin-related traits CCBE1 nearGene-5 pha003063 rs7244658 chr18 57369893 T G 4.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1652080 chr18 57372654 G A 1.18E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1652080 chr18 57372654 G A 1.34E-08 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1652080 chr18 57372654 G A 2.34E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3097407 chr18 57377022 A G 1.74E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs3097407 chr18 57377022 A G 1.90E-05 Soluble levels of adhesion molecules / / pha003072 rs3114281 chr18 57383568 G T 0.00009314 Sarcoidosis / / 22952805 rs1791317 chr18 57383880 T C 0.00007314 Sarcoidosis / / 22952805 rs870470 chr18 57386600 G A 6.26E-05 Coronary heart disease / / pha003035 rs1629874 chr18 57398775 C T 7.18E-05 Orofacial clefts / / 22419666 rs1629874 chr18 57398775 C T 7.21E-05 Coronary heart disease / / pha003035 rs1893669 chr18 57401381 T G 7.75E-05 Coronary heart disease / / pha003035 rs1943427 chr18 57404439 C T 5.49E-05 Coronary heart disease / / pha003035 rs1788897 chr18 57419473 T C 4.46E-04 Schizophrenia / / 19197363 rs1630473 chr18 57451692 T A 1.80E-05 Urinary metabolites / / 21572414 rs1791329 chr18 57472992 C G 2.25E-04 Alzheimer's disease / / 17998437 rs1788835 chr18 57482945 C T 3.90E-05 Prion diseases / / 22210626 rs9951126 chr18 57484296 T A 8.40E-05 Electrocardiographic conduction measures / / 19389651 rs11660733 chr18 57488788 C T 7.63E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1943423 chr18 57490324 G A 0.000251 5-fluorouracil induced haematologic in response to colorectal cancer treatment / / 22310351 rs8093763 chr18 57503378 G A 3.00E-08 Bleomycin sensitivity / / 21106707 rs7229174 chr18 57519110 A G 1.33E-04 Multiple complex diseases / / 17554300 rs7240884 chr18 57568693 A G 1.50E-05 Chronic lymphocytic leukemia PMAIP1 intron 24292274 rs8083367 chr18 57579119 G T 2.17E-04 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs11665646 chr18 57592339 C T 8.99E-05 Cognitive performance / / 19734545 rs11664183 chr18 57599723 A G 2.10E-05 Urinary metabolites / / 21572414 rs4293477 chr18 57601463 T C 2.30E-05 Urinary metabolites / / 21572414 rs7407281 chr18 57605621 A G 1.80E-05 Urinary metabolites / / 21572414 rs8088707 chr18 57609263 G A 2.50E-05 Urinary metabolites / / 21572414 rs7236893 chr18 57612861 T G 7.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs7231112 chr18 57612891 G A 7.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs7231112 chr18 57612891 G A 7.21E-04 Smoking cessation / / 24665060 rs4368253 chr18 57622287 T C 9.83E-04 Multiple complex diseases / / 17554300 rs4368253 chr18 57622287 T C 3.00E-08 Chronic lymphocytic leukemia / / 23770605 rs7242745 chr18 57632301 G A 7.62E-04 Obesity (extreme) / / 21935397 rs7229781 chr18 57633654 G A 7.29E-04 Obesity (extreme) / / 21935397 rs8084031 chr18 57636560 C T 2.33E-04 Type 2 diabetes / / 17463246 rs8088893 chr18 57639517 G A 7.60E-06 Urinary metabolites / / 21572414 rs7227333 chr18 57645433 G A 2.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17066440 chr18 57648275 T C 1.68E-10 Gallstones / / 17632509 rs8098130 chr18 57653727 C T 1.50E-05 Urinary metabolites / / 21572414 rs755682 chr18 57654361 C T 9.50E-06 Urinary metabolites / / 21572414 rs11877823 chr18 57662696 G C 8.42E-06 Asthma (childhood onset) / / 23829686 rs12964056 chr18 57673799 A G 7.00E-07 Body mass index / / 24348519 rs2000745 chr18 57677304 T C 8.24E-04 Coronary heart disease / / 21971053 rs2187176 chr18 57679365 A G 2.77E-04 Alzheimer's disease (late onset) / / 21379329 rs1942899 chr18 57716523 T G 9.17E-04 Multiple complex diseases / / 17554300 rs9958194 chr18 57720398 T C 4.82E-05 Erythrocyte counts / / pha003101 rs4613164 chr18 57725188 T G 2.59E-04 Body mass index / / 17255346 rs3897645 chr18 57728947 T C 5.43E-04 Multiple complex diseases / / 17554300 rs4940927 chr18 57732689 A G 3.59E-05 Obesity (extreme) / / 21935397 rs8085349 chr18 57733428 A G 7.55E-04 HIV-1 viral setpoint / / 17641165 rs7234864 chr18 57734857 C T 3.35E-05 Obesity (extreme) / / 21935397 rs7234864 chr18 57734857 C T 4.00E-17 Body mass index / / 23669352 rs7241535 chr18 57738602 T G 3.35E-05 Obesity (extreme) / / 21935397 rs11664369 chr18 57739072 C T 3.35E-05 Obesity (extreme) / / 21935397 rs1942866 chr18 57741783 C G 5.98E-06 Body mass index / / 19557197 rs1942866 chr18 57741783 C G 6.80E-04 Type 2 diabetes / / 22158537 rs8086627 chr18 57743096 C A 6.11E-06 Body mass index / / 19557197 rs7240566 chr18 57744189 A G 8.31E-06 Body mass index / / 19557197 rs7240566 chr18 57744189 A G 3.61E-05 Obesity (extreme) / / 21935397 rs11520442 chr18 57744576 T C 8.42E-06 Body mass index / / 19557197 rs11520442 chr18 57744576 T C 3.65E-05 Obesity (extreme) / / 21935397 rs1942863 chr18 57745744 T C 6.70E-06 Body mass index / / 19557197 rs1942863 chr18 57745744 T C 2.69E-04 Type 2 diabetes / / 22158537 rs12957347 chr18 57751014 T C 8.40E-06 Body mass index / / 19557197 rs12957347 chr18 57751014 T C 7.00E-06 Metabolic syndrome / / 20694148 rs12957347 chr18 57751014 T C 3.69E-05 Obesity (extreme) / / 21935397 rs4299252 chr18 57751185 A T 8.64E-06 Body mass index / / 19557197 rs4299252 chr18 57751185 A T 3.69E-05 Obesity (extreme) / / 21935397 rs8091524 chr18 57751960 T C 8.68E-06 Body mass index / / 19557197 rs8091524 chr18 57751960 T C 3.69E-05 Obesity (extreme) / / 21935397 rs8084085 chr18 57754018 T C 4.07E-05 Obesity (extreme) / / 21935397 rs8084085 chr18 57754018 T C 3.37E-04 Type 2 diabetes / / 22158537 rs6567155 chr18 57755117 C T 8.41E-06 Body mass index / / 19557197 rs6567155 chr18 57755117 C T 3.70E-05 Obesity (extreme) / / 21935397 rs1942860 chr18 57756055 C T 8.28E-06 Body mass index / / 19557197 rs1942860 chr18 57756055 C T 3.58E-05 Obesity (extreme) / / 21935397 rs11662368 chr18 57757978 A G 8.82E-06 Body mass index / / 19557197 rs11662368 chr18 57757978 A G 3.32E-05 Obesity (extreme) / / 21935397 rs8086895 chr18 57758635 A G 8.87E-04 Obesity (extreme) / / 21935397 rs12956755 chr18 57759059 G T 8.82E-04 Obesity (extreme) / / 21935397 rs1539952 chr18 57766512 A G 8.72E-06 Body mass index / / 19557197 rs1539952 chr18 57766512 A G 2.75E-05 Obesity (extreme) / / 21935397 rs11660783 chr18 57767635 T C 2.85E-06 Body mass index / / 19557197 rs11660783 chr18 57767635 T C 1.80E-04 Obesity (extreme) / / 21935397 rs9966951 chr18 57775295 G A 3.91E-04 Obesity (extreme) / / 21935397 rs9951795 chr18 57777991 C G 3.92E-04 Obesity (extreme) / / 21935397 rs948760 chr18 57781188 A G 3.92E-04 Obesity (extreme) / / 21935397 rs1893512 chr18 57787559 T C 3.94E-04 Obesity (extreme) / / 21935397 rs756190 chr18 57790052 A T 3.89E-04 Obesity (extreme) / / 21935397 rs6567157 chr18 57790225 T G 3.79E-04 Obesity (extreme) / / 21935397 rs8087080 chr18 57791081 G T 3.75E-04 Obesity (extreme) / / 21935397 rs1942880 chr18 57793209 C T 3.64E-04 Obesity (extreme) / / 21935397 rs8084834 chr18 57793589 C A 3.63E-04 Obesity (extreme) / / 21935397 rs953442 chr18 57797485 T C 5.80E-06 Body mass index / / 19557197 rs953442 chr18 57797485 T C 1.18E-05 Obesity (extreme) / / 21935397 rs952044 chr18 57798110 C T 3.55E-04 Obesity (extreme) / / 21935397 rs1942859 chr18 57799449 T A 3.54E-04 Obesity (extreme) / / 21935397 rs201807788 chr18 57804346 A AT 2.76E-06 Body mass index / / 19557197 rs8095404 chr18 57804346 A T 2.76E-06 Body mass index / / 19557197 rs17700144 chr18 57811982 G A 4.56E-18 Body mass index / / 19079261 rs17700144 chr18 57811982 G A 4.05E-06 Waist circumference / / 19557197 rs17700144 chr18 57811982 G A 9.80E-19 Smoking behavior / / 20418888 rs17700144 chr18 57811982 G A 6.00E-11 Obesity (early onset extreme) / / 20421936 rs17700144 chr18 57811982 G A 3.42E-05 Obesity (extreme) / / 21935397 rs145967119 chr18 57812145 C T 0.0000138 Carotid intima media thickness / / 23152477 rs574988 chr18 57813648 G C 9.61E-07 Body mass index / / 19557197 rs574988 chr18 57813648 G C 2.19E-04 Type 2 diabetes / / 22158537 rs521663 chr18 57822240 T C 9.71E-07 Body mass index / / 19557197 rs565239 chr18 57827198 G A 1.02E-06 Body mass index / / 19557197 rs565239 chr18 57827198 G A 1.43E-04 Type 2 diabetes / / 22158537 rs681630 chr18 57827605 A G 1.64E-06 Body mass index / / 19557197 rs681630 chr18 57827605 A G 2.46E-04 Type 2 diabetes / / 22158537 rs536783 chr18 57828038 C T 1.78E-06 Body mass index / / 19557197 rs536783 chr18 57828038 C T 1.32E-04 Type 2 diabetes / / 22158537 rs2331841 chr18 57828637 G A 1.90E-06 Body mass index / / 19557197 rs2331841 chr18 57828637 G A 1.21E-04 Type 2 diabetes / / 22158537 rs2331841 chr18 57828637 G A 2.00E-11 Body mass index / / 22344221 rs6567160 chr18 57829135 T C 9.26E-07 Waist circumference / / 19557197 rs6567160 chr18 57829135 T C 3.69E-06 Obesity (extreme) / / 21935397 rs6567160 chr18 57829135 T C 4.67E-05 Type 2 diabetes / / 22158537 rs6567160 chr18 57829135 T C 2.76E-15 Body mass index / / 22344219 rs6567160 chr18 57829135 T C 2.96E-11 Body mass index / / 23583978 rs6567160 chr18 57829135 T C 3.00E-11 Fat body mass / / 24064335 rs6567160 chr18 57829135 T C 8.00E-19 Body mass index / / 24064335 rs649721 chr18 57830095 A C 2.25E-06 Body mass index / / 19557197 rs633265 chr18 57831468 G T 1.06E-04 HIV-1 viral setpoint / / 17641165 rs633265 chr18 57831468 G T 2.90E-06 Body mass index / / 19557197 rs633265 chr18 57831468 G T 8.90E-05 Smoking behavior / / 20418888 rs487720 chr18 57832535 G A 3.03E-06 Body mass index / / 19557197 rs565970 chr18 57833724 T C 3.30E-06 Body mass index / / 19557197 rs565970 chr18 57833724 T C 3.72E-04 Type 2 diabetes / / 22158537 rs683430 chr18 57833802 A T 3.32E-06 Body mass index / / 19557197 rs682614 chr18 57833920 A G 4.23E-06 Body mass index / / 19557197 rs682614 chr18 57833920 A G 2.88E-04 Type 2 diabetes / / 22158537 rs1673518 chr18 57835365 A G 4.29E-06 Body mass index / / 19557197 rs1673518 chr18 57835365 A G 1.33E-04 Type 2 diabetes / / 22158537 rs2051312 chr18 57836715 T C 4.47E-06 Body mass index / / 19557197 rs2051312 chr18 57836715 T C 3.25E-04 Type 2 diabetes / / 22158537 rs474112 chr18 57836832 T G 4.68E-06 Body mass index / / 19557197 rs474112 chr18 57836832 T G 3.25E-04 Type 2 diabetes / / 22158537 rs2051311 chr18 57836880 T C 9.37E-05 HIV-1 viral setpoint / / 17641165 rs2051311 chr18 57836880 T C 5.00E-06 Body mass index / / 19557197 rs2051311 chr18 57836880 T C 3.75E-04 Type 2 diabetes / / 22158537 rs1619975 chr18 57837224 T C 5.34E-06 Body mass index / / 19557197 rs1619975 chr18 57837224 T C 2.13E-04 Type 2 diabetes / / 22158537 rs1673514 chr18 57837466 A T 3.89E-05 Type 2 diabetes / / 22158537 rs666181 chr18 57837748 C T 4.97E-06 Body mass index / / 19557197 rs666181 chr18 57837748 C T 1.74E-04 Type 2 diabetes / / 22158537 rs663129 chr18 57838401 G A 1.11E-06 Waist circumference / / 19557197 rs663129 chr18 57838401 G A 4.61E-06 Obesity (extreme) / / 21935397 rs663129 chr18 57838401 G A 4.81E-05 Type 2 diabetes / / 22158537 rs663129 chr18 57838401 G A 3.55E-11 Obesity / / 22484627 rs571312 chr18 57839769 C A 7.18E-06 Waist circumference / / 19557197 rs571312 chr18 57839769 C A 6.00E-42 Body mass index / / 20935630 rs571312 chr18 57839769 C A 4.62E-06 Obesity (extreme) / / 21935397 rs571312 chr18 57839769 C A 3.28E-04 Type 2 diabetes / / 22158537 rs571312 chr18 57839769 C A 6.43E-42 Body mass index / / 23001569 rs571312 chr18 57839769 C A 0.0007 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs545708 chr18 57840219 C T 5.48E-06 Body mass index / / 19557197 rs545708 chr18 57840219 C T 3.76E-04 Type 2 diabetes / / 22158537 rs591166 chr18 57841589 T A 5.11E-06 Body mass index / / 19557197 rs591166 chr18 57841589 T A 5.13E-04 Type 2 diabetes / / 22158537 rs591166 chr18 57841589 T A 7.00E-14 Body mass index / / 24861553 rs589850 chr18 57841891 G A 5.23E-06 Body mass index / / 19557197 rs589850 chr18 57841891 G A 2.61E-04 Type 2 diabetes / / 22158537 rs975918 chr18 57842408 C T 5.34E-06 Body mass index / / 19557197 rs975918 chr18 57842408 C T 1.54E-04 Type 2 diabetes / / 22158537 rs1350341 chr18 57842533 G A 9.23E-05 HIV-1 viral setpoint / / 17641165 rs1350341 chr18 57842533 G A 6.84E-06 Body mass index / / 19557197 rs1350341 chr18 57842533 G A 6.40E-05 Smoking behavior / / 20418888 rs1350341 chr18 57842533 G A 2.42E-04 Type 2 diabetes / / 22158537 rs993887 chr18 57842698 C T 5.15E-06 Body mass index / / 19557197 rs611428 chr18 57842885 G T 5.21E-06 Body mass index / / 19557197 rs611428 chr18 57842885 G T 3.74E-04 Type 2 diabetes / / 22158537 rs562622 chr18 57843496 A T 5.21E-06 Body mass index / / 19557197 rs562622 chr18 57843496 A T 1.07E-04 Type 2 diabetes / / 22158537 rs559623 chr18 57843875 A C 5.09E-06 Body mass index / / 19557197 rs559623 chr18 57843875 A C 2.21E-04 Type 2 diabetes / / 22158537 rs6567161 chr18 57846935 G A 5.03E-06 Body mass index / / 19557197 rs523288 chr18 57848369 A T 8.04E-07 Waist circumference / / 19557197 rs523288 chr18 57848369 A T 5.79E-06 Obesity (extreme) / / 21935397 rs2168711 chr18 57848531 T C 7.63E-07 Waist circumference / / 19557197 rs2168711 chr18 57848531 T C 5.82E-06 Obesity (extreme) / / 21935397 rs2168711 chr18 57848531 T C 6.19E-04 Type 2 diabetes / / 22158537 rs12967135 chr18 57849023 G A 7.24E-07 Waist circumference / / 19557197 rs12967135 chr18 57849023 G A 7.00E-09 HDL cholesterol / / 20686565 rs12967135 chr18 57849023 G A 5.84E-06 Obesity (extreme) / / 21935397 rs12967135 chr18 57849023 G A 3.25E-05 Type 2 diabetes / / 22158537 rs12967135 chr18 57849023 G A 4.00E-08 HDL cholesterol / / 24097068 rs538656 chr18 57850422 G T 6.72E-07 Waist circumference / / 19557197 rs538656 chr18 57850422 G T 7.79E-06 Obesity (extreme) / / 21935397 rs538656 chr18 57850422 G T 3.13E-04 Type 2 diabetes / / 22158537 rs538656 chr18 57850422 G T 2.00E-36 Obesity / / 23563607 rs17782313 chr18 57851097 T C 3.00E-15 Body mass index / / 18454148 rs17782313 chr18 57851097 T C 5.00E-18 Body mass index / / 19079261 rs17782313 chr18 57851097 T C 5.00E-15 Obesity / / 19151714 rs17782313 chr18 57851097 T C 6.28E-07 Waist circumference / / 19557197 rs17782313 chr18 57851097 T C 4.60E-18 Smoking behavior / / 20418888 rs17782313 chr18 57851097 T C 4.00E-11 Height / / 20881960 rs17782313 chr18 57851097 T C 7.87E-06 Obesity (extreme) / / 21935397 rs17782313 chr18 57851097 T C 5.09E-04 Type 2 diabetes / / 22158537 rs17782313 chr18 57851097 T C 1.38E-10 Body mass index / / 24064335 rs17782313 chr18 57851097 T C 1.52E-08 Fat body mass / / 24064335 rs10871777 chr18 57851763 A G 5.82E-07 Waist circumference / / 19557197 rs10871777 chr18 57851763 A G 6.00E-11 Obesity (extreme) / / 20421936 rs10871777 chr18 57851763 A G 7.89E-06 Obesity (extreme) / / 21935397 rs10871777 chr18 57851763 A G 2.57E-04 Type 2 diabetes / / 22158537 rs10871777 chr18 57851763 A G 2.00E-27 Obesity / / 23563607 rs10871777 chr18 57851763 A G 3.02E-08 Fat body mass / / 24064335 rs10871777 chr18 57851763 A G 6.72E-11 Body mass index / / 24064335 rs476828 chr18 57852587 T C 4.12E-07 Waist circumference / / 19557197 rs476828 chr18 57852587 T C 7.91E-06 Obesity (extreme) / / 21935397 rs476828 chr18 57852587 T C 9.00E-14 Obesity (early onset extreme) / / 23563609 rs475134 chr18 57852752 C T 5.13E-06 Body mass index / / 19557197 rs475134 chr18 57852752 C T 5.67E-04 Type 2 diabetes / / 22158537 rs11152213 chr18 57852948 A C 3.58E-07 Waist circumference / / 19557197 rs11152213 chr18 57852948 A C 7.79E-06 Obesity (extreme) / / 21935397 rs11152213 chr18 57852948 A C 3.50E-04 Type 2 diabetes / / 22158537 rs11152213 chr18 57852948 A C 3.00E-22 Obesity / / 23563607 rs1942873 chr18 57855886 G C 6.64E-05 Obesity (extreme) / / 21935397 rs492443 chr18 57858802 A G 3.01E-06 Waist circumference / / 19557197 rs492443 chr18 57858802 A G 8.87E-07 Obesity (extreme) / / 21935397 rs8089364 chr18 57858829 T C 9.77E-07 Waist circumference / / 19557197 rs8089364 chr18 57858829 T C 7.17E-07 Obesity (extreme) / / 21935397 rs8089364 chr18 57858829 T C 0.00000006 Type 2 diabetes (males) / / 22885922 rs8089364 chr18 57858829 T C 0.00082 Type 2 diabetes (females) / / 22885922 rs8089364 chr18 57858829 T C 4.00E-21 Body mass index / / 23563607 rs12969709 chr18 57859563 C A 9.34E-07 Waist circumference / / 19557197 rs12969709 chr18 57859563 C A 7.49E-07 Obesity (extreme) / / 21935397 rs921971 chr18 57861663 T C 9.15E-07 Waist circumference / / 19557197 rs921971 chr18 57861663 T C 7.50E-07 Obesity (extreme) / / 21935397 rs1457489 chr18 57861961 G A 9.18E-07 Waist circumference / / 19557197 rs1457489 chr18 57861961 G A 7.63E-07 Obesity (extreme) / / 21935397 rs12954782 chr18 57864092 C G 9.09E-07 Waist circumference / / 19557197 rs12954782 chr18 57864092 C G 7.65E-07 Obesity (extreme) / / 21935397 rs9947301 chr18 57869590 C T 5.82E-09 Obesity / / 23563607 rs9947403 chr18 57869750 C T 2.80E-04 Obesity (extreme) / / 21935397 rs9947403 chr18 57869750 C T 3.60E-05 Sodium levels / / pha003093 rs639407 chr18 57870179 A G 3.30E-04 Obesity (extreme) / / 21935397 rs8084515 chr18 57872449 A T 2.86E-04 Obesity (extreme) / / 21935397 rs12955983 chr18 57872989 A G 2.85E-06 Waist circumference / / 19557197 rs12955983 chr18 57872989 A G 8.70E-07 Obesity (extreme) / / 21935397 rs12955983 chr18 57872989 A G 2.00E-06 Urate levels / / 23263486 rs11665563 chr18 57876034 C T 1.36E-06 Waist circumference / / 19557197 rs11665563 chr18 57876034 C T 8.92E-07 Obesity (extreme) / / 21935397 rs11663816 chr18 57876227 T C 1.55E-06 Waist circumference / / 19557197 rs11663816 chr18 57876227 T C 3.13E-06 Obesity (extreme) / / 21935397 rs11664883 chr18 57877800 T A 1.43E-06 Waist circumference / / 19557197 rs11664883 chr18 57877800 T A 9.01E-07 Obesity (extreme) / / 21935397 rs489693 chr18 57882787 C A 4.00E-07 Waist circumference / / 19557197 rs489693 chr18 57882787 C A 1.15E-04 Obesity (extreme) / / 21935397 rs489693 chr18 57882787 C A 6.00E-12 Antipsychotic drug-induced weight gain / / 22566560 rs646749 chr18 57883125 G A 5.37E-04 HIV-1 viral setpoint / / 17641165 rs12970134 chr18 57884750 G A 2.00E-09 Waist circumference and related phenotypes / / 18454146 rs12970134 chr18 57884750 G A 1.00E-12 Body mass index / / 19079260 rs12970134 chr18 57884750 G A 5.00E-13 Weight / / 19079260 rs12970134 chr18 57884750 G A 1.47E-06 Waist circumference / / 19557197 rs12970134 chr18 57884750 G A 2.60E-06 Smoking behavior / / 20418888 rs12970134 chr18 57884750 G A 1.03E-06 Obesity (extreme) / / 21935397 rs12970134 chr18 57884750 G A 0.000000012 Type 2 diabetes / / 22885922 rs12970134 chr18 57884750 G A 0.0000064 Triglycerides / / 22885922 rs12970134 chr18 57884750 G A 0.0000097 HDL cholesterol / / 22885922 rs12970134 chr18 57884750 G A 2.30E-19 Body mass index / / 22885922 rs12970134 chr18 57884750 G A 3.00E-08 Type 2 diabetes / / 24509480 rs9958386 chr18 57890825 C T 2.62E-04 Obesity (extreme) / / 21935397 rs8083289 chr18 57893618 C A,G 1.02E-06 Waist circumference / / 19557197 rs8083289 chr18 57893618 C A,G 7.86E-07 Obesity (extreme) / / 21935397 rs528074 chr18 57894123 T G 3.15E-04 Obesity (extreme) / / 21935397 rs557416 chr18 57895059 A G 3.24E-04 Obesity (extreme) / / 21935397 rs477181 chr18 57896038 G A,T 3.23E-04 Obesity (extreme) / / 21935397 rs477181 chr18 57896038 G A,T 1.16E-05 Sodium levels / / pha003093 rs502933 chr18 57896474 C A 3.23E-04 Obesity (extreme) / / 21935397 rs502933 chr18 57896474 C A 1.16E-05 Sodium levels / / pha003093 rs17175643 chr18 57896742 C T 1.44E-06 Waist circumference / / 19557197 rs17175643 chr18 57896742 C T 7.13E-07 Obesity (extreme) / / 21935397 rs12960928 chr18 57897803 T C 3.08E-06 Waist circumference / / 19557197 rs12960928 chr18 57897803 T C 7.99E-07 Obesity (extreme) / / 21935397 rs2219375 chr18 57898549 G A 2.61E-04 Obesity (extreme) / / 21935397 rs8089366 chr18 57898600 G T 2.60E-04 Obesity (extreme) / / 21935397 rs8091286 chr18 57901137 G A 2.75E-04 Obesity (extreme) / / 21935397 rs2083 chr18 57901782 C T 2.75E-04 Obesity (extreme) / / 21935397 rs7227739 chr18 57901950 T G 2.75E-04 Obesity (extreme) / / 21935397 rs12456624 chr18 57903086 G T 2.52E-04 Obesity (extreme) / / 21935397 rs12964203 chr18 57903604 T C 2.72E-06 Waist circumference / / 19557197 rs12964203 chr18 57903604 T C 6.41E-07 Obesity (extreme) / / 21935397 rs590654 chr18 57904011 G A 2.93E-04 Obesity (extreme) / / 21935397 rs590215 chr18 57904088 C T 8.44E-06 Waist circumference / / 19557197 rs590215 chr18 57904088 C T 7.93E-07 Obesity (extreme) / / 21935397 rs534234 chr18 57904207 G A 2.97E-04 Obesity (extreme) / / 21935397 rs2168708 chr18 57907311 G T 3.52E-06 Waist circumference / / 19557197 rs2168708 chr18 57907311 G T 6.99E-07 Obesity (extreme) / / 21935397 rs12966550 chr18 57911330 A G 3.46E-06 Waist circumference / / 19557197 rs12966550 chr18 57911330 A G 7.43E-07 Obesity (extreme) / / 21935397 rs9956274 chr18 57912703 C T 8.83E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs9955666 chr18 57912785 G A 2.35E-04 Obesity (extreme) / / 21935397 rs4450508 chr18 57913434 G A 9.50E-04 Obesity (extreme) / / 21935397 rs75914913 chr18 57918100 G T 0.0000219 Menopause (age at onset) / / 23424626 rs1379444 chr18 57923480 C A 6.37E-05 Cognitive test performance / / 20125193 rs9956279 chr18 57942799 C T 7.99E-13 Obesity / / 23563607 rs2168709 chr18 57945105 G A 3.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs17066768 chr18 57958450 C T 4.83E-04 Multiple complex diseases / / 17554300 rs17773430 chr18 57963117 T C 6.00E-06 Obesity and blood pressure / / 22013104 rs117454233 chr18 57986927 A G 0.0000217 Menopause (age at onset) / / 23424626 rs11152221 chr18 58017249 T C 4.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11152221 chr18 58017249 T C 8.09E-04 Stroke / / pha002886 rs35748167 chr18 58037433 G C 9.31E-09 Chronic lymphocytic leukemia / / 23770605 rs2229616 chr18 58039276 C T 0.00000246 Body mass index (males) MC4R missense 23001569 rs2229616 chr18 58039276 C T 6.39E-12 Body mass index MC4R missense 23001569 rs17066846 chr18 58044818 T G 0.0000329 Body mass index / / 23001569 rs17066846 chr18 58044818 T G 7.52E-06 Body mass index / / 23669352 rs11873305 chr18 58049192 A C 0.00000038 Type 2 diabetes / / 22885922 rs8097783 chr18 58051294 G A 6.08E-04 Multiple complex diseases / / 17554300 rs8097783 chr18 58051294 G A 9.06E-04 Alzheimer's disease / / 17998437 rs8083286 chr18 58060461 A G 8.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs11878133 chr18 58067037 T C 4.00E-06 Age-related macular degeneration / / 20385819 rs11152222 chr18 58093902 T G 1.00E-04 Prostate cancer / / 21743057 rs1943231 chr18 58094199 G T 7.75E-04 Type 2 diabetes / / 17463246 rs4257308 chr18 58109190 C T 6.00E-06 Tuberculosis / / 20694014 rs7236588 chr18 58110883 T C 1.36E-05 Tuberculosis / / 20694014 rs1943238 chr18 58115236 A C 8.70E-05 Tuberculosis / / 20694014 rs1943240 chr18 58116442 A G 8.39E-06 Tuberculosis / / 20694014 rs2156336 chr18 58117967 C T 2.60E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2000777 chr18 58120859 C A 7.36E-04 Alzheimer's disease / / 17998437 rs11877994 chr18 58154299 T A 0.0005638 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11877994 chr18 58154299 T A 5.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs500817 chr18 58154350 C A 9.50E-05 Bladder cancer / / 19648920 rs11659639 chr18 58167612 T G 2.13E-07 Blood pressure / / 21378095 rs590915 chr18 58184556 G T 2.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs472418 chr18 58187465 C A 1.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12455135 chr18 58208260 C T 5.17E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs17067050 chr18 58211298 A G 7.29E-04 Type 2 diabetes / / 17463246 rs574117 chr18 58211563 C T 2.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12960864 chr18 58211616 A C 2.68E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs695020 chr18 58215086 C A 5.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11152236 chr18 58221171 T C 4.29E-04 Iron levels / / pha002876 rs1430387 chr18 58227112 T C 6.55E-04 Iron levels / / pha002876 rs603119 chr18 58256651 T C 7.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9952630 chr18 58288450 A G 8.07E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9946227 chr18 58314252 A C 4.84E-04 Smoking quantity / / 24665060 rs17067223 chr18 58325680 C G 4.95E-04 Multiple complex diseases / / 17554300 rs2168303 chr18 58375934 A G 2.00E-07 Gout / / 23263486 rs9965653 chr18 58402885 T C 2.40E-06 Central corneal thickness / / 20485516 rs9956748 chr18 58474850 C A 7.53E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7227646 chr18 58523815 A T 6.60E-04 Type 2 diabetes / / 17463246 rs9646627 chr18 58529953 A G 1.45E-24 Narcolepsy / / 19629137 rs17609410 chr18 58563363 G T 8.89E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7233420 chr18 58573151 G T 7.08E-04 Smoking initiation / / 24665060 rs17682962 chr18 58581791 C A 3.44E-04 Multiple complex diseases / / 17554300 rs6567192 chr18 58618060 G A 3.95E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2332197 chr18 58717342 A G 7.10E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1426284 chr18 58738938 A G 5.17E-05 Coronary heart disease / / 21606135 rs8090450 chr18 58752218 G A 4.96E-05 Coronary heart disease / / 21606135 rs242689 chr18 58767733 G A 5.04E-04 Multiple complex diseases / / 17554300 rs17067791 chr18 58785483 G A 1.02E-04 Coronary heart disease / / 21606135 rs10460149 chr18 58787931 C T 3.60E-04 Coronary heart disease / / 21606135 rs2032712 chr18 58794916 C T 6.32E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11152281 chr18 58806312 G A 6.07E-04 Multiple complex diseases / / 17554300 rs12455952 chr18 58840518 T G 2.00E-05 Endometriosis / / 21151130 rs1008632 chr18 58869249 C T 8.30E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs154894 chr18 58874142 A G 1.35E-04 Multiple complex diseases / / 17554300 rs10503052 chr18 58899633 G A 7.98E-04 Type 2 diabetes / / 17463246 rs10503052 chr18 58899633 G A 3.20E-06 Urinary metabolites / / 21572414 rs954142 chr18 58907361 C A 2.87E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs4941005 chr18 58926526 C T 6.43E-04 Smoking cessation / / 24665060 rs969327 chr18 58927350 T G 4.95E-04 Multiple complex diseases / / 17554300 rs1355120 chr18 58954487 C T 7.80E-05 Electrocardiographic conduction measures / / 19389651 rs12455825 chr18 58957920 G C 4.90E-05 Multiple complex diseases / / 17554300 rs6567205 chr18 58964894 G A 7.70E-05 Electrocardiographic conduction measures / / 19389651 rs8084714 chr18 58990531 C T 8.40E-05 Electrocardiographic conduction measures / / 19389651 rs17068170 chr18 58994409 T C 1.63E-04 Multiple complex diseases / / 17554300 rs6567206 chr18 59005831 G T 9.04E-07 Schizophrenia / / 21926974 rs12607636 chr18 59008302 G A 3.25E-04 Nicotine dependence / / 17158188 rs17068201 chr18 59012686 G C 1.17E-04 Birth weight / / 17255346 rs7233985 chr18 59019891 G T 0.0000716 Tuberculosis with early age of onset / / 22551897 rs11664910 chr18 59028063 A G 2.30E-06 Prostate cancer (early onset) / / 24740154 rs8097281 chr18 59042221 G A 6.60E-04 Type 2 diabetes / / 17463246 rs8088963 chr18 59047314 A G 1.36E-04 Multiple complex diseases / / 17554300 rs8088963 chr18 59047314 A G 1.19E-05 Serum metabolites / / 19043545 rs10871791 chr18 59059262 C T 2.06E-05 Suicide attempts in bipolar disorder / / 21423239 rs6567212 chr18 59082312 G A 4.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs2215460 chr18 59089325 G T 7.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs9958456 chr18 59103006 T C 2.80E-05 Urinary metabolites / / 21572414 rs1155659 chr18 59109238 A G 1.35E-04 Alzheimer's disease / / 17998437 rs12958629 chr18 59110259 A G 7.82E-04 Multiple complex diseases LOC100505626 intron 17554300 rs1893636 chr18 59131800 A G 9.09E-04 Multiple complex diseases / / 17554300 rs2535357 chr18 59142511 A G 2.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2535358 chr18 59142950 A G 2.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7234184 chr18 59144468 C T 9.66E-04 Multiple complex diseases / / 17554300 rs647535 chr18 59144815 G T 3.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17749052 chr18 59172317 T C 1.88E-05 Alzheimer's disease (late onset) CDH20 intron 21379329 rs579378 chr18 59173921 T A 5.25E-04 Smoking cessation CDH20 intron 24665060 rs492160 chr18 59174132 G T 1.52E-05 Cognitive test performance CDH20 intron 20125193 rs1943330 chr18 59174759 C A 3.66E-06 Alzheimer's disease (late onset) CDH20 missense 21379329 rs1943330 chr18 59174759 C A 7.53E-05 Glucose levels CDH20 missense pha003061 rs8083225 chr18 59194760 G A 4.78E-04 Smoking initiation CDH20 intron 24665060 rs12969490 chr18 59199237 G A 5.51E-05 Smoking quantity CDH20 intron 24665060 rs9783862 chr18 59199434 T C 1.09E-04 Smoking quantity CDH20 intron 24665060 rs7239572 chr18 59205707 C T 1.18E-04 Smoking quantity CDH20 intron 24665060 rs673401 chr18 59207432 C T 3.18E-04 Alcohol dependence CDH20 intron 20201924 rs17068541 chr18 59223754 T C 3.72E-05 Cognitive test performance / / 20125193 rs17619983 chr18 59240251 G A 8.24E-06 Asthma / / 21790008 rs1943338 chr18 59244189 T C 6.25E-04 Multiple complex diseases / / 17554300 rs4941029 chr18 59244746 T A,C,G 3.61E-04 Multiple complex diseases / / 17554300 rs17068591 chr18 59257857 T G 8.94E-04 Multiple complex diseases / / 17554300 rs11664738 chr18 59257973 T C 2.90E-06 Urinary metabolites / / 21572414 rs1840047 chr18 59258545 T C 3.52E-04 Multiple complex diseases / / 17554300 rs2032366 chr18 59266371 C T 6.00E-06 Obesity-related traits / / 23251661 rs713485 chr18 59270925 G A 7.30E-05 Bone mineral density (spine) / / 19079262 rs9949138 chr18 59280720 G A 6.59E-04 Type 2 diabetes / / 17463246 rs9952336 chr18 59281636 G A 6.33E-04 Type 2 diabetes / / 17463246 rs9944595 chr18 59281948 T G 7.87E-04 Type 2 diabetes / / 17463246 rs1377169 chr18 59282156 A G 8.38E-05 Major depressive disorder (broad) / / 20038947 rs1377169 chr18 59282156 A G 6.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs11876431 chr18 59287409 A G 8.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs12454307 chr18 59294347 T C 7.18E-05 Major depressive disorder (broad) / / 20038947 rs12454307 chr18 59294347 T C 5.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs17694377 chr18 59295890 T C 1.80E-06 Urinary metabolites / / 21572414 rs17694481 chr18 59296547 A G 7.06E-04 Type 2 diabetes / / 17463246 rs17068758 chr18 59325637 A G 4.16E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1452589 chr18 59336601 T C 9.01E-04 Multiple complex diseases / / 17554300 rs1945486 chr18 59370004 T A 2.19E-05 Asthma / / 23181788 rs4941053 chr18 59418576 T C 9.43E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4319862 chr18 59493334 G T 3.83E-05 Calcium intake levels and metabolic syndrome RNF152 intron 22170361 rs8091174 chr18 59494069 C T 1.00E-04 Osteoarthritis (knee and hip) RNF152 intron 21177295 rs8091174 chr18 59494069 C T 2.04E-05 Osteoarthritis (knee and hip) RNF152 intron 21177295 rs8091174 chr18 59494069 C T 9.69E-05 Osteoarthritis (knee and hip) RNF152 intron 21177295 rs9944883 chr18 59504161 C A 3.19E-04 Multiple complex diseases RNF152 intron 17554300 rs4131216 chr18 59505348 A G 7.29E-04 Multiple complex diseases RNF152 intron 17554300 rs9958268 chr18 59550066 T A 4.66E-04 Body mass index RNF152 intron 17255346 rs9958268 chr18 59550066 T A 1.71E-04 Suicide attempts in bipolar disorder RNF152 intron 21423239 rs7505697 chr18 59555405 G A 1.19E-04 Body mass index RNF152 intron 17255346 rs7232902 chr18 59564053 G T 8.91E-05 Potassium levels / / pha003086 rs17623861 chr18 59579590 A G 3.26E-04 Multiple complex diseases / / 17554300 rs948785 chr18 59585959 T C 9.79E-04 Type 2 diabetes / / 17463246 rs6420563 chr18 59586364 G A 7.57E-04 Depression (quantitative trait) / / 20800221 rs10469243 chr18 59615834 G A 5.92E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9646628 chr18 59624353 A G 5.92E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11152324 chr18 59624975 G A 1.51E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17069176 chr18 59642132 T C 1.50E-05 Urinary metabolites / / 21572414 rs514874 chr18 59643567 C T 1.36E-04 Multiple complex diseases / / 17554300 rs1346949 chr18 59647836 T A 6.73E-05 Cardiovascular disease / / 22029572 rs1346950 chr18 59647905 C T 5.40E-06 Urinary metabolites / / 21572414 rs8098844 chr18 59648259 G A 1.40E-05 Urinary metabolites / / 21572414 rs7228493 chr18 59650717 C T 1.60E-05 Urinary metabolites / / 21572414 rs17069203 chr18 59659783 G A 1.20E-05 Urinary metabolites / / 21572414 rs651408 chr18 59660180 G A 1.10E-04 Vaspin levels / / 22907691 rs651408 chr18 59660180 G A 0.0001102 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs586025 chr18 59691300 G A 9.68E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs615062 chr18 59691752 T C 9.68E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs8093819 chr18 59698876 G A 5.46E-05 Glycosylated haemoglobin levels / / 17255346 rs9945382 chr18 59705182 G T 2.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9636100 chr18 59711310 A G 8.43E-07 Paget's disease / / 20436471 rs4941104 chr18 59729644 C T 5.08E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIGN intron 20877124 rs4941107 chr18 59751331 A G 1.75E-07 Paget's disease PIGN intron 20436471 rs663354 chr18 59754290 C T 2.36E-08 Paget's disease PIGN intron 20436471 rs663354 chr18 59754290 C T 2.89E-04 Heart Failure PIGN intron pha002884 rs12604216 chr18 59759334 A G 3.81E-06 Lymphocyte counts PIGN intron 22286170 rs677295 chr18 59761656 C T 3.40E-05 Paget's disease PIGN intron 20436471 rs12607624 chr18 59779231 G A 4.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIGN intron 20877124 rs9807301 chr18 59797377 T C 1.71E-05 Dengue shock syndrome PIGN intron 22001756 rs17069506 chr18 59821843 T C 5.20E-05 Response to statin therapy PIGN missense 20339536 rs4941117 chr18 59836405 A G 8.58E-05 Vaspin levels PIGN intron 22907691 rs4941117 chr18 59836405 A G 0.0000858 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit PIGN intron 22907730 rs17644227 chr18 59865998 G A 6.13E-05 Type 2 diabetes KIAA1468 intron 17463246 rs9967295 chr18 59875310 C T 2.20E-06 Urinary metabolites KIAA1468 intron 21572414 rs1587999 chr18 59876495 A G 8.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KIAA1468 intron 20877124 rs1587999 chr18 59876495 A G 1.90E-06 Urinary metabolites KIAA1468 intron 21572414 rs12150701 chr18 59881654 C T 8.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KIAA1468 intron 20877124 rs17069634 chr18 59896187 C T 3.80E-06 Urinary metabolites KIAA1468 intron 21572414 rs17069657 chr18 59924710 T C 1.40E-05 Urinary metabolites KIAA1468 intron 21572414 rs3752093 chr18 59925938 G A 8.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KIAA1468 intron 20877124 rs2980980 chr18 59946568 A G 1.14E-04 Vaspin levels KIAA1468 intron 22907691 rs2980980 chr18 59946568 A G 0.0001138 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit KIAA1468 intron 22907730 rs2980981 chr18 59947118 G A 1.68E-04 Heart Failure KIAA1468 intron pha002884 rs2939421 chr18 59959991 T C 2.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KIAA1468 intron 20877124 rs2980996 chr18 59979135 C T 3.35E-08 Paget's disease / / 20436471 rs2980996 chr18 59979135 C T 9.55E-05 Heart Failure / / pha002884 rs7226991 chr18 59988691 G A 9.97E-04 Heart Failure / / pha002884 rs12956925 chr18 60013640 G A 8.88E-07 Glycosylated haemoglobin levels TNFRSF11A intron 17255346 rs4500848 chr18 60014463 T C 1.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TNFRSF11A intron 20877124 rs12455775 chr18 60019850 T G 8.90E-04 Acute lung injury TNFRSF11A intron 22295056 rs7236060 chr18 60023282 G A 1.65E-05 Vitiligo TNFRSF11A intron 22561518 rs1805034 chr18 60027241 C T 3.60E-05 Inflammatory demyelinating disease TNFRSF11A missense 19850125 rs8083511 chr18 60028655 A C 1.17E-04 Longevity TNFRSF11A intron 22279548 rs17069898 chr18 60029281 A G 5.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TNFRSF11A intron 20877124 rs7231887 chr18 60031489 G A 4.15E-05 Lipoprotein A [Lp(a)] levels in plasma TNFRSF11A intron 21592478 rs884205 chr18 60054857 A C 9.00E-09 Bone mineral density (spine) / / 19801982 rs884205 chr18 60054857 A C 2.00E-17 Bone mineral density / / 22504420 rs884205 chr18 60054857 A C 2.95E-05 Bone mineral density / / 24249740 rs884205 chr18 60054857 A C 2.95E-05 Bone mineral density / / 24249740 rs884205 chr18 60054857 A C 3.18E-05 Bone mineral density / / 24249740 rs884205 chr18 60054857 A C 6.04E-04 Bone mineral density / / 24249740 rs884205 chr18 60054857 A C 6.04E-04 Bone mineral density / / 24249740 rs884205 chr18 60054857 A C 1.84E-08 Bone mineral density (paediatric,skull) / / 24945404 rs884205 chr18 60054857 A C 2.00E-07 Bone mineral density (paediatric,skull) / / 24945404 rs884205 chr18 60054857 A C 2.00E-08 Bone mineral density (paediatric,skull) / / 24945404 rs2957128 chr18 60060735 A G 9.91E-05 Cholesterol / / 17255346 rs2957128 chr18 60060735 A G 2.00E-11 Paget's disease / / 20436471 rs3017365 chr18 60063341 G A 6.01E-05 Cholesterol / / 17255346 rs6567280 chr18 60063622 A G 9.05E-05 Prostate cancer / / 18264096 rs3017366 chr18 60065821 A G 5.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2277731 chr18 60066939 G C 2.00E-04 Cardiovascular disease adverse events in renal patients treated with calcineurin inhibitors / / 16155738 rs3017368 chr18 60067128 A G 5.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2980976 chr18 60080112 G A 5.95E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2980976 chr18 60080112 G A 3.00E-07 Response to antipsychotic treatment / / 23241943 rs3018362 chr18 60082093 A G 1.00E-06 Bone mineral density (hip) / / 18445777 rs3018362 chr18 60082093 A G 5.00E-13 Paget's disease / / 20436471 rs3018362 chr18 60082093 A G 8.00E-21 Paget's disease / / 21623375 rs8097062 chr18 60085040 G T 1.28E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12150753 chr18 60089644 C T 0.0002 Migraine / / 22678113 rs17070008 chr18 60115718 C T 2.02E-04 Blood pressure / / 17255346 rs694419 chr18 60126112 T C 1.00E-08 Serum albumin level / / 23022100 rs694419 chr18 60126112 T C 4.00E-09 Serum albumin level / / 23022100 rs6567288 chr18 60218334 G A 2.96E-04 Multiple complex diseases ZCCHC2 intron 17554300 rs2048793 chr18 60224279 T A 9.72E-04 Multiple complex diseases ZCCHC2 intron 17554300 rs2048793 chr18 60224279 T A 1.83E-04 Bipolar disorder,schizoaffective ZCCHC2 intron 19567891 rs8097720 chr18 60225194 C T 0.000042 Salmonella-induced pyroptosis ZCCHC2 intron 22837397 rs3760569 chr18 60239081 T C 5.08E-04 Multiple complex diseases ZCCHC2 intron 17554300 rs3760569 chr18 60239081 T C 6.80E-05 Bipolar disorder,schizoaffective ZCCHC2 intron 19567891 rs3760570 chr18 60239287 A G 5.16E-04 Multiple complex diseases ZCCHC2 intron 17554300 rs3760570 chr18 60239287 A G 7.10E-04 Bipolar disorder,schizoaffective ZCCHC2 intron 19567891 rs1052315 chr18 60253761 C T 1.71E-04 Bipolar disorder,schizoaffective / / 19567891 rs2282551 chr18 60254789 T C 9.15E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs601278 chr18 60270175 A G 5.04E-04 Heart Failure / / pha002884 rs2105728 chr18 60270612 G A 5.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs10439027 chr18 60287284 T C 2.40E-05 F-cell distribution / / 21326311 rs7229543 chr18 60314821 G A 3.00E-05 Diabetic retinopathy / / 21441570 rs7230656 chr18 60314838 C T 6.50E-05 Diabetic retinopathy / / 21441570 rs7235438 chr18 60314872 T C 6.50E-05 Diabetic retinopathy / / 21441570 rs17669923 chr18 60315701 A G 6.00E-05 Diabetic retinopathy / / 21441570 rs8087081 chr18 60347199 T A 5.66E-08 Blood pressure / / 21996601 rs306212 chr18 60424354 T C 1.34E-05 Serum metabolites PHLPP1 intron 19043545 rs4941161 chr18 60510487 C T 4.67E-05 Caffeine consumption PHLPP1 intron 21490707 rs541425 chr18 60532841 A G 6.48E-04 Type 2 diabetes PHLPP1 intron 17463246 rs673965 chr18 60589197 T C 2.83E-05 Serum metabolites PHLPP1 intron 19043545 rs7229094 chr18 60608663 C T 7.52E-05 Lung function (forced vital capacity) PHLPP1 intron 24023788 rs7235367 chr18 60609723 G A 8.30E-04 Alcohol dependence PHLPP1 intron 20201924 rs842026 chr18 60625250 T G 1.40E-05 Urinary metabolites PHLPP1 intron 21572414 rs693250 chr18 60641347 A C 8.20E-05 Diabetic retinopathy PHLPP1 intron 21441570 rs515563 chr18 60643748 A G 2.10E-04 Type 2 diabetes and 6 quantitative traits PHLPP1 intron 17848626 rs515469 chr18 60643783 A T 2.90E-05 Urinary metabolites PHLPP1 intron 21572414 rs8095193 chr18 60683115 C T 1.33E-04 Stroke / / pha002886 rs2877745 chr18 60683641 C T 3.40E-05 Systemic sclerosis / / 21750679 rs11661682 chr18 60686927 G A 5.50E-04 Stroke / / pha002886 rs7232459 chr18 60703005 G A 0.0000802 Migraine / / 22678113 rs7232459 chr18 60703005 G A 8.02E-05 Migraine / / 22683712 rs6567315 chr18 60708726 A G 4.09E-04 Alzheimer's disease (late onset) / / 21379329 rs7238248 chr18 60717454 G A 7.42E-04 Type 2 diabetes / / 17463246 rs7350995 chr18 60720240 T C 6.78E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6567322 chr18 60735449 A G 8.80E-05 Endometriosis / / 21151130 rs6567322 chr18 60735449 A G 4.76E-05 Blood Pressure / / pha003043 rs9947451 chr18 60743100 G A 0.0001 Migraine / / 22678113 rs9945969 chr18 60754772 G A 3.89E-04 Alzheimer's disease (late onset) / / 21379329 rs2061450 chr18 60760812 G A 3.05E-04 Longevity / / 22279548 rs2061450 chr18 60760812 G A 2.42E-05 Blood Pressure / / pha003043 rs17676919 chr18 60783729 A G 5.42E-06 Multiple complex diseases / / 17554300 rs8086644 chr18 60788559 G A 3.24E-04 Glycemic traits (pregnancy) / / 23903356 rs4987867 chr18 60791072 C T 0.000000854 HDL cholesterol BCL2 UTR-3 23063622 rs4987867 chr18 60791072 C T 7.92E-17 Triglycerides BCL2 UTR-3 23063622 rs4987856 chr18 60793494 C T 5.71E-11 Chronic lymphocytic leukemia BCL2 UTR-3 23770605 rs4987855 chr18 60793549 C T 3.00E-12 Chronic lymphocytic leukemia BCL2 UTR-3 23770605 rs4987852 chr18 60793921 T C 8.00E-11 Chronic lymphocytic leukemia BCL2 UTR-3 23770605 rs4987852 chr18 60793921 T C 8.00E-05 Chronic lymphocytic leukemia BCL2 UTR-3 24292274 rs17756073 chr18 60809783 A G 7.91E-04 Multiple complex diseases BCL2 intron 17554300 rs12457831 chr18 60810240 G C 2.05E-04 Response to cytadine analogues (cytosine arabinoside) BCL2 intron 24483146 rs4456611 chr18 60810452 C T 0.00041 Coronary artery calcification BCL2 intron 23727086 rs3943258 chr18 60813636 T C 0.00028 Coronary artery calcification BCL2 intron 23727086 rs2046135 chr18 60814252 T A 7.90E-04 Coronary heart disease BCL2 intron 21966275 rs12457170 chr18 60816836 G A 3.40E-04 Atrial fibrillation BCL2 intron 21846873 rs12454712 chr18 60845884 T C 5.03E-04 Taste perception BCL2 intron 22132133 rs12454712 chr18 60845884 T C 2.14E-08 Type 2 diabetes BCL2 intron 22325160 rs17679032 chr18 60857160 T C 6.58E-05 Celiac disease BCL2 intron 23936387 rs899967 chr18 60859321 C G 7.00E-06 Cardiac Troponin-T levels BCL2 intron 23247143 rs7243091 chr18 60880562 G A 1.07E-05 Glucose levels BCL2 intron pha003058 rs4987765 chr18 60905022 T C 3.91E-04 Multiple complex diseases BCL2 intron 17554300 rs4941189 chr18 60907927 C T 1.89E-04 Lung function (forced expiratory volume in 1 second) BCL2 intron 24023788 rs4941189 chr18 60907927 C T 3.46E-04 Lung function (forced vital capacity) BCL2 intron 24023788 rs4987764 chr18 60908132 A G 6.43E-05 Tunica Media BCL2 intron pha003036 rs4987756 chr18 60909111 A G 0.00000378 Ankle-brachial index BCL2 intron 22361517 rs10503079 chr18 60912366 C T 4.20E-04 Insulin resistance BCL2 intron 21901158 rs7234941 chr18 60922851 C T 2.47E-04 Multiple complex diseases BCL2 intron 17554300 rs7234941 chr18 60922851 C T 2.20E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) BCL2 intron 24023788 rs3744951 chr18 60925980 T C 8.06E-04 Multiple complex diseases BCL2 intron 17554300 rs7242402 chr18 60941958 C T 7.88E-04 Psoriasis BCL2 intron 20953187 rs1381547 chr18 60957339 T C 6.01E-04 Type 2 diabetes BCL2 intron 17463246 rs12458289 chr18 60978586 G T 3.55E-04 Multiple complex diseases BCL2 intron 17554300 rs698708 chr18 60995261 G C 8.36E-05 Insulin resistance KDSR UTR-3 21901158 rs2850767 chr18 61001114 G T 7.73E-04 Aortic root size KDSR intron 21223598 rs2551408 chr18 61001922 T A 7.08E-04 Insulin resistance KDSR intron 21901158 rs7231949 chr18 61013635 C T 3.45E-04 Gallstones KDSR intron 17632509 rs1541296 chr18 61022115 G A 1.60E-04 Lipid traits KDSR intron 17903299 rs1541296 chr18 61022115 G A 4.34E-04 Insulin resistance KDSR intron 21901158 rs489520 chr18 61029511 A G 6.59E-05 Calcium levels KDSR intron pha003085 rs9946122 chr18 61046267 A G 4.07E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs952245 chr18 61067959 T C 7.17E-04 Diabetic retinopathy VPS4B intron 20871662 rs17071050 chr18 61070715 A C 4.12E-04 Coronary heart disease VPS4B intron 21971053 rs9959062 chr18 61130601 T C 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6567349 chr18 61135775 T C 2.61E-04 Type 2 diabetes / / 17463246 rs6567350 chr18 61135838 A G 2.71E-04 Type 2 diabetes / / 17463246 rs8083105 chr18 61137936 C T 2.79E-04 Type 2 diabetes / / 17463246 rs8083911 chr18 61138100 A G 3.96E-04 Type 2 diabetes / / 17463246 rs9320018 chr18 61139559 A G 4.01E-04 Type 2 diabetes / / 17463246 rs79285331 chr18 61145707 C T 3.00E-06 PR interval in Tripanosoma cruzi seropositivity SERPINB5 intron 24324551 rs1396782 chr18 61163925 T C 8.27E-04 Response to taxane treatment (placlitaxel) SERPINB5 intron 23006423 rs6567365 chr18 61164602 T C 1.79E-16 Narcolepsy SERPINB5 intron 19629137 rs2032224 chr18 61176266 C A 9.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule) / / 24025145 rs1111283 chr18 61223296 G A 4.38E-04 Multiple complex diseases / / 17554300 rs9959343 chr18 61265870 C T 1.77E-05 Depression (quantitative trait) SERPINB13 UTR-3 23290196 rs2168312 chr18 61281648 G A 2.67E-05 Meningococcal disease / / 20694013 rs2168312 chr18 61281648 G A 1.47E-05 Depression (quantitative trait) / / 23290196 rs611263 chr18 61290257 C T 8.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs645623 chr18 61294936 T C 5.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2077781 chr18 61303978 G T 2.36E-05 Depression (quantitative trait) / / 23290196 rs2276203 chr18 61306690 G A 2.51E-05 Depression (quantitative trait) SERPINB4 intron 23290196 rs4941210 chr18 61322043 C T 2.92E-05 Depression (quantitative trait) / / 23290196 rs11664693 chr18 61330572 G C 2.88E-05 Depression (quantitative trait) / / 23290196 rs12327459 chr18 61333757 T C 8.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1589595 chr18 61339178 T C 3.66E-05 Depression (quantitative trait) / / 23290196 rs1011947 chr18 61344012 G A 3.41E-05 Meningococcal disease / / 20694013 rs1011947 chr18 61344012 G A 3.36E-05 Depression (quantitative trait) / / 23290196 rs8091788 chr18 61363389 G A 8.14E-05 Depression (quantitative trait) / / 23290196 rs9960039 chr18 61372047 G A 7.14E-04 Multiple complex diseases SERPINB11 intron 17554300 rs1581426 chr18 61375519 C T 5.52E-04 Multiple complex diseases SERPINB11 intron 17554300 rs6567383 chr18 61375683 T C 3.66E-05 Bipolar disorder SERPINB11 intron 17486107 rs1395268 chr18 61377579 A C 8.00E-05 Prostate cancer SERPINB11 missense 21743057 rs1395268 chr18 61377579 A C 9.66E-05 Depression (quantitative trait) SERPINB11 missense 23290196 rs4940595 chr18 61379838 T G 6.26E-04 Multiple complex diseases / / 17554300 rs11152402 chr18 61380357 G A 6.45E-04 Multiple complex diseases SERPINB11 intron 17554300 rs1522723 chr18 61384980 C T 6.40E-04 Multiple complex diseases SERPINB11 intron 17554300 rs1395265 chr18 61390316 C A 6.11E-05 Heart Rate SERPINB11 cds-synon pha003051 rs1395266 chr18 61390332 C T 6.29E-05 Heart Rate SERPINB11 missense pha003051 rs1395267 chr18 61390361 T C 8.73E-05 Heart Rate SERPINB11 missense pha003051 rs8087490 chr18 61392190 C T 5.25E-05 Heart Rate / / pha003051 rs931850 chr18 61393834 C T 6.33E-05 Heart Rate / / pha003051 rs931849 chr18 61393959 C T 1.00E-05 Prostate cancer / / 21743057 rs11873703 chr18 61448703 T C 9.41E-04 Multiple complex diseases SERPINB7 intron 17554300 rs10503087 chr18 61476454 G T 3.86E-05 Bilirubin levels,in serum / / 19389676 rs1701609 chr18 61486945 C T 9.36E-05 Diabetes Mellitus / / pha003059 rs1701607 chr18 61487807 C T 9.36E-05 Diabetes Mellitus / / pha003059 rs1701603 chr18 61488067 C T 9.36E-05 Diabetes Mellitus / / pha003059 rs986982 chr18 61497804 G A 5.00E-05 Prostate cancer / / 21743057 rs1243056 chr18 61508463 A G 9.94E-05 Meningococcal disease / / 20694013 rs1243059 chr18 61509286 A G 4.84E-05 Meningococcal disease / / 20694013 rs1243062 chr18 61512366 G A 7.08E-05 Meningococcal disease / / 20694013 rs9320028 chr18 61517170 A G 5.26E-09 Lymphocyte counts / / 22286170 rs17072020 chr18 61565138 T G 0.00000218 HDL cholesterol SERPINB2 intron 23063622 rs17072020 chr18 61565138 T G 7.50E-15 LDL cholesterol SERPINB2 intron 23063622 rs8099238 chr18 61586637 A C 7.96E-05 Multiple complex diseases SERPINB10 intron 17554300 rs9952485 chr18 61622791 G A 1.60E-04 Multiple complex diseases HMSD intron 17554300 rs9950903 chr18 61630803 A C 3.97E-04 Multiple complex diseases / / 17554300 rs8090586 chr18 61630884 G C 4.54E-04 Multiple complex diseases / / 17554300 rs1006755 chr18 61631046 A G 5.80E-04 Multiple complex diseases / / 17554300 rs7229716 chr18 61641991 A G 3.93E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SERPINB8 intron 20031582 rs1944268 chr18 61647479 A T 9.25E-04 Obesity (extreme) SERPINB8 intron 21935397 rs3786343 chr18 61647895 C T 2.27E-05 Male-pattern baldness SERPINB8 intron 18849994 rs6567409 chr18 61652035 G A 1.72E-05 Serum albumin level SERPINB8 intron pha003084 rs3169983 chr18 61654297 A G 4.81E-04 Multiple complex diseases SERPINB8 missense 17554300 rs514315 chr18 61656785 T C 1.20E-09 Psoriasis / / 20953187 rs514315 chr18 61656785 T C 2.99E-09 Psoriasis / / 20953187 rs10513930 chr18 61683766 T C 7.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4941236 chr18 61685225 C T 4.30E-04 Lipid traits / / 17903299 rs1517166 chr18 61697297 T C 8.11E-05 Amyotrophic lateral sclerosis / / 20801717 rs1517166 chr18 61697297 T C 0.000000888 Amyotrophic lateral sclerosis / / 23587638 rs1517166 chr18 61697297 T C 0.0000731 Amyotrophic lateral sclerosis / / 23587638 rs8094641 chr18 61722900 A G 2.00E-05 Subclinical atherosclerosis / / 17903303 rs11152416 chr18 61725540 G T 0.0000935 alzheimer's disease (late onset) / / 22785395 rs17072566 chr18 61767608 C T 3.80E-06 Urinary metabolites LINC00305 intron 21572414 rs4941244 chr18 61776007 T C 5.60E-06 Urinary metabolites LINC00305 intron 21572414 rs2850711 chr18 61787038 A T 1.50E-05 Subclinical atherosclerosis LINC00305 intron 17903303 rs9963373 chr18 61791809 G C 6.40E-06 Urinary metabolites LINC00305 intron 21572414 rs4941246 chr18 61802304 C T 6.43E-07 Systemic lupus erythematosus and Systemic sclerosis LINC00305 intron 23740937 rs9950644 chr18 61802478 T C 5.80E-06 Urinary metabolites LINC00305 intron 21572414 rs6567414 chr18 61825851 A G 8.78E-05 Orofacial clefts LOC284294 intron 22419666 rs17072633 chr18 61825999 T C 6.69E-04 Type 2 diabetes LOC284294 intron 17463246 rs6567416 chr18 61840388 T C 2.00E-04 Cognitive impairment induced by topiramate LOC284294 intron 22091778 rs6567416 chr18 61840388 T C 4.56E-06 Lymphocyte counts LOC284294 intron pha003094 rs6567416 chr18 61840388 T C 5.55E-07 Neutrophil count LOC284294 intron pha003095 rs8091006 chr18 61842934 T C 4.05E-04 Multiple complex diseases LOC284294 intron 17554300 rs9675798 chr18 61856967 T G 5.27E-04 Multiple complex diseases LOC284294 intron 17554300 rs7237857 chr18 61861406 A G 6.38E-05 Odorant perception LOC284294 intron 23910658 rs4534959 chr18 61877156 A G 7.00E-07 Airflow obstruction LOC284294 intron 22837378 rs8093550 chr18 61877777 C T 5.25E-07 Longevity,exceptional LOC284294 intron 20595579 rs11876820 chr18 61891408 C G 4.12E-05 Educational attainment LOC284294 intron 21694764 rs4514783 chr18 61918306 G T 3.85E-05 Educational attainment LOC284294 intron 21694764 rs1421536 chr18 61978222 G A 5.18E-05 Height LOC284294 intron pha003010 rs2112058 chr18 61984038 T G 1.18E-04 Alzheimer's disease LOC284294 intron 17998437 rs8096869 chr18 62001089 T C 4.50E-05 Height LOC284294 intron pha003010 rs966194 chr18 62009588 T C 2.30E-05 Urinary metabolites LOC284294 intron 21572414 rs10515992 chr18 62019724 G A 6.95E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) LOC284294 intron 24192120 rs17072919 chr18 62030967 G C 6.95E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) LOC284294 intron 24192120 rs17797346 chr18 62033261 C T 7.13E-04 Multiple complex diseases LOC284294 intron 17554300 rs1421521 chr18 62085506 G A 4.29E-04 Coronary heart disease LOC284294 intron 21606135 rs1157774 chr18 62088801 T A 7.16E-04 Coronary Artery Disease LOC284294 intron 17634449 rs9960678 chr18 62164462 T C 2.17E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs4553720 chr18 62170726 T C 7.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs9807390 chr18 62219626 G A 4.86E-04 Smoking initiation / / 24665060 rs7227162 chr18 62220863 C A 0.0007696 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7227162 chr18 62220863 C A 7.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12967515 chr18 62226823 T G 6.30E-04 Smoking initiation / / 24665060 rs4473292 chr18 62227062 T C 0.0006896 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4473292 chr18 62227062 T C 6.90E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12456712 chr18 62229306 T C 0.0006803 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12456712 chr18 62229306 T C 6.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11872310 chr18 62229526 G A 8.20E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4346287 chr18 62230171 G A 0.0006578 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4346287 chr18 62230171 G A 6.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4346287 chr18 62230171 G A 3.46E-04 Heart Failure / / pha002885 rs12457505 chr18 62230598 T C 0.0006547 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12457505 chr18 62230598 T C 6.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12454837 chr18 62230679 C G 0.0006209 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12454837 chr18 62230679 C G 6.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4461176 chr18 62232009 G A 0.0005941 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4461176 chr18 62232009 G A 5.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7231878 chr18 62237244 C T 6.23E-04 Smoking initiation / / 24665060 rs9959555 chr18 62251803 C T 9.04E-05 Heart Failure / / pha002885 rs4640284 chr18 62254831 T C 5.73E-04 Smoking initiation / / 24665060 rs8089909 chr18 62255693 A G 4.72E-04 Smoking initiation / / 24665060 rs4074450 chr18 62257411 G A 4.26E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1506232 chr18 62279611 T C 5.60E-04 Alzheimer's disease / / 24755620 rs12456549 chr18 62280807 G A 1.50E-05 Urinary metabolites / / 21572414 rs2959502 chr18 62283530 T C 7.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs2959503 chr18 62283587 A G 7.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs17814846 chr18 62309341 A G 7.75E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2333279 chr18 62313805 A G 2.39E-04 Multiple complex diseases / / 17554300 rs11876093 chr18 62368130 T G 3.16E-04 Self-reported allergy / / 23817569 rs1506223 chr18 62383183 A G 8.15E-07 Bipolar disorder / / 21771265 rs17073641 chr18 62418444 A C 1.00E-07 Age-related macular degeneration (smoking status interaction) / / 23577725 rs12052035 chr18 62418984 C T 2.10E-05 Endometriosis / / 21151130 rs2062980 chr18 62422906 G T 8.49E-05 Postoperative ventricular dysfunction / / 21980348 rs937798 chr18 62431734 T A 5.27E-06 Venous thromboembolism / / 22672568 rs778783 chr18 62441442 T C 5.90E-07 Age-related macular degeneration (smoking status interaction) / / 23577725 rs17073711 chr18 62461340 C T 5.99E-04 Multiple complex diseases / / 17554300 rs9966410 chr18 62467064 C G 8.79E-04 Multiple complex diseases / / 17554300 rs62101514 chr18 62483370 G T 0.00008691 Sarcoidosis / / 22952805 rs12458648 chr18 62487734 T C 0.00007834 Sarcoidosis / / 22952805 rs62101515 chr18 62488188 A G 0.00007834 Sarcoidosis / / 22952805 rs11151161 chr18 62490251 G C 0.00007834 Sarcoidosis / / 22952805 rs17073791 chr18 62493181 A G 0.00007834 Sarcoidosis / / 22952805 rs10871579 chr18 62493588 G A 0.00007834 Sarcoidosis / / 22952805 rs17073794 chr18 62494229 A T 0.00007834 Sarcoidosis / / 22952805 rs62101534 chr18 62495048 T C 0.00007834 Sarcoidosis / / 22952805 rs1595902 chr18 62495585 T C 0.00007834 Sarcoidosis / / 22952805 rs1595903 chr18 62496493 T C 0.00007834 Sarcoidosis / / 22952805 rs11663842 chr18 62498237 T C 0.00007834 Sarcoidosis / / 22952805 rs62101539 chr18 62500757 T C 0.00007834 Sarcoidosis / / 22952805 rs1440540 chr18 62501691 T G 0.00007834 Sarcoidosis / / 22952805 rs1470133 chr18 62504658 G A 0.00007874 Sarcoidosis / / 22952805 rs8098946 chr18 62506122 G A 3.12E-04 Self-reported allergy / / 23817569 rs62101541 chr18 62506222 C T 0.00006868 Sarcoidosis / / 22952805 rs1440544 chr18 62507924 A G 0.00008864 Sarcoidosis / / 22952805 rs11874447 chr18 62508290 T C 3.91E-04 Self-reported allergy / / 23817569 rs9964806 chr18 62508766 C A,G,T 1.18E-04 Self-reported allergy / / 23817569 rs10871581 chr18 62508931 A G 0.0000714 Sarcoidosis / / 22952805 rs17073845 chr18 62511373 G C 0.00007322 Sarcoidosis / / 22952805 rs17073847 chr18 62511595 A G 0.00007322 Sarcoidosis / / 22952805 rs1595905 chr18 62512984 A T 0.00007322 Sarcoidosis / / 22952805 rs62099270 chr18 62514331 A G 0.00006539 Sarcoidosis / / 22952805 rs62099272 chr18 62515263 C A 0.00007416 Sarcoidosis / / 22952805 rs9966592 chr18 62515864 T C 2.60E-04 Self-reported allergy / / 23817569 rs9676063 chr18 62549673 T C 5.18E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs748899 chr18 62551882 G A 1.89E-04 Multiple complex diseases / / 17554300 rs748899 chr18 62551882 G A 2.05E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1942694 chr18 62602805 G A 3.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17074003 chr18 62609303 T C 6.01E-04 Multiple complex diseases / / 17554300 rs17074003 chr18 62609303 T C 4.55E-05 Schizophrenia / / 19571809 rs17074003 chr18 62609303 T C 4.56E-05 Schizophrenia / / pha002859 rs1942707 chr18 62617555 G C 4.59E-05 Multiple complex diseases / / 17554300 rs10164157 chr18 62630036 A G 3.77E-04 Multiple complex diseases / / 17554300 rs4302142 chr18 62630715 T C 2.97E-05 Multiple complex diseases / / 17554300 rs9947925 chr18 62639031 G A 2.09E-04 Multiple complex diseases / / 17554300 rs1942711 chr18 62667823 T A 2.31E-04 Multiple complex diseases / / 17554300 rs17175096 chr18 62720186 T C 8.40E-04 Suicidal ideation / / 22030708 rs17260685 chr18 62737718 A G 2.87E-04 Multiple complex diseases / / 17554300 rs448398 chr18 62764587 A C 4.91E-04 Multiple complex diseases / / 17554300 rs176148 chr18 62773435 C T 4.63E-04 Multiple complex diseases / / 17554300 rs176148 chr18 62773435 C T 3.51E-06 Serum metabolites / / 19043545 rs176137 chr18 62783053 T G 2.28E-04 Multiple complex diseases / / 17554300 rs176137 chr18 62783053 T G 9.93E-05 Serum metabolites / / 19043545 rs1035207 chr18 62822004 G C 2.86E-04 Multiple complex diseases / / 17554300 rs1035207 chr18 62822004 G C 8.32E-06 Serum metabolites / / 19043545 rs1179809 chr18 62823750 C G 6.67E-04 Type 2 diabetes / / 17463246 rs1179809 chr18 62823750 C G 3.92E-04 Multiple complex diseases / / 17554300 rs1179809 chr18 62823750 C G 7.27E-05 Serum metabolites / / 19043545 rs1179808 chr18 62824358 A C 7.14E-04 Type 2 diabetes / / 17463246 rs1179808 chr18 62824358 A C 6.85E-04 Multiple complex diseases / / 17554300 rs3862718 chr18 62826488 G C 5.80E-04 Multiple complex diseases / / 17554300 rs17178107 chr18 62827687 T C 9.71E-04 Multiple complex diseases / / 17554300 rs9954012 chr18 62846497 C T 7.26E-05 Multiple complex diseases / / 17554300 rs3862723 chr18 62856730 T A 4.88E-05 Multiple complex diseases / / 17554300 rs605920 chr18 62884918 C G 6.00E-06 Cardiac Troponin-T levels / / 23247143 rs17179730 chr18 62893870 T C 3.74E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs637644 chr18 62898666 A G 4.02E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs637644 chr18 62898666 A G 3.31E-05 Vitiligo / / 19890347 rs637644 chr18 62898666 A G 0.0000361 Polycystic ovary syndrome / / 22951595 rs637644 chr18 62898666 A G 3.61E-05 Intracranial aneurysm / / 22961961 rs637644 chr18 62898666 A G 7.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) / / 24025145 rs563754 chr18 62917869 A T 4.70E-05 Kidney function and endocine traits / / 17903292 rs673942 chr18 62939695 C A 1.46E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs6566162 chr18 62956303 A G 2.27E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs8083346 chr18 62998775 T G 6.00E-06 D-dimer levels / / 21502573 rs470490 chr18 63031236 G T 5.00E-06 Atrioventricular conduction / / 21041692 rs616329 chr18 63031900 T C 2.10E-05 Urinary metabolites / / 21572414 rs610091 chr18 63115253 G A 5.29E-04 Telomere length / / 23900074 rs2850699 chr18 63117493 T G 2.78E-05 Bipolar disorder / / 18317468 rs2850700 chr18 63117642 C T 1.93E-05 Bipolar disorder / / 18317468 rs2850701 chr18 63122038 T G 2.31E-05 Bipolar disorder / / 18317468 rs2658046 chr18 63122230 A G 2.00E-05 Bipolar disorder / / 18317468 rs7241038 chr18 63138314 C T 1.84E-05 Bipolar disorder / / 18317468 rs11660957 chr18 63146668 A G 5.52E-04 Telomere length / / 23900074 rs4455070 chr18 63154361 A T 1.34E-05 Bipolar disorder / / 18317468 rs976882 chr18 63154964 C T 1.38E-05 Bipolar disorder / / 18317468 rs12970791 chr18 63165803 G T 1.22E-05 Bipolar disorder / / 18317468 rs1444067 chr18 63170686 G T 5.56E-06 Bipolar disorder / / 18317468 rs4941342 chr18 63195218 T C 4.50E-04 Alcohol dependence / / 20201924 rs17778588 chr18 63213157 T C 8.55E-06 Post-operative nausea and vomiting / / 21694509 rs4941345 chr18 63302058 A G 6.00E-05 Lung cancer / / 18978790 rs1942816 chr18 63419849 T G 2.77E-04 Multiple complex diseases CDH7 intron 17554300 rs10503102 chr18 63451970 G A 5.77E-04 Type 2 diabetes CDH7 intron 17846124 rs1484720 chr18 63473557 A G 4.22E-05 Multiple complex diseases CDH7 intron 17554300 rs17061843 chr18 63483279 C T 1.13E-04 Multiple complex diseases CDH7 intron 17554300 rs2587412 chr18 63542507 G A 2.52E-04 Aortic root size CDH7 intron 21223598 rs2587413 chr18 63546822 T C 5.52E-04 Aortic root size CDH7 intron 21223598 rs2587436 chr18 63565463 G A 3.07E-04 Aortic root size / / 21223598 rs2160595 chr18 63591149 A G 2.38E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs1385281 chr18 63591228 G A 1.69E-04 Cognition,early reading ability / / 17684495 rs17075606 chr18 63620374 T C 0.000012 Mean arterial pressure / / 22510845 rs1030070 chr18 63642205 A C 0.0001933 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1030070 chr18 63642205 A C 1.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9962706 chr18 63653465 T C 0.0001933 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9962706 chr18 63653465 T C 1.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2587376 chr18 63662702 G A 4.26E-04 Multiple complex diseases / / 17554300 rs2041939 chr18 63666356 C T 4.55E-05 Orofacial clefts / / 22419666 rs10503105 chr18 63820674 C T 1.40E-05 Coronary spasm / / 18075462 rs2029535 chr18 63884609 C T 2.57E-05 Coronary heart disease / / pha003035 rs2029536 chr18 63884706 T C 4.25E-05 Coronary heart disease / / pha003035 rs12953418 chr18 63895148 G A 2.70E-05 Urinary metabolites / / 21572414 rs17076069 chr18 63896265 G A 6.24E-04 Smoking quantity / / 24665060 rs2333546 chr18 63906678 C T 1.50E-04 Taste perception / / 22132133 rs12968584 chr18 63909974 G A 4.45E-04 Taste perception / / 22132133 rs8087026 chr18 63914889 G T 7.96E-05 Smoking quantity / / 24665060 rs8089756 chr18 63948778 T C 2.89E-04 Smoking quantity / / 24665060 rs11151259 chr18 63956802 A T 4.92E-04 Multiple complex diseases / / 17554300 rs7231695 chr18 63984153 A G 5.20E-06 Urinary metabolites / / 21572414 rs4891441 chr18 64071576 C A 2.94E-05 Major depressive disorder / / 20516156 rs4891441 chr18 64071576 C A 6.34E-05 Age-related macular degeneration / / 21909106 rs1787492 chr18 64105860 G T 4.68E-06 Age-related macular degeneration / / 21909106 rs9319710 chr18 64122863 A G 6.56E-04 Schizophrenia / / 19197363 rs725901 chr18 64142167 G A 7.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12454396 chr18 64148687 C T 7.47E-06 Osteoarthritis / / 22763110 rs2097020 chr18 64169016 G A 1.29E-05 Serum metabolites / / 19043545 rs508987 chr18 64186503 C T 6.28E-05 Multiple complex diseases CDH19 intron 17554300 rs503730 chr18 64206046 A G 3.15E-05 Multiple complex diseases CDH19 intron 17554300 rs12955031 chr18 64250279 T G 6.72E-05 Psoriasis CDH19 intron 18364390 rs556372 chr18 64316535 T C 3.59E-05 Attention deficit hyperactivity disorder / / 20732627 rs545245 chr18 64317219 T C 6.77E-05 Bipolar disorder / / 19488044 rs545245 chr18 64317219 T C 3.24E-05 Attention deficit hyperactivity disorder / / 20732627 rs41511945 chr18 64319060 A G 3.39E-04 Multiple complex diseases / / 17554300 rs41451347 chr18 64323507 C G 3.36E-04 Multiple complex diseases / / 17554300 rs2040213 chr18 64335789 A T 0.0007064 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2040213 chr18 64335789 A T 7.06E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8083155 chr18 64350545 T A 1.40E-05 White blood cell types / / 21738478 rs9319712 chr18 64378956 T C 9.88E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11151300 chr18 64398988 A G 2.73E-04 Coronary heart disease / / 21606135 rs1552553 chr18 64444457 C T 3.90E-05 HIV-1 control / / 20041166 rs12606152 chr18 64445511 A C 4.42E-05 HIV-1 control / / 20041166 rs12963469 chr18 64449197 C G 7.64E-04 Smoking initiation / / 24665060 rs10516001 chr18 64480206 A G 1.61E-04 Myocardial Infarction / / pha002883 rs1016425 chr18 64524728 T C 2.30E-05 Urinary metabolites / / 21572414 rs2059663 chr18 64527019 G A 3.96E-05 HIV-1 control / / 20041166 rs4507010 chr18 64610339 A G 1.30E-05 Urinary metabolites / / 21572414 rs8083788 chr18 64691152 A G 2.90E-05 Urinary metabolites / / 21572414 rs73963337 chr18 64697353 C G 2.13E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs28708459 chr18 64698046 T A 7.86E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs28562244 chr18 64698137 C T 7.79E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs73963343 chr18 64699974 C T 9.00E-08 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs4299253 chr18 64736109 T C 3.23E-04 Multiple complex diseases / / 17554300 rs4891590 chr18 64741828 C T 6.00E-07 Lipid levels / / 18193043 rs4330007 chr18 64748326 A C 1.16E-05 Prion diseases / / 22210626 rs12955475 chr18 64803830 A G 9.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs9967050 chr18 64825748 A G 1.70E-04 Scoliosis / / 21216876 rs8093493 chr18 64854418 A C 1.60E-05 Urinary metabolites / / 21572414 rs11875173 chr18 64855949 T C 8.81E-06 Bone mineral density / / 21124946 rs11663569 chr18 64918161 G A 4.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs12966198 chr18 64928623 G C 7.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs8099213 chr18 64952213 C T 5.00E-06 Multiple myeloma (IgH translocation) / / 23502783 rs11877435 chr18 64960749 A G 9.12E-04 Multiple complex diseases / / 17554300 rs4891316 chr18 64973343 T C 1.30E-04 Multiple complex diseases / / 17554300 rs17077064 chr18 64976306 C T 4.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs9959981 chr18 64978543 A G 8.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs12955611 chr18 64986813 A G 5.16E-05 Serum metabolites / / 19043545 rs12959961 chr18 64992502 T A 9.44E-05 Serum metabolites / / 19043545 rs1378583 chr18 65004314 C T 7.33E-05 Serum metabolites / / 19043545 rs1378583 chr18 65004314 C T 2.40E-05 Urinary metabolites / / 21572414 rs7240954 chr18 65017049 G A 5.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs2124349 chr18 65017100 G A 4.00E-06 Cognitive performance / / 19734545 rs7240846 chr18 65017147 C A 7.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs2061158 chr18 65017612 T C 2.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs10503113 chr18 65037339 C A 4.39E-05 Cognitive impairment induced by topiramate / / 22091778 rs2045262 chr18 65043085 T C 2.12E-05 Vascular dementia / / 22116812 rs2045262 chr18 65043085 T C 2.29E-05 Basophils / / pha003087 rs1455750 chr18 65056273 C T 1.50E-05 Urinary metabolites / / 21572414 rs7505354 chr18 65057900 T C 5.28E-05 Cognitive impairment induced by topiramate / / 22091778 rs4477825 chr18 65059326 G C 1.80E-05 Urinary metabolites / / 21572414 rs12956812 chr18 65062205 A G 5.28E-05 Cognitive impairment induced by topiramate / / 22091778 rs4471801 chr18 65120212 G A 8.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2127771 chr18 65136748 G A 8.77E-04 Taste perception / / 22132133 rs12955986 chr18 65148334 A G 6.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17077389 chr18 65175712 T C 8.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DSEL UTR-3 20877124 rs2279269 chr18 65179829 G A 8.55E-04 Response to taxane treatment (placlitaxel) DSEL missense 23006423 rs1351407 chr18 65193147 G T 7.71E-05 Information processing speed LOC643542 intron 21130836 rs1904846 chr18 65193272 A G 8.53E-04 Schizophrenia LOC643542 intron 19197363 rs1904846 chr18 65193272 A G 4.86E-04 Alzheimer's disease (late onset) LOC643542 intron 21379329 rs1383399 chr18 65197580 G A 2.45E-04 Alzheimer's disease (late onset) LOC643542 intron 21379329 rs12955020 chr18 65212138 C T 3.76E-04 Alzheimer's disease (late onset) LOC643542 intron 21379329 rs3886594 chr18 65223793 G A 6.42E-05 Vascular dementia LOC643542 intron 22116812 rs12607959 chr18 65226341 C G 7.04E-06 Major depressive disorder (broad) LOC643542 intron 20038947 rs17077486 chr18 65242298 G A 3.39E-05 Multiple complex diseases LOC643542 intron 17554300 rs1867413 chr18 65242889 T C 5.54E-06 Major depressive disorder (broad) LOC643542 intron 20038947 rs1444115 chr18 65244641 T C 9.79E-05 Intelligence LOC643542 intron 21826061 rs7504475 chr18 65250728 G A 9.54E-05 Major depressive disorder (broad) LOC643542 intron 20038947 rs281552 chr18 65258604 T C 5.06E-04 HIV-1 viral setpoint LOC643542 intron 17641165 rs7236007 chr18 65269343 T C 9.52E-05 Major depressive disorder (broad) LOC643542 intron 20038947 rs176004 chr18 65274155 A G 5.35E-04 HIV-1 viral setpoint LOC643542 intron 17641165 rs176004 chr18 65274155 A G 9.88E-04 Myocardial Infarction LOC643542 intron pha002883 rs17754585 chr18 65284854 G A 7.47E-04 Multiple complex diseases LOC643542 intron 17554300 rs17077540 chr18 65285279 A G 7.49E-05 Major depressive disorder (broad) LOC643542 intron 20038947 rs17077540 chr18 65285279 A G 2.00E-07 Major depressive disorder LOC643542 intron 20125088 rs12966710 chr18 65286267 A G 1.10E-05 Urinary metabolites LOC643542 intron 21572414 rs1562072 chr18 65287449 T A 3.10E-04 Type 2 diabetes and 6 quantitative traits LOC643542 intron 17848626 rs12956332 chr18 65289883 G A 5.51E-05 Longevity LOC643542 intron 20304771 rs12958645 chr18 65302501 C A 9.86E-05 Longevity LOC643542 intron 20304771 rs12963356 chr18 65303277 A G 9.15E-05 Longevity LOC643542 intron 20304771 rs12963356 chr18 65303277 A G 2.21E-06 Triglycerides LOC643542 intron pha003080 rs7237695 chr18 65303621 C T 7.49E-05 Longevity LOC643542 intron 20304771 rs17828615 chr18 65304895 G A 3.28E-05 Odorant perception LOC643542 intron 23910658 rs12605030 chr18 65306397 C T 5.73E-05 Longevity LOC643542 intron 20304771 rs12965352 chr18 65310323 G A 4.80E-05 Longevity LOC643542 intron 20304771 rs7237209 chr18 65314102 C T 2.90E-05 Type 2 diabetes LOC643542 intron 17460697 rs2440514 chr18 65318483 G C 8.46E-05 Longevity LOC643542 intron 20304771 rs2448709 chr18 65318536 G T 7.73E-04 Alcohol dependence LOC643542 intron 20201924 rs2440515 chr18 65318652 G A 1.67E-04 Osteoarthritis (knee and hip) LOC643542 intron 21177295 rs2440515 chr18 65318652 G A 2.03E-05 Osteoarthritis (knee and hip) LOC643542 intron 21177295 rs2440515 chr18 65318652 G A 5.88E-06 Triglycerides LOC643542 intron pha003080 rs2218416 chr18 65360863 T G 1.38E-06 Asthma (childhood onset) LOC643542 intron 23829686 rs7235753 chr18 65365036 A G 7.76E-04 Multiple complex diseases LOC643542 intron 17554300 rs11151383 chr18 65365278 T C 7.02E-05 Cognitive impairment induced by topiramate LOC643542 intron 22091778 rs1562070 chr18 65380031 A C 2.03E-04 Cholesterol LOC643542 intron 17255346 rs2448727 chr18 65380820 G C 2.88E-04 Cholesterol LOC643542 intron 17255346 rs1373364 chr18 65395349 G A 8.84E-04 Multiple complex diseases LOC643542 intron 17554300 rs1373365 chr18 65395551 G C 9.81E-05 Multiple complex diseases LOC643542 intron 17554300 rs13353224 chr18 65400425 A G 9.00E-06 Hyperactive-impulsive symptoms LOC643542 intron 18821565 rs9953346 chr18 65423581 A G 9.07E-04 Response to taxane treatment (placlitaxel) LOC643542 intron 23006423 rs6566316 chr18 65428683 T G 5.21E-04 Taste perception LOC643542 intron 22132133 rs11874977 chr18 65429532 A G 5.32E-05 F-cell distribution LOC643542 intron 21326311 rs17077971 chr18 65457839 G T 7.68E-08 Schizophrenia LOC643542 intron 21926974 rs11660238 chr18 65470134 C T 2.00E-06 Bipolar disorder (body mass index interaction) LOC643542 intron 24322204 rs114535501 chr18 65470749 A G 6.00E-06 Bipolar disorder (body mass index interaction) LOC643542 intron 24322204 rs74789784 chr18 65471518 C T 2.00E-06 Bipolar disorder (body mass index interaction) LOC643542 intron 24322204 rs75687134 chr18 65472043 G A 2.00E-06 Bipolar disorder (body mass index interaction) LOC643542 intron 24322204 rs9941446 chr18 65481053 G A 4.50E-05 Response to hepatitis C treatment LOC643542 intron 19684573 rs11661646 chr18 65483812 C G 6.00E-06 Bipolar disorder (body mass index interaction) LOC643542 intron 24322204 rs753610 chr18 65498575 G A 6.45E-06 Liver disease in chronic hepatitis B virus infection LOC643542 intron 24065354 rs654875 chr18 65499249 G T 1.55E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) LOC643542 intron 24023788 rs638006 chr18 65507075 G A 9.61E-04 Obesity (extreme) LOC643542 intron 21935397 rs636662 chr18 65507366 A T 9.58E-04 Obesity (extreme) LOC643542 intron 21935397 rs17766247 chr18 65508268 A G 3.78E-06 Liver disease in chronic hepatitis B virus infection LOC643542 intron 24065354 rs504131 chr18 65508329 C T 9.46E-04 Obesity (extreme) LOC643542 intron 21935397 rs569775 chr18 65512408 G A 8.54E-04 Obesity (extreme) LOC643542 intron 21935397 rs565364 chr18 65512819 G T 8.52E-04 Obesity (extreme) LOC643542 intron 21935397 rs2613164 chr18 65515082 C T 6.74E-04 Obesity (extreme) LOC643542 intron 21935397 rs633865 chr18 65526817 C A 7.13E-05 Orofacial clefts LOC643542 intron 22419666 rs580923 chr18 65536126 G A 5.97E-04 Obesity (extreme) LOC643542 intron 21935397 rs12969376 chr18 65536297 T C 9.60E-04 Obesity (extreme) LOC643542 intron 21935397 rs8084950 chr18 65537352 G T 9.69E-04 Obesity (extreme) LOC643542 intron 21935397 rs8095222 chr18 65548431 A C 4.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC643542 intron 20877124 rs12963461 chr18 65556969 G T 1.86E-04 Multiple complex diseases LOC643542 intron 17554300 rs11661918 chr18 65624456 A G 3.09E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9675979 chr18 65631583 A G 1.25E-04 Dental caries / / 21940522 rs4891329 chr18 65668864 C T 4.93E-04 Smoking initiation / / 24665060 rs4891331 chr18 65669259 A G 2.63E-05 Smoking initiation / / 24665060 rs11663199 chr18 65673751 A G 2.80E-05 Urinary metabolites / / 21572414 rs1518024 chr18 65703862 C T 5.47E-06 Cognitive impairment induced by topiramate / / 22091778 rs2319298 chr18 65759635 A G 9.56E-04 Alzheimer's disease / / 17998437 rs12961892 chr18 65783629 A G 8.19E-04 Depression (quantitative trait) / / 20800221 rs1400953 chr18 65783646 C T 4.20E-04 Type 2 diabetes / / 23209189 rs1400953 chr18 65783646 C T 2.46E-05 Glucose levels / / pha003057 rs8094982 chr18 65789338 T C 6.95E-05 Hemoglobin / / pha003096 rs2138963 chr18 65800573 C T 4.11E-05 Glucose levels / / pha003057 rs9948101 chr18 65800775 C T 7.46E-04 Depression (quantitative trait) / / 20800221 rs6566347 chr18 65810472 A G 8.66E-04 Depression (quantitative trait) / / 20800221 rs8086608 chr18 65810561 C T 7.06E-04 Depression (quantitative trait) / / 20800221 rs9950102 chr18 65811182 C T 8.73E-04 Depression (quantitative trait) / / 20800221 rs4522509 chr18 65811421 C T 8.81E-04 Depression (quantitative trait) / / 20800221 rs1518017 chr18 65811548 C T 8.30E-04 Depression (quantitative trait) / / 20800221 rs1518018 chr18 65811727 C T 7.39E-04 Depression (quantitative trait) / / 20800221 rs1607320 chr18 65812483 G A 9.28E-04 Depression (quantitative trait) / / 20800221 rs683979 chr18 65853788 C T 9.38E-04 Nicotine dependence / / 17158188 rs6566351 chr18 65887287 T C 9.30E-05 Schizophrenia / / 19197363 rs9962099 chr18 65912071 T C 8.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs645257 chr18 65928633 C T 8.25E-04 Multiple complex diseases / / 17554300 rs1010444 chr18 66057032 C T 5.70E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs8095325 chr18 66060991 C T 6.49E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9953072 chr18 66061008 C T 6.85E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs1476801 chr18 66061728 T C 6.29E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs8097533 chr18 66064840 G A 7.19E-05 Post-operative nausea and vomiting / / 21694509 rs8097533 chr18 66064840 G A 3.94E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs569057 chr18 66073870 A C 2.57E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs512195 chr18 66075478 T G 2.82E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs17284501 chr18 66076119 G T 4.03E-04 Multiple complex diseases / / 17554300 rs559131 chr18 66077814 T C 3.54E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs621527 chr18 66085062 G T 4.33E-05 Receptive language ability / / 24687471 rs7241738 chr18 66085798 G T 4.35E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs17212908 chr18 66095231 C T 7.60E-04 Alcohol dependence / / 20201924 rs17079143 chr18 66100523 C G 5.52E-04 Acute lung injury / / 22295056 rs17079154 chr18 66112319 A G 9.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs499158 chr18 66114745 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs560499 chr18 66116851 C T 9.77E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs560499 chr18 66116851 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2319410 chr18 66118048 A C 9.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12967088 chr18 66134611 G A 8.01E-05 Multiple complex diseases / / 17554300 rs17228566 chr18 66135767 T G 1.90E-08 Metabolite levels / / 23281178 rs17079195 chr18 66137894 A C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs17079195 chr18 66137894 A C 8.84E-05 Insulin-related traits / / pha002901 rs8089578 chr18 66146100 A T 1.91E-04 Type 2 diabetes / / 17463246 rs1516807 chr18 66146722 T C 7.56E-04 Type 2 diabetes / / 17463246 rs4891688 chr18 66151075 C T 1.97E-04 Vaspin levels / / 22907691 rs4891688 chr18 66151075 C T 0.0001971 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs8093762 chr18 66160263 T C 4.98E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17804782 chr18 66189148 C T 4.26E-04 Alzheimer's disease / / 17998437 rs4891691 chr18 66189690 T G 5.11E-05 Coronary heart disease / / pha003055 rs17232800 chr18 66292259 T G 3.00E-06 Attention deficit hyperactivity disorder / / 23728934 rs689193 chr18 66313774 G C 3.36E-05 Attention deficit hyperactivity disorder / / 23728934 rs1704734 chr18 66314072 A T 6.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs1704734 chr18 66314072 A T 3.40E-05 Attention deficit hyperactivity disorder / / 23728934 rs1704734 chr18 66314072 A T 8.69E-05 Bipolar Disorder / / pha002858 rs489710 chr18 66314284 T C 7.22E-04 Taste perception / / 22132133 rs489710 chr18 66314284 T C 2.90E-05 Attention deficit hyperactivity disorder / / 23728934 rs627419 chr18 66315758 T C 3.85E-05 Major depressive disorder (broad) / / 20038947 rs676186 chr18 66316978 A T 2.68E-05 Attention deficit hyperactivity disorder / / 23728934 rs7227628 chr18 66318982 T C 1.15E-05 Attention deficit hyperactivity disorder / / 23728934 rs2665375 chr18 66320294 C G 3.09E-05 Attention deficit hyperactivity disorder / / 23728934 rs507533 chr18 66321165 C A 6.63E-06 Attention deficit hyperactivity disorder / / 23728934 rs12606250 chr18 66327314 C T 4.12E-04 Longevity / / 22279548 rs17079595 chr18 66373235 G A 4.36E-05 Cognitive impairment induced by topiramate TMX3 intron 22091778 rs309247 chr18 66383064 C G 0.000000977 Stroke CCDC102B intron 23422753 rs17079623 chr18 66393240 C T 6.94E-04 Response to taxane treatment (placlitaxel) CCDC102B intron 23006423 rs677592 chr18 66445276 T C 1.76E-05 Platelet counts CCDC102B intron 21507922 rs677592 chr18 66445276 T C 8.72E-04 White matter integrity CCDC102B intron 22425255 rs8092610 chr18 66461890 C T 9.35E-04 Diabetic retinopathy CCDC102B intron 20871662 rs6566386 chr18 66485549 A C 3.13E-04 Type 2 diabetes CCDC102B intron 17463246 rs12373467 chr18 66495872 A C 4.28E-04 Type 2 diabetes CCDC102B intron 17463246 rs12454464 chr18 66502969 C A 3.19E-04 Smoking quantity CCDC102B intron 24665060 rs9962491 chr18 66510920 C T 3.15E-04 Suicide attempts in bipolar disorder CCDC102B intron 21041247 rs2187094 chr18 66513615 A G 1.50E-04 HIV-1 viral setpoint CCDC102B missense 17641165 rs5022262 chr18 66519755 T G 1.70E-05 Urinary metabolites CCDC102B intron 21572414 rs9948116 chr18 66525909 G A 2.46E-04 Suicide attempts in bipolar disorder CCDC102B intron 21041247 rs8088744 chr18 66534812 G T 1.03E-04 HIV-1 viral setpoint CCDC102B intron 17641165 rs12606133 chr18 66536474 T C 1.46E-04 HIV-1 viral setpoint CCDC102B intron 17641165 rs2051303 chr18 66539830 T A 1.54E-04 Suicide attempts in bipolar disorder CCDC102B intron 21041247 rs2051301 chr18 66540223 T C 1.54E-04 Suicide attempts in bipolar disorder CCDC102B intron 21041247 rs2004027 chr18 66542108 T A 1.53E-04 Suicide attempts in bipolar disorder CCDC102B intron 21041247 rs1539893 chr18 66544755 G A 3.00E-06 Liver enzyme levels (alanine transaminase) CCDC102B intron 24124411 rs2051294 chr18 66559385 C A 2.13E-05 Relative hand skill in reading disability CCDC102B intron 24068947 rs2156061 chr18 66563036 A G 8.43E-05 Relative hand skill in reading disability CCDC102B intron 24068947 rs11660484 chr18 66574045 G A 7.98E-05 Relative hand skill in reading disability CCDC102B intron 24068947 rs7238095 chr18 66574279 C A 1.36E-05 Relative hand skill in reading disability CCDC102B intron 24068947 rs12965053 chr18 66574738 C G 7.98E-05 Relative hand skill in reading disability CCDC102B intron 24068947 rs12970524 chr18 66575759 G A 7.52E-05 Relative hand skill in reading disability CCDC102B intron 24068947 rs12962140 chr18 66577584 C A 7.15E-05 Relative hand skill in reading disability CCDC102B intron 24068947 rs3862694 chr18 66582325 T C 5.29E-04 Multiple complex diseases CCDC102B intron 17554300 rs4891350 chr18 66589114 G A 3.28E-05 Relative hand skill in reading disability CCDC102B intron 24068947 rs10503134 chr18 66600079 C T 4.26E-05 Relative hand skill in reading disability CCDC102B intron 24068947 rs12957357 chr18 66606800 G A 7.92E-05 Relative hand skill in reading disability CCDC102B intron 24068947 rs9965063 chr18 66608638 G A 3.26E-06 Uric acid levels CCDC102B intron 21294900 rs1961712 chr18 66652846 A G 4.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CCDC102B intron 20877124 rs2195739 chr18 66655830 T A 6.50E-04 Body mass index CCDC102B intron 21701565 rs665143 chr18 66656915 T C 9.11E-05 Multiple complex diseases CCDC102B intron 17554300 rs17819720 chr18 66700483 T G 3.68E-06 White blood cell count CCDC102B intron 21738479 rs17819720 chr18 66700483 T G 9.91E-06 Sleep duration CCDC102B intron 22105623 rs10503141 chr18 66708214 G A 8.26E-04 Body mass index CCDC102B intron 21701565 rs17080156 chr18 66717462 G T 1.48E-04 Multiple complex diseases CCDC102B intron 17554300 rs17080166 chr18 66717802 T C 1.25E-04 Multiple complex diseases CCDC102B intron 17554300 rs1991676 chr18 66752454 A G 1.75E-05 Orofacial clefts / / 22419666 rs17080308 chr18 66754553 C T 4.78E-05 Psoriasis / / 20953190 rs17080448 chr18 66799522 T G 6.25E-04 Multiple complex diseases / / 17554300 rs11151487 chr18 66826511 C T 5.44E-04 Acute lung injury / / 22295056 rs9954546 chr18 66851719 C T 0.00030269 Hypertension (early onset hypertension) / / 22479346 rs672613 chr18 66878714 G A 1.71E-05 Bipolar disorder and schizophrenia / / 20889312 rs658812 chr18 66879535 C A 3.76E-04 Acute lung injury / / 22295056 rs644798 chr18 66880314 C A 2.64E-04 Acute lung injury / / 22295056 rs611297 chr18 66883245 T A 3.05E-04 Multiple complex diseases / / 17554300 rs583991 chr18 66883372 C T 1.63E-04 Celiac disease / / 23936387 rs10513957 chr18 66888437 G C 4.15E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs545319 chr18 66891048 C G 9.72E-04 Multiple complex diseases / / 17554300 rs579026 chr18 66896274 A G 5.36E-04 Multiple complex diseases / / 17554300 rs567379 chr18 66900419 G A 8.77E-04 Multiple complex diseases / / 17554300 rs1858031 chr18 66911915 A C 3.62E-04 Taste perception / / 22132133 rs605314 chr18 66930261 G T 2.16E-05 Graves' disease / / 21841780 rs11877565 chr18 67016267 T G 8.56E-04 Multiple complex diseases / / 17554300 rs8094418 chr18 67021486 C T 9.50E-06 Urinary metabolites / / 21572414 rs12605657 chr18 67021818 G A 9.80E-06 Urinary metabolites / / 21572414 rs12604900 chr18 67027545 A G 5.13E-04 Multiple complex diseases / / 17554300 rs924522 chr18 67034762 A G 9.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs1372766 chr18 67091599 C T 1.45E-05 Cognitive test performance DOK6 intron 20125193 rs9952684 chr18 67139528 G T 1.50E-06 Urinary metabolites DOK6 intron 21572414 rs17184557 chr18 67142857 T A 9.00E-07 Osteoporosis DOK6 intron 20548944 rs2053519 chr18 67147256 T A 1.47E-04 Coronary Artery Disease DOK6 intron 17634449 rs17185211 chr18 67148381 G A 7.76E-04 Multiple complex diseases DOK6 intron 17554300 rs17081004 chr18 67149873 T A,C,G 7.06E-05 Bipolar disorder DOK6 intron 17486107 rs17081073 chr18 67158989 A T 1.34E-04 Multiple complex diseases DOK6 intron 17554300 rs17081109 chr18 67182665 C A 6.32E-04 Type 2 diabetes DOK6 intron 17463246 rs17081109 chr18 67182665 C A 8.94E-04 Coronary Artery Disease DOK6 intron 17634449 rs6566429 chr18 67184951 T C 7.22E-04 Type 2 diabetes DOK6 intron 17463246 rs1548053 chr18 67194122 T C 1.22E-05 Type 2 diabetes DOK6 intron 17463246 rs1372768 chr18 67195441 T G 3.23E-05 Vitiligo DOK6 intron 19890347 rs17773790 chr18 67203278 C A 4.08E-04 Alzheimer's disease (late onset) DOK6 intron 21379329 rs10513964 chr18 67206142 A G 2.14E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) DOK6 intron 24023788 rs10513964 chr18 67206142 A G 3.62E-04 Lung function (forced expiratory volume in 1 second) DOK6 intron 24023788 rs12955246 chr18 67211639 C T 6.41E-05 Coronary heart disease DOK6 intron pha003032 rs1036840 chr18 67217542 A G 0.00066 Salmonella-induced pyroptosis DOK6 intron 22837397 rs1036840 chr18 67217542 A G 3.82E-04 Lung function (forced expiratory volume in 1 second) DOK6 intron 24023788 rs4352137 chr18 67258707 G A 5.45E-04 Multiple complex diseases DOK6 intron 17554300 rs4555246 chr18 67276722 G A,T 1.71E-05 Chronic kidney disease DOK6 intron 21931561 rs4555246 chr18 67276722 G A,T 3.08E-05 Chronic kidney disease DOK6 intron 21931561 rs4555246 chr18 67276722 G A,T 5.33E-07 Chronic kidney disease DOK6 intron 21931561 rs571461077 chr18 67276722 G GAAAT 1.71E-05 Chronic kidney disease DOK6 intron 21931561 rs571461077 chr18 67276722 G GAAAT 3.08E-05 Chronic kidney disease DOK6 intron 21931561 rs571461077 chr18 67276722 G GAAAT 5.33E-07 Chronic kidney disease DOK6 intron 21931561 rs58206678 chr18 67276722 G GAAAT,GAAATAAATAAATAAAT 1.71E-05 Chronic kidney disease DOK6 intron 21931561 rs58206678 chr18 67276722 G GAAAT,GAAATAAATAAATAAAT 3.08E-05 Chronic kidney disease DOK6 intron 21931561 rs58206678 chr18 67276722 G GAAAT,GAAATAAATAAATAAAT 5.33E-07 Chronic kidney disease DOK6 intron 21931561 rs12326139 chr18 67278525 T C 1.29E-04 Response to cytidine analogues (gemcitabine) DOK6 intron 24483146 rs12456201 chr18 67279176 T C 1.59E-04 White matter integrity DOK6 intron 22425255 rs10084092 chr18 67279724 C A 1.35E-05 Smoking cessation DOK6 intron 18519826 rs10084092 chr18 67279724 C A 3.39E-04 Response to cytidine analogues (gemcitabine) DOK6 intron 24483146 rs9953044 chr18 67283020 A T 1.67E-05 Response to cytidine analogues (gemcitabine) DOK6 intron 24483146 rs10513968 chr18 67283141 A G 1.00E-06 Response to cytidine analogues (gemcitabine) DOK6 intron 24483146 rs12456443 chr18 67283450 G A 1.67E-05 Response to cytidine analogues (gemcitabine) DOK6 intron 24483146 rs7237341 chr18 67285684 G T 1.62E-04 Response to cytidine analogues (gemcitabine) DOK6 intron 24483146 rs10513969 chr18 67286974 G T 3.56E-04 Response to cytidine analogues (gemcitabine) DOK6 intron 24483146 rs4243311 chr18 67293079 C T 2.60E-04 Response to cytidine analogues (gemcitabine) DOK6 intron 24483146 rs4891761 chr18 67297844 T A 1.39E-04 Response to cytidine analogues (gemcitabine) DOK6 intron 24483146 rs8096788 chr18 67300881 A G 2.80E-05 Urinary metabolites DOK6 intron 21572414 rs7506960 chr18 67304536 G A 6.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DOK6 intron 20877124 rs4372782 chr18 67309264 A G 7.74E-04 Type 2 diabetes DOK6 intron 17463246 rs9963298 chr18 67314118 A G 7.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DOK6 intron 20877124 rs10871647 chr18 67315898 A G 8.71E-05 Smoking cessation DOK6 intron 18519826 rs12606443 chr18 67320210 T G 1.20E-05 Urinary metabolites DOK6 intron 21572414 rs9954832 chr18 67323154 G A 4.50E-04 Type 2 diabetes DOK6 intron 22158537 rs11660034 chr18 67324753 T C 3.29E-04 Type 2 diabetes DOK6 intron 22158537 rs4445986 chr18 67326733 C T 4.26E-04 Type 2 diabetes DOK6 intron 22158537 rs7229112 chr18 67329913 C G 7.16E-04 Alzheimer's disease DOK6 intron 17998437 rs4243315 chr18 67333846 C T 5.78E-05 Smoking cessation DOK6 intron 18519826 rs11151527 chr18 67347133 A G 2.65E-04 Nicotine smoking DOK6 intron 19268276 rs8096331 chr18 67347909 T A 4.92E-04 Multiple complex diseases DOK6 intron 17554300 rs10513971 chr18 67352367 C T 7.00E-08 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) DOK6 intron 17982456 rs10513972 chr18 67352445 G A 4.44E-04 Type 2 diabetes DOK6 intron 17463246 rs4131991 chr18 67356036 C T 6.05E-05 Femoral neck bone geometry DOK6 intron 22087292 rs4312402 chr18 67363227 T C 3.00E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) DOK6 intron 17982456 rs4312402 chr18 67363227 T C 1.73E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) DOK6 intron 23648065 rs4426448 chr18 67365668 A G 2.81E-04 Celiac disease DOK6 cds-synon 23936387 rs11875338 chr18 67366496 A G 3.88E-04 Multiple complex diseases DOK6 intron 17554300 rs12957360 chr18 67393698 A G 8.45E-06 Femoral neck bone geometry DOK6 intron 22087292 rs7233752 chr18 67399208 A G 0.0000535 Tuberculosis with early age of onset DOK6 intron 22551897 rs2298785 chr18 67427168 G A 0.0000338 Tuberculosis with early age of onset DOK6 intron 22551897 rs882114 chr18 67466881 T C 1.60E-05 Urinary metabolites DOK6 intron 21572414 rs11151540 chr18 67467993 A G 1.90E-05 Urinary metabolites DOK6 intron 21572414 rs9962323 chr18 67468162 G C 2.40E-05 Urinary metabolites DOK6 intron 21572414 rs12104016 chr18 67471466 G A 6.78E-05 Cognitive test performance DOK6 intron 20125193 rs7227328 chr18 67489884 G C 5.66E-04 Nicotine smoking DOK6 intron 19268276 rs7237652 chr18 67511067 A G 9.37E-04 Tourette syndrome DOK6 UTR-3 22889924 rs201800621 chr18 67516845 G C 1.00E-10 Mean platelet volume / / 19820697 rs201800621 chr18 67516845 G C 1.40E-10 Mean platelet volume / / 22423221 rs75761474 chr18 67516845 GA G 1.00E-10 Mean platelet volume / / 19820697 rs75761474 chr18 67516845 GA G 1.40E-10 Mean platelet volume / / 22423221 rs893001 chr18 67516845 G GA,GC 1.00E-10 Mean platelet volume / / 19820697 rs893001 chr18 67516845 G GA,GC 1.40E-10 Mean platelet volume / / 22423221 rs1790575 chr18 67519079 C T 9.98E-05 Type 1 diabetes / / 21980299 rs727088 chr18 67530439 G A 5.00E-09 Inflammatory bowel disease / / 23128233 rs763361 chr18 67531642 T C 1.00E-08 Type 1 diabetes CD226 missense 17554260 rs763361 chr18 67531642 T C 1.00E-09 Type 1 diabetes autoantibodies CD226 missense 21829393 rs763361 chr18 67531642 T C 1.00E-08 Multiple sclerosis CD226 missense 22190364 rs763361 chr18 67531642 T C 4.66E-08 Primary sclerosing cholangitis CD226 missense 23603763 rs1790588 chr18 67535184 T C 4.90E-04 Myasthenia gravis CD226 intron 23055271 rs1790933 chr18 67536187 T G 2.03E-04 Multiple complex diseases CD226 intron 17554300 rs12969657 chr18 67536496 C T 3.00E-11 Mean platelet volume CD226 intron 22139419 rs12969657 chr18 67536496 C T 2.00E-05 Mean platelet volume CD226 intron 24026423 rs1788097 chr18 67543688 C T 3.06E-08 Primary sclerosing cholangitis CD226 intron 23603763 rs2469434 chr18 67544046 T C 1.00E-08 Rheumatoid arthritis CD226 intron 24390342 rs2469434 chr18 67544046 T C 6.70E-04 Rheumatoid arthritis CD226 intron 24390342 rs2469434 chr18 67544046 T C 9.00E-10 Rheumatoid arthritis CD226 intron 24390342 rs2051323 chr18 67550412 T C 7.40E-04 Multiple complex diseases CD226 intron 17554300 rs17842596 chr18 67565579 G A 2.24E-04 White matter integrity CD226 intron 22425255 rs10432228 chr18 67568249 A G 1.00E-04 Information processing speed CD226 intron 21130836 rs3937015 chr18 67599516 T C 1.17E-05 Tuberculosis CD226 intron 20694014 rs12970649 chr18 67605807 C T 1.87E-05 Tuberculosis CD226 intron 20694014 rs930292 chr18 67709118 A G 4.07E-04 Multiple complex diseases RTTN intron 17554300 rs1821579 chr18 67710394 A G 9.51E-04 Multiple complex diseases RTTN intron 17554300 rs7226831 chr18 67847005 G C 8.90E-04 Multiple complex diseases RTTN intron 17554300 rs7226831 chr18 67847005 G C 2.90E-05 Urinary metabolites RTTN intron 21572414 rs176097 chr18 67895835 G A 0.000788 Salmonella-induced pyroptosis / / 22837397 rs12454981 chr18 67923967 C G 1.86E-04 Multiple complex diseases / / 17554300 rs9964939 chr18 67928211 G A 6.25E-35 Narcolepsy / / 19629137 rs1872335 chr18 67938421 C T 6.74E-04 Multiple complex diseases / / 17554300 rs713129 chr18 67960404 G C 2.55E-04 Multiple complex diseases SOCS6 intron 17554300 rs713130 chr18 67960594 A G 3.42E-06 Eosinophil counts SOCS6 intron pha003088 rs7242186 chr18 67981861 G A 8.80E-04 Alcohol dependence SOCS6 intron 20201924 rs2231555 chr18 67991256 C T 0.000000329 Cholesterol,total SOCS6 intron 23063622 rs2231555 chr18 67991256 C T 7.84E-08 HDL cholesterol SOCS6 intron 23063622 rs2231563 chr18 67992432 C T 5.10E-05 Multiple complex diseases SOCS6 cds-synon 17554300 rs8085079 chr18 67998275 T C 1.42E-04 Multiple complex diseases / / 17554300 rs12969372 chr18 68006697 G A 3.78E-04 Multiple complex diseases / / 17554300 rs1484735 chr18 68006741 A C 1.91E-06 Eosinophil counts / / pha003088 rs12955656 chr18 68018022 G A 4.89E-05 Multiple complex diseases / / 17554300 rs17082456 chr18 68028600 T G 1.49E-04 Multiple complex diseases / / 17554300 rs1440329 chr18 68037116 C T 7.74E-04 Alzheimer's disease / / 22005930 rs7244215 chr18 68043316 G A 6.80E-04 Substance dependence / / 21818250 rs17082526 chr18 68044659 C T 3.27E-04 Multiple complex diseases / / 17554300 rs11663878 chr18 68050903 A G 4.26E-04 Type 2 diabetes / / 17463246 rs2919369 chr18 68061937 C T 6.42E-04 Type 2 diabetes / / 17463246 rs8090371 chr18 68066510 C T 1.80E-05 Urinary metabolites / / 21572414 rs1986841 chr18 68129711 G A 4.28E-05 Parkinson's disease / / 17052657 rs8092443 chr18 68142414 G A 1.00E-06 Response to antipsychotic treatment / / 20195266 rs11663206 chr18 68153620 T C 2.00E-06 Response to antipsychotic treatment / / 20195266 rs10469109 chr18 68157794 G A 4.49E-05 Cognitive test performance / / 20125193 rs17082712 chr18 68164578 G C 3.82E-04 Alzheimer's disease / / 17998437 rs17082715 chr18 68165907 G C 4.53E-04 Multiple complex diseases / / 17554300 rs17082721 chr18 68167121 G A 5.96E-04 Nicotine dependence / / 17158188 rs2091757 chr18 68252102 T C 3.82E-05 Bipolar disorder / / 20451256 rs17082884 chr18 68271139 C T 6.77E-04 Multiple complex diseases / / 17554300 rs1912379 chr18 68309730 G A 8.50E-04 Type 2 diabetes / / 21874001 rs7239381 chr18 68322859 C T 8.02E-05 Epilepsy (remission after treatment) / / 23962720 rs1510040 chr18 68326250 T C 6.55E-05 Epilepsy (remission after treatment) / / 23962720 rs2063329 chr18 68338943 A G 4.03E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12967006 chr18 68356416 A C 1.98E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs17083022 chr18 68370032 T C 1.82E-04 Multiple complex diseases / / 17554300 rs17062128 chr18 68392931 G A 9.65E-04 Multiple complex diseases / / 17554300 rs8095920 chr18 68426681 T C 7.78E-04 Multiple complex diseases / / 17554300 rs8095171 chr18 68426862 C T 9.10E-04 Multiple complex diseases / / 17554300 rs1282616 chr18 68427883 T G 8.57E-04 Multiple complex diseases / / 17554300 rs1282645 chr18 68438580 A G 3.48E-05 Nonalcoholic fatty liver disease / / 21423719 rs1529210 chr18 68459549 C T 1.19E-04 Schizophrenia / / 19197363 rs1282598 chr18 68460065 T G 6.70E-04 Multiple complex diseases / / 17554300 rs1395858 chr18 68604705 C T 1.35E-05 Prion diseases / / 22210626 rs1395851 chr18 68624501 C T 5.63E-05 Bipolar disorder / / 19488044 rs1395851 chr18 68624501 C T 4.64E-05 Bipolar Disorder / / pha002863 rs2135854 chr18 68624993 A G 3.19E-04 Multiple complex diseases / / 17554300 rs2660917 chr18 68628078 T C 8.00E-06 Iron status biomarkers / / 19084217 rs1881600 chr18 68670903 A C 3.78E-04 Alzheimer's disease (late onset) / / 21379329 rs1590106 chr18 68690786 G A 3.73E-04 Alzheimer's disease (late onset) / / 21379329 rs1942200 chr18 68705548 G A 7.87E-04 Multiple complex diseases / / 17554300 rs2848871 chr18 68750255 T C 3.40E-05 Cognitive test performance / / 20125193 rs961013 chr18 68780405 C T 5.80E-05 Bipolar disorder / / 21771265 rs8083695 chr18 68809883 C G 4.65E-05 Type 2 diabetes / / 17463246 rs17083844 chr18 68842243 G A 6.00E-06 Systemic lupus erythematosus / / 18204098 rs4891907 chr18 68857317 T G 7.67E-05 Waist-Hip Ratio / / pha003013 rs8098181 chr18 68863939 T G 3.72E-04 Multiple complex diseases / / 17554300 rs6566520 chr18 68866594 G T 1.77E-04 Multiple complex diseases / / 17554300 rs12969802 chr18 68867258 A G 3.48E-04 Multiple complex diseases / / 17554300 rs4439856 chr18 68871013 G C 5.40E-04 Multiple complex diseases / / 17554300 rs4439856 chr18 68871013 G C 1.00E-04 Response to antidepressant treatment (citalopram) / / 23726668 rs17277769 chr18 68871790 G C 6.60E-04 Multiple complex diseases / / 17554300 rs1376201 chr18 68908351 A G 2.07E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs8086780 chr18 68919203 C T 3.98E-05 Dengue shock syndrome / / 22001756 rs10514002 chr18 68932930 T A 1.14E-04 Type 2 diabetes / / 17846124 rs9951245 chr18 68957961 G A 8.00E-04 Thyroid cancer / / 23894154 rs41464346 chr18 68987579 G A 9.92E-04 Multiple complex diseases / / 17554300 rs334430 chr18 69038591 G A 1.40E-06 Glycosylated haemoglobin levels / / 17255346 rs17213348 chr18 69065102 T C 2.48E-04 IgE levels / / 17255346 rs12961449 chr18 69066206 C T 4.40E-06 Odorant perception / / 23910658 rs2009217 chr18 69116214 T C 1.30E-04 Response to antidepressants / / 19736353 rs1037537 chr18 69128043 A G 6.87E-04 Coronary Artery Disease / / 17634449 rs9959543 chr18 69141525 A G 4.92E-04 Multiple complex diseases / / 17554300 rs768718 chr18 69153381 C T 8.00E-05 Prostate cancer / / 21743057 rs10469188 chr18 69153703 A G 8.00E-05 Prostate cancer / / 21743057 rs10514013 chr18 69154730 A G 6.30E-04 Crohn's disease / / 17684544 rs10514013 chr18 69154730 A G 2.97E-04 Iron levels / / pha002876 rs7238698 chr18 69158858 A G 8.00E-05 Prostate cancer / / 21743057 rs9319819 chr18 69159876 C A 8.00E-05 Prostate cancer / / 21743057 rs8095198 chr18 69160768 G T 8.00E-05 Prostate cancer / / 21743057 rs2627 chr18 69161026 A G 8.00E-05 Prostate cancer / / 21743057 rs8096472 chr18 69161140 T C 8.00E-05 Prostate cancer / / 21743057 rs2187422 chr18 69162557 A G 8.00E-05 Prostate cancer / / 21743057 rs11151670 chr18 69171321 G A 8.00E-05 Prostate cancer / / 21743057 rs7238469 chr18 69172373 T A 8.00E-05 Prostate cancer / / 21743057 rs7239293 chr18 69172939 T C 8.00E-05 Prostate cancer / / 21743057 rs12964365 chr18 69181285 C T 2.70E-05 Cognitive test performance / / 20125193 rs7227159 chr18 69200852 C T 2.91E-04 Iron levels LOC100505776 intron pha002876 rs719328 chr18 69209130 T C 1.59E-04 Iron levels LOC100505776 intron pha002876 rs7234122 chr18 69233599 G A 3.58E-04 Insulin resistance LOC100505776 intron 21901158 rs9953717 chr18 69243739 T C 7.66E-05 Breast cancer LOC100505776 intron pha002853 rs1539909 chr18 69248595 T C 4.00E-06 Response to TNF-alpha inhibitors in rheumatoid arthritis / / 22569225 rs4340418 chr18 69310465 C T 5.95E-04 Rheumatoid arthritis / / 21452313 rs2040237 chr18 69313851 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2040237 chr18 69313851 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6566561 chr18 69354190 G A 1 Drug response to Etoposide / / 17537913 rs6650703 chr18 69356762 G A 1 Drug response to Etoposide / / 17537913 rs11665307 chr18 69365300 T C 3.00E-07 IgG glycosylation / / 23382691 rs2887004 chr18 69379390 A G 2.00E-06 IgG glycosylation / / 23382691 rs2887004 chr18 69379390 A G 6.00E-06 IgG glycosylation / / 23382691 rs12604093 chr18 69392569 C G 1.10E-05 Urinary metabolites / / 21572414 rs868812 chr18 69395903 C T 5.24E-04 Myopia (pathological) / / 21095009 rs1505743 chr18 69396486 G A 0.0007686 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1505743 chr18 69396486 G A 7.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9958165 chr18 69397050 G A 0.0001241 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9958165 chr18 69397050 G A 1.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8090713 chr18 69398027 G T 0.0008181 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8090713 chr18 69398027 G T 8.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9950623 chr18 69399805 G A 0.000801 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9950623 chr18 69399805 G A 8.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17085008 chr18 69401163 G A 0.0000283 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17085008 chr18 69401163 G A 2.83E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9956999 chr18 69401783 G T 0.0008009 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9956999 chr18 69401783 G T 8.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7227772 chr18 69401880 A G 2.30E-05 Urinary metabolites / / 21572414 rs17085070 chr18 69416594 G A 6.67E-04 Multiple complex diseases / / 17554300 rs17085106 chr18 69439073 G T 4.00E-08 Orofacial clefts / / 19656524 rs8099373 chr18 69441644 A G 3.09E-05 Multiple complex diseases / / 17554300 rs62101785 chr18 69441988 T A 0.0000857 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17317349 chr18 69441994 A G 0.0000799 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs939720 chr18 69487299 A G 7.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2685459 chr18 69499778 C A 2.85E-04 Multiple complex diseases / / 17554300 rs924943 chr18 69500505 G A 7.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11151717 chr18 69518866 C T 1.43E-05 Height / / 22021425 rs4891959 chr18 69544922 A G 6.75E-04 Multiple complex diseases / / 17554300 rs4891960 chr18 69545226 A C 8.23E-04 Multiple complex diseases / / 17554300 rs9963169 chr18 69577293 T C 2.88E-04 Multiple complex diseases / / 17554300 rs4414583 chr18 69587022 A G 2.63E-04 Multiple complex diseases / / 17554300 rs4891966 chr18 69616117 T C 8.75E-04 White matter integrity / / 22425255 rs9961593 chr18 69622633 T G 8.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9957008 chr18 69633468 T C 4.39E-05 Epilepsy (remission after treatment) / / 23962720 rs2171372 chr18 69639041 C A 2.55E-05 Epilepsy (remission after treatment) / / 23962720 rs8089679 chr18 69644104 C A 4.35E-05 Epilepsy (remission after treatment) / / 23962720 rs1487329 chr18 69661376 G A 1.85E-05 Coronary heart disease / / pha003032 rs10514031 chr18 69663285 C T 2.58E-04 Type 2 diabetes / / 17846124 rs3895960 chr18 69682966 A C 1.70E-05 Urinary metabolites / / 21572414 rs1580487 chr18 69699093 A T 3.37E-04 Type 2 diabetes / / 17463246 rs2129588 chr18 69703287 C T 8.93E-06 Triglycerides / / 19074352 rs2129588 chr18 69703287 C T 8.93E-06 Polyunsaturated fatty acid levels,in plasma / / 19148276 rs12957729 chr18 69734897 C T 3.17E-04 Alzheimer's disease / / 22005930 rs12956293 chr18 69739226 T C 5.21E-04 Alzheimer's disease / / 22005930 rs10514036 chr18 69743289 A G 2.48E-05 Colorectal cancer / / 21242260 rs17085505 chr18 69743464 A C 2.18E-06 Alcohol and nictotine co-dependence / / 20158304 rs12966394 chr18 69762798 T A 2.18E-04 Alzheimer's disease / / 22005930 rs11151726 chr18 69764200 G C 1.35E-04 Multiple complex diseases / / 17554300 rs12962989 chr18 69765894 G T 2.16E-04 Alzheimer's disease / / 22005930 rs337718 chr18 69774278 T C 9.00E-06 Multiple sclerosis (severity) / / 19010793 rs966352 chr18 69846671 T C 5.59E-04 Type 2 diabetes / / 17463246 rs11660214 chr18 69877667 G T 3.38E-05 Coronary heart disease / / pha003033 rs4430852 chr18 69892744 C T 5.08E-05 Cortisol secretion,in saliva / / 21316860 rs17258944 chr18 69906029 A G 6.50E-05 Cognitive impairment induced by topiramate / / 22091778 rs7232482 chr18 69907724 G T 5.06E-05 Cervical cancer / / 24700089 rs7238505 chr18 69912062 T C 6.52E-06 Cervical cancer / / 24700089 rs8097717 chr18 69913058 G A 9.06E-05 Cervical cancer / / 24700089 rs8085971 chr18 69917163 A T 1.17E-05 Cervical cancer / / 24700089 rs8088832 chr18 69926757 T C 4.00E-06 Cervical cancer / / 24700089 rs11151739 chr18 69940328 A G 2.18E-05 Cognitive impairment induced by topiramate / / 22091778 rs11876001 chr18 69940551 T C 6.55E-05 Cervical cancer / / 24700089 rs9319837 chr18 69956454 C T 1.19E-04 Multiple complex diseases / / 17554300 rs4891472 chr18 69973987 A G 1.54E-04 Multiple complex diseases / / 17554300 rs7245374 chr18 69999553 T C 7.24E-04 Major depressive disorder / / 22472876 rs11151759 chr18 70049627 C A 2.10E-05 Urinary metabolites / / 21572414 rs9964855 chr18 70051553 C T 3.20E-04 Multiple complex diseases / / 17554300 rs12454536 chr18 70065404 G C 2.60E-05 Urinary metabolites / / 21572414 rs7507030 chr18 70094199 T C 5.32E-05 Insulin Resistance / / pha003062 rs11872891 chr18 70095903 G A 9.05E-05 Cardiovascular disease / / pha003064 rs12956651 chr18 70114455 A G 9.56E-04 Alzheimer's disease / / 22005930 rs12953687 chr18 70117338 A G 9.51E-04 Alzheimer's disease / / 22005930 rs7229057 chr18 70117895 T A 8.85E-04 Alzheimer's disease / / 22005930 rs9963769 chr18 70121318 C T 7.82E-06 White blood cell count / / 21738479 rs7228776 chr18 70149733 C T 2.35E-09 Metabolite levels / / 23281178 rs2217560 chr18 70150939 G A 7.00E-10 Pulmonary arterial hypertension (without BMPR2 mutations) / / 23502781 rs1432067 chr18 70157358 T C 2.35E-09 Metabolite levels / / 23281178 rs7226690 chr18 70161540 G A 2.35E-09 Metabolite levels / / 23281178 rs1432069 chr18 70162160 C T 2.35E-09 Metabolite levels / / 23281178 rs1432070 chr18 70162291 C T 2.35E-09 Metabolite levels / / 23281178 rs8097096 chr18 70164250 G A 2.35E-09 Metabolite levels / / 23281178 rs17086130 chr18 70165380 C T 1.27E-04 Aortic root size / / 21223598 rs658995 chr18 70207340 A G 8.99E-04 Type 2 diabetes CBLN2 intron 17463246 rs17086172 chr18 70227021 T C 2.42E-06 Pulmonary function / / 19300500 rs17086172 chr18 70227021 T C 7.00E-06 Airflow obstruction / / 22837378 rs17086174 chr18 70228633 G C 2.43E-06 Pulmonary function / / 19300500 rs638052 chr18 70228903 C T 9.37E-05 Pulmonary function / / 19300500 rs640733 chr18 70229436 C T 2.45E-06 Pulmonary function / / 19300500 rs11665041 chr18 70243572 T C 5.36E-04 Smoking initiation / / 24665060 rs681058 chr18 70245971 C T 2.59E-06 Pulmonary function / / 19300500 rs654316 chr18 70247295 A G 3.33E-06 Pulmonary function / / 19300500 rs1432077 chr18 70272899 G T 6.13E-06 Pulmonary function / / 19300500 rs8093502 chr18 70285457 C T 2.00E-06 Smoking initiation / / 24665060 rs9949190 chr18 70306079 T A 6.51E-04 Multiple complex diseases / / 17554300 rs9966507 chr18 70308101 A G 5.43E-04 Multiple complex diseases / / 17554300 rs12605716 chr18 70361275 G A 7.37E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs4493152 chr18 70377310 C A 2.83E-04 Multiple complex diseases / / 17554300 rs8099576 chr18 70383595 C T 2.30E-05 Urinary metabolites / / 21572414 rs4892034 chr18 70399988 A T 7.00E-05 Prostate cancer / / 21743057 rs4891485 chr18 70402118 T C 6.00E-05 Prostate cancer / / 21743057 rs12605543 chr18 70403565 G T 6.43E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4892036 chr18 70403694 T C 3.00E-05 Prostate cancer / / 21743057 rs10514054 chr18 70421051 C A 2.54E-05 Atopy NETO1 intron 21094521 rs9789191 chr18 70433629 C T 3.33E-05 Cognitive impairment induced by topiramate NETO1 intron 22091778 rs41418949 chr18 70442068 C T 6.00E-07 Economic and political preferences (time) NETO1 intron 22566634 rs11151798 chr18 70450411 C T 1.00E-04 Cognitive impairment induced by topiramate NETO1 intron 22091778 rs17294876 chr18 70456290 G A 8.28E-05 Response to cytadine analogues (cytosine arabinoside) NETO1 intron 24483146 rs9636083 chr18 70473328 T C 3.38E-05 Glucose levels NETO1 intron pha003061 rs8089921 chr18 70476729 C T 8.32E-04 Suicide attempts in bipolar disorder NETO1 intron 21423239 rs10514055 chr18 70477427 A G 3.57E-04 Response to cytadine analogues (cytosine arabinoside) NETO1 intron 24483146 rs4892047 chr18 70484827 G A 8.73E-04 Type 2 diabetes NETO1 intron 17463246 rs12967151 chr18 70486199 T G 2.84E-04 Suicide attempts in bipolar disorder NETO1 intron 21423239 rs17086414 chr18 70502862 G A 3.90E-04 Alzheimer's disease NETO1 intron 22005930 rs4891489 chr18 70511322 G A 2.43E-04 Follicular lymphoma NETO1 intron 21533074 rs12963148 chr18 70514119 G A 7.58E-04 Myopia (pathological) NETO1 intron 21095009 rs748016 chr18 70516052 C T 9.82E-04 Myopia (pathological) NETO1 intron 21095009 rs8098624 chr18 70518219 T C 3.86E-04 Multiple complex diseases NETO1 intron 17554300 rs17734170 chr18 70518817 G A 0.000057 Salmonella-induced pyroptosis NETO1 intron 22837397 rs1109070 chr18 70523579 T C 6.69E-04 Alzheimer's disease NETO1 intron 17998437 rs9948277 chr18 70530711 G A 3.64E-05 Lipoprotein-associated phospholipase A2 activity and mass NETO1 intron 20442857 rs2156107 chr18 70546470 C T 2.01E-04 Multiple complex diseases LOC100505797 intron 17554300 rs2156107 chr18 70546470 C T 1.37E-04 Schizophrenia LOC100505797 intron 20832056 rs2156107 chr18 70546470 C T 1.00E-06 Fractional exhaled nitric oxide (childhood) LOC100505797 intron 24315451 rs2156107 chr18 70546470 C T 3.00E-06 Fractional exhaled nitric oxide (childhood) LOC100505797 intron 24315451 rs2187116 chr18 70546687 G A 1.97E-04 Schizophrenia LOC100505797 intron 20832056 rs8086712 chr18 70567250 A G 1.96E-04 Schizophrenia / / 20832056 rs8092114 chr18 70573772 T G 5.77E-05 Cholesterol / / pha003073 rs8092114 chr18 70573772 T G 1.58E-05 ldl cholesterol / / pha003076 rs8092114 chr18 70573772 T G 6.45E-05 Cholesterol / / pha003078 rs4644937 chr18 70612590 C T 4.38E-04 Alzheimer's disease (late onset) / / 21379329 rs6566683 chr18 70622938 A G 1.59E-04 Multiple complex diseases / / 17554300 rs4892063 chr18 70661548 G A 2.40E-05 Urinary metabolites / / 21572414 rs17798004 chr18 70665383 T A 4.42E-04 Type 2 diabetes / / 17463246 rs17736134 chr18 70665806 A G 9.22E-04 Type 2 diabetes / / 17463246 rs2469060 chr18 70673107 C T 4.60E-04 Type 2 diabetes / / 17463246 rs11151820 chr18 70673545 A C 8.51E-04 Type 2 diabetes / / 17463246 rs17086725 chr18 70677377 T G 9.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs2432835 chr18 70683199 T C 0.0000153 post-traumatic stress disorder / / 22869035 rs2432835 chr18 70683199 T C 1.53E-05 Schizophrenia / / 22883433 rs2052662 chr18 70705208 A G 8.76E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs2469009 chr18 70713335 A G 1.27E-04 Type 2 diabetes / / 17463246 rs7242928 chr18 70720811 T C 0.0000944 Sarcoidosis / / 22952805 rs2194633 chr18 70744164 A G 1.31E-04 Celiac disease / / 23936387 rs1503024 chr18 70791395 A G 5.03E-04 Alzheimer's disease / / 17998437 rs9963861 chr18 70819143 A G 2.99E-20 Varicose Veins / / pha001414 rs1158869 chr18 70843010 C T 9.80E-06 Psoriasis LOC400655 intron 19169255 rs9963971 chr18 70896329 A C 4.99E-06 Corneal structure LOC400655 intron 22003120 rs8082724 chr18 70916656 G A 1.00E-07 Urinary metabolites LOC400655 intron 21572414 rs12960908 chr18 70919984 T G 5.76E-04 Longevity LOC400655 intron 22279548 rs12606100 chr18 70951987 C T 8.72E-06 Aging (time to event) / / 21782286 rs1943829 chr18 70956779 C T 1.63E-04 Sudden cardiac arrest / / 21658281 rs4316844 chr18 70974144 G A 4.25E-05 Major depressive disorder / / 19107115 rs17087292 chr18 70976852 T C 8.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8091228 chr18 70983468 T C 4.74E-04 Multiple complex diseases / / 17554300 rs2226859 chr18 71044198 G T 2.11E-04 Diabetic retinopathy / / 20871662 rs1943816 chr18 71058622 A G 1.00E-07 P-tau181p levels / / 20932310 rs1943816 chr18 71058622 A G 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs4525583 chr18 71065831 A T 2.36E-04 Obesity (extreme) / / 21935397 rs6566726 chr18 71067017 C A 8.91E-04 Myocardial Infarction / / pha002883 rs1943807 chr18 71067126 C T 9.44E-04 Obesity (extreme) / / 21935397 rs12969596 chr18 71069742 C A 3.91E-05 Major depressive disorder (broad) / / 20038947 rs12970112 chr18 71069901 G A 4.33E-05 Major depressive disorder (broad) / / 20038947 rs4508503 chr18 71071196 G T 2.92E-05 Major depressive disorder (broad) / / 20038947 rs4508503 chr18 71071196 G T 4.60E-05 Bronchopulmonary dysplasia / / 23897914 rs12960951 chr18 71071302 A G 7.74E-05 Cytomegalovirus antibody response / / 21993531 rs883493 chr18 71071467 G T 3.81E-05 Major depressive disorder (broad) / / 20038947 rs4243342 chr18 71073486 T C 4.04E-05 Major depressive disorder (broad) / / 20038947 rs4892099 chr18 71073497 T G 5.06E-05 Major depressive disorder (broad) / / 20038947 rs4614818 chr18 71074051 T C 4.57E-05 Major depressive disorder (broad) / / 20038947 rs4614819 chr18 71074109 A T 2.17E-05 Major depressive disorder (broad) / / 20038947 rs9963825 chr18 71075801 T C 2.41E-04 Type 2 diabetes / / 17463246 rs4528670 chr18 71076103 G A 8.59E-05 Major depressive disorder (broad) / / 20038947 rs4627461 chr18 71076298 T C 9.89E-05 Major depressive disorder (broad) / / 20038947 rs9319871 chr18 71077666 T C 9.09E-05 Major depressive disorder (broad) / / 20038947 rs8087112 chr18 71078121 T C 9.15E-05 Major depressive disorder (broad) / / 20038947 rs8089528 chr18 71078224 A G 4.28E-05 Bronchopulmonary dysplasia / / 23897914 rs9950597 chr18 71078837 T C 8.55E-05 Major depressive disorder (broad) / / 20038947 rs12965392 chr18 71093539 A G 5.92E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12966046 chr18 71093730 G C 5.92E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17819948 chr18 71103611 T C 8.30E-05 Tooth agenesis (maxillary third molar) / / 24172245 rs17241824 chr18 71104038 T C 3.55E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11873008 chr18 71104597 C T 6.31E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs8098925 chr18 71106858 T C 1.07E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs8099090 chr18 71106985 T C 1.18E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11875511 chr18 71107484 A G 1.18E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7242045 chr18 71116233 T C 5.03E-04 Smoking quantity / / 24665060 rs11151863 chr18 71119879 A G 9.81E-05 Cytomegalovirus antibody response / / 21993531 rs17087632 chr18 71126065 G A,C 2.10E-04 Multiple complex diseases / / 17554300 rs4892107 chr18 71145784 T C 6.10E-05 Type 2 diabetes / / 17463246 rs13380914 chr18 71161787 C A 1.20E-04 Weight loss (gastric bypass surgery) / / 23643386 rs7240777 chr18 71167752 G A 3.00E-08 Thyroid hormone levels / / 23408906 rs7226384 chr18 71182888 A G 4.56E-04 Multiple complex diseases / / 17554300 rs7244951 chr18 71211108 A T 1.04E-04 Type 2 diabetes / / 17463246 rs1943872 chr18 71221580 T C 2.55E-04 Multiple complex diseases / / 17554300 rs1943874 chr18 71221855 T C 4.32E-04 Multiple complex diseases / / 17554300 rs17087826 chr18 71225456 A C 2.88E-04 Multiple complex diseases / / 17554300 rs17087827 chr18 71226887 C T 1.36E-04 Coronary Artery Disease / / 17634449 rs1943891 chr18 71251150 T C 7.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs7236844 chr18 71251489 G A 5.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs17754718 chr18 71260859 C T 6.61E-04 Coronary heart disease / / 21606135 rs8099013 chr18 71261792 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2051413 chr18 71274950 A G 8.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs4405633 chr18 71275627 G A 3.13E-04 Multiple complex diseases / / 17554300 rs10514081 chr18 71275963 A C,G,T 2.40E-05 Urinary metabolites / / 21572414 rs4892117 chr18 71278910 T C 3.21E-05 Multiple complex diseases / / 17554300 rs1943869 chr18 71279620 C G 8.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs1943860 chr18 71292932 C T 5.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs17829298 chr18 71293027 C T 2.34E-05 Multiple complex diseases / / 17554300 rs1943858 chr18 71293688 T C 4.02E-04 Coronary heart disease / / 21606135 rs17829352 chr18 71293982 G A 6.13E-04 Coronary heart disease / / 21606135 rs17829352 chr18 71293982 G A 8.85E-04 Body mass index / / 21701565 rs1943856 chr18 71294079 T C 9.23E-04 Coronary heart disease / / 21606135 rs1943856 chr18 71294079 T C 7.42E-04 Body mass index / / 21701565 rs11662228 chr18 71300976 C T 6.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs11662228 chr18 71300976 C T 5.44E-04 Smoking initiation / / 24665060 rs2703496 chr18 71301150 T A 8.89E-04 Body mass index / / 21701565 rs11876675 chr18 71302916 G A 7.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs17762504 chr18 71308623 T A 9.30E-04 Coronary heart disease / / 21606135 rs17762504 chr18 71308623 T A 8.03E-05 Body mass index / / 21701565 rs8095367 chr18 71322506 C T 7.98E-05 Serum metabolites / / 19043545 rs4892122 chr18 71322722 G A 9.10E-04 Coronary heart disease / / 21606135 rs17763239 chr18 71322793 T G 7.98E-05 Serum metabolites / / 19043545 rs17763263 chr18 71322909 T C 7.98E-05 Serum metabolites / / 19043545 rs9953978 chr18 71347427 G A 5.76E-04 Coronary heart disease / / 21606135 rs9953978 chr18 71347427 G A 6.49E-04 Body mass index / / 21701565 rs10514087 chr18 71385891 C T 2.72E-04 Alzheimer's disease (late onset) / / 21379329 rs17088303 chr18 71445607 G T 1.50E-05 Urinary metabolites / / 21572414 rs4321279 chr18 71446883 C T 1.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs754826 chr18 71453044 C T 9.02E-05 Hypertension / / pha003041 rs75366668 chr18 71454947 C T 4.53E-04 Acne (severe) / / 24927181 rs4892138 chr18 71458785 A G 1.11E-05 Hypertension / / pha003041 rs12605110 chr18 71460438 T C 2.99E-04 Blood pressure / / 17255346 rs1430540 chr18 71469667 C T 6.57E-05 Body Mass Index / / pha002896 rs9319883 chr18 71476081 G A 4.58E-04 Parkinson's disease / / 17052657 rs17088339 chr18 71476133 T A 6.00E-06 Coronary artery calcification / / 23870195 rs8090593 chr18 71516958 T G 3.10E-05 Bone mineral density (BMD),in women / / 20164292 rs17088439 chr18 71522091 T G 3.00E-06 Smooth-surface caries / / 24556642 rs7229063 chr18 71533168 A G 5.70E-04 Type 2 diabetes / / 17463246 rs2115980 chr18 71555376 C A 9.72E-05 Blood Pressure / / pha003048 rs9948124 chr18 71559138 G A 4.06E-05 Cervical cancer / / 24700089 rs9957017 chr18 71560116 C T 6.64E-05 Cervical cancer / / 24700089 rs7230183 chr18 71563906 C G 5.23E-05 Body mass (lean) / / 19268274 rs41377344 chr18 71579437 C G 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2278331 chr18 71581506 T G 2.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2278331 chr18 71581506 T G 5.00E-06 Sleep duration / / 23728906 rs17088532 chr18 71595003 C G 4.95E-04 Multiple complex diseases / / 17554300 rs4310957 chr18 71605864 G T 0.000009 Primary sclerosing cholangitis / / 22521342 rs10514103 chr18 71615597 C T 5.73E-04 Multiple complex diseases / / 17554300 rs11664093 chr18 71622316 T C 7.44E-04 Multiple complex diseases / / 17554300 rs17062275 chr18 71624552 G T 1.55E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs2850516 chr18 71632918 C T 6.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1112273 chr18 71637416 G T 6.65E-04 Smoking initiation / / 24665060 rs1943918 chr18 71660684 T C 5.35E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs2702614 chr18 71673215 G A,C,T 2.02E-05 Prion diseases / / 22210626 rs2702611 chr18 71675035 G C 1.24E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs2850492 chr18 71680332 T C 2.84E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs12454155 chr18 71693583 C T 8.91E-04 Body mass index / / 21701565 rs1943940 chr18 71705192 T C 6.00E-07 Diastolic blood pressure (alcohol consumption interaction) / / 24376456 rs1943940 chr18 71705192 T C 8.00E-07 Mean arterial pressure (alcohol consumption interaction) / / 24376456 rs9945428 chr18 71788676 C A 7.00E-09 Venous thromboembolism (gene x gene interaction) FBXO15 intron 23509962 rs17088802 chr18 71797093 G C 9.19E-04 Parkinson's disease FBXO15 intron 16252231 rs8086078 chr18 71799576 G C 7.20E-05 Age-related macular degeneration FBXO15 intron 21197116 rs8086078 chr18 71799576 G C 3.24E-06 Age-related macular degeneration FBXO15 intron pha000001 rs8086078 chr18 71799576 G C 1.26E-05 Age-related macular degeneration FBXO15 intron pha002856 rs4556879 chr18 71805503 C T 9.75E-07 Meningococcal disease FBXO15 intron 20694013 rs9319893 chr18 71808441 A C 8.58E-04 Multiple complex diseases FBXO15 intron 17554300 rs9952197 chr18 71811235 G A 1.47E-06 Meningococcal disease FBXO15 intron 20694013 rs3813108 chr18 71815486 T G 9.00E-05 Age-related macular degeneration / / pha002856 rs3737510 chr18 71815965 C A,T 9.02E-05 Amyotrophic lateral sclerosis (sporadic) TIMM21 UTR-5 24529757 rs3737512 chr18 71816278 G A 1.11E-06 Meningococcal disease TIMM21 missense 20694013 rs10514115 chr18 71828849 T C 6.18E-05 Age-related macular degeneration / / pha000002 rs17088883 chr18 71828924 C T 5.48E-06 Meningococcal disease / / 20694013 rs1790856 chr18 71847082 G A 4.64E-05 Nonalcoholic fatty liver disease / / 21423719 rs948798 chr18 71865093 C T 5.71E-05 Bladder cancer (smoking interaction) / / 24662972 rs8097258 chr18 71875519 T C 6.90E-06 Urinary metabolites / / 21572414 rs9951925 chr18 71878517 C A 2.00E-06 Chronic obstructive pulmonary disease-related biomarkers / / 23144326 rs11151933 chr18 71883827 A G 2.80E-05 Urinary metabolites / / 21572414 rs12457387 chr18 71891988 C G 4.38E-04 Cocaine dependence / / 23958962 rs12457387 chr18 71891988 C G 4.96E-05 Cocaine dependence / / 23958962 rs12607592 chr18 71892443 G C 7.80E-06 Urinary metabolites / / 21572414 rs9319895 chr18 71896469 G A 7.85E-04 Acute lung injury / / 22295056 rs12606263 chr18 71897381 A G 6.00E-05 Prostate cancer / / 21743057 rs17803877 chr18 71909320 A C 4.85E-04 Body mass index / / 21701565 rs17803877 chr18 71909320 A C 6.08E-04 Body mass index / / 21701565 rs1790866 chr18 71915176 T G 1.00E-05 Personality dimensions / / 18957941 rs1790866 chr18 71915176 T G 6.96E-04 Body mass index / / 21701565 rs11151937 chr18 71915673 C G 1.76E-04 Body mass index / / 21701565 rs11151937 chr18 71915673 C G 4.97E-04 Body mass index / / 21701565 rs1790858 chr18 71924819 C T 8.78E-04 Multiple complex diseases CYB5A intron 17554300 rs7238784 chr18 71927852 G T 2.06E-04 Body mass index CYB5A intron 21701565 rs7238784 chr18 71927852 G T 2.54E-04 Body mass index CYB5A intron 21701565 rs9953007 chr18 71930071 C T 3.51E-04 Body mass index CYB5A intron 21701565 rs9953007 chr18 71930071 C T 4.71E-05 Body mass index CYB5A intron 21701565 rs59162905 chr18 71930150 C T 7.68E-05 Epilepsy (remission after treatment) CYB5A intron 23962720 rs2032265 chr18 71930889 A G 8.75E-04 Alzheimer's disease CYB5A intron 22005930 rs74866423 chr18 71932976 C T 7.86E-05 Epilepsy (remission after treatment) CYB5A intron 23962720 rs17089026 chr18 71936165 T G 8.06E-05 Epilepsy (remission after treatment) CYB5A intron 23962720 rs7239151 chr18 71936464 G A 6.38E-04 Multiple complex diseases CYB5A intron 17554300 rs1614856 chr18 71936780 T C 1.70E-05 Personality dimensions CYB5A intron 18957941 rs1614856 chr18 71936780 T C 4.17E-04 Body mass index CYB5A intron 21701565 rs1614856 chr18 71936780 T C 7.62E-05 Body mass index CYB5A intron 21701565 rs1790901 chr18 71937145 T G 1.30E-05 Personality dimensions CYB5A intron 18957941 rs1790901 chr18 71937145 T G 2.73E-04 Body mass index CYB5A intron 21701565 rs1790901 chr18 71937145 T G 4.61E-05 Body mass index CYB5A intron 21701565 rs4891538 chr18 71937252 G A 4.70E-04 Body mass index CYB5A intron 21701565 rs4891538 chr18 71937252 G A 6.68E-05 Body mass index CYB5A intron 21701565 rs4892190 chr18 71937461 G A 2.63E-04 Body mass index CYB5A intron 21701565 rs4892190 chr18 71937461 G A 4.56E-05 Body mass index CYB5A intron 21701565 rs78542257 chr18 71938029 G T 8.21E-05 Epilepsy (remission after treatment) CYB5A intron 23962720 rs10514121 chr18 71942329 G A 4.41E-05 Epilepsy (remission after treatment) CYB5A intron 23962720 rs8084744 chr18 71943195 C T 8.12E-04 Body mass index CYB5A intron 21701565 rs17089038 chr18 71943371 G A 6.35E-04 Multiple complex diseases CYB5A intron 17554300 rs17230973 chr18 71943751 A G 2.74E-04 Body mass index CYB5A intron 21701565 rs17230973 chr18 71943751 A G 8.63E-05 Body mass index CYB5A intron 21701565 rs2850585 chr18 71948921 A G 2.52E-04 Body mass index CYB5A intron 21701565 rs1573486 chr18 71955979 G A 8.98E-04 Body mass index CYB5A intron 21701565 rs1582404 chr18 71971089 C T 3.13E-04 Body mass index / / 21701565 rs1582404 chr18 71971089 C T 6.36E-05 Body mass index / / 21701565 rs4328535 chr18 71978076 C T 6.94E-04 Body mass index / / 21701565 rs10514126 chr18 71978184 A G 2.84E-04 Body mass index / / 21701565 rs10514126 chr18 71978184 A G 5.84E-05 Body mass index / / 21701565 rs733124 chr18 71982461 T C 4.75E-04 Body mass index / / 21701565 rs733124 chr18 71982461 T C 4.82E-04 Body mass index / / 21701565 rs7236071 chr18 71992294 G A 6.51E-04 Body mass index C18orf63 intron 21701565 rs4891549 chr18 71993111 G T 5.56E-04 Body mass index C18orf63 intron 21701565 rs9807250 chr18 72023852 C T 5.02E-05 Personality dimensions C18orf63 UTR-3 18957941 rs8094904 chr18 72055128 A G 8.26E-05 Bipolar disorder / / 22925353 rs17089172 chr18 72055187 G C 8.60E-04 Coronary Artery Disease / / 17634449 rs1365251 chr18 72055824 T C 9.57E-05 Bipolar disorder / / 22925353 rs17089177 chr18 72057164 G A 1.49E-22 Narcolepsy / / 19629137 rs12956327 chr18 72061594 G T 1.57E-05 Cocaine dependence / / 23958962 rs11662509 chr18 72073388 C T 2.33E-04 Coronary Artery Disease / / 17634449 rs2278155 chr18 72103646 A G 9.29E-05 Vitiligo FAM69C UTR-3 22951725 rs9961740 chr18 72108304 T C 0.00009873 Sarcoidosis FAM69C intron 22952805 rs10514132 chr18 72115547 G A 1.80E-05 Urinary metabolites FAM69C intron 21572414 rs10514133 chr18 72115844 T C 1.40E-05 Urinary metabolites FAM69C intron 21572414 rs2162256 chr18 72122611 A G 9.82E-05 Waist Circumference FAM69C intron pha003025 rs2162256 chr18 72122611 A G 6.54E-05 Weight FAM69C intron pha003027 rs4892225 chr18 72134852 T C 1.42E-05 Body Mass Index / / pha003009 rs2114230 chr18 72139229 T C 1.79E-05 Body Mass Index / / pha003009 rs7240571 chr18 72142598 T C 0.000594 Salmonella-induced pyroptosis / / 22837397 rs9319907 chr18 72143386 G T 8.57E-05 Body Mass Index / / pha003007 rs9319907 chr18 72143386 G T 1.35E-06 Body Mass Index / / pha003009 rs9319907 chr18 72143386 G T 2.08E-05 Waist Circumference / / pha003025 rs9319907 chr18 72143386 G T 4.41E-05 Weight / / pha003026 rs9319907 chr18 72143386 G T 2.80E-06 Weight / / pha003027 rs890339 chr18 72146557 A T 7.77E-04 Multiple complex diseases / / 17554300 rs747175 chr18 72154720 T C 3.40E-06 Body Mass Index / / pha003009 rs747175 chr18 72154720 T C 4.98E-05 Weight / / pha003027 rs11876710 chr18 72159310 T A 4.13E-05 Multiple complex diseases / / 17554300 rs4891558 chr18 72170359 T C 5.33E-04 Type 2 diabetes CNDP2 intron 17463246 rs4891558 chr18 72170359 T C 9.76E-06 Lymphocyte counts CNDP2 intron 22286170 rs12971120 chr18 72174023 A G 2.00E-07 Refractive error CNDP2 intron 23396134 rs1035760 chr18 72184237 A G 1.00E-04 Information processing speed CNDP2 intron 21130836 rs2241508 chr18 72186404 G A 1.80E-05 Systemic sclerosis CNDP2 intron 21750679 rs2346064 chr18 72213416 T C 6.98E-04 Response to taxane treatment (placlitaxel) CNDP1 intron 23006423 rs17089382 chr18 72218701 C T 3.28E-06 Osteoarthritis CNDP1 intron 22763110 rs12961730 chr18 72225989 T C 5.94E-04 Type 2 diabetes CNDP1 intron 17463246 rs7506258 chr18 72235432 G C 3.49E-04 Multiple complex diseases CNDP1 intron 17554300 rs7242384 chr18 72248250 A G 3.68E-04 Multiple complex diseases CNDP1 intron 17554300 rs7506051 chr18 72256617 A C 7.00E-07 Smoking behavior / / 20418888 rs7506112 chr18 72262042 T C 1.70E-06 Stroke (ischemic) LOC400657 intron 22384361 rs7506112 chr18 72262042 T C 4.97E-05 Socioeconomic Factors LOC400657 intron pha003066 rs8099286 chr18 72266470 C A 8.27E-04 Alzheimer's disease / / 17998437 rs7245160 chr18 72266846 A G 4.22E-05 Amyotrophic Lateral Sclerosis / / 18057069 rs115368653 chr18 72344002 G A 0.00014 Breast cancer (ER positive) ZNF407 missense 23555315 rs17817969 chr18 72344238 C T 7.16E-06 Male-pattern baldness ZNF407 cds-synon 18849994 rs17055278 chr18 72349629 T C 9.80E-06 Telomere length ZNF407 intron 23001564 rs488199 chr18 72380146 T C 1.50E-05 Urinary metabolites ZNF407 intron 21572414 rs10221304 chr18 72381941 C T 7.00E-06 Urinary metabolites ZNF407 intron 21572414 rs17818946 chr18 72390746 A G 3.06E-05 Male-pattern baldness ZNF407 intron 18849994 rs547335 chr18 72452702 C T 1.51E-04 Response to taxane treatment (placlitaxel) ZNF407 intron 23006423 rs9947276 chr18 72492689 A T 9.00E-06 Alcohol dependence (age at onset) ZNF407 intron 24962325 rs7228254 chr18 72493161 G C 9.25E-06 Alcohol dependence (age at onset) ZNF407 intron 24962325 rs7228438 chr18 72493314 G T 9.25E-06 Alcohol dependence (age at onset) ZNF407 intron 24962325 rs1974956 chr18 72494841 G A 9.72E-06 Alcohol dependence (age at onset) ZNF407 intron 24962325 rs7229235 chr18 72494992 G A 9.65E-06 Alcohol dependence (age at onset) ZNF407 intron 24962325 rs8099493 chr18 72500444 A G 1.10E-05 Urinary metabolites ZNF407 intron 21572414 rs12956780 chr18 72504018 G A 9.44E-06 Alcohol dependence (age at onset) ZNF407 intron 24962325 rs12956238 chr18 72525280 G A 5.32E-05 Response to taxane treatment (placlitaxel) ZNF407 intron 23006423 rs2628101 chr18 72528536 G T 4.66E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines ZNF407 intron 21844884 rs966123 chr18 72538424 T C 1.58E-04 Response to taxane treatment (placlitaxel) ZNF407 intron 23006423 rs2042703 chr18 72540401 C T 2.21E-04 Response to taxane treatment (placlitaxel) ZNF407 intron 23006423 rs2628126 chr18 72593118 C T 0.000161 Salmonella-induced pyroptosis ZNF407 intron 22837397 rs9961200 chr18 72594471 T A 6.31E-04 Multiple complex diseases ZNF407 intron 17554300 rs17055816 chr18 72594505 G A 1.16E-04 Multiple complex diseases ZNF407 intron 17554300 rs4891224 chr18 72786303 G A 7.71E-04 Schizophrenia / / 19197363 rs17056274 chr18 72787046 A G 4.00E-06 Estradiol levels / / 22675492 rs17056307 chr18 72799796 G T 8.10E-05 HIV-1 control / / 20041166 rs906517 chr18 72802103 T C 1.08E-04 Schizophrenia / / 19197363 rs906517 chr18 72802103 T C 5.40E-05 Schizophrenia / / 19571808 rs894575 chr18 72816432 A C 4.37E-04 Multiple complex diseases / / 17554300 rs7230274 chr18 72829212 A C 8.26E-05 Waist Circumference / / pha003025 rs8083466 chr18 72835488 G A 3.08E-05 Body Mass Index / / pha003009 rs8083466 chr18 72835488 G A 5.80E-05 Height / / pha003010 rs8083466 chr18 72835488 G A 3.19E-05 Waist Circumference / / pha003023 rs8083466 chr18 72835488 G A 3.92E-07 Waist Circumference / / pha003024 rs8083466 chr18 72835488 G A 6.36E-07 Waist Circumference / / pha003025 rs8083466 chr18 72835488 G A 3.34E-07 Weight / / pha003026 rs8083466 chr18 72835488 G A 6.22E-07 Weight / / pha003027 rs10514157 chr18 72865164 C T 7.49E-05 Myopia (pathological) / / 21640322 rs744142 chr18 72875327 T C 2.10E-05 Obesity (extreme) / / 21935397 rs596996 chr18 72875983 C T 2.20E-05 Obesity (extreme) / / 21935397 rs17056473 chr18 72876952 A G 4.99E-05 Obesity (extreme) / / 21935397 rs787583 chr18 72884470 G A 2.86E-04 Hearing function / / 17255346 rs611916 chr18 72894668 G T 0.00001204 Sarcoidosis / / 22952805 rs609303 chr18 72895242 G A 0.000001611 Sarcoidosis / / 22952805 rs9948784 chr18 72897161 G A 1.00E-06 IgG glycosylation / / 23382691 rs9948784 chr18 72897161 G A 2.00E-06 IgG glycosylation / / 23382691 rs1702831 chr18 72897368 C A 0.000009081 Sarcoidosis / / 22952805 rs655156 chr18 72898181 T C 0.000002493 Sarcoidosis / / 22952805 rs629126 chr18 72906003 T C 3.53E-04 Type 2 diabetes LOC100652904 intron 17463246 rs629081 chr18 72906037 T C 4.34E-05 Rheumatoid arthritis LOC100652904 intron 17804836 rs1047521 chr18 72909505 C A 1.34E-04 Type 2 diabetes ZADH2 UTR-3 17463246 rs615360 chr18 72909795 T C 1.10E-04 Type 2 diabetes ZADH2 UTR-3 17463246 rs2581651 chr18 72926042 T C 1.82E-04 Insulin resistance TSHZ1 intron 21901158 rs2639993 chr18 72926078 G A 6.90E-05 Insulin resistance TSHZ1 intron 21901158 rs2581652 chr18 72926545 G A 7.90E-05 Insulin resistance TSHZ1 intron 21901158 rs2639974 chr18 72928735 T G 6.81E-04 Insulin resistance TSHZ1 intron 21901158 rs1866732 chr18 72933187 A G 3.48E-05 Cortisol secretion,in saliva TSHZ1 intron 21316860 rs1866732 chr18 72933187 A G 2.90E-06 Insulin resistance TSHZ1 intron 21901158 rs2639966 chr18 72938186 C T 1.80E-05 Urinary metabolites TSHZ1 intron 21572414 rs2119245 chr18 72969409 A T 1.99E-04 Multiple complex diseases TSHZ1 intron 17554300 rs2581644 chr18 72987489 T C 4.00E-05 Asperger disorder TSHZ1 intron 21182207 rs1946907 chr18 73016504 G C 2.35E-04 Acute lung injury / / 22295056 rs1866734 chr18 73022850 C A 6.78E-05 Heart Rate / / pha003053 rs1822043 chr18 73023660 C T 8.43E-04 Type 2 diabetes / / 17463246 rs17192047 chr18 73029332 C G 5.45E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7230870 chr18 73029408 A G 2.41E-04 Esophageal cancer (squamous cell) / / 20729853 rs4891058 chr18 73036797 C T 5.53E-05 Esophageal cancer (squamous cell) / / 20729853 rs1898165 chr18 73040376 G A 5.60E-06 Urinary metabolites / / 21572414 rs7236285 chr18 73041178 A G 2.40E-05 Urinary metabolites / / 21572414 rs62090893 chr18 73050334 G A 3.00E-07 Anorexia nervosa / / 23568457 rs7237804 chr18 73050400 G A 9.96E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12957502 chr18 73070279 A C 7.70E-06 Urinary metabolites / / 21572414 rs17056857 chr18 73070637 G A 8.50E-06 Urinary metabolites / / 21572414 rs13381538 chr18 73075550 G A 1.60E-05 Urinary metabolites / / 21572414 rs12458682 chr18 73097909 T C 9.87E-05 Glucose levels / / pha003058 rs4891066 chr18 73099691 G A 2.89E-05 Glucose levels / / pha003058 rs4380126 chr18 73102339 G A 1.51E-04 Body mass index / / 21701565 rs4291998 chr18 73102380 C T 1.34E-04 Body mass index / / 21701565 rs892944 chr18 73121331 A G 4.73E-04 Body mass index / / 21701565 rs7235563 chr18 73139335 C G 6.61E-05 Bipolar disorder C18orf62 intron 19488044 rs7235563 chr18 73139335 C G 9.13E-05 Bipolar Disorder C18orf62 intron pha002863 rs3213875 chr18 73184048 C T 8.00E-05 Bipolar disorder / / 19488044 rs3213875 chr18 73184048 C T 9.37E-05 Bipolar Disorder / / pha002863 rs1865721 chr18 73192446 C T 5.00E-06 Intelligence / / 22449649 rs1821449 chr18 73285950 T A 3.89E-04 Multiple complex diseases / / 17554300 rs12965975 chr18 73309283 C T 0.00000868 Child behavior checklist/1.5-5 pervasive developmental problems / / 23049896 rs4263026 chr18 73309989 G C 2.39E-04 Aortic root size / / 21223598 rs4263026 chr18 73309989 G C 3.47E-05 Serum alpha1-antitrypsin levels / / 23990791 rs11665640 chr18 73318771 C T 8.71E-04 Schizophrenia / / 19197363 rs8083887 chr18 73353711 G A 2.29E-08 Multiple complex diseases / / 17554300 rs2584295 chr18 73356731 T C 1.26E-04 Prion diseases / / 22210626 rs2584466 chr18 73378887 T C 8.89E-06 Major depressive disorder / / 21621269 rs2584466 chr18 73378887 T C 0.000878 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2584466 chr18 73378887 T C 8.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2067487 chr18 73390201 T G 6.54E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7233038 chr18 73414912 G T 3.43E-05 Bipolar Disorder LOC100505853 intron pha002863 rs17057956 chr18 73457059 T C 1.90E-06 Serum uric acid levels / / 17997608 rs1943199 chr18 73462854 T G 2.00E-08 Rheumatoid arthritis (ACPA-negative) / / 24532677 rs11150911 chr18 73498528 A C 7.69E-05 Breast cancer / / pha002853 rs4427892 chr18 73505605 G C 5.81E-04 Multiple complex diseases / / 17554300 rs12326088 chr18 73507569 T G 6.00E-06 Obesity-related traits / / 23251661 rs1460277 chr18 73510530 A G 1.50E-04 Breast cancer / / pha002853 rs1380711 chr18 73515143 G A 4.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11150915 chr18 73516816 T C 4.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1017745 chr18 73527636 C T 6.00E-06 Response to amphetamines / / 22952603 rs3943367 chr18 73527827 T C 7.02E-07 Pure-tone audiometry / / pha001968 rs2612366 chr18 73528080 T C 4.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1017747 chr18 73528162 C T 4.55E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9956878 chr18 73536711 G T 2.00E-06 Obesity-related traits / / 23251661 rs9956878 chr18 73536711 G T 8.00E-06 Obesity-related traits / / 23251661 rs9963380 chr18 73542303 A G 2.66E-04 Multiple complex diseases / / 17554300 rs8085188 chr18 73544676 T C 2.40E-04 Type 2 diabetes / / 17463246 rs2732216 chr18 73544968 C T 3.36E-04 Type 2 diabetes / / 17463246 rs9959259 chr18 73549963 G A 9.00E-06 Obesity-related traits / / 23251661 rs2612391 chr18 73555117 G T 6.60E-04 Alcohol dependence / / 20201924 rs9963891 chr18 73569207 G A 9.13E-04 Insulin resistance / / 21901158 rs9783867 chr18 73580129 A G 7.18E-08 Multiple complex diseases / / 17554300 rs2732231 chr18 73604404 T C 9.21E-04 Stroke / / pha002886 rs17058484 chr18 73613266 C A 1.45E-04 Type 2 diabetes / / 17463246 rs9973118 chr18 73615723 G T 6.53E-04 Insulin resistance / / 21901158 rs12326802 chr18 73657606 A G 3.72E-06 Basophils / / pha003087 rs11150922 chr18 73669763 G A 3.96E-04 Type 2 diabetes / / 17463246 rs9959776 chr18 73713028 T G 1.68E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2405941 chr18 73740844 C T 3.15E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1653115 chr18 73745200 T C 8.30E-04 Type 2 diabetes / / 17463246 rs4891112 chr18 73758103 G A 2.05E-04 Alcohol dependence / / 24277619 rs12456486 chr18 73761413 C T 5.57E-04 Alzheimer's disease / / 24755620 rs1030565 chr18 73763670 A C 2.05E-04 Alcohol dependence / / 24277619 rs11150928 chr18 73787298 T C 3.30E-05 Multiple complex diseases / / 17554300 rs4456593 chr18 73796017 A G 2.11E-05 ldl cholesterol / / pha003076 rs4456593 chr18 73796017 A G 2.06E-05 ldl cholesterol / / pha003077 rs359752 chr18 73806052 T C 1.82E-05 Serum metabolites / / 19043545 rs7237886 chr18 73811509 G A 1.65E-04 Arthritis (juvenile idiopathic) / / 22354554 rs4891008 chr18 73814740 G A 2.30E-05 Urinary metabolites / / 21572414 rs1653156 chr18 73814770 G A 4.28E-05 ldl cholesterol / / pha003076 rs1653156 chr18 73814770 G A 5.46E-05 ldl cholesterol / / pha003077 rs1653157 chr18 73814793 G A 4.07E-05 ldl cholesterol / / pha003076 rs1653157 chr18 73814793 G A 6.08E-05 ldl cholesterol / / pha003077 rs724881 chr18 73815538 C T 4.07E-05 ldl cholesterol / / pha003076 rs724881 chr18 73815538 C T 6.08E-05 ldl cholesterol / / pha003077 rs10514202 chr18 73838971 C T 0.0000536 Panic disorder LOC339298 splice-5 23149450 rs10514202 chr18 73838971 C T 5.36E-05 Serum tamsulosin hydrochloride concentration LOC339298 splice-5 23151678 rs12962858 chr18 73842356 C T 0.0000652 Panic disorder LOC339298 intron 23149450 rs12962858 chr18 73842356 C T 6.52E-05 Serum tamsulosin hydrochloride concentration LOC339298 intron 23151678 rs11660890 chr18 73850392 T C 6.04E-05 Panic disorder LOC339298 intron 19165232 rs12605519 chr18 73868446 T C 2.72E-04 Type 2 diabetes / / 17463246 rs12605519 chr18 73868446 T C 6.91E-04 Multiple complex diseases / / 17554300 rs6565851 chr18 73887392 T C 7.75E-04 Type 2 diabetes / / 17463246 rs8091904 chr18 73983921 G A 9.11E-05 Body Mass Index / / pha003022 rs7243425 chr18 73991986 A C 6.58E-04 Multiple complex diseases / / 17554300 rs9950773 chr18 74021181 G A 4.82E-05 Body Mass Index / / pha003019 rs9950773 chr18 74021181 G A 1.15E-05 Body Mass Index / / pha003022 rs2114266 chr18 74022505 G A 2.64E-05 Body Mass Index / / pha003022 rs690227 chr18 74039882 G A 1.10E-05 Urinary metabolites / / 21572414 rs690227 chr18 74039882 G A 9.42E-05 Parkinson's disease (motor and cognition) / / 22658654 rs690227 chr18 74039882 G A 9.42E-05 Immune response to anthrax vaccine / / 22658931 rs690654 chr18 74049614 T C 6.30E-06 Urinary metabolites / / 21572414 rs11150946 chr18 74074707 C T 8.73E-04 Multiple complex diseases ZNF516 intron 17554300 rs690378 chr18 74081272 G A 1.67E-04 Type 2 diabetes ZNF516 intron 17846124 rs690378 chr18 74081272 G A 1.14E-04 Attention deficit hyperactivity disorder ZNF516 intron 23728934 rs11150948 chr18 74086083 C A 4.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZNF516 intron 20877124 rs11150948 chr18 74086083 C A 7.59E-04 Suicide attempts in bipolar disorder ZNF516 intron 21423239 rs11150948 chr18 74086083 C A 5.56E-04 Age-related macular degeneration ZNF516 intron 22125219 rs591107 chr18 74089140 G A 5.68E-04 Suicide attempts in bipolar disorder ZNF516 intron 21423239 rs4891159 chr18 74101941 G A 2.11E-04 Multiple complex diseases ZNF516 intron 17554300 rs4891159 chr18 74101941 G A 1.00E-06 Longevity ZNF516 intron 20834067 rs683306 chr18 74112473 C G 9.37E-05 Multiple complex diseases ZNF516 intron 17554300 rs12457482 chr18 74119418 T C 4.62E-04 Aortic root size ZNF516 intron 21223598 rs689902 chr18 74119969 T C 8.31E-05 Response to cytidine analogues (gemcitabine) ZNF516 intron 24483146 rs2554830 chr18 74127702 A G 5.86E-05 Response to cytidine analogues (gemcitabine) ZNF516 intron 24483146 rs17059345 chr18 74128178 T G 8.54E-05 Heart Rate ZNF516 intron pha003051 rs2848961 chr18 74129886 G C 7.63E-04 Multiple complex diseases ZNF516 intron 17554300 rs2848961 chr18 74129886 G C 0.000251 Breast cancer early age of onset ZNF516 intron 18463975 rs2848961 chr18 74129886 G C 5.04E-05 Response to cytidine analogues (gemcitabine) ZNF516 intron 24483146 rs609487 chr18 74134382 C G 7.57E-04 Multiple complex diseases ZNF516 intron 17554300 rs609487 chr18 74134382 C G 8.91E-05 Response to cytidine analogues (gemcitabine) ZNF516 intron 24483146 rs10514217 chr18 74144939 A C,G 7.82E-05 Multiple complex diseases ZNF516 intron 17554300 rs1056714 chr18 74149526 T C 4.83E-05 Multiple complex diseases ZNF516 intron 17554300 rs2848958 chr18 74157068 C T 5.77E-05 Response to cytidine analogues (gemcitabine) ZNF516 intron 24483146 rs2848958 chr18 74157068 C T 6.43E-05 Blood Pressure ZNF516 intron pha003044 rs17059379 chr18 74160316 T A 4.20E-06 Multiple complex diseases ZNF516 intron 17554300 rs678870 chr18 74167077 A G 5.12E-05 Response to cytidine analogues (gemcitabine) ZNF516 intron 24483146 rs680253 chr18 74167427 C A 9.99E-05 Response to cytidine analogues (gemcitabine) ZNF516 intron 24483146 rs4891023 chr18 74179590 T C 9.38E-04 Multiple complex diseases ZNF516 intron 17554300 rs6565887 chr18 74182975 T C 4.00E-08 Renal transplant outcome ZNF516 intron 23432519 rs586692 chr18 74188768 A G 4.45E-04 Suicide attempts in bipolar disorder ZNF516 intron 21423239 rs3866685 chr18 74193763 A G 4.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZNF516 intron 20877124 rs3866685 chr18 74193763 A G 5.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZNF516 intron 20877124 rs3866685 chr18 74193763 A G 2.94E-04 Response to TNF antagonist treatment ZNF516 intron 21061259 rs4267414 chr18 74218509 C A 1.08E-04 Arthritis (juvenile idiopathic) / / 22354554 rs10164068 chr18 74252603 C G 4.40E-05 Parkinson's disease (age of onset) LOC284276 intron 19772629 rs1828132 chr18 74259932 C T 4.37E-04 Type 2 diabetes LOC284276 intron 17463246 rs7232061 chr18 74269894 G A 1.36E-04 Schizophrenia LOC284276 intron 19197363 rs9675976 chr18 74270301 G A 1.00E-04 Information processing speed / / 21130836 rs13381277 chr18 74318610 A G 4.00E-06 Dental caries / / 23064961 rs9945487 chr18 74343156 C T 4.03E-04 Heart Failure / / pha002885 rs11664649 chr18 74346906 C A 8.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs2406210 chr18 74348916 C A 1.85E-05 Lymphocyte counts / / pha003094 rs4433895 chr18 74375014 A C 8.06E-04 Type 2 diabetes / / 17463246 rs9967433 chr18 74378063 C T 4.55E-04 Smoking initiation / / 24665060 rs4891184 chr18 74380643 A G 8.40E-04 Type 2 diabetes / / 17463246 rs17059738 chr18 74380690 G A 2.20E-05 Urinary metabolites / / 21572414 rs7241797 chr18 74403352 A G 5.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs4300745 chr18 74411595 G A 1.33E-04 Alzheimer's disease (late onset) / / 21379329 rs12607337 chr18 74415209 A C 7.73E-04 Type 2 diabetes / / 17463246 rs7227535 chr18 74420740 G T 6.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs9947426 chr18 74436702 C T 3.92E-05 Serum metabolites / / 19043545 rs11660857 chr18 74437679 C T 1.03E-05 Breast cancer / / 21060860 rs11150978 chr18 74441415 A G 3.62E-06 Breast cancer / / 21060860 rs4891196 chr18 74448729 C T 0.0008191 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4891196 chr18 74448729 C T 8.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs34771771 chr18 74449444 TG T 7.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs8093872 chr18 74449444 T A 7.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs4273136 chr18 74449674 A G 0.0007754 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4273136 chr18 74449674 A G 7.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4243291 chr18 74453418 A G 1.75E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9944757 chr18 74461083 G T 1.38E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs11659976 chr18 74461523 G A,C,T 7.93E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs4606813 chr18 74478276 G A 1.02E-05 Age-related macular degeneration / / pha002890 rs12957632 chr18 74482432 C T 1.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs4890871 chr18 74484734 G A 8.30E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4890871 chr18 74484734 G A 4.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs4890871 chr18 74484734 G A 6.14E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs12961290 chr18 74487836 T G 1.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs2406341 chr18 74487868 G A 2.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs2406342 chr18 74488280 G T 6.72E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2406342 chr18 74488280 G T 3.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs2406342 chr18 74488280 G T 2.50E-05 Urinary metabolites / / 21572414 rs2406342 chr18 74488280 G T 2.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs7226599 chr18 74491132 G A 3.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs11663505 chr18 74491325 T G 3.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs6565917 chr18 74491675 A G 6.70E-04 Alcohol dependence / / 20201924 rs12959734 chr18 74493389 C T 8.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs9916924 chr18 74501151 C T 3.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs2406343 chr18 74503771 T C 4.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs17059976 chr18 74564679 A T 6.16E-04 Multiple complex diseases ZNF236 intron 17554300 rs4890866 chr18 74602400 A G 1.19E-06 Multiple complex diseases ZNF236 intron 17554300 rs10514227 chr18 74613914 G A 2.85E-06 HDL cholesterol ZNF236 intron pha003074 rs562832 chr18 74627099 C T 9.40E-04 Alcohol dependence ZNF236 intron 21314694 rs9959626 chr18 74631202 C T 3.65E-04 Multiple complex diseases ZNF236 intron 17554300 rs12968415 chr18 74660346 C T 8.05E-05 HDL cholesterol ZNF236 intron pha003074 rs8086634 chr18 74701192 C T 6.40E-04 Lipid traits MBP intron 24386095 rs470144 chr18 74701642 T C 7.79E-05 Tourette syndrome MBP intron 22889924 rs9676113 chr18 74702864 G A 6.37E-04 Tourette syndrome MBP intron 22889924 rs11661054 chr18 74704275 C A 1.01E-05 Parkinson's disease MBP intron 21812969 rs12456341 chr18 74708059 T C 7.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MBP intron 20877124 rs470903 chr18 74715269 A G 5.89E-05 Tourette syndrome MBP intron 22889924 rs2051344 chr18 74715653 G T 6.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MBP intron 20877124 rs509620 chr18 74717615 G T 5.94E-05 Tourette syndrome MBP intron 22889924 rs2282557 chr18 74725166 C T 1.01E-04 Type 2 diabetes MBP UTR-3 17463246 rs11663697 chr18 74735135 G T 9.00E-06 QT interval MBP intron 23166209 rs2282572 chr18 74737942 C T 2.69E-04 Type 2 diabetes MBP intron 17463246 rs11150993 chr18 74738525 C G 4.05E-04 Type 2 diabetes MBP intron 17463246 rs3900176 chr18 74739022 T C 5.85E-04 Response to alcohol consumption (flushing response) MBP intron 24277619 rs4890888 chr18 74779866 G A 2.00E-05 Urinary metabolites MBP intron 21572414 rs7234903 chr18 74794898 A T 8.43E-04 Alzheimer's disease MBP intron 17998437 rs1667914 chr18 74803084 G A 9.57E-04 Myocardial Infarction MBP intron pha002883 rs2000811 chr18 74809328 C T 2.70E-08 Rheumatoid arthritis MBP intron 21673997 rs1667918 chr18 74816958 A G 1.97E-04 Coronary heart disease MBP intron 21606135 rs1629089 chr18 74825768 C A 7.85E-05 Major depressive disorder (broad) MBP intron 20038947 rs1789094 chr18 74846185 C T 3.31E-04 Hemoglobin concentration / / 20534544 rs9951586 chr18 74857318 C T 2.92E-04 Hemoglobin concentration / / 20534544 rs1667952 chr18 74857974 A G 2.92E-04 Hemoglobin concentration / / 20534544 rs1789110 chr18 74859044 C A 4.00E-07 Age-related macular degeneration (GA) / / 22705344 rs12604612 chr18 74870477 T C 8.37E-04 Obesity (extreme) / / 21935397 rs9966136 chr18 74881660 T A 6.21E-04 Depression (quantitative trait) / / 20800221 rs4890912 chr18 74885941 G A 7.24E-04 Myocardial Infarction / / pha002873 rs7242877 chr18 74904461 T C 4.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17060645 chr18 74911280 G A 1.58E-05 Blood Pressure / / pha003049 rs9952288 chr18 74912282 C T 7.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8097739 chr18 74912348 C T 1.09E-04 Lymphocyte counts / / 22286170 rs10871546 chr18 74920824 C T 5.92E-04 Type 2 diabetes / / 17463246 rs2717096 chr18 74929042 G A 0.0000015 Lumbar spine bone mineral density / / 22692763 rs2717096 chr18 74929042 G A 0.000274 Lumbar spine bone mineral density (males) / / 22692763 rs7239621 chr18 74929495 C T 6.38E-05 Glucose levels / / pha003058 rs7239621 chr18 74929495 C T 7.35E-06 Glucose levels / / pha003061 rs7230283 chr18 74931463 G T 6.38E-05 Glucose levels / / pha003058 rs7230283 chr18 74931463 G T 7.35E-06 Glucose levels / / pha003061 rs12964446 chr18 74933003 A C 5.24E-04 Alcohol dependence / / 24277619 rs12964446 chr18 74933003 A C 4.15E-05 Glucose levels / / pha003061 rs9956473 chr18 74936640 T C 2.10E-04 Myasthenia gravis / / 23055271 rs4890812 chr18 74940312 C T 9.22E-05 Creatinine levels / / pha003069 rs8084125 chr18 74952758 T C 7.00E-06 Obesity-related traits / / 23251661 rs12953809 chr18 74958649 C T 9.89E-04 HIV-1 viral setpoint / / 17641165 rs2717128 chr18 74987632 A G 1.00E-06 RR interval (heart rate) / / 20031603 rs11877361 chr18 74996807 G A 9.26E-04 Multiple complex diseases / / 17554300 rs1944550 chr18 75015563 A G 7.60E-05 Alcoholism (heaviness of drinking) / / 21529783 rs1009134 chr18 75076053 G A 4.57E-05 Lymphocyte counts / / pha003094 rs4480888 chr18 75089915 C T 3.70E-05 Socioeconomic Factors / / pha003066 rs11151040 chr18 75091318 C T 0.000076 Pancreatic cancer and survival / / 22665904 rs7241510 chr18 75114185 T C 3.68E-04 Blood pressure / / 17255346 rs12456229 chr18 75118412 C A 5.50E-05 Myasthenia gravis / / 23055271 rs4467164 chr18 75123436 T C 8.19E-05 Personality dimensions / / 18957941 rs6565965 chr18 75127574 T C 3.07E-05 Personality dimensions / / 18957941 rs6565965 chr18 75127574 T C 1.20E-04 Myasthenia gravis / / 23055271 rs1942598 chr18 75147897 A C 5.29E-04 Smoking initiation / / 24665060 rs948717 chr18 75164214 T G 8.17E-04 Multiple complex diseases / / 17554300 rs7505330 chr18 75220197 T G 8.36E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7505169 chr18 75240052 G T 7.17E-04 Type 2 diabetes / / 17463246 rs12957544 chr18 75242528 A G 5.52E-04 Coronary heart disease / / 21606135 rs7236489 chr18 75252389 C T 3.28E-04 Multiple complex diseases / / 17554300 rs7236489 chr18 75252389 C T 8.19E-05 Personality dimensions / / 18957941 rs11151064 chr18 75262263 G A 3.49E-06 Rheumatoid arthritis / / 19503088 rs4474778 chr18 75269784 G A 4.12E-06 Rheumatoid arthritis / / 19503088 rs2032278 chr18 75284037 A G 5.15E-06 Rheumatoid arthritis / / 19503088 rs4890968 chr18 75301313 C T 6.42E-04 Type 2 diabetes / / 17463246 rs1829651 chr18 75310478 T C 1.14E-05 Type 2 diabetes / / 17463246 rs9962181 chr18 75312002 T G 9.20E-05 Homocysteine levels,in plasma / / 19525478 rs165148 chr18 75314973 C T 9.81E-07 Rheumatoid arthritis / / 19503088 rs4890971 chr18 75315336 T G 6.22E-04 Type 2 diabetes / / 17463246 rs165147 chr18 75315500 C T 9.87E-07 Rheumatoid arthritis / / 19503088 rs165118 chr18 75319107 G A 5.13E-07 Rheumatoid arthritis / / 19503088 rs8094766 chr18 75324205 C T 9.46E-04 Type 2 diabetes / / 17463246 rs954905 chr18 75332507 A G 9.04E-07 Rheumatoid arthritis / / 19503088 rs1521475 chr18 75333250 C T 8.42E-04 Type 2 diabetes / / 17463246 rs1521475 chr18 75333250 C T 6.44E-06 Sickle cell anemia (severity) / / 20029952 rs165134 chr18 75334439 G T 4.81E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs905443 chr18 75335587 A C 2.36E-06 Rheumatoid arthritis / / 19503088 rs11663447 chr18 75366853 G C 5.00E-05 Prostate cancer / / 21743057 rs517543 chr18 75367624 C T 5.95E-06 Rheumatoid arthritis / / 19503088 rs517543 chr18 75367624 C T 3.47E-04 Cognitive decline / / 23732972 rs622479 chr18 75367748 T C 5.87E-06 Rheumatoid arthritis / / 19503088 rs6566017 chr18 75367921 C A 6.48E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs487355 chr18 75368601 G A 1.51E-04 Iron levels / / pha002876 rs484522 chr18 75368906 A G 5.39E-06 Rheumatoid arthritis / / 19503088 rs12232653 chr18 75373758 T G 6.00E-06 Urinary metabolites / / 21572414 rs1876865 chr18 75390648 T C 1.27E-05 HIV-1 viral setpoint / / 21490045 rs9807163 chr18 75399395 C A 9.09E-05 Orofacial clefts / / 20023658 rs9807163 chr18 75399395 C A 2.06E-04 Alcohol dependence / / 20201924 rs2055518 chr18 75453275 A G 8.93E-04 Myocardial Infarction / / pha002883 rs11659329 chr18 75474861 C T 1.40E-06 Urinary metabolites / / 21572414 rs2654179 chr18 75475146 C T 2.89E-04 Osteoarthritis / / 19508968 rs2727057 chr18 75475349 C T 2.60E-05 Urinary metabolites / / 21572414 rs1032914 chr18 75499666 C T 3.36E-05 Osteoarthritis / / 19508968 rs4890850 chr18 75512158 C T 2.21E-04 Osteoarthritis / / 19508968 rs4890850 chr18 75512158 C T 8.66E-05 Heart Failure / / pha002884 rs1506270 chr18 75522640 G A 8.63E-04 Heart Failure / / pha002884 rs1160529 chr18 75525117 T C 3.75E-04 Type 2 diabetes / / 17463246 rs2135401 chr18 75539208 C A 4.27E-06 Cognitive impairment induced by topiramate / / 22091778 rs7241566 chr18 75547049 T C 3.90E-05 Osteoarthritis / / 19508968 rs12955505 chr18 75578926 A G 8.77E-05 Bone mineral density / / 19181680 rs1876175 chr18 75583342 C T 9.05E-05 Bone mineral density / / 19181680 rs9961113 chr18 75605399 T C 1.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs9973133 chr18 75634258 T C 3.66E-04 Multiple complex diseases / / 17554300 rs9973133 chr18 75634258 T C 9.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12455580 chr18 75638023 T C 2.00E-06 IgG glycosylation / / 23382691 rs12455580 chr18 75638023 T C 7.00E-06 IgG glycosylation / / 23382691 rs11661856 chr18 75653523 G A 1.00E-06 Inflammatory biomarkers / / 22228203 rs8095771 chr18 75664583 T G 5.99E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs8088260 chr18 75667838 G A 1.94E-04 Cholesterol / / 17255346 rs4129743 chr18 75679215 G A 6.04E-04 Parkinson's disease / / 17052657 rs4129744 chr18 75679444 C T 1.20E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7505122 chr18 75680090 A G 9.42E-04 Type 2 diabetes / / 17463246 rs11151097 chr18 75683465 T C 1.05E-05 Parkinson's disease (motor and cognition) / / 22658654 rs11151097 chr18 75683465 T C 1.05E-05 Immune response to anthrax vaccine / / 22658931 rs7504625 chr18 75691372 A C 4.27E-05 Parkinson's disease (motor and cognition) / / 22658654 rs7504625 chr18 75691372 A C 4.27E-05 Immune response to anthrax vaccine / / 22658931 rs7504279 chr18 75703041 T C 8.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs7241695 chr18 75704873 G A 4.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs7506184 chr18 75708208 G C 2.20E-06 Urinary metabolites / / 21572414 rs12960788 chr18 75714642 T A 7.40E-06 Urinary metabolites / / 21572414 rs6506726 chr18 75772888 T C 1.08E-04 Alzheimer's disease / / 17998437 rs11873161 chr18 75786773 T C 8.68E-04 Alcohol dependence / / 20201924 rs7228984 chr18 75817704 T C 8.83E-05 Prostate cancer / / pha002878 rs4798951 chr18 75832975 A T 5.67E-04 Type 2 diabetes / / 17463246 rs1472763 chr18 75846089 G C 9.60E-07 Urinary metabolites / / 21572414 rs1472763 chr18 75846089 G C 6.49E-05 Depression (quantitative trait) / / 23290196 rs2411412 chr18 75872726 G C 4.75E-04 Multiple complex diseases / / 17554300 rs6506722 chr18 75872855 C G 5.91E-04 Multiple complex diseases / / 17554300 rs4798993 chr18 75884353 C T 7.39E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs7239844 chr18 75893127 T C 4.79E-04 Multiple complex diseases / / 17554300 rs4798896 chr18 75912922 A G 4.00E-06 Schizophrenia / / 23212062 rs8085365 chr18 75918296 C T 7.79E-21 Adiponectin levels / / 20887962 rs9304055 chr18 75937274 G A 8.96E-04 Type 2 diabetes / / 17463246 rs1587893 chr18 75938925 T C 5.80E-05 Subclinical atherosclerosis / / 17903303 rs1039610 chr18 75948807 G A 4.90E-05 Subclinical atherosclerosis / / 17903303 rs1039611 chr18 75967361 T G 6.24E-04 Multiple complex diseases / / 17554300 rs953846 chr18 75967953 A G 1.27E-04 Type 2 diabetes / / 17463246 rs6506794 chr18 75973176 A G 8.18E-05 Type 2 diabetes / / 17463246 rs12955535 chr18 76044165 G A 2.21E-04 Stroke / / pha002886 rs8085865 chr18 76047493 A G 7.00E-05 Prostate cancer / / 21743057 rs7504842 chr18 76049993 T C 9.56E-05 Serum metabolites / / 19043545 rs594517 chr18 76062527 G A 1.95E-04 Birth weight / / 17255346 rs9949324 chr18 76080113 G A 7.00E-05 Suicidal ideation / / 22030708 rs592629 chr18 76085495 C T 6.42E-05 Stroke / / pha002887 rs592629 chr18 76085495 C T 5.75E-05 Coronary heart disease / / pha003035 rs12327418 chr18 76085704 T C 1.23E-05 Coronary heart disease / / pha003035 rs618670 chr18 76086727 G A 4.20E-04 Suicidal ideation / / 22030708 rs621340 chr18 76089907 T G 1.18E-05 Diabetes Mellitus / / pha003060 rs7240015 chr18 76136951 A G 4.77E-08 Narcolepsy / / 19629137 rs7245277 chr18 76137272 T C 1.90E-05 Celiac disease / / 17558408 rs673112 chr18 76155578 C A 6.35E-05 Tourette syndrome / / 22889924 rs1893755 chr18 76156397 G C 2.00E-05 Urinary metabolites / / 21572414 rs9947138 chr18 76157317 G A 3.00E-05 Schizophrenia / / 19571809 rs626675 chr18 76157746 G A 5.44E-05 Schizophrenia / / 19571809 rs663402 chr18 76158004 C T 1.05E-04 Tourette syndrome / / 22889924 rs9965776 chr18 76160008 C T 8.45E-04 Tourette syndrome / / 22889924 rs592226 chr18 76161084 T A 5.80E-06 Urinary metabolites / / 21572414 rs674119 chr18 76164638 G A 6.01E-04 Tourette syndrome / / 22889924 rs12326991 chr18 76178452 T C 7.62E-04 Alcohol dependence / / 20201924 rs2168838 chr18 76218048 T A 7.29E-05 Sarcoidosis / / 19165924 rs2168838 chr18 76218048 T A 9.20E-04 Coronary heart disease / / 21606135 rs185750 chr18 76270349 C T 3.85E-04 Multiple complex diseases / / 17554300 rs4799159 chr18 76280463 A G 4.00E-04 Suicidal ideation / / 22030708 rs721467 chr18 76305023 A T 6.31E-05 Femoral neck bone geometry / / 22087292 rs10401125 chr18 76336288 C T 3.67E-04 Alcohol dependence / / 20201924 rs9960787 chr18 76337612 G A 1.91E-04 Alcohol dependence / / 20201924 rs2002842 chr18 76409597 C A 6.00E-06 Rheumatoid arthritis / / 18668548 rs66591657 chr18 76415450 A G 4.00E-06 Response to amphetamines / / 22952603 rs67057673 chr18 76415468 G C 8.75E-06 Response to amphetamines / / 22952603 rs34995188 chr18 76415480 T A 8.25E-06 Response to amphetamines / / 22952603 rs12955300 chr18 76415963 C T 1.60E-05 Endometriosis / / 21151130 rs12955300 chr18 76415963 C T 7.99E-04 Smoking cessation / / 24665060 rs12962467 chr18 76416004 A G 5.58E-06 Response to amphetamines / / 22952603 rs2931060 chr18 76425127 T C 4.72E-04 Common variable immunodeficiency / / 21497890 rs2941853 chr18 76426068 C T 2.71E-05 Lymphocyte counts / / pha003094 rs2941853 chr18 76426068 C T 6.88E-05 Neutrophil count / / pha003095 rs11877847 chr18 76431377 C A 0.000562 Salmonella-induced pyroptosis / / 22837397 rs12605652 chr18 76435166 G A 3.00E-06 Bone mineral density (BMD),in women / / 20164292 rs2941794 chr18 76453854 G A 5.77E-16 Multiple complex diseases / / 17554300 rs878627 chr18 76456503 C T 3.42E-04 Lung function (forced vital capacity) / / 24023788 rs11659609 chr18 76463038 G A 4.40E-05 Bone mineral density (BMD),in women / / 20164292 rs2175427 chr18 76489287 C T 4.12E-04 Multiple complex diseases / / 17554300 rs2941787 chr18 76501589 A G 6.71E-04 Smoking initiation / / 24665060 rs9945493 chr18 76503253 G A 1.71E-07 Alzheimer's disease / / 21059989 rs9945493 chr18 76503253 G A 4.94E-04 Alzheimer's disease / / 21059989 rs9945493 chr18 76503253 G A 8.97E-06 Alzheimer's disease / / 21059989 rs9945493 chr18 76503253 G A 5.00E-06 Alcohol dependence / / 21956439 rs9949091 chr18 76507259 A G 8.82E-05 Smoking initiation / / 24665060 rs878333 chr18 76563175 G A 1.20E-04 Multiple complex diseases / / 17554300 rs12967884 chr18 76591635 A G 7.00E-06 Subcutaneous adipose tissue / / 22589738 rs11664670 chr18 76593838 C T 7.26E-05 Coronary heart disease / / pha003056 rs2927260 chr18 76628060 A G 0.000803625 Hypertension (early onset hypertension) / / 22479346 rs9955278 chr18 76656348 T C 8.76E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs9951602 chr18 76657779 C T 9.00E-06 Obesity-related traits / / 23251661 rs2959414 chr18 76665175 G A 2.24E-05 Coronary heart disease / / pha003035 rs11661468 chr18 76669931 C T 7.11E-04 Smoking initiation / / 24665060 rs1075470 chr18 76671085 G A 3.68E-04 Smoking initiation / / 24665060 rs11081668 chr18 76675811 A C 6.35E-04 Smoking initiation / / 24665060 rs2959407 chr18 76682915 C T 2.65E-04 Smoking initiation / / 24665060 rs3933778 chr18 76684386 A G 4.00E-05 Prostate cancer / / 21743057 rs936503 chr18 76687314 G A 2.49E-05 Breast cancer (survival) / / 20332263 rs936503 chr18 76687314 G A 4.37E-04 Smoking initiation / / 24665060 rs11081669 chr18 76691845 G T 3.27E-05 Smoking initiation / / 24665060 rs6506876 chr18 76693565 A G 2.95E-04 Type 2 diabetes / / 17463246 rs668335 chr18 76735000 T A 7.60E-06 Urinary metabolites / / 21572414 rs1623269 chr18 76736333 G A 3.60E-06 Urinary metabolites / / 21572414 rs610806 chr18 76736380 C T 3.60E-06 Urinary metabolites / / 21572414 rs594821 chr18 76745589 C T 6.07E-06 Hearing function SALL3 intron 21493956 rs7241993 chr18 76773973 C T 2.00E-09 Prostate cancer / / 23535732 rs500934 chr18 76813487 T C 1.52E-04 Multiple complex diseases / / 17554300 rs545449 chr18 76815173 C T 5.65E-04 Type 2 diabetes / / 17463246 rs685000 chr18 76817520 G A 9.68E-04 Type 2 diabetes / / 17463246 rs474539 chr18 76817565 C G 3.84E-04 Type 2 diabetes / / 17463246 rs4380112 chr18 76831142 T C 5.99E-04 Type 2 diabetes ATP9B intron 17463246 rs601235 chr18 76832059 T C 1.37E-04 Multiple complex diseases ATP9B intron 17554300 rs1787273 chr18 76877173 G T 1.31E-04 Multiple complex diseases ATP9B intron 17554300 rs9948326 chr18 76887872 A T 2.47E-04 Multiple complex diseases ATP9B intron 17554300 rs8085899 chr18 76887893 C T 9.10E-04 Multiple complex diseases ATP9B intron 17554300 rs2032222 chr18 76893805 G C 9.49E-04 Multiple complex diseases ATP9B intron 17554300 rs7228827 chr18 76900411 C T 5.13E-08 Metabolite levels ATP9B intron 23281178 rs9947482 chr18 76902482 G A 9.38E-08 Metabolite levels ATP9B intron 23281178 rs9959586 chr18 76909243 A G 4.33E-08 Metabolite levels ATP9B intron 23281178 rs4799018 chr18 76945115 C T 1.67E-04 Smoking initiation ATP9B intron 24665060 rs9944629 chr18 77021059 G A 4.47E-04 Type 2 diabetes ATP9B intron 17463246 rs9965202 chr18 77107934 C T 1.71E-05 Response to metformin ATP9B intron 21186350 rs12604865 chr18 77110713 G T 1.83E-05 Response to metformin ATP9B intron 21186350 rs6506757 chr18 77111540 T C 1.94E-05 Response to metformin ATP9B intron 21186350 rs1110784 chr18 77137202 A G 7.04E-05 Aging (time to event) ATP9B intron 21782286 rs3859314 chr18 77148973 A G 6.14E-05 Multiple sclerosis / / 20598377 rs2230112 chr18 77171061 T G 0.0005636 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) NFATC1 cds-synon 23233654 rs2230112 chr18 77171061 T G 5.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) NFATC1 cds-synon 23233662 rs1017860 chr18 77172206 T C 6.30E-04 Coronary heart disease NFATC1 intron 21966275 rs4799055 chr18 77182003 T G 1.43E-05 Blood Pressure NFATC1 intron pha003039 rs1667682 chr18 77258581 T C 7.18E-04 Multiple complex diseases NFATC1 intron 17554300 rs8099113 chr18 77266154 G A 4.20E-04 Myasthenia gravis NFATC1 intron 23055271 rs372741 chr18 77269289 G A 6.26E-05 Body Fat Distribution NFATC1 intron pha003016 rs372741 chr18 77269289 G A 9.87E-05 Body Fat Distribution NFATC1 intron pha003017 rs372741 chr18 77269289 G A 9.47E-05 Body Fat Distribution NFATC1 intron pha003018 rs372741 chr18 77269289 G A 7.61E-05 Body Mass Index NFATC1 intron pha003019 rs177820 chr18 77276964 A G 2.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NFATC1 intron 20877124 rs177820 chr18 77276964 A G 7.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NFATC1 intron 20877124 rs6506775 chr18 77286067 C T 5.87E-04 Suicide attempts in bipolar disorder NFATC1 intron 21423239 rs9518 chr18 77288806 T C 4.11E-06 Eosinophil counts NFATC1 UTR-3 pha003088 rs308528 chr18 77290167 G A 0.0003814 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs308528 chr18 77290167 G A 3.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs183374 chr18 77291418 G A 0.0001394 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs183374 chr18 77291418 G A 1.39E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4799062 chr18 77299280 G A 6.90E-05 Schizophrenia / / 19571808 rs4799062 chr18 77299280 G A 0.0000309 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4799062 chr18 77299280 G A 3.09E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7233804 chr18 77321874 G A 2.01E-05 Cortisol secretion,in saliva / / 21316860 rs7233024 chr18 77325446 C A 4.09E-06 Retinopathy in non-diabetics / / 23393555 rs2460395 chr18 77332718 A G 0.0001425 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2460395 chr18 77332718 A G 1.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs614569 chr18 77340427 T C 1.41E-04 Schizophrenia / / 19197363 rs614569 chr18 77340427 T C 9.00E-06 Urinary metabolites / / 21572414 rs4021815 chr18 77351355 T A,C,G 4.36E-05 Hemoglobin / / pha003098 rs660749 chr18 77356003 T C 3.45E-04 Osteoarthritis / / 19508968 rs506246 chr18 77373296 G T 1.70E-05 Personality dimensions / / 18957941 rs7231598 chr18 77390317 G A 1.86E-04 Body mass index / / 21701565 rs11877070 chr18 77390921 G C 3.10E-06 Urinary metabolites / / 21572414 rs7233060 chr18 77392379 G A 1.19E-04 Body mass index / / 21701565 rs7233060 chr18 77392379 G A 4.57E-04 Body mass index / / 21701565 rs7233060 chr18 77392379 G A 3.00E-07 Schizophrenia / / 23212062 rs649867 chr18 77400047 C T 2.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs649867 chr18 77400047 C T 2.30E-04 Suicidal ideation / / 22030708 rs8098133 chr18 77414556 T A 7.76E-04 Alzheimer's disease / / 22005930 rs496281 chr18 77441822 C G 1.06E-04 Multiple complex diseases CTDP1 intron 17554300 rs3859315 chr18 77442583 T G 6.49E-04 Alzheimer's disease CTDP1 intron 22005930 rs3859316 chr18 77442622 C A 5.99E-04 Alzheimer's disease CTDP1 intron 22005930 rs500795 chr18 77448041 T C 2.94E-04 Multiple complex diseases CTDP1 intron 17554300 rs12605631 chr18 77450915 A G 9.75E-04 Multiple complex diseases CTDP1 intron 17554300 rs898619 chr18 77455577 C T 4.22E-04 Alzheimer's disease CTDP1 intron 22005930 rs70198 chr18 77455690 C T 9.84E-05 Multiple complex diseases CTDP1 intron 17554300 rs3809936 chr18 77463175 C G 4.58E-04 Alzheimer's disease CTDP1 intron 22005930 rs3786235 chr18 77469713 C G 6.69E-04 Alzheimer's disease CTDP1 intron 22005930 rs8087647 chr18 77471613 C T 6.75E-04 Alzheimer's disease CTDP1 intron 22005930 rs2279103 chr18 77473127 C T 5.70E-04 Suicidal ideation CTDP1 missense 22030708 rs8084175 chr18 77477515 C T 6.99E-04 Alzheimer's disease CTDP1 intron 22005930 rs9953991 chr18 77488572 C G 7.36E-04 Alzheimer's disease CTDP1 intron 22005930 rs9956086 chr18 77489169 G A 7.43E-04 Alzheimer's disease CTDP1 intron 22005930 rs503347 chr18 77491280 C T 2.11E-04 Multiple complex diseases CTDP1 intron 17554300 rs9946977 chr18 77516217 C T 4.12E-04 Alzheimer's disease / / 22005930 rs12605690 chr18 77518329 G A 7.27E-04 Alzheimer's disease / / 22005930 rs632281 chr18 77521740 T G 4.24E-04 Alzheimer's disease / / 22005930 rs554659 chr18 77526086 A G 7.56E-04 Alzheimer's disease / / 22005930 rs551017 chr18 77526471 A G 4.21E-04 Alzheimer's disease / / 22005930 rs665138 chr18 77527009 G A 4.22E-04 Alzheimer's disease / / 22005930 rs523386 chr18 77527195 G A 7.20E-04 Suicidal ideation / / 22030708 rs652717 chr18 77527531 A G 7.15E-04 Alzheimer's disease / / 22005930 rs496036 chr18 77527876 T C 8.06E-04 Alzheimer's disease / / 22005930 rs576937 chr18 77528799 G C 7.15E-04 Alzheimer's disease / / 22005930 rs545853 chr18 77529844 G A 7.74E-04 Multiple complex diseases / / 17554300 rs585811 chr18 77539764 C A 4.11E-05 Prostate cancer / / pha002878 rs2061566 chr18 77551738 A G 2.33E-04 Multiple complex diseases / / 17554300 rs2061566 chr18 77551738 A G 7.13E-04 Aortic root size / / 21223598 rs526260 chr18 77553173 A G 1.15E-04 Smoking initiation / / 24665060 rs611517 chr18 77554063 G C 4.70E-05 Response to statin therapy / / 20339536 rs4799088 chr18 77573548 A G 9.00E-06 Amyotrophic lateral sclerosis / / 20801717 rs12968863 chr18 77584986 A T 1.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs2126083 chr18 77585701 G A 1.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs12457472 chr18 77586350 T G 6.05E-05 Suicide attempts in bipolar disorder / / 21423239 rs537962 chr18 77592660 C G 2.10E-05 Bipolar disorder / / 19488044 rs537962 chr18 77592660 C G 1.37E-05 Bipolar disorder and schizophrenia / / 20889312 rs537962 chr18 77592660 C G 6.97E-05 Bipolar disorder / / 22925353 rs537962 chr18 77592660 C G 1.39E-05 Bipolar Disorder / / pha002858 rs4799092 chr18 77608203 C G 2.94E-05 Bipolar disorder / / 19488044 rs4799092 chr18 77608203 C G 2.18E-05 Bipolar disorder and schizophrenia / / 20889312 rs4799092 chr18 77608203 C G 5.05E-05 Bipolar disorder / / 22925353 rs4799092 chr18 77608203 C G 2.00E-05 Bipolar Disorder / / pha002858 rs62103177 chr18 77624479 G A 4.00E-10 Opioid sensitivity KCNG2 intron 24143882 rs891488 chr18 77637424 T C 3.76E-04 Lung function (forced vital capacity) KCNG2 intron 24023788 rs2115998 chr18 77640942 G T 9.70E-04 Endometriosis KCNG2 intron 23104006 rs7505298 chr18 77650347 T G 9.77E-04 Acute lung injury KCNG2 intron 22295056 rs11081573 chr18 77699893 C T 2.44E-04 Multiple complex diseases PQLC1 intron 17554300 rs8093291 chr18 77701294 G A 4.43E-06 C-reactive protein PQLC1 intron 22492993 rs10853392 chr18 77708781 G A 9.81E-04 Parkinson's disease PQLC1 intron 17052657 rs12953577 chr18 77716624 G A 9.16E-04 Alcohol dependence / / 21314694 rs4799115 chr18 77736365 T A 1.58E-04 Blood pressure TXNL4A intron 17255346 rs12607007 chr18 77764073 T C 3.55E-04 Multiple complex diseases / / 17554300 rs12604993 chr18 77765220 C T 1.22E-04 Multiple complex diseases / / 17554300 rs12604993 chr18 77765220 C T 2.38E-07 Primary nonsyndromic vesicoureteric reflex / / 19959718 rs11664762 chr18 77780683 C T 4.60E-06 Urinary metabolites / / 21572414 rs1808592 chr18 77786210 G A 6.05E-04 Multiple complex diseases / / 17554300 rs12964779 chr18 77794810 G A 5.20E-06 Urinary metabolites RBFA intron 21572414 rs4644918 chr18 77795232 A T 4.00E-06 Urinary metabolites RBFA intron 21572414 rs7228489 chr18 77795985 A G 7.56E-04 Multiple complex diseases RBFA intron 17554300 rs4799124 chr18 77799495 T C 9.11E-04 Multiple complex diseases RBFA intron 17554300 rs11664633 chr18 77803750 G A 5.30E-06 Urinary metabolites RBFA intron 21572414 rs7227096 chr18 77826306 G A 1.97E-04 Multiple complex diseases / / 17554300 rs4442895 chr18 77826399 C A,G 2.86E-04 Blood pressure / / 17255346 rs7237754 chr18 77833127 A G 1.47E-04 Amyotrophic Lateral Sclerosis LOC100506070 intron 17362836 rs558084 chr18 77839701 T C 1.01E-04 Multiple complex diseases / / 17554300 rs1715230 chr18 77848002 T C 3.41E-04 Blood pressure / / 17255346 rs11662458 chr18 77868036 G A 7.20E-04 Amyotrophic Lateral Sclerosis ADNP2 intron 17362836 rs9304062 chr18 77888708 G A 4.17E-05 Bipolar disorder ADNP2 intron 21771265 rs11662921 chr18 77891443 G T 6.90E-04 Multiple complex diseases ADNP2 intron 17554300 rs11660007 chr18 77891511 A T 5.85E-04 Multiple complex diseases ADNP2 intron 17554300 rs1064059 chr18 77893683 A G 6.48E-04 Multiple complex diseases ADNP2 cds-synon 17554300 rs1064059 chr18 77893683 A G 4.17E-05 Bipolar disorder ADNP2 cds-synon 21771265 rs12953980 chr18 77908065 A G 6.07E-04 Alcohol dependence LOC100130522 intron 24277619 rs8083877 chr18 77950543 T C 3.91E-04 Body mass index PARD6G intron 21701565 rs4799144 chr18 77957325 G A 1.39E-04 Multiple complex diseases PARD6G intron 17554300 rs1122752 chr18 77998375 A G 3.73E-04 Blood pressure PARD6G intron 17255346 rs6506819 chr18 78002239 T C 2.43E-04 Body mass index PARD6G intron 21701565 rs11668555 chr19 267213 C T 7.28E-04 Taste perception / / 22132133 rs12459906 chr19 276245 T C 1.69E-04 Stroke / / pha002887 rs4897940 chr19 301639 A G 4.60E-05 Non-word repetition / / 23738518 rs4897941 chr19 301668 G C 4.60E-05 Non-word repetition / / 23738518 rs4897942 chr19 301900 G A 4.60E-05 Non-word repetition / / 23738518 rs7246500 chr19 315788 G A 1.90E-05 Urinary metabolites MIER2 intron 21572414 rs7253509 chr19 331028 G A 8.37E-05 Non-alcoholic fatty liver disease histology (other) MIER2 intron 20708005 rs6510725 chr19 348743 T C 3.00E-06 Non-small cell lung cancer / / 23144319 rs2278285 chr19 366680 G A 2.85E-04 Type 2 diabetes THEG intron 17463246 rs1549697 chr19 376008 C T 1.20E-04 Schizophrenia(treatment response to risperidone) THEG UTR-5 19850283 rs3764571 chr19 376382 T C 2.30E-05 Urinary metabolites / / 21572414 rs12611418 chr19 388413 A C 1.29E-04 Stroke / / pha002887 rs7508251 chr19 401714 A G 6.37E-06 Hemoglobin / / pha003098 rs7508251 chr19 401714 A G 5.83E-07 Erythrocyte counts / / pha003099 rs12978500 chr19 406934 C A 1.00E-06 Obesity-related traits C2CD4C UTR-3 23251661 rs753948 chr19 412730 C T 5.48E-04 Alzheimer's disease / / 17998437 rs140148508 chr19 438830 T C 0.00027 Breast cancer SHC2 missense 23555315 rs2009673 chr19 485177 T C 1.80E-05 Diabetic retinopathy / / 21441570 rs758503 chr19 495722 G T 7.73E-05 Body mass index / / 17255346 rs7246543 chr19 504830 C G,T 3.80E-05 Iron levels MADCAM1 cds-synon 21208937 rs4919908 chr19 508626 C T 1 Drug response to Etoposide TPGS1 intron 17537913 rs4919908 chr19 508626 C T 5.40E-04 Coronary heart disease TPGS1 intron 21971053 rs4919910 chr19 509717 C T 1 Drug response to Etoposide TPGS1 intron 17537913 rs4919910 chr19 509717 C T 1.66E-04 Multiple complex diseases TPGS1 intron 17554300 rs4919910 chr19 509717 C T 5.58E-04 Coronary heart disease TPGS1 intron 21971053 rs2288951 chr19 538487 G A 6.08E-04 Lymphocyte counts CDC34 intron 22286170 rs12609053 chr19 575083 G C 2.37E-04 Multiple complex diseases BSG intron 17554300 rs2283573 chr19 579100 C T 5.01E-06 Multiple complex diseases BSG intron 17554300 rs8637 chr19 582775 A G 1.95E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines BSG UTR-3 21844884 rs3814895 chr19 588860 T C 7.08E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12610384 chr19 634095 A G 1.59E-04 Multiple complex diseases POLRMT nearGene-5 17554300 rs3814892 chr19 638853 G A 2.08E-05 Celiac disease / / 23936387 rs2074460 chr19 647039 T C 9.31E-04 Amyotrophic Lateral Sclerosis RNF126 nearGene-3 17362836 rs11671100 chr19 711637 C A 1.55E-04 Smoking quantity PALM intron 24665060 rs12459842 chr19 750583 C T 7.96E-04 Smoking quantity / / 24665060 rs8110536 chr19 756985 T G 2.98E-05 Paclitaxel-induced neuropathy C19orf21 cds-synon 23776197 rs3761007 chr19 850574 G A 3.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ELANE nearGene-5 20877124 rs3761007 chr19 850574 G A 4.30E-05 Atrial fibrillation ELANE nearGene-5 21846873 rs1683564 chr19 859214 C A 0.00025 Coronary artery calcification CFD nearGene-5 23727086 rs2365702 chr19 881413 A G 5.85E-04 Amyotrophic Lateral Sclerosis MED16 intron 17827064 rs1060442 chr19 885818 A G 6.54E-04 Stroke (pediatric) MED16 cds-synon 22990015 rs11881003 chr19 908998 G A 5.72E-04 Smoking initiation R3HDM4 intron 24665060 rs350134 chr19 923744 G A 8.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8108687 chr19 927971 A G 1.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARID3A intron 20877124 rs8108687 chr19 927971 A G 2.83E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ARID3A intron 20877124 rs2159128 chr19 950380 G T 3.00E-07 Vertical cup-disc ratio ARID3A intron 20548946 rs1637995 chr19 960445 A G 9.00E-06 Alcohol dependence ARID3A intron 21956439 rs4807336 chr19 976024 G C 1.63E-05 Personality dimensions / / 22628180 rs7249037 chr19 988136 G A 8.60E-04 Alcohol dependence WDR18 intron 20201924 rs115882880 chr19 1001777 C A 2.00E-04 Alzheimer's disease (late onset) GRIN3B intron 23571587 rs4807395 chr19 1002847 A G 2.90E-04 Alcohol dependence GRIN3B intron 20201924 rs4807395 chr19 1002847 A G 7.40E-04 Alcohol dependence GRIN3B intron 20201924 rs4807395 chr19 1002847 A G 4.54E-04 Alzheimer's disease GRIN3B intron 24755620 rs3764650 chr19 1046520 T G 1.56E-05 Type 2 diabetes and other traits ABCA7 intron 19734900 rs3764650 chr19 1046520 T G 5.00E-17 Alzheimer's disease ABCA7 intron 21460840 rs3764650 chr19 1046520 T G 2.85E-05 Alzheimer's disease (late onset) ABCA7 intron 21460841 rs3764650 chr19 1046520 T G 4.50E-17 Prion diseases ABCA7 intron 22210626 rs115550680 chr19 1050420 A G 2.00E-09 Alzheimer's disease (late onset) ABCA7 intron 23571587 rs3752246 chr19 1056492 G C 6.00E-07 Alzheimer's disease (late onset) ABCA7 missense 21460841 rs4147918 chr19 1058176 A G 1.70E-19 Health and aging,CVD and cancer age of onset ABCA7 missense 22174011 rs4147918 chr19 1058176 A G 4.50E-14 Health and aging,CVD and cancer age of onset ABCA7 missense 22174011 rs4147918 chr19 1058176 A G 0.00017 Breast cancer (ER positive) ABCA7 missense 23555315 rs4147929 chr19 1063443 A G 1.00E-15 Alzheimer's disease (late onset) ABCA7 intron 24162737 rs115553053 chr19 1082844 C T 1.00E-04 Alzheimer's disease (late onset) HMHA1 cds-synon 23571587 rs10416031 chr19 1095151 A G 2.59E-05 Cognitive impairment induced by topiramate POLR2E intron 22091778 rs8103188 chr19 1103465 A G 7.23E-04 Lymphocyte counts / / 22286170 rs2074452 chr19 1107160 C T 4.39E-05 Multiple complex diseases / / 17554300 rs2074920 chr19 1119019 C T 1.20E-04 IgE levels in asthmatics SBNO2 cds-synon 23967269 rs2072280 chr19 1122147 G A 1.50E-04 IgE levels in asthmatics SBNO2 cds-synon 23967269 rs4807569 chr19 1123378 A C 2.81E-05 Multiple complex diseases SBNO2 intron 17554300 rs4807569 chr19 1123378 A C 1.06E-09 Crohn's disease SBNO2 intron 18587394 rs4807569 chr19 1123378 A C 2.12E-09 Multiple sclerosis SBNO2 intron 22190364 rs2024092 chr19 1124031 G A 1.80E-10 Crohn's disease SBNO2 intron 18587394 rs2024092 chr19 1124031 G A 8.00E-22 Crohn's disease SBNO2 intron 23128233 rs2024092 chr19 1124031 G A 2.56E-05 Magnesium levels SBNO2 intron pha003092 rs740495 chr19 1124835 A G 8.00E-12 Crohn's disease SBNO2 intron 21102463 rs2074916 chr19 1127720 G A 2.60E-06 Multiple complex diseases SBNO2 cds-synon 17554300 rs10413074 chr19 1130986 G A 3.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SBNO2 intron 20877124 rs35576999 chr19 1199676 G A 0.000068 Asthma (exacerbation) / / 23706709 rs147615524 chr19 1205889 C T 2.00E-06 PR interval in Tripanosoma cruzi seropositivity STK11 UTR-5 24324551 rs3764640 chr19 1207238 G T 8.00E-06 Alzheimer's disease STK11 intron 22005930 rs741765 chr19 1221545 C T 1.92E-04 Alzheimer's disease STK11 intron 22005930 rs3746106 chr19 1250109 C A 8.90E-05 Glucose levels MIDN UTR-5 pha003058 rs3746106 chr19 1250109 C A 4.72E-05 Glucose levels MIDN UTR-5 pha003061 rs2379239 chr19 1283757 G A 1.28E-04 Myocardial Infarction / / pha002873 rs10424501 chr19 1297502 G A 4.46E-04 Smoking initiation EF/2 intron 24665060 rs10405308 chr19 1312728 G A 1.81E-07 Crohn's disease and psoriasis / / 22482804 rs3826942 chr19 1360575 G A 3.20E-04 Type 2 diabetes MUM1 missense 17463246 rs6510605 chr19 1374641 G A 4.30E-04 Multiple complex diseases MUM1 intron 17554300 rs266805 chr19 1376723 G A 2.70E-05 Type 2 diabetes MUM1 UTR-3 23209189 rs2332496 chr19 1384690 G A 4.91E-04 Stroke NDUFS7 intron pha002886 rs7251833 chr19 1408904 A G 4.67E-06 Age-related macular degeneration DAZAP1 intron pha000001 rs3786978 chr19 1413574 T C 7.49E-06 Reading and spelling DAZAP1 intron 23738518 rs3786982 chr19 1415875 C T 4.00E-05 Menopause (age at onset) DAZAP1 intron 22267201 rs3786982 chr19 1415875 C T 1.71E-05 Reading and spelling DAZAP1 intron 23738518 rs4807927 chr19 1423199 A G 1.00E-06 Reading and spelling DAZAP1 intron 23738518 rs4807927 chr19 1423199 A G 6.00E-06 Word reading DAZAP1 intron 23738518 rs11666805 chr19 1425448 C T 1.70E-05 Word reading DAZAP1 intron 23738518 rs11666805 chr19 1425448 C T 5.71E-06 Reading and spelling DAZAP1 intron 23738518 rs3786983 chr19 1427260 C T 1.70E-05 Word reading DAZAP1 intron 23738518 rs3786983 chr19 1427260 C T 5.71E-06 Reading and spelling DAZAP1 intron 23738518 rs3760995 chr19 1436874 A C 2.69E-05 Word reading / / 23738518 rs3760995 chr19 1436874 A C 2.84E-05 Reading and spelling / / 23738518 rs2292453 chr19 1526470 G A 7.23E-04 Alcohol dependence PLK5 intron 24277619 rs1875960 chr19 1537467 T C 5.28E-04 Insulin resistance / / 21901158 rs16994456 chr19 1538945 C G 6.56E-04 Glycemic traits (pregnancy) / / 23903356 rs10402423 chr19 1546180 G A 4.20E-05 HIV-1 control / / 20041166 rs7252741 chr19 1580334 T C 5.52E-04 Alcohol dependence MBD3 intron 24277619 rs1860661 chr19 1650134 A G 4.00E-10 Hodgkin's lymphoma TCF3 intron 24920014 rs10405317 chr19 1691725 T G 8.00E-04 Atrial fibrillation / / 21846873 rs9676750 chr19 1697633 A G 1.39E-04 Celiac disease / / 23936387 rs4807137 chr19 1745610 G A 3.73E-05 Aging (time to event) / / 21782286 rs4807140 chr19 1773999 C T 1.20E-04 Endometriosis ONECUT3 intron 21151130 rs7253430 chr19 1803582 G T 7.00E-06 Obesity-related traits ATP8B3 intron 23251661 rs17604735 chr19 1807018 A G 1.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ATP8B3 intron 20877124 rs7249302 chr19 1808683 T C 3.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ATP8B3 intron 20877124 rs7250872 chr19 1811603 C T 2.00E-06 Bipolar disorder ATP8B3 missense 19416921 rs4807154 chr19 1858873 C T 6.00E-04 Alcohol dependence KLF16 intron 20201924 rs4807156 chr19 1871341 T C 6.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1061828 chr19 1925970 T C 6.84E-05 Cognitive test performance SCAMP4 UTR-3 20125193 rs8112134 chr19 1931642 G C 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs17684904 chr19 1933930 G A 3.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs12609309 chr19 1989480 A G 4.01E-04 Alzheimer's disease (late onset) BTBD2 intron 21379329 rs3810414 chr19 1993444 T C 5.70E-05 Age-related macular degeneration BTBD2 intron pha002856 rs2074625 chr19 1997729 C A 4.29E-06 Age-related macular degeneration BTBD2 intron pha002856 rs10414066 chr19 2061715 C T 4.76E-04 Hemoglobin concentration / / 20534544 rs7256023 chr19 2080051 C T 8.05E-05 Glucose levels MOB3A intron pha003057 rs9967630 chr19 2099820 A G 6.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10413398 chr19 2106696 T C 2.47E-04 Alcohol dependence AP3D1 intron 21314694 rs2385821 chr19 2120154 A G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) AP3D1 intron 17982456 rs2159213 chr19 2136102 T C 1.85E-09 Red blood cell traits AP3D1 intron 23222517 rs2108825 chr19 2136515 T C 2.68E-07 Red blood cell traits AP3D1 intron 23222517 rs12460763 chr19 2138507 A G 3.93E-04 Schizophrenia(treatment response to risperidone) AP3D1 intron 19850283 rs2238599 chr19 2140009 C T 8.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) AP3D1 intron 20877124 rs2238599 chr19 2140009 C T 6.41E-07 Red blood cell traits AP3D1 intron 23222517 rs2238612 chr19 2149694 T C 6.41E-09 Red blood cell traits AP3D1 intron 23222517 rs3803915 chr19 2160529 C A 5.00E-06 Body mass index / / 19851299 rs3803915 chr19 2160529 C A 4.00E-09 Myocardial infarction / / 24916648 rs12983357 chr19 2170868 G A,C 1.80E-05 Immunoglobulin A DOT1L intron 20694011 rs12986413 chr19 2170954 A T 3.00E-08 Height DOT1L intron 18391950 rs1015670 chr19 2171490 G A 2.62E-08 Red blood cell traits DOT1L intron 23222517 rs12982593 chr19 2175891 C A 2.52E-08 Red blood cell traits DOT1L intron 23222517 rs11880992 chr19 2176403 G A 2.00E-12 Height DOT1L intron 23563607 rs12982744 chr19 2177193 C G 3.00E-16 Height DOT1L intron 20881960 rs12982744 chr19 2177193 C G 1.00E-11 Osteoarthritis DOT1L intron 22566624 rs2864419 chr19 2183175 G T 4.89E-05 Osteoarthritis (knee and hip) DOT1L intron 21177295 rs2864419 chr19 2183175 G T 6.62E-05 Osteoarthritis (knee and hip) DOT1L intron 21177295 rs12974139 chr19 2184005 T C 1.69E-06 Osteoarthritis DOT1L intron 22763110 rs2074553 chr19 2190774 T A 2.02E-07 Red blood cell traits DOT1L intron 23222517 rs12459507 chr19 2224387 A C 3.46E-06 Basophils DOT1L intron pha003087 rs7253181 chr19 2238667 G T 1.87E-05 Psoriasis SF3A2 intron 20953190 rs733846 chr19 2241327 G T 1.93E-04 Multiple complex diseases SF3A2 intron 17554300 rs7249235 chr19 2242829 A C 8.55E-05 Diabetes (gestational) SF3A2 intron 22233651 rs12985777 chr19 2268055 T C 1.10E-04 Height / / 21998595 rs2523178 chr19 2275079 A G 8.00E-06 Height C19orf35 UTR-3 21998595 rs7251424 chr19 2321430 T C 1.36E-05 Parkinson's disease / / 21738487 rs10413189 chr19 2334538 C T 8.66E-04 Response to taxane treatment (placlitaxel) SPPL2B intron 23006423 rs2074546 chr19 2352639 A G 3.87E-05 Parkinson's disease SPPL2B intron 21738487 rs17763599 chr19 2369415 G T 3.50E-05 Parkinson's disease / / 21738487 rs4806846 chr19 2410484 G A 8.00E-06 Neuroticism TMPRSS9 intron 23229837 rs199844209 chr19 2425409 C G 0.000031 Breast cancer(er negative) TMPRSS9 missense 23555315 rs7252121 chr19 2426037 C T 0.00071 Breast cancer TMPRSS9 missense 23555315 rs4807265 chr19 2441106 G A 5.89E-04 Response to taxane treatment (placlitaxel) LMNB2 intron 23006423 rs4806851 chr19 2451266 G A 2.06E-04 Response to taxane treatment (placlitaxel) LMNB2 intron 23006423 rs8109281 chr19 2481612 C G 0.00013 Coronary artery calcification / / 23727086 rs887029 chr19 2498447 A G 8.95E-04 Parkinson's disease / / 17052657 rs6510683 chr19 2547015 A C 5.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity GNG7 intron 24324551 rs4334421 chr19 2580057 A G 9.50E-05 Amyotrophic Lateral Sclerosis GNG7 intron 17362836 rs3936139 chr19 2587576 C T 2.90E-04 Parkinson's disease GNG7 intron 17052657 rs8102584 chr19 2666837 G T 5.45E-04 Suicide attempts in bipolar disorder GNG7 intron 21423239 rs2110119 chr19 2668611 G A 5.37E-04 Suicide attempts in bipolar disorder GNG7 intron 21423239 rs1468703 chr19 2670293 T C 5.26E-04 Suicide attempts in bipolar disorder GNG7 intron 21423239 rs185543003 chr19 2714170 T C 4.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity / / 24324551 rs759071 chr19 2728577 A G 8.31E-04 Multiple complex diseases / / 17554300 rs142404413 chr19 2834336 C T 0.00015 Breast cancer ZNF554 missense 23555315 rs1610062 chr19 2843533 G A 4.84E-05 Stroke ZNF555 intron pha002887 rs4807347 chr19 2857287 A C 0.00000956 Migraine ZNF555 UTR-3 22678113 rs4807347 chr19 2857287 A C 9.56E-06 Migraine ZNF555 UTR-3 22683712 rs10418996 chr19 2860166 T G 0.0000648 Migraine ZNF555 UTR-3 22678113 rs10418996 chr19 2860166 T G 6.48E-05 Migraine ZNF555 UTR-3 22683712 rs887500 chr19 2862785 G T 0.0000514 Migraine / / 22678113 rs887500 chr19 2862785 G T 5.14E-05 Migraine / / 22683712 rs887502 chr19 2862806 C T 6.71E-04 Type 2 diabetes / / 17463246 rs2058324 chr19 2884516 T C 1.80E-05 Lung adenocarcinoma / / 19836008 rs11084971 chr19 2905913 G T 3.58E-05 HDL cholesterol ZNF57 intron pha003075 rs3855680 chr19 2906475 A C 4.89E-04 Lymphocyte counts ZNF57 intron 22286170 rs4807359 chr19 2906556 C A 5.37E-05 Soluble levels of adhesion molecules ZNF57 intron pha003072 rs2288958 chr19 2917287 C A 5.24E-05 Soluble levels of adhesion molecules ZNF57 missense pha003072 rs6510730 chr19 2989697 T C 2.65E-04 Smoking initiation TLE6 cds-synon 24665060 rs216279 chr19 3005231 G C 2.31E-05 Type 2 diabetes TLE2 intron 17463246 rs83488 chr19 3006274 C T 9.26E-04 Amyotrophic Lateral Sclerosis TLE2 intron 17827064 rs3760961 chr19 3013374 A G 8.68E-05 ldl cholesterol TLE2 intron pha003077 rs3760961 chr19 3013374 A G 4.17E-06 Cholesterol TLE2 intron pha003083 rs7249809 chr19 3020691 A G 3.10E-06 Lung adenocarcinoma TLE2 intron 22797724 rs1688128 chr19 3030168 T C 8.27E-04 Parkinson's disease TLE2 intron 17052657 rs1688128 chr19 3030168 T C 6.60E-05 Lung adenocarcinoma TLE2 intron 22797724 rs11880198 chr19 3159769 A G 6.00E-06 Heart failure G/15 intron 20445134 rs11880198 chr19 3159769 A G 7.10E-04 Heart Failure G/15 intron pha002884 rs550581 chr19 3191604 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) NCLN intron 20708005 rs11085004 chr19 3215237 C T 5.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4807431 chr19 3245938 A G 1.20E-05 Bipolar disorder and schizophrenia CELF5 intron 20889312 rs17764205 chr19 3251219 T G 5.00E-06 Bipolar disorder and schizophrenia CELF5 intron 20889312 rs10424519 chr19 3253532 G C 1.87E-05 Bipolar disorder and schizophrenia CELF5 intron 20889312 rs8112130 chr19 3253928 C T 5.42E-06 Bipolar disorder and schizophrenia CELF5 intron 20889312 rs11669985 chr19 3257415 C G 1.79E-05 Bipolar disorder and schizophrenia CELF5 intron 20889312 rs312933 chr19 3268785 A G 3.78E-05 Hematocrit CELF5 intron pha003097 rs11669592 chr19 3318510 A G 4.00E-06 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4807441 chr19 3323420 C T 1.07E-04 Myopia (pathological) / / 21095009 rs28859095 chr19 3329809 A G 1.60E-05 Bipolar disorder / / 22925353 rs918171 chr19 3336539 T C 3.70E-05 Endometrial cancer / / 21499250 rs759635 chr19 3351890 C T 5.70E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs3810420 chr19 3365583 A G 4.50E-05 Type 2 diabetes NFIC intron 17460697 rs11085016 chr19 3372514 G A 6.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NFIC intron 20877124 rs758504 chr19 3412035 C T 4.23E-04 Type 2 diabetes NFIC intron 17463246 rs7507204 chr19 3428834 G C 4.00E-16 Height NFIC intron 20881960 rs4806934 chr19 3432252 A G 7.40E-04 Stroke NFIC intron pha002887 rs72974768 chr19 3435545 G A 3.00E-06 QRS duration in Tripanosoma cruzi seropositivity NFIC intron 24324551 rs1860193 chr19 3481650 C T 8.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2240754 chr19 3552093 C T 6.39E-04 White matter integrity MFSD12 intron 22425255 rs1715093 chr19 3554783 A G 4.48E-04 White matter integrity MFSD12 intron 22425255 rs6510761 chr19 3565909 T C 5.65E-05 Celiac disease / / 23936387 rs182473859 chr19 3589461 C T 0.00011 Breast cancer GIPC3 missense 23555315 rs17348907 chr19 3590334 A G 3.99E-05 Orofacial clefts GIPC3 UTR-3 22419666 rs1476707 chr19 3610776 G A 1.92E-05 Cognitive performance C19orf29 UTR-3 19734545 rs12977510 chr19 3613472 G T 6.00E-06 Obesity-related traits C19orf29 missense 23251661 rs7250088 chr19 3705677 C G 2.53E-05 Serum metabolites / / 19043545 rs1046268 chr19 3750615 T C 2.82E-05 Inflammation TJP3 missense pha002897 rs1046278 chr19 3750690 A C 3.76E-05 Inflammation / / pha002897 rs8102086 chr19 3752874 A C,G 5.32E-05 Inflammation APBA3 missense pha002897 rs12459781 chr19 3762119 T C 1.28E-10 Lymphocyte counts / / 22286170 rs13960 chr19 3762698 C T 5.05E-05 Lung adenocarcinoma MRPL54 UTR-5 19836008 rs12104221 chr19 3797100 C T 3.00E-08 Obesity-related traits MATK intron 23251661 rs6510774 chr19 3841051 C T 2.01E-04 Parkinson's disease ZFR2 intron 21248740 rs4807521 chr19 3856656 T C 6.70E-04 Suicide attempts in bipolar disorder ZFR2 intron 21423239 rs11882561 chr19 3864992 C A 9.93E-15 Metabolite levels ZFR2 intron 22286219 rs12979239 chr19 3866925 A G 8.75E-05 Hypertension ZFR2 intron pha003042 rs10412199 chr19 3927771 G A 3.00E-06 Aging (time to event) ATCAY UTR-3 21782286 rs4807532 chr19 3928369 A G 5.32E-05 Staphylococcus aureus infection ATCAY nearGene-3 24847357 rs10406174 chr19 3944240 G A 6.00E-06 Age-related macular degeneration / / 23326517 rs10406174 chr19 3944240 G A 7.00E-06 Age-related macular degeneration / / 23326517 rs7255123 chr19 3958397 A G 4.11E-05 Staphylococcus aureus infection / / 24847357 rs7255123 chr19 3958397 A G 7.90E-05 Pancreatic cancer / / pha002889 rs745414 chr19 3974965 G A 9.65E-05 Alcohol dependence / / 21314694 rs7257356 chr19 4013389 C T 7.34E-05 Nephrolithiasis PIAS4 intron 22396660 rs8113562 chr19 4014065 G A 5.12E-05 Nephrolithiasis PIAS4 intron 22396660 rs12982708 chr19 4020370 C T 1.53E-05 Word reading PIAS4 intron 23738518 rs350897 chr19 4112895 C T 4.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP2K2 intron 20877124 rs350896 chr19 4112988 G A 4.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAP2K2 intron 20877124 rs164632 chr19 4139849 C T 0.0000133 Cholesterol,total / / 23063622 rs350824 chr19 4141209 C A 6.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs350872 chr19 4156841 G A 5.84E-05 Serum albumin level CREB3L3 intron pha003084 rs3760905 chr19 4182939 G T 1.91E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 25044411 rs12978469 chr19 4210356 G A 2.79E-04 Smoking initiation ANKRD24 missense 24665060 rs8110516 chr19 4214467 G A 3.59E-05 Smoking initiation ANKRD24 intron 24665060 rs353693 chr19 4217207 T A,C,G 2.01E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ANKRD24 missense 24023788 rs4740 chr19 4236996 G A 3.40E-14 Leukemia(T-cell recognition in patients) EBI3 missense 21062987 rs4740 chr19 4236996 G A 4.65E-05 Caffeine consumption EBI3 missense 21490707 rs4905 chr19 4237067 A G 3.40E-14 Leukemia(T-cell recognition in patients) EBI3 cds-synon 21062987 rs1045750 chr19 4251069 T C 7.59E-05 Caffeine consumption CCDC94 cds-synon 21490707 rs8107226 chr19 4287377 G T 8.44E-04 Response to cytadine analogues (cytosine arabinoside) SHD intron 24483146 rs888932 chr19 4292597 C T 5.52E-04 Response to cytadine analogues (cytosine arabinoside) TMIGD2 cds-synon 24483146 rs2041774 chr19 4355203 G A 5.94E-08 Red blood cell traits MPND intron 23222517 rs2041775 chr19 4355300 T C 3.31E-07 Red blood cell traits MPND intron 23222517 rs12462529 chr19 4359525 A G 4.96E-10 Red blood cell traits MPND intron 23222517 rs7769 chr19 4360543 G A 9.68E-12 Red blood cell traits SH3GL1 UTR-3 23222517 rs107288 chr19 4365397 T C 5.69E-09 Red blood cell traits SH3GL1 intron 23222517 rs732716 chr19 4366219 A G 5.98E-13 Red blood cell traits SH3GL1 intron 23222517 rs11085073 chr19 4375162 G A 4.90E-12 Red blood cell traits SH3GL1 intron 23222517 rs11085074 chr19 4386352 A G 1.68E-10 Red blood cell traits SH3GL1 intron 23222517 rs2247205 chr19 4391485 C T 7.91E-09 Red blood cell traits SH3GL1 intron 23222517 rs73234 chr19 4394310 G C 1.30E-09 Red blood cell traits SH3GL1 intron 23222517 rs243342 chr19 4406160 G A 2.00E-07 Red blood cell traits CHAF1A intron 23222517 rs2267943 chr19 4413735 C T 1.68E-09 Red blood cell traits CHAF1A intron 23222517 rs11668886 chr19 4423419 C T 8.08E-12 Red blood cell traits CHAF1A intron 23222517 rs243372 chr19 4432973 G A 6.37E-07 Red blood cell traits CHAF1A intron 23222517 rs243375 chr19 4437089 C T 1.58E-08 Red blood cell traits CHAF1A intron 23222517 rs932276 chr19 4439525 G A 2.71E-09 Red blood cell traits CHAF1A intron 23222517 rs9352 chr19 4442336 C T 2.53E-07 Red blood cell traits CHAF1A missense 23222517 rs243382 chr19 4442529 T C 2.53E-07 Red blood cell traits CHAF1A intron 23222517 rs2293930 chr19 4444856 C T 2.54E-09 Red blood cell traits / / 23222517 rs243387 chr19 4445156 A G 9.60E-10 Red blood cell traits UBXN6 UTR-3 23222517 rs741923 chr19 4448843 G A 2.14E-09 Red blood cell traits UBXN6 intron 23222517 rs2077444 chr19 4449410 T C 3.36E-07 Red blood cell traits UBXN6 intron 23222517 rs1610092 chr19 4480081 G A 3.58E-08 Red blood cell traits / / 23222517 rs3929104 chr19 4480167 T A 3.77E-08 Red blood cell traits / / 23222517 rs16992406 chr19 4480751 G T 1.32E-10 Red blood cell traits / / 23222517 rs8109595 chr19 4481994 G C 4.04E-08 Red blood cell traits / / 23222517 rs12984070 chr19 4483485 A G 7.76E-11 Red blood cell traits / / 23222517 rs16992410 chr19 4487806 A G 6.06E-04 Alcohol dependence / / 20201924 rs1610091 chr19 4488470 C T 1.02E-08 Red blood cell traits / / 23222517 rs892160 chr19 4499939 T C 9.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs10406797 chr19 4500205 A G 1.01E-07 Red blood cell traits / / 23222517 rs8887 chr19 4502201 T C 3.01E-08 Red blood cell traits PLIN4 UTR-3 23222517 rs11673616 chr19 4506915 A G 5.57E-04 Suicide attempts in bipolar disorder PLIN4 intron 21423239 rs11673616 chr19 4506915 A G 3.12E-07 Red blood cell traits PLIN4 intron 23222517 rs892158 chr19 4507716 T C 8.03E-04 Suicide attempts in bipolar disorder PLIN4 intron 21423239 rs4991027 chr19 4509059 C T 6.12E-04 Suicide attempts in bipolar disorder PLIN4 intron 21423239 rs4991027 chr19 4509059 C T 3.78E-07 Red blood cell traits PLIN4 intron 23222517 rs7260518 chr19 4511955 T C 5.20E-04 Suicide attempts in bipolar disorder PLIN4 missense 21423239 rs201218136 chr19 4552446 G A 3.80E-09 Prostate-specific antigen SEMA6B missense 23555315 rs1610093 chr19 4554774 T C 2.13E-06 Osteoarthritis SEMA6B intron 22763110 rs10408176 chr19 4554886 T C 0.000061 Polycystic ovary syndrome SEMA6B intron 22951595 rs10408176 chr19 4554886 T C 6.10E-05 Intracranial aneurysm SEMA6B intron 22961961 rs10410702 chr19 4622380 A G 6.75E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12610495 chr19 4717672 A G 6.07E-05 Alzheimer's disease (late onset) DPP9 intron 21379329 rs12610495 chr19 4717672 A G 2.00E-12 Interstitial lung disease DPP9 intron 23583980 rs12610495 chr19 4717672 A G 8.42E-09 Interstitial lung disease DPP9 intron 23583980 rs12610495 chr19 4717672 A G 9.57E-09 Interstitial lung disease DPP9 intron 23583980 rs2109069 chr19 4719443 G A 1.46E-04 Alzheimer's disease (late onset) DPP9 intron 21379329 rs2109069 chr19 4719443 G A 1.22E-08 Interstitial lung disease DPP9 intron 23583980 rs2109069 chr19 4719443 G A 2.14E-08 Interstitial lung disease DPP9 intron 23583980 rs879564 chr19 4768917 A G 1.00E-07 Thyroid peroxidase antibody positivity / / 24586183 rs12610046 chr19 4774214 A C 1.02E-04 Myocardial Infarction / / pha002883 rs6510827 chr19 4830628 T C 9.00E-08 Vitiligo TICAM1 intron 22561518 rs17363814 chr19 4844633 C T 6.50E-05 Personality dimensions PLIN3 intron 18957941 rs1055919 chr19 4852137 C T 6.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PLIN3 cds-synon 20877124 rs1055919 chr19 4852137 C T 7.17E-05 Glucose levels PLIN3 cds-synon pha003061 rs2271057 chr19 4852337 A C 6.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PLIN3 intron 20877124 rs35967093 chr19 4883741 A T 6.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2602707 chr19 4915938 C T 3.55E-04 Multiple complex diseases UHRF1 intron 17554300 rs2123731 chr19 4929473 A G 7.50E-17 Progranulin levels UHRF1 cds-synon 21087763 rs2123731 chr19 4929473 A G 7.50E-17 Myocardial infarction UHRF1 cds-synon 21211798 rs8107449 chr19 4933777 G A 1.17E-04 Iron levels UHRF1 intron pha002876 rs1982468 chr19 4953351 T G 1.62E-04 Response to tamoxifen in breast cancer UHRF1 intron 22180457 rs881416 chr19 4958380 C T 3.46E-04 Smoking initiation UHRF1 intron 24665060 rs33938520 chr19 4984588 C T 8.79E-04 Response to taxane treatment (placlitaxel) KDM4B intron 23006423 rs11880464 chr19 4995926 C T 2.12E-04 Response to taxane treatment (placlitaxel) KDM4B intron 23006423 rs10407399 chr19 5009466 G T 2.24E-04 Hemoglobin concentration KDM4B intron 20534544 rs263063 chr19 5022604 T C 6.00E-06 Periodontitis (CDC/AAP) KDM4B intron 24024966 rs10419990 chr19 5037083 A C,G,T 2.50E-05 Urinary metabolites KDM4B intron 21572414 rs263057 chr19 5037351 A G 2.78E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) KDM4B intron 24023788 rs11878982 chr19 5041049 C T 3.97E-04 Response to taxane treatment (placlitaxel) KDM4B intron 23006423 rs2240678 chr19 5041178 T C 2.30E-05 Urinary metabolites KDM4B cds-synon 21572414 rs2613776 chr19 5076777 C T 8.55E-05 Bipolar disorder KDM4B intron 22925353 rs2291148 chr19 5077583 G A 1.30E-05 Urinary metabolites KDM4B intron 21572414 rs11673509 chr19 5080647 C T 1.10E-06 Urinary metabolites KDM4B intron 21572414 rs11673509 chr19 5080647 C T 6.00E-06 Periodontitis (CDC/AAP) KDM4B intron 24024966 rs4807685 chr19 5081179 T C 5.75E-04 Iron levels KDM4B intron pha002876 rs1552046 chr19 5122051 T C 3.60E-05 Response to statin therapy KDM4B intron 20339536 rs2620851 chr19 5122764 A G 3.50E-05 Response to statin therapy KDM4B intron 20339536 rs2620850 chr19 5122817 A G 3.50E-05 Response to statin therapy KDM4B intron 20339536 rs741698 chr19 5127398 C T 3.72E-04 Amyotrophic Lateral Sclerosis KDM4B intron 17362836 rs2613793 chr19 5145264 T C 3.70E-05 Response to statin therapy KDM4B intron 20339536 rs11514 chr19 5153606 G A 9.57E-04 Age-related macular degeneration KDM4B UTR-3 21909106 rs2620812 chr19 5189268 T C 4.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs2620812 chr19 5189268 T C 2.55E-05 Heart Rate / / pha003053 rs16992854 chr19 5189789 C T 9.81E-04 Alzheimer's disease / / 17998437 rs2620805 chr19 5190988 A G 3.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs2230611 chr19 5212482 G A 1.26E-04 Arthritis (juvenile idiopathic) PTPRS cds-synon 22354554 rs8107943 chr19 5212923 T C 3.30E-06 Urinary metabolites PTPRS intron 21572414 rs10423783 chr19 5225981 T C 5.72E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PTPRS intron 21844884 rs12610082 chr19 5227008 C A 5.80E-07 Urinary metabolites PTPRS intron 21572414 rs62115085 chr19 5231078 C T 7.51E-05 Epilepsy (remission after treatment) PTPRS intron 23962720 rs55965103 chr19 5248977 G A 8.11E-05 Epilepsy (remission after treatment) PTPRS intron 23962720 rs4807016 chr19 5258490 G A 1.20E-04 Alcohol dependence PTPRS intron 20201924 rs4807016 chr19 5258490 G A 8.30E-05 Alcohol dependence PTPRS intron 20201924 rs4807016 chr19 5258490 G A 8.29E-05 Alcoholism PTPRS intron pha002892 rs1034917 chr19 5274384 C T 3.65E-04 Coronary heart disease PTPRS intron 21971053 rs7507640 chr19 5355661 G T 8.05E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12985637 chr19 5382472 T C 1.70E-05 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs11667049 chr19 5421962 A G 9.16E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs11667049 chr19 5421962 A G 6.77E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs1384936 chr19 5423643 C T 1.56E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs4807760 chr19 5425795 T C 4.48E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs8111234 chr19 5426449 T C 7.55E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2082463 chr19 5439549 T C 8.84E-04 Type 2 diabetes / / 17463246 rs2240747 chr19 5456930 A C 2.10E-05 Cognitive performance / / 19734545 rs11671309 chr19 5469640 G A 3.42E-05 Bipolar disorder and schizophrenia / / 20889312 rs11878567 chr19 5512811 C T 4.98E-05 HIV-1 viral setpoint / / 17641165 rs8113645 chr19 5561076 A G 3.92E-04 IgE levels / / 17255346 rs732505 chr19 5582535 G A 9.00E-06 vWF and FVIII levels / / 21810271 rs150472516 chr19 5590371 C T 0.000025 Prostate cancer SAFB2 missense 23555315 rs2285963 chr19 5591735 G A 2.00E-05 Melanoma SAFB2 intron 21926416 rs10413286 chr19 5595354 T C 3.89E-04 Smoking quantity SAFB2 intron 24665060 rs806711 chr19 5618654 C T 7.40E-05 Blood Pressure SAFB2 intron pha003039 rs806702 chr19 5624290 G T 5.66E-05 Blood Pressure SAFB intron pha003039 rs17205911 chr19 5652572 G T 6.75E-04 Parkinson's disease SAFB intron 16252231 rs1129046 chr19 5654449 G A 1.29E-04 Amyotrophic lateral sclerosis (sporadic) SAFB cds-synon 24529757 rs200586681 chr19 5687901 G C 0.00041 Prostate cancer HSD11B1L missense 23555315 rs3097891 chr19 5743824 A G 4.22E-05 Creutzfeldt-Jakob disease (variant) CATSPERD intron 22137330 rs1026466 chr19 5775337 G C 6.64E-05 Lymphocyte counts CATSPERD intron 22286170 rs3745640 chr19 5783905 G A 9.03E-06 Glycemic traits (pregnancy) PRR22 missense 23903356 rs1379868 chr19 5827097 A G 7.46E-05 HIV-1 viral setpoint NRTN intron 17641165 rs778809 chr19 5830302 G A 1.09E-55 Tumor biomarkers FUT6 nearGene-3 23300138 rs778809 chr19 5830302 G A 2.16E-08 Elevated serum carcinoembryonic antigen levels FUT6 nearGene-3 24941225 rs12986368 chr19 5830922 C T 1.24E-39 Tumor biomarkers FUT6 UTR-3 23300138 rs778805 chr19 5832209 G A 1.28E-08 N-glycan levels,in plasma FUT6 missense 21908519 rs778805 chr19 5832209 G A 4.85E-08 N-glycan levels,in plasma FUT6 missense 21908519 rs778805 chr19 5832209 G A 5.53E-12 N-glycan levels,in plasma FUT6 missense 21908519 rs778805 chr19 5832209 G A 7.60E-58 Tumor biomarkers FUT6 missense 23300138 rs778805 chr19 5832209 G A 1.77E-08 Elevated serum carcinoembryonic antigen levels FUT6 missense 24941225 rs3916080 chr19 5832899 C A 4.82E-40 Tumor biomarkers FUT6 intron 23300138 rs17271883 chr19 5834212 C T 5.00E-132 Tumor biomarkers FUT6 intron 23300138 rs1678849 chr19 5836964 G A 2.45E-13 Tumor biomarkers FUT6 intron 23300138 rs8101385 chr19 5838595 C T 8.28E-08 Tumor biomarkers FUT6 intron 23300138 rs778798 chr19 5839613 A C 4.90E-09 Tumor biomarkers FUT6 UTR-5 23300138 rs3760776 chr19 5839746 G A 1.00E-12 N-glycan levels FUT6 nearGene-5 21203500 rs3760776 chr19 5839746 G A 3.00E-12 N-glycan levels FUT6 nearGene-5 21203500 rs3760776 chr19 5839746 G A 4.00E-17 N-glycan levels FUT6 nearGene-5 21203500 rs3760776 chr19 5839746 G A 9.00E-10 N-glycan levels FUT6 nearGene-5 21203500 rs3760776 chr19 5839746 G A 1.07E-16 N-glycan levels,in plasma FUT6 nearGene-5 21908519 rs3760776 chr19 5839746 G A 1.31E-08 N-glycan levels,in plasma FUT6 nearGene-5 21908519 rs3760776 chr19 5839746 G A 1.34E-21 N-glycan levels,in plasma FUT6 nearGene-5 21908519 rs3760776 chr19 5839746 G A 1.80E-09 N-glycan levels,in plasma FUT6 nearGene-5 21908519 rs3760776 chr19 5839746 G A 2.39E-13 N-glycan levels,in plasma FUT6 nearGene-5 21908519 rs3760776 chr19 5839746 G A 2.56E-14 N-glycan levels,in plasma FUT6 nearGene-5 21908519 rs3760776 chr19 5839746 G A 2.80E-20 N-glycan levels,in plasma FUT6 nearGene-5 21908519 rs3760776 chr19 5839746 G A 3.18E-29 N-glycan levels,in plasma FUT6 nearGene-5 21908519 rs3760776 chr19 5839746 G A 3.31E-12 N-glycan levels,in plasma FUT6 nearGene-5 21908519 rs3760776 chr19 5839746 G A 3.64E-09 N-glycan levels,in plasma FUT6 nearGene-5 21908519 rs3760776 chr19 5839746 G A 4.35E-13 N-glycan levels,in plasma FUT6 nearGene-5 21908519 rs3760776 chr19 5839746 G A 4.56E-19 N-glycan levels,in plasma FUT6 nearGene-5 21908519 rs3760776 chr19 5839746 G A 7.80E-10 N-glycan levels,in plasma FUT6 nearGene-5 21908519 rs3760776 chr19 5839746 G A 8.66E-17 N-glycan levels,in plasma FUT6 nearGene-5 21908519 rs3760776 chr19 5839746 G A 4.00E-13 Vitamin B12 levels FUT6 nearGene-5 22367966 rs3760776 chr19 5839746 G A 2.00E-56 Tumor biomarkers FUT6 nearGene-5 23300138 rs3760776 chr19 5839746 G A 2.06E-13 Elevated serum carcinoembryonic antigen levels FUT6 nearGene-5 24941225 rs3760775 chr19 5841356 G T 1.00E-35 Tumor biomarkers FUT6 nearGene-5 23300138 rs3760775 chr19 5841356 G T 3.00E-290 Tumor biomarkers FUT6 nearGene-5 23300138 rs3760775 chr19 5841356 G T 8.00E-19 Elevated serum carcinoembryonic antigen levels FUT6 nearGene-5 24941225 rs3760771 chr19 5842169 C A 2.59E-42 Tumor biomarkers / / 23300138 rs874232 chr19 5843609 T C 3.60E-29 Tumor biomarkers FUT3 UTR-3 23300138 rs28362458 chr19 5844838 C T 0.00000219 HDL cholesterol FUT3 missense 23063622 rs28362458 chr19 5844838 C T 5.89E-08 LDL cholesterol FUT3 missense 23063622 rs28362458 chr19 5844838 C T 7.11E-11 Cholesterol,total FUT3 missense 23063622 rs2561796 chr19 5847079 C A 7.25E-39 Tumor biomarkers FUT3 intron 23300138 rs11673407 chr19 5851336 A G 1.06E-14 Tumor biomarkers FUT3 intron 23300138 rs2306969 chr19 5851801 A G 1.22E-22 Tumor biomarkers FUT3 nearGene-5 23300138 rs2306969 chr19 5851801 A G 3.00E-08 Elevated serum carcinoembryonic antigen levels FUT3 nearGene-5 24941225 rs1674159 chr19 5886732 T C 5.20E-04 Longevity / / 22279548 rs778800 chr19 5900247 T C 2.08E-04 Menopause (age at onset) NDUFA11 intron 22267201 rs420458 chr19 5909780 T C 7.51E-04 Response to cytidine analogues (gemcitabine) VMAC UTR-3 24483146 rs274793 chr19 5928185 T C 2.20E-04 Obesity,menopause RANBP3 intron 21424828 rs12462305 chr19 5936689 G A 4.32E-05 Type 2 diabetes RANBP3 intron 17463246 rs10407413 chr19 5947871 A G 3.78E-05 Bipolar disorder RANBP3 intron 17486107 rs4807826 chr19 5954162 A C 1.80E-05 Amyotrophic lateral sclerosis (sporadic) RANBP3 intron 24529757 rs12986266 chr19 5998890 T G 6.66E-04 Type 2 diabetes RFX2 intron 17463246 rs1865028 chr19 6015066 T C 1.70E-04 Coronary heart disease RFX2 intron 21966275 rs7254081 chr19 6028227 C A 0.00059 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines RFX2 intron 23204130 rs673153 chr19 6033976 T C 7.88E-04 Schizophrenia RFX2 intron 19197363 rs673153 chr19 6033976 T C 3.35E-04 B cell non-Hodgkin lymphoma RFX2 intron 23749188 rs2288846 chr19 6042059 C T 4.42E-04 Response to statin treatment (atorvastatin),change in cholesterol levels RFX2 missense 20031582 rs2288846 chr19 6042059 C T 9.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) RFX2 missense 23648065 rs574937 chr19 6068553 C G 4.57E-04 Type 2 diabetes RFX2 intron 17463246 rs574937 chr19 6068553 C G 3.73E-05 Alzheimer's disease RFX2 intron 17998437 rs10401349 chr19 6075713 G A 3.55E-06 Bipolar disorder and schizophrenia RFX2 intron 20889312 rs637094 chr19 6077059 A G 6.58E-05 Post-operative nausea and vomiting RFX2 intron 21694509 rs11880706 chr19 6080482 C G 2.00E-06 Bipolar disorder and schizophrenia RFX2 intron 20889312 rs11666200 chr19 6084992 C T 2.29E-04 Alzheimer's disease RFX2 intron 17998437 rs17304450 chr19 6095431 G A 8.34E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) RFX2 intron 23648065 rs11670606 chr19 6096400 T C 5.20E-04 Type 2 diabetes RFX2 intron 17463246 rs11670606 chr19 6096400 T C 3.02E-04 Alzheimer's disease RFX2 intron 17998437 rs10411815 chr19 6102181 T C 5.50E-06 Bipolar disorder and schizophrenia RFX2 intron 20889312 rs10405147 chr19 6102780 G T 4.57E-06 Bipolar disorder and schizophrenia RFX2 intron 20889312 rs74980839 chr19 6147676 C A 0.00039 Prostate cancer ACSBG2 missense 23555315 rs148118752 chr19 6147939 AT A 6.53E-05 Multiple complex diseases ACSBG2 intron 17554300 rs8112226 chr19 6147939 A T 6.53E-05 Multiple complex diseases ACSBG2 intron 17554300 rs9304930 chr19 6158492 T C 3.73E-04 Fibrinogen ACSBG2 intron 17255346 rs10425093 chr19 6205825 G A 0.0008757 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10425093 chr19 6205825 G A 8.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6417192 chr19 6263495 G T 4.06E-04 Multiple complex diseases MLLT1 intron 17554300 rs1560694 chr19 6267827 A G 3.66E-04 Parkinson's disease MLLT1 intron 17052657 rs11085169 chr19 6300023 T C 9.64E-04 Acute lung injury / / 22295056 rs7260240 chr19 6320963 G A 1.98E-04 Prostate cancer ACER1 intron 23023329 rs1982082 chr19 6322442 C T 1.50E-05 Aging (time to event) ACER1 intron 21782286 rs2335192 chr19 6333290 T C 4.29E-06 Response to tocilizumab in rheumatoid arthritis ACER1 intron 22491018 rs8102597 chr19 6391219 A G 4.80E-05 Hypothyroidism GTF2F1 intron 22493691 rs6510896 chr19 6402648 T C 4.22E-05 Receptive language ability LOC390877 intron 24687471 rs3892396 chr19 6404507 A G 3.61E-04 Type 2 diabetes LOC390877 intron 17463246 rs1663803 chr19 6472247 A G 3.29E-04 Amyotrophic lateral sclerosis (sporadic) DENND1C intron 24529757 rs3745571 chr19 6475613 T C 8.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) DENND1C intron 23648065 rs3844450 chr19 6481459 A C 6.05E-05 Myopia (pathological) DENND1C intron 21095009 rs348337 chr19 6530656 T C 2.42E-05 Hypertension / / pha003042 rs348374 chr19 6547141 A G 1.41E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs348384 chr19 6552386 C T 1.16E-05 Blood Pressure and Arterial Stiffness / / 17903302 rs348384 chr19 6552386 C T 6.52E-05 ldl cholesterol / / pha003077 rs422981 chr19 6556778 A G 3.30E-05 Cognitive impairment induced by topiramate / / 22091778 rs348347 chr19 6564402 A G 7.05E-04 Stroke / / pha002886 rs11666589 chr19 6594602 T C 4.84E-04 Obesity (extreme) / / 21935397 rs168259 chr19 6595779 G A 4.74E-04 Obesity (extreme) / / 21935397 rs395909 chr19 6617161 A G 2.68E-06 Cognitive impairment induced by topiramate / / 22091778 rs454453 chr19 6645695 C T 3.90E-04 Multiple sclerosis / / 17660530 rs390821 chr19 6645759 A G 6.14E-05 Multiple sclerosis / / 17660530 rs1077667 chr19 6668972 C T 9.00E-14 Multiple sclerosis TNFSF14 intron 21833088 rs1077667 chr19 6668972 C T 1.00E-05 Attention deficit hyperactivity disorder (combined symptoms) TNFSF14 intron 23527680 rs344555 chr19 6679360 T C 0.0000622 HDL cholesterol C3 intron 23063622 rs344550 chr19 6682953 C G 0.0000712 HDL cholesterol C3 intron 23063622 rs2241392 chr19 6685983 G C 2.69E-04 Response to platinum-based chemotherapy in small-cell lung cancer C3 intron 20463552 rs11569536 chr19 6686089 G A 4.05E-04 Multiple complex diseases C3 intron 17554300 rs11569523 chr19 6689042 C T 4.44E-05 Brain derived neurotrophic factor levels,in serum C3 intron 22047184 rs3745567 chr19 6690771 C T 2.00E-09 Complement C3 and C4 levels C3 intron 23028341 rs432001 chr19 6693683 A G 3.46E-06 Age-related macular degeneration C3 intron pha002869 rs432001 chr19 6693683 A G 1.40E-05 Age-related macular degeneration C3 intron pha002890 rs423490 chr19 6697406 A G 0.000295 Salmonella-induced pyroptosis C3 cds-synon 22837397 rs11569471 chr19 6697590 G A 1.63E-08 Triglycerides C3 intron 23063622 rs366510 chr19 6697829 G T 0.0000786 Salmonella-induced pyroptosis C3 intron 22837397 rs445750 chr19 6701513 G A 2.10E-05 Urinary metabolites C3 intron 21572414 rs445750 chr19 6701513 G A 0.0000705 Salmonella-induced pyroptosis C3 intron 22837397 rs433594 chr19 6702042 A G 0.000061 Salmonella-induced pyroptosis C3 intron 22837397 rs406514 chr19 6702598 G A 0.000334 Salmonella-induced pyroptosis C3 intron 22837397 rs451760 chr19 6703072 G A 2.60E-05 Urinary metabolites C3 intron 21572414 rs11569441 chr19 6705113 A G 5.36E-09 Triglycerides C3 intron 23063622 rs11672613 chr19 6705246 T C 8.76E-05 Cholesterol C3 intron pha003073 rs11672613 chr19 6705246 T C 7.03E-05 Cholesterol C3 intron pha003078 rs11569440 chr19 6706296 G A 1.23E-08 Triglycerides C3 intron 23063622 rs2230199 chr19 6718387 G C 1.00E-10 Age-related macular degeneration C3 missense 20385819 rs2230199 chr19 6718387 G C 2.00E-08 Age-related macular degeneration C3 missense 20385826 rs2230199 chr19 6718387 G C 1.00E-08 Age-related macular degeneration C3 missense 20861866 rs2230199 chr19 6718387 G C 4.89E-05 Age-related macular degeneration C3 missense 21197116 rs2230199 chr19 6718387 G C 5.00E-29 Age-related macular degeneration C3 missense 21665990 rs2230199 chr19 6718387 G C 1.00E-12 Age-related macular degeneration (CNV) C3 missense 22705344 rs2230199 chr19 6718387 G C 5.00E-13 Age-related macular degeneration (GA) C3 missense 22705344 rs2230199 chr19 6718387 G C 1.00E-41 Age-related macular degeneration C3 missense 23455636 rs2250656 chr19 6718534 T C 3.89E-08 Age-related macular degeneration C3 intron pha002869 rs2250656 chr19 6718534 T C 1.26E-07 Age-related macular degeneration C3 intron pha002890 rs11569397 chr19 6720301 A G 3.86E-04 Multiple complex diseases C3 intron 17554300 rs339394 chr19 6720628 G C 4.82E-10 Triglycerides C3 UTR-5 23063622 rs339392 chr19 6722022 G T 4.68E-04 Body mass index C3 nearGene-5 21701565 rs171094 chr19 6727365 G A 5.27E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs171094 chr19 6727365 G A 4.62E-04 Body mass index / / 21701565 rs171094 chr19 6727365 G A 1.39E-05 Age-related macular degeneration / / pha002890 rs339404 chr19 6745105 T C 0.000178 Height (Pygmy height) TRIP10 intron 22570615 rs2305806 chr19 6755007 T C 4.80E-07 Lymphocyte counts SH2D3A cds-synon 22286170 rs811292 chr19 6782052 G A 9.85E-05 Major depressive disorder (broad) VAV1 intron 20038947 rs479660 chr19 6782498 C T 9.94E-05 Major depressive disorder (broad) VAV1 intron 20038947 rs568259 chr19 6782574 C T 8.89E-05 Major depressive disorder (broad) VAV1 intron 20038947 rs2546143 chr19 6782701 G A 2.26E-05 Major depressive disorder (broad) VAV1 intron 20038947 rs691528 chr19 6786271 G A 9.74E-05 Major depressive disorder (broad) VAV1 intron 20038947 rs579371 chr19 6786503 G A 9.72E-05 Major depressive disorder (broad) VAV1 intron 20038947 rs659657 chr19 6788939 T C 9.08E-05 Major depressive disorder (broad) VAV1 intron 20038947 rs472835 chr19 6788979 C T 9.10E-05 Major depressive disorder (broad) VAV1 intron 20038947 rs2546124 chr19 6791475 G A 9.79E-05 Major depressive disorder (broad) VAV1 intron 20038947 rs2660485 chr19 6792286 T C 7.91E-05 Major depressive disorder (broad) VAV1 intron 20038947 rs2546128 chr19 6792315 A G 8.35E-05 Major depressive disorder (broad) VAV1 intron 20038947 rs2617809 chr19 6792843 T C 8.77E-05 Major depressive disorder (broad) VAV1 intron 20038947 rs2546129 chr19 6792868 A G 8.26E-05 Major depressive disorder (broad) VAV1 intron 20038947 rs2546131 chr19 6793829 T C 7.02E-05 Major depressive disorder (broad) VAV1 intron 20038947 rs2546132 chr19 6793918 G T 6.68E-05 Major depressive disorder (broad) VAV1 intron 20038947 rs2660487 chr19 6794942 G A 5.95E-05 Major depressive disorder (broad) VAV1 intron 20038947 rs2617815 chr19 6795147 A G 5.43E-05 Major depressive disorder (broad) VAV1 intron 20038947 rs2617816 chr19 6795389 A G 5.78E-05 Major depressive disorder (broad) VAV1 intron 20038947 rs4807900 chr19 6795472 G A 5.68E-05 Major depressive disorder (broad) VAV1 intron 20038947 rs332425 chr19 6801953 C A 0.0003872 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) VAV1 intron 23233654 rs332425 chr19 6801953 C A 3.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) VAV1 intron 23233662 rs332426 chr19 6801966 G A 0.0003814 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) VAV1 intron 23233654 rs332426 chr19 6801966 G A 3.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) VAV1 intron 23233662 rs12232870 chr19 6803250 G A 0.00000233 LDL cholesterol VAV1 intron 23063622 rs8108646 chr19 6806689 A G 2.04E-25 Narcolepsy VAV1 intron 19629137 rs12978597 chr19 6807732 T A 0.00000212 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) VAV1 intron 23233654 rs12978597 chr19 6807732 T A 2.12E-06 Methotrexate clearance (acute lymphoblastic leukemia) VAV1 intron 23233662 rs12710098 chr19 6808547 T G 0.00000203 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) VAV1 intron 23233654 rs12710098 chr19 6808547 T G 2.03E-06 Methotrexate clearance (acute lymphoblastic leukemia) VAV1 intron 23233662 rs12610223 chr19 6808656 G A 3.67E-05 Graves' disease VAV1 intron 21841780 rs12610223 chr19 6808656 G A 0.00000146 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) VAV1 intron 23233654 rs12610223 chr19 6808656 G A 1.46E-06 Methotrexate clearance (acute lymphoblastic leukemia) VAV1 intron 23233662 rs4807101 chr19 6815948 C T 1.06E-05 Alcohol dependence VAV1 intron 23089632 rs10419349 chr19 6836689 C T 4.36E-08 Triglycerides VAV1 intron 23063622 rs186715 chr19 6878136 T G 2.50E-05 Nicotine smoking / / 19268276 rs3826782 chr19 6887736 G A 5.00E-05 Cognitive performance EMR1 intron 19734545 rs3826782 chr19 6887736 G A 8.00E-07 Periodontitis EMR1 intron 23459936 rs673320 chr19 6909565 C A 4.75E-04 Alcohol dependence EMR1 intron 21314694 rs459998 chr19 6914530 T C 2.52E-04 Cocaine dependence EMR1 intron 23958962 rs459998 chr19 6914530 T C 8.64E-05 Cocaine dependence EMR1 intron 23958962 rs3895916 chr19 6927996 A G 6.42E-04 Heart Failure EMR1 intron pha002884 rs460375 chr19 6941161 G C 1.20E-05 Malaria / / 19465909 rs465543 chr19 6941867 G A 6.10E-05 Malaria / / 19465909 rs465543 chr19 6941867 G A 9.12E-05 Prostate cancer / / pha002878 rs7256163 chr19 6958134 A G 0.000113 Gains in maximal O2 uptake response EMR4P intron 21183627 rs460698 chr19 6961182 G A 9.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) EMR4P intron 17982456 rs252579 chr19 6972357 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs252579 chr19 6972357 C T 1.13E-05 Cognitive impairment induced by topiramate / / 22091778 rs4807918 chr19 6977118 C A 5.78E-04 Type 2 diabetes EMR4P intron 17463246 rs7260101 chr19 6977869 T G 6.19E-04 Type 2 diabetes EMR4P intron 17463246 rs7256969 chr19 6977924 A G 5.56E-04 Type 2 diabetes EMR4P intron 17463246 rs2035973 chr19 6980763 C T 4.61E-04 Type 2 diabetes EMR4P intron 17463246 rs1874002 chr19 6981885 T C 3.35E-04 Type 2 diabetes EMR4P intron 17463246 rs11878694 chr19 6996509 A G 8.51E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs11878694 chr19 6996509 A G 5.59E-06 Parkinson's disease / / 21738487 rs6510942 chr19 7011766 T C 3.61E-04 Type 2 diabetes / / 17463246 rs966591 chr19 7083629 A G 6.79E-04 Multiple complex diseases ZNF557 cds-synon 17554300 rs8110740 chr19 7083761 A G 4.67E-04 Multiple complex diseases ZNF557 UTR-3 17554300 rs6510944 chr19 7084307 T C 7.28E-04 Multiple complex diseases ZNF557 UTR-3 17554300 rs2352958 chr19 7084747 C T 4.14E-04 Multiple complex diseases ZNF557 UTR-3 17554300 rs768489 chr19 7085480 T G 5.03E-04 Multiple complex diseases ZNF557 UTR-3 17554300 rs34306118 chr19 7105830 T A 0.0000968 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs34488330 chr19 7105841 A C 0.0000981 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1864193 chr19 7114213 C A 2.27E-04 Alcohol dependence INSR UTR-3 21314694 rs1549616 chr19 7132570 T C 0.00021 Salmonella-induced pyroptosis INSR intron 22837397 rs11667110 chr19 7136609 C G 4.33E-04 Aortic root size INSR intron 21223598 rs16994200 chr19 7141871 G C 6.01E-04 Multiple complex diseases INSR intron 17554300 rs2059807 chr19 7166109 A G 1.00E-08 Polycystic ovary syndrome INSR intron 22885925 rs3815901 chr19 7166541 A G 0.0000833 Triglycerides INSR intron 23063622 rs2303672 chr19 7168405 T C 0.000000136 Triglycerides INSR intron 23063622 rs8112883 chr19 7179320 G T 0.00000476 Triglycerides INSR intron 23063622 rs8112883 chr19 7179320 G T 0.00000855 Triglycerides INSR intron 23063622 rs8108622 chr19 7182753 T A 2.50E-10 Height INSR intron 21194676 rs8108622 chr19 7182753 T A 5.00E-04 Height INSR intron 21194676 rs8108622 chr19 7182753 T A 5.60E-07 Height INSR intron 21194676 rs10500204 chr19 7182963 A C 5.60E-04 Alcohol dependence INSR intron 20201924 rs891088 chr19 7184762 A G 2.00E-12 Height INSR intron 20881960 rs2115386 chr19 7196565 C T 3.06E-04 Amyotrophic Lateral Sclerosis INSR intron 17827064 rs2115386 chr19 7196565 C T 3.00E-06 Diabetic retinopathy INSR intron 21441570 rs1035942 chr19 7199803 A G 1.00E-07 Urate levels INSR intron 23263486 rs2042902 chr19 7204470 G A 3.90E-05 Diabetic retinopathy INSR intron 21441570 rs12609995 chr19 7205937 A C 0.0000146 Triglycerides INSR intron 23063622 rs7508679 chr19 7222832 T C 9.95E-05 Type 2 diabetes INSR intron 17463246 rs7508679 chr19 7222832 T C 4.70E-05 Hypothyroidism INSR intron 22493691 rs4804416 chr19 7223848 T G 5.00E-06 Hypothyroidism INSR intron 22493691 rs4804416 chr19 7223848 T G 2.00E-06 Thyroid hormone levels INSR intron 23408906 rs4804416 chr19 7223848 T G 3.00E-10 Thyroid hormone levels INSR intron 23408906 rs7248104 chr19 7224431 G A 5.23E-04 Type 2 diabetes INSR intron 17463246 rs7248104 chr19 7224431 G A 6.60E-05 Hypothyroidism INSR intron 22493691 rs7248104 chr19 7224431 G A 5.00E-10 Triglycerides INSR intron 24097068 rs4804418 chr19 7226144 T C 0.0000671 Triglycerides INSR intron 23063622 rs4804424 chr19 7229677 A G 9.99E-04 Type 2 diabetes INSR intron 17463246 rs12460755 chr19 7231679 G A 0.000151438 Fasting insulin-related traits INSR intron 22885924 rs890862 chr19 7233604 T C 8.80E-04 Myocardial infarction INSR intron 21107343 rs4804103 chr19 7235389 C T 6.29E-04 Schizophrenia INSR intron 19197363 rs11673642 chr19 7284597 A T 6.56E-04 Obesity (extreme) INSR intron 21935397 rs6603096 chr19 7415723 G T 2.20E-05 Urinary metabolites / / 21572414 rs6603109 chr19 7424528 A T 2.00E-06 Sexual dysfunction (SSRI/SNRI-related) / / 22445761 rs9329383 chr19 7484741 A G 7.30E-05 Bone mineral density (spine) ARHGEF18 intron 19079262 rs4804602 chr19 7487313 G A 5.12E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) ARHGEF18 intron 23648065 rs11260076 chr19 7488671 A G 8.67E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) ARHGEF18 intron 23648065 rs8110645 chr19 7504404 C T 7.62E-05 Cleft lip ARHGEF18 intron 20436469 rs12610760 chr19 7516243 A G 8.90E-04 Alcohol dependence ARHGEF18 intron 20201924 rs2287919 chr19 7529415 C T 7.00E-04 Alcohol dependence ARHGEF18 intron 20201924 rs7245775 chr19 7536221 G A 3.74E-04 Multiple complex diseases ARHGEF18 UTR-3 17554300 rs484870 chr19 7569282 A G 1.00E-04 Upper aerodigestive tract cancers C19orf45 missense 21437268 rs4804662 chr19 7575408 A G 4.48E-05 Femoral neck bone geometry / / 22087292 rs604959 chr19 7599735 A C 2.31E-06 Common variable immunodeficiency PNPLA6 UTR-5 21497890 rs654059 chr19 7602421 T C 5.53E-05 Femoral neck bone geometry PNPLA6 intron 22087292 rs501580 chr19 7608428 A T 2.68E-04 Multiple complex diseases PNPLA6 intron 17554300 rs7250363 chr19 7615865 C T 2.24E-04 Multiple complex diseases PNPLA6 intron 17554300 rs7260296 chr19 7635689 C T 1.23E-09 Multiple complex diseases / / 17554300 rs4804750 chr19 7654988 T A 4.10E-06 Urinary metabolites / / 21572414 rs4134813 chr19 7694021 A C 1.47E-05 Lymphocyte counts XAB2 intron 22286170 rs3745367 chr19 7734511 G A 3.00E-06 Resistin levels RETN intron 22843503 rs1423096 chr19 7739177 T C 1.00E-07 Resistin levels / / 24123702 rs28364072 chr19 7755285 A G 1 Drug response to Budesonide FCER2 intron 17980418 rs28364072 chr19 7755285 A G 1 Drug response to Nedocromil FCER2 intron 17980418 rs1990975 chr19 7766274 T A,C,G 9.29E-04 Response to cytadine analogues (cytosine arabinoside) FCER2 intron 24483146 rs3760688 chr19 7768634 C T 1.82E-04 Suicide attempts in bipolar disorder FCER2 nearGene-5 21423239 rs11260025 chr19 7781753 T C 2.21E-05 Weight loss (gastric bypass surgery) / / 23643386 rs4804802 chr19 7807610 A G 5.57E-05 Hearing function CD209 UTR-3 17255346 rs17159889 chr19 7809631 C T 3.51E-04 Multiple complex diseases CD209 intron 17554300 rs868878 chr19 7831047 G A 9.27E-05 Melanoma CLEC4M missense 21926416 rs868875 chr19 7831166 A G 7.68E-05 Soluble levels of adhesion molecules CLEC4M intron pha003072 rs8113469 chr19 7832959 C T 6.77E-05 Major depressive disorder CLEC4M intron 21621269 rs3745376 chr19 7833690 G T 5.06E-04 Alcohol dependence CLEC4M intron 21314694 rs3745376 chr19 7833690 G T 6.72E-05 Caffeine consumption CLEC4M intron 21490707 rs807969 chr19 7838484 T G 1.10E-05 Triglycerides / / 19074352 rs653488 chr19 7840356 T C 3.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4239552 chr19 7848679 C T 2.96E-05 Coronary heart disease / / pha003031 rs4804233 chr19 7850017 A G 8.55E-04 Alzheimer's disease / / 17998437 rs558718 chr19 7909883 A G 4.00E-06 HIV-1 viral setpoint EVI5L intron 20205591 rs555609 chr19 7913974 T C 4.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EVI5L cds-synon 20877124 rs35672116 chr19 7991334 A G 6.40E-05 HIV-1 control / / 20041166 rs11542189 chr19 8000001 C T 6.40E-05 HIV-1 control TIMM44 cds-synon 20041166 rs4804837 chr19 8000601 C T 3.63E-05 Odorant perception TIMM44 intron 23910658 rs12972972 chr19 8012094 C T 4.00E-04 Acne (severe) / / 24927181 rs10426443 chr19 8111982 G A 8.37E-06 Osteoarthritis / / 22763110 rs1104768 chr19 8115720 T G 2.59E-04 Tourette syndrome / / 22889924 rs2032887 chr19 8121360 A G 1.23E-04 Amyotrophic lateral sclerosis CCL25 missense 20801718 rs1129763 chr19 8121369 C T 9.63E-04 Response to taxane treatment (placlitaxel) CCL25 missense 23006423 rs17160128 chr19 8132698 A G 6.32E-05 Fibrinogen FBN3 intron pha003068 rs17261689 chr19 8136027 T C 1.90E-05 Personality dimensions FBN3 intron 18957941 rs17160134 chr19 8137192 C T 1.40E-05 Personality dimensions FBN3 intron 18957941 rs4804061 chr19 8166377 T C 2.00E-08 Sphingolipid levels FBN3 intron 19798445 rs10411526 chr19 8172681 A G 7.55E-04 Alcohol dependence FBN3 intron 24277619 rs12460407 chr19 8181037 T C 2.66E-04 Cognitive decline FBN3 intron 23732972 rs3813777 chr19 8196222 T C 9.48E-05 Lung function (forced expiratory volume in 1 second) FBN3 intron pha003102 rs11260062 chr19 8214970 A C 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7250249 chr19 8250610 T C 7.34E-06 Hypertension / / pha003041 rs7258249 chr19 8271721 G A 2.00E-27 Sphingolipid levels / / 19798445 rs7258249 chr19 8271721 G A 1.00E-34 Sphingolipid levels / / 22359512 rs11666866 chr19 8285607 G A 6.66E-21 Sphingolipid levels CERS4 intron 19798445 rs1466448 chr19 8289519 C A 4.80E-25 Sphingolipid levels CERS4 intron 19798445 rs2967625 chr19 8298411 G A 3.42E-15 Sphingolipid levels CERS4 intron 19798445 rs1007545 chr19 8303705 G A 5.25E-04 Type 2 diabetes CERS4 intron 17463246 rs36253 chr19 8324893 T G 7.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CERS4 intron 20877124 rs28133 chr19 8327502 T C 4.90E-11 Sphingolipid levels / / 19798445 rs2278236 chr19 8431581 G A 0.000000646 HDL cholesterol ANGPTL4 intron 22629316 rs2278236 chr19 8431581 G A 0.000058 HDL cholesterol (female) ANGPTL4 intron 22629316 rs2278236 chr19 8431581 G A 0.00000134 HDL cholesterol ANGPTL4 intron 23063622 rs2278236 chr19 8431581 G A 4.24E-04 Myocardial Infarction ANGPTL4 intron pha002873 rs7255436 chr19 8433196 C A 3.00E-08 HDL cholesterol ANGPTL4 intron 20686565 rs7255436 chr19 8433196 C A 2.00E-08 HDL cholesterol ANGPTL4 intron 24097068 rs2967605 chr19 8469738 C T 1.00E-08 HDL cholesterol / / 19060906 rs2967605 chr19 8469738 C T 1.00E-08 Coronary heart disease / / 21347282 rs1133893 chr19 8486884 G A 1.92E-04 Lung function (forced expiratory volume in 1 second) MARCH2 missense 24023788 rs1133893 chr19 8486884 G A 2.05E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) MARCH2 missense 24023788 rs17160491 chr19 8512940 T G 2.60E-04 Response to taxane treatment (placlitaxel) HNRNPM intron 23006423 rs17160495 chr19 8516278 A T 3.09E-04 Response to taxane treatment (placlitaxel) HNRNPM intron 23006423 rs7508502 chr19 8525595 C T 3.93E-04 Multiple complex diseases HNRNPM intron 17554300 rs7408960 chr19 8542005 A G 1.78E-04 Multiple complex diseases HNRNPM intron 17554300 rs7259200 chr19 8543921 G A 1.87E-04 Suicide attempts in bipolar disorder HNRNPM intron 21423239 rs1599871 chr19 8548175 A C 4.15E-04 Suicide attempts in bipolar disorder HNRNPM intron 21423239 rs2277987 chr19 8552273 A G 5.96E-04 Response to taxane treatment (placlitaxel) HNRNPM intron 23006423 rs7507526 chr19 8553322 C T 7.14E-04 Suicide attempts in bipolar disorder HNRNPM intron 21423239 rs4239541 chr19 8564474 G A,C,T 0.00015 Prostate cancer (non-advanced prostate cancer) PRAM1 missense 23555315 rs4239541 chr19 8564474 G A,C,T 0.0002 Prostate cancer PRAM1 missense 23555315 rs10403336 chr19 8566880 C T 5.79E-04 Celiac disease PRAM1 intron 23936387 rs2287863 chr19 8579011 T C 1.90E-04 Amyotrophic Lateral Sclerosis ZNF414 UTR-5 17827064 rs1054623 chr19 8586086 C A 5.00E-04 Amyotrophic Lateral Sclerosis MYO1F UTR-3 17827064 rs10408143 chr19 8587782 T C 5.60E-04 Response to taxane treatment (placlitaxel) MYO1F intron 23006423 rs2303686 chr19 8615268 T C 9.84E-04 Coronary heart disease MYO1F intron 21971053 rs2303686 chr19 8615268 T C 3.48E-04 Lung function (forced vital capacity) MYO1F intron 24023788 rs4072910 chr19 8644031 G C 4.00E-13 Height / / 20881960 rs7249094 chr19 8672000 G A 1.00E-06 Height ADAMTS10 intron 18391951 rs2967721 chr19 8757835 A G 2.70E-05 Urinary metabolites / / 21572414 rs9305032 chr19 8783378 C T 6.01E-04 Multiple complex diseases / / 17554300 rs2164983 chr19 8789381 C A 7.00E-09 Atopic dermatitis / / 22197932 rs10410943 chr19 8808900 A C,G 4.30E-04 Type 2 diabetes ACTL9 missense 17460697 rs7259203 chr19 8811833 G C,T 1.59E-14 Familial hypercholesterolemia (LDL receptor mutation present) / / 22968135 rs7259203 chr19 8811833 G C,T 4.32E-11 Familial hypercholesterolemia / / 22968135 rs301407 chr19 8814892 T C 1.82E-05 Attention deficit hyperactivity disorder / / 23728934 rs301410 chr19 8815355 A G 6.56E-05 Attention deficit hyperactivity disorder / / 23728934 rs10412487 chr19 8973217 T C 5.81E-05 Alcohol dependence MUC16 intron 19581569 rs11085766 chr19 8999675 A C 9.64E-04 Heart Failure MUC16 intron pha002884 rs4804375 chr19 9005719 A G 1.30E-05 Urinary metabolites MUC16 cds-synon 21572414 rs1833777 chr19 9058907 G C 7.62E-04 Type 2 diabetes MUC16 missense 17463246 rs1867691 chr19 9065632 T C 4.43E-04 Type 2 diabetes MUC16 missense 17463246 rs1862458 chr19 9069792 G A 1.30E-04 Tourette syndrome MUC16 missense 22889924 rs1862460 chr19 9069892 A C 8.72E-05 Tourette syndrome MUC16 missense 22889924 rs2591591 chr19 9074950 G T 2.71E-04 Type 2 diabetes MUC16 missense 17463246 rs2547074 chr19 9076858 C T 2.71E-04 Type 2 diabetes MUC16 missense 17463246 rs2591595 chr19 9076991 C T 1.89E-04 Type 2 diabetes MUC16 cds-synon 17463246 rs1862461 chr19 9077264 T G 2.71E-04 Type 2 diabetes MUC16 cds-synon 17463246 rs1862462 chr19 9077436 G A 3.56E-04 Type 2 diabetes MUC16 missense 17463246 rs2431795 chr19 9078190 C T 2.60E-04 Type 2 diabetes MUC16 intron 17463246 rs2431791 chr19 9079464 G T 2.54E-04 Type 2 diabetes MUC16 intron 17463246 rs11085805 chr19 9085004 T C 1.87E-04 Tourette syndrome MUC16 missense 22889924 rs4520945 chr19 9086318 G A 4.95E-04 Tourette syndrome MUC16 missense 22889924 rs4239544 chr19 9097589 T C 5.87E-04 Tourette syndrome / / 22889924 rs6511838 chr19 9150838 T C 5.55E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4804397 chr19 9195068 G A 2.08E-04 Multiple complex diseases / / 17554300 rs2441035 chr19 9195598 T G 2.50E-04 Multiple complex diseases / / 17554300 rs2569402 chr19 9200017 A G 1.93E-04 Multiple complex diseases / / 17554300 rs2053074 chr19 9202085 A G 4.30E-04 Multiple complex diseases / / 17554300 rs2053074 chr19 9202085 A G 6.87E-05 Type 1 diabetes / / 18978792 rs2195951 chr19 9225685 T C 1.85E-05 Waist Circumference OR7G1 missense pha003025 rs118114660 chr19 9237457 G T 0.00045 Prostate cancer OR7G3 missense 23555315 rs714395 chr19 9246205 C T 9.24E-04 Lymphocyte counts / / 22286170 rs2033483 chr19 9254342 A G 6.51E-10 Familial hypercholesterolemia ZNF317 intron 22968135 rs12459040 chr19 9260637 T A 3.76E-04 Multiple complex diseases ZNF317 intron 17554300 rs1045354 chr19 9273300 C A 9.97E-04 Multiple complex diseases ZNF317 UTR-3 17554300 rs10405511 chr19 9295591 A G 1.55E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs61729907 chr19 9325252 G A 0.0000171 Perception of the odorant androstenone OR7D4 missense 22362865 rs8101575 chr19 9328662 C T 1.97E-04 Multiple complex diseases / / 17554300 rs12975784 chr19 9401159 C T 8.02E-06 Lymphocyte counts / / pha003094 rs12975784 chr19 9401159 C T 3.52E-05 Neutrophil count / / pha003095 rs13535 chr19 9454173 A G 8.83E-09 Lymphocyte counts ZNF559 UTR-3 22286170 rs11669550 chr19 9487592 T A 3.50E-06 Urinary metabolites ZNF177 intron 21572414 rs141562027 chr19 9578028 C T 0.00051 Prostate cancer ZNF560 missense 23555315 rs10422772 chr19 9723423 C T 1.41E-08 Familial hypercholesterolemia ZNF561 intron 22968135 rs10405652 chr19 9741123 G T 2.03E-08 Familial hypercholesterolemia LOC284385 intron 22968135 rs10411082 chr19 9741216 G A 4.51E-08 Familial hypercholesterolemia LOC284385 intron 22968135 rs10418705 chr19 9768925 A G 3.16E-08 Familial hypercholesterolemia ZNF562 intron 22968135 rs10417523 chr19 9820194 A C 1.87E-08 Familial hypercholesterolemia / / 22968135 rs2112837 chr19 9831184 A G 1.37E-05 Bipolar disorder / / 19488044 rs2112837 chr19 9831184 A G 5.59E-05 Bipolar Disorder / / pha002863 rs10401153 chr19 9861798 G C 8.60E-04 Multiple complex diseases / / 17554300 rs10415132 chr19 9863483 G A 2.08E-08 Familial hypercholesterolemia / / 22968135 rs7247038 chr19 9878695 T C 4.16E-08 Familial hypercholesterolemia ZNF846 intron 22968135 rs11556087 chr19 9968139 G A 1.50E-04 Response to cytadine analogues (cytosine arabinoside) OLFM2 missense 24483146 rs889122 chr19 9995867 G T 2.23E-04 Multiple complex diseases OLFM2 intron 17554300 rs1862471 chr19 10000322 C G 2.00E-07 Menarche (age at onset) OLFM2 intron 21102462 rs918539 chr19 10013840 G C 9.74E-05 Multiple complex diseases OLFM2 intron 17554300 rs8104943 chr19 10027470 T C 4.07E-04 Multiple complex diseases OLFM2 intron 17554300 rs2277968 chr19 10071669 C T 4.27E-05 Asthma COL5A3 intron 20159242 rs3745592 chr19 10106671 C G 5.52E-05 Schizophrenia COL5A3 intron 24043878 rs3745598 chr19 10109179 A G 1.20E-05 Urinary metabolites COL5A3 intron 21572414 rs2287802 chr19 10112688 A G 6.20E-05 Response to statin therapy COL5A3 intron 20339536 rs2287802 chr19 10112688 A G 4.00E-06 Upper aerodigestive tract cancers COL5A3 intron 21437268 rs2431820 chr19 10135284 T C 0.0000106 Familial hypercholesterolemia (LDL receptor mutation present) / / 22968135 rs2431820 chr19 10135284 T C 1.05E-10 Familial hypercholesterolemia / / 22968135 rs10401453 chr19 10137663 A G 5.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10401453 chr19 10137663 A G 4.30E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs8113341 chr19 10165932 A G 1.12E-04 IgE levels / / 17255346 rs10417403 chr19 10172516 T C 3.33E-08 Familial hypercholesterolemia / / 22968135 rs7255032 chr19 10194884 C T 5.53E-04 Multiple complex diseases / / 17554300 rs8109578 chr19 10213154 G A 4.00E-07 Protein quantitative trait loci ANGPTL6 intron 18464913 rs1551570 chr19 10218030 C T 2.00E-04 Cognitive impairment induced by topiramate PPAN intron 22091778 rs1551570 chr19 10218030 C T 4.00E-10 Narcolepsy PPAN intron 24204295 rs9305012 chr19 10260869 T C 8.52E-04 Atopy DNMT1 intron 21625490 rs9305012 chr19 10260869 T C 1.16E-05 Thiazide-induced adverse metabolic effects in hypertensive patients DNMT1 intron 23400010 rs2228611 chr19 10267077 T C 2.00E-04 Cognitive impairment induced by topiramate DNMT1 cds-synon 22091778 rs10423341 chr19 10267266 C A 6.54E-06 Thiazide-induced adverse metabolic effects in hypertensive patients DNMT1 intron 23400010 rs2241531 chr19 10271034 C G 9.69E-06 Thiazide-induced adverse metabolic effects in hypertensive patients DNMT1 intron 23400010 rs2162560 chr19 10279454 G A 1.00E-04 Cognitive impairment induced by topiramate DNMT1 intron 22091778 rs2162560 chr19 10279454 G A 1.00E-04 Cognitive impairment induced by topiramate DNMT1 intron 22091778 rs7253062 chr19 10295124 G A 3.75E-05 Cognitive impairment induced by topiramate DNMT1 intron 22091778 rs7253062 chr19 10295124 G A 4.18E-05 Cognitive impairment induced by topiramate DNMT1 intron 22091778 rs8112895 chr19 10305162 A G 5.39E-06 Thiazide-induced adverse metabolic effects in hypertensive patients DNMT1 intron 23400010 rs2116940 chr19 10310392 A G 3.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs16999714 chr19 10316450 A G 9.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs17291414 chr19 10317215 G A 3.91E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11085721 chr19 10317976 G C 6.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs10404517 chr19 10327893 T C 3.90E-15 Soluble ICAM-1 / / 21533024 rs10409243 chr19 10332988 C T 7.21E-04 Suicide attempts in bipolar disorder S1PR2 UTR-3 21423239 rs10409243 chr19 10332988 C T 5.00E-47 Soluble ICAM-1 S1PR2 UTR-3 21533024 rs10409243 chr19 10332988 C T 6.23E-07 LDL lipoproteins S1PR2 UTR-3 pha002902 rs2116941 chr19 10334443 A C 8.80E-37 Soluble ICAM-1 S1PR2 UTR-3 21533024 rs2288937 chr19 10340912 A G 1.10E-21 Soluble ICAM-1 S1PR2 intron 21533024 rs12610520 chr19 10349118 G A 2.68E-04 White matter integrity / / 22425255 rs12462481 chr19 10356432 G A 9.10E-11 Soluble ICAM-1 / / 21533024 rs12462481 chr19 10356432 G A 8.41E-04 White matter integrity / / 22425255 rs8111930 chr19 10368050 A G 8.80E-45 Soluble ICAM-1 MRPL4 intron 21533024 rs8111930 chr19 10368050 A G 8.69E-05 Atopy MRPL4 intron 21625490 rs11115 chr19 10370542 C T 9.01E-04 Type 2 diabetes MRPL4 UTR-3 22158537 rs1059849 chr19 10370654 A G 1.50E-17 Soluble ICAM-1 MRPL4 UTR-3 21533024 rs5030339 chr19 10380137 G A 2.59E-14 LDL cholesterol ICAM1 nearGene-5 23063622 rs5030339 chr19 10380137 G A 3.20E-24 HDL cholesterol ICAM1 nearGene-5 23063622 rs5030339 chr19 10380137 G A 5.11E-30 Cholesterol,total ICAM1 nearGene-5 23063622 rs5491 chr19 10385540 A T 1.50E-06 Health and aging,CVD and cancer age of onset ICAM1 missense 22174011 rs5491 chr19 10385540 A T 2.20E-49 Health and aging,CVD and cancer age of onset ICAM1 missense 22174011 rs5491 chr19 10385540 A T 2.70E-23 Health and aging,CVD and cancer age of onset ICAM1 missense 22174011 rs5491 chr19 10385540 A T 4.10E-13 Health and aging,CVD and cancer age of onset ICAM1 missense 22174011 rs5491 chr19 10385540 A T 4.50E-38 Health and aging,CVD and cancer age of onset ICAM1 missense 22174011 rs5491 chr19 10385540 A T 4.60E-17 Health and aging,CVD and cancer age of onset ICAM1 missense 22174011 rs5491 chr19 10385540 A T 5.00E-66 Health and aging,CVD and cancer age of onset ICAM1 missense 22174011 rs5030359 chr19 10388462 G A 0.0000302 LDL cholesterol (female) ICAM1 intron 22629316 rs5030359 chr19 10388462 G A 0.0000591 LDL cholesterol (male) ICAM1 intron 22629316 rs5030359 chr19 10388462 G A 1.24E-08 LDL cholesterol ICAM1 intron 22629316 rs5030359 chr19 10388462 G A 4.02E-08 LDL cholesterol ICAM1 intron 23236364 rs5030359 chr19 10388462 G A 5.22E-09 Cholesterol,total ICAM1 intron 23236364 rs5030392 chr19 10388477 C T 1.10E-15 Soluble ICAM-1 ICAM1 intron 21533024 rs5030361 chr19 10389509 C T 0.000000734 HDL cholesterol ICAM1 intron 23063622 rs5030361 chr19 10389509 C T 3.05E-23 LDL cholesterol ICAM1 intron 23063622 rs1799969 chr19 10394792 G A 4.00E-47 Soluble ICAM-1 ICAM1 missense 18604267 rs1799969 chr19 10394792 G A 1.00E-120 Soluble ICAM-1 ICAM1 missense 21533024 rs5498 chr19 10395683 A G 5.00E-25 Soluble ICAM-1 ICAM1 missense 18604267 rs5498 chr19 10395683 A G 6.00E-89 Soluble ICAM-1 ICAM1 missense 21533024 rs5030383 chr19 10396843 C T 9.40E-16 Triglycerides ICAM1 UTR-3 23063622 rs923366 chr19 10397223 C T 3.60E-83 Soluble ICAM-1 ICAM1 UTR-3 21533024 rs281437 chr19 10397238 C T 3.00E-10 Soluble ICAM-1 ICAM1 UTR-3 18604267 rs3093030 chr19 10397403 C T 4.00E-23 Soluble levels of adhesion molecules / / 20167578 rs3093030 chr19 10397403 C T 5.80E-84 Soluble ICAM-1 / / 21533024 rs2569693 chr19 10399904 C T 1.90E-37 Soluble ICAM-1 ICAM5 nearGene-5 21533024 rs281440 chr19 10400304 G A 1.60E-52 Soluble ICAM-1 ICAM5 nearGene-5 21533024 rs2075741 chr19 10401098 G C 4.60E-83 Soluble ICAM-1 ICAM5 intron 21533024 rs1056538 chr19 10402938 G A 1.00E-04 Breast cancer and prostate cancer ICAM5 missense 15604251 rs2228615 chr19 10403368 G A 7.50E-37 Soluble ICAM-1 ICAM5 missense 21533024 rs2569702 chr19 10403947 T C 2.06E-04 Multiple complex diseases ICAM5 intron 17554300 rs892188 chr19 10409793 C T 1.45E-04 Multiple complex diseases / / 17554300 rs2291473 chr19 10415781 T C 9.38E-05 Body Mass Index ZGLP1 missense pha003021 rs74956615 chr19 10427721 T A 5.21E-11 Rheumatoid arthritis RAVER1 UTR-3 23143596 rs3745264 chr19 10429566 C A 1.63E-04 Multiple complex diseases RAVER1 intron 17554300 rs3745264 chr19 10429566 C A 1.25E-10 Familial hypercholesterolemia (LDL receptor mutation present) RAVER1 intron 22968135 rs3745264 chr19 10429566 C A 6.00E-17 Familial hypercholesterolemia RAVER1 intron 22968135 rs281423 chr19 10435493 T C 2.40E-18 Soluble ICAM-1 RAVER1 intron 21533024 rs7507634 chr19 10436562 C T 1.36E-20 Familial hypercholesterolemia RAVER1 intron 22968135 rs7507634 chr19 10436562 C T 2.59E-18 Familial hypercholesterolemia (LDL receptor mutation present) RAVER1 intron 22968135 rs10410977 chr19 10443254 C A 6.75E-07 Personality dimensions RAVER1 intron 22628180 rs2230399 chr19 10444603 C G 4.40E-08 Soluble ICAM-1 ICAM3 missense 21533024 rs2278442 chr19 10444826 G A 2.70E-30 Soluble ICAM-1 ICAM3 intron 21533024 rs2278442 chr19 10444826 G A 1.20E-04 Multiple sclerosis ICAM3 intron 21833088 rs2304237 chr19 10446568 T C 4.10E-28 Soluble ICAM-1 ICAM3 missense 21533024 rs2304240 chr19 10449392 A G 2.21E-35 Familial hypercholesterolemia ICAM3 cds-synon 22968135 rs2304240 chr19 10449392 A G 2.59E-19 Familial hypercholesterolemia (LDL receptor mutation present) ICAM3 cds-synon 22968135 rs3176768 chr19 10449665 C T 1.45E-04 Multiple complex diseases ICAM3 intron 17554300 rs281414 chr19 10450285 G A 8.35E-04 Myopia (pathological) ICAM3 cds-synon 21095009 rs281414 chr19 10450285 G A 1.60E-14 Soluble ICAM-1 ICAM3 cds-synon 21533024 rs34536443 chr19 10463118 G C 1.23E-12 Primary biliary cirrhosis TYK2 missense 22961000 rs34536443 chr19 10463118 G C 9.10E-31 Psoriasis TYK2 missense 23143594 rs34536443 chr19 10463118 G C 1.57E-14 Rheumatoid arthritis TYK2 missense 23143596 rs34536443 chr19 10463118 G C 2.24E-14 Rheumatoid arthritis (CCP positive) TYK2 missense 23143596 rs34536443 chr19 10463118 G C 0.00000068 Oligoarticular juvenile idiopathic arthritis TYK2 missense 23603761 rs34536443 chr19 10463118 G C 0.00000941 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis TYK2 missense 23603761 rs34536443 chr19 10463118 G C 1.00E-10 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) TYK2 missense 23603761 rs34536443 chr19 10463118 G C 4.40E-16 Rheumatoid arthritis TYK2 missense 24390342 rs34536443 chr19 10463118 G C 5.00E-16 Rheumatoid arthritis TYK2 missense 24390342 rs12720356 chr19 10469975 A C 4.00E-11 Psoriasis TYK2 missense 20953190 rs12720356 chr19 10469975 A C 1.00E-12 Crohn's disease TYK2 missense 21102463 rs12720356 chr19 10469975 A C 0.0000122 Rheumatoid arthritis TYK2 missense 23143596 rs280519 chr19 10472933 A G 4.00E-09 Psoriasis TYK2 intron 20953190 rs280519 chr19 10472933 A G 1.78E-08 Familial hypercholesterolemia TYK2 intron 22968135 rs2304256 chr19 10475652 C A 4.00E-09 Type 1 diabetes TYK2 missense 19966805 rs2304256 chr19 10475652 C A 1.80E-09 Soluble ICAM-1 TYK2 missense 21533024 rs2304256 chr19 10475652 C A 1.00E-10 Type 1 diabetes autoantibodies TYK2 missense 21829393 rs2304256 chr19 10475652 C A 6.08E-09 Primary biliary cirrhosis TYK2 missense 22961000 rs7254474 chr19 10509365 A G 9.10E-05 Parkinson's disease (familial) CDC37 intron 18985386 rs7254474 chr19 10509365 A G 4.20E-16 Soluble ICAM-1 CDC37 intron 21533024 rs11879191 chr19 10512911 G A 2.00E-18 Inflammatory bowel disease CDC37 intron 23128233 rs8112449 chr19 10520064 G A 9.04E-05 Multiple complex diseases / / 17554300 rs8112449 chr19 10520064 G A 1.00E-06 Multiple sclerosis / / 21833088 rs8112449 chr19 10520064 G A 3.63E-08 Familial hypercholesterolemia / / 22968135 rs11878850 chr19 10542610 T C 8.70E-13 Soluble ICAM-1 PDE4A intron 21533024 rs11878850 chr19 10542610 T C 1.71E-05 Coronary heart disease PDE4A intron pha003056 rs11670504 chr19 10546771 A G 3.34E-04 Multiple complex diseases PDE4A intron 17554300 rs1051738 chr19 10577843 C A 1.60E-12 Soluble ICAM-1 PDE4A missense 21533024 rs1051738 chr19 10577843 C A 1.34E-05 Type 1 diabetes PDE4A missense 21980299 rs7256672 chr19 10579474 T G 2.10E-24 Soluble ICAM-1 PDE4A UTR-3 21533024 rs7256672 chr19 10579474 T G 1.14E-08 Familial hypercholesterolemia PDE4A UTR-3 22968135 rs9676881 chr19 10596780 G A 9.12E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs11668429 chr19 10616303 T G 4.00E-04 Myasthenia gravis / / 23055271 rs35754357 chr19 10621108 G GA 1.60E-08 Soluble ICAM-1 / / 21533024 rs7246953 chr19 10621108 G A 1.60E-08 Soluble ICAM-1 / / 21533024 rs7251213 chr19 10640380 A G 4.09E-05 Type 2 diabetes / / 17463246 rs7251213 chr19 10640380 A G 2.38E-06 Lipid traits / / 24023261 rs7251213 chr19 10640380 A G 2.91E-05 Lipid traits / / 24023261 rs10439163 chr19 10645495 A G 6.32E-05 Type 2 diabetes / / 17463246 rs10439163 chr19 10645495 A G 2.37E-06 Lipid traits / / 24023261 rs4371270 chr19 10651171 G A 9.04E-05 Body Mass Index / / pha003014 rs4371270 chr19 10651171 G A 4.60E-05 Waist Circumference / / pha003024 rs2360750 chr19 10656442 G C 6.33E-04 Type 2 diabetes ATG4D intron 17463246 rs6511703 chr19 10666450 T C 7.32E-04 Type 2 diabetes KRI1 intron 17463246 rs1982074 chr19 10668673 A G 8.83E-05 Waist Circumference KRI1 missense pha003024 rs1465701 chr19 10678842 T C 7.17E-05 Body Mass Index CDKN2D intron pha003014 rs1465701 chr19 10678842 T C 6.99E-05 Waist Circumference CDKN2D intron pha003024 rs10403668 chr19 10686123 G A 8.26E-05 Lipoprotein-associated phospholipase A2 activity and mass AP1M2 intron 20442857 rs12983573 chr19 10701833 T C 5.61E-05 Serum metabolites / / 19043545 rs2288904 chr19 10742170 A G 1.45E-05 Myopia (pathological) SLC44A2 missense 23049088 rs10405617 chr19 10752968 A G 5.07E-05 Cognitive test performance SLC44A2 intron 20125193 rs2569512 chr19 10790162 T C 5.40E-14 Progranulin levels ILF3 intron 21087763 rs2569512 chr19 10790162 T C 5.40E-14 Myocardial infarction ILF3 intron 21211798 rs2569507 chr19 10798904 G A 1.80E-05 Psoriasis ILF3 intron 20953189 rs2569507 chr19 10798904 G A 7.00E-06 Obesity-related traits ILF3 intron 23251661 rs13465 chr19 10802792 A G 6.37E-04 Type 2 diabetes ILF3 UTR-3 17463246 rs13465 chr19 10802792 A G 1.11E-12 LDL cholesterol ILF3 UTR-3 23063622 rs13465 chr19 10802792 A G 5.01E-12 Cholesterol,total ILF3 UTR-3 23063622 rs13465 chr19 10802792 A G 0.00037 Coronary artery calcification ILF3 UTR-3 23727086 rs892085 chr19 10818092 G A 3.00E-17 Psoriasis QTRT1 intron 23143594 rs11672431 chr19 10823940 G T 7.39E-05 Cognitive performance QTRT1 cds-synon 19734545 rs11671653 chr19 10838486 G A 4.60E-05 Personality dimensions DNM2 intron 18957941 rs11671653 chr19 10838486 G A 9.00E-07 Coronary heart disease DNM2 intron 21347282 rs1560734 chr19 10841049 T C 4.60E-05 Personality dimensions DNM2 intron 18957941 rs11881315 chr19 10909953 C T 3.05E-06 LDL lipoproteins DNM2 intron pha002902 rs17265047 chr19 10913354 C G 4.27E-04 Type 2 diabetes DNM2 intron 17463246 rs17265047 chr19 10913354 C G 5.50E-04 Lipid levels DNM2 intron 18193043 rs11085748 chr19 10927540 T C 3.73E-04 Type 2 diabetes DNM2 intron 17463246 rs11085749 chr19 10961273 G A 3.56E-05 LDL lipoproteins C19orf38 intron pha002902 rs11878377 chr19 10965270 C T 7.51E-05 Eosinophil counts C19orf38 intron pha003088 rs1541596 chr19 10987013 A G 9.43E-05 Rheumatoid arthritis CARM1 intron 21452313 rs1541596 chr19 10987013 A G 8.97E-05 LDL lipoproteins CARM1 intron pha002902 rs1549926 chr19 11002862 A C 7.05E-05 Eosinophil counts CARM1 intron pha003088 rs1529711 chr19 11023434 C T 1.52E-13 Familial hypercholesterolemia (LDL receptor mutation present) CARM1 intron 22968135 rs1529711 chr19 11023434 C T 8.58E-12 Familial hypercholesterolemia CARM1 intron 22968135 rs11085752 chr19 11065409 A C 3.00E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs11879293 chr19 11072610 G A 3.54E-04 Myocardial Infarction SMARCA4 intron pha002883 rs11879293 chr19 11072610 G A 7.54E-05 LDL lipoproteins SMARCA4 intron pha002902 rs12610607 chr19 11084994 A G 5.00E-05 Eosinophil counts SMARCA4 intron pha003088 rs11669133 chr19 11092139 G A 1.00E-08 Coronary heart disease SMARCA4 intron 21347282 rs2075022 chr19 11136315 C T 1.38E-06 Lipoprotein-associated phospholipase A2 activity and mass SMARCA4 intron 20442857 rs4804561 chr19 11140144 A G 2.40E-05 Eosinophil counts SMARCA4 intron pha003088 rs12052201 chr19 11159096 G T 7.77E-04 Multiple complex diseases SMARCA4 intron 17554300 rs12052058 chr19 11159525 G T 7.62E-04 Multiple complex diseases SMARCA4 intron 17554300 rs1529729 chr19 11163562 C T 6.14E-04 Coronary Artery Disease SMARCA4 intron 17634449 rs1529729 chr19 11163562 C T 4.52E-08 Lipid levels SMARCA4 intron 19913121 rs1529729 chr19 11163562 C T 6.74E-05 Lipoprotein-associated phospholipase A2 activity and mass SMARCA4 intron 20442857 rs1529729 chr19 11163562 C T 3.06E-06 Cardiovascular disease risk factors SMARCA4 intron 21239051 rs1529729 chr19 11163562 C T 1.10E-10 Soluble ICAM-1 SMARCA4 intron 21533024 rs1529729 chr19 11163562 C T 3.39E-11 Cholesterol,total SMARCA4 intron 23063622 rs1529729 chr19 11163562 C T 5.64E-11 LDL cholesterol SMARCA4 intron 23063622 rs1122608 chr19 11163601 G T 7.94E-04 Type 2 diabetes SMARCA4 intron 17463246 rs1122608 chr19 11163601 G T 4.40E-04 Multiple complex diseases SMARCA4 intron 17554300 rs1122608 chr19 11163601 G T 2.00E-09 Myocardial infarction (early onset) SMARCA4 intron 19198609 rs1122608 chr19 11163601 G T 3.18E-05 Cardiovascular disease risk factors SMARCA4 intron 21239051 rs1122608 chr19 11163601 G T 2.00E-09 Coronary heart disease SMARCA4 intron 21347282 rs1122608 chr19 11163601 G T 1.00E-09 Coronary heart disease SMARCA4 intron 21378990 rs1122608 chr19 11163601 G T 9.73E-10 Pericardial fat SMARCA4 intron 22589742 rs1122608 chr19 11163601 G T 0.0000007 Coronary artery disease (CAD) age >50 SMARCA4 intron 23202125 rs1122608 chr19 11163601 G T 1.24E-33 LDL cholesterol SMARCA4 intron 23202125 rs1122608 chr19 11163601 G T 2.70E-09 Coronary artery disease (CAD) age <=50 SMARCA4 intron 23202125 rs1122608 chr19 11163601 G T 4.52E-10 Coronary artery disease (CAD) (males) SMARCA4 intron 23202125 rs1122608 chr19 11163601 G T 4.59E-26 Cholesterol,total SMARCA4 intron 23202125 rs1122608 chr19 11163601 G T 5.39E-08 Coronary artery disease with myocardial infarction SMARCA4 intron 23202125 rs1122608 chr19 11163601 G T 2.00E-11 Coronary artery disease or large artery stroke SMARCA4 intron 24262325 rs1122608 chr19 11163601 G T 3.00E-11 Coronary artery disease SMARCA4 intron 24262325 rs1122608 chr19 11163601 G T 3.00E-12 Coronary artery disease or ischemic stroke SMARCA4 intron 24262325 rs10415811 chr19 11177408 T C 7.20E-04 Coronary heart disease / / 21606135 rs73013202 chr19 11179709 C G 7.15E-07 Coronary heart disease / / 22319020 rs10423733 chr19 11185919 T C 2.65E-11 Metabolite levels / / 22286219 rs55997232 chr19 11188117 C T 2.00E-12 Metabolite levels / / 22286219 rs55791371 chr19 11188153 A C 8.00E-17 Lipid metabolism phenotypes / / 22286219 rs56125973 chr19 11188164 T C 4.97E-16 Metabolite levels / / 22286219 rs56289821 chr19 11188247 G A 1.07E-10 Metabolite levels / / 22286219 rs189596789 chr19 11189620 G A 4.98E-08 Menopause (age at onset) / / 23424626 rs61194703 chr19 11192193 A T 4.77E-16 Metabolite levels / / 22286219 rs11668477 chr19 11195030 A G 1.50E-08 LDL cholesterol / / 18262040 rs11668477 chr19 11195030 A G 2.00E-07 LDL cholesterol / / 19060910 rs11668477 chr19 11195030 A G 2.74E-22 Triglycerides / / 19060911 rs11668477 chr19 11195030 A G 1.60E-12 Lipid levels / / 19802338 rs11668477 chr19 11195030 A G 2.40E-14 Lipid levels / / 19802338 rs11668477 chr19 11195030 A G 2.00E-07 Coronary heart disease / / 21347282 rs11668477 chr19 11195030 A G 3.23E-08 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs11668477 chr19 11195030 A G 4.51E-11 Metabolite levels / / 22286219 rs11668477 chr19 11195030 A G 2.10E-07 Infantile hypertrophic pyloric stenosis / / 22306654 rs11668477 chr19 11195030 A G 1.51E-07 LDL lipoproteins / / pha002902 rs11668477 chr19 11195030 A G 9.13E-05 Waist-Hip Ratio / / pha003029 rs11668477 chr19 11195030 A G 7.39E-05 ldl cholesterol / / pha003076 rs8106503 chr19 11196886 T C 9.10E-11 Metabolite levels / / 22286219 rs17248720 chr19 11198187 C T 2.10E-15 Lipid levels LDLR nearGene-5 19913121 rs17248720 chr19 11198187 C T 7.86E-25 Lipid levels LDLR nearGene-5 19913121 rs17248720 chr19 11198187 C T 9.41E-11 Metabolite levels LDLR nearGene-5 22286219 rs17248720 chr19 11198187 C T 1.69E-70 Cholesterol,total LDLR nearGene-5 23063622 rs17248720 chr19 11198187 C T 5.14E-72 LDL cholesterol LDLR nearGene-5 23063622 rs17248720 chr19 11198187 C T 7.13E-10 LDL cholesterol LDLR nearGene-5 23236364 rs17249141 chr19 11200008 C T 2.00E-17 LDL cholesterol LDLR nearGene-5 23726366 rs17249141 chr19 11200008 C T 2.43E-17 LDL cholesterol LDLR nearGene-5 23726366 rs6511720 chr19 11202306 G T 2.67E-04 Cholesterol LDLR intron 17255346 rs6511720 chr19 11202306 G T 4.00E-26 LDL cholesterol LDLR intron 18193043 rs6511720 chr19 11202306 G T 2.00E-51 LDL cholesterol LDLR intron 18193044 rs6511720 chr19 11202306 G T 2.00E-26 LDL cholesterol LDLR intron 19060906 rs6511720 chr19 11202306 G T 6.84E-18 Triglycerides LDLR intron 19060911 rs6511720 chr19 11202306 G T 5.20E-15 Lipid levels LDLR intron 19802338 rs6511720 chr19 11202306 G T 7.00E-18 Lipid levels LDLR intron 19802338 rs6511720 chr19 11202306 G T 6.77E-15 Lipid levels LDLR intron 19913121 rs6511720 chr19 11202306 G T 7.30E-24 Lipid levels LDLR intron 19913121 rs6511720 chr19 11202306 G T 1.49E-25 Lipid levels LDLR intron 19936222 rs6511720 chr19 11202306 G T 1.60E-10 Lipid levels LDLR intron 19936222 rs6511720 chr19 11202306 G T 1.88E-13 Lipid levels LDLR intron 19936222 rs6511720 chr19 11202306 G T 1.90E-08 Lipid levels LDLR intron 19936222 rs6511720 chr19 11202306 G T 2.09E-09 Lipid levels LDLR intron 19936222 rs6511720 chr19 11202306 G T 2.27E-31 Lipid levels LDLR intron 19936222 rs6511720 chr19 11202306 G T 2.77E-18 Lipid levels LDLR intron 19936222 rs6511720 chr19 11202306 G T 2.96E-12 Lipid levels LDLR intron 19936222 rs6511720 chr19 11202306 G T 4.27E-15 Lipid levels LDLR intron 19936222 rs6511720 chr19 11202306 G T 4.80E-25 Lipid levels LDLR intron 19936222 rs6511720 chr19 11202306 G T 2.80E-05 Response to statin therapy LDLR intron 20339536 rs6511720 chr19 11202306 G T 4.00E-117 LDL cholesterol LDLR intron 20686565 rs6511720 chr19 11202306 G T 7.00E-97 Cholesterol,total LDLR intron 20686565 rs6511720 chr19 11202306 G T 2.00E-51 Coronary heart disease LDLR intron 21347282 rs6511720 chr19 11202306 G T 1.00E-07 Carotid intima media thickness LDLR intron 21909108 rs6511720 chr19 11202306 G T 5.00E-11 Cardiovascular disease risk factors LDLR intron 21943158 rs6511720 chr19 11202306 G T 1.10E-08 Coronary heart disease LDLR intron 21966275 rs6511720 chr19 11202306 G T 5.20E-15 LDL cholesterol LDLR intron 21977987 rs6511720 chr19 11202306 G T 3.00E-11 Lipoprotein-associated phospholipase A2 activity and mass LDLR intron 22003152 rs6511720 chr19 11202306 G T 5.20E-30 Metabolic syndrome phenotype LDLR intron 22022282 rs6511720 chr19 11202306 G T 8.30E-28 Metabolic syndrome phenotype LDLR intron 22022282 rs6511720 chr19 11202306 G T 1.34E-14 Metabolite levels LDLR intron 22286219 rs6511720 chr19 11202306 G T 1.38E-49 LDL cholesterol LDLR intron 22629316 rs6511720 chr19 11202306 G T 3.07E-25 LDL cholesterol (male) LDLR intron 22629316 rs6511720 chr19 11202306 G T 7.51E-29 LDL cholesterol (female) LDLR intron 22629316 rs6511720 chr19 11202306 G T 4.00E-09 Metabolite levels (atherosclerosis) LDLR intron 22916037 rs6511720 chr19 11202306 G T 1.27E-79 LDL cholesterol LDLR intron 23063622 rs6511720 chr19 11202306 G T 1.73E-71 Cholesterol,total LDLR intron 23063622 rs6511720 chr19 11202306 G T 0.00000014 Apolipoprotein B levels response after 40mg daily simvastatin treatment LDLR intron 23100282 rs6511720 chr19 11202306 G T 0.00000043 LDL cholesterol response after 40mg daily simvastatin treatment LDLR intron 23100282 rs6511720 chr19 11202306 G T 3.80E-25 LDL cholesterol LDLR intron 23100282 rs6511720 chr19 11202306 G T 4.10E-27 Apolipoprotein B levels LDLR intron 23100282 rs6511720 chr19 11202306 G T 3.80E-25 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) LDLR intron 23103227 rs6511720 chr19 11202306 G T 1.79E-16 Cholesterol,total LDLR intron 23236364 rs6511720 chr19 11202306 G T 2.56E-17 LDL cholesterol LDLR intron 23236364 rs6511720 chr19 11202306 G T 2.00E-10 Abdominal aortic aneurysm LDLR intron 24046328 rs6511720 chr19 11202306 G T 3.00E-115 LDL cholesterol LDLR intron 24097068 rs6511720 chr19 11202306 G T 4.00E-262 LDL cholesterol LDLR intron 24097068 rs6511720 chr19 11202306 G T 5.00E-202 Cholesterol,total LDLR intron 24097068 rs17242787 chr19 11202460 T A 2.19E-09 LDL cholesterol LDLR intron 22629316 rs17242787 chr19 11202460 T A 0.000000176 LDL cholesterol LDLR intron 23236364 rs17242787 chr19 11202460 T A 4.67E-09 Cholesterol,total LDLR intron 23236364 rs8102912 chr19 11205975 G A 1.26E-06 Lipid levels LDLR intron 19913121 rs8102912 chr19 11205975 G A 2.24E-11 Lipid levels LDLR intron 19913121 rs8102912 chr19 11205975 G A 1.09E-26 Cholesterol,total LDLR intron 23063622 rs8102912 chr19 11205975 G A 2.90E-26 LDL cholesterol LDLR intron 23063622 rs8110695 chr19 11206530 T A,C 1.12E-08 Lipid levels LDLR intron 19913121 rs8110695 chr19 11206530 T A,C 2.77E-05 Lipid levels LDLR intron 19913121 rs8110695 chr19 11206530 T A,C 4.46E-19 LDL cholesterol LDLR intron 23063622 rs8110695 chr19 11206530 T A,C 6.59E-16 Cholesterol,total LDLR intron 23063622 rs6511721 chr19 11206575 G A 4.30E-12 LDL cholesterol LDLR intron 23063622 rs6511721 chr19 11206575 G A 4.53E-12 Cholesterol,total LDLR intron 23063622 rs17242381 chr19 11206729 T C 5.93E-14 Metabolite levels LDLR intron 22286219 rs17242395 chr19 11206969 G A 7.81E-13 Metabolite levels LDLR intron 22286219 rs17248769 chr19 11209576 G A 3.59E-13 Metabolite levels LDLR intron 22286219 rs17248776 chr19 11210254 G C 3.68E-13 Metabolite levels LDLR intron 22286219 rs2228671 chr19 11210912 C T 1.10E-08 LDL cholesterol LDLR cds-synon 18262040 rs2228671 chr19 11210912 C T 4.00E-14 LDL cholesterol LDLR cds-synon 19060911 rs2228671 chr19 11210912 C T 9.00E-24 Cholesterol,total LDLR cds-synon 19060911 rs2228671 chr19 11210912 C T 2.20E-12 Lipid levels LDLR cds-synon 19802338 rs2228671 chr19 11210912 C T 5.20E-10 Lipid levels LDLR cds-synon 19802338 rs2228671 chr19 11210912 C T 5.00E-06 Lipid levels LDLR cds-synon 19913121 rs2228671 chr19 11210912 C T 6.52E-10 Lipid levels LDLR cds-synon 19913121 rs2228671 chr19 11210912 C T 4.00E-14 Coronary heart disease LDLR cds-synon 21347282 rs2228671 chr19 11210912 C T 2.70E-05 Coronary heart disease LDLR cds-synon 21966275 rs2228671 chr19 11210912 C T 4.22E-08 Lipoprotein-associated phospholipase A2 activity and mass LDLR cds-synon 22003152 rs2228671 chr19 11210912 C T 8.21E-13 Metabolite levels LDLR cds-synon 22286219 rs2228671 chr19 11210912 C T 6.30E-07 Infantile hypertrophic pyloric stenosis LDLR cds-synon 22306654 rs2228671 chr19 11210912 C T 4.52E-46 LDL cholesterol LDLR cds-synon 23063622 rs2228671 chr19 11210912 C T 6.38E-45 Cholesterol,total LDLR cds-synon 23063622 rs2228671 chr19 11210912 C T 0.00015 LDL cholesterol LDLR cds-synon 23100282 rs2228671 chr19 11210912 C T 4.20E-04 Infantile hypertrophic pyloric stenosis LDLR cds-synon 23989729 rs2228671 chr19 11210912 C T 8.37E-05 Abdominal aortic aneurysm LDLR cds-synon 24046328 rs2228671 chr19 11210912 C T 2.34E-06 LDL lipoproteins LDLR cds-synon pha002902 rs2569559 chr19 11214533 T G 1.74E-08 Lipid levels LDLR intron 19913121 rs2569559 chr19 11214533 T G 5.26E-05 Lipid levels LDLR intron 19913121 rs2569559 chr19 11214533 T G 3.60E-25 Cholesterol,total LDLR intron 23063622 rs2569559 chr19 11214533 T G 5.51E-25 LDL cholesterol LDLR intron 23063622 rs10423288 chr19 11215846 T C 0.0000364 Cholesterol,total LDLR intron 23063622 rs5930 chr19 11224265 A G 2.33E-12 LDL cholesterol LDLR cds-synon 23063622 rs5930 chr19 11224265 A G 8.91E-15 Cholesterol,total LDLR cds-synon 23063622 rs5929 chr19 11226800 C T 2.82E-05 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) LDLR cds-synon 21541012 rs2738446 chr19 11227326 C G 5.40E-04 Coronary Artery Disease LDLR intron 17634449 rs2738446 chr19 11227326 C G 3.48E-05 Lipoprotein-associated phospholipase A2 activity and mass LDLR intron 20442857 rs2738446 chr19 11227326 C G 2.00E-12 Metabolite levels LDLR intron 21909109 rs2738446 chr19 11227326 C G 0.000000047 LDL cholesterol LDLR intron 23063622 rs2738446 chr19 11227326 C G 9.90E-10 Cholesterol,total LDLR intron 23063622 rs2738446 chr19 11227326 C G 1.85E-05 Lipid traits LDLR intron 24023261 rs688 chr19 11227602 C T 1 Drug response to Atenolol LDLR cds-synon 15453913 rs688 chr19 11227602 C T 1 Drug response to Irbesartan LDLR cds-synon 15453913 rs688 chr19 11227602 C T 7.95E-04 Coronary Artery Disease LDLR cds-synon 17634449 rs688 chr19 11227602 C T 7.27E-07 Cardiovascular disease LDLR cds-synon 18179892 rs688 chr19 11227602 C T 6.30E-05 Lipoprotein-associated phospholipase A2 activity and mass LDLR cds-synon 20442857 rs688 chr19 11227602 C T 1.66E-11 LDL cholesterol LDLR cds-synon 22629316 rs688 chr19 11227602 C T 1.84E-13 Cholesterol,total LDLR cds-synon 23063622 rs688 chr19 11227602 C T 7.73E-12 LDL cholesterol LDLR cds-synon 23063622 rs688 chr19 11227602 C T 0.000011 Apolipoprotein B levels LDLR cds-synon 23100282 rs688 chr19 11227602 C T 0.00078 LDL cholesterol LDLR cds-synon 23100282 rs688 chr19 11227602 C T 1.69E-05 Lipid traits LDLR cds-synon 24023261 rs2738450 chr19 11228965 C A 1.97E-12 LDL cholesterol LDLR intron 23063622 rs2738450 chr19 11228965 C A 3.18E-14 Cholesterol,total LDLR intron 23063622 rs2738452 chr19 11229218 A G 1.73E-12 LDL cholesterol LDLR intron 23063622 rs2738452 chr19 11229218 A G 1.95E-14 Cholesterol,total LDLR intron 23063622 rs5925 chr19 11230881 T C 2.49E-12 LDL cholesterol LDLR cds-synon 23063622 rs5925 chr19 11230881 T C 2.94E-14 Cholesterol,total LDLR cds-synon 23063622 rs4804144 chr19 11236180 C A 4.55E-10 Cholesterol,total LDLR intron 23063622 rs4804144 chr19 11236180 C A 9.08E-10 LDL cholesterol LDLR intron 23063622 rs2738459 chr19 11238473 A C,G,T 7.00E-06 LDL cholesterol LDLR intron 20864672 rs6413504 chr19 11241915 A G 7.10E-05 Type 2 diabetes LDLR intron 17293876 rs6413504 chr19 11241915 A G 1.04E-09 LDL cholesterol LDLR intron 23063622 rs6413504 chr19 11241915 A G 2.87E-10 Cholesterol,total LDLR intron 23063622 rs5742911 chr19 11243445 A G 3.07E-15 LDL cholesterol LDLR UTR-3 23063622 rs5742911 chr19 11243445 A G 3.47E-15 Cholesterol,total LDLR UTR-3 23063622 rs17249085 chr19 11244531 G T 0.0000331 Cholesterol,total LDLR nearGene-3 23063622 rs8107532 chr19 11255993 C T 1.62E-05 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) / / 21541012 rs4804146 chr19 11256176 C T 7.00E-06 Lipid traits / / 24386095 rs892115 chr19 11263650 G T 3.81E-04 Acute lung injury SPC24 intron 22295056 rs892115 chr19 11263650 G T 0.0000396 Coronary artery disease SPC24 intron 23202125 rs11671937 chr19 11264514 C T 4.59E-04 Acute lung injury SPC24 intron 22295056 rs7251031 chr19 11266693 T G 9.84E-06 Major depressive disorder / / 21621269 rs17001200 chr19 11267437 A C,G 5.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17001200 chr19 11267437 A C,G 2.96E-04 White matter integrity / / 22425255 rs7247404 chr19 11268556 G A 7.68E-04 Acute lung injury / / 22295056 rs4804148 chr19 11270867 C T 1.32E-04 Myocardial Infarction / / pha002883 rs3185010 chr19 11275842 G A,C,T 2.70E-05 Urinary metabolites KANK2 UTR-3 21572414 rs4804149 chr19 11284028 T C 3.64E-05 Attention deficit hyperactivity disorder KANK2 intron 22012869 rs4804149 chr19 11284028 T C 1.09E-77 Familial hypercholesterolemia (LDL receptor mutation present) KANK2 intron 22968135 rs4804149 chr19 11284028 T C 2.75E-12 Familial hypercholesterolemia (LDL receptor mutation absent) KANK2 intron 22968135 rs4804149 chr19 11284028 T C 6.82E-58 Familial hypercholesterolemia KANK2 intron 22968135 rs387865 chr19 11284539 T C 1.61E-10 Familial hypercholesterolemia KANK2 intron 22968135 rs387865 chr19 11284539 T C 1.81E-09 Familial hypercholesterolemia (LDL receptor mutation present) KANK2 intron 22968135 rs11880312 chr19 11297434 G A 8.87E-04 Response to taxane treatment (placlitaxel) KANK2 intron 23006423 rs8111456 chr19 11301147 A G 3.30E-10 Familial hypercholesterolemia KANK2 intron 22968135 rs17699030 chr19 11330942 A G 8.00E-06 Bipolar disorder and schizophrenia DOCK6 intron 20889312 rs3826815 chr19 11332505 C T 1.77E-04 Alcohol consumption DOCK6 intron 23743675 rs3810308 chr19 11333596 T C 1.76E-04 Alcohol consumption DOCK6 intron 23743675 rs4804154 chr19 11334179 C T 1.25E-04 Alcohol consumption DOCK6 intron 23743675 rs4804155 chr19 11334295 C G 5.00E-06 Coronary heart disease DOCK6 intron 21347282 rs10406522 chr19 11341635 T C 1.65E-06 Cholesterol DOCK6 intron pha003073 rs10406522 chr19 11341635 T C 5.16E-07 ldl cholesterol DOCK6 intron pha003076 rs10406522 chr19 11341635 T C 2.37E-06 Cholesterol DOCK6 intron pha003078 rs12463177 chr19 11341680 G A,C 1.55E-04 Alcohol consumption DOCK6 intron 23743675 rs12979813 chr19 11342703 A G 2.00E-09 HDL cholesterol DOCK6 intron 23726366 rs17699089 chr19 11343795 A G 1.40E-04 Alcohol consumption DOCK6 intron 23743675 rs737337 chr19 11347493 T C 3.00E-09 HDL cholesterol DOCK6 cds-synon 20686565 rs737337 chr19 11347493 T C 5.00E-17 HDL cholesterol DOCK6 cds-synon 24097068 rs12609039 chr19 11348960 G A 1.62E-05 Cholesterol DOCK6 missense pha003073 rs12609039 chr19 11348960 G A 8.48E-05 ldl cholesterol DOCK6 missense pha003076 rs12609039 chr19 11348960 G A 2.66E-05 Cholesterol DOCK6 missense pha003078 rs2278426 chr19 11350488 C T 3.00E-09 HDL cholesterol C19orf80 missense 23505323 rs2116877 chr19 11358440 C T 2.90E-05 Major depressive disorder DOCK6 intron 21042317 rs322151 chr19 11417200 C T 7.79E-05 Systemic sclerosis TSPAN16 intron 21750679 rs318720 chr19 11497104 T G 3.32E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs111956126 chr19 11508192 G A 0.00024 Breast cancer RGL3 STOP-GAIN 23555315 rs317913 chr19 11510314 A G 2.00E-14 Health and aging,CVD and cancer age of onset RGL3 intron 22174011 rs317913 chr19 11510314 A G 7.30E-14 Health and aging,CVD and cancer age of onset RGL3 intron 22174011 rs17426435 chr19 11546269 G A 0.00062 Breast cancer PRKCSH UTR-5 23555315 rs313624 chr19 11552910 G A 2.18E-08 Familial hypercholesterolemia PRKCSH intron 22968135 rs1062958 chr19 11616807 A G 2.41E-04 Coronary heart disease ECSIT UTR-3 21606135 rs17001450 chr19 11625280 G A 6.70E-05 Orofacial clefts ECSIT intron 22419666 rs11880637 chr19 11655010 A T 6.00E-06 IgG glycosylation CNN1 intron 23382691 rs7253363 chr19 11682495 T G 9.00E-06 Multiple sclerosis (severity) / / 19010793 rs889366 chr19 11698138 G A 2.13E-05 Myopia (pathological) / / 23049088 rs4545929 chr19 11727503 T C 1.60E-05 Urinary metabolites ZNF627 intron 21572414 rs206863 chr19 11789015 A G 6.47E-05 Anorexia nervosa ZNF833P intron 24514567 rs7249376 chr19 11830764 A T 2.50E-05 Multiple complex diseases / / 17554300 rs4804636 chr19 11842323 C T 1.07E-14 Familial hypercholesterolemia (LDL receptor mutation present) ZNF823 intron 22968135 rs4804636 chr19 11842323 C T 3.15E-11 Familial hypercholesterolemia ZNF823 intron 22968135 rs286262 chr19 11847615 G A 1.29E-14 Familial hypercholesterolemia (LDL receptor mutation present) ZNF823 intron 22968135 rs286262 chr19 11847615 G A 2.43E-10 Familial hypercholesterolemia ZNF823 intron 22968135 rs7252602 chr19 11865607 T G 6.31E-04 Sarcoidosis / / 19165924 rs8104298 chr19 11867513 A T 6.31E-04 Sarcoidosis / / 19165924 rs7251224 chr19 11870583 T C 1.88E-05 Blood Pressure / / pha003048 rs670240 chr19 11884037 T G 2.10E-05 Response to Vitamin E supplementation ZNF441 intron 22437554 rs444131 chr19 11885777 G A 1.60E-05 Response to Vitamin E supplementation ZNF441 intron 22437554 rs441052 chr19 11886854 T C 1.30E-05 Response to Vitamin E supplementation ZNF441 intron 22437554 rs799193 chr19 11891003 G A 6.32E-04 Multiple complex diseases ZNF441 missense 17554300 rs3095917 chr19 11919620 T A 4.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs400106 chr19 11943697 G A 2.31E-04 Suicide attempts in bipolar disorder ZNF440 missense 21423239 rs17705580 chr19 11975425 G C 3.78E-04 Multiple complex diseases / / 17554300 rs279220 chr19 11990258 C A 8.23E-04 Parkinson's disease / / 17052657 rs10404066 chr19 12034606 G C 4.73E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs3745672 chr19 12146370 T C 1.00E-06 Multiple sclerosis ZNF433 UTR-5 20598377 rs7259845 chr19 12186761 A G 6.89E-05 Post-operative nausea and vomiting ZNF844 missense 21694509 rs17638629 chr19 12225372 T G 7.00E-06 Cognitive performance / / 20125193 rs17001836 chr19 12296284 A G 4.40E-04 Multiple complex diseases ZNF136 intron 17554300 rs2458998 chr19 12370583 T C 2.50E-04 Type 2 diabetes / / 17463246 rs11880217 chr19 12418795 C T 4.89E-10 Familial hypercholesterolemia / / 22968135 rs7246738 chr19 12434902 T C 5.48E-04 Alcohol dependence ZNF563 intron 20201924 rs12610507 chr19 12436410 A C 8.69E-04 Alcohol dependence ZNF563 intron 20201924 rs12610507 chr19 12436410 A C 1.70E-09 Familial hypercholesterolemia ZNF563 intron 22968135 rs1593000 chr19 12439868 C T 2.31E-04 Alcohol dependence ZNF563 intron 20201924 rs9676962 chr19 12441244 C T 5.84E-04 Alcohol dependence ZNF563 intron 20201924 rs11666603 chr19 12496934 T C 0.00000781 LDL cholesterol particle diameter / / 23263444 rs731723 chr19 12588119 T C 7.36E-05 Erythrocyte counts ZNF709 intron pha003099 rs10153481 chr19 12625451 G A 4.24E-05 Erythrocyte counts / / pha003099 rs7247513 chr19 12691185 C T 2.06E-06 Multiple complex diseases ZNF490 UTR-3 17554300 rs7247513 chr19 12691185 C T 2.00E-06 Bipolar disorder ZNF490 UTR-3 21254220 rs12979795 chr19 12717847 A G 4.12E-05 Multiple complex diseases ZNF490 intron 17554300 rs12979795 chr19 12717847 A G 4.77E-05 Serum metabolites ZNF490 intron 19043545 rs10411619 chr19 12752425 T C 1.00E-09 Pulmonary emphysema / / 24383474 rs10411619 chr19 12752425 T C 6.70E-05 Pulmonary emphysema / / 24383474 rs1054486 chr19 12774208 G C 1.91E-08 Other erythrocyte phenotypes MAN2B1 missense 19862010 rs722571 chr19 12811379 T C 1.68E-05 Parkinson's disease TNPO2 UTR-3 17052657 rs896388 chr19 12849966 G A 7.33E-05 Waist Circumference AS/1 intron pha003023 rs8177491 chr19 12857415 C G 1.10E-04 Multiple complex diseases AS/1 intron 17554300 rs11671604 chr19 12931689 A T 7.80E-11 Other erythrocyte phenotypes / / 19862010 rs11671604 chr19 12931689 A T 7.59E-07 Red blood cell traits / / 23222517 rs7255045 chr19 12932269 G A 2.00E-12 Mean corpuscular volume / / 19862010 rs7255045 chr19 12932269 G A 4.27E-08 Red blood cell traits / / 23222517 rs10419408 chr19 12942750 A G 2.61E-11 Other erythrocyte phenotypes RTBDN intron 19862010 rs10419408 chr19 12942750 A G 5.51E-10 Red blood cell traits RTBDN intron 23222517 rs4804737 chr19 12947938 T C 1.74E-11 Other erythrocyte phenotypes / / 19862010 rs4804737 chr19 12947938 T C 5.73E-09 Red blood cell traits / / 23222517 rs10426080 chr19 12957850 A G 3.01E-11 Other erythrocyte phenotypes MAST1 intron 19862010 rs10426080 chr19 12957850 A G 3.55E-11 Red blood cell traits MAST1 intron 23222517 rs2290689 chr19 12958360 T C 5.30E-11 Other erythrocyte phenotypes MAST1 intron 19862010 rs2290689 chr19 12958360 T C 1.07E-10 Red blood cell traits MAST1 intron 23222517 rs2290688 chr19 12958697 T C 1.01E-10 Other erythrocyte phenotypes MAST1 cds-synon 19862010 rs2290688 chr19 12958697 T C 2.33E-10 Red blood cell traits MAST1 cds-synon 23222517 rs1078264 chr19 12963143 T C 1.09E-08 Other erythrocyte phenotypes MAST1 cds-synon 19862010 rs1078264 chr19 12963143 T C 1.24E-09 Red blood cell traits MAST1 cds-synon 23222517 rs8107930 chr19 12972397 G C 5.11E-07 Red blood cell traits MAST1 intron 23222517 rs4614850 chr19 12974636 G T 1.14E-10 Other erythrocyte phenotypes MAST1 intron 19862010 rs4614850 chr19 12974636 G T 4.59E-10 Red blood cell traits MAST1 intron 23222517 rs2242512 chr19 12975599 G A 1.16E-10 Other erythrocyte phenotypes MAST1 intron 19862010 rs2242512 chr19 12975599 G A 4.44E-10 Red blood cell traits MAST1 intron 23222517 rs7256794 chr19 12975608 T C 2.44E-07 Red blood cell traits MAST1 intron 23222517 rs2242514 chr19 12982798 A G 7.89E-09 Other erythrocyte phenotypes MAST1 intron 19862010 rs2242514 chr19 12982798 A G 1.05E-07 Red blood cell traits MAST1 intron 23222517 rs11085822 chr19 12985576 A G 1.21E-10 Other erythrocyte phenotypes MAST1 cds-synon 19862010 rs11085822 chr19 12985576 A G 4.96E-10 Red blood cell traits MAST1 cds-synon 23222517 rs10404876 chr19 12987605 T C 8.31E-09 Other erythrocyte phenotypes D/SE2 intron 19862010 rs10404876 chr19 12987605 T C 2.45E-07 Red blood cell traits D/SE2 intron 23222517 rs7249143 chr19 12992579 G T 3.45E-11 Other erythrocyte phenotypes / / 19862010 rs7249143 chr19 12992579 G T 2.95E-13 Red blood cell traits / / 23222517 rs12609744 chr19 12994140 T C 3.37E-11 Other erythrocyte phenotypes / / 19862010 rs12609744 chr19 12994140 T C 5.53E-13 Red blood cell traits / / 23222517 rs3817621 chr19 12998205 G C 2.76E-08 Red blood cell traits KLF1 nearGene-5 23222517 rs8110787 chr19 12999458 C T 5.44E-04 Smoking initiation KLF1 nearGene-5 24665060 rs11085824 chr19 13001547 A G 1.00E-11 Mean corpuscular hemoglobin GCDH nearGene-5 19862010 rs11085824 chr19 13001547 A G 1.56E-19 Red blood cell traits GCDH nearGene-5 23222517 rs11085824 chr19 13001547 A G 2.11E-04 Smoking initiation GCDH nearGene-5 24665060 rs2242517 chr19 13002563 T G 1.39E-16 Red blood cell traits GCDH intron 23222517 rs11085825 chr19 13007458 C T 1.58E-09 Other erythrocyte phenotypes GCDH intron 19862010 rs11085825 chr19 13007458 C T 0.000000002 Mean corpuscular hemoglobin GCDH intron 22560525 rs11085825 chr19 13007458 C T 1.83E-14 Red blood cell traits GCDH intron 23222517 rs11085825 chr19 13007458 C T 3.70E-05 Platelet counts GCDH intron 23263863 rs11085825 chr19 13007458 C T 5.04E-04 Smoking initiation GCDH intron 24665060 rs1060218 chr19 13008607 G T 6.69E-04 Smoking initiation GCDH cds-synon 24665060 rs8012 chr19 13010520 A G 6.00E-45 Blood metabolite levels GCDH missense 24816252 rs9384 chr19 13010643 G T 1.12E-10 Other erythrocyte phenotypes GCDH UTR-3 19862010 rs9384 chr19 13010643 G T 1.77E-18 Red blood cell traits GCDH UTR-3 23222517 rs17706531 chr19 13015530 A G 1.32E-10 Other erythrocyte phenotypes SYCE2 intron 19862010 rs17706531 chr19 13015530 A G 8.50E-19 Red blood cell traits SYCE2 intron 23222517 rs741702 chr19 13024250 A C 1.88E-10 Other erythrocyte phenotypes SYCE2 intron 19862010 rs741702 chr19 13024250 A C 8.00E-20 Red blood cell traits SYCE2 intron 23222517 rs741702 chr19 13024250 A C 8.31E-04 Smoking initiation SYCE2 intron 24665060 rs2965214 chr19 13029188 G A 1.68E-10 Other erythrocyte phenotypes SYCE2 intron 19862010 rs2965214 chr19 13029188 G A 4.82E-19 Red blood cell traits SYCE2 intron 23222517 rs8113575 chr19 13030280 G A 1.89E-10 Other erythrocyte phenotypes / / 19862010 rs8113575 chr19 13030280 G A 1.22E-18 Red blood cell traits / / 23222517 rs1045913 chr19 13035006 G A 3.94E-04 Amyotrophic lateral sclerosis (sporadic) FARSA cds-synon 24529757 rs1045913 chr19 13035006 G A 5.83E-04 Smoking initiation FARSA cds-synon 24665060 rs62109865 chr19 13037734 G A 8.00E-06 Antibody status in Tripanosoma cruzi seropositivity FARSA intron 24324551 rs2293683 chr19 13039284 A G 7.85E-09 Other erythrocyte phenotypes FARSA intron 19862010 rs2293683 chr19 13039284 A G 0.000000002 Mean corpuscular hemoglobin FARSA intron 22560525 rs2293683 chr19 13039284 A G 7.75E-17 Red blood cell traits FARSA intron 23222517 rs2967890 chr19 13040647 G A 2.91E-09 Familial hypercholesterolemia FARSA intron 22968135 rs2967890 chr19 13040647 G A 2.69E-12 Red blood cell traits FARSA intron 23222517 rs1010222 chr19 13048608 A G 1.66E-08 Other erythrocyte phenotypes CALR nearGene-5 19862010 rs1010222 chr19 13048608 A G 0.000000003 Mean corpuscular hemoglobin CALR nearGene-5 22560525 rs1010222 chr19 13048608 A G 1.56E-18 Red blood cell traits CALR nearGene-5 23222517 rs1049481 chr19 13054781 G T 7.19E-16 Red blood cell traits CALR UTR-3 23222517 rs2974755 chr19 13062663 C T 8.91E-16 Red blood cell traits RAD23A intron 23222517 rs7395 chr19 13064322 G T 3.09E-07 Red blood cell traits RAD23A UTR-3 23222517 rs11667602 chr19 13076121 A C 0.00058 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11667602 chr19 13076121 A C 5.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10419350 chr19 13155709 A G 6.00E-07 Urinary metabolites NFIX intron 21572414 rs11085829 chr19 13174312 G A 4.03E-06 Bipolar disorder NFIX intron 21926972 rs11085829 chr19 13174312 G A 0.000249 Bipolar disorder NFIX intron 23070075 rs8111717 chr19 13229501 T G 3.53E-04 Smoking cessation /CC1 intron 24665060 rs2159214 chr19 13231995 G A 3.39E-05 Rheumatoid arthritis /CC1 intron 21452313 rs10408126 chr19 13245968 C T 4.00E-06 Obesity-related traits /CC1 intron 23251661 rs150928114 chr19 13249098 G A 0.000063 Breast cancer /CC1 missense 23555315 rs8109821 chr19 13282235 A G 1.16E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs16042 chr19 13341037 G A 7.05E-10 Familial hypercholesterolemia CAC/1A intron 22968135 rs4926242 chr19 13368031 T C 2.15E-04 Lung function (forced vital capacity) CAC/1A intron 24023788 rs4926250 chr19 13383718 A C 2.90E-04 Type 2 diabetes CAC/1A intron 17463246 rs8104916 chr19 13398235 T C 7.91E-04 Multiple complex diseases CAC/1A intron 17554300 rs8182538 chr19 13416170 G A 4.63E-04 Suicide attempts in bipolar disorder CAC/1A intron 21041247 rs4433935 chr19 13416280 C T 4.67E-04 Suicide attempts in bipolar disorder CAC/1A intron 21041247 rs4499352 chr19 13416350 T G 4.73E-04 Suicide attempts in bipolar disorder CAC/1A intron 21041247 rs1502017 chr19 13430324 G A 8.71E-05 Acute lymphoblastic leukemia (childhood) CAC/1A intron 22076464 rs1502017 chr19 13430324 G A 7.05E-04 Tourette syndrome CAC/1A intron 22889924 rs10425496 chr19 13441387 A G 2.78E-04 Multiple complex diseases CAC/1A intron 17554300 rs10426233 chr19 13442039 C T 4.11E-04 Depression (quantitative trait) CAC/1A intron 20800221 rs12985786 chr19 13467036 G A 8.86E-05 Parkinson's disease CAC/1A intron 21812969 rs12985786 chr19 13467036 G A 1.68E-04 Celiac disease CAC/1A intron 23936387 rs3764615 chr19 13563952 C A 2.62E-04 Lung function (forced expiratory volume in 1 second) CAC/1A intron 17255346 rs12609735 chr19 13588516 T C 2.92E-04 Multiple complex diseases CAC/1A intron 17554300 rs2112461 chr19 13590331 T C 8.52E-05 Bladder cancer CAC/1A intron 19648920 rs1120559 chr19 13599576 C T 3.74E-04 Type 2 diabetes CAC/1A intron 17463246 rs11670445 chr19 13629683 G T 3.09E-04 Acute lung injury / / 22295056 rs11667968 chr19 13630816 A G 3.15E-04 Acute lung injury LOC100507353 intron 22295056 rs12978698 chr19 13631505 G A 3.15E-04 Acute lung injury LOC100507353 intron 22295056 rs11669140 chr19 13631916 A C 3.11E-04 Acute lung injury LOC100507353 intron 22295056 rs10409463 chr19 13632383 T C 7.09E-04 Multiple complex diseases LOC100507353 intron 17554300 rs12984539 chr19 13636226 T C 3.15E-04 Acute lung injury LOC100507353 intron 22295056 rs7259336 chr19 13638423 A C 7.14E-04 Multiple complex diseases LOC100507353 intron 17554300 rs1833619 chr19 13647830 A G 0.0000974 Follicular lymphoma LOC100507353 intron 23025665 rs7258227 chr19 13659050 T C 3.10E-04 Acute lung injury LOC100507353 intron 22295056 rs11665851 chr19 13660449 G A 8.78E-04 Acute lung injury LOC100507353 intron 22295056 rs11085868 chr19 13712366 C T 1.00E-04 Information processing speed / / 21130836 rs346172 chr19 13843233 T C 2.23E-04 Multiple sclerosis / / 17660530 rs2910225 chr19 13866957 T C 3.23E-05 Acute lymphoblastic leukemia (childhood) CCDC130 intron 22076464 rs386082 chr19 13890017 C T 1.78E-04 Multiple complex diseases / / 17554300 rs445352 chr19 13894517 T C 3.66E-04 Multiple complex diseases / / 17554300 rs3745454 chr19 13936640 G A 9.40E-05 Cognitive impairment induced by topiramate ZSWIM4 intron 22091778 rs12610873 chr19 13942587 G A 1.20E-04 Alcohol dependence ZSWIM4 UTR-3 20201924 rs1531213 chr19 13951790 G A 1.64E-26 Narcolepsy / / 19629137 rs6511901 chr19 14027652 C T 7.61E-04 Response to cytidine analogues (gemcitabine) CC2D1A intron 24483146 rs2305776 chr19 14029269 A C 2.17E-04 Response to cytidine analogues (gemcitabine) CC2D1A intron 24483146 rs1059721 chr19 14041601 G A 1.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CC2D1A UTR-3 20877124 rs3816553 chr19 14092911 G A 4.91E-05 Taste perception RFX1 intron 22132133 rs7251796 chr19 14135656 C T 2.34E-05 Alcohol consumption / / 23743675 rs7247578 chr19 14138147 C T 4.77E-05 Alcohol consumption / / 23743675 rs7249702 chr19 14138212 G A 4.31E-05 Alcohol consumption / / 23743675 rs12327666 chr19 14139921 G A 9.00E-06 Obesity-related traits RLN3 intron 23251661 rs2420413 chr19 14153820 C G 8.81E-04 Acute lung injury IL27RA intron 22295056 rs12151240 chr19 14339702 A C 4.16E-05 Information processing speed / / 21130836 rs4528684 chr19 14351574 C T 1.00E-06 Heart failure / / 20400778 rs12460783 chr19 14416651 A G 6.24E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs888876 chr19 14416793 T C 8.72E-04 Taste perception / / 22132133 rs4517893 chr19 14509187 A G 2.26E-04 Type 2 diabetes CD97 intron 20818381 rs12985089 chr19 14524126 T C 5.18E-05 Parent of origin effect on language impairment (child trend) DDX39A intron 24571439 rs2901186 chr19 14532748 G A 7.65E-04 Taste perception / / 22132133 rs3786654 chr19 14557821 A G 3.30E-06 Nephrolithiasis PKN1 intron 22396660 rs2420538 chr19 14573654 A G 3.96E-06 Nephrolithiasis PKN1 intron 22396660 rs4926214 chr19 14574252 A G 8.55E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) PKN1 intron 23648065 rs1042728 chr19 14581063 A G 5.95E-05 Body Mass Index PKN1 cds-synon pha003020 rs8109740 chr19 14604154 T A 9.38E-04 Suicide attempts in bipolar disorder GIPC1 intron 21423239 rs7254715 chr19 14609211 A G 5.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs4926221 chr19 14614242 A C 9.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs10401423 chr19 14614403 C T 9.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs11669213 chr19 14644804 T A 2.09E-04 Multiple complex diseases TECR intron 17554300 rs8104167 chr19 14664933 C T 2.60E-04 IgE levels TECR intron 17255346 rs11085898 chr19 14679428 A G 4.97E-05 Pulmonary function in asthmatics NDUFB7 intron 23541324 rs7254215 chr19 14713493 G A 7.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) CLEC17A intron 23453885 rs7254215 chr19 14713493 G A 8.35E-05 Body Mass Index CLEC17A intron pha003021 rs10407394 chr19 14804183 A G 4.03E-06 Lymphocyte counts ZNF333 intron 22286170 rs11085908 chr19 14822559 T G 5.27E-04 Lymphocyte counts ZNF333 intron 22286170 rs3885179 chr19 14827830 C A 3.10E-05 Major depressive disorder ZNF333 missense 19065144 rs3885179 chr19 14827830 C A 9.72E-05 Major depressive disorder ZNF333 missense 21621269 rs3885179 chr19 14827830 C A 6.10E-05 Major depressive disorder ZNF333 missense pha002850 rs4808387 chr19 14839160 T C 1.16E-05 Receptive language ability / / 24687471 rs7248991 chr19 14848467 T A 1.05E-05 Receptive language ability EMR2 intron 24687471 rs10403842 chr19 14857891 A G 7.27E-06 Receptive language ability EMR2 intron 24687471 rs999967 chr19 14863522 A G 7.44E-06 Receptive language ability EMR2 intron 24687471 rs2335212 chr19 14864032 A G 7.25E-06 Receptive language ability EMR2 intron 24687471 rs2335213 chr19 14864228 T C 7.36E-06 Receptive language ability EMR2 intron 24687471 rs3965461 chr19 14893513 A G 4.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs9305050 chr19 14907953 C G 1.35E-04 Type 2 diabetes / / 17463246 rs17230384 chr19 14926539 T C 4.12E-04 Type 2 diabetes / / 17463246 rs8101893 chr19 14940001 T C 3.41E-05 Major depression (suicidal thoughts and behavior) / / 21750702 rs17276460 chr19 14945948 G T 4.23E-06 Phospholipid levels (plasma) / / 21829377 rs16980016 chr19 14985805 G A 5.82E-04 Multiple complex diseases / / 17554300 rs16980016 chr19 14985805 G A 7.95E-05 Chronic obstructive pulmonary disease / / 19300482 rs16980016 chr19 14985805 G A 7.95E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10405163 chr19 14987134 G C 7.01E-04 Multiple complex diseases / / 17554300 rs10408968 chr19 14988977 A T 8.21E-04 Multiple complex diseases / / 17554300 rs8106889 chr19 14990005 G A 4.60E-04 Multiple complex diseases / / 17554300 rs10409376 chr19 14997907 C T 4.69E-04 Multiple complex diseases / / 17554300 rs12983299 chr19 15030909 T C 8.27E-04 Type 2 diabetes / / 17463246 rs715159 chr19 15039519 A G 4.61E-05 Blood Pressure / / pha003044 rs715158 chr19 15039616 T G 9.17E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs715158 chr19 15039616 T G 4.64E-05 Orofacial clefts / / 22419666 rs7255992 chr19 15045306 T A 7.02E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs10401807 chr19 15071009 G A 6.23E-04 Myopia (pathological) SLC1A6 intron 21095009 rs3746295 chr19 15083693 C A 6.23E-05 Blood Pressure / / pha003044 rs7255326 chr19 15111506 C T 0.00038 Salmonella-induced pyroptosis / / 22837397 rs10424547 chr19 15133787 C A 2.64E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) CCDC105 cds-synon 23648065 rs8112667 chr19 15133926 C A 6.90E-05 Scoliosis CCDC105 missense 21216876 rs8112667 chr19 15133926 C A 3.60E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) CCDC105 missense 23648065 rs8112667 chr19 15133926 C A 9.33E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) CCDC105 missense 23648065 rs8112667 chr19 15133926 C A 2.28E-05 Blood Pressure CCDC105 missense pha003039 rs8112667 chr19 15133926 C A 1.05E-05 Blood Pressure CCDC105 missense pha003045 rs8112667 chr19 15133926 C A 7.30E-05 Blood Pressure CCDC105 missense pha003047 rs10518246 chr19 15159981 G A 8.13E-04 Acute lung injury / / 22295056 rs10425745 chr19 15169836 T A 2.75E-04 Acute lung injury / / 22295056 rs8102919 chr19 15179244 T C 5.71E-04 Acute lung injury / / 22295056 rs12975625 chr19 15198764 T C 3.79E-04 Sudden cardiac arrest OR1I1 cds-synon 21658281 rs13301 chr19 15225348 T C 3.82E-04 Aspirin exacerbated respiratory disease in asthmatics / / 23180272 rs2074261 chr19 15226611 C A 2.02E-04 Aspirin exacerbated respiratory disease in asthmatics ILVBL intron 23180272 rs1468198 chr19 15228178 T C 7.92E-05 Aspirin exacerbated respiratory disease in asthmatics ILVBL intron 23180272 rs7507755 chr19 15228542 A G 3.28E-04 Aspirin exacerbated respiratory disease in asthmatics ILVBL intron 23180272 rs2240299 chr19 15228982 C T 3.15E-04 Aspirin exacerbated respiratory disease in asthmatics ILVBL intron 23180272 rs12974057 chr19 15246479 A G 5.21E-04 Type 2 diabetes / / 17463246 rs10403708 chr19 15253698 A G 8.03E-04 Type 2 diabetes / / 17463246 rs34338511 chr19 15295165 G A 1.42E-10 HDL cholesterol NOTCH3 missense 23063622 rs34338511 chr19 15295165 G A 1.63E-14 Triglycerides NOTCH3 missense 23063622 rs7258434 chr19 15325310 G A 9.28E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs11666141 chr19 15434382 T C 1.13E-05 Alopecia areata / / 22027810 rs7248490 chr19 15469197 A G 8.36E-05 Self-reported allergy AKAP8 intron 23817569 rs4809184 chr19 15471856 T C 5.77E-05 Self-reported allergy AKAP8 intron 23817569 rs12710298 chr19 15472375 G A 6.98E-05 Self-reported allergy AKAP8 intron 23817569 rs4808299 chr19 15478762 T G 8.27E-05 Self-reported allergy AKAP8 intron 23817569 rs9305061 chr19 15479367 G A 7.54E-05 Self-reported allergy AKAP8 intron 23817569 rs61757556 chr19 15483942 C T 0.00025 Prostate cancer AKAP8 missense 23555315 rs4809185 chr19 15485350 C T 8.56E-05 Self-reported allergy AKAP8 intron 23817569 rs8106751 chr19 15485829 A G 8.81E-05 Self-reported allergy AKAP8 intron 23817569 rs8105619 chr19 15486025 G C 7.60E-05 Self-reported allergy AKAP8 intron 23817569 rs12611023 chr19 15486059 T C 7.48E-05 Self-reported allergy AKAP8 intron 23817569 rs12609449 chr19 15486216 C T 9.09E-05 Self-reported allergy AKAP8 intron 23817569 rs2366267 chr19 15492848 T C 1.01E-04 Self-reported allergy AKAP8L intron 23817569 rs7257091 chr19 15497486 G A 9.06E-05 Self-reported allergy AKAP8L intron 23817569 rs8109755 chr19 15500876 C A 9.32E-05 Self-reported allergy AKAP8L intron 23817569 rs7253129 chr19 15504064 G C 9.43E-05 Self-reported allergy AKAP8L intron 23817569 rs7247749 chr19 15508130 G A 9.09E-05 Self-reported allergy AKAP8L intron 23817569 rs10775618 chr19 15512731 A G 7.70E-05 Self-reported allergy AKAP8L intron 23817569 rs10775619 chr19 15512844 A T 6.99E-05 Self-reported allergy AKAP8L intron 23817569 rs12972998 chr19 15513054 G A 7.91E-05 Self-reported allergy AKAP8L intron 23817569 rs7246816 chr19 15514660 G A 7.70E-05 Self-reported allergy AKAP8L intron 23817569 rs7253443 chr19 15517695 A C 4.14E-05 Self-reported allergy AKAP8L intron 23817569 rs12608834 chr19 15520536 G A 8.22E-05 Self-reported allergy AKAP8L intron 23817569 rs2058323 chr19 15521175 T C 5.30E-05 Self-reported allergy AKAP8L intron 23817569 rs4808302 chr19 15521767 G A 5.77E-05 Self-reported allergy AKAP8L intron 23817569 rs6512030 chr19 15526376 A G 8.22E-04 Alzheimer's disease AKAP8L intron 17998437 rs6512030 chr19 15526376 A G 4.82E-05 Self-reported allergy AKAP8L intron 23817569 rs3786853 chr19 15528983 C T 8.82E-04 Multiple complex diseases AKAP8L intron 17554300 rs7254099 chr19 15533821 A G 3.94E-05 Self-reported allergy WIZ UTR-3 23817569 rs887898 chr19 15539439 A G 4.17E-05 Self-reported allergy WIZ intron 23817569 rs1005953 chr19 15549255 C T 4.77E-05 Self-reported allergy WIZ intron 23817569 rs201708162 chr19 15572397 A G 0.000046 Breast cancer RASAL3 missense 23555315 rs11666779 chr19 15575801 T C 5.51E-05 Cognitive impairment induced by topiramate / / 22091778 rs6512039 chr19 15616256 T G 3.74E-05 Type 2 diabetes / / 17463246 rs2060261 chr19 15621180 G A 4.36E-04 Type 2 diabetes CYP4F22 intron 17463246 rs1273510 chr19 15629669 T C 3.86E-04 Type 2 diabetes CYP4F22 intron 17463246 rs1273522 chr19 15640972 G A 2.00E-05 Thyroid peroxidase antibody levels CYP4F22 intron 24586183 rs8112108 chr19 15666533 C T 0.000781589 Hypertension (early onset hypertension) / / 22479346 rs1273516 chr19 15677710 G A 9.00E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs1273516 chr19 15677710 G A 0.0000633 Menopause (age at onset) / / 23424626 rs16980564 chr19 15683078 A G 1.10E-05 Urinary metabolites / / 21572414 rs34640057 chr19 15685824 C T 0.00009039 Sarcoidosis / / 22952805 rs12978342 chr19 15686016 G T 0.00008036 Sarcoidosis / / 22952805 rs4808318 chr19 15686706 G C 0.00009044 Sarcoidosis / / 22952805 rs682765 chr19 15701078 A C,G,T 2.70E-05 Urinary metabolites / / 21572414 rs3764563 chr19 15724203 A G 3.00E-07 Inflammatory biomarkers CYP4F8 nearGene-5 22228203 rs1320319 chr19 15725424 C T 6.43E-06 Response to platinum-based chemotherapy in non-small-cell lung cancer CYP4F8 nearGene-5 21483023 rs7254518 chr19 15727766 G A 4.23E-05 Alcohol consumption CYP4F8 intron 23953852 rs2072599 chr19 15730034 C T 5.01E-04 Rheumatoid arthritis CYP4F8 intron 21452313 rs2176918 chr19 15730922 A G 3.50E-05 Alcohol consumption CYP4F8 intron 23953852 rs7256985 chr19 15732070 G T 4.22E-05 Alcohol consumption CYP4F8 intron 23953852 rs4646530 chr19 15735238 T A 9.93E-04 Multiple complex diseases CYP4F8 intron 17554300 rs4646531 chr19 15736903 T C 7.87E-04 Rheumatoid arthritis CYP4F8 intron 21452313 rs3794987 chr19 15750891 A G 1.16E-05 Alcohol consumption CYP4F3 nearGene-5 23953852 rs1290618 chr19 15752137 C T 3.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CYP4F3 intron 20877124 rs8106799 chr19 15753759 G A 9.40E-08 Metabolite levels CYP4F3 intron 23281178 rs2203999 chr19 15754975 C T 9.40E-08 Metabolite levels CYP4F3 intron 23281178 rs2204000 chr19 15755112 G A 9.40E-08 Metabolite levels CYP4F3 intron 23281178 rs2077080 chr19 15755392 G C 9.40E-08 Metabolite levels CYP4F3 intron 23281178 rs2077040 chr19 15755840 T C 9.40E-08 Metabolite levels CYP4F3 intron 23281178 rs2072598 chr19 15757528 A G 9.40E-08 Metabolite levels CYP4F3 intron 23281178 rs4808346 chr19 15758931 T C 7.94E-08 Metabolite levels CYP4F3 intron 23281178 rs10401516 chr19 15760577 C T 8.74E-08 Metabolite levels CYP4F3 intron 23281178 rs718258 chr19 15766419 G A 6.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CYP4F3 intron 20877124 rs7258240 chr19 15772414 G A 3.31E-04 Cognitive decline / / 23732972 rs4808352 chr19 15777931 T C 4.67E-04 Multiple complex diseases / / 17554300 rs7251084 chr19 15780041 G A 6.41E-04 Multiple complex diseases / / 17554300 rs7255963 chr19 15780747 C T 1.01E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3813137 chr19 15782397 C T 9.73E-04 Telomere length CYP4F12 nearGene-5 23900074 rs7253210 chr19 15784116 G A 3.47E-04 Coronary Artery Disease CYP4F12 intron 17634449 rs10426695 chr19 15790251 C A 4.67E-05 Blood Pressure CYP4F12 intron pha003043 rs10420354 chr19 15796946 C T 7.27E-05 Alzheimer's disease (age of onset) CYP4F12 intron 22005931 rs645827 chr19 15797409 T A 6.27E-04 Response to taxane treatment (placlitaxel) CYP4F12 intron 23006423 rs631193 chr19 15798394 A G 3.74E-04 Response to taxane treatment (placlitaxel) CYP4F12 intron 23006423 rs627753 chr19 15799130 A G 9.37E-04 Response to taxane treatment (placlitaxel) CYP4F12 intron 23006423 rs677449 chr19 15799276 C T 2.42E-04 Multiple complex diseases CYP4F12 intron 17554300 rs616514 chr19 15799343 G T 4.76E-04 Response to taxane treatment (placlitaxel) CYP4F12 intron 23006423 rs677903 chr19 15799366 G A 2.81E-04 Response to taxane treatment (placlitaxel) CYP4F12 intron 23006423 rs583946 chr19 15800153 C T 6.16E-04 Response to taxane treatment (placlitaxel) CYP4F12 intron 23006423 rs597012 chr19 15800729 C G 3.51E-04 Response to taxane treatment (placlitaxel) CYP4F12 intron 23006423 rs626580 chr19 15802751 C A 7.10E-04 Response to taxane treatment (placlitaxel) CYP4F12 intron 23006423 rs596252 chr19 15807212 T G 8.50E-04 Response to taxane treatment (placlitaxel) CYP4F12 intron 23006423 rs624512 chr19 15808890 G A 9.13E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs610354 chr19 15809248 A G 9.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11670742 chr19 15830468 G A 8.55E-05 Alzheimer's disease (age of onset) / / 22005931 rs7257304 chr19 15863023 T C 6.18E-07 Schizophrenia / / 22037555 rs1036251 chr19 15907115 G A 1.76E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1036251 chr19 15907115 G A 2.99E-05 Heart Rate / / pha003054 rs17641311 chr19 15909516 C T 4.15E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2189784 chr19 15959200 G A 5.01E-08 Metabolite levels / / 23281178 rs7251874 chr19 15962509 A G 7.15E-08 Metabolite levels / / 23281178 rs2269931 chr19 15963306 A G 9.80E-04 Type 2 diabetes / / 17463246 rs2079288 chr19 15964203 T C 2.99E-04 Alzheimer's disease (late onset) / / 21379329 rs12610967 chr19 15977929 C A 3.02E-13 Metabolite levels / / 23281178 rs12609820 chr19 15978057 T C 3.33E-15 Metabolite levels / / 23281178 rs12611242 chr19 15978564 G A 4.07E-13 Metabolite levels / / 23281178 rs12610189 chr19 15978641 T G 5.41E-04 Taste perception / / 22132133 rs12610189 chr19 15978641 T G 5.00E-06 Response to Vitamin E supplementation / / 22437554 rs12610189 chr19 15978641 T G 3.51E-13 Metabolite levels / / 23281178 rs8101038 chr19 15982864 C T 3.74E-13 Metabolite levels / / 23281178 rs2886297 chr19 15983971 G A 1.10E-05 Response to Vitamin E supplementation / / 22437554 rs7254940 chr19 15984508 C T 7.96E-13 Metabolite levels / / 23281178 rs3093208 chr19 15988582 A G 1.17E-21 LDL cholesterol / / 23063622 rs3093208 chr19 15988582 A G 3.18E-18 Cholesterol,total / / 23063622 rs3093207 chr19 15988658 T C 1.22E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs3093207 chr19 15988658 T C 4.64E-13 Metabolite levels / / 23281178 rs2108622 chr19 15990431 C T 1 Drug response to Warfarin CYP4F2 missense 17341693 rs2108622 chr19 15990431 C T 1 Drug response to Warfarin CYP4F2 missense 17846394 rs2108622 chr19 15990431 C T 1 Drug response to Warfarin CYP4F2 missense 18250228 rs2108622 chr19 15990431 C T 1 Drug response to Warfarin CYP4F2 missense 18281915 rs2108622 chr19 15990431 C T 1 Drug response to Warfarin CYP4F2 missense 19228618 rs2108622 chr19 15990431 C T 1 Drug response to Acenocoumarol CYP4F2 missense 19270263 rs2108622 chr19 15990431 C T 1 Drug response to Warfarin CYP4F2 missense 19297519 rs2108622 chr19 15990431 C T 3.00E-10 Warfarin maintenance dose CYP4F2 missense 19300499 rs2108622 chr19 15990431 C T 3.00E-10 Acenocoumarol maintenance dosage CYP4F2 missense 19578179 rs2108622 chr19 15990431 C T 1 Drug response to Warfarin CYP4F2 missense 19794411 rs2108622 chr19 15990431 C T 3.00E-08 Warfarin maintenance dose CYP4F2 missense 20833655 rs2108622 chr19 15990431 C T 1.00E-10 Vitamin E levels CYP4F2 missense 21729881 rs2108622 chr19 15990431 C T 2.00E-07 Response to Vitamin E supplementation CYP4F2 missense 22437554 rs2108622 chr19 15990431 C T 9.00E-24 Metabolite levels CYP4F2 missense 23281178 rs2074901 chr19 15997422 A C 9.43E-04 Suicide attempts in bipolar disorder CYP4F2 intron 21423239 rs2074901 chr19 15997422 A C 8.30E-06 Coronary heart disease CYP4F2 intron 21966275 rs2074901 chr19 15997422 A C 4.32E-08 Metabolite levels CYP4F2 intron 23281178 rs1558139 chr19 15997564 G A 6.00E-05 Electrocardiographic traits and heart rate variability CYP4F2 intron 17903306 rs3093135 chr19 16004371 A T 4.32E-08 Metabolite levels CYP4F2 intron 23281178 rs3093111 chr19 16007770 G A 9.45E-09 LDL cholesterol CYP4F2 intron 23063622 rs2074902 chr19 16008099 T C 4.32E-08 Metabolite levels CYP4F2 intron 23281178 rs3093105 chr19 16008388 A C 0.00006 Stroke CYP4F2 missense 23422753 rs3761014 chr19 16011763 C G 2.10E-10 Metabolite levels / / 23281178 rs2018454 chr19 16012612 A G 3.77E-10 Metabolite levels / / 23281178 rs2018460 chr19 16012757 C T 2.61E-04 Multiple complex diseases / / 17554300 rs2018460 chr19 16012757 C T 6.54E-10 Metabolite levels / / 23281178 rs4808408 chr19 16020376 C T 2.98E-04 Fibrinogen / / 17255346 rs17829862 chr19 16020407 G C 4.67E-04 Parkinson's disease / / 16252231 rs1060467 chr19 16024538 A G 1.60E-06 Response to Vitamin E supplementation CYP4F11 UTR-3 22437554 rs7249167 chr19 16037359 A G 2.70E-04 Coronary Artery Disease CYP4F11 intron 17634449 rs7249167 chr19 16037359 A G 1.52E-05 Brain structure CYP4F11 intron 22504417 rs3810427 chr19 16046650 C A 3.90E-05 Body mass index CYP4F11 nearGene-5 22446040 rs7251890 chr19 16072037 A C 6.26E-04 Alcohol dependence / / 24277619 rs10402349 chr19 16108217 T C 6.38E-04 Multiple complex diseases / / 17554300 rs1990026 chr19 16128817 G T 0.0007136 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC126536 intron 23233654 rs1990026 chr19 16128817 G T 7.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC126536 intron 23233662 rs4808428 chr19 16143066 T G 2.94E-04 Smoking initiation / / 24665060 rs8101981 chr19 16144586 A G 2.29E-04 Alzheimer's disease (late onset) FLJ25328 intron 21460841 rs10403813 chr19 16153445 G A 0.00063 Paclitaxel-induced cytotoxicity in lymphoblastoid cell lines / / 23204130 rs8109288 chr19 16185559 G A 9.70E-05 Blood cell counts and traits,in red and white blood cells TPM4 intron 21153663 rs8109288 chr19 16185559 G A 1.00E-11 Mean platelet volume TPM4 intron 22139419 rs8109288 chr19 16185559 G A 3.00E-10 Platelet counts TPM4 intron 22139419 rs8109288 chr19 16185559 G A 3.00E-09 Mean platelet volume TPM4 intron 22423221 rs8109288 chr19 16185559 G A 5.00E-10 Mean platelet volume TPM4 intron 22423221 rs1862602 chr19 16186065 G C 1.60E-10 Triglycerides TPM4 intron 23063622 rs16981094 chr19 16189567 A C 9.17E-11 Triglycerides TPM4 intron 23063622 rs2032882 chr19 16244817 A G 2.73E-04 Multiple complex diseases / / 17554300 rs4808458 chr19 16247665 G A 6.90E-06 Urinary metabolites HSH2D intron 21572414 rs16981122 chr19 16257003 G T 7.18E-09 Triglycerides HSH2D intron 23063622 rs2262138 chr19 16352403 C T 2.10E-04 Blood Pressure and Arterial Stiffness / / 17903302 rs4538126 chr19 16398369 T C 6.31E-04 Multiple complex diseases / / 17554300 rs12185505 chr19 16400823 C A 1.01E-05 Parkinson's disease / / 17052657 rs454185 chr19 16404521 C T 3.40E-04 Multiple complex diseases / / 17554300 rs373044 chr19 16405117 T C 6.03E-04 Multiple complex diseases / / 17554300 rs390017 chr19 16406034 A G 4.86E-05 Relative hand skill in reading disability / / 24068947 rs12985716 chr19 16407011 G C 8.46E-05 Relative hand skill in reading disability / / 24068947 rs406298 chr19 16409903 C G 2.20E-05 Urinary metabolites / / 21572414 rs501537 chr19 16425503 G A 6.47E-05 Bladder cancer / / 19648920 rs501537 chr19 16425503 G A 3.02E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs429294 chr19 16426889 C T 9.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs875622 chr19 16467759 A G 6.77E-04 Suicide attempts in bipolar disorder EPS15L1 intron 21423239 rs875622 chr19 16467759 A G 4.00E-06 White matter integrity EPS15L1 intron 23218918 rs8113386 chr19 16471871 G C 1.10E-04 Kidney function and endocine traits EPS15L1 intron 17903292 rs2290669 chr19 16495774 A C 5.52E-04 Suicide attempts in bipolar disorder EPS15L1 intron 21423239 rs1870071 chr19 16505106 T C 9.35E-06 White blood cell count EPS15L1 intron 21738479 rs4808047 chr19 16527834 T C 5.14E-04 Suicide attempts in bipolar disorder EPS15L1 intron 21423239 rs10411936 chr19 16548375 A G 3.00E-12 White blood cell count EPS15L1 intron 21738480 rs10411936 chr19 16548375 A G 2.00E-07 Multiple sclerosis EPS15L1 intron 22190364 rs7256818 chr19 16558766 C A 9.96E-06 White blood cell count EPS15L1 intron 21738479 rs8108300 chr19 16609453 G A 1.51E-04 Response to taxane treatment (placlitaxel) C19orf44 intron 23006423 rs728116 chr19 16611978 T C 7.24E-04 Response to taxane treatment (placlitaxel) C19orf44 cds-synon 23006423 rs7251978 chr19 16612365 G A 7.84E-04 Response to taxane treatment (placlitaxel) C19orf44 intron 23006423 rs6512116 chr19 16613476 C A 7.71E-04 Response to taxane treatment (placlitaxel) C19orf44 intron 23006423 rs12459711 chr19 16614665 T C 7.24E-04 Response to taxane treatment (placlitaxel) C19orf44 intron 23006423 rs8109218 chr19 16616420 A C 6.70E-04 Response to taxane treatment (placlitaxel) C19orf44 intron 23006423 rs10416645 chr19 16637009 T C 8.97E-04 Response to taxane treatment (placlitaxel) CHERP intron 23006423 rs10413178 chr19 16676327 T C 7.14E-05 Depression (quantitative trait) SLC35E1 intron 23290196 rs2216670 chr19 16694094 T G 1.00E-04 Schizophrenia MED26 intron 19197363 rs12462428 chr19 16694610 T C 3.78E-05 Bipolar disorder MED26 intron 20451256 rs3786603 chr19 16735788 C T 7.05E-05 Schizophrenia MED26 intron 19197363 rs111323173 chr19 16773301 G A 0.0008428 Sarcoidosis TMEM38A intron 22952805 rs7252665 chr19 16774993 G A 0.0008535 Sarcoidosis TMEM38A intron 22952805 rs142539859 chr19 16775962 G A 0.0007761 Sarcoidosis TMEM38A intron 22952805 rs2547108 chr19 16899731 A G 2.21E-05 Stroke NWD1 intron 22306652 rs73008597 chr19 16908639 C T 0.0003 Prostate cancer NWD1 missense 23555315 rs2227341 chr19 16999700 G A 0.000000427 Cholesterol,total / / 23063622 rs2227341 chr19 16999700 G A 2.71E-09 LDL cholesterol / / 23063622 rs2227359 chr19 17005029 C T 0.000000196 Cholesterol,total CPAMD8 intron 23063622 rs2227359 chr19 17005029 C T 1.18E-10 LDL cholesterol CPAMD8 intron 23063622 rs2227368 chr19 17006947 A C 1.02E-12 Triglycerides CPAMD8 intron 23063622 rs773853 chr19 17020688 A G 8.03E-05 Alzheimer's disease CPAMD8 intron 17998437 rs17196155 chr19 17070740 A T 7.66E-04 Alzheimer's disease CPAMD8 intron 17998437 rs12975235 chr19 17088458 G A 1.15E-05 Brain lesion load CPAMD8 intron 19010793 rs2353203 chr19 17099980 G A 3.80E-04 Alcohol dependence CPAMD8 intron 20201924 rs4808064 chr19 17111411 A G 7.71E-05 Glycosylated haemoglobin levels CPAMD8 intron 17255346 rs11669497 chr19 17111674 T C 3.24E-05 Brain lesion load CPAMD8 intron 19010793 rs3745341 chr19 17112827 T C 1.02E-05 Brain lesion load CPAMD8 intron 19010793 rs3745345 chr19 17113147 A G 2.88E-05 Brain lesion load CPAMD8 cds-synon 19010793 rs8112434 chr19 17115847 A G 3.55E-05 Blood Pressure CPAMD8 intron pha003046 rs8112544 chr19 17115898 A G 6.48E-04 Smoking initiation CPAMD8 intron 24665060 rs11666377 chr19 17118433 C T 7.00E-06 Brain lesion load CPAMD8 intron 19010793 rs6512158 chr19 17121533 A C 9.55E-06 Brain lesion load CPAMD8 intron 19010793 rs16981567 chr19 17152552 A G 8.16E-04 Multiple complex diseases / / 17554300 rs16981571 chr19 17158694 G A 9.42E-04 Multiple complex diseases / / 17554300 rs4808557 chr19 17160564 T C 2.09E-04 Multiple complex diseases / / 17554300 rs2305758 chr19 17163661 C T 7.49E-05 Multiple complex diseases HAUS8 cds-synon 17554300 rs2278997 chr19 17166981 G A 2.22E-04 Blood pressure HAUS8 intron 17255346 rs1130222 chr19 17170885 C A,G,T 0.000066 Breast cancer HAUS8 STOP-GAIN 23555315 rs2124896 chr19 17180812 G A 1.30E-05 Blood pressure HAUS8 intron 24001895 rs1979261 chr19 17193518 A G 2.44E-04 Self-reported allergy MYO9B intron 23817569 rs1979260 chr19 17193551 A G 2.67E-04 Self-reported allergy MYO9B intron 23817569 rs10405158 chr19 17195997 A G 2.43E-04 Self-reported allergy MYO9B intron 23817569 rs13343952 chr19 17197064 G C 2.26E-04 Self-reported allergy MYO9B intron 23817569 rs11671858 chr19 17201520 T G 2.49E-04 Self-reported allergy MYO9B intron 23817569 rs3745349 chr19 17212992 C T 8.95E-04 Amyotrophic lateral sclerosis (sporadic) MYO9B cds-synon 24529757 rs7246865 chr19 17219105 G A 2.25E-07 Blood pressure MYO9B intron 21909110 rs7246865 chr19 17219105 G A 1.65E-04 Longevity MYO9B intron 22279548 rs11667918 chr19 17232499 C T 8.77E-04 Alcohol dependence MYO9B intron 21314694 rs11667918 chr19 17232499 C T 1.30E-09 Glycated hemoglobin levels MYO9B intron 22290723 rs11667918 chr19 17232499 C T 9.00E-12 Glycated hemoglobin levels MYO9B intron 24647736 rs8103970 chr19 17268511 G A 3.52E-04 Suicide attempts in bipolar disorder MYO9B intron 21423239 rs7256689 chr19 17273893 G T 6.35E-04 Suicide attempts in bipolar disorder MYO9B cds-synon 21423239 rs8112726 chr19 17278384 T G 5.19E-07 Breast cancer MYO9B intron 20852631 rs8112726 chr19 17278384 T G 6.37E-04 Suicide attempts in bipolar disorder MYO9B intron 21423239 rs4808583 chr19 17278979 G T 3.30E-04 Suicide attempts in bipolar disorder MYO9B intron 21423239 rs6512173 chr19 17282250 G C 6.50E-04 Suicide attempts in bipolar disorder MYO9B intron 21423239 rs2279008 chr19 17283303 T C 3.00E-08 Height MYO9B intron 20881960 rs2279006 chr19 17283657 C T 0.0000797 Placental abruption MYO9B cds-synon 23205182 rs75251420 chr19 17316802 G A 0.0000087 Breast cancer(er negative) MYO9B missense 23555315 rs2288544 chr19 17337025 C T 1.73E-06 Breast cancer / / 20852631 rs10421287 chr19 17352961 C T 1.39E-09 Breast cancer NR2F6 intron 20852631 rs10419742 chr19 17352985 G C 4.42E-08 Breast cancer NR2F6 intron 20852631 rs891205 chr19 17354586 C A 1.28E-06 Breast cancer NR2F6 intron 20852631 rs4808611 chr19 17354825 C T 3.24E-09 Breast cancer NR2F6 intron 20852631 rs4808611 chr19 17354825 C T 4.71E-06 Hippocampal volume in schizophrenia NR2F6 intron 23805179 rs73012590 chr19 17358188 T A 3.60E-09 Breast cancer / / 20852631 rs34963425 chr19 17358189 C A 3.05E-09 Breast cancer / / 20852631 rs35630819 chr19 17359299 C T 1.24E-07 Breast cancer / / 20852631 rs35686037 chr19 17359535 C T 3.08E-09 Breast cancer / / 20852631 rs35686037 chr19 17359535 C T 8.31E-07 Hippocampal volume in schizophrenia / / 23805179 rs10415471 chr19 17361064 C T 3.08E-09 Breast cancer USHBP1 cds-synon 20852631 rs7247167 chr19 17363059 C G 4.42E-08 Breast cancer USHBP1 intron 20852631 rs7246243 chr19 17363068 G A 4.42E-08 Breast cancer USHBP1 intron 20852631 rs68179022 chr19 17363444 G C 1.07E-09 Breast cancer USHBP1 intron 20852631 rs73012598 chr19 17364085 C T 3.59E-09 Breast cancer USHBP1 intron 20852631 rs7248801 chr19 17366806 C T 1.48E-06 Breast cancer USHBP1 intron 20852631 rs4464206 chr19 17367585 G C 1.38E-06 Breast cancer USHBP1 intron 20852631 rs12982178 chr19 17371568 T C 1.81E-09 Breast cancer USHBP1 intron 20852631 rs12982178 chr19 17371568 T C 1.08E-06 Hippocampal volume in schizophrenia USHBP1 intron 23805179 rs58925582 chr19 17372199 C T 1.81E-09 Breast cancer USHBP1 intron 20852631 rs12104352 chr19 17376948 G T 5.90E-07 Breast cancer / / 20852631 rs35256297 chr19 17376948 GT G 5.90E-07 Breast cancer / / 20852631 rs12980812 chr19 17377558 C G 1.01E-08 Breast cancer / / 20852631 rs10424178 chr19 17379558 C T 1.17E-09 Breast cancer BABAM1 intron 20852631 rs10424178 chr19 17379558 C T 1.76E-06 Hippocampal volume in schizophrenia BABAM1 intron 23805179 rs10420922 chr19 17382505 A T 2.37E-09 Breast cancer BABAM1 intron 20852631 rs35604430 chr19 17382990 A G 1.18E-09 Breast cancer BABAM1 intron 20852631 rs62126227 chr19 17383602 C T 3.13E-07 Breast cancer BABAM1 intron 20852631 rs10402468 chr19 17384003 C A 1.62E-09 Breast cancer BABAM1 intron 20852631 rs3745185 chr19 17384267 G A 3.86E-07 Breast cancer BABAM1 intron 20852631 rs10416654 chr19 17385176 T C 1.65E-09 Breast cancer BABAM1 intron 20852631 rs11291512 chr19 17385380 TA T 1.71E-09 Breast cancer BABAM1 intron 20852631 rs3837926 chr19 17385380 T A 1.71E-09 Breast cancer BABAM1 intron 20852631 rs398034105 chr19 17385380 TA T 1.71E-09 Breast cancer BABAM1 intron 20852631 rs11086064 chr19 17385381 A T 2.05E-06 Breast cancer BABAM1 intron 20852631 rs67412075 chr19 17385502 A G 1.67E-09 Breast cancer BABAM1 intron 20852631 rs10418154 chr19 17386006 A G 1.69E-09 Breast cancer BABAM1 intron 20852631 rs10418362 chr19 17386107 A T 1.69E-09 Breast cancer BABAM1 intron 20852631 rs35552009 chr19 17386107 A AT 1.69E-09 Breast cancer BABAM1 intron 20852631 rs398120865 chr19 17386107 A AT 1.69E-09 Breast cancer BABAM1 intron 20852631 rs34084277 chr19 17387176 A G 3.75E-09 Breast cancer BABAM1 intron 20852631 rs61634114 chr19 17387254 G A 1.71E-09 Breast cancer BABAM1 intron 20852631 rs73014418 chr19 17388014 T C 1.72E-09 Breast cancer BABAM1 intron 20852631 rs56028644 chr19 17388790 C T 1.71E-09 Breast cancer BABAM1 intron 20852631 rs10426697 chr19 17389156 C T 4.19E-08 Breast cancer BABAM1 intron 20852631 rs10406920 chr19 17389648 C T 1.75E-09 Breast cancer BABAM1 intron 20852631 rs10406920 chr19 17389648 C T 6.75E-06 Hippocampal volume in schizophrenia BABAM1 intron 23805179 rs8170 chr19 17389704 G A 2.00E-09 Breast cancer BABAM1 cds-synon 20852631 rs8170 chr19 17389704 G A 4.00E-06 Ovarian cancer BABAM1 cds-synon 20852633 rs8170 chr19 17389704 G A 2.00E-07 Ovarian cancer BABAM1 cds-synon 23535730 rs8170 chr19 17389704 G A 3.00E-14 Ovarian cancer BABAM1 cds-synon 23535730 rs8170 chr19 17389704 G A 9.00E-13 Breast cancer BABAM1 cds-synon 23535733 rs8170 chr19 17389704 G A 4.00E-13 Breast Cancer in BRCA1 mutation carriers BABAM1 cds-synon 23544013 rs8170 chr19 17389704 G A 6.75E-06 Hippocampal volume in schizophrenia BABAM1 cds-synon 23805179 rs8170 chr19 17389704 G A 1.26E-07 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) BABAM1 cds-synon 24325915 rs4808075 chr19 17390291 T C 9.36E-12 Breast cancer / / 20852631 rs11667618 chr19 17390478 C T 3.22E-07 Breast cancer / / 20852631 rs11667661 chr19 17390579 C T 3.23E-07 Breast cancer / / 20852631 rs4609972 chr19 17390917 G C 2.75E-09 Breast cancer / / 20852631 rs10419397 chr19 17391328 G A 9.89E-12 Breast cancer / / 20852631 rs8100241 chr19 17392894 G A 3.91E-09 Breast cancer ANKLE1 missense 20852631 rs8100241 chr19 17392894 G A 4.00E-08 Breast cancer ANKLE1 missense 22976474 rs8100241 chr19 17392894 G A 6.30E-04 Response to cytadine analogues (cytosine arabinoside) ANKLE1 missense 24483146 rs73509996 chr19 17393449 T G 1.77E-09 Breast cancer ANKLE1 intron 20852631 rs56069439 chr19 17393925 C A 1.06E-11 Breast cancer ANKLE1 intron 20852631 rs2363956 chr19 17394124 T G 5.54E-09 Breast cancer ANKLE1 missense 20852631 rs2363956 chr19 17394124 T G 1.00E-07 Ovarian cancer ANKLE1 missense 20852633 rs2363956 chr19 17394124 T G 2.00E-08 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) ANKLE1 missense 24325915 rs2363956 chr19 17394124 T G 9.74E-04 Response to cytadine analogues (cytosine arabinoside) ANKLE1 missense 24483146 rs66753001 chr19 17394839 A G 1.63E-09 Breast cancer ANKLE1 intron 20852631 rs4808076 chr19 17395401 C T 1.63E-09 Breast cancer ANKLE1 intron 20852631 rs748850 chr19 17396942 C T 3.40E-09 Breast cancer ANKLE1 intron 20852631 rs10425939 chr19 17397244 C T 1.55E-09 Breast cancer ANKLE1 cds-synon 20852631 rs1465581 chr19 17397481 G T 1.07E-11 Breast cancer ANKLE1 UTR-3 20852631 rs11668840 chr19 17399625 T C 3.55E-09 Breast cancer / / 20852631 rs11668840 chr19 17399625 T C 5.01E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7245873 chr19 17401315 G A 3.84E-07 Breast cancer / / 20852631 rs67397200 chr19 17401404 C G 1.25E-11 Breast cancer / / 20852631 rs12974508 chr19 17401521 C T 3.58E-09 Breast cancer / / 20852631 rs12975707 chr19 17401680 A G 3.81E-07 Breast cancer / / 20852631 rs61494113 chr19 17401859 G A 1.29E-11 Breast cancer / / 20852631 rs4808616 chr19 17403033 C A 1.30E-11 Breast cancer ABHD8 UTR-3 20852631 rs11540855 chr19 17403361 A G 1.65E-09 Breast cancer ABHD8 UTR-3 20852631 rs28473003 chr19 17406167 C T 1.66E-09 Breast cancer ABHD8 intron 20852631 rs34546260 chr19 17407597 G A 1.40E-09 Breast cancer ABHD8 intron 20852631 rs12982058 chr19 17409380 C T 2.47E-09 Breast cancer ABHD8 intron 20852631 rs10424198 chr19 17409671 C T 6.57E-08 Breast cancer ABHD8 intron 20852631 rs62126253 chr19 17409949 C T 1.49E-06 Breast cancer ABHD8 intron 20852631 rs2303745 chr19 17420289 G T 1.00E-06 Systemic lupus erythematosus / / 23273568 rs10423120 chr19 17422036 A G 9.21E-08 Breast cancer DDA1 intron 20852631 rs971694 chr19 17422833 T C 2.70E-04 Iris characteristics DDA1 intron 21835309 rs12327712 chr19 17424947 T G 9.66E-08 Breast cancer DDA1 intron 20852631 rs77331626 chr19 17434093 T A 7.00E-24 Rheumatoid arthritis ANO8 UTR-3 24390342 rs11666308 chr19 17437744 T C 4.71E-07 Breast cancer ANO8 intron 20852631 rs8110408 chr19 17440542 C G 1.32E-07 Breast cancer ANO8 intron 20852631 rs60397819 chr19 17451369 G T 1.99E-06 Breast cancer GTPBP3 intron 20852631 rs2364542 chr19 17457552 G A 2.87E-09 Breast cancer / / 20852631 rs12974368 chr19 17459902 G A 1.77E-06 Breast cancer / / 20852631 rs73016427 chr19 17468090 G A 4.45E-07 Breast cancer PLVAP intron 20852631 rs7252581 chr19 17469382 A G 2.00E-04 Information processing speed PLVAP intron 21130836 rs73016432 chr19 17475225 G T 2.17E-06 Breast cancer PLVAP intron 20852631 rs7248564 chr19 17477318 C T 3.35E-04 Suicide attempts in bipolar disorder PLVAP intron 21041247 rs4808629 chr19 17503996 C T 1.30E-04 Bone mineral density (BMD),in women / / 20164292 rs2303680 chr19 17531450 G A 1.92E-05 Bone mineral traits,in men FAM125A intron 21427758 rs7254837 chr19 17546710 T C 3.93E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) TMEM221 UTR-3 23648065 rs11665774 chr19 17580707 A G 4.00E-06 Osteoarthritis / / 22566624 rs8109783 chr19 17588762 G A 3.06E-06 Response to antidepressants SLC27A1 intron 20360315 rs11666579 chr19 17590281 G T 3.00E-06 Response to antidepressants SLC27A1 intron 20360315 rs10418441 chr19 17680101 C T 7.07E-08 Narcolepsy GLT25D1 intron 19629137 rs10419511 chr19 17734848 C T 8.68E-05 Bipolar disorder and schizophrenia UNC13A intron 20889312 rs10419511 chr19 17734848 C T 3.28E-04 Type 2 diabetes UNC13A intron 22238593 rs12608932 chr19 17752689 A C 1.38E-04 Amyotrophic Lateral Sclerosis UNC13A intron 17362836 rs12608932 chr19 17752689 A C 3.00E-14 Amyotrophic lateral sclerosis UNC13A intron 19734901 rs12608932 chr19 17752689 A C 5.14E-08 Amyotrophic lateral sclerosis UNC13A intron 20801717 rs12608932 chr19 17752689 A C 5.00E-08 Amyotrophic lateral sclerosis UNC13A intron 22959728 rs12608932 chr19 17752689 A C 8.30E-09 Amyotrophic lateral sclerosis UNC13A intron 24234648 rs12608932 chr19 17752689 A C 6.00E-06 Amyotrophic lateral sclerosis (sporadic) UNC13A intron 24256812 rs10416963 chr19 17762890 G A 8.00E-06 Obesity-related traits UNC13A intron 23251661 rs11666188 chr19 17769322 A G 1.04E-05 Hemoglobin UNC13A intron pha003098 rs17710624 chr19 17776294 A G 8.93E-04 Body mass index UNC13A intron 21701565 rs4808677 chr19 17783019 G A 8.92E-04 Body mass index UNC13A intron 21701565 rs17654300 chr19 17788648 T C 3.66E-04 Type 2 diabetes UNC13A intron 17463246 rs10413542 chr19 17788940 G C 6.13E-04 Multiple complex diseases UNC13A intron 17554300 rs8111532 chr19 17835520 A G 4.98E-06 Cognitive impairment induced by topiramate MAP1S intron 22091778 rs13382133 chr19 17858936 C T 2.64E-05 Cognitive impairment induced by topiramate FCHO1 intron 22091778 rs12979056 chr19 17862131 G A 9.00E-04 Gamma gluatamyl transferase levels (interaction with age) FCHO1 intron 22010049 rs6512223 chr19 17871232 G A 6.12E-08 Cognitive impairment induced by topiramate FCHO1 intron 22091778 rs6512223 chr19 17871232 G A 1.56E-05 Blood Pressure FCHO1 intron pha003050 rs4239635 chr19 17878722 A G 9.12E-06 Cognitive impairment induced by topiramate FCHO1 intron 22091778 rs4808095 chr19 17880628 T G 8.62E-05 Cognitive impairment induced by topiramate FCHO1 intron 22091778 rs4808687 chr19 17882922 T C 5.98E-04 Multiple complex diseases FCHO1 intron 17554300 rs4808691 chr19 17893374 A G 7.48E-04 Multiple complex diseases FCHO1 intron 17554300 rs265548 chr19 17902334 T C 1.00E-13 Tumor biomarkers / / 23300138 rs265545 chr19 17903465 C T 6.05E-10 Tumor biomarkers / / 23300138 rs36692 chr19 17906839 C T 5.23E-04 HIV-1 viral setpoint B3GNT3 intron 17641165 rs36692 chr19 17906839 C T 3.88E-09 Tumor biomarkers B3GNT3 intron 23300138 rs12980842 chr19 17909836 G A 7.16E-08 Tumor biomarkers B3GNT3 intron 23300138 rs36690 chr19 17910483 C T 3.88E-09 Tumor biomarkers B3GNT3 intron 23300138 rs7256058 chr19 17914484 G A 9.15E-11 Tumor biomarkers B3GNT3 intron 23300138 rs7245542 chr19 17914522 T C 8.25E-11 Tumor biomarkers B3GNT3 intron 23300138 rs2161488 chr19 17916034 G C 7.06E-11 Tumor biomarkers B3GNT3 intron 23300138 rs3212799 chr19 17937516 C T 0.000000686 Triglycerides JAK3 UTR-3 23063622 rs3212756 chr19 17947847 G T 0.000000153 Triglycerides JAK3 intron 23063622 rs867174 chr19 17952930 A G 2.75E-06 Nephrolithiasis JAK3 intron 22396660 rs3212701 chr19 17957024 C T 2.69E-05 Cognitive decline JAK3 intron 22054870 rs13345965 chr19 17959012 C T 9.29E-05 Cognitive impairment induced by topiramate JAK3 nearGene-5 22091778 rs12327843 chr19 18004912 T C 2.26E-06 Nephrolithiasis SLC5A5 UTR-3 22396660 rs4808105 chr19 18053340 T C 3.67E-04 Eating disorders CCDC124 intron 23568457 rs8104153 chr19 18054132 G C 0.00039 Prostate cancer CCDC124 missense 23555315 rs10153455 chr19 18095277 G A 4.32E-04 Lung function (forced vital capacity) KCNN1 intron 24023788 rs1057261 chr19 18109314 A G 2.70E-04 Suicide attempts in bipolar disorder KCNN1 UTR-3 21423239 rs12984174 chr19 18132540 T C 9.00E-06 Pulmonary function in asthmatics / / 23541324 rs388159 chr19 18141996 C T 2.06E-05 Pulmonary function in asthmatics / / 23541324 rs388159 chr19 18141996 C T 3.47E-05 Pulmonary function in asthmatics / / 23541324 rs10422102 chr19 18157498 G A 7.21E-05 Coronary heart disease / / pha003056 rs10424480 chr19 18157551 A G 7.79E-05 Coronary heart disease / / pha003056 rs445521 chr19 18169314 T G 2.80E-05 Urinary metabolites / / 21572414 rs372889 chr19 18173603 T C 4.69E-05 Diabetic nephropathy IL12RB1 intron 21150874 rs372889 chr19 18173603 T C 1.26E-04 Type 2 diabetes IL12RB1 intron 22238593 rs11086090 chr19 18232754 G T 5.74E-06 Serum alpha1-antitrypsin levels MAST3 intron 23990791 rs12462442 chr19 18233195 G A 5.74E-06 Serum alpha1-antitrypsin levels MAST3 intron 23990791 rs12611216 chr19 18234005 G A 1.01E-05 Serum alpha1-antitrypsin levels MAST3 intron 23990791 rs740691 chr19 18234441 C T 2.58E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAST3 cds-synon 20877124 rs740691 chr19 18234441 C T 7.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAST3 cds-synon 20877124 rs740691 chr19 18234441 C T 1.53E-04 Attention deficit hyperactivity disorder MAST3 cds-synon 22420046 rs740692 chr19 18234567 G T 1.74E-05 Serum alpha1-antitrypsin levels MAST3 intron 23990791 rs740693 chr19 18234639 G A 2.59E-05 Serum alpha1-antitrypsin levels MAST3 intron 23990791 rs12609740 chr19 18240298 G A 4.16E-05 Serum alpha1-antitrypsin levels MAST3 intron 23990791 rs273496 chr19 18241857 C T 5.77E-04 Smoking initiation MAST3 intron 24665060 rs874628 chr19 18304700 A G 1.00E-04 Information processing speed MPV17L2 missense 21130836 rs874628 chr19 18304700 A G 1.00E-08 Multiple sclerosis MPV17L2 missense 21833088 rs1042050 chr19 18329240 T C 0.000438 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PDE4C cds-synon 23233654 rs1042050 chr19 18329240 T C 4.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) PDE4C cds-synon 23233662 rs4808764 chr19 18332400 T C 0.0004407 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PDE4C intron 23233654 rs4808764 chr19 18332400 T C 4.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) PDE4C intron 23233662 rs2074973 chr19 18333273 A G 0.0004437 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PDE4C intron 23233654 rs2074973 chr19 18333273 A G 4.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) PDE4C intron 23233662 rs8112975 chr19 18340910 A G 7.85E-04 Multiple complex diseases PDE4C intron 17554300 rs271831 chr19 18347539 A G 3.68E-05 Information processing speed PDE4C intron 21130836 rs202121427 chr19 18368694 G T 0.00026 Breast cancer KIAA1683 cds-synon 23555315 rs2891654 chr19 18369120 G A 2.00E-04 Information processing speed KIAA1683 intron 21130836 rs73003205 chr19 18370790 A C 0.0000143 Primary biliary cirrhosis KIAA1683 intron 22936693 rs73003205 chr19 18370790 A C 0.0000747 Primary biliary cirrhosis in females KIAA1683 intron 22936693 rs73003205 chr19 18370790 A C 0.00016 Primary biliary cirrhosis (anti-mitochondrial antibody positive) KIAA1683 intron 22936693 rs10425001 chr19 18371197 C T 3.67E-05 Cholesterol KIAA1683 intron 17255346 rs2277922 chr19 18376522 T G 1.00E-04 Information processing speed KIAA1683 missense 21130836 rs3746186 chr19 18377274 A G 7.96E-05 Information processing speed KIAA1683 missense 21130836 rs1469023 chr19 18378219 A G 5.84E-05 Information processing speed KIAA1683 missense 21130836 rs6512255 chr19 18393682 C T 4.84E-04 IgE levels / / 17255346 rs2059038 chr19 18416930 T A 4.99E-04 Taste perception / / 22132133 rs4808781 chr19 18416972 A G 8.37E-04 Multiple complex diseases / / 17554300 rs4808781 chr19 18416972 A G 5.34E-04 Taste perception / / 22132133 rs2232965 chr19 18426950 T C 3.50E-05 Bone mineral density (spine) LSM4 intron 19079262 rs2232965 chr19 18426950 T C 3.46E-04 Taste perception LSM4 intron 22132133 rs2232965 chr19 18426950 T C 1.19E-04 Lung function (forced expiratory volume in 1 second) LSM4 intron 24023788 rs1035364 chr19 18428880 T C 5.18E-04 Taste perception LSM4 intron 22132133 rs1862145 chr19 18432929 G A 5.30E-05 Lung function (forced expiratory volume in 1 second) LSM4 intron 24023788 rs2241351 chr19 18433225 T C 3.50E-05 Asthma LSM4 intron 22561531 rs12985909 chr19 18439383 C T 7.54E-07 Crohn's disease / / 18587394 rs12985909 chr19 18439383 C T 4.68E-04 Taste perception / / 22132133 rs4641872 chr19 18440942 G T 3.68E-05 Bipolar disorder and schizophrenia / / 20889312 rs10415765 chr19 18448105 T C 3.16E-05 Parkinson's disease / / 21812969 rs9636202 chr19 18449238 G A 2.20E-04 Type 2 diabetes / / 17463246 rs1978423 chr19 18450713 T C 3.81E-07 Telomere length / / 21573004 rs2112176 chr19 18455679 A C 8.38E-05 Smoking quantity PGPEP1 intron 24665060 rs11086106 chr19 18461458 C T 2.63E-04 Longevity PGPEP1 intron 22279548 rs7248363 chr19 18467886 T C 1.00E-06 Bipolar disorder and schizophrenia PGPEP1 intron 20889312 rs7248363 chr19 18467886 T C 3.85E-05 Schizophrenia PGPEP1 intron pha002857 rs888663 chr19 18484922 G T 3.57E-05 Coronary heart disease / / pha003031 rs78015699 chr19 18487667 C T 7.00E-06 Periodontitis (Mean PAL) / / 24024966 rs6512265 chr19 18502835 G A 0.0002 Breast cancer LRRC25 missense 23555315 rs1560117 chr19 18512932 C T 6.35E-04 White matter integrity LOC100653010 intron 22425255 rs13344313 chr19 18517767 G A 3.21E-05 Nephrolithiasis / / 22396660 rs7258465 chr19 18533642 T C 2.16E-05 Self-reported allergy SSBP4 intron 23817569 rs10405636 chr19 18538742 A C 1.63E-05 Self-reported allergy SSBP4 cds-synon 23817569 rs10442 chr19 18545341 A C,G,T 1.64E-05 Self-reported allergy ISY/1 UTR-3 23817569 rs1043327 chr19 18554972 A G 2.39E-05 Self-reported allergy ELL UTR-3 23817569 rs748609 chr19 18560282 T C 2.02E-05 Self-reported allergy ELL intron 23817569 rs2303695 chr19 18562624 C T 2.42E-05 Self-reported allergy ELL intron 23817569 rs731945 chr19 18567039 C T 7.72E-05 Osteoarthritis ELL intron 19508968 rs731945 chr19 18567039 C T 6.00E-06 Self-reported allergy ELL intron 23817569 rs10164319 chr19 18569833 G A 2.17E-05 Self-reported allergy ELL intron 23817569 rs1560118 chr19 18570035 G A 1.98E-05 Self-reported allergy ELL intron 23817569 rs4808801 chr19 18571141 A G 5.00E-15 Breast cancer ELL intron 23535729 rs4808801 chr19 18571141 A G 5.10E-05 Breast cancer ELL intron 23535733 rs4808801 chr19 18571141 A G 2.11E-05 Self-reported allergy ELL intron 23817569 rs8103622 chr19 18572834 C T 2.26E-05 Self-reported allergy ELL intron 23817569 rs1560119 chr19 18573675 A G 2.06E-05 Self-reported allergy ELL intron 23817569 rs2278238 chr19 18576484 T C 2.27E-05 Self-reported allergy ELL intron 23817569 rs34786858 chr19 18576484 T TG 2.27E-05 Self-reported allergy ELL intron 23817569 rs10425982 chr19 18586519 T A 2.17E-05 Self-reported allergy ELL intron 23817569 rs7256534 chr19 18586791 C T 2.32E-05 Self-reported allergy ELL intron 23817569 rs7251067 chr19 18600056 G A 2.95E-05 Cytomegalovirus antibody response ELL intron 21993531 rs7253990 chr19 18604085 C G 2.04E-05 Self-reported allergy ELL intron 23817569 rs875396 chr19 18611147 A G 3.93E-05 Self-reported allergy ELL intron 23817569 rs7252707 chr19 18612257 G A 4.11E-05 Self-reported allergy ELL intron 23817569 rs8107347 chr19 18612748 G A 2.98E-05 Self-reported allergy ELL intron 23817569 rs17211813 chr19 18613917 C T 2.43E-04 IgE levels ELL intron 17255346 rs8109573 chr19 18617151 G T 4.20E-05 Self-reported allergy ELL intron 23817569 rs4808136 chr19 18618867 G A 4.20E-05 Self-reported allergy ELL intron 23817569 rs4808136 chr19 18618867 G A 5.00E-14 Blood metabolite levels ELL intron 24816252 rs271628 chr19 18624333 A G 4.42E-05 Self-reported allergy ELL intron 23817569 rs271626 chr19 18627067 T C 5.00E-04 Primary sclerosing cholangitis ELL intron 19944697 rs271626 chr19 18627067 T C 4.59E-05 Self-reported allergy ELL intron 23817569 rs271624 chr19 18627953 A G 3.81E-05 Self-reported allergy ELL intron 23817569 rs76195 chr19 18629830 T C 4.35E-05 Self-reported allergy ELL intron 23817569 rs271621 chr19 18631332 C A 3.86E-05 Self-reported allergy ELL intron 23817569 rs2283617 chr19 18706504 G A 1.43E-05 Major depressive disorder (broad) CRLF1 intron 20038947 rs2238647 chr19 18710535 G A 8.20E-06 Major depressive disorder (broad) CRLF1 cds-synon 20038947 rs7249956 chr19 18715203 C A 8.11E-06 Major depressive disorder (broad) CRLF1 intron 20038947 rs916791 chr19 18724157 G A 6.73E-05 Self-reported allergy TMEM59L intron 23817569 rs7256751 chr19 18739497 C T 3.17E-05 Multiple complex diseases / / 17554300 rs4808839 chr19 18744288 T C 1.54E-04 Self-reported allergy / / 23817569 rs1991017 chr19 18746593 T A 1.13E-04 Esophageal adenocarcinoma / / 24121790 rs1991017 chr19 18746593 T A 2.79E-06 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs1991017 chr19 18746593 T A 9.22E-05 Barrett's esophagus / / 24121790 rs3764628 chr19 18747605 G T 4.00E-06 Orofacial clefts / / 22419666 rs3764628 chr19 18747605 G T 1.13E-04 Self-reported allergy / / 23817569 rs11665980 chr19 18749354 G A 7.02E-05 Self-reported allergy KLHL26 intron 23817569 rs3795027 chr19 18780799 C T 1.75E-05 Orofacial clefts KLHL26 UTR-3 22419666 rs10419226 chr19 18803172 T G 4.00E-10 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) CRTC1 intron 24121790 rs10419226 chr19 18803172 T G 6.00E-08 Barrett's esophagus CRTC1 intron 24121790 rs10419226 chr19 18803172 T G 8.00E-07 Esophageal adenocarcinoma CRTC1 intron 24121790 rs10423674 chr19 18817903 C A 6.00E-09 Menarche (age at onset) CRTC1 intron 21102462 rs10423674 chr19 18817903 C A 1.46E-06 Esophageal adenocarcinoma CRTC1 intron 24121790 rs10423674 chr19 18817903 C A 1.75E-09 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) CRTC1 intron 24121790 rs10423674 chr19 18817903 C A 1.92E-06 Barrett's esophagus CRTC1 intron 24121790 rs2238655 chr19 18964442 C T 5.61E-04 Type 2 diabetes UPF1 intron 17463246 rs1122821 chr19 19050957 A G 3.15E-05 Insulin Resistance HOMER3 UTR-5 pha003062 rs1122821 chr19 19050957 A G 3.29E-05 Insulin-related traits HOMER3 UTR-5 pha003063 rs10411413 chr19 19120381 C T 9.63E-12 HDL cholesterol SUGP2 intron 23063622 rs34729281 chr19 19120381 C CG 9.63E-12 HDL cholesterol SUGP2 intron 23063622 rs2285851 chr19 19126913 G T 3.82E-05 Orofacial clefts SUGP2 intron 22419666 rs10422058 chr19 19158200 T C 2.74E-11 HDL cholesterol ARMC6 intron 23063622 rs10405178 chr19 19175752 T G 7.81E-12 HDL cholesterol SLC25A42 intron 23063622 rs2012318 chr19 19208240 C T 7.93E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SLC25A42 intron 20031582 rs7360000 chr19 19266848 C T 2.03E-10 Cholesterol,total MEF2BNB-MEF2B intron 23063622 rs7360000 chr19 19266848 C T 3.79E-08 LDL cholesterol MEF2BNB-MEF2B intron 23063622 rs3890384 chr19 19275735 C T 1.36E-06 Type 2 diabetes MEF2BNB-MEF2B intron 23300278 rs7249142 chr19 19276359 A G 9.00E-06 IgG glycosylation MEF2BNB-MEF2B intron 23382691 rs11671119 chr19 19286077 C T 1.11E-95 Multiple complex diseases MEF2BNB-MEF2B intron 17554300 rs10896 chr19 19287928 A G 1.65E-04 Pancreatic cancer MEF2BNB UTR-3 pha002874 rs2238671 chr19 19293192 C T 5.89E-05 Cognitive test performance MEF2BNB UTR-3 20125193 rs11668319 chr19 19295875 A G 1.49E-10 Cholesterol,total MEF2BNB-MEF2B intron 23063622 rs11668319 chr19 19295875 A G 4.04E-08 LDL cholesterol MEF2BNB-MEF2B intron 23063622 rs12459686 chr19 19299961 C A 0.0000396 Cholesterol,total MEF2BNB-MEF2B intron 23063622 rs3761081 chr19 19301186 G A 7.40E-05 Potassium levels MEF2BNB-MEF2B intron pha003086 rs2228603 chr19 19329924 C T 5.90E-08 Lipid levels NCAN missense 18193043 rs2228603 chr19 19329924 C T 6.86E-13 Triglycerides NCAN missense 19060911 rs2228603 chr19 19329924 C T 1.53E-05 Lipid levels NCAN missense 19913121 rs2228603 chr19 19329924 C T 1.53E-05 Lipid levels NCAN missense 19913121 rs2228603 chr19 19329924 C T 4.90E-06 Lipid levels NCAN missense 19936222 rs2228603 chr19 19329924 C T 1.22E-11 Nonalcoholic fatty liver disease NCAN missense 21423719 rs2228603 chr19 19329924 C T 1.03E-12 LDL cholesterol NCAN missense 23063622 rs2228603 chr19 19329924 C T 2.87E-20 Cholesterol,total NCAN missense 23063622 rs2228603 chr19 19329924 C T 6.45E-19 Triglycerides NCAN missense 23063622 rs2238675 chr19 19336608 C T 4.84E-08 Triglycerides NCAN intron 19060911 rs2238675 chr19 19336608 C T 3.27E-13 Cholesterol,total NCAN intron 23063622 rs2238675 chr19 19336608 C T 4.90E-14 Triglycerides NCAN intron 23063622 rs2238675 chr19 19336608 C T 9.69E-08 LDL cholesterol NCAN intron 23063622 rs10402729 chr19 19355100 T C 0.000000211 LDL cholesterol NCAN intron 23063622 rs10402729 chr19 19355100 T C 1.95E-14 HDL cholesterol NCAN intron 23063622 rs1064395 chr19 19361735 G A 2.00E-09 Bipolar disorder NCAN UTR-3 21353194 rs2074296 chr19 19373689 A G 0.00000151 Cholesterol,total / / 23063622 rs2074296 chr19 19373689 A G 0.000004 LDL cholesterol / / 23063622 rs2074296 chr19 19373689 A G 1.60E-09 Triglycerides / / 23063622 rs8105094 chr19 19374061 C T 0.000000576 LDL cholesterol / / 23063622 rs8105094 chr19 19374061 C T 5.41E-10 Triglycerides / / 23063622 rs8105094 chr19 19374061 C T 9.18E-10 Cholesterol,total / / 23063622 rs58542926 chr19 19379549 C T 9.38E-09 Vitamin E alpha tocopherol TM6SF2 missense 23696881 rs17750998 chr19 19388446 G A 5.35E-04 Iron levels SUGP1 intron pha002876 rs2023883 chr19 19405480 G A 1.33E-11 Cholesterol,total SUGP1 intron 23063622 rs2023883 chr19 19405480 G A 1.65E-12 Triglycerides SUGP1 intron 23063622 rs2023883 chr19 19405480 G A 8.41E-08 LDL cholesterol SUGP1 intron 23063622 rs10401969 chr19 19407718 T C 2.30E-07 Lipid levels SUGP1 intron 18193043 rs10401969 chr19 19407718 T C 2.00E-08 LDL cholesterol SUGP1 intron 19060906 rs10401969 chr19 19407718 T C 2.00E-29 Triglycerides SUGP1 intron 20686565 rs10401969 chr19 19407718 T C 3.00E-38 Cholesterol,total SUGP1 intron 20686565 rs10401969 chr19 19407718 T C 7.00E-22 LDL cholesterol SUGP1 intron 20686565 rs10401969 chr19 19407718 T C 1.00E-11 LDL cholesterol SUGP1 intron 20864672 rs10401969 chr19 19407718 T C 2.00E-08 Coronary heart disease SUGP1 intron 21347282 rs10401969 chr19 19407718 T C 1.10E-10 Metabolic syndrome phenotype SUGP1 intron 22022282 rs10401969 chr19 19407718 T C 1.40E-08 Metabolic syndrome phenotype SUGP1 intron 22022282 rs10401969 chr19 19407718 T C 0.000000007 Type 2 diabetes SUGP1 intron 22885922 rs10401969 chr19 19407718 T C 0.00000029 Type 2 diabetes (males) SUGP1 intron 22885922 rs10401969 chr19 19407718 T C 0.00014 Type 2 diabetes (females) SUGP1 intron 22885922 rs10401969 chr19 19407718 T C 1.60E-29 Triglycerides SUGP1 intron 22885922 rs10401969 chr19 19407718 T C 2.90E-38 Cholesterol,total SUGP1 intron 22885922 rs10401969 chr19 19407718 T C 6.70E-22 LDL cholesterol SUGP1 intron 22885922 rs10401969 chr19 19407718 T C 0.00002 Cholesterol,total SUGP1 intron 23063622 rs10401969 chr19 19407718 T C 9.32E-09 Vitamin E alpha tocopherol SUGP1 intron 23696881 rs10401969 chr19 19407718 T C 1.00E-69 Triglycerides SUGP1 intron 24097068 rs10401969 chr19 19407718 T C 3.00E-54 LDL cholesterol SUGP1 intron 24097068 rs10401969 chr19 19407718 T C 4.00E-77 Cholesterol,total SUGP1 intron 24097068 rs1859287 chr19 19422187 T C 4.86E-12 Cholesterol,total SUGP1 intron 23063622 rs1859287 chr19 19422187 T C 5.28E-08 LDL cholesterol SUGP1 intron 23063622 rs1859287 chr19 19422187 T C 6.99E-13 Triglycerides SUGP1 intron 23063622 rs2011503 chr19 19443986 T C 9.00E-08 Bipolar disorder MAU2 intron 24618891 rs2285627 chr19 19467937 T C 4.87E-08 Triglycerides MAU2 UTR-3 23063622 rs2285628 chr19 19467996 T A 0.000000101 LDL cholesterol MAU2 UTR-3 23063622 rs2285628 chr19 19467996 T A 2.68E-12 Triglycerides MAU2 UTR-3 23063622 rs2285628 chr19 19467996 T A 9.81E-12 Cholesterol,total MAU2 UTR-3 23063622 rs2905424 chr19 19473445 T C 3.00E-09 Schizophrenia / / 23974872 rs2905425 chr19 19475717 G C 0.000000254 Triglycerides / / 23063622 rs2905425 chr19 19475717 G C 0.000000678 Cholesterol,total / / 23063622 rs2965200 chr19 19476365 G A 8.43E-05 Epilepsy (remission after treatment) / / 23962720 rs2905426 chr19 19478022 G T 9.06E-05 Epilepsy (remission after treatment) / / 23962720 rs2315283 chr19 19480575 T C 9.87E-05 Epilepsy (remission after treatment) / / 23962720 rs34538000 chr19 19481379 G T 8.45E-05 Epilepsy (remission after treatment) / / 23962720 rs10415849 chr19 19505087 C T 6.06E-07 Carotenoid and tocopherol levels GATAD2A intron 19185284 rs10415849 chr19 19505087 C T 1.65E-12 LDL cholesterol GATAD2A intron 23063622 rs10415849 chr19 19505087 C T 2.27E-17 Triglycerides GATAD2A intron 23063622 rs10415849 chr19 19505087 C T 5.33E-20 Cholesterol,total GATAD2A intron 23063622 rs1469713 chr19 19528806 A G 0.000000233 Cholesterol,total GATAD2A intron 23063622 rs1469713 chr19 19528806 A G 0.000016 LDL cholesterol GATAD2A intron 23063622 rs4808199 chr19 19545099 G A 3.20E-05 Triglycerides GATAD2A intron 19074352 rs4808199 chr19 19545099 G A 1.92E-08 LDL cholesterol GATAD2A intron 23063622 rs4808199 chr19 19545099 G A 2.29E-10 Triglycerides GATAD2A intron 23063622 rs4808199 chr19 19545099 G A 4.67E-13 Cholesterol,total GATAD2A intron 23063622 rs4808200 chr19 19554803 G A 0.00000129 Triglycerides GATAD2A intron 23063622 rs7256149 chr19 19566255 T C 7.61E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs4808957 chr19 19567248 A G 7.59E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs4808202 chr19 19568439 G A 7.57E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs4808203 chr19 19568659 T C 1.10E-05 Lipid levels GATAD2A intron 18193043 rs4808203 chr19 19568659 T C 9.72E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs4808959 chr19 19572108 T G 6.25E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs9917108 chr19 19572785 A G 7.50E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs1808653 chr19 19578072 T C 7.42E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs2099334 chr19 19578450 A G 7.40E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs10405625 chr19 19579046 T G 7.40E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs747050 chr19 19584987 C G 7.31E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs10401193 chr19 19591066 A G 1.70E-14 Lymphocyte counts GATAD2A intron 22286170 rs10419912 chr19 19597055 G A 6.86E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs2315610 chr19 19597240 T C 6.75E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs751856 chr19 19602945 A G 5.72E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs4808964 chr19 19603692 C A 5.27E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs2288852 chr19 19605348 T C 5.71E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs1865034 chr19 19605763 C T 5.71E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs2082421 chr19 19606264 C T 5.64E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs1047361 chr19 19606634 G A 5.70E-05 Epilepsy (remission after treatment) GATAD2A cds-synon 23962720 rs6511038 chr19 19607564 A C 5.69E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs10402451 chr19 19608537 A G 5.69E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs3794990 chr19 19610030 A G 5.68E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs3794991 chr19 19610596 C T 1.20E-06 Lipid levels GATAD2A intron 18193043 rs3794991 chr19 19610596 C T 4.41E-06 Lipid levels GATAD2A intron 19913121 rs3794991 chr19 19610596 C T 6.33E-04 Lipid levels GATAD2A intron 19913121 rs3794991 chr19 19610596 C T 6.39E-04 Lipid levels GATAD2A intron 19913121 rs3794991 chr19 19610596 C T 5.70E-09 Type 2 diabetes GATAD2A intron 22325160 rs3794991 chr19 19610596 C T 0.00000441 Triglycerides (males) GATAD2A intron 22629316 rs3794991 chr19 19610596 C T 0.00000569 Triglycerides (females) GATAD2A intron 22629316 rs3794991 chr19 19610596 C T 4.83E-10 Triglycerides GATAD2A intron 22629316 rs3794991 chr19 19610596 C T 0.000000634 Triglycerides in females GATAD2A intron 23063622 rs3794991 chr19 19610596 C T 1.57E-18 Total cholesterol in males GATAD2A intron 23063622 rs3794991 chr19 19610596 C T 1.96E-10 Total cholesterol in females GATAD2A intron 23063622 rs3794991 chr19 19610596 C T 4.21E-15 Triglycerides in males GATAD2A intron 23063622 rs3794991 chr19 19610596 C T 5.93E-18 LDL cholesterol GATAD2A intron 23063622 rs3794991 chr19 19610596 C T 8.05E-24 Triglycerides GATAD2A intron 23063622 rs3794991 chr19 19610596 C T 8.26E-29 Cholesterol,total GATAD2A intron 23063622 rs3794993 chr19 19611550 C A 5.68E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs16996119 chr19 19612625 G T 0.000000035 LDL cholesterol GATAD2A intron 23063622 rs892022 chr19 19613381 G A 5.60E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs892021 chr19 19613480 T C 5.66E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs3752151 chr19 19616026 T C 5.59E-05 Epilepsy (remission after treatment) GATAD2A intron 23962720 rs1063966 chr19 19616742 G A 5.65E-05 Epilepsy (remission after treatment) GATAD2A UTR-3 23962720 rs1054284 chr19 19616953 T G 5.58E-05 Epilepsy (remission after treatment) GATAD2A UTR-3 23962720 rs6626 chr19 19617655 T C 5.65E-05 Epilepsy (remission after treatment) GATAD2A UTR-3 23962720 rs10282 chr19 19619317 T C 5.70E-05 Epilepsy (remission after treatment) GATAD2A UTR-3 23962720 rs6909 chr19 19619542 A G 5.64E-05 Epilepsy (remission after treatment) GATAD2A UTR-3 23962720 rs10402627 chr19 19621038 T C 5.64E-05 Epilepsy (remission after treatment) / / 23962720 rs7250893 chr19 19625547 A G 5.64E-05 Epilepsy (remission after treatment) TSSK6 cds-synon 23962720 rs7252888 chr19 19628037 G A 1.04E-20 Lymphocyte counts NDUFA13 intron 22286170 rs7253807 chr19 19631444 A T 5.62E-05 Epilepsy (remission after treatment) NDUFA13 intron 23962720 rs4808965 chr19 19631655 A G 5.62E-05 Epilepsy (remission after treatment) NDUFA13 intron 23962720 rs4808967 chr19 19640524 T C 3.34E-05 Epilepsy (remission after treatment) YJEFN3 intron 23962720 rs10422819 chr19 19643028 C A 5.02E-05 Epilepsy (remission after treatment) YJEFN3 intron 23962720 rs2304098 chr19 19646272 T C 0.00000115 Triglycerides YJEFN3 intron 23063622 rs2304098 chr19 19646272 T C 5.30E-05 Epilepsy (remission after treatment) YJEFN3 intron 23962720 rs1054930 chr19 19648346 G C 5.46E-05 Epilepsy (remission after treatment) YJEFN3 UTR-3 23962720 rs4808208 chr19 19650096 A G 5.62E-05 Epilepsy (remission after treatment) CILP2 intron 23962720 rs16996148 chr19 19658472 G T 3.00E-09 Triglycerides / / 18193043 rs16996148 chr19 19658472 G T 3.00E-08 LDL cholesterol / / 18193044 rs16996148 chr19 19658472 G T 4.00E-09 Triglycerides / / 18193044 rs16996148 chr19 19658472 G T 1.69E-06 Lipid levels / / 19913121 rs16996148 chr19 19658472 G T 5.75E-04 Lipid levels / / 19913121 rs16996148 chr19 19658472 G T 6.01E-04 Lipid levels / / 19913121 rs16996148 chr19 19658472 G T 3.00E-09 Coronary heart disease / / 21347282 rs16996148 chr19 19658472 G T 1.23E-22 Triglycerides / / 23063622 rs16996148 chr19 19658472 G T 2.80E-26 Triglycerides / / 23063622 rs16996148 chr19 19658472 G T 2.83E-24 Cholesterol,total / / 23063622 rs16996148 chr19 19658472 G T 7.55E-15 LDL cholesterol / / 23063622 rs17216525 chr19 19662220 C T 4.00E-11 Triglycerides / / 19060906 rs892023 chr19 19663850 A G 0.0000344 Triglycerides / / 23063622 rs16996163 chr19 19688302 C T 1.93E-08 LDL cholesterol PBX4 intron 23063622 rs7252981 chr19 19692579 T C 0.000066 LDL cholesterol PBX4 intron 23063622 rs16996185 chr19 19720788 T G 2.90E-141 Type 2 diabetes PBX4 intron 22885922 rs12610185 chr19 19721722 G A 4.74E-12 Triglycerides PBX4 intron 19060911 rs12610185 chr19 19721722 G A 9.09E-07 Carotenoid and tocopherol levels PBX4 intron 19185284 rs12610185 chr19 19721722 G A 5.64E-07 Lipid levels PBX4 intron 19913121 rs12610185 chr19 19721722 G A 2.90E-04 Lipid levels PBX4 intron 19936222 rs12610185 chr19 19721722 G A 7.50E-04 Lipid levels PBX4 intron 19936222 rs12610185 chr19 19721722 G A 0.00003 Type 2 diabetes PBX4 intron 22885922 rs12610185 chr19 19721722 G A 1.70E-14 LDL cholesterol PBX4 intron 23063622 rs12610185 chr19 19721722 G A 2.58E-22 Triglycerides PBX4 intron 23063622 rs12610185 chr19 19721722 G A 2.84E-24 Cholesterol,total PBX4 intron 23063622 rs12610185 chr19 19721722 G A 4.00E-06 Obesity-related traits PBX4 intron 23251661 rs10500212 chr19 19723215 C T 6.79E-07 Lipid levels PBX4 intron 19913121 rs10500212 chr19 19723215 C T 1.14E-21 Triglycerides PBX4 intron 23063622 rs10500212 chr19 19723215 C T 8.13E-14 LDL cholesterol PBX4 intron 23063622 rs10500212 chr19 19723215 C T 9.25E-24 Cholesterol,total PBX4 intron 23063622 rs2304128 chr19 19746151 G T 2.64E-13 Triglycerides GMIP intron 19060911 rs2304128 chr19 19746151 G T 8.58E-06 Carotenoid and tocopherol levels GMIP intron 19185284 rs2304128 chr19 19746151 G T 1.83E-04 Lipid levels GMIP intron 19913121 rs2304128 chr19 19746151 G T 3.15E-07 Lipid levels GMIP intron 19913121 rs2304128 chr19 19746151 G T 3.31E-04 Lipid levels GMIP intron 19913121 rs2304128 chr19 19746151 G T 1.40E-04 Lipid levels GMIP intron 19936222 rs2304128 chr19 19746151 G T 1.47E-18 Triglycerides GMIP intron 23063622 rs2304128 chr19 19746151 G T 3.34E-16 Total cholesterol in males GMIP intron 23063622 rs2304128 chr19 19746151 G T 5.55E-09 Total cholesterol in females GMIP intron 23063622 rs2304128 chr19 19746151 G T 6.54E-25 Cholesterol,total GMIP intron 23063622 rs2304128 chr19 19746151 G T 7.14E-16 LDL cholesterol GMIP intron 23063622 rs892035 chr19 19758190 T C 7.09E-04 Response to cytadine analogues (cytosine arabinoside) ATP13A1 intron 24483146 rs2304130 chr19 19789528 A G 2.00E-15 Cholesterol,total ZNF101 intron 19060911 rs2304130 chr19 19789528 A G 3.00E-06 Triglycerides ZNF101 intron 19060911 rs2304130 chr19 19789528 A G 4.00E-08 Triglycerides ZNF101 intron 20864672 rs2304130 chr19 19789528 A G 3.00E-06 Coronary heart disease ZNF101 intron 21347282 rs2304130 chr19 19789528 A G 6.00E-09 Sphingolipid levels ZNF101 intron 22359512 rs2304130 chr19 19789528 A G 1.10E-97 Type 2 diabetes ZNF101 intron 22885922 rs2304130 chr19 19789528 A G 9.71E-06 Triglycerides ZNF101 intron pha002904 rs1540593 chr19 19853233 T A 9.16E-04 Alzheimer's disease / / 22005930 rs8104983 chr19 19859845 A G 3.08E-04 Depression (quantitative trait) / / 20800221 rs2023414 chr19 19860495 C T 9.44E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs35075703 chr19 19860828 A G 9.05E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs247785 chr19 19864309 G T 2.63E-04 Alzheimer's disease / / 24755620 rs4808983 chr19 19882476 C T 3.96E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) LOC284440 intron 24023788 rs248940 chr19 19883691 A G 9.18E-04 Response to taxane treatment (placlitaxel) LOC284440 intron 23006423 rs248940 chr19 19883691 A G 3.78E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LOC284440 intron 24023788 rs1560189 chr19 19887108 C T 9.81E-04 Multiple complex diseases LOC284440 intron 17554300 rs10411195 chr19 20036176 T C 6.00E-06 Smoking behavior ZNF93 intron 19247474 rs6511061 chr19 20054823 G A 7.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs7258519 chr19 20056348 T C 3.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7258519 chr19 20056348 T C 4.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4809015 chr19 20061125 T C 4.70E-05 Bipolar disorder / / 18317468 rs8104863 chr19 20108062 T C 5.27E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs17699483 chr19 20111004 C G 5.43E-04 Multiple complex diseases / / 17554300 rs258576 chr19 20111994 A G 0.000704 Salmonella-induced pyroptosis / / 22837397 rs10420011 chr19 20140614 G A 4.23E-04 Alzheimer's disease ZNF682 intron 17998437 rs1725939 chr19 20238148 A C 2.00E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs1618723 chr19 20242274 G A 1.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs836896 chr19 20291263 T C 1.40E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) ZNF486 intron 23648065 rs1654260 chr19 20329111 G A 8.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs1654261 chr19 20329637 G A 8.49E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs7247148 chr19 20411543 A G 8.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs10408131 chr19 20465101 A G 6.93E-04 Insulin resistance / / 21901158 rs7254670 chr19 20466055 T C 5.99E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs9653141 chr19 20481452 C A 2.90E-05 Urinary metabolites / / 21572414 rs8111389 chr19 20489861 A G 1.10E-05 Urinary metabolites / / 21572414 rs1862273 chr19 20653638 C T 2.69E-04 Smoking cessation / / 24665060 rs8106213 chr19 20657781 G A 1.15E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11666947 chr19 20661008 G T 5.43E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2545902 chr19 20683430 A G 3.52E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2545902 chr19 20683430 A G 5.48E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2545904 chr19 20684670 C A 1.12E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2545904 chr19 20684670 C A 2.01E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2562664 chr19 20700754 C G 1.41E-04 Insulin resistance / / 21901158 rs7251507 chr19 20797079 A G 7.99E-04 Type 2 diabetes / / 17463246 rs7251507 chr19 20797079 A G 3.09E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs8109263 chr19 20797644 G T 1.99E-06 Bipolar disorder / / 21771265 rs8100262 chr19 20821502 T G 2.37E-05 Triglycerides ZNF626 intron 19074352 rs8100262 chr19 20821502 T G 2.37E-05 Polyunsaturated fatty acid levels,in plasma ZNF626 intron 19148276 rs4808260 chr19 20846271 C G 7.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients / / 23400010 rs12609807 chr19 20887230 A G 4.90E-06 Asparaginase sensitivity in blood cell lines / / 21072045 rs7258003 chr19 20899284 A G 7.90E-05 Adiposity / / 19461586 rs2358606 chr19 20973728 C T 7.59E-04 Alzheimer's disease / / 22005930 rs587212 chr19 20997796 A G 4.15E-04 Multiple complex diseases / / 17554300 rs668184 chr19 21000781 T C 9.37E-04 Multiple complex diseases / / 17554300 rs7249876 chr19 21088856 G A 5.51E-04 Alzheimer's disease / / 22005930 rs12980935 chr19 21109784 A G 1.00E-04 Information processing speed ZNF85 intron 21130836 rs10426340 chr19 21157697 T C 2.53E-06 Multiple complex diseases / / 17554300 rs9304979 chr19 21158134 T G 9.52E-05 Erythrocyte counts / / pha003101 rs1862466 chr19 21164399 A G 9.74E-05 Erythrocyte counts / / pha003101 rs11085421 chr19 21168754 C A 5.93E-05 Birth weight / / 17255346 rs10418706 chr19 21178242 T C 2.40E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7252277 chr19 21216153 A G 2.24E-04 Type 2 diabetes ZNF430 intron 17463246 rs8112054 chr19 21243863 C A 4.34E-04 Type 2 diabetes / / 17463246 rs8112216 chr19 21244049 C T 1.49E-04 Birth weight / / 17255346 rs7249283 chr19 21246621 T G 7.51E-05 Birth weight / / 17255346 rs7260268 chr19 21270521 A T 6.36E-04 Multiple complex diseases ZNF714 intron 17554300 rs10401931 chr19 21271248 A C 1.09E-04 Birth weight ZNF714 intron 17255346 rs11085431 chr19 21306913 T C 2.47E-04 Birth weight ZNF714 UTR-3 17255346 rs7250987 chr19 21329836 T C 4.41E-04 Type 2 diabetes ZNF431 intron 17463246 rs10407774 chr19 21380909 C T 1.30E-05 Urinary metabolites / / 21572414 rs8101643 chr19 21384253 C T 6.32E-05 HIV-1 viral setpoint / / 21490045 rs9749580 chr19 21391844 T C 6.54E-05 HIV-1 viral setpoint / / 21490045 rs634661 chr19 21420882 T C 8.03E-05 Orofacial clefts / / 22419666 rs694208 chr19 21424224 G A 5.52E-05 Type 2 diabetes / / 17463246 rs499445 chr19 21503652 T C 7.99E-04 Type 2 diabetes ZNF708 intron 17463246 rs1142653 chr19 21544571 G A 5.57E-04 Type 2 diabetes / / 17463246 rs3951363 chr19 21619651 G A 4.46E-04 Smoking cessation / / 24665060 rs2650808 chr19 21661037 G C 0.000472 Salmonella-induced pyroptosis / / 22837397 rs2650781 chr19 21665637 T C 0.000434 Salmonella-induced pyroptosis / / 22837397 rs2562456 chr19 21666210 C T 2.00E-10 Pain / / 19207018 rs2562456 chr19 21666210 C T 0.00085 Prostate cancer / / 23555315 rs1984771 chr19 21691797 C T 3.20E-04 Multiple complex diseases ZNF429 intron 17554300 rs2650757 chr19 21703545 A G 5.77E-04 Lymphocyte counts ZNF429 intron 22286170 rs1401926 chr19 21740932 T C 1.33E-04 Type 2 diabetes / / 17463246 rs7255865 chr19 21804968 A G 0.000178 Oxaliplatin induced mucositis in response to colorectal cancer treatment / / 22310351 rs4808289 chr19 21836844 T G 2.17E-04 Lung function (forced expiratory volume in 1 second) LOC400682 intron 24023788 rs9304990 chr19 21841379 A C 7.61E-05 Glycosylated haemoglobin levels LOC400682 UTR-3 17255346 rs2359386 chr19 21845617 G A 4.95E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs12232841 chr19 21857227 T G 5.93E-05 Alcohol dependence / / 21703634 rs12461975 chr19 21862108 C A 3.22E-04 Obesity (extreme) / / 21935397 rs8104675 chr19 21891943 C T 9.54E-04 Multiple complex diseases / / 17554300 rs4338909 chr19 21922636 T G 0.000491 Salmonella-induced pyroptosis ZNF100 intron 22837397 rs568571236 chr19 21922636 TAAAA T 0.000491 Salmonella-induced pyroptosis ZNF100 intron 22837397 rs10411674 chr19 21935742 G A 2.50E-05 Urinary metabolites ZNF100 intron 21572414 rs12463030 chr19 21947607 T C 1.46E-04 Obesity (extreme) ZNF100 intron 21935397 rs17701305 chr19 21948020 A G 1.46E-04 Obesity (extreme) ZNF100 intron 21935397 rs11085493 chr19 21948748 T C 7.08E-04 Obesity (extreme) ZNF100 intron 21935397 rs8101143 chr19 21956136 G A 2.00E-07 Capecitabine sensitivity / / 22864933 rs1397579 chr19 21976964 T C 3.55E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7248004 chr19 21996666 G A 2.95E-04 Multiple complex diseases ZNF43 intron 17554300 rs1229933 chr19 22075704 T G 7.30E-05 Waist-Hip Ratio / / pha003029 rs10424424 chr19 22110219 C T 0.000205 Salmonella-induced pyroptosis / / 22837397 rs17701834 chr19 22121458 T G 3.78E-06 Cholesterol / / pha003073 rs17701834 chr19 22121458 T G 4.71E-06 ldl cholesterol / / pha003076 rs17701834 chr19 22121458 T G 3.28E-06 Cholesterol / / pha003078 rs2522096 chr19 22123417 C A 2.16E-04 Alzheimer's disease (late onset) / / 21460841 rs2079062 chr19 22125212 T G 1.77E-04 Alzheimer's disease (late onset) / / 21460841 rs2666451 chr19 22130481 T C 0.000177 Salmonella-induced pyroptosis / / 22837397 rs2262909 chr19 22135270 A C 4.00E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs1849003 chr19 22142261 C T 1.78E-04 Alzheimer's disease (late onset) / / 21460841 rs1859093 chr19 22143339 T G 1.58E-04 Alzheimer's disease (late onset) / / 21460841 rs12971678 chr19 22145476 A C 7.19E-04 Body mass index / / 23669352 rs7253518 chr19 22145667 C T 1.53E-04 Alzheimer's disease (late onset) / / 21460841 rs11085505 chr19 22148671 G C 7.54E-04 Alzheimer's disease (late onset) / / 21460841 rs2188971 chr19 22152182 T A,C,G 1.88E-04 Alzheimer's disease (late onset) ZNF208 UTR-3 21460841 rs2359812 chr19 22153495 A T 1.91E-04 Alzheimer's disease (late onset) ZNF208 UTR-3 21460841 rs2214301 chr19 22154954 C T 1.92E-04 Alzheimer's disease (late onset) ZNF208 missense 21460841 rs10426971 chr19 22158167 G A 0.000214 Salmonella-induced pyroptosis ZNF208 intron 22837397 rs1987975 chr19 22158299 C A 1.99E-04 Alzheimer's disease (late onset) ZNF208 intron 21460841 rs1987974 chr19 22158402 T A 2.02E-04 Alzheimer's disease (late onset) ZNF208 intron 21460841 rs8103214 chr19 22158992 C T 2.05E-04 Alzheimer's disease (late onset) ZNF208 intron 21460841 rs7247121 chr19 22161490 T C 1.87E-04 Alzheimer's disease (late onset) ZNF208 intron 21460841 rs2359813 chr19 22168141 C T 1.88E-04 Alzheimer's disease (late onset) ZNF208 intron 21460841 rs10423507 chr19 22169856 G A 0.0000554 Salmonella-induced pyroptosis ZNF208 intron 22837397 rs1988501 chr19 22175566 T G 1.87E-04 Alzheimer's disease (late onset) ZNF208 intron 21460841 rs10418451 chr19 22178291 G A 0.0000556 Salmonella-induced pyroptosis ZNF208 intron 22837397 rs9304993 chr19 22178685 A G 1.88E-04 Alzheimer's disease (late onset) ZNF208 intron 21460841 rs4932723 chr19 22180721 C G 1.89E-04 Alzheimer's disease (late onset) ZNF208 intron 21460841 rs7248488 chr19 22188709 A C 1.89E-04 Alzheimer's disease (late onset) ZNF208 intron 21460841 rs8105991 chr19 22193131 T C 0.000158 Salmonella-induced pyroptosis ZNF208 intron 22837397 rs10412244 chr19 22202166 A C 2.67E-05 HIV-1 viral setpoint / / 17641165 rs8101471 chr19 22210883 T C 9.62E-04 Insulin resistance / / 21901158 rs1975167 chr19 22215066 A T 2.14E-04 Multiple complex diseases / / 17554300 rs8105767 chr19 22215441 A G 1.11E-09 Telomere length / / 23535734 rs417947 chr19 22224030 G A 7.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs431346 chr19 22228215 T C 4.25E-05 Alzheimer's disease (late onset) / / 21460841 rs436194 chr19 22228527 A G 4.73E-05 Alzheimer's disease (late onset) / / 21460841 rs431474 chr19 22228792 A G 4.70E-05 Alzheimer's disease (late onset) / / 21460841 rs394457 chr19 22230428 G T 4.65E-05 Alzheimer's disease (late onset) / / 21460841 rs417628 chr19 22230794 C A 4.87E-05 Alzheimer's disease (late onset) / / 21460841 rs402281 chr19 22231312 G C 5.02E-05 Alzheimer's disease (late onset) / / 21460841 rs399990 chr19 22232796 G A 5.14E-05 Alzheimer's disease (late onset) / / 21460841 rs8108152 chr19 22234201 A C 5.19E-05 Alzheimer's disease (late onset) / / 21460841 rs415291 chr19 22235307 C G 5.43E-05 Alzheimer's disease (late onset) ZNF257 UTR-5 21460841 rs387343 chr19 22235491 T A,G 5.43E-05 Alzheimer's disease (late onset) ZNF257 intron 21460841 rs387315 chr19 22235526 T C 5.49E-05 Alzheimer's disease (late onset) ZNF257 intron 21460841 rs408312 chr19 22235577 C T 5.62E-05 Alzheimer's disease (late onset) ZNF257 intron 21460841 rs423926 chr19 22235620 G C 5.51E-05 Alzheimer's disease (late onset) ZNF257 intron 21460841 rs7247228 chr19 22250136 C T 1.22E-05 Cholesterol ZNF257 intron pha003073 rs7247228 chr19 22250136 C T 1.47E-05 ldl cholesterol ZNF257 intron pha003076 rs7247228 chr19 22250136 C T 9.59E-06 Cholesterol ZNF257 intron pha003078 rs2043315 chr19 22252823 T C 1.22E-05 Cholesterol ZNF257 intron pha003073 rs2043315 chr19 22252823 T C 1.47E-05 ldl cholesterol ZNF257 intron pha003076 rs2043315 chr19 22252823 T C 9.59E-06 Cholesterol ZNF257 intron pha003078 rs452707 chr19 22304145 C T 1.69E-04 Longevity / / 22279548 rs17554694 chr19 22317148 G A 4.50E-04 Multiple complex diseases / / 17554300 rs7257051 chr19 22319292 A G 4.23E-05 Calcium levels / / pha003085 rs3813591 chr19 22321256 T C 6.73E-05 Calcium levels / / pha003085 rs412658 chr19 22359440 C T 1.00E-08 Telomere length / / 23001564 rs10419926 chr19 22364620 A G 5.07E-05 Calcium levels ZNF676 intron pha003085 rs281205 chr19 22407824 T C 1.79E-04 Orofacial clefts / / 22419666 rs281205 chr19 22407824 T C 4.45E-05 Calcium levels / / pha003085 rs10426665 chr19 22428809 G A 5.98E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs283147 chr19 22438069 A C 3.68E-05 F-cell distribution / / 21326311 rs283147 chr19 22438069 A C 4.25E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs283168 chr19 22450922 A G 4.13E-05 Personality dimensions / / 22628180 rs283164 chr19 22453794 A T 4.09E-05 Personality dimensions / / 22628180 rs3926992 chr19 22505876 A G 5.20E-08 Urinary metabolites / / 21572414 rs1975174 chr19 22515251 G T 2.00E-06 Telomere length / / 20421499 rs7249610 chr19 22533517 G A 5.30E-05 Multiple complex diseases / / 17554300 rs8111537 chr19 22535545 C G 2.20E-05 Urinary metabolites / / 21572414 rs12459636 chr19 22542439 A G 1.80E-05 Urinary metabolites / / 21572414 rs12608842 chr19 22548013 G C 1.60E-05 Urinary metabolites / / 21572414 rs1865075 chr19 22554854 T C 6.00E-06 Dental caries / / 23259602 rs10454118 chr19 22559605 G C 1.90E-05 Urinary metabolites / / 21572414 rs2033494 chr19 22600546 A G 1.30E-08 Urinary metabolites ZNF98 intron 21572414 rs10404998 chr19 22608374 T C 3.00E-06 Dental caries / / 23259602 rs931608 chr19 22614122 A C 3.00E-07 Response to statin therapy (LDL-C) / / 22331829 rs931608 chr19 22614122 A C 1.00E-06 Dental caries / / 23064961 rs10415391 chr19 22652436 C T 2.69E-04 Smoking initiation / / 24665060 rs11669012 chr19 22675183 C T 5.35E-04 Myocardial Infarction / / pha002883 rs2915928 chr19 22693596 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2915927 chr19 22693766 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12609165 chr19 22703480 C T 8.10E-04 Alzheimer's disease / / 22005930 rs1216119 chr19 22709845 C A 4.54E-04 Multiple complex diseases / / 17554300 rs2915922 chr19 22714096 C G 4.72E-04 Obesity (extreme) / / 21935397 rs2361019 chr19 22729613 T A 9.80E-06 Urinary metabolites / / 21572414 rs2361019 chr19 22729613 T A 3.27E-04 Coronary heart disease / / 21606135 rs10412333 chr19 22734546 T C 2.48E-04 Smoking quantity / / 24665060 rs8106765 chr19 22737194 A G 5.77E-04 Multiple complex diseases / / 17554300 rs8111998 chr19 22741675 C T 8.00E-07 Corneal structure / / 21979947 rs16999432 chr19 22772647 C T 9.23E-05 Alcohol consumption / / 23953852 rs7246048 chr19 22775634 T C 9.35E-05 Alcohol consumption / / 23953852 rs11673496 chr19 22789430 G A 2.25E-05 Schizophrenia (treatment refractory) / / 22479419 rs11673496 chr19 22789430 G A 1.75E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs16999483 chr19 22794671 T A 7.57E-05 Multiple complex diseases / / 17554300 rs11671104 chr19 22794686 A C 4.00E-06 Colorectal cancer (diet interaction) / / 24743840 rs16999493 chr19 22795315 T C 7.33E-05 Multiple complex diseases / / 17554300 rs16999493 chr19 22795315 T C 2.80E-05 Urinary metabolites / / 21572414 rs3813587 chr19 22799293 T G 3.91E-04 Multiple complex diseases / / 17554300 rs937078 chr19 22811667 G A 0.0000831 Salmonella-induced pyroptosis / / 22837397 rs16999519 chr19 22814076 C T 0.000147 Salmonella-induced pyroptosis / / 22837397 rs16999519 chr19 22814076 C T 0.0000863 Panic disorder / / 23149450 rs16999519 chr19 22814076 C T 8.63E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs16999521 chr19 22815530 A G 0.000252 Salmonella-induced pyroptosis / / 22837397 rs2361023 chr19 22816867 C T 0.000102 Salmonella-induced pyroptosis / / 22837397 rs12979848 chr19 22820798 G A 0.000293 Salmonella-induced pyroptosis ZNF492 intron 22837397 rs34682021 chr19 22826728 C T 0.000157 Salmonella-induced pyroptosis ZNF492 intron 22837397 rs7250285 chr19 22837108 C T 6.09E-04 Alcohol dependence ZNF492 intron 24277619 rs12980342 chr19 22849357 T C 0.00029 Salmonella-induced pyroptosis ZNF492 UTR-3 22837397 rs12975767 chr19 22862809 A C 0.000187 Salmonella-induced pyroptosis / / 22837397 rs4933025 chr19 22874166 C A 0.000197 Salmonella-induced pyroptosis / / 22837397 rs8103012 chr19 22879285 C T 0.000132 Salmonella-induced pyroptosis / / 22837397 rs2042897 chr19 22896667 A T 0.000101 Salmonella-induced pyroptosis / / 22837397 rs8108467 chr19 22897567 T C 0.000162 Salmonella-induced pyroptosis / / 22837397 rs8107643 chr19 22897658 A G 6.64E-04 Multiple complex diseases / / 17554300 rs7247191 chr19 22899585 C T 0.0000884 Salmonella-induced pyroptosis / / 22837397 rs1864004 chr19 22902362 T G 4.82E-04 Multiple complex diseases / / 17554300 rs16999569 chr19 22902710 A G 0.000719 Salmonella-induced pyroptosis / / 22837397 rs12980129 chr19 22908911 C G 4.33E-05 Multiple complex diseases / / 17554300 rs12980129 chr19 22908911 C G 0.000621 Salmonella-induced pyroptosis / / 22837397 rs16999009 chr19 22909658 G A 0.000252 Salmonella-induced pyroptosis / / 22837397 rs16999009 chr19 22909658 G A 0.0000388 Panic disorder / / 23149450 rs16999009 chr19 22909658 G A 3.88E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs9676498 chr19 22910510 A G 0.000152 Salmonella-induced pyroptosis / / 22837397 rs7248030 chr19 22913486 C G 0.000659 Salmonella-induced pyroptosis / / 22837397 rs2361260 chr19 22914144 A G 0.000177 Salmonella-induced pyroptosis / / 22837397 rs2112610 chr19 22916851 G A 0.000226 Salmonella-induced pyroptosis / / 22837397 rs16999580 chr19 22923487 C T 0.000185 Salmonella-induced pyroptosis / / 22837397 rs12974988 chr19 22925965 G T 5.65E-04 Alcohol dependence / / 24277619 rs16999587 chr19 22934973 T C 0.000583 Salmonella-induced pyroptosis / / 22837397 rs6511380 chr19 22950070 C T 0.000765 Salmonella-induced pyroptosis ZNF99 intron 22837397 rs6511383 chr19 22956900 C T 7.02E-04 Alcohol dependence ZNF99 intron 24277619 rs437859 chr19 23007349 G A 1.50E-05 Urinary metabolites / / 21572414 rs437859 chr19 23007349 G A 0.000306 Salmonella-induced pyroptosis / / 22837397 rs428613 chr19 23009919 G C 2.60E-05 Urinary metabolites / / 21572414 rs428613 chr19 23009919 G C 0.000366 Salmonella-induced pyroptosis / / 22837397 rs2569728 chr19 23014004 C T 0.000555 Salmonella-induced pyroptosis / / 22837397 rs7246967 chr19 23056346 T G 4.00E-06 Bronchopulmonary dysplasia / / 23897914 rs7246529 chr19 23065123 C T 8.54E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs8111895 chr19 23073205 G A 2.10E-04 Myasthenia gravis / / 23055271 rs8111895 chr19 23073205 G A 3.24E-04 Iron levels / / pha002876 rs3862488 chr19 23089316 A G 1.00E-14 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs8110734 chr19 23387788 A C 8.29E-05 Type 2 diabetes / / 17463246 rs7246878 chr19 23389068 C T 1.95E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4932844 chr19 23422195 C A 8.62E-04 Amyotrophic Lateral Sclerosis ZNF724P intron 17362836 rs295367 chr19 23441936 T C 8.73E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs431270 chr19 23468966 A C 3.17E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs29991 chr19 23540672 T C 1.11E-11 Metabolite levels ZNF91 UTR-3 22286219 rs1044095 chr19 23545250 A G 3.17E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) ZNF91 cds-synon 23648065 rs652312 chr19 23624199 A T 3.79E-04 Multiple complex diseases / / 17554300 rs4115613 chr19 23658883 C T 8.45E-05 Insulin resistance / / 21901158 rs1817867 chr19 23659458 G A 7.34E-04 Multiple complex diseases / / 17554300 rs2640203 chr19 23685823 T C 7.01E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs12461367 chr19 23738428 T C 9.64E-04 Type 2 diabetes / / 17463246 rs797880 chr19 23742358 C T 2.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2364606 chr19 23824985 T A 8.23E-04 Multiple complex diseases / / 17554300 rs7246142 chr19 23930879 C T 7.71E-04 Tourette syndrome ZNF681 intron 22889924 rs10422765 chr19 23938402 T C 1.54E-07 Cognitive impairment induced by topiramate ZNF681 intron 22091778 rs10422765 chr19 23938402 T C 2.29E-05 Cognitive impairment induced by topiramate ZNF681 intron 22091778 rs10422765 chr19 23938402 T C 3.75E-07 Cognitive impairment induced by topiramate ZNF681 intron 22091778 rs10422765 chr19 23938402 T C 7.27E-07 Cognitive impairment induced by topiramate ZNF681 intron 22091778 rs57155026 chr19 23938402 T TAC 1.54E-07 Cognitive impairment induced by topiramate ZNF681 intron 22091778 rs57155026 chr19 23938402 T TAC 2.29E-05 Cognitive impairment induced by topiramate ZNF681 intron 22091778 rs57155026 chr19 23938402 T TAC 3.75E-07 Cognitive impairment induced by topiramate ZNF681 intron 22091778 rs57155026 chr19 23938402 T TAC 7.27E-07 Cognitive impairment induced by topiramate ZNF681 intron 22091778 rs11667496 chr19 23958838 A G 1.45E-12 Gender RPSAP58 intron 22362730 rs7249993 chr19 23961781 A G 4.20E-04 Multiple complex diseases RPSAP58 intron 17554300 rs7259400 chr19 23964068 G C 0.0000017 Mean arterial pressure RPSAP58 intron 22510845 rs7408667 chr19 24000858 T A 4.99E-04 Multiple complex diseases RPSAP58 intron 17554300 rs6511642 chr19 24041651 C G 7.91E-05 Multiple complex diseases / / 17554300 rs4932927 chr19 24045852 C T 9.40E-05 Response to statin therapy / / 20339536 rs4932927 chr19 24045852 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4932927 chr19 24045852 C T 3.93E-05 Cognitive impairment induced by topiramate / / 22091778 rs7257737 chr19 24056803 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7257737 chr19 24056803 C T 6.31E-05 Cognitive impairment induced by topiramate / / 22091778 rs17725202 chr19 24059276 G A 3.12E-04 Tourette syndrome / / 22889924 rs8113266 chr19 24060980 C A 4.43E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs8113608 chr19 24061144 G A 2.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11670289 chr19 24066956 C T 7.44E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10418417 chr19 24080807 T C 7.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6511674 chr19 24084419 T G 7.20E-04 Multiple complex diseases / / 17554300 rs10420981 chr19 24112777 C T 8.06E-04 Response to taxane treatment (placlitaxel) ZNF726 intron 23006423 rs2195987 chr19 24149545 C T 1.80E-06 Urinary metabolites / / 21572414 rs10402888 chr19 24152735 A C 4.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7250712 chr19 24168088 A T 1.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7254714 chr19 24168558 G A 1.45E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4313914 chr19 24176996 A G 8.71E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4635459 chr19 24181822 T C 7.11E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7257520 chr19 24209547 A T 2.99E-05 Multiple complex diseases / / 17554300 rs8104657 chr19 24217064 G T 7.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs8113462 chr19 24222489 A G 2.65E-05 Multiple complex diseases / / 17554300 rs7260598 chr19 24222786 A G 6.00E-06 Response to taxane treatment (placlitaxel) / / 23006423 rs6511680 chr19 24225576 T C 7.06E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10414075 chr19 24238451 A G 3.15E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10414075 chr19 24238451 A G 9.67E-06 Obesity-related traits / / 23251661 rs10403038 chr19 24240656 A G 1.82E-05 Multiple complex diseases / / 17554300 rs17304569 chr19 24240905 C T 7.76E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs12462134 chr19 24250828 G A 6.47E-04 Type 2 diabetes / / 17463246 rs7507208 chr19 24261686 G A 4.47E-05 Myopia (severe) / / 23933737 rs4416149 chr19 24276353 G T 4.23E-06 Response to taxane treatment (placlitaxel) ZNF254 intron 23006423 rs10420762 chr19 24282231 G A 4.29E-04 Response to taxane treatment (placlitaxel) ZNF254 intron 23006423 rs8110507 chr19 24282272 G A,C,T 6.64E-06 Response to taxane treatment (placlitaxel) ZNF254 intron 23006423 rs4932745 chr19 24300721 T G 3.83E-04 Response to taxane treatment (placlitaxel) ZNF254 intron 23006423 rs7260280 chr19 24322822 T G 5.67E-06 Response to taxane treatment (placlitaxel) / / 23006423 rs9305015 chr19 24340502 G A 3.30E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs10500223 chr19 24346024 A G 2.80E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2278443 chr19 24346532 T C 5.32E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7508396 chr19 24348925 A C 5.35E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17620029 chr19 24354312 T C 2.63E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11668609 chr19 24355493 G C 3.00E-06 Response to taxane treatment (docetaxel) / / 23006423 rs17687371 chr19 24356260 C T 7.54E-04 Multiple complex diseases / / 17554300 rs10500224 chr19 24356307 A G 4.02E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs8100720 chr19 24358391 A C 5.32E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs985196 chr19 24368053 A G 2.77E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17000162 chr19 24368149 G A 2.89E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10411891 chr19 24368534 C T 6.87E-04 Multiple complex diseases / / 17554300 rs13344859 chr19 24370088 T C 4.07E-04 Multiple complex diseases / / 17554300 rs10405242 chr19 24374419 T C 1.21E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17000660 chr19 24374857 A C 2.23E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs7253132 chr19 24378197 A C 1.50E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4045101 chr19 24446469 T C 3.89E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1830180 chr19 24455963 A G 5.32E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2255598 chr19 24457120 A G 5.80E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1852408 chr19 24461655 T C 1.33E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs8189856 chr19 24487350 A G 6.69E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs4254432 chr19 28075834 C T 7.09E-06 Suicidal ideation / / 20877300 rs2396212 chr19 28121629 C T 2.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs11882251 chr19 28127201 C T 2.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs2189362 chr19 28142247 A G 2.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs2241024 chr19 28257393 G A 9.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs8104465 chr19 28305076 G A 4.62E-04 Multiple complex diseases LOC100506694 intron 17554300 rs8111283 chr19 28314030 T A 6.29E-05 Serum metabolites LOC100506694 intron 19043545 rs56775919 chr19 28330225 G A 0.00003641 Sarcoidosis LOC100506694 intron 22952805 rs11880417 chr19 28330908 A G 3.77E-05 Hypertension LOC100506694 intron 21082022 rs73533061 chr19 28331905 C G 0.00003613 Sarcoidosis LOC100506694 intron 22952805 rs76473101 chr19 28331905 CAA CA,CG 0.00003613 Sarcoidosis LOC100506694 intron 22952805 rs59435543 chr19 28366359 T C 0.00003555 Sarcoidosis LOC100506694 intron 22952805 rs12459082 chr19 28383336 G A 6.68E-04 Depression (quantitative trait) LOC100506694 intron 20800221 rs16968523 chr19 28384703 C T 5.79E-04 Alcohol consumption (maxi-drinks) LOC100506694 intron 24277619 rs7255207 chr19 28385923 C T 7.16E-04 Alcohol consumption (maxi-drinks) LOC100506694 intron 24277619 rs2215705 chr19 28386386 T C 7.29E-05 Brain derived neurotrophic factor levels,in serum LOC100506694 intron 22047184 rs10516700 chr19 28389129 T C 6.06E-04 Depression (quantitative trait) LOC100506694 intron 20800221 rs16968564 chr19 28389609 C T 5.97E-04 Depression (quantitative trait) LOC100506694 intron 20800221 rs4804973 chr19 28392956 G A 7.16E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs7258218 chr19 28399120 C A 5.79E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs811029 chr19 28403552 A G 2.25E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs8102487 chr19 28404607 A C 2.25E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs811033 chr19 28406229 G A 1.86E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs10414401 chr19 28411971 C T 1.86E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs16968869 chr19 28414086 G A 7.01E-04 Depression (quantitative trait) / / 20800221 rs2215263 chr19 28414576 T C 4.25E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs16969007 chr19 28422023 T G 6.13E-04 Depression (quantitative trait) / / 20800221 rs16969062 chr19 28424257 G T 6.22E-04 Depression (quantitative trait) / / 20800221 rs7252365 chr19 28424586 C G 1.71E-04 Depression (quantitative trait) / / 20800221 rs17620671 chr19 28424757 C T 7.74E-04 Depression (quantitative trait) / / 20800221 rs7255713 chr19 28424869 C G 1.69E-04 Depression (quantitative trait) / / 20800221 rs12461645 chr19 28445630 G A 8.01E-04 Depression (quantitative trait) / / 20800221 rs17620912 chr19 28460549 A G 2.10E-05 Urinary metabolites / / 21572414 rs75225298 chr19 28521398 C G 0.00003216 Sarcoidosis / / 22952805 rs7248819 chr19 28540971 C T 2.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7250467 chr19 28569401 T G 1.90E-05 Amyotrophic Lateral Sclerosis / / 17362836 rs10420392 chr19 28586861 C T 1.16E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10420392 chr19 28586861 C T 6.56E-04 Schizophrenia / / 19197363 rs2867823 chr19 28597809 C A 9.94E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs11669016 chr19 28604705 G T 7.33E-04 Depression (quantitative trait) / / 20800221 rs11671110 chr19 28608226 T C 7.51E-04 Depression (quantitative trait) / / 20800221 rs934106 chr19 28609887 C G 4.48E-04 Multiple complex diseases / / 17554300 rs11084839 chr19 28610147 C T 7.56E-04 Depression (quantitative trait) / / 20800221 rs11667233 chr19 28612739 C G 7.51E-04 Depression (quantitative trait) / / 20800221 rs10500233 chr19 28614693 T C 7.03E-05 Post-operative nausea and vomiting / / 21694509 rs1834971 chr19 28616860 A G 5.72E-04 Multiple complex diseases / / 17554300 rs11672858 chr19 28617530 C G 9.36E-04 Depression (quantitative trait) / / 20800221 rs11084844 chr19 28619351 C T 8.08E-04 Depression (quantitative trait) / / 20800221 rs1105167 chr19 28628797 T C 2.00E-05 Coronary heart disease / / 21606135 rs869089 chr19 28629412 C T 1.19E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs8101247 chr19 28648863 G C 9.36E-04 Alzheimer's disease / / 22005930 rs4806017 chr19 28649422 C A 2.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4806017 chr19 28649422 C A 3.85E-04 Alzheimer's disease / / 22005930 rs7258917 chr19 28651867 T C 9.18E-04 Alzheimer's disease / / 22005930 rs7253180 chr19 28652531 G T 7.43E-04 Alzheimer's disease / / 22005930 rs10414579 chr19 28654541 T G 8.76E-04 Alzheimer's disease / / 22005930 rs876372 chr19 28654782 C T 9.26E-04 Alzheimer's disease / / 22005930 rs7257418 chr19 28655993 A G 3.98E-04 Alzheimer's disease / / 22005930 rs12610066 chr19 28663197 G A 7.17E-04 Alzheimer's disease / / 22005930 rs934105 chr19 28664023 A T 7.99E-04 Alzheimer's disease / / 22005930 rs1971746 chr19 28666048 T C 7.23E-04 Alzheimer's disease / / 22005930 rs1820710 chr19 28675899 C T 7.57E-04 Alzheimer's disease / / 22005930 rs1820709 chr19 28676058 G A 9.59E-04 Alzheimer's disease / / 22005930 rs4806047 chr19 28678263 T C 8.22E-04 Alzheimer's disease / / 22005930 rs4806048 chr19 28678337 T C 4.07E-04 Alzheimer's disease / / 22005930 rs2868471 chr19 28678723 G A 7.52E-04 Alzheimer's disease / / 22005930 rs10425948 chr19 28679650 C A 7.43E-04 Alzheimer's disease / / 22005930 rs885084 chr19 28683556 G A 3.92E-04 Heart Failure / / pha002884 rs934109 chr19 28685647 A G 7.07E-04 Alzheimer's disease / / 22005930 rs4806074 chr19 28711798 T C 1.00E-04 Colorectal cancer / / 19723657 rs1840819 chr19 28734078 A C 7.37E-05 Colorectal cancer / / 19723657 rs11879734 chr19 28750407 A T 2.49E-04 Type 2 diabetes / / 17463246 rs10425269 chr19 28769619 G A 6.59E-04 Type 2 diabetes / / 17463246 rs7258875 chr19 28782862 C T 4.96E-05 Type 2 diabetes / / 17463246 rs4806222 chr19 28793035 G A 4.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4806230 chr19 28796676 G T 4.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2159327 chr19 28835571 G A 2.66E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs7249328 chr19 28858362 C T 7.03E-05 Magnesium levels / / pha003092 rs995834 chr19 28866596 G A 1.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs11666652 chr19 28888340 C T 5.22E-05 Diabetes Mellitus / / pha003059 rs10421826 chr19 28899182 G A 9.78E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs8100542 chr19 28914298 G C 2.01E-04 Cholesterol / / 17255346 rs17685204 chr19 28914976 T C 5.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs12709831 chr19 28915182 G A 2.85E-04 Cholesterol / / 17255346 rs7255960 chr19 28935756 C T 6.90E-05 Alzheimer's disease (late onset) / / 21379329 rs8182556 chr19 28938290 C T 7.30E-04 Body mass index / / 21701565 rs7251331 chr19 28950204 C T 2.28E-04 Alzheimer's disease (late onset) / / 21379329 rs6508901 chr19 28974103 G C 1.10E-05 Urinary metabolites / / 21572414 rs4389251 chr19 28974637 C T 1.30E-05 Urinary metabolites / / 21572414 rs4389251 chr19 28974637 C T 7.18E-04 Body mass index / / 21701565 rs7508722 chr19 28974774 T C 1.40E-05 Urinary metabolites / / 21572414 rs4239554 chr19 28975402 G A 9.46E-05 Cognitive test performance / / 20125193 rs4239555 chr19 28975927 C T 3.30E-06 Urinary metabolites / / 21572414 rs4805229 chr19 29000203 T C 1.34E-05 Male-pattern baldness / / 18849994 rs12608944 chr19 29001523 C G 3.50E-06 Urinary metabolites / / 21572414 rs7247342 chr19 29002291 C T 3.50E-06 Urinary metabolites / / 21572414 rs2869774 chr19 29003484 T C 5.50E-06 Urinary metabolites / / 21572414 rs2024140 chr19 29004322 A G 3.50E-06 Urinary metabolites / / 21572414 rs7260196 chr19 29004936 A G 5.44E-04 Smoking initiation / / 24665060 rs8113142 chr19 29012921 T C 5.00E-06 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs12459632 chr19 29034470 C T 5.88E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs4141232 chr19 29035556 T C 1.02E-05 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs4141232 chr19 29035556 T C 2.00E-07 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs4141232 chr19 29035556 T C 9.00E-06 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs4141232 chr19 29035556 T C 9.31E-06 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs758209 chr19 29037340 A G 5.40E-06 Urinary metabolites / / 21572414 rs1860075 chr19 29039349 G C 2.30E-06 Urinary metabolites / / 21572414 rs4805245 chr19 29040169 A G 2.30E-06 Urinary metabolites / / 21572414 rs4805246 chr19 29040199 C T 2.30E-06 Urinary metabolites / / 21572414 rs991545 chr19 29043220 T C 3.80E-06 Urinary metabolites / / 21572414 rs10404746 chr19 29045851 C T 1.80E-06 Urinary metabolites / / 21572414 rs10427040 chr19 29049606 G A 2.40E-06 Urinary metabolites / / 21572414 rs929440 chr19 29080584 T C 4.05E-04 Body mass index / / 21701565 rs929440 chr19 29080584 T C 5.60E-04 Body mass index / / 21701565 rs1476739 chr19 29083380 A G 4.65E-04 Body mass index / / 21701565 rs1476739 chr19 29083380 A G 5.64E-04 Body mass index / / 21701565 rs11083572 chr19 29095875 T C 5.00E-08 Narcolepsy / / 19629137 rs4805257 chr19 29130465 C T 1.40E-05 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs10401833 chr19 29136582 T C 6.79E-05 Prostate cancer / / pha002877 rs10408473 chr19 29137209 T C 6.19E-04 Body mass index / / 21701565 rs10408473 chr19 29137209 T C 8.83E-04 Body mass index / / 21701565 rs10408473 chr19 29137209 T C 5.33E-04 Smoking initiation / / 24665060 rs1160836 chr19 29164618 T A 1.08E-04 Multiple complex diseases / / 17554300 rs7249844 chr19 29228263 C T 2.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7257245 chr19 29239439 T G 3.66E-06 Major depressive disorder (broad) / / 20038947 rs12462886 chr19 29263690 G T 1.73E-06 Major depressive disorder (broad) / / 20038947 rs4805267 chr19 29268343 C T 1.00E-05 Urinary metabolites / / 21572414 rs10413307 chr19 29277890 G A 2.30E-05 Urinary metabolites / / 21572414 rs16961896 chr19 29282209 G A 1.84E-04 Type 2 diabetes / / 17463246 rs16961899 chr19 29282427 A G 1.90E-04 Type 2 diabetes / / 17463246 rs4804853 chr19 29285471 T C 5.00E-06 Urinary metabolites / / 21572414 rs1473189 chr19 29309499 G A 3.85E-05 Serum metabolites / / 19043545 rs1473188 chr19 29309594 T C 3.85E-05 Serum metabolites / / 19043545 rs1473188 chr19 29309594 T C 4.19E-06 Major depressive disorder (broad) / / 20038947 rs4805270 chr19 29309694 G A 2.80E-05 Urinary metabolites / / 21572414 rs12976416 chr19 29361486 C A 5.70E-04 Stroke / / pha002887 rs144754174 chr19 29361486 C CTTTTTTAGGATTTACCCCTT 5.70E-04 Stroke / / pha002887 rs71169797 chr19 29361486 C CTTTTTTAGGATTTACCCCTT 5.70E-04 Stroke / / pha002887 rs10425332 chr19 29364087 G A 9.90E-05 Response to statin therapy / / 20339536 rs12151257 chr19 29374810 C T 1.23E-04 Insulin resistance / / 21901158 rs4805296 chr19 29378806 C T 4.11E-04 Type 2 diabetes / / 17463246 rs7250708 chr19 29382896 C G 3.91E-04 Type 2 diabetes / / 17463246 rs6509109 chr19 29382978 A G 3.95E-04 Type 2 diabetes / / 17463246 rs11083723 chr19 29387655 C T 1.64E-04 Insulin resistance / / 21901158 rs11879691 chr19 29390854 C T 6.97E-04 Obesity (extreme) / / 21935397 rs8108438 chr19 29390873 C T 5.52E-05 Obesity (extreme) / / 21935397 rs8108541 chr19 29390916 C T 1.31E-04 Obesity (extreme) / / 21935397 rs8109135 chr19 29391087 A G 5.31E-05 Obesity (extreme) / / 21935397 rs734145 chr19 29392192 T C 6.98E-04 Obesity (extreme) / / 21935397 rs734146 chr19 29392205 A T 4.87E-05 Obesity (extreme) / / 21935397 rs7252491 chr19 29392746 C A 4.81E-05 Obesity (extreme) / / 21935397 rs4805297 chr19 29394364 G A 1.15E-04 Obesity (extreme) / / 21935397 rs17772698 chr19 29395558 A G 4.71E-05 Obesity (extreme) / / 21935397 rs8107677 chr19 29395614 T C 4.67E-05 Obesity (extreme) / / 21935397 rs8103259 chr19 29395623 G A 4.64E-05 Obesity (extreme) / / 21935397 rs8106631 chr19 29396048 G A 6.83E-04 Obesity (extreme) / / 21935397 rs4805298 chr19 29396344 C T 4.60E-05 Obesity (extreme) / / 21935397 rs4805299 chr19 29396829 T G 6.82E-04 Obesity (extreme) / / 21935397 rs889349 chr19 29397258 G A 6.82E-04 Obesity (extreme) / / 21935397 rs889350 chr19 29397340 A G 6.82E-04 Obesity (extreme) / / 21935397 rs1423703 chr19 29398626 G T 3.99E-04 Obesity (extreme) / / 21935397 rs1423702 chr19 29398631 G T 6.83E-04 Obesity (extreme) / / 21935397 rs1423701 chr19 29398721 C T 6.83E-04 Obesity (extreme) / / 21935397 rs7507702 chr19 29398855 C T 4.86E-05 Obesity (extreme) / / 21935397 rs6509122 chr19 29399652 C T 6.85E-04 Obesity (extreme) / / 21935397 rs2113129 chr19 29399692 C T 6.85E-04 Obesity (extreme) / / 21935397 rs10417077 chr19 29400017 G T 6.86E-04 Obesity (extreme) / / 21935397 rs10417120 chr19 29400069 G A 6.86E-04 Obesity (extreme) / / 21935397 rs10419624 chr19 29400146 A G 6.86E-04 Obesity (extreme) / / 21935397 rs8112381 chr19 29401046 G A 8.25E-04 Obesity (extreme) / / 21935397 rs979628 chr19 29401520 T C 6.85E-04 Obesity (extreme) / / 21935397 rs979629 chr19 29401695 G C 6.83E-04 Obesity (extreme) / / 21935397 rs2902965 chr19 29401768 T C 6.81E-04 Obesity (extreme) / / 21935397 rs1423699 chr19 29402035 A G 6.87E-04 Obesity (extreme) / / 21935397 rs1345832 chr19 29403570 C A 6.89E-04 Obesity (extreme) / / 21935397 rs1345831 chr19 29403700 T G 6.95E-04 Obesity (extreme) / / 21935397 rs12974259 chr19 29404647 T A 7.01E-04 Obesity (extreme) / / 21935397 rs889356 chr19 29404979 T C 7.09E-04 Obesity (extreme) / / 21935397 rs889357 chr19 29405051 C T 7.15E-04 Obesity (extreme) / / 21935397 rs1991016 chr19 29407243 T C 7.24E-04 Obesity (extreme) / / 21935397 rs2161623 chr19 29407567 C T 7.33E-04 Obesity (extreme) / / 21935397 rs1345833 chr19 29407739 A G 7.42E-04 Obesity (extreme) / / 21935397 rs889359 chr19 29408397 T C 7.60E-04 Obesity (extreme) / / 21935397 rs12709873 chr19 29408562 C T 7.96E-04 Obesity (extreme) / / 21935397 rs7359994 chr19 29408858 T C 8.23E-04 Obesity (extreme) / / 21935397 rs889344 chr19 29409179 G C 8.26E-04 Obesity (extreme) / / 21935397 rs4804859 chr19 29413053 T C 5.52E-04 Obesity (extreme) / / 21935397 rs17690917 chr19 29436656 C T 4.06E-04 Obesity (extreme) / / 21935397 rs2865276 chr19 29437846 T G 8.35E-04 Alzheimer's disease / / 17998437 rs1368481 chr19 29449024 T C 9.66E-04 Obesity (extreme) / / 21935397 rs4513216 chr19 29455590 A G 9.40E-04 Obesity (extreme) / / 21935397 rs12460607 chr19 29458085 A C 9.37E-04 Obesity (extreme) / / 21935397 rs10425144 chr19 29472817 C T 9.33E-04 Obesity (extreme) / / 21935397 rs8104331 chr19 29486865 G A 9.97E-05 Prion diseases / / 22210626 rs8104331 chr19 29486865 G A 5.75E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs8102754 chr19 29489042 T A 3.10E-05 Obesity (extreme) / / 21935397 rs8102754 chr19 29489042 T A 8.00E-06 Anger / / 24489884 rs17691054 chr19 29490619 C T 4.17E-04 Obesity (extreme) / / 21935397 rs892176 chr19 29496363 A G 4.15E-04 Obesity (extreme) LOC100505835 intron 21935397 rs7258936 chr19 29509214 T C 1.30E-05 Urinary metabolites / / 21572414 rs7247484 chr19 29515771 T C 1.17E-04 Prion diseases / / 22210626 rs2902970 chr19 29520570 C A,G,T 6.47E-06 C-Reactive Protein / / pha003070 rs1433116 chr19 29525308 A G 8.07E-05 Post-operative nausea and vomiting / / 21694509 rs13382157 chr19 29541618 G A 4.95E-04 Insulin resistance / / 21901158 rs8103835 chr19 29599650 A G 9.37E-05 Partial epilepsies / / 20522523 rs16962569 chr19 29620129 T C 8.30E-04 Taste perception / / 22132133 rs17685936 chr19 29645920 A G 8.74E-05 Alcohol consumption / / 23953852 rs12976102 chr19 29653398 A G 4.49E-04 Multiple complex diseases / / 17554300 rs2903018 chr19 29655286 G T 4.77E-08 Pancreatic cancer / / 22158540 rs10518258 chr19 29676774 C A 2.27E-04 Multiple complex diseases / / 17554300 rs10518258 chr19 29676774 C A 1.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs16962592 chr19 29679198 A C 2.20E-05 Urinary metabolites / / 21572414 rs10423528 chr19 29728064 A T 1.87E-04 Acute lung injury / / 22295056 rs17691420 chr19 29730876 G C 4.77E-05 Schizophrenia / / 19571809 rs17691420 chr19 29730876 G C 3.10E-05 Schizophrenia / / pha002859 rs11083866 chr19 29736342 G A 3.64E-04 Sudden cardiac arrest / / 21658281 rs11083866 chr19 29736342 G A 5.00E-06 Lentiform nucleus volume / / 22903471 rs4805358 chr19 29749444 T C 1.75E-04 Parkinson's disease / / 17052657 rs4805358 chr19 29749444 T C 6.51E-05 Psoriasis / / 20953190 rs879122 chr19 29755681 C T 1.24E-04 Osteoarthritis / / 19508968 rs879122 chr19 29755681 C T 3.00E-06 Urinary metabolites / / 21572414 rs2193516 chr19 29757697 G A 3.29E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs888301 chr19 29761748 T C 6.06E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs12460869 chr19 29764587 T C 3.58E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs12610908 chr19 29782730 G A 1.25E-04 Parkinson's disease LOC284395 intron 17052657 rs7408479 chr19 29784673 A G 8.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) LOC284395 intron 23648065 rs4805363 chr19 29785848 T C 8.35E-05 Orofacial clefts LOC284395 intron 22419666 rs10425007 chr19 29812397 T C 8.58E-04 Multiple complex diseases LOC284395 intron 17554300 rs10423259 chr19 29820105 G A 9.04E-04 Multiple complex diseases LOC284395 intron 17554300 rs10423829 chr19 29832331 G C 9.06E-04 Multiple complex diseases LOC284395 intron 17554300 rs1558364 chr19 29865345 G A 9.53E-04 Multiple complex diseases LOC284395 intron 17554300 rs8107989 chr19 29867796 C G 1.95E-04 Alzheimer's disease LOC284395 intron 17998437 rs17703317 chr19 29880615 G A 4.20E-04 Alzheimer's disease LOC284395 intron 17998437 rs17703317 chr19 29880615 G A 8.40E-06 Urinary metabolites LOC284395 intron 21572414 rs13344206 chr19 29880707 G A 1.90E-05 Urinary metabolites LOC284395 intron 21572414 rs12984061 chr19 29885279 C A 3.03E-05 Personality dimensions LOC284395 intron 22628180 rs8111783 chr19 29890018 A G 1.33E-05 Personality dimensions LOC284395 intron 22628180 rs11669309 chr19 29892297 C T 8.53E-05 Blood Pressure LOC284395 intron pha002898 rs7256832 chr19 29894805 A G 2.35E-05 Personality dimensions LOC284395 intron 22628180 rs7256832 chr19 29894805 A G 4.04E-05 Blood Pressure LOC284395 intron pha002898 rs12460899 chr19 29899675 G A 3.75E-05 Personality dimensions LOC284395 intron 22628180 rs8110188 chr19 29901750 T C 1.03E-06 Age-related macular degeneration LOC284395 intron pha002869 rs8110188 chr19 29901750 T C 6.42E-06 Age-related macular degeneration LOC284395 intron pha002890 rs17717398 chr19 29902465 G A 3.73E-05 Personality dimensions LOC284395 intron 22628180 rs12986207 chr19 29903677 G A 4.00E-06 Bulimia nervosa LOC284395 intron 23568457 rs10425935 chr19 29908107 A G 3.00E-06 Obesity-related traits LOC284395 intron 23251661 rs892073 chr19 29912294 G T 8.00E-06 Obesity-related traits LOC284395 intron 23251661 rs8107574 chr19 29919225 C T 3.89E-04 Lung function (forced expiratory volume in 1 second) LOC284395 intron 24023788 rs10423905 chr19 29928853 A C 5.40E-04 Alcohol dependence LOC284395 intron 20201924 rs10423905 chr19 29928853 A C 6.60E-04 Alcohol dependence LOC284395 intron 20201924 rs10423905 chr19 29928853 A C 2.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC284395 intron 20877124 rs10423566 chr19 29929061 C G 1.28E-04 Multiple complex diseases LOC284395 intron 17554300 rs4805419 chr19 29973368 C T 1.00E-05 Urinary metabolites LOC284395 intron 21572414 rs7245731 chr19 29975118 A G 1.00E-05 Urinary metabolites LOC284395 intron 21572414 rs1036229 chr19 29980510 G A 2.50E-05 Celiac disease LOC284395 intron 17558408 rs11083982 chr19 29982068 G C 5.58E-05 Coronary Artery Disease LOC284395 intron 17634449 rs747430 chr19 29989938 G A 4.53E-04 Alzheimer's disease LOC284395 intron 17998437 rs8113045 chr19 29995803 A G 3.02E-05 Coronary Artery Disease LOC284395 intron 17634449 rs8113045 chr19 29995803 A G 5.92E-04 Alzheimer's disease LOC284395 intron 17998437 rs12460708 chr19 29998993 C T 6.53E-04 Suicide attempts in bipolar disorder LOC284395 intron 21423239 rs2082455 chr19 30007635 T C 8.47E-05 HIV-1 control LOC284395 intron 20041166 rs1368457 chr19 30027123 A G 5.20E-04 Alzheimer's disease VSTM2B intron 17998437 rs12978071 chr19 30029240 G A 8.05E-04 Type 2 diabetes VSTM2B intron 17463246 rs17595436 chr19 30031289 G C 9.85E-04 Type 2 diabetes VSTM2B intron 17463246 rs13382165 chr19 30054067 G C 6.97E-04 Multiple complex diseases VSTM2B intron 17554300 rs8106649 chr19 30056335 G A 1.57E-05 Smoking initiation / / 24665060 rs11669470 chr19 30060767 T C 1.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs7250581 chr19 30064396 A G 9.12E-06 Multiple complex diseases / / 17554300 rs7250581 chr19 30064396 A G 9.12E-06 Coronary Artery Disease / / 17634449 rs16963005 chr19 30064955 A G 1.42E-05 Suicide attempts in bipolar disorder / / 21423239 rs4804890 chr19 30065645 T C 2.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs12463027 chr19 30066593 G A 7.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs8101645 chr19 30067061 C T 3.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs2288898 chr19 30067525 G A 3.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs2288897 chr19 30067606 G A 3.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs2288895 chr19 30067853 A G 3.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs2288895 chr19 30067853 A G 7.30E-04 Atrial fibrillation / / 21846873 rs2288894 chr19 30067969 G A 4.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs10853814 chr19 30068010 T A 3.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs10853815 chr19 30068100 T G 4.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs2288893 chr19 30068260 C T 1.14E-05 Smoking initiation / / 24665060 rs4805434 chr19 30070326 T C 3.40E-06 Diabetic retinopathy / / 21441570 rs7249400 chr19 30070530 T C 3.30E-06 Diabetic retinopathy / / 21441570 rs7252718 chr19 30070787 T C 3.20E-06 Diabetic retinopathy / / 21441570 rs11670734 chr19 30071031 C G 8.78E-04 Multiple complex diseases / / 17554300 rs11670734 chr19 30071031 C G 3.20E-06 Diabetic retinopathy / / 21441570 rs10853818 chr19 30071263 C A 3.10E-06 Diabetic retinopathy / / 21441570 rs10853819 chr19 30071274 G A 3.00E-06 Diabetic retinopathy / / 21441570 rs10853820 chr19 30071287 T C 9.82E-04 Multiple complex diseases / / 17554300 rs10853820 chr19 30071287 T C 2.90E-06 Diabetic retinopathy / / 21441570 rs10853821 chr19 30071359 T C 2.90E-06 Diabetic retinopathy / / 21441570 rs12608899 chr19 30071417 A G 6.11E-05 Smoking initiation / / 24665060 rs6509494 chr19 30072420 C T 2.40E-06 Diabetic retinopathy / / 21441570 rs6509495 chr19 30072690 C T 2.40E-06 Diabetic retinopathy / / 21441570 rs4805435 chr19 30073152 G A 6.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs11666885 chr19 30073470 G A 5.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs11668107 chr19 30074083 C A 5.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs12459467 chr19 30076094 A G 2.30E-06 Diabetic retinopathy / / 21441570 rs10406970 chr19 30076221 A G 2.30E-06 Diabetic retinopathy / / 21441570 rs7249044 chr19 30076415 A T 4.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs11667631 chr19 30077077 A G 2.30E-06 Diabetic retinopathy / / 21441570 rs4284747 chr19 30078252 T C 2.20E-06 Diabetic retinopathy / / 21441570 rs4503920 chr19 30078306 C T 2.20E-06 Diabetic retinopathy / / 21441570 rs10421601 chr19 30078526 C T 2.20E-06 Diabetic retinopathy / / 21441570 rs9304703 chr19 30078553 T G 7.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs12973126 chr19 30079100 A G 2.10E-06 Diabetic retinopathy / / 21441570 rs10403021 chr19 30079604 C T 2.00E-06 Diabetic retinopathy / / 21441570 rs7249291 chr19 30080142 G A 4.07E-04 Smoking initiation / / 24665060 rs4239558 chr19 30080437 C T 4.95E-04 Smoking initiation / / 24665060 rs8108836 chr19 30082203 T C 5.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs4805439 chr19 30083281 G A 8.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs4462718 chr19 30084584 C T 6.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs10518279 chr19 30085145 A G 9.23E-04 Multiple complex diseases / / 17554300 rs10518279 chr19 30085145 A G 2.30E-06 Diabetic retinopathy / / 21441570 rs10414410 chr19 30086007 C A 5.00E-06 Smoking initiation / / 24665060 rs10415250 chr19 30086077 A G 7.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs4805442 chr19 30088393 A G 4.30E-04 Lung adenocarcinoma / / 21242121 rs4805442 chr19 30088393 A G 1.18E-05 Corneal astigmatism / / 23761726 rs8112833 chr19 30090527 T A 4.13E-04 Multiple complex diseases / / 17554300 rs891061 chr19 30102477 C T 7.27E-04 B cell non-Hodgkin lymphoma POP4 intron 23749188 rs12463130 chr19 30111656 T C 2.60E-05 Endometriosis / / 21151130 rs17272128 chr19 30114528 A C 9.26E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10407049 chr19 30131562 G C 3.10E-06 Urinary metabolites / / 21572414 rs8102949 chr19 30172341 T C 5.63E-04 Alcohol dependence / / 21314694 rs9566 chr19 30192475 G A 2.99E-05 Blood Pressure C19orf12 UTR-3 pha003047 rs1048123 chr19 30192505 G C 6.82E-04 Multiple complex diseases C19orf12 UTR-3 17554300 rs16963154 chr19 30199851 C T 9.73E-04 Multiple complex diseases C19orf12 intron 17554300 rs7247955 chr19 30200521 T C 0.00008011 Sarcoidosis C19orf12 intron 22952805 rs16963159 chr19 30201323 G A 4.30E-05 Lymphocyte counts C19orf12 intron 22286170 rs6509625 chr19 30224982 A T 9.16E-08 Metabolite levels / / 23281178 rs12974501 chr19 30232446 A G 8.74E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs16963260 chr19 30248429 G C 9.07E-05 Multiple complex diseases / / 17554300 rs8102137 chr19 30296853 T C 2.00E-11 Bladder cancer / / 20972438 rs8102137 chr19 30296853 T C 1.00E-11 Bladder cancer / / 24163127 rs3218064 chr19 30312350 C T 3.36E-04 Type 2 diabetes CCNE1 intron 22238593 rs3218065 chr19 30312582 G A 2.50E-04 Alcohol dependence CCNE1 intron 20201924 rs1862541 chr19 30322301 G T 1.04E-04 Premature ovarian failure / / 19508998 rs918587 chr19 30325256 T C 4.01E-04 Tourette syndrome / / 22889924 rs8110447 chr19 30330444 G A 1.31E-04 Stroke / / pha002887 rs17599667 chr19 30350666 T C 1.94E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs34722 chr19 30366802 C A 7.16E-05 HIV-1 viral setpoint / / 22174851 rs184583 chr19 30371590 T A 3.72E-05 Diabetic nephropathy / / pha002852 rs184583 chr19 30371590 T A 2.90E-05 Diabetic nephropathy / / pha002864 rs335016 chr19 30373392 C A 5.78E-05 Asthma / / 21804549 rs1811302 chr19 30376793 C T 3.80E-04 Multiple complex diseases / / 17554300 rs4144518 chr19 30458485 T C 7.60E-05 Hypothyroidism URI1 intron 22493691 rs12460600 chr19 30537150 A G 3.70E-05 Hypothyroidism / / 22493691 rs6509942 chr19 30554951 A T 2.00E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs277079 chr19 30566056 A G 5.80E-05 Hypothyroidism / / 22493691 rs6509949 chr19 30577229 T C 7.50E-05 Tunica Media / / pha003037 rs440675 chr19 30580597 A G 9.89E-05 Iron levels / / 19880490 rs440675 chr19 30580597 A G 9.89E-05 Iron levels / / pha002876 rs387863 chr19 30583717 G A 5.62E-04 Taste perception / / 22132133 rs399246 chr19 30595364 T C 3.30E-04 Parkinson's disease / / 17052657 rs8101993 chr19 30603533 T C 7.24E-05 Brain lesion load / / 19010793 rs335776 chr19 30612444 A C 0.0007 Salmonella-induced pyroptosis / / 22837397 rs10413028 chr19 30642023 G A 0.0000534 Skin naphthyl-keratin adduct (NKA) levels in workers exposed to naphthalene / / 22391508 rs7252787 chr19 30708635 T C 8.01E-04 Smoking quantity / / 24665060 rs4805532 chr19 30736785 T C 2.96E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs12980381 chr19 30740884 T C 3.23E-04 Type 2 diabetes / / 17463246 rs4804925 chr19 30823387 A G 3.09E-05 Hypertension / / 21082022 rs16964099 chr19 30825568 C T 2.63E-04 Obesity (extreme) / / 21935397 rs12977050 chr19 30828695 G A 9.28E-05 Cognitive performance / / 19734545 rs12977050 chr19 30828695 G A 1.56E-04 Obesity (extreme) / / 21935397 rs1433078 chr19 30840250 G T 2.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11673050 chr19 30844089 C T 9.49E-04 Type 2 diabetes / / 17463246 rs10406668 chr19 30848139 T C 1.55E-04 Obesity (extreme) / / 21935397 rs17540054 chr19 30848537 C G 6.75E-04 Type 2 diabetes / / 17463246 rs4805554 chr19 30849140 C T 2.63E-04 Obesity (extreme) / / 21935397 rs10405711 chr19 30875521 A G 8.27E-05 Multiple complex diseases ZNF536 intron 17554300 rs12462707 chr19 30877151 A T 3.62E-05 Type 1 diabetes ZNF536 intron 18978792 rs1821274 chr19 30880839 G T 2.19E-04 Multiple complex diseases ZNF536 intron 17554300 rs1368445 chr19 30909735 T C 3.04E-05 Alzheimer's disease ZNF536 intron 21098978 rs7247381 chr19 30920536 T C 8.60E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) ZNF536 intron 23648065 rs7247381 chr19 30920536 T C 2.39E-05 Colorectal cancer ZNF536 intron 24448986 rs33428 chr19 30937843 A G 3.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) ZNF536 intron 23648065 rs33430 chr19 30939443 A G 5.18E-04 Obesity (extreme) ZNF536 intron 21935397 rs33431 chr19 30939989 C T 9.31E-04 Obesity (extreme) ZNF536 intron 21935397 rs33432 chr19 30940430 T C 4.74E-04 Obesity (extreme) ZNF536 intron 21935397 rs33435 chr19 30943455 G A 4.45E-05 Obesity (extreme) ZNF536 intron 21935397 rs33436 chr19 30943677 A G 5.33E-05 Obesity (extreme) ZNF536 intron 21935397 rs33436 chr19 30943677 A G 5.00E-06 Obesity-related traits ZNF536 intron 23251661 rs33439 chr19 30945171 C T 5.52E-05 Obesity (extreme) ZNF536 intron 21935397 rs33442 chr19 30948242 T C 7.57E-04 Obesity (extreme) ZNF536 intron 21935397 rs12459372 chr19 30948957 A G 1.57E-05 Obesity (extreme) ZNF536 intron 21935397 rs759952 chr19 30949343 A G 1.39E-05 Obesity (extreme) ZNF536 intron 21935397 rs3786814 chr19 30951278 G A 3.78E-04 Obesity (extreme) ZNF536 intron 21935397 rs3786813 chr19 30951378 A G 2.59E-05 Obesity (extreme) ZNF536 intron 21935397 rs3786812 chr19 30951400 T C 4.98E-05 Obesity (extreme) ZNF536 intron 21935397 rs9304822 chr19 30952094 T A 2.57E-05 Obesity (extreme) ZNF536 intron 21935397 rs12985250 chr19 30952185 G A 3.67E-04 Obesity (extreme) ZNF536 intron 21935397 rs12985528 chr19 30952360 G A 3.45E-04 Obesity (extreme) ZNF536 intron 21935397 rs10460186 chr19 30952557 C A 2.11E-05 Obesity (extreme) ZNF536 intron 21935397 rs3786811 chr19 30952806 T C 5.38E-05 Obesity (extreme) ZNF536 intron 21935397 rs3786811 chr19 30952806 T C 3.91E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ZNF536 intron 24023788 rs3786805 chr19 30963378 T C 9.41E-06 Kawasaki disease ZNF536 intron 21221998 rs3786805 chr19 30963378 T C 3.68E-04 Aortic root size ZNF536 intron 21223598 rs3786804 chr19 30963505 T C 9.41E-06 Kawasaki disease ZNF536 intron 21221998 rs3786804 chr19 30963505 T C 1.58E-04 Aortic root size ZNF536 intron 21223598 rs12165121 chr19 30963730 A G 1.30E-04 Aortic root size ZNF536 intron 21223598 rs8110509 chr19 30981639 C A 1.31E-06 Brain structure ZNF536 intron 22504417 rs8100439 chr19 30983806 C A 2.62E-05 Brain structure ZNF536 intron 22504417 rs919803 chr19 30987104 T C 3.85E-04 Brain structure ZNF536 intron 22504417 rs3786800 chr19 30990700 T C 3.00E-12 Myopia (pathological) ZNF536 intron 23049088 rs1003467 chr19 30991130 A C 9.59E-05 Cognitive impairment induced by topiramate ZNF536 intron 22091778 rs12459057 chr19 30996525 A G 7.01E-04 Type 2 diabetes ZNF536 intron 17463246 rs12459057 chr19 30996525 A G 2.44E-04 Brain structure ZNF536 intron 22504417 rs12460937 chr19 30999532 A T 8.41E-04 Type 2 diabetes ZNF536 intron 17463246 rs9676954 chr19 31008054 C G 2.54E-04 Brain structure ZNF536 intron 22504417 rs78104793 chr19 31009112 C T 0.00004398 Sarcoidosis ZNF536 intron 22952805 rs7248805 chr19 31018491 C G 7.67E-04 Brain structure ZNF536 intron 22504417 rs3786791 chr19 31026875 C T 1.92E-04 Brain structure ZNF536 intron 22504417 rs10518269 chr19 31028666 C T 3.24E-04 Brain structure ZNF536 intron 22504417 rs16796 chr19 31030768 C T 4.23E-04 Type 2 diabetes ZNF536 intron 17463246 rs73539109 chr19 31032392 G T 8.74E-06 Serum dimethylarginine levels (asymmetric) ZNF536 intron 24159190 rs10418356 chr19 31035686 C G 7.00E-06 Serum dimethylarginine levels (asymmetric) ZNF536 intron 24159190 rs8112353 chr19 31036134 C T 7.83E-06 Serum dimethylarginine levels (asymmetric) ZNF536 intron 24159190 rs7258855 chr19 31036758 G A 8.60E-06 Serum dimethylarginine levels (asymmetric) ZNF536 intron 24159190 rs78056641 chr19 31037249 C T 9.30E-06 Serum dimethylarginine levels (asymmetric) ZNF536 intron 24159190 rs7253628 chr19 31047269 A G 5.01E-04 Brain structure ZNF536 intron 22504417 rs8101081 chr19 31049031 A T 2.95E-04 Brain structure / / 22504417 rs9676752 chr19 31059067 T C 8.44E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12610504 chr19 31064591 A G 8.38E-04 Insulin resistance / / 21901158 rs12610504 chr19 31064591 A G 5.74E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12609319 chr19 31065018 C T 7.16E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4239561 chr19 31067654 C T 4.09E-04 Insulin resistance / / 21901158 rs8109875 chr19 31069639 G A 6.00E-04 Insulin resistance / / 21901158 rs17614350 chr19 31081730 T C 6.95E-04 Type 2 diabetes / / 17463246 rs746961 chr19 31099890 A G 8.00E-07 Select biomarker traits / / 17903293 rs4511648 chr19 31107012 T C 2.77E-04 Lung function (forced vital capacity) / / 24023788 rs2043314 chr19 31113570 T C 9.40E-05 Height / / 18391952 rs4805590 chr19 31118591 C T 9.59E-04 Coronary heart disease / / 21606135 rs10417396 chr19 31125229 A T 9.64E-04 Coronary heart disease / / 21606135 rs2867078 chr19 31135211 G A 3.07E-04 Coronary heart disease / / 21606135 rs10423090 chr19 31151734 T C 8.43E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7254787 chr19 31168859 C T 1.74E-04 Type 2 diabetes / / 17463246 rs7255838 chr19 31207592 T C 3.49E-04 Multiple complex diseases / / 17554300 rs4805605 chr19 31217314 A T 7.15E-05 Alzheimer's disease / / 22832961 rs1990763 chr19 31227678 G A 7.90E-04 Multiple complex diseases / / 17554300 rs17615623 chr19 31229053 A C 2.83E-04 Multiple complex diseases / / 17554300 rs1354137 chr19 31236495 T G 4.45E-04 Alzheimer's disease (late onset) / / 21379329 rs2867469 chr19 31243102 A G 3.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1911951 chr19 31257696 A C 9.54E-04 Myopia (pathological) / / 21095009 rs1077644 chr19 31279584 G T 5.95E-05 Information processing speed / / 21130836 rs1549951 chr19 31292344 T C 5.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1549951 chr19 31292344 T C 8.16E-05 Melanoma / / 21926416 rs6510181 chr19 31292719 C A 7.63E-05 Melanoma / / 21926416 rs880550 chr19 31301247 T C 7.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1865106 chr19 31301718 T C 1.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10414458 chr19 31304355 A G 6.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12971522 chr19 31306594 G A 2.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs934432 chr19 31308584 T G 1.98E-05 Melanoma / / 21926416 rs934433 chr19 31308777 G A 2.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs934433 chr19 31308777 G A 2.22E-05 Melanoma / / 21926416 rs12975977 chr19 31310818 T C 5.72E-04 Myopia (pathological) / / 21095009 rs2195979 chr19 31321306 C T 2.80E-05 Urinary metabolites / / 21572414 rs11084564 chr19 31321565 C T 2.30E-05 Urinary metabolites / / 21572414 rs10413894 chr19 31339330 C G 4.96E-04 Multiple complex diseases / / 17554300 rs17545624 chr19 31340752 A G 2.13E-06 Cardiovascular disease / / 18179892 rs17545624 chr19 31340752 A G 9.72E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2020362 chr19 31341267 A G 9.00E-05 Type 2 diabetes / / 17903298 rs4805632 chr19 31342912 C T 1.40E-05 Urinary metabolites / / 21572414 rs10425253 chr19 31346535 G A 2.00E-05 Type 2 diabetes / / 17903298 rs7359991 chr19 31367508 C T 5.01E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2198895 chr19 31369194 A G 4.70E-05 Triglycerides / / 19074352 rs1466297 chr19 31373134 T C 8.94E-04 Multiple complex diseases / / 17554300 rs12978650 chr19 31375761 A G 9.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs278158 chr19 31377262 G T 7.98E-04 Multiple complex diseases / / 17554300 rs7245959 chr19 31379109 T C 3.00E-06 Fractional exhaled nitric oxide (childhood) / / 24315451 rs7245959 chr19 31379109 T C 6.00E-06 Fractional exhaled nitric oxide (childhood) / / 24315451 rs7507779 chr19 31428814 C G,T 8.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs10413629 chr19 31429173 A T 7.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs10418584 chr19 31439680 T C 8.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs595064 chr19 31443717 C T 9.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs183245 chr19 31444487 A G 8.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs16964905 chr19 31449403 G T 8.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs10408383 chr19 31453053 G A 9.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs16964945 chr19 31492079 G C 4.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs16964948 chr19 31494861 C T 4.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs897780 chr19 31500020 A G 8.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs10418485 chr19 31500379 C T 4.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs882016 chr19 31500859 T C 4.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs276731 chr19 31514822 G A 1.50E-05 Urinary metabolites / / 21572414 rs11673246 chr19 31571547 C A 2.78E-05 Personality dimensions / / 22628180 rs12459897 chr19 31596778 G T 8.00E-07 Phospholipid levels (plasma) / / 21829377 rs10422145 chr19 31601443 G A,T 1.13E-05 Word reading / / 23738518 rs10422145 chr19 31601443 G A,T 2.19E-05 Reading and spelling / / 23738518 rs276197 chr19 31629785 G A 4.90E-06 Phospholipid levels (plasma) / / 21829377 rs750499 chr19 31651267 T C 3.11E-05 Neutrophil count / / pha003095 rs6510186 chr19 31654615 T C 9.02E-05 Lymphocyte counts / / pha003094 rs6510186 chr19 31654615 T C 3.95E-05 Neutrophil count / / pha003095 rs1353535 chr19 31680980 A T 6.97E-04 Smoking initiation / / 24665060 rs7247234 chr19 31757616 G T 2.40E-06 Urinary metabolites / / 21572414 rs17581484 chr19 31783499 C T 1.95E-04 Alzheimer's disease TSHZ3 intron 17998437 rs17581484 chr19 31783499 C T 2.69E-04 Bipolar disorder,schizoaffective TSHZ3 intron 19567891 rs17496703 chr19 31784595 T C 1.90E-04 Alzheimer's disease TSHZ3 intron 17998437 rs11883254 chr19 31790322 G A 2.22E-04 Iron levels TSHZ3 intron pha002876 rs16965445 chr19 31800220 G A 0.0000033 Stroke TSHZ3 intron 23422753 rs1078373 chr19 31801130 G A 6.00E-06 Cognitive performance TSHZ3 intron 19734545 rs10412617 chr19 31802550 A G 3.55E-05 Cognitive performance TSHZ3 intron 19734545 rs12460841 chr19 31810800 G A 0.000325 fMRI brain tests in schizophrenia TSHZ3 intron 22440650 rs7258461 chr19 31824834 C T 3.93E-05 Pulmonary function TSHZ3 intron 20010835 rs3760828 chr19 31829286 T C 4.16E-05 Pulmonary function TSHZ3 intron 20010835 rs10418984 chr19 31838378 C T 1.46E-05 Pulmonary function TSHZ3 intron 20010835 rs1353531 chr19 31846907 G T 2.57E-05 Pulmonary function / / 20010835 rs7249887 chr19 31849368 C T 4.04E-05 Pulmonary function / / 20010835 rs12610813 chr19 31850047 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2542282 chr19 31875286 T C 7.92E-04 Type 2 diabetes / / 17463246 rs7260437 chr19 31892178 A G 2.92E-04 Rheumatoid arthritis / / 21452313 rs16965610 chr19 31894118 A C 1.54E-05 Testosterone levels / / 22675492 rs1008144 chr19 31894873 T C 3.67E-04 Rheumatoid arthritis / / 21452313 rs8108330 chr19 31898275 G A 4.97E-04 Rheumatoid arthritis / / 21452313 rs1820183 chr19 31910364 C T 1.31E-04 Rheumatoid arthritis / / 21452313 rs11880316 chr19 31911129 C A 4.00E-06 Estradiol levels / / 22675492 rs10406589 chr19 31922887 C T 1.24E-04 Rheumatoid arthritis / / 21452313 rs10420013 chr19 31925003 G A 1.10E-04 Rheumatoid arthritis / / 21452313 rs6510206 chr19 31931845 T C 8.85E-05 Rheumatoid arthritis / / 21452313 rs407470 chr19 31937986 A G 6.26E-05 Rheumatoid arthritis / / 21452313 rs12975463 chr19 31940087 C T 4.30E-04 Urinary metabolites / / 21572414 rs2052572 chr19 31947536 G A 7.17E-05 Rheumatoid arthritis / / 21452313 rs2052572 chr19 31947536 G A 4.40E-05 Age-related macular degeneration / / 21665990 rs8106336 chr19 31949453 T C 2.97E-04 Rheumatoid arthritis / / 21452313 rs10414271 chr19 31958905 C A 6.51E-05 Rheumatoid arthritis / / 21452313 rs10421853 chr19 31960060 C A 4.80E-05 Rheumatoid arthritis / / 21452313 rs12973926 chr19 31960867 A T 2.56E-04 Type 1 diabetes nephropathy / / 23028342 rs10518285 chr19 32003668 T C 1.81E-04 Bipolar disorder,schizoaffective / / 19567891 rs7247652 chr19 32023183 C T 1.32E-04 Aortic root size / / 21223598 rs16965838 chr19 32030817 G T 2.32E-06 Multiple complex diseases / / 17554300 rs10403928 chr19 32070564 A G 8.40E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11084596 chr19 32104979 T C 9.77E-05 Type 2 diabetes / / 17463246 rs16965958 chr19 32110644 A G 3.10E-04 Urinary metabolites / / 21572414 rs16965971 chr19 32115754 T C 1.46E-04 Multiple complex diseases / / 17554300 rs7248300 chr19 32154926 C A 5.07E-04 Multiple complex diseases / / 17554300 rs16966122 chr19 32158464 A G 8.78E-04 Multiple complex diseases / / 17554300 rs16966122 chr19 32158464 A G 2.00E-06 Narcolepsy with cataplexy / / 23496005 rs17501293 chr19 32159870 T C 5.95E-04 Multiple complex diseases / / 17554300 rs8110097 chr19 32162212 A G 2.34E-04 Multiple complex diseases / / 17554300 rs12463343 chr19 32162875 A G 4.89E-04 Multiple complex diseases / / 17554300 rs8104309 chr19 32166846 T G 2.00E-05 Rheumatoid arthritis / / 17804836 rs7254799 chr19 32212996 C G 8.59E-04 Type 2 diabetes / / 17463246 rs6510214 chr19 32216134 T G 7.38E-05 Cognitive impairment induced by topiramate / / 22091778 rs277432 chr19 32226182 C T 8.43E-04 Schizophrenia / / 19197363 rs277432 chr19 32226182 C T 9.12E-05 Longevity / / 22279548 rs16966229 chr19 32232310 T C 1.14E-04 Multiple complex diseases / / 17554300 rs16966238 chr19 32239512 T A 7.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs277422 chr19 32255438 G A 8.66E-05 Hypertension / / pha003041 rs399775 chr19 32262152 G A 4.68E-05 Hypertension / / pha003041 rs10153458 chr19 32264430 C T 9.03E-04 Multiple complex diseases / / 17554300 rs10412222 chr19 32286166 A G 4.21E-05 Multiple complex diseases / / 17554300 rs606605 chr19 32314563 A C 1.43E-04 Multiple complex diseases / / 17554300 rs510077 chr19 32314624 A C 1.19E-04 Multiple complex diseases / / 17554300 rs658168 chr19 32319742 T C 1.40E-05 Urinary metabolites / / 21572414 rs673162 chr19 32372022 T C 5.51E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs41490548 chr19 32394781 C G 9.09E-05 Multiple complex diseases / / 17554300 rs12982128 chr19 32444568 C T 6.28E-05 Post-operative nausea and vomiting / / 21694509 rs17703610 chr19 32471523 A C 5.00E-06 Alcohol dependence / / 21956439 rs17774281 chr19 32472010 G A 1.14E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs17703657 chr19 32475670 T C 1.00E-04 Information processing speed / / 21130836 rs11882799 chr19 32509513 C T 1.24E-04 Multiple complex diseases / / 17554300 rs758102 chr19 32563293 A G 7.90E-05 Body Mass Index / / pha003019 rs758102 chr19 32563293 A G 9.08E-05 Body Mass Index / / pha003020 rs2867743 chr19 32574053 A G 1.84E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2867743 chr19 32574053 A G 5.95E-05 Lung function (forced vital capacity) / / 24023788 rs7256006 chr19 32579416 A G 4.51E-05 Serum metabolites / / 19043545 rs1030688 chr19 32601553 A C 8.77E-04 Parkinson's disease / / 17052657 rs1030689 chr19 32604570 T C 2.40E-04 Rheumatoid arthritis / / 21452313 rs1030689 chr19 32604570 T C 4.26E-04 Tourette syndrome / / 22889924 rs16966737 chr19 32611285 A T 4.49E-04 Type 2 diabetes / / 17463246 rs871900 chr19 32621441 G A 1.09E-06 Fibrinogen / / 17255346 rs8112050 chr19 32631274 C T 3.19E-05 Schizophrenia / / 21926974 rs17774635 chr19 32631494 G A 1.08E-06 Fibrinogen / / 17255346 rs17774647 chr19 32631532 G A 8.47E-06 Fibrinogen / / 17255346 rs1074552 chr19 32636434 A G 3.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17512892 chr19 32669991 G A 6.56E-05 Body Fat Distribution / / pha003018 rs4275957 chr19 32674453 A G 7.62E-05 Body Fat Distribution / / pha003018 rs4275957 chr19 32674453 A G 7.56E-05 Coronary heart disease / / pha003056 rs10410583 chr19 32675151 G A 8.47E-05 Bipolar disorder / / 20451256 rs10410583 chr19 32675151 G A 0.0001 Dyslexia / / 23190410 rs10411220 chr19 32675407 G A 2.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs12976005 chr19 32676303 G C 1.50E-04 Suicide attempts in bipolar disorder / / 21041247 rs4334417 chr19 32676359 A G 8.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs7260436 chr19 32677094 C A 2.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs7260548 chr19 32677182 C T 4.33E-04 Suicide attempts in bipolar disorder / / 21041247 rs10412127 chr19 32691508 G A 4.29E-04 Multiple complex diseases / / 17554300 rs1076404 chr19 32692331 C T 5.56E-05 Multiple complex diseases / / 17554300 rs8104449 chr19 32708612 A T 2.40E-05 Urinary metabolites / / 21572414 rs8103676 chr19 32798938 T C 1.61E-04 Blood pressure / / 17255346 rs7255223 chr19 32824310 C A 2.41E-04 Multiple complex diseases / / 17554300 rs6510241 chr19 32828881 A G 3.19E-05 Height / / pha003010 rs6510241 chr19 32828881 A G 8.18E-05 Height / / pha003011 rs8104048 chr19 32829306 T C 5.11E-04 Multiple complex diseases / / 17554300 rs11670997 chr19 32829666 T A 2.20E-05 Urinary metabolites / / 21572414 rs2868083 chr19 32864565 G A 6.26E-05 Height ZNF507 intron pha003011 rs1015838 chr19 32881053 A G 5.98E-05 Height / / pha003011 rs2012353 chr19 32899293 G A 2.42E-05 Bipolar Disorder DPY19L3 intron pha002863 rs16967057 chr19 32914078 A C 2.34E-05 Bipolar disorder DPY19L3 intron 19488044 rs16967057 chr19 32914078 A C 2.87E-06 Bipolar Disorder DPY19L3 intron pha002863 rs2111504 chr19 32917455 T A 2.00E-06 Bipolar disorder DPY19L3 intron 19488044 rs2111504 chr19 32917455 T A 1.57E-07 Bipolar Disorder DPY19L3 intron pha002863 rs11671562 chr19 32979847 C T 2.64E-04 Celiac disease / / 23936387 rs1988952 chr19 33004201 G A 5.40E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs2059058 chr19 33006378 A G 5.94E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs10405015 chr19 33029646 T G 5.40E-04 Urinary metabolites / / 21572414 rs1862214 chr19 33035849 G C 4.00E-04 Lung cancer,smokers with versus smokers without / / 16549820 rs6510257 chr19 33041245 A G 7.07E-04 Multiple complex diseases / / 17554300 rs2868145 chr19 33047114 A G 3.20E-05 Follicular lymphoma / / 21533074 rs2868145 chr19 33047114 A G 1.06E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs10401677 chr19 33061120 C A 1.61E-04 Lung function (forced vital capacity) / / 24023788 rs17692896 chr19 33089431 G A 7.00E-07 Major depressive disorder ANKRD27 intron 23377640 rs10426856 chr19 33096406 A G 6.09E-04 Multiple complex diseases ANKRD27 intron 17554300 rs395136 chr19 33106742 A G 1.23E-04 Multiple complex diseases ANKRD27 intron 17554300 rs438268 chr19 33109904 T C 4.10E-05 Serum metabolites ANKRD27 intron 19043545 rs8109518 chr19 33111888 T A 3.93E-04 Multiple complex diseases ANKRD27 intron 17554300 rs10420153 chr19 33112957 C T 6.46E-04 Suicide attempts in bipolar disorder ANKRD27 intron 21423239 rs2302969 chr19 33113295 G A 2.70E-04 Urinary metabolites ANKRD27 intron 21572414 rs4805780 chr19 33114406 T C 5.46E-04 Suicide attempts in bipolar disorder ANKRD27 intron 21423239 rs6510271 chr19 33117666 T C 7.70E-04 Suicide attempts in bipolar disorder ANKRD27 cds-synon 21423239 rs8110604 chr19 33122567 G A 4.00E-04 Urinary metabolites ANKRD27 intron 21572414 rs7250780 chr19 33123576 T C 4.40E-04 Urinary metabolites ANKRD27 intron 21572414 rs9304837 chr19 33123928 A G 4.00E-04 Urinary metabolites ANKRD27 intron 21572414 rs10405549 chr19 33126176 T C 3.90E-04 Urinary metabolites ANKRD27 intron 21572414 rs10426107 chr19 33126521 C G 3.90E-04 Urinary metabolites ANKRD27 intron 21572414 rs62124309 chr19 33129747 C T 3.90E-04 Urinary metabolites ANKRD27 intron 21572414 rs2042262 chr19 33130091 C T 3.90E-04 Urinary metabolites ANKRD27 intron 21572414 rs62124310 chr19 33130501 C T 3.90E-04 Urinary metabolites ANKRD27 intron 21572414 rs731674 chr19 33132395 A G 4.50E-04 Insulin resistance ANKRD27 intron 21901158 rs259229 chr19 33134425 G A 9.03E-06 Serum metabolites ANKRD27 intron 19043545 rs259228 chr19 33134635 A G 5.57E-05 Serum metabolites ANKRD27 intron 19043545 rs259219 chr19 33138067 T C 2.80E-05 Serum metabolites ANKRD27 intron 19043545 rs259218 chr19 33138125 G A 8.25E-05 Serum metabolites ANKRD27 intron 19043545 rs259217 chr19 33138368 G A 5.77E-05 Serum metabolites ANKRD27 intron 19043545 rs62124326 chr19 33141777 C T 4.80E-04 Urinary metabolites ANKRD27 intron 21572414 rs8112647 chr19 33154311 G A 3.03E-07 Multiple complex diseases ANKRD27 intron 17554300 rs259276 chr19 33160953 C G 7.80E-04 Urinary metabolites ANKRD27 intron 21572414 rs13313735 chr19 33161007 A G 7.40E-05 Urinary metabolites ANKRD27 intron 21572414 rs259286 chr19 33164759 C T 9.61E-05 Serum metabolites ANKRD27 intron 19043545 rs259294 chr19 33169003 A C 9.65E-04 Amyotrophic Lateral Sclerosis RGS9BP UTR-3 17362836 rs10417773 chr19 33169097 G T 1.80E-05 Urinary metabolites RGS9BP UTR-3 21572414 rs8107934 chr19 33173076 T C 1.40E-08 Urinary metabolites / / 21572414 rs62124338 chr19 33176191 G A 1.20E-08 Urinary metabolites / / 21572414 rs3892630 chr19 33181484 C T 1.00E-10 Red blood cell traits / / 23222517 rs881273 chr19 33182320 G A 1.60E-05 Urinary metabolites / / 21572414 rs8108837 chr19 33182802 C T 2.00E-08 Urinary metabolites / / 21572414 rs61732600 chr19 33183352 G C 1.30E-08 Urinary metabolites NUDT19 cds-synon 21572414 rs4805801 chr19 33183812 C T 1.10E-09 Urinary metabolites NUDT19 intron 21572414 rs35709439 chr19 33190263 C T 1.30E-10 Urinary metabolites NUDT19 intron 21572414 rs6510279 chr19 33190285 T C 6.90E-06 Urinary metabolites NUDT19 intron 21572414 rs6510280 chr19 33190422 G A 1.50E-08 Urinary metabolites NUDT19 intron 21572414 rs8101812 chr19 33190796 T G 1.90E-08 Urinary metabolites NUDT19 intron 21572414 rs4805008 chr19 33193520 G A 5.10E-06 Urinary metabolites NUDT19 intron 21572414 rs9676978 chr19 33196336 A G 2.10E-08 Urinary metabolites NUDT19 intron 21572414 rs1827700 chr19 33196989 A G 3.90E-08 Urinary metabolites NUDT19 intron 21572414 rs12975541 chr19 33197355 C T 3.40E-08 Urinary metabolites NUDT19 intron 21572414 rs7256355 chr19 33199477 C A 1.40E-08 Urinary metabolites NUDT19 intron 21572414 rs8113684 chr19 33199753 T C 3.40E-09 Urinary metabolites NUDT19 intron 21572414 rs8112297 chr19 33199783 G A 4.80E-08 Urinary metabolites NUDT19 intron 21572414 rs11879169 chr19 33203675 A G 1.40E-06 Urinary metabolites NUDT19 UTR-3 21572414 rs1061686 chr19 33204544 T C 8.26E-07 Red blood cell traits NUDT19 UTR-3 23222517 rs7256750 chr19 33207645 T G 1.80E-05 Urinary metabolites / / 21572414 rs1559175 chr19 33210247 A G 2.20E-05 Urinary metabolites / / 21572414 rs1559176 chr19 33210389 A G 8.80E-07 Urinary metabolites / / 21572414 rs12983541 chr19 33213199 T C 1.00E-06 Urinary metabolites TDRD12 intron 21572414 rs12463266 chr19 33213526 T C 8.00E-07 Urinary metabolites TDRD12 intron 21572414 rs12984580 chr19 33214829 T C 5.70E-05 Urinary metabolites TDRD12 intron 21572414 rs508455 chr19 33216592 G A,C,T 1.20E-10 Urinary metabolites TDRD12 intron 21572414 rs11880959 chr19 33217367 T C 8.30E-07 Urinary metabolites TDRD12 intron 21572414 rs11880352 chr19 33217382 A T 8.30E-07 Urinary metabolites TDRD12 intron 21572414 rs7351070 chr19 33218011 T C 6.30E-05 Urinary metabolites TDRD12 intron 21572414 rs8102279 chr19 33221326 T C 1.70E-07 Urinary metabolites TDRD12 intron 21572414 rs12983074 chr19 33221559 G A 3.40E-05 Urinary metabolites TDRD12 intron 21572414 rs12983865 chr19 33223005 G T 5.80E-05 Urinary metabolites TDRD12 intron 21572414 rs10408725 chr19 33223998 A C 5.90E-07 Urinary metabolites TDRD12 intron 21572414 rs12151325 chr19 33225174 T C 5.80E-07 Urinary metabolites TDRD12 intron 21572414 rs12985444 chr19 33230180 C G 2.00E-06 Urinary metabolites TDRD12 intron 21572414 rs977708 chr19 33231786 T C 5.70E-07 Urinary metabolites TDRD12 intron 21572414 rs7258269 chr19 33232962 G A 5.40E-09 Urinary metabolites TDRD12 intron 21572414 rs7260313 chr19 33233424 A G 5.60E-07 Urinary metabolites TDRD12 intron 21572414 rs17699213 chr19 33234018 A G 5.40E-09 Urinary metabolites TDRD12 intron 21572414 rs7252343 chr19 33235489 G A 5.60E-07 Urinary metabolites TDRD12 intron 21572414 rs34687315 chr19 33237814 G A 1.60E-09 Urinary metabolites TDRD12 intron 21572414 rs12973557 chr19 33238089 T C 5.60E-07 Urinary metabolites TDRD12 intron 21572414 rs12610846 chr19 33238999 C T 1.70E-05 Urinary metabolites TDRD12 intron 21572414 rs4805804 chr19 33239105 G T 1.50E-05 Urinary metabolites TDRD12 intron 21572414 rs4805805 chr19 33239450 C G 5.60E-07 Urinary metabolites TDRD12 intron 21572414 rs4254433 chr19 33239988 G A 3.40E-09 Urinary metabolites TDRD12 intron 21572414 rs2042263 chr19 33240000 G A 5.60E-07 Urinary metabolites TDRD12 intron 21572414 rs9783983 chr19 33240570 G A 4.40E-05 Urinary metabolites TDRD12 intron 21572414 rs4805806 chr19 33241732 T C 3.60E-05 Urinary metabolites TDRD12 intron 21572414 rs7249281 chr19 33242652 T A 5.60E-07 Urinary metabolites TDRD12 intron 21572414 rs7246228 chr19 33245021 T C 5.60E-07 Urinary metabolites TDRD12 intron 21572414 rs10404914 chr19 33246317 A G 5.60E-07 Urinary metabolites TDRD12 intron 21572414 rs8100942 chr19 33246599 G A 5.90E-05 Urinary metabolites TDRD12 intron 21572414 rs10405092 chr19 33249914 G C 4.90E-05 Urinary metabolites TDRD12 intron 21572414 rs4805807 chr19 33250428 G A 4.00E-09 Urinary metabolites TDRD12 intron 21572414 rs34174673 chr19 33252045 C T 3.90E-09 Urinary metabolites TDRD12 intron 21572414 rs8103603 chr19 33252513 G A 4.40E-07 Urinary metabolites TDRD12 intron 21572414 rs10445597 chr19 33253707 A G 3.80E-09 Urinary metabolites TDRD12 intron 21572414 rs873002 chr19 33253922 G A 1.90E-07 Urinary metabolites TDRD12 intron 21572414 rs4422091 chr19 33254768 T C 6.50E-07 Urinary metabolites TDRD12 intron 21572414 rs2868188 chr19 33254878 A G 4.30E-07 Urinary metabolites TDRD12 intron 21572414 rs4239574 chr19 33256835 G T 2.60E-07 Urinary metabolites TDRD12 intron 21572414 rs755691 chr19 33258817 G A 4.30E-07 Urinary metabolites TDRD12 intron 21572414 rs12610378 chr19 33258995 A G 4.30E-07 Urinary metabolites TDRD12 intron 21572414 rs8113187 chr19 33263229 A G 4.20E-07 Urinary metabolites TDRD12 intron 21572414 rs12608647 chr19 33264348 G T 4.70E-07 Urinary metabolites TDRD12 intron 21572414 rs58026555 chr19 33265013 A G 8.10E-09 Urinary metabolites TDRD12 intron 21572414 rs4805808 chr19 33265236 G A 4.20E-07 Urinary metabolites TDRD12 intron 21572414 rs7260438 chr19 33267177 G A 3.20E-07 Urinary metabolites TDRD12 intron 21572414 rs10853922 chr19 33268425 T A 4.30E-08 Urinary metabolites TDRD12 intron 21572414 rs6510288 chr19 33270156 A C,G 4.50E-07 Urinary metabolites TDRD12 intron 21572414 rs6510290 chr19 33271059 G A 4.20E-07 Urinary metabolites TDRD12 intron 21572414 rs4805010 chr19 33276506 C A 2.70E-04 Urinary metabolites TDRD12 intron 21572414 rs60342693 chr19 33280017 G T 1.10E-06 Urinary metabolites TDRD12 intron 21572414 rs2278279 chr19 33281127 C T 3.70E-07 Urinary metabolites TDRD12 intron 21572414 rs11881633 chr19 33281924 A G 4.00E-07 Urinary metabolites / / 21572414 rs11878874 chr19 33282109 C T 1.20E-05 Urinary metabolites / / 21572414 rs6510293 chr19 33282623 G C 1.20E-05 Urinary metabolites / / 21572414 rs6510294 chr19 33282716 T G 3.70E-07 Urinary metabolites / / 21572414 rs7257919 chr19 33284449 G A 3.70E-07 Urinary metabolites / / 21572414 rs8110217 chr19 33287526 C T 3.70E-07 Urinary metabolites / / 21572414 rs10424621 chr19 33287815 G A 1.20E-05 Urinary metabolites / / 21572414 rs8108045 chr19 33292296 G A 3.80E-07 Urinary metabolites / / 21572414 rs12976876 chr19 33292568 A T 7.40E-05 Urinary metabolites / / 21572414 rs35241694 chr19 33292897 C G 1.50E-06 Urinary metabolites / / 21572414 rs11673502 chr19 33293607 C T 3.00E-09 Urinary metabolites / / 21572414 rs56018232 chr19 33296106 C T 5.70E-04 Urinary metabolites / / 21572414 rs55977451 chr19 33298122 A G 3.00E-09 Urinary metabolites / / 21572414 rs10408313 chr19 33298286 G A 4.00E-07 Urinary metabolites / / 21572414 rs11670513 chr19 33302823 C T 4.10E-07 Urinary metabolites / / 21572414 rs11671862 chr19 33304298 C T 7.90E-08 Urinary metabolites / / 21572414 rs8107900 chr19 33304690 C T 4.10E-07 Urinary metabolites / / 21572414 rs8111278 chr19 33304713 T C 4.10E-07 Urinary metabolites / / 21572414 rs12463019 chr19 33305504 C T 4.10E-07 Urinary metabolites / / 21572414 rs12461363 chr19 33305527 T A 3.50E-07 Urinary metabolites / / 21572414 rs8105249 chr19 33307000 A G 1.10E-05 Urinary metabolites / / 21572414 rs8108383 chr19 33307071 T C 4.10E-07 Urinary metabolites / / 21572414 rs11671229 chr19 33307117 A G 2.40E-08 Urinary metabolites / / 21572414 rs6510295 chr19 33307307 A T 3.30E-07 Urinary metabolites / / 21572414 rs12151363 chr19 33309030 A T 2.90E-09 Urinary metabolites / / 21572414 rs3760945 chr19 33309413 G A 4.10E-07 Urinary metabolites / / 21572414 rs58018786 chr19 33310148 A G 7.20E-10 Urinary metabolites / / 21572414 rs12327875 chr19 33313324 T C 4.10E-07 Urinary metabolites / / 21572414 rs28439934 chr19 33313704 T G 4.20E-07 Urinary metabolites / / 21572414 rs17206198 chr19 33314913 A G 3.30E-04 Urinary metabolites / / 21572414 rs4805812 chr19 33315118 T C 4.60E-07 Urinary metabolites / / 21572414 rs8101263 chr19 33315506 G C 4.40E-07 Urinary metabolites / / 21572414 rs17206212 chr19 33315613 G A 3.10E-08 Urinary metabolites / / 21572414 rs1035478 chr19 33316323 C T 9.20E-07 Urinary metabolites / / 21572414 rs3746022 chr19 33317307 T C 7.50E-07 Urinary metabolites / / 21572414 rs56734203 chr19 33317421 C A 3.90E-07 Urinary metabolites / / 21572414 rs2112916 chr19 33317664 T A 4.60E-07 Urinary metabolites / / 21572414 rs3746024 chr19 33317690 T C 4.90E-11 Urinary metabolites / / 21572414 rs3746028 chr19 33317912 A G 4.88E-05 Body Mass Index / / pha003015 rs6510297 chr19 33319544 A G 4.60E-07 Urinary metabolites / / 21572414 rs17272183 chr19 33321213 A G 1.60E-09 Urinary metabolites SLC7A9 nearGene-3 21572414 rs17272190 chr19 33321775 C G 1.30E-09 Urinary metabolites SLC7A9 intron 21572414 rs7253612 chr19 33321997 G C 3.67E-04 Suicide attempts in bipolar disorder SLC7A9 intron 21423239 rs7259264 chr19 33322945 A G 1.60E-05 Urinary metabolites SLC7A9 intron 21572414 rs7258013 chr19 33323042 G A 4.80E-07 Urinary metabolites SLC7A9 intron 21572414 rs17272197 chr19 33329144 T C 5.80E-09 Urinary metabolites SLC7A9 intron 21572414 rs11668337 chr19 33329770 A G 5.60E-09 Urinary metabolites SLC7A9 intron 21572414 rs2032869 chr19 33330666 C G 1.50E-06 Urinary metabolites SLC7A9 intron 21572414 rs7247583 chr19 33330917 C T 2.75E-04 Suicide attempts in bipolar disorder SLC7A9 intron 21423239 rs11670575 chr19 33331544 A G 1.60E-09 Urinary metabolites SLC7A9 intron 21572414 rs929816 chr19 33331913 C T 2.85E-04 Suicide attempts in bipolar disorder SLC7A9 intron 21423239 rs11671987 chr19 33332312 C G 5.40E-09 Urinary metabolites SLC7A9 intron 21572414 rs11671809 chr19 33332516 G A 3.70E-09 Urinary metabolites SLC7A9 intron 21572414 rs9304838 chr19 33332828 C G 1.60E-06 Urinary metabolites SLC7A9 intron 21572414 rs3815760 chr19 33334415 T C 3.60E-06 Urinary metabolites SLC7A9 intron 21572414 rs12979191 chr19 33336774 A G 1.50E-06 Urinary metabolites SLC7A9 intron 21572414 rs8102775 chr19 33343722 C G 4.80E-06 Urinary metabolites SLC7A9 intron 21572414 rs8113265 chr19 33346204 G A 8.50E-07 Urinary metabolites SLC7A9 intron 21572414 rs11666467 chr19 33346799 G C 2.20E-09 Urinary metabolites SLC7A9 intron 21572414 rs11671799 chr19 33346883 T C 2.10E-09 Urinary metabolites SLC7A9 intron 21572414 rs17238865 chr19 33349179 G A 1.40E-09 Urinary metabolites SLC7A9 intron 21572414 rs2287880 chr19 33349295 T C 1.40E-09 Urinary metabolites SLC7A9 intron 21572414 rs2287879 chr19 33349488 T C 3.70E-10 Urinary metabolites SLC7A9 intron 21572414 rs11666241 chr19 33349676 T A 1.30E-08 Urinary metabolites SLC7A9 intron 21572414 rs2868194 chr19 33350060 T C 2.10E-09 Urinary metabolites SLC7A9 intron 21572414 rs2287878 chr19 33351695 T C 7.20E-05 Urinary metabolites SLC7A9 intron 21572414 rs12979811 chr19 33352654 A G 6.70E-04 Urinary metabolites SLC7A9 intron 21572414 rs1007161 chr19 33353041 G A 6.30E-04 Urinary metabolites SLC7A9 cds-synon 21572414 rs1007160 chr19 33353061 G T 6.30E-04 Urinary metabolites SLC7A9 missense 21572414 rs11084672 chr19 33353357 C T 6.20E-09 Urinary metabolites SLC7A9 intron 21572414 rs11084673 chr19 33353464 G A 2.30E-04 Urinary metabolites SLC7A9 cds-synon 21572414 rs11668777 chr19 33354189 C T 5.50E-10 Urinary metabolites SLC7A9 intron 21572414 rs11668595 chr19 33354401 G A 9.50E-12 Urinary metabolites SLC7A9 intron 21572414 rs11668597 chr19 33354404 G A 9.50E-12 Urinary metabolites SLC7A9 intron 21572414 rs6510300 chr19 33354992 A G 5.20E-12 Urinary metabolites SLC7A9 intron 21572414 rs6510300 chr19 33354992 A G 1.00E-15 Urinary metabolites (H-NMR features) SLC7A9 intron 24586186 rs6510300 chr19 33354992 A G 1.30E-19 Urinary metabolites (H-NMR features) SLC7A9 intron 24586186 rs6510300 chr19 33354992 A G 2.00E-17 Urinary metabolites (H-NMR features) SLC7A9 intron 24586186 rs12150889 chr19 33355055 A G 7.40E-04 Urinary metabolites SLC7A9 missense 21572414 rs12150890 chr19 33355069 A G 2.80E-09 Urinary metabolites SLC7A9 cds-synon 21572414 rs12151145 chr19 33355356 C T 1.90E-09 Urinary metabolites SLC7A9 intron 21572414 rs12460876 chr19 33356891 T C 3.00E-15 Chronic kidney disease SLC7A9 intron 20383146 rs12460876 chr19 33356891 T C 2.20E-15 Urinary metabolites SLC7A9 intron 21572414 rs12460876 chr19 33356891 T C 8.63E-11 Chronic kidney disease SLC7A9 intron 22479191 rs12460876 chr19 33356891 T C 3.70E-04 Glomerular filtration rate SLC7A9 intron 23535967 rs12460876 chr19 33356891 T C 4.30E-04 Glomerular filtration rate SLC7A9 intron 23535967 rs12460876 chr19 33356891 T C 4.50E-04 Glomerular filtration rate SLC7A9 intron 23535967 rs12460876 chr19 33356891 T C 5.00E-04 Glomerular filtration rate SLC7A9 intron 23535967 rs12460876 chr19 33356891 T C 5.20E-04 Glomerular filtration rate SLC7A9 intron 23535967 rs12460876 chr19 33356891 T C 8.70E-04 Glomerular filtration rate SLC7A9 intron 23535967 rs17206254 chr19 33356962 C T 1.30E-10 Urinary metabolites SLC7A9 intron 21572414 rs17206261 chr19 33357099 G A 1.10E-10 Urinary metabolites SLC7A9 intron 21572414 rs12976336 chr19 33357318 A G 6.20E-10 Urinary metabolites SLC7A9 intron 21572414 rs35975406 chr19 33357433 G C 3.50E-15 Urinary metabolites SLC7A9 intron 21572414 rs7247977 chr19 33358355 T C 1.00E-14 Urinary metabolites SLC7A9 intron 21572414 rs16967511 chr19 33358527 A C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SLC7A9 intron 22628534 rs57910615 chr19 33360342 G A 8.00E-11 Urinary metabolites SLC7A9 intron 21572414 rs7252778 chr19 33360369 C A 4.80E-15 Urinary metabolites SLC7A9 intron 21572414 rs2287876 chr19 33360652 A T 4.70E-04 Urinary metabolites SLC7A9 UTR-5 21572414 rs1990990 chr19 33361794 C T 1.40E-07 Urinary metabolites SLC7A9 nearGene-5 21572414 rs8101881 chr19 33364628 C T 6.00E-27 Urinary metabolites / / 21572414 rs8101881 chr19 33364628 C T 1.00E-33 Urinary metabolites (H-NMR features) / / 24586186 rs8101881 chr19 33364628 C T 1.00E-33 Urinary metabolites (H-NMR features) / / 24586186 rs8101881 chr19 33364628 C T 2.00E-33 Urinary metabolites (H-NMR features) / / 24586186 rs8101881 chr19 33364628 C T 1.00E-16 Blood metabolite levels / / 24816252 rs10164326 chr19 33365292 C G 6.30E-10 Urinary metabolites / / 21572414 rs10164326 chr19 33365292 C G 8.07E-05 Parkinson's disease (motor and cognition) / / 22658654 rs10164326 chr19 33365292 C G 8.07E-05 Immune response to anthrax vaccine / / 22658931 rs11084678 chr19 33365430 A G 2.00E-09 Urinary metabolites / / 21572414 rs11667378 chr19 33365591 C T 7.00E-11 Urinary metabolites / / 21572414 rs7254267 chr19 33365834 G A 8.51E-04 Multiple complex diseases / / 17554300 rs11666472 chr19 33367233 T C 6.60E-11 Urinary metabolites / / 21572414 rs34035782 chr19 33368066 C T 1.50E-09 Urinary metabolites / / 21572414 rs11671966 chr19 33369611 C A 2.50E-10 Urinary metabolites / / 21572414 rs746641 chr19 33369655 A C 4.00E-05 Urinary metabolites / / 21572414 rs745961 chr19 33370070 A G 9.40E-04 Urinary metabolites / / 21572414 rs745960 chr19 33370084 T A 5.30E-04 Urinary metabolites CEP89 missense 21572414 rs17206282 chr19 33370566 T C 8.60E-04 Urinary metabolites CEP89 intron 21572414 rs55970832 chr19 33370702 A G 9.30E-04 Urinary metabolites CEP89 intron 21572414 rs11665689 chr19 33370952 G A 9.30E-04 Urinary metabolites CEP89 intron 21572414 rs11670103 chr19 33371039 A C 5.60E-11 Urinary metabolites CEP89 intron 21572414 rs17206303 chr19 33371145 G A 8.80E-04 Urinary metabolites CEP89 intron 21572414 rs17272267 chr19 33371193 G A 3.11E-04 Type 2 diabetes CEP89 intron 17463246 rs11666273 chr19 33372601 T C 9.00E-04 Urinary metabolites CEP89 intron 21572414 rs17272274 chr19 33373040 G A 3.60E-11 Urinary metabolites CEP89 intron 21572414 rs11667425 chr19 33373634 T C 5.50E-11 Urinary metabolites CEP89 intron 21572414 rs4805014 chr19 33376020 G A 1.70E-08 Urinary metabolites CEP89 intron 21572414 rs58744764 chr19 33376203 G A,C,T 4.90E-11 Urinary metabolites CEP89 intron 21572414 rs60858882 chr19 33376519 T C 8.10E-04 Urinary metabolites CEP89 intron 21572414 rs4536580 chr19 33376963 T C 4.80E-11 Urinary metabolites CEP89 intron 21572414 rs2868197 chr19 33377053 T C 8.80E-04 Urinary metabolites CEP89 intron 21572414 rs2868197 chr19 33377053 T C 5.85E-08 Lymphocyte counts CEP89 intron 22286170 rs35158384 chr19 33379243 T C 5.10E-11 Urinary metabolites CEP89 intron 21572414 rs59084925 chr19 33379462 A G 7.90E-04 Urinary metabolites CEP89 intron 21572414 rs4550589 chr19 33380497 T C 5.10E-11 Urinary metabolites CEP89 intron 21572414 rs2098700 chr19 33381610 T C 7.90E-04 Urinary metabolites CEP89 intron 21572414 rs12150992 chr19 33383404 G T 2.30E-10 Urinary metabolites CEP89 intron 21572414 rs12151320 chr19 33383905 A G 3.60E-11 Urinary metabolites CEP89 intron 21572414 rs12151322 chr19 33383963 A T 5.20E-11 Urinary metabolites CEP89 intron 21572414 rs59563992 chr19 33387267 G A 1.90E-04 Urinary metabolites CEP89 intron 21572414 rs4134430 chr19 33387685 C T 4.90E-08 Urinary metabolites CEP89 intron 21572414 rs10418340 chr19 33390796 G A 7.00E-11 Urinary metabolites / / 21572414 rs10426667 chr19 33391006 T G 5.70E-08 Urinary metabolites CEP89 intron 21572414 rs16967545 chr19 33391684 T C 7.40E-08 Urinary metabolites CEP89 intron 21572414 rs8111033 chr19 33391738 C A 3.50E-05 Urinary metabolites CEP89 intron 21572414 rs11880965 chr19 33393053 T C 2.20E-05 Urinary metabolites CEP89 intron 21572414 rs10410304 chr19 33394188 T G 6.62E-04 Type 2 diabetes CEP89 intron 17463246 rs4805015 chr19 33395413 G A 1.60E-10 Urinary metabolites CEP89 intron 21572414 rs4805016 chr19 33395472 T C 7.50E-08 Urinary metabolites CEP89 intron 21572414 rs6510304 chr19 33396227 T C 7.00E-10 Urinary metabolites CEP89 intron 21572414 rs57948858 chr19 33397665 A C 6.60E-08 Urinary metabolites CEP89 intron 21572414 rs61395248 chr19 33397705 A G 3.60E-05 Urinary metabolites CEP89 intron 21572414 rs2082424 chr19 33398289 A C 1.50E-10 Urinary metabolites CEP89 intron 21572414 rs2404982 chr19 33400133 G C 7.10E-08 Urinary metabolites CEP89 intron 21572414 rs8111100 chr19 33402100 G A 3.60E-05 Urinary metabolites CEP89 intron 21572414 rs8101313 chr19 33402166 T A 8.40E-11 Urinary metabolites CEP89 intron 21572414 rs8101546 chr19 33402300 T C 3.60E-09 Urinary metabolites CEP89 intron 21572414 rs8111351 chr19 33402301 G A 2.20E-07 Urinary metabolites CEP89 intron 21572414 rs8101667 chr19 33402419 T C 4.70E-12 Urinary metabolites CEP89 intron 21572414 rs6510305 chr19 33402700 T C 4.80E-09 Urinary metabolites CEP89 intron 21572414 rs7248010 chr19 33403405 C G 7.50E-08 Urinary metabolites CEP89 intron 21572414 rs7246178 chr19 33406442 A G 1.50E-10 Urinary metabolites CEP89 intron 21572414 rs7260149 chr19 33406484 G T 1.20E-10 Urinary metabolites CEP89 intron 21572414 rs7246326 chr19 33406549 A G 5.80E-11 Urinary metabolites CEP89 intron 21572414 rs8104077 chr19 33407111 A G 1.50E-10 Urinary metabolites CEP89 intron 21572414 rs7253595 chr19 33407953 C G 8.20E-11 Urinary metabolites CEP89 intron 21572414 rs3752223 chr19 33408410 C T 6.60E-08 Urinary metabolites CEP89 intron 21572414 rs10404708 chr19 33409772 T A 1.80E-13 Urinary metabolites CEP89 intron 21572414 rs2016867 chr19 33410289 T C 1.20E-10 Urinary metabolites CEP89 intron 21572414 rs1036217 chr19 33410388 T C 2.60E-08 Urinary metabolites CEP89 intron 21572414 rs10418164 chr19 33411139 T G 8.30E-12 Urinary metabolites CEP89 intron 21572414 rs10412219 chr19 33413246 G C 5.20E-14 Urinary metabolites CEP89 intron 21572414 rs10410936 chr19 33416685 C T 4.30E-04 Urinary metabolites CEP89 intron 21572414 rs3813152 chr19 33417313 T C 8.60E-10 Urinary metabolites CEP89 intron 21572414 rs8102681 chr19 33419560 C G 1.20E-04 Urinary metabolites CEP89 intron 21572414 rs36061317 chr19 33421157 C T 1.20E-04 Urinary metabolites CEP89 intron 21572414 rs1865038 chr19 33421486 T C 3.20E-10 Urinary metabolites CEP89 intron 21572414 rs919775 chr19 33421869 A G 4.80E-06 Urinary metabolites CEP89 intron 21572414 rs919776 chr19 33422134 T A 9.90E-04 Type 2 diabetes CEP89 intron 17463246 rs919776 chr19 33422134 T A 1.40E-04 Urinary metabolites CEP89 intron 21572414 rs10416920 chr19 33422691 A G 1.10E-04 Urinary metabolites CEP89 intron 21572414 rs4805827 chr19 33423502 T C 1.20E-04 Urinary metabolites CEP89 intron 21572414 rs34802140 chr19 33427308 G T 1.20E-04 Urinary metabolites CEP89 intron 21572414 rs3816031 chr19 33428166 T G 5.00E-06 Urinary metabolites CEP89 intron 21572414 rs2304099 chr19 33428350 C T 1.20E-04 Urinary metabolites CEP89 intron 21572414 rs2304100 chr19 33428423 G T 1.10E-04 Urinary metabolites CEP89 intron 21572414 rs12461782 chr19 33430816 T G 7.90E-06 Urinary metabolites CEP89 intron 21572414 rs7250603 chr19 33431483 T G 8.30E-05 Urinary metabolites CEP89 intron 21572414 rs6510306 chr19 33432709 T C 1.30E-04 Urinary metabolites CEP89 intron 21572414 rs4635450 chr19 33433749 T C 3.00E-10 Urinary metabolites CEP89 intron 21572414 rs4805018 chr19 33433846 A G 1.20E-04 Urinary metabolites CEP89 intron 21572414 rs7251236 chr19 33435765 A G 1.30E-04 Urinary metabolites CEP89 intron 21572414 rs4805021 chr19 33436367 G A 4.20E-09 Urinary metabolites CEP89 intron 21572414 rs4805022 chr19 33436576 T A 1.10E-04 Urinary metabolites CEP89 intron 21572414 rs10418619 chr19 33436687 A G 1.10E-04 Urinary metabolites CEP89 intron 21572414 rs9676565 chr19 33438039 T C 1.10E-04 Urinary metabolites CEP89 intron 21572414 rs12710001 chr19 33439158 T C 3.40E-04 Urinary metabolites CEP89 intron 21572414 rs3764635 chr19 33439485 G A 7.70E-09 Urinary metabolites CEP89 intron 21572414 rs4805829 chr19 33440598 T G 9.50E-05 Urinary metabolites CEP89 intron 21572414 rs28581517 chr19 33441555 A G 1.10E-04 Urinary metabolites CEP89 intron 21572414 rs8100062 chr19 33441935 T G 1.10E-04 Urinary metabolites CEP89 intron 21572414 rs8111221 chr19 33442002 A C 7.10E-05 Urinary metabolites CEP89 intron 21572414 rs8100180 chr19 33442013 T C 7.60E-09 Urinary metabolites CEP89 intron 21572414 rs8110525 chr19 33442506 G C 7.50E-09 Urinary metabolites CEP89 intron 21572414 rs4805830 chr19 33444067 G A 1.80E-04 Urinary metabolites CEP89 intron 21572414 rs2944021 chr19 33444456 A G 1.76E-07 Rheumatoid arthritis CEP89 intron 21452313 rs10411735 chr19 33444707 C T 7.10E-05 Urinary metabolites CEP89 cds-synon 21572414 rs10423939 chr19 33445068 T C 1.60E-06 Urinary metabolites CEP89 intron 21572414 rs10425179 chr19 33445631 T C 5.60E-05 Urinary metabolites CEP89 intron 21572414 rs4805831 chr19 33446689 A G 4.10E-04 Urinary metabolites CEP89 intron 21572414 rs4805832 chr19 33446691 G A 4.60E-04 Urinary metabolites CEP89 intron 21572414 rs4805833 chr19 33446754 A G 1.20E-04 Urinary metabolites CEP89 intron 21572414 rs8106312 chr19 33447798 C T 1.30E-04 Urinary metabolites CEP89 intron 21572414 rs8107282 chr19 33448204 A G 9.20E-06 Urinary metabolites CEP89 intron 21572414 rs4805834 chr19 33453659 T C 5.00E-11 Creatinine levels CEP89 intron 20383145 rs4805834 chr19 33453659 T C 4.30E-10 Urinary metabolites CEP89 intron 21572414 rs28623087 chr19 33454249 G A 1.70E-07 Urinary metabolites CEP89 intron 21572414 rs10401336 chr19 33455589 C T 7.10E-09 Urinary metabolites CEP89 intron 21572414 rs10401336 chr19 33455589 C T 5.30E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CEP89 intron 22566498 rs10413622 chr19 33455897 T G 2.50E-07 Urinary metabolites CEP89 intron 21572414 rs10408230 chr19 33456012 A T 2.50E-07 Urinary metabolites CEP89 intron 21572414 rs4805835 chr19 33456652 A T 4.10E-10 Urinary metabolites CEP89 intron 21572414 rs10422403 chr19 33458133 C T 9.50E-08 Urinary metabolites CEP89 intron 21572414 rs4805837 chr19 33459592 A G 2.00E-05 Urinary metabolites CEP89 intron 21572414 rs1133771 chr19 33459996 C T 7.90E-05 Urinary metabolites CEP89 intron 21572414 rs9676744 chr19 33460113 T G 7.90E-05 Urinary metabolites CEP89 intron 21572414 rs4570989 chr19 33460476 G A 8.00E-05 Urinary metabolites CEP89 intron 21572414 rs2404713 chr19 33460536 A G 4.90E-05 Urinary metabolites CEP89 intron 21572414 rs2404712 chr19 33461848 A G 2.60E-05 Urinary metabolites CEP89 intron 21572414 rs7245980 chr19 33464048 A G 2.70E-05 Urinary metabolites C19orf40 intron 21572414 rs6510314 chr19 33466782 G A 1.70E-04 Urinary metabolites C19orf40 intron 21572414 rs7258185 chr19 33467576 G A 1.80E-04 Urinary metabolites C19orf40 cds-synon 21572414 rs7247715 chr19 33467620 T C 1.10E-04 Urinary metabolites C19orf40 UTR-3 21572414 rs4805025 chr19 33468067 C T 2.50E-05 Urinary metabolites / / 21572414 rs4805840 chr19 33468482 A G 1.70E-05 Urinary metabolites / / 21572414 rs10422161 chr19 33472406 C G 8.70E-04 Urinary metabolites RHPN2 intron 21572414 rs17316183 chr19 33508382 T G 6.63E-04 Acute lung injury RHPN2 intron 22295056 rs73039434 chr19 33524919 T G 3.00E-06 Obesity-related traits RHPN2 intron 23251661 rs13343954 chr19 33527888 T C 7.00E-08 Colorectal cancer RHPN2 intron 24737748 rs8113612 chr19 33530811 A G 7.44E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RHPN2 intron 20877124 rs10411210 chr19 33532300 C T 5.00E-09 Colorectal cancer RHPN2 intron 19011631 rs10411210 chr19 33532300 C T 5.00E-09 Nasopharyngeal carcinoma RHPN2 intron 20512145 rs10411210 chr19 33532300 C T 3.00E-06 Colorectal cancer RHPN2 intron 24836286 rs7259371 chr19 33534641 G A 5.70E-06 Colorectal cancer RHPN2 intron 19011631 rs7259371 chr19 33534641 G A 3.20E-06 Systemic lupus erythematosus and Systemic sclerosis RHPN2 intron 23740937 rs8106293 chr19 33536376 G A 1.35E-04 Multiple complex diseases RHPN2 intron 17554300 rs12972060 chr19 33537096 T C 4.90E-05 Temporomandibular joint disorders RHPN2 intron 23746317 rs6510337 chr19 33545701 C T 5.76E-05 Cleft lip RHPN2 intron 20436469 rs6510337 chr19 33545701 C T 3.85E-05 Orofacial clefts RHPN2 intron 22863734 rs7343107 chr19 33547883 G C 1.51E-04 Bone mineral density RHPN2 intron 24249740 rs7343107 chr19 33547883 G C 6.94E-04 Bone mineral density RHPN2 intron 24249740 rs1559088 chr19 33551061 C T 5.80E-04 Multiple complex diseases RHPN2 intron 17554300 rs7258173 chr19 33554109 T A 0.000000693 Lumbar spine bone mineral density (premenopausal) RHPN2 intron 23074152 rs2019603 chr19 33577367 T C 4.06E-04 Multiple complex diseases GPATCH1 intron 17554300 rs12608825 chr19 33581219 A G 3.91E-04 Multiple complex diseases GPATCH1 intron 17554300 rs12610266 chr19 33581237 C G 5.08E-04 Multiple complex diseases GPATCH1 intron 17554300 rs7247748 chr19 33594023 T C 4.12E-04 Multiple complex diseases GPATCH1 intron 17554300 rs10416218 chr19 33599127 T C 7.00E-11 Bone mineral density GPATCH1 intron 22504420 rs10416218 chr19 33599127 T C 3.64E-04 Bone mineral density GPATCH1 intron 24249740 rs10416218 chr19 33599127 T C 5.27E-04 Bone mineral density GPATCH1 intron 24249740 rs3786934 chr19 33602856 A G 3.85E-05 Type 2 diabetes GPATCH1 intron 17463246 rs10416265 chr19 33605300 A G 2.00E-13 Bone properties (heel) GPATCH1 missense 24430505 rs10416265 chr19 33605300 A G 4.00E-12 Bone properties (heel) GPATCH1 missense 24430505 rs2287680 chr19 33608566 G A 4.93E-04 Multiple complex diseases GPATCH1 intron 17554300 rs1981818 chr19 33615122 A G 2.86E-04 Multiple complex diseases GPATCH1 intron 17554300 rs3848596 chr19 33635761 C T 3.43E-04 Type 2 diabetes WDR88 cds-synon 17463246 rs3848597 chr19 33635853 G A 2.26E-04 Type 2 diabetes WDR88 intron 17463246 rs11084710 chr19 33652356 G A 1.85E-05 Alzheimer's disease WDR88 intron 21098978 rs10407579 chr19 33653412 C T 1.89E-05 Alzheimer's disease WDR88 intron 21098978 rs17760633 chr19 33668090 A G 9.60E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs11670126 chr19 33681470 G A 9.63E-06 Erythrocyte counts / / pha003090 rs10406787 chr19 33711686 A G 6.30E-06 Major depressive disorder SLC7A10 intron 19107115 rs8106493 chr19 33713928 C T 1.00E-06 Visceral adipose tissue adjusted for BMI SLC7A10 intron 22589738 rs8106493 chr19 33713928 C T 5.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio SLC7A10 intron 22589738 rs11672303 chr19 33726375 T C 0.0000622 Asthma / / 22694930 rs17694108 chr19 33731551 G A 3.41E-04 Multiple complex diseases / / 17554300 rs17694108 chr19 33731551 G A 6.00E-15 Inflammatory bowel disease / / 23128233 rs17694108 chr19 33731551 G A 0.00000104 Primary sclerosing cholangitis / / 23603763 rs10500264 chr19 33750314 G A 4.00E-10 Inflammatory bowel disease (early onset) / / 19915574 rs10500264 chr19 33750314 G A 4.00E-10 Multiple sclerosis / / 22190364 rs736289 chr19 33757062 T C 9.00E-09 Crohn's disease / / 21102463 rs1990966 chr19 33775326 C T 7.71E-04 Myopia (pathological) / / 21095009 rs877567 chr19 33782911 G A 1.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7251505 chr19 33802542 G A 3.21E-06 Waist-hip ratio / / 20935629 rs10518275 chr19 33850841 A G 8.90E-04 Cystic fibrosis(lung disease) / / 19242412 rs4805877 chr19 33876394 A G 9.59E-04 Multiple complex diseases / / 17554300 rs7258031 chr19 33886354 C T 5.10E-06 Waist-hip ratio PEPD intron 20935629 rs7258031 chr19 33886354 C T 9.91E-05 Type 2 diabetes PEPD intron 22158537 rs889140 chr19 33889000 G A 6.41E-05 Type 2 diabetes PEPD intron 22158537 rs889140 chr19 33889000 G A 4.00E-12 Adiponectin levels PEPD intron 24105470 rs34910385 chr19 33890295 T G 5.80E-06 Urinary metabolites PEPD intron 21572414 rs3786897 chr19 33893008 A G 1.00E-08 Type 2 diabetes PEPD intron 22158537 rs3786897 chr19 33893008 A G 3.30E-04 Type 2 diabetes PEPD intron 24509480 rs3786901 chr19 33897478 A C 7.44E-06 Type 2 diabetes PEPD intron 22158537 rs731839 chr19 33899065 G A 6.32E-06 Type 2 diabetes PEPD intron 22158537 rs731839 chr19 33899065 G A 8.00E-12 Adiponectin levels PEPD intron 22479202 rs731839 chr19 33899065 G A 5.10E-12 Fasting insulin-related traits PEPD intron 22885924 rs731839 chr19 33899065 G A 5.13E-12 Body mass index PEPD intron 22885924 rs731839 chr19 33899065 G A 3.00E-09 Triglycerides PEPD intron 24097068 rs4805885 chr19 33906123 T C 2.00E-08 Adiponectin levels PEPD intron 22479202 rs8182584 chr19 33909710 T G 9.00E-08 Fasting insulin-related traits (interaction with BMI) PEPD intron 22581228 rs8182584 chr19 33909710 T G 0.00000072 Fasting insulin-related traits PEPD intron 22885922 rs8182584 chr19 33909710 T G 0.00048 Type 2 diabetes PEPD intron 22885922 rs8182579 chr19 33909851 C T 9.75E-05 Chronic Hepatitis C infection PEPD intron 21725309 rs10500265 chr19 33914285 C G 9.90E-04 Type 2 diabetes PEPD intron 17846125 rs4362488 chr19 33914944 A G 9.53E-05 Chronic Hepatitis C infection PEPD intron 21725309 rs11670528 chr19 33930229 G C 4.20E-07 Urinary metabolites PEPD intron 21572414 rs1477336 chr19 33946893 C T 3.42E-05 Smoking cessation PEPD intron 18519826 rs1477336 chr19 33946893 C T 3.48E-04 Smoking cessation PEPD intron 18519826 rs17761012 chr19 33950277 C T 1.33E-04 Smoking cessation PEPD intron 18519826 rs33825 chr19 33989245 G A 2.33E-05 Bipolar disorder PEPD intron 17486107 rs33825 chr19 33989245 G A 8.85E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PEPD intron 20031582 rs33824 chr19 33990439 C T 9.78E-05 Schizophrenia (cytomegalovirus infection interaction) PEPD intron 23358160 rs33823 chr19 34000725 T C 8.11E-05 Schizophrenia (cytomegalovirus infection interaction) PEPD intron 23358160 rs3786922 chr19 34006380 C T 2.99E-05 Smoking cessation PEPD intron 18519826 rs153508 chr19 34009392 T C 2.17E-05 Type 2 diabetes PEPD intron 22158537 rs10415555 chr19 34010189 A G 1.85E-07 Panic disorder PEPD intron 19165232 rs33840 chr19 34010289 T C 1.00E-04 Type 2 diabetes PEPD intron 22158537 rs33845 chr19 34014316 A G 3.14E-05 Type 2 diabetes PEPD nearGene-5 22158537 rs4805902 chr19 34019755 C T 4.50E-04 Osteoarthritis (knee and hip) / / 21177295 rs4805902 chr19 34019755 C T 5.06E-05 Osteoarthritis (knee and hip) / / 21177295 rs4805902 chr19 34019755 C T 5.30E-06 Urinary metabolites / / 21572414 rs33847 chr19 34020401 T C 1.79E-04 Vaspin levels / / 22907691 rs33847 chr19 34020401 T C 0.0001794 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs4805903 chr19 34028391 G A 4.49E-04 Parkinson's disease / / 17052657 rs153703 chr19 34029698 T C 7.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs754692 chr19 34044317 G A 1.16E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs1864131 chr19 34045599 G A 6.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1864132 chr19 34045675 A G 6.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs12327733 chr19 34065833 A G 4.30E-04 HIV-1 viral setpoint / / 17641165 rs17324938 chr19 34069166 T G 0.000222653 Hypertension (early onset hypertension) / / 22479346 rs17324938 chr19 34069166 T G 5.20E-04 Tourette syndrome / / 22889924 rs17227288 chr19 34070198 C T 4.64E-04 Type 2 diabetes / / 17463246 rs8103587 chr19 34105378 T C 4.80E-04 HIV-1 viral setpoint / / 17641165 rs8112967 chr19 34117092 A G 1.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CHST8 intron 20877124 rs8112967 chr19 34117092 A G 3.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CHST8 intron 20877124 rs8105751 chr19 34131461 A G 2.56E-05 Psoriasis CHST8 intron 20953190 rs10853928 chr19 34133709 T C 3.90E-04 Type 2 diabetes CHST8 intron 17463246 rs7250759 chr19 34159360 G T 1.63E-05 Elbow pain CHST8 intron pha003008 rs9304851 chr19 34161998 T C 3.84E-05 Elbow pain CHST8 intron pha003008 rs741587 chr19 34167905 T A 7.56E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) CHST8 intron 22566498 rs4805924 chr19 34168273 C T 6.00E-07 Response to antipsychotic treatment in schizophrenia (working memory) CHST8 intron 21107309 rs16968393 chr19 34177675 C T 1.36E-09 Multiple complex diseases CHST8 intron 17554300 rs11084747 chr19 34185484 T C 2.40E-05 Urinary metabolites CHST8 intron 21572414 rs2041728 chr19 34189637 G A 8.57E-04 Type 2 diabetes CHST8 intron 17463246 rs2041728 chr19 34189637 G A 4.35E-05 Schizophrenia CHST8 intron 19571811 rs6510394 chr19 34199767 G A 8.59E-05 Cytomegalovirus antibody response CHST8 intron 21993531 rs10401769 chr19 34200415 C T 6.21E-05 Cytomegalovirus antibody response CHST8 intron 21993531 rs284670 chr19 34210449 G A 0.000552 Salmonella-induced pyroptosis CHST8 intron 22837397 rs284669 chr19 34210782 G A 0.000424 Salmonella-induced pyroptosis CHST8 intron 22837397 rs284683 chr19 34219871 C T 0.000476 Salmonella-induced pyroptosis CHST8 intron 22837397 rs284689 chr19 34231238 C T 8.49E-04 Multiple complex diseases CHST8 intron 17554300 rs284688 chr19 34231542 T C 5.74E-04 Multiple complex diseases CHST8 intron 17554300 rs285686 chr19 34270846 A T 4.12E-05 Serum metabolites / / 19043545 rs285680 chr19 34277686 G T 7.16E-06 Myopia (pathological) / / 21640322 rs14810 chr19 34304903 C G 7.62E-05 Obesity (extreme) KCTD15 UTR-3 21935397 rs185350 chr19 34306816 C T 4.71E-04 Obesity (extreme) / / 21935397 rs29944 chr19 34306898 A G 8.02E-05 Obesity (extreme) / / 21935397 rs29943 chr19 34308210 T C 7.05E-05 Obesity (extreme) / / 21935397 rs29942 chr19 34309277 A G 6.34E-05 Obesity (extreme) / / 21935397 rs29941 chr19 34309532 A G 5.00E-09 Weight / / 19079260 rs29941 chr19 34309532 A G 7.00E-12 Body mass index / / 19079260 rs29941 chr19 34309532 A G 5.60E-06 Smoking behavior / / 20418888 rs29941 chr19 34309532 A G 3.00E-09 Body mass index / / 20935630 rs29941 chr19 34309532 A G 6.34E-05 Obesity (extreme) / / 21935397 rs29941 chr19 34309532 A G 3.01E-09 Body mass index / / 23001569 rs29939 chr19 34310800 A G 6.30E-05 Obesity (extreme) / / 21935397 rs29938 chr19 34311481 T C 1.56E-04 Obesity (extreme) / / 21935397 rs29937 chr19 34311948 G T 5.08E-05 Obesity (extreme) / / 21935397 rs256335 chr19 34315896 C T 8.89E-05 Alzheimer's disease (late onset) / / 20885792 rs256335 chr19 34315896 C T 2.03E-04 Obesity (extreme) / / 21935397 rs368794 chr19 34320452 T A 1.41E-04 Obesity (extreme) / / 21935397 rs2546057 chr19 34320854 A C 2.05E-04 Obesity (extreme) / / 21935397 rs2546057 chr19 34320854 A C 5.40E-04 Alzheimer's disease / / 22005930 rs2546057 chr19 34320854 A C 3.00E-07 Major depressive disorder / / 23377640 rs398426 chr19 34321258 G T 5.00E-06 Major depressive disorder / / 23377640 rs11084753 chr19 34322137 A G 2.00E-08 Body mass index / / 19079261 rs11084753 chr19 34322137 A G 2.30E-08 Smoking behavior / / 20418888 rs11084753 chr19 34322137 A G 5.90E-04 Menarche (age at onset) / / 21102462 rs11084753 chr19 34322137 A G 1.37E-04 Obesity (extreme) / / 21935397 rs415237 chr19 34323214 T C 3.26E-05 Obesity (extreme) / / 21935397 rs552523 chr19 34325770 G A 0.000087 Type 2 diabetes (females) / / 22885922 rs17326595 chr19 34333846 C T 9.56E-04 Obesity (extreme) / / 21935397 rs166988 chr19 34333914 C T 1.00E-06 Obesity-related traits / / 23251661 rs2377288 chr19 34347742 G A 6.67E-05 Obesity (extreme) / / 21935397 rs17326700 chr19 34352771 G A 8.98E-04 Obesity (extreme) / / 21935397 rs10500267 chr19 34355502 C T 3.73E-04 Alzheimer's disease (late onset) / / 21379329 rs12975931 chr19 34364064 A G 6.60E-05 Monocyte chemoattractant protein-1 / / pha003071 rs7247921 chr19 34364123 A G 6.60E-05 Monocyte chemoattractant protein-1 / / pha003071 rs1017205 chr19 34365640 T C 9.29E-04 Multiple complex diseases / / 17554300 rs12609992 chr19 34371044 G A 8.02E-06 Monocyte chemoattractant protein-1 / / pha003071 rs4560028 chr19 34375631 T C 4.06E-05 Monocyte chemoattractant protein-1 / / pha003071 rs10403217 chr19 34464266 A T 9.28E-05 Aortic root size / / 21223598 rs4805964 chr19 34467960 A G 1.07E-04 Aortic root size / / 21223598 rs16968761 chr19 34495457 G C 8.29E-04 Aortic root size / / 21223598 rs7254953 chr19 34519994 T C 5.71E-04 Response to alcohol consumption (flushing response) / / 24277619 rs7245865 chr19 34523783 A G 6.37E-04 Type 2 diabetes / / 17463246 rs4805974 chr19 34556297 G A 0.000136 5-fluorouracil induced haematologic in response to colorectal cancer treatment / / 22310351 rs4805975 chr19 34556604 G A 2.81E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs16968855 chr19 34583658 G A 6.00E-06 Urinary metabolites / / 21572414 rs1260534 chr19 34600936 T C 2.20E-05 Urinary metabolites / / 21572414 rs8100126 chr19 34610341 A G 2.52E-05 Aging (time to event) / / 21782286 rs12611086 chr19 34626932 C T 6.00E-04 Smoking initiation / / 24665060 rs587259 chr19 34656406 C T 9.00E-04 Alzheimer's disease (late onset) / / 21460841 rs640466 chr19 34670725 T C 5.43E-04 Multiple complex diseases LSM14A intron 17554300 rs1759092 chr19 34676538 G A 6.84E-04 Multiple complex diseases LSM14A intron 17554300 rs1651801 chr19 34677149 T C 3.20E-04 Lymphocyte counts LSM14A intron 22286170 rs2434990 chr19 34684740 G A 5.82E-04 Multiple complex diseases LSM14A intron 17554300 rs2482997 chr19 34686784 C A 6.50E-04 Multiple complex diseases LSM14A intron 17554300 rs520194 chr19 34691449 T C 1.23E-05 Cortisol secretion,in saliva LSM14A intron 21316860 rs682977 chr19 34704129 C T 5.56E-04 Multiple complex diseases LSM14A intron 17554300 rs629018 chr19 34723732 C T 5.13E-04 Multiple complex diseases / / 17554300 rs6510416 chr19 34737425 A C 1.07E-04 Lung function (forced vital capacity) / / 24023788 rs4806004 chr19 34752049 G A 5.81E-05 Lung function (forced vital capacity) KIAA0355 intron 24023788 rs7359931 chr19 34754797 G A 5.84E-04 Multiple complex diseases KIAA0355 intron 17554300 rs7250413 chr19 34760936 C G 7.93E-04 Multiple complex diseases KIAA0355 intron 17554300 rs10407640 chr19 34766588 G A 7.00E-06 Functional MRI KIAA0355 intron 20215924 rs12463220 chr19 34786010 C A 5.74E-05 Lung function (forced vital capacity) KIAA0355 intron 24023788 rs179186 chr19 34799429 A C 7.18E-05 Lung function (forced vital capacity) KIAA0355 intron 24023788 rs1669261 chr19 34808949 T C 9.57E-05 HDL cholesterol KIAA0355 intron pha003075 rs1669261 chr19 34808949 T C 1.74E-05 Lipid levels KIAA0355 intron pha003082 rs189030 chr19 34820159 C T 6.92E-04 Multiple complex diseases KIAA0355 intron 17554300 rs189030 chr19 34820159 C T 2.25E-04 Lung function (forced expiratory volume in 1 second) KIAA0355 intron 24023788 rs189030 chr19 34820159 C T 7.16E-05 Lung function (forced vital capacity) KIAA0355 intron 24023788 rs7254168 chr19 34834364 G A 1.37E-04 Lung function (forced vital capacity) KIAA0355 intron 24023788 rs422732 chr19 34848450 A C 2.06E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs422732 chr19 34848450 A C 7.04E-05 Lung function (forced vital capacity) / / 24023788 rs8191385 chr19 34870707 G A 3.63E-04 Multiple complex diseases GPI intron 17554300 rs1864139 chr19 34872382 G A 2.38E-04 Multiple complex diseases GPI cds-synon 17554300 rs1030216 chr19 34958931 G A 3.31E-05 Stroke (ischemic) UBA2 intron 22941190 rs2965282 chr19 34984792 C T 7.79E-05 Lipid levels WTIP intron pha003082 rs8100257 chr19 34996265 G A 5.96E-04 Taste perception / / 22132133 rs10408252 chr19 35002775 G A 1.27E-04 Taste perception / / 22132133 rs2241386 chr19 35003390 G A 3.54E-05 Cognitive impairment induced by topiramate / / 22091778 rs8101636 chr19 35040060 C T 1.70E-05 Urinary metabolites / / 21572414 rs2199639 chr19 35052255 C T 3.45E-04 HIV-1 viral setpoint / / 17641165 rs2199640 chr19 35060238 G A 9.73E-04 HIV-1 viral setpoint / / 17641165 rs7250631 chr19 35076374 C A 6.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs11671402 chr19 35080484 G A 9.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs11671693 chr19 35080580 C T 9.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs2126968 chr19 35082395 C T 3.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs1564200 chr19 35085872 C T 9.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs6510431 chr19 35086400 G A 4.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs11668528 chr19 35090017 G A 0.0007212 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11668528 chr19 35090017 G A 7.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1270260 chr19 35093681 C T 8.28E-04 Alzheimer's disease / / 17998437 rs7259736 chr19 35096264 G A 9.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs1117963 chr19 35113489 T C 7.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs12981034 chr19 35122538 G A 7.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs11667217 chr19 35123796 C T 8.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs897769 chr19 35126762 A G 7.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs10411245 chr19 35134580 C T 7.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs8112457 chr19 35135920 C T 9.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs7260033 chr19 35136617 C T 6.33E-04 Suicide attempts in bipolar disorder SCGB2B3P cds-synon 21423239 rs11671675 chr19 35138256 C T 8.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs989251 chr19 35139578 T C 9.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs2198904 chr19 35144126 A C 7.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs10402195 chr19 35145695 A C 6.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs11671715 chr19 35146226 T C 8.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs10416893 chr19 35147640 A T 7.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs10421615 chr19 35147803 C A 8.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs8106017 chr19 35158921 A C 5.11E-05 Lipoproteins / / pha003079 rs2290652 chr19 35175208 A G 4.57E-07 Rheumatoid arthritis ZNF302 missense 21452313 rs17704366 chr19 35181101 A G 9.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs6510445 chr19 35202552 G A 4.14E-05 Lipoproteins / / pha003079 rs12459103 chr19 35223228 C T 5.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs7254347 chr19 35235290 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs17718432 chr19 35259048 C T 2.00E-04 Cognitive impairment induced by topiramate ZNF599 intron 22091778 rs17718432 chr19 35259048 C T 4.22E-05 Lipoproteins ZNF599 intron pha003079 rs117610843 chr19 35260442 C T 0.00018 Breast cancer ZNF599 missense 23555315 rs17775194 chr19 35273699 C A 1.40E-05 Recombination rate / / 21698098 rs7250748 chr19 35311970 A C 2.62E-04 Type 2 diabetes LOC400685 intron 17463246 rs755733 chr19 35321775 G T 7.27E-04 Schizophrenia LOC400685 intron 19197363 rs10422961 chr19 35422808 C T 3.00E-04 Iris characteristics ZNF30 missense 21835309 rs2651080 chr19 35449760 G C 3.20E-04 Iris characteristics ZNF792 cds-synon 21835309 rs2546024 chr19 35451330 A G 8.60E-05 Parkinson's disease (familial) ZNF792 intron 18985386 rs2546039 chr19 35458746 C G 1.66E-04 Acute lung injury / / 22295056 rs11084796 chr19 35500640 T G 2.20E-05 Urinary metabolites GRAMD1A intron 21572414 rs2290642 chr19 35501051 T C 7.20E-06 Urinary metabolites GRAMD1A cds-synon 21572414 rs41523449 chr19 35537706 G A 4.36E-04 Type 2 diabetes HPN intron 17463246 rs870379 chr19 35543756 G A 8.47E-05 Suicide attempts in bipolar disorder HPN intron 21041247 rs4806073 chr19 35555190 T C 3.00E-15 Serum albumin level HPN intron 23022100 rs4806073 chr19 35555190 T C 4.00E-18 Serum albumin level HPN intron 23022100 rs2305744 chr19 35556123 G A 4.97E-05 IgE levels in asthmatics (D.f. specific) HPN intron 23967269 rs11671010 chr19 35559474 T C 2.00E-13 Serum albumin level LOC100128675 intron 23022100 rs4806077 chr19 35577163 C T 3.68E-04 White matter integrity LOC100128675 intron 22425255 rs2290650 chr19 35612286 A G 1.63E-04 Glycosylated haemoglobin levels FXYD3 UTR-3 17255346 rs2290650 chr19 35612286 A G 6.70E-05 Endometriosis FXYD3 UTR-3 21151130 rs1672997 chr19 35630362 A G 6.58E-05 Glycosylated haemoglobin levels FXYD1 intron 17255346 rs1673006 chr19 35635231 C T 2.11E-04 Smoking initiation FXYD7 intron 24665060 rs2285515 chr19 35660450 T C 7.66E-05 Behcet's disease FXYD5 intron pha002888 rs10426624 chr19 35673243 A C 0.00000491 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs10426076 chr19 35673333 C T 0.00000476 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs4806110 chr19 35687075 C T 5.34E-04 Tourette syndrome / / 22889924 rs541169 chr19 35719020 C T 6.01E-05 Orofacial clefts FAM187B STOP-GAIN 20023658 rs541169 chr19 35719020 C T 3.92E-05 Calcium levels FAM187B STOP-GAIN pha003085 rs565791 chr19 35719106 A G 3.90E-05 Coronary heart disease FAM187B missense pha003031 rs11673347 chr19 35719257 G A 2.29E-04 Lung function (forced vital capacity) FAM187B cds-synon 24023788 rs11673347 chr19 35719257 G A 3.90E-04 Lung function (forced expiratory volume in 1 second) FAM187B cds-synon 24023788 rs11669258 chr19 35724000 A C 3.53E-04 Schizophrenia / / 20832056 rs10422195 chr19 35724024 G A 2.96E-04 Schizophrenia / / 20832056 rs10422195 chr19 35724024 G A 3.11E-04 Sudden cardiac arrest / / 21658281 rs11666282 chr19 35807845 C T 7.70E-04 Alcohol dependence / / 20201924 rs11666282 chr19 35807845 C T 9.53E-04 Alzheimer's disease / / 24755620 rs35715143 chr19 35832389 G A 2.68E-14 HDL cholesterol CD22 missense 23063622 rs10406069 chr19 35836530 G A 5.01E-04 Obesity (extreme) CD22 missense 21935397 rs3088063 chr19 35838076 C T 6.31E-05 Lipid levels CD22 UTR-3 19913121 rs3088063 chr19 35838076 C T 9.55E-05 Lipid levels CD22 UTR-3 19913121 rs10426830 chr19 35838978 G T 4.87E-05 Lipid levels / / 19913121 rs417030 chr19 35847075 C T 8.06E-05 Cytomegalovirus antibody response / / 21993531 rs12459138 chr19 35848339 G A 8.06E-05 Cytomegalovirus antibody response / / 21993531 rs10414199 chr19 35867279 C T 0.0000106 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10414199 chr19 35867279 C T 1.06E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11883057 chr19 35868758 A G 3.13E-04 Smoking cessation / / 24665060 rs16970276 chr19 35870348 G A 0.0000113 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16970276 chr19 35870348 G A 1.13E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4806146 chr19 35870987 T G 5.89E-04 HIV-1 viral setpoint / / 17641165 rs7260133 chr19 35890434 G C 0.0000269 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7260133 chr19 35890434 G C 2.69E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12978242 chr19 35891254 G A 0.0000134 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12978242 chr19 35891254 G A 1.34E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs756971 chr19 35943769 A G 4.22E-04 Type 2 diabetes / / 17463246 rs6510489 chr19 35973289 T C 8.00E-06 Bipolar disorder / / 22925353 rs12150953 chr19 36023448 A G 2.48E-04 Smoking quantity / / 24665060 rs12151182 chr19 36023732 G A 5.03E-04 Smoking quantity / / 24665060 rs12151019 chr19 36023805 A G 3.95E-04 Smoking quantity / / 24665060 rs17705657 chr19 36024742 G T 5.45E-04 Smoking quantity GAPDHS intron 24665060 rs12972040 chr19 36068062 G C 4.73E-04 Alcohol dependence / / 21314694 rs2285415 chr19 36122441 G A 1.55E-04 Common variable immunodeficiency RBM42 intron 21497890 rs7254601 chr19 36147315 A G 2.40E-04 Iris characteristics COX6B1 intron 21835309 rs4806187 chr19 36149761 A G 2.91E-04 Suicide attempts in bipolar disorder COX6B1 nearGene-3 21423239 rs10422762 chr19 36157167 G A 7.69E-05 Suicide attempts in bipolar disorder / / 21423239 rs2285421 chr19 36168914 T C 6.44E-04 Suicide attempts in bipolar disorder UPK1A missense 21423239 rs12461333 chr19 36192905 C G 1.90E-05 White matter hyperintensity burden / / 21681796 rs17776911 chr19 36224973 T C 4.82E-04 Smoking initiation MLL4 intron 24665060 rs12459634 chr19 36230174 T C 4.91E-10 Lymphocyte counts IGFLR1 UTR-3 22286170 rs10420134 chr19 36261928 A G 3.70E-05 Parkinson's disease (age of onset) / / 19772629 rs2291067 chr19 36273534 G A 9.21E-04 Parkinson's disease ARHGAP33 cds-synon 17052657 rs10409299 chr19 36324324 A G 3.89E-04 Type 2 diabetes NPHS1 intron 17463246 rs113825926 chr19 36340009 G A 0.00044 Breast cancer NPHS1 missense 23555315 rs17706323 chr19 36444363 T C 2.20E-05 Urinary metabolites / / 21572414 rs2073894 chr19 36501445 C T 2.98E-05 Response to mTOR inhibitor (rapamycin) ALKBH6 intron 24009623 rs2073896 chr19 36508392 A G 3.31E-05 Response to mTOR inhibitor (rapamycin) CLIP3 intron 24009623 rs4806248 chr19 36515091 A C 6.92E-05 Response to mTOR inhibitor (rapamycin) CLIP3 intron 24009623 rs4806249 chr19 36518816 T A 7.71E-05 Pulmonary function CLIP3 intron 20010835 rs7251912 chr19 36521820 G C 8.28E-05 Pulmonary function CLIP3 intron 20010835 rs4806255 chr19 36533195 A C 9.61E-05 Brain derived neurotrophic factor levels,in serum THAP8 intron 22047184 rs7250448 chr19 36543413 T G 5.85E-04 Myopia (pathological) THAP8 intron 21095009 rs12608517 chr19 36558113 T C 4.16E-05 Rheumatoid arthritis WDR62 intron 17804836 rs2023865 chr19 36563057 C T 2.60E-04 Myopia (pathological) WDR62 intron 21095009 rs7245762 chr19 36563749 T C 3.28E-04 Myopia (pathological) WDR62 intron 21095009 rs17884571 chr19 36630479 C T 9.36E-08 Triglycerides / / 23063622 rs2438517 chr19 36720390 C T 4.09E-05 Hearing function ZNF146 intron 17255346 rs2438517 chr19 36720390 C T 3.45E-05 Lymphocyte counts ZNF146 intron 22286170 rs2432054 chr19 36720452 A G 6.31E-05 Hearing function ZNF146 intron 17255346 rs2070132 chr19 36727365 G A 9.78E-04 Hearing function ZNF146 missense 17255346 rs2972533 chr19 36739067 A G 1.04E-04 Multiple complex diseases / / 17554300 rs2972527 chr19 36746225 C A 2.48E-05 Coronary heart disease / / pha003033 rs4806292 chr19 36758897 C T 9.06E-04 Multiple complex diseases / / 17554300 rs2967506 chr19 36856251 G T 7.47E-06 Coronary heart disease ZFP14 intron pha003033 rs12462725 chr19 36858085 T C 6.73E-05 Intelligence ZFP14 intron 21826061 rs8111845 chr19 36876843 A C 4.77E-05 Coronary heart disease / / pha003033 rs2271842 chr19 36900778 A C 9.20E-05 Intelligence ZFP82 intron 21826061 rs2912437 chr19 37024770 A C 6.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10424565 chr19 37038416 T C 5.08E-04 Multiple complex diseases ZNF529 cds-synon 17554300 rs3108580 chr19 37056330 C T 7.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZNF529 intron 20877124 rs2162296 chr19 37100250 T C 1.08E-04 Amyotrophic lateral sclerosis ZNF382 intron 20801718 rs3108207 chr19 37171202 T G 3.20E-05 Lymphocyte counts / / pha003094 rs3108207 chr19 37171202 T G 2.77E-05 Neutrophil count / / pha003095 rs3108558 chr19 37179123 A G 4.47E-05 Lymphocyte counts / / pha003094 rs3108558 chr19 37179123 A G 4.27E-05 Neutrophil count / / pha003095 rs3108581 chr19 37217437 T C 4.17E-05 Lymphocyte counts / / pha003094 rs3108581 chr19 37217437 T C 3.82E-05 Neutrophil count / / pha003095 rs3108582 chr19 37221835 A G 3.85E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs826978 chr19 37243648 A G 6.53E-04 Multiple complex diseases ZNF850 intron 17554300 rs826969 chr19 37247472 G T 3.15E-05 Alcohol and nictotine co-dependence ZNF850 intron 20158304 rs1227820 chr19 37257517 G A 1.00E-04 Cognitive impairment induced by topiramate ZNF850 intron 22091778 rs2290681 chr19 37263968 C A 1.13E-04 Multiple complex diseases / / 17554300 rs1673086 chr19 37264017 C T 9.72E-06 Cognitive impairment induced by topiramate / / 22091778 rs543518 chr19 37386211 C T 3.59E-05 Elbow pain ZNF829 intron pha003008 rs9304878 chr19 37397301 C T 4.44E-04 Alzheimer's disease ZNF829 intron 17998437 rs10416960 chr19 37428465 T G 9.64E-05 Elbow pain ZNF568 intron pha003008 rs505717 chr19 37430316 A G 1.20E-06 Lipid traits ZNF568 intron 17903299 rs544543 chr19 37430823 A G 2.50E-06 Lipid traits ZNF568 intron 17903299 rs524802 chr19 37446947 G A 7.60E-07 Lipid traits ZNF568 intron 17903299 rs1375476 chr19 37465175 C T 2.52E-04 Body mass index ZNF568 intron 17255346 rs1667337 chr19 37467512 A G 3.14E-04 Body mass index ZNF568 intron 17255346 rs1644666 chr19 37475486 A G 2.15E-04 Body mass index ZNF568 intron 17255346 rs1612652 chr19 37477640 C T 2.15E-04 Body mass index ZNF568 intron 17255346 rs1644673 chr19 37478711 G A 1.71E-04 Body mass index ZNF568 intron 17255346 rs1667353 chr19 37481153 A G 2.15E-04 Body mass index ZNF568 intron 17255346 rs703536 chr19 37507234 G A 6.65E-04 Insulin resistance / / 21901158 rs1402468 chr19 37620248 T A 3.23E-04 Body mass index ZNF420 UTR-3 17255346 rs1533736 chr19 37654976 A G 8.35E-05 Otosclerosis ZNF585A intron 19230858 rs11673344 chr19 37684966 A G 5.00E-06 Obesity-related traits ZNF585B intron 23251661 rs320887 chr19 37693438 T C 3.07E-05 Asthma ZNF585B intron pha003128 rs1234261 chr19 37720972 C T 4.62E-07 Otosclerosis ZNF383 intron 19230858 rs320881 chr19 37737850 A G 3.20E-05 Asthma / / pha003128 rs7246657 chr19 37747108 T C 7.00E-06 Coronary artery calcification / / 23870195 rs1530500 chr19 37823811 A G 1.67E-06 Otosclerosis / / 19230858 rs256733 chr19 37875631 T C 7.82E-06 Otosclerosis ZNF527 intron 19230858 rs1465434 chr19 37915232 G A 7.17E-04 Bone mass and geometry ZNF569 intron 17903296 rs4803228 chr19 38043260 G T 2.35E-04 Amyotrophic lateral sclerosis (sporadic) ZNF540 intron 24529757 rs12151280 chr19 38067890 A C 4.19E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ZNF571 intron 24023788 rs11083428 chr19 38083967 A C 1.04E-05 Serum metabolites ZNF571 intron 19043545 rs147806327 chr19 38127024 T C 0.000024 Prostate cancer (advanced) ZFP30 missense 23555315 rs2927743 chr19 38132334 A G 4.07E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) ZFP30 intron 24023788 rs11083430 chr19 38139488 A G 5.60E-05 Serum metabolites ZFP30 intron 19043545 rs958305 chr19 38189440 T C 2.18E-06 Paclitaxel sensitivity in NCI60 cancer cell lines ZNF607 missense 21314952 rs11083433 chr19 38209301 C T 5.34E-06 Lymphocyte counts ZNF607 intron 22286170 rs17306508 chr19 38210451 G T 1.83E-04 Amyotrophic lateral sclerosis (sporadic) ZNF607 UTR-5 24529757 rs241935 chr19 38293963 C A 9.65E-05 Multiple sclerosis / / 20598377 rs16975712 chr19 38295293 A G 3.26E-04 Multiple complex diseases / / 17554300 rs2305105 chr19 38314767 A G 4.17E-04 Type 2 diabetes LOC644554 intron 17463246 rs16975963 chr19 38325536 C G 2.21E-04 Multiple complex diseases LOC100631378 intron 17554300 rs16975963 chr19 38325536 C G 1.00E-06 Longevity LOC100631378 intron 20834067 rs8105305 chr19 38403099 T C 3.48E-05 Height SIPA1L3 intron pha003010 rs4802150 chr19 38415814 T G 2.18E-05 Height SIPA1L3 intron pha003010 rs6508755 chr19 38472722 A G 6.30E-06 Urinary metabolites SIPA1L3 intron 21572414 rs833914 chr19 38474127 C A,G 5.13E-06 Hearing function SIPA1L3 intron 21493956 rs1643459 chr19 38476173 A G 9.53E-04 Type 2 diabetes SIPA1L3 intron 17463246 rs833904 chr19 38485465 C T 3.20E-04 Type 2 diabetes SIPA1L3 intron 17463246 rs860627 chr19 38486192 T C 9.75E-04 Type 2 diabetes SIPA1L3 intron 17463246 rs17309382 chr19 38505037 C T 2.00E-04 Cognitive impairment induced by topiramate SIPA1L3 intron 22091778 rs17309382 chr19 38505037 C T 2.00E-04 Cognitive impairment induced by topiramate SIPA1L3 intron 22091778 rs1421675 chr19 38518469 A C 2.76E-04 Multiple complex diseases SIPA1L3 intron 17554300 rs8107385 chr19 38632752 G T 7.97E-04 Heart Failure SIPA1L3 intron pha002884 rs8102476 chr19 38735613 C T 2.00E-11 Prostate cancer / / 19767754 rs8102476 chr19 38735613 C T 2.00E-11 Nasopharyngeal carcinoma / / 20512145 rs8102476 chr19 38735613 C T 1.56E-06 Esophageal cancer (squamous cell) / / 20729853 rs10993 chr19 38743591 G T 9.20E-05 Type 2 diabetes PPP1R14A cds-synon 17463246 rs7253245 chr19 38753786 G T 3.71E-05 Lymphocyte counts SPINT2 nearGene-5 22286170 rs3786872 chr19 38756089 C G 1.60E-05 Urinary metabolites SPINT2 intron 21572414 rs3843754 chr19 38807184 G A 1.82E-05 Sickle cell anemia (severity) / / 20029952 rs12609878 chr19 38882781 T G 1.60E-05 Sickle cell anemia (severity) SPRED3 intron 20029952 rs3745963 chr19 38896295 A G 6.27E-05 Type 2 diabetes FAM98C intron 17463246 rs4075613 chr19 38903099 A G 5.20E-05 Alzheimer's disease RASGRP4 intron 22005930 rs10412098 chr19 38905683 A G 1.43E-05 Alzheimer's disease RASGRP4 cds-synon 22005930 rs3810342 chr19 38907585 T G 1.64E-04 Alzheimer's disease RASGRP4 intron 22005930 rs12609246 chr19 38909639 A G 8.54E-06 Coronary heart disease RASGRP4 intron pha003031 rs12609246 chr19 38909639 A G 7.29E-05 HDL cholesterol RASGRP4 intron pha003074 rs892055 chr19 38912764 A G 5.00E-06 Asperger disorder RASGRP4 missense 21182207 rs3745844 chr19 38942248 G A 1.65E-05 Prostate cancer RYR1 intron 18264096 rs16972654 chr19 38980118 C G 3.18E-04 Type 2 diabetes RYR1 intron 17463246 rs16972654 chr19 38980118 C G 2.20E-05 Urinary metabolites RYR1 intron 21572414 rs11880126 chr19 38980593 G A 1.94E-04 Taste perception RYR1 intron 22132133 rs11880894 chr19 38981539 C T 1.23E-06 Tardive dyskinesia RYR1 intron 20939080 rs2071090 chr19 39015454 T C 3.60E-08 Left ventricular hypertrophy RYR1 intron 21828061 rs10500279 chr19 39035068 G C 1.00E-08 Left ventricular hypertrophy RYR1 intron 21828061 rs2960321 chr19 39048163 C A 2.50E-08 Left ventricular hypertrophy RYR1 intron 21828061 rs2960339 chr19 39053691 T C 5.68E-05 Lung adenocarcinoma RYR1 intron 19836008 rs10445564 chr19 39094893 A G 1.20E-09 Health and aging,CVD and cancer age of onset MAP4K1 intron 22174011 rs10445564 chr19 39094893 A G 9.30E-08 Health and aging,CVD and cancer age of onset MAP4K1 intron 22174011 rs2232997 chr19 39109975 C T 5.64E-05 Lung adenocarcinoma EIF3K intron 19836008 rs2232997 chr19 39109975 C T 9.04E-05 Post-operative nausea and vomiting EIF3K intron 21694509 rs732135 chr19 39141974 C T 5.30E-05 Lung adenocarcinoma ACTN4 intron 19836008 rs755690 chr19 39167360 A G 5.82E-05 Parkinson's disease ACTN4 intron 21738487 rs973009 chr19 39174332 G A 3.14E-05 Multiple complex diseases ACTN4 intron 17554300 rs973009 chr19 39174332 G A 4.00E-06 Migraine with aura ACTN4 intron 23793025 rs973009 chr19 39174332 G A 4.19E-05 Migraine - clinic-based ACTN4 intron 23793025 rs973009 chr19 39174332 G A 4.64E-05 Migraine ACTN4 intron 23793025 rs11083473 chr19 39179934 A G 2.20E-05 Urinary metabolites ACTN4 intron 21572414 rs10426809 chr19 39186950 A G 2.50E-05 Urinary metabolites ACTN4 intron 21572414 rs11083475 chr19 39188112 G A 2.00E-06 Heart rate ACTN4 intron 23583979 rs4802747 chr19 39190588 C T 6.69E-05 Lymphocyte counts ACTN4 intron 22286170 rs12978914 chr19 39223717 C T 3.50E-05 Lung adenocarcinoma CAPN12 intron 19836008 rs7248584 chr19 39258110 C T 5.79E-04 Type 2 diabetes / / 17463246 rs10403583 chr19 39291771 A G 4.30E-05 Bone mineral density (spine) / / 19079262 rs10775532 chr19 39294769 T C 2.13E-05 Heart Rate LGALS4 intron pha003053 rs7250734 chr19 39297624 T C 0.0000644 Sarcoidosis LGALS4 intron 22952805 rs10417292 chr19 39298414 T C 0.00006419 Sarcoidosis LGALS4 intron 22952805 rs2099339 chr19 39410119 A G 2.53E-04 Lung function (forced vital capacity) SARS2 intron 24023788 rs10416055 chr19 39435485 G A 4.93E-04 Lung function (forced vital capacity) FBXO17 intron 24023788 rs10402813 chr19 39449411 T G 6.03E-05 Body Mass Index FBXO17 intron pha003022 rs12151188 chr19 39455534 T C 3.77E-04 Multiple complex diseases FBXO17 intron 17554300 rs650027 chr19 39481684 A G 1.64E-05 Body Mass Index / / pha003014 rs2318895 chr19 39506781 C T 4.71E-04 Multiple complex diseases / / 17554300 rs6508841 chr19 39514844 C T 5.18E-05 Serum metabolites / / 19043545 rs4803193 chr19 39535685 G A 8.00E-04 Coronary heart disease / / 21971053 rs7259197 chr19 39542089 A G 5.87E-04 Coronary heart disease / / 21971053 rs481802 chr19 39573851 C A 6.73E-04 Rheumatoid arthritis / / 21452313 rs472265 chr19 39580737 A G 9.00E-06 Type 2 diabetes PAPL intron 21490949 rs1654245 chr19 39583160 G A 1.20E-05 Urinary metabolites PAPL intron 21572414 rs11669124 chr19 39623252 G A 2.34E-05 Amyotrophic lateral sclerosis PAK4 intron 20801717 rs11669124 chr19 39623252 G A 3.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PAK4 intron 20877124 rs11669124 chr19 39623252 G A 5.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PAK4 intron 20877124 rs11669124 chr19 39623252 G A 0.0000288 Amyotrophic lateral sclerosis PAK4 intron 23587638 rs8106521 chr19 39683715 A G 2.28E-05 Response to hepatitis C treatment / / 19684573 rs892015 chr19 39684909 A C 1.06E-05 Response to hepatitis C treatment / / 19684573 rs11879005 chr19 39710903 C T 6.07E-05 Waist Circumference / / pha003023 rs11879005 chr19 39710903 C T 2.84E-05 Hemoglobin / / pha003096 rs11879005 chr19 39710903 C T 4.28E-05 Erythrocyte counts / / pha003101 rs12972991 chr19 39731747 A C 1.72E-21 Response to hepatitis C treatment / / 19684573 rs12980275 chr19 39731783 A G 2.54E-27 Response to hepatitis C treatment / / 19684573 rs12980275 chr19 39731783 A G 5.00E-17 Lipid levels in hepatitis C treatment / / 22497812 rs8103142 chr19 39735106 T C 1.40E-29 Response to hepatitis C treatment IL28B missense 19749757 rs28416813 chr19 39735644 C G 5.52E-28 Response to hepatitis C treatment / / 19749757 rs12979860 chr19 39738787 C T 1.00E-28 Response to hepatitis C treatment / / 19684573 rs12979860 chr19 39738787 C T 2.00E-30 Chronic Hepatitis C infection / / 23420232 rs8109886 chr19 39742762 C A 1.54E-16 Response to hepatitis C treatment / / 19684573 rs8099917 chr19 39743165 T G 3.70E-26 Response to hepatitis C treatment / / 19684573 rs8099917 chr19 39743165 T G 3.00E-32 Response to hepatitis C treatment / / 19749757 rs8099917 chr19 39743165 T G 9.00E-09 Response to hepatitis C treatment / / 19749758 rs8099917 chr19 39743165 T G 6.00E-09 Chronic Hepatitis C infection / / 20060832 rs8099917 chr19 39743165 T G 1.00E-20 Response to hepatitis C treatment / / 21228123 rs4803223 chr19 39746219 A G 7.85E-16 Response to hepatitis C treatment / / 19684573 rs12980602 chr19 39752820 T C 6.10E-09 Response to hepatitis C treatment / / 19684573 rs664893 chr19 39757572 G A 4.64E-07 Multiple complex diseases / / 17554300 rs664893 chr19 39757572 G A 1.37E-32 Narcolepsy / / 19629137 rs7359950 chr19 39763765 C T 5.90E-06 Psoriasis / / 20953190 rs8107861 chr19 39784152 G A 3.03E-04 Type 2 diabetes / / 17463246 rs30461 chr19 39789115 A G 3.30E-05 Alcoholism (heaviness of drinking) IL29 missense 21529783 rs194014 chr19 39792460 G A 2.59E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs8108034 chr19 39813853 T G 2.82E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3786949 chr19 39826479 G A 2.50E-05 Alcoholism (heaviness of drinking) GMFG intron 21529783 rs30454 chr19 39844176 G A 7.10E-05 Alcoholism (heaviness of drinking) SAMD4B intron 21529783 rs30453 chr19 39845544 T G 6.92E-06 Obesity-related traits SAMD4B intron 23251661 rs562638 chr19 39849789 A G 6.00E-06 Obesity-related traits SAMD4B intron 23251661 rs685125 chr19 39850102 T C 5.54E-06 Obesity-related traits SAMD4B intron 23251661 rs11666780 chr19 39853527 T C 7.51E-04 Smoking initiation SAMD4B intron 24665060 rs36270 chr19 39874945 T C 7.26E-06 Obesity-related traits / / 23251661 rs2353678 chr19 39931059 G C 9.57E-05 Lymphocyte counts / / 22286170 rs4802035 chr19 40013920 C G 4.67E-04 Acute lung injury / / 22295056 rs1368468 chr19 40024324 C T 6.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12978311 chr19 40025826 C G 2.49E-05 Cognitive test performance / / 20125193 rs7249902 chr19 40075733 G A 3.85E-04 Alzheimer's disease / / 22005930 rs10500280 chr19 40084787 C T 7.56E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17795657 chr19 40097690 C T 2.96E-05 Chronic Hepatitis C infection LGALS13 intron 21725309 rs10409495 chr19 40105536 T C 8.01E-04 Smoking quantity / / 24665060 rs10414890 chr19 40106388 A G 0.0002 Migraine / / 22678113 rs8103033 chr19 40170053 G A 8.00E-06 Obesity-related traits / / 23251661 rs16973566 chr19 40176917 T C 8.30E-06 Response to citalopram treatment / / 19846067 rs3786939 chr19 40196182 G A 5.79E-05 Male-pattern baldness LGALS14 intron 18849994 rs12611334 chr19 40229409 C G 2.00E-06 Schizophrenia / / 23894747 rs1972537 chr19 40256328 G A 9.55E-04 Alcohol dependence / / 21314694 rs2190846 chr19 40264738 A G 1.09E-04 Smoking cessation / / 24665060 rs12463156 chr19 40269473 G A 4.25E-05 HDL particle features LEUTX intron pha002900 rs998973 chr19 40273322 C T 5.03E-04 Smoking initiation LEUTX intron 24665060 rs12162264 chr19 40273416 G A 1.80E-05 Urinary metabolites LEUTX intron 21572414 rs3810385 chr19 40306704 T C 6.00E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs3810384 chr19 40309305 C T 6.86E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs7253739 chr19 40310497 T C 9.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs12980289 chr19 40320339 A T 7.16E-04 Suicide attempts in bipolar disorder DYRK1B intron 21423239 rs718066 chr19 40321840 T C 7.43E-04 Suicide attempts in bipolar disorder DYRK1B intron 21423239 rs2354800 chr19 40324587 G T 7.21E-04 Suicide attempts in bipolar disorder DYRK1B intron 21423239 rs2072290 chr19 40325016 T C 7.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs11880094 chr19 40325640 C T 6.27E-04 Suicide attempts in bipolar disorder FBL intron 21423239 rs616650 chr19 40328615 C T 3.89E-04 Alcohol dependence FBL intron 21314694 rs12975624 chr19 40335037 G A 9.01E-04 Suicide attempts in bipolar disorder FBL intron 21423239 rs11666032 chr19 40340391 G T 0.00017 Coronary artery calcification / / 23727086 rs7252868 chr19 40350729 T C 2.62E-04 Response to TNF antagonist treatment / / 21061259 rs7252463 chr19 40359556 C T 1.96E-07 Non-small cell lung cancer FCGBP intron 21866343 rs2231738 chr19 40450048 T C 6.00E-04 Atrial fibrillation / / 21846873 rs8105066 chr19 40489470 G A 8.43E-08 Lymphocyte counts / / 22286170 rs234355 chr19 40529943 T C 6.90E-05 Multiple complex diseases / / 17554300 rs7259136 chr19 40600681 C T 6.66E-05 Epilepsy (remission after treatment) / / 23962720 rs62110061 chr19 40606433 G A 9.45E-05 Epilepsy (remission after treatment) / / 23962720 rs10418532 chr19 40616899 G A 6.91E-05 Epilepsy (remission after treatment) / / 23962720 rs1327185 chr19 40626283 G A 1.24E-04 Multiple complex diseases / / 17554300 rs10419430 chr19 40636577 G C 7.27E-05 Epilepsy (remission after treatment) / / 23962720 rs62106581 chr19 40648910 A T 7.82E-05 Epilepsy (remission after treatment) / / 23962720 rs73551672 chr19 40648933 T G 7.82E-05 Epilepsy (remission after treatment) / / 23962720 rs10402740 chr19 40701181 G C 1.84E-05 Fibrinogen MAP3K10 intron 17255346 rs969531 chr19 40778866 T C 5.02E-05 Fibrinogen AKT2 intron 17255346 rs969531 chr19 40778866 T C 1.09E-04 Progressive supranuclear palsy AKT2 intron 21685912 rs7250897 chr19 40783233 T C 1.54E-04 Fibrinogen AKT2 intron 17255346 rs7247916 chr19 40816530 A G 6.20E-05 Alcoholism (heaviness of drinking) / / 21529783 rs4257318 chr19 40829213 T C 0.000231 Salmonella-induced pyroptosis C19orf47 intron 22837397 rs4802074 chr19 40848081 C G 1.39E-05 Fibrinogen C19orf47 intron 17255346 rs4802074 chr19 40848081 C G 6.75E-05 Progressive supranuclear palsy C19orf47 intron 21685912 rs4150987 chr19 40931868 A C,G,T 8.98E-04 Response to cytadine analogues (cytosine arabinoside) SERTAD1 UTR-5 24483146 rs7258094 chr19 41012190 C T 2.80E-16 Progranulin levels SPTBN4 cds-synon 21087763 rs7258094 chr19 41012190 C T 2.80E-16 Myocardial infarction SPTBN4 cds-synon 21211798 rs814528 chr19 41014922 T C 4.83E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SPTBN4 intron 24023788 rs10413521 chr19 41023511 C T 1.15E-04 Multiple complex diseases SPTBN4 intron 17554300 rs10413556 chr19 41023601 A G 1.17E-04 Multiple complex diseases SPTBN4 intron 17554300 rs10410907 chr19 41033109 C T 1.36E-04 Lung function (forced expiratory volume in 1 second) SPTBN4 intron 24023788 rs10410907 chr19 41033109 C T 1.74E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SPTBN4 intron 24023788 rs814518 chr19 41084693 G A 9.13E-06 Rheumatoid arthritis SHKBP1 intron 19503088 rs418007 chr19 41087817 T C 7.37E-04 Multiple complex diseases SHKBP1 intron 17554300 rs418007 chr19 41087817 T C 2.98E-12 Narcolepsy SHKBP1 intron 19629137 rs8107014 chr19 41127465 C T 0.000476 Breast cancer early age of onset LTBP4 intron 18463975 rs2561554 chr19 41168196 G T 1.44E-05 Kawasaki disease / / 22081228 rs10401344 chr19 41192417 C T 2.46E-05 Kawasaki disease NUMBL intron 22446961 rs10401344 chr19 41192417 C T 5.20E-05 Kawasaki disease NUMBL intron 22446962 rs2604913 chr19 41218611 G A 4.61E-04 Amyotrophic Lateral Sclerosis ADCK4 intron 17827064 rs28493229 chr19 41224204 G C 2.00E-12 Kawasaki disease ITPKC intron 22081228 rs2607414 chr19 41267129 T C 1.52E-04 Multiple complex diseases SNRPA intron 17554300 rs2279011 chr19 41269288 G T 3.90E-06 Smoking behavior SNRPA intron 20418888 rs17713068 chr19 41270055 T G 8.72E-06 Kawasaki disease SNRPA intron 22446961 rs2607424 chr19 41275147 C T 2.23E-04 Multiple complex diseases / / 17554300 rs2233152 chr19 41281016 G A 5.89E-06 Kawasaki disease / / 22081228 rs2233152 chr19 41281016 G A 1.69E-05 Kawasaki disease / / 22446961 rs2233152 chr19 41281016 G A 4.00E-10 Kawasaki disease / / 22446962 rs2287692 chr19 41289756 G A 6.53E-06 Kawasaki disease RAB4B intron 22081228 rs10403040 chr19 41296046 T A 2.10E-05 Kawasaki disease RAB4B intron 22446961 rs12151282 chr19 41298419 T C 9.80E-05 Smoking behavior RAB4B intron 20418888 rs7252227 chr19 41301115 G T 1.30E-06 Smoking behavior RAB4B intron 20418888 rs7937 chr19 41302706 C T 5.30E-09 Smoking behavior RAB4B UTR-3 20418888 rs7937 chr19 41302706 C T 3.00E-09 Chronic obstructive pulmonary disease RAB4B UTR-3 22080838 rs11881124 chr19 41305740 A G 3.50E-05 Kawasaki disease EGLN2 intron 22446962 rs11881124 chr19 41305740 A G 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes EGLN2 intron 22628534 rs2644916 chr19 41309211 T C 6.40E-06 Smoking behavior EGLN2 intron 20418888 rs3733829 chr19 41310571 A G 1.00E-08 Smoking behavior EGLN2 intron 20418890 rs3733829 chr19 41310571 A G 1.00E-08 Smoking behavior EGLN2 intron 22832964 rs7251418 chr19 41341589 A G 7.57E-04 Multiple complex diseases / / 17554300 rs7251418 chr19 41341589 A G 1.40E-06 Smoking behavior / / 20418888 rs7251570 chr19 41341750 A G 2.30E-09 Smoking behavior / / 20418888 rs4343391 chr19 41344368 G C 4.70E-07 Smoking behavior / / 20418888 rs8192729 chr19 41350996 C T 7.30E-04 Smoking initiation CYP2A6 intron 24665060 rs56256500 chr19 41354171 G A,C,T 1 Drug response to Nicotine CYP2A6 missense 18216723 rs1801272 chr19 41354533 A T 5.00E-06 Smoking behavior CYP2A6 missense 23049750 rs4105144 chr19 41358624 T C 2.00E-12 Smoking behavior / / 20418888 rs8102683 chr19 41363765 T C 8.40E-10 Smoking behavior / / 20418888 rs8102683 chr19 41363765 T C 4.00E-42 Smoking behavior / / 23049750 rs1496402 chr19 41366134 T A 9.10E-12 Smoking behavior / / 20418888 rs12461383 chr19 41370338 C G 3.10E-10 Smoking behavior / / 20418888 rs5007415 chr19 41393760 C A 8.71E-05 Prion diseases / / 22210626 rs10419393 chr19 41404196 A G 1.80E-04 Smoking cessation / / 18519826 rs7254188 chr19 41407343 G A 9.45E-05 Prion diseases / / 22210626 rs3852872 chr19 41416143 C T 8.40E-06 Smoking behavior / / 20418888 rs3852873 chr19 41416260 T G 3.70E-06 Smoking behavior / / 20418888 rs12459565 chr19 41427539 G C 1.90E-05 Smoking behavior / / 20418888 rs3844443 chr19 41431935 T C 2.34E-05 Smoking cessation CYP2B7P1 intron 18519826 rs3844443 chr19 41431935 T C 2.20E-05 Smoking behavior CYP2B7P1 intron 20418888 rs3844443 chr19 41431935 T C 5.86E-06 Lipoproteins CYP2B7P1 intron pha003079 rs4099161 chr19 41433818 T G 0.0000061 Femoral neck bone mineral density CYP2B7P1 intron 23436924 rs3843043 chr19 41433931 C T 9.40E-06 Smoking behavior CYP2B7P1 intron 20418888 rs3843043 chr19 41433931 C T 5.86E-06 Lipoproteins CYP2B7P1 intron pha003079 rs3844444 chr19 41434047 A G 1.30E-05 Smoking behavior CYP2B7P1 intron 20418888 rs1820025 chr19 41436546 G C 1.60E-05 Smoking behavior CYP2B7P1 intron 20418888 rs4124633 chr19 41449603 T C 1.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CYP2B7P1 intron 20877124 rs3889806 chr19 41459241 T C 5.60E-05 Smoking behavior / / 20418888 rs7251950 chr19 41482742 C T 8.87E-05 Smoking cessation / / 18519826 rs7251950 chr19 41482742 C T 5.70E-05 Smoking behavior / / 20418888 rs1808002 chr19 41485194 C T 2.30E-05 Smoking behavior / / 20418888 rs10418990 chr19 41490404 G C 9.50E-05 Smoking behavior / / 20418888 rs34223104 chr19 41497129 T C 1 Drug response to Bupropion / / 15722458 rs8192709 chr19 41497274 C T 1 Drug response to Cyclophosphamide CYP2B6 missense 19005482 rs33980385 chr19 41497293 A G 3.62E-09 Triglycerides CYP2B6 missense 23063622 rs33980385 chr19 41497293 A G 4.25E-20 Cholesterol,total CYP2B6 missense 23063622 rs33980385 chr19 41497293 A G 5.00E-24 LDL cholesterol CYP2B6 missense 23063622 rs33980385 chr19 41497293 A G 5.25E-74 HDL cholesterol CYP2B6 missense 23063622 rs10426235 chr19 41499816 G A 0.00000739 Sasang constitution (Taeum) CYP2B6 intron 22394158 rs12721655 chr19 41510282 A G 1 Drug response to Bupropion CYP2B6 missense 14551287 rs12721655 chr19 41510282 A G 1 Drug response to Bupropion CYP2B6 missense 15190123 rs12721655 chr19 41510282 A G 1 Drug response to Bupropion CYP2B6 missense 17638512 rs4803419 chr19 41512792 C T 4.40E-15 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) CYP2B6 intron 23080225 rs3745274 chr19 41512841 G T 1 Drug response to Efavirenz CYP2B6 missense 15194512 rs3745274 chr19 41512841 G T 1 Drug response to Efavirenz CYP2B6 missense 17559344 rs3745274 chr19 41512841 G T 1 Drug response to Efavirenz CYP2B6 missense 17638512 rs3745274 chr19 41512841 G T 1 Drug response to Efavirenz CYP2B6 missense 18171905 rs3745274 chr19 41512841 G T 1 Drug response to Cyclophosphamide CYP2B6 missense 19005482 rs3745274 chr19 41512841 G T 0.0000499 Ankle-brachial index CYP2B6 missense 22361517 rs3745274 chr19 41512841 G T 8.50E-41 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) CYP2B6 missense 23080225 rs36079186 chr19 41512918 T C 1 Drug response to Efavirenz CYP2B6 missense 17235330 rs58425034 chr19 41514965 G C 1 Drug response to Nevirapine CYP2B6 intron 20017669 rs2279343 chr19 41515263 A G 1 Drug response to Bupropion CYP2B6 missense 14515060 rs2279343 chr19 41515263 A G 1 Drug response to Nicotine CYP2B6 missense 14515060 rs2279343 chr19 41515263 A G 1 Drug response to Bupropion CYP2B6 missense 17015050 rs2279343 chr19 41515263 A G 1 Drug response to Nicotine CYP2B6 missense 17015050 rs2279343 chr19 41515263 A G 1 Drug response to Bupropion CYP2B6 missense 18695978 rs2279343 chr19 41515263 A G 1 Drug response to Nicotine CYP2B6 missense 18695978 rs2279343 chr19 41515263 A G 1 Drug response to Cyclophosphamide CYP2B6 missense 19005482 rs28399499 chr19 41518221 T C 1 Drug response to Efavirenz CYP2B6 missense 16272958 rs28399499 chr19 41518221 T C 1 Drug response to Efavirenz CYP2B6 missense 16495778 rs28399499 chr19 41518221 T C 1 Drug response to Efavirenz CYP2B6 missense 17638512 rs28399499 chr19 41518221 T C 1 Drug response to Nevirapine CYP2B6 missense 20017669 rs28399499 chr19 41518221 T C 9.90E-11 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) CYP2B6 missense 23080225 rs34097093 chr19 41518370 C T 1 Drug response to Efavirenz CYP2B6 STOP-GAIN 17235330 rs7260329 chr19 41521638 G A 6.00E-06 Smoking behavior CYP2B6 intron 20418888 rs3786551 chr19 41521746 C G 4.60E-06 Smoking behavior CYP2B6 intron 20418888 rs3786552 chr19 41521757 C G 3.80E-06 Smoking behavior CYP2B6 intron 20418888 rs2291287 chr19 41522451 A G 2.42E-06 Cognitive impairment induced by topiramate CYP2B6 intron 22091778 rs1042389 chr19 41524153 T C 8.18E-04 Premature ovarian failure CYP2B6 UTR-3 19508998 rs1552223 chr19 41525952 G A 3.13E-04 Alcohol dependence / / 21314694 rs11666982 chr19 41531368 T G 2.27E-05 Socioeconomic Factors / / pha003067 rs1709115 chr19 41619575 T C 3.23E-04 Smoking quantity CYP2F1 nearGene-5 24665060 rs12975986 chr19 41622615 C T 1.32E-04 Smoking initiation CYP2F1 intron 24665060 rs1645685 chr19 41668003 T C 6.02E-06 Cognitive impairment induced by topiramate / / 22091778 rs2458634 chr19 41670581 G A 2.84E-05 Cognitive impairment induced by topiramate / / 22091778 rs8105815 chr19 41673848 G T 8.00E-06 Prion diseases / / 22210626 rs8101017 chr19 41723887 G T 2.77E-05 HIV-1 control / / 20041166 rs6508974 chr19 41733145 G C 2.20E-05 Urinary metabolites AXL intron 21572414 rs11879562 chr19 41804976 G C 5.00E-05 Malaria HNRNPUL1 intron 19465909 rs4803455 chr19 41851509 C A 5.30E-04 Asperger disorder TGFB1 intron 21182207 rs4803455 chr19 41851509 C A 3.16E-04 Migraine without aura TGFB1 intron 23793025 rs4803455 chr19 41851509 C A 8.00E-07 Migraine TGFB1 intron 23793025 rs2241716 chr19 41854086 C T 1.86E-07 Colorectal cancer TGFB1 intron 24836286 rs2241715 chr19 41856886 A C 3.30E-05 Asthma TGFB1 intron 19910030 rs1800469 chr19 41860296 A G 1.00E-08 Colorectal cancer / / 24836286 rs2241714 chr19 41869392 T C 1.36E-08 Colorectal cancer B9D2 missense 24836286 rs1529717 chr19 41883198 G A 9.28E-05 Amyotrophic Lateral Sclerosis TMEM91 UTR-5 17827064 rs77399851 chr19 41884327 T C 0.00063 Prostate cancer TMEM91 missense 23555315 rs17318596 chr19 41937095 G A 5.00E-16 Height / / 20881960 rs17318596 chr19 41937095 G A 0.000147 Coronary artery disease / / 23202125 rs7260605 chr19 41947635 C T 0.00032 Breast cancer (ER positive) / / 23555315 rs11672691 chr19 41985587 A G 1.00E-08 Prostate cancer LOC100505495 intron 23065704 rs11672691 chr19 41985587 A G 2.00E-12 Prostate cancer LOC100505495 intron 23065704 rs887391 chr19 41985624 C T 4.99E-04 Amyotrophic Lateral Sclerosis LOC100505495 intron 17362836 rs12462897 chr19 42037969 A G 7.20E-05 Serum metabolites / / 19043545 rs7255742 chr19 42049821 A G 9.03E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs4803480 chr19 42066279 A G 1.00E-07 Schizophrenia / / 21682944 rs16975393 chr19 42106367 C A 2.73E-04 Alcohol dependence / / 21314694 rs1990301 chr19 42147477 G T 1.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12985771 chr19 42229176 A C 2.22E-04 Amyotrophic lateral sclerosis (sporadic) CEACAM5 intron 24529757 rs3795018 chr19 42261720 G A 7.39E-05 Serum metabolites CEACAM6 intron 19043545 rs2701 chr19 42275099 A G 1.05E-05 Alcohol dependence CEACAM6 UTR-3 21314694 rs1076976 chr19 42293949 A G 2.64E-04 Alzheimer's disease / / 17998437 rs7251960 chr19 42306043 T C 2.66E-04 Alcohol dependence CEACAM3 intron 21314694 rs3752172 chr19 42312933 G A 6.00E-04 Intelligence (childhood) CEACAM3 cds-synon 23358156 rs8110199 chr19 42316236 G A 3.58E-04 Alzheimer's disease / / 17998437 rs2199830 chr19 42317003 G A 8.65E-04 Alzheimer's disease / / 17998437 rs10401928 chr19 42317651 A C 4.26E-04 Alzheimer's disease / / 17998437 rs6508999 chr19 42322547 G A 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7408605 chr19 42337718 T C 6.60E-05 HIV-1 control / / 20041166 rs3922888 chr19 42343526 G T 3.00E-05 HIV-1 control LYPD4 intron 20041166 rs4803512 chr19 42357455 A C 8.00E-04 Alzheimer's disease / / 17998437 rs8103772 chr19 42358362 T C 3.18E-09 HDL cholesterol / / 23063622 rs3810153 chr19 42385469 A G 0.000089 Coronary artery calcification / / 23727086 rs8099939 chr19 42521108 T G 2.00E-06 Bipolar disorder GRIK5 intron 21771265 rs11880124 chr19 42683791 A G 3.99E-05 Bipolar disorder / / 21771265 rs11878620 chr19 42747229 G A 1.30E-05 Fasting plasma glucose / / 19060907 rs10410198 chr19 42781137 T C 4.95E-04 Smoking cessation LOC100652741 intron 24665060 rs2615614 chr19 42807809 T C 1.20E-05 Urinary metabolites PRR19 intron 21572414 rs201180083 chr19 42840173 G A 0.00022 Breast cancer MEGF8 missense 23555315 rs34052647 chr19 42911769 G A 0.00000965 LDL cholesterol LIPE missense 23236364 rs11665870 chr19 42964971 A G 9.30E-05 Personality dimensions / / 18957941 rs7247618 chr19 43132421 T C 7.60E-05 Personality dimensions / / 18957941 rs10402401 chr19 43139284 C T 5.20E-05 Personality dimensions / / 18957941 rs10407775 chr19 43145417 A G,T 4.80E-05 Personality dimensions / / 18957941 rs116433230 chr19 43414890 C A 0.000043 Prostate cancer PSG6 missense 23555315 rs116433230 chr19 43414890 C A 0.00041 Prostate cancer (non-advanced prostate cancer) PSG6 missense 23555315 rs4352152 chr19 43467855 G A 5.02E-05 Progressive supranuclear palsy / / 21685912 rs9789336 chr19 43496614 C T 1.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs8106604 chr19 43528428 A G 5.88E-04 Suicide attempts in bipolar disorder PSG11 intron 21423239 rs10417319 chr19 43628830 A G 1.50E-05 Urinary metabolites / / 21572414 rs10402173 chr19 43637216 G A 1.10E-05 Urinary metabolites / / 21572414 rs2190835 chr19 43671903 T A 2.60E-05 Urinary metabolites PSG5 UTR-3 21572414 rs7249777 chr19 43698250 A G 9.30E-04 Suicide attempts in bipolar disorder PSG4 intron 21423239 rs4239522 chr19 43700234 C G 6.75E-04 Suicide attempts in bipolar disorder PSG4 intron 21423239 rs7247251 chr19 43700921 C T 6.86E-04 Suicide attempts in bipolar disorder PSG4 intron 21423239 rs4803591 chr19 43769833 G A 3.71E-04 Suicide attempts in bipolar disorder PSG9 intron 21423239 rs3746296 chr19 43772270 G T 2.54E-04 Suicide attempts in bipolar disorder PSG9 cds-synon 21423239 rs3746297 chr19 43772302 C T 5.34E-04 Suicide attempts in bipolar disorder PSG9 splice-5 21423239 rs4802166 chr19 43774105 G C 5.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs4803593 chr19 43776500 A G 7.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs10420737 chr19 43779007 G A 5.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs10420248 chr19 43779075 A G 9.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs4803595 chr19 43794153 T A 6.09E-05 Multiple complex diseases / / 17554300 rs17711503 chr19 43808474 A G 2.81E-05 Blood Pressure / / pha003040 rs8113515 chr19 43815568 C A 6.81E-05 Vascular dementia / / 22116812 rs6509088 chr19 43870887 C T 6.21E-05 Serum metabolites / / 19043545 rs7259375 chr19 43885085 T C 3.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs41354744 chr19 43905590 T G 1.04E-04 Multiple complex diseases TEX101 intron 17554300 rs11083708 chr19 43908615 T C 3.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TEX101 intron 20877124 rs11083708 chr19 43908615 T C 4.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TEX101 intron 20877124 rs4340422 chr19 43912962 A G 5.00E-05 Schizophrenia(treatment response to risperidone) TEX101 intron 19850283 rs2355990 chr19 43921285 G A 5.54E-04 Stroke TEX101 intron pha002886 rs3746004 chr19 43982338 G A 6.50E-04 Suicide attempts in bipolar disorder PHLDB3 intron 21423239 rs17724968 chr19 43995239 C T 2.50E-04 Suicide attempts in bipolar disorder PHLDB3 intron 21423239 rs11668385 chr19 44040807 A G 9.35E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2307184 chr19 44050231 G T 0.000000155 Triglycerides XRCC1 missense 23063622 rs25487 chr19 44055726 T C 4.40E-05 Carotid intima media thickness XRCC1 missense 19679847 rs25487 chr19 44055726 T C 1 Drug response to Cisplatin XRCC1 missense 19786980 rs25487 chr19 44055726 T C 1 Drug response to Cyclophosphamide XRCC1 missense 19786980 rs1799782 chr19 44057574 G A 3.80E-04 Coronary heart disease XRCC1 missense 21966275 rs731420 chr19 44057972 G A 7.70E-04 Response to cytidine analogues (gemcitabine) XRCC1 intron 24483146 rs2293036 chr19 44058048 G A 4.86E-05 Height XRCC1 intron 22021425 rs3213313 chr19 44067002 C G 3.19E-04 Response to cytidine analogues (gemcitabine) XRCC1 intron 24483146 rs12611088 chr19 44072802 G A 1.00E-06 Plasma amyloid beta peptide concentrations (ABx-42) XRCC1 intron 24535457 rs3810378 chr19 44081601 G C 1.18E-04 Type 2 diabetes LOC390940 intron 17463246 rs304719 chr19 44108635 G A 2.16E-05 Body mass index / / 17255346 rs304720 chr19 44109856 C G 5.17E-05 Body mass index / / 17255346 rs304720 chr19 44109856 C G 2.35E-04 Multiple complex diseases / / 17554300 rs368745 chr19 44124368 G T 2.47E-05 Smoking cessation / / 24665060 rs3046 chr19 44124735 T C 4.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs3046 chr19 44124735 T C 2.72E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs10402946 chr19 44139182 C T 1.04E-04 Birth weight CADM4 intron 17255346 rs4760 chr19 44153100 A G 1.90E-04 Coronary heart disease PLAUR missense 21966275 rs4251884 chr19 44159784 G A 1.49E-08 HDL cholesterol PLAUR intron 23063622 rs2239372 chr19 44162954 A G 1.85E-05 Lung function (forced expiratory volume in 1 second) PLAUR intron pha003103 rs4251856 chr19 44163855 C T 0.00000193 LDL cholesterol PLAUR intron 23063622 rs436681 chr19 44185926 G A 4.28E-04 Stroke / / pha002887 rs346044 chr19 44193644 T C 7.70E-05 Waist-Hip Ratio / / pha003013 rs346062 chr19 44198577 G A 2.70E-05 Urinary metabolites / / 21572414 rs10410645 chr19 44214740 G T 0.000033 Total hip bone mineral density / / 23436924 rs10410645 chr19 44214740 G T 0.0000825 Intertrochanter bone mineral density / / 23436924 rs346532 chr19 44248878 A G 4.01E-07 Red blood cell traits SMG9 intron 23222517 rs164070 chr19 44254972 C T 2.00E-06 Urinary metabolites SMG9 intron 21572414 rs346522 chr19 44262545 A G 4.52E-07 Red blood cell traits / / 23222517 rs347518 chr19 44272188 G A 9.00E-06 Urinary metabolites KCNN4 intron 21572414 rs3760982 chr19 44286513 A G 2.00E-10 Breast cancer / / 23535729 rs3760983 chr19 44286660 T C 1.25E-04 Multiple complex diseases / / 17554300 rs10426528 chr19 44299298 C T 3.80E-06 Multiple complex diseases / / 17554300 rs349045 chr19 44299892 T C 6.59E-05 Multiple complex diseases / / 17554300 rs2356400 chr19 44321776 A G 7.45E-04 Lymphocyte counts LYPD5 intron 22286170 rs2356401 chr19 44321849 C T 0.0000699 Cholesterol,total LYPD5 intron 23063622 rs349036 chr19 44339960 C T 2.58E-04 Multiple complex diseases ZNF283 intron 17554300 rs239943 chr19 44374716 A T 2.54E-04 Multiple complex diseases / / 17554300 rs432454 chr19 44398831 C G 3.72E-04 Multiple complex diseases LOC100505715 intron 17554300 rs397913 chr19 44398940 A G 1.99E-04 Multiple complex diseases LOC100505715 intron 17554300 rs368089 chr19 44399084 T C 2.46E-04 Multiple complex diseases LOC100505715 intron 17554300 rs396973 chr19 44399306 A G 2.96E-04 Multiple complex diseases LOC100505715 intron 17554300 rs436249 chr19 44399565 C T 2.33E-04 Multiple complex diseases LOC100505715 intron 17554300 rs430308 chr19 44400375 C G 3.24E-04 Multiple complex diseases LOC100505715 intron 17554300 rs417699 chr19 44417575 A G 2.03E-04 Multiple complex diseases ZNF45 cds-synon 17554300 rs407731 chr19 44418077 C T 1.53E-04 Multiple complex diseases ZNF45 missense 17554300 rs425221 chr19 44418544 A G 1.93E-04 Multiple complex diseases ZNF45 cds-synon 17554300 rs388685 chr19 44418680 G C 4.06E-04 Multiple complex diseases ZNF45 missense 17554300 rs384329 chr19 44423981 T C 2.57E-04 Multiple complex diseases ZNF45 intron 17554300 rs444816 chr19 44438366 T C 4.83E-04 Hypertension ZNF45 intron 21082022 rs10416702 chr19 44446850 T G 6.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs435957 chr19 44458142 G A 3.00E-04 Gamma gluatamyl transferase levels (interaction with age) ZNF221 intron 22010049 rs381872 chr19 44466156 C T 4.80E-05 Hypertension ZNF221 intron 21082022 rs413061 chr19 44466754 G C 8.40E-05 Multiple complex diseases ZNF221 intron 17554300 rs413061 chr19 44466754 G C 7.16E-04 Lymphocyte counts ZNF221 intron 22286170 rs383133 chr19 44467096 T G 7.93E-06 Hypertension ZNF221 intron 21082022 rs462723 chr19 44482707 A C,G,T 4.12E-04 Multiple complex diseases / / 17554300 rs385016 chr19 44484155 C T 3.36E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs397706 chr19 44488085 A G 2.22E-04 Acute lung injury / / 22295056 rs398981 chr19 44488527 A G 1.62E-04 Acute lung injury ZNF155 intron 22295056 rs425530 chr19 44488786 C T 1.65E-04 Acute lung injury ZNF155 intron 22295056 rs430746 chr19 44490972 G A 3.19E-04 Type 2 diabetes ZNF155 intron 17463246 rs430746 chr19 44490972 G A 8.30E-06 Urinary metabolites ZNF155 intron 21572414 rs2191566 chr19 44511389 G T 5.90E-04 Multiple complex diseases ZNF230 intron 17554300 rs2191566 chr19 44511389 G T 4.00E-07 Acute lymphoblastic leukemia (childhood) ZNF230 intron 19684603 rs2191566 chr19 44511389 G T 4.00E-07 Nasopharyngeal carcinoma ZNF230 intron 20512145 rs454904 chr19 44511589 A G 6.72E-04 Multiple complex diseases ZNF230 intron 17554300 rs6509133 chr19 44522913 C T 5.62E-04 Multiple complex diseases / / 17554300 rs6509133 chr19 44522913 C T 1.09E-06 Acute lymphoblastic leukemia (childhood) / / 19684603 rs12610472 chr19 44564401 T C 6.75E-04 Multiple complex diseases ZNF223 intron 17554300 rs6509138 chr19 44570393 C A 6.01E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ZNF223 missense 20031582 rs8105003 chr19 44573415 G A 3.05E-04 Weight loss (gastric bypass surgery) / / 23643386 rs9646633 chr19 44575027 A G 3.12E-04 Alcohol consumption / / 23743675 rs11666432 chr19 44576302 C T 2.04E-04 Alcohol consumption ZNF284 UTR-5 23743675 rs7252213 chr19 44576863 G A 2.04E-04 Alcohol consumption ZNF284 intron 23743675 rs4550576 chr19 44578447 A G 1.68E-04 Alcohol consumption ZNF284 intron 23743675 rs57895932 chr19 44580758 T C 1.73E-04 Alcohol consumption ZNF284 intron 23743675 rs4803674 chr19 44585159 T A 1.82E-04 Multiple complex diseases ZNF284 intron 17554300 rs8113249 chr19 44591360 G A 1.20E-04 Alcohol consumption ZNF284 missense 23743675 rs8113487 chr19 44591554 G C 6.47E-05 Alcohol consumption ZNF284 UTR-3 23743675 rs55876899 chr19 44592202 C T 2.47E-05 Alcohol consumption / / 23743675 rs56353321 chr19 44592403 T C 6.07E-05 Alcohol consumption / / 23743675 rs62115524 chr19 44592935 A G 7.19E-05 Alcohol consumption / / 23743675 rs8108021 chr19 44595422 A G 6.22E-05 Alcohol consumption / / 23743675 rs4802204 chr19 44597295 C A 7.92E-05 Alcohol consumption / / 23743675 rs4802205 chr19 44597429 G A 7.98E-05 Alcohol consumption / / 23743675 rs4429390 chr19 44598868 T G 1.44E-04 Alcohol consumption ZNF224 intron 23743675 rs4459653 chr19 44599615 C T 8.00E-06 Alzheimer's disease (late onset) ZNF224 intron 20885792 rs4459653 chr19 44599615 C T 8.00E-06 Alzheimer's disease (late onset) ZNF224 intron 21460841 rs4459653 chr19 44599615 C T 1.16E-04 Alcohol consumption ZNF224 intron 23743675 rs4802206 chr19 44600236 C T 9.09E-05 Alcohol consumption ZNF224 intron 23743675 rs4802207 chr19 44600377 C T 9.20E-06 Alzheimer's disease (late onset) ZNF224 intron 20885792 rs4802207 chr19 44600377 C T 9.20E-06 Alzheimer's disease (late onset) ZNF224 intron 21460841 rs4802207 chr19 44600377 C T 7.27E-05 Alcohol consumption ZNF224 intron 23743675 rs10410306 chr19 44601537 T C 8.57E-05 Alcohol consumption ZNF224 intron 23743675 rs7250005 chr19 44602959 C T 9.83E-05 Alcohol consumption ZNF224 intron 23743675 rs7250004 chr19 44602992 A G 8.31E-05 Alcohol consumption ZNF224 intron 23743675 rs8104573 chr19 44603385 A G 8.57E-05 Alcohol consumption ZNF224 intron 23743675 rs8108404 chr19 44603975 G T 5.38E-05 Alcohol consumption ZNF224 intron 23743675 rs62115526 chr19 44604914 T C 6.42E-05 Alcohol consumption ZNF224 intron 23743675 rs4803676 chr19 44605123 G A 1.64E-04 Alcohol consumption ZNF224 intron 23743675 rs8105860 chr19 44606928 A G 1.12E-04 Alcohol consumption ZNF224 intron 23743675 rs28539456 chr19 44607547 G T 8.92E-05 Alcohol consumption ZNF224 intron 23743675 rs28446946 chr19 44607619 T C 9.01E-05 Alcohol consumption ZNF224 intron 23743675 rs10420143 chr19 44608082 A G 2.75E-05 Alcohol consumption ZNF224 intron 23743675 rs8113750 chr19 44608789 C T 1.14E-04 Alcohol consumption ZNF224 intron 23743675 rs4803677 chr19 44608963 C T 1.42E-04 Alcohol consumption ZNF224 intron 23743675 rs4803678 chr19 44609147 C T 1.46E-04 Alcohol consumption ZNF224 intron 23743675 rs4803679 chr19 44609160 A T 1.43E-04 Alcohol consumption ZNF224 intron 23743675 rs4803680 chr19 44609293 T C 1.55E-04 Alcohol consumption ZNF224 intron 23743675 rs4803681 chr19 44609485 G A 1.43E-04 Alcohol consumption ZNF224 intron 23743675 rs8101657 chr19 44609724 T A 1.61E-04 Alcohol consumption ZNF224 intron 23743675 rs3172 chr19 44609846 C G 1.59E-04 Alcohol consumption ZNF224 intron 23743675 rs7249827 chr19 44610029 C A 1.65E-04 Alcohol consumption ZNF224 intron 23743675 rs7249834 chr19 44610095 A G 1.50E-04 Alcohol consumption ZNF224 intron 23743675 rs7250076 chr19 44610295 A G 1.26E-04 Alcohol consumption ZNF224 intron 23743675 rs7250171 chr19 44610305 C T 1.10E-04 Alcohol consumption ZNF224 intron 23743675 rs2068061 chr19 44610665 A G 2.26E-04 Multiple complex diseases ZNF224 missense 17554300 rs2068061 chr19 44610665 A G 1.49E-04 Alcohol consumption ZNF224 missense 23743675 rs4239529 chr19 44610798 A T 1.23E-04 Alcohol consumption ZNF224 missense 23743675 rs4508518 chr19 44611420 A G 1.45E-04 Alcohol consumption ZNF224 cds-synon 23743675 rs3746321 chr19 44612005 A G 6.64E-05 Alcohol consumption ZNF224 cds-synon 23743675 rs3200505 chr19 44612014 A T 6.73E-05 Alcohol consumption ZNF224 cds-synon 23743675 rs3746319 chr19 44612231 A G 3.00E-05 Alzheimer's disease (late onset) ZNF224 missense 20885792 rs3746319 chr19 44612231 A G 3.00E-05 Alzheimer's disease (late onset) ZNF224 missense 21460841 rs3746319 chr19 44612231 A G 1.24E-04 Alcohol consumption ZNF224 missense 23743675 rs6509141 chr19 44613119 C T 8.71E-05 Alcohol consumption LOC100379224 intron 23743675 rs2061332 chr19 44613661 A C 8.72E-05 Multiple complex diseases LOC100379224 intron 17554300 rs2061332 chr19 44613661 A C 3.90E-05 Alzheimer's disease (late onset) LOC100379224 intron 20885792 rs2061332 chr19 44613661 A C 3.90E-05 Alzheimer's disease (late onset) LOC100379224 intron 21460841 rs2061332 chr19 44613661 A C 1.20E-04 Alcohol consumption LOC100379224 intron 23743675 rs2061333 chr19 44614208 C T 2.00E-06 Alzheimer's disease LOC100379224 intron 19118814 rs2061333 chr19 44614208 C T 1.50E-06 Alzheimer's disease (late onset) LOC100379224 intron 21460841 rs2061333 chr19 44614208 C T 1.37E-04 Alcohol consumption LOC100379224 intron 23743675 rs2284978 chr19 44617310 A G 1.18E-04 Alcohol consumption / / 23743675 rs6509142 chr19 44617385 C T 8.90E-06 Lung adenocarcinoma / / 22797724 rs2300962 chr19 44620203 C T 6.61E-05 Alcohol consumption ZNF225 intron 23743675 rs8099869 chr19 44623376 C T 1.04E-04 Alcohol consumption ZNF225 intron 23743675 rs7253485 chr19 44625042 A G 1.85E-04 Alcohol consumption ZNF225 intron 23743675 rs2356750 chr19 44625909 G A 2.00E-04 Alcohol consumption ZNF225 intron 23743675 rs4802208 chr19 44627912 G C 1.49E-04 Alcohol consumption ZNF225 intron 23743675 rs7251868 chr19 44628357 G A 2.15E-04 Alcohol consumption ZNF225 intron 23743675 rs10853771 chr19 44629448 C T 7.06E-05 Alcohol consumption ZNF225 intron 23743675 rs7508762 chr19 44629878 T C 8.18E-05 Alcohol consumption ZNF225 intron 23743675 rs2168778 chr19 44631219 T C 1.05E-04 Alcohol consumption ZNF225 intron 23743675 rs16978732 chr19 44633056 C T 1.79E-04 Multiple complex diseases ZNF225 intron 17554300 rs2284980 chr19 44633474 T C 1.46E-04 Alcohol consumption ZNF225 intron 23743675 rs2284981 chr19 44633558 G C 8.45E-05 Alcohol consumption ZNF225 intron 23743675 rs10406335 chr19 44633953 G A 9.00E-04 Alzheimer's disease (late onset) ZNF225 intron 21460841 rs10406335 chr19 44633953 G A 1.44E-04 Alcohol consumption ZNF225 intron 23743675 rs9304638 chr19 44634086 C T 7.16E-05 Alcohol consumption ZNF225 intron 23743675 rs10413511 chr19 44634811 G A 1.37E-04 Alcohol consumption ZNF225 intron 23743675 rs10413195 chr19 44634903 A G 2.58E-04 Alcohol consumption ZNF225 intron 23743675 rs41360748 chr19 44639110 A G 4.06E-05 Multiple complex diseases / / 17554300 rs1236715 chr19 44639558 C G 8.45E-05 Alcohol consumption / / 23743675 rs1236716 chr19 44640929 G A 7.97E-05 Alcohol consumption / / 23743675 rs10409884 chr19 44706874 A G 4.81E-05 Multiple complex diseases / / 17554300 rs7247369 chr19 44714898 G T 5.33E-04 Type 2 diabetes / / 17463246 rs922064 chr19 44732835 A G 7.61E-04 Multiple complex diseases ZNF227 intron 17554300 rs1233441 chr19 44766581 G A 8.45E-04 Multiple complex diseases ZNF233 intron 17554300 rs2609881 chr19 44831989 T G 5.38E-07 Systemic lupus erythematosus ZFP112 missense pha002867 rs10422017 chr19 44837246 A G 4.46E-04 Multiple complex diseases ZFP112 intron 17554300 rs4142248 chr19 44888276 T C 4.77E-04 Alcohol dependence / / 20201924 rs4142248 chr19 44888276 T C 3.00E-15 Myopia (pathological) / / 23049088 rs2571177 chr19 44924127 T C 5.72E-04 Alzheimer's disease / / 22005930 rs2734459 chr19 44928885 C A 1.31E-04 Alzheimer's disease / / 22005930 rs2734457 chr19 44929633 A G 5.78E-04 Alzheimer's disease / / 22005930 rs2722693 chr19 44929776 T G 5.78E-04 Alzheimer's disease / / 22005930 rs3763954 chr19 44930430 G A 5.70E-05 Lung adenocarcinoma ZNF229 UTR-3 22797724 rs1062098 chr19 44930738 T C 8.83E-05 Personality dimensions ZNF229 UTR-3 18957941 rs2734453 chr19 44930880 G A 1.11E-04 Alzheimer's disease ZNF229 UTR-3 22005930 rs1434579 chr19 44932972 C T 4.00E-06 Tuberculosis ZNF229 missense 20694014 rs204531 chr19 44957508 G A 3.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs644148 chr19 44970935 T G 8.00E-06 Personality dimensions / / 18957941 rs644148 chr19 44970935 T G 9.00E-07 Personality dimensions / / 18957941 rs644148 chr19 44970935 T G 8.00E-06 Personality dimensions / / 21173776 rs1897824 chr19 44977071 C T 9.42E-08 Hepatitis B / / 24162738 rs17714261 chr19 44977262 T C 7.74E-04 Coronary heart disease / / 21606135 rs12459705 chr19 44978109 G T 5.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs1897820 chr19 44981883 C G 8.10E-04 Birth weight ZNF180 missense 17255346 rs2253563 chr19 44983567 C G 6.02E-04 Birth weight ZNF180 missense 17255346 rs2293166 chr19 45004823 A G 0.0000037 Femoral neck bone mineral density / / 23436924 rs7250326 chr19 45008242 G C 0.0000036 Femoral neck bone mineral density / / 23436924 rs12981961 chr19 45009977 C T 8.09E-05 Personality dimensions / / 18957941 rs10407556 chr19 45013262 G A 1.19E-05 Tunica Media CEACAM20 intron pha003037 rs13343790 chr19 45013679 C G 0.0000058 Femoral neck bone mineral density CEACAM20 intron 23436924 rs1465723 chr19 45017249 T C 1.91E-05 Tunica Media CEACAM20 missense pha003037 rs10414398 chr19 45021210 G A 0.00000092 Stroke CEACAM20 missense 23422753 rs930461 chr19 45043259 T A 7.00E-05 Memory performance / / 22105620 rs1727748 chr19 45048323 C T 3.30E-05 Alzheimer's disease CEACAM22P intron 24755620 rs1727753 chr19 45058204 G A 2.48E-04 Alzheimer's disease CEACAM22P intron 24755620 rs7258420 chr19 45059310 A C 2.55E-06 Lipid traits CEACAM22P intron 21777205 rs1727757 chr19 45064435 A G 2.35E-04 Alzheimer's disease / / 24755620 rs846848 chr19 45074177 G T 9.73E-05 Alzheimer's disease (late onset) / / 21460841 rs7259313 chr19 45103698 T C 3.28E-05 Creatinine levels / / pha003069 rs846885 chr19 45110415 G T 3.96E-04 Multiple complex diseases / / 17554300 rs846902 chr19 45114420 A G 2.38E-04 Multiple complex diseases / / 17554300 rs846866 chr19 45134110 A C 2.97E-04 Celiac disease IGSF23 intron 23936387 rs203717 chr19 45139812 C T 1.22E-05 Multiple complex diseases IGSF23 UTR-3 17554300 rs7255066 chr19 45146103 T C 7.35E-05 Type 2 diabetes and other traits PVR nearGene-5 19734900 rs7255066 chr19 45146103 T C 1.00E-06 Multiple sclerosis PVR nearGene-5 21833088 rs7255066 chr19 45146103 T C 2.10E-04 Celiac disease PVR nearGene-5 23936387 rs1058402 chr19 45150614 G A 7.38E-04 Atopy PVR missense 21625490 rs714948 chr19 45165912 C A 1.74E-05 Alzheimer's disease (late onset) PVR UTR-3 21379329 rs714948 chr19 45165912 C A 2.40E-08 Alzheimer's disease (late onset) PVR UTR-3 21460841 rs714948 chr19 45165912 C A 7.95E-05 Alzheimer's disease PVR UTR-3 22832961 rs714948 chr19 45165912 C A 2.03E-10 Alzheimer's disease PVR UTR-3 24755620 rs2965155 chr19 45188471 T C 5.79E-04 Multiple complex diseases / / 17554300 rs12150959 chr19 45191157 G T 1.70E-06 Urinary metabolites / / 21572414 rs12150984 chr19 45202027 G A 5.31E-06 Alzheimer's disease (late onset) / / 21460841 rs2965164 chr19 45202052 C T 8.69E-05 Alzheimer's disease (late onset) / / 21379329 rs2965164 chr19 45202052 C T 6.41E-05 Alzheimer's disease (late onset) / / 21460841 rs2119660 chr19 45202640 G T 1.90E-06 Urinary metabolites CEACAM16 intron 21572414 rs8108277 chr19 45205877 T C 1.90E-04 Alzheimer's disease CEACAM16 intron 24755620 rs114907619 chr19 45206624 T C 0.000034 Breast cancer (ER positive) CEACAM16 missense 23555315 rs7248283 chr19 45208682 G T 9.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) CEACAM16 intron 23233662 rs4802234 chr19 45222600 G T 9.22E-06 Longevity / / 22279548 rs2965109 chr19 45225345 C T 1.60E-07 Alzheimer's disease / / 19734903 rs2965109 chr19 45225345 C T 1.92E-13 Alzheimer's disease (late onset) / / 21460841 rs2965109 chr19 45225345 C T 1.35E-09 Alzheimer's disease / / 22832961 rs2965109 chr19 45225345 C T 1.23E-05 Alzheimer's disease (late onset) / / 23565137 rs2965109 chr19 45225345 C T 1.36E-04 Alzheimer's disease (late onset) / / 23565137 rs2965109 chr19 45225345 C T 1.70E-05 Alzheimer's disease (late onset) / / 23565137 rs2965109 chr19 45225345 C T 8.51E-04 Alzheimer's disease / / 24755620 rs7254776 chr19 45227742 T C 1.50E-07 Alzheimer's disease / / 19734903 rs7254776 chr19 45227742 T C 1.87E-12 Alzheimer's disease (late onset) / / 21460841 rs7254776 chr19 45227742 T C 9.02E-09 Alzheimer's disease / / 22832961 rs7254776 chr19 45227742 T C 1.57E-05 Alzheimer's disease (late onset) / / 23565137 rs7254776 chr19 45227742 T C 8.82E-06 Alzheimer's disease (late onset) / / 23565137 rs7254776 chr19 45227742 T C 9.82E-05 Alzheimer's disease (late onset) / / 23565137 rs4803745 chr19 45230752 A T 2.59E-04 Alzheimer's disease (late onset) / / 23565137 rs4803745 chr19 45230752 A T 7.84E-05 Alzheimer's disease (late onset) / / 23565137 rs2927488 chr19 45231478 G A 1.78E-05 Alzheimer's disease / / 19734903 rs2927488 chr19 45231478 G A 1.65E-05 Alzheimer's disease (late onset) / / 21460841 rs2927488 chr19 45231478 G A 5.12E-04 Alzheimer's disease / / 24755620 rs1551891 chr19 45231821 G A 3.16E-08 Alzheimer's disease (late onset) / / 23565137 rs1551891 chr19 45231821 G A 3.23E-09 Alzheimer's disease (late onset) / / 23565137 rs62117160 chr19 45232161 G A 1.85E-10 Metabolite levels / / 22286219 rs1004165 chr19 45232205 G A 4.60E-05 Height / / pha003010 rs2965106 chr19 45232374 G A 1.33E-07 Alzheimer's disease (late onset) / / 23565137 rs2965106 chr19 45232374 G A 2.55E-05 Alzheimer's disease (late onset) / / 23565137 rs2965106 chr19 45232374 G A 3.64E-06 Alzheimer's disease (late onset) / / 23565137 rs62117161 chr19 45233385 A G 1.29E-11 Alzheimer's disease (late onset) / / 23565137 rs62117161 chr19 45233385 A G 3.46E-12 Alzheimer's disease (late onset) / / 23565137 rs8104467 chr19 45233489 A G 1.67E-05 Alzheimer's disease (late onset) / / 23565137 rs8104467 chr19 45233489 A G 7.78E-06 Alzheimer's disease (late onset) / / 23565137 rs8108110 chr19 45234124 A G 1.05E-05 Alzheimer's disease (late onset) / / 23565137 rs8108110 chr19 45234124 A G 5.43E-06 Alzheimer's disease (late onset) / / 23565137 rs2965101 chr19 45237812 T C 6.58E-09 Triglycerides / / 19060911 rs2965101 chr19 45237812 T C 4.55E-07 Type 2 diabetes and other traits / / 19734900 rs2965101 chr19 45237812 T C 8.54E-10 Alzheimer's disease / / 19734903 rs2965101 chr19 45237812 T C 1.09E-04 Alzheimer's disease (late onset) / / 21379329 rs2965101 chr19 45237812 T C 2.36E-12 Alzheimer's disease (late onset) / / 21460841 rs2965101 chr19 45237812 T C 1.20E-11 Alzheimer's disease / / 21627779 rs2965101 chr19 45237812 T C 1.59E-09 Alzheimer's disease / / 22832961 rs2965101 chr19 45237812 T C 1.21E-15 LDL cholesterol / / 23063622 rs2965101 chr19 45237812 T C 1.71E-10 Cholesterol,total / / 23063622 rs2965101 chr19 45237812 T C 1.90E-05 Alzheimer's disease (late onset) / / 23565137 rs2965101 chr19 45237812 T C 3.17E-05 Alzheimer's disease (late onset) / / 23565137 rs2965101 chr19 45237812 T C 4.40E-06 Alzheimer's disease / / 24755620 rs2965101 chr19 45237812 T C 5.67E-05 LDL lipoproteins / / pha002902 rs2927436 chr19 45239185 A G 2.30E-05 Alzheimer's disease (late onset) / / 23565137 rs2927436 chr19 45239185 A G 4.70E-06 Alzheimer's disease (late onset) / / 23565137 rs62117162 chr19 45239536 C A 1.75E-08 Alzheimer's disease (late onset) / / 23565137 rs62117162 chr19 45239536 C A 1.75E-09 Alzheimer's disease (late onset) / / 23565137 rs17728272 chr19 45240371 C T 3.10E-06 Alzheimer's disease / / 19734903 rs17728272 chr19 45240371 C T 1.68E-05 Alzheimer's disease (late onset) / / 21460841 rs2927438 chr19 45242107 A G 2.95E-11 Type 2 diabetes and other traits / / 19734900 rs2927438 chr19 45242107 A G 1.49E-04 Amyotrophic lateral sclerosis / / 20801718 rs2927438 chr19 45242107 A G 2.44E-04 Alzheimer's disease (late onset) / / 21379329 rs2927438 chr19 45242107 A G 2.76E-08 Alzheimer's disease (late onset) / / 21460841 rs2927438 chr19 45242107 A G 5.82E-05 Alzheimer's disease / / 22005930 rs2927438 chr19 45242107 A G 2.51E-11 Alzheimer's disease / / 22832961 rs2927438 chr19 45242107 A G 1.82E-08 LDL cholesterol / / 23063622 rs2927438 chr19 45242107 A G 4.57E-09 Cholesterol,total / / 23063622 rs2927438 chr19 45242107 A G 1.33E-04 Barrett's esophagus / / 24121790 rs2927438 chr19 45242107 A G 1.71E-04 Esophageal adenocarcinoma / / 24121790 rs2927438 chr19 45242107 A G 2.00E-06 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs2927438 chr19 45242107 A G 3.32E-07 Alzheimer's disease / / 24755620 rs1531517 chr19 45242173 G A 1.93E-04 Lipid levels / / 19913121 rs1531517 chr19 45242173 G A 1.96E-13 Lipid levels / / 19913121 rs1531517 chr19 45242173 G A 2.22E-16 Lipid levels / / 19913121 rs1531517 chr19 45242173 G A 7.11E-07 Alzheimer's disease (late onset) / / 21460841 rs1531517 chr19 45242173 G A 4.32E-11 Cardiovascular disease risk factors / / 21943158 rs1531517 chr19 45242173 G A 1.29E-08 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs1531517 chr19 45242173 G A 1.40E-09 Sphingolipid levels / / 22359512 rs1531517 chr19 45242173 G A 0.00000268 HDL cholesterol / / 23063622 rs1531517 chr19 45242173 G A 2.16E-28 Cholesterol,total / / 23063622 rs1531517 chr19 45242173 G A 3.78E-09 Total cholesterol in males / / 23063622 rs1531517 chr19 45242173 G A 5.38E-22 Total cholesterol in females / / 23063622 rs1531517 chr19 45242173 G A 7.72E-50 LDL cholesterol / / 23063622 rs1531517 chr19 45242173 G A 1.69E-09 Alzheimer's disease (late onset) / / 23565137 rs1531517 chr19 45242173 G A 1.74E-08 Alzheimer's disease (late onset) / / 23565137 rs1531517 chr19 45242173 G A 5.13E-15 Alzheimer's disease (late onset) / / 23565137 rs2927439 chr19 45242740 A G 1.06E-05 Alzheimer's disease (late onset) / / 23565137 rs2927439 chr19 45242740 A G 2.66E-05 Alzheimer's disease (late onset) / / 23565137 rs2927439 chr19 45242740 A G 6.83E-05 Alzheimer's disease (late onset) / / 23565137 rs62117204 chr19 45242967 C T 2.39E-09 Alzheimer's disease (late onset) / / 23565137 rs62117204 chr19 45242967 C T 2.61E-08 Alzheimer's disease (late onset) / / 23565137 rs12977877 chr19 45245172 G A 9.93E-11 Metabolite levels / / 22286219 rs4803750 chr19 45247627 A G 2.40E-11 LDL cholesterol / / 18262040 rs4803750 chr19 45247627 A G 7.81E-14 Triglycerides / / 19060911 rs4803750 chr19 45247627 A G 2.78E-05 Type 2 diabetes and other traits / / 19734900 rs4803750 chr19 45247627 A G 3.60E-14 Lipid levels / / 19802338 rs4803750 chr19 45247627 A G 8.70E-19 Lipid levels / / 19802338 rs4803750 chr19 45247627 A G 1.20E-26 Lipid levels / / 19936222 rs4803750 chr19 45247627 A G 1.30E-27 Lipid levels / / 19936222 rs4803750 chr19 45247627 A G 1.48E-37 Lipid levels / / 19936222 rs4803750 chr19 45247627 A G 2.40E-19 Lipid levels / / 19936222 rs4803750 chr19 45247627 A G 3.46E-51 Lipid levels / / 19936222 rs4803750 chr19 45247627 A G 3.88E-04 Alzheimer's disease (late onset) / / 21379329 rs4803750 chr19 45247627 A G 6.72E-07 Alzheimer's disease (late onset) / / 21460841 rs4803750 chr19 45247627 A G 9.04E-14 Cardiovascular disease risk factors / / 21943158 rs4803750 chr19 45247627 A G 1.30E-33 Metabolic syndrome phenotype / / 22022282 rs4803750 chr19 45247627 A G 2.40E-14 Metabolic syndrome phenotype / / 22022282 rs4803750 chr19 45247627 A G 3.20E-05 Metabolic syndrome phenotype / / 22022282 rs4803750 chr19 45247627 A G 4.20E-55 Metabolic syndrome phenotype / / 22022282 rs4803750 chr19 45247627 A G 7.80E-09 Metabolic syndrome phenotype / / 22022282 rs4803750 chr19 45247627 A G 6.40E-09 Sphingolipid levels / / 22359512 rs4803750 chr19 45247627 A G 2.20E-09 LDL cholesterol / / 23063622 rs4803750 chr19 45247627 A G 0.00000026 Apolipoprotein B levels response after 40mg daily simvastatin treatment / / 23100282 rs4803750 chr19 45247627 A G 0.0000067 LDL cholesterol response after 40mg daily simvastatin treatment / / 23100282 rs4803750 chr19 45247627 A G 1.10E-29 Apolipoprotein B levels / / 23100282 rs4803750 chr19 45247627 A G 5.60E-36 LDL cholesterol / / 23100282 rs4803750 chr19 45247627 A G 5.60E-36 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) / / 23103227 rs4803750 chr19 45247627 A G 3.36E-05 LDL lipoproteins / / pha002902 rs8100239 chr19 45253104 T A 2.53E-04 Alzheimer's disease BCL3 intron 17998437 rs8100239 chr19 45253104 T A 3.60E-08 Alzheimer's disease BCL3 intron 19734903 rs8100239 chr19 45253104 T A 2.04E-09 Alzheimer's disease (late onset) BCL3 intron 21460841 rs8100239 chr19 45253104 T A 3.37E-06 Alzheimer's disease (late onset) BCL3 intron 23565137 rs8103315 chr19 45254168 C A 2.94E-07 Type 2 diabetes and other traits BCL3 intron 19734900 rs8103315 chr19 45254168 C A 5.10E-06 Alzheimer's disease BCL3 intron 19734903 rs8103315 chr19 45254168 C A 1.24E-06 Alzheimer's disease (late onset) BCL3 intron 21379329 rs8103315 chr19 45254168 C A 7.23E-13 Alzheimer's disease (late onset) BCL3 intron 21460841 rs8103315 chr19 45254168 C A 6.16E-14 Alzheimer's disease BCL3 intron 22832961 rs8103315 chr19 45254168 C A 1.87E-08 Alzheimer's disease BCL3 intron 24755620 rs2927457 chr19 45256947 G A 6.05E-04 Response to taxane treatment (placlitaxel) BCL3 intron 23006423 rs35980686 chr19 45260350 T C 0.000000419 Triglycerides BCL3 missense 23063622 rs35980686 chr19 45260350 T C 2.68E-09 LDL cholesterol BCL3 missense 23063622 rs35980686 chr19 45260350 T C 3.24E-20 Cholesterol,total BCL3 missense 23063622 rs35980686 chr19 45260350 T C 6.73E-13 HDL cholesterol BCL3 missense 23063622 rs2927453 chr19 45271184 C A,T 4.89E-08 LDL cholesterol / / 23063622 rs899087 chr19 45294557 T C 5.09E-05 Alzheimer's disease CBLC intron 22832961 rs3208856 chr19 45296806 C A,G,T 2.60E-08 Lipoprotein-associated phospholipase A2 activity and mass CBLC missense 22003152 rs3208856 chr19 45296806 C A,G,T 0.000073 Prostate cancer CBLC missense 23555315 rs2927477 chr19 45313715 T C 2.98E-12 Alzheimer's disease (late onset) BCAM intron 21460841 rs2927477 chr19 45313715 T C 1.77E-07 Alzheimer's disease BCAM intron 22832961 rs28399653 chr19 45315445 G A 2.50E-09 Lipid levels BCAM missense 19802338 rs28399653 chr19 45315445 G A 2.70E-10 Lipid levels BCAM missense 19802338 rs28399654 chr19 45316588 G A 6.20E-09 Lipid levels BCAM missense 19802338 rs28399654 chr19 45316588 G A 7.60E-09 Lipid levels BCAM missense 19802338 rs10405693 chr19 45326664 C T 2.83E-12 Alzheimer's disease / / 24755620 rs1871045 chr19 45326768 C T 3.40E-08 Triglycerides / / 19060911 rs1871045 chr19 45326768 C T 8.98E-06 Alzheimer's disease (late onset) / / 21460841 rs1871045 chr19 45326768 C T 4.00E-06 Waist-to-hip circumference ratio (interaction) / / 23192594 rs1871045 chr19 45326768 C T 3.57E-06 Alzheimer's disease / / 24755620 rs4803759 chr19 45327459 T C 2.20E-06 Alzheimer's disease / / 19734903 rs4803759 chr19 45327459 T C 7.27E-15 Alzheimer's disease (late onset) / / 21460841 rs4803759 chr19 45327459 T C 1.62E-04 Heart rate / / 23583979 rs4803759 chr19 45327459 T C 6.38E-06 Alzheimer's disease / / 24755620 rs10402271 chr19 45329214 T G 5.58E-04 Type 2 diabetes / / 17463246 rs10402271 chr19 45329214 T G 4.95E-04 Alzheimer's disease / / 17998437 rs10402271 chr19 45329214 T G 1.20E-09 Lipid levels / / 18193043 rs10402271 chr19 45329214 T G 4.10E-08 LDL cholesterol / / 18262040 rs10402271 chr19 45329214 T G 1.26E-14 Triglycerides / / 19060911 rs10402271 chr19 45329214 T G 2.90E-17 Alzheimer's disease / / 19136949 rs10402271 chr19 45329214 T G 1.54E-26 Type 2 diabetes and other traits / / 19734900 rs10402271 chr19 45329214 T G 1.90E-14 Alzheimer's disease / / 19734903 rs10402271 chr19 45329214 T G 3.30E-08 Lipid levels / / 19802338 rs10402271 chr19 45329214 T G 2.06E-12 Lipid levels / / 19913121 rs10402271 chr19 45329214 T G 7.05E-13 Lipid levels / / 19913121 rs10402271 chr19 45329214 T G 1.68E-05 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs10402271 chr19 45329214 T G 2.14E-07 Alzheimer's disease (late onset) / / 20885792 rs10402271 chr19 45329214 T G 7.43E-10 Alzheimer's disease (late onset) / / 21379329 rs10402271 chr19 45329214 T G 1.87E-31 Alzheimer's disease (late onset) / / 21460841 rs10402271 chr19 45329214 T G 4.71E-15 Alzheimer's disease / / 21627779 rs10402271 chr19 45329214 T G 1.19E-05 Alzheimer's disease / / 22005930 rs10402271 chr19 45329214 T G 1.54E-17 Alzheimer's disease / / 22832961 rs10402271 chr19 45329214 T G 1.53E-34 Cholesterol,total / / 23063622 rs10402271 chr19 45329214 T G 4.42E-42 LDL cholesterol / / 23063622 rs10402271 chr19 45329214 T G 2.10E-04 Response to alcohol consumption (flushing response) / / 24277619 rs10402271 chr19 45329214 T G 1.98E-17 Alzheimer's disease / / 24755620 rs4802238 chr19 45331725 C T 7.90E-14 Alzheimer's disease / / 19734903 rs4803760 chr19 45333834 T C 6.30E-11 Lipid levels / / 19802338 rs4803760 chr19 45333834 T C 8.80E-11 Lipid levels / / 19802338 rs4803760 chr19 45333834 T C 8.30E-05 Response to statin therapy / / 20339536 rs4803760 chr19 45333834 T C 2.46E-07 Alzheimer's disease (late onset) / / 21460841 rs4803760 chr19 45333834 T C 2.90E-08 Metabolic syndrome phenotype / / 22022282 rs4803760 chr19 45333834 T C 4.10E-48 Metabolic syndrome phenotype / / 22022282 rs4803760 chr19 45333834 T C 4.80E-13 Metabolic syndrome phenotype / / 22022282 rs4803760 chr19 45333834 T C 9.40E-05 Metabolic syndrome phenotype / / 22022282 rs4803760 chr19 45333834 T C 9.90E-32 Metabolic syndrome phenotype / / 22022282 rs4803760 chr19 45333834 T C 4.75E-05 Response to statin therapy / / 22368281 rs4803760 chr19 45333834 T C 1.96E-05 Body Mass Index / / pha003009 rs7359852 chr19 45336035 T C 2.00E-16 Alzheimer's disease / / 19734903 rs7359852 chr19 45336035 T C 9.55E-35 Alzheimer's disease (late onset) / / 21460841 rs7359852 chr19 45336035 T C 1.06E-18 Alzheimer's disease / / 22832961 rs2927480 chr19 45337385 G C 2.00E-16 Alzheimer's disease / / 19734903 rs2927480 chr19 45337385 G C 8.48E-35 Alzheimer's disease (late onset) / / 21460841 rs2927480 chr19 45337385 G C 9.64E-19 Alzheimer's disease / / 22832961 rs4605275 chr19 45338493 T C 4.70E-08 LDL cholesterol / / 18262040 rs4605275 chr19 45338493 T C 1.13E-14 Alzheimer's disease (late onset) / / 21460841 rs2972564 chr19 45344458 A G 1.79E-05 Alzheimer's disease (late onset) / / 21460841 rs1985096 chr19 45346551 A T 3.51E-08 Response to statin therapy / / 22368281 rs10426423 chr19 45348253 C T 3.33E-04 Alzheimer's disease PVRL2 nearGene-5 24755620 rs2306149 chr19 45349963 C A 2.49E-04 Alzheimer's disease PVRL2 intron 24755620 rs1871047 chr19 45351746 A G 1.31E-08 Type 2 diabetes and other traits PVRL2 intron 19734900 rs1871047 chr19 45351746 A G 1.10E-07 Alzheimer's disease PVRL2 intron 19734903 rs1871047 chr19 45351746 A G 4.50E-11 Alzheimer's disease (late onset) PVRL2 intron 21460841 rs1871047 chr19 45351746 A G 5.49E-12 Alzheimer's disease PVRL2 intron 21627779 rs1871047 chr19 45351746 A G 4.87E-07 Alzheimer's disease PVRL2 intron 24755620 rs1871046 chr19 45351937 T C 6.80E-07 Alzheimer's disease PVRL2 intron 19734903 rs1871046 chr19 45351937 T C 4.60E-11 Alzheimer's disease (late onset) PVRL2 intron 21460841 rs7255063 chr19 45352419 G C 2.10E-04 Alzheimer's disease PVRL2 intron 24755620 rs4803763 chr19 45357291 G C 2.00E-16 Alzheimer's disease PVRL2 intron 19734903 rs4803763 chr19 45357291 G C 2.20E-10 Lipid levels PVRL2 intron 19913121 rs4803763 chr19 45357291 G C 2.75E-12 Lipid levels PVRL2 intron 19913121 rs4803763 chr19 45357291 G C 2.21E-47 Alzheimer's disease (late onset) PVRL2 intron 21460841 rs4803763 chr19 45357291 G C 5.89E-26 Alzheimer's disease PVRL2 intron 22832961 rs4803763 chr19 45357291 G C 6.72E-27 Cholesterol,total PVRL2 intron 23063622 rs4803763 chr19 45357291 G C 8.44E-30 LDL cholesterol PVRL2 intron 23063622 rs440277 chr19 45361224 G A 5.38E-06 Type 2 diabetes and other traits PVRL2 intron 19734900 rs440277 chr19 45361224 G A 2.60E-09 Alzheimer's disease PVRL2 intron 19734903 rs440277 chr19 45361224 G A 3.02E-06 Alzheimer's disease (late onset) PVRL2 intron 21379329 rs440277 chr19 45361224 G A 3.20E-12 Alzheimer's disease (late onset) PVRL2 intron 21460841 rs440277 chr19 45361224 G A 4.55E-11 Alzheimer's disease PVRL2 intron 21627779 rs440277 chr19 45361224 G A 4.79E-07 Alzheimer's disease PVRL2 intron 24755620 rs3852856 chr19 45361574 G A 3.90E-11 Cholesterol,total PVRL2 intron 23063622 rs3852856 chr19 45361574 G A 5.33E-12 LDL cholesterol PVRL2 intron 23063622 rs365653 chr19 45361646 A G 3.22E-17 Metabolite levels PVRL2 intron 22286219 rs377702 chr19 45362667 G A 4.30E-06 Alzheimer's disease PVRL2 intron 19136949 rs377702 chr19 45362667 G A 8.38E-11 Type 2 diabetes and other traits PVRL2 intron 19734900 rs377702 chr19 45362667 G A 3.91E-04 Alzheimer's disease (late onset) PVRL2 intron 21379329 rs377702 chr19 45362667 G A 4.07E-10 Alzheimer's disease (late onset) PVRL2 intron 21460841 rs377702 chr19 45362667 G A 1.79E-04 Alzheimer's disease PVRL2 intron 22005930 rs377702 chr19 45362667 G A 1.99E-07 Alzheimer's disease PVRL2 intron 24755620 rs12978931 chr19 45363700 A G 5.20E-06 Alzheimer's disease PVRL2 intron 19734903 rs12978931 chr19 45363700 A G 2.45E-16 Alzheimer's disease (late onset) PVRL2 intron 21460841 rs519825 chr19 45366779 T C 2.97E-10 Alzheimer's disease (late onset) PVRL2 intron 21460841 rs519825 chr19 45366779 T C 1.65E-04 Alzheimer's disease PVRL2 intron 22005930 rs8105340 chr19 45367777 C T 1.94E-04 Alzheimer's disease (late onset) PVRL2 intron 21379329 rs8105340 chr19 45367777 C T 7.23E-07 Alzheimer's disease (late onset) PVRL2 intron 21460841 rs8105340 chr19 45367777 C T 7.39E-04 Alzheimer's disease PVRL2 intron 24755620 rs12610605 chr19 45370838 G A 6.10E-05 Personality dimensions PVRL2 intron 18957941 rs12610605 chr19 45370838 G A 7.65E-07 Type 2 diabetes and other traits PVRL2 intron 19734900 rs12610605 chr19 45370838 G A 1.59E-07 Alzheimer's disease (late onset) PVRL2 intron 20885792 rs12610605 chr19 45370838 G A 4.84E-04 Alzheimer's disease (late onset) PVRL2 intron 21379329 rs12610605 chr19 45370838 G A 2.90E-13 Alzheimer's disease (late onset) PVRL2 intron 21460841 rs12610605 chr19 45370838 G A 1.38E-13 Alzheimer's disease (late onset) PVRL2 intron 23565137 rs12610605 chr19 45370838 G A 1.40E-16 Alzheimer's disease (late onset) PVRL2 intron 23565137 rs12610605 chr19 45370838 G A 3.48E-11 Alzheimer's disease (late onset) PVRL2 intron 23565137 rs12610605 chr19 45370838 G A 1.40E-04 Alzheimer's disease PVRL2 intron 24755620 rs416041 chr19 45370854 G A 4.49E-10 Alzheimer's disease (late onset) PVRL2 intron 21460841 rs416041 chr19 45370854 G A 1.76E-04 Alzheimer's disease PVRL2 intron 22005930 rs416041 chr19 45370854 G A 0.0000675 Triglycerides PVRL2 intron 23063622 rs416041 chr19 45370854 G A 3.78E-05 Alzheimer's disease PVRL2 intron 24755620 rs4803766 chr19 45371168 G A 0.00000011 LDL cholesterol PVRL2 intron 23063622 rs8104483 chr19 45372354 T G 4.42E-04 Alzheimer's disease PVRL2 intron 17998437 rs8104483 chr19 45372354 T G 0.000000383 Cholesterol,total PVRL2 intron 23063622 rs8104483 chr19 45372354 T G 2.66E-09 LDL cholesterol PVRL2 intron 23063622 rs395908 chr19 45373565 G A 3.10E-05 Response to statin therapy PVRL2 intron 22368281 rs519113 chr19 45376284 C G 1.25E-11 Lipid levels PVRL2 intron 19913121 rs519113 chr19 45376284 C G 2.14E-08 Lipid levels PVRL2 intron 19913121 rs519113 chr19 45376284 C G 8.00E-11 HDL cholesterol PVRL2 intron 21909109 rs519113 chr19 45376284 C G 5.74E-35 LDL cholesterol PVRL2 intron 23063622 rs519113 chr19 45376284 C G 9.62E-23 Cholesterol,total PVRL2 intron 23063622 rs519113 chr19 45376284 C G 5.00E-39 Alzheimer's disease (late onset) PVRL2 intron 23565137 rs519113 chr19 45376284 C G 5.10E-39 Alzheimer's disease (late onset) PVRL2 intron 23565137 rs2075642 chr19 45377467 G A 1.19E-10 LDL cholesterol PVRL2 intron 23063622 rs2075642 chr19 45377467 G A 2.19E-09 Cholesterol,total PVRL2 intron 23063622 rs387976 chr19 45379060 A C 2.67E-05 Type 2 diabetes and other traits PVRL2 intron 19734900 rs387976 chr19 45379060 A C 6.70E-08 Lipid levels PVRL2 intron 19802338 rs387976 chr19 45379060 A C 1.33E-08 Lipid levels PVRL2 intron 19913121 rs387976 chr19 45379060 A C 1.54E-07 Lipid levels PVRL2 intron 19913121 rs387976 chr19 45379060 A C 1.05E-08 Alzheimer's disease (late onset) PVRL2 intron 21460841 rs387976 chr19 45379060 A C 2.65E-20 Cholesterol,total PVRL2 intron 23063622 rs387976 chr19 45379060 A C 8.57E-24 LDL cholesterol PVRL2 intron 23063622 rs11667640 chr19 45379791 C T 2.34E-05 Type 2 diabetes and other traits PVRL2 intron 19734900 rs11667640 chr19 45379791 C T 2.01E-04 Alzheimer's disease (late onset) PVRL2 intron 21379329 rs11667640 chr19 45379791 C T 2.38E-08 Alzheimer's disease PVRL2 intron 21627779 rs6859 chr19 45382034 A G 6.00E-14 Alzheimer's disease PVRL2 UTR-3 18823527 rs6859 chr19 45382034 A G 1.64E-09 Triglycerides PVRL2 UTR-3 19060911 rs6859 chr19 45382034 A G 5.50E-34 Alzheimer's disease PVRL2 UTR-3 19136949 rs6859 chr19 45382034 A G 6.95E-41 Type 2 diabetes and other traits PVRL2 UTR-3 19734900 rs6859 chr19 45382034 A G 4.95E-15 Alzheimer's disease PVRL2 UTR-3 19734903 rs6859 chr19 45382034 A G 3.90E-12 Lipid levels PVRL2 UTR-3 19802338 rs6859 chr19 45382034 A G 4.40E-09 Lipid levels PVRL2 UTR-3 19802338 rs6859 chr19 45382034 A G 1.49E-10 Lipid levels PVRL2 UTR-3 19913121 rs6859 chr19 45382034 A G 7.83E-10 Lipid levels PVRL2 UTR-3 19913121 rs6859 chr19 45382034 A G 1.00E-07 Alzheimer's disease (late onset) PVRL2 UTR-3 20885792 rs6859 chr19 45382034 A G 9.92E-24 Alzheimer's disease (late onset) PVRL2 UTR-3 21379329 rs6859 chr19 45382034 A G 2.89E-50 Alzheimer's disease (late onset) PVRL2 UTR-3 21460841 rs6859 chr19 45382034 A G 1.27E-13 Alzheimer's disease PVRL2 UTR-3 22005930 rs6859 chr19 45382034 A G 5.00E-07 Alzheimer's disease PVRL2 UTR-3 22159054 rs6859 chr19 45382034 A G 2.47E-29 Alzheimer's disease PVRL2 UTR-3 22832961 rs6859 chr19 45382034 A G 0.0000802 HDL cholesterol PVRL2 UTR-3 23063622 rs6859 chr19 45382034 A G 4.84E-12 LDL cholesterol (male) PVRL2 UTR-3 23063622 rs6859 chr19 45382034 A G 4.85E-25 Cholesterol,total PVRL2 UTR-3 23063622 rs6859 chr19 45382034 A G 5.81E-32 LDL cholesterol PVRL2 UTR-3 23063622 rs6859 chr19 45382034 A G 8.11E-20 LDL cholesterol (female) PVRL2 UTR-3 23063622 rs6859 chr19 45382034 A G 7.87E-28 Alzheimer's disease PVRL2 UTR-3 24755620 rs11669338 chr19 45382984 T G 1.20E-09 Alzheimer's disease PVRL2 intron 19734903 rs11673139 chr19 45383037 A T 1.20E-09 Alzheimer's disease PVRL2 intron 19734903 rs11673139 chr19 45383037 A T 6.93E-16 Alzheimer's disease (late onset) PVRL2 intron 21460841 rs11673139 chr19 45383037 A T 9.90E-12 Alzheimer's disease PVRL2 intron 22832961 rs11673139 chr19 45383037 A T 7.78E-08 Triglycerides PVRL2 intron 23063622 rs3852861 chr19 45383061 G T 9.50E-06 Alzheimer's disease PVRL2 intron 19734903 rs3852861 chr19 45383061 G T 2.29E-19 Alzheimer's disease (late onset) PVRL2 intron 21460841 rs3852861 chr19 45383061 G T 7.64E-11 Alzheimer's disease PVRL2 intron 22832961 rs3852861 chr19 45383061 G T 5.32E-11 Alzheimer's disease PVRL2 intron 24755620 rs3745150 chr19 45385759 G C 2.00E-16 Alzheimer's disease PVRL2 intron 19734903 rs3745150 chr19 45385759 G C 6.75E-31 Alzheimer's disease (late onset) PVRL2 intron 21460841 rs3745150 chr19 45385759 G C 1.24E-17 Alzheimer's disease PVRL2 intron 22832961 rs12972156 chr19 45387459 C G 1.28E-10 Metabolite levels PVRL2 intron 22286219 rs12972156 chr19 45387459 C G 2.31E-15 Alzheimer's disease biomarkers PVRL2 intron 23562540 rs12972156 chr19 45387459 C G 3.03E-15 Alzheimer's disease biomarkers PVRL2 intron 23562540 rs12972156 chr19 45387459 C G 6.35E-37 Alzheimer's disease biomarkers PVRL2 intron 23562540 rs12972970 chr19 45387596 G A 1.08E-10 Metabolite levels PVRL2 intron 22286219 rs12972970 chr19 45387596 G A 1.28E-15 Alzheimer's disease biomarkers PVRL2 intron 23562540 rs12972970 chr19 45387596 G A 3.74E-40 Alzheimer's disease biomarkers PVRL2 intron 23562540 rs12972970 chr19 45387596 G A 8.24E-16 Alzheimer's disease biomarkers PVRL2 intron 23562540 rs34342646 chr19 45388130 G A 7.72E-11 Metabolite levels PVRL2 intron 22286219 rs34342646 chr19 45388130 G A 0.0000017 Cholesterol,total PVRL2 intron 23063622 rs34342646 chr19 45388130 G A 1.17E-15 Alzheimer's disease biomarkers PVRL2 intron 23562540 rs34342646 chr19 45388130 G A 4.17E-40 Alzheimer's disease biomarkers PVRL2 intron 23562540 rs34342646 chr19 45388130 G A 5.54E-16 Alzheimer's disease biomarkers PVRL2 intron 23562540 rs283813 chr19 45389174 T A 7.20E-07 Alzheimer's disease PVRL2 intron 19734903 rs283813 chr19 45389174 T A 1.85E-08 Lipid levels PVRL2 intron 19913121 rs283813 chr19 45389174 T A 2.61E-08 Lipid levels PVRL2 intron 19913121 rs283813 chr19 45389174 T A 5.60E-09 Cardiovascular disease risk factors PVRL2 intron 21943158 rs283813 chr19 45389174 T A 0.0000409 Triglycerides in females PVRL2 intron 23063622 rs283813 chr19 45389174 T A 1.32E-15 Triglycerides in males PVRL2 intron 23063622 rs283813 chr19 45389174 T A 4.51E-18 Triglycerides PVRL2 intron 23063622 rs283813 chr19 45389174 T A 7.20E-11 Cholesterol,total PVRL2 intron 23063622 rs283813 chr19 45389174 T A 8.86E-40 LDL cholesterol PVRL2 intron 23063622 rs283813 chr19 45389174 T A 0.00000036 Cholesterol,total PVRL2 intron 23236364 rs283813 chr19 45389174 T A 7.27E-12 LDL cholesterol PVRL2 intron 23236364 rs7254892 chr19 45389596 G A 1.30E-10 Metabolic syndrome phenotype PVRL2 intron 22022282 rs7254892 chr19 45389596 G A 2.00E-11 Metabolic syndrome phenotype PVRL2 intron 22022282 rs7254892 chr19 45389596 G A 5.52E-17 Metabolite levels PVRL2 intron 22286219 rs7254892 chr19 45389596 G A 5.30E-13 Sphingolipid levels PVRL2 intron 22359512 rs6857 chr19 45392254 C T 5.50E-22 Lipid levels PVRL2 UTR-3 18193043 rs6857 chr19 45392254 C T 2.00E-16 Alzheimer's disease PVRL2 UTR-3 19734903 rs6857 chr19 45392254 C T 1.50E-05 Response to statin therapy PVRL2 UTR-3 20339536 rs6857 chr19 45392254 C T 2.60E-44 Alzheimer's disease PVRL2 UTR-3 21098978 rs6857 chr19 45392254 C T 1.05E-230 Alzheimer's disease (late onset) PVRL2 UTR-3 21460841 rs6857 chr19 45392254 C T 1.43E-15 Lipoprotein-associated phospholipase A2 activity and mass PVRL2 UTR-3 22003152 rs6857 chr19 45392254 C T 1.25E-51 Alzheimer's disease PVRL2 UTR-3 22005930 rs6857 chr19 45392254 C T 2.00E-10 Alzheimer's disease (age of onset) PVRL2 UTR-3 22005931 rs6857 chr19 45392254 C T 5.89E-06 Response to statin therapy PVRL2 UTR-3 22368281 rs6857 chr19 45392254 C T 4.64E-134 Alzheimer's disease PVRL2 UTR-3 22832961 rs6857 chr19 45392254 C T 0.000000415 HDL cholesterol PVRL2 UTR-3 23063622 rs6857 chr19 45392254 C T 1.49E-11 Cholesterol,total PVRL2 UTR-3 23063622 rs6857 chr19 45392254 C T 3.71E-10 LDL cholesterol PVRL2 UTR-3 23063622 rs6857 chr19 45392254 C T 1.00E-06 Age-related macular degeneration PVRL2 UTR-3 23326517 rs6857 chr19 45392254 C T 1.00E-10 Alzheimer's disease biomarkers PVRL2 UTR-3 23419831 rs6857 chr19 45392254 C T 3.73E-20 C-reactive protein PVRL2 UTR-3 23844046 rs71352238 chr19 45394336 T C 2.90E-04 Response to statin therapy (LDL-C) TOMM40 nearGene-5 22331829 rs71352238 chr19 45394336 T C 0.0000017 Cholesterol,total TOMM40 nearGene-5 23063622 rs71352238 chr19 45394336 T C 1.78E-16 Alzheimer's disease biomarkers TOMM40 nearGene-5 23562540 rs71352238 chr19 45394336 T C 2.46E-16 Alzheimer's disease biomarkers TOMM40 nearGene-5 23562540 rs71352238 chr19 45394336 T C 5.68E-39 Alzheimer's disease biomarkers TOMM40 nearGene-5 23562540 rs157580 chr19 45395266 G A 1.24E-05 Cholesterol TOMM40 intron 17255346 rs157580 chr19 45395266 G A 5.00E-08 LDL cholesterol TOMM40 intron 19060910 rs157580 chr19 45395266 G A 2.00E-19 LDL cholesterol TOMM40 intron 19060911 rs157580 chr19 45395266 G A 4.00E-07 HDL cholesterol TOMM40 intron 19060911 rs157580 chr19 45395266 G A 1.00E-40 Alzheimer's disease TOMM40 intron 19125160 rs157580 chr19 45395266 G A 7.40E-42 Alzheimer's disease TOMM40 intron 19136949 rs157580 chr19 45395266 G A 9.62E-54 Type 2 diabetes and other traits TOMM40 intron 19734900 rs157580 chr19 45395266 G A 2.00E-16 Alzheimer's disease TOMM40 intron 19734903 rs157580 chr19 45395266 G A 1.03E-07 Lipid levels TOMM40 intron 19913121 rs157580 chr19 45395266 G A 4.66E-07 Lipid levels TOMM40 intron 19913121 rs157580 chr19 45395266 G A 3.79E-10 Lipid levels TOMM40 intron 19936222 rs157580 chr19 45395266 G A 7.50E-06 Response to statin therapy TOMM40 intron 20339536 rs157580 chr19 45395266 G A 7.78E-13 Alzheimer's disease (late onset) TOMM40 intron 20885792 rs157580 chr19 45395266 G A 1.00E-06 Alzheimer's disease biomarkers TOMM40 intron 21123754 rs157580 chr19 45395266 G A 2.00E-19 Coronary heart disease TOMM40 intron 21347282 rs157580 chr19 45395266 G A 5.51E-23 Alzheimer's disease (late onset) TOMM40 intron 21379329 rs157580 chr19 45395266 G A 2.91E-65 Alzheimer's disease (late onset) TOMM40 intron 21460841 rs157580 chr19 45395266 G A 8.00E-89 Alzheimer's disease TOMM40 intron 21627779 rs157580 chr19 45395266 G A 1.61E-05 Alzheimer's disease (age of onset) TOMM40 intron 22005931 rs157580 chr19 45395266 G A 1.02E-15 Metabolite levels TOMM40 intron 22286219 rs157580 chr19 45395266 G A 1.01E-36 Alzheimer's disease TOMM40 intron 22832961 rs157580 chr19 45395266 G A 1.30E-12 Total cholesterol in males TOMM40 intron 23063622 rs157580 chr19 45395266 G A 1.44E-09 Triglycerides TOMM40 intron 23063622 rs157580 chr19 45395266 G A 2.34E-33 LDL cholesterol TOMM40 intron 23063622 rs157580 chr19 45395266 G A 2.94E-10 LDL cholesterol (male) TOMM40 intron 23063622 rs157580 chr19 45395266 G A 3.67E-26 Total cholesterol in females TOMM40 intron 23063622 rs157580 chr19 45395266 G A 4.02E-27 LDL cholesterol (female) TOMM40 intron 23063622 rs157580 chr19 45395266 G A 4.41E-36 Cholesterol,total TOMM40 intron 23063622 rs157580 chr19 45395266 G A 1.76E-08 C-reactive protein TOMM40 intron 23844046 rs157580 chr19 45395266 G A 9.60E-35 Alzheimer's disease TOMM40 intron 24755620 rs157580 chr19 45395266 G A 4.96E-08 LDL lipoproteins TOMM40 intron pha002902 rs2075650 chr19 45395619 A G 5.23E-06 Cholesterol TOMM40 intron 17255346 rs2075650 chr19 45395619 A G 7.10E-14 LDL cholesterol TOMM40 intron 18262040 rs2075650 chr19 45395619 A G 1.00E-07 C-reactive protein TOMM40 intron 18439552 rs2075650 chr19 45395619 A G 3.00E-19 Cholesterol,total TOMM40 intron 19060911 rs2075650 chr19 45395619 A G 3.70E-120 Alzheimer's disease TOMM40 intron 19136949 rs2075650 chr19 45395619 A G 1.75E-157 Type 2 diabetes and other traits TOMM40 intron 19734900 rs2075650 chr19 45395619 A G 2.00E-157 Alzheimer's disease TOMM40 intron 19734902 rs2075650 chr19 45395619 A G 2.00E-16 Alzheimer's disease TOMM40 intron 19734903 rs2075650 chr19 45395619 A G 1.30E-12 Lipid levels TOMM40 intron 19802338 rs2075650 chr19 45395619 A G 1.14E-14 Lipid levels TOMM40 intron 19913121 rs2075650 chr19 45395619 A G 8.38E-18 Lipid levels TOMM40 intron 19913121 rs2075650 chr19 45395619 A G 3.00E-11 Alzheimer's disease TOMM40 intron 20061627 rs2075650 chr19 45395619 A G 3.10E-06 Response to statin therapy TOMM40 intron 20339536 rs2075650 chr19 45395619 A G 1.00E-295 Alzheimer's disease TOMM40 intron 20460622 rs2075650 chr19 45395619 A G 5.00E-36 Alzheimer's disease (late onset) TOMM40 intron 20885792 rs2075650 chr19 45395619 A G 3.00E-07 AB1-42 levels TOMM40 intron 20932310 rs2075650 chr19 45395619 A G 7.40E-52 Alzheimer's disease TOMM40 intron 21098978 rs2075650 chr19 45395619 A G 1.00E-06 Alzheimer's disease biomarkers TOMM40 intron 21123754 rs2075650 chr19 45395619 A G 2.95E-81 Alzheimer's disease (late onset) TOMM40 intron 21379329 rs2075650 chr19 45395619 A G 3.00E-17 Longevity TOMM40 intron 21418511 rs2075650 chr19 45395619 A G 2.66E-207 Alzheimer's disease (late onset) TOMM40 intron 21460841 rs2075650 chr19 45395619 A G 2.00E-14 Cardiovascular disease risk factors TOMM40 intron 21943158 rs2075650 chr19 45395619 A G 4.00E-08 Cardiovascular disease risk factors TOMM40 intron 21943158 rs2075650 chr19 45395619 A G 3.20E-08 Coronary heart disease TOMM40 intron 21966275 rs2075650 chr19 45395619 A G 8.07E-15 Lipoprotein-associated phospholipase A2 activity and mass TOMM40 intron 22003152 rs2075650 chr19 45395619 A G 8.94E-46 Alzheimer's disease TOMM40 intron 22005930 rs2075650 chr19 45395619 A G 4.11E-08 Alzheimer's disease (age of onset) TOMM40 intron 22005931 rs2075650 chr19 45395619 A G 1.80E-157 Prion diseases TOMM40 intron 22210626 rs2075650 chr19 45395619 A G 2.36E-10 Longevity TOMM40 intron 22279548 rs2075650 chr19 45395619 A G 0.000527 Aging TOMM40 intron 22445811 rs2075650 chr19 45395619 A G 5.41E-06 Vitiligo TOMM40 intron 22561518 rs2075650 chr19 45395619 A G 8.00E-08 Age-related macular degeneration TOMM40 intron 22694956 rs2075650 chr19 45395619 A G 1.66E-113 Alzheimer's disease TOMM40 intron 22832961 rs2075650 chr19 45395619 A G 2.19E-09 Composite episodic memory score TOMM40 intron 22865056 rs2075650 chr19 45395619 A G 0.000737 Body mass index (females) TOMM40 intron 23001569 rs2075650 chr19 45395619 A G 5.99E-11 Body mass index TOMM40 intron 23001569 rs2075650 chr19 45395619 A G 1.11E-13 Triglycerides TOMM40 intron 23063622 rs2075650 chr19 45395619 A G 2.40E-55 Cholesterol,total TOMM40 intron 23063622 rs2075650 chr19 45395619 A G 4.30E-23 HDL cholesterol TOMM40 intron 23063622 rs2075650 chr19 45395619 A G 5.53E-59 LDL cholesterol TOMM40 intron 23063622 rs2075650 chr19 45395619 A G 0.000013 Apolipoprotein B levels response after 40mg daily simvastatin treatment TOMM40 intron 23100282 rs2075650 chr19 45395619 A G 0.000036 LDL cholesterol response after 40mg daily simvastatin treatment TOMM40 intron 23100282 rs2075650 chr19 45395619 A G 1.60E-38 LDL cholesterol TOMM40 intron 23100282 rs2075650 chr19 45395619 A G 3.70E-31 Apolipoprotein B levels TOMM40 intron 23100282 rs2075650 chr19 45395619 A G 1.60E-38 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) TOMM40 intron 23103227 rs2075650 chr19 45395619 A G 1.08E-41 Coronary artery disease (CAD) (females) TOMM40 intron 23202125 rs2075650 chr19 45395619 A G 1.10E-16 HDL cholesterol TOMM40 intron 23202125 rs2075650 chr19 45395619 A G 1.31E-19 Triglycerides TOMM40 intron 23202125 rs2075650 chr19 45395619 A G 1.33E-84 Cholesterol,total TOMM40 intron 23202125 rs2075650 chr19 45395619 A G 3.76E-110 LDL cholesterol TOMM40 intron 23202125 rs2075650 chr19 45395619 A G 4.56E-81 Coronary artery disease (CAD) age <=50 TOMM40 intron 23202125 rs2075650 chr19 45395619 A G 5.86E-11 Coronary artery disease TOMM40 intron 23202125 rs2075650 chr19 45395619 A G 6.54E-91 Coronary artery disease with myocardial infarction TOMM40 intron 23202125 rs2075650 chr19 45395619 A G 6.72E-81 Coronary artery disease (CAD) (males) TOMM40 intron 23202125 rs2075650 chr19 45395619 A G 7.10E-71 Coronary artery disease (CAD) age >50 TOMM40 intron 23202125 rs2075650 chr19 45395619 A G 2.00E-08 Cognitive decline TOMM40 intron 23207651 rs2075650 chr19 45395619 A G 1.00E-06 Age-related macular degeneration TOMM40 intron 23326517 rs2075650 chr19 45395619 A G 2.74E-22 C-reactive protein TOMM40 intron 23505291 rs2075650 chr19 45395619 A G 2.21E-39 Alzheimer's disease biomarkers TOMM40 intron 23562540 rs2075650 chr19 45395619 A G 4.29E-16 Alzheimer's disease biomarkers TOMM40 intron 23562540 rs2075650 chr19 45395619 A G 4.92E-06 Alzheimer's disease biomarkers TOMM40 intron 23562540 rs2075650 chr19 45395619 A G 2.00E-21 C-reactive protein TOMM40 intron 23844046 rs2075650 chr19 45395619 A G 9.00E-116 Alzheimer's disease TOMM40 intron 24755620 rs2075650 chr19 45395619 A G 4.00E-13 Alzheimer's disease TOMM40 intron 24770881 rs2075650 chr19 45395619 A G 1.05E-05 LDL lipoproteins TOMM40 intron pha002902 rs2075650 chr19 45395619 A G 1.81E-05 Triglycerides TOMM40 intron pha002904 rs157581 chr19 45395714 T C 0.000000886 Triglycerides TOMM40 cds-synon 23063622 rs34404554 chr19 45395909 C G 1.02E-10 Metabolite levels TOMM40 intron 22286219 rs34404554 chr19 45395909 C G 1.01E-39 Alzheimer's disease biomarkers TOMM40 intron 23562540 rs34404554 chr19 45395909 C G 1.33E-16 Alzheimer's disease biomarkers TOMM40 intron 23562540 rs34404554 chr19 45395909 C G 3.58E-16 Alzheimer's disease biomarkers TOMM40 intron 23562540 rs34404554 chr19 45395909 C G 1.82E-12 Alzheimer's disease TOMM40 intron 24770881 rs11556505 chr19 45396144 C T 5.02E-11 Metabolite levels TOMM40 cds-synon 22286219 rs11556505 chr19 45396144 C T 1.06E-39 Alzheimer's disease biomarkers TOMM40 cds-synon 23562540 rs11556505 chr19 45396144 C T 1.68E-16 Alzheimer's disease biomarkers TOMM40 cds-synon 23562540 rs11556505 chr19 45396144 C T 3.48E-16 Alzheimer's disease biomarkers TOMM40 cds-synon 23562540 rs11556505 chr19 45396144 C T 1.53E-12 Alzheimer's disease TOMM40 cds-synon 24770881 rs157582 chr19 45396219 C T 3.55E-45 Alzheimer's disease (late onset) TOMM40 intron 20885792 rs157582 chr19 45396219 C T 2.16E-201 Alzheimer's disease (late onset) TOMM40 intron 21460841 rs157582 chr19 45396219 C T 9.28E-52 Alzheimer's disease TOMM40 intron 22005930 rs157582 chr19 45396219 C T 2.74E-09 Alzheimer's disease (age of onset) TOMM40 intron 22005931 rs157582 chr19 45396219 C T 1.00E-08 Metabolic syndrome TOMM40 intron 22399527 rs157582 chr19 45396219 C T 7.37E-115 Alzheimer's disease TOMM40 intron 22832961 rs157582 chr19 45396219 C T 7.57E-14 C-reactive protein TOMM40 intron 23844046 rs59007384 chr19 45396665 G T 7.00E-09 Alzheimer's disease biomarkers TOMM40 intron 23419831 rs157583 chr19 45396673 G T 7.20E-06 Alzheimer's disease TOMM40 intron 19734903 rs157584 chr19 45396899 T C 0.00006432 Sarcoidosis TOMM40 intron 22952805 rs157584 chr19 45396899 T C 2.00E-06 Alzheimer's disease (late onset) TOMM40 intron 23565137 rs157584 chr19 45396899 T C 5.54E-05 Alzheimer's disease (late onset) TOMM40 intron 23565137 rs157585 chr19 45397512 A C 0.000005064 Sarcoidosis TOMM40 intron 22952805 rs157588 chr19 45398264 C T 0.000008173 Sarcoidosis TOMM40 intron 22952805 rs157588 chr19 45398264 C T 1.18E-06 Alzheimer's disease (late onset) TOMM40 intron 23565137 rs157588 chr19 45398264 C T 3.34E-05 Alzheimer's disease (late onset) TOMM40 intron 23565137 rs11668327 chr19 45398633 G C 1.12E-11 Metabolite levels TOMM40 intron 22286219 rs157590 chr19 45398716 A C 0.00003321 Sarcoidosis TOMM40 intron 22952805 rs157590 chr19 45398716 A C 2.83E-05 Alzheimer's disease (late onset) TOMM40 intron 23565137 rs157590 chr19 45398716 A C 9.28E-07 Alzheimer's disease (late onset) TOMM40 intron 23565137 rs76366838 chr19 45399896 G A 7.72E-08 Cholesterol,total TOMM40 intron 23063622 rs61679753 chr19 45400747 T A 5.58E-17 Metabolite levels TOMM40 intron 22286219 rs8106922 chr19 45401666 A G 7.60E-27 Alzheimer's disease TOMM40 intron 19136949 rs8106922 chr19 45401666 A G 5.37E-39 Type 2 diabetes and other traits TOMM40 intron 19734900 rs8106922 chr19 45401666 A G 2.00E-16 Alzheimer's disease TOMM40 intron 19734903 rs8106922 chr19 45401666 A G 2.94E-12 Alzheimer's disease (late onset) TOMM40 intron 20885792 rs8106922 chr19 45401666 A G 7.09E-22 Alzheimer's disease (late onset) TOMM40 intron 21379329 rs8106922 chr19 45401666 A G 4.24E-45 Alzheimer's disease (late onset) TOMM40 intron 21460841 rs8106922 chr19 45401666 A G 5.58E-62 Alzheimer's disease TOMM40 intron 21627779 rs8106922 chr19 45401666 A G 2.03E-10 Alzheimer's disease TOMM40 intron 22005930 rs8106922 chr19 45401666 A G 0.00000575 LDL cholesterol TOMM40 intron 22629316 rs8106922 chr19 45401666 A G 2.16E-28 Alzheimer's disease TOMM40 intron 22832961 rs8106922 chr19 45401666 A G 4.41E-11 LDL cholesterol TOMM40 intron 23063622 rs8106922 chr19 45401666 A G 0.0000143 C-reactive protein TOMM40 intron 23505291 rs8106922 chr19 45401666 A G 1.17E-25 Alzheimer's disease TOMM40 intron 24755620 rs8106922 chr19 45401666 A G 6.64E-05 Inflammation TOMM40 intron pha002897 rs115881343 chr19 45403216 C T 4.00E-09 Cognitive decline (age-related) TOMM40 intron 24468470 rs1160985 chr19 45403412 C T 4.00E-13 C-reactive protein TOMM40 intron 22939635 rs1160985 chr19 45403412 C T 1.27E-14 Alzheimer's disease (late onset) TOMM40 intron 23565137 rs1160985 chr19 45403412 C T 7.52E-09 Alzheimer's disease (late onset) TOMM40 intron 23565137 rs1160985 chr19 45403412 C T 9.61E-07 Alzheimer's disease (late onset) TOMM40 intron 23565137 rs1160985 chr19 45403412 C T 2.00E-21 LDL cholesterol TOMM40 intron 23726366 rs1160985 chr19 45403412 C T 4.00E-13 Lipid traits TOMM40 intron 24386095 rs1160985 chr19 45403412 C T 1.19E-05 Intracerebral hemorrhage TOMM40 intron 24656865 rs760136 chr19 45403858 A G 1.13E-06 Alzheimer's disease (late onset) TOMM40 intron 23565137 rs760136 chr19 45403858 A G 1.52E-08 Alzheimer's disease (late onset) TOMM40 intron 23565137 rs760136 chr19 45403858 A G 1.30E-05 Intracerebral hemorrhage TOMM40 intron 24656865 rs741780 chr19 45404431 T C 1.07E-06 Alzheimer's disease (late onset) TOMM40 intron 23565137 rs741780 chr19 45404431 T C 1.43E-08 Alzheimer's disease (late onset) TOMM40 intron 23565137 rs741780 chr19 45404431 T C 1.23E-05 Intracerebral hemorrhage TOMM40 intron 24656865 rs405697 chr19 45404691 A G 5.42E-34 Alzheimer's disease (late onset) TOMM40 intron 21460841 rs405697 chr19 45404691 A G 1.97E-18 Alzheimer's disease TOMM40 intron 22832961 rs1038025 chr19 45404972 T C 1.11E-06 Alzheimer's disease (late onset) TOMM40 intron 23565137 rs1038025 chr19 45404972 T C 1.49E-08 Alzheimer's disease (late onset) TOMM40 intron 23565137 rs1038025 chr19 45404972 T C 1.21E-05 Intracerebral hemorrhage TOMM40 intron 24656865 rs1038026 chr19 45405062 A G 1.10E-06 Alzheimer's disease (late onset) TOMM40 intron 23565137 rs1038026 chr19 45405062 A G 1.47E-08 Alzheimer's disease (late onset) TOMM40 intron 23565137 rs1038026 chr19 45405062 A G 1.24E-05 Intracerebral hemorrhage TOMM40 intron 24656865 rs10119 chr19 45406673 G A 2.00E-16 Alzheimer's disease TOMM40 UTR-3 19734903 rs10119 chr19 45406673 G A 5.29E-143 Alzheimer's disease (late onset) TOMM40 UTR-3 21460841 rs10119 chr19 45406673 G A 4.64E-06 Alzheimer's disease (age of onset) TOMM40 UTR-3 22005931 rs10119 chr19 45406673 G A 3.14E-85 Alzheimer's disease TOMM40 UTR-3 22832961 rs10119 chr19 45406673 G A 0.000000228 Triglycerides TOMM40 UTR-3 23063622 rs10119 chr19 45406673 G A 2.51E-11 C-reactive protein TOMM40 UTR-3 23844046 rs7259620 chr19 45407788 G A 1.15E-06 Alzheimer's disease (late onset) APOE nearGene-5 23565137 rs7259620 chr19 45407788 G A 1.39E-08 Alzheimer's disease (late onset) APOE nearGene-5 23565137 rs7259620 chr19 45407788 G A 8.60E-06 Intracerebral hemorrhage APOE nearGene-5 24656865 rs769446 chr19 45408628 T C 1.42E-16 Metabolite levels APOE nearGene-5 22286219 rs405509 chr19 45408836 T G 5.19E-10 Triglycerides APOE nearGene-5 19060911 rs405509 chr19 45408836 T G 6.20E-27 Alzheimer's disease APOE nearGene-5 19136949 rs405509 chr19 45408836 T G 4.88E-37 Type 2 diabetes and other traits APOE nearGene-5 19734900 rs405509 chr19 45408836 T G 2.00E-16 Alzheimer's disease APOE nearGene-5 19734903 rs405509 chr19 45408836 T G 5.10E-10 Lipid levels APOE nearGene-5 19802338 rs405509 chr19 45408836 T G 1.06E-04 Lipid levels APOE nearGene-5 19913121 rs405509 chr19 45408836 T G 2.80E-10 Lipid levels APOE nearGene-5 19913121 rs405509 chr19 45408836 T G 1.70E-10 Lipid levels APOE nearGene-5 19936222 rs405509 chr19 45408836 T G 2.47E-10 Lipid levels APOE nearGene-5 19936222 rs405509 chr19 45408836 T G 2.70E-08 Lipid levels APOE nearGene-5 19936222 rs405509 chr19 45408836 T G 8.13E-14 Alzheimer's disease (late onset) APOE nearGene-5 20885792 rs405509 chr19 45408836 T G 2.87E-24 Alzheimer's disease (late onset) APOE nearGene-5 21379329 rs405509 chr19 45408836 T G 3.68E-49 Alzheimer's disease (late onset) APOE nearGene-5 21460841 rs405509 chr19 45408836 T G 1.49E-09 Alzheimer's disease APOE nearGene-5 22005930 rs405509 chr19 45408836 T G 5.70E-08 Response to statin therapy APOE nearGene-5 22368281 rs405509 chr19 45408836 T G 1.89E-12 LDL cholesterol APOE nearGene-5 22629316 rs405509 chr19 45408836 T G 3.78E-27 Alzheimer's disease APOE nearGene-5 22832961 rs405509 chr19 45408836 T G 0.00000128 HDL cholesterol APOE nearGene-5 23063622 rs405509 chr19 45408836 T G 2.24E-32 LDL cholesterol APOE nearGene-5 23063622 rs405509 chr19 45408836 T G 3.65E-14 Cholesterol,total APOE nearGene-5 23063622 rs405509 chr19 45408836 T G 0.00000019 LDL cholesterol APOE nearGene-5 23100282 rs405509 chr19 45408836 T G 1.90E-07 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) APOE nearGene-5 23103227 rs405509 chr19 45408836 T G 0.000000136 C-reactive protein APOE nearGene-5 23505291 rs405509 chr19 45408836 T G 2.29E-27 Alzheimer's disease APOE nearGene-5 24755620 rs440446 chr19 45409167 C G 5.60E-23 Triglycerides APOE intron 23063622 rs769449 chr19 45410002 G A 9.00E-21 C-reactive protein APOE intron 18439548 rs769449 chr19 45410002 G A 2.40E-16 Lipid levels APOE intron 19802338 rs769449 chr19 45410002 G A 1.10E-11 Lipid levels APOE intron 19936222 rs769449 chr19 45410002 G A 1.10E-36 Lipid levels APOE intron 19936222 rs769449 chr19 45410002 G A 1.10E-44 Lipid levels APOE intron 19936222 rs769449 chr19 45410002 G A 1.37E-21 Lipid levels APOE intron 19936222 rs769449 chr19 45410002 G A 1.49E-09 Lipid levels APOE intron 19936222 rs769449 chr19 45410002 G A 1.70E-33 Lipid levels APOE intron 19936222 rs769449 chr19 45410002 G A 2.19E-11 Lipid levels APOE intron 19936222 rs769449 chr19 45410002 G A 2.20E-12 Lipid levels APOE intron 19936222 rs769449 chr19 45410002 G A 2.30E-10 Lipid levels APOE intron 19936222 rs769449 chr19 45410002 G A 2.36E-11 Lipid levels APOE intron 19936222 rs769449 chr19 45410002 G A 2.80E-11 Lipid levels APOE intron 19936222 rs769449 chr19 45410002 G A 7.00E-27 Lipid levels APOE intron 19936222 rs769449 chr19 45410002 G A 3.05E-25 Metabolite levels APOE intron 22286219 rs769449 chr19 45410002 G A 1.81E-07 Vitiligo APOE intron 22561518 rs769449 chr19 45410002 G A 0.00000051 Cholesterol,total APOE intron 23063622 rs769449 chr19 45410002 G A 2.00E-16 Alzheimer's disease biomarkers APOE intron 23562540 rs769449 chr19 45410002 G A 2.00E-18 Alzheimer's disease biomarkers APOE intron 23562540 rs769449 chr19 45410002 G A 9.02E-47 Alzheimer's disease biomarkers APOE intron 23562540 rs769449 chr19 45410002 G A 5.00E-07 Lipid traits APOE intron 24023260 rs769449 chr19 45410002 G A 5.00E-19 Cognitive decline (age-related) APOE intron 24468470 rs769450 chr19 45410444 G A 0.000000693 LDL cholesterol APOE intron 22629316 rs769450 chr19 45410444 G A 1.87E-15 LDL cholesterol APOE intron 23063622 rs769450 chr19 45410444 G A 4.22E-09 Cholesterol,total APOE intron 23063622 rs769450 chr19 45410444 G A 0.00000599 C-reactive protein APOE intron 23505291 rs429358 chr19 45411941 T C 1 Drug response to Simvastatin APOE missense 10736278 rs429358 chr19 45411941 T C 1 Drug response to Statins APOE missense 10736278 rs429358 chr19 45411941 T C 1 Drug response to Statins APOE missense 12668918 rs429358 chr19 45411941 T C 1 Drug response to Statins APOE missense 15262670 rs429358 chr19 45411941 T C 1 Drug response to Ritonavir APOE missense 15809899 rs429358 chr19 45411941 T C 1 Drug response to Ritonavir APOE missense 16417409 rs429358 chr19 45411941 T C 1 Drug response to Acitretin APOE missense 16433808 rs429358 chr19 45411941 T C 1 Drug response to Statins APOE missense 17353665 rs429358 chr19 45411941 T C 1 Drug response to Statins APOE missense 17567623 rs429358 chr19 45411941 T C 1 Drug response to Ritonavir APOE missense 17700364 rs429358 chr19 45411941 T C 4.21E-10 Response to statin treatment (atorvastatin),change in cholesterol levels APOE missense 20031582 rs429358 chr19 45411941 T C 1.00E-06 Alzheimer's disease biomarkers APOE missense 21123754 rs429358 chr19 45411941 T C 0.00000102 alzheimer's disease (late onset) APOE missense 22785395 rs429358 chr19 45411941 T C 5.00E-14 Alzheimer's disease biomarkers APOE missense 23419831 rs7412 chr19 45412079 C T 1 Drug response to Simvastatin APOE missense 10736278 rs7412 chr19 45412079 C T 1 Drug response to Statins APOE missense 10736278 rs7412 chr19 45412079 C T 1 Drug response to Statins APOE missense 12668918 rs7412 chr19 45412079 C T 1 Drug response to Statins APOE missense 15262670 rs7412 chr19 45412079 C T 1 Drug response to Ritonavir APOE missense 15809899 rs7412 chr19 45412079 C T 1 Drug response to Ritonavir APOE missense 16417409 rs7412 chr19 45412079 C T 1 Drug response to Acitretin APOE missense 16433808 rs7412 chr19 45412079 C T 1 Drug response to Statins APOE missense 17353665 rs7412 chr19 45412079 C T 1 Drug response to Statins APOE missense 17567623 rs7412 chr19 45412079 C T 1 Drug response to Ritonavir APOE missense 17700365 rs7412 chr19 45412079 C T 5.54E-30 Response to statin treatment (atorvastatin),change in cholesterol levels APOE missense 20031582 rs7412 chr19 45412079 C T 2.00E-05 Coronary heart disease APOE missense 21966275 rs7412 chr19 45412079 C T 3.00E-58 Lipid metabolism phenotypes APOE missense 22286219 rs7412 chr19 45412079 C T 2.00E-47 Response to statin therapy (LDL-C) APOE missense 22331829 rs7412 chr19 45412079 C T 1.52E-71 LDL cholesterol APOE missense 23063622 rs7412 chr19 45412079 C T 1.55E-36 Cholesterol,total APOE missense 23063622 rs7412 chr19 45412079 C T 2.00E-09 LDL cholesterol APOE missense 23067351 rs7412 chr19 45412079 C T 2.10E-215 LDL cholesterol APOE missense 23100282 rs7412 chr19 45412079 C T 2.70E-30 LDL cholesterol response after 40mg daily simvastatin treatment APOE missense 23100282 rs7412 chr19 45412079 C T 4.90E-29 Apolipoprotein B levels response after 40mg daily simvastatin treatment APOE missense 23100282 rs7412 chr19 45412079 C T 5.90E-154 Apolipoprotein B levels APOE missense 23100282 rs7412 chr19 45412079 C T 2.10E-215 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) APOE missense 23103227 rs7412 chr19 45412079 C T 0.000886 Coronary artery disease APOE missense 23202125 rs7412 chr19 45412079 C T 2.00E-30 Lipid traits APOE missense 24023260 rs7412 chr19 45412079 C T 3.00E-53 Lipid traits APOE missense 24023260 rs1065853 chr19 45413233 G T 1.76E-09 LDL cholesterol / / 23696881 rs72654473 chr19 45414399 C A 1.08E-12 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs439401 chr19 45414451 T C 2.00E-09 Triglycerides / / 19060911 rs439401 chr19 45414451 T C 1.60E-31 Alzheimer's disease / / 19136949 rs439401 chr19 45414451 T C 2.65E-23 Type 2 diabetes and other traits / / 19734900 rs439401 chr19 45414451 T C 2.00E-16 Alzheimer's disease / / 19734903 rs439401 chr19 45414451 T C 1.38E-08 Lipid levels / / 19936222 rs439401 chr19 45414451 T C 1.70E-15 Lipid levels / / 19936222 rs439401 chr19 45414451 T C 1.77E-11 Lipid levels / / 19936222 rs439401 chr19 45414451 T C 2.09E-12 Lipid levels / / 19936222 rs439401 chr19 45414451 T C 3.58E-12 Lipid levels / / 19936222 rs439401 chr19 45414451 T C 4.70E-08 Lipid levels / / 19936222 rs439401 chr19 45414451 T C 5.94E-10 Lipid levels / / 19936222 rs439401 chr19 45414451 T C 6.18E-10 Lipid levels / / 19936222 rs439401 chr19 45414451 T C 7.30E-16 Lipid levels / / 19936222 rs439401 chr19 45414451 T C 4.10E-04 Blood cell counts and other traits / / 20139978 rs439401 chr19 45414451 T C 1.00E-30 Triglycerides / / 20686565 rs439401 chr19 45414451 T C 3.80E-12 Alzheimer's disease (late onset) / / 20885792 rs439401 chr19 45414451 T C 1.00E-06 Alzheimer's disease biomarkers / / 21123754 rs439401 chr19 45414451 T C 4.11E-15 Alzheimer's disease (late onset) / / 21379329 rs439401 chr19 45414451 T C 1.00E-08 HDL Cholesterol - Triglycerides (HDLC-TG) / / 21386085 rs439401 chr19 45414451 T C 1.06E-49 Alzheimer's disease (late onset) / / 21460841 rs439401 chr19 45414451 T C 1.79E-48 Alzheimer's disease / / 21627779 rs439401 chr19 45414451 T C 2.70E-07 Alzheimer's disease (age of onset) / / 22005931 rs439401 chr19 45414451 T C 0.0000811 Triglycerides (females) / / 22629316 rs439401 chr19 45414451 T C 1.85E-15 Triglycerides / / 22629316 rs439401 chr19 45414451 T C 3.78E-15 Triglycerides (males) / / 22629316 rs439401 chr19 45414451 T C 4.00E-34 Alzheimer's disease / / 22832961 rs439401 chr19 45414451 T C 0.000148 HDL cholesterol / / 23063622 rs439401 chr19 45414451 T C 2.12E-33 Triglycerides / / 23063622 rs439401 chr19 45414451 T C 2.53E-08 Cholesterol,total / / 23063622 rs439401 chr19 45414451 T C 2.73E-33 Triglycerides / / 23063622 rs439401 chr19 45414451 T C 8.78E-04 Lipid traits / / 24386095 rs439401 chr19 45414451 T C 8.82E-29 Alzheimer's disease / / 24755620 rs439401 chr19 45414451 T C 1.74E-05 Triglycerides / / pha003080 rs445925 chr19 45415640 G A 2.90E-05 Response to statin therapy / / 20339536 rs445925 chr19 45415640 G A 9.00E-19 Cardiovascular disease risk factors / / 20838585 rs445925 chr19 45415640 G A 2.00E-08 Carotid intima media thickness / / 21909108 rs445925 chr19 45415640 G A 4.00E-06 Carotid intima media thickness / / 21909108 rs445925 chr19 45415640 G A 2.80E-30 LDL cholesterol / / 21977987 rs445925 chr19 45415640 G A 3.28E-10 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs445925 chr19 45415640 G A 1.30E-35 Metabolic syndrome phenotype / / 22022282 rs445925 chr19 45415640 G A 3.80E-09 Metabolic syndrome phenotype / / 22022282 rs445925 chr19 45415640 G A 3.80E-14 Metabolic syndrome phenotype / / 22022282 rs445925 chr19 45415640 G A 4.30E-05 Metabolic syndrome phenotype / / 22022282 rs445925 chr19 45415640 G A 5.10E-54 Metabolic syndrome phenotype / / 22022282 rs445925 chr19 45415640 G A 6.42E-12 Metabolite levels / / 22286219 rs445925 chr19 45415640 G A 9.20E-26 Sphingolipid levels / / 22359512 rs445925 chr19 45415640 G A 1.19E-13 Response to statin therapy / / 22368281 rs445925 chr19 45415640 G A 6.00E-42 Metabolite levels (atherosclerosis) / / 22916037 rs445925 chr19 45415640 G A 2.00E-14 Apolipoprotein Levels / / 23031429 rs445925 chr19 45415640 G A 4.00E-11 Apolipoprotein Levels / / 23031429 rs445925 chr19 45415640 G A 1.00E-56 Lipoprotein-associated phospholipase A2 activity and mass / / 23118302 rs445925 chr19 45415640 G A 1.99E-41 Coronary artery disease (CAD) age <=50 / / 23202125 rs445925 chr19 45415640 G A 2.01E-71 Coronary artery disease (CAD) (males) / / 23202125 rs445925 chr19 45415640 G A 2.50E-71 Coronary artery disease with myocardial infarction / / 23202125 rs445925 chr19 45415640 G A 3.26E-31 Coronary artery disease (CAD) age >50 / / 23202125 rs445925 chr19 45415640 G A 9.42E-11 Coronary artery disease / / 23202125 rs445925 chr19 45415640 G A 9.52E-31 Coronary artery disease (CAD) (females) / / 23202125 rs445925 chr19 45415640 G A 0.000036 LDL cholesterol / / 23696881 rs445925 chr19 45415640 G A 5.00E-23 Blood metabolite ratios / / 24816252 rs7256200 chr19 45415935 G T 3.41E-25 Metabolite levels APOC1 nearGene-5 22286219 rs483082 chr19 45416178 G T 3.41E-15 Metabolite levels APOC1 nearGene-5 22286219 rs389261 chr19 45420343 G A 0.000000323 LDL cholesterol (male) APOC1 intron 22629316 rs389261 chr19 45420343 G A 1.10E-14 LDL cholesterol APOC1 intron 22629316 rs389261 chr19 45420343 G A 2.92E-09 LDL cholesterol (female) APOC1 intron 22629316 rs389261 chr19 45420343 G A 1.70E-17 LDL cholesterol APOC1 intron 23236364 rs389261 chr19 45420343 G A 2.07E-11 Cholesterol,total APOC1 intron 23236364 rs12721046 chr19 45421254 G A 1.01E-17 Lipid levels APOC1 intron 19913121 rs12721046 chr19 45421254 G A 3.47E-04 Lipid levels APOC1 intron 19913121 rs12721046 chr19 45421254 G A 7.58E-14 Lipid levels APOC1 intron 19913121 rs12721046 chr19 45421254 G A 9.60E-16 Metabolite levels APOC1 intron 22286219 rs12721046 chr19 45421254 G A 0.000000167 HDL cholesterol APOC1 intron 22629316 rs12721046 chr19 45421254 G A 0.0000337 HDL cholesterol (female) APOC1 intron 22629316 rs12721046 chr19 45421254 G A 0.000564 HDL cholesterol (male) APOC1 intron 22629316 rs12721046 chr19 45421254 G A 1.31E-12 LDL cholesterol (male) APOC1 intron 22629316 rs12721046 chr19 45421254 G A 2.03E-19 LDL cholesterol (female) APOC1 intron 22629316 rs12721046 chr19 45421254 G A 2.23E-29 LDL cholesterol APOC1 intron 22629316 rs12721046 chr19 45421254 G A 1.51E-14 HDL cholesterol APOC1 intron 23063622 rs12721046 chr19 45421254 G A 2.65E-23 LDL cholesterol (male) APOC1 intron 23063622 rs12721046 chr19 45421254 G A 4.28E-57 LDL cholesterol APOC1 intron 23063622 rs12721046 chr19 45421254 G A 5.59E-38 LDL cholesterol (female) APOC1 intron 23063622 rs12721046 chr19 45421254 G A 6.63E-53 Cholesterol,total APOC1 intron 23063622 rs12721046 chr19 45421254 G A 7.72E-10 Triglycerides APOC1 intron 23063622 rs12721046 chr19 45421254 G A 6.79E-21 C-reactive protein APOC1 intron 23505291 rs12721054 chr19 45422587 A G 1.15E-14 Triglycerides (males) APOC1 UTR-3 22629316 rs12721054 chr19 45422587 A G 3.17E-14 Triglycerides (females) APOC1 UTR-3 22629316 rs12721054 chr19 45422587 A G 5.55E-26 Triglycerides APOC1 UTR-3 22629316 rs12721054 chr19 45422587 A G 1.31E-28 Triglycerides APOC1 UTR-3 23236364 rs12721054 chr19 45422587 A G 4.75E-08 Cholesterol,total APOC1 UTR-3 23236364 rs12721054 chr19 45422587 A G 3.00E-19 Triglycerides APOC1 UTR-3 23726366 rs56131196 chr19 45422846 G A 4.00E-12 Alzheimer's disease biomarkers APOC1 nearGene-3 23419831 rs4420638 chr19 45422946 A G 5.64E-07 Cholesterol APOC1 nearGene-3 17255346 rs4420638 chr19 45422946 A G 3.00E-13 Triglycerides APOC1 nearGene-3 17463246 rs4420638 chr19 45422946 A G 1.00E-39 Alzheimer's disease (late onset) APOC1 nearGene-3 17474819 rs4420638 chr19 45422946 A G 1.68E-04 Multiple complex diseases APOC1 nearGene-3 17554300 rs4420638 chr19 45422946 A G 1.00E-39 Alzheimer's disease APOC1 nearGene-3 17975299 rs4420638 chr19 45422946 A G 2.00E-44 Alzheimer's disease APOC1 nearGene-3 17998437 rs4420638 chr19 45422946 A G 3.57E-14 Cardiovascular disease APOC1 nearGene-3 18179892 rs4420638 chr19 45422946 A G 3.00E-43 LDL cholesterol APOC1 nearGene-3 18193043 rs4420638 chr19 45422946 A G 1.00E-60 LDL cholesterol APOC1 nearGene-3 18193044 rs4420638 chr19 45422946 A G 1.00E-20 LDL cholesterol APOC1 nearGene-3 18262040 rs4420638 chr19 45422946 A G 2.00E-07 LDL cholesterol APOC1 nearGene-3 18802019 rs4420638 chr19 45422946 A G 4.00E-27 LDL cholesterol APOC1 nearGene-3 19060906 rs4420638 chr19 45422946 A G 2.00E-06 Quantitative traits APOC1 nearGene-3 19197348 rs4420638 chr19 45422946 A G 3.00E-07 Quantitative traits APOC1 nearGene-3 19197348 rs4420638 chr19 45422946 A G 5.00E-06 Quantitative traits APOC1 nearGene-3 19197348 rs4420638 chr19 45422946 A G 3.61E-06 Waist circumference APOC1 nearGene-3 19557197 rs4420638 chr19 45422946 A G 5.00E-27 C-reactive protein APOC1 nearGene-3 19567438 rs4420638 chr19 45422946 A G 2.00E-16 Alzheimer's disease APOC1 nearGene-3 19734903 rs4420638 chr19 45422946 A G 3.99E-05 Blood cell counts and other traits APOC1 nearGene-3 20139978 rs4420638 chr19 45422946 A G 6.30E-07 Response to statin therapy APOC1 nearGene-3 20339536 rs4420638 chr19 45422946 A G 6.00E-24 Lipoprotein-associated phospholipase A2 activity and mass APOC1 nearGene-3 20442857 rs4420638 chr19 45422946 A G 4.00E-21 HDL cholesterol APOC1 nearGene-3 20686565 rs4420638 chr19 45422946 A G 5.00E-111 Cholesterol,total APOC1 nearGene-3 20686565 rs4420638 chr19 45422946 A G 9.00E-147 LDL cholesterol APOC1 nearGene-3 20686565 rs4420638 chr19 45422946 A G 2.00E-40 LDL cholesterol APOC1 nearGene-3 20864672 rs4420638 chr19 45422946 A G 3.00E-07 C-reactive protein APOC1 nearGene-3 21196492 rs4420638 chr19 45422946 A G 9.00E-139 C-reactive protein APOC1 nearGene-3 21300955 rs4420638 chr19 45422946 A G 1.00E-60 Coronary heart disease APOC1 nearGene-3 21347282 rs4420638 chr19 45422946 A G 1.28E-253 Alzheimer's disease (late onset) APOC1 nearGene-3 21460841 rs4420638 chr19 45422946 A G 2.00E-16 Longevity APOC1 nearGene-3 21740922 rs4420638 chr19 45422946 A G 7.50E-10 Cardiovascular disease risk factors APOC1 nearGene-3 21943158 rs4420638 chr19 45422946 A G 5.00E-30 Lipoprotein-associated phospholipase A2 activity and mass APOC1 nearGene-3 22003152 rs4420638 chr19 45422946 A G 1.00E-12 Alzheimer's disease (age of onset) APOC1 nearGene-3 22005931 rs4420638 chr19 45422946 A G 1.00E-31 Metabolic syndrome phenotype APOC1 nearGene-3 22022282 rs4420638 chr19 45422946 A G 1.20E-06 Metabolic syndrome phenotype APOC1 nearGene-3 22022282 rs4420638 chr19 45422946 A G 1.70E-57 Metabolic syndrome phenotype APOC1 nearGene-3 22022282 rs4420638 chr19 45422946 A G 5.00E-12 Metabolic syndrome phenotype APOC1 nearGene-3 22022282 rs4420638 chr19 45422946 A G 8.70E-04 Metabolic syndrome phenotype APOC1 nearGene-3 22022282 rs4420638 chr19 45422946 A G 4.00E-27 Cognitive decline APOC1 nearGene-3 22054870 rs4420638 chr19 45422946 A G 2.60E-09 Sphingolipid levels APOC1 nearGene-3 22359512 rs4420638 chr19 45422946 A G 1.16E-09 Response to statin therapy APOC1 nearGene-3 22368281 rs4420638 chr19 45422946 A G 8.00E-149 Alzheimer's disease APOC1 nearGene-3 22832961 rs4420638 chr19 45422946 A G 0.00000387 HDL cholesterol APOC1 nearGene-3 23063622 rs4420638 chr19 45422946 A G 0.000295 Triglycerides APOC1 nearGene-3 23063622 rs4420638 chr19 45422946 A G 2.54E-12 LDL cholesterol APOC1 nearGene-3 23063622 rs4420638 chr19 45422946 A G 3.13E-12 Cholesterol,total APOC1 nearGene-3 23063622 rs4420638 chr19 45422946 A G 0.00000057 Apolipoprotein B levels response after 40mg daily simvastatin treatment APOC1 nearGene-3 23100282 rs4420638 chr19 45422946 A G 0.0000064 LDL cholesterol response after 40mg daily simvastatin treatment APOC1 nearGene-3 23100282 rs4420638 chr19 45422946 A G 2.10E-38 LDL cholesterol APOC1 nearGene-3 23100282 rs4420638 chr19 45422946 A G 3.10E-32 Apolipoprotein B levels APOC1 nearGene-3 23100282 rs4420638 chr19 45422946 A G 6.40E-06 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) APOC1 nearGene-3 23103227 rs4420638 chr19 45422946 A G 2.00E-20 Age-related macular degeneration APOC1 nearGene-3 23455636 rs4420638 chr19 45422946 A G 1.55E-15 C-reactive protein APOC1 nearGene-3 23844046 rs4420638 chr19 45422946 A G 1.00E-14 Lipid traits APOC1 nearGene-3 24023261 rs4420638 chr19 45422946 A G 1.00E-149 Cholesterol,total APOC1 nearGene-3 24097068 rs4420638 chr19 45422946 A G 2.00E-178 LDL cholesterol APOC1 nearGene-3 24097068 rs4420638 chr19 45422946 A G 2.00E-21 HDL cholesterol APOC1 nearGene-3 24097068 rs4420638 chr19 45422946 A G 2.00E-26 Longevity (85 years and older) APOC1 nearGene-3 24688116 rs4420638 chr19 45422946 A G 3.00E-36 Longevity (90 years and older) APOC1 nearGene-3 24688116 rs4803770 chr19 45427353 C G 2.60E-15 Alzheimer's disease / / 19734903 rs4803770 chr19 45427353 C G 1.11E-24 Alzheimer's disease (late onset) / / 21460841 rs4803770 chr19 45427353 C G 5.23E-17 Alzheimer's disease / / 22832961 rs5112 chr19 45430280 C G 9.40E-07 Alzheimer's disease / / 19734903 rs7258987 chr19 45432520 G A,C,T 0.00000214 Triglycerides APOC1P1 intron 23236364 rs7259004 chr19 45432557 G C 4.10E-06 Response to statin therapy APOC1P1 intron 20339536 rs7259004 chr19 45432557 G C 5.00E-10 Sphingolipid levels APOC1P1 intron 22359512 rs5157 chr19 45447161 T C 0.000000837 HDL cholesterol APOC4 intron 23063622 rs12721109 chr19 45447221 G A 3.88E-19 Lipid levels APOC4 intron 19913121 rs12721109 chr19 45447221 G A 5.06E-14 Lipid levels APOC4 intron 19913121 rs12721109 chr19 45447221 G A 1.40E-11 Cardiovascular disease risk factors APOC4 intron 21943158 rs12721109 chr19 45447221 G A 7.72E-27 LDL cholesterol APOC4 intron 22629316 rs12721109 chr19 45447221 G A 2.18E-50 Cholesterol,total APOC4 intron 23063622 rs12721109 chr19 45447221 G A 3.45E-73 LDL cholesterol APOC4 intron 23063622 rs12721108 chr19 45447241 G T 2.80E-06 Alzheimer's disease APOC4 intron 19734903 rs5167 chr19 45448465 T G 3.43E-08 Type 2 diabetes and other traits APOC4 missense 19734900 rs5167 chr19 45448465 T G 4.98E-05 Alzheimer's disease (late onset) APOC4 missense 21460841 rs5167 chr19 45448465 T G 6.12E-11 HDL cholesterol APOC4 missense 23063622 rs5167 chr19 45448465 T G 5.65E-04 Alzheimer's disease APOC4 missense 24755620 rs12709885 chr19 45448884 A T 2.00E-04 Atrial fibrillation / / 21846873 rs2288912 chr19 45449199 C G 0.00000122 LDL cholesterol / / 23063622 rs2288912 chr19 45449199 C G 3.01E-08 HDL cholesterol / / 23063622 rs12709888 chr19 45451662 G A 4.86E-06 Lipid levels APOC2 intron 19913121 rs7257468 chr19 45453144 C T 0.00027 Coronary artery calcification APOC2 nearGene-3 23727086 rs12709889 chr19 45453239 G A 1.76E-08 HDL cholesterol APOC2 nearGene-3 23063622 rs3760627 chr19 45457180 T C 3.97E-07 Type 2 diabetes and other traits / / 19734900 rs3760627 chr19 45457180 T C 3.97E-07 Alzheimer's disease (late onset) / / 21460841 rs3760627 chr19 45457180 T C 0.00028 Coronary artery calcification / / 23727086 rs2239375 chr19 45459851 T C 0.00046 Coronary artery calcification CLPTM1 intron 23727086 rs16979595 chr19 45477381 G A 6.10E-04 Type 2 diabetes CLPTM1 intron 17463246 rs16979595 chr19 45477381 G A 5.79E-06 Cardiovascular disease CLPTM1 intron 18179892 rs16979595 chr19 45477381 G A 6.23E-07 Alzheimer's disease (late onset) CLPTM1 intron 21460841 rs16979595 chr19 45477381 G A 1.61E-04 Alzheimer's disease CLPTM1 intron 24755620 rs2075620 chr19 45480037 A G 4.14E-05 Non-word repetition CLPTM1 intron 23738518 rs7253458 chr19 45482570 C T 4.14E-05 Non-word repetition CLPTM1 intron 23738518 rs7257916 chr19 45482884 T C 7.80E-05 Type 2 diabetes and other traits CLPTM1 intron 19734900 rs8111069 chr19 45483438 A C 6.09E-06 Type 2 diabetes and other traits CLPTM1 intron 19734900 rs8111069 chr19 45483438 A C 6.09E-06 Alzheimer's disease (late onset) CLPTM1 intron 21460841 rs11083755 chr19 45490065 C T 4.57E-05 Non-word repetition CLPTM1 intron 23738518 rs7251460 chr19 45506772 T A 0.0000225 Cholesterol,total RELB intron 23063622 rs10424046 chr19 45536036 C G 8.90E-06 Alzheimer's disease (late onset) RELB intron 21460841 rs2889490 chr19 45550407 A G 3.20E-07 Urinary metabolites CLASRP intron 21572414 rs10416445 chr19 45556662 A G 8.10E-07 Urinary metabolites CLASRP intron 21572414 rs2304195 chr19 45562871 C T 2.50E-07 Urinary metabolites CLASRP intron 21572414 rs12974182 chr19 45563255 T C 1.80E-07 Urinary metabolites CLASRP intron 21572414 rs7250924 chr19 45585706 T C 2.42E-05 Alzheimer's disease (late onset) GEMIN7 intron 21460841 rs1469704 chr19 45589595 C T 1.87E-05 Alzheimer's disease (late onset) GEMIN7 intron 21460841 rs2060250 chr19 45590988 G A 1.07E-05 Alzheimer's disease (late onset) GEMIN7 intron 21460841 rs16979659 chr19 45594658 G C 7.38E-05 Tuberculosis GEMIN7 UTR-3 24057671 rs10405086 chr19 45627235 C T 1.25E-04 Alzheimer's disease (late onset) PPP1R37 intron 23565137 rs10405086 chr19 45627235 C T 2.13E-05 Alzheimer's disease (late onset) PPP1R37 intron 23565137 rs10413253 chr19 45628566 C T 1.03E-04 Alzheimer's disease (late onset) PPP1R37 intron 23565137 rs10413253 chr19 45628566 C T 2.06E-05 Alzheimer's disease (late onset) PPP1R37 intron 23565137 rs17643262 chr19 45631816 G A 2.75E-14 Alzheimer's disease (late onset) PPP1R37 intron 21460841 rs17643262 chr19 45631816 G A 1.82E-04 Alzheimer's disease PPP1R37 intron 22005930 rs17643262 chr19 45631816 G A 1.40E-09 Alzheimer's disease (late onset) PPP1R37 intron 23565137 rs17643262 chr19 45631816 G A 1.58E-05 Alzheimer's disease (late onset) PPP1R37 intron 23565137 rs17643262 chr19 45631816 G A 4.00E-04 Alzheimer's disease (late onset) PPP1R37 intron 23565137 rs17643262 chr19 45631816 G A 9.78E-05 Alzheimer's disease (late onset) PPP1R37 intron 23565137 rs17643262 chr19 45631816 G A 6.70E-05 Alzheimer's disease PPP1R37 intron 24755620 rs754366 chr19 45633686 G A 1.14E-04 Alzheimer's disease (late onset) PPP1R37 intron 23565137 rs754366 chr19 45633686 G A 5.90E-05 Alzheimer's disease (late onset) PPP1R37 intron 23565137 rs10408847 chr19 45634682 G C 8.76E-04 Alzheimer's disease PPP1R37 intron 22005930 rs10408847 chr19 45634682 G C 1.21E-04 Alzheimer's disease (late onset) PPP1R37 intron 23565137 rs10408847 chr19 45634682 G C 2.11E-05 Alzheimer's disease (late onset) PPP1R37 intron 23565137 rs1114832 chr19 45636201 C T 5.90E-06 Alzheimer's disease PPP1R37 intron 19136949 rs1114832 chr19 45636201 C T 2.22E-09 Type 2 diabetes and other traits PPP1R37 intron 19734900 rs1114832 chr19 45636201 C T 3.43E-05 Alzheimer's disease (late onset) PPP1R37 intron 21379329 rs1114832 chr19 45636201 C T 2.41E-14 Alzheimer's disease (late onset) PPP1R37 intron 21460841 rs1114832 chr19 45636201 C T 3.55E-05 Alzheimer's disease PPP1R37 intron 24755620 rs1114831 chr19 45636319 C A 2.88E-14 Alzheimer's disease (late onset) PPP1R37 intron 21460841 rs1114831 chr19 45636319 C A 1.77E-04 Alzheimer's disease PPP1R37 intron 22005930 rs1114831 chr19 45636319 C A 6.44E-05 Alzheimer's disease PPP1R37 intron 24755620 rs10425074 chr19 45640124 A G 2.37E-04 Blood pressure PPP1R37 intron 17255346 rs10425074 chr19 45640124 A G 1.91E-05 Type 2 diabetes and other traits PPP1R37 intron 19734900 rs1048699 chr19 45650386 C T 3.60E-06 Alzheimer's disease PPP1R37 UTR-3 19136949 rs1048699 chr19 45650386 C T 1.51E-09 Type 2 diabetes and other traits PPP1R37 UTR-3 19734900 rs1048699 chr19 45650386 C T 4.25E-05 Alzheimer's disease (late onset) PPP1R37 UTR-3 21379329 rs1048699 chr19 45650386 C T 5.18E-14 Alzheimer's disease (late onset) PPP1R37 UTR-3 21460841 rs1048699 chr19 45650386 C T 2.79E-04 Alzheimer's disease PPP1R37 UTR-3 22005930 rs1048699 chr19 45650386 C T 9.56E-05 Alzheimer's disease PPP1R37 UTR-3 24755620 rs1048699 chr19 45650386 C T 8.42E-05 Body Mass Index PPP1R37 UTR-3 pha003007 rs1048699 chr19 45650386 C T 7.27E-05 Weight PPP1R37 UTR-3 pha003027 rs1005451 chr19 45652079 T C 8.99E-04 Alzheimer's disease / / 22005930 rs10421247 chr19 45657486 C T 8.42E-06 Alzheimer's disease (late onset) NKPD1 intron 21460841 rs10416371 chr19 45660136 A C 5.45E-09 Alzheimer's disease (late onset) NKPD1 intron 21460841 rs10416371 chr19 45660136 A C 3.52E-08 Alzheimer's disease NKPD1 intron 22832961 rs7253652 chr19 45681134 G C 2.40E-05 Urinary metabolites TRAPPC6A intron 21572414 rs2159324 chr19 45695738 T C 2.00E-06 Quantitative traits / / 19197348 rs2159324 chr19 45695738 T C 4.00E-07 Quantitative traits / / 19197348 rs3848527 chr19 45699289 C G 0.0000462 Panic disorder / / 23149450 rs3848527 chr19 45699289 C G 4.62E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs606757 chr19 45707830 A C 7.57E-05 Alzheimer's disease (late onset) / / 21460841 rs582747 chr19 45707917 T G 1.24E-06 Alzheimer's disease (late onset) / / 21460841 rs605003 chr19 45708239 A G 1.24E-06 Alzheimer's disease (late onset) / / 21460841 rs2627641 chr19 45708758 A G 4.65E-04 Alzheimer's disease (late onset) / / 21379329 rs2627641 chr19 45708758 A G 1.40E-06 Alzheimer's disease (late onset) / / 21460841 rs597668 chr19 45708888 T C 5.24E-05 Type 2 diabetes and other traits / / 19734900 rs597668 chr19 45708888 T C 1.38E-06 Alzheimer's disease (late onset) / / 21460841 rs597668 chr19 45708888 T C 6.45E-09 Prion diseases / / 22210626 rs7249082 chr19 45710276 A G 1.04E-06 Alzheimer's disease (late onset) / / 21460841 rs10415983 chr19 45711598 C T 8.57E-07 Alzheimer's disease (late onset) / / 21460841 rs10422797 chr19 45726106 T C 9.22E-17 Alzheimer's disease (late onset) EXOC3L2 intron 21379329 rs10422797 chr19 45726106 T C 1.02E-06 Alzheimer's disease EXOC3L2 intron 24755620 rs346763 chr19 45729275 G A 8.28E-06 Alzheimer's disease (late onset) EXOC3L2 intron 21379329 rs346763 chr19 45729275 G A 3.67E-07 Alzheimer's disease EXOC3L2 intron 24755620 rs17356664 chr19 45740771 C T 4.00E-10 Platelet counts / / 22139419 rs17356664 chr19 45740771 C T 0.00000023 Common carotid artery thickness (average of near and far wall measures) / / 23487405 rs17356664 chr19 45740771 C T 0.00000051 Common carotid artery thickness (far walls) / / 23487405 rs17356664 chr19 45740771 C T 0.00000163 Common carotid artery thickness (near walls) / / 23487405 rs17356664 chr19 45740771 C T 1.00E-04 Platelet counts / / 24026423 rs2240672 chr19 45769575 G A 6.36E-04 Alzheimer's disease MARK4 intron 24755620 rs345409 chr19 45779635 T C 6.52E-04 Alzheimer's disease MARK4 intron 24755620 rs11672894 chr19 45801951 C T 0.0000016 Common carotid artery thickness (far walls) MARK4 intron 23487405 rs11672894 chr19 45801951 C T 0.0000028 Common carotid artery thickness (average of near and far wall measures) MARK4 intron 23487405 rs344797 chr19 45808142 T G 9.22E-04 Alcohol dependence MARK4 UTR-3 21314694 rs7260463 chr19 45814860 G T 0.00000266 Common carotid artery thickness (far walls) CKM intron 23487405 rs13181 chr19 45854919 T G 1 Drug response to Fluorouracil ERCC2 missense 18267032 rs13181 chr19 45854919 T G 1 Drug response to Leucovorin ERCC2 missense 18267032 rs13181 chr19 45854919 T G 1 Drug response to Cisplatin ERCC2 missense 19434073 rs13181 chr19 45854919 T G 9.00E-07 Lung Cancer (DNA repair capacity) ERCC2 missense 23108145 rs238416 chr19 45857049 T C 0.00034 Coronary artery calcification ERCC2 intron 23727086 rs238410 chr19 45861452 G A 3.11E-11 Triglycerides ERCC2 intron 23063622 rs1799793 chr19 45867259 C T 1 Drug response to Cisplatin ERCC2 missense 19786980 rs1799793 chr19 45867259 C T 1 Drug response to Cyclophosphamide ERCC2 missense 19786980 rs3212986 chr19 45912736 C A 1 Drug response to Platinum CD3EAP missense 19362955 rs3212986 chr19 45912736 C A 1 Drug response to Cisplatin CD3EAP missense 19786980 rs3212986 chr19 45912736 C A 1 Drug response to Cyclophosphamide CD3EAP missense 19786980 rs11615 chr19 45923653 A G 1 Drug response to Platinum ERCC1 cds-synon 19362955 rs11615 chr19 45923653 A G 1 Drug response to Cisplatin ERCC1 cds-synon 19786980 rs11615 chr19 45923653 A G 1 Drug response to Cyclophosphamide ERCC1 cds-synon 19786980 rs6509215 chr19 45982780 T G 5.53E-04 Lymphocyte counts / / 22286170 rs2301283 chr19 46024584 T C,G 0.00012 Coronary artery calcification VASP cds-synon 23727086 rs2301284 chr19 46025388 G A 4.56E-04 Response to taxane treatment (placlitaxel) VASP intron 23006423 rs4802260 chr19 46027752 C T 2.98E-08 Lymphocyte counts VASP intron 22286170 rs8111589 chr19 46034558 C T 1.50E-04 Alcohol dependence OPA3 intron 20201924 rs8111589 chr19 46034558 C T 4.00E-06 Depression and alcohol dependence OPA3 intron 22064162 rs8111589 chr19 46034558 C T 0.00000827 Alcohol dependence OPA3 intron 23691058 rs11673516 chr19 46059364 T G 6.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OPA3 intron 20877124 rs11673516 chr19 46059364 T G 6.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OPA3 intron 20877124 rs11673516 chr19 46059364 T G 2.50E-05 Urinary metabolites OPA3 intron 21572414 rs1264226 chr19 46063167 G A 6.80E-04 Alcohol dependence OPA3 intron 20201924 rs16979890 chr19 46066318 G A 3.40E-04 Alcohol dependence OPA3 intron 20201924 rs7256951 chr19 46076226 T C 6.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) OPA3 intron 20877124 rs892100 chr19 46080682 C T 6.92E-06 Reading disability and language impairment OPA3 intron 24024963 rs7252448 chr19 46142053 C T 5.35E-05 Bladder cancer EML2 intron 19648920 rs12972158 chr19 46158473 C T 3.70E-05 Tooth agenesis (mandibular third molar) / / 24172245 rs8108269 chr19 46158513 T G 0.000000021 Type 2 diabetes / / 22885922 rs8108269 chr19 46158513 T G 0.00000022 Type 2 diabetes (females) / / 22885922 rs8108269 chr19 46158513 T G 0.00066 HDL cholesterol / / 22885922 rs8108269 chr19 46158513 T G 5.40E-22 Triglycerides / / 22885922 rs8108269 chr19 46158513 T G 5.00E-06 Type 2 diabetes / / 24509480 rs11671664 chr19 46172278 G A 0.00000261 Type 2 diabetes GIPR intron 22325160 rs11671664 chr19 46172278 G A 6.00E-14 Body mass index GIPR intron 22344219 rs11671664 chr19 46172278 G A 7.00E-14 Body mass index GIPR intron 22344221 rs11671664 chr19 46172278 G A 3.00E-12 Body mass index GIPR intron 24861553 rs11672660 chr19 46180184 C T 2.72E-27 2-hour glucose tolerance test GIPR intron 22885924 rs11672660 chr19 46180184 C T 5.83E-09 Fasting blood glucose GIPR intron 22885924 rs11672660 chr19 46180184 C T 0.00000274 Body mass index GIPR intron 23001569 rs1800437 chr19 46181392 G C 3.00E-14 Obesity GIPR missense 23563607 rs10423928 chr19 46182304 T A 3.00E-12 Two-hour glucose challenge GIPR intron 20081857 rs10423928 chr19 46182304 T A 8.30E-13 2-hour glucose tolerance test GIPR intron 22885924 rs10423928 chr19 46182304 T A 4.00E-13 Obesity GIPR intron 23563607 rs7245708 chr19 46195756 A C 1.00E-06 Subcutaneous adipose tissue QPCTL UTR-5 22589738 rs7245708 chr19 46195756 A C 2.00E-06 Subcutaneous adipose tissue QPCTL UTR-5 22589738 rs2302593 chr19 46196634 C A,G 9.26E-10 Fasting blood glucose QPCTL intron 22885924 rs2287019 chr19 46202172 C T 2.00E-16 Body mass index QPCTL intron 20935630 rs2287019 chr19 46202172 C T 1.88E-16 Body mass index QPCTL intron 23001569 rs4803848 chr19 46205050 T C 1.10E-04 Bipolar disorder QPCTL intron 17486107 rs4803848 chr19 46205050 T C 2.87E-04 Type 2 diabetes QPCTL intron 22158537 rs16980013 chr19 46267453 G T 3.50E-12 Progranulin levels / / 21087763 rs16980013 chr19 46267453 G T 3.50E-12 Myocardial infarction / / 21211798 rs10418454 chr19 46280417 C T 8.45E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines DMPK intron 21844884 rs3760843 chr19 46288706 A T 4.19E-07 Multiple complex diseases DMWD intron 17554300 rs8109951 chr19 46289503 C T 0.000509 Type 2 diabetes DMWD cds-synon 22325160 rs8111071 chr19 46307406 A G 6.13E-06 Multiple complex diseases RSPH6A intron 17554300 rs8111071 chr19 46307406 A G 4.00E-06 Sudden cardiac arrest RSPH6A intron 21658281 rs10500292 chr19 46327933 C T 0.000000154 Fasting blood glucose SYMPK intron 22885924 rs16980051 chr19 46345886 T C 1.65E-08 Fasting blood glucose SYMPK intron 22885924 rs10420834 chr19 46347542 G T 5.93E-04 Multiple complex diseases SYMPK intron 17554300 rs34255979 chr19 46384830 C T 3.56E-04 Smoking quantity / / 24665060 rs1422626 chr19 46431372 C T 1.47E-05 Cognitive test performance / / 20125193 rs7260239 chr19 46435809 A C 3.51E-04 Multiple complex diseases / / 17554300 rs11672738 chr19 46451214 C T 5.82E-05 Lipoproteins NOVA2 intron pha003079 rs12463085 chr19 46469411 A G 8.01E-04 Response to cytidine analogues (gemcitabine) NOVA2 intron 24483146 rs2341634 chr19 46470305 T C 3.48E-04 Multiple complex diseases NOVA2 intron 17554300 rs2341634 chr19 46470305 T C 6.30E-04 Response to cytidine analogues (gemcitabine) NOVA2 intron 24483146 rs2341635 chr19 46470434 G A 5.91E-04 Response to cytidine analogues (gemcitabine) NOVA2 intron 24483146 rs1010693 chr19 46513183 G T 7.20E-04 Response to cytadine analogues (cytosine arabinoside) CCDC61 intron 24483146 rs1114090 chr19 46547330 A G 9.62E-05 Psoriasis / / 18364390 rs10403760 chr19 46570740 G A 3.53E-04 Type 2 diabetes LOC400706 intron 17463246 rs10403760 chr19 46570740 G A 5.14E-08 Metabolite levels LOC400706 intron 23281178 rs2341903 chr19 46659516 C A 4.70E-04 Suicide attempts in bipolar disorder IGFL2 intron 21423239 rs10408162 chr19 46664400 A G 2.45E-04 Response to statin treatment (atorvastatin),change in cholesterol levels IGFL2 UTR-3 20031582 rs1989583 chr19 46674011 T C 4.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs4803902 chr19 46680300 A T 6.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs12974081 chr19 46681557 C T 4.80E-05 Parkinson's disease (age of onset) / / 19772629 rs7255414 chr19 46720664 G T 7.73E-05 Blood Pressure / / pha003044 rs1019212 chr19 46729219 G A 4.76E-07 Primary biliary cirrhosis / / 23000144 rs1019212 chr19 46729219 G A 0.000000476 Facial morphology / / 23028347 rs1008591 chr19 46730614 A G 4.34E-07 Primary biliary cirrhosis / / 23000144 rs1008591 chr19 46730614 A G 0.000000434 Facial morphology / / 23028347 rs187146043 chr19 46733560 T G 0.000019 Breast cancer(er negative) IGFL1 missense 23555315 rs10404394 chr19 46741568 G C 4.16E-04 Multiple complex diseases / / 17554300 rs10424322 chr19 46742424 C T 0.0000106 Femoral neck bone mineral density / / 23436924 rs10424322 chr19 46742424 C T 0.0000685 Total hip bone mineral density / / 23436924 rs4803913 chr19 46768753 A G 1.94E-05 Alcohol consumption / / 23743675 rs2013666 chr19 46787126 A G 6.06E-04 Obesity (extreme) / / 21935397 rs4803920 chr19 46794772 G C 6.16E-04 Obesity (extreme) / / 21935397 rs3826795 chr19 46800433 G A 3.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy) HIF3A intron 24554482 rs8100021 chr19 46806630 A G 7.09E-04 Multiple complex diseases HIF3A intron 17554300 rs11665853 chr19 46834683 A G 6.65E-05 Post-operative nausea and vomiting HIF3A intron 21694509 rs4802307 chr19 46849806 G T 2.00E-10 Crohn's disease PPP5C nearGene-5 23128233 rs917946 chr19 46860058 A G 5.97E-04 Body mass index PPP5C intron 21701565 rs11671133 chr19 46874634 A G 2.70E-05 Urinary metabolites PPP5C intron 21572414 rs1024782 chr19 46887567 C T 3.90E-04 Body mass index PPP5C intron 21701565 rs10412551 chr19 46913749 G A 9.34E-04 Suicide attempts in bipolar disorder CCDC8 UTR-3 21423239 rs7246254 chr19 46918791 G A 5.17E-07 Multiple complex diseases CCDC8 nearGene-5 17554300 rs1317877 chr19 46926384 T C 1.80E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs404997 chr19 46930147 A G 1.86E-04 Multiple complex diseases / / 17554300 rs73566890 chr19 46934156 T C 5.20E-06 Personality dimensions / / 23658558 rs371657 chr19 46937731 G C 1.19E-04 Type 2 diabetes / / 17463246 rs56206848 chr19 46938335 C T 6.95E-06 Personality dimensions / / 23658558 rs56982446 chr19 46945079 A G 2.38E-06 Personality dimensions / / 23658558 rs17801669 chr19 46946640 G C 3.31E-06 Personality dimensions / / 23658558 rs10416550 chr19 46954262 C T 7.72E-05 Triglycerides / / pha003080 rs55843704 chr19 46954296 G A 9.71E-06 Personality dimensions / / 23658558 rs4803953 chr19 46959007 C A 5.55E-05 Bipolar disorder / / 19488044 rs7248888 chr19 46974003 C T 5.00E-06 Colorectal cancer (diet interaction) PNMAL1 missense 24743840 rs10408465 chr19 47025655 T C 4.27E-05 Orofacial clefts LOC100506012 intron 22419666 rs8111536 chr19 47049928 A C 1.90E-06 Bleomycin sensitivity LOC100506012 intron 21106707 rs4803983 chr19 47070426 G A 2.00E-05 Urinary metabolites LOC100506012 intron 21572414 rs6509286 chr19 47076278 C A 6.30E-06 Common variable immunodeficiency LOC100506012 intron 21497890 rs6509286 chr19 47076278 C A 2.60E-05 Esophageal cancer (squamous cell) LOC100506012 intron 22960999 rs8102898 chr19 47083386 C G 4.97E-04 Suicide attempts in bipolar disorder LOC100506012 intron 21423239 rs11083838 chr19 47088239 C T 5.16E-04 Suicide attempts in bipolar disorder LOC100506012 intron 21423239 rs4274528 chr19 47090085 T C 6.26E-04 Suicide attempts in bipolar disorder LOC100506012 intron 21423239 rs11083840 chr19 47119910 T G 1.70E-04 Coronary heart disease / / 21966275 rs1126510 chr19 47123783 A G 2.00E-09 Ulcerative colitis PTGIR UTR-3 23128233 rs3810295 chr19 47138646 G A,C,T 4.30E-05 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) / / 24325915 rs873286 chr19 47163774 G A 4.17E-05 Intracranial aneurysm DACT3 intron 20613766 rs60652743 chr19 47205707 A G 6.51E-10 Primary sclerosing cholangitis PRKD2 intron 23603763 rs11083846 chr19 47207654 G A 4.00E-09 Chronic lymphocytic leukemia PRKD2 intron 18758461 rs11083846 chr19 47207654 G A 4.00E-09 Nasopharyngeal carcinoma PRKD2 intron 20512145 rs425105 chr19 47208481 T C 3.00E-11 Type 1 diabetes PRKD2 intron 19430480 rs425105 chr19 47208481 T C 2.70E-11 Multiple sclerosis PRKD2 intron 22190364 rs10412340 chr19 47221758 G A 4.10E-04 Alcohol dependence / / 20201924 rs3786704 chr19 47224590 C T 7.20E-04 Alcohol dependence STRN4 intron 20201924 rs160544 chr19 47234885 G A 4.34E-05 Tunica Media STRN4 intron pha003038 rs10401422 chr19 47244530 C A 5.29E-04 Oral cancers (chewing tobacco related) STRN4 intron 22503698 rs11668878 chr19 47268373 G T 4.00E-07 Chronic lymphocytic leukemia / / 20062064 rs11668878 chr19 47268373 G T 4.00E-07 Nasopharyngeal carcinoma / / 20512145 rs4804000 chr19 47276454 G A 1.04E-04 Multiple complex diseases / / 17554300 rs4804000 chr19 47276454 G A 6.31E-08 Type 1 diabetes / / 21980299 rs3027957 chr19 47287507 T C 1.25E-05 Chronic lymphocytic leukemia SLC1A5 intron 24292274 rs312187 chr19 47342239 A T 9.00E-06 Urinary metabolites AP2S1 intron 21572414 rs10164289 chr19 47483922 G A 6.78E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines ARHGAP35 intron 21844884 rs3810291 chr19 47569003 G A 2.00E-12 Body mass index ZC3H4 UTR-3 20935630 rs3810291 chr19 47569003 G A 2.66E-05 Body mass index ZC3H4 UTR-3 22344219 rs3810291 chr19 47569003 G A 1.64E-12 Body mass index ZC3H4 UTR-3 23001569 rs3810291 chr19 47569003 G A 9.00E-07 Body mass index ZC3H4 UTR-3 24861553 rs3745618 chr19 47575716 C T 2.00E-06 Obesity-related traits ZC3H4 cds-synon 23251661 rs8101091 chr19 47600601 A G 4.20E-04 Iris characteristics ZC3H4 intron 21835309 rs307896 chr19 47661493 G A 5.00E-07 Multiple sclerosis SAE1 intron 21833088 rs17729227 chr19 47664951 T C 1.14E-04 Multiple complex diseases SAE1 intron 17554300 rs3745621 chr19 47689921 C G 3.10E-04 Height SAE1 intron 17255346 rs2032809 chr19 47736216 T C 9.64E-05 LDL lipoproteins BBC3 nearGene-5 pha002902 rs10414428 chr19 47740491 A G 7.56E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10853782 chr19 47793109 C T 1.49E-04 Fibrinogen / / 17255346 rs11673207 chr19 47794681 T C 1.55E-04 Fibrinogen / / 17255346 rs7254232 chr19 47796800 A G 3.00E-06 Periodontitis (Chronic) / / 25008200 rs2972607 chr19 47850277 A G 8.08E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs2341877 chr19 47853157 C T 4.85E-04 Myopia (pathological) DHX34 intron 21095009 rs2280694 chr19 47879538 A C 4.76E-04 Myopia (pathological) DHX34 intron 21095009 rs10419083 chr19 47879874 C T 6.34E-05 Schizophrenia(age at onset) DHX34 intron 21688384 rs10403927 chr19 47881778 T G 9.24E-05 Schizophrenia(age at onset) DHX34 intron 21688384 rs2547370 chr19 47892668 C T 6.62E-04 Myopia (pathological) / / 21095009 rs12976740 chr19 47924128 G A 1.73E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10421978 chr19 47928003 G A 1.00E-04 Information processing speed / / 21130836 rs698705 chr19 47937466 A G 3.67E-05 Opioid sensitivity SLC8A2 intron 23183491 rs830140 chr19 47947982 A G 5.63E-04 Alcohol dependence SLC8A2 intron 24277619 rs3848535 chr19 47948228 G A 7.56E-05 Cognitive test performance SLC8A2 intron 20125193 rs17271418 chr19 47985220 G A 1.43E-05 Lipid traits KPTN intron 22028671 rs17271418 chr19 47985220 G A 5.47E-05 Parent of origin effect on language impairment (paternal) KPTN intron 24571439 rs830150 chr19 47989988 A C 8.90E-04 Alzheimer's disease LOC100505681 intron 24755620 rs7257240 chr19 48135746 G A 3.56E-05 Parent of origin effect on language impairment (paternal) GLTSCR1 intron 24571439 rs2068832 chr19 48146728 A G 3.18E-05 Parent of origin effect on language impairment (paternal) GLTSCR1 intron 24571439 rs1012003 chr19 48162131 T C 6.54E-04 Parkinson's disease GLTSCR1 intron 17052657 rs2334283 chr19 48163540 A G 3.93E-05 Parent of origin effect on language impairment (paternal) GLTSCR1 intron 24571439 rs3745760 chr19 48205725 T C 8.00E-07 HIV-1 susceptibility GLTSCR1 UTR-3 22174851 rs11672818 chr19 48232246 C T 1.13E-04 Bipolar disorder,schizoaffective EHD2 intron 19567891 rs12461370 chr19 48241984 C T 7.64E-04 Alzheimer's disease EHD2 intron 17998437 rs1862485 chr19 48282172 T A,C 7.10E-05 Endometriosis SEPW1 intron 23104006 rs2042286 chr19 48289303 T C 9.19E-04 Alzheimer's disease / / 22005930 rs11666029 chr19 48323733 G A 6.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CRX nearGene-5 20877124 rs10405809 chr19 48327215 G A 3.42E-04 Multiple complex diseases CRX intron 17554300 rs17272610 chr19 48328739 A T 5.89E-10 Dehydroepiandrosterone sulphate levels CRX intron 21533175 rs8100396 chr19 48329853 T C 1.56E-10 Dehydroepiandrosterone sulphate levels CRX intron 21533175 rs6509345 chr19 48330007 G T 3.76E-05 Gaucher disease severity CRX intron 22388998 rs11665715 chr19 48330297 C T 7.30E-04 Iris characteristics CRX intron 21835309 rs8108689 chr19 48338835 A G 3.39E-05 Post-operative nausea and vomiting CRX intron 21694509 rs11666668 chr19 48341391 G A 5.66E-05 Lung function (forced expiratory volume in 1 second) CRX intron 24023788 rs11668505 chr19 48348363 A G 2.00E-06 Lung function (forced vital capacity) / / 24023788 rs11668505 chr19 48348363 A G 2.68E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs10410350 chr19 48352364 A G 3.88E-12 Dehydroepiandrosterone sulphate levels / / 21533175 rs4483956 chr19 48357152 A G 9.06E-05 Vaspin levels / / 22907691 rs4483956 chr19 48357152 A G 0.0000906 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs17272617 chr19 48357360 G A 2.15E-12 Dehydroepiandrosterone sulphate levels / / 21533175 rs296396 chr19 48365523 T C 7.94E-16 Dehydroepiandrosterone sulphate levels / / 21533175 rs296396 chr19 48365523 T C 1.00E-12 Blood metabolite levels / / 24816252 rs296396 chr19 48365523 T C 1.00E-92 Blood metabolite levels / / 24816252 rs296391 chr19 48368534 C T 5.20E-17 Dehydroepiandrosterone sulphate levels / / 21533175 rs296381 chr19 48371102 C T 3.71E-17 Dehydroepiandrosterone sulphate levels / / 21533175 rs296381 chr19 48371102 C T 1.00E-10 Blood metabolite levels / / 24816252 rs296381 chr19 48371102 C T 5.00E-143 Blood metabolite levels / / 24816252 rs188440 chr19 48372133 C T 8.76E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs188440 chr19 48372133 C T 6.28E-13 Dehydroepiandrosterone sulphate levels / / 21533175 rs182420 chr19 48372195 C T 3.67E-13 Dehydroepiandrosterone sulphate levels / / 21533175 rs182420 chr19 48372195 C T 6.00E-12 Blood metabolite levels / / 24816252 rs296368 chr19 48372298 C T 3.68E-13 Dehydroepiandrosterone sulphate levels / / 21533175 rs296365 chr19 48374551 C G 9.12E-13 Dehydroepiandrosterone sulphate levels SULT2A1 UTR-3 21533175 rs4149452 chr19 48377519 C T 9.61E-05 Heart Rate SULT2A1 intron pha003054 rs2910393 chr19 48381128 T C 2.17E-13 Dehydroepiandrosterone sulphate levels SULT2A1 intron 21533175 rs2547231 chr19 48385057 C A 1.76E-17 Dehydroepiandrosterone sulphate levels SULT2A1 intron 21533175 rs2547231 chr19 48385057 C A 3.00E-11 Blood metabolite levels SULT2A1 intron 24816252 rs2547231 chr19 48385057 C A 3.00E-191 Blood metabolite ratios SULT2A1 intron 24816252 rs2547231 chr19 48385057 C A 3.00E-22 Blood metabolite levels SULT2A1 intron 24816252 rs2547231 chr19 48385057 C A 4.00E-16 Blood metabolite levels SULT2A1 intron 24816252 rs212099 chr19 48389002 T A 1.96E-18 Dehydroepiandrosterone sulphate levels SULT2A1 intron 21533175 rs2910400 chr19 48394042 G T 9.37E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2910397 chr19 48398117 C T 1.20E-11 Dehydroepiandrosterone sulphate levels / / 21533175 rs296376 chr19 48401329 G A 5.60E-05 Dengue shock syndrome / / 22001756 rs2637125 chr19 48401893 G A 3.00E-19 Dehydroepiandrosterone sulphate levels / / 21533175 rs182421 chr19 48403483 A G 2.52E-18 Dehydroepiandrosterone sulphate levels / / 21533175 rs1017993 chr19 48404176 C T 8.08E-19 Dehydroepiandrosterone sulphate levels / / 21533175 rs2932760 chr19 48404465 G A 7.89E-09 Dehydroepiandrosterone sulphate levels / / 21533175 rs2972619 chr19 48406374 C T 7.19E-19 Dehydroepiandrosterone sulphate levels / / 21533175 rs2972515 chr19 48464978 A G 1.17E-08 Dehydroepiandrosterone sulphate levels / / 21533175 rs16981893 chr19 48465125 G A 4.62E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs16981893 chr19 48465125 G A 1.57E-08 Dehydroepiandrosterone sulphate levels / / 21533175 rs2972516 chr19 48465312 C T 4.76E-19 Dehydroepiandrosterone sulphate levels / / 21533175 rs7252494 chr19 48481117 G A 2.40E-05 Urinary metabolites BSPH1 intron 21572414 rs10412317 chr19 48507720 T C 5.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ELSPBP1 intron 20877124 rs12975551 chr19 48508006 T C 5.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ELSPBP1 intron 20877124 rs7255053 chr19 48508641 A C 1.80E-05 Urinary metabolites ELSPBP1 intron 21572414 rs16982100 chr19 48511888 T G 2.00E-05 Urinary metabolites ELSPBP1 intron 21572414 rs41494755 chr19 48517387 G A 1.10E-05 Urinary metabolites ELSPBP1 intron 21572414 rs16959494 chr19 48517676 C T 3.38E-05 Body Mass Index ELSPBP1 intron pha003014 rs10401488 chr19 48518435 T C 9.96E-04 Suicide attempts in bipolar disorder ELSPBP1 intron 21423239 rs10415347 chr19 48520517 G A,C,T 9.88E-04 Suicide attempts in bipolar disorder ELSPBP1 intron 21423239 rs3815908 chr19 48522869 T C 3.00E-08 Intelligence ELSPBP1 intron 22449649 rs3936340 chr19 48527582 C T 2.00E-06 Intelligence ELSPBP1 intron 22449649 rs16959498 chr19 48528656 C T 1.00E-04 Prostate cancer / / 21743057 rs2560966 chr19 48531216 T G 3.49E-05 Nephrolithiasis / / 22396660 rs10405324 chr19 48543596 G C 9.20E-06 Urinary metabolites CABP5 intron 21572414 rs10405324 chr19 48543596 G C 1.84E-04 Alzheimer's disease CABP5 intron 24755620 rs8105198 chr19 48543862 G A 2.52E-05 Nephrolithiasis CABP5 cds-synon 22396660 rs7258246 chr19 48548870 T A,C 4.64E-04 Alzheimer's disease / / 24755620 rs2386980 chr19 48552661 T C 1.20E-05 Urinary metabolites PLA2G4C intron 21572414 rs2386980 chr19 48552661 T C 6.14E-04 Alzheimer's disease PLA2G4C intron 24755620 rs11564541 chr19 48598754 T A 3.13E-12 Triglycerides PLA2G4C missense 23063622 rs156631 chr19 48598823 A G 7.98E-04 Glycosylated haemoglobin levels PLA2G4C missense 17255346 rs251684 chr19 48601454 T C 8.78E-04 Type 2 diabetes PLA2G4C cds-synon 17463246 rs11564538 chr19 48601512 G A 4.17E-05 Bipolar disorder and schizophrenia PLA2G4C missense 20889312 rs11564534 chr19 48602951 C A 4.28E-04 Suicide attempts in bipolar disorder PLA2G4C missense 21423239 rs1653554 chr19 48608472 A G 9.91E-05 Prostate cancer PLA2G4C intron 18264096 rs2307279 chr19 48608598 C G 7.68E-05 stroke (ischemic) PLA2G4C missense 17434096 rs380359 chr19 48609715 C T 7.68E-05 stroke (ischemic) PLA2G4C intron 17434096 rs251693 chr19 48615437 C T 3.55E-15 Lymphocyte counts PLA2G4C nearGene-5 22286170 rs3786764 chr19 48635433 G C 5.81E-05 Mammographic density LIG1 intron 22532574 rs10407902 chr19 48680984 C G 6.13E-04 Type 2 diabetes C19orf68 intron 17463246 rs972800 chr19 48689393 T G 4.48E-04 Multiple complex diseases C19orf68 intron 17554300 rs11880822 chr19 48702978 G A 9.70E-04 Multiple complex diseases / / 17554300 rs1062808 chr19 48711476 T C 1.92E-13 Lymphocyte counts CARD8 UTR-3 22286170 rs2009373 chr19 48719414 T C 3.69E-06 Lipid levels CARD8 intron 19016617 rs2009530 chr19 48719688 C A 4.92E-06 Crohn's disease CARD8 intron 17684544 rs12052070 chr19 48719991 C G 3.04E-04 Response to platinum-based chemotherapy in small-cell lung cancer CARD8 intron 20463552 rs10500299 chr19 48722180 C T 6.05E-05 Alcohol consumption CARD8 cds-synon pha001401 rs150982505 chr19 48734262 C A 0.000057 Breast cancer(er negative) CARD8 missense 23555315 rs10405717 chr19 48751808 C T 1.41E-04 Rheumatoid arthritis CARD8 intron 21452313 rs16981882 chr19 48755267 T C 2.30E-04 Rheumatoid arthritis CARD8 intron 21452313 rs10403848 chr19 48756775 G A 2.75E-04 Rheumatoid arthritis CARD8 intron 21452313 rs8103388 chr19 48792518 A G 1.70E-05 Height / / 22021425 rs8102349 chr19 48832554 A G 1.53E-04 Attention deficit hyperactivity disorder EMP3 intron 22420046 rs3745720 chr19 48836082 A C 8.50E-04 Alcohol dependence / / 20201924 rs34997741 chr19 48935653 T C 4.46E-04 Alcohol dependence GRIN2D intron 21314694 rs1799270 chr19 48969879 T C 7.38E-05 Cognitive test performance / / 20125193 rs10407332 chr19 49040006 G C 9.78E-04 Multiple complex diseases / / 17554300 rs3848542 chr19 49061724 G A 4.35E-05 Waist Circumference SULT2B1 intron pha003023 rs2544785 chr19 49085710 C T 4.00E-04 Body mass index SULT2B1 intron 24827717 rs2665581 chr19 49089795 T C 3.64E-04 Amyotrophic lateral sclerosis (sporadic) SULT2B1 intron 24529757 rs10426377 chr19 49092234 C A 1.13E-04 Fibrinogen SULT2B1 intron 17255346 rs10426377 chr19 49092234 C A 7.29E-06 Osteoarthritis SULT2B1 intron 22763110 rs3786749 chr19 49095278 T C 7.86E-12 Tumor biomarkers SULT2B1 intron 23300138 rs3786749 chr19 49095278 T C 1.00E-10 Elevated serum carcinoembryonic antigen levels SULT2B1 intron 24941225 rs3815691 chr19 49099955 C T 7.29E-08 Tumor biomarkers SULT2B1 intron 23300138 rs12462337 chr19 49101548 A G 5.96E-08 Tumor biomarkers SULT2B1 intron 23300138 rs4149456 chr19 49101990 G A 1.58E-08 Tumor biomarkers SULT2B1 intron 23300138 rs454715 chr19 49114236 T G 0.00000397 Triglycerides FAM83E intron 23063622 rs454715 chr19 49114236 T G 0.0000556 LDL cholesterol FAM83E intron 23063622 rs368654 chr19 49116555 A G 6.10E-04 Major depressive disorder FAM83E cds-synon 21042317 rs433852 chr19 49117104 C T 1.42E-10 Tumor biomarkers / / 23300138 rs433852 chr19 49117104 C T 5.00E-08 Elevated serum carcinoembryonic antigen levels / / 24941225 rs2292342 chr19 49118371 G A 6.10E-12 Tumor biomarkers RPL18 nearGene-3 23300138 rs2292342 chr19 49118371 G A 7.00E-12 Elevated serum carcinoembryonic antigen levels RPL18 nearGene-3 24941225 rs3745734 chr19 49134388 G C 3.74E-08 Tumor biomarkers DBP intron 23300138 rs12608544 chr19 49136651 G A 2.81E-14 Tumor biomarkers DBP intron 23300138 rs12608544 chr19 49136651 G A 2.00E-12 Elevated serum carcinoembryonic antigen levels DBP intron 24941225 rs11880333 chr19 49144790 C T 4.61E-08 Tumor biomarkers CA11 intron 23300138 rs11880333 chr19 49144790 C T 5.00E-12 Elevated serum carcinoembryonic antigen levels CA11 intron 24941225 rs8111500 chr19 49152955 G A 8.49E-12 Tumor biomarkers SEC1 intron 23300138 rs8111500 chr19 49152955 G A 4.00E-09 Elevated serum carcinoembryonic antigen levels SEC1 intron 24941225 rs16982206 chr19 49177994 T C 2.20E-13 Tumor biomarkers SEC1 intron 23300138 rs3826837 chr19 49183226 G A 3.90E-14 Tumor biomarkers SEC1 intron 23300138 rs16982241 chr19 49202859 G A 3.20E-05 Bladder cancer FUT2 intron 21824976 rs516316 chr19 49206145 G C 2.78E-06 Obesity-related traits FUT2 intron 23251661 rs516246 chr19 49206172 C T 8.00E-10 Liver enzyme levels (gamma-glutamyl transferase) FUT2 intron 22001757 rs516246 chr19 49206172 C T 1.98E-04 Major depressive disorder FUT2 intron 22472876 rs516246 chr19 49206172 C T 1.00E-15 Crohn's disease FUT2 intron 23128233 rs516246 chr19 49206172 C T 2.00E-06 Obesity-related traits FUT2 intron 23251661 rs492602 chr19 49206417 A G 5.00E-17 Vitamin B12 levels FUT2 cds-synon 18776911 rs492602 chr19 49206417 A G 2.00E-10 Cholesterol,total FUT2 cds-synon 20686565 rs492602 chr19 49206417 A G 2.86E-06 Obesity-related traits FUT2 cds-synon 23251661 rs492602 chr19 49206417 A G 1.00E-16 Cholesterol,total FUT2 cds-synon 24097068 rs681343 chr19 49206462 C T 2.78E-06 Obesity-related traits FUT2 cds-synon 23251661 rs281377 chr19 49206603 C T 9.55E-05 Osteoarthritis FUT2 cds-synon 19508968 rs281377 chr19 49206603 C T 1.00E-15 Liver enzyme levels (alkaline phosphatase) FUT2 cds-synon 22001757 rs281377 chr19 49206603 C T 7.37E-05 Orofacial clefts FUT2 cds-synon 22419666 rs281377 chr19 49206603 C T 0.0000021 Primary sclerosing cholangitis FUT2 cds-synon 22521342 rs281377 chr19 49206603 C T 2.90E-08 Tumor biomarkers FUT2 cds-synon 23300138 rs1047781 chr19 49206631 A T 4.00E-36 Vitamin B12 levels FUT2 missense 22367966 rs1047781 chr19 49206631 A T 6.00E-209 Tumor biomarkers FUT2 missense 23300138 rs1047781 chr19 49206631 A T 8.00E-176 Tumor biomarkers FUT2 missense 23300138 rs1047781 chr19 49206631 A T 1.00E-56 Elevated serum carcinoembryonic antigen levels FUT2 missense 24941225 rs601338 chr19 49206674 G A 1.40E-08 Liver enzyme levels (gamma-glutamyl transferase) FUT2 STOP-GAIN 22001757 rs601338 chr19 49206674 G A 0.0000027 Primary sclerosing cholangitis FUT2 STOP-GAIN 22521342 rs601338 chr19 49206674 G A 2.88E-06 Obesity-related traits FUT2 STOP-GAIN 23251661 rs601338 chr19 49206674 G A 0.00000869 Primary sclerosing cholangitis FUT2 STOP-GAIN 23603763 rs601338 chr19 49206674 G A 2.00E-20 Blood metabolite ratios FUT2 STOP-GAIN 24816252 rs601338 chr19 49206674 G A 3.00E-11 Blood metabolite levels FUT2 STOP-GAIN 24816252 rs601338 chr19 49206674 G A 1 Drug response to Cyanocobalamin FUT2 STOP-GAIN 7876235 rs602662 chr19 49206985 G A 3.00E-20 Folate pathway vitamin levels FUT2 missense 19303062 rs602662 chr19 49206985 G A 2.00E-15 Folate pathway vitamin levels FUT2 missense 19744961 rs602662 chr19 49206985 G A 4.23E-05 Type 1 diabetes FUT2 missense 21980299 rs602662 chr19 49206985 G A 0.0000019 Primary sclerosing cholangitis FUT2 missense 22521342 rs602662 chr19 49206985 G A 4.70E-15 Lewis system Lea antigen FUT2 missense 22611595 rs485186 chr19 49207206 A G 9.74E-05 Psoriasis FUT2 cds-synon 20953190 rs569970 chr19 49207718 T C 7.67E-06 Obesity-related traits FUT2 UTR-3 23251661 rs504963 chr19 49208865 G A 2.00E-08 Crohn's disease FUT2 UTR-3 20570966 rs504963 chr19 49208865 G A 4.31E-06 Obesity-related traits FUT2 UTR-3 23251661 rs503279 chr19 49209010 T C 4.00E-20 Metabolic traits FUT2 UTR-3 21886157 rs503279 chr19 49209010 T C 3.47E-06 Obesity-related traits FUT2 UTR-3 23251661 rs503279 chr19 49209010 T C 1.00E-13 Blood metabolite ratios FUT2 UTR-3 24816252 rs676388 chr19 49211969 T C 9.82E-05 Psoriasis / / 20953190 rs281379 chr19 49214274 G A 7.00E-12 Crohn's disease / / 21102463 rs281379 chr19 49214274 G A 5.00E-08 Pubertal anthropometrics / / 23449627 rs281380 chr19 49214470 T C 9.80E-07 Urinary metabolites / / 21572414 rs281380 chr19 49214470 T C 2.00E-06 Multiple sclerosis / / 21833088 rs281381 chr19 49214748 T C 6.51E-04 Major depressive disorder / / 22472876 rs281393 chr19 49224484 C T 5.30E-04 Major depressive disorder RASIP1 intron 22472876 rs281393 chr19 49224484 C T 0.0000599 Bipolar disorder RASIP1 intron 23637625 rs2287921 chr19 49228272 T C 2.00E-25 Retinal vascular caliber RASIP1 intron 21060863 rs2287921 chr19 49228272 T C 3.00E-06 Bipolar disorder RASIP1 intron 21926972 rs2287921 chr19 49228272 T C 0.000000285 Bipolar disorder RASIP1 intron 23070075 rs2287921 chr19 49228272 T C 1.00E-12 Urinary metabolites (H-NMR features) RASIP1 intron 24586186 rs2287921 chr19 49228272 T C 3.00E-36 Urinary metabolites (H-NMR features) RASIP1 intron 24586186 rs2287921 chr19 49228272 T C 7.00E-19 Urinary metabolites (H-NMR features) RASIP1 intron 24586186 rs281407 chr19 49233335 G A 7.75E-20 Tumor biomarkers RASIP1 intron 23300138 rs281408 chr19 49233406 C A 1.61E-04 Major depressive disorder RASIP1 intron 22472876 rs281408 chr19 49233406 C A 4.00E-32 Urinary metabolites (H-NMR features) RASIP1 intron 24586186 rs973579 chr19 49241976 A G 1.73E-04 Major depressive disorder RASIP1 intron 22472876 rs2307019 chr19 49244220 G A 5.75E-04 Major depressive disorder IZUMO1 missense 22472876 rs838147 chr19 49246866 A G 1.89E-04 Major depressive disorder IZUMO1 intron 22472876 rs838147 chr19 49246866 A G 7.00E-07 Dietary macronutrient intake IZUMO1 intron 23636237 rs8108136 chr19 49247693 C T 4.65E-04 Major depressive disorder IZUMO1 intron 22472876 rs8108468 chr19 49247786 G A 4.94E-04 Major depressive disorder IZUMO1 cds-synon 22472876 rs8111399 chr19 49247963 G T 5.06E-04 Major depressive disorder IZUMO1 intron 22472876 rs12982115 chr19 49248640 A G 5.48E-04 Major depressive disorder IZUMO1 intron 22472876 rs838145 chr19 49248730 G A 3.00E-07 Dietary macronutrient intake IZUMO1 intron 23636237 rs838145 chr19 49248730 G A 4.00E-10 Dietary macronutrient intake IZUMO1 intron 23636237 rs12975781 chr19 49249698 C T 5.00E-04 Bladder cancer IZUMO1 UTR-5 21824976 rs8104897 chr19 49249814 C A 5.12E-04 Major depressive disorder IZUMO1 UTR-5 22472876 rs8105137 chr19 49249888 G A 4.89E-04 Major depressive disorder IZUMO1 UTR-5 22472876 rs838144 chr19 49250239 C T 2.07E-04 Major depressive disorder IZUMO1 nearGene-5 22472876 rs11667321 chr19 49250538 A G 2.86E-04 Major depressive disorder IZUMO1 nearGene-5 22472876 rs2071699 chr19 49254504 G A 8.25E-13 Tumor biomarkers FUT1 missense 23300138 rs2071699 chr19 49254504 G A 3.00E-10 Elevated serum carcinoembryonic antigen levels FUT1 missense 24941225 rs838133 chr19 49259529 A G 8.00E-09 Dietary macronutrient intake FGF21 cds-synon 23372041 rs838133 chr19 49259529 A G 7.00E-09 Homocysteine levels FGF21 cds-synon 23824729 rs599951 chr19 49280140 C T 3.25E-04 Birth weight / / 17255346 rs4802507 chr19 49304660 T G 1.30E-16 Leukemia(T-cell recognition in patients) BCAT2 intron 21062987 rs736170 chr19 49313000 T C 1.30E-16 Leukemia(T-cell recognition in patients) BCAT2 intron 21062987 rs2098684 chr19 49321007 A C 6.24E-04 Myocardial Infarction HSD17B14 intron pha002873 rs17272645 chr19 49342366 C G 1.40E-05 Urinary metabolites PLEKHA4 intron 21572414 rs17206700 chr19 49361255 T C 1.44E-05 Leukocyte Counts PLEKHA4 intron pha003091 rs17272673 chr19 49362992 C A 1.55E-05 Leukocyte Counts PLEKHA4 intron pha003091 rs488463 chr19 49372244 G A 1.29E-05 Lymphocyte counts / / 22286170 rs45533432 chr19 49376683 A G 0.000000012 Prostate cancer (advanced) PPP1R15A missense 23555315 rs45533432 chr19 49376683 A G 0.00015 Breast cancer PPP1R15A missense 23555315 rs45533432 chr19 49376683 A G 0.0001 Prostate cancer PPP1R15A missense 23555315 rs7260579 chr19 49400634 C T 3.20E-09 Stroke TULP2 missense 23422753 rs9676447 chr19 49424247 C T 1.01E-05 Attention deficit hyperactivity disorder NUCB1 intron 18980221 rs9676447 chr19 49424247 C T 1.25E-05 Attention deficit hyperactivity disorder NUCB1 intron 20732625 rs9676447 chr19 49424247 C T 1.31E-06 Attention deficit hyperactivity disorder NUCB1 intron pha002875 rs2270939 chr19 49442933 T C 4.90E-04 Major depressive disorder DHDH cds-synon 21042317 rs11666105 chr19 49445817 T C 4.00E-04 Major depressive disorder DHDH missense 21042317 rs3765148 chr19 49447713 G A 2.00E-04 Cognitive impairment induced by topiramate DHDH missense 22091778 rs11667200 chr19 49455925 A T 8.76E-04 Lymphocyte counts / / 22286170 rs11667351 chr19 49456154 G T 5.37E-06 Response to tocilizumab in rheumatoid arthritis BAX nearGene-5 22491018 rs12980441 chr19 49482522 C T 3.52E-05 Height GYS1 intron pha003011 rs12980441 chr19 49482522 C T 5.63E-05 Lung function (forced vital capacity) GYS1 intron pha003104 rs3764618 chr19 49497155 A G 4.00E-08 Follicle stimulating hormone GYS1 nearGene-5 24049095 rs3810177 chr19 49535024 T C 9.82E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12986153 chr19 49546270 A C 9.86E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4002419 chr19 49554132 C T 8.92E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs3795055 chr19 49610389 T C 4.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) SNRNP70 intron 23648065 rs4802562 chr19 49617238 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs4802562 chr19 49617238 A G 4.56E-05 Insulin-related traits / / pha002901 rs1009213 chr19 49618778 A G 8.60E-04 Iris characteristics LIN7B intron 21835309 rs3764625 chr19 49649051 T G 9.77E-04 Multiple complex diseases PPFIA3 intron 17554300 rs3786557 chr19 49681281 G A 5.20E-06 Urinary metabolites TRPM4 intron 21572414 rs1177825 chr19 49738482 C T 4.85E-04 Alcohol dependence / / 20201924 rs4318314 chr19 49745289 G T 4.41E-04 Fibrinogen / / 17255346 rs352815 chr19 49755059 T C 1.30E-04 Fibrinogen / / 17255346 rs352818 chr19 49755490 T C 2.01E-04 Fibrinogen / / 17255346 rs352818 chr19 49755490 T C 9.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs419174 chr19 49755660 G A 1.28E-04 Multiple complex diseases / / 17554300 rs352822 chr19 49759232 G T 6.30E-05 Suicide attempts in bipolar disorder / / 21423239 rs2303759 chr19 49869051 T G 5.00E-09 Multiple sclerosis DKKL1 missense 21833088 rs2288481 chr19 49878196 G A 7.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DKKL1 missense 20877124 rs10405154 chr19 49899076 G A 0.00018 Prostate cancer CCDC155 missense 23555315 rs11672810 chr19 49943778 G A 9.36E-04 Lymphocyte counts SLC17A7 intron 22286170 rs2293012 chr19 49954807 T G 0.00064 Prostate cancer PIH1D1 missense 23555315 rs3786567 chr19 49991789 C T 1.50E-05 Urinary metabolites RPL13A intron 21572414 rs1064257 chr19 49993535 C G 2.70E-08 Urate (in serum),gout RPL13A cds-synon 21983786 rs2280401 chr19 50000009 G A 3.00E-08 Blood cell counts and other traits RPS11 intron 20139978 rs2280401 chr19 50000009 G A 3.35E-08 Blood cell counts and other traits RPS11 intron 20139978 rs2280401 chr19 50000009 G A 9.00E-13 Metabolite levels RPS11 intron 21909109 rs2280401 chr19 50000009 G A 3.00E-06 Serum total protein level RPS11 intron 23022100 rs2280401 chr19 50000009 G A 6.00E-09 Serum albumin level RPS11 intron 23022100 rs2280401 chr19 50000009 G A 7.00E-08 Serum total protein level RPS11 intron 23022100 rs2280401 chr19 50000009 G A 8.00E-07 Serum albumin level RPS11 intron 23022100 rs62128084 chr19 50014801 G C 2.20E-08 Urate (in serum),gout / / 21983786 rs1132990 chr19 50028163 A G 1.23E-05 Cognitive test performance FCGRT intron 20125193 rs12104272 chr19 50148052 G A 1.89E-04 Multiple complex diseases SCAF1 intron 17554300 rs12104272 chr19 50148052 G A 6.97E-05 Schizophrenia SCAF1 intron 19571809 rs2230667 chr19 50165702 C T 3.01E-27 HDL cholesterol IRF3 missense 23063622 rs2230667 chr19 50165702 C T 7.32E-20 LDL cholesterol IRF3 missense 23063622 rs2230667 chr19 50165702 C T 7.57E-34 Cholesterol,total IRF3 missense 23063622 rs2230667 chr19 50165702 C T 8.20E-10 Triglycerides IRF3 missense 23063622 rs3745469 chr19 50177171 G A 5.85E-06 Lymphocyte counts BCL2L12 UTR-3 22286170 rs10415880 chr19 50189156 G A 8.88E-05 Rheumatoid arthritis PRMT1 intron 17804836 rs10415880 chr19 50189156 G A 2.45E-05 Post-operative nausea and vomiting PRMT1 intron 21694509 rs10417008 chr19 50203553 T C 1.92E-05 Interstitial lung disease CPT1C intron 23583980 rs8105199 chr19 50206231 G A 0.000000131 Cholesterol,total CPT1C intron 23063622 rs8105199 chr19 50206231 G A 3.60E-09 LDL cholesterol CPT1C intron 23063622 rs62128132 chr19 50217955 T C 4.70E-11 Urate (in serum),gout / / 21983786 rs3810265 chr19 50223266 G A 4.00E-06 Panic disorder / / 19165232 rs8102150 chr19 50230327 C G 7.00E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs10408812 chr19 50276132 G A 2.00E-04 Cognitive impairment induced by topiramate AP2A1 intron 22091778 rs10408812 chr19 50276132 G A 9.52E-05 Cognitive impairment induced by topiramate AP2A1 intron 22091778 rs10424031 chr19 50286993 C G 8.36E-04 Aortic root size AP2A1 intron 21223598 rs7251251 chr19 50294150 G A 5.23E-05 HIV-1 control AP2A1 intron 20041166 rs2286948 chr19 50316754 C T 6.88E-04 Alcohol dependence / / 21314694 rs2017698 chr19 50338236 C T 1.00E-07 Blood trace element (Se levels) MED25 intron 23720494 rs752522 chr19 50338453 C G,T 7.84E-05 Alcohol and nictotine co-dependence MED25 intron 20158304 rs2290775 chr19 50375242 C T 0.0000583 Nicotine dependence (smoking) AKT1S1 intron 22377092 rs4287688 chr19 50389830 G A 4.97E-04 Multiple complex diseases TBC1D17 intron 17554300 rs1290753 chr19 50401661 C T 0.0000757 Nonsyndromic striae distensae (stretch marks) IL4I1 intron 23633020 rs1290754 chr19 50404939 T G 2.67E-05 Monocyte counts IL4I1 cds-synon pha003089 rs1299491 chr19 50419399 A C 8.70E-08 Meningococcal disease NUP62 intron 20694013 rs3826777 chr19 50431388 G A 3.86E-05 Monocyte counts NUP62 intron pha003089 rs283526 chr19 50435862 C T 5.47E-05 Monocyte counts ATF5 missense pha003089 rs3170545 chr19 50436715 G A 1.06E-04 Lymphocyte counts ATF5 UTR-3 22286170 rs16981612 chr19 50483541 C T 6.03E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) VRK3 intron 23648065 rs7254850 chr19 50492030 C T 5.81E-04 Response to cytadine analogues (cytosine arabinoside) VRK3 intron 24483146 rs10424282 chr19 50492860 C G 8.39E-10 Lymphocyte counts VRK3 intron 22286170 rs745952 chr19 50497523 C T 2.00E-05 Post-operative nausea and vomiting VRK3 intron 21694509 rs3786673 chr19 50502912 C T 7.10E-04 Response to taxane treatment (placlitaxel) VRK3 intron 23006423 rs3745495 chr19 50524332 A G 8.48E-04 HIV-1 viral setpoint VRK3 intron 17641165 rs11883067 chr19 50540471 G A 2.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) ZNF473 intron 23648065 rs10422999 chr19 50563220 C A 9.82E-04 Alcohol dependence LOC100287477 missense 21314694 rs8101040 chr19 50563899 C A 1.40E-05 Post-operative nausea and vomiting FLJ26850 intron 21694509 rs34423127 chr19 50675995 A G 2.03E-04 Multiple complex diseases / / 17554300 rs4802666 chr19 50721074 G A 5.00E-06 Disc degeneration (lumbar) MYH14 intron 22993228 rs584975 chr19 50741570 G A 1.03E-04 Cholesterol MYH14 intron 17255346 rs662382 chr19 50750945 G A 4.15E-04 Blood pressure MYH14 intron 17255346 rs11670669 chr19 50751798 G A 4.24E-06 Alcohol and nictotine co-dependence MYH14 intron 20158304 rs8112720 chr19 50771322 T C 6.70E-05 Blood Pressure MYH14 intron pha003046 rs1078446 chr19 50803403 A G 3.58E-04 Response to taxane treatment (placlitaxel) MYH14 intron 23006423 rs2230245 chr19 50909765 C T 6.00E-06 Obesity-related traits POLD1 cds-synon 23251661 rs3745516 chr19 50926742 A G 8.00E-11 Primary biliary cirrhosis SPIB intron 20639880 rs3745516 chr19 50926742 A G 2.00E-13 Primary biliary cirrhosis SPIB intron 21399635 rs1726773 chr19 50927570 T C 2.73E-07 Primary biliary cirrhosis SPIB intron 21399635 rs2445828 chr19 50941807 A G 2.52E-04 Smoking initiation MYBPC2 intron 24665060 rs25668 chr19 50965272 T C 1.72E-05 Smoking initiation MYBPC2 cds-synon 24665060 rs1274604 chr19 50969325 A G 5.60E-05 Smoking initiation MYBPC2 intron 24665060 rs1274597 chr19 50973259 T C 4.37E-04 Smoking initiation FAM71E1 intron 24665060 rs1274596 chr19 50973476 A G 1.08E-04 Smoking initiation FAM71E1 intron 24665060 rs921938 chr19 50982086 C A 1.75E-05 Smoking initiation C19orf63 intron 24665060 rs2431821 chr19 50995098 G A 2.42E-05 Smoking initiation / / 24665060 rs2463241 chr19 50996961 A G 3.02E-05 Smoking initiation / / 24665060 rs1298062 chr19 51004754 A G 7.00E-06 Smoking initiation / / 24665060 rs2305761 chr19 51015869 G A 1.56E-05 Hemoglobin ASPDH intron pha003098 rs2305761 chr19 51015869 G A 4.91E-05 Erythrocyte counts ASPDH intron pha003099 rs889131 chr19 51017835 G A 2.19E-05 Smoking initiation ASPDH UTR-5 24665060 rs1726774 chr19 51018817 A G 2.29E-04 Smoking initiation / / 24665060 rs1014205 chr19 51036235 C G 3.50E-06 Urinary metabolites LRRC4B intron 21572414 rs8107394 chr19 51046577 C T 2.90E-05 Body Mass Index LRRC4B intron pha003015 rs12610929 chr19 51059088 A G 3.71E-05 Platelet counts LRRC4B intron pha003100 rs8100750 chr19 51083595 T C 1.89E-11 Narcolepsy / / 19629137 rs1895373 chr19 51109793 C A 7.60E-04 Lymphocyte counts / / 22286170 rs9676278 chr19 51113245 T G 1.10E-06 Urinary metabolites / / 21572414 rs4801843 chr19 51159189 C T 6.10E-05 Myopia (pathological) C19orf81 intron 21095009 rs8101383 chr19 51166691 C G 0.0000223 Panic disorder SHANK1 intron 23149450 rs8101383 chr19 51166691 C G 2.23E-05 Serum tamsulosin hydrochloride concentration SHANK1 intron 23151678 rs3745532 chr19 51206053 A G 2.21E-04 Response to cytadine analogues (cytosine arabinoside) SHANK1 intron 24483146 rs722036 chr19 51230490 A G 8.65E-05 Serum metabolites / / 19043545 rs722036 chr19 51230490 A G 8.92E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12459891 chr19 51279882 C T 1.79E-04 Myopia (pathological) / / 21095009 rs1465557 chr19 51281225 A C 9.40E-05 Response to statin therapy / / 20339536 rs4802742 chr19 51303304 A C 1.25E-04 Response to statin treatment (atorvastatin),change in cholesterol levels C19orf48 intron 20031582 rs2659056 chr19 51335943 T C 1.20E-07 Prostate cancer KLK15 nearGene-5 18264097 rs2569729 chr19 51345821 G A 4.79E-04 Multiple complex diseases / / 17554300 rs266849 chr19 51349090 G A 8.90E-17 Prostate cancer / / 18264097 rs266849 chr19 51349090 G A 6.00E-10 Prostate-specific antigen levels / / 21160077 rs266849 chr19 51349090 G A 1.68E-08 Prostate-specific antigen / / 23555315 rs266870 chr19 51351934 T C 2.10E-09 Prostate cancer / / 18264097 rs266870 chr19 51351934 T C 1.30E-09 Prostate-specific antigen levels / / 21160077 rs1061477 chr19 51360096 T C 0.000000023 Asthma KLK3 intron 23040885 rs17632542 chr19 51361757 T C 3.00E-46 Prostate-specific antigen levels KLK3 missense 21160077 rs17632542 chr19 51361757 T C 9.95E-09 Prostate-specific antigen KLK3 missense 23555315 rs17632542 chr19 51361757 T C 1.00E-07 Prostate cancer (early onset) KLK3 missense 24740154 rs17632542 chr19 51361757 T C 2.00E-28 Prostate cancer KLK3 missense 24753544 rs1058205 chr19 51363398 C T 1.80E-20 Prostate cancer KLK3 UTR-3 18264097 rs1058205 chr19 51363398 C T 5.40E-20 Prostate-specific antigen levels KLK3 UTR-3 21160077 rs1058205 chr19 51363398 C T 8.00E-21 Prostate-specific antigen levels KLK3 UTR-3 24919509 rs2735839 chr19 51364623 A G 2.00E-18 Prostate cancer / / 18264097 rs2735839 chr19 51364623 A G 2.00E-18 Nasopharyngeal carcinoma / / 20512145 rs2735839 chr19 51364623 A G 1.80E-21 Prostate-specific antigen levels / / 21160077 rs2735839 chr19 51364623 A G 6.00E-37 Prostate-specific antigen levels / / 23269536 rs2735839 chr19 51364623 A G 0.000058 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs2735839 chr19 51364623 A G 0.00031 Prostate cancer / / 23555315 rs2735839 chr19 51364623 A G 6.39E-08 Prostate-specific antigen / / 23555315 rs2735839 chr19 51364623 A G 3.70E-05 Prostate cancer (early onset) / / 24740154 rs4141856 chr19 51368504 C T 5.09E-07 Blood pressure / / 21996601 rs2739459 chr19 51369074 G A 1.89E-07 PCA3 expression level / / 23555189 rs2739461 chr19 51369451 T C 1.00E-07 PCA3 expression level / / 23555189 rs2739464 chr19 51369848 G A 1.13E-07 PCA3 expression level / / 23555189 rs2739466 chr19 51370252 A G 1.13E-07 PCA3 expression level / / 23555189 rs2739468 chr19 51370543 A C 6.94E-08 PCA3 expression level / / 23555189 rs2739469 chr19 51370593 T C 1.13E-07 PCA3 expression level / / 23555189 rs1506684 chr19 51371419 A G 1.90E-09 Prostate-specific antigen levels / / 21160077 rs1506684 chr19 51371419 A G 1.00E-07 PCA3 expression level / / 23555189 rs2569739 chr19 51372395 C T 4.74E-07 PCA3 expression level / / 23555189 rs965537 chr19 51372797 C T 1.10E-07 PCA3 expression level / / 23555189 rs1997563 chr19 51373190 T C 2.28E-07 PCA3 expression level / / 23555189 rs2739472 chr19 51373279 T C 1.13E-07 PCA3 expression level / / 23555189 rs2739473 chr19 51373385 A G 1.13E-07 PCA3 expression level / / 23555189 rs2739475 chr19 51373626 A G 1.13E-07 PCA3 expression level / / 23555189 rs2739476 chr19 51373818 A G 1.39E-07 PCA3 expression level / / 23555189 rs10424878 chr19 51374967 A G 1.00E-08 PCA3 expression level KLK2 nearGene-5 23555189 rs2664156 chr19 51377163 T C 6.00E-06 Celiac disease KLK2 intron 23936387 rs198972 chr19 51379893 C T 2.78E-07 Prostate-specific antigen levels KLK2 cds-synon 23359319 rs198972 chr19 51379893 C T 3.63E-05 Blood Pressure KLK2 cds-synon pha003050 rs198977 chr19 51381777 C T 2.73E-20 Ratio of free to total prostate-specific antigen KLK2 missense 23555315 rs16987929 chr19 51385253 A G 7.90E-11 Prostate-specific antigen levels KLKP1 nearGene-3 23359319 rs8103659 chr19 51385402 A G 1.35E-10 Prostate-specific antigen levels / / 23359319 rs198957 chr19 51389560 C T 1.81E-10 Prostate-specific antigen levels KLKP1 intron 23359319 rs198956 chr19 51390353 A G 1.83E-10 Prostate-specific antigen levels KLKP1 intron 23359319 rs7256586 chr19 51390809 C A 6.51E-11 Prostate-specific antigen levels KLKP1 intron 23359319 rs1354774 chr19 51393118 A G 6.00E-20 Prostate-specific antigen levels KLKP1 intron 23359319 rs2739482 chr19 51394286 C T 2.28E-10 Prostate-specific antigen levels KLKP1 intron 23359319 rs61044983 chr19 51396922 G T 7.77E-11 Prostate-specific antigen levels KLKP1 intron 23359319 rs8105985 chr19 51398071 C A 7.77E-11 Prostate-specific antigen levels KLKP1 intron 23359319 rs1629856 chr19 51398888 A C 1.68E-10 Prostate-specific antigen levels / / 23359319 rs2659107 chr19 51400812 C T 5.18E-04 Telomere length / / 23900074 rs1560719 chr19 51400836 A G 4.15E-04 Telomere length / / 23900074 rs806021 chr19 51405673 T C 1.63E-04 Telomere length / / 23900074 rs1654553 chr19 51411116 T C 7.46E-04 Telomere length KLK4 intron 23900074 rs198966 chr19 51412010 G A 0.0000261 Alcohol craving with or without dependence KLK4 cds-synon 22481050 rs2242670 chr19 51412315 A G 5.11E-05 Telomere length KLK4 intron 23900074 rs198967 chr19 51413021 G A 0.0000184 Alcohol craving with or without dependence KLK4 intron 22481050 rs7248321 chr19 51418505 T C 5.35E-04 Heart Failure / / pha002885 rs1701930 chr19 51419546 A G 2.00E-06 Obesity-related traits / / 23251661 rs7245858 chr19 51430596 A G 2.00E-06 Alzheimer's disease (cognitive decline) LOC390956 missense 23535033 rs8104441 chr19 51441807 T C 8.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs268905 chr19 51450929 C T 7.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KLK5 intron 20877124 rs1654531 chr19 51475649 G A 2.11E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1654523 chr19 51485194 C T 6.53E-04 Alzheimer's disease KLK7 intron 24755620 rs1701948 chr19 51489456 C T 5.33E-04 Weight loss (gastric bypass surgery) / / 23643386 rs1654558 chr19 51495709 C T 1.90E-05 Urinary metabolites / / 21572414 rs78983379 chr19 51519225 C T 0.000082 Prostate cancer (advanced) KLK10 missense 23555315 rs1048328 chr19 51527364 G A 6.78E-05 Basophils KLK11 missense pha003087 rs2250066 chr19 51529119 C T 8.90E-05 Homocysteine levels,in plasma KLK11 intron 19525478 rs2569469 chr19 51549198 A G 1.82E-04 Vaspin levels / / 22907691 rs2569469 chr19 51549198 A G 0.000182 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs10445581 chr19 51583728 C G 3.16E-05 Type 2 diabetes KLK14 intron 17463246 rs10500304 chr19 51584598 T G 3.85E-04 Type 2 diabetes KLK14 intron 17463246 rs2072689 chr19 51585615 C T 7.60E-04 Iron levels KLK14 intron pha002876 rs3745542 chr19 51587643 C T 8.74E-06 Melanoma / / 21926416 rs9917107 chr19 51614461 T G 8.74E-05 Cognitive impairment induced by topiramate / / 22091778 rs2455066 chr19 51641675 T C 6.29E-04 Type 2 diabetes / / 17463246 rs7252297 chr19 51651491 T C 6.08E-04 Alzheimer's disease SIGLEC7 intron 17998437 rs1568004 chr19 51699614 T G 0.00005086 Sarcoidosis / / 22952805 rs1566577 chr19 51699823 A G 0.00003715 Sarcoidosis / / 22952805 rs12985029 chr19 51713365 G A 1.89E-05 Alzheimer's disease (late onset) / / 21460841 rs3852865 chr19 51714065 G A 9.45E-06 Alzheimer's disease (late onset) / / 21460841 rs3826656 chr19 51726613 G A 6.00E-06 Alzheimer's disease / / 18976728 rs3826656 chr19 51726613 G A 3.80E-05 Schizophrenia / / 19571809 rs3826656 chr19 51726613 G A 6.00E-06 Alzheimer's disease (late onset) / / 21460841 rs3865444 chr19 51727962 C A 2.00E-09 Alzheimer's disease (late onset) / / 21460841 rs3865444 chr19 51727962 C A 1.60E-09 Prion diseases / / 22210626 rs3865444 chr19 51727962 C A 3.00E-06 Alzheimer's disease (late onset) / / 24162737 rs1354106 chr19 51737991 T G 8.17E-05 Alzheimer's disease (late onset) CD33 intron 21460841 rs1697531 chr19 51745142 G T 2.42E-04 Blood pressure / / 17255346 rs1697531 chr19 51745142 G T 4.70E-05 Serum metabolites / / 19043545 rs1878047 chr19 51773802 A G 5.00E-06 Body mass index / / 19851299 rs10414689 chr19 51796299 T C 9.00E-07 Palmitic acid (16:0) plasma levels / / 23362303 rs1399834 chr19 51797326 A G 7.42E-04 Coronary heart disease / / 21606135 rs8107232 chr19 51848824 A G 7.94E-06 Bone mineral density ETFB intron 21124946 rs8107235 chr19 51848834 A G 6.31E-06 Bone mineral density ETFB intron 21124946 rs8102334 chr19 51851729 G A 3.29E-06 Bone mineral density ETFB intron 21124946 rs12983461 chr19 51880341 T G 4.42E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2547319 chr19 51883149 T G 2.06E-04 Response to cytidine analogues (gemcitabine) LIM2 nearGene-3 24483146 rs6509535 chr19 51915953 A C 5.13E-05 Blood pressure (response to calcium channel blocker) SIGLEC10 intron 24192120 rs140402033 chr19 51957493 T C 0.000056 Breast cancer(er negative) SIGLEC8 missense 23555315 rs10414941 chr19 51988280 G A 6.26E-05 Lymphocyte counts / / pha003094 rs1993461 chr19 51989254 A G 6.26E-05 Lymphocyte counts / / pha003094 rs726763 chr19 51991428 G A 2.70E-05 Urinary metabolites / / 21572414 rs6509544 chr19 52003331 G C 9.22E-04 Multiple complex diseases SIGLEC12 missense 17554300 rs10421023 chr19 52009850 T C 4.75E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10421023 chr19 52009850 T C 9.12E-04 Rheumatoid arthritis / / 21452313 rs8110247 chr19 52010404 A G 8.71E-04 Rheumatoid arthritis / / 21452313 rs13343377 chr19 52011598 C A 3.53E-04 Rheumatoid arthritis / / 21452313 rs962130 chr19 52014006 G A 3.25E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs8105279 chr19 52014427 C T 5.34E-04 Obesity (extreme) / / 21935397 rs12463300 chr19 52016530 A G 2.40E-05 Urinary metabolites / / 21572414 rs16982764 chr19 52017487 T C 5.25E-04 Obesity (extreme) / / 21935397 rs8106598 chr19 52017940 C T 4.61E-06 Rheumatoid arthritis / / 19503088 rs8106598 chr19 52017940 C T 3.41E-04 Hemoglobin concentration / / 20534544 rs8106598 chr19 52017940 C T 6.75E-04 Rheumatoid arthritis / / 21452313 rs12972180 chr19 52018540 C T 4.45E-05 Acute lung injury / / 22295056 rs7247380 chr19 52020776 G A 3.46E-04 Obesity (extreme) / / 21935397 rs17239287 chr19 52022033 T C 7.34E-04 Rheumatoid arthritis / / 21452313 rs10221457 chr19 52028950 A G 1.28E-04 Multiple complex diseases SIGLEC6 intron 17554300 rs2005199 chr19 52033206 G A 2.72E-04 Rheumatoid arthritis SIGLEC6 missense 21452313 rs12609761 chr19 52035059 A C 5.10E-05 Cognitive test performance SIGLEC6 UTR-5 20125193 rs12609761 chr19 52035059 A C 3.68E-04 Rheumatoid arthritis SIGLEC6 UTR-5 21452313 rs4801875 chr19 52043612 G T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs3794986 chr19 52047314 G T 3.77E-05 Coronary heart disease / / pha003033 rs4802810 chr19 52050226 G A 3.04E-05 C-Reactive Protein / / pha003070 rs10412859 chr19 52058461 C T 2.74E-06 Left ventricular hypertrophy / / pha003052 rs7257832 chr19 52068727 G T 4.28E-04 Multiple complex diseases / / 17554300 rs7257832 chr19 52068727 G T 1.23E-05 Left ventricular hypertrophy / / pha003052 rs1125620 chr19 52069900 T C 0.0000231 Colorectal adenoma (excluding hyperplasic) / / 23677573 rs1125620 chr19 52069900 T C 0.0000231 Colorectal adenoma (including hyperplasic) / / 23677573 rs1543922 chr19 52084836 C T 3.00E-07 Response to tocilizumab in rheumatoid arthritis ZNF175 intron 22491018 rs35088603 chr19 52093744 G A 1.80E-10 Urinary metabolites / / 21572414 rs7252645 chr19 52097461 A C 1.57E-05 Height / / pha003010 rs7252645 chr19 52097461 A C 6.55E-05 Height / / pha003011 rs4801882 chr19 52127053 G A 0.0000788 Carotid intima media thickness SIGLEC5 intron 23152477 rs2278831 chr19 52131119 A G 8.25E-04 Schizophrenia SIGLEC5 missense 19197363 rs10408696 chr19 52172109 C T 9.40E-05 Orofacial clefts / / 22419666 rs11670215 chr19 52187568 T G 5.61E-04 Alcohol dependence / / 20201924 rs12462673 chr19 52198654 A G 8.85E-06 Suicide attempts in bipolar disorder LINC00085 intron 21041247 rs12462673 chr19 52198654 A G 9.34E-06 Suicide attempts in bipolar disorder LINC00085 intron 21041247 rs10417548 chr19 52228013 A G 2.70E-05 Urinary metabolites / / 21572414 rs1993104 chr19 52240249 C T 2.80E-06 Primary tooth development (time to first tooth eruption) / / 23704328 rs8104633 chr19 52246115 C T 2.00E-04 Information processing speed / / 21130836 rs11667868 chr19 52259571 A G 2.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs11084114 chr19 52259923 G C 2.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs11666254 chr19 52263162 A G 2.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs4802865 chr19 52298125 T G 6.15E-05 Suicide attempts in bipolar disorder / / 21423239 rs961551 chr19 52301781 C T 1.90E-04 Suicide attempts in bipolar disorder FPR3 intron 21423239 rs4802868 chr19 52305106 G C 1.68E-04 Suicide attempts in bipolar disorder FPR3 intron 21423239 rs12459754 chr19 52306424 C T 1.83E-04 Suicide attempts in bipolar disorder FPR3 intron 21423239 rs12459560 chr19 52318380 G T 2.08E-05 Blood Pressure FPR3 intron pha003039 rs17695224 chr19 52324216 G A 2.00E-13 HDL cholesterol FPR3 intron 24097068 rs10500310 chr19 52333018 T C 1.00E-06 Urinary metabolites / / 21572414 rs62110082 chr19 52338641 T C 1.00E-06 Bipolar disorder (body mass index interaction) / / 24322204 rs2109658 chr19 52342124 T G 4.50E-06 Urinary metabolites / / 21572414 rs10411161 chr19 52372976 C T 7.00E-06 Breast cancer ZNF577 intron 21424380 rs6509585 chr19 52374118 C T 1.30E-05 Urinary metabolites ZNF577 intron 21572414 rs7256273 chr19 52374377 G A 2.90E-05 Urinary metabolites ZNF577 intron 21572414 rs8107969 chr19 52376952 T A 1.50E-05 Urinary metabolites ZNF577 cds-synon 21572414 rs8111551 chr19 52383649 T C 9.40E-05 Mammographic density ZNF577 UTR-5 22532574 rs7250138 chr19 52385232 G C 7.62E-05 Mammographic density ZNF577 intron 22532574 rs8101509 chr19 52408826 T G 1.60E-05 Type 2 diabetes / / 17293876 rs2867321 chr19 52426086 C T 2.01E-04 Multiple complex diseases / / 17554300 rs11666461 chr19 52437487 T G 6.89E-04 Multiple complex diseases ZNF613 intron 17554300 rs11881650 chr19 52450139 G T 1.09E-04 Coronary Artery Disease / / 17634449 rs11672744 chr19 52453762 T C 8.84E-04 Multiple complex diseases / / 17554300 rs1549932 chr19 52455249 G A 0.000000308 CD8+ T cell IFN-gamma response to smallpox vaccine / / 22661280 rs8109375 chr19 52460050 T C 8.89E-04 Multiple complex diseases / / 17554300 rs2278419 chr19 52471813 T C 3.30E-05 Type 2 diabetes ZNF350 intron 17293876 rs11084127 chr19 52495380 C T 7.40E-06 Type 2 diabetes ZNF615 UTR-3 17293876 rs11084128 chr19 52495646 A T 8.80E-06 Type 2 diabetes ZNF615 UTR-3 17293876 rs2288887 chr19 52495803 A G 1.30E-05 Type 2 diabetes ZNF615 UTR-3 17293876 rs2288887 chr19 52495803 A G 1.30E-05 Type 2 diabetes ZNF615 UTR-3 19184112 rs1978717 chr19 52497250 G A 4.90E-06 Type 2 diabetes ZNF615 missense 17293876 rs1978717 chr19 52497250 G A 4.90E-06 Type 2 diabetes ZNF615 missense 19184112 rs1836002 chr19 52498522 G T 1.10E-05 Type 2 diabetes ZNF615 intron 17293876 rs11878803 chr19 52501321 G A 1.07E-05 Parkinson's disease ZNF615 intron pha002868 rs7260171 chr19 52530495 C T 7.64E-04 Multiple complex diseases ZNF614 intron 17554300 rs2288884 chr19 52532271 C T 5.00E-08 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction) / / 24280104 rs3752120 chr19 52552021 C T 4.81E-08 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction) ZNF432 UTR-5 24280104 rs3450 chr19 52552999 T C 7.56E-09 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction) / / 24280104 rs11669439 chr19 52572300 C T 8.80E-04 Suicide attempts in bipolar disorder ZNF841 intron 21041247 rs2043298 chr19 52573067 C A 3.94E-04 Gallstones ZNF841 intron 17632509 rs8101936 chr19 52576479 T A 8.51E-04 Suicide attempts in bipolar disorder ZNF841 intron 21041247 rs1560690 chr19 52578347 A G 8.47E-04 Suicide attempts in bipolar disorder ZNF841 intron 21041247 rs6509621 chr19 52581022 G A 2.30E-05 Urinary metabolites ZNF841 intron 21572414 rs12460587 chr19 52586919 T G 2.00E-09 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction) ZNF841 intron 24280104 rs7250212 chr19 52589332 T C 5.10E-06 Urinary metabolites ZNF841 intron 21572414 rs11666341 chr19 52601399 G A 1.00E-09 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction) / / 24280104 rs10411428 chr19 52607765 C T 1.00E-09 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction) / / 24280104 rs8111640 chr19 52621644 A G 4.49E-04 Lymphocyte counts ZNF616 intron 22286170 rs8107315 chr19 52647893 C T 1.05E-05 Tunica Media / / pha003037 rs12460375 chr19 52665989 C G 2.20E-05 Urinary metabolites ZNF836 intron 21572414 rs2013899 chr19 52668697 A G 4.30E-05 Type 2 diabetes ZNF836 intron 17463246 rs10423794 chr19 52709746 C A 1.00E-04 Cognitive impairment induced by topiramate PPP2R1A intron 22091778 rs8106271 chr19 52713028 G A 8.88E-05 Cognitive impairment induced by topiramate PPP2R1A intron 22091778 rs10417820 chr19 52726346 A G 4.20E-04 Schizophrenia PPP2R1A intron 20832056 rs10421191 chr19 52730342 A G 0.0006747 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10421191 chr19 52730342 A G 6.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9304726 chr19 52768083 T A,C,G 4.17E-04 Acute lung injury / / 22295056 rs2657940 chr19 52863836 G A 1.78E-04 Vaspin levels ZNF610 intron 22907691 rs2657940 chr19 52863836 G A 0.0001776 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks ZNF610 intron 22907730 rs324125 chr19 52887282 A G 7.60E-09 Stroke ZNF880 missense 23422753 rs324119 chr19 52899556 C A,G,T 8.43E-04 Alcohol dependence / / 21314694 rs324119 chr19 52899556 C A,G,T 5.08E-04 Alcohol consumption / / 23743675 rs8182486 chr19 52932420 A G 1.69E-04 Rheumatoid arthritis (ACPA-negative) / / 24532677 rs1428180 chr19 52941171 T C 0.0000112 Polycystic ovary syndrome ZNF534 missense 22951595 rs1428180 chr19 52941171 T C 1.12E-05 Intracranial aneurysm ZNF534 missense 22961961 rs1896644 chr19 52945170 G A 9.84E-04 Type 2 diabetes / / 17463246 rs2561012 chr19 52947667 G A 6.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2561018 chr19 52949568 G A 8.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2608543 chr19 52949680 C T 8.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11084166 chr19 52963650 G A 3.55E-04 Myopia (pathological) ZNF578 intron 21095009 rs7252479 chr19 53009092 C A 7.70E-04 Aortic root size ZNF578 intron 21223598 rs1984450 chr19 53013799 A G 2.70E-04 Type 2 diabetes ZNF578 intron 17463246 rs1984450 chr19 53013799 A G 7.48E-04 Multiple complex diseases ZNF578 intron 17554300 rs144870963 chr19 53057722 A G 0.00005 Breast cancer(er negative) ZNF808 missense 23555315 rs329967 chr19 53071155 A G 5.23E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7246745 chr19 53113711 G T 9.89E-05 Taste perception / / 22132133 rs8106200 chr19 53137583 C T 6.42E-04 Myocardial Infarction ZNF83 intron pha002883 rs329961 chr19 53152923 T C 2.70E-04 Type 2 diabetes and 6 quantitative traits ZNF83 intron 17848626 rs12980139 chr19 53186105 G A 1.80E-05 Urinary metabolites ZNF83 intron 21572414 rs11084178 chr19 53212361 C T 2.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZNF611 intron 20877124 rs10404486 chr19 53284135 C T 9.00E-09 Phospholipid levels (plasma) ZNF600 intron 22359512 rs10407941 chr19 53288136 C T 3.49E-04 Multiple complex diseases ZNF600 intron 17554300 rs10404881 chr19 53292844 A C 7.38E-04 Body mass index / / 21701565 rs10422970 chr19 53295536 T C 2.60E-05 Urinary metabolites / / 21572414 rs10402737 chr19 53296410 G T 5.52E-04 Type 2 diabetes / / 17463246 rs3815 chr19 53297177 A T 6.27E-05 Pulmonary function / / 20010834 rs8108824 chr19 53298745 A T 1.80E-05 Urinary metabolites / / 21572414 rs2013647 chr19 53330669 C T 1.20E-08 Gallstones / / 17632509 rs10423685 chr19 53331914 T C 1.12E-05 Post-operative nausea and vomiting / / 21694509 rs1062967 chr19 53342152 T C 3.59E-05 Post-operative nausea and vomiting ZNF468 UTR-3 21694509 rs7258677 chr19 53362705 G A 1.90E-05 Urinary metabolites / / 21572414 rs8111139 chr19 53374562 T C 4.67E-04 Alzheimer's disease / / 22005930 rs2162919 chr19 53381429 G T 1.06E-05 Alzheimer's disease ZNF320 UTR-3 22005930 rs142045433 chr19 53381938 T C 1.16E-05 Acne (severe) ZNF320 UTR-3 24927181 rs6509701 chr19 53384185 C T 5.00E-06 Alzheimer's disease ZNF320 cds-synon 22005930 rs8109094 chr19 53395303 A T 1.09E-05 Alzheimer's disease / / 22005930 rs9304742 chr19 53451291 T C 1.80E-10 Psoriasis ZNF816-ZNF321P intron 20953187 rs9304742 chr19 53451291 T C 2.11E-09 Psoriasis ZNF816-ZNF321P intron 20953187 rs10415443 chr19 53464864 C G 4.83E-04 Multiple complex diseases ZNF816 intron 17554300 rs4803025 chr19 53465524 G T 7.08E-04 Tourette syndrome ZNF816 intron 22889924 rs9967593 chr19 53470436 C T 4.45E-05 Erythrocyte counts / / pha003101 rs1661957 chr19 53478109 G A 4.54E-05 Erythrocyte counts ZNF702P intron pha003101 rs1661917 chr19 53505812 C T 7.00E-06 Urinary metabolites / / 21572414 rs16984291 chr19 53505860 G A 7.00E-06 Urinary metabolites / / 21572414 rs1650940 chr19 53507299 C G 7.00E-06 Urinary metabolites / / 21572414 rs1650937 chr19 53508214 C A 1.20E-05 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines / / 21483694 rs1650936 chr19 53508512 G T 1.20E-05 Urinary metabolites / / 21572414 rs1661906 chr19 53509678 A T 8.01E-04 Multiple complex diseases / / 17554300 rs7259688 chr19 53554240 T C 4.90E-06 Lung cancer ERVV-2 UTR-3 18385738 rs7254015 chr19 53581151 T C 1.39E-04 Lung function (forced expiratory volume in 1 second) ZNF160 intron 24023788 rs10419891 chr19 53587370 A C 1.07E-04 Arthritis (juvenile idiopathic) ZNF160 intron 22354554 rs3745180 chr19 53619391 A C 4.11E-05 Calcium levels ZNF415 intron pha003085 rs1661919 chr19 53631294 C G 5.00E-06 Urinary metabolites ZNF415 intron 21572414 rs10423632 chr19 53633550 A G 6.08E-04 Alcohol dependence ZNF415 intron 21314694 rs9967612 chr19 53634927 G T 6.55E-05 Prion diseases ZNF415 intron 22210626 rs9967612 chr19 53634927 G T 3.57E-05 Body Composition ZNF415 intron pha003012 rs2195310 chr19 53645291 T C 5.39E-04 Smoking initiation ZNF347 missense 24665060 rs16984547 chr19 53682042 T C 4.00E-06 Asthma ZNF665 intron 22561531 rs11666426 chr19 53694547 T C 3.36E-04 Abdominal aortic aneurysm ZNF665 intron 22055160 rs17272903 chr19 53708045 T C 7.01E-04 Type 2 diabetes / / 17463246 rs4358051 chr19 53708301 G A 5.07E-04 Type 2 diabetes / / 17463246 rs12462453 chr19 53708503 C G 7.49E-04 Type 2 diabetes / / 17463246 rs12981894 chr19 53723679 C T 5.67E-04 Type 2 diabetes / / 17463246 rs7246435 chr19 53743134 T C 8.16E-05 Alopecia areata ZNF677 intron 22027810 rs116784215 chr19 53747024 C G 0.000056 Breast cancer(er negative) ZNF677 missense 23555315 rs1469440 chr19 53759521 C T 6.60E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs12609049 chr19 53762537 C T 8.79E-04 Type 2 diabetes VN1R2 cds-synon 17463246 rs1978613 chr19 53768337 A T 4.52E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs4263048 chr19 53777330 G A 2.35E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs10412241 chr19 53778196 G A 7.04E-04 Insulin resistance / / 21901158 rs2965260 chr19 53780026 T C 9.00E-06 IgG glycosylation / / 23382691 rs7255074 chr19 53814574 C T 5.31E-05 Arthritis (juvenile idiopathic) / / 22354554 rs2865266 chr19 53825811 T C 3.41E-04 Body mass index / / 23669352 rs7253970 chr19 53826264 T A 4.60E-07 Urinary metabolites / / 21572414 rs17305094 chr19 53832300 G A 8.39E-05 Cognitive impairment induced by topiramate / / 22091778 rs12975688 chr19 53872428 C T 7.64E-05 Erythrocyte counts ZNF525 intron pha003099 rs4599028 chr19 53970581 A G 7.33E-05 Coronary heart disease / / pha003031 rs1284532 chr19 54011889 T C 1.62E-04 Type 2 diabetes / / 17463246 rs2708754 chr19 54025972 A G 5.79E-05 Aging (time to event) ZNF331 intron 21782286 rs11672737 chr19 54043263 G A 8.00E-06 Urinary metabolites ZNF331 intron 21572414 rs11672776 chr19 54043388 G A 1.50E-06 Urinary metabolites ZNF331 intron 21572414 rs10409187 chr19 54075317 C T 2.97E-04 Multiple complex diseases ZNF331 intron 17554300 rs16985044 chr19 54075433 G A 7.32E-04 Amyotrophic lateral sclerosis (sporadic) ZNF331 intron 24529757 rs17207173 chr19 54077870 C T 6.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZNF331 intron 20877124 rs10403457 chr19 54083601 C G 7.98E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1541925 chr19 54106547 G A 5.31E-06 Hearing function LOC284379 intron 21493956 rs10424747 chr19 54107686 G A 2.83E-05 Post-operative nausea and vomiting / / 21694509 rs16985088 chr19 54123261 T C 4.93E-04 Multiple complex diseases / / 17554300 rs8111919 chr19 54128771 G A 4.26E-04 Smoking initiation / / 24665060 rs1293700 chr19 54145953 A G 2.00E-06 Urinary metabolites / / 21572414 rs11671149 chr19 54170468 T C 2.95E-06 Hearing function / / 21493956 rs7254165 chr19 54206657 T G 7.27E-05 Cognitive impairment induced by topiramate / / 22091778 rs4801998 chr19 54219769 G A 7.10E-10 Narcolepsy / / 19629137 rs13382088 chr19 54219839 G A 2.88E-04 Insulin resistance / / 21901158 rs892031 chr19 54221141 G A 2.96E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7253869 chr19 54231277 C T 0.000847 Salmonella-induced pyroptosis / / 22837397 rs3848577 chr19 54288501 C T 8.65E-05 Cognitive test performance / / 20125193 rs3848577 chr19 54288501 C T 4.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2042295 chr19 54298975 C G 7.54E-05 Serum metabolites NLRP12 intron 19043545 rs2042296 chr19 54299014 C T 7.54E-05 Serum metabolites NLRP12 intron 19043545 rs3888090 chr19 54317914 T C 3.30E-04 Atrial fibrillation NLRP12 intron 21846873 rs3848584 chr19 54317933 T C 3.20E-04 Atrial fibrillation NLRP12 intron 21846873 rs11671984 chr19 54331671 T C 1.13E-05 Monocyte counts / / pha003089 rs7259148 chr19 54332061 T C 3.32E-04 Alzheimer's disease / / 22005930 rs7259148 chr19 54332061 T C 9.51E-05 Monocyte counts / / pha003089 rs3865481 chr19 54352596 A G 2.78E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs307941 chr19 54385104 T C 3.99E-05 Height PRKCG nearGene-5 pha003010 rs3745405 chr19 54395098 G T 3.43E-04 Blood pressure PRKCG intron 17255346 rs35387445 chr19 54449656 C T 3.66E-05 Tuberculosis / / 20694014 rs462094 chr19 54517268 A G 1.20E-05 Esophageal cancer (squamous cell) / / 20729853 rs71365421 chr19 54540667 G A 2.17E-06 Malignant pleural mesothelioma / / 23626673 rs2114650 chr19 54551282 G A 9.38E-05 Heart Failure VSTM1 intron pha002884 rs10423754 chr19 54604822 T C 9.00E-06 Response to taxane treatment (docetaxel) NDUFA3 nearGene-5 23006423 rs8111677 chr19 54605278 C T 6.06E-05 Response to taxane treatment (placlitaxel) NDUFA3 nearGene-5 23006423 rs254259 chr19 54606405 T C 1.46E-04 Response to taxane treatment (placlitaxel) NDUFA3 intron 23006423 rs254256 chr19 54609170 A G 5.70E-04 Response to taxane treatment (placlitaxel) NDUFA3 intron 23006423 rs621147 chr19 54611287 G A 2.01E-04 Response to taxane treatment (placlitaxel) TFPT intron 23006423 rs254262 chr19 54612628 A G 3.00E-06 Obesity-related traits TFPT intron 23251661 rs254262 chr19 54612628 A G 8.00E-06 Obesity-related traits TFPT intron 23251661 rs254262 chr19 54612628 A G 3.25E-05 Cholesterol TFPT intron pha003073 rs254262 chr19 54612628 A G 5.57E-05 Cholesterol TFPT intron pha003078 rs10418693 chr19 54622488 C T 2.36E-04 Response to taxane treatment (placlitaxel) PRPF31 intron 23006423 rs10424816 chr19 54630208 C A 6.32E-04 Menopause (age at onset) PRPF31 intron 22267201 rs10853869 chr19 54631097 G A 7.39E-05 Triglycerides PRPF31 intron pha003080 rs8102427 chr19 54631148 C T 5.09E-04 Smoking initiation PRPF31 intron 24665060 rs1055234 chr19 54658001 C G 6.77E-04 Response to taxane treatment (placlitaxel) CNOT3 intron 23006423 rs2576452 chr19 54676433 C T 2.00E-29 Blood metabolite ratios TMC4 intron 24816252 rs8736 chr19 54677189 C T 8.00E-18 Blood metabolite levels MBOAT7 UTR-3 24816252 rs2278499 chr19 54682867 T C 1.00E-04 Cognitive impairment induced by topiramate MBOAT7 intron 22091778 rs40167 chr19 54682975 A G 1.75E-07 Obesity-related traits MBOAT7 intron 23251661 rs36631 chr19 54691414 A G 4.82E-04 Response to cytadine analogues (cytosine arabinoside) MBOAT7 intron 24483146 rs40357 chr19 54693527 C T 4.49E-08 Obesity-related traits MBOAT7 UTR-5 23251661 rs183716 chr19 54693554 C G 5.97E-08 Obesity-related traits MBOAT7 UTR-5 23251661 rs7595 chr19 54697079 C T 3.00E-08 Obesity-related traits TSEN34 cds-synon 23251661 rs16985475 chr19 54707864 G A 1.24E-04 Alzheimer's disease RPS9 intron 17998437 rs17273267 chr19 54709328 T C 2.77E-04 Response to taxane treatment (placlitaxel) RPS9 intron 23006423 rs11666543 chr19 54711981 G A 5.01E-04 Response to taxane treatment (placlitaxel) RPS9 nearGene-3 23006423 rs3852892 chr19 54722595 G A 9.63E-04 Acute lung injury LILRB3 intron 22295056 rs2361797 chr19 54753543 A G 1.80E-05 Urinary metabolites / / 21572414 rs402071 chr19 54767879 T C 8.64E-06 Hepatocellular carcinoma / / 22807686 rs7254645 chr19 54775389 C T 9.47E-05 Hepatocellular carcinoma / / 22807686 rs380573 chr19 54785593 A G 9.51E-05 Orofacial clefts LILRB2 nearGene-5 22419666 rs386000 chr19 54792761 G C 4.00E-16 HDL cholesterol / / 20686565 rs386000 chr19 54792761 G C 3.00E-23 HDL cholesterol / / 24097068 rs17305346 chr19 54795336 G A 3.83E-05 Hepatocellular carcinoma / / 22807686 rs103294 chr19 54797848 C T 5.00E-16 Prostate cancer / / 23023329 rs103294 chr19 54797848 C T 5.72E-11 HDL cholesterol / / 23063622 rs8102662 chr19 54851228 A G 4.33E-05 Colorectal cancer LILRA4 nearGene-5 19723657 rs8102662 chr19 54851228 A G 0.00000002 Joint damage severity in rheumatoid arthritis LILRA4 nearGene-5 23696630 rs4806747 chr19 54860011 A G 4.16E-04 Alzheimer's disease (late onset) / / 21379329 rs8112280 chr19 54863993 G A 1.65E-15 LDL cholesterol / / 23063622 rs3745442 chr19 54872698 C G 0.00000116 Triglycerides LAIR1 missense 23063622 rs3745442 chr19 54872698 C G 2.73E-08 Cholesterol,total LAIR1 missense 23063622 rs11084332 chr19 54880811 T C 0.00017 Coronary artery calcification / / 23727086 rs11084337 chr19 54916104 C T 9.00E-07 Blood trace element (Se levels) / / 23720494 rs1862486 chr19 54940041 C T 2.39E-05 Response to mTOR inhibitor (everolimus) TTYH1 intron 24009623 rs10425451 chr19 54952513 C T 4.14E-07 Lymphocyte counts / / 22286170 rs3813149 chr19 54963552 A G 5.71E-05 Response to methylphenidate treatment LENG8 intron 21130132 rs10425613 chr19 54989236 T C 5.12E-05 Graves' disease / / 21841780 rs8108901 chr19 54997046 G A 1.10E-05 ldl cholesterol / / pha003077 rs10418813 chr19 55006103 C T 2.57E-04 Myopia (pathological) / / 21095009 rs6509880 chr19 55017416 T C 4.30E-04 Response to taxane treatment (placlitaxel) LAIR2 intron 23006423 rs2363059 chr19 55026398 T C 8.73E-05 Blood Pressure / / pha003039 rs8109847 chr19 55033973 G T 2.80E-04 Iris characteristics / / 21835309 rs4470262 chr19 55036661 G A 6.84E-04 Myopia (pathological) / / 21095009 rs10420030 chr19 55064414 A C 8.64E-05 Smoking quantity / / 24665060 rs10402506 chr19 55074470 A G 9.89E-04 Alcohol dependence / / 21314694 rs12980993 chr19 55105409 A C 7.05E-04 Alcohol dependence LILRA1 intron 21314694 rs400322 chr19 55172578 A G 1.00E-04 Chronic fatigue syndrome LILRB4 nearGene-5 21912186 rs1749313 chr19 55173542 G A 9.88E-05 Glucose levels LILRB4 nearGene-5 pha003061 rs11574583 chr19 55178778 G A 6.15E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines LILRB4 intron 21844884 rs11574597 chr19 55182696 C T 4.61E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1654656 chr19 55183977 T C 4.48E-04 Myopia (pathological) / / 21095009 rs11084367 chr19 55213281 G A 8.17E-05 Bipolar disorder and schizophrenia / / 20889312 rs12151161 chr19 55217589 A G 4.32E-05 Neuroblastoma / / pha002895 rs12982559 chr19 55225076 C A 9.37E-05 Relative hand skill in reading disability LILRP2 nearGene-3 24068947 rs11883241 chr19 55225613 C T 2.91E-04 Cholesterol / / 17255346 rs678812 chr19 55326594 A G 8.94E-04 Type 2 diabetes KIR3DL1 intron 17463246 rs671600 chr19 55357424 T C 4.08E-11 Hirschsprung's disease KIR2DS4 intron 19196962 rs3826878 chr19 55377211 A G 2.00E-05 Alcohol dependence KIR3DL2 intron 24277619 rs11672983 chr19 55383051 G A 7.00E-11 Inflammatory bowel disease / / 23128233 rs1865096 chr19 55396900 A G 8.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FCAR cds-synon 20877124 rs11880295 chr19 55432529 C T 3.41E-04 Amyotrophic lateral sclerosis / / 23624525 rs269912 chr19 55481398 G A 8.37E-04 Multiple complex diseases NLRP2 cds-synon 17554300 rs11667105 chr19 55509865 G A 4.01E-05 Lymphocyte counts NLRP2 intron 22286170 rs12981732 chr19 55524375 C T 4.01E-07 Lymphocyte counts / / 22286170 rs1671150 chr19 55525497 A G 1.47E-04 Cocaine dependence GP6 missense 23958962 rs1671150 chr19 55525497 A G 4.76E-04 Cocaine dependence GP6 missense 23958962 rs1671151 chr19 55525894 G A 2.80E-04 Cocaine dependence GP6 cds-synon 23958962 rs1671151 chr19 55525894 G A 5.62E-04 Cocaine dependence GP6 cds-synon 23958962 rs1671152 chr19 55526345 T G 8.00E-14 Platelet aggregation / / 20526338 rs1671152 chr19 55526345 T G 2.25E-04 Cocaine dependence / / 23958962 rs1671152 chr19 55526345 T G 5.15E-04 Cocaine dependence / / 23958962 rs1671152 chr19 55526345 T G 5.67E-05 Cocaine dependence / / 23958962 rs1671152 chr19 55526345 T G 8.84E-04 Cocaine dependence / / 23958962 rs1654413 chr19 55526359 A T 0.00025 Prostate cancer / / 23555315 rs1654413 chr19 55526359 A T 1.78E-05 Cocaine dependence / / 23958962 rs1654413 chr19 55526359 A T 4.63E-05 Cocaine dependence / / 23958962 rs2304167 chr19 55527081 C T 0.00007 Prostate cancer GP6 missense 23555315 rs2304167 chr19 55527081 C T 0.00019 Prostate cancer (non-advanced prostate cancer) GP6 missense 23555315 rs2304167 chr19 55527081 C T 2.09E-04 Cocaine dependence GP6 missense 23958962 rs2304167 chr19 55527081 C T 8.44E-05 Cocaine dependence GP6 missense 23958962 rs1654416 chr19 55530035 C T 1.56E-04 Type 2 diabetes GP6 missense 17463246 rs11671922 chr19 55535289 A G 3.86E-04 Type 2 diabetes GP6 intron 17463246 rs11084381 chr19 55535412 T C 2.15E-04 Prion diseases GP6 intron 22210626 rs11084382 chr19 55535434 A G 4.60E-05 Type 2 diabetes GP6 intron 17463246 rs11668169 chr19 55535482 T C 3.38E-04 Type 2 diabetes GP6 intron 17463246 rs11668169 chr19 55535482 T C 1.41E-04 Smoking cessation GP6 intron 18519826 rs11672026 chr19 55535515 A G 2.50E-04 Type 2 diabetes GP6 intron 17463246 rs1654419 chr19 55535881 A G 3.24E-04 Type 2 diabetes GP6 intron 17463246 rs1654420 chr19 55536206 T A 3.13E-04 Type 2 diabetes GP6 intron 17463246 rs1613662 chr19 55536595 G A 5.74E-04 Cocaine dependence GP6 missense 23958962 rs1654421 chr19 55537462 A G 3.69E-04 Type 2 diabetes GP6 intron 17463246 rs17836542 chr19 55549386 C G 9.56E-05 Lipid levels GP6 intron 19913121 rs1671214 chr19 55552823 A G 1.90E-05 Smoking cessation / / 18519826 rs1671214 chr19 55552823 A G 8.11E-05 Alzheimer's disease (late onset) / / 21460841 rs1671214 chr19 55552823 A G 2.00E-05 Urinary metabolites / / 21572414 rs1671215 chr19 55553019 C A 8.82E-05 Alzheimer's disease (late onset) / / 21460841 rs1671215 chr19 55553019 C A 5.77E-04 Aspirin exacerbated respiratory disease in asthmatics / / 23180272 rs200577842 chr19 55591614 G A 0.000044 Breast cancer (ER positive) EPS8L1 missense 23555315 rs10417874 chr19 55632393 G A 2.73E-04 Alcohol dependence / / 21314694 rs2288529 chr19 55665689 C G 5.54E-04 Multiple complex diseases TNNI3 intron 17554300 rs3729709 chr19 55667806 T C 7.30E-07 Fasting plasma glucose TNNI3 intron 19060907 rs7248997 chr19 55680746 A G 2.76E-06 Cortisol secretion,in saliva / / 21316860 rs6509932 chr19 55681925 A G 6.06E-04 Multiple complex diseases / / 17554300 rs3859540 chr19 55682046 C T 6.18E-05 Crohn's disease / / 17684544 rs16986289 chr19 55682903 C T 2.04E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6509933 chr19 55683104 T C 1.33E-05 Cortisol secretion,in saliva / / 21316860 rs4644955 chr19 55738634 T C 8.90E-04 Cholesterol TMEM86B missense 17255346 rs12709948 chr19 55746777 G A 7.66E-04 Smoking initiation PPP6R1 intron 24665060 rs61743087 chr19 55748338 G A 0.00028 Breast cancer (ER positive) PPP6R1 cds-synon 23555315 rs3745920 chr19 55756980 A G 8.45E-04 Parkinson's disease PPP6R1 cds-synon 17052657 rs12983684 chr19 55760460 G A 5.08E-05 Left ventricular hypertrophy PPP6R1 intron pha003052 rs4473307 chr19 55766806 T G 8.60E-05 Alcohol withdrawal symptoms PPP6R1 intron 22072270 rs10411896 chr19 55783552 A C 5.95E-04 Amyotrophic lateral sclerosis (sporadic) HSPBP1 intron 24529757 rs1551562 chr19 55814881 A G 4.15E-04 Parkinson's disease BRSK1 intron 17052657 rs1551562 chr19 55814881 A G 3.10E-04 Fibrinogen BRSK1 intron 17255346 rs1551562 chr19 55814881 A G 1.04E-09 Menopause (age at onset) BRSK1 intron 19448619 rs1172822 chr19 55819845 C T 6.00E-11 Menopause (age at onset) BRSK1 intron 19448619 rs1172822 chr19 55819845 C T 2.00E-19 Menarche and menopause (age at onset) BRSK1 intron 19448621 rs1172822 chr19 55819845 C T 1.80E-19 Menopause (age at onset) BRSK1 intron 23424626 rs2384687 chr19 55831188 A G 1.39E-10 Menopause (age at onset) TMEM150B intron 19448619 rs2384687 chr19 55831188 A G 2.40E-18 Menopause (age at onset) TMEM150B intron 23424626 rs10412726 chr19 55832427 T G 9.10E-04 Acute lung injury TMEM150B intron 22295056 rs10411773 chr19 55832555 G A 9.10E-04 Acute lung injury TMEM150B intron 22295056 rs734518 chr19 55832884 G A 9.19E-04 Acute lung injury TMEM150B intron 22295056 rs11668344 chr19 55833664 A G 1.00E-59 Menopause (age at onset) TMEM150B intron 22267201 rs11668344 chr19 55833664 A G 5.00E-26 Menopause (age at onset) TMEM150B intron 23307926 rs897798 chr19 55833754 A G 3.91E-08 Menopause (age at onset) TMEM150B intron 19448619 rs897798 chr19 55833754 A G 5.46E-04 Acute lung injury TMEM150B intron 22295056 rs897798 chr19 55833754 A G 1.10E-14 Menopause (age at onset) TMEM150B intron 23424626 rs11084394 chr19 55842045 T C 4.40E-04 Alcohol dependence / / 20201924 rs11084394 chr19 55842045 T C 6.60E-04 Alcohol dependence / / 20201924 rs2384685 chr19 55854313 G A 7.71E-05 Parkinson's disease (motor and cognition) SUV420H2 intron 22658654 rs2384685 chr19 55854313 G A 7.71E-05 Immune response to anthrax vaccine SUV420H2 intron 22658931 rs12976922 chr19 55870351 T C 7.85E-04 Suicide attempts in bipolar disorder FAM71E2 missense 21423239 rs4252568 chr19 55874642 C T 3.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs1042506 chr19 55877111 A C 1.91E-04 Suicide attempts in bipolar disorder IL11 UTR-3 21423239 rs4252548 chr19 55879672 C T 1.60E-07 Height IL11 missense 21194676 rs4252548 chr19 55879672 C T 7.10E-13 Height IL11 missense 21194676 rs4252548 chr19 55879672 C T 9.60E-07 Height IL11 missense 21194676 rs1126757 chr19 55879872 C T 3.00E-06 Response to antidepressants IL11 cds-synon 20360315 rs6509940 chr19 55883879 C T 7.57E-04 Smoking quantity / / 24665060 rs2305788 chr19 55890834 G A 6.20E-04 Coronary heart disease TMEM238 intron 21966275 rs4806668 chr19 55897170 T G 5.12E-05 Bipolar disorder / / 20451256 rs147614077 chr19 55897956 G A 0.00018 Prostate cancer RPL28 missense 23555315 rs12709950 chr19 55913678 C A 5.26E-04 Prostate cancer mortality UBE2S intron 20978177 rs2891577 chr19 55914444 T C 1.06E-04 Multiple complex diseases UBE2S intron 17554300 rs4801702 chr19 56009881 T C 6.68E-05 Blood pressure SSC5D intron 17255346 rs626616 chr19 56032163 A G 4.77E-05 Lymphocyte counts / / 22286170 rs310451 chr19 56050844 A G 7.54E-04 Multiple complex diseases / / 17554300 rs149546760 chr19 56091332 G C 5.00E-06 Periodontitis (Mean PAL) ZNF579 intron 24024966 rs140900046 chr19 56111075 G A 4.00E-06 Periodontitis (Mean PAL) / / 24024966 rs751729 chr19 56132661 G A 4.84E-04 Myocardial Infarction ZNF784 UTR-3 pha002873 rs310475 chr19 56153868 G A 9.87E-05 Coronary heart disease ZNF580 UTR-5 pha003055 rs310436 chr19 56178559 T C 8.45E-04 Depression (quantitative trait) U2AF2 intron 20800221 rs2287831 chr19 56220444 T G 1.18E-05 stroke (ischemic) NLRP9 intron 17434096 rs11882068 chr19 56227165 A G 3.25E-05 Breast cancer(er negative) NLRP9 intron 21062454 rs1019488 chr19 56231997 T C 4.42E-05 Serum metabolites NLRP9 intron 19043545 rs10423927 chr19 56235537 A G 8.95E-04 Heart Failure NLRP9 intron pha002885 rs7259060 chr19 56251290 G A 3.50E-05 White blood cell types / / 21738478 rs17634917 chr19 56265664 A G 3.00E-06 Major depressive disorder / / 23377640 rs17634917 chr19 56265664 A G 6.00E-06 Major depressive disorder / / 23377640 rs10425892 chr19 56268917 C T 5.80E-06 Urinary metabolites / / 21572414 rs1423071 chr19 56293701 G A 4.65E-06 Alcohol dependence / / 20201924 rs1423071 chr19 56293701 G A 4.65E-06 Alcoholism / / pha002891 rs10419435 chr19 56312145 T C 1.33E-04 Sudden cardiac arrest NLRP11 intron 21658281 rs299175 chr19 56313528 G A 4.00E-06 Multiple sclerosis (severity) NLRP11 intron 19010793 rs7245988 chr19 56313790 T C 0.00022 Erectile dysfunction after radiotherapy for prostate cancer NLRP11 intron 23021708 rs299170 chr19 56316470 G A 4.29E-05 Coronary heart disease NLRP11 intron 21606135 rs299165 chr19 56319525 A G 9.75E-04 Type 2 diabetes NLRP11 intron 17463246 rs10500321 chr19 56319571 A G 8.00E-04 Chronic fatigue syndrome NLRP11 intron 21912186 rs12461110 chr19 56320663 G A 9.00E-10 Menopause (age at onset) NLRP11 missense 22267201 rs12461110 chr19 56320663 G A 9.00E-08 Menopause (age at onset) NLRP11 missense 23307926 rs12610400 chr19 56323209 T C 2.25E-04 Parkinson's disease NLRP11 intron 17052657 rs12610400 chr19 56323209 T C 4.59E-07 Height NLRP11 intron pha003010 rs12610400 chr19 56323209 T C 6.99E-07 Height NLRP11 intron pha003011 rs7248235 chr19 56340369 C T 2.84E-05 Height NLRP11 intron pha003010 rs7248235 chr19 56340369 C T 6.79E-07 Height NLRP11 intron pha003011 rs2616943 chr19 56341574 G A 1.20E-05 Height NLRP11 intron pha003010 rs2616943 chr19 56341574 G A 2.28E-07 Height NLRP11 intron pha003011 rs302476 chr19 56343087 T C 7.47E-04 Alzheimer's disease NLRP11 intron 17998437 rs302469 chr19 56348516 G T 8.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NLRP4 intron 20877124 rs441827 chr19 56369189 G A 4.76E-04 Heart Failure NLRP4 missense pha002884 rs16986718 chr19 56369314 G A 3.57E-05 Blood Pressure NLRP4 cds-synon pha003045 rs16986718 chr19 56369314 G A 8.50E-05 Blood Pressure NLRP4 cds-synon pha003047 rs140863186 chr19 56370608 A G 0.000093 Prostate cancer (advanced) NLRP4 missense 23555315 rs4801648 chr19 56436840 C T 8.49E-05 Serum metabolites NLRP13 intron 19043545 rs382958 chr19 56439438 G A 2.00E-04 Chronic fatigue syndrome NLRP13 intron 21912186 rs11883015 chr19 56439615 C T 7.34E-04 Insulin resistance NLRP13 intron 21901158 rs35081406 chr19 56441446 G A 9.68E-04 Insulin resistance NLRP13 intron 21901158 rs2043599 chr19 56451049 A G 5.00E-07 Immune reponse to smallpox (secreted IFN-alpha) / / 22610502 rs11671038 chr19 56455447 A G 6.40E-06 Urinary metabolites / / 21572414 rs919782 chr19 56455984 G C 7.30E-06 Urinary metabolites / / 21572414 rs12611033 chr19 56474236 G A 1.77E-04 Suicide attempts in bipolar disorder NLRP8 intron 21041247 rs11084419 chr19 56490943 C T 1.51E-04 Suicide attempts in bipolar disorder NLRP8 intron 21041247 rs16986856 chr19 56497960 C A 8.00E-06 Obesity-related traits NLRP8 intron 23251661 rs12462690 chr19 56511217 G A 8.70E-06 Urinary metabolites NLRP5 intron 21572414 rs4801658 chr19 56515594 T C 8.16E-04 Nicotine smoking NLRP5 intron 19268276 rs387220 chr19 56521022 A C 7.31E-05 Lung function (forced vital capacity) NLRP5 intron pha003104 rs16986877 chr19 56521381 A G 1.28E-04 Blood pressure (response to calcium channel blocker) NLRP5 intron 24192120 rs3097879 chr19 56528046 A T 2.38E-05 Biliary atresia NLRP5 intron 20460270 rs306428 chr19 56530664 A G 5.09E-04 Bipolar disorder NLRP5 intron 19259986 rs11084422 chr19 56548392 C T 8.46E-04 Obesity (extreme) NLRP5 intron 21935397 rs16986899 chr19 56549510 T C 8.81E-04 Nicotine smoking NLRP5 missense 19268276 rs10409555 chr19 56572832 G A 5.80E-05 Major depressive disorder NLRP5 missense 21042317 rs11672395 chr19 56595717 T C 8.76E-04 Multiple complex diseases / / 17554300 rs684653 chr19 56623343 T C 5.62E-04 Type 2 diabetes ZNF787 intron 17463246 rs506547 chr19 56629389 G T 5.97E-04 Type 2 diabetes ZNF787 intron 17463246 rs578991 chr19 56631228 G A 6.86E-04 Type 2 diabetes ZNF787 intron 17463246 rs659424 chr19 56637491 T G 6.86E-04 Type 2 diabetes / / 17463246 rs3745836 chr19 56652592 G A 8.64E-04 Multiple complex diseases ZNF444 UTR-5 17554300 rs10405607 chr19 56684824 T C 3.10E-04 Asthma / / 20698975 rs10405607 chr19 56684824 T C 7.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7258661 chr19 56691601 C A 8.30E-07 Blood cell counts and traits,in red and white blood cells GALP intron 21153663 rs3745833 chr19 56693620 C G 5.00E-05 Alzheimer's disease (late onset) GALP missense 21460841 rs12709954 chr19 56716579 C T 1.50E-06 Urinary metabolites / / 21572414 rs2033486 chr19 56752381 T A 6.90E-04 Type 2 diabetes / / 17463246 rs8110429 chr19 56754719 C G 7.02E-06 Serum metabolites / / 19043545 rs10410314 chr19 56781053 G A 7.06E-04 Smoking cessation / / 24665060 rs4801699 chr19 56785231 C T 5.43E-05 Post-operative nausea and vomiting / / 21694509 rs11084444 chr19 56817035 G A 1.90E-05 Urinary metabolites LOC100506374 intron 21572414 rs11882259 chr19 56817112 G C 1.80E-05 Urinary metabolites LOC100506374 intron 21572414 rs8110950 chr19 56897289 C G 3.03E-04 Depression (quantitative trait) ZNF582 intron 20800221 rs9636161 chr19 56900486 C T 7.12E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) ZNF582 intron 23648065 rs12980022 chr19 56910989 T C 4.50E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6509996 chr19 56914994 T C 2.44E-04 Parkinson's disease / / 16252231 rs917649 chr19 56924761 A G 7.40E-05 Cognitive test performance ZNF583 intron 20125193 rs917650 chr19 56931672 C T 4.37E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) ZNF583 intron 24236485 rs4281830 chr19 56933285 G A 1.30E-07 Platelet aggregation(pre- and post-aspirin) ZNF583 intron 20529293 rs917652 chr19 56934111 A G 1.60E-07 Platelet aggregation(pre- and post-aspirin) ZNF583 intron 20529293 rs3810340 chr19 56935527 A G 1.30E-07 Platelet aggregation(pre- and post-aspirin) ZNF583 cds-synon 20529293 rs8104319 chr19 56939571 G A 8.42E-06 Cognitive test performance / / 20125193 rs8104319 chr19 56939571 G A 1.70E-06 Bone mineral density (BMD),in women / / 20164292 rs8104319 chr19 56939571 G A 1.30E-07 Platelet aggregation(pre- and post-aspirin) / / 20529293 rs3760849 chr19 56953585 T C 9.47E-05 Cognitive test performance ZNF667 missense 20125193 rs3760849 chr19 56953585 T C 1.70E-05 Bone mineral density (BMD),in women ZNF667 missense 20164292 rs12709959 chr19 56968314 C T 6.44E-04 Multiple complex diseases ZNF667 intron 17554300 rs4801321 chr19 56970750 A G 1.40E-04 Myasthenia gravis ZNF667 intron 23055271 rs4801163 chr19 56975386 G T 2.40E-05 Bone mineral density (BMD),in women ZNF667 intron 20164292 rs3760848 chr19 56981382 T C 4.30E-04 Myasthenia gravis ZNF667 intron 23055271 rs1542038 chr19 56984278 C T 8.52E-04 Multiple complex diseases ZNF667 intron 17554300 rs1542038 chr19 56984278 C T 6.48E-05 Serum metabolites ZNF667 intron 19043545 rs1542039 chr19 56984375 T C 3.95E-04 Multiple complex diseases ZNF667 intron 17554300 rs1542039 chr19 56984375 T C 6.48E-05 Serum metabolites ZNF667 intron 19043545 rs17273407 chr19 56996595 C G 7.10E-04 Response to taxane treatment (placlitaxel) LOC100128252 intron 23006423 rs17305409 chr19 56997668 A G 4.00E-08 Urinary metabolites LOC100128252 intron 21572414 rs985113 chr19 57000173 T G 4.00E-08 Urinary metabolites LOC100128252 intron 21572414 rs985113 chr19 57000173 T G 4.50E-05 Blood Pressure LOC100128252 intron pha003046 rs17207460 chr19 57000270 T C 8.53E-06 Blood Pressure LOC100128252 intron pha003046 rs17305423 chr19 57000806 G A 4.00E-08 Urinary metabolites LOC100128252 intron 21572414 rs877394 chr19 57002137 A G 4.54E-04 Response to taxane treatment (placlitaxel) LOC100128252 intron 23006423 rs3971706 chr19 57006069 G A 1.15E-04 Multiple complex diseases / / 17554300 rs10426952 chr19 57006853 A G 4.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs8107062 chr19 57033504 A G 3.12E-05 Lymphocyte counts ZNF471 intron 22286170 rs399970 chr19 57063916 T G 5.93E-04 Cognition,early reading ability ZFP28 intron 17684495 rs34863160 chr19 57089835 A G 9.00E-06 Obesity-related traits ZNF470 missense 23251661 rs1035115 chr19 57108783 T C 4.72E-04 Depression (quantitative trait) ZNF71 intron 20800221 rs10420820 chr19 57109821 C T 2.19E-05 Epilepsy ZNF71 intron 22116939 rs3752183 chr19 57113178 C T 1.60E-05 Epilepsy ZNF71 intron 22116939 rs3752183 chr19 57113178 C T 3.54E-05 Vaspin levels ZNF71 intron 22907691 rs3752183 chr19 57113178 C T 0.0000354 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit ZNF71 intron 22907730 rs1035116 chr19 57131436 C T 8.65E-05 Vaspin levels ZNF71 intron 22907691 rs1035116 chr19 57131436 C T 0.0000865 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit ZNF71 intron 22907730 rs10404342 chr19 57132238 C A 8.00E-06 IgE levels in asthmatics ZNF71 intron 23967269 rs1548866 chr19 57145434 C T 4.80E-04 Myasthenia gravis / / 23055271 rs12608576 chr19 57160640 G T 3.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC147670 intron 20877124 rs10408500 chr19 57226683 G A 2.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs1029837 chr19 57234652 T C 2.83E-05 Schizophrenia(age at onset) / / 21688384 rs4801372 chr19 57235156 G T 9.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12610778 chr19 57293831 G A 8.42E-04 Alzheimer's disease ZIM2 intron 22005930 rs12985183 chr19 57383453 T C 1.28E-05 Hypertension / / pha003041 rs12985183 chr19 57383453 T C 6.09E-05 Blood Pressure / / pha003045 rs12985183 chr19 57383453 T C 1.11E-05 Blood Pressure / / pha003048 rs2870478 chr19 57388895 A C 1.39E-04 Heart Failure / / pha002884 rs4801190 chr19 57421106 G A 5.15E-04 Depression (quantitative trait) / / 20800221 rs4801191 chr19 57421150 G A 2.72E-04 Depression (quantitative trait) / / 20800221 rs7259443 chr19 57422295 C G 8.17E-04 Depression (quantitative trait) / / 20800221 rs7256874 chr19 57444239 C T 4.70E-04 Multiple complex diseases / / 17554300 rs12974285 chr19 57445328 T C 1.77E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7258452 chr19 57447994 C T 7.60E-04 Multiple complex diseases / / 17554300 rs7259756 chr19 57448220 T C 7.70E-04 Multiple complex diseases / / 17554300 rs2870479 chr19 57449293 C G 9.17E-04 Multiple complex diseases / / 17554300 rs8102873 chr19 57488423 C T 8.60E-06 Urinary metabolites / / 21572414 rs2048429 chr19 57489784 T C 7.18E-04 Insulin resistance / / 21901158 rs13343495 chr19 57533173 T G 3.40E-06 Urinary metabolites / / 21572414 rs8108432 chr19 57535252 A G 4.92E-04 Alcohol dependence / / 20201924 rs12459720 chr19 57540861 T C 3.40E-06 Urinary metabolites / / 21572414 rs7255773 chr19 57544602 A G 9.66E-04 Multiple complex diseases / / 17554300 rs73058954 chr19 57573371 A G 6.79E-06 Stroke (ischemic) / / 21957438 rs10403926 chr19 57588298 A G 4.91E-04 Myocardial Infarction / / pha002873 rs10403926 chr19 57588298 A G 8.34E-04 Heart Failure / / pha002884 rs1016438 chr19 57591038 G A 6.99E-05 Caffeine consumption / / 21490707 rs7247555 chr19 57597066 A G 5.42E-04 Fibrinogen / / 17255346 rs7247555 chr19 57597066 A G 2.56E-04 Coronary Artery Disease / / 17634449 rs11084487 chr19 57605453 T C 8.70E-05 Bipolar disorder / / 22925353 rs7256254 chr19 57613598 A G 9.91E-04 Multiple complex diseases / / 17554300 rs4801433 chr19 57646570 T C 4.23E-04 Response to statin treatment (atorvastatin),change in cholesterol levels ZIM3 missense 20031582 rs10418052 chr19 57661875 G A 6.80E-04 Smoking initiation / / 24665060 rs7245501 chr19 57663794 G A 0.0002 Migraine DUXA UTR-3 22678113 rs11672517 chr19 57678194 G A 7.00E-14 Dupuytren's disease DUXA intron 21732829 rs8106506 chr19 57686211 G A 8.77E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs740400 chr19 57686804 C T 4.07E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs8108292 chr19 57713295 A G 3.65E-06 Coronary heart disease ZNF264 intron pha003030 rs8110121 chr19 57717081 G A 4.71E-04 White matter integrity ZNF264 intron 22425255 rs2074858 chr19 57723007 G C 0.00031 Breast cancer ZNF264 missense 23555315 rs917340 chr19 57723013 G A 0.00028 Breast cancer ZNF264 missense 23555315 rs2361128 chr19 57739247 A G 1.63E-04 Glycosylated haemoglobin levels / / 17255346 rs2361128 chr19 57739247 A G 4.40E-05 Obesity-related traits / / 17903300 rs758099 chr19 57743334 C T 3.86E-05 Coronary heart disease AURKC intron pha003030 rs1544492 chr19 57746072 C T 4.62E-05 Coronary heart disease AURKC intron pha003030 rs2014572 chr19 57760018 G A 7.00E-06 Hyperactive-impulsive symptoms ZNF805 missense 18821565 rs2097983 chr19 57781095 A C 8.16E-04 Alcohol dependence / / 21314694 rs10409978 chr19 57796678 G A 6.92E-05 Rheumatoid arthritis ZNF460 intron 17804836 rs7251728 chr19 57800388 A G 8.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZNF460 intron 20877124 rs3746228 chr19 57804362 G A 9.74E-04 Alcohol dependence ZNF460 UTR-3 21314694 rs862703 chr19 57865082 T C 9.82E-04 Suicide attempts in bipolar disorder ZNF304 intron 21423239 rs7250521 chr19 57870147 G A 1.89E-04 Lymphocyte counts ZNF304 UTR-3 22286170 rs886206 chr19 57884052 C T 4.40E-05 Multiple complex diseases ZNF547 intron 17554300 rs726260 chr19 57952035 A G 1.59E-04 Suicide attempts in bipolar disorder ZNF749 intron 21423239 rs7249430 chr19 57954628 G A 7.85E-04 Suicide attempts in bipolar disorder ZNF749 intron 21423239 rs886336 chr19 57963511 G A 2.40E-05 Urinary metabolites / / 21572414 rs12977381 chr19 57984190 C A 1.36E-05 Asthma ZNF772 UTR-3 23181788 rs7259303 chr19 58004563 G A 0.00065 Prostate cancer ZNF419 missense 23555315 rs144559367 chr19 58049931 A G 0.00014 Breast cancer (ER positive) ZNF549 missense 23555315 rs2269816 chr19 58064287 T C 8.90E-04 Suicide attempts in bipolar disorder ZNF550 intron 21423239 rs61734156 chr19 58067680 C T 0.00028 Breast cancer ZNF550 missense 23555315 rs12975913 chr19 58070240 C T 8.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs12610728 chr19 58073675 A G 2.92E-04 Type 2 diabetes / / 17463246 rs10423167 chr19 58091877 A C 1.14E-04 Type 2 diabetes / / 17463246 rs11880137 chr19 58095678 C G 8.45E-04 Suicide attempts in bipolar disorder ZIK1 UTR-5 21423239 rs2074205 chr19 58101310 T C 9.53E-04 Type 2 diabetes ZIK1 intron 17463246 rs9677004 chr19 58117083 A G 7.67E-04 Taste perception ZNF530 missense 22132133 rs9749439 chr19 58135349 T G 0.000302 Height (Pygmy height) / / 22570615 rs10417057 chr19 58177308 T C 5.12E-04 Insulin resistance / / 21901158 rs9749360 chr19 58186051 A G 3.88E-04 Insulin resistance ZSCAN4 intron 21901158 rs12162232 chr19 58194405 G A 1.49E-04 Insulin resistance ZNF551 intron 21901158 rs12981782 chr19 58201360 C T 9.87E-04 Alzheimer's disease / / 17998437 rs12981782 chr19 58201360 C T 3.73E-07 Telomere length / / 23001564 rs4801515 chr19 58218846 A G 4.73E-04 Lung function (forced expiratory volume in 1 second) ZNF154 intron 24023788 rs9676736 chr19 58234915 T C 2.01E-04 Lung function (forced expiratory volume in 1 second) ZNF671 intron 24023788 rs12611312 chr19 58275804 C A 5.10E-04 Multiple complex diseases / / 17554300 rs10422444 chr19 58278429 T C 4.04E-05 Body Mass Index / / pha003022 rs2303756 chr19 58331012 T C 2.08E-04 Parkinson's disease / / 17052657 rs10415951 chr19 58419874 T C 1.70E-04 Obesity (extreme) ZNF417 UTR-3 21935397 rs8108626 chr19 58432496 T C 2.26E-04 Obesity (extreme) / / 21935397 rs1544930 chr19 58436020 C T 5.78E-04 Obesity (extreme) ZNF418 intron 21935397 rs3760622 chr19 58447904 C G 2.24E-04 Obesity (extreme) / / 21935397 rs257654 chr19 58457931 A G 3.26E-05 Cognitive impairment induced by topiramate ZNF256 intron 22091778 rs257656 chr19 58460208 A T 7.11E-04 Obesity (extreme) / / 21935397 rs257662 chr19 58464629 T C 6.97E-04 Obesity (extreme) / / 21935397 rs257664 chr19 58465464 C T 6.82E-04 Obesity (extreme) / / 21935397 rs8106858 chr19 58469016 C T 9.00E-06 Obesity-related traits / / 23251661 rs257675 chr19 58484209 A C 1.00E-04 Cognitive impairment induced by topiramate C19orf18 intron 22091778 rs8105738 chr19 58495660 G C 9.74E-04 Obesity (extreme) ZNF606 intron 21935397 rs11880378 chr19 58500271 T G 9.58E-04 Obesity (extreme) ZNF606 intron 21935397 rs11668979 chr19 58501951 C G 9.50E-04 Obesity (extreme) ZNF606 intron 21935397 rs4801538 chr19 58506237 C T 9.38E-04 Obesity (extreme) ZNF606 intron 21935397 rs7245862 chr19 58506784 C T 9.28E-04 Obesity (extreme) ZNF606 intron 21935397 rs3088169 chr19 58509356 G C 9.24E-04 Obesity (extreme) ZNF606 intron 21935397 rs7248365 chr19 58510503 T C 9.10E-04 Obesity (extreme) ZNF606 intron 21935397 rs1035522 chr19 58510932 T C 9.03E-04 Obesity (extreme) ZNF606 intron 21935397 rs10411019 chr19 58516230 T C 8.36E-04 Obesity (extreme) LOC100128398 intron 21935397 rs2228276 chr19 58579640 C T 9.52E-08 Gender ZNF135 cds-synon 22362730 rs159667 chr19 58648359 C T 8.23E-05 Serum metabolites ZNF329 intron 19043545 rs159667 chr19 58648359 C T 7.80E-05 Malaria ZNF329 intron 19465909 rs159667 chr19 58648359 C T 2.20E-05 Urinary metabolites ZNF329 intron 21572414 rs7248493 chr19 58711108 C G 1.03E-06 Multiple complex diseases ZNF274 intron 17554300 rs735507 chr19 58720360 A G 2.10E-05 Urinary metabolites ZNF274 intron 21572414 rs260461 chr19 58770883 G A 8.00E-06 Attention deficit hyperactivity disorder ZNF544 intron 18821565 rs12462307 chr19 58784732 T C 7.29E-04 Response to taxane treatment (placlitaxel) LOC100506561 intron 23006423 rs11671486 chr19 58793064 C G 7.20E-06 Urinary metabolites ZNF8 intron 21572414 rs8105044 chr19 58796805 G C 7.80E-06 Urinary metabolites ZNF8 intron 21572414 rs11671477 chr19 58800346 A G 1.42E-05 Type 2 diabetes ZNF8 intron 17463246 rs11671477 chr19 58800346 A G 7.90E-06 Urinary metabolites ZNF8 intron 21572414 rs11672773 chr19 58801784 A G 1.10E-05 Urinary metabolites ZNF8 intron 21572414 rs7359922 chr19 58830261 T C 1.27E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs893182 chr19 58865068 T C 0.00012 Coronary artery calcification A1BG-AS1 intron 23727086 rs8100801 chr19 58892060 A G 0.0000504 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ZNF837 intron 22628534 rs4801583 chr19 58918405 A G 9.70E-06 Lymphocyte counts / / 22286170 rs1465789 chr19 58946056 G A 0.000124 Breast cancer early age of onset ZNF132 missense 18463975 rs1005050 chr19 58949579 C T 2.94E-05 Lymphocyte counts ZNF132 intron 22286170 rs11669741 chr19 58960481 T C 0.000294 Breast cancer early age of onset / / 18463975 rs11669741 chr19 58960481 T C 3.11E-09 Lymphocyte counts / / 22286170 rs58632700 chr19 58992001 C T 1.00E-07 Obesity-related traits ZNF446 missense 23251661 rs11669345 chr19 59062259 C T 4.20E-05 Scoliosis / / 21216876 rs3794963 chr19 59071051 C G 1.75E-04 Sudden cardiac arrest LOC100131691 intron 21658281 rs10448 chr19 59093239 T C 6.11E-05 Odorant perception / / 23910658 rs6135141 chr20 74347 G A 9.57E-04 Myocardial Infarction DEFB125 intron pha002883 rs6111385 chr20 76962 T C 2.09E-04 Parkinson's disease DEFB125 cds-synon 17052657 rs6515824 chr20 97122 C T 3.02E-04 Coronary heart disease / / 21971053 rs6116236 chr20 100699 C T 7.75E-04 Coronary heart disease / / 21971053 rs6038037 chr20 109272 C G 4.98E-04 Multiple complex diseases / / 17554300 rs4142303 chr20 139841 A T 4.65E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs6032887 chr20 164083 T C 8.61E-06 Obesity-related traits / / 23251661 rs13036722 chr20 168020 T C 7.00E-07 Obesity-related traits / / 23251661 rs6078732 chr20 186405 A G 8.89E-05 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs4813140 chr20 196604 G C 2.40E-05 Urinary metabolites / / 21572414 rs13045643 chr20 210061 G A 0.00023 Prostate cancer DEFB129 cds-synon 23555315 rs12481306 chr20 220290 C T 8.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs1978761 chr20 222836 C T 3.43E-05 Height / / pha003010 rs10222024 chr20 225058 A G 1.69E-05 Height / / pha003010 rs10221990 chr20 225605 G A 7.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs10222031 chr20 225622 T C 6.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs6111254 chr20 226153 G A 6.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs11908659 chr20 226430 T C 5.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs12479791 chr20 228355 A T 2.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs13038867 chr20 228706 G A 8.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs13037598 chr20 228740 T A 7.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs438305 chr20 230983 C T 1.85E-05 Height / / pha003010 rs365548 chr20 237618 A T 5.60E-04 Pulmonary function / / 23932459 rs6082056 chr20 264997 G A 6.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C20orf96 intron 20877124 rs6082956 chr20 288996 T C 8.51E-05 Bipolar disorder / / 19488044 rs6082956 chr20 288996 T C 6.19E-05 Bipolar Disorder / / pha002863 rs6037430 chr20 344079 T C 9.74E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs6051520 chr20 351944 T G 2.00E-07 Information processing speed / / 21130836 rs6084242 chr20 357050 C T 3.92E-05 Information processing speed / / 21130836 rs6139007 chr20 360789 T C 0.0000443 Interleukin-6 (IL-6) levels / / 23505291 rs2273463 chr20 425434 C T 8.74E-05 Stroke TBC1D20 intron pha002886 rs6052239 chr20 453461 T C 8.11E-04 Multiple complex diseases / / 17554300 rs157806 chr20 456717 T C 2.51E-04 Response to alcohol consumption (flushing response) / / 24277619 rs6037828 chr20 489009 C T 8.80E-10 Fetal hemoglobin levels CSNK2A1 intron 18245381 rs6116499 chr20 525493 G A 0.00029 Coronary artery calcification CSNK2A1 nearGene-5 23727086 rs6037986 chr20 536429 G A 0.000586 Salmonella-induced pyroptosis / / 22837397 rs6084946 chr20 549918 G C 5.00E-06 IgG glycosylation / / 23382691 rs6038071 chr20 565077 C T 3.00E-04 Colorectal cancer / / 20610541 rs282163 chr20 588089 A C 3.05E-04 Suicide attempts in bipolar disorder TCF15 intron 21423239 rs3761308 chr20 591694 C T 7.64E-05 Cognitive impairment induced by topiramate / / 22091778 rs12624577 chr20 591820 T C 6.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs282165 chr20 592038 C T 2.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs282167 chr20 592525 A G 1.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs282168 chr20 592801 T G 3.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs282169 chr20 593076 T C 2.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs6139718 chr20 593308 T C 9.88E-05 Suicide attempts in bipolar disorder / / 21423239 rs4815810 chr20 593661 A G 4.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs1533087 chr20 594780 T C 1.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs1533087 chr20 594780 T C 9.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs4813750 chr20 598427 C T 9.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs282160 chr20 600964 C T 2.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs282161 chr20 601035 C T 2.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs6139752 chr20 602622 G A 8.39E-05 Suicide attempts in bipolar disorder / / 21423239 rs6038187 chr20 603024 C T 9.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs6133220 chr20 603620 G T 4.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs6053462 chr20 605323 A G 2.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs6085198 chr20 605422 C G 7.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs4815836 chr20 605889 C T 5.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs911448 chr20 610661 T C 5.07E-04 Smoking initiation / / 24665060 rs6107706 chr20 635054 T G 6.57E-05 Progressive supranuclear palsy / / 21685912 rs12480949 chr20 638921 A G 1.38E-06 Waist Circumference / / pha003023 rs4815889 chr20 665551 A G 9.30E-06 Urinary metabolites / / 21572414 rs1535235 chr20 668559 T C 1.26E-05 Multiple complex diseases / / 17554300 rs2180579 chr20 673748 T C 8.30E-06 Obesity-related traits / / 17658951 rs6117232 chr20 689537 C T 9.50E-05 Alcoholism (heaviness of drinking) / / 21529783 rs1114734 chr20 694894 T C 5.13E-04 Type 2 diabetes / / 17463246 rs6140090 chr20 731744 A G 2.35E-04 Alzheimer's disease / / 22005930 rs3746805 chr20 744450 G A 8.49E-04 Type 2 diabetes SLC52A3 cds-synon 17463246 rs6140125 chr20 745547 C A 3.46E-20 Esophageal cancer (squamous cell) SLC52A3 intron 20729853 rs6054627 chr20 747835 A G 6.37E-04 Alcohol dependence SLC52A3 intron 21314694 rs6054678 chr20 753917 T C 6.20E-04 Type 2 diabetes / / 17463246 rs13042395 chr20 754511 C T 1.21E-11 Esophageal cancer (squamous cell) / / 20729853 rs6117615 chr20 759315 A G 7.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel) / / 24025145 rs645059 chr20 771876 A G 0.000422 Salmonella-induced pyroptosis / / 22837397 rs673261 chr20 806878 C T 5.80E-04 Multiple complex diseases / / 17554300 rs548601339 chr20 809930 C CAT 2.67E-04 Multiple complex diseases / / 17554300 rs610274 chr20 809930 C T 2.67E-04 Multiple complex diseases / / 17554300 rs6108038 chr20 819662 G A 7.00E-06 Obesity-related traits FAM110A intron 23251661 rs1045410 chr20 826666 G T 2.65E-04 Alzheimer's disease (late onset) FAM110A UTR-3 21379329 rs4816023 chr20 832763 G A 3.34E-04 Alzheimer's disease (late onset) / / 21379329 rs12625746 chr20 834480 C T 9.56E-05 Alzheimer's disease (late onset) / / 21379329 rs6140448 chr20 837800 T C 3.67E-04 Alzheimer's disease (late onset) / / 21379329 rs16994418 chr20 849993 C G 2.87E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1411192 chr20 851769 G A 2.86E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1888087 chr20 853435 T G 2.35E-05 Response to taxane treatment (placlitaxel) ANGPT4 UTR-3 23006423 rs882806 chr20 857271 T C 8.57E-04 Response to taxane treatment (placlitaxel) ANGPT4 intron 23006423 rs6108118 chr20 872509 T G 0.0000541 Triglycerides ANGPT4 intron 23063622 rs4816051 chr20 873749 T G 0.0000924 Nicotine dependence (smoking) ANGPT4 intron 22377092 rs2144151 chr20 883644 T G 7.00E-06 Urinary metabolites ANGPT4 intron 21572414 rs910389 chr20 894722 G A 5.63E-05 Schizophrenia ANGPT4 intron 19571809 rs910389 chr20 894722 G A 0.00026 Coronary artery calcification ANGPT4 intron 23727086 rs11087800 chr20 894951 G A 1.45E-05 Gaucher disease severity ANGPT4 intron 22388998 rs478451 chr20 896012 G A 9.50E-05 Personality dimensions ANGPT4 intron 18957941 rs502522 chr20 896299 T C 6.57E-06 Hearing function ANGPT4 intron 21493956 rs475922 chr20 909771 C T 2.42E-05 Myopia (pathological) / / 23049088 rs533608 chr20 920850 G A 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs502716 chr20 926397 G A 3.00E-08 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy) / / 24554482 rs502716 chr20 926397 G A 4.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy) / / 24554482 rs533747 chr20 927457 A C 4.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs533747 chr20 927457 A C 0.000137359 Hypertension (early onset hypertension) / / 22479346 rs500655 chr20 929504 G T 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs530652 chr20 930560 T C 3.12E-05 Brain structure / / 22504417 rs6056141 chr20 933185 T C 7.36E-04 Smoking cessation / / 24665060 rs6140734 chr20 934313 G A 5.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs6056182 chr20 934617 C T 7.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs550408 chr20 934948 T C 4.70E-05 Hypothyroidism / / 22493691 rs2223961 chr20 946462 T C 4.43E-04 Multiple complex diseases RSPO4 intron 17554300 rs2207323 chr20 946498 G C 2.88E-04 Multiple complex diseases RSPO4 intron 17554300 rs6140836 chr20 955412 T C 7.09E-04 Wegener's granulomatosis RSPO4 intron 23740775 rs1884114 chr20 966504 G T 1.26E-04 Multiple complex diseases RSPO4 intron 17554300 rs6140884 chr20 968892 C T 2.79E-04 HIV-1 viral setpoint RSPO4 intron 17641165 rs6056488 chr20 976269 A G 4.53E-04 Suicide attempts in bipolar disorder RSPO4 intron 21041247 rs6056491 chr20 977164 A G 1.56E-04 Suicide attempts in bipolar disorder RSPO4 intron 21041247 rs6039433 chr20 979720 T C 4.92E-04 Suicide attempts in bipolar disorder RSPO4 intron 21041247 rs1884106 chr20 981118 A G 7.87E-04 Multiple complex diseases RSPO4 intron 17554300 rs6086845 chr20 986114 T A 6.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs4816142 chr20 1001760 T C 4.83E-05 Cognitive test performance / / 20125193 rs4816142 chr20 1001760 T C 9.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs2207322 chr20 1002255 T C 9.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs2873433 chr20 1004630 A G 5.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs4816146 chr20 1005873 C T 6.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs879013 chr20 1009679 G A 3.04E-04 Endometrial cancer / / 24096698 rs879013 chr20 1009679 G A 6.13E-04 Endometrial cancer / / 24096698 rs879012 chr20 1009788 C T 2.20E-06 Stroke (ischemic) / / 22384361 rs879012 chr20 1009788 C T 9.30E-06 Stroke (ischemic) / / 22384361 rs4816153 chr20 1012798 G A 4.44E-04 Tourette syndrome / / 22889924 rs4816153 chr20 1012798 G A 1.18E-04 Endometrial cancer / / 24096698 rs4816153 chr20 1012798 G A 2.02E-04 Endometrial cancer / / 24096698 rs2064729 chr20 1017193 T C 2.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs6056801 chr20 1020318 C T 2.87E-04 Lung function (forced vital capacity) / / 24023788 rs878250 chr20 1039416 G C 3.40E-04 Coronary Artery Disease / / 17634449 rs6133763 chr20 1040936 C T 4.53E-04 Coronary Artery Disease / / 17634449 rs6087048 chr20 1041244 G T 3.14E-04 Coronary Artery Disease / / 17634449 rs4816183 chr20 1041549 T C 7.05E-04 Coronary Artery Disease / / 17634449 rs6087091 chr20 1050896 C T 3.97E-04 Lung function (forced vital capacity) / / 24023788 rs6039726 chr20 1064620 C T 3.93E-05 Coronary Artery Disease / / 17634449 rs986031 chr20 1069432 G A 7.50E-04 Coronary Artery Disease / / 17634449 rs4813923 chr20 1077097 G A 5.00E-06 Urinary metabolites / / 21572414 rs6074148 chr20 1098486 C T 2.40E-05 Urinary metabolites PSMF1 intron 21572414 rs1803415 chr20 1099523 T G 5.23E-04 Stroke PSMF1 missense pha002886 rs2268065 chr20 1102532 G A 5.83E-04 Stroke PSMF1 intron pha002886 rs2284371 chr20 1112168 A T 8.90E-06 Urinary metabolites PSMF1 intron 21572414 rs2179450 chr20 1125924 T C 3.80E-06 Urinary metabolites PSMF1 intron 21572414 rs1883522 chr20 1126724 G A 8.17E-04 Stroke PSMF1 intron pha002886 rs6077915 chr20 1130033 C T 3.85E-05 Cognitive impairment induced by topiramate PSMF1 intron 22091778 rs2300186 chr20 1134900 T C 1.76E-05 Alzheimer's disease PSMF1 intron 21098978 rs2300185 chr20 1135413 T C 2.40E-04 Coronary Artery Disease PSMF1 intron 17634449 rs2300185 chr20 1135413 T C 2.27E-05 Alzheimer's disease PSMF1 intron 21098978 rs6074191 chr20 1136156 C A 1.73E-05 Alzheimer's disease PSMF1 intron 21098978 rs4813945 chr20 1136656 G A 2.27E-05 Alzheimer's disease PSMF1 intron 21098978 rs6134051 chr20 1137204 G A 2.28E-05 Alzheimer's disease PSMF1 intron 21098978 rs2072965 chr20 1146136 T C 1.17E-05 Alzheimer's disease PSMF1 UTR-3 21098978 rs4813044 chr20 1148783 A G 1.92E-05 Alzheimer's disease / / 21098978 rs3746814 chr20 1152237 A G 2.07E-05 Alzheimer's disease / / 21098978 rs6040293 chr20 1153225 G C 2.18E-05 Alzheimer's disease / / 21098978 rs8119636 chr20 1162370 A G 7.11E-05 Cognitive test performance TMEM74B intron 20125193 rs6033064 chr20 1175527 T C 2.85E-05 Type 2 diabetes / / 17463246 rs6078104 chr20 1175894 G A 8.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs6040523 chr20 1183414 T C 7.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs397020 chr20 1205886 T C 8.00E-07 Multiple sclerosis / / 19010793 rs970084 chr20 1221171 G A 5.00E-06 Response to cytadine analogues (cytosine arabinoside) RAD21L1 intron 24483146 rs7273889 chr20 1252492 G A 3.48E-04 Multiple complex diseases SNPH intron 17554300 rs7273889 chr20 1252492 G A 9.23E-04 Alzheimer's disease SNPH intron 22005930 rs6074381 chr20 1261152 A G 5.57E-05 Response to cytadine analogues (cytosine arabinoside) SNPH intron 24483146 rs6078462 chr20 1267130 T C 2.48E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SNPH intron 24023788 rs912107 chr20 1272686 T C 2.18E-04 Fibrinogen SNPH intron 17255346 rs12624916 chr20 1295639 G A 1.42E-04 Lung function (forced expiratory volume in 1 second) SDCBP2 intron 24023788 rs6041386 chr20 1300456 C T 8.15E-06 Potassium levels SDCBP2 intron pha003086 rs4319993 chr20 1302727 A G 2.17E-06 Potassium levels SDCBP2 intron pha003086 rs6041420 chr20 1304120 T C 1.28E-05 Multiple sclerosis (brain glutamate levels) SDCBP2 intron 20802204 rs3764712 chr20 1313762 A G 2.86E-05 Potassium levels LOC100507495 intron pha003086 rs6109526 chr20 1323192 T C 3.94E-04 Gallstones LOC100507495 intron 17632509 rs6033557 chr20 1348542 A G 0.000088 Nicotine dependence (smoking) LOC100507495 intron 22377092 rs6134733 chr20 1349052 C T 2.14E-05 Orofacial clefts LOC100507495 intron 22419666 rs1323135 chr20 1357852 G T 2.02E-07 Esophageal cancer (squamous cell) FKBP1A intron 22960999 rs396721 chr20 1365530 C G 0.000000029 Cholesterol,total FKBP1A intron 23063622 rs4239709 chr20 1383729 T A 5.31E-04 Multiple complex diseases / / 17554300 rs6042018 chr20 1384298 T C 6.68E-04 Multiple complex diseases / / 17554300 rs6033672 chr20 1384338 G A 5.07E-04 Multiple complex diseases / / 17554300 rs7262035 chr20 1397898 A G 6.20E-05 Coronary heart disease / / pha003033 rs11696447 chr20 1406877 G A 9.03E-04 Multiple complex diseases / / 17554300 rs932524 chr20 1420336 C T 1.96E-05 Lymphocyte counts / / 22286170 rs16994239 chr20 1437148 A G 1.13E-04 Cognitive function NSFL1C intron 24684796 rs6042507 chr20 1459060 T G 4.00E-08 Circulating myeloperoxidase levels (serum) SIRPB2 missense 23620142 rs6110193 chr20 1471610 C T 2.42E-04 Iron levels SIRPB2 intron pha002876 rs715217 chr20 1472408 C T 5.50E-06 Urinary metabolites / / 21572414 rs6042682 chr20 1486637 T C 1.70E-05 Urinary metabolites / / 21572414 rs2422577 chr20 1492420 T C 9.74E-04 Response to alcohol consumption (flushing response) / / 24277619 rs1121672 chr20 1498363 G T 6.25E-04 Type 2 diabetes / / 17463246 rs4813157 chr20 1499127 A C 2.83E-06 Rheumatoid arthritis / / 19503088 rs2251801 chr20 1504992 T G 4.45E-04 Type 2 diabetes / / 17463246 rs6110353 chr20 1512273 C T 2.42E-04 Response to alcohol consumption (flushing response) / / 24277619 rs2249431 chr20 1533205 T C 3.57E-04 Nicotine smoking SIRPD intron 19268276 rs147405398 chr20 1551621 T C 0.00031 Breast cancer SIRPB1 missense 23555315 rs2209313 chr20 1599142 C T 8.98E-05 Attention deficit hyperactivity disorder SIRPB1 intron 22420046 rs11696842 chr20 1600794 C T 6.54E-05 Attention deficit hyperactivity disorder / / 22420046 rs2281808 chr20 1610551 T C 9.42E-04 Multiple complex diseases SIRPG intron 17554300 rs2281808 chr20 1610551 T C 1.00E-11 Type 1 diabetes SIRPG intron 19430480 rs2281808 chr20 1610551 T C 1.20E-11 Multiple sclerosis SIRPG intron 22190364 rs3746722 chr20 1610939 G A 4.57E-05 Alcohol and nictotine co-dependence SIRPG cds-synon 20158304 rs1535883 chr20 1612819 A G 5.39E-05 Alcohol and nictotine co-dependence SIRPG intron 20158304 rs1535883 chr20 1612819 A G 2.24E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SIRPG intron 24023788 rs2318044 chr20 1614288 T C 1.55E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SIRPG intron 24023788 rs9798668 chr20 1619952 C T 7.00E-07 Parkinson's disease (interaction with coffee consumption) SIRPG intron 21876681 rs963168 chr20 1638578 T C 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs963168 chr20 1638578 T C 1.05E-06 Primary biliary cirrhosis / / 21399635 rs4814413 chr20 1642302 T C 1.89E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs6110853 chr20 1650040 G A 8.71E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7345130 chr20 1656854 C T 5.56E-05 Coronary Artery Disease / / 17634449 rs6034368 chr20 1658258 C T 5.43E-05 Coronary Artery Disease / / 17634449 rs6034368 chr20 1658258 C T 1.38E-04 Lung cancer / / 19414679 rs4473456 chr20 1659992 C A 8.95E-05 Coronary Artery Disease / / 17634449 rs4254565 chr20 1660099 G A 6.30E-04 Weight loss (gastric bypass surgery) / / 23643386 rs6043722 chr20 1661245 G A 2.39E-06 Primary biliary cirrhosis / / 21399635 rs202536 chr20 1666253 C G 1.44E-04 Multiple complex diseases / / 17554300 rs202536 chr20 1666253 C G 1.11E-06 Type 1 diabetes / / 21980299 rs202520 chr20 1675292 A G 9.80E-04 Multiple complex diseases / / 17554300 rs7274477 chr20 1676943 G A 8.88E-04 Multiple complex diseases / / 17554300 rs517578 chr20 1689270 C T 9.72E-07 Serum metabolites / / 19043545 rs517578 chr20 1689270 C T 6.03E-04 Smoking initiation / / 24665060 rs599837 chr20 1689557 A G 4.07E-05 stroke (ischemic) / / 17434096 rs202493 chr20 1693713 T C 1.63E-05 stroke (ischemic) / / 17434096 rs6135782 chr20 1704114 T C 6.18E-06 Alzheimer's disease / / 21059989 rs202456 chr20 1714362 C T 1.55E-05 stroke (ischemic) / / 17434096 rs622259 chr20 1726903 G A 8.30E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs480355 chr20 1727401 C T 8.30E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs619145 chr20 1727507 G T 8.30E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6034677 chr20 1741300 G T 3.13E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6034677 chr20 1741300 G T 9.60E-04 Myocardial Infarction / / pha002883 rs202490 chr20 1748126 C T 2.54E-05 Cognitive impairment induced by topiramate / / 22091778 rs202490 chr20 1748126 C T 1.87E-04 Myocardial Infarction / / pha002883 rs6080550 chr20 1759590 C T 2.00E-09 Non-obstructive azoospermia LOC100289473 intron 22197933 rs6080552 chr20 1760811 G C 4.28E-10 Non-obstructive azoospermia / / 22197933 rs200885 chr20 1767896 G T 3.33E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs200892 chr20 1791760 C G 3.70E-04 Glaucoma-related traits / / 22058429 rs58532 chr20 1792434 G A 3.70E-04 Glaucoma-related traits / / 22058429 rs200889 chr20 1794342 G A 2.90E-04 Glaucoma-related traits / / 22058429 rs6044815 chr20 1796112 C A 2.40E-04 Glaucoma-related traits / / 22058429 rs200888 chr20 1796461 G T 3.77E-04 Smoking quantity / / 24665060 rs6044876 chr20 1807061 C A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs156353 chr20 1813373 T C 1.60E-04 Glaucoma-related traits / / 22058429 rs156353 chr20 1813373 T C 4.00E-04 Glaucoma-related traits / / 22058429 rs6034870 chr20 1815620 A G 3.08E-04 Fibrinogen / / 17255346 rs12625221 chr20 1833498 C G 8.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs635290 chr20 1841245 G A 8.19E-05 Body Mass Index / / pha003022 rs11698167 chr20 1848203 T C 5.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs6080978 chr20 1862420 C T 6.55E-04 Multiple complex diseases / / 17554300 rs6075340 chr20 1894335 G A 2.95E-04 Tourette syndrome SIRPA intron 22889924 rs3790341 chr20 1917209 G A 9.50E-05 Waist-Hip Ratio SIRPA intron pha003029 rs3828016 chr20 1917290 A G 3.21E-04 Multiple complex diseases SIRPA intron 17554300 rs3828016 chr20 1917290 A G 1.90E-07 Myocardial Infarction SIRPA intron pha002883 rs4814776 chr20 1921523 C A 4.75E-04 Aortic root size / / 21223598 rs6136489 chr20 1923734 T G 8.00E-11 Mean platelet volume / / 19820697 rs6136489 chr20 1923734 T G 7.70E-11 Mean platelet volume / / 22423221 rs13042885 chr20 1924707 C T 6.00E-14 Mean platelet volume / / 22139419 rs13042885 chr20 1924707 C T 2.00E-05 Mean platelet volume / / 24026423 rs6035126 chr20 1929542 C T 5.00E-06 Liver enzyme levels (alanine transaminase) / / 24124411 rs13433286 chr20 1931500 A G 4.94E-06 Liver enzyme levels (alanine transaminase) / / 24124411 rs6035140 chr20 1936292 C T 1.07E-04 Aortic root size / / 21223598 rs6045666 chr20 1940504 T C 2.97E-06 Aortic root size / / 21223598 rs6045666 chr20 1940504 T C 1.70E-05 Urinary metabolites / / 21572414 rs6045676 chr20 1941171 G A,C 3.00E-08 Aortic root size / / 21223598 rs6045676 chr20 1941171 G A,C 3.90E-06 Urinary metabolites / / 21572414 rs6045677 chr20 1941488 A G 7.63E-06 Aortic root size / / 21223598 rs910077 chr20 1945956 C A 7.53E-05 Cardiovascular disease / / pha003065 rs6045700 chr20 1946337 A C 5.60E-06 Urinary metabolites / / 21572414 rs6045733 chr20 1950858 G A 3.11E-05 Body Fat Distribution / / pha003016 rs8123727 chr20 1972761 A G 8.27E-05 Adipocyte fatty acid-binding protein concentration,in serum PDYN intron 21863005 rs6035310 chr20 1988599 A C 2.32E-07 Cardiovascular disease / / 18179892 rs6081597 chr20 1995534 A G 4.53E-05 Major depressive disorder (broad) / / 20038947 rs6081597 chr20 1995534 A G 7.00E-07 Immune response to smallpox vaccine (IL-6) / / 22542470 rs13433251 chr20 1999855 G C 8.48E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4405822 chr20 2050481 G T 2.27E-05 Coronary heart disease / / pha003030 rs6106185 chr20 2059311 G C 7.51E-04 Body mass index / / 21701565 rs6112747 chr20 2059834 C T 3.29E-04 Body mass index / / 21701565 rs1418029 chr20 2060151 G A 2.13E-04 Body mass index / / 21701565 rs1418029 chr20 2060151 G A 2.40E-05 Body mass index / / 21701565 rs6046629 chr20 2062981 A G 8.63E-05 Coronary heart disease / / pha003030 rs6112821 chr20 2074323 T C 3.00E-07 Immune response to measles-mumps-rubella vaccine / / 24811271 rs6046762 chr20 2077456 C T 1.56E-04 Body mass index / / 21701565 rs6046762 chr20 2077456 C T 4.79E-04 Body mass index / / 21701565 rs1418031 chr20 2077642 C T 1.25E-04 Body mass index / / 21701565 rs1418031 chr20 2077642 C T 4.15E-04 Body mass index / / 21701565 rs1418032 chr20 2077744 G C 8.92E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs4814973 chr20 2088222 T C 8.99E-05 Coronary heart disease STK35 intron pha003030 rs6137005 chr20 2088698 A G 1.80E-04 Primary sclerosing cholangitis STK35 intron 19944697 rs6132308 chr20 2102598 T C 2.30E-04 Primary sclerosing cholangitis STK35 intron 19944697 rs6112930 chr20 2106355 G A 4.30E-05 Primary sclerosing cholangitis STK35 intron 19944697 rs6112930 chr20 2106355 G A 4.09E-04 Body mass index STK35 intron 21701565 rs17779543 chr20 2108592 A G 6.08E-05 Coronary heart disease STK35 intron pha003030 rs6106265 chr20 2108880 A T 6.33E-04 Body mass index STK35 intron 21701565 rs2153741 chr20 2126096 A G 1.90E-05 Urinary metabolites STK35 UTR-3 21572414 rs2064850 chr20 2151350 A G 3.44E-04 Body mass index / / 21701565 rs16982162 chr20 2155148 G C 2.52E-05 Femoral neck bone geometry / / 22087292 rs4815018 chr20 2159791 A G 4.29E-04 Body mass index / / 21701565 rs6113123 chr20 2160542 G A 6.37E-05 Femoral neck bone geometry / / 22087292 rs4530434 chr20 2161495 G A 8.28E-04 Body mass index / / 21701565 rs1581710 chr20 2162580 G C 4.62E-04 Body mass index / / 21701565 rs1581711 chr20 2162598 G A 3.10E-04 Body mass index / / 21701565 rs10854247 chr20 2164954 G A 2.12E-05 Femoral neck bone geometry / / 22087292 rs6082335 chr20 2166427 T C 2.78E-05 Atopy / / 21094521 rs1590203 chr20 2169066 C G 6.74E-04 Body mass index / / 21701565 rs6047451 chr20 2198899 A C 3.00E-04 Prostate cancer mortality / / 20978177 rs6082438 chr20 2204811 T G 4.90E-06 Urinary metabolites / / 21572414 rs12479918 chr20 2205941 T C 8.60E-06 Urinary metabolites / / 21572414 rs59586681 chr20 2220310 A T 3.00E-09 Basal cell carcinoma / / 24403052 rs6047591 chr20 2223481 A G 1.18E-04 Response to alcohol consumption (flushing response) / / 24277619 rs6082600 chr20 2262537 T C 1.10E-04 Basal cell carcinoma / / 24403052 rs214748 chr20 2270015 C T 9.10E-04 Basal cell carcinoma / / 24403052 rs214754 chr20 2272683 A G 0.0001432 Sarcoidosis / / 22952805 rs214755 chr20 2273987 A T 0.00001771 Sarcoidosis / / 22952805 rs214755 chr20 2273987 A T 8.20E-04 Basal cell carcinoma / / 24403052 rs214756 chr20 2274381 G A 0.00001357 Sarcoidosis / / 22952805 rs214757 chr20 2274810 G A 0.00002163 Sarcoidosis / / 22952805 rs6106479 chr20 2275515 C T 0.0003884 Sarcoidosis / / 22952805 rs214758 chr20 2275528 C T 0.00001441 Sarcoidosis / / 22952805 rs214760 chr20 2275976 C T 0.00001428 Sarcoidosis / / 22952805 rs214762 chr20 2277892 T C 0.00001504 Sarcoidosis TGM3 intron 22952805 rs214763 chr20 2278028 G A 0.00001504 Sarcoidosis TGM3 intron 22952805 rs214766 chr20 2278553 G A 0.0001654 Sarcoidosis TGM3 intron 22952805 rs214768 chr20 2278992 A G 0.00001531 Sarcoidosis TGM3 intron 22952805 rs214769 chr20 2279081 G A 0.00001531 Sarcoidosis TGM3 intron 22952805 rs214770 chr20 2279435 A G 0.00001531 Sarcoidosis TGM3 intron 22952805 rs214770 chr20 2279435 A G 6.20E-04 Basal cell carcinoma TGM3 intron 24403052 rs214772 chr20 2279894 C T 0.00001109 Sarcoidosis TGM3 intron 22952805 rs214773 chr20 2279909 C T 0.00001108 Sarcoidosis TGM3 intron 22952805 rs214774 chr20 2280300 C T 0.0000105 Sarcoidosis TGM3 intron 22952805 rs214775 chr20 2280355 T C 0.00001152 Sarcoidosis TGM3 intron 22952805 rs214776 chr20 2280391 G A 0.00001301 Sarcoidosis TGM3 intron 22952805 rs214778 chr20 2280615 A G 0.0000142 Sarcoidosis TGM3 intron 22952805 rs214781 chr20 2281284 A C 0.00004884 Sarcoidosis TGM3 intron 22952805 rs214782 chr20 2281970 G A 0.00005046 Sarcoidosis TGM3 intron 22952805 rs214782 chr20 2281970 G A 6.00E-17 Basal cell carcinoma TGM3 intron 24403052 rs214783 chr20 2282049 A C 0.00004525 Sarcoidosis TGM3 intron 22952805 rs214784 chr20 2282665 C T 0.00004837 Sarcoidosis TGM3 intron 22952805 rs214785 chr20 2283457 C T 0.00004248 Sarcoidosis TGM3 intron 22952805 rs214786 chr20 2283573 A G 0.000007238 Sarcoidosis TGM3 intron 22952805 rs214788 chr20 2283684 G A 0.000001421 Sarcoidosis TGM3 intron 22952805 rs214789 chr20 2284264 A G 0.00000124 Sarcoidosis TGM3 intron 22952805 rs214790 chr20 2284906 G A 0.000002223 Sarcoidosis TGM3 intron 22952805 rs214791 chr20 2284974 C T 0.000002223 Sarcoidosis TGM3 intron 22952805 rs214792 chr20 2285035 G A 0.000002223 Sarcoidosis TGM3 intron 22952805 rs214793 chr20 2285705 C T 0.000002388 Sarcoidosis TGM3 intron 22952805 rs214794 chr20 2286057 G A 0.000002631 Sarcoidosis TGM3 intron 22952805 rs214795 chr20 2286191 C G 0.000002498 Sarcoidosis TGM3 intron 22952805 rs214799 chr20 2286704 T G 0.000003037 Sarcoidosis TGM3 intron 22952805 rs214801 chr20 2288590 G A 0.00001788 Sarcoidosis TGM3 intron 22952805 rs214801 chr20 2288590 G A 2.50E-04 Basal cell carcinoma TGM3 intron 24403052 rs214803 chr20 2290333 C A 5.00E-16 Basal cell carcinoma TGM3 missense 24403052 rs214804 chr20 2290532 T G 0.00001594 Sarcoidosis TGM3 intron 22952805 rs214805 chr20 2290547 C T 0.00001299 Sarcoidosis TGM3 intron 22952805 rs214806 chr20 2291888 A T 0.00003286 Sarcoidosis TGM3 intron 22952805 rs214807 chr20 2292273 G A 1.10E-04 Basal cell carcinoma TGM3 intron 24403052 rs13037722 chr20 2315305 T C 2.31E-04 Celiac disease TGM3 intron 23936387 rs6082805 chr20 2327417 T C 4.23E-04 Alzheimer's disease / / 22005930 rs6048338 chr20 2329083 C G 7.80E-04 Alzheimer's disease / / 22005930 rs2422705 chr20 2337295 T A 9.07E-05 Femoral neck bone geometry / / 22087292 rs2422708 chr20 2338224 T C 2.03E-05 Femoral neck bone geometry / / 22087292 rs6137776 chr20 2338454 C T 2.81E-05 Femoral neck bone geometry / / 22087292 rs6082883 chr20 2339151 C T 9.80E-05 Smoking cessation / / 24665060 rs2422728 chr20 2350192 C T 1.50E-05 Urinary metabolites / / 21572414 rs2422728 chr20 2350192 C T 1.81E-05 Femoral neck bone geometry / / 22087292 rs1474680 chr20 2351714 A G 1.50E-05 Bladder cancer / / 21824976 rs2422735 chr20 2352682 T G 6.60E-06 Urinary metabolites / / 21572414 rs6132559 chr20 2354193 C T 7.00E-05 Serum metabolites / / 19043545 rs4813474 chr20 2354561 C T 5.23E-04 Smoking cessation / / 24665060 rs1040487 chr20 2356111 A G 1.10E-05 Urinary metabolites / / 21572414 rs1967678 chr20 2364386 C T 7.86E-05 Orofacial clefts TGM6 intron 22419666 rs6083041 chr20 2372985 G A 3.11E-05 Psoriasis TGM6 intron 20953190 rs6083041 chr20 2372985 G A 7.43E-05 Stroke TGM6 intron pha002886 rs34972666 chr20 2384972 A G 3.00E-08 Alzheimer's disease (cognitive decline) TGM6 intron 23535033 rs6137946 chr20 2394641 T C 2.60E-05 Urinary metabolites TGM6 intron 21572414 rs10485600 chr20 2400503 C A 3.25E-04 Alzheimer's disease (late onset) TGM6 intron 21379329 rs6049635 chr20 2489419 T C 2.74E-05 Cortisol secretion,in saliva ZNF343 intron 21316860 rs4815273 chr20 2500871 C T 5.65E-07 Response to diuretic therapy in hypertension / / 23753411 rs4815273 chr20 2500871 C T 7.36E-05 Response to diuretic therapy in hypertension / / 23753411 rs6083538 chr20 2502740 C T 1.28E-04 Response to diuretic therapy in hypertension / / 23753411 rs6083538 chr20 2502740 C T 7.95E-07 Response to diuretic therapy in hypertension / / 23753411 rs6114758 chr20 2505124 G A 3.15E-06 Body Fat Distribution / / pha003016 rs6114758 chr20 2505124 G A 3.65E-06 Body Fat Distribution / / pha003017 rs6114758 chr20 2505124 G A 1.10E-06 Body Fat Distribution / / pha003018 rs6076240 chr20 2508538 G C 1.70E-04 Lymphocyte counts / / 22286170 rs6049839 chr20 2518565 G T 8.00E-06 Systemic lupus erythematosus TMC2 intron 21408207 rs6050469 chr20 2575369 G A 2.00E-06 Obesity-related traits TMC2 intron 23251661 rs6083915 chr20 2618140 T C 7.61E-04 Lymphocyte counts TMC2 cds-synon 22286170 rs5026920 chr20 2639728 C T 9.22E-04 Multiple complex diseases IDH3B UTR-3 17554300 rs60717353 chr20 2639728 C CGCAGATCAGAGGCAGGATGTGGCTACCGAGCAGGCAAAGATGATGGGAAAT 9.22E-04 Multiple complex diseases IDH3B UTR-3 17554300 rs71311113 chr20 2639728 C CGCAGATCAGAGGCAGGATGTGGCTACCGAGCAGGCAAAGATGATGGGAAAT 9.22E-04 Multiple complex diseases IDH3B UTR-3 17554300 rs2073192 chr20 2644996 G A 2.55E-04 Insulin resistance IDH3B nearGene-5 21901158 rs2422824 chr20 2647370 T C 9.72E-04 Multiple complex diseases / / 17554300 rs1810636 chr20 2654925 A C 3.40E-17 Pancreatic cancer / / 21849791 rs1810636 chr20 2654925 A C 6.06E-08 Pelvic organ prolapse / / 22105264 rs6051107 chr20 2657276 A G 3.85E-04 Aortic root size / / 21223598 rs4815533 chr20 2684924 A G 2.90E-04 Glaucoma-related traits EBF4 intron 22058429 rs6084148 chr20 2712329 C T 0.0000662 Transmission distortion EBF4 intron 22377632 rs4815541 chr20 2725678 T C 8.99E-04 Insulin resistance EBF4 intron 21901158 rs1005304 chr20 2735182 G A 6.86E-04 Schizophrenia EBF4 intron 19197363 rs6138892 chr20 2755488 T C 3.00E-07 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs215536 chr20 2772495 T G 4.01E-04 Parkinson's disease / / 17052657 rs6051397 chr20 2772654 C T 4.61E-04 Parkinson's disease / / 17052657 rs7360412 chr20 2800801 A C 7.00E-06 White matter integrity / / 23218918 rs6084184 chr20 2812772 A G 6.67E-05 Nephrolithiasis / / 22396660 rs6138952 chr20 2901540 A G 9.73E-04 Amyotrophic lateral sclerosis (sporadic) PTPRA intron 24529757 rs6138953 chr20 2910880 T G 0.0000018 Fasting blood glucose PTPRA intron 23487342 rs1178027 chr20 2945759 C T 4.25E-04 Amyotrophic lateral sclerosis (sporadic) PTPRA missense 24529757 rs8125955 chr20 3019957 A C 8.04E-04 Type 2 diabetes / / 17463246 rs8125955 chr20 3019957 A C 7.40E-04 Alcohol dependence / / 20201924 rs8125955 chr20 3019957 A C 6.66E-04 Endometrial cancer / / 24096698 rs2422843 chr20 3081680 C T 1.36E-05 Cognitive impairment induced by topiramate / / 22091778 rs17255260 chr20 3087576 G A 3.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs864140 chr20 3088010 G A 8.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs201315119 chr20 3089969 C CA,CC 6.59E-04 Suicide attempts in bipolar disorder UBOX5 UTR-3 21423239 rs6051581 chr20 3089969 C A 6.59E-04 Suicide attempts in bipolar disorder UBOX5 UTR-3 21423239 rs6037486 chr20 3091270 T C 9.98E-04 Suicide attempts in bipolar disorder UBOX5 intron 21423239 rs857250 chr20 3113818 A C 1.91E-05 Serum metabolites UBOX5 intron 19043545 rs306757 chr20 3119133 G A 9.01E-05 Response to platinum-based chemotherapy in small-cell lung cancer UBOX5 intron 20463552 rs857252 chr20 3119555 T G 0.0000086 LDL cholesterol response after 40mg daily simvastatin treatment UBOX5 intron 23100282 rs857252 chr20 3119555 T G 0.000029 Apolipoprotein B levels response after 40mg daily simvastatin treatment UBOX5 intron 23100282 rs7263489 chr20 3176072 C T 6.13E-04 Suicide attempts in bipolar disorder DDRGK1 intron 21423239 rs11697186 chr20 3185123 A T 5.00E-17 Response to hepatitis C treatment DDRGK1 intron 21659334 rs11697186 chr20 3185123 A T 9.00E-25 Response to hepatitis C treatment DDRGK1 intron 21659334 rs6139030 chr20 3187733 T C 1.00E-15 Response to hepatitis C treatment / / 21659334 rs6139030 chr20 3187733 T C 2.00E-25 Response to hepatitis C treatment / / 21659334 rs1127354 chr20 3193842 C A,G,T 1 Drug response to Mercaptopurine ITPA missense 18685564 rs1127354 chr20 3193842 C A,G,T 1 Drug response to Azathioprine ITPA missense 19129747 rs1127354 chr20 3193842 C A,G,T 2.00E-58 Chronic Hepatitis C infection ITPA missense 20173735 rs1127354 chr20 3193842 C A,G,T 4.00E-44 Ribavirin-induced anemia ITPA missense 20637204 rs7270101 chr20 3193893 A C 9.00E-76 Chronic Hepatitis C infection ITPA intron 20173735 rs2422862 chr20 3199703 G A 4.90E-05 Brain lesion load ITPA intron 19010793 rs2422863 chr20 3201966 C T 3.98E-05 Brain lesion load ITPA intron 19010793 rs2422863 chr20 3201966 C T 2.14E-04 Suicide attempts in bipolar disorder ITPA intron 21423239 rs3810560 chr20 3207819 T C 1.37E-04 Alzheimer's disease (late onset) SLC4A11 nearGene-3 21379329 rs3827075 chr20 3214819 T G 2.63E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SLC4A11 cds-synon 24023788 rs6051669 chr20 3216203 T C 1.16E-04 Suicide attempts in bipolar disorder SLC4A11 intron 21423239 rs6037513 chr20 3223225 T C 1.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs6037513 chr20 3223225 T C 5.25E-05 Cognitive impairment induced by topiramate / / 22091778 rs6037514 chr20 3229418 C T 1.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs732923 chr20 3231340 C G 2.41E-04 Suicide attempts in bipolar disorder C20orf194 UTR-3 21423239 rs6051689 chr20 3241613 C T 1.82E-04 Suicide attempts in bipolar disorder C20orf194 intron 21423239 rs6084320 chr20 3244564 C T 7.30E-04 Suicide attempts in bipolar disorder C20orf194 intron 21423239 rs2326084 chr20 3251356 A C 7.31E-04 Suicide attempts in bipolar disorder C20orf194 intron 21423239 rs2326084 chr20 3251356 A C 9.37E-05 Cognitive impairment induced by topiramate C20orf194 intron 22091778 rs2236087 chr20 3255905 G A 6.26E-05 Gallstones C20orf194 intron 17632509 rs2236090 chr20 3257799 A G 1.96E-04 Suicide attempts in bipolar disorder C20orf194 intron 21423239 rs2236091 chr20 3257980 A G 1.36E-04 Suicide attempts in bipolar disorder C20orf194 intron 21423239 rs1884506 chr20 3258118 C T 9.14E-04 Suicide attempts in bipolar disorder C20orf194 intron 21423239 rs2422864 chr20 3285140 T C 5.45E-04 Suicide attempts in bipolar disorder C20orf194 missense 21423239 rs6051727 chr20 3287121 T C 1.80E-04 Suicide attempts in bipolar disorder C20orf194 intron 21423239 rs6051727 chr20 3287121 T C 1.00E-04 Cognitive impairment induced by topiramate C20orf194 intron 22091778 rs2208029 chr20 3314702 T C 9.62E-04 Suicide attempts in bipolar disorder C20orf194 intron 21423239 rs8120964 chr20 3314962 C A 2.05E-04 Suicide attempts in bipolar disorder C20orf194 intron 21423239 rs6051761 chr20 3321568 C T 2.54E-07 Lymphocyte counts C20orf194 intron 22286170 rs976041 chr20 3325420 T C 3.48E-04 Suicide attempts in bipolar disorder C20orf194 intron 21423239 rs6084343 chr20 3326222 C T 6.50E-05 Suicide attempts in bipolar disorder C20orf194 intron 21423239 rs9789821 chr20 3334039 G A 3.58E-04 Suicide attempts in bipolar disorder C20orf194 intron 21423239 rs6037577 chr20 3345618 C T 2.70E-05 Suicide attempts in bipolar disorder C20orf194 intron 21423239 rs6084352 chr20 3348407 A G 2.11E-05 Suicide attempts in bipolar disorder C20orf194 intron 21423239 rs6115865 chr20 3359303 C T 3.61E-04 Longevity C20orf194 intron 22279548 rs2008901 chr20 3361908 G A 4.70E-04 Suicide attempts in bipolar disorder C20orf194 intron 21423239 rs239490 chr20 3369365 T C 2.90E-04 Suicide attempts in bipolar disorder C20orf194 intron 21423239 rs965469 chr20 3381549 T C 1.00E-09 IFN-related cytopenia C20orf194 intron 21703177 rs6133043 chr20 3436231 G A 3.43E-05 Cognitive impairment induced by topiramate / / 22091778 rs11696647 chr20 3450635 A G 2.75E-04 Type 2 diabetes ATRN nearGene-5 17463246 rs1552323 chr20 3450811 G A 2.05E-05 Blood Pressure ATRN nearGene-5 pha003043 rs8120279 chr20 3452763 T C 3.63E-04 Type 2 diabetes ATRN intron 17463246 rs238724 chr20 3469332 C G 6.90E-06 Urinary metabolites ATRN intron 21572414 rs235594 chr20 3532573 A G 9.76E-05 Type 2 diabetes ATRN intron 17463246 rs235590 chr20 3534340 G A 4.21E-04 Type 2 diabetes ATRN intron 17463246 rs237640 chr20 3544216 G A 2.01E-04 Type 2 diabetes ATRN intron 17463246 rs235561 chr20 3552199 T C 9.13E-04 Type 2 diabetes ATRN intron 17463246 rs235544 chr20 3560655 C T 2.84E-04 Type 2 diabetes ATRN intron 17463246 rs3117584 chr20 3567066 A T 1.90E-05 Coffee consumption ATRN intron 21357676 rs235549 chr20 3609912 C T 5.71E-04 Type 2 diabetes ATRN intron 17463246 rs2595582 chr20 3630107 G A 9.95E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) ATRN UTR-3 23648065 rs432647 chr20 3630249 T C 5.34E-04 Type 2 diabetes ATRN UTR-3 17463246 rs487377 chr20 3658931 C T 8.88E-05 Blood Pressure ADAM33 intron pha003040 rs554743 chr20 3662142 C T 3.15E-04 Taste perception ADAM33 intron 22132133 rs609203 chr20 3670945 C A 4.40E-06 Urinary metabolites SIGLEC1 intron 21572414 rs609203 chr20 3670945 C A 6.56E-05 Taste perception SIGLEC1 intron 22132133 rs199636258 chr20 3673557 G A 0.000054 Breast cancer(er negative) SIGLEC1 missense 23555315 rs754525 chr20 3676034 G A 3.28E-04 Taste perception SIGLEC1 intron 22132133 rs2295343 chr20 3735601 A G 8.41E-05 Sensory disturbances after bilateral sagittal split ramus osteotomy C20orf27 intron 23834954 rs683808 chr20 3749886 A G 5.99E-05 Coronary heart disease / / pha003030 rs13043330 chr20 3756597 T C 3.90E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13043330 chr20 3756597 T C 7.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs1968648 chr20 3763349 T C 2.59E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6084472 chr20 3771858 C A 3.62E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4815603 chr20 3772527 A T 1.77E-05 Multiple complex diseases / / 17554300 rs3761218 chr20 3776175 C T 7.00E-06 Bipolar disorder CDC25B nearGene-5 17554300 rs3761218 chr20 3776175 C T 1.00E-06 Bipolar disorder CDC25B nearGene-5 21254220 rs6037668 chr20 3803428 C A 3.55E-04 Amyotrophic lateral sclerosis (sporadic) AP5S1 intron 24529757 rs4815617 chr20 3827309 C T 8.00E-06 Asthma MAVS nearGene-5 20159242 rs6084496 chr20 3830462 C T 6.79E-06 Alcohol and nictotine co-dependence MAVS intron 20158304 rs6133067 chr20 3839754 C T 0.000292319 Hypertension (early onset hypertension) MAVS intron 22479346 rs7269320 chr20 3846397 C T 2.70E-05 Urinary metabolites MAVS missense 21572414 rs7272495 chr20 3853551 G A 5.53E-04 Depression (quantitative trait) MAVS UTR-3 20800221 rs6052140 chr20 3862208 C T 9.23E-04 Multiple complex diseases / / 17554300 rs6084530 chr20 3934766 C A 7.75E-04 Smoking cessation RNF24 intron 24665060 rs2253977 chr20 3939140 T C 5.27E-05 Blood Pressure RNF24 intron pha003048 rs2300216 chr20 3946057 A G 8.12E-04 Depression (quantitative trait) RNF24 intron 20800221 rs998132 chr20 3965054 G A 3.96E-06 Blood Pressure RNF24 intron pha003048 rs6052222 chr20 3972793 G A 5.59E-04 Acute lung injury RNF24 intron 22295056 rs6052257 chr20 4018579 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6052257 chr20 4018579 A G 4.61E-05 Blood Pressure / / pha003048 rs945767 chr20 4038492 C T 8.84E-05 Elbow pain / / pha003008 rs6139278 chr20 4039627 T C 1.51E-05 Elbow pain / / pha003008 rs6133072 chr20 4041272 A G 1.00E-04 Glaucoma-related traits / / 22058429 rs6133072 chr20 4041272 A G 3.20E-04 Glaucoma-related traits / / 22058429 rs6139279 chr20 4041406 T C 1.10E-04 Glaucoma-related traits / / 22058429 rs6139279 chr20 4041406 T C 3.20E-04 Glaucoma-related traits / / 22058429 rs6139280 chr20 4042050 T C 1.10E-04 Glaucoma-related traits / / 22058429 rs6139280 chr20 4042050 T C 3.20E-04 Glaucoma-related traits / / 22058429 rs6076598 chr20 4043286 G A 9.79E-05 Erythrocyte counts / / pha003101 rs6139281 chr20 4043534 G A 1.10E-04 Glaucoma-related traits / / 22058429 rs6139281 chr20 4043534 G A 3.20E-04 Glaucoma-related traits / / 22058429 rs10454158 chr20 4043887 A G 1.10E-04 Glaucoma-related traits / / 22058429 rs10454158 chr20 4043887 A G 3.20E-04 Glaucoma-related traits / / 22058429 rs4815630 chr20 4044585 C T 1.10E-04 Glaucoma-related traits / / 22058429 rs4815630 chr20 4044585 C T 3.20E-04 Glaucoma-related traits / / 22058429 rs17838906 chr20 4045027 T G 1.10E-04 Glaucoma-related traits / / 22058429 rs17838906 chr20 4045027 T G 3.20E-04 Glaucoma-related traits / / 22058429 rs4815631 chr20 4045277 A G 1.10E-04 Glaucoma-related traits / / 22058429 rs4815631 chr20 4045277 A G 3.20E-04 Glaucoma-related traits / / 22058429 rs4815632 chr20 4045292 T C 1.10E-04 Glaucoma-related traits / / 22058429 rs4815632 chr20 4045292 T C 3.20E-04 Glaucoma-related traits / / 22058429 rs4813653 chr20 4045429 A G 1.10E-04 Glaucoma-related traits / / 22058429 rs4813653 chr20 4045429 A G 3.20E-04 Glaucoma-related traits / / 22058429 rs4815633 chr20 4045515 G A 1.10E-04 Glaucoma-related traits / / 22058429 rs4815633 chr20 4045515 G A 3.20E-04 Glaucoma-related traits / / 22058429 rs4815634 chr20 4045697 A G 1.10E-04 Glaucoma-related traits / / 22058429 rs4815634 chr20 4045697 A G 3.20E-04 Glaucoma-related traits / / 22058429 rs6139282 chr20 4045738 C T 1.10E-04 Glaucoma-related traits / / 22058429 rs6139282 chr20 4045738 C T 3.20E-04 Glaucoma-related traits / / 22058429 rs6139283 chr20 4045796 C T 1.10E-04 Glaucoma-related traits / / 22058429 rs6139283 chr20 4045796 C T 3.20E-04 Glaucoma-related traits / / 22058429 rs6133073 chr20 4045819 G A 1.10E-04 Glaucoma-related traits / / 22058429 rs6133073 chr20 4045819 G A 3.20E-04 Glaucoma-related traits / / 22058429 rs6052281 chr20 4046114 T G 1.10E-04 Glaucoma-related traits / / 22058429 rs6052281 chr20 4046114 T G 3.20E-04 Glaucoma-related traits / / 22058429 rs6052282 chr20 4046188 T C 1.10E-04 Glaucoma-related traits / / 22058429 rs6052282 chr20 4046188 T C 3.20E-04 Glaucoma-related traits / / 22058429 rs6052287 chr20 4046524 T C 1.10E-04 Glaucoma-related traits / / 22058429 rs6052287 chr20 4046524 T C 3.20E-04 Glaucoma-related traits / / 22058429 rs6116178 chr20 4046718 T C 1.10E-04 Glaucoma-related traits / / 22058429 rs6116178 chr20 4046718 T C 3.20E-04 Glaucoma-related traits / / 22058429 rs6052288 chr20 4046785 A G 1.10E-04 Glaucoma-related traits / / 22058429 rs6052288 chr20 4046785 A G 3.20E-04 Glaucoma-related traits / / 22058429 rs6139285 chr20 4047037 C T 1.10E-04 Glaucoma-related traits / / 22058429 rs6139285 chr20 4047037 C T 3.20E-04 Glaucoma-related traits / / 22058429 rs6139286 chr20 4047325 G A 1.10E-04 Glaucoma-related traits / / 22058429 rs6139286 chr20 4047325 G A 3.20E-04 Glaucoma-related traits / / 22058429 rs6133074 chr20 4047379 C T 1.10E-04 Glaucoma-related traits / / 22058429 rs6133074 chr20 4047379 C T 3.20E-04 Glaucoma-related traits / / 22058429 rs6133075 chr20 4047407 C A 1.10E-04 Glaucoma-related traits / / 22058429 rs6133075 chr20 4047407 C A 3.20E-04 Glaucoma-related traits / / 22058429 rs17838909 chr20 4047688 C G 1.10E-04 Glaucoma-related traits / / 22058429 rs17838909 chr20 4047688 C G 3.20E-04 Glaucoma-related traits / / 22058429 rs6037741 chr20 4048252 C T 1.10E-04 Glaucoma-related traits / / 22058429 rs6037741 chr20 4048252 C T 3.20E-04 Glaucoma-related traits / / 22058429 rs4815636 chr20 4048671 C T 1.10E-04 Glaucoma-related traits / / 22058429 rs4815636 chr20 4048671 C T 3.20E-04 Glaucoma-related traits / / 22058429 rs6037743 chr20 4048739 A G 1.10E-04 Glaucoma-related traits / / 22058429 rs6037743 chr20 4048739 A G 3.20E-04 Glaucoma-related traits / / 22058429 rs6052297 chr20 4049124 T C 1.10E-04 Glaucoma-related traits / / 22058429 rs6052297 chr20 4049124 T C 3.20E-04 Glaucoma-related traits / / 22058429 rs4815639 chr20 4049259 G A 1.10E-04 Glaucoma-related traits / / 22058429 rs4815639 chr20 4049259 G A 3.20E-04 Glaucoma-related traits / / 22058429 rs4815640 chr20 4049526 G C 1.10E-04 Glaucoma-related traits / / 22058429 rs4815640 chr20 4049526 G C 3.20E-04 Glaucoma-related traits / / 22058429 rs6133077 chr20 4049729 C T 1.10E-04 Glaucoma-related traits / / 22058429 rs6133077 chr20 4049729 C T 3.10E-04 Glaucoma-related traits / / 22058429 rs867722 chr20 4052298 G A 2.60E-04 Glaucoma-related traits / / 22058429 rs867722 chr20 4052298 G A 9.00E-05 Glaucoma-related traits / / 22058429 rs945763 chr20 4056123 T C 5.99E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6052360 chr20 4091972 C T 2.61E-04 Coronary heart disease / / 21606135 rs4813669 chr20 4092860 A G 1.10E-04 Myasthenia gravis / / 23055271 rs6116209 chr20 4094296 C T 2.40E-05 Urinary metabolites / / 21572414 rs6037767 chr20 4100321 T C 2.10E-04 Alcohol dependence / / 20201924 rs6037767 chr20 4100321 T C 1.68E-05 Hemoglobin / / pha003096 rs6037767 chr20 4100321 T C 1.02E-05 Hematocrit / / pha003097 rs6037767 chr20 4100321 T C 6.87E-06 Erythrocyte counts / / pha003101 rs1741344 chr20 4101800 C T 3.00E-09 Height / / 20881960 rs1741288 chr20 4102954 G A 0.0000018 Diabetic nephropathy in Type 1 diabetes / / 22721967 rs1741289 chr20 4124784 A T 7.45E-04 Type 2 diabetes / / 17463246 rs927091 chr20 4145021 A G 9.87E-04 Type 2 diabetes SMOX intron 17463246 rs16989303 chr20 4169079 G A 6.00E-06 Panic disorder / / 19165232 rs1556832 chr20 4215557 C T 9.00E-06 Preeclampsia ADRA1D intron 23551011 rs4815670 chr20 4216864 A G 4.44E-06 Testosterone levels ADRA1D intron 22675492 rs6052456 chr20 4225573 C T 0.000000375 CD8+ T cell IFN-gamma response to smallpox vaccine ADRA1D intron 22661280 rs1886844 chr20 4239658 G T 5.32E-04 Acute lung injury / / 22295056 rs4813680 chr20 4240417 C A 8.30E-05 Alcohol dependence / / 20201924 rs4813680 chr20 4240417 C A 8.33E-05 Alcoholism / / pha002893 rs8115863 chr20 4240509 T C 8.30E-05 Alcohol dependence / / 20201924 rs8115863 chr20 4240509 T C 8.33E-05 Alcoholism / / pha002893 rs6133102 chr20 4247106 C T 5.27E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs6084686 chr20 4259841 G A 6.60E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs6052484 chr20 4260610 G A 4.10E-04 Glaucoma-related traits / / 22058429 rs4815683 chr20 4260649 A C 1.60E-04 Bone mineral density / / 21927923 rs1338404 chr20 4263591 T C 9.20E-05 Alzheimer's disease (late onset) / / 21379329 rs3859666 chr20 4285532 A G 5.61E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6037811 chr20 4287971 G A 7.91E-05 Cognitive test performance / / 20125193 rs6116308 chr20 4295353 G A 1.53E-04 Multiple complex diseases / / 17554300 rs489284 chr20 4321551 T A 5.40E-04 Smoking initiation / / 24665060 rs6076665 chr20 4334541 G T 7.20E-06 Urinary metabolites / / 21572414 rs3912089 chr20 4338058 T C 4.80E-05 Amyotrophic lateral sclerosis / / 23624525 rs159784 chr20 4348037 G A 5.47E-05 Parent of origin effect on language impairment (paternal) / / 24571439 rs159788 chr20 4352104 A G 7.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs159788 chr20 4352104 A G 0.000648 Bipolar disorder / / 23637625 rs192717 chr20 4353884 G T 3.25E-05 Cognitive impairment induced by topiramate / / 22091778 rs4815697 chr20 4364866 A G 6.38E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6076667 chr20 4367040 C A 9.33E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6139415 chr20 4378871 A G 2.94E-05 Alcohol dependence / / 21703634 rs3904864 chr20 4379086 A G 1.26E-04 Longevity / / 22279548 rs3904864 chr20 4379086 A G 4.35E-05 Erythrocyte counts / / pha003101 rs586446 chr20 4387134 C T 2.00E-06 IgG glycosylation / / 23382691 rs586446 chr20 4387134 C T 5.00E-06 IgG glycosylation / / 23382691 rs297715 chr20 4390249 G A 2.10E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs297717 chr20 4390433 T C 2.10E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs297718 chr20 4390527 G A 2.10E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs297733 chr20 4409955 G T 6.21E-04 Obesity (extreme) / / 21935397 rs6052568 chr20 4424494 G A 9.36E-04 Multiple complex diseases / / 17554300 rs6052568 chr20 4424494 G A 4.91E-04 Obesity (extreme) / / 21935397 rs297676 chr20 4443634 G A 2.01E-04 Celiac disease / / 23936387 rs297765 chr20 4487111 A G 2.00E-04 Type 2 diabetes / / 17846126 rs8115602 chr20 4493931 T G 4.41E-04 Myocardial Infarction / / pha002873 rs11087645 chr20 4517076 T C 7.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs6052634 chr20 4522943 G A 9.76E-06 Smoking quantity / / 24665060 rs911165 chr20 4544779 G A 7.72E-04 Multiple complex diseases / / 17554300 rs4815715 chr20 4552904 C T 2.14E-04 Multiple complex diseases / / 17554300 rs6116430 chr20 4556395 A G 4.76E-04 Type 2 diabetes / / 17463246 rs6133142 chr20 4557877 T C 3.88E-04 Acute lung injury / / 22295056 rs6076702 chr20 4571240 C T 6.24E-04 Type 2 diabetes / / 17463246 rs6076703 chr20 4571478 C A 0.000882 Salmonella-induced pyroptosis / / 22837397 rs6139494 chr20 4591715 T C 9.00E-04 Multiple complex diseases / / 17554300 rs6052699 chr20 4611877 G A 2.00E-06 Platelet aggregation / / 20526338 rs1981105 chr20 4614486 G A 6.79E-05 Prion diseases / / 22210626 rs6037908 chr20 4617391 A G 2.18E-04 Premature ovarian failure / / 19508998 rs6037908 chr20 4617391 A G 3.00E-04 HIV(mother-to-child transmission) / / 20487506 rs2326508 chr20 4630165 T C 5.93E-05 Prion diseases / / 22210626 rs6052751 chr20 4645073 G A 1.15E-07 Prion diseases / / 22210626 rs2025115 chr20 4648538 A G 7.01E-05 Prion diseases / / 22210626 rs10485513 chr20 4655602 A G 1.00E-04 Asthma / / 19910028 rs7270994 chr20 4655816 G A 1.00E-04 Asthma / / 19910028 rs6052761 chr20 4657017 T C 2.27E-06 Asthma / / 19910028 rs6052761 chr20 4657017 T C 1.04E-05 Prion diseases / / 22210626 rs2756271 chr20 4665262 A C,G,T 2.26E-08 Prion diseases PRNP nearGene-5 22210626 rs6084833 chr20 4672759 G A 2.76E-05 Prion diseases PRNP intron 22210626 rs6107516 chr20 4677092 G A 3.00E-18 Creutzfeldt-Jakob disease (variant) PRNP intron 22137330 rs6107516 chr20 4677092 G A 2.36E-18 Prion diseases PRNP intron 22210626 rs11087653 chr20 4679519 G A 7.70E-04 Alcohol dependence PRNP intron 21314694 rs1799990 chr20 4680251 A G 2.00E-21 Creutzfeldt-Jakob disease PRNP missense 19081515 rs1799990 chr20 4680251 A G 7.00E-07 Prion diseases PRNP missense 22210626 rs2065706 chr20 4683295 T C 3.50E-09 Creutzfeldt-Jakob disease (variant) / / 22137330 rs6116477 chr20 4684661 T C 5.61E-09 Prion diseases / / 22210626 rs6052780 chr20 4689474 G A 8.03E-08 Creutzfeldt-Jakob disease (variant) / / 22137330 rs6037938 chr20 4690665 C T 5.48E-04 Type 2 diabetes / / 17463246 rs6037938 chr20 4690665 C T 2.03E-05 Prion diseases / / 22210626 rs873050 chr20 4694063 C T 8.39E-05 Coronary Artery Disease / / 17634449 rs6116492 chr20 4698626 G T 5.00E-07 Creutzfeldt-Jakob disease (variant) / / 22137330 rs2326510 chr20 4701211 G T 7.18E-04 Volumetric brain MRI / / 17903297 rs6037941 chr20 4716479 A G 0.0000643 Panic disorder PRNT intron 23149450 rs6037941 chr20 4716479 A G 6.43E-05 Serum tamsulosin hydrochloride concentration PRNT intron 23151678 rs6052818 chr20 4725883 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6052824 chr20 4728075 G A 9.50E-04 Insulin resistance / / 21901158 rs6037950 chr20 4731022 C T 7.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs6084858 chr20 4731109 C T 9.08E-04 Alzheimer's disease / / 17998437 rs730999 chr20 4731377 A G 7.02E-04 Alzheimer's disease / / 17998437 rs968433 chr20 4742080 C G 1.65E-04 Alcohol dependence / / 21314694 rs6084875 chr20 4742705 G A 2.00E-06 Systemic lupus erythematosus / / 24871463 rs6084878 chr20 4744291 C T 0.0001 Migraine / / 22678113 rs12480756 chr20 4749032 C T 0.00000227 Panic disorder / / 23149450 rs12480756 chr20 4749032 C T 2.27E-06 Serum tamsulosin hydrochloride concentration / / 23151678 rs2422958 chr20 4749289 C A 7.30E-05 Triglycerides / / 19074352 rs2422958 chr20 4749289 C A 0.0000643 Panic disorder / / 23149450 rs2422958 chr20 4749289 C A 6.43E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs16990147 chr20 4751336 G T 8.17E-05 Formal thought disorder in schizophrenia / / 22648509 rs6052862 chr20 4751487 T G 5.91E-05 IgE levels in asthmatics (D.f. specific) / / 23967269 rs12625405 chr20 4757364 T C 0.0000152 Panic disorder / / 23149450 rs12625405 chr20 4757364 T C 1.52E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs2422979 chr20 4764682 T C 1.60E-04 Myasthenia gravis RASSF2 UTR-3 23055271 rs2423011 chr20 4785315 G A 7.38E-05 IgE levels in asthmatics (D.p. specific) RASSF2 intron 23967269 rs4815745 chr20 4788171 A G 1.19E-05 Cognitive test performance RASSF2 intron 20125193 rs1885303 chr20 4794243 C T 1.66E-04 Attention deficit hyperactivity disorder RASSF2 intron 23728934 rs2423037 chr20 4794989 G A 8.16E-05 Attention deficit hyperactivity disorder RASSF2 intron 23728934 rs13039769 chr20 4798628 A G 4.28E-04 Suicide attempts in bipolar disorder RASSF2 intron 21423239 rs2295782 chr20 4805281 T C 4.53E-05 Suicide attempts in bipolar disorder / / 21423239 rs2295783 chr20 4805354 T C 5.11E-05 Suicide attempts in bipolar disorder / / 21423239 rs7266763 chr20 4811846 C T 2.78E-04 Type 2 diabetes / / 17463246 rs6052912 chr20 4812666 G T 1.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs6052937 chr20 4835338 C A 7.99E-04 Suicide attempts in bipolar disorder SLC23A2 UTR-3 21423239 rs6052942 chr20 4840591 G T 3.82E-04 Amyotrophic lateral sclerosis (sporadic) SLC23A2 intron 24529757 rs6052972 chr20 4918661 G A 8.62E-04 Multiple complex diseases SLC23A2 intron 17554300 rs1519860 chr20 4923286 C T 6.19E-04 Type 2 diabetes SLC23A2 intron 17463246 rs6053022 chr20 4973456 A G 4.97E-07 Autism SLC23A2 intron 22843504 rs4815759 chr20 4979886 G A 8.82E-04 Multiple complex diseases SLC23A2 intron 17554300 rs373542 chr20 5020237 G A 9.89E-05 Information processing speed / / 21130836 rs405249 chr20 5024034 C T 6.52E-04 Multiple complex diseases / / 17554300 rs261360 chr20 5037774 G A 3.00E-06 Hair morphology / / 19896111 rs6053066 chr20 5043706 T C 4.06E-04 Smoking cessation / / 24665060 rs6053067 chr20 5044402 T C 6.06E-04 Smoking cessation / / 24665060 rs17349 chr20 5099516 G A 3.80E-05 Personality dimensions PC/ intron 18957941 rs6053127 chr20 5109789 G A 0.00024 Coronary artery calcification CDS2 intron 23727086 rs16990673 chr20 5126387 A G 9.44E-04 Suicide attempts in bipolar disorder CDS2 intron 21423239 rs12625930 chr20 5128299 C T 9.34E-04 Suicide attempts in bipolar disorder CDS2 intron 21423239 rs11700061 chr20 5130157 A G 6.75E-05 Suicide attempts in bipolar disorder CDS2 intron 21423239 rs6053165 chr20 5139680 G A 6.64E-04 Multiple complex diseases CDS2 intron 17554300 rs6038080 chr20 5146631 T C 9.90E-04 Suicide attempts in bipolar disorder CDS2 intron 21423239 rs11699947 chr20 5149921 A G 9.06E-04 Suicide attempts in bipolar disorder CDS2 intron 21423239 rs11699315 chr20 5150716 G T 9.09E-04 Suicide attempts in bipolar disorder CDS2 intron 21423239 rs7266351 chr20 5151040 A G 9.12E-04 Suicide attempts in bipolar disorder CDS2 intron 21423239 rs17178947 chr20 5152048 G A 9.00E-04 Suicide attempts in bipolar disorder CDS2 intron 21423239 rs17776782 chr20 5152613 C G 9.20E-04 Suicide attempts in bipolar disorder CDS2 intron 21423239 rs10485483 chr20 5158354 C A 7.77E-04 Suicide attempts in bipolar disorder CDS2 intron 21423239 rs16990713 chr20 5160469 C G 5.11E-05 Suicide attempts in bipolar disorder CDS2 intron 21423239 rs2295509 chr20 5163263 G A 4.35E-05 Suicide attempts in bipolar disorder CDS2 intron 21423239 rs11697819 chr20 5168735 A G 7.81E-04 Suicide attempts in bipolar disorder CDS2 intron 21423239 rs6116685 chr20 5174981 C G 5.56E-04 Multiple complex diseases CDS2 UTR-3 17554300 rs1292244 chr20 5179693 A C 2.50E-05 Urinary metabolites / / 21572414 rs11699336 chr20 5185702 G C 7.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs6116695 chr20 5194373 T C 4.92E-04 Taste perception / / 22132133 rs6107598 chr20 5200227 C T 2.27E-04 Taste perception / / 22132133 rs2326614 chr20 5247393 G A 4.53E-05 Asthma / / 22561531 rs2038410 chr20 5249302 C T 1.12E-06 Suicide attempts in bipolar disorder / / 21041247 rs2038410 chr20 5249302 C T 3.08E-04 Suicide attempts in bipolar disorder / / 21041247 rs6038108 chr20 5253641 T C 1.35E-04 Suicide attempts in bipolar disorder / / 21041247 rs6038109 chr20 5254768 T C 1.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs6038110 chr20 5254928 G A 1.60E-04 Suicide attempts in bipolar disorder / / 21041247 rs6038110 chr20 5254928 G A 8.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs6116721 chr20 5255078 T A,G 2.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs6116721 chr20 5255078 T A,G 3.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs6038111 chr20 5255159 C A 1.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs6038111 chr20 5255159 C A 8.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs996389 chr20 5255899 G T 1.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs996389 chr20 5255899 G T 8.75E-04 Suicide attempts in bipolar disorder / / 21041247 rs6053245 chr20 5256385 T C 1.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs6053245 chr20 5256385 T C 8.58E-04 Suicide attempts in bipolar disorder / / 21041247 rs6515995 chr20 5256774 T G 1.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs6515995 chr20 5256774 T G 8.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs6085061 chr20 5259931 T C 1.69E-04 Suicide attempts in bipolar disorder / / 21041247 rs6085061 chr20 5259931 T C 8.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs6085062 chr20 5259966 C G 1.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs6085062 chr20 5259966 C G 8.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs2145083 chr20 5260540 A G 1.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs2145083 chr20 5260540 A G 8.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs6038114 chr20 5261029 G A 1.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs6038114 chr20 5261029 G A 8.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs6038115 chr20 5261132 G A 1.30E-04 Suicide attempts in bipolar disorder / / 21041247 rs6038115 chr20 5261132 G A 8.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs4553880 chr20 5261206 T C 1.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs4553880 chr20 5261206 T C 8.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs6116726 chr20 5261399 C T 2.06E-04 Suicide attempts in bipolar disorder / / 21041247 rs6116726 chr20 5261399 C T 3.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs4384857 chr20 5261440 G C 1.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs4384857 chr20 5261440 G C 7.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs4597612 chr20 5261578 T G 1.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs4597612 chr20 5261578 T G 7.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs6107609 chr20 5262119 T C 2.60E-04 Suicide attempts in bipolar disorder / / 21041247 rs6107609 chr20 5262119 T C 7.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs4580454 chr20 5262168 G C 7.13E-04 Suicide attempts in bipolar disorder / / 21041247 rs2326618 chr20 5263444 A G 3.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs2326618 chr20 5263444 A G 7.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs910970 chr20 5271710 C T 4.39E-05 Suicide attempts in bipolar disorder / / 21041247 rs910970 chr20 5271710 C T 7.20E-04 Suicide attempts in bipolar disorder / / 21041247 rs6038126 chr20 5273314 C T 3.89E-05 Suicide attempts in bipolar disorder / / 21041247 rs6038126 chr20 5273314 C T 7.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs2234397 chr20 5273382 G A 7.70E-04 Suicide attempts in bipolar disorder / / 21041247 rs2234397 chr20 5273382 G A 8.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs6053263 chr20 5274381 C G 5.85E-05 Suicide attempts in bipolar disorder / / 21041247 rs117106081 chr20 5282850 C T 8.92E-04 Acne (severe) PROKR2 missense 24399259 rs3746682 chr20 5283256 C G 8.41E-04 Bipolar disorder PROKR2 cds-synon 19259986 rs6053286 chr20 5290502 T C 1.37E-05 Kawasaki disease PROKR2 intron 22446961 rs1884749 chr20 5298630 A G 2.93E-05 Kawasaki disease / / 22446961 rs1884748 chr20 5298668 C T 3.91E-05 Kawasaki disease / / 22446961 rs6053301 chr20 5298809 C T 9.42E-05 Serum metabolites / / 19043545 rs1555324 chr20 5303028 G C 1.71E-04 Response to TNF antagonist treatment / / 21061259 rs6116762 chr20 5337412 A C 1.04E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs6139737 chr20 5453856 G C 7.02E-04 Oral cancers (chewing tobacco related) LOC643406 intron 22503698 rs2022259 chr20 5464732 T C 9.73E-05 Blood Pressure / / pha003045 rs2022259 chr20 5464732 T C 8.21E-05 Blood Pressure / / pha003047 rs6038180 chr20 5465449 T C 7.13E-05 Blood Pressure / / pha003047 rs910702 chr20 5467063 C T 7.30E-04 Smoking cessation / / 24665060 rs6139746 chr20 5474296 C T 6.89E-05 Serum metabolites / / 19043545 rs6053474 chr20 5520122 A C,G,T 7.21E-04 Alzheimer's disease / / 24755620 rs6139762 chr20 5546694 C T 8.78E-04 Parkinson's disease GPCPD1 intron 17052657 rs2295371 chr20 5554689 T C 2.00E-04 Cognitive impairment induced by topiramate GPCPD1 intron 22091778 rs238295 chr20 5588449 A G 6.00E-09 Cortical structure GPCPD1 intron 22343285 rs16991130 chr20 5589451 A G 6.87E-05 Cognitive performance GPCPD1 intron 19734545 rs6085232 chr20 5611026 T C 6.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6139785 chr20 5624707 A C 1.30E-05 Urinary metabolites / / 21572414 rs8119133 chr20 5644184 C A 9.80E-05 Blood Pressure / / pha003050 rs6139797 chr20 5649902 G A 0.00009082 Sarcoidosis / / 22952805 rs6139800 chr20 5654708 C G 2.07E-04 Type 2 diabetes / / 17463246 rs16991189 chr20 5697972 T C 0.000000595 Ejection fraction / / 23275298 rs6085256 chr20 5707548 C T 9.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17286495 chr20 5782350 A G 5.05E-05 Blood Pressure C20orf196 intron pha003043 rs4815864 chr20 5787582 G A 7.39E-05 Bipolar disorder C20orf196 intron 17486107 rs237085 chr20 5794958 A G 3.12E-04 Suicide attempts in bipolar disorder C20orf196 intron 21423239 rs1294704 chr20 5799408 C T 6.97E-04 Suicide attempts in bipolar disorder C20orf196 intron 21423239 rs1294717 chr20 5808814 A G 4.13E-04 Suicide attempts in bipolar disorder C20orf196 intron 21423239 rs237082 chr20 5812427 A G 9.75E-04 Alzheimer's disease C20orf196 intron 22005930 rs6139850 chr20 5812888 C T 7.69E-06 HDL cholesterol C20orf196 intron pha003075 rs237083 chr20 5812900 A T 7.17E-04 Alzheimer's disease C20orf196 intron 22005930 rs237084 chr20 5813582 C T 1.59E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) C20orf196 intron 23648065 rs6053733 chr20 5815074 A G 3.70E-06 Subclinical atherosclerosis C20orf196 intron 17903303 rs6053733 chr20 5815074 A G 5.43E-06 Lipid levels C20orf196 intron 19016617 rs6053733 chr20 5815074 A G 8.65E-04 Alzheimer's disease C20orf196 intron 22005930 rs237103 chr20 5816169 G T 8.60E-04 Alzheimer's disease C20orf196 intron 22005930 rs6038300 chr20 5816858 C T 8.78E-06 HDL cholesterol C20orf196 intron pha003075 rs237102 chr20 5817533 G A 1.62E-04 Aortic root size C20orf196 intron 21223598 rs237102 chr20 5817533 G A 8.67E-04 Alzheimer's disease C20orf196 intron 22005930 rs237101 chr20 5817549 A G 8.66E-04 Alzheimer's disease C20orf196 intron 22005930 rs237100 chr20 5817640 G A 4.04E-04 Aortic root size C20orf196 intron 21223598 rs237098 chr20 5818658 G A 2.00E-05 Prostate cancer C20orf196 intron 21743057 rs237098 chr20 5818658 G A 8.85E-04 Alzheimer's disease C20orf196 intron 22005930 rs237097 chr20 5819545 T C 2.00E-05 Prostate cancer C20orf196 intron 21743057 rs237096 chr20 5819844 C T 3.17E-04 Aortic root size C20orf196 intron 21223598 rs237096 chr20 5819844 C T 2.00E-05 Prostate cancer C20orf196 intron 21743057 rs237096 chr20 5819844 C T 9.14E-04 Alzheimer's disease C20orf196 intron 22005930 rs237096 chr20 5819844 C T 9.37E-04 Lymphocyte counts C20orf196 intron 22286170 rs237095 chr20 5819937 A C 8.61E-04 Alzheimer's disease C20orf196 intron 22005930 rs237094 chr20 5820000 T C 2.00E-05 Prostate cancer C20orf196 intron 21743057 rs237094 chr20 5820000 T C 8.36E-04 Alzheimer's disease C20orf196 intron 22005930 rs237091 chr20 5821185 G A 1.54E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) C20orf196 intron 23648065 rs1287024 chr20 5823642 C T 2.10E-05 Urinary metabolites C20orf196 intron 21572414 rs1287023 chr20 5823795 G A 5.53E-05 Aortic root size C20orf196 intron 21223598 rs1287023 chr20 5823795 G A 2.60E-05 Urinary metabolites C20orf196 intron 21572414 rs1287021 chr20 5824893 T C 3.00E-05 Prostate cancer C20orf196 intron 21743057 rs1287021 chr20 5824893 T C 7.29E-04 Alzheimer's disease C20orf196 intron 22005930 rs6053740 chr20 5827061 G A 4.93E-04 Aortic root size C20orf196 intron 21223598 rs6053740 chr20 5827061 G A 1.40E-05 Urinary metabolites C20orf196 intron 21572414 rs6053740 chr20 5827061 G A 8.00E-05 Prostate cancer C20orf196 intron 21743057 rs6053740 chr20 5827061 G A 7.32E-04 Alzheimer's disease C20orf196 intron 22005930 rs2655015 chr20 5827321 T C 8.00E-05 Prostate cancer C20orf196 intron 21743057 rs1287071 chr20 5828375 A G 8.00E-05 Prostate cancer C20orf196 intron 21743057 rs4815868 chr20 5840539 A G 8.00E-06 Information processing speed C20orf196 intron 21130836 rs6053754 chr20 5842518 T C 3.40E-05 Lipid traits C20orf196 intron 17903299 rs1287052 chr20 5864948 A G 6.55E-05 Fibrinogen / / 17255346 rs1287052 chr20 5864948 A G 4.66E-04 Multiple complex diseases / / 17554300 rs6038317 chr20 5865636 A C 2.14E-05 Fibrinogen / / 17255346 rs6038317 chr20 5865636 A C 9.04E-04 Multiple complex diseases / / 17554300 rs16991419 chr20 5871386 G T 4.90E-05 Information processing speed / / 21130836 rs236151 chr20 5903517 A G 4.41E-05 Rheumatoid arthritis CHGB missense 17804836 rs381571 chr20 5914424 C T 1.75E-05 Cognitive decline / / 22054870 rs236164 chr20 5917428 C T 8.21E-05 Cognitive decline / / 22054870 rs236170 chr20 5918693 G A 2.36E-05 Cognitive decline TRMT6 UTR-3 22054870 rs236114 chr20 5935385 T C 1.00E-10 Menopause (age at onset) MCM8 intron 19448619 rs236114 chr20 5935385 T C 9.71E-11 Menopause (age at onset) MCM8 intron 23424626 rs454422 chr20 5943693 C A 1.00E-06 HIV-1 viral setpoint MCM8 intron 20205591 rs16991615 chr20 5948227 G A 1.00E-21 Menarche and menopause (age at onset) MCM8 missense 19448621 rs16991615 chr20 5948227 G A 1.40E-06 Age at menarche,age at menopause MCM8 missense 22131368 rs16991615 chr20 5948227 G A 8.90E-06 Age at menarche,age at menopause MCM8 missense 22131368 rs16991615 chr20 5948227 G A 1.00E-73 Menopause (age at onset) MCM8 missense 22267201 rs16991615 chr20 5948227 G A 5.00E-12 Menopause (age at onset) MCM8 missense 23307926 rs16991615 chr20 5948227 G A 1.21E-21 Menopause (age at onset) MCM8 missense 23424626 rs4815879 chr20 5949534 G A 2.00E-06 Preeclampsia MCM8 intron 23551011 rs16991617 chr20 5953833 A G 5.00E-06 Cognitive decline MCM8 cds-synon 22054870 rs16991627 chr20 5969359 G A 3.09E-05 Multiple complex diseases MCM8 intron 17554300 rs16991630 chr20 5970135 A G 5.83E-06 Cognitive decline MCM8 intron 22054870 rs6053815 chr20 5970438 G C 1.03E-04 Type 2 diabetes MCM8 intron 17463246 rs6139887 chr20 5986234 T C 3.80E-05 Alzheimer's disease / / 17998437 rs6139887 chr20 5986234 T C 3.10E-05 Lymphocyte counts / / 22286170 rs17221851 chr20 6002348 A G 8.88E-06 Alzheimer's disease (late onset) CRLS1 intron 21379329 rs1028410 chr20 6009174 G A 9.44E-05 Major depressive disorder CRLS1 intron 21621269 rs6117041 chr20 6015940 T C 6.98E-05 Psoriasis CRLS1 intron 18364390 rs2235816 chr20 6018711 G A 5.25E-05 Major depressive disorder CRLS1 UTR-3 21621269 rs6076920 chr20 6029317 C G 8.60E-07 Obesity (early onset extreme) LRRN4 intron 18159244 rs2326679 chr20 6035228 C T 2.00E-06 Menopause (age at onset) / / 19448619 rs1884641 chr20 6039909 A C 5.20E-04 Suicidal ideation / / 22030708 rs6085382 chr20 6049356 T C 4.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6085382 chr20 6049356 T C 0.000271 Salmonella-induced pyroptosis / / 22837397 rs6053875 chr20 6052876 A G 0.000816 Salmonella-induced pyroptosis / / 22837397 rs3789332 chr20 6070440 A G 4.60E-06 Personality dimensions FERMT1 intron 23658558 rs6053908 chr20 6086772 C T 5.10E-05 Celiac disease FERMT1 intron 17558408 rs6516104 chr20 6089513 C T 6.19E-04 Crohn's disease and Celiac disease FERMT1 intron 21298027 rs2295435 chr20 6096695 C T 3.14E-06 Cocaine dependence FERMT1 intron 23958962 rs2295435 chr20 6096695 C T 6.84E-05 Cocaine dependence FERMT1 intron 23958962 rs2295435 chr20 6096695 C T 7.74E-04 Cocaine dependence FERMT1 intron 23958962 rs10373 chr20 6100088 A G 7.05E-04 Alzheimer's disease FERMT1 cds-synon 17998437 rs6076949 chr20 6119179 G A 1.46E-04 Alzheimer's disease / / 17998437 rs1361722 chr20 6140308 G T 4.58E-04 Type 2 diabetes / / 17463246 rs3852936 chr20 6144454 C A 7.70E-04 Type 2 diabetes / / 17463246 rs2021715 chr20 6149392 T C 8.70E-04 Type 2 diabetes / / 17463246 rs7270088 chr20 6156745 A G 2.63E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7270088 chr20 6156745 A G 4.42E-06 Tunica Media / / pha003037 rs6117127 chr20 6160585 G A 6.90E-04 Multiple complex diseases / / 17554300 rs6133296 chr20 6166488 T G 2.34E-05 Multiple complex diseases / / 17554300 rs954388 chr20 6175064 T C 4.43E-05 Multiple complex diseases / / 17554300 rs6076960 chr20 6186157 A C 6.00E-06 Smooth-surface caries / / 24556642 rs6054014 chr20 6222240 T C 6.44E-05 Serum metabolites / / 19043545 rs6133302 chr20 6230570 C T 7.77E-05 Cognitive test performance / / 20125193 rs6054028 chr20 6232334 A G 6.44E-05 Serum metabolites / / 19043545 rs6038399 chr20 6239082 T C 8.21E-05 Serum metabolites / / 19043545 rs7354540 chr20 6243193 G A 1.59E-05 Cognitive test performance / / 20125193 rs6117185 chr20 6245805 A C 1.40E-05 Cognitive test performance / / 20125193 rs6117186 chr20 6259760 G C 6.18E-04 Multiple complex diseases / / 17554300 rs10211689 chr20 6275579 A G 3.60E-04 Multiple complex diseases / / 17554300 rs237689 chr20 6281698 A G 3.23E-04 Multiple complex diseases / / 17554300 rs237692 chr20 6283226 A G 3.61E-04 Multiple complex diseases / / 17554300 rs237693 chr20 6284995 A G 6.08E-05 Type 2 diabetes / / 17463246 rs237693 chr20 6284995 A G 3.48E-04 Multiple complex diseases / / 17554300 rs237695 chr20 6289592 G T 7.70E-04 Multiple complex diseases / / 17554300 rs6038449 chr20 6337980 C T 5.19E-05 Neuroblastoma / / pha002895 rs2182712 chr20 6368089 T G 1.93E-06 Cognitive impairment induced by topiramate / / 22091778 rs2209761 chr20 6371011 C T 5.14E-05 Neuroblastoma / / pha002895 rs6085533 chr20 6375460 T A 1.00E-06 Metabolite levels (X-11787) / / 23934736 rs445074 chr20 6378809 A G 1.85E-04 Multiple complex diseases / / 17554300 rs445218 chr20 6378912 A G 2.79E-04 Multiple complex diseases / / 17554300 rs453114 chr20 6379635 T G 3.49E-04 Multiple complex diseases / / 17554300 rs654433 chr20 6380022 T C 2.12E-04 Multiple complex diseases / / 17554300 rs34033947 chr20 6380344 T A 3.00E-06 Colorectal cancer / / 24737748 rs373038 chr20 6380637 A G 2.66E-04 Multiple complex diseases / / 17554300 rs2209763 chr20 6381747 T C 1.81E-04 Multiple complex diseases / / 17554300 rs355527 chr20 6388068 T C 1.20E-06 Colorectal cancer / / 19011631 rs6133312 chr20 6398192 C T 9.87E-04 Multiple complex diseases / / 17554300 rs1115460 chr20 6398572 G A 1.77E-04 Multiple complex diseases / / 17554300 rs2876032 chr20 6399494 T C 1.91E-04 Multiple complex diseases / / 17554300 rs961253 chr20 6404281 C A 2.00E-10 Colorectal cancer / / 19011631 rs961253 chr20 6404281 C A 2.00E-10 Nasopharyngeal carcinoma / / 20512145 rs961253 chr20 6404281 C A 5.16E-05 Colorectal cancer / / 21761138 rs961253 chr20 6404281 C A 3.67E-05 Colorectal cancer / / 23266556 rs961253 chr20 6404281 C A 7.74E-04 Colorectal cancer / / 24836286 rs6085552 chr20 6409005 A G 8.25E-04 Multiple complex diseases / / 17554300 rs6085552 chr20 6409005 A G 1.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7265115 chr20 6416883 G A 3.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11087730 chr20 6429185 G T 3.90E-04 Multiple complex diseases / / 17554300 rs6054264 chr20 6431267 T C 3.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6054291 chr20 6452773 A C 2.04E-04 Smoking initiation / / 24665060 rs6054292 chr20 6454661 A G 7.84E-05 Cortisol secretion,in saliva / / 21316860 rs10485705 chr20 6468261 G T 4.30E-04 Alcohol dependence / / 20201924 rs1970008 chr20 6468371 A G 8.30E-04 Alcohol dependence / / 20201924 rs6117294 chr20 6470805 T G 3.00E-04 Alcohol dependence / / 20201924 rs6117294 chr20 6470805 T G 4.90E-04 Alcohol dependence / / 20201924 rs6117294 chr20 6470805 T G 4.81E-04 Myocardial Infarction / / pha002883 rs16992325 chr20 6484249 G T 3.06E-07 Multiple complex diseases / / 17554300 rs1575127 chr20 6510902 T C 9.86E-04 Multiple complex diseases / / 17554300 rs6140028 chr20 6542370 G T 2.11E-04 Type 2 diabetes / / 17463246 rs6107836 chr20 6555461 A G 4.65E-04 Coronary Artery Disease / / 17634449 rs2145275 chr20 6573455 C T 5.23E-05 Interstitial lung disease / / 23583980 rs6140038 chr20 6582162 C T 1.00E-06 Conotruncal heart defects / / 24800985 rs6054403 chr20 6605301 G A 1.81E-04 Insulin resistance / / 21901158 rs6107853 chr20 6609877 G A 0.0007339 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6107853 chr20 6609877 G A 7.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6107853 chr20 6609877 G A 2.00E-06 Body mass index / / 23669352 rs4142039 chr20 6610854 A G 0.0007302 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4142039 chr20 6610854 A G 7.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2024962 chr20 6613051 G A 0.0007486 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2024962 chr20 6613051 G A 7.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6038566 chr20 6615197 A G 0.0007199 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6038566 chr20 6615197 A G 7.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs967417 chr20 6620893 G A 2.00E-08 Height / / 18391951 rs2145270 chr20 6621685 C T 6.00E-06 Body mass index / / 19079261 rs2145270 chr20 6621685 C T 7.20E-06 Smoking behavior / / 20418888 rs2145270 chr20 6621685 C T 5.00E-18 Height / / 23563607 rs979012 chr20 6623374 T C 5.27E-05 Body Mass Index / / pha003021 rs2145272 chr20 6626218 G A 2.00E-24 Height / / 20881960 rs2326845 chr20 6628587 G T 2.74E-04 Type 2 diabetes / / 17463246 rs6054431 chr20 6641051 G C 2.45E-05 Serum metabolites / / 19043545 rs6038574 chr20 6650474 A G 5.83E-04 Smoking initiation / / 24665060 rs765302 chr20 6656028 C G 9.87E-05 Asthma / / 23181788 rs6038577 chr20 6660393 T C 0.0000932 Primary sclerosing cholangitis / / 23603763 rs1040569 chr20 6662854 C T 2.21E-04 Multiple complex diseases / / 17554300 rs2143712 chr20 6663715 A G 5.51E-04 Myopia (pathological) / / 21095009 rs2223753 chr20 6667135 A T 1.30E-04 Asthma / / 23181788 rs6038585 chr20 6671980 A G 4.10E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs6054464 chr20 6672360 G A 6.06E-05 Body Mass Index / / pha003015 rs6054464 chr20 6672360 G A 7.82E-05 Cardiovascular disease / / pha003065 rs6038589 chr20 6676355 C G 3.75E-05 Attention deficit hyperactivity disorder / / 23728934 rs2038211 chr20 6680693 T G 3.67E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6085660 chr20 6691069 C T 1.90E-04 Blood Pressure and Arterial Stiffness / / 17903302 rs4813802 chr20 6699595 T G 7.00E-06 Colorectal cancer / / 23266556 rs4813802 chr20 6699595 T G 9.89E-06 Colorectal cancer / / 24737748 rs4813802 chr20 6699595 T G 9.87E-06 Colorectal cancer / / 24836286 rs6054486 chr20 6700202 T G 9.16E-06 Epilepsy / / 22116939 rs235762 chr20 6703826 T C 2.97E-08 Metabolite levels / / 23281178 rs235763 chr20 6705246 T C 0.0000031 Asthma (exacerbation) / / 23706709 rs2876052 chr20 6711572 C T 4.93E-04 Insulin resistance / / 21901158 rs2273074 chr20 6751089 G A 1.00E-06 Obesity-related traits BMP2 missense 23251661 rs235768 chr20 6759115 A T 0.0000345 Type 2 diabetes BMP2 missense 22325160 rs235768 chr20 6759115 A T 7.22E-06 Axial length BMP2 missense 24144296 rs170986 chr20 6760431 C A 6.50E-05 Parent of origin effect on language impairment (child trend) BMP2 UTR-3 24571439 rs6054512 chr20 6761512 C T 4.00E-07 Axial length / / 24144296 rs235770 chr20 6761765 T C 2.00E-08 Refractive error / / 23396134 rs235770 chr20 6761765 T C 4.36E-07 Axial length / / 24144296 rs235771 chr20 6762025 G A 8.02E-06 Axial length / / 24144296 rs28488 chr20 6762221 C T 3.03E-06 Axial length / / 24144296 rs235772 chr20 6762719 C T 2.89E-06 Axial length / / 24144296 rs173107 chr20 6765841 A C 1.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6054517 chr20 6771370 C A 7.22E-04 Alcohol dependence / / 20201924 rs13044579 chr20 6774420 A G 4.12E-05 Insulin resistance / / 21901158 rs16992637 chr20 6814338 T C 2.40E-04 Multiple complex diseases / / 17554300 rs1028395 chr20 6860859 C T 3.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs1883719 chr20 6862289 C A 2.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs720858 chr20 6862979 C T 4.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs6038634 chr20 6863919 A G 4.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs6038644 chr20 6893128 A G 1.09E-04 Celiac disease / / 23936387 rs8124692 chr20 6909492 C A 1.97E-05 Bipolar disorder / / 20451256 rs6054610 chr20 6910864 A T 3.03E-04 Height / / 17255346 rs6140121 chr20 6912028 T A 3.66E-04 Height / / 17255346 rs6054616 chr20 6920028 C G 3.18E-04 Height / / 17255346 rs6107895 chr20 6922676 A G 2.72E-04 Height / / 17255346 rs2057039 chr20 6922810 T C 2.74E-04 Height / / 17255346 rs6085753 chr20 6925667 T C 2.74E-04 Height / / 17255346 rs7267551 chr20 6932220 T C 7.09E-05 Bipolar disorder / / 20451256 rs6054631 chr20 6942420 T C 6.11E-05 Blood Pressure / / pha002903 rs6085781 chr20 6948587 G A 0.0000177 VLDL cholesterol particle diameter / / 23263444 rs6085781 chr20 6948587 G A 1.23E-05 Height / / pha003011 rs6077115 chr20 6952829 T G 9.34E-04 Type 2 diabetes / / 17463246 rs6085802 chr20 6963240 A G 7.19E-05 Height / / pha003010 rs6085802 chr20 6963240 A G 2.03E-05 Height / / pha003011 rs6085806 chr20 6964082 T G 8.31E-05 Height / / pha003010 rs6085806 chr20 6964082 T G 2.60E-05 Height / / pha003011 rs952793 chr20 6970831 C T 8.15E-05 Attention deficit hyperactivity disorder / / 23728934 rs6085820 chr20 6980635 G T 9.00E-06 Alzheimer's disease (late onset) / / 22881374 rs2149639 chr20 6990833 T C 6.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs2209982 chr20 6997406 G A 8.10E-06 Urinary metabolites / / 21572414 rs1571459 chr20 6997712 T C 6.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs6054679 chr20 7000414 A T 2.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs2183182 chr20 7002489 C T 4.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs4616543 chr20 7006604 C T 8.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs995635 chr20 7008708 G A 5.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs995636 chr20 7008824 G A 1.90E-05 Urinary metabolites / / 21572414 rs16992973 chr20 7009158 G A 0.0000552 Brain activation patterns in response to human facial expressions-with the fusiform gyrus for the positive faces task / / 22828495 rs16992973 chr20 7009158 G A 1.26E-09 Brain activation patterns in response to human facial expressions-for the negative faces task / / 22828495 rs16992973 chr20 7009158 G A 2.85E-08 Brain activation patterns in response to human facial expressions-for the positive faces task / / 22828495 rs16992973 chr20 7009158 G A 1.26E-09 Airflow obstruction / / 22837378 rs6085834 chr20 7009854 T C 5.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs2149642 chr20 7014445 T C 5.90E-07 Urinary metabolites / / 21572414 rs232649 chr20 7067750 A G 8.40E-06 Urinary metabolites / / 21572414 rs142092 chr20 7093432 T C 2.90E-04 Insulin resistance / / 21901158 rs1159530 chr20 7103709 G C 5.27E-04 Multiple complex diseases / / 17554300 rs1884302 chr20 7106289 T C 1.00E-39 Sagittal craniosynostosis / / 23160099 rs6054768 chr20 7129677 C T 8.95E-07 QT interval / / 19587794 rs6038724 chr20 7129738 T C 8.48E-07 QT interval / / 19587794 rs6054770 chr20 7131752 G A 8.44E-07 QT interval / / 19587794 rs6054771 chr20 7132210 T C 8.44E-07 QT interval / / 19587794 rs6107933 chr20 7132516 G A 8.38E-07 QT interval / / 19587794 rs6038725 chr20 7133039 A T 8.45E-07 QT interval / / 19587794 rs6117650 chr20 7135633 G A 9.91E-07 QT interval / / 19587794 rs6054776 chr20 7136016 G C 9.89E-07 QT interval / / 19587794 rs6054777 chr20 7136244 G A 9.89E-07 QT interval / / 19587794 rs6038726 chr20 7136322 C G 9.84E-07 QT interval / / 19587794 rs6038727 chr20 7136357 C G 9.89E-07 QT interval / / 19587794 rs6038729 chr20 7137757 A C 6.25E-07 QT interval / / 19587794 rs719563 chr20 7142997 G A 7.62E-07 QT interval / / 19587794 rs17373665 chr20 7171612 T C 3.37E-04 Aortic root size / / 21223598 rs6085920 chr20 7180056 T A 6.00E-06 Uric acid levels / / 18759275 rs990654 chr20 7184635 T G 1.83E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6054805 chr20 7191569 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6054815 chr20 7199666 A T 8.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6140212 chr20 7199917 T C 2.98E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6085947 chr20 7232828 G A 2.80E-05 Urinary metabolites / / 21572414 rs6085948 chr20 7233350 G A 7.80E-06 Urinary metabolites / / 21572414 rs6085955 chr20 7238994 G C 2.80E-05 Urinary metabolites / / 21572414 rs6107955 chr20 7253477 G A 1.06E-05 Coronary heart disease / / pha003056 rs6117734 chr20 7253500 C T 9.52E-06 Coronary heart disease / / pha003056 rs16993349 chr20 7266858 A G 9.20E-04 Type 2 diabetes / / 17463246 rs6085977 chr20 7272507 A T 2.05E-05 Odorant perception / / 23910658 rs6054906 chr20 7294903 G A 3.00E-06 Response to amphetamines / / 22952603 rs6054907 chr20 7294973 A G 9.51E-06 Response to amphetamines / / 22952603 rs16993414 chr20 7308538 T C 5.30E-07 Fasting plasma glucose / / 19060907 rs2423194 chr20 7313534 G A 1.00E-04 Prostate cancer / / 21743057 rs7262084 chr20 7323563 G A 1.00E-04 Prostate cancer / / 21743057 rs6140264 chr20 7376354 G A 1.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2423243 chr20 7376672 G A 4.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2423244 chr20 7377090 G C 3.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs6086031 chr20 7380416 A G 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs6054970 chr20 7383634 C T 4.17E-04 Alzheimer's disease / / 17998437 rs6054973 chr20 7385958 T C 1.00E-07 Asthma (childhood onset) / / 23829686 rs7270010 chr20 7420179 C T 2.90E-05 Urinary metabolites / / 21572414 rs971103 chr20 7441840 A G 6.18E-05 Cognitive test performance / / 20125193 rs4813827 chr20 7453335 T C 7.44E-05 Cognitive test performance / / 20125193 rs6055034 chr20 7453861 A G 7.42E-04 Type 2 diabetes / / 17463246 rs6086075 chr20 7496565 A C 2.78E-04 Alzheimer's disease (late onset) / / 21379329 rs6108011 chr20 7552504 C T 6.00E-06 Hemostatic factors and hematological phenotypes / / 17903294 rs6108011 chr20 7552504 C T 5.12E-04 Stroke / / pha002886 rs8121908 chr20 7553042 T C 5.90E-04 Multiple complex diseases / / 17554300 rs2014101 chr20 7570459 A G 7.77E-04 Obesity (extreme) / / 21935397 rs2207696 chr20 7573011 A G 8.29E-04 Obesity (extreme) / / 21935397 rs6055170 chr20 7588116 C T 7.36E-04 Obesity (extreme) / / 21935397 rs971060 chr20 7588599 T A 9.01E-04 Obesity (extreme) / / 21935397 rs6108021 chr20 7589392 T G 3.55E-04 Multiple complex diseases / / 17554300 rs6108022 chr20 7589406 T C 5.95E-04 Multiple complex diseases / / 17554300 rs2223532 chr20 7591479 C T 8.75E-04 Obesity (extreme) / / 21935397 rs2206397 chr20 7591596 T C 8.75E-04 Obesity (extreme) / / 21935397 rs6055180 chr20 7594928 G A 8.73E-04 Obesity (extreme) / / 21935397 rs6055182 chr20 7596750 T A 8.85E-04 Obesity (extreme) / / 21935397 rs6086122 chr20 7603590 A G 6.38E-04 Obesity (extreme) / / 21935397 rs6117887 chr20 7605773 C G 6.68E-04 Obesity (extreme) / / 21935397 rs6108026 chr20 7608657 A G 2.45E-05 Calcium levels / / pha003085 rs2223531 chr20 7614537 A G 8.14E-04 Obesity (extreme) / / 21935397 rs1040479 chr20 7617221 A G 8.23E-04 Obesity (extreme) / / 21935397 rs1040479 chr20 7617221 A G 3.40E-04 Smoking quantity / / 24665060 rs6086132 chr20 7618077 A G 4.06E-04 Smoking quantity / / 24665060 rs4813836 chr20 7620823 T C 8.15E-04 Obesity (extreme) / / 21935397 rs6086136 chr20 7621465 C T 8.09E-04 Obesity (extreme) / / 21935397 rs6086143 chr20 7624747 A C 2.17E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs6077236 chr20 7625986 C T 7.81E-04 Obesity (extreme) / / 21935397 rs6086144 chr20 7626342 T C 7.82E-04 Obesity (extreme) / / 21935397 rs2050081 chr20 7627224 A G 7.81E-04 Obesity (extreme) / / 21935397 rs6108030 chr20 7627294 G A 1.95E-05 Calcium levels / / pha003085 rs17403161 chr20 7630428 T A 6.90E-06 Urinary metabolites / / 21572414 rs2223535 chr20 7631706 A G 7.78E-04 Obesity (extreme) / / 21935397 rs2206406 chr20 7632355 A G 7.77E-04 Obesity (extreme) / / 21935397 rs6055231 chr20 7633349 C T 7.76E-04 Obesity (extreme) / / 21935397 rs6086146 chr20 7633484 A C,T 7.76E-04 Obesity (extreme) / / 21935397 rs4278998 chr20 7634063 A T 7.76E-04 Obesity (extreme) / / 21935397 rs6038913 chr20 7635654 G A 7.75E-04 Obesity (extreme) / / 21935397 rs6055235 chr20 7636126 T G 7.74E-04 Obesity (extreme) / / 21935397 rs2223534 chr20 7639093 G T 7.74E-04 Obesity (extreme) / / 21935397 rs6055240 chr20 7644199 T G 7.67E-04 Obesity (extreme) / / 21935397 rs6055241 chr20 7644651 T C 7.65E-04 Obesity (extreme) / / 21935397 rs6140373 chr20 7649364 G A 1.00E-05 Urinary metabolites / / 21572414 rs1474673 chr20 7652458 T A 6.59E-04 Obesity (extreme) / / 21935397 rs4813838 chr20 7653342 C T 6.60E-04 Obesity (extreme) / / 21935397 rs6055249 chr20 7654897 A G 2.18E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs2064267 chr20 7654978 T C 5.04E-04 Obesity (extreme) / / 21935397 rs2143197 chr20 7656210 G C 6.53E-04 Obesity (extreme) / / 21935397 rs2143196 chr20 7656312 G A 6.53E-04 Obesity (extreme) / / 21935397 rs6038918 chr20 7657356 C A 6.49E-04 Obesity (extreme) / / 21935397 rs6055258 chr20 7671888 C A 6.63E-04 Insulin resistance / / 21901158 rs6108046 chr20 7704428 C T 3.83E-04 Heart Failure / / pha002884 rs6140410 chr20 7737540 T C 7.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs6077251 chr20 7752366 C T 3.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs16993989 chr20 7754302 A G 3.54E-05 Multiple complex diseases / / 17554300 rs2092380 chr20 7756027 G A 2.50E-05 Urinary metabolites / / 21572414 rs2092380 chr20 7756027 G A 3.87E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs6086197 chr20 7757151 C A 3.21E-04 Multiple complex diseases / / 17554300 rs1160462 chr20 7781590 G C 1.11E-04 Aortic root size / / 21223598 rs6077264 chr20 7805987 G T 2.10E-04 Insulin resistance / / 21901158 rs2423273 chr20 7806720 A G 2.67E-04 Insulin resistance / / 21901158 rs2423279 chr20 7812350 T C 2.00E-07 Colorectal cancer / / 23263487 rs2423279 chr20 7812350 T C 7.00E-09 Colorectal cancer / / 23263487 rs2423279 chr20 7812350 T C 3.00E-12 Colorectal cancer / / 24836286 rs8123426 chr20 7830355 T A 7.91E-04 Insulin resistance / / 21901158 rs6077278 chr20 7836143 C T 6.99E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs8116938 chr20 7838533 G A 6.99E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs16994091 chr20 7847156 C T 6.99E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs2423322 chr20 7873112 A G 0.00000448 Central corneal thickness HAO1 intron 22661486 rs2423322 chr20 7873112 A G 4.48E-06 Testosterone levels HAO1 intron 22675492 rs2423322 chr20 7873112 A G 7.83E-05 Cholesterol HAO1 intron pha003073 rs2423322 chr20 7873112 A G 9.18E-05 Cholesterol HAO1 intron pha003078 rs2423334 chr20 7905947 T C 7.88E-04 Multiple complex diseases HAO1 intron 17554300 rs6055400 chr20 7908901 C G 7.75E-04 Multiple complex diseases HAO1 intron 17554300 rs7266916 chr20 7911792 A G 3.60E-08 Metabolite levels HAO1 intron 23281178 rs2235248 chr20 7912198 T A 8.12E-04 Multiple complex diseases HAO1 intron 17554300 rs6086287 chr20 7913141 T G 8.67E-05 Multiple complex diseases HAO1 intron 17554300 rs4140560 chr20 7913981 A G 2.33E-08 Metabolite levels HAO1 intron 23281178 rs7260781 chr20 7915927 A C 2.00E-08 Metabolite levels HAO1 intron 23281178 rs12625899 chr20 7918544 G C 2.00E-08 Metabolite levels HAO1 intron 23281178 rs16994212 chr20 7922919 A G 7.11E-04 Multiple complex diseases / / 17554300 rs2206900 chr20 7940429 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1569726 chr20 7951656 G A 6.20E-04 Stroke / / pha002886 rs6038994 chr20 7954930 G A 9.24E-09 Metabolite levels / / 23281178 rs7270019 chr20 7955347 A G 5.72E-08 Metabolite levels / / 23281178 rs8764 chr20 7962072 A C 4.17E-05 Sodium levels TMX4 UTR-3 pha003093 rs2076014 chr20 7963318 G A 2.00E-05 Urinary metabolites TMX4 intron 21572414 rs6055440 chr20 7966623 A G 7.90E-05 Multiple complex diseases TMX4 intron 17554300 rs1883202 chr20 7974005 G T 1.14E-06 Multiple complex diseases TMX4 intron 17554300 rs6140496 chr20 7990831 G T 1.60E-05 Urinary metabolites TMX4 intron 21572414 rs6133524 chr20 7992804 G A 2.30E-05 Urinary metabolites TMX4 intron 21572414 rs7269501 chr20 8004812 G A 2.08E-05 Kawasaki disease / / 22081228 rs6039005 chr20 8006196 G T 7.30E-04 Alcohol dependence / / 20201924 rs6039012 chr20 8012880 T G 9.14E-04 Type 2 diabetes / / 17463246 rs6133533 chr20 8036950 G T 4.19E-05 Body mass index / / 21701565 rs6133533 chr20 8036950 G T 6.60E-05 Body mass index / / 21701565 rs4239774 chr20 8074116 G A 0.00000207 Behcet's disease / / 23041938 rs6118083 chr20 8114704 A G 7.00E-06 Cognitive performance PLCB1 intron 20125193 rs13041373 chr20 8115957 A T 5.10E-06 Personality dimensions PLCB1 intron 21173776 rs6140549 chr20 8118531 A G 6.96E-05 Cognitive test performance PLCB1 intron 20125193 rs7271063 chr20 8153919 G A 1.08E-04 Height PLCB1 intron 17255346 rs6118101 chr20 8176269 A G 1.87E-04 Multiple complex diseases PLCB1 intron 17554300 rs12480099 chr20 8181902 A G 6.89E-05 Cognitive test performance PLCB1 intron 20125193 rs6077326 chr20 8186446 T C 4.21E-05 Cognitive test performance PLCB1 intron 20125193 rs6086371 chr20 8209717 C T 1.09E-04 Nicotine smoking PLCB1 intron 19268276 rs1474581 chr20 8220069 A C 3.78E-05 Rheumatoid arthritis PLCB1 intron 21452313 rs2719791 chr20 8267739 C T 4.39E-05 Nicotine smoking PLCB1 intron 19268276 rs2719791 chr20 8267739 C T 3.43E-05 Lupus nephritis in systemic lupus erythematosus PLCB1 intron 24925725 rs2745761 chr20 8277943 G A,C 6.00E-06 Response to irinotecan in non-small-cell lung cancer PLCB1 intron 22664479 rs6133573 chr20 8291657 T C 2.67E-04 Alcohol consumption (maxi-drinks) PLCB1 intron 24277619 rs6039135 chr20 8292683 G A 7.28E-04 Alzheimer's disease PLCB1 intron 17998437 rs6140613 chr20 8389911 T G 9.43E-05 Cognitive test performance PLCB1 intron 20125193 rs708915 chr20 8400667 T A 7.99E-04 Bipolar disorder PLCB1 intron 19259986 rs8117270 chr20 8433773 C T 1.79E-04 Multiple complex diseases PLCB1 intron 17554300 rs4471960 chr20 8450247 A G 8.00E-05 Immunoglobulin A PLCB1 intron 20694011 rs2022645 chr20 8451486 A C 4.22E-04 Response to alcohol consumption (flushing response) PLCB1 intron 24277619 rs10485724 chr20 8456324 T C 1.40E-05 Urinary metabolites PLCB1 intron 21572414 rs10485724 chr20 8456324 T C 9.04E-04 Stroke PLCB1 intron pha002887 rs2423356 chr20 8457900 T C 2.27E-04 Multiple complex diseases PLCB1 intron 17554300 rs6055858 chr20 8473578 T G 3.92E-05 Age-related macular degeneration PLCB1 intron 22125219 rs6077372 chr20 8487377 A T 4.30E-04 Suicide attempts in bipolar disorder PLCB1 intron 21423239 rs6140629 chr20 8488087 T C 5.28E-04 Suicide attempts in bipolar disorder PLCB1 intron 21423239 rs2050090 chr20 8489780 T C 9.40E-05 Serum metabolites PLCB1 intron 19043545 rs6118219 chr20 8490370 G T 1.01E-04 Age-related macular degeneration PLCB1 intron 22125219 rs16994849 chr20 8490861 A G 4.43E-04 Suicide attempts in bipolar disorder PLCB1 intron 21423239 rs6086478 chr20 8492925 A T 4.40E-04 Suicide attempts in bipolar disorder PLCB1 intron 21423239 rs7273511 chr20 8498416 T C 8.01E-05 Alzheimer's disease PLCB1 intron 21098978 rs6055881 chr20 8507713 T C 8.80E-05 Suicide attempts in bipolar disorder PLCB1 intron 21041247 rs1569604 chr20 8508036 A G 4.93E-04 Suicide attempts in bipolar disorder PLCB1 intron 21041247 rs2143205 chr20 8511004 T C 1.83E-04 Suicide attempts in bipolar disorder PLCB1 intron 21041247 rs2423364 chr20 8516695 C T 1.91E-04 Suicide attempts in bipolar disorder PLCB1 intron 21041247 rs2423366 chr20 8517451 A G 2.33E-04 Suicide attempts in bipolar disorder PLCB1 intron 21041247 rs2423366 chr20 8517451 A G 2.00E-05 Urinary metabolites PLCB1 intron 21572414 rs8119707 chr20 8525767 T C 3.70E-04 Smoking initiation PLCB1 intron 24665060 rs2206423 chr20 8528408 T C 2.43E-04 White matter integrity PLCB1 intron 22425255 rs6055910 chr20 8553750 A G 9.38E-04 Depression (quantitative trait) PLCB1 intron 20800221 rs12624339 chr20 8563082 A G 2.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PLCB1 intron 20877124 rs12624339 chr20 8563082 A G 9.26E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PLCB1 intron 20877124 rs2327046 chr20 8564915 A C 2.01E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer PLCB1 intron 21483023 rs6055922 chr20 8564967 A G 1.97E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer PLCB1 intron 21483023 rs6055923 chr20 8565034 G T 2.01E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer PLCB1 intron 21483023 rs6039206 chr20 8575671 C T 7.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PLCB1 intron 20877124 rs6055954 chr20 8604114 T A 1.88E-04 Alzheimer's disease PLCB1 intron 22005930 rs6118272 chr20 8605092 G C 1.93E-04 Alzheimer's disease PLCB1 intron 22005930 rs13038516 chr20 8606219 G C 4.31E-04 Alzheimer's disease PLCB1 intron 22005930 rs1535067 chr20 8607333 C T 4.35E-04 Alzheimer's disease PLCB1 intron 22005930 rs6055957 chr20 8611319 C A 3.47E-04 Alzheimer's disease PLCB1 intron 22005930 rs2223837 chr20 8611999 G A 8.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PLCB1 intron 20877124 rs6039211 chr20 8616588 A G 0.00000997 Confectionary intake PLCB1 intron 23408455 rs1018443 chr20 8626903 C T 2.35E-04 Alzheimer's disease PLCB1 intron 22005930 rs6055974 chr20 8629857 A G 2.34E-04 Alzheimer's disease PLCB1 intron 22005930 rs6140666 chr20 8630552 G C 4.86E-04 Type 2 diabetes PLCB1 intron 17463246 rs6086548 chr20 8630603 G A 2.35E-04 Alzheimer's disease PLCB1 intron 22005930 rs6055976 chr20 8630692 C A 2.41E-04 Alzheimer's disease PLCB1 intron 22005930 rs6118283 chr20 8634106 T G 5.97E-04 Alzheimer's disease PLCB1 intron 22005930 rs2076639 chr20 8639474 C A 5.38E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) PLCB1 intron 23648065 rs2295179 chr20 8678446 G A 3.44E-04 Hypertension PLCB1 intron 21082022 rs2057144 chr20 8687464 G T 2.17E-05 Cognitive impairment induced by topiramate PLCB1 intron 22091778 rs8123323 chr20 8695581 C T 5.98E-05 Hypertension PLCB1 intron 21082022 rs6077414 chr20 8704552 T C 1.00E-06 Estradiol plasma levels (breast cancer) PLCB1 intron 23518928 rs17446441 chr20 8708166 A G 4.02E-04 Amyotrophic Lateral Sclerosis PLCB1 intron 17362836 rs17446441 chr20 8708166 A G 2.64E-05 Aging (time to event) PLCB1 intron 21782286 rs17446441 chr20 8708166 A G 8.15E-04 Smoking initiation PLCB1 intron 24665060 rs6086570 chr20 8711693 T C 9.24E-05 Non-alcoholic fatty liver disease histology (other) PLCB1 intron 20708005 rs6039249 chr20 8729119 A G 4.82E-04 Smoking initiation PLCB1 intron 24665060 rs2327101 chr20 8734263 A G 2.20E-07 Primary biliary cirrhosis PLCB1 intron 23000144 rs2327101 chr20 8734263 A G 0.00000022 Facial morphology PLCB1 intron 23028347 rs6056066 chr20 8738169 T C 2.33E-07 Primary biliary cirrhosis PLCB1 intron 23000144 rs6056066 chr20 8738169 T C 0.000000233 Facial morphology PLCB1 intron 23028347 rs6133617 chr20 8743637 T G 9.79E-04 Multiple complex diseases PLCB1 intron 17554300 rs1015092 chr20 8750062 A G 2.50E-07 Primary biliary cirrhosis PLCB1 intron 23000144 rs1015092 chr20 8750062 A G 0.00000025 Facial morphology PLCB1 intron 23028347 rs6056100 chr20 8757812 C T 8.45E-04 Multiple complex diseases PLCB1 intron 17554300 rs4496390 chr20 8761068 G A 8.28E-04 Amyotrophic Lateral Sclerosis PLCB1 intron 17362836 rs975633 chr20 8765289 T C 2.56E-07 Primary biliary cirrhosis PLCB1 intron 23000144 rs975633 chr20 8765289 T C 0.000000256 Facial morphology PLCB1 intron 23028347 rs718712 chr20 8766008 G A 4.02E-05 Serum metabolites PLCB1 intron 19043545 rs6039266 chr20 8766071 A G 7.02E-04 Multiple complex diseases PLCB1 intron 17554300 rs6039266 chr20 8766071 A G 2.56E-07 Primary biliary cirrhosis PLCB1 intron 23000144 rs6039266 chr20 8766071 A G 0.000000256 Facial morphology PLCB1 intron 23028347 rs2206489 chr20 8766796 G A 3.49E-04 Amyotrophic Lateral Sclerosis PLCB1 intron 17362836 rs2206489 chr20 8766796 G A 9.67E-05 Non-alcoholic fatty liver disease histology (other) PLCB1 intron 20708005 rs6056111 chr20 8767841 A C 7.56E-04 Amyotrophic Lateral Sclerosis PLCB1 intron 17362836 rs2327089 chr20 8769180 C T 2.59E-07 Primary biliary cirrhosis PLCB1 intron 23000144 rs2327089 chr20 8769180 C T 0.000000259 Facial morphology PLCB1 intron 23028347 rs4633993 chr20 8770108 A C 5.14E-04 Multiple complex diseases PLCB1 intron 17554300 rs4633993 chr20 8770108 A C 2.59E-07 Primary biliary cirrhosis PLCB1 intron 23000144 rs4633993 chr20 8770108 A C 0.000000259 Facial morphology PLCB1 intron 23028347 rs2294597 chr20 8770822 C T 7.17E-04 Amyotrophic Lateral Sclerosis PLCB1 cds-synon 17362836 rs2294597 chr20 8770822 C T 9.67E-05 Non-alcoholic fatty liver disease histology (other) PLCB1 cds-synon 20708005 rs4053148 chr20 8772544 A G 2.84E-07 Primary biliary cirrhosis PLCB1 intron 23000144 rs4053148 chr20 8772544 A G 0.000000283 Facial morphology PLCB1 intron 23028347 rs6039272 chr20 8772874 T C 3.34E-07 Primary biliary cirrhosis PLCB1 intron 23000144 rs6039272 chr20 8772874 T C 0.000000334 Facial morphology PLCB1 intron 23028347 rs6056119 chr20 8773295 T C 2.84E-07 Primary biliary cirrhosis PLCB1 intron 23000144 rs6056119 chr20 8773295 T C 0.000000283 Facial morphology PLCB1 intron 23028347 rs6056126 chr20 8775670 T C 2.91E-07 Primary biliary cirrhosis PLCB1 intron 23000144 rs6056126 chr20 8775670 T C 0.000000291 Facial morphology PLCB1 intron 23028347 rs1997752 chr20 8787329 G A 5.69E-04 Response to taxane treatment (placlitaxel) PLCB1 intron 23006423 rs16995282 chr20 8795984 A G 2.24E-04 Response to taxane treatment (placlitaxel) PLCB1 intron 23006423 rs6108195 chr20 8797304 G C 1.30E-05 Urinary metabolites PLCB1 intron 21572414 rs6140752 chr20 8822308 G T 8.63E-04 Alzheimer's disease PLCB1 intron 17998437 rs6056209 chr20 8836771 G A 2.00E-06 Cognitive performance PLCB1 intron 19734545 rs6108205 chr20 8845372 T C 1.17E-05 Cognitive performance PLCB1 intron 19734545 rs6086678 chr20 8853275 A T 6.27E-04 Multiple complex diseases PLCB1 intron 17554300 rs6086678 chr20 8853275 A T 8.00E-05 Lupus PLCB1 intron 17911428 rs3848840 chr20 8859149 T C 5.53E-04 Multiple complex diseases PLCB1 intron 17554300 rs3761168 chr20 8865718 C A 8.00E-08 Social communication problems PLCB1 nearGene-3 24564958 rs12626115 chr20 8885143 C T 5.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12626115 chr20 8885143 C T 7.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6056252 chr20 8894975 A G 0.000333268 Hypertension (early onset hypertension) / / 22479346 rs12151880 chr20 8899426 C T 2.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12151880 chr20 8899426 C T 5.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6086699 chr20 8912457 G A 8.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6118393 chr20 8922819 G A 1.39E-04 Type 2 diabetes / / 17463246 rs16995421 chr20 8923164 G A 3.55E-05 Multiple complex diseases / / 17554300 rs6056278 chr20 8926960 G T 3.54E-04 Type 2 diabetes / / 17463246 rs3922993 chr20 8930468 C G 1.89E-04 Type 2 diabetes / / 17463246 rs2808806 chr20 8942998 G A 5.66E-04 Stroke / / pha002886 rs6516421 chr20 8945635 G A 0.000246902 Hypertension (early onset hypertension) / / 22479346 rs2206266 chr20 8949064 T C 7.10E-04 Alcohol dependence / / 21314694 rs4813881 chr20 8968642 A T 0.0000785 5-fluorouracil induced diarrhoea in response to colorectal cancer treatment / / 22310351 rs4813881 chr20 8968642 A T 1.44E-05 Parkinson's disease (motor and cognition) / / 22658654 rs4813881 chr20 8968642 A T 9.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6108228 chr20 8978063 T G 6.89E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs226181 chr20 8994390 G C 5.71E-04 Multiple complex diseases / / 17554300 rs8119079 chr20 9006453 C A 4.52E-09 Metabolite levels / / 23281178 rs13043535 chr20 9014874 T C 2.30E-05 Personality dimensions / / 18957941 rs1884869 chr20 9022092 T C 6.13E-05 Hearing impairment / / 19047183 rs932584 chr20 9046743 C A 2.07E-04 Type 2 diabetes / / 17463246 rs6039376 chr20 9060337 A G 8.74E-04 Amyotrophic lateral sclerosis (sporadic) PLCB4 intron 24529757 rs6118476 chr20 9064332 T A 9.52E-06 Thiazide-induced adverse metabolic effects in hypertensive patients PLCB4 intron 23400010 rs16995546 chr20 9082318 C T 5.36E-04 Multiple complex diseases PLCB4 intron 17554300 rs964309 chr20 9098090 C A 4.17E-04 Multiple complex diseases PLCB4 intron 17554300 rs13041524 chr20 9110759 G A 2.20E-05 Urinary metabolites PLCB4 intron 21572414 rs13039478 chr20 9122002 C G 2.20E-05 Urinary metabolites PLCB4 intron 21572414 rs6086794 chr20 9131299 A G 3.55E-04 Type 2 diabetes PLCB4 intron 17463246 rs6039410 chr20 9177112 A G 1.00E-04 Cognitive impairment induced by topiramate PLCB4 intron 22091778 rs8183334 chr20 9184660 T G 7.66E-05 Cognitive impairment induced by topiramate PLCB4 intron 22091778 rs16995654 chr20 9191578 C T 3.20E-05 Blood pressure PLCB4 intron 24001895 rs5011374 chr20 9212186 C A 5.45E-04 Parkinson's disease PLCB4 intron 16252231 rs5011374 chr20 9212186 C A 5.96E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PLCB4 intron 20877124 rs6039424 chr20 9225164 C G 8.04E-05 Parkinson's disease PLCB4 intron 16252231 rs6056500 chr20 9240838 A C 3.38E-05 Cognitive impairment induced by topiramate PLCB4 intron 22091778 rs6056505 chr20 9243782 C T 9.44E-05 Cognitive impairment induced by topiramate PLCB4 intron 22091778 rs2145267 chr20 9249184 C G 9.00E-04 Acute lymphoblastic leukemia (childhood) PLCB4 intron 20189245 rs2145267 chr20 9249184 C G 9.02E-04 Blood pressure PLCB4 intron 24001895 rs2206138 chr20 9252390 A G 6.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PLCB4 intron 20877124 rs6140909 chr20 9259371 G A 3.43E-05 Parkinson's disease PLCB4 intron 21738487 rs16995736 chr20 9281420 T G 6.00E-04 Acute lymphoblastic leukemia (childhood) PLCB4 intron 20189245 rs6056552 chr20 9309713 T G 5.13E-05 Type 2 diabetes PLCB4 intron 17463246 rs6056552 chr20 9309713 T G 1.96E-04 Parkinson's disease PLCB4 intron 21248740 rs8115510 chr20 9313941 T C 6.86E-05 Tunica Media PLCB4 intron pha003036 rs7268671 chr20 9322989 A G 6.30E-06 Urinary metabolites PLCB4 intron 21572414 rs7268671 chr20 9322989 A G 7.78E-05 Tunica Media PLCB4 intron pha003036 rs725941 chr20 9349033 G A 2.35E-05 Platelet counts PLCB4 intron pha003100 rs2072910 chr20 9365303 T C 3.00E-10 Neutrophil count PLCB4 intron 20172861 rs7265537 chr20 9368554 A G 6.80E-05 HDL cholesterol PLCB4 intron pha003074 rs2179321 chr20 9371825 G T 1.42E-05 Platelet counts PLCB4 intron pha003100 rs6118591 chr20 9374520 T C 2.38E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) PLCB4 intron 24023788 rs6133707 chr20 9379949 A G 3.64E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) PLCB4 intron 24023788 rs731177 chr20 9394833 A G 9.49E-05 Multiple complex diseases PLCB4 intron 17554300 rs3819579 chr20 9408245 G A 8.85E-04 Acute lung injury PLCB4 intron 22295056 rs3787306 chr20 9450367 C T 7.57E-04 Acute lung injury PLCB4 intron 22295056 rs2076393 chr20 9459234 G A 4.68E-04 Acute lung injury PLCB4 intron 22295056 rs2076393 chr20 9459234 G A 7.20E-04 Response to cytidine analogues (gemcitabine) PLCB4 intron 24483146 rs4816144 chr20 9493480 C T 4.05E-05 Orofacial clefts / / 22419666 rs6056659 chr20 9493892 C A 0.000474 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs2232256 chr20 9495287 C T 1.63E-04 Age-related macular degeneration LAMP5 UTR-5 22125219 rs926475 chr20 9499399 G A 2.38E-04 Age-related macular degeneration LAMP5 intron 22125219 rs10485733 chr20 9544722 T C 9.69E-05 Weight PAK7 intron pha003027 rs11700112 chr20 9547018 C G 9.41E-05 Hearing function PAK7 missense 17255346 rs6039505 chr20 9547288 T G 3.80E-05 HIV-1 control PAK7 intron 20041166 rs6077567 chr20 9569769 G A 6.10E-05 HIV-1 control PAK7 intron 20041166 rs6056725 chr20 9574063 C A 2.02E-04 Premature ovarian failure PAK7 intron 19508998 rs6140980 chr20 9585479 T C 2.55E-04 Sudden cardiac arrest PAK7 intron 21658281 rs6056766 chr20 9611448 A G 5.58E-05 Cognitive impairment induced by topiramate PAK7 intron 22091778 rs6086964 chr20 9611551 C A 3.26E-05 Cognitive impairment induced by topiramate PAK7 intron 22091778 rs6516479 chr20 9618761 A G 6.93E-04 Type 2 diabetes PAK7 intron 20818381 rs4813894 chr20 9619475 A G 8.49E-04 Type 2 diabetes PAK7 intron 20818381 rs747996 chr20 9628822 G C 2.56E-04 Multiple sclerosis PAK7 intron 17660530 rs17408919 chr20 9644206 C A 3.47E-04 Multiple sclerosis PAK7 intron 17660530 rs2423395 chr20 9645420 G A 8.32E-04 Response to taxane treatment (placlitaxel) PAK7 intron 23006423 rs6140991 chr20 9645874 T C 8.34E-04 Type 2 diabetes PAK7 intron 17463246 rs6133735 chr20 9646834 C T 2.71E-04 HIV-1 viral setpoint PAK7 intron 17641165 rs2423402 chr20 9649353 C T 1.76E-04 Multiple complex diseases PAK7 intron 17554300 rs6108327 chr20 9657563 C G 7.67E-05 Calcium intake levels and metabolic syndrome PAK7 intron 22170361 rs2143256 chr20 9664539 G T 6.26E-04 Response to taxane treatment (placlitaxel) PAK7 intron 23006423 rs2423422 chr20 9672074 A C 8.96E-05 Age-related macular degeneration PAK7 intron pha000002 rs6118724 chr20 9746345 G A 4.14E-04 Multiple complex diseases PAK7 intron 17554300 rs6056855 chr20 9752408 A C 3.76E-04 Multiple complex diseases PAK7 intron 17554300 rs17502794 chr20 9756655 G A 5.42E-04 Multiple complex diseases PAK7 intron 17554300 rs6077598 chr20 9756882 G A 3.76E-04 Multiple complex diseases PAK7 intron 17554300 rs6039573 chr20 9758387 C G 2.76E-04 Multiple complex diseases PAK7 intron 17554300 rs6118730 chr20 9763329 G A 7.81E-04 Multiple complex diseases PAK7 intron 17554300 rs6087018 chr20 9763507 T C 5.73E-04 Multiple complex diseases PAK7 intron 17554300 rs6118732 chr20 9764925 A G 5.16E-04 Multiple complex diseases PAK7 intron 17554300 rs6077600 chr20 9776732 C G 5.80E-05 Acute lymphoblastic leukemia (childhood) PAK7 intron 19684603 rs6056891 chr20 9778729 G A 8.00E-06 Obesity-related traits PAK7 intron 23251661 rs2423477 chr20 9791900 A G 3.90E-05 Brain structure PAK7 intron 22504417 rs2050107 chr20 9796339 C T 6.58E-05 Coronary Artery Disease PAK7 intron 17634449 rs17412657 chr20 9799765 T C 3.54E-04 Taste perception PAK7 intron 22132133 rs6056909 chr20 9807527 T C 2.20E-04 Premature ovarian failure PAK7 intron 19508998 rs221020 chr20 9810872 A T 7.10E-04 Coronary Artery Disease PAK7 intron 17634449 rs221013 chr20 9815528 T C 3.09E-05 Pulmonary function in asthmatics PAK7 intron 23541324 rs6039600 chr20 9832733 G C 7.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs6039601 chr20 9833213 G A 8.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs6056938 chr20 9836339 A G 8.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs6056942 chr20 9842719 C T 6.62E-04 Suicide attempts in bipolar disorder / / 21423239 rs16996477 chr20 9846055 G T 4.84E-04 Multiple complex diseases / / 17554300 rs16996531 chr20 9872603 G T 1.64E-04 Multiple complex diseases / / 17554300 rs6039626 chr20 9889702 A G 3.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs6057010 chr20 9892542 A G 3.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs6108352 chr20 9893062 C T 3.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs6118801 chr20 9895378 G A 3.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs2225532 chr20 9898310 G A,C,T 1.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs870842 chr20 9909366 G T 2.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs6057030 chr20 9909558 G A 1.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs2210455 chr20 9919383 T G 3.70E-05 Major depressive disorder / / 20516156 rs41358849 chr20 9967393 T C 6.99E-06 Multiple complex diseases / / 17554300 rs8115116 chr20 9986085 A G 4.47E-04 Alzheimer's disease / / 17998437 rs8115116 chr20 9986085 A G 7.24E-04 Alzheimer's disease / / 24755620 rs6118852 chr20 9987409 A G 4.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs6133776 chr20 9993667 G C 4.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs6133777 chr20 9995950 T G 4.98E-05 Bipolar disorder / / 17486107 rs12481420 chr20 10009227 A G 8.70E-04 Alzheimer's disease LOC100131208 intron 17998437 rs16996688 chr20 10028725 A G 1.97E-04 Multiple complex diseases ANKRD5 intron 17554300 rs656111 chr20 10030931 C A 6.68E-06 Schizophrenia ANKRD5 intron 22037552 rs6087119 chr20 10036202 G A 3.02E-04 Height ANKRD5 missense 17255346 rs666519 chr20 10038994 C T 1.26E-04 Height LOC100131208 intron 17255346 rs559129 chr20 10041304 C T 4.86E-04 Type 2 diabetes LOC100131208 intron 17463246 rs660454 chr20 10050828 T C 1.12E-04 Multiple complex diseases LOC100131208 intron 17554300 rs6104550 chr20 10068488 T C 7.28E-04 Longevity LOC100131208 intron 22279548 rs6032780 chr20 10071187 G A 9.95E-04 Multiple complex diseases LOC100131208 intron 17554300 rs6032780 chr20 10071187 G A 4.15E-05 Aortic root size LOC100131208 intron 21223598 rs4141508 chr20 10092505 G A 8.06E-04 Type 2 diabetes LOC100131208 intron 17463246 rs1018485 chr20 10095132 G A 8.06E-04 Type 2 diabetes LOC100131208 intron 17463246 rs555185 chr20 10107686 C T 9.87E-04 Type 2 diabetes LOC100131208 intron 17463246 rs12624858 chr20 10110488 C T 7.11E-04 Type 2 diabetes LOC100131208 intron 17463246 rs1158389 chr20 10113638 G C 6.94E-05 Major depressive disorder LOC100131208 intron 21621269 rs6032806 chr20 10123424 C T 0.000295 Salmonella-induced pyroptosis LOC100131208 intron 22837397 rs2210585 chr20 10129600 A G 2.28E-05 Sensory disturbances after bilateral sagittal split ramus osteotomy LOC100131208 intron 23834954 rs17517821 chr20 10133139 T C 5.26E-05 Serum metabolites LOC100131208 intron 19043545 rs6039743 chr20 10140090 G A 1.60E-04 Height LOC100131208 intron 17255346 rs6131056 chr20 10149664 G A 6.65E-04 Multiple complex diseases LOC100131208 intron 17554300 rs6077681 chr20 10154444 T C 9.04E-04 Alcohol dependence LOC100131208 intron 24277619 rs883381 chr20 10165727 G T 2.50E-05 Urinary metabolites LOC100131208 intron 21572414 rs883382 chr20 10165933 A G 2.79E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) LOC100131208 intron 23648065 rs2327263 chr20 10183018 T A 9.28E-04 Acute lung injury LOC100131208 intron 22295056 rs6039763 chr20 10183517 A G 2.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) LOC100131208 intron 23648065 rs6039764 chr20 10183783 C G 9.28E-04 Acute lung injury LOC100131208 intron 22295056 rs4813921 chr20 10190093 A C 4.23E-04 Acute lung injury LOC100131208 intron 22295056 rs6032824 chr20 10193271 A G 4.50E-04 Acute lung injury LOC100131208 intron 22295056 rs1889189 chr20 10197086 T C 7.09E-04 Acute lung injury LOC100131208 intron 22295056 rs1889189 chr20 10197086 T C 1.89E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) LOC100131208 intron 23648065 rs6039769 chr20 10198954 A C 4.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) LOC100131208 intron 23648065 rs6077693 chr20 10206917 G A 4.14E-05 Cognitive test performance S/P25 intron 20125193 rs1158497 chr20 10217900 A G 3.89E-04 Bipolar disorder S/P25 intron 19259986 rs363012 chr20 10219799 A G 6.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) S/P25 intron 20877124 rs363012 chr20 10219799 A G 3.40E-04 Suicide attempts in bipolar disorder S/P25 intron 21041247 rs362582 chr20 10254287 T A 3.88E-04 Multiple complex diseases S/P25 intron 17554300 rs362584 chr20 10254475 G A 5.03E-05 Personality dimensions S/P25 intron 18957941 rs362584 chr20 10254475 G A 5.00E-05 Personality dimensions S/P25 intron 21173776 rs363006 chr20 10280083 G A 6.55E-04 Multiple complex diseases S/P25 intron 17554300 rs6039824 chr20 10283150 T C 1.00E-04 Prostate cancer S/P25 intron 21743057 rs6133863 chr20 10304419 A C 7.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs6131075 chr20 10305562 T A 8.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs6039847 chr20 10306503 T C 8.18E-05 Cognitive test performance / / 20125193 rs6039847 chr20 10306503 T C 7.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs6039848 chr20 10306574 T C 5.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs11087009 chr20 10320483 T G 6.30E-06 Urinary metabolites / / 21572414 rs1540902 chr20 10321276 C A 7.50E-05 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs11087010 chr20 10329195 G A 1.60E-05 Urinary metabolites / / 21572414 rs6133879 chr20 10340311 C T 6.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6133904 chr20 10382822 G T 1.40E-05 Urinary metabolites / / 21572414 rs6108559 chr20 10392179 C T 2.00E-05 Urinary metabolites MKKS intron 21572414 rs6133922 chr20 10401073 A G 4.40E-06 Endometriosis MKKS intron 21151130 rs16991555 chr20 10402591 T C 2.43E-04 Glycosylated haemoglobin levels MKKS intron 17255346 rs6074138 chr20 10418801 G A 9.61E-05 Prostate cancer C20orf94 intron 22923026 rs2026316 chr20 10422353 G T 9.75E-05 Serum metabolites C20orf94 intron 19043545 rs6077794 chr20 10422575 G A 3.62E-05 Serum metabolites C20orf94 intron 19043545 rs2150684 chr20 10429601 T C 9.75E-05 Serum metabolites C20orf94 intron 19043545 rs6104614 chr20 10430788 A G 9.48E-05 Serum metabolites C20orf94 intron 19043545 rs6032881 chr20 10432766 G A 4.60E-06 Urinary metabolites C20orf94 intron 21572414 rs622293 chr20 10471619 G C 1.78E-04 Arthritis (juvenile idiopathic) C20orf94 intron 22354554 rs652325 chr20 10476071 G A 1.62E-04 Arthritis (juvenile idiopathic) C20orf94 intron 22354554 rs677673 chr20 10481772 A T 8.47E-04 Type 2 diabetes C20orf94 intron 17463246 rs676277 chr20 10539539 G C 2.84E-04 Type 2 diabetes C20orf94 intron 17463246 rs640336 chr20 10561369 T C 7.67E-04 Type 2 diabetes C20orf94 intron 17463246 rs640336 chr20 10561369 T C 0.0005 Coronary arterial lesions in patients with Kawasaki disease C20orf94 intron 23454411 rs6077844 chr20 10579996 A G 5.37E-04 Multiple complex diseases C20orf94 intron 17554300 rs2143619 chr20 10614435 A G 9.08E-06 Colorectal cancer / / 24448986 rs8708 chr20 10618574 T C 1.13E-04 Oral cancers (chewing tobacco related) JAG1 UTR-3 22503698 rs10485741 chr20 10637057 T C 9.38E-05 Panic disorder JAG1 cds-synon 19165232 rs34271232 chr20 10637057 T TG 9.38E-05 Panic disorder JAG1 cds-synon 19165232 rs2273061 chr20 10639543 G A 5.00E-08 Bone mineral density JAG1 intron 20096396 rs3790160 chr20 10639988 T C 3.00E-19 Bone mineral density JAG1 intron 22504420 rs6108658 chr20 10640960 C T 9.44E-04 Type 2 diabetes JAG1 intron 17463246 rs3748478 chr20 10641575 C T 9.92E-04 Multiple complex diseases JAG1 intron 17554300 rs6040065 chr20 10643051 C T 9.44E-04 Type 2 diabetes JAG1 intron 17463246 rs8119569 chr20 10643201 C T 9.44E-04 Type 2 diabetes JAG1 intron 17463246 rs7267595 chr20 10643850 A C 8.65E-04 Alcohol dependence JAG1 intron 21314694 rs11907050 chr20 10644074 A G 9.44E-04 Type 2 diabetes JAG1 intron 17463246 rs910118 chr20 10656087 C A 6.69E-04 Multiple complex diseases JAG1 nearGene-5 17554300 rs910118 chr20 10656087 C A 6.30E-05 Amyotrophic lateral sclerosis (sporadic) JAG1 nearGene-5 24529757 rs6032919 chr20 10680763 T G 7.21E-04 Type 2 diabetes / / 17463246 rs6032927 chr20 10692201 G T 6.15E-04 Type 2 diabetes / / 17463246 rs2423513 chr20 10692279 C G 6.09E-04 Multiple complex diseases / / 17554300 rs973542 chr20 10692559 G A 2.70E-04 Crohn's disease / / 17684544 rs6077888 chr20 10692989 C T 2.70E-04 Crohn's disease / / 17684544 rs6134007 chr20 10701027 G A 1.11E-04 Multiple complex diseases / / 17554300 rs6108692 chr20 10724491 C G 7.11E-04 Insulin resistance / / 21901158 rs6032937 chr20 10730636 C A 9.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs6104657 chr20 10738950 A C,G,T 0.000017 Major depressive disorder / / 22915352 rs6134030 chr20 10748899 G T 7.13E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs6108701 chr20 10766162 C T 5.51E-05 Prostate cancer / / pha002878 rs4813944 chr20 10769877 T C 2.03E-05 Schizophrenia / / 20185149 rs6040194 chr20 10829979 G T 0.00000195 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs6108719 chr20 10834078 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2024683 chr20 10843840 A G 7.90E-04 Alcohol dependence / / 20201924 rs2273203 chr20 10847669 T C 5.06E-04 Multiple complex diseases / / 17554300 rs1884137 chr20 10850346 G A 3.27E-04 Multiple complex diseases / / 17554300 rs1884136 chr20 10850464 G T 9.00E-06 Information processing speed / / 21130836 rs6108727 chr20 10853731 C A 3.65E-05 Job-related exhaustion / / 23620144 rs6134067 chr20 10862592 A T 6.34E-04 Multiple complex diseases / / 17554300 rs6074198 chr20 10887771 A G 3.70E-05 Telomere length / / 23001564 rs2144184 chr20 10891798 T C 1.31E-04 Height / / 17255346 rs2144184 chr20 10891798 T C 8.67E-04 Multiple complex diseases / / 17554300 rs4142362 chr20 10903699 A C 8.25E-04 Multiple complex diseases / / 17554300 rs1409860 chr20 10904550 G T 2.94E-04 Multiple complex diseases / / 17554300 rs1887319 chr20 10922146 C T 4.50E-05 Type 2 diabetes / / 17463246 rs16990000 chr20 10948813 A G 4.00E-05 HIV-1 control / / 20041166 rs6040258 chr20 10950239 C T 3.40E-06 Urinary metabolites / / 21572414 rs62185668 chr20 10961935 C A 2.00E-11 Urinary bladder cancer / / 24861552 rs1887320 chr20 10965998 G A 1.38E-04 Type 2 diabetes / / 17463246 rs1327235 chr20 10969030 A G 1.32E-04 Type 2 diabetes / / 17463246 rs1327235 chr20 10969030 A G 4.00E-08 Blood pressure / / 21909110 rs1327235 chr20 10969030 A G 1.00E-15 Diastolic blood pressure / / 21909115 rs1327235 chr20 10969030 A G 2.00E-08 Systolic blood pressure / / 21909115 rs2327327 chr20 10973258 G T 3.03E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs6077997 chr20 10974926 G A 7.81E-05 Multiple complex diseases / / 17554300 rs6108793 chr20 10975841 T C 8.42E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs6104690 chr20 10988099 G A 7.00E-07 Bladder cancer / / 24163127 rs17189227 chr20 10988855 A G 9.20E-04 Tourette syndrome / / 22889924 rs4813953 chr20 10991138 T C 2.00E-10 Urinary bladder cancer / / 24861552 rs4813955 chr20 11008382 A C 4.44E-05 IgE levels in asthmatics (D.p. specific) / / 23967269 rs6033014 chr20 11015459 T C 6.98E-05 Aging (time to event) / / 21782286 rs6074234 chr20 11028705 G A 8.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4142363 chr20 11029046 C T 9.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs6033021 chr20 11051459 T G 7.66E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs11697745 chr20 11056347 A C 3.92E-04 Type 2 diabetes / / 17463246 rs6078047 chr20 11058072 A G 0.00047 Breast cancer early age of onset / / 18463975 rs6108827 chr20 11093866 G A 9.55E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs6040373 chr20 11116192 A G 5.61E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs12481309 chr20 11126060 T A 5.77E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs1028479 chr20 11144338 G A 3.65E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs6040399 chr20 11157011 A T 1.00E-06 Response to citalopram treatment / / 22760553 rs6040399 chr20 11157011 A T 7.00E-07 Response to citalopram treatment / / 22760553 rs2207418 chr20 11174903 G A 9.00E-06 Cardiac hypertrophy / / 21348951 rs11905884 chr20 11187616 T G 3.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6033061 chr20 11199629 A G 1.53E-05 Relative hand skill / / 24068947 rs6040439 chr20 11202285 T A 6.47E-06 Relative hand skill / / 24068947 rs6040441 chr20 11204258 G A 2.02E-05 Relative hand skill / / 24068947 rs2223853 chr20 11204883 A T 1.62E-05 Relative hand skill / / 24068947 rs6074263 chr20 11209119 G A 1.08E-05 Relative hand skill / / 24068947 rs6040448 chr20 11209476 G A 3.93E-06 Relative hand skill / / 24068947 rs6040449 chr20 11209522 G A 4.00E-06 Relative hand skill / / 24068947 rs726867 chr20 11227697 T C 1.03E-05 Relative hand skill / / 24068947 rs2207105 chr20 11231353 G T 5.73E-06 Relative hand skill / / 24068947 rs6040476 chr20 11231875 G A 1.14E-05 Relative hand skill / / 24068947 rs1883952 chr20 11236424 T G 1.47E-05 Relative hand skill / / 24068947 rs6040484 chr20 11238791 A G 1.68E-05 Relative hand skill / / 24068947 rs4813974 chr20 11242433 C T 1.41E-04 Glaucoma (primary open-angle) / / 22419738 rs13433103 chr20 11251165 T G 6.96E-04 Insulin resistance LOC339593 intron 21901158 rs4485619 chr20 11303676 T C 1.57E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs6108924 chr20 11332779 G A 6.64E-04 Smoking quantity / / 24665060 rs6104740 chr20 11336809 C A 1.15E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs6040571 chr20 11336889 C T 6.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs62193988 chr20 11360517 C A 2.93E-05 Intracerebral hemorrhage / / 24656865 rs996384 chr20 11367780 C A 1.10E-04 IgE levels in asthmatics / / 23967269 rs8119692 chr20 11368551 G A 4.54E-06 Leprosy / / 22019778 rs4610128 chr20 11374805 A G 1.10E-04 IgE levels in asthmatics / / 23967269 rs2179832 chr20 11381828 T C 1.40E-05 Urinary metabolites / / 21572414 rs6074298 chr20 11382312 C T 3.77E-05 Personality dimensions / / 22628180 rs6040669 chr20 11412024 T C 0.00072 Salmonella-induced pyroptosis / / 22837397 rs6078181 chr20 11418544 T C 6.32E-04 Type 2 diabetes / / 17463246 rs10485749 chr20 11426730 A G 1.65E-04 adolescent idiopathic scoliosis / / 24023777 rs2224184 chr20 11501142 T C 1.20E-05 Urinary metabolites / / 21572414 rs4814019 chr20 11508980 A C 1.41E-05 Schizophrenia / / 19197363 rs17800346 chr20 11552387 A C 2.30E-05 Urinary metabolites / / 21572414 rs2144637 chr20 11573224 T G 7.84E-04 Multiple complex diseases / / 17554300 rs2224182 chr20 11573668 C G 3.28E-04 Alzheimer's disease / / 24755620 rs6033187 chr20 11574717 C T 5.52E-04 Alzheimer's disease / / 24755620 rs714235 chr20 11590160 A G 1.43E-05 Alzheimer's disease / / 21627779 rs6078265 chr20 11599971 C T 6.67E-04 Alzheimer's disease / / 24755620 rs1474897 chr20 11606625 T C 5.31E-04 Alzheimer's disease / / 24755620 rs1513579 chr20 11606648 A T 5.31E-04 Alzheimer's disease / / 24755620 rs17800370 chr20 11613200 G A 1.13E-04 Alzheimer's disease / / 24755620 rs6033206 chr20 11699643 T C 1.20E-05 Diabetic retinopathy / / 21441570 rs970657 chr20 11707888 A C 2.40E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2670436 chr20 11752439 G A 8.50E-04 Insulin resistance / / 21901158 rs1996132 chr20 11760981 C G 4.11E-04 Type 2 diabetes / / 17463246 rs6078334 chr20 11763061 A G 6.98E-04 Alzheimer's disease / / 17998437 rs2423611 chr20 11790702 G A 3.66E-04 Multiple complex diseases / / 17554300 rs2423611 chr20 11790702 G A 2.48E-24 Narcolepsy / / 19629137 rs2423618 chr20 11809442 T C 1.59E-05 Major depressive disorder C20orf61 intron 20516156 rs2423618 chr20 11809442 T C 2.21E-05 Anxiety and major depressive disorder C20orf61 intron 24047446 rs2423618 chr20 11809442 T C 5.92E-04 Smoking quantity C20orf61 intron 24665060 rs8115066 chr20 11809996 A T 4.68E-04 Smoking quantity C20orf61 intron 24665060 rs4083993 chr20 11811903 A G 5.00E-04 Smoking quantity C20orf61 intron 24665060 rs2247968 chr20 11812215 A G 9.77E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines C20orf61 intron 21844884 rs8123788 chr20 11821024 T C 2.23E-04 Smoking quantity C20orf61 intron 24665060 rs3848735 chr20 11821582 G C 6.89E-04 Smoking quantity C20orf61 intron 24665060 rs16992747 chr20 11823433 C T 3.06E-04 Smoking quantity C20orf61 intron 24665060 rs7263991 chr20 11824434 T C 3.04E-04 Smoking quantity C20orf61 intron 24665060 rs3905133 chr20 11825678 G T 6.31E-04 Smoking quantity C20orf61 intron 24665060 rs17225450 chr20 11829507 C T 6.68E-04 Smoking quantity C20orf61 intron 24665060 rs4813063 chr20 11891608 A G 8.70E-04 Type 2 diabetes and 6 quantitative traits BTBD3 intron 17848626 rs141676257 chr20 11900442 G A 0.00021 Prostate cancer BTBD3 missense 23555315 rs4814049 chr20 11946072 A T 9.21E-04 Depression (quantitative trait) / / 20800221 rs6078410 chr20 11946861 C T 8.98E-04 Depression (quantitative trait) / / 20800221 rs2223712 chr20 11955659 G A 2.42E-05 Multiple sclerosis / / 17660530 rs2223712 chr20 11955659 G A 7.50E-04 Smoking cessation / / 24665060 rs2327600 chr20 11959916 C T 5.86E-04 Stroke / / pha002886 rs2327595 chr20 11961965 C T 7.79E-04 Stroke / / pha002886 rs6131293 chr20 11995427 A G 3.67E-07 Obsessive-compulsive disorder / / 22889921 rs6131295 chr20 11996267 G A 3.84E-08 Obsessive-compulsive disorder / / 22889921 rs6109227 chr20 11999145 A T 2.11E-07 Obsessive-compulsive disorder / / 22889921 rs6033274 chr20 12001554 C T 1.66E-06 Obsessive-compulsive disorder / / 22889921 rs6134437 chr20 12003383 T C 1.97E-06 Obsessive-compulsive disorder / / 22889921 rs6134438 chr20 12003410 G A 2.83E-06 Obsessive-compulsive disorder / / 22889921 rs6134439 chr20 12003484 G A 1.97E-06 Obsessive-compulsive disorder / / 22889921 rs6078440 chr20 12019288 A G 6.15E-04 Multiple complex diseases / / 17554300 rs16992846 chr20 12019569 A G 1.94E-08 Metabolite levels / / 23281178 rs6041046 chr20 12025424 G C 8.54E-04 Insulin resistance / / 21901158 rs7268377 chr20 12039845 T G 7.07E-04 Premature ovarian failure / / 19508998 rs6041067 chr20 12049197 T G 7.47E-04 Premature ovarian failure / / 19508998 rs6033294 chr20 12052533 T C 7.47E-04 Premature ovarian failure / / 19508998 rs7261415 chr20 12064152 T C 5.79E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6041082 chr20 12067997 T G 4.78E-04 Insulin resistance / / 21901158 rs6041088 chr20 12074811 G C 5.80E-04 Insulin resistance / / 21901158 rs6033305 chr20 12079061 T C 2.60E-04 Insulin resistance / / 21901158 rs11907106 chr20 12082642 G A 4.00E-06 Obesity-related traits / / 23251661 rs6041093 chr20 12088568 A G 9.15E-05 Orofacial clefts / / 22419666 rs6041099 chr20 12093791 A C 4.03E-05 Glucose levels / / pha003058 rs6078460 chr20 12096897 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6041101 chr20 12097831 C A,T 8.51E-05 Insulin resistance / / 21901158 rs4344977 chr20 12116447 T C 8.65E-05 Insulin resistance / / 21901158 rs8119501 chr20 12118793 G A 6.31E-05 Orofacial clefts / / 22419666 rs6033323 chr20 12125993 T C 8.17E-04 Insulin resistance / / 21901158 rs6041137 chr20 12126072 G C 3.38E-04 Multiple complex diseases / / 17554300 rs6041137 chr20 12126072 G C 6.63E-04 Insulin resistance / / 21901158 rs13042372 chr20 12132323 C T 1.43E-04 Insulin resistance / / 21901158 rs13039035 chr20 12133935 A G 4.41E-05 Insulin resistance / / 21901158 rs13039261 chr20 12147751 T A 6.41E-04 Insulin resistance / / 21901158 rs13044874 chr20 12150580 G A 1.05E-04 Multiple complex diseases / / 17554300 rs13044874 chr20 12150580 G A 7.49E-04 Insulin resistance / / 21901158 rs6134468 chr20 12156846 C T 2.80E-05 Coronary heart disease / / pha003030 rs17800586 chr20 12191174 G A 4.61E-06 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs41383844 chr20 12191719 A G 2.46E-06 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs6033346 chr20 12194298 G A 5.49E-06 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs6041194 chr20 12202151 G A 1.18E-05 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs6041203 chr20 12205941 G T 7.13E-06 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs17225634 chr20 12220606 A G 5.26E-06 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs4814072 chr20 12224116 T C 2.90E-05 Urinary metabolites / / 21572414 rs6074396 chr20 12224896 T C 2.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6074396 chr20 12224896 T C 1.40E-05 Urinary metabolites / / 21572414 rs6074396 chr20 12224896 T C 5.52E-05 Cognitive decline / / 22054870 rs6074396 chr20 12224896 T C 0.000254 Salmonella-induced pyroptosis / / 22837397 rs6074396 chr20 12224896 T C 1.95E-04 Heart Failure / / pha002885 rs4814074 chr20 12227793 G A 7.16E-06 Bipolar disorder / / 21771265 rs12479608 chr20 12228787 G A 1.00E-05 Bipolar disorder / / 21771265 rs2876278 chr20 12230024 G A 6.93E-04 Heart Failure / / pha002885 rs4814077 chr20 12230651 T C 1.59E-04 Heart Failure / / pha002885 rs6131316 chr20 12237727 C T 8.52E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2224189 chr20 12242333 T C 2.56E-05 Cognitive decline / / 22054870 rs6041230 chr20 12247573 C T 6.77E-04 Smoking initiation / / 24665060 rs6109339 chr20 12266763 G A 3.35E-04 Birth weight / / 17255346 rs4268989 chr20 12273530 G A 1.43E-04 Birth weight / / 17255346 rs6109344 chr20 12276356 A G 3.11E-04 Birth weight / / 17255346 rs11697678 chr20 12279538 T C 9.01E-04 Multiple complex diseases / / 17554300 rs9917465 chr20 12279584 A G 4.06E-04 Aortic root size / / 21223598 rs6078518 chr20 12299029 C T 8.93E-04 Schizophrenia / / 19197363 rs6041265 chr20 12307489 G A 4.41E-05 Vitiligo / / 22951725 rs3891632 chr20 12354280 C T 8.95E-06 Multiple complex diseases / / 17554300 rs6109389 chr20 12377990 T C 2.00E-05 Urinary metabolites / / 21572414 rs6134537 chr20 12378641 C G 7.03E-05 Cervical cancer / / 24700089 rs6041319 chr20 12390696 G T 9.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs6109425 chr20 12443787 G T 9.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs6134584 chr20 12521501 G A 2.43E-04 Smoking initiation / / 24665060 rs6041477 chr20 12588583 A G 2.75E-04 Smoking initiation / / 24665060 rs6033459 chr20 12590921 G A 4.04E-04 Smoking initiation / / 24665060 rs2327523 chr20 12594790 G C 3.52E-04 Smoking initiation / / 24665060 rs7274881 chr20 12595371 T C 3.04E-04 Smoking initiation / / 24665060 rs12480885 chr20 12614084 C T 2.56E-04 Myocardial Infarction / / pha002883 rs13039010 chr20 12624679 G A 9.33E-04 Multiple complex diseases / / 17554300 rs7345016 chr20 12624737 C T 7.46E-04 Multiple complex diseases / / 17554300 rs8182659 chr20 12629226 G C 7.48E-04 Multiple complex diseases / / 17554300 rs12625561 chr20 12632043 G A 1.81E-04 Multiple complex diseases / / 17554300 rs197196 chr20 12639060 C T 5.67E-04 Alzheimer's disease / / 17998437 rs10485760 chr20 12649066 T C 3.18E-05 Cognitive performance / / 19734545 rs1452320 chr20 12650325 A G 3.34E-04 Response to TNF antagonist treatment / / 21061259 rs4814140 chr20 12651634 C T 5.24E-04 Multiple complex diseases / / 17554300 rs6041532 chr20 12652435 C T 3.80E-05 Response to lithium treatment in bipolar disorder / / 19448189 rs6041535 chr20 12653620 C T 4.10E-04 Multiple complex diseases / / 17554300 rs912543 chr20 12661633 C G 2.34E-04 IgE levels / / 17255346 rs6041542 chr20 12661944 C T 1.08E-04 IgE levels / / 17255346 rs6078717 chr20 12661980 G C 2.45E-04 IgE levels / / 17255346 rs17226070 chr20 12679999 A G 8.02E-04 Type 2 diabetes / / 17463246 rs6104958 chr20 12707998 C T 7.26E-05 Cognitive impairment induced by topiramate / / 22091778 rs6134655 chr20 12718736 G A,C 3.11E-05 Cognitive impairment induced by topiramate / / 22091778 rs1413020 chr20 12730042 C G 3.00E-06 Body mass index (interaction) / / 23192594 rs845587 chr20 12744198 A C 4.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6104978 chr20 12768527 A T 9.50E-05 Multiple complex diseases / / 17554300 rs1321936 chr20 12826999 G A 6.23E-05 Coronary heart disease / / 24778558 rs4289259 chr20 12855605 A G 7.22E-04 Multiple complex diseases / / 17554300 rs6109595 chr20 12861103 A C 1.47E-04 Breast cancer / / pha002853 rs2073233 chr20 12874585 T C 1.00E-06 Brain structure / / 20171287 rs399736 chr20 12887363 T C 1.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs6131408 chr20 12888320 T C 1.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs570376 chr20 12889314 G A 5.48E-05 Suicide attempts in bipolar disorder / / 21423239 rs6134716 chr20 12889506 G A 4.69E-05 Suicide attempts in bipolar disorder / / 21423239 rs6131410 chr20 12889747 T A 4.55E-05 Suicide attempts in bipolar disorder / / 21423239 rs6134717 chr20 12890206 G A 3.35E-05 Cognitive test performance / / 20125193 rs6134717 chr20 12890206 G A 4.55E-05 Suicide attempts in bipolar disorder / / 21423239 rs2327454 chr20 12893188 T A 6.67E-04 Smoking initiation / / 24665060 rs9680021 chr20 12898621 A C 9.84E-04 Alcohol dependence / / 24277619 rs3908399 chr20 12901275 G A 5.20E-05 Kidney function and endocine traits / / 17903292 rs187232 chr20 12902426 G T 1.32E-04 Type 2 diabetes / / 17463246 rs4814176 chr20 12959398 T C 3.00E-17 Blood metabolite levels / / 24816252 rs4814176 chr20 12959398 T C 7.00E-33 Blood metabolite ratios / / 24816252 rs6078854 chr20 12960153 T A 9.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs364585 chr20 12962718 A G 4.00E-10 LDL cholesterol / / 24097068 rs3848751 chr20 12965401 T G 1.60E-08 Sphingolipid levels / / 19798445 rs168622 chr20 12966089 T G 5.20E-25 Serum metabolites / / 20037589 rs6078860 chr20 12966738 C T 0.00000499 Cytarabine sensitivity / / 23538338 rs680379 chr20 12969400 A G 8.00E-15 Sphingolipid levels / / 19798445 rs680379 chr20 12969400 A G 2.00E-16 Sphingolipid levels / / 22359512 rs6078866 chr20 12974567 A G 1.57E-08 Sphingolipid levels / / 19798445 rs360534 chr20 12988524 G A 3.22E-05 Alcohol dependence / / 21703634 rs6033574 chr20 13005069 A T 5.85E-04 Multiple complex diseases SPTLC3 intron 17554300 rs6033574 chr20 13005069 A T 5.16E-05 Serum metabolites SPTLC3 intron 19043545 rs934336 chr20 13011890 C T 9.51E-04 Alzheimer's disease SPTLC3 intron 17998437 rs1367743 chr20 13012737 T A 8.33E-04 Multiple complex diseases SPTLC3 intron 17554300 rs6041821 chr20 13036800 G T 9.25E-04 Amyotrophic Lateral Sclerosis SPTLC3 intron 17362836 rs6109675 chr20 13039962 G A 8.10E-04 Type 2 diabetes and 6 quantitative traits SPTLC3 intron 17848626 rs243881 chr20 13048263 T C 1.40E-04 Type 2 diabetes and 6 quantitative traits SPTLC3 intron 17848626 rs2073302 chr20 13052671 G A 6.87E-04 Multiple complex diseases SPTLC3 intron 17554300 rs8126205 chr20 13053282 G T 5.55E-04 Multiple complex diseases SPTLC3 intron 17554300 rs10485764 chr20 13056070 C A 3.11E-04 Type 2 diabetes SPTLC3 intron 17846124 rs2327690 chr20 13061302 A C 2.04E-04 Lung function (forced vital capacity) SPTLC3 intron 24023788 rs3895211 chr20 13067378 T C 0.0002607 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPTLC3 intron 23233654 rs3895211 chr20 13067378 T C 2.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) SPTLC3 intron 23233662 rs6041870 chr20 13092482 T C 9.91E-05 Cognitive impairment induced by topiramate SPTLC3 intron 22091778 rs1014380 chr20 13095232 T C 2.36E-04 Schizophrenia SPTLC3 intron 21674006 rs17812191 chr20 13110280 T C 3.08E-04 Multiple complex diseases SPTLC3 intron 17554300 rs6033623 chr20 13112699 G A 8.37E-06 Response to tocilizumab in rheumatoid arthritis SPTLC3 intron 22491018 rs6078936 chr20 13118901 A C 7.48E-06 Response to tocilizumab in rheumatoid arthritis SPTLC3 intron 22491018 rs17190927 chr20 13123733 T G 8.00E-07 Personality dimensions SPTLC3 intron 21368711 rs6078937 chr20 13130096 G T 4.43E-06 Response to tocilizumab in rheumatoid arthritis SPTLC3 intron 22491018 rs6078938 chr20 13134768 T C 1.96E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SPTLC3 cds-synon 23648065 rs1321255 chr20 13139821 T G 9.69E-04 Obesity (extreme) SPTLC3 intron 21935397 rs6033633 chr20 13141809 T C 9.65E-04 Obesity (extreme) SPTLC3 intron 21935397 rs6041927 chr20 13142371 A G 7.13E-04 Obesity (extreme) SPTLC3 intron 21935397 rs7264061 chr20 13143562 A C 5.65E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) SPTLC3 intron 23648065 rs2144134 chr20 13148152 C G 4.00E-06 Body mass index (interaction) / / 23192594 rs6041937 chr20 13151531 G A 4.22E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs6109753 chr20 13190909 T C 3.23E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs6105047 chr20 13192648 C T 4.77E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs1407341 chr20 13193945 A T 6.02E-04 Multiple complex diseases / / 17554300 rs6041963 chr20 13204935 T G 1.09E-04 Obesity (extreme) ISM1 intron 21935397 rs1407335 chr20 13222858 A C 7.00E-06 Metabolite levels (X-11787) ISM1 intron 23934736 rs6109781 chr20 13233011 A C 3.60E-04 Osteoarthritis ISM1 intron 19508968 rs243903 chr20 13242166 T C 6.80E-05 Suicide attempts in bipolar disorder ISM1 intron 21423239 rs243903 chr20 13242166 T C 1.93E-04 Vaspin levels ISM1 intron 22907691 rs243903 chr20 13242166 T C 0.0001933 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks ISM1 intron 22907730 rs243904 chr20 13242662 T C 9.69E-05 Suicide attempts in bipolar disorder ISM1 intron 21423239 rs243906 chr20 13243396 C T 9.98E-05 Suicide attempts in bipolar disorder ISM1 intron 21423239 rs243895 chr20 13246323 T C 8.12E-05 Suicide attempts in bipolar disorder ISM1 intron 21423239 rs17191004 chr20 13264554 G A 2.19E-05 Duodenal ulcer ISM1 intron 22387998 rs4814215 chr20 13270683 T C 3.77E-05 Lipoproteins ISM1 intron pha003079 rs6078976 chr20 13270765 C T 5.98E-04 Obesity (extreme) ISM1 intron 21935397 rs6074585 chr20 13275202 G C 1.10E-04 Obesity (extreme) ISM1 intron 21935397 rs6078979 chr20 13279124 T A 1.23E-04 Obesity (extreme) ISM1 intron 21935397 rs17191018 chr20 13279196 A G 4.60E-05 Diabetic nephropathy ISM1 intron 20347642 rs543022 chr20 13284989 T C 5.28E-04 Myopia (pathological) / / 21095009 rs1076052 chr20 13287505 C T 4.96E-04 Myopia (pathological) / / 21095009 rs1223267 chr20 13289798 C A 9.84E-04 Multiple complex diseases / / 17554300 rs1223271 chr20 13296912 G A 5.00E-06 Parkinson's disease / / 19915575 rs6079027 chr20 13355430 T G 1.43E-04 Myocardial Infarction / / pha002883 rs4813127 chr20 13366624 T C 7.74E-04 Parkinson's disease / / 17052657 rs6079058 chr20 13401065 T C 7.63E-05 Sudden cardiac arrest TASP1 intron 21658281 rs16993972 chr20 13407962 A G 2.16E-05 Multiple complex diseases TASP1 intron 17554300 rs6105103 chr20 13428236 G A 4.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TASP1 intron 20877124 rs2070334 chr20 13433707 C T 8.50E-05 HIV-1 control TASP1 intron 20041166 rs6042145 chr20 13455377 G A 7.02E-04 Type 2 diabetes TASP1 intron 17463246 rs2273480 chr20 13464030 C A 6.60E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TASP1 intron 20877124 rs6042222 chr20 13557267 A G 3.33E-05 Body mass (lean) TASP1 intron 19268274 rs13037694 chr20 13560308 T C 6.15E-04 Type 2 diabetes TASP1 intron 17463246 rs13037694 chr20 13560308 T C 6.19E-04 Multiple complex diseases TASP1 intron 17554300 rs13045526 chr20 13595807 G A 6.00E-05 Multiple complex diseases TASP1 intron 17554300 rs6033777 chr20 13607380 C T 7.35E-05 Graves' disease TASP1 intron 21841780 rs2423729 chr20 13618382 A G 5.31E-05 Graves' disease TASP1 intron 21841780 rs16994094 chr20 13631197 A G 2.89E-06 Multiple complex diseases / / 17554300 rs6109993 chr20 13635155 A C 3.57E-05 Hemoglobin / / pha003098 rs6042314 chr20 13696129 G C 7.00E-06 Intelligence (childhood) ESF1 intron 23358156 rs10485767 chr20 13753470 G A 8.78E-05 Type 2 diabetes ESF1 intron 17846125 rs6042367 chr20 13788172 T C 4.72E-04 Type 2 diabetes C20orf7 intron 17463246 rs6134976 chr20 13809713 G A 5.11E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6134980 chr20 13814609 C T 4.81E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2423760 chr20 13821604 C T 2.30E-04 Insulin resistance / / 21901158 rs2073290 chr20 13830137 A C 8.48E-04 Alcohol consumption (maxi-drinks) SEL1L2 missense 24277619 rs6079225 chr20 13907179 G C 3.90E-06 Major depressive disorder SEL1L2 intron 21042317 rs1321238 chr20 13908548 C A 3.50E-06 Major depressive disorder SEL1L2 intron 21042317 rs1884559 chr20 13909450 G A 7.70E-06 Major depressive disorder SEL1L2 intron 21042317 rs2423762 chr20 13911291 A G 6.75E-04 Smoking initiation SEL1L2 intron 24665060 rs6042435 chr20 13916402 A C 4.40E-06 Major depressive disorder SEL1L2 intron 21042317 rs6079229 chr20 13923319 T C 6.92E-04 Tourette syndrome SEL1L2 intron 22889924 rs1535190 chr20 13924948 C G 7.40E-06 Major depressive disorder SEL1L2 intron 21042317 rs6079240 chr20 13950270 G T 7.57E-04 Tourette syndrome SEL1L2 intron 22889924 rs6110115 chr20 13963728 A C 2.00E-06 Urinary metabolites SEL1L2 intron 21572414 rs3848777 chr20 13971235 C T 4.18E-04 Stroke (pediatric) SEL1L2 UTR-5 22990015 rs17226852 chr20 13973760 T C 1.50E-06 Major depressive disorder / / 21042317 rs8117766 chr20 13974270 G A 2.10E-06 Major depressive disorder / / 21042317 rs34812325 chr20 13976594 T TA 1.30E-05 Urinary metabolites MACROD2 intron 21572414 rs6110117 chr20 13977991 G A 7.23E-04 Tourette syndrome MACROD2 intron 22889924 rs8119080 chr20 13987613 G A 2.10E-06 Major depressive disorder MACROD2 intron 21042317 rs2263684 chr20 13998098 G A 4.80E-05 Major depressive disorder MACROD2 intron 21042317 rs2257832 chr20 14016348 G T 3.50E-05 Major depressive disorder MACROD2 intron 21042317 rs6074678 chr20 14031392 A G 2.00E-06 Urinary metabolites MACROD2 intron 21572414 rs8126084 chr20 14157277 A T 1.65E-04 Suicide attempts in bipolar disorder MACROD2 intron 21423239 rs6105227 chr20 14188759 G T 2.68E-04 Multiple complex diseases MACROD2 intron 17554300 rs2876375 chr20 14206268 G T 3.27E-04 Suicide attempts in bipolar disorder MACROD2 intron 21423239 rs6079359 chr20 14209706 T A 5.50E-04 Suicide attempts in bipolar disorder MACROD2 intron 21423239 rs1114953 chr20 14212961 C T 5.58E-04 Suicide attempts in bipolar disorder MACROD2 intron 21423239 rs6033907 chr20 14214927 C A 5.70E-04 Suicide attempts in bipolar disorder MACROD2 intron 21423239 rs1998487 chr20 14215646 A G 5.15E-04 Suicide attempts in bipolar disorder MACROD2 intron 21423239 rs6042606 chr20 14217152 C T 5.49E-04 Suicide attempts in bipolar disorder MACROD2 intron 21423239 rs6033916 chr20 14227053 G A 5.47E-04 Suicide attempts in bipolar disorder MACROD2 intron 21423239 rs16994428 chr20 14227720 A G 5.59E-04 Suicide attempts in bipolar disorder MACROD2 intron 21423239 rs3747927 chr20 14230505 G A 0.0000535 fMRI brain tests in schizophrenia MACROD2 intron 22440650 rs2327841 chr20 14237257 T G 7.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MACROD2 intron 20877124 rs1555411 chr20 14240742 G A 7.38E-04 Suicide attempts in bipolar disorder MACROD2 intron 21423239 rs2423779 chr20 14241784 T G 5.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MACROD2 intron 20877124 rs2208454 chr20 14265415 G T 1.44E-07 Brain infarcts,covert MRI-defined MACROD2 intron 20044523 rs994567 chr20 14270096 G A 8.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MACROD2 intron 20877124 rs6105243 chr20 14281082 G A 3.19E-04 Multiple complex diseases MACROD2 intron 17554300 rs6079391 chr20 14306953 G T 9.47E-05 Non-alcoholic fatty liver disease histology (other) FLRT3 missense 20708005 rs2301025 chr20 14310955 C T 9.47E-05 Non-alcoholic fatty liver disease histology (other) FLRT3 intron 20708005 rs6079395 chr20 14327899 G A 7.00E-06 Non-alcoholic fatty liver disease histology (other) MACROD2 intron 20708005 rs1998237 chr20 14353346 C T 9.28E-04 Type 2 diabetes MACROD2 intron 17463246 rs1998237 chr20 14353346 C T 5.67E-05 Coronary heart disease MACROD2 intron pha003031 rs11905518 chr20 14387281 A G 9.44E-05 Coronary heart disease MACROD2 intron pha003031 rs6110278 chr20 14388215 C T 4.00E-07 Mean platelet volume MACROD2 intron 19820697 rs6079423 chr20 14395593 T C 8.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MACROD2 intron 20877124 rs6110305 chr20 14455497 T C 1.30E-05 Urinary metabolites MACROD2 intron 21572414 rs426611 chr20 14475033 G A 4.87E-04 Myocardial Infarction MACROD2 intron pha002883 rs6105279 chr20 14478367 T C 7.75E-04 Type 2 diabetes MACROD2 intron 17463246 rs2327856 chr20 14485947 C A 3.81E-05 Cognitive test performance MACROD2 intron 20125193 rs2327856 chr20 14485947 C A 4.58E-04 Myocardial Infarction MACROD2 intron pha002883 rs6079468 chr20 14498396 A C 4.50E-07 Bipolar disorder MACROD2 intron 22182935 rs6079482 chr20 14517220 T C 4.20E-05 Alcohol dependence MACROD2 intron 20201924 rs6079482 chr20 14517220 T C 5.70E-04 Alcohol dependence MACROD2 intron 20201924 rs6079482 chr20 14517220 T C 4.19E-05 Alcoholism MACROD2 intron pha002892 rs1535213 chr20 14522894 G A 9.80E-05 Hypothyroidism MACROD2 intron 22493691 rs4814311 chr20 14526692 G A 5.22E-05 Bipolar disorder MACROD2 intron 22925353 rs2423816 chr20 14534799 A G 7.80E-05 Bipolar disorder MACROD2 intron 22925353 rs1535216 chr20 14535356 G C 4.37E-05 Bipolar disorder MACROD2 intron 22925353 rs6110333 chr20 14548676 C T 3.40E-04 Alcohol dependence MACROD2 intron 20201924 rs6042808 chr20 14579605 T G 3.30E-06 Urinary metabolites MACROD2 intron 21572414 rs6135199 chr20 14583257 C T 2.71E-04 Type 2 diabetes MACROD2 intron 17463246 rs1932943 chr20 14593867 C T 3.00E-04 Type 2 diabetes MACROD2 intron 17463246 rs6135208 chr20 14596779 T A 9.78E-04 Type 2 diabetes MACROD2 intron 17463246 rs6033992 chr20 14609157 A G 3.34E-04 Multiple complex diseases MACROD2 intron 17554300 rs6042838 chr20 14629913 A C 2.90E-05 Urinary metabolites MACROD2 intron 21572414 rs1932955 chr20 14661106 A G 8.65E-05 Information processing speed MACROD2 intron 21130836 rs1932954 chr20 14662721 G A 5.05E-04 White matter integrity MACROD2 intron 22425255 rs6074780 chr20 14706879 T A 7.12E-05 Crohn's disease MACROD2 intron 17684544 rs4141463 chr20 14747471 T C 4.00E-08 Autism MACROD2 intron 20663923 rs6074798 chr20 14761710 G A 7.32E-05 Cognitive test performance MACROD2 intron 20125193 rs16995050 chr20 14811021 T A 9.88E-05 Multiple complex diseases MACROD2 intron 17554300 rs10485515 chr20 14849853 G A 7.80E-04 Crohn's disease MACROD2 intron 17684544 rs6110458 chr20 14862972 C T 3.00E-04 Acute lymphoblastic leukemia (childhood) MACROD2 intron 20189245 rs6110458 chr20 14862972 C T 1.81E-07 Autism MACROD2 intron 22843504 rs14135 chr20 14865156 T C 3.00E-04 Acute lymphoblastic leukemia (childhood) MACROD2 intron 20189245 rs14135 chr20 14865156 T C 1.78E-07 Autism MACROD2 intron 22843504 rs6079596 chr20 14866618 G T 3.87E-05 Orofacial clefts MACROD2 intron 22419666 rs1475531 chr20 14867422 G T 2.01E-07 Autism MACROD2 intron 22843504 rs2225302 chr20 14868353 A T 4.00E-04 Acute lymphoblastic leukemia (childhood) MACROD2 intron 20189245 rs913785 chr20 14869903 A G 3.94E-04 Multiple complex diseases MACROD2 intron 17554300 rs2423849 chr20 14904170 G A 1.56E-04 Insulin resistance MACROD2 intron 21901158 rs6079611 chr20 14907661 T C 1.72E-05 Lipoproteins MACROD2 intron pha003079 rs2423853 chr20 14914709 T A 3.37E-04 Suicide attempts in bipolar disorder MACROD2 intron 21041247 rs6043066 chr20 15013509 A G 8.87E-05 Waist-Hip Ratio MACROD2 intron pha003029 rs421941 chr20 15042599 T G 4.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MACROD2 intron 20877124 rs421941 chr20 15042599 T G 7.11E-04 Myopia (pathological) MACROD2 intron 21095009 rs11698155 chr20 15063214 T C 1.96E-05 Serum metabolites MACROD2 intron 19043545 rs3932489 chr20 15066439 C T 3.16E-04 Multiple complex diseases MACROD2 intron 17554300 rs6043091 chr20 15077030 G T 5.15E-05 Common variable immunodeficiency MACROD2 intron 21497890 rs17272168 chr20 15078068 A G 7.63E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MACROD2 intron 22566498 rs377256 chr20 15078724 A G 3.21E-04 Multiple complex diseases MACROD2 intron 17554300 rs2143245 chr20 15082546 T C 4.36E-04 Multiple complex diseases MACROD2 intron 17554300 rs17357550 chr20 15088999 A G 8.86E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MACROD2 intron 22566498 rs17272709 chr20 15090170 A G 8.10E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MACROD2 intron 22566498 rs17357786 chr20 15093016 G C 8.10E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MACROD2 intron 22566498 rs1040882 chr20 15099751 A G 8.85E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MACROD2 intron 22566498 rs1040881 chr20 15099816 T C 8.85E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MACROD2 intron 22566498 rs11699739 chr20 15101464 T C 8.11E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) MACROD2 intron 22566498 rs10485517 chr20 15103600 G A 7.04E-07 Statin-induced myopathy MACROD2 intron 21826682 rs11908639 chr20 15118513 G A 4.19E-04 Multiple complex diseases MACROD2 intron 17554300 rs1743471 chr20 15120323 A G 2.56E-04 Multiple complex diseases MACROD2 intron 17554300 rs11087123 chr20 15120744 A G 3.83E-06 Eating disorders MACROD2 intron 23568457 rs11087123 chr20 15120744 A G 4.00E-06 Eating disorders MACROD2 intron 23568457 rs17700500 chr20 15135938 G A 1.28E-04 Multiple complex diseases MACROD2 intron 17554300 rs6131646 chr20 15140653 A G 0.000783 Salmonella-induced pyroptosis MACROD2 intron 22837397 rs16995403 chr20 15150840 A C 1.94E-05 Blood pressure MACROD2 intron 24001895 rs199307 chr20 15177580 A G 8.00E-06 Obesity-related traits MACROD2 UTR-5 23251661 rs175276 chr20 15207464 T C 8.90E-04 Myopia (pathological) MACROD2 intron 21095009 rs458032 chr20 15219500 T C 2.37E-04 Amyotrophic Lateral Sclerosis MACROD2 intron 18057069 rs175310 chr20 15223632 C T 8.42E-04 Myopia (pathological) MACROD2 intron 21095009 rs7267421 chr20 15227636 G A 8.00E-06 Amyotrophic lateral sclerosis (sporadic) MACROD2 intron 24529757 rs392184 chr20 15228295 G A 6.43E-04 Type 2 diabetes MACROD2 intron 17463246 rs10485520 chr20 15234769 C T 2.32E-04 Blood pressure MACROD2 intron 17255346 rs453349 chr20 15251031 G A 1.44E-04 Response to taxane treatment (placlitaxel) MACROD2 intron 23006423 rs367421 chr20 15254689 G C 3.60E-05 Subclinical atherosclerosis MACROD2 intron 17903303 rs2423942 chr20 15323282 A G 9.26E-06 Male fertility MACROD2 intron 22633400 rs2058828 chr20 15331007 A G 1.04E-05 Male fertility MACROD2 intron 22633400 rs6110577 chr20 15335754 T C 5.00E-06 Obesity (extreme) MACROD2 intron 19553259 rs6135395 chr20 15336682 A G 3.54E-04 Alzheimer's disease (late onset) MACROD2 intron 21379329 rs7269753 chr20 15337955 T A 2.71E-04 Multiple complex diseases MACROD2 intron 17554300 rs6079789 chr20 15346624 C T 8.97E-04 Self-reported allergy MACROD2 intron 23817569 rs6079791 chr20 15354464 A G 9.75E-04 Self-reported allergy MACROD2 intron 23817569 rs6074885 chr20 15363504 A C 9.32E-04 Self-reported allergy MACROD2 intron 23817569 rs399698 chr20 15368919 G T 1.33E-04 Rheumatoid arthritis MACROD2 intron 21452313 rs6034171 chr20 15380660 C A 2.20E-05 Multiple complex diseases MACROD2 intron 17554300 rs6079801 chr20 15381648 G A 7.29E-05 Male fertility MACROD2 intron 22633400 rs6079802 chr20 15382355 T C 2.98E-05 Male fertility MACROD2 intron 22633400 rs1003625 chr20 15390182 C G 3.01E-05 Odorant perception MACROD2 intron 23910658 rs6135407 chr20 15397676 C T 4.91E-05 Staphylococcus aureus infection MACROD2 intron 24847357 rs433078 chr20 15399984 A G 1.25E-06 Waist-Hip Ratio MACROD2 intron pha003013 rs433078 chr20 15399984 A G 8.15E-07 Waist-Hip Ratio MACROD2 intron pha003028 rs4814369 chr20 15404290 G C 2.50E-05 Urinary metabolites MACROD2 intron 21572414 rs4814372 chr20 15404481 G A 1.90E-05 Urinary metabolites MACROD2 intron 21572414 rs6034188 chr20 15411848 C T 2.18E-05 Waist-Hip Ratio MACROD2 intron pha003013 rs6034188 chr20 15411848 C T 1.08E-05 Waist-Hip Ratio MACROD2 intron pha003028 rs6110606 chr20 15422124 A C 2.61E-06 Waist-Hip Ratio MACROD2 intron pha003013 rs6110606 chr20 15422124 A C 1.31E-06 Waist-Hip Ratio MACROD2 intron pha003028 rs11698317 chr20 15428111 G A 7.11E-04 Type 2 diabetes MACROD2 intron 17463246 rs6074899 chr20 15437569 C T 1.20E-06 Systemic lupus erythematosus and Systemic sclerosis MACROD2 intron 23740937 rs2224300 chr20 15443446 A G 1.65E-04 Type 2 diabetes MACROD2 intron 17463246 rs2224300 chr20 15443446 A G 5.81E-04 Multiple complex diseases MACROD2 intron 17554300 rs6043298 chr20 15446369 C T 7.41E-04 Depression (quantitative trait) MACROD2 intron 20800221 rs2208133 chr20 15448563 T C 6.90E-05 Response to statin therapy MACROD2 intron 20339536 rs2208133 chr20 15448563 T C 8.00E-06 Asthma MACROD2 intron 21790008 rs2180525 chr20 15451179 G A 5.16E-04 Depression (quantitative trait) MACROD2 intron 20800221 rs6034196 chr20 15453539 C G 5.09E-04 Depression (quantitative trait) MACROD2 intron 20800221 rs6043303 chr20 15454466 A G 4.99E-04 Depression (quantitative trait) MACROD2 intron 20800221 rs6043305 chr20 15455186 A G 4.97E-04 Depression (quantitative trait) MACROD2 intron 20800221 rs6043308 chr20 15455846 A G 4.95E-04 Depression (quantitative trait) MACROD2 intron 20800221 rs4814393 chr20 15505825 G A 2.67E-05 Erythrocyte counts MACROD2 intron pha003090 rs1233731 chr20 15522501 C T 7.52E-06 Cognitive impairment induced by topiramate MACROD2 intron 22091778 rs1233731 chr20 15522501 C T 1.67E-05 Erythrocyte counts MACROD2 intron pha003090 rs10485529 chr20 15526582 C T 3.27E-06 Erythrocyte counts MACROD2 intron pha003090 rs737006 chr20 15528591 A G 1.20E-05 Hypertension MACROD2 intron 22384028 rs747398 chr20 15549323 G T 7.19E-05 Cytomegalovirus antibody response MACROD2 intron 21993531 rs12481689 chr20 15565140 A G 1.20E-05 Triglycerides MACROD2 intron 19074352 rs12481689 chr20 15565140 A G 1.20E-05 Polyunsaturated fatty acid levels,in plasma MACROD2 intron 19148276 rs17694839 chr20 15590487 C T 3.22E-04 Sarcoidosis MACROD2 intron 19165924 rs200741 chr20 15592014 T C 2.32E-04 Alzheimer's disease (late onset) MACROD2 intron 21379329 rs200744 chr20 15594367 C T 3.72E-04 Alzheimer's disease (late onset) MACROD2 intron 21379329 rs200744 chr20 15594367 C T 7.41E-07 Corneal structure MACROD2 intron 22003120 rs200745 chr20 15595264 G A 7.42E-05 Cognitive test performance MACROD2 intron 20125193 rs200752 chr20 15599531 G A 7.00E-09 Hypertension MACROD2 intron 21626137 rs200755 chr20 15602333 G A 7.90E-05 Celiac disease MACROD2 intron 17558408 rs6079910 chr20 15603153 C G 3.72E-04 Multiple complex diseases MACROD2 intron 17554300 rs200759 chr20 15606421 T C 7.00E-09 Hypertension MACROD2 intron 21626137 rs200761 chr20 15608025 G A 0.0008832 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MACROD2 intron 23233654 rs200761 chr20 15608025 G A 8.83E-04 Methotrexate clearance (acute lymphoblastic leukemia) MACROD2 intron 23233662 rs956506 chr20 15608581 G A 7.92E-04 Response to taxane treatment (placlitaxel) MACROD2 intron 23006423 rs16996175 chr20 15610171 C G 1.99E-05 Multiple complex diseases MACROD2 intron 17554300 rs200767 chr20 15613161 C A 0.0006517 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MACROD2 intron 23233654 rs200767 chr20 15613161 C A 6.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) MACROD2 intron 23233662 rs6131684 chr20 15624156 A G 8.81E-04 Multiple complex diseases MACROD2 intron 17554300 rs1420440 chr20 15634021 G T 4.45E-04 Parkinson's disease MACROD2 intron 17052657 rs455659 chr20 15644641 G A 4.01E-04 Parkinson's disease MACROD2 intron 17052657 rs6135478 chr20 15646981 A C 4.37E-04 Parkinson's disease MACROD2 intron 17052657 rs6043422 chr20 15649366 G A 7.25E-05 Parkinson's disease MACROD2 intron 17052657 rs2423969 chr20 15651436 G A 6.57E-05 Longevity MACROD2 intron 20304771 rs2423970 chr20 15651466 A G 7.24E-05 Longevity MACROD2 intron 20304771 rs1362512 chr20 15651887 A G 1.93E-04 Multiple complex diseases MACROD2 intron 17554300 rs1362512 chr20 15651887 A G 7.25E-05 Longevity MACROD2 intron 20304771 rs10485537 chr20 15652148 A G 7.05E-04 Multiple complex diseases MACROD2 intron 17554300 rs13037804 chr20 15657994 C T 3.98E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MACROD2 intron 20877124 rs11700244 chr20 15695993 C A 6.03E-05 Cleft lip MACROD2 intron 20436469 rs6043515 chr20 15734759 A G 2.90E-04 Multiple complex diseases MACROD2 intron 17554300 rs6135530 chr20 15777250 T C 3.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MACROD2 intron 20877124 rs6135546 chr20 15790136 G A 8.00E-04 Response to taxane treatment (placlitaxel) MACROD2 intron 23006423 rs6043569 chr20 15816005 C T 4.60E-04 Smoking initiation MACROD2 intron 24665060 rs4814404 chr20 15816772 C T 4.38E-04 Type 2 diabetes MACROD2 intron 17463246 rs175810 chr20 15827930 G C 3.35E-04 Type 2 diabetes MACROD2 intron 17463246 rs175810 chr20 15827930 G C 0.00000148 Ovarian follicle number and menopause MACROD2 intron 22696150 rs6034316 chr20 15857880 T C 1.21E-04 Birth weight MACROD2 intron 17255346 rs761684 chr20 15858290 T C 2.35E-06 Carotenoid and tocopherol levels MACROD2 intron 19185284 rs761684 chr20 15858290 T C 1.73E-05 Telomere length MACROD2 intron 21573004 rs6074962 chr20 15869075 C T 2.12E-06 Carotenoid and tocopherol levels MACROD2 intron 19185284 rs175786 chr20 15870601 T C 6.45E-04 Suicide attempts in bipolar disorder MACROD2 intron 21423239 rs6043600 chr20 15872970 G A 2.94E-05 Schizophrenia MACROD2 intron 19571809 rs6043600 chr20 15872970 G A 6.18E-05 Schizophrenia MACROD2 intron pha002859 rs717145 chr20 15878091 T C 5.00E-06 Biomarkers MACROD2 intron 17903293 rs6034327 chr20 15898030 T C 3.66E-04 Type 2 diabetes MACROD2 intron 17463246 rs6034328 chr20 15902630 C T 4.87E-04 Substance dependence MACROD2 intron 21818250 rs1339258 chr20 15956742 G A 9.42E-06 Type 2 diabetes MACROD2 intron 17463246 rs1339258 chr20 15956742 G A 4.20E-04 Multiple complex diseases MACROD2 intron 17554300 rs6080069 chr20 15957780 G A 2.76E-05 Type 2 diabetes MACROD2 intron 17463246 rs6074984 chr20 15957841 T G 1.04E-05 Type 2 diabetes MACROD2 intron 17463246 rs6074984 chr20 15957841 T G 5.50E-04 Multiple complex diseases MACROD2 intron 17554300 rs775095 chr20 15969077 T G 3.20E-05 HIV-1 progression MACROD2 intron 20064070 rs11700097 chr20 15971797 G C 1.50E-04 Major depressive disorder MACROD2 intron 22472876 rs1547117 chr20 15981119 G A 9.00E-04 Major depressive disorder MACROD2 intron 22472876 rs775114 chr20 15987595 G A 6.92E-04 Suicide attempts in bipolar disorder MACROD2 intron 21423239 rs775112 chr20 15990705 T C 4.38E-04 Suicide attempts in bipolar disorder MACROD2 intron 21423239 rs775107 chr20 15994409 T C 7.25E-04 Suicide attempts in bipolar disorder MACROD2 intron 21423239 rs6080097 chr20 15998826 C T 1.00E-04 Prostate cancer MACROD2 intron 21743057 rs6135641 chr20 15999666 A G 6.91E-04 Smoking initiation MACROD2 intron 24665060 rs6080100 chr20 16003406 T C 2.80E-05 Lung cancer MACROD2 intron 18385738 rs6080100 chr20 16003406 T C 6.96E-04 Tourette syndrome MACROD2 intron 22889924 rs6080100 chr20 16003406 T C 7.00E-06 Presence of antiphospholipid antibodies MACROD2 intron 23509613 rs6080100 chr20 16003406 T C 8.44E-05 Receptive language ability MACROD2 intron 24687471 rs708980 chr20 16004320 G A 8.48E-04 Suicide attempts in bipolar disorder MACROD2 intron 21423239 rs880169 chr20 16009795 A G 1.83E-04 Multiple complex diseases MACROD2 intron 17554300 rs6135650 chr20 16019675 C A 1.30E-05 Coronary heart disease MACROD2 intron pha003035 rs12625514 chr20 16024095 C T 8.21E-04 Response to taxane treatment (placlitaxel) MACROD2 intron 23006423 rs6131768 chr20 16027036 T C 9.25E-04 Multiple complex diseases MACROD2 intron 17554300 rs11697805 chr20 16029530 C G 3.03E-04 Multiple complex diseases MACROD2 intron 17554300 rs6080106 chr20 16029837 C A 3.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MACROD2 intron 20877124 rs775126 chr20 16030196 C T 7.22E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MACROD2 intron 20877124 rs6043706 chr20 16040896 G C 6.54E-04 Type 2 diabetes / / 17463246 rs16997051 chr20 16041200 T C 4.55E-04 Multiple complex diseases / / 17554300 rs775122 chr20 16045679 A G 9.03E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs16997087 chr20 16054982 T C 1.00E-10 Brain connectivity / / 23471985 rs16997087 chr20 16054982 T C 2.00E-09 Brain connectivity / / 23471985 rs2066089 chr20 16056180 A G 3.02E-04 Multiple complex diseases / / 17554300 rs1225897 chr20 16076022 A G 1.80E-05 Urinary metabolites / / 21572414 rs809588 chr20 16078265 T C 7.23E-04 Type 2 diabetes / / 17463246 rs6034382 chr20 16078328 A G 4.61E-04 Multiple complex diseases / / 17554300 rs6080131 chr20 16106040 A G 8.16E-04 Alcohol dependence / / 20201924 rs965627 chr20 16113273 A G 7.51E-04 Multiple complex diseases / / 17554300 rs2760548 chr20 16116408 T A 6.74E-04 Acute lung injury / / 22295056 rs6080133 chr20 16118054 T A 6.74E-04 Acute lung injury / / 22295056 rs2760552 chr20 16121064 G A 6.74E-04 Acute lung injury / / 22295056 rs2760554 chr20 16124097 T A 5.97E-04 Acute lung injury / / 22295056 rs2788930 chr20 16124113 T C 5.97E-04 Acute lung injury / / 22295056 rs2760555 chr20 16125695 A G 5.97E-04 Acute lung injury / / 22295056 rs1323304 chr20 16126843 G C 6.54E-04 Acute lung injury / / 22295056 rs1923958 chr20 16136520 A C 6.54E-04 Acute lung injury / / 22295056 rs6043769 chr20 16137880 C A 6.54E-04 Acute lung injury / / 22295056 rs1890496 chr20 16139008 A G 9.05E-04 Acute lung injury / / 22295056 rs6131786 chr20 16152909 A G 1.33E-05 Epilepsy (remission after treatment) / / 23962720 rs6131788 chr20 16153510 A G 1.47E-05 Epilepsy (remission after treatment) / / 23962720 rs6131789 chr20 16153969 C T 1.42E-05 Epilepsy (remission after treatment) / / 23962720 rs6135691 chr20 16154086 T A 1.42E-05 Epilepsy (remission after treatment) / / 23962720 rs6080165 chr20 16169932 T C 7.76E-04 Multiple complex diseases / / 17554300 rs6080165 chr20 16169932 T C 5.40E-06 Urinary metabolites / / 21572414 rs6080166 chr20 16169949 A G 8.62E-04 Multiple complex diseases / / 17554300 rs6080166 chr20 16169949 A G 4.70E-06 Urinary metabolites / / 21572414 rs6080167 chr20 16170011 C A 3.20E-06 Urinary metabolites / / 21572414 rs6080169 chr20 16172267 C T 5.90E-07 Urinary metabolites / / 21572414 rs4814446 chr20 16174128 C T 5.48E-05 Cognitive test performance / / 20125193 rs4814447 chr20 16174204 A G 1.10E-05 Urinary metabolites / / 21572414 rs4814451 chr20 16176303 A G 8.70E-07 Urinary metabolites / / 21572414 rs6080171 chr20 16176897 C A 2.90E-06 Urinary metabolites / / 21572414 rs4814453 chr20 16178261 G A 6.45E-05 Cognitive test performance / / 20125193 rs6075029 chr20 16180745 C T 2.40E-05 Urinary metabolites / / 21572414 rs3904199 chr20 16183972 A G 2.70E-05 Urinary metabolites / / 21572414 rs6110956 chr20 16185505 G A 2.70E-05 Urinary metabolites / / 21572414 rs6043812 chr20 16192242 A T 1.27E-04 Fibrinogen / / 17255346 rs6043812 chr20 16192242 A T 4.73E-04 Multiple complex diseases / / 17554300 rs2788916 chr20 16232677 G A 4.45E-05 Lung adenocarcinoma / / 19836008 rs1329827 chr20 16234206 A G 7.90E-04 Alzheimer's disease / / 22005930 rs12480506 chr20 16241416 A G 7.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs877500 chr20 16248453 T C 8.82E-05 Alzheimer's disease / / 22005930 rs17730901 chr20 16250822 G T 7.81E-05 Melanoma / / 21926416 rs4814465 chr20 16251083 T C 2.19E-04 Multiple complex diseases / / 17554300 rs4814465 chr20 16251083 T C 1.08E-04 Alzheimer's disease / / 22005930 rs4814466 chr20 16253819 G A 6.35E-05 Melanoma KIF16B UTR-3 21926416 rs6111006 chr20 16257484 G A 2.49E-04 Multiple complex diseases KIF16B intron 17554300 rs6111006 chr20 16257484 G A 6.20E-04 Insulin resistance KIF16B intron 21901158 rs6111006 chr20 16257484 G A 1.99E-04 Alzheimer's disease KIF16B intron 22005930 rs11907241 chr20 16258519 T C 9.38E-04 Type 2 diabetes KIF16B intron 17463246 rs6105564 chr20 16262545 T C 8.07E-05 Melanoma KIF16B intron 21926416 rs6043850 chr20 16263388 T C 1.96E-04 Alzheimer's disease KIF16B intron 22005930 rs6043873 chr20 16273202 G A 4.02E-04 Alzheimer's disease KIF16B intron 22005930 rs6111021 chr20 16273853 A C 1.13E-04 Alzheimer's disease KIF16B intron 22005930 rs6111022 chr20 16273933 C T 1.35E-04 Alzheimer's disease KIF16B intron 22005930 rs2180445 chr20 16288999 G A 3.50E-05 Response to statin therapy KIF16B intron 20339536 rs6111042 chr20 16291006 A G 3.40E-05 Response to statin therapy KIF16B intron 20339536 rs6043882 chr20 16295374 C G 3.75E-04 Insulin resistance KIF16B intron 21901158 rs12480966 chr20 16295704 G A 1.00E-04 Prostate cancer KIF16B intron 21743057 rs6111050 chr20 16297472 T C 3.40E-05 Response to statin therapy KIF16B intron 20339536 rs6111051 chr20 16298159 C G 1.40E-05 Response to statin therapy KIF16B intron 20339536 rs6111052 chr20 16298417 G A 2.70E-05 Response to statin therapy KIF16B intron 20339536 rs2144901 chr20 16298609 C T 3.40E-05 Response to statin therapy KIF16B intron 20339536 rs4814468 chr20 16299019 T C 2.80E-05 Response to statin therapy KIF16B intron 20339536 rs2328015 chr20 16300353 G C 3.30E-05 Response to statin therapy KIF16B intron 20339536 rs2208059 chr20 16311310 T C 4.00E-07 Ileal carcinoids KIF16B intron 21139019 rs2144883 chr20 16325140 T C 5.11E-04 Insulin resistance KIF16B intron 21901158 rs2328019 chr20 16327825 C T 6.54E-04 Insulin resistance KIF16B intron 21901158 rs2180441 chr20 16327843 G A 8.44E-04 Insulin resistance KIF16B intron 21901158 rs2180442 chr20 16330934 C G 3.66E-04 Insulin resistance KIF16B intron 21901158 rs6080236 chr20 16334002 A C 1.07E-05 Glucose levels KIF16B intron pha003058 rs6105593 chr20 16384768 C T 3.03E-04 Alzheimer's disease KIF16B intron 17998437 rs1304062 chr20 16392109 C T 4.90E-04 Multiple complex diseases KIF16B intron 17554300 rs6135748 chr20 16398077 G A 5.45E-05 Alzheimer's disease KIF16B intron 17998437 rs6080252 chr20 16398879 G A 2.00E-04 Alzheimer's disease KIF16B intron 17998437 rs10485552 chr20 16431656 T C 0.0000001 Mean arterial pressure KIF16B intron 22510845 rs1028540 chr20 16446032 C T 9.99E-04 Suicide attempts in bipolar disorder KIF16B intron 21423239 rs1028541 chr20 16446126 A T 6.14E-04 Suicide attempts in bipolar disorder KIF16B intron 21423239 rs6043973 chr20 16448809 G A 3.83E-04 Depression (quantitative trait) KIF16B intron 20800221 rs6043979 chr20 16451642 A C 1.00E-08 Intelligence KIF16B intron 22449649 rs6034491 chr20 16459787 T C 2.89E-04 Suicide attempts in bipolar disorder KIF16B intron 21423239 rs6044011 chr20 16467350 A G 8.54E-04 Suicide attempts in bipolar disorder KIF16B intron 21423239 rs17673447 chr20 16468187 A G 9.33E-04 Alzheimer's disease KIF16B intron 17998437 rs1555194 chr20 16469782 A G 5.13E-04 Suicide attempts in bipolar disorder KIF16B intron 21423239 rs2143988 chr20 16472825 G A 4.91E-04 Multiple complex diseases KIF16B intron 17554300 rs8123698 chr20 16479128 G A 8.96E-04 Suicide attempts in bipolar disorder KIF16B intron 21423239 rs16997751 chr20 16479717 T C 6.21E-04 Suicide attempts in bipolar disorder KIF16B intron 21423239 rs6080286 chr20 16510024 T C 7.66E-04 Response to taxane treatment (placlitaxel) KIF16B intron 23006423 rs17674942 chr20 16513316 T A,C 5.79E-04 Response to taxane treatment (placlitaxel) KIF16B intron 23006423 rs6075068 chr20 16517950 C G 4.80E-04 Response to taxane treatment (placlitaxel) KIF16B intron 23006423 rs6044098 chr20 16523707 C T 6.04E-04 Myopia (pathological) KIF16B intron 21095009 rs6044102 chr20 16525467 C T 7.17E-04 Myopia (pathological) KIF16B intron 21095009 rs6075069 chr20 16528914 C T 3.63E-04 Response to taxane treatment (placlitaxel) KIF16B intron 23006423 rs6514689 chr20 16532878 C T 3.37E-04 Myopia (pathological) KIF16B intron 21095009 rs16997877 chr20 16533162 T C 8.68E-05 Obsessive-compulsive disorder KIF16B intron 24821223 rs6044112 chr20 16536414 C T 7.00E-07 Response to taxane treatment (docetaxel) KIF16B intron 23006423 rs6044114 chr20 16538643 G A 9.29E-05 Lipoprotein-associated phospholipase A2 activity and mass KIF16B intron 20442857 rs2328045 chr20 16561909 C G 2.68E-04 Lymphocyte counts / / 22286170 rs6135804 chr20 16563272 G A 2.30E-06 Urinary metabolites / / 21572414 rs2050406 chr20 16615735 C T 3.52E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs11087179 chr20 16644031 A G 5.12E-04 Alzheimer's disease / / 17998437 rs11697065 chr20 16644129 T C 1.40E-05 Body Mass Index / / pha003020 rs6044228 chr20 16663069 T C 1.50E-04 Primary sclerosing cholangitis / / 19944697 rs6044228 chr20 16663069 T C 2.10E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs4814541 chr20 16680210 G A 3.77E-07 Multiple complex diseases / / 17554300 rs17684891 chr20 16680616 A G 8.81E-04 Multiple complex diseases / / 17554300 rs17685144 chr20 16689756 C T 5.60E-05 Mammographic density / / 22532574 rs6044262 chr20 16694602 G A 1.85E-04 Smoking initiation / / 24665060 rs3787509 chr20 16708109 A T 9.03E-05 Asthma / / 11022011 rs3761296 chr20 16709662 C A 5.41E-05 Diabetic retinopathy / / 20871662 rs16998203 chr20 16739519 C G 4.42E-06 Lipid traits / / 21777205 rs4491792 chr20 16740825 T C 4.00E-06 Post-traumatic stress disorder (asjusted for relatedness) / / 23726511 rs6080411 chr20 16753985 A G 5.21E-05 Schizophrenia / / 20185149 rs4813250 chr20 16761605 G T 9.53E-05 Schizophrenia / / 20185149 rs6075131 chr20 16842276 G A 5.41E-05 Aging (time to event) / / 21782286 rs17763056 chr20 16859716 T C 8.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17690253 chr20 16894293 T G 1.39E-04 Smoking cessation / / 24665060 rs6044514 chr20 16908038 C T 2.21E-05 Multiple complex diseases / / 17554300 rs6034689 chr20 16918617 G T 5.70E-06 Urinary metabolites / / 21572414 rs6034690 chr20 16922582 C T 2.88E-04 Cholesterol / / 17255346 rs6105683 chr20 16934608 C T 4.85E-05 Scoliosis / / 21216876 rs6044554 chr20 16968919 T G 9.82E-04 Multiple complex diseases / / 17554300 rs41492957 chr20 16969014 C T 9.40E-07 Obesity (early onset extreme) / / 18159244 rs6044560 chr20 16977946 G A 2.76E-04 Scoliosis / / 21216876 rs1016214 chr20 16992615 A G 9.67E-05 Scoliosis / / 21216876 rs17692104 chr20 16995693 T C 3.50E-05 Personality dimensions / / 18957941 rs763771 chr20 16998375 T C 5.10E-04 Insulin resistance / / 21901158 rs16998603 chr20 17018974 G A 2.37E-06 Obesity (early onset extreme) / / 18159244 rs6080539 chr20 17029494 T C 1.99E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6034731 chr20 17030098 C T 8.24E-04 Insulin resistance / / 21901158 rs4396776 chr20 17053777 C A 2.00E-05 Endometriosis / / 21151130 rs16998724 chr20 17075978 C A 1.99E-05 Multiple complex diseases / / 17554300 rs16998727 chr20 17077510 G A 9.82E-05 Hirschsprung's disease / / 19196962 rs852069 chr20 17122593 A G 3.00E-08 Menarche (age at onset) / / 21102462 rs852075 chr20 17131269 T C 3.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs708984 chr20 17133062 C T 2.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6136008 chr20 17164461 G A 5.76E-04 Type 2 diabetes / / 17463246 rs6044678 chr20 17181298 A C 2.98E-04 Multiple complex diseases / / 17554300 rs3818916 chr20 17207721 G T 2.00E-04 Alcohol dependence PCSK2 UTR-5 20201924 rs3818916 chr20 17207721 G T 4.00E-04 Alcohol dependence PCSK2 UTR-5 20201924 rs1578405 chr20 17228744 A G 3.73E-04 Alcohol dependence PCSK2 intron 24277619 rs13043551 chr20 17239518 G A 4.50E-06 Urinary metabolites PCSK2 intron 21572414 rs1883531 chr20 17246651 C G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) PCSK2 intron 17982456 rs6080616 chr20 17252213 G A 1.36E-05 Post-operative nausea and vomiting PCSK2 intron 21694509 rs2206452 chr20 17283410 G A 2.10E-05 Urinary metabolites PCSK2 intron 21572414 rs6136060 chr20 17288277 A G 8.64E-04 Multiple complex diseases PCSK2 intron 17554300 rs6136064 chr20 17295110 A G 1.94E-05 Tardive dyskinesia PCSK2 intron 20939080 rs926492 chr20 17311577 C T 4.97E-05 Cognitive test performance PCSK2 intron 20125193 rs737141 chr20 17329725 C T 7.20E-06 Diabetic retinopathy PCSK2 intron 21441570 rs10485570 chr20 17355748 C T 4.21E-05 HDL cholesterol PCSK2 intron pha003075 rs4814615 chr20 17357573 G A 3.40E-06 Subclinical atherosclerosis PCSK2 intron 17903303 rs4814615 chr20 17357573 G A 5.00E-06 Dialysis-related mortality PCSK2 intron 21546767 rs11698484 chr20 17368381 C T 2.00E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) PCSK2 intron 24023788 rs6044777 chr20 17368542 C T 8.00E-06 Biochemical measures PCSK2 intron 19260141 rs6044777 chr20 17368542 C T 2.96E-04 Stroke PCSK2 intron pha002887 rs17715103 chr20 17369589 C T 2.67E-06 Obesity-related traits PCSK2 intron 23251661 rs6111532 chr20 17380490 G A 7.76E-04 Insulin resistance PCSK2 intron 21901158 rs742424 chr20 17408503 A G 1.20E-05 Urinary metabolites PCSK2 intron 21572414 rs6044808 chr20 17410843 T C 4.89E-04 Stroke PCSK2 intron pha002887 rs2021786 chr20 17421978 T C 7.00E-06 Preschool internalizing problems PCSK2 intron 24839885 rs6044832 chr20 17433598 T G 3.41E-04 Endometrial cancer PCSK2 intron 24096698 rs6044832 chr20 17433598 T G 9.36E-04 Endometrial cancer PCSK2 intron 24096698 rs6044834 chr20 17436473 T G 8.00E-08 Obesity-related traits PCSK2 intron 23251661 rs718740 chr20 17444837 T C 2.47E-04 Coronary heart disease PCSK2 intron 21971053 rs4362633 chr20 17445135 A C 2.40E-07 Obesity-related traits PCSK2 intron 23251661 rs2072960 chr20 17451285 A G 4.62E-05 Serum metabolites PCSK2 intron 19043545 rs2269036 chr20 17453135 G A 1.73E-04 Coronary Artery Disease PCSK2 intron 17634449 rs761015 chr20 17456418 C T 2.07E-04 Height PCSK2 intron 17255346 rs1076688 chr20 17471061 A G 3.40E-04 Height / / 17255346 rs1076688 chr20 17471061 A G 1.40E-05 Cognitive function / / 24684796 rs6080716 chr20 17473419 T A 1.80E-05 Cognitive function / / 24684796 rs4814622 chr20 17473656 G C 1.80E-05 Cognitive function / / 24684796 rs6080719 chr20 17477592 C T 3.65E-04 Height BFSP1 missense 17255346 rs6111549 chr20 17479730 T C 2.20E-05 Leukocyte Counts BFSP1 intron pha003091 rs6034837 chr20 17486576 T C 3.63E-04 Lung function (forced expiratory volume in 1 second) BFSP1 intron 24023788 rs7270359 chr20 17487007 C G 9.96E-04 Suicide attempts in bipolar disorder BFSP1 intron 21423239 rs3828011 chr20 17488415 A G 9.96E-05 Stroke (ischemic) BFSP1 intron 22941190 rs3790329 chr20 17488636 G A 2.00E-06 Urinary metabolites BFSP1 intron 21572414 rs6044855 chr20 17488944 T G 2.28E-04 Cholesterol BFSP1 intron 17255346 rs201933 chr20 17520898 A G 3.69E-04 Lung function (forced expiratory volume in 1 second) BFSP1 intron 24023788 rs201932 chr20 17522798 T G 1.36E-04 Suicide attempts in bipolar disorder BFSP1 intron 21423239 rs16999416 chr20 17541830 G A 4.10E-07 Urinary metabolites / / 21572414 rs17791782 chr20 17566069 A T 7.60E-06 Urinary metabolites DSTN intron 21572414 rs17791782 chr20 17566069 A T 6.00E-06 Presence of antiphospholipid antibodies DSTN intron 23509613 rs11698138 chr20 17591579 A G 1.60E-05 Myasthenia gravis / / 23055271 rs12480819 chr20 17592300 A G 3.00E-06 Migraine - clinic-based / / 23793025 rs1132274 chr20 17596155 C A 7.09E-05 Femoral neck bone geometry RRBP1 missense 22087292 rs9768 chr20 17600022 C T 4.10E-06 Urinary metabolites RRBP1 intron 21572414 rs3790308 chr20 17652403 G A 2.89E-04 Birth weight RRBP1 intron 17255346 rs6080774 chr20 17652784 A G 0.000061 Primary sclerosing cholangitis RRBP1 intron 22521342 rs6080788 chr20 17683380 A G 2.72E-05 Tunica Media BANF2 intron pha003038 rs6080790 chr20 17683753 G A 4.45E-05 Depression (quantitative trait) BANF2 intron 20800221 rs6131989 chr20 17691406 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) BANF2 intron 20708005 rs2296902 chr20 17703051 A G 3.51E-04 Depression (quantitative trait) BANF2 intron 20800221 rs2182948 chr20 17707401 T C 1.90E-05 Urinary metabolites BANF2 intron 21572414 rs6034892 chr20 17714319 T C 4.48E-04 Multiple complex diseases BANF2 intron 17554300 rs6044981 chr20 17714525 T C 5.66E-04 Type 2 diabetes BANF2 intron 17463246 rs6044981 chr20 17714525 T C 2.25E-04 Multiple complex diseases BANF2 intron 17554300 rs6044981 chr20 17714525 T C 7.98E-05 Serum metabolites BANF2 intron 19043545 rs2077520 chr20 17721518 A G 4.54E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs6044991 chr20 17726683 A G 9.60E-05 Alcoholism (heaviness of drinking) / / 21529783 rs6044991 chr20 17726683 A G 1.58E-04 Smoking initiation / / 24665060 rs2769856 chr20 17734643 T C 4.18E-04 Multiple complex diseases / / 17554300 rs35426455 chr20 17741758 T C 1.10E-05 Urinary metabolites / / 21572414 rs6111664 chr20 17744632 G A 8.90E-04 Parkinson's disease / / 17052657 rs8117187 chr20 17750390 G A 5.96E-04 Rheumatoid arthritis / / 21452313 rs12479597 chr20 17766019 G A 2.20E-05 Urinary metabolites / / 21572414 rs2618634 chr20 17767035 G C 6.39E-06 Serum metabolites / / 19043545 rs2618623 chr20 17773838 A G 1.21E-05 Serum metabolites / / 19043545 rs6080834 chr20 17775259 G A 6.21E-05 Post-operative nausea and vomiting / / 21694509 rs4813285 chr20 17777201 A G 4.44E-06 Type 2 diabetes / / 21573907 rs2618627 chr20 17780208 C T 3.12E-04 Obesity (extreme) / / 21935397 rs2745820 chr20 17780641 T C 2.58E-04 Obesity (extreme) / / 21935397 rs2745821 chr20 17780921 T G 3.25E-04 Obesity (extreme) / / 21935397 rs16823 chr20 17791064 G A 4.72E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10485572 chr20 17795053 G A 7.03E-04 Multiple complex diseases / / 17554300 rs10485572 chr20 17795053 G A 2.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10485572 chr20 17795053 G A 5.88E-04 Lymphocyte counts / / 22286170 rs2077147 chr20 17825143 T C 3.00E-06 IgG glycosylation / / 23382691 rs2745851 chr20 17829280 G A 1.83E-05 Parkinson's disease (motor and cognition) / / 22658654 rs2745851 chr20 17829280 G A 1.83E-05 Immune response to anthrax vaccine / / 22658931 rs2745851 chr20 17829280 G A 1.00E-06 IgG glycosylation / / 23382691 rs2745851 chr20 17829280 G A 2.00E-06 IgG glycosylation / / 23382691 rs2745851 chr20 17829280 G A 4.00E-06 IgG glycosylation / / 23382691 rs2745851 chr20 17829280 G A 6.00E-07 IgG glycosylation / / 23382691 rs2745851 chr20 17829280 G A 9.00E-06 IgG glycosylation / / 23382691 rs2745851 chr20 17829280 G A 9.00E-06 IgG glycosylation / / 23382691 rs2745851 chr20 17829280 G A 9.00E-07 IgG glycosylation / / 23382691 rs1977107 chr20 17843824 T C 4.90E-05 Response to statin therapy / / 20339536 rs2328223 chr20 17845921 A C 6.00E-09 LDL cholesterol / / 24097068 rs4814671 chr20 17846386 T A 5.10E-05 Response to statin therapy / / 20339536 rs2745865 chr20 17847735 T C 4.90E-05 Response to statin therapy / / 20339536 rs6080886 chr20 17867063 A G 5.50E-04 Smoking quantity / / 24665060 rs11699560 chr20 17889881 C T 3.54E-05 Magnesium levels / / pha003092 rs7273481 chr20 17895382 A G 1.12E-04 Multiple complex diseases / / 17554300 rs6105851 chr20 17955038 G A 3.01E-04 Lymphocyte counts C20orf72 intron 22286170 rs6080964 chr20 18063552 G A 7.51E-04 Obesity (extreme) / / 21935397 rs4813301 chr20 18070328 G A 1.47E-04 Alcohol dependence / / 21314694 rs17725255 chr20 18079131 T C 2.00E-06 Anorexia nervosa / / 21079607 rs1928099 chr20 18101276 G A 1.30E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs117280420 chr20 18122912 C G 0.00045 Breast cancer PET117 missense 23555315 rs11299 chr20 18123022 T C 7.38E-05 Obesity (extreme) CSRP2BP UTR-5 21935397 rs6132035 chr20 18138397 A G 7.89E-05 Obesity (extreme) CSRP2BP intron 21935397 rs12626093 chr20 18139042 A C 7.91E-05 Obesity (extreme) CSRP2BP intron 21935397 rs13045938 chr20 18139552 G A 9.00E-05 Obesity (extreme) CSRP2BP intron 21935397 rs6514845 chr20 18154229 C G 5.24E-04 Multiple complex diseases CSRP2BP intron 17554300 rs6081034 chr20 18176501 T G 4.29E-04 Multiple complex diseases / / 17554300 rs6081034 chr20 18176501 T G 1.20E-05 Odorant perception / / 23910658 rs6045264 chr20 18205644 G T 3.59E-04 Obesity (extreme) / / 21935397 rs2284897 chr20 18289998 G A 1.71E-04 Multiple complex diseases ZNF133 intron 17554300 rs3918466 chr20 18292818 A C 9.30E-04 Multiple complex diseases ZNF133 intron 17554300 rs2424167 chr20 18325355 A G 1.15E-05 Multiple sclerosis (age of onset) / / 19010793 rs2038237 chr20 18348063 G T 9.63E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2328292 chr20 18362176 C T 1.55E-05 Multiple complex diseases / / 17554300 rs2328293 chr20 18362297 C T 7.74E-04 Bone mass and geometry / / 17903296 rs17733134 chr20 18366623 G A 2.46E-04 Response to taxane treatment (placlitaxel) DZANK1 intron 23006423 rs2076642 chr20 18368350 C T 1.71E-04 Prion diseases DZANK1 intron 22210626 rs4361192 chr20 18375581 T C 4.70E-05 Psoriasis DZANK1 intron 18364390 rs4361192 chr20 18375581 T C 4.05E-04 Alzheimer's disease (late onset) DZANK1 intron 21379329 rs6136365 chr20 18390129 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) DZANK1 intron 20708005 rs6136365 chr20 18390129 T C 3.04E-05 Prion diseases DZANK1 intron 22210626 rs6132058 chr20 18400755 C T 6.79E-04 Type 2 diabetes DZANK1 intron 17463246 rs6105916 chr20 18405681 A G 6.75E-04 Type 2 diabetes DZANK1 intron 17463246 rs16979106 chr20 18407117 A C 4.81E-04 Multiple complex diseases DZANK1 intron 17554300 rs16979106 chr20 18407117 A C 4.16E-05 Response to cytidine analogues (gemcitabine) DZANK1 intron 24483146 rs16979132 chr20 18412208 T C 3.62E-04 Response to cytidine analogues (gemcitabine) DZANK1 intron 24483146 rs2424197 chr20 18433821 G A 8.45E-04 Type 2 diabetes DZANK1 intron 17463246 rs16979233 chr20 18456379 A G 8.58E-05 Multiple complex diseases POLR3F intron 17554300 rs11087256 chr20 18473958 T G 7.44E-04 Multiple complex diseases RBBP9 intron 17554300 rs2247746 chr20 18477614 A G 3.72E-05 Multiple complex diseases RBBP9 intron 17554300 rs1022684 chr20 18487506 T C 1.02E-05 Multiple complex diseases SEC23B nearGene-5 17554300 rs6075351 chr20 18490913 G A 9.33E-05 Brain lesion load SEC23B intron 19010793 rs1109030 chr20 18506677 C T 1.90E-04 Multiple complex diseases SEC23B intron 17554300 rs12481256 chr20 18514885 G A 8.19E-04 Taste perception SEC23B intron 22132133 rs2273525 chr20 18522933 C T 5.04E-05 Multiple complex diseases SEC23B intron 17554300 rs11087257 chr20 18556618 C T 2.52E-04 Taste perception / / 22132133 rs6136423 chr20 18574247 G A 5.04E-06 Hearing impairment DTD1 intron 19047183 rs2295573 chr20 18609314 T C 9.32E-04 Alzheimer's disease DTD1 intron 17998437 rs6081259 chr20 18610874 A T 3.65E-05 Multiple complex diseases DTD1 intron 17554300 rs927158 chr20 18614607 T G 9.73E-04 Alzheimer's disease DTD1 intron 17998437 rs1040792 chr20 18615063 C T 2.70E-04 Multiple complex diseases DTD1 intron 17554300 rs1040792 chr20 18615063 C T 4.98E-04 Alzheimer's disease DTD1 intron 17998437 rs6081267 chr20 18618017 C G 3.64E-04 Multiple complex diseases DTD1 intron 17554300 rs4813338 chr20 18645033 A G 7.65E-04 Multiple complex diseases DTD1 intron 17554300 rs4813338 chr20 18645033 A G 8.59E-05 Hearing impairment DTD1 intron 19047183 rs2145247 chr20 18680688 T C 5.98E-05 Multiple complex diseases DTD1 intron 17554300 rs6035106 chr20 18690104 T C 1.60E-04 Multiple complex diseases DTD1 intron 17554300 rs6035106 chr20 18690104 T C 4.64E-05 Hearing impairment DTD1 intron 19047183 rs911012 chr20 18706481 G A 4.57E-05 Multiple complex diseases DTD1 intron 17554300 rs6132107 chr20 18706738 A G 8.65E-07 Hearing impairment DTD1 intron 19047183 rs4814783 chr20 18716729 C T 5.92E-04 Taste perception DTD1 intron 22132133 rs911011 chr20 18717018 G A 3.22E-05 Multiple complex diseases DTD1 intron 17554300 rs6081341 chr20 18720419 T C 8.97E-04 Amyotrophic Lateral Sclerosis DTD1 intron 17362836 rs6081341 chr20 18720419 T C 1.27E-04 Multiple complex diseases DTD1 intron 17554300 rs6081341 chr20 18720419 T C 8.59E-05 Glucose levels DTD1 intron pha003057 rs16979575 chr20 18720437 C G 2.48E-05 Multiple complex diseases DTD1 intron 17554300 rs16979611 chr20 18743217 G C 1.43E-04 Multiple complex diseases DTD1 intron 17554300 rs6081362 chr20 18743789 A G 8.20E-06 Urinary metabolites DTD1 intron 21572414 rs8182677 chr20 18762037 G A 8.75E-04 Multiple complex diseases / / 17554300 rs6081377 chr20 18776786 T C 9.40E-07 Alcohol consumption / / 23953852 rs6035133 chr20 18791146 G A 2.00E-07 Urinary metabolites C20orf78 intron 21572414 rs6045628 chr20 18795113 G A 1.76E-04 Multiple complex diseases C20orf78 intron 17554300 rs6045634 chr20 18798055 A G 9.60E-08 Urinary metabolites C20orf78 intron 21572414 rs6105966 chr20 18798399 A G 1.31E-04 Longevity C20orf78 intron 22279548 rs41526044 chr20 18800670 C T 9.38E-05 Multiple complex diseases C20orf78 intron 17554300 rs6136523 chr20 18801036 C T 1.40E-05 Urinary metabolites C20orf78 intron 21572414 rs6136525 chr20 18806046 C T 2.20E-05 Urinary metabolites C20orf78 intron 21572414 rs6136530 chr20 18810705 C T 2.50E-05 Urinary metabolites C20orf78 UTR-5 21572414 rs742731 chr20 18885738 G A 6.00E-04 Asperger disorder / / 21182207 rs742731 chr20 18885738 G A 2.00E-06 Fasting insulin (interaction) / / 24204828 rs742731 chr20 18885738 G A 5.00E-06 Homeostasis model assessment of insulin resistance (interaction) / / 24204828 rs2876503 chr20 18886663 G A 6.84E-06 Fasting insulin (interaction) / / 24204828 rs6105992 chr20 18920874 T C 6.25E-04 Multiple complex diseases / / 17554300 rs6081442 chr20 18936139 A T 3.33E-05 Multiple complex diseases / / 17554300 rs6081451 chr20 18952598 C T 2.70E-05 Urinary metabolites / / 21572414 rs6081456 chr20 18959491 G A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2104197 chr20 18980368 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs911896 chr20 18982052 A G 5.19E-04 Multiple complex diseases / / 17554300 rs1475126 chr20 18982355 A T 9.58E-04 Multiple complex diseases / / 17554300 rs6035189 chr20 18987154 T C 6.22E-05 Longevity / / 20304771 rs1535487 chr20 18989951 A C 4.69E-05 Longevity / / 20304771 rs6045766 chr20 18999826 G T 6.86E-04 White matter integrity / / 22425255 rs1033815 chr20 19055731 G A 6.25E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6045837 chr20 19096625 A G 6.00E-06 Urinary metabolites / / 21572414 rs6045837 chr20 19096625 A G 1.30E-05 Memory performance / / 22105620 rs6045840 chr20 19097867 C G 6.00E-06 Urinary metabolites / / 21572414 rs6045840 chr20 19097867 C G 3.40E-06 Memory performance / / 22105620 rs6045843 chr20 19098511 T C 7.30E-06 Urinary metabolites / / 21572414 rs6045843 chr20 19098511 T C 1.20E-05 Memory performance / / 22105620 rs6136630 chr20 19099085 A G 3.11E-04 Alzheimer's disease (late onset) / / 21379329 rs2208796 chr20 19100148 G A 6.50E-06 Urinary metabolites / / 21572414 rs2208796 chr20 19100148 G A 3.00E-06 Memory performance / / 22105620 rs2208796 chr20 19100148 G A 0.000000379 Brain activation patterns in response to human facial expressions-for the positive faces task / / 22828495 rs2208796 chr20 19100148 G A 0.000000379 Brain activation patterns in response to human facial expressions-with the fusiform gyrus for the positive faces task / / 22828495 rs2208796 chr20 19100148 G A 2.69E-10 Brain activation patterns in response to human facial expressions-for the negative faces task / / 22828495 rs2208796 chr20 19100148 G A 2.69E-10 Airflow obstruction / / 22837378 rs6081498 chr20 19102422 G C 9.92E-05 Bipolar disorder / / 19488044 rs6075475 chr20 19111256 G A 8.61E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1570344 chr20 19118163 A G 6.58E-04 Rheumatoid arthritis / / 21452313 rs6035231 chr20 19125010 T C 6.91E-04 Heart Failure / / pha002885 rs6075479 chr20 19152492 G T 5.17E-05 Alzheimer's disease (late onset) / / 21379329 rs6075479 chr20 19152492 G T 9.35E-04 Rheumatoid arthritis / / 21452313 rs6075479 chr20 19152492 G T 8.76E-05 Cognitive impairment induced by topiramate / / 22091778 rs7272481 chr20 19162559 A G 4.99E-08 Neuroblastoma / / 18463370 rs3748483 chr20 19190195 T C 2.05E-04 Alzheimer's disease (late onset) / / 21379329 rs3748483 chr20 19190195 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6136651 chr20 19196096 G A 1.81E-05 Type 2 diabetes SLC24A3 intron 17846124 rs6136651 chr20 19196096 G A 1.80E-05 Type 2 diabetes SLC24A3 intron 21647700 rs6081541 chr20 19212890 A G 1.00E-06 Psychosis (atypical) SLC24A3 intron 24132900 rs3790167 chr20 19220911 C A 8.60E-04 Multiple complex diseases SLC24A3 intron 17554300 rs4814837 chr20 19241680 C T 9.98E-04 Response to taxane treatment (placlitaxel) SLC24A3 intron 23006423 rs6081555 chr20 19245723 G T 8.36E-04 Response to taxane treatment (placlitaxel) SLC24A3 intron 23006423 rs3790171 chr20 19258393 T C 3.64E-08 Neuroblastoma SLC24A3 intron 18463370 rs1569767 chr20 19261623 G A 4.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC24A3 missense 20877124 rs16980339 chr20 19291764 G A 6.81E-04 Multiple complex diseases SLC24A3 intron 17554300 rs6136681 chr20 19310043 A C 4.26E-04 Aortic root size SLC24A3 intron 21223598 rs150897529 chr20 19317729 G A 1.30E-05 Acne (severe) SLC24A3 intron 24927181 rs8114946 chr20 19319384 G A 2.04E-04 Aortic root size SLC24A3 intron 21223598 rs7267519 chr20 19320521 A T 7.08E-04 Aortic root size SLC24A3 intron 21223598 rs6514997 chr20 19334048 G A 8.76E-05 Cognitive impairment induced by topiramate SLC24A3 intron 22091778 rs6046024 chr20 19346184 T C 8.45E-04 Aortic root size SLC24A3 intron 21223598 rs6112327 chr20 19348676 A T 1.00E-05 Malaria SLC24A3 intron 19465909 rs6112330 chr20 19353525 G A 3.15E-05 Multiple complex diseases SLC24A3 intron 17554300 rs2424234 chr20 19363979 T C 3.00E-06 Pulmonary function decline SLC24A3 intron 22424883 rs16980475 chr20 19372326 G C 9.28E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines SLC24A3 intron 21844884 rs4813357 chr20 19398745 C T 8.57E-05 Lymphocyte counts SLC24A3 intron pha003094 rs6112365 chr20 19402606 A G 5.91E-05 Lymphocyte counts SLC24A3 intron pha003094 rs13044355 chr20 19406526 G A 1.06E-05 Lymphocyte counts SLC24A3 intron pha003094 rs6136727 chr20 19414947 G A 7.13E-07 Lymphocyte counts SLC24A3 intron pha003094 rs6136727 chr20 19414947 G A 7.07E-06 Neutrophil count SLC24A3 intron pha003095 rs6081598 chr20 19417070 T C 2.74E-05 Lymphocyte counts SLC24A3 intron pha003094 rs2328385 chr20 19420941 C T 1.72E-06 Lymphocyte counts SLC24A3 intron pha003094 rs2328385 chr20 19420941 C T 1.74E-05 Neutrophil count SLC24A3 intron pha003095 rs1535020 chr20 19427892 G A 2.73E-05 Lymphocyte counts SLC24A3 intron pha003094 rs6081600 chr20 19437539 A G 1.99E-05 Lymphocyte counts SLC24A3 intron pha003094 rs6081600 chr20 19437539 A G 2.03E-05 Neutrophil count SLC24A3 intron pha003095 rs6106080 chr20 19439993 G A 2.41E-05 Bipolar disorder and schizophrenia SLC24A3 intron 20889312 rs6035345 chr20 19440011 C T 1.93E-05 Neutrophil count SLC24A3 intron pha003095 rs3790217 chr20 19441650 A C 9.08E-05 Lymphocyte counts SLC24A3 intron pha003094 rs3790217 chr20 19441650 A C 1.64E-05 Neutrophil count SLC24A3 intron pha003095 rs6046109 chr20 19442549 A G 6.67E-05 Neutrophil count SLC24A3 intron pha003095 rs2206638 chr20 19449783 A G 9.21E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers SLC24A3 intron 21775533 rs2206638 chr20 19449783 A G 5.19E-05 Neutrophil count SLC24A3 intron pha003095 rs41391846 chr20 19462800 G A 6.40E-04 Multiple complex diseases SLC24A3 intron 17554300 rs761222 chr20 19463352 T C 9.02E-05 Parkinson's disease (motor and cognition) SLC24A3 intron 22658654 rs761222 chr20 19463352 T C 9.02E-05 Immune response to anthrax vaccine SLC24A3 intron 22658931 rs2206641 chr20 19497646 T C 1.48E-05 Glucose levels SLC24A3 intron pha003057 rs651862 chr20 19498915 C T 6.18E-06 Glucose levels SLC24A3 intron pha003057 rs636116 chr20 19500070 A G 4.27E-06 Multiple sclerosis SLC24A3 intron 17660530 rs16980729 chr20 19501920 C G 5.45E-04 Multiple complex diseases SLC24A3 intron 17554300 rs6035365 chr20 19507863 T A 8.18E-04 Multiple complex diseases SLC24A3 intron 17554300 rs3790241 chr20 19510926 A G 8.20E-04 Type 2 diabetes and 6 quantitative traits SLC24A3 intron 17848626 rs3790261 chr20 19560664 G A 4.55E-06 Hypertension,salt-sensitive SLC24A3 cds-synon 21573014 rs6112470 chr20 19562579 C T 4.28E-05 Hypertension,salt-sensitive SLC24A3 intron 21573014 rs6112470 chr20 19562579 C T 6.39E-04 Hypertension,salt-sensitive SLC24A3 intron 21573014 rs3790268 chr20 19571581 G C 3.00E-07 Matrix metalloproteinase levels SLC24A3 intron 20031604 rs942994 chr20 19599829 C T 9.14E-05 Response to methylphenidate treatment SLC24A3 intron 21130132 rs6046263 chr20 19685244 T A 1.85E-05 Progressive supranuclear palsy SLC24A3 intron 21685912 rs4814885 chr20 19691446 A G 8.29E-05 Progressive supranuclear palsy SLC24A3 intron 21685912 rs16981035 chr20 19702513 G A 8.51E-04 Amyotrophic lateral sclerosis (sporadic) SLC24A3 UTR-3 24529757 rs769122 chr20 19708351 T C 7.20E-07 Urinary metabolites / / 21572414 rs808683 chr20 19716670 T C 1.70E-05 Urinary metabolites / / 21572414 rs808683 chr20 19716670 T C 3.68E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs808687 chr20 19717751 T A 1.13E-04 Alzheimer's disease / / 17998437 rs808689 chr20 19718087 G A 8.24E-05 Alzheimer's disease / / 17998437 rs12481636 chr20 19721222 T C 2.50E-05 Urinary metabolites / / 21572414 rs808695 chr20 19722107 A C 8.18E-05 Alzheimer's disease / / 17998437 rs808701 chr20 19724043 C T 9.90E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs6112546 chr20 19729157 A T 9.24E-05 Multiple complex diseases / / 17554300 rs808706 chr20 19729311 C T 1.24E-04 Alzheimer's disease / / 17998437 rs6081731 chr20 19730620 A C 7.86E-04 Type 2 diabetes / / 17463246 rs6081741 chr20 19744341 G A 6.20E-07 Inflammatory biomarkers / / 22291609 rs6035436 chr20 19757555 C G 1.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs17298185 chr20 19760160 G A 1.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs16981111 chr20 19760553 T C 2.54E-04 Multiple complex diseases / / 17554300 rs17370440 chr20 19763787 T A 1.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs16981118 chr20 19764816 A C 5.05E-04 Hemoglobin concentration / / 20534544 rs16981118 chr20 19764816 A C 8.32E-04 Smoking cessation / / 24665060 rs4813372 chr20 19772734 G C 2.40E-05 Urinary metabolites / / 21572414 rs16981125 chr20 19776391 A G 1.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs6136836 chr20 19777525 T C 1.40E-04 Suicide attempts in bipolar disorder / / 21041247 rs17298654 chr20 19782288 T G 1.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs12481484 chr20 19782668 G A 1.20E-05 Urinary metabolites / / 21572414 rs17370886 chr20 19783315 G T 1.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs16981142 chr20 19790531 G C 2.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs16981145 chr20 19790550 G C 1.34E-07 Lipid traits / / 22028671 rs16981148 chr20 19790602 G A 2.82E-04 Suicide attempts in bipolar disorder / / 21041247 rs6136840 chr20 19792762 C G 1.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs6136842 chr20 19794718 C G 2.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs13045300 chr20 19797047 G T 2.90E-05 Urinary metabolites / / 21572414 rs6046346 chr20 19802188 C T 5.00E-06 Obesity-related traits / / 23251661 rs6081761 chr20 19806708 G A 1.09E-04 Nicotine dependence / / 17158188 rs11908323 chr20 19807479 A G 5.95E-04 Nicotine dependence / / 17158188 rs6112602 chr20 19820703 C A 5.40E-05 Cognitive function / / 24684796 rs4814909 chr20 19824870 A G 1.23E-04 Alzheimer's disease / / 17998437 rs16981220 chr20 19832038 C T 6.00E-04 Aortic root size / / 21223598 rs7263747 chr20 19832792 C A 2.29E-05 Height / / pha003010 rs7263747 chr20 19832792 C A 4.65E-05 Height / / pha003011 rs6136859 chr20 19833437 C T 2.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs4813376 chr20 19851455 T G 6.11E-07 Bipolar disorder and schizophrenia / / 20889312 rs4813377 chr20 19851466 A G 5.72E-06 Bipolar disorder and schizophrenia / / 20889312 rs6046396 chr20 19852503 G A 5.41E-05 Bipolar disorder / / 19488044 rs6046396 chr20 19852503 G A 4.00E-07 Bipolar disorder and schizophrenia / / 20889312 rs6046396 chr20 19852503 G A 5.09E-05 Bipolar Disorder / / pha002858 rs4814920 chr20 19865956 A T 3.00E-06 Bipolar disorder (body mass index interaction) RIN2 nearGene-5 24322204 rs6136874 chr20 19868883 C T 9.42E-05 Bipolar disorder and schizophrenia RIN2 intron 20889312 rs17301932 chr20 19874222 G A 5.05E-05 Multiple sclerosis RIN2 intron 17660530 rs369005 chr20 19905715 C T 4.87E-04 Stroke RIN2 intron pha002887 rs16981330 chr20 19915251 G T 8.25E-05 Graves' disease RIN2 intron 21841780 rs16981333 chr20 19916144 T C 9.31E-05 Graves' disease RIN2 intron 21841780 rs199541 chr20 19917570 A G 4.05E-05 Erythrocyte counts RIN2 intron pha003101 rs16981353 chr20 19924737 C G 8.69E-04 Type 2 diabetes RIN2 intron 17463246 rs16981353 chr20 19924737 C G 6.07E-04 Multiple complex diseases RIN2 intron 17554300 rs6112689 chr20 19940022 T C 9.22E-05 Magnesium levels RIN2 intron pha003092 rs2328472 chr20 19946076 T C 5.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RIN2 intron 20877124 rs3803981 chr20 19951534 T A 0.00001 Prostate cancer RIN2 missense 23555315 rs199583 chr20 19960184 T C 9.47E-04 Multiple complex diseases RIN2 intron 17554300 rs199604 chr20 19971112 G A 7.65E-04 Insulin resistance RIN2 intron 21901158 rs6075602 chr20 19980024 A G 9.00E-04 Acute lung injury RIN2 intron 22295056 rs6112714 chr20 19985970 G A 9.58E-05 Schizophrenia / / 19571809 rs169203 chr20 19989680 A G 2.59E-04 Multiple complex diseases / / 17554300 rs200185 chr20 20026427 A T 2.30E-06 Personality dimensions CRNKL1 intron 21173776 rs2073123 chr20 20030870 T C 7.01E-04 Heart Failure CRNKL1 intron pha002884 rs2255255 chr20 20032998 T C 5.58E-04 Heart Failure CRNKL1 missense pha002884 rs2273058 chr20 20033319 A G 5.11E-04 Heart Failure CRNKL1 missense pha002884 rs6075608 chr20 20034055 T G 2.89E-05 Cognitive test performance C20orf26 intron 20125193 rs6046580 chr20 20037794 C A 7.80E-05 Elbow pain C20orf26 intron pha003008 rs6035539 chr20 20039506 T A 7.63E-04 Prostate cancer mortality C20orf26 intron 20978177 rs200180 chr20 20045922 G C 7.40E-06 Personality dimensions C20orf26 intron 21173776 rs6081862 chr20 20047559 T C 1.82E-04 Lymphocyte counts C20orf26 intron 22286170 rs6081864 chr20 20048865 C T 2.89E-05 Cognitive test performance C20orf26 intron 20125193 rs200183 chr20 20050397 G A 3.19E-05 Type 2 diabetes C20orf26 intron 17463246 rs200184 chr20 20051890 C T 5.05E-05 Blood pressure C20orf26 intron 17255346 rs974203 chr20 20057456 T A 2.25E-04 Multiple complex diseases C20orf26 intron 17554300 rs9808594 chr20 20059715 C T 5.69E-04 Substance dependence C20orf26 intron 21818250 rs6112750 chr20 20065823 C T 4.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) C20orf26 intron 20877124 rs6081870 chr20 20070642 A G 9.57E-04 Response to taxane treatment (placlitaxel) C20orf26 intron 23006423 rs6081870 chr20 20070642 A G 4.61E-04 Smoking initiation C20orf26 intron 24665060 rs6046614 chr20 20071634 T C 6.60E-04 Obesity (extreme) C20orf26 intron 21935397 rs6081871 chr20 20072205 A G 8.21E-04 Obesity (extreme) C20orf26 intron 21935397 rs1883797 chr20 20079500 A G 6.94E-04 Multiple complex diseases C20orf26 intron 17554300 rs7265615 chr20 20123624 G T 7.06E-05 Aging (time to event) C20orf26 intron 21782286 rs6046677 chr20 20145218 A G 8.85E-04 Multiple complex diseases C20orf26 intron 17554300 rs6075630 chr20 20150027 C T 2.45E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) C20orf26 cds-synon 24236485 rs6075630 chr20 20150027 C T 2.66E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) C20orf26 cds-synon 24236485 rs6106205 chr20 20158867 T C 4.08E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) C20orf26 intron 24236485 rs6106205 chr20 20158867 T C 4.27E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) C20orf26 intron 24236485 rs6046712 chr20 20167347 C T 1.02E-05 Intracerebral hemorrhage C20orf26 intron 24656865 rs6046712 chr20 20167347 C T 7.06E-06 Intracerebral hemorrhage C20orf26 intron 24656865 rs6035581 chr20 20185874 C T 1.31E-04 Multiple complex diseases C20orf26 intron 17554300 rs7269093 chr20 20246569 T C 6.68E-05 Schizophrenia C20orf26 intron 19571811 rs6112842 chr20 20247354 G T 0.000405 Salmonella-induced pyroptosis C20orf26 intron 22837397 rs2424317 chr20 20257958 C T 0.000603 Salmonella-induced pyroptosis C20orf26 cds-synon 22837397 rs1927333 chr20 20258395 C T 1.00E-04 Prostate cancer C20orf26 intron 21743057 rs6075637 chr20 20260314 G A 1.42E-04 Birth weight C20orf26 intron 17255346 rs6075637 chr20 20260314 G A 5.48E-04 HIV-1 viral setpoint C20orf26 intron 17641165 rs1000269 chr20 20298483 G A 1.90E-04 Prostate cancer mortality C20orf26 intron 20978177 rs6046790 chr20 20303376 G A 1.90E-04 Prostate cancer mortality C20orf26 intron 20978177 rs6046805 chr20 20324341 G A 4.40E-05 Vaspin levels C20orf26 intron 22907691 rs6106240 chr20 20342797 A G 3.90E-05 Multiple complex diseases / / 17554300 rs6046818 chr20 20346178 T C 2.01E-04 Tourette syndrome / / 22889924 rs12480398 chr20 20354892 C T 9.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs6035613 chr20 20356386 C T 7.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs6081988 chr20 20381930 T C 9.60E-05 Hearing function RALGAPA2 intron 17255346 rs6081988 chr20 20381930 T C 9.20E-04 Alzheimer's disease RALGAPA2 intron 24755620 rs17717757 chr20 20390623 C T 8.74E-04 Aortic root size RALGAPA2 intron 21223598 rs6046863 chr20 20423019 G A 9.35E-04 Type 2 diabetes RALGAPA2 intron 17463246 rs6046874 chr20 20445380 C T 7.76E-04 Type 2 diabetes RALGAPA2 intron 17463246 rs6046893 chr20 20456798 C A 2.43E-04 Type 2 diabetes RALGAPA2 intron 17463246 rs6075671 chr20 20505658 C G 5.14E-04 Type 2 diabetes RALGAPA2 intron 17463246 rs6035647 chr20 20534363 A G 2.26E-04 Type 2 diabetes RALGAPA2 intron 17463246 rs6082047 chr20 20540036 C A 2.32E-04 Type 2 diabetes RALGAPA2 intron 17463246 rs6082050 chr20 20544136 T C 2.52E-04 Type 2 diabetes RALGAPA2 intron 17463246 rs1210347 chr20 20553512 A G 7.92E-05 Type 2 diabetes RALGAPA2 intron 17463246 rs6035660 chr20 20588257 A G 1.65E-04 Type 2 diabetes RALGAPA2 intron 17463246 rs6046959 chr20 20588434 C T 2.14E-04 Type 2 diabetes RALGAPA2 intron 17463246 rs6082070 chr20 20604468 G A 1.66E-04 Type 2 diabetes RALGAPA2 intron 17463246 rs6132333 chr20 20634106 T C 1.00E-06 IgG glycosylation RALGAPA2 intron 23382691 rs6132333 chr20 20634106 T C 3.00E-06 IgG glycosylation RALGAPA2 intron 23382691 rs6132333 chr20 20634106 T C 5.00E-06 IgG glycosylation RALGAPA2 intron 23382691 rs6132333 chr20 20634106 T C 7.00E-07 IgG glycosylation RALGAPA2 intron 23382691 rs6132333 chr20 20634106 T C 8.00E-06 IgG glycosylation RALGAPA2 intron 23382691 rs7265332 chr20 20637029 G A 1.66E-04 Type 2 diabetes RALGAPA2 intron 17463246 rs731866 chr20 20639045 A G 1.61E-04 Type 2 diabetes RALGAPA2 intron 17463246 rs2144280 chr20 20655466 G A 5.25E-04 Type 2 diabetes RALGAPA2 intron 17463246 rs7351929 chr20 20664674 A G 1.66E-04 Type 2 diabetes RALGAPA2 intron 17463246 rs6137105 chr20 20675154 A C 1.57E-04 Type 2 diabetes RALGAPA2 intron 17463246 rs6046994 chr20 20681135 G A 2.13E-04 Type 2 diabetes RALGAPA2 intron 17463246 rs6082124 chr20 20706992 G A 3.06E-04 Type 2 diabetes / / 17463246 rs6137118 chr20 20707652 T C 9.64E-05 Type 2 diabetes / / 17463246 rs6082126 chr20 20713651 T G 4.74E-04 Type 2 diabetes / / 17463246 rs6082131 chr20 20716714 C T 1.38E-04 Type 2 diabetes / / 17463246 rs6047025 chr20 20730273 C T 2.49E-05 Type 2 diabetes / / 17463246 rs6047026 chr20 20730674 A G 5.31E-05 Type 2 diabetes / / 17463246 rs6075703 chr20 20736751 C T 9.65E-05 Type 2 diabetes / / 17463246 rs6035711 chr20 20823718 T C 3.90E-05 Cognitive function / / 24684796 rs6035712 chr20 20825776 T G 2.00E-04 Suicidal ideation / / 22030708 rs6047116 chr20 20848968 A G 2.00E-06 Cognitive function / / 24684796 rs6082212 chr20 20849072 T C 5.32E-04 Multiple complex diseases / / 17554300 rs6075741 chr20 20926707 G C 2.29E-04 Insulin resistance / / 21901158 rs6082253 chr20 20932499 G A 2.54E-04 Myocardial Infarction / / pha002883 rs7273530 chr20 20940527 C A 4.91E-04 Insulin resistance / / 21901158 rs6137189 chr20 20942571 C T 8.50E-06 Primary sclerosing cholangitis / / 19944697 rs8126336 chr20 20948042 A G 4.82E-04 Smoking cessation / / 24665060 rs6137194 chr20 20948861 T C 5.80E-05 Age-related macular degeneration / / 20861866 rs6137194 chr20 20948861 T C 4.35E-05 Age-related macular degeneration / / 21197116 rs6137194 chr20 20948861 T C 9.23E-06 Age-related macular degeneration / / pha000001 rs6137194 chr20 20948861 T C 9.28E-06 Age-related macular degeneration / / pha002856 rs6082263 chr20 20952189 G A 4.27E-04 Parkinson's disease / / 17052657 rs4813406 chr20 20961267 C A 7.59E-05 Bipolar disorder / / 18317468 rs4813407 chr20 20961292 C A 1.00E-05 Cognitive function / / 24684796 rs6082268 chr20 20962105 A C 1.58E-04 Hearing function / / 17255346 rs6132376 chr20 20997246 A G 0.0007254 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6132376 chr20 20997246 A G 7.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6113104 chr20 20997934 T G 0.0006565 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6113104 chr20 20997934 T G 6.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6113105 chr20 20998986 G A 0.0006288 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6113105 chr20 20998986 G A 6.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1474949 chr20 21011163 A G 4.73E-04 Bipolar disorder,schizoaffective / / 19567891 rs1474949 chr20 21011163 A G 8.56E-05 Schizophrenia / / 20185149 rs6082289 chr20 21019305 T C 1.89E-05 Schizophrenia / / 20185149 rs978216 chr20 21024623 C T 3.60E-04 Lung function (forced vital capacity) / / 24023788 rs978216 chr20 21024623 C T 3.70E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6047244 chr20 21077903 A G 8.56E-04 Insulin resistance / / 21901158 rs6047255 chr20 21095936 A G 7.96E-05 Alcohol dependence / / 21703634 rs6047258 chr20 21098277 T G 8.06E-04 Multiple complex diseases / / 17554300 rs6082329 chr20 21100138 A C 7.95E-05 Alcohol dependence / / 21703634 rs4815021 chr20 21120543 C T 1.12E-05 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs1884762 chr20 21124667 G C 8.64E-05 Coronary Artery Disease PLK1S1 intron 17634449 rs4815022 chr20 21124872 T C 8.42E-06 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs3762194 chr20 21126723 A G 8.48E-06 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs1884763 chr20 21128127 A G 8.43E-06 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs13041255 chr20 21130707 T C 8.42E-06 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs4813414 chr20 21133212 A G 8.42E-06 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs6047273 chr20 21134799 T C 1.73E-05 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs6047274 chr20 21135126 T C 8.43E-06 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs4815024 chr20 21138367 C A 8.69E-06 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs2093069 chr20 21140342 C T 8.84E-06 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs6047279 chr20 21142353 T C 3.38E-04 Multiple complex diseases PLK1S1 intron 17554300 rs6047279 chr20 21142353 T C 9.01E-06 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs2236178 chr20 21142813 T C 5.00E-06 Lupus nephritis in systemic lupus erythematosus PLK1S1 missense 24925725 rs6047280 chr20 21143935 G T 1.37E-05 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs6035795 chr20 21145885 A G 8.14E-04 Multiple complex diseases PLK1S1 intron 17554300 rs6035795 chr20 21145885 A G 1.14E-05 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs6047281 chr20 21146287 A G 1.14E-05 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs6082339 chr20 21152742 G A 1.13E-05 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs6035803 chr20 21153782 G C 8.28E-04 Multiple complex diseases PLK1S1 intron 17554300 rs6035803 chr20 21153782 G C 5.69E-05 Coronary Artery Disease PLK1S1 intron 17634449 rs6047293 chr20 21154487 G A 1.13E-05 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs910975 chr20 21156169 A G 1.13E-05 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs2093070 chr20 21157510 T G 1.13E-05 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs6035808 chr20 21157565 T C 1.13E-05 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs8120377 chr20 21168361 G T 1.30E-05 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs8120293 chr20 21168395 C T 1.30E-05 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs765585 chr20 21171172 C T 1.30E-05 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs879064 chr20 21175550 T C 9.35E-04 Multiple complex diseases PLK1S1 intron 17554300 rs879064 chr20 21175550 T C 4.49E-05 Coronary Artery Disease PLK1S1 intron 17634449 rs879064 chr20 21175550 T C 1.45E-05 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs6137286 chr20 21179752 C T 5.36E-05 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs6137292 chr20 21195803 C A 6.59E-04 Multiple complex diseases PLK1S1 intron 17554300 rs6137292 chr20 21195803 C A 6.78E-05 Lupus nephritis in systemic lupus erythematosus PLK1S1 intron 24925725 rs4813418 chr20 21202815 A G 2.05E-04 Coronary Artery Disease PLK1S1 intron 17634449 rs13042216 chr20 21222126 G C 9.53E-04 Multiple complex diseases PLK1S1 intron 17554300 rs13042216 chr20 21222126 G C 1.88E-04 Coronary Artery Disease PLK1S1 intron 17634449 rs2328621 chr20 21231919 C T 9.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs6082361 chr20 21246620 G A 4.59E-04 Coronary Artery Disease / / 17634449 rs17736770 chr20 21252862 A G 4.97E-04 Obesity (extreme) / / 21935397 rs16982655 chr20 21261512 G C 3.59E-04 Multiple complex diseases / / 17554300 rs202834 chr20 21301991 G A 6.74E-05 Multiple complex diseases XRN2 intron 17554300 rs2296730 chr20 21367741 A G 1.17E-04 Coronary Artery Disease XRN2 intron 17634449 rs809220 chr20 21414037 T C 7.41E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs804382 chr20 21429848 G A 1.74E-22 Lymphocyte counts / / 22286170 rs4813428 chr20 21451848 C T 2.10E-05 Urinary metabolites / / 21572414 rs6082455 chr20 21552504 G A 9.44E-05 Blood Pressure / / pha003048 rs743156 chr20 21559089 T C 4.49E-04 Insulin resistance / / 21901158 rs2424382 chr20 21565207 G A 7.63E-04 Insulin resistance / / 21901158 rs2424384 chr20 21567305 G A 3.49E-04 Insulin resistance / / 21901158 rs1014889 chr20 21570837 A G 7.09E-04 Insulin resistance / / 21901158 rs6035902 chr20 21582338 A G 8.73E-04 Insulin resistance / / 21901158 rs6082475 chr20 21619273 C T 2.40E-05 Urinary metabolites / / 21572414 rs2424386 chr20 21620667 A G 2.50E-05 Urinary metabolites / / 21572414 rs6035924 chr20 21662517 T G 1.16E-04 Cognitive function / / 24684796 rs7275114 chr20 21662974 T C 2.69E-04 Multiple complex diseases / / 17554300 rs6047583 chr20 21675671 G A 1.16E-04 Cognitive function / / 24684796 rs972014 chr20 21766736 C T 1.50E-11 Male-pattern baldness / / 22693459 rs1476396 chr20 21770657 C G 4.76E-17 Male-pattern baldness / / 22693459 rs2208309 chr20 21771761 G A 4.63E-17 Male-pattern baldness / / 22693459 rs2208310 chr20 21771845 T G 4.31E-10 Male-pattern baldness / / 22693459 rs2224366 chr20 21771909 G C 4.29E-10 Male-pattern baldness / / 22693459 rs6047630 chr20 21774842 C G 9.71E-04 Type 2 diabetes / / 17463246 rs1476398 chr20 21775783 A G 6.15E-09 Male-pattern baldness / / 22693459 rs2208312 chr20 21776735 T C 5.15E-14 Male-pattern baldness / / 22693459 rs2208314 chr20 21776875 A C 4.65E-14 Male-pattern baldness / / 22693459 rs2876622 chr20 21777915 A G 4.32E-17 Male-pattern baldness / / 22693459 rs6047632 chr20 21780197 C T 4.83E-14 Male-pattern baldness / / 22693459 rs6082512 chr20 21780905 T C 5.94E-17 Male-pattern baldness / / 22693459 rs6082513 chr20 21780972 A C 6.15E-17 Male-pattern baldness / / 22693459 rs6047635 chr20 21781625 T G 1.57E-11 Male-pattern baldness / / 22693459 rs873137 chr20 21784131 A C 1.08E-11 Male-pattern baldness / / 22693459 rs6137444 chr20 21785639 C T 3.11E-06 Male-pattern baldness / / 18849994 rs6137444 chr20 21785639 C T 1.10E-18 Male-pattern baldness / / 22693459 rs1540930 chr20 21788175 C G 2.72E-09 Male-pattern baldness / / 22693459 rs6075840 chr20 21788459 A T 1.24E-11 Male-pattern baldness / / 22693459 rs6137445 chr20 21789803 A G 1.13E-11 Male-pattern baldness / / 22693459 rs4815066 chr20 21790075 A C 2.06E-09 Male-pattern baldness / / 22693459 rs6137446 chr20 21790861 A G 8.77E-12 Male-pattern baldness / / 22693459 rs6137448 chr20 21791008 A T 9.93E-19 Male-pattern baldness / / 22693459 rs6047641 chr20 21791854 T G 6.54E-06 Personality dimensions / / 18957941 rs6047641 chr20 21791854 T G 6.50E-06 Personality dimensions / / 21173776 rs6047641 chr20 21791854 T G 3.97E-09 Male-pattern baldness / / 22693459 rs6047643 chr20 21793400 A T 1.78E-09 Male-pattern baldness / / 22693459 rs2180700 chr20 21796855 G T 8.25E-19 Male-pattern baldness / / 22693459 rs1540931 chr20 21797349 A C 1.06E-10 Male-pattern baldness / / 22693459 rs6035959 chr20 21801469 G A 2.63E-14 Male-pattern baldness / / 22693459 rs6082519 chr20 21801501 T A 3.15E-21 Male-pattern baldness / / 22693459 rs16983003 chr20 21803314 T A 1.13E-09 Male-pattern baldness / / 22693459 rs4281974 chr20 21803581 G A 5.11E-20 Male-pattern baldness / / 22693459 rs6082520 chr20 21812118 C T 4.73E-21 Male-pattern baldness / / 22693459 rs2224261 chr20 21814035 T C 4.98E-21 Male-pattern baldness / / 22693459 rs6113393 chr20 21815192 C T 1.65E-26 Male-pattern baldness / / 22693459 rs1535199 chr20 21818308 G A 1.83E-26 Male-pattern baldness / / 22693459 rs6113394 chr20 21821149 T G 3.60E-05 Personality dimensions / / 18957941 rs6113394 chr20 21821149 T G 1.88E-26 Male-pattern baldness / / 22693459 rs6106421 chr20 21821217 C T 1.89E-26 Male-pattern baldness / / 22693459 rs6113395 chr20 21821262 A G 3.70E-05 Personality dimensions / / 18957941 rs6113395 chr20 21821262 A G 1.89E-26 Male-pattern baldness / / 22693459 rs6047663 chr20 21821910 C T 1.97E-26 Male-pattern baldness / / 22693459 rs4405823 chr20 21824164 T A 1.99E-26 Male-pattern baldness / / 22693459 rs8122229 chr20 21824282 A G 4.00E-05 Personality dimensions / / 18957941 rs8122229 chr20 21824282 A G 2.05E-26 Male-pattern baldness / / 22693459 rs2328647 chr20 21830507 A G 5.40E-05 Personality dimensions / / 18957941 rs2328647 chr20 21830507 A G 3.83E-26 Male-pattern baldness / / 22693459 rs2064773 chr20 21833737 G A 2.40E-16 Male-pattern baldness / / 22693459 rs2144882 chr20 21833826 C T 1.89E-09 Male-pattern baldness / / 22693459 rs6047676 chr20 21842889 C T 1.78E-26 Male-pattern baldness / / 22693459 rs1014883 chr20 21844630 A G 1.80E-26 Male-pattern baldness / / 22693459 rs1014884 chr20 21844694 T C 4.80E-05 Personality dimensions / / 18957941 rs1014884 chr20 21844694 T C 2.11E-26 Male-pattern baldness / / 22693459 rs1014885 chr20 21844827 C T 5.00E-05 Personality dimensions / / 18957941 rs1014885 chr20 21844827 C T 1.05E-26 Male-pattern baldness / / 22693459 rs6047677 chr20 21847479 G C 2.04E-26 Male-pattern baldness / / 22693459 rs12479719 chr20 21850786 A G 2.80E-13 Male-pattern baldness / / 22693459 rs997078 chr20 21850850 T A 2.21E-26 Male-pattern baldness / / 22693459 rs987050 chr20 21852049 A C 2.92E-26 Male-pattern baldness / / 22693459 rs2180439 chr20 21853100 C T 3.00E-15 Male-pattern baldness / / 18849994 rs2180439 chr20 21853100 C T 4.70E-05 Personality dimensions / / 18957941 rs2180439 chr20 21853100 C T 4.00E-17 Male-pattern baldness / / 22032556 rs6047683 chr20 21853193 A C 2.39E-26 Male-pattern baldness / / 22693459 rs6047684 chr20 21853764 G A 2.39E-26 Male-pattern baldness / / 22693459 rs6047685 chr20 21855904 A T 2.39E-26 Male-pattern baldness / / 22693459 rs6035971 chr20 21856148 A T 2.40E-26 Male-pattern baldness / / 22693459 rs6113404 chr20 21863825 T C 4.21E-30 Male-pattern baldness / / 22693459 rs6075852 chr20 21866151 A G 3.50E-07 Male-pattern baldness / / 18849994 rs6075852 chr20 21866151 A G 7.41E-33 Male-pattern baldness / / 22693459 rs6075854 chr20 21866377 G A 3.04E-30 Male-pattern baldness / / 22693459 rs6075855 chr20 21866547 T C 4.64E-30 Male-pattern baldness / / 22693459 rs6035978 chr20 21875139 T C 2.47E-30 Male-pattern baldness / / 22693459 rs6035979 chr20 21875172 G T 2.42E-30 Male-pattern baldness / / 22693459 rs6047705 chr20 21875655 T C 2.34E-30 Male-pattern baldness / / 22693459 rs4815081 chr20 21877020 G A 2.17E-30 Male-pattern baldness / / 22693459 rs1998076 chr20 21880045 A G 1.30E-07 Male-pattern baldness / / 18849994 rs1998076 chr20 21880045 A G 1.89E-30 Male-pattern baldness / / 22693459 rs6137473 chr20 21884693 G A 5.58E-06 Male-pattern baldness / / 18849994 rs6137473 chr20 21884693 G A 8.18E-28 Male-pattern baldness / / 22693459 rs4544515 chr20 21885311 C T 1.74E-33 Male-pattern baldness / / 22693459 rs1884588 chr20 21885500 C T 2.78E-33 Male-pattern baldness / / 22693459 rs1884589 chr20 21885619 A C 2.94E-33 Male-pattern baldness / / 22693459 rs6113415 chr20 21886167 G A 3.04E-33 Male-pattern baldness / / 22693459 rs6113416 chr20 21886362 C T 3.35E-33 Male-pattern baldness / / 22693459 rs6047715 chr20 21887266 A T 3.47E-33 Male-pattern baldness / / 22693459 rs6113418 chr20 21889318 T A 3.61E-33 Male-pattern baldness / / 22693459 rs1884592 chr20 21890690 C T 8.58E-06 Male-pattern baldness / / 18849994 rs1884592 chr20 21890690 C T 3.99E-33 Male-pattern baldness / / 22693459 rs1884593 chr20 21890817 C A 3.75E-33 Male-pattern baldness / / 22693459 rs6082558 chr20 21891163 G A 3.75E-33 Male-pattern baldness / / 22693459 rs6137476 chr20 21897656 A G 8.58E-06 Male-pattern baldness / / 18849994 rs6075858 chr20 21899029 G A 3.13E-27 Male-pattern baldness / / 22693459 rs6047731 chr20 21899141 G A 8.58E-06 Male-pattern baldness / / 18849994 rs6047732 chr20 21899248 G C 3.70E-33 Male-pattern baldness / / 22693459 rs2208054 chr20 21899708 A G 3.64E-33 Male-pattern baldness / / 22693459 rs2208055 chr20 21899864 A G 3.60E-33 Male-pattern baldness / / 22693459 rs4390829 chr20 21900117 A G 2.74E-33 Male-pattern baldness / / 22693459 rs3818179 chr20 21901123 T A,C,G 4.03E-33 Male-pattern baldness / / 22693459 rs3818182 chr20 21901398 A C,G,T 4.02E-33 Male-pattern baldness / / 22693459 rs6515191 chr20 21905732 T A 4.43E-33 Male-pattern baldness / / 22693459 rs6113424 chr20 21906780 G A 7.05E-06 Male-pattern baldness / / 18849994 rs6113424 chr20 21906780 G A 3.34E-33 Male-pattern baldness / / 22693459 rs6113425 chr20 21907562 G A 2.80E-33 Male-pattern baldness / / 22693459 rs2281526 chr20 21908332 C G 2.52E-33 Male-pattern baldness / / 22693459 rs927059 chr20 21914194 T C 7.56E-33 Male-pattern baldness / / 22693459 rs6113431 chr20 21916356 A T 2.57E-33 Male-pattern baldness / / 22693459 rs2024885 chr20 21917393 A G 7.05E-06 Male-pattern baldness / / 18849994 rs2024885 chr20 21917393 A G 2.90E-33 Male-pattern baldness / / 22693459 rs2328680 chr20 21918106 C T 2.52E-33 Male-pattern baldness / / 22693459 rs2328681 chr20 21918213 T C 2.50E-33 Male-pattern baldness / / 22693459 rs2328682 chr20 21918288 G A 2.47E-33 Male-pattern baldness / / 22693459 rs1007169 chr20 21918310 G T 2.39E-33 Male-pattern baldness / / 22693459 rs2208050 chr20 21918427 G A 2.03E-33 Male-pattern baldness / / 22693459 rs2208051 chr20 21918471 A G 1.55E-33 Male-pattern baldness / / 22693459 rs2328684 chr20 21918642 T G 1.43E-33 Male-pattern baldness / / 22693459 rs6047744 chr20 21918898 G T 1.23E-33 Male-pattern baldness / / 22693459 rs6047745 chr20 21919054 C A 1.03E-33 Male-pattern baldness / / 22693459 rs6113435 chr20 21920688 C G 9.32E-34 Male-pattern baldness / / 22693459 rs2424409 chr20 21929051 G C 1.28E-14 Male-pattern baldness / / 22693459 rs2424410 chr20 21929057 A C 6.08E-34 Male-pattern baldness / / 22693459 rs6035995 chr20 21931683 A G 6.97E-06 Male-pattern baldness / / 18849994 rs6035995 chr20 21931683 A G 8.21E-34 Male-pattern baldness / / 22693459 rs1080275 chr20 21936485 A G 5.54E-34 Male-pattern baldness / / 22693459 rs6047761 chr20 21938282 A C 5.11E-34 Male-pattern baldness / / 22693459 rs4815086 chr20 21938530 A C 5.31E-34 Male-pattern baldness / / 22693459 rs4815087 chr20 21938603 G C 4.51E-34 Male-pattern baldness / / 22693459 rs2424414 chr20 21943803 T C 1.56E-09 Male-pattern baldness / / 22693459 rs201543 chr20 21946928 A G 7.05E-06 Male-pattern baldness / / 18849994 rs969921 chr20 21947184 A T 3.96E-34 Male-pattern baldness / / 22693459 rs6106434 chr20 21949593 G A 1.82E-16 Male-pattern baldness / / 22693459 rs2207878 chr20 21951847 A G 6.19E-06 Male-pattern baldness / / 18849994 rs2207878 chr20 21951847 A G 2.99E-28 Male-pattern baldness / / 22693459 rs970616 chr20 21952054 C A 1.37E-16 Male-pattern baldness / / 22693459 rs6047768 chr20 21953649 A G 6.09E-06 Male-pattern baldness / / 18849994 rs6047768 chr20 21953649 A G 3.19E-28 Male-pattern baldness / / 22693459 rs6047769 chr20 21958049 G A 8.47E-06 Male-pattern baldness / / 18849994 rs6047769 chr20 21958049 G A 4.35E-34 Male-pattern baldness / / 22693459 rs2424417 chr20 21959906 A T 1.39E-09 Male-pattern baldness / / 22693459 rs1555264 chr20 21961410 A G 8.64E-06 Male-pattern baldness / / 18849994 rs1555264 chr20 21961410 A G 3.98E-28 Male-pattern baldness / / 22693459 rs1555265 chr20 21961472 C T 6.71E-34 Male-pattern baldness / / 22693459 rs6036003 chr20 21961964 G A 5.00E-34 Male-pattern baldness / / 22693459 rs169311 chr20 21962333 A C 2.37E-34 Male-pattern baldness / / 22693459 rs2424420 chr20 21963048 T C 7.59E-15 Male-pattern baldness / / 22693459 rs201546 chr20 21967950 A G 4.77E-09 Male-pattern baldness / / 22693459 rs2424422 chr20 21968219 C A 5.93E-15 Male-pattern baldness / / 22693459 rs2424424 chr20 21969511 T C 1.05E-10 Male-pattern baldness / / 22693459 rs2009652 chr20 21972581 T C 3.74E-34 Male-pattern baldness / / 22693459 rs6036007 chr20 21974590 T C 3.77E-34 Male-pattern baldness / / 22693459 rs201548 chr20 21974835 C T 3.77E-34 Male-pattern baldness / / 22693459 rs6106438 chr20 21975026 T C 3.13E-34 Male-pattern baldness / / 22693459 rs6113456 chr20 21977094 T G 8.92E-35 Male-pattern baldness / / 22693459 rs6047798 chr20 21985498 G A 2.82E-34 Male-pattern baldness / / 22693459 rs1980551 chr20 21985781 A G 1.66E-34 Male-pattern baldness / / 22693459 rs1980552 chr20 21986005 C T 1.53E-34 Male-pattern baldness / / 22693459 rs6047799 chr20 21986312 C A 1.36E-38 Male-pattern baldness / / 22693459 rs6047801 chr20 21987459 T G 1.46E-09 Male-pattern baldness / / 22693459 rs127747 chr20 21988830 A G 3.14E-39 Male-pattern baldness / / 22693459 rs6047804 chr20 21989973 C T 5.47E-09 Male-pattern baldness / / 22693459 rs201559 chr20 21997115 T C 3.92E-39 Male-pattern baldness / / 22693459 rs16983261 chr20 21997430 T C 0.00000016 Internal carotid artery thickness (near walls) / / 23487405 rs16983261 chr20 21997430 T C 0.00000226 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs201561 chr20 21999213 G C 5.37E-39 Male-pattern baldness / / 22693459 rs201562 chr20 22000174 G T 1.13E-27 Male-pattern baldness / / 22693459 rs201563 chr20 22000281 C T 3.91E-39 Male-pattern baldness / / 22693459 rs201564 chr20 22007602 A G 9.74E-23 Male-pattern baldness / / 22693459 rs201565 chr20 22009335 C T 3.65E-39 Male-pattern baldness / / 22693459 rs201569 chr20 22012862 C T 1.01E-22 Male-pattern baldness / / 22693459 rs201571 chr20 22013514 C T 4.31E-06 Male-pattern baldness / / 18849994 rs201571 chr20 22013514 C T 9.73E-28 Male-pattern baldness / / 22693459 rs6113469 chr20 22014133 T C 0.00000367 Internal carotid artery thickness (near walls) / / 23487405 rs201572 chr20 22014754 C T 7.83E-28 Male-pattern baldness / / 22693459 rs201574 chr20 22015564 T C 2.96E-39 Male-pattern baldness / / 22693459 rs6113474 chr20 22019819 G T 0.00000016 Internal carotid artery thickness (near walls) / / 23487405 rs6113474 chr20 22019819 G T 0.00000226 Internal carotid artery thickness (average of near and far walls) / / 23487405 rs201587 chr20 22027674 G A 2.44E-39 Male-pattern baldness / / 22693459 rs4815089 chr20 22027787 C T 5.64E-09 Male-pattern baldness / / 22693459 rs6047837 chr20 22033559 T C 1.58E-09 Male-pattern baldness / / 22693459 rs201593 chr20 22033819 G A 1.80E-39 Male-pattern baldness / / 22693459 rs6047838 chr20 22033920 A G 5.64E-10 Male-pattern baldness / / 22693459 rs201594 chr20 22034671 C T 2.29E-39 Male-pattern baldness / / 22693459 rs4815090 chr20 22035416 G T 4.43E-21 Male-pattern baldness LOC100270679 intron 22693459 rs6113483 chr20 22036524 G C 4.72E-23 Male-pattern baldness LOC100270679 intron 22693459 rs6047844 chr20 22037575 T C 2.00E-39 Male-pattern baldness LOC100270679 intron 22693459 rs6137526 chr20 22038726 C T 6.63E-23 Male-pattern baldness LOC100270679 intron 22693459 rs6132477 chr20 22040422 C T 4.98E-23 Male-pattern baldness LOC100270679 intron 22693459 rs16983348 chr20 22040957 A G 3.39E-09 Male-pattern baldness LOC100270679 intron 22693459 rs913063 chr20 22042418 A C 1.57E-38 Male-pattern baldness LOC100270679 intron 22693459 rs6137527 chr20 22043921 C T 4.27E-23 Male-pattern baldness LOC100270679 intron 22693459 rs6036026 chr20 22044205 T C 1.51E-38 Male-pattern baldness LOC100270679 intron 22693459 rs4813445 chr20 22047177 G A 1.48E-38 Male-pattern baldness LOC100270679 intron 22693459 rs6036029 chr20 22049177 C T 1.48E-38 Male-pattern baldness / / 22693459 rs4813446 chr20 22049759 T C 1.47E-38 Male-pattern baldness LOC100270679 intron 22693459 rs1160312 chr20 22050503 A G 1.00E-14 Male-pattern baldness LOC100270679 intron 18849991 rs1160312 chr20 22050503 A G 1.47E-38 Male-pattern baldness LOC100270679 intron 22693459 rs1887056 chr20 22051811 A C 1.39E-38 Male-pattern baldness LOC100270679 intron 22693459 rs16983367 chr20 22052059 G T 2.47E-09 Male-pattern baldness LOC100270679 intron 22693459 rs2104504 chr20 22057175 T C 6.10E-10 Male-pattern baldness / / 22693459 rs6113491 chr20 22057415 A C 8.63E-06 Male-pattern baldness / / 18849994 rs6113491 chr20 22057415 A C 3.10E-37 Male-pattern baldness / / 22693459 rs6113495 chr20 22061487 A G 3.68E-23 Male-pattern baldness / / 22693459 rs6113496 chr20 22061632 G T 1.02E-38 Male-pattern baldness / / 22693459 rs6113501 chr20 22064973 G A 3.79E-23 Male-pattern baldness / / 22693459 rs11698943 chr20 22065466 A G 4.50E-23 Male-pattern baldness / / 22693459 rs10485628 chr20 22066991 G A 5.63E-10 Male-pattern baldness / / 22693459 rs6036037 chr20 22070525 A C 8.62E-37 Male-pattern baldness / / 22693459 rs6137533 chr20 22070663 C T 3.64E-23 Male-pattern baldness / / 22693459 rs4813447 chr20 22074096 G A 6.48E-10 Male-pattern baldness / / 22693459 rs16983417 chr20 22075074 A G 4.33E-04 Multiple complex diseases / / 17554300 rs6113508 chr20 22076189 A G 4.28E-23 Male-pattern baldness / / 22693459 rs6113509 chr20 22077352 G A 4.22E-23 Male-pattern baldness / / 22693459 rs1883751 chr20 22080540 G A 4.47E-23 Male-pattern baldness / / 22693459 rs4815092 chr20 22081333 C G 3.28E-05 Serum metabolites / / 19043545 rs4815092 chr20 22081333 C G 2.00E-22 Male-pattern baldness / / 22693459 rs6036041 chr20 22082448 A G 2.04E-28 Male-pattern baldness / / 22693459 rs201141 chr20 22086415 T C 2.24E-09 Male-pattern baldness / / 22693459 rs201142 chr20 22086860 G A 2.24E-09 Male-pattern baldness / / 22693459 rs201144 chr20 22087538 A G 9.48E-10 Male-pattern baldness / / 22693459 rs201145 chr20 22087670 A G 2.05E-38 Male-pattern baldness / / 22693459 rs201146 chr20 22088650 C A 1.93E-38 Male-pattern baldness / / 22693459 rs201147 chr20 22089083 T A 2.46E-09 Male-pattern baldness / / 22693459 rs201149 chr20 22090387 T A,G 5.02E-37 Male-pattern baldness / / 22693459 rs201150 chr20 22090581 T A 7.44E-37 Male-pattern baldness / / 22693459 rs6047915 chr20 22102153 T C 2.48E-09 Male-pattern baldness / / 22693459 rs6047917 chr20 22104421 A G 6.03E-37 Male-pattern baldness / / 22693459 rs2206754 chr20 22105843 T C 3.67E-09 Male-pattern baldness / / 22693459 rs11698068 chr20 22106230 A G 7.12E-37 Male-pattern baldness / / 22693459 rs2328700 chr20 22107727 T C 3.60E-09 Male-pattern baldness / / 22693459 rs6137547 chr20 22109895 A G 1.25E-22 Male-pattern baldness / / 22693459 rs1303872 chr20 22111034 C T 9.58E-33 Male-pattern baldness / / 22693459 rs1303873 chr20 22111381 T C 3.34E-09 Male-pattern baldness / / 22693459 rs804516 chr20 22115729 A G 2.38E-36 Male-pattern baldness / / 22693459 rs6113534 chr20 22117778 C G 4.09E-22 Male-pattern baldness / / 22693459 rs804520 chr20 22119141 A G 6.82E-35 Male-pattern baldness / / 22693459 rs804521 chr20 22119263 A G 1.05E-09 Male-pattern baldness / / 22693459 rs973106 chr20 22119832 G A 4.95E-22 Male-pattern baldness / / 22693459 rs804522 chr20 22120289 C T 1.04E-09 Male-pattern baldness / / 22693459 rs708996 chr20 22122158 G C 2.66E-32 Male-pattern baldness / / 22693459 rs804524 chr20 22122810 T C 7.66E-35 Male-pattern baldness / / 22693459 rs6113539 chr20 22123129 G A 4.11E-22 Male-pattern baldness / / 22693459 rs804525 chr20 22123209 C A 2.48E-09 Male-pattern baldness / / 22693459 rs804527 chr20 22124417 G T 1.01E-09 Male-pattern baldness / / 22693459 rs804529 chr20 22125884 A C 1.01E-09 Male-pattern baldness / / 22693459 rs708997 chr20 22127048 A C 1.01E-09 Male-pattern baldness / / 22693459 rs708999 chr20 22127894 C T 1.04E-09 Male-pattern baldness / / 22693459 rs804530 chr20 22128470 T C 2.58E-09 Male-pattern baldness / / 22693459 rs804531 chr20 22128554 G A 2.89E-29 Male-pattern baldness / / 22693459 rs6113543 chr20 22129323 A G,T 5.25E-22 Male-pattern baldness / / 22693459 rs804532 chr20 22129555 G A 2.72E-09 Male-pattern baldness / / 22693459 rs804533 chr20 22129932 G A 1.09E-34 Male-pattern baldness / / 22693459 rs1415798 chr20 22130529 C G 4.40E-22 Male-pattern baldness / / 22693459 rs1415799 chr20 22131194 C T 4.07E-22 Male-pattern baldness / / 22693459 rs804536 chr20 22135307 T C 5.83E-09 Male-pattern baldness / / 22693459 rs2328701 chr20 22136001 G C 1.51E-34 Male-pattern baldness / / 22693459 rs804537 chr20 22136092 C T 3.38E-09 Male-pattern baldness / / 22693459 rs6113547 chr20 22136156 G T 0.00000264 Internal carotid artery thickness (near walls) / / 23487405 rs804538 chr20 22136273 G A 1.12E-08 Male-pattern baldness / / 22693459 rs804539 chr20 22136709 G C 1.55E-08 Male-pattern baldness / / 22693459 rs6047929 chr20 22136786 G A 8.13E-25 Male-pattern baldness / / 22693459 rs6113548 chr20 22136839 T C 4.16E-22 Male-pattern baldness / / 22693459 rs1090265 chr20 22139447 T C 1.79E-08 Male-pattern baldness / / 22693459 rs6113551 chr20 22139934 T A 3.70E-16 Male-pattern baldness / / 22693459 rs6137561 chr20 22144267 A G 4.69E-19 Male-pattern baldness / / 22693459 rs804569 chr20 22151652 G A 1.94E-04 IgE levels / / 17255346 rs804578 chr20 22159926 G A 1.82E-04 IgE levels / / 17255346 rs804596 chr20 22186593 A G 1.75E-04 Tourette syndrome / / 22889924 rs804606 chr20 22192446 T C 9.34E-04 Alzheimer's disease / / 22005930 rs804610 chr20 22194770 A G 3.10E-04 Alzheimer's disease / / 22005930 rs6113583 chr20 22195065 T C 9.51E-04 Alzheimer's disease / / 22005930 rs6113583 chr20 22195065 T C 3.72E-15 Male-pattern baldness / / 22693459 rs1159466 chr20 22196023 G C 4.87E-17 Male-pattern baldness / / 22693459 rs6137582 chr20 22197211 A G 8.48E-04 Alzheimer's disease / / 22005930 rs6137582 chr20 22197211 A G 3.44E-16 Male-pattern baldness / / 22693459 rs2876633 chr20 22197686 T A 7.92E-04 Alzheimer's disease / / 22005930 rs2876633 chr20 22197686 T A 2.29E-16 Male-pattern baldness / / 22693459 rs742655 chr20 22199503 T C 3.89E-17 Male-pattern baldness LOC100505651 intron 22693459 rs804614 chr20 22200414 A G 4.29E-17 Male-pattern baldness LOC100505651 intron 22693459 rs804615 chr20 22201175 T C 2.82E-17 Male-pattern baldness / / 22693459 rs804615 chr20 22201175 T C 9.86E-04 Tourette syndrome / / 22889924 rs804616 chr20 22201839 C T 4.16E-17 Male-pattern baldness LOC100505651 intron 22693459 rs804617 chr20 22203480 G T 3.61E-17 Male-pattern baldness LOC100505651 intron 22693459 rs709006 chr20 22203740 T C 3.60E-17 Male-pattern baldness LOC100505651 intron 22693459 rs709007 chr20 22203787 A G 3.54E-17 Male-pattern baldness LOC100505651 intron 22693459 rs804618 chr20 22204465 G A 3.60E-17 Male-pattern baldness LOC100505651 intron 22693459 rs1090292 chr20 22206969 C T 4.73E-17 Male-pattern baldness LOC100505651 intron 22693459 rs1090293 chr20 22207156 G A 4.92E-17 Male-pattern baldness LOC100505651 intron 22693459 rs4815098 chr20 22209538 G A 6.49E-04 Alzheimer's disease LOC100505651 intron 22005930 rs4815098 chr20 22209538 G A 3.23E-16 Male-pattern baldness LOC100505651 intron 22693459 rs1415801 chr20 22211414 T G 6.70E-04 Alzheimer's disease LOC100505651 intron 22005930 rs1415801 chr20 22211414 T G 3.16E-16 Male-pattern baldness LOC100505651 intron 22693459 rs12625314 chr20 22212946 C T 6.71E-04 Alzheimer's disease LOC100505651 intron 22005930 rs12625314 chr20 22212946 C T 3.14E-16 Male-pattern baldness LOC100505651 intron 22693459 rs12625315 chr20 22212962 C T 6.39E-04 Alzheimer's disease LOC100505651 intron 22005930 rs12625315 chr20 22212962 C T 7.69E-14 Male-pattern baldness LOC100505651 intron 22693459 rs1337907 chr20 22214901 G A 8.40E-04 Alzheimer's disease / / 22005930 rs6106481 chr20 22223640 A G 9.08E-04 Multiple complex diseases / / 17554300 rs6106481 chr20 22223640 A G 8.61E-04 Alzheimer's disease / / 22005930 rs6106481 chr20 22223640 A G 2.89E-11 Male-pattern baldness / / 22693459 rs6113592 chr20 22229505 A G 5.79E-04 Alzheimer's disease / / 22005930 rs6113592 chr20 22229505 A G 2.85E-09 Male-pattern baldness / / 22693459 rs6047978 chr20 22239448 A C 6.32E-04 Alzheimer's disease / / 22005930 rs6047978 chr20 22239448 A C 2.96E-09 Male-pattern baldness / / 22693459 rs1337908 chr20 22241466 T A 3.06E-11 Male-pattern baldness / / 22693459 rs804688 chr20 22242336 G A 6.89E-04 Multiple complex diseases / / 17554300 rs10485630 chr20 22245867 T G 5.93E-04 Alzheimer's disease / / 22005930 rs10485630 chr20 22245867 T G 1.40E-09 Male-pattern baldness / / 22693459 rs6047982 chr20 22246450 T G 7.08E-04 Alzheimer's disease / / 22005930 rs6047982 chr20 22246450 T G 1.25E-09 Male-pattern baldness / / 22693459 rs6113604 chr20 22252275 C T 7.35E-11 Male-pattern baldness / / 22693459 rs4815101 chr20 22255000 C G 1.14E-10 Male-pattern baldness / / 22693459 rs4815102 chr20 22255173 G T 7.49E-11 Male-pattern baldness / / 22693459 rs6113607 chr20 22256270 T C 1.14E-10 Male-pattern baldness / / 22693459 rs200366 chr20 22260551 A G 1.97E-15 Male-pattern baldness / / 22693459 rs6106493 chr20 22260893 C T 7.85E-11 Male-pattern baldness / / 22693459 rs1569781 chr20 22262264 G T 7.93E-11 Male-pattern baldness / / 22693459 rs1569782 chr20 22262427 C G 1.20E-10 Male-pattern baldness / / 22693459 rs2295099 chr20 22263132 G A 3.16E-12 Male-pattern baldness / / 22693459 rs200369 chr20 22265098 A C 1.45E-11 Male-pattern baldness / / 22693459 rs1028444 chr20 22267058 T C 2.46E-09 Male-pattern baldness / / 22693459 rs6047999 chr20 22268484 T C 2.08E-09 Male-pattern baldness / / 22693459 rs1832371 chr20 22271089 G A 2.22E-09 Male-pattern baldness / / 22693459 rs183216 chr20 22274859 T A 1.20E-11 Male-pattern baldness / / 22693459 rs980970 chr20 22274930 C T 2.38E-09 Male-pattern baldness / / 22693459 rs199780 chr20 22275649 T G 1.20E-11 Male-pattern baldness / / 22693459 rs199781 chr20 22276485 G C 1.80E-11 Male-pattern baldness / / 22693459 rs4813452 chr20 22276813 T G 3.67E-09 Male-pattern baldness / / 22693459 rs6113622 chr20 22280603 T C 2.76E-09 Male-pattern baldness / / 22693459 rs17192817 chr20 22281873 T C 4.03E-09 Male-pattern baldness / / 22693459 rs172036 chr20 22282355 T C 9.43E-12 Male-pattern baldness / / 22693459 rs199790 chr20 22283878 C T 1.32E-11 Male-pattern baldness / / 22693459 rs199793 chr20 22287303 G A 7.49E-13 Male-pattern baldness / / 22693459 rs8124887 chr20 22290780 G A 5.20E-04 Multiple complex diseases / / 17554300 rs8124887 chr20 22290780 G A 2.57E-08 Male-pattern baldness / / 22693459 rs4815103 chr20 22291219 C A 8.79E-04 Multiple complex diseases / / 17554300 rs4815103 chr20 22291219 C A 2.40E-08 Male-pattern baldness / / 22693459 rs199796 chr20 22291932 C T 7.59E-11 Male-pattern baldness / / 22693459 rs4564856 chr20 22297047 A G 7.23E-04 Multiple complex diseases / / 17554300 rs169230 chr20 22300304 G A 4.30E-09 Male-pattern baldness / / 22693459 rs2424430 chr20 22302296 A G 2.85E-05 Multiple complex diseases / / 17554300 rs431904 chr20 22304851 C T 5.48E-05 Multiple complex diseases / / 17554300 rs1570043 chr20 22306243 G C 1.10E-05 Multiple complex diseases / / 17554300 rs172038 chr20 22361396 A G 6.02E-05 Hypertension / / 21082022 rs199843 chr20 22365546 T G 4.69E-05 Hypertension / / 21082022 rs2757072 chr20 22391189 G A 4.00E-04 Tourette syndrome LOC284788 intron 22889924 rs2181063 chr20 22427370 C G 8.78E-05 Depression (quantitative trait) / / 20800221 rs2181063 chr20 22427370 C G 7.41E-04 Type 2 diabetes / / 22158537 rs6036116 chr20 22430350 T C 8.81E-05 Depression (quantitative trait) / / 20800221 rs6036116 chr20 22430350 T C 4.55E-04 Smoking initiation / / 24665060 rs11907086 chr20 22431290 A G 5.38E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs6048104 chr20 22436058 G A 8.38E-05 Depression (quantitative trait) / / 20800221 rs6048104 chr20 22436058 G A 8.35E-05 Type 2 diabetes / / 22158537 rs6048105 chr20 22436129 T G 8.35E-05 Depression (quantitative trait) / / 20800221 rs6048105 chr20 22436129 T G 1.03E-04 Type 2 diabetes / / 22158537 rs6036118 chr20 22440480 G T 1.00E-04 Depression (quantitative trait) / / 20800221 rs6036118 chr20 22440480 G T 9.34E-05 Type 2 diabetes / / 22158537 rs6036119 chr20 22441124 T C 9.89E-05 Depression (quantitative trait) / / 20800221 rs6036120 chr20 22441181 T C 9.85E-05 Depression (quantitative trait) / / 20800221 rs6048109 chr20 22441952 G C 9.55E-05 Depression (quantitative trait) / / 20800221 rs6048109 chr20 22441952 G C 1.21E-04 Type 2 diabetes / / 22158537 rs6048110 chr20 22441996 G A 6.55E-05 Depression (quantitative trait) / / 20800221 rs6048110 chr20 22441996 G A 8.02E-05 Type 2 diabetes / / 22158537 rs6036127 chr20 22445714 C T 9.52E-05 Depression (quantitative trait) / / 20800221 rs6036127 chr20 22445714 C T 4.32E-04 Type 2 diabetes / / 22158537 rs3935234 chr20 22447954 G C 9.66E-05 Depression (quantitative trait) / / 20800221 rs6082740 chr20 22521216 A G 9.25E-04 Multiple complex diseases / / 17554300 rs1203867 chr20 22531141 C T 6.70E-05 Thyroid stimulating hormone / / 24722205 rs6113722 chr20 22557099 G A 7.76E-13 Fasting blood glucose LINC00261 intron 22885924 rs6048205 chr20 22559601 A G 2.00E-12 Fasting glucose-related traits (interaction with BMI) / / 22581228 rs1209523 chr20 22567942 C T 2.20E-11 Fasting glucose-related traits / / 20152958 rs6048209 chr20 22571083 A G 1.40E-07 Fasting glucose-related traits / / 20152958 rs1203917 chr20 22576515 T C 4.00E-05 Vascular dementia / / 22116812 rs12106148 chr20 22578719 A C 8.56E-04 Multiple complex diseases / / 17554300 rs6036158 chr20 22581060 T C 3.15E-05 Vascular dementia / / 22116812 rs1203944 chr20 22596879 T C 9.41E-04 Type 2 diabetes / / 17463246 rs4815135 chr20 22644589 C G 6.20E-04 Type 2 diabetes / / 17463246 rs6137726 chr20 22672420 C A 9.00E-07 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2404490 chr20 22698972 C T 0.000000928 Ejection fraction / / 23275298 rs6132542 chr20 22703167 T C 8.81E-04 Type 2 diabetes / / 17463246 rs7262725 chr20 22711424 C T 2.80E-05 Urinary metabolites / / 21572414 rs17816810 chr20 22727849 C A 3.88E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs17754749 chr20 22732451 C T 1.85E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs6036213 chr20 22738735 C T 1.50E-05 Urinary metabolites / / 21572414 rs6048333 chr20 22738814 G A 1.50E-05 Urinary metabolites / / 21572414 rs2424460 chr20 22740897 T C 2.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs2424460 chr20 22740897 T C 3.00E-06 Smoking initiation / / 24665060 rs6048352 chr20 22780354 A G 7.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs12626120 chr20 22780715 G A 1.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs6048354 chr20 22780826 A G 1.22E-05 Alcohol consumption / / 23743675 rs8115044 chr20 22781262 C A 1.87E-05 Suicide attempts in bipolar disorder / / 21423239 rs11905714 chr20 22782125 A G 4.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs11907812 chr20 22782586 T C 3.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs16984513 chr20 22782904 T C 6.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs2404447 chr20 22783872 C T 5.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs7268645 chr20 22784953 C T 5.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs7272134 chr20 22786030 A G 5.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs16984521 chr20 22786316 G A 5.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs4815146 chr20 22786434 C T 1.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs11907997 chr20 22786890 C T 3.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs7267722 chr20 22787622 T C 3.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs7274781 chr20 22787713 G A 3.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs742850 chr20 22789681 C G 7.92E-05 Serum metabolites / / 19043545 rs17828161 chr20 22790772 T C 4.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs16984562 chr20 22792429 A G 7.47E-04 Multiple complex diseases / / 17554300 rs6048361 chr20 22792747 G A 9.72E-05 Serum metabolites / / 19043545 rs6048372 chr20 22804426 A G 7.92E-05 Serum metabolites / / 19043545 rs16984704 chr20 22846508 C T 2.27E-30 Narcolepsy / / 19629137 rs6075982 chr20 22887257 C T 3.00E-06 Obesity-related traits / / 23251661 rs6082932 chr20 22914887 G T 5.51E-06 Obesity-related traits / / 23251661 rs1331065 chr20 22918621 A G 3.61E-04 Multiple complex diseases / / 17554300 rs6082944 chr20 22935485 T C 4.90E-05 Monocyte chemoattractant protein-1 / / pha003071 rs869611 chr20 22939045 G A 6.42E-05 Osteoarthritis (knee and hip) / / 21177295 rs1360400 chr20 22961890 G A 7.32E-05 Response to hepatitis C treatment / / 19684573 rs1360400 chr20 22961890 G A 7.22E-06 Osteoarthritis / / 22763110 rs4290724 chr20 22966362 C A 9.14E-05 Response to hepatitis C treatment / / 19684573 rs2424494 chr20 22977175 T A 6.52E-04 Multiple complex diseases / / 17554300 rs2746619 chr20 22979563 A G 3.50E-04 Multiple complex diseases / / 17554300 rs1005920 chr20 22980470 T C 5.63E-04 Multiple complex diseases / / 17554300 rs11696134 chr20 23011468 A G 7.50E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs3176134 chr20 23028137 C T 6.98E-08 HDL cholesterol THBD UTR-3 23063622 rs191884040 chr20 23030102 C T 0.00029 Breast cancer THBD missense 23555315 rs13306848 chr20 23030343 C T 0.000000025 HDL cholesterol THBD nearGene-5 23063622 rs3176130 chr20 23031656 C T 2.00E-07 PR interval in Tripanosoma cruzi seropositivity THBD nearGene-5 24324551 rs1040585 chr20 23040066 C A 1.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs16984890 chr20 23045714 G T 6.01E-05 Suicide attempts in bipolar disorder / / 21423239 rs2424512 chr20 23045980 G A 9.81E-05 Suicide attempts in bipolar disorder / / 21423239 rs2424513 chr20 23046024 G A 6.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs2424514 chr20 23048633 A G 3.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs2424515 chr20 23048733 A G 4.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs2567617 chr20 23049547 G A 4.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs2749816 chr20 23049826 A C 5.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs2144940 chr20 23050806 C T 1.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs1998081 chr20 23057482 T C 3.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs1998082 chr20 23057678 T C 5.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs17682491 chr20 23057867 C T 1.10E-05 Urinary metabolites / / 21572414 rs17682515 chr20 23059279 A C 1.20E-05 Urinary metabolites / / 21572414 rs7492 chr20 23060257 A G 1.47E-04 Suicide attempts in bipolar disorder CD93 UTR-3 21423239 rs2749812 chr20 23062927 A G 2.85E-06 Brain structure CD93 UTR-3 22504417 rs3746732 chr20 23065342 A G 8.78E-05 Suicide attempts in bipolar disorder CD93 cds-synon 21423239 rs1884654 chr20 23069201 A T 1.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs6036306 chr20 23074031 C G 3.10E-04 Suicide attempts in bipolar disorder / / 21423239 rs1884655 chr20 23074375 G A 1.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs844808 chr20 23075036 C A 5.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs844813 chr20 23078996 C T 5.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs6083004 chr20 23080369 A C 1.57E-06 Obesity-related traits / / 23251661 rs844820 chr20 23082108 A G 6.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs844824 chr20 23082817 G C 1.10E-04 Multiple complex diseases / / 17554300 rs844824 chr20 23082817 G C 1.93E-05 Suicide attempts in bipolar disorder / / 21423239 rs1884657 chr20 23083437 T C 1.35E-05 Suicide attempts in bipolar disorder / / 21423239 rs844832 chr20 23085858 G A 3.80E-05 Suicide attempts in bipolar disorder / / 21423239 rs844833 chr20 23086083 T C 1.21E-05 Suicide attempts in bipolar disorder / / 21423239 rs844834 chr20 23086504 T C 1.74E-05 Suicide attempts in bipolar disorder / / 21423239 rs844835 chr20 23086772 C G 1.78E-05 Suicide attempts in bipolar disorder / / 21423239 rs844836 chr20 23087160 T C 1.81E-05 Suicide attempts in bipolar disorder / / 21423239 rs844837 chr20 23088815 A G 1.80E-05 Suicide attempts in bipolar disorder / / 21423239 rs844838 chr20 23088876 G T 1.93E-05 Suicide attempts in bipolar disorder / / 21423239 rs844839 chr20 23090092 C T 3.59E-05 Suicide attempts in bipolar disorder / / 21423239 rs844841 chr20 23090339 G A 3.71E-05 Suicide attempts in bipolar disorder / / 21423239 rs844844 chr20 23092353 T A,C,G 4.82E-05 Suicide attempts in bipolar disorder / / 21423239 rs844847 chr20 23092700 A G 8.80E-05 Multiple complex diseases / / 17554300 rs844847 chr20 23092700 A G 2.76E-05 Suicide attempts in bipolar disorder / / 21423239 rs844849 chr20 23093456 A G 2.97E-05 Suicide attempts in bipolar disorder / / 21423239 rs1320561 chr20 23097880 G A 8.06E-04 Alcohol dependence / / 21314694 rs1320561 chr20 23097880 G A 1.00E-06 Obesity-related traits / / 23251661 rs844867 chr20 23100202 A G 3.14E-04 Multiple complex diseases / / 17554300 rs844867 chr20 23100202 A G 3.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs844882 chr20 23104521 C T 7.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs844885 chr20 23105180 A G 3.22E-04 Multiple complex diseases / / 17554300 rs844885 chr20 23105180 A G 7.25E-05 Suicide attempts in bipolar disorder / / 21423239 rs844886 chr20 23105844 T A 2.09E-04 Multiple complex diseases / / 17554300 rs844886 chr20 23105844 T A 5.26E-05 Suicide attempts in bipolar disorder / / 21423239 rs844887 chr20 23106084 A G 5.26E-05 Suicide attempts in bipolar disorder / / 21423239 rs844888 chr20 23106737 T C 5.77E-04 Multiple complex diseases / / 17554300 rs844888 chr20 23106737 T C 5.26E-05 Suicide attempts in bipolar disorder / / 21423239 rs844889 chr20 23106879 T C 4.73E-05 Suicide attempts in bipolar disorder / / 21423239 rs844891 chr20 23109883 C G 1.67E-04 Suicide attempts in bipolar disorder LOC200261 intron 21423239 rs844892 chr20 23110808 C T 2.13E-04 Suicide attempts in bipolar disorder LOC200261 intron 21423239 rs844895 chr20 23113092 T C 6.97E-04 Suicide attempts in bipolar disorder LOC200261 intron 21423239 rs699796 chr20 23113445 C T 7.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs699797 chr20 23113454 A G 7.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs699798 chr20 23114248 A T 8.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs946371 chr20 23129794 A T 0.0000156 LDL cholesterol particle diameter / / 23263444 rs844906 chr20 23132057 C T 1.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs844909 chr20 23133689 G T 4.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs844910 chr20 23137436 T C 4.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs844914 chr20 23141445 A C 5.98E-06 Liver enzyme levels (alanine transaminase) / / 24124411 rs844917 chr20 23141655 T C 6.00E-06 Liver enzyme levels (alanine transaminase) / / 24124411 rs6083025 chr20 23144070 G A 6.90E-04 Type 2 diabetes / / 17463246 rs6076033 chr20 23144098 A G 5.94E-04 Type 2 diabetes / / 17463246 rs6083026 chr20 23145255 G A 5.00E-04 Type 2 diabetes / / 17463246 rs6137866 chr20 23179989 G A 4.10E-04 Stroke / / pha002887 rs6083035 chr20 23181354 T C 7.12E-04 Stroke / / pha002887 rs6048646 chr20 23241767 G A,C 2.53E-04 Multiple complex diseases / / 17554300 rs1573172 chr20 23261339 T C 2.55E-04 Multiple complex diseases / / 17554300 rs4815191 chr20 23268637 T C 6.00E-06 Obesity-related traits / / 23251661 rs4815192 chr20 23271822 G T 1.39E-05 Bone mineral traits,in men / / 21427758 rs4815192 chr20 23271822 G T 6.45E-05 Bone mineral traits,in men / / 21427758 rs4815192 chr20 23271822 G T 9.81E-05 Bone mineral traits,in men / / 21427758 rs2995719 chr20 23296320 T C 5.66E-05 Serum metabolites / / 19043545 rs2995720 chr20 23296874 G A 3.79E-04 Multiple complex diseases / / 17554300 rs2995720 chr20 23296874 G A 1.65E-05 Serum metabolites / / 19043545 rs2995722 chr20 23297320 A G 7.12E-04 Multiple complex diseases / / 17554300 rs1984279 chr20 23313192 A C 3.89E-05 Parkinson's disease / / 16252231 rs2153987 chr20 23322400 C T 5.44E-06 Age-related macular degeneration / / pha000002 rs2066451 chr20 23324651 A G 6.64E-05 Heart Rate / / pha003054 rs1419008 chr20 23351889 C T 8.29E-04 Suicide attempts in bipolar disorder GZF1 UTR-3 21423239 rs1419008 chr20 23351889 C T 2.29E-05 Body Mass Index GZF1 UTR-3 pha003007 rs1419008 chr20 23351889 C T 5.60E-05 Weight GZF1 UTR-3 pha003026 rs1419008 chr20 23351889 C T 1.42E-05 Weight GZF1 UTR-3 pha003027 rs16985303 chr20 23358358 T C 1.41E-04 Insulin resistance /PB intron 21901158 rs2243448 chr20 23378345 G A 4.05E-04 Parkinson's disease /PB intron 16252231 rs6132607 chr20 23390373 G C 6.98E-04 Parkinson's disease /PB intron 16252231 rs6076072 chr20 23406519 A C 2.20E-05 Suicide attempts in bipolar disorder / / 21423239 rs12625994 chr20 23419312 C T 7.21E-05 Insulin resistance / / 21901158 rs3746736 chr20 23424613 T C 1.30E-05 Parkinson's disease CSTL1 missense 16252231 rs1076776 chr20 23427399 A G 9.53E-04 Alzheimer's disease / / 17998437 rs6114094 chr20 23434267 T C 5.76E-04 Type 2 diabetes / / 17463246 rs6114100 chr20 23445597 G A 6.62E-04 Type 2 diabetes / / 17463246 rs6036424 chr20 23459976 G T 1.87E-04 Type 2 diabetes / / 17463246 rs6114142 chr20 23461082 A G 1.02E-04 Type 2 diabetes / / 17463246 rs6137975 chr20 23461778 C T 1.63E-04 Type 2 diabetes / / 17463246 rs3004119 chr20 23489678 C T 1.61E-06 Sickle cell anemia (severity) / / 20029952 rs6076080 chr20 23491778 C T 8.81E-06 Suicide attempts in bipolar disorder / / 21423239 rs6076082 chr20 23516958 G A 8.88E-04 Multiple complex diseases CSTT intron 17554300 rs1555356 chr20 23524713 A C 6.75E-04 Tourette syndrome / / 22889924 rs6048891 chr20 23551375 G A 4.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4346460 chr20 23569400 C T 7.50E-05 Blood Pressure / / pha002898 rs6036461 chr20 23576754 G C 1.76E-05 Multiple complex diseases / / 17554300 rs6048920 chr20 23576844 T C 2.24E-05 Multiple complex diseases / / 17554300 rs4815222 chr20 23576964 G A 1.42E-04 Multiple complex diseases / / 17554300 rs1158167 chr20 23578189 G A 9.00E-09 Cystatin C / / 17903292 rs1158167 chr20 23578189 G A 6.50E-04 Volumetric brain MRI / / 17903297 rs3004139 chr20 23578674 C T 2.18E-23 Plasma cystastin c levels in acute coronary syndrome / / 24952865 rs2208289 chr20 23579526 A G 1.74E-04 Multiple complex diseases / / 17554300 rs3004145 chr20 23582876 C G 1.23E-04 Multiple complex diseases / / 17554300 rs13037490 chr20 23583725 T C 1.10E-24 Plasma cystastin c levels in acute coronary syndrome CST9 UTR-3 24952865 rs726217 chr20 23584116 G A 3.10E-04 Kidney function and endocine traits CST9 UTR-3 17903292 rs13043610 chr20 23586941 G A 4.32E-25 Plasma cystastin c levels in acute coronary syndrome / / 24952865 rs6036465 chr20 23588003 G T 2.93E-04 Multiple complex diseases / / 17554300 rs17751897 chr20 23592714 T C 6.20E-25 Plasma cystastin c levels in acute coronary syndrome / / 24952865 rs2983644 chr20 23592966 C A 1.00E-11 Plasma cystastin c levels in acute coronary syndrome / / 24952865 rs6048933 chr20 23595637 T G 1.27E-25 Plasma cystastin c levels in acute coronary syndrome / / 24952865 rs6048946 chr20 23602307 G T 1.29E-25 Plasma cystastin c levels in acute coronary syndrome / / 24952865 rs1011226 chr20 23605833 A C 1.93E-04 Multiple complex diseases / / 17554300 rs12625716 chr20 23606845 G A 2.43E-04 Multiple complex diseases / / 17554300 rs6048952 chr20 23607257 A G 4.85E-26 Plasma cystastin c levels in acute coronary syndrome / / 24952865 rs911119 chr20 23612737 C T 2.00E-138 Chronic kidney disease / / 20383146 rs35610040 chr20 23616469 T C 1.00E-26 Plasma cystastin c levels in acute coronary syndrome CST3 intron 24952865 rs3827143 chr20 23619617 A G 4.95E-26 Plasma cystastin c levels in acute coronary syndrome CST3 nearGene-5 24952865 rs2424582 chr20 23622550 G A 2.76E-05 Multiple complex diseases / / 17554300 rs2145231 chr20 23625547 G A 1.10E-05 Kidney function and endocine traits / / 17903292 rs911122 chr20 23625746 G A 1.36E-04 Multiple complex diseases / / 17554300 rs2424591 chr20 23637093 G T 2.12E-16 Plasma cystastin c levels in acute coronary syndrome / / 24952865 rs16985615 chr20 23642427 T C 4.00E-07 Plasma cystastin c levels in acute coronary syndrome / / 24952865 rs3004153 chr20 23642458 G A 1.70E-12 Plasma cystastin c levels in acute coronary syndrome / / 24952865 rs1884861 chr20 23647482 G C 7.13E-04 Type 2 diabetes / / 17463246 rs4134385 chr20 23725019 A G 4.93E-06 Alcohol dependence / / 23089632 rs6036517 chr20 23737359 C T 7.76E-04 Multiple complex diseases / / 17554300 rs6138060 chr20 23746867 C G 4.50E-06 Digit length ratio / / 20303062 rs6049097 chr20 23753552 C T 4.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6132660 chr20 23763450 A G 4.85E-04 Multiple complex diseases / / 17554300 rs8126263 chr20 23766277 C T 5.66E-06 Alcohol withdrawal symptoms / / 22072270 rs6049130 chr20 23776643 C G,T 9.40E-04 Multiple complex diseases / / 17554300 rs6083269 chr20 23785807 A G 4.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6076132 chr20 23801747 A C 6.74E-04 Celiac disease / / 23936387 rs4407312 chr20 23807028 A C 5.00E-18 Progranulin levels CST2 intron 21087763 rs4407312 chr20 23807028 A C 5.00E-18 Myocardial infarction CST2 intron 21211798 rs8182947 chr20 23811186 T C 2.67E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs6114326 chr20 23815299 C T 8.63E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6138150 chr20 23847009 T C 3.00E-06 Response to TNF antagonist treatment / / 18615156 rs2071445 chr20 23857982 A G 7.23E-04 Obesity (extreme) CST5 intron 21935397 rs2071443 chr20 23859753 C T 7.26E-04 Obesity (extreme) CST5 intron 21935397 rs6076157 chr20 23862844 G A 7.10E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6076157 chr20 23862844 G A 8.33E-05 Prostate cancer / / pha002878 rs6083315 chr20 23863795 G A 7.52E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs6049203 chr20 23865477 C T 3.85E-06 IgE levels / / 22075330 rs6049205 chr20 23867670 A G 3.87E-06 IgE levels / / 22075330 rs4074167 chr20 23868926 G C 4.37E-06 IgE levels / / 22075330 rs6138158 chr20 23872072 A G 4.22E-06 IgE levels / / 22075330 rs13037793 chr20 23872373 A T 1.36E-05 IgE levels / / 22075330 rs6138159 chr20 23873518 A G 4.24E-04 Schizophrenia / / 19197363 rs6138159 chr20 23873518 A G 4.11E-06 IgE levels / / 22075330 rs6036568 chr20 23883788 A G 4.00E-06 IgE levels / / 22075330 rs6049224 chr20 23889307 G C 3.91E-06 IgE levels / / 22075330 rs6049227 chr20 23891497 G C 5.90E-06 IgE levels / / 22075330 rs6083320 chr20 23891641 G A 9.28E-06 IgE levels / / 22075330 rs1857051 chr20 23893840 A T 2.95E-05 IgE levels / / 22075330 rs2995108 chr20 23894550 G A 3.09E-05 IgE levels / / 22075330 rs2257471 chr20 23914024 T C 3.32E-04 Type 2 diabetes / / 17846125 rs9967923 chr20 23953078 G A 4.28E-05 Multiple complex diseases / / 17554300 rs3887942 chr20 23977072 A G 1.00E-05 Parkinson's disease (age of onset) / / 19772629 rs6036602 chr20 23981505 G T 0.000605 Salmonella-induced pyroptosis / / 22837397 rs6049352 chr20 24019472 A T 5.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs16986203 chr20 24047323 G A 7.18E-05 Biliary atresia / / 20460270 rs6049375 chr20 24058407 C T 8.00E-06 Erectile dysfunction and prostate cancer treatment / / 20932654 rs6036635 chr20 24063534 C A 4.25E-05 Multiple complex diseases / / 17554300 rs6049385 chr20 24073964 T C 4.70E-06 Urinary metabolites / / 21572414 rs6036642 chr20 24079492 A C 5.40E-06 Urinary metabolites / / 21572414 rs1555286 chr20 24118582 G A 8.20E-04 Insulin response / / 19430760 rs6049436 chr20 24130700 T C 9.64E-06 Multiple complex diseases / / 17554300 rs2208014 chr20 24146378 T C 8.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs11698401 chr20 24164937 C T 1.24E-04 Alzheimer's disease (late onset) / / 21379329 rs224159 chr20 24180615 T C 8.07E-04 Suicide attempts in bipolar disorder FLJ33581 intron 21041247 rs858064 chr20 24220241 T G 1.41E-04 Sarcoidosis / / 19165924 rs858063 chr20 24220574 G A 7.38E-05 Body Mass Index / / pha003021 rs224786 chr20 24248344 C T 7.26E-04 Type 2 diabetes / / 17463246 rs224791 chr20 24261606 T C 9.36E-05 Body Composition / / pha003012 rs6106837 chr20 24284845 A T 6.21E-05 Sarcoidosis / / 19165924 rs6036736 chr20 24303066 T C 2.64E-04 Multiple complex diseases / / 17554300 rs8116738 chr20 24317910 G A 6.61E-05 Glucose levels / / pha003057 rs1016591 chr20 24343834 G A 1.36E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs6114701 chr20 24394569 C T 1.97E-05 Cognitive test performance / / 20125193 rs6138298 chr20 24428285 C A 2.40E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs6114735 chr20 24445155 A G 2.08E-04 Vaspin levels / / 22907691 rs6114735 chr20 24445155 A G 0.0002077 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs6049735 chr20 24471903 A G 8.58E-05 Schizophrenia SYNDIG1 intron 24253340 rs11907737 chr20 24472761 G A 7.24E-04 Type 2 diabetes SYNDIG1 intron 17463246 rs13041233 chr20 24503530 A G 0.000207315 Hypertension (early onset hypertension) SYNDIG1 intron 22479346 rs6114760 chr20 24515211 C T 0.000711642 Hypertension (early onset hypertension) SYNDIG1 intron 22479346 rs1326298 chr20 24532613 C T 4.48E-04 HIV-1 viral setpoint SYNDIG1 intron 17641165 rs8126241 chr20 24546861 C T 7.43E-04 Depression (quantitative trait) SYNDIG1 intron 20800221 rs17250061 chr20 24556797 T C 4.85E-04 HIV-1 viral setpoint SYNDIG1 intron 17641165 rs6049811 chr20 24589790 T G 9.71E-04 Alcohol dependence SYNDIG1 intron 21314694 rs17823746 chr20 24591028 G A 4.36E-05 HIV-1 viral setpoint SYNDIG1 intron 17641165 rs4815286 chr20 24597696 C T 1.89E-04 HIV-1 viral setpoint SYNDIG1 intron 17641165 rs13038938 chr20 24601943 A C 1.30E-05 Urinary metabolites SYNDIG1 intron 21572414 rs1883924 chr20 24609645 A G 4.31E-05 Pancreatic cancer SYNDIG1 intron pha002874 rs4813524 chr20 24612808 G A 6.58E-05 HIV-1 viral setpoint SYNDIG1 intron 17641165 rs11699457 chr20 24615239 G A 2.00E-04 Dietary macronutrient intake SYNDIG1 intron 23636237 rs2179800 chr20 24616339 A G 7.10E-05 Serum metabolites SYNDIG1 intron 19043545 rs77759768 chr20 24622871 A C 6.81E-06 Personality dimensions SYNDIG1 intron 23658558 rs6114812 chr20 24623774 T G 3.25E-04 HIV-1 viral setpoint SYNDIG1 intron 17641165 rs6049829 chr20 24629040 G A 2.24E-04 HIV-1 viral setpoint SYNDIG1 intron 17641165 rs6049834 chr20 24636082 G A 2.46E-04 HIV-1 viral setpoint SYNDIG1 intron 17641165 rs761440 chr20 24656927 T C 9.65E-04 Depression (quantitative trait) / / 20800221 rs6036896 chr20 24713912 G A 9.98E-04 Alzheimer's disease / / 22005930 rs6036896 chr20 24713912 G A 4.81E-04 Myocardial Infarction / / pha002873 rs714689 chr20 24714340 C T 9.73E-04 Alzheimer's disease / / 22005930 rs2424631 chr20 24716288 A C 8.30E-05 Bipolar disorder and schizophrenia / / 20889312 rs2424635 chr20 24717085 C A 7.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs6083603 chr20 24727733 A G 3.48E-04 Multiple complex diseases / / 17554300 rs2424676 chr20 24742663 G A 8.51E-05 Orofacial clefts / / 20023658 rs2892219 chr20 24747488 A G 7.00E-04 Multiple complex diseases / / 17554300 rs2424681 chr20 24748829 T C 2.79E-05 Post-operative nausea and vomiting / / 21694509 rs1000042 chr20 24758596 C T 8.81E-04 Multiple complex diseases / / 17554300 rs12624499 chr20 24763590 C A 5.64E-05 Suicide attempts in bipolar disorder / / 21423239 rs6076283 chr20 24800969 T C 2.90E-05 Post-operative nausea and vomiting / / 21694509 rs6036924 chr20 24811468 G A 5.42E-04 Type 2 diabetes / / 17463246 rs6050013 chr20 24812054 T C 6.73E-04 Multiple complex diseases / / 17554300 rs11698140 chr20 24838577 G A 9.12E-04 Multiple complex diseases / / 17554300 rs11700219 chr20 24840164 A G 1.12E-04 Iron levels / / pha002876 rs6050129 chr20 24898485 G A 8.82E-05 Platelet counts / / pha003100 rs6050170 chr20 24917052 C T 1.72E-04 Multiple complex diseases / / 17554300 rs227653 chr20 24930085 G A 6.40E-04 Cholesterol CST7 UTR-5 17255346 rs11697253 chr20 24995014 A G 1.28E-31 Narcolepsy ACSS1 intron 19629137 rs6138466 chr20 24997137 A G 1.24E-04 Cholesterol ACSS1 intron 17255346 rs6050259 chr20 25011423 T C 2.36E-04 Hearing function ACSS1 cds-synon 17255346 rs6050259 chr20 25011423 T C 0.0000018 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) ACSS1 cds-synon 23080225 rs6138473 chr20 25012155 C T 5.30E-15 Progranulin levels ACSS1 intron 21087763 rs6138473 chr20 25012155 C T 5.30E-15 Myocardial infarction ACSS1 intron 21211798 rs6132789 chr20 25012809 T C 3.61E-04 Hearing function ACSS1 intron 17255346 rs6050267 chr20 25019099 G A 9.00E-06 Cognitive performance ACSS1 intron 20125193 rs8114108 chr20 25032075 T C 0.0000315 Alcohol craving with or without dependence ACSS1 intron 22481050 rs6037013 chr20 25040884 C T 5.75E-04 Multiple complex diseases / / 17554300 rs6050312 chr20 25070097 T A 9.91E-04 Multiple complex diseases / / 17554300 rs2207634 chr20 25071454 G A 8.99E-04 Multiple complex diseases / / 17554300 rs6076316 chr20 25072682 G T 5.12E-05 Post-operative nausea and vomiting / / 21694509 rs4815375 chr20 25108383 A G 6.69E-04 Multiple complex diseases / / 17554300 rs6050372 chr20 25133225 A G 6.09E-04 Parkinson's disease / / 17052657 rs6050379 chr20 25136824 A G 4.70E-04 Parkinson's disease / / 17052657 rs11087499 chr20 25138922 T C 3.51E-04 Multiple complex diseases / / 17554300 rs2268879 chr20 25177805 T C 8.09E-05 Information processing speed ENTPD6 intron 21130836 rs6115089 chr20 25193849 C A 0.0000904 Type 2 diabetes ENTPD6 intron 22325160 rs2073077 chr20 25195913 T C 0.000375 Type 2 diabetes ENTPD6 intron 22325160 rs1044573 chr20 25206654 A G 1.00E-06 Allergic rhinitis ENTPD6 UTR-3 22036096 rs8119343 chr20 25220536 C T 9.35E-05 HDL cholesterol / / pha003075 rs2281558 chr20 25240189 G T 5.00E-06 Calcium levels PYGB intron 24068962 rs2474772 chr20 25250163 G A 3.32E-05 Multiple complex diseases PYGB intron 17554300 rs139672965 chr20 25266900 G A 8.00E-06 Serum dimethylarginine levels (asymmetric) PYGB intron 24159190 rs2297497 chr20 25297909 G A 4.59E-08 Lymphocyte counts ABHD12 intron 22286170 rs7267979 chr20 25298087 A G 7.00E-10 Liver enzyme levels (alkaline phosphatase) ABHD12 intron 22001757 rs4815412 chr20 25350325 G A 4.53E-04 Lymphocyte counts ABHD12 intron 22286170 rs6076347 chr20 25398790 G A 3.80E-04 Insulin response GINS1 missense 19430760 rs6115178 chr20 25400154 C T 7.61E-05 HDL cholesterol GINS1 intron pha003075 rs146288604 chr20 25457055 A G 0.0000095 Breast cancer (ER positive) NINL missense 23555315 rs146288604 chr20 25457055 A G 0.000081 Breast cancer NINL missense 23555315 rs7272126 chr20 25488884 C T 3.11E-05 HDL cholesterol NINL intron pha003075 rs16987806 chr20 25492190 C T 6.07E-05 HDL cholesterol NINL intron pha003075 rs6138600 chr20 25521346 A T 2.44E-04 Aortic root size NINL intron 21223598 rs4815436 chr20 25573423 G A 3.50E-07 Urinary metabolites / / 21572414 rs4815436 chr20 25573423 G A 9.40E-04 Pulmonary function / / 23932459 rs242127 chr20 25584535 T C 1.80E-06 Urinary metabolites / / 21572414 rs6083897 chr20 25585911 A C 1.30E-06 Urinary metabolites / / 21572414 rs958075 chr20 25595123 G A 6.77E-05 Pulmonary function /NP UTR-3 20010835 rs8120594 chr20 25599655 A G 1.52E-09 Esophageal cancer /NP intron 21642993 rs6115275 chr20 25720354 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2185914 chr20 25844993 A C 3.47E-04 Multiple complex diseases / / 17554300 rs6107104 chr20 25922993 G A 2.08E-04 Glycosylated haemoglobin levels / / 17255346 rs6138769 chr20 25966617 C T 8.41E-04 Multiple complex diseases / / 17554300 rs845984 chr20 26137161 G A 1.54E-04 Insulin resistance / / 21901158 rs845982 chr20 26146163 C T 4.84E-05 Blood Pressure / / pha003043 rs845785 chr20 26194104 G A 2.65E-05 HDL particle features / / pha002900 rs845789 chr20 26198853 C A 2.59E-05 HDL particle features / / pha002900 rs845796 chr20 26225145 T C 8.73E-05 Blood Pressure / / pha003043 rs1307632 chr20 26266313 A T 2.42E-04 Type 2 diabetes / / 17463246 rs2180584 chr20 29445644 G A 3.27E-05 Post-operative nausea and vomiting / / 21694509 rs6119158 chr20 29461957 C A 2.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs6119169 chr20 29478157 C T 3.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs6119184 chr20 29485754 T A 4.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs6119059 chr20 29586147 T C 4.75E-05 Height / / 22021425 rs6060617 chr20 29849652 G T 1.46E-04 Parkinson's disease / / 21248740 rs6121224 chr20 29860684 A G 1.77E-04 Parkinson's disease / / 21248740 rs6141273 chr20 29904377 G A 5.70E-05 Coronary heart disease / / 24778558 rs17247853 chr20 29911380 T C 6.90E-05 Tunica Media / / pha003037 rs17248462 chr20 29955447 G A 4.92E-04 Multiple complex diseases / / 17554300 rs6057657 chr20 29963830 A G 2.77E-05 Parkinson's disease / / 21248740 rs6059244 chr20 30010483 A G 4.80E-05 Alzheimer's disease (late onset) DEFB122 intron 20885792 rs6059244 chr20 30010483 A G 4.80E-05 Alzheimer's disease (late onset) DEFB122 intron 21460841 rs2180566 chr20 30018854 C T 3.80E-05 Alzheimer's disease (late onset) / / 20885792 rs2180566 chr20 30018854 C T 3.80E-05 Alzheimer's disease (late onset) / / 21460841 rs3761199 chr20 30062456 C G 8.07E-05 Serum metabolites / / 19043545 rs717064 chr20 30066356 G T 7.77E-05 Lung adenocarcinoma REM1 intron 19836008 rs6058022 chr20 30109829 G A 1.18E-04 Arthritis (juvenile idiopathic) HM13 intron 22354554 rs6059980 chr20 30147145 C G 1.74E-04 Arthritis (juvenile idiopathic) HM13 intron 22354554 rs11906851 chr20 30154237 G C 1.24E-04 Arthritis (juvenile idiopathic) HM13 intron 22354554 rs6120719 chr20 30156378 T G 5.28E-05 Arthritis (juvenile idiopathic) HM13 intron 22354554 rs2889488 chr20 30185758 G A 8.68E-07 Red blood cell traits / / 23222517 rs6058189 chr20 30192389 A G 9.17E-07 Red blood cell traits ID1 nearGene-5 23222517 rs6058197 chr20 30194899 A G 9.40E-07 Red blood cell traits MIR3193 nearGene-5 23222517 rs6060286 chr20 30197663 C A 6.77E-07 Red blood cell traits / / 23222517 rs6060323 chr20 30204156 C T 8.93E-07 Red blood cell traits / / 23222517 rs6060344 chr20 30207316 A G 8.87E-07 Red blood cell traits / / 23222517 rs6060359 chr20 30209740 A G 7.77E-07 Red blood cell traits / / 23222517 rs6088793 chr20 30211597 T C 7.50E-07 Red blood cell traits / / 23222517 rs6087700 chr20 30217560 A G 7.11E-07 Red blood cell traits / / 23222517 rs6120937 chr20 30219721 C T 5.78E-07 Red blood cell traits / / 23222517 rs7266471 chr20 30220599 T A 5.37E-07 Red blood cell traits / / 23222517 rs6060399 chr20 30220823 C T 5.04E-07 Red blood cell traits / / 23222517 rs6119651 chr20 30259246 C A 9.77E-04 Multiple complex diseases BCL2L1 intron 17554300 rs6060627 chr20 30262159 C T 6.45E-07 Telomere length BCL2L1 intron 23900074 rs6060633 chr20 30263317 G T 1.72E-05 Telomere length BCL2L1 intron 23900074 rs6060652 chr20 30266845 A G 9.53E-07 Telomere length BCL2L1 intron 23900074 rs6088962 chr20 30268184 C T 7.51E-07 Red blood cell traits BCL2L1 intron 23222517 rs6060763 chr20 30282223 T C 5.63E-04 Multiple complex diseases BCL2L1 intron 17554300 rs6060763 chr20 30282223 T C 2.22E-05 Telomere length BCL2L1 intron 23900074 rs6060812 chr20 30292803 C T 1.73E-05 Telomere length BCL2L1 intron 23900074 rs6060821 chr20 30294034 G A 9.72E-04 Multiple complex diseases BCL2L1 intron 17554300 rs6089070 chr20 30377773 G A 9.30E-04 Multiple complex diseases TPX2 intron 17554300 rs6089071 chr20 30378384 C G 9.75E-04 Multiple complex diseases TPX2 intron 17554300 rs6060960 chr20 30394517 A C 5.92E-04 Multiple complex diseases / / 17554300 rs11908397 chr20 30410311 G A 0.000000884 LDL cholesterol MYLK2 intron 23063622 rs6119729 chr20 30413163 C T 6.90E-04 Multiple complex diseases MYLK2 intron 17554300 rs6058470 chr20 30416827 A T 9.18E-04 Multiple complex diseases MYLK2 intron 17554300 rs17341431 chr20 30506121 A G 8.66E-04 Obesity (extreme) TTLL9 intron 21935397 rs7271152 chr20 30506673 C A 4.34E-04 Suicide attempts in bipolar disorder TTLL9 intron 21423239 rs6061032 chr20 30511108 G A 2.34E-04 Suicide attempts in bipolar disorder TTLL9 intron 21423239 rs6061036 chr20 30518568 G A 4.69E-04 Suicide attempts in bipolar disorder TTLL9 intron 21423239 rs6089122 chr20 30521932 A G 5.11E-04 Suicide attempts in bipolar disorder TTLL9 intron 21423239 rs6089122 chr20 30521932 A G 8.37E-04 White matter integrity TTLL9 intron 22425255 rs6061043 chr20 30527065 T C 7.32E-05 Suicide attempts in bipolar disorder TTLL9 cds-synon 21423239 rs6061043 chr20 30527065 T C 2.20E-05 Asthma (bronchodilator response) TTLL9 cds-synon 22792082 rs6061045 chr20 30532043 A G 9.15E-05 Suicide attempts in bipolar disorder / / 21423239 rs6061046 chr20 30532709 T C 8.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs6061046 chr20 30532709 T C 1.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs6089127 chr20 30533949 A G 1.16E-04 Suicide attempts in bipolar disorder PDRG1 intron 21423239 rs6061062 chr20 30552100 G A 9.73E-05 Basophils / / pha003087 rs6119747 chr20 30565696 T G 9.22E-04 Multiple complex diseases XKR7 intron 17554300 rs140563493 chr20 30610508 A T 0.000087 Prostate cancer (advanced) C20orf160 missense 23555315 rs242609 chr20 30673424 C T 7.27E-04 Multiple complex diseases HCK intron 17554300 rs6089170 chr20 30677208 C T 6.79E-08 Metabolite levels HCK intron 23281178 rs926688 chr20 30680338 G T 6.71E-08 Metabolite levels HCK intron 23281178 rs980368 chr20 30681543 A G 6.71E-08 Metabolite levels HCK intron 23281178 rs6121337 chr20 30681999 T C 6.71E-08 Metabolite levels HCK intron 23281178 rs7271281 chr20 30716979 T C 1.60E-05 Urinary metabolites TM9SF4 intron 21572414 rs6142618 chr20 30725648 A G 6.00E-10 Inflammatory bowel disease TM9SF4 intron 23128233 rs4911198 chr20 30727683 C T 3.72E-04 Multiple complex diseases TM9SF4 intron 17554300 rs6061194 chr20 30745269 A G 1.10E-05 Urinary metabolites TM9SF4 intron 21572414 rs2424887 chr20 30992291 G A 5.80E-05 Personality dimensions ASXL1 intron 18957941 rs875519 chr20 31091235 T C 9.39E-04 Amyotrophic Lateral Sclerosis C20orf112 intron 17827064 rs11697969 chr20 31239298 A G 1.25E-04 Multiple complex diseases C20orf203 intron 17554300 rs2424898 chr20 31339261 T C 0.000269904 Hypertension (early onset hypertension) / / 22479346 rs2424908 chr20 31360383 C T 5.10E-05 Eosinophil counts DNMT3B intron pha003088 rs6119954 chr20 31364166 G A 2.60E-05 Urinary metabolites DNMT3B intron 21572414 rs6141813 chr20 31366243 A G 9.55E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) DNMT3B intron 23648065 rs2424913 chr20 31374259 C T 5.40E-06 Alcohol and nictotine co-dependence DNMT3B intron 22488850 rs4911259 chr20 31376282 T G 3.49E-04 Type 2 diabetes DNMT3B intron 17463246 rs4911259 chr20 31376282 T G 1.00E-09 Inflammatory bowel disease DNMT3B intron 23128233 rs6119285 chr20 31376995 C T 4.00E-06 Attention deficit hyperactivity disorder (combined symptoms) DNMT3B intron 23527680 rs6057648 chr20 31384880 C A 4.00E-06 Attention deficit hyperactivity disorder (combined symptoms) DNMT3B intron 23527680 rs6058893 chr20 31392777 C T 8.40E-04 Type 2 diabetes DNMT3B intron 17463246 rs6119286 chr20 31395477 G A 4.00E-06 Attention deficit hyperactivity disorder (combined symptoms) DNMT3B intron 23527680 rs2424932 chr20 31396536 A G 3.41E-04 Coronary heart disease DNMT3B UTR-3 21971053 rs6058897 chr20 31398105 A C 9.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs437302 chr20 31398368 G A 4.65E-05 Major depressive disorder / / 21621269 rs437302 chr20 31398368 G A 6.98E-05 Major depressive disorder / / pha002850 rs8118663 chr20 31398876 A G 1.60E-04 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs853858 chr20 31402217 G A 7.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs853858 chr20 31402217 G A 6.99E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs17123673 chr20 31409605 A G 4.56E-04 Smoking cessation MAPRE1 intron 24665060 rs242551 chr20 31409792 T C 4.97E-04 Suicide attempts in bipolar disorder MAPRE1 intron 21423239 rs187178 chr20 31410279 A G 4.88E-04 Suicide attempts in bipolar disorder MAPRE1 intron 21423239 rs6057651 chr20 31410337 G A 4.00E-06 Attention deficit hyperactivity disorder (combined symptoms) MAPRE1 intron 23527680 rs6057651 chr20 31410337 G A 7.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) MAPRE1 intron 23527680 rs242553 chr20 31411825 T C 5.02E-04 Suicide attempts in bipolar disorder MAPRE1 intron 21423239 rs6057652 chr20 31419809 A C 4.00E-06 Attention deficit hyperactivity disorder (combined symptoms) MAPRE1 intron 23527680 rs6057652 chr20 31419809 A C 7.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) MAPRE1 intron 23527680 rs410488 chr20 31425069 A G 7.65E-04 Type 2 diabetes MAPRE1 intron 17463246 rs410488 chr20 31425069 A G 7.60E-04 Suicide attempts in bipolar disorder MAPRE1 intron 21423239 rs2235760 chr20 31427342 C T 4.00E-06 Urinary metabolites MAPRE1 intron 21572414 rs2070090 chr20 31427635 C T 2.64E-04 Schizophrenia(treatment response to risperidone) MAPRE1 cds-synon 19850283 rs709047 chr20 31430191 A G 4.05E-04 Suicide attempts in bipolar disorder MAPRE1 intron 21423239 rs242535 chr20 31433190 C T 4.35E-04 Suicide attempts in bipolar disorder MAPRE1 intron 21423239 rs242535 chr20 31433190 C T 1.40E-05 Urinary metabolites MAPRE1 intron 21572414 rs242536 chr20 31435260 T G 4.73E-04 Suicide attempts in bipolar disorder MAPRE1 intron 21423239 rs242536 chr20 31435260 T G 1.60E-05 Urinary metabolites MAPRE1 intron 21572414 rs242538 chr20 31436747 C T 4.59E-04 Suicide attempts in bipolar disorder MAPRE1 UTR-3 21423239 rs242538 chr20 31436747 C T 4.30E-06 Urinary metabolites MAPRE1 UTR-3 21572414 rs7270085 chr20 31437607 G A 4.00E-06 Attention deficit hyperactivity disorder (combined symptoms) MAPRE1 UTR-3 23527680 rs6141829 chr20 31439209 A C,G,T 4.50E-06 Urinary metabolites / / 21572414 rs6119294 chr20 31440228 G A 5.10E-06 Urinary metabolites / / 21572414 rs6119294 chr20 31440228 G A 7.88E-04 QT interval / / 22726844 rs242528 chr20 31441956 T C 4.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs242528 chr20 31441956 T C 9.60E-06 Urinary metabolites / / 21572414 rs6057659 chr20 31445147 G A 5.00E-06 Attention deficit hyperactivity disorder (combined symptoms) / / 23527680 rs853853 chr20 31446645 A G 5.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs8123073 chr20 31446858 A G 5.00E-06 Attention deficit hyperactivity disorder (combined symptoms) EFCAB8 intron 23527680 rs17123726 chr20 31447368 A G 5.00E-06 Attention deficit hyperactivity disorder (combined symptoms) EFCAB8 intron 23527680 rs17370071 chr20 31452956 C T 7.21E-04 Type 2 diabetes EFCAB8 intron 17463246 rs2014837 chr20 31461082 T C 2.50E-05 Urinary metabolites EFCAB8 intron 21572414 rs6119304 chr20 31502332 A C 7.16E-05 HIV-1 viral setpoint EFCAB8 intron 21490045 rs11697967 chr20 31511702 A C 6.80E-04 Alcohol dependence EFCAB8 intron 21314694 rs41492345 chr20 31512285 G A 3.53E-05 Response to platinum-based chemotherapy in small-cell lung cancer EFCAB8 intron 20463552 rs13045180 chr20 31531544 C T 9.00E-06 Type 1 diabetes nephropathy EFCAB8 STOP-GAIN 23028342 rs751695 chr20 31566127 T C 8.60E-04 Iron levels / / pha002876 rs11698949 chr20 31568098 C A 3.94E-04 Alzheimer's disease (late onset) / / 21379329 rs11696442 chr20 31571037 C T 3.50E-04 Alzheimer's disease (late onset) / / 21379329 rs190097 chr20 31585415 T C 4.95E-05 Brain derived neurotrophic factor levels,in serum SUN5 intron 22047184 rs440139 chr20 31585545 C T 4.44E-05 Brain derived neurotrophic factor levels,in serum SUN5 intron 22047184 rs4911280 chr20 31586302 C A 6.36E-05 Brain derived neurotrophic factor levels,in serum SUN5 intron 22047184 rs17123980 chr20 31589773 G A 3.55E-28 Narcolepsy SUN5 intron 19629137 rs1543572 chr20 31593016 A G 3.37E-05 Lung adenocarcinoma SUN5 nearGene-5 19836008 rs1543572 chr20 31593016 A G 9.54E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SUN5 nearGene-5 20877124 rs6059013 chr20 31593868 G A 7.76E-05 Personality dimensions BPIFB2 nearGene-5 18957941 rs6120085 chr20 31598781 T C 8.79E-04 Alcohol dependence BPIFB2 intron 21314694 rs6057703 chr20 31608250 C A 3.44E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BPIFB2 intron 20877124 rs11696113 chr20 31612644 C T 4.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6059023 chr20 31616268 C T 4.60E-04 Alzheimer's disease / / 24755620 rs4911287 chr20 31627291 A G 2.30E-06 Response to antidepressants BPIFB6 missense 19736353 rs439255 chr20 31630724 G A 5.02E-04 Alzheimer's disease BPIFB6 intron 24755620 rs221981 chr20 31648856 G A 5.88E-05 Alzheimer's disease (late onset) BPIFB3 intron 21379329 rs6088085 chr20 31649372 A G 3.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BPIFB3 intron 20877124 rs4911290 chr20 31652292 G A 1.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BPIFB3 missense 20877124 rs2093067 chr20 31652816 A G 4.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BPIFB3 intron 20877124 rs2093067 chr20 31652816 A G 3.34E-04 Alzheimer's disease (late onset) BPIFB3 intron 21379329 rs729865 chr20 31654093 C T 6.71E-04 Alzheimer's disease BPIFB3 intron 24755620 rs2424948 chr20 31672456 G T 4.15E-04 Insulin resistance BPIFB4 intron 21901158 rs2070325 chr20 31673846 A G 1.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BPIFB4 missense 20877124 rs2070325 chr20 31673846 A G 5.98E-05 Longevity BPIFB4 missense 21612516 rs2889732 chr20 31676804 A C 7.92E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BPIFB4 missense 20877124 rs2024934 chr20 31682778 C A 9.09E-04 Parkinson's disease BPIFB4 intron 17052657 rs2024934 chr20 31682778 C A 2.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BPIFB4 intron 20877124 rs2057262 chr20 31687132 C A 1.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BPIFB4 intron 20877124 rs11699009 chr20 31688241 T C 1.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BPIFB4 missense 20877124 rs11696307 chr20 31688260 C T 1.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BPIFB4 missense 20877124 rs2070328 chr20 31690354 G A 9.09E-04 Parkinson's disease BPIFB4 intron 17052657 rs78109725 chr20 31696171 C A 8.75E-05 Cocaine dependence BPIFB4 intron 23958962 rs6059101 chr20 31718653 C T 4.00E-06 Ulcerative colitis / / 20848476 rs6087456 chr20 31740804 G A 1.80E-04 Hearing function / / 17255346 rs6120127 chr20 31749725 A C 9.07E-06 Smooth-surface caries / / 24556642 rs17124271 chr20 31753607 T C 8.51E-06 Smooth-surface caries / / 24556642 rs7268823 chr20 31755539 G T 8.45E-06 Smooth-surface caries / / 24556642 rs6579083 chr20 31760708 G A 8.76E-06 Smooth-surface caries BPIFA2 intron 24556642 rs8120668 chr20 31767704 C G 8.95E-06 Smooth-surface caries BPIFA2 intron 24556642 rs6120141 chr20 31768655 T C 3.00E-06 Smooth-surface caries BPIFA2 intron 24556642 rs17396317 chr20 31790377 G A 0.0000515 Otitis media (children 3 years old or younger) / / 23133572 rs17124372 chr20 31798437 T C 2.00E-06 Smooth-surface caries / / 24556642 rs17305657 chr20 31806588 T C 3.17E-10 Melanoma BPIFA3 intron 18488026 rs17305657 chr20 31806588 T C 1.18E-07 Melanoma BPIFA3 intron 21983787 rs17305657 chr20 31806588 T C 0.0000328 Otitis media (children 3 years old or younger) BPIFA3 intron 23133572 rs3818222 chr20 31812923 G A 0.0000328 Otitis media (children 3 years old or younger) BPIFA3 missense 23133572 rs4911305 chr20 31813134 C T 7.50E-04 Response to taxane treatment (placlitaxel) BPIFA3 intron 23006423 rs1321417 chr20 31815973 C T 1.07E-05 Intracerebral hemorrhage / / 24656865 rs6059169 chr20 31817604 A C 0.000233 Otitis media (children 3 years old or younger) / / 23133572 rs6059169 chr20 31817604 A C 1.36E-05 Intracerebral hemorrhage / / 24656865 rs6059171 chr20 31818704 G A 8.35E-06 Intracerebral hemorrhage / / 24656865 rs6057775 chr20 31819628 T G 9.56E-06 Intracerebral hemorrhage / / 24656865 rs6057776 chr20 31819650 A G 9.37E-06 Intracerebral hemorrhage / / 24656865 rs6059173 chr20 31821543 G A 8.94E-06 Intracerebral hemorrhage / / 24656865 rs6057778 chr20 31821770 G C 8.90E-06 Intracerebral hemorrhage / / 24656865 rs1998149 chr20 31822170 C A 8.72E-06 Intracerebral hemorrhage / / 24656865 rs6059177 chr20 31822420 A C 8.85E-06 Intracerebral hemorrhage / / 24656865 rs6059178 chr20 31822547 G C 8.85E-06 Intracerebral hemorrhage / / 24656865 rs750065 chr20 31822887 T A,C 9.91E-06 Intracerebral hemorrhage / / 24656865 rs2752901 chr20 31822999 G A 1.65E-05 Intracerebral hemorrhage / / 24656865 rs2752902 chr20 31823024 T C 7.06E-06 Intracerebral hemorrhage / / 24656865 rs2752903 chr20 31823390 T C 9.37E-06 Intracerebral hemorrhage / / 24656865 rs6141897 chr20 31824665 T G 6.62E-06 Intracerebral hemorrhage BPIFA1 intron 24656865 rs3787145 chr20 31824852 C T 9.98E-06 Intracerebral hemorrhage BPIFA1 intron 24656865 rs6059181 chr20 31825373 A G 8.79E-06 Intracerebral hemorrhage BPIFA1 intron 24656865 rs1407019 chr20 31825797 G A 8.79E-06 Intracerebral hemorrhage BPIFA1 intron 24656865 rs6059183 chr20 31826027 T C 0.000301 Otitis media (children 3 years old or younger) BPIFA1 intron 23133572 rs6059183 chr20 31826027 T C 8.79E-06 Intracerebral hemorrhage BPIFA1 intron 24656865 rs6141898 chr20 31826130 G T 8.79E-06 Intracerebral hemorrhage BPIFA1 intron 24656865 rs6059184 chr20 31826465 C T 8.79E-06 Intracerebral hemorrhage BPIFA1 intron 24656865 rs6059185 chr20 31826732 T C 8.78E-06 Intracerebral hemorrhage BPIFA1 intron 24656865 rs3746392 chr20 31827330 G A,T 7.96E-06 Intracerebral hemorrhage BPIFA1 intron 24656865 rs6141899 chr20 31827439 A G 8.78E-06 Intracerebral hemorrhage BPIFA1 intron 24656865 rs6059186 chr20 31828254 T C 8.78E-06 Intracerebral hemorrhage BPIFA1 intron 24656865 rs12480799 chr20 31830712 T C 8.77E-06 Intracerebral hemorrhage BPIFA1 intron 24656865 rs10875488 chr20 31830773 A G 1.64E-05 Intracerebral hemorrhage BPIFA1 intron 24656865 rs1047595 chr20 31830955 T C 9.23E-06 Intracerebral hemorrhage BPIFA1 UTR-3 24656865 rs2295575 chr20 31831108 C A 8.78E-06 Intracerebral hemorrhage BPIFA1 UTR-3 24656865 rs6120186 chr20 31831745 A G 8.54E-06 Intracerebral hemorrhage / / 24656865 rs6059191 chr20 31833188 A C 8.48E-06 Intracerebral hemorrhage / / 24656865 rs6141900 chr20 31837363 C A 1.62E-05 Intracerebral hemorrhage / / 24656865 rs6059197 chr20 31838520 A G 8.47E-06 Intracerebral hemorrhage / / 24656865 rs911137 chr20 31838820 G A 1.02E-05 Intracerebral hemorrhage / / 24656865 rs6141901 chr20 31839058 G T 1.96E-05 Intracerebral hemorrhage / / 24656865 rs6057786 chr20 31840452 A G 7.77E-06 Intracerebral hemorrhage / / 24656865 rs6059204 chr20 31841671 G A 7.27E-06 Intracerebral hemorrhage / / 24656865 rs2377864 chr20 31844770 C T 9.96E-06 Intracerebral hemorrhage / / 24656865 rs6057793 chr20 31845481 T C 1.00E-05 Intracerebral hemorrhage / / 24656865 rs6141902 chr20 31845531 C T 1.91E-05 Intracerebral hemorrhage / / 24656865 rs11697797 chr20 31846011 A G 1.93E-05 Intracerebral hemorrhage / / 24656865 rs6059211 chr20 31846053 G A 1.01E-05 Intracerebral hemorrhage / / 24656865 rs6057794 chr20 31846600 A G 1.71E-05 Intracerebral hemorrhage / / 24656865 rs11696598 chr20 31847816 G C 2.06E-05 Intracerebral hemorrhage / / 24656865 rs6057798 chr20 31848114 T C 9.79E-06 Intracerebral hemorrhage / / 24656865 rs11696793 chr20 31848154 C T 2.09E-05 Intracerebral hemorrhage / / 24656865 rs6059214 chr20 31848471 A C 1.02E-05 Intracerebral hemorrhage / / 24656865 rs6059216 chr20 31848838 A G 1.04E-05 Intracerebral hemorrhage / / 24656865 rs6141903 chr20 31849421 G A 2.07E-05 Intracerebral hemorrhage / / 24656865 rs6057800 chr20 31849506 A G 1.81E-05 Intracerebral hemorrhage / / 24656865 rs6141904 chr20 31850339 T C 2.37E-05 Intracerebral hemorrhage / / 24656865 rs6141378 chr20 31850648 G A 2.50E-05 Intracerebral hemorrhage / / 24656865 rs6059219 chr20 31851118 T A 1.32E-05 Intracerebral hemorrhage / / 24656865 rs6119356 chr20 31851429 T C 1.33E-05 Intracerebral hemorrhage / / 24656865 rs6119363 chr20 31876510 C T 0.0000114 Antisocial behavior BPIFB1 intron 23077488 rs1884885 chr20 31877898 C T 3.69E-05 Cognitive impairment induced by topiramate BPIFB1 intron 22091778 rs6059240 chr20 31896025 C A 1.76E-04 Multiple complex diseases BPIFB1 intron 17554300 rs721970 chr20 31903533 A G 8.86E-10 Melanoma / / 18488026 rs4911320 chr20 31914031 G T 1.78E-05 Height / / 22021425 rs293737 chr20 31925478 G C 1.30E-05 Urinary metabolites / / 21572414 rs293728 chr20 31933280 T C 8.72E-04 Response to TNF antagonist treatment / / 21061259 rs11698045 chr20 31938046 C T 1.50E-05 Endometriosis / / 21151130 rs293712 chr20 31940540 G A 4.80E-05 Endometriosis / / 21151130 rs293713 chr20 31942247 A G 3.69E-04 Type 2 diabetes / / 17463246 rs291671 chr20 31950845 G A 7.74E-08 Melanoma CDK5RAP1 intron 18488026 rs291671 chr20 31950845 G A 2.00E-15 Hair color CDK5RAP1 intron 20585627 rs291671 chr20 31950845 G A 2.47E-04 Iron levels CDK5RAP1 intron pha002876 rs6059286 chr20 31957992 A G 1.95E-04 Multiple complex diseases CDK5RAP1 intron 17554300 rs291705 chr20 31969658 C T 5.25E-04 Type 2 diabetes CDK5RAP1 intron 17463246 rs291700 chr20 31981849 T C 1.48E-04 Type 2 diabetes CDK5RAP1 cds-synon 17463246 rs291700 chr20 31981849 T C 2.90E-07 Height CDK5RAP1 cds-synon 21194676 rs291700 chr20 31981849 T C 4.00E-04 Height CDK5RAP1 cds-synon 21194676 rs291700 chr20 31981849 T C 4.40E-10 Height CDK5RAP1 cds-synon 21194676 rs291695 chr20 31988202 A G 0.0004 Coronary artery calcification CDK5RAP1 intron 23727086 rs291689 chr20 32003974 T C 1.38E-04 Type 2 diabetes SNTA1 intron 17463246 rs6087487 chr20 32015036 G A 4.50E-05 Endometriosis SNTA1 intron 21151130 rs928204 chr20 32047393 T C 7.49E-04 Multiple complex diseases / / 17554300 rs6059349 chr20 32080115 A G 9.70E-12 Protein C levels CBFA2T2 intron 20802025 rs209665 chr20 32128889 T G 9.70E-05 Pericardial fat CBFA2T2 intron 22589742 rs209677 chr20 32140287 T C 5.93E-04 Type 2 diabetes CBFA2T2 intron 17463246 rs17124861 chr20 32227729 C T 1.61E-04 Multiple complex diseases CBFA2T2 intron 17554300 rs3213183 chr20 32262962 G A 5.66E-04 Type 2 diabetes / / 17463246 rs2071054 chr20 32265839 A G 4.02E-05 Melanoma E2F1 intron 18488026 rs3213150 chr20 32272201 G A 8.70E-05 Pericardial fat E2F1 intron 22589742 rs910397 chr20 32295541 C T 1.10E-04 Endometriosis PXMP4 missense 21151130 rs1074683 chr20 32304653 C G 1.00E-14 Height PXMP4 intron 23563607 rs7274811 chr20 32333181 G T 6.00E-22 Height ZNF341 intron 20881960 rs2626552 chr20 32384844 C T 2.59E-13 Protein C levels LOC100652854 intron 20802025 rs910398 chr20 32386270 G A 9.35E-04 Type 2 diabetes LOC100652854 intron 17463246 rs910398 chr20 32386270 G A 9.50E-05 Personality dimensions LOC100652854 intron 18957941 rs910398 chr20 32386270 G A 1.86E-14 Protein C levels LOC100652854 intron 20802025 rs13042412 chr20 32407584 A G 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CHMP4B intron 22628534 rs6087528 chr20 32410944 T A 1.34E-17 Protein C levels CHMP4B intron 20802025 rs2747539 chr20 32418368 C T 3.34E-25 Protein C levels CHMP4B intron 20802025 rs13043926 chr20 32420456 G C 1.87E-18 Protein C levels CHMP4B intron 20802025 rs4911368 chr20 32421742 G A 1.10E-24 Protein C levels CHMP4B intron 20802025 rs6088314 chr20 32424060 T C 4.64E-19 Protein C levels CHMP4B intron 20802025 rs6088316 chr20 32426842 A G 3.98E-11 Common traits (Other) CHMP4B intron 20585627 rs6087534 chr20 32443974 C T 2.07E-26 Protein C levels / / 20802025 rs6579122 chr20 32446247 G A 3.51E-04 Multiple complex diseases / / 17554300 rs1040552 chr20 32449329 A G 1.64E-18 Protein C levels / / 20802025 rs4911369 chr20 32452176 T C 1.11E-25 Protein C levels / / 20802025 rs4911134 chr20 32452215 C T 1.07E-25 Protein C levels / / 20802025 rs4911370 chr20 32452908 A G 8.71E-19 Protein C levels / / 20802025 rs7261505 chr20 32454413 G A 1.09E-40 Protein C levels / / 20802025 rs8122909 chr20 32454448 T C 4.98E-41 Protein C levels / / 20802025 rs6088323 chr20 32455866 A T 5.97E-23 Protein C levels / / 20802025 rs6059506 chr20 32461708 G A 5.80E-04 Multiple complex diseases / / 17554300 rs6120401 chr20 32467139 C T 6.18E-04 Alcohol dependence / / 21314694 rs742614 chr20 32482632 A G 3.00E-07 Stearic acid (18:0) plasma levels / / 23362303 rs2092477 chr20 32484429 T C 9.87E-09 Protein C levels / / 20802025 rs2092477 chr20 32484429 T C 4.54E-05 Information processing speed / / 21130836 rs2050210 chr20 32485650 C A 1.00E-04 Information processing speed / / 21130836 rs6120423 chr20 32495585 C T 3.87E-04 Multiple complex diseases / / 17554300 rs6088343 chr20 32496065 C T 5.32E-10 Protein C levels / / 20802025 rs6088343 chr20 32496065 C T 2.77E-05 Information processing speed / / 21130836 rs62209647 chr20 32505658 G C 7.72E-05 Melanoma / / 21926416 rs6142044 chr20 32506595 A T 5.71E-11 Protein C levels / / 20802025 rs6142046 chr20 32514061 C T 8.20E-05 Serum metabolites / / 19043545 rs6142047 chr20 32514386 C T 5.15E-05 Melanoma / / 18488026 rs4911377 chr20 32516317 G A 5.13E-04 Type 2 diabetes / / 17463246 rs6120440 chr20 32517585 G A 5.74E-04 Type 2 diabetes / / 17463246 rs2143533 chr20 32518672 C G 6.38E-04 Type 2 diabetes / / 17463246 rs761238 chr20 32519988 G T 1.26E-10 Common traits (Other) / / 20585627 rs6142050 chr20 32527128 G A 1.29E-07 Common traits (Other) / / 20585627 rs6142050 chr20 32527128 G A 6.31E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs6579129 chr20 32533524 A T 5.31E-10 Protein C levels / / 20802025 rs4911379 chr20 32535305 A C 3.96E-05 Melanoma / / 18488026 rs4911379 chr20 32535305 A C 1.17E-09 Common traits (Other) / / 20585627 rs4324393 chr20 32536833 G A 1.10E-31 Protein C levels / / 20802025 rs976728 chr20 32537352 C T 1.93E-48 Protein C levels / / 20802025 rs976728 chr20 32537352 C T 4.56E-04 Obesity (extreme) / / 21935397 rs6120450 chr20 32538412 C T 1.08E-31 Protein C levels / / 20802025 rs6088352 chr20 32540598 G A 1.46E-33 Protein C levels / / 20802025 rs6088353 chr20 32541568 G T 5.69E-31 Protein C levels / / 20802025 rs13041173 chr20 32542814 A G 8.29E-10 Protein C levels / / 20802025 rs17091441 chr20 32544176 T C 6.45E-04 Multiple complex diseases / / 17554300 rs6059588 chr20 32544409 G A 9.17E-31 Protein C levels / / 20802025 rs6088358 chr20 32550503 C T 1.33E-30 Protein C levels / / 20802025 rs6059592 chr20 32552643 T G 1.26E-30 Protein C levels / / 20802025 rs6059594 chr20 32556777 G A 3.00E-06 IgG glycosylation / / 23382691 rs6059594 chr20 32556777 G A 4.00E-06 IgG glycosylation / / 23382691 rs6059594 chr20 32556777 G A 5.00E-06 IgG glycosylation / / 23382691 rs6059594 chr20 32556777 G A 7.00E-06 IgG glycosylation / / 23382691 rs6059594 chr20 32556777 G A 9.00E-06 IgG glycosylation / / 23382691 rs6119437 chr20 32566141 C T 7.90E-33 Protein C levels / / 20802025 rs6120472 chr20 32566975 C T 7.54E-33 Protein C levels / / 20802025 rs6088370 chr20 32569992 A T 7.19E-33 Protein C levels / / 20802025 rs2284378 chr20 32588095 T C 5.69E-05 Melanoma RALY intron 18488026 rs2284378 chr20 32588095 T C 6.03E-10 Common traits (Other) RALY intron 20585627 rs2284378 chr20 32588095 T C 6.80E-04 Melanoma RALY intron 21983787 rs2284378 chr20 32588095 T C 1.00E-08 Breast cancer RALY intron 22976474 rs2300202 chr20 32588682 G T 2.40E-33 Protein C levels RALY intron 20802025 rs2284380 chr20 32594714 C T 8.32E-31 Protein C levels RALY intron 20802025 rs2268081 chr20 32603830 A C 2.05E-33 Protein C levels RALY intron 20802025 rs4911145 chr20 32615223 A G 6.03E-08 Common traits (Other) RALY intron 20585627 rs2268083 chr20 32625935 C T 1.58E-40 Protein C levels RALY intron 20802025 rs6088387 chr20 32629322 G T 3.12E-34 Protein C levels RALY intron 20802025 rs2284385 chr20 32637001 A G 2.33E-34 Protein C levels RALY intron 20802025 rs9974023 chr20 32638828 A C,G,T 2.36E-34 Protein C levels RALY intron 20802025 rs4911146 chr20 32640047 C G 8.40E-06 Biomarkers RALY intron 17903293 rs6088389 chr20 32641915 G T 2.42E-34 Protein C levels RALY intron 20802025 rs2268086 chr20 32648738 A G 5.62E-08 Common traits (Other) RALY intron 20585627 rs2268087 chr20 32648985 G T 2.50E-34 Protein C levels RALY intron 20802025 rs2284390 chr20 32657590 G A 2.79E-34 Protein C levels RALY intron 20802025 rs6119446 chr20 32659330 C G 2.54E-34 Protein C levels RALY intron 20802025 rs2284391 chr20 32661951 T A 2.53E-34 Protein C levels RALY intron 20802025 rs2268089 chr20 32667298 T C 9.02E-06 Melanoma RALY intron 18488026 rs2268089 chr20 32667298 T C 8.32E-10 Common traits (Other) RALY intron 20585627 rs6088393 chr20 32674497 G A 1.65E-40 Protein C levels / / 20802025 rs6059662 chr20 32675727 A G 3.17E-04 Type 2 diabetes / / 17463246 rs6088397 chr20 32682112 A G 2.54E-34 Protein C levels EIF2S2 intron 20802025 rs6088398 chr20 32690520 G C 2.02E-34 Protein C levels EIF2S2 intron 20802025 rs2038123 chr20 32696065 A G 1.98E-34 Protein C levels EIF2S2 intron 20802025 rs6119459 chr20 32727075 T C 1.45E-34 Protein C levels / / 20802025 rs4911414 chr20 32729444 T G 6.00E-37 Burning and freckling / / 18488028 rs4911414 chr20 32729444 T G 3.02E-09 Common traits (Other) / / 20585627 rs4911414 chr20 32729444 T G 1.62E-07 Melanoma / / 21983787 rs4911414 chr20 32729444 T G 1.30E-04 Hair color / / 23548203 rs4911414 chr20 32729444 T G 4.00E-09 Tanning / / 23548203 rs1015362 chr20 32738612 C T 6.00E-37 Burning and freckling / / 18488028 rs6059698 chr20 32757997 C T 1.09E-09 Protein C levels / / 20802025 rs6059698 chr20 32757997 C T 7.08E-04 Obesity (extreme) / / 21935397 rs17332951 chr20 32764183 T C 5.90E-51 Protein C levels / / 20802025 rs17332951 chr20 32764183 T C 9.39E-04 Obesity (extreme) / / 21935397 rs6059703 chr20 32768431 C T 5.59E-11 Protein C levels / / 20802025 rs6059709 chr20 32779379 T C 7.74E-12 Protein C levels / / 20802025 rs6059710 chr20 32780650 C T 9.51E-13 Protein C levels / / 20802025 rs6059710 chr20 32780650 C T 5.80E-04 Obesity (extreme) / / 21935397 rs6059711 chr20 32780822 C T 1.15E-14 Protein C levels / / 20802025 rs6059711 chr20 32780822 C T 8.29E-04 Obesity (extreme) / / 21935397 rs6059711 chr20 32780822 C T 4.24E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2065912 chr20 32783487 G T 1.11E-24 Protein C levels / / 20802025 rs2065912 chr20 32783487 G T 3.75E-04 Obesity (extreme) / / 21935397 rs6087561 chr20 32783827 T C 2.05E-28 Protein C levels / / 20802025 rs6087561 chr20 32783827 T C 6.58E-05 Obesity (extreme) / / 21935397 rs12480555 chr20 32784494 A G 2.57E-28 Protein C levels / / 20802025 rs12480555 chr20 32784494 A G 4.14E-05 Obesity (extreme) / / 21935397 rs6088423 chr20 32788141 T G 2.61E-28 Protein C levels / / 20802025 rs6088423 chr20 32788141 T G 3.68E-05 Obesity (extreme) / / 21935397 rs6088423 chr20 32788141 T G 3.42E-05 Gaucher disease severity / / 22388998 rs6088425 chr20 32791520 T A 2.44E-25 Protein C levels / / 20802025 rs6088425 chr20 32791520 T A 3.62E-05 Obesity (extreme) / / 21935397 rs6120568 chr20 32793500 T C 2.85E-28 Protein C levels / / 20802025 rs6120568 chr20 32793500 T C 3.55E-05 Obesity (extreme) / / 21935397 rs12625272 chr20 32794161 C G 2.85E-28 Protein C levels / / 20802025 rs12625272 chr20 32794161 C G 3.46E-05 Obesity (extreme) / / 21935397 rs6088429 chr20 32798730 C T 3.01E-28 Protein C levels / / 20802025 rs6088429 chr20 32798730 C T 3.43E-05 Obesity (extreme) / / 21935397 rs6059729 chr20 32806891 A G 8.39E-36 Protein C levels / / 20802025 rs6059729 chr20 32806891 A G 2.75E-05 Obesity (extreme) / / 21935397 rs6119473 chr20 32809249 T C 2.37E-33 Protein C levels / / 20802025 rs6119473 chr20 32809249 T C 2.73E-05 Obesity (extreme) / / 21935397 rs6087565 chr20 32821459 A G 5.93E-27 Protein C levels / / 20802025 rs6087565 chr20 32821459 A G 2.26E-05 Obesity (extreme) / / 21935397 rs819178 chr20 32825792 A G 6.09E-27 Protein C levels / / 20802025 rs819178 chr20 32825792 A G 2.18E-05 Obesity (extreme) / / 21935397 rs6088443 chr20 32832131 C T 1.21E-30 Protein C levels / / 20802025 rs6088443 chr20 32832131 C T 1.97E-05 Obesity (extreme) / / 21935397 rs819164 chr20 32839454 A G 2.43E-26 Protein C levels / / 20802025 rs819164 chr20 32839454 A G 2.10E-05 Obesity (extreme) / / 21935397 rs819163 chr20 32842357 T G 2.52E-32 Protein C levels / / 20802025 rs819163 chr20 32842357 T G 1.96E-05 Obesity (extreme) / / 21935397 rs6120577 chr20 32842533 C T 1.80E-04 Multiple complex diseases / / 17554300 rs6120580 chr20 32844530 C T 1.17E-34 Protein C levels / / 20802025 rs6120580 chr20 32844530 C T 1.78E-05 Obesity (extreme) / / 21935397 rs2378132 chr20 32846036 A G 7.82E-35 Protein C levels / / 20802025 rs2378132 chr20 32846036 A G 1.78E-05 Obesity (extreme) / / 21935397 rs819136 chr20 32848719 G A 1.15E-25 Protein C levels ASIP intron 20802025 rs819136 chr20 32848719 G A 1.90E-05 Obesity (extreme) ASIP intron 21935397 rs819162 chr20 32852282 A T 7.24E-35 Protein C levels ASIP intron 20802025 rs819162 chr20 32852282 A T 1.77E-05 Obesity (extreme) ASIP intron 21935397 rs6088454 chr20 32854577 A T 4.19E-34 Protein C levels ASIP intron 20802025 rs6088454 chr20 32854577 A T 1.77E-05 Obesity (extreme) ASIP intron 21935397 rs819142 chr20 32861007 G A 4.24E-34 Protein C levels / / 20802025 rs819142 chr20 32861007 G A 2.03E-05 Obesity (extreme) / / 21935397 rs819144 chr20 32861556 T G 1.10E-33 Protein C levels / / 20802025 rs819144 chr20 32861556 T G 2.03E-05 Obesity (extreme) / / 21935397 rs819145 chr20 32861827 T G 4.48E-34 Protein C levels / / 20802025 rs819145 chr20 32861827 T G 2.05E-05 Obesity (extreme) / / 21935397 rs819177 chr20 32864303 C G 8.19E-32 Protein C levels / / 20802025 rs819177 chr20 32864303 C G 2.07E-05 Obesity (extreme) / / 21935397 rs819176 chr20 32865844 T G 4.55E-34 Protein C levels / / 20802025 rs819176 chr20 32865844 T G 2.08E-05 Obesity (extreme) / / 21935397 rs819175 chr20 32866181 G C 4.43E-34 Protein C levels / / 20802025 rs819175 chr20 32866181 G C 2.09E-05 Obesity (extreme) / / 21935397 rs819173 chr20 32866562 C T 7.44E-34 Protein C levels / / 20802025 rs819173 chr20 32866562 C T 2.29E-05 Obesity (extreme) / / 21935397 rs819172 chr20 32867506 T C 1.91E-39 Protein C levels / / 20802025 rs819172 chr20 32867506 T C 3.19E-05 Obesity (extreme) / / 21935397 rs819133 chr20 32870314 T G 4.01E-34 Protein C levels AHCY intron 20802025 rs819133 chr20 32870314 T G 2.11E-05 Obesity (extreme) AHCY intron 21935397 rs864702 chr20 32871550 A G 2.11E-33 Protein C levels AHCY intron 20802025 rs864702 chr20 32871550 A G 2.11E-05 Obesity (extreme) AHCY intron 21935397 rs866027 chr20 32874310 G A 5.54E-34 Protein C levels AHCY intron 20802025 rs866027 chr20 32874310 G A 2.12E-05 Obesity (extreme) AHCY intron 21935397 rs1205357 chr20 32877766 C T 4.74E-37 Protein C levels AHCY intron 20802025 rs1205357 chr20 32877766 C T 6.50E-05 Obesity (extreme) AHCY intron 21935397 rs819159 chr20 32879720 A T 1.01E-30 Protein C levels AHCY intron 20802025 rs819159 chr20 32879720 A T 2.10E-05 Obesity (extreme) AHCY intron 21935397 rs819158 chr20 32880738 G A 5.96E-34 Protein C levels AHCY intron 20802025 rs819158 chr20 32880738 G A 2.10E-05 Obesity (extreme) AHCY intron 21935397 rs819156 chr20 32881023 A C 1.75E-33 Protein C levels AHCY intron 20802025 rs819156 chr20 32881023 A C 2.09E-05 Obesity (extreme) AHCY intron 21935397 rs819148 chr20 32888537 G A 5.14E-34 Protein C levels AHCY intron 20802025 rs819148 chr20 32888537 G A 2.02E-05 Obesity (extreme) AHCY intron 21935397 rs819147 chr20 32889704 C T 5.54E-34 Protein C levels AHCY intron 20802025 rs819147 chr20 32889704 C T 2.02E-05 Obesity (extreme) AHCY intron 21935397 rs819147 chr20 32889704 C T 0.00000422 Panic disorder AHCY intron 23149450 rs819147 chr20 32889704 C T 4.22E-06 Serum tamsulosin hydrochloride concentration AHCY intron 23151678 rs1205366 chr20 32890337 T C 1.99E-05 Obesity (extreme) AHCY intron 21935397 rs819146 chr20 32891200 G T 2.58E-34 Protein C levels AHCY UTR-5 20802025 rs819146 chr20 32891200 G T 1.96E-05 Obesity (extreme) AHCY UTR-5 21935397 rs1205350 chr20 32898339 G A 3.95E-32 Protein C levels AHCY intron 20802025 rs1205349 chr20 32899674 G C 3.65E-12 Protein C levels AHCY nearGene-5 20802025 rs1205349 chr20 32899674 G C 5.62E-04 Obesity (extreme) AHCY nearGene-5 21935397 rs819167 chr20 32903687 A G 3.93E-55 Protein C levels / / 20802025 rs819167 chr20 32903687 A G 1.88E-04 Obesity (extreme) / / 21935397 rs819168 chr20 32903845 T G 2.98E-55 Protein C levels / / 20802025 rs819168 chr20 32903845 T G 1.88E-04 Obesity (extreme) / / 21935397 rs843901 chr20 32904636 T G 6.58E-59 Protein C levels / / 20802025 rs843901 chr20 32904636 T G 1.86E-04 Obesity (extreme) / / 21935397 rs819131 chr20 32907849 G A 6.31E-59 Protein C levels / / 20802025 rs819131 chr20 32907849 G A 7.50E-04 Obesity (extreme) / / 21935397 rs17302686 chr20 32910305 G A 8.03E-80 Protein C levels / / 20802025 rs17302686 chr20 32910305 G A 9.40E-04 Obesity (extreme) / / 21935397 rs1205339 chr20 32924967 A G 4.37E-07 Common traits (Other) / / 20585627 rs12624640 chr20 32952125 G A 4.44E-08 Protein C levels ITCH intron 20802025 rs12624640 chr20 32952125 G A 3.83E-04 Alzheimer's disease (late onset) ITCH intron 21379329 rs4911154 chr20 32996101 G A 3.62E-04 Type 2 diabetes ITCH intron 17463246 rs6088498 chr20 33020446 A G 2.70E-05 Urinary metabolites ITCH intron 21572414 rs17303568 chr20 33022797 A G 2.57E-83 Protein C levels ITCH intron 20802025 rs10485505 chr20 33025567 C T 1.03E-79 Protein C levels ITCH intron 20802025 rs7266300 chr20 33037408 A T 9.44E-83 Protein C levels ITCH intron 20802025 rs11700080 chr20 33046761 A G 2.18E-12 Protein C levels ITCH intron 20802025 rs11700080 chr20 33046761 A G 2.49E-05 Cardiovascular disease ITCH intron pha003064 rs6059866 chr20 33075810 T G 4.85E-11 Narcolepsy ITCH intron 19629137 rs6120663 chr20 33081906 C A 6.46E-10 Protein C levels ITCH intron 20802025 rs6088515 chr20 33110042 G A 3.28E-04 Type 2 diabetes DYNLRB1 intron 17463246 rs2281695 chr20 33129164 T C 1.80E-08 Skin sensitivity to sun / / 18488028 rs2281695 chr20 33129164 T C 2.63E-07 Common traits (Other) / / 20585627 rs6059908 chr20 33132159 T C 3.80E-07 Common traits (Other) / / 20585627 rs6088519 chr20 33132191 C T 3.00E-06 Alcohol dependence / / 23089632 rs6088520 chr20 33132364 C T 5.27E-05 Interstitial lung disease / / 23583980 rs2424994 chr20 33132917 C T 3.45E-06 Melanoma / / 18488026 rs2424994 chr20 33132917 C T 6.03E-08 Common traits (Other) / / 20585627 rs6088521 chr20 33133184 A C 8.51E-09 Protein C levels / / 20802025 rs764598 chr20 33161150 C G 1.50E-85 Protein C levels PIGU intron 20802025 rs764597 chr20 33161225 G A 4.38E-04 Multiple complex diseases PIGU intron 17554300 rs764597 chr20 33161225 G A 1.20E-05 Urinary metabolites PIGU intron 21572414 rs2889849 chr20 33164277 T C 1.88E-04 Type 2 diabetes PIGU intron 17463246 rs4302281 chr20 33171645 A G 1.74E-04 Type 2 diabetes PIGU intron 17463246 rs910873 chr20 33171772 G A 1.00E-15 Melanoma PIGU intron 18488026 rs910873 chr20 33171772 G A 1.00E-15 Nasopharyngeal carcinoma PIGU intron 20512145 rs910873 chr20 33171772 G A 9.80E-05 Melanoma PIGU intron 24980573 rs4564863 chr20 33179367 T C 1.74E-04 Type 2 diabetes PIGU intron 17463246 rs2378199 chr20 33186480 T C 2.00E-04 Type 2 diabetes and 6 quantitative traits PIGU intron 17848626 rs2378199 chr20 33186480 T C 5.20E-09 Skin sensitivity to sun PIGU intron 18488028 rs6058089 chr20 33194257 A G 1.91E-04 Type 2 diabetes PIGU intron 17463246 rs6142206 chr20 33212055 G A 1.60E-09 Protein C levels PIGU intron 20802025 rs2378249 chr20 33218090 G A 3.90E-09 Skin sensitivity to sun PIGU intron 18488028 rs6059956 chr20 33220070 T C 4.40E-04 Multiple complex diseases PIGU intron 17554300 rs6059956 chr20 33220070 T C 1.80E-05 Urinary metabolites PIGU intron 21572414 rs6059961 chr20 33231490 T C 6.80E-04 Type 2 diabetes and 6 quantitative traits PIGU intron 17848626 rs6579184 chr20 33279853 G A 4.46E-04 Multiple complex diseases / / 17554300 rs6087619 chr20 33288511 G C 2.78E-09 Protein C levels / / 20802025 rs910869 chr20 33292777 C T 2.78E-09 Protein C levels TP53INP2 intron 20802025 rs910870 chr20 33292893 T C 3.64E-09 Protein C levels TP53INP2 intron 20802025 rs6119512 chr20 33306904 T C 2.32E-09 Protein C levels NCOA6 intron 20802025 rs6060017 chr20 33313042 C A 2.54E-04 Type 2 diabetes NCOA6 intron 17463246 rs6088590 chr20 33313566 T C 1.77E-09 Protein C levels NCOA6 intron 20802025 rs4911441 chr20 33316546 T C 7.38E-15 Protein C levels NCOA6 intron 20802025 rs6087623 chr20 33317662 C G 1.73E-09 Protein C levels NCOA6 intron 20802025 rs6141509 chr20 33319388 G A 7.25E-15 Protein C levels NCOA6 intron 20802025 rs6141509 chr20 33319388 G A 8.80E-07 Alcohol dependence NCOA6 intron 23089632 rs1018503 chr20 33325516 T G 3.05E-05 Serum metabolites NCOA6 intron 19043545 rs1018503 chr20 33325516 T G 8.99E-15 Protein C levels NCOA6 intron 20802025 rs6119516 chr20 33328024 C A,G,T 1.66E-09 Protein C levels NCOA6 intron 20802025 rs3787223 chr20 33331385 A G 2.30E-04 Type 2 diabetes NCOA6 intron 17463246 rs3787222 chr20 33333040 T A 1.68E-09 Protein C levels NCOA6 intron 20802025 rs6120708 chr20 33335526 G A 1.69E-09 Protein C levels NCOA6 intron 20802025 rs6087624 chr20 33336085 C G 7.29E-15 Protein C levels NCOA6 intron 20802025 rs6060030 chr20 33340313 C T 5.60E-04 Type 2 diabetes NCOA6 intron 17463246 rs2378259 chr20 33341688 G A 7.42E-15 Protein C levels NCOA6 intron 20802025 rs1884432 chr20 33342439 T C 1.48E-04 Type 2 diabetes NCOA6 intron 17463246 rs6087625 chr20 33342477 G A 3.18E-09 Protein C levels NCOA6 intron 20802025 rs6087625 chr20 33342477 G A 2.20E-05 Urinary metabolites NCOA6 intron 21572414 rs6088594 chr20 33343157 G A 2.48E-04 Type 2 diabetes NCOA6 intron 17463246 rs1998028 chr20 33344595 A T 1.72E-09 Protein C levels NCOA6 intron 20802025 rs6060034 chr20 33351864 T C 4.90E-09 Skin sensitivity to sun NCOA6 intron 18488028 rs6060034 chr20 33351864 T C 1.70E-07 Common traits (Other) NCOA6 intron 20585627 rs4911442 chr20 33355046 G A 2.86E-11 Melanoma NCOA6 intron 18488026 rs4911442 chr20 33355046 G A 1.80E-05 Melanoma NCOA6 intron 21706340 rs4911442 chr20 33355046 G A 8.60E-05 Melanoma NCOA6 intron 21983787 rs2295353 chr20 33356511 C T 1.21E-09 Protein C levels NCOA6 intron 20802025 rs6060038 chr20 33357715 G A 5.31E-17 Protein C levels NCOA6 intron 20802025 rs6060038 chr20 33357715 G A 6.88E-07 Alcohol dependence NCOA6 intron 23089632 rs6058115 chr20 33358397 T G 4.20E-04 Type 2 diabetes and 6 quantitative traits NCOA6 intron 17848626 rs2180276 chr20 33360785 T A 1.21E-09 Protein C levels NCOA6 intron 20802025 rs6060043 chr20 33364584 C T 4.50E-09 Skin sensitivity to sun NCOA6 intron 18488028 rs6060043 chr20 33364584 C T 1.62E-07 Common traits (Other) NCOA6 intron 20585627 rs6060047 chr20 33367400 T G 2.31E-04 Type 2 diabetes NCOA6 intron 17463246 rs6060048 chr20 33370266 T C 3.11E-15 Protein C levels NCOA6 intron 20802025 rs6060052 chr20 33382665 T G 5.04E-15 Protein C levels NCOA6 intron 20802025 rs2424997 chr20 33384805 A G 6.60E-15 Protein C levels NCOA6 intron 20802025 rs2425001 chr20 33394868 A T 5.54E-15 Protein C levels NCOA6 intron 20802025 rs7271289 chr20 33397303 C T 9.93E-08 Melanoma NCOA6 intron 18488026 rs6088615 chr20 33400474 T C 1.30E-09 Protein C levels NCOA6 intron 20802025 rs2425003 chr20 33403584 C A 3.25E-04 Type 2 diabetes NCOA6 intron 17463246 rs12625149 chr20 33425812 G A,C,T 9.69E-04 Multiple complex diseases / / 17554300 rs17092148 chr20 33435161 G T 1.38E-04 Type 2 diabetes GGT7 intron 17463246 rs6088624 chr20 33436852 T A 1.98E-09 Protein C levels GGT7 intron 20802025 rs2076668 chr20 33437621 G A 1.48E-09 Protein C levels GGT7 intron 20802025 rs6119535 chr20 33442138 A C 1.47E-09 Protein C levels GGT7 intron 20802025 rs6120747 chr20 33449769 T C 1.45E-09 Protein C levels GGT7 intron 20802025 rs17122844 chr20 33452600 C T 4.66E-27 Protein C levels GGT7 intron 20802025 rs17122844 chr20 33452600 C T 1.62E-04 Atopy GGT7 intron 21625490 rs6088638 chr20 33470514 T C 0.0000883 Coronary artery disease ACSS2 intron 23202125 rs2295097 chr20 33478221 A C 6.59E-116 Protein C levels ACSS2 intron 20802025 rs17309872 chr20 33515788 A T 9.59E-117 Protein C levels GSS nearGene-3 20802025 rs2236270 chr20 33523155 G T 1.05E-09 Protein C levels GSS intron 20802025 rs2273684 chr20 33529766 T G 0.000000472 Bipolar disorder GSS intron 23070075 rs6060124 chr20 33536897 C A 0.000203 Alcohol dependence GSS intron 23089632 rs6060124 chr20 33536897 C A 4.41E-07 Alcohol dependence GSS intron 23089632 rs2025096 chr20 33540000 G A 1.35E-29 Protein C levels GSS intron 20802025 rs6088660 chr20 33542896 C T 8.25E-04 Multiple complex diseases GSS intron 17554300 rs13041792 chr20 33545055 G A 4.40E-30 Protein C levels MYH7B intron 20802025 rs17310467 chr20 33545616 A G 7.62E-183 Protein C levels MYH7B intron 20802025 rs17310467 chr20 33545616 A G 4.00E-34 Hemostatic factors and hematological phenotypes MYH7B intron 22443383 rs6088662 chr20 33547633 T G 4.34E-30 Protein C levels MYH7B intron 20802025 rs6088662 chr20 33547633 T G 6.13E-04 Major depressive disorder MYH7B intron 22472876 rs6088664 chr20 33551100 G A 3.23E-06 Alcohol dependence MYH7B intron 23089632 rs17401737 chr20 33552642 C A 7.00E-183 Protein C levels MYH7B intron 20802025 rs6579204 chr20 33553677 A G 0.00000454 Alcohol dependence MYH7B intron 23089632 rs7263251 chr20 33554320 T C 7.29E-04 Multiple complex diseases MYH7B intron 17554300 rs6120777 chr20 33560172 G A 3.02E-26 Protein C levels MYH7B intron 20802025 rs11906160 chr20 33565755 G A 6.06E-183 Protein C levels MYH7B missense 20802025 rs11906160 chr20 33565755 G A 1.00E-06 Anticoagulant levels MYH7B missense 22216198 rs6088667 chr20 33566722 T G 1.18E-29 Protein C levels MYH7B intron 20802025 rs6088667 chr20 33566722 T G 6.99E-04 Major depressive disorder MYH7B intron 22472876 rs7261167 chr20 33576205 G A 2.09E-173 Protein C levels MYH7B intron 20802025 rs1885120 chr20 33576989 C G 9.83E-16 Melanoma MYH7B intron 18488026 rs1885120 chr20 33576989 C G 7.10E-05 Melanoma MYH7B intron 24980573 rs2425012 chr20 33581955 G A 1.00E-05 Height MYH7B cds-synon 21194676 rs2425012 chr20 33581955 G A 3.40E-13 Height MYH7B cds-synon 21194676 rs2425012 chr20 33581955 G A 3.60E-09 Height MYH7B cds-synon 21194676 rs3746435 chr20 33587198 G C 4.08E-31 Protein C levels MYH7B missense 20802025 rs1058003 chr20 33590417 G A 1.58E-38 Protein C levels TRPC4AP UTR-3 20802025 rs752448 chr20 33592248 C T 5.17E-04 Major depressive disorder TRPC4AP intron 22472876 rs6060151 chr20 33594226 G T 1.20E-38 Protein C levels TRPC4AP intron 20802025 rs6060151 chr20 33594226 G T 7.73E-05 Atopy TRPC4AP intron 21625490 rs17092215 chr20 33595913 C T 2.88E-183 Protein C levels TRPC4AP intron 20802025 rs3818253 chr20 33596876 G A 5.88E-31 Protein C levels TRPC4AP intron 20802025 rs3818253 chr20 33596876 G A 4.70E-04 Major depressive disorder TRPC4AP intron 22472876 rs3818253 chr20 33596876 G A 3.88E-08 Bipolar disorder TRPC4AP intron 23070075 rs6120790 chr20 33599090 A T 8.74E-31 Protein C levels TRPC4AP intron 20802025 rs7273734 chr20 33599403 G C 1.96E-183 Protein C levels TRPC4AP intron 20802025 rs1885117 chr20 33600740 C T 8.51E-31 Protein C levels TRPC4AP intron 20802025 rs3736802 chr20 33604042 T C 1.03E-38 Protein C levels TRPC4AP intron 20802025 rs3736802 chr20 33604042 T C 7.56E-07 Alcohol dependence TRPC4AP intron 23089632 rs10485508 chr20 33605098 C T 2.21E-183 Protein C levels TRPC4AP intron 20802025 rs6579211 chr20 33605857 G A 1.73E-183 Protein C levels TRPC4AP intron 20802025 rs6120797 chr20 33606002 G A 7.81E-31 Protein C levels TRPC4AP intron 20802025 rs6119560 chr20 33606977 G C 7.75E-31 Protein C levels TRPC4AP intron 20802025 rs6088678 chr20 33607551 C T 1.34E-30 Protein C levels TRPC4AP intron 20802025 rs6088678 chr20 33607551 C T 5.31E-04 Major depressive disorder TRPC4AP intron 22472876 rs7274866 chr20 33608616 A G 1.06E-181 Protein C levels TRPC4AP intron 20802025 rs7271729 chr20 33610992 C T 1.08E-181 Protein C levels TRPC4AP intron 20802025 rs6060162 chr20 33611461 C G 9.08E-39 Protein C levels TRPC4AP intron 20802025 rs6087660 chr20 33616528 T C 9.70E-39 Protein C levels TRPC4AP intron 20802025 rs2378332 chr20 33617250 A G 9.94E-39 Protein C levels TRPC4AP intron 20802025 rs6088686 chr20 33623437 C T 7.61E-31 Protein C levels TRPC4AP intron 20802025 rs6120804 chr20 33623701 C A 7.70E-31 Protein C levels TRPC4AP intron 20802025 rs6120804 chr20 33623701 C A 5.33E-04 Major depressive disorder TRPC4AP intron 22472876 rs4911460 chr20 33624330 G A 1.07E-38 Protein C levels TRPC4AP intron 20802025 rs6060170 chr20 33624466 C G 1.10E-38 Protein C levels TRPC4AP intron 20802025 rs6088687 chr20 33624750 G A 1.12E-38 Protein C levels TRPC4AP intron 20802025 rs6087664 chr20 33626216 C G 2.39E-04 Multiple complex diseases TRPC4AP intron 17554300 rs6087664 chr20 33626216 C G 5.63E-11 Alzheimer's disease (late onset) TRPC4AP intron 18449908 rs6087664 chr20 33626216 C G 4.09E-38 Protein C levels TRPC4AP intron 20802025 rs6060172 chr20 33628805 A G 1.17E-38 Protein C levels TRPC4AP intron 20802025 rs6120812 chr20 33629427 T C 8.32E-31 Protein C levels TRPC4AP intron 20802025 rs10875492 chr20 33631407 C T 1.18E-38 Protein C levels TRPC4AP intron 20802025 rs3803938 chr20 33632600 C T 1.19E-38 Protein C levels TRPC4AP intron 20802025 rs3803937 chr20 33632687 C A 1.20E-38 Protein C levels TRPC4AP intron 20802025 rs6088690 chr20 33633326 A G 8.35E-31 Protein C levels TRPC4AP intron 20802025 rs6088691 chr20 33633758 C T 6.96E-31 Protein C levels TRPC4AP intron 20802025 rs6088691 chr20 33633758 C T 6.11E-04 Major depressive disorder TRPC4AP intron 22472876 rs11696652 chr20 33637060 T G 8.37E-31 Protein C levels TRPC4AP intron 20802025 rs6088692 chr20 33638588 A G 2.89E-04 Multiple complex diseases TRPC4AP intron 17554300 rs6088692 chr20 33638588 A G 5.63E-11 Alzheimer's disease (late onset) TRPC4AP intron 18449908 rs6088692 chr20 33638588 A G 6.09E-39 Protein C levels TRPC4AP intron 20802025 rs6087666 chr20 33640242 G A 8.35E-31 Protein C levels TRPC4AP intron 20802025 rs8117847 chr20 33642480 C T 4.50E-183 Protein C levels TRPC4AP intron 20802025 rs6120816 chr20 33644358 G C 1.82E-04 Multiple complex diseases TRPC4AP intron 17554300 rs6120816 chr20 33644358 G C 6.99E-11 Alzheimer's disease (late onset) TRPC4AP intron 18449908 rs6120816 chr20 33644358 G C 2.03E-38 Protein C levels TRPC4AP intron 20802025 rs1885119 chr20 33645649 T C 2.42E-04 Multiple complex diseases TRPC4AP intron 17554300 rs1885119 chr20 33645649 T C 5.63E-11 Alzheimer's disease (late onset) TRPC4AP intron 18449908 rs1885119 chr20 33645649 T C 5.12E-39 Protein C levels TRPC4AP intron 20802025 rs9941751 chr20 33645709 A G 8.92E-182 Protein C levels TRPC4AP intron 20802025 rs2889873 chr20 33646841 G A 8.30E-182 Protein C levels TRPC4AP intron 20802025 rs7263253 chr20 33649376 T C 7.28E-182 Protein C levels TRPC4AP intron 20802025 rs717593 chr20 33652964 G C 6.26E-182 Protein C levels TRPC4AP intron 20802025 rs6120819 chr20 33653038 T C 6.58E-31 Protein C levels TRPC4AP intron 20802025 rs1998233 chr20 33657126 G A 4.07E-07 Common traits (Other) TRPC4AP cds-synon 20585627 rs2145557 chr20 33667560 A G 1.22E-38 Protein C levels TRPC4AP intron 20802025 rs2145557 chr20 33667560 A G 8.13E-05 Atopy TRPC4AP intron 21625490 rs6120828 chr20 33674460 T C 2.58E-30 Protein C levels TRPC4AP intron 20802025 rs6060216 chr20 33678078 T C 1.10E-38 Protein C levels TRPC4AP intron 20802025 rs7261312 chr20 33684909 A T 5.41E-184 Protein C levels / / 20802025 rs6060230 chr20 33689308 C T 6.55E-183 Protein C levels / / 20802025 rs8117100 chr20 33692261 T C 2.66E-184 Protein C levels / / 20802025 rs6060239 chr20 33694580 T C 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6060239 chr20 33694580 T C 8.68E-110 Protein C levels / / 20802025 rs6060240 chr20 33694699 C A 5.27E-110 Protein C levels / / 20802025 rs6058181 chr20 33694801 T C 3.08E-110 Protein C levels / / 20802025 rs6060244 chr20 33699435 G A 2.02E-180 Protein C levels / / 20802025 rs6060245 chr20 33699625 A G 9.78E-186 Protein C levels / / 20802025 rs6088716 chr20 33700499 C T 4.01E-33 Protein C levels / / 20802025 rs6060246 chr20 33701107 A G 1.51E-160 Protein C levels / / 20802025 rs17092297 chr20 33703134 G A 1.87E-185 Protein C levels / / 20802025 rs3746429 chr20 33703607 C T 1.25E-27 Protein C levels EDEM2 missense 20802025 rs3746429 chr20 33703607 C T 4.35E-04 Bone properties (heel) EDEM2 missense 24430505 rs6088721 chr20 33706011 A C 2.08E-33 Protein C levels EDEM2 intron 20802025 rs2273805 chr20 33706575 T A 2.12E-33 Protein C levels EDEM2 intron 20802025 rs2065108 chr20 33706822 C T 1.61E-04 Multiple complex diseases EDEM2 intron 17554300 rs2065108 chr20 33706822 C T 3.85E-10 Alzheimer's disease (late onset) EDEM2 intron 18449908 rs2065108 chr20 33706822 C T 2.14E-33 Protein C levels EDEM2 intron 20802025 rs2378333 chr20 33708890 T G 5.29E-33 Protein C levels EDEM2 intron 20802025 rs6120838 chr20 33711624 T A 2.35E-33 Protein C levels EDEM2 intron 20802025 rs149260082 chr20 33711831 T C 0.000091 Prostate cancer (advanced) EDEM2 missense 23555315 rs6088724 chr20 33712915 C T 2.87E-33 Protein C levels EDEM2 intron 20802025 rs6088727 chr20 33713639 G A 1.41E-04 Multiple complex diseases EDEM2 intron 17554300 rs6088727 chr20 33713639 G A 3.85E-10 Alzheimer's disease (late onset) EDEM2 intron 18449908 rs6088727 chr20 33713639 G A 2.78E-33 Protein C levels EDEM2 intron 20802025 rs6088728 chr20 33713674 T C 5.13E-33 Protein C levels EDEM2 intron 20802025 rs2295887 chr20 33714187 G A 1.74E-33 Protein C levels EDEM2 intron 20802025 rs6087677 chr20 33714805 T C 1.47E-33 Protein C levels EDEM2 intron 20802025 rs1535466 chr20 33718706 G A 2.88E-07 Common traits (Other) EDEM2 intron 20585627 rs6120843 chr20 33718993 C G 4.67E-130 Protein C levels EDEM2 intron 20802025 rs1033797 chr20 33719687 T C 4.04E-130 Protein C levels EDEM2 intron 20802025 rs1033799 chr20 33720033 C A 1.73E-118 Protein C levels EDEM2 intron 20802025 rs6060257 chr20 33720157 G T 3.13E-128 Protein C levels EDEM2 intron 20802025 rs11908683 chr20 33720920 T C 5.02E-191 Protein C levels EDEM2 intron 20802025 rs2295888 chr20 33722863 A G 3.66E-191 Protein C levels EDEM2 intron 20802025 rs2295888 chr20 33722863 A G 5.00E-13 Prothrombin time EDEM2 intron 22703881 rs7361656 chr20 33729147 T G 7.76E-08 Common traits (Other) EDEM2 intron 20585627 rs11906318 chr20 33729442 A C 2.10E-194 Protein C levels EDEM2 intron 20802025 rs6120849 chr20 33730387 C T 5.88E-04 Multiple complex diseases EDEM2 intron 17554300 rs6120849 chr20 33730387 C T 7.00E-37 Protein C levels EDEM2 intron 20802025 rs6060266 chr20 33733078 T C 2.27E-36 Protein C levels EDEM2 intron 20802025 rs1415771 chr20 33734493 G A 2.56E-38 Protein C levels EDEM2 intron 20802025 rs1415771 chr20 33734493 G A 5.03E-06 Alcohol dependence EDEM2 intron 23089632 rs945959 chr20 33734905 G C 2.43E-38 Protein C levels EDEM2 intron 20802025 rs1124511 chr20 33736697 A C 2.27E-38 Protein C levels / / 20802025 rs6060270 chr20 33736814 G T 1.50E-25 Protein C levels / / 20802025 rs11907010 chr20 33737661 C T 1.15E-198 Protein C levels / / 20802025 rs6058194 chr20 33739831 G A 2.98E-36 Protein C levels / / 20802025 rs11696967 chr20 33743609 A C 3.15E-36 Protein C levels / / 20802025 rs6088732 chr20 33744134 C T 5.29E-33 Protein C levels / / 20802025 rs6088733 chr20 33744904 A G 4.37E-36 Protein C levels / / 20802025 rs6088735 chr20 33745676 C T 7.35E-36 Protein C levels / / 20802025 rs6088738 chr20 33747331 G A 1.38E-04 Multiple complex diseases / / 17554300 rs6088738 chr20 33747331 G A 3.81E-35 Protein C levels / / 20802025 rs6060278 chr20 33753262 T C 9.60E-36 Protein C levels / / 20802025 rs8119351 chr20 33754405 G A 2.68E-203 Protein C levels / / 20802025 rs8119351 chr20 33754405 G A 8.71E-05 Cognitive impairment induced by topiramate / / 22091778 rs8119351 chr20 33754405 G A 3.96E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6088747 chr20 33754604 G T 2.27E-04 Height / / 18193045 rs2069940 chr20 33759272 C G 1.24E-201 Protein C levels / / 20802025 rs2069940 chr20 33759272 C G 1.86E-04 Lymphocyte counts / / 22286170 rs2069952 chr20 33763951 C T 4.08E-04 Height PROCR intron 18193045 rs867186 chr20 33764554 A G 6.00E-37 Coagulation factor levels PROCR missense 20231535 rs867186 chr20 33764554 A G 2.00E-200 Protein C levels PROCR missense 20802025 rs867186 chr20 33764554 A G 4.00E-06 D-dimer levels PROCR missense 21502573 rs867186 chr20 33764554 A G 1.84E-36 FVII levels PROCR missense 21676895 rs867186 chr20 33764554 A G 3.20E-08 Coronary heart disease PROCR missense 21966275 rs867186 chr20 33764554 A G 4.00E-09 Anticoagulant levels PROCR missense 22216198 rs867186 chr20 33764554 A G 2.00E-06 Hemostatic factors and hematological phenotypes PROCR missense 22443383 rs867186 chr20 33764554 A G 5.12E-08 Coronary artery disease PROCR missense 23202125 rs1415774 chr20 33765616 A G 4.13E-04 Height / / 18193045 rs2065979 chr20 33767690 T C 4.22E-04 Height / / 18193045 rs7265317 chr20 33768523 T C 7.29E-07 FVII levels / / 21676895 rs6060285 chr20 33770487 G T 4.19E-04 Height / / 18193045 rs11167260 chr20 33775200 G A 6.78E-202 Protein C levels / / 20802025 rs11167260 chr20 33775200 G A 2.16E-38 FVII levels / / 21676895 rs11167260 chr20 33775200 G A 2.40E-37 FVII levels / / 21676895 rs11167260 chr20 33775200 G A 4.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6087685 chr20 33777612 G C 4.64E-19 Protein C levels / / 20802025 rs6058202 chr20 33777983 A G 4.38E-04 Height / / 18193045 rs633198 chr20 33778434 T C 4.35E-04 Height / / 18193045 rs6060300 chr20 33780970 T C 4.11E-33 Protein C levels / / 20802025 rs4911478 chr20 33782625 A C 4.32E-04 Height / / 18193045 rs6060301 chr20 33783242 G T 7.94E-07 Common traits (Other) / / 20585627 rs1577924 chr20 33784288 C G 4.37E-04 Height / / 18193045 rs6142324 chr20 33789043 C T 4.46E-04 Height / / 18193045 rs8114671 chr20 33789142 C A 4.39E-04 Height / / 18193045 rs8114671 chr20 33789142 C A 1.00E-15 Height / / 23563607 rs2093058 chr20 33791281 G A 4.44E-04 Height / / 18193045 rs6088764 chr20 33793159 C A 4.17E-18 Protein C levels / / 20802025 rs17092456 chr20 33796192 G C 2.09E-178 Protein C levels / / 20802025 rs6120870 chr20 33797488 A G 4.37E-12 Protein C levels / / 20802025 rs17406518 chr20 33799176 A C 2.17E-142 Protein C levels / / 20802025 rs6088765 chr20 33799280 T G 1.50E-04 Height / / 18193045 rs6088765 chr20 33799280 T G 2.00E-08 Ulcerative colitis / / 23128233 rs11699306 chr20 33801283 T C 1.35E-133 Protein C levels / / 20802025 rs2425019 chr20 33819415 A G 6.89E-05 Height MMP24 intron 18193045 rs2425019 chr20 33819415 A G 1.50E-12 Height MMP24 intron 21194676 rs2425019 chr20 33819415 A G 2.10E-15 Height MMP24 intron 21194676 rs2425019 chr20 33819415 A G 2.40E-26 Height MMP24 intron 21194676 rs12479765 chr20 33825378 G A 3.49E-19 Protein C levels MMP24 intron 20802025 rs6120880 chr20 33829406 C G,T 6.31E-05 Height MMP24 intron 18193045 rs6088776 chr20 33835773 T C 3.08E-10 Protein C levels MMP24 intron 20802025 rs2247828 chr20 33839939 A G 2.00E-04 Cognitive impairment induced by topiramate MMP24 intron 22091778 rs2425024 chr20 33844938 A C 8.09E-04 Multiple complex diseases MMP24 intron 17554300 rs2425024 chr20 33844938 A C 1.36E-23 Protein C levels MMP24 intron 20802025 rs2425024 chr20 33844938 A C 2.00E-04 Cognitive impairment induced by topiramate MMP24 intron 22091778 rs1555322 chr20 33849179 G A 4.00E-06 Attention deficit hyperactivity disorder MMP24 intron 18839057 rs2275274 chr20 33857544 C A,G,T 2.19E-88 Protein C levels MMP24 intron 20802025 rs2275274 chr20 33857544 C A,G,T 1.95E-04 Obesity (extreme) MMP24 intron 21935397 rs2275274 chr20 33857544 C A,G,T 4.71E-04 Smoking quantity MMP24 intron 24665060 rs6060341 chr20 33863633 A G 8.98E-32 Protein C levels MMP24 UTR-3 20802025 rs2297789 chr20 33867248 A T 9.26E-33 Protein C levels EIF6 intron 20802025 rs619865 chr20 33867697 A G 2.22E-04 Multiple complex diseases EIF6 intron 17554300 rs619865 chr20 33867697 A G 1.60E-08 Skin sensitivity to sun EIF6 intron 18488028 rs619865 chr20 33867697 A G 5.00E-14 Freckling EIF6 intron 20585627 rs619865 chr20 33867697 A G 5.21E-04 Iron levels EIF6 intron pha002876 rs2250205 chr20 33867924 G A 4.63E-33 Protein C levels EIF6 intron 20802025 rs2250205 chr20 33867924 G A 4.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EIF6 intron 20877124 rs932562 chr20 33871310 T C 1.17E-32 Protein C levels EIF6 intron 20802025 rs932562 chr20 33871310 T C 5.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EIF6 intron 20877124 rs2425046 chr20 33871661 T C 9.34E-04 Multiple complex diseases EIF6 intron 17554300 rs2425047 chr20 33871675 A C 2.77E-32 Protein C levels EIF6 intron 20802025 rs1802241 chr20 33872215 C A 0.000064 Breast cancer(er negative) EIF6 missense 23555315 rs78127944 chr20 33874600 C T 0.000095 Breast cancer(er negative) FAM83C missense 23555315 rs2425049 chr20 33874720 C T 1.50E-38 Protein C levels FAM83C missense 20802025 rs2425050 chr20 33879478 A G 8.74E-30 Protein C levels FAM83C intron 20802025 rs8120559 chr20 33880546 G A 1.35E-11 Protein C levels / / 20802025 rs6058224 chr20 33881774 G A 1.40E-30 Protein C levels / / 20802025 rs6058224 chr20 33881774 G A 5.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13037376 chr20 33885155 T C 2.67E-22 Protein C levels / / 20802025 rs8114520 chr20 33885892 A T 2.06E-09 Protein C levels / / 20802025 rs6060355 chr20 33890061 G A 2.46E-06 Height UQCC nearGene-3 18193045 rs3764732 chr20 33891004 G A 1.63E-04 Blood pressure UQCC UTR-3 17255346 rs3764732 chr20 33891004 G A 2.47E-19 Protein C levels UQCC UTR-3 20802025 rs878639 chr20 33894463 A G 1.92E-06 Height UQCC intron 18193045 rs6058227 chr20 33895947 C T 9.24E-44 Protein C levels UQCC intron 20802025 rs6058227 chr20 33895947 C T 8.21E-06 Height UQCC intron 22216288 rs3795159 chr20 33896262 C G 1.69E-06 Height UQCC intron 18193045 rs6579229 chr20 33897584 C T 1.30E-29 Protein C levels UQCC intron 20802025 rs2145082 chr20 33905326 C T 7.10E-04 Multiple complex diseases UQCC intron 17554300 rs2145082 chr20 33905326 C T 1.12E-05 Height UQCC intron 18193045 rs1406948 chr20 33905619 G A 8.30E-07 Height UQCC intron 18193045 rs1406949 chr20 33905904 C A 8.26E-07 Height UQCC intron 18193045 rs4911488 chr20 33906573 C G 3.49E-19 Protein C levels UQCC intron 20802025 rs6060369 chr20 33907161 T C 2.00E-16 Height UQCC intron 18193045 rs6060369 chr20 33907161 T C 1.00E-16 Height UQCC intron 18391950 rs6060369 chr20 33907161 T C 2.18E-05 Height UQCC intron 19570815 rs6088791 chr20 33907909 T C 1.01E-06 Height UQCC intron 18193045 rs2425056 chr20 33909245 G A 4.73E-06 Height UQCC intron 18193045 rs6060370 chr20 33909752 T C 4.79E-06 Height UQCC intron 18193045 rs6088792 chr20 33909784 C T 1.50E-05 Height UQCC intron 18193045 rs6088792 chr20 33909784 C T 8.00E-07 Height UQCC intron 18391951 rs17323916 chr20 33910581 G A 1.39E-05 Height UQCC intron 18193045 rs6120904 chr20 33913291 G A 1.31E-29 Protein C levels UQCC intron 20802025 rs6060371 chr20 33913322 G T 1.18E-06 Height UQCC intron 18193045 rs6060373 chr20 33914208 A G 1.18E-06 Height UQCC intron 18193045 rs6060373 chr20 33914208 A G 2.00E-17 Height UQCC intron 18391952 rs6060373 chr20 33914208 A G 2.00E-07 Spine bone size UQCC intron 23207799 rs17092565 chr20 33914245 T G 1.31E-18 Protein C levels UQCC intron 20802025 rs2425060 chr20 33914701 T C 4.56E-06 Height UQCC intron 18193045 rs1570002 chr20 33916796 G A 1.53E-29 Protein C levels UQCC intron 20802025 rs4911489 chr20 33917087 C T 6.08E-19 Protein C levels UQCC intron 20802025 rs17092579 chr20 33918232 A G 6.07E-19 Protein C levels UQCC intron 20802025 rs6060375 chr20 33920975 T C 1.72E-27 Protein C levels UQCC intron 20802025 rs6060378 chr20 33923001 T G 4.36E-06 Height UQCC intron 18193045 rs2425062 chr20 33923566 A G 1.17E-06 Height UQCC intron 18193045 rs2248393 chr20 33926103 C G 3.12E-06 Height UQCC intron 18193045 rs1540927 chr20 33931344 A G 2.93E-06 Height UQCC intron 18193045 rs941664 chr20 33939973 G C 1.73E-05 Height UQCC intron 18193045 rs941665 chr20 33943281 C T 1.61E-05 Height UQCC intron 18193045 rs4911491 chr20 33947285 C G 3.08E-06 Height UQCC intron 18193045 rs4911492 chr20 33951799 G A 3.27E-06 Height UQCC intron 18193045 rs4911178 chr20 33952620 G A 3.26E-06 Height UQCC intron 18193045 rs745931 chr20 33956004 A T 3.07E-06 Height UQCC intron 18193045 rs1570004 chr20 33958253 A T 3.05E-06 Height UQCC intron 18193045 rs6142358 chr20 33960308 C T 3.01E-06 Height UQCC intron 18193045 rs17331061 chr20 33963174 T G 2.63E-34 Protein C levels UQCC intron 20802025 rs725908 chr20 33968067 T C 1.80E-07 Height UQCC intron 18193045 rs6141548 chr20 33971085 A G 2.42E-06 Height UQCC intron 18193045 rs4911494 chr20 33971914 C T 2.32E-06 Height UQCC missense 18193045 rs4911495 chr20 33971978 A C 3.90E-20 Protein C levels UQCC intron 20802025 rs4911496 chr20 33972053 C T 2.31E-06 Height UQCC intron 18193045 rs4911179 chr20 33972899 A C 2.25E-06 Height UQCC intron 18193045 rs4911180 chr20 33972948 G A 2.38E-06 Height UQCC intron 18193045 rs6088813 chr20 33975181 C A 2.27E-06 Height UQCC intron 18193045 rs6088813 chr20 33975181 C A 1.00E-13 Height UQCC intron 19343178 rs6088815 chr20 33976474 G C 2.17E-06 Height UQCC intron 18193045 rs1210224 chr20 33980860 T C 1.35E-05 Height UQCC intron 18193045 rs1204656 chr20 33982846 G A 8.65E-06 Height UQCC intron 18193045 rs6142373 chr20 33983314 T A 1.84E-06 Height UQCC intron 18193045 rs6579234 chr20 33983485 A G 1.69E-06 Height UQCC intron 18193045 rs6142374 chr20 33985568 C T 1.64E-06 Height UQCC intron 18193045 rs1886691 chr20 33986271 T C 1.71E-06 Height UQCC intron 18193045 rs6088820 chr20 33987298 T C 1.67E-06 Height UQCC intron 18193045 rs6142376 chr20 33992761 T A 1.99E-06 Height UQCC intron 18193045 rs6088823 chr20 33994265 G T 1.99E-06 Height UQCC intron 18193045 rs6087702 chr20 33995945 T A 1.98E-06 Height UQCC intron 18193045 rs6142379 chr20 33999267 A G 1.76E-06 Height UQCC intron 18193045 rs6087704 chr20 34001058 C T 1.66E-06 Height UQCC nearGene-5 18193045 rs6060402 chr20 34005240 T C 1.71E-06 Height / / 18193045 rs6060402 chr20 34005240 T C 0.000864 Salmonella-induced pyroptosis / / 22837397 rs6088832 chr20 34006176 C T 4.42E-05 Height / / 18193045 rs4911499 chr20 34007622 C T 4.33E-36 Protein C levels / / 20802025 rs224320 chr20 34010556 A G 3.24E-51 Protein C levels / / 20802025 rs224320 chr20 34010556 A G 1.23E-04 Telomere length / / 21573004 rs8123070 chr20 34017598 G A 1.61E-04 Multiple complex diseases / / 17554300 rs6087709 chr20 34017944 C G 7.96E-06 Height / / 18193045 rs224328 chr20 34019018 C T 2.25E-33 Protein C levels / / 20802025 rs224328 chr20 34019018 C T 4.98E-04 Insulin resistance / / 21901158 rs224329 chr20 34019579 C T 1.35E-06 Height / / 18193045 rs224330 chr20 34022196 C T 6.19E-21 Protein C levels GDF5 cds-synon 20802025 rs224332 chr20 34022672 C A 6.19E-21 Protein C levels GDF5 intron 20802025 rs224333 chr20 34023962 G A 2.98E-06 Height GDF5 intron 18193045 rs224333 chr20 34023962 G A 8.00E-37 Height GDF5 intron 23563607 rs224334 chr20 34024719 G A 5.37E-21 Protein C levels GDF5 intron 20802025 rs143384 chr20 34025756 A G 3.65E-05 Height GDF5 UTR-5 18193045 rs143384 chr20 34025756 A G 1.00E-58 Height GDF5 UTR-5 20881960 rs143384 chr20 34025756 A G 8.09E-04 Height GDF5 UTR-5 22216288 rs143383 chr20 34025983 A G 5.01E-12 Height GDF5 UTR-5 18193045 rs143383 chr20 34025983 A G 2.00E-13 Osteoarthritis (knee and hip) GDF5 UTR-5 21177295 rs143383 chr20 34025983 A G 9.00E-05 Osteoarthritis (knee and hip) GDF5 UTR-5 21177295 rs739329 chr20 34027636 G A 2.55E-21 Protein C levels GDF5 nearGene-5 20802025 rs2274238 chr20 34089718 G T 1.11E-09 Protein C levels CEP250 cds-synon 20802025 rs7274597 chr20 34094549 C T 2.82E-08 Protein C levels CEP250 intron 20802025 rs2236164 chr20 34097353 T C 2.00E-06 Height CEP250 intron 20189936 rs6060448 chr20 34112192 G C 1.60E-04 Brain structure C20orf173 intron 22504417 rs224400 chr20 34113993 A T 1.47E-16 Protein C levels C20orf173 intron 20802025 rs17092750 chr20 34114960 A T 3.63E-04 Multiple complex diseases C20orf173 UTR-3 17554300 rs17092750 chr20 34114960 A T 1.51E-16 Protein C levels C20orf173 UTR-3 20802025 rs6060450 chr20 34117408 G A 1.33E-16 Protein C levels C20orf173 UTR-5 20802025 rs6060456 chr20 34132204 T C 1.31E-16 Protein C levels ERGIC3 intron 20802025 rs224415 chr20 34135629 G A 5.49E-05 Brain structure ERGIC3 intron 22504417 rs6060462 chr20 34142512 G A 1.19E-16 Protein C levels ERGIC3 intron 20802025 rs224419 chr20 34143092 A G 1.22E-04 Brain structure ERGIC3 intron 22504417 rs17845241 chr20 34144746 A AA,AG 9.91E-17 Protein C levels ERGIC3 cds-synon 20802025 rs8825 chr20 34144746 A G 9.91E-17 Protein C levels ERGIC3 cds-synon 20802025 rs8120157 chr20 34146779 T C 1.50E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2277862 chr20 34152782 C T 4.00E-10 Cholesterol,total / / 20686565 rs2277862 chr20 34152782 C T 5.00E-11 Cholesterol,total / / 24097068 rs224430 chr20 34153341 C T 2.61E-04 Brain structure FER1L4 intron 22504417 rs224435 chr20 34154087 A G 2.49E-04 Brain structure FER1L4 intron 22504417 rs224436 chr20 34154124 T C 4.85E-04 Brain structure FER1L4 intron 22504417 rs224437 chr20 34154371 C A 2.10E-04 Brain structure FER1L4 intron 22504417 rs7264396 chr20 34154741 C T 2.13E-04 Brain structure FER1L4 intron 22504417 rs224440 chr20 34159447 C G 1.84E-04 Brain structure FER1L4 intron 22504417 rs1557203 chr20 34164463 A G 2.50E-17 Protein C levels FER1L4 intron 20802025 rs6087720 chr20 34169284 T G 1.32E-09 Protein C levels FER1L4 intron 20802025 rs6119628 chr20 34170174 C A 3.27E-05 Brain structure FER1L4 intron 22504417 rs6088887 chr20 34171324 G A 1.19E-09 Protein C levels FER1L4 intron 20802025 rs6060488 chr20 34173178 A G 1.25E-09 Protein C levels / / 20802025 rs6120993 chr20 34185161 G T 3.41E-09 Protein C levels FER1L4 intron 20802025 rs3746410 chr20 34190870 A G 6.16E-07 Lymphocyte counts FER1L4 intron 22286170 rs6060499 chr20 34191629 T C 9.31E-04 Multiple complex diseases FER1L4 intron 17554300 rs882436 chr20 34195271 A C 1.06E-44 Protein C levels FER1L4 intron 20802025 rs761827 chr20 34207897 C T 4.07E-08 Protein C levels SPAG4 intron 20802025 rs12625191 chr20 34211293 C G 2.09E-41 Protein C levels / / 20802025 rs2425068 chr20 34214723 T C 1.30E-09 Protein C levels CPNE1 splice-5 20802025 rs6060517 chr20 34216340 T C 2.83E-37 Protein C levels CPNE1 intron 20802025 rs2230219 chr20 34219480 G A 7.57E-43 Protein C levels CPNE1 cds-synon 20802025 rs11543244 chr20 34220755 C T 0.000259 Salmonella-induced pyroptosis CPNE1 missense 22837397 rs926994 chr20 34221023 G A 7.37E-43 Protein C levels CPNE1 intron 20802025 rs17426419 chr20 34229645 T C 1.67E-42 Protein C levels CPNE1 intron 20802025 rs6060536 chr20 34236987 T C 1.50E-42 Protein C levels RBM12 UTR-3 20802025 rs17426738 chr20 34237934 G A 1.52E-42 Protein C levels RBM12 UTR-3 20802025 rs17427233 chr20 34246117 T G 1.58E-42 Protein C levels CPNE1 intron 20802025 rs6060540 chr20 34247849 C T 2.60E-42 Protein C levels CPNE1 intron 20802025 rs6058292 chr20 34248769 T C 1.39E-42 Protein C levels CPNE1 intron 20802025 rs6121019 chr20 34250648 G T 1.23E-42 Protein C levels CPNE1 intron 20802025 rs6121021 chr20 34252438 A C 8.31E-43 Protein C levels CPNE1 intron 20802025 rs6119636 chr20 34253018 G C 6.99E-43 Protein C levels / / 20802025 rs6060545 chr20 34253803 C T 5.15E-43 Protein C levels / / 20802025 rs6121022 chr20 34255007 A C 4.59E-43 Protein C levels / / 20802025 rs6121023 chr20 34256640 A C 4.34E-43 Protein C levels NFS1 UTR-3 20802025 rs2180280 chr20 34257351 T C 4.18E-43 Protein C levels NFS1 UTR-3 20802025 rs6060546 chr20 34257663 A C 3.45E-43 Protein C levels NFS1 intron 20802025 rs17336615 chr20 34262011 A C 7.18E-44 Protein C levels NFS1 intron 20802025 rs6060548 chr20 34264565 T A 2.94E-43 Protein C levels NFS1 intron 20802025 rs6121029 chr20 34274437 T C 2.00E-43 Protein C levels NFS1 intron 20802025 rs11907022 chr20 34283626 A G 3.10E-43 Protein C levels NFS1 intron 20802025 rs11907022 chr20 34283626 A G 3.68E-04 Smoking initiation NFS1 intron 24665060 rs3088078 chr20 34288854 C T 1.02E-43 Protein C levels ROMO1 UTR-3 20802025 rs17343651 chr20 34296166 G C 7.55E-17 Protein C levels RBM39 intron 20802025 rs11699044 chr20 34312713 C T 1.22E-18 Lymphocyte counts RBM39 intron 22286170 rs6060582 chr20 34313297 C T 1.45E-04 Multiple complex diseases RBM39 intron 17554300 rs6121037 chr20 34330583 G C 6.25E-15 Protein C levels RBM39 nearGene-5 20802025 rs3761135 chr20 34332400 C T 1.52E-43 Protein C levels / / 20802025 rs11906854 chr20 34383634 A G 7.00E-06 Migraine - clinic-based PHF20 intron 23793025 rs17430100 chr20 34384646 A G 3.92E-45 Protein C levels PHF20 intron 20802025 rs6060612 chr20 34390527 A G 6.31E-10 Common traits (Other) PHF20 intron 20585627 rs17345771 chr20 34429931 C T 5.28E-45 Protein C levels PHF20 intron 20802025 rs2425168 chr20 34440380 A T 5.87E-45 Protein C levels PHF20 intron 20802025 rs2425173 chr20 34445142 G A 2.72E-08 Protein C levels PHF20 intron 20802025 rs2425174 chr20 34445375 C G 6.16E-45 Protein C levels PHF20 intron 20802025 rs2064511 chr20 34448810 G A,C,T 2.75E-08 Protein C levels PHF20 intron 20802025 rs6060649 chr20 34458599 G T 9.56E-45 Protein C levels PHF20 intron 20802025 rs6058339 chr20 34460479 C T 1.69E-07 Melanoma PHF20 intron 18488026 rs6060658 chr20 34470012 T G 3.03E-44 Protein C levels PHF20 intron 20802025 rs7267005 chr20 34489565 T C 6.10E-32 Narcolepsy PHF20 intron 19629137 rs6060684 chr20 34509678 T G 3.62E-44 Protein C levels PHF20 intron 20802025 rs6121089 chr20 34513655 G A 3.66E-44 Protein C levels PHF20 intron 20802025 rs6058368 chr20 34515490 A G 3.67E-44 Protein C levels PHF20 intron 20802025 rs6060690 chr20 34517135 T C 6.84E-45 Protein C levels PHF20 intron 20802025 rs6060702 chr20 34529734 G A 3.53E-04 Multiple complex diseases PHF20 intron 17554300 rs6060717 chr20 34544647 T C 6.31E-04 Smoking cessation / / 24665060 rs11908470 chr20 34545063 A G 3.82E-44 Protein C levels / / 20802025 rs6119683 chr20 34546036 C T 1.87E-44 Protein C levels / / 20802025 rs1341603 chr20 34556216 A G 4.85E-04 Smoking quantity / / 24665060 rs17347958 chr20 34560609 G A 5.34E-47 Protein C levels C20orf152 missense 20802025 rs17093270 chr20 34562581 T C 1.66E-44 Protein C levels C20orf152 intron 20802025 rs138969375 chr20 34572607 C T 0.00002 Prostate cancer (advanced) C20orf152 missense 23555315 rs6142475 chr20 34578224 C T 9.28E-46 Protein C levels C20orf152 intron 20802025 rs6060752 chr20 34597962 G A 6.87E-46 Protein C levels C20orf152 intron 20802025 rs6142483 chr20 34611880 C G 1.45E-18 Protein C levels C20orf152 intron 20802025 rs1204552 chr20 34638903 T A 1.47E-09 Melanoma / / 18488026 rs3850528 chr20 34702658 C G 2.10E-04 Type 2 diabetes and 6 quantitative traits EPB41L1 intron 17848626 rs17362569 chr20 34711838 A G 1.86E-16 Protein C levels EPB41L1 intron 20802025 rs6141600 chr20 34712310 T C 6.00E-12 Height EPB41L1 intron 23563607 rs1474976 chr20 34732372 C A 3.16E-10 Common traits (Other) EPB41L1 intron 20585627 rs17362834 chr20 34735205 A C 3.42E-16 Protein C levels EPB41L1 intron 20802025 rs911128 chr20 34743164 G C 3.49E-16 Protein C levels EPB41L1 intron 20802025 rs6060827 chr20 34743922 T C 3.52E-16 Protein C levels EPB41L1 intron 20802025 rs11700361 chr20 34822315 C T 9.45E-04 Multiple complex diseases / / 17554300 rs6058435 chr20 34829868 A G 2.74E-04 Alzheimer's disease C20orf4 intron 24755620 rs17436024 chr20 34843093 C T 4.69E-16 Protein C levels C20orf4 intron 20802025 rs2425193 chr20 34848116 C T 6.19E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2425196 chr20 34850364 C T 1.51E-04 Smoking quantity / / 24665060 rs2425204 chr20 34856662 A G 9.76E-19 Protein C levels / / 20802025 rs2425207 chr20 34859043 G A 1.20E-18 Protein C levels / / 20802025 rs8115222 chr20 34865240 A G 4.00E-06 Obesity-related traits / / 23251661 rs2425215 chr20 34870005 T G 1.33E-18 Protein C levels / / 20802025 rs13038810 chr20 34870223 A G 2.51E-08 Protein C levels / / 20802025 rs2425219 chr20 34874349 C T 1.93E-18 Protein C levels / / 20802025 rs6060891 chr20 34875145 C T 9.77E-08 Common traits (Other) / / 20585627 rs6121201 chr20 34885607 T C 5.51E-04 Multiple complex diseases / / 17554300 rs4239689 chr20 34950604 A G 3.58E-10 Protein C levels / / 20802025 rs6129410 chr20 34981382 G A 1.96E-04 Obesity (extreme) / / 21935397 rs6129926 chr20 35001278 T C 1.94E-04 Obesity (extreme) DLGAP4 intron 21935397 rs2425223 chr20 35001520 T C 8.98E-04 Multiple complex diseases DLGAP4 intron 17554300 rs7363475 chr20 35037246 C T 3.56E-08 Protein C levels DLGAP4 intron 20802025 rs6017722 chr20 35043789 A G 4.41E-08 Protein C levels DLGAP4 intron 20802025 rs6032628 chr20 35044292 G A 4.44E-08 Protein C levels DLGAP4 intron 20802025 rs4077554 chr20 35046673 C T 4.45E-08 Protein C levels DLGAP4 intron 20802025 rs906467 chr20 35048595 T C 4.16E-08 Protein C levels DLGAP4 intron 20802025 rs906466 chr20 35048632 G A 1.74E-10 Protein C levels DLGAP4 intron 20802025 rs221308 chr20 35276398 G A 8.76E-04 Type 2 diabetes SLA2 nearGene-5 17463246 rs2206444 chr20 35316777 T A 1.35E-08 Protein C levels NDRG3 intron 20802025 rs2298308 chr20 35412834 G A 1.68E-08 Protein C levels SOGA1 UTR-3 20802025 rs1146250 chr20 35467713 G A 7.05E-04 Type 2 diabetes SOGA1 cds-synon 17463246 rs11699738 chr20 35490340 G A 4.26E-04 Iron levels SOGA1 intron pha002876 rs11697895 chr20 35500058 G A 1.20E-05 Urinary metabolites / / 21572414 rs1291117 chr20 35502240 A G 4.73E-05 Coronary heart disease / / pha003032 rs4812641 chr20 35590249 C A 8.63E-05 Attention deficit hyperactivity disorder / / 22420046 rs6073285 chr20 35717715 T C 4.66E-04 Multiple complex diseases RBL1 intron 17554300 rs1780671 chr20 35748416 T A 1.07E-04 Type 2 diabetes C20orf132 intron 17463246 rs1624888 chr20 35748894 C G 9.19E-04 Type 2 diabetes C20orf132 intron 17463246 rs8115854 chr20 35766337 A G 2.00E-06 Hippocampal atrophy C20orf132 missense 19668339 rs1780686 chr20 35780519 G A 2.17E-04 Type 2 diabetes C20orf132 intron 17463246 rs1615246 chr20 35783494 T C 1.81E-04 Type 2 diabetes C20orf132 missense 17463246 rs1291079 chr20 35800743 T C 8.02E-04 Type 2 diabetes C20orf132 intron 17463246 rs1291080 chr20 35801808 T C 2.10E-04 Type 2 diabetes C20orf132 intron 17463246 rs8120307 chr20 35803188 T C 6.93E-05 Hippocampal atrophy C20orf132 intron 19668339 rs6031882 chr20 35809783 T C 6.00E-06 Hippocampal atrophy RPN2 intron 19668339 rs4812880 chr20 35823690 G A 4.63E-04 Type 2 diabetes RPN2 intron 17463246 rs6073647 chr20 35826414 G A 5.68E-04 Type 2 diabetes RPN2 intron 17463246 rs7268848 chr20 35826430 G A 5.98E-04 Type 2 diabetes RPN2 intron 17463246 rs2076398 chr20 35827682 G T 2.98E-04 Type 2 diabetes RPN2 intron 17463246 rs2076398 chr20 35827682 G T 3.57E-04 Lymphocyte counts RPN2 intron 22286170 rs2272950 chr20 35838372 T A 2.80E-04 Type 2 diabetes RPN2 intron 17463246 rs6513975 chr20 35846976 A G 1.22E-04 Type 2 diabetes RPN2 intron 17463246 rs765630 chr20 35850996 G A 4.86E-04 Type 2 diabetes RPN2 intron 17463246 rs4810454 chr20 35861973 C T 2.46E-04 Type 2 diabetes RPN2 intron 17463246 rs4810455 chr20 35862002 T A 5.70E-04 Type 2 diabetes RPN2 intron 17463246 rs2281202 chr20 35862708 T C 5.98E-04 Type 2 diabetes RPN2 intron 17463246 rs6104281 chr20 35881456 C A 9.66E-05 Multiple complex diseases GHRH intron 17554300 rs747182 chr20 35982889 T C 2.85E-04 Lymphocyte counts SRC intron 22286170 rs6018199 chr20 36009657 T G 5.11E-05 HIV-1 progression to AIDS and death SRC intron 21811574 rs17194885 chr20 36068389 A C 4.00E-06 Retinopathy in non-diabetics / / 23393555 rs6018946 chr20 36131085 T A 2.46E-04 Multiple sclerosis / / 17660530 rs6095371 chr20 36207509 C T 2.02E-04 Multiple complex diseases / / 17554300 rs6125574 chr20 36229435 A G 2.74E-04 Multiple complex diseases / / 17554300 rs6063366 chr20 36233045 C T 2.41E-04 Multiple complex diseases / / 17554300 rs6125601 chr20 36240021 G A 6.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6012636 chr20 36242860 C T 9.53E-05 Serum metabolites / / 19043545 rs6512578 chr20 36243810 T G 9.36E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6125623 chr20 36246413 T C 3.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs5011367 chr20 36249002 A G 7.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6063396 chr20 36253934 T C 5.24E-04 Multiple complex diseases / / 17554300 rs6067104 chr20 36261921 C T 1.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs198493 chr20 36270066 T C 8.81E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6020113 chr20 36303045 G A 4.10E-07 Memory performance / / 22105620 rs6012770 chr20 36304115 G A 8.00E-07 Memory performance / / 22105620 rs6020125 chr20 36304850 G T 1.15E-05 Cognitive impairment induced by topiramate / / 22091778 rs6020130 chr20 36305452 G A 1.15E-05 Cognitive impairment induced by topiramate / / 22091778 rs7363432 chr20 36306730 A G 3.51E-06 Body mass index / / 18325910 rs7363432 chr20 36306730 A G 1.50E-06 Memory performance / / 22105620 rs6095722 chr20 36310628 A G 1.74E-05 Body mass index / / 18325910 rs6095722 chr20 36310628 A G 2.90E-06 Memory performance / / 22105620 rs16986890 chr20 36326523 A G 1.38E-04 Body mass index CTNNBL1 intron 18325910 rs16986890 chr20 36326523 A G 3.11E-05 Body mass index CTNNBL1 intron 18325910 rs16986890 chr20 36326523 A G 7.70E-08 Memory performance CTNNBL1 intron 22105620 rs6020395 chr20 36339324 G C 3.46E-05 Prostate cancer CTNNBL1 intron 18264096 rs6020395 chr20 36339324 G C 3.46E-05 Body mass index CTNNBL1 intron 18325910 rs6020395 chr20 36339324 G C 7.71E-06 Body mass index CTNNBL1 intron 18325910 rs6020395 chr20 36339324 G C 4.80E-07 Memory performance CTNNBL1 intron 22105620 rs6125996 chr20 36354669 C G 2.65E-08 Multiple complex diseases CTNNBL1 intron 17554300 rs16986921 chr20 36382521 C T 5.88E-07 Prostate cancer CTNNBL1 intron 18264096 rs16986921 chr20 36382521 C T 5.88E-07 Body mass index CTNNBL1 intron 18325910 rs16986921 chr20 36382521 C T 6.54E-08 Body mass index CTNNBL1 intron 18325910 rs16986921 chr20 36382521 C T 2.90E-06 Memory performance CTNNBL1 intron 22105620 rs6020712 chr20 36386612 G A 7.92E-07 Prostate cancer CTNNBL1 intron 18264096 rs6020712 chr20 36386612 G A 1.20E-07 Body mass index CTNNBL1 intron 18325910 rs6020712 chr20 36386612 G A 6.96E-04 Body mass index CTNNBL1 intron 18325910 rs6020712 chr20 36386612 G A 7.92E-07 Body mass index CTNNBL1 intron 18325910 rs6020712 chr20 36386612 G A 1.00E-06 Memory performance CTNNBL1 intron 22105620 rs6013029 chr20 36399580 G T 2.69E-07 Prostate cancer CTNNBL1 intron 18264096 rs6013029 chr20 36399580 G T 1.11E-07 Body mass index CTNNBL1 intron 18325910 rs6013029 chr20 36399580 G T 4.99E-08 Body mass index CTNNBL1 intron 18325910 rs6013029 chr20 36399580 G T 7.80E-04 Body mass index CTNNBL1 intron 18325910 rs6013029 chr20 36399580 G T 3.80E-06 Memory performance CTNNBL1 intron 22105620 rs6020846 chr20 36405667 A G 2.45E-05 Prostate cancer CTNNBL1 intron 18264096 rs6020846 chr20 36405667 A G 1.21E-05 Body mass index CTNNBL1 intron 18325910 rs6020846 chr20 36405667 A G 7.01E-06 Body mass index CTNNBL1 intron 18325910 rs6020846 chr20 36405667 A G 1.10E-06 Memory performance CTNNBL1 intron 22105620 rs4811196 chr20 36469694 G A 1.00E-06 Bone mineral density CTNNBL1 intron 17903296 rs9679781 chr20 36471998 A G 4.10E-07 Memory performance CTNNBL1 intron 22105620 rs4811247 chr20 36496915 G A 6.44E-04 Type 2 diabetes CTNNBL1 intron 17463246 rs910760 chr20 36499995 A C 8.20E-04 Type 2 diabetes and 6 quantitative traits CTNNBL1 intron 17848626 rs4809878 chr20 36506621 T G 5.52E-13 Metabolite levels / / 22286219 rs1569940 chr20 36529578 C T 2.85E-04 Taste perception / / 22132133 rs4811354 chr20 36561196 T A 5.26E-05 Lymphocyte counts VSTM2L intron 22286170 rs6013504 chr20 36583396 C T 2.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16987050 chr20 36587883 C T 9.11E-05 Orofacial clefts / / 22419666 rs6022419 chr20 36650065 A G 2.00E-05 Asperger disorder TTI1 intron 21182207 rs6022716 chr20 36688893 A G 7.11E-05 Bipolar Disorder RPRD1B intron pha002858 rs6023059 chr20 36737771 T C 7.48E-05 Bipolar disorder and schizophrenia / / 20889312 rs6023059 chr20 36737771 T C 6.26E-05 Bipolar Disorder / / pha002858 rs7271155 chr20 36791496 C T 3.80E-06 Urinary metabolites TGM2 intron 21572414 rs7270898 chr20 36791828 G A 5.70E-06 Urinary metabolites TGM2 intron 21572414 rs7275079 chr20 36793245 C T 5.50E-06 Urinary metabolites TGM2 intron 21572414 rs4809987 chr20 36823666 A G 4.82E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs75727053 chr20 36824720 T G 1.00E-08 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs6127471 chr20 36844038 C T 5.00E-29 Heart rate KIAA1755 intron 23583979 rs877600 chr20 36863040 G A 4.75E-07 Personality dimensions KIAA1755 intron 23658558 rs1205450 chr20 36864541 A G 1.01E-06 Personality dimensions KIAA1755 intron 23658558 rs1205452 chr20 36865116 T C 2.23E-06 Personality dimensions KIAA1755 intron 23658558 rs4353702 chr20 36900290 A G 6.62E-05 Basophils / / pha003087 rs6024863 chr20 36950990 A T 7.56E-04 Multiple complex diseases BPI intron 17554300 rs6024905 chr20 36957837 G A 1.00E-06 Bipolar disorder and schizophrenia BPI intron 20889312 rs5743533 chr20 36959318 G A 1.71E-04 Response to statin treatment (atorvastatin),change in cholesterol levels BPI intron 20031582 rs6127771 chr20 36959732 C T 4.80E-06 Type 2 diabetes BPI intron 17460697 rs6024947 chr20 36966260 G A 0.00000022 HDL cholesterol / / 23063622 rs11086556 chr20 36969972 A G 2.30E-04 Atrial fibrillation / / 21846873 rs11536940 chr20 36977636 G A 2.00E-06 Periodontitis (DPAL) LBP intron 24024966 rs1739654 chr20 36977970 G A 5.00E-06 IgG glycosylation LBP cds-synon 23382691 rs1780627 chr20 36997632 T C 6.56E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) LBP intron 23648065 rs2232613 chr20 36997655 C T 4.97E-04 Multiple complex diseases LBP missense 17554300 rs1002154 chr20 37077620 C T 1.84E-05 Blood Pressure SNHG11 intron pha003043 rs1303567 chr20 37106157 C A 5.20E-05 HIV-1 control RALGAPB intron 20041166 rs805540 chr20 37166358 G A 5.00E-05 HIV-1 control RALGAPB intron 20041166 rs13043114 chr20 37173486 G A 0.0000533 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes RALGAPB intron 22628534 rs2864932 chr20 37186009 C A 5.00E-05 HIV-1 control RALGAPB intron 20041166 rs1883784 chr20 37235138 A G 6.84E-04 Lymphocyte counts ARHGAP40 intron 22286170 rs34862565 chr20 37378721 G A 0.00022 Prostate cancer (non-advanced prostate cancer) ACTR5 missense 23555315 rs6128907 chr20 37387862 T C 0.000406 Salmonella-induced pyroptosis ACTR5 intron 22837397 rs6128918 chr20 37391432 G A 0.00048 Salmonella-induced pyroptosis ACTR5 intron 22837397 rs6124015 chr20 37392789 A G 0.000529 Salmonella-induced pyroptosis ACTR5 intron 22837397 rs6124026 chr20 37399987 A G 0.0000928 Salmonella-induced pyroptosis ACTR5 intron 22837397 rs2748665 chr20 37405344 C T 6.39E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2015901 chr20 37455995 C T 4.08E-04 Amyotrophic Lateral Sclerosis PPP1R16B intron 17362836 rs4381836 chr20 37472902 G A 3.35E-04 Amyotrophic Lateral Sclerosis PPP1R16B intron 17362836 rs6071609 chr20 37492299 C T 8.43E-04 Acute lung injury PPP1R16B intron 22295056 rs6065096 chr20 37501340 G A 3.69E-05 Acute lung injury PPP1R16B intron 22295056 rs6071615 chr20 37501412 T C 3.57E-05 Acute lung injury PPP1R16B intron 22295056 rs6129124 chr20 37515934 A G 1.59E-04 White matter integrity PPP1R16B intron 22425255 rs10392 chr20 37550935 G A 2.87E-05 Obsessive-compulsive disorder PPP1R16B UTR-3 24821223 rs926393 chr20 37646028 G A 7.41E-04 Amyotrophic Lateral Sclerosis DHX35 intron 17362836 rs6129158 chr20 37673967 A G 2.04E-04 Lymphocyte counts / / 22286170 rs926392 chr20 37690464 A G 5.00E-07 Dialysis-related mortality / / 21546767 rs2103613 chr20 37696520 A G 9.00E-04 Multiple complex diseases / / 17554300 rs12625595 chr20 37715636 A T 6.89E-04 Type 2 diabetes / / 17463246 rs6071653 chr20 37717550 C T 7.25E-04 Type 2 diabetes / / 17463246 rs6028276 chr20 37726011 A T 7.97E-04 Type 2 diabetes / / 17463246 rs6124112 chr20 37753702 T C 4.60E-05 Pulmonary function / / 19300500 rs12625154 chr20 37775431 G T 2.98E-04 Stroke / / pha002886 rs12481160 chr20 37785438 T G 1.30E-05 Urinary metabolites / / 21572414 rs6028335 chr20 37845477 A G 5.00E-06 Alcohol and nictotine co-dependence LOC339568 intron 22488850 rs6028341 chr20 37856073 G A 7.76E-04 Smoking cessation / / 24665060 rs7262615 chr20 37911295 T C 1.94E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1884712 chr20 37914526 G A 6.32E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2067008 chr20 37965099 G A 5.11E-04 Nicotine dependence / / 17158188 rs2206437 chr20 37992741 T A 9.15E-04 Multiple complex diseases / / 17554300 rs13045507 chr20 38006656 C T 2.16E-04 Birth weight / / 17255346 rs2179443 chr20 38017102 G C 4.40E-04 Breast cancer and prostate cancer / / 17903305 rs4810264 chr20 38020577 C G 6.11E-04 Nicotine dependence / / 17158188 rs6093170 chr20 38022657 G A 5.58E-05 Multiple complex diseases / / 17554300 rs8121586 chr20 38030174 C T 2.51E-04 Birth weight / / 17255346 rs2143216 chr20 38066525 G A 2.22E-04 Birth weight / / 17255346 rs7268711 chr20 38070211 G A 3.53E-04 Birth weight / / 17255346 rs13036738 chr20 38078988 A C 4.45E-05 Birth weight / / 17255346 rs16988087 chr20 38087936 G A 6.64E-05 Birth weight / / 17255346 rs1883514 chr20 38088199 A G 1.42E-04 Birth weight / / 17255346 rs1883515 chr20 38088247 A G 3.80E-05 Lipid levels / / 18193043 rs6028466 chr20 38129002 G A 3.00E-07 Telomere length / / 21460395 rs6028476 chr20 38138711 C T 1.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7264045 chr20 38140100 C T 9.75E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6129355 chr20 38145701 G T 9.34E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6016105 chr20 38189420 G C 4.20E-04 Multiple complex diseases / / 17554300 rs4264615 chr20 38214850 G T 6.57E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs805937 chr20 38259543 T C 6.56E-06 Multiple complex diseases / / 17554300 rs1701852 chr20 38265145 C T 1.68E-05 Multiple complex diseases / / 17554300 rs1395363 chr20 38265611 T G 4.12E-04 Multiple complex diseases / / 17554300 rs2658740 chr20 38265808 T C 5.42E-04 Multiple complex diseases / / 17554300 rs1701853 chr20 38266161 G A 7.11E-05 Multiple complex diseases / / 17554300 rs1655328 chr20 38268700 G C 4.98E-06 Multiple complex diseases / / 17554300 rs1629959 chr20 38268861 T C 2.47E-04 Multiple complex diseases / / 17554300 rs1701856 chr20 38271171 C T 4.85E-06 Multiple complex diseases / / 17554300 rs1160080 chr20 38272090 G A 2.04E-06 Multiple complex diseases / / 17554300 rs1701858 chr20 38272443 A C 1.15E-04 Multiple complex diseases / / 17554300 rs1395364 chr20 38272697 G A 1.13E-05 Multiple complex diseases / / 17554300 rs6028593 chr20 38292415 T C 1.10E-06 Testosterone levels / / 22675492 rs789430 chr20 38292897 T C 9.81E-04 Multiple complex diseases / / 17554300 rs11698332 chr20 38300576 C T 0.00000295 Tuberculosis with late age of onset / / 22551897 rs6016142 chr20 38300807 C T 6.00E-08 Estradiol levels / / 22675492 rs6028607 chr20 38313305 A C 4.49E-06 Testosterone levels / / 22675492 rs17793544 chr20 38322218 T C 4.52E-06 Testosterone levels / / 22675492 rs292858 chr20 38333579 A G 1.42E-05 Testosterone levels / / 22675492 rs292870 chr20 38338620 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs16988392 chr20 38342557 G A 4.95E-04 Multiple complex diseases / / 17554300 rs6016162 chr20 38365951 G A 6.35E-06 Testosterone levels / / 22675492 rs6028637 chr20 38382625 C T 9.04E-04 Insulin resistance / / 21901158 rs6028637 chr20 38382625 C T 1.33E-05 Testosterone levels / / 22675492 rs17800079 chr20 38384990 T C 1.08E-05 Testosterone levels / / 22675492 rs6028642 chr20 38386587 G T 9.82E-06 Testosterone levels / / 22675492 rs6028644 chr20 38387674 T C 9.66E-04 Insulin resistance / / 21901158 rs17206293 chr20 38401589 A T 1.93E-05 Testosterone levels / / 22675492 rs16988470 chr20 38406485 G A 2.27E-04 Multiple complex diseases / / 17554300 rs17800951 chr20 38419842 T G 1.58E-05 Testosterone levels / / 22675492 rs13039016 chr20 38437069 C T 7.17E-04 White matter integrity / / 22425255 rs211863 chr20 38454167 G A 3.28E-05 Schizophrenia / / 19571811 rs4812412 chr20 38467674 A G 5.73E-05 Diabetic nephropathy / / pha002864 rs8116303 chr20 38481575 G A 3.33E-04 IgE levels / / 17255346 rs8116303 chr20 38481575 G A 2.62E-04 Schizophrenia / / 20832056 rs1884673 chr20 38517535 C T 1.90E-04 IgE levels / / 17255346 rs16988582 chr20 38523264 T C 3.94E-04 IgE levels / / 17255346 rs55734731 chr20 38572414 C T 4.00E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs6093263 chr20 38574581 C T 2.50E-08 Urinary metabolites / / 21572414 rs6016200 chr20 38574690 A G 2.50E-05 Urinary metabolites / / 21572414 rs62212409 chr20 38576752 C G 4.12E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs6028738 chr20 38579290 G A 3.80E-06 Urinary metabolites / / 21572414 rs6101780 chr20 38581798 T G 3.84E-04 Multiple complex diseases / / 17554300 rs12479736 chr20 38584590 A G 5.87E-07 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs2025127 chr20 38593928 T C 3.70E-06 Urinary metabolites / / 21572414 rs6028756 chr20 38597634 A G 3.10E-06 Urinary metabolites / / 21572414 rs12479923 chr20 38606110 C T 2.00E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6124202 chr20 38616582 T C 5.35E-05 Coronary heart disease / / pha003033 rs4616538 chr20 38619046 G A 5.79E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13039424 chr20 38622091 T C 2.44E-05 Coronary heart disease / / 21606135 rs10485664 chr20 38630778 A G 2.62E-05 Coronary heart disease / / 21606135 rs6071894 chr20 38632402 G T 1.20E-05 Urinary metabolites / / 21572414 rs2208652 chr20 38639140 G T 3.31E-05 Coronary heart disease / / pha003033 rs927377 chr20 38639838 C T 1.67E-05 Coronary heart disease / / pha003033 rs8120917 chr20 38644558 G A 6.00E-06 Obesity-related traits / / 23251661 rs748382 chr20 38651152 C A 1.30E-05 Urinary metabolites / / 21572414 rs4812422 chr20 38651886 C G 1.36E-04 Coronary heart disease / / 21606135 rs6071903 chr20 38652740 T A 1.90E-05 Urinary metabolites / / 21572414 rs12479552 chr20 38653603 T C 2.30E-04 Multiple complex diseases / / 17554300 rs6028806 chr20 38661339 C T 4.50E-05 Myasthenia gravis / / 23055271 rs2870137 chr20 38685541 C T 8.13E-05 Multiple sclerosis (age of onset) / / 19010793 rs2870137 chr20 38685541 C T 3.00E-06 Cytomegalovirus antibody response / / 21993531 rs3092776 chr20 38703009 C T 0.00029 Coronary artery calcification / / 23727086 rs2010380 chr20 38733753 C T 3.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6016275 chr20 38792298 C T 6.60E-05 Cognitive test performance / / 20125193 rs6016275 chr20 38792298 C T 3.42E-04 Amyotrophic lateral sclerosis / / 23624525 rs6028932 chr20 38799248 T C 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6016283 chr20 38801643 T C 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6065212 chr20 38809964 A G 2.10E-05 Urinary metabolites / / 21572414 rs6028945 chr20 38820805 G T 2.00E-07 Response to TNF antagonist treatment / / 18615156 rs6101890 chr20 38823993 A C 9.10E-05 Lipid levels / / pha003082 rs6028950 chr20 38826357 A G 3.16E-04 Type 2 diabetes / / 17463246 rs1358789 chr20 38849555 G A 0.00008418 Sarcoidosis / / 22952805 rs1321333 chr20 38849642 A G 8.55E-05 Orofacial clefts / / 22419666 rs1321333 chr20 38849642 A G 0.00006971 Sarcoidosis / / 22952805 rs8123577 chr20 38849765 C A 5.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6065218 chr20 38862775 A G 8.63E-04 Acute lung injury / / 22295056 rs6071980 chr20 38868576 T C 2.51E-08 Tuberculosis with early age of onset / / 22551897 rs4812435 chr20 38872419 T C 1.52E-04 Type 2 diabetes / / 17463246 rs1004483 chr20 38875017 A G 3.23E-04 Type 2 diabetes / / 17463246 rs6124220 chr20 38880243 C T 5.17E-04 Multiple complex diseases / / 17554300 rs6129532 chr20 38884188 G T 1.39E-05 Gaucher disease severity / / 22388998 rs6129532 chr20 38884188 G T 1.77E-04 Lung function (forced vital capacity) / / 24023788 rs6129533 chr20 38884795 C G 3.99E-04 Multiple complex diseases / / 17554300 rs6065223 chr20 38886400 T A 5.97E-04 Type 2 diabetes / / 17463246 rs16988891 chr20 38886461 C T 8.30E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs13036801 chr20 38886900 C T 3.24E-04 Multiple complex diseases / / 17554300 rs6124225 chr20 38893386 A G 2.12E-05 Gaucher disease severity / / 22388998 rs6124225 chr20 38893386 A G 2.85E-04 Lung function (forced vital capacity) / / 24023788 rs5009524 chr20 38894887 A T 2.17E-05 Educational attainment / / 21694764 rs7268865 chr20 38905602 T A 1.07E-04 Multiple complex diseases / / 17554300 rs13042092 chr20 38947208 A T 1.30E-04 Multiple complex diseases / / 17554300 rs6029030 chr20 38951541 A G 2.02E-04 Multiple complex diseases / / 17554300 rs6029045 chr20 38968064 G T 1.19E-04 Multiple complex diseases / / 17554300 rs728331 chr20 38987586 G A 1.15E-04 Multiple complex diseases / / 17554300 rs6029061 chr20 38988773 A G 1.58E-04 Multiple complex diseases / / 17554300 rs2224282 chr20 38989027 C G 1.87E-04 Multiple complex diseases / / 17554300 rs1535208 chr20 38989963 G A 1.48E-04 Multiple complex diseases / / 17554300 rs6029073 chr20 38998610 C T 2.00E-04 Multiple complex diseases / / 17554300 rs6029074 chr20 38999927 C G 1.39E-04 Multiple complex diseases / / 17554300 rs6029079 chr20 39003884 A G 1.66E-04 Multiple complex diseases / / 17554300 rs9653623 chr20 39024238 T C 1.29E-04 Multiple complex diseases / / 17554300 rs8124695 chr20 39028436 C A 8.00E-10 Dupuytren's disease / / 21732829 rs6101973 chr20 39039283 T C 1.13E-05 Multiple complex diseases / / 17554300 rs3092155 chr20 39041871 A G 4.37E-06 Alcohol and nictotine co-dependence / / 20158304 rs16989035 chr20 39045004 A G 1.25E-04 Multiple complex diseases / / 17554300 rs16985186 chr20 39055032 A G 3.37E-05 Brain structure / / 22504417 rs6093346 chr20 39066915 G A 7.58E-07 Brain structure / / 22504417 rs7267007 chr20 39068372 T C 1.54E-06 Brain structure / / 22504417 rs6029123 chr20 39086995 G T 4.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2902940 chr20 39091487 A G 1.00E-08 LDL cholesterol / / 20686565 rs2902940 chr20 39091487 A G 6.00E-11 Cholesterol,total / / 20686565 rs2902940 chr20 39091487 A G 2.00E-11 LDL cholesterol / / 24097068 rs2902940 chr20 39091487 A G 9.00E-10 Cholesterol,total / / 24097068 rs2143877 chr20 39092895 A G 1.12E-09 Multiple complex diseases / / 17554300 rs2143877 chr20 39092895 A G 5.75E-05 Schizophrenia / / 19571809 rs6029138 chr20 39112906 C A 3.59E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs6029143 chr20 39118662 C T 2.66E-04 Height / / 17255346 rs6102059 chr20 39228784 C T 4.00E-09 LDL cholesterol / / 19060906 rs6102059 chr20 39228784 C T 4.00E-09 Coronary heart disease / / 21347282 rs6029228 chr20 39255548 T G 1.67E-07 Cleft lip / / 20436469 rs6029228 chr20 39255548 T G 4.76E-06 Orofacial clefts / / 22863734 rs6072081 chr20 39261054 A G 1.14E-09 Cleft lip / / 20436469 rs6072081 chr20 39261054 A G 9.13E-08 Orofacial clefts / / 22863734 rs6065259 chr20 39261979 G A 1.25E-09 Cleft lip / / 20436469 rs6065259 chr20 39261979 G A 1.40E-07 Orofacial clefts / / 22863734 rs6102074 chr20 39268185 G T 5.83E-07 Cleft lip / / 20436469 rs6102074 chr20 39268185 G T 6.90E-06 Orofacial clefts / / 22863734 rs17820943 chr20 39268516 C T 3.09E-11 Cleft lip / / 20436469 rs17820943 chr20 39268516 C T 1.09E-08 Orofacial clefts / / 22863734 rs13041247 chr20 39269074 T C 1.62E-11 Cleft lip / / 20436469 rs13041247 chr20 39269074 T C 6.00E-09 Orofacial clefts / / 22863734 rs6029247 chr20 39270768 T C 8.94E-05 Serum metabolites / / 19043545 rs11696257 chr20 39270816 C T 1.96E-11 Cleft lip / / 20436469 rs11696257 chr20 39270816 C T 8.02E-09 Orofacial clefts / / 22863734 rs11698025 chr20 39274083 G A 5.18E-06 Cleft lip / / 20436469 rs6093375 chr20 39274282 T G 8.03E-04 Type 2 diabetes / / 17463246 rs6072087 chr20 39275892 T C 3.70E-05 Orofacial clefts / / 22863734 rs6102085 chr20 39281629 G A 5.70E-04 Lipid levels / / 19936222 rs6102085 chr20 39281629 G A 1.86E-08 Cleft lip / / 20436469 rs6102085 chr20 39281629 G A 6.90E-08 Orofacial clefts / / 22863734 rs6016404 chr20 39282720 A C 1.29E-05 Cleft lip / / 20436469 rs6016404 chr20 39282720 A C 1.22E-05 Orofacial clefts / / 22863734 rs742748 chr20 39293397 T C 1.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs35361608 chr20 39313690 A AG 6.07E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6029273 chr20 39313690 A G 6.07E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2425417 chr20 39327359 C T 5.67E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3091920 chr20 39368297 T G 1.36E-04 IgE levels / / 17255346 rs3092223 chr20 39369301 A G 2.10E-04 IgE levels / / 17255346 rs6102127 chr20 39375762 C T 6.95E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1883702 chr20 39377281 T C 6.60E-06 Serum metabolites / / 19043545 rs1883702 chr20 39377281 T C 4.38E-04 Amyotrophic lateral sclerosis / / 23624525 rs974672 chr20 39380665 C G 1.00E-05 Serum metabolites / / 19043545 rs6102131 chr20 39384344 C A 1.26E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2865892 chr20 39403896 C T 2.10E-05 Lipid levels / / 19936222 rs2865892 chr20 39403896 C T 2.20E-04 Lipid levels / / 19936222 rs2865892 chr20 39403896 C T 5.30E-04 Lipid levels / / 19936222 rs6093397 chr20 39435359 C G 3.72E-04 Multiple complex diseases / / 17554300 rs4812466 chr20 39439483 G T 6.00E-06 Metabolite levels (HVA-5-HIAA Factor score) / / 23319000 rs6029356 chr20 39449305 G A 3.15E-05 Follicular lymphoma / / 21533074 rs6072161 chr20 39471427 T C 7.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6072161 chr20 39471427 T C 3.00E-07 IgG glycosylation / / 23382691 rs6029379 chr20 39473115 T C 0.0000808 Nicotine dependence (smoking) / / 22377092 rs6072163 chr20 39476952 G A 2.12E-04 Hemoglobin concentration / / 20534544 rs6102185 chr20 39478533 G A 0.0000614 Nicotine dependence (smoking) / / 22377092 rs6102185 chr20 39478533 G A 1.00E-06 IgG glycosylation / / 23382691 rs6102185 chr20 39478533 G A 2.00E-06 IgG glycosylation / / 23382691 rs6102185 chr20 39478533 G A 5.00E-06 IgG glycosylation / / 23382691 rs11696653 chr20 39497468 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6129694 chr20 39497686 G T 7.46E-05 Schizophrenia / / 19571809 rs4142345 chr20 39513502 A G 8.73E-04 Multiple complex diseases / / 17554300 rs11905698 chr20 39520463 G A 9.76E-04 Multiple complex diseases / / 17554300 rs6102209 chr20 39536311 T C 0.00000192 Major depressive disorder age at onset>25 / / 22915352 rs2223955 chr20 39577519 G A 2.00E-06 Asthma / / 21790008 rs2425455 chr20 39577602 T C 8.78E-05 Cholesterol / / pha003073 rs2425455 chr20 39577602 T C 8.08E-06 ldl cholesterol / / pha003076 rs3092685 chr20 39583952 C T 7.57E-04 Tourette syndrome / / 22889924 rs3092685 chr20 39583952 C T 1.39E-04 Pancreatic cancer / / pha002874 rs3091955 chr20 39589967 C T 8.51E-05 Serum metabolites / / 19043545 rs734532 chr20 39611802 G A 3.33E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) LOC100128988 intron 23648065 rs6093416 chr20 39614783 G A 4.10E-04 Type 2 diabetes and 6 quantitative traits LOC100128988 intron 17848626 rs117756447 chr20 39670470 A G 0.0000574 Carotid intima media thickness TOP1 intron 23152477 rs6029526 chr20 39672618 T A 3.00E-17 Cholesterol,total TOP1 intron 20686565 rs6029526 chr20 39672618 T A 3.00E-19 LDL cholesterol TOP1 intron 20686565 rs6029526 chr20 39672618 T A 0.00058 Prostate cancer TOP1 intron 23555315 rs6029526 chr20 39672618 T A 1.00E-16 Cholesterol,total TOP1 intron 24097068 rs6029526 chr20 39672618 T A 5.00E-18 LDL cholesterol TOP1 intron 24097068 rs8122094 chr20 39681683 C G 2.24E-05 Coronary heart disease TOP1 intron 21606135 rs1997833 chr20 39690342 T C 2.59E-04 Taste perception TOP1 intron 22132133 rs2076574 chr20 39721373 A G 2.24E-05 Prostate cancer TOP1 intron 22923026 rs6072275 chr20 39743905 G A 1.66E-08 Fasting blood glucose TOP1 intron 22885924 rs6129760 chr20 39746403 A G 9.83E-06 Prostate cancer TOP1 intron 22923026 rs12624863 chr20 39782899 A G 3.28E-05 Taste perception PLCG1 intron 22132133 rs2228246 chr20 39792063 A G 1.50E-04 Suicidal ideation PLCG1 missense 22030708 rs753381 chr20 39797465 T C 4.30E-08 Metabolic syndrome phenotype PLCG1 missense 22022282 rs753381 chr20 39797465 T C 1.61E-11 Cholesterol,total PLCG1 missense 23063622 rs2235366 chr20 39808660 G T 4.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZHX3 UTR-3 20877124 rs2664537 chr20 39813729 G A 1.50E-04 Suicidal ideation ZHX3 UTR-3 22030708 rs6124325 chr20 39816385 G A 6.16E-05 Taste perception ZHX3 intron 22132133 rs6129766 chr20 39821898 C T 1.65E-05 Taste perception ZHX3 intron 22132133 rs17265513 chr20 39832628 T C 8.64E-08 Fasting blood glucose ZHX3 missense 22885924 rs6102322 chr20 39872768 C T 5.70E-06 Prostate cancer ZHX3 intron 22923026 rs6072317 chr20 39881517 G T 2.30E-04 Suicidal ideation ZHX3 intron 22030708 rs6129784 chr20 39885529 T C 6.95E-04 Nicotine smoking ZHX3 intron 19268276 rs6129802 chr20 39920014 C T 8.62E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZHX3 intron 20877124 rs4812491 chr20 39929608 G A 5.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12480916 chr20 39932356 T G 5.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6016541 chr20 39936005 C T 3.14E-06 Corneal structure / / 22003120 rs6072343 chr20 39968188 G A 9.00E-05 Suicidal ideation / / 22030708 rs12625565 chr20 39986085 A C 4.02E-05 Intracerebral hemorrhage LPIN3 missense 24656865 rs6072351 chr20 39988139 G C 3.19E-05 Intracerebral hemorrhage LPIN3 UTR-3 24656865 rs75209388 chr20 40001041 G A 7.05E-06 Intracerebral hemorrhage / / 24656865 rs6102391 chr20 40008482 T C 6.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4518023 chr20 40020769 C A 8.00E-05 Suicidal ideation / / 22030708 rs13037749 chr20 40064559 A G 8.00E-06 Hippocampal atrophy CHD6 intron 22745009 rs4142393 chr20 40078085 C T 9.22E-05 Hepatocellular carcinoma CHD6 intron 22807686 rs3092194 chr20 40116207 G A 4.41E-06 Hepatocellular carcinoma CHD6 intron 22807686 rs6029710 chr20 40130086 G A 1.73E-05 Hepatocellular carcinoma CHD6 intron 22807686 rs16985879 chr20 40152547 T C 7.53E-04 Suicide attempts in bipolar disorder CHD6 intron 21041247 rs16985881 chr20 40153172 A G 7.53E-04 Suicide attempts in bipolar disorder CHD6 intron 21041247 rs73611298 chr20 40153847 G C 2.84E-11 Metabolite levels CHD6 intron 22286219 rs6102451 chr20 40157709 G A 7.53E-04 Suicide attempts in bipolar disorder CHD6 intron 21041247 rs2866743 chr20 40170873 A G 7.60E-04 Suicide attempts in bipolar disorder CHD6 intron 21041247 rs6093497 chr20 40201535 A G 7.60E-04 Suicide attempts in bipolar disorder CHD6 intron 21041247 rs6129876 chr20 40212877 G A 7.59E-04 Suicide attempts in bipolar disorder CHD6 intron 21041247 rs2425463 chr20 40237810 T G 2.07E-04 IgE levels CHD6 intron 17255346 rs2425463 chr20 40237810 T G 1.75E-05 Heart Rate CHD6 intron pha003051 rs6124365 chr20 40253687 A C 7.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs1011049 chr20 40277568 C T 7.58E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6124368 chr20 40278595 A G 4.46E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs941796 chr20 40290806 G A 3.70E-05 Major depressive disorder / / 19065144 rs941796 chr20 40290806 G A 5.21E-05 Major depressive disorder / / 21621269 rs941796 chr20 40290806 G A 1.79E-05 Major depressive disorder / / pha002850 rs6016596 chr20 40300232 A G 6.72E-05 Major depressive disorder / / 21621269 rs6016596 chr20 40300232 A G 6.01E-05 Major depressive disorder / / pha002850 rs6129896 chr20 40305351 A G 3.54E-05 Major depressive disorder / / 21621269 rs12480046 chr20 40305932 C T 8.63E-05 Major depressive disorder (broad) / / 20038947 rs12480143 chr20 40307826 A G 3.50E-05 Major depressive disorder / / 19065144 rs12480143 chr20 40307826 A G 5.73E-05 Major depressive disorder / / 21621269 rs12480143 chr20 40307826 A G 2.99E-05 Major depressive disorder / / pha002850 rs17210039 chr20 40309230 A G 3.73E-05 Major depressive disorder / / 21621269 rs2866705 chr20 40330362 T C 1.61E-04 Longevity / / 22279548 rs941797 chr20 40338375 T A 1.50E-05 Urinary metabolites / / 21572414 rs16986005 chr20 40341122 G A 4.93E-04 Multiple complex diseases / / 17554300 rs16986005 chr20 40341122 G A 1.06E-04 Alcohol dependence / / 21314694 rs3091599 chr20 40396811 C T 1.22E-05 Multiple complex diseases / / 17554300 rs6065392 chr20 40436666 T C 5.02E-05 Neuroticism / / 23229837 rs6129957 chr20 40463964 A G 4.33E-05 Cognitive performance / / 19734545 rs6513747 chr20 40482585 C T 5.86E-05 Smoking cessation / / 24665060 rs6029852 chr20 40492858 A G 7.08E-05 Schizophrenia / / 19571809 rs12481621 chr20 40509905 G A 2.20E-05 Asthma / / 23181788 rs2076395 chr20 40524765 T C 1.20E-05 Urinary metabolites / / 21572414 rs2179434 chr20 40534202 G A 3.33E-05 Height / / pha003011 rs16986312 chr20 40568950 G A 8.96E-04 Alzheimer's disease / / 17998437 rs4812563 chr20 40579609 T C 1.21E-05 Endometrial cancer / / 24096698 rs4812563 chr20 40579609 T C 1.81E-04 Endometrial cancer / / 24096698 rs1884034 chr20 40608629 T C 2.65E-05 Cognitive impairment induced by topiramate / / 22091778 rs6029910 chr20 40609084 C T 2.09E-05 Colorectal cancer / / 19723657 rs6065420 chr20 40625470 A G 1.01E-05 Cognitive impairment induced by topiramate / / 22091778 rs6130000 chr20 40626474 C T 7.76E-05 Suicide attempts in bipolar disorder / / 21423239 rs4812566 chr20 40643624 C T 6.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs6029929 chr20 40645040 T C 3.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs4812568 chr20 40645590 C T 3.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs4810349 chr20 40645690 T C 3.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs1884029 chr20 40666883 C A 4.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs4630824 chr20 40668430 G A 1.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs41354748 chr20 40668846 T C 6.14E-05 Multiple sclerosis / / 17660530 rs2207221 chr20 40670738 A C 2.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs2013923 chr20 40679231 G T 2.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs8118745 chr20 40679500 A G 2.52E-05 Cognitive impairment induced by topiramate / / 22091778 rs6102652 chr20 40680350 C T 1.82E-05 Cognitive impairment induced by topiramate / / 22091778 rs1884033 chr20 40683594 G A 2.51E-05 Colorectal cancer / / 19723657 rs2866941 chr20 40696442 T C 9.23E-05 Aortic root size / / 21223598 rs1078394 chr20 40696760 A C,T 5.75E-04 Aortic root size / / 21223598 rs6016677 chr20 40700626 G A 1.69E-04 Alzheimer's disease / / 24755620 rs1884040 chr20 40706494 C T 5.80E-05 Colorectal cancer PTPRT UTR-3 19723657 rs746413 chr20 40709990 T C 4.30E-05 Diabetic retinopathy PTPRT intron 21441570 rs909776 chr20 40727886 A G 3.58E-04 Taste perception PTPRT intron 22132133 rs4810352 chr20 40737112 A G 7.71E-05 Femoral neck bone geometry PTPRT intron 22087292 rs17221179 chr20 40762637 T C 6.16E-04 Suicide attempts in bipolar disorder PTPRT intron 21423239 rs6124419 chr20 40762868 G A 5.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTPRT intron 20877124 rs4239693 chr20 40768353 T C 5.92E-06 Carotenoid and tocopherol levels PTPRT intron 19185284 rs6030011 chr20 40783392 A G 8.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PTPRT intron 20877124 rs7272567 chr20 40786441 C T 6.63E-04 Suicide attempts in bipolar disorder PTPRT intron 21423239 rs1569549 chr20 40791519 G A 5.69E-04 Suicide attempts in bipolar disorder PTPRT intron 21423239 rs7262414 chr20 40811780 C A 9.94E-05 Multiple complex diseases PTPRT intron 17554300 rs7262414 chr20 40811780 C A 9.97E-05 Pulmonary function in asthmatics PTPRT intron 23541324 rs7345986 chr20 40840779 A G 9.00E-06 Periodontitis (Mean PAL) PTPRT intron 24024966 rs8115491 chr20 40847486 T C 7.02E-05 Pulmonary function in asthmatics PTPRT intron 23541324 rs8116325 chr20 40912206 C A 3.90E-05 Parkinson's disease PTPRT intron 21738487 rs8116325 chr20 40912206 C A 0.000603941 Hypertension (early onset hypertension) PTPRT intron 22479346 rs6124439 chr20 40919935 G A 6.05E-05 Parkinson's disease PTPRT intron 21738487 rs11696306 chr20 40926125 T C 1.04E-05 Sudden cardiac arrest PTPRT intron 21658281 rs763474 chr20 40964152 C A 4.26E-04 Lung function (forced vital capacity) PTPRT intron 24023788 rs12481463 chr20 40966436 A G 4.76E-05 Femoral neck bone geometry PTPRT intron 22087292 rs6072697 chr20 40987533 T C 5.52E-05 Orofacial clefts PTPRT intron 22419666 rs4812591 chr20 40994026 T C 6.58E-04 Multiple complex diseases PTPRT intron 17554300 rs6030171 chr20 40994094 T C 1.90E-06 Thyroid function PTPRT intron 20826269 rs6030171 chr20 40994094 T C 3.00E-06 IgG glycosylation PTPRT intron 23382691 rs6030171 chr20 40994094 T C 7.33E-05 Diabetes Mellitus PTPRT intron pha003059 rs1015385 chr20 41003185 C A 1.50E-05 Gallbladder disease PTPRT intron pha001403 rs6030189 chr20 41015030 C T 2.55E-04 Age-related macular degeneration PTPRT intron 22125219 rs6513787 chr20 41025906 C A 3.62E-07 Carotenoid and tocopherol levels PTPRT intron 19185284 rs2425491 chr20 41029114 A G 3.30E-06 Urinary metabolites PTPRT intron 21572414 rs1883269 chr20 41044482 G A 1.70E-06 Urinary metabolites PTPRT intron 21572414 rs4812596 chr20 41046745 T C 3.00E-07 Urinary metabolites PTPRT intron 21572414 rs6030218 chr20 41053747 T C 1.97E-04 Parkinson's disease PTPRT intron 17052657 rs3903491 chr20 41057927 C G 9.10E-08 Urinary metabolites PTPRT intron 21572414 rs7262344 chr20 41061213 A C 0.000134 Salmonella-induced pyroptosis PTPRT intron 22837397 rs6030239 chr20 41066599 C T 3.50E-07 Urinary metabolites PTPRT intron 21572414 rs11700137 chr20 41066671 T A 2.80E-06 Urinary metabolites PTPRT intron 21572414 rs6030245 chr20 41070559 T C 0.00004425 Sarcoidosis PTPRT intron 22952805 rs6030245 chr20 41070559 T C 6.70E-04 Smoking quantity PTPRT intron 24665060 rs6072747 chr20 41072019 G T 6.63E-04 Multiple complex diseases PTPRT intron 17554300 rs3890324 chr20 41072655 C A 2.00E-06 Age-related nuclear cataracts PTPRT intron 24951543 rs999113 chr20 41074316 G A 2.24E-04 Multiple complex diseases PTPRT intron 17554300 rs6016798 chr20 41075396 T C 3.29E-05 Serum metabolites PTPRT intron 19043545 rs2076082 chr20 41076751 T A 3.04E-05 Serum metabolites PTPRT intron 19043545 rs6065482 chr20 41082232 T C 2.02E-05 Serum metabolites PTPRT intron 19043545 rs11086837 chr20 41084668 A G 1.74E-05 Cognitive impairment induced by topiramate PTPRT intron 22091778 rs6130141 chr20 41093484 C T 1.09E-04 Body mass index PTPRT intron 17255346 rs230153 chr20 41107656 C T 2.59E-04 Body mass index PTPRT intron 17255346 rs172981 chr20 41109702 T C 1.45E-06 Osteoarthritis PTPRT intron 22763110 rs230155 chr20 41109921 C T 2.63E-04 Body mass index PTPRT intron 17255346 rs6030274 chr20 41118095 C T 7.59E-05 Adipocyte fatty acid-binding protein concentration,in serum PTPRT intron 21863005 rs6016807 chr20 41118123 C T 7.67E-05 Adipocyte fatty acid-binding protein concentration,in serum PTPRT intron 21863005 rs6093659 chr20 41121507 T C 7.67E-05 Adipocyte fatty acid-binding protein concentration,in serum PTPRT intron 21863005 rs6124468 chr20 41128954 G A,C,T 2.20E-05 Urinary metabolites PTPRT intron 21572414 rs6016824 chr20 41182311 A G 5.05E-05 Socioeconomic Factors PTPRT intron pha003067 rs6016826 chr20 41184009 C A 0.000121 Salmonella-induced pyroptosis PTPRT intron 22837397 rs6016826 chr20 41184009 C A 2.79E-05 Socioeconomic Factors PTPRT intron pha003067 rs6016827 chr20 41184337 A C 7.03E-05 Socioeconomic Factors PTPRT intron pha003067 rs6072793 chr20 41185524 T G 6.14E-05 Socioeconomic Factors PTPRT intron pha003067 rs4812609 chr20 41188318 G A 7.90E-05 Socioeconomic Factors PTPRT intron pha003067 rs6072794 chr20 41189977 C T 2.29E-05 Post-operative nausea and vomiting PTPRT intron 21694509 rs6102917 chr20 41219419 C G 3.88E-05 Bipolar disorder PTPRT intron 21926972 rs6030363 chr20 41236820 C T 8.99E-04 Alzheimer's disease PTPRT intron 22005930 rs6102947 chr20 41240852 C T 0.0000513 Bipolar disorder PTPRT intron 23070075 rs6102950 chr20 41243024 A G 8.49E-05 Gallstones PTPRT intron 17632509 rs10485695 chr20 41256515 T C 0.0005438 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) PTPRT intron 23233654 rs10485695 chr20 41256515 T C 5.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) PTPRT intron 23233662 rs35349846 chr20 41266942 C T 4.74E-05 Cognitive test performance PTPRT intron 20125193 rs2206426 chr20 41286043 A G 9.97E-05 Major depressive disorder PTPRT intron 21621269 rs2206426 chr20 41286043 A G 9.22E-05 Major depressive disorder PTPRT intron pha002850 rs16987231 chr20 41309420 A G 6.77E-04 Multiple complex diseases PTPRT intron 17554300 rs7268336 chr20 41313082 A G 7.31E-05 Cognitive impairment induced by topiramate PTPRT intron 22091778 rs2425524 chr20 41316944 T G 3.60E-04 Lipid traits PTPRT intron 17903299 rs4812631 chr20 41326127 G A 2.13E-04 Insulin resistance PTPRT intron 21901158 rs17749109 chr20 41351028 C T 8.91E-04 Alzheimer's disease PTPRT intron 17998437 rs6016881 chr20 41355674 C G 1.56E-04 Aortic root size PTPRT intron 21223598 rs6016884 chr20 41363243 A G 3.11E-04 Multiple complex diseases PTPRT intron 17554300 rs6016884 chr20 41363243 A G 3.44E-05 Brain structure PTPRT intron 22504417 rs4812639 chr20 41364512 C T 3.14E-05 Brain structure PTPRT intron 22504417 rs6030450 chr20 41365250 G A 4.52E-05 Brain structure PTPRT intron 22504417 rs1022818 chr20 41365700 G A 3.86E-05 Brain structure PTPRT intron 22504417 rs1022819 chr20 41369589 G A 7.47E-04 Multiple complex diseases PTPRT intron 17554300 rs1022819 chr20 41369589 G A 3.00E-05 Brain structure PTPRT intron 22504417 rs6030453 chr20 41369963 C T 4.00E-05 Brain structure PTPRT intron 22504417 rs1028688 chr20 41370400 T C 4.80E-05 HIV-1 control PTPRT intron 20041166 rs6016887 chr20 41373856 C T 5.03E-05 Hearing function PTPRT intron 17255346 rs6072855 chr20 41384414 G C 6.46E-04 Insulin resistance PTPRT intron 21901158 rs9808582 chr20 41391320 T C 2.04E-05 Cardiovascular disease PTPRT intron pha003065 rs6072861 chr20 41393973 C T 4.34E-05 Cardiovascular disease PTPRT intron pha003065 rs6065532 chr20 41395294 G A 2.48E-05 Cardiovascular disease PTPRT intron pha003065 rs6072869 chr20 41399171 A G 8.95E-04 Premature ovarian failure PTPRT intron 19508998 rs1885831 chr20 41402907 A G 9.87E-05 Cognitive impairment induced by topiramate PTPRT intron 22091778 rs17749217 chr20 41403661 C T 9.89E-05 Femoral neck bone geometry PTPRT intron 22087292 rs13042473 chr20 41409901 T G 2.00E-06 Fractional exhaled nitric oxide (childhood) PTPRT intron 24315451 rs13042473 chr20 41409901 T G 8.00E-06 Fractional exhaled nitric oxide (childhood) PTPRT intron 24315451 rs12480719 chr20 41410055 C T 2.70E-05 Urinary metabolites PTPRT intron 21572414 rs6103041 chr20 41412265 T C 9.97E-04 Multiple complex diseases PTPRT intron 17554300 rs3092043 chr20 41414408 T C 8.46E-04 Type 2 diabetes PTPRT intron 17463246 rs208250 chr20 41415745 T C 3.71E-04 Suicide attempts in bipolar disorder PTPRT intron 21423239 rs208250 chr20 41415745 T C 9.89E-05 Stroke (ischemic) PTPRT intron 22941190 rs4812645 chr20 41422283 A G 7.59E-04 Multiple complex diseases PTPRT intron 17554300 rs12481078 chr20 41423380 G A 7.04E-04 Response to cytadine analogues (cytosine arabinoside) PTPRT intron 24483146 rs208229 chr20 41461593 G T 8.39E-04 Type 2 diabetes PTPRT intron 17463246 rs1397854 chr20 41465048 C T 2.96E-04 Response to cytadine analogues (cytosine arabinoside) PTPRT intron 24483146 rs13042490 chr20 41467006 C T 1.00E-04 Information processing speed PTPRT intron 21130836 rs8125304 chr20 41473735 A G 6.72E-06 Stroke (ischemic) PTPRT intron 21957438 rs208273 chr20 41494726 G A 7.23E-05 Serum metabolites PTPRT intron 19043545 rs206668 chr20 41538983 T C 6.83E-05 Alzheimer's disease PTPRT intron 17998437 rs206148 chr20 41648663 T C 1.40E-05 Urinary metabolites PTPRT intron 21572414 rs206154 chr20 41649750 T C 2.10E-05 Urinary metabolites PTPRT intron 21572414 rs206159 chr20 41653353 T A 2.20E-05 Urinary metabolites PTPRT intron 21572414 rs11697664 chr20 41661732 C T 1.47E-04 Type 2 diabetes PTPRT intron 17463246 rs2425553 chr20 41670237 C T 1.94E-05 Paclitaxel-induced neuropathy PTPRT intron 23776197 rs2425570 chr20 41678351 C T 2.10E-05 Urinary metabolites PTPRT intron 21572414 rs1106978 chr20 41678428 G A 2.10E-05 Urinary metabolites PTPRT intron 21572414 rs6103143 chr20 41707148 T G 4.95E-04 Multiple complex diseases PTPRT intron 17554300 rs2425584 chr20 41721166 T C 6.91E-05 Magnesium levels PTPRT intron pha003092 rs6030645 chr20 41723482 C T 1.90E-04 Smoking initiation PTPRT intron 24665060 rs927057 chr20 41729903 G A 8.50E-04 Amyotrophic Lateral Sclerosis PTPRT intron 17362836 rs2425594 chr20 41731299 A C 8.03E-05 Smoking initiation PTPRT intron 24665060 rs16987770 chr20 41742176 C T 1.91E-04 Type 2 diabetes PTPRT intron 17463246 rs16987770 chr20 41742176 C T 5.23E-04 Multiple complex diseases PTPRT intron 17554300 rs6030661 chr20 41748131 A G 5.11E-04 Amyotrophic Lateral Sclerosis PTPRT intron 17362836 rs17750840 chr20 41756972 T C 6.45E-04 Multiple complex diseases PTPRT intron 17554300 rs1572929 chr20 41770532 A G 3.17E-05 Type 2 diabetes PTPRT intron 17463246 rs947202 chr20 41778943 G A 8.24E-04 Multiple complex diseases PTPRT intron 17554300 rs947203 chr20 41778957 T A 4.71E-04 Multiple complex diseases PTPRT intron 17554300 rs6073003 chr20 41781599 A C 7.79E-05 Alzheimer's disease (late onset) PTPRT intron 21379329 rs926293 chr20 41944207 A G 3.19E-04 Type 2 diabetes / / 17463246 rs926292 chr20 41947176 C T 5.43E-04 Type 2 diabetes / / 17463246 rs926291 chr20 41947428 T C 4.54E-04 Type 2 diabetes / / 17463246 rs6030780 chr20 41947771 G A 1.28E-04 Type 2 diabetes / / 17463246 rs6103238 chr20 41947912 G A 4.32E-04 Type 2 diabetes / / 17463246 rs4583528 chr20 41949755 A G 4.87E-04 HIV-1 viral setpoint / / 17641165 rs4583528 chr20 41949755 A G 1.10E-04 HIV-1 viral setpoint / / 21490045 rs6103249 chr20 41965936 T C 6.51E-04 Smoking initiation / / 24665060 rs6073055 chr20 41973190 G A 3.72E-04 Type 2 diabetes / / 17463246 rs4810383 chr20 41980858 T G 7.64E-04 Multiple complex diseases / / 17554300 rs4812699 chr20 41981482 C T 4.29E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs74942834 chr20 41986162 G A 0.0000237 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6093813 chr20 41990629 C T 0.0000209 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs58314244 chr20 41990895 G A 0.0000211 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2010809 chr20 41991601 C T 2.00E-06 Smooth-surface caries / / 23470693 rs2010809 chr20 41991601 C T 0.0000252 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6093816 chr20 41992025 G C 0.0000548 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs73287748 chr20 41992197 G A 0.0000281 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs57083567 chr20 41994192 C A 0.0000252 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6065606 chr20 42002322 C T 6.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6103260 chr20 42002450 G T 0.0000329 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs59902181 chr20 42006987 G C 0.0000423 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs16988006 chr20 42007913 T A 9.92E-04 Multiple complex diseases / / 17554300 rs11086875 chr20 42008658 A G 4.22E-04 HIV-1 viral setpoint / / 17641165 rs6103264 chr20 42009189 T G 0.0000473 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs57571670 chr20 42009545 T C 0.0000472 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6017025 chr20 42010953 A G 0.0000425 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4810385 chr20 42074998 G A 1.90E-05 Urinary metabolites / / 21572414 rs6030998 chr20 42258960 C T 4.12E-04 Alzheimer's disease (late onset) IFT52 intron 21379329 rs285171 chr20 42337875 C G 2.76E-06 Alcohol and nictotine co-dependence MYBL2 intron 20158304 rs285176 chr20 42345960 C T 5.46E-04 Multiple complex diseases / / 17554300 rs3117532 chr20 42362645 C T 2.95E-05 Cognitive performance / / 19734545 rs285198 chr20 42364734 G A 1.42E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs285198 chr20 42364734 G A 7.87E-06 Prostate cancer / / 24185611 rs370971 chr20 42371095 G A 4.01E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs370971 chr20 42371095 G A 4.92E-06 Prostate cancer / / 24185611 rs880064 chr20 42375432 G A 5.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6017164 chr20 42382106 G A 8.89E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6073190 chr20 42390973 C T 4.01E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2179631 chr20 42438167 C T 5.96E-04 Alzheimer's disease / / 24755620 rs761267 chr20 42463470 C A 1.86E-04 Parkinson's disease / / 17052657 rs6017203 chr20 42473223 T C 7.16E-07 Schizophrenia / / 21926974 rs6103489 chr20 42487204 C T 4.00E-06 Response to amphetamines / / 22952603 rs11696193 chr20 42525490 A G 4.40E-04 Alcohol dependence / / 20201924 rs11696193 chr20 42525490 A G 6.20E-05 Alcohol dependence / / 20201924 rs11696193 chr20 42525490 A G 6.20E-05 Alcoholism / / pha002892 rs4812755 chr20 42533424 T A 7.80E-05 Panic disorder / / 19165232 rs11697653 chr20 42538019 T A 6.36E-09 Narcolepsy / / 19629137 rs6103515 chr20 42555486 G A 3.87E-04 Alzheimer's disease (late onset) TOX2 intron 21379329 rs6103520 chr20 42562360 G T 3.72E-05 Melanoma TOX2 intron 21926416 rs6130484 chr20 42565968 C T 3.03E-05 Melanoma TOX2 intron 21926416 rs6130486 chr20 42573592 C T 3.20E-05 Melanoma TOX2 intron 21926416 rs6031252 chr20 42573822 C A 6.00E-06 Conduct disorder (symptom count) TOX2 intron 20585324 rs11700304 chr20 42574362 C T 4.14E-04 Response to cytadine analogues (cytosine arabinoside) TOX2 intron 24483146 rs4812774 chr20 42579188 C T 4.14E-04 Response to cytadine analogues (cytosine arabinoside) TOX2 intron 24483146 rs6124611 chr20 42620085 T C 1.67E-05 Bipolar disorder TOX2 intron 17486107 rs6031318 chr20 42672411 G A 7.35E-05 Meningococcal disease TOX2 intron 20694013 rs6103592 chr20 42691387 A G 5.05E-04 Multiple complex diseases TOX2 intron 17554300 rs2143495 chr20 42693650 A G 1.00E-04 Cognitive impairment induced by topiramate TOX2 intron 22091778 rs1555124 chr20 42698851 G C 0.000002279 Sarcoidosis / / 22952805 rs6031337 chr20 42699984 T C 0.00001883 Sarcoidosis / / 22952805 rs6093929 chr20 42701981 A G 2.71E-04 Multiple complex diseases / / 17554300 rs6073307 chr20 42704807 C T 1.47E-05 Cognitive impairment induced by topiramate / / 22091778 rs6031367 chr20 42714527 C A 9.60E-04 Type 2 diabetes / / 17463246 rs6031367 chr20 42714527 C A 8.21E-04 Multiple complex diseases / / 17554300 rs932415 chr20 42720099 A C 4.41E-04 Multiple complex diseases / / 17554300 rs6073330 chr20 42737494 C A 3.85E-05 Neuroblastoma / / pha002895 rs6093935 chr20 42743454 A G 5.22E-04 Type 2 diabetes JPH2 cds-synon 17463246 rs1075174 chr20 42750324 A C 5.45E-05 Multiple complex diseases JPH2 intron 17554300 rs6031407 chr20 42757500 A G 3.25E-05 Suicidal ideation JPH2 intron 20877300 rs878559 chr20 42768065 A T 8.77E-04 Multiple complex diseases JPH2 intron 17554300 rs4239696 chr20 42768890 T C 1.37E-04 Multiple complex diseases JPH2 intron 17554300 rs2017246 chr20 42775843 A G 6.27E-04 Alcohol dependence JPH2 intron 20201924 rs1124314 chr20 42793961 A G 8.31E-04 Insulin resistance JPH2 intron 21901158 rs6031432 chr20 42795321 G A 7.35E-05 Multiple complex diseases JPH2 intron 17554300 rs2179680 chr20 42795850 A G 3.44E-05 Coronary heart disease JPH2 intron 21606135 rs4812790 chr20 42802697 C G,T 5.58E-04 Coronary heart disease JPH2 intron 21606135 rs4812791 chr20 42802761 C T 2.58E-04 Coronary heart disease JPH2 intron 21606135 rs6130556 chr20 42803776 T C 1.84E-04 Multiple complex diseases JPH2 intron 17554300 rs738498 chr20 42807909 G A 7.84E-04 Coronary heart disease JPH2 intron 21606135 rs4810412 chr20 42813435 G T 1.63E-04 Multiple complex diseases JPH2 intron 17554300 rs1971447 chr20 42826555 C A 5.68E-04 Suicide attempts in bipolar disorder C20orf111 intron 21423239 rs6130568 chr20 42834765 C T 3.34E-04 Acute lung injury C20orf111 intron 22295056 rs2143607 chr20 42838712 C G 6.86E-04 Multiple complex diseases C20orf111 intron 17554300 rs3843762 chr20 42839990 T C 3.30E-07 Type 2 diabetes LOC100505783 intron 21874001 rs16988852 chr20 42841629 G A 1.96E-04 Type 2 diabetes LOC100505783 intron 17463246 rs16988852 chr20 42841629 G A 4.20E-07 Type 2 diabetes LOC100505783 intron 21874001 rs6130569 chr20 42841898 G A 2.82E-04 Type 2 diabetes LOC100505783 intron 17463246 rs12624924 chr20 42845269 T C 4.20E-07 Type 2 diabetes LOC100505783 intron 21874001 rs4812805 chr20 42853466 C G 8.74E-04 Type 2 diabetes / / 17463246 rs6017291 chr20 42854134 A G 6.00E-06 Cognitive performance / / 20125193 rs16985330 chr20 42857648 C T 8.74E-04 Type 2 diabetes / / 17463246 rs6031469 chr20 42862010 G T 8.74E-04 Type 2 diabetes / / 17463246 rs2867799 chr20 42868146 C T 8.74E-04 Type 2 diabetes / / 17463246 rs6073383 chr20 42869564 T A 5.92E-04 Type 2 diabetes / / 22158537 rs6031470 chr20 42870224 A G 8.74E-04 Type 2 diabetes / / 17463246 rs6031471 chr20 42870355 C G 8.74E-04 Type 2 diabetes / / 17463246 rs4810414 chr20 42872923 G C 8.74E-04 Type 2 diabetes / / 17463246 rs2867800 chr20 42874509 C A 7.30E-04 Type 2 diabetes / / 22158537 rs2143641 chr20 42890019 G A 2.60E-07 Type 2 diabetes GDAP1L1 intron 21874001 rs6031485 chr20 42890507 A G 9.67E-04 Type 2 diabetes GDAP1L1 intron 17463246 rs4810415 chr20 42892151 C G 7.91E-05 Type 2 diabetes GDAP1L1 intron 22158537 rs7273969 chr20 42892769 C A 7.26E-05 Type 2 diabetes GDAP1L1 intron 22158537 rs4366964 chr20 42895906 C A 1.90E-07 Type 2 diabetes GDAP1L1 intron 21874001 rs12481690 chr20 42896460 A G 6.85E-05 Type 2 diabetes GDAP1L1 intron 22158537 rs4812810 chr20 42899532 T C 8.53E-06 Type 2 diabetes GDAP1L1 intron 22158537 rs12481568 chr20 42901255 A T 2.20E-07 Type 2 diabetes GDAP1L1 intron 21874001 rs6017310 chr20 42906438 A G 6.91E-05 Type 2 diabetes GDAP1L1 intron 22158537 rs1884607 chr20 42907542 A G 8.00E-05 Type 2 diabetes GDAP1L1 intron 22158537 rs2208064 chr20 42911322 A G 7.89E-05 Type 2 diabetes / / 22158537 rs2868090 chr20 42917767 A T 5.25E-05 Type 2 diabetes / / 22158537 rs7265147 chr20 42918757 G A 4.57E-05 Type 2 diabetes / / 22158537 rs1884609 chr20 42922128 C T 1.60E-07 Type 2 diabetes / / 21874001 rs6031503 chr20 42924921 A G 5.76E-05 Type 2 diabetes / / 22158537 rs4812816 chr20 42930872 C A 3.81E-05 Type 2 diabetes / / 22158537 rs13045189 chr20 42933720 A C 8.24E-05 Type 2 diabetes / / 22158537 rs4812817 chr20 42934021 A G 6.34E-05 Type 2 diabetes / / 22158537 rs13037113 chr20 42937103 A C 4.43E-05 Type 2 diabetes FITM2 intron 22158537 rs6031507 chr20 42941628 T C 2.51E-04 Type 2 diabetes / / 22158537 rs12625067 chr20 42944024 C T 1.30E-07 Type 2 diabetes / / 21874001 rs6017317 chr20 42946966 T G 1.00E-11 Type 2 diabetes / / 22158537 rs6017317 chr20 42946966 T G 1.12E-11 Type 2 diabetes / / 23300278 rs4812829 chr20 42989267 G A 3.00E-10 Type 2 diabetes HNF4A intron 21874001 rs4812829 chr20 42989267 G A 0.00015 Type 2 diabetes HNF4A intron 22885922 rs4812829 chr20 42989267 G A 2.60E-10 Type 2 diabetes HNF4A intron 23300278 rs4812829 chr20 42989267 G A 5.00E-08 Type 2 diabetes HNF4A intron 24509480 rs6103716 chr20 42999630 A C 4.80E-05 Type 2 diabetes HNF4A intron 17463248 rs6103716 chr20 42999630 A C 4.00E-05 Aortic root size HNF4A intron 21223598 rs6031559 chr20 42999839 A C 5.04E-05 Aortic root size HNF4A intron 21223598 rs6031580 chr20 43015281 A G 6.90E-05 Parkinson's disease (age of onset) HNF4A intron 19772629 rs4812831 chr20 43018260 G A 1.60E-04 Type 2 diabetes HNF4A intron 17463248 rs4812831 chr20 43018260 G A 5.50E-08 Type 2 diabetes HNF4A intron 21874001 rs4812831 chr20 43018260 G A 0.0000212 Type 2 diabetes HNF4A intron 22325160 rs2868094 chr20 43026616 T C 4.56E-05 Cognitive impairment induced by topiramate HNF4A intron 22091778 rs2868095 chr20 43034468 A G 0.000018 Coronary artery calcification HNF4A intron 23727086 rs3212184 chr20 43035160 G C 0.0002 Coronary artery calcification HNF4A intron 23727086 rs6031587 chr20 43038249 C T 0.0000276 HDL cholesterol HNF4A intron 23063622 rs11574736 chr20 43039537 G C 4.90E-05 Urate levels HNF4A intron 23263486 rs1800961 chr20 43042364 C T 8.00E-10 HDL cholesterol HNF4A missense 19060906 rs1800961 chr20 43042364 C T 3.56E-08 Lipid levels HNF4A missense 19936222 rs1800961 chr20 43042364 C T 1.00E-15 HDL cholesterol HNF4A missense 20686565 rs1800961 chr20 43042364 C T 6.00E-13 Cholesterol,total HNF4A missense 20686565 rs1800961 chr20 43042364 C T 4.50E-06 Fibrinogen HNF4A missense 20978265 rs1800961 chr20 43042364 C T 2.00E-09 C-reactive protein HNF4A missense 21300955 rs1800961 chr20 43042364 C T 8.00E-10 Coronary heart disease HNF4A missense 21347282 rs1800961 chr20 43042364 C T 1.50E-06 FVII levels HNF4A missense 21676895 rs1800961 chr20 43042364 C T 2.16E-38 FVII levels HNF4A missense 21676895 rs1800961 chr20 43042364 C T 0.00015 Type 2 diabetes (females) HNF4A missense 22885922 rs1800961 chr20 43042364 C T 8.00E-06 C-reactive protein HNF4A missense 22939635 rs1800961 chr20 43042364 C T 3.11E-10 Cholesterol,total HNF4A missense 23063622 rs1800961 chr20 43042364 C T 6.40E-10 Total cholesterol in females HNF4A missense 23063622 rs1800961 chr20 43042364 C T 8.56E-13 HDL cholesterol HNF4A missense 23063622 rs1800961 chr20 43042364 C T 1.00E-24 Cholesterol,total HNF4A missense 24097068 rs1800961 chr20 43042364 C T 2.00E-34 HDL cholesterol HNF4A missense 24097068 rs1800961 chr20 43042364 C T 7.13E-07 HDL particle features HNF4A missense pha002900 rs3212197 chr20 43044207 T C 2.80E-04 HDL particle features HNF4A intron 21283740 rs11086925 chr20 43047348 G A 2.20E-05 Urinary metabolites HNF4A intron 21572414 rs6031595 chr20 43054660 T A 1.60E-06 Gamma gluatamyl transferase levels (interaction with age) HNF4A intron 22010049 rs6031596 chr20 43054871 A G 5.70E-06 Gamma gluatamyl transferase levels (interaction with age) HNF4A intron 22010049 rs6017342 chr20 43065028 A C 9.00E-17 Ulcerative colitis / / 19915572 rs6017342 chr20 43065028 A C 1.00E-20 Ulcerative colitis / / 21297633 rs6017342 chr20 43065028 A C 9.00E-17 Multiple sclerosis / / 22190364 rs6017342 chr20 43065028 A C 1.00E-43 Ulcerative colitis / / 23128233 rs1983 chr20 43123028 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) TTPAL UTR-3 20708005 rs6513932 chr20 43123541 G C 5.82E-04 Type 2 diabetes / / 17463246 rs7270791 chr20 43125129 A G 5.57E-04 Type 2 diabetes SERINC3 intron 17463246 rs2157436 chr20 43253131 C T 0.000056 Coronary artery calcification ADA intron 23727086 rs244072 chr20 43259306 A G 0.000091 Asthma (exacerbation) ADA intron 23706709 rs6103805 chr20 43283691 A T 1.17E-04 Insulin resistance / / 21901158 rs6031702 chr20 43285217 T C 5.01E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4812849 chr20 43311088 A C 7.80E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4812854 chr20 43329838 T C 1.59E-05 Tunica Media / / pha003038 rs6031753 chr20 43335028 T C 9.06E-05 Waist Circumference / / pha003023 rs967689 chr20 43335574 C T 8.35E-05 Height / / pha003010 rs967689 chr20 43335574 C T 2.29E-05 Height / / pha003011 rs6017408 chr20 43363529 T C 6.59E-06 Obesity-related traits / / 23251661 rs13038016 chr20 43370497 A G 1.26E-06 Obesity-related traits / / 23251661 rs11696845 chr20 43371320 C T 5.00E-07 Obesity-related traits / / 23251661 rs6073535 chr20 43373859 T C 9.75E-07 Obesity-related traits / / 23251661 rs4810439 chr20 43377870 C G 5.35E-04 Multiple complex diseases KCNK15 intron 17554300 rs1980577 chr20 43382112 A G 1.88E-06 Obesity-related traits RIMS4 UTR-3 23251661 rs2903760 chr20 43455745 C T 2.40E-06 Socioeconomic Factors / / pha003066 rs2868161 chr20 43477423 G T 8.81E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7273626 chr20 43485941 A G 4.48E-05 Socioeconomic Factors / / pha003066 rs2868162 chr20 43489380 T G 4.67E-05 Socioeconomic Factors / / pha003066 rs2425656 chr20 43506247 G A 1.99E-07 Asthma / / 21790008 rs2179069 chr20 43507254 A C 4.23E-06 Asthma / / 21790008 rs2072729 chr20 43548431 A G 5.23E-05 HDL cholesterol PABPC1L intron pha003075 rs1998034 chr20 43557596 C T 7.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PABPC1L intron 20877124 rs3746584 chr20 43565622 G A 6.31E-04 Multiple complex diseases PABPC1L intron 17554300 rs1804644 chr20 43572217 T C 1.27E-05 Age-related macular degeneration TOMM34 cds-synon pha000001 rs2234206 chr20 43577620 C G 5.33E-04 Multiple complex diseases TOMM34 intron 17554300 rs2299971 chr20 43578485 C T 4.92E-04 Multiple complex diseases TOMM34 intron 17554300 rs927000 chr20 43598705 C T 1.46E-05 Bipolar disorder and schizophrenia STK4 intron 20889312 rs17322289 chr20 43599951 T C 2.83E-05 Neuroblastoma STK4 intron pha002895 rs2284271 chr20 43605421 C T 9.38E-05 Melanoma STK4 intron 21926416 rs2284271 chr20 43605421 C T 4.03E-08 Metabolite levels STK4 intron 23281178 rs17420378 chr20 43629135 G A 2.72E-04 Multiple complex diseases STK4 missense 17554300 rs2180291 chr20 43637979 C A 1.90E-05 Urinary metabolites STK4 intron 21572414 rs2284272 chr20 43644031 T C 5.25E-05 Bipolar disorder STK4 intron 22925353 rs6124684 chr20 43721493 C T 9.00E-06 Bipolar disorder KCNS1 UTR-3 22925353 rs6031991 chr20 43730442 G A 6.18E-05 Multiple complex diseases / / 17554300 rs6104012 chr20 43734571 A G 1.19E-04 Vaspin levels / / 22907691 rs6104012 chr20 43734571 A G 0.0000591 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs6104012 chr20 43734571 A G 0.0001186 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs734685 chr20 43741523 C T 8.19E-04 Multiple complex diseases WFDC5 intron 17554300 rs734685 chr20 43741523 C T 0.0000069 Asthma WFDC5 intron 23040885 rs7361168 chr20 43773737 C T 3.00E-06 IgG glycosylation / / 23382691 rs2664581 chr20 43804522 A C 6.49E-05 Amyotrophic lateral sclerosis (sporadic) PI3 missense 24529757 rs144708311 chr20 43851523 G A 0.00054 Prostate cancer (non-advanced prostate cancer) SEMG2 missense 23555315 rs6017525 chr20 43871071 A G 2.74E-04 Renal cell carcinoma / / 22010048 rs6094118 chr20 43893582 G A 1.11E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs991048 chr20 43898227 T C 5.76E-04 Multiple complex diseases / / 17554300 rs2743396 chr20 43923473 T C 1.95E-06 Leprosy MATN4 intron 22019778 rs733380 chr20 43935985 A G 4.58E-04 Smoking cessation MATN4 intron 24665060 rs6104115 chr20 43949741 G A 4.42E-04 Acute lung injury / / 22295056 rs11696248 chr20 43950816 T C 1.12E-04 Acute lung injury / / 22295056 rs11697800 chr20 43950837 G C 1.17E-04 Acute lung injury / / 22295056 rs11697824 chr20 43951000 G A 1.18E-04 Acute lung injury / / 22295056 rs4599 chr20 43954407 T C 4.75E-04 Acute lung injury SDC4 UTR-3 22295056 rs4599 chr20 43954407 T C 0.0000142 HDL cholesterol particle diameter SDC4 UTR-3 23263444 rs2267867 chr20 43965903 A G 7.10E-04 Acute lung injury SDC4 intron 22295056 rs2284277 chr20 43967310 G A 7.10E-04 Acute lung injury SDC4 intron 22295056 rs2228384 chr20 43976991 A G 3.97E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SDC4 missense 24023788 rs1008953 chr20 43980726 T C 1.00E-07 Psoriasis / / 20953189 rs2250900 chr20 44041068 T C 8.99E-04 Type 2 diabetes / / 17463246 rs2250900 chr20 44041068 T C 3.54E-04 Multiple complex diseases / / 17554300 rs1028306 chr20 44045880 G A 8.73E-04 Type 2 diabetes PIGT intron 17463246 rs6094137 chr20 44049483 G A 3.85E-04 Multiple complex diseases PIGT intron 17554300 rs4810449 chr20 44051444 G A,C,T 4.70E-05 Response to lithium treatment in bipolar disorder PIGT intron 19448189 rs2745061 chr20 44072196 C T 1.49E-09 Sickle cell anemia (severity) / / 20029952 rs6130840 chr20 44090343 T C 7.04E-04 Sarcoidosis / / 19165924 rs16990209 chr20 44094550 A C 1.38E-04 Sudden cardiac arrest / / 21658281 rs6073746 chr20 44094969 C T 6.12E-04 Multiple complex diseases / / 17554300 rs6065823 chr20 44114873 T C 4.39E-04 Smoking quantity / / 24665060 rs11696501 chr20 44124523 A G 9.00E-07 Brain structure / / 20171287 rs11696501 chr20 44124523 A G 3.71E-04 Smoking quantity / / 24665060 rs16990235 chr20 44124549 C A 2.09E-04 Multiple complex diseases / / 17554300 rs2868301 chr20 44125763 C T 0.0002232 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2868301 chr20 44125763 C T 2.23E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17431461 chr20 44127443 T C 0.0003268 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17431461 chr20 44127443 T C 3.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1883519 chr20 44130596 G A 0.0001973 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1883519 chr20 44130596 G A 1.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6032255 chr20 44133329 G A 0.0003269 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6032255 chr20 44133329 G A 3.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs909878 chr20 44135521 C T 0.0002177 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs909878 chr20 44135521 C T 2.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6032259 chr20 44141331 A G 1.80E-05 Urinary metabolites SPINT3 missense 21572414 rs7268906 chr20 44152720 G C 0.000297 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7268906 chr20 44152720 G C 2.97E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8124746 chr20 44155080 G C 0.0002912 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8124746 chr20 44155080 G C 2.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7265247 chr20 44158791 T G 0.0003121 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7265247 chr20 44158791 T G 3.12E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1883521 chr20 44159798 T C 4.68E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4402827 chr20 44161982 A G 0.000379 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4402827 chr20 44161982 A G 3.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6032275 chr20 44165097 C G 0.0003775 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPINLW1-WFDC6 UTR-3 23233654 rs6032275 chr20 44165097 C G 3.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) SPINLW1-WFDC6 UTR-3 23233662 rs6032276 chr20 44165587 C T 0.0003811 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SPINLW1-WFDC6 UTR-3 23233654 rs6032276 chr20 44165587 C T 3.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) SPINLW1-WFDC6 UTR-3 23233662 rs2227290 chr20 44176142 G T 5.85E-04 Smoking quantity / / 24665060 rs2050095 chr20 44178585 T C 0.0002057 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2050095 chr20 44178585 T C 2.06E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs988463 chr20 44178972 A G 3.88E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs988462 chr20 44179299 A G 0.0003312 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs988462 chr20 44179299 A G 3.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17348421 chr20 44180813 G A 0.0002926 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs17348421 chr20 44180813 G A 2.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs12480391 chr20 44181161 G A 0.0003536 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs12480391 chr20 44181161 G A 3.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs12480402 chr20 44181227 G T 0.0003813 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs12480402 chr20 44181227 G T 3.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs2294559 chr20 44181723 A G 0.000189 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs2294559 chr20 44181723 A G 1.89E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs3817886 chr20 44181980 C A 0.0003928 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs3817886 chr20 44181980 C A 3.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs12479931 chr20 44182410 T C 0.0003992 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs12479931 chr20 44182410 T C 3.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs12480794 chr20 44182466 C T 0.0004054 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs12480794 chr20 44182466 C T 4.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs7268787 chr20 44182613 G A 0.0004122 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs7268787 chr20 44182613 G A 4.12E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6514012 chr20 44183040 T G 0.0004188 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6514012 chr20 44183040 T G 4.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6032301 chr20 44183623 A T 0.0004258 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6032301 chr20 44183623 A T 4.26E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6032303 chr20 44184100 A G 0.0004587 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6032303 chr20 44184100 A G 4.59E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6032305 chr20 44184285 G A 0.0004661 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6032305 chr20 44184285 G A 4.66E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs2250860 chr20 44184375 T C 0.0004737 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 missense 23233654 rs2250860 chr20 44184375 T C 4.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 missense 23233662 rs6032310 chr20 44185010 C T 0.0005163 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6032310 chr20 44185010 C T 5.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs2868304 chr20 44185487 A G 0.0005311 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs2868304 chr20 44185487 A G 5.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6032317 chr20 44186962 A G 0.0005528 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6032317 chr20 44186962 A G 5.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6017616 chr20 44186985 T C 0.0005603 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6017616 chr20 44186985 T C 5.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6017618 chr20 44187132 C T 0.0005761 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6017618 chr20 44187132 C T 5.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6032318 chr20 44187201 T C 0.000584 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6032318 chr20 44187201 T C 5.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs1569612 chr20 44187923 T C 0.0005922 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs1569612 chr20 44187923 T C 5.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6104221 chr20 44188147 C T 0.0006 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6104221 chr20 44188147 C T 6.00E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs7263748 chr20 44188870 A C 0.0006058 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs7263748 chr20 44188870 A C 6.06E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6032319 chr20 44188941 A G 0.0006032 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6032319 chr20 44188941 A G 6.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs7265308 chr20 44189015 T C 0.0006002 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs7265308 chr20 44189015 T C 6.00E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6032321 chr20 44189277 T A 0.0005979 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6032321 chr20 44189277 T A 5.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6032322 chr20 44189497 T C 0.0005949 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6032322 chr20 44189497 T C 5.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6032323 chr20 44189693 T C 0.0005928 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6032323 chr20 44189693 T C 5.93E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6017620 chr20 44190203 G A 0.0005912 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6017620 chr20 44190203 G A 5.91E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs2272956 chr20 44190996 A G 0.0005867 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs2272956 chr20 44190996 A G 5.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs1977096 chr20 44191768 C A 0.0005788 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs1977096 chr20 44191768 C A 5.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs2903786 chr20 44191909 T G 0.0005764 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs2903786 chr20 44191909 T G 5.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6104222 chr20 44192086 C T 0.0005747 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6104222 chr20 44192086 C T 5.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6094168 chr20 44192517 G C 0.0005717 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6094168 chr20 44192517 G C 5.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs2868305 chr20 44193916 G A 0.0005694 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs2868305 chr20 44193916 G A 5.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs2903787 chr20 44194093 C G 0.000567 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs2903787 chr20 44194093 C G 5.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs2868308 chr20 44194125 T C 0.0005446 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs2868308 chr20 44194125 T C 5.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs2868309 chr20 44194184 A C 0.0005164 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs2868309 chr20 44194184 A C 5.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs4812913 chr20 44194760 G A 0.0005109 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs4812913 chr20 44194760 G A 5.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs4812914 chr20 44194869 A G 0.0005091 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs4812914 chr20 44194869 A G 5.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs4812915 chr20 44194893 A C 0.0005074 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs4812915 chr20 44194893 A C 5.07E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs4812916 chr20 44194914 T C 8.30E-06 Urinary metabolites WFDC8 intron 21572414 rs6094169 chr20 44195492 T G 0.0005027 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6094169 chr20 44195492 T G 5.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6032330 chr20 44196140 C T 0.000501 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6032330 chr20 44196140 C T 5.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6104228 chr20 44196200 C A 0.0004997 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6104228 chr20 44196200 C A 5.00E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs10485457 chr20 44196233 G A 0.0004791 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs10485457 chr20 44196233 G A 4.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs201660221 chr20 44196982 A AT 0.000441 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs201660221 chr20 44196982 A AT 4.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6094170 chr20 44196982 A T 0.000441 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6094170 chr20 44196982 A T 4.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6065836 chr20 44197087 G A 1.20E-05 Urinary metabolites WFDC8 intron 21572414 rs6104229 chr20 44197259 C A 0.0004377 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6104229 chr20 44197259 C A 4.38E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6104230 chr20 44197329 C G 0.0004369 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6104230 chr20 44197329 C G 4.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs8122982 chr20 44197544 A T 0.0004346 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs8122982 chr20 44197544 A T 4.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6017625 chr20 44199261 C T 0.0004307 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs6017625 chr20 44199261 C T 4.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs7264976 chr20 44201879 A G 0.0004286 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC8 intron 23233654 rs7264976 chr20 44201879 A G 4.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs6032343 chr20 44204290 G A 9.96E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC8 intron 23233662 rs3091845 chr20 44211104 A T 0.0004237 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs3091845 chr20 44211104 A T 4.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3091718 chr20 44216791 T G 0.0007049 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs3091718 chr20 44216791 T G 7.05E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3091929 chr20 44216911 G A 1.21E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs932389 chr20 44220872 T G 0.0006397 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs932389 chr20 44220872 T G 6.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3092506 chr20 44221060 G T 0.0006389 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs3092506 chr20 44221060 G T 6.39E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2092373 chr20 44223310 C G 0.0006359 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2092373 chr20 44223310 C G 6.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2092374 chr20 44223637 T G 0.0006346 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2092374 chr20 44223637 T G 6.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3092549 chr20 44226981 C G 0.0006137 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs3092549 chr20 44226981 C G 6.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3091658 chr20 44227220 G A 0.0006125 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs3091658 chr20 44227220 G A 6.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2425710 chr20 44227493 T C 0.0006133 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2425710 chr20 44227493 T C 6.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs139643257 chr20 44237357 G A 0.00062 Prostate cancer WFDC9 missense 23555315 rs2425714 chr20 44240226 T A 0.0006151 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC9 intron 23233654 rs2425714 chr20 44240226 T A 6.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC9 intron 23233662 rs978779 chr20 44243542 A T 0.0006254 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC9 intron 23233654 rs978779 chr20 44243542 A T 6.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC9 intron 23233662 rs3092353 chr20 44246135 T C 0.0006275 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC9 intron 23233654 rs3092353 chr20 44246135 T C 6.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC9 intron 23233662 rs3092488 chr20 44247383 T C 0.0006276 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) WFDC9 intron 23233654 rs3092488 chr20 44247383 T C 6.28E-04 Methotrexate clearance (acute lymphoblastic leukemia) WFDC9 intron 23233662 rs6032449 chr20 44336716 C T 4.79E-04 Type 2 diabetes WFDC13 UTR-3 17463246 rs232262 chr20 44350931 C G 8.26E-04 Type 2 diabetes / / 17463246 rs2200586 chr20 44351554 T C 3.53E-12 Metabolite levels SPINT4 intron 22286219 rs1685195 chr20 44359847 C T 6.30E-04 Multiple complex diseases / / 17554300 rs457153 chr20 44361491 G A 6.77E-04 Multiple complex diseases / / 17554300 rs462202 chr20 44371446 A G 6.69E-04 Type 2 diabetes / / 17463246 rs462202 chr20 44371446 A G 8.94E-04 Multiple complex diseases / / 17554300 rs467129 chr20 44371905 G T 6.31E-04 Multiple complex diseases / / 17554300 rs457570 chr20 44371922 C G 5.70E-04 Multiple complex diseases / / 17554300 rs459681 chr20 44372005 T C 3.86E-04 Multiple complex diseases / / 17554300 rs459955 chr20 44378059 T C 8.65E-04 Type 2 diabetes / / 17463246 rs459955 chr20 44378059 T C 8.15E-04 Multiple complex diseases / / 17554300 rs462145 chr20 44378211 A G 8.27E-04 Multiple complex diseases / / 17554300 rs462145 chr20 44378211 A G 8.96E-04 Alcohol dependence / / 21314694 rs800684 chr20 44401404 C G 9.62E-05 Diabetes (gestational) / / 22233651 rs2664529 chr20 44402869 C T 1.62E-04 Type 2 diabetes WFDC3 UTR-3 17463246 rs2064504 chr20 44403710 A G 8.52E-05 Response to acetaminophen (hepatotoxicity) WFDC3 intron 21177773 rs6124741 chr20 44404647 C T 8.31E-05 Response to acetaminophen (hepatotoxicity) WFDC3 intron 21177773 rs6032530 chr20 44412463 G A 1.62E-04 Type 2 diabetes WFDC3 intron 17463246 rs6032532 chr20 44413410 G C 1.82E-04 Type 2 diabetes WFDC3 intron 17463246 rs6032544 chr20 44422373 T C 2.22E-04 Type 2 diabetes DNTTIP1 intron 17463246 rs6032545 chr20 44422705 G T 6.48E-05 Response to acetaminophen (hepatotoxicity) DNTTIP1 intron 21177773 rs12480887 chr20 44427418 A G 8.28E-12 Metabolite levels DNTTIP1 intron 22286219 rs12480887 chr20 44427418 A G 6.44E-05 HDL particle features DNTTIP1 intron pha002900 rs6514063 chr20 44433017 C T 3.10E-04 Glaucoma (primary open-angle) DNTTIP1 intron 22419738 rs6094214 chr20 44454778 T G 0.000000171 HDL cholesterol TNNC2 intron 23063622 rs57799507 chr20 44462924 G A 0.00029 Breast cancer SNX21 missense 23555315 rs1967656 chr20 44488199 T C 1.06E-06 Type 2 diabetes ZSWIM3 intron 17463246 rs6514065 chr20 44496819 C G 2.44E-06 Type 2 diabetes ZSWIM3 intron 17463246 rs1045493 chr20 44506418 G A 5.87E-07 Type 2 diabetes ZSWIM3 cds-synon 17463246 rs17446462 chr20 44506661 G A 2.00E-04 Glaucoma (primary open-angle) ZSWIM3 cds-synon 22419738 rs142962530 chr20 44511697 A G 0.000019 Prostate cancer (advanced) ZSWIM1 missense 23555315 rs4608591 chr20 44523782 C T 3.20E-05 Type 2 diabetes CTSA intron 17463246 rs389877 chr20 44532484 G C 4.17E-11 Metabolite levels PLTP intron 22286219 rs6073950 chr20 44533110 A T 2.39E-11 Metabolite levels PLTP intron 22286219 rs6065904 chr20 44534651 G A 3.58E-40 Lipid levels PLTP intron 19936222 rs6065904 chr20 44534651 G A 2.00E-31 Lipid metabolism phenotypes PLTP intron 22286219 rs6065904 chr20 44534651 G A 1.85E-10 Triglycerides PLTP intron 23063622 rs6065904 chr20 44534651 G A 5.19E-14 HDL cholesterol (female) PLTP intron 23063622 rs6065904 chr20 44534651 G A 8.17E-13 HDL cholesterol PLTP intron 23063622 rs11569646 chr20 44534862 T C 5.56E-11 Triglycerides PLTP intron 23063622 rs6073952 chr20 44536932 G A 6.92E-23 Metabolite levels PLTP intron 22286219 rs6073952 chr20 44536932 G A 1.01E-10 HDL cholesterol PLTP intron 23063622 rs6073952 chr20 44536932 G A 7.69E-10 Triglycerides in females PLTP intron 23063622 rs6073952 chr20 44536932 G A 9.65E-10 Triglycerides PLTP intron 23063622 rs6065905 chr20 44537837 T C 1.17E-22 Metabolite levels PLTP intron 22286219 rs378114 chr20 44538427 T C 5.53E-14 Metabolite levels PLTP intron 22286219 rs378114 chr20 44538427 T C 2.81E-05 HDL particle features PLTP intron pha002900 rs435306 chr20 44538484 G T 6.29E-14 Metabolite levels PLTP intron 22286219 rs58847685 chr20 44544947 T C 5.51E-25 Metabolite levels / / 22286219 rs4810479 chr20 44545048 C T 1.00E-55 Lipid levels / / 19936222 rs4810479 chr20 44545048 C T 1.18E-08 Lipid levels / / 19936222 rs4810479 chr20 44545048 C T 2.80E-08 Lipid levels / / 19936222 rs4810479 chr20 44545048 C T 3.33E-04 Alcohol dependence / / 20201924 rs4810479 chr20 44545048 C T 1.67E-08 HDL particle features / / 21283740 rs4810479 chr20 44545048 C T 1.42E-23 Metabolite levels / / 22286219 rs4810479 chr20 44545048 C T 1.90E-09 HDL cholesterol / / 22629316 rs4810479 chr20 44545048 C T 7.11E-12 HDL cholesterol (female) / / 22629316 rs4810479 chr20 44545048 C T 2.00E-42 Metabolite levels (atherosclerosis) / / 22916037 rs4810479 chr20 44545048 C T 3.27E-10 Triglycerides / / 23063622 rs4810479 chr20 44545048 C T 5.44E-13 HDL cholesterol / / 23063622 rs4810479 chr20 44545048 C T 0.0000198 HDL cholesterol / / 23236364 rs17447545 chr20 44547068 A G 5.84E-18 Metabolite levels / / 22286219 rs59329875 chr20 44547672 T C 1.16E-24 Metabolite levels / / 22286219 rs2868346 chr20 44547970 C T 8.05E-24 Metabolite levels / / 22286219 rs3843763 chr20 44548193 C T 1.05E-12 Metabolite levels / / 22286219 rs6073957 chr20 44549476 T C 1.12E-24 Metabolite levels / / 22286219 rs12185764 chr20 44550020 C T 1.11E-24 Metabolite levels / / 22286219 rs6073958 chr20 44551855 T C 5.49E-28 Metabolite levels / / 22286219 rs2903809 chr20 44552895 C A 7.67E-12 Metabolite levels / / 22286219 rs6065906 chr20 44554015 T C 1.00E-14 Lipid levels / / 19936222 rs6065906 chr20 44554015 T C 1.28E-15 Lipid levels / / 19936222 rs6065906 chr20 44554015 T C 1.39E-08 Lipid levels / / 19936222 rs6065906 chr20 44554015 T C 1.47E-45 Lipid levels / / 19936222 rs6065906 chr20 44554015 T C 1.80E-14 Lipid levels / / 19936222 rs6065906 chr20 44554015 T C 2.00E-11 Lipid levels / / 19936222 rs6065906 chr20 44554015 T C 3.10E-12 Lipid levels / / 19936222 rs6065906 chr20 44554015 T C 3.20E-28 Lipid levels / / 19936222 rs6065906 chr20 44554015 T C 3.30E-49 Lipid levels / / 19936222 rs6065906 chr20 44554015 T C 3.86E-13 Lipid levels / / 19936222 rs6065906 chr20 44554015 T C 4.40E-08 Lipid levels / / 19936222 rs6065906 chr20 44554015 T C 5.00E-10 Lipid levels / / 19936222 rs6065906 chr20 44554015 T C 6.00E-79 Lipid levels / / 19936222 rs6065906 chr20 44554015 T C 7.00E-38 Lipid levels / / 19936222 rs6065906 chr20 44554015 T C 8.30E-37 Lipid levels / / 19936222 rs6065906 chr20 44554015 T C 2.00E-22 HDL cholesterol / / 20686565 rs6065906 chr20 44554015 T C 5.00E-18 Triglycerides / / 20686565 rs6065906 chr20 44554015 T C 1.29E-24 Metabolite levels / / 22286219 rs6065906 chr20 44554015 T C 2.00E-34 Triglycerides / / 24097068 rs6065906 chr20 44554015 T C 5.00E-40 HDL cholesterol / / 24097068 rs58952297 chr20 44560820 C T 3.39E-23 Metabolite levels / / 22286219 rs1057208 chr20 44563007 C T 2.11E-26 Metabolite levels / / 22286219 rs6065908 chr20 44569930 C T 3.88E-23 Metabolite levels PCIF1 intron 22286219 rs6073966 chr20 44570192 C T 1.68E-26 Metabolite levels PCIF1 intron 22286219 rs1111750 chr20 44574238 T C 6.71E-05 Cognitive performance PCIF1 intron 19734545 rs16990949 chr20 44575493 C T 4.25E-05 Bipolar disorder and schizophrenia PCIF1 intron 20889312 rs7679 chr20 44576502 T C 6.60E-08 Fetal hemoglobin levels PCIF1 UTR-3 18245381 rs7679 chr20 44576502 T C 4.00E-09 HDL cholesterol PCIF1 UTR-3 19060906 rs7679 chr20 44576502 T C 7.00E-11 Triglycerides PCIF1 UTR-3 19060906 rs7679 chr20 44576502 T C 4.00E-09 Coronary heart disease PCIF1 UTR-3 21347282 rs7679 chr20 44576502 T C 2.91E-22 Metabolite levels PCIF1 UTR-3 22286219 rs4465830 chr20 44585420 A G 6.67E-26 Metabolite levels ZNF335 intron 22286219 rs6073971 chr20 44589970 C T 4.36E-26 Metabolite levels ZNF335 intron 22286219 rs6073972 chr20 44590298 C G 3.35E-25 Metabolite levels ZNF335 intron 22286219 rs11906879 chr20 44591324 T C 7.28E-05 Type 2 diabetes ZNF335 intron 17463246 rs6104410 chr20 44607601 A G 1.26E-13 Metabolite levels / / 22286219 rs6017718 chr20 44610737 T G 2.40E-11 Metabolite levels / / 22286219 rs6017721 chr20 44616397 A G 5.21E-12 Metabolite levels / / 22286219 rs1888235 chr20 44623967 C T 2.90E-14 Metabolite levels / / 22286219 rs6073984 chr20 44630653 A G 3.32E-12 Metabolite levels / / 22286219 rs6073985 chr20 44630804 A G 2.31E-17 Metabolite levels / / 22286219 rs3918241 chr20 44635735 T A 8.14E-12 Metabolite levels MMP9 nearGene-5 22286219 rs3918242 chr20 44635976 C T 6.98E-12 Metabolite levels MMP9 nearGene-5 22286219 rs3918245 chr20 44636910 T G 9.75E-04 Bipolar disorder MMP9 nearGene-5 19259986 rs2274755 chr20 44639692 G T 9.64E-12 Metabolite levels MMP9 intron 22286219 rs2236416 chr20 44640575 A G 1.08E-11 Metabolite levels MMP9 intron 22286219 rs17577 chr20 44643111 G A,C,T 2.22E-11 Metabolite levels MMP9 missense 22286219 rs17577 chr20 44643111 G A,C,T 0.0000144 HDL cholesterol MMP9 missense 23063622 rs3918261 chr20 44643592 A G 1.69E-11 Metabolite levels MMP9 intron 22286219 rs3918270 chr20 44645339 G A 1.69E-11 Metabolite levels LOC100128028 intron 22286219 rs10432735 chr20 44650318 A T 1.87E-11 Metabolite levels / / 22286219 rs62215576 chr20 44652397 C T 0.00000017 Joint damage severity in rheumatoid arthritis SLC12A5 intron 23696630 rs11908352 chr20 44656140 C A 0.00000017 Joint damage severity in rheumatoid arthritis SLC12A5 intron 23696630 rs2868364 chr20 44658296 G A 5.88E-05 Smoking quantity SLC12A5 intron 24665060 rs6104433 chr20 44659335 G A 4.95E-04 Multiple complex diseases SLC12A5 intron 17554300 rs2297201 chr20 44684978 C T 1.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC12A5 intron 20877124 rs17450969 chr20 44693897 G A 7.34E-08 Adiponectin levels NCOA5 intron 20887962 rs2425752 chr20 44702120 T C 5.00E-10 Multiple sclerosis NCOA5 intron 21833088 rs2425752 chr20 44702120 T C 9.28E-05 Kawasaki disease NCOA5 intron 22446961 rs2425752 chr20 44702120 T C 1.00E-04 Multiple sclerosis NCOA5 intron 24234648 rs16991058 chr20 44702167 G T 6.30E-06 Response to lithium treatment in bipolar disorder NCOA5 intron 19448189 rs6074015 chr20 44712175 C T 2.70E-04 Alcohol dependence NCOA5 intron 20201924 rs6074015 chr20 44712175 C T 4.70E-04 Alcohol dependence NCOA5 intron 20201924 rs2868764 chr20 44722011 G T 9.40E-05 Kawasaki disease / / 22446961 rs6131010 chr20 44724305 A G 8.50E-07 Multiple sclerosis / / 19525955 rs6131010 chr20 44724305 A G 8.44E-05 Kawasaki disease / / 22446961 rs6032661 chr20 44733811 A G 3.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6032662 chr20 44734310 C T 1.37E-09 Rheumatoid arthritis (CCP positive) / / 23143596 rs6032662 chr20 44734310 C T 4.38E-10 Rheumatoid arthritis / / 23143596 rs1535044 chr20 44739156 G A 0.000551 fMRI brain tests in schizophrenia / / 22440650 rs6074022 chr20 44740196 C T 7.91E-07 Rheumatoid arthritis / / 17804836 rs6074022 chr20 44740196 C T 1.00E-07 Multiple sclerosis / / 19525955 rs6074022 chr20 44740196 C T 2.65E-06 Multiple sclerosis / / 21833088 rs6074022 chr20 44740196 C T 5.00E-06 Multiple sclerosis / / 22190364 rs1569723 chr20 44742064 C A 5.72E-07 Rheumatoid arthritis / / 17804836 rs1569723 chr20 44742064 C A 2.90E-07 Multiple sclerosis / / 19525955 rs1569723 chr20 44742064 C A 6.00E-09 Kawasaki disease / / 22446961 rs1569723 chr20 44742064 C A 1.00E-13 Inflammatory bowel disease / / 23128233 rs11569302 chr20 44747104 C T 2.65E-09 Cholesterol,total CD40 intron 23063622 rs11569302 chr20 44747104 C T 3.07E-09 LDL cholesterol CD40 intron 23063622 rs11569302 chr20 44747104 C T 5.89E-08 Triglycerides CD40 intron 23063622 rs4810485 chr20 44747947 T G 8.00E-09 Rheumatoid arthritis CD40 intron 18794853 rs4810485 chr20 44747947 T G 3.00E-09 Rheumatoid arthritis CD40 intron 20453842 rs4810485 chr20 44747947 T G 2.80E-09 Celiac disease and Rheumatoid arthritis CD40 intron 21383967 rs4810485 chr20 44747947 T G 8.20E-09 Multiple sclerosis CD40 intron 22190364 rs4810485 chr20 44747947 T G 2.93E-06 Kawasaki disease CD40 intron 22446961 rs4810485 chr20 44747947 T G 0.00000022 Rheumatoid arthritis CD40 intron 23143596 rs4810485 chr20 44747947 T G 8.86E-11 Rheumatoid arthritis (CCP positive) CD40 intron 23143596 rs4810485 chr20 44747947 T G 2.70E-05 Rheumatoid arthritis CD40 intron 24782177 rs4239702 chr20 44749251 T C 1.00E-16 Rheumatoid arthritis CD40 intron 24390342 rs4239702 chr20 44749251 T C 4.00E-18 Rheumatoid arthritis CD40 intron 24390342 rs11569321 chr20 44751363 C T 0.0000013 Triglycerides CD40 missense 23063622 rs11569321 chr20 44751363 C T 3.01E-09 Cholesterol,total CD40 missense 23063622 rs11569321 chr20 44751363 C T 5.36E-09 LDL cholesterol CD40 missense 23063622 rs11569325 chr20 44753811 T C 0.00000191 Triglycerides CD40 intron 23063622 rs3746821 chr20 44755111 G T 1.76E-04 Multiple complex diseases CD40 intron 17554300 rs3746821 chr20 44755111 G T 9.71E-05 Multiple sclerosis CD40 intron 17660530 rs3746821 chr20 44755111 G T 3.98E-05 Kawasaki disease CD40 intron 22446961 rs7273698 chr20 44756823 C T 0.000000042 LDL cholesterol CD40 missense 23063622 rs7273698 chr20 44756823 C T 0.000000304 Cholesterol,total CD40 missense 23063622 rs12481282 chr20 44761377 G C 9.14E-06 Response to amphetamines / / 22952603 rs12480534 chr20 44761485 T G 9.00E-06 Response to amphetamines / / 22952603 rs4813003 chr20 44763284 C T 3.73E-05 Kawasaki disease / / 22446961 rs4813003 chr20 44763284 C T 5.00E-08 Kawasaki disease / / 22446962 rs4810486 chr20 44766403 A G 2.72E-05 Kawasaki disease / / 22446961 rs1883834 chr20 44773838 A C 1.69E-05 Kawasaki disease / / 22446961 rs1883835 chr20 44773987 A G 1.10E-05 Kawasaki disease / / 22446961 rs6104485 chr20 44784840 A G 5.32E-04 Type 2 diabetes / / 17463246 rs2425756 chr20 44790262 T G 3.10E-04 Type 2 diabetes / / 17463246 rs2425764 chr20 44800445 A G 2.34E-05 Multiple sclerosis / / 17660530 rs1321000 chr20 44801026 A G 2.12E-04 Type 2 diabetes / / 17463246 rs2868767 chr20 44824624 A G 4.95E-04 Hemoglobin concentration CDH22 intron 20534544 rs6074067 chr20 44842922 G A 2.33E-05 Height CDH22 intron pha003011 rs2425795 chr20 44868295 C T 6.00E-04 Acute lymphoblastic leukemia (childhood) CDH22 intron 20189245 rs3904166 chr20 44873421 G T 2.47E-06 Height CDH22 intron pha003011 rs3091897 chr20 44878266 C G 2.03E-04 Type 2 diabetes CDH22 intron 17463246 rs2425804 chr20 44878927 A T 3.62E-04 Type 2 diabetes CDH22 intron 17463246 rs2868715 chr20 44885356 C T 8.36E-04 Depression (quantitative trait) / / 20800221 rs2868714 chr20 44886189 G A 8.34E-04 Depression (quantitative trait) / / 20800221 rs2425824 chr20 44897741 A G 2.37E-04 Type 2 diabetes / / 17463246 rs2425830 chr20 44899130 C T 2.91E-04 Type 2 diabetes / / 17463246 rs6065944 chr20 44900733 C A 9.77E-04 Depression (quantitative trait) / / 20800221 rs6065944 chr20 44900733 C A 2.82E-05 Height / / pha003010 rs6065944 chr20 44900733 C A 1.34E-06 Height / / pha003011 rs6074085 chr20 44902426 A G 6.55E-04 Multiple complex diseases / / 17554300 rs3904163 chr20 44905385 G A 9.85E-04 Depression (quantitative trait) / / 20800221 rs3904163 chr20 44905385 G A 8.21E-05 Height / / pha003010 rs3904163 chr20 44905385 G A 6.64E-06 Height / / pha003011 rs6032745 chr20 44908527 T C 4.96E-04 Depression (quantitative trait) / / 20800221 rs6065945 chr20 44921631 C G 5.00E-06 IgG glycosylation / / 23382691 rs11087002 chr20 44922750 C T 1.30E-05 Multiple complex diseases / / 17554300 rs12625834 chr20 44949039 G A 1.83E-05 Alzheimer's disease (age of onset) / / 22005931 rs12626058 chr20 44949301 G A 1.76E-05 Alzheimer's disease (age of onset) / / 22005931 rs4810496 chr20 44954283 G A 2.31E-05 Alzheimer's disease (age of onset) / / 22005931 rs6124782 chr20 44955649 C T 1.36E-04 Obesity (extreme) / / 21935397 rs4810497 chr20 44958765 C G 1.33E-04 Obesity (extreme) / / 21935397 rs6124783 chr20 44959929 G A 5.14E-04 Taste perception / / 22132133 rs6124784 chr20 44960997 C T 1.08E-04 Obesity (extreme) / / 21935397 rs11698591 chr20 44962472 T C 6.40E-05 Cognitive test performance / / 20125193 rs2425873 chr20 44963439 G C 8.39E-04 Type 2 diabetes / / 17463246 rs6065961 chr20 44968255 C A 2.98E-04 Celiac disease / / 23936387 rs6017787 chr20 44974696 T G 1 Drug response to Etoposide / / 17537913 rs12480667 chr20 44983517 G A 1.90E-04 Attention deficit hyperactivity disorder SLC35C2 intron pha002875 rs10211808 chr20 44985764 G T 5.65E-05 Cognitive performance SLC35C2 intron 19734545 rs10211808 chr20 44985764 G T 8.74E-04 Tourette syndrome SLC35C2 intron 22889924 rs2297056 chr20 44996450 A G 5.65E-05 Cognitive performance ELMO2 intron 19734545 rs1033475 chr20 45045928 A C 9.72E-05 Multiple complex diseases / / 17554300 rs6017819 chr20 45051215 T C 4.79E-05 Cognitive performance / / 19734545 rs446112 chr20 45076909 A G 1 Drug response to Etoposide / / 17537913 rs460869 chr20 45077974 G A 1 Drug response to Etoposide / / 17537913 rs435891 chr20 45079267 T C 4.29E-04 Tourette syndrome / / 22889924 rs7274072 chr20 45079795 G A 1 Drug response to Etoposide / / 17537913 rs279728 chr20 45080421 C T 3.64E-04 Tourette syndrome / / 22889924 rs460703 chr20 45081842 G A 1 Drug response to Etoposide / / 17537913 rs456210 chr20 45081971 A G 1 Drug response to Etoposide / / 17537913 rs4809590 chr20 45084827 G A 6.94E-05 Type 2 diabetes / / 17463246 rs6094345 chr20 45089680 G A 2.50E-04 Type 2 diabetes / / 17463246 rs279716 chr20 45105432 T C 4.90E-04 Tourette syndrome / / 22889924 rs636493 chr20 45110334 T C 4.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs636493 chr20 45110334 T C 1.00E-04 Spine bone size / / 21947420 rs461863 chr20 45110934 G A 7.03E-04 Type 2 diabetes / / 17463246 rs601470 chr20 45116400 T A 4.33E-04 Insulin resistance / / 21901158 rs847052 chr20 45141833 T C 3.04E-05 Coronary heart disease ZNF334 intron pha003031 rs847104 chr20 45151273 A G 2.92E-05 Coronary heart disease / / pha003031 rs6017896 chr20 45154757 A G 2.12E-04 Smoking initiation / / 24665060 rs6094371 chr20 45157328 G A 8.48E-04 Multiple complex diseases / / 17554300 rs847059 chr20 45184757 T C 1.10E-05 Urinary metabolites / / 21572414 rs202399 chr20 45191804 A G 3.90E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs847068 chr20 45197192 A G 2.87E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs440744 chr20 45199242 C T 3.99E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs374564 chr20 45199417 T C 3.99E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs863672 chr20 45199926 C T 4.00E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs430891 chr20 45201501 A G 5.33E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs2694877 chr20 45202637 A G 3.94E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs2694876 chr20 45202771 G T 4.00E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs381118 chr20 45203026 T C 3.93E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs454302 chr20 45203100 T C 3.95E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs412753 chr20 45203306 A G 3.97E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs375578 chr20 45203360 G T 3.98E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs454103 chr20 45203365 T G 4.02E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs3091661 chr20 45203421 C A 2.24E-05 Cognitive performance SLC13A3 intron 19734545 rs3091661 chr20 45203421 C A 4.05E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs3092554 chr20 45203442 G A 4.08E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs393990 chr20 45204535 G T 2.67E-05 Cognitive performance SLC13A3 intron 19734545 rs393990 chr20 45204535 G T 4.32E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs393990 chr20 45204535 G T 2.49E-04 Common variable immunodeficiency SLC13A3 intron 21497890 rs399940 chr20 45204600 C T 4.11E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs439143 chr20 45204763 C A 4.09E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs386843 chr20 45205138 A G 6.81E-04 Type 2 diabetes SLC13A3 intron 17463246 rs386843 chr20 45205138 A G 3.35E-05 Cognitive performance SLC13A3 intron 19734545 rs386843 chr20 45205138 A G 1.43E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs413635 chr20 45205482 C T 2.95E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs2745731 chr20 45205891 A C 3.05E-05 Major depressive disorder (broad) SLC13A3 intron 20038947 rs389905 chr20 45212455 T G 3.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC13A3 intron 20877124 rs389905 chr20 45212455 T G 6.21E-04 Tourette syndrome SLC13A3 intron 22889924 rs863675 chr20 45212620 T C 5.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC13A3 intron 20877124 rs941206 chr20 45261041 A C 7.90E-08 Urinary metabolites SLC13A3 intron 21572414 rs1004571 chr20 45278169 A G 1.73E-04 Chronic kidney disease SLC13A3 intron 24351856 rs1004571 chr20 45278169 A G 6.23E-05 Glomerular filtration rate SLC13A3 intron 24351856 rs1004571 chr20 45278169 A G 5.24E-06 Height SLC13A3 intron pha003010 rs6066043 chr20 45288453 G A 3.73E-08 Chronic kidney disease SLC13A3 intron 24351856 rs6066043 chr20 45288453 G A 5.23E-09 Glomerular filtration rate SLC13A3 intron 24351856 rs6066043 chr20 45288453 G A 1.82E-05 Height SLC13A3 intron pha003010 rs4810537 chr20 45306928 A G 2.67E-04 Chronic kidney disease SLC13A3 intron 24351856 rs4810537 chr20 45306928 A G 6.08E-05 Glomerular filtration rate SLC13A3 intron 24351856 rs11550540 chr20 45315769 T C 6.25E-04 Suicide attempts in bipolar disorder TP53RK missense 21423239 rs3091619 chr20 45324760 C T 9.22E-05 Height / / pha003010 rs998422 chr20 45359408 A G 5.00E-04 Atrial fibrillation SLC2A10 intron 21846873 rs3091904 chr20 45361455 T C 9.00E-04 Atrial fibrillation SLC2A10 intron 21846873 rs11699667 chr20 45367764 G C 4.70E-04 Schizophrenia / / 20832056 rs4810560 chr20 45440598 G T 0.0000337 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2868890 chr20 45450419 G A 0.00000804 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs3092771 chr20 45455046 C T 0.000071 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs3092231 chr20 45455263 T C 0.0000151 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6066084 chr20 45460323 G A 2.00E-06 Quantitative traits / / 19197348 rs3092084 chr20 45461866 C T 9.52E-04 Nicotine dependence / / 17158188 rs6018103 chr20 45480059 C A 1.33E-04 Multiple complex diseases / / 17554300 rs3091995 chr20 45484155 G A 0.0000108 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6066093 chr20 45493264 T C 5.33E-04 Glaucoma (primary open-angle) / / 22419738 rs6066093 chr20 45493264 T C 2.81E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6124878 chr20 45497723 G A 4.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs6018135 chr20 45513745 C T 0.0000454 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs6124882 chr20 45523914 G A 0.0000544 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs6122533 chr20 45528050 C A 0.0000603 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs6124883 chr20 45532122 T C 8.17E-04 Schizophrenia EYA2 intron 19197363 rs6124885 chr20 45534053 A G 0.0000135 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs6066110 chr20 45539797 A G 6.73E-04 Alcohol dependence EYA2 intron 21314694 rs6012072 chr20 45541630 C T 0.0000805 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs6122535 chr20 45543036 A G 0.0000499 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs6124891 chr20 45543298 C A,T 0.000055 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs6018165 chr20 45543619 T G 0.0000741 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs6122536 chr20 45543676 C T 4.03E-05 Cognitive performance EYA2 intron 19734545 rs6122536 chr20 45543676 C T 0.0000641 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs6018167 chr20 45545183 A G 0.0000597 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs6018168 chr20 45546172 A G 4.35E-05 Cognitive performance EYA2 intron 19734545 rs6018168 chr20 45546172 A G 0.0000787 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs6124892 chr20 45548456 A G 0.0000538 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs6124893 chr20 45549765 G A 0.0000472 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs4810576 chr20 45549871 G A 7.62E-04 Smoking initiation EYA2 intron 24665060 rs6018178 chr20 45551311 A T 0.0000345 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs6122537 chr20 45551469 A G 0.0000469 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs6012078 chr20 45551601 C G 0.0000329 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs6124894 chr20 45551790 T A 0.0000325 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs6124895 chr20 45551958 C T 0.0000606 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs6122538 chr20 45552078 C A 0.000061 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs67559658 chr20 45553106 G A 0.0000797 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs6018181 chr20 45553964 C G 0.0000325 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs6122541 chr20 45554374 G A 0.0000328 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs6012080 chr20 45554748 C T 3.61E-05 Cognitive performance EYA2 intron 19734545 rs6012080 chr20 45554748 C T 0.0000294 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs6124897 chr20 45555644 C T 0.0000345 Nonsyndromic striae distensae (stretch marks) EYA2 intron 23633020 rs1412956 chr20 45557017 A G 5.59E-04 Smoking initiation EYA2 intron 24665060 rs6018185 chr20 45557451 T C 4.50E-04 Alcohol dependence EYA2 intron 20201924 rs6018185 chr20 45557451 T C 9.00E-04 Alcohol dependence EYA2 intron 20201924 rs6066121 chr20 45557469 A G 8.15E-05 Smoking initiation EYA2 intron 24665060 rs1206744 chr20 45572595 C A 5.69E-05 Insulin resistance EYA2 intron 21901158 rs4809607 chr20 45594395 G A 1.34E-05 Monocyte chemoattractant protein-1 EYA2 intron pha003071 rs13041757 chr20 45600280 G A 6.08E-06 Lung cancer EYA2 intron 19414679 rs13037327 chr20 45608564 A G 8.44E-05 Parkinson's disease (motor and cognition) EYA2 intron 22658654 rs13037327 chr20 45608564 A G 8.44E-05 Immune response to anthrax vaccine EYA2 intron 22658931 rs6018223 chr20 45632937 G A 2.81E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EYA2 intron 20877124 rs6094553 chr20 45640459 T A 3.02E-04 Multiple complex diseases EYA2 intron 17554300 rs3827062 chr20 45644463 C G 4.45E-05 Type 2 diabetes EYA2 intron 17463246 rs6066174 chr20 45662736 C T 8.80E-04 Type 2 diabetes EYA2 intron 17463246 rs1417449 chr20 45673546 A G 6.18E-06 Thiazide-induced adverse metabolic effects in hypertensive patients EYA2 intron 23400010 rs947019 chr20 45674247 T G 3.80E-06 Thiazide-induced adverse metabolic effects in hypertensive patients EYA2 intron 23400010 rs878131 chr20 45680502 A G 4.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients EYA2 intron 23400010 rs1206809 chr20 45688668 A G 6.80E-04 Multiple complex diseases EYA2 intron 17554300 rs1206810 chr20 45695362 T C 5.79E-04 Multiple complex diseases EYA2 intron 17554300 rs1206815 chr20 45702414 A G 4.06E-04 Multiple complex diseases EYA2 intron 17554300 rs1206818 chr20 45705792 A C 2.53E-04 Multiple complex diseases EYA2 intron 17554300 rs1206819 chr20 45705902 A G 4.42E-04 Multiple complex diseases EYA2 intron 17554300 rs2298003 chr20 45726271 C G 6.07E-05 Multiple complex diseases EYA2 intron 17554300 rs6018279 chr20 45735427 G A 9.65E-04 Multiple complex diseases EYA2 intron 17554300 rs6094594 chr20 45739758 G A 7.23E-05 Asthma EYA2 intron pha003128 rs2868853 chr20 45742310 C T 1.03E-06 Multiple complex diseases EYA2 intron 17554300 rs3787249 chr20 45744355 A G 1.37E-06 Multiple complex diseases EYA2 intron 17554300 rs8124673 chr20 45751284 A G 4.71E-06 Multiple complex diseases EYA2 intron 17554300 rs11086194 chr20 45758585 C G 4.86E-04 Insulin resistance EYA2 intron 21901158 rs6066209 chr20 45762795 G T 4.72E-04 Multiple complex diseases EYA2 intron 17554300 rs3746491 chr20 45801553 A G 3.95E-04 Type 2 diabetes EYA2 intron 17463246 rs7262634 chr20 45834279 T C 1.00E-06 Response to protease inhibitor treatment in hepatitis c (bilirubin toxicity) / / 24503447 rs3746488 chr20 45858421 C T 6.71E-05 Orofacial clefts ZMYND8 intron 22419666 rs4810622 chr20 45877226 C T 4.70E-04 Suicidal ideation ZMYND8 intron 22030708 rs11696358 chr20 45888390 C G 9.43E-06 Asthma ZMYND8 intron 11022011 rs6122571 chr20 45906136 T C 5.07E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZMYND8 intron 20877124 rs6122571 chr20 45906136 T C 6.26E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZMYND8 intron 20877124 rs6122571 chr20 45906136 T C 4.80E-04 Alcohol consumption (maxi-drinks) ZMYND8 intron 24277619 rs6018424 chr20 45986984 C T 7.73E-05 Lipid levels / / 19913121 rs6063100 chr20 45989180 C T 2.52E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs6018425 chr20 45989730 T C 4.63E-04 Type 2 diabetes / / 17463246 rs6018425 chr20 45989730 T C 2.50E-05 Urinary metabolites / / 21572414 rs6018427 chr20 45990319 A G 2.20E-05 Urinary metabolites / / 21572414 rs6012184 chr20 46043982 G T 7.37E-04 Type 2 diabetes / / 17463246 rs6018477 chr20 46059823 A C 4.49E-04 Alcohol dependence / / 20201924 rs6066333 chr20 46071366 T C 2.10E-05 Urinary metabolites / / 21572414 rs2425938 chr20 46080276 A G 8.40E-06 Urinary metabolites / / 21572414 rs1211646 chr20 46081415 A G 3.60E-06 Urinary metabolites / / 21572414 rs4809636 chr20 46086478 T C 1.25E-05 Coronary heart disease / / pha003055 rs4810643 chr20 46093917 G A 1.50E-05 Major depressive disorder / / 19107115 rs6094710 chr20 46095649 G A 2.00E-10 Osteoarthritis (hip) / / 23989986 rs6063127 chr20 46139662 C G 1.86E-04 Multiple complex diseases NCOA3 intron 17554300 rs6125042 chr20 46186327 A G 8.43E-04 Parkinson's disease NCOA3 intron 17052657 rs1569438 chr20 46186571 C A 5.12E-04 Amyotrophic lateral sclerosis (sporadic) NCOA3 intron 24529757 rs6125048 chr20 46208605 G T 2.00E-06 Response to treatment for acute lymphoblastic leukemia NCOA3 intron 19176441 rs2425975 chr20 46209502 G C 3.92E-04 Body mass index NCOA3 intron 21701565 rs2235734 chr20 46292149 T G 8.09E-05 Bipolar disorder SULF2 intron 20451256 rs7260675 chr20 46319738 G A 5.04E-04 Insulin resistance SULF2 intron 21901158 rs4239650 chr20 46327885 T C 5.03E-05 Cervical cancer SULF2 intron 24700089 rs1610377 chr20 46336530 T G 2.40E-06 Urinary metabolites SULF2 intron 21572414 rs4810663 chr20 46340506 C T 3.45E-04 Crohn's disease SULF2 intron 17435756 rs6063140 chr20 46344747 T G 2.53E-04 IgE levels SULF2 intron 17255346 rs6063141 chr20 46346459 G T 6.45E-05 Heart Failure SULF2 intron pha002884 rs4810669 chr20 46355261 T C 4.03E-05 Cognitive test performance SULF2 intron 20125193 rs11905745 chr20 46361490 G A 3.94E-05 Intracerebral hemorrhage SULF2 intron 24656865 rs4809647 chr20 46361758 T C 1.80E-05 Urinary metabolites SULF2 intron 21572414 rs6125093 chr20 46365274 T G 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SULF2 intron 22628534 rs6063144 chr20 46373841 T C 4.57E-04 Suicide attempts in bipolar disorder SULF2 intron 21423239 rs872111 chr20 46389178 C T 2.87E-06 Myocardial Infarction SULF2 intron pha002883 rs4810685 chr20 46400713 T C 7.00E-06 Attention deficit hyperactivity disorder (time to onset) SULF2 intron 18937294 rs7267937 chr20 46423399 C T 0.00001234 Sarcoidosis / / 22952805 rs7261107 chr20 46423429 T G 0.00006983 Sarcoidosis / / 22952805 rs11698405 chr20 46423862 A G 0.00009592 Sarcoidosis / / 22952805 rs4809653 chr20 46424692 G C 0.000008468 Sarcoidosis / / 22952805 rs13038095 chr20 46425576 G T 2.00E-07 Atrial fibrillation / / 20173747 rs6018694 chr20 46428073 C G 0.00001244 Sarcoidosis / / 22952805 rs6018700 chr20 46431567 C G 0.00001555 Sarcoidosis / / 22952805 rs6018702 chr20 46432166 T C 0.00001555 Sarcoidosis / / 22952805 rs6066482 chr20 46432236 A C 7.10E-06 Urinary metabolites / / 21572414 rs4810697 chr20 46432927 A G 0.0000157 Sarcoidosis / / 22952805 rs6012271 chr20 46434083 A G 0.00002248 Sarcoidosis / / 22952805 rs6018703 chr20 46434928 G T 0.00001622 Sarcoidosis / / 22952805 rs6018704 chr20 46435019 G A 0.00001622 Sarcoidosis / / 22952805 rs4810701 chr20 46436610 A T 0.00004539 Sarcoidosis / / 22952805 rs2145135 chr20 46437272 A G 0.00003373 Sarcoidosis / / 22952805 rs6122616 chr20 46439232 C T 6.32E-05 Myopia (pathological) / / 21640322 rs12480416 chr20 46440319 C T 1.60E-05 Urinary metabolites / / 21572414 rs2869224 chr20 46445608 C T 7.51E-04 Type 2 diabetes / / 17463246 rs10854177 chr20 46453023 G T 0.00009583 Sarcoidosis / / 22952805 rs6012279 chr20 46454042 A G 0.00005013 Sarcoidosis / / 22952805 rs6066502 chr20 46478591 T G 8.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6066502 chr20 46478591 T G 1.96E-05 Myopia (pathological) / / 21640322 rs1361931 chr20 46501753 G A 4.65E-05 Cognitive impairment induced by topiramate / / 22091778 rs6066523 chr20 46511510 C T 7.70E-04 Smoking cessation / / 24665060 rs2426002 chr20 46513513 C T 8.80E-06 Urinary metabolites / / 21572414 rs6063178 chr20 46543831 G T 6.68E-04 Alzheimer's disease / / 17998437 rs2426053 chr20 46566785 C A 5.44E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs4809667 chr20 46570587 C A 6.47E-04 Smoking quantity / / 24665060 rs11699451 chr20 46574914 T C 6.57E-05 Cognitive impairment induced by topiramate / / 22091778 rs2869313 chr20 46578103 C T 2.30E-07 White blood cell count / / 21738479 rs11908089 chr20 46626722 C T 0.000255 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11908089 chr20 46626722 C T 2.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11906231 chr20 46628597 A C 0.000583233 Hypertension (early onset hypertension) / / 22479346 rs4810750 chr20 46638086 G A 7.48E-04 Type 2 diabetes / / 17463246 rs11699123 chr20 46646389 T A 9.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11696988 chr20 46658235 T C 0.0008013 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11696988 chr20 46658235 T C 8.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11699012 chr20 46658416 A G 0.0007977 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11699012 chr20 46658416 A G 7.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11698887 chr20 46661671 T C 0.0007401 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11698887 chr20 46661671 T C 7.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6018919 chr20 46735710 T G 7.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4141549 chr20 46749181 T C 1.99E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100506053 intron 20877124 rs4141549 chr20 46749181 T C 7.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100506053 intron 20877124 rs17331951 chr20 46775516 A G 7.74E-05 Type 2 diabetes / / 17463246 rs11700195 chr20 46778503 C T 6.20E-04 Alzheimer's disease / / 17998437 rs11700186 chr20 46778574 A G 3.76E-04 Alzheimer's disease / / 17998437 rs11086243 chr20 46779235 C T 3.00E-06 Nephrotic syndrome (acquired) / / 21441931 rs227876 chr20 46782932 A G 2.16E-04 Type 2 diabetes / / 17463246 rs382820 chr20 46794060 G A 3.53E-05 Epilepsy (remission after treatment) / / 23962720 rs363895 chr20 46794207 G A 3.77E-05 Epilepsy (remission after treatment) / / 23962720 rs364110 chr20 46794262 T A 4.05E-05 Epilepsy (remission after treatment) / / 23962720 rs363898 chr20 46794330 G T 3.94E-05 Epilepsy (remission after treatment) / / 23962720 rs755393 chr20 46794727 T C 3.93E-05 Epilepsy (remission after treatment) / / 23962720 rs827930 chr20 46795403 G A 8.43E-05 Epilepsy (remission after treatment) / / 23962720 rs827929 chr20 46795444 G C 8.43E-05 Epilepsy (remission after treatment) / / 23962720 rs1077021 chr20 46795742 A C 8.47E-05 Epilepsy (remission after treatment) / / 23962720 rs228215 chr20 46801036 C T 3.61E-05 Odorant perception / / 23910658 rs62202398 chr20 46801224 G A 9.00E-06 Alcohol consumption / / 23743675 rs228219 chr20 46801820 G C 5.99E-04 Smoking initiation / / 24665060 rs228220 chr20 46802078 T C 5.99E-04 Smoking initiation / / 24665060 rs60630422 chr20 46802989 C A 2.77E-05 Alcohol consumption / / 23743675 rs228224 chr20 46803126 T C 4.46E-04 Smoking initiation / / 24665060 rs615124 chr20 46803865 T A 5.32E-04 Smoking initiation / / 24665060 rs688975 chr20 46804477 T C 4.41E-04 Smoking initiation / / 24665060 rs12624655 chr20 46804959 G T 1.07E-05 Alcohol consumption / / 23743675 rs676250 chr20 46805021 G A 2.57E-04 Smoking initiation / / 24665060 rs11907901 chr20 46814475 C T 7.90E-05 Endometriosis / / 21151130 rs852335 chr20 46816900 A G 1.31E-04 Vaspin levels / / 22907691 rs852335 chr20 46816900 A G 0.0001312 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs6095016 chr20 46845066 C T 6.26E-04 Type 2 diabetes / / 17463246 rs226839 chr20 46876537 T C 6.09E-05 Asthma / / 23181788 rs465387 chr20 46885907 G A 0.000559 Salmonella-induced pyroptosis / / 22837397 rs6125267 chr20 46924609 A G 1.63E-04 Smoking initiation / / 24665060 rs6066696 chr20 46952686 T A 1.69E-04 Suicide attempts in bipolar disorder / / 21041247 rs6066696 chr20 46952686 T A 7.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs6125292 chr20 46958153 A G 6.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6019048 chr20 46960253 T C 6.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2296090 chr20 47012256 A C 9.75E-04 Stroke / / pha002887 rs6012416 chr20 47033829 G A 4.45E-05 Colorectal cancer / / 19723657 rs7263053 chr20 47063526 C T 3.90E-04 Crohn's disease / / 17684544 rs6122682 chr20 47063883 T C 7.00E-04 Crohn's disease / / 17684544 rs13043694 chr20 47088154 G A 3.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs4810796 chr20 47088200 G A 3.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs910191 chr20 47088732 A G 2.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs4402823 chr20 47089525 T C 3.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs4458264 chr20 47089537 C T 3.00E-06 Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) / / 23527680 rs6019224 chr20 47103614 C A 6.17E-06 Potassium levels / / pha003086 rs6012446 chr20 47110130 C T 1.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs6012446 chr20 47110130 C T 5.16E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs1321010 chr20 47144037 C T 2.81E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs16993895 chr20 47155435 T C 7.22E-04 Smoking quantity / / 24665060 rs16993927 chr20 47192391 A G 1.18E-04 Multiple complex diseases / / 17554300 rs4810831 chr20 47226012 T C 1.85E-04 Myopia (pathological) / / 21095009 rs4809712 chr20 47248057 G A 7.09E-04 Tourette syndrome PREX1 intron 22889924 rs4596036 chr20 47258613 G A 6.68E-04 Longevity PREX1 intron 22279548 rs761272 chr20 47315581 A G 0.000876863 Hypertension (early onset hypertension) PREX1 intron 22479346 rs6095248 chr20 47320932 T C 9.38E-04 Type 2 diabetes PREX1 intron 17463246 rs926629 chr20 47335736 A G 0.000606173 Hypertension (early onset hypertension) PREX1 intron 22479346 rs968479 chr20 47339628 A G 0.000151066 Hypertension (early onset hypertension) PREX1 intron 22479346 rs6063312 chr20 47343059 G T 2.00E-06 Tonometry PREX1 intron 17903302 rs11699576 chr20 47349878 A C 6.27E-04 Amyotrophic Lateral Sclerosis PREX1 intron 17362836 rs4809722 chr20 47354008 G A 4.95E-04 Amyotrophic Lateral Sclerosis PREX1 intron 17362836 rs6066836 chr20 47356483 A G 0.000418 Height (Pygmy height) PREX1 intron 22570615 rs6095280 chr20 47365072 C G 2.29E-04 Multiple complex diseases PREX1 intron 17554300 rs1883744 chr20 47369447 A G 7.35E-05 Serum metabolites PREX1 intron 19043545 rs13045364 chr20 47375591 G A 5.38E-05 Serum metabolites PREX1 intron 19043545 rs2426087 chr20 47379811 G A 2.00E-06 Narcolepsy with cataplexy PREX1 intron 23496005 rs2426090 chr20 47382056 A G 9.19E-05 Serum metabolites PREX1 intron 19043545 rs2426092 chr20 47384255 A C 0.000186 Height (Pygmy height) PREX1 intron 22570615 rs1555140 chr20 47386456 A G 8.42E-05 Serum metabolites PREX1 intron 19043545 rs6125463 chr20 47389100 G A 8.77E-06 Lipid traits PREX1 intron 21777205 rs2208589 chr20 47408414 A G 9.28E-04 Multiple complex diseases PREX1 intron 17554300 rs11700187 chr20 47410937 G A 2.70E-05 Urinary metabolites PREX1 intron 21572414 rs2869675 chr20 47420680 C T 7.15E-06 Kawasaki disease PREX1 intron 21221998 rs2869675 chr20 47420680 C T 5.15E-05 Post-operative nausea and vomiting PREX1 intron 21694509 rs6012536 chr20 47423563 A G 8.32E-09 Kawasaki disease PREX1 intron 21221998 rs6095302 chr20 47429565 C T 8.32E-09 Kawasaki disease PREX1 intron 21221998 rs1885290 chr20 47445579 C T 6.87E-04 Multiple complex diseases / / 17554300 rs720727 chr20 47447960 C T 9.09E-04 Multiple complex diseases / / 17554300 rs17366684 chr20 47470297 T C 6.96E-04 Type 2 diabetes / / 17463246 rs17366684 chr20 47470297 T C 3.79E-04 Multiple complex diseases / / 17554300 rs6019480 chr20 47495431 T C 9.88E-04 Multiple complex diseases / / 17554300 rs4809731 chr20 47495767 C G 8.33E-04 Type 2 diabetes / / 17463246 rs4809731 chr20 47495767 C G 6.27E-04 Multiple complex diseases / / 17554300 rs6095343 chr20 47499355 T C 9.18E-04 Rheumatoid arthritis / / 21452313 rs6019500 chr20 47511015 G A 9.47E-05 IgE levels / / 17255346 rs7266065 chr20 47531817 G A 0.00003887 Sarcoidosis / / 22952805 rs6095360 chr20 47532536 A G 0.00004314 Sarcoidosis / / 22952805 rs6512554 chr20 47532750 A G 0.00004174 Sarcoidosis / / 22952805 rs13037557 chr20 47534590 C T 0.00004174 Sarcoidosis / / 22952805 rs34651656 chr20 47534729 G A 0.00004174 Sarcoidosis / / 22952805 rs6019535 chr20 47541517 G A 0.00002794 Sarcoidosis ARFGEF2 intron 22952805 rs6012564 chr20 47541600 G A 7.00E-06 Anger ARFGEF2 intron 24489884 rs34984028 chr20 47549047 C T 0.00002794 Sarcoidosis ARFGEF2 intron 22952805 rs6095367 chr20 47550488 C T 0.0000285 Sarcoidosis ARFGEF2 intron 22952805 rs189331311 chr20 47552467 G C 0.00004544 Sarcoidosis ARFGEF2 intron 22952805 rs6019547 chr20 47561091 G A 0.00002794 Sarcoidosis ARFGEF2 intron 22952805 rs1883881 chr20 47565779 C A 2.00E-05 Anger ARFGEF2 intron 24489884 rs1983639 chr20 47572282 G A 0.0000416 Sarcoidosis ARFGEF2 intron 22952805 rs7264180 chr20 47579780 T C 0.00006561 Sarcoidosis ARFGEF2 intron 22952805 rs2295031 chr20 47580347 A G 0.00006561 Sarcoidosis ARFGEF2 intron 22952805 rs2295027 chr20 47582884 G A 0.0000416 Sarcoidosis ARFGEF2 intron 22952805 rs6019557 chr20 47583372 T G 0.0000416 Sarcoidosis ARFGEF2 intron 22952805 rs6019558 chr20 47583480 C A 0.0000416 Sarcoidosis ARFGEF2 intron 22952805 rs6090932 chr20 47598298 A C 0.0000416 Sarcoidosis ARFGEF2 intron 22952805 rs1569749 chr20 47601509 A G 0.0000416 Sarcoidosis ARFGEF2 intron 22952805 rs1997854 chr20 47602339 A G 0.0000416 Sarcoidosis ARFGEF2 intron 22952805 rs6019573 chr20 47602832 G T 0.00004611 Sarcoidosis ARFGEF2 intron 22952805 rs1569750 chr20 47603241 A G 0.00001897 Sarcoidosis ARFGEF2 intron 22952805 rs1048590 chr20 47610297 G T 0.0000416 Sarcoidosis ARFGEF2 intron 22952805 rs2295033 chr20 47610896 C T 0.0000416 Sarcoidosis ARFGEF2 intron 22952805 rs2024957 chr20 47616271 G A 0.00004611 Sarcoidosis ARFGEF2 intron 22952805 rs6019580 chr20 47625905 T C 0.00006438 Sarcoidosis ARFGEF2 intron 22952805 rs3818223 chr20 47626485 G C 0.00006438 Sarcoidosis ARFGEF2 intron 22952805 rs2295578 chr20 47626601 G C 0.00007118 Sarcoidosis ARFGEF2 intron 22952805 rs2295579 chr20 47626736 A T 0.00006438 Sarcoidosis ARFGEF2 intron 22952805 rs2295580 chr20 47626847 T A,C,G 0.00006438 Sarcoidosis ARFGEF2 cds-synon 22952805 rs6095395 chr20 47627095 A G 0.00003094 Sarcoidosis ARFGEF2 intron 22952805 rs6019581 chr20 47627572 C A 0.00007118 Sarcoidosis ARFGEF2 intron 22952805 rs6019582 chr20 47627605 C T 0.00006438 Sarcoidosis ARFGEF2 intron 22952805 rs6012581 chr20 47627845 C T 0.00006438 Sarcoidosis ARFGEF2 intron 22952805 rs3818224 chr20 47628170 T C 0.00006438 Sarcoidosis ARFGEF2 intron 22952805 rs2273531 chr20 47628434 T C 0.00006438 Sarcoidosis ARFGEF2 intron 22952805 rs730544 chr20 47635818 G C 0.00004543 Sarcoidosis ARFGEF2 intron 22952805 rs2869692 chr20 47638256 G A 0.00002728 Sarcoidosis ARFGEF2 intron 22952805 rs7270848 chr20 47639737 A G 0.00003932 Sarcoidosis ARFGEF2 intron 22952805 rs6019591 chr20 47640029 T A 0.00003932 Sarcoidosis ARFGEF2 intron 22952805 rs66970580 chr20 47641339 T C 0.00003932 Sarcoidosis ARFGEF2 intron 22952805 rs13041022 chr20 47642476 G A 0.00003932 Sarcoidosis ARFGEF2 intron 22952805 rs7262379 chr20 47642579 A G 0.00003932 Sarcoidosis ARFGEF2 intron 22952805 rs6019594 chr20 47643554 C G 0.00003932 Sarcoidosis ARFGEF2 intron 22952805 rs6019595 chr20 47644032 A G 0.00003932 Sarcoidosis ARFGEF2 intron 22952805 rs6095400 chr20 47645989 A C 0.00003932 Sarcoidosis ARFGEF2 intron 22952805 rs6095401 chr20 47646621 G A 0.00003932 Sarcoidosis ARFGEF2 intron 22952805 rs6019600 chr20 47646932 C T 0.0000436 Sarcoidosis ARFGEF2 intron 22952805 rs3091529 chr20 47647068 G A 1.95E-05 Cortisol secretion,in saliva ARFGEF2 intron 21316860 rs6012586 chr20 47647417 T C 0.00003932 Sarcoidosis ARFGEF2 intron 22952805 rs6019601 chr20 47647662 T C 0.00003932 Sarcoidosis ARFGEF2 intron 22952805 rs13042947 chr20 47647876 T C 0.00003932 Sarcoidosis ARFGEF2 intron 22952805 rs1022688 chr20 47648856 G A 0.0000201 Sarcoidosis ARFGEF2 intron 22952805 rs6019602 chr20 47651492 G A 0.00003932 Sarcoidosis ARFGEF2 UTR-3 22952805 rs707533 chr20 47652254 A G 0.00003932 Sarcoidosis ARFGEF2 UTR-3 22952805 rs707534 chr20 47652338 A G 0.00003932 Sarcoidosis ARFGEF2 UTR-3 22952805 rs6019603 chr20 47653406 T C 0.00003932 Sarcoidosis / / 22952805 rs6019604 chr20 47653498 G A 0.00003932 Sarcoidosis / / 22952805 rs927160 chr20 47654564 C G 0.00003932 Sarcoidosis / / 22952805 rs6019608 chr20 47655617 C T 0.0000436 Sarcoidosis / / 22952805 rs6019609 chr20 47655768 C G 0.00003932 Sarcoidosis / / 22952805 rs11905116 chr20 47658064 A G 0.00006433 Sarcoidosis / / 22952805 rs6095407 chr20 47661470 G C 0.00003932 Sarcoidosis / / 22952805 rs3817652 chr20 47663368 A G 0.00003932 Sarcoidosis CSE1L intron 22952805 rs6019613 chr20 47664667 C T 0.00003932 Sarcoidosis CSE1L intron 22952805 rs10485609 chr20 47665612 A G 2.40E-04 Cognition,early reading ability CSE1L intron 17684495 rs6090939 chr20 47665825 A G 0.00003932 Sarcoidosis CSE1L intron 22952805 rs6090940 chr20 47666027 G T 0.00003932 Sarcoidosis CSE1L intron 22952805 rs6012590 chr20 47667237 C T 0.00003932 Sarcoidosis CSE1L intron 22952805 rs6012591 chr20 47667342 T C 0.00003932 Sarcoidosis CSE1L intron 22952805 rs7509369 chr20 47668037 G A 0.00003932 Sarcoidosis CSE1L intron 22952805 rs2869694 chr20 47668383 C T 0.00003932 Sarcoidosis CSE1L intron 22952805 rs73611328 chr20 47669980 T C 0.00003932 Sarcoidosis CSE1L intron 22952805 rs6019618 chr20 47671538 T C 0.00003932 Sarcoidosis CSE1L intron 22952805 rs3795082 chr20 47673002 G C 0.00005441 Sarcoidosis CSE1L intron 22952805 rs6090941 chr20 47676951 G A 0.00003932 Sarcoidosis CSE1L intron 22952805 rs6095416 chr20 47677007 C G,T 0.00003932 Sarcoidosis CSE1L intron 22952805 rs6012592 chr20 47677162 C A 0.00004566 Sarcoidosis CSE1L intron 22952805 rs66501340 chr20 47677185 T C 0.00005695 Sarcoidosis CSE1L intron 22952805 rs6019619 chr20 47677834 T C 0.00002465 Sarcoidosis CSE1L intron 22952805 rs6012593 chr20 47677835 G A 0.00003682 Sarcoidosis CSE1L intron 22952805 rs6095417 chr20 47678201 G A 0.0000555 Sarcoidosis CSE1L intron 22952805 rs6019620 chr20 47679300 T A 0.00003932 Sarcoidosis CSE1L intron 22952805 rs6019621 chr20 47679963 C T 0.00003932 Sarcoidosis CSE1L intron 22952805 rs2075675 chr20 47685493 T C 0.00003932 Sarcoidosis CSE1L intron 22952805 rs6019624 chr20 47685815 G A 0.00004652 Sarcoidosis CSE1L intron 22952805 rs6512567 chr20 47688620 T G 0.00004377 Sarcoidosis CSE1L intron 22952805 rs2075676 chr20 47691211 C A 0.00004377 Sarcoidosis CSE1L intron 22952805 rs2426117 chr20 47693160 G A 0.00004377 Sarcoidosis CSE1L intron 22952805 rs2426120 chr20 47697253 T A 0.00004377 Sarcoidosis CSE1L intron 22952805 rs2426121 chr20 47697732 A C 0.00004126 Sarcoidosis CSE1L intron 22952805 rs2426122 chr20 47697939 A G 0.00004377 Sarcoidosis CSE1L intron 22952805 rs16994382 chr20 47700764 T C 5.91E-04 Multiple complex diseases CSE1L intron 17554300 rs2426125 chr20 47700982 A G 0.00001777 Sarcoidosis CSE1L intron 22952805 rs2075678 chr20 47701339 A G 1.16E-05 Cortisol secretion,in saliva CSE1L intron 21316860 rs1885163 chr20 47701765 T C 0.00001777 Sarcoidosis CSE1L intron 22952805 rs1538482 chr20 47705496 T C 0.00001918 Sarcoidosis CSE1L intron 22952805 rs2426130 chr20 47713932 T C 6.31E-04 Suicide attempts in bipolar disorder / / 21041247 rs1556876 chr20 47716451 A C 6.51E-04 Iron levels / / pha002876 rs2426133 chr20 47723262 T C 6.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs6066968 chr20 47727341 A G 3.50E-04 Myasthenia gravis / / 23055271 rs3818261 chr20 47736312 G A 8.58E-04 Type 2 diabetes STAU1 intron 17463246 rs348258 chr20 47768988 C T 0.00002745 Sarcoidosis STAU1 intron 22952805 rs3092427 chr20 47774781 G T 0.00006093 Sarcoidosis STAU1 intron 22952805 rs348267 chr20 47775921 C T 0.00006093 Sarcoidosis STAU1 intron 22952805 rs2426139 chr20 47780105 G A 0.00006231 Sarcoidosis STAU1 intron 22952805 rs348276 chr20 47786190 G A 0.00006093 Sarcoidosis STAU1 intron 22952805 rs348263 chr20 47795420 C T 0.00006017 Sarcoidosis STAU1 intron 22952805 rs6019687 chr20 47831904 T G 3.25E-04 Multiple complex diseases / / 17554300 rs6512575 chr20 47833418 A C 4.72E-04 Multiple complex diseases / / 17554300 rs6019695 chr20 47837868 G A 5.31E-05 Suicide attempts in bipolar disorder DDX27 intron 21041247 rs11553387 chr20 47841660 G A,C,T 9.35E-04 Iron levels DDX27 missense pha002876 rs1079661 chr20 47850614 A T 1.42E-04 Attention deficit hyperactivity disorder DDX27 intron pha002875 rs238150 chr20 47851919 T C 9.98E-04 Iron levels DDX27 intron pha002876 rs238158 chr20 47856309 C T 2.00E-05 Urinary metabolites DDX27 intron 21572414 rs238203 chr20 47858922 T G 4.72E-04 Multiple complex diseases DDX27 intron 17554300 rs238204 chr20 47859015 A G 2.83E-04 Multiple complex diseases DDX27 intron 17554300 rs7689 chr20 47862450 T C 2.10E-05 Urinary metabolites ZNFX1 UTR-3 21572414 rs238215 chr20 47870506 T C 1.65E-04 Multiple complex diseases ZNFX1 intron 17554300 rs238215 chr20 47870506 T C 1.20E-05 Anger ZNFX1 intron 24489884 rs6012627 chr20 47872796 A G 5.57E-05 Suicide attempts in bipolar disorder ZNFX1 intron 21041247 rs238196 chr20 47898217 G A 2.80E-07 Urinary metabolites ZNFX1-AS1 intron 21572414 rs237743 chr20 47903019 G A 1.00E-20 Height ZNFX1-AS1 intron 20881960 rs237708 chr20 47913026 T G 2.30E-05 Urinary metabolites / / 21572414 rs237707 chr20 47914458 T C 2.20E-05 Urinary metabolites / / 21572414 rs761498 chr20 47916450 C T 7.78E-05 Suicide attempts in bipolar disorder / / 21041247 rs11907908 chr20 47923614 C T 8.91E-05 Suicide attempts in bipolar disorder / / 21041247 rs381262 chr20 47933479 G A 5.99E-04 Type 2 diabetes / / 17463246 rs1847326 chr20 47945746 C A 3.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs6019750 chr20 47947469 C G 4.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs6019751 chr20 47947715 C T 4.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs6012644 chr20 47948503 G C 7.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs7261606 chr20 47953769 C T 7.80E-04 Suicide attempts in bipolar disorder / / 21041247 rs1007129 chr20 47955131 C T 5.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs237450 chr20 47982128 G A 5.00E-06 QT interval / / 23534349 rs6019794 chr20 48009445 A G 7.82E-04 Bipolar disorder KCNB1 intron 19259986 rs1847328 chr20 48018427 A G 0.00005452 Sarcoidosis KCNB1 intron 22952805 rs6063399 chr20 48019818 A G 8.00E-06 Obesity-related traits KCNB1 intron 23251661 rs6019815 chr20 48020649 G T 0.00001699 Sarcoidosis KCNB1 intron 22952805 rs16994565 chr20 48021074 T C 0.00001904 Sarcoidosis KCNB1 intron 22952805 rs55982958 chr20 48021467 T C 0.00001904 Sarcoidosis KCNB1 intron 22952805 rs16994569 chr20 48021631 T C 0.00001879 Sarcoidosis KCNB1 intron 22952805 rs6019816 chr20 48021708 G T 0.00002785 Sarcoidosis KCNB1 intron 22952805 rs7348799 chr20 48021727 T C 0.00001879 Sarcoidosis KCNB1 intron 22952805 rs56359026 chr20 48021937 C T 0.00001879 Sarcoidosis KCNB1 intron 22952805 rs56287623 chr20 48021968 T C 0.00001879 Sarcoidosis KCNB1 intron 22952805 rs56376132 chr20 48022073 A G 0.00001879 Sarcoidosis KCNB1 intron 22952805 rs55781755 chr20 48022079 T A 0.00001879 Sarcoidosis KCNB1 intron 22952805 rs56059929 chr20 48022158 T C 0.00002296 Sarcoidosis KCNB1 intron 22952805 rs6090975 chr20 48026562 T G 3.13E-04 Lung function (forced expiratory volume in 1 second) KCNB1 intron 24023788 rs6090975 chr20 48026562 T G 9.68E-05 Lung function (forced vital capacity) KCNB1 intron 24023788 rs6125647 chr20 48027463 A C 2.27E-04 Lung function (forced expiratory volume in 1 second) KCNB1 intron 24023788 rs6125647 chr20 48027463 A C 6.73E-05 Lung function (forced vital capacity) KCNB1 intron 24023788 rs926673 chr20 48030010 G T 5.50E-05 Brain lesion load KCNB1 intron 19010793 rs926673 chr20 48030010 G T 9.49E-05 Lung function (forced expiratory volume in 1 second) KCNB1 intron 24023788 rs237459 chr20 48031630 T C 7.40E-04 Type 2 diabetes and 6 quantitative traits KCNB1 intron 17848626 rs237461 chr20 48033171 T C 9.00E-05 Prostate cancer KCNB1 intron 21743057 rs237462 chr20 48033203 C T 6.76E-05 Brain lesion load KCNB1 intron 19010793 rs237462 chr20 48033203 C T 9.00E-05 Prostate cancer KCNB1 intron 21743057 rs119416 chr20 48035597 G A 7.51E-04 Coronary Artery Disease KCNB1 intron 17634449 rs237472 chr20 48043736 C A 1.70E-05 Urinary metabolites KCNB1 intron 21572414 rs7264104 chr20 48060146 C T 6.08E-05 Multiple complex diseases KCNB1 intron 17554300 rs13044588 chr20 48080030 C T 1.92E-06 Response to hepatitis C treatment KCNB1 intron 19684573 rs60747977 chr20 48081230 G A 0.00009853 Sarcoidosis KCNB1 intron 22952805 rs10485612 chr20 48084652 A G 0.00001919 Sarcoidosis KCNB1 intron 22952805 rs802950 chr20 48085832 C A 7.09E-04 Suicide attempts in bipolar disorder KCNB1 intron 21423239 rs4809745 chr20 48087871 G A 4.30E-04 Stroke KCNB1 intron pha002887 rs566604 chr20 48094590 A G 3.89E-04 Multiple complex diseases KCNB1 intron 17554300 rs566604 chr20 48094590 A G 2.80E-05 Urinary metabolites KCNB1 intron 21572414 rs544187 chr20 48107408 C T 8.41E-05 Heart Failure / / pha002884 rs729824 chr20 48127176 T C 7.25E-05 Bipolar disorder PTGIS intron 17486107 rs5629 chr20 48129706 G T 4.85E-04 Type 2 diabetes PTGIS cds-synon 17463246 rs6019876 chr20 48129987 G C 5.59E-04 Type 2 diabetes PTGIS intron 17463246 rs6019876 chr20 48129987 G C 1.61E-04 Lymphocyte counts PTGIS intron 22286170 rs6012696 chr20 48190386 G A 8.00E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs235008 chr20 48225985 T C 0.00009851 Sarcoidosis LOC728671 intron 22952805 rs235012 chr20 48228502 A C 0.00009746 Sarcoidosis LOC728671 intron 22952805 rs235013 chr20 48228936 G C 0.00009168 Sarcoidosis LOC728671 intron 22952805 rs6095600 chr20 48266705 C A 7.20E-04 Multiple complex diseases B4GALT5 intron 17554300 rs16994768 chr20 48279932 A T 1.57E-04 Multiple complex diseases B4GALT5 intron 17554300 rs6012712 chr20 48297253 A G 6.84E-04 Multiple complex diseases B4GALT5 intron 17554300 rs6512586 chr20 48301146 G A 8.42E-04 Multiple complex diseases B4GALT5 intron 17554300 rs1571367 chr20 48327700 G A 7.61E-04 Multiple complex diseases B4GALT5 intron 17554300 rs1980946 chr20 48344311 C G 4.00E-06 Palmitic acid (16:0) plasma levels / / 23362303 rs7260990 chr20 48377294 G A 8.07E-04 Multiple complex diseases / / 17554300 rs681074 chr20 48381482 A G 2.95E-05 Tuberculosis / / 24057671 rs582998 chr20 48394591 T C 3.87E-05 Tuberculosis / / 24057671 rs667008 chr20 48404464 A G 4.57E-04 Coronary heart disease / / 21606135 rs663890 chr20 48405168 G T 1.38E-04 Cognitive decline / / 23732972 rs605138 chr20 48420133 C T 8.41E-04 Type 2 diabetes / / 17463246 rs4297943 chr20 48423756 G A 2.19E-04 Cognitive decline / / 23732972 rs6063437 chr20 48430294 T G 1.40E-05 Urinary metabolites SLC9A8 intron 21572414 rs6012750 chr20 48430680 A G 2.90E-04 Amyotrophic Lateral Sclerosis SLC9A8 intron 17362836 rs17785895 chr20 48433059 A G 9.41E-06 Osteoarthritis SLC9A8 intron 22763110 rs8118160 chr20 48434636 A G 2.00E-04 Alcohol dependence SLC9A8 intron 20201924 rs4809760 chr20 48454671 A G 2.50E-04 Alcohol dependence SLC9A8 intron 20201924 rs2982414 chr20 48463058 A G 3.70E-04 Parkinson's disease SLC9A8 intron 17052657 rs2982414 chr20 48463058 A G 5.99E-04 Amyotrophic Lateral Sclerosis SLC9A8 intron 17362836 rs17786105 chr20 48466885 A G 1.50E-04 Alcohol dependence SLC9A8 intron 20201924 rs17786105 chr20 48466885 A G 6.80E-04 Alcohol dependence SLC9A8 intron 20201924 rs530461 chr20 48467716 G A 5.90E-04 Amyotrophic Lateral Sclerosis SLC9A8 intron 17362836 rs596195 chr20 48474768 T C 8.05E-04 Amyotrophic Lateral Sclerosis SLC9A8 intron 17362836 rs686996 chr20 48476266 C G 2.60E-04 Parkinson's disease SLC9A8 intron 17052657 rs627898 chr20 48480254 A C 2.60E-04 Parkinson's disease SLC9A8 intron 17052657 rs662708 chr20 48483623 G C 1.00E-05 Urinary metabolites SLC9A8 intron 21572414 rs568124 chr20 48484125 C T 3.02E-04 Parkinson's disease SLC9A8 intron 17052657 rs2281223 chr20 48484241 G A 2.20E-04 Alcohol dependence SLC9A8 intron 20201924 rs487096 chr20 48499259 G A,C 2.10E-05 Urinary metabolites SLC9A8 intron 21572414 rs483508 chr20 48499609 C T 5.22E-04 Parkinson's disease SLC9A8 intron 17052657 rs13433386 chr20 48507912 A G 3.85E-04 Multiple complex diseases SLC9A8 UTR-3 17554300 rs495337 chr20 48522330 G A 6.92E-05 Parkinson's disease SPATA2 cds-synon 17052657 rs495337 chr20 48522330 G A 1.00E-08 Psoriasis SPATA2 cds-synon 18364390 rs495337 chr20 48522330 G A 2.00E-07 Psoriasis SPATA2 cds-synon 20953189 rs495337 chr20 48522330 G A 2.00E-06 Psoriasis SPATA2 cds-synon 20953190 rs495337 chr20 48522330 G A 1.00E-08 Multiple sclerosis SPATA2 cds-synon 22190364 rs636987 chr20 48524288 A C 0.000219712 Primary sclerosing cholangitis SPATA2 intron 23603763 rs2268324 chr20 48529761 A G 1.57E-04 Multiple complex diseases SPATA2 intron 17554300 rs2235617 chr20 48554977 C G 8.80E-06 Parkinson's disease RNF114 intron 17052657 rs2235617 chr20 48554977 C G 2.00E-06 Psoriasis RNF114 intron 20953190 rs1056198 chr20 48556229 C T 2.16E-05 Parkinson's disease RNF114 intron 17052657 rs1056198 chr20 48556229 C T 1.50E-14 Psoriasis RNF114 intron 23143594 rs6125829 chr20 48568929 G T 1.40E-05 Parkinson's disease RNF114 UTR-3 17052657 rs2235616 chr20 48569127 G A 1.41E-05 Parkinson's disease RNF114 UTR-3 17052657 rs11697848 chr20 48575315 C T 1.00E-11 Systemic lupus erythematosus / / 24871463 rs6091080 chr20 48603887 G C 4.87E-04 Multiple complex diseases S/I1 intron 17554300 rs6020218 chr20 48650389 T C 1.96E-05 Tunica Media / / pha003036 rs6125878 chr20 48664874 T G 1.92E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11699870 chr20 48675298 T C 1.80E-05 Response to statin therapy / / 20339536 rs1049679 chr20 48698783 A G 6.15E-06 Post-operative nausea and vomiting UBE2V1 UTR-3 21694509 rs6122879 chr20 48749447 G A 7.36E-04 Smoking cessation TMEM189 intron 24665060 rs232734 chr20 48766851 T C 8.79E-04 Type 2 diabetes TMEM189 intron 17463246 rs4591400 chr20 48782534 G A 3.00E-04 Alzheimer's disease / / 17998437 rs8114447 chr20 48794917 T C 1.94E-04 Insulin resistance / / 21901158 rs932905 chr20 48796131 G A 6.57E-05 Cytomegalovirus antibody response / / 21993531 rs4253440 chr20 48808153 G A 1.77E-08 LDL cholesterol CEBPB missense 23063622 rs4253440 chr20 48808153 G A 3.33E-11 HDL cholesterol CEBPB missense 23063622 rs4253440 chr20 48808153 G A 3.82E-16 Cholesterol,total CEBPB missense 23063622 rs2904254 chr20 48812127 T C 4.56E-04 Tourette syndrome / / 22889924 rs10485613 chr20 48837861 C T 4.92E-04 Coronary Artery Disease / / 17634449 rs4811006 chr20 48839519 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4811011 chr20 48851192 A G 3.51E-06 Lipid traits / / 21777205 rs6095840 chr20 48861847 G A 5.60E-05 Response to statin therapy / / 20339536 rs6020394 chr20 48867316 C T 6.80E-05 Response to statin therapy / / 20339536 rs2274950 chr20 48894424 A C 9.80E-04 Multiple complex diseases LOC100506115 intron 17554300 rs1971480 chr20 48897080 G T 0.00000674 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4811017 chr20 48898315 C T 0.00000748 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4811018 chr20 48898447 A G 0.00000764 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6020420 chr20 48901345 G C 0.0000102 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6067391 chr20 48903581 G A 0.0000046 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2904263 chr20 48905989 A G 0.00000367 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs913670 chr20 48906516 T C 0.00000344 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4811023 chr20 48908693 T G 0.00000475 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6012892 chr20 48909966 C T 0.00000602 Nonsyndromic striae distensae (stretch marks) LOC284751 intron 23633020 rs1041302 chr20 48911432 G A 0.00000721 Nonsyndromic striae distensae (stretch marks) LOC284751 intron 23633020 rs6067394 chr20 48913503 T C 0.0000062 Nonsyndromic striae distensae (stretch marks) LOC284751 intron 23633020 rs13041874 chr20 48913574 C T 0.0000849 Nonsyndromic striae distensae (stretch marks) LOC284751 intron 23633020 rs6091130 chr20 48914352 C A 0.0000915 Nonsyndromic striae distensae (stretch marks) LOC284751 intron 23633020 rs6063499 chr20 48914922 G C 1.10E-05 Urinary metabolites / / 21572414 rs4811026 chr20 48915735 A G 0.0000162 Nonsyndromic striae distensae (stretch marks) LOC284751 intron 23633020 rs6063500 chr20 48916411 G A 0.00000992 Nonsyndromic striae distensae (stretch marks) LOC284751 intron 23633020 rs7269352 chr20 48918420 A G 3.70E-04 Alcohol dependence LOC284751 intron 20201924 rs7269352 chr20 48918420 A G 6.60E-04 Alcohol dependence LOC284751 intron 20201924 rs928072 chr20 48934778 A G 6.94E-05 Alcohol and nictotine co-dependence / / 20158304 rs6020445 chr20 48939863 A G 4.75E-06 Glucose levels / / pha003058 rs913678 chr20 48955424 T C 5.00E-08 Inflammatory bowel disease / / 23128233 rs913678 chr20 48955424 T C 3.19E-05 Behcet's disease / / pha002888 rs13038647 chr20 48974248 T C 5.16E-05 Major depressive disorder (broad) / / 20038947 rs7266895 chr20 48982515 G A 1.20E-06 Stroke (ischemic) / / 22384361 rs6067417 chr20 48983697 C T 1.51E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs6095892 chr20 48985871 T C 6.40E-07 Stroke (ischemic) / / 22384361 rs4811058 chr20 49011501 T C 3.80E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs13038695 chr20 49048440 A G 7.13E-04 Myopia (pathological) / / 21095009 rs6020502 chr20 49051640 A G 1.10E-05 Fasting plasma glucose / / 19060907 rs6095959 chr20 49072651 A C 3.67E-05 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia / / 24039173 rs4811072 chr20 49086117 G A 6.50E-05 Parkinson's disease / / pha002865 rs1997791 chr20 49096428 C A 1.95E-05 Parkinson's disease / / pha002865 rs6020561 chr20 49119556 C T 9.62E-04 Alzheimer's disease / / 22005930 rs941798 chr20 49163235 A G 2.60E-04 Multiple complex diseases PTPN1 intron 17554300 rs6512654 chr20 49170157 T G 6.30E-05 Ankylosing spondylitis PTPN1 intron 22138694 rs4602269 chr20 49172235 C T 2.42E-07 Lymphocyte counts PTPN1 intron 22286170 rs3787345 chr20 49185423 C T 4.03E-04 Alzheimer's disease PTPN1 intron 22005930 rs718050 chr20 49196930 A G 1.62E-04 Lung function (forced vital capacity) PTPN1 intron 24023788 rs718050 chr20 49196930 A G 4.56E-05 Lung function (forced expiratory volume in 1 second) PTPN1 intron 24023788 rs3787348 chr20 49196998 G T 4.08E-04 Multiple complex diseases PTPN1 intron 17554300 rs6020677 chr20 49289227 A G 1.86E-05 Cognitive impairment induced by topiramate / / 22091778 rs6020693 chr20 49304623 G C 2.90E-05 Urinary metabolites / / 21572414 rs6020697 chr20 49306745 C T 2.00E-05 Urinary metabolites / / 21572414 rs231584 chr20 49339595 C T 7.06E-06 Socioeconomic Factors / / pha003066 rs2064278 chr20 49363182 G T 1.13E-05 Cleft lip PARD6B intron 20436469 rs2064278 chr20 49363182 G T 2.79E-05 Orofacial clefts PARD6B intron 22863734 rs6020721 chr20 49367076 T G 3.06E-04 Birth weight PARD6B UTR-3 17255346 rs6122972 chr20 49375242 A G 9.72E-06 Cleft lip / / 20436469 rs6122972 chr20 49375242 A G 3.00E-06 Bipolar disorder / / 21771265 rs6122972 chr20 49375242 A G 9.82E-05 Orofacial clefts / / 22863734 rs117440705 chr20 49398443 C T 2.02E-05 Epilepsy (remission after treatment) / / 23962720 rs1124952 chr20 49434526 A G 3.49E-04 Lymphocyte counts BCAS4 intron 22286170 rs6020772 chr20 49442655 C T 7.61E-04 Lymphocyte counts BCAS4 intron 22286170 rs8121702 chr20 49485512 A G 1.83E-05 Coronary heart disease BCAS4 intron pha003031 rs6020814 chr20 49489180 G T 2.88E-04 Tourette syndrome BCAS4 intron 22889924 rs6020814 chr20 49489180 G T 1.14E-05 Coronary heart disease BCAS4 intron pha003031 rs6096141 chr20 49490888 T C 8.57E-04 Tourette syndrome BCAS4 intron 22889924 rs2426219 chr20 49585432 A C 7.97E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6013049 chr20 49594418 C T 3.87E-04 Multiple complex diseases / / 17554300 rs4811103 chr20 49595815 C T 1.75E-05 Reading and spelling / / 23738518 rs4811117 chr20 49671435 T G 6.06E-04 Multiple complex diseases / / 17554300 rs4811117 chr20 49671435 T G 5.00E-06 Molar-incisor hypomineralization / / 23918034 rs911020 chr20 49671946 T C 3.14E-07 Primary biliary cirrhosis / / 23000144 rs911020 chr20 49671946 T C 0.000000314 Facial morphology / / 23028347 rs1123093 chr20 49673473 A G 6.58E-06 Molar-incisor hypomineralization / / 23918034 rs6020940 chr20 49674849 G A 2.09E-07 Primary biliary cirrhosis / / 23000144 rs6020940 chr20 49674849 G A 0.000000209 Facial morphology / / 23028347 rs6020957 chr20 49687635 T C 2.79E-07 Primary biliary cirrhosis / / 23000144 rs6020957 chr20 49687635 T C 0.000000279 Facial morphology / / 23028347 rs911015 chr20 49690171 A G 3.01E-07 Primary biliary cirrhosis / / 23000144 rs911015 chr20 49690171 A G 0.000000301 Facial morphology / / 23028347 rs6020962 chr20 49691019 A C 8.73E-05 Serum metabolites / / 19043545 rs11086322 chr20 49714756 G A 1.49E-04 Nicotine dependence / / 17158188 rs6067645 chr20 49716117 G A 0.0008674 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6067645 chr20 49716117 G A 8.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6126166 chr20 49730940 C T 2.21E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs230014 chr20 49739860 G A 4.00E-06 QT interval (interaction) / / 23459443 rs1204759 chr20 49757406 C T 1.30E-06 Urinary metabolites / / 21572414 rs230031 chr20 49760917 T C 8.87E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11908586 chr20 49769214 G A 8.42E-07 Brachial circumference / / 22479309 rs6021011 chr20 49774249 G A 1.72E-06 Brachial circumference / / 22479309 rs2143630 chr20 49777878 A G 7.41E-05 Bipolar Disorder / / pha002863 rs6063623 chr20 49906076 C G 1.76E-04 Gallstones / / 17632509 rs12480160 chr20 49990155 A G 1.82E-05 Cognitive performance / / 19734545 rs1569736 chr20 50006322 C A 7.81E-04 Myocardial Infarction NFATC2 UTR-3 pha002883 rs2426299 chr20 50017995 T C 1.50E-05 Urinary metabolites NFATC2 intron 21572414 rs6021183 chr20 50022149 C T 7.40E-06 Urinary metabolites NFATC2 intron 21572414 rs6021185 chr20 50023571 T C 3.60E-06 Urinary metabolites NFATC2 intron 21572414 rs6067758 chr20 50024048 T C 2.80E-05 Urinary metabolites NFATC2 intron 21572414 rs4811174 chr20 50048133 T C 3.26E-04 Lung function (forced expiratory volume in 1 second) NFATC2 intron 24023788 rs145231526 chr20 50048783 G A 0.000074 Breast cancer(er negative) NFATC2 missense 23555315 rs880324 chr20 50054190 G A 1.68E-05 Multiple complex diseases NFATC2 intron 17554300 rs715147 chr20 50055350 G A 0.00000316 Primary sclerosing cholangitis NFATC2 intron 23603763 rs3787207 chr20 50056419 C T 2.43E-04 Insulin resistance NFATC2 intron 21901158 rs12624399 chr20 50067215 T C 5.70E-04 Coronary heart disease NFATC2 intron 21966275 rs228840 chr20 50071258 A G 5.40E-04 Coronary heart disease NFATC2 intron 21966275 rs228840 chr20 50071258 A G 3.10E-05 Blood Pressure NFATC2 intron pha003047 rs17199748 chr20 50087696 C T 2.39E-04 Multiple complex diseases NFATC2 intron 17554300 rs1570161 chr20 50101680 C A 0.00000153 HDL cholesterol NFATC2 intron 23063622 rs754285 chr20 50103185 C T 2.70E-05 Urinary metabolites NFATC2 intron 21572414 rs4809847 chr20 50108320 G T 5.00E-06 Amyotrophic lateral sclerosis (sporadic) NFATC2 intron 24529757 rs6021247 chr20 50108980 G A 3.30E-04 Type 2 diabetes and 6 quantitative traits NFATC2 intron 17848626 rs6021247 chr20 50108980 G A 2.05E-04 Oral cancers (chewing tobacco related) NFATC2 intron 22503698 rs6123045 chr20 50118842 C T 5.32E-07 Thiazolidinedione-induced edema NFATC2 intron 20628086 rs17728960 chr20 50129716 T C 6.93E-08 Self-reported allergy NFATC2 intron 23817569 rs3787187 chr20 50132162 A G 6.11E-04 QT interval NFATC2 intron 22726844 rs6021264 chr20 50134683 A G 1.09E-07 Self-reported allergy NFATC2 intron 23817569 rs16996066 chr20 50135844 C T 3.98E-04 Multiple complex diseases NFATC2 intron 17554300 rs17801791 chr20 50139020 C A 7.10E-08 Self-reported allergy NFATC2 intron 23817569 rs6021268 chr20 50141141 T C 4.45E-08 Self-reported allergy NFATC2 intron 23817569 rs6021270 chr20 50141264 T C 7.00E-09 Self-reported allergy NFATC2 intron 23817569 rs6126249 chr20 50142623 G A 9.55E-09 Self-reported allergy NFATC2 intron 23817569 rs6123048 chr20 50147400 A G 1.05E-08 Self-reported allergy NFATC2 intron 23817569 rs6096463 chr20 50148037 G A 9.69E-09 Self-reported allergy NFATC2 intron 23817569 rs3787186 chr20 50153344 T C 1.36E-04 Multiple complex diseases NFATC2 intron 17554300 rs6021276 chr20 50155386 T C 1.66E-04 Multiple complex diseases NFATC2 intron 17554300 rs6013210 chr20 50165634 C G 6.71E-07 Schizophrenia NFATC2 intron 21926974 rs17801923 chr20 50171340 A G 5.11E-04 Response to taxane treatment (placlitaxel) NFATC2 intron 23006423 rs6096473 chr20 50181272 G A 7.98E-05 Bipolar disorder / / 20451256 rs2143722 chr20 50198026 C G 7.71E-05 Bipolar disorder / / 20451256 rs1546920 chr20 50200782 C T 2.47E-04 Cognitive decline / / 23732972 rs6096487 chr20 50201217 G A 2.47E-04 Cognitive decline / / 23732972 rs6021301 chr20 50205040 T C 8.54E-04 Heart Failure / / pha002884 rs6021304 chr20 50212534 G A 3.91E-05 Socioeconomic Factors / / pha003066 rs3818004 chr20 50224206 G A 3.25E-06 Coronary restenosis ATP9A intron 21878436 rs742754 chr20 50228092 C T 6.20E-04 Multiple complex diseases ATP9A intron 17554300 rs742754 chr20 50228092 C T 2.54E-06 Coronary restenosis ATP9A intron 21878436 rs6067846 chr20 50230076 C T 8.17E-05 Post-operative nausea and vomiting ATP9A intron 21694509 rs3746417 chr20 50248259 C T 5.60E-04 Multiple complex diseases ATP9A intron 17554300 rs6021346 chr20 50266043 G A 6.62E-04 Multiple complex diseases ATP9A intron 17554300 rs2235858 chr20 50274179 T C 8.90E-05 Rheumatoid arthritis ATP9A intron 17804836 rs6126330 chr20 50347120 C A 1.31E-04 Tourette syndrome ATP9A intron 22889924 rs6096573 chr20 50383679 C T 5.92E-05 Pulmonary function in asthmatics ATP9A intron 23541324 rs6021451 chr20 50419395 T G 3.20E-04 Type 2 diabetes SALL4 nearGene-5 17463246 rs16996249 chr20 50420032 A G 3.35E-05 Multiple complex diseases SALL4 nearGene-5 17554300 rs6096597 chr20 50437573 T C 6.61E-04 Myocardial Infarction / / pha002873 rs6021473 chr20 50445821 C T 9.57E-04 Obesity (extreme) / / 21935397 rs6013289 chr20 50459950 G C 4.40E-04 Type 2 diabetes / / 17463246 rs6067979 chr20 50479879 G C 8.03E-05 Multiple complex diseases / / 17554300 rs6021512 chr20 50480790 T C 8.32E-04 Rheumatoid arthritis / / 21452313 rs6096631 chr20 50488314 G C 7.95E-06 Glycemic traits (pregnancy) / / 23903356 rs6123098 chr20 50521290 A G 5.22E-04 Smoking initiation / / 24665060 rs4809879 chr20 50550526 A G 2.40E-06 Parkinson's disease (familial) / / 18985386 rs2869621 chr20 50556670 A G 2.90E-05 Lung cancer / / 18385738 rs2869621 chr20 50556670 A G 4.34E-05 Heart Failure / / pha002885 rs6068020 chr20 50559652 T C 5.00E-07 Male infertility / / 19478329 rs6068024 chr20 50567611 G A 9.47E-04 Myocardial Infarction / / pha002873 rs6021571 chr20 50574627 T C 4.81E-04 Multiple complex diseases / / 17554300 rs6013347 chr20 50627796 G A 3.66E-04 Acute lung injury / / 22295056 rs6021626 chr20 50629454 C T 5.22E-04 Acute lung injury / / 22295056 rs6512783 chr20 50633472 C T 3.12E-04 Acute lung injury / / 22295056 rs6013355 chr20 50637660 A G 5.00E-06 Subcutaneous adipose tissue / / 22589738 rs6021639 chr20 50644475 T C 1.21E-05 Alcohol consumption / / 23953852 rs17803622 chr20 50647891 C T 2.28E-04 Celiac disease / / 23936387 rs6013359 chr20 50657049 G A 4.82E-05 Cognitive test performance / / 20125193 rs6021649 chr20 50659153 A G 9.26E-05 Type 2 diabetes / / 17463246 rs6021649 chr20 50659153 A G 4.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6021661 chr20 50674526 A G 2.00E-04 Myopia (pathological) / / 21095009 rs743093 chr20 50695849 A G 1.38E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs743093 chr20 50695849 A G 1.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs743093 chr20 50695849 A G 8.73E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6013382 chr20 50702633 C T 5.00E-06 Amyotrophic lateral sclerosis ZFP64 intron 17362836 rs6013382 chr20 50702633 C T 1.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZFP64 intron 20877124 rs6013382 chr20 50702633 C T 8.71E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZFP64 intron 20877124 rs6068073 chr20 50710691 T C 3.48E-05 Erythrocyte counts ZFP64 intron pha003101 rs6021700 chr20 50711402 A T 1.14E-04 Alzheimer's disease ZFP64 intron 17998437 rs8120171 chr20 50712059 C T 7.85E-05 Obsessive-compulsive disorder ZFP64 intron 24821223 rs8120171 chr20 50712059 C T 7.85E-05 Obsessive-compulsive disorder ZFP64 intron 24821223 rs3818198 chr20 50777026 A G 7.02E-05 HIV-1 viral setpoint ZFP64 intron 22174851 rs6091465 chr20 50788017 C A 8.28E-04 Alzheimer's disease ZFP64 intron 17998437 rs6091465 chr20 50788017 C A 7.76E-06 Alzheimer's disease ZFP64 intron 24755620 rs6063765 chr20 50825149 C T 7.71E-04 Depression (quantitative trait) / / 20800221 rs6063766 chr20 50825358 C T 6.81E-04 Depression (quantitative trait) / / 20800221 rs8123919 chr20 50826346 C T 7.07E-05 Personality dimensions / / 18957941 rs13043316 chr20 50827159 C G 5.80E-04 Depression (quantitative trait) / / 20800221 rs11697616 chr20 50828285 G A 4.89E-04 Depression (quantitative trait) / / 20800221 rs6068102 chr20 50839147 T C 3.76E-04 Depression (quantitative trait) / / 20800221 rs998867 chr20 50843271 G C 3.63E-04 Depression (quantitative trait) / / 20800221 rs2016367 chr20 50843305 C G 3.10E-05 Multiple sclerosis / / 17660530 rs2016367 chr20 50843305 C G 7.33E-04 Alzheimer's disease / / 17998437 rs2016367 chr20 50843305 C G 6.58E-04 Depression (quantitative trait) / / 20800221 rs2016367 chr20 50843305 C G 7.08E-05 Postoperative ventricular dysfunction / / 21980348 rs6021796 chr20 50846844 T C 5.42E-04 Depression (quantitative trait) / / 20800221 rs6021796 chr20 50846844 T C 5.48E-04 Alzheimer's disease / / 24755620 rs6096824 chr20 50853887 G A 4.81E-04 Depression (quantitative trait) / / 20800221 rs6126516 chr20 50855171 C T 5.20E-04 Depression (quantitative trait) / / 20800221 rs6126516 chr20 50855171 C T 7.22E-04 Alzheimer's disease / / 24755620 rs1998152 chr20 50860315 A G 3.86E-04 Depression (quantitative trait) / / 20800221 rs6013417 chr20 50864670 T G 5.21E-04 Depression (quantitative trait) / / 20800221 rs4809897 chr20 50866193 G A 3.42E-04 Depression (quantitative trait) / / 20800221 rs6013418 chr20 50870937 T C 3.17E-04 Alzheimer's disease (late onset) / / 21460841 rs6021819 chr20 50872267 C T 5.73E-04 Depression (quantitative trait) / / 20800221 rs6021820 chr20 50873729 C T 5.76E-04 Depression (quantitative trait) / / 20800221 rs2869635 chr20 50874520 A G 6.17E-04 Type 2 diabetes / / 17463246 rs2869635 chr20 50874520 A G 5.72E-04 Body mass index / / 21701565 rs2869635 chr20 50874520 A G 6.73E-05 Body mass index / / 21701565 rs2057078 chr20 50878124 T C 5.93E-04 Depression (quantitative trait) / / 20800221 rs13045010 chr20 50878672 C T 4.56E-04 Depression (quantitative trait) / / 20800221 rs2057079 chr20 50878683 G C 5.94E-04 Depression (quantitative trait) / / 20800221 rs6013423 chr20 50879729 A G 5.93E-04 Depression (quantitative trait) / / 20800221 rs6021824 chr20 50880658 T A 6.28E-04 Depression (quantitative trait) / / 20800221 rs6013426 chr20 50880949 C T 6.28E-04 Depression (quantitative trait) / / 20800221 rs6096841 chr20 50884797 G C 5.62E-04 Depression (quantitative trait) / / 20800221 rs6021830 chr20 50889596 C G 5.65E-04 Depression (quantitative trait) / / 20800221 rs6021835 chr20 50893173 G T 5.99E-04 Depression (quantitative trait) / / 20800221 rs13040613 chr20 50893858 G C 4.28E-04 Depression (quantitative trait) / / 20800221 rs4809901 chr20 50895335 C T 4.42E-04 Depression (quantitative trait) / / 20800221 rs6126524 chr20 50897803 G T 8.98E-04 Body mass index / / 21701565 rs6068121 chr20 50898577 A G 4.41E-04 Depression (quantitative trait) / / 20800221 rs6068122 chr20 50902254 A T 3.47E-04 Depression (quantitative trait) / / 20800221 rs1016404 chr20 50902910 A G 8.80E-04 Depression (quantitative trait) / / 20800221 rs6068123 chr20 50904777 C T 4.00E-04 Depression (quantitative trait) / / 20800221 rs6091490 chr20 50905406 C T 3.99E-04 Depression (quantitative trait) / / 20800221 rs4811318 chr20 50906010 G C 3.96E-04 Depression (quantitative trait) / / 20800221 rs6068124 chr20 50907182 G A 3.92E-04 Depression (quantitative trait) / / 20800221 rs16996625 chr20 50932092 C G 7.48E-05 Body mass index / / 21701565 rs16996625 chr20 50932092 C G 8.47E-04 Body mass index / / 21701565 rs6123155 chr20 50935474 C T 5.58E-04 Body mass index / / 21701565 rs6123155 chr20 50935474 C T 6.43E-04 Body mass index / / 21701565 rs4811327 chr20 50942403 C T 1.16E-04 Body mass index / / 21701565 rs10485623 chr20 50946162 A G 2.85E-04 Body mass index / / 21701565 rs10485623 chr20 50946162 A G 3.52E-05 Body mass index / / 21701565 rs11698664 chr20 50953271 A G 7.54E-05 Body mass index / / 21701565 rs11698664 chr20 50953271 A G 8.57E-04 Body mass index / / 21701565 rs6096889 chr20 50957837 G A 4.13E-04 Body mass index / / 21701565 rs16996700 chr20 50981945 T C 5.66E-04 Body mass index / / 21701565 rs16996700 chr20 50981945 T C 8.74E-04 Body mass index / / 21701565 rs1883864 chr20 50986203 T A 8.83E-04 Body mass index / / 21701565 rs6068154 chr20 50987391 A G 5.56E-04 Body mass index / / 21701565 rs6068154 chr20 50987391 A G 5.72E-05 Body mass index / / 21701565 rs7360046 chr20 51009262 A G 1.77E-04 Body mass index / / 21701565 rs7360046 chr20 51009262 A G 2.12E-05 Body mass index / / 21701565 rs4811338 chr20 51009514 T G 7.73E-04 Body mass index / / 21701565 rs4811338 chr20 51009514 T G 7.80E-04 Body mass index / / 21701565 rs4811340 chr20 51009757 G C 8.29E-04 Body mass index / / 21701565 rs4811340 chr20 51009757 G C 6.00E-07 Thyroid peroxidase antibody positivity / / 24586183 rs4283481 chr20 51012192 A T 4.33E-05 Body mass index / / 21701565 rs4283481 chr20 51012192 A T 4.71E-04 Body mass index / / 21701565 rs1555278 chr20 51012964 C T 7.83E-04 Type 2 diabetes / / 17463246 rs1555278 chr20 51012964 C T 2.03E-04 Multiple complex diseases / / 17554300 rs2092953 chr20 51016879 G A 3.27E-04 Body mass index / / 21701565 rs2092953 chr20 51016879 G A 5.32E-05 Body mass index / / 21701565 rs4811346 chr20 51023109 A C 1.54E-04 Body mass index / / 21701565 rs4811346 chr20 51023109 A C 1.63E-05 Body mass index / / 21701565 rs4371408 chr20 51024233 A G 7.93E-04 Body mass index / / 21701565 rs4371408 chr20 51024233 A G 8.09E-04 Body mass index / / 21701565 rs6096956 chr20 51054793 G A 8.22E-04 Type 2 diabetes / / 17463246 rs4809907 chr20 51086905 G A 7.54E-04 Body mass index / / 21701565 rs6091540 chr20 51087862 C T 1.71E-04 Sexual dimorphism in anthropometric traits / / 23754948 rs17203351 chr20 51092558 C G 6.54E-04 Type 2 diabetes / / 17463246 rs13041126 chr20 51092996 T C 5.55E-04 Type 2 diabetes / / 17463246 rs13041126 chr20 51092996 T C 2.00E-08 Obesity / / 23563607 rs13044871 chr20 51093676 C G 5.55E-04 Type 2 diabetes / / 17463246 rs17806313 chr20 51094563 A G 6.96E-04 Type 2 diabetes / / 17463246 rs6091544 chr20 51098633 G A 5.12E-04 Type 2 diabetes / / 17463246 rs6126578 chr20 51099214 T C 1.95E-04 Type 2 diabetes / / 17463246 rs6068208 chr20 51112562 A G 7.91E-04 Taste perception / / 22132133 rs6021953 chr20 51126865 G A 8.46E-06 Cognitive test performance / / 20125193 rs10460621 chr20 51192657 C T 1.67E-04 Body mass index / / 21701565 rs10460621 chr20 51192657 C T 6.04E-04 Body mass index / / 21701565 rs17733118 chr20 51205234 C T 2.88E-04 Type 2 diabetes / / 17463246 rs6063838 chr20 51208280 C A 1.39E-04 Body mass index / / 21701565 rs6063838 chr20 51208280 C A 4.73E-04 Body mass index / / 21701565 rs2869659 chr20 51210712 A G 3.21E-04 Body mass index / / 21701565 rs6063841 chr20 51214293 A C 0.000632996 Hypertension (early onset hypertension) / / 22479346 rs6063844 chr20 51221245 G A 7.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs6068268 chr20 51221379 T C 7.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs6068269 chr20 51221478 C T 7.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs6068270 chr20 51221602 C T 9.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs6068271 chr20 51222246 C T 5.65E-04 Multiple complex diseases / / 17554300 rs6068271 chr20 51222246 C T 8.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs6068271 chr20 51222246 C T 0.000507078 Hypertension (early onset hypertension) / / 22479346 rs6068274 chr20 51222943 G A 6.16E-04 Multiple complex diseases / / 17554300 rs6068274 chr20 51222943 G A 9.78E-04 Suicide attempts in bipolar disorder / / 21423239 rs6512851 chr20 51228187 A G 7.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs6512851 chr20 51228187 A G 0.000706069 Hypertension (early onset hypertension) / / 22479346 rs6068276 chr20 51228767 A C 9.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs6068280 chr20 51235613 A G 6.76E-05 Suicide attempts in bipolar disorder / / 21423239 rs8183283 chr20 51236973 G A 8.57E-04 Depression (quantitative trait) / / 20800221 rs1555185 chr20 51245688 G A 9.43E-04 Depression (quantitative trait) / / 20800221 rs1568721 chr20 51246672 T G 1.68E-04 Multiple complex diseases / / 17554300 rs856411 chr20 51259176 T C 3.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs856408 chr20 51260705 T C 9.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs865034 chr20 51261615 T C 7.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs856406 chr20 51262972 C T 8.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs865608 chr20 51263369 G A 8.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs865608 chr20 51263369 G A 7.42E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs856405 chr20 51263728 G C 9.71E-04 Suicide attempts in bipolar disorder / / 21423239 rs856393 chr20 51267885 A G 9.82E-04 Alzheimer's disease / / 22005930 rs6022029 chr20 51275165 A G 5.70E-05 Cognitive performance / / 19734545 rs727662 chr20 51275465 A G 9.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs6022031 chr20 51278134 A G 7.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs6013496 chr20 51278346 C T 7.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs4811374 chr20 51279104 C G 6.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs4811375 chr20 51279205 G A 6.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs6063858 chr20 51282552 A G 3.00E-04 Lipid traits / / 17903299 rs1883529 chr20 51285209 G T 2.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs17807252 chr20 51286439 A G 9.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs17807252 chr20 51286439 A G 5.80E-06 Urinary metabolites / / 21572414 rs1568723 chr20 51288041 C T 9.98E-04 Suicide attempts in bipolar disorder / / 21423239 rs6022037 chr20 51289061 T C 4.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs4811379 chr20 51290198 A G 4.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs4809913 chr20 51290319 C G 4.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs4809914 chr20 51291960 G T 4.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs4811380 chr20 51292085 C T 6.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs926488 chr20 51294444 A G 3.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs1523537 chr20 51296162 T C 4.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs6013499 chr20 51299742 T G 5.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs6013500 chr20 51299960 A G 5.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs13041225 chr20 51309194 C T 8.33E-05 Cognitive impairment induced by topiramate / / 22091778 rs6126645 chr20 51312015 T C 1.10E-05 Tuberculosis / / 24057671 rs856333 chr20 51316741 A G 1.39E-04 Taste perception / / 22132133 rs4811385 chr20 51316850 A G 5.00E-09 Other erythrocyte phenotypes / / 19862010 rs6013509 chr20 51318351 G A 1.00E-10 Hemoglobin / / 19862010 rs6126646 chr20 51319080 C T 5.41E-09 Other erythrocyte phenotypes / / 19862010 rs856327 chr20 51320768 G A 8.86E-05 Taste perception / / 22132133 rs6097096 chr20 51339051 G T 3.39E-04 Alzheimer's disease / / 22005930 rs6013520 chr20 51387250 A G 5.97E-04 Multiple complex diseases / / 17554300 rs6022102 chr20 51425077 T C 4.20E-05 Methamphetamine dependence / / 23594818 rs2031979 chr20 51475632 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs16997135 chr20 51483858 C T 4.57E-04 Type 2 diabetes / / 17463246 rs4811406 chr20 51488814 G A 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2253356 chr20 51498186 G C 2.30E-04 Bipolar disorder,schizoaffective / / 19567891 rs1080404 chr20 51504829 G A 4.88E-04 Body mass index / / 21701565 rs2772443 chr20 51506134 T C 4.62E-04 Body mass index / / 21701565 rs1329837 chr20 51518892 A G 2.33E-04 Glycemic traits (pregnancy) / / 23903356 rs6013565 chr20 51536364 A G 3.49E-04 Taste perception / / 22132133 rs1923116 chr20 51544356 T C 5.42E-04 Type 2 diabetes / / 17463246 rs8121971 chr20 51548734 G A 4.12E-04 Sleep latency / / 23728906 rs4811411 chr20 51557055 C T 2.73E-06 Insulin-related traits / / 22791750 rs6097169 chr20 51557161 G A 5.00E-07 Body mass index (non-asthmatics) / / 23517042 rs731428 chr20 51560160 T C 8.53E-05 Depression (quantitative trait) / / 23290196 rs1884889 chr20 51565306 G A 1.30E-05 Urinary metabolites / / 21572414 rs6097170 chr20 51568950 A G 1.16E-04 Sleep quality / / 23728906 rs6097170 chr20 51568950 A G 8.20E-04 Stroke / / pha002887 rs16997356 chr20 51579787 T A 1.50E-05 Urinary metabolites / / 21572414 rs16997358 chr20 51582072 A T 9.17E-06 Attention deficit hyperactivity disorder / / 20732625 rs10485813 chr20 51583983 A G 8.20E-06 Attention deficit hyperactivity disorder / / 20732625 rs6022196 chr20 51598314 G A 1.00E-04 Cognitive impairment induced by topiramate TSHZ2 intron 22091778 rs6022196 chr20 51598314 G A 2.00E-04 Cognitive impairment induced by topiramate TSHZ2 intron 22091778 rs6022197 chr20 51598824 T C 1.00E-04 Cognitive impairment induced by topiramate TSHZ2 intron 22091778 rs6022197 chr20 51598824 T C 2.00E-04 Cognitive impairment induced by topiramate TSHZ2 intron 22091778 rs6022197 chr20 51598824 T C 3.46E-05 Cognitive impairment induced by topiramate TSHZ2 intron 22091778 rs6022204 chr20 51619338 G A 8.26E-05 Hypertension TSHZ2 intron 21082022 rs2252098 chr20 51620301 C T 0.0000386 Type 2 diabetes TSHZ2 intron 22325160 rs2256452 chr20 51632942 C T 2.63E-04 Blood pressure TSHZ2 intron 17255346 rs2256551 chr20 51633501 A G 2.71E-04 Blood pressure TSHZ2 intron 17255346 rs2256551 chr20 51633501 A G 6.50E-05 Sleep and circadian phenotypes TSHZ2 intron 17903308 rs910380 chr20 51649478 T C 2.77E-05 Alcohol consumption TSHZ2 intron pha001401 rs17328948 chr20 51652167 A G 1.52E-04 Scoliosis TSHZ2 intron 21216876 rs6013611 chr20 51653799 G C 4.01E-04 Response to taxane treatment (placlitaxel) TSHZ2 intron 23006423 rs6091627 chr20 51670372 T G 8.31E-05 Response to taxane treatment (placlitaxel) TSHZ2 intron 23006423 rs1293435 chr20 51682625 C T 8.13E-04 Multiple complex diseases TSHZ2 intron 17554300 rs1936963 chr20 51699817 T C 8.08E-04 Myocardial Infarction TSHZ2 intron pha002873 rs16997525 chr20 51720422 T C 5.30E-04 Substance dependence TSHZ2 intron 21818250 rs2800999 chr20 51722623 G T 0.0005 Prostate cancer TSHZ2 intron 23555315 rs1293430 chr20 51734779 T G 6.07E-04 Smoking initiation TSHZ2 intron 24665060 rs1293427 chr20 51737601 T C 8.64E-08 Metabolite levels TSHZ2 intron 23281178 rs1293425 chr20 51740178 A G 1.20E-05 Hypothyroidism TSHZ2 intron 22493691 rs11697971 chr20 51744786 A G 6.54E-06 Serum metabolites TSHZ2 intron 19043545 rs11697971 chr20 51744786 A G 9.91E-05 Height TSHZ2 intron pha003010 rs11698011 chr20 51744925 C A 4.42E-05 Serum metabolites TSHZ2 intron 19043545 rs2107323 chr20 51751206 T C 8.09E-05 Height TSHZ2 intron pha003010 rs16997592 chr20 51754137 G A 6.34E-05 Height TSHZ2 intron pha003010 rs6022299 chr20 51762114 T C 3.46E-05 Serum metabolites TSHZ2 intron 19043545 rs6123255 chr20 51770691 A G 7.18E-05 Cognitive impairment induced by topiramate TSHZ2 intron 22091778 rs118174081 chr20 51778123 C T 3.00E-06 Bipolar disorder (body mass index interaction) TSHZ2 intron 24322204 rs1293395 chr20 51784702 G T 5.88E-04 Parkinson's disease TSHZ2 intron 17052657 rs1293381 chr20 51808899 A G 7.57E-04 Tourette syndrome TSHZ2 intron 22889924 rs2426460 chr20 51810111 A G 3.06E-06 ldl cholesterol TSHZ2 intron pha003077 rs2426460 chr20 51810111 A G 9.32E-07 Cholesterol TSHZ2 intron pha003083 rs1296358 chr20 51811386 G A 4.37E-06 ldl cholesterol TSHZ2 intron pha003077 rs1296358 chr20 51811386 G A 9.19E-07 Cholesterol TSHZ2 intron pha003083 rs2243747 chr20 51811748 C G 2.50E-05 Bilirubin levels TSHZ2 intron 19414484 rs35570044 chr20 51811748 C CG 2.50E-05 Bilirubin levels TSHZ2 intron 19414484 rs56290013 chr20 51820027 G T 9.81E-06 Telomere length TSHZ2 intron 24478790 rs2426467 chr20 51840680 T C 1.41E-04 Insulin resistance TSHZ2 intron 21901158 rs6022348 chr20 51848072 G A 9.74E-04 Iron levels TSHZ2 intron pha002876 rs6091653 chr20 51873712 T C 2.22E-05 Erythrocyte counts TSHZ2 intron pha003090 rs6091655 chr20 51884576 G A 4.54E-05 Erythrocyte counts TSHZ2 intron pha003090 rs1877430 chr20 51888122 A G 9.32E-04 Alzheimer's disease TSHZ2 intron 24755620 rs1543080 chr20 51897115 C A 5.59E-05 Alcohol dependence TSHZ2 intron 21314694 rs6022377 chr20 51909682 G A 3.48E-05 Response to taxane treatment (placlitaxel) TSHZ2 intron 23006423 rs6013656 chr20 51911199 G A 2.04E-04 Response to taxane treatment (placlitaxel) TSHZ2 intron 23006423 rs4811423 chr20 51914724 A G 1.14E-04 Response to taxane treatment (placlitaxel) TSHZ2 intron 23006423 rs6022378 chr20 51917248 A G 5.20E-04 Alcohol dependence TSHZ2 intron 20201924 rs1996017 chr20 51922638 T C 4.60E-04 Alcohol dependence TSHZ2 intron 20201924 rs6512879 chr20 51923969 T G 4.30E-05 Malaria TSHZ2 intron 19465909 rs413066 chr20 51964156 G C 6.39E-04 Alzheimer's disease TSHZ2 intron 22005930 rs156611 chr20 51986727 C G 6.00E-05 Serum metabolites TSHZ2 intron 19043545 rs156618 chr20 51993574 C T 9.43E-05 Multiple complex diseases TSHZ2 intron 17554300 rs156627 chr20 52003295 C T 4.03E-05 Cognitive test performance TSHZ2 intron 20125193 rs156627 chr20 52003295 C T 1.62E-04 Lung function (forced expiratory volume in 1 second) TSHZ2 intron 24023788 rs468211 chr20 52017238 A G 2.11E-04 Lung function (forced expiratory volume in 1 second) TSHZ2 intron 24023788 rs468211 chr20 52017238 A G 6.16E-05 Lung function (forced vital capacity) TSHZ2 intron 24023788 rs16998074 chr20 52027742 C T 8.03E-05 Personality dimensions TSHZ2 intron 18957941 rs11697255 chr20 52037408 C T 3.78E-04 Suicide attempts in bipolar disorder TSHZ2 intron 21423239 rs16998095 chr20 52048361 C T 1.50E-06 Urinary metabolites TSHZ2 intron 21572414 rs7360757 chr20 52060067 C T 1.99E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TSHZ2 intron 20877124 rs16998132 chr20 52107666 T C 7.72E-04 Multiple complex diseases TSHZ2 UTR-3 17554300 rs67691565 chr20 52169857 G A 0.0000915 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2766664 chr20 52171241 A G 3.98E-04 Self-reported allergy / / 23817569 rs6126871 chr20 52181756 G C 9.51E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2766671 chr20 52184502 C T 5.94E-06 Alopecia areata ZNF217 UTR-3 22027810 rs1555926 chr20 52184944 C T 6.30E-05 Response to statin therapy ZNF217 UTR-3 20339536 rs34323943 chr20 52192637 T A,C,G 0.00008 Breast cancer ZNF217 missense 23555315 rs6063966 chr20 52193088 C T 1.70E-05 Urinary metabolites ZNF217 missense 21572414 rs6063966 chr20 52193088 C T 0.000056 Breast cancer ZNF217 missense 23555315 rs2766680 chr20 52212273 G A 5.50E-05 Response to statin therapy / / 20339536 rs2041278 chr20 52268995 T G 6.00E-06 Obesity-related traits / / 23251661 rs6091723 chr20 52278258 G A 1.63E-04 Alcohol dependence / / 21314694 rs6097523 chr20 52297394 C T 4.56E-04 Rheumatoid arthritis / / 21452313 rs6022677 chr20 52311833 G A 8.90E-04 Multiple complex diseases / / 17554300 rs10854193 chr20 52328338 G A 9.58E-05 Prostate cancer / / 22923026 rs6063982 chr20 52337118 C T 1.90E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs6022698 chr20 52346953 C G 6.40E-06 Calcium levels / / 20705733 rs6091737 chr20 52349892 T C 6.00E-06 Calcium levels / / 20705733 rs6091737 chr20 52349892 T C 7.54E-05 Insulin resistance / / 21901158 rs6063986 chr20 52356646 C T 4.25E-04 Schizophrenia / / 19197363 rs2041317 chr20 52363607 G T 2.08E-04 Type 2 diabetes / / 17463246 rs6068655 chr20 52384089 A G 2.00E-05 Urinary metabolites / / 21572414 rs6063991 chr20 52388268 A G 1.58E-04 IgE levels / / 17255346 rs6097573 chr20 52394457 C A 3.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs13041092 chr20 52395514 A C 3.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs9753640 chr20 52395909 T A 3.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs6126970 chr20 52415107 C T 1.12E-04 Arthritis (juvenile idiopathic) / / 22354554 rs6022766 chr20 52428220 C A 3.30E-05 Age-related macular degeneration / / 20385819 rs6022784 chr20 52442226 T A 3.18E-04 Type 2 diabetes / / 17463246 rs6022786 chr20 52447303 A G 2.00E-09 Polycystic ovary syndrome / / 22885925 rs6126982 chr20 52456445 T G 6.49E-04 Taste perception / / 22132133 rs4809944 chr20 52501962 A G 5.51E-08 Meningococcal disease / / 20694013 rs1476720 chr20 52528106 C T 4.43E-05 Serum metabolites / / 19043545 rs6013838 chr20 52548367 G A 1.59E-05 Rheumatoid arthritis (ACPA-negative) / / 24532677 rs16998568 chr20 52551750 C T 3.05E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs4811485 chr20 52552780 C T 2.17E-04 Type 2 diabetes / / 17463246 rs10485441 chr20 52564368 C T 5.54E-05 Coronary heart disease BCAS1 intron pha003031 rs393744 chr20 52578414 T C 2.79E-04 Amyotrophic lateral sclerosis (sporadic) BCAS1 intron 24529757 rs208390 chr20 52590227 T C 9.97E-05 Coronary heart disease BCAS1 intron pha003031 rs2299726 chr20 52597175 A G 7.25E-05 Coronary heart disease BCAS1 intron pha003031 rs208366 chr20 52600431 A G 3.65E-05 Height BCAS1 intron pha003010 rs208366 chr20 52600431 A G 8.69E-05 Height BCAS1 intron pha003011 rs2276498 chr20 52610496 C G 7.00E-06 Bipolar disorder and schizophrenia BCAS1 intron 20889312 rs2276496 chr20 52611188 T C 3.99E-13 Metabolite levels BCAS1 intron 22286219 rs6013871 chr20 52625731 A G 4.65E-04 Myocardial Infarction BCAS1 intron pha002883 rs6127058 chr20 52628804 T C 2.12E-05 Bipolar disorder and schizophrenia BCAS1 intron 20889312 rs158544 chr20 52640828 C T 5.00E-04 Tourette syndrome BCAS1 intron 22889924 rs11905945 chr20 52658593 T C 3.09E-05 Bipolar disorder and schizophrenia BCAS1 intron 20889312 rs2299700 chr20 52660741 T C 8.94E-04 Iron levels BCAS1 intron pha002876 rs6127073 chr20 52671273 G A 4.00E-05 Bipolar disorder and schizophrenia BCAS1 intron 20889312 rs2870304 chr20 52673217 A G 1.60E-05 Bipolar disorder and schizophrenia BCAS1 intron 20889312 rs461140 chr20 52677959 T C 3.56E-07 Post-operative nausea and vomiting BCAS1 intron 21694509 rs11699339 chr20 52688306 C T 1.56E-05 Intracerebral hemorrhage / / 24656865 rs11699339 chr20 52688306 C T 3.89E-05 Intracerebral hemorrhage / / 24656865 rs13037207 chr20 52688797 G C 1.12E-05 Intracerebral hemorrhage / / 24656865 rs13037207 chr20 52688797 G C 3.02E-05 Intracerebral hemorrhage / / 24656865 rs290396 chr20 52689838 C A 1.64E-05 Intracerebral hemorrhage / / 24656865 rs290396 chr20 52689838 C A 2.93E-05 Intracerebral hemorrhage / / 24656865 rs6064043 chr20 52690458 T G 1.18E-05 Intracerebral hemorrhage / / 24656865 rs6064043 chr20 52690458 T G 3.56E-06 Intracerebral hemorrhage / / 24656865 rs6512935 chr20 52691156 A G 1.15E-05 Intracerebral hemorrhage / / 24656865 rs6512935 chr20 52691156 A G 3.93E-06 Intracerebral hemorrhage / / 24656865 rs6068770 chr20 52692678 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6068772 chr20 52696990 C T 1.42E-05 Intracerebral hemorrhage / / 24656865 rs6068772 chr20 52696990 C T 4.78E-05 Intracerebral hemorrhage / / 24656865 rs6068773 chr20 52697270 C T 1.95E-05 Intracerebral hemorrhage / / 24656865 rs6068773 chr20 52697270 C T 3.66E-06 Intracerebral hemorrhage / / 24656865 rs6068774 chr20 52697624 G T 1.11E-05 Intracerebral hemorrhage / / 24656865 rs6068774 chr20 52697624 G T 4.97E-05 Intracerebral hemorrhage / / 24656865 rs6064045 chr20 52701293 C T 7.00E-06 IgG glycosylation / / 23382691 rs209960 chr20 52716084 T C 6.10E-05 Type 2 diabetes / / 17846125 rs6127097 chr20 52723895 C T 3.85E-04 Multiple complex diseases / / 17554300 rs12479682 chr20 52738937 C T 1.83E-04 Coronary heart disease / / 21971053 rs17217119 chr20 52742590 A G 7.85E-05 Nephrolithiasis / / 22396660 rs2762926 chr20 52762418 G T 2.99E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2762926 chr20 52762418 G T 5.53E-05 Blood Pressure / / pha003049 rs2762932 chr20 52768391 T C 1.90E-05 Bipolar disorder / / 17486107 rs2762932 chr20 52768391 T C 6.67E-04 Aortic root size / / 21223598 rs2762932 chr20 52768391 T C 8.10E-07 Multiple sclerosis / / 21833088 rs1570669 chr20 52774427 A G 9.00E-12 Calcium levels CYP24A1 intron 24068962 rs6022994 chr20 52779999 A C 6.91E-04 Multiple complex diseases CYP24A1 intron 17554300 rs6022994 chr20 52779999 A C 0.000045 Mean arterial pressure CYP24A1 intron 22510845 rs2245153 chr20 52786406 T C 8.80E-04 Coronary heart disease CYP24A1 intron 21966275 rs2248359 chr20 52791518 C T 3.00E-11 Multiple sclerosis CYP24A1 nearGene-5 21833088 rs2248359 chr20 52791518 C T 8.50E-04 Multiple sclerosis CYP24A1 nearGene-5 24234648 rs2426498 chr20 52796681 C G 2.78E-04 Type 2 diabetes / / 17463246 rs2585423 chr20 52802989 T C 7.48E-05 Post-operative nausea and vomiting / / 21694509 rs6023009 chr20 52806276 T C 5.08E-04 Smoking cessation / / 24665060 rs16999165 chr20 52807221 A G 2.00E-08 Atopic dermatitis / / 23042114 rs2256501 chr20 52812435 G A,C,T 5.40E-05 Blood Pressure / / pha003046 rs1418926 chr20 52827268 T G 3.70E-06 Urinary metabolites PFDN4 intron 21572414 rs1418926 chr20 52827268 T G 8.58E-04 Response to taxane treatment (placlitaxel) PFDN4 intron 23006423 rs13039601 chr20 52841034 A G 2.95E-05 Brain lesion load / / 19010793 rs13039601 chr20 52841034 A G 6.05E-06 Inflammation / / pha002897 rs2585417 chr20 52843799 G A 5.00E-06 Obesity-related traits / / 23251661 rs6013938 chr20 52855872 G A 6.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6097867 chr20 52868443 A T 8.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs292118 chr20 52868496 C T 5.09E-04 Parkinson's disease / / 17052657 rs292118 chr20 52868496 C T 7.67E-04 Smoking initiation / / 24665060 rs1382015 chr20 52891915 G A 7.95E-05 Multiple complex diseases / / 17554300 rs6013952 chr20 52905277 G A 2.74E-04 Coronary Artery Disease / / 17634449 rs1981306 chr20 52916541 G A 5.89E-04 Smoking quantity / / 24665060 rs1293144 chr20 52917208 T G 2.30E-05 Type 2 diabetes / / 17293876 rs1293144 chr20 52917208 T G 2.30E-05 Type 2 diabetes / / 19184112 rs1293143 chr20 52918459 T C 7.31E-04 Parkinson's disease / / 17052657 rs1293143 chr20 52918459 T C 1.60E-05 Type 2 diabetes / / 17293876 rs1293143 chr20 52918459 T C 1.91E-05 Brain lesion load / / 19010793 rs1293143 chr20 52918459 T C 1.60E-05 Type 2 diabetes / / 19184112 rs16999466 chr20 52949009 T C 5.85E-05 Multiple complex diseases / / 17554300 rs1293151 chr20 52951584 C T 1.20E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6064068 chr20 52971851 C T 1.80E-05 Urinary metabolites / / 21572414 rs6014014 chr20 53038298 A G 2.55E-04 Multiple complex diseases / / 17554300 rs6023232 chr20 53043792 G T 0.0000503 Migraine / / 22678113 rs6023232 chr20 53043792 G T 5.03E-05 Migraine / / 22683712 rs6014050 chr20 53168776 A G 2.40E-06 Urinary metabolites DOK5 intron 21572414 rs6023357 chr20 53172928 A C 2.20E-05 Urinary metabolites DOK5 intron 21572414 rs16999772 chr20 53173157 A C 9.70E-06 Urinary metabolites DOK5 intron 21572414 rs16999772 chr20 53173157 A C 9.08E-05 Cognitive decline DOK5 intron 22054870 rs6014055 chr20 53176688 C G 1.10E-05 Urinary metabolites DOK5 intron 21572414 rs6014055 chr20 53176688 C G 7.59E-05 Cognitive decline DOK5 intron 22054870 rs6014057 chr20 53178662 C G 9.70E-06 Urinary metabolites DOK5 intron 21572414 rs7274170 chr20 53191712 C T 8.42E-06 Age-related macular degeneration DOK5 intron pha000002 rs7271632 chr20 53203078 G A 4.81E-06 Alzheimer's disease DOK5 intron 17998437 rs6098099 chr20 53208593 A C 7.90E-05 Intelligence (childhood) DOK5 intron 23358156 rs6014076 chr20 53211426 C T 8.86E-04 Alzheimer's disease DOK5 intron 17998437 rs967377 chr20 53222217 T C 6.79E-05 Orofacial clefts DOK5 intron 22419666 rs6023447 chr20 53258398 C G 4.39E-05 Multiple complex diseases DOK5 intron 17554300 rs2023454 chr20 53267111 C G 5.00E-07 Functional MRI DOK5 UTR-3 20215924 rs6023509 chr20 53305251 C A 2.08E-04 Multiple complex diseases / / 17554300 rs1883844 chr20 53320239 C T 8.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs6068963 chr20 53325604 G A 0.0005713 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6068963 chr20 53325604 G A 5.71E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6068963 chr20 53325604 G A 6.91E-05 Creatinine levels / / pha003069 rs6127270 chr20 53355127 C A 2.15E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6023560 chr20 53360093 A G 2.38E-25 Narcolepsy / / 19629137 rs6014161 chr20 53382213 C A 3.98E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6023583 chr20 53384031 T C 3.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6023594 chr20 53398823 T G 9.01E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs13037755 chr20 53411019 C T 5.00E-06 Relative hand skill / / 24068947 rs157640 chr20 53414539 T G 5.00E-06 Celiac disease / / 23936387 rs157649 chr20 53420586 G A 6.33E-05 Celiac disease / / 23936387 rs467214 chr20 53423914 G A 0.0004397 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs467214 chr20 53423914 G A 4.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs458332 chr20 53425217 A G 5.62E-05 Blood Pressure / / pha003043 rs6098265 chr20 53435918 T C 0.0006035 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6098265 chr20 53435918 T C 6.04E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6098279 chr20 53445298 T C 1.81E-06 Esophageal cancer (squamous cell) / / 20729853 rs6091985 chr20 53445939 G C 3.30E-05 Psychosis (methamphetamine induced) / / 23594818 rs6064117 chr20 53458592 G A 4.20E-05 Psychosis (methamphetamine induced) / / 23594818 rs6023640 chr20 53458805 T G 1.34E-07 Esophageal cancer (squamous cell) / / 20729853 rs6023640 chr20 53458805 T G 2.73E-05 Wegener's granulomatosis / / 23740775 rs1512060 chr20 53462975 C T 6.00E-06 Axial length / / 24144296 rs1022753 chr20 53484855 C T 7.93E-04 Alzheimer's disease / / 17998437 rs6023667 chr20 53493309 T C 2.76E-05 White matter integrity / / 22425255 rs912508 chr20 53493990 G A 7.92E-05 Body Mass Index / / pha003007 rs372833153 chr20 53496294 CAG C 7.92E-05 Body Mass Index / / pha003007 rs6023669 chr20 53496294 C A 7.92E-05 Body Mass Index / / pha003007 rs6023672 chr20 53497139 C T 4.79E-05 Waist-Hip Ratio / / pha003029 rs8124023 chr20 53513053 T C 1.84E-04 White matter integrity / / 22425255 rs283277 chr20 53536824 C A 1.58E-05 Nicotine smoking / / 19268276 rs288830 chr20 53555183 G A 5.87E-07 Rheumatoid arthritis / / 19503088 rs6127331 chr20 53558674 C T 6.53E-04 Alzheimer's disease / / 17998437 rs950276 chr20 53608572 G A 3.03E-05 Multiple complex diseases / / 17554300 rs6098422 chr20 53707375 G A 6.71E-04 Multiple complex diseases / / 17554300 rs6092078 chr20 53801129 G A 3.00E-06 Response to antipsychotic treatment / / 20195266 rs2840578 chr20 53845647 G A 3.46E-05 Multiple complex diseases / / 17554300 rs6092092 chr20 53858278 G A 1.50E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs9679820 chr20 53918329 A G 7.15E-23 Narcolepsy / / 19629137 rs211948 chr20 53938290 G A 3.52E-04 Alzheimer's disease / / 17998437 rs6069251 chr20 53951140 T A 8.40E-04 Suicide attempts in bipolar disorder / / 21423239 rs6092112 chr20 53960066 C T 9.01E-04 Multiple complex diseases / / 17554300 rs11696476 chr20 53965364 A C 8.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs11086499 chr20 53971664 T C 5.74E-05 Aortic root size / / 21223598 rs13038437 chr20 53986364 C T 8.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs3852922 chr20 54009670 A G 3.20E-04 Aortic root size / / 21223598 rs56840 chr20 54047236 G C 0.0000142 LDL cholesterol particle diameter / / 23263444 rs212600 chr20 54054665 A G 0.000000153 LDL cholesterol particle diameter / / 23263444 rs212600 chr20 54054665 A G 0.00000287 HDL cholesterol particle diameter / / 23263444 rs3852925 chr20 54067599 A G 4.12E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6024151 chr20 54101054 T C 2.49E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7273623 chr20 54124458 A G 2.70E-05 Urinary metabolites / / 21572414 rs11696973 chr20 54126509 G T 4.24E-04 Migraine / / 23793025 rs11696973 chr20 54126509 G T 8.00E-06 Migraine without aura / / 23793025 rs6024193 chr20 54128999 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6098654 chr20 54134876 T C 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2180470 chr20 54142809 C T 2.52E-04 Type 2 diabetes / / 17463246 rs2244665 chr20 54153759 A G 8.13E-05 Hypertension / / 21082022 rs2224272 chr20 54158005 G T 2.18E-04 Type 2 diabetes / / 17463246 rs682132 chr20 54172468 G A 5.34E-06 Hypertension / / 21082022 rs487331 chr20 54175364 T C 2.76E-06 Hypertension / / 21082022 rs555848 chr20 54179728 C T 3.52E-06 Hypertension / / 21082022 rs6024243 chr20 54189465 T A 5.70E-05 Cognitive function / / 24684796 rs13042475 chr20 54196341 T C 7.30E-04 Parkinson's disease / / 17052657 rs4811610 chr20 54219375 T C 7.51E-04 Parkinson's disease / / 17052657 rs6024269 chr20 54230997 T G 6.37E-04 Major depressive disorder / / 22472876 rs1040697 chr20 54231318 A G 7.67E-04 Major depressive disorder / / 22472876 rs761828 chr20 54237085 T G 5.64E-04 Insulin resistance / / 21901158 rs585038 chr20 54237745 C T 6.21E-04 Multiple complex diseases / / 17554300 rs1337245 chr20 54239617 A G 6.74E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs16978670 chr20 54247290 G A 1.73E-08 Metabolite levels / / 23281178 rs410631 chr20 54250605 G C 1.42E-05 Insulin resistance / / 21901158 rs4535106 chr20 54252894 C A 3.29E-04 Insulin resistance / / 21901158 rs2870643 chr20 54254363 T A 8.32E-04 Insulin resistance / / 21901158 rs431960 chr20 54255278 G C 4.65E-04 Insulin resistance / / 21901158 rs6123512 chr20 54255844 G A 5.41E-05 C-Reactive Protein / / pha003070 rs366496 chr20 54257450 C T 9.69E-06 Obesity-related traits / / 23251661 rs6069386 chr20 54293549 A C 8.40E-06 Iron levels / / 21208937 rs6024403 chr20 54347434 A C 9.80E-05 Tooth agenesis (maxillary third molar) / / 24172245 rs6024437 chr20 54380555 C T 8.51E-05 HIV-1 viral setpoint / / 22174851 rs6024460 chr20 54395541 A G 9.03E-05 HIV-1 viral setpoint / / 22174851 rs6024466 chr20 54397951 A C 4.51E-04 Prostate cancer mortality / / 20978177 rs6024483 chr20 54421129 T C 7.75E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6092190 chr20 54421204 A C 5.83E-04 Multiple complex diseases / / 17554300 rs228993 chr20 54491643 C A 2.14E-04 Alzheimer's disease / / 17998437 rs6069477 chr20 54491980 G A 3.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs6024512 chr20 54493817 C G 2.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs6024512 chr20 54493817 C G 3.07E-04 Smoking quantity / / 24665060 rs6014555 chr20 54494978 G A 3.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs2015541 chr20 54511115 G A,C,T 2.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6069486 chr20 54514837 A G 7.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16979159 chr20 54528147 T C 6.55E-05 Cognitive test performance / / 20125193 rs6069499 chr20 54540328 T C 8.86E-05 Blood Pressure / / pha003046 rs6098930 chr20 54540435 T C 5.10E-06 Urinary metabolites / / 21572414 rs1370271 chr20 54541019 T C 6.58E-04 Alcohol dependence / / 21314694 rs914432 chr20 54552181 A G 3.12E-05 Height / / pha003011 rs2011703 chr20 54556388 T C 4.90E-04 Multiple complex diseases / / 17554300 rs2011703 chr20 54556388 T C 3.62E-06 Glucose levels / / pha003058 rs2011703 chr20 54556388 T C 8.80E-05 Glucose levels / / pha003061 rs6014573 chr20 54579459 C A 4.04E-05 Neuroblastoma / / pha002895 rs987017 chr20 54596536 T A 8.14E-04 Type 2 diabetes / / 17463246 rs16979272 chr20 54616175 G A 2.70E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6069551 chr20 54633205 A C 9.25E-05 Neuroblastoma / / pha002895 rs6024610 chr20 54662209 A T 8.99E-04 Multiple complex diseases / / 17554300 rs6024619 chr20 54677950 G A 4.54E-05 Neuroblastoma / / pha002895 rs6123547 chr20 54722875 G T 4.80E-04 Type 2 diabetes / / 17463246 rs6513194 chr20 54726056 T A 7.03E-04 Type 2 diabetes / / 17463246 rs6513195 chr20 54726569 G A 6.29E-04 Type 2 diabetes / / 17463246 rs6513195 chr20 54726569 G A 6.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1886957 chr20 54734769 T C 2.06E-06 Glucose levels / / pha003058 rs1886957 chr20 54734769 T C 3.90E-05 Glucose levels / / pha003061 rs6014619 chr20 54746137 C G 5.33E-04 Alcohol dependence / / 21314694 rs6092262 chr20 54763127 T G 1.90E-05 Parkinson's disease (age of onset) / / 19772629 rs6069640 chr20 54773641 G A 8.60E-05 Parkinson's disease (age of onset) / / 19772629 rs6064350 chr20 54775788 C T 8.53E-05 Cognitive impairment induced by topiramate / / 22091778 rs6024688 chr20 54777524 T C 8.53E-05 Cognitive impairment induced by topiramate / / 22091778 rs6123557 chr20 54807252 C T 2.42E-11 Esophageal cancer / / 21642993 rs6069670 chr20 54814658 G T 2.43E-06 Lipid traits / / 21777205 rs6069674 chr20 54831274 C T 5.43E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs1926065 chr20 54831337 G A 7.61E-05 Schizophrenia / / 21926974 rs6123571 chr20 54831962 G T 8.15E-05 Height / / 17255346 rs6123571 chr20 54831962 G T 5.06E-04 Multiple complex diseases / / 17554300 rs6127702 chr20 54832230 G A 5.91E-05 Schizophrenia / / 19571811 rs6127702 chr20 54832230 G A 2.30E-05 Urinary metabolites / / 21572414 rs6014657 chr20 54833431 C A 5.25E-06 Attention deficit hyperactivity disorder / / 20732627 rs6069675 chr20 54834133 G T 9.69E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs913000 chr20 54836354 T C 3.34E-05 Attention deficit hyperactivity disorder / / 20732627 rs913000 chr20 54836354 T C 0.0008804 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs913000 chr20 54836354 T C 8.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4811685 chr20 54839794 T C 8.10E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1980818 chr20 54840706 C G 1.37E-05 Attention deficit hyperactivity disorder / / 20732627 rs1980818 chr20 54840706 C G 2.80E-05 Urinary metabolites / / 21572414 rs6064361 chr20 54841008 T C 2.20E-05 Attention deficit hyperactivity disorder / / 20732627 rs1326022 chr20 54844025 A G 1.64E-05 Attention deficit hyperactivity disorder / / 20732627 rs1326021 chr20 54844146 C T 1.55E-05 Attention deficit hyperactivity disorder / / 20732627 rs6064362 chr20 54845796 G A 2.00E-05 Attention deficit hyperactivity disorder / / 20732627 rs6014664 chr20 54848977 C T 7.38E-06 Attention deficit hyperactivity disorder / / 20732627 rs932792 chr20 54851746 C A 3.22E-05 Attention deficit hyperactivity disorder / / 20732627 rs6069689 chr20 54858425 G A 0.0005539 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6069689 chr20 54858425 G A 5.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6024763 chr20 54858742 C T 0.0005563 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6024763 chr20 54858742 C T 5.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2182356 chr20 54859034 G T 0.0004565 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2182356 chr20 54859034 G T 4.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6069690 chr20 54861043 G T 0.000468 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6069690 chr20 54861043 G T 4.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6069692 chr20 54861281 A G 0.0003552 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6069692 chr20 54861281 A G 3.55E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs927809 chr20 54862685 T C 0.0003828 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs927809 chr20 54862685 T C 3.83E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6024768 chr20 54863750 G C 0.0003396 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6024768 chr20 54863750 G C 3.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8122798 chr20 54865811 G T 0.000335 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8122798 chr20 54865811 G T 3.35E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1926069 chr20 54866110 T A 0.0003299 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1926069 chr20 54866110 T A 3.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2007072 chr20 54871895 G A 0.0002596 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2007072 chr20 54871895 G A 2.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2426606 chr20 54872859 C T 0.0002629 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2426606 chr20 54872859 C T 2.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2426607 chr20 54872931 C T 0.0002619 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2426607 chr20 54872931 C T 2.62E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2007484 chr20 54873170 T C 5.83E-04 Multiple complex diseases / / 17554300 rs2426608 chr20 54873468 G T 0.0002613 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2426608 chr20 54873468 G T 2.61E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6127723 chr20 54873707 A G 1.63E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1041153 chr20 54876878 G A 0.0007163 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1041153 chr20 54876878 G A 7.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6024783 chr20 54884338 A C 6.21E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16979829 chr20 54947050 T G 9.13E-05 Parent of origin effect on language impairment (maternal) AURKA intron 24571439 rs6064392 chr20 54984768 G T 9.65E-04 Acute lung injury / / 22295056 rs6064392 chr20 54984768 G T 3.57E-05 HDL cholesterol / / pha003074 rs6127744 chr20 54986274 G T 3.69E-05 HDL cholesterol / / pha003074 rs11697922 chr20 54991842 T G 4.21E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CASS4 intron 20877124 rs11698292 chr20 54997400 T C 3.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CASS4 intron 20877124 rs41490147 chr20 54997748 A G 2.40E-10 Multiple complex diseases CASS4 intron 17554300 rs6014724 chr20 54998544 A G 7.30E-04 Acute lung injury CASS4 intron 22295056 rs6099146 chr20 55009854 A G 2.43E-04 Acute lung injury CASS4 intron 22295056 rs927174 chr20 55015166 A C 4.61E-04 Acute lung injury CASS4 intron 22295056 rs7274581 chr20 55018260 T C 3.00E-08 Alzheimer's disease (late onset) CASS4 intron 24162737 rs16979933 chr20 55020557 T C 4.62E-04 Acute lung injury CASS4 intron 22295056 rs401897 chr20 55029758 T C 6.50E-04 Neuroticism CASS4 intron 17667963 rs6014735 chr20 55035994 T C 1.76E-04 Glycosylated haemoglobin levels / / 17255346 rs6014735 chr20 55035994 T C 6.67E-04 Multiple complex diseases / / 17554300 rs1570044 chr20 55036313 C T 2.32E-04 Glycosylated haemoglobin levels / / 17255346 rs1570044 chr20 55036313 C T 6.46E-05 Personality dimensions / / 18957941 rs4811702 chr20 55039481 A G 1.96E-04 Glycosylated haemoglobin levels / / 17255346 rs6024908 chr20 55057214 G C 9.26E-05 Glycosylated haemoglobin levels C20orf43 intron 17255346 rs6024908 chr20 55057214 G C 3.81E-04 Multiple complex diseases C20orf43 intron 17554300 rs8125425 chr20 55067135 G A 9.92E-04 Multiple complex diseases C20orf43 intron 17554300 rs6024911 chr20 55072472 A G 4.20E-04 Amyotrophic Lateral Sclerosis C20orf43 intron 17362836 rs3209183 chr20 55108617 C A 0.00026 Prostate cancer FAM209B missense 23555315 rs6024938 chr20 55109304 C T 6.00E-06 Obesity-related traits FAM209B intron 23251661 rs6069771 chr20 55115834 A G 9.09E-05 Personality dimensions / / 18957941 rs6092326 chr20 55116737 C T 2.77E-05 Osteoarthritis / / 19508968 rs729972 chr20 55117111 C T 1.81E-05 Suicide attempts in bipolar disorder / / 21423239 rs6099191 chr20 55119413 A G 5.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs6099193 chr20 55120267 G C 1.60E-04 Suicide attempts in bipolar disorder / / 21423239 rs11700226 chr20 55122725 C T 2.47E-05 Suicide attempts in bipolar disorder / / 21423239 rs869261 chr20 55125954 A G 2.63E-05 Suicide attempts in bipolar disorder / / 21423239 rs1884422 chr20 55126914 C T 4.14E-04 Suicide attempts in bipolar disorder / / 21423239 rs6069776 chr20 55130674 C T 9.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs1884424 chr20 55131571 A G 3.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs11696207 chr20 55131787 T G 3.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs11696208 chr20 55131788 T G 3.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs4811713 chr20 55132478 T C 1.95E-05 Osteoarthritis / / 19508968 rs4811713 chr20 55132478 T C 3.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs6064417 chr20 55133228 A G 3.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs6064418 chr20 55134076 C T 3.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs6024958 chr20 55147226 A G 6.50E-05 Response to statin therapy / / 20339536 rs6024978 chr20 55165067 A C 1.02E-04 Bipolar disorder / / 17486107 rs4811719 chr20 55178081 G A 2.40E-04 Blood pressure / / 21228793 rs1570532 chr20 55184293 T C 9.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs3827102 chr20 55202984 T A,C,G 0.00000477 Major depressive disorder / / 22915352 rs2024966 chr20 55233110 T G 5.44E-05 Stroke / / pha002887 rs4811724 chr20 55252119 C T 5.70E-06 Urinary metabolites / / 21572414 rs4811724 chr20 55252119 C T 4.79E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) / / 23648065 rs2870758 chr20 55265904 A C 0.000502 Height (Pygmy height) / / 22570615 rs2870763 chr20 55269324 G A 0.000767 Height (Pygmy height) / / 22570615 rs4811741 chr20 55287399 A G 1.32E-04 Alzheimer's disease / / 17998437 rs6025100 chr20 55289145 C T 2.64E-04 Multiple complex diseases / / 17554300 rs6025100 chr20 55289145 C T 1.00E-05 Urinary metabolites / / 21572414 rs2426644 chr20 55292543 T G 5.05E-05 Bipolar disorder / / 17486107 rs2426669 chr20 55310124 T A 9.50E-04 Multiple complex diseases / / 17554300 rs16980283 chr20 55331697 G A 3.80E-06 Urinary metabolites / / 21572414 rs6069865 chr20 55332944 T G 4.10E-06 Urinary metabolites / / 21572414 rs6069865 chr20 55332944 T G 7.10E-08 Kawasaki disease / / 22446962 rs2145699 chr20 55334992 C A 1.30E-05 Urinary metabolites / / 21572414 rs6014819 chr20 55335907 G A 1.30E-05 Urinary metabolites / / 21572414 rs6014819 chr20 55335907 G A 1.10E-07 Kawasaki disease / / 22446962 rs6025146 chr20 55336037 A G 9.20E-07 Kawasaki disease / / 22446962 rs6014820 chr20 55336267 C T 1.30E-05 Urinary metabolites / / 21572414 rs4811748 chr20 55351114 C G 8.27E-04 Multiple complex diseases / / 17554300 rs6025157 chr20 55351869 A G 1.24E-04 Multiple complex diseases / / 17554300 rs6025158 chr20 55352312 C G 7.76E-05 IgE levels / / 22075330 rs2093283 chr20 55362831 G A 1.70E-05 Urinary metabolites / / 21572414 rs2426689 chr20 55369594 C T 2.65E-04 Type 2 diabetes / / 17463246 rs6127856 chr20 55373556 C T 5.94E-04 Type 2 diabetes / / 17463246 rs6127856 chr20 55373556 C T 7.68E-04 Coronary Artery Disease / / 17634449 rs6069883 chr20 55378451 G A 6.73E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4811754 chr20 55392174 A C 6.61E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12479616 chr20 55420654 T C 1.03E-04 Coronary heart disease / / 21606135 rs12481021 chr20 55421778 A G 6.72E-05 Coronary heart disease / / 21606135 rs6069909 chr20 55428489 T C 6.18E-04 Type 2 diabetes / / 17463246 rs1007963 chr20 55438231 T G 6.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs6025211 chr20 55439363 C T 4.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs6025229 chr20 55452397 G A 3.14E-04 Alzheimer's disease / / 17998437 rs6099313 chr20 55452732 C T 0.000863736 Hypertension (early onset hypertension) / / 22479346 rs6014857 chr20 55453688 G A 8.41E-04 Multiple complex diseases / / 17554300 rs6099314 chr20 55454659 A G 4.00E-07 Chronic obstructive pulmonary disease (moderate to severe) / / 24621683 rs7261954 chr20 55457631 G A 6.30E-04 Type 2 diabetes / / 17463246 rs6025234 chr20 55458290 T C 3.69E-04 Type 2 diabetes / / 17463246 rs4810051 chr20 55462898 G A 0.000540602 Hypertension (early onset hypertension) / / 22479346 rs2246237 chr20 55464575 G A 0.000407255 Hypertension (early onset hypertension) / / 22479346 rs6069930 chr20 55506457 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs9974012 chr20 55533289 C T 8.72E-05 Pulmonary function in asthmatics / / 23541324 rs7270476 chr20 55546577 C A 3.03E-04 Body mass index / / 21701565 rs910832 chr20 55564705 T C 8.03E-05 Cognitive impairment induced by topiramate / / 22091778 rs6069957 chr20 55579411 G A 4.74E-05 Blood Pressure / / pha003043 rs1276377 chr20 55597892 C T 3.22E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1276377 chr20 55597892 C T 5.46E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16980631 chr20 55607784 T G 4.36E-04 Multiple complex diseases / / 17554300 rs331603 chr20 55618946 A G 9.75E-05 Parkinson's disease / / 21738487 rs331603 chr20 55618946 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs331610 chr20 55622859 A G 4.02E-05 Parkinson's disease / / 21738487 rs6127916 chr20 55627407 T C 2.92E-04 Schizophrenia / / 19197363 rs331615 chr20 55638537 T A 9.00E-07 White blood cell types / / 21738478 rs6127921 chr20 55638750 A C 1.00E-06 Response to citalopram treatment / / 19846067 rs6127921 chr20 55638750 A C 3.00E-06 Response to citalopram treatment / / 19846067 rs6127921 chr20 55638750 A C 3.45E-06 Vaspin levels / / 22907691 rs331617 chr20 55639848 T C 1.61E-05 Parkinson's disease / / 21738487 rs6069974 chr20 55641291 T G 2.28E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs927839 chr20 55644152 C T 6.73E-05 Parkinson's disease / / 21738487 rs6127923 chr20 55646198 C T 4.44E-05 Common variable immunodeficiency / / 21497890 rs979316 chr20 55656322 T C 9.14E-05 Parkinson's disease / / 21738487 rs17400154 chr20 55661952 A G 6.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs6014918 chr20 55662514 G A 3.60E-06 Urinary metabolites / / 21572414 rs6069985 chr20 55672636 G A 6.58E-05 Cognitive test performance / / 20125193 rs3761201 chr20 55681143 G A 0.000708 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs3761201 chr20 55681143 G A 7.08E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs3761203 chr20 55681196 G T 0.0007093 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs3761203 chr20 55681196 G T 7.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs717908 chr20 55682387 A G 3.00E-04 Psoriasis / / 20953189 rs11699237 chr20 55683996 T C 3.00E-06 Schizophrenia / / 23212062 rs6064496 chr20 55695838 C A 0.0004041 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6064496 chr20 55695838 C A 4.04E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11697721 chr20 55702728 A G 0.0005857 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11697721 chr20 55702728 A G 5.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6025387 chr20 55706197 G A 0.0006716 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6025387 chr20 55706197 G A 6.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6014936 chr20 55706841 C A,T 0.0006812 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6014936 chr20 55706841 C A,T 6.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7272946 chr20 55707409 T C 0.0007005 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7272946 chr20 55707409 T C 7.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11697631 chr20 55707918 G A 0.0007315 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11697631 chr20 55707918 G A 7.32E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6064501 chr20 55713417 T C 0.0007682 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6064501 chr20 55713417 T C 7.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6025407 chr20 55717661 T C 4.38E-04 Parkinson's disease / / 17052657 rs13040929 chr20 55725731 C T 1.04E-04 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs6025450 chr20 55800296 C T 1.68E-04 Multiple complex diseases BMP7 intron 17554300 rs186660 chr20 55816126 T C 1 Drug response to Etoposide BMP7 intron 17537913 rs6127983 chr20 55824475 T C 1 Drug response to Etoposide BMP7 intron 17537913 rs182784 chr20 55824533 A G 1 Drug response to Etoposide BMP7 intron 17537913 rs6127984 chr20 55824593 G A 1 Drug response to Etoposide BMP7 intron 17537913 rs6070035 chr20 55825693 A G 1 Drug response to Etoposide BMP7 intron 17537913 rs8116259 chr20 55826168 A G 1 Drug response to Etoposide BMP7 intron 17537913 rs6014975 chr20 55895429 T C 9.66E-04 Rheumatoid arthritis / / 21452313 rs6014975 chr20 55895429 T C 6.24E-05 Lung Cancer (DNA repair capacity) / / 23108145 rs4811837 chr20 55929881 T C 4.49E-04 Multiple complex diseases RAE1 intron 17554300 rs4811839 chr20 55932607 T G 9.53E-04 Response to cytadine analogues (cytosine arabinoside) RAE1 intron 24483146 rs2426708 chr20 55936882 A G 9.53E-04 Response to cytadine analogues (cytosine arabinoside) RAE1 intron 24483146 rs6025517 chr20 55940921 T C 5.88E-04 Rheumatoid arthritis RAE1 intron 21452313 rs911901 chr20 55952187 A G 6.20E-04 Response to cytadine analogues (cytosine arabinoside) RAE1 intron 24483146 rs99595 chr20 55989808 C T 1.94E-09 Red blood cell traits / / 23222517 rs737092 chr20 55990405 T C 4.00E-13 Red blood cell traits / / 23222517 rs6123697 chr20 55991479 G A 6.93E-08 Red blood cell traits / / 23222517 rs6092477 chr20 55991695 G A 1.00E-08 Blood cell counts and other traits / / 20139978 rs6092477 chr20 55991695 G A 1.37E-08 Blood cell counts and other traits / / 20139978 rs6092477 chr20 55991695 G A 7.18E-08 Red blood cell traits / / 23222517 rs6014994 chr20 55991823 C A,G,T 6.65E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs6014994 chr20 55991823 C A,G,T 8.78E-05 Lung function (forced vital capacity) / / pha003104 rs6025553 chr20 55995609 C T 3.77E-08 Red blood cell traits / / 23222517 rs11696581 chr20 55996735 G A 1.93E-05 Cognitive test performance / / 20125193 rs4811846 chr20 55997468 T C 1.97E-05 Rheumatoid arthritis / / 17804836 rs1543434 chr20 56008768 G A 6.52E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs2426728 chr20 56012085 G A 7.03E-05 Schizophrenia(age at onset) / / 21688384 rs2426729 chr20 56012674 C T 4.12E-05 Schizophrenia(age at onset) / / 21688384 rs328505 chr20 56018698 G T 1.56E-04 Myocardial Infarction / / pha002883 rs6025564 chr20 56020865 C G 5.60E-05 Response to statin therapy / / 20339536 rs328506 chr20 56029604 T C 4.26E-04 Multiple complex diseases / / 17554300 rs328506 chr20 56029604 T C 2.00E-06 Type 2 diabetes / / 23300278 rs6025573 chr20 56032028 T C 7.95E-04 Type 2 diabetes / / 17463246 rs1467468 chr20 56032526 T G 1.40E-06 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs6025579 chr20 56039613 C T 3.00E-05 Response to statin therapy / / 20339536 rs6070114 chr20 56041510 G A 2.60E-05 Response to statin therapy / / 20339536 rs6015006 chr20 56042700 T C 6.20E-06 Response to statin therapy / / 20339536 rs6064552 chr20 56042866 C T 6.30E-06 Response to statin therapy / / 20339536 rs6070116 chr20 56044184 A G 4.00E-06 Response to statin therapy / / 20339536 rs17409421 chr20 56044352 C T 5.90E-06 Response to statin therapy / / 20339536 rs12151868 chr20 56044642 G A 4.80E-06 Response to statin therapy / / 20339536 rs12151866 chr20 56044744 C G 4.80E-06 Response to statin therapy / / 20339536 rs12151923 chr20 56044837 T C 5.54E-04 Fibrinogen / / 17255346 rs12151923 chr20 56044837 T C 1.80E-05 Response to statin therapy / / 20339536 rs6025582 chr20 56045772 C T 3.90E-05 Parkinson's disease (age of onset) / / 19772629 rs6070117 chr20 56052955 C T 1.08E-05 Cognitive impairment induced by topiramate / / 22091778 rs59972978 chr20 56058355 A T 5.00E-06 Alcohol consumption / / 23743675 rs4810080 chr20 56058727 A G 4.35E-07 Obesity-related traits / / 23251661 rs6099650 chr20 56058999 T C 3.42E-05 Multiple complex diseases / / 17554300 rs6099650 chr20 56058999 T C 5.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs6099650 chr20 56058999 T C 8.30E-06 Urinary metabolites / / 21572414 rs6099650 chr20 56058999 T C 2.40E-07 Obesity-related traits / / 23251661 rs6099653 chr20 56062803 C G 1.23E-07 Obesity-related traits / / 23251661 rs3810541 chr20 56063319 C T 1.23E-07 Obesity-related traits / / 23251661 rs6099656 chr20 56064267 T C 7.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs6099656 chr20 56064267 T C 7.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2865387 chr20 56066837 A G 9.83E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6025590 chr20 56070505 A G 6.83E-04 Type 2 diabetes / / 17463246 rs6025590 chr20 56070505 A G 7.68E-05 Cognitive test performance / / 20125193 rs6025590 chr20 56070505 A G 6.06E-04 Suicide attempts in bipolar disorder / / 21041247 rs6025590 chr20 56070505 A G 4.00E-08 Obesity-related traits / / 23251661 rs11086611 chr20 56071296 G A 1.68E-07 Obesity-related traits / / 23251661 rs2182970 chr20 56071653 T G 5.55E-04 Suicide attempts in bipolar disorder / / 21041247 rs2182970 chr20 56071653 T G 2.46E-06 Obesity-related traits / / 23251661 rs2209885 chr20 56074907 C G 6.21E-04 Suicide attempts in bipolar disorder CTCFL intron 21041247 rs11700100 chr20 56080049 T C 8.00E-06 Response to cytadine analogues (cytosine arabinoside) CTCFL intron 24483146 rs12625924 chr20 56095152 A G 9.88E-04 Alzheimer's disease CTCFL intron 17998437 rs6025606 chr20 56098733 T C 4.54E-04 Smoking cessation CTCFL missense 24665060 rs6025610 chr20 56110293 C T 4.58E-04 Smoking cessation / / 24665060 rs6099671 chr20 56115725 T C 1.85E-04 Smoking cessation / / 24665060 rs8119374 chr20 56118666 T C 1.03E-04 Smoking cessation / / 24665060 rs4810081 chr20 56120030 T C 1.32E-04 Smoking cessation / / 24665060 rs4810082 chr20 56120049 C T 9.04E-05 Smoking cessation / / 24665060 rs6070149 chr20 56129738 T C 4.43E-04 Smoking cessation / / 24665060 rs17496809 chr20 56131053 G A 0.000515172 Fasting blood glucose / / 22885924 rs8192708 chr20 56138621 A G 9.90E-05 Alzheimer's disease (late onset) PCK1 missense 21460841 rs6015032 chr20 56148376 G A 1.43E-05 Hippocampal atrophy / / 19668339 rs6025639 chr20 56150737 C T 7.01E-04 Parkinson's disease / / 16252231 rs1546912 chr20 56155434 A T 2.55E-04 Body mass index / / 21701565 rs2073146 chr20 56169863 C A 4.69E-04 Homeostasis model assessment of beta-cell function (interaction) / / 24204828 rs6064572 chr20 56179422 C A 1.05E-04 Glycosylated haemoglobin levels ZBP1 UTR-3 17255346 rs6064572 chr20 56179422 C A 8.02E-05 Coronary heart disease ZBP1 UTR-3 pha003056 rs2073145 chr20 56190634 C T 2.00E-06 Hippocampal atrophy ZBP1 missense 19668339 rs13042465 chr20 56199319 A C 5.58E-05 Alzheimer's disease (late onset) / / 21379329 rs17499060 chr20 56203102 T C 6.18E-05 Body Fat Distribution / / pha003016 rs17499060 chr20 56203102 T C 3.48E-05 Body Fat Distribution / / pha003017 rs718307 chr20 56206029 G A 9.61E-04 Nicotine dependence / / 17158188 rs718307 chr20 56206029 G A 1.04E-04 Alzheimer's disease (late onset) / / 21379329 rs4811895 chr20 56206309 G A 3.92E-04 Nicotine dependence / / 17158188 rs6099690 chr20 56210436 T C 7.01E-04 Nicotine dependence / / 17158188 rs927171 chr20 56232583 C A 4.19E-04 Response to taxane treatment (placlitaxel) PMEPA1 intron 23006423 rs203386 chr20 56240718 G C 5.71E-04 Multiple complex diseases PMEPA1 intron 17554300 rs6025714 chr20 56244993 C T 5.90E-04 Type 2 diabetes PMEPA1 intron 17463246 rs157093 chr20 56252956 C T 9.33E-05 Post-operative nausea and vomiting PMEPA1 intron 21694509 rs6025743 chr20 56299156 C G 4.00E-06 Urinary metabolites / / 21572414 rs6128144 chr20 56319966 A G 1.30E-05 Urinary metabolites / / 21572414 rs6099738 chr20 56321231 G A 1.00E-05 Urinary metabolites / / 21572414 rs4368388 chr20 56321560 C G 4.91E-04 Multiple complex diseases / / 17554300 rs16981322 chr20 56331949 A G 5.70E-04 Multiple complex diseases / / 17554300 rs13037273 chr20 56337814 G C 2.20E-05 Urinary metabolites / / 21572414 rs6128156 chr20 56348590 T G 2.20E-06 Urinary metabolites / / 21572414 rs205791 chr20 56371084 A G 2.20E-05 Urinary metabolites / / 21572414 rs205798 chr20 56375825 C T 3.39E-05 Triglycerides / / pha003081 rs205798 chr20 56375825 C T 9.51E-06 Lipid levels / / pha003082 rs6025805 chr20 56402006 C T 4.68E-05 Brain lesion load / / 19010793 rs13045889 chr20 56425219 C T 3.82E-05 Amyotrophic lateral sclerosis / / 20801717 rs12481680 chr20 56428705 T G 2.00E-07 Response to fenofibrate (adiponectin levels) / / 23149075 rs35569127 chr20 56431237 G GA 6.26E-05 Arthritis (juvenile idiopathic) / / 22354554 rs6025837 chr20 56431237 G A 6.26E-05 Arthritis (juvenile idiopathic) / / 22354554 rs6128206 chr20 56435341 T C 0.0000503 Amyotrophic lateral sclerosis / / 23587638 rs4810108 chr20 56449176 T G 1.87E-05 Elbow pain / / pha003008 rs913879 chr20 56459934 A G 8.58E-05 Hemoglobin concentration / / 20534544 rs6099816 chr20 56460394 A C 7.57E-04 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) / / 24121790 rs11905007 chr20 56460774 G A 2.84E-04 Alzheimer's disease / / 17998437 rs8124301 chr20 56471603 C T 3.21E-09 Common variable immunodeficiency / / 21497890 rs6025887 chr20 56478997 T C 2.54E-04 Parkinson's disease / / 17052657 rs16981461 chr20 56490700 G A,C 1.15E-04 Multiple complex diseases / / 17554300 rs8119092 chr20 56493170 A G 8.16E-06 Obesity-related traits / / 23251661 rs6099847 chr20 56501979 T C 7.00E-06 Obesity-related traits / / 23251661 rs6099854 chr20 56512205 G A 8.00E-06 Obesity-related traits / / 23251661 rs6099854 chr20 56512205 G A 2.79E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs10485810 chr20 56521283 A G 2.55E-04 Stroke / / pha002887 rs2426763 chr20 56534936 T C 6.56E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6025934 chr20 56535862 C T 4.30E-08 Platelet aggregation(pre- and post-aspirin) / / 20529293 rs16981543 chr20 56551001 C T 1.30E-05 Personality dimensions / / 18957941 rs6025956 chr20 56551299 C A 1.30E-05 Personality dimensions / / 18957941 rs6025957 chr20 56551422 G A 1.50E-05 Personality dimensions / / 18957941 rs6070325 chr20 56555807 G C 5.06E-04 Insulin resistance / / 21901158 rs6025975 chr20 56586118 A G 5.44E-05 White matter integrity / / 22425255 rs7262054 chr20 56621312 C T 6.84E-05 Hepatocellular carcinoma / / 22807686 rs2865443 chr20 56647981 A G 4.07E-08 Metabolite levels / / 23281178 rs6015183 chr20 56651006 T C 1.64E-04 Type 2 diabetes / / 17463246 rs1334109 chr20 56655360 T G 1.29E-04 Parkinson's disease / / 17052657 rs6070346 chr20 56663274 T C 4.00E-06 Pulmonary function decline / / 22424883 rs11698339 chr20 56664812 A G 1.55E-04 Schizophrenia / / 19197363 rs6128270 chr20 56681806 C T 4.62E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12624625 chr20 56704400 A G 4.57E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6099952 chr20 56716578 G A 3.53E-05 Multiple complex diseases / / 17554300 rs17531288 chr20 56719358 C T 4.16E-05 Aging (time to event) / / 21782286 rs6128273 chr20 56719673 C A 2.03E-04 Schizophrenia / / 19197363 rs6128273 chr20 56719673 C A 8.02E-04 Alcohol dependence / / 20201924 rs6513369 chr20 56735271 C T 3.42E-04 Smoking cessation C20orf85 intron 18519826 rs6513369 chr20 56735271 C T 8.18E-05 Smoking cessation C20orf85 intron 18519826 rs884341 chr20 56736674 A G 7.69E-05 Smoking cessation / / 18519826 rs6015215 chr20 56744920 T C 2.41E-06 Smoking cessation / / 18519826 rs6070379 chr20 56767553 G A 4.15E-04 Tourette syndrome / / 22889924 rs550913 chr20 56795389 G A 6.72E-05 Lipoproteins ANKRD60 intron pha003079 rs4811971 chr20 56796784 G A 6.00E-06 Height ANKRD60 intron 19893584 rs595292 chr20 56820702 G T 3.24E-05 Oral cancers (chewing tobacco related) PPP4R1L intron 22503698 rs1537479 chr20 56826668 C T 9.95E-04 Coronary heart disease PPP4R1L intron 21606135 rs13038464 chr20 56872296 T C 9.17E-05 Alzheimer's disease (late onset) PPP4R1L intron 21379329 rs529525 chr20 56879349 T C 3.15E-04 Alzheimer's disease (late onset) PPP4R1L intron 21379329 rs561354 chr20 56880429 T C 3.17E-04 Alzheimer's disease (late onset) PPP4R1L intron 21379329 rs531317 chr20 56891471 A G 7.92E-04 Coronary heart disease RAB22A intron 21606135 rs485013 chr20 56895025 G A 9.51E-05 Alzheimer's disease (late onset) RAB22A intron 21379329 rs511145 chr20 56903898 A C 4.23E-04 Alzheimer's disease (late onset) RAB22A intron 21379329 rs1045402 chr20 56941728 G C 4.83E-04 Multiple complex diseases RAB22A UTR-3 17554300 rs6064647 chr20 56946001 A G 7.52E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs6064647 chr20 56946001 A G 6.32E-05 Diabetes Mellitus / / pha003059 rs6015265 chr20 56969673 G T 1.70E-04 Multiple complex diseases VAPB intron 17554300 rs2268921 chr20 56979416 G T 3.59E-04 Lung function (forced expiratory volume in 1 second) VAPB intron 24023788 rs6026243 chr20 56984094 T G 2.40E-05 Cognitive test performance VAPB intron 20125193 rs7400 chr20 57020556 G C 1.67E-04 Multiple complex diseases VAPB UTR-3 17554300 rs4812002 chr20 57048350 A G 6.15E-04 Sarcoidosis APCDD1L intron 19165924 rs1555296 chr20 57081130 C G 2.96E-04 IgE levels APCDD1L intron 17255346 rs2208087 chr20 57086674 G A 5.90E-06 Urinary metabolites APCDD1L intron 21572414 rs1077577 chr20 57087269 T G 9.90E-05 Cognitive test performance APCDD1L intron 20125193 rs749210 chr20 57087712 G A 1.59E-05 Left ventricular hypertrophy APCDD1L intron pha003052 rs7273606 chr20 57109328 C T 2.84E-04 Multiple complex diseases LOC149773 intron 17554300 rs6026339 chr20 57111529 C G 7.03E-04 Depression (quantitative trait) LOC149773 intron 20800221 rs4812013 chr20 57112959 T C 6.80E-04 White matter integrity LOC149773 intron 22425255 rs2223964 chr20 57118426 T C 8.94E-05 Blood Pressure LOC149773 intron pha003043 rs6015305 chr20 57120653 A G 5.58E-04 Multiple complex diseases LOC149773 intron 17554300 rs6513396 chr20 57128202 T C 3.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC149773 intron 20877124 rs6070519 chr20 57153844 C G 7.65E-05 Bipolar disorder and schizophrenia LOC149773 intron 20889312 rs11699206 chr20 57155480 G C 2.15E-04 Alzheimer's disease LOC149773 intron 24755620 rs7266327 chr20 57158616 G A 4.20E-06 Urinary metabolites LOC149773 intron 21572414 rs4812020 chr20 57164080 G A 2.10E-04 Smoking behavior LOC149773 intron 23049750 rs127430 chr20 57164855 A G 1.00E-06 Cardiovascular disease risk factors LOC149773 intron 20838585 rs6015314 chr20 57167225 A G 3.73E-04 Body mass index LOC149773 intron 17255346 rs6026398 chr20 57180009 A G 7.73E-05 Alzheimer's disease LOC149773 intron 17998437 rs6026398 chr20 57180009 A G 8.69E-05 Major depressive disorder (broad) LOC149773 intron 20038947 rs6026398 chr20 57180009 A G 1.73E-04 Alzheimer's disease LOC149773 intron pha002879 rs11086650 chr20 57183256 T C 3.20E-04 Response to cytadine analogues (cytosine arabinoside) LOC149773 intron 24483146 rs127432 chr20 57184277 T C 4.49E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LOC149773 intron 22566498 rs127433 chr20 57184288 T C 8.90E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LOC149773 intron 22566498 rs742928 chr20 57191330 G C 9.40E-04 Type 2 diabetes LOC149773 intron 17463246 rs6070536 chr20 57192802 C T 8.28E-04 Response to cytadine analogues (cytosine arabinoside) LOC149773 intron 24483146 rs6128386 chr20 57193549 T C 1.00E-06 Response to cytadine analogues (cytosine arabinoside) LOC149773 intron 24483146 rs6128386 chr20 57193549 T C 5.08E-04 Response to cytidine analogues (gemcitabine) LOC149773 intron 24483146 rs6123812 chr20 57195870 A G 2.01E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4812022 chr20 57201828 C T 7.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs1977137 chr20 57203003 T C 1.20E-05 Urinary metabolites / / 21572414 rs10460622 chr20 57203431 G A 7.53E-04 Type 2 diabetes / / 17463246 rs6026415 chr20 57204029 G A 1.60E-05 Urinary metabolites / / 21572414 rs1886842 chr20 57204978 G A 6.41E-05 Serum metabolites / / 19043545 rs6015320 chr20 57205047 G A 2.18E-05 Serum metabolites / / 19043545 rs6026417 chr20 57205161 T C 9.06E-05 Serum metabolites / / 19043545 rs6015326 chr20 57207701 T C 2.40E-05 Urinary metabolites / / 21572414 rs6100163 chr20 57260920 C T 5.25E-05 Multiple complex diseases STX16-NPEPL1 intron 17554300 rs6015352 chr20 57310727 T C 4.34E-04 Type 2 diabetes / / 17463246 rs6015353 chr20 57310806 G T 8.79E-04 Type 2 diabetes / / 17463246 rs7273692 chr20 57322318 G T 5.69E-04 Multiple complex diseases / / 17554300 rs16982271 chr20 57338028 C G 8.34E-04 Multiple complex diseases / / 17554300 rs6100206 chr20 57345204 T G 2.25E-04 Multiple complex diseases / / 17554300 rs6100223 chr20 57372192 C T 2.00E-06 Bipolar disorder / / 20451256 rs6100226 chr20 57374243 C T 2.00E-05 Smoking behavior / / 20418888 rs6015376 chr20 57377139 C G 1.55E-05 Bipolar disorder / / 20451256 rs965808 chr20 57408426 C A 5.00E-09 DNA methylation (variation) G/S-AS1 intron 23725790 rs8125112 chr20 57431165 T C 4.59E-05 Serum albumin level G/S intron pha003084 rs6100260 chr20 57452881 C T 9.80E-06 Obesity-related traits G/S intron 23251661 rs6092704 chr20 57468478 A C 3.69E-04 Alzheimer's disease (late onset) G/S intron 21379329 rs6026584 chr20 57469073 T C 3.47E-04 Multiple complex diseases G/S intron 17554300 rs6026584 chr20 57469073 T C 9.00E-09 Renal function-related traits (BUN) G/S intron 22797727 rs3730164 chr20 57470517 G A 1.90E-05 Urinary metabolites G/S intron 21572414 rs13831 chr20 57475191 A G 6.00E-06 Event-related brain oscillations G/S intron 21184583 rs919197 chr20 57480933 T C 7.53E-04 Multiple complex diseases G/S intron 17554300 rs234621 chr20 57490248 C A 7.69E-05 Body Mass Index / / pha003009 rs234621 chr20 57490248 C A 3.79E-05 Body Fat Distribution / / pha003017 rs151331 chr20 57492504 G A 6.68E-05 Serum metabolites / / 19043545 rs12480262 chr20 57559630 A G 3.94E-04 Smoking quantity TH1L intron 24665060 rs2273359 chr20 57562102 C G 6.00E-08 Response to diuretic therapy in hypertension TH1L intron 23753411 rs4812048 chr20 57587771 C T 7.60E-06 Urinary metabolites / / 21572414 rs4812048 chr20 57587771 C T 1.00E-09 Mean platelet volume / / 22139419 rs4812048 chr20 57587771 C T 7.00E-06 Mean platelet volume / / 24026423 rs151352 chr20 57601995 A G 7.55E-04 Alzheimer's disease / / 22005930 rs151337 chr20 57602791 T C 7.11E-04 Alzheimer's disease / / 22005930 rs151358 chr20 57610059 C A 2.24E-06 Parkinson's disease SLMO2 UTR-3 21812969 rs151358 chr20 57610059 C A 0.000043 post-traumatic stress disorder SLMO2 UTR-3 22869035 rs151358 chr20 57610059 C A 4.30E-05 Schizophrenia SLMO2 UTR-3 22883433 rs151358 chr20 57610059 C A 6.44E-05 Platelet counts SLMO2 UTR-3 23263863 rs151361 chr20 57614002 A G 6.70E-06 Urinary metabolites SLMO2 intron 21572414 rs151361 chr20 57614002 A G 9.00E-09 Mean platelet volume SLMO2 intron 22423221 rs151361 chr20 57614002 A G 0.0000901 post-traumatic stress disorder SLMO2 intron 22869035 rs151361 chr20 57614002 A G 9.01E-05 Schizophrenia SLMO2 intron 22883433 rs3761258 chr20 57618596 C G 4.90E-06 Urinary metabolites / / 21572414 rs3761258 chr20 57618596 C G 3.30E-06 Lymphocyte counts / / 22286170 rs6070703 chr20 57621857 C T 3.56E-04 Obesity (extreme) / / 21935397 rs6070706 chr20 57628239 C T 8.30E-06 Urinary metabolites / / 21572414 rs6070706 chr20 57628239 C T 4.79E-05 Pancreatic cancer / / pha002874 rs6070710 chr20 57642182 T G 1.09E-04 Obesity (extreme) / / 21935397 rs11697681 chr20 57647421 G C 1.10E-04 Obesity (extreme) / / 21935397 rs6064744 chr20 57672527 C T 4.64E-04 Obesity (extreme) / / 21935397 rs171042 chr20 57704379 C T 1.80E-05 Urinary metabolites / / 21572414 rs6026728 chr20 57723130 C T 8.49E-04 Multiple complex diseases / / 17554300 rs1535271 chr20 57734753 G A 5.99E-04 Type 2 diabetes / / 17463246 rs6026748 chr20 57745815 G A 4.35E-08 Blood pressure / / 21909110 rs6015450 chr20 57751117 A G 2.00E-06 Blood pressure / / 21909110 rs6015450 chr20 57751117 A G 2.00E-12 Blood pressure / / 21909110 rs6015450 chr20 57751117 A G 4.00E-14 Hypertension / / 21909115 rs6015450 chr20 57751117 A G 4.00E-23 Systolic blood pressure / / 21909115 rs6015450 chr20 57751117 A G 6.00E-23 Diastolic blood pressure / / 21909115 rs16982520 chr20 57758720 A G 2.00E-07 Hypertension / / 19430479 rs16982520 chr20 57758720 A G 2.00E-07 Coronary heart disease / / 21347282 rs194869 chr20 57769962 C T 9.04E-05 Orofacial clefts ZNF831 intron 22419666 rs260007 chr20 57771610 T G 7.21E-04 Multiple complex diseases ZNF831 intron 17554300 rs12624940 chr20 57777894 C T 4.61E-04 Type 2 diabetes ZNF831 intron 22158537 rs11086668 chr20 57785057 T C 4.77E-04 Type 2 diabetes ZNF831 intron 22158537 rs7264385 chr20 57789801 A G 1.39E-04 Schizophrenia ZNF831 intron 19197363 rs12625057 chr20 57790436 A C 7.00E-06 Response to antipsychotic therapy (extrapyramidal side effects) ZNF831 intron 19875103 rs6070744 chr20 57790618 T C 1.67E-04 Premature ovarian failure ZNF831 intron 19508998 rs6070744 chr20 57790618 T C 1.20E-04 Pancreatic cancer ZNF831 intron pha002874 rs259964 chr20 57824309 A G 1.00E-12 Inflammatory bowel disease ZNF831 intron 23128233 rs259964 chr20 57824309 A G 0.000110862 Primary sclerosing cholangitis ZNF831 intron 23603763 rs259962 chr20 57824960 T C 2.60E-05 Urinary metabolites ZNF831 intron 21572414 rs259954 chr20 57837766 G A 2.82E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6128521 chr20 57842217 T C 0.0007026 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6128521 chr20 57842217 T C 7.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4812068 chr20 57843903 T C 0.000723 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4812068 chr20 57843903 T C 7.23E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6100397 chr20 57850935 T G 6.70E-04 Suicide attempts in bipolar disorder / / 21041247 rs6100397 chr20 57850935 T G 6.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs6092765 chr20 57854010 T C 6.67E-05 Waist-Hip Ratio / / pha003013 rs6092765 chr20 57854010 T C 4.36E-05 Waist-Hip Ratio / / pha003028 rs3026622 chr20 57857023 G A 0.0003475 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs3026622 chr20 57857023 G A 3.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs155005 chr20 57870259 T A 8.20E-05 Epilepsy (remission after treatment) / / 23962720 rs11570255 chr20 57875916 G A 3.06E-11 Triglycerides EDN3 missense 23063622 rs11570255 chr20 57875916 G A 3.14E-27 HDL cholesterol EDN3 missense 23063622 rs11570255 chr20 57875916 G A 5.07E-22 LDL cholesterol EDN3 missense 23063622 rs11570255 chr20 57875916 G A 9.52E-36 Cholesterol,total EDN3 missense 23063622 rs260741 chr20 57876155 G A 7.62E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) EDN3 intron 22566498 rs197174 chr20 57878080 T C 5.85E-04 Multiple complex diseases EDN3 intron 17554300 rs3026606 chr20 57878080 T TC,TT 5.85E-04 Multiple complex diseases EDN3 intron 17554300 rs11570324 chr20 57893253 A T 1.69E-10 Cholesterol,total EDN3 intron 23063622 rs3026550 chr20 57912176 T G 2.46E-05 Multiple complex diseases / / 17554300 rs460775 chr20 57913395 T C 8.55E-05 Tunica Media / / pha003037 rs6128541 chr20 57917689 T C 3.32E-05 Multiple complex diseases / / 17554300 rs6128541 chr20 57917689 T C 1.80E-06 Crohn's disease / / 18587394 rs6128541 chr20 57917689 T C 9.29E-05 Schizophrenia / / 19197363 rs1964825 chr20 57919516 G A 6.88E-04 Multiple complex diseases / / 17554300 rs1964825 chr20 57919516 G A 2.77E-04 Schizophrenia / / 19197363 rs197820 chr20 57945113 A G 6.97E-05 Coronary heart disease / / pha003035 rs7267528 chr20 57957021 C T 1.03E-04 Smoking initiation / / 24665060 rs16982696 chr20 57970885 A G 5.90E-04 Multiple complex diseases / / 17554300 rs6100433 chr20 57974591 C T 2.55E-05 Serum metabolites / / 19043545 rs6070795 chr20 57990847 G T 7.12E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2137862 chr20 58010129 T C 2.04E-04 Multiple complex diseases / / 17554300 rs6064789 chr20 58037851 A G 1.15E-05 Lung function (forced vital capacity) / / pha003104 rs6123898 chr20 58071830 G A 2.49E-04 Multiple complex diseases / / 17554300 rs6026918 chr20 58072646 G T 4.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6026918 chr20 58072646 G T 6.60E-05 Waist-Hip Ratio / / pha003013 rs6026918 chr20 58072646 G T 8.74E-05 Waist-Hip Ratio / / pha003028 rs1374957 chr20 58088954 C T 5.48E-05 Hemoglobin concentration / / 20534544 rs3905228 chr20 58105747 A C 9.26E-04 Alzheimer's disease / / 24755620 rs6100488 chr20 58114167 T C 5.04E-05 Bladder cancer / / 19648920 rs7267048 chr20 58134215 G A 4.27E-04 Obesity (extreme) / / 21935397 rs6064811 chr20 58139017 G A 7.19E-05 Obesity (extreme) / / 21935397 rs3848704 chr20 58141296 C T 1.71E-04 Obesity (extreme) / / 21935397 rs6128626 chr20 58141712 A G 5.26E-04 Obesity (extreme) / / 21935397 rs3848705 chr20 58142077 A G 1.74E-04 Obesity (extreme) / / 21935397 rs3848706 chr20 58144187 C A 4.69E-04 Multiple complex diseases / / 17554300 rs3848706 chr20 58144187 C A 1.48E-04 Sarcoidosis / / 19165924 rs3848706 chr20 58144187 C A 1.78E-04 Obesity (extreme) / / 21935397 rs6015529 chr20 58144761 A G 6.58E-05 Obesity (extreme) / / 21935397 rs4812097 chr20 58144954 C T 1.84E-04 Obesity (extreme) / / 21935397 rs4812098 chr20 58144990 A G 6.82E-05 Obesity (extreme) / / 21935397 rs4812104 chr20 58145967 C A 1.90E-04 Obesity (extreme) / / 21935397 rs4812108 chr20 58146343 G A 5.18E-04 Multiple complex diseases / / 17554300 rs4812108 chr20 58146343 G A 7.27E-05 Obesity (extreme) / / 21935397 rs6026972 chr20 58147511 T G 8.69E-04 Obesity (extreme) / / 21935397 rs1105262 chr20 58148699 T G 8.55E-04 Obesity (extreme) / / 21935397 rs2426791 chr20 58162053 G C 6.44E-04 Multiple complex diseases PHACTR3 intron 17554300 rs6026990 chr20 58177615 T A 6.00E-07 Response to tocilizumab in rheumatoid arthritis PHACTR3 intron 22491018 rs6026995 chr20 58181699 C T 8.00E-04 Obesity (extreme) PHACTR3 intron 21935397 rs6128644 chr20 58188354 C T 7.93E-04 Obesity (extreme) PHACTR3 intron 21935397 rs6123921 chr20 58190157 A G 9.83E-04 Obesity (extreme) PHACTR3 intron 21935397 rs6026999 chr20 58191101 G A 9.69E-04 Obesity (extreme) PHACTR3 intron 21935397 rs1555365 chr20 58193074 G A 3.91E-04 Obesity (extreme) PHACTR3 intron 21935397 rs6027005 chr20 58199218 C T 1.82E-04 Multiple complex diseases PHACTR3 intron 17554300 rs6027005 chr20 58199218 C T 1.30E-05 Urinary metabolites PHACTR3 intron 21572414 rs6128653 chr20 58211295 C T 7.93E-04 Smoking cessation PHACTR3 intron 24665060 rs6015543 chr20 58235648 T C 2.25E-04 HIV-1 viral setpoint PHACTR3 intron 17641165 rs12481511 chr20 58274520 T C 1.03E-04 Gallstones PHACTR3 intron 17632509 rs1416390 chr20 58284470 C G 2.76E-04 Type 2 diabetes PHACTR3 intron 17463246 rs2426820 chr20 58288281 T G 2.80E-04 Myocardial Infarction PHACTR3 intron pha002873 rs6015561 chr20 58291961 G A 3.87E-04 Type 2 diabetes PHACTR3 intron 17463246 rs1182469 chr20 58317251 A T 4.75E-04 Coronary Artery Disease PHACTR3 intron 17634449 rs1182484 chr20 58344353 A C,G,T 2.50E-05 Urinary metabolites PHACTR3 intron 21572414 rs6027132 chr20 58384451 C T 1.74E-05 Alcohol consumption PHACTR3 intron 23743675 rs6070956 chr20 58384810 C T 1.58E-05 Alcohol consumption PHACTR3 intron 23743675 rs1182531 chr20 58393002 G T 4.00E-07 Rheumatoid arthritis PHACTR3 intron 17804836 rs1182532 chr20 58393545 C A 5.33E-04 Smoking quantity PHACTR3 intron 24665060 rs746219 chr20 58399419 G A,T 3.44E-06 Multiple complex diseases PHACTR3 intron 17554300 rs6027185 chr20 58475307 G A 1.53E-04 Multiple complex diseases SYCP2 cds-synon 17554300 rs723680 chr20 58544820 G A 4.60E-06 Sickle cell anemia (severity) CDH26 intron 20029952 rs2065411 chr20 58617669 C A 7.48E-05 Cognitive test performance / / 20125193 rs195031 chr20 58618251 G A 6.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6123968 chr20 58648660 C T 6.43E-04 Bipolar disorder / / 19259986 rs6027281 chr20 58656151 T C 7.10E-08 Body mass index / / 24886709 rs1475029 chr20 58669008 A G 5.67E-07 Gallstones LOC729296 intron 17632509 rs6100707 chr20 58671692 G A 2.92E-04 Multiple complex diseases LOC729296 intron 17554300 rs12481513 chr20 58672416 C T 1.92E-04 Multiple complex diseases LOC729296 intron 17554300 rs6513478 chr20 58676661 T G 7.59E-04 Multiple complex diseases / / 17554300 rs6100725 chr20 58687269 G A 3.29E-04 Multiple complex diseases / / 17554300 rs6064888 chr20 58697577 A G 7.21E-05 Multiple complex diseases / / 17554300 rs6027337 chr20 58712478 C A 6.79E-04 Alzheimer's disease / / 17998437 rs6027343 chr20 58717668 C T 8.71E-04 Coronary Artery Disease LOC284757 intron 17634449 rs13040185 chr20 58735575 T A 7.77E-04 Coronary Artery Disease LOC284757 intron 17634449 rs13039826 chr20 58736063 C T 9.38E-04 Coronary Artery Disease LOC284757 intron 17634449 rs6092900 chr20 58784498 T C 1.00E-05 Urinary metabolites LOC284757 intron 21572414 rs560822 chr20 58786247 A G 8.79E-04 White matter integrity LOC284757 intron 22425255 rs487656 chr20 58790814 A G 1.70E-06 Urinary metabolites LOC284757 intron 21572414 rs4812157 chr20 58792610 T C 2.30E-06 Urinary metabolites LOC284757 intron 21572414 rs2865793 chr20 58799401 T G 1.91E-05 Attention deficit hyperactivity disorder LOC284757 intron 20732625 rs6100796 chr20 58800873 C T 2.03E-05 Attention deficit hyperactivity disorder LOC284757 intron 20732625 rs7271202 chr20 58801643 G A 1.05E-05 Attention deficit hyperactivity disorder LOC284757 intron 20732625 rs1535028 chr20 58814428 T C 2.48E-05 Attention deficit hyperactivity disorder LOC284757 intron 20732625 rs17800962 chr20 58815577 G A 2.60E-05 Urinary metabolites LOC284757 intron 21572414 rs17728211 chr20 58815871 C T 2.60E-05 Urinary metabolites LOC284757 intron 21572414 rs17801257 chr20 58892520 G A 7.26E-04 Multiple complex diseases LOC284757 intron 17554300 rs6100861 chr20 58894423 G A 7.16E-05 Chronic obstructive pulmonary disease LOC284757 intron 19300482 rs6100861 chr20 58894423 G A 7.16E-05 Response to statin treatment (atorvastatin),change in cholesterol levels LOC284757 intron 20031582 rs11698685 chr20 58895846 G A 1.00E-06 Type 1 diabetes nephropathy / / 23028342 rs6027506 chr20 58896715 A G 5.00E-06 Type 1 diabetes nephropathy / / 23028342 rs6027511 chr20 58898209 T C 9.00E-06 Lentiform nucleus volume / / 22903471 rs17801293 chr20 58901720 A G 5.10E-06 White blood cell count / / 21738479 rs6100868 chr20 58908464 G A 2.40E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs354748 chr20 58911562 G T 1.50E-05 Urinary metabolites / / 21572414 rs6027527 chr20 58912221 C T 7.57E-05 AIDS / / 19754311 rs354747 chr20 58912660 A G 4.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6027541 chr20 58921477 A G 2.40E-05 Urinary metabolites / / 21572414 rs1461178 chr20 58922899 T C 2.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1461178 chr20 58922899 T C 7.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7264923 chr20 58923936 A C 2.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7264923 chr20 58923936 A C 7.94E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs181376 chr20 58924542 T G 8.44E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2208306 chr20 58925805 A C 5.29E-05 Smoking initiation / / 24665060 rs968032 chr20 58928479 T G 2.19E-05 Type 2 diabetes / / 17463246 rs2865801 chr20 58930476 G A 2.69E-04 Smoking initiation / / 24665060 rs168525 chr20 58937346 T G 6.32E-04 Smoking initiation / / 24665060 rs55681231 chr20 58946489 C A 7.00E-07 Metabolite levels (MHPG) / / 23319000 rs6027558 chr20 58948164 G A 8.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6027558 chr20 58948164 G A 8.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16983858 chr20 58951673 A G 8.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6027561 chr20 58953207 C T 5.16E-05 Cognitive test performance / / 20125193 rs7267489 chr20 58971103 C T 2.00E-06 Pericardial fat / / 22589742 rs7269082 chr20 58971174 C A 2.00E-06 Pericardial fat / / 22589742 rs1530089 chr20 58989894 A G 5.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs911168 chr20 58997083 T G 4.70E-05 Amyotrophic lateral sclerosis / / 20801717 rs6100898 chr20 59003029 G A 6.01E-05 Serum metabolites / / 19043545 rs348840 chr20 59005072 A C 2.65E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs90754 chr20 59067099 G A 8.36E-05 Major depressive disorder / / 22472876 rs17729098 chr20 59077648 T C 1.68E-06 Attention deficit hyperactivity disorder / / 20732625 rs17729098 chr20 59077648 T C 1.68E-06 Attention deficit hyperactivity disorder / / 20732627 rs6071223 chr20 59078074 A G 9.28E-04 Stroke / / pha002886 rs6027678 chr20 59113601 A G 4.98E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6071238 chr20 59126139 C T 6.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs16983998 chr20 59126822 T C 7.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs6071240 chr20 59127363 C T 6.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs6071241 chr20 59127398 T C 5.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs6071242 chr20 59129299 G C 6.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs6071243 chr20 59129488 G T 5.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs6071252 chr20 59140813 A G 7.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs6071254 chr20 59143600 G A 7.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs846193 chr20 59164954 A G 5.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs846206 chr20 59177068 T C 2.98E-05 Blood Pressure / / pha003039 rs11908218 chr20 59179271 G A 6.60E-05 Personality dimensions / / 18957941 rs6027712 chr20 59184993 C A 7.00E-05 Personality dimensions / / 18957941 rs6128870 chr20 59185488 G A 2.48E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs846212 chr20 59197643 A G 3.48E-04 Alzheimer's disease / / 17998437 rs16984131 chr20 59235948 T G 6.10E-05 Personality dimensions / / 18957941 rs1201885 chr20 59253774 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6027755 chr20 59268710 G A 6.00E-06 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1201959 chr20 59286946 G A 5.30E-04 Type 2 diabetes / / 23209189 rs1202031 chr20 59315127 A G 1.21E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs4810207 chr20 59329911 T A 3.54E-04 Multiple complex diseases / / 17554300 rs6015829 chr20 59345638 G A 7.10E-05 Tooth agenesis (mandibular third molar) / / 24172245 rs1885008 chr20 59348278 T C 6.76E-07 Lymphocyte counts / / pha003094 rs1885008 chr20 59348278 T C 4.64E-05 Neutrophil count / / pha003095 rs1202075 chr20 59350288 C T 5.54E-07 Lymphocyte counts / / pha003094 rs1202075 chr20 59350288 C T 3.49E-05 Neutrophil count / / pha003095 rs1629243 chr20 59352330 A G 5.54E-07 Lymphocyte counts / / pha003094 rs1629243 chr20 59352330 A G 3.49E-05 Neutrophil count / / pha003095 rs2426919 chr20 59362391 T C 4.09E-05 Cognitive test performance / / 20125193 rs6015839 chr20 59372363 T C 6.17E-05 Cognitive impairment induced by topiramate / / 22091778 rs10153975 chr20 59390992 T C 8.33E-04 Alcohol dependence / / 20201924 rs10485470 chr20 59394915 C T 2.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1010715 chr20 59395019 G T 1.40E-04 Multiple complex diseases / / 17554300 rs17201745 chr20 59398393 T C 3.65E-05 Schizophrenia / / 20185149 rs17201793 chr20 59422619 T A 1.88E-05 Multiple complex diseases / / 17554300 rs4812218 chr20 59422846 T C 3.80E-06 Schizophrenia / / 20185149 rs17201877 chr20 59435606 T C 3.29E-05 Schizophrenia / / 20185149 rs17794052 chr20 59436966 T G 3.65E-05 Schizophrenia / / 20185149 rs16984422 chr20 59449464 A G 7.20E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6027898 chr20 59456185 A C 8.69E-05 HDL cholesterol / / pha003075 rs2426937 chr20 59480404 C T 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2024675 chr20 59493500 C T 1.64E-05 Serum metabolites / / 19043545 rs2024676 chr20 59493559 G A 7.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs2426960 chr20 59493906 G A 6.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs978716 chr20 59495071 G A 5.35E-06 Serum metabolites / / 19043545 rs13039252 chr20 59497525 T C 2.47E-05 Serum metabolites / / 19043545 rs7270247 chr20 59503917 A C 7.45E-06 Serum metabolites / / 19043545 rs725475 chr20 59505488 T C 7.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs6071442 chr20 59508514 C T 7.85E-04 Suicide attempts in bipolar disorder / / 21041247 rs6128962 chr20 59508811 A G 8.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs8114429 chr20 59569516 G A 6.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs8114429 chr20 59569516 G A 6.18E-05 Heart Rate / / pha003054 rs6124047 chr20 59570371 G A 3.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16984493 chr20 59570740 C A 5.81E-04 Multiple complex diseases / / 17554300 rs6093041 chr20 59588585 G A 8.92E-04 Multiple complex diseases / / 17554300 rs6101183 chr20 59591960 C T 2.00E-04 Breast cancer and prostate cancer / / 17903305 rs6093043 chr20 59598168 G A 5.28E-05 Cognitive impairment induced by topiramate / / 22091778 rs1077381 chr20 59623849 C T 2.50E-05 Urinary metabolites / / 21572414 rs2865972 chr20 59624948 A T 8.08E-04 Multiple complex diseases / / 17554300 rs6065036 chr20 59625880 T C 2.69E-10 Narcolepsy / / 19629137 rs7263962 chr20 59625949 A G 7.79E-05 Multiple complex diseases / / 17554300 rs17804935 chr20 59628262 T C 7.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6071467 chr20 59635608 T G 5.10E-05 Multiple complex diseases / / 17554300 rs6071467 chr20 59635608 T G 6.36E-04 Alzheimer's disease / / 17998437 rs6129028 chr20 59635795 A G 2.19E-04 Cognitive decline / / 23732972 rs6129029 chr20 59635852 A G 4.61E-05 Multiple complex diseases / / 17554300 rs2208299 chr20 59635953 T C 4.56E-05 Multiple complex diseases / / 17554300 rs6028004 chr20 59636621 G C 9.36E-04 Multiple complex diseases / / 17554300 rs6071469 chr20 59636741 A C 2.11E-05 Multiple complex diseases / / 17554300 rs4423667 chr20 59637121 G A 2.70E-05 Multiple complex diseases / / 17554300 rs2093154 chr20 59637942 G T 2.98E-05 Multiple complex diseases / / 17554300 rs2093154 chr20 59637942 G T 2.00E-04 Asthma (childhood onset) / / 21359210 rs6129032 chr20 59638856 C A 4.37E-05 Multiple complex diseases / / 17554300 rs6129032 chr20 59638856 C A 8.21E-04 Myocardial Infarction / / pha002883 rs1001796 chr20 59639907 C G 2.81E-04 Multiple complex diseases / / 17554300 rs13040003 chr20 59640730 C A 3.33E-05 Vascular dementia / / 22116812 rs6129036 chr20 59643091 A G 2.48E-04 Multiple complex diseases / / 17554300 rs6071495 chr20 59691812 A T 8.04E-05 Type 2 diabetes / / 17463246 rs729681 chr20 59693586 G A 4.83E-05 Body Mass Index / / pha003014 rs6071503 chr20 59701987 T C 2.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1321413 chr20 59712061 C T 6.77E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6071527 chr20 59743351 A G 9.44E-04 Multiple complex diseases / / 17554300 rs6071527 chr20 59743351 A G 2.22E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs4810223 chr20 59745796 T G 9.58E-05 Interstitial lung disease / / 23583980 rs817691 chr20 59755640 C T 6.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs817697 chr20 59757223 C A 6.75E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs860148 chr20 59765295 C T 8.00E-06 Metabolite levels (X-11787) / / 23934736 rs2426971 chr20 59770941 A G 9.87E-04 Multiple complex diseases / / 17554300 rs2426973 chr20 59771388 T C 1.57E-04 Self-reported allergy / / 23817569 rs2426984 chr20 59785417 A C 8.20E-04 Multiple complex diseases / / 17554300 rs1857198 chr20 59786250 C T 2.06E-07 Inflammatory biomarkers / / 22291609 rs6129076 chr20 59787651 C T 2.01E-07 Inflammatory biomarkers / / 22291609 rs2426990 chr20 59788003 A G 2.02E-07 Inflammatory biomarkers / / 22291609 rs6129077 chr20 59791342 C G 2.36E-07 Inflammatory biomarkers / / 22291609 rs6028074 chr20 59791971 C G 2.37E-07 Inflammatory biomarkers / / 22291609 rs11697871 chr20 59794039 T C 2.55E-07 Inflammatory biomarkers / / 22291609 rs6065074 chr20 59796217 G T 3.11E-07 Inflammatory biomarkers / / 22291609 rs6015934 chr20 59800060 G A 3.70E-07 Inflammatory biomarkers / / 22291609 rs6513566 chr20 59800109 A C 5.29E-08 Inflammatory biomarkers / / 22291609 rs1891490 chr20 59803161 T C 1.70E-07 Inflammatory biomarkers / / 22291609 rs17204046 chr20 59803632 A G 6.08E-04 Multiple complex diseases / / 17554300 rs2866004 chr20 59825042 G A 3.22E-04 Suicide attempts in bipolar disorder / / 21423239 rs2866004 chr20 59825042 G A 8.32E-07 Inflammatory biomarkers / / 22291609 rs3752252 chr20 59829847 C T 3.42E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs6065080 chr20 59832791 T C 4.48E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs6101282 chr20 59834206 G A 6.91E-04 Type 2 diabetes CDH4 intron 17463246 rs6101282 chr20 59834206 G A 8.66E-05 Acute lymphoblastic leukemia (childhood) CDH4 intron 22076464 rs6101282 chr20 59834206 G A 1.82E-04 Response to taxane treatment (placlitaxel) CDH4 intron 23006423 rs6101283 chr20 59834496 G A 1.82E-04 Response to taxane treatment (placlitaxel) CDH4 intron 23006423 rs6101284 chr20 59836389 A G 3.08E-04 Response to taxane treatment (placlitaxel) CDH4 intron 23006423 rs4812290 chr20 59847088 C T 9.57E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CDH4 intron 21844884 rs1970546 chr20 59853938 A G 4.00E-08 Volumetric brain MRI CDH4 intron 17903297 rs2427045 chr20 59871744 G A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes CDH4 intron 22628534 rs2427059 chr20 59877362 C T 9.67E-04 Multiple complex diseases CDH4 intron 17554300 rs2427064 chr20 59881271 G A 9.37E-04 Alzheimer's disease CDH4 intron 22005930 rs6028103 chr20 59886152 C T 4.27E-07 Delayed encephalopathy in acute carbon monoxide poisoning CDH4 intron 24265751 rs6028103 chr20 59886152 C T 5.09E-07 Delayed encephalopathy in acute carbon monoxide poisoning CDH4 intron 24265751 rs6101320 chr20 59913132 T C 1.40E-04 Myocardial Infarction CDH4 intron pha002883 rs6015950 chr20 59917078 G A 2.68E-05 Fibrinogen CDH4 intron pha003068 rs6513576 chr20 59919026 C T 1.18E-04 Nonalcoholic fatty liver disease CDH4 intron 21423719 rs4468878 chr20 59928237 T C 1.00E-06 Longevity CDH4 intron 20834067 rs4925189 chr20 59947044 G A 6.00E-07 T-tau levels CDH4 intron 20932310 rs8121037 chr20 59957189 T C 1.82E-05 Brain derived neurotrophic factor levels,in serum CDH4 intron 22047184 rs6061663 chr20 59967785 T C 7.50E-06 Urinary metabolites CDH4 intron 21572414 rs6061302 chr20 59972542 C T 5.39E-04 Insulin resistance CDH4 intron 21901158 rs6061722 chr20 59975048 T C 2.80E-05 Bipolar disorder and schizophrenia CDH4 intron 20889312 rs1892318 chr20 59988069 C T 9.10E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2252678 chr20 59989639 A G 7.60E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2243584 chr20 59990283 G A 7.09E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs913551 chr20 59995678 C G 5.50E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs6089292 chr20 59997046 G C 7.64E-04 Acute lung injury CDH4 intron 22295056 rs6089293 chr20 59998158 T C 4.75E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs6121849 chr20 60000028 T C 8.71E-04 Type 2 diabetes CDH4 intron 17463246 rs2427093 chr20 60001676 G C 6.25E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs1892313 chr20 60003420 G A 1.19E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2427094 chr20 60005225 A G 5.84E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2246588 chr20 60008995 T C 5.55E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2282017 chr20 60009130 A G 5.59E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs932878 chr20 60009487 C G 1.39E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs6089621 chr20 60011357 T G 6.40E-04 Type 2 diabetes CDH4 intron 17463246 rs6089314 chr20 60012172 G A 5.48E-04 Type 2 diabetes CDH4 intron 17463246 rs2427098 chr20 60012799 C T 3.92E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs6089629 chr20 60012863 C T 5.44E-04 Type 2 diabetes CDH4 intron 17463246 rs6061412 chr20 60013601 T C 4.25E-04 Lung function (forced vital capacity) CDH4 intron 24023788 rs1891779 chr20 60014775 T C 3.81E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs1892310 chr20 60014957 T A 2.45E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2427101 chr20 60018673 G T 1.87E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2427102 chr20 60020278 G T 1.56E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs1892309 chr20 60020347 G A 1.27E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs1892308 chr20 60020573 A G 1.50E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2427103 chr20 60020866 T C 1.62E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2427104 chr20 60022160 T C 7.88E-05 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs6062092 chr20 60022733 C A 1.10E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs4925349 chr20 60023530 A G 8.51E-05 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2427106 chr20 60026047 G A 4.94E-05 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2427107 chr20 60026354 T C 5.04E-05 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs1536773 chr20 60026374 T C 8.28E-05 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs1969973 chr20 60026447 T C 4.69E-05 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2427111 chr20 60034954 A G 5.10E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2427112 chr20 60035378 C G 4.79E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2149481 chr20 60053234 T C 3.35E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2245193 chr20 60056415 T C 4.73E-05 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2427134 chr20 60065771 A G 4.38E-05 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs6089403 chr20 60073326 T C 4.55E-05 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2427141 chr20 60080305 C T 8.02E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2427142 chr20 60080431 G A 3.88E-05 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs1571433 chr20 60082582 A G 2.55E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2427144 chr20 60082886 T A 9.54E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs1361855 chr20 60085676 G A 5.42E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2427145 chr20 60086218 T G 7.31E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2427146 chr20 60086318 C T 6.16E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2427147 chr20 60086778 T C 5.90E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2225224 chr20 60087082 C T 5.92E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2427153 chr20 60090382 G C 3.78E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs2427158 chr20 60091406 A G 3.83E-04 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs767725 chr20 60097129 A G 2.23E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) CDH4 intron 23648065 rs6061265 chr20 60098515 C T 9.75E-05 Suicide attempts in bipolar disorder CDH4 intron 21423239 rs116896199 chr20 60106873 A G 5.00E-06 Bipolar disorder (body mass index interaction) CDH4 intron 24322204 rs6061641 chr20 60139227 C A 1.80E-04 Endometriosis CDH4 intron 21151130 rs2185916 chr20 60147860 T C 4.52E-04 Coronary Artery Disease CDH4 intron 17634449 rs6121731 chr20 60204905 T C 9.94E-04 Multiple complex diseases CDH4 intron 17554300 rs6121731 chr20 60204905 T C 4.18E-05 Bipolar disorder and schizophrenia CDH4 intron 20889312 rs2024714 chr20 60212494 C T 3.42E-04 Multiple complex diseases CDH4 intron 17554300 rs2024714 chr20 60212494 C T 1.00E-06 Longevity CDH4 intron 20834067 rs2427216 chr20 60214214 C A 3.36E-07 Sarcoidosis CDH4 intron 19165924 rs2427216 chr20 60214214 C A 6.56E-05 Bipolar disorder and schizophrenia CDH4 intron 20889312 rs2236414 chr20 60239507 C T 5.86E-05 Heart Rate CDH4 intron pha003053 rs944260 chr20 60243411 G A 2.00E-06 Sudden cardiac arrest CDH4 intron 21658281 rs1122269 chr20 60243836 C T 1.78E-04 Response to cytidine analogues (gemcitabine) CDH4 intron 24483146 rs4925193 chr20 60256090 T C 1.70E-05 Urinary metabolites CDH4 intron 21572414 rs4925269 chr20 60258466 G A 9.20E-06 Urinary metabolites CDH4 intron 21572414 rs16985437 chr20 60258851 G A 3.00E-06 Axial length CDH4 intron 24144296 rs6061309 chr20 60259549 G C 4.32E-06 Axial length CDH4 intron 24144296 rs11906745 chr20 60290716 A G 3.00E-04 Gamma gluatamyl transferase levels (interaction with age) CDH4 intron 22010049 rs16985493 chr20 60293563 G A 4.00E-06 Migraine - clinic-based CDH4 intron 23793025 rs4925275 chr20 60294279 A G 6.50E-05 Response to statin therapy CDH4 intron 20339536 rs2183432 chr20 60294651 C T 3.80E-05 Response to statin therapy CDH4 intron 20339536 rs6061766 chr20 60297659 C T 7.60E-05 Response to statin therapy CDH4 intron 20339536 rs6061784 chr20 60315878 T C 7.95E-04 Major depressive disorder CDH4 intron 22472876 rs7267604 chr20 60317511 G A 7.93E-04 Depression (quantitative trait) CDH4 intron 20800221 rs6142849 chr20 60327870 G A 7.76E-04 Type 2 diabetes CDH4 intron 17463246 rs6142849 chr20 60327870 G A 1.68E-04 Smoking initiation CDH4 intron 24665060 rs6061348 chr20 60333233 C T 1.00E-04 Brain size CDH4 intron 22156575 rs1539470 chr20 60338466 A C 4.30E-05 Major depressive disorder CDH4 intron 21042317 rs12480265 chr20 60338514 C T 8.69E-04 Insulin resistance CDH4 intron 21901158 rs6061808 chr20 60339580 C G 2.49E-04 Height CDH4 intron 17255346 rs6061808 chr20 60339580 C G 6.03E-04 Multiple complex diseases CDH4 intron 17554300 rs34937312 chr20 60348084 C T 0.000057 Breast cancer CDH4 missense 23555315 rs11907516 chr20 60365079 G A 1.97E-04 Premature ovarian failure CDH4 intron 19508998 rs6061823 chr20 60369585 T C 9.53E-04 Amyotrophic Lateral Sclerosis CDH4 intron 17362836 rs4925295 chr20 60381799 G A 2.00E-06 beta2-Glycoprotein I (beta2-GPI) plasma levels CDH4 intron 23279374 rs1418795 chr20 60394547 G A 2.91E-04 Body mass index CDH4 intron 17255346 rs6061845 chr20 60398804 G A 2.25E-04 Body mass index CDH4 intron 17255346 rs4925203 chr20 60451598 T C 0.0000626 Tuberculosis with early age of onset CDH4 intron 22551897 rs4925203 chr20 60451598 T C 7.40E-05 Heart Rate CDH4 intron pha003053 rs2153932 chr20 60456075 A G 2.93E-05 Heart Rate CDH4 intron pha003053 rs1740362 chr20 60467252 T C 6.94E-04 Type 2 diabetes CDH4 intron 17463246 rs4925207 chr20 60467272 C T 9.44E-05 Psoriasis CDH4 intron 20953190 rs6089556 chr20 60504089 T C 4.73E-04 Nicotine smoking CDH4 intron 19268276 rs6061910 chr20 60508182 G A 1.00E-07 Obesity-related traits CDH4 cds-synon 23251661 rs6061910 chr20 60508182 G A 4.00E-06 Obesity-related traits CDH4 cds-synon 23251661 rs4925325 chr20 60514224 G A 7.00E-06 Obesity-related traits CDH4 UTR-3 23251661 rs17750066 chr20 60576195 T C 6.62E-04 Stroke TAF4 intron pha002887 rs2296086 chr20 60584072 T G 1.30E-16 Progranulin levels TAF4 intron 21087763 rs2296086 chr20 60584072 T G 1.30E-16 Myocardial infarction TAF4 intron 21211798 rs6142922 chr20 60594886 A C 4.54E-04 Alzheimer's disease (late onset) TAF4 intron 21379329 rs7363358 chr20 60668364 T A 1.40E-06 Urinary metabolites / / 21572414 rs6061445 chr20 60741393 A G 4.50E-06 Urinary metabolites SS18L1 intron 21572414 rs6142969 chr20 60749183 C T 2.78E-04 Alcohol dependence SS18L1 intron 20201924 rs6142970 chr20 60750857 C T 1.04E-04 Alcohol dependence SS18L1 intron 20201924 rs13037893 chr20 60760805 A G 3.00E-04 Cognitive impairment induced by topiramate GTPBP5 intron 22091778 rs6062130 chr20 60765422 C T 1.00E-05 Iris characteristics GTPBP5 intron 21835309 rs41284984 chr20 60768573 C T 0.0003 Prostate cancer GTPBP5 missense 23555315 rs6062177 chr20 60842933 A G 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes OSBPL2 intron 22628534 rs4925370 chr20 60867591 A G 8.11E-06 Osteoarthritis OSBPL2 intron 22763110 rs6062210 chr20 60890375 C T 7.67E-04 Multiple complex diseases LAMA5 intron 17554300 rs199776859 chr20 60892077 A C 0.0003 Breast cancer LAMA5 missense 23555315 rs3810550 chr20 60912117 C T 3.24E-04 Type 2 diabetes LAMA5 intron 17463246 rs3810550 chr20 60912117 C T 7.33E-04 Multiple complex diseases LAMA5 intron 17554300 rs4925386 chr20 60921044 T C 2.00E-10 Colorectal cancer LAMA5 intron 20972440 rs4925386 chr20 60921044 T C 6.40E-06 Urinary metabolites LAMA5 intron 21572414 rs2427308 chr20 60969451 C T 3.00E-11 Colorectal cancer CABLES2 intron 24737748 rs1570023 chr20 60986249 T C 4.07E-05 HIV-1 progression to AIDS and death C20orf151 intron 21811574 rs1321353 chr20 61014681 T G 1.28E-07 Red blood cell traits / / 23222517 rs11906647 chr20 61014853 G T 2.80E-05 Urinary metabolites / / 21572414 rs2427345 chr20 61015611 C T 4.00E-08 Prostate cancer / / 23535732 rs2427350 chr20 61019137 T C 3.63E-07 Red blood cell traits / / 23222517 rs6061245 chr20 61044227 T C 9.00E-04 Alcohol dependence GATA5 intron 21314694 rs11204426 chr20 61047465 A G 9.25E-04 Major depressive disorder GATA5 intron 22472876 rs13036466 chr20 61079637 C T 4.24E-04 Alzheimer's disease (late onset) / / 21379329 rs144307950 chr20 61079637 C CATT 4.24E-04 Alzheimer's disease (late onset) / / 21379329 rs75518188 chr20 61079637 C CATT 4.24E-04 Alzheimer's disease (late onset) / / 21379329 rs6062284 chr20 61141981 T G 7.17E-04 Smoking cessation C20orf166-AS1 intron 24665060 rs3934574 chr20 61143487 T C 3.62E-04 Smoking cessation / / 24665060 rs6062275 chr20 61146909 C T 5.91E-04 Multiple complex diseases C20orf166-AS1 intron 17554300 rs4246446 chr20 61158870 T C 5.05E-04 Multiple complex diseases C20orf166 intron 17554300 rs11906462 chr20 61158952 C T 1.84E-05 Hypertension C20orf166 intron pha003042 rs872626 chr20 61290360 C T 3.01E-04 Amyotrophic Lateral Sclerosis SLCO4A1 intron 17362836 rs34985812 chr20 61299525 G A 5.58E-05 Postoperative ventricular dysfunction SLCO4A1 cds-synon 21980348 rs12481701 chr20 61301855 G A 1.01E-04 Amyotrophic Lateral Sclerosis SLCO4A1 intron 17362836 rs4809480 chr20 61307430 G A 2.27E-04 Aortic root size / / 21223598 rs2427379 chr20 61314335 C T 4.70E-05 Parkinson's disease (familial) / / 18985386 rs6010861 chr20 61315002 T A,C,G 4.70E-05 Parkinson's disease (familial) / / 18985386 rs6062833 chr20 61317233 A G 3.79E-04 Type 2 diabetes / / 17463246 rs6062847 chr20 61322018 C T 8.97E-04 Multiple complex diseases / / 17554300 rs6062847 chr20 61322018 C T 2.54E-05 Smoking initiation / / 24665060 rs2427386 chr20 61323883 C T 9.37E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2427399 chr20 61331445 G A 2.20E-05 Urinary metabolites / / 21572414 rs2427402 chr20 61347731 C A 5.59E-04 Response to statin treatment (atorvastatin),change in cholesterol levels NTSR1 intron 20031582 rs34601531 chr20 61351003 C CG 1.02E-06 Phospholipid levels (plasma) NTSR1 intron 21829377 rs397713950 chr20 61351003 C CG 1.02E-06 Phospholipid levels (plasma) NTSR1 intron 21829377 rs7264749 chr20 61351003 C G,T 1.02E-06 Phospholipid levels (plasma) NTSR1 intron 21829377 rs6062957 chr20 61351085 G A 1.56E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) NTSR1 intron 24023788 rs16983213 chr20 61375168 C T 0.000576 Salmonella-induced pyroptosis NTSR1 intron 22837397 rs11907465 chr20 61375576 G A 0.00062 Salmonella-induced pyroptosis NTSR1 intron 22837397 rs11907547 chr20 61376127 G A 0.000449 Salmonella-induced pyroptosis NTSR1 intron 22837397 rs856937 chr20 61385787 A G 2.09E-04 Breast cancer NTSR1 intron pha002853 rs2249938 chr20 61387404 G A 1.52E-04 Breast cancer NTSR1 intron pha002853 rs746192 chr20 61391977 G T 0.00064 Prostate cancer NTSR1 UTR-3 23555315 rs6089784 chr20 61399562 C T 7.85E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6089784 chr20 61399562 C T 7.97E-05 Hypertension / / pha003041 rs6122279 chr20 61424077 C T 6.56E-05 Taste perception / / 22132133 rs6122316 chr20 61447759 T C 1.23E-05 Dengue shock syndrome COL9A3 nearGene-5 22001756 rs6010757 chr20 61467985 C T 3.43E-04 Type 2 diabetes COL9A3 intron 17463246 rs17854409 chr20 61491494 T C 9.00E-06 Obesity-related traits TCFL5 missense 23251661 rs6062729 chr20 61500129 T G 9.50E-06 Urinary metabolites / / 21572414 rs6090149 chr20 61504725 A C 9.48E-04 HIV-1 viral setpoint / / 17641165 rs6090149 chr20 61504725 A C 8.25E-05 Serum metabolites / / 19043545 rs6011456 chr20 61530724 T G 2.00E-16 Progranulin levels DIDO1 intron 21087763 rs6011456 chr20 61530724 T G 2.00E-16 Myocardial infarction DIDO1 intron 21211798 rs6011460 chr20 61532837 G C 4.47E-04 Schizophrenia DIDO1 intron 20832056 rs13040088 chr20 61549202 A G 0.00007238 Sarcoidosis DIDO1 intron 22952805 rs4809436 chr20 61551510 A G 2.10E-05 Urinary metabolites DIDO1 intron 21572414 rs6011478 chr20 61556771 A G 3.83E-04 Schizophrenia DIDO1 intron 20832056 rs12480117 chr20 61558274 G A 0.00001993 Sarcoidosis DIDO1 intron 22952805 rs1052826 chr20 61576777 A G 1.38E-05 Brain structure C20orf11 UTR-3 22504417 rs3746750 chr20 61598899 A G 1.75E-04 Glycemic traits (pregnancy) SLC17A9 UTR-3 23903356 rs1047126 chr20 61599474 C T 5.15E-04 Glycemic traits (pregnancy) SLC17A9 UTR-3 23903356 rs11698778 chr20 61605769 G A 7.12E-05 Glucose levels / / pha003057 rs2277769 chr20 61666805 C T 8.81E-04 Type 2 diabetes LOC63930 intron 17463246 rs6089829 chr20 61669036 A G 3.00E-06 Prostate cancer (gene x gene interaction) LOC63930 intron 22219177 rs4809467 chr20 61671688 A G 2.00E-04 Cognitive impairment induced by topiramate LOC63930 intron 22091778 rs11698703 chr20 61679007 A G 3.76E-05 Attention deficit hyperactivity disorder LOC63930 intron 22420046 rs6062787 chr20 61688888 G T 1.40E-05 Urinary metabolites LOC63930 intron 21572414 rs6011579 chr20 61696594 G A 1.07E-04 Birth weight LOC63930 intron 17255346 rs6062792 chr20 61702029 G A 6.42E-04 Type 2 diabetes LOC63930 intron 17463246 rs4809479 chr20 61702737 C T 2.34E-04 Birth weight LOC63930 intron 17255346 rs12625378 chr20 61705952 G T 9.82E-06 Multiple complex diseases LOC63930 intron 17554300 rs6090223 chr20 61706149 A G 1.49E-05 Multiple complex diseases LOC63930 intron 17554300 rs6011600 chr20 61712990 G A 5.37E-04 Multiple complex diseases LOC63930 intron 17554300 rs910928 chr20 61720769 C T 1.60E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6011613 chr20 61731627 T C 6.66E-05 Cognitive performance HAR1B intron 19734545 rs2313978 chr20 61760067 A G 6.67E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6011674 chr20 61854452 C T 2.00E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6090314 chr20 61857552 G A 0.0000648 Gains in maximal O2 uptake response / / 21183627 rs11908424 chr20 61863955 C T 9.67E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6011696 chr20 61875102 G T 6.82E-04 Response to cytadine analogues (cytosine arabinoside) NKAIN4 intron 24483146 rs1406961 chr20 61895920 A C 5.00E-07 Cardiovascular disease risk factors / / 21779381 rs2273499 chr20 61910270 G A 0.00056 Prostate cancer ARFGAP1 missense 23555315 rs2236196 chr20 61977556 G A 1 Drug response to Nicotine CHR/4 UTR-3 19290018 rs3787138 chr20 61979224 G A 9.26E-04 Suicide attempts in bipolar disorder CHR/4 intron 21423239 rs1044396 chr20 61981134 G A 1 Drug response to Nicotine CHR/4 cds-synon 19290018 rs6011776 chr20 61983756 C T 9.99E-04 Suicide attempts in bipolar disorder CHR/4 intron 21423239 rs755203 chr20 61994264 G A 2.00E-04 Information processing speed CHR/4 nearGene-5 21130836 rs735501 chr20 62000202 T C 4.88E-04 Multiple complex diseases / / 17554300 rs2038442 chr20 62028210 G A 6.00E-05 Type 2 diabetes / / 17463246 rs3746367 chr20 62035103 C T 2.30E-05 Iron levels / / 21208937 rs6062927 chr20 62056013 G A 4.78E-09 Esophageal cancer KCNQ2 intron 21642993 rs4809563 chr20 62077530 C A 4.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNQ2 intron 20877124 rs914464 chr20 62099386 T C 3.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNQ2 intron 20877124 rs310602 chr20 62109170 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6011853 chr20 62111572 T C 3.80E-07 Health and aging,CVD and cancer age of onset / / 22174011 rs6011853 chr20 62111572 T C 8.20E-10 Health and aging,CVD and cancer age of onset / / 22174011 rs2274860 chr20 62126299 C T 6.71E-05 Parent of origin effect on language impairment (maternal) EEF1A2 cds-synon 24571439 rs310619 chr20 62127521 G A 3.83E-04 Smoking initiation EEF1A2 intron 24665060 rs3810481 chr20 62193445 G A 6.00E-05 Upper aerodigestive tract cancers PRIC285 missense 21437268 rs311499 chr20 62217589 T C 3.48E-05 Breast cancer / / 21060860 rs13043255 chr20 62218916 G C 2.72E-04 Major depressive disorder / / 22472876 rs3810492 chr20 62219740 G A 2.20E-04 Major depressive disorder GMEB2 UTR-3 22472876 rs1151621 chr20 62219837 A G 3.49E-04 Body mass index GMEB2 UTR-3 17255346 rs2872810 chr20 62241931 T C 9.68E-04 Multiple complex diseases GMEB2 intron 17554300 rs2872810 chr20 62241931 T C 8.37E-04 Recombination rate GMEB2 intron 21698098 rs6062292 chr20 62264325 G T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6011002 chr20 62297802 A G 3.00E-06 Dental caries RTEL1 intron 23259602 rs6010620 chr20 62309839 A G 3.00E-09 Glioma (high-grade) RTEL1 intron 19578366 rs6010620 chr20 62309839 A G 3.00E-12 Glioma RTEL1 intron 19578367 rs6010620 chr20 62309839 A G 3.00E-12 Nasopharyngeal carcinoma RTEL1 intron 20512145 rs6010620 chr20 62309839 A G 2.00E-09 Glioma RTEL1 intron 21531791 rs6010620 chr20 62309839 A G 3.00E-08 Atopic dermatitis RTEL1 intron 21666691 rs6010620 chr20 62309839 A G 1.00E-10 Glioma RTEL1 intron 22886559 rs6010620 chr20 62309839 A G 5.00E-19 Glioma (high-grade) RTEL1 intron 24908248 rs2297440 chr20 62312299 T C 2.06E-11 Glioma RTEL1 intron 19578367 rs4809324 chr20 62318220 T C 2.00E-09 Glioma (high-grade) RTEL1 intron 19578366 rs4809324 chr20 62318220 T C 2.00E-09 Nasopharyngeal carcinoma RTEL1 intron 20512145 rs2297441 chr20 62327582 G A 1.25E-04 Multiple complex diseases RTEL1 UTR-3 17554300 rs2297441 chr20 62327582 G A 1.30E-09 Crohn's disease RTEL1 UTR-3 18587394 rs2297441 chr20 62327582 G A 2.00E-10 Ulcerative colitis RTEL1 UTR-3 21297633 rs6011040 chr20 62337406 A G 8.92E-05 Multiple complex diseases ARFRP1 intron 17554300 rs6011040 chr20 62337406 A G 9.30E-04 Alzheimer's disease ARFRP1 intron 17998437 rs1291211 chr20 62337622 A G 3.31E-06 Height ARFRP1 intron pha003011 rs6062501 chr20 62341931 T G 1.47E-05 Chronic lymphocytic leukemia ZGPAT intron 24292274 rs3761121 chr20 62342695 T C 0.000145303 Primary sclerosing cholangitis ZGPAT intron 23603763 rs2315008 chr20 62343956 T G 9.00E-15 Inflammatory bowel disease ZGPAT intron 18758464 rs2315008 chr20 62343956 T G 9.00E-15 Multiple sclerosis ZGPAT intron 22190364 rs6062504 chr20 62348907 A G 1.00E-23 Inflammatory bowel disease ZGPAT intron 23128233 rs4809330 chr20 62349586 A G 3.00E-15 Crohn's disease ZGPAT intron 21102463 rs2738758 chr20 62349625 C G 9.12E-04 Type 2 diabetes ZGPAT intron 17463246 rs2738758 chr20 62349625 C G 1.88E-05 Multiple complex diseases ZGPAT intron 17554300 rs2738758 chr20 62349625 C G 2.66E-06 Crohn's disease ZGPAT intron 18587394 rs6062509 chr20 62362563 G T 4.00E-16 Prostate cancer ZGPAT intron 23535732 rs199550529 chr20 62364653 G T 0.00085 Prostate cancer ZGPAT missense 23555315 rs1151625 chr20 62369997 C T 2.02E-05 Height LIME1 missense pha003011 rs2427536 chr20 62372813 G A 2.55E-05 Height SLC2A4RG cds-synon pha003011 rs7273624 chr20 62385479 G A 5.17E-04 Oral cancers (chewing tobacco related) ZBTB46 intron 22503698 rs6011096 chr20 62398015 T C 7.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ZBTB46 intron 20877124 rs6089982 chr20 62401143 C T 4.32E-04 Multiple complex diseases ZBTB46 intron 17554300 rs6062314 chr20 62409713 C T 1.00E-07 Multiple sclerosis ZBTB46 intron 21833088 rs2315656 chr20 62418337 G A 4.00E-06 Obesity-related traits ZBTB46 intron 23251661 rs755017 chr20 62421622 A G 6.71E-09 Telomere length ZBTB46 cds-synon 23535734 rs2281929 chr20 62422080 T C 6.42E-04 Multiple complex diseases ZBTB46 missense 17554300 rs2247297 chr20 62473704 A G 1.50E-04 Acute lung injury C20orf181 intron 22295056 rs2427542 chr20 62482282 C G 1.57E-04 Acute lung injury / / 22295056 rs2427554 chr20 62549565 G A 1.30E-05 Urinary metabolites D/JC5 intron 21572414 rs817362 chr20 62559964 G A 2.02E-04 Tourette syndrome D/JC5 intron 22889924 rs817318 chr20 62586262 T C 1.15E-04 Telomere length UCKL1 intron 23900074 rs817332 chr20 62599612 C T 2.61E-04 Telomere length ZNF512B intron 23900074 rs2427587 chr20 62641209 G A 7.96E-04 Lymphocyte counts PRPF6 intron 22286170 rs2427590 chr20 62642057 T C 2.06E-08 Lymphocyte counts PRPF6 intron 22286170 rs2275292 chr20 62661052 T C 6.50E-06 Carotid intima media thickness PRPF6 intron 21909108 rs816953 chr20 62688359 T C 6.47E-05 Waist-Hip Ratio / / pha003029 rs4377388 chr20 62721250 G C 7.19E-04 Multiple complex diseases OPRL1 intron 17554300 rs2229205 chr20 62729431 C T 2.40E-05 Urinary metabolites OPRL1 cds-synon 21572414 rs6089789 chr20 62731992 T C 9.13E-04 Multiple complex diseases OPRL1 UTR-3 17554300 rs910883 chr20 62739567 A G 9.02E-05 Heart rate / / 23583979 rs116204599 chr20 62741327 G A,T 1.95E-17 Metabolite levels / / 22286219 rs573217 chr20 62776135 A G 4.69E-04 Multiple complex diseases / / 17554300 rs506434 chr20 62779292 T C 8.51E-04 Multiple complex diseases / / 17554300 rs915333 chr20 62780623 G A 2.00E-05 Urinary metabolites / / 21572414 rs3003172 chr20 62786928 G T 9.34E-07 Height / / 20400458 rs3003172 chr20 62786928 G T 9.30E-07 Obesity,menopause / / 21424828 rs745165 chr20 62820660 A C 2.50E-05 Urinary metabolites MYT1 intron 21572414 rs2012987 chr20 62826143 T G 6.18E-06 Scoliosis MYT1 intron 21216876 rs2273443 chr20 62836382 C T 4.40E-04 Alzheimer's disease (late onset) MYT1 intron 21379329 rs148972645 chr20 62838961 A G 0.00053 Breast cancer MYT1 missense 23555315 rs351881 chr20 62843660 C T 2.19E-13 Gender MYT1 intron 22362730 rs912239 chr20 62846531 C T 7.86E-04 Depression (quantitative trait) MYT1 intron 20800221 rs168448 chr20 62852575 A T 1.18E-04 Depression (quantitative trait) MYT1 intron 20800221 rs2015810 chr20 62852930 C T 1.19E-04 Depression (quantitative trait) MYT1 intron 20800221 rs2009307 chr20 62856701 G A 3.89E-04 Depression (quantitative trait) MYT1 intron 20800221 rs2427622 chr20 62860980 A G 5.31E-05 HIV-1 control MYT1 intron 20041166 rs3003146 chr20 62869736 C T 7.12E-04 Smoking initiation MYT1 intron 24665060 rs6011358 chr20 62878881 G A 2.18E-06 Basophils / / pha003087 rs6062356 chr20 62879331 T G 1.30E-06 Basophils / / pha003087 rs17491728 chr20 62894380 G A 3.93E-05 Bipolar disorder PCMTD2 intron 20451256 rs2427636 chr20 62894424 C T 3.81E-05 Bipolar disorder PCMTD2 intron 20451256 rs6062359 chr20 62900380 T G 6.72E-04 Multiple complex diseases PCMTD2 intron 17554300 rs11905831 chr20 62903550 A G 3.17E-04 Smoking initiation PCMTD2 intron 24665060 rs10439884 chr21 10971951 G A 2.00E-06 Celiac disease TPTE intron 23936387 rs240446 chr21 10979098 A C 6.82E-04 Response to taxane treatment (placlitaxel) TPTE intron 23006423 rs456706 chr21 11001104 C T 8.26E-04 Prostate cancer mortality / / 20978177 rs240444 chr21 11002011 T C 9.19E-05 Schizophrenia / / 19571809 rs240444 chr21 11002011 T C 2.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs1148737 chr21 14669931 G A 4.98E-05 Information processing speed / / 21130836 rs41493147 chr21 14760841 G A 7.39E-04 Multiple complex diseases / / 17554300 rs2257224 chr21 14768343 A G 4.70E-04 Type 2 diabetes / / 23209189 rs2257226 chr21 14773232 G T 4.90E-04 Type 2 diabetes / / 23209189 rs468601 chr21 14847294 A G 2.60E-05 Type 2 diabetes / / 17460697 rs2821923 chr21 14914874 G A 7.57E-04 Taste perception / / 22132133 rs7281173 chr21 14945115 T C 8.93E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs115141738 chr21 15166804 G T 1.39E-06 Post-operative nausea and vomiting / / 21694509 rs35082157 chr21 15218287 A AT 1.20E-05 Urinary metabolites C21orf15 intron 21572414 rs7276809 chr21 15292364 T C 6.78E-04 Multiple complex diseases / / 17554300 rs417836 chr21 15336261 A G 2.39E-04 Multiple complex diseases ANKRD20A11P intron 17554300 rs1297083 chr21 15372509 C T 9.21E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1297085 chr21 15373007 A G 4.14E-04 Multiple complex diseases / / 17554300 rs4816223 chr21 15447212 T G 6.30E-06 Urinary metabolites / / 21572414 rs7278400 chr21 15448560 T C 1.20E-05 Urinary metabolites / / 21572414 rs7281927 chr21 15448599 G C 8.90E-06 Urinary metabolites / / 21572414 rs117787046 chr21 15459769 G A 0.00000028 Age-related cataract and Alzheimer's disease (cortical cataract and temporal horn volume) / / 22984439 rs117787046 chr21 15459769 G A 0.000169 Age-related cataract and Alzheimer's disease (cortical cataract) / / 22984439 rs2822404 chr21 15474153 T C 8.19E-04 Depression (quantitative trait) / / 20800221 rs2822404 chr21 15474153 T C 3.17E-04 Heart Failure / / pha002884 rs2403729 chr21 15491560 G A 4.46E-05 Blood Pressure LIPI intron pha003047 rs9980668 chr21 15511035 G A 6.40E-05 Blood Pressure LIPI intron pha003047 rs389468 chr21 15594465 T C 8.53E-05 Prion diseases RBM11 intron 22210626 rs10482851 chr21 15595195 C A 1.30E-05 Urinary metabolites RBM11 intron 21572414 rs393270 chr21 15620391 A C 5.81E-04 Multiple complex diseases / / 17554300 rs2822514 chr21 15628668 G C 1.80E-05 Urinary metabolites / / 21572414 rs372992 chr21 15634304 A G 2.62E-04 Alzheimer's disease (late onset) / / 21379329 rs2822522 chr21 15647431 A C 3.81E-04 Alzheimer's disease (late onset) ABCC13 intron 21379329 rs718670 chr21 15648154 C T 2.34E-04 Coronary heart disease ABCC13 intron 21606135 rs718671 chr21 15648179 A G 3.91E-04 Coronary heart disease ABCC13 intron 21606135 rs2822524 chr21 15648485 G T 5.70E-05 Neuroblastoma ABCC13 intron pha002895 rs2822531 chr21 15650119 G A 3.79E-04 Lung function (forced vital capacity) ABCC13 intron 24023788 rs2822556 chr21 15668384 T C 7.49E-05 Neuroblastoma ABCC13 intron pha002895 rs2822557 chr21 15671024 G A 2.87E-04 Birth weight ABCC13 intron 17255346 rs2822557 chr21 15671024 G A 1.50E-04 Alcohol dependence ABCC13 intron 20201924 rs2822560 chr21 15674632 C T 8.73E-08 Non-word repetition / / 23738518 rs2192161 chr21 15681994 G A 7.00E-08 Non-word repetition / / 23738518 rs1153330 chr21 15684254 G A 2.69E-04 Dental caries / / 21940522 rs909257 chr21 15684554 A G 7.34E-08 Non-word repetition / / 23738518 rs887772 chr21 15685452 T G 2.67E-04 Birth weight / / 17255346 rs887772 chr21 15685452 T G 7.80E-04 Alcohol dependence / / 20201924 rs8131875 chr21 15687493 A G 7.80E-05 Alcohol dependence / / 20201924 rs8131875 chr21 15687493 A G 7.83E-05 Alcoholism / / pha002892 rs9975944 chr21 15688269 C T 2.90E-05 Major depressive disorder / / 21042317 rs2822567 chr21 15692070 C T 4.10E-05 Major depressive disorder / / 21042317 rs1297152 chr21 15693476 T C 4.84E-05 Lipid traits / / 22028671 rs2822572 chr21 15696202 A C 7.30E-05 Birth weight / / 17255346 rs17002266 chr21 15696271 T C 1.09E-07 Non-word repetition / / 23738518 rs2245589 chr21 15697243 A G 2.41E-04 Parkinson's disease / / 16252231 rs12329784 chr21 15705665 C G 9.63E-08 Non-word repetition / / 23738518 rs7283184 chr21 15709414 G A 1.20E-07 Non-word repetition / / 23738518 rs2822582 chr21 15709614 T G 6.10E-04 Alcohol dependence / / 20201924 rs2822584 chr21 15709849 T A 1.44E-07 Non-word repetition / / 23738518 rs2822586 chr21 15710017 T C 6.80E-04 Alcohol dependence / / 20201924 rs2822586 chr21 15710017 T C 7.00E-04 Alcohol dependence / / 20201924 rs12482528 chr21 15710293 C T 6.04E-07 Non-word repetition / / 23738518 rs2822589 chr21 15711540 T C 8.50E-04 Alcohol dependence / / 20201924 rs2178907 chr21 15713544 G A 7.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2178907 chr21 15713544 G A 3.27E-05 Neuroblastoma / / pha002895 rs2822597 chr21 15714072 C T 1.85E-04 Birth weight / / 17255346 rs2822609 chr21 15717794 A T 4.64E-07 Non-word repetition / / 23738518 rs74919661 chr21 15719711 C T 0.00008431 Sarcoidosis / / 22952805 rs2822612 chr21 15720403 A G 5.54E-05 Neuroblastoma / / pha002895 rs2822614 chr21 15720721 C T 3.94E-04 Birth weight / / 17255346 rs2822616 chr21 15722284 G C 2.84E-04 Birth weight / / 17255346 rs2403771 chr21 15728797 G A 1.20E-04 Alzheimer's disease / / 21059989 rs2403771 chr21 15728797 G A 6.20E-06 Alzheimer's disease / / 21059989 rs2822623 chr21 15729775 T C 1.50E-05 Coffee consumption / / 21357676 rs2822633 chr21 15740108 T C 2.37E-05 Major depressive disorder / / 21621269 rs2822637 chr21 15743386 T C 7.10E-04 Taste perception / / 22132133 rs11088017 chr21 15744767 G A 7.10E-04 Taste perception HSPA13 UTR-3 22132133 rs2822661 chr21 15787738 G A 8.45E-04 Taste perception / / 22132133 rs2822662 chr21 15788373 A G 2.22E-04 Taste perception / / 22132133 rs728069 chr21 15800962 C T 1.99E-04 Taste perception / / 22132133 rs6516781 chr21 15816204 A G 1.05E-05 Taste perception / / 22132133 rs9978374 chr21 15819721 C T 7.36E-06 Taste perception / / 22132133 rs34893275 chr21 15821478 T TC,TTC 9.65E-06 Periodontitis (CDC/AAP) / / 24024966 rs2822669 chr21 15830578 C T 5.70E-04 Breast cancer and prostate cancer / / 17903305 rs1006899 chr21 15845052 A G 6.00E-06 Bone mineral density (spine) / / 19079262 rs2822687 chr21 15853435 C T 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2822708 chr21 15871066 T G 1.57E-04 Insulin resistance SAMSN1 intron 21901158 rs3761320 chr21 15884949 A T 9.49E-05 Alzheimer's disease (late onset) SAMSN1 intron 21460841 rs2049857 chr21 15885104 C T 1.02E-04 Alzheimer's disease (late onset) SAMSN1 intron 21460841 rs2822716 chr21 15890874 G A 2.92E-05 Alzheimer's disease (late onset) SAMSN1 intron 21460841 rs760345 chr21 15893594 T C 2.59E-05 Alzheimer's disease (late onset) SAMSN1 intron 21460841 rs1882911 chr21 15894278 G A 1.67E-05 Alzheimer's disease (late onset) SAMSN1 intron 21460841 rs8132898 chr21 15894980 T C 1.67E-05 Alzheimer's disease (late onset) SAMSN1 intron 21460841 rs2822740 chr21 15898864 T C 1.62E-04 Alzheimer's disease (late onset) SAMSN1 intron 21379329 rs2822748 chr21 15899612 G A 4.68E-04 Alzheimer's disease (late onset) SAMSN1 intron 21379329 rs2822752 chr21 15902286 C A 6.94E-05 Alzheimer's disease (late onset) SAMSN1 intron 21460841 rs2822761 chr21 15916134 A G 5.19E-04 Type 2 diabetes SAMSN1 intron 17463246 rs7281104 chr21 15918577 G C 7.93E-04 Type 2 diabetes SAMSN1 cds-synon 17463246 rs7281104 chr21 15918577 G C 8.91E-04 Multiple complex diseases SAMSN1 cds-synon 17554300 rs7281104 chr21 15918577 G C 9.51E-04 Type 2 diabetes SAMSN1 cds-synon 22238593 rs12329657 chr21 15918714 A G 5.18E-04 Type 2 diabetes SAMSN1 intron 17463246 rs2822765 chr21 15921516 A G 5.82E-04 Type 2 diabetes SAMSN1 intron 17463246 rs7282042 chr21 15932610 A G 6.80E-05 Tooth agenesis (maxillary third molar) SAMSN1 intron 24172245 rs760347 chr21 15940389 C T 6.85E-04 Alcohol dependence SAMSN1 intron 21314694 rs2178935 chr21 15942193 A G 9.32E-05 Multiple complex diseases SAMSN1 intron 17554300 rs2822793 chr21 15955911 C T 3.73E-04 Atopy / / 21625490 rs12162546 chr21 15976639 A T 6.59E-06 Type 2 diabetes LOC388813 intron 23300278 rs458959 chr21 16002341 T C 6.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC388813 intron 20877124 rs77774360 chr21 16004875 G A 6.74E-05 Epilepsy (remission after treatment) LOC388813 intron 23962720 rs457165 chr21 16056850 G A 9.13E-05 Birth weight / / 17255346 rs462841 chr21 16056989 C T 2.42E-04 Birth weight / / 17255346 rs462841 chr21 16056989 C T 6.64E-04 Coronary heart disease / / 21971053 rs988831 chr21 16057936 G A 6.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2822835 chr21 16058975 G A 3.55E-05 Calcium levels / / pha003085 rs9979303 chr21 16076956 C T 1.83E-05 Elbow pain / / pha003008 rs2822859 chr21 16083523 A G 1.90E-05 Urinary metabolites / / 21572414 rs2822860 chr21 16084002 C T 1.40E-05 Urinary metabolites / / 21572414 rs2822860 chr21 16084002 C T 2.17E-05 Elbow pain / / pha003008 rs2822861 chr21 16084161 A G 2.39E-05 Elbow pain / / pha003008 rs460014 chr21 16091441 G A 3.30E-06 Urinary metabolites / / 21572414 rs1292735 chr21 16102653 G A 9.33E-04 Type 2 diabetes / / 17463246 rs1292739 chr21 16110191 T G 2.05E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2822881 chr21 16114659 T C 6.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4817371 chr21 16138971 G A,T 4.20E-05 Cognitive performance / / 19734545 rs2822930 chr21 16159601 T C 6.90E-04 Type 2 diabetes / / 17463246 rs2822930 chr21 16159601 T C 3.50E-05 Memory performance / / 22105620 rs2822934 chr21 16168506 G T 4.90E-05 Memory performance / / 22105620 rs13047199 chr21 16205619 A G 5.66E-04 Type 2 diabetes / / 17463246 rs13047199 chr21 16205619 A G 3.00E-05 Memory performance / / 22105620 rs17274666 chr21 16229815 C T 3.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs2822964 chr21 16229925 C T 7.64E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2178998 chr21 16239937 T G 2.09E-04 Aortic root size / / 21223598 rs2822965 chr21 16241868 T C 9.66E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1980424 chr21 16242577 C T 3.11E-26 Narcolepsy / / 19629137 rs6517092 chr21 16273542 A G,T 2.80E-05 Urinary metabolites / / 21572414 rs17274722 chr21 16298530 C T 8.85E-04 Coronary heart disease / / 21606135 rs2253363 chr21 16318226 G A 1.03E-04 Longevity / / 22279548 rs2822986 chr21 16329821 G A 2.62E-05 Cognitive performance / / 19734545 rs2822987 chr21 16330894 T C 8.06E-05 Cognitive performance / / 19734545 rs143359165 chr21 16337963 T A 0.00013 Breast cancer NRIP1 missense 23555315 rs2229741 chr21 16340289 C T 6.00E-07 Cognitive performance NRIP1 cds-synon 19734545 rs13050325 chr21 16343812 A G 8.53E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) NRIP1 intron 24023788 rs4816445 chr21 16346881 T C 7.26E-05 Hemoglobin NRIP1 intron pha003098 rs909388 chr21 16351448 A C 6.67E-05 Colorectal cancer NRIP1 intron 24836286 rs2823025 chr21 16424421 A G 6.38E-06 Type 1 diabetes NRIP1 intron 18978792 rs2823026 chr21 16424469 C T 7.40E-05 Major depressive disorder NRIP1 intron 21042317 rs2142219 chr21 16431542 C T 6.10E-05 Major depressive disorder NRIP1 intron 21042317 rs2142219 chr21 16431542 C T 5.49E-04 Myocardial Infarction NRIP1 intron pha002873 rs2823032 chr21 16440962 C T 8.20E-06 Multiple complex diseases / / 17554300 rs2254152 chr21 16444535 G A 8.44E-06 Multiple complex diseases / / 17554300 rs2254152 chr21 16444535 G A 0.000734613 Hypertension (early onset hypertension) / / 22479346 rs2823036 chr21 16447754 T C 3.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2254729 chr21 16448219 A G 2.15E-05 Multiple complex diseases / / 17554300 rs2243778 chr21 16450918 G A 1.55E-05 Multiple complex diseases / / 17554300 rs975336 chr21 16451845 G A 3.74E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2244105 chr21 16453356 G A 5.05E-04 Hemoglobin concentration / / 20534544 rs2823061 chr21 16481665 G A 2.13E-04 Multiple complex diseases / / 17554300 rs2823068 chr21 16487700 A G 0.000272 Salmonella-induced pyroptosis / / 22837397 rs2026851 chr21 16488347 T C 4.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs41475045 chr21 16489956 A G 1.13E-04 Multiple complex diseases / / 17554300 rs926164 chr21 16513247 A C 4.70E-04 Multiple complex diseases / / 17554300 rs2823093 chr21 16520832 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2823093 chr21 16520832 G A 7.00E-16 Breast cancer / / 23535729 rs2256038 chr21 16521176 G A 6.40E-05 Lipid traits / / 17903299 rs2823097 chr21 16523144 G C 8.00E-05 Lipid traits / / 17903299 rs9974170 chr21 16529628 C T 9.28E-05 Waist Circumference / / pha003023 rs1882961 chr21 16556367 C T 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2823139 chr21 16576783 G A 4.61E-04 Type 2 diabetes / / 17463246 rs1997596 chr21 16578448 C T 9.37E-04 Type 2 diabetes / / 17463246 rs2823144 chr21 16582933 C G 1.83E-04 Type 2 diabetes / / 17463246 rs9808777 chr21 16587477 T C 0.000156065 Hypertension (early onset hypertension) / / 22479346 rs13046557 chr21 16588359 T C 0.000549557 Hypertension (early onset hypertension) / / 22479346 rs2823179 chr21 16600107 T G 7.21E-04 Multiple complex diseases / / 17554300 rs2823204 chr21 16658943 A C 4.89E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2823206 chr21 16661170 C T 3.11E-04 Smoking initiation / / 24665060 rs1882879 chr21 16666163 A G 8.82E-04 Type 2 diabetes / / 17463246 rs722098 chr21 16685598 A G 0.00041 Coronary artery calcification / / 23727086 rs2049882 chr21 16711501 G A 5.08E-05 Cognitive impairment induced by topiramate / / 22091778 rs16982473 chr21 16732004 G T 4.37E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs2823253 chr21 16781136 C A 8.09E-04 Multiple complex diseases / / 17554300 rs2823263 chr21 16790213 T C 1.80E-06 Malaria / / 19465909 rs2242829 chr21 16794579 A T 9.53E-04 Multiple complex diseases / / 17554300 rs1736135 chr21 16805220 T C 5.68E-05 Multiple complex diseases / / 17554300 rs1736135 chr21 16805220 T C 7.00E-09 Crohn's disease / / 18587394 rs1736135 chr21 16805220 T C 2.00E-07 Ulcerative colitis / / 20228799 rs1736135 chr21 16805220 T C 7.00E-09 Asthma / / 21150878 rs1736135 chr21 16805220 T C 7.00E-09 Asthma / / 21907864 rs1736135 chr21 16805220 T C 7.40E-09 Multiple sclerosis / / 22190364 rs972010 chr21 16807029 T C 1.31E-04 Aortic root size / / 21223598 rs991774 chr21 16811110 A G 2.06E-04 Multiple complex diseases / / 17554300 rs1736145 chr21 16811996 T C 3.04E-04 Multiple complex diseases / / 17554300 rs1736020 chr21 16812552 C A 1.10E-04 Multiple complex diseases / / 17554300 rs1736020 chr21 16812552 C A 3.36E-08 Crohn's disease / / 18587394 rs1736020 chr21 16812552 C A 9.00E-12 Crohn's disease / / 21102463 rs1297260 chr21 16812599 C T 2.80E-04 Multiple complex diseases / / 17554300 rs1736023 chr21 16812882 C T 9.76E-04 Multiple complex diseases / / 17554300 rs1736023 chr21 16812882 C T 3.44E-04 Aortic root size / / 21223598 rs1297265 chr21 16817051 A G 7.00E-13 Ulcerative colitis / / 21297633 rs1297267 chr21 16817439 A G 5.10E-06 Urinary metabolites / / 21572414 rs2823286 chr21 16817938 G A 9.00E-30 Inflammatory bowel disease / / 23128233 rs1297268 chr21 16818167 C G 6.10E-06 Urinary metabolites / / 21572414 rs1736159 chr21 16831729 G C 7.70E-06 Urinary metabolites / / 21572414 rs2823295 chr21 16848564 T C 1.42E-05 Leukocyte Counts / / pha003091 rs2823322 chr21 16893032 G A 4.00E-04 Longevity and age-related phenotypes / / 17903295 rs2823324 chr21 16895833 G T 8.35E-05 Parkinson's disease / / 21248740 rs2242838 chr21 16900417 G A 5.08E-05 Parkinson's disease / / 21738487 rs2823357 chr21 16914905 G A 6.00E-07 Parkinson's disease / / 21738487 rs2179030 chr21 16916111 C T 8.91E-07 Parkinson's disease / / 21738487 rs10482872 chr21 16930996 G C 2.16E-29 Varicose Veins / / pha001414 rs16987706 chr21 16993068 G T 8.87E-05 Multiple complex diseases / / 17554300 rs16987706 chr21 16993068 G T 7.44E-05 Panic disorder / / 19165232 rs2823455 chr21 17069166 C T 9.00E-06 Panic disorder / / 19165232 rs2823460 chr21 17086756 A G 6.69E-06 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines / / 21483694 rs459684 chr21 17100275 T C 1.52E-04 Birth weight / / 17255346 rs2026853 chr21 17199289 G A 7.43E-04 Multiple complex diseases USP25 intron 17554300 rs389270 chr21 17295733 T C 7.00E-04 Asperger disorder / / 21182207 rs8129104 chr21 17312072 A G 2.45E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2823529 chr21 17349273 T C 9.90E-05 Interstitial lung disease / / 23583980 rs2823543 chr21 17375633 T C 4.46E-06 Multiple complex diseases / / 17554300 rs2823588 chr21 17432845 T C 2.30E-05 Urinary metabolites / / 21572414 rs1023125 chr21 17435462 A G 1.40E-05 Urinary metabolites / / 21572414 rs16993384 chr21 17445961 C G 5.82E-04 Multiple complex diseases LINC00478 intron 17554300 rs2823602 chr21 17452276 T G 8.40E-07 Urinary metabolites LINC00478 intron 21572414 rs2823606 chr21 17454672 G A 1.31E-06 Obesity-related traits LINC00478 intron 23251661 rs16993505 chr21 17456314 T C 4.27E-04 Multiple complex diseases LINC00478 intron 17554300 rs2823607 chr21 17456613 C A 1.70E-06 Urinary metabolites LINC00478 intron 21572414 rs2823607 chr21 17456613 C A 6.63E-06 Obesity-related traits LINC00478 intron 23251661 rs9975788 chr21 17464815 C T 7.51E-08 Obesity-related traits LINC00478 intron 23251661 rs9983980 chr21 17472366 C T 8.30E-07 Obesity-related traits LINC00478 intron 23251661 rs11088565 chr21 17474231 C T 9.51E-08 Obesity-related traits LINC00478 intron 23251661 rs9978366 chr21 17479278 A C 4.66E-06 Obesity-related traits LINC00478 intron 23251661 rs2823612 chr21 17479553 T C 7.25E-07 Obesity-related traits LINC00478 intron 23251661 rs2823614 chr21 17480892 C A 1.37E-06 Obesity-related traits LINC00478 intron 23251661 rs11909251 chr21 17482387 G T 1.27E-07 Obesity-related traits LINC00478 intron 23251661 rs2823615 chr21 17483133 A T 2.00E-05 Urinary metabolites LINC00478 intron 21572414 rs2823615 chr21 17483133 A T 5.00E-08 Obesity-related traits LINC00478 intron 23251661 rs2823616 chr21 17484058 G A 1.45E-06 Obesity-related traits LINC00478 intron 23251661 rs4818252 chr21 17488119 T C 9.64E-06 Obesity-related traits LINC00478 intron 23251661 rs11088567 chr21 17508670 C G 5.70E-08 Urinary metabolites LINC00478 intron 21572414 rs995078 chr21 17511329 T A 1.50E-06 Urinary metabolites LINC00478 intron 21572414 rs1319028 chr21 17530674 A G 6.62E-05 Personality dimensions LINC00478 intron 18957941 rs2051347 chr21 17563269 C A 1.40E-05 Urinary metabolites LINC00478 intron 21572414 rs238946 chr21 17623086 A G 1.68E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2823692 chr21 17626771 C A 2.25E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2823696 chr21 17627817 A T 3.57E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs239009 chr21 17628003 G A 3.32E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2823697 chr21 17628166 C T 3.57E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs9808741 chr21 17628509 G T 3.50E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2823699 chr21 17628689 T C 3.41E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2823700 chr21 17628793 C G 3.29E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2823702 chr21 17629738 G A 3.25E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs239010 chr21 17630127 G A 3.15E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2823703 chr21 17630926 G C 3.09E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2823704 chr21 17631152 C T 2.97E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2823705 chr21 17631213 G A 2.90E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs1389074 chr21 17631428 T C 2.67E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs1389073 chr21 17631636 T G 2.65E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs1389071 chr21 17631801 A T 2.54E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs4381854 chr21 17631821 T C 2.46E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2823709 chr21 17632364 A G 2.39E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2823710 chr21 17632623 G A 2.28E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs238962 chr21 17632943 C T 6.94E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2823712 chr21 17633092 A G 2.06E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2823713 chr21 17633166 A T 2.01E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2251006 chr21 17633525 C T 1.93E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs4465860 chr21 17633584 T C 1.89E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2823716 chr21 17633793 G A 1.78E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2823717 chr21 17633846 T A 1.76E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs1492957 chr21 17634094 C T 1.82E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2823718 chr21 17634419 A G 1.83E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2823720 chr21 17634706 C A 1.86E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs6517695 chr21 17635519 G T 1.84E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs238964 chr21 17635537 C G 1.82E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2823721 chr21 17635832 A G 1.77E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2823722 chr21 17635956 T C 1.66E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs2823725 chr21 17636991 A T 2.39E-04 Suicide attempts in bipolar disorder LINC00478 intron 21041247 rs11088581 chr21 17640326 A T 6.78E-05 Epilepsy (remission after treatment) LINC00478 intron 23962720 rs1492960 chr21 17640333 T C 6.79E-05 Epilepsy (remission after treatment) LINC00478 intron 23962720 rs2823729 chr21 17640854 G A 8.33E-05 Epilepsy (remission after treatment) LINC00478 intron 23962720 rs239066 chr21 17665589 A C 1.49E-04 Alzheimer's disease (late onset) LINC00478 intron 21379329 rs239066 chr21 17665589 A C 6.03E-05 Post-operative nausea and vomiting LINC00478 intron 21694509 rs2823743 chr21 17667720 T C 1.00E-06 Chronic obstructive pulmonary disease-related biomarkers LINC00478 intron 23144326 rs1449516 chr21 17670775 A G 1.99E-04 Smoking quantity LINC00478 intron 24665060 rs239029 chr21 17709380 T A 4.21E-04 Multiple complex diseases LINC00478 intron 17554300 rs412841 chr21 17734686 C G 9.79E-04 Type 2 diabetes LINC00478 intron 17463246 rs412841 chr21 17734686 C G 5.58E-04 Multiple complex diseases LINC00478 intron 17554300 rs2823756 chr21 17742330 A G 5.73E-06 Blood pressure LINC00478 intron 21378095 rs9982918 chr21 17746754 C A 7.00E-07 Parkinson's disease (interaction with coffee consumption) LINC00478 intron 21876681 rs240462 chr21 17752828 A T 3.25E-04 Multiple complex diseases LINC00478 intron 17554300 rs1449522 chr21 17758842 T C 2.05E-05 Renal cell carcinoma LINC00478 intron 22010048 rs2823771 chr21 17763748 T G 3.64E-04 Multiple complex diseases LINC00478 intron 17554300 rs2823772 chr21 17765128 A T 5.08E-04 Multiple complex diseases LINC00478 intron 17554300 rs17468498 chr21 17767773 A G 3.84E-04 Multiple complex diseases LINC00478 intron 17554300 rs2823779 chr21 17768524 A G 8.87E-04 Suicide attempts in bipolar disorder LINC00478 intron 21423239 rs2823779 chr21 17768524 A G 1.11E-04 Response to radiotherapy in cancer (late toxicity) LINC00478 intron 24785509 rs2823779 chr21 17768524 A G 7.00E-06 Response to radiotherapy in cancer (late toxicity) LINC00478 intron 24785509 rs140918225 chr21 17772069 G GTT 1.07E-04 Suicide attempts in bipolar disorder LINC00478 intron 21423239 rs2596105 chr21 17772069 G T 1.07E-04 Suicide attempts in bipolar disorder LINC00478 intron 21423239 rs1074741 chr21 17774836 G A 0.000775763 Hypertension (early onset hypertension) LINC00478 intron 22479346 rs1900938 chr21 17775056 T C 9.14E-04 Suicide attempts in bipolar disorder LINC00478 intron 21423239 rs6517700 chr21 17777827 C T 1.75E-04 Myocardial Infarction LINC00478 intron pha002883 rs1449518 chr21 17786964 T C 3.49E-04 Suicide attempts in bipolar disorder LINC00478 intron 21423239 rs3737408 chr21 17791751 A G 4.84E-04 Suicide attempts in bipolar disorder LINC00478 intron 21423239 rs11911987 chr21 17800512 G A 4.06E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) LINC00478 intron 24023788 rs2823792 chr21 17807929 G A 4.03E-04 Suicide attempts in bipolar disorder LINC00478 intron 21423239 rs2823806 chr21 17815037 A G 9.69E-04 Type 2 diabetes LINC00478 intron 17463246 rs2823810 chr21 17822099 C T 8.84E-04 Suicide attempts in bipolar disorder LINC00478 intron 21423239 rs2823811 chr21 17823641 T C 8.31E-04 Suicide attempts in bipolar disorder LINC00478 intron 21423239 rs10482880 chr21 17824466 A G 2.04E-09 Pure-tone audiometry LINC00478 intron pha001964 rs10482880 chr21 17824466 A G 1.40E-11 Pure-tone audiometry LINC00478 intron pha001968 rs2039241 chr21 17828046 G A 9.75E-04 Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) LINC00478 intron 24121790 rs2823819 chr21 17828291 A G 7.00E-07 Attention deficit hyperactivity disorder LINC00478 intron 20732626 rs990628 chr21 17832871 G A 5.10E-04 Celiac disease LINC00478 intron 23936387 rs9305769 chr21 17843932 G C 2.22E-04 Multiple complex diseases LINC00478 intron 17554300 rs2039242 chr21 17859658 G A 7.51E-04 Multiple complex diseases LINC00478 intron 17554300 rs7279732 chr21 17868772 G A 8.10E-04 Amyotrophic lateral sclerosis (sporadic) LINC00478 intron 24529757 rs1075080 chr21 18044653 A G 7.31E-05 Alcohol consumption / / pha001399 rs2823962 chr21 18046232 A G 9.00E-06 Amyotrophic lateral sclerosis / / 19451621 rs2823980 chr21 18062714 A C 4.19E-05 Multiple complex diseases / / 17554300 rs2824026 chr21 18122773 G A 4.21E-05 Bipolar disorder and schizophrenia / / 20889312 rs2824026 chr21 18122773 G A 6.68E-05 Bipolar disorder / / 22925353 rs1034120 chr21 18196922 C T 5.56E-05 Breast cancer / / pha002853 rs975184 chr21 18208721 T A 6.14E-04 Multiple complex diseases / / 17554300 rs2824072 chr21 18209387 C T 1.70E-05 Urinary metabolites / / 21572414 rs11088596 chr21 18213908 G A 2.81E-04 Multiple complex diseases / / 17554300 rs2824088 chr21 18217431 A T 2.80E-05 Urinary metabolites / / 21572414 rs13046523 chr21 18217599 A T 6.52E-04 Multiple complex diseases / / 17554300 rs979045 chr21 18221925 C T 3.92E-06 Rheumatoid arthritis / / 19503088 rs421241 chr21 18276053 G A 1.90E-05 Urinary metabolites / / 21572414 rs2824117 chr21 18284079 A C 1.60E-05 Urinary metabolites / / 21572414 rs2243683 chr21 18303271 A G 8.60E-04 Suicide attempts in bipolar disorder / / 21041247 rs7282020 chr21 18304035 C A 4.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs2824148 chr21 18306250 G A 4.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs2824149 chr21 18307704 C T 4.53E-04 Suicide attempts in bipolar disorder / / 21041247 rs11701807 chr21 18308154 T C 4.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs2824177 chr21 18386306 T A 1.98E-05 Sleep duration / / 22105623 rs7278205 chr21 18401879 A G 5.83E-04 Type 2 diabetes / / 17463246 rs2824203 chr21 18425733 T C 5.23E-05 Insulin Resistance / / pha003062 rs2824203 chr21 18425733 T C 7.46E-05 Insulin-related traits / / pha003063 rs2223078 chr21 18431170 C T 4.18E-05 Insulin Resistance / / pha003062 rs2223078 chr21 18431170 C T 7.05E-05 Insulin-related traits / / pha003063 rs7281703 chr21 18452225 T G 6.98E-05 Pulmonary function in asthmatics / / 23541324 rs2824226 chr21 18457828 A G 9.95E-05 Lipid levels / / pha003082 rs2226798 chr21 18485391 T G 6.26E-05 Serum metabolites / / 19043545 rs11088618 chr21 18498426 T A 2.47E-05 Serum metabolites / / 19043545 rs2824265 chr21 18624069 G A 8.27E-06 Type 2 diabetes / / 17463246 rs2824269 chr21 18636290 T C 9.47E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4536738 chr21 18740538 G A 6.70E-05 Blood Pressure / / pha003040 rs208880 chr21 18758843 G A 7.32E-04 Multiple complex diseases / / 17554300 rs2824288 chr21 18780383 C G 4.69E-07 Ventricular fibrillation in acute MI / / 20622880 rs2824289 chr21 18784523 T A 3.33E-07 Ventricular fibrillation in acute MI / / 20622880 rs2824290 chr21 18785657 A G 7.40E-04 Type 2 diabetes / / 17463246 rs2824290 chr21 18785657 A G 3.31E-07 Ventricular fibrillation in acute MI / / 20622880 rs208910 chr21 18786234 T C 4.42E-10 Ventricular fibrillation in acute MI / / 20622880 rs8130544 chr21 18786341 T C 3.22E-07 Ventricular fibrillation in acute MI / / 20622880 rs2824292 chr21 18787176 G A 1.00E-05 Ventricular fibrillation in acute MI / / 20622880 rs2824292 chr21 18787176 G A 3.36E-10 Ventricular fibrillation in acute MI / / 20622880 rs2824292 chr21 18787176 G A 7.40E-05 Ventricular fibrillation in acute MI / / 20622880 rs2824292 chr21 18787176 G A 3.30E-10 Sudden cardiac death / / 21461030 rs2824293 chr21 18787514 G A 3.34E-10 Ventricular fibrillation in acute MI / / 20622880 rs2824294 chr21 18787918 C T 3.61E-08 Ventricular fibrillation in acute MI / / 20622880 rs12483129 chr21 18789166 T C 6.07E-09 Ventricular fibrillation in acute MI / / 20622880 rs1493100 chr21 18791892 A G 6.07E-08 Ventricular fibrillation in acute MI / / 20622880 rs9978331 chr21 18792933 A G 1.35E-08 Ventricular fibrillation in acute MI / / 20622880 rs208918 chr21 18797279 T A 3.57E-07 Ventricular fibrillation in acute MI / / 20622880 rs4818351 chr21 18798755 T C 4.92E-08 Ventricular fibrillation in acute MI / / 20622880 rs13050588 chr21 18799748 C T 4.84E-08 Ventricular fibrillation in acute MI / / 20622880 rs208926 chr21 18800329 C A 5.13E-07 Ventricular fibrillation in acute MI / / 20622880 rs1389158 chr21 18814425 A G 6.34E-17 Gallbladder disease C21orf37 intron pha001404 rs2824317 chr21 18830252 C T 1.47E-05 Platelet counts / / 21507922 rs1967939 chr21 18836316 C A 4.72E-04 Type 2 diabetes / / 17463246 rs2824330 chr21 18857908 G A 1.44E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2824332 chr21 18863967 C T 1.22E-04 Epilepsy / / 22116939 rs2849886 chr21 18864186 T C 3.13E-05 Cardiovascular disease / / pha003065 rs2824333 chr21 18873476 C T 1.76E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs211953 chr21 18890217 G A 8.91E-05 Blood Pressure CXADR intron pha002903 rs2824335 chr21 18900044 C A 4.30E-04 Epilepsy CXADR intron 22116939 rs2249100 chr21 18929744 C A 4.01E-04 Nicotine dependence CXADR intron 17158188 rs2249443 chr21 18932352 G A 5.86E-04 Nicotine dependence CXADR intron 17158188 rs2249449 chr21 18932443 A G 8.56E-04 Nicotine dependence CXADR intron 17158188 rs437470 chr21 18937758 A G 7.69E-04 Stroke (pediatric) CXADR missense 22990015 rs4818362 chr21 18945035 T C 3.90E-04 Smoking cessation CXADR intron 24665060 rs9977638 chr21 18968320 C T 1.86E-04 Longevity BTG3 intron 22279548 rs2824395 chr21 18979968 A C 5.87E-04 Multiple complex diseases BTG3 intron 17554300 rs1389995 chr21 19024565 A C 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2824431 chr21 19040421 T C 4.70E-06 Urinary metabolites / / 21572414 rs7278715 chr21 19042323 G A 3.30E-06 Urinary metabolites / / 21572414 rs2824434 chr21 19044235 G A 1.60E-05 Urinary metabolites / / 21572414 rs1389997 chr21 19046075 G T 1.40E-05 Urinary metabolites / / 21572414 rs728015 chr21 19046753 T C 5.00E-06 Urinary metabolites / / 21572414 rs8130508 chr21 19049865 G A 1.30E-05 Urinary metabolites / / 21572414 rs2824442 chr21 19054808 C G 3.30E-05 Response to statin therapy / / 20339536 rs2824443 chr21 19055599 G A 2.30E-05 Response to statin therapy / / 20339536 rs11702360 chr21 19061797 C T 3.00E-05 Response to statin therapy / / 20339536 rs2824444 chr21 19063194 T C 8.20E-05 Response to statin therapy / / 20339536 rs2824449 chr21 19068204 T A 9.60E-05 Response to statin therapy / / 20339536 rs201108466 chr21 19076449 G GC 7.60E-05 Response to statin therapy / / 20339536 rs2039248 chr21 19076449 G C 7.60E-05 Response to statin therapy / / 20339536 rs34941929 chr21 19076449 G GC 7.60E-05 Response to statin therapy / / 20339536 rs2088116 chr21 19077619 A G 7.40E-05 Response to statin therapy / / 20339536 rs11702277 chr21 19086320 G A 4.50E-05 Response to statin therapy / / 20339536 rs2405643 chr21 19089606 C T 2.80E-05 Response to statin therapy / / 20339536 rs2101523 chr21 19097889 C T 3.80E-06 Urinary metabolites / / 21572414 rs2298404 chr21 19099907 G A 1.10E-06 Urinary metabolites / / 21572414 rs1123018 chr21 19099969 G A 2.00E-06 Urinary metabolites / / 21572414 rs243597 chr21 19158039 C G 6.23E-04 Type 2 diabetes C21orf91-OT1 intron 17463246 rs243597 chr21 19158039 C G 1.06E-07 Lymphocyte counts C21orf91-OT1 intron 22286170 rs173390 chr21 19170566 T G 2.37E-04 Parkinson's disease C21orf91 intron 17052657 rs243556 chr21 19190427 C T 3.08E-05 Intelligence C21orf91 intron 21826061 rs2824502 chr21 19204795 T C 6.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10482890 chr21 19210322 G A 5.20E-04 Type 2 diabetes and 6 quantitative traits CHODL-AS1 intron 17848626 rs2824531 chr21 19254879 G A 3.16E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CHODL-AS1 intron 24023788 rs10482891 chr21 19263991 T C 1.53E-08 Pure-tone audiometry / / pha001964 rs7280675 chr21 19270944 T G 2.84E-07 Common variable immunodeficiency / / 21497890 rs1573440 chr21 19275494 T C 5.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs2824538 chr21 19276031 A G 5.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs2824540 chr21 19278614 A G 4.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs741908 chr21 19285768 T C 6.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs760351 chr21 19286164 A G 6.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs7276331 chr21 19287365 T C 6.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs197581 chr21 19321203 G A 4.91E-04 Smoking initiation CHODL intron 24665060 rs200801 chr21 19333646 G A 1.78E-05 Type 2 diabetes CHODL intron 17668382 rs2254434 chr21 19335631 C T 3.86E-05 Type 2 diabetes CHODL intron 17668382 rs149786 chr21 19338037 A G 3.09E-04 IgE levels CHODL intron 17255346 rs17002246 chr21 19340411 A G 6.98E-04 Multiple complex diseases CHODL intron 17554300 rs1108858 chr21 19352736 A G 7.60E-04 Multiple complex diseases CHODL intron 17554300 rs12483463 chr21 19357790 A G 2.48E-05 Serum metabolites CHODL intron 19043545 rs34637349 chr21 19357790 A AG 2.48E-05 Serum metabolites CHODL intron 19043545 rs150210 chr21 19362312 C T 9.49E-05 Height CHODL intron pha003010 rs158081 chr21 19369001 G A 2.36E-05 Type 2 diabetes CHODL intron 17668382 rs3133060 chr21 19408302 T C 2.79E-04 Lung function (forced expiratory volume in 1 second) CHODL intron 17255346 rs2258385 chr21 19410642 A C 1.30E-04 Lung function (forced expiratory volume in 1 second) CHODL intron 17255346 rs9305836 chr21 19432147 T G 8.14E-04 Multiple complex diseases CHODL intron 17554300 rs157731 chr21 19438152 G A 9.10E-05 Cognitive function CHODL intron 24684796 rs2248200 chr21 19474615 C T 8.85E-05 Systemic sclerosis CHODL intron 21750679 rs1688165 chr21 19474777 A G 8.27E-05 Systemic sclerosis CHODL intron 21750679 rs982274 chr21 19479731 G T 6.00E-06 Amyotrophic lateral sclerosis (sporadic) CHODL intron 24529757 rs2055011 chr21 19481354 G A 9.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) CHODL intron 23648065 rs1491783 chr21 19481895 T C 4.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) CHODL intron 23648065 rs205667 chr21 19492146 T G 0.0000418 Height (Pygmy height) CHODL intron 22570615 rs2150385 chr21 19496036 T C 2.44E-05 Hypertension CHODL intron pha003042 rs2824642 chr21 19504104 C G 1.71E-04 Nicotine smoking CHODL intron 19268276 rs2824643 chr21 19504855 C T 3.10E-05 Response to statins (simvastatin,lovastatin) in NCI60 cancer cell lines CHODL intron 21483694 rs2254058 chr21 19525167 G A 8.93E-05 Height CHODL intron pha003010 rs2254058 chr21 19525167 G A 6.75E-06 Height CHODL intron pha003011 rs2824664 chr21 19528144 T C 3.60E-06 Job-related exhaustion CHODL intron 23620144 rs2824665 chr21 19529714 A G 5.07E-05 Multiple complex diseases CHODL intron 17554300 rs77600076 chr21 19531442 A C 1.00E-06 Bulimia nervosa CHODL intron 23568457 rs2824674 chr21 19536385 G T 1.83E-06 Odorant perception CHODL intron 23910658 rs909258 chr21 19538376 T C 8.94E-05 Cognitive impairment induced by topiramate CHODL intron 22091778 rs11911479 chr21 19541320 T C 2.08E-05 Blood Pressure CHODL intron pha003043 rs2824688 chr21 19552880 A G 2.50E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CHODL intron 20031582 rs8131052 chr21 19557045 C T 2.20E-05 Lung adenocarcinoma CHODL intron 22797724 rs2824695 chr21 19559058 A G 4.89E-04 Nicotine smoking CHODL intron 19268276 rs16998278 chr21 19629160 G A 9.65E-04 Multiple complex diseases CHODL intron 17554300 rs9979144 chr21 19634690 A G 7.43E-05 Cholesterol CHODL intron pha003083 rs10222071 chr21 19661279 A G 4.87E-05 Type 2 diabetes TMPRSS15 intron 22158537 rs2824721 chr21 19670118 G A 4.72E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs10482896 chr21 19674235 C T 1.53E-04 Insulin resistance TMPRSS15 intron 21901158 rs2824724 chr21 19674681 G A 2.97E-04 Lung function (forced expiratory volume in 1 second) TMPRSS15 intron 17255346 rs7277309 chr21 19679960 G C 4.85E-06 Stroke (ischemic) TMPRSS15 intron 22941190 rs11701138 chr21 19683303 G A 1.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TMPRSS15 intron 20877124 rs12483073 chr21 19693464 G C 3.56E-04 Type 2 diabetes TMPRSS15 intron 17463246 rs2244884 chr21 19709819 C T 2.16E-04 Self-reported allergy TMPRSS15 intron 23817569 rs2406176 chr21 19719426 T G 8.86E-12 Meningococcal disease TMPRSS15 intron 20694013 rs2406176 chr21 19719426 T G 2.60E-05 Urinary metabolites TMPRSS15 intron 21572414 rs13052606 chr21 19722546 A C 8.46E-05 Cholesterol TMPRSS15 intron pha003073 rs13052606 chr21 19722546 A C 7.29E-05 Cholesterol TMPRSS15 intron pha003078 rs2824773 chr21 19735401 T C 5.90E-05 Cognitive impairment induced by topiramate TMPRSS15 intron 22091778 rs2824800 chr21 19766366 T C 8.15E-04 Type 2 diabetes TMPRSS15 intron 17463246 rs2824810 chr21 19780942 C G 6.38E-04 Type 2 diabetes / / 17463246 rs2824816 chr21 19791091 A C 3.90E-05 HIV-1 control / / 20041166 rs1735790 chr21 19866130 A G 1.60E-05 Urinary metabolites / / 21572414 rs1740142 chr21 19931541 A G 7.10E-06 Urinary metabolites / / 21572414 rs1735798 chr21 19957049 C A 2.10E-05 Urinary metabolites / / 21572414 rs2824920 chr21 19959365 A C 1.20E-05 Urinary metabolites / / 21572414 rs2824922 chr21 19962484 T C 2.40E-05 Urinary metabolites / / 21572414 rs2824943 chr21 19973214 G T 2.20E-05 Urinary metabolites / / 21572414 rs1569389 chr21 19974397 A C 2.30E-05 Urinary metabolites / / 21572414 rs2824946 chr21 19975066 T C 2.20E-05 Urinary metabolites / / 21572414 rs2824948 chr21 19975775 G A 9.28E-04 Alzheimer's disease / / 17998437 rs981203 chr21 19976671 C G 1.10E-05 Urinary metabolites / / 21572414 rs981204 chr21 19976743 G A 1.00E-05 Urinary metabolites / / 21572414 rs8131098 chr21 19983813 T G 1.50E-05 Urinary metabolites / / 21572414 rs2824960 chr21 19994260 G A 1.10E-05 Urinary metabolites / / 21572414 rs2223140 chr21 19997428 C T 1.00E-05 Urinary metabolites / / 21572414 rs12483031 chr21 20008462 G C 1.30E-05 Urinary metabolites / / 21572414 rs967885 chr21 20023842 C T 9.08E-05 Cognitive performance / / 19734545 rs967885 chr21 20023842 C T 6.95E-05 Waist-Hip Ratio / / pha003013 rs2824976 chr21 20026836 T G 7.60E-05 Cognitive performance / / 19734545 rs2824976 chr21 20026836 T G 5.33E-05 Waist-Hip Ratio / / pha003013 rs8130094 chr21 20039566 T C 9.66E-05 Cognitive performance / / 19734545 rs9975541 chr21 20050573 G A 1.90E-04 Alcohol dependence / / 20201924 rs9975541 chr21 20050573 G A 8.70E-05 Alcohol dependence / / 20201924 rs9975541 chr21 20050573 G A 8.70E-05 Alcoholism / / pha002893 rs2824988 chr21 20051354 C T 8.81E-04 Parkinson's disease / / 16252231 rs2824988 chr21 20051354 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7276233 chr21 20064471 A G 0.000787 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7276233 chr21 20064471 A G 7.87E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2210236 chr21 20066704 C G 4.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs8127439 chr21 20072663 T C 0.0007388 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8127439 chr21 20072663 T C 7.39E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs8133676 chr21 20075866 T C 0.0007326 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs8133676 chr21 20075866 T C 7.33E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2825007 chr21 20077579 A G 0.000719 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2825007 chr21 20077579 A G 7.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2825018 chr21 20082159 T C 0.0006753 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2825018 chr21 20082159 T C 6.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2825021 chr21 20083219 A G 0.0006663 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2825021 chr21 20083219 A G 6.66E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6517829 chr21 20084175 T C 0.0006627 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6517829 chr21 20084175 T C 6.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2210241 chr21 20089406 T C 0.0006484 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2210241 chr21 20089406 T C 6.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2212768 chr21 20091498 C T 0.0006695 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2212768 chr21 20091498 C T 6.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4513371 chr21 20092099 A G 0.0008058 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4513371 chr21 20092099 A G 8.06E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1981379 chr21 20093045 C T 0.0008457 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1981379 chr21 20093045 C T 8.46E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1573443 chr21 20124969 C T 2.06E-04 Epilepsy / / 22116939 rs11700947 chr21 20126875 C T 1.13E-04 Epilepsy / / 22116939 rs9984345 chr21 20133449 T G 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs8129581 chr21 20136039 C T 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2825131 chr21 20174695 A G 7.00E-05 Prostate cancer / / 21743057 rs2825133 chr21 20176411 C T 8.00E-06 Prostate cancer / / 21743057 rs2825137 chr21 20177103 T C 3.01E-04 Type 2 diabetes / / 17463246 rs2825180 chr21 20202332 T C 8.56E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2096973 chr21 20223958 C A 1.90E-05 Urinary metabolites / / 21572414 rs77019609 chr21 20234877 G A 4.70E-05 Epilepsy (remission after treatment) / / 23962720 rs390962 chr21 20260632 C T 6.18E-04 Coronary Artery Disease / / 17634449 rs17002954 chr21 20279481 A G 1.34E-09 Multiple complex diseases / / 17554300 rs2825226 chr21 20282174 G A 4.33E-05 Height / / pha003010 rs9981885 chr21 20330637 A C 1.00E-08 Fasting plasma glucose LOC100505973 intron 19060907 rs2825234 chr21 20332314 G A 7.93E-04 Rheumatoid arthritis LOC100505973 intron 21452313 rs2825240 chr21 20338594 G A 6.04E-04 Type 2 diabetes LOC100505973 intron 17463246 rs376691 chr21 20356538 G A 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2825256 chr21 20363475 T A 9.08E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2825264 chr21 20372569 T G 0.000323 Salmonella-induced pyroptosis / / 22837397 rs2825272 chr21 20391180 G A 0.000326 Salmonella-induced pyroptosis / / 22837397 rs2825300 chr21 20406584 A C 1.99E-04 Stroke / / pha002887 rs7276718 chr21 20407289 T C 3.36E-05 Hypertension (essential hypertension) / / 22184326 rs7281316 chr21 20407327 C A 9.44E-04 Obesity (extreme) / / 21935397 rs2103500 chr21 20407555 T C 8.52E-05 Hypertension / / pha003041 rs2226409 chr21 20468652 C T 6.03E-05 Type 2 diabetes / / 17463246 rs8129059 chr21 20474150 T C 5.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs1475897 chr21 20477026 A G 4.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs17777230 chr21 20517947 C T 6.95E-04 Acute lung injury / / 22295056 rs2825388 chr21 20536649 T A 8.00E-06 Attention deficit hyperactivity disorder symptoms (interaction) / / 18846501 rs2825399 chr21 20548260 C T 5.35E-06 Post-operative nausea and vomiting / / 21694509 rs2825400 chr21 20548365 A C 8.04E-05 Bipolar disorder and schizophrenia / / 20889312 rs6517861 chr21 20598416 G A 3.23E-07 Schizophrenia / / 21926974 rs8134931 chr21 20602286 T A 9.02E-04 Multiple complex diseases / / 17554300 rs2825509 chr21 20673617 T C 7.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs2825544 chr21 20740552 T C 4.85E-07 Alzheimer's disease (late onset) / / 21460841 rs2825544 chr21 20740552 T C 7.78E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs2825556 chr21 20764950 T C 2.86E-04 Lung function (forced vital capacity) / / 24023788 rs2825556 chr21 20764950 T C 3.54E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs723745 chr21 20767350 G A 9.72E-04 Multiple complex diseases / / 17554300 rs2825560 chr21 20773423 T C 1.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs1387616 chr21 20827199 A G 4.69E-04 Hemoglobin concentration / / 20534544 rs1387616 chr21 20827199 A G 5.60E-05 Alcoholism (heaviness of drinking) / / 21529783 rs2825590 chr21 20828514 G A 4.69E-04 Hemoglobin concentration / / 20534544 rs6517876 chr21 20862250 A G 9.94E-05 Suicide attempts in bipolar disorder / / 21423239 rs2825610 chr21 20871584 C A 2.23E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2825610 chr21 20871584 C A 4.10E-05 Lung function (forced vital capacity) / / 24023788 rs963137 chr21 20872085 A T 9.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs2407129 chr21 20878162 A C,G 7.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs4443081 chr21 20878563 T C 4.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs8128156 chr21 20882709 T G 3.30E-06 Urinary metabolites / / 21572414 rs4816799 chr21 20883188 T C 4.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs4816801 chr21 20883323 T A 5.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs8128540 chr21 20883490 C T 4.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs8131462 chr21 20889874 G T 9.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs950700 chr21 20891592 A G 6.87E-04 Multiple complex diseases / / 17554300 rs2017498 chr21 20891682 A C 7.30E-07 Urinary metabolites / / 21572414 rs422621 chr21 20891961 G A 2.70E-06 Urinary metabolites / / 21572414 rs1079827 chr21 20974589 C T 8.27E-05 Type 2 diabetes / / 17463246 rs9977125 chr21 20980235 C T 0.00012 Anxiety Composite (ARBQ) in children / / 23565138 rs11908784 chr21 21000919 A G 9.50E-06 Urinary metabolites / / 21572414 rs2825701 chr21 21014317 T A 1.00E-05 Urinary metabolites / / 21572414 rs2825708 chr21 21020664 A C 1.70E-05 Urinary metabolites / / 21572414 rs1989458 chr21 21035092 A G 1.15E-04 Schizophrenia / / 21674006 rs2825724 chr21 21039806 T C 2.55E-05 Height / / pha003011 rs2825730 chr21 21048041 G A 3.07E-04 Alzheimer's disease (late onset) / / 21379329 rs2825730 chr21 21048041 G A 9.80E-05 Height / / pha003010 rs2825750 chr21 21062011 A G 8.30E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2246513 chr21 21072770 G A 5.86E-05 Femoral neck bone geometry / / 22087292 rs952125 chr21 21098201 A C 4.77E-04 Obesity (extreme) / / 21935397 rs468941 chr21 21173531 C A 1.72E-04 Sarcoidosis / / 19165924 rs2825802 chr21 21177887 T C 4.61E-06 Serum metabolites / / 19043545 rs2825810 chr21 21189775 A G 2.90E-05 Post-operative nausea and vomiting / / 21694509 rs8133473 chr21 21266813 G T 2.29E-05 Height / / pha003011 rs1475873 chr21 21277651 A G 7.11E-04 Schizophrenia / / 19197363 rs2825891 chr21 21289415 T G 8.98E-05 Information processing speed / / 21130836 rs2825925 chr21 21348764 T C 2.00E-05 Urinary metabolites / / 21572414 rs2825926 chr21 21350768 C T 2.70E-05 Type 2 diabetes / / 17463246 rs377685 chr21 21351117 C T 4.53E-04 Type 2 diabetes / / 17463246 rs377685 chr21 21351117 C T 5.76E-04 Multiple complex diseases / / 17554300 rs12482714 chr21 21360856 T C 4.36E-04 Type 2 diabetes / / 17463246 rs78774993 chr21 21371811 G A 0.0000635 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11088770 chr21 21375004 T C 0.0000987 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs2825943 chr21 21388493 A G 2.20E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs17196976 chr21 21390028 C G 3.99E-05 Multiple complex diseases / / 17554300 rs2825957 chr21 21395574 T C 1.47E-04 Vaspin levels / / 22907691 rs2825957 chr21 21395574 T C 0.0001468 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs2825981 chr21 21435148 G A 5.43E-05 Diabetes Mellitus / / pha003060 rs7283906 chr21 21490482 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7283906 chr21 21490482 C T 2.79E-05 Coronary heart disease / / pha003031 rs11910910 chr21 21492291 C T 6.98E-05 Coronary heart disease / / pha003031 rs2212682 chr21 21527469 G T 6.86E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2826064 chr21 21556446 G C 5.21E-04 Alzheimer's disease / / 17998437 rs12626643 chr21 21561404 C A 4.30E-04 Multiple complex diseases / / 17554300 rs12626645 chr21 21561425 C T 6.37E-04 Multiple complex diseases / / 17554300 rs1023373 chr21 21563750 G A 4.08E-05 Coronary heart disease / / pha003031 rs2826078 chr21 21569418 G A 3.55E-04 Multiple complex diseases / / 17554300 rs2826081 chr21 21575587 G A 6.59E-04 Multiple complex diseases / / 17554300 rs2826082 chr21 21575807 G A 3.82E-05 Coronary heart disease / / pha003031 rs2826089 chr21 21585396 G A 7.56E-04 Multiple complex diseases / / 17554300 rs12626280 chr21 21620911 A G 9.66E-05 Diabetes Mellitus / / pha003060 rs2826108 chr21 21630425 C T 6.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs2826111 chr21 21632687 A G 9.64E-04 Type 2 diabetes / / 17463246 rs928862 chr21 21637719 A G 4.00E-05 Major depressive disorder / / 19065144 rs928862 chr21 21637719 A G 6.51E-05 Major depressive disorder (broad) / / 20038947 rs928862 chr21 21637719 A G 2.06E-05 Major depressive disorder / / 21621269 rs928862 chr21 21637719 A G 3.77E-05 Major depressive disorder / / pha002850 rs1487933 chr21 21672002 G C 5.18E-05 Male fertility / / 22633400 rs2826174 chr21 21698075 C T 4.55E-04 Alzheimer's disease / / 17998437 rs2826190 chr21 21714363 T C 3.22E-04 Alzheimer's disease / / 17998437 rs10432923 chr21 21753571 C T 8.02E-04 Alzheimer's disease / / 24755620 rs874320 chr21 21776409 C T 9.02E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1888414 chr21 21777730 T C,G 8.72E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1888414 chr21 21777730 T C,G 2.00E-07 Hippocampal atrophy / / 19668339 rs8133125 chr21 21804099 G A 2.27E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs73223220 chr21 21809632 T C 7.56E-06 Personality dimensions / / 23658558 rs66528304 chr21 21812647 A G 5.93E-06 Personality dimensions / / 23658558 rs67483822 chr21 21812926 G A,C 7.88E-06 Personality dimensions / / 23658558 rs2989314 chr21 21812972 C A 5.61E-05 Age-related macular degeneration / / pha002890 rs73216895 chr21 21815142 A G 7.46E-06 Personality dimensions / / 23658558 rs1735888 chr21 21816449 G C 7.96E-04 Multiple complex diseases / / 17554300 rs1735884 chr21 21820408 C T 4.00E-06 Obesity-related traits / / 23251661 rs1735884 chr21 21820408 C T 4.00E-06 Obesity-related traits / / 23251661 rs1735884 chr21 21820408 C T 7.00E-06 Obesity-related traits / / 23251661 rs2826276 chr21 21835951 A G 3.10E-04 Stroke / / pha002887 rs2826288 chr21 21846633 A G 1.99E-04 Stroke / / pha002887 rs2826340 chr21 21885302 A T 2.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs7279330 chr21 21892531 A G 9.12E-05 Multiple complex diseases / / 17554300 rs7279330 chr21 21892531 A G 3.35E-05 Panic disorder / / 19165232 rs2226805 chr21 21894041 C T 4.59E-04 Smoking initiation / / 24665060 rs17801179 chr21 21900027 A G 2.52E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs4818571 chr21 21903798 A G 2.30E-05 Waist-Hip Ratio / / pha003029 rs2826355 chr21 21905320 C T 7.89E-05 Waist-Hip Ratio / / pha003029 rs2826380 chr21 21920607 C T 8.66E-05 Body Mass Index / / pha003022 rs10470220 chr21 21935399 G T 8.06E-04 Multiple complex diseases / / 17554300 rs229369 chr21 22078587 G A 2.87E-05 Alcohol consumption / / 23743675 rs2128345 chr21 22085847 A G 5.83E-04 Multiple complex diseases / / 17554300 rs2128345 chr21 22085847 A G 8.48E-05 Alcohol consumption / / 23743675 rs463877 chr21 22090256 T C 5.80E-05 Alcohol consumption / / 23743675 rs170676 chr21 22096341 G C 7.50E-05 Alcohol consumption / / 23743675 rs2826489 chr21 22097542 T C 3.08E-05 Cognitive test performance / / 20125193 rs2826494 chr21 22104695 C G 1.90E-13 Response to lithium treatment in bipolar disorder / / 21961650 rs460639 chr21 22125690 T C 9.63E-04 Multiple complex diseases LINC00320 intron 17554300 rs459513 chr21 22127110 T C 1.56E-04 Parkinson's disease LINC00320 intron 21248740 rs2826509 chr21 22145137 A G 9.56E-04 Multiple complex diseases LINC00320 intron 17554300 rs2826520 chr21 22162833 C A 3.20E-05 Homocysteine levels,in plasma LINC00320 intron 19525478 rs13052576 chr21 22165883 A G 0.0007266 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LINC00320 intron 23233654 rs13052576 chr21 22165883 A G 7.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) LINC00320 intron 23233662 rs13048398 chr21 22168229 G T 0.000114 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LINC00320 intron 23233654 rs13048398 chr21 22168229 G T 1.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) LINC00320 intron 23233662 rs2826530 chr21 22186388 T A 9.64E-05 Schizophrenia(age at onset) / / 21688384 rs2826538 chr21 22188735 C T 0.00000593 Preeclampsia / / 22432041 rs9637120 chr21 22200200 G A 3.12E-04 Insulin resistance / / 21901158 rs2826548 chr21 22201791 G A 0.000737 Salmonella-induced pyroptosis / / 22837397 rs2826553 chr21 22205888 A G 8.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs9983966 chr21 22217119 C T 4.50E-04 Type 2 diabetes / / 17463246 rs17003741 chr21 22217810 A G 0.0005108 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17003741 chr21 22217810 A G 5.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2826558 chr21 22219685 G A 8.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs2826563 chr21 22225861 C T 0.0007364 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2826563 chr21 22225861 C T 7.36E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2826564 chr21 22226005 A G 1.18E-04 Body mass index / / 17255346 rs2849925 chr21 22227624 C T 4.44E-05 Intelligence / / 21826061 rs2143655 chr21 22255229 G A 0.0005033 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2143655 chr21 22255229 G A 5.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10482915 chr21 22335508 G A 1.97E-04 Body mass index / / 17255346 rs10482915 chr21 22335508 G A 3.96E-05 Anorexia nervosa / / 24514567 rs2826625 chr21 22341051 G A 5.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7275484 chr21 22348115 A G 9.85E-04 Tourette syndrome / / 22889924 rs2826638 chr21 22349423 T C 1.42E-05 Body mass index / / 17255346 rs2826642 chr21 22355750 G A 3.04E-05 Body mass index / / 17255346 rs7510019 chr21 22371932 G A 1.18E-05 Suicide attempts in bipolar disorder NCAM2 intron 21423239 rs7509723 chr21 22403814 T C 1.89E-04 Multiple complex diseases NCAM2 intron 17554300 rs2826659 chr21 22487854 A C 7.00E-06 Alcohol dependence (age at onset) NCAM2 intron 24962325 rs2826660 chr21 22488414 A G 6.52E-06 Alcohol dependence (age at onset) NCAM2 intron 24962325 rs2245652 chr21 22510239 A G 5.86E-04 Multiple complex diseases NCAM2 intron 17554300 rs2249862 chr21 22607110 G C 9.34E-05 Serum metabolites NCAM2 intron 19043545 rs2826753 chr21 22622666 G A 9.00E-04 Myocardial infarction NCAM2 intron 21107343 rs2826753 chr21 22622666 G A 5.79E-04 Schizophrenia NCAM2 intron 21674006 rs2826756 chr21 22627620 A G 6.07E-04 Alzheimer's disease NCAM2 intron 24755620 rs4605456 chr21 22636834 C T 8.79E-05 Alcoholism NCAM2 intron pha002893 rs8127865 chr21 22643720 A G 5.20E-05 Alcohol dependence NCAM2 intron 20201924 rs8127865 chr21 22643720 A G 8.50E-04 Alcohol dependence NCAM2 intron 20201924 rs8127865 chr21 22643720 A G 5.20E-05 Alcoholism NCAM2 intron pha002893 rs2826767 chr21 22660796 C T 1.90E-05 Corneal structure NCAM2 intron 22003120 rs2826769 chr21 22661749 G A 9.61E-04 Alzheimer's disease NCAM2 intron 24755620 rs7275647 chr21 22665041 C T 6.59E-05 Serum metabolites NCAM2 intron 19043545 rs2218433 chr21 22677774 A G 6.96E-05 Alcoholism NCAM2 intron pha002893 rs7279496 chr21 22679636 C A 8.95E-05 Alcoholism NCAM2 intron pha002893 rs8126935 chr21 22687580 A G 7.53E-05 Alcoholism NCAM2 intron pha002893 rs11088859 chr21 22689344 G A 4.00E-08 Obesity NCAM2 intron 21552555 rs2826803 chr21 22706651 T C 8.21E-05 Age-related macular degeneration NCAM2 intron pha002856 rs3787601 chr21 22794742 G C 2.50E-04 Multiple complex diseases NCAM2 intron 17554300 rs2826833 chr21 22804674 C T 1.70E-05 Parkinson's disease (age of onset) NCAM2 intron 19772629 rs2826840 chr21 22810077 A G 1.00E-04 Asthma (bronchodilator response) NCAM2 intron 22792082 rs9980359 chr21 22835723 G A 5.85E-04 Multiple complex diseases NCAM2 intron 17554300 rs2826851 chr21 22835946 A G 6.40E-04 Type 2 diabetes and 6 quantitative traits NCAM2 intron 17848626 rs2826852 chr21 22836013 A C 9.15E-04 Multiple complex diseases NCAM2 intron 17554300 rs233783 chr21 22883278 A C 1.17E-04 Attention deficit hyperactivity disorder NCAM2 intron 22420046 rs233783 chr21 22883278 A C 1.36E-05 Left ventricular hypertrophy NCAM2 intron pha003052 rs2826877 chr21 22892128 C T 1.54E-04 Atopy NCAM2 intron 21625490 rs13049184 chr21 22896615 T C 0.000087 Uterine leiomyomata NCAM2 intron 23040493 rs2826891 chr21 22910116 C T 1.00E-06 Longevity NCAM2 intron 20834067 rs2826893 chr21 22912031 T C 3.55E-04 Fibrinogen NCAM2 UTR-3 17255346 rs12482461 chr21 22931980 G A 0.0000401 Panic disorder / / 23149450 rs12482461 chr21 22931980 G A 4.01E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs1785683 chr21 22947278 T C 6.45E-05 Erythrocyte counts / / pha003099 rs41499345 chr21 22951400 T G 4.81E-04 Type 2 diabetes / / 17463246 rs10488908 chr21 22982833 A T 2.57E-05 Iron status biomarkers / / 19084217 rs10488909 chr21 22985063 C T 2.03E-04 Response to TNF antagonist treatment / / 21061259 rs2223148 chr21 23035381 G A 4.15E-05 Left ventricular hypertrophy / / pha003052 rs2826940 chr21 23043241 G A 4.06E-05 Left ventricular hypertrophy / / pha003052 rs2826942 chr21 23044990 T C 5.83E-05 Left ventricular hypertrophy / / pha003052 rs1735936 chr21 23077899 A G 9.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs1735970 chr21 23124089 A G 3.50E-05 Amyotrophic lateral sclerosis / / 20801717 rs2014791 chr21 23145950 T C 8.46E-05 Major depressive disorder (broad) / / 20038947 rs8131512 chr21 23149250 A G 2.10E-06 Alcohol and nictotine co-dependence / / 20158304 rs2827029 chr21 23156988 G A 4.89E-04 Coronary heart disease / / 21971053 rs17004006 chr21 23164667 T A 4.44E-05 Kawasaki disease / / 22446961 rs2827039 chr21 23164745 T C 4.01E-05 Serum metabolites / / 19043545 rs2827042 chr21 23170925 T C 7.92E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2245501 chr21 23194676 C T 4.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs2827078 chr21 23196417 G A 7.38E-04 Multiple complex diseases / / 17554300 rs2827082 chr21 23197189 T C 2.21E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2144515 chr21 23232251 T C 2.80E-05 Urinary metabolites / / 21572414 rs2748549 chr21 23234135 G T 2.40E-05 Urinary metabolites / / 21572414 rs7276784 chr21 23245832 C T 2.55E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2827106 chr21 23252543 T C 9.53E-04 Type 2 diabetes / / 17463246 rs7275311 chr21 23266183 A G 2.84E-05 Cognitive test performance / / 20125193 rs7275311 chr21 23266183 A G 7.38E-05 Post-operative nausea and vomiting / / 21694509 rs2827119 chr21 23286889 G T 9.63E-04 Multiple complex diseases / / 17554300 rs2827120 chr21 23287052 T C 2.70E-05 Urinary metabolites / / 21572414 rs2827124 chr21 23287763 G C 2.70E-05 Urinary metabolites / / 21572414 rs2827129 chr21 23291775 C T 0.000096 Migraine / / 22678113 rs2827129 chr21 23291775 C T 9.60E-05 Migraine / / 22683712 rs9983075 chr21 23295913 G C 6.27E-04 Smoking initiation / / 24665060 rs9981165 chr21 23340459 A T 9.06E-05 Tuberculosis / / 20694014 rs8130847 chr21 23340792 T C 0.000866 Salmonella-induced pyroptosis / / 22837397 rs2827182 chr21 23358432 C T 3.10E-04 Alcohol dependence / / 20201924 rs2827182 chr21 23358432 C T 3.30E-04 Alcohol dependence / / 20201924 rs2827186 chr21 23359536 A G 2.43E-05 Serum metabolites / / 19043545 rs6518128 chr21 23372112 C G 3.10E-04 Multiple complex diseases / / 17554300 rs9982805 chr21 23383609 C A 2.60E-05 Attention deficit hyperactivity disorder / / 20732625 rs1892780 chr21 23392840 G T 0.000240692 Hypertension (early onset hypertension) / / 22479346 rs17004107 chr21 23444685 G A 6.76E-27 Narcolepsy / / 19629137 rs4818662 chr21 23445054 C T 0.000259374 Hypertension (early onset hypertension) / / 22479346 rs11701180 chr21 23552204 A G 5.00E-04 Multiple complex diseases / / 17554300 rs9975273 chr21 23555614 G A 5.50E-07 Urinary metabolites / / 21572414 rs2827269 chr21 23556002 A G 2.59E-05 Glucose levels / / pha003058 rs2212382 chr21 23568033 C A 9.24E-05 Hemoglobin / / pha003098 rs2827312 chr21 23631676 G T 8.00E-06 Alcoholism (heaviness of drinking) / / 21529783 rs2827338 chr21 23654246 C A 6.25E-05 Triglycerides / / pha003081 rs1007436 chr21 23655900 C T 8.48E-05 Body Mass Index / / pha003015 rs1007436 chr21 23655900 C T 4.04E-05 Cardiovascular disease / / pha003065 rs2827378 chr21 23674287 A G 6.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs9982275 chr21 23674904 T C 3.47E-04 Multiple complex diseases / / 17554300 rs9974431 chr21 23676678 C T 6.80E-06 Urinary metabolites / / 21572414 rs9306072 chr21 23739048 G C 4.93E-05 Suicide attempts in bipolar disorder / / 21423239 rs2226538 chr21 23750006 A G 9.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs2827441 chr21 23751023 G T 1.61E-05 Suicide attempts in bipolar disorder / / 21423239 rs2827442 chr21 23751295 A G 5.97E-05 Suicide attempts in bipolar disorder / / 21423239 rs2827443 chr21 23751877 A C 2.12E-04 Suicide attempts in bipolar disorder / / 21423239 rs2827446 chr21 23753859 G A 6.62E-05 Suicide attempts in bipolar disorder / / 21423239 rs7364047 chr21 23755408 T G 8.94E-05 Suicide attempts in bipolar disorder / / 21423239 rs2827447 chr21 23758584 C T 1.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs2827448 chr21 23758844 C T 9.37E-05 Suicide attempts in bipolar disorder / / 21423239 rs2827449 chr21 23759285 A G 8.53E-05 Suicide attempts in bipolar disorder / / 21423239 rs2827450 chr21 23759395 C T 8.84E-05 Suicide attempts in bipolar disorder / / 21423239 rs2827451 chr21 23759472 G A 8.88E-05 Suicide attempts in bipolar disorder / / 21423239 rs9975901 chr21 23762017 G A 8.92E-05 Suicide attempts in bipolar disorder / / 21423239 rs9978352 chr21 23762268 G A 8.75E-05 Suicide attempts in bipolar disorder / / 21423239 rs2827454 chr21 23769401 C G 1.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs2827487 chr21 23777228 G A 8.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs2827489 chr21 23777686 T C 5.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs2827491 chr21 23779121 T C 4.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs2827523 chr21 23814121 T C 8.49E-04 Multiple complex diseases / / 17554300 rs2827532 chr21 23822568 C A,G,T 5.17E-04 Multiple complex diseases / / 17554300 rs2088843 chr21 23931687 G T 2.73E-04 Multiple complex diseases / / 17554300 rs12482963 chr21 23972323 C T 6.23E-04 Response to alcohol consumption (flushing response) / / 24277619 rs2827633 chr21 23975186 A C 6.66E-04 Multiple complex diseases / / 17554300 rs2827634 chr21 23975806 G A 5.93E-04 Alcohol dependence / / 24277619 rs9977882 chr21 23986788 T G 2.18E-04 Type 2 diabetes / / 17463246 rs2827649 chr21 24019306 C T 3.17E-05 Cognitive impairment induced by topiramate / / 22091778 rs2827649 chr21 24019306 C T 4.17E-05 Cognitive impairment induced by topiramate / / 22091778 rs2827649 chr21 24019306 C T 9.90E-05 Cognitive impairment induced by topiramate / / 22091778 rs2827652 chr21 24020233 A G 1.99E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2827652 chr21 24020233 A G 7.03E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2827664 chr21 24025905 T C 3.58E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs2827664 chr21 24025905 T C 7.87E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2827669 chr21 24026876 C T 8.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs2827676 chr21 24030707 T C 4.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs978881 chr21 24043069 C T 1.31E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs978881 chr21 24043069 C T 1.39E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs7280372 chr21 24047696 G A 0.00084 Endometrial cancer / / 22426144 rs17004261 chr21 24096305 A G 8.87E-04 Multiple complex diseases / / 17554300 rs724525 chr21 24110833 G A 4.42E-04 Multiple complex diseases / / 17554300 rs183087 chr21 24118504 A T 5.19E-04 Multiple complex diseases / / 17554300 rs41457944 chr21 24137973 T C 9.05E-04 Type 2 diabetes / / 17463246 rs11909052 chr21 24161829 T C 3.39E-05 Multiple complex diseases / / 17554300 rs7279441 chr21 24198815 A G 8.00E-06 Self-rated health / / 20707712 rs2827750 chr21 24231207 T G 3.86E-04 Multiple complex diseases / / 17554300 rs928849 chr21 24246692 A G 1.54E-04 Multiple complex diseases / / 17554300 rs243276 chr21 24253085 T G 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs64727 chr21 24283578 A G 6.48E-04 Acute lung injury / / 22295056 rs716117 chr21 24297622 A G 2.57E-05 Weight / / pha003027 rs716117 chr21 24297622 A G 8.19E-05 C-Reactive Protein / / pha003070 rs2827775 chr21 24313493 C T 5.26E-06 Parkinson's disease / / 17052657 rs2827775 chr21 24313493 C T 3.52E-05 C-Reactive Protein / / pha003070 rs767055 chr21 24333621 G A 9.99E-05 C-Reactive Protein / / pha003070 rs2827784 chr21 24339568 C T 6.44E-06 C-Reactive Protein / / pha003070 rs244181 chr21 24340168 G A 5.27E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12482786 chr21 24344615 T C 1.38E-05 C-Reactive Protein / / pha003070 rs2827800 chr21 24415141 A G 0.0000164 HDL cholesterol particle diameter / / 23263444 rs2827805 chr21 24417865 G A 5.60E-06 Urinary metabolites / / 21572414 rs4816890 chr21 24420502 T G 5.60E-06 Urinary metabolites / / 21572414 rs9983634 chr21 24423306 T C 1.00E-05 Urinary metabolites / / 21572414 rs2827877 chr21 24490947 T C 0.0006916 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2827877 chr21 24490947 T C 6.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2827879 chr21 24492713 C T 0.0005853 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2827879 chr21 24492713 C T 5.85E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2827880 chr21 24499572 A G 0.0004156 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2827880 chr21 24499572 A G 4.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2827883 chr21 24506612 C T 0.0007158 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2827883 chr21 24506612 C T 7.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2827914 chr21 24522393 G A 0.0004291 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2827914 chr21 24522393 G A 4.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2827921 chr21 24525850 T C 0.0004303 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2827921 chr21 24525850 T C 4.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1857853 chr21 24529096 C T 0.0008192 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1857853 chr21 24529096 C T 8.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10084589 chr21 24559181 C T 3.63E-05 Monocyte counts / / pha003089 rs1506011 chr21 24568341 C T 2.33E-08 Non-small cell lung cancer,hypertriglyceridemia with bexarotene treatment of / / 21737656 rs9680422 chr21 24590183 G A 4.56E-04 IgE levels / / 17255346 rs2827965 chr21 24596367 G A 6.19E-04 Smoking quantity / / 24665060 rs2827980 chr21 24602986 A G 5.90E-05 Volumetric brain MRI / / 17903297 rs8131740 chr21 24638106 A G 5.41E-04 Suicide attempts in bipolar disorder / / 21423239 rs1557375 chr21 24639393 T C 3.09E-04 Myopia (pathological) / / 21095009 rs2828003 chr21 24644984 C T 6.75E-05 Smoking initiation / / 24665060 rs2828013 chr21 24656088 T C 7.02E-04 Myopia (pathological) / / 21095009 rs2828019 chr21 24667856 G A 2.20E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13048053 chr21 24672729 G A 7.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2828056 chr21 24691977 T C 9.03E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2828060 chr21 24694861 C T 3.54E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2828099 chr21 24753158 A G 5.00E-05 Insulin response D21S2088E intron 19430760 rs2828104 chr21 24764752 C A 1.86E-05 Cognitive test performance / / 20125193 rs2828104 chr21 24764752 C A 1.52E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1394370 chr21 24768844 G C 4.06E-05 Serum metabolites / / 19043545 rs66857536 chr21 24789556 TC T 5.00E-06 Visceral fat / / 22589738 rs76768891 chr21 24789556 T G 5.00E-06 Visceral fat / / 22589738 rs200705 chr21 24809444 G A 4.06E-04 Smoking initiation / / 24665060 rs2828173 chr21 24836244 A T 4.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs2828176 chr21 24836509 G A 5.53E-05 Lung adenocarcinoma / / 19836008 rs2828183 chr21 24840017 G A 3.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs2828183 chr21 24840017 G A 8.27E-05 Prostate cancer / / 22923026 rs2828200 chr21 24868622 G T 5.74E-04 Heart Failure / / pha002884 rs2226814 chr21 24902400 C T 1.94E-05 Body Mass Index / / pha003006 rs2226814 chr21 24902400 C T 1.50E-05 Waist Circumference / / pha003024 rs2226814 chr21 24902400 C T 4.04E-05 Weight / / pha003026 rs2828234 chr21 24909662 T C 7.17E-04 Multiple complex diseases / / 17554300 rs9984595 chr21 24910072 A G 5.81E-04 Multiple complex diseases / / 17554300 rs7275627 chr21 24937134 T C 1.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs2828264 chr21 24942410 G A 5.97E-05 Waist Circumference / / pha003024 rs2828268 chr21 24944202 C T 6.80E-05 Body Mass Index / / pha003006 rs169476 chr21 25014133 T C 8.62E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2828371 chr21 25022316 G A 1.90E-06 Response to lithium treatment in bipolar disorder / / 19448189 rs2828379 chr21 25027421 A G 6.89E-04 Myocardial Infarction / / pha002873 rs12152057 chr21 25056215 A C 5.96E-04 Alzheimer's disease / / 24755620 rs2828434 chr21 25069439 G T 1.33E-05 Alcohol and nictotine co-dependence / / 20158304 rs7275880 chr21 25111803 T A 5.27E-05 Multiple complex diseases / / 17554300 rs207528 chr21 25137123 T C 3.13E-04 Insulin resistance / / 21901158 rs2828520 chr21 25143119 G A 4.00E-07 Major depressive disorder / / 20125088 rs2040256 chr21 25148252 A G 0.0000677 Panic disorder / / 23149450 rs2040256 chr21 25148252 A G 6.77E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs2828571 chr21 25241468 T G 9.31E-05 Psoriasis / / 18364390 rs2828572 chr21 25241584 C T 3.04E-04 Multiple complex diseases / / 17554300 rs9980781 chr21 25265711 A G 1.54E-04 Multiple complex diseases / / 17554300 rs4816921 chr21 25328443 G A 2.60E-05 Urinary metabolites / / 21572414 rs2828651 chr21 25329955 C A 7.10E-06 Urinary metabolites / / 21572414 rs2828655 chr21 25333108 G C 6.28E-04 Type 2 diabetes / / 17463246 rs2828665 chr21 25353295 G A 1.23E-04 Prion diseases / / 22210626 rs16999214 chr21 25413337 A C 3.22E-04 Type 2 diabetes / / 17463246 rs1910670 chr21 25427744 A C 1.47E-05 Orofacial clefts / / 22419666 rs2253239 chr21 25429900 C T 6.57E-05 Orofacial clefts / / 22419666 rs2844315 chr21 25431019 T G 5.72E-05 Orofacial clefts / / 22419666 rs1783354 chr21 25441897 G A 2.65E-04 IgE levels / / 17255346 rs1783354 chr21 25441897 G A 0.0000405 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1699640 chr21 25448281 A T 6.18E-05 Serum metabolites / / 19043545 rs1699640 chr21 25448281 A T 5.10E-06 Urinary metabolites / / 21572414 rs2019006 chr21 25452702 T C 1.57E-04 Iron levels / / pha002876 rs1910662 chr21 25455176 T C 1.57E-04 Iron levels / / pha002876 rs2040258 chr21 25469662 C T 5.39E-05 Cognitive test performance / / 20125193 rs1613016 chr21 25473817 C T 5.50E-05 Cognitive test performance / / 20125193 rs16999508 chr21 25489609 G T 1.47E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs16999508 chr21 25489609 G T 1.47E-05 White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy / / 24578207 rs2249039 chr21 25490828 G A 5.43E-05 Cognitive test performance / / 20125193 rs2828848 chr21 25506358 A T 1.60E-05 Urinary metabolites / / 21572414 rs2828869 chr21 25522504 C T 4.84E-04 Lung function (forced vital capacity) / / 24023788 rs2828893 chr21 25562298 C T 8.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17398828 chr21 25563034 T G 8.70E-04 Alcohol dependence / / 20201924 rs2828897 chr21 25564985 C T 8.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12482241 chr21 25565589 C T 8.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1910615 chr21 25591285 C A 7.34E-04 Multiple complex diseases / / 17554300 rs979914 chr21 25593955 A G 3.91E-04 Multiple complex diseases / / 17554300 rs979914 chr21 25593955 A G 3.25E-04 Coronary Artery Disease / / 17634449 rs1910608 chr21 25595870 G A 2.30E-05 Urinary metabolites / / 21572414 rs975171 chr21 25599454 T C 4.27E-04 Multiple complex diseases / / 17554300 rs9980488 chr21 25605368 G A 3.17E-04 Multiple complex diseases / / 17554300 rs2828939 chr21 25621896 G C 1.10E-05 Urinary metabolites / / 21572414 rs2828941 chr21 25636605 A G 8.37E-04 Multiple complex diseases / / 17554300 rs7276503 chr21 25662984 T A,G 5.80E-06 Urinary metabolites / / 21572414 rs2828964 chr21 25664495 G T 6.70E-06 Urinary metabolites / / 21572414 rs2572306 chr21 25672493 G A 2.93E-05 Alzheimer's disease (late onset) / / 21379329 rs2829002 chr21 25712819 A G 1.60E-05 Tunica Media / / pha003038 rs2829017 chr21 25738344 T C 9.84E-05 Cognitive impairment induced by topiramate / / 22091778 rs2829037 chr21 25770592 C T 2.87E-05 Cognitive impairment induced by topiramate / / 22091778 rs4816958 chr21 25808101 C T 5.75E-04 Multiple complex diseases / / 17554300 rs16999927 chr21 25839323 G A 9.25E-04 Obesity (extreme) / / 21935397 rs12483406 chr21 25843681 T A 8.84E-04 Obesity (extreme) / / 21935397 rs10482950 chr21 25846325 A G 8.78E-04 Obesity (extreme) / / 21935397 rs2829114 chr21 25856788 T C 8.40E-06 Urinary metabolites / / 21572414 rs2829123 chr21 25860277 G C 1.40E-05 Urinary metabolites / / 21572414 rs2186435 chr21 25884428 A G 3.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11087922 chr21 25889085 T C 3.70E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2829150 chr21 25894735 A C 3.44E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2829152 chr21 25895803 G A 9.17E-04 Type 2 diabetes / / 17463246 rs1543760 chr21 25900251 A T 7.76E-08 Metabolite levels / / 23281178 rs2829156 chr21 25910760 C A 9.08E-05 Neuroblastoma / / pha002895 rs2898057 chr21 25913674 G A 3.46E-04 Multiple complex diseases / / 17554300 rs2829160 chr21 25918589 T G 0.0002 Migraine / / 22678113 rs2226818 chr21 25955673 A G 3.03E-04 Schizophrenia / / 19197363 rs2829215 chr21 26017301 A G 8.83E-04 Intracranial aneurysm / / 20613766 rs2408982 chr21 26017929 C T 2.29E-06 Height / / pha003010 rs2408982 chr21 26017929 C T 1.53E-06 Height / / pha003011 rs2829226 chr21 26024211 A G 2.40E-05 Height / / pha003011 rs2829233 chr21 26029245 C T 2.50E-05 Urinary metabolites / / 21572414 rs17000204 chr21 26031520 T C 2.00E-06 Urinary metabolites / / 21572414 rs16997421 chr21 26032659 C T 7.30E-06 Urinary metabolites / / 21572414 rs2829257 chr21 26058659 G T 7.86E-04 Type 2 diabetes / / 17463246 rs2829267 chr21 26066865 G A 1.42E-04 Type 2 diabetes / / 17463246 rs2829276 chr21 26070727 C T 1.11E-04 Type 2 diabetes / / 17463246 rs2829282 chr21 26077616 T C 6.38E-05 Type 2 diabetes / / 17463246 rs7282401 chr21 26077884 G A 0.000497 Salmonella-induced pyroptosis / / 22837397 rs2829287 chr21 26085506 C T 7.01E-05 Bipolar disorder and schizophrenia / / 20889312 rs2248225 chr21 26085924 T C 4.03E-04 Type 2 diabetes / / 17463246 rs2298518 chr21 26086691 C T 7.57E-05 Waist Circumference / / pha003024 rs8133722 chr21 26086808 A G 0.000464 Salmonella-induced pyroptosis / / 22837397 rs2248339 chr21 26086854 C T 5.37E-04 Type 2 diabetes / / 17463246 rs2829295 chr21 26092453 A G 8.45E-04 Spine bone size / / 23207799 rs2829308 chr21 26105503 G A 7.96E-04 Alzheimer's disease / / 22005930 rs1009930 chr21 26119438 G A 6.65E-05 Attention deficit hyperactivity disorder / / 22420046 rs2829319 chr21 26123945 C A 1.54E-04 Multiple complex diseases / / 17554300 rs2829321 chr21 26124623 A G 3.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs2829322 chr21 26125098 T C 3.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs7283443 chr21 26125665 C T 3.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs2829324 chr21 26126056 C A 3.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs2829332 chr21 26128796 G T 6.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs2829333 chr21 26129541 C G 4.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs7282208 chr21 26130710 G A 4.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs6516631 chr21 26131997 G T 4.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs7275741 chr21 26134774 G A 2.21E-04 Multiple complex diseases / / 17554300 rs2829339 chr21 26136806 A G 2.03E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2829353 chr21 26145156 C A 2.98E-04 Multiple complex diseases / / 17554300 rs10482954 chr21 26145186 A T 7.35E-04 Multiple complex diseases / / 17554300 rs9974711 chr21 26145577 G A 5.32E-04 Multiple complex diseases / / 17554300 rs2829354 chr21 26145781 A G 2.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs2829355 chr21 26147773 A G 9.86E-04 Multiple complex diseases / / 17554300 rs41378746 chr21 26154890 T C 3.46E-04 Multiple complex diseases / / 17554300 rs41462748 chr21 26156907 T C 2.90E-04 Multiple complex diseases / / 17554300 rs2829368 chr21 26158141 C T 1.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs9982565 chr21 26158947 A G 1.08E-04 Suicide attempts in bipolar disorder / / 21423239 rs9974291 chr21 26159695 C G 1.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs2829373 chr21 26163365 C T 7.57E-04 Multiple complex diseases / / 17554300 rs9977282 chr21 26167616 G A,T 3.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs4816988 chr21 26170594 G A 6.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs2829385 chr21 26173210 A G 8.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs2829388 chr21 26174872 C A 6.55E-04 White matter integrity / / 22425255 rs2829428 chr21 26204228 T C 6.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs2829429 chr21 26204697 G A 8.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs11700693 chr21 26215045 C T 1.50E-04 Alcohol dependence LOC339622 intron 20201924 rs11700693 chr21 26215045 C T 5.92E-05 Erythrocyte counts LOC339622 intron pha003099 rs532723366 chr21 26215045 CTCTG C 1.50E-04 Alcohol dependence LOC339622 intron 20201924 rs532723366 chr21 26215045 CTCTG C 5.92E-05 Erythrocyte counts LOC339622 intron pha003099 rs6516643 chr21 26222398 T C 3.40E-04 Alcohol dependence LOC339622 intron 20201924 rs1892727 chr21 26232568 T G 7.99E-05 Serum albumin level LOC339622 intron pha003084 rs2829444 chr21 26242424 G T 4.80E-04 Type 2 diabetes LOC339622 intron 17463246 rs2829447 chr21 26257231 C T 5.50E-04 Parkinson's disease LOC339622 intron 16252231 rs2829447 chr21 26257231 C T 5.67E-29 Metabolite levels LOC339622 intron 22286219 rs2829449 chr21 26263549 T C 8.73E-04 Schizophrenia LOC339622 intron 19197363 rs2829451 chr21 26266638 A G 4.48E-05 Erythrocyte counts LOC339622 intron pha003099 rs2829456 chr21 26273456 T C 4.44E-05 Erythrocyte counts LOC339622 intron pha003099 rs12627329 chr21 26283993 A C 3.96E-05 Erythrocyte counts LOC339622 intron pha003099 rs17770708 chr21 26284664 G A 4.50E-06 Parkinson's disease (age of onset) LOC339622 intron 19772629 rs9636766 chr21 26300382 T C 4.04E-04 Multiple complex diseases LOC339622 intron 17554300 rs2226351 chr21 26337939 A G 1.30E-04 Obesity-related traits LOC339622 intron 17903300 rs17000583 chr21 26340199 A G 2.40E-04 Alcohol dependence LOC339622 intron 20201924 rs928261 chr21 26456343 T C 5.00E-05 Tooth agenesis (maxillary third molar) / / 24172245 rs2829538 chr21 26463074 T C 2.00E-04 Alcohol dependence / / 20201924 rs2829538 chr21 26463074 T C 4.80E-04 Alcohol dependence / / 20201924 rs928263 chr21 26511678 T A 9.36E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs2829588 chr21 26535453 T G 6.86E-05 Coronary heart disease / / pha003055 rs2829621 chr21 26567688 C G 8.22E-04 Depression (quantitative trait) / / 20800221 rs2829629 chr21 26572876 A G 5.66E-04 Depression (quantitative trait) / / 20800221 rs2829634 chr21 26575933 T C 5.79E-04 Depression (quantitative trait) / / 20800221 rs2829636 chr21 26577135 T C 4.76E-04 Depression (quantitative trait) / / 20800221 rs2829638 chr21 26577704 C T 4.78E-04 Depression (quantitative trait) / / 20800221 rs2829643 chr21 26582390 T G 7.80E-05 Cognitive function / / 24684796 rs1543772 chr21 26584284 C A 8.35E-04 Depression (quantitative trait) / / 20800221 rs2829644 chr21 26586324 A G 7.80E-05 Cognitive function / / 24684796 rs2829644 chr21 26586324 A G 5.52E-05 Coronary heart disease / / pha003055 rs2829647 chr21 26596313 T C 2.12E-04 Depression (quantitative trait) / / 20800221 rs2829648 chr21 26596637 T C 8.47E-04 Depression (quantitative trait) / / 20800221 rs12626495 chr21 26609246 C T 2.84E-04 Depression (quantitative trait) / / 20800221 rs11087949 chr21 26610323 G A 6.48E-04 Depression (quantitative trait) / / 20800221 rs11909262 chr21 26612782 T C 4.72E-04 Depression (quantitative trait) / / 20800221 rs2829656 chr21 26616200 T C 5.36E-05 Coronary heart disease / / pha003055 rs2829660 chr21 26622137 G A 6.57E-04 Depression (quantitative trait) / / 20800221 rs2040271 chr21 26625261 T C 7.20E-05 Cognitive function / / 24684796 rs2829662 chr21 26625977 C T 7.20E-05 Cognitive function / / 24684796 rs2829664 chr21 26626573 C G 5.97E-05 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs2829664 chr21 26626573 C G 2.60E-05 Cognitive function / / 24684796 rs2829669 chr21 26628258 C T 4.66E-04 Depression (quantitative trait) / / 20800221 rs2829671 chr21 26630543 C T 5.25E-04 Depression (quantitative trait) / / 20800221 rs2829674 chr21 26635799 C T 1.47E-04 Type 2 diabetes / / 17463246 rs2829675 chr21 26636067 C T 4.64E-04 Depression (quantitative trait) / / 20800221 rs9977253 chr21 26645083 C T 5.00E-06 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2829689 chr21 26674476 C T 5.08E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7283848 chr21 26692371 C A 6.35E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2829700 chr21 26694924 T G 9.38E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2829702 chr21 26699109 A G 5.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2829703 chr21 26699228 A G 5.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2829713 chr21 26705959 T C 8.07E-04 Type 2 diabetes / / 17463246 rs7281863 chr21 26753671 A C 1.66E-04 Type 2 diabetes / / 17846124 rs7281883 chr21 26753727 A C 3.06E-04 Type 2 diabetes / / 17846124 rs7282298 chr21 26753929 C T 4.59E-04 Type 2 diabetes / / 17846124 rs1547233 chr21 26769507 T C 4.03E-04 Colorectal cancer LINC00158 intron 24448986 rs2829729 chr21 26769928 T C 0.0000341 Nicotine dependence (smoking) LINC00158 intron 22377092 rs2829735 chr21 26786307 C A 2.50E-07 Alcohol and nictotine co-dependence LINC00158 intron 22488850 rs547301762 chr21 26786307 C CTGCT 2.50E-07 Alcohol and nictotine co-dependence LINC00158 intron 22488850 rs2829746 chr21 26798089 G A 0.0000393 Nicotine dependence (smoking) LINC00158 intron 22377092 rs1120839 chr21 26814416 G A 0.0000379 Nicotine dependence (smoking) / / 22377092 rs2829750 chr21 26825565 G A 2.58E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs8127977 chr21 26826514 T C 2.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs12483240 chr21 26829777 C T 3.00E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs2829751 chr21 26829787 G C 3.04E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs7276641 chr21 26877698 C T 2.49E-13 Multiple complex diseases / / 17554300 rs17001080 chr21 26908384 T C 5.85E-04 Multiple complex diseases / / 17554300 rs926963 chr21 26920056 T A 5.61E-04 Lymphocyte counts / / 22286170 rs1893650 chr21 26940815 T C 1.00E-04 Cognitive impairment induced by topiramate MIR155HG intron 22091778 rs17001239 chr21 27002377 C T 2.00E-06 Cognitive performance / / 19734545 rs17001239 chr21 27002377 C T 4.07E-04 Smoking initiation / / 24665060 rs763332 chr21 27009778 G A 0.0000903 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2829841 chr21 27023022 C T 0.0000356 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes JAM2 intron 22628534 rs2829854 chr21 27039196 A C 3.76E-05 Smoking initiation JAM2 intron 24665060 rs11087972 chr21 27058726 C T 9.30E-06 Urinary metabolites JAM2 intron 21572414 rs2051180 chr21 27068897 G A 4.40E-06 Urinary metabolites JAM2 intron 21572414 rs2829870 chr21 27078428 T A 5.32E-04 Type 2 diabetes JAM2 intron 17463246 rs10482968 chr21 27135562 C A 2.41E-04 Bulimia nervosa GABPA intron 23568457 rs17001377 chr21 27167993 G A 8.70E-07 Urinary metabolites / / 21572414 rs17001387 chr21 27176172 A G 6.50E-07 Urinary metabolites / / 21572414 rs2226329 chr21 27206617 G A 3.28E-04 Multiple complex diseases / / 17554300 rs2226329 chr21 27206617 G A 2.70E-05 Urinary metabolites / / 21572414 rs2829955 chr21 27233348 C G 9.12E-04 Multiple complex diseases / / 17554300 rs2089242 chr21 27266475 A C 1.10E-05 Urinary metabolites APP intron 21572414 rs7280059 chr21 27271030 A G 2.27E-05 Multiple complex diseases APP intron 17554300 rs7280059 chr21 27271030 A G 1.42E-06 Gallstones APP intron 17632509 rs2829976 chr21 27272474 T G 0.000000512 LDL cholesterol APP intron 23063622 rs2829976 chr21 27272474 T G 3.58E-08 Cholesterol,total APP intron 23063622 rs2829978 chr21 27274368 T C 0.000000049 Cholesterol,total APP intron 23063622 rs2829978 chr21 27274368 T C 1.36E-08 LDL cholesterol APP intron 23063622 rs3827216 chr21 27297266 A C 1.89E-08 Triglycerides APP intron 23063622 rs7279104 chr21 27314770 G A 7.43E-12 Triglycerides APP intron 23063622 rs11087984 chr21 27323003 T A 0.00000234 Triglycerides APP intron 23063622 rs2829996 chr21 27326756 T A 6.78E-04 Multiple complex diseases APP intron 17554300 rs2829997 chr21 27326859 G A 1.00E-05 Prostate cancer APP intron 21743057 rs216762 chr21 27336168 C T 3.56E-05 Cognitive test performance APP intron 20125193 rs3787629 chr21 27337916 T C 7.08E-09 Triglycerides APP intron 23063622 rs9636774 chr21 27339629 C T 0.000000297 Triglycerides APP intron 23063622 rs128648 chr21 27342992 C T 5.06E-04 Type 2 diabetes APP intron 17463246 rs128647 chr21 27343167 G A 2.17E-04 Amyotrophic lateral sclerosis (sporadic) APP intron 24529757 rs7283500 chr21 27343288 T C 3.53E-05 Response to antidepressant treatment (citalopram) APP intron 23726668 rs2096488 chr21 27344189 A C 6.90E-04 Multiple complex diseases APP intron 17554300 rs7276036 chr21 27361704 G A 2.76E-04 Alcohol dependence APP intron 20201924 rs2830026 chr21 27423131 C T 0.00048 Coronary artery calcification APP intron 23727086 rs6516719 chr21 27425323 C T 0.00045 Coronary artery calcification APP intron 23727086 rs2830031 chr21 27429317 C T 4.55E-04 Multiple complex diseases APP intron 17554300 rs9980729 chr21 27441414 C G 5.39E-05 Insulin resistance APP intron 21901158 rs7281821 chr21 27457717 T C 8.43E-06 Insulin resistance APP intron 21901158 rs2830045 chr21 27458409 A G 0.00000631 Alcohol dependence APP intron 23691058 rs2830050 chr21 27464270 A G 8.60E-05 Multiple complex diseases APP intron 17554300 rs2154481 chr21 27473875 C T 0.0002029 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) APP intron 23233654 rs2154481 chr21 27473875 C T 2.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) APP intron 23233662 rs2830054 chr21 27476104 G T 9.60E-05 Temporomandibular joint disorders APP intron 23746317 rs2234988 chr21 27477087 A G 9.42E-06 Multiple complex diseases APP intron 17554300 rs2256331 chr21 27478014 G T 0.0002451 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) APP intron 23233654 rs2256331 chr21 27478014 G T 2.45E-04 Methotrexate clearance (acute lymphoblastic leukemia) APP intron 23233662 rs2830066 chr21 27494202 C T 2.78E-04 Multiple complex diseases APP intron 17554300 rs2830066 chr21 27494202 C T 0.0002239 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) APP intron 23233654 rs2830066 chr21 27494202 C T 2.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) APP intron 23233662 rs2830068 chr21 27496667 T C 3.06E-04 Amyotrophic Lateral Sclerosis APP intron 17827064 rs9984764 chr21 27497497 G A 0.000000114 Cholesterol,total APP intron 23063622 rs9984764 chr21 27497497 G A 0.000000906 HDL cholesterol APP intron 23063622 rs2830073 chr21 27501142 T C 3.51E-04 Multiple complex diseases APP intron 17554300 rs2830075 chr21 27502442 C T 5.38E-05 Multiple complex diseases APP intron 17554300 rs2830076 chr21 27502468 T C 1.15E-04 Multiple complex diseases APP intron 17554300 rs2830077 chr21 27502723 C A 0.0002125 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) APP intron 23233654 rs2830077 chr21 27502723 C A 2.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) APP intron 23233662 rs432766 chr21 27508060 T C 3.57E-04 Multiple complex diseases APP intron 17554300 rs432766 chr21 27508060 T C 0.0002138 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) APP intron 23233654 rs432766 chr21 27508060 T C 2.14E-04 Methotrexate clearance (acute lymphoblastic leukemia) APP intron 23233662 rs16997475 chr21 27508721 G A 9.56E-06 Schizophrenia APP intron 21926974 rs2830086 chr21 27512956 A T 6.19E-05 Multiple complex diseases APP intron 17554300 rs375369 chr21 27514373 G A 7.02E-04 Multiple complex diseases APP intron 17554300 rs375369 chr21 27514373 G A 0.0002102 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) APP intron 23233654 rs375369 chr21 27514373 G A 2.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) APP intron 23233662 rs2830088 chr21 27514740 T C 0.0002133 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) APP intron 23233654 rs2830088 chr21 27514740 T C 2.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) APP intron 23233662 rs2830089 chr21 27515239 C G 0.0002131 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) APP intron 23233654 rs2830089 chr21 27515239 C G 2.13E-04 Methotrexate clearance (acute lymphoblastic leukemia) APP intron 23233662 rs467021 chr21 27517077 A C 0.0002086 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) APP intron 23233654 rs467021 chr21 27517077 A C 2.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) APP intron 23233662 rs2186302 chr21 27520714 T C 5.22E-05 Multiple complex diseases APP intron 17554300 rs2186302 chr21 27520714 T C 7.48E-04 Amyotrophic Lateral Sclerosis APP intron 17827064 rs2154482 chr21 27520931 G T 0.0002121 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) APP intron 23233654 rs2154482 chr21 27520931 G T 2.12E-04 Methotrexate clearance (acute lymphoblastic leukemia) APP intron 23233662 rs12483003 chr21 27522908 T C 0.0002023 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) APP intron 23233654 rs12483003 chr21 27522908 T C 2.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) APP intron 23233662 rs436011 chr21 27527690 C A 1.44E-04 Multiple complex diseases APP intron 17554300 rs368196 chr21 27531267 T C 0.0002039 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) APP intron 23233654 rs368196 chr21 27531267 T C 2.04E-04 Methotrexate clearance (acute lymphoblastic leukemia) APP intron 23233662 rs465235 chr21 27533022 C G 0.0002044 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) APP intron 23233654 rs465235 chr21 27533022 C G 2.04E-04 Methotrexate clearance (acute lymphoblastic leukemia) APP intron 23233662 rs462281 chr21 27537769 A G 2.30E-04 Blood pressure APP intron 17255346 rs466448 chr21 27544108 A G 0.0002287 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100289065 intron 23233654 rs466448 chr21 27544108 A G 2.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100289065 intron 23233662 rs442901 chr21 27546569 G C 0.0002595 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) LOC100289065 intron 23233654 rs442901 chr21 27546569 G C 2.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) LOC100289065 intron 23233662 rs2156079 chr21 27548330 G A 4.43E-04 Multiple complex diseases / / 17554300 rs364106 chr21 27550428 G A 4.05E-04 Blood pressure / / 17255346 rs380207 chr21 27553278 C T 2.08E-04 Blood pressure / / 17255346 rs465353 chr21 27553309 T G 5.98E-04 Multiple complex diseases / / 17554300 rs465353 chr21 27553309 T G 0.0002765 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs465353 chr21 27553309 T G 2.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs463886 chr21 27555072 A G 8.26E-04 Multiple complex diseases / / 17554300 rs457792 chr21 27563105 G A 0.0002792 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs457792 chr21 27563105 G A 2.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs17001793 chr21 27571469 C T 0.0003862 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17001793 chr21 27571469 C T 3.86E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2409168 chr21 27573945 T G 0.0003842 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2409168 chr21 27573945 T G 3.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2409169 chr21 27573984 A G 0.0003833 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2409169 chr21 27573984 A G 3.83E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12627689 chr21 27576519 T C 0.0003766 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12627689 chr21 27576519 T C 3.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs467491 chr21 27597890 C T 3.83E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2830154 chr21 27641865 A T 6.64E-05 Pulmonary function / / 20010835 rs2830155 chr21 27642567 A G 6.68E-05 Pulmonary function / / 20010835 rs2830157 chr21 27644590 C T 9.33E-05 Pulmonary function / / 20010835 rs462390 chr21 27666236 T C 7.48E-05 Intelligence / / 21826061 rs2830165 chr21 27676592 T G 6.49E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs461626 chr21 27677790 G A 9.70E-05 Glucose levels / / pha002899 rs1543651 chr21 27686646 A G 1.10E-05 Urinary metabolites / / 21572414 rs41450451 chr21 27687150 A G 6.60E-06 Urinary metabolites / / 21572414 rs8132767 chr21 27688232 A G 2.50E-05 Urinary metabolites / / 21572414 rs4817105 chr21 27688357 G A 7.29E-04 Type 2 diabetes / / 17463246 rs41417845 chr21 27695987 A G 2.50E-05 Urinary metabolites / / 21572414 rs2212897 chr21 27704308 A G 9.33E-04 Obesity (extreme) / / 21935397 rs13050454 chr21 27706323 G A 4.27E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13050454 chr21 27706323 G A 4.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs976105 chr21 27709447 G C 9.45E-05 Pulmonary function / / 20010835 rs976105 chr21 27709447 G C 4.42E-04 Obesity (extreme) / / 21935397 rs2212898 chr21 27711206 T A 3.87E-05 Pulmonary function / / 20010835 rs2212898 chr21 27711206 T A 4.27E-04 Obesity (extreme) / / 21935397 rs7277841 chr21 27712177 A G,T 3.84E-05 Pulmonary function / / 20010835 rs7277841 chr21 27712177 A G,T 4.27E-04 Obesity (extreme) / / 21935397 rs9975851 chr21 27716654 C T 4.00E-06 Airflow obstruction / / 22837378 rs2117454 chr21 27723281 T C 1.36E-04 Gallbladder cancer / / 22318345 rs10775636 chr21 27725900 T A,C 3.64E-04 Obesity (extreme) / / 21935397 rs219683 chr21 27733586 A G 3.03E-05 Glucose levels / / pha002899 rs219693 chr21 27736992 A G 4.08E-05 Glucose levels / / pha002899 rs219693 chr21 27736992 A G 2.75E-05 Insulin-related traits / / pha002901 rs219710 chr21 27747839 G A,C,T 1.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2830200 chr21 27777778 T C 1.24E-04 Autism spectrum disorders (language delay) / / 21519539 rs2830204 chr21 27780065 C T 2.00E-06 Urinary metabolites / / 21572414 rs1029258 chr21 27788804 A C 5.10E-06 Urinary metabolites / / 21572414 rs150757 chr21 27799401 A G 0.0000034 Amygdala reactivity / / 22856363 rs2830234 chr21 27832331 G T 9.42E-06 Interstitial lung disease / / 23583980 rs191997 chr21 27833284 T A 4.82E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs184357 chr21 27834320 A G 2.84E-04 Multiple complex diseases / / 17554300 rs2830236 chr21 27834624 G C 3.00E-06 Urinary metabolites / / 21572414 rs17002173 chr21 27834679 A G 5.10E-06 Urinary metabolites / / 21572414 rs17002187 chr21 27840793 G A 4.40E-06 Urinary metabolites CYYR1 UTR-3 21572414 rs2830246 chr21 27847903 C T 7.01E-04 Premature ovarian failure CYYR1 intron 19508998 rs6516735 chr21 27861792 G A 5.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CYYR1 intron 20877124 rs219628 chr21 27865420 C T 8.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CYYR1 intron 20877124 rs219628 chr21 27865420 C T 7.49E-05 Height CYYR1 intron pha003011 rs219630 chr21 27865877 C T 5.62E-05 Height CYYR1 intron pha003011 rs219633 chr21 27868059 A G 6.15E-05 Height CYYR1 intron pha003011 rs2830261 chr21 27873895 C T 3.99E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CYYR1 intron 20877124 rs12627243 chr21 27877118 C T 3.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CYYR1 intron 20877124 rs222972 chr21 27878577 C T 4.71E-05 Lung function (forced expiratory volume in 1 second) CYYR1 intron pha003103 rs6516737 chr21 27913147 G A 1.14E-06 Multiple complex diseases CYYR1 intron 17554300 rs395640 chr21 27969859 A G 1.36E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs1605150 chr21 27997671 C T 8.00E-04 Multiple complex diseases / / 17554300 rs366344 chr21 28002707 T C 3.93E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs465446 chr21 28022267 C A 5.79E-04 Response to TNF antagonist treatment / / 21061259 rs465446 chr21 28022267 C A 9.90E-06 Urinary metabolites / / 21572414 rs366384 chr21 28024225 G A 6.50E-06 Urinary metabolites / / 21572414 rs226261 chr21 28031976 T A 4.48E-57 Multiple complex diseases / / 17554300 rs9979305 chr21 28033085 G A 6.36E-04 Multiple complex diseases / / 17554300 rs9984081 chr21 28058794 C G 3.04E-04 Multiple complex diseases / / 17554300 rs2830395 chr21 28063806 A T 8.66E-06 Body mass (lean) / / 19268274 rs2830406 chr21 28069707 A G 4.31E-04 Obesity (extreme) / / 21935397 rs2409191 chr21 28108823 A G 9.29E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs1893577 chr21 28112756 T C 1.63E-06 Pancreatic cancer / / 22158540 rs2830448 chr21 28113180 G T 2.31E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2830457 chr21 28124166 A G 6.02E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2212815 chr21 28127680 C T 6.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9636785 chr21 28132381 T C 1.02E-05 Vascular dementia / / 22116812 rs2830487 chr21 28146189 G A 3.35E-04 Coronary Artery Disease / / 17634449 rs2830487 chr21 28146189 G A 0.000416 Salmonella-induced pyroptosis / / 22837397 rs2830487 chr21 28146189 G A 2.00E-07 Metabolite levels (HVA) / / 23319000 rs2830487 chr21 28146189 G A 5.00E-07 Metabolite levels (HVA-5-HIAA Factor score) / / 23319000 rs2830487 chr21 28146189 G A 3.08E-04 Smoking initiation / / 24665060 rs2830502 chr21 28157754 G A 5.27E-04 Multiple complex diseases / / 17554300 rs2830519 chr21 28162719 A G 6.77E-05 Waist-Hip Ratio / / pha003029 rs457752 chr21 28171749 T C 2.67E-04 Multiple complex diseases / / 17554300 rs457752 chr21 28171749 T C 5.82E-04 Body mass index / / 21701565 rs457864 chr21 28171926 A C 2.78E-06 Esophageal cancer (squamous cell) / / 22960999 rs460420 chr21 28183652 T C 5.29E-04 Multiple complex diseases / / 17554300 rs460420 chr21 28183652 T C 3.96E-04 Body mass index / / 21701565 rs2830544 chr21 28184009 T C 7.47E-04 Body mass index / / 21701565 rs468969 chr21 28191916 A G 7.05E-04 Coronary Artery Disease / / 17634449 rs468522 chr21 28192688 G A 1.83E-04 Coronary Artery Disease / / 17634449 rs2830549 chr21 28204504 T C 4.73E-04 Multiple complex diseases / / 17554300 rs229040 chr21 28207390 A C 5.15E-05 Asthma / / 11022011 rs229040 chr21 28207390 A C 1.16E-04 Multiple complex diseases / / 17554300 rs9636786 chr21 28209494 T C 8.62E-06 Rheumatoid arthritis ADAMTS1 UTR-3 21452313 rs2830551 chr21 28215325 C A 1.12E-04 Attention deficit hyperactivity disorder ADAMTS1 intron pha002875 rs390955 chr21 28218457 A C 3.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs467691 chr21 28286590 G T 2.17E-04 Type 2 diabetes / / 17463246 rs229070 chr21 28290937 G C 8.13E-04 Bipolar disorder ADAMTS5 UTR-3 19259986 rs2830581 chr21 28293800 G A 1.33E-05 Relative hand skill in reading disability ADAMTS5 UTR-3 24068947 rs151065 chr21 28296324 A G 1.88E-04 Type 2 diabetes ADAMTS5 UTR-3 17463246 rs229079 chr21 28298049 A G 2.61E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADAMTS5 intron 20877124 rs226794 chr21 28302355 A G 6.99E-04 Type 2 diabetes ADAMTS5 missense 17463246 rs162496 chr21 28306575 A G 4.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADAMTS5 intron 20877124 rs2249333 chr21 28310174 A T 4.79E-04 Type 2 diabetes ADAMTS5 intron 17463246 rs229053 chr21 28316268 C A 7.53E-05 Post-operative nausea and vomiting ADAMTS5 intron 21694509 rs233896 chr21 28324568 T G 7.00E-05 Iris characteristics ADAMTS5 intron 21835309 rs233598 chr21 28330838 T G 4.99E-04 Multiple complex diseases ADAMTS5 intron 17554300 rs1995097 chr21 28364232 G T 4.28E-05 Hypertension / / 19609347 rs2830609 chr21 28369660 A C 2.17E-05 Relative hand skill in reading disability / / 24068947 rs8127178 chr21 28375679 G A 9.00E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs8127178 chr21 28375679 G A 1.79E-06 Post-operative nausea and vomiting / / 21694509 rs8130700 chr21 28381228 T G 9.78E-05 Triglycerides / / pha003080 rs977152 chr21 28385362 A G 2.99E-05 Post-operative nausea and vomiting / / 21694509 rs4143412 chr21 28395527 G A 6.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs233579 chr21 28403966 G A 6.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1012766 chr21 28407139 A G 4.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs667362 chr21 28407515 G A 5.29E-04 Bipolar disorder,schizoaffective / / 19567891 rs2830643 chr21 28408023 A C 5.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2830657 chr21 28442032 C T 6.13E-04 HIV-1 viral setpoint / / 17641165 rs41432046 chr21 28460820 T C 4.02E-04 Type 2 diabetes / / 17463246 rs10482982 chr21 28472489 A G 5.44E-04 Schizophrenia / / 19197363 rs2830701 chr21 28483361 C T 8.90E-05 Coronary heart disease / / pha003032 rs1537090 chr21 28499343 C T 4.90E-04 Insulin resistance / / 21901158 rs1788312 chr21 28520045 G A 4.86E-04 Type 2 diabetes / / 17463246 rs235944 chr21 28561716 T C 9.41E-04 Type 2 diabetes / / 17846124 rs2830757 chr21 28563495 A C 4.76E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9984025 chr21 28567290 G A 0.000233 Salmonella-induced pyroptosis / / 22837397 rs914130 chr21 28574546 C A 0.000422 Salmonella-induced pyroptosis / / 22837397 rs1351018 chr21 28595178 A G 0.000007865 Sarcoidosis / / 22952805 rs235938 chr21 28596893 T C 5.16E-04 Alcohol dependence / / 24277619 rs2830793 chr21 28606470 G A 0.00000392 Sasang constitution (Soeum) / / 22394158 rs2039270 chr21 28611275 A G 1.19E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1477717 chr21 28614871 C T 5.64E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs235930 chr21 28636987 T C 3.50E-05 Body mass index / / 17255346 rs237046 chr21 28643300 A G 1.90E-04 Body mass index / / 17255346 rs237047 chr21 28643868 C T 1.63E-04 Body mass index / / 17255346 rs1034355 chr21 28649659 C T 1.43E-04 Body mass index / / 17255346 rs2156292 chr21 28649962 C T 7.12E-05 Body mass index / / 17255346 rs457603 chr21 28657949 C T 5.00E-06 Liver enzyme levels (aspartate transaminase) / / 24124411 rs452621 chr21 28659396 T C 4.57E-06 Liver enzyme levels (aspartate transaminase) / / 24124411 rs2830839 chr21 28665143 A T 3.35E-04 Type 2 diabetes / / 17463246 rs2830840 chr21 28665347 G C 4.14E-05 Serum metabolites / / 19043545 rs2830840 chr21 28665347 G C 5.00E-06 Response to citalopram treatment / / 19846067 rs239606 chr21 28665594 C T 7.91E-04 Multiple complex diseases / / 17554300 rs2830848 chr21 28681196 G A 6.29E-05 Inflammation / / pha002897 rs239713 chr21 28696476 T C 5.00E-07 AB1-42 levels / / 20932310 rs2830856 chr21 28712814 T C 2.71E-06 Esophageal cancer (squamous cell) / / 20729853 rs2830862 chr21 28726805 C G 5.98E-04 Multiple complex diseases / / 17554300 rs9977499 chr21 28734997 C T 4.00E-06 Dialysis-related mortality / / 21546767 rs1452093 chr21 28744356 A G 2.00E-06 Dialysis-related mortality / / 21546767 rs2167597 chr21 28745816 C T 8.96E-05 Crohn's disease / / 20570966 rs7275326 chr21 28785912 A G 2.50E-05 Urinary metabolites / / 21572414 rs469709 chr21 28801007 C T 5.51E-04 Common variable immunodeficiency / / 21497890 rs181146 chr21 28804674 A G 6.91E-04 Multiple complex diseases / / 17554300 rs151754 chr21 28815953 T C 1.22E-04 Multiple complex diseases / / 17554300 rs239620 chr21 28824409 C A 6.98E-04 Alzheimer's disease / / 24755620 rs98990 chr21 28834867 G A 7.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs98991 chr21 28834910 A G 7.02E-04 Suicide attempts in bipolar disorder / / 21423239 rs2830971 chr21 28859322 T C 4.01E-04 Type 2 diabetes / / 17463246 rs242367 chr21 28865972 C A 1.97E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs242372 chr21 28870360 A G 1.60E-04 Statin-induced myopathy / / 21826682 rs2830987 chr21 28876415 T G 3.02E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2830988 chr21 28877292 C T 5.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs469473 chr21 28881204 C T 1.90E-05 Urinary metabolites / / 21572414 rs1987950 chr21 28883017 C A 5.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2830991 chr21 28886568 G C 3.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2830992 chr21 28888680 A C 3.92E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs242324 chr21 28905981 C T 3.60E-06 Urinary metabolites / / 21572414 rs1379660 chr21 28929855 A G 2.60E-05 Urinary metabolites / / 21572414 rs1379661 chr21 28929958 C G 7.80E-06 Urinary metabolites / / 21572414 rs2831007 chr21 28941967 T G 2.08E-05 Vaspin levels / / 22907691 rs2831007 chr21 28941967 T G 0.0000208 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs1598848 chr21 28946276 A G 7.00E-07 Response to cytidine analogues (gemcitabine) / / 24483146 rs2125209 chr21 28951347 C T 4.41E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2831023 chr21 28957233 G A 1.97E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9981345 chr21 28985655 C T 7.00E-07 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs4594527 chr21 29008316 T C 3.83E-05 Serum metabolites / / 19043545 rs2409209 chr21 29009029 G A 9.60E-07 Serum metabolites / / 19043545 rs2831137 chr21 29100042 A G 4.60E-06 Bipolar disorder,affective LINC00113 intron 20528957 rs2831138 chr21 29100067 G T 3.44E-06 Bipolar disorder,affective LINC00113 intron 20528957 rs16981123 chr21 29117583 G C 1.76E-04 Bipolar disorder,affective LINC00113 intron 20528957 rs243727 chr21 29140076 A G 9.53E-04 Prostate cancer mortality / / 20978177 rs243660 chr21 29177637 G A 0.00008632 Sarcoidosis / / 22952805 rs200753086 chr21 29207605 G GTT 7.59E-04 Prostate cancer mortality / / 20978177 rs243698 chr21 29207605 G T 7.59E-04 Prostate cancer mortality / / 20978177 rs9975542 chr21 29285000 G A 3.84E-05 Multiple complex diseases / / 17554300 rs16981502 chr21 29325967 G T 9.65E-04 Multiple complex diseases / / 17554300 rs2103509 chr21 29333472 C G 2.50E-05 Urinary metabolites / / 21572414 rs2831312 chr21 29360719 A G 7.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2205560 chr21 29368095 C T 6.56E-04 Type 2 diabetes / / 17463246 rs2210246 chr21 29414455 A G 4.55E-04 Type 2 diabetes / / 17463246 rs2210247 chr21 29418900 A G 7.44E-04 Smoking initiation / / 24665060 rs7275895 chr21 29426612 T A 9.08E-05 Type 2 diabetes / / 17463246 rs7275895 chr21 29426612 T A 7.65E-05 Cognitive decline / / 22054870 rs2409292 chr21 29430972 A G 3.82E-05 Cognitive decline / / 22054870 rs2831443 chr21 29433337 C T 3.88E-05 Type 2 diabetes / / 17463246 rs974608 chr21 29436018 C G 5.48E-05 Type 2 diabetes / / 17463246 rs974608 chr21 29436018 C G 3.40E-05 Cognitive decline / / 22054870 rs2831451 chr21 29440312 T C 7.73E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2179019 chr21 29445286 A G 9.37E-04 Type 2 diabetes / / 17463246 rs2179019 chr21 29445286 A G 4.69E-05 Cognitive decline / / 22054870 rs2831482 chr21 29464782 G A 4.17E-05 Kawasaki disease LOC100652994 intron 22081228 rs9305354 chr21 29475196 C T 8.00E-06 Urinary albumin excretion / / 17903292 rs9305355 chr21 29475217 G A 5.00E-05 Kidney function and endocine traits / / 17903292 rs2037986 chr21 29476477 G T 4.00E-07 Asthma (childhood onset) / / 17611496 rs2831511 chr21 29485359 C T 9.71E-05 Systemic sclerosis / / 21750679 rs2831515 chr21 29485857 T C 1.13E-04 Blood pressure / / 17255346 rs7276221 chr21 29500942 A G 4.52E-05 Nonalcoholic fatty liver disease / / 21423719 rs2831525 chr21 29505657 A C 8.31E-06 Primary biliary cirrhosis / / 21399635 rs1571671 chr21 29509929 A C 1.10E-05 Multiple complex diseases / / 17554300 rs4817219 chr21 29511914 C T 2.70E-04 Multiple complex diseases / / 17554300 rs2263504 chr21 29513918 C G 1.18E-04 Multiple complex diseases / / 17554300 rs2103733 chr21 29514049 T C 1.23E-04 Multiple complex diseases / / 17554300 rs2831543 chr21 29523047 A G 6.15E-04 Type 2 diabetes / / 17463246 rs2831547 chr21 29525767 T C 3.35E-05 Smoking cessation / / 24665060 rs1013194 chr21 29531827 C T 2.24E-05 Hypertension (early onset hypertension) / / 22479346 rs2831588 chr21 29540438 C A 2.22E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2831605 chr21 29545193 C T 6.82E-05 Type 2 diabetes / / 17846124 rs2831605 chr21 29545193 C T 4.41E-05 Pulmonary function / / 17903307 rs2831605 chr21 29545193 C T 6.80E-05 Type 2 diabetes / / 21647700 rs2831617 chr21 29559644 T C 6.20E-04 Biomarkers / / 17903293 rs2831618 chr21 29559878 G A 6.40E-04 Biomarkers / / 17903293 rs2831620 chr21 29559998 T C 6.40E-04 Biomarkers / / 17903293 rs2831639 chr21 29579868 G A 3.86E-04 Multiple complex diseases / / 17554300 rs2831647 chr21 29582221 C G 2.39E-04 Multiple complex diseases / / 17554300 rs2831649 chr21 29582347 G A 3.77E-04 Multiple complex diseases / / 17554300 rs2831649 chr21 29582347 G A 5.01E-05 Major depressive disorder (broad) / / 20038947 rs2831659 chr21 29589268 A G 6.14E-04 Multiple complex diseases / / 17554300 rs2831665 chr21 29596582 C G 3.06E-04 Multiple complex diseases / / 17554300 rs2831666 chr21 29596694 C A 3.89E-04 Multiple complex diseases / / 17554300 rs2831689 chr21 29647804 T C 1.61E-04 Vaspin levels / / 22907691 rs2831689 chr21 29647804 T C 0.0001611 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs2831693 chr21 29659922 G A 0.000648052 Hypertension (early onset hypertension) / / 22479346 rs9977955 chr21 29683463 A G 4.50E-05 Multiple complex diseases / / 17554300 rs2409300 chr21 29723272 T C 2.57E-04 Multiple complex diseases / / 17554300 rs2831758 chr21 29766796 A C 9.12E-04 Alzheimer's disease / / 17998437 rs16982350 chr21 29777369 A C 9.35E-04 Multiple complex diseases / / 17554300 rs2250997 chr21 29803601 T C 2.75E-04 Multiple complex diseases / / 17554300 rs2250997 chr21 29803601 T C 7.07E-04 Alzheimer's disease / / 17998437 rs13047178 chr21 29816143 C T 5.57E-05 Serum metabolites / / 19043545 rs11088067 chr21 29816373 A T 3.90E-05 Serum metabolites / / 19043545 rs10482991 chr21 29817710 C G 3.90E-05 Serum metabolites / / 19043545 rs7283006 chr21 29820563 G A 4.78E-05 Serum metabolites / / 19043545 rs2831873 chr21 29882659 G A 2.88E-05 Pulmonary function / / 19300500 rs2831877 chr21 29885186 A C 2.94E-05 Pulmonary function / / 19300500 rs2831886 chr21 29893891 T C 6.89E-05 Tunica Media / / pha003034 rs2831887 chr21 29894545 C T 2.94E-05 Pulmonary function / / 19300500 rs2178939 chr21 29898507 T C 6.89E-05 Tunica Media / / pha003034 rs2150392 chr21 29912452 C A 2.15E-04 Multiple complex diseases / / 17554300 rs977689 chr21 29922390 G T 5.91E-05 Pulmonary function / / 19300500 rs17781982 chr21 29976843 G T 6.47E-04 Multiple complex diseases / / 17554300 rs2831936 chr21 30000573 A G 3.10E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs8129139 chr21 30058933 G T 4.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs982279 chr21 30060546 T C 2.40E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2205423 chr21 30061531 G C 2.24E-06 Left ventricular mass / / 21212386 rs2205423 chr21 30061531 G C 9.30E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4817242 chr21 30063749 A G 4.61E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4817244 chr21 30071603 A G 2.21E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7276179 chr21 30072448 C T 4.80E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4816322 chr21 30072918 A G 3.60E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9305380 chr21 30075486 A C 2.69E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2831965 chr21 30075897 G C 2.40E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9980601 chr21 30076432 T G 3.53E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2831966 chr21 30076780 A C 3.04E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2831980 chr21 30093105 G C 7.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2409318 chr21 30099405 T C 5.99E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11701765 chr21 30115651 A C,G,T 5.00E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs2832042 chr21 30116127 T G 5.28E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs2832045 chr21 30116753 T C 4.01E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs11700653 chr21 30117319 C T 7.28E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs16983159 chr21 30118326 G C 4.26E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs2832067 chr21 30136868 G A 6.75E-04 Type 2 diabetes / / 17463246 rs2832067 chr21 30136868 G A 8.75E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2832068 chr21 30136915 T C 2.73E-04 Schizophrenia(treatment response to risperidone) / / 19850283 rs2832077 chr21 30141021 G A 2.00E-06 Cognitive test performance / / 17903297 rs2832082 chr21 30153127 C G 9.28E-05 Serum metabolites / / 19043545 rs16983259 chr21 30153698 G A 9.08E-05 Multiple complex diseases / / 17554300 rs2832089 chr21 30161789 A C 8.34E-04 Type 2 diabetes / / 17463246 rs16983303 chr21 30162575 C A 6.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs8134569 chr21 30164122 C T 6.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs2037972 chr21 30179535 G A 8.57E-05 Biliary atresia / / 20460270 rs1003671 chr21 30201119 G A 5.47E-04 Type 2 diabetes / / 17463246 rs4817258 chr21 30239378 C T 3.24E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs8134005 chr21 30244170 G A 6.83E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2205449 chr21 30252088 T A 6.69E-05 Response to taxane treatment (placlitaxel) N6AMT1 intron 23006423 rs2254160 chr21 30252562 A G 5.72E-05 Response to taxane treatment (placlitaxel) N6AMT1 intron 23006423 rs2776227 chr21 30274908 G A 2.68E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2142374 chr21 30277054 A G 4.61E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2832137 chr21 30280016 A T 1.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2472209 chr21 30281420 C T 9.94E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs11701464 chr21 30285392 T C 2.60E-05 Urinary metabolites / / 21572414 rs2255564 chr21 30347990 T C 9.17E-05 Schizophrenia LTN1 intron 24253340 rs2832149 chr21 30354112 C T 3.44E-04 Type 2 diabetes LTN1 intron 17463246 rs2245431 chr21 30357163 G T 7.91E-05 Schizophrenia LTN1 cds-synon 24253340 rs2832151 chr21 30359993 G T 2.69E-04 Multiple complex diseases LTN1 intron 17554300 rs11700764 chr21 30390557 C T 1.88E-04 Type 2 diabetes RWDD2B intron 17463246 rs2832159 chr21 30458564 G A 9.64E-05 Lymphocyte counts C21orf7 intron 22286170 rs4350836 chr21 30470384 G A 1.42E-04 Type 2 diabetes C21orf7 intron 17463246 rs4350836 chr21 30470384 G A 2.30E-05 Urinary metabolites C21orf7 intron 21572414 rs2832173 chr21 30470512 A G 1.70E-04 Type 2 diabetes C21orf7 intron 17463246 rs2832173 chr21 30470512 A G 2.50E-05 Urinary metabolites C21orf7 intron 21572414 rs2832173 chr21 30470512 A G 3.91E-06 Odorant perception C21orf7 intron 23910658 rs2832191 chr21 30489300 A C 5.00E-06 Dental caries C21orf7 intron 23259602 rs2832206 chr21 30504654 T C 8.89E-04 Multiple complex diseases C21orf7 intron 17554300 rs16983765 chr21 30507998 C A 7.69E-04 Multiple complex diseases C21orf7 intron 17554300 rs8129616 chr21 30520085 G A 6.79E-04 Response to taxane treatment (placlitaxel) C21orf7 intron 23006423 rs2251087 chr21 30527999 C T 2.31E-04 Response to taxane treatment (placlitaxel) C21orf7 intron 23006423 rs2776252 chr21 30531705 G A 1.59E-04 Response to taxane treatment (placlitaxel) C21orf7 intron 23006423 rs2832227 chr21 30533076 A G 0.0000392 Coronary artery disease C21orf7 intron 23202125 rs2832231 chr21 30536946 T C 2.60E-04 Multiple complex diseases C21orf7 intron 17554300 rs2255055 chr21 30537045 C T 1.17E-05 Post-operative nausea and vomiting C21orf7 intron 21694509 rs2832233 chr21 30546000 A G 2.18E-04 Multiple complex diseases C21orf7 intron 17554300 rs2832238 chr21 30549361 G T 7.60E-04 Crohn's disease / / 17684544 rs2832249 chr21 30557651 A G 5.69E-04 Type 2 diabetes / / 17463246 rs2832249 chr21 30557651 A G 4.01E-04 Multiple complex diseases / / 17554300 rs8132759 chr21 30590951 G A 9.91E-04 Multiple complex diseases LINC00189 intron 17554300 rs2832267 chr21 30591662 C G 2.39E-05 Response to mTOR inhibitor (everolimus) LINC00189 intron 24009623 rs2832270 chr21 30594532 G A 5.54E-05 Iron levels LINC00189 intron 19880490 rs2832270 chr21 30594532 G A 8.00E-06 Response to mTOR inhibitor (everolimus) LINC00189 intron 24009623 rs2832270 chr21 30594532 G A 5.54E-05 Iron levels LINC00189 intron pha002876 rs8135008 chr21 30595101 C T 8.50E-04 Multiple complex diseases LINC00189 intron 17554300 rs11909745 chr21 30610621 A G 6.79E-04 Alcohol consumption LINC00189 intron 23743675 rs2832278 chr21 30611490 A G 6.23E-04 Alcohol consumption LINC00189 intron 23743675 rs1153280 chr21 30678072 G A 2.71E-07 Pancreatic cancer BACH1 intron 22158540 rs1153287 chr21 30685611 G A 1.45E-07 Pancreatic cancer BACH1 intron 22158540 rs1236481 chr21 30697673 A G 1.43E-06 Pancreatic cancer BACH1 intron 22158540 rs2832284 chr21 30697723 A G 1.23E-05 Multiple complex diseases BACH1 intron 17554300 rs1153294 chr21 30701096 T C 3.42E-08 Pancreatic cancer BACH1 intron 22158540 rs17744121 chr21 30713598 A G 6.00E-06 Visceral fat BACH1 intron 22589738 rs372883 chr21 30717737 T C 2.00E-13 Pancreatic cancer BACH1 UTR-3 22158540 rs117214 chr21 30720834 C T 3.25E-04 Multiple complex diseases BACH1 intron 17554300 rs117214 chr21 30720834 C T 1.74E-07 Pancreatic cancer BACH1 intron 22158540 rs2027605 chr21 30726773 A G 1.06E-07 Pancreatic cancer BACH1 intron 22158540 rs2832290 chr21 30728863 A G 1.34E-07 Pancreatic cancer BACH1 intron 22158540 rs2832308 chr21 30757494 G T 6.37E-04 Coronary Artery Disease / / 17634449 rs7277179 chr21 30758760 G A 1.88E-04 Coronary Artery Disease / / 17634449 rs2832329 chr21 30825601 G A 1.10E-04 Lung function (forced vital capacity) / / 24023788 rs9981313 chr21 30830393 T G 9.52E-04 Coronary heart disease / / 21606135 rs2832335 chr21 30831133 C T 0.0000386 Coronary artery calcification / / 23394302 rs2832337 chr21 30832471 T C 3.22E-04 Iron levels / / pha002876 rs8132309 chr21 30845873 C T 0.0000631 Coronary artery calcification / / 23394302 rs2832357 chr21 30863894 A G 2.33E-07 QT interval / / 19587794 rs10482996 chr21 30864812 C T 4.59E-07 QT interval / / 19587794 rs2211887 chr21 30865148 T C 4.70E-07 QT interval / / 19587794 rs980007 chr21 30865282 A G 4.73E-07 QT interval / / 19587794 rs2000460 chr21 30867124 A G 4.76E-07 QT interval / / 19587794 rs963073 chr21 30867452 T C 3.92E-07 QT interval / / 19587794 rs963072 chr21 30867636 T C 4.70E-07 QT interval / / 19587794 rs2832361 chr21 30871124 C T 5.23E-07 QT interval / / 19587794 rs2832367 chr21 30873969 C T 5.29E-07 QT interval / / 19587794 rs16984337 chr21 30910045 T C 3.49E-05 Multiple complex diseases GRIK1 intron 17554300 rs2154490 chr21 30915962 A G 2.00E-05 Type 2 diabetes GRIK1 intron 17463249 rs2154490 chr21 30915962 A G 1.05E-04 Multiple complex diseases GRIK1 intron 17554300 rs2832394 chr21 30918775 C T 2.94E-04 Multiple complex diseases GRIK1 intron 17554300 rs2832408 chr21 30973268 T G 1.55E-04 Type 2 diabetes GRIK1 intron 17463246 rs2832408 chr21 30973268 T G 1.75E-04 Multiple complex diseases GRIK1 intron 17554300 rs363428 chr21 30975653 G A 6.84E-05 Type 2 diabetes GRIK1 intron 17463246 rs363428 chr21 30975653 G A 6.59E-04 Multiple complex diseases GRIK1 intron 17554300 rs363449 chr21 30984275 C G 1.94E-04 Type 2 diabetes GRIK1 intron 17463246 rs363449 chr21 30984275 C G 5.65E-04 Multiple complex diseases GRIK1 intron 17554300 rs363449 chr21 30984275 C G 4.80E-04 Mathematical ability GRIK1 intron 20039944 rs363449 chr21 30984275 C G 6.00E-04 Mathematical ability GRIK1 intron 20039944 rs363443 chr21 30986463 C A 9.97E-05 Type 2 diabetes GRIK1 intron 17463246 rs363443 chr21 30986463 C A 8.74E-04 Multiple complex diseases GRIK1 intron 17554300 rs363437 chr21 30989800 T C 6.68E-04 Multiple complex diseases GRIK1 intron 17554300 rs2832413 chr21 30993297 G T 4.78E-04 Suicide attempts in bipolar disorder GRIK1 intron 21423239 rs2832414 chr21 30994121 A G 4.62E-04 Suicide attempts in bipolar disorder GRIK1 intron 21423239 rs2154487 chr21 31004794 C G 7.65E-04 Type 2 diabetes GRIK1 intron 17463246 rs2245338 chr21 31007346 C T 2.49E-04 Suicide attempts in bipolar disorder GRIK1 intron 21041247 rs9680502 chr21 31010748 C A 8.47E-04 Suicide attempts in bipolar disorder GRIK1 intron 21423239 rs7277926 chr21 31010768 G C 3.46E-05 Type 2 diabetes GRIK1 intron 17463246 rs1016700 chr21 31011393 G A 8.53E-05 Type 2 diabetes GRIK1 intron 17463246 rs1016700 chr21 31011393 G A 5.30E-04 Multiple complex diseases GRIK1 intron 17554300 rs363598 chr21 31013159 T C 5.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) GRIK1 intron 23453885 rs363529 chr21 31014321 C G 3.99E-04 Suicide attempts in bipolar disorder GRIK1 intron 21041247 rs363526 chr21 31014489 A C 1.21E-04 Type 2 diabetes GRIK1 intron 17463246 rs2249140 chr21 31017340 C T 1.89E-04 Type 2 diabetes GRIK1 intron 17463246 rs2832424 chr21 31023250 A C 7.28E-04 Suicide attempts in bipolar disorder GRIK1 intron 21041247 rs11088125 chr21 31024018 T C 2.38E-05 Type 2 diabetes GRIK1 intron 17463246 rs363569 chr21 31032703 C T 6.91E-04 Suicide attempts in bipolar disorder GRIK1 intron 21041247 rs11701584 chr21 31033942 C T 2.82E-04 Type 2 diabetes GRIK1 intron 17463246 rs363550 chr21 31046299 C G 7.74E-04 Suicide attempts in bipolar disorder GRIK1 intron 21041247 rs16984760 chr21 31046753 G A 1.17E-04 Multiple complex diseases GRIK1 intron 17554300 rs363512 chr21 31050817 G A 4.00E-06 Hyperactive-impulsive symptoms GRIK1 intron 18821565 rs363512 chr21 31050817 G A 0.0003 Change in depression severity with Norepinephrine reuptake inhibitors (NRI) GRIK1 intron 23091423 rs363512 chr21 31050817 G A 2.15E-05 Leukocyte Counts GRIK1 intron pha003091 rs3787671 chr21 31073100 T G 3.80E-05 Body mass index GRIK1 intron 22446040 rs933117 chr21 31100797 G A 6.00E-06 Body mass index GRIK1 intron 22446040 rs403305 chr21 31118058 T G 5.08E-05 Body mass index GRIK1 intron 22446040 rs2832438 chr21 31137937 T C 3.91E-07 Primary biliary cirrhosis GRIK1 intron 23000144 rs2832438 chr21 31137937 T C 0.000000391 Facial morphology GRIK1 intron 23028347 rs459617 chr21 31140753 C T 3.49E-04 Schizophrenia (cytomegalovirus infection interaction) GRIK1 intron 23358160 rs455804 chr21 31146169 A C 5.00E-10 Hepatocellular carcinoma GRIK1 intron 22807686 rs2248218 chr21 31153686 G A 2.90E-05 Cardiovascular disease adverse events in renal patients treated with calcineurin inhibitors GRIK1 intron 16155738 rs437489 chr21 31172702 T C 7.46E-04 HIV-1 viral setpoint GRIK1 intron 17641165 rs2256478 chr21 31175928 C T 7.70E-05 Cardiovascular disease adverse events in renal patients treated with calcineurin inhibitors GRIK1 intron 16155738 rs458685 chr21 31177511 A G 6.54E-05 Type 2 diabetes GRIK1 intron 17846124 rs458685 chr21 31177511 A G 6.00E-06 Breast cancer GRIK1 intron 17903305 rs458685 chr21 31177511 A G 6.00E-06 Nasopharyngeal carcinoma GRIK1 intron 20512145 rs458685 chr21 31177511 A G 6.50E-05 Type 2 diabetes GRIK1 intron 21647700 rs2256853 chr21 31178626 G A 3.94E-06 Post-operative nausea and vomiting GRIK1 intron 21694509 rs456784 chr21 31184827 A G 1.16E-05 Serum metabolites GRIK1 intron 19043545 rs379182 chr21 31187165 G A 7.51E-04 HIV-1 viral setpoint GRIK1 intron 17641165 rs16985084 chr21 31195016 C T 8.24E-04 Multiple complex diseases GRIK1 intron 17554300 rs9983495 chr21 31196773 G T 5.49E-05 Epilepsy GRIK1 intron 22116939 rs2268215 chr21 31240416 A C 8.88E-06 Periodontitis (DPAL) GRIK1 intron 24024966 rs457352 chr21 31244478 C T 7.00E-06 Periodontitis (DPAL) GRIK1 intron 24024966 rs457531 chr21 31271516 C T 1.73E-07 Paclitaxel sensitivity in NCI60 cancer cell lines GRIK1 intron 21314952 rs2832484 chr21 31297409 G A 9.78E-04 Response to cytidine analogues (gemcitabine) GRIK1 intron 24483146 rs2832489 chr21 31299470 G A 5.75E-04 Response to cytidine analogues (gemcitabine) GRIK1 intron 24483146 rs467092 chr21 31306654 C T 3.12E-05 Multiple sclerosis GRIK1 intron 17660530 rs2832499 chr21 31317009 A G 1.71E-04 Hemoglobin concentration / / 20534544 rs977780 chr21 31325249 C T 9.52E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2832504 chr21 31325862 C T 9.52E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9305406 chr21 31386243 G A 8.00E-06 Response to statin therapy / / 20339536 rs2832542 chr21 31405797 G A 7.72E-05 Tuberculosis / / 24057671 rs1943956 chr21 31423770 C A 2.94E-05 Multiple complex diseases / / 17554300 rs2832574 chr21 31424402 C T 3.43E-05 Amyotrophic Lateral Sclerosis / / 17827064 rs615319 chr21 31434180 G A 2.16E-04 Multiple complex diseases / / 17554300 rs502503 chr21 31436965 A G 8.63E-04 Multiple complex diseases / / 17554300 rs2832578 chr21 31440069 G C 5.37E-04 Multiple complex diseases / / 17554300 rs10432780 chr21 31460885 A G 9.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs16986002 chr21 31498185 C G 8.03E-04 Multiple complex diseases / / 17554300 rs2832664 chr21 31599912 T C 9.90E-04 Multiple complex diseases / / 17554300 rs13051865 chr21 31609467 T C 1.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16986321 chr21 31611421 G A 6.96E-04 Multiple complex diseases / / 17554300 rs2832736 chr21 31639653 G A 6.22E-04 Multiple complex diseases / / 17554300 rs2832737 chr21 31640228 T C 8.09E-04 Multiple complex diseases / / 17554300 rs2832791 chr21 31690846 G T 8.26E-04 Parkinson's disease / / 17052657 rs7276022 chr21 31736157 C G 1.55E-04 Multiple complex diseases / / 17554300 rs2832886 chr21 31825764 C T 2.50E-04 Cognition,early reading ability / / 17684495 rs12627596 chr21 31945230 T A 9.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs198935 chr21 31946127 T C 1.11E-04 Smoking initiation / / 24665060 rs198936 chr21 31948095 T C 2.10E-05 Urinary metabolites / / 21572414 rs198936 chr21 31948095 T C 3.67E-04 Smoking initiation / / 24665060 rs128592 chr21 31956409 T C 6.78E-04 Smoking initiation / / 24665060 rs9305427 chr21 31971631 G T 9.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs198915 chr21 31973516 T A 8.95E-04 Suicide attempts in bipolar disorder KRTAP22-1 missense 21423239 rs1702405 chr21 31992864 A G 8.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs1785487 chr21 31994954 C G 6.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs174897 chr21 31997166 T C 8.32E-04 Suicide attempts in bipolar disorder / / 21423239 rs1507402 chr21 32005489 T C 8.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs198867 chr21 32008275 A C 8.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs198871 chr21 32010708 C T 5.77E-04 Smoking initiation / / 24665060 rs2832973 chr21 32034536 C T 1.29E-04 Smoking initiation / / 24665060 rs2832975 chr21 32036541 A G 2.30E-05 Urinary metabolites / / 21572414 rs1507395 chr21 32036980 T C 1.60E-05 Urinary metabolites / / 21572414 rs1507396 chr21 32038030 G A 1.41E-04 Smoking initiation / / 24665060 rs16986992 chr21 32038923 T C 1.34E-04 Smoking initiation / / 24665060 rs2048126 chr21 32055022 A G 8.43E-05 Periodontitis (Chronic) / / 25008200 rs13046373 chr21 32060490 A G 4.00E-06 HDL cholesterol / / 23726366 rs9305434 chr21 32075211 C T 7.91E-05 Periodontitis (Chronic) / / 25008200 rs2833017 chr21 32086323 G T 5.20E-05 Periodontitis (Chronic) / / 25008200 rs2833026 chr21 32089375 G A 1.22E-04 Smoking initiation / / 24665060 rs2833027 chr21 32089609 A G 5.05E-04 Smoking initiation / / 24665060 rs2833030 chr21 32090837 A T 2.21E-04 Smoking initiation / / 24665060 rs2833035 chr21 32092798 T C 1.78E-04 Smoking initiation / / 24665060 rs2833045 chr21 32098611 G A 1.06E-04 Smoking initiation / / 24665060 rs2833047 chr21 32103499 G A 1.97E-04 Smoking initiation / / 24665060 rs2833052 chr21 32104291 A G 1.43E-04 Smoking initiation / / 24665060 rs10084616 chr21 32110767 A C 1.43E-04 Smoking initiation / / 24665060 rs6516977 chr21 32112596 G A 1.54E-04 Smoking initiation / / 24665060 rs2833073 chr21 32118200 A G 1.67E-04 Smoking initiation / / 24665060 rs2833074 chr21 32119576 C G 2.57E-04 Smoking initiation / / 24665060 rs2833075 chr21 32120157 C A 1.59E-04 Smoking initiation / / 24665060 rs998415 chr21 32129088 A C 1.34E-04 Smoking initiation / / 24665060 rs11908783 chr21 32136238 C A 5.22E-04 Smoking initiation / / 24665060 rs2833081 chr21 32143723 A C 1.20E-04 Smoking initiation / / 24665060 rs7283316 chr21 32216253 G A 9.00E-06 Information processing speed / / 21130836 rs4817359 chr21 32217530 T C 7.86E-06 Menarche (age at onset) / / 19282985 rs12482128 chr21 32219380 T C 1.30E-06 Urinary metabolites / / 21572414 rs2833138 chr21 32227792 A G 2.20E-05 Urinary metabolites / / 21572414 rs2105494 chr21 32230329 T A 8.61E-06 Menarche (age at onset) / / 19282985 rs11908965 chr21 32252137 G T 3.40E-06 Urinary metabolites / / 21572414 rs1892669 chr21 32291501 C T 8.50E-05 Type 2 diabetes / / 17463246 rs1892669 chr21 32291501 C T 2.34E-04 Multiple complex diseases / / 17554300 rs1892669 chr21 32291501 C T 9.90E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs1557278 chr21 32295397 C T 6.91E-04 Type 2 diabetes / / 17463246 rs2833162 chr21 32296251 T C 5.91E-04 Type 2 diabetes / / 17463246 rs2833162 chr21 32296251 T C 8.91E-04 Multiple complex diseases / / 17554300 rs11909679 chr21 32304057 G A 9.40E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs11909638 chr21 32304174 A T 8.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs8134605 chr21 32304266 G C 8.00E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs2833188 chr21 32362378 G A 0.0004 Coronary arterial lesions in patients with Kawasaki disease / / 23454411 rs2833193 chr21 32391807 C G 5.74E-05 Multiple complex diseases / / 17554300 rs2833195 chr21 32398308 G C 0.0009 Coronary arterial lesions in patients with Kawasaki disease / / 23454411 rs12482609 chr21 32404803 T C 2.28E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs9982266 chr21 32405977 T C 5.40E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2833197 chr21 32407116 C T 8.81E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2011628 chr21 32415634 C T 6.14E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2833210 chr21 32421758 A C 2.50E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2833222 chr21 32425795 C T 2.77E-04 Multiple complex diseases / / 17554300 rs16987645 chr21 32427232 G T 1.83E-04 Multiple complex diseases / / 17554300 rs1475591 chr21 32440540 T C 6.00E-06 Coronary heart disease / / 21347282 rs2833256 chr21 32444485 G A 6.73E-04 Multiple complex diseases / / 17554300 rs11701477 chr21 32471849 C T 2.90E-05 Lipid levels / / pha003082 rs7281210 chr21 32485200 G A 8.82E-04 Type 2 diabetes / / 17463246 rs2833273 chr21 32487977 G C 2.48E-04 Type 2 diabetes / / 17463246 rs2247802 chr21 32510011 C T 7.30E-06 Urinary metabolites TIAM1 intron 21572414 rs2833297 chr21 32510414 A G 7.93E-04 Common variable immunodeficiency TIAM1 intron 21497890 rs8127726 chr21 32514524 G A 4.63E-04 Type 2 diabetes TIAM1 intron 17463246 rs2833306 chr21 32524232 C T 3.37E-04 Lung function (forced vital capacity) TIAM1 intron 24023788 rs2248656 chr21 32528960 A G 5.13E-05 Blood Pressure TIAM1 intron pha002898 rs13340018 chr21 32555796 T C 4.04E-17 Multiple complex diseases TIAM1 intron 17554300 rs16987943 chr21 32571289 A G 4.07E-04 Multiple complex diseases TIAM1 intron 17554300 rs16987969 chr21 32588571 T G 1.60E-04 Multiple complex diseases TIAM1 intron 17554300 rs16987983 chr21 32603494 G A 6.87E-19 Multiple complex diseases TIAM1 intron 17554300 rs2268225 chr21 32666803 T C 5.59E-06 Neuroblastoma TIAM1 intron pha002895 rs2284498 chr21 32682256 C T 6.80E-04 Type 2 diabetes and 6 quantitative traits TIAM1 intron 17848626 rs2284498 chr21 32682256 C T 8.57E-04 Suicide attempts in bipolar disorder TIAM1 intron 21423239 rs13045983 chr21 32686829 A G 8.39E-04 Suicide attempts in bipolar disorder TIAM1 intron 21423239 rs2833373 chr21 32686908 C T 6.57E-04 Suicide attempts in bipolar disorder TIAM1 intron 21423239 rs7281523 chr21 32691163 G A 2.04E-04 Multiple complex diseases TIAM1 intron 17554300 rs13050231 chr21 32695140 C T 6.86E-04 Suicide attempts in bipolar disorder TIAM1 intron 21423239 rs13050344 chr21 32695264 A G 6.74E-04 Suicide attempts in bipolar disorder TIAM1 intron 21423239 rs13052140 chr21 32697218 T G 4.73E-04 Suicide attempts in bipolar disorder TIAM1 intron 21423239 rs9984586 chr21 32698590 T C 3.33E-04 Multiple complex diseases TIAM1 intron 17554300 rs2833374 chr21 32699323 C T 1.88E-04 Multiple complex diseases TIAM1 intron 17554300 rs13048400 chr21 32699583 C T 6.52E-04 Suicide attempts in bipolar disorder TIAM1 intron 21423239 rs2833380 chr21 32709435 C T 3.00E-04 Type 2 diabetes and 6 quantitative traits TIAM1 intron 17848626 rs2833380 chr21 32709435 C T 7.72E-04 Suicide attempts in bipolar disorder TIAM1 intron 21423239 rs2833380 chr21 32709435 C T 5.03E-05 Recombination rate TIAM1 intron 21698098 rs2833382 chr21 32714111 C A 3.75E-04 Suicide attempts in bipolar disorder TIAM1 intron 21423239 rs9976177 chr21 32714289 C T 7.42E-04 Suicide attempts in bipolar disorder TIAM1 intron 21423239 rs13046768 chr21 32716753 T C 2.85E-04 Suicide attempts in bipolar disorder TIAM1 intron 21423239 rs2833385 chr21 32720679 T C 1.27E-04 Suicide attempts in bipolar disorder TIAM1 intron 21423239 rs542178 chr21 32736169 T C 2.39E-05 Type 2 diabetes TIAM1 intron 17463246 rs2284504 chr21 32748414 G A 3.14E-05 Amyotrophic lateral sclerosis TIAM1 intron 20801718 rs2284504 chr21 32748414 G A 0.0004099 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TIAM1 intron 23233654 rs2284504 chr21 32748414 G A 4.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) TIAM1 intron 23233662 rs2300359 chr21 32748831 G A 0.0004096 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TIAM1 intron 23233654 rs2300359 chr21 32748831 G A 4.10E-04 Methotrexate clearance (acute lymphoblastic leukemia) TIAM1 intron 23233662 rs2833390 chr21 32753121 T C 0.000409 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) TIAM1 intron 23233654 rs2833390 chr21 32753121 T C 4.09E-04 Methotrexate clearance (acute lymphoblastic leukemia) TIAM1 intron 23233662 rs16988188 chr21 32754936 C T 8.76E-04 Taste perception TIAM1 intron 22132133 rs16988188 chr21 32754936 C T 3.00E-04 Lung function (forced vital capacity) TIAM1 intron 24023788 rs535985 chr21 32775339 A G 3.01E-05 Cognitive test performance TIAM1 intron 20125193 rs535985 chr21 32775339 A G 1.24E-06 Amyotrophic lateral sclerosis TIAM1 intron 20801718 rs2833405 chr21 32794635 T C 9.26E-04 Multiple complex diseases TIAM1 intron 17554300 rs13048773 chr21 32794956 C T 8.10E-06 Urinary metabolites TIAM1 intron 21572414 rs558059 chr21 32810899 C A 9.63E-05 Non-alcoholic fatty liver disease histology (other) TIAM1 intron 20708005 rs553833 chr21 32816922 T C 3.48E-04 Response to statin treatment (atorvastatin),change in cholesterol levels TIAM1 intron 20031582 rs580140 chr21 32817507 A G 3.00E-06 Renal sinus fat TIAM1 intron 22044751 rs577738 chr21 32818752 C T 1.28E-04 Lung function (forced expiratory volume in 1 second) TIAM1 intron 24023788 rs8133912 chr21 32844412 T G 5.86E-04 Response to statin treatment (atorvastatin),change in cholesterol levels TIAM1 intron 20031582 rs13045986 chr21 32846583 G A 1.73E-27 Narcolepsy TIAM1 intron 19629137 rs2833422 chr21 32851853 A C 7.73E-05 Major depressive disorder (broad) TIAM1 intron 20038947 rs2833423 chr21 32852003 A T 4.53E-05 Major depressive disorder (broad) TIAM1 intron 20038947 rs2833426 chr21 32855150 T C 9.28E-05 Major depressive disorder (broad) TIAM1 intron 20038947 rs7280029 chr21 32856215 G C 8.85E-05 Major depressive disorder (broad) TIAM1 intron 20038947 rs8131958 chr21 32858220 C T 7.18E-05 Major depressive disorder (broad) TIAM1 intron 20038947 rs2250608 chr21 32870552 T G 2.70E-05 Urinary metabolites TIAM1 intron 21572414 rs73199525 chr21 32884848 G A 7.00E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity TIAM1 intron 24324551 rs2833434 chr21 32891089 T C 3.60E-06 Urinary metabolites TIAM1 intron 21572414 rs9979653 chr21 32906992 C A 4.61E-06 Multiple sclerosis (brain glutamate levels) TIAM1 intron 20802204 rs4817403 chr21 32915961 A G 1.22E-04 Amyotrophic lateral sclerosis TIAM1 intron 20801718 rs13048019 chr21 32918294 C T 3.00E-08 Amyotrophic lateral sclerosis TIAM1 intron 20801718 rs13048019 chr21 32918294 C T 6.66E-05 Cognitive impairment induced by topiramate TIAM1 intron 22091778 rs2833447 chr21 32940469 T C 4.41E-05 Elbow pain / / pha003008 rs2833448 chr21 32943415 T C 4.11E-04 Insulin resistance / / 21901158 rs2833451 chr21 32949556 T C 1.99E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs2833457 chr21 32957234 C A 9.80E-04 Type 2 diabetes / / 17463246 rs2833459 chr21 32957765 A G 9.60E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9977656 chr21 32964307 T C 8.88E-04 Type 2 diabetes / / 17463246 rs2833468 chr21 32964341 A G 9.17E-04 Multiple complex diseases / / 17554300 rs2833468 chr21 32964341 A G 9.11E-05 Serum metabolites / / 19043545 rs2833470 chr21 32966164 C A 5.17E-05 Glycosylated haemoglobin levels / / 17255346 rs9976033 chr21 32967318 T A 1.95E-05 Serum metabolites / / 19043545 rs2187297 chr21 32967473 C A 7.55E-04 Multiple complex diseases / / 17554300 rs2833472 chr21 32968152 T C 8.93E-05 Glycosylated haemoglobin levels / / 17255346 rs7281948 chr21 32970928 A C 1.23E-05 Educational attainment / / 21694764 rs2409416 chr21 32975321 G T 8.84E-06 Amyotrophic lateral sclerosis / / 20801718 rs12627601 chr21 32984187 C A 2.57E-06 Amyotrophic lateral sclerosis / / 20801718 rs8132771 chr21 32999423 G A 1.96E-05 Rhegmatogenous retinal detachment / / 23585552 rs2833473 chr21 32999554 G A 6.43E-14 Esophageal cancer / / 21642993 rs1008270 chr21 33002145 C A 3.62E-06 Sickle cell anemia (severity) / / 20029952 rs9974610 chr21 33018369 A G 6.16E-05 Major depressive disorder (broad) / / 20038947 rs9974610 chr21 33018369 A G 3.84E-04 Suicide attempts in bipolar disorder / / 21423239 rs8128956 chr21 33021417 T A 7.34E-04 Alcohol dependence / / 21314694 rs2173962 chr21 33022020 T C 7.16E-04 Alcohol dependence / / 21314694 rs2173962 chr21 33022020 T C 2.40E-05 Urinary metabolites / / 21572414 rs2833478 chr21 33051524 T C 6.70E-04 Alzheimer's disease SCAF4 intron 24755620 rs2833480 chr21 33054761 G A 1.64E-04 Suicide attempts in bipolar disorder SCAF4 intron 21423239 rs2173963 chr21 33062432 C T 5.42E-04 Alzheimer's disease SCAF4 intron 24755620 rs720935 chr21 33084257 A G 4.69E-04 Alzheimer's disease SCAF4 intron 24755620 rs2833487 chr21 33087863 A G 6.04E-04 Alcohol dependence SCAF4 intron 21314694 rs204732 chr21 33092843 G A 8.76E-04 Suicide attempts in bipolar disorder SCAF4 intron 21423239 rs16988472 chr21 33123281 A G 2.50E-05 Urinary metabolites / / 21572414 rs2833503 chr21 33151896 C T 7.87E-04 Multiple complex diseases / / 17554300 rs2833523 chr21 33179773 G A 2.10E-05 Urinary metabolites / / 21572414 rs12482716 chr21 33207694 C T 8.88E-05 Major depressive disorder / / 21621269 rs79728973 chr21 33209503 G A 9.90E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs77292666 chr21 33214050 G A 6.00E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs1573462 chr21 33220718 A G 2.36E-04 Type 2 diabetes / / 17463246 rs964603 chr21 33221021 A G 2.10E-04 Type 2 diabetes / / 17463246 rs13050102 chr21 33242525 C T 5.83E-04 Stroke / / pha002887 rs2211781 chr21 33249294 A C 5.62E-05 Blood Pressure HUNK intron pha003040 rs17664292 chr21 33259510 G A 3.73E-05 Parkinson's disease (motor and cognition) HUNK intron 22658654 rs17664292 chr21 33259510 G A 3.73E-05 Immune response to anthrax vaccine HUNK intron 22658931 rs9982597 chr21 33279566 C T 3.90E-05 Cognitive function HUNK intron 24684796 rs2833556 chr21 33285300 G A 5.00E-07 Response to antipsychotic treatment in schizophrenia (reasoning) HUNK intron 21107309 rs2833556 chr21 33285300 G A 0.0007 Prostate cancer HUNK intron 23555315 rs1010674 chr21 33292070 T C 2.20E-05 Urinary metabolites HUNK intron 21572414 rs11910494 chr21 33296113 A G 8.00E-06 IgG glycosylation HUNK intron 23382691 rs1892650 chr21 33297806 C A 1.50E-05 Urinary metabolites HUNK intron 21572414 rs8130926 chr21 33333331 T C 3.00E-05 Schizophrenia(age at onset) HUNK intron 21688384 rs2211678 chr21 33339340 T C 8.26E-05 stroke (ischemic) HUNK intron 17434096 rs2833586 chr21 33340086 C T 1.63E-05 Schizophrenia(age at onset) HUNK intron 21688384 rs9305481 chr21 33347434 T C 4.22E-04 Premature ovarian failure HUNK intron 19508998 rs2032084 chr21 33354764 A G 6.79E-05 Cognitive impairment induced by topiramate HUNK intron 22091778 rs737103 chr21 33355760 G A 3.70E-06 Urinary metabolites HUNK intron 21572414 rs12165267 chr21 33364621 C T 4.94E-04 Amyotrophic lateral sclerosis (sporadic) HUNK intron 24529757 rs2833595 chr21 33367733 T C 9.62E-05 Cognitive impairment induced by topiramate HUNK intron 22091778 rs2833607 chr21 33381040 G A 2.00E-06 Vitiligo / / 19890347 rs10470164 chr21 33384319 T C 1.41E-04 Multiple complex diseases / / 17554300 rs2833610 chr21 33385186 A G 4.00E-06 Type 2 diabetes / / 21490949 rs2833610 chr21 33385186 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs17666683 chr21 33388393 G T 4.83E-04 Multiple complex diseases / / 17554300 rs9977744 chr21 33400910 T C 2.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs9974134 chr21 33407363 C A 2.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs9982468 chr21 33415077 C T 2.44E-04 Suicide attempts in bipolar disorder / / 21041247 rs2833622 chr21 33420670 C G 9.90E-04 Alzheimer's disease / / 17998437 rs6517072 chr21 33426886 C T 1.98E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2833626 chr21 33427852 A G 3.00E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2833628 chr21 33428767 A G 3.17E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4817450 chr21 33437648 T C 2.22E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs7277441 chr21 33441610 C T 3.63E-04 Osteoarthritis / / 19508968 rs9980209 chr21 33472035 T C 8.30E-04 Multiple complex diseases / / 17554300 rs8132452 chr21 33485023 G A 2.46E-04 Multiple complex diseases / / 17554300 rs2833693 chr21 33552512 T C 4.00E-06 Temperament / / 22832960 rs2833695 chr21 33554131 T C 8.80E-05 Diabetes Mellitus / / pha003060 rs2833724 chr21 33574244 G C 6.46E-04 Type 2 diabetes / / 17463246 rs2833736 chr21 33582722 G A 4.23E-05 Serum metabolites / / 19043545 rs2017901 chr21 33584340 C T 6.09E-05 Serum metabolites / / 19043545 rs41361358 chr21 33591101 C G 6.16E-05 Multiple complex diseases / / 17554300 rs4816428 chr21 33605001 T C 2.82E-05 Cognitive test performance / / 20125193 rs2833752 chr21 33643856 T C 3.97E-05 Amyotrophic lateral sclerosis MIS18A intron 20801718 rs2833754 chr21 33644965 C T 3.97E-05 Amyotrophic lateral sclerosis MIS18A intron 20801718 rs9975800 chr21 33675195 A G 1.30E-04 Obesity,menopause MRAP intron 21424828 rs2236611 chr21 33685280 C T 2.79E-06 Blood pressure URB1 UTR-3 21422096 rs2236611 chr21 33685280 C T 3.18E-04 Blood pressure URB1 UTR-3 21422096 rs2236611 chr21 33685280 C T 5.11E-04 Blood pressure URB1 UTR-3 21422096 rs2833795 chr21 33755763 G A 4.09E-04 Hemoglobin concentration URB1 cds-synon 20534544 rs2833836 chr21 33814533 G T 7.27E-05 Cognitive performance C21orf63 intron 19734545 rs2833836 chr21 33814533 G T 1.18E-04 Myocardial Infarction C21orf63 intron pha002873 rs2833837 chr21 33814613 A G 9.55E-05 Cognitive performance C21orf63 intron 19734545 rs10854359 chr21 33826744 C T 0.0000514 post-traumatic stress disorder C21orf63 intron 22869035 rs10854359 chr21 33826744 C T 5.14E-05 Schizophrenia C21orf63 intron 22883433 rs1041823 chr21 33832194 T C 0.000051 post-traumatic stress disorder C21orf63 intron 22869035 rs1041823 chr21 33832194 T C 5.10E-05 Schizophrenia C21orf63 intron 22883433 rs2833842 chr21 33834290 T A 3.75E-04 Multiple complex diseases C21orf63 intron 17554300 rs2833846 chr21 33852188 G A 8.30E-04 Multiple complex diseases C21orf63 intron 17554300 rs2255066 chr21 33919140 A G 1.70E-05 Urinary metabolites / / 21572414 rs2833899 chr21 33933263 T C 4.08E-06 Schizophrenia / / 21926974 rs1782954 chr21 33967319 G A 9.30E-06 Urinary metabolites / / 21572414 rs1720137 chr21 33971786 C T 1.80E-05 Urinary metabolites / / 21572414 rs2833927 chr21 34008532 C T 7.99E-04 Suicide attempts in bipolar disorder SYNJ1 intron 21041247 rs2833934 chr21 34024444 C T 8.96E-04 Suicide attempts in bipolar disorder SYNJ1 intron 21041247 rs2833950 chr21 34155039 G A 2.90E-07 Urinary metabolites C21orf49 intron 21572414 rs17696057 chr21 34164832 G A 1.54E-04 Amyotrophic Lateral Sclerosis C21orf62 UTR-3 17362836 rs2154427 chr21 34168573 G A,C,T 6.42E-08 Bilirubin levels,in serum C21orf49 intron 20639394 rs2833979 chr21 34220611 A G 2.28E-04 Height / / 17255346 rs2833980 chr21 34223288 T C 1.28E-04 Height / / 17255346 rs2833981 chr21 34223915 T C 1.88E-04 Height / / 17255346 rs7282519 chr21 34228594 A G 1.34E-04 Height / / 17255346 rs11088233 chr21 34240068 T C 2.85E-04 Height / / 17255346 rs11909639 chr21 34240116 T C 1.87E-04 Height / / 17255346 rs2065287 chr21 34243137 T C 3.60E-05 Odorant perception / / 23910658 rs2833988 chr21 34257618 C T 1.48E-04 Height / / 17255346 rs2833990 chr21 34260092 T C 2.25E-04 Height / / 17255346 rs2833991 chr21 34262687 A C 5.00E-06 IgG glycosylation / / 23382691 rs8130718 chr21 34319004 G A 1.86E-04 Type 2 diabetes / / 17463246 rs2105476 chr21 34319543 G C 1.10E-05 Urinary metabolites / / 21572414 rs2834028 chr21 34324076 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2014341 chr21 34345967 A G 8.50E-06 Urinary metabolites / / 21572414 rs2834046 chr21 34359143 G A 7.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2070384 chr21 34363525 G T 2.10E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2070384 chr21 34363525 G T 3.14E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4817514 chr21 34368569 G A 6.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs117124364 chr21 34369761 C T 9.00E-06 Bulimia nervosa / / 23568457 rs4817515 chr21 34374254 T C 6.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2834060 chr21 34375854 T C 5.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2834061 chr21 34376382 A G 9.40E-06 Type 2 diabetes / / 17460697 rs8130506 chr21 34381769 A G 3.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7275842 chr21 34405843 C T 0.00007566 Sarcoidosis / / 22952805 rs743331 chr21 34407966 T C 8.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs12233311 chr21 34409257 G A 8.60E-04 Suicide attempts in bipolar disorder / / 21041247 rs2834072 chr21 34410464 A G 8.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs2834072 chr21 34410464 A G 0.00001821 Sarcoidosis / / 22952805 rs6517138 chr21 34412135 A G 0.00009898 Sarcoidosis / / 22952805 rs12482007 chr21 34414023 A G 9.14E-04 Alzheimer's disease / / 17998437 rs12482007 chr21 34414023 A G 0.00009543 Sarcoidosis / / 22952805 rs11088236 chr21 34416187 C T 0.00009748 Sarcoidosis / / 22952805 rs8131457 chr21 34453897 T C 8.57E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7281400 chr21 34456591 A T 8.67E-04 Alzheimer's disease / / 22005930 rs4816446 chr21 34461342 T A 9.73E-04 Alzheimer's disease / / 22005930 rs4817527 chr21 34464085 G A 7.70E-06 Personality dimensions / / 21173776 rs9979091 chr21 34472860 G A 9.86E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs13047973 chr21 34485912 G A 5.95E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs2834091 chr21 34497748 G A 5.00E-04 Premature ovarian failure / / 19508998 rs8131080 chr21 34512570 T G 3.63E-04 Taste perception / / 22132133 rs2834115 chr21 34532556 A G 3.32E-04 Age-related macular degeneration / / 22125219 rs41496746 chr21 34542303 A G 1.29E-04 Multiple complex diseases C21orf54 intron 17554300 rs6517147 chr21 34542787 A G 7.00E-07 Inflammatory biomarkers / / 22228203 rs2834126 chr21 34546118 A G 1.03E-04 Prion diseases / / 22210626 rs2834132 chr21 34555833 G A 9.96E-05 Orofacial clefts / / 22863734 rs2834143 chr21 34579832 A G 4.10E-04 Type 2 diabetes / / 17463246 rs17860116 chr21 34602321 C T 6.26E-04 Endometrial cancer IF/R2 UTR-5 24096698 rs2284550 chr21 34618285 G A 5.33E-04 Type 2 diabetes IF/R2 intron 17463246 rs2834164 chr21 34621948 A C 7.74E-04 Type 2 diabetes IF/R2 intron 17463246 rs9979085 chr21 34640230 C G 7.26E-09 HDL cholesterol IL10RB intron 23063622 rs8134758 chr21 34641495 T C 0.000000121 HDL cholesterol IL10RB intron 23063622 rs2834168 chr21 34650791 A G 0.0000053 Narcolepsy (non-HLA narcolepsy) IL10RB intron 23459209 rs2244305 chr21 34652958 C T 2.18E-04 Multiple complex diseases IL10RB intron 17554300 rs2834173 chr21 34656070 T C 4.88E-04 Multiple complex diseases IL10RB intron 17554300 rs2850001 chr21 34656653 G A 4.66E-04 Multiple complex diseases IL10RB intron 17554300 rs2855250 chr21 34657806 A G 3.86E-04 Multiple complex diseases IL10RB intron 17554300 rs2855250 chr21 34657806 A G 0.00032 Coronary artery calcification IL10RB intron 23727086 rs2266590 chr21 34659396 A G 3.77E-04 Multiple complex diseases IL10RB intron 17554300 rs765429 chr21 34660001 C T 4.29E-04 Multiple complex diseases IL10RB intron 17554300 rs2247960 chr21 34661145 A G 5.00E-04 Multiple complex diseases IL10RB intron 17554300 rs2247961 chr21 34661173 T G 4.24E-04 Multiple complex diseases IL10RB intron 17554300 rs2248118 chr21 34662711 G A 8.51E-04 Multiple complex diseases IL10RB intron 17554300 rs999261 chr21 34666160 A G 6.75E-04 Multiple complex diseases IL10RB intron 17554300 rs10854364 chr21 34673163 A T 4.88E-05 Multiple complex diseases / / 17554300 rs2834188 chr21 34689253 A G 2.00E-08 Narcolepsy / / 24204295 rs41349446 chr21 34689690 C T 9.90E-04 Type 2 diabetes / / 17463246 rs2252931 chr21 34704320 G A 5.05E-08 Multiple complex diseases IF/R1 intron 17554300 rs17875833 chr21 34721527 G A 0.000000221 Triglycerides IF/R1 missense 23063622 rs17875833 chr21 34721527 G A 0.000000395 Cholesterol,total IF/R1 missense 23063622 rs17875834 chr21 34721782 C T 0.0000011 Triglycerides IF/R1 missense 23063622 rs17875834 chr21 34721782 C T 0.0000012 HDL cholesterol IF/R1 missense 23063622 rs1041867 chr21 34727252 T G 6.25E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) IF/R1 intron 22566498 rs2834201 chr21 34729377 G T 8.63E-04 Multiple complex diseases IF/R1 UTR-3 17554300 rs9980664 chr21 34734510 C A 3.00E-06 Cognitive decline (age-related) / / 24468470 rs12329794 chr21 34753038 G A 5.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs7280245 chr21 34756611 A G 5.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs73194058 chr21 34764288 C A 1.00E-06 Rheumatoid arthritis / / 24390342 rs73194058 chr21 34764288 C A 3.00E-08 Rheumatoid arthritis / / 24390342 rs2284553 chr21 34776695 A G 2.00E-16 Crohn's disease IFNGR2 intron 23128233 rs2268241 chr21 34781050 G A 5.00E-06 Obesity-related traits IFNGR2 intron 23251661 rs9808753 chr21 34787312 A G 0.00041 Coronary artery calcification IFNGR2 missense 23727086 rs2834213 chr21 34792910 A G 4.41E-04 Insulin resistance IFNGR2 intron 21901158 rs2834215 chr21 34796886 A G 3.00E-07 Crohn's disease IFNGR2 intron 22936669 rs1044218 chr21 34821570 G A 5.31E-04 Amyotrophic lateral sclerosis (sporadic) TMEM50B UTR-3 24529757 rs8971 chr21 34883618 T C 6.96E-05 Age-related macular degeneration GART missense pha002856 rs12626309 chr21 34888704 A T 8.58E-04 Multiple complex diseases GART intron 17554300 rs2834232 chr21 34892896 C T 6.96E-05 Age-related macular degeneration GART intron pha002856 rs7279549 chr21 34916613 T C 2.48E-04 Response to cytidine analogues (gemcitabine) SON intron 24483146 rs13047599 chr21 34926260 C T 4.44E-04 Response to cytidine analogues (gemcitabine) SON missense 24483146 rs11088256 chr21 34943543 G T 3.44E-04 Response to cytidine analogues (gemcitabine) SON intron 24483146 rs4816463 chr21 34999978 A G 4.59E-05 Insulin resistance CRYZL1 intron 21901158 rs8133982 chr21 35018470 A G 3.04E-04 Response to cytidine analogues (gemcitabine) ITSN1 intron 24483146 rs2834247 chr21 35056729 G A 6.07E-04 Insulin resistance ITSN1 intron 21901158 rs2834252 chr21 35085900 A G 9.09E-04 Type 2 diabetes ITSN1 intron 17463246 rs2834252 chr21 35085900 A G 2.81E-04 Multiple complex diseases ITSN1 intron 17554300 rs2834255 chr21 35124253 A G 2.83E-04 Response to taxane treatment (placlitaxel) ITSN1 intron 23006423 rs2254480 chr21 35186743 A G 6.21E-04 Oral cancers (chewing tobacco related) ITSN1 intron 22503698 rs2834268 chr21 35199880 A G 9.92E-04 Type 2 diabetes ITSN1 intron 17463246 rs2284568 chr21 35202591 G A 8.04E-05 HIV-1 viral setpoint ITSN1 intron 22174851 rs8127139 chr21 35226367 G A 0.000759 Salmonella-induced pyroptosis ITSN1 intron 22837397 rs2282469 chr21 35229419 T C 0.0000382 Oxaliplatin induced diarrhea in response to colorectal cancer treatment ITSN1 intron 22310351 rs2268257 chr21 35236467 A G 2.87E-04 Lung function (forced vital capacity) ITSN1 intron 24023788 rs9979150 chr21 35241880 G A 1.26E-04 Multiple complex diseases ITSN1 intron 17554300 rs11910015 chr21 35338638 G A 7.20E-12 Red blood cell traits LOC100506334 intron 23222517 rs743417 chr21 35347960 C T 2.51E-05 Hepatocellular carcinoma / / 22807686 rs2070513 chr21 35353874 G T 6.87E-04 Type 2 diabetes / / 17463246 rs2032314 chr21 35354523 T C 8.00E-10 Red blood cell traits / / 23222517 rs11088265 chr21 35355618 A G 6.98E-04 Type 2 diabetes / / 17463246 rs2834317 chr21 35356706 G A 9.05E-07 Red blood cell traits / / 23222517 rs2834319 chr21 35357025 T C 4.22E-07 Red blood cell traits / / 23222517 rs2834328 chr21 35363675 C T 5.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2834328 chr21 35363675 C T 7.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2834332 chr21 35369681 G A 1.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2834332 chr21 35369681 G A 5.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs743416 chr21 35372249 T G 1.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs743416 chr21 35372249 T G 5.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16997893 chr21 35390852 T C 5.30E-04 Response to TNF antagonist treatment / / 21061259 rs2834352 chr21 35402896 A G 8.26E-04 Response to TNF antagonist treatment / / 21061259 rs2834354 chr21 35403013 G C 8.26E-04 Response to TNF antagonist treatment / / 21061259 rs4817614 chr21 35408729 A G 9.30E-04 Type 2 diabetes / / 17463246 rs2154505 chr21 35486237 C T 3.20E-04 Multiple complex diseases MRPS6 intron 17554300 rs7283009 chr21 35504228 A G 2.72E-05 Multiple complex diseases MRPS6 intron 17554300 rs17738942 chr21 35504541 C T 1.70E-05 Recombination rate MRPS6 intron 21698098 rs2409517 chr21 35512558 T C 4.70E-04 Insulin resistance MRPS6 intron 21901158 rs873811 chr21 35543467 C T 5.50E-05 Breast cancer / / pha002853 rs7277241 chr21 35544641 G A 7.74E-05 Breast cancer / / pha002853 rs12627001 chr21 35552433 T C 2.86E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2834402 chr21 35559911 T G 9.17E-04 Insulin resistance LINC00310 intron 21901158 rs1072130 chr21 35582703 A C 9.64E-04 Multiple complex diseases / / 17554300 rs1072130 chr21 35582703 A C 9.81E-04 Insulin resistance / / 21901158 rs9982601 chr21 35599128 C T 6.00E-11 Myocardial infarction (early onset) / / 19198609 rs9982601 chr21 35599128 C T 6.00E-11 Coronary heart disease / / 21347282 rs9982601 chr21 35599128 C T 4.00E-10 Coronary heart disease / / 21378990 rs9982601 chr21 35599128 C T 4.22E-10 Pericardial fat / / 22589742 rs9982601 chr21 35599128 C T 1.74E-10 Coronary artery disease with myocardial infarction / / 23202125 rs9982601 chr21 35599128 C T 1.90E-12 Coronary artery disease (CAD) age <=50 / / 23202125 rs9982601 chr21 35599128 C T 3.81E-09 Coronary artery disease (CAD) (males) / / 23202125 rs9982601 chr21 35599128 C T 7.18E-08 Coronary artery disease (CAD) age >50 / / 23202125 rs9982601 chr21 35599128 C T 7.67E-17 Coronary artery disease / / 23202125 rs9982601 chr21 35599128 C T 3.00E-10 Coronary artery disease / / 24262325 rs8131284 chr21 35607496 T C 6.32E-05 Pulmonary function / / 20010835 rs9978407 chr21 35618638 G A 1.55E-05 Multiple complex diseases / / 17554300 rs9978407 chr21 35618638 G A 6.89E-04 Coronary Artery Disease / / 17634449 rs9978407 chr21 35618638 G A 9.14E-05 Pulmonary function / / 20010835 rs7278204 chr21 35621365 A G 8.47E-05 Pulmonary function / / 20010835 rs973754 chr21 35633530 A G 2.63E-04 Height / / 17255346 rs973754 chr21 35633530 A G 2.66E-05 Multiple complex diseases / / 17554300 rs973754 chr21 35633530 A G 8.42E-05 Pulmonary function / / 20010835 rs7280612 chr21 35633710 C T 7.96E-05 Pulmonary function / / 20010835 rs7278845 chr21 35637462 A G 7.60E-05 Pulmonary function / / 20010835 rs7278845 chr21 35637462 A G 3.61E-07 Coronary heart disease / / 22319020 rs2834430 chr21 35641868 A G 2.21E-05 Pulmonary function / / 20010835 rs9974878 chr21 35642446 G A 2.11E-05 Pulmonary function / / 20010835 rs16991450 chr21 35644017 A C 6.36E-04 Smoking initiation / / 24665060 rs2834431 chr21 35644228 A G 1.99E-05 Pulmonary function / / 20010835 rs16991453 chr21 35647104 C T 1.32E-04 Height / / 17255346 rs16991453 chr21 35647104 C T 2.08E-04 Multiple complex diseases / / 17554300 rs16991453 chr21 35647104 C T 1.91E-05 Pulmonary function / / 20010835 rs2000434 chr21 35647604 G A 8.23E-04 Type 2 diabetes / / 17463246 rs2834435 chr21 35647853 G A 1.22E-04 Height / / 17255346 rs2834435 chr21 35647853 G A 3.91E-04 Multiple complex diseases / / 17554300 rs2834435 chr21 35647853 G A 1.01E-05 Pulmonary function / / 20010835 rs8132042 chr21 35651290 T C 3.42E-05 Pulmonary function / / 20010835 rs9978142 chr21 35652239 A T 4.77E-06 Pulmonary function / / 20010835 rs9978142 chr21 35652239 A T 3.00E-08 Pulmonary function / / 21946350 rs9978142 chr21 35652239 A T 3.17E-05 Pulmonary function (interaction) / / 23284291 rs10470171 chr21 35652644 C T 1.31E-05 Pulmonary function / / 20010835 rs762158 chr21 35653670 C G 1.71E-05 Pulmonary function / / 20010835 rs7277800 chr21 35655734 G A 4.72E-05 Pulmonary function / / 20010835 rs8127788 chr21 35659107 T G 3.46E-04 Parkinson's disease / / 17052657 rs8127788 chr21 35659107 T G 7.66E-06 Coronary heart disease / / pha003031 rs2211695 chr21 35663453 C T 9.11E-04 Multiple complex diseases / / 17554300 rs8128875 chr21 35685936 A G 5.19E-05 ldl cholesterol / / pha003077 rs8128875 chr21 35685936 A G 3.49E-05 Cholesterol / / pha003083 rs2834442 chr21 35690786 T A 5.00E-12 Height / / 20881960 rs1013063 chr21 35698390 T C 5.00E-06 Body mass index (interaction) / / 23192594 rs6517224 chr21 35708224 G A 5.75E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2834461 chr21 35716371 A C 6.52E-05 Coronary heart disease / / pha003031 rs2834463 chr21 35717467 G A 4.15E-05 Stroke / / pha002887 rs8128316 chr21 35721560 C T 3.45E-06 Coronary heart disease / / pha003031 rs2834465 chr21 35726754 C T 2.32E-04 Smoking quantity / / 24665060 rs2834467 chr21 35729280 A G 4.35E-05 Response to Vitamin E supplementation / / 22437554 rs117876865 chr21 35816697 G A 0.000000855 Menopause (age at onset) / / 23424626 rs16991703 chr21 35820965 A G 2.38E-05 Lung adenocarcinoma KCNE1 UTR-3 19836008 rs1547356 chr21 35822572 A G 1.10E-05 Urinary metabolites KCNE1 intron 21572414 rs11088283 chr21 35823779 G A 0.0000488 Ankle-brachial index KCNE1 intron 22361517 rs1012944 chr21 35825266 A G 7.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNE1 intron 20877124 rs1012944 chr21 35825266 A G 4.90E-05 Orofacial clefts KCNE1 intron 22419666 rs1007294 chr21 35838907 G T 4.18E-04 Amyotrophic Lateral Sclerosis KCNE1 intron 17827064 rs16991720 chr21 35856762 A C 3.69E-10 Cholesterol,total KCNE1 intron 23063622 rs16991720 chr21 35856762 A C 5.39E-12 LDL cholesterol KCNE1 intron 23063622 rs16991720 chr21 35856762 A C 8.59E-10 Triglycerides KCNE1 intron 23063622 rs2834497 chr21 35861717 A G 1.00E-04 Information processing speed KCNE1 intron 21130836 rs727957 chr21 35880072 G T 2.00E-12 Electrocardiographic traits KCNE1 intron 20062063 rs727957 chr21 35880072 G T 0.00025 Prostate cancer KCNE1 intron 23555315 rs2834512 chr21 35911599 G A 0.000000021 Rheumatoid arthritis RCAN1 intron 23143596 rs2834512 chr21 35911599 G A 3.06E-08 Rheumatoid arthritis (CCP positive) RCAN1 intron 23143596 rs2247884 chr21 35924126 G A 6.70E-04 Multiple complex diseases RCAN1 intron 17554300 rs8130115 chr21 35938325 A C 9.61E-05 Multiple complex diseases RCAN1 intron 17554300 rs2250442 chr21 35970612 C G 6.58E-04 Type 2 diabetes RCAN1 intron 17463246 rs743302 chr21 35975470 T C 2.80E-04 Type 2 diabetes and 6 quantitative traits RCAN1 intron 17848626 rs743302 chr21 35975470 T C 4.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RCAN1 intron 20877124 rs9305554 chr21 35979071 G T 2.10E-05 Urinary metabolites RCAN1 intron 21572414 rs2268274 chr21 35984463 T C 1.46E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) RCAN1 intron 24023788 rs2268274 chr21 35984463 T C 3.82E-05 Lung function (forced expiratory volume in 1 second) RCAN1 intron 24023788 rs13049531 chr21 35994711 G A 3.17E-04 Body mass index / / 17255346 rs13049531 chr21 35994711 G A 1.27E-05 Suicide attempts in depression or bipolar disorder / / 24964207 rs8126530 chr21 35996944 G C 9.16E-05 Type 2 diabetes / / 17463246 rs2070439 chr21 36011213 G T 1.20E-04 Suicidal ideation / / 22030708 rs2070440 chr21 36011689 A T 4.41E-04 Lymphocyte counts / / 22286170 rs4364091 chr21 36028883 A T 9.04E-05 Multiple complex diseases / / 17554300 rs733014 chr21 36063552 G A 6.20E-06 Odorant perception CLIC6 intron 23910658 rs7282726 chr21 36127330 C T 2.93E-05 Body Mass Index LOC100506385 intron pha003019 rs2253319 chr21 36188046 C T 2.96E-04 Nicotine smoking RUNX1 intron 19268276 rs9976946 chr21 36208062 C T 5.10E-04 Multiple complex diseases RUNX1 intron 17554300 rs9976946 chr21 36208062 C T 5.00E-06 Preeclampsia RUNX1 intron 23551011 rs2834649 chr21 36209650 G A 6.31E-04 Nicotine smoking RUNX1 intron 19268276 rs2834650 chr21 36210100 C T 2.78E-04 Multiple complex diseases RUNX1 intron 17554300 rs2186290 chr21 36219716 T G 0.0006643 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RUNX1 intron 23233654 rs2186290 chr21 36219716 T G 6.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) RUNX1 intron 23233662 rs2268284 chr21 36220679 T C 0.0000478 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RUNX1 intron 23233654 rs2268284 chr21 36220679 T C 4.78E-05 Methotrexate clearance (acute lymphoblastic leukemia) RUNX1 intron 23233662 rs2409535 chr21 36222560 T C 0.0006647 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RUNX1 intron 23233654 rs2409535 chr21 36222560 T C 6.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) RUNX1 intron 23233662 rs968625 chr21 36223627 G A 1.59E-05 Major depressive disorder RUNX1 intron 19107115 rs2834655 chr21 36238507 G A 5.00E-07 Immune response to smallpox vaccine (IL-6) RUNX1 intron 22542470 rs13053063 chr21 36255821 T G 2.80E-05 Urinary metabolites RUNX1 intron 21572414 rs2834664 chr21 36275439 T C 2.00E-04 Cognitive impairment induced by topiramate RUNX1 intron 22091778 rs9985174 chr21 36277558 T A 7.90E-04 Atrial fibrillation RUNX1 intron 21846873 rs2834669 chr21 36280043 A G 0.00021 Coronary artery calcification RUNX1 intron 23727086 rs2834670 chr21 36280376 A G 3.43E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RUNX1 intron 20877124 rs9984470 chr21 36285911 C T 1.40E-05 Iron levels RUNX1 intron 21208937 rs2834672 chr21 36289022 G A 8.64E-04 Insulin resistance RUNX1 intron 21901158 rs2834680 chr21 36309463 T C 5.17E-04 Stroke RUNX1 intron pha002887 rs8126567 chr21 36313618 C T 5.40E-06 Iron levels RUNX1 intron 21208937 rs11701453 chr21 36338916 C G 1.65E-07 Dilated cardiomyopathy RUNX1 intron 20975947 rs11701555 chr21 36339264 G A 7.38E-05 Cholesterol RUNX1 intron 17255346 rs11701555 chr21 36339264 G A 0.000031 Salmonella-induced pyroptosis RUNX1 intron 22837397 rs2014300 chr21 36357861 A G 8.00E-22 Esophageal cancer RUNX1 intron 21642993 rs2242876 chr21 36362546 C A 0.00000136 Cholesterol,total RUNX1 intron 23063622 rs7282535 chr21 36377221 A T 1.68E-04 Nicotine smoking RUNX1 intron 19268276 rs2242888 chr21 36387828 T C 5.40E-04 Type 2 diabetes RUNX1 intron 17463246 rs882776 chr21 36388287 C T 9.18E-04 Type 2 diabetes RUNX1 intron 17463246 rs1474479 chr21 36405666 C T 8.18E-04 Type 2 diabetes RUNX1 intron 17463246 rs9980210 chr21 36406550 T C 4.61E-04 Type 2 diabetes RUNX1 intron 17463246 rs2294163 chr21 36407390 G A 7.32E-04 Amyotrophic lateral sclerosis (sporadic) RUNX1 intron 24529757 rs9983044 chr21 36416332 C G 2.00E-07 Phospholipid levels (plasma) RUNX1 intron 21829377 rs2071029 chr21 36422478 C T 8.10E-06 Urinary metabolites RUNX1 nearGene-5 21572414 rs2834741 chr21 36431262 T A 6.70E-04 Insulin resistance / / 21901158 rs2834744 chr21 36436615 C T 7.77E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2834745 chr21 36436718 G A 7.77E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2242900 chr21 36453837 A G 3.00E-05 Lung cancer / / 18978790 rs2242900 chr21 36453837 A G 4.41E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs2834755 chr21 36463838 T G 2.40E-06 Urinary metabolites / / 21572414 rs2834763 chr21 36472289 C A 4.71E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2834772 chr21 36483159 C T 9.49E-04 Type 2 diabetes / / 17463246 rs17812953 chr21 36488822 T C 1.70E-04 Psoriasis / / 20953189 rs2834778 chr21 36489487 G A 2.35E-04 Stroke / / pha002887 rs2834779 chr21 36491334 T G 7.68E-04 Rheumatoid arthritis / / 21452313 rs2834787 chr21 36502558 A G 9.20E-04 Multiple complex diseases / / 17554300 rs8131196 chr21 36505568 A G 2.48E-04 Rheumatoid arthritis / / 21452313 rs2834792 chr21 36505688 C T 1.10E-04 Rheumatoid arthritis / / 21452313 rs17812977 chr21 36505877 C T 3.80E-04 Multiple complex diseases / / 17554300 rs16992859 chr21 36507008 G A 9.89E-04 Type 2 diabetes / / 17463246 rs16992859 chr21 36507008 G A 1.11E-04 Multiple complex diseases / / 17554300 rs7281056 chr21 36515788 C T 2.70E-05 Urinary metabolites / / 21572414 rs1997624 chr21 36521655 C T 1.90E-05 Urinary metabolites / / 21572414 rs2409589 chr21 36529043 C T 5.20E-05 Cognitive test performance / / 20125193 rs4459802 chr21 36530416 T C 2.55E-05 Cognitive test performance / / 20125193 rs2834807 chr21 36531645 A C 3.90E-04 Insulin resistance / / 21901158 rs2834812 chr21 36533662 C T 9.00E-06 HIV-1 control / / 20041166 rs2225422 chr21 36536455 C A 5.94E-04 Type 2 diabetes / / 17463246 rs2834822 chr21 36553349 T C 5.16E-04 Multiple complex diseases / / 17554300 rs2248159 chr21 36576601 G A 1.99E-05 Systemic lupus erythematosus / / pha002867 rs1033335 chr21 36585069 C T 1.19E-05 Blood pressure / / 24001895 rs1033335 chr21 36585069 C T 5.56E-04 Blood pressure / / 24001895 rs2242699 chr21 36618025 C T 6.82E-04 Multiple complex diseases / / 17554300 rs2242699 chr21 36618025 C T 2.07E-05 Blood pressure / / 24001895 rs2247614 chr21 36631687 G C 1.10E-05 Sleep and circadian phenotypes / / 17903308 rs2075898 chr21 36645273 T C 4.10E-05 Personality dimensions / / 18957941 rs2834890 chr21 36677318 G A 1.92E-04 Arthritis (juvenile idiopathic) / / 22354554 rs2242714 chr21 36677687 G A 4.64E-04 Multiple complex diseases / / 17554300 rs2834902 chr21 36688528 A C 8.00E-06 Corneal curvature / / 22969067 rs2834903 chr21 36688770 T C 6.27E-04 Multiple complex diseases / / 17554300 rs8129030 chr21 36712588 T A 5.44E-09 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs9979383 chr21 36715761 C T 3.69E-08 Rheumatoid arthritis (CCP positive) / / 23143596 rs9979383 chr21 36715761 C T 5.00E-10 Rheumatoid arthritis / / 23143596 rs9979383 chr21 36715761 C T 0.0000477 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis / / 23603761 rs9979383 chr21 36715761 C T 0.000105 Oligoarticular juvenile idiopathic arthritis / / 23603761 rs9979383 chr21 36715761 C T 1.06E-08 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs17813061 chr21 36732182 C T 5.79E-04 Aortic root size / / 21223598 rs8133843 chr21 36738242 G A 2.00E-08 Rheumatoid arthritis / / 24390342 rs8133843 chr21 36738242 G A 3.00E-09 Rheumatoid arthritis / / 24390342 rs760138 chr21 36775154 G A 1.90E-04 Multiple complex diseases LOC100506403 intron 17554300 rs2834929 chr21 36775722 C T 1.90E-04 Multiple complex diseases LOC100506403 intron 17554300 rs4817721 chr21 36786185 C T 5.58E-04 Multiple complex diseases LOC100506403 intron 17554300 rs7277670 chr21 36787961 A G 2.28E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100506403 intron 20877124 rs2834932 chr21 36798021 T C 9.71E-04 Alzheimer's disease LOC100506403 intron 24755620 rs2834939 chr21 36832908 A G 1.80E-05 Lipoproteins LOC100506403 intron pha003079 rs16993221 chr21 36849419 A T 2.53E-04 Multiple complex diseases LOC100506403 intron 17554300 rs16993221 chr21 36849419 A T 2.00E-08 C-reactive protein and white blood cell count LOC100506403 intron 22788528 rs16993446 chr21 37012212 C T 2.07E-04 Multiple complex diseases / / 17554300 rs12483148 chr21 37013621 T C 5.00E-06 Obesity-related traits / / 23251661 rs2835099 chr21 37072670 C T 4.73E-05 Sudden cardiac arrest / / 21658281 rs7278588 chr21 37074965 A G 5.85E-06 Waist-Hip Ratio / / pha003029 rs2142028 chr21 37075177 C G 6.62E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2222956 chr21 37101040 G A 1 Drug response to Etoposide / / 17537913 rs2222956 chr21 37101040 G A 6.31E-05 Blood Pressure / / pha003039 rs2835123 chr21 37120781 A G 9.19E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs2835128 chr21 37122194 T C 4.46E-05 Waist-Hip Ratio / / pha003029 rs1883054 chr21 37122288 C T 1.73E-05 Blood Pressure / / pha003039 rs1011820 chr21 37129292 T C 5.01E-05 Waist-Hip Ratio / / pha003029 rs2835137 chr21 37136803 T G 4.15E-05 Waist-Hip Ratio / / pha003029 rs2835138 chr21 37137617 C A 3.88E-05 Waist-Hip Ratio / / pha003029 rs2835138 chr21 37137617 C A 3.32E-05 Blood Pressure / / pha003039 rs433074 chr21 37155661 T G 4.58E-04 Alzheimer's disease (late onset) / / 21379329 rs433074 chr21 37155661 T G 6.65E-05 Waist-Hip Ratio / / pha003029 rs9980922 chr21 37208735 T G 4.87E-05 Blood Pressure / / pha003039 rs9980922 chr21 37208735 T G 2.26E-05 Blood Pressure / / pha003045 rs9980922 chr21 37208735 T G 9.47E-05 Blood Pressure / / pha003047 rs2091856 chr21 37210411 T C 9.20E-05 Blood Pressure / / pha003039 rs2091856 chr21 37210411 T C 8.41E-05 Blood Pressure / / pha003045 rs13052228 chr21 37212090 G A 8.20E-04 Obesity (extreme) / / 21935397 rs741754 chr21 37221474 T C 1.43E-05 Blood Pressure / / pha003039 rs741754 chr21 37221474 T C 8.76E-05 Blood Pressure / / pha003045 rs2835153 chr21 37229471 G A 9.10E-05 Blood Pressure / / pha003039 rs367467 chr21 37290673 G A 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2835162 chr21 37301530 A G 8.40E-05 Height / / pha003010 rs16993715 chr21 37303698 C T 3.00E-04 Dietary macronutrient intake / / 23636237 rs1467367 chr21 37316103 T C 7.98E-04 Acute lung injury / / 22295056 rs1467366 chr21 37316280 G A 6.77E-04 Acute lung injury / / 22295056 rs2835189 chr21 37342121 T G 4.57E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2835189 chr21 37342121 T G 8.34E-04 Stroke / / pha002887 rs2212918 chr21 37381952 C T 8.83E-04 Bipolar disorder / / 19259986 rs2212918 chr21 37381952 C T 4.56E-04 Schizophrenia / / 20832056 rs2835248 chr21 37417489 G A 6.78E-05 Bipolar disorder SETD4 intron 19259986 rs2835249 chr21 37419038 G A 7.90E-06 Response to lithium treatment in bipolar disorder SETD4 intron 19448189 rs2018721 chr21 37422966 C T 7.32E-05 Bipolar disorder SETD4 intron 19259986 rs762360 chr21 37425955 C T 9.94E-05 Bipolar disorder SETD4 intron 19259986 rs2835261 chr21 37427907 G A 1.03E-04 Schizophrenia SETD4 intron 20832056 rs1143663 chr21 37442675 G A 1 Drug response to Daunorubicin CBR1 missense 19204081 rs1143663 chr21 37442675 G A 1 Drug response to Doxorubicin CBR1 missense 19204081 rs41557318 chr21 37443349 C T 1 Drug response to Daunorubicin CBR1 missense 19204081 rs41557318 chr21 37443349 C T 1 Drug response to Doxorubicin CBR1 missense 19204081 rs735143 chr21 37460862 A G 4.92E-04 Bipolar disorder LOC100133286 intron 19259986 rs9978576 chr21 37476359 A G 5.45E-06 Lymphocyte counts LOC100133286 intron 22286170 rs4817775 chr21 37485062 A C 9.00E-07 Bone mineral density LOC100133286 intron 22504420 rs2835280 chr21 37488404 T C 2.28E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LOC100133286 intron 20031582 rs2226827 chr21 37494010 G A 1.68E-04 Amyotrophic lateral sclerosis (sporadic) LOC100133286 intron 24529757 rs2226827 chr21 37494010 G A 5.18E-05 Socioeconomic Factors LOC100133286 intron pha003066 rs8133052 chr21 37507501 G A 1 Drug response to Doxorubicin CBR3 missense 18551042 rs1056892 chr21 37518706 G A 1 Drug response to Doxorubicin CBR3 missense 18551042 rs1056892 chr21 37518706 G A 0.00029 Prostate cancer (non-advanced prostate cancer) CBR3 missense 23555315 rs2835293 chr21 37542418 A G 1.10E-06 Urinary metabolites DOPEY2 intron 21572414 rs2835301 chr21 37557225 A T 7.02E-05 Multiple complex diseases DOPEY2 intron 17554300 rs1573306 chr21 37558042 A G 3.77E-04 Type 2 diabetes DOPEY2 intron 17463246 rs6517335 chr21 37559979 G A 3.77E-04 Type 2 diabetes DOPEY2 intron 17463246 rs2243723 chr21 37571593 A G 8.66E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DOPEY2 intron 20877124 rs2247051 chr21 37577586 G A 7.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DOPEY2 intron 20877124 rs2850080 chr21 37589050 A G 7.95E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DOPEY2 intron 20877124 rs7280062 chr21 37606670 T C 3.16E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) DOPEY2 intron 24023788 rs12627688 chr21 37617142 T C 4.50E-06 Urinary metabolites DOPEY2 intron 21572414 rs2835327 chr21 37622102 G A 1.20E-05 Urinary metabolites DOPEY2 intron 21572414 rs2835327 chr21 37622102 G A 7.25E-04 Coronary heart disease DOPEY2 intron 21606135 rs2835331 chr21 37637805 T C 2.40E-05 Urinary metabolites DOPEY2 intron 21572414 rs2284642 chr21 37651313 G T 9.14E-04 Multiple complex diseases DOPEY2 intron 17554300 rs2284642 chr21 37651313 G T 6.70E-04 Alcohol dependence DOPEY2 intron 20201924 rs2284642 chr21 37651313 G T 8.10E-04 Alcohol dependence DOPEY2 intron 20201924 rs2835340 chr21 37733063 T C 1.19E-05 Neuroblastoma MORC3 intron pha002895 rs218626 chr21 37754032 G A 4.70E-05 Neuroblastoma / / pha002895 rs218634 chr21 37794921 G A 1.40E-06 Kidney stones / / 19561606 rs2835345 chr21 37801434 C A 1.92E-04 Pulmonary function / / 23932459 rs2835345 chr21 37801434 C A 8.00E-06 Pulmonary function / / 23932459 rs9981659 chr21 37807852 G A 5.32E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs9984974 chr21 37809377 A G 2.00E-06 Myopia (pathological) / / 23049088 rs9984974 chr21 37809377 A G 5.95E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs9985126 chr21 37809408 C T 5.32E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs2835349 chr21 37814114 T C 6.33E-05 Nephrolithiasis / / 22396660 rs2835358 chr21 37817653 G A 5.98E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs9974322 chr21 37818305 A G 6.61E-05 Lupus nephritis in systemic lupus erythematosus / / 24925725 rs219781 chr21 37832621 G T 3.20E-08 Kidney stones CLDN14 nearGene-3 19561606 rs219780 chr21 37833307 C T 4.00E-12 Kidney stones CLDN14 cds-synon 19561606 rs219778 chr21 37834641 A G 3.20E-08 Kidney stones CLDN14 intron 19561606 rs170183 chr21 37848334 G A 1.17E-05 Bone mineral density CLDN14 intron 24249740 rs170183 chr21 37848334 G A 2.00E-07 Bone mineral density CLDN14 intron 24249740 rs170183 chr21 37848334 G A 4.00E-09 Bone mineral density CLDN14 intron 24249740 rs170183 chr21 37848334 G A 6.00E-08 Bone mineral density CLDN14 intron 24249740 rs219737 chr21 37859660 T C 4.88E-04 Response to cytidine analogues (gemcitabine) CLDN14 intron 24483146 rs2835379 chr21 37893365 G A 1.81E-04 Multiple complex diseases CLDN14 intron 17554300 rs914148 chr21 37907311 T A 1.46E-05 Multiple sclerosis CLDN14 intron 17660530 rs9984896 chr21 37935669 A C 5.00E-06 QT interval CLDN14 intron 23166209 rs16994356 chr21 38005642 T G 9.25E-05 Multiple complex diseases / / 17554300 rs401789 chr21 38006139 G A 3.73E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs6517368 chr21 38007943 T C 2.00E-06 Asthma and hay fever / / 24388013 rs2734394 chr21 38014652 C T 5.00E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs419945 chr21 38015205 A G 5.49E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs375697 chr21 38017529 A G 1.76E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs2017054 chr21 38018119 A G 2.61E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs16994374 chr21 38020187 C T 2.32E-04 Multiple complex diseases / / 17554300 rs16994378 chr21 38020306 G A 2.66E-04 Multiple complex diseases / / 17554300 rs1573308 chr21 38038694 A G 2.60E-05 Urinary metabolites / / 21572414 rs9977677 chr21 38052785 G A 2.00E-04 Primary nonsyndromic vesicoureteric reflex / / 19959718 rs2835440 chr21 38062096 C T 4.97E-04 Suicide attempts in bipolar disorder / / 21423239 rs9977521 chr21 38082812 C T 9.78E-04 Alcohol dependence SIM2 intron 24277619 rs2835444 chr21 38087642 A G 5.21E-04 Suicide attempts in bipolar disorder SIM2 intron 21423239 rs13050963 chr21 38091643 C T 4.27E-04 Iron levels SIM2 intron pha002876 rs6517378 chr21 38096210 C T 2.20E-04 Suicide attempts in bipolar disorder SIM2 intron 21423239 rs2850097 chr21 38097116 T A 1.32E-04 Suicide attempts in bipolar disorder SIM2 intron 21423239 rs2249959 chr21 38097221 T C 1.69E-04 Suicide attempts in bipolar disorder SIM2 intron 21423239 rs2250702 chr21 38103630 C T 1.96E-04 Suicide attempts in bipolar disorder SIM2 intron 21423239 rs2250702 chr21 38103630 C T 4.23E-05 Brain structure SIM2 intron 22504417 rs2835449 chr21 38106209 C T 1.68E-04 Suicide attempts in bipolar disorder SIM2 intron 21423239 rs2073417 chr21 38120718 G A 5.84E-04 Taste perception SIM2 UTR-3 22132133 rs2850103 chr21 38129942 C A 2.70E-05 Urinary metabolites HLCS intron 21572414 rs2850104 chr21 38130030 C A 1.60E-05 Urinary metabolites HLCS intron 21572414 rs7275269 chr21 38140659 G C 8.04E-04 Response to taxane treatment (placlitaxel) HLCS intron 23006423 rs9981318 chr21 38149390 C T 2.30E-06 Urinary metabolites HLCS intron 21572414 rs9985116 chr21 38152310 C T 2.10E-06 Urinary metabolites HLCS intron 21572414 rs3787751 chr21 38160163 T C 1.90E-04 Smoking initiation HLCS intron 24665060 rs8132225 chr21 38163322 T C 6.49E-05 Parkinson's disease HLCS intron 21248740 rs7280984 chr21 38231868 T C 0.00067773 Hypertension (early onset hypertension) HLCS intron 22479346 rs2835511 chr21 38239499 G A 0.000119915 Hypertension (early onset hypertension) HLCS intron 22479346 rs2898312 chr21 38246278 T C 2.19E-05 Serum metabolites HLCS intron 19043545 rs12482724 chr21 38248682 A G 7.40E-04 Multiple complex diseases HLCS intron 17554300 rs11088368 chr21 38253895 T G 3.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HLCS intron 20877124 rs2835523 chr21 38260090 A G 5.87E-06 Serum metabolites HLCS intron 19043545 rs2835525 chr21 38264824 G A 3.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HLCS intron 20877124 rs6517390 chr21 38264982 A C 0.000151337 Hypertension (early onset hypertension) HLCS intron 22479346 rs8132874 chr21 38275738 T C 3.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HLCS intron 20877124 rs6517391 chr21 38281189 C T 3.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HLCS intron 20877124 rs11702761 chr21 38290619 T A 3.22E-04 Suicide attempts in bipolar disorder HLCS intron 21423239 rs2073423 chr21 38302129 C T 0.000661626 Hypertension (early onset hypertension) HLCS intron 22479346 rs3787771 chr21 38306141 T C 1.17E-05 Response to tocilizumab in rheumatoid arthritis HLCS intron 22491018 rs16994604 chr21 38306415 G A 9.61E-04 Multiple complex diseases HLCS intron 17554300 rs2835539 chr21 38308552 C T 5.75E-06 Response to tocilizumab in rheumatoid arthritis HLCS intron 22491018 rs3819154 chr21 38334762 G C 5.50E-05 Pericardial fat HLCS intron 22589742 rs7281251 chr21 38350382 A G 0.000319058 Hypertension (early onset hypertension) HLCS intron 22479346 rs16994660 chr21 38353554 C T 8.60E-05 Pericardial fat HLCS intron 22589742 rs150799198 chr21 38390362 G A 0.000077 Prostate cancer (advanced) DSCR6 missense 23555315 rs9974455 chr21 38399356 A C 9.80E-04 Type 2 diabetes / / 17463246 rs9974455 chr21 38399356 A C 4.04E-05 Serum metabolites / / 19043545 rs2835561 chr21 38401539 G T 7.72E-04 Type 2 diabetes / / 17463246 rs2835561 chr21 38401539 G T 3.59E-05 Serum metabolites / / 19043545 rs2835561 chr21 38401539 G T 4.21E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2835561 chr21 38401539 G T 4.30E-05 Lung function (forced vital capacity) / / 24023788 rs9978006 chr21 38401803 G C 8.98E-04 Type 2 diabetes / / 17463246 rs9978006 chr21 38401803 G C 4.24E-05 Serum metabolites / / 19043545 rs2835570 chr21 38439504 A G 2.82E-04 Multiple complex diseases PIGP intron 17554300 rs2835583 chr21 38459725 A G 4.43E-04 Multiple complex diseases TTC3 intron 17554300 rs3819262 chr21 38460890 G T 6.13E-04 Amyotrophic Lateral Sclerosis TTC3 intron 17362836 rs67875417 chr21 38460890 GG GGG,GTT 6.13E-04 Amyotrophic Lateral Sclerosis TTC3 intron 17362836 rs2835599 chr21 38466937 G T 2.19E-04 Urinary albumin excretion rate in type 1 diabetes TTC3 intron 24595857 rs2032088 chr21 38477330 G A 6.13E-04 Amyotrophic Lateral Sclerosis TTC3 intron 17362836 rs2032088 chr21 38477330 G A 6.26E-09 Lymphocyte counts TTC3 intron 22286170 rs1003719 chr21 38491095 A G 2.00E-10 Eye color TTC3 intron 20463881 rs6517404 chr21 38494918 G A 8.90E-04 Alzheimer's disease TTC3 intron 17998437 rs2018521 chr21 38517264 T C 9.90E-04 Type 2 diabetes and 6 quantitative traits TTC3 intron 17848626 rs2244185 chr21 38539119 A G 1.40E-04 Type 2 diabetes and 6 quantitative traits TTC3 intron 17848626 rs2040125 chr21 38549236 A G 7.77E-04 Alzheimer's disease TTC3 intron 17998437 rs2040126 chr21 38549303 C A 3.11E-04 Multiple complex diseases TTC3 intron 17554300 rs4817859 chr21 38609051 T G 3.04E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) DSCR3 intron 24023788 rs1009923 chr21 38643970 A G 5.45E-05 Multiple complex diseases / / 17554300 rs9976694 chr21 38660388 C T 3.04E-04 Breast cancer / / 21060860 rs2212736 chr21 38676484 C T 5.32E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9978132 chr21 38694499 C A 7.22E-05 Chronic obstructive pulmonary disease / / 19300482 rs9978132 chr21 38694499 C A 7.22E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11909066 chr21 38702185 A C 2.22E-05 Calcium levels / / pha003085 rs2835702 chr21 38724311 T C 0.000000584 Antisocial behavior / / 23077488 rs12106331 chr21 38727277 A G 0.000000569 Antisocial behavior / / 23077488 rs12483205 chr21 38740824 A G 5.00E-06 HIV-1 replication DYRK1A intron 21364930 rs1475887 chr21 38749183 A G 8.21E-04 Multiple complex diseases DYRK1A intron 17554300 rs11701543 chr21 38755883 C T 9.59E-05 Personality dimensions DYRK1A intron 18957941 rs11701543 chr21 38755883 C T 1.30E-05 Urinary metabolites DYRK1A intron 21572414 rs41483945 chr21 38764244 G A 2.20E-05 Urinary metabolites DYRK1A intron 21572414 rs2835725 chr21 38791156 A G 8.05E-04 Alcohol dependence DYRK1A intron 20201924 rs2835727 chr21 38791673 A T 2.00E-05 Urinary metabolites DYRK1A UTR-5 21572414 rs2835731 chr21 38796728 C T 2.81E-05 Personality dimensions DYRK1A intron 18957941 rs2835731 chr21 38796728 C T 2.80E-05 Personality dimensions DYRK1A intron 21173776 rs2835731 chr21 38796728 C T 1.00E-05 Urinary metabolites DYRK1A intron 21572414 rs16995099 chr21 38800037 C T 8.92E-04 Multiple complex diseases DYRK1A intron 17554300 rs2835735 chr21 38802816 G A 3.13E-04 Multiple complex diseases DYRK1A intron 17554300 rs11700462 chr21 38817812 G A 5.00E-06 IgG glycosylation DYRK1A intron 23382691 rs2835762 chr21 38845798 C T 1.18E-05 AIDS progression DYRK1A intron 19115949 rs8132830 chr21 38848134 T G 4.03E-04 Lymphocyte counts DYRK1A intron 22286170 rs2835771 chr21 38861833 C T 0.0000105 Antisocial behavior DYRK1A intron 23077488 rs2835788 chr21 38906071 C G 3.88E-05 Type 2 diabetes / / 17463246 rs2835810 chr21 38932778 T C 6.00E-06 Metabolic syndrome / / 20694148 rs2835811 chr21 38934053 G A 4.15E-06 AIDS progression / / 19115949 rs9981415 chr21 38966021 G C 2.10E-05 Parkinson's disease (age of onset) / / 19772629 rs73220488 chr21 38987025 C T 1.80E-08 Electroencephalographic traits in alcoholism / / 22554406 rs75938265 chr21 38987039 C T 1.90E-08 Electroencephalographic traits in alcoholism / / 22554406 rs2835831 chr21 38987233 T C 1.80E-08 Electroencephalographic traits in alcoholism / / 22554406 rs2835833 chr21 38987897 G A 2.00E-08 Electroencephalographic traits in alcoholism / / 22554406 rs4816567 chr21 38988155 T C 2.00E-08 Electroencephalographic traits in alcoholism / / 22554406 rs73220491 chr21 38988323 T G 1.80E-08 Electroencephalographic traits in alcoholism / / 22554406 rs4816568 chr21 38988346 A G 1.80E-08 Electroencephalographic traits in alcoholism / / 22554406 rs4817877 chr21 38988393 G C 2.00E-08 Electroencephalographic traits in alcoholism / / 22554406 rs2835835 chr21 38989072 G A 2.10E-08 Electroencephalographic traits in alcoholism / / 22554406 rs2835836 chr21 38989187 A C 1.80E-08 Electroencephalographic traits in alcoholism / / 22554406 rs73220494 chr21 38989276 C T 2.90E-08 Electroencephalographic traits in alcoholism / / 22554406 rs111576572 chr21 38989564 A G 2.90E-08 Electroencephalographic traits in alcoholism / / 22554406 rs73220495 chr21 38989712 G A 2.80E-08 Electroencephalographic traits in alcoholism / / 22554406 rs2835837 chr21 38990443 G A 2.10E-08 Electroencephalographic traits in alcoholism / / 22554406 rs2835838 chr21 38990994 A G 1.70E-08 Electroencephalographic traits in alcoholism / / 22554406 rs2835839 chr21 38991034 T C 1.70E-08 Electroencephalographic traits in alcoholism / / 22554406 rs2835840 chr21 38991321 G C 1.70E-08 Electroencephalographic traits in alcoholism / / 22554406 rs857980 chr21 38995142 G A 1.70E-08 Electroencephalographic traits in alcoholism / / 22554406 rs702858 chr21 38995169 A G 1.70E-08 Electroencephalographic traits in alcoholism / / 22554406 rs702859 chr21 38997701 G A 1.60E-08 Electroencephalographic traits in alcoholism KCNJ6 cds-synon 22554406 rs857979 chr21 38998093 A G 1.60E-08 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs857978 chr21 38998126 A G 2.20E-08 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs857976 chr21 39001177 C A 2.30E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs857975 chr21 39001613 T G 3.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KCNJ6 intron 20877124 rs857975 chr21 39001613 T G 8.30E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1787330 chr21 39002787 G A 8.30E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1515050 chr21 39003142 T C 8.00E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1787331 chr21 39003525 T G 8.00E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2154553 chr21 39004501 G A 6.70E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs857974 chr21 39005741 A G 6.70E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs857973 chr21 39007498 A G 5.50E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs721014 chr21 39008109 A G 5.60E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs857947 chr21 39008539 C T 3.10E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs702860 chr21 39008629 C T 3.10E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs857946 chr21 39009303 A T 3.10E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs111372083 chr21 39010676 C T 3.70E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835848 chr21 39011073 C T 3.10E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835849 chr21 39011524 T C 3.10E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs73222307 chr21 39012225 G A 3.10E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs717859 chr21 39012802 G A 3.10E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835850 chr21 39012977 T C 3.50E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs73222309 chr21 39013686 C T 3.10E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835852 chr21 39014128 G A 3.10E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs73222314 chr21 39014802 A G 3.10E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835853 chr21 39014892 C A 3.10E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835855 chr21 39015754 T A 3.10E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs17814920 chr21 39015897 G A 6.80E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1787423 chr21 39016910 G C 4.50E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1475839 chr21 39021941 C T 3.10E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs10483038 chr21 39024771 T C 9.66E-04 Age-related macular degeneration KCNJ6 intron 21909106 rs10483038 chr21 39024771 T C 6.60E-10 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835872 chr21 39027272 G A 5.00E-10 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs4817881 chr21 39031902 C T 7.90E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835880 chr21 39032477 A G 2.80E-10 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs66815183 chr21 39032828 C T 7.20E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835881 chr21 39033131 G A 9.80E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2850123 chr21 39034762 T C 1.40E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1709822 chr21 39035485 A G 1.50E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1709821 chr21 39035622 T C 1.50E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs7278101 chr21 39035873 T C 6.60E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1787393 chr21 39035934 G A 1.30E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1709820 chr21 39035971 A C 8.70E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1709819 chr21 39036115 A C 8.60E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1787394 chr21 39036176 C A 8.70E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1709818 chr21 39036211 T C 8.70E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1709817 chr21 39036349 T A 8.70E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1787395 chr21 39036478 A C 8.70E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1787396 chr21 39036487 A C 8.70E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs73222345 chr21 39036569 G A 1.40E-09 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs8134288 chr21 39036989 T C 8.60E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1787397 chr21 39037378 A G 8.60E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1787398 chr21 39037504 A C 8.60E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1709835 chr21 39037636 A G 8.60E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1709833 chr21 39037805 A G 8.60E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1787399 chr21 39037883 A G 8.60E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1709832 chr21 39038167 T G 8.60E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1787400 chr21 39038217 G C 8.60E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1787401 chr21 39038893 C T 8.60E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1787402 chr21 39038990 C T 4.00E-08 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835886 chr21 39040342 C T 4.50E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835887 chr21 39040359 T C 4.50E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1008542 chr21 39040561 G A 4.50E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1008543 chr21 39040776 G A 4.50E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1008544 chr21 39040869 T C 4.50E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs9982323 chr21 39041628 G A 4.50E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs8134478 chr21 39041817 T G 4.50E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs8133572 chr21 39041923 C G 2.20E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs4816576 chr21 39042259 G A 2.20E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs11700477 chr21 39043011 C G 3.90E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs12233305 chr21 39046853 C A 5.20E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs67739865 chr21 39049101 G A 3.30E-08 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1787404 chr21 39049362 A G 9.30E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1709826 chr21 39049473 G A 8.50E-08 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs3827195 chr21 39049817 C T 2.70E-08 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835888 chr21 39049859 T C 8.70E-08 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1787406 chr21 39051168 C A 7.40E-08 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2898334 chr21 39052584 G T 7.10E-04 Type 2 diabetes and 6 quantitative traits KCNJ6 intron 17848626 rs8126563 chr21 39052624 C T 4.00E-08 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs4452239 chr21 39052655 T G 1.10E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs4477996 chr21 39052666 C T 1.10E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1888467 chr21 39052780 G T 1.40E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs724545 chr21 39052878 G T 1.40E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1399592 chr21 39053862 T G 4.00E-04 Chronic fatigue syndrome KCNJ6 intron 21912186 rs1399592 chr21 39053862 T G 1.30E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1399591 chr21 39053957 C T 1.00E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1399590 chr21 39054071 G A 9.00E-08 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835891 chr21 39056227 T C 6.88E-04 Multiple complex diseases KCNJ6 intron 17554300 rs2835893 chr21 39060893 G A 6.10E-08 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs858008 chr21 39065630 A G 4.30E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835894 chr21 39066042 A G 7.00E-08 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835895 chr21 39066353 C T 7.50E-08 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835896 chr21 39066640 C T 7.50E-08 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1005546 chr21 39068872 G A 5.20E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1005545 chr21 39069197 C G 5.50E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs62221645 chr21 39071226 T C 1.40E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835898 chr21 39071781 T A,C 1.40E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835900 chr21 39075749 G T 1.10E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835901 chr21 39076914 C T 4.60E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835903 chr21 39077237 G C 4.30E-06 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs12482570 chr21 39077777 A G 1.10E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs1515056 chr21 39082585 C G 1.20E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2835910 chr21 39085907 C T 1.10E-07 Electroencephalographic traits in alcoholism KCNJ6 intron 22554406 rs2070995 chr21 39086965 T C 1 Drug response to Morphine KCNJ6 cds-synon 19756153 rs858032 chr21 39101940 T C 7.44E-05 Multiple complex diseases KCNJ6 intron 17554300 rs858032 chr21 39101940 T C 7.62E-04 Suicide attempts in bipolar disorder KCNJ6 intron 21423239 rs858020 chr21 39112556 T C 7.49E-04 Type 2 diabetes KCNJ6 intron 17463246 rs2835927 chr21 39120344 T C 2.33E-04 Multiple complex diseases KCNJ6 intron 17554300 rs2835937 chr21 39126224 A G 3.28E-04 Multiple complex diseases KCNJ6 intron 17554300 rs2835938 chr21 39126336 T A 4.29E-04 Multiple complex diseases KCNJ6 intron 17554300 rs762145 chr21 39146318 C T 8.70E-06 Smoking behavior KCNJ6 intron 19188921 rs4817889 chr21 39165570 A G 1.87E-05 Glucose levels KCNJ6 intron pha003061 rs2211842 chr21 39183533 A C 3.22E-04 Insulin resistance KCNJ6 intron 21901158 rs6517434 chr21 39188056 C T 7.07E-06 Multiple complex diseases KCNJ6 intron 17554300 rs2835989 chr21 39192552 A G 4.57E-04 Insulin resistance KCNJ6 intron 21901158 rs6517435 chr21 39195222 A G 3.05E-04 Fibrinogen KCNJ6 intron 17255346 rs2154556 chr21 39198887 T C 9.67E-05 Non-alcoholic fatty liver disease histology (other) KCNJ6 intron 20708005 rs2836007 chr21 39206891 C T 9.68E-05 Depression (quantitative trait) KCNJ6 intron 23290196 rs2211846 chr21 39207740 G A 6.08E-05 Depression (quantitative trait) KCNJ6 intron 23290196 rs2836012 chr21 39210521 T A 6.21E-05 Depression (quantitative trait) KCNJ6 intron 23290196 rs2836014 chr21 39211005 C A 6.48E-05 Depression (quantitative trait) KCNJ6 intron 23290196 rs3787851 chr21 39216353 C T 8.32E-05 Depression (quantitative trait) KCNJ6 intron 23290196 rs2836021 chr21 39217408 T C 5.59E-05 Depression (quantitative trait) KCNJ6 intron 23290196 rs981288 chr21 39220549 G T 6.39E-04 Insulin resistance KCNJ6 intron 21901158 rs3787857 chr21 39221249 T G 2.06E-04 Lung function (forced expiratory volume in 1 second) KCNJ6 intron 24023788 rs7276928 chr21 39225737 G A 2.46E-04 Vaspin levels KCNJ6 intron 22907691 rs7276928 chr21 39225737 G A 0.0002455 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit KCNJ6 intron 22907730 rs915569 chr21 39235347 G A 2.30E-05 Urinary metabolites KCNJ6 intron 21572414 rs2836034 chr21 39257377 A G 4.56E-05 Renal cell carcinoma KCNJ6 intron 23184150 rs722557 chr21 39278677 C T 3.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) KCNJ6 intron 17982456 rs2836048 chr21 39284298 G A 6.41E-04 Parkinson's disease KCNJ6 intron 17052657 rs2836050 chr21 39284835 C T 1.50E-05 Urinary metabolites KCNJ6 intron 21572414 rs2836061 chr21 39325234 C T 0.00007866 Sarcoidosis / / 22952805 rs4817907 chr21 39346702 A G 2.10E-05 Urinary metabolites / / 21572414 rs17193509 chr21 39366613 G A 2.20E-04 Alzheimer's disease / / 17998437 rs2255450 chr21 39382885 T C 7.25E-04 Smoking initiation / / 24665060 rs12482611 chr21 39417989 G A 9.59E-04 Iron levels / / pha002876 rs11700417 chr21 39470758 C T 5.98E-04 Multiple complex diseases DSCR4 intron 17554300 rs2211856 chr21 39500557 T C 1.73E-04 Fibrinogen DSCR8 intron 17255346 rs2836162 chr21 39504356 A G 2.53E-04 Lung function (forced vital capacity) DSCR8 intron 24023788 rs9647177 chr21 39523464 C T 7.73E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DSCR8 intron 20877124 rs2836185 chr21 39564262 A G 3.15E-04 Multiple complex diseases / / 17554300 rs2186344 chr21 39606769 C T 8.17E-06 Glucose levels / / pha002899 rs2836245 chr21 39628029 G T 8.99E-04 Multiple complex diseases / / 17554300 rs928769 chr21 39637429 G A 6.42E-04 Type 2 diabetes KCNJ15 intron 17463246 rs928769 chr21 39637429 G A 3.46E-05 Glucose levels KCNJ15 intron pha002899 rs6517455 chr21 39655400 T G 4.80E-06 Urinary metabolites KCNJ15 intron 21572414 rs2836285 chr21 39656505 T C 8.48E-05 Erythrocyte counts KCNJ15 intron pha003099 rs2836304 chr21 39696219 A C 8.83E-05 Erythrocyte counts / / pha003099 rs2836317 chr21 39715946 C T 5.66E-04 Multiple complex diseases / / 17554300 rs2836325 chr21 39721552 G A 1.08E-04 Multiple complex diseases / / 17554300 rs2836326 chr21 39721764 C G 3.00E-06 Metabolite levels (HVA) / / 23319000 rs2836327 chr21 39722419 A G 3.19E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2836364 chr21 39767874 C T 3.36E-05 Alcohol dependence ERG intron 19581569 rs2073359 chr21 39775084 C T 8.53E-05 Hematocrit ERG intron pha003097 rs2073359 chr21 39775084 C T 2.33E-06 Erythrocyte counts ERG intron pha003101 rs989554 chr21 39786927 G A 2.49E-04 Amyotrophic Lateral Sclerosis ERG intron 17362836 rs3787894 chr21 39788804 G A 1.12E-05 Erythrocyte counts ERG intron pha003101 rs1571704 chr21 39794880 T G 3.78E-04 Amyotrophic Lateral Sclerosis ERG intron 17827064 rs3746880 chr21 39795202 T G 2.87E-04 Amyotrophic Lateral Sclerosis ERG intron 17362836 rs17230519 chr21 39799356 G A 6.44E-04 Type 2 diabetes ERG intron 17463246 rs2836389 chr21 39803662 T C 8.47E-04 Parkinson's disease ERG intron 17052657 rs2836389 chr21 39803662 T C 5.50E-07 Hepatitis B ERG intron 21750111 rs1573262 chr21 39804987 A C 2.50E-05 Urinary metabolites ERG intron 21572414 rs2836392 chr21 39805875 A G 1.52E-04 Parkinson's disease ERG intron 17052657 rs7275212 chr21 39852551 A T 2.00E-18 White blood cell types ERG intron 21738478 rs2212933 chr21 39856991 A C 6.92E-04 Multiple complex diseases ERG intron 17554300 rs2836439 chr21 39865150 C T 6.64E-07 Autism ERG intron 22843504 rs2836444 chr21 39871435 T C 3.00E-05 Multiple sclerosis (brain glutamate levels) ERG intron 20802204 rs8134689 chr21 39890830 A G 3.37E-05 Cognitive performance ERG intron 19734545 rs2836464 chr21 39896592 G A 3.51E-05 Personality dimensions ERG intron 18957941 rs2836480 chr21 39907437 G A 0.000303 Salmonella-induced pyroptosis ERG intron 22837397 rs2836485 chr21 39908413 G C 8.39E-05 Body mass index ERG intron 21701565 rs2836488 chr21 39908540 C T 0.0000575 Salmonella-induced pyroptosis ERG intron 22837397 rs2836489 chr21 39910680 C T 1.54E-04 Depression (quantitative trait) ERG intron 20800221 rs2836489 chr21 39910680 C T 1.15E-05 Body mass index ERG intron 21701565 rs2836489 chr21 39910680 C T 4.07E-04 Body mass index ERG intron 21701565 rs1888475 chr21 39912467 G A 0.000049 Salmonella-induced pyroptosis ERG intron 22837397 rs1999328 chr21 39930706 C A 2.90E-05 Urinary metabolites ERG intron 21572414 rs1999328 chr21 39930706 C A 5.52E-05 Schizophrenia (cytomegalovirus infection interaction) ERG intron 23358160 rs2836518 chr21 39938412 C A 1.32E-05 Schizophrenia (cytomegalovirus infection interaction) ERG intron 23358160 rs2836522 chr21 39943085 T G 0.000595 Salmonella-induced pyroptosis ERG intron 22837397 rs2836524 chr21 39945829 G A 5.41E-05 Hematocrit ERG intron pha003097 rs2836528 chr21 39948102 T C 4.47E-04 Blood pressure ERG intron 17255346 rs8130680 chr21 39948136 A G 6.92E-04 Type 2 diabetes ERG intron 17463246 rs3761364 chr21 39948154 C T 3.44E-04 Blood pressure ERG intron 17255346 rs2836529 chr21 39948379 A C 4.47E-04 Blood pressure ERG intron 17255346 rs6517472 chr21 39953486 C T 7.41E-04 Multiple complex diseases ERG intron 17554300 rs2836565 chr21 39976701 G A 4.49E-05 Glucose levels ERG intron pha003058 rs2836565 chr21 39976701 G A 9.56E-05 Glucose levels ERG intron pha003061 rs16996589 chr21 39991146 A G 5.95E-05 Response to taxane treatment (placlitaxel) ERG intron 23006423 rs2836574 chr21 39991893 A G 8.39E-04 Response to taxane treatment (placlitaxel) ERG intron 23006423 rs8130434 chr21 40036243 T C 5.98E-04 Multiple complex diseases / / 17554300 rs2836602 chr21 40039169 T A 3.37E-04 Multiple complex diseases / / 17554300 rs743446 chr21 40056423 A C 5.00E-06 Neonatal lupus / / 20662065 rs2070527 chr21 40067495 A C 2.06E-04 Type 2 diabetes / / 17463246 rs2836651 chr21 40103951 C T 2.69E-05 Cognitive performance / / 19734545 rs2836652 chr21 40104446 C T 2.74E-05 Parkinson's disease (motor and cognition) / / 22658654 rs16996780 chr21 40124309 G A 3.95E-04 Multiple complex diseases LINC00114 intron 17554300 rs2836667 chr21 40126511 G A 9.60E-04 Type 2 diabetes LINC00114 intron 17463246 rs2410053 chr21 40127310 C T 7.07E-04 Multiple complex diseases LINC00114 intron 17554300 rs2836681 chr21 40146540 T C 2.26E-28 Narcolepsy / / 19629137 rs1209921 chr21 40156275 G C 4.90E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1209921 chr21 40156275 G C 2.41E-05 Bone mass and geometry / / 17903296 rs1209926 chr21 40157124 T C 3.21E-05 Bone mass and geometry / / 17903296 rs1209926 chr21 40157124 T C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1209927 chr21 40157281 T C 0.0000801 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1309152 chr21 40159390 G A 0.0001 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1209949 chr21 40171453 A G 4.15E-04 Type 2 diabetes / / 17463246 rs1209950 chr21 40173528 C T 3.00E-07 Non-small cell lung cancer (survival) / / 21079520 rs1209952 chr21 40175827 C T 4.56E-04 Multiple complex diseases / / 17554300 rs1209954 chr21 40181766 A G 1.55E-04 Type 2 diabetes ETS2 intron 17463246 rs2836718 chr21 40237243 C T 5.13E-05 Pulmonary function / / 20010835 rs9680143 chr21 40237353 A T 5.18E-05 Pulmonary function / / 20010835 rs4817966 chr21 40237762 C A 5.28E-05 Pulmonary function / / 20010835 rs7279223 chr21 40240269 C G 5.65E-05 Pulmonary function / / 20010835 rs13051097 chr21 40240738 T C 7.79E-05 Pulmonary function / / 20010835 rs468708 chr21 40243459 C T 4.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2000639 chr21 40280522 A C 2.70E-05 Hepatitis B vaccine response FLJ45139 intron 21764829 rs9979250 chr21 40283733 C T 4.00E-07 Periodontitis (Mean PAL) FLJ45139 intron 24024966 rs2836753 chr21 40291187 T C 7.35E-04 Type 2 diabetes FLJ45139 intron 17463246 rs2836753 chr21 40291187 T C 8.28E-06 Multiple complex diseases FLJ45139 intron 17554300 rs2836754 chr21 40291740 T C 7.35E-04 Type 2 diabetes FLJ45139 intron 17463246 rs2836754 chr21 40291740 T C 5.00E-07 Crohn's disease FLJ45139 intron 17554261 rs2836754 chr21 40291740 T C 1.07E-07 Multiple complex diseases FLJ45139 intron 17554300 rs2836757 chr21 40294024 A G 1.09E-05 Multiple complex diseases FLJ45139 intron 17554300 rs2836757 chr21 40294024 A G 3.47E-06 Systemic lupus erythematosus and Systemic sclerosis FLJ45139 intron 23740937 rs2836766 chr21 40310700 T C 3.15E-04 Multiple complex diseases / / 17554300 rs2836768 chr21 40311493 G T 1.24E-05 Multiple complex diseases / / 17554300 rs2836770 chr21 40314704 A G 5.10E-04 Multiple complex diseases / / 17554300 rs2836770 chr21 40314704 A G 6.19E-05 Amyotrophic lateral sclerosis / / 20801717 rs2836770 chr21 40314704 A G 3.00E-06 Immune response to smallpox vaccine (IL-6) / / 22542470 rs9983113 chr21 40315316 G T 0.0000437 Amyotrophic lateral sclerosis / / 23587638 rs9983113 chr21 40315316 G T 0.0000578 Amyotrophic lateral sclerosis / / 23587638 rs11702281 chr21 40320382 T G 1.52E-04 Alzheimer's disease / / 22005930 rs932243 chr21 40328320 T G 6.83E-04 Alzheimer's disease / / 22005930 rs6517494 chr21 40330767 T G 2.04E-05 Socioeconomic Factors / / pha003067 rs2836788 chr21 40336891 A G 2.78E-05 Socioeconomic Factors / / pha003067 rs2836800 chr21 40347685 C T 3.65E-04 Alcohol dependence / / 21314694 rs2836803 chr21 40351780 G A 0.00000947 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs2836808 chr21 40356648 T C 4.13E-05 Alzheimer's disease / / 17998437 rs2836809 chr21 40360134 G A 8.01E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2836810 chr21 40360248 T C 8.01E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2410071 chr21 40363374 T C 8.01E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LOC100506471 intron 22566498 rs732340 chr21 40363690 C T 8.01E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LOC100506471 intron 22566498 rs732339 chr21 40363878 G T 8.01E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) LOC100506471 intron 22566498 rs2836823 chr21 40380249 C T 2.00E-06 Nicotine dependence / / 17158188 rs2836823 chr21 40380249 C T 2.00E-06 Coronary heart disease / / 21347282 rs2836837 chr21 40390231 T C 7.07E-05 Serum metabolites / / 19043545 rs2836840 chr21 40391781 C G 3.08E-05 Serum metabolites / / 19043545 rs2242930 chr21 40400958 G A 1.74E-04 Alcohol dependence / / 20201924 rs2242930 chr21 40400958 G A 5.20E-05 Asthma (bronchodilator response) / / 22792082 rs2242936 chr21 40423471 T C 5.88E-04 White matter integrity / / 22425255 rs2836860 chr21 40423964 C T 3.91E-05 Serum metabolites / / 19043545 rs4279007 chr21 40424954 A G 6.79E-05 Serum metabolites / / 19043545 rs999789 chr21 40426451 C T 1.65E-05 Multiple complex diseases / / 17554300 rs445593 chr21 40448382 A G 0.000198293 Primary sclerosing cholangitis / / 23603763 rs8132483 chr21 40451844 G A 5.88E-05 Self-reported allergy / / 23817569 rs369906 chr21 40453036 C T 2.80E-05 Type 2 diabetes / / 17460697 rs2242944 chr21 40465178 G A 8.00E-20 Ankylosing spondylitis / / 20062062 rs4817986 chr21 40465512 G T 2.00E-11 Fibrinogen / / 23969696 rs2836878 chr21 40465534 G A 4.00E-12 Inflammatory bowel disease / / 18758464 rs2836878 chr21 40465534 G A 2.00E-22 Ulcerative colitis / / 21297633 rs2836878 chr21 40465534 G A 2.00E-07 C-reactive protein / / 21300955 rs2836878 chr21 40465534 G A 1.40E-08 Multiple sclerosis / / 22190364 rs2836878 chr21 40465534 G A 5.00E-48 Inflammatory bowel disease / / 23128233 rs2836883 chr21 40466744 G A 3.19E-17 Primary sclerosing cholangitis / / 23603763 rs378108 chr21 40469520 A G 2.00E-11 Ankylosing spondylitis / / 21743469 rs2836891 chr21 40489027 C T 4.51E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs2836912 chr21 40506194 G A 3.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4816613 chr21 40515769 G A 9.33E-04 Type 2 diabetes / / 17463246 rs4817994 chr21 40515904 G C 9.33E-04 Type 2 diabetes / / 17463246 rs2150410 chr21 40569779 G A 4.00E-06 Temperament (bipolar disorder) BRWD1 intron 22365631 rs8132230 chr21 40584081 G A 8.60E-06 Temperament (bipolar disorder) BRWD1 intron 22365631 rs2150415 chr21 40615367 T C 4.95E-04 Type 2 diabetes BRWD1 intron 17463246 rs6517532 chr21 40642189 C T 4.80E-05 Temperament (bipolar disorder) BRWD1 intron 22365631 rs7275773 chr21 40646090 T C 4.40E-06 Temperament (bipolar disorder) BRWD1 intron 22365631 rs2836975 chr21 40663620 T C 1.11E-05 Lymphocyte counts BRWD1 intron 22286170 rs1984748 chr21 40669898 G A 1.60E-05 Temperament (bipolar disorder) BRWD1 intron 22365631 rs8131150 chr21 40677315 C G 9.40E-06 Temperament (bipolar disorder) BRWD1 intron 22365631 rs726046 chr21 40712367 A C 2.80E-05 Urinary metabolites / / 21572414 rs2776307 chr21 40713833 C G 9.08E-05 Serum metabolites / / 19043545 rs2070867 chr21 40715132 G A 2.90E-05 Urinary metabolites HMGN1 intron 21572414 rs2244352 chr21 40757973 T G 3.20E-05 Osteoarthritis (knee and hip) WRB intron 21177295 rs2244352 chr21 40757973 T G 6.94E-04 Osteoarthritis (knee and hip) WRB intron 21177295 rs2244352 chr21 40757973 T G 8.10E-04 Osteoarthritis (knee and hip) WRB intron 21177295 rs2244352 chr21 40757973 T G 7.38E-05 Post-operative nausea and vomiting WRB intron 21694509 rs2065313 chr21 40798163 G T 1.90E-05 Urinary metabolites LCA5L intron 21572414 rs2178881 chr21 40844300 T C 0.0003885 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) SH3BGR intron 23233654 rs2178881 chr21 40844300 T C 3.89E-04 Methotrexate clearance (acute lymphoblastic leukemia) SH3BGR intron 23233662 rs9974333 chr21 40871810 T C 8.86E-05 Glucose levels SH3BGR missense pha003061 rs7282142 chr21 40885108 G A 3.09E-04 Type 2 diabetes SH3BGR intron 17463246 rs517871 chr21 40909706 G A 8.76E-05 Weight / / pha003027 rs587935 chr21 40910740 C T 8.76E-05 Weight / / pha003027 rs2837074 chr21 40919955 G A 3.76E-04 Premature ovarian failure / / 19508998 rs523372 chr21 40937929 T G 6.15E-05 Premature ovarian failure / / 19508998 rs523372 chr21 40937929 T G 6.15E-05 Other erythrocyte phenotypes / / 19862010 rs4818059 chr21 40942788 G A 6.82E-04 Premature ovarian failure / / 19508998 rs1734930 chr21 40946124 G A 1.36E-04 Premature ovarian failure / / 19508998 rs551680 chr21 40954708 G A 4.70E-05 Personality dimensions / / 18957941 rs535457 chr21 40967471 G A 1.20E-05 Personality dimensions / / 18957941 rs2837102 chr21 41004152 A G 8.10E-05 Monocyte counts / / pha003089 rs609145 chr21 41016588 T A 3.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs11700951 chr21 41020752 A G 8.37E-05 Orofacial clefts / / 22419666 rs10854398 chr21 41021752 T C 6.06E-06 Suicide attempts in bipolar disorder / / 21041247 rs10854398 chr21 41021752 T C 8.49E-04 Suicide attempts in bipolar disorder / / 21041247 rs596958 chr21 41023491 A G 1.00E-04 Schizophrenia / / 19197363 rs8132770 chr21 41025884 A T 7.15E-06 Suicide attempts in bipolar disorder / / 21041247 rs8132770 chr21 41025884 A T 7.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs2239385 chr21 41027747 G A 3.96E-05 Schizophrenia / / 19197363 rs2837108 chr21 41031610 C T 1.05E-04 Atopy B3GALT5 intron 21625490 rs734413 chr21 41032804 G A 6.60E-07 Bipolar disorder,schizoaffective B3GALT5 cds-synon 19567891 rs4818065 chr21 41037723 A G 2.32E-07 Bipolar disorder,schizoaffective / / 19567891 rs4818067 chr21 41040695 C T 1.00E-04 Information processing speed / / 21130836 rs2837111 chr21 41041821 C T 4.51E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs4818070 chr21 41048661 A G 1.04E-04 Glycosylated haemoglobin levels / / 17255346 rs4173 chr21 41049045 G A 9.97E-05 Glycosylated haemoglobin levels / / 17255346 rs2837117 chr21 41055809 G T 2.15E-04 Glycosylated haemoglobin levels / / 17255346 rs980184 chr21 41056338 G A 4.48E-05 Multiple complex diseases / / 17554300 rs8126503 chr21 41057477 C A 7.87E-06 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs7276199 chr21 41059230 G A 8.03E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs8127619 chr21 41096818 C T 3.69E-05 Tourette syndrome / / 22889924 rs2205106 chr21 41097438 C T 5.23E-05 Multiple complex diseases / / 17554300 rs368269 chr21 41099937 C T 9.49E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1735151 chr21 41123301 T C 9.00E-06 Coronary heart disease IGSF5 intron 21347282 rs2837167 chr21 41129928 G A 2.84E-04 Stroke IGSF5 intron pha002886 rs2837170 chr21 41130448 C A 3.12E-06 Parkinson's disease IGSF5 intron 17052657 rs4816652 chr21 41130526 C T 6.54E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs4816653 chr21 41130543 C T 6.76E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs2837175 chr21 41131945 T C 6.52E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs2837175 chr21 41131945 T C 9.66E-07 LDL lipoproteins IGSF5 intron pha002902 rs9983659 chr21 41132177 T C 6.46E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs2837176 chr21 41132346 G C 6.40E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs2837178 chr21 41132443 G A 5.99E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs2837182 chr21 41135326 G A 7.22E-08 Metabolite levels IGSF5 intron 23281178 rs2837183 chr21 41135338 T C 5.79E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs8129909 chr21 41137416 T C 1.69E-140 Multiple complex diseases IGSF5 intron 17554300 rs12626544 chr21 41137499 A G 5.91E-04 Suicide attempts in bipolar disorder IGSF5 cds-synon 21041247 rs2837193 chr21 41141852 G A 1.41E-04 Arthritis (juvenile idiopathic) IGSF5 intron 22354554 rs2837196 chr21 41142595 A G 5.45E-05 Stroke IGSF5 intron pha002886 rs2837202 chr21 41144006 A T 2.50E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs2837202 chr21 41144006 A T 8.08E-05 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs16998436 chr21 41145963 T C 3.79E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs2837204 chr21 41146069 T C 2.72E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs2837205 chr21 41146524 C T 3.32E-04 Stroke IGSF5 intron pha002886 rs16998444 chr21 41146701 G A 3.84E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs4816657 chr21 41146835 A C 2.14E-04 Alzheimer's disease IGSF5 intron 17998437 rs2205205 chr21 41149964 G A 3.87E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs7278733 chr21 41151449 A G 4.05E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs4337554 chr21 41156580 A G 1.83E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs9680296 chr21 41157216 G A 4.93E-04 Insulin resistance IGSF5 intron 21901158 rs11088495 chr21 41159677 C T 1.13E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs2837218 chr21 41159977 G C 8.14E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs2837220 chr21 41160938 T C 4.88E-05 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs2837220 chr21 41160938 T C 5.17E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs760285 chr21 41161654 A G 7.03E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs11701338 chr21 41162008 C T 7.02E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs2837223 chr21 41163233 T C 7.00E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs16998519 chr21 41165249 T G 2.77E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs16998521 chr21 41165418 G A 2.77E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs2837225 chr21 41165462 C A 8.34E-04 Suicide attempts in bipolar disorder IGSF5 missense 21041247 rs2837226 chr21 41167005 C A 6.03E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs458406 chr21 41167828 T G 7.58E-04 Multiple complex diseases IGSF5 intron 17554300 rs16998550 chr21 41170253 T C 3.09E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs16998556 chr21 41171685 G T 3.17E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs2837227 chr21 41172166 C T 8.65E-05 Serum metabolites IGSF5 intron 19043545 rs2837227 chr21 41172166 C T 6.22E-04 Suicide attempts in bipolar disorder IGSF5 intron 21041247 rs2837227 chr21 41172166 C T 8.46E-05 LDL lipoproteins IGSF5 intron pha002902 rs2837229 chr21 41173714 C T 6.05E-04 Suicide attempts in bipolar disorder IGSF5 UTR-3 21041247 rs2837232 chr21 41179213 G A 8.01E-05 Serum metabolites / / 19043545 rs2837232 chr21 41179213 G A 5.88E-04 Suicide attempts in bipolar disorder / / 21041247 rs2410182 chr21 41180076 A G 6.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs2410182 chr21 41180076 A G 7.00E-07 Systolic blood pressure (alcohol consumption interaction) / / 24376456 rs2410182 chr21 41180076 A G 9.98E-04 Stroke / / pha002886 rs460707 chr21 41182794 C T 9.89E-04 Type 2 diabetes / / 17463246 rs460707 chr21 41182794 C T 4.50E-05 Stroke / / pha002886 rs458297 chr21 41183190 G A 9.62E-05 Arthritis (juvenile idiopathic) / / 22354554 rs1984023 chr21 41192203 G A 6.44E-05 LDL lipoproteins / / pha002902 rs462782 chr21 41193094 T G 5.01E-05 Serum metabolites / / 19043545 rs462782 chr21 41193094 T G 6.84E-05 Arthritis (juvenile idiopathic) / / 22354554 rs94967 chr21 41195307 G A 1.40E-05 Urinary metabolites / / 21572414 rs459814 chr21 41204047 T C 8.73E-05 Stroke / / pha002886 rs9980807 chr21 41205511 C T 9.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs463825 chr21 41206507 C T 3.02E-04 Type 2 diabetes / / 17463246 rs741866 chr21 41207955 C T 9.89E-05 Serum metabolites / / 19043545 rs741866 chr21 41207955 C T 8.71E-04 Suicide attempts in bipolar disorder / / 21041247 rs1004663 chr21 41209790 G C 8.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs12627540 chr21 41214958 C A 8.18E-04 Suicide attempts in bipolar disorder / / 21041247 rs2837246 chr21 41215018 T C 7.34E-04 Suicide attempts in bipolar disorder / / 21041247 rs9982859 chr21 41217916 T C 8.13E-04 Suicide attempts in bipolar disorder / / 21041247 rs2837249 chr21 41220127 G A 8.20E-04 Suicide attempts in bipolar disorder / / 21041247 rs2837253 chr21 41221256 G A 8.00E-07 Systolic blood pressure (alcohol consumption interaction) / / 24376456 rs2837253 chr21 41221256 G A 4.21E-05 LDL lipoproteins / / pha002902 rs2837258 chr21 41224073 C A 7.76E-04 Suicide attempts in bipolar disorder / / 21041247 rs398802 chr21 41225542 T G 8.76E-05 Type 2 diabetes / / 17463246 rs398802 chr21 41225542 T G 7.80E-04 Stroke / / pha002886 rs380673 chr21 41232560 A G 1.91E-04 Arthritis (juvenile idiopathic) / / 22354554 rs2837262 chr21 41233613 G A 4.82E-24 Narcolepsy / / 19629137 rs2183577 chr21 41250541 G C,T 3.18E-05 Bilirubin levels,in serum PCP4 intron 19389676 rs760150 chr21 41253722 G T 7.38E-05 Erythrocyte counts PCP4 intron pha003101 rs2249609 chr21 41254102 G A 2.47E-05 Bilirubin levels,in serum PCP4 intron 19389676 rs2244084 chr21 41277049 A G 7.51E-05 Major depressive disorder (broad) PCP4 intron 20038947 rs2244189 chr21 41278302 C T 4.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) PCP4 intron 23648065 rs3819595 chr21 41282698 C T 5.66E-05 Waist Circumference PCP4 intron pha003023 rs9808736 chr21 41284590 C T 1.15E-04 Depression (quantitative trait) PCP4 intron 20800221 rs7276341 chr21 41287057 A G 6.98E-04 Alcohol dependence PCP4 intron 21314694 rs1888504 chr21 41295673 A G 4.20E-06 Urinary metabolites PCP4 intron 21572414 rs2837302 chr21 41303895 C T 3.96E-04 Multiple complex diseases / / 17554300 rs2837302 chr21 41303895 C T 3.20E-04 Alcohol dependence / / 20201924 rs9981433 chr21 41309565 G T 3.85E-05 Diabetic nephropathy / / 21150874 rs9981433 chr21 41309565 G T 5.52E-05 Type 2 diabetes / / 22238593 rs2837313 chr21 41322629 C T 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs2837318 chr21 41324103 T G 9.06E-05 Lipoproteins / / pha003079 rs1734920 chr21 41344911 T G 3.00E-06 Smoking initiation / / 24665060 rs981436 chr21 41366245 G A 8.41E-12 Metabolite levels / / 22286219 rs2837361 chr21 41369655 T C 2.69E-04 Hearing function / / 17255346 rs2837371 chr21 41383143 C A 8.10E-04 Iron levels / / pha002876 rs2837378 chr21 41387324 C T 1.40E-05 Lung cancer DSCAM intron 18978787 rs11702444 chr21 41390971 A G 8.91E-04 Alzheimer's disease DSCAM intron 17998437 rs9981861 chr21 41415044 T C 4.00E-06 Non-small cell lung cancer (survival) DSCAM intron 21079520 rs10470192 chr21 41430206 G C 8.91E-04 Suicide attempts in bipolar disorder DSCAM intron 21423239 rs2837420 chr21 41442648 A G 1.59E-04 Nicotine smoking DSCAM intron 19268276 rs420863 chr21 41445334 T C 4.34E-04 Type 2 diabetes DSCAM intron 17463246 rs7282774 chr21 41451446 T A 1.70E-05 Coffee consumption DSCAM intron 21357676 rs2297263 chr21 41455854 G A 7.86E-05 Blood Pressure DSCAM cds-synon pha002898 rs2205129 chr21 41464434 G A 8.67E-04 Suicide attempts in bipolar disorder DSCAM intron 21423239 rs9981252 chr21 41472685 G A 8.67E-04 Type 2 diabetes DSCAM intron 17463246 rs451518 chr21 41479698 C T 7.82E-04 Multiple sclerosis (OCB status) DSCAM intron 23785401 rs16999304 chr21 41491366 T C 1.97E-04 Alcohol dependence DSCAM intron 20201924 rs2837437 chr21 41498026 T C 8.10E-04 Alcohol dependence DSCAM intron 20201924 rs2837450 chr21 41512900 G C 0.0002715 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DSCAM intron 23233654 rs2837450 chr21 41512900 G C 2.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) DSCAM intron 23233662 rs4402848 chr21 41519133 A G 1.21E-04 Smoking cessation DSCAM intron 24665060 rs11911749 chr21 41524631 T C 3.25E-04 Substance dependence DSCAM intron 21818250 rs16999395 chr21 41524880 T C 2.41E-04 Response to cytadine analogues (cytosine arabinoside) DSCAM intron 24483146 rs8130234 chr21 41536157 G A 6.80E-04 Type 2 diabetes DSCAM intron 17463246 rs2205143 chr21 41537377 T C 6.80E-04 Type 2 diabetes DSCAM intron 17463246 rs2837480 chr21 41546955 T C 4.60E-04 Amyotrophic Lateral Sclerosis DSCAM intron 17827064 rs7278294 chr21 41547881 A G 4.14E-04 Type 2 diabetes DSCAM intron 17463246 rs11908938 chr21 41548251 T C 3.66E-04 Type 2 diabetes DSCAM intron 17463246 rs570765323 chr21 41548251 T TG 3.66E-04 Type 2 diabetes DSCAM intron 17463246 rs2837484 chr21 41566372 C A 2.89E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DSCAM intron 20877124 rs1571718 chr21 41575334 C T 8.55E-04 Type 2 diabetes DSCAM intron 17463246 rs1571721 chr21 41575716 C T 9.03E-04 Type 2 diabetes DSCAM intron 17463246 rs9984703 chr21 41577876 A G 2.74E-04 Type 2 diabetes DSCAM intron 17463246 rs9984703 chr21 41577876 A G 6.00E-07 Parkinson's disease (interaction with coffee consumption) DSCAM intron 21876681 rs2837500 chr21 41577895 C T 7.31E-04 Type 2 diabetes DSCAM intron 17463246 rs2837501 chr21 41577933 T C 7.77E-05 Amyotrophic Lateral Sclerosis DSCAM intron 17827064 rs2837502 chr21 41578090 C G 8.85E-04 Type 2 diabetes DSCAM intron 17463246 rs2837504 chr21 41578585 T C 9.31E-05 Type 2 diabetes DSCAM intron 17463246 rs444584 chr21 41595726 T C 9.45E-05 Type 2 diabetes DSCAM intron 17463246 rs415565 chr21 41596019 C T 1.43E-04 Type 2 diabetes DSCAM intron 17463246 rs376508 chr21 41596185 A G 1.23E-04 Type 2 diabetes DSCAM intron 17463246 rs447940 chr21 41596300 T C 9.05E-05 Type 2 diabetes DSCAM intron 17463246 rs2837516 chr21 41597421 C T 7.27E-04 Type 2 diabetes DSCAM intron 17463246 rs435386 chr21 41598373 C T 1.67E-04 Type 2 diabetes DSCAM intron 17463246 rs2837524 chr21 41605145 C T 4.99E-04 Alcohol and nictotine co-dependence DSCAM intron 20158304 rs2837525 chr21 41607491 G T 8.79E-04 Type 2 diabetes DSCAM intron 17463246 rs2837526 chr21 41607764 G A 6.99E-04 Type 2 diabetes DSCAM intron 17463246 rs1882758 chr21 41610796 T C 5.18E-04 Type 2 diabetes DSCAM intron 17463246 rs2837534 chr21 41622294 T C 1.34E-04 Response to taxane treatment (placlitaxel) DSCAM intron 23006423 rs2837535 chr21 41623392 G T 4.98E-04 Type 2 diabetes DSCAM intron 17463246 rs2837536 chr21 41624622 C T 5.39E-04 Type 2 diabetes DSCAM intron 17463246 rs2837536 chr21 41624622 C T 8.36E-05 Response to taxane treatment (placlitaxel) DSCAM intron 23006423 rs2837553 chr21 41662870 C T 5.66E-06 Rheumatoid arthritis DSCAM intron 19503088 rs9977943 chr21 41667233 T G 8.90E-05 Blood Pressure DSCAM intron pha003040 rs2837554 chr21 41667378 A G 5.86E-05 Calcium levels DSCAM intron pha003085 rs1000126 chr21 41685421 T C 9.76E-04 Multiple complex diseases DSCAM intron 17554300 rs16999671 chr21 41688383 G A 6.30E-05 Multiple complex diseases DSCAM intron 17554300 rs1571717 chr21 41698322 T C 0.000467 Common carotid artery thickness (average of near and far wall measures) DSCAM intron 23487405 rs727333 chr21 41702947 C A 1.00E-06 Estradiol plasma levels (breast cancer) DSCAM intron 23518928 rs11701859 chr21 41715687 A G 2.55E-04 Depression (quantitative trait) DSCAM intron 20800221 rs16999692 chr21 41727744 C T 2.71E-04 Depression (quantitative trait) DSCAM intron 20800221 rs11911007 chr21 41730197 T C 2.71E-04 Depression (quantitative trait) DSCAM intron 20800221 rs16998067 chr21 41733181 C A 2.70E-04 Depression (quantitative trait) DSCAM intron 20800221 rs2837579 chr21 41737909 T C 2.67E-04 Depression (quantitative trait) DSCAM intron 20800221 rs2837580 chr21 41738635 A G 2.61E-04 Depression (quantitative trait) DSCAM intron 20800221 rs2837582 chr21 41739752 T C 5.73E-04 Multiple complex diseases DSCAM intron 17554300 rs1980406 chr21 41743639 T C 2.13E-04 Depression (quantitative trait) DSCAM intron 20800221 rs1980406 chr21 41743639 T C 1.12E-05 Epilepsy DSCAM intron 22116939 rs16999705 chr21 41743884 C T 6.91E-04 Multiple complex diseases DSCAM intron 17554300 rs11911056 chr21 41744294 C T 2.14E-04 Depression (quantitative trait) DSCAM intron 20800221 rs2837588 chr21 41748059 T C 9.33E-04 Multiple complex diseases DSCAM intron 17554300 rs2837590 chr21 41749546 C G 7.51E-04 Multiple complex diseases DSCAM intron 17554300 rs11910278 chr21 41751640 T C 2.97E-04 Depression (quantitative trait) DSCAM intron 20800221 rs8132934 chr21 41759666 A T 1.34E-04 Depression (quantitative trait) DSCAM intron 20800221 rs16999725 chr21 41760168 A C 1.08E-04 Depression (quantitative trait) DSCAM intron 20800221 rs2210268 chr21 41763258 G T 1.08E-05 Systolic blood pressure in sickle cell anemia DSCAM intron 24058526 rs765310 chr21 41764387 G T 8.34E-04 Prostate cancer mortality DSCAM intron 20978177 rs2205082 chr21 41764987 G A 9.71E-04 Prostate cancer mortality DSCAM intron 20978177 rs2205083 chr21 41765016 G A 8.02E-05 Prostate cancer mortality DSCAM intron 20978177 rs2837623 chr21 41800106 T C 3.47E-04 Multiple complex diseases DSCAM intron 17554300 rs10483067 chr21 41800854 T C 6.91E-04 Multiple complex diseases DSCAM intron 17554300 rs2142077 chr21 41816195 G A 5.24E-05 Response to cholinesterase inhibitors in Alzheimer's disease DSCAM intron 23374588 rs2837630 chr21 41818543 T C 5.40E-07 Urinary metabolites DSCAM intron 21572414 rs2837632 chr21 41819281 C T 1.20E-06 Urinary metabolites DSCAM intron 21572414 rs1040315 chr21 41824852 A G 1.09E-04 Scoliosis DSCAM intron 21216876 rs1040315 chr21 41824852 A G 5.07E-06 Anxiety in major depressive disorder DSCAM intron 24047446 rs4818135 chr21 41831237 A G 1.61E-06 Scoliosis DSCAM intron 21216876 rs2222973 chr21 41833884 T C 2.27E-06 Scoliosis DSCAM intron 21216876 rs7409930 chr21 41834449 T C 2.27E-06 Scoliosis DSCAM intron 21216876 rs2837645 chr21 41841790 T C 1.90E-06 Urinary metabolites DSCAM intron 21572414 rs7409798 chr21 41843039 C T 4.60E-06 Urinary metabolites DSCAM intron 21572414 rs16999832 chr21 41844939 G A 2.20E-06 Urinary metabolites DSCAM intron 21572414 rs1997549 chr21 41845436 G A 3.00E-06 Urinary metabolites DSCAM intron 21572414 rs10854403 chr21 41853760 T A 2.30E-05 Urinary metabolites DSCAM intron 21572414 rs2837654 chr21 41854661 T C 2.80E-06 Urinary metabolites DSCAM intron 21572414 rs8130587 chr21 41865052 C T 5.70E-04 Amyotrophic lateral sclerosis (sporadic) DSCAM intron 24529757 rs4816685 chr21 41875741 G A 8.30E-06 Urinary metabolites DSCAM intron 21572414 rs2178842 chr21 41877148 G A 1.10E-05 Urinary metabolites DSCAM intron 21572414 rs9980603 chr21 41886583 T C 9.87E-05 Cognitive impairment induced by topiramate DSCAM intron 22091778 rs9980603 chr21 41886583 T C 3.00E-07 Anxiety in major depressive disorder DSCAM intron 24047446 rs2837672 chr21 41897372 G T 2.70E-05 Urinary metabolites DSCAM intron 21572414 rs2837688 chr21 41907697 C T 1.40E-05 Urinary metabolites DSCAM intron 21572414 rs2837689 chr21 41907723 G A 1.40E-05 Urinary metabolites DSCAM intron 21572414 rs2837693 chr21 41910362 G A 1.01E-05 Anxiety in major depressive disorder DSCAM intron 24047446 rs2837693 chr21 41910362 G A 5.34E-06 Anxiety in major depressive disorder DSCAM intron 24047446 rs1010146 chr21 41915945 T A 5.65E-04 Multiple complex diseases DSCAM intron 17554300 rs1467751 chr21 41934862 C T 6.30E-05 Parkinson's disease (age of onset) DSCAM intron 19772629 rs9981739 chr21 41941298 G A 2.70E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) DSCAM intron 24023788 rs8127599 chr21 41948547 A G 4.34E-05 Duodenal ulcer DSCAM intron 22387998 rs11430170 chr21 41951756 C CA 7.83E-04 Alzheimer's disease DSCAM intron 22005930 rs2837713 chr21 41951756 C A 7.83E-04 Alzheimer's disease DSCAM intron 22005930 rs464299 chr21 41952633 C T 9.77E-05 Parent of origin effect on language impairment (maternal) DSCAM intron 24571439 rs455772 chr21 41962135 G A 0.0000114 HDL cholesterol particle diameter DSCAM intron 23263444 rs2837727 chr21 41962212 T G 7.43E-05 Bipolar disorder and schizophrenia DSCAM intron 20889312 rs9976207 chr21 41964487 C T 1.92E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) DSCAM intron 24023788 rs460699 chr21 41964695 C T 7.70E-05 Parkinson's disease DSCAM intron 21738487 rs2837734 chr21 41965186 G A 7.09E-05 Bipolar disorder and schizophrenia DSCAM intron 20889312 rs2837740 chr21 41967516 C T 3.62E-06 Parkinson's disease DSCAM intron 21738487 rs13046236 chr21 41982629 G A 3.68E-05 Parkinson's disease DSCAM intron 21738487 rs2837751 chr21 41986768 C A 2.99E-05 Ulcerative colitis DSCAM intron 19915573 rs2837751 chr21 41986768 C A 1.68E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) DSCAM intron 24023788 rs2837754 chr21 41991059 G A 3.72E-05 Vaspin levels DSCAM intron 22907691 rs2837754 chr21 41991059 G A 0.0000372 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks DSCAM intron 22907730 rs3804024 chr21 41993707 T C 8.10E-05 Vaspin levels DSCAM intron 22907691 rs3804024 chr21 41993707 T C 0.000081 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks DSCAM intron 22907730 rs3804024 chr21 41993707 T C 3.00E-06 Obesity-related traits DSCAM intron 23251661 rs3804024 chr21 41993707 T C 9.00E-07 Obesity-related traits DSCAM intron 23251661 rs12626815 chr21 41994933 C T 6.81E-05 Response to cytadine analogues (cytosine arabinoside) DSCAM intron 24483146 rs7279213 chr21 41998571 A G 2.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DSCAM intron 20877124 rs2837757 chr21 42001199 C T 2.69E-05 Response to cytadine analogues (cytosine arabinoside) DSCAM intron 24483146 rs2837757 chr21 42001199 C T 7.83E-04 Response to cytidine analogues (gemcitabine) DSCAM intron 24483146 rs2142125 chr21 42010384 A G 9.43E-05 Non-alcoholic fatty liver disease histology (other) DSCAM intron 20708005 rs2837758 chr21 42019009 C T 9.50E-04 Crohn's disease DSCAM intron 17684544 rs9975719 chr21 42024151 C T 5.82E-04 Aortic root size DSCAM intron 21223598 rs1537112 chr21 42029143 T C 8.70E-09 Urinary metabolites DSCAM intron 21572414 rs8130310 chr21 42040542 C G 5.78E-04 Multiple complex diseases DSCAM intron 17554300 rs2837780 chr21 42050958 T C 1.70E-05 Urinary metabolites DSCAM intron 21572414 rs8133206 chr21 42067195 T C 1.71E-04 Self-reported allergy DSCAM intron 23817569 rs6517607 chr21 42067941 T C 1.72E-04 Self-reported allergy DSCAM intron 23817569 rs12152040 chr21 42069068 T C 3.00E-04 Pancreatic cancer DSCAM intron 20484958 rs11910405 chr21 42077795 A C 4.46E-04 Self-reported allergy DSCAM intron 23817569 rs7276043 chr21 42085920 T C 9.74E-06 Major depressive disorder DSCAM intron 22472876 rs2837796 chr21 42092057 T C 8.87E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DSCAM intron 20877124 rs13049429 chr21 42105119 T C 7.90E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) DSCAM intron 23648065 rs2248626 chr21 42112134 C T 3.45E-04 Type 2 diabetes DSCAM intron 17463246 rs2837808 chr21 42124101 T C 1.79E-04 Type 2 diabetes DSCAM intron 17463246 rs8128946 chr21 42156432 A G 6.30E-04 Alcohol dependence DSCAM intron 20201924 rs8128946 chr21 42156432 A G 6.60E-04 Alcohol dependence DSCAM intron 20201924 rs2837826 chr21 42168699 G A 4.64E-04 Schizophrenia DSCAM intron 19197363 rs2837828 chr21 42174960 A G 1.00E-06 Neutrophil count DSCAM intron 21507922 rs2837857 chr21 42216955 C T 2.00E-06 Tuberculosis DSCAM intron 24057671 rs741772 chr21 42234205 T C 2.50E-06 Urinary metabolites / / 21572414 rs2837858 chr21 42251261 G A 1.85E-04 Smoking initiation / / 24665060 rs2091876 chr21 42270001 G C 8.51E-04 Type 2 diabetes / / 17463246 rs2837868 chr21 42274208 G T 3.55E-04 Tourette syndrome / / 22889924 rs9982394 chr21 42281364 G T 7.04E-04 Acute lung injury / / 22295056 rs11700509 chr21 42282191 T A,C,G 4.40E-04 Type 2 diabetes / / 17463246 rs17000509 chr21 42426742 T C 0.0008831 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17000509 chr21 42426742 T C 8.83E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs744549 chr21 42462562 C T 3.36E-04 Myopia (pathological) / / 21095009 rs2837942 chr21 42469244 C T 3.36E-04 Myopia (pathological) / / 21095009 rs16998084 chr21 42471628 A G 5.00E-06 Economic and political preferences (immigration/crime) / / 22566634 rs13050861 chr21 42485808 A G 5.16E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs8128456 chr21 42502060 G A 0.000741 Salmonella-induced pyroptosis / / 22837397 rs13049109 chr21 42502830 T C 0.000504 Salmonella-induced pyroptosis / / 22837397 rs2837960 chr21 42511918 T G 1.44E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2837960 chr21 42511918 T G 2.00E-06 Rheumatoid arthritis / / 17554300 rs2007397 chr21 42516192 G A 2.20E-04 Volumetric brain MRI LINC00323 intron 17903297 rs2837964 chr21 42520646 A C 9.25E-04 Myopia (pathological) / / 21095009 rs2016240 chr21 42530260 T C 2.34E-05 Insulin-related traits / / pha003063 rs6517653 chr21 42534253 A C 1.32E-05 Insulin-related traits / / pha003063 rs8133241 chr21 42561034 A G 3.28E-04 Acute lung injury BACE2 intron 22295056 rs17000646 chr21 42573646 G A 2.65E-04 Height BACE2 intron 17255346 rs10483073 chr21 42577297 C A 1.70E-04 Volumetric brain MRI BACE2 intron 17903297 rs746064 chr21 42581448 G A 4.03E-04 Multiple complex diseases BACE2 intron 17554300 rs746064 chr21 42581448 G A 3.21E-06 Glycemic traits (pregnancy) BACE2 intron 23903356 rs746064 chr21 42581448 G A 7.31E-06 Glycemic traits (pregnancy) BACE2 intron 23903356 rs2410406 chr21 42581529 A C 3.43E-06 Glycemic traits (pregnancy) BACE2 intron 23903356 rs1077339 chr21 42581575 A G 3.26E-06 Glycemic traits (pregnancy) BACE2 intron 23903356 rs737288 chr21 42581637 G T 1.40E-08 Glycemic traits (pregnancy) BACE2 intron 23903356 rs737288 chr21 42581637 G T 1.51E-10 Glycemic traits (pregnancy) BACE2 intron 23903356 rs737287 chr21 42581703 C T 5.38E-06 Glycemic traits (pregnancy) BACE2 intron 23903356 rs7510366 chr21 42581927 T C 7.40E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BACE2 intron 20877124 rs914178 chr21 42582187 A G 1.35E-06 Glycemic traits (pregnancy) BACE2 intron 23903356 rs914179 chr21 42582382 T C 1.34E-06 Glycemic traits (pregnancy) BACE2 intron 23903356 rs914180 chr21 42582424 T C 1.34E-06 Glycemic traits (pregnancy) BACE2 intron 23903356 rs914181 chr21 42582752 A G 2.25E-06 Glycemic traits (pregnancy) BACE2 intron 23903356 rs914182 chr21 42582981 A G 2.29E-06 Glycemic traits (pregnancy) BACE2 intron 23903356 rs6517656 chr21 42583738 G A 3.50E-10 Glycemic traits (pregnancy) BACE2 intron 23903356 rs6517656 chr21 42583738 G A 6.00E-16 Glycemic traits (pregnancy) BACE2 intron 23903356 rs6517657 chr21 42584141 T C 1.64E-06 Glycemic traits (pregnancy) BACE2 intron 23903356 rs13052926 chr21 42585088 A G 1.00E-05 Glycemic traits (pregnancy) BACE2 intron 23903356 rs13052926 chr21 42585088 A G 1.65E-06 Glycemic traits (pregnancy) BACE2 intron 23903356 rs2837968 chr21 42586604 C T 8.26E-04 Multiple complex diseases BACE2 intron 17554300 rs7278856 chr21 42598887 T G 6.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BACE2 intron 20877124 rs914186 chr21 42619657 G A 7.56E-05 Type 2 diabetes BACE2 intron 17463246 rs2837990 chr21 42620149 G A 1.34E-04 Scoliosis BACE2 intron 21216876 rs2837997 chr21 42629652 C T 7.56E-04 Myocardial Infarction BACE2 intron pha002873 rs4818226 chr21 42633065 A G 2.31E-04 Blood pressure BACE2 intron 17255346 rs2838001 chr21 42646992 C T 1.95E-04 Insulin resistance BACE2 intron 21901158 rs2410417 chr21 42658486 A C 9.20E-05 Personality dimensions / / 23903073 rs1888517 chr21 42665680 A G 2.79E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs928300 chr21 42676917 A T 9.47E-05 Bipolar disorder and schizophrenia / / 20889312 rs10775668 chr21 42678029 C T 3.41E-04 Type 2 diabetes / / 17463246 rs2838007 chr21 42682644 T C 6.13E-04 Type 2 diabetes / / 17463246 rs2838009 chr21 42694284 G T 3.18E-11 Tumor biomarkers FAM3B intron 23300138 rs371674 chr21 42695445 G C 9.63E-12 Tumor biomarkers FAM3B intron 23300138 rs441810 chr21 42698907 A G 3.00E-22 Tumor biomarkers FAM3B intron 23300138 rs441810 chr21 42698907 A G 2.00E-08 Elevated serum carcinoembryonic antigen levels FAM3B intron 24941225 rs2158354 chr21 42710175 T C 8.81E-05 Cholesterol FAM3B intron 17255346 rs2158354 chr21 42710175 T C 2.90E-09 Tumor biomarkers FAM3B intron 23300138 rs7278951 chr21 42711456 G A 3.77E-08 Tumor biomarkers FAM3B intron 23300138 rs424513 chr21 42711678 T G 9.05E-04 Response to taxane treatment (placlitaxel) FAM3B intron 23006423 rs424992 chr21 42711936 T C 2.72E-08 Tumor biomarkers FAM3B intron 23300138 rs376350 chr21 42714288 T A 3.28E-08 Tumor biomarkers FAM3B intron 23300138 rs1859297 chr21 42716548 G A 8.01E-04 Response to cytadine analogues (cytosine arabinoside) FAM3B intron 24483146 rs2838018 chr21 42720211 A G 4.58E-08 Tumor biomarkers FAM3B intron 23300138 rs2838020 chr21 42721876 C T 7.92E-08 Tumor biomarkers FAM3B intron 23300138 rs7278220 chr21 42725380 G A 3.66E-08 Tumor biomarkers FAM3B intron 23300138 rs45430 chr21 42746081 C T 3.00E-09 Melanoma MX2 intron 21983787 rs2074560 chr21 42752338 A G 7.23E-06 Magnesium levels MX2 intron pha003092 rs2838031 chr21 42753064 G A 8.82E-04 Type 2 diabetes MX2 intron 17463246 rs11910411 chr21 42759500 G C 5.39E-04 Response to statin treatment (atorvastatin),change in cholesterol levels MX2 intron 20031582 rs466092 chr21 42774541 A G 1.28E-05 Periodontitis (Chronic) MX2 intron 25008200 rs758342 chr21 42790341 T C 2.74E-04 Alcohol dependence / / 24277619 rs459482 chr21 42793791 C G 2.00E-06 IgG glycosylation MX1 UTR-5 23382691 rs459482 chr21 42793791 C G 3.00E-07 IgG glycosylation MX1 UTR-5 23382691 rs457920 chr21 42794758 G A 1.58E-04 Blood pressure (response to calcium channel blocker) MX1 UTR-5 24192120 rs2280807 chr21 42821265 A G 3.56E-05 Amyotrophic lateral sclerosis (sporadic) MX1 intron 24529757 rs460976 chr21 42835494 A G 1.50E-04 Multiple complex diseases / / 17554300 rs11910678 chr21 42836986 T C 8.46E-05 Multiple complex diseases TMPRSS2 UTR-3 17554300 rs2156301 chr21 42856949 T C 8.36E-04 Suicide attempts in bipolar disorder TMPRSS2 intron 21423239 rs2298857 chr21 42857981 G A 6.70E-06 Urinary metabolites TMPRSS2 intron 21572414 rs386638 chr21 42865047 C T 8.28E-04 Suicide attempts in bipolar disorder TMPRSS2 intron 21423239 rs3761373 chr21 42870522 C T 1.42E-05 HDL particle features TMPRSS2 intron pha002900 rs9984523 chr21 42884031 C T 8.76E-05 Response to acetaminophen (hepatotoxicity) / / 21177773 rs6517673 chr21 42892056 G A 1.20E-04 Asperger disorder / / 21182207 rs2838046 chr21 42898366 A G 2.46E-05 stroke (ischemic) / / 17434096 rs2838065 chr21 42933708 A G 9.23E-04 Parkinson's disease / / 17052657 rs11702046 chr21 42941137 C T 7.23E-05 Lipid levels / / pha003082 rs9977018 chr21 43036969 T G 2.00E-09 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2838077 chr21 43040140 T C 2.03E-06 Height / / pha003010 rs9978080 chr21 43040617 T C 2.56E-05 Waist Circumference / / pha003023 rs2838083 chr21 43063044 A G 0.0000754 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs17176538 chr21 43064230 G C 0.0000838 Salmonella-induced pyroptosis / / 22837397 rs8132754 chr21 43080711 G T 3.61E-05 Asthma / / 23181788 rs2838088 chr21 43092201 C T 1.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel) / / 24025145 rs7279238 chr21 43092206 C A 6.47E-05 Suicide attempts in bipolar disorder / / 21423239 rs11700823 chr21 43121333 A G 9.22E-04 Type 2 diabetes / / 17463246 rs11700823 chr21 43121333 A G 3.35E-04 Multiple complex diseases / / 17554300 rs2838089 chr21 43127927 A T 8.15E-04 Acute lung injury / / 22295056 rs6586227 chr21 43128337 A C 3.69E-04 Acute lung injury / / 22295056 rs4919929 chr21 43129442 C T 2.22E-05 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction) / / 24280104 rs9982491 chr21 43131861 A G 7.86E-04 Coronary heart disease / / 21971053 rs13051745 chr21 43133659 C T 4.78E-06 Alcohol and nictotine co-dependence LINC00479 intron 20158304 rs2838104 chr21 43149896 G A 3.22E-04 Multiple complex diseases / / 17554300 rs2838109 chr21 43154953 T C 5.65E-04 Multiple complex diseases / / 17554300 rs9637287 chr21 43155163 G C 5.45E-04 Multiple complex diseases / / 17554300 rs2838111 chr21 43156740 C A 2.22E-04 Scoliosis / / 21216876 rs11701487 chr21 43158106 G C 5.85E-04 Multiple complex diseases / / 17554300 rs3746890 chr21 43160438 T C 7.11E-04 Multiple complex diseases RIPK4 UTR-3 17554300 rs12483161 chr21 43167406 A C 1.15E-04 Scoliosis RIPK4 intron 21216876 rs13049286 chr21 43176799 T G 3.40E-05 Schizophrenia (treatment refractory) RIPK4 cds-synon 22479419 rs3827219 chr21 43180486 C T 2.66E-05 Schizophrenia (treatment refractory) RIPK4 intron 22479419 rs2838116 chr21 43182319 C T 8.61E-04 Body mass index RIPK4 intron 21701565 rs4919944 chr21 43185765 A C 4.50E-04 Response to cytadine analogues (cytosine arabinoside) RIPK4 intron 24483146 rs2838120 chr21 43188023 A G 6.70E-05 Scoliosis RIPK4 nearGene-5 21216876 rs13048349 chr21 43194459 G T 6.80E-05 Pericardial fat / / 22589742 rs13050469 chr21 43194647 T C 6.70E-05 Pericardial fat / / 22589742 rs3017541 chr21 43195637 A G 1.14E-04 Scoliosis / / 21216876 rs2838123 chr21 43217269 A G 9.28E-05 Height / / pha003011 rs2236691 chr21 43220178 T C 3.99E-04 Myocardial Infarction PRDM15 UTR-3 pha002883 rs2838128 chr21 43222779 A G 9.35E-05 Height PRDM15 intron pha003011 rs2838129 chr21 43223338 A G 2.33E-04 Body mass index PRDM15 intron 21701565 rs7279297 chr21 43227915 A G 3.00E-06 Tanning PRDM15 intron 19340012 rs2839392 chr21 43255509 C T 4.50E-05 Height PRDM15 intron pha003010 rs2839392 chr21 43255509 C T 2.27E-06 Height PRDM15 intron pha003011 rs8130834 chr21 43270134 T C 1.69E-04 Coronary heart disease PRDM15 intron 21606135 rs4346474 chr21 43273404 A T 2.93E-04 Coronary heart disease PRDM15 intron 21606135 rs915832 chr21 43275495 A G 7.00E-06 Response to taxane treatment (placlitaxel) PRDM15 intron 23006423 rs11203189 chr21 43285426 A G 6.10E-04 Response to taxane treatment (placlitaxel) PRDM15 intron 23006423 rs11203190 chr21 43285513 T C 6.68E-04 Response to taxane treatment (placlitaxel) PRDM15 intron 23006423 rs2839396 chr21 43286209 T C 7.78E-04 Body mass index PRDM15 intron 21701565 rs2839398 chr21 43286352 C G 5.00E-06 Parkinson's disease PRDM15 intron 22451204 rs2839398 chr21 43286352 C G 4.06E-04 Response to taxane treatment (placlitaxel) PRDM15 intron 23006423 rs13049896 chr21 43296188 G A 0.0000867 Asthma PRDM15 intron 22694930 rs2236438 chr21 43305937 G A 7.50E-06 Height C2CD2 UTR-3 pha003011 rs511247 chr21 43319534 A C 1.44E-04 Prion diseases C2CD2 intron 22210626 rs2839416 chr21 43319605 T G 5.57E-05 Lung function (forced expiratory volume in 1 second) C2CD2 intron pha003103 rs2839417 chr21 43319737 A G 1.85E-04 Insulin resistance C2CD2 intron 21901158 rs2839418 chr21 43319784 A G 8.05E-04 Type 2 diabetes C2CD2 intron 17463246 rs9983549 chr21 43334067 T A 9.75E-04 Suicide attempts in bipolar disorder C2CD2 intron 21423239 rs3746909 chr21 43342046 G A 1.07E-04 Amyotrophic Lateral Sclerosis C2CD2 intron 17827064 rs451390 chr21 43343510 G C 2.00E-07 Tuberculosis C2CD2 intron 24057671 rs7279279 chr21 43363109 G A 3.33E-04 Type 2 diabetes C2CD2 intron 17463246 rs10483084 chr21 43395324 G A 4.68E-04 Type 2 diabetes / / 17463246 rs10483084 chr21 43395324 G A 3.71E-12 Lymphocyte counts / / 22286170 rs9977968 chr21 43397111 G A 7.37E-05 Cognitive impairment induced by topiramate / / 22091778 rs11702415 chr21 43397385 T C 4.29E-04 Type 2 diabetes / / 17463246 rs11702690 chr21 43407668 A G 4.79E-05 Alcohol dependence ZNF295 UTR-3 19581569 rs2187239 chr21 43420555 C A 1.70E-05 Urinary metabolites ZNF295 intron 21572414 rs928874 chr21 43422525 C T 9.33E-04 Multiple complex diseases ZNF295 intron 17554300 rs8132937 chr21 43427492 G A 2.90E-05 Urinary metabolites ZNF295 intron 21572414 rs2839440 chr21 43443498 C T 1.00E-06 Preeclampsia ZNF295-AS1 intron 23551011 rs2839446 chr21 43455125 T C 2.21E-04 Hearing function / / 17255346 rs457186 chr21 43456164 C T 2.89E-04 Hearing function / / 17255346 rs4920059 chr21 43458706 C T 2.79E-05 Celiac disease / / 23936387 rs4920059 chr21 43458706 C T 9.50E-05 Blood Pressure / / pha003039 rs2839452 chr21 43466047 T C 9.52E-04 Iron levels / / pha002876 rs2839458 chr21 43469650 G A 6.83E-04 Tourette syndrome / / 22889924 rs17114247 chr21 43478135 C T 1.13E-05 Alcohol and nictotine co-dependence / / 20158304 rs17114247 chr21 43478135 C T 1.31E-06 Alcohol and nictotine co-dependence / / 20158304 rs220264 chr21 43482415 A G 2.34E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs220265 chr21 43482583 T G 3.43E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs150802 chr21 43486168 G T 3.54E-04 Response to cytadine analogues (cytosine arabinoside) UMODL1 intron 24483146 rs220282 chr21 43493756 A G 8.10E-06 Stroke (ischemic) UMODL1 intron 22384361 rs2839461 chr21 43501351 G A 9.72E-06 Fibrinogen UMODL1 intron pha003068 rs220299 chr21 43502762 C T 4.00E-07 Obesity-related traits UMODL1 intron 23251661 rs1475911 chr21 43513480 A C 9.00E-06 IgG glycosylation UMODL1 intron 23382691 rs220313 chr21 43519369 G T 5.87E-04 Suicide attempts in bipolar disorder UMODL1 intron 21423239 rs220110 chr21 43522650 C A,G,T 0.0000085 Chronic kidney disease UMODL1 intron 23539754 rs220116 chr21 43526411 T C 7.45E-04 Suicide attempts in bipolar disorder UMODL1 intron 21423239 rs201642313 chr21 43529776 G A 0.00000098 Breast cancer (ER positive) UMODL1 missense 23555315 rs201642313 chr21 43529776 G A 0.000056 Breast cancer UMODL1 missense 23555315 rs220150 chr21 43541342 C T 6.01E-04 Suicide attempts in bipolar disorder UMODL1 intron 21423239 rs9984766 chr21 43547612 G A 2.71E-04 Insulin resistance UMODL1 intron 21901158 rs2839470 chr21 43548239 T C 8.00E-05 Prostate cancer UMODL1 intron 21743057 rs220161 chr21 43549293 C G 7.83E-04 Multiple complex diseases UMODL1 intron 17554300 rs4462876 chr21 43566375 T C 3.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs9978616 chr21 43567671 A C 3.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs1026400 chr21 43587824 G A 6.07E-04 Type 2 diabetes / / 17463246 rs9975154 chr21 43639741 C G 1.00E-06 Parkinson's disease (interaction with coffee consumption) ABCG1 intron 21876681 rs170444 chr21 43650456 A G 7.69E-04 Multiple complex diseases ABCG1 intron 17554300 rs170444 chr21 43650456 A G 0.000000879 Triglycerides ABCG1 intron 23063622 rs170444 chr21 43650456 A G 1.69E-13 Cholesterol,total ABCG1 intron 23063622 rs4148112 chr21 43650776 C T 5.00E-07 Amyotrophic lateral sclerosis (sporadic) ABCG1 intron 24529757 rs178744 chr21 43662796 C T 3.19E-04 Multiple complex diseases ABCG1 intron 17554300 rs225376 chr21 43674122 G C 4.30E-05 Parkinson's disease ABCG1 intron 21812969 rs225376 chr21 43674122 G C 7.05E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) ABCG1 intron 23648065 rs7281093 chr21 43674859 G A 8.70E-05 Response to ximelagatran treatment ABCG1 intron 17505501 rs225378 chr21 43675694 A G 0.00000878 Type 2 diabetes ABCG1 intron 22325160 rs3787986 chr21 43678808 C T 8.03E-05 Cognitive performance ABCG1 intron 19734545 rs3787986 chr21 43678808 C T 9.95E-06 Common variable immunodeficiency ABCG1 intron 21497890 rs915841 chr21 43679438 T C 6.93E-05 Cognitive performance ABCG1 intron 19734545 rs915842 chr21 43679513 C T 8.87E-05 Cognitive performance ABCG1 intron 19734545 rs915843 chr21 43679554 C T 8.87E-05 Cognitive performance ABCG1 intron 19734545 rs2839481 chr21 43687142 G T 2.21E-04 Multiple complex diseases ABCG1 intron 17554300 rs532345 chr21 43689491 C T 1.48E-04 Response to platinum-based chemotherapy in non-small-cell lung cancer ABCG1 intron 21483023 rs532345 chr21 43689491 C T 5.40E-04 Coronary heart disease ABCG1 intron 21966275 rs691687 chr21 43689870 A G 1.48E-04 Response to platinum-based chemotherapy in non-small-cell lung cancer ABCG1 intron 21483023 rs8126601 chr21 43694980 G A 0.000000232 Triglycerides ABCG1 intron 23063622 rs2234718 chr21 43697195 A G 8.19E-04 Alzheimer's disease ABCG1 intron 24755620 rs2839482 chr21 43700432 A G 2.94E-04 Body mass index ABCG1 intron 21701565 rs2839482 chr21 43700432 A G 6.53E-04 Body mass index ABCG1 intron 21701565 rs3788007 chr21 43706776 G A 1.19E-04 Alcohol dependence ABCG1 intron 20201924 rs425215 chr21 43707101 C G 8.00E-07 Common traits (Other) ABCG1 intron 20585627 rs7277991 chr21 43709682 T G 6.83E-04 Type 2 diabetes ABCG1 intron 17463246 rs13050646 chr21 43712049 G A,T 9.92E-05 IgE levels ABCG1 intron 22075330 rs3788010 chr21 43716022 G A 1.90E-05 Elbow pain ABCG1 intron pha003008 rs8133510 chr21 43729979 G A 2.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8133510 chr21 43729979 G A 3.18E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2236705 chr21 43732828 C A 3.21E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) TFF3 intron 24023788 rs691567 chr21 43743039 A G 2.80E-05 Urinary metabolites / / 21572414 rs225424 chr21 43746695 G A 8.68E-04 Suicide attempts in bipolar disorder / / 21041247 rs9982439 chr21 43749200 T C 3.06E-07 Alopecia areata / / 22027810 rs225336 chr21 43767414 A T 1.80E-05 Urinary metabolites TFF2 intron 21572414 rs1079380 chr21 43770283 G A 2.58E-04 Alzheimer's disease (late onset) TFF2 intron 21379329 rs3814896 chr21 43771711 A G 5.38E-04 Schizophrenia / / 19197363 rs225340 chr21 43772947 C T 1.19E-04 Parkinson's disease / / 17052657 rs225344 chr21 43775884 G A 3.00E-05 Memory (short-term) / / 20038948 rs178740 chr21 43777672 C T 9.44E-05 Cytomegalovirus antibody response / / 21993531 rs1547374 chr21 43778895 A G 1.44E-04 Parkinson's disease / / 17052657 rs1547374 chr21 43778895 A G 4.00E-13 Pancreatic cancer / / 22158540 rs13051704 chr21 43786371 G C 1.00E-14 Progranulin levels TFF1 intron 21087763 rs13051704 chr21 43786371 G C 1.00E-14 Myocardial infarction TFF1 intron 21211798 rs462149 chr21 43789899 A G 9.64E-06 Cytomegalovirus antibody response / / 21993531 rs2839501 chr21 43805637 C T 1.86E-05 Schizophrenia TMPRSS3 cds-synon 24253340 rs10887973 chr21 43806193 T G 2.33E-05 Schizophrenia TMPRSS3 intron 24253340 rs928302 chr21 43810084 C T 1.23E-05 Nicotine smoking TMPRSS3 missense 19268276 rs11909987 chr21 43822402 C A 3.62E-05 Response to acetaminophen (hepatotoxicity) UBASH3A nearGene-5 21177773 rs9784215 chr21 43823736 C A 2.73E-05 Response to acetaminophen (hepatotoxicity) UBASH3A nearGene-5 21177773 rs7283281 chr21 43825519 G C 8.80E-04 Multiple complex diseases UBASH3A intron 17554300 rs3746923 chr21 43826344 C T 2.56E-05 Response to acetaminophen (hepatotoxicity) UBASH3A intron 21177773 rs11203203 chr21 43836186 G A 2.37E-04 Multiple complex diseases UBASH3A intron 17554300 rs11203203 chr21 43836186 G A 2.00E-09 Type 1 diabetes UBASH3A intron 19430480 rs11203203 chr21 43836186 G A 1.00E-09 Vitiligo UBASH3A intron 20410501 rs11203203 chr21 43836186 G A 4.00E-06 Rheumatoid arthritis UBASH3A intron 20453842 rs11203203 chr21 43836186 G A 1.00E-08 Celiac disease and Rheumatoid arthritis UBASH3A intron 21383967 rs11203203 chr21 43836186 G A 1.44E-07 Type 1 diabetes UBASH3A intron 21980299 rs11203203 chr21 43836186 G A 0.000029 Primary sclerosing cholangitis UBASH3A intron 22521342 rs11203203 chr21 43836186 G A 5.81E-12 Vitiligo UBASH3A intron 22561518 rs11203203 chr21 43836186 G A 8.54E-08 Primary sclerosing cholangitis UBASH3A intron 23603763 rs9976767 chr21 43836390 A G 2.00E-08 Type 1 diabetes UBASH3A intron 18840781 rs9976767 chr21 43836390 A G 2.00E-08 Multiple sclerosis UBASH3A intron 22190364 rs9976767 chr21 43836390 A G 0.0004 Primary sclerosing cholangitis UBASH3A intron 22521342 rs3788013 chr21 43841328 C A 1.00E-07 Type 1 diabetes autoantibodies UBASH3A intron 21829393 rs2839511 chr21 43848521 G A 2.48E-05 Vitiligo UBASH3A intron 20410501 rs2839511 chr21 43848521 G A 1.17E-08 Vitiligo UBASH3A intron 21326295 rs883390 chr21 43853789 A G 1.90E-06 Lymphocyte counts UBASH3A intron 22286170 rs1893592 chr21 43855067 A C 3.00E-09 Celiac disease UBASH3A intron 22057235 rs1893592 chr21 43855067 A C 1.30E-04 Rheumatoid arthritis UBASH3A intron 24390342 rs1893592 chr21 43855067 A C 7.00E-12 Rheumatoid arthritis UBASH3A intron 24390342 rs1893592 chr21 43855067 A C 9.80E-09 Rheumatoid arthritis UBASH3A intron 24390342 rs2839517 chr21 43865297 C T 5.92E-05 Myopia (pathological) UBASH3A intron 23049088 rs2839518 chr21 43865313 T C 9.30E-05 Eosinophil counts UBASH3A intron pha003088 rs3827233 chr21 43867787 G C 1.10E-05 Urinary metabolites UBASH3A UTR-3 21572414 rs2839519 chr21 43867844 G A 0.00000019 Confectionary intake UBASH3A nearGene-3 23408455 rs2839520 chr21 43869663 G A 0.0000163 Otitis media (children 3 years old or younger) / / 23133572 rs6650873 chr21 43873302 T C 2.74E-06 Spine bone size / / 23207799 rs1573415 chr21 43874542 C T 4.85E-04 Body mass index / / 21701565 rs2000765 chr21 43875543 G C 7.50E-04 Body mass index / / 21701565 rs2839525 chr21 43876937 T G 0.000055 Confectionary intake / / 23408455 rs2839527 chr21 43878213 G A 7.34E-04 Body mass index / / 21701565 rs12483601 chr21 43881562 G A 2.80E-04 Body mass index / / 21701565 rs12483601 chr21 43881562 G A 5.70E-04 Body mass index / / 21701565 rs2839535 chr21 43905327 C T 2.56E-04 Myocardial Infarction RSPH1 intron pha002873 rs2839535 chr21 43905327 C T 1.44E-06 Magnesium levels RSPH1 intron pha003092 rs9979100 chr21 43913370 G A 1.46E-05 Magnesium levels RSPH1 intron pha003092 rs7283383 chr21 43913421 G A 3.65E-04 Myocardial Infarction RSPH1 intron pha002873 rs7283383 chr21 43913421 G A 1.47E-05 Magnesium levels RSPH1 intron pha003092 rs8134499 chr21 43943658 G A 8.90E-05 Personality dimensions SLC37A1 intron 18957941 rs228049 chr21 43952437 C T 3.53E-05 Magnesium levels SLC37A1 intron pha003092 rs228068 chr21 43960219 C A 3.73E-04 Multiple complex diseases SLC37A1 intron 17554300 rs435725 chr21 43997911 A G 8.18E-05 Response to citalopram treatment SLC37A1 intron 19846067 rs453647 chr21 44000078 T C 9.86E-04 Alzheimer's disease SLC37A1 intron 24755620 rs400625 chr21 44001795 A G 4.37E-04 Alzheimer's disease / / 24755620 rs449888 chr21 44003992 A G 2.80E-05 Response to citalopram treatment / / 19846067 rs449888 chr21 44003992 A G 3.10E-04 Alzheimer's disease / / 24755620 rs417252 chr21 44004253 T C 2.70E-04 Alzheimer's disease / / 24755620 rs408465 chr21 44006207 C T 7.06E-06 Response to citalopram treatment / / 19846067 rs408465 chr21 44006207 C T 6.43E-04 Lymphocyte counts / / 22286170 rs401074 chr21 44013491 A G 8.59E-05 HDL particle features / / pha002900 rs401809 chr21 44017952 T G 4.81E-05 HDL particle features / / pha002900 rs433632 chr21 44020423 A G 5.78E-05 HDL particle features / / pha002900 rs1788421 chr21 44022258 G A 8.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11701162 chr21 44026143 C A 1.81E-05 Response to citalopram treatment / / 19846067 rs11701162 chr21 44026143 C A 6.16E-05 Vaspin levels / / 22907691 rs375694 chr21 44033960 A G 1.60E-05 Type 2 diabetes / / 17293876 rs375694 chr21 44033960 A G 1.60E-05 Type 2 diabetes / / 19184112 rs9977607 chr21 44036553 T C 5.09E-04 Smoking quantity / / 24665060 rs366994 chr21 44039597 C T 2.80E-05 Urinary metabolites / / 21572414 rs11910362 chr21 44042101 T C 7.55E-04 Body mass index / / 21701565 rs2839565 chr21 44042154 T C 4.24E-04 Multiple complex diseases / / 17554300 rs438983 chr21 44053351 A G 3.20E-04 Smoking quantity / / 24665060 rs915848 chr21 44053466 T C 6.62E-04 Body mass index / / 21701565 rs915848 chr21 44053466 T C 7.73E-04 Glaucoma (primary open-angle) / / 22605921 rs1539971 chr21 44061575 C A 7.29E-04 Body mass index / / 21701565 rs3819902 chr21 44100015 A C 5.38E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PDE9A intron 20031582 rs3819902 chr21 44100015 A C 4.00E-04 Alzheimer's disease (late onset) PDE9A intron 21460841 rs1515756 chr21 44114770 T G 2.80E-05 Urinary metabolites PDE9A intron 21572414 rs2245730 chr21 44125328 A C 0.0009 Change in depression severity with antidepressants (NRI or SRI) PDE9A intron 23091423 rs12626774 chr21 44139048 C G 9.90E-06 Urinary metabolites PDE9A intron 21572414 rs2269150 chr21 44141449 T C 2.10E-05 Urinary metabolites PDE9A intron 21572414 rs4920141 chr21 44141629 A T 4.30E-06 Urinary metabolites PDE9A intron 21572414 rs9979235 chr21 44156769 A G 6.00E-06 Pulmonary function decline PDE9A intron 22424883 rs2839580 chr21 44157091 T G 5.23E-07 Hearing impairment PDE9A intron 19047183 rs2250870 chr21 44157187 C T 5.30E-06 Urinary metabolites PDE9A intron 21572414 rs2839581 chr21 44158405 C A 8.60E-04 Multiple complex diseases PDE9A intron 17554300 rs2839581 chr21 44158405 C A 3.43E-05 Intelligence PDE9A intron 21826061 rs17115411 chr21 44168991 C T 5.65E-04 Alzheimer's disease PDE9A intron 17998437 rs2284967 chr21 44172913 T C 6.42E-04 Parkinson's disease PDE9A intron 17052657 rs1547379 chr21 44180916 G A 4.25E-04 Parkinson's disease PDE9A intron 17052657 rs2269165 chr21 44181908 T C 3.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE9A intron 20877124 rs2269169 chr21 44182517 A C 3.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE9A intron 20877124 rs2269169 chr21 44182517 A C 5.11E-05 Eosinophil counts PDE9A intron pha003088 rs2284975 chr21 44187744 A C 3.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE9A intron 20877124 rs2284975 chr21 44187744 A C 7.54E-05 Eosinophil counts PDE9A intron pha003088 rs2284976 chr21 44188112 G A 2.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE9A intron 20877124 rs2284976 chr21 44188112 G A 4.39E-05 Eosinophil counts PDE9A intron pha003088 rs12483164 chr21 44201769 A C 2.82E-04 Smoking initiation / / 24665060 rs1573418 chr21 44205926 C T 2.72E-04 Alzheimer's disease / / 17998437 rs6586250 chr21 44270229 C T 0.00019 Prostate cancer WDR4 missense 23555315 rs8133179 chr21 44272327 G A 2.62E-05 Information processing speed WDR4 intron 21130836 rs460128 chr21 44274007 T A 1.08E-07 Facial morphology WDR4 intron 22341974 rs463498 chr21 44277414 C T 7.55E-08 Facial morphology WDR4 intron 22341974 rs13052751 chr21 44284413 C T 9.86E-06 Hypertension WDR4 intron pha003042 rs4148972 chr21 44323461 G A 7.08E-05 Response to cholinesterase inhibitors in Alzheimer's disease NDUFV3 cds-synon 23374588 rs4148974 chr21 44323720 C T 7.65E-08 Facial morphology NDUFV3 STOP-GAIN 22341974 rs2839603 chr21 44324506 T C 5.78E-16 Lymphocyte counts NDUFV3 intron 22286170 rs2839603 chr21 44324506 T C 2.05E-07 Facial morphology NDUFV3 intron 22341974 rs11203166 chr21 44343636 A G 2.12E-07 Facial morphology / / 22341974 rs8130781 chr21 44361310 C T 1.20E-05 Urinary metabolites / / 21572414 rs8130292 chr21 44362904 G T 9.50E-06 Urinary metabolites / / 21572414 rs8130292 chr21 44362904 G T 1.06E-04 Vaspin levels / / 22907691 rs8130292 chr21 44362904 G T 0.0001063 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs8132110 chr21 44364737 C T 9.71E-05 Information processing speed / / 21130836 rs428432 chr21 44401569 A G 1.70E-05 Urinary metabolites PKNOX1 intron 21572414 rs234692 chr21 44431614 T C 4.23E-06 Cognitive test performance PKNOX1 intron 20125193 rs2839619 chr21 44436177 G A 8.00E-06 Biochemical measures PKNOX1 intron 19260141 rs2839619 chr21 44436177 G A 8.00E-06 Biochemical measures PKNOX1 intron 19260141 rs2839619 chr21 44436177 G A 7.99E-05 Cognitive test performance PKNOX1 intron 20125193 rs2839619 chr21 44436177 G A 2.60E-05 Urinary metabolites PKNOX1 intron 21572414 rs3737434 chr21 44437142 A G 1.65E-05 Cognitive test performance PKNOX1 intron 20125193 rs234720 chr21 44445292 C T 2.00E-07 Cognitive performance PKNOX1 intron 20125193 rs2839627 chr21 44448718 C T 7.81E-05 stroke (ischemic) PKNOX1 intron 17434096 rs2839627 chr21 44448718 C T 6.00E-06 Information processing speed PKNOX1 intron 21130836 rs234729 chr21 44449095 G A 7.95E-04 Insulin resistance PKNOX1 intron 21901158 rs466791 chr21 44469954 C T 8.32E-06 Left ventricular mass / / 21212386 rs2124459 chr21 44475714 T C 9.40E-04 Alzheimer's disease CBS intron 17998437 rs6586282 chr21 44478497 C T 3.00E-10 Homocysteine levels CBS intron 20031578 rs6586282 chr21 44478497 C T 5.00E-06 Blood trace element (Se levels) CBS intron 23720494 rs234709 chr21 44486964 C T 4.00E-24 Homocysteine levels CBS intron 23824729 rs2851391 chr21 44487404 T C 4.00E-06 Obesity-related traits CBS intron 23251661 rs2851391 chr21 44487404 T C 2.00E-12 Homocysteine levels CBS intron 23824729 rs2851391 chr21 44487404 T C 1.00E-11 Blood metabolite levels CBS intron 24816252 rs234714 chr21 44488033 T C 3.00E-26 Plasma homocysteine levels (post-methionine load test) CBS intron 24651765 rs8127036 chr21 44503173 C T 2.17E-06 Cardiovascular disease / / pha003065 rs1789956 chr21 44519655 G A 7.51E-04 Type 2 diabetes U2AF1 intron 17463246 rs1888523 chr21 44525219 G A 8.51E-05 Hypertension U2AF1 intron pha003041 rs8132259 chr21 44549658 T C 5.04E-05 Smoking initiation / / 24665060 rs9983902 chr21 44551581 C T 5.04E-05 Type 2 diabetes / / 17463246 rs1475891 chr21 44574541 C T 2.32E-04 Suicide attempts in bipolar disorder LOC100288336 intron 21423239 rs9975933 chr21 44577524 G A 2.98E-04 Suicide attempts in bipolar disorder LOC100288336 intron 21423239 rs872331 chr21 44589215 C T 2.22E-04 Response to alcohol consumption (flushing response) CRYAA cds-synon 24277619 rs11911275 chr21 44593140 A G 2.00E-09 Age-related nuclear cataracts CRYAA nearGene-3 24951543 rs2212838 chr21 44618563 A C 5.48E-06 Schizophrenia / / 24253340 rs2096853 chr21 44716050 A C 6.34E-04 Multiple complex diseases / / 17554300 rs17768485 chr21 44722770 C T 6.69E-04 Multiple complex diseases / / 17554300 rs504022 chr21 44731138 T G 6.18E-05 Lung cancer / / 18978787 rs504022 chr21 44731138 T G 8.80E-11 Glaucoma / / 21532571 rs2838271 chr21 44761874 G A 2.88E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs643608 chr21 44768562 C T 1.00E-06 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs76208778 chr21 44776311 C T 0.0000752 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs496300 chr21 44779680 C T 4.00E-07 Metabolic syndrome LOC100505974 intron 20694148 rs564779 chr21 44785422 T C 4.45E-04 Parkinson's disease / / 17052657 rs565629 chr21 44785510 T C 6.18E-04 Parkinson's disease / / 17052657 rs7510165 chr21 44786241 C T 2.00E-13 Health and aging,CVD and cancer age of onset / / 22174011 rs7510165 chr21 44786241 C T 2.80E-21 Health and aging,CVD and cancer age of onset / / 22174011 rs7510165 chr21 44786241 C T 4.20E-11 Health and aging,CVD and cancer age of onset / / 22174011 rs857569 chr21 44788512 A G 5.13E-04 Parkinson's disease / / 17052657 rs9637161 chr21 44792929 G A 3.10E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs9982923 chr21 44811720 C T 1.31E-05 Multiple complex diseases / / 17554300 rs17004543 chr21 44815868 A C 1.42E-04 Multiple complex diseases / / 17554300 rs229347 chr21 44848070 G A 4.06E-04 HIV-1 viral setpoint / / 17641165 rs9680399 chr21 44871063 G A 6.64E-04 Alcohol dependence / / 20201924 rs2838303 chr21 44871189 C T 9.03E-05 Cognitive performance / / 19734545 rs8131995 chr21 44874605 G A 1.00E-04 Prostate cancer / / 21743057 rs7281094 chr21 44874702 G A 9.04E-05 IgE levels / / 17255346 rs230642 chr21 44915533 T G 2.96E-04 IgE levels / / 17255346 rs162379 chr21 44925334 A G 1.61E-05 IgE levels / / 17255346 rs162378 chr21 44925905 A G 3.25E-04 IgE levels / / 17255346 rs162377 chr21 44926001 C T 6.20E-06 IgE levels / / 17255346 rs162376 chr21 44926759 C A 4.13E-05 IgE levels / / 17255346 rs162375 chr21 44927015 C T 5.09E-06 IgE levels / / 17255346 rs162370 chr21 44931821 G A 4.42E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17004572 chr21 44934871 C T 6.60E-04 Primary sclerosing cholangitis / / 19944697 rs162366 chr21 44935383 A G 2.17E-04 IgE levels / / 17255346 rs162394 chr21 44943550 C G 7.13E-06 IgE levels / / 17255346 rs162344 chr21 44954522 G A 1.52E-04 IgE levels HSF2BP intron 17255346 rs11911293 chr21 44970337 A G 4.61E-04 Multiple complex diseases HSF2BP intron 17554300 rs7283362 chr21 44973667 G C 1.60E-05 Urinary metabolites HSF2BP intron 21572414 rs9983763 chr21 44990578 G A 1.38E-04 IgE levels HSF2BP intron 17255346 rs2838320 chr21 44995037 A G 1.58E-05 IgE levels HSF2BP intron 17255346 rs2838326 chr21 45014315 G A 1.70E-05 Urinary metabolites HSF2BP intron 21572414 rs2329442 chr21 45041790 T C 8.29E-05 IgE levels HSF2BP intron 17255346 rs9980185 chr21 45057905 A G 2.80E-05 Urinary metabolites HSF2BP intron 21572414 rs1598206 chr21 45058776 A G 2.20E-05 Urinary metabolites HSF2BP intron 21572414 rs2838336 chr21 45071741 C T 4.50E-06 Lymphocyte counts HSF2BP intron 22286170 rs4818858 chr21 45083097 A G 3.94E-04 IgE levels RRP1B intron 17255346 rs4818858 chr21 45083097 A G 4.15E-04 Insulin resistance RRP1B intron 21901158 rs2155722 chr21 45096206 G A 3.73E-04 IgE levels RRP1B cds-synon 17255346 rs2155722 chr21 45096206 G A 7.26E-05 Multiple sclerosis RRP1B cds-synon 17660530 rs2838351 chr21 45110784 A G 1.30E-06 Blood pressure RRP1B intron 21909110 rs762400 chr21 45113629 C G 4.71E-04 IgE levels RRP1B UTR-3 17255346 rs9941787 chr21 45116042 A G 1.68E-04 IgE levels / / 17255346 rs11700909 chr21 45118701 G C 3.65E-04 IgE levels / / 17255346 rs8129601 chr21 45119104 T C 5.74E-05 Multiple sclerosis / / 17660530 rs4819288 chr21 45120173 G C 5.94E-04 Insulin resistance / / 21901158 rs2838358 chr21 45151046 C T 1.61E-04 Parkinson's disease PDXK intron 16252231 rs766241 chr21 45151638 G A 6.79E-04 Smoking cessation PDXK intron 24665060 rs9974754 chr21 45151874 G A 1.82E-05 Anxiety in major depressive disorder PDXK intron 24047446 rs4819314 chr21 45199738 C A 4.12E-04 HIV-1 viral setpoint / / 17641165 rs2838371 chr21 45215046 T C 1.36E-04 Taste perception RRP1 intron 22132133 rs2838378 chr21 45217559 T C 4.79E-05 Age-related macular degeneration RRP1 cds-synon 21197116 rs2838378 chr21 45217559 T C 3.09E-04 Taste perception RRP1 cds-synon 22132133 rs2838378 chr21 45217559 T C 5.90E-05 Temperament (bipolar disorder) RRP1 cds-synon 22365631 rs731935 chr21 45220570 T C 4.06E-04 Taste perception RRP1 intron 22132133 rs762408 chr21 45223997 A G 2.07E-04 Taste perception / / 22132133 rs6518322 chr21 45225868 A G 6.80E-05 Temperament (bipolar disorder) / / 22365631 rs2329577 chr21 45227299 G A 8.78E-07 Lymphocyte counts LOC284837 intron 22286170 rs2329577 chr21 45227299 G A 9.40E-05 Temperament (bipolar disorder) LOC284837 intron 22365631 rs9985006 chr21 45232322 T C 6.36E-04 Taste perception / / 22132133 rs2838399 chr21 45237978 T C 6.41E-04 Taste perception / / 22132133 rs2186927 chr21 45239995 T C 1.32E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs1573336 chr21 45240137 T C 2.15E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs2838407 chr21 45246326 G A 5.84E-06 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs4819348 chr21 45348954 C G 6.23E-05 Response to platinum-based chemotherapy in small-cell lung cancer AGPAT3 intron 20463552 rs4818873 chr21 45368885 G A 5.31E-04 Type 2 diabetes AGPAT3 intron 17463246 rs2838447 chr21 45370888 A G 2.02E-04 Taste perception AGPAT3 intron 22132133 rs2838458 chr21 45398656 C T 1.33E-06 Phospholipid levels (plasma) AGPAT3 intron 21829377 rs1058694 chr21 45404120 C T 3.29E-07 Phospholipid levels (plasma) AGPAT3 UTR-3 21829377 rs7435 chr21 45404338 A G 2.00E-07 Phospholipid levels (plasma) AGPAT3 UTR-3 21829377 rs965733 chr21 45435998 C G 8.78E-04 Bipolar disorder,schizoaffective TRAPPC10 intron 19567891 rs2256441 chr21 45446589 G A 8.52E-04 Bipolar disorder,schizoaffective TRAPPC10 intron 19567891 rs2238704 chr21 45448138 T C 7.98E-04 Bipolar disorder,schizoaffective TRAPPC10 intron 19567891 rs7280236 chr21 45595060 C T 1.66E-05 Alcohol dependence / / 21703634 rs743479 chr21 45611950 C T 4.30E-09 Crohn's disease / / 18587394 rs2838517 chr21 45613825 T C 6.11E-05 Multiple complex diseases / / 17554300 rs2838519 chr21 45615023 G A 5.02E-05 Multiple complex diseases / / 17554300 rs2838519 chr21 45615023 G A 2.00E-14 Crohn's disease / / 21102463 rs2838519 chr21 45615023 G A 6.00E-11 Ulcerative colitis / / 21297633 rs2838519 chr21 45615023 G A 0.0000049 Primary sclerosing cholangitis / / 23603763 rs762421 chr21 45615561 G A 3.85E-05 Multiple complex diseases / / 17554300 rs762421 chr21 45615561 G A 1.00E-09 Crohn's disease / / 18587394 rs762421 chr21 45615561 G A 1.00E-09 Asthma / / 21150878 rs762421 chr21 45615561 G A 1.41E-09 Multiple sclerosis / / 22190364 rs762422 chr21 45615638 G A 4.95E-05 Multiple complex diseases / / 17554300 rs7282490 chr21 45615741 G A 2.00E-26 Inflammatory bowel disease / / 23128233 rs2838520 chr21 45615896 T C 4.43E-05 Multiple complex diseases / / 17554300 rs2838521 chr21 45615917 T C 3.87E-05 Multiple complex diseases / / 17554300 rs2070553 chr21 45617161 C T 0.000487 Salmonella-induced pyroptosis / / 22837397 rs58911644 chr21 45629121 A T 6.20E-07 Celiac disease / / 22057235 rs7283760 chr21 45640629 G A 9.63E-06 Celiac disease and Rheumatoid arthritis / / 21383967 rs4819388 chr21 45647421 T C 2.00E-09 Celiac disease ICOSLG UTR-3 20190752 rs4819388 chr21 45647421 T C 2.00E-09 Asthma ICOSLG UTR-3 21150878 rs4819388 chr21 45647421 T C 2.46E-09 Celiac disease and Rheumatoid arthritis ICOSLG UTR-3 21383967 rs4819388 chr21 45647421 T C 2.46E-09 Multiple sclerosis ICOSLG UTR-3 22190364 rs2236668 chr21 45650009 T C,G 4.60E-05 Rheumatoid arthritis ICOSLG intron 24390342 rs2236668 chr21 45650009 T C,G 5.70E-07 Rheumatoid arthritis ICOSLG intron 24390342 rs397897657 chr21 45650009 T TG 4.60E-05 Rheumatoid arthritis ICOSLG intron 24390342 rs397897657 chr21 45650009 T TG 5.70E-07 Rheumatoid arthritis ICOSLG intron 24390342 rs56323213 chr21 45650009 T TG 4.60E-05 Rheumatoid arthritis ICOSLG intron 24390342 rs56323213 chr21 45650009 T TG 5.70E-07 Rheumatoid arthritis ICOSLG intron 24390342 rs9984995 chr21 45653981 C T 0.00000233 HDL cholesterol ICOSLG intron 23063622 rs378299 chr21 45661343 C T 6.32E-04 Schizophrenia / / 19197363 rs2838540 chr21 45687581 A G 1.37E-04 Vaspin levels / / 22907691 rs2838540 chr21 45687581 A G 0.000137 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs2075876 chr21 45709153 G A 4.00E-09 Rheumatoid arthritis AIRE intron 21505073 rs1078480 chr21 45711202 A G 5.67E-04 Schizophrenia AIRE intron 19197363 rs2256817 chr21 45715386 G A 1.72E-04 Hearing function AIRE intron 17255346 rs760426 chr21 45715814 A G 2.89E-05 Triglycerides AIRE intron pha003081 rs2236669 chr21 45721192 T C 4.80E-05 Iris characteristics PFKL intron 21835309 rs2838567 chr21 45893907 T C 2.06E-04 Hemoglobin concentration / / 20534544 rs17004662 chr21 45946957 C T 1.60E-04 Multiple complex diseases TSPEAR intron 17554300 rs425667 chr21 45992131 C T 4.58E-04 Iron levels TSPEAR intron pha002876 rs418260 chr21 46012524 T C 5.86E-05 Schizophrenia (cytomegalovirus infection interaction) TSPEAR intron 23358160 rs392686 chr21 46023668 T G 9.82E-04 Oral cancers (chewing tobacco related) TSPEAR intron 22503698 rs8132500 chr21 46028252 G A 2.05E-04 Age-related macular degeneration TSPEAR intron 22125219 rs233268 chr21 46039321 T A 7.17E-04 Type 2 diabetes TSPEAR intron 17463246 rs463741 chr21 46042170 C T 7.47E-04 Type 2 diabetes TSPEAR intron 17463246 rs2329835 chr21 46049290 G A 2.40E-06 Urinary metabolites TSPEAR intron 21572414 rs2838614 chr21 46075307 C T 2.90E-05 Urinary metabolites TSPEAR intron 21572414 rs17284014 chr21 46087583 G A 5.71E-04 Smoking initiation TSPEAR intron 24665060 rs2838626 chr21 46097193 T C 6.98E-04 Alzheimer's disease TSPEAR intron 17998437 rs235386 chr21 46151401 C T 9.76E-07 Lymphocyte counts / / 22286170 rs690279 chr21 46173229 G C 9.71E-05 Epilepsy (remission after treatment) / / 23962720 rs2838670 chr21 46176907 G A 7.19E-04 Spine bone size / / 23207799 rs1368991 chr21 46204235 G T 2.63E-05 Waist Circumference UBE2G2 intron pha003023 rs2838684 chr21 46204511 A G 6.20E-04 Type 2 diabetes and 6 quantitative traits UBE2G2 intron 17848626 rs2838689 chr21 46220610 T C 6.27E-04 Multiple complex diseases UBE2G2 intron 17554300 rs1141 chr21 46221167 T C 7.18E-04 Multiple complex diseases UBE2G2 intron 17554300 rs2329902 chr21 46227163 A G 1.45E-04 Multiple complex diseases SUMO3 intron 17554300 rs2017089 chr21 46229393 C T 9.71E-05 Waist Circumference SUMO3 intron pha003023 rs9974306 chr21 46262621 G A 9.04E-05 Relative hand skill / / 24068947 rs84191 chr21 46269496 A G 0.000425 Salmonella-induced pyroptosis / / 22837397 rs2838729 chr21 46319417 A G 8.68E-04 Response to taxane treatment (placlitaxel) ITGB2 intron 23006423 rs2838732 chr21 46322945 C T 0.00004 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer ITGB2 intron 21245432 rs3746972 chr21 46327835 A G 0.000142 Bipolar disorder ITGB2 intron 23637625 rs760456 chr21 46329415 G C 0.00002919 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ITGB2 intron 23233654 rs760456 chr21 46329415 G C 2.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) ITGB2 intron 23233662 rs3788147 chr21 46329669 T C 0.0001582 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ITGB2 intron 23233654 rs3788147 chr21 46329669 T C 6.76E-04 Methotrexate clearance (acute lymphoblastic leukemia) ITGB2 intron 23233662 rs2838735 chr21 46335282 T C 3.80E-05 Immunoglobulin A ITGB2 intron 20694011 rs3788151 chr21 46337565 C T 1.00E-04 Prostate cancer ITGB2 intron 21743057 rs2838738 chr21 46344426 A G 4.40E-06 Urinary metabolites ITGB2 intron 21572414 rs9979028 chr21 46378439 G A 8.00E-07 Parkinson's disease (interaction with coffee consumption) FAM207A intron 21876681 rs3827260 chr21 46393090 C T 4.00E-05 Prostate cancer FAM207A intron 21743057 rs2838752 chr21 46410660 C T 4.50E-22 Health and aging,CVD and cancer age of onset / / 22174011 rs2838752 chr21 46410660 C T 4.50E-28 Health and aging,CVD and cancer age of onset / / 22174011 rs2838752 chr21 46410660 C T 4.90E-14 Health and aging,CVD and cancer age of onset / / 22174011 rs2838752 chr21 46410660 C T 5.40E-08 Health and aging,CVD and cancer age of onset / / 22174011 rs1974412 chr21 46419158 T C 6.53E-04 Insulin resistance / / 21901158 rs2838753 chr21 46441947 A C 1.87E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2838756 chr21 46454391 T C 2.47E-05 Multiple complex diseases / / 17554300 rs4818756 chr21 46477130 A G 2.89E-05 Height / / pha003010 rs870144 chr21 46505979 A C 6.71E-04 Insulin resistance ADARB1 intron 21901158 rs870144 chr21 46505979 A C 5.83E-05 Lymphocyte counts ADARB1 intron pha003094 rs870144 chr21 46505979 A C 6.15E-05 Neutrophil count ADARB1 intron pha003095 rs2838774 chr21 46510316 G T 5.08E-04 Insulin resistance ADARB1 intron 21901158 rs3788156 chr21 46510442 G A 2.12E-04 Insulin resistance ADARB1 intron 21901158 rs414743 chr21 46512075 G A 8.78E-05 Cognitive test performance ADARB1 intron 20125193 rs414743 chr21 46512075 G A 3.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADARB1 intron 20877124 rs431529 chr21 46531737 T C 2.56E-04 Insulin resistance ADARB1 intron 21901158 rs385674 chr21 46542670 G A 1.60E-05 Urinary metabolites ADARB1 intron 21572414 rs385674 chr21 46542670 G A 1.64E-04 Coronary heart disease ADARB1 intron 21606135 rs385674 chr21 46542670 G A 8.34E-04 Insulin resistance ADARB1 intron 21901158 rs412626 chr21 46546040 A G 1.25E-04 Coronary heart disease ADARB1 intron 21606135 rs412626 chr21 46546040 A G 7.85E-04 Insulin resistance ADARB1 intron 21901158 rs391815 chr21 46548611 G A 1.40E-05 Urinary metabolites ADARB1 intron 21572414 rs391815 chr21 46548611 G A 1.35E-04 Coronary heart disease ADARB1 intron 21606135 rs419322 chr21 46551702 G A 6.66E-05 Cognitive test performance ADARB1 intron 20125193 rs419322 chr21 46551702 G A 4.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ADARB1 intron 20877124 rs3788164 chr21 46556216 T C 7.13E-04 Alcohol consumption (maxi-drinks) ADARB1 intron 24277619 rs453176 chr21 46583016 T C 2.37E-05 Serum alpha1-antitrypsin levels ADARB1 intron 23990791 rs407550 chr21 46584076 G C 2.37E-05 Serum alpha1-antitrypsin levels ADARB1 intron 23990791 rs2838797 chr21 46593248 T C 4.03E-04 Multiple complex diseases ADARB1 intron 17554300 rs17004749 chr21 46593983 T C 2.54E-05 Serum alpha1-antitrypsin levels ADARB1 intron 23990791 rs7279483 chr21 46597274 G C 2.65E-05 Serum alpha1-antitrypsin levels ADARB1 intron 23990791 rs2838803 chr21 46600126 C T 5.55E-04 Multiple complex diseases ADARB1 intron 17554300 rs8134789 chr21 46619558 G A 6.49E-04 Multiple complex diseases ADARB1 intron 17554300 rs2838815 chr21 46629590 C T 3.00E-06 Pulmonary function ADARB1 intron 17903307 rs2225434 chr21 46634146 T C 9.68E-06 Pulmonary function ADARB1 intron 17903307 rs2838820 chr21 46646005 T C 5.18E-04 Multiple complex diseases ADARB1 UTR-3 17554300 rs1051385 chr21 46646264 T C 9.90E-05 Lung cancer ADARB1 UTR-3 18978787 rs914210 chr21 46647078 G A 7.94E-04 Multiple complex diseases / / 17554300 rs4592938 chr21 46652490 G A 3.23E-07 Common variable immunodeficiency / / 21497890 rs11910403 chr21 46656983 G T 4.61E-04 Multiple complex diseases / / 17554300 rs2838846 chr21 46670874 G A 6.06E-176 Multiple complex diseases / / 17554300 rs2838873 chr21 46739353 C T 9.35E-07 Serum metabolites / / 19043545 rs2838873 chr21 46739353 C T 1.22E-05 Type 1 diabetes / / 21980299 rs9977697 chr21 46740019 T G 7.41E-07 Serum metabolites / / 19043545 rs2838875 chr21 46756700 C T 5.07E-04 Tourette syndrome / / 22889924 rs2246417 chr21 46759503 T C 2.54E-04 Tourette syndrome LINC00316 intron 22889924 rs2838887 chr21 46768530 C A 0.000621 Salmonella-induced pyroptosis / / 22837397 rs2150447 chr21 46775473 G A 0.000361 Salmonella-induced pyroptosis / / 22837397 rs7282991 chr21 46781023 T C 5.43E-05 Parkinson's disease / / 21812969 rs2183593 chr21 46792102 T C 5.43E-05 Parkinson's disease / / 21812969 rs4819085 chr21 46806423 G A 2.13E-04 Tourette syndrome / / 22889924 rs9306126 chr21 46816363 C T 2.67E-04 Tourette syndrome / / 22889924 rs1980978 chr21 46818397 G A 4.78E-04 Acute lung injury / / 22295056 rs9637198 chr21 46820082 C T 1.74E-04 Multiple complex diseases / / 17554300 rs9637198 chr21 46820082 C T 5.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2838906 chr21 46821907 T C 1.28E-04 Alzheimer's disease (late onset) / / 21379329 rs2838923 chr21 46846944 A G 3.61E-05 Brain structure COL18A1 intron 22504417 rs2838923 chr21 46846944 A G 8.00E-07 Hippocampal atrophy COL18A1 intron 22745009 rs4819119 chr21 46883153 A G 2.53E-04 Myopia (pathological) COL18A1 intron 21095009 rs2282117 chr21 46889666 G T 1.47E-04 Myopia (pathological) COL18A1 intron 21095009 rs2236462 chr21 46897221 C T 4.13E-04 Myopia (pathological) COL18A1 intron 21095009 rs1556329 chr21 46912386 C T 6.97E-04 Myopia (pathological) COL18A1 intron 21095009 rs2236479 chr21 46919132 G A 8.90E-23 Pancreatic cancer COL18A1 intron 21849791 rs2236479 chr21 46919132 G A 6.61E-09 Pelvic organ prolapse COL18A1 intron 22105264 rs7409857 chr21 46922436 A G 4.52E-04 Multiple complex diseases COL18A1 intron 17554300 rs10483080 chr21 46926002 C G 3.00E-05 Type 2 diabetes and 6 quantitative traits COL18A1 intron 17848626 rs1051298 chr21 46934826 G A 1 Drug response to Bevacizumab SLC19A1 UTR-3 19841321 rs1051298 chr21 46934826 G A 1 Drug response to Pemetrexed SLC19A1 UTR-3 19841321 rs142899279 chr21 46950811 C A 8.90E-09 Breast cancer SLC19A1 missense 23555315 rs914232 chr21 46952750 T C 7.56E-04 Aortic root size SLC19A1 intron 21223598 rs2330183 chr21 46953292 C T 1.59E-07 Atopy SLC19A1 intron 19961619 rs1051266 chr21 46957794 T C 1 Drug response to Methotrexate SLC19A1 missense 12411325 rs1051266 chr21 46957794 T C 1 Drug response to Methotrexate SLC19A1 missense 12915598 rs1051266 chr21 46957794 T C 1 Drug response to Methotrexate SLC19A1 missense 15457444 rs1051266 chr21 46957794 T C 1 Drug response to Methotrexate SLC19A1 missense 15564880 rs1051266 chr21 46957794 T C 1 Drug response to Methotrexate SLC19A1 missense 15677700 rs1051266 chr21 46957794 T C 1 Drug response to Methotrexate SLC19A1 missense 17410198 rs1051266 chr21 46957794 T C 1 Drug response to Methotrexate SLC19A1 missense 18256692 rs1888533 chr21 47000839 G T 1.50E-05 Type 2 diabetes / / 17293876 rs1888533 chr21 47000839 G T 1.50E-05 Type 2 diabetes / / 19184112 rs2838964 chr21 47018813 G A 4.75E-04 Multiple complex diseases / / 17554300 rs9976523 chr21 47032395 G A 6.27E-05 Bipolar disorder / / 19488044 rs11701130 chr21 47041808 G T 6.49E-05 Bipolar disorder / / 19488044 rs11701130 chr21 47041808 G T 8.80E-05 Response to statin therapy / / 20339536 rs11701130 chr21 47041808 G T 9.45E-05 Bipolar disorder and schizophrenia / / 20889312 rs11701130 chr21 47041808 G T 5.06E-05 Cognitive decline / / 22054870 rs2330186 chr21 47052223 A G 1.41E-04 Gallstones / / 17632509 rs2330186 chr21 47052223 A G 9.75E-04 Alzheimer's disease / / 17998437 rs2838977 chr21 47095353 T C 4.76E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1964928 chr21 47119124 C T 7.70E-05 Kawasaki disease / / 22081228 rs4819143 chr21 47124178 G A 9.48E-05 Bipolar disorder and schizophrenia / / 20889312 rs4819143 chr21 47124178 G A 1.00E-06 Insulin resistance / / 21901158 rs8127571 chr21 47165429 A G 2.00E-07 Immune reponse to smallpox (secreted IFN-alpha) / / 22610502 rs9980602 chr21 47166636 T G 6.00E-07 Parkinson's disease (interaction with coffee consumption) / / 21876681 rs56127133 chr21 47218228 T C,G 2.17E-18 Metabolite levels / / 22286219 rs2839010 chr21 47243032 A G 2.77E-04 Alzheimer's disease (late onset) / / 21379329 rs2150453 chr21 47253215 G A 5.54E-05 Bipolar disorder LOC100129027 intron 17486107 rs11701789 chr21 47276285 A G 4.57E-04 Lung function (forced vital capacity) PCBP3 intron 24023788 rs2839020 chr21 47280001 A G 8.69E-04 Multiple complex diseases PCBP3 intron 17554300 rs2839020 chr21 47280001 A G 8.52E-05 Bipolar disorder PCBP3 intron 19488044 rs3788210 chr21 47283897 G T 2.40E-05 Urinary metabolites PCBP3 intron 21572414 rs2839025 chr21 47288453 A G 1.00E-04 Information processing speed PCBP3 intron 21130836 rs7278253 chr21 47323009 G A 1.00E-04 Gallstones PCBP3 intron 17632509 rs2839054 chr21 47328449 A G 9.08E-06 Bipolar disorder PCBP3 intron 17486107 rs3788239 chr21 47351173 A G 6.22E-06 Biliary atresia PCBP3 intron 20460270 rs8133858 chr21 47360338 C T 3.27E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PCBP3 intron 20877124 rs2839070 chr21 47366354 T G 9.40E-04 Alzheimer's disease / / 17998437 rs9975272 chr21 47399375 A G 5.40E-07 Urinary metabolites / / 21572414 rs9978314 chr21 47416324 C T 3.82E-04 Type 2 diabetes COL6A1 intron 17463246 rs9978314 chr21 47416324 C T 2.58E-04 Multiple complex diseases COL6A1 intron 17554300 rs13047753 chr21 47431917 G A 1.00E-05 Iris characteristics / / 21835309 rs1475888 chr21 47439474 A G 5.20E-04 Diabetic nephropathy / / 20347642 rs2839081 chr21 47441315 C T 1.00E-05 Urinary metabolites / / 21572414 rs2839082 chr21 47442334 C T 2.10E-05 Urinary metabolites / / 21572414 rs13046217 chr21 47442576 T C 5.40E-06 Urinary metabolites / / 21572414 rs13046217 chr21 47442576 T C 9.00E-05 Iris characteristics / / 21835309 rs4293630 chr21 47445791 A G 7.00E-06 Alcoholism (alcohol dependence factor score) / / 21529783 rs9984052 chr21 47483799 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs16978810 chr21 47488332 C A 3.00E-07 Smoking initiation / / 24665060 rs13050660 chr21 47546244 T C 7.08E-05 Psoriasis COL6A2 intron 20953190 rs12626746 chr21 47548011 T C 7.37E-04 Tourette syndrome COL6A2 intron 22889924 rs11908960 chr21 47562417 T C 3.43E-05 Smoking initiation FTCD intron 24665060 rs17004504 chr21 47571162 G A 1.98E-05 Lipoprotein A [Lp(a)] levels in plasma FTCD intron 21592478 rs17004505 chr21 47571209 T C 1.51E-05 Amyotrophic lateral sclerosis (sporadic) FTCD intron 24529757 rs4819208 chr21 47572244 G A 3.50E-04 Multiple complex diseases FTCD intron 17554300 rs13046285 chr21 47593225 A G 3.37E-04 Type 2 diabetes C21orf56 intron 17463246 rs2968 chr21 47608580 G A,C,T 8.08E-04 Lymphocyte counts LSS UTR-3 22286170 rs17293705 chr21 47611799 G A 4.30E-20 Health and aging,CVD and cancer age of onset LSS missense 22174011 rs17293705 chr21 47611799 G A 4.40E-19 Health and aging,CVD and cancer age of onset LSS missense 22174011 rs17293705 chr21 47611799 G A 5.20E-08 Health and aging,CVD and cancer age of onset LSS missense 22174011 rs2075906 chr21 47625544 C T 7.03E-05 Scoliosis LSS intron 21216876 rs2839156 chr21 47641196 G A 1.32E-04 Scoliosis LSS intron 21216876 rs2839168 chr21 47661615 T C 1.01E-07 Lymphocyte counts MCM3AP intron 22286170 rs12482209 chr21 47664275 G C 3.67E-04 Multiple complex diseases MCM3AP intron 17554300 rs2839178 chr21 47678774 A G 1.60E-04 Suicidal ideation MCM3AP intron 22030708 rs2839182 chr21 47686152 C T 9.96E-05 Scoliosis MCM3AP intron 21216876 rs2839186 chr21 47690068 C T 1.00E-09 Testicular germ cell tumor MCM3AP intron 23666240 rs2839188 chr21 47692798 C T 6.34E-04 Mammographic density MCM3AP intron 22532574 rs17182566 chr21 47703734 G A 2.43E-04 Smoking initiation MCM3AP missense 24665060 rs2249060 chr21 47773177 C T 8.73E-05 Colorectal cancer PCNT missense 24836286 rs4819241 chr21 47782064 C T 1.62E-04 Schizophrenia PCNT intron 20832056 rs2839227 chr21 47786524 A G 2.60E-04 Schizophrenia PCNT missense 20832056 rs2839227 chr21 47786524 A G 2.93E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy PCNT missense 23834954 rs6518289 chr21 47787002 T C 5.61E-04 Response to taxane treatment (placlitaxel) PCNT missense 23006423 rs2839232 chr21 47792874 G A 2.41E-04 Schizophrenia PCNT intron 20832056 rs2839234 chr21 47796874 G A 1.46E-04 Schizophrenia PCNT intron 20832056 rs2839235 chr21 47800592 T C 1.60E-05 Kidney function and endocine traits PCNT intron 17903292 rs2073382 chr21 47818298 T C 2.20E-04 Scoliosis PCNT intron 21216876 rs6518291 chr21 47821588 A G 3.24E-04 Schizophrenia PCNT missense 20832056 rs2839251 chr21 47841692 C T 9.41E-05 Schizophrenia PCNT intron 20832056 rs2078203 chr21 47881309 A G 3.41E-04 Schizophrenia DIP2A intron 20832056 rs8132320 chr21 47886796 A G 2.51E-04 Schizophrenia DIP2A intron 20832056 rs2839274 chr21 47895181 A G 2.48E-04 Schizophrenia DIP2A intron 20832056 rs8134014 chr21 47902205 T G 9.71E-04 Response to cytidine analogues (gemcitabine) DIP2A intron 24483146 rs16979385 chr21 47979801 T C 3.20E-04 Multiple complex diseases DIP2A intron 17554300 rs9975723 chr21 47986670 G T 4.77E-04 Smoking cessation DIP2A intron 24665060 rs9941870 chr21 47988153 G A 1.71E-04 Smoking cessation DIP2A UTR-3 24665060 rs9978739 chr21 47991098 G A 4.47E-04 Smoking cessation / / 24665060 rs2839342 chr21 48015686 T C 2.33E-04 Type 2 diabetes / / 17463246 rs2239574 chr21 48019811 C T 6.74E-04 Type 2 diabetes S100B intron 17463246 rs881827 chr21 48019868 G A 9.00E-06 Lymphocyte counts S100B intron 22286170 rs9982863 chr21 48030465 A G 9.00E-04 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) / / 23103227 rs3747011 chr21 48084628 A G 1.02E-04 Amyotrophic lateral sclerosis (sporadic) PRMT2 UTR-3 24529757 rs4911642 chr22 16504399 C T 5.00E-06 Celiac disease / / 23936387 rs5748616 chr22 16888900 G C 2.47E-05 Serum metabolites / / 19043545 rs5746647 chr22 17057138 G T 8.64E-04 Alcohol dependence / / 20201924 rs5746647 chr22 17057138 G T 2.00E-06 HIV-1 viral setpoint / / 22174851 rs5747999 chr22 17075353 C A 4.23E-04 Type 2 diabetes / / 17463246 rs5747999 chr22 17075353 C A 6.10E-06 Urinary metabolites / / 21572414 rs2096537 chr22 17094749 A C 5.39E-05 Response to tocilizumab in rheumatoid arthritis TPTEP1 intron 22491018 rs4819849 chr22 17152611 A G 1.47E-05 Meningococcal disease ANKRD62P1-PARP4P3 intron 20694013 rs17433377 chr22 17228796 G A 2.09E-04 White matter integrity / / 22425255 rs874836 chr22 17301843 A G 3.32E-05 Attention deficit hyperactivity disorder XKR3 intron 22420046 rs9606478 chr22 17305777 G A 9.18E-04 Multiple complex diseases / / 17554300 rs16981741 chr22 17309881 A G 6.21E-04 Multiple complex diseases / / 17554300 rs16981741 chr22 17309881 A G 1.16E-04 Bipolar disorder,schizoaffective / / 19567891 rs175149 chr22 17310741 A G 1.60E-05 Meningococcal disease / / 20694013 rs165650 chr22 17313798 G C 8.71E-04 Multiple complex diseases / / 17554300 rs17435801 chr22 17316313 T C 1.55E-04 Multiple complex diseases / / 17554300 rs17435801 chr22 17316313 T C 6.25E-05 Bipolar disorder,schizoaffective / / 19567891 rs165611 chr22 17318150 T C 1.02E-04 Substance dependence / / 21818250 rs165611 chr22 17318150 T C 8.13E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs2075120 chr22 17326432 C T 5.59E-04 Multiple complex diseases / / 17554300 rs2075120 chr22 17326432 C T 5.74E-04 Bipolar disorder,schizoaffective / / 19567891 rs2075120 chr22 17326432 C T 1.62E-04 Substance dependence / / 21818250 rs12169910 chr22 17331656 C T 0.000575 Salmonella-induced pyroptosis / / 22837397 rs5994039 chr22 17338134 A G 8.25E-04 Multiple complex diseases / / 17554300 rs738043 chr22 17353947 G A 3.70E-04 Bipolar disorder,schizoaffective / / 19567891 rs9606527 chr22 17387645 C A 6.76E-04 Obesity (extreme) / / 21935397 rs7292561 chr22 17398508 T C 3.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs7293026 chr22 17398800 T C 1.02E-04 Bipolar disorder / / 17486107 rs8136206 chr22 17399211 C A 1.90E-05 Urinary metabolites / / 21572414 rs9306241 chr22 17404911 C G 2.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs759081 chr22 17405173 T C 4.67E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs7290057 chr22 17408116 G A 1.54E-04 Suicide attempts in bipolar disorder / / 21423239 rs9605179 chr22 17412216 A G 1.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs16981911 chr22 17450538 G A 3.23E-04 Multiple complex diseases GAB4 intron 17554300 rs5994129 chr22 17492203 G A 3.50E-05 Erythrocyte counts / / pha003101 rs2241046 chr22 17586471 C T 5.34E-04 Multiple complex diseases IL17RA intron 17554300 rs1468488 chr22 17590744 T C 4.52E-05 Serum alpha1-antitrypsin levels IL17RA UTR-3 23990791 rs2895332 chr22 17591089 G A 6.14E-04 Type 2 diabetes IL17RA UTR-3 17463246 rs971768 chr22 17597462 G A 7.89E-05 Cognitive impairment induced by topiramate CECR6 UTR-3 22091778 rs971768 chr22 17597462 G A 5.68E-05 Platelet counts CECR6 UTR-3 pha003100 rs4819964 chr22 17605824 G A 4.32E-04 Multiple complex diseases / / 17554300 rs5748926 chr22 17649774 T C 3.05E-04 Major depressive disorder / / 22472876 rs2231496 chr22 17669151 C T 5.28E-05 Type 2 diabetes CECR1 intron 17463246 rs17807317 chr22 17680519 A C 9.51E-05 Prion diseases CECR1 UTR-5 22210626 rs5748954 chr22 17698080 T C 9.82E-04 Multiple complex diseases / / 17554300 rs5747035 chr22 17718606 T C 4.03E-05 Bipolar disorder / / 17486107 rs5749001 chr22 17746528 T C 3.70E-04 Type 2 diabetes CECR3 intron 17463246 rs5749001 chr22 17746528 T C 4.85E-04 Alzheimer's disease CECR3 intron 17998437 rs9606682 chr22 17791564 T C 8.33E-05 Erythrocyte counts / / pha003099 rs9605254 chr22 17795408 A G 8.77E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs9605258 chr22 17799368 T G 5.94E-04 Type 2 diabetes / / 17463246 rs5994258 chr22 17803593 A G 2.06E-05 Height / / pha003010 rs5994267 chr22 17809117 A T 8.63E-05 Bipolar disorder and schizophrenia / / 20889312 rs9618000 chr22 17853714 A G 6.79E-05 Cognitive test performance / / 20125193 rs9604740 chr22 17873099 G A 1.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs737916 chr22 17880070 A G 1.53E-04 Multiple complex diseases / / 17554300 rs2401116 chr22 17881797 G A 6.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs16982400 chr22 17897544 T C 4.06E-05 Nicotine smoking / / 19268276 rs17808723 chr22 17904558 T A 3.92E-07 Multiple complex diseases / / 17554300 rs722751 chr22 17982621 A C 8.38E-04 Suicide attempts in bipolar disorder CECR2 intron 21423239 rs4819594 chr22 17986811 T C 9.52E-05 Parkinson's disease CECR2 intron 21248740 rs1296757 chr22 17989378 C T 9.95E-04 Response to taxane treatment (placlitaxel) CECR2 intron 23006423 rs174294 chr22 17994585 C T 9.79E-04 Obesity (extreme) CECR2 intron 21935397 rs174301 chr22 17997454 T C 1.65E-04 Multiple complex diseases CECR2 intron 17554300 rs174302 chr22 17997619 T G 7.88E-04 Obesity (extreme) CECR2 intron 21935397 rs174335 chr22 18016508 G A 1.23E-04 Response to cytidine analogues (gemcitabine) CECR2 intron 24483146 rs2284826 chr22 18047058 C A 1.40E-05 Urinary metabolites SLC25A18 intron 21572414 rs174371 chr22 18061337 G A 1.51E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SLC25A18 intron 24023788 rs5992749 chr22 18076523 G A 9.00E-05 Prostate cancer ATP6V1E1 intron 21743057 rs1296820 chr22 18077720 G T 8.68E-05 Celiac disease ATP6V1E1 intron 23936387 rs1296826 chr22 18079518 T C 6.11E-05 Celiac disease ATP6V1E1 intron 23936387 rs737995 chr22 18102393 C T 1.00E-04 Prostate cancer ATP6V1E1 intron 21743057 rs5992761 chr22 18102627 A G 1.00E-04 Prostate cancer ATP6V1E1 intron 21743057 rs9604779 chr22 18119145 T C 8.32E-05 Bipolar disorder / / 19488044 rs9604779 chr22 18119145 T C 5.29E-05 Bipolar Disorder / / pha002858 rs181390 chr22 18222263 A G 2.00E-04 End-stage renal disease BID intron 19929986 rs181396 chr22 18224155 G A 8.85E-04 Acute lung injury BID intron 22295056 rs8190315 chr22 18226764 T C 2.12E-04 Celiac disease BID missense 23936387 rs181405 chr22 18233000 G A 2.13E-04 Acute lung injury BID intron 22295056 rs181408 chr22 18235305 T C 7.75E-04 Acute lung injury BID intron 22295056 rs181409 chr22 18236035 C G 6.76E-04 Acute lung injury BID intron 22295056 rs181410 chr22 18237436 T A 1.20E-04 Coronary heart disease BID intron 21966275 rs5746474 chr22 18245932 T C 4.87E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) BID intron 24023788 rs366542 chr22 18258382 C T 6.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs5992834 chr22 18261496 G A 2.56E-04 Celiac disease / / 23936387 rs5992838 chr22 18264831 A G 8.83E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5992838 chr22 18264831 A G 5.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs5992105 chr22 18283247 A G 9.00E-06 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) MICAL3 intron 24023788 rs2277831 chr22 18299197 A G 2.28E-05 Osteoarthritis (knee and hip) MICAL3 intron 21177295 rs2277831 chr22 18299197 A G 8.44E-04 Osteoarthritis (knee and hip) MICAL3 intron 21177295 rs5992117 chr22 18308320 C A 8.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MICAL3 intron 20877124 rs873387 chr22 18339012 A G 1.94E-05 Gaucher disease severity MICAL3 intron 22388998 rs1057721 chr22 18343843 T C 2.50E-05 Urinary metabolites MICAL3 UTR-3 21572414 rs4819639 chr22 18347127 C T 3.70E-05 Gaucher disease severity MICAL3 UTR-3 22388998 rs1076113 chr22 18368147 C T 1.10E-05 Urinary metabolites MICAL3 intron 21572414 rs7288764 chr22 18373871 T C 3.74E-04 Multiple complex diseases MICAL3 intron 17554300 rs5992900 chr22 18394484 T C 6.76E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines MICAL3 intron 21844884 rs5747405 chr22 18395877 C T 1.87E-04 Celiac disease MICAL3 intron 23936387 rs9604803 chr22 18398207 C A 5.64E-04 Alzheimer's disease MICAL3 intron 24755620 rs4484121 chr22 18413975 T C 5.68E-06 Cognitive impairment induced by topiramate MICAL3 intron 22091778 rs9605439 chr22 18420055 T C 5.79E-04 Alzheimer's disease MICAL3 intron 24755620 rs9618172 chr22 18428163 C A,T 4.28E-04 Alzheimer's disease (late onset) MICAL3 intron 21379329 rs1109052 chr22 18430193 C T 6.75E-04 Alzheimer's disease MICAL3 intron 24755620 rs12166570 chr22 18438752 C T 1.38E-04 Alzheimer's disease (late onset) MICAL3 intron 21379329 rs1076540 chr22 18439958 C T 1.00E-16 Liver enzyme levels (gamma-glutamyl transferase) MICAL3 intron 22001757 rs5992917 chr22 18443699 G T 4.79E-04 Amyotrophic lateral sclerosis (sporadic) MICAL3 intron 24529757 rs1978968 chr22 18448113 C T 2.00E-06 Presence of antiphospholipid antibodies MICAL3 intron 23509613 rs448627 chr22 18455232 G A 1.53E-04 Multiple complex diseases MICAL3 intron 17554300 rs10854521 chr22 18482600 G A 7.44E-06 Cardiovascular disease MICAL3 intron 18179892 rs424765 chr22 18486017 T C 7.00E-05 Serum metabolites MICAL3 intron 19043545 rs424765 chr22 18486017 T C 8.34E-04 Prostate cancer mortality MICAL3 intron 20978177 rs390495 chr22 18504801 T G 1.34E-04 Celiac disease MICAL3 intron 23936387 rs4819660 chr22 18518634 G A 2.50E-67 Multiple complex diseases / / 17554300 rs975826 chr22 18520582 G A 5.03E-04 Type 2 diabetes / / 17463246 rs462904 chr22 18526789 T G 4.54E-05 Parkinson's disease / / 17052657 rs5992986 chr22 18545811 T G 3.37E-04 Sudden cardiac arrest / / 21658281 rs11703744 chr22 18546667 G A 5.30E-06 Personality dimensions / / 21173776 rs17207304 chr22 18549152 T C 3.42E-04 Multiple complex diseases / / 17554300 rs10483096 chr22 18551780 A G 3.60E-05 Type 2 diabetes / / 17293876 rs10483096 chr22 18551780 A G 3.60E-05 Type 2 diabetes / / 19184112 rs361594 chr22 18577338 T C 2.58E-06 Serum metabolites / / 19043545 rs467504 chr22 18583267 T C 8.70E-06 Serum metabolites / / 19043545 rs361893 chr22 18594931 T C 1.00E-04 Cognitive impairment induced by topiramate TUBA8 intron 22091778 rs361893 chr22 18594931 T C 1.58E-05 Cognitive impairment induced by topiramate TUBA8 intron 22091778 rs361800 chr22 18596289 G A 8.84E-04 Multiple complex diseases TUBA8 intron 17554300 rs362043 chr22 18596449 G T 5.64E-04 Suicide attempts in bipolar disorder TUBA8 intron 21423239 rs361834 chr22 18597404 G A 8.82E-04 Suicide attempts in bipolar disorder TUBA8 intron 21423239 rs361540 chr22 18601415 A G 7.35E-04 Suicide attempts in bipolar disorder TUBA8 intron 21423239 rs361540 chr22 18601415 A G 2.00E-04 Atrial fibrillation TUBA8 intron 21846873 rs465067 chr22 18602028 C T 0.000000007 LDL cholesterol TUBA8 intron 23063622 rs466456 chr22 18605129 G A 2.04E-04 Multiple complex diseases TUBA8 intron 17554300 rs362195 chr22 18609046 G A 6.65E-04 Premature ovarian failure TUBA8 intron 19508998 rs145621219 chr22 18609493 G A 0.000046 Prostate cancer (advanced) TUBA8 missense 23555315 rs362249 chr22 18610110 A G 1.00E-04 Atrial fibrillation TUBA8 intron 21846873 rs361557 chr22 18611223 A G 1.00E-04 Atrial fibrillation TUBA8 intron 21846873 rs2252257 chr22 18640300 G A 1.68E-06 Esophageal cancer (squamous cell) USP18 intron 22960999 rs2543958 chr22 18877787 T G 7.46E-05 Systemic sclerosis / / 21750679 rs144323192 chr22 18901008 G A 0.0000049 Breast cancer(er negative) PRODH missense 23555315 rs759404 chr22 18916180 C T 7.29E-04 Schizophrenia PRODH intron 19197363 rs367766 chr22 18917031 T C 2.65E-04 Type 2 diabetes PRODH intron 17463246 rs5992340 chr22 18937513 T A 5.90E-06 Urinary metabolites / / 21572414 rs5992340 chr22 18937513 T A 4.02E-05 Schizophrenia(age at onset) / / 21688384 rs2540641 chr22 18959684 C A 1.41E-04 Multiple complex diseases DGCR5 intron 17554300 rs2540641 chr22 18959684 C A 3.00E-59 Blood metabolite levels DGCR5 intron 24816252 rs2019061 chr22 18963340 G A 1.48E-04 Smoking initiation DGCR5 intron 24665060 rs2540647 chr22 18966617 G A 2.00E-70 Blood metabolite ratios DGCR5 intron 24816252 rs2023634 chr22 18972450 A G 1.80E-05 Urinary metabolites DGCR5 intron 21572414 rs2023634 chr22 18972450 A G 2.00E-22 Metabolic traits DGCR5 intron 21886157 rs2871005 chr22 18996226 T C 4.81E-04 Multiple complex diseases / / 17554300 rs17810548 chr22 19003938 C T 7.76E-04 Parkinson's disease LOC100506454 intron 16252231 rs10160 chr22 19026025 A G 9.90E-05 Schizophrenia DGCR2 UTR-3 24253340 rs16983300 chr22 19085538 C T 4.24E-04 Multiple complex diseases DGCR2 intron 17554300 rs2189490 chr22 19094165 C T 3.12E-04 Body mass index DGCR2 intron 21701565 rs2189490 chr22 19094165 C T 6.98E-05 Schizophrenia DGCR2 intron 24253340 rs2105421 chr22 19097680 G C 5.37E-04 Body mass index DGCR2 intron 21701565 rs2525079 chr22 19098966 T C 1.79E-05 stroke (ischemic) DGCR2 intron 17434096 rs5993533 chr22 19099419 A G 1.79E-05 stroke (ischemic) DGCR2 intron 17434096 rs8141504 chr22 19120697 C T 6.24E-17 Triglycerides DGCR14 UTR-3 23063622 rs16983371 chr22 19123952 T C 1.93E-04 Type 2 diabetes DGCR14 intron 17463246 rs2096376 chr22 19147441 C T 1.70E-12 Metabolite levels / / 22286219 rs5746668 chr22 19149151 T G 1.44E-13 Metabolite levels / / 22286219 rs2079194 chr22 19150134 C T 1.30E-13 Metabolite levels / / 22286219 rs2097789 chr22 19150261 T A 8.26E-13 Metabolite levels / / 22286219 rs4819507 chr22 19152772 C A 5.97E-14 Metabolite levels / / 22286219 rs807669 chr22 19154522 T C 3.00E-16 Metabolite levels / / 22286219 rs807670 chr22 19154608 A C 4.76E-12 Metabolite levels / / 22286219 rs2000338 chr22 19155662 G A 2.87E-13 Metabolite levels / / 22286219 rs712964 chr22 19156117 T C 8.22E-16 Metabolite levels / / 22286219 rs712964 chr22 19156117 T C 3.00E-11 Metabolite levels (atherosclerosis) / / 22916037 rs712963 chr22 19156543 A G 1.29E-15 Metabolite levels / / 22286219 rs807672 chr22 19157819 C G 7.75E-14 Metabolite levels / / 22286219 rs807673 chr22 19158116 G A 1.60E-05 Smoking quantity / / 24665060 rs712959 chr22 19159015 C T 1.52E-15 Metabolite levels LOC100652736 UTR-5 22286219 rs807666 chr22 19160549 C T 8.09E-16 Metabolite levels / / 22286219 rs5746671 chr22 19160899 A G 2.14E-12 Metabolite levels / / 22286219 rs807667 chr22 19161327 G A 1.34E-15 Metabolite levels / / 22286219 rs2040771 chr22 19161935 C T 2.06E-12 Metabolite levels / / 22286219 rs11089258 chr22 19162276 C T 7.91E-14 Metabolite levels / / 22286219 rs12485084 chr22 19162326 A G 2.21E-12 Metabolite levels / / 22286219 rs807668 chr22 19162686 A G 8.06E-16 Metabolite levels / / 22286219 rs8141941 chr22 19166263 G A 7.98E-15 Metabolite levels SLC25A1 UTR-5 22286219 rs762528 chr22 19166680 A G 2.30E-14 Metabolite levels / / 22286219 rs738904 chr22 19167385 C A 8.08E-13 Metabolite levels CLTCL1 UTR-3 22286219 rs712958 chr22 19167409 T C 2.23E-14 Metabolite levels CLTCL1 UTR-3 22286219 rs2800974 chr22 19168087 G A 1.37E-15 Metabolite levels CLTCL1 intron 22286219 rs2800973 chr22 19168616 T C 2.59E-14 Metabolite levels CLTCL1 intron 22286219 rs762529 chr22 19170205 C G 2.59E-14 Metabolite levels CLTCL1 intron 22286219 rs1780642 chr22 19170604 T C 8.12E-16 Metabolite levels CLTCL1 intron 22286219 rs1018764 chr22 19172006 T C 1.99E-15 Metabolite levels CLTCL1 intron 22286219 rs5748028 chr22 19172281 G A 5.46E-15 Metabolite levels CLTCL1 intron 22286219 rs1771540 chr22 19173933 T A 8.19E-16 Metabolite levels CLTCL1 intron 22286219 rs1780640 chr22 19174597 C T 8.00E-16 Metabolite levels CLTCL1 intron 22286219 rs1780639 chr22 19174603 T C 8.50E-16 Metabolite levels CLTCL1 intron 22286219 rs1780637 chr22 19178250 A G 8.38E-16 Metabolite levels CLTCL1 intron 22286219 rs756651 chr22 19179367 T C 1.81E-15 Metabolite levels CLTCL1 intron 22286219 rs762522 chr22 19180575 C T 1.77E-14 Metabolite levels CLTCL1 intron 22286219 rs762523 chr22 19180589 A G 2.01E-15 Metabolite levels CLTCL1 intron 22286219 rs9605955 chr22 19181557 C T 1.63E-12 Metabolite levels CLTCL1 intron 22286219 rs762527 chr22 19183470 A G 8.44E-16 Metabolite levels CLTCL1 intron 22286219 rs1633399 chr22 19183787 A G 3.91E-05 Response to hepatitis C treatment CLTCL1 missense 19684573 rs1061325 chr22 19184095 T C 2.59E-13 Metabolite levels CLTCL1 missense 22286219 rs2282684 chr22 19184244 C T 3.30E-12 Metabolite levels CLTCL1 intron 22286219 rs5746682 chr22 19185526 C T 4.00E-14 Metabolite levels CLTCL1 intron 22286219 rs723414 chr22 19185736 G A 3.28E-14 Metabolite levels CLTCL1 intron 22286219 rs9605957 chr22 19187375 G A 2.33E-11 Metabolite levels CLTCL1 intron 22286219 rs2236759 chr22 19187427 C G 3.56E-12 Metabolite levels CLTCL1 intron 22286219 rs2854643 chr22 19189706 T C 9.96E-16 Metabolite levels CLTCL1 intron 22286219 rs11089259 chr22 19190143 C T 2.05E-14 Metabolite levels CLTCL1 intron 22286219 rs1780643 chr22 19191725 T C 1.88E-15 Metabolite levels CLTCL1 intron 22286219 rs5746685 chr22 19192596 C G 1.84E-14 Metabolite levels CLTCL1 intron 22286219 rs9604934 chr22 19194868 C T 3.26E-12 Metabolite levels CLTCL1 intron 22286219 rs807547 chr22 19195680 T C 3.91E-05 Response to hepatitis C treatment CLTCL1 missense 19684573 rs2073740 chr22 19196112 C A 4.22E-12 Metabolite levels CLTCL1 intron 22286219 rs698423 chr22 19197896 T C 3.25E-15 Metabolite levels CLTCL1 cds-synon 22286219 rs712952 chr22 19197949 G A 4.04E-05 Response to hepatitis C treatment CLTCL1 missense 19684573 rs885978 chr22 19198226 A G 3.07E-14 Metabolite levels CLTCL1 intron 22286219 rs885979 chr22 19198375 T C 1.17E-11 Metabolite levels CLTCL1 intron 22286219 rs698422 chr22 19205826 A T 8.42E-15 Metabolite levels CLTCL1 intron 22286219 rs712948 chr22 19206499 A G 8.43E-15 Metabolite levels CLTCL1 intron 22286219 rs2073755 chr22 19210740 T C 8.64E-04 Response to cytadine analogues (cytosine arabinoside) CLTCL1 intron 24483146 rs9604935 chr22 19211665 C T 2.06E-11 Metabolite levels CLTCL1 intron 22286219 rs9605960 chr22 19214636 G C 1.34E-11 Metabolite levels CLTCL1 intron 22286219 rs1206544 chr22 19215039 C T 3.42E-15 Metabolite levels CLTCL1 intron 22286219 rs807458 chr22 19220648 G A,T 2.44E-13 Metabolite levels CLTCL1 intron 22286219 rs2073754 chr22 19221406 T G 3.02E-12 Metabolite levels CLTCL1 intron 22286219 rs807459 chr22 19223352 T C 3.81E-05 Response to hepatitis C treatment CLTCL1 missense 19684573 rs7286849 chr22 19223579 C A 2.86E-12 Metabolite levels CLTCL1 intron 22286219 rs809901 chr22 19228736 C T 1.21E-15 Metabolite levels CLTCL1 intron 22286219 rs9605962 chr22 19233615 C T 9.51E-12 Metabolite levels CLTCL1 intron 22286219 rs28651174 chr22 19236489 C T 2.65E-13 Metabolite levels CLTCL1 intron 22286219 rs807431 chr22 19242361 G A 9.09E-16 Metabolite levels CLTCL1 intron 22286219 rs2518866 chr22 19244338 C T 5.88E-04 Type 2 diabetes CLTCL1 intron 17463246 rs1091013 chr22 19248587 C T 2.83E-12 Metabolite levels CLTCL1 intron 22286219 rs9605972 chr22 19253274 T C 1.83E-15 Metabolite levels CLTCL1 intron 22286219 rs1340958 chr22 19253332 A G 3.15E-12 Metabolite levels CLTCL1 intron 22286219 rs2518840 chr22 19255856 A C 1.23E-11 Metabolite levels CLTCL1 intron 22286219 rs7410403 chr22 19256781 A G 5.40E-11 Metabolite levels CLTCL1 intron 22286219 rs35826599 chr22 19257470 TA T 2.91E-12 Metabolite levels CLTCL1 intron 22286219 rs4819508 chr22 19257470 T A 2.91E-12 Metabolite levels CLTCL1 intron 22286219 rs199637033 chr22 19260575 CCA C 2.99E-12 Metabolite levels CLTCL1 intron 22286219 rs77218764 chr22 19260575 C CCA 2.99E-12 Metabolite levels CLTCL1 intron 22286219 rs9617783 chr22 19260575 C A,T 2.99E-12 Metabolite levels CLTCL1 intron 22286219 rs35713313 chr22 19262852 T TG 6.05E-12 Metabolite levels CLTCL1 intron 22286219 rs362148 chr22 19262852 T C 6.05E-12 Metabolite levels CLTCL1 intron 22286219 rs361787 chr22 19263698 C T 8.88E-16 Metabolite levels CLTCL1 intron 22286219 rs361991 chr22 19263892 T C 1.02E-10 Metabolite levels CLTCL1 intron 22286219 rs361956 chr22 19265799 C T 1.17E-11 Metabolite levels CLTCL1 intron 22286219 rs361639 chr22 19268024 A G 1.33E-12 Metabolite levels CLTCL1 intron 22286219 rs2283646 chr22 19273902 A G 1.56E-11 Metabolite levels CLTCL1 intron 22286219 rs5993581 chr22 19285816 G A 9.20E-16 Metabolite levels / / 22286219 rs885982 chr22 19338201 T C 5.43E-04 Multiple complex diseases HIRA intron 17554300 rs2023639 chr22 19347730 C T 2.89E-04 Multiple complex diseases HIRA intron 17554300 rs737810 chr22 19348199 G A 2.10E-05 Urinary metabolites HIRA intron 21572414 rs3747062 chr22 19375500 G A,C,T 3.68E-04 Smoking initiation HIRA intron 24665060 rs11089274 chr22 19390804 T C 8.53E-04 Response to cytadine analogues (cytosine arabinoside) HIRA intron 24483146 rs7286556 chr22 19399781 G A 4.40E-04 Multiple complex diseases HIRA intron 17554300 rs9618567 chr22 19413706 C T 2.79E-05 Response to hepatitis C treatment HIRA intron 19684573 rs9618567 chr22 19413706 C T 8.53E-04 Response to cytadine analogues (cytosine arabinoside) HIRA intron 24483146 rs7575 chr22 19423250 G A 7.18E-04 Type 2 diabetes MRPL40 missense 17463246 rs885975 chr22 19430472 C T 1.12E-05 Cognitive impairment induced by topiramate C22orf39 intron 22091778 rs712979 chr22 19431038 A G 1.03E-07 Cognitive impairment induced by topiramate C22orf39 UTR-3 22091778 rs5748218 chr22 19451186 C A 2.04E-07 Cognitive impairment induced by topiramate UFD1L intron 22091778 rs5748243 chr22 19486391 C T 3.47E-04 Multiple complex diseases CDC45 intron 17554300 rs9618586 chr22 19486600 C T 8.14E-05 Multiple complex diseases CDC45 intron 17554300 rs3788299 chr22 19490853 T C 1.35E-06 Alzheimer's disease CDC45 intron 21627779 rs2073734 chr22 19504192 G C 3.38E-04 Smoking initiation CDC45 intron 24665060 rs13447284 chr22 19505531 C T 1.93E-06 Alzheimer's disease CDC45 intron 21627779 rs5993665 chr22 19509729 G A 2.04E-05 Functional impairment in major depressive disorder,bipolar disorder and schizophrenia / / 24039173 rs13056098 chr22 19524902 T C 1.73E-04 HIV-1 viral setpoint / / 17641165 rs8142386 chr22 19541048 A G 2.90E-06 Malignant mesothelioma / / 23827383 rs5746779 chr22 19558475 A G 5.88E-06 Glaucoma (primary open-angle) / / 22605921 rs2106139 chr22 19565257 G A 6.00E-06 IgG glycosylation / / 23382691 rs5748309 chr22 19566365 T C 8.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs737857 chr22 19575953 A G 2.19E-06 Cardiovascular disease / / 18179892 rs756656 chr22 19580185 A C 4.57E-05 Hepatitis B vaccine response / / 21764829 rs5993714 chr22 19581830 A G 5.98E-04 Suicide attempts in bipolar disorder / / 21041247 rs5993715 chr22 19581946 G T 5.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs5992433 chr22 19582066 C T 5.86E-04 Suicide attempts in bipolar disorder / / 21041247 rs7510644 chr22 19617637 G C 9.41E-04 Acute lung injury / / 22295056 rs1476445 chr22 19621011 C T 4.57E-05 HIV-1 viral setpoint / / 17641165 rs13057911 chr22 19623386 G T 7.94E-04 Acute lung injury / / 22295056 rs13053792 chr22 19624104 C T 7.94E-04 Acute lung injury / / 22295056 rs6518565 chr22 19632365 G A 4.21E-04 Multiple complex diseases / / 17554300 rs5748391 chr22 19659099 A G 5.75E-04 Parkinson's disease / / 17052657 rs1123657 chr22 19675944 G T 9.95E-05 Blood Pressure / / pha003039 rs5748403 chr22 19681349 G A 4.31E-05 Blood Pressure / / pha003039 rs4819833 chr22 19691502 T C 6.00E-08 DNA methylation (parent-of-origin) / / 23725790 rs8142156 chr22 19692751 C T 9.12E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs9618670 chr22 19694333 C T 9.12E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs5748410 chr22 19718144 G A 4.56E-04 Schizophrenia / / 20832056 rs7293017 chr22 19733811 G A 6.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2238773 chr22 19752973 C T 7.99E-08 Interleukin levels (IL10,IL1Ra,IL6),in plasma TBX1 intron 22205395 rs2238776 chr22 19757892 G A,T 2.33E-09 Interleukin levels (IL10,IL1Ra,IL6),in plasma TBX1 intron 22205395 rs737869 chr22 19759437 G C 9.40E-05 Parkinson's disease (age of onset) TBX1 intron 19772629 rs5748427 chr22 19775287 A G 9.02E-05 Erythrocyte counts / / pha003101 rs2269726 chr22 19785006 T C 9.88E-05 Erythrocyte counts GNB1L intron pha003101 rs748806 chr22 19787736 C T 2.98E-20 Lymphocyte counts GNB1L intron 22286170 rs5993833 chr22 19792619 A G 4.90E-04 Multiple complex diseases GNB1L intron 17554300 rs5993834 chr22 19792712 T C 4.87E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) GNB1L intron 24023788 rs9306226 chr22 19817433 T C 9.50E-05 Attention deficit hyperactivity disorder GNB1L intron pha002875 rs7287254 chr22 19825223 A C 7.48E-05 Lung function (forced expiratory volume in 1 second) GNB1L intron pha003103 rs13053155 chr22 19844671 G A 1.07E-04 Hearing function / / 17255346 rs3788305 chr22 19871778 A G 9.96E-05 Lymphocyte counts TXNRD2 intron 22286170 rs3804047 chr22 19879637 A G 3.00E-06 Staphylococcus aureus infection TXNRD2 intron 24847357 rs3788317 chr22 19889825 G T 2.00E-07 Glaucoma (primary open-angle) TXNRD2 intron 22922875 rs756661 chr22 19905802 G A 2.59E-04 Multiple complex diseases TXNRD2 intron 17554300 rs1978058 chr22 19908219 C T 7.62E-04 Suicide attempts in bipolar disorder TXNRD2 intron 21423239 rs1012157 chr22 19909977 A G 2.50E-05 Urinary metabolites TXNRD2 intron 21572414 rs7289747 chr22 19910716 A C 9.60E-06 Schizophrenia TXNRD2 intron 21791550 rs7289747 chr22 19910716 A C 9.67E-06 Schizophrenia TXNRD2 intron 21926974 rs7289747 chr22 19910716 A C 0.0000096 Psychosis TXNRD2 intron 23164818 rs7287604 chr22 19915680 C T 1.70E-05 Urinary metabolites TXNRD2 intron 21572414 rs7290448 chr22 19915939 G A 2.30E-05 Urinary metabolites TXNRD2 intron 21572414 rs9605030 chr22 19921137 C T 0.0000043 Asthma (exacerbation) TXNRD2 intron 23706709 rs737865 chr22 19930121 A G 1 Drug response to Bupropion COMT intron 16876132 rs4633 chr22 19950235 C T 5.45E-07 Body mass index COMT cds-synon 24827717 rs4680 chr22 19951271 G A 1 Drug response to Morphine COMT missense 17156920 rs4680 chr22 19951271 G A 1.00E-13 Blood metabolite levels COMT missense 24816252 rs4680 chr22 19951271 G A 5.00E-178 Blood metabolite levels COMT missense 24816252 rs5993889 chr22 19955375 T G 0.000000219 HDL cholesterol COMT intron 23063622 rs165599 chr22 19956781 G A 1 Drug response to Bupropion COMT UTR-3 16876132 rs165599 chr22 19956781 G A 1 Drug response to Risperidone COMT UTR-3 19451915 rs2239395 chr22 19962203 T G 5.89E-05 Psoriasis ARVCF intron 18364390 rs2073746 chr22 19978558 T C 6.20E-15 Progranulin levels ARVCF intron 21087763 rs2073746 chr22 19978558 T C 6.20E-15 Myocardial infarction ARVCF intron 21211798 rs1034565 chr22 19984211 C T 0.000151 Coronary artery disease ARVCF intron 23202125 rs1034566 chr22 19984277 C T 3.00E-08 Platelet counts ARVCF intron 22139419 rs2073741 chr22 19989890 C T 3.58E-04 Heart Failure ARVCF intron pha002885 rs877118 chr22 19996570 C T 8.94E-05 Body Composition ARVCF intron pha003012 rs877118 chr22 19996570 C T 4.27E-05 Body Mass Index ARVCF intron pha003021 rs2238796 chr22 19999073 C T 3.53E-04 Nicotine smoking ARVCF intron 19268276 rs2518827 chr22 20010730 A G 9.84E-05 Lymphocyte counts C22orf25 intron 22286170 rs2520733 chr22 20022498 C G 2.85E-04 Alzheimer's disease C22orf25 intron 22005930 rs17817689 chr22 20040602 C T 9.68E-05 Alzheimer's disease C22orf25 intron 22005930 rs729894 chr22 20041741 C T 1.03E-04 Alzheimer's disease C22orf25 intron 22005930 rs399162 chr22 20046687 G A 3.60E-04 Adiposity C22orf25 intron 19461586 rs2286483 chr22 20049465 T C 5.39E-05 Alzheimer's disease C22orf25 intron 22005930 rs2286484 chr22 20049495 G A 5.34E-05 Alzheimer's disease C22orf25 intron 22005930 rs3804044 chr22 20052442 A G 3.60E-05 Alzheimer's disease C22orf25 UTR-3 22005930 rs5992507 chr22 20057458 A G 3.51E-05 Alzheimer's disease / / 22005930 rs5992507 chr22 20057458 A G 2.48E-04 Stroke / / pha002887 rs2073778 chr22 20074575 C T 3.28E-05 Alzheimer's disease DGCR8 intron 22005930 rs720012 chr22 20098582 G A 4.21E-05 Alzheimer's disease DGCR8 UTR-3 22005930 rs885980 chr22 20102090 T C 1.29E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines TRMT2A intron 21844884 rs2238798 chr22 20107729 G A 4.27E-05 Alzheimer's disease RANBP1 intron 22005930 rs175163 chr22 20113777 T C 9.88E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines RANBP1 intron 21844884 rs175164 chr22 20115562 C T 1.00E-04 Prostate cancer / / 21743057 rs175165 chr22 20116015 T G 1.65E-04 Parkinson's disease / / 17052657 rs175165 chr22 20116015 T G 8.59E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs2871052 chr22 20116972 G C 9.57E-04 Type 2 diabetes / / 17463246 rs175174 chr22 20127554 A G 9.43E-04 Alzheimer's disease ZDHHC8 intron 22005930 rs2292570 chr22 20135340 T C 4.79E-05 Alzheimer's disease ZDHHC8 UTR-3 22005930 rs175182 chr22 20139299 C T 7.59E-04 Alzheimer's disease / / 22005930 rs16982973 chr22 20140295 C T 3.51E-05 Multiple complex diseases / / 17554300 rs619015 chr22 20142379 C G 4.49E-04 Alzheimer's disease / / 22005930 rs175200 chr22 20168509 G A 4.10E-05 Type 2 diabetes / / 17463248 rs438798 chr22 20169499 A G 4.20E-05 Type 2 diabetes / / 17463248 rs10212087 chr22 20171251 C T 5.58E-05 Rheumatoid arthritis / / 17804836 rs75766 chr22 20174853 C A 1.65E-04 Smoking initiation / / 24665060 rs2871058 chr22 20178147 A G 9.74E-04 Multiple complex diseases / / 17554300 rs613930 chr22 20185119 C A 1.71E-04 Parkinson's disease / / 17052657 rs613930 chr22 20185119 C A 3.59E-05 Post-operative nausea and vomiting / / 21694509 rs625704 chr22 20185457 G A 5.47E-04 Parkinson's disease / / 17052657 rs625704 chr22 20185457 G A 4.72E-06 Post-operative nausea and vomiting / / 21694509 rs681112 chr22 20186102 T C 5.47E-04 Parkinson's disease / / 17052657 rs655656 chr22 20187575 C T 1.98E-04 Parkinson's disease LOC284865 intron 17052657 rs701428 chr22 20228542 A G 2.16E-04 Amyotrophic Lateral Sclerosis RTN4R nearGene-3 17362836 rs701428 chr22 20228542 A G 2.00E-06 Obesity-related traits RTN4R nearGene-3 23251661 rs854971 chr22 20233429 T C 3.39E-04 Amyotrophic Lateral Sclerosis RTN4R intron 17362836 rs9606305 chr22 20258973 G A 5.63E-05 Orofacial clefts / / 22419666 rs6518604 chr22 20323211 G A 2.37E-05 Glycosylated haemoglobin levels / / 17255346 rs6518604 chr22 20323211 G A 6.87E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs2041969 chr22 20743536 A C 3.18E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs887023 chr22 20761899 C T 6.59E-06 Creutzfeldt-Jakob disease (variant) ZNF74 UTR-3 22137330 rs5752676 chr22 20774614 G A 7.40E-07 Urinary metabolites / / 21572414 rs5752681 chr22 20774808 G A 2.70E-07 Urinary metabolites / / 21572414 rs1005640 chr22 20789074 T C 1.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SCARF2 intron 20877124 rs1005640 chr22 20789074 T C 1.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SCARF2 intron 20877124 rs5763911 chr22 20797289 T C 6.00E-06 Retinopathy in non-diabetics KLHL22 intron 23393555 rs361988 chr22 20810054 C T 8.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KLHL22 intron 20877124 rs361988 chr22 20810054 C T 6.02E-05 Elbow pain KLHL22 intron pha003008 rs165889 chr22 20821874 A T 7.69E-04 Multiple complex diseases KLHL22 intron 17554300 rs5749587 chr22 20827264 T C 5.93E-04 Multiple complex diseases KLHL22 intron 17554300 rs9623544 chr22 20828638 A G 8.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KLHL22 intron 20877124 rs9623544 chr22 20828638 A G 6.89E-05 Elbow pain KLHL22 intron pha003008 rs1572877 chr22 20842384 C G 2.39E-04 Multiple complex diseases KLHL22 intron 17554300 rs7291930 chr22 20876509 A G 2.07E-04 Multiple complex diseases MED15 intron 17554300 rs11090206 chr22 20881678 C A 5.00E-04 Gamma gluatamyl transferase levels (interaction with age) MED15 intron 22010049 rs5758468 chr22 20911756 A C 2.61E-04 Multiple complex diseases MED15 intron 17554300 rs165591 chr22 20946302 G T 2.10E-04 Iris characteristics / / 21835309 rs165626 chr22 20954760 A G 2.51E-04 Parkinson's disease / / 17052657 rs561595 chr22 20960707 A G 2.71E-05 Coronary heart disease / / pha003032 rs1557798 chr22 20963373 G A 0.000215 Salmonella-induced pyroptosis / / 22837397 rs5759632 chr22 20982876 C T 6.12E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs596235 chr22 20983592 T C 6.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16988632 chr22 20985012 C A,G,T 1.77E-06 Cognitive decline / / 23207651 rs661440 chr22 20990057 T C 6.77E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs580204 chr22 20991062 T C 9.93E-06 Response to taxane treatment (placlitaxel) / / 23006423 rs624100 chr22 21001422 G T 4.81E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17211605 chr22 21005422 A G 9.15E-05 Lung adenocarcinoma / / 19836008 rs9612574 chr22 21011216 G C 7.71E-08 Biliary atresia / / 20460270 rs474117 chr22 21019273 T C 9.50E-08 Health and aging,CVD and cancer age of onset / / 22174011 rs674478 chr22 21021264 A G 4.15E-05 Bipolar disorder / / 19488044 rs674478 chr22 21021264 A G 9.45E-05 Bipolar Disorder / / pha002863 rs520698 chr22 21024880 A G 5.40E-06 Type 2 diabetes / / 17463248 rs565979 chr22 21028946 T C 7.00E-05 Type 2 diabetes / / 17463248 rs479275 chr22 21029223 A T 9.50E-05 Type 2 diabetes / / 17463248 rs491228 chr22 21033371 A G 7.50E-05 Type 2 diabetes / / 17463248 rs591446 chr22 21034650 G A 9.70E-05 Type 2 diabetes / / 17463248 rs2072513 chr22 21099297 T C 4.39E-04 Multiple complex diseases PI4KA intron 17554300 rs165888 chr22 21207892 G C 6.44E-04 Type 2 diabetes PI4KA intron 17463246 rs5761195 chr22 21249705 G C 2.16E-04 Schizophrenia / / 24043878 rs8142366 chr22 21302806 A G 3.38E-09 HDL cholesterol CRKL intron 23063622 rs178252 chr22 21312429 G A 4.57E-09 Lymphocyte counts / / 22286170 rs2018682 chr22 21317432 C T 5.00E-05 Postoperative ventricular dysfunction / / 21980348 rs756875 chr22 21318433 G A 6.65E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs178260 chr22 21324308 G T 1.37E-05 Alcohol and nictotine co-dependence AIFM3 intron 20158304 rs112544 chr22 21346485 T C 8.96E-07 Carotenoid and tocopherol levels LZTR1 intron 19185284 rs756876 chr22 21346719 A C 2.91E-05 Blood Pressure LZTR1 intron pha002903 rs178293 chr22 21349579 C T 1.10E-16 Progranulin levels LZTR1 intron 21087763 rs178293 chr22 21349579 C T 1.10E-16 Myocardial infarction LZTR1 intron 21211798 rs3747081 chr22 21352120 G A 6.81E-06 Osteoarthritis LZTR1 UTR-3 22763110 rs3747081 chr22 21352120 G A 6.82E-05 Blood Pressure LZTR1 UTR-3 pha002903 rs3747084 chr22 21353925 G A,C,T 3.77E-04 Acne (severe) / / 24927181 rs2516542 chr22 21363505 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2516542 chr22 21363505 C T 1.89E-04 Acne (severe) / / 24927181 rs399647 chr22 21365384 A G 4.06E-05 Cognitive test performance MGC16703 intron 20125193 rs9625334 chr22 21371227 C A 3.19E-04 Multiple complex diseases P2RX6 intron 17554300 rs9625334 chr22 21371227 C A 4.59E-05 Schizophrenia P2RX6 intron 19571809 rs8141816 chr22 21374550 A G 4.80E-06 Urinary metabolites P2RX6 intron 21572414 rs429738 chr22 21421425 A C 8.24E-04 Alzheimer's disease / / 24755620 rs370279 chr22 21422096 A C 5.08E-04 Alzheimer's disease / / 24755620 rs422942 chr22 21423993 C G 8.25E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs408718 chr22 21425769 C T 9.87E-04 Heart Failure / / pha002885 rs392358 chr22 21426113 A G 8.00E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs364968 chr22 21426740 T C 8.38E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs403653 chr22 21427577 A G 5.60E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs403653 chr22 21427577 A G 2.01E-04 Alzheimer's disease / / 24755620 rs421166 chr22 21428523 G A 6.59E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs396705 chr22 21429385 C A 3.99E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs400946 chr22 21431054 T C 3.00E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs439792 chr22 21431181 C A 2.60E-06 Antibody status in Tripanosoma cruzi seropositivity / / 24324551 rs421390 chr22 21438417 C A 7.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs2519458 chr22 21458772 G A 5.87E-04 Acute lung injury BCRP2 intron 22295056 rs2519459 chr22 21458804 T G 5.58E-04 Acute lung injury BCRP2 intron 22295056 rs140392 chr22 21462353 A G 4.53E-05 Celiac disease BCRP2 intron 23936387 rs465500 chr22 21798907 A G 5.20E-05 Systemic lupus erythematosus HIC2 intron 23273568 rs463426 chr22 21809185 T C 5.20E-05 Systemic lupus erythematosus / / 23273568 rs8139142 chr22 21910280 T C 1.53E-07 Red blood cell traits UBE2L3 intron 23222517 rs390408 chr22 21912272 A G 8.80E-05 Psoriasis UBE2L3 intron 20953190 rs131654 chr22 21917190 G T 1.00E-16 Systemic lupus erythematosus UBE2L3 intron 19838193 rs131654 chr22 21917190 G T 1.50E-04 Systemic lupus erythematosus UBE2L3 intron 23273568 rs131654 chr22 21917190 G T 8.38E-05 Erythrocyte counts UBE2L3 intron pha003099 rs131656 chr22 21917450 G A 2.64E-06 Hepatitis B UBE2L3 intron 24162738 rs131658 chr22 21917626 C G 4.46E-06 Hepatitis B UBE2L3 intron 24162738 rs140488 chr22 21919671 A G 2.07E-06 Hepatitis B UBE2L3 intron 24162738 rs201008924 chr22 21919671 A ACCG 2.07E-06 Hepatitis B UBE2L3 intron 24162738 rs131664 chr22 21920403 G A 2.06E-06 Hepatitis B UBE2L3 intron 24162738 rs59391722 chr22 21920817 G C 8.75E-07 Hepatitis B UBE2L3 intron 24162738 rs131665 chr22 21920903 A G 2.07E-06 Hepatitis B UBE2L3 intron 24162738 rs140489 chr22 21921294 G A 2.67E-06 Hepatitis B UBE2L3 intron 24162738 rs140490 chr22 21921686 G T 2.33E-06 Hepatitis B UBE2L3 intron 24162738 rs140491 chr22 21922364 T C 2.12E-06 Hepatitis B UBE2L3 intron 24162738 rs11089620 chr22 21922456 C G 7.80E-07 Hepatitis B UBE2L3 intron 24162738 rs2266959 chr22 21922904 G T 1.00E-16 Inflammatory bowel disease UBE2L3 intron 23128233 rs2266959 chr22 21922904 G T 0.000298 Oligoarticular juvenile idiopathic arthritis UBE2L3 intron 23603761 rs2266959 chr22 21922904 G T 6.20E-09 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) UBE2L3 intron 23603761 rs2266959 chr22 21922904 G T 6.93E-08 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis UBE2L3 intron 23603761 rs2266959 chr22 21922904 G T 1.64E-05 Systemic lupus erythematosus and Systemic sclerosis UBE2L3 intron 23740937 rs2266959 chr22 21922904 G T 7.80E-07 Hepatitis B UBE2L3 intron 24162738 rs140492 chr22 21923144 A C 2.33E-06 Hepatitis B UBE2L3 intron 24162738 rs2256609 chr22 21925017 A G 8.75E-07 Hepatitis B UBE2L3 intron 24162738 rs140498 chr22 21927064 G A 2.07E-06 Hepatitis B UBE2L3 intron 24162738 rs140499 chr22 21927231 C T 2.07E-06 Hepatitis B UBE2L3 intron 24162738 rs2266961 chr22 21928597 C G 8.98E-07 Hepatitis B UBE2L3 intron 24162738 rs181359 chr22 21928641 G A 5.00E-16 Crohn's disease UBE2L3 intron 21102463 rs181359 chr22 21928641 G A 2.07E-06 Hepatitis B UBE2L3 intron 24162738 rs181360 chr22 21928916 T G 3.07E-06 Hepatitis B UBE2L3 intron 24162738 rs73166619 chr22 21930093 C T 8.98E-07 Hepatitis B UBE2L3 intron 24162738 rs5754166 chr22 21930777 C T 8.02E-07 Hepatitis B UBE2L3 intron 24162738 rs181362 chr22 21932068 C T 1.00E-08 HDL cholesterol UBE2L3 intron 20686565 rs181362 chr22 21932068 C T 4.00E-18 HDL cholesterol UBE2L3 intron 24097068 rs181362 chr22 21932068 C T 2.07E-06 Hepatitis B UBE2L3 intron 24162738 rs181363 chr22 21932264 A G 2.07E-06 Hepatitis B UBE2L3 intron 24162738 rs181366 chr22 21933780 C T 2.07E-06 Hepatitis B UBE2L3 intron 24162738 rs66534072 chr22 21936152 C G 2.64E-06 Hepatitis B UBE2L3 intron 24162738 rs374387 chr22 21936835 C A 5.11E-06 Hepatitis B UBE2L3 intron 24162738 rs5749485 chr22 21938224 A C 2.64E-06 Hepatitis B UBE2L3 intron 24162738 rs5998576 chr22 21938590 C T 3.08E-06 Hepatitis B UBE2L3 intron 24162738 rs73166622 chr22 21938863 G C 2.78E-06 Hepatitis B UBE2L3 intron 24162738 rs5754217 chr22 21939675 G T 7.53E-08 Systemic lupus erythematosus UBE2L3 intron 18204446 rs5754217 chr22 21939675 G T 6.26E-06 Crohn's disease UBE2L3 intron 18587394 rs5754217 chr22 21939675 G T 3.82E-05 Systemic lupus erythematosus UBE2L3 intron 19838193 rs5754217 chr22 21939675 G T 1.88E-08 Celiac disease and Rheumatoid arthritis UBE2L3 intron 21383967 rs5754217 chr22 21939675 G T 2.00E-06 Systemic lupus erythematosus UBE2L3 intron 21408207 rs5754217 chr22 21939675 G T 9.00E-10 Red blood cell traits UBE2L3 intron 23222517 rs5754217 chr22 21939675 G T 5.00E-06 Systemic lupus erythematosus UBE2L3 intron 23273568 rs5754217 chr22 21939675 G T 9.84E-07 Ulcerative colitis UBE2L3 intron 23511034 rs5754217 chr22 21939675 G T 2.38E-06 Hepatitis B UBE2L3 intron 24162738 rs5749493 chr22 21939687 C A 2.64E-06 Hepatitis B UBE2L3 intron 24162738 rs4820091 chr22 21940189 T G 7.75E-07 Red blood cell traits UBE2L3 intron 23222517 rs4820091 chr22 21940189 T G 2.46E-06 Hepatitis B UBE2L3 intron 24162738 rs5749495 chr22 21940310 A G 1.03E-06 Hepatitis B UBE2L3 intron 24162738 rs12484550 chr22 21941915 C T 4.30E-07 Hepatitis B UBE2L3 intron 24162738 rs5998599 chr22 21941981 A G 3.02E-06 Hepatitis B UBE2L3 intron 24162738 rs9621715 chr22 21942007 G A 4.30E-07 Hepatitis B UBE2L3 intron 24162738 rs5754234 chr22 21942978 A T 4.30E-07 Hepatitis B UBE2L3 intron 24162738 rs1034329 chr22 21943938 T C 2.50E-06 Hepatitis B UBE2L3 intron 24162738 rs2283789 chr22 21944478 T G 2.64E-06 Hepatitis B UBE2L3 intron 24162738 rs5749502 chr22 21945096 T A 4.30E-07 Hepatitis B UBE2L3 intron 24162738 rs5998619 chr22 21945851 G A 2.51E-06 Hepatitis B UBE2L3 intron 24162738 rs73166630 chr22 21945978 G A,T 4.35E-07 Hepatitis B UBE2L3 intron 24162738 rs73166632 chr22 21946173 A G 2.64E-06 Hepatitis B UBE2L3 intron 24162738 rs2266963 chr22 21947467 C G 3.88E-07 Hepatitis B UBE2L3 intron 24162738 rs2070512 chr22 21949411 A C 2.49E-06 Hepatitis B UBE2L3 intron 24162738 rs4821104 chr22 21950405 A G 5.70E-07 Hepatitis B UBE2L3 intron 24162738 rs417986 chr22 21951558 C T 9.06E-06 Hepatitis B UBE2L3 intron 24162738 rs5754295 chr22 21951740 C A 2.36E-06 Hepatitis B UBE2L3 intron 24162738 rs5994638 chr22 21953276 A G 2.08E-06 Hepatitis B UBE2L3 intron 24162738 rs5998644 chr22 21953288 T C 2.08E-06 Hepatitis B UBE2L3 intron 24162738 rs2283790 chr22 21956653 A G 4.55E-05 Crohn's disease UBE2L3 intron 18587394 rs2283790 chr22 21956653 A G 2.79E-06 Hepatitis B UBE2L3 intron 24162738 rs5754323 chr22 21957992 T C 2.19E-06 Hepatitis B UBE2L3 intron 24162738 rs2266964 chr22 21958304 A G 2.57E-06 Hepatitis B UBE2L3 intron 24162738 rs11089629 chr22 21958872 T G 2.41E-06 Hepatitis B UBE2L3 intron 24162738 rs4821108 chr22 21959038 G C 2.53E-06 Hepatitis B UBE2L3 intron 24162738 rs5754344 chr22 21963786 A G 7.49E-07 Hepatitis B UBE2L3 intron 24162738 rs4821112 chr22 21964761 G A 1.00E-08 Blood cell counts and other traits UBE2L3 intron 20139978 rs4821112 chr22 21964761 G A 1.04E-08 Blood cell counts and other traits UBE2L3 intron 20139978 rs4821112 chr22 21964761 G A 7.70E-04 Myopia (pathological) UBE2L3 intron 21095009 rs4821112 chr22 21964761 G A 2.23E-08 Celiac disease and Rheumatoid arthritis UBE2L3 intron 21383967 rs4821112 chr22 21964761 G A 5.50E-06 Systemic lupus erythematosus UBE2L3 intron 21408207 rs4821112 chr22 21964761 G A 9.34E-09 Red blood cell traits UBE2L3 intron 23222517 rs4821112 chr22 21964761 G A 6.00E-06 Systemic lupus erythematosus UBE2L3 intron 23273568 rs4821112 chr22 21964761 G A 1.46E-06 Hepatitis B UBE2L3 intron 24162738 rs5754352 chr22 21964951 C T 1.46E-06 Hepatitis B UBE2L3 intron 24162738 rs5998672 chr22 21966442 G A 4.48E-06 Hepatitis B UBE2L3 intron 24162738 rs738127 chr22 21968221 G A 1.47E-06 Hepatitis B UBE2L3 intron 24162738 rs4821114 chr22 21970810 G C 7.24E-07 Hepatitis B UBE2L3 intron 24162738 rs8139079 chr22 21971632 T G 1.47E-06 Hepatitis B UBE2L3 intron 24162738 rs2876971 chr22 21972401 T G 1.28E-06 Hepatitis B UBE2L3 intron 24162738 rs4821116 chr22 21973319 C T 2.00E-12 Hepatitis B UBE2L3 intron 24162738 rs7444 chr22 21976934 T C 2.61E-06 Hepatitis B UBE2L3 UTR-3 24162738 rs7445 chr22 21977047 C A,G,T 1.43E-06 Hepatitis B UBE2L3 UTR-3 24162738 rs11089637 chr22 21979096 T C 2.51E-07 Red blood cell traits / / 23222517 rs11089637 chr22 21979096 T C 1.39E-06 Hepatitis B / / 24162738 rs11089637 chr22 21979096 T C 2.00E-07 Rheumatoid arthritis / / 24390342 rs11089637 chr22 21979096 T C 2.00E-09 Rheumatoid arthritis / / 24390342 rs11089637 chr22 21979096 T C 8.90E-04 Rheumatoid arthritis / / 24390342 rs4821124 chr22 21979289 T C 5.70E-11 Celiac disease / / 22057235 rs4821124 chr22 21979289 T C 0.000000038 Psoriasis / / 23143594 rs4821124 chr22 21979289 T C 4.77E-07 Hepatitis B / / 24162738 rs12158299 chr22 21979584 C T 2.06E-06 Hepatitis B / / 24162738 rs9619386 chr22 21979938 C A,T 2.47E-06 Hepatitis B / / 24162738 rs5754422 chr22 21980257 A G 1.91E-06 Hepatitis B / / 24162738 rs5754426 chr22 21980638 T C 1.92E-06 Hepatitis B / / 24162738 rs4821130 chr22 21980894 C T 1.92E-06 Hepatitis B / / 24162738 rs878825 chr22 21982249 T C 2.25E-06 Hepatitis B / / 24162738 rs2298428 chr22 21982892 C T 2.00E-07 Celiac disease YDJC missense 20190752 rs2298428 chr22 21982892 C T 3.00E-10 Celiac disease and Rheumatoid arthritis YDJC missense 21383967 rs2298428 chr22 21982892 C T 2.10E-06 Systemic lupus erythematosus YDJC missense 21408207 rs2298428 chr22 21982892 C T 2.53E-07 Red blood cell traits YDJC missense 23222517 rs2298428 chr22 21982892 C T 6.82E-07 Hepatitis B YDJC missense 24162738 rs2298429 chr22 21983260 A G 4.16E-06 Hepatitis B YDJC intron 24162738 rs13054355 chr22 21997070 G A 9.18E-04 Heart Failure SDF2L1 intron pha002885 rs861844 chr22 22006219 G T 3.21E-05 Type 2 diabetes / / 17846124 rs861844 chr22 22006219 G T 3.20E-05 Type 2 diabetes / / 21647700 rs861844 chr22 22006219 G T 6.43E-05 Sudden cardiac arrest / / 21658281 rs861844 chr22 22006219 G T 6.95E-06 Lymphocyte counts / / 22286170 rs396913 chr22 22039863 A C 8.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PPIL2 intron 20877124 rs12170039 chr22 22046787 G A 3.43E-05 Psoriasis PPIL2 intron 20953190 rs79384503 chr22 22047969 C T 2.00E-06 PR interval in Tripanosoma cruzi seropositivity PPIL2 intron 24324551 rs12484060 chr22 22049783 C T 3.10E-04 Multiple complex diseases PPIL2 cds-synon 17554300 rs710172 chr22 22055280 A G 3.35E-05 Psoriasis YPEL1 UTR-3 20953190 rs710172 chr22 22055280 A G 2.00E-04 Cognitive impairment induced by topiramate YPEL1 UTR-3 22091778 rs8135616 chr22 22082788 C T 3.70E-04 Diabetic nephropathy YPEL1 intron 20347642 rs13515 chr22 22115886 C T 5.29E-04 Heart rate MAPK1 UTR-3 23583979 rs2283792 chr22 22131125 T G 5.00E-09 Multiple sclerosis MAPK1 intron 21833088 rs2283792 chr22 22131125 T G 3.60E-04 Multiple sclerosis MAPK1 intron 24234648 rs17759796 chr22 22190163 C A 1.30E-04 Atrial fibrillation MAPK1 intron 21846873 rs8141815 chr22 22191585 G A 3.86E-04 Alcohol consumption (maxi-drinks) MAPK1 intron 24277619 rs8141815 chr22 22191585 G A 1.22E-05 Heart Rate MAPK1 intron pha003053 rs9610417 chr22 22199970 C T 1.97E-04 Amyotrophic Lateral Sclerosis MAPK1 intron 17362836 rs4820214 chr22 22250166 C T 0.0001404 Sarcoidosis / / 22952805 rs17759843 chr22 22274745 G A 1.00E-04 Information processing speed PPM1F UTR-3 21130836 rs240065 chr22 22296119 C T 8.27E-04 Schizophrenia PPM1F intron 19197363 rs412050 chr22 22307519 G C 6.00E-06 Attention deficit hyperactivity disorder / / 18839057 rs2266978 chr22 22328349 T C 3.24E-04 Myocardial Infarction TOP3B intron pha002883 rs1016548 chr22 22355496 A G 3.86E-05 Cognitive impairment induced by topiramate PRAMEL intron 22091778 rs61139 chr22 22360650 G T 2.48E-04 Alzheimer's disease PRAMEL intron 17998437 rs448735 chr22 22386434 A T 5.96E-04 Alzheimer's disease PRAMEL intron 17998437 rs439721 chr22 22388086 G C 6.67E-04 Alzheimer's disease PRAMEL intron 17998437 rs5756660 chr22 22401170 G A 9.48E-05 Blood pressure / / 17255346 rs6000790 chr22 22416297 A G 8.89E-04 Alzheimer's disease / / 17998437 rs5756725 chr22 22417696 G A 3.22E-04 Blood pressure / / 17255346 rs5750488 chr22 22436273 G A 1.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs5750498 chr22 22441313 G T 8.34E-05 Cognitive impairment induced by topiramate / / 22091778 rs5756832 chr22 22446460 C T 6.73E-05 Cognitive impairment induced by topiramate / / 22091778 rs6000910 chr22 22447493 A G 2.70E-04 Type 2 diabetes / / 17463246 rs16983057 chr22 22454680 A G 7.39E-05 Cognitive impairment induced by topiramate / / 22091778 rs8140543 chr22 22464245 C T 3.33E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs11089937 chr22 22506569 A C 8.00E-06 Periodontitis (PAL4Q3) / / 24024966 rs987710 chr22 22512415 G A 6.07E-05 Cognitive test performance / / 20125193 rs987710 chr22 22512415 G A 1.00E-06 Iron status biomarkers / / 21483845 rs987710 chr22 22512415 G A 5.00E-07 Iron status biomarkers / / 21483845 rs987710 chr22 22512415 G A 2.76E-04 Heart Failure / / pha002885 rs743516 chr22 22521498 G A 8.30E-06 Soluble leptin receptor levels / / 20167575 rs5995601 chr22 22524871 A G 4.25E-04 Self-reported allergy / / 23817569 rs9623054 chr22 22552114 C T 9.97E-06 Periodontitis (CDC/AAP) / / 24024966 rs9611214 chr22 22552844 T A 6.54E-04 Multiple complex diseases / / 17554300 rs9611215 chr22 22552919 G T 4.12E-04 Multiple complex diseases / / 17554300 rs5757411 chr22 22560835 G A 2.50E-07 Urinary metabolites / / 21572414 rs4820363 chr22 22566131 C A 1.39E-08 Multiple complex diseases / / 17554300 rs5750739 chr22 22568820 T C 9.51E-04 Type 2 diabetes / / 17463246 rs10854726 chr22 22600210 T C 6.75E-05 Heart Rate / / pha003053 rs10854726 chr22 22600210 T C 8.24E-05 Heart Rate / / pha003054 rs6001881 chr22 22694486 A G 5.72E-04 Premature ovarian failure / / 19508998 rs11090042 chr22 22701823 G A 1.78E-06 Esophageal cancer (squamous cell) / / 20729853 rs10483112 chr22 22726968 C T 3.90E-04 Crohn's disease / / 17684544 rs16987822 chr22 22729244 T C 4.44E-04 Alzheimer's disease (late onset) / / 21379329 rs25244 chr22 22751215 G A 3.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs5751168 chr22 22845240 T C 4.00E-06 Prostate cancer (gene x gene interaction) ZNF280B intron 22219177 rs6519366 chr22 22909590 C T 3.94E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs2330191 chr22 22916106 T C 3.94E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs715594 chr22 22916960 T C 3.94E-05 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs5751346 chr22 22931688 T G 1.42E-04 Attention deficit hyperactivity disorder / / 22420046 rs16989599 chr22 22946825 G A 7.81E-04 Multiple complex diseases / / 17554300 rs5759068 chr22 22958868 T C 0.0000052 Apolipoprotein B levels response after 40mg daily simvastatin treatment / / 23100282 rs5759068 chr22 22958868 T C 0.000054 LDL cholesterol response after 40mg daily simvastatin treatment / / 23100282 rs455578 chr22 23002699 C T 9.77E-04 Insulin resistance / / 21901158 rs438844 chr22 23022027 T C 0.000328 Height (Pygmy height) / / 22570615 rs6003222 chr22 23031579 T C 1.27E-04 Celiac disease / / 23936387 rs5996347 chr22 23031721 C T 6.28E-05 Aging (time to event) / / 21782286 rs3814997 chr22 23035233 T C 1.23E-04 Celiac disease / / 23936387 rs1065464 chr22 23154582 G A,C 6.78E-04 Body mass index / / 17255346 rs16993280 chr22 23157485 G A 4.59E-04 Body mass index / / 17255346 rs367216 chr22 23208519 A C 7.07E-05 Body mass index / / 17255346 rs1475930 chr22 23250737 T C 4.92E-06 Systemic lupus erythematosus and Systemic sclerosis / / 23740937 rs6003388 chr22 23258438 A G 6.30E-05 Diabetic retinopathy / / 21441570 rs9612164 chr22 23258457 C G 6.20E-05 Diabetic retinopathy / / 21441570 rs6003389 chr22 23259859 G A 6.10E-05 Diabetic retinopathy / / 21441570 rs5996419 chr22 23261330 G A 6.10E-05 Diabetic retinopathy / / 21441570 rs429942 chr22 23275227 T C 5.40E-06 Urinary metabolites / / 21572414 rs429942 chr22 23275227 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs463235 chr22 23278593 T C 3.18E-05 Coronary heart disease / / pha003031 rs455929 chr22 23283083 T G 8.39E-05 Platelet counts / / pha003100 rs2012607 chr22 23285252 G A 9.12E-05 Brain lesion load / / 19010793 rs8137688 chr22 23285694 G A 3.12E-05 Tourette syndrome / / 22889924 rs915613 chr22 23299769 G A 5.82E-05 Erythrocyte counts / / pha003101 rs2013551 chr22 23301330 T C 5.60E-05 Erythrocyte counts / / pha003101 rs11913797 chr22 23337705 T C 2.06E-04 Glycosylated haemoglobin levels / / 17255346 rs6003481 chr22 23375490 T C 1.12E-04 Multiple complex diseases / / 17554300 rs875602 chr22 23395684 C T 3.45E-06 Post-operative nausea and vomiting / / 21694509 rs6003495 chr22 23399743 A G 9.86E-05 Post-operative nausea and vomiting / / 21694509 rs13054331 chr22 23407063 G A 1.18E-05 Post-operative nausea and vomiting RTDR1 intron 21694509 rs3788337 chr22 23412017 G A 4.53E-04 Alzheimer's disease (late onset) RTDR1 intron 21379329 rs3788339 chr22 23417677 A G 0.0004249 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) G/Z intron 23233654 rs3788339 chr22 23417677 A G 4.25E-04 Methotrexate clearance (acute lymphoblastic leukemia) G/Z intron 23233662 rs4820539 chr22 23477970 A G 2.00E-07 Bone mineral density RTDR1 intron 22504420 rs74701880 chr22 23482658 C T 0.000052 Breast cancer(er negative) RTDR1 UTR-5 23555315 rs1807460 chr22 23505934 T C 2.90E-04 Type 2 diabetes and 6 quantitative traits RAB36 UTR-3 17848626 rs6003555 chr22 23554311 T C 4.48E-26 Narcolepsy BCR intron 19629137 rs5996498 chr22 23564966 A G 2.39E-05 Multiple complex diseases BCR intron 17554300 rs762601 chr22 23568858 A G 1.85E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) BCR intron 24023788 rs2156921 chr22 23569063 G A 6.93E-04 Oral cancers (chewing tobacco related) BCR intron 22503698 rs2156921 chr22 23569063 G A 1.82E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) BCR intron 24023788 rs4822375 chr22 23575642 A G 9.98E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) BCR intron 24023788 rs1005184 chr22 23580987 A G 2.78E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) BCR intron 24023788 rs9612266 chr22 23588165 G A 9.46E-04 Acute lung injury BCR intron 22295056 rs5751614 chr22 23593051 G A 6.00E-06 Height BCR intron 18391951 rs12166802 chr22 23616433 C T 1.76E-04 Rheumatoid arthritis (ACPA-negative) BCR intron 24532677 rs140504 chr22 23627369 A G 1.46E-05 Cognitive test performance BCR missense 20125193 rs5996516 chr22 23635924 G C 8.05E-05 Response to platinum-based chemotherapy in small-cell lung cancer BCR intron 20463552 rs2267023 chr22 23636118 A G 1.18E-05 Response to platinum-based chemotherapy in small-cell lung cancer BCR intron 20463552 rs2267025 chr22 23636541 G A 8.73E-06 Response to platinum-based chemotherapy in small-cell lung cancer BCR intron 20463552 rs5759686 chr22 23638635 C T 8.73E-06 Response to platinum-based chemotherapy in small-cell lung cancer BCR intron 20463552 rs6003605 chr22 23643212 C T 5.90E-04 Response to cytadine analogues (cytosine arabinoside) BCR intron 24483146 rs4822378 chr22 23644677 T G 5.24E-05 Cognitive test performance BCR intron 20125193 rs9608102 chr22 23644794 C T 3.75E-05 Cognitive test performance BCR intron 20125193 rs9608102 chr22 23644794 C T 8.00E-06 Immune response to smallpox vaccine (IL-6) BCR intron 22542470 rs131686 chr22 23646953 T A 1.80E-04 Major depressive disorder BCR intron 22472876 rs131690 chr22 23648009 G A 1.84E-04 Major depressive disorder BCR intron 22472876 rs131693 chr22 23649242 T G 2.14E-04 Major depressive disorder BCR intron 22472876 rs6003667 chr22 23717556 G C 3.50E-07 Urinary metabolites CES5AP1 intron 21572414 rs17001191 chr22 23720211 G A 1.41E-04 Multiple complex diseases CES5AP1 intron 17554300 rs5019659 chr22 23720420 T C 8.59E-04 Multiple complex diseases CES5AP1 intron 17554300 rs7349056 chr22 23731801 A G 5.75E-04 Schizophrenia / / 19197363 rs2003752 chr22 23742105 G A 5.89E-05 Nephrolithiasis / / 22396660 rs4822406 chr22 23757964 C A 5.92E-04 Type 2 diabetes / / 17463246 rs2017377 chr22 23761660 A G 3.65E-04 Type 2 diabetes / / 17463246 rs8138381 chr22 23762264 T C 2.60E-05 Urinary metabolites / / 21572414 rs8138134 chr22 23762667 C T 8.03E-04 Type 2 diabetes / / 17463246 rs4822410 chr22 23765265 A G 3.00E-06 Pulmonary function decline / / 22424883 rs5759802 chr22 23779822 C T 1.51E-05 Nephrolithiasis / / 22396660 rs6519442 chr22 23813258 T G 1.72E-06 Parkinson's disease / / 17052657 rs6519442 chr22 23813258 T G 1.26E-05 Longevity,exceptional / / 20595579 rs6519442 chr22 23813258 T G 1.55E-04 Myocardial Infarction / / pha002873 rs6519443 chr22 23813308 G C 7.14E-04 Parkinson's disease / / 17052657 rs12169718 chr22 23815573 G A 1.23E-04 Intracranial aneurysm / / 20613766 rs12169718 chr22 23815573 G A 4.65E-05 Post-operative nausea and vomiting / / 21694509 rs5759839 chr22 23817240 G A 1.00E-05 Urinary metabolites LOC388882 intron 21572414 rs5759844 chr22 23817891 G A 6.70E-06 Urinary metabolites LOC388882 intron 21572414 rs7290879 chr22 23826866 G A 9.59E-04 Type 2 diabetes LOC388882 intron 17463246 rs7290879 chr22 23826866 G A 1.90E-05 Urinary metabolites LOC388882 intron 21572414 rs6003740 chr22 23829623 A G 1.20E-06 Urinary metabolites / / 21572414 rs5759868 chr22 23855657 A G 6.19E-04 Multiple complex diseases / / 17554300 rs131356 chr22 23860188 T C 6.93E-05 Bipolar disorder and schizophrenia / / 20889312 rs131356 chr22 23860188 T C 2.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs131357 chr22 23860506 C T 5.27E-05 Bipolar disorder and schizophrenia / / 20889312 rs131357 chr22 23860506 C T 2.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs107261 chr22 23862788 A G 3.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs5759887 chr22 23874416 G A,T 1.73E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs131408 chr22 23890836 T C 6.00E-06 Peripheral artery disease / / 25009551 rs179307 chr22 23895043 A G 7.07E-05 Psoriasis / / 18364390 rs140174 chr22 23922983 A G 8.00E-06 Migraine IGLL1 nearGene-5 21448238 rs7287616 chr22 23929852 C T 7.52E-06 Osteoarthritis / / 22763110 rs7287616 chr22 23929852 C T 5.89E-05 Cholesterol / / pha003083 rs6003824 chr22 23993051 G T 2.20E-05 Urinary metabolites GUSBP11 intron 21572414 rs6003826 chr22 23993358 T C 9.19E-04 Multiple complex diseases GUSBP11 intron 17554300 rs6003826 chr22 23993358 T C 2.20E-05 Urinary metabolites GUSBP11 intron 21572414 rs3747106 chr22 23995213 C T 2.60E-05 Urinary metabolites GUSBP11 intron 21572414 rs2330555 chr22 24013288 G A 2.69E-05 Post-operative nausea and vomiting GUSBP11 intron 21694509 rs12157657 chr22 24014229 C T 3.90E-04 Multiple complex diseases GUSBP11 intron 17554300 rs738785 chr22 24022631 C T 1.98E-07 Gallstones GUSBP11 intron 17632509 rs3747110 chr22 24024815 C T 5.73E-05 Cognitive impairment induced by topiramate GUSBP11 intron 22091778 rs5751710 chr22 24028627 C T 4.41E-04 Blood pressure GUSBP11 intron 17255346 rs13057362 chr22 24032771 T A 5.93E-04 Multiple complex diseases GUSBP11 intron 17554300 rs2070446 chr22 24035970 C T 6.57E-04 Blood pressure RGL4 missense 17255346 rs1076123 chr22 24096783 T C 9.44E-04 Insulin resistance / / 21901158 rs2267029 chr22 24117916 A G 6.40E-04 Response to taxane treatment (placlitaxel) MMP11 intron 23006423 rs2073387 chr22 24129005 T G 6.40E-04 Response to taxane treatment (placlitaxel) SMARCB1 nearGene-5 23006423 rs2073390 chr22 24133570 G A 3.11E-04 Type 2 diabetes SMARCB1 intron 17463246 rs2073390 chr22 24133570 G A 2.08E-04 Response to taxane treatment (placlitaxel) SMARCB1 intron 23006423 rs5760022 chr22 24134394 T C 6.40E-04 Response to taxane treatment (placlitaxel) SMARCB1 intron 23006423 rs17630758 chr22 24136542 G A 2.40E-04 Type 2 diabetes SMARCB1 intron 17463246 rs17630758 chr22 24136542 G A 5.33E-04 Multiple complex diseases SMARCB1 intron 17554300 rs2267032 chr22 24148273 A G 5.80E-04 Alcohol dependence SMARCB1 intron 20201924 rs2267032 chr22 24148273 A G 8.80E-04 Alcohol dependence SMARCB1 intron 20201924 rs5760045 chr22 24155614 G A 3.36E-06 Lymphocyte counts SMARCB1 intron 22286170 rs738800 chr22 24158315 C A 8.67E-04 Response to taxane treatment (placlitaxel) SMARCB1 intron 23006423 rs2186369 chr22 24170996 T G 1.00E-10 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 1.00E-10 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 1.00E-12 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 1.00E-12 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 1.00E-16 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 2.00E-07 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 2.00E-08 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 2.00E-08 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 2.00E-08 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 2.00E-14 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 3.00E-08 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 3.00E-13 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 4.00E-06 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 4.00E-09 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 4.00E-09 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 5.00E-10 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 7.00E-16 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 8.00E-15 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 9.00E-10 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 9.00E-17 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 9.00E-17 IgG glycosylation SMARCB1 intron 23382691 rs2186369 chr22 24170996 T G 9.00E-17 IgG glycosylation SMARCB1 intron 23382691 rs6003914 chr22 24186637 T C 9.59E-04 Stroke / / pha002887 rs2275979 chr22 24204158 A G 5.44E-06 Bone mineral traits,in men SLC2A11 intron 21427758 rs4822442 chr22 24221295 T G 6.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SLC2A11 intron 20877124 rs5751761 chr22 24243736 C T 1.15E-19 Lymphocyte counts / / 22286170 rs17004053 chr22 24250835 A G 4.56E-04 Multiple complex diseases / / 17554300 rs9608216 chr22 24257779 C T 5.62E-05 Vascular dementia / / 22116812 rs9608216 chr22 24257779 C T 1.70E-04 Celiac disease / / 23936387 rs915590 chr22 24261143 A G 1.10E-05 Urinary metabolites / / 21572414 rs2330638 chr22 24270033 A G 6.22E-05 Cognitive test performance / / 20125193 rs2739330 chr22 24295286 T C 2.00E-09 Liver enzyme levels (gamma-glutamyl transferase) / / 22001757 rs738809 chr22 24405492 A G 1.70E-04 Hearing function / / 17255346 rs2267051 chr22 24427825 T C 7.75E-04 Type 2 diabetes CABIN1 intron 17463246 rs5760189 chr22 24442459 C T 4.41E-04 Taste perception CABIN1 intron 22132133 rs3827321 chr22 24464377 A G 8.00E-04 Atrial fibrillation CABIN1 intron 21846873 rs4820581 chr22 24480503 G A 5.45E-05 Amyotrophic lateral sclerosis CABIN1 intron 23624525 rs10427943 chr22 24527298 G T 1.73E-09 HDL cholesterol CABIN1 intron 23063622 rs2001106 chr22 24535229 T C 3.79E-05 Amyotrophic lateral sclerosis LOC100652894 missense 23624525 rs2001106 chr22 24535229 T C 5.69E-04 Heart Failure LOC100652894 missense pha002885 rs146769197 chr22 24567910 C T 0.000031 Breast cancer (ER positive) CABIN1 missense 23555315 rs8141797 chr22 24582041 A G 2.00E-09 Amyotrophic lateral sclerosis SUSD2 missense 23624525 rs5996675 chr22 24618331 A G 0.00014 Salmonella-induced pyroptosis GGT5 intron 22837397 rs9624447 chr22 24681555 C T 2.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SPECC1L intron 20877124 rs204710 chr22 24717850 A G 0.00042 Prostate cancer SPECC1L missense 23555315 rs204718 chr22 24761467 G A 0.00042 Prostate cancer SPECC1L missense 23555315 rs79612614 chr22 24788697 A C 1.14E-06 Acne (severe) SPECC1L intron 24927181 rs5760410 chr22 24815406 G A 1 Drug response to Methotrexate / / 18256692 rs5760410 chr22 24815406 G A 1 Drug response to Methotrexate / / 18539621 rs2298383 chr22 24825511 C T 1 Drug response to Methotrexate ADORA2A intron 18539621 rs3761422 chr22 24826672 T C 1 Drug response to Methotrexate ADORA2A intron 18539621 rs2267076 chr22 24830595 T C 1 Drug response to Methotrexate ADORA2A intron 18539621 rs2236624 chr22 24836024 T C 1 Drug response to Methotrexate ADORA2A intron 18539621 rs17651189 chr22 24844883 T C 8.26E-04 Type 2 diabetes C22orf45 intron 17463246 rs17651189 chr22 24844883 T C 6.00E-07 Acne (severe) C22orf45 intron 24927181 rs80134322 chr22 24849753 C T 1.37E-06 Acne (severe) C22orf45 intron 24927181 rs3788371 chr22 24893336 A G 5.00E-04 Atrial fibrillation UPB1 intron 21846873 rs140335 chr22 24913423 T C 2.22E-04 Heart Failure UPB1 intron pha002885 rs1314 chr22 24922452 T G 6.16E-04 Amyotrophic Lateral Sclerosis UPB1 UTR-3 17362836 rs11090327 chr22 24929771 A G 2.37E-04 IgE levels / / 17255346 rs11090327 chr22 24929771 A G 1.26E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs8136239 chr22 24932967 C A 7.44E-05 Multiple complex diseases / / 17554300 rs6004179 chr22 24933069 C T 4.63E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs117493866 chr22 24936096 G A 5.97E-07 Acne (severe) / / 24927181 rs9704 chr22 24936970 A G 3.55E-04 Amyotrophic Lateral Sclerosis C22orf13 UTR-3 17362836 rs12170895 chr22 24943294 C T 1.79E-04 IgE levels C22orf13 intron 17255346 rs5760472 chr22 24953571 A G 9.83E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity SNRPD3 intron 24324551 rs3788374 chr22 24954832 C T 2.16E-04 Amyotrophic Lateral Sclerosis SNRPD3 intron 17362836 rs201525843 chr22 24982125 C T 0.0001 Breast cancer (ER positive) FAM211B missense 23555315 rs5760485 chr22 24986473 T C 2.70E-11 Gamma gluatamyl transferase levels (interaction with age) GGT1 intron 22010049 rs2154611 chr22 24989920 C T 6.00E-11 Gamma gluatamyl transferase levels (interaction with age) GGT1 intron 22010049 rs4820599 chr22 24990213 A G 4.00E-11 Liver enzyme levels GGT1 intron 18940312 rs4820599 chr22 24990213 A G 6.82E-22 Blood cell counts and other traits GGT1 intron 20139978 rs4820599 chr22 24990213 A G 7.00E-53 Gamma glutamyl transpeptidase GGT1 intron 21909109 rs4820599 chr22 24990213 A G 2.50E-11 Gamma gluatamyl transferase levels (interaction with age) GGT1 intron 22010049 rs2070477 chr22 24990916 G A 1.50E-11 Gamma gluatamyl transferase levels (interaction with age) GGT1 intron 22010049 rs6519519 chr22 24991863 C T 1.50E-11 Gamma gluatamyl transferase levels (interaction with age) GGT1 intron 22010049 rs6519520 chr22 24991895 A G 2.50E-11 Gamma gluatamyl transferase levels (interaction with age) GGT1 intron 22010049 rs5751901 chr22 24992266 T C 2.00E-07 Protein quantitative trait loci GGT1 intron 18464913 rs5751901 chr22 24992266 T C 6.95E-58 Blood cell counts and other traits GGT1 intron 20139978 rs5751901 chr22 24992266 T C 8.70E-12 Gamma gluatamyl transferase levels (interaction with age) GGT1 intron 22010049 rs5760492 chr22 24995202 G A 1.00E-11 Gamma gluatamyl transferase levels (interaction with age) GGT1 intron 22010049 rs2006227 chr22 24995756 C A 0.000000017 Gamma-glutamyl transferase (GGT) GGT1 intron 23696881 rs2330795 chr22 24996582 G A 8.80E-18 Liver enzyme levels (gamma-glutamyl transferase) GGT1 intron 22001757 rs2330795 chr22 24996582 G A 1.00E-11 Gamma gluatamyl transferase levels (interaction with age) GGT1 intron 22010049 rs5751902 chr22 24996630 C T 8.00E-20 Blood cell counts and other traits GGT1 intron 20139978 rs5751902 chr22 24996630 C T 8.06E-20 Blood cell counts and other traits GGT1 intron 20139978 rs5751902 chr22 24996630 C T 8.06E-20 Hepatitis B GGT1 intron 21750111 rs2017869 chr22 24997309 G C 2.80E-11 Gamma gluatamyl transferase levels (interaction with age) GGT1 intron 22010049 rs2017869 chr22 24997309 G C 7.94E-08 Gamma-glutamyl transferase (GGT) GGT1 intron 23696881 rs2073398 chr22 24999104 C G 1.00E-109 Liver enzyme levels (gamma-glutamyl transferase) GGT1 intron 22001757 rs2073398 chr22 24999104 C G 1.60E-11 Gamma gluatamyl transferase levels (interaction with age) GGT1 intron 22010049 rs2330809 chr22 25002081 C T 2.00E-13 Blood metabolite levels GGT1 intron 24816252 rs2001180 chr22 25004206 T G 8.90E-08 Gamma gluatamyl transferase levels (interaction with age) GGT1 intron 22010049 rs186765281 chr22 25010855 A G 0.00054 Prostate cancer GGT1 missense 23555315 rs17661237 chr22 25086816 C G 9.70E-06 Gamma gluatamyl transferase levels (interaction with age) / / 22010049 rs915611 chr22 25095452 C A 8.09E-05 Cortisol secretion,in saliva / / 21316860 rs7286060 chr22 25154776 C T 1.68E-04 Multiple complex diseases PIWIL3 intron 17554300 rs2330929 chr22 25219930 T C 5.25E-04 Alzheimer's disease SGSM1 intron 17998437 rs2330929 chr22 25219930 T C 7.91E-05 Male fertility SGSM1 intron 22633400 rs713651 chr22 25228089 A G 1.24E-04 Type 2 diabetes SGSM1 intron 17463246 rs713651 chr22 25228089 A G 4.92E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SGSM1 intron 20877124 rs6004307 chr22 25231408 G A 5.98E-05 Type 2 diabetes SGSM1 intron 17463246 rs6004307 chr22 25231408 G A 4.55E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SGSM1 intron 20877124 rs139643 chr22 25231570 G A 7.75E-04 Alzheimer's disease SGSM1 intron 17998437 rs5996775 chr22 25238292 C T 3.21E-04 Nicotine smoking SGSM1 intron 19268276 rs7291798 chr22 25238729 G T 2.55E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SGSM1 intron 20031582 rs139676 chr22 25248765 A G 0.0000119 C-reactive protein SGSM1 intron 23505291 rs139719 chr22 25282765 T C 1.60E-06 Asthma (aspirin-intolerant) SGSM1 intron 21072201 rs139724 chr22 25284829 A G 9.20E-04 Amyotrophic Lateral Sclerosis SGSM1 intron 17362836 rs139724 chr22 25284829 A G 5.62E-04 Nicotine smoking SGSM1 intron 19268276 rs5760712 chr22 25291076 C T 3.91E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SGSM1 intron 20031582 rs2073201 chr22 25294369 G A 4.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SGSM1 missense 20877124 rs2073201 chr22 25294369 G A 4.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SGSM1 missense 20877124 rs9620460 chr22 25317044 T C 0.0003 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes SGSM1 intron 22628534 rs5760740 chr22 25322173 C G 5.86E-04 Nicotine smoking SGSM1 UTR-3 19268276 rs5760760 chr22 25357408 C T 7.49E-04 Smoking initiation / / 24665060 rs965197 chr22 25410266 A G 9.95E-05 Post-operative nausea and vomiting / / 21694509 rs11704260 chr22 25458733 A G 8.99E-04 Response to cytadine analogues (cytosine arabinoside) KIAA1671 intron 24483146 rs5760831 chr22 25477703 C T 1.64E-04 Type 2 diabetes KIAA1671 intron 17463246 rs5760831 chr22 25477703 C T 4.55E-04 Multiple complex diseases KIAA1671 intron 17554300 rs5760836 chr22 25480981 A G 1.20E-05 Urinary metabolites KIAA1671 intron 21572414 rs6004430 chr22 25481215 A G 9.77E-06 Type 2 diabetes KIAA1671 intron 17463246 rs5996834 chr22 25483921 C T 1.10E-05 Urinary metabolites KIAA1671 intron 21572414 rs5760855 chr22 25500496 G T 3.99E-05 Gaucher disease severity KIAA1671 intron 22388998 rs713876 chr22 25509747 A G 8.06E-04 Suicide attempts in bipolar disorder KIAA1671 intron 21041247 rs5752064 chr22 25520095 T C 7.84E-04 Suicide attempts in bipolar disorder KIAA1671 intron 21041247 rs875353 chr22 25545612 G A 7.12E-04 Suicide attempts in bipolar disorder KIAA1671 intron 21041247 rs875352 chr22 25545909 G C 7.20E-04 Suicide attempts in bipolar disorder KIAA1671 intron 21041247 rs9624730 chr22 25546617 C T 7.23E-04 Suicide attempts in bipolar disorder KIAA1671 intron 21041247 rs9624734 chr22 25548986 C T 7.29E-04 Suicide attempts in bipolar disorder KIAA1671 intron 21041247 rs5752073 chr22 25549183 C T 3.99E-04 Alzheimer's disease (late onset) KIAA1671 intron 21379329 rs9624735 chr22 25549405 G A 7.36E-04 Suicide attempts in bipolar disorder KIAA1671 intron 21041247 rs6004449 chr22 25550247 A G 7.43E-04 Suicide attempts in bipolar disorder KIAA1671 intron 21041247 rs16979674 chr22 25555283 G A 8.49E-04 Suicide attempts in bipolar disorder KIAA1671 intron 21041247 rs6004454 chr22 25555789 G A 4.53E-05 Type 2 diabetes KIAA1671 intron 17463246 rs6004454 chr22 25555789 G A 7.56E-04 Suicide attempts in bipolar disorder KIAA1671 intron 21041247 rs6004456 chr22 25555948 G A 8.29E-04 Suicide attempts in bipolar disorder KIAA1671 intron 21041247 rs16979683 chr22 25560579 A C 4.30E-05 Type 2 diabetes KIAA1671 intron 17463246 rs16979683 chr22 25560579 A C 7.30E-04 Suicide attempts in bipolar disorder KIAA1671 intron 21041247 rs16979684 chr22 25560601 A C 2.18E-05 Type 2 diabetes KIAA1671 intron 17463246 rs16979684 chr22 25560601 A C 7.32E-04 Suicide attempts in bipolar disorder KIAA1671 intron 21041247 rs7285325 chr22 25565420 G A 8.41E-04 Suicide attempts in bipolar disorder KIAA1671 intron 21041247 rs5752075 chr22 25572748 C A 5.55E-05 Serum metabolites KIAA1671 intron 19043545 rs5760892 chr22 25572922 A T 5.10E-05 Bipolar disorder and schizophrenia KIAA1671 intron 20889312 rs6004466 chr22 25577846 T C 3.62E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines KIAA1671 intron 21844884 rs17607104 chr22 25586662 G A 4.81E-05 Bipolar disorder and schizophrenia KIAA1671 intron 20889312 rs8138250 chr22 25606665 T C 8.30E-05 Kawasaki disease / / 22081228 rs4820621 chr22 25608548 T C 8.20E-05 Response to statin therapy / / 20339536 rs4820623 chr22 25611223 T C 8.80E-05 Response to statin therapy / / 20339536 rs2227247 chr22 25611588 T G 8.90E-05 Response to statin therapy / / 20339536 rs5760913 chr22 25612280 G A 9.20E-05 Response to statin therapy / / 20339536 rs4822579 chr22 25613183 G A 1.16E-04 Age-related macular degeneration / / 22125219 rs12169700 chr22 25615059 G T 0.00037656 Hypertension (early onset hypertension) CRYBB2 nearGene-5 22479346 rs8136087 chr22 25615710 A G 0.000225759 Hypertension (early onset hypertension) CRYBB2 intron 22479346 rs2330995 chr22 25641025 C A 2.13E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs12158362 chr22 25661376 G C 1.23E-04 Insulin resistance / / 21901158 rs5996879 chr22 25668730 C A 1.03E-04 Celiac disease / / 23936387 rs133164 chr22 25719288 T C 5.26E-04 Body mass index / / 21701565 rs133164 chr22 25719288 T C 7.91E-04 Body mass index / / 21701565 rs133197 chr22 25755649 A G 6.70E-04 Suicide attempts in bipolar disorder LRP5L intron 21423239 rs9624808 chr22 25770032 G A 3.15E-05 Multiple complex diseases LRP5L intron 17554300 rs5761054 chr22 25775535 C T 1.00E-04 Prostate cancer LRP5L intron 21743057 rs10222306 chr22 25784405 C A 3.80E-04 Height / / 17255346 rs1207587 chr22 25835514 A G 6.82E-04 Coronary heart disease / / 21971053 rs1930961 chr22 25875265 T C 9.00E-06 Bipolar disorder (mood-incongruent) / / 23092984 rs17681001 chr22 25887125 C G 7.95E-04 Multiple complex diseases / / 17554300 rs507715 chr22 25907905 C A 7.23E-05 Prostate cancer / / 22923026 rs2780695 chr22 25909811 G A 7.53E-05 Prostate cancer / / 22923026 rs12160908 chr22 25928620 C T 2.13E-05 Staphylococcus aureus infection / / 24847357 rs576895 chr22 25931580 T C 6.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs5752178 chr22 25945826 C T 6.30E-04 Parkinson's disease / / 17052657 rs12158587 chr22 26019540 A C 3.69E-08 Triglycerides ADRBK2 intron 23063622 rs16980525 chr22 26058622 A G 6.60E-04 Smoking initiation ADRBK2 intron 24665060 rs8142284 chr22 26069506 C T 9.53E-09 Triglycerides ADRBK2 intron 23063622 rs5752196 chr22 26071558 G A 5.00E-04 Acute lymphoblastic leukemia (childhood) ADRBK2 intron 20189245 rs5752196 chr22 26071558 G A 3.66E-05 C-Reactive Protein ADRBK2 intron pha003070 rs9608416 chr22 26111018 G A 7.10E-05 Amyotrophic Lateral Sclerosis ADRBK2 intron 17362836 rs12627968 chr22 26126015 T C 8.88E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs9608419 chr22 26135929 C T 1.71E-04 Body mass index / / 17255346 rs5761163 chr22 26139378 A G 3.44E-07 Schizophrenia MYO18B intron 19571811 rs5761163 chr22 26139378 A G 4.45E-04 Alzheimer's disease (late onset) MYO18B intron 21379329 rs133860 chr22 26144760 C T 1.43E-04 Body mass index MYO18B intron 17255346 rs11090409 chr22 26146429 T G 3.17E-04 Body mass index MYO18B intron 17255346 rs6004755 chr22 26147557 A G 2.49E-04 Body mass index MYO18B intron 17255346 rs133866 chr22 26148077 C T 8.78E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MYO18B intron 20877124 rs16980675 chr22 26150608 A G 2.01E-04 Type 2 diabetes MYO18B intron 17463246 rs133885 chr22 26159289 G A 8.00E-10 Mathematical ability in children with dyslexia MYO18B missense 23423138 rs3925154 chr22 26232616 A C 2.50E-04 Multiple complex diseases MYO18B intron 17554300 rs695251 chr22 26233304 T C 3.59E-04 Multiple complex diseases MYO18B intron 17554300 rs2072012 chr22 26241994 T C 8.23E-06 Uric acid levels MYO18B intron 21294900 rs5752236 chr22 26250645 C T 4.76E-04 Alzheimer's disease MYO18B intron 17998437 rs695613 chr22 26252865 A G 8.25E-05 Multiple complex diseases MYO18B intron 17554300 rs695613 chr22 26252865 A G 5.42E-04 Coronary Artery Disease MYO18B intron 17634449 rs695427 chr22 26254248 A G 5.11E-04 Parkinson's disease MYO18B intron 17052657 rs695430 chr22 26278427 A G 6.62E-04 Alzheimer's disease MYO18B intron 22005930 rs695670 chr22 26278468 C T 9.30E-04 Multiple complex diseases MYO18B intron 17554300 rs695317 chr22 26278679 A G 7.21E-04 Myopia (pathological) MYO18B intron 21095009 rs2331193 chr22 26306095 A T 4.04E-04 Depression (quantitative trait) MYO18B intron 20800221 rs5761313 chr22 26313745 G T 7.77E-04 Depression (quantitative trait) MYO18B intron 20800221 rs16981083 chr22 26333515 G A 9.68E-05 Multiple complex diseases MYO18B intron 17554300 rs2018701 chr22 26337086 T C 3.40E-05 Cardiovascular disease adverse events in renal patients treated with calcineurin inhibitors MYO18B intron 16155738 rs2269640 chr22 26337911 C T 7.54E-05 Chronic obstructive pulmonary disease MYO18B intron 19300482 rs2072007 chr22 26343805 A G 8.96E-04 Suicide attempts in bipolar disorder MYO18B intron 21423239 rs4820663 chr22 26354655 A C 8.89E-05 Lung function (forced expiratory volume in 1 second) MYO18B intron 24023788 rs5997009 chr22 26359733 G A 2.78E-04 Alzheimer's disease MYO18B intron 22005930 rs11703998 chr22 26359777 A G 1.17E-04 IgE levels MYO18B intron 17255346 rs11703998 chr22 26359777 A G 3.70E-05 Cardiovascular disease MYO18B intron pha003064 rs6004864 chr22 26379837 T C 6.94E-05 Longevity MYO18B intron 20304771 rs6004867 chr22 26380058 C T 5.43E-05 Longevity MYO18B intron 20304771 rs16981163 chr22 26389510 G A 5.02E-05 Longevity MYO18B intron 20304771 rs9613072 chr22 26392874 C T 5.96E-04 Amyotrophic Lateral Sclerosis MYO18B intron 17362836 rs8139900 chr22 26394724 A G 4.00E-06 Uric acid levels MYO18B intron 21294900 rs8139900 chr22 26394724 A G 9.17E-04 Suicide attempts in bipolar disorder MYO18B intron 21423239 rs8136667 chr22 26396280 C T 7.50E-05 Longevity MYO18B intron 20304771 rs9620582 chr22 26397504 G C 4.11E-05 Longevity MYO18B intron 20304771 rs1001021 chr22 26403599 G A 2.00E-06 Schizophrenia,bipolar disorder and depression (combined) MYO18B intron 20713499 rs6004887 chr22 26406136 G T 9.31E-05 Longevity MYO18B intron 20304771 rs6004890 chr22 26406991 A G 9.23E-05 Longevity MYO18B intron 20304771 rs6004895 chr22 26412755 C A 6.07E-04 Suicide attempts in bipolar disorder MYO18B intron 21423239 rs761670 chr22 26417956 C T 8.50E-05 Waist Circumference MYO18B intron pha003025 rs761670 chr22 26417956 C T 5.98E-05 Weight MYO18B intron pha003027 rs4822682 chr22 26418568 C T 6.56E-04 Suicide attempts in bipolar disorder MYO18B intron 21423239 rs5997024 chr22 26421591 A G 1.64E-06 Response to tocilizumab in rheumatoid arthritis MYO18B intron 22491018 rs16981226 chr22 26421793 A G 8.93E-07 Response to tocilizumab in rheumatoid arthritis MYO18B intron 22491018 rs41531549 chr22 26422292 G C 4.21E-04 Multiple complex diseases MYO18B intron 17554300 rs2236005 chr22 26422980 A G 9.26E-06 Response to tocilizumab in rheumatoid arthritis MYO18B missense 22491018 rs11913497 chr22 26425299 T C 2.28E-04 Type 2 diabetes MYO18B intron 17463246 rs5997026 chr22 26431850 T C 1.82E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs7292706 chr22 26436287 G A 1.49E-06 Multiple complex diseases / / 17554300 rs6004913 chr22 26438495 A G 9.71E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs6004919 chr22 26455216 C T 7.01E-05 Amyotrophic lateral sclerosis / / 20801717 rs6004919 chr22 26455216 C T 0.0000191 Amyotrophic lateral sclerosis / / 23587638 rs6004919 chr22 26455216 C T 0.0000358 Amyotrophic lateral sclerosis / / 23587638 rs134695 chr22 26483608 A G 3.44E-04 Coronary Artery Disease / / 17634449 rs134697 chr22 26484948 A G 1.48E-05 Height / / pha003010 rs4607039 chr22 26491170 A C 3.02E-05 Glucose levels / / pha003061 rs134703 chr22 26500417 A G 3.30E-05 Height / / pha003010 rs134704 chr22 26501884 C T 8.44E-04 Multiple complex diseases / / 17554300 rs134710 chr22 26504002 A G 5.55E-04 Multiple complex diseases / / 17554300 rs134717 chr22 26507645 C T 7.10E-05 Height / / pha003010 rs134735 chr22 26518455 T G 1.50E-05 Urinary metabolites / / 21572414 rs134748 chr22 26543287 G T 2.34E-04 Cognitive decline / / 23732972 rs9608466 chr22 26561478 G A 3.89E-06 Age-related macular degeneration / / 21197116 rs2049988 chr22 26562140 C T 7.10E-05 Age-related macular degeneration / / 20861866 rs2049988 chr22 26562140 C T 1.28E-05 Age-related macular degeneration / / pha000002 rs5752275 chr22 26590200 T C 2.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SEZ6L intron 20877124 rs5752275 chr22 26590200 T C 1.80E-05 Urinary metabolites SEZ6L intron 21572414 rs1535145 chr22 26620244 G A 4.62E-05 Lipid levels SEZ6L intron pha003082 rs2067970 chr22 26630688 T C 2.97E-06 Coronary heart disease SEZ6L intron pha003031 rs4822693 chr22 26633178 C T 6.59E-04 Body mass index SEZ6L intron 21701565 rs2847316 chr22 26637298 A C 1.56E-04 Tourette syndrome SEZ6L intron 22889924 rs5761435 chr22 26638677 G T 4.47E-05 Lipid levels SEZ6L intron pha003082 rs17302009 chr22 26641384 C T 1.17E-04 Smoking initiation SEZ6L intron 24665060 rs17302009 chr22 26641384 C T 6.66E-05 Left ventricular hypertrophy SEZ6L intron pha003052 rs717191 chr22 26642679 G A 5.65E-05 Telomere length SEZ6L intron 21573004 rs1941120 chr22 26648940 T C 1.00E-05 Urinary metabolites SEZ6L intron 21572414 rs1941120 chr22 26648940 T C 6.07E-04 Alzheimer's disease SEZ6L intron 24755620 rs9613142 chr22 26649421 C T 1.60E-05 Urinary metabolites SEZ6L intron 21572414 rs9613142 chr22 26649421 C T 6.07E-04 Alzheimer's disease SEZ6L intron 24755620 rs1207393 chr22 26653362 C G 5.00E-06 Airflow obstruction SEZ6L intron 22837378 rs9608476 chr22 26657664 A G 1.00E-06 Urinary metabolites SEZ6L intron 21572414 rs4640491 chr22 26661500 G A 1.20E-05 Urinary metabolites SEZ6L intron 21572414 rs4640491 chr22 26661500 G A 6.47E-04 Alzheimer's disease SEZ6L intron 24755620 rs17394336 chr22 26665807 G A 4.49E-05 Left ventricular hypertrophy SEZ6L intron pha003052 rs137183 chr22 26670085 A C 6.80E-04 Amyotrophic Lateral Sclerosis SEZ6L intron 17827064 rs5997062 chr22 26678128 C T 6.00E-05 Prostate cancer SEZ6L intron 21743057 rs677499 chr22 26681640 C T 4.94E-04 Response to alcohol consumption (flushing response) SEZ6L intron 24277619 rs17303828 chr22 26683635 T C 2.41E-05 Fibrinogen SEZ6L intron pha003068 rs688034 chr22 26689635 C T 4.00E-06 Coronary heart disease SEZ6L intron 17554300 rs688034 chr22 26689635 C T 6.90E-06 Coronary Artery Disease SEZ6L intron 17634449 rs688034 chr22 26689635 C T 5.79E-04 Bipolar disorder,schizoaffective SEZ6L intron 19567891 rs688034 chr22 26689635 C T 4.00E-06 Coronary heart disease SEZ6L intron 21347282 rs137205 chr22 26690539 G A 2.50E-04 Multiple complex diseases SEZ6L intron 17554300 rs591044 chr22 26697195 T C 6.00E-06 Insulin resistance SEZ6L intron 21901158 rs604459 chr22 26703588 G A 7.87E-05 Multiple complex diseases SEZ6L intron 17554300 rs604459 chr22 26703588 G A 6.09E-05 Insulin resistance SEZ6L intron 21901158 rs144295883 chr22 26706747 C T 0.000095 Breast cancer (ER positive) SEZ6L cds-synon 23555315 rs6519647 chr22 26713964 G T 1.33E-05 Alcohol dependence SEZ6L intron 23089632 rs6519647 chr22 26713964 G T 2.71E-04 Substance dependence phenotypes SEZ6L intron 24832863 rs6519647 chr22 26713964 G T 4.62E-07 Substance dependence phenotypes SEZ6L intron 24832863 rs581562 chr22 26715393 A G 3.98E-04 Amyotrophic Lateral Sclerosis SEZ6L intron 17827064 rs3788378 chr22 26715923 G A 1.57E-04 Substance dependence phenotypes SEZ6L intron 24832863 rs3788378 chr22 26715923 G A 6.78E-06 Substance dependence phenotypes SEZ6L intron 24832863 rs596392 chr22 26717679 C A,G,T 0.00000794 Interleukin-6 (IL-6) levels SEZ6L intron 23505291 rs596392 chr22 26717679 C A,G,T 0.0007 C-reactive protein SEZ6L intron 23505291 rs16981743 chr22 26722351 G C 7.61E-04 Multiple complex diseases SEZ6L intron 17554300 rs4822706 chr22 26729721 T C 7.43E-05 Neutrophil count SEZ6L intron pha003095 rs6005016 chr22 26733299 G A 5.30E-04 Multiple complex diseases SEZ6L intron 17554300 rs678655 chr22 26734141 C T 0.00045 Coronary artery calcification SEZ6L intron 23727086 rs17305959 chr22 26735632 C T 9.98E-06 Bipolar disorder and schizophrenia SEZ6L intron 20889312 rs17306064 chr22 26735813 T C 3.67E-05 Bipolar disorder and schizophrenia SEZ6L intron 20889312 rs3788395 chr22 26738732 G A 1.62E-04 Taste perception SEZ6L intron 22132133 rs1033427 chr22 26740281 T G 9.92E-05 Cognitive impairment induced by topiramate SEZ6L intron 22091778 rs595817 chr22 26766024 T C 1.40E-05 Body mass index (asthmatics) SEZ6L intron 23517042 rs654245 chr22 26767267 A G 7.92E-04 Multiple complex diseases SEZ6L intron 17554300 rs655825 chr22 26768596 C T 0.00007142 Sarcoidosis SEZ6L intron 22952805 rs595042 chr22 26770876 C T 8.43E-04 Type 2 diabetes SEZ6L intron 17846124 rs1893221 chr22 26771294 A G 1.39E-04 Glycosylated haemoglobin levels SEZ6L intron 17255346 rs5752314 chr22 26772006 A G 1.22E-04 Glycosylated haemoglobin levels SEZ6L intron 17255346 rs738400 chr22 26773254 T C 1.95E-04 Glycosylated haemoglobin levels SEZ6L intron 17255346 rs667577 chr22 26774580 A G 1.90E-04 Alcohol dependence SEZ6L intron 20201924 rs667577 chr22 26774580 A G 8.60E-05 Alcohol dependence SEZ6L intron 20201924 rs667577 chr22 26774580 A G 8.58E-05 Alcoholism SEZ6L intron pha002892 rs5761503 chr22 26777025 A G 4.22E-05 Glycosylated haemoglobin levels SEZ6L UTR-3 17255346 rs5752315 chr22 26777440 G A 6.48E-05 Glycosylated haemoglobin levels SEZ6L UTR-3 17255346 rs2212611 chr22 26789768 A G 0.0002031 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2212611 chr22 26789768 A G 2.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2226691 chr22 26789849 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2226691 chr22 26789849 G A 0.0002121 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2226691 chr22 26789849 G A 2.12E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2226690 chr22 26789906 T C 0.0001747 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2226690 chr22 26789906 T C 1.75E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2331250 chr22 26790704 G T 0.0001696 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs2331250 chr22 26790704 G T 1.70E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4239922 chr22 26790885 G C 0.0001645 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4239922 chr22 26790885 G C 1.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs13056467 chr22 26803206 C T 8.84E-06 Glucose levels / / pha003058 rs3213582 chr22 26842061 G A 3.40E-04 Smoking quantity / / 24665060 rs5752327 chr22 26844070 A G 6.67E-07 Glucose levels / / pha003058 rs722997 chr22 26849666 T C 6.67E-07 Glucose levels HPS4 intron pha003058 rs1894704 chr22 26853905 C A 5.28E-05 Glucose levels HPS4 missense pha003058 rs1894706 chr22 26854441 G A 4.30E-05 Glucose levels HPS4 missense pha003058 rs9608491 chr22 26870985 A G 4.31E-04 Smoking initiation HPS4 intron 24665060 rs5761557 chr22 26878024 A G 8.40E-04 Alcohol dependence HPS4 UTR-5 20201924 rs4820682 chr22 26884039 G A 2.92E-04 Celiac disease SRRD missense 23936387 rs2187956 chr22 26894985 C T 2.87E-04 Celiac disease TFIP11 intron 23936387 rs1008530 chr22 26895337 G A 2.87E-04 Celiac disease TFIP11 cds-synon 23936387 rs713900 chr22 26898242 A G 4.48E-06 Glucose levels TFIP11 intron pha003058 rs134157 chr22 26916722 C T 2.46E-04 Alcohol dependence / / 24277619 rs2283817 chr22 26923155 T C 8.45E-05 Self-reported allergy TPST2 intron 23817569 rs2283822 chr22 26924312 C T 9.38E-04 Alcohol dependence TPST2 intron 24277619 rs2283825 chr22 26924535 C T 8.43E-04 Alcohol dependence TPST2 intron 21314694 rs1011312 chr22 26927221 T C 3.48E-04 Type 2 diabetes TPST2 intron 17463246 rs4822733 chr22 26930156 A G 7.51E-04 Alzheimer's disease TPST2 intron 17998437 rs2283839 chr22 26969061 A C 7.66E-04 Alcohol dependence TPST2 intron 21314694 rs763090 chr22 26970016 T C 7.75E-05 Nicotine smoking TPST2 intron 19268276 rs17404243 chr22 26970902 G T 5.49E-04 Alzheimer's disease TPST2 intron 17998437 rs4822743 chr22 26981039 A G 6.36E-04 Rheumatoid arthritis TPST2 intron 21452313 rs4822743 chr22 26981039 A G 3.20E-05 Alcohol dependence TPST2 intron 24277619 rs9613221 chr22 26986826 A G 0.000364 Salmonella-induced pyroptosis / / 22837397 rs9613228 chr22 27002223 G A 4.58E-05 Schizophrenia CRYBB1 intron 19571809 rs4822752 chr22 27011420 C T 6.02E-04 Multiple complex diseases CRYBB1 intron 17554300 rs4822752 chr22 27011420 C T 5.85E-06 Bipolar disorder CRYBB1 intron 18317468 rs4822752 chr22 27011420 C T 9.82E-05 Schizophrenia CRYBB1 intron 19571809 rs4822752 chr22 27011420 C T 9.00E-06 Bipolar disorder and schizophrenia CRYBB1 intron 20889312 rs5761635 chr22 27014467 C T 9.76E-04 Multiple complex diseases CRYBB1 nearGene-5 17554300 rs2071862 chr22 27021401 G A 5.14E-05 Type 2 diabetes CRYBA4 intron 21799836 rs2071862 chr22 27021401 G A 6.86E-04 Alcohol dependence CRYBA4 intron 24277619 rs6005101 chr22 27033321 T C 4.83E-05 Type 2 diabetes / / 21799836 rs16982515 chr22 27041283 C G 3.00E-06 IgG glycosylation / / 23382691 rs744016 chr22 27042106 C T 5.00E-06 RR interval (heart rate) / / 20031603 rs16982543 chr22 27048858 T C 3.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16982551 chr22 27049032 A G 1.97E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs16982554 chr22 27049119 A G 4.53E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs739310 chr22 27051299 A G 7.00E-06 Obesity-related traits / / 23251661 rs739310 chr22 27051299 A G 2.99E-05 Waist Circumference / / pha003024 rs739310 chr22 27051299 A G 4.64E-05 Waist-Hip Ratio / / pha003029 rs2331291 chr22 27058821 C T 5.00E-07 Myocardial infarction MIAT intron 17066261 rs62224896 chr22 27062296 G A 1.40E-06 Myocardial infarction / / 17066261 rs2301523 chr22 27062669 G A 1.90E-06 Myocardial infarction / / 17066261 rs2301523 chr22 27062669 G A 1.90E-06 Myocardial infarction / / 17211523 rs34403716 chr22 27064576 G A 1.70E-06 Myocardial infarction / / 17066261 rs35955962 chr22 27065224 G A 2.10E-06 Myocardial infarction / / 17066261 rs35870418 chr22 27065794 C T 3.00E-06 Myocardial infarction / / 17066261 rs9625066 chr22 27068702 C A 2.56E-06 Coronary heart disease / / 22319020 rs739312 chr22 27073858 A C 4.60E-05 Type 2 diabetes / / 21799836 rs1543809 chr22 27093202 T A 6.46E-06 Suicide attempts in bipolar disorder / / 21423239 rs978695 chr22 27095014 C T 4.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs2331294 chr22 27095710 G A 5.64E-06 Suicide attempts in bipolar disorder / / 21423239 rs2331295 chr22 27095712 G A 6.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs5752388 chr22 27109475 T C 5.12E-06 Suicide attempts in bipolar disorder / / 21423239 rs5761697 chr22 27110259 C T 5.18E-06 Suicide attempts in bipolar disorder / / 21423239 rs5761699 chr22 27111321 T C 3.98E-06 Liver disease in chronic hepatitis B virus infection / / 24065354 rs5761699 chr22 27111321 T C 7.64E-06 Liver disease in chronic hepatitis B virus infection / / 24065354 rs5761702 chr22 27116420 C G 3.72E-04 Suicide attempts in bipolar disorder / / 21423239 rs5761704 chr22 27119061 C T 4.82E-04 Coronary heart disease / / 21606135 rs6005150 chr22 27122480 C T 1.03E-04 Coronary heart disease / / 21606135 rs5761709 chr22 27123638 G T 1.42E-04 Coronary heart disease / / 21606135 rs5761710 chr22 27123944 T C 7.63E-05 Coronary heart disease / / 21606135 rs5761711 chr22 27129747 A G 8.43E-06 Coronary heart disease / / 21606135 rs4822791 chr22 27186321 G A 5.00E-06 Alcohol dependence / / 21956439 rs9608521 chr22 27199237 C T 7.62E-07 Autism / / 22843504 rs2213707 chr22 27211191 A G 1.25E-05 Fibrinogen / / pha003068 rs2213769 chr22 27241464 G A 4.45E-04 Hemoglobin concentration / / 20534544 rs9625099 chr22 27250195 G A 5.70E-06 Urinary metabolites / / 21572414 rs16982952 chr22 27252185 A C 1.10E-05 Urinary metabolites / / 21572414 rs136557 chr22 27258572 G T 0.000167 Breast cancer early age of onset / / 18463975 rs9306430 chr22 27316435 C T 3.15E-05 Cognitive test performance / / 20125193 rs2213760 chr22 27336747 T C 9.07E-04 Myopia (pathological) / / 21095009 rs2157461 chr22 27338819 C T 7.74E-04 Myopia (pathological) / / 21095009 rs16983214 chr22 27343454 G A 9.95E-04 Type 2 diabetes / / 17463246 rs16983214 chr22 27343454 G A 2.00E-06 Cognitive function / / 24684796 rs16983218 chr22 27343533 T C 6.66E-04 Type 2 diabetes / / 17463246 rs16983218 chr22 27343533 T C 4.88E-06 Cognitive function / / 24684796 rs9620647 chr22 27343892 G A 8.14E-05 Coronary heart disease / / pha003032 rs2187898 chr22 27346779 T C 6.89E-05 Alzheimer's disease / / 21098978 rs5761859 chr22 27347402 G A 6.89E-05 Alzheimer's disease / / 21098978 rs5761860 chr22 27347493 A T 6.89E-05 Alzheimer's disease / / 21098978 rs5752451 chr22 27348321 C T 6.91E-05 Alzheimer's disease / / 21098978 rs5761863 chr22 27348456 A G 6.86E-05 Alzheimer's disease / / 21098978 rs5761880 chr22 27364300 T C 6.38E-05 Insulin-related traits / / pha003063 rs11090463 chr22 27377569 G A 5.10E-04 Lipopolysaccharide induced cytokine levels / / 23823136 rs11090463 chr22 27377569 G A 5.30E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2157465 chr22 27381346 G A 9.88E-04 Insulin resistance / / 21901158 rs4345013 chr22 27381837 T C 4.90E-05 Electrocardiographic traits and heart rate variability / / 17903306 rs16983365 chr22 27392102 G A 7.33E-05 Potassium levels / / pha003086 rs16983370 chr22 27394733 C T 9.23E-05 Insulin Resistance / / pha003062 rs16983370 chr22 27394733 C T 3.65E-05 Insulin-related traits / / pha003063 rs4417 chr22 27416825 T C 5.00E-06 Subcutaneous adipose tissue volume in HIV-infected men / / 21897333 rs2142541 chr22 27430078 T G 1.10E-05 Age-related macular degeneration / / 20385819 rs742004 chr22 27435820 G A 3.00E-06 Metabolite levels (HVA/MHPG ratio) / / 23319000 rs9613351 chr22 27435896 C A 3.17E-06 Metabolite levels (MHPG) / / 23319000 rs9608567 chr22 27435897 A G 3.17E-06 Metabolite levels (MHPG) / / 23319000 rs9608568 chr22 27436049 G A 2.86E-06 Metabolite levels (MHPG) / / 23319000 rs738157 chr22 27436164 A G 4.60E-06 Metabolite levels (MHPG) / / 23319000 rs738158 chr22 27436289 A G 4.60E-06 Metabolite levels (MHPG) / / 23319000 rs5761918 chr22 27436778 T C 4.60E-06 Metabolite levels (MHPG) / / 23319000 rs5752470 chr22 27436940 A G 4.60E-06 Metabolite levels (MHPG) / / 23319000 rs9613352 chr22 27437467 C T 4.31E-06 Metabolite levels (MHPG) / / 23319000 rs9613353 chr22 27440291 T C 9.06E-05 Body Mass Index / / pha003021 rs9613353 chr22 27440291 T C 9.45E-05 Left ventricular hypertrophy / / pha003052 rs9608573 chr22 27464157 C T 7.07E-04 Acute lung injury / / 22295056 rs17430741 chr22 27479480 C T 9.96E-05 Type 2 diabetes / / 17463246 rs10854797 chr22 27485111 C T 2.17E-05 Tunica Media / / pha003036 rs10854797 chr22 27485111 C T 9.13E-05 Diabetes Mellitus / / pha003059 rs10854797 chr22 27485111 C T 9.90E-06 Diabetes Mellitus / / pha003060 rs760528 chr22 27485301 G A 1.48E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs738163 chr22 27506926 C T 3.68E-04 Insulin resistance / / 21901158 rs11704703 chr22 27526095 A G 6.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1003704 chr22 27527005 C T 6.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs5762004 chr22 27539202 T C 1.64E-05 Type 2 diabetes / / 17463246 rs134965 chr22 27552544 G A 6.80E-05 Response to statin therapy / / 20339536 rs9625159 chr22 27552564 T C 9.50E-05 HIV-1 control / / 20041166 rs849453 chr22 27566619 C G 7.70E-05 Recombination rate / / 21698098 rs8143105 chr22 27584291 G A 0.00000846 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs1519221 chr22 27622907 A G 3.60E-04 Smoking initiation / / 24665060 rs5997202 chr22 27625874 T A 7.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs10483132 chr22 27627598 C T 8.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs549378 chr22 27645258 C T 0.000580963 Hypertension (early onset hypertension) / / 22479346 rs6519704 chr22 27648272 T C 9.25E-05 Lymphocyte counts / / pha003094 rs134784 chr22 27652075 A G 3.48E-05 Hypertension (early onset hypertension) / / 22479346 rs134790 chr22 27653397 C T 4.13E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs79137 chr22 27657507 G A 3.36E-05 Lung adenocarcinoma / / 19836008 rs518350 chr22 27657544 C T 2.70E-04 Asthma (bronchodilator response) / / 23508266 rs738214 chr22 27659774 G A 5.76E-04 Type 2 diabetes / / 17463246 rs4820748 chr22 27660461 C T 4.67E-04 Type 2 diabetes / / 17463246 rs47808 chr22 27670885 C T 1.40E-05 Urinary metabolites / / 21572414 rs134809 chr22 27674547 G A 2.20E-06 Urinary metabolites / / 21572414 rs9625199 chr22 27700289 G A 1.73E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs477611 chr22 27710703 G A 3.30E-06 Urinary metabolites / / 21572414 rs543981 chr22 27712996 T C 1.00E-04 Information processing speed / / 21130836 rs497150 chr22 27717716 A G 1.67E-05 Psoriasis risk prediction / / 21214922 rs572159 chr22 27730109 A G 8.12E-04 Type 2 diabetes / / 17463246 rs572159 chr22 27730109 A G 3.03E-04 Multiple complex diseases / / 17554300 rs572159 chr22 27730109 A G 9.10E-05 Myasthenia gravis / / 23055271 rs490362 chr22 27731470 C T 1.00E-04 Fibrinogen / / pha003068 rs9608600 chr22 27732598 C T 1.89E-04 Type 2 diabetes / / 17463246 rs9620685 chr22 27735210 T G 2.99E-04 Multiple complex diseases / / 17554300 rs483997 chr22 27738226 G T 5.90E-04 Insulin resistance / / 21901158 rs533794 chr22 27745625 C A 0.000785382 Hypertension (early onset hypertension) / / 22479346 rs16984375 chr22 27747124 T C 0.0000946 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs569626 chr22 27747270 G A 8.00E-04 Crohn's disease / / 17684544 rs569626 chr22 27747270 G A 2.52E-05 Personality dimensions / / 22628180 rs9613438 chr22 27766758 G A 0.0000743 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs73158434 chr22 27769191 C T 0.0000801 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs73158437 chr22 27769389 G A 0.0000801 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs150597257 chr22 27771910 G A 0.0000897 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs8138626 chr22 27773323 A G 0.0000729 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs16984485 chr22 27791806 T C 9.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs5752534 chr22 27792500 C A 2.70E-05 Urinary metabolites / / 21572414 rs5752534 chr22 27792500 C A 5.60E-05 Schizophrenia / / 21791550 rs5752534 chr22 27792500 C A 0.000056 Psychosis / / 23164818 rs16984531 chr22 27802431 A G 3.53E-04 Multiple complex diseases / / 17554300 rs1159795 chr22 27818596 C T 7.84E-05 Basophils / / pha003087 rs4822879 chr22 27836850 A G 0.000555359 Hypertension (early onset hypertension) / / 22479346 rs6005451 chr22 27852183 T C 4.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs5762162 chr22 27861922 G A 8.57E-05 Personality dimensions / / 18957941 rs5762164 chr22 27862191 T C 5.00E-04 Type 2 diabetes / / 17463246 rs9625239 chr22 27867567 G A,C,T 7.73E-04 Type 2 diabetes / / 17463246 rs5762185 chr22 27877298 A G 6.63E-05 Multiple complex diseases / / 17554300 rs926837 chr22 27879170 C T 1.06E-04 Pancreatic cancer / / pha002874 rs1474813 chr22 27881885 C T 2.54E-04 Schizophrenia / / 19197363 rs5762198 chr22 27887895 C A 3.78E-05 Serum metabolites / / 19043545 rs4822889 chr22 27893974 G T 6.72E-05 stroke (ischemic) / / 17434096 rs8141487 chr22 27905762 C T 6.41E-05 Smoking initiation / / 24665060 rs9608617 chr22 27906244 G C 2.96E-05 Attention deficit hyperactivity disorder / / 18980221 rs9608617 chr22 27906244 G C 3.52E-05 Attention deficit hyperactivity disorder / / pha002875 rs5762222 chr22 27909106 A G 2.59E-04 Smoking initiation / / 24665060 rs9625253 chr22 27912970 G C 2.81E-04 Birth weight / / 17255346 rs2207362 chr22 27913387 G A 4.08E-05 Attention deficit hyperactivity disorder / / pha002875 rs8136304 chr22 27917070 G A 1.82E-04 Smoking initiation / / 24665060 rs1983659 chr22 27922759 C T 7.71E-05 Type 2 diabetes and other traits / / 19734900 rs8137397 chr22 27925604 C G 3.83E-04 Smoking initiation / / 24665060 rs12628909 chr22 27941726 T C 9.46E-05 Waist Circumference / / pha003023 rs910545 chr22 27946986 T C 1.16E-04 Parkinson's disease / / 17052657 rs5752592 chr22 27967652 G A 5.21E-05 Neuroblastoma / / pha002895 rs5762257 chr22 27968208 T C 2.40E-05 Response to statin therapy / / 20339536 rs9613477 chr22 27989890 T C 5.11E-05 Myocardial Infarction / / pha002873 rs12484213 chr22 28000527 G A 7.08E-05 Calcium levels / / pha003085 rs732110 chr22 28015322 A C 0.0000089 Uterine leiomyomata / / 23040493 rs16985162 chr22 28019493 T C 2.76E-04 Multiple complex diseases / / 17554300 rs16985179 chr22 28029538 C T 2.80E-05 Urinary metabolites / / 21572414 rs16985179 chr22 28029538 C T 6.00E-06 Alcohol consumption / / 23743675 rs134025 chr22 28044057 T G 1.90E-05 Urinary metabolites / / 21572414 rs9608637 chr22 28054814 G A 1.60E-05 Urinary metabolites / / 21572414 rs134100 chr22 28071706 C T 5.83E-05 stroke (ischemic) / / 17434096 rs5762311 chr22 28090207 G A 7.00E-06 Sudden cardiac arrest / / 21658281 rs5762311 chr22 28090207 G A 0.00058 Prostate cancer / / 23555315 rs4820773 chr22 28102627 G A 6.26E-04 Response to alcohol consumption (flushing response) / / 24277619 rs4820773 chr22 28102627 G A 2.95E-04 Heart Failure / / pha002884 rs4820774 chr22 28102894 A G 1.63E-04 Sudden cardiac arrest / / 21658281 rs11090507 chr22 28105851 G A 7.49E-05 Serum metabolites / / 19043545 rs134133 chr22 28129239 C A 1.34E-05 Serum metabolites / / 19043545 rs738353 chr22 28130072 C T 0.000123 Gains in maximal O2 uptake response / / 21183627 rs2267107 chr22 28152601 G A 9.82E-04 Myopia (pathological) MN1 intron 21095009 rs5762347 chr22 28159672 G A 9.30E-06 Urinary metabolites MN1 intron 21572414 rs5762347 chr22 28159672 G A 5.98E-06 Osteoarthritis MN1 intron 22763110 rs2283846 chr22 28165334 A G 1.40E-05 Urinary metabolites MN1 intron 21572414 rs5997301 chr22 28166402 C G 8.49E-04 Response to taxane treatment (placlitaxel) MN1 intron 23006423 rs12158991 chr22 28178948 G A 8.49E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) MN1 intron 24236485 rs116805592 chr22 28246308 A G 5.50E-04 Smoking cessation LOC100507669 intron 24665060 rs720621 chr22 28313583 A C 1.10E-05 Personality dimensions PITPNB intron 18957941 rs12169097 chr22 28364148 A G 4.00E-04 Myocardial Infarction TTC28-AS1 intron pha002883 rs7292562 chr22 28368096 T C 0.000397 Salmonella-induced pyroptosis TTC28-AS1 intron 22837397 rs5752673 chr22 28372703 C T 1.98E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) TTC28-AS1 intron 24023788 rs5762430 chr22 28378472 A G 7.00E-07 Obesity TTC28 cds-synon 21552555 rs5762448 chr22 28408444 A C 4.95E-05 Cholesterol TTC28 intron pha003073 rs9625391 chr22 28450331 A G 0.000724 Salmonella-induced pyroptosis TTC28 intron 22837397 rs12166740 chr22 28456751 T C 0.000642 Salmonella-induced pyroptosis TTC28 intron 22837397 rs16985967 chr22 28487192 C T 0.000301 Salmonella-induced pyroptosis TTC28 intron 22837397 rs9620768 chr22 28487731 C G 0.000444 Salmonella-induced pyroptosis TTC28 intron 22837397 rs9620769 chr22 28502867 A C 0.000296 Salmonella-induced pyroptosis TTC28 intron 22837397 rs9620770 chr22 28508216 C A 0.000377 Salmonella-induced pyroptosis TTC28 intron 22837397 rs16986037 chr22 28519110 A G 0.000321 Salmonella-induced pyroptosis TTC28 intron 22837397 rs16986077 chr22 28548967 C T 0.000382 Salmonella-induced pyroptosis TTC28 intron 22837397 rs12167735 chr22 28616080 T C 0.000762 Salmonella-induced pyroptosis TTC28 intron 22837397 rs134176 chr22 28624319 T C 6.60E-04 Multiple complex diseases TTC28 intron 17554300 rs738996 chr22 28645300 C T 3.56E-04 Multiple complex diseases TTC28 intron 17554300 rs9306454 chr22 28663405 A G 1.65E-04 Multiple complex diseases TTC28 intron 17554300 rs5762543 chr22 28668803 G A 2.94E-04 Alzheimer's disease TTC28 intron 17998437 rs2056962 chr22 28672406 G A 1.46E-04 Multiple complex diseases TTC28 intron 17554300 rs6005754 chr22 28682616 T C 0.0000162 Nicotine dependence (smoking) TTC28 intron 22377092 rs738199 chr22 28756581 A G 5.99E-07 Red blood cell traits TTC28 intron 23222517 rs1534884 chr22 28772817 C T 7.45E-05 Arthritis (juvenile idiopathic) TTC28 intron 22354554 rs737622 chr22 28877715 G T 1 Drug response to Methamphetamine TTC28 intron 17606664 rs695267 chr22 28899748 G T 1.89E-07 Red blood cell traits TTC28 intron 23222517 rs1547014 chr22 29100711 T C 1.00E-08 Vertical cup-disc ratio CHEK2 intron 20548946 rs1547014 chr22 29100711 T C 7.24E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CHEK2 intron 24023788 rs4822983 chr22 29115066 C T 2.00E-22 Esophageal cancer (squamous cell) CHEK2 intron 22960999 rs17879961 chr22 29121087 A G 1.00E-13 Lung cancer CHEK2 missense 24880342 rs17879961 chr22 29121087 A G 3.00E-11 Lung cancer CHEK2 missense 24880342 rs738722 chr22 29130012 T C 1.00E-08 Esophageal cancer and gastric cancer CHEK2 intron 20729852 rs738722 chr22 29130012 T C 6.57E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CHEK2 intron 24023788 rs5762763 chr22 29132389 G C 8.33E-05 Multiple complex diseases CHEK2 intron 17554300 rs5762766 chr22 29135889 T C 9.03E-04 Alzheimer's disease CHEK2 intron 24755620 rs714191 chr22 29145411 T C 2.57E-04 Alzheimer's disease HSCB intron 24755620 rs5752791 chr22 29153547 C T 6.22E-04 Alzheimer's disease / / 17998437 rs5752792 chr22 29153759 C T 4.78E-05 Multiple complex diseases / / 17554300 rs6005863 chr22 29156448 A G 1.81E-04 Amyotrophic lateral sclerosis / / 23624525 rs4820792 chr22 29161007 C T 4.00E-07 Breast size / / 22747683 rs5762788 chr22 29174770 C A 1.27E-05 Esophageal cancer (squamous cell) CCDC117 intron 22960999 rs1222 chr22 29185113 A C 6.80E-04 Multiple complex diseases CCDC117 UTR-3 17554300 rs2239815 chr22 29192670 T C 4.00E-15 Esophageal cancer (squamous cell) XBP1 intron 22960999 rs763073 chr22 29215542 G A 3.80E-04 Breast cancer / / 19330027 rs5762862 chr22 29252732 G A 6.03E-07 Red blood cell traits / / 23222517 rs5762870 chr22 29261159 C T 4.81E-04 Response to TNF antagonist treatment / / 21061259 rs2064261 chr22 29287730 C T 6.85E-04 Response to TNF antagonist treatment ZNRF3 intron 21061259 rs5762893 chr22 29314636 T C 1.14E-06 Lung adenocarcinoma ZNRF3 intron 19836008 rs7290364 chr22 29333123 C T 1.54E-06 Lung adenocarcinoma ZNRF3 intron 19836008 rs16986861 chr22 29343188 G C 8.72E-07 Red blood cell traits ZNRF3 intron 23222517 rs5752839 chr22 29345890 C T 1.37E-06 Lung adenocarcinoma ZNRF3 intron 19836008 rs13056243 chr22 29349306 C T 1.95E-07 Red blood cell traits ZNRF3 intron 23222517 rs16986864 chr22 29350911 G T 1.70E-05 Urinary metabolites ZNRF3 intron 21572414 rs16986864 chr22 29350911 G T 5.19E-07 Red blood cell traits ZNRF3 intron 23222517 rs4055 chr22 29352495 A C 4.83E-07 Red blood cell traits ZNRF3 intron 23222517 rs8140640 chr22 29379557 T C 2.77E-04 Type 2 diabetes ZNRF3 intron 17463246 rs4823000 chr22 29379891 T C 2.77E-04 Type 2 diabetes ZNRF3 intron 17463246 rs5762936 chr22 29381377 C T 8.40E-05 Hypertension ZNRF3 intron 19609347 rs12627758 chr22 29382831 A G 2.77E-04 Type 2 diabetes ZNRF3 intron 17463246 rs41341948 chr22 29384656 T G 4.57E-04 Type 2 diabetes ZNRF3 intron 17463246 rs16986951 chr22 29404706 T G 4.47E-05 Type 2 diabetes ZNRF3 intron 17463246 rs41382448 chr22 29405742 G C 1.87E-06 Bilirubin levels ZNRF3 intron 23371916 rs4140643 chr22 29408419 T C 2.70E-05 Urinary metabolites ZNRF3 intron 21572414 rs8137391 chr22 29422227 C T 7.75E-04 Multiple complex diseases ZNRF3 intron 17554300 rs8137254 chr22 29429997 T C 1.50E-05 Urinary metabolites ZNRF3 intron 21572414 rs4823006 chr22 29451671 A G 3.00E-11 Waist-hip ratio ZNRF3 UTR-3 20935629 rs6005975 chr22 29454477 T C 1.26E-04 Arthritis (juvenile idiopathic) / / 22354554 rs41281607 chr22 29456467 T C 0.0001 Breast cancer C22orf31 missense 23555315 rs9625679 chr22 29456699 A G 4.61E-05 Meningococcal disease C22orf31 missense 20694013 rs6005977 chr22 29456733 T C 7.56E-05 Acute lung injury C22orf31 cds-synon 22295056 rs134559 chr22 29458441 A G 2.77E-04 Smoking cessation / / 24665060 rs760628 chr22 29459732 A G 6.44E-04 Tourette syndrome / / 22889924 rs134607 chr22 29475124 A G 7.00E-04 Lymphocyte counts KREMEN1 intron 22286170 rs713861 chr22 29485794 G A 6.67E-05 Schizophrenia KREMEN1 intron 19571809 rs1540900 chr22 29490148 T C 4.12E-05 Orofacial clefts KREMEN1 intron 22419666 rs126077 chr22 29502728 G A 5.89E-04 Response to cytadine analogues (cytosine arabinoside) KREMEN1 intron 24483146 rs134678 chr22 29503955 T C 5.89E-04 Response to cytadine analogues (cytosine arabinoside) KREMEN1 intron 24483146 rs33958791 chr22 29524534 G A 1.28E-05 Parkinson's disease (motor and cognition) KREMEN1 intron 22658654 rs9680618 chr22 29566978 C T 4.17E-05 Parkinson's disease (motor and cognition) / / 22658654 rs9680618 chr22 29566978 C T 4.17E-05 Immune response to anthrax vaccine / / 22658931 rs132323 chr22 29567431 T C 1.89E-04 Alzheimer's disease (late onset) / / 21379329 rs132390 chr22 29621477 C T 3.00E-09 Breast cancer EMID1 intron 23535729 rs1997719 chr22 29628741 C T 2.48E-05 Blood pressure EMID1 intron 24001895 rs3765300 chr22 29628806 G A 7.98E-04 Response to cytidine analogues (gemcitabine) EMID1 intron 24483146 rs9608745 chr22 29649775 G A 3.25E-04 Suicide attempts in bipolar disorder EMID1 intron 21423239 rs3765303 chr22 29650774 C T 9.78E-06 Coronary heart disease EMID1 intron pha003032 rs2301290 chr22 29661341 G A 6.60E-05 Personality dimensions RHBDD3 intron 18957941 rs5763131 chr22 29685752 A G 1.63E-04 Parkinson's disease EWSR1 intron 17052657 rs3788412 chr22 29750186 T C 3.77E-05 HIV-1 viral setpoint AP1B1 intron 22174851 rs174772 chr22 29775023 C A 6.11E-04 Alzheimer's disease AP1B1 intron 17998437 rs5752905 chr22 29777291 A G 9.19E-04 Alzheimer's disease AP1B1 intron 17998437 rs2267138 chr22 29793641 A G 3.00E-06 Myopia (pathological) / / 23049088 rs12484045 chr22 29828751 A C 9.91E-04 Prostate cancer mortality / / 20978177 rs5763241 chr22 29839168 T C 9.65E-05 Formal thought disorder in schizophrenia / / 22648509 rs13053817 chr22 29847722 C A 2.00E-06 Carotid atherosclerosis in HIV infection / / 20009918 rs5763254 chr22 29863152 T C 4.96E-04 Tourette syndrome / / 22889924 rs2283859 chr22 29904519 T C 3.99E-05 Vaspin levels THOC5 intron 22907691 rs2283859 chr22 29904519 T C 0.0000399 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks THOC5 intron 22907730 rs2283859 chr22 29904519 T C 0.0001655 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit THOC5 intron 22907730 rs8135828 chr22 29929239 G A 2.00E-07 Lipid traits THOC5 intron 24023261 rs5763305 chr22 29930195 T C 1.57E-05 Lipid traits THOC5 intron 24023261 rs737980 chr22 29937239 C A 3.24E-06 Esophageal cancer (squamous cell) THOC5 intron 22960999 rs16987839 chr22 29983138 G A 7.93E-05 Vaspin levels / / 22907691 rs16987839 chr22 29983138 G A 0.0000793 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs6006220 chr22 30051433 C T 5.15E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NF2 intron 20877124 rs2857641 chr22 30057574 A G 4.28E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) NF2 intron 24192120 rs2527335 chr22 30065967 G T 5.28E-04 Amyotrophic lateral sclerosis (sporadic) NF2 intron 24529757 rs2857648 chr22 30066568 C G 2.30E-06 Urinary metabolites NF2 intron 21572414 rs16987928 chr22 30076720 G A 2.50E-05 Urinary metabolites NF2 intron 21572414 rs2530678 chr22 30081715 G A 7.76E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NF2 intron 20877124 rs2530678 chr22 30081715 G A 1.00E-04 Cognitive impairment induced by topiramate NF2 intron 22091778 rs2267151 chr22 30088039 T G 3.20E-06 Urinary metabolites NF2 intron 21572414 rs2530682 chr22 30103476 G A 6.55E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9614037 chr22 30121285 G A 6.25E-04 Myopia (pathological) CABP7 intron 21095009 rs9614037 chr22 30121285 G A 3.75E-05 Cognitive impairment induced by topiramate CABP7 intron 22091778 rs7287478 chr22 30122657 C T 3.21E-05 Cognitive impairment induced by topiramate CABP7 intron 22091778 rs5997507 chr22 30125596 C T 4.34E-04 Response to cytadine analogues (cytosine arabinoside) CABP7 UTR-3 24483146 rs140101 chr22 30128380 C T 1.99E-05 Cognitive test performance ZMAT5 intron 20125193 rs140129 chr22 30150549 C T 6.75E-05 Cognitive test performance ZMAT5 intron 20125193 rs131271 chr22 30151582 A G 6.57E-05 Cognitive test performance ZMAT5 intron 20125193 rs131272 chr22 30153655 A G 6.57E-05 Cognitive test performance ZMAT5 intron 20125193 rs131273 chr22 30153721 T C 6.57E-05 Cognitive test performance ZMAT5 intron 20125193 rs131285 chr22 30157940 T C 6.57E-05 Cognitive test performance ZMAT5 intron 20125193 rs6006249 chr22 30180911 A G 9.57E-06 Telomere length / / 24478790 rs140147 chr22 30184599 G A 8.99E-04 Type 2 diabetes ASCC2 UTR-3 17463246 rs140149 chr22 30185613 C T 9.23E-05 Cognitive impairment induced by topiramate ASCC2 intron 22091778 rs2349225 chr22 30193548 A T 3.40E-06 Lung cancer ASCC2 intron 21725308 rs12485243 chr22 30199926 C T 9.30E-04 Endometriosis ASCC2 intron 23104006 rs36578 chr22 30211512 A G 7.30E-06 Lung cancer ASCC2 intron 21725308 rs11549795 chr22 30221120 C T 1.45E-05 Renal cell carcinoma ASCC2 missense 23184150 rs1076137 chr22 30223991 A G 3.40E-05 Lung cancer ASCC2 intron 21725308 rs73394838 chr22 30225973 A G 9.00E-06 Telomere length ASCC2 intron 24478790 rs3958025 chr22 30229399 C G,T 3.30E-05 Lung cancer ASCC2 intron 21725308 rs5752968 chr22 30233446 A G 3.30E-05 Lung cancer ASCC2 intron 21725308 rs4820821 chr22 30240575 C A 9.33E-05 Multiple complex diseases / / 17554300 rs4823057 chr22 30241061 A G 1.34E-04 Multiple complex diseases / / 17554300 rs5752972 chr22 30250312 A T 9.89E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4993442 chr22 30253256 G T 1.50E-06 Lung cancer / / 21725308 rs9625870 chr22 30261219 A G 3.78E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3788418 chr22 30280162 A G 3.71E-05 Multiple complex diseases MTMR3 intron 17554300 rs9625874 chr22 30288625 A G 1.00E-06 Lung cancer MTMR3 intron 21725308 rs3887275 chr22 30300112 C G 2.40E-07 Lung cancer MTMR3 intron 21725308 rs8136147 chr22 30304234 C T 2.40E-07 Lung cancer MTMR3 intron 21725308 rs4823063 chr22 30308780 G C 9.20E-07 Lung cancer MTMR3 intron 21725308 rs7291756 chr22 30326102 A G 8.90E-05 Endometriosis MTMR3 intron 23104006 rs36590 chr22 30328070 T C 2.10E-07 Lung cancer MTMR3 intron 21725308 rs36594 chr22 30334382 C T 2.10E-07 Lung cancer MTMR3 intron 21725308 rs36600 chr22 30337586 T C 6.00E-13 Lung cancer MTMR3 intron 21725308 rs36604 chr22 30340138 C A 9.20E-07 Lung cancer MTMR3 intron 21725308 rs36605 chr22 30340356 A T 2.20E-07 Lung cancer MTMR3 intron 21725308 rs36606 chr22 30340410 A T 9.60E-07 Lung cancer MTMR3 intron 21725308 rs737903 chr22 30343846 T A 3.63E-05 Pulmonary function MTMR3 intron 19300500 rs200426271 chr22 30344457 T TG 2.20E-07 Lung cancer MTMR3 intron 21725308 rs36609 chr22 30344457 T G 2.20E-07 Lung cancer MTMR3 intron 21725308 rs737904 chr22 30348652 A T 1.10E-06 Lung cancer MTMR3 intron 21725308 rs5763634 chr22 30350532 T C 1.10E-06 Lung cancer MTMR3 intron 21725308 rs57003371 chr22 30353252 A AT,ATT 1.10E-06 Lung cancer MTMR3 intron 21725308 rs5763640 chr22 30353252 A T 1.10E-06 Lung cancer MTMR3 intron 21725308 rs5763644 chr22 30355676 G A 1.10E-06 Lung cancer MTMR3 intron 21725308 rs2051764 chr22 30361881 G A 2.50E-07 Lung cancer MTMR3 intron 21725308 rs4239932 chr22 30368384 T G 8.30E-07 Lung cancer MTMR3 intron 21725308 rs5763662 chr22 30378703 C T 1.00E-08 LDL cholesterol MTMR3 intron 24097068 rs2017677 chr22 30383262 G C 2.10E-07 Lung cancer MTMR3 intron 21725308 rs17713999 chr22 30384053 A G 4.41E-05 Pulmonary function MTMR3 intron 19300500 rs737909 chr22 30388758 T G 2.10E-07 Lung cancer MTMR3 intron 21725308 rs737909 chr22 30388758 T G 2.31E-05 Esophageal cancer (squamous cell) MTMR3 intron 22960999 rs737909 chr22 30388758 T G 3.59E-04 Crohn's disease MTMR3 intron 23266558 rs5763681 chr22 30389846 C T 4.64E-05 Multiple complex diseases MTMR3 intron 17554300 rs3788423 chr22 30390990 T C 1.50E-07 Lung cancer MTMR3 intron 21725308 rs3788423 chr22 30390990 T C 3.59E-04 Crohn's disease MTMR3 intron 23266558 rs2412963 chr22 30391281 G A 1.50E-07 Lung cancer MTMR3 intron 21725308 rs5763688 chr22 30393503 C G 9.76E-04 Type 2 diabetes MTMR3 intron 17463246 rs17646919 chr22 30400861 A G 2.56E-05 Pulmonary function MTMR3 intron 19300500 rs17646919 chr22 30400861 A G 6.33E-04 Taste perception MTMR3 intron 22132133 rs41156 chr22 30404653 T C 1.00E-04 Cognitive impairment induced by topiramate MTMR3 intron 22091778 rs41172 chr22 30422865 T C 1.50E-09 Lung cancer MTMR3 UTR-3 21725308 rs12537 chr22 30423460 C T 1.00E-11 IgA nephropathy MTMR3 UTR-3 22197929 rs41173 chr22 30424863 C G 7.78E-04 Taste perception MTMR3 UTR-3 22132133 rs28257 chr22 30429115 A G 6.50E-08 Lung cancer / / 21725308 rs41175 chr22 30432137 T C 1.40E-09 Lung cancer / / 21725308 rs41176 chr22 30432403 C A 2.26E-05 Type 1 diabetes / / 18978792 rs1476514 chr22 30433822 G A 3.52E-04 Multiple complex diseases / / 17554300 rs41178 chr22 30440533 G A 1.40E-09 Lung cancer / / 21725308 rs41179 chr22 30441677 A G 1.40E-09 Lung cancer / / 21725308 rs193473 chr22 30448399 A G 3.70E-08 Lung cancer / / 21725308 rs1989870 chr22 30472254 G A 3.01E-05 Type 1 diabetes / / 18978792 rs8141404 chr22 30474216 C T 2.60E-05 Urinary metabolites / / 21572414 rs8141404 chr22 30474216 C T 4.70E-08 Lung cancer / / 21725308 rs757026 chr22 30474310 C A 4.15E-06 Multiple complex diseases / / 17554300 rs2412970 chr22 30486826 A G 3.76E-04 Type 1 diabetes HORMAD2 intron 21980299 rs2412970 chr22 30486826 A G 3.00E-14 Inflammatory bowel disease HORMAD2 intron 23128233 rs5763766 chr22 30491512 G A 5.59E-05 Multiple complex diseases HORMAD2 intron 17554300 rs7510705 chr22 30493918 A G 3.00E-09 Lung cancer HORMAD2 intron 21725308 rs2412971 chr22 30494371 G A 2.00E-09 Nephropathy HORMAD2 intron 21399633 rs9625919 chr22 30500958 G T 4.70E-08 Lung cancer HORMAD2 intron 21725308 rs6006356 chr22 30503171 G A 4.70E-05 Lung cancer HORMAD2 intron 21725308 rs718772 chr22 30504207 A G 2.70E-05 Urinary metabolites HORMAD2 intron 21572414 rs718772 chr22 30504207 A G 9.80E-08 Lung cancer HORMAD2 intron 21725308 rs5763779 chr22 30504652 A G 1.86E-05 Type 1 diabetes HORMAD2 intron 18978792 rs4337577 chr22 30512128 G C 4.90E-09 Lung cancer HORMAD2 intron 21725308 rs4239933 chr22 30512414 C G 7.50E-08 Lung cancer HORMAD2 intron 21725308 rs11090598 chr22 30521770 A G 1.00E-07 Lung cancer HORMAD2 intron 21725308 rs8135823 chr22 30522459 T G 2.70E-05 Urinary metabolites HORMAD2 intron 21572414 rs2412973 chr22 30529631 C A 2.00E-09 Inflammatory bowel disease (early onset) HORMAD2 intron 19915574 rs2412973 chr22 30529631 C A 1.90E-06 Nephropathy HORMAD2 intron 21399633 rs2412973 chr22 30529631 C A 2.00E-09 Multiple sclerosis HORMAD2 intron 22190364 rs4820830 chr22 30531091 C T 2.34E-05 Type 1 diabetes HORMAD2 intron 18978792 rs5997579 chr22 30537526 T C 7.20E-04 Multiple complex diseases HORMAD2 intron 17554300 rs5997579 chr22 30537526 T C 9.20E-05 Lung cancer HORMAD2 intron 21725308 rs9620953 chr22 30546245 C T 1.30E-07 Lung cancer HORMAD2 intron 21725308 rs9625933 chr22 30555216 G A 2.30E-08 Lung cancer HORMAD2 intron 21725308 rs2214047 chr22 30556101 G T 1.75E-05 Multiple complex diseases HORMAD2 intron 17554300 rs5753028 chr22 30556845 T C 2.86E-07 Multiple complex diseases HORMAD2 intron 17554300 rs8141765 chr22 30562239 C A 1.90E-08 Lung cancer HORMAD2 intron 21725308 rs8138286 chr22 30562987 A C 1.90E-08 Lung cancer HORMAD2 intron 21725308 rs2412976 chr22 30567907 C G 2.09E-05 Type 1 diabetes HORMAD2 intron 18978792 rs1978083 chr22 30570443 C G 2.00E-09 Lung cancer HORMAD2 intron 21725308 rs10483158 chr22 30575163 A G 2.62E-05 Cognitive performance / / 19734545 rs12167333 chr22 30575812 C T 2.70E-05 Urinary metabolites / / 21572414 rs12167333 chr22 30575812 C T 3.00E-09 Lung cancer / / 21725308 rs2412979 chr22 30580161 T C 2.30E-05 Multiple complex diseases / / 17554300 rs5753037 chr22 30581722 C T 3.00E-16 Type 1 diabetes / / 19430480 rs5753037 chr22 30581722 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs5753037 chr22 30581722 C T 2.60E-16 Multiple sclerosis / / 22190364 rs2412980 chr22 30592069 T C 4.00E-06 Dialysis-related mortality / / 21546767 rs713875 chr22 30592487 C G 7.00E-12 Crohn's disease / / 21102463 rs713875 chr22 30592487 C G 9.70E-06 Lung cancer / / 21725308 rs9614157 chr22 30597810 A G 5.90E-11 Lung cancer / / 21725308 rs9614158 chr22 30597880 A G 3.20E-10 Lung cancer / / 21725308 rs17728461 chr22 30598552 C G 5.90E-11 Lung cancer / / 21725308 rs17728461 chr22 30598552 C G 2.19E-05 Esophageal cancer (squamous cell) / / 22960999 rs16988387 chr22 30599451 C T 5.76E-05 Multiple complex diseases / / 17554300 rs2023683 chr22 30599596 G A 3.20E-10 Lung cancer / / 21725308 rs9614159 chr22 30601243 G A 2.00E-10 Lung cancer / / 21725308 rs9614162 chr22 30604102 G A 9.60E-11 Lung cancer / / 21725308 rs5997591 chr22 30604667 A C 4.00E-04 Obesity (extreme) / / 21935397 rs12484740 chr22 30606927 A G 4.85E-05 Multiple complex diseases / / 17554300 rs16988402 chr22 30613841 C T 0.0000485 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs67087719 chr22 30615511 C T 0.0000485 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs11089441 chr22 30654464 G T 8.79E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs5763918 chr22 30661184 T C 8.54E-04 Heart Failure OSM intron pha002885 rs9608859 chr22 30667277 T C 1.90E-04 Coronary heart disease / / 21966275 rs6006426 chr22 30669883 G A 8.47E-04 Type 2 diabetes / / 17463246 rs6006427 chr22 30669993 C T 4.33E-04 Smoking initiation / / 24665060 rs11704358 chr22 30672352 G T 9.39E-04 Myocardial Infarction / / pha002883 rs724055 chr22 30675923 A C 1.23E-04 Type 2 diabetes / / 17463246 rs1043099 chr22 30681257 C A,G 7.00E-09 Rheumatoid arthritis GATSL3 UTR-3 24449572 rs929454 chr22 30692353 A T 6.29E-04 Type 2 diabetes TBC1D10A intron 17463246 rs929454 chr22 30692353 A T 8.16E-06 Lymphocyte counts TBC1D10A intron 22286170 rs4339043 chr22 30735908 A G 6.07E-04 Type 2 diabetes SF3A1 intron 17463246 rs4820834 chr22 30751627 G A 9.00E-06 Coronary artery calcification SF3A1 intron 23870195 rs5753118 chr22 30785421 G A 5.30E-07 Urinary metabolites / / 21572414 rs715504 chr22 30792115 C T 5.24E-05 Waist Circumference / / pha003024 rs4820848 chr22 30843495 G A 2.45E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs5753152 chr22 30846623 A G 2.18E-04 Substance dependence / / 21818250 rs5753152 chr22 30846623 A G 5.06E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11089450 chr22 30846644 G T 2.07E-04 Multiple complex diseases / / 17554300 rs4820851 chr22 30854663 G A 5.06E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2240345 chr22 30857373 A C 5.57E-04 Response to taxane treatment (placlitaxel) SEC14L3 missense 23006423 rs5749104 chr22 30857448 A G 8.62E-04 Response to taxane treatment (placlitaxel) SEC14L3 cds-synon 23006423 rs2412986 chr22 30861640 C T 5.06E-04 Response to taxane treatment (placlitaxel) SEC14L3 intron 23006423 rs757663 chr22 30862763 C T 5.06E-04 Response to taxane treatment (placlitaxel) SEC14L3 intron 23006423 rs5753161 chr22 30862839 A G 5.06E-04 Response to taxane treatment (placlitaxel) SEC14L3 intron 23006423 rs2066926 chr22 30868102 T C 1.67E-04 Multiple complex diseases SEC14L3 nearGene-5 17554300 rs8141318 chr22 30875517 C T 1.04E-05 Blood Pressure / / pha003048 rs9608938 chr22 30881651 A G 4.66E-06 Blood Pressure / / pha003048 rs8141286 chr22 30902418 T C 6.84E-05 Blood Pressure / / pha003048 rs6518702 chr22 30948752 C T 5.30E-04 Adiponectin levels / / 24105470 rs5753220 chr22 30986350 T C 5.75E-05 Bipolar disorder PES1 intron 18317468 rs5753220 chr22 30986350 T C 7.85E-10 Esophageal cancer (squamous cell) PES1 intron 20729853 rs5753220 chr22 30986350 T C 5.47E-04 Response to taxane treatment (placlitaxel) PES1 intron 23006423 rs5749131 chr22 31001822 A G 7.83E-05 Smoking initiation PES1 intron 24665060 rs9621047 chr22 31004127 G A 2.46E-04 Smoking initiation TCN2 intron 24665060 rs740233 chr22 31007919 A G 1.81E-04 Smoking initiation TCN2 intron 24665060 rs11913239 chr22 31009839 C T 6.49E-09 Wilms tumor TCN2 intron 22544364 rs2267162 chr22 31010997 C T 1.12E-06 Wilms tumor TCN2 intron 22544364 rs7290898 chr22 31011280 A C,G,T 2.97E-09 Wilms tumor TCN2 intron 22544364 rs2267163 chr22 31011557 T C 3.05E-04 Smoking initiation TCN2 intron 24665060 rs4820021 chr22 31011882 A T 8.97E-05 Major depressive disorder (broad) TCN2 intron 20038947 rs5749135 chr22 31011906 C T 3.22E-04 Smoking initiation TCN2 intron 24665060 rs16988855 chr22 31011923 T C 5.40E-09 Wilms tumor TCN2 intron 22544364 rs2283873 chr22 31013296 G A 5.00E-12 Wilms tumor TCN2 intron 22544364 rs2009857 chr22 31014377 C T 5.40E-09 Wilms tumor TCN2 intron 22544364 rs7288627 chr22 31015562 G A 5.40E-09 Wilms tumor TCN2 intron 22544364 rs7288385 chr22 31015573 C A 5.40E-09 Wilms tumor TCN2 intron 22544364 rs4820888 chr22 31017322 A G 2.05E-04 Smoking initiation TCN2 intron 24665060 rs8141515 chr22 31018072 T C 1.17E-08 Wilms tumor TCN2 intron 22544364 rs2267166 chr22 31018078 G A 1.17E-08 Wilms tumor TCN2 intron 22544364 rs2301955 chr22 31018646 C T 3.10E-04 Iris characteristics TCN2 intron 21835309 rs2301955 chr22 31018646 C T 3.22E-04 Smoking initiation TCN2 intron 24665060 rs1131603 chr22 31018975 T C 7.60E-10 Health and aging,CVD and cancer age of onset TCN2 missense 22174011 rs2072195 chr22 31022733 A T 1.13E-06 Wilms tumor TCN2 UTR-3 22544364 rs5749144 chr22 31024697 T A 4.07E-04 Smoking initiation / / 24665060 rs7289553 chr22 31024856 A G 1.15E-04 Smoking initiation / / 24665060 rs731991 chr22 31025189 A G 5.89E-05 Smoking initiation / / 24665060 rs5997711 chr22 31025863 T C 5.93E-04 Smoking initiation / / 24665060 rs4820891 chr22 31032309 C T 3.84E-04 Smoking initiation SLC35E4 UTR-5 24665060 rs8139950 chr22 31037370 T C 5.79E-04 Smoking initiation SLC35E4 intron 24665060 rs7288635 chr22 31091633 A C 7.54E-05 Bone mineral density OSBP2 intron 19181680 rs16988993 chr22 31103788 C T 0.00000114 HDL cholesterol OSBP2 intron 23063622 rs5753281 chr22 31105269 A C 4.36E-05 Heart Rate OSBP2 intron pha003054 rs7285562 chr22 31113433 G A 2.00E-04 Atrial fibrillation OSBP2 intron 21846873 rs136380 chr22 31116753 C T 2.80E-04 Type 2 diabetes OSBP2 intron 17463246 rs4820897 chr22 31117495 T C 6.91E-06 Heart Rate OSBP2 intron pha003054 rs5749157 chr22 31118395 C A 3.00E-05 Heart Rate OSBP2 intron pha003054 rs136354 chr22 31134390 A G 1.96E-04 Parkinson's disease OSBP2 intron 21248740 rs136351 chr22 31141239 G A 1.71E-04 Parkinson's disease OSBP2 intron 21248740 rs9609078 chr22 31153276 G A 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) OSBP2 intron 23648065 rs5749162 chr22 31156296 G A 9.50E-05 Atrial fibrillation OSBP2 intron 21846873 rs136319 chr22 31169761 T G 6.27E-05 Multiple sclerosis OSBP2 intron 20598377 rs5997762 chr22 31171274 A G 3.96E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) OSBP2 intron 24023788 rs16989109 chr22 31189055 T A 8.76E-06 Height OSBP2 intron 22021425 rs136287 chr22 31192023 C T 5.11E-05 Amyotrophic lateral sclerosis OSBP2 intron 20801717 rs742205 chr22 31223456 C T 7.08E-04 Acute lung injury OSBP2 intron 22295056 rs5753336 chr22 31227373 A G 8.49E-04 Acute lung injury OSBP2 intron 22295056 rs5753337 chr22 31227728 C T 8.87E-04 Acute lung injury OSBP2 intron 22295056 rs5997787 chr22 31254954 T C 3.60E-05 Atrial fibrillation OSBP2 intron 21846873 rs5997788 chr22 31255029 G T 3.30E-06 Atrial fibrillation OSBP2 intron 21846873 rs35396069 chr22 31266452 C A 0.00000102 Cholesterol,total OSBP2 missense 23063622 rs35396069 chr22 31266452 C A 1.41E-26 HDL cholesterol OSBP2 missense 23063622 rs11089481 chr22 31288769 G A 7.85E-04 Amyotrophic Lateral Sclerosis OSBP2 intron 17362836 rs5997802 chr22 31290637 A G 6.94E-04 Amyotrophic Lateral Sclerosis OSBP2 intron 17362836 rs2074578 chr22 31329056 G C 1.64E-04 Multiple complex diseases MORC2 intron 17554300 rs1003480 chr22 31346752 A G 1.35E-04 Multiple complex diseases MORC2 intron 17554300 rs4820921 chr22 31378447 G A 6.94E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs111383589 chr22 31438361 C T 2.00E-06 Bulimia nervosa / / 23568457 rs5994366 chr22 31451457 C G 4.16E-05 Glycosylated haemoglobin levels / / 17255346 rs7291565 chr22 31453321 C T 1.96E-04 Glycosylated haemoglobin levels / / 17255346 rs7291565 chr22 31453321 C T 5.20E-04 Multiple complex diseases / / 17554300 rs7285683 chr22 31459194 A G 9.14E-05 ldl cholesterol / / pha003076 rs5753454 chr22 31475307 G A 6.91E-06 Pancreatic cancer SMTN nearGene-5 pha002889 rs3747152 chr22 31520338 G A 7.53E-05 Formal thought disorder in schizophrenia INPP5J intron 22648509 rs2232183 chr22 31532960 C T 2.99E-05 Post-operative nausea and vomiting PLA2G3 missense 21694509 rs5753472 chr22 31533225 G A 1.30E-29 Progranulin levels PLA2G3 intron 21087763 rs5753472 chr22 31533225 G A 1.30E-29 Myocardial infarction PLA2G3 intron 21211798 rs2072193 chr22 31533796 G C 3.72E-04 Type 2 diabetes PLA2G3 missense 17463246 rs878718 chr22 31552702 A G 8.01E-04 Body mass index / / 21701565 rs1034589 chr22 31579233 C T 2.49E-08 Diabetic nephropathy RNF185 intron 21150874 rs1034589 chr22 31579233 C T 9.86E-04 Type 2 diabetes RNF185 intron 22238593 rs2106294 chr22 31645759 C T 4.00E-06 Type 2 diabetes nephropathy LIMK2 intron 21150874 rs2106294 chr22 31645759 C T 7.49E-04 Type 2 diabetes LIMK2 intron 22238593 rs4820043 chr22 31647094 A G 3.04E-08 Diabetic nephropathy LIMK2 intron 21150874 rs4820043 chr22 31647094 A G 9.86E-04 Type 2 diabetes LIMK2 intron 22238593 rs4820043 chr22 31647094 A G 1.82E-04 Lymphocyte counts LIMK2 intron 22286170 rs2413045 chr22 31665862 A G 3.67E-05 Paclitaxel-induced neuropathy LIMK2 intron 23776197 rs4141404 chr22 31675185 A C 3.00E-06 Paclitaxel-induced neuropathy LIMK2 UTR-3 23776197 rs11704523 chr22 31681150 G A 3.10E-05 Asthma PIK3IP1 intron 23181788 rs2073861 chr22 31685256 C G 6.01E-08 Narcolepsy PIK3IP1 intron 19629137 rs131213 chr22 31753849 G A 5.39E-05 Insulin resistance / / 21901158 rs9606843 chr22 31853371 A C 3.69E-04 Smoking initiation EIF4ENIF1 intron 24665060 rs5753638 chr22 31869892 T C 9.32E-04 Obesity (extreme) EIF4ENIF1 intron 21935397 rs7289941 chr22 31884405 T C 5.35E-04 Smoking initiation EIF4ENIF1 intron 24665060 rs5749286 chr22 31900359 C A 6.51E-11 Diabetic nephropathy SFI1 intron 21150874 rs1018490 chr22 31996625 A C 3.49E-04 Smoking initiation SFI1 intron 24665060 rs6518752 chr22 31999127 G A 3.50E-04 Smoking initiation SFI1 intron 24665060 rs11704616 chr22 31999476 C T 2.12E-05 Bipolar disorder SFI1 intron 17486107 rs8140312 chr22 32005594 C T 2.22E-04 Smoking initiation SFI1 intron 24665060 rs11703808 chr22 32024980 A G 7.00E-08 Intelligence PISD intron 22449649 rs9306268 chr22 32034475 C T 6.54E-04 Type 2 diabetes / / 17463246 rs5998069 chr22 32046022 G A 2.04E-05 Schizophrenia / / 19571809 rs131243 chr22 32124778 C T 9.15E-06 Type 2 diabetes PRR14L intron 21573907 rs10483161 chr22 32210763 T C 1.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) DEPDC5 intron 17982456 rs5994434 chr22 32229649 G A 5.00E-07 Intelligence DEPDC5 intron 22449649 rs9621346 chr22 32230185 G A 6.50E-05 Memory performance DEPDC5 intron 22105620 rs7287054 chr22 32240721 A G 3.80E-06 Chronic Hepatitis C infection DEPDC5 intron 21725309 rs470072 chr22 32263131 C T 4.43E-05 Amyotrophic lateral sclerosis DEPDC5 intron 20801717 rs470072 chr22 32263131 C T 8.67E-05 Chronic Hepatitis C infection DEPDC5 intron 21725309 rs5998152 chr22 32263162 T C 1.19E-07 Chronic Hepatitis C infection DEPDC5 intron 21725309 rs1012068 chr22 32265903 T G 1.00E-13 Chronic Hepatitis C infection DEPDC5 intron 21725309 rs1012068 chr22 32265903 T G 1.27E-13 Hepatocellular carcinoma (hepatitis B virus related) DEPDC5 intron 23242368 rs737084 chr22 32268400 A G 5.93E-06 Chronic Hepatitis C infection DEPDC5 intron 21725309 rs5994443 chr22 32275353 T C 5.26E-04 Chronic Hepatitis C infection DEPDC5 intron 21725309 rs5998161 chr22 32285303 T G 9.24E-05 Cognitive performance DEPDC5 intron 19734545 rs5994449 chr22 32304179 T A 1.31E-05 Chronic Hepatitis C infection / / 21725309 rs16989636 chr22 32308680 T C 1.39E-05 Chronic Hepatitis C infection / / 21725309 rs4820994 chr22 32311619 A G 2.99E-06 Chronic Hepatitis C infection / / 21725309 rs5753816 chr22 32312842 T C 4.90E-06 Chronic Hepatitis C infection / / 21725309 rs5753818 chr22 32313933 C T 9.43E-06 Chronic Hepatitis C infection / / 21725309 rs11703779 chr22 32322384 T C 4.16E-06 Chronic Hepatitis C infection / / 21725309 rs5994451 chr22 32323511 T G 1.15E-05 Chronic Hepatitis C infection / / 21725309 rs4820996 chr22 32324030 A G 4.16E-06 Chronic Hepatitis C infection / / 21725309 rs2015580 chr22 32326021 C T 9.19E-05 Chronic Hepatitis C infection / / 21725309 rs4820057 chr22 32327794 A G 6.81E-04 Alzheimer's disease / / 24755620 rs3788437 chr22 32331594 A G 5.85E-04 Alzheimer's disease C22orf24 intron 24755620 rs9609389 chr22 32335416 G A 9.27E-04 Alzheimer's disease C22orf24 intron 24755620 rs5998196 chr22 32355455 T C 3.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4821004 chr22 32366359 C T 2.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17744994 chr22 32413527 C T 5.37E-06 White blood cell count / / 21738479 rs738993 chr22 32437340 G A 9.50E-05 Information processing speed SLC5A1 nearGene-5 21130836 rs17745316 chr22 32446805 G A 4.38E-04 Alzheimer's disease SLC5A1 intron 24755620 rs5998267 chr22 32554985 A G 2.70E-05 Urinary metabolites C22orf42 missense 21572414 rs136457 chr22 32584659 A G 1.90E-06 Urinary metabolites / / 21572414 rs136458 chr22 32584710 G C 1.90E-06 Urinary metabolites / / 21572414 rs136460 chr22 32584826 T C 2.00E-06 Urinary metabolites / / 21572414 rs136477 chr22 32588352 A C 9.80E-07 Urinary metabolites RFPL2 intron 21572414 rs136485 chr22 32592120 T A 8.20E-06 Urinary metabolites RFPL2 intron 21572414 rs1467388 chr22 32607057 A G 3.34E-04 Type 2 diabetes / / 17463246 rs1467388 chr22 32607057 A G 6.87E-06 Stroke (ischemic) / / 22941190 rs5998319 chr22 32619091 T G 1.69E-06 Stroke (ischemic) SLC5A4 intron 22941190 rs5998320 chr22 32619215 T C 1.50E-06 Stroke (ischemic) SLC5A4 intron 22941190 rs2294205 chr22 32621211 G C 3.70E-06 Urinary metabolites SLC5A4 intron 21572414 rs2294208 chr22 32621619 C T 2.10E-06 Urinary metabolites SLC5A4 intron 21572414 rs5998322 chr22 32625210 C T 3.91E-07 Stroke (ischemic) SLC5A4 cds-synon 22941190 rs5998331 chr22 32634877 G A 4.55E-07 Stroke (ischemic) SLC5A4 intron 22941190 rs5998364 chr22 32664612 G A 9.52E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4821043 chr22 32667097 C T 2.90E-04 Smoking initiation / / 24665060 rs5753959 chr22 32710985 A G 8.24E-06 Asthma / / 21790008 rs5753966 chr22 32715559 A C 8.91E-04 Type 2 diabetes / / 17463246 rs2072811 chr22 32722656 C T 8.60E-04 Schizophrenia / / 19197363 rs5998432 chr22 32745916 C T 9.00E-07 T-tau levels / / 20932310 rs9621435 chr22 32774944 T C 3.23E-05 Body Composition LOC339666 intron pha003012 rs9621435 chr22 32774944 T C 2.79E-05 Body Mass Index LOC339666 intron pha003021 rs12530 chr22 32783904 T C 3.00E-06 IgG glycosylation C22orf28 UTR-3 23382691 rs9680823 chr22 32790981 C G 9.99E-05 Multiple complex diseases C22orf28 intron 17554300 rs9609538 chr22 32809832 T C 7.00E-04 Epithelial ovarian cancer / / 24190013 rs2076054 chr22 32832874 C T 9.11E-04 Myopia (pathological) BPIFC intron 21095009 rs2076054 chr22 32832874 C T 3.22E-04 Tourette syndrome BPIFC intron 22889924 rs2076054 chr22 32832874 C T 8.00E-06 Migraine with aura BPIFC intron 23793025 rs738261 chr22 32833169 A C 8.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) BPIFC intron 20877124 rs5754097 chr22 32851712 C T 7.99E-04 Alzheimer's disease BPIFC intron 24755620 rs9609560 chr22 32856999 G A 3.17E-04 Body mass index / / 17255346 rs5998500 chr22 32859702 C T 2.07E-08 Red blood cell traits / / 23222517 rs8135723 chr22 32860250 T C 1.73E-07 Red blood cell traits / / 23222517 rs9609562 chr22 32860792 C T 4.28E-07 Red blood cell traits / / 23222517 rs9606957 chr22 32861083 T G 7.43E-09 Red blood cell traits / / 23222517 rs738263 chr22 32862382 G A 0.000000001 Mean corpuscular volume / / 22560525 rs738263 chr22 32862382 G A 2.64E-10 Red blood cell traits / / 23222517 rs9606958 chr22 32864879 G A 5.39E-08 Red blood cell traits / / 23222517 rs9609564 chr22 32865533 C G 1.02E-07 Red blood cell traits / / 23222517 rs5998504 chr22 32865604 A G 7.69E-10 Red blood cell traits / / 23222517 rs5998505 chr22 32865675 C T 3.19E-08 Red blood cell traits / / 23222517 rs5994574 chr22 32866934 T C 0.00000002 Mean corpuscular hemoglobin / / 22560525 rs5994574 chr22 32866934 T C 3.00E-10 Mean corpuscular volume / / 22560525 rs5994574 chr22 32866934 T C 2.70E-11 Red blood cell traits / / 23222517 rs5998508 chr22 32867160 G C 1.29E-11 Red blood cell traits / / 23222517 rs9609565 chr22 32867528 G A 4.00E-10 Hematological parameters / / 19820697 rs9609565 chr22 32867528 G A 1.58E-09 Red blood cell traits / / 23222517 rs8140067 chr22 32871442 C A 3.42E-11 Red blood cell traits FBXO7 intron 23222517 rs5749445 chr22 32872258 A C 1.91E-10 Red blood cell traits FBXO7 intron 23222517 rs5754109 chr22 32872593 G A 6.04E-13 Red blood cell traits FBXO7 intron 23222517 rs2142718 chr22 32873127 G C 5.61E-08 Red blood cell traits FBXO7 intron 23222517 rs7291067 chr22 32873496 C A 4.98E-08 Red blood cell traits FBXO7 intron 23222517 rs738264 chr22 32874258 G T 1.99E-10 Red blood cell traits FBXO7 intron 23222517 rs738265 chr22 32874449 G A 2.97E-10 Red blood cell traits FBXO7 intron 23222517 rs2247590 chr22 32874551 A G 4.17E-09 Red blood cell traits FBXO7 intron 23222517 rs11107 chr22 32875190 G A 0.000000003 Mean corpuscular volume FBXO7 missense 22560525 rs715542 chr22 32875871 G A 3.54E-10 Red blood cell traits FBXO7 intron 23222517 rs1033407 chr22 32876647 C A 9.18E-10 Red blood cell traits FBXO7 intron 23222517 rs715567 chr22 32877009 T A 3.58E-13 Red blood cell traits FBXO7 intron 23222517 rs5754110 chr22 32878244 T C 9.02E-05 Smoking cessation FBXO7 intron 18519826 rs5754110 chr22 32878244 T C 6.05E-12 Red blood cell traits FBXO7 intron 23222517 rs9609567 chr22 32878510 C T 3.75E-09 Red blood cell traits FBXO7 intron 23222517 rs6518785 chr22 32879317 T A 5.28E-04 Type 2 diabetes FBXO7 intron 17463246 rs4820079 chr22 32879617 G T 7.55E-08 Red blood cell traits FBXO7 intron 23222517 rs5749446 chr22 32880585 T C 3.00E-13 Red blood cell traits FBXO7 intron 23222517 rs17771806 chr22 32881581 C T 1.50E-05 Urinary metabolites FBXO7 intron 21572414 rs9609570 chr22 32881600 C T 6.43E-09 Red blood cell traits FBXO7 intron 23222517 rs5754111 chr22 32881746 G A 5.84E-10 Red blood cell traits FBXO7 intron 23222517 rs5749447 chr22 32882121 G A 2.06E-10 Red blood cell traits FBXO7 intron 23222517 rs3788448 chr22 32882808 A G 4.27E-11 Red blood cell traits FBXO7 intron 23222517 rs3788449 chr22 32883103 G A 3.23E-10 Red blood cell traits FBXO7 intron 23222517 rs3788450 chr22 32883128 G A 1.33E-12 Red blood cell traits FBXO7 intron 23222517 rs3827335 chr22 32883282 A G 4.18E-09 Red blood cell traits FBXO7 intron 23222517 rs4821066 chr22 32883344 A G 3.71E-09 Red blood cell traits FBXO7 intron 23222517 rs5998513 chr22 32884036 T A 3.07E-10 Red blood cell traits FBXO7 intron 23222517 rs7354804 chr22 32884381 C T 1.60E-10 Red blood cell traits FBXO7 intron 23222517 rs2267178 chr22 32885549 C T 2.30E-10 Red blood cell traits FBXO7 intron 23222517 rs2267179 chr22 32885780 C T 6.21E-05 Smoking cessation FBXO7 intron 18519826 rs2267179 chr22 32885780 C T 3.65E-10 Red blood cell traits FBXO7 intron 23222517 rs5749450 chr22 32886477 G T 0.00000003 Mean corpuscular volume FBXO7 intron 22560525 rs5749450 chr22 32886477 G T 1.58E-07 Red blood cell traits FBXO7 intron 23222517 rs738981 chr22 32886785 C T 1.87E-05 Smoking cessation FBXO7 intron 18519826 rs738981 chr22 32886785 C T 2.28E-10 Red blood cell traits FBXO7 intron 23222517 rs738982 chr22 32886998 T C 4.79E-12 Red blood cell traits FBXO7 intron 23222517 rs9726 chr22 32887150 C T 4.84E-10 Red blood cell traits FBXO7 cds-synon 23222517 rs6518786 chr22 32887498 T C 6.43E-12 Red blood cell traits FBXO7 intron 23222517 rs17772071 chr22 32887661 A G 4.79E-10 Red blood cell traits FBXO7 intron 23222517 rs17698823 chr22 32887732 C T 9.28E-09 Red blood cell traits FBXO7 intron 23222517 rs1029298 chr22 32887782 A G 4.12E-10 Red blood cell traits FBXO7 intron 23222517 rs1029299 chr22 32887949 T C 3.97E-12 Red blood cell traits FBXO7 intron 23222517 rs1029302 chr22 32888622 A G 7.49E-09 Red blood cell traits FBXO7 intron 23222517 rs7291957 chr22 32889815 A T 1.19E-08 Red blood cell traits FBXO7 intron 23222517 rs5749452 chr22 32891690 T C 2.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FBXO7 intron 20877124 rs5749452 chr22 32891690 T C 0.0007686 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FBXO7 intron 23233654 rs5749452 chr22 32891690 T C 7.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) FBXO7 intron 23233662 rs9609571 chr22 32891896 G C 6.88E-12 Red blood cell traits FBXO7 intron 23222517 rs5754115 chr22 32893905 C T 4.24E-09 Red blood cell traits FBXO7 intron 23222517 rs5754116 chr22 32893920 C T 3.67E-10 Red blood cell traits FBXO7 intron 23222517 rs2269501 chr22 32895731 T C 1.68E-12 Red blood cell traits / / 23222517 rs2269502 chr22 32895892 A G 2.79E-10 Red blood cell traits / / 23222517 rs2269503 chr22 32896113 A T 4.64E-10 Red blood cell traits / / 23222517 rs4820080 chr22 32897530 G A 3.83E-12 Red blood cell traits / / 23222517 rs2285089 chr22 32898291 G A 2.35E-12 Red blood cell traits / / 23222517 rs9621472 chr22 32904634 T C 2.50E-05 Urinary metabolites / / 21572414 rs3213515 chr22 32904927 T C 7.59E-04 Multiple complex diseases / / 17554300 rs3213515 chr22 32904927 T C 1.84E-07 Red blood cell traits / / 23222517 rs8142308 chr22 32905470 G A 1.63E-10 Red blood cell traits / / 23222517 rs1894451 chr22 32907769 A C 3.69E-07 Red blood cell traits / / 23222517 rs762907 chr22 32930263 C T 1.46E-04 Type 2 diabetes SYN3 intron 17463246 rs135478 chr22 32936813 C T 2.88E-04 Response to cholinesterase inhibitors in Alzheimer's disease SYN3 intron 23374588 rs2858335 chr22 32938416 A G 2.66E-04 Multiple complex diseases SYN3 intron 17554300 rs2710375 chr22 32943741 A T 2.40E-05 Urinary metabolites SYN3 intron 21572414 rs11089573 chr22 32944778 C A 2.28E-04 Lung function (forced expiratory volume in 1 second) SYN3 intron 17255346 rs9606982 chr22 32951827 G A 9.44E-04 White matter integrity SYN3 intron 22425255 rs1009401 chr22 32988254 T C 8.13E-05 Cognitive impairment induced by topiramate SYN3 intron 22091778 rs16990824 chr22 32999059 T C 9.84E-04 Response to cytidine analogues (gemcitabine) SYN3 intron 24483146 rs16990831 chr22 33001276 G A 5.18E-05 Major depressive disorder (broad) SYN3 intron 20038947 rs5749471 chr22 33006503 A C 1.50E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) SYN3 intron 23648065 rs9621508 chr22 33013062 A C 2.47E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) SYN3 intron 23648065 rs13340089 chr22 33032041 C T 8.04E-04 White matter integrity SYN3 intron 22425255 rs4821083 chr22 33056341 T C 3.00E-10 Height SYN3 intron 20881960 rs115106883 chr22 33059665 G C 5.00E-07 Height SYN3 intron 21998595 rs200483076 chr22 33084511 A C 1.00E-11 Age-related macular degeneration SYN3 intron 20385819 rs200483076 chr22 33084511 A C 4.00E-09 Age-related macular degeneration SYN3 intron 20385826 rs200483076 chr22 33084511 A C 2.00E-15 Age-related macular degeneration SYN3 intron 21665990 rs737825 chr22 33104377 G A 1.78E-05 Multiple complex diseases SYN3 intron 17554300 rs756481 chr22 33105227 A G 2.06E-04 Lung function (forced vital capacity) SYN3 intron 24023788 rs756481 chr22 33105227 A G 4.38E-05 Serum albumin level SYN3 intron pha003084 rs2899193 chr22 33109382 G C 6.91E-06 C-reactive protein SYN3 intron 22492993 rs9621545 chr22 33121988 C G 4.44E-05 Multiple sclerosis SYN3 intron 19525953 rs3788488 chr22 33127481 T C 1.81E-04 Lung function (forced expiratory volume in 1 second) SYN3 intron 24023788 rs3788488 chr22 33127481 T C 2.89E-04 Lung function (forced vital capacity) SYN3 intron 24023788 rs4339044 chr22 33132890 C T 2.51E-04 Lung function (forced expiratory volume in 1 second) SYN3 intron 24023788 rs732446 chr22 33135768 T G 9.08E-05 Lung function (forced expiratory volume in 1 second) SYN3 intron 24023788 rs762884 chr22 33135922 G A 2.78E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SYN3 intron 20031582 rs762884 chr22 33135922 G A 8.30E-05 Non-alcoholic fatty liver disease histology (other) SYN3 intron 20708005 rs5994617 chr22 33142908 A G 1.65E-04 Lung function (forced expiratory volume in 1 second) SYN3 intron 24023788 rs9619305 chr22 33144874 T G 6.81E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SYN3 intron 20031582 rs6518791 chr22 33147787 T C 6.52E-04 Multiple complex diseases SYN3 intron 17554300 rs5754250 chr22 33151251 C T 3.15E-04 Multiple complex diseases SYN3 intron 17554300 rs4821100 chr22 33164460 A G 8.56E-04 Type 2 diabetes SYN3 intron 17463246 rs17503 chr22 33173944 G A 7.30E-05 Serum albumin level SYN3 intron pha003084 rs7287772 chr22 33188307 T C 2.03E-05 Lung function (forced vital capacity) SYN3 intron 24023788 rs7287772 chr22 33188307 T C 3.33E-04 Lung function (forced expiratory volume in 1 second) SYN3 intron 24023788 rs11704261 chr22 33206863 G T 4.33E-04 Lung function (forced vital capacity) TIMP3 intron 24023788 rs16991252 chr22 33213923 C T 0.000000162 HDL cholesterol TIMP3 intron 23063622 rs11703156 chr22 33229804 G A 9.48E-04 Corneal structure TIMP3 intron 22003120 rs242076 chr22 33229830 A G 9.20E-04 Multiple complex diseases TIMP3 intron 17554300 rs2071947 chr22 33246032 C T 3.73E-05 Cognitive performance TIMP3 intron 19734545 rs2283885 chr22 33248902 G A 4.26E-05 Cognitive performance TIMP3 intron 19734545 rs12165359 chr22 33249271 C T 1.10E-04 Glycosylated haemoglobin levels TIMP3 intron 17255346 rs12165603 chr22 33250756 G A 2.11E-10 HDL cholesterol TIMP3 intron 23063622 rs2267185 chr22 33258217 G A,C,T 4.60E-04 Type 2 diabetes TIMP3 UTR-3 17463246 rs2040435 chr22 33263431 C T 1.90E-05 Urinary metabolites SYN3 intron 21572414 rs5749531 chr22 33263558 T C 8.90E-06 Urinary metabolites SYN3 intron 21572414 rs2040437 chr22 33266415 A C 1.80E-05 Urinary metabolites SYN3 intron 21572414 rs5754319 chr22 33270348 C A 1.73E-04 Glycemic traits (pregnancy) SYN3 intron 23903356 rs5754319 chr22 33270348 C A 9.28E-06 Glycemic traits (pregnancy) SYN3 intron 23903356 rs5754321 chr22 33270461 T C 1.38E-05 Glycemic traits (pregnancy) SYN3 intron 23903356 rs5754321 chr22 33270461 T C 2.42E-04 Glycemic traits (pregnancy) SYN3 intron 23903356 rs5754322 chr22 33272699 T C 1.97E-04 Glycemic traits (pregnancy) SYN3 intron 23903356 rs137500 chr22 33276686 A G 8.48E-04 Multiple complex diseases SYN3 intron 17554300 rs137500 chr22 33276686 A G 9.60E-05 Lung function (forced vital capacity) SYN3 intron 24023788 rs137514 chr22 33286796 G T 3.75E-05 Cognitive test performance SYN3 intron 20125193 rs137528 chr22 33298130 G A 9.72E-05 Lung function (forced vital capacity) SYN3 intron 24023788 rs5754331 chr22 33300101 T C 1.24E-04 Lung function (forced expiratory volume in 1 second) SYN3 intron 24023788 rs80693 chr22 33300347 G T 1.45E-04 Suicide attempts in bipolar disorder SYN3 intron 21423239 rs137543 chr22 33308118 T C 2.00E-05 Urinary metabolites SYN3 intron 21572414 rs9609656 chr22 33316280 C T 8.32E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SYN3 intron 20031582 rs9609656 chr22 33316280 C T 5.97E-05 Glucose levels SYN3 intron pha002899 rs9609656 chr22 33316280 C T 3.44E-05 Insulin-related traits SYN3 intron pha002901 rs25112 chr22 33332712 T A 1.08E-04 Multiple complex diseases SYN3 intron 17554300 rs17779789 chr22 33347576 T C 3.63E-04 Multiple complex diseases SYN3 intron 17554300 rs11704652 chr22 33348093 G A 1.49E-04 Multiple complex diseases SYN3 intron 17554300 rs11089599 chr22 33363999 G T 7.16E-05 Multiple complex diseases SYN3 intron 17554300 rs2042794 chr22 33364457 A G 1.09E-04 Multiple complex diseases SYN3 intron 17554300 rs2081727 chr22 33366051 A G 9.02E-05 Multiple complex diseases SYN3 intron 17554300 rs241715 chr22 33383563 A G 2.29E-05 Eosinophil counts SYN3 intron pha003088 rs9609681 chr22 33419847 C T 6.56E-05 Acute lymphoblastic leukemia (childhood) SYN3 intron 19684603 rs133967 chr22 33422218 G A 3.75E-04 Lung function (forced vital capacity) SYN3 intron 24023788 rs16991717 chr22 33445757 A G 5.12E-04 Suicide attempts in bipolar disorder SYN3 intron 21423239 rs5998715 chr22 33462641 T G 6.30E-04 Smoking initiation / / 24665060 rs16991760 chr22 33474244 A T 5.67E-04 Type 2 diabetes / / 17463246 rs2040403 chr22 33479580 A G 1.96E-05 Pulmonary function in asthmatics / / 23541324 rs2040403 chr22 33479580 A G 3.90E-04 Smoking initiation / / 24665060 rs2027847 chr22 33494722 G A 8.30E-04 Type 2 diabetes / / 17463246 rs13054205 chr22 33513085 G A 4.76E-04 Type 2 diabetes / / 17463246 rs743793 chr22 33561746 T C 6.00E-07 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs5994683 chr22 33561994 G C 9.04E-05 Major depressive disorder (broad) / / 20038947 rs1015740 chr22 33564443 A G 5.60E-04 Alzheimer's disease / / 17998437 rs10483170 chr22 33565885 C G 2.28E-05 Major depressive disorder (broad) / / 20038947 rs4821132 chr22 33566587 C T 6.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs2213457 chr22 33568560 G T 5.66E-05 Major depressive disorder (broad) / / 20038947 rs12483930 chr22 33569454 C G 0.0000287 Coronary artery calcification / / 23394302 rs4141436 chr22 33637087 C T 5.39E-05 Hemoglobin concentration / / 20534544 rs17722172 chr22 33670584 G A 7.98E-05 Alzheimer's disease (late onset) LARGE cds-synon 21379329 rs7285350 chr22 33678629 T G 1.35E-04 Alzheimer's disease (late onset) LARGE intron 21379329 rs5749598 chr22 33683442 T C 3.49E-04 Alzheimer's disease (late onset) LARGE intron 21379329 rs9621675 chr22 33698546 C T 5.29E-04 Alzheimer's disease LARGE intron 17998437 rs16992105 chr22 33700948 G C 4.77E-04 Type 2 diabetes LARGE intron 17463246 rs8138316 chr22 33706143 C T 4.36E-05 Major depressive disorder LARGE intron 19107115 rs2267193 chr22 33746526 G C 8.00E-06 Visceral fat LARGE intron 22589738 rs715487 chr22 33791374 C A 3.39E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) LARGE intron 17982456 rs715487 chr22 33791374 C A 2.42E-05 Sodium levels LARGE intron pha003093 rs9609779 chr22 33799128 C A 4.57E-05 Sodium levels LARGE intron pha003093 rs5994737 chr22 33804804 C T 9.41E-04 Amyotrophic Lateral Sclerosis LARGE intron 17362836 rs5994737 chr22 33804804 C T 6.50E-04 Heart Failure LARGE intron pha002884 rs7287710 chr22 33807636 T C 0.0000878 Polycystic ovary syndrome LARGE intron 22951595 rs7287710 chr22 33807636 T C 8.78E-05 Intracranial aneurysm LARGE intron 22961961 rs5998935 chr22 33807835 G A 9.37E-05 Nicotine smoking LARGE intron 19268276 rs8138344 chr22 33820256 G T 9.20E-04 Type 2 diabetes and 6 quantitative traits LARGE intron 17848626 rs5998941 chr22 33828996 G A 1.58E-05 Tardive dyskinesia LARGE intron 20939080 rs760544 chr22 33831799 C T 5.82E-05 Tardive dyskinesia LARGE intron 20939080 rs7284217 chr22 33845831 A C 2.08E-04 Lung function (forced expiratory volume in 1 second) LARGE intron 17255346 rs7284217 chr22 33845831 A C 9.26E-04 Type 2 diabetes LARGE intron 17463246 rs5754566 chr22 33862494 G T 4.60E-05 Cognitive impairment induced by topiramate LARGE intron 22091778 rs2413187 chr22 33864817 A G 3.71E-06 Post-traumatic stress disorder LARGE intron 24080187 rs12167294 chr22 33884396 G A 6.35E-04 Multiple complex diseases LARGE intron 17554300 rs5994767 chr22 33914824 A G 2.80E-04 Birth weight LARGE intron 17255346 rs7287479 chr22 33921753 T A 2.16E-04 Multiple complex diseases LARGE intron 17554300 rs5754597 chr22 33932624 A G 8.78E-04 Response to taxane treatment (placlitaxel) LARGE intron 23006423 rs5749626 chr22 33933970 T C 2.06E-05 Aging (time to event) LARGE intron 21782286 rs762057 chr22 33950513 G A 0.0000944 Antithrombin LARGE intron 23705025 rs713703 chr22 33956080 T C 0.0000313 Antithrombin LARGE intron 23705025 rs5754612 chr22 33964576 A C 6.47E-04 Coronary Artery Disease LARGE intron 17634449 rs3819662 chr22 33965497 A G 4.21E-04 Coronary Artery Disease LARGE intron 17634449 rs2413194 chr22 33967289 C T 5.33E-04 Acute lung injury LARGE intron 22295056 rs130423 chr22 33984394 A G 3.45E-05 Glucose levels LARGE intron pha003061 rs7293114 chr22 33985315 A G 2.80E-05 Alcohol consumption LARGE intron 23953852 rs738971 chr22 33986543 A G 3.00E-05 Glucose levels LARGE intron pha003061 rs11089627 chr22 33993081 T C 2.22E-05 Glucose levels LARGE intron pha003058 rs11089627 chr22 33993081 T C 1.03E-05 Glucose levels LARGE intron pha003061 rs2239746 chr22 34000175 T C 6.48E-06 Glucose levels LARGE intron pha003058 rs2239746 chr22 34000175 T C 1.99E-06 Glucose levels LARGE intron pha003061 rs695366 chr22 34000928 T G 9.75E-06 Glucose levels LARGE intron pha003058 rs695366 chr22 34000928 T G 3.41E-06 Glucose levels LARGE intron pha003061 rs695271 chr22 34002731 A G 7.89E-04 Multiple complex diseases LARGE intron 17554300 rs762859 chr22 34011334 A G 9.11E-06 Glucose levels LARGE intron pha003058 rs762859 chr22 34011334 A G 2.38E-06 Glucose levels LARGE intron pha003061 rs9306281 chr22 34013807 C T 9.11E-06 Glucose levels LARGE intron pha003058 rs9306281 chr22 34013807 C T 2.38E-06 Glucose levels LARGE intron pha003061 rs240595 chr22 34018750 A C 9.11E-06 Glucose levels LARGE intron pha003058 rs240595 chr22 34018750 A C 2.38E-06 Glucose levels LARGE intron pha003061 rs738961 chr22 34021461 G A 5.73E-06 Adipocyte fatty acid-binding protein concentration,in serum LARGE intron 21863005 rs738961 chr22 34021461 G A 6.53E-05 Glucose levels LARGE intron pha003058 rs240590 chr22 34021876 A G 9.94E-06 Glucose levels LARGE intron pha003058 rs240590 chr22 34021876 A G 6.03E-06 Glucose levels LARGE intron pha003061 rs240588 chr22 34024097 G T 6.00E-06 Glucose levels LARGE intron pha003058 rs240588 chr22 34024097 G T 4.23E-06 Glucose levels LARGE intron pha003061 rs5749640 chr22 34024204 T C 1.17E-04 Type 2 diabetes LARGE intron 17463246 rs19801 chr22 34050561 C T 1.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LARGE intron 20877124 rs240346 chr22 34058890 G A 8.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LARGE intron 20877124 rs240354 chr22 34061156 T C 7.59E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LARGE intron 20877124 rs240358 chr22 34066384 A G 5.49E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LARGE intron 20877124 rs2267249 chr22 34066846 C T 4.45E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) LARGE intron 24023788 rs2267260 chr22 34077196 T C 0.0000372 Coronary artery calcification LARGE intron 23394302 rs5754638 chr22 34078057 A T 8.00E-06 Alcohol dependence (age at onset) LARGE intron 24962325 rs240080 chr22 34096135 G A 6.11E-05 ldl cholesterol LARGE intron pha003077 rs240080 chr22 34096135 G A 3.62E-05 Cholesterol LARGE intron pha003083 rs5749649 chr22 34104444 A C 4.17E-04 Amyotrophic Lateral Sclerosis LARGE intron 17827064 rs2267271 chr22 34113589 G A 2.73E-04 Amyotrophic lateral sclerosis LARGE intron 23624525 rs239319 chr22 34120608 T C 1.89E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) LARGE intron 23648065 rs28374 chr22 34166139 T C 1.50E-04 Response to taxane treatment (placlitaxel) LARGE intron 23006423 rs4821182 chr22 34168478 C T 5.08E-06 Brachial circumference LARGE intron 22479309 rs5749665 chr22 34196508 T C 2.24E-04 Response to taxane treatment (placlitaxel) LARGE intron 23006423 rs5754679 chr22 34197367 T C 5.92E-04 Response to taxane treatment (placlitaxel) LARGE intron 23006423 rs5754682 chr22 34202284 C T 8.45E-04 Longevity LARGE intron 22279548 rs5754682 chr22 34202284 C T 8.99E-04 Response to taxane treatment (placlitaxel) LARGE intron 23006423 rs2267293 chr22 34211556 G T 1.39E-04 Smoking cessation LARGE intron 18519826 rs1573654 chr22 34211592 A G 1.09E-04 Type 2 diabetes LARGE intron 17463246 rs2227023 chr22 34213356 T C 2.46E-04 Response to taxane treatment (placlitaxel) LARGE intron 23006423 rs4821186 chr22 34217224 T C 6.06E-04 Type 2 diabetes LARGE intron 17463246 rs2267296 chr22 34219939 A G 5.92E-04 Colorectal cancer LARGE intron 24737748 rs2267298 chr22 34224916 C A 3.16E-05 Cortisol secretion,in saliva LARGE intron 21316860 rs2267299 chr22 34225482 C T 1.17E-04 Bladder cancer LARGE intron 19648920 rs1894428 chr22 34226185 A G 1.57E-04 Smoking cessation LARGE intron 18519826 rs1894429 chr22 34226440 T C 2.55E-06 Smoking cessation LARGE intron 18519826 rs13058342 chr22 34238831 T C 1.59E-04 Age-related macular degeneration LARGE intron 22125219 rs5749682 chr22 34248314 C A 2.00E-07 Diabetic nephropathy LARGE intron 21150874 rs5749682 chr22 34248314 C A 8.74E-04 Type 2 diabetes LARGE intron 22238593 rs1009385 chr22 34249434 G A 1.68E-04 Age-related macular degeneration LARGE intron 22125219 rs5749683 chr22 34252374 C T 5.58E-04 Multiple complex diseases LARGE intron 17554300 rs2277840 chr22 34252545 G A 1.42E-05 Multiple complex diseases LARGE intron 17554300 rs17809399 chr22 34257133 G A 4.84E-07 Diabetic nephropathy LARGE intron 21150874 rs7290399 chr22 34266265 A G 6.12E-04 Amyotrophic Lateral Sclerosis LARGE intron 17362836 rs11705063 chr22 34270568 T C 2.05E-04 Glycosylated haemoglobin levels LARGE intron 17255346 rs9621795 chr22 34271782 A G 3.65E-05 Schizophrenia LARGE intron 19571809 rs9621795 chr22 34271782 A G 6.59E-06 Schizophrenia LARGE intron 21926974 rs9621795 chr22 34271782 A G 0.0000166 Schizophrenia LARGE intron 23637625 rs13055480 chr22 34289857 A G 1.16E-04 Glycosylated haemoglobin levels LARGE intron 17255346 rs2213360 chr22 34291750 A G 1.27E-04 Alcohol dependence LARGE intron 20201924 rs4821197 chr22 34325300 C T 6.02E-04 Multiple complex diseases / / 17554300 rs130503 chr22 34338666 A G 1.07E-04 Multiple complex diseases / / 17554300 rs5754783 chr22 34379623 G T 6.14E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs723568 chr22 34386083 G A 5.77E-04 Alzheimer's disease / / 22005930 rs7286472 chr22 34386473 A G 1.10E-04 Blood pressure measurement (cold pressor test) / / 24165912 rs7286472 chr22 34386473 A G 3.00E-07 Blood pressure measurement (cold pressor test) / / 24165912 rs4821204 chr22 34392013 A G 9.31E-05 Alzheimer's disease / / 22005930 rs4820127 chr22 34395171 C T 6.17E-05 Alzheimer's disease / / 22005930 rs5754792 chr22 34396981 G T 4.19E-05 Alzheimer's disease / / 22005930 rs5754793 chr22 34398083 C T 6.86E-05 Alzheimer's disease / / 22005930 rs242888 chr22 34422094 G A 8.74E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs242885 chr22 34423169 C T 2.16E-05 Body mass (lean) / / 19268274 rs129315 chr22 34424170 T G 8.74E-05 Brain derived neurotrophic factor levels,in serum / / 22047184 rs5999183 chr22 34447501 A G 0.00000303 Internal carotid artery thickness (far walls) / / 23487405 rs5999190 chr22 34463035 T G 4.64E-05 Body mass (lean) / / 19268274 rs5999191 chr22 34463080 G A 5.49E-04 Multiple complex diseases / / 17554300 rs5999191 chr22 34463080 G A 4.53E-05 Body mass (lean) / / 19268274 rs5754819 chr22 34470167 A G 2.40E-05 Urinary metabolites / / 21572414 rs9621844 chr22 34481608 C T 2.51E-04 Smoking initiation / / 24665060 rs9609948 chr22 34506382 A G 8.93E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs130671 chr22 34528445 C T 9.92E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5754850 chr22 34546682 G A 4.75E-04 Alzheimer's disease (late onset) / / 21379329 rs5754852 chr22 34548646 T C 6.69E-05 Lung function (forced vital capacity) / / pha003104 rs5999230 chr22 34557399 T G 9.52E-05 HIV-1 viral setpoint / / 22174851 rs4821230 chr22 34576097 G A 4.45E-04 Multiple complex diseases / / 17554300 rs390647 chr22 34600013 C T 2.65E-06 Coronary Artery Disease / / 17634449 rs738956 chr22 34601332 A G 8.13E-06 Coronary artery calcification / / 23870195 rs5754891 chr22 34602188 A G 7.00E-06 Coronary artery calcification / / 23870195 rs169360 chr22 34605957 C T 5.99E-04 Type 2 diabetes / / 22158537 rs8142322 chr22 34614920 C A 3.10E-04 Coronary Artery Disease / / 17634449 rs41537244 chr22 34619445 A G 2.24E-04 Coronary Artery Disease / / 17634449 rs5754914 chr22 34640046 T C 5.04E-04 Type 2 diabetes / / 22158537 rs5749770 chr22 34642970 A G 8.92E-04 Type 2 diabetes / / 17463246 rs5994882 chr22 34646980 A C 5.55E-05 Intelligence / / 21826061 rs5999265 chr22 34654148 A G 2.84E-05 Intelligence / / 21826061 rs11703579 chr22 34669084 C T 9.09E-05 Intelligence / / 21826061 rs713765 chr22 34675903 T G 2.01E-05 Intelligence / / 21826061 rs5999295 chr22 34726496 G C 7.83E-04 Type 2 diabetes / / 17463246 rs5999296 chr22 34727120 A G 3.23E-04 Type 2 diabetes / / 17463246 rs738959 chr22 34740703 A C 8.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs738959 chr22 34740703 A C 8.80E-06 Intelligence / / 21826061 rs470049 chr22 34759241 G A 4.80E-05 Myasthenia gravis / / 23055271 rs5755023 chr22 34799261 A G 1.75E-05 Pulmonary function in asthmatics / / 23541324 rs1459029 chr22 34813253 C T 6.73E-05 Type 2 diabetes / / 17463246 rs1034394 chr22 34823828 A G 2.00E-06 Major depressive disorder / / 23377640 rs13055293 chr22 34832523 G T 7.93E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17824280 chr22 34847299 C T 8.14E-08 Metabolite levels / / 23281178 rs1459037 chr22 34851133 C T 9.40E-05 Triglycerides / / 19074352 rs1459037 chr22 34851133 C T 7.37E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs2609850 chr22 34851377 C A 7.28E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs130575 chr22 34859793 A G 5.00E-06 Attention deficit hyperactivity disorder / / 18821565 rs130578 chr22 34863375 G A 3.60E-04 Type 2 diabetes / / 17463246 rs4423 chr22 34869196 G A 8.26E-05 Type 2 diabetes / / 17463246 rs135165 chr22 34873663 A T 3.90E-04 Type 2 diabetes / / 17463246 rs130592 chr22 34874101 T G 1.51E-04 Smoking initiation / / 24665060 rs130695 chr22 34882579 A G 4.21E-04 Type 2 diabetes / / 17463246 rs5755064 chr22 34884877 C G 4.49E-04 Type 2 diabetes / / 17463246 rs738968 chr22 34889097 T G 8.00E-08 Immune reponse to smallpox (secreted TNF-alpha) / / 22610502 rs130707 chr22 34900232 T C 8.28E-04 Multiple complex diseases / / 17554300 rs130718 chr22 34905776 A G 6.34E-04 Type 2 diabetes / / 17463246 rs4821261 chr22 34941576 T C 9.00E-06 Behavioural disinhibition (generation interaction) / / 23942779 rs5755125 chr22 34993396 C G 1.47E-04 Multiple complex diseases / / 17554300 rs9621978 chr22 35010255 A G 2.21E-05 Orofacial clefts / / 22419666 rs1806394 chr22 35027603 A G 9.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9607167 chr22 35030618 C A 0.0003456 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs9607167 chr22 35030618 C A 3.46E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9607168 chr22 35034774 C T 9.79E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2899228 chr22 35041350 G A 8.60E-05 Calcium levels / / pha003085 rs5755184 chr22 35041876 G A 9.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12170130 chr22 35082433 C T 2.61E-05 HDL cholesterol / / pha003074 rs2213447 chr22 35087464 G A 1.45E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7291034 chr22 35090375 G A 1.85E-04 Multiple complex diseases / / 17554300 rs7286473 chr22 35090489 T G 1.94E-04 Multiple complex diseases / / 17554300 rs7285667 chr22 35104936 G A 4.52E-04 Multiple complex diseases / / 17554300 rs5749938 chr22 35105928 A G 0.0000686 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs5749938 chr22 35105928 A G 6.86E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1540300 chr22 35115913 G C 5.05E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs5755254 chr22 35131593 A G 4.49E-04 Response to TNF antagonist treatment / / 21061259 rs9622012 chr22 35131614 C G 6.90E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs5999510 chr22 35139740 G A 2.51E-04 Multiple complex diseases / / 17554300 rs4493363 chr22 35144411 G A 4.00E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs137270 chr22 35167583 G A 2.11E-05 Alcohol and nictotine co-dependence / / 20158304 rs941435 chr22 35230303 T C 1.99E-06 Phospholipid levels (plasma) / / 21829377 rs5749970 chr22 35230810 C T 1.52E-06 Phospholipid levels (plasma) / / 21829377 rs715489 chr22 35237581 C T 2.22E-05 Type 2 diabetes / / 17463246 rs7286095 chr22 35242350 G A 4.60E-05 Malaria / / 19465909 rs5995024 chr22 35262664 G C 2.46E-04 Type 2 diabetes / / 17463246 rs5995024 chr22 35262664 G C 7.35E-04 Multiple complex diseases / / 17554300 rs5995026 chr22 35271517 C G 2.25E-05 Type 2 diabetes / / 17463246 rs10483185 chr22 35274183 T C 3.69E-05 Type 2 diabetes / / 17463246 rs137219 chr22 35292510 A C 7.99E-04 Response to TNF antagonist treatment / / 21061259 rs1573674 chr22 35301788 G A 6.18E-04 Type 2 diabetes / / 17463246 rs739059 chr22 35315368 A G 1.82E-04 Myocardial Infarction / / pha002873 rs8135998 chr22 35320699 T C 3.96E-04 Multiple complex diseases / / 17554300 rs1159413 chr22 35337888 G A 8.94E-04 Type 2 diabetes / / 17463246 rs7284640 chr22 35341977 T C 3.97E-04 Type 2 diabetes / / 17463246 rs5755445 chr22 35342654 T C 1.87E-04 Multiple complex diseases / / 17554300 rs2157216 chr22 35344317 A G 6.60E-04 Type 2 diabetes / / 17463246 rs1013513 chr22 35353740 C A 9.63E-04 Type 2 diabetes / / 17463246 rs5750009 chr22 35355325 G A 8.73E-04 Type 2 diabetes / / 17463246 rs5755469 chr22 35369739 T C 3.09E-04 Fibrinogen / / 17255346 rs9619497 chr22 35371248 G A 5.00E-06 Metabolite levels (HVA-5-HIAA Factor score) / / 23319000 rs73166096 chr22 35378256 T C 8.74E-06 Stroke (ischemic) / / 21957438 rs5755495 chr22 35398839 C G 3.90E-04 Multiple complex diseases / / 17554300 rs5755536 chr22 35430624 T A 4.87E-04 Type 2 diabetes / / 17463246 rs361863 chr22 35463162 A G 9.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) ISX missense 21239504 rs5755575 chr22 35491969 G A 5.50E-04 Coronary Artery Disease / / 17634449 rs2413298 chr22 35502640 G C 7.13E-04 Coronary Artery Disease / / 17634449 rs9622147 chr22 35503072 C T 5.45E-04 Alcohol dependence / / 21314694 rs7284619 chr22 35517673 T C 7.55E-06 Recombination rate / / 21698098 rs1473816 chr22 35532734 G A 3.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs134225 chr22 35533408 T G 1.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs134226 chr22 35533620 A G 9.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs4821368 chr22 35534933 G C 2.43E-04 Suicide attempts in bipolar disorder / / 21041247 rs134229 chr22 35536380 G C 2.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs739301 chr22 35538698 A G 2.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs540006882 chr22 35539717 CT C 2.70E-04 Suicide attempts in bipolar disorder / / 21041247 rs5755606 chr22 35539717 C T 2.70E-04 Suicide attempts in bipolar disorder / / 21041247 rs5999742 chr22 35540423 G A 1.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs5750066 chr22 35540522 T G 1.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs9610223 chr22 35540650 C T 1.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs134300 chr22 35558414 A G 1.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2413305 chr22 35559579 A G 5.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2413306 chr22 35559695 G A 1.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6518933 chr22 35560386 G A 1.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs134370 chr22 35567413 G C 8.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs134378 chr22 35569690 T G 8.63E-04 Suicide attempts in bipolar disorder / / 21041247 rs134381 chr22 35571497 T C 3.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs134386 chr22 35573856 T C 8.54E-04 Suicide attempts in bipolar disorder / / 21041247 rs2213877 chr22 35574374 G A 3.83E-04 Multiple complex diseases / / 17554300 rs2213877 chr22 35574374 G A 2.98E-04 Alzheimer's disease / / 17998437 rs134406 chr22 35579346 C T 8.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs134409 chr22 35580096 A G 4.82E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs134410 chr22 35580597 T C 1.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2187961 chr22 35581399 G A 7.84E-06 Behcet's disease / / pha002888 rs134415 chr22 35583297 A G 2.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs134422 chr22 35585990 C T 9.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs134426 chr22 35587480 A G 1.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs134430 chr22 35588600 C A 1.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs134432 chr22 35588844 A G 1.10E-05 Urinary metabolites / / 21572414 rs3752596 chr22 35590706 G A 6.47E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs134434 chr22 35591035 G A 8.45E-04 Suicide attempts in bipolar disorder / / 21041247 rs134434 chr22 35591035 G A 8.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4821375 chr22 35592615 T C 8.53E-04 Suicide attempts in bipolar disorder / / 21041247 rs4821376 chr22 35592689 G A 8.63E-04 Suicide attempts in bipolar disorder / / 21041247 rs134442 chr22 35595331 T C 8.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs134443 chr22 35595528 C T 8.70E-04 Suicide attempts in bipolar disorder / / 21041247 rs713819 chr22 35595720 A G 1.61E-04 Multiple complex diseases / / 17554300 rs713819 chr22 35595720 A G 8.23E-04 Alzheimer's disease / / 17998437 rs134445 chr22 35596150 C T 8.71E-04 Suicide attempts in bipolar disorder / / 21041247 rs10483188 chr22 35596232 C T 3.51E-04 Multiple complex diseases / / 17554300 rs5995078 chr22 35598379 T A 3.90E-05 Triglycerides / / 19074352 rs5999762 chr22 35599782 A G 1.10E-05 Urinary metabolites / / 21572414 rs5755655 chr22 35622616 G T 3.90E-06 Urinary metabolites / / 21572414 rs5755661 chr22 35629782 C T 2.00E-05 Urinary metabolites / / 21572414 rs2092331 chr22 35631544 C T 2.28E-05 Behcet's disease / / pha002888 rs2103642 chr22 35631590 A G 1.10E-05 Urinary metabolites / / 21572414 rs4820187 chr22 35647722 A G 9.08E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2092029 chr22 35652241 C T 3.36E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2092029 chr22 35652241 C T 4.47E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs5755674 chr22 35653473 C T 2.04E-04 Response to taxane treatment (placlitaxel) HMGXB4 UTR-5 23006423 rs2235146 chr22 35654943 G C 9.24E-04 Suicide attempts in bipolar disorder HMGXB4 intron 21423239 rs4820189 chr22 35658225 A G 2.64E-04 Response to taxane treatment (placlitaxel) HMGXB4 intron 23006423 rs2235148 chr22 35664941 T C 3.18E-04 Response to taxane treatment (placlitaxel) HMGXB4 intron 23006423 rs12485178 chr22 35667486 G A 7.16E-04 Response to taxane treatment (placlitaxel) HMGXB4 intron 23006423 rs4821387 chr22 35669441 A G 6.30E-04 Response to taxane treatment (placlitaxel) HMGXB4 intron 23006423 rs760513 chr22 35669809 C T 3.18E-04 Response to taxane treatment (placlitaxel) HMGXB4 intron 23006423 rs932290 chr22 35672183 G A 5.40E-05 Triglycerides HMGXB4 intron 19074352 rs2235150 chr22 35672843 T G 1.89E-04 Response to taxane treatment (placlitaxel) HMGXB4 intron 23006423 rs5755683 chr22 35675537 G A 2.75E-04 Response to taxane treatment (placlitaxel) HMGXB4 intron 23006423 rs741996 chr22 35684059 C T 2.23E-04 Response to taxane treatment (placlitaxel) HMGXB4 intron 23006423 rs5750093 chr22 35684533 G C 2.50E-04 Multiple complex diseases HMGXB4 intron 17554300 rs7291420 chr22 35688623 C T 3.06E-04 Coronary heart disease HMGXB4 intron 21606135 rs1474557 chr22 35690179 T C 4.02E-04 Response to taxane treatment (placlitaxel) HMGXB4 UTR-3 23006423 rs1474558 chr22 35690183 A G 2.23E-04 Response to taxane treatment (placlitaxel) HMGXB4 UTR-3 23006423 rs4821392 chr22 35690532 A G 3.13E-04 Response to taxane treatment (placlitaxel) HMGXB4 UTR-3 23006423 rs138726 chr22 35694295 A G 2.30E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs138744 chr22 35699883 C T 2.83E-04 Response to taxane treatment (placlitaxel) TOM1 intron 23006423 rs138764 chr22 35703128 T C 1.12E-04 Response to taxane treatment (placlitaxel) TOM1 intron 23006423 rs138777 chr22 35711098 A G 4.45E-05 Response to taxane treatment (placlitaxel) TOM1 intron 23006423 rs138777 chr22 35711098 A G 4.00E-05 Lipid traits TOM1 intron 24023260 rs138777 chr22 35711098 A G 5.00E-08 Cholesterol,total TOM1 intron 24097068 rs11704301 chr22 35711543 A C 7.90E-04 Type 2 diabetes TOM1 intron 23209189 rs16995569 chr22 35712491 T C 6.31E-04 Multiple complex diseases TOM1 intron 17554300 rs129433 chr22 35742524 C T 1.03E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) TOM1 intron 23648065 rs5755703 chr22 35754413 C A 4.00E-06 Smoking cessation / / 24665060 rs9622186 chr22 35773954 A G 2.32E-72 Cholesterol,total / / 23063622 rs9622186 chr22 35773954 A G 2.39E-38 LDL cholesterol / / 23063622 rs9622186 chr22 35773954 A G 3.30E-53 HDL cholesterol / / 23063622 rs9622186 chr22 35773954 A G 4.12E-23 Triglycerides / / 23063622 rs2071748 chr22 35777618 G A 3.00E-06 Obesity-related traits HMOX1 intron 23251661 rs8140370 chr22 35779635 T G 3.82E-09 HDL cholesterol HMOX1 intron 23063622 rs2285112 chr22 35789263 A G 4.36E-06 Obesity-related traits HMOX1 intron 23251661 rs17880056 chr22 35789835 C T 5.04E-09 HDL cholesterol HMOX1 UTR-3 23063622 rs11555832 chr22 35789869 A G 0.000000906 HDL cholesterol HMOX1 UTR-3 23063622 rs1078979 chr22 35795413 A G 1.89E-05 Bipolar disorder / / 17486107 rs133416 chr22 35806376 T C 8.74E-04 Coronary heart disease MCM5 intron 21606135 rs133422 chr22 35813158 A G 1.31E-05 Cytomegalovirus antibody response MCM5 intron 21993531 rs133426 chr22 35815296 C T 4.25E-04 Acute lung injury MCM5 intron 22295056 rs5999854 chr22 35913606 A G 2.97E-05 Arthritis (juvenile idiopathic) / / 22354554 rs139059 chr22 35919446 G A 1.12E-05 Post-operative nausea and vomiting / / 21694509 rs1883299 chr22 35923105 G A 0.000860627 Hypertension (early onset hypertension) / / 22479346 rs8139398 chr22 35941944 C T 9.10E-05 Suicide attempts in bipolar disorder RASD2 intron 21423239 rs8137058 chr22 35944774 G A 7.44E-05 Suicide attempts in bipolar disorder RASD2 intron 21423239 rs11912323 chr22 35972779 C T 6.60E-05 Pericardial fat / / 22589742 rs5999879 chr22 35978764 C G 1.06E-04 Multiple complex diseases / / 17554300 rs5755767 chr22 35980060 A G 3.00E-04 Type 2 diabetes / / 17463246 rs9610322 chr22 35980173 G A 3.85E-04 Coronary heart disease / / 21606135 rs9610322 chr22 35980173 G A 3.20E-05 Pericardial fat / / 22589742 rs5750124 chr22 35993150 T C 5.44E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs5750124 chr22 35993150 T C 1.90E-05 Pericardial fat / / 22589742 rs4821419 chr22 35993783 C A 5.30E-05 Pericardial fat / / 22589742 rs4821421 chr22 35994283 A G 2.20E-05 Pericardial fat / / 22589742 rs5750125 chr22 35996298 T A 2.60E-05 Pericardial fat / / 22589742 rs5755786 chr22 35997200 T A 8.00E-05 Pericardial fat / / 22589742 rs5750126 chr22 35997387 G A 8.10E-05 Pericardial fat / / 22589742 rs4821422 chr22 36000547 A G 2.70E-05 Pericardial fat / / 22589742 rs4821423 chr22 36001162 T C 4.20E-05 Pericardial fat / / 22589742 rs4820205 chr22 36001258 T C 2.70E-05 Pericardial fat / / 22589742 rs4140603 chr22 36001569 T C 3.10E-05 Pericardial fat / / 22589742 rs4821424 chr22 36001860 G A 1.66E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4821424 chr22 36001860 G A 8.60E-05 Pericardial fat / / 22589742 rs3788512 chr22 36002420 T C 6.50E-05 Pericardial fat MB nearGene-3 22589742 rs5755790 chr22 36006732 G A 1.42E-04 Response to statin treatment (atorvastatin),change in cholesterol levels MB intron 20031582 rs1997882 chr22 36016472 T C 9.11E-04 Type 2 diabetes MB intron 17463246 rs5755867 chr22 36074043 T C 2.30E-05 Major depressive disorder / / 21042317 rs135109 chr22 36080506 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs4820209 chr22 36104647 A G 2.15E-05 Smoking initiation / / 24665060 rs5755921 chr22 36104730 C T 1.09E-04 Smoking initiation / / 24665060 rs4821439 chr22 36114263 C T 1.22E-04 Smoking initiation APOL5 intron 24665060 rs2009168 chr22 36117854 G A 4.78E-04 Smoking initiation APOL5 intron 24665060 rs5999984 chr22 36120510 G C 4.52E-04 Alcohol dependence APOL5 intron 21314694 rs2076671 chr22 36122930 C T 2.60E-04 Smoking initiation APOL5 missense 24665060 rs2073198 chr22 36123313 G A 1.63E-04 Smoking initiation APOL5 intron 24665060 rs2016586 chr22 36125264 T G 3.00E-06 Body mass index APOL5 intron 24348519 rs2016586 chr22 36125264 T G 3.26E-04 Smoking initiation APOL5 intron 24665060 rs7285826 chr22 36125586 T G 1.34E-04 Smoking initiation / / 24665060 rs5750169 chr22 36129851 A T 1.89E-04 Smoking initiation / / 24665060 rs13053958 chr22 36132832 C T 6.31E-04 Smoking initiation / / 24665060 rs5750178 chr22 36204303 G A 8.33E-05 Femoral neck bone geometry RBFOX2 intron 22087292 rs6000032 chr22 36306266 G A 5.58E-05 Femoral neck bone geometry RBFOX2 intron 22087292 rs5750200 chr22 36311770 T G 5.34E-06 Rheumatoid arthritis RBFOX2 intron 19503088 rs5750200 chr22 36311770 T G 8.07E-05 Monocyte counts RBFOX2 intron pha003089 rs5756012 chr22 36347646 C A 9.19E-05 Femoral neck bone geometry RBFOX2 intron 22087292 rs2899258 chr22 36355358 T G 5.46E-06 Rheumatoid arthritis RBFOX2 intron 19503088 rs2899258 chr22 36355358 T G 8.07E-05 Monocyte counts RBFOX2 intron pha003089 rs5756039 chr22 36406534 G A 9.98E-05 Femoral neck bone geometry RBFOX2 intron 22087292 rs16996292 chr22 36445533 G A 1.02E-04 Type 2 diabetes / / 22238593 rs6518987 chr22 36445592 T C 3.16E-05 Type 2 diabetes / / 22238593 rs2413378 chr22 36472343 T C 0.000824 Common carotid artery thickness (average of near and far wall measures) / / 23487405 rs739203 chr22 36480881 C T 4.39E-05 Cholesterol / / pha003073 rs739203 chr22 36480881 C T 1.95E-05 Cholesterol / / pha003078 rs16996381 chr22 36511279 G A 2.96E-07 Diabetic nephropathy / / 21150874 rs1476029 chr22 36517932 C T 9.97E-04 Multiple complex diseases / / 17554300 rs1476029 chr22 36517932 C T 8.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs1894605 chr22 36525981 T G 7.94E-06 Longevity,exceptional / / 20595579 rs5756080 chr22 36527967 A G 6.53E-04 Type 2 diabetes / / 17463246 rs132617 chr22 36533785 C T 2.22E-04 Gallstones / / 17632509 rs132617 chr22 36533785 C T 7.16E-05 Panic disorder / / 19165232 rs132617 chr22 36533785 C T 0.0000575 Panic disorder / / 23149450 rs132617 chr22 36533785 C T 5.75E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs61731692 chr22 36537725 G A 0.00031 Prostate cancer APOL3 cds-synon 23555315 rs3827346 chr22 36537893 A G 1.40E-05 Temporomandibular joint disorders APOL3 cds-synon 23746317 rs80575 chr22 36539754 G T 3.50E-05 Temporomandibular joint disorders APOL3 intron 23746317 rs132628 chr22 36541825 C T 1.90E-05 Urinary metabolites APOL3 intron 21572414 rs132647 chr22 36551158 T C 1.30E-05 Urinary metabolites APOL3 intron 21572414 rs148712729 chr22 36556882 T C 0.000022 Breast cancer(er negative) APOL3 missense 23555315 rs148712729 chr22 36556882 T C 0.0003 Breast cancer APOL3 missense 23555315 rs132655 chr22 36557550 C T 1.90E-05 Urinary metabolites APOL3 UTR-5 21572414 rs132660 chr22 36562236 G T 2.70E-05 Urinary metabolites / / 21572414 rs132667 chr22 36565029 G A 2.40E-05 Urinary metabolites / / 21572414 rs132700 chr22 36587704 T C 0.0006693 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) APOL4 missense 23233654 rs132700 chr22 36587704 T C 6.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) APOL4 missense 23233662 rs132717 chr22 36596652 C T 1.81E-05 Blood Pressure APOL4 intron pha003048 rs132735 chr22 36597881 G T 3.09E-05 Blood Pressure APOL4 UTR-5 pha003048 rs132746 chr22 36605391 C T 3.58E-05 Lung adenocarcinoma / / 19836008 rs132746 chr22 36605391 C T 7.54E-05 Myopia (pathological) / / 21095009 rs9610448 chr22 36608205 A G 5.27E-06 Stroke (ischemic) / / 22941190 rs4820222 chr22 36609739 C T 4.66E-06 Stroke (ischemic) / / 22941190 rs8140086 chr22 36610386 A G 4.17E-06 Stroke (ischemic) / / 22941190 rs8140384 chr22 36610571 C T 3.94E-06 Stroke (ischemic) / / 22941190 rs4479522 chr22 36612966 A G 3.23E-06 Stroke (ischemic) / / 22941190 rs4821469 chr22 36616445 T C 2.00E-19 End-stage renal disease (non-diabetic) / / 20532800 rs136145 chr22 36635967 A G 1.00E-05 Urinary metabolites APOL2 UTR-5 21572414 rs2239785 chr22 36661330 G A 5.00E-13 Glomerulosclerosis APOL1 missense 20668430 rs735854 chr22 36679058 T C 9.00E-06 optic disc size (rim) MYH9 intron 20395239 rs735853 chr22 36679215 C G 4.77E-10 Diabetic nephropathy MYH9 intron 21150874 rs735853 chr22 36679215 C G 4.59E-04 Type 2 diabetes MYH9 intron 22238593 rs875726 chr22 36691969 G A 3.50E-05 Lung adenocarcinoma MYH9 intron 22797724 rs16996648 chr22 36692752 T C 4.64E-04 Multiple complex diseases MYH9 intron 17554300 rs8138016 chr22 36702149 G A 1.61E-07 Multiple complex diseases MYH9 intron 17554300 rs1009150 chr22 36702300 C T 2.70E-05 Lung adenocarcinoma MYH9 intron 22797724 rs8136069 chr22 36722490 C A 6.98E-04 Alzheimer's disease MYH9 intron 24755620 rs4820234 chr22 36729074 A G 8.63E-04 Alzheimer's disease MYH9 intron 24755620 rs2413398 chr22 36730947 T G 9.49E-05 Schizophrenia MYH9 intron 19571811 rs1557540 chr22 36732537 C T 8.37E-04 Alzheimer's disease MYH9 intron 24755620 rs739097 chr22 36746079 G A 7.61E-04 Alzheimer's disease MYH9 intron 24755620 rs136206 chr22 36755498 A G 3.52E-04 Alzheimer's disease MYH9 intron 24755620 rs136213 chr22 36759815 A G 3.90E-04 Body mass index MYH9 intron 21701565 rs738278 chr22 36794184 G A 1.27E-04 Myopia (pathological) / / 21095009 rs909675 chr22 36844619 C A 7.36E-04 Parkinson's disease / / 17052657 rs139954 chr22 36849915 T C 8.38E-05 Myopia (pathological) / / 21095009 rs139985 chr22 36857291 G A 5.85E-05 Myopia (pathological) / / 21095009 rs146269725 chr22 36876729 T C 0.00002 Breast cancer (ER positive) TXN2 missense 23555315 rs146269725 chr22 36876729 T C 0.00011 Breast cancer TXN2 missense 23555315 rs5756219 chr22 36891858 C A 1.99E-04 Schizophrenia FOXRED2 intron 19197363 rs2076083 chr22 36912724 C T 1.90E-04 Schizophrenia EIF3D intron 21674006 rs8140240 chr22 36919343 A G 9.95E-05 Pulmonary function in asthmatics EIF3D intron 23541324 rs8140727 chr22 36933283 T C 7.64E-04 Type 2 diabetes / / 17463246 rs6000319 chr22 36934821 G A 6.46E-04 Type 2 diabetes / / 17463246 rs5750269 chr22 36941065 G A 4.48E-04 Body mass index / / 17255346 rs2267339 chr22 36966242 G T 4.50E-06 Type 2 diabetes CACNG2 intron 17463248 rs2050140 chr22 36971957 A C 4.05E-04 Lung function (forced expiratory volume in 1 second) CACNG2 intron 24023788 rs9622421 chr22 36978325 A G 1.50E-04 Multiple complex diseases CACNG2 intron 17554300 rs4820242 chr22 36982675 G A 8.59E-04 Endometrial cancer CACNG2 intron 24096698 rs926543 chr22 36989327 T G 8.30E-04 Response to taxane treatment (placlitaxel) CACNG2 intron 23006423 rs4821508 chr22 36999514 T G 3.44E-04 Height CACNG2 intron 17255346 rs6000351 chr22 37010867 G A 9.16E-24 Narcolepsy CACNG2 intron 19629137 rs6000351 chr22 37010867 G A 2.95E-05 Alcohol and nictotine co-dependence CACNG2 intron 20158304 rs12160203 chr22 37010929 G A 3.47E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CACNG2 intron 20031582 rs2283992 chr22 37015271 A T 8.30E-04 Coronary Artery Disease CACNG2 intron 17634449 rs2283993 chr22 37015329 G A 5.64E-04 Coronary Artery Disease CACNG2 intron 17634449 rs9622436 chr22 37032163 A G 8.32E-04 Multiple complex diseases CACNG2 intron 17554300 rs2179871 chr22 37091631 T C 3.61E-05 Waist Circumference CACNG2 intron pha003023 rs2284017 chr22 37096927 T C 1 Drug response to Lithium CACNG2 intron 18408563 rs2284018 chr22 37097564 C T 1 Drug response to Lithium CACNG2 intron 18408563 rs5750285 chr22 37104248 C G 1 Drug response to Lithium / / 18408563 rs715582 chr22 37117084 G A 8.20E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4821520 chr22 37135134 G T 5.36E-04 Type 2 diabetes / / 17463246 rs2009667 chr22 37171611 A G 5.91E-04 Schizophrenia IFT27 intron 19197363 rs2022068 chr22 37199806 A G 7.00E-06 Pit-and-Fissure caries PVALB intron 23470693 rs739031 chr22 37208149 G T 2.00E-06 Obesity-related traits PVALB intron 23251661 rs4820255 chr22 37209296 G C 2.00E-06 Sexual dysfunction (female) PVALB intron 22509378 rs762920 chr22 37212536 A C 3.45E-06 Obesity-related traits PVALB intron 23251661 rs762919 chr22 37230208 G A 3.23E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs131833 chr22 37239914 G A 8.90E-04 Myopia (pathological) / / 21095009 rs2269513 chr22 37243584 C T 3.91E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2269513 chr22 37243584 C T 4.96E-04 Lung function (forced vital capacity) / / 24023788 rs10211998 chr22 37244877 A G 3.30E-05 Type 2 diabetes / / 17293876 rs5756371 chr22 37245020 T C 4.20E-05 Type 2 diabetes / / 17293876 rs4821544 chr22 37258503 T C 1.75E-05 Crohn's disease NCF4 intron 17435756 rs4821544 chr22 37258503 T C 6.00E-06 Atopic dermatitis NCF4 intron 22197932 rs760519 chr22 37263706 C T 5.90E-04 Smoking initiation NCF4 intron 24665060 rs2072710 chr22 37268501 A G 5.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NCF4 intron 20877124 rs2072711 chr22 37268555 A G 5.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NCF4 intron 20877124 rs2072711 chr22 37268555 A G 6.30E-05 Multiple sclerosis NCF4 intron 21833088 rs5756391 chr22 37298344 A G 9.02E-04 Multiple complex diseases / / 17554300 rs4821558 chr22 37308785 T C 4.80E-04 Crohn's disease CSF2RB nearGene-5 23850713 rs2075726 chr22 37310046 G A 9.00E-06 Ankylosing spondylitis CSF2RB intron 22138694 rs4821564 chr22 37314290 T C 4.29E-04 Aortic root size CSF2RB intron 21223598 rs4821566 chr22 37314507 C G 2.90E-04 Smoking cessation CSF2RB intron 18519826 rs4821566 chr22 37314507 C G 3.03E-07 Smoking cessation CSF2RB intron 18519826 rs9607391 chr22 37314770 A T 7.42E-04 Multiple complex diseases CSF2RB intron 17554300 rs9607397 chr22 37315988 C T 2.34E-06 Smoking cessation CSF2RB intron 18519826 rs1534882 chr22 37329545 A G 0.00001 Endoxifen sentivity (7 uM) CSF2RB intron 23508821 rs1534882 chr22 37329545 A G 0.00005 Endoxifen sentivity (10 uM) CSF2RB intron 23508821 rs11705394 chr22 37329676 T C 3.60E-04 Coronary heart disease CSF2RB intron 21966275 rs2075937 chr22 37330082 T C 3.34E-04 Schizophrenia CSF2RB intron 19197363 rs738149 chr22 37330249 A G 0.000007 Endoxifen sentivity (7 uM) CSF2RB intron 23508821 rs738149 chr22 37330249 A G 0.00003 Endoxifen sentivity (10 uM) CSF2RB intron 23508821 rs16997510 chr22 37333406 T G 3.70E-05 Multiple complex diseases CSF2RB intron 17554300 rs131843 chr22 37337409 C T 2.07E-05 Iron status biomarkers / / 19084217 rs8137446 chr22 37347959 C T 9.90E-05 Response to statin therapy / / 20339536 rs8137446 chr22 37347959 C T 2.03E-04 Pemphigus vulgaris / / 22437316 rs4820265 chr22 37357136 C A 6.54E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs8138123 chr22 37363964 G A 8.26E-05 Erythrocyte counts LOC100506241 intron pha003099 rs6519043 chr22 37372327 G A 0.000136 Sarcoidosis / / 22952805 rs10470277 chr22 37374751 C T 5.41E-04 Multiple complex diseases / / 17554300 rs5756437 chr22 37375668 G A 8.30E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs5756444 chr22 37378451 T C 3.95E-05 Malignant pleural mesothelioma / / 23626673 rs5756453 chr22 37382250 A G 2.79E-09 Red blood cell traits / / 23222517 rs6000522 chr22 37383047 C T 0.00007727 Sarcoidosis / / 22952805 rs4821578 chr22 37383615 G A 0.00007727 Sarcoidosis / / 22952805 rs5756454 chr22 37383809 G T 9.90E-06 Urinary metabolites / / 21572414 rs2032476 chr22 37386057 G A 0.00007803 Sarcoidosis / / 22952805 rs713829 chr22 37386920 T C 0.00008604 Sarcoidosis / / 22952805 rs5750354 chr22 37387119 C G 6.40E-06 Urinary metabolites / / 21572414 rs5750354 chr22 37387119 C G 9.31E-07 Red blood cell traits / / 23222517 rs6000523 chr22 37387461 C T 0.0000941 Sarcoidosis TEX33 intron 22952805 rs2001060 chr22 37391997 G T 7.22E-07 Red blood cell traits TEX33 intron 23222517 rs146129761 chr22 37396024 G C 0.0008 Prostate cancer TEX33 missense 23555315 rs916213 chr22 37397550 T C 2.71E-12 Red blood cell traits TEX33 intron 23222517 rs12628330 chr22 37398642 G T 6.59E-07 Red blood cell traits TEX33 intron 23222517 rs2413441 chr22 37400560 C G,T 0.0007002 Sarcoidosis TEX33 intron 22952805 rs2413443 chr22 37401051 C T 7.72E-11 Red blood cell traits TEX33 intron 23222517 rs2413444 chr22 37401101 G A 0.0005058 Sarcoidosis TEX33 intron 22952805 rs2413447 chr22 37401532 G A 3.33E-09 Red blood cell traits TEX33 intron 23222517 rs738986 chr22 37401792 G T 1.40E-10 Red blood cell traits TEX33 intron 23222517 rs5750364 chr22 37402211 A G 6.67E-11 Red blood cell traits TEX33 intron 23222517 rs2413448 chr22 37402780 G T 5.79E-11 Red blood cell traits TEX33 intron 23222517 rs130596 chr22 37402819 T C 3.63E-09 Other erythrocyte phenotypes TEX33 intron 19862010 rs130596 chr22 37402819 T C 4.47E-07 Red blood cell traits TEX33 intron 23222517 rs2413449 chr22 37402910 A G 0.0004335 Sarcoidosis TEX33 intron 22952805 rs2413449 chr22 37402910 A G 3.27E-11 Red blood cell traits TEX33 intron 23222517 rs5756470 chr22 37403302 C T 0.000545 Sarcoidosis TEX33 intron 22952805 rs5756470 chr22 37403302 C T 3.57E-11 Red blood cell traits TEX33 intron 23222517 rs5756471 chr22 37404249 G A 0.000432 Sarcoidosis / / 22952805 rs5756471 chr22 37404249 G A 1.24E-08 Red blood cell traits / / 23222517 rs6000532 chr22 37404837 G A 3.13E-11 Red blood cell traits / / 23222517 rs9610629 chr22 37405630 C T 4.39E-08 Other erythrocyte phenotypes / / 19862010 rs9610629 chr22 37405630 C T 2.28E-14 Red blood cell traits / / 23222517 rs9610630 chr22 37405865 C T 4.54E-08 Other erythrocyte phenotypes / / 19862010 rs9610630 chr22 37405865 C T 5.23E-15 Red blood cell traits / / 23222517 rs2157152 chr22 37405911 A C 2.84E-08 Other erythrocyte phenotypes / / 19862010 rs2157152 chr22 37405911 A C 3.44E-14 Red blood cell traits / / 23222517 rs2187724 chr22 37406257 T G 9.66E-10 Red blood cell traits / / 23222517 rs6000533 chr22 37406334 T C 5.16E-15 Red blood cell traits / / 23222517 rs5750366 chr22 37406401 G T 6.79E-12 Red blood cell traits / / 23222517 rs5756477 chr22 37407527 T C 4.97E-08 Other erythrocyte phenotypes TST intron 19862010 rs5756477 chr22 37407527 T C 1.68E-14 Red blood cell traits TST intron 23222517 rs130598 chr22 37408135 T C 4.27E-13 Red blood cell traits TST intron 23222517 rs130599 chr22 37408719 T C 6.63E-13 Red blood cell traits TST intron 23222517 rs130607 chr22 37410967 T C 3.35E-09 Red blood cell traits TST intron 23222517 rs5750370 chr22 37412967 G A 2.91E-08 Red blood cell traits TST intron 23222517 rs3753145 chr22 37423486 T G 4.43E-07 Red blood cell traits MPST intron 23222517 rs8141597 chr22 37424848 T C 1.47E-08 Other erythrocyte phenotypes MPST intron 19862010 rs8141597 chr22 37424848 T C 1.00E-10 Mean corpuscular volume MPST intron 22560525 rs8141597 chr22 37424848 T C 8.00E-11 Mean corpuscular hemoglobin MPST intron 22560525 rs8141597 chr22 37424848 T C 4.44E-09 Red blood cell traits MPST intron 23222517 rs5756492 chr22 37424991 G A 1.43E-07 Red blood cell traits MPST intron 23222517 rs5750373 chr22 37425031 G A 3.50E-08 Hemoglobin MPST intron 19820698 rs5750373 chr22 37425031 G A 6.25E-09 Other erythrocyte phenotypes MPST intron 19862010 rs5750373 chr22 37425031 G A 4.16E-15 Red blood cell traits MPST intron 23222517 rs228129 chr22 37428599 A G 1.78E-12 Other erythrocyte phenotypes / / 19862010 rs228129 chr22 37428599 A G 2.40E-08 Iron status biomarkers / / 21149283 rs228129 chr22 37428599 A G 0.00000002 Hemoglobin / / 22560525 rs228129 chr22 37428599 A G 3.00E-16 Mean corpuscular hemoglobin / / 22560525 rs228129 chr22 37428599 A G 4.00E-12 Mean corpuscular volume / / 22560525 rs228129 chr22 37428599 A G 1.17E-17 Red blood cell traits / / 23222517 rs228129 chr22 37428599 A G 1.33E-04 Iron levels / / pha002876 rs135167 chr22 37429129 C T 1.13E-13 Other erythrocyte phenotypes / / 19862010 rs135167 chr22 37429129 C T 1.51E-17 Red blood cell traits / / 23222517 rs25095 chr22 37434028 G A 1.34E-13 Other erythrocyte phenotypes / / 19862010 rs25095 chr22 37434028 G A 1.57E-23 Red blood cell traits / / 23222517 rs130618 chr22 37435443 T A 1.15E-13 Other erythrocyte phenotypes / / 19862010 rs130618 chr22 37435443 T A 2.34E-23 Red blood cell traits / / 23222517 rs2160907 chr22 37435900 A G 2.77E-10 Red blood cell traits / / 23222517 rs130619 chr22 37436348 T C 1.20E-13 Other erythrocyte phenotypes / / 19862010 rs130619 chr22 37436348 T C 2.03E-24 Red blood cell traits / / 23222517 rs130624 chr22 37438651 G T 3.70E-12 Other erythrocyte phenotypes / / 19862010 rs130624 chr22 37438651 G T 3.63E-08 Iron status biomarkers / / 21149283 rs130624 chr22 37438651 G T 1.00E-19 Mean corpuscular hemoglobin / / 22560525 rs130624 chr22 37438651 G T 4.00E-15 Mean corpuscular volume / / 22560525 rs130624 chr22 37438651 G T 8.00E-10 Hemoglobin / / 22560525 rs130624 chr22 37438651 G T 3.03E-18 Red blood cell traits / / 23222517 rs130624 chr22 37438651 G T 1.87E-04 Iron levels / / pha002876 rs7285681 chr22 37439701 G C 6.84E-08 Red blood cell traits / / 23222517 rs11913810 chr22 37447046 G C 9.83E-07 Red blood cell traits / / 23222517 rs2235320 chr22 37453256 G T 1.00E-13 Mean corpuscular volume KCTD17 intron 22560525 rs2235320 chr22 37453256 G T 7.00E-17 Mean corpuscular hemoglobin KCTD17 intron 22560525 rs2235320 chr22 37453256 G T 2.84E-08 Red blood cell traits KCTD17 intron 23222517 rs2235320 chr22 37453256 G T 3.29E-04 Iron levels KCTD17 intron pha002876 rs2235321 chr22 37462926 G A 1.32E-12 Other erythrocyte phenotypes TMPRSS6 cds-synon 19862010 rs2235321 chr22 37462926 G A 4.57E-10 Iron status biomarkers TMPRSS6 cds-synon 21149283 rs2235321 chr22 37462926 G A 1.49E-10 Red blood cell traits TMPRSS6 cds-synon 23222517 rs855791 chr22 37462936 A G 1.79E-05 Iron status biomarkers TMPRSS6 missense 19084217 rs855791 chr22 37462936 A G 2.00E-13 Hemoglobin TMPRSS6 missense 19820698 rs855791 chr22 37462936 A G 1.00E-10 Iron status biomarkers TMPRSS6 missense 19820699 rs855791 chr22 37462936 A G 5.00E-07 Iron status biomarkers TMPRSS6 missense 19820699 rs855791 chr22 37462936 A G 3.00E-25 Hemoglobin TMPRSS6 missense 19862010 rs855791 chr22 37462936 A G 3.93E-07 Iron levels TMPRSS6 missense 19880490 rs855791 chr22 37462936 A G 1.22E-15 Blood cell counts and other traits TMPRSS6 missense 20139978 rs855791 chr22 37462936 A G 4.82E-10 Blood cell counts and other traits TMPRSS6 missense 20139978 rs855791 chr22 37462936 A G 4.84E-25 Blood cell counts and other traits TMPRSS6 missense 20139978 rs855791 chr22 37462936 A G 5.00E-25 Blood cell counts and other traits TMPRSS6 missense 20139978 rs855791 chr22 37462936 A G 7.73E-14 Blood cell counts and other traits TMPRSS6 missense 20139978 rs855791 chr22 37462936 A G 3.00E-14 Glycated Hemoglobin levels TMPRSS6 missense 20858683 rs855791 chr22 37462936 A G 1.00E-12 Red blood cell traits TMPRSS6 missense 20927387 rs855791 chr22 37462936 A G 5.00E-09 Red blood cell traits TMPRSS6 missense 20927387 rs855791 chr22 37462936 A G 2.00E-15 Iron status biomarkers TMPRSS6 missense 21149283 rs855791 chr22 37462936 A G 4.00E-09 Hepcidin levels TMPRSS6 missense 21785125 rs855791 chr22 37462936 A G 5.00E-07 Hepcidin levels TMPRSS6 missense 21785125 rs855791 chr22 37462936 A G 9.00E-11 Hepcidin levels TMPRSS6 missense 21785125 rs855791 chr22 37462936 A G 1.00E-15 Mean corpuscular hemoglobin concentration TMPRSS6 missense 22560525 rs855791 chr22 37462936 A G 2.00E-31 Mean corpuscular volume TMPRSS6 missense 22560525 rs855791 chr22 37462936 A G 5.00E-11 Hemoglobin TMPRSS6 missense 22560525 rs855791 chr22 37462936 A G 9.00E-41 Mean corpuscular hemoglobin TMPRSS6 missense 22560525 rs855791 chr22 37462936 A G 2.74E-14 Glycated hemoglobin levels TMPRSS6 missense 22885924 rs855791 chr22 37462936 A G 1.00E-69 Red blood cell traits TMPRSS6 missense 23222517 rs855791 chr22 37462936 A G 2.00E-06 Mean corpuscular hemoglobin TMPRSS6 missense 23263863 rs855791 chr22 37462936 A G 2.00E-09 Mean corpuscular volume TMPRSS6 missense 23263863 rs855791 chr22 37462936 A G 3.00E-08 Hematology traits TMPRSS6 missense 23263863 rs855791 chr22 37462936 A G 4.00E-07 Mean corpuscular hemoglobin concentration TMPRSS6 missense 23263863 rs855791 chr22 37462936 A G 5.00E-14 Mean corpuscular hemoglobin TMPRSS6 missense 23263863 rs855791 chr22 37462936 A G 7.00E-12 Mean corpuscular volume TMPRSS6 missense 23263863 rs855791 chr22 37462936 A G 7.00E-19 Mean corpuscular hemoglobin TMPRSS6 missense 23263863 rs855791 chr22 37462936 A G 2.35E-04 Glycated hemoglobin levels TMPRSS6 missense 24244560 rs855791 chr22 37462936 A G 3.93E-07 Iron levels TMPRSS6 missense pha002876 rs5756504 chr22 37467270 C T 6.65E-12 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs5756504 chr22 37467270 C T 8.90E-05 Iron levels TMPRSS6 intron 19880490 rs5756504 chr22 37467270 C T 1.64E-10 Blood cell counts and other traits TMPRSS6 intron 20139978 rs5756504 chr22 37467270 C T 2.00E-10 Blood cell counts and other traits TMPRSS6 intron 20139978 rs5756504 chr22 37467270 C T 3.04E-08 Iron status biomarkers TMPRSS6 intron 21149283 rs5756504 chr22 37467270 C T 1.00E-19 Mean corpuscular hemoglobin TMPRSS6 intron 22560525 rs5756504 chr22 37467270 C T 2.00E-15 Mean corpuscular volume TMPRSS6 intron 22560525 rs5756504 chr22 37467270 C T 1.56E-21 Red blood cell traits TMPRSS6 intron 23222517 rs5756504 chr22 37467270 C T 8.90E-05 Iron levels TMPRSS6 intron pha002876 rs5756505 chr22 37467354 G C 2.14E-15 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs5756505 chr22 37467354 G C 7.87E-10 Iron status biomarkers TMPRSS6 intron 21149283 rs5756505 chr22 37467354 G C 5.09E-23 Red blood cell traits TMPRSS6 intron 23222517 rs5756506 chr22 37467392 G C 1.00E-09 Hematological parameters TMPRSS6 intron 19820697 rs5756506 chr22 37467392 G C 7.93E-12 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs5756506 chr22 37467392 G C 9.29E-20 Blood cell counts and other traits TMPRSS6 intron 20139978 rs5756506 chr22 37467392 G C 9.79E-09 Iron status biomarkers TMPRSS6 intron 21149283 rs5756506 chr22 37467392 G C 8.41E-18 Red blood cell traits TMPRSS6 intron 23222517 rs4820268 chr22 37469591 G A 6.00E-06 Iron status biomarkers TMPRSS6 cds-synon 19084217 rs4820268 chr22 37469591 G A 1.98E-13 Hemoglobin TMPRSS6 cds-synon 19820698 rs4820268 chr22 37469591 G A 3.00E-10 Hematology traits TMPRSS6 cds-synon 19853236 rs4820268 chr22 37469591 G A 4.00E-12 Hematology traits TMPRSS6 cds-synon 19853236 rs4820268 chr22 37469591 G A 1.25E-25 Other erythrocyte phenotypes TMPRSS6 cds-synon 19862010 rs4820268 chr22 37469591 G A 5.00E-09 Iron levels TMPRSS6 cds-synon 19880490 rs4820268 chr22 37469591 G A 1.00E-12 Red blood cell traits TMPRSS6 cds-synon 20927387 rs4820268 chr22 37469591 G A 1.33E-14 Iron status biomarkers TMPRSS6 cds-synon 21149283 rs4820268 chr22 37469591 G A 4.00E-11 Iron levels TMPRSS6 cds-synon 21208937 rs4820268 chr22 37469591 G A 0.000000003 Hemoglobin TMPRSS6 cds-synon 22560525 rs4820268 chr22 37469591 G A 1.00E-38 Mean corpuscular hemoglobin TMPRSS6 cds-synon 22560525 rs4820268 chr22 37469591 G A 2.00E-14 Mean corpuscular hemoglobin concentration TMPRSS6 cds-synon 22560525 rs4820268 chr22 37469591 G A 3.00E-29 Mean corpuscular volume TMPRSS6 cds-synon 22560525 rs4820268 chr22 37469591 G A 1.15E-31 Red blood cell traits TMPRSS6 cds-synon 23222517 rs4820268 chr22 37469591 G A 1.58E-05 Platelet counts TMPRSS6 cds-synon 23263863 rs4820268 chr22 37469591 G A 6.00E-07 Iron levels TMPRSS6 cds-synon pha002876 rs13055107 chr22 37469821 G A 3.46E-10 Red blood cell traits TMPRSS6 intron 23222517 rs2413450 chr22 37470224 T C 1.96E-13 Hemoglobin TMPRSS6 intron 19820698 rs2413450 chr22 37470224 T C 2.00E-13 Hematocrit TMPRSS6 intron 19862010 rs2413450 chr22 37470224 T C 3.00E-41 Mean corpuscular volume TMPRSS6 intron 19862010 rs2413450 chr22 37470224 T C 9.00E-34 Mean corpuscular hemoglobin TMPRSS6 intron 19862010 rs2413450 chr22 37470224 T C 1.16E-19 Blood cell counts and other traits TMPRSS6 intron 20139978 rs2413450 chr22 37470224 T C 2.76E-11 Blood cell counts and other traits TMPRSS6 intron 20139978 rs2413450 chr22 37470224 T C 5.00E-06 Blood cell counts and other traits TMPRSS6 intron 20139978 rs2413450 chr22 37470224 T C 5.33E-06 Blood cell counts and other traits TMPRSS6 intron 20139978 rs2413450 chr22 37470224 T C 1.06E-13 Iron status biomarkers TMPRSS6 intron 21149283 rs2413450 chr22 37470224 T C 4.41E-31 Red blood cell traits TMPRSS6 intron 23222517 rs2413450 chr22 37470224 T C 4.00E-07 Red blood cell traits TMPRSS6 intron 23935956 rs2413450 chr22 37470224 T C 9.00E-06 Red blood cell traits TMPRSS6 intron 23935956 rs855788 chr22 37474079 G A 9.48E-10 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs855788 chr22 37474079 G A 2.00E-14 Mean corpuscular hemoglobin TMPRSS6 intron 22560525 rs855788 chr22 37474079 G A 3.00E-10 Mean corpuscular volume TMPRSS6 intron 22560525 rs855788 chr22 37474079 G A 3.13E-16 Red blood cell traits TMPRSS6 intron 23222517 rs17750017 chr22 37476569 T A 1.31E-04 Coronary Artery Disease TMPRSS6 intron 17634449 rs2743820 chr22 37477970 T C 2.74E-14 Red blood cell traits TMPRSS6 intron 23222517 rs7286184 chr22 37478775 A G 1.58E-08 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs7286184 chr22 37478775 A G 8.65E-12 Red blood cell traits TMPRSS6 intron 23222517 rs2543519 chr22 37480269 A G 8.24E-08 Red blood cell traits TMPRSS6 intron 23222517 rs2111833 chr22 37480797 C T 5.21E-14 Red blood cell traits TMPRSS6 cds-synon 23222517 rs2235323 chr22 37485193 T C 9.98E-09 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs2235323 chr22 37485193 T C 4.02E-15 Red blood cell traits TMPRSS6 intron 23222517 rs2235324 chr22 37485724 T C 0.000000004 Mean corpuscular volume TMPRSS6 missense 22560525 rs2235324 chr22 37485724 T C 1.00E-12 Mean corpuscular hemoglobin TMPRSS6 missense 22560525 rs2235324 chr22 37485724 T C 8.16E-14 Red blood cell traits TMPRSS6 missense 23222517 rs736852 chr22 37486205 T C 5.64E-12 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs736852 chr22 37486205 T C 7.96E-18 Red blood cell traits TMPRSS6 intron 23222517 rs2019848 chr22 37486265 G A 3.45E-08 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs2019848 chr22 37486265 G A 2.11E-16 Red blood cell traits TMPRSS6 intron 23222517 rs1421312 chr22 37487810 A G 3.45E-08 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs1421312 chr22 37487810 A G 0.000000002 Mean corpuscular volume TMPRSS6 intron 22560525 rs1421312 chr22 37487810 A G 4.00E-13 Mean corpuscular hemoglobin TMPRSS6 intron 22560525 rs1421312 chr22 37487810 A G 3.94E-17 Red blood cell traits TMPRSS6 intron 23222517 rs2543514 chr22 37489274 G C 5.12E-12 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs2543514 chr22 37489274 G C 7.87E-18 Red blood cell traits TMPRSS6 intron 23222517 rs2543513 chr22 37490396 A G 5.38E-12 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs2543513 chr22 37490396 A G 1.42E-20 Red blood cell traits TMPRSS6 intron 23222517 rs2413451 chr22 37490691 A G 4.38E-12 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs2413451 chr22 37490691 A G 1.66E-20 Red blood cell traits TMPRSS6 intron 23222517 rs2251655 chr22 37490692 C T 4.29E-12 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs2251655 chr22 37490692 C T 1.61E-20 Red blood cell traits TMPRSS6 intron 23222517 rs2743824 chr22 37491545 T C 4.95E-12 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs2743824 chr22 37491545 T C 1.67E-18 Red blood cell traits TMPRSS6 intron 23222517 rs2543509 chr22 37491839 A G 4.51E-12 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs2543509 chr22 37491839 A G 2.59E-14 Red blood cell traits TMPRSS6 intron 23222517 rs2743825 chr22 37492201 T G 1.75E-12 Red blood cell traits TMPRSS6 intron 23222517 rs2160906 chr22 37493178 G A 0.000000003 Mean corpuscular hemoglobin concentration TMPRSS6 intron 22560525 rs2160906 chr22 37493178 G A 1.00E-12 Mean corpuscular hemoglobin TMPRSS6 intron 22560525 rs2160906 chr22 37493178 G A 1.31E-14 Red blood cell traits TMPRSS6 intron 23222517 rs732755 chr22 37494318 T C 4.94E-09 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs732755 chr22 37494318 T C 5.61E-16 Red blood cell traits TMPRSS6 intron 23222517 rs8139988 chr22 37494721 T C 3.75E-09 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs8139988 chr22 37494721 T C 5.36E-16 Red blood cell traits TMPRSS6 intron 23222517 rs228904 chr22 37494814 A G 0.000000004 Mean corpuscular hemoglobin concentration TMPRSS6 intron 22560525 rs228904 chr22 37494814 A G 8.00E-13 Mean corpuscular hemoglobin TMPRSS6 intron 22560525 rs2017764 chr22 37494915 G A 2.22E-09 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs2017764 chr22 37494915 G A 6.80E-16 Red blood cell traits TMPRSS6 intron 23222517 rs733655 chr22 37495051 T C 1.36E-11 Red blood cell traits TMPRSS6 intron 23222517 rs2281090 chr22 37495370 G A 4.94E-09 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs2281090 chr22 37495370 G A 3.09E-16 Red blood cell traits TMPRSS6 intron 23222517 rs2281091 chr22 37495550 C T 4.74E-09 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs2281091 chr22 37495550 C T 1.02E-13 Red blood cell traits TMPRSS6 intron 23222517 rs7289616 chr22 37496410 G A 2.87E-09 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs7289616 chr22 37496410 G A 1.48E-16 Red blood cell traits TMPRSS6 intron 23222517 rs9619658 chr22 37496847 C T 3.62E-09 Other erythrocyte phenotypes TMPRSS6 intron 19862010 rs9619658 chr22 37496847 C T 9.36E-14 Red blood cell traits TMPRSS6 intron 23222517 rs228907 chr22 37497593 G A 8.98E-05 Parkinson's disease TMPRSS6 intron 17052657 rs228907 chr22 37497593 G A 2.45E-10 Hemoglobin TMPRSS6 intron 19820698 rs17750152 chr22 37498026 C T 1.19E-09 Red blood cell traits TMPRSS6 intron 23222517 rs4140590 chr22 37498731 G A 1.42E-09 Red blood cell traits TMPRSS6 intron 23222517 rs4140589 chr22 37499019 G A 2.20E-10 Red blood cell traits TMPRSS6 intron 23222517 rs5756515 chr22 37499692 A G 6.17E-08 Red blood cell traits TMPRSS6 UTR-5 23222517 rs2235329 chr22 37502423 T C 3.95E-11 Red blood cell traits / / 23222517 rs228913 chr22 37504157 A C 7.99E-04 Parkinson's disease / / 17052657 rs228918 chr22 37506680 T C 4.37E-10 Hemoglobin / / 19820698 rs228918 chr22 37506680 T C 3.55E-10 Red blood cell traits / / 23222517 rs228919 chr22 37506713 G T 4.39E-10 Hemoglobin / / 19820698 rs228919 chr22 37506713 G T 2.62E-10 Red blood cell traits / / 23222517 rs228921 chr22 37506876 A G 1.89E-10 Hemoglobin / / 19820698 rs228921 chr22 37506876 A G 3.01E-13 Red blood cell traits / / 23222517 rs5756520 chr22 37508507 G A 2.72E-10 Hemoglobin / / 19820698 rs5756520 chr22 37508507 G A 5.94E-10 Red blood cell traits / / 23222517 rs11914132 chr22 37509087 C T 3.54E-08 Hemoglobin / / 19820698 rs11914132 chr22 37509087 C T 6.80E-15 Red blood cell traits / / 23222517 rs11089823 chr22 37509179 T C 2.41E-08 Hemoglobin / / 19820698 rs11089823 chr22 37509179 T C 2.85E-09 Other erythrocyte phenotypes / / 19862010 rs11089823 chr22 37509179 T C 3.67E-11 Red blood cell traits / / 23222517 rs11089824 chr22 37509186 A C 2.41E-08 Hemoglobin / / 19820698 rs11089824 chr22 37509186 A C 2.96E-09 Other erythrocyte phenotypes / / 19862010 rs11089824 chr22 37509186 A C 6.42E-16 Red blood cell traits / / 23222517 rs926331 chr22 37510072 C T 6.02E-08 Red blood cell traits / / 23222517 rs763668 chr22 37511076 C G 2.02E-08 Hemoglobin / / 19820698 rs763668 chr22 37511076 C G 4.44E-09 Other erythrocyte phenotypes / / 19862010 rs763668 chr22 37511076 C G 5.10E-07 Red blood cell traits / / 23222517 rs6000570 chr22 37514339 G A 3.06E-07 Red blood cell traits / / 23222517 rs228942 chr22 37524619 G T 8.17E-05 Post-operative nausea and vomiting IL2RB missense 21694509 rs228947 chr22 37526529 G A 1.53E-05 Post-operative nausea and vomiting IL2RB intron 21694509 rs3218315 chr22 37529724 G A 9.13E-04 Depression (quantitative trait) IL2RB intron 20800221 rs3218315 chr22 37529724 G A 6.30E-09 Post-operative nausea and vomiting IL2RB intron 21694509 rs3218312 chr22 37530332 A G 7.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) IL2RB intron 20877124 rs3218312 chr22 37530332 A G 8.78E-05 Cognitive impairment induced by topiramate IL2RB intron 22091778 rs228954 chr22 37532665 T C 9.75E-04 Depression (quantitative trait) IL2RB intron 20800221 rs3218355 chr22 37532954 G A 1.74E-05 HIV-1 control IL2RB intron 20041166 rs228956 chr22 37533143 T C 0.00000215 Cholesterol,total IL2RB intron 23063622 rs228957 chr22 37533786 C G 4.23E-04 Depression (quantitative trait) IL2RB intron 20800221 rs2284033 chr22 37534034 G A 6.05E-04 Depression (quantitative trait) IL2RB intron 20800221 rs2284033 chr22 37534034 G A 1.00E-08 Asthma IL2RB intron 20860503 rs2284033 chr22 37534034 G A 1.20E-08 Asthma IL2RB intron 21907864 rs2284033 chr22 37534034 G A 1.20E-08 Asthma IL2RB intron 22561531 rs2284033 chr22 37534034 G A 0.000000599 Oligoarticular juvenile idiopathic arthritis IL2RB intron 23603761 rs2284033 chr22 37534034 G A 1.55E-08 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) IL2RB intron 23603761 rs2281094 chr22 37535471 C T 6.52E-06 Post-operative nausea and vomiting IL2RB intron 21694509 rs228963 chr22 37535948 A G 9.48E-04 Depression (quantitative trait) IL2RB intron 20800221 rs397960003 chr22 37535948 A AG 9.48E-04 Depression (quantitative trait) IL2RB intron 20800221 rs228966 chr22 37537514 T C 9.55E-04 Depression (quantitative trait) IL2RB intron 20800221 rs3218258 chr22 37544245 G A 5.18E-06 Tuberculosis IL2RB intron 24057671 rs3218255 chr22 37544486 G A 2.00E-07 Tuberculosis IL2RB intron 24057671 rs3218253 chr22 37544810 G A 8.70E-04 Type 2 diabetes IL2RB intron 17463246 rs3218253 chr22 37544810 G A 4.09E-06 Multiple complex diseases IL2RB intron 17554300 rs3218253 chr22 37544810 G A 0.00000001 Rheumatoid arthritis IL2RB intron 23143596 rs3218253 chr22 37544810 G A 2.51E-04 Rheumatoid arthritis IL2RB intron 24449572 rs3218251 chr22 37545505 T A 0.000000191 Rheumatoid arthritis (CCP positive) IL2RB intron 23143596 rs3218251 chr22 37545505 T A 0.00000019 Rheumatoid arthritis IL2RB intron 23143596 rs3218251 chr22 37545505 T A 2.10E-05 Rheumatoid arthritis IL2RB intron 24390342 rs3218251 chr22 37545505 T A 6.00E-06 Rheumatoid arthritis IL2RB intron 24390342 rs6000582 chr22 37547494 G T 0.000000012 Triglycerides / / 23063622 rs6000582 chr22 37547494 G T 8.57E-10 HDL cholesterol / / 23063622 rs743777 chr22 37551607 A G 1.00E-06 Rheumatoid arthritis / / 17554300 rs743777 chr22 37551607 A G 3.00E-10 Celiac disease and Rheumatoid arthritis / / 21383967 rs743777 chr22 37551607 A G 2.00E-06 Rheumatoid arthritis / / 21653640 rs743777 chr22 37551607 A G 2.00E-06 Type 1 diabetes autoantibodies / / 21829393 rs743777 chr22 37551607 A G 3.00E-10 Multiple sclerosis / / 22190364 rs743779 chr22 37552237 A G 5.74E-05 HIV-1 viral setpoint / / 22174851 rs229484 chr22 37554839 C G 3.59E-06 Type 1 diabetes / / 19966805 rs229492 chr22 37560592 C T 2.63E-05 Parkinson's disease / / 17052657 rs16997854 chr22 37562146 C T 6.58E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs12171227 chr22 37562467 G A 6.79E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs12167757 chr22 37567490 G A 5.76E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs11089825 chr22 37575398 C T 5.90E-04 Multiple complex diseases / / 17554300 rs4821595 chr22 37575977 G A 8.68E-04 Heart Failure / / pha002885 rs229526 chr22 37581422 G C 8.33E-08 Type 1 diabetes C1QTNF6 missense 21980299 rs229526 chr22 37581422 G C 9.00E-06 Hypothyroidism C1QTNF6 missense 22493691 rs229527 chr22 37581485 C A 2.00E-16 Vitiligo C1QTNF6 missense 20410501 rs229527 chr22 37581485 C A 4.36E-09 Vitiligo C1QTNF6 missense 21326295 rs229527 chr22 37581485 C A 6.43E-17 Vitiligo C1QTNF6 missense 22561518 rs229527 chr22 37581485 C A 5.00E-20 Graves' disease C1QTNF6 missense 23612905 rs229527 chr22 37581485 C A 5.96E-05 Response to methotrexate in juvenile idiopathic arthritis C1QTNF6 missense 24709693 rs2160908 chr22 37586792 C T 5.00E-06 Parasitemia in Tripanosoma cruzi seropositivity / / 24324551 rs5756546 chr22 37589805 C T 1.12E-04 Vitiligo / / 20410501 rs5756546 chr22 37589805 C T 8.30E-05 Hypothyroidism / / 22493691 rs229540 chr22 37591290 T G 4.13E-07 Multiple complex diseases / / 17554300 rs229540 chr22 37591290 T G 2.28E-05 Type 1 diabetes / / 18978792 rs229541 chr22 37591318 G A 3.39E-07 Multiple complex diseases / / 17554300 rs229541 chr22 37591318 G A 2.00E-08 Type 1 diabetes / / 18978792 rs229541 chr22 37591318 G A 2.00E-07 Type 1 diabetes / / 19430480 rs229541 chr22 37591318 G A 2.00E-08 Multiple sclerosis / / 22190364 rs16997923 chr22 37598826 G A 1.37E-04 Multiple complex diseases / / 17554300 rs229562 chr22 37599065 G T 7.78E-04 Multiple complex diseases / / 17554300 rs13053175 chr22 37613309 C T 1.00E-06 Longevity / / 20834067 rs6572 chr22 37621445 C G 6.90E-05 Immunoglobulin A RAC2 UTR-3 20694011 rs2284037 chr22 37626102 A G 1.14E-04 Pancreatic cancer RAC2 intron pha002874 rs12170612 chr22 37632180 G T 4.11E-04 Alzheimer's disease RAC2 intron 24755620 rs2284038 chr22 37635055 A G 5.98E-06 Brain infarcts,covert MRI-defined RAC2 intron 20044523 rs2284038 chr22 37635055 A G 6.40E-08 Graves' disease RAC2 intron 23612905 rs5750402 chr22 37661288 C A 3.90E-05 Major depressive disorder / / 21042317 rs4820279 chr22 37666786 C T 1.94E-04 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs4820279 chr22 37666786 C T 4.60E-05 Major depressive disorder / / 21042317 rs739036 chr22 37671677 C T 2.02E-04 Schizophrenia / / 19197363 rs4820280 chr22 37673107 C T 5.43E-06 Socioeconomic Factors / / pha003067 rs2267364 chr22 37677404 T C 4.39E-04 Parkinson's disease / / 17052657 rs727048 chr22 37677892 T C 5.03E-04 Parkinson's disease / / 17052657 rs727048 chr22 37677892 T C 9.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs8141057 chr22 37677949 C A 8.88E-05 Cognitive test performance / / 20125193 rs3213556 chr22 37678551 A G 6.62E-04 Parkinson's disease CYTH4 UTR-5 17052657 rs3213556 chr22 37678551 A G 7.86E-04 Suicide attempts in bipolar disorder CYTH4 UTR-5 21423239 rs10084630 chr22 37679487 C G,T 9.00E-06 Response to methotrexate in juvenile idiopathic arthritis CYTH4 intron 24709693 rs1041894 chr22 37679671 C T 5.24E-05 Cognitive test performance CYTH4 intron 20125193 rs1981476 chr22 37717819 A T 3.68E-04 Type 2 diabetes / / 17463246 rs1008184 chr22 37720268 A G 6.56E-04 Acute lung injury / / 22295056 rs713939 chr22 37726660 T C 8.45E-04 Acute lung injury / / 22295056 rs739187 chr22 37728254 T C 6.69E-04 Acute lung injury / / 22295056 rs7292549 chr22 37729706 T A 1.68E-04 Acute lung injury / / 22295056 rs5756636 chr22 37735969 G A 3.17E-05 Acute lung injury / / 22295056 rs4821633 chr22 37738621 G A 1.98E-05 Acute lung injury / / 22295056 rs4821638 chr22 37751698 A G 5.37E-05 Information processing speed / / 21130836 rs739189 chr22 37753999 C A 2.28E-05 Reading and spelling / / 23738518 rs739189 chr22 37753999 C A 8.23E-05 Response to methotrexate in juvenile idiopathic arthritis / / 24709693 rs5756670 chr22 37799369 A G 0.0000136 Major depressive disorder ELFN2 intron 23149448 rs6000718 chr22 37800000 A G 8.67E-04 Suicide attempts in bipolar disorder ELFN2 intron 21041247 rs4821667 chr22 37830081 C A 4.35E-04 Tourette syndrome / / 22889924 rs11912853 chr22 37831611 G T 7.36E-04 Multiple complex diseases / / 17554300 rs2097454 chr22 37843260 C T 5.35E-04 Alzheimer's disease / / 24755620 rs3788527 chr22 37865057 G A 5.71E-04 Type 2 diabetes / / 17463246 rs5750446 chr22 37902926 G A 2.66E-04 Blood pressure CARD10 intron 17255346 rs5750446 chr22 37902926 G A 8.74E-05 Coronary heart disease CARD10 intron pha003031 rs9607469 chr22 37919267 G A 3.00E-12 Optic disc parameters / / 21307088 rs6000782 chr22 37928186 A C 3.00E-06 Autoimmune hepatitis type-1 / / 24768677 rs78578442 chr22 37939252 G A 0.00007889 Sarcoidosis / / 22952805 rs61081870 chr22 37943636 C G 0.00005397 Sarcoidosis / / 22952805 rs7292090 chr22 37944409 A C 0.00001946 Sarcoidosis / / 22952805 rs6000794 chr22 37944798 A G 0.00002196 Sarcoidosis / / 22952805 rs8138262 chr22 37945142 C T 0.00002722 Sarcoidosis / / 22952805 rs7288824 chr22 37945608 G A 0.00001945 Sarcoidosis / / 22952805 rs6000795 chr22 37945952 C T 0.00001477 Sarcoidosis / / 22952805 rs6000796 chr22 37946031 A G 0.00001297 Sarcoidosis / / 22952805 rs10427553 chr22 37946292 G A 0.000008579 Sarcoidosis / / 22952805 rs73418131 chr22 37946767 G C 0.0000241 Sarcoidosis / / 22952805 rs7284882 chr22 37946940 A G 0.00005467 Sarcoidosis / / 22952805 rs5995458 chr22 37947369 A T 0.00002185 Sarcoidosis / / 22952805 rs4821670 chr22 37970866 T C 7.42E-05 Alcohol dependence LGALS2 intron 21703634 rs4821670 chr22 37970866 T C 6.68E-05 Receptive language ability LGALS2 intron 24687471 rs5750457 chr22 37976791 T C 1.00E-04 Cognitive impairment induced by topiramate LGALS2 nearGene-5 22091778 rs12157904 chr22 37982012 A C 2.00E-06 Response to antidepressant treatment / / 22041458 rs4547623 chr22 37992704 G A 6.11E-05 Warfarin maintenance dose / / 19300499 rs4547623 chr22 37992704 G A 5.13E-05 Rheumatoid arthritis / / 21452313 rs3761442 chr22 38003070 C T 3.91E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs9622658 chr22 38003624 C T 8.51E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7290615 chr22 38005877 C T 1.30E-05 Urinary metabolites GGA1 intron 21572414 rs2294972 chr22 38010035 A C 7.33E-04 Response to cytidine analogues (gemcitabine) GGA1 intron 24483146 rs713977 chr22 38040842 C T 8.77E-04 White matter integrity SH3BP1 intron 22425255 rs8138057 chr22 38061544 G A 1.23E-21 Cholesterol,total PDXP intron 23063622 rs8138057 chr22 38061544 G A 1.44E-08 Triglycerides PDXP intron 23063622 rs8138057 chr22 38061544 G A 2.11E-11 HDL cholesterol PDXP intron 23063622 rs8138057 chr22 38061544 G A 2.94E-12 LDL cholesterol PDXP intron 23063622 rs713835 chr22 38064650 C T 6.20E-06 Subcutaneous adipose tissue volume in HIV-infected men / / 21897333 rs4820294 chr22 38071043 G A 5.20E-06 Subcutaneous adipose tissue volume in HIV-infected men / / 21897333 rs929039 chr22 38071511 T C 7.30E-06 Subcutaneous adipose tissue volume in HIV-infected men / / 21897333 rs12627973 chr22 38096697 A G 5.03E-04 Rheumatoid arthritis TRIOBP intron 21452313 rs5750477 chr22 38102346 C T 3.78E-04 Alzheimer's disease (late onset) TRIOBP intron 21379329 rs4820297 chr22 38105981 C T 3.96E-04 Alzheimer's disease (late onset) TRIOBP intron 20885792 rs5750482 chr22 38117943 T C 9.43E-05 Non-alcoholic fatty liver disease histology (other) TRIOBP intron 20708005 rs762982 chr22 38144235 C T 1.50E-05 Lipid levels TRIOBP intron 18193043 rs16985637 chr22 38163777 C G 3.13E-05 Attention deficit hyperactivity disorder TRIOBP intron pha002875 rs4821714 chr22 38192452 C T 9.63E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs6000905 chr22 38241432 A G 1.33E-05 Monocyte counts / / pha003089 rs139838 chr22 38268922 G A 6.05E-04 Oral cancers (chewing tobacco related) EIF3L intron 22503698 rs139842 chr22 38272929 C T 1.13E-05 Monocyte counts EIF3L intron pha003089 rs9610864 chr22 38286144 C T 1.25E-05 Monocyte counts / / pha003089 rs5995513 chr22 38287663 C T 4.97E-04 Multiple complex diseases / / 17554300 rs84770 chr22 38390128 T G 8.96E-05 Monocyte counts / / pha003089 rs139897 chr22 38399098 A G 9.53E-05 Monocyte counts / / pha003089 rs139898 chr22 38399979 A G 6.26E-05 Monocyte counts / / pha003089 rs8142185 chr22 38451080 A C 6.84E-05 Attention deficit hyperactivity disorder / / 23728934 rs3026682 chr22 38452482 G A 1 Drug response to Methamphetamine / / 17606665 rs713729 chr22 38455469 T A 1 Drug response to Methamphetamine PICK1 intron 17606663 rs2076369 chr22 38463652 T G 1 Drug response to Methamphetamine PICK1 intron 17606663 rs8135665 chr22 38476276 C T 2.00E-11 Age-related macular degeneration SLC16A8 intron 23455636 rs200068984 chr22 38483189 A G 0.0000024 Prostate cancer (advanced) BAIAP2L2 missense 23555315 rs4821738 chr22 38500480 G T 5.33E-05 Body Mass Index BAIAP2L2 intron pha003014 rs11570734 chr22 38518622 A G 6.14E-05 Erythrocyte counts PLA2G6 intron pha003090 rs11570641 chr22 38540206 C T 0.00000166 Triglycerides PLA2G6 intron 23063622 rs2284063 chr22 38544298 A G 2.00E-09 Melanoma PLA2G6 intron 19578364 rs2284063 chr22 38544298 A G 3.00E-08 Cutaneous nevi PLA2G6 intron 19578365 rs2284063 chr22 38544298 A G 2.00E-09 Nasopharyngeal carcinoma PLA2G6 intron 20512145 rs2284063 chr22 38544298 A G 1.50E-06 Melanoma PLA2G6 intron 21706340 rs6001027 chr22 38545619 A G 2.00E-06 Melanoma PLA2G6 intron 21983787 rs132941 chr22 38545942 T C 4.30E-07 Cutaneous nevi PLA2G6 intron 19578365 rs5756931 chr22 38546033 T C 4.00E-08 Triglycerides PLA2G6 intron 20686565 rs5756931 chr22 38546033 T C 3.00E-08 Triglycerides PLA2G6 intron 24097068 rs84473 chr22 38557326 T C 1.00E-06 Cutaneous nevi PLA2G6 intron 19578365 rs132985 chr22 38563471 C T 2.60E-07 Melanoma PLA2G6 intron 21706340 rs132985 chr22 38563471 C T 2.80E-05 Melanoma PLA2G6 intron 24980573 rs132985 chr22 38563471 C T 3.86E-06 Erythrocyte counts PLA2G6 intron pha003090 rs4821751 chr22 38564457 T C 4.40E-05 Parkinson's disease (age of onset) PLA2G6 intron 19772629 rs738322 chr22 38569006 A G 1.00E-06 Cutaneous nevi PLA2G6 intron 21478494 rs738322 chr22 38569006 A G 3.00E-07 Melanoma PLA2G6 intron 21706340 rs738322 chr22 38569006 A G 3.84E-06 Erythrocyte counts PLA2G6 intron pha003090 rs133029 chr22 38576315 C T 0.000000292 Triglycerides PLA2G6 intron 23063622 rs133029 chr22 38576315 C T 0.0000129 Triglycerides in males PLA2G6 intron 23063622 rs2277844 chr22 38577515 G A 0.000000564 Triglycerides PLA2G6 intron 23063622 rs4821757 chr22 38588510 A G 5.48E-04 Type 2 diabetes / / 17463246 rs4608623 chr22 38597378 G T 1.00E-07 Cutaneous nevi / / 19578365 rs4821767 chr22 38614129 C A 5.90E-07 Cutaneous nevi / / 19578365 rs12485196 chr22 38662396 T C 1.35E-04 Height TMEM184B intron 17255346 rs12485196 chr22 38662396 T C 3.37E-04 Schizophrenia TMEM184B intron 19197363 rs135745 chr22 38683637 G C 2.57E-04 Multiple complex diseases / / 17554300 rs6001093 chr22 38701393 C T 0.00037 Coronary artery calcification CSNK1E intron 23727086 rs6001093 chr22 38701393 C T 4.10E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CSNK1E intron 24023788 rs1997644 chr22 38715222 G A 7.93E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CSNK1E nearGene-5 20877124 rs7288109 chr22 38746369 C T 4.36E-04 Lung function (forced vital capacity) LOC400927 intron 24023788 rs6001102 chr22 38753956 C G 8.40E-05 Malaria LOC400927 intron 19465909 rs885867 chr22 38811282 C T 0.00038617 Hypertension (early onset hypertension) / / 22479346 rs11089887 chr22 38818676 C G 8.70E-04 Blood pressure / / 21228793 rs2267386 chr22 38832112 G A 1.00E-06 Conotruncal heart defects KCNJ4 intron 24800985 rs196074 chr22 38832512 G A 8.89E-04 Multiple complex diseases KCNJ4 intron 17554300 rs196074 chr22 38832512 G A 6.35E-05 Response to taxane treatment (placlitaxel) KCNJ4 intron 23006423 rs9610956 chr22 38839874 G A 3.54E-05 Nonalcoholic fatty liver disease KCNJ4 intron 21423719 rs138435 chr22 38877918 T C 4.24E-06 Lymphocyte counts KDELR3 intron 22286170 rs138457 chr22 38898051 T C 0.00003 Prostate cancer DDX17 intron 23555315 rs1946990 chr22 38912771 A G 7.00E-04 Multiple complex diseases / / 17554300 rs1980455 chr22 38925719 A C 4.80E-06 Prostate cancer DMC1 intron 22923026 rs6001148 chr22 38936420 C T 4.80E-04 Multiple complex diseases DMC1 intron 17554300 rs5757133 chr22 38947835 C A,G,T 8.30E-05 Multiple complex diseases DMC1 intron 17554300 rs5750630 chr22 38985818 A C 8.10E-04 Multiple complex diseases LOC646851 intron 17554300 rs4821797 chr22 39016182 T C 4.84E-06 Prostate cancer LOC646851 intron 22923026 rs5757187 chr22 39021522 G A 5.06E-04 Multiple complex diseases LOC646851 intron 17554300 rs5757203 chr22 39044152 G C 6.75E-04 Multiple complex diseases LOC646851 intron 17554300 rs2072795 chr22 39064209 G A 9.74E-04 Multiple complex diseases CBY1 intron 17554300 rs2072796 chr22 39064230 A G 5.69E-04 Multiple complex diseases CBY1 intron 17554300 rs4821807 chr22 39065582 A G 7.46E-04 Multiple complex diseases CBY1 intron 17554300 rs5757231 chr22 39071658 A G 9.69E-04 Multiple complex diseases / / 17554300 rs5757251 chr22 39100128 G A 0.00029 Prostate cancer / / 23555315 rs5750672 chr22 39104168 A G 9.60E-04 Multiple complex diseases GTPBP1 intron 17554300 rs4821815 chr22 39105707 G A 6.47E-06 Prostate cancer GTPBP1 intron 22923026 rs2235230 chr22 39124467 C T 8.47E-04 Multiple complex diseases GTPBP1 intron 17554300 rs2235229 chr22 39124912 C T 2.99E-05 Prostate cancer GTPBP1 intron 22923026 rs4820346 chr22 39125074 C G 4.55E-04 Type 2 diabetes GTPBP1 intron 17463246 rs138705 chr22 39133803 C T 2.20E-05 Prostate cancer SUN2 intron 22923026 rs138705 chr22 39133803 C T 0.000000118 Amyotrophic lateral sclerosis SUN2 intron 23587638 rs138705 chr22 39133803 C T 0.0000319 Amyotrophic lateral sclerosis SUN2 intron 23587638 rs138708 chr22 39138332 G A 0.00022 Prostate cancer SUN2 missense 23555315 rs138708 chr22 39138332 G A 0.00061 Prostate cancer (non-advanced prostate cancer) SUN2 missense 23555315 rs138712 chr22 39141600 G A 2.00E-05 Prostate cancer SUN2 intron 23668334 rs4821818 chr22 39166039 C T 5.95E-04 Coronary heart disease / / 21971053 rs738144 chr22 39178375 G A 7.00E-06 IgG glycosylation D/L4 intron 23382691 rs12484954 chr22 39181596 G C 0.0000135 Sasang constitution (Soyang) D/L4 intron 22394158 rs7288826 chr22 39214774 G T 2.13E-05 Alcohol and nictotine co-dependence NPTXR UTR-3 20158304 rs741977 chr22 39216301 T C 1.79E-04 Type 2 diabetes NPTXR UTR-3 22158537 rs737776 chr22 39229593 A G 6.14E-04 Amyotrophic Lateral Sclerosis NPTXR intron 17362836 rs1076116 chr22 39237837 C G 5.44E-04 Multiple complex diseases NPTXR intron 17554300 rs4603874 chr22 39300048 A G 7.39E-04 Alzheimer's disease / / 17998437 rs729809 chr22 39316732 A G 5.24E-04 Alzheimer's disease / / 22005930 rs5757372 chr22 39320602 C T 1.40E-05 Urinary metabolites / / 21572414 rs5757373 chr22 39320828 C T 1.30E-05 Urinary metabolites / / 21572414 rs1014971 chr22 39332623 C T 8.00E-12 Bladder cancer / / 20972438 rs1014971 chr22 39332623 C T 1.00E-11 Bladder cancer / / 24163127 rs2076109 chr22 39381826 A G 8.80E-17 Leukemia(T-cell recognition in patients) APOBEC3B missense 21062987 rs139298 chr22 39497452 A G 7.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) APOBEC3H missense 20877124 rs139316 chr22 39499763 T C 5.00E-06 Multiple myeloma APOBEC3H UTR-3 23955597 rs139317 chr22 39499902 C T 3.00E-06 Multiple myeloma APOBEC3H UTR-3 23955597 rs139371 chr22 39519196 T C 9.00E-06 Multiple myeloma (IgH translocation) / / 23502783 rs139371 chr22 39519196 T C 8.00E-08 Multiple myeloma / / 23955597 rs79501 chr22 39522940 C T 9.64E-05 Bipolar disorder / / 19488044 rs79501 chr22 39522940 C T 5.01E-04 Smoking initiation / / 24665060 rs710190 chr22 39527790 T C 1.00E-08 Multiple myeloma CBX7 UTR-3 23955597 rs713841 chr22 39529029 A G 4.00E-08 Multiple myeloma CBX7 UTR-3 23955597 rs713841 chr22 39529029 A G 4.99E-04 Smoking initiation CBX7 UTR-3 24665060 rs139385 chr22 39530132 C A 2.00E-08 Multiple myeloma CBX7 intron 23955597 rs714016 chr22 39532554 A C 1.94E-04 Smoking initiation CBX7 intron 24665060 rs139390 chr22 39532853 A G 1.97E-04 Smoking initiation CBX7 intron 24665060 rs139393 chr22 39537932 T C 3.63E-04 Smoking initiation CBX7 intron 24665060 rs139394 chr22 39538214 A C 2.02E-04 Smoking initiation CBX7 intron 24665060 rs877529 chr22 39542292 G A 8.00E-16 Multiple myeloma CBX7 intron 23955597 rs12158877 chr22 39549426 T G 1.00E-08 Multiple myeloma / / 23955597 rs139412 chr22 39553003 G A 7.45E-04 Smoking initiation / / 24665060 rs139416 chr22 39554749 T C 5.23E-04 Smoking initiation / / 24665060 rs139426 chr22 39560666 G A 5.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs139426 chr22 39560666 G A 1.00E-07 Multiple myeloma / / 23955597 rs5750769 chr22 39592181 C T 3.82E-04 Alcohol dependence / / 21314694 rs5757556 chr22 39603929 G A 5.37E-04 Type 2 diabetes / / 17463246 rs12484719 chr22 39608080 G C 9.90E-06 Urinary metabolites / / 21572414 rs12484710 chr22 39608193 C A 1.10E-05 Urinary metabolites / / 21572414 rs5750776 chr22 39608733 T A 6.40E-06 Urinary metabolites / / 21572414 rs135175 chr22 39612084 A G 9.26E-04 White matter integrity / / 22425255 rs4990919 chr22 39622940 T C 9.82E-05 Lung adenocarcinoma PDGFB intron 19836008 rs9611116 chr22 39624052 A G 7.32E-05 Bipolar disorder PDGFB intron 19488044 rs9622978 chr22 39625068 G T 9.62E-05 Bipolar disorder PDGFB intron 19488044 rs4821874 chr22 39626375 A C 8.50E-04 Coronary heart disease PDGFB intron 21966275 rs5750781 chr22 39634434 A C 2.55E-04 Intracranial aneurysm PDGFB intron 22286173 rs130653 chr22 39642740 A T 6.47E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) PDGFB nearGene-5 22566498 rs135173 chr22 39646201 T C 1.96E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2413583 chr22 39659773 C T 1.00E-26 Crohn's disease / / 21102463 rs2413583 chr22 39659773 C T 9.10E-06 Urinary metabolites / / 21572414 rs2413583 chr22 39659773 C T 4.00E-33 Inflammatory bowel disease / / 23128233 rs17304019 chr22 39661597 G A 2.55E-04 Celiac disease / / 23936387 rs968451 chr22 39670851 G T 1.00E-09 Primary biliary cirrhosis / / 21399635 rs1003643 chr22 39676494 T G 5.83E-07 Primary biliary cirrhosis / / 21399635 rs1003644 chr22 39676744 G A 3.20E-07 Primary biliary cirrhosis / / 21399635 rs54211 chr22 39687484 A G 8.00E-07 Sudden cardiac arrest / / 21658281 rs16985788 chr22 39690151 G A 9.27E-04 Multiple complex diseases / / 17554300 rs137602 chr22 39693408 G A 5.01E-04 Blood pressure / / 21909110 rs17000979 chr22 39700758 C T 9.82E-04 Multiple complex diseases / / 17554300 rs17000979 chr22 39700758 C T 4.90E-07 Urinary metabolites / / 21572414 rs17000981 chr22 39708017 C T 1.60E-07 Urinary metabolites / / 21572414 rs5757611 chr22 39708357 C T 1.10E-12 Primary biliary cirrhosis / / 21399635 rs5757611 chr22 39708357 C T 4.89E-07 Lymphocyte counts / / 22286170 rs2014842 chr22 39709009 G A 4.30E-10 Primary biliary cirrhosis RPL3 intron 21399635 rs2076125 chr22 39711351 A G 1.10E-12 Primary biliary cirrhosis RPL3 intron 21399635 rs12627970 chr22 39721745 A G 2.80E-13 Primary biliary cirrhosis / / 21399635 rs11704319 chr22 39722886 G A 0.0000015 Primary biliary cirrhosis / / 22936693 rs5757618 chr22 39724551 A T 1.95E-11 Primary biliary cirrhosis / / 22961000 rs137686 chr22 39739638 C G 3.22E-04 Type 2 diabetes / / 17463246 rs137686 chr22 39739638 C G 1.00E-11 IgG glycosylation / / 23382691 rs2267407 chr22 39747050 G A 1.29E-13 Primary biliary cirrhosis SYNGR1 intron 22961000 rs909685 chr22 39747671 T A 0.000000079 Primary biliary cirrhosis SYNGR1 intron 22936693 rs909685 chr22 39747671 T A 1.00E-16 Rheumatoid arthritis SYNGR1 intron 24390342 rs909685 chr22 39747671 T A 2.00E-07 Rheumatoid arthritis SYNGR1 intron 24390342 rs909685 chr22 39747671 T A 6.00E-12 Rheumatoid arthritis SYNGR1 intron 24390342 rs137699 chr22 39748854 A G 8.00E-06 IgG glycosylation SYNGR1 intron 23382691 rs5757628 chr22 39749981 G A 9.81E-09 Primary biliary cirrhosis SYNGR1 intron 22936693 rs715505 chr22 39751251 G C 0.00000121 Primary biliary cirrhosis in females SYNGR1 intron 22936693 rs715505 chr22 39751251 G C 6.30E-11 Primary biliary cirrhosis (anti-mitochondrial antibody positive) SYNGR1 intron 22936693 rs715505 chr22 39751251 G C 9.58E-12 Primary biliary cirrhosis SYNGR1 intron 22936693 rs715505 chr22 39751251 G C 5.12E-13 Primary biliary cirrhosis SYNGR1 intron 22961000 rs61616683 chr22 39755773 C T 3.12E-13 Primary biliary cirrhosis SYNGR1 intron 22961000 rs2049985 chr22 39756650 G C 2.96E-13 Primary biliary cirrhosis SYNGR1 intron 22961000 rs739363 chr22 39760883 C A 6.82E-05 Cognitive impairment induced by topiramate SYNGR1 intron 22091778 rs5757642 chr22 39764824 T C 1.00E-04 Alcohol dependence SYNGR1 intron 20201924 rs1569499 chr22 39769818 T C 5.54E-05 Alcohol dependence SYNGR1 intron 20201924 rs1569499 chr22 39769818 T C 5.54E-05 Alcoholism SYNGR1 intron pha002891 rs4821888 chr22 39770597 A G 1.14E-05 Alcohol dependence SYNGR1 intron 20201924 rs4821888 chr22 39770597 A G 1.14E-05 Alcoholism SYNGR1 intron pha002891 rs1010170 chr22 39778327 T C 8.61E-04 Alzheimer's disease SYNGR1 UTR-3 17998437 rs1043395 chr22 39780961 C T 8.90E-05 Orofacial clefts SYNGR1 UTR-3 22419666 rs6001585 chr22 39812986 C A 6.00E-06 Crohn's disease TAB1 intron 20570966 rs35469986 chr22 39813759 T A,C,G 0.00077 Prostate cancer TAB1 missense 23555315 rs4821897 chr22 39835587 A G 3.00E-12 IgG glycosylation / / 23382691 rs4821897 chr22 39835587 A G 4.00E-18 IgG glycosylation / / 23382691 rs5757676 chr22 39841700 T C 1.00E-07 IgG glycosylation / / 23382691 rs909674 chr22 39859169 C A 1.00E-10 IgG glycosylation MGAT3 intron 23382691 rs909674 chr22 39859169 C A 1.00E-16 IgG glycosylation MGAT3 intron 23382691 rs909674 chr22 39859169 C A 1.00E-24 IgG glycosylation MGAT3 intron 23382691 rs909674 chr22 39859169 C A 2.00E-06 IgG glycosylation MGAT3 intron 23382691 rs909674 chr22 39859169 C A 2.00E-10 IgG glycosylation MGAT3 intron 23382691 rs909674 chr22 39859169 C A 2.00E-10 IgG glycosylation MGAT3 intron 23382691 rs909674 chr22 39859169 C A 2.00E-10 IgG glycosylation MGAT3 intron 23382691 rs909674 chr22 39859169 C A 2.00E-15 IgG glycosylation MGAT3 intron 23382691 rs909674 chr22 39859169 C A 3.00E-08 IgG glycosylation MGAT3 intron 23382691 rs909674 chr22 39859169 C A 3.00E-09 IgG glycosylation MGAT3 intron 23382691 rs909674 chr22 39859169 C A 3.00E-09 IgG glycosylation MGAT3 intron 23382691 rs909674 chr22 39859169 C A 3.00E-13 IgG glycosylation MGAT3 intron 23382691 rs909674 chr22 39859169 C A 4.00E-16 IgG glycosylation MGAT3 intron 23382691 rs909674 chr22 39859169 C A 5.00E-10 IgG glycosylation MGAT3 intron 23382691 rs909674 chr22 39859169 C A 6.00E-10 IgG glycosylation MGAT3 intron 23382691 rs909674 chr22 39859169 C A 6.00E-16 IgG glycosylation MGAT3 intron 23382691 rs909674 chr22 39859169 C A 9.00E-06 IgG glycosylation MGAT3 intron 23382691 rs909674 chr22 39859169 C A 9.00E-06 IgG glycosylation MGAT3 intron 23382691 rs909674 chr22 39859169 C A 9.00E-24 IgG glycosylation MGAT3 intron 23382691 rs2899319 chr22 39874314 A C 6.49E-04 Schizophrenia MGAT3 intron 19197363 rs1048310 chr22 39913282 T G 9.61E-06 Obesity-related traits SMCR7L UTR-3 23251661 rs2413598 chr22 39950172 T G 2.02E-05 Cognitive performance / / 19734545 rs2413599 chr22 39952098 G A 1.94E-04 Multiple complex diseases / / 17554300 rs9611198 chr22 39955873 A C 8.00E-06 Schizophrenia / / 22883433 rs3788556 chr22 39972162 T C 5.00E-08 IgG glycosylation CAC/1I intron 23382691 rs132577 chr22 39984086 A T 1.85E-08 Brain activation patterns in response to human facial expressions-for the negative faces task CAC/1I intron 22828495 rs132577 chr22 39984086 A T 8.73E-08 Brain activation patterns in response to human facial expressions-for the positive faces task CAC/1I intron 22828495 rs132577 chr22 39984086 A T 1.85E-08 Airflow obstruction CAC/1I intron 22837378 rs5750854 chr22 39990775 C T 8.13E-05 Cognitive test performance CAC/1I intron 20125193 rs5750854 chr22 39990775 C T 5.75E-04 Response to cytadine analogues (cytosine arabinoside) CAC/1I intron 24483146 rs3788568 chr22 40011273 G A,C,T 1.18E-04 Type 2 diabetes CAC/1I intron 19184112 rs2092179 chr22 40034593 T C 8.73E-05 Neutrophil count CAC/1I intron pha003095 rs136849 chr22 40055250 T C 6.50E-05 Response to statin therapy CAC/1I intron 20339536 rs136852 chr22 40057273 T C 6.40E-05 Response to statin therapy CAC/1I cds-synon 20339536 rs136853 chr22 40058186 A G 4.90E-05 Response to statin therapy CAC/1I missense 20339536 rs4820386 chr22 40068051 C T 3.43E-05 Cognitive test performance CAC/1I intron 20125193 rs5750871 chr22 40069449 A G 5.12E-04 Lymphocyte counts CAC/1I intron 22286170 rs4820387 chr22 40070446 A G 2.60E-05 Cognitive test performance CAC/1I intron 20125193 rs2294369 chr22 40075400 G A 9.00E-08 Response to methotrexate in juvenile idiopathic arthritis CAC/1I missense 24709693 rs6001649 chr22 40089893 A G 5.48E-04 Multiple complex diseases / / 17554300 rs12484428 chr22 40102614 C T 6.30E-05 Hemoglobin / / pha003096 rs12484428 chr22 40102614 C T 6.73E-05 Hematocrit / / pha003097 rs6001655 chr22 40103934 A G 5.40E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs8140044 chr22 40106982 C T 1.72E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10427663 chr22 40117397 G A 8.12E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs137954 chr22 40288830 A G 7.12E-04 Multiple complex diseases ENTHD1 intron 17554300 rs137963 chr22 40303934 C T 8.30E-05 Response to statin therapy GRAP2 intron 20339536 rs137977 chr22 40320361 C A 1.04E-04 Bipolar disorder GRAP2 intron 17486107 rs137989 chr22 40336845 T C 6.80E-05 Response to statin therapy GRAP2 intron 20339536 rs137991 chr22 40340775 T C 9.10E-05 Response to statin therapy GRAP2 intron 20339536 rs2267420 chr22 40348520 G A 3.73E-05 HIV-1 progression GRAP2 intron 20064070 rs9611234 chr22 40357667 G A 2.05E-05 Bipolar disorder and schizophrenia GRAP2 intron 20889312 rs138006 chr22 40362946 A G 1.83E-04 Alzheimer's disease GRAP2 intron 24755620 rs2284078 chr22 40363778 G A 2.44E-04 Alzheimer's disease GRAP2 intron 24755620 rs3021274 chr22 40395084 T C 1.77E-04 Coronary Artery Disease FAM83F intron 17634449 rs11912922 chr22 40403171 C T 3.61E-05 Suicidal ideation FAM83F intron 20877300 rs11704416 chr22 40436973 G C 4.00E-06 Prostate cancer / / 23065704 rs11704416 chr22 40436973 G C 4.00E-07 Prostate cancer / / 23065704 rs9623117 chr22 40452119 T C 5.00E-07 Prostate cancer TNRC6B intron 19117981 rs9623117 chr22 40452119 T C 5.00E-07 Nasopharyngeal carcinoma TNRC6B intron 20512145 rs5995802 chr22 40461419 C G 9.42E-04 Coronary Artery Disease TNRC6B intron 17634449 rs6001762 chr22 40495473 C T 8.54E-04 Parkinson's disease TNRC6B intron 17052657 rs17001638 chr22 40504374 G C 9.01E-05 Multiple complex diseases TNRC6B intron 17554300 rs6001794 chr22 40529415 G T 1.50E-05 Urinary metabolites TNRC6B intron 21572414 rs17323619 chr22 40538717 G C 2.70E-05 Urinary metabolites TNRC6B intron 21572414 rs9611280 chr22 40552119 G A 8.75E-05 Insulin Resistance TNRC6B missense pha003062 rs9611280 chr22 40552119 G A 8.94E-05 Insulin-related traits TNRC6B missense pha003063 rs9611280 chr22 40552119 G A 9.24E-05 Creatinine levels TNRC6B missense pha003069 rs568063097 chr22 40559484 A AAAC 4.15E-06 Coronary heart disease TNRC6B intron 22319020 rs6001811 chr22 40559484 A C 4.15E-06 Coronary heart disease TNRC6B intron 22319020 rs6001834 chr22 40600487 G A 3.11E-04 Coronary Artery Disease TNRC6B intron 17634449 rs5995839 chr22 40606293 A T 2.69E-04 Coronary Artery Disease TNRC6B intron 17634449 rs138038 chr22 40620565 G A 3.04E-04 Coronary Artery Disease TNRC6B intron 17634449 rs5757882 chr22 40631033 C T 2.08E-04 Coronary Artery Disease TNRC6B intron 17634449 rs5750909 chr22 40631110 G C 1.64E-04 Coronary Artery Disease TNRC6B intron 17634449 rs5750910 chr22 40632772 A G 1.68E-04 Coronary Artery Disease TNRC6B intron 17634449 rs6001848 chr22 40636799 A G 9.90E-06 Urinary metabolites TNRC6B intron 21572414 rs2157369 chr22 40642652 C G 3.88E-04 Coronary Artery Disease TNRC6B intron 17634449 rs9611302 chr22 40650284 G A 5.97E-05 Insulin Resistance TNRC6B intron pha003062 rs9611302 chr22 40650284 G A 5.81E-05 Insulin-related traits TNRC6B intron pha003063 rs12484776 chr22 40652873 A G 3.00E-12 Uterine fibroids TNRC6B intron 21460842 rs12628051 chr22 40654276 T C 3.00E-06 Prostate cancer (gene x gene interaction) TNRC6B intron 22219177 rs4821940 chr22 40659573 T C 5.34E-04 Coronary Artery Disease TNRC6B intron 17634449 rs9611305 chr22 40665067 T C 2.43E-04 Coronary Artery Disease TNRC6B intron 17634449 rs4821941 chr22 40675091 A G 4.00E-06 Prostate cancer (gene x gene interaction) TNRC6B intron 22219177 rs6001864 chr22 40684060 C G 3.90E-06 Urinary metabolites TNRC6B intron 21572414 rs139909 chr22 40697581 C T 2.00E-07 Height TNRC6B intron 19570815 rs2072858 chr22 40708679 T C 1.20E-05 Urinary metabolites TNRC6B intron 21572414 rs139920 chr22 40726749 C T 5.40E-06 Dietary macronutrient intake TNRC6B UTR-3 23372041 rs470113 chr22 40729614 A G 5.40E-05 Schizophrenia TNRC6B UTR-3 19571808 rs9611312 chr22 40734790 T C 2.00E-04 Personality dimensions / / 23903073 rs12484697 chr22 40736472 G A 7.04E-04 Multiple complex diseases / / 17554300 rs12484697 chr22 40736472 G A 4.30E-05 Schizophrenia / / 19571808 rs17001846 chr22 40744053 A G 5.45E-04 Multiple complex diseases ADSL intron 17554300 rs8135371 chr22 40757228 A C 6.93E-04 Asparaginase sensitivity in blood cell lines ADSL intron 21072045 rs8135371 chr22 40757228 A C 7.40E-04 Asparaginase sensitivity in blood cell lines ADSL intron 21072045 rs17001868 chr22 40778231 A C 6.64E-05 Cognitive impairment induced by topiramate SGSM3 intron 22091778 rs9611324 chr22 40781162 T C 3.90E-05 Schizophrenia SGSM3 intron 19571808 rs9611328 chr22 40791972 G A 9.56E-04 Multiple complex diseases SGSM3 intron 17554300 rs760701 chr22 40800518 G A 3.23E-04 Multiple complex diseases SGSM3 intron 17554300 rs2235318 chr22 40800544 C A,G,T 2.68E-04 Bulimia nervosa SGSM3 intron 23568457 rs5757949 chr22 40820151 T C 4.00E-06 Height MKL1 intron 19570815 rs6001911 chr22 40825193 A G 7.06E-04 Multiple complex diseases MKL1 intron 17554300 rs6001911 chr22 40825193 A G 3.99E-05 Bipolar disorder and schizophrenia MKL1 intron 20889312 rs6001930 chr22 40876234 T C 7.27E-04 Multiple complex diseases MKL1 intron 17554300 rs6001930 chr22 40876234 T C 9.00E-19 Breast cancer MKL1 intron 23535729 rs6001930 chr22 40876234 T C 2.00E-06 Breast cancer MKL1 intron 23535733 rs5750948 chr22 40886744 A C 6.98E-05 Coronary heart disease MKL1 intron pha003030 rs5758008 chr22 40959260 A G 1.50E-04 Longevity MKL1 intron 22279548 rs17002030 chr22 40989374 T C 1.68E-05 Bipolar disorder and schizophrenia MKL1 intron 20889312 rs17002034 chr22 40996367 G T 4.00E-06 Bipolar disorder and schizophrenia MKL1 intron 20889312 rs17002036 chr22 40997111 G A 4.78E-06 Bipolar disorder and schizophrenia MKL1 intron 20889312 rs12159200 chr22 41042091 A C 6.00E-07 Treatment response for severe sepsis / / 22310353 rs133055 chr22 41050871 G A 2.90E-06 Dietary macronutrient intake / / 23372041 rs133067 chr22 41074168 C T 3.72E-04 Alzheimer's disease MCHR1 nearGene-5 24755620 rs9611386 chr22 41078533 A G 3.48E-04 Alzheimer's disease MCHR1 UTR-3 22005930 rs12160628 chr22 41117441 C T 1.51E-04 Type 2 diabetes / / 17463246 rs5995941 chr22 41144917 C T 3.29E-05 Multiple complex diseases / / 17554300 rs5758072 chr22 41167872 T C 0.00000428 Sasang constitution (Soeum) SLC25A17 intron 22394158 rs138298 chr22 41184102 G A 1.70E-05 Urinary metabolites SLC25A17 intron 21572414 rs138312 chr22 41202136 C T 2.00E-04 Information processing speed SLC25A17 intron 21130836 rs13054099 chr22 41215672 T C 2.14E-04 Self-reported allergy LOC100652788 intron 23817569 rs5758093 chr22 41216028 A G 8.28E-04 Alzheimer's disease LOC100652788 intron 22005930 rs5758098 chr22 41220756 A G 3.28E-04 Multiple complex diseases ST13 UTR-3 17554300 rs5758108 chr22 41250439 G T 2.32E-04 Type 2 diabetes ST13 intron 17463246 rs6002182 chr22 41258144 A G 4.86E-05 Glucose levels XPNPEP3 UTR-3 pha003058 rs6002182 chr22 41258144 A G 3.81E-05 Glucose levels XPNPEP3 UTR-3 pha003061 rs138351 chr22 41262852 C T 6.73E-04 Type 2 diabetes XPNPEP3 intron 17463246 rs138351 chr22 41262852 C T 4.15E-04 Multiple complex diseases XPNPEP3 intron 17554300 rs5758163 chr22 41392658 C T 1.44E-05 Cognitive impairment induced by topiramate / / 22091778 rs9611466 chr22 41426299 A T 3.58E-04 Self-reported allergy / / 23817569 rs12484477 chr22 41429084 G A 3.32E-04 Self-reported allergy / / 23817569 rs4820425 chr22 41431342 C A,G,T 3.00E-08 Crohn's disease / / 22936669 rs4820425 chr22 41431342 C A,G,T 3.06E-04 Self-reported allergy / / 23817569 rs4821990 chr22 41438710 T G 6.16E-04 Alzheimer's disease / / 24755620 rs5758209 chr22 41461865 T G 8.39E-06 Schizophrenia / / 21926974 rs5758209 chr22 41461865 T G 0.00000506 Schizophrenia / / 23637625 rs11090039 chr22 41496800 G A 2.84E-04 Self-reported allergy EP300 intron 23817569 rs4822006 chr22 41519362 T C 0.00080266 Hypertension (early onset hypertension) EP300 intron 22479346 rs4822006 chr22 41519362 T C 8.56E-05 Hemoglobin EP300 intron pha003098 rs2064560 chr22 41530040 A G 3.51E-04 Self-reported allergy EP300 intron 23817569 rs4820428 chr22 41537589 A G 3.78E-04 Self-reported allergy EP300 intron 23817569 rs9611505 chr22 41540279 T C 3.29E-04 Self-reported allergy EP300 intron 23817569 rs20551 chr22 41548008 A G 2.93E-04 Self-reported allergy EP300 missense 23817569 rs2057070 chr22 41564287 T C 3.52E-04 Self-reported allergy EP300 intron 23817569 rs9611510 chr22 41569124 T C 3.41E-04 Self-reported allergy EP300 intron 23817569 rs2076578 chr22 41569609 C T 3.76E-05 Serum metabolites EP300 intron 19043545 rs2092563 chr22 41592677 G A 3.51E-04 Self-reported allergy / / 23817569 rs139438 chr22 41605639 C T 2.80E-05 Hemoglobin L3MBTL2 intron pha003098 rs200329304 chr22 41605639 C CTT 2.80E-05 Hemoglobin L3MBTL2 intron pha003098 rs3818003 chr22 41609690 C T 2.78E-04 Self-reported allergy L3MBTL2 intron 23817569 rs139453 chr22 41610242 A G 2.74E-05 Hemoglobin L3MBTL2 intron pha003098 rs139460 chr22 41611063 T C 2.80E-05 Hemoglobin L3MBTL2 intron pha003098 rs9611519 chr22 41613188 C T 2.88E-04 Self-reported allergy L3MBTL2 cds-synon 23817569 rs2273085 chr22 41615376 C T 2.87E-04 Self-reported allergy L3MBTL2 intron 23817569 rs5758264 chr22 41616284 T G 2.87E-04 Self-reported allergy L3MBTL2 intron 23817569 rs5758267 chr22 41619350 T A 2.88E-04 Self-reported allergy L3MBTL2 intron 23817569 rs2179744 chr22 41621714 G A 2.50E-04 Self-reported allergy L3MBTL2 intron 23817569 rs5758268 chr22 41622419 A T 2.42E-04 Self-reported allergy L3MBTL2 intron 23817569 rs139484 chr22 41627543 T G 2.45E-05 Hemoglobin CHADL intron pha003098 rs5751069 chr22 41627775 C G 1.99E-04 Self-reported allergy CHADL intron 23817569 rs3171692 chr22 41642212 C T 1.44E-05 Self-reported allergy RANGAP1 UTR-3 23817569 rs1983631 chr22 41644074 C T 1.30E-05 Self-reported allergy RANGAP1 intron 23817569 rs9611528 chr22 41648502 T C 4.62E-04 Hemoglobin concentration RANGAP1 intron 20534544 rs9611528 chr22 41648502 T C 1.10E-05 Self-reported allergy RANGAP1 intron 23817569 rs104974 chr22 41651034 G A 0.000723613 Hypertension (early onset hypertension) RANGAP1 intron 22479346 rs139507 chr22 41651467 T C 0.000447493 Hypertension (early onset hypertension) RANGAP1 intron 22479346 rs139515 chr22 41656133 A G 1.58E-09 Lymphocyte counts RANGAP1 intron 22286170 rs5751071 chr22 41656332 G A 6.22E-06 Self-reported allergy RANGAP1 intron 23817569 rs5751072 chr22 41656509 G A 5.47E-06 Self-reported allergy RANGAP1 intron 23817569 rs2284079 chr22 41658632 C T 5.08E-06 Self-reported allergy RANGAP1 intron 23817569 rs2235852 chr22 41661154 G T 4.62E-04 Hemoglobin concentration RANGAP1 intron 20534544 rs2235852 chr22 41661154 G T 4.00E-06 Self-reported allergy RANGAP1 intron 23817569 rs139526 chr22 41667727 A G 0.000416295 Hypertension (early onset hypertension) RANGAP1 intron 22479346 rs9611542 chr22 41677317 C T 8.63E-06 Self-reported allergy RANGAP1 intron 23817569 rs1535048 chr22 41684093 C T 5.41E-06 Self-reported allergy / / 23817569 rs1984584 chr22 41684426 G A 0.000354832 Hypertension (early onset hypertension) / / 22479346 rs1984839 chr22 41685937 G C 4.38E-06 Self-reported allergy / / 23817569 rs2024566 chr22 41697338 A G 4.51E-06 Self-reported allergy / / 23817569 rs2024567 chr22 41699206 G C 4.50E-06 Self-reported allergy ZC3H7B intron 23817569 rs17002407 chr22 41744334 A G 3.00E-04 Multiple complex diseases ZC3H7B intron 17554300 rs4822024 chr22 41757647 G A 7.00E-10 Vitiligo / / 22561518 rs6002352 chr22 41759076 G A 2.18E-04 Multiple complex diseases / / 17554300 rs17002414 chr22 41759303 C T 4.78E-04 Multiple complex diseases / / 17554300 rs79008 chr22 41850500 A G 1.46E-04 Vitiligo / / 22561518 rs9611602 chr22 41908405 T C 7.19E-04 Response to taxane treatment (placlitaxel) ACO2 intron 23006423 rs1810460 chr22 41927700 C T 3.61E-04 Amyotrophic lateral sclerosis (sporadic) POLR3H intron 24529757 rs5996039 chr22 41981957 A G 3.11E-04 Response to taxane treatment (placlitaxel) PMM1 intron 23006423 rs8139993 chr22 41995335 T C 3.11E-04 Response to taxane treatment (placlitaxel) PPPDE2 UTR-3 23006423 rs5751129 chr22 42015765 C T 9.47E-04 Response to taxane treatment (placlitaxel) PPPDE2 intron 23006423 rs132793 chr22 42063681 A G 3.65E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2064189 chr22 42127999 T C 1.54E-05 Lymphocyte counts MEI1 intron 22286170 rs2064189 chr22 42127999 T C 5.14E-04 Response to taxane treatment (placlitaxel) MEI1 intron 23006423 rs5751144 chr22 42128097 G A 5.14E-04 Response to taxane treatment (placlitaxel) MEI1 intron 23006423 rs4822050 chr22 42177453 G C 3.28E-04 Response to taxane treatment (placlitaxel) MEI1 intron 23006423 rs126092 chr22 42178441 G A 8.10E-04 Response to taxane treatment (placlitaxel) MEI1 intron 23006423 rs139568 chr22 42210985 T C 2.24E-04 Response to taxane treatment (placlitaxel) CCDC134 intron 23006423 rs7364180 chr22 42218856 A G 1.00E-06 Alzheimer's disease biomarkers CCDC134 intron 21123754 rs5996074 chr22 42236337 G A 2.70E-07 Esophageal cancer (squamous cell) SREBF2 intron 22960999 rs5996074 chr22 42236337 G A 0.000000193 Body mass index SREBF2 intron 23001569 rs5996074 chr22 42236337 G A 0.000273 Body mass index (females) SREBF2 intron 23001569 rs2255957 chr22 42241372 G A 1.01E-05 Alzheimer's disease SREBF2 intron 17998437 rs11702960 chr22 42269532 C T 5.29E-04 Parkinson's disease SREBF2 intron 17052657 rs2228314 chr22 42276742 G C 7.55E-04 Response to taxane treatment (placlitaxel) SREBF2 missense 23006423 rs17379759 chr22 42299535 A G 5.66E-04 Insulin resistance SREBF2 intron 21901158 rs5758511 chr22 42336172 G A 3.00E-06 Birth weight CENPM STOP-GAIN 23202124 rs3752591 chr22 42339516 A G 8.50E-05 Obesity-related traits CENPM intron 17903300 rs3752591 chr22 42339516 A G 8.13E-05 Multiple sclerosis CENPM intron 20598377 rs8140869 chr22 42344297 G A 9.09E-04 Multiple complex diseases / / 17554300 rs6519301 chr22 42385967 A G 2.58E-05 Bipolar disorder and schizophrenia SEPT3 intron 20889312 rs1062753 chr22 42392811 G A 2.00E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) SEPT3 UTR-3 24528284 rs1062753 chr22 42392811 G A 7.99E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) SEPT3 UTR-3 24528284 rs129857 chr22 42399686 T C 2.53E-05 Bipolar disorder and schizophrenia WBP2NL intron 20889312 rs133335 chr22 42416056 A G 2.90E-05 Bipolar disorder and schizophrenia WBP2NL missense 20889312 rs133340 chr22 42417687 T A 3.85E-05 Bipolar disorder and schizophrenia WBP2NL intron 20889312 rs1063392 chr22 42454950 A G 9.92E-05 Bipolar disorder and schizophrenia /GA UTR-3 20889312 rs2854827 chr22 42461918 G A 4.90E-04 Iris characteristics /GA intron 21835309 rs133367 chr22 42463366 C T 3.38E-05 Bipolar disorder and schizophrenia /GA intron 20889312 rs5751216 chr22 42508937 G T 1.90E-05 Bipolar disorder and schizophrenia LOC100132273 intron 20889312 rs5751222 chr22 42517922 T A 0.0000484 Body mass index LOC100132273 intron 23001569 rs1058172 chr22 42523528 C T 7.99E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) CYP2D6 missense 24528284 rs1058172 chr22 42523528 C T 8.00E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) CYP2D6 missense 24528284 rs28371725 chr22 42523805 C T 1 Drug response to Metoprolol CYP2D6 intron 19037197 rs3892097 chr22 42524947 C T 1 Drug response to Tamoxifen CYP2D6 splice-5 16361630 rs3892097 chr22 42524947 C T 1 Drug response to Clomipramine CYP2D6 splice-5 16958828 rs3892097 chr22 42524947 C T 1 Drug response to Codeine CYP2D6 splice-5 16958828 rs3892097 chr22 42524947 C T 1 Drug response to Desipramine CYP2D6 splice-5 16958828 rs3892097 chr22 42524947 C T 1 Drug response to Imipramine CYP2D6 splice-5 16958828 rs3892097 chr22 42524947 C T 1 Drug response to Nortriptyline CYP2D6 splice-5 16958828 rs3892097 chr22 42524947 C T 1 Drug response to Venlafaxine CYP2D6 splice-5 16958828 rs3892097 chr22 42524947 C T 1 Drug response to Clomipramine CYP2D6 splice-5 1782973 rs3892097 chr22 42524947 C T 1 Drug response to Codeine CYP2D6 splice-5 1782973 rs3892097 chr22 42524947 C T 1 Drug response to Desipramine CYP2D6 splice-5 1782973 rs3892097 chr22 42524947 C T 1 Drug response to Imipramine CYP2D6 splice-5 1782973 rs3892097 chr22 42524947 C T 1 Drug response to Nortriptyline CYP2D6 splice-5 1782973 rs3892097 chr22 42524947 C T 1 Drug response to Venlafaxine CYP2D6 splice-5 1782973 rs3892097 chr22 42524947 C T 1 Drug response to Tamoxifen CYP2D6 splice-5 18024866 rs3892097 chr22 42524947 C T 1 Drug response to Clomipramine CYP2D6 splice-5 18070221 rs3892097 chr22 42524947 C T 1 Drug response to Codeine CYP2D6 splice-5 18070221 rs3892097 chr22 42524947 C T 1 Drug response to Desipramine CYP2D6 splice-5 18070221 rs3892097 chr22 42524947 C T 1 Drug response to Imipramine CYP2D6 splice-5 18070221 rs3892097 chr22 42524947 C T 1 Drug response to Nortriptyline CYP2D6 splice-5 18070221 rs3892097 chr22 42524947 C T 1 Drug response to Venlafaxine CYP2D6 splice-5 18070221 rs3892097 chr22 42524947 C T 1 Drug response to Metoprolol CYP2D6 splice-5 19037197 rs374050826 chr22 42525086 A C 1 Drug response to Venlafaxine CYP2D6 frameshift 16958828 rs374050826 chr22 42525086 A C 1 Drug response to Metoprolol CYP2D6 frameshift 19037197 rs1065852 chr22 42526694 G A 1 Drug response to Metoprolol CYP2D6 missense 19037197 rs1065852 chr22 42526694 G A 2.00E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) CYP2D6 missense 24528284 rs1065852 chr22 42526694 G A 7.99E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) CYP2D6 missense 24528284 rs1065852 chr22 42526694 G A 8.00E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) CYP2D6 missense 24528284 rs1058174 chr22 42536263 G A 7.99E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs5751229 chr22 42545221 G A 1.60E-04 Menopause (age at onset) / / 22267201 rs742086 chr22 42552253 T G 3.40E-04 Iris characteristics / / 21835309 rs8142673 chr22 42596253 C A 1.23E-05 Odorant perception TCF20 intron 23910658 rs17002890 chr22 42607817 C T 2.23E-04 Multiple complex diseases TCF20 missense 17554300 rs1033459 chr22 42619067 A G 7.99E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs1033460 chr22 42619308 A G 7.99E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs5758659 chr22 42622003 C T 2.52E-05 Bipolar disorder and schizophrenia / / 20889312 rs5758660 chr22 42623718 C A 1.48E-05 Bipolar disorder and schizophrenia / / 20889312 rs5996135 chr22 42641458 T C 1.70E-05 Urinary metabolites / / 21572414 rs134869 chr22 42652074 G A 1.94E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1107554 chr22 42667594 G C 8.21E-06 Lymphocyte counts LOC388906 intron 22286170 rs1001587 chr22 42670111 C T 7.99E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs1001586 chr22 42670293 G T 7.99E-16 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) / / 24528284 rs134882 chr22 42670965 T C 7.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs134900 chr22 42683343 G C 1.84E-05 Bipolar disorder and schizophrenia / / 20889312 rs134902 chr22 42683997 G A 1.13E-05 Bipolar disorder and schizophrenia / / 20889312 rs17002948 chr22 42688724 T G 5.45E-05 Angioedema in response to angiotensin-converting enzyme inhibitor / / 23838604 rs4822104 chr22 42698800 T C 4.49E-04 Multiple complex diseases / / 17554300 rs739150 chr22 42728168 C T 4.86E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6002695 chr22 42742451 G A 7.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs5996145 chr22 42756497 T C 1.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs5996145 chr22 42756497 T C 8.71E-05 Cholesterol / / pha003073 rs9623573 chr22 42776276 C T 1.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2142831 chr22 42801452 A G 2.11E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NFAM1 intron 20877124 rs7287634 chr22 42806731 A C 4.90E-06 Urinary metabolites NFAM1 intron 21572414 rs8137110 chr22 42811162 T G 2.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NFAM1 intron 20877124 rs9623589 chr22 42817652 T G 6.95E-04 Insulin resistance NFAM1 intron 21901158 rs13057831 chr22 42873532 T C 3.09E-04 Alzheimer's disease / / 22005930 rs4822135 chr22 42876604 T C 8.35E-04 Alzheimer's disease / / 24755620 rs1043606 chr22 42981678 T C 8.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) POLDIP3 UTR-3 20877124 rs137098 chr22 42988117 T C 1.62E-05 Cognitive impairment induced by topiramate POLDIP3 intron 22091778 rs1540311 chr22 43007594 G C 8.17E-04 Response to statin treatment (atorvastatin),change in cholesterol levels POLDIP3 intron 20031582 rs137127 chr22 43019632 C A 3.87E-05 Cognitive impairment induced by topiramate CYB5R3 intron 22091778 rs130329 chr22 43061594 C A 3.52E-05 Longevity / / 21612516 rs17003212 chr22 43079754 T C 3.40E-04 Alcohol dependence / / 20201924 rs17003212 chr22 43079754 T C 7.50E-04 Alcohol dependence / / 20201924 rs736013 chr22 43084613 T C 1.50E-04 Alcohol dependence / / 20201924 rs736013 chr22 43084613 T C 3.40E-04 Alcohol dependence / / 20201924 rs5996223 chr22 43086173 T A 3.88E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs3747193 chr22 43088463 G T 1.50E-04 Alcohol dependence A4GALT UTR-3 20201924 rs130396 chr22 43092851 A C 2.67E-05 Serum metabolites A4GALT intron 19043545 rs4365558 chr22 43143899 T C 4.70E-05 Myocardial Infarction / / pha002883 rs7287569 chr22 43153146 C A 3.50E-13 P system P1 antigen / / 22611595 rs7287569 chr22 43153146 C A 7.68E-04 Alcohol dependence / / 24277619 rs7287569 chr22 43153146 C A 3.53E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4393836 chr22 43193641 G A 6.09E-05 Smoking initiation ARFGAP3 intron 24665060 rs5758962 chr22 43225174 A C 2.76E-04 Smoking initiation ARFGAP3 intron 24665060 rs5758976 chr22 43233333 A G 1.34E-04 Smoking initiation ARFGAP3 intron 24665060 rs7364130 chr22 43249200 T C 1.02E-04 Smoking initiation ARFGAP3 intron 24665060 rs753086 chr22 43266247 G A 7.14E-05 Smoking initiation PACSIN2 UTR-3 24665060 rs5759010 chr22 43278148 C T 2.02E-04 Smoking initiation PACSIN2 intron 24665060 rs2267462 chr22 43283082 C T 7.58E-04 Smoking initiation PACSIN2 intron 24665060 rs2076157 chr22 43289236 C T 7.73E-05 Smoking initiation PACSIN2 intron 24665060 rs2076158 chr22 43289738 C T 3.31E-04 Smoking initiation PACSIN2 intron 24665060 rs2267465 chr22 43299878 G A 1.58E-04 Smoking initiation PACSIN2 intron 24665060 rs2267470 chr22 43306541 A G 2.22E-04 Smoking initiation PACSIN2 intron 24665060 rs2284094 chr22 43325441 A G 2.80E-04 Smoking initiation PACSIN2 intron 24665060 rs10483216 chr22 43347186 G A 6.50E-05 Smoking initiation PACSIN2 intron 24665060 rs11090130 chr22 43366830 T C 3.53E-05 Multiple complex diseases PACSIN2 intron 17554300 rs7511534 chr22 43372372 T C 2.30E-11 Lymphocyte counts PACSIN2 intron 22286170 rs2018340 chr22 43390319 G A 5.56E-05 Smoking initiation PACSIN2 intron 24665060 rs11912530 chr22 43424283 G A 6.00E-05 Prostate cancer / / 21743057 rs5751416 chr22 43432826 G A 0.00057 Prostate cancer / / 23555315 rs10427606 chr22 43457862 A G 2.50E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TTLL1 intron 20877124 rs135007 chr22 43494731 G A 5.26E-04 Smoking quantity / / 24665060 rs5996274 chr22 43498114 G A 8.18E-04 Acute lung injury / / 22295056 rs135015 chr22 43498161 T C 7.02E-04 Alcohol dependence / / 21314694 rs5759167 chr22 43500212 G T 6.00E-29 Prostate cancer / / 19767753 rs5759167 chr22 43500212 G T 6.00E-29 Nasopharyngeal carcinoma / / 20512145 rs5759167 chr22 43500212 G T 1.00E-05 Prostate cancer / / 21743057 rs5759167 chr22 43500212 G T 0.00025 Prostate cancer / / 23555315 rs1883264 chr22 43509846 G C 1.70E-04 Weight loss (gastric bypass surgery) BIK intron 23643386 rs738276 chr22 43510219 A G 2.00E-04 Cognitive impairment induced by topiramate BIK intron 22091778 rs4988399 chr22 43516745 T C 1.08E-04 Acute lung injury BIK intron 22295056 rs742134 chr22 43518275 A G 6.00E-06 Prostate cancer BIK intron 21743057 rs742134 chr22 43518275 A G 4.01E-04 Smoking initiation BIK intron 24665060 rs735573 chr22 43523456 G C 1.47E-25 Triglycerides BIK intron 23063622 rs7402 chr22 43529029 C T 5.78E-04 Systemic lupus erythematosus and Systemic sclerosis MCAT UTR-3 23740937 rs9333327 chr22 43553852 G C 7.14E-05 Type 2 diabetes TSPO intron 17463246 rs80411 chr22 43561675 T G 1.95E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs2071724 chr22 43577048 C A 7.75E-04 Coronary heart disease TTLL12 intron 21971053 rs2071724 chr22 43577048 C A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes TTLL12 intron 22628534 rs138949 chr22 43577624 C T 2.00E-04 Cognitive impairment induced by topiramate TTLL12 intron 22091778 rs13058467 chr22 43579049 T C 4.00E-07 Molar-incisor hypomineralization TTLL12 missense 23918034 rs11703432 chr22 43600281 T G 7.51E-07 Molar-incisor hypomineralization SCUBE1 intron 23918034 rs11704836 chr22 43605654 C T 7.50E-07 Molar-incisor hypomineralization SCUBE1 intron 23918034 rs11704919 chr22 43605770 G A 8.61E-07 Molar-incisor hypomineralization SCUBE1 intron 23918034 rs2071725 chr22 43609760 G A 1.21E-07 Systemic lupus erythematosus SCUBE1 intron 18204446 rs2071725 chr22 43609760 G A 5.33E-06 Molar-incisor hypomineralization SCUBE1 intron 23918034 rs12053796 chr22 43614099 T C 4.63E-05 Bipolar disorder,affective SCUBE1 intron 20528957 rs139014 chr22 43624765 T C 5.00E-06 IgG glycosylation SCUBE1 intron 23382691 rs139021 chr22 43632100 G A 6.00E-04 Smoking quantity SCUBE1 intron 24665060 rs139021 chr22 43632100 G A 3.55E-05 Blood Pressure SCUBE1 intron pha003043 rs5751452 chr22 43635573 T C 2.00E-06 Response to fenofibrate (adiponectin levels) SCUBE1 intron 23149075 rs5759225 chr22 43640728 A G 8.43E-06 Colorectal cancer SCUBE1 intron 21242260 rs17516897 chr22 43642153 T C 2.23E-06 ldl cholesterol SCUBE1 intron pha003077 rs17516897 chr22 43642153 T C 2.49E-05 Cholesterol SCUBE1 intron pha003083 rs737612 chr22 43647416 A G 4.52E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SCUBE1 intron 20877124 rs73420094 chr22 43654278 G A 0.00037 Prostate cancer SCUBE1 missense 23555315 rs5759236 chr22 43659191 T A 2.85E-05 Body mass index SCUBE1 intron 19584900 rs5759236 chr22 43659191 T A 6.59E-05 Body mass index SCUBE1 intron 19584900 rs139042 chr22 43670094 G A 4.36E-04 Smoking cessation SCUBE1 intron 24665060 rs763265 chr22 43684002 A G 4.03E-06 Post-operative nausea and vomiting SCUBE1 intron 21694509 rs5751478 chr22 43703991 A G 1.00E-04 Prostate cancer SCUBE1 intron 21743057 rs9612040 chr22 43718554 G T 1.60E-05 Urinary metabolites SCUBE1 intron 21572414 rs2859442 chr22 43719439 T C 9.50E-06 Urinary metabolites SCUBE1 intron 21572414 rs9612041 chr22 43726509 T G 8.00E-06 Urinary metabolites SCUBE1 intron 21572414 rs9608016 chr22 43731557 C T 8.90E-06 Urinary metabolites SCUBE1 intron 21572414 rs715001 chr22 43745197 C A 8.81E-04 Depression (quantitative trait) / / 20800221 rs9612058 chr22 43773877 A T 3.49E-05 Odorant perception / / 23910658 rs5751487 chr22 43776061 T C 1.03E-04 Smoking quantity / / 24665060 rs1555242 chr22 43779867 G T 1.42E-04 Smoking quantity / / 24665060 rs5759310 chr22 43781027 C T 2.81E-04 Smoking quantity / / 24665060 rs743031 chr22 43783371 G A 4.19E-04 Smoking quantity / / 24665060 rs736030 chr22 43783951 T C 1.74E-04 Smoking quantity / / 24665060 rs9612061 chr22 43785168 T C 7.78E-05 Glucose levels / / pha003061 rs9608023 chr22 43786019 T C 9.02E-04 Type 2 diabetes / / 17463246 rs5759316 chr22 43797027 G T 4.44E-04 Smoking quantity / / 24665060 rs7286402 chr22 43811592 A G 2.86E-04 Smoking quantity MPPED1 intron 24665060 rs2180154 chr22 43814457 C A 2.24E-04 Response to taxane treatment (placlitaxel) MPPED1 intron 23006423 rs11090163 chr22 43819757 A G 5.95E-04 Smoking quantity MPPED1 intron 24665060 rs4822289 chr22 43823014 T G 4.84E-04 Smoking quantity MPPED1 intron 24665060 rs135080 chr22 43824571 C T 3.89E-04 Type 2 diabetes MPPED1 intron 17463246 rs739018 chr22 43826267 G A 4.35E-05 Blood Pressure MPPED1 intron pha003049 rs182725627 chr22 43831058 G C 0.000041 Prostate cancer (advanced) MPPED1 missense 23555315 rs80318 chr22 43863297 C T 7.08E-05 Erythrocyte counts MPPED1 intron pha003101 rs12483905 chr22 43914396 G A 1.41E-04 Body mass index / / 23669352 rs12627976 chr22 43982546 T C 8.98E-04 Taste perception EFCAB6 intron 22132133 rs4823124 chr22 44015291 A G 1.15E-04 Lung function (forced vital capacity) EFCAB6 intron 24023788 rs16990878 chr22 44042348 C T 5.93E-06 Asthma (childhood onset) EFCAB6 intron 23829686 rs9614174 chr22 44082454 A C 2.78E-05 Staphylococcus aureus infection EFCAB6 intron 24847357 rs10483219 chr22 44128975 T C 3.63E-05 Bilirubin levels,in serum EFCAB6 intron 19389676 rs8140172 chr22 44204319 C T 4.10E-04 Major depressive disorder EFCAB6 intron 21042317 rs8140172 chr22 44204319 C T 6.00E-06 IgG glycosylation EFCAB6 intron 23382691 rs7291445 chr22 44216801 T C 2.28E-04 Multiple complex diseases / / 17554300 rs138054 chr22 44219572 A G 2.95E-05 Parkinson's disease / / 21738487 rs470089 chr22 44248504 G A 9.00E-06 Type 2 diabetes (dietary heme iron intake interaction) SULT4A1 intron 23386860 rs2285164 chr22 44249905 G A 0.0000401 Ovarian cancer survival SULT4A1 intron 22891074 rs138127 chr22 44272236 G C 6.80E-04 Type 2 diabetes / / 17463246 rs470093 chr22 44276171 T G 7.00E-06 Staphylococcus aureus infection PNPLA5 UTR-3 24847357 rs4823153 chr22 44296050 T C 8.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs2076213 chr22 44322922 T G 4.09E-04 Lung function (forced expiratory volume in 1 second) PNPLA3 missense 17255346 rs734561 chr22 44324104 C T 5.84E-04 Aortic root size PNPLA3 intron 21223598 rs738409 chr22 44324727 C G 4.00E-34 Nonalcoholic fatty liver disease PNPLA3 missense 21423719 rs738409 chr22 44324727 C G 5.80E-09 Soluble ICAM-1 PNPLA3 missense 21533024 rs738409 chr22 44324727 C G 5.90E-10 Hepatitis B PNPLA3 missense 21750111 rs738409 chr22 44324727 C G 1.00E-45 Liver enzyme levels (alanine transaminase) PNPLA3 missense 22001757 rs738409 chr22 44324727 C G 1.00E-10 Nonalcoholic fatty liver disease PNPLA3 missense 22719876 rs738409 chr22 44324727 C G 2.09E-23 Fatty liver disease PNPLA3 missense 23477746 rs738409 chr22 44324727 C G 1.80E-04 Non-alcoholic fatty liver disease PNPLA3 missense 23535911 rs738408 chr22 44324730 C T 6.41E-19 Fatty liver disease PNPLA3 cds-synon 23477746 rs12483959 chr22 44325996 G A 2.00E-18 Metabolite levels PNPLA3 intron 21909109 rs12483959 chr22 44325996 G A 2.00E-39 Metabolite levels PNPLA3 intron 21909109 rs12483959 chr22 44325996 G A 6.00E-13 Fatty liver disease PNPLA3 intron 23477746 rs11090617 chr22 44326700 C T 5.98E-13 Fatty liver disease PNPLA3 intron 23477746 rs1883350 chr22 44328043 T C 1.62E-04 Lymphocyte counts PNPLA3 intron 22286170 rs1883350 chr22 44328043 T C 4.56E-10 Fatty liver disease PNPLA3 intron 23477746 rs4823173 chr22 44328730 G A 5.93E-13 Fatty liver disease PNPLA3 intron 23477746 rs2076211 chr22 44329078 C T 5.94E-13 Fatty liver disease PNPLA3 intron 23477746 rs1977081 chr22 44330128 T C 3.21E-13 Fatty liver disease PNPLA3 intron 23477746 rs4823174 chr22 44330274 G A 4.01E-04 Coronary heart disease PNPLA3 intron 21971053 rs1883349 chr22 44331943 G A 2.56E-12 Fatty liver disease PNPLA3 intron 23477746 rs2281135 chr22 44332570 G A 8.00E-16 Liver enzyme levels PNPLA3 intron 18940312 rs2281135 chr22 44332570 G A 3.04E-11 Blood cell counts and other traits PNPLA3 intron 20139978 rs2281135 chr22 44332570 G A 4.95E-13 Fatty liver disease PNPLA3 intron 23477746 rs2072907 chr22 44332653 C G 5.03E-13 Fatty liver disease PNPLA3 intron 23477746 rs2072905 chr22 44333479 C G 5.12E-13 Fatty liver disease PNPLA3 intron 23477746 rs2896019 chr22 44333694 T G 1.98E-12 Blood cell counts and other traits PNPLA3 intron 20139978 rs2896019 chr22 44333694 T G 2.00E-12 Blood cell counts and other traits PNPLA3 intron 20139978 rs2896019 chr22 44333694 T G 2.31E-12 Blood cell counts and other traits PNPLA3 intron 20139978 rs2896019 chr22 44333694 T G 1.98E-12 Hepatitis B PNPLA3 intron 21750111 rs2896019 chr22 44333694 T G 5.20E-13 Fatty liver disease PNPLA3 intron 23477746 rs2896019 chr22 44333694 T G 2.00E-20 Non-alcoholic fatty liver disease PNPLA3 intron 23535911 rs2896019 chr22 44333694 T G 3.70E-04 Non-alcoholic fatty liver disease PNPLA3 intron 23535911 rs2073081 chr22 44335744 T C 1.46E-11 Fatty liver disease PNPLA3 intron 23477746 rs1010023 chr22 44336098 T C 5.17E-13 Fatty liver disease PNPLA3 intron 23477746 rs1010022 chr22 44336310 A G 5.17E-13 Fatty liver disease PNPLA3 intron 23477746 rs926633 chr22 44337533 G A 8.60E-09 Soluble ICAM-1 PNPLA3 intron 21533024 rs926633 chr22 44337533 G A 5.17E-13 Fatty liver disease PNPLA3 intron 23477746 rs3810622 chr22 44338134 T C 1.70E-17 Non-alcoholic fatty liver disease PNPLA3 intron 23535911 rs2294916 chr22 44340922 T G 3.22E-13 Fatty liver disease PNPLA3 intron 23477746 rs4823179 chr22 44341193 T C 4.49E-13 Fatty liver disease PNPLA3 intron 23477746 rs1474745 chr22 44349236 T C 1.78E-12 Fatty liver disease / / 23477746 rs1474746 chr22 44350417 C G 1.30E-06 Serum metabolites SAMM50 nearGene-5 19043545 rs738491 chr22 44354111 C T 3.90E-06 Nonalcoholic fatty liver disease SAMM50 intron 22719876 rs738491 chr22 44354111 C T 2.47E-08 Fatty liver disease SAMM50 intron 23477746 rs738491 chr22 44354111 C T 3.90E-11 Non-alcoholic fatty liver disease SAMM50 intron 23535911 rs2073082 chr22 44360007 G A 8.00E-07 Nonalcoholic fatty liver disease SAMM50 intron 22719876 rs2073082 chr22 44360007 G A 1.00E-07 Non-alcoholic fatty liver disease SAMM50 intron 23535911 rs9626074 chr22 44363736 C T 5.85E-05 Coronary heart disease SAMM50 intron pha003055 rs3761472 chr22 44368122 A G 1.10E-06 Nonalcoholic fatty liver disease SAMM50 missense 22719876 rs3761472 chr22 44368122 A G 1.36E-12 Fatty liver disease SAMM50 missense 23477746 rs3761472 chr22 44368122 A G 1.50E-14 Non-alcoholic fatty liver disease SAMM50 missense 23535911 rs738494 chr22 44370439 A C 7.51E-05 Coronary heart disease SAMM50 intron pha003055 rs4823182 chr22 44377442 A G 1.88E-13 Fatty liver disease SAMM50 intron 23477746 rs2235776 chr22 44377999 C T 9.20E-07 Nonalcoholic fatty liver disease SAMM50 intron 22719876 rs2235776 chr22 44377999 C T 6.52E-12 Fatty liver disease SAMM50 intron 23477746 rs2235777 chr22 44378809 C T 6.51E-12 Fatty liver disease SAMM50 intron 23477746 rs2294922 chr22 44379565 G C 3.68E-18 Fatty liver disease SAMM50 intron 23477746 rs6006602 chr22 44383400 C T 3.08E-12 Fatty liver disease SAMM50 intron 23477746 rs6006468 chr22 44383432 G C 3.19E-12 Fatty liver disease SAMM50 intron 23477746 rs6006469 chr22 44383617 C G 3.62E-12 Fatty liver disease SAMM50 intron 23477746 rs2073079 chr22 44385594 A G 2.85E-11 Fatty liver disease SAMM50 intron 23477746 rs6006470 chr22 44387996 G C 2.40E-06 Serum metabolites SAMM50 intron 19043545 rs3788604 chr22 44388417 A G 5.80E-12 Fatty liver disease SAMM50 intron 23477746 rs3827385 chr22 44388817 T C 3.22E-11 Fatty liver disease SAMM50 intron 23477746 rs2235778 chr22 44389514 T C 3.24E-12 Fatty liver disease SAMM50 intron 23477746 rs2235779 chr22 44390366 A G 3.70E-04 Depression (quantitative trait) SAMM50 intron 20800221 rs2281298 chr22 44391234 G A 9.19E-04 Multiple complex diseases SAMM50 intron 17554300 rs2281298 chr22 44391234 G A 4.54E-11 Fatty liver disease SAMM50 intron 23477746 rs2143571 chr22 44391686 G A 8.86E-04 Multiple complex diseases SAMM50 intron 17554300 rs2143571 chr22 44391686 G A 7.14E-09 Blood cell counts and other traits SAMM50 intron 20139978 rs2143571 chr22 44391686 G A 6.00E-07 Nonalcoholic fatty liver disease SAMM50 intron 22719876 rs2143571 chr22 44391686 G A 4.53E-11 Fatty liver disease SAMM50 intron 23477746 rs2143571 chr22 44391686 G A 3.50E-13 Non-alcoholic fatty liver disease SAMM50 intron 23535911 rs6006473 chr22 44393075 C T 3.10E-06 Nonalcoholic fatty liver disease / / 22719876 rs6006473 chr22 44393075 C T 7.04E-12 Fatty liver disease / / 23477746 rs6006473 chr22 44393075 C T 2.00E-04 Non-alcoholic fatty liver disease / / 23535911 rs6006473 chr22 44393075 C T 3.20E-10 Non-alcoholic fatty liver disease / / 23535911 rs2401514 chr22 44394019 T A 4.53E-11 Fatty liver disease / / 23477746 rs2073080 chr22 44394402 C T 8.00E-07 Nonalcoholic fatty liver disease / / 22719876 rs2073080 chr22 44394402 C T 4.53E-11 Fatty liver disease / / 23477746 rs2281292 chr22 44395389 A C 3.10E-06 Nonalcoholic fatty liver disease PARVB intron 22719876 rs2281292 chr22 44395389 A C 6.36E-12 Fatty liver disease PARVB intron 23477746 rs1007863 chr22 44395451 T C 5.90E-12 Fatty liver disease PARVB missense 23477746 rs5764455 chr22 44398524 A G 1.60E-12 Non-alcoholic fatty liver disease PARVB intron 23535911 rs5764455 chr22 44398524 A G 3.40E-06 Non-alcoholic fatty liver disease PARVB intron 23535911 rs6006611 chr22 44400698 G A 1.80E-04 Non-alcoholic fatty liver disease PARVB intron 23535911 rs6006611 chr22 44400698 G A 1.80E-12 Non-alcoholic fatty liver disease PARVB intron 23535911 rs9614308 chr22 44404522 A G 1.00E-04 Cognitive impairment induced by topiramate PARVB intron 22091778 rs6006632 chr22 44447046 A G 1.89E-04 Lung function (forced vital capacity) PARVB intron 24023788 rs2284155 chr22 44455473 A G 5.21E-04 Amyotrophic Lateral Sclerosis PARVB intron 17362836 rs130314 chr22 44467910 A G 1.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PARVB intron 20877124 rs16991456 chr22 44491577 T C 4.49E-05 Myopia (pathological) PARVB intron 23049088 rs2267610 chr22 44499643 T C 0.000592 Salmonella-induced pyroptosis PARVB intron 22837397 rs11703393 chr22 44512124 A G 2.91E-04 Response to cholinesterase inhibitors in Alzheimer's disease PARVB intron 23374588 rs16991517 chr22 44513846 A G 2.24E-04 Multiple complex diseases PARVB intron 17554300 rs2896050 chr22 44523593 G A 1.36E-04 Type 2 diabetes PARVB intron 17463246 rs9614203 chr22 44525374 G A 4.04E-04 Multiple complex diseases PARVB intron 17554300 rs75617873 chr22 44526105 A C 5.00E-07 Alzheimer's disease (cognitive decline) PARVB intron 23535033 rs2267616 chr22 44530844 A C 3.03E-05 Asthma PARVB intron pha003128 rs5764558 chr22 44544028 G A 3.92E-04 Type 2 diabetes PARVB intron 17463246 rs2072949 chr22 44544349 C T 7.27E-05 Coronary heart disease PARVB intron pha003056 rs2272940 chr22 44559995 G A 1.40E-04 Type 2 diabetes PARVB intron 17463246 rs5764106 chr22 44561287 T C 2.00E-06 IgG glycosylation PARVB intron 23382691 rs5764106 chr22 44561287 T C 5.00E-06 IgG glycosylation PARVB intron 23382691 rs5764106 chr22 44561287 T C 1.84E-05 Hemoglobin PARVB intron pha003096 rs5764106 chr22 44561287 T C 6.86E-05 Erythrocyte counts PARVB intron pha003101 rs139107 chr22 44569980 G A 1.53E-05 Coronary restenosis PARVG intron 21878436 rs139120 chr22 44574547 A G 4.60E-04 Alzheimer's disease PARVG intron 17998437 rs139131 chr22 44581046 C T 6.78E-05 Sensory disturbances after bilateral sagittal split ramus osteotomy PARVG intron 23834954 rs6519830 chr22 44582264 G A 7.99E-04 Schizophrenia PARVG intron 19197363 rs16991676 chr22 44612253 C A 4.94E-04 Multiple complex diseases / / 17554300 rs139248 chr22 44619786 G A 1.30E-05 Urinary metabolites / / 21572414 rs139262 chr22 44625708 A T 7.18E-04 Type 2 diabetes / / 17463246 rs139263 chr22 44626164 A G 7.13E-05 Depression (quantitative trait) / / 23290196 rs139265 chr22 44628068 G A 5.15E-05 Depression (quantitative trait) / / 23290196 rs135416 chr22 44666892 A G 4.86E-05 Longevity KIAA1644 intron 21612516 rs3935378 chr22 44695088 C T 1.64E-05 Bone mineral traits,in men KIAA1644 intron 21427758 rs3935378 chr22 44695088 C T 2.95E-05 Bone mineral traits,in men KIAA1644 intron 21427758 rs3935378 chr22 44695088 C T 3.54E-06 Bone mineral traits,in men KIAA1644 intron 21427758 rs7510924 chr22 44708655 T C 1.05E-04 Celiac disease KIAA1644 UTR-5 23936387 rs6519878 chr22 44735500 T C 9.41E-04 Multiple complex diseases / / 17554300 rs8137340 chr22 44741589 T C 2.50E-05 Asthma / / 20698975 rs5765896 chr22 44744080 T C 2.40E-05 Amyotrophic lateral sclerosis / / 23624525 rs949441 chr22 44744884 G A 4.66E-06 Sleep latency / / 23728906 rs739161 chr22 44745251 T C 3.75E-06 Cardiovascular disease / / 18179892 rs739161 chr22 44745251 T C 1.50E-06 Urinary metabolites / / 21572414 rs2014530 chr22 44757071 C T 3.92E-05 Alcohol dependence / / 19581569 rs9614538 chr22 44757439 G A 2.75E-04 Type 2 diabetes / / 17463246 rs763040 chr22 44763606 G A 2.90E-05 Urinary metabolites / / 21572414 rs9614858 chr22 44764401 T C 2.50E-05 Urinary metabolites / / 21572414 rs2097443 chr22 44768559 C T 3.82E-05 Urinary albumin excretion rate in type 1 diabetes / / 24595857 rs989677 chr22 44768831 G C 8.78E-04 Coronary heart disease / / 21606135 rs4823354 chr22 44769667 C T 6.13E-04 Coronary heart disease / / 21606135 rs1041886 chr22 44771618 G T 4.24E-04 Lung function (forced vital capacity) / / 24023788 rs1041887 chr22 44771763 T C 2.93E-05 Cognitive test performance / / 20125193 rs4823362 chr22 44772640 T C 2.22E-04 Lung function (forced vital capacity) / / 24023788 rs7285004 chr22 44774700 T C 4.80E-06 Thyroid function / / 20826269 rs2071815 chr22 44778738 A G 6.90E-05 Cognitive test performance / / 20125193 rs135900 chr22 44779303 G A 0.000192 Salmonella-induced pyroptosis / / 22837397 rs713756 chr22 44798310 G A 5.19E-05 Rheumatoid arthritis / / 17804836 rs5765228 chr22 44830242 G T 1.80E-05 Urinary metabolites / / 21572414 rs80303 chr22 44836249 A C 2.27E-04 Common variable immunodeficiency / / 21497890 rs12159288 chr22 44880526 T G 2.14E-06 Gallstones / / 17632509 rs1123146 chr22 44929806 G A 4.62E-04 Response to TNF antagonist treatment / / 21061259 rs1123145 chr22 44929974 A G 5.82E-04 Type 2 diabetes / / 17463246 rs876231 chr22 44934672 A G 0.000316 fMRI brain tests in schizophrenia / / 22440650 rs2002981 chr22 44946665 C A 1.80E-05 Telomere length / / 23001564 rs4823339 chr22 44958208 T A 3.37E-04 Type 2 diabetes / / 17463246 rs138597 chr22 44968530 G A 7.00E-06 Economic and political preferences (time) / / 22566634 rs742196 chr22 44974767 C A 2.00E-05 Urinary metabolites / / 21572414 rs16992538 chr22 44985305 G A 6.84E-05 Prostate cancer / / 22923026 rs4823246 chr22 45011761 G A 3.00E-06 Economic and political preferences (feminism/equality) LINC00229 intron 22566634 rs11704309 chr22 45011952 G A 9.35E-04 Multiple complex diseases LINC00229 intron 17554300 rs9614845 chr22 45014135 C T 4.80E-05 Cognitive performance LINC00229 intron 19734545 rs9614856 chr22 45030752 C T 1.23E-05 Lung function (forced vital capacity) / / 24023788 rs2097535 chr22 45109666 C T 6.34E-04 Myocardial Infarction PRR5 intron pha002883 rs1077165 chr22 45110765 T C 9.34E-04 Myocardial Infarction PRR5 intron pha002883 rs1077166 chr22 45111105 A G 8.40E-05 Myopia (pathological) PRR5 intron 21640322 rs763217 chr22 45117594 T C 3.89E-04 Multiple complex diseases PRR5 intron 17554300 rs3827390 chr22 45123977 G C 4.70E-05 Insulin resistance PRR5 intron 21901158 rs132404 chr22 45130373 A G 5.87E-05 Serum metabolites PRR5 intron 19043545 rs129574 chr22 45131555 T G 2.78E-04 Alzheimer's disease (late onset) PRR5 intron 21460841 rs132413 chr22 45136360 G A 9.73E-05 Alzheimer's disease (late onset) PRR5-ARHGAP8 intron 21460841 rs5765956 chr22 45150659 C T 5.94E-06 Cleft lip ARHGAP8 intron 20436469 rs5765956 chr22 45150659 C T 2.00E-06 Orofacial clefts ARHGAP8 intron 22863734 rs1029314 chr22 45157213 C T 3.99E-04 Suicide attempts in bipolar disorder ARHGAP8 intron 21423239 rs4823252 chr22 45166701 A G 4.79E-05 Prostate cancer ARHGAP8 intron 22923026 rs132470 chr22 45169376 C T 1.13E-05 IgE levels in asthmatics (D.f. specific) ARHGAP8 intron 23967269 rs9614922 chr22 45174712 G A 8.26E-05 Monocyte chemoattractant protein-1 ARHGAP8 intron pha003071 rs16992796 chr22 45183014 A G 3.00E-06 Electroencephalographic traits in alcoholism ARHGAP8 intron 22554406 rs16992816 chr22 45189402 G A 7.36E-04 Coronary heart disease ARHGAP8 intron 21971053 rs9626245 chr22 45192621 A G 6.45E-04 Coronary heart disease ARHGAP8 intron 21971053 rs1076933 chr22 45198494 A G 4.21E-05 Multiple complex diseases ARHGAP8 intron 17554300 rs6007306 chr22 45205827 A G 7.44E-04 Multiple complex diseases ARHGAP8 intron 17554300 rs6007308 chr22 45220994 G A 2.82E-04 Amyotrophic Lateral Sclerosis ARHGAP8 intron 17362836 rs1544279 chr22 45231892 A G 2.47E-04 Amyotrophic Lateral Sclerosis ARHGAP8 intron 17362836 rs136675 chr22 45237686 G A 2.30E-06 Urinary metabolites ARHGAP8 intron 21572414 rs6007316 chr22 45238877 G A 7.00E-05 Personality dimensions ARHGAP8 intron 18957941 rs136678 chr22 45240256 T G 2.70E-06 Urinary metabolites ARHGAP8 intron 21572414 rs2269544 chr22 45245850 C G 1.40E-05 Urinary metabolites ARHGAP8 intron 21572414 rs4336044 chr22 45255460 G A 2.00E-05 Urinary metabolites ARHGAP8 intron 21572414 rs2071761 chr22 45257942 C T 4.14E-04 Rheumatoid arthritis ARHGAP8 intron 21452313 rs2071762 chr22 45258324 C T 3.43E-04 Rheumatoid arthritis ARHGAP8 missense 21452313 rs3747226 chr22 45279529 A G 6.90E-05 Cholesterol PHF21B intron pha003073 rs4823406 chr22 45285070 A G 4.76E-04 Hemoglobin concentration PHF21B intron 20534544 rs1894524 chr22 45302662 G A 5.30E-05 Cortisol secretion,in saliva PHF21B intron 21316860 rs9614587 chr22 45303328 A G 5.02E-04 Acute lung injury PHF21B intron 22295056 rs9614975 chr22 45303715 C T 7.17E-04 Acute lung injury PHF21B intron 22295056 rs9614976 chr22 45304506 A G 5.28E-04 Acute lung injury PHF21B intron 22295056 rs4514991 chr22 45330934 G A 5.72E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PHF21B intron 20031582 rs136698 chr22 45337892 T G 2.21E-04 Multiple complex diseases PHF21B intron 17554300 rs6007397 chr22 45339200 C T 4.05E-04 Alcohol consumption (maxi-drinks) PHF21B intron 24277619 rs5765113 chr22 45394902 C G 2.16E-04 Multiple complex diseases PHF21B intron 17554300 rs131992 chr22 45409136 C T 4.52E-04 Taste perception / / 22132133 rs5766295 chr22 45413299 C G 2.80E-05 Urinary metabolites / / 21572414 rs140560 chr22 45425741 G C 7.96E-04 Type 2 diabetes / / 17463246 rs132024 chr22 45425844 A G 6.95E-04 Type 2 diabetes / / 17463246 rs6007413 chr22 45430316 C G 4.80E-05 Nicotine smoking / / 19268276 rs132039 chr22 45435202 T C 3.32E-05 Prion diseases / / 22210626 rs132045 chr22 45437092 G T 3.54E-05 Prion diseases / / 22210626 rs140572 chr22 45451727 C A 5.14E-05 Myocardial Infarction / / pha002873 rs17628328 chr22 45454839 G A 6.33E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2057114 chr22 45465068 A C 2.34E-05 Waist Circumference / / pha003023 rs8136226 chr22 45472574 C T 1.11E-05 Waist Circumference / / pha003023 rs12628020 chr22 45479161 G A 9.17E-06 Waist Circumference / / pha003023 rs8141541 chr22 45498115 C A 2.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs5766424 chr22 45502533 G A 2.92E-04 Multiple complex diseases / / 17554300 rs5766424 chr22 45502533 G A 2.50E-05 Serum metabolites / / 19043545 rs5766424 chr22 45502533 G A 6.12E-04 Coronary heart disease / / 21606135 rs6007455 chr22 45513168 A G 3.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs9306489 chr22 45525484 A G 2.34E-05 Major depressive disorder / / 20516156 rs132813 chr22 45528073 C T 1.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs80428 chr22 45545400 T C 9.60E-05 Diabetic retinopathy LOC100506714 intron 21441570 rs132829 chr22 45551071 T C 4.10E-05 Diabetic retinopathy LOC100506714 intron 21441570 rs132830 chr22 45551123 G A 8.10E-05 Diabetic retinopathy LOC100506714 intron 21441570 rs13054435 chr22 45553459 G A 8.57E-04 HIV-1 viral setpoint LOC100506714 intron 17641165 rs132875 chr22 45566912 C A 6.41E-06 Coronary heart disease NUP50 UTR-5 pha003031 rs132881 chr22 45567580 C A 6.13E-04 Lymphocyte counts NUP50 intron 22286170 rs226524 chr22 45577231 T C 3.00E-06 Coronary heart disease NUP50 cds-synon pha003031 rs6007500 chr22 45583935 A G 3.90E-04 Smoking initiation / / 24665060 rs226518 chr22 45586517 G C,T 7.10E-05 Diabetic retinopathy / / 21441570 rs9626655 chr22 45612551 C T 3.39E-05 Personality dimensions KIAA0930 intron 22628180 rs5766556 chr22 45614803 A G 3.88E-05 Personality dimensions KIAA0930 intron 22628180 rs5766557 chr22 45614893 T C 3.86E-05 Personality dimensions KIAA0930 intron 22628180 rs5766560 chr22 45618558 T C 3.16E-05 Personality dimensions KIAA0930 intron 22628180 rs5766562 chr22 45620501 T G 3.15E-05 Personality dimensions KIAA0930 intron 22628180 rs5766564 chr22 45622351 A G 2.48E-05 IgE levels in asthmatics KIAA0930 intron 23967269 rs5766565 chr22 45622684 A G 2.74E-04 Blood pressure KIAA0930 intron 17255346 rs5766565 chr22 45622684 A G 4.30E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KIAA0930 intron 20877124 rs11090735 chr22 45634738 T C 9.64E-05 IgE levels in asthmatics KIAA0930 intron 23967269 rs5766584 chr22 45638535 G T 2.04E-04 Prion diseases / / 22210626 rs5766584 chr22 45638535 G T 9.05E-05 IgE levels in asthmatics / / 23967269 rs6006959 chr22 45648846 A G 3.00E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs58667 chr22 45668012 C T 4.00E-07 Pulmonary function in asthmatics / / 23541324 rs7287869 chr22 45697923 C G 5.83E-06 Personality dimensions / / 23658558 rs104664 chr22 45711854 G A 6.14E-05 Pulmonary function in asthmatics FAM118A intron 23541324 rs3827393 chr22 45736153 G A 7.02E-05 Pulmonary function in asthmatics FAM118A intron 23541324 rs2294202 chr22 45738327 T A 4.52E-05 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs6006992 chr22 45742760 A G 2.02E-30 Lymphocyte counts SMC1B intron 22286170 rs6006992 chr22 45742760 A G 7.24E-05 Pulmonary function in asthmatics SMC1B intron 23541324 rs5765273 chr22 45747952 A G 5.99E-04 Multiple complex diseases SMC1B intron 17554300 rs470062 chr22 45767369 A G 6.21E-05 Pulmonary function in asthmatics SMC1B cds-synon 23541324 rs9614653 chr22 45767391 C T 0.00016 Prostate cancer SMC1B missense 23555315 rs9614466 chr22 45811362 A G 1.00E-04 Alcohol dependence RIBC2 intron 20201924 rs9614670 chr22 45838817 C T 6.84E-04 Alcohol dependence / / 20201924 rs5765377 chr22 45853566 A G 9.62E-04 Type 2 diabetes / / 17463246 rs80680 chr22 45911590 G C 2.97E-04 IgE levels FBLN1 intron 17255346 rs2238809 chr22 45911714 G A 6.00E-05 Prostate cancer FBLN1 intron 21743057 rs2238810 chr22 45912376 G A 6.00E-05 Prostate cancer FBLN1 intron 21743057 rs136738 chr22 45928019 T C 3.44E-05 Parkinson's disease (motor and cognition) FBLN1 intron 22658654 rs136738 chr22 45928019 T C 3.44E-05 Immune response to anthrax vaccine FBLN1 intron 22658931 rs736767 chr22 45959859 G C 4.50E-05 Bilirubin levels FBLN1 intron 19414484 rs1985671 chr22 45961904 G T 2.00E-08 Temperament (bipolar disorder) FBLN1 intron 22365631 rs2071869 chr22 45972551 A G 8.69E-05 Cognitive test performance FBLN1 intron 20125193 rs6006779 chr22 45989116 C T 4.14E-05 Multiple complex diseases FBLN1 intron 17554300 rs17564689 chr22 46006110 A G 2.35E-05 Soluble levels of adhesion molecules / / pha003072 rs9614732 chr22 46029523 T G 4.26E-04 Alzheimer's disease (late onset) / / 21379329 rs134846 chr22 46040779 T G 4.78E-04 Alzheimer's disease (late onset) / / 21379329 rs2351088 chr22 46040996 A C 3.08E-05 Soluble levels of adhesion molecules / / pha003072 rs134855 chr22 46060541 C T 3.57E-04 Alzheimer's disease / / 17998437 rs134863 chr22 46073604 C T 1.40E-05 Urinary metabolites ATXN10 intron 21572414 rs134864 chr22 46074258 G A 2.20E-05 Urinary metabolites ATXN10 intron 21572414 rs4481093 chr22 46084030 T C 8.30E-05 Non-alcoholic fatty liver disease histology (other) ATXN10 intron 20708005 rs138154 chr22 46107105 G A 9.43E-05 Non-alcoholic fatty liver disease histology (other) ATXN10 intron 20708005 rs6006800 chr22 46133853 A G 9.47E-05 Non-alcoholic fatty liver disease histology (other) ATXN10 intron 20708005 rs5765620 chr22 46179537 C T 4.00E-04 Type 2 diabetes ATXN10 intron 17463246 rs7284693 chr22 46213591 A G 2.52E-04 Alcohol dependence ATXN10 intron 21314694 rs5765659 chr22 46235461 A C 2.89E-04 Aortic root size ATXN10 intron 21223598 rs4823324 chr22 46238123 T C 9.30E-06 Reading disability and language impairment ATXN10 intron 24024963 rs136033 chr22 46255004 A G 9.16E-05 Cognitive test performance / / 20125193 rs6519955 chr22 46421842 G T 3.00E-33 Dupuytren's disease / / 21732829 rs6519999 chr22 46444452 T A 2.90E-05 Urinary metabolites / / 21572414 rs9627391 chr22 46447097 C T 3.35E-06 Serum metabolites C22orf26 UTR-3 19043545 rs9627403 chr22 46448476 A G 5.77E-05 Serum metabolites C22orf26 intron 19043545 rs7289457 chr22 46456603 C T 7.09E-05 Serum metabolites / / 19043545 rs873492 chr22 46497890 C A 8.50E-05 Type 2 diabetes MIRLET7BHG intron 17293876 rs910360 chr22 46502305 T C 3.70E-06 Urinary metabolites MIRLET7BHG intron 21572414 rs7292014 chr22 46502723 A G 3.10E-06 Urinary metabolites MIRLET7BHG intron 21572414 rs4253624 chr22 46550959 T C 1.32E-10 HDL cholesterol PPARA intron 23063622 rs4253642 chr22 46563419 A G 1.33E-15 Cholesterol,total PPARA intron 23063622 rs4253642 chr22 46563419 A G 1.64E-24 HDL cholesterol PPARA intron 23063622 rs4253642 chr22 46563419 A G 2.80E-09 LDL cholesterol PPARA intron 23063622 rs9626737 chr22 46570342 A G 1.88E-04 Celiac disease PPARA intron 23936387 rs5766743 chr22 46607378 A G 9.62E-04 Breast cancer PPARA intron 20852631 rs4253728 chr22 46610067 G A 8.25E-04 Breast cancer PPARA intron 20852631 rs4253754 chr22 46615144 G A 6.08E-04 Breast cancer PPARA intron 20852631 rs5767743 chr22 46621994 T C 4.80E-05 Lung adenocarcinoma PPARA intron 22797724 rs4253772 chr22 46627603 C T 1.00E-08 Cholesterol,total PPARA intron 24097068 rs4253772 chr22 46627603 C T 3.00E-08 LDL cholesterol PPARA intron 24097068 rs9626814 chr22 46637254 G A 1.34E-24 Narcolepsy PPARA UTR-3 19629137 rs78023664 chr22 46647844 G A 5.94E-04 Acne (severe) / / 24927181 rs6007732 chr22 46652303 A T 8.24E-04 Multiple complex diseases PKDREJ UTR-3 17554300 rs6008361 chr22 46652372 G A 9.79E-04 Multiple complex diseases PKDREJ UTR-3 17554300 rs6007740 chr22 46654323 G A 8.36E-04 Multiple complex diseases PKDREJ cds-synon 17554300 rs8143066 chr22 46656607 G A 6.58E-04 Multiple complex diseases PKDREJ cds-synon 17554300 rs9627351 chr22 46663094 G A 3.54E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9615330 chr22 46665006 A G 7.12E-04 Multiple complex diseases TTC38 intron 17554300 rs9615913 chr22 46668515 T A 7.33E-04 Multiple complex diseases TTC38 intron 17554300 rs6007761 chr22 46670394 T C 3.68E-04 Multiple complex diseases TTC38 intron 17554300 rs9615338 chr22 46670720 G C 9.34E-04 Multiple complex diseases TTC38 intron 17554300 rs739164 chr22 46684558 T C 7.12E-05 Multiple complex diseases TTC38 intron 17554300 rs10854854 chr22 46684706 C G 4.28E-05 Type 2 diabetes TTC38 intron 17463246 rs10854854 chr22 46684706 C G 6.10E-05 Multiple complex diseases TTC38 intron 17554300 rs6007794 chr22 46685017 G A 5.18E-04 Multiple complex diseases TTC38 intron 17554300 rs11703435 chr22 46685563 G A 5.49E-04 Multiple complex diseases TTC38 intron 17554300 rs6007845 chr22 46718417 A T 3.50E-04 Multiple complex diseases GTSE1 intron 17554300 rs6008700 chr22 46722560 C T 1.91E-04 Multiple complex diseases GTSE1 intron 17554300 rs9615347 chr22 46728153 A G 6.68E-04 Multiple complex diseases / / 17554300 rs6008770 chr22 46748310 T C 1.51E-04 Multiple complex diseases TRMU intron 17554300 rs9615958 chr22 46751122 T C 4.43E-04 Multiple complex diseases TRMU intron 17554300 rs9615351 chr22 46760481 C G 9.12E-04 Height CELSR1 missense 17255346 rs7293002 chr22 46765995 G A 3.69E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CELSR1 intron 21844884 rs7293002 chr22 46765995 G A 6.09E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CELSR1 intron 21844884 rs6007897 chr22 46780521 T C 1.00E-04 Stroke (ischemic) CELSR1 missense 19403135 rs6007897 chr22 46780521 T C 8.00E-04 Stroke (ischemic) CELSR1 missense 19403135 rs4044210 chr22 46786315 T C 1.00E-04 Stroke (ischemic) CELSR1 missense 19403135 rs9615982 chr22 46791452 C T 2.40E-05 Urinary metabolites CELSR1 intron 21572414 rs9615362 chr22 46795141 C A 2.90E-04 Hearing function CELSR1 intron 17255346 rs9627450 chr22 46807234 T C 1.53E-04 Hearing function CELSR1 intron 17255346 rs6008813 chr22 46812585 G A 4.34E-07 Prostate cancer CELSR1 intron 24185611 rs16995232 chr22 46817321 A G 2.15E-04 Nicotine dependence CELSR1 intron 17158188 rs6007903 chr22 46828205 T C 1.00E-04 Cognitive impairment induced by topiramate CELSR1 intron 22091778 rs4823545 chr22 46838154 T C 6.57E-05 Lipid levels CELSR1 intron pha003082 rs4823813 chr22 46853292 T C 7.21E-04 Alzheimer's disease CELSR1 intron 17998437 rs5768793 chr22 46863319 C T 6.00E-05 Recombination rate CELSR1 intron 21698098 rs1984519 chr22 46876483 G A 6.28E-04 Multiple complex diseases CELSR1 intron 17554300 rs1984519 chr22 46876483 G A 6.01E-05 Serum metabolites CELSR1 intron 19043545 rs3827410 chr22 46879687 C A 9.86E-06 Myopia (pathological) CELSR1 intron 21640322 rs3827410 chr22 46879687 C A 2.80E-04 Response to cytidine analogues (gemcitabine) CELSR1 intron 24483146 rs9616027 chr22 46896491 G A 1.47E-04 Response to cytadine analogues (cytosine arabinoside) CELSR1 intron 24483146 rs5768857 chr22 46900462 C T 3.75E-04 Response to cytadine analogues (cytosine arabinoside) CELSR1 intron 24483146 rs4823839 chr22 46913774 T C 7.97E-06 Colorectal cancer CELSR1 intron 21242260 rs17589429 chr22 46916280 T C 7.07E-06 Colorectal cancer CELSR1 intron 21242260 rs6008891 chr22 46920776 A G 2.45E-04 Lung function (forced expiratory volume in 1 second) CELSR1 intron 24023788 rs6008891 chr22 46920776 A G 3.85E-05 Lung function (forced vital capacity) CELSR1 intron 24023788 rs4823556 chr22 46921060 T C 4.21E-04 White matter integrity CELSR1 intron 22425255 rs738237 chr22 46968286 C T 4.04E-04 Stroke / / pha002887 rs11090889 chr22 46976557 G A 4.04E-05 Orofacial clefts / / 22419666 rs875778 chr22 46984306 T C 9.70E-04 Alcohol dependence / / 24277619 rs6520049 chr22 46996309 C T 5.08E-05 Rheumatoid arthritis / / 21452313 rs4823569 chr22 46998144 C T 4.44E-06 Rheumatoid arthritis / / 21452313 rs138476 chr22 47028314 A T 1.30E-05 Urinary metabolites GRAMD4 intron 21572414 rs138475 chr22 47030240 A C 7.07E-05 Rheumatoid arthritis GRAMD4 intron 21452313 rs138473 chr22 47032086 A G 8.42E-05 Lung function (forced vital capacity) GRAMD4 intron 24023788 rs801720 chr22 47082159 C A 9.88E-05 Relative hand skill CERK UTR-3 24068947 rs801719 chr22 47082345 C T 1.26E-05 Relative hand skill CERK UTR-3 24068947 rs17151 chr22 47090233 A G 7.36E-04 Multiple complex diseases CERK intron 17554300 rs36211081 chr22 47091143 A C 0.00017 Breast cancer CERK missense 23555315 rs6008954 chr22 47102392 T C 2.37E-04 Multiple complex diseases CERK intron 17554300 rs6008954 chr22 47102392 T C 9.29E-04 Response to cytadine analogues (cytosine arabinoside) CERK intron 24483146 rs135693 chr22 47102495 C G 1.10E-06 Urinary metabolites CERK intron 21572414 rs135694 chr22 47102525 T A 1.60E-06 Urinary metabolites CERK intron 21572414 rs135702 chr22 47109525 A G 5.86E-04 Multiple complex diseases CERK intron 17554300 rs13054785 chr22 47109621 T C 7.50E-04 Multiple complex diseases CERK intron 17554300 rs710122 chr22 47198055 G A 7.33E-06 Osteoporosis TBC1D22A intron 20548944 rs812942 chr22 47200180 A G 7.00E-05 Prostate cancer TBC1D22A intron 21743057 rs140535 chr22 47271747 T C 2.69E-04 Fibrinogen TBC1D22A intron 17255346 rs131874 chr22 47275902 T C 1.45E-05 Fibrinogen TBC1D22A intron 17255346 rs131874 chr22 47275902 T C 2.44E-04 Alzheimer's disease (late onset) TBC1D22A intron 21379329 rs1981438 chr22 47288122 T C 9.20E-04 Acute lung injury TBC1D22A intron 22295056 rs2156927 chr22 47288807 G A 7.92E-04 Acute lung injury TBC1D22A intron 22295056 rs738932 chr22 47292488 A G 2.41E-04 Fibrinogen TBC1D22A intron 17255346 rs738932 chr22 47292488 A G 9.31E-06 Smoking behavior TBC1D22A intron 19188921 rs762646 chr22 47294167 A G 2.39E-05 Smoking behavior TBC1D22A intron 19188921 rs6009041 chr22 47295877 T C 7.71E-06 Smoking behavior TBC1D22A intron 19188921 rs6007995 chr22 47297593 T G 9.17E-04 Alzheimer's disease TBC1D22A intron 17998437 rs5767396 chr22 47301789 A G 9.63E-04 Multiple complex diseases TBC1D22A intron 17554300 rs1107131 chr22 47302307 G A 9.90E-05 Serum metabolites TBC1D22A intron 19043545 rs916000 chr22 47303124 T C 5.85E-06 Cardiovascular disease TBC1D22A intron pha003065 rs5769232 chr22 47303927 A C 1.06E-05 Alzheimer's disease (late onset) TBC1D22A intron 21379329 rs5769232 chr22 47303927 A C 7.29E-05 Cardiovascular disease TBC1D22A intron pha003065 rs738935 chr22 47311404 A T 6.06E-05 Tardive dyskinesia TBC1D22A intron 20939080 rs4431 chr22 47338438 G A 3.21E-05 Serum metabolites TBC1D22A intron 19043545 rs136066 chr22 47343818 T A 3.35E-05 Birth weight TBC1D22A intron 17255346 rs136067 chr22 47343997 G A 3.58E-05 Birth weight TBC1D22A intron 17255346 rs136070 chr22 47345410 C T 1.86E-05 Birth weight TBC1D22A intron 17255346 rs136093 chr22 47358135 A G 1.60E-05 Urinary metabolites TBC1D22A intron 21572414 rs11913054 chr22 47360389 G A 4.98E-04 Multiple complex diseases TBC1D22A intron 17554300 rs470059 chr22 47372368 C T 5.39E-04 Response to statin treatment (atorvastatin),change in cholesterol levels TBC1D22A intron 20031582 rs6009104 chr22 47416299 T C 5.23E-04 Response to statin treatment (atorvastatin),change in cholesterol levels TBC1D22A intron 20031582 rs140539 chr22 47440770 T C 9.85E-04 Multiple complex diseases TBC1D22A intron 17554300 rs2180149 chr22 47497208 G A 7.86E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines TBC1D22A intron 21844884 rs738662 chr22 47519604 G A 1.82E-04 Response to platinum-based chemotherapy in small-cell lung cancer TBC1D22A intron 20463552 rs735252 chr22 47520809 T A,C,G 8.76E-04 Acute lung injury TBC1D22A intron 22295056 rs1474855 chr22 47522464 A G 1.26E-04 Acute lung injury TBC1D22A intron 22295056 rs5766687 chr22 47528634 A G 9.74E-05 Acute lung injury TBC1D22A intron 22295056 rs738665 chr22 47529157 G A 1.18E-04 Acute lung injury TBC1D22A intron 22295056 rs5767523 chr22 47530945 G A 1.78E-04 Response to platinum-based chemotherapy in small-cell lung cancer TBC1D22A intron 20463552 rs4823597 chr22 47531320 C T 4.01E-05 Sarcoidosis TBC1D22A intron 19165924 rs4823597 chr22 47531320 C T 1.13E-04 Acute lung injury TBC1D22A intron 22295056 rs4823469 chr22 47532014 T C 1.13E-04 Acute lung injury TBC1D22A intron 22295056 rs5766691 chr22 47532396 A G 4.01E-05 Sarcoidosis TBC1D22A intron 19165924 rs5766691 chr22 47532396 A G 1.00E-06 Longevity TBC1D22A intron 20834067 rs5766691 chr22 47532396 A G 1.13E-04 Acute lung injury TBC1D22A intron 22295056 rs5767526 chr22 47532591 T C 1.04E-04 Acute lung injury TBC1D22A intron 22295056 rs5766693 chr22 47532641 T C 1.50E-04 Acute lung injury TBC1D22A intron 22295056 rs5766697 chr22 47541292 G A 1.85E-04 Obesity (extreme) TBC1D22A intron 21935397 rs13057083 chr22 47543791 A G 8.79E-05 Obesity (extreme) TBC1D22A intron 21935397 rs13057083 chr22 47543791 A G 3.05E-05 Schizophrenia (cytomegalovirus infection interaction) TBC1D22A intron 23358160 rs2295249 chr22 47543943 C T 1.93E-04 Obesity (extreme) TBC1D22A intron 21935397 rs5766699 chr22 47544979 A G 1.95E-04 Obesity (extreme) TBC1D22A intron 21935397 rs7292231 chr22 47546271 T C 1.45E-04 Obesity (extreme) TBC1D22A intron 21935397 rs5767536 chr22 47547142 A G 2.30E-04 Obesity (extreme) TBC1D22A intron 21935397 rs738667 chr22 47548112 C A 2.56E-04 Obesity (extreme) TBC1D22A intron 21935397 rs738667 chr22 47548112 C A 0.000555932 Hypertension (early onset hypertension) TBC1D22A intron 22479346 rs738669 chr22 47548321 C T 2.52E-04 Obesity (extreme) TBC1D22A intron 21935397 rs5767541 chr22 47548538 G A 5.02E-04 Obesity (extreme) TBC1D22A intron 21935397 rs738670 chr22 47548877 A G 2.34E-04 Obesity (extreme) TBC1D22A intron 21935397 rs738671 chr22 47548949 G A 5.02E-04 Obesity (extreme) TBC1D22A intron 21935397 rs4823601 chr22 47549823 A G 1.77E-04 Obesity (extreme) TBC1D22A intron 21935397 rs6008046 chr22 47551527 T C 7.29E-04 Coronary heart disease TBC1D22A intron 21971053 rs5767545 chr22 47552621 G A 3.29E-04 Obesity (extreme) TBC1D22A intron 21935397 rs5767547 chr22 47553037 C G 3.56E-04 Obesity (extreme) TBC1D22A intron 21935397 rs6007611 chr22 47553250 T C 8.66E-04 Obesity (extreme) TBC1D22A intron 21935397 rs910542 chr22 47556343 C T 3.69E-04 Obesity (extreme) TBC1D22A intron 21935397 rs754892 chr22 47556506 C A 3.74E-04 Obesity (extreme) TBC1D22A intron 21935397 rs761739 chr22 47557223 G C 3.70E-04 Obesity (extreme) TBC1D22A intron 21935397 rs4823471 chr22 47557409 C T 3.69E-04 Obesity (extreme) TBC1D22A intron 21935397 rs4823472 chr22 47557477 G C 2.03E-04 Obesity (extreme) TBC1D22A intron 21935397 rs4823603 chr22 47557638 G A 3.69E-04 Obesity (extreme) TBC1D22A intron 21935397 rs4823603 chr22 47557638 G A 6.43E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) TBC1D22A intron 23648065 rs4823473 chr22 47557878 A G 3.77E-04 Obesity (extreme) TBC1D22A intron 21935397 rs4823473 chr22 47557878 A G 6.68E-04 Coronary heart disease TBC1D22A intron 21971053 rs5005651 chr22 47558035 G A 3.86E-04 Obesity (extreme) TBC1D22A intron 21935397 rs17763276 chr22 47558106 C T 3.90E-04 Obesity (extreme) TBC1D22A intron 21935397 rs4823605 chr22 47558684 C T 5.50E-04 Obesity (extreme) TBC1D22A intron 21935397 rs5767553 chr22 47559449 G T 5.59E-04 Obesity (extreme) TBC1D22A intron 21935397 rs5766701 chr22 47559797 G A 5.75E-04 Obesity (extreme) TBC1D22A intron 21935397 rs9626952 chr22 47560334 A G 3.04E-04 Multiple complex diseases TBC1D22A intron 17554300 rs9626952 chr22 47560334 A G 4.78E-04 Alzheimer's disease TBC1D22A intron 17998437 rs9626954 chr22 47560432 C G 1.28E-04 Alzheimer's disease TBC1D22A intron 17998437 rs5766705 chr22 47561347 G C 6.38E-04 Obesity (extreme) TBC1D22A intron 21935397 rs4823608 chr22 47562997 T C 4.04E-04 Obesity (extreme) TBC1D22A intron 21935397 rs2294295 chr22 47571085 C T 8.30E-05 Serum metabolites TBC1D22A UTR-3 19043545 rs135139 chr22 47632019 G T 9.70E-04 Multiple complex diseases / / 17554300 rs11704468 chr22 47659014 C T 6.80E-04 Alcohol dependence / / 20201924 rs5767645 chr22 47670894 T C 0.0000006 Amygdala reactivity / / 22856363 rs11090754 chr22 47671207 T C 2.16E-06 Alcohol and nictotine co-dependence / / 20158304 rs11090754 chr22 47671207 T C 2.84E-05 Body Mass Index / / pha003009 rs11090754 chr22 47671207 T C 7.55E-05 Waist Circumference / / pha003024 rs11090754 chr22 47671207 T C 8.59E-05 Weight / / pha003026 rs11090754 chr22 47671207 T C 4.37E-05 Weight / / pha003027 rs9626986 chr22 47675283 T C 5.21E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5767675 chr22 47710815 G A 2.08E-04 Osteoarthritis / / 19508968 rs16996717 chr22 47722522 C T 1.87E-04 Multiple complex diseases / / 17554300 rs140530 chr22 47752111 G T 3.14E-04 Parkinson's disease LOC339685 intron 17052657 rs11090762 chr22 47755325 G T 8.00E-06 Parkinson's disease LOC339685 intron 17052657 rs9615156 chr22 47780845 C T 5.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs11090767 chr22 47783452 G A 7.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs470123 chr22 47786315 G C 8.71E-04 Multiple complex diseases / / 17554300 rs12483769 chr22 47790072 T C 3.65E-04 Multiple complex diseases / / 17554300 rs910081 chr22 47797442 C T 3.46E-05 Multiple complex diseases / / 17554300 rs4823639 chr22 47800559 A G 6.57E-05 Serum albumin level / / pha003084 rs10483235 chr22 47814553 T C 5.22E-04 Multiple complex diseases / / 17554300 rs16996808 chr22 47817083 A G 7.54E-04 Insulin resistance / / 21901158 rs2040411 chr22 47836412 G A 9.77E-05 Suicide attempts in bipolar disorder / / 21423239 rs11912983 chr22 47837738 A C 6.94E-04 Multiple complex diseases / / 17554300 rs1076930 chr22 47846204 A C 4.69E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs8139889 chr22 47879110 T G 4.05E-04 Multiple complex diseases / / 17554300 rs2301382 chr22 47893053 G A 6.53E-05 Cognitive test performance / / 20125193 rs12159918 chr22 47906614 T C 6.53E-05 Cognitive test performance / / 20125193 rs130486 chr22 47943525 G A 1.07E-05 Fibrinogen / / pha003068 rs5767804 chr22 47948588 G A 5.39E-04 Smoking quantity / / 24665060 rs135589 chr22 47990929 T C 1.50E-06 Urinary metabolites / / 21572414 rs5767849 chr22 48022020 C A 3.16E-04 Obesity (extreme) FLJ46257 intron 21935397 rs11705127 chr22 48023818 C T 2.55E-04 Obesity (extreme) FLJ46257 intron 21935397 rs6359 chr22 48085915 T C 5.01E-04 Type 2 diabetes / / 17463246 rs6359 chr22 48085915 T C 7.28E-04 Schizophrenia / / 19197363 rs4823673 chr22 48086483 G A 7.61E-04 Multiple complex diseases / / 17554300 rs400116 chr22 48107054 G A 1.48E-04 Schizophrenia / / 19197363 rs397723 chr22 48112790 G A 1.36E-07 Primary biliary cirrhosis / / 23000144 rs397723 chr22 48112790 G A 0.000000136 Facial morphology / / 23028347 rs132183 chr22 48124010 G A 1.00E-04 Serum metabolites / / 19043545 rs132192 chr22 48130194 T C 2.23E-27 Narcolepsy / / 19629137 rs6007738 chr22 48146737 G A 9.88E-04 Multiple complex diseases / / 17554300 rs6007738 chr22 48146737 G A 6.15E-04 White matter integrity / / 22425255 rs5767972 chr22 48149985 A G 9.05E-05 Serum metabolites / / 19043545 rs878487 chr22 48177116 A G 3.19E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs9627141 chr22 48178105 A G 6.51E-05 Leukocyte Counts / / pha003091 rs5767992 chr22 48188253 T C 8.00E-06 Obesity-related traits / / 23251661 rs5767998 chr22 48196022 C A 1.71E-05 Alzheimer's disease (late onset) / / 21460841 rs8184974 chr22 48198191 G A 1.82E-05 Alzheimer's disease (late onset) / / 21460841 rs5768002 chr22 48199780 A G 2.05E-05 Alzheimer's disease (late onset) / / 21460841 rs932548 chr22 48200547 C T 5.34E-05 Alzheimer's disease (late onset) / / 21460841 rs932550 chr22 48200601 T A 5.98E-05 Alzheimer's disease (late onset) / / 21460841 rs5768003 chr22 48201014 A C 6.63E-05 Alzheimer's disease (late onset) / / 21460841 rs4823695 chr22 48202655 G A 8.85E-04 Coronary heart disease / / 21971053 rs5768005 chr22 48206356 G A 7.88E-05 Alzheimer's disease (late onset) / / 21460841 rs6008401 chr22 48209008 G T 3.37E-05 Alzheimer's disease (late onset) / / 21460841 rs6008401 chr22 48209008 G T 3.40E-05 Myopia (pathological) / / 23049088 rs1884698 chr22 48213482 C T 2.84E-05 Coronary heart disease / / pha003033 rs9615651 chr22 48218843 G A 1.84E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6008409 chr22 48219820 C T 9.12E-04 Aortic root size / / 21223598 rs5768035 chr22 48224624 C G 1.40E-05 Urinary metabolites / / 21572414 rs5766895 chr22 48224843 G C 7.20E-06 Urinary metabolites / / 21572414 rs5766898 chr22 48225779 T C 6.60E-06 Urinary metabolites / / 21572414 rs5766899 chr22 48225861 G A 7.80E-06 Urinary metabolites / / 21572414 rs2103957 chr22 48250736 G A 8.21E-05 Blood Pressure / / pha003039 rs2103957 chr22 48250736 G A 2.75E-05 Blood Pressure / / pha003045 rs728592 chr22 48271771 G A 6.99E-04 Heart Failure / / pha002884 rs6008436 chr22 48278977 C A 9.41E-06 Heart Failure / / pha002885 rs2338258 chr22 48284025 C T 4.74E-04 Obesity (extreme) / / 21935397 rs9627183 chr22 48284514 G A 3.00E-06 Attention deficit hyperactivity disorder / / 18821564 rs5768117 chr22 48289754 A C 5.22E-05 Information processing speed / / 21130836 rs9615662 chr22 48295349 A G 8.10E-04 Type 2 diabetes / / 23209189 rs5768162 chr22 48317040 C T 7.95E-04 Multiple complex diseases / / 17554300 rs5768163 chr22 48317103 G A 8.59E-04 Multiple complex diseases / / 17554300 rs874960 chr22 48318132 A G 9.47E-06 Multiple sclerosis / / 17660530 rs9615234 chr22 48321123 G A 1.97E-04 Multiple complex diseases / / 17554300 rs1884516 chr22 48325524 A G 2.11E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs5768202 chr22 48334119 T C 3.50E-05 Response to statin therapy / / 20339536 rs16998000 chr22 48360485 T C 2.47E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13055322 chr22 48365123 C T 8.87E-04 Schizophrenia (cytomegalovirus infection interaction) / / 23358160 rs5768220 chr22 48371721 T C 1.10E-05 Urinary metabolites / / 21572414 rs202143901 chr22 48371985 A G 1.30E-05 Urinary metabolites / / 21572414 rs5768221 chr22 48371985 A AC,AT 1.30E-05 Urinary metabolites / / 21572414 rs10483240 chr22 48394746 C T 3.94E-05 Anxiety and major depressive disorder / / 24047446 rs738704 chr22 48434712 T C 4.01E-04 Alzheimer's disease / / 17998437 rs117294 chr22 48453591 A C,G 7.00E-06 Economic and political preferences (fairness) / / 22566634 rs1014674 chr22 48453666 C A 3.02E-05 Alcohol dependence / / 21703634 rs737791 chr22 48457696 G A 8.12E-06 Alcohol dependence / / 21703634 rs7289613 chr22 48483385 C T 4.39E-05 Heart Rate / / pha003054 rs5768341 chr22 48484533 T C 3.26E-05 Waist-Hip Ratio / / pha003029 rs5767024 chr22 48500387 C T 2.79E-04 Major depressive disorder / / 22472876 rs7292083 chr22 48509092 C T 2.40E-05 Iron levels / / 21208937 rs16998380 chr22 48510196 T C 3.80E-05 Duodenal ulcer / / 22387998 rs16998380 chr22 48510196 T C 4.60E-05 Orofacial clefts / / 22419666 rs16998380 chr22 48510196 T C 4.70E-05 Elbow pain / / pha003008 rs131137 chr22 48546285 A C 9.30E-05 Schizophrenia / / 21791550 rs131137 chr22 48546285 A C 0.000093 Psychosis / / 23164818 rs9615766 chr22 48549033 T C 1.68E-04 Multiple complex diseases / / 17554300 rs6008567 chr22 48562589 T C 1.65E-04 Acute lung injury / / 22295056 rs133527 chr22 48588489 C G 2.19E-04 Acute lung injury / / 22295056 rs133528 chr22 48590929 A G 9.43E-04 Acute lung injury / / 22295056 rs5768434 chr22 48598852 C T 0.000000117 Bisphosphonate-induced osteonecrosis of the jaw / / 22267851 rs5767064 chr22 48607014 G A 2.79E-05 Pulmonary function in asthmatics / / 23541324 rs738184 chr22 48615721 C T 1.25E-07 Body Mass Index / / pha003009 rs13054085 chr22 48630184 G A 2.00E-06 Obesity-related traits / / 23251661 rs133545 chr22 48631684 C A 3.37E-04 Alzheimer's disease / / 24755620 rs133565 chr22 48639993 A G 5.27E-07 Body Mass Index / / pha003009 rs133565 chr22 48639993 A G 1.11E-05 Body Mass Index / / pha003015 rs133565 chr22 48639993 A G 2.60E-05 Waist Circumference / / pha003025 rs133565 chr22 48639993 A G 9.22E-06 Weight / / pha003027 rs1004689 chr22 48651997 T G 2.00E-06 DNA methylation (variation) / / 23725790 rs2338676 chr22 48652711 A G 3.17E-05 Body Mass Index / / pha003009 rs4500 chr22 48655892 G C 1.72E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs133580 chr22 48659880 C T 4.99E-05 Serum metabolites / / 19043545 rs133603 chr22 48677261 T C 6.15E-04 Parkinson's disease / / 17052657 rs6008618 chr22 48694866 C T 3.07E-04 Type 2 diabetes / / 17463246 rs133624 chr22 48700237 A T 1.44E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs133629 chr22 48706516 G A 8.46E-05 Caffeine consumption / / 21490707 rs13054702 chr22 48711616 C T 7.52E-05 Erythrocyte counts / / pha003099 rs742019 chr22 48715863 C T 9.45E-05 Cognitive impairment induced by topiramate / / 22091778 rs133672 chr22 48741583 C T 9.30E-06 Urinary metabolites / / 21572414 rs4407 chr22 48741798 A G 7.14E-06 Serum metabolites / / 19043545 rs4407 chr22 48741798 A G 2.00E-06 Endometrial cancer / / 24096698 rs4407 chr22 48741798 A G 2.29E-06 Endometrial cancer / / 24096698 rs4407 chr22 48741798 A G 3.00E-06 Endometrial cancer / / 24096698 rs4823758 chr22 48766824 A C 4.33E-04 Type 2 diabetes / / 17463246 rs8138593 chr22 48773268 A G 2.87E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs1475988 chr22 48812241 T C 2.49E-04 Suicide attempts in bipolar disorder / / 21423239 rs5768594 chr22 48812871 A G 2.34E-04 Suicide attempts in bipolar disorder / / 21423239 rs2338710 chr22 48816291 G C 6.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs739107 chr22 48816435 C T 6.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs4823767 chr22 48817460 C T 6.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs6007849 chr22 48819202 T C 3.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs5768604 chr22 48819677 T A 2.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs762971 chr22 48821349 G C 2.31E-04 Suicide attempts in bipolar disorder / / 21423239 rs5767143 chr22 48821854 A G 2.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs5768605 chr22 48822541 A G 2.04E-04 Suicide attempts in bipolar disorder / / 21423239 rs4823769 chr22 48823666 T C 2.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs12169256 chr22 48829386 C T 3.98E-04 Myopia (pathological) / / 21095009 rs5768614 chr22 48830394 G A 1.10E-06 Urinary metabolites / / 21572414 rs12172263 chr22 48837907 G A 5.62E-05 Body Mass Index / / pha003022 rs2071751 chr22 48840707 C T 9.74E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2032489 chr22 48843478 C T 8.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16999223 chr22 48859169 T C 0.000814 Salmonella-induced pyroptosis / / 22837397 rs9615901 chr22 48863114 C T 0.000040822 Hypertension (early onset hypertension) / / 22479346 rs3827414 chr22 48864678 A G 8.04E-04 Myocardial Infarction / / pha002883 rs5767167 chr22 48873545 A C 3.96E-05 Waist-Hip Ratio / / pha003029 rs5768690 chr22 48902117 G A 4.67E-04 Myocardial Infarction FAM19A5 intron pha002883 rs6008748 chr22 48909082 T C 0.0000425 Amyotrophic lateral sclerosis FAM19A5 intron 23587638 rs80088139 chr22 48923459 C G 5.00E-06 Bipolar disorder (body mass index interaction) FAM19A5 intron 24322204 rs4823800 chr22 48923775 A C 0.0000492 Amyotrophic lateral sclerosis FAM19A5 intron 23587638 rs5768709 chr22 48929569 A G 1.00E-10 Pancreatic cancer FAM19A5 intron 22158540 rs133468 chr22 48947796 C T 5.27E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines FAM19A5 intron 21844884 rs7292688 chr22 49020407 C T 8.72E-04 Response to taxane treatment (placlitaxel) FAM19A5 intron 23006423 rs7292688 chr22 49020407 C T 5.66E-04 Response to cytadine analogues (cytosine arabinoside) FAM19A5 intron 24483146 rs4261817 chr22 49045798 T C 9.82E-05 Cognitive impairment induced by topiramate FAM19A5 intron 22091778 rs4261817 chr22 49045798 T C 6.53E-05 Hemoglobin FAM19A5 intron pha003096 rs4261817 chr22 49045798 T C 8.88E-05 Hematocrit FAM19A5 intron pha003097 rs5771884 chr22 49046349 T C 5.20E-04 Allergic sensitization FAM19A5 intron 23817571 rs8142256 chr22 49050435 T C 1.00E-04 Cognitive impairment induced by topiramate FAM19A5 intron 22091778 rs17823579 chr22 49059226 C T 9.20E-06 Urinary metabolites FAM19A5 intron 21572414 rs5771917 chr22 49059311 T G 3.21E-04 Multiple complex diseases FAM19A5 intron 17554300 rs16999682 chr22 49065908 C G 7.16E-04 Multiple complex diseases FAM19A5 intron 17554300 rs16999684 chr22 49066878 A C 3.13E-05 Nicotine smoking FAM19A5 intron 19268276 rs2057204 chr22 49067053 A G 7.16E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) FAM19A5 intron 24236485 rs5771934 chr22 49069450 T C 9.03E-05 Nicotine smoking FAM19A5 intron 19268276 rs130094 chr22 49071768 A G 9.25E-04 Multiple complex diseases FAM19A5 intron 17554300 rs132220 chr22 49076564 G A 1.83E-04 Amyotrophic Lateral Sclerosis FAM19A5 intron 17362836 rs132221 chr22 49076768 C T 2.55E-04 Amyotrophic Lateral Sclerosis FAM19A5 intron 17362836 rs910570 chr22 49076870 A G 6.30E-06 Urinary metabolites FAM19A5 intron 21572414 rs5771717 chr22 49081164 G A 1.51E-04 Multiple complex diseases FAM19A5 intron 17554300 rs130110 chr22 49083887 T C 1.10E-05 Amyotrophic Lateral Sclerosis FAM19A5 intron 17362836 rs733572 chr22 49090335 C G 2.84E-04 Multiple complex diseases FAM19A5 intron 17554300 rs4925446 chr22 49099888 T C 1.50E-04 Smoking behavior FAM19A5 intron 23049750 rs132248 chr22 49110377 T C 4.86E-04 Multiple complex diseases FAM19A5 intron 17554300 rs132250 chr22 49115439 T C 9.44E-05 Insulin resistance FAM19A5 intron 21901158 rs130222 chr22 49136285 G A 1.26E-04 Multiple complex diseases FAM19A5 intron 17554300 rs6010521 chr22 49143944 G C 5.95E-04 Type 2 diabetes FAM19A5 intron 17463246 rs131958 chr22 49145300 G A 2.11E-04 Multiple complex diseases FAM19A5 intron 17554300 rs131958 chr22 49145300 G A 7.70E-05 Memory performance FAM19A5 intron 22105620 rs9628484 chr22 49152560 G A 3.24E-05 Myopia (pathological) / / 21640322 rs13056461 chr22 49155087 G A 9.03E-05 Cognitive performance / / 19734545 rs13057753 chr22 49155317 C T 6.35E-05 Myopia (pathological) / / 21640322 rs131016 chr22 49171558 C T 3.35E-04 Multiple complex diseases / / 17554300 rs131021 chr22 49173615 C T 9.13E-05 Myopia (pathological) / / 21640322 rs6010529 chr22 49177741 A G 8.68E-04 Alcohol dependence / / 21314694 rs131031 chr22 49180535 A G 5.83E-05 Type 2 diabetes / / 17463246 rs9617466 chr22 49203940 A G 7.06E-05 Height / / pha003011 rs8139003 chr22 49204613 A G 3.24E-05 Psoriasis / / 20953187 rs9628576 chr22 49215890 T C 9.83E-05 Multiple complex diseases / / 17554300 rs6009447 chr22 49313512 C G 7.05E-04 Type 2 diabetes / / 17463246 rs6009447 chr22 49313512 C G 4.29E-05 Serum metabolites / / 19043545 rs1004827 chr22 49334650 A G 8.00E-06 Cholesterol / / pha003083 rs2180055 chr22 49336423 C T 6.05E-05 Cholesterol / / pha003083 rs2024700 chr22 49350024 A C 1.89E-04 Smoking initiation / / 24665060 rs4823946 chr22 49363849 T C 2.39E-05 Bipolar disorder / / 22925353 rs742977 chr22 49378494 G A 2.46E-04 Nicotine dependence / / 17158188 rs17178433 chr22 49416835 T G 6.89E-04 Multiple complex diseases / / 17554300 rs17000257 chr22 49431668 A G 9.78E-04 Multiple complex diseases / / 17554300 rs5769835 chr22 49431702 G T 6.24E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs5769835 chr22 49431702 G T 7.89E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs13053967 chr22 49431959 G A 7.88E-04 Smoking cessation / / 24665060 rs5769389 chr22 49434131 A G 8.19E-05 Cognitive impairment induced by topiramate / / 22091778 rs5769840 chr22 49436004 C T 4.16E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs17000271 chr22 49446381 T C 2.06E-05 Multiple sclerosis / / 17660530 rs4823984 chr22 49449618 T G 4.96E-04 Multiple complex diseases / / 17554300 rs135248 chr22 49527783 A G 2.70E-05 Blood Pressure / / pha003043 rs739195 chr22 49530626 G A 4.18E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9616445 chr22 49534864 A C 7.32E-05 Alzheimer's disease (age of onset) / / 22005931 rs9616446 chr22 49534988 A C 7.58E-05 Alzheimer's disease (age of onset) / / 22005931 rs9616449 chr22 49535461 C T 7.08E-05 Alzheimer's disease (age of onset) / / 22005931 rs9616451 chr22 49536709 A G 6.26E-05 Alzheimer's disease (age of onset) / / 22005931 rs9616237 chr22 49537896 C G 5.27E-05 Alzheimer's disease (age of onset) / / 22005931 rs4823920 chr22 49557356 T G 4.06E-04 HIV-1 viral setpoint / / 17641165 rs187395447 chr22 49562096 A G 0.00008044 Sarcoidosis / / 22952805 rs5769444 chr22 49577306 G A 3.35E-04 Type 2 diabetes / / 17463246 rs11090936 chr22 49582574 G A 3.10E-04 Type 2 diabetes / / 17463246 rs8139488 chr22 49589684 A G 3.10E-04 Type 2 diabetes / / 17463246 rs6520088 chr22 49594014 T C 2.20E-05 Tunica Media / / pha003036 rs5769452 chr22 49595814 C A 5.44E-07 Glycemic traits (pregnancy) / / 23903356 rs5769452 chr22 49595814 C A 5.69E-06 Glycemic traits (pregnancy) / / 23903356 rs11913533 chr22 49597489 T C 9.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6520090 chr22 49603667 A G 2.12E-05 Tunica Media / / pha003036 rs916249 chr22 49609689 C A 2.54E-06 Tunica Media / / pha003036 rs8140508 chr22 49610259 T C 5.65E-06 Tunica Media / / pha003036 rs9616521 chr22 49623957 T C 1.65E-05 Tunica Media / / pha003036 rs6009556 chr22 49625070 T C 4.35E-04 Alzheimer's disease (late onset) / / 21379329 rs2858631 chr22 49640785 T C 1.70E-05 Urinary metabolites / / 21572414 rs767219 chr22 49642470 C T 7.94E-05 Smoking cessation / / 24665060 rs2688140 chr22 49644340 A G 7.12E-04 Alzheimer's disease / / 24755620 rs2688136 chr22 49647886 G A 5.26E-04 Alzheimer's disease / / 24755620 rs2858638 chr22 49648936 C T 2.10E-05 Urinary metabolites / / 21572414 rs2858639 chr22 49649724 C T 8.50E-06 Urinary metabolites / / 21572414 rs2688133 chr22 49650157 T C 4.80E-06 Urinary metabolites / / 21572414 rs2858641 chr22 49651777 C T 2.10E-05 Urinary metabolites / / 21572414 rs2858642 chr22 49651937 A C 1.20E-05 Urinary metabolites / / 21572414 rs2858642 chr22 49651937 A C 3.71E-04 Coronary heart disease / / 21606135 rs5769526 chr22 49675668 A G 1.60E-05 Urinary metabolites / / 21572414 rs5770180 chr22 49675958 T A 1.80E-05 Urinary metabolites / / 21572414 rs7290877 chr22 49684418 G A 8.35E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs5769541 chr22 49688404 G C 2.10E-05 Urinary metabolites / / 21572414 rs2858509 chr22 49689312 C T 6.18E-05 Socioeconomic Factors / / pha003067 rs762926 chr22 49690620 T C 3.16E-05 Erythrocyte counts / / pha003101 rs2243690 chr22 49690989 G A 3.16E-05 Erythrocyte counts / / pha003101 rs7285686 chr22 49697476 T C 7.45E-04 Multiple complex diseases / / 17554300 rs9627696 chr22 49701877 G A 7.42E-04 Multiple complex diseases / / 17554300 rs11912713 chr22 49710325 G A 6.44E-05 Insulin resistance / / 21901158 rs35716329 chr22 49710325 G GA 6.44E-05 Insulin resistance / / 21901158 rs6009619 chr22 49714484 T C 6.32E-04 Insulin resistance / / 21901158 rs7287432 chr22 49714669 G T 6.13E-04 Insulin resistance / / 21901158 rs7287593 chr22 49714781 G A 7.59E-04 Insulin resistance / / 21901158 rs73173200 chr22 49720926 G A 3.02E-06 Personality dimensions / / 23658558 rs12169496 chr22 49723435 A G 2.78E-04 Hearing function / / 17255346 rs12169496 chr22 49723435 A G 3.76E-05 Multiple complex diseases / / 17554300 rs12628115 chr22 49723455 C T 2.44E-04 Coronary Artery Disease / / 17634449 rs860237 chr22 49729558 A C 5.75E-04 Multiple complex diseases / / 17554300 rs17000793 chr22 49731737 G C 1.24E-04 Hearing function / / 17255346 rs17000793 chr22 49731737 G C 3.25E-04 Type 2 diabetes / / 17463246 rs17000793 chr22 49731737 G C 7.89E-04 Multiple complex diseases / / 17554300 rs848734 chr22 49736955 A G 1.16E-04 Multiple complex diseases / / 17554300 rs8138195 chr22 49739747 T C 5.56E-04 Coronary heart disease / / 21971053 rs3213523 chr22 49745407 T C 2.75E-06 Body mass index / / 24827717 rs17000838 chr22 49750715 G A 5.92E-04 Tourette syndrome / / 22889924 rs2269520 chr22 49761264 C T 3.52E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs5770310 chr22 49767410 G T 8.05E-04 Coronary Artery Disease / / 17634449 rs5770344 chr22 49779694 T C 2.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs5770363 chr22 49783510 G T 7.22E-05 stroke (ischemic) / / 17434096 rs5769630 chr22 49793009 C A 3.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs9628003 chr22 49800082 C T 8.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs17000918 chr22 49812502 C A 4.00E-09 Immune reponse to smallpox (secreted IL-1beta) / / 22610502 rs10854865 chr22 49813232 A G 1.20E-04 Type 2 diabetes / / 17463246 rs9616618 chr22 49827532 G C 6.27E-04 Alzheimer's disease / / 17998437 rs8138283 chr22 49841479 A G 4.99E-05 Brain structure / / 22504417 rs9627735 chr22 49842289 A T 6.00E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs9628021 chr22 49842416 G A 6.53E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs714006 chr22 49847719 G A 9.15E-05 Erythrocyte counts / / pha003090 rs41521145 chr22 49864708 A G 2.15E-08 Multiple complex diseases / / 17554300 rs17246357 chr22 49868168 G A 2.10E-05 Urinary metabolites / / 21572414 rs6009720 chr22 49873496 T C 4.63E-04 Multiple complex diseases / / 17554300 rs4605480 chr22 49876931 T C 5.04E-04 Type 2 diabetes / / 17463246 rs470017 chr22 49912000 G T 2.00E-05 Cognitive function / / 24684796 rs134458 chr22 49916533 G A 2.26E-05 Paget's disease / / 20436471 rs5770525 chr22 49930353 C A 9.27E-04 Suicide attempts in bipolar disorder / / 21423239 rs5770527 chr22 49932138 A G 8.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs135776 chr22 49939322 C G 2.20E-05 Urinary metabolites / / 21572414 rs135851 chr22 49977557 A C 3.32E-10 Gallstones / / 17632509 rs5770562 chr22 49978502 C T 5.18E-04 Type 2 diabetes / / 17463246 rs2071893 chr22 49978575 T C 6.02E-04 Type 2 diabetes / / 17463246 rs2071901 chr22 50034660 G A 5.80E-04 Suicide attempts in bipolar disorder C22orf34 intron 21423239 rs5770619 chr22 50044516 G A 8.31E-04 Suicide attempts in bipolar disorder C22orf34 intron 21423239 rs2012378 chr22 50072755 C T 5.77E-04 Multiple complex diseases / / 17554300 rs2012378 chr22 50072755 C T 5.84E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs6009820 chr22 50085456 C T 9.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6009822 chr22 50085731 G A 7.42E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs6009824 chr22 50086373 G A 7.00E-06 Natriuretic peptide levels / / 21273288 rs6009824 chr22 50086373 G A 5.73E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs4824080 chr22 50091359 C T 8.06E-04 Coronary Artery Disease / / 17634449 rs738413 chr22 50092148 C A 8.29E-04 Multiple complex diseases / / 17554300 rs12168899 chr22 50101815 T C 2.60E-06 Asthma (childhood onset) / / 23829686 rs9616730 chr22 50120255 A G 2.60E-05 Urinary metabolites / / 21572414 rs4824093 chr22 50128268 G A 8.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs41518148 chr22 50178812 G A 5.81E-04 Multiple complex diseases BRD1 intron 17554300 rs9628141 chr22 50209855 G A 6.27E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines BRD1 intron 21844884 rs138880 chr22 50218611 A C 2.00E-07 Schizophrenia / / 23894747 rs1569958 chr22 50245583 C T 2.12E-04 Multiple complex diseases / / 17554300 rs6520066 chr22 50294988 C T 9.36E-05 Schizophrenia / / 19571811 rs3922872 chr22 50297888 T C 1.88E-04 Acne (severe) ALG12 missense 24927181 rs146322225 chr22 50303554 T C 0.0000076 Breast cancer ALG12 missense 23555315 rs28460675 chr22 50332005 G T 0.0000997 Nicotine dependence (smoking) / / 22377092 rs62231870 chr22 50345556 G C 7.71E-06 Acne (severe) / / 24927181 rs56091001 chr22 50346042 C T 4.00E-06 Acne (severe) / / 24927181 rs28372448 chr22 50350971 G A 8.00E-06 Cannabis dependence / / 21668797 rs5771069 chr22 50435480 A G 4.00E-08 Ulcerative colitis IL17REL missense 20228798 rs5771069 chr22 50435480 A G 2.00E-07 Ulcerative colitis IL17REL missense 21297633 rs5771069 chr22 50435480 A G 4.00E-08 Multiple sclerosis IL17REL missense 22190364 rs5771069 chr22 50435480 A G 0.00058 Primary sclerosing cholangitis IL17REL missense 22521342 rs137866 chr22 50447384 G A 7.45E-04 Type 2 diabetes IL17REL intron 17463246 rs137878 chr22 50456791 G A 4.30E-04 Alcohol dependence / / 20201924 rs137878 chr22 50456791 G A 6.90E-04 Alcohol dependence / / 20201924 rs1079653 chr22 50474857 A G 2.42E-04 Stroke TTLL8 intron pha002886 rs9628315 chr22 50480108 C T 8.56E-04 Stroke TTLL8 missense pha002886 rs7290681 chr22 50492235 G A 1.20E-05 Urinary metabolites TTLL8 intron 21572414 rs4838820 chr22 50527818 G A 2.50E-05 Urinary metabolites MOV10L1 nearGene-5 21572414 rs4838823 chr22 50534909 T G 2.30E-05 Urinary metabolites MOV10L1 intron 21572414 rs9617024 chr22 50543760 T C 2.10E-05 Urinary metabolites MOV10L1 intron 21572414 rs9617024 chr22 50543760 T C 8.18E-04 Lymphocyte counts MOV10L1 intron 22286170 rs138229 chr22 50557407 A G 3.64E-04 Schizophrenia MOV10L1 intron 19197363 rs138229 chr22 50557407 A G 9.00E-06 Behavioural disinhibition (generation interaction) MOV10L1 intron 23942779 rs2272836 chr22 50582550 C A 6.78E-06 Obesity-related traits MOV10L1 cds-synon 23251661 rs4838811 chr22 50585442 C G 7.70E-06 Urinary metabolites MOV10L1 intron 21572414 rs2015453 chr22 50586803 G C 8.00E-06 Urinary metabolites MOV10L1 intron 21572414 rs5771086 chr22 50595842 T C 5.05E-04 Hemoglobin concentration MOV10L1 intron 20534544 rs760753 chr22 50597545 A G 3.20E-06 Urinary metabolites MOV10L1 intron 21572414 rs5771204 chr22 50614476 T C 7.66E-04 Response to taxane treatment (placlitaxel) PANX2 intron 23006423 rs7288889 chr22 50625166 T G 5.21E-04 Taste perception TRABD intron 22132133 rs735119 chr22 50628746 T A,G 5.21E-04 Taste perception TRABD intron 22132133 rs6010202 chr22 50644177 G A 4.89E-04 Response to taxane treatment (placlitaxel) SELO intron 23006423 rs5771104 chr22 50651839 G A 4.58E-04 Response to taxane treatment (placlitaxel) SELO intron 23006423 rs11703673 chr22 50652427 C T 7.83E-04 Response to taxane treatment (placlitaxel) SELO intron 23006423 rs5771242 chr22 50661869 T C 1.00E-06 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) TUBGCP6 intron 24023788 rs5771242 chr22 50661869 T C 3.87E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TUBGCP6 intron 24023788 rs4838865 chr22 50664612 A G 1.46E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) TUBGCP6 missense 24023788 rs4838865 chr22 50664612 A G 6.31E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) TUBGCP6 missense 24023788 rs730936 chr22 50665860 T C 5.52E-05 Erythrocyte counts TUBGCP6 intron pha003101 rs17836662 chr22 50672154 G A 9.39E-05 Serum metabolites TUBGCP6 intron 19043545 rs5771259 chr22 50675962 G A 4.77E-05 Type 2 diabetes TUBGCP6 intron 17463246 rs7511006 chr22 50676259 T C 1.00E-06 Obesity-related traits TUBGCP6 intron 23251661 rs5771109 chr22 50678571 T C 1.28E-06 Obesity-related traits TUBGCP6 intron 23251661 rs139896192 chr22 50682785 C T 0.0000037 Breast cancer (ER positive) TUBGCP6 missense 23555315 rs139896192 chr22 50682785 C T 0.000051 Breast cancer TUBGCP6 missense 23555315 rs5771270 chr22 50682865 G A 3.90E-06 Obesity-related traits TUBGCP6 cds-synon 23251661 rs12163302 chr22 50859164 C G 0.000728 Salmonella-induced pyroptosis PPP6R2 intron 22837397 rs1053744 chr22 50885775 A G 3.00E-07 Asthma (aspirin-intolerant) SBF1 cds-synon 21072201 rs5770980 chr22 50886220 T C 8.82E-04 Response to taxane treatment (placlitaxel) SBF1 intron 23006423 rs4824118 chr22 50896121 C T 5.08E-05 Smoking cessation SBF1 intron 24665060 rs11703111 chr22 50896901 G A 1.55E-05 Smoking cessation SBF1 intron 24665060 rs2236030 chr22 50899310 G A 6.90E-16 Progranulin levels SBF1 intron 21087763 rs2236030 chr22 50899310 G A 6.90E-16 Myocardial infarction SBF1 intron 21211798 rs5771040 chr22 50902390 A G 2.00E-06 IgG glycosylation SBF1 intron 23382691 rs8138406 chr22 50937445 C T 7.20E-08 Red blood cell traits / / 23222517 rs762669 chr22 50943423 G A 3.27E-11 Other erythrocyte phenotypes LMF2 intron 19862010 rs762669 chr22 50943423 G A 2.29E-07 Red blood cell traits LMF2 intron 23222517 rs128941 chr22 50944163 G A 4.52E-04 Parkinson's disease LMF2 cds-synon 17052657 rs128941 chr22 50944163 G A 1.54E-07 Red blood cell traits LMF2 cds-synon 23222517 rs131820 chr22 50952570 A C,G,T 1.24E-10 Other erythrocyte phenotypes NCAPH2 intron 19862010 rs131820 chr22 50952570 A C,G,T 7.11E-10 Red blood cell traits NCAPH2 intron 23222517 rs131817 chr22 50955538 A G 6.62E-05 HIV(mother-to-child transmission) NCAPH2 intron 20487506 rs131816 chr22 50957462 C A,G,T 1.07E-11 Other erythrocyte phenotypes NCAPH2 intron 19862010 rs131816 chr22 50957462 C A,G,T 1.17E-11 Red blood cell traits NCAPH2 intron 23222517 rs3091397 chr22 50957520 G A 9.40E-13 Other erythrocyte phenotypes NCAPH2 intron 19862010 rs3091397 chr22 50957520 G A 1.51E-15 Red blood cell traits NCAPH2 intron 23222517 rs2782 chr22 50961854 T C 1.37E-09 Other erythrocyte phenotypes NCAPH2 UTR-3 19862010 rs2782 chr22 50961854 T C 1.00E-06 Blood cell counts and traits,in red and white blood cells NCAPH2 UTR-3 21153663 rs2782 chr22 50961854 T C 7.16E-13 Red blood cell traits NCAPH2 UTR-3 23222517 rs12148 chr22 50962208 T G 1.23E-09 Other erythrocyte phenotypes SCO2 cds-synon 19862010 rs12148 chr22 50962208 T G 5.64E-13 Red blood cell traits SCO2 cds-synon 23222517 rs140523 chr22 50962782 C G,T 1.23E-09 Other erythrocyte phenotypes SCO2 missense 19862010 rs140523 chr22 50962782 C G,T 1.58E-10 Red blood cell traits SCO2 missense 23222517 rs470119 chr22 50966914 T C 8.77E-09 Other erythrocyte phenotypes TYMP intron 19862010 rs470119 chr22 50966914 T C 4.00E-08 Blood cell counts and other traits TYMP intron 20139978 rs470119 chr22 50966914 T C 4.37E-08 Blood cell counts and other traits TYMP intron 20139978 rs470119 chr22 50966914 T C 2.21E-12 Red blood cell traits TYMP intron 23222517 rs140522 chr22 50971266 T C 4.97E-11 Other erythrocyte phenotypes ODF3B nearGene-5 19862010 rs140522 chr22 50971266 T C 2.00E-08 Multiple sclerosis ODF3B nearGene-5 21833088 rs140522 chr22 50971266 T C 0.00000002 Mean corpuscular volume ODF3B nearGene-5 22560525 rs140522 chr22 50971266 T C 5.00E-23 Red blood cell traits ODF3B nearGene-5 23222517 rs131794 chr22 50971752 A C 1.00E-15 Mean corpuscular volume ODF3B nearGene-5 19862010 rs131794 chr22 50971752 A C 1.81E-12 Red blood cell traits ODF3B nearGene-5 23222517 rs131794 chr22 50971752 A C 4.00E-16 Blood metabolite levels ODF3B nearGene-5 24816252 rs131788 chr22 50976754 T C 4.86E-07 Red blood cell traits / / 23222517 rs131788 chr22 50976754 T C 9.00E-06 Obesity-related traits / / 23251661 rs140521 chr22 50978024 C A 1.55E-10 Other erythrocyte phenotypes / / 19862010 rs140521 chr22 50978024 C A 1.86E-11 Red blood cell traits / / 23222517 rs5770871 chr22 50978262 G A 5.14E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs131784 chr22 50981436 G A 3.91E-11 Other erythrocyte phenotypes / / 19862010 rs131784 chr22 50981436 G A 9.08E-08 Red blood cell traits / / 23222517 rs140519 chr22 50988062 G T 5.20E-08 Red blood cell traits KLHDC7B cds-synon 23222517 rs131779 chr22 50988193 A G 1.97E-08 Red blood cell traits KLHDC7B missense 23222517 rs131778 chr22 50989326 A G 2.76E-08 Red blood cell traits KLHDC7B UTR-3 23222517 rs6009989 chr22 50989678 A G 1.10E-09 Health and aging,CVD and cancer age of onset SYCE3 missense 22174011 rs6009989 chr22 50989678 A G 4.50E-12 Health and aging,CVD and cancer age of onset SYCE3 missense 22174011 rs6520149 chr22 50990669 G A 2.84E-04 Type 2 diabetes SYCE3 intron 17463246 rs131777 chr22 50991033 C T 1.01E-07 Red blood cell traits SYCE3 intron 23222517 rs6009921 chr22 50991205 G A 5.82E-04 Type 2 diabetes SYCE3 intron 17463246 rs4824130 chr22 50998973 A C 8.01E-07 Red blood cell traits SYCE3 intron 23222517 rs140518 chr22 50999182 C T 1.30E-05 F-cell distribution SYCE3 intron 21326311 rs140518 chr22 50999182 C T 5.69E-07 Red blood cell traits SYCE3 intron 23222517 rs140516 chr22 51004053 T C 2.40E-07 Red blood cell traits / / 23222517 rs131766 chr22 51004104 C T 4.70E-08 Red blood cell traits / / 23222517 rs2334104 chr22 51006716 G A 1.28E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs470117 chr22 51009953 C T 1.80E-05 Urinary metabolites CPT1B missense 21572414 rs470117 chr22 51009953 C T 2.49E-07 Red blood cell traits CPT1B missense 23222517 rs140515 chr22 51015210 G C,T 1.50E-09 Red blood cell traits CPT1B intron 23222517 rs131758 chr22 51017082 T A 6.50E-07 Red blood cell traits CPT1B UTR-5 23222517 rs5770917 chr22 51017353 T C 6.00E-08 Narcolepsy CHKB-CPT1B intron 18820697 rs140514 chr22 51018579 A G 2.15E-08 Red blood cell traits CHKB intron 23222517 rs6009932 chr22 51023340 A G 1.00E-04 Atrial fibrillation CHKB nearGene-5 21846873 rs131750 chr22 51024308 T C 4.79E-07 Red blood cell traits / / 23222517 rs131749 chr22 51024624 T C 6.81E-07 Red blood cell traits / / 23222517 rs131748 chr22 51024837 G A 8.44E-08 Red blood cell traits / / 23222517 rs131746 chr22 51025595 C G 4.97E-08 Red blood cell traits / / 23222517 rs140513 chr22 51028255 C T 1.08E-07 Red blood cell traits / / 23222517 rs3091399 chr22 51030749 A G 2.20E-05 Urinary metabolites / / 21572414 rs5770953 chr22 51062938 C T 3.49E-06 Personality dimensions ARSA UTR-3 22628180 rs6151429 chr22 51063477 T C 5.00E-13 Blood metabolite levels ARSA UTR-3 24816252 rs6151429 chr22 51063477 T C 7.00E-18 Blood metabolite levels ARSA UTR-3 24816252 rs131715 chr22 51066921 G A 9.30E-04 Response to cytadine analogues (cytosine arabinoside) ARSA nearGene-5 24483146 rs6010044 chr22 51101938 A C 3.00E-08 Fibrinogen / / 23969696 rs9616906 chr22 51104680 G A 4.86E-04 Multiple complex diseases / / 17554300 rs9616906 chr22 51104680 G A 1.00E-06 Longevity / / 20834067 rs739365 chr22 51140316 C T 1.63E-04 Lymphocyte counts SHANK3 intron 22286170 rs756638 chr22 51171693 G A 8.61E-04 Taste perception SHANK3 nearGene-3 22132133 rs3810648 chr22 51175626 A G 2.95E-04 Cholesterol LOC100506917 intron 17255346 rs3810648 chr22 51175626 A G 2.80E-04 Alzheimer's disease (late onset) LOC100506917 intron 21379329 rs2285395 chr22 51178090 G A 4.83E-05 Cholesterol ACR intron 17255346 rs2285395 chr22 51178090 G A 1.38E-04 Alzheimer's disease (late onset) ACR intron 21379329 rs28729663 chr22 51219006 G A 0.000182 Schizophrenia RABL2B intron 23637625 rs41323649 chrMT 228 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2857290 chrMT 16270 C T 3.42E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs311187 chrX 2716346 G A 0.0000264 Trunk fat mass XG intron 23436924 rs5939373 chrX 2776372 T C 7.71E-04 Body mass index GYG2 intron 21701565 rs5939384 chrX 2789848 T G 2.60E-05 Urinary metabolites GYG2 intron 21572414 rs9334 chrX 2822253 C T 2.40E-05 Urinary metabolites ARSD UTR-3 21572414 rs1043269 chrX 2823683 T G 2.70E-05 Urinary metabolites ARSD UTR-3 21572414 rs6642067 chrX 2830291 T C 1.50E-06 Urinary metabolites ARSD intron 21572414 rs3747394 chrX 2847133 A G 2.75E-05 Smoking initiation ARSD intron 24665060 rs5982925 chrX 2850801 G C 8.61E-04 Spine bone size / / 23207799 rs211640 chrX 2871011 G C 2.00E-05 Urinary metabolites ARSE intron 21572414 rs190023 chrX 2873845 C A 1.10E-05 Urinary metabolites ARSE intron 21572414 rs12393627 chrX 2885723 A G 6.00E-12 Height / / 21998595 rs12393627 chrX 2885723 A G 5.00E-12 Height / / 22021425 rs17335184 chrX 3137404 G A 3.33E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1622778 chrX 3224257 A G 1.36E-05 Schizophrenia / / 19571809 rs1635235 chrX 3228891 A G 1.25E-05 Schizophrenia MXRA5 cds-synon 19571809 rs148675322 chrX 3228966 C G 0.0008 Prostate cancer MXRA5 missense 23555315 rs1635238 chrX 3231850 G A 6.27E-06 Schizophrenia MXRA5 intron 19571809 rs1635239 chrX 3232699 C A 3.04E-06 Schizophrenia MXRA5 intron 19571809 rs1726206 chrX 3233112 C A 5.28E-06 Schizophrenia MXRA5 intron 19571809 rs1635242 chrX 3235724 C T 4.11E-04 Amyotrophic Lateral Sclerosis MXRA5 missense 17362836 rs1726199 chrX 3239545 C T 9.42E-04 Parkinson's disease MXRA5 missense 17052657 rs1635247 chrX 3241050 G A 8.14E-05 Schizophrenia MXRA5 cds-synon 19571809 rs1635250 chrX 3241791 G A 9.24E-04 Parkinson's disease MXRA5 cds-synon 17052657 rs7392139 chrX 3369355 C T 7.11E-04 Parkinson's disease / / 17052657 rs7059886 chrX 3410669 A G 1.00E-06 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs6641783 chrX 3445846 A G 6.26E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6641574 chrX 3446714 T C 8.01E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6641786 chrX 3447762 C T 8.01E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6567560 chrX 3459334 T C 5.75E-04 Type 2 diabetes / / 17463246 rs2895159 chrX 3463531 G A 7.12E-06 Asthma / / 21790008 rs17051658 chrX 3542075 T C 5.10E-06 Urinary metabolites PRKX intron 21572414 rs1861736 chrX 3628427 T C 2.22E-04 Amyotrophic Lateral Sclerosis PRKX intron 17362836 rs6641876 chrX 3664074 T C 7.13E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs3957336 chrX 3881944 G C 4.08E-05 Alcohol consumption / / pha001397 rs3957336 chrX 3881944 G C 2.95E-05 Alcohol consumption / / pha001399 rs3957336 chrX 3881944 G C 1.68E-05 Alcohol consumption / / pha001401 rs6639107 chrX 4012697 G A 8.83E-04 Alzheimer's disease / / 17998437 rs5916481 chrX 4053502 G A 6.43E-04 Alzheimer's disease / / 17998437 rs5916527 chrX 4129081 A C 4.53E-05 Biliary atresia / / 20460270 rs16997645 chrX 4131703 G A 4.92E-05 Biliary atresia / / 20460270 rs12838671 chrX 4134850 C A 3.12E-07 Mammographic density / / 22532574 rs5961472 chrX 4136963 T C 5.05E-07 Mammographic density / / 22532574 rs5916542 chrX 4150894 A T 2.32E-06 Statin-induced myopathy / / 21826682 rs6529954 chrX 4184349 A G 4.67E-07 Mammographic density / / 22532574 rs5916576 chrX 4198722 T C 4.12E-07 Breast cancer / / 20852631 rs5916576 chrX 4198722 T C 4.60E-06 Urinary metabolites / / 21572414 rs5916578 chrX 4203054 T G 3.68E-05 Type 2 diabetes / / 17463246 rs12844948 chrX 4217034 C T 1.81E-04 Mammographic density / / 22532574 rs2363842 chrX 4217768 T C 3.54E-07 Mammographic density / / 22532574 rs6654825 chrX 4219922 G C 9.40E-06 Urinary metabolites / / 21572414 rs5962157 chrX 4230632 C T 1.60E-05 Urinary metabolites / / 21572414 rs5962161 chrX 4278707 A G 1.60E-05 Urinary metabolites / / 21572414 rs5961488 chrX 4288060 A G 1.60E-05 Urinary metabolites / / 21572414 rs3848952 chrX 4288788 A G 4.13E-04 Smoking quantity / / 24665060 rs5962163 chrX 4294496 A G 1.80E-05 Urinary metabolites / / 21572414 rs5962164 chrX 4294558 A G 6.40E-06 Urinary metabolites / / 21572414 rs5962164 chrX 4294558 A G 6.22E-04 Smoking quantity / / 24665060 rs1296160 chrX 4472028 A G 5.84E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5916677 chrX 4576808 G C 4.10E-06 Urinary metabolites / / 21572414 rs5916687 chrX 4596138 G A 3.00E-06 Amyotrophic lateral sclerosis / / 19734901 rs7055613 chrX 4645454 C T 8.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs5915797 chrX 4697321 T A 9.55E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs5915797 chrX 4697321 T A 1.62E-05 Alzheimer's disease / / 17998437 rs5915801 chrX 4698009 C G 1.12E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs5915801 chrX 4698009 C G 9.70E-07 Alzheimer's disease / / 17998437 rs1918245 chrX 4714367 G A 6.56E-05 Response to hepatitis C treatment / / 19684573 rs1527126 chrX 4730787 A G 3.86E-06 Rheumatoid arthritis / / 19503088 rs1527121 chrX 4734364 T A 8.20E-06 Urinary metabolites / / 21572414 rs6530524 chrX 4779779 C T 9.16E-05 Schizophrenia(age at onset) / / 21688384 rs4393058 chrX 4786239 T G 2.19E-05 Schizophrenia(age at onset) / / 21688384 rs17314064 chrX 4815806 T G 0.0000536 Panic disorder / / 23149450 rs17314064 chrX 4815806 T G 5.36E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs5961574 chrX 4830243 G A 4.24E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11095628 chrX 4911676 A T 1.72E-04 Type 2 diabetes / / 17463246 rs2100181 chrX 4930267 C A 4.40E-05 Hypothyroidism / / 22493691 rs11798405 chrX 4930801 A G 7.61E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11798405 chrX 4930801 A G 0.000186 Autism / / 22935194 rs17219798 chrX 5094340 G A 7.30E-04 Alcohol dependence / / 20201924 rs5915520 chrX 5128502 G A 5.47E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6638512 chrX 5184702 C T 2.00E-25 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs5916033 chrX 5185649 C T 4.33E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7059273 chrX 5485507 G A 1.43E-06 Alzheimer's disease / / 17998437 rs5916200 chrX 5591815 A G 8.23E-11 Metabolite levels / / 22286219 rs12843751 chrX 5686147 A C 3.70E-05 Bipolar disorder / / 20451256 rs12843751 chrX 5686147 A C 8.90E-06 Urinary metabolites / / 21572414 rs7061815 chrX 5686916 G T 2.10E-05 Urinary metabolites / / 21572414 rs5961361 chrX 5687741 G A 1.75E-05 Bipolar disorder / / 20451256 rs7885928 chrX 5697701 T C 7.28E-05 Bipolar disorder / / 20451256 rs7885928 chrX 5697701 T C 2.28E-04 Prostate cancer mortality / / 20978177 rs7885928 chrX 5697701 T C 8.20E-06 Urinary metabolites / / 21572414 rs12558715 chrX 5706920 C T 2.80E-06 Urinary metabolites / / 21572414 rs17305593 chrX 5713122 G A 6.40E-05 Bipolar disorder / / 20451256 rs17305593 chrX 5713122 G A 1.10E-05 Urinary metabolites / / 21572414 rs12840166 chrX 5727932 A G 7.10E-06 Urinary metabolites / / 21572414 rs6639512 chrX 5745268 G C 1.50E-05 Urinary metabolites / / 21572414 rs5961372 chrX 5747155 G A 2.90E-05 Urinary metabolites / / 21572414 rs17305859 chrX 5825543 C A 2.80E-05 Urinary metabolites NLGN4X intron 21572414 rs6639583 chrX 5949912 T C 8.60E-05 Schizophrenia NLGN4X intron 21791550 rs6639583 chrX 5949912 T C 0.000086 Psychosis NLGN4X intron 23164818 rs1882411 chrX 5972382 C T 5.20E-06 Schizophrenia NLGN4X intron 19571808 rs1882411 chrX 5972382 C T 1.88E-05 F-cell distribution NLGN4X intron 21326311 rs1882411 chrX 5972382 C T 3.35E-05 Major depression (suicidal thoughts and behavior) NLGN4X intron 21750702 rs5915642 chrX 6003778 T C 1.13E-05 F-cell distribution NLGN4X intron 21326311 rs6639594 chrX 6009208 C T 7.78E-06 F-cell distribution NLGN4X intron 21326311 rs1882409 chrX 6133812 G A 1.15E-04 Amyotrophic Lateral Sclerosis NLGN4X intron 17827064 rs16983988 chrX 6134432 A T 3.13E-05 Antineutrophil cytoplasmic antibody-associated vasculitis NLGN4X intron 22808956 rs5916341 chrX 6135980 C T 2.47E-04 Amyotrophic Lateral Sclerosis NLGN4X intron 17362836 rs7881412 chrX 6169460 G A 6.68E-04 Type 2 diabetes / / 17463246 rs5961979 chrX 6216939 C T 6.31E-04 Parkinson's disease / / 17052657 rs5961979 chrX 6216939 C T 8.70E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1840485 chrX 6219033 C T 2.61E-04 Parkinson's disease / / 17052657 rs1840485 chrX 6219033 C T 9.65E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7885458 chrX 6220474 T C 3.70E-04 Parkinson's disease / / 17052657 rs7885458 chrX 6220474 T C 3.00E-06 Biochemical measures / / 19260141 rs6638610 chrX 6284463 G A 9.77E-04 Parkinson's disease / / 17052657 rs1993352 chrX 6285300 C T 6.85E-04 Parkinson's disease / / 17052657 rs5915677 chrX 6304884 A G 7.40E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4826726 chrX 6307647 A G 7.40E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs5989492 chrX 6532221 C T 2.50E-06 Urinary metabolites / / 21572414 rs5989487 chrX 6533721 G A 2.30E-06 Urinary metabolites / / 21572414 rs6638625 chrX 6702509 G A 0.00000134 Major depressive disorder age at onset<20 / / 22915352 rs5989582 chrX 6746228 G T 5.43E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs5989585 chrX 6747031 G T 4.33E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs5989586 chrX 6747306 T C 1.94E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs5989502 chrX 6748340 C A 3.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3924355 chrX 6763396 C G 6.57E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4128334 chrX 6766390 A G 3.09E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7883256 chrX 6771244 T A 1.30E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6638626 chrX 6774755 C T 4.46E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6529987 chrX 6775065 T A 7.74E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12401133 chrX 6776197 G A 3.37E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs5978906 chrX 6840872 G A 8.21E-05 Bipolar disorder and schizophrenia / / 20889312 rs4830686 chrX 6870562 T C 8.60E-06 Urinary metabolites / / 21572414 rs5934946 chrX 6880329 T C 1.50E-05 Urinary metabolites / / 21572414 rs4830733 chrX 6884441 T C 1.60E-05 Urinary metabolites / / 21572414 rs6639741 chrX 6899463 G A 1.10E-05 Urinary metabolites / / 21572414 rs5979871 chrX 6905602 T G 5.50E-06 Urinary metabolites / / 21572414 rs7056478 chrX 6986388 C T 2.70E-05 Urinary metabolites HDHD1 intron 21572414 rs1997185 chrX 6996913 G C 2.70E-05 Urinary metabolites HDHD1 intron 21572414 rs802910 chrX 7114581 T C 2.20E-05 Urinary metabolites / / 21572414 rs6639783 chrX 7157128 T C 2.20E-05 Urinary metabolites STS intron 21572414 rs5979315 chrX 7204036 G A 1.90E-05 Urinary metabolites STS intron 21572414 rs151332463 chrX 7268296 C G 0.00013 Breast cancer (ER positive) STS missense 23555315 rs12010072 chrX 7343948 C G 1.40E-05 Urinary metabolites / / 21572414 rs16984498 chrX 7344237 G C 1.20E-05 Urinary metabolites / / 21572414 rs12011131 chrX 7344571 C T 5.00E-04 Parkinson's disease / / 17052657 rs16984504 chrX 7345549 A G 1.30E-05 Urinary metabolites / / 21572414 rs12687040 chrX 7398875 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs5979637 chrX 7404595 T G 2.08E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5979643 chrX 7408367 C T 1.10E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5979667 chrX 7412510 G T 1.84E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5978567 chrX 7422760 C T 1.07E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5979736 chrX 7433866 A C 1.12E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5979755 chrX 7439290 G T 1.47E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5979755 chrX 7439290 G T 6.30E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs722220 chrX 7450372 C T 1.27E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs722220 chrX 7450372 C T 7.26E-04 Type 2 diabetes / / 17463246 rs5978600 chrX 7452627 G A 3.24E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7885520 chrX 7458596 A T 2.33E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7884299 chrX 7458791 G A 7.57E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11095466 chrX 7463058 A G 1.98E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2130835 chrX 7470499 A C 2.23E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2130835 chrX 7470499 A C 3.00E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs980816 chrX 7483102 A C 1.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6638698 chrX 7483860 A G 1.62E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7883778 chrX 7485019 A G 2.41E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6639885 chrX 7496168 A G 1.27E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6639885 chrX 7496168 A G 8.98E-05 Type 2 diabetes / / 17463246 rs7876886 chrX 7517325 A C 2.25E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6639903 chrX 7537276 A G 1.05E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1388185 chrX 7537989 A G 1.05E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6638714 chrX 7538892 G C 6.68E-05 Type 2 diabetes / / 17463246 rs1352741 chrX 7539155 G A 8.26E-05 Type 2 diabetes / / 17463246 rs11095468 chrX 7544925 G A 2.48E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5979984 chrX 7545728 A G 2.22E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1602407 chrX 7552529 A G 4.19E-04 Type 2 diabetes / / 17463246 rs7062732 chrX 7598977 G A 3.48E-04 Type 2 diabetes / / 17463246 rs12689028 chrX 7686400 T C 1.19E-08 Colorectal cancer / / 22532847 rs12689330 chrX 7729452 T C 2.43E-04 Type 2 diabetes / / 17463246 rs10521665 chrX 7745631 G A 9.98E-05 Type 2 diabetes / / 17463246 rs17310951 chrX 7770460 G A 1.10E-05 HIV-1 control / / 20041166 rs4831037 chrX 7861358 G A 9.28E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs5934349 chrX 8010400 A G 1.75E-04 Breast cancer / / pha002853 rs1037526 chrX 8034580 C T 3.65E-04 Parkinson's disease / / 17052657 rs1037526 chrX 8034580 C T 7.77E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5933637 chrX 8038191 G A 2.53E-04 Parkinson's disease / / 17052657 rs5933640 chrX 8039846 A G 2.45E-04 Parkinson's disease / / 17052657 rs10521668 chrX 8055498 G A 1.57E-05 Post-operative nausea and vomiting / / 21694509 rs1869588 chrX 8075942 C T 2.43E-04 Parkinson's disease / / 17052657 rs1869588 chrX 8075942 C T 7.19E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5978816 chrX 8076813 A G 7.93E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4830566 chrX 8084603 G A 6.63E-04 Parkinson's disease / / 17052657 rs4830566 chrX 8084603 G A 8.29E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7063537 chrX 8111437 A C 2.84E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7877108 chrX 8165052 T G 2.15E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1454623 chrX 8172359 G A 6.08E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1997471 chrX 8173248 G A 1.63E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16998643 chrX 8174332 T C 5.94E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7890261 chrX 8217903 G A 5.19E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs6530145 chrX 8221971 C T 3.90E-06 Urinary metabolites / / 21572414 rs6530146 chrX 8225752 A G 1.60E-05 Urinary metabolites / / 21572414 rs6640079 chrX 8341868 G A 2.02E-08 Statin-induced myopathy / / 21826682 rs11795583 chrX 8354637 G C 4.59E-04 Type 2 diabetes / / 17463246 rs6530163 chrX 8366507 G C 4.12E-04 Type 2 diabetes / / 17463246 rs5978863 chrX 8366726 A G 7.16E-04 Type 2 diabetes / / 17463246 rs7892812 chrX 8394253 A G 8.00E-06 Cognitive performance / / 19734545 rs10521594 chrX 8407329 C A 5.40E-05 Major depressive disorder / / 19065144 rs5933657 chrX 8421675 A G 2.20E-07 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs6640144 chrX 8452482 T C 3.82E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs808141 chrX 8488524 A G 2.50E-05 Urinary metabolites / / 21572414 rs16985077 chrX 8599803 G C 4.17E-05 Panic disorder KAL1 intron 19165232 rs12007434 chrX 8617113 A G 0.00075 Trichophyton tonsurans susceptibility KAL1 intron 22704677 rs5978944 chrX 8658847 A G 7.51E-06 Cholesterol KAL1 intron 17255346 rs972385 chrX 8661200 T G 2.64E-05 Cholesterol KAL1 intron 17255346 rs6530200 chrX 8682950 C T 1.58E-05 Cholesterol KAL1 intron 17255346 rs1236386 chrX 8696383 C T 1.76E-05 Cholesterol KAL1 intron 17255346 rs5978974 chrX 8790694 C T 1.55E-04 Cholesterol / / 17255346 rs6530209 chrX 8798549 C A 7.71E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs929228 chrX 8821555 T C 5.54E-05 Fibrinogen / / 17255346 rs5978280 chrX 8876117 G A 1.89E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5933686 chrX 8878134 A G 2.90E-05 Urinary metabolites / / 21572414 rs5978990 chrX 8909398 T C 3.53E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5934505 chrX 8913826 T C 2.00E-08 Androgen levels / / 22936694 rs5978998 chrX 8962383 C T 8.87E-05 Bipolar disorder and schizophrenia / / 20889312 rs12011282 chrX 9178515 G A 1.21E-05 Adverse response to lamotrigine and phenytoin / / 22379998 rs11095507 chrX 9229149 A G 6.71E-04 Parkinson's disease / / 17052657 rs1024443 chrX 9247999 T G 2.30E-04 Parkinson's disease / / 17052657 rs1024443 chrX 9247999 T G 1.77E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5934574 chrX 9295882 T C 4.25E-05 Anxiety in major depressive disorder / / 24047446 rs2521389 chrX 9456801 G A 5.04E-04 Amyotrophic Lateral Sclerosis TBL1X intron 17362836 rs2521370 chrX 9480453 A G 2.20E-05 Urinary metabolites TBL1X intron 21572414 rs5934655 chrX 9557779 C T 2.40E-05 Urinary metabolites TBL1X intron 21572414 rs3752627 chrX 9571393 A G 1.92E-05 Type 2 diabetes TBL1X intron 17463246 rs17280788 chrX 9678573 C T 1.83E-04 Amyotrophic Lateral Sclerosis TBL1X intron 17362836 rs2521655 chrX 9742043 A G 1.22E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1014743 chrX 9745276 G T 1.67E-04 Parkinson's disease / / 17052657 rs5934683 chrX 9751474 T C 2.11E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5934683 chrX 9751474 T C 1.90E-05 Urinary metabolites / / 21572414 rs5934683 chrX 9751474 T C 7.00E-10 Colorectal cancer / / 22634755 rs5934683 chrX 9751474 T C 0.0000006 Paclitaxel-induced sensory peripheral neuropathy / / 22843789 rs2040621 chrX 9758945 C T 2.16E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SHROOM2 intron 20031582 rs2405942 chrX 9814135 G A 7.74E-04 Cognitive impairment induced by topiramate SHROOM2 intron 22091778 rs2405942 chrX 9814135 G A 2.00E-10 Prostate cancer SHROOM2 intron 23535732 rs5934706 chrX 9829986 C A 8.04E-05 Type 2 diabetes SHROOM2 intron 17463246 rs1016625 chrX 9831101 A C 2.01E-04 Cholesterol SHROOM2 intron 17255346 rs1016627 chrX 9831571 G A 5.13E-06 Type 2 diabetes SHROOM2 intron 17463246 rs3788949 chrX 9908341 T C 7.80E-04 Amyotrophic Lateral Sclerosis SHROOM2 intron 17362836 rs5934722 chrX 9910182 C A 2.80E-05 Urinary metabolites SHROOM2 intron 21572414 rs6640579 chrX 9932158 C T 1.30E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6640588 chrX 9988639 C G 2.20E-05 Urinary metabolites WWC3 intron 21572414 rs5978365 chrX 10006452 T C 2.52E-05 Bipolar disorder and schizophrenia WWC3 intron 20889312 rs16985871 chrX 10023651 C G 1.08E-05 Bipolar disorder and schizophrenia WWC3 intron 20889312 rs11797705 chrX 10024068 A G 5.94E-05 Bipolar disorder and schizophrenia WWC3 intron 20889312 rs11796740 chrX 10033083 G A 9.00E-05 Bipolar disorder and schizophrenia WWC3 intron 20889312 rs11796119 chrX 10036515 C G 2.87E-05 Bipolar disorder and schizophrenia WWC3 intron 20889312 rs12850255 chrX 10036687 T A 1.35E-05 Bipolar disorder and schizophrenia WWC3 intron 20889312 rs7059930 chrX 10037284 A G 1.52E-05 Bipolar disorder and schizophrenia WWC3 intron 20889312 rs7059930 chrX 10037284 A G 4.34E-04 Dental caries WWC3 intron 21940522 rs765810 chrX 10039178 T C 4.47E-05 Bipolar disorder and schizophrenia WWC3 intron 20889312 rs1476467 chrX 10073864 G A 3.48E-05 Cognitive impairment induced by topiramate WWC3 intron 22091778 rs41404246 chrX 10187120 T G 1.50E-05 Urinary metabolites CLCN4 intron 21572414 rs6639006 chrX 10226233 A C 2.80E-05 Urinary metabolites / / 21572414 rs5934830 chrX 10227871 G A 1.80E-05 Urinary metabolites / / 21572414 rs12388359 chrX 10231691 G T 4.00E-06 Alcohol dependence / / 19581569 rs2214261 chrX 10305329 G A 9.83E-05 Alcohol dependence / / 19581569 rs17281018 chrX 10381675 G A 5.42E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7053320 chrX 10541110 C T 2.44E-12 Metabolite levels MID1 intron 22286219 rs5979356 chrX 10842287 A G 7.70E-04 Amyotrophic Lateral Sclerosis MID1 intron 17362836 rs5934953 chrX 11048692 T C 1.00E-07 Cognitive performance / / 19734545 rs2238894 chrX 11164830 G A 2.74E-08 HDL cholesterol ARHGAP6 intron 23063622 rs6530432 chrX 11211491 C T 1.25E-04 Type 2 diabetes ARHGAP6 intron 17463246 rs5933866 chrX 11220077 T C 9.19E-05 stroke (ischemic) ARHGAP6 intron 17434096 rs2238902 chrX 11260526 T G 3.15E-04 Type 2 diabetes ARHGAP6 intron 17463246 rs2897589 chrX 11279311 A C 4.82E-04 Type 2 diabetes ARHGAP6 intron 17463246 rs5934988 chrX 11292465 A C 2.56E-04 Type 2 diabetes ARHGAP6 intron 17463246 rs6640729 chrX 11346716 T G 1.63E-05 HIV-1 control ARHGAP6 intron 20041166 rs5978434 chrX 11433808 G A 7.92E-05 HIV-1 control ARHGAP6 intron 20041166 rs5978435 chrX 11434093 T C 0.00000916 Colorectal cancer (males) ARHGAP6 intron 22532847 rs5978462 chrX 11708631 T C 5.16E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs999700 chrX 11717299 T C 5.44E-04 Alcohol dependence / / 20201924 rs17327788 chrX 11741488 A G 7.56E-04 Coronary Artery Disease / / 17634449 rs12850074 chrX 11760251 G A 5.80E-07 Urinary metabolites / / 21572414 rs5935161 chrX 11794720 G A 1.18E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12014765 chrX 11798436 T G 3.04E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12014765 chrX 11798436 T G 4.67E-05 Prion diseases / / 22210626 rs10521619 chrX 11800356 A G 3.86E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12558485 chrX 11800870 G A 2.80E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2905931 chrX 11816375 C A 5.75E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs858083 chrX 11821187 G T 3.84E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2905932 chrX 11832943 A G 3.03E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1527111 chrX 11913247 A G 2.89E-04 Parkinson's disease / / 17052657 rs1527111 chrX 11913247 A G 1.38E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2091418 chrX 11938978 G T 1.57E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs860759 chrX 12016874 G T 4.32E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4830761 chrX 12148139 T C 6.95E-05 Intelligence / / 21826061 rs1076177 chrX 12148433 T C 4.08E-05 Intelligence / / 21826061 rs857351 chrX 12153563 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2188727 chrX 12210595 T C 5.80E-04 Parkinson's disease FRMPD4 intron 17052657 rs2407769 chrX 12214665 A G 6.87E-04 Alzheimer's disease FRMPD4 intron 17998437 rs5935271 chrX 12233899 C T 6.58E-04 Amyotrophic Lateral Sclerosis FRMPD4 intron 17362836 rs5978509 chrX 12299461 G A 4.24E-05 Bipolar disorder and schizophrenia FRMPD4 intron 20889312 rs5978509 chrX 12299461 G A 9.53E-05 Bipolar disorder FRMPD4 intron 22925353 rs5933996 chrX 12409058 C T 2.65E-04 Amyotrophic Lateral Sclerosis FRMPD4 intron 17362836 rs6639176 chrX 12435321 G A 9.02E-04 Response to taxane treatment (placlitaxel) FRMPD4 intron 23006423 rs5934006 chrX 12497256 C T 4.15E-04 Response to taxane treatment (placlitaxel) FRMPD4 intron 23006423 rs5978537 chrX 12503178 G A 2.70E-05 Urinary metabolites FRMPD4 intron 21572414 rs5979636 chrX 12512109 T C 7.45E-05 Cognitive test performance FRMPD4 intron 20125193 rs5934013 chrX 12547490 A G 3.61E-05 HIV(mother-to-child transmission) FRMPD4 intron 20487506 rs5935372 chrX 12570439 T C 6.10E-05 HIV-1 control FRMPD4 intron 20041166 rs5978550 chrX 12590806 C T 1.40E-05 Urinary metabolites FRMPD4 intron 21572414 rs5979665 chrX 12591448 G T 2.30E-05 Urinary metabolites FRMPD4 intron 21572414 rs1438483 chrX 12593795 T C 2.03E-06 Post-operative nausea and vomiting FRMPD4 intron 21694509 rs5979668 chrX 12595868 A G 3.44E-07 Post-operative nausea and vomiting FRMPD4 intron 21694509 rs10217843 chrX 12604438 C T 8.08E-04 Response to cytadine analogues (cytosine arabinoside) FRMPD4 intron 24483146 rs7879491 chrX 12653953 C G 1.60E-05 Urinary metabolites FRMPD4 intron 21572414 rs5935377 chrX 12679458 T C 6.74E-04 Schizophrenia FRMPD4 intron 19197363 rs4355984 chrX 12703336 T C 1.53E-04 Amyotrophic Lateral Sclerosis FRMPD4 intron 17362836 rs4240151 chrX 12722121 A G 3.22E-04 Amyotrophic Lateral Sclerosis FRMPD4 intron 17362836 rs4830474 chrX 12731579 G T 2.92E-04 Amyotrophic Lateral Sclerosis FRMPD4 intron 17362836 rs17256004 chrX 12825639 T C 4.90E-04 Response to taxane treatment (placlitaxel) PRPS2 intron 23006423 rs1266347 chrX 12827635 A G 1.74E-04 Amyotrophic Lateral Sclerosis PRPS2 intron 17362836 rs1731479 chrX 12890453 C T 2.42E-04 Vaspin levels TLR7 intron 22907691 rs1731479 chrX 12890453 C T 0.0002418 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit TLR7 intron 22907730 rs179003 chrX 12913941 G T 5.30E-06 Urinary metabolites / / 21572414 rs178999 chrX 12916457 A G 2.70E-06 Urinary metabolites / / 21572414 rs1548731 chrX 12927947 T C 9.48E-04 Amyotrophic Lateral Sclerosis TLR8 intron 17827064 rs5744081 chrX 12938471 C A 1.30E-05 HIV-1 control TLR8 cds-synon 20041166 rs5979785 chrX 12971524 C T 4.33E-05 Type 1 diabetes / / 18978792 rs5979785 chrX 12971524 C T 6.00E-08 Celiac disease / / 20190752 rs7878221 chrX 13222257 A G 1.17E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11095609 chrX 13398601 A G 5.94E-04 Amyotrophic Lateral Sclerosis LOC100506610 intron 17362836 rs5978629 chrX 13428332 C T 4.25E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17256332 chrX 13442742 T C 1.51E-04 Type 2 diabetes / / 17463246 rs17328315 chrX 13452450 G A 2.60E-05 Urinary metabolites / / 21572414 rs5935595 chrX 13548780 A G 9.60E-06 Urinary metabolites / / 21572414 rs12010628 chrX 13576593 T G 1.65E-05 Parkinson's disease / / 17052657 rs891702 chrX 13584813 T C 2.06E-04 Parkinson's disease / / 17052657 rs5978649 chrX 13615118 A G 4.00E-06 Multiple sclerosis EGFL6 intron 23412934 rs16979025 chrX 13626599 T G 1.83E-04 Tourette syndrome EGFL6 intron 22889924 rs4830888 chrX 13710933 T C 5.81E-04 Amyotrophic Lateral Sclerosis RAB9A intron 17362836 rs7066678 chrX 13714750 G A 1.19E-04 Amyotrophic Lateral Sclerosis RAB9A intron 17362836 rs4830891 chrX 13725941 A G 5.12E-04 Amyotrophic Lateral Sclerosis RAB9A intron 17362836 rs17264385 chrX 13839191 T C 9.58E-04 Response to cytidine analogues (gemcitabine) GPM6B intron 24483146 rs17264406 chrX 13854319 C T 4.06E-04 Response to cytidine analogues (gemcitabine) GPM6B intron 24483146 rs5979978 chrX 13858374 A G 4.66E-04 Parkinson's disease GPM6B intron 16252231 rs12854298 chrX 13932666 C A 3.65E-06 Parkinson's disease GPM6B intron 17052657 rs952076 chrX 13946956 T C 5.32E-06 Parkinson's disease GPM6B intron 17052657 rs7051988 chrX 14211968 T C 2.96E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16979482 chrX 14239313 T C 1.47E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7889151 chrX 14247237 G A 1.24E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1011614 chrX 14259113 T C 6.78E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6628053 chrX 14291174 G A 1.30E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs756909 chrX 14347127 A T 0.0000516 Panic disorder / / 23149450 rs756909 chrX 14347127 A T 5.16E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs7879330 chrX 14485645 G A 5.11E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs9306749 chrX 14493455 C T 3.45E-04 Alzheimer's disease / / 17998437 rs17300926 chrX 14511621 C A 4.47E-04 Alzheimer's disease / / 17998437 rs5935757 chrX 14519870 G A 1.50E-05 Bone mineral density (spine) / / 19079262 rs3027341 chrX 14589113 C T 9.88E-04 Amyotrophic Lateral Sclerosis GLRA2 intron 17362836 rs3027358 chrX 14604159 G A 5.40E-04 Amyotrophic Lateral Sclerosis GLRA2 intron 17362836 rs2238912 chrX 14612381 C T 1.19E-04 Amyotrophic Lateral Sclerosis GLRA2 intron 17362836 rs3020867 chrX 14800499 T C 1.46E-04 Alzheimer's disease / / pha002879 rs17311224 chrX 14804437 G A 6.12E-04 Type 2 diabetes / / 17463246 rs5980075 chrX 14950531 A G 5.00E-07 Waist-to-hip circumference ratio (interaction) / / 23192594 rs2023673 chrX 14976431 C T 2.60E-05 Urinary metabolites / / 21572414 rs5980083 chrX 14979765 T C 8.70E-04 Alcohol dependence / / 20201924 rs1444011 chrX 15079745 G A 7.64E-05 Parkinson's disease / / 21738487 rs5978707 chrX 15089359 G A 1.51E-04 Type 2 diabetes / / 17463246 rs17216148 chrX 15100744 T C 9.94E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2317411 chrX 15166677 G T 8.36E-05 Bipolar disorder / / 17486107 rs6628825 chrX 15180610 T C 9.78E-06 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs5935919 chrX 15290053 T G 7.39E-05 HIV-1 viral setpoint ASB9 nearGene-5 22174851 rs4830943 chrX 15409720 G A 7.70E-06 Urinary metabolites PIR intron 21572414 rs5936023 chrX 15727977 G A 6.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs798159 chrX 15900328 A G 4.00E-05 Diabetic nephropathy / / pha002866 rs12847158 chrX 16181713 T C 5.94E-04 Tourette syndrome / / 22889924 rs2107107 chrX 16204348 G A 2.31E-04 Tourette syndrome / / 22889924 rs2189270 chrX 16209973 G A 8.22E-05 Varicose Veins / / pha001413 rs1229076 chrX 16221373 C T 3.33E-04 Tourette syndrome / / 22889924 rs1795686 chrX 16227488 A G 5.19E-05 Varicose Veins / / pha001413 rs2522982 chrX 16232377 A G 3.04E-04 Tourette syndrome / / 22889924 rs1795702 chrX 16241270 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1634652 chrX 16245846 T A 7.32E-06 Lipid traits / / 21777205 rs2702239 chrX 16247643 C T 7.32E-06 Lipid traits / / 21777205 rs2702237 chrX 16248353 T A 7.32E-06 Lipid traits / / 21777205 rs1615079 chrX 16256336 G C 7.32E-06 Lipid traits / / 21777205 rs17311954 chrX 16421637 C G 0.0000458 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7061971 chrX 16511720 A G 1.06E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12012246 chrX 16514426 A G 1.47E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4831038 chrX 16525639 G A 2.43E-04 Hearing function / / 17255346 rs12010046 chrX 16527823 T G 2.43E-04 Hearing function / / 17255346 rs2522940 chrX 16540771 G T 2.71E-04 Hearing function / / 17255346 rs5936152 chrX 16624224 G A 9.60E-04 Tourette syndrome CTPS2 intron 22889924 rs7888210 chrX 16675441 T C 2.93E-04 Tourette syndrome CTPS2 intron 22889924 rs4831054 chrX 16721930 C T 9.78E-04 Type 2 diabetes CTPS2 intron 17463246 rs6632882 chrX 16765220 T C 3.00E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SYAP1 intron 24023788 rs6632912 chrX 16905630 C T 6.10E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7057371 chrX 16924880 G A 8.43E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2101036 chrX 16930124 G A 6.10E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12014699 chrX 17013966 T C 1.07E-04 Amyotrophic Lateral Sclerosis REPS2 intron 17362836 rs7058279 chrX 17080716 T C 3.74E-04 Alcohol dependence REPS2 intron 20201924 rs5924599 chrX 17139624 G C 8.16E-05 Tuberculosis REPS2 intron 24057671 rs5924602 chrX 17151123 T G 8.57E-05 Tuberculosis REPS2 intron 24057671 rs11797250 chrX 17167482 G T 4.61E-05 Tuberculosis REPS2 UTR-3 24057671 rs11864 chrX 17171300 A G 1.11E-04 Amyotrophic Lateral Sclerosis REPS2 UTR-3 17362836 rs7890034 chrX 17179487 T C 1.72E-04 Type 2 diabetes / / 17463246 rs7064269 chrX 17186660 G A 1.40E-04 Type 2 diabetes / / 17463246 rs7064269 chrX 17186660 G A 6.75E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12393815 chrX 17189476 T G 6.23E-05 Type 2 diabetes / / 17463246 rs7054725 chrX 17205636 A G 4.55E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12387561 chrX 17206973 C T 6.14E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7881950 chrX 17208545 T C 4.55E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6527782 chrX 17211520 G A 6.14E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7049284 chrX 17211678 A G 4.55E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12010218 chrX 17586348 C A 3.93E-06 Post-operative nausea and vomiting NHS intron 21694509 rs4825352 chrX 17595322 G A 7.93E-06 Post-operative nausea and vomiting NHS intron 21694509 rs4825280 chrX 17669042 T A 2.54E-06 Wilms tumor NHS intron 22544364 rs978158 chrX 17677803 A T 2.54E-06 Wilms tumor NHS intron 22544364 rs6633014 chrX 17692151 C T 2.54E-06 Wilms tumor NHS intron 22544364 rs5955717 chrX 17693746 C T 2.54E-06 Wilms tumor NHS intron 22544364 rs5955731 chrX 17695190 C A 2.54E-06 Wilms tumor NHS intron 22544364 rs5955543 chrX 17698397 A G 1.00E-09 Wilms tumor NHS intron 22544364 rs12392874 chrX 17699505 C A 2.54E-06 Wilms tumor NHS intron 22544364 rs4825243 chrX 17699834 C A 2.54E-06 Wilms tumor NHS intron 22544364 rs12845504 chrX 17846752 C T 1.50E-06 Urinary metabolites RAI2 intron 21572414 rs5909473 chrX 18419750 G A 8.60E-04 Alzheimer's disease / / 17998437 rs6629282 chrX 18617921 T G 8.20E-05 Parkinson's disease CDKL5 intron 17052657 rs6633130 chrX 18742642 G A 3.22E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers PPEF1 intron 21775533 rs239755 chrX 18859525 G A 4.90E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs239748 chrX 18883358 T C 1.17E-06 Parkinson's disease / / pha002868 rs5909264 chrX 19046881 A G 2.00E-06 Urinary metabolites GPR64 intron 21572414 rs5909265 chrX 19048943 A G 2.00E-06 Urinary metabolites GPR64 intron 21572414 rs5909267 chrX 19050633 G A 1.90E-05 Urinary metabolites GPR64 intron 21572414 rs6633191 chrX 19067622 G T 2.70E-05 Urinary metabolites GPR64 intron 21572414 rs6633192 chrX 19067926 T C 5.42E-04 Smoking initiation GPR64 intron 24665060 rs5955711 chrX 19186678 C G 9.05E-05 Alzheimer's disease / / pha002879 rs5955534 chrX 19198487 T C 4.93E-05 Bipolar disorder / / 22925353 rs960190 chrX 19209307 T C 4.97E-05 Parkinson's disease / / 16252231 rs6633214 chrX 19230414 G A 9.37E-04 Type 2 diabetes / / 17463246 rs1390170 chrX 19406119 A G 9.94E-04 Parkinson's disease MAP3K15 intron 17052657 rs5909289 chrX 19458598 T C 1.17E-05 Suicidal ideation MAP3K15 intron 20877300 rs5955786 chrX 19468789 C T 2.38E-04 Birth weight MAP3K15 intron 17255346 rs16997315 chrX 19501973 A G 4.66E-11 Diabetic nephropathy MAP3K15 intron pha002852 rs1458783 chrX 19525525 C T 5.29E-04 Amyotrophic Lateral Sclerosis MAP3K15 intron 17362836 rs12013533 chrX 19561853 T C 2.73E-04 Parkinson's disease SH3KBP1 intron 17052657 rs7049939 chrX 19578484 A G 3.33E-04 Parkinson's disease SH3KBP1 intron 17052657 rs7049939 chrX 19578484 A G 5.21E-04 Amyotrophic Lateral Sclerosis SH3KBP1 intron 17362836 rs5909125 chrX 19592299 T C 5.03E-04 Parkinson's disease SH3KBP1 intron 17052657 rs4131939 chrX 19700342 C T 7.67E-05 Bipolar disorder and schizophrenia SH3KBP1 intron 20889312 rs5955573 chrX 19723880 G C 5.58E-05 Bipolar disorder and schizophrenia SH3KBP1 intron 20889312 rs7889157 chrX 19842599 A C 9.91E-04 Amyotrophic Lateral Sclerosis SH3KBP1 intron 17362836 rs5950432 chrX 20396383 A G 7.82E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5990801 chrX 20406077 A G 2.70E-05 Urinary metabolites / / 21572414 rs7876243 chrX 20563226 T C 1.21E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5990890 chrX 20593798 T G 0.000158 Colorectal cancer vs. adenoma controls / / 22532847 rs1375088 chrX 20718669 T C 5.15E-04 Parkinson's disease / / 17052657 rs5991001 chrX 21054048 C T 2.27E-05 Bipolar disorder and schizophrenia / / 20889312 rs5990860 chrX 21075762 G A 2.21E-04 Parkinson's disease / / 17052657 rs11094807 chrX 21493739 T C 2.92E-06 Age-related macular degeneration CNKSR2 intron pha000001 rs743626 chrX 21760000 C T 2.30E-05 Urinary metabolites SMPX intron 21572414 rs17275121 chrX 21785121 G A 6.56E-05 Prion diseases / / 22210626 rs5951466 chrX 21787240 G A 2.80E-05 Urinary metabolites / / 21572414 rs7053644 chrX 21801462 T C 3.86E-05 Prion diseases / / 22210626 rs2071210 chrX 21869983 A G 1.97E-05 Prion diseases MBTPS2 intron 22210626 rs6629431 chrX 21929897 C T 3.68E-04 Bipolar disorder / / 18317468 rs6629434 chrX 21931325 G A 3.05E-04 Bipolar disorder / / 18317468 rs7062810 chrX 21942355 T C 1.85E-04 Prion diseases / / 22210626 rs2238957 chrX 21961749 G A 6.42E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SMS intron 20031582 rs12688591 chrX 21983447 T G 6.60E-04 Type 2 diabetes SMS intron 17463246 rs10521911 chrX 22001799 G A 4.68E-05 Type 2 diabetes SMS intron 17463246 rs7891381 chrX 22004719 A G 8.35E-04 Type 2 diabetes SMS intron 17463246 rs7891381 chrX 22004719 A G 1.80E-05 Urinary metabolites SMS intron 21572414 rs5951678 chrX 22008984 C T 8.74E-04 Type 2 diabetes SMS intron 17463246 rs5951678 chrX 22008984 C T 2.30E-05 Urinary metabolites SMS intron 21572414 rs2301304 chrX 22061743 G A 2.89E-04 Cholesterol PHEX intron 17255346 rs5951698 chrX 22134658 A G 6.00E-06 Tourette syndrome PHEX intron 22889924 rs1540283 chrX 22148051 C T 9.00E-09 Immune reponse to smallpox (secreted IFN-alpha) PHEX intron 22610502 rs12559632 chrX 22160992 G A 3.00E-06 F-cell distribution PHEX intron 21326311 rs3752433 chrX 22239720 C T 3.00E-07 Anger PHEX intron 24489884 rs5951424 chrX 22301981 A T 2.00E-05 Urinary metabolites / / 21572414 rs11094824 chrX 22302699 G A 1.84E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4130326 chrX 22319966 G A 5.31E-06 Statin-induced myopathy / / 21826682 rs5951443 chrX 22397349 C T 2.68E-04 Rheumatoid arthritis / / 21452313 rs5951589 chrX 22415197 G A 2.78E-04 Parkinson's disease / / 17052657 rs4526486 chrX 22425687 A T 7.24E-04 Parkinson's disease / / 17052657 rs1567197 chrX 22446730 G A 8.27E-04 Parkinson's disease / / 17052657 rs11094835 chrX 22463536 C T 9.60E-04 Breast cancer (survival) / / 22232737 rs5926054 chrX 22503611 G A 7.50E-04 Parkinson's disease / / 17052657 rs5926064 chrX 22506861 A G 1.00E-05 Urinary metabolites / / 21572414 rs4828932 chrX 22508710 T C 2.10E-05 Urinary metabolites / / 21572414 rs6528135 chrX 22510075 C A 1.90E-05 Urinary metabolites / / 21572414 rs1395983 chrX 22513076 T G 2.10E-05 Urinary metabolites / / 21572414 rs5970960 chrX 22525238 A G 6.88E-04 Parkinson's disease / / 17052657 rs986111 chrX 22536038 A G 8.43E-04 Alzheimer's disease / / 17998437 rs5925733 chrX 22544039 T C 1.70E-05 Urinary metabolites / / 21572414 rs5925815 chrX 22580396 T C 2.63E-04 Parkinson's disease / / 17052657 rs5925583 chrX 22590534 A C 5.95E-04 Parkinson's disease / / 17052657 rs4133312 chrX 22622990 G A 6.85E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4636385 chrX 22624292 G A 6.32E-05 Bipolar disorder and schizophrenia / / 20889312 rs6633594 chrX 22648169 T G 7.22E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7060552 chrX 22654198 G A 9.80E-06 Urinary metabolites / / 21572414 rs5926023 chrX 22657834 G C 4.40E-06 Urinary metabolites / / 21572414 rs5970629 chrX 22660468 G A 5.80E-06 Urinary metabolites / / 21572414 rs5925651 chrX 22669231 C A 5.71E-08 Common variable immunodeficiency / / 21497890 rs5926043 chrX 22730393 T C 3.57E-04 Parkinson's disease / / 17052657 rs5970876 chrX 22760288 A C 2.49E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4828841 chrX 22813789 A C 9.45E-06 Parkinson's disease / / 17052657 rs5926070 chrX 22820488 T C 4.17E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6528204 chrX 22856062 A G 2.70E-05 Urinary metabolites / / 21572414 rs5926097 chrX 22856079 A G 9.40E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7889437 chrX 22865694 G T 5.09E-05 Cognitive impairment induced by topiramate / / 22091778 rs5925696 chrX 22892077 A G 3.00E-06 Erectile dysfunction and prostate cancer treatment / / 20932654 rs4618863 chrX 22982459 T C 5.00E-04 Major depressive disorder / / 19065144 rs4618863 chrX 22982459 T C 1.90E-05 Urinary metabolites / / 21572414 rs12690411 chrX 22996273 T G 6.49E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5926195 chrX 22997533 A G 2.44E-05 F-cell distribution / / 21326311 rs6528242 chrX 23039623 C A 2.90E-05 Urinary metabolites / / 21572414 rs7050912 chrX 23040601 C T 2.80E-05 Urinary metabolites / / 21572414 rs4520319 chrX 23132857 G A 7.50E-05 Hypothyroidism / / 22493691 rs5926231 chrX 23164537 T C 2.14E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5970698 chrX 23209109 T C 4.25E-04 Parkinson's disease / / 17052657 rs7065749 chrX 23213761 C T 4.02E-04 Parkinson's disease / / 17052657 rs5971087 chrX 23285900 G T 1.09E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6526260 chrX 23286240 T C 4.29E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5971088 chrX 23287229 A G 8.88E-05 Cognitive test performance / / 20125193 rs5926285 chrX 23310205 A C 3.51E-04 Amyotrophic Lateral Sclerosis PTCHD1-AS intron 17362836 rs886546 chrX 23322621 C A 3.80E-05 Multiple sclerosis (age of onset) PTCHD1-AS intron 19010793 rs5971098 chrX 23324545 C T 1.00E-05 Urinary metabolites PTCHD1-AS intron 21572414 rs7888572 chrX 23348954 A G 6.84E-04 Parkinson's disease PTCHD1-AS intron 17052657 rs7879064 chrX 23359342 T G 2.30E-05 Urinary metabolites PTCHD1 intron 21572414 rs7064366 chrX 23366722 G A 1.50E-05 Urinary metabolites PTCHD1 intron 21572414 rs5971108 chrX 23382666 G C 3.00E-04 Major depressive disorder PTCHD1 intron 19065144 rs5971108 chrX 23382666 G C 4.37E-05 Major depressive disorder PTCHD1 intron 21621269 rs1881055 chrX 23383193 C T 9.71E-04 Amyotrophic Lateral Sclerosis PTCHD1 intron 17362836 rs5925760 chrX 23383444 G A 1.00E-07 Immune reponse to smallpox (secreted IFN-alpha) PTCHD1 intron 22610502 rs1033055 chrX 23566531 T G 1.40E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5925574 chrX 23573229 T G 2.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6526310 chrX 23573706 C A 2.06E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6629683 chrX 23577800 G A 6.22E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5970756 chrX 23620148 A G 7.00E-06 Urinary metabolites / / 21572414 rs7876326 chrX 23626268 G C 4.40E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs5970594 chrX 23626473 T A 3.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6627955 chrX 23626983 T C 9.12E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4375154 chrX 23637116 A G 9.94E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs5925853 chrX 23645800 T C 1.90E-05 Urinary metabolites / / 21572414 rs17347621 chrX 23739761 A G 2.31E-06 Liver disease in chronic hepatitis B virus infection ACOT9 intron 24065354 rs5925883 chrX 23742979 G A 1.24E-04 Amyotrophic Lateral Sclerosis ACOT9 intron 17362836 rs5925924 chrX 23780626 A G 8.94E-05 Bipolar disorder / / 18317468 rs873637 chrX 23804871 T C 2.78E-05 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs5925910 chrX 23846420 G A 5.91E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7886064 chrX 23858688 A G 1.99E-04 Amyotrophic Lateral Sclerosis APOO intron 17362836 rs12398674 chrX 23879842 G T 1.75E-04 Amyotrophic Lateral Sclerosis APOO intron 17362836 rs2707159 chrX 23917323 C T 4.50E-06 Suicidal ideation APOO intron 20877300 rs2520237 chrX 23919514 T C 9.57E-06 Suicidal ideation APOO intron 20877300 rs2707164 chrX 23928489 C T 3.94E-04 Amyotrophic Lateral Sclerosis CXorf58 missense 17362836 rs6526366 chrX 24039777 C T 3.53E-04 Amyotrophic Lateral Sclerosis KLHL15 intron 17362836 rs5990018 chrX 24072731 T G 2.12E-08 Triglycerides EIF2S3 nearGene-5 23063622 rs5949272 chrX 24080269 G C 1.40E-05 Urinary metabolites EIF2S3 intron 21572414 rs7065853 chrX 24081613 A G 1.90E-05 Urinary metabolites EIF2S3 intron 21572414 rs12556742 chrX 24086924 A G 2.20E-05 Urinary metabolites EIF2S3 intron 21572414 rs4390116 chrX 24087725 T C 2.20E-05 Urinary metabolites EIF2S3 intron 21572414 rs2318792 chrX 24092704 T A 2.20E-05 Urinary metabolites EIF2S3 intron 21572414 rs2873797 chrX 24092733 G A 1.50E-05 Urinary metabolites EIF2S3 intron 21572414 rs11094949 chrX 24104646 G A 1.20E-05 Urinary metabolites / / 21572414 rs5949279 chrX 24109012 C T 2.00E-05 Urinary metabolites / / 21572414 rs7051306 chrX 24115998 A G 2.10E-05 Urinary metabolites / / 21572414 rs7057074 chrX 24125811 A T 1.70E-05 Urinary metabolites / / 21572414 rs5949232 chrX 24163287 G A 8.50E-04 Alcohol dependence / / 20201924 rs4431778 chrX 24273642 C T 2.60E-05 Cognitive impairment induced by topiramate / / 22091778 rs2074614 chrX 24521889 T C 4.77E-04 Alzheimer's disease PDK3 intron 17998437 rs17217647 chrX 24529193 A G 8.21E-04 Alzheimer's disease PDK3 intron 17998437 rs3764770 chrX 24766651 G A 7.34E-04 Tourette syndrome POLA1 intron 22889924 rs5944680 chrX 24826107 A G 6.06E-04 Type 2 diabetes POLA1 intron 17463246 rs5943992 chrX 24873648 A G 8.20E-04 Type 2 diabetes POLA1 intron 17463246 rs11573534 chrX 25014784 A G 7.80E-04 Parkinson's disease POLA1 UTR-3 16252231 rs10126819 chrX 25174003 A G 2.94E-04 Smoking initiation / / 24665060 rs5986752 chrX 25221790 C T 2.52E-04 Birth weight / / 17255346 rs7052867 chrX 25696720 A G 3.92E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs895058 chrX 25697442 A C 4.91E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4355977 chrX 25698075 A G 3.92E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1025952 chrX 25735888 C T 6.00E-06 F-cell distribution / / 21326311 rs6630120 chrX 25736480 A G 1.48E-05 F-cell distribution / / 21326311 rs5944185 chrX 25853614 T C 7.00E-06 Erectile dysfunction and prostate cancer treatment / / 20932654 rs901709 chrX 25890856 A G 3.96E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs5944423 chrX 26349501 T C 5.91E-06 Metabolite levels (MHPG) / / 23319000 rs6526555 chrX 26369899 A C 4.00E-06 Metabolite levels (HVA/MHPG ratio) / / 23319000 rs6526555 chrX 26369899 A C 5.00E-06 Metabolite levels (5-HIAA/ MHPG Ratio) / / 23319000 rs5986326 chrX 26465788 C T 3.76E-06 Metabolite levels (MHPG) / / 23319000 rs12845487 chrX 26546225 T G 1.57E-06 Cognitive decline / / 22054870 rs5986623 chrX 26583133 G T 7.58E-06 Metabolite levels (MHPG) / / 23319000 rs5986629 chrX 26633883 G A 5.23E-04 Type 2 diabetes / / 17463246 rs1351260 chrX 26948596 T C 8.56E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5926715 chrX 26957606 A G 9.22E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5926787 chrX 26972488 T C 5.21E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1898744 chrX 27065804 A G 4.19E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1438959 chrX 27071026 C A 1.44E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16987731 chrX 27089516 A G 9.38E-04 Alzheimer's disease / / 17998437 rs1898741 chrX 27103640 T C 7.57E-04 Type 2 diabetes / / 17463246 rs6628240 chrX 27174477 A G 7.08E-04 Parkinson's disease / / 17052657 rs6628260 chrX 27355693 C T 6.86E-04 Parkinson's disease / / 17052657 rs5926439 chrX 27472762 C G 2.30E-05 Urinary metabolites / / 21572414 rs178347 chrX 27552993 T A 2.15E-04 Blood pressure / / 17255346 rs221356 chrX 27604520 A G 3.59E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs221378 chrX 27606000 G A 2.68E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs5926847 chrX 27654754 A G 7.81E-04 Type 2 diabetes / / 17463246 rs5971431 chrX 27703102 T C 1.29E-06 Common variable immunodeficiency / / 21497890 rs5926501 chrX 27825703 G A 2.01E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) MAGEB10 nearGene-5 24023788 rs5926501 chrX 27825703 G A 6.06E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) MAGEB10 nearGene-5 24023788 rs5926910 chrX 27830391 A G 3.31E-05 Multiple sclerosis MAGEB10 intron 17660530 rs1368769 chrX 27839572 T C 5.63E-05 Multiple sclerosis MAGEB10 missense 17660530 rs12557898 chrX 27839617 G A 2.43E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) MAGEB10 missense 24023788 rs28940302 chrX 27882097 G T 1 Drug response to Warfarin / / 14765194 rs28940302 chrX 27882097 G T 1 Drug response to Warfarin / / 18234403 rs7879393 chrX 27960693 C T 1.73E-04 Parkinson's disease / / 17052657 rs5971230 chrX 27968705 T C 2.84E-04 Parkinson's disease / / 17052657 rs5971147 chrX 28005110 T C 2.80E-05 Urinary metabolites / / 21572414 rs5971305 chrX 28233053 G A 8.00E-06 Erectile dysfunction and prostate cancer treatment / / 20932654 rs965077 chrX 28276321 A C 1.24E-05 Post-operative nausea and vomiting / / 21694509 rs12846446 chrX 28305313 T C 9.65E-04 Type 2 diabetes / / 17463246 rs1921501 chrX 28484869 C T 5.73E-04 Type 2 diabetes / / 17463246 rs5985781 chrX 28499317 G A 6.13E-04 Type 2 diabetes / / 17463246 rs6526781 chrX 28526076 A C 2.02E-04 Type 2 diabetes / / 17463246 rs5943450 chrX 28530433 T G 6.92E-05 Type 2 diabetes / / 17463246 rs2060978 chrX 28566741 G A 3.58E-04 Type 2 diabetes / / 17463246 rs2060978 chrX 28566741 G A 3.77E-04 Alzheimer's disease / / 17998437 rs5985883 chrX 28639740 T G 5.86E-04 Alzheimer's disease IL1RAPL1 intron 17998437 rs5985883 chrX 28639740 T G 1.10E-05 Urinary metabolites IL1RAPL1 intron 21572414 rs197003 chrX 28652417 T C 2.70E-05 Urinary metabolites IL1RAPL1 intron 21572414 rs197006 chrX 28656998 G A 1.50E-04 Alzheimer's disease IL1RAPL1 intron 17998437 rs197022 chrX 28682695 C T 2.68E-04 Alzheimer's disease IL1RAPL1 intron 17998437 rs642519 chrX 28685498 T C 7.36E-05 Alzheimer's disease IL1RAPL1 intron 17998437 rs115125 chrX 28690286 G T 1.49E-04 Response to cytadine analogues (cytosine arabinoside) IL1RAPL1 intron 24483146 rs10521945 chrX 28749116 C T 7.89E-04 Schizophrenia IL1RAPL1 intron 21674006 rs5943559 chrX 28853204 A G 3.91E-04 Response to taxane treatment (placlitaxel) IL1RAPL1 intron 23006423 rs4893555 chrX 28872079 G A 2.98E-04 Response to taxane treatment (placlitaxel) IL1RAPL1 intron 23006423 rs4893599 chrX 28872608 A G 2.98E-04 Response to taxane treatment (placlitaxel) IL1RAPL1 intron 23006423 rs5985950 chrX 29087721 G A 2.90E-04 Response to taxane treatment (placlitaxel) IL1RAPL1 intron 23006423 rs225061 chrX 29152222 A C 1.91E-04 Type 2 diabetes IL1RAPL1 intron 17463246 rs225050 chrX 29167809 A G 4.33E-04 Lung function (forced expiratory volume in 1 second) IL1RAPL1 intron 17255346 rs1015928 chrX 29361952 T G 9.10E-05 Birth weight IL1RAPL1 intron 17255346 rs5927617 chrX 29374282 G A 4.34E-05 Birth weight IL1RAPL1 intron 17255346 rs5971905 chrX 29415656 G A 1.22E-04 Parkinson's disease IL1RAPL1 intron 17052657 rs1534965 chrX 29507021 A G 8.65E-04 Response to taxane treatment (placlitaxel) IL1RAPL1 intron 23006423 rs1040463 chrX 29507158 A G 7.61E-04 Response to taxane treatment (placlitaxel) IL1RAPL1 intron 23006423 rs6526874 chrX 29526520 T C 5.70E-08 Bronchopulmonary dysplasia IL1RAPL1 intron 21836138 rs4829223 chrX 29573081 C A 4.75E-04 Amyotrophic Lateral Sclerosis IL1RAPL1 intron 17362836 rs7049454 chrX 29579727 G A 6.10E-04 Type 2 diabetes IL1RAPL1 intron 17463246 rs4460557 chrX 29619854 A G 2.73E-04 Type 2 diabetes IL1RAPL1 intron 17463246 rs4829242 chrX 29631530 C T 9.44E-05 Intelligence IL1RAPL1 intron 21826061 rs4829242 chrX 29631530 C T 8.10E-08 Bronchopulmonary dysplasia IL1RAPL1 intron 21836138 rs4829117 chrX 29631783 C T 3.74E-04 Type 2 diabetes IL1RAPL1 intron 17463246 rs7890572 chrX 29640818 A G 1.00E-07 Cardiovascular disease risk factors IL1RAPL1 intron 20838585 rs6630944 chrX 29720587 T C 5.78E-04 Amyotrophic Lateral Sclerosis IL1RAPL1 intron 17362836 rs1419850 chrX 29920545 C T 1.30E-04 Height IL1RAPL1 intron 17255346 rs17329526 chrX 30023077 A G 8.90E-06 Urinary metabolites / / 21572414 rs5929060 chrX 30107551 C A 1.75E-04 Lung function (forced vital capacity) / / 24023788 rs5929060 chrX 30107551 C A 4.24E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1859830 chrX 30108255 A G 1.36E-04 Lung function (forced vital capacity) / / 24023788 rs1859830 chrX 30108255 A G 2.69E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs200682519 chrX 30108411 T TC,TG 1.35E-04 Lung function (forced vital capacity) / / 24023788 rs200682519 chrX 30108411 T TC,TG 2.70E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6526946 chrX 30108411 T C 1.35E-04 Lung function (forced vital capacity) / / 24023788 rs6526946 chrX 30108411 T C 2.70E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs6628506 chrX 30119777 A G 1.00E-06 Metabolite levels (HVA/MHPG ratio) / / 23319000 rs6631052 chrX 30199471 T C 4.80E-06 Urinary metabolites / / 21572414 rs5973789 chrX 30199657 A G 4.60E-06 Urinary metabolites / / 21572414 rs5972089 chrX 30201263 T G 4.80E-06 Urinary metabolites / / 21572414 rs758029 chrX 30202265 T G 2.40E-06 Urinary metabolites / / 21572414 rs5972093 chrX 30240810 A C 4.80E-06 Urinary metabolites / / 21572414 rs12557517 chrX 30266619 T C 9.60E-06 Urinary metabolites MAGEB1 intron 21572414 rs5972096 chrX 30272842 T G 1.80E-05 Urinary metabolites / / 21572414 rs17329638 chrX 30276575 C T 9.60E-06 Urinary metabolites / / 21572414 rs5929084 chrX 30316180 C T 5.97E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2864927 chrX 30320705 G A 5.62E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4829424 chrX 30321976 A G 4.63E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5927496 chrX 30362703 C T 2.52E-06 Common variable immunodeficiency / / 21497890 rs12009203 chrX 30476062 G A 2.50E-05 Urinary metabolites / / 21572414 rs5971488 chrX 30480171 T C 1.90E-05 Urinary metabolites / / 21572414 rs4829186 chrX 30532864 A G 7.57E-05 Parkinson's disease / / 17052657 rs12835268 chrX 30539162 T C 0.000034 Pancreatic cancer and survival / / 22665904 rs2710410 chrX 30565477 G A 4.20E-04 Parkinson's disease / / 17052657 rs2710410 chrX 30565477 G A 1.12E-04 Cholesterol / / 17255346 rs2710410 chrX 30565477 G A 7.50E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2710405 chrX 30585731 T C 9.20E-06 Urinary metabolites CXorf21 intron 21572414 rs4609338 chrX 30725923 C T 1.73E-05 Post-operative nausea and vomiting GK intron 21694509 rs5972224 chrX 30753378 A G 3.55E-05 Post-operative nausea and vomiting / / 21694509 rs2868570 chrX 30756868 A C 1.96E-05 Post-operative nausea and vomiting / / 21694509 rs5927606 chrX 30758654 A G 5.83E-06 Post-operative nausea and vomiting / / 21694509 rs6631214 chrX 30975047 T C 5.90E-05 HIV-1 control / / 20041166 rs6631215 chrX 30975509 A C 5.90E-05 HIV-1 control / / 20041166 rs11095197 chrX 30976947 C T 1.44E-07 Common variable immunodeficiency / / 21497890 rs5927654 chrX 30995997 C T 1.37E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10521962 chrX 31007336 A G 3.92E-13 Gout / / pha001406 rs5971535 chrX 31013090 G A 1.03E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs808178 chrX 31118468 G A 7.66E-04 Type 2 diabetes / / 17463246 rs5927693 chrX 31198204 A G 4.80E-06 Urinary metabolites DMD intron 21572414 rs2178539 chrX 31207044 C A 1.60E-05 Urinary metabolites DMD intron 21572414 rs2141755 chrX 31231672 C T 7.34E-04 Amyotrophic Lateral Sclerosis DMD intron 17362836 rs5972339 chrX 31236681 G C 2.66E-04 Parkinson's disease DMD intron 17052657 rs5971557 chrX 31241938 A G 5.45E-04 Amyotrophic Lateral Sclerosis DMD intron 17362836 rs1882262 chrX 31263648 T C 4.70E-04 Parkinson's disease DMD intron 17052657 rs1573953 chrX 31270474 G T 8.36E-04 Parkinson's disease DMD intron 17052657 rs2141757 chrX 31286408 A G 8.00E-04 Parkinson's disease DMD intron 17052657 rs5972370 chrX 31337537 G T 4.93E-04 Response to taxane treatment (placlitaxel) DMD intron 23006423 rs5972371 chrX 31337695 G C 4.82E-04 Response to taxane treatment (placlitaxel) DMD intron 23006423 rs5972373 chrX 31339102 A G 9.94E-04 Response to taxane treatment (placlitaxel) DMD intron 23006423 rs12557137 chrX 31348807 G T 1.41E-06 HIV-1 control DMD intron 20041166 rs2692992 chrX 31354785 G T 1.10E-06 Urinary metabolites DMD intron 21572414 rs1921968 chrX 31437805 C T 3.46E-04 Alcohol dependence DMD intron 21314694 rs16989651 chrX 31481840 T C 1.80E-05 Urinary metabolites DMD intron 21572414 rs16989652 chrX 31482629 G A 3.93E-05 Type 2 diabetes DMD intron 17463246 rs16989652 chrX 31482629 G A 1.70E-05 Urinary metabolites DMD intron 21572414 rs10521971 chrX 31498800 T C 1.09E-09 Pure-tone audiometry DMD intron pha001964 rs10521971 chrX 31498800 T C 1.21E-11 Pure-tone audiometry DMD intron pha001968 rs16989685 chrX 31527329 G A 6.12E-04 Type 2 diabetes DMD intron 17463246 rs2738305 chrX 31753997 A G 1.81E-04 Lung function (forced vital capacity) DMD intron 24023788 rs6628643 chrX 31806027 C T 9.91E-04 Type 2 diabetes DMD intron 17463246 rs1463493 chrX 31852903 G A 8.50E-04 Amyotrophic Lateral Sclerosis DMD intron 17362836 rs10521981 chrX 31889084 T C 3.11E-05 Cognitive impairment induced by topiramate DMD intron 22091778 rs1350475 chrX 31897630 C T 7.43E-04 Response to statin treatment (atorvastatin),change in cholesterol levels DMD intron 20031582 rs12014135 chrX 31911408 T G 1.30E-05 Urinary metabolites DMD intron 21572414 rs16989995 chrX 31993053 T C 7.93E-06 Liver disease in chronic hepatitis B virus infection DMD intron 24065354 rs16990008 chrX 32015376 A G 2.00E-06 Response to antidepressant treatment DMD intron 22041458 rs1293908 chrX 32020257 C T 9.39E-04 Parkinson's disease DMD intron 17052657 rs1293891 chrX 32027155 C T 8.27E-04 Parkinson's disease DMD intron 17052657 rs1475939 chrX 32029750 C T 9.46E-04 Tourette syndrome DMD intron 22889924 rs7887541 chrX 32071504 T C 6.50E-13 Bronchopulmonary dysplasia DMD intron 21836138 rs2897164 chrX 32102726 G T 6.66E-05 Intelligence DMD intron 21826061 rs10521986 chrX 32111579 C T 3.52E-05 Statin-induced myopathy DMD intron 21826682 rs2405543 chrX 32115141 G A 8.40E-04 Alcohol dependence DMD intron 20201924 rs921896 chrX 32213962 T C 4.00E-06 Anxiety in major depressive disorder DMD intron 24047446 rs5972504 chrX 32217186 T C 7.40E-07 Urinary metabolites DMD intron 21572414 rs1456737 chrX 32225255 A C 5.00E-06 Bipolar disorder and schizophrenia DMD intron 20889312 rs2182194 chrX 32290801 G A 8.50E-06 Urinary metabolites DMD intron 21572414 rs5971615 chrX 32304724 C G 5.52E-05 Bipolar disorder and schizophrenia DMD intron 20889312 rs5927957 chrX 32312216 C T 2.58E-04 Type 2 diabetes DMD intron 17463246 rs6418643 chrX 32316546 C T 3.23E-04 Type 2 diabetes DMD intron 17463246 rs5927969 chrX 32349435 T G 5.80E-13 Bronchopulmonary dysplasia DMD intron 21836138 rs6527185 chrX 32364768 C T 8.20E-05 Bipolar disorder DMD intron 19488044 rs6527185 chrX 32364768 C T 3.99E-05 Bipolar Disorder DMD intron pha002863 rs7056962 chrX 32384048 C T 4.03E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers DMD intron 21775533 rs2207796 chrX 32396824 G T 5.00E-04 Major depressive disorder DMD intron 19065144 rs10521998 chrX 32437853 A C 4.91E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers DMD intron 21775533 rs2405829 chrX 32454346 A G 3.82E-06 Major depressive disorder (broad) DMD intron 20038947 rs2076366 chrX 32456711 G C 2.13E-05 Major depressive disorder (broad) DMD intron 20038947 rs6631584 chrX 32464706 A G 5.59E-05 Schizophrenia DMD intron 24253340 rs170608 chrX 32481863 T C 7.77E-04 Amyotrophic Lateral Sclerosis DMD intron 17362836 rs228392 chrX 32487337 G A 4.20E-06 Urinary metabolites DMD intron 21572414 rs7884521 chrX 32508989 C T 4.28E-04 Lung function (forced expiratory volume in 1 second) DMD intron 17255346 rs228312 chrX 32510702 C T 7.45E-04 Coronary heart disease DMD intron 21971053 rs228314 chrX 32511992 C A 8.90E-07 Urinary metabolites DMD intron 21572414 rs228327 chrX 32531441 G T 7.01E-04 Bilirubin levels,in serum DMD intron 19389676 rs721699 chrX 32558332 C T 9.89E-04 Parkinson's disease DMD intron 17052657 rs721699 chrX 32558332 C T 1.17E-04 Amyotrophic Lateral Sclerosis DMD intron 17362836 rs6631599 chrX 32564847 C G 2.88E-04 Bilirubin levels,in serum DMD intron 19389676 rs228378 chrX 32565209 C A 2.14E-04 Hearing function DMD intron 17255346 rs3792533 chrX 32582581 A G 5.77E-04 Amyotrophic Lateral Sclerosis DMD intron 17362836 rs5928027 chrX 32605879 G A 3.91E-04 Amyotrophic Lateral Sclerosis DMD intron 17362836 rs808556 chrX 32606331 G T 1.45E-04 Schizophrenia DMD intron 21674006 rs699457 chrX 32628882 T C 1.25E-05 Common variable immunodeficiency DMD intron 21497890 rs5927088 chrX 32641044 A G 1.43E-04 Amyotrophic Lateral Sclerosis DMD intron 17362836 rs5927094 chrX 32690974 G A 9.50E-06 Urinary metabolites DMD intron 21572414 rs1318655 chrX 32764130 G T 4.17E-04 Amyotrophic Lateral Sclerosis DMD intron 17362836 rs7888988 chrX 32876077 T C 6.67E-05 Cognitive test performance DMD intron 20125193 rs6527237 chrX 32890872 G A 7.95E-05 Breast cancer DMD intron 21060860 rs1884851 chrX 32898078 A G 2.84E-05 Post-operative nausea and vomiting DMD intron 21694509 rs12559198 chrX 32898332 G C 9.30E-04 Type 2 diabetes DMD intron 17463246 rs11095249 chrX 32908878 A G 6.14E-05 Post-operative nausea and vomiting DMD intron 21694509 rs5928107 chrX 32920542 A G 7.19E-04 Parkinson's disease DMD intron 17052657 rs5928107 chrX 32920542 A G 1.86E-04 Amyotrophic Lateral Sclerosis DMD intron 17362836 rs5927110 chrX 32924941 A G 4.44E-05 Post-operative nausea and vomiting DMD intron 21694509 rs6628760 chrX 33025366 C T 5.30E-04 Amyotrophic Lateral Sclerosis DMD intron 17362836 rs949762 chrX 33046897 T C 2.83E-05 Post-operative nausea and vomiting DMD intron 21694509 rs982767 chrX 33064680 C T 5.36E-04 Parkinson's disease DMD intron 17052657 rs5928167 chrX 33087356 T G 4.22E-04 Amyotrophic Lateral Sclerosis DMD intron 17362836 rs5928167 chrX 33087356 T G 2.92E-04 Smoking initiation DMD intron 24665060 rs6527261 chrX 33117564 A T 6.70E-06 Urinary metabolites DMD intron 21572414 rs2182289 chrX 33125527 T C 2.90E-05 Urinary metabolites DMD intron 21572414 rs2064265 chrX 33269759 T A 8.45E-04 Response to taxane treatment (placlitaxel) DMD intron 23006423 rs3946125 chrX 33315969 G T 2.43E-04 Parkinson's disease DMD intron 17052657 rs3946125 chrX 33315969 G T 3.80E-04 Major depressive disorder DMD intron 21042317 rs5971709 chrX 33320612 G A 1.90E-04 Parkinson's disease DMD intron 17052657 rs5971709 chrX 33320612 G A 8.51E-04 Amyotrophic Lateral Sclerosis DMD intron 17362836 rs1518967 chrX 33694413 T C 8.35E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5972939 chrX 33712422 G A 5.24E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5972944 chrX 33723402 T C 7.11E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1518981 chrX 33729402 T C 5.40E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5928363 chrX 33784063 A T 4.00E-06 Tuberculosis / / 24057671 rs113065570 chrX 33811841 C T 8.00E-06 Periodontitis (Mean PAL) / / 24024966 rs10522025 chrX 33913056 A G 1.90E-04 Statin-induced myopathy / / 21826682 rs2455621 chrX 33961764 A G 7.00E-05 Bone mineral density (spine) / / 19079262 rs3006120 chrX 34137327 G A 6.25E-04 Alcohol dependence / / 20201924 rs5928439 chrX 34180828 A G 7.58E-04 Alcohol dependence / / 20201924 rs12387514 chrX 34195241 T C 8.72E-05 Glycosylated haemoglobin levels / / 17255346 rs12391355 chrX 34218952 G A 8.39E-05 Glycosylated haemoglobin levels / / 17255346 rs5973117 chrX 34219083 G A 3.30E-04 Smoking cessation / / 24665060 rs5927236 chrX 34234946 G A 7.28E-05 Glycosylated haemoglobin levels / / 17255346 rs5927237 chrX 34235117 C T 7.28E-05 Glycosylated haemoglobin levels / / 17255346 rs5928473 chrX 34235392 C T 7.45E-05 Glycosylated haemoglobin levels / / 17255346 rs5928474 chrX 34236497 G A 6.83E-05 Glycosylated haemoglobin levels / / 17255346 rs5927238 chrX 34241058 G C 7.36E-05 Glycosylated haemoglobin levels / / 17255346 rs12390917 chrX 34259115 C A 6.20E-05 Glycosylated haemoglobin levels / / 17255346 rs5927254 chrX 34283333 C T 4.20E-05 Bone mineral density (spine) / / 19079262 rs1939358 chrX 34284629 A T 6.23E-05 Glycosylated haemoglobin levels / / 17255346 rs11095329 chrX 34296351 G A 1.99E-04 Glycosylated haemoglobin levels / / 17255346 rs5928497 chrX 34299889 C T 8.02E-05 Glycosylated haemoglobin levels / / 17255346 rs7065811 chrX 34346454 C T 1.86E-05 Smoking cessation / / 24665060 rs5928535 chrX 34403462 T C 9.65E-05 Asthma / / 20159242 rs4366222 chrX 34424609 C A 1.59E-04 Glycosylated haemoglobin levels / / 17255346 rs5971857 chrX 34444816 G A 1.63E-04 Glycosylated haemoglobin levels / / 17255346 rs5928555 chrX 34445054 A G 1.86E-04 Glycosylated haemoglobin levels / / 17255346 rs7880264 chrX 34450846 T C 4.37E-05 Glycosylated haemoglobin levels / / 17255346 rs5971861 chrX 34471796 C T 6.99E-05 Glycosylated haemoglobin levels / / 17255346 rs5927282 chrX 34520076 C T 9.40E-06 Alcohol and nictotine co-dependence / / 22488850 rs5973212 chrX 34532174 G A 9.43E-05 Premature ovarian failure / / 19508998 rs5973212 chrX 34532174 G A 9.43E-05 Other erythrocyte phenotypes / / 19862010 rs10522026 chrX 34541795 T C 3.71E-04 Bilirubin levels,in serum / / 19389676 rs6632039 chrX 34657756 G T 6.03E-06 Crohn's disease TMEM47 intron 17804789 rs4500217 chrX 34753177 A G 7.99E-04 Body mass index / / 21701565 rs5927313 chrX 34760967 T C 6.33E-04 Body mass index / / 21701565 rs5973249 chrX 34788482 C T 7.52E-04 Premature ovarian failure / / 19508998 rs4300141 chrX 34797580 A C 4.45E-04 Body mass index / / 21701565 rs7065813 chrX 34808669 A G 4.07E-04 Body mass index / / 21701565 rs5928654 chrX 34809828 C T 2.77E-04 Body mass index / / 21701565 rs5928675 chrX 34870683 G A 5.02E-04 Body mass index / / 21701565 rs4271113 chrX 34892503 G A 9.00E-07 Multiple sclerosis / / 23412934 rs5971902 chrX 34897286 G T 4.66E-04 Body mass index / / 21701565 rs4333765 chrX 34898293 G A 5.48E-04 Body mass index / / 21701565 rs5928685 chrX 34900842 T C 4.35E-04 Body mass index / / 21701565 rs3128086 chrX 35007511 G A 2.47E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs3128071 chrX 35081555 G A 2.92E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4610908 chrX 35184535 G A 5.81E-04 Alcohol dependence / / 20201924 rs4610908 chrX 35184535 G A 5.49E-06 Alcohol dependence / / 20202923 rs4610908 chrX 35184535 G A 5.70E-07 Alcohol dependence / / 22096494 rs4610908 chrX 35184535 G A 3.20E-07 Alcohol and nictotine co-dependence / / 22488850 rs5927375 chrX 35253119 A G 1.11E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11795773 chrX 35332900 A G 6.32E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5928813 chrX 35338583 C T 4.45E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1837895 chrX 35354643 G A 6.43E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4829362 chrX 35368082 A G 2.10E-05 Urinary metabolites / / 21572414 rs5973368 chrX 35387159 A C 9.03E-04 Parkinson's disease / / 17052657 rs5928869 chrX 35464300 C T 2.20E-05 Urinary metabolites / / 21572414 rs1565455 chrX 35471816 T C 2.10E-05 Urinary metabolites / / 21572414 rs1844629 chrX 35484710 G C 2.10E-05 Urinary metabolites / / 21572414 rs985041 chrX 35493024 T G 2.10E-05 Urinary metabolites / / 21572414 rs1159797 chrX 35514468 G A 2.50E-05 Urinary metabolites / / 21572414 rs4829161 chrX 35804572 T C 2.60E-05 Urinary metabolites / / 21572414 rs6632360 chrX 35812813 G T 2.40E-05 Urinary metabolites / / 21572414 rs1571471 chrX 35821763 G A 4.83E-04 Body mass index MAGEB16 UTR-3 21701565 rs1571471 chrX 35821763 G A 8.52E-04 Body mass index MAGEB16 UTR-3 21701565 rs5971978 chrX 35822378 C G 3.11E-04 Body mass index / / 21701565 rs5971978 chrX 35822378 C G 5.45E-04 Body mass index / / 21701565 rs1329347 chrX 35822874 A C 4.80E-04 Body mass index / / 21701565 rs1329347 chrX 35822874 A C 8.39E-04 Body mass index / / 21701565 rs5928994 chrX 35828365 G A 8.86E-04 Body mass index / / 21701565 rs5928995 chrX 35831035 A G 3.96E-04 Body mass index / / 21701565 rs5928995 chrX 35831035 A G 6.00E-04 Body mass index / / 21701565 rs1928395 chrX 35831244 C T 5.06E-04 Body mass index / / 21701565 rs1928395 chrX 35831244 C T 8.72E-04 Body mass index / / 21701565 rs1329352 chrX 35837979 A G 4.99E-04 Body mass index / / 21701565 rs1329352 chrX 35837979 A G 8.02E-04 Body mass index / / 21701565 rs5973620 chrX 36262245 G A 1.95E-04 Glycosylated haemoglobin levels CXorf30 intron 17255346 rs12009741 chrX 36501470 A G 0.00022 Prostate cancer / / 23555315 rs28680858 chrX 36976855 T C 6.00E-04 Alcohol dependence / / 20201924 rs142884749 chrX 37027276 A G 0.0003 Breast cancer FAM47C missense 23555315 rs28797478 chrX 37034677 G A 4.10E-04 Alcohol dependence / / 20201924 rs4506367 chrX 37700828 A C 2.85E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) DYNLT3 intron 24023788 rs1120997 chrX 37793485 A C 9.57E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs872690 chrX 37854727 T C 9.00E-06 Erectile dysfunction and prostate cancer treatment / / 20932654 rs761913 chrX 37859510 T G 5.68E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5918462 chrX 37910066 G A 8.48E-04 Type 2 diabetes SYTL5 intron 17463246 rs1003752 chrX 37911769 G C 9.36E-04 Type 2 diabetes SYTL5 intron 17463246 rs1006517 chrX 37912275 G A 8.52E-04 Type 2 diabetes SYTL5 intron 17463246 rs17147097 chrX 37924432 A G 1.97E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SYTL5 intron 24023788 rs150712362 chrX 37933437 T C 1.13E-10 Nonsyndromic striae distensae (stretch marks) SYTL5 intron 23633020 rs56156506 chrX 37999652 A T 1.00E-06 Anorexia nervosa / / 23568457 rs35318931 chrX 38009121 G A 1.10E-13 Nonsyndromic striae distensae (stretch marks) SRPX missense 23633020 rs7890623 chrX 38011836 T C 1.21E-10 Nonsyndromic striae distensae (stretch marks) SRPX intron 23633020 rs7890623 chrX 38011836 T C 1.42E-04 Response to cytadine analogues (cytosine arabinoside) SRPX intron 24483146 rs5918486 chrX 38017271 A G 0.0000395 Nonsyndromic striae distensae (stretch marks) SRPX intron 23633020 rs6521056 chrX 38017492 A T 0.00000522 Nonsyndromic striae distensae (stretch marks) SRPX intron 23633020 rs112900563 chrX 38017972 A G 1.57E-10 Nonsyndromic striae distensae (stretch marks) SRPX intron 23633020 rs4609327 chrX 38034006 T G 0.00000328 Nonsyndromic striae distensae (stretch marks) SRPX intron 23633020 rs5918493 chrX 38042226 A G 0.00000898 Nonsyndromic striae distensae (stretch marks) SRPX intron 23633020 rs5917547 chrX 38047308 G A 0.00000841 Nonsyndromic striae distensae (stretch marks) SRPX intron 23633020 rs2146005 chrX 38054425 T C 0.00000849 Nonsyndromic striae distensae (stretch marks) SRPX intron 23633020 rs5917549 chrX 38062355 G A 0.00000209 Nonsyndromic striae distensae (stretch marks) SRPX intron 23633020 rs5918498 chrX 38062940 A G 0.000000305 Nonsyndromic striae distensae (stretch marks) SRPX intron 23633020 rs969928 chrX 38064927 T C 0.00000239 Nonsyndromic striae distensae (stretch marks) SRPX intron 23633020 rs5918500 chrX 38069249 C T 1.54E-07 Common variable immunodeficiency SRPX intron 21497890 rs5918500 chrX 38069249 C T 0.00000195 Nonsyndromic striae distensae (stretch marks) SRPX intron 23633020 rs5918502 chrX 38074017 G A 0.00000198 Nonsyndromic striae distensae (stretch marks) SRPX intron 23633020 rs5918503 chrX 38074516 T G 0.00000236 Nonsyndromic striae distensae (stretch marks) SRPX intron 23633020 rs4827341 chrX 38076034 C T 0.00000293 Nonsyndromic striae distensae (stretch marks) SRPX intron 23633020 rs6609428 chrX 38093914 T C 6.36E-04 Stroke (pediatric) / / 22990015 rs6521165 chrX 38115485 A C 3.44E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10521410 chrX 38116722 T C 1.18E-05 Hearing function / / 17255346 rs3021107 chrX 38116869 T C 4.01E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3021103 chrX 38122907 G A 1.80E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs41312110 chrX 38134296 G A 0.00000944 Nonsyndromic striae distensae (stretch marks) RPGR intron 23633020 rs17246798 chrX 38137412 T C 1.20E-05 Urinary metabolites RPGR intron 21572414 rs12853995 chrX 38198137 G A 1.20E-05 Urinary metabolites / / 21572414 rs2235125 chrX 38262808 G A 4.28E-05 Bipolar disorder OTC intron 18317468 rs5963419 chrX 38272193 T C 3.44E-05 Bipolar disorder OTC intron 18317468 rs5963432 chrX 38292130 T C 3.99E-05 Bipolar disorder / / 18317468 rs1882999 chrX 38295022 A G 3.53E-05 Bipolar disorder / / 18317468 rs5963436 chrX 38297157 T C 3.58E-05 Bipolar disorder / / 18317468 rs5963043 chrX 38380320 C G 2.88E-04 Type 2 diabetes / / 17463246 rs5963460 chrX 38383348 C T 7.29E-04 Type 2 diabetes / / 17463246 rs5963465 chrX 38383613 C T 8.21E-04 Type 2 diabetes / / 17463246 rs5963466 chrX 38384022 A T 7.66E-04 Type 2 diabetes / / 17463246 rs5963490 chrX 38393285 G A 9.63E-04 Type 2 diabetes / / 17463246 rs6520492 chrX 38402646 T C 8.45E-04 Type 2 diabetes / / 17463246 rs12689529 chrX 38476858 G A 1.80E-06 Urinary metabolites TSPAN7 intron 21572414 rs12556777 chrX 38480080 G T 2.00E-06 Urinary metabolites TSPAN7 intron 21572414 rs35233462 chrX 38585148 G A 3.92E-06 Psoriasis / / 20953190 rs5917628 chrX 38634614 G A 8.31E-04 Type 2 diabetes / / 17463246 rs7056426 chrX 38639856 T C 9.03E-04 Parkinson's disease / / 17052657 rs7056426 chrX 38639856 T C 1.19E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7056426 chrX 38639856 T C 6.58E-04 Type 2 diabetes / / 17463246 rs5917632 chrX 38659681 T C 1.61E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10521415 chrX 38699743 G A 5.34E-04 Parkinson's disease / / 17052657 rs10521415 chrX 38699743 G A 1.70E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6520536 chrX 38710525 A T 5.47E-04 Type 2 diabetes / / 17463246 rs199860 chrX 38742763 T C 4.85E-07 Breast cancer / / 20852631 rs6520541 chrX 38782553 G A 2.56E-05 Type 2 diabetes / / 23945395 rs909379 chrX 38870239 T C 7.40E-05 Personality dimensions / / 18957941 rs2223154 chrX 38899248 T C 1.34E-05 Alzheimer's disease / / 17998437 rs175407 chrX 38902197 G A 4.55E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5917725 chrX 38984257 A G 1.88E-04 Alzheimer's disease / / 17998437 rs5917739 chrX 39013685 G A 3.67E-04 Alzheimer's disease / / 17998437 rs5917741 chrX 39016349 G A 2.57E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5963600 chrX 39019825 T C 2.20E-05 Urinary metabolites / / 21572414 rs12008016 chrX 39019882 A T 2.20E-05 Urinary metabolites / / 21572414 rs5917744 chrX 39024726 C T 2.86E-04 Hearing function / / 17255346 rs11266242 chrX 39030880 G T 1.00E-05 Urinary metabolites / / 21572414 rs11266243 chrX 39031508 G A 9.90E-06 Urinary metabolites / / 21572414 rs5917746 chrX 39032920 C G 1.34E-04 Hearing function / / 17255346 rs5917279 chrX 39052477 T C 1.66E-04 Hearing function / / 17255346 rs441619 chrX 39058705 T C 7.10E-07 Urinary metabolites / / 21572414 rs12557056 chrX 39069341 C T 2.30E-06 Urinary metabolites / / 21572414 rs1393535 chrX 39072865 G T 8.99E-04 Bipolar disorder / / 19259986 rs953918 chrX 39078490 G A 3.00E-06 Urinary metabolites / / 21572414 rs969777 chrX 39091534 T C 2.30E-05 Urinary metabolites / / 21572414 rs873901 chrX 39097242 T A 4.00E-06 Urinary metabolites / / 21572414 rs2873429 chrX 39099553 C T 4.10E-06 Urinary metabolites / / 21572414 rs5963619 chrX 39107286 G A 7.28E-05 Cognitive test performance / / 20125193 rs10126663 chrX 39148512 C T 2.37E-04 Parkinson's disease / / 17052657 rs5917292 chrX 39181411 C T 5.81E-07 Hearing function LOC286442 intron 17255346 rs4827139 chrX 39185636 G T 7.76E-04 Amyotrophic Lateral Sclerosis LOC286442 intron 17362836 rs953524 chrX 39227207 G A 7.76E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5917795 chrX 39235565 C T 3.31E-05 Hearing function / / 17255346 rs17247856 chrX 39248542 G A 7.43E-07 Hearing function / / 17255346 rs902253 chrX 39261018 G A 6.60E-05 HIV-1 control / / 20041166 rs5917814 chrX 39290117 G C 7.03E-04 Type 2 diabetes / / 17463246 rs5917854 chrX 39485120 C T 1.78E-11 Metabolite levels / / 22286219 rs206029 chrX 39528180 G C 3.14E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs206032 chrX 39530129 C G 2.37E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs5917876 chrX 39677104 T C 9.25E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs3008910 chrX 39715655 T C 9.83E-05 Femoral neck bone geometry / / 22087292 rs3008922 chrX 39729727 A G 5.17E-04 Parkinson's disease / / 17052657 rs4827181 chrX 39741474 C T 8.57E-05 Cognitive performance / / 19734545 rs17145638 chrX 39885630 T C 2.00E-07 Pit-and-Fissure caries / / 23470693 rs5917925 chrX 39905422 G T 7.30E-07 Rheumatoid arthritis / / 19503088 rs5963722 chrX 39908717 T C 3.89E-04 IgE levels / / 17255346 rs6520623 chrX 40042533 A C 7.19E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2939568 chrX 40097231 A C 2.01E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7876589 chrX 40118831 T C 6.81E-04 Parkinson's disease / / 17052657 rs869829 chrX 40160929 A G 8.74E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2948491 chrX 40180689 C T 5.18E-07 Common variable immunodeficiency / / 21497890 rs2948486 chrX 40193013 T G 9.03E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3008962 chrX 40197541 G A 7.77E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2961401 chrX 40198417 A G 1.45E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2961393 chrX 40229112 A G 5.58E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs3008939 chrX 40285009 T C 2.79E-05 Bipolar disorder / / 20451256 rs5963178 chrX 40350325 G A 4.12E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7054029 chrX 40351243 G A 6.73E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12008633 chrX 40402279 G T 3.31E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5963842 chrX 40614696 C T 1.48E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs5963897 chrX 40792395 C T 4.40E-04 Myasthenia gravis / / 23055271 rs5917393 chrX 40802981 T G 1.52E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7063608 chrX 40847826 C T 4.29E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1243779 chrX 40885562 A G 4.50E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4827256 chrX 41093413 A T 9.50E-05 Parkinson's disease (age of onset) USP9X UTR-3 19772629 rs1467317 chrX 41173758 G A 9.10E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10521420 chrX 41202159 G A 6.07E-04 Schizophrenia DDX3X intron 21674006 rs5963958 chrX 41212321 A G 1.98E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1782566 chrX 41224835 G A 1.08E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2103110 chrX 41225153 C T 6.29E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1794648 chrX 41252835 A G 7.36E-04 Premature ovarian failure / / 19508998 rs1894571 chrX 41271838 A G 3.32E-04 Type 2 diabetes / / 17463246 rs5918168 chrX 41296675 C T 1.20E-05 Urinary metabolites / / 21572414 rs2807171 chrX 41342919 C A 9.31E-04 Parkinson's disease / / 17052657 rs5918201 chrX 41412729 T C 2.57E-05 Multiple sclerosis (age of onset) CASK intron 19010793 rs5918205 chrX 41438939 C T 1.60E-05 Urinary metabolites CASK intron 21572414 rs5918213 chrX 41493905 C T 3.66E-06 Coronary arterial lesions in patients with Kawasaki disease CASK intron 23677057 rs206044 chrX 41980258 A G 3.45E-05 Bipolar disorder and schizophrenia / / 20889312 rs12558641 chrX 41985852 C T 5.22E-05 Schizophrenia / / pha002857 rs2213601 chrX 42000616 A G 6.03E-04 Parkinson's disease / / 17052657 rs6610695 chrX 42362678 A G 1.46E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1572056 chrX 42501440 A G 1.60E-05 Urinary metabolites / / 21572414 rs4084280 chrX 42579174 G C 3.20E-08 Breast cancer / / 20852631 rs5964215 chrX 42648004 T C 6.28E-04 Alcohol dependence / / 20201924 rs5964217 chrX 42649528 G A 3.44E-04 Alcohol dependence / / 20201924 rs12394030 chrX 42658685 G A 2.30E-05 Urinary metabolites / / 21572414 rs2187857 chrX 42659453 T G 2.60E-05 Urinary metabolites / / 21572414 rs2157385 chrX 42659478 C A 2.30E-05 Urinary metabolites / / 21572414 rs5991588 chrX 42662929 C T 5.81E-04 Alcohol dependence / / 20201924 rs5991517 chrX 42679472 A G 2.60E-05 Urinary metabolites / / 21572414 rs5991519 chrX 42680024 A G 2.90E-05 Urinary metabolites / / 21572414 rs10521427 chrX 42730383 C G 1.05E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs205828 chrX 42776949 T C 2.63E-04 Alzheimer's disease / / pha002879 rs205869 chrX 42804453 C A 8.76E-07 Statin-induced myopathy / / 21826682 rs205870 chrX 42804508 A G 2.03E-06 Statin-induced myopathy / / 21826682 rs1983167 chrX 42848384 T C 6.48E-07 Restless legs syndrome / / 17637780 rs1983167 chrX 42848384 T C 5.22E-05 Primary nonsyndromic vesicoureteric reflex / / 19959718 rs7881785 chrX 42854606 A G 9.01E-07 Restless legs syndrome / / 17637780 rs7881785 chrX 42854606 A G 6.97E-05 Primary nonsyndromic vesicoureteric reflex / / 19959718 rs11797347 chrX 42863662 G A 3.76E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5991566 chrX 42923587 T C 0.0003 Breast cancer / / 23555315 rs5950942 chrX 42927865 C A 1.86E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5950978 chrX 43064004 T C 4.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5991642 chrX 43208288 G A 1.48E-04 Smoking initiation / / 24665060 rs5991644 chrX 43215305 T C 1.48E-04 Smoking initiation / / 24665060 rs4319236 chrX 43229524 A G 3.59E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4319236 chrX 43229524 A G 2.33E-04 Smoking initiation / / 24665060 rs5951013 chrX 43253273 G A 2.28E-04 Smoking initiation / / 24665060 rs4986511 chrX 43265370 G A 1.93E-04 Smoking initiation / / 24665060 rs5950905 chrX 43304444 A G 3.31E-04 Smoking initiation / / 24665060 rs6520868 chrX 43310423 A G 4.03E-04 Smoking initiation / / 24665060 rs7055281 chrX 43317390 A G 2.72E-04 Smoking initiation / / 24665060 rs2153338 chrX 43353368 G A 2.17E-04 Smoking initiation / / 24665060 rs12057128 chrX 43372884 C A 1.79E-04 Smoking initiation / / 24665060 rs5906974 chrX 43551321 C T 4.84E-07 Statin-induced myopathy MAOA intron 21826682 rs5905859 chrX 43591500 C A 2.00E-05 Urinary metabolites MAOA intron 21572414 rs5905859 chrX 43591500 C A 0.000019 alzheimer's disease (late onset) MAOA intron 22785395 rs3027409 chrX 43607033 T G 7.00E-06 Smoking behavior / / 19247474 rs6609257 chrX 43612708 G A 0.000124 Sasang constitution / / 22889377 rs1799836 chrX 43627999 T C 1.01E-04 Amyotrophic Lateral Sclerosis MAOB intron 17362836 rs10521432 chrX 43633740 G A 1.40E-05 Urinary metabolites MAOB intron 21572414 rs10521432 chrX 43633740 G A 8.09E-05 Bipolar Disorder MAOB intron pha002863 rs2238973 chrX 43814083 G A 6.88E-05 Alzheimer's disease NDP intron pha002879 rs766117 chrX 43816206 T C 2.22E-07 Post-operative nausea and vomiting NDP intron 21694509 rs5952411 chrX 43821947 C T 8.06E-05 Response to cytadine analogues (cytosine arabinoside) NDP intron 24483146 rs5952979 chrX 43822631 T G 3.66E-04 Response to cytadine analogues (cytosine arabinoside) NDP intron 24483146 rs1335102 chrX 43994847 C T 3.00E-07 Urinary metabolites / / 21572414 rs12014086 chrX 44180651 G A 4.06E-06 Liver disease in chronic hepatitis B virus infection EFHC2 intron 24065354 rs5906918 chrX 44191332 G T 2.75E-04 Amyotrophic Lateral Sclerosis EFHC2 intron 17362836 rs6520916 chrX 44202283 A G 4.93E-04 Amyotrophic Lateral Sclerosis EFHC2 intron 17362836 rs5906942 chrX 44221231 A G 6.67E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1451510 chrX 44242605 G A 1.66E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5906953 chrX 44273900 T G 9.89E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5905808 chrX 44279637 A G 3.93E-04 Parkinson's disease / / 17052657 rs5906975 chrX 44327594 C T 4.40E-06 Urinary metabolites / / 21572414 rs7056356 chrX 44338315 T C 1.40E-05 Urinary metabolites / / 21572414 rs6610953 chrX 44400186 G A 6.00E-06 Personality dimensions FUNDC1 intron 18957941 rs6610953 chrX 44400186 G A 1.70E-06 Personality dimensions FUNDC1 intron 21173776 rs6610998 chrX 44510950 C A 3.30E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5952612 chrX 44542020 A G 9.57E-05 Telomere length / / 21573004 rs5905408 chrX 44569800 A G 2.40E-05 Urinary metabolites / / 21572414 rs17147003 chrX 44705439 G A 4.16E-04 Coronary Artery Disease / / 17634449 rs6611070 chrX 45008291 T C 1.81E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) CXorf36 UTR-3 24023788 rs4582677 chrX 45036182 G A 1.30E-06 Urinary metabolites CXorf36 intron 21572414 rs4072569 chrX 45046574 A G 2.50E-05 Urinary metabolites CXorf36 intron 21572414 rs5905953 chrX 45110632 T C 4.15E-05 Cognitive impairment induced by topiramate / / 22091778 rs5905986 chrX 45222065 T C 4.98E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1033383 chrX 45224649 C T 5.41E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2142616 chrX 45241947 C T 4.26E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5905467 chrX 45304530 A G 2.32E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5906035 chrX 45437079 A G 3.15E-04 Height / / 17255346 rs6521034 chrX 45531317 T C 2.90E-06 Urinary metabolites / / 21572414 rs6651648 chrX 45532458 G T 1.50E-05 Urinary metabolites / / 21572414 rs2022501 chrX 45540361 C A 9.60E-06 Urinary metabolites / / 21572414 rs5905476 chrX 45550312 G A 7.45E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1780838 chrX 45564320 T C 2.23E-04 Alzheimer's disease / / 17998437 rs1207315 chrX 45574041 A G 7.70E-04 Alzheimer's disease / / 17998437 rs1207314 chrX 45575298 G T 7.70E-04 Alzheimer's disease / / 17998437 rs2745708 chrX 45610875 T C 6.94E-05 Bipolar disorder / / 17486107 rs5905484 chrX 45671994 C T 1.48E-04 Vaspin levels / / 22907691 rs5905484 chrX 45671994 C T 0.0001482 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs5905485 chrX 45681372 G T 1.87E-04 Vaspin levels / / 22907691 rs5905485 chrX 45681372 G T 0.000187 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs2206355 chrX 45685205 G A 2.23E-04 Vaspin levels / / 22907691 rs2206355 chrX 45685205 G A 0.0002232 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs7058787 chrX 45698719 C T 2.11E-04 Vaspin levels / / 22907691 rs7058787 chrX 45698719 C T 0.0000244 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs7058787 chrX 45698719 C T 0.0002108 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs5906089 chrX 45702804 T C 1.70E-05 Urinary metabolites / / 21572414 rs7063583 chrX 45751886 T C 5.36E-05 Cognitive impairment induced by topiramate / / 22091778 rs5905495 chrX 45752484 C T 5.86E-05 Cognitive impairment induced by topiramate / / 22091778 rs5952809 chrX 45759156 G A 5.90E-05 Cognitive impairment induced by topiramate / / 22091778 rs17245080 chrX 45833822 T C 2.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17245080 chrX 45833822 T C 7.89E-04 Smoking cessation / / 24665060 rs506963 chrX 45838946 A G 2.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs571167 chrX 45841391 C T 2.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs847593 chrX 45842413 T C 2.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs548533 chrX 45844016 G A 2.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs547049 chrX 45848422 T C 2.54E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs479554 chrX 45852623 C T 2.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs527850 chrX 45870836 T G 2.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs485783 chrX 45875987 A G 2.02E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs485783 chrX 45875987 A G 5.39E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2148106 chrX 45898681 C T 4.29E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs5906203 chrX 46293233 T C 1.00E-05 Urinary metabolites / / 21572414 rs17261432 chrX 46301693 G A 6.94E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1409197 chrX 46304404 C T 1.20E-05 Urinary metabolites / / 21572414 rs6521109 chrX 46311767 G C 1.60E-05 Urinary metabolites ZNF673 intron 21572414 rs5905540 chrX 46312521 C T 1.50E-05 Urinary metabolites ZNF673 intron 21572414 rs5952884 chrX 46316574 G C 1.30E-05 Urinary metabolites ZNF673 intron 21572414 rs6521112 chrX 46325813 G C 1.50E-05 Urinary metabolites ZNF673 intron 21572414 rs2182341 chrX 46331860 G A 1.30E-05 Urinary metabolites ZNF673 intron 21572414 rs5906215 chrX 46335819 C T 2.50E-05 Urinary metabolites / / 21572414 rs1100916 chrX 46349022 T C 7.80E-06 Urinary metabolites / / 21572414 rs5952890 chrX 46352982 T A 1.30E-05 Urinary metabolites / / 21572414 rs5906223 chrX 46375639 G T 1.40E-05 Urinary metabolites ZNF674 intron 21572414 rs5906226 chrX 46380304 C T 1.30E-05 Urinary metabolites ZNF674 intron 21572414 rs2003665 chrX 46388442 G A 1.30E-05 Urinary metabolites ZNF674 intron 21572414 rs5906232 chrX 46388458 T G 1.30E-05 Urinary metabolites ZNF674 intron 21572414 rs2011100 chrX 46388656 C T 1.30E-05 Urinary metabolites ZNF674 intron 21572414 rs1569481 chrX 46392023 C T 1.40E-05 Urinary metabolites ZNF674 intron 21572414 rs10126199 chrX 46417031 T C 1.10E-05 Urinary metabolites / / 21572414 rs5952909 chrX 46450026 A G 6.00E-06 Urinary metabolites CHST7 intron 21572414 rs5906247 chrX 46468780 C G 4.80E-06 Urinary metabolites SLC9A7 intron 21572414 rs909662 chrX 46501378 G A 6.78E-04 Response to cytadine analogues (cytosine arabinoside) SLC9A7 intron 24483146 rs17327362 chrX 46506998 T G 1.50E-05 Urinary metabolites SLC9A7 intron 21572414 rs5906254 chrX 46542778 A G 6.38E-04 Response to cytadine analogues (cytosine arabinoside) SLC9A7 intron 24483146 rs28445915 chrX 46544025 A G 5.11E-04 Response to cytadine analogues (cytosine arabinoside) SLC9A7 intron 24483146 rs5952927 chrX 46562925 C A 0.000375 Breast cancer early age of onset SLC9A7 intron 18463975 rs5906282 chrX 46699803 A G 2.40E-05 Urinary metabolites RP2 intron 21572414 rs5952970 chrX 46759656 A G 2.10E-05 Urinary metabolites / / 21572414 rs3135225 chrX 46834525 G T 1.90E-05 Urinary metabolites PHF16 intron 21572414 rs5906310 chrX 46881568 A T 1.90E-05 Urinary metabolites PHF16 intron 21572414 rs12008521 chrX 46904746 G A,C,T 1.60E-05 Urinary metabolites PHF16 intron 21572414 rs2239791 chrX 46913494 C G 2.30E-05 Urinary metabolites PHF16 intron 21572414 rs4492499 chrX 47002808 A G 7.17E-04 Parkinson's disease NDUFB11 intron 17052657 rs6611365 chrX 47174276 G A 4.00E-07 optic disc size (disc) / / 20395239 rs12840611 chrX 47352994 A G 2.56E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5906420 chrX 47377451 C T 3.34E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs41450952 chrX 47381658 C T 4.79E-04 Type 2 diabetes / / 17463246 rs5906425 chrX 47400809 A C 4.55E-04 Smoking initiation / / 24665060 rs2071777 chrX 47423799 T G 4.92E-05 Parkinson's disease ARAF intron 17052657 rs12394306 chrX 47436047 A C 1.90E-20 HDL cholesterol SYN1 intron 23063622 rs12394306 chrX 47436047 A C 7.25E-11 LDL cholesterol SYN1 intron 23063622 rs2239459 chrX 47468530 G A 7.77E-04 Amyotrophic Lateral Sclerosis SYN1 intron 17362836 rs5953073 chrX 47494346 A G 2.63E-09 HDL cholesterol / / 23063622 rs3848864 chrX 47722004 G A 9.40E-05 Post-operative nausea and vomiting ZNF81 intron 21694509 rs5905637 chrX 47761328 A G 2.46E-05 Post-operative nausea and vomiting ZNF81 intron 21694509 rs492359 chrX 47853884 A C 5.20E-04 Coronary Artery Disease ZNF182 intron 17634449 rs12387999 chrX 47895066 G A 7.70E-08 Common variable immunodeficiency / / 21497890 rs142513793 chrX 47906480 C T 2.00E-07 Tuberculosis / / 24057671 rs2272657 chrX 48318899 A G 4.50E-05 Anger SLC38A5 intron 24489884 rs2293952 chrX 48320301 C G 2.60E-05 Urinary metabolites SLC38A5 intron 21572414 rs3027518 chrX 48755937 T A 3.54E-04 Birth weight PQBP1 intron 17255346 rs2283733 chrX 49073385 G A 2.30E-05 Urinary metabolites CAC/1F intron 21572414 rs5906864 chrX 49440249 C T 1.73E-04 Type 2 diabetes / / 17463246 rs1882984 chrX 49470545 T G 5.88E-05 Parkinson's disease / / 17052657 rs1882984 chrX 49470545 T G 3.08E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4824801 chrX 49486929 A T 9.59E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs231720 chrX 49628658 T C 1.38E-04 Parkinson's disease / / 17052657 rs1553510 chrX 49683253 C T 4.67E-06 Age-related macular degeneration / / pha000001 rs1934179 chrX 50182184 G A 3.00E-21 Hypospadias DGKK intron 21113153 rs17281496 chrX 50335675 G C 7.86E-07 Breast cancer SHROOM4 UTR-3 20852631 rs5915277 chrX 50336022 A T 9.43E-04 Parkinson's disease SHROOM4 UTR-3 17052657 rs2295544 chrX 50341598 G A 5.05E-04 Parkinson's disease SHROOM4 intron 17052657 rs2295544 chrX 50341598 G A 2.41E-04 Amyotrophic Lateral Sclerosis SHROOM4 intron 17362836 rs2153529 chrX 50514167 G A 1.85E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) SHROOM4 intron 24023788 rs6614576 chrX 50554716 G A 6.04E-04 Type 2 diabetes SHROOM4 intron 17463246 rs4826667 chrX 50817478 G A 7.90E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs6614655 chrX 50920976 G T 6.87E-05 Age-related macular degeneration (extreme sampling) / / 23577725 rs6614392 chrX 50923903 A G 1.92E-04 Age-related macular degeneration (extreme sampling) / / 23577725 rs1151701 chrX 50967440 A G 1.36E-04 Age-related macular degeneration (extreme sampling) / / 23577725 rs12856464 chrX 51062436 A G 5.88E-04 Parkinson's disease / / 17052657 rs1503783 chrX 51097378 C T 3.46E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1327300 chrX 51119041 G A 2.32E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12857136 chrX 51122841 A G 7.39E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1327301 chrX 51210057 C T 1.20E-07 Prostate cancer / / 18264097 rs1327301 chrX 51210057 C T 2.00E-10 Prostate cancer / / 19767753 rs1327301 chrX 51210057 C T 2.00E-10 Nasopharyngeal carcinoma / / 20512145 rs1327301 chrX 51210057 C T 6.66E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1327302 chrX 51210615 G A 9.58E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs5945617 chrX 51227221 T G 9.58E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs5945572 chrX 51229683 A G 9.60E-08 Prostate cancer / / 18264097 rs5945572 chrX 51229683 A G 4.00E-13 Prostate cancer / / 18264098 rs5945572 chrX 51229683 A G 4.00E-13 Nasopharyngeal carcinoma / / 20512145 rs5945572 chrX 51229683 A G 0.000068 Prostate cancer / / 23555315 rs5945572 chrX 51229683 A G 0.00027 Prostate cancer (non-advanced prostate cancer) / / 23555315 rs5945572 chrX 51229683 A G 9.58E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs5945619 chrX 51241672 C T 4.05E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5945619 chrX 51241672 C T 2.00E-09 Prostate cancer / / 18264097 rs5945619 chrX 51241672 C T 2.00E-09 Nasopharyngeal carcinoma / / 20512145 rs1419039 chrX 51348176 G A 7.31E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1419040 chrX 51352035 G A 1.80E-08 Prostate cancer / / 18264097 rs7057039 chrX 51362611 G A 5.43E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4604628 chrX 51387252 C T 2.10E-08 Prostate cancer / / 18264097 rs6614467 chrX 51410649 G T 1.90E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs5945677 chrX 51438171 A G 1.57E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11796743 chrX 51486195 A C 6.18E-04 Response to cytadine analogues (cytosine arabinoside) GSPT2 nearGene-5 24483146 rs5991820 chrX 51514120 A G 6.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs5991735 chrX 51552884 G A 2.40E-08 Prostate cancer MAGED1 intron 18264097 rs12392286 chrX 51554254 G A 5.83E-04 Response to cytadine analogues (cytosine arabinoside) MAGED1 intron 24483146 rs5991739 chrX 51610969 G A 2.97E-04 Celiac disease MAGED1 intron 23936387 rs1130004 chrX 51615868 T G 1.70E-05 Urinary metabolites MAGED1 intron 21572414 rs28538558 chrX 51626534 G A 5.47E-04 Response to cytadine analogues (cytosine arabinoside) MAGED1 intron 24483146 rs11796891 chrX 51633963 T C 5.47E-04 Response to cytadine analogues (cytosine arabinoside) MAGED1 intron 24483146 rs12396986 chrX 51821765 A G 9.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11797897 chrX 51823616 G A 9.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12395065 chrX 51830505 A T 9.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9724403 chrX 51830951 T C 9.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12389310 chrX 51835461 C T 9.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9724204 chrX 51842111 T C 9.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13440787 chrX 51849211 C G 9.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10217920 chrX 51850190 T C 9.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs13440631 chrX 51851024 T C 9.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9724108 chrX 51868494 C T 9.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11091782 chrX 51870817 G A 9.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11091783 chrX 51872314 T C 9.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11798454 chrX 51875317 G T 9.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs9723362 chrX 51876818 G A 9.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs5985985 chrX 51885462 G A 9.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs5943644 chrX 51912237 T C 9.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10127016 chrX 53152096 G T 1.90E-07 Common variable immunodeficiency / / 21497890 rs2182285 chrX 53227343 A G 9.28E-04 Type 2 diabetes KDM5C intron 17463246 rs5933533 chrX 53241443 T C 9.27E-04 Type 2 diabetes KDM5C intron 17463246 rs6638372 chrX 53242303 T C 9.39E-04 Type 2 diabetes KDM5C intron 17463246 rs4830340 chrX 53313326 C T 9.54E-04 Amyotrophic Lateral Sclerosis IQSEC2 intron 17362836 rs2480443 chrX 53329263 T C 5.12E-05 Psoriasis IQSEC2 intron 18364390 rs880441 chrX 53344023 C A 8.08E-04 Schizophrenia IQSEC2 intron 19197363 rs4129175 chrX 53789793 A G 1.10E-05 Urinary metabolites / / 21572414 rs9698549 chrX 53797237 T C 2.60E-05 Urinary metabolites / / 21572414 rs7065696 chrX 53974054 C G 4.00E-07 Bipolar disorder and schizophrenia PHF8 intron 21057379 rs704145 chrX 55035283 C T 1.94E-04 Amyotrophic Lateral Sclerosis ALAS2 nearGene-3 17362836 rs4124595 chrX 55137978 A G 0.0005 Breast cancer / / 23555315 rs5914256 chrX 55215222 A G 3.56E-05 Smoking initiation / / 24665060 rs1927276 chrX 55226932 A C 3.59E-05 Smoking initiation / / 24665060 rs1927282 chrX 55230288 T C 3.57E-05 Smoking initiation / / 24665060 rs5913794 chrX 55235334 T C 3.59E-05 Smoking initiation / / 24665060 rs5914269 chrX 55244435 C T 3.67E-05 Smoking initiation / / 24665060 rs2296807 chrX 55289720 C A,G,T 2.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) / / 21239504 rs4826381 chrX 55289774 T C 3.24E-05 Smoking initiation / / 24665060 rs2370131 chrX 55290697 A C 3.41E-05 Smoking initiation PAGE3 intron 24665060 rs4826275 chrX 55314400 C T 3.36E-05 Smoking initiation / / 24665060 rs11091412 chrX 55361937 C T 8.99E-05 Celiac disease / / 23936387 rs4240023 chrX 55393079 T C 8.00E-08 Smoking initiation / / 24665060 rs4826404 chrX 55476165 G A 9.37E-08 Smoking initiation / / 24665060 rs2499862 chrX 55510918 T C 1.20E-07 Smoking initiation USP51 nearGene-3 24665060 rs3126259 chrX 55574773 T G 0.0005 Breast cancer / / 23555315 rs4265330 chrX 55678960 G T 2.02E-07 Smoking initiation XAGE-4 intron 24665060 rs5914419 chrX 55727823 T C 2.78E-07 Smoking initiation / / 24665060 rs2375467 chrX 55822080 A G 2.81E-07 Smoking initiation / / 24665060 rs2104429 chrX 55827933 C A 2.98E-07 Smoking initiation / / 24665060 rs1325570 chrX 55839022 A G 2.84E-07 Smoking initiation / / 24665060 rs4826434 chrX 55904934 C A 1.06E-07 Smoking initiation / / 24665060 rs4466536 chrX 55951885 G T 1.01E-06 Smoking initiation / / 24665060 rs4639650 chrX 55953313 C T 3.11E-06 Smoking initiation / / 24665060 rs6417935 chrX 55960724 T C 8.79E-04 Alcohol dependence / / 20201924 rs17002956 chrX 55962728 C T 3.11E-06 Smoking initiation / / 24665060 rs6612428 chrX 55977075 G A 9.05E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7876496 chrX 55979154 G T 3.11E-06 Smoking initiation / / 24665060 rs5913884 chrX 56001913 G A 3.11E-06 Smoking initiation / / 24665060 rs2150887 chrX 56083761 T C 3.11E-06 Smoking initiation / / 24665060 rs12011574 chrX 56126084 C A 2.10E-06 Smoking initiation / / 24665060 rs7887731 chrX 56144769 G A 7.99E-04 Parkinson's disease / / 16252231 rs12008339 chrX 56271129 C T 1.33E-06 Smoking initiation KLF8 intron 24665060 rs5960712 chrX 56303019 C T 1.33E-06 Smoking initiation KLF8 intron 24665060 rs3922927 chrX 56313931 G A 1.66E-04 Amyotrophic Lateral Sclerosis KLF8 UTR-3 17362836 rs6521385 chrX 56344706 C T 1.31E-06 Smoking initiation / / 24665060 rs7876062 chrX 56350557 G A 1.82E-06 Smoking initiation / / 24665060 rs7058584 chrX 56395194 T C 1.98E-04 Smoking initiation / / 24665060 rs7474221 chrX 56402920 G A 6.41E-05 Smoking initiation / / 24665060 rs5913935 chrX 56428273 C T 3.18E-05 Cognitive test performance / / 20125193 rs6521432 chrX 56431114 G A 4.76E-05 Smoking initiation / / 24665060 rs12394781 chrX 56443641 T C 4.74E-05 Smoking initiation / / 24665060 rs5960178 chrX 56449026 C T 1.41E-05 Smoking initiation / / 24665060 rs5914664 chrX 56469000 T C 5.84E-04 Smoking initiation / / 24665060 rs2039598 chrX 56474134 A G 5.35E-04 Smoking initiation / / 24665060 rs6417955 chrX 56534176 A G 4.78E-05 Smoking initiation / / 24665060 rs4826475 chrX 56546856 A C 4.79E-05 Smoking initiation / / 24665060 rs5960184 chrX 56573376 A G 4.93E-05 Smoking initiation / / 24665060 rs5914708 chrX 56579462 A G 4.74E-05 Smoking initiation / / 24665060 rs4826508 chrX 56811695 C T 1.00E-12 Blood trace element (Zn levels) LOC550643 intron 23720494 rs6612721 chrX 56956036 A G 2.30E-05 Urinary metabolites / / 21572414 rs912956 chrX 57010138 C T 0.000000193 Colorectal cancer SPIN3 intron 22532847 rs529013 chrX 57224700 A G 2.90E-05 Urinary metabolites / / 21572414 rs519224 chrX 57235305 T C 2.80E-05 Urinary metabolites / / 21572414 rs4826553 chrX 57457985 C T 8.50E-06 Urinary metabolites FAAH2 intron 21572414 rs5946807 chrX 58248880 C T 2.10E-05 Urinary metabolites / / 21572414 rs12559663 chrX 62255022 G A 2.40E-06 Urinary metabolites / / 21572414 rs12006616 chrX 62600135 A G 9.08E-05 Psoriasis / / 20953190 rs10127000 chrX 62625199 G T 6.00E-06 Periodontitis (Mean PAL) / / 24024966 rs12556578 chrX 62733089 A G 9.73E-06 Intelligence LOC92249 intron 21826061 rs12688535 chrX 62747056 T C 7.35E-04 Prostate cancer LOC92249 intron 23023329 rs2152466 chrX 63283604 C T 1.49E-05 Age-related macular degeneration / / pha000001 rs6524881 chrX 63618824 G C 4.80E-06 Age-related macular degeneration / / pha000001 rs5964778 chrX 63644888 T C 4.80E-06 Age-related macular degeneration / / pha000001 rs4419959 chrX 63675520 G C 1.16E-05 Age-related macular degeneration / / pha000001 rs12557468 chrX 63787412 C A 1.50E-05 Intelligence / / 21826061 rs7890561 chrX 63940112 T C 8.45E-06 Age-related macular degeneration / / pha000001 rs5918890 chrX 64087388 C T 3.47E-04 Celiac disease / / 23936387 rs12559168 chrX 64253096 A G 3.65E-05 Intelligence ZC4H2 intron 21826061 rs7064929 chrX 64367019 G A 7.00E-07 Erectile dysfunction and prostate cancer treatment / / 20932654 rs5964445 chrX 64811035 A C 8.86E-06 Age-related macular degeneration / / pha000001 rs7050592 chrX 64885677 T C 8.86E-06 Age-related macular degeneration MSN nearGene-5 pha000001 rs5965007 chrX 64959577 A G 5.41E-06 Age-related macular degeneration MSN intron pha000001 rs6525038 chrX 65193018 A G 3.46E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7054364 chrX 65392636 C A 4.90E-05 Vascular dementia HEPH intron 22116812 rs7054364 chrX 65392636 C A 1.33E-25 Male-pattern baldness HEPH intron 22693459 rs6624875 chrX 65408445 C T 2.90E-27 Male-pattern baldness HEPH intron 22693459 rs2206203 chrX 65415174 T G 1.77E-27 Male-pattern baldness HEPH intron 22693459 rs1011526 chrX 65416087 G A 4.70E-05 Vascular dementia HEPH intron 22116812 rs1011526 chrX 65416087 G A 1.77E-27 Male-pattern baldness HEPH intron 22693459 rs806607 chrX 65427040 T C 3.11E-29 Male-pattern baldness HEPH cds-synon 22693459 rs806608 chrX 65428529 G T 5.05E-29 Male-pattern baldness HEPH intron 22693459 rs806610 chrX 65433539 A G 4.82E-29 Male-pattern baldness HEPH intron 22693459 rs1264216 chrX 65435257 T G 4.82E-29 Male-pattern baldness HEPH intron 22693459 rs1091486 chrX 65439464 C T 5.05E-29 Male-pattern baldness HEPH intron 22693459 rs1068533 chrX 65456807 A G 4.12E-05 Serum metabolites HEPH intron 19043545 rs5919042 chrX 65516678 G A 1.84E-26 Male-pattern baldness / / 22693459 rs5919043 chrX 65516899 G A 1.84E-26 Male-pattern baldness / / 22693459 rs601552 chrX 65531859 T C 1.01E-29 Male-pattern baldness / / 22693459 rs1463435 chrX 65532178 C T 5.08E-16 Male-pattern baldness / / 22693459 rs6624177 chrX 65538623 C T 8.23E-31 Male-pattern baldness / / 22693459 rs1585131 chrX 65574589 C A 2.15E-30 Male-pattern baldness / / 22693459 rs5964522 chrX 65604855 T A 1.24E-34 Male-pattern baldness / / 22693459 rs1379146 chrX 65606361 T A 1.32E-34 Male-pattern baldness / / 22693459 rs2840240 chrX 65606556 C G 1.24E-34 Male-pattern baldness / / 22693459 rs5965182 chrX 65606693 T A 6.00E-06 Erectile dysfunction and prostate cancer treatment / / 20932654 rs1926341 chrX 65611304 C T 7.12E-35 Male-pattern baldness / / 22693459 rs5965189 chrX 65628237 G A 8.97E-35 Male-pattern baldness / / 22693459 rs4240047 chrX 65628863 A T 8.97E-35 Male-pattern baldness / / 22693459 rs7888975 chrX 65630272 G A 6.94E-35 Male-pattern baldness / / 22693459 rs5965192 chrX 65632779 A G 8.15E-35 Male-pattern baldness / / 22693459 rs4827479 chrX 65657889 A G 9.24E-13 Male-pattern baldness / / 22693459 rs5919100 chrX 65661898 T G 4.36E-46 Male-pattern baldness / / 22693459 rs4361890 chrX 65670241 C T 2.28E-46 Male-pattern baldness / / 22693459 rs4240049 chrX 65672338 G A 2.28E-46 Male-pattern baldness / / 22693459 rs5919108 chrX 65672412 A G 1.83E-46 Male-pattern baldness / / 22693459 rs4357442 chrX 65672594 A G 1.83E-46 Male-pattern baldness / / 22693459 rs5919110 chrX 65672801 A T 1.14E-16 Male-pattern baldness / / 22693459 rs5919135 chrX 65718338 T C 5.03E-47 Male-pattern baldness / / 22693459 rs1331101 chrX 65723858 A C 9.09E-47 Male-pattern baldness / / 22693459 rs5918648 chrX 65733844 T C 6.21E-31 Male-pattern baldness / / 22693459 rs6624219 chrX 65759842 G A 6.80E-04 Type 2 diabetes / / 17463246 rs1586315 chrX 65808595 T C 9.28E-04 Type 2 diabetes / / 17463246 rs1586315 chrX 65808595 T C 1.51E-49 Male-pattern baldness / / 22693459 rs4827379 chrX 65813960 T C 1.14E-16 Male-pattern baldness / / 22693459 rs1385699 chrX 65824986 C T 3.00E-53 Male-pattern baldness EDA2R missense 22693459 rs1352015 chrX 65843843 G A 3.00E-53 Male-pattern baldness EDA2R intron 22693459 rs5919174 chrX 65914654 A G 7.92E-76 Male-pattern baldness / / 22693459 rs5919175 chrX 65922033 A G 5.23E-76 Male-pattern baldness / / 22693459 rs775358 chrX 65932849 C T 2.33E-81 Male-pattern baldness / / 22693459 rs16990143 chrX 65952293 A G 7.30E-78 Male-pattern baldness / / 22693459 rs775362 chrX 65979173 T C 7.30E-78 Male-pattern baldness / / 22693459 rs3843789 chrX 66017027 T C 5.42E-42 Male-pattern baldness / / 22693459 rs5919200 chrX 66047345 G A 6.37E-83 Male-pattern baldness / / 22693459 rs4827384 chrX 66068591 G A 7.61E-40 Male-pattern baldness / / 22693459 rs1041668 chrX 66085956 G A 1.70E-83 Male-pattern baldness / / 22693459 rs7878229 chrX 66102322 T C 3.24E-36 Male-pattern baldness / / 22693459 rs4548330 chrX 66115123 T G 2.57E-86 Male-pattern baldness / / 22693459 rs5919235 chrX 66170500 G A 4.62E-88 Male-pattern baldness / / 22693459 rs7057795 chrX 66221897 T C 2.70E-83 Male-pattern baldness / / 22693459 rs471205 chrX 66238317 C T 5.11E-39 Male-pattern baldness / / 22693459 rs476709 chrX 66238929 C T 2.23E-83 Male-pattern baldness / / 22693459 rs505520 chrX 66258914 A C 4.68E-84 Male-pattern baldness / / 22693459 rs574001 chrX 66262673 A C 1.30E-83 Male-pattern baldness / / 22693459 rs532649 chrX 66267248 A G 7.38E-05 Vascular dementia / / 22116812 rs532649 chrX 66267248 A G 7.13E-87 Male-pattern baldness / / 22693459 rs485454 chrX 66268202 A G 8.01E-05 Vascular dementia / / 22116812 rs485454 chrX 66268202 A G 1.22E-83 Male-pattern baldness / / 22693459 rs489099 chrX 66268374 T C 9.94E-87 Male-pattern baldness / / 22693459 rs531840 chrX 66273571 C T 4.26E-86 Male-pattern baldness / / 22693459 rs5919247 chrX 66287684 C T 7.68E-87 Male-pattern baldness / / 22693459 rs5918688 chrX 66288055 A G 2.81E-76 Male-pattern baldness / / 22693459 rs4827524 chrX 66298187 A G 6.45E-87 Male-pattern baldness / / 22693459 rs989345 chrX 66301034 G A 6.95E-05 Vascular dementia / / 22116812 rs989345 chrX 66301034 G A 2.74E-87 Male-pattern baldness / / 22693459 rs5919266 chrX 66304556 G T 3.39E-86 Male-pattern baldness / / 22693459 rs1567524 chrX 66311801 T C 5.93E-87 Male-pattern baldness / / 22693459 rs5919270 chrX 66315730 G A 5.09E-87 Male-pattern baldness / / 22693459 rs1511061 chrX 66316124 C T 6.82E-90 Male-pattern baldness / / 22693459 rs1511060 chrX 66316431 C T 9.60E-05 Vascular dementia / / 22116812 rs1511060 chrX 66316431 C T 1.62E-86 Male-pattern baldness / / 22693459 rs5918694 chrX 66318768 T C 9.38E-05 Vascular dementia / / 22116812 rs5918694 chrX 66318768 T C 1.01E-86 Male-pattern baldness / / 22693459 rs4827392 chrX 66321962 C A 9.92E-05 Vascular dementia / / 22116812 rs4827392 chrX 66321962 C A 5.77E-87 Male-pattern baldness / / 22693459 rs5919272 chrX 66325497 G A 5.10E-87 Male-pattern baldness / / 22693459 rs5918696 chrX 66325555 T C 3.73E-87 Male-pattern baldness / / 22693459 rs4827527 chrX 66330152 G A 7.97E-87 Male-pattern baldness / / 22693459 rs938059 chrX 66336727 C A 8.87E-05 Vascular dementia / / 22116812 rs938059 chrX 66336727 C A 9.42E-87 Male-pattern baldness / / 22693459 rs938058 chrX 66337100 G A 9.42E-87 Male-pattern baldness / / 22693459 rs981065 chrX 66338169 C T 9.07E-87 Male-pattern baldness / / 22693459 rs1988995 chrX 66347684 T C 9.83E-05 Vascular dementia / / 22116812 rs1988995 chrX 66347684 T C 9.91E-86 Male-pattern baldness / / 22693459 rs1511058 chrX 66348636 C T 7.47E-86 Male-pattern baldness / / 22693459 rs1397631 chrX 66352696 C T 3.37E-36 Male-pattern baldness / / 22693459 rs984094 chrX 66352935 A G 1.17E-86 Male-pattern baldness / / 22693459 rs5964588 chrX 66358966 T G 1.22E-86 Male-pattern baldness / / 22693459 rs5919285 chrX 66359172 G A 1.22E-86 Male-pattern baldness / / 22693459 rs5919287 chrX 66360614 T C 1.22E-86 Male-pattern baldness / / 22693459 rs1027970 chrX 66375137 C T 1.24E-86 Male-pattern baldness / / 22693459 rs2221799 chrX 66376616 G A 1.67E-86 Male-pattern baldness / / 22693459 rs4272525 chrX 66387636 T C 2.82E-86 Male-pattern baldness / / 22693459 rs5919309 chrX 66394853 T C 4.62E-86 Male-pattern baldness / / 22693459 rs12007727 chrX 66405429 G A 2.60E-49 Male-pattern baldness / / 22693459 rs5918719 chrX 66412861 C T 1.75E-86 Male-pattern baldness / / 22693459 rs5919321 chrX 66419950 G A 3.89E-86 Male-pattern baldness / / 22693459 rs5919325 chrX 66430671 A G 2.97E-86 Male-pattern baldness / / 22693459 rs2335503 chrX 66434921 C T 3.27E-86 Male-pattern baldness / / 22693459 rs5919335 chrX 66443497 A G 1.62E-83 Male-pattern baldness / / 22693459 rs6625150 chrX 66448968 A C 2.73E-83 Male-pattern baldness / / 22693459 rs12009759 chrX 66449487 G A 1.35E-46 Male-pattern baldness / / 22693459 rs2335868 chrX 66476869 T C 2.80E-83 Male-pattern baldness / / 22693459 rs12558842 chrX 66481800 C A 4.86E-85 Male-pattern baldness / / 22693459 rs6625155 chrX 66481893 C T 4.16E-85 Male-pattern baldness / / 22693459 rs5918737 chrX 66497811 T C 5.52E-83 Male-pattern baldness / / 22693459 rs4827539 chrX 66507096 C T 5.40E-06 Vascular dementia / / 22116812 rs5919362 chrX 66508679 T G 5.31E-06 Vascular dementia / / 22116812 rs4601479 chrX 66510458 G A 5.46E-06 Vascular dementia / / 22116812 rs6625163 chrX 66510984 G A 5.00E-11 Male-pattern baldness / / 18849991 rs6625163 chrX 66510984 G A 5.41E-06 Vascular dementia / / 22116812 rs5919363 chrX 66512103 G A 4.20E-06 Vascular dementia / / 22116812 rs5919363 chrX 66512103 G A 9.49E-86 Male-pattern baldness / / 22693459 rs5965383 chrX 66519508 G T 3.05E-06 Vascular dementia / / 22116812 rs5965383 chrX 66519508 G T 2.14E-85 Male-pattern baldness / / 22693459 rs2335506 chrX 66519714 G A 3.98E-06 Vascular dementia / / 22116812 rs2335506 chrX 66519714 G A 4.71E-85 Male-pattern baldness / / 22693459 rs2335508 chrX 66520650 A G 3.74E-06 Vascular dementia / / 22116812 rs2335508 chrX 66520650 A G 4.70E-85 Male-pattern baldness / / 22693459 rs6625174 chrX 66530532 G A 4.29E-06 Vascular dementia / / 22116812 rs6625174 chrX 66530532 G A 1.30E-85 Male-pattern baldness / / 22693459 rs2878642 chrX 66538729 A G 4.98E-06 Vascular dementia / / 22116812 rs2878642 chrX 66538729 A G 1.63E-84 Male-pattern baldness / / 22693459 rs2336175 chrX 66540111 A G 3.94E-06 Vascular dementia / / 22116812 rs2336175 chrX 66540111 A G 2.26E-80 Male-pattern baldness / / 22693459 rs4484837 chrX 66541098 A G 6.69E-34 Male-pattern baldness / / 22693459 rs5918745 chrX 66554840 T C 3.21E-91 Male-pattern baldness / / 22693459 rs2497936 chrX 66558336 C T 1.64E-67 Male-pattern baldness / / 22693459 rs2497938 chrX 66563018 T C 3.00E-22 Male-pattern baldness / / 22032556 rs2497938 chrX 66563018 T C 3.69E-06 Vascular dementia / / 22116812 rs2497938 chrX 66563018 T C 2.00E-91 Male-pattern baldness / / 22693459 rs2497939 chrX 66564014 A C 3.96E-06 Vascular dementia / / 22116812 rs2497939 chrX 66564014 A C 4.01E-82 Male-pattern baldness / / 22693459 rs2223842 chrX 66564352 A C 3.81E-06 Vascular dementia / / 22116812 rs2223842 chrX 66564352 A C 2.42E-85 Male-pattern baldness / / 22693459 rs2497943 chrX 66566096 T G 4.10E-06 Vascular dementia / / 22116812 rs2497943 chrX 66566096 T G 2.51E-84 Male-pattern baldness / / 22693459 rs2473897 chrX 66566450 T C 4.06E-06 Vascular dementia / / 22116812 rs2473897 chrX 66566450 T C 8.34E-85 Male-pattern baldness / / 22693459 rs2497944 chrX 66567742 G A 3.02E-06 Vascular dementia / / 22116812 rs2223841 chrX 66570171 T C 3.96E-06 Vascular dementia / / 22116812 rs2223841 chrX 66570171 T C 3.90E-85 Male-pattern baldness / / 22693459 rs2473896 chrX 66570727 T C 3.96E-06 Vascular dementia / / 22116812 rs2473896 chrX 66570727 T C 5.01E-85 Male-pattern baldness / / 22693459 rs2473895 chrX 66571037 C T 3.91E-06 Vascular dementia / / 22116812 rs2473895 chrX 66571037 C T 6.85E-85 Male-pattern baldness / / 22693459 rs2207080 chrX 66573743 A G 3.69E-06 Vascular dementia / / 22116812 rs2207080 chrX 66573743 A G 1.47E-84 Male-pattern baldness / / 22693459 rs721451 chrX 66576324 A G 3.06E-06 Vascular dementia / / 22116812 rs721451 chrX 66576324 A G 7.80E-83 Male-pattern baldness / / 22693459 rs2473891 chrX 66576473 C T 4.20E-06 Vascular dementia / / 22116812 rs2473891 chrX 66576473 C T 5.19E-86 Male-pattern baldness / / 22693459 rs2473870 chrX 66613181 A G 2.19E-83 Male-pattern baldness / / 22693459 rs2497911 chrX 66627440 C A 5.58E-06 Vascular dementia / / 22116812 rs2497911 chrX 66627440 C A 2.23E-83 Male-pattern baldness / / 22693459 rs2497917 chrX 66632343 G A 1.83E-83 Male-pattern baldness / / 22693459 rs2497928 chrX 66648216 A C 3.93E-06 Vascular dementia / / 22116812 rs2497928 chrX 66648216 A C 1.66E-85 Male-pattern baldness / / 22693459 rs2497930 chrX 66652704 A C 2.26E-85 Male-pattern baldness / / 22693459 rs2497931 chrX 66656276 A C 1.53E-07 Vascular dementia / / 22116812 rs2473849 chrX 66664083 C A 5.25E-06 Vascular dementia / / 22116812 rs2497935 chrX 66664266 A G 2.26E-85 Male-pattern baldness / / 22693459 rs6625187 chrX 66676395 C T 8.13E-05 Vaspin levels / / 22907691 rs6625187 chrX 66676395 C T 0.0000813 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs2207041 chrX 66707389 C A 4.04E-68 Male-pattern baldness / / 22693459 rs962458 chrX 66745964 A G 1.66E-38 Male-pattern baldness / / 22693459 rs12007229 chrX 66748355 C A 1.33E-08 Vascular dementia / / 22116812 rs7888856 chrX 66751555 A G 1.95E-68 Male-pattern baldness / / 22693459 rs12396249 chrX 66777066 G A 3.30E-06 Vascular dementia AR intron 22116812 rs12396249 chrX 66777066 G A 9.90E-69 Male-pattern baldness AR intron 22693459 rs1204038 chrX 66788225 G A 6.32E-70 Male-pattern baldness AR intron 22693459 rs2255702 chrX 66798111 C T 6.32E-70 Male-pattern baldness AR intron 22693459 rs5918757 chrX 66806030 G A 5.50E-70 Male-pattern baldness AR intron 22693459 rs5919393 chrX 66825357 C T 5.37E-06 Vascular dementia AR intron 22116812 rs5919393 chrX 66825357 C T 1.85E-68 Male-pattern baldness AR intron 22693459 rs4827545 chrX 66828385 A G 1.55E-68 Male-pattern baldness AR intron 22693459 rs5918760 chrX 66838751 T C 8.63E-69 Male-pattern baldness AR intron 22693459 rs6624304 chrX 66875756 T C 3.08E-05 Vascular dementia AR intron 22116812 rs6624304 chrX 66875756 T C 8.53E-62 Male-pattern baldness AR intron 22693459 rs1337080 chrX 66878919 G A 2.91E-35 Male-pattern baldness AR intron 22693459 rs5918762 chrX 66914801 T C 8.53E-62 Male-pattern baldness AR intron 22693459 rs5918764 chrX 66937707 A G 2.91E-35 Male-pattern baldness AR intron 22693459 rs12014709 chrX 66938466 T G 9.32E-06 Vascular dementia AR intron 22116812 rs5031002 chrX 66942625 G A 2.00E-07 LDL cholesterol AR intron 19060910 rs5031002 chrX 66942625 G A 2.00E-07 Coronary heart disease AR intron 21347282 rs5964607 chrX 66956431 T C 1.09E-37 Male-pattern baldness / / 22693459 rs1931542 chrX 66959642 A G 1.03E-37 Male-pattern baldness / / 22693459 rs1572502 chrX 66965118 C T 1.02E-37 Male-pattern baldness / / 22693459 rs1415271 chrX 66968233 C A 1.00E-37 Male-pattern baldness / / 22693459 rs5019585 chrX 66968601 A G 1.25E-37 Male-pattern baldness / / 22693459 rs1931545 chrX 66978571 T G 8.85E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1931545 chrX 66978571 T G 1.09E-37 Male-pattern baldness / / 22693459 rs3927643 chrX 66981596 T C 1.09E-37 Male-pattern baldness / / 22693459 rs6625208 chrX 66983518 C T 1.20E-37 Male-pattern baldness / / 22693459 rs9699051 chrX 66987757 G A 2.65E-33 Male-pattern baldness / / 22693459 rs7057791 chrX 66991359 C T 1.44E-37 Male-pattern baldness / / 22693459 rs12010636 chrX 66997141 C T 2.65E-33 Male-pattern baldness / / 22693459 rs5919427 chrX 67003584 C A 1.15E-37 Male-pattern baldness / / 22693459 rs4370673 chrX 67018026 A C 1.02E-35 Male-pattern baldness / / 22693459 rs5919432 chrX 67021550 C T 7.60E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5919432 chrX 67021550 C T 1.00E-08 Prostate cancer / / 21743467 rs5919432 chrX 67021550 C T 4.71E-05 Vascular dementia / / 22116812 rs5919432 chrX 67021550 C T 7.27E-36 Male-pattern baldness / / 22693459 rs4456006 chrX 67028222 C A 7.60E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4456006 chrX 67028222 C A 4.87E-05 Vascular dementia / / 22116812 rs4456006 chrX 67028222 C A 2.58E-38 Male-pattern baldness / / 22693459 rs5964614 chrX 67033937 T G 8.33E-38 Male-pattern baldness / / 22693459 rs4827556 chrX 67062490 C T 4.63E-05 Vascular dementia / / 22116812 rs4827556 chrX 67062490 C T 3.49E-37 Male-pattern baldness / / 22693459 rs7885198 chrX 67089063 A G 1.15E-31 Male-pattern baldness / / 22693459 rs2781516 chrX 67102031 G A 4.66E-23 Male-pattern baldness / / 22693459 rs5965478 chrX 67169422 G T 1.44E-27 Male-pattern baldness / / 22693459 rs2363785 chrX 67171298 G T 1.44E-27 Male-pattern baldness / / 22693459 rs7050236 chrX 67173332 G A 1.03E-28 Male-pattern baldness / / 22693459 rs7050236 chrX 67173332 G A 2.81E-05 Endometrial cancer / / 24096698 rs7050236 chrX 67173332 G A 8.71E-05 Endometrial cancer / / 24096698 rs16989069 chrX 67173731 C T 2.41E-28 Male-pattern baldness / / 22693459 rs16990427 chrX 67173790 G A 1.41E-28 Male-pattern baldness / / 22693459 rs5964632 chrX 67176605 T C 3.77E-28 Male-pattern baldness / / 22693459 rs16990434 chrX 67177694 C T 4.57E-29 Male-pattern baldness / / 22693459 rs4562482 chrX 67177760 A C 3.29E-28 Male-pattern baldness / / 22693459 rs3898332 chrX 67177803 A G 5.19E-30 Male-pattern baldness / / 22693459 rs5919492 chrX 67183584 T G 1.18E-29 Male-pattern baldness / / 22693459 rs11094062 chrX 67188528 A G 6.49E-28 Male-pattern baldness / / 22693459 rs12009526 chrX 67202934 G A 2.20E-30 Male-pattern baldness / / 22693459 rs5918801 chrX 67208935 G T 2.20E-30 Male-pattern baldness / / 22693459 rs12008699 chrX 67251413 G A 4.00E-33 Male-pattern baldness / / 22693459 rs2765950 chrX 67259924 A G 3.69E-18 Male-pattern baldness / / 22693459 rs16990499 chrX 67286067 C A 4.00E-33 Male-pattern baldness OPHN1 intron 22693459 rs5918809 chrX 67287853 A G 1.12E-29 Male-pattern baldness OPHN1 intron 22693459 rs17217221 chrX 67293333 C T 7.21E-30 Male-pattern baldness OPHN1 intron 22693459 rs12013576 chrX 67296128 T C 2.17E-30 Male-pattern baldness OPHN1 intron 22693459 rs5919529 chrX 67358208 T C 9.45E-05 Celiac disease OPHN1 intron 23936387 rs7881511 chrX 67364303 G A 1.25E-08 Male-pattern baldness OPHN1 intron 22693459 rs12011480 chrX 67371477 C T 3.26E-28 Male-pattern baldness OPHN1 intron 22693459 rs12389669 chrX 67381901 C A 1.25E-08 Male-pattern baldness OPHN1 intron 22693459 rs12854385 chrX 67385944 A C 3.20E-09 Male-pattern baldness OPHN1 intron 22693459 rs5980817 chrX 67874382 T C 3.26E-04 Amyotrophic Lateral Sclerosis STARD8 intron 17362836 rs5980668 chrX 67915900 G A 9.63E-06 Periodontitis (Mean PAL) STARD8 intron 24024966 rs17302410 chrX 67954838 G A 3.54E-04 Coronary Artery Disease / / 17634449 rs5937118 chrX 68126086 G A 1.71E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6624385 chrX 68384125 C T 9.86E-04 Response to cytidine analogues (gemcitabine) PJA1 intron 24483146 rs4596804 chrX 68389129 G A 2.27E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4596804 chrX 68389129 G A 3.60E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1926354 chrX 68405165 T C 7.83E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs943166 chrX 68411445 C T 7.07E-04 Alcohol dependence / / 20201924 rs3904331 chrX 68420848 A G 6.69E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs3915920 chrX 68437340 G A 2.20E-05 Urinary metabolites / / 21572414 rs5981189 chrX 68444370 C A 3.18E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7059244 chrX 68450238 C T 2.40E-05 Urinary metabolites / / 21572414 rs1537137 chrX 68526866 C T 7.87E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10521344 chrX 68585842 C G 1.96E-04 Type 2 diabetes / / 17463246 rs10521345 chrX 68590934 G A 1.96E-04 Type 2 diabetes / / 17463246 rs17217759 chrX 68591156 T C 1.28E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1408786 chrX 68599270 A G 3.02E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1408786 chrX 68599270 A G 6.82E-05 Lung function (forced expiratory volume in 1 second) / / 24023788 rs5981225 chrX 68648758 G A 7.76E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7056340 chrX 68790706 G A 1.04E-05 Common variable immunodeficiency / / 21497890 rs7056340 chrX 68790706 G A 7.34E-04 Tourette syndrome / / 22889924 rs11796357 chrX 68798703 A G 3.00E-22 Primary tooth development (time to first tooth eruption) / / 23704328 rs11796357 chrX 68798703 A G 7.00E-19 Primary tooth development (number of teeth) / / 23704328 rs4844096 chrX 68805318 A G 5.00E-11 Primary tooth development (number of teeth) / / 20195514 rs5936708 chrX 68844248 A G 3.10E-04 Myasthenia gravis EDA intron 23055271 rs1327347 chrX 68856453 A G 3.49E-04 Tourette syndrome EDA intron 22889924 rs1327347 chrX 68856453 A G 3.60E-04 Myasthenia gravis EDA intron 23055271 rs5936487 chrX 68892916 G A 6.00E-11 Primary tooth development (time to first tooth eruption) EDA intron 20195514 rs2804344 chrX 69013321 C T 9.82E-04 Parkinson's disease EDA intron 17052657 rs5936752 chrX 69018663 A C 5.46E-04 Response to cytidine analogues (gemcitabine) EDA intron 24483146 rs5936753 chrX 69020596 T C 6.36E-04 Response to cytidine analogues (gemcitabine) EDA intron 24483146 rs4562502 chrX 69034378 C T 2.48E-04 Response to cytidine analogues (gemcitabine) EDA intron 24483146 rs5936510 chrX 69056749 G A 3.38E-04 Tourette syndrome EDA intron 22889924 rs5936510 chrX 69056749 G A 4.41E-04 Response to cytidine analogues (gemcitabine) EDA intron 24483146 rs5980665 chrX 69057567 G A 4.41E-04 Response to cytidine analogues (gemcitabine) EDA intron 24483146 rs11094136 chrX 69059041 C G 7.59E-04 Response to cytidine analogues (gemcitabine) EDA intron 24483146 rs5936511 chrX 69063974 A G 4.41E-04 Response to cytidine analogues (gemcitabine) EDA intron 24483146 rs12688186 chrX 69081136 C A 4.84E-04 Response to cytidine analogues (gemcitabine) EDA intron 24483146 rs5980666 chrX 69096680 G A 7.31E-04 Response to cytidine analogues (gemcitabine) EDA intron 24483146 rs1202987 chrX 69102019 C T 9.23E-04 Response to taxane treatment (placlitaxel) EDA intron 23006423 rs5936518 chrX 69127562 G T 9.50E-04 Amyotrophic Lateral Sclerosis EDA intron 17362836 rs5936795 chrX 69137688 C T 9.79E-04 Tourette syndrome EDA intron 22889924 rs1938018 chrX 69177761 A G 6.09E-05 Cognitive test performance EDA intron 20125193 rs6625561 chrX 69225199 T C 4.00E-04 Bipolar disorder EDA intron 17486107 rs6625561 chrX 69225199 T C 1.70E-05 Urinary metabolites EDA intron 21572414 rs7882379 chrX 69245198 A G 6.47E-04 Amyotrophic Lateral Sclerosis EDA intron 17362836 rs1409993 chrX 69266212 A G 4.70E-04 Amyotrophic Lateral Sclerosis AWAT2 intron 17362836 rs1409993 chrX 69266212 A G 6.42E-04 Bilirubin levels,in serum AWAT2 intron 19389676 rs6625573 chrX 69297141 T C 5.13E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5980684 chrX 69300000 C T 3.59E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11796550 chrX 69302766 G A 9.22E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs838361 chrX 69309307 G A 4.97E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs471492 chrX 69316314 A G 8.91E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4844107 chrX 69365923 G A 1.09E-04 Amyotrophic Lateral Sclerosis IGBP1 intron 17362836 rs1152190 chrX 69476341 C T 3.39E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs3843841 chrX 69485529 A C 4.01E-04 Alcohol dependence / / 20201924 rs17264923 chrX 69499165 T C 2.00E-05 Urinary metabolites ARR3 intron 21572414 rs1199468 chrX 69512976 G A 2.12E-04 Type 2 diabetes KIF4A intron 17463246 rs1199460 chrX 69559871 T G 6.98E-04 Type 2 diabetes KIF4A intron 17463246 rs5980931 chrX 69629721 T C 7.07E-04 Type 2 diabetes KIF4A intron 17463246 rs1925926 chrX 69653661 G T 1.92E-04 Amyotrophic Lateral Sclerosis GDPD2 nearGene-3 17362836 rs7889367 chrX 69666915 C T 6.64E-05 Fibrinogen DLG3 intron 17255346 rs4844229 chrX 69707492 A G 8.44E-12 HDL cholesterol DLG3 intron 23063622 rs1044422 chrX 69724094 G A 2.38E-04 Fibrinogen DLG3 UTR-3 17255346 rs3752323 chrX 69725361 C T 1.00E-04 Cognitive impairment induced by topiramate DLG3 nearGene-3 22091778 rs6525372 chrX 69744251 G A 2.69E-05 Post-operative nausea and vomiting / / 21694509 rs5936918 chrX 69772848 A G 3.85E-04 Fibrinogen TEX11 intron 17255346 rs6624496 chrX 69947684 C T 4.56E-04 Lung function (forced expiratory volume in 1 second) TEX11 intron 24023788 rs7878853 chrX 70068848 T C 8.98E-04 Response to cytidine analogues (gemcitabine) TEX11 intron 24483146 rs5937040 chrX 70193977 T C 8.02E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5937044 chrX 70200693 A G 8.02E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5936630 chrX 70754534 A G 8.34E-05 Parkinson's disease OGT intron 17052657 rs5936630 chrX 70754534 A G 2.99E-04 Amyotrophic Lateral Sclerosis OGT intron 17362836 rs11796215 chrX 70761281 C A 6.89E-04 Response to cytadine analogues (cytosine arabinoside) OGT intron 24483146 rs17174150 chrX 70880638 C A 8.12E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12559758 chrX 71384613 T C 6.79E-04 Type 2 diabetes / / 17463246 rs646297 chrX 71538575 T C 6.98E-05 Asthma / / 20159242 rs2984299 chrX 71621767 A G 9.06E-04 Amyotrophic Lateral Sclerosis HDAC8 intron 17362836 rs5938202 chrX 72382068 G A 9.04E-04 Alzheimer's disease / / 17998437 rs5937610 chrX 72480507 C A 7.25E-04 Alzheimer's disease / / 17998437 rs5937611 chrX 72480526 C T 3.90E-04 Alzheimer's disease / / 17998437 rs1592770 chrX 72585968 G A 9.15E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5938998 chrX 72638450 G A 7.98E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17312304 chrX 72743401 T G 3.59E-05 Creutzfeldt-Jakob disease (variant) / / 22137330 rs12008691 chrX 72835433 T A 2.40E-05 Urinary metabolites CHIC1 intron 21572414 rs2790964 chrX 72881703 G A 2.40E-05 Urinary metabolites CHIC1 intron 21572414 rs2790965 chrX 72904584 G A 2.40E-05 Urinary metabolites CHIC1 UTR-3 21572414 rs7057757 chrX 72907078 C T 2.40E-05 Urinary metabolites / / 21572414 rs12012798 chrX 72930554 C T 2.40E-05 Urinary metabolites / / 21572414 rs16992417 chrX 72931288 T G 2.40E-05 Urinary metabolites / / 21572414 rs1337657 chrX 73001041 C T 2.40E-05 Urinary metabolites / / 21572414 rs195678 chrX 73092562 G A 8.60E-06 Urinary metabolites / / 21572414 rs479640 chrX 73668829 C T 3.61E-04 Lung function (forced expiratory volume in 1 second) SLC16A2 intron 24023788 rs496549 chrX 73676286 A G 3.78E-04 Lung function (forced expiratory volume in 1 second) SLC16A2 intron 24023788 rs6647061 chrX 73889397 C A 1.50E-04 Lung function (forced vital capacity) / / 24023788 rs6647577 chrX 74132540 G A 3.95E-05 Lung function (forced vital capacity) KIAA2022 intron 24023788 rs6647583 chrX 74146249 T G 9.92E-05 Lung function (forced vital capacity) KIAA2022 nearGene-5 24023788 rs6647628 chrX 74320164 G A 1.39E-04 Lung function (forced vital capacity) ABCB7 intron 24023788 rs4148831 chrX 74375460 C T 4.47E-05 Lung function (forced vital capacity) ABCB7 intron 24023788 rs5981813 chrX 74438998 C T 2.10E-05 Urinary metabolites / / 21572414 rs5938070 chrX 74667078 G C 1.36E-08 Multiple complex diseases ZDHHC15 intron 17554300 rs7061864 chrX 74825373 C T 8.51E-04 Type 2 diabetes / / 17463246 rs2213481 chrX 75286200 G A 6.80E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2213480 chrX 75286248 T C 7.57E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5937496 chrX 75347434 G A 6.00E-07 Amyotrophic lateral sclerosis / / 19734901 rs4465127 chrX 75360523 A G 5.69E-04 Type 2 diabetes / / 17463246 rs5981408 chrX 75373941 T C 9.55E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2311978 chrX 75788843 T C 2.00E-09 Asthma (childhood onset) / / 17611496 rs6648110 chrX 75871495 C G 7.23E-04 Type 2 diabetes / / 17463246 rs6648142 chrX 75928566 G A 7.09E-04 Type 2 diabetes / / 17463246 rs170875 chrX 76025246 C G 7.17E-04 Type 2 diabetes / / 17463246 rs233872 chrX 76031066 T C 1.70E-04 Type 2 diabetes / / 17463246 rs192069 chrX 76053556 C T 4.30E-04 Type 2 diabetes / / 17463246 rs1618121 chrX 76057747 T G 1.73E-04 Type 2 diabetes / / 17463246 rs7881752 chrX 76197380 C T 7.09E-04 Type 2 diabetes / / 17463246 rs5982340 chrX 76230687 A G 7.09E-04 Type 2 diabetes / / 17463246 rs3099706 chrX 76287953 C T 7.09E-04 Type 2 diabetes / / 17463246 rs2227291 chrX 77268502 G C 1 Drug response to Docetaxel ATP7A missense 20038957 rs2227291 chrX 77268502 G C 1 Drug response to Thalidomide ATP7A missense 20038957 rs4826248 chrX 77372275 T C 5.34E-04 Smoking initiation PGK1 intron 24665060 rs5912838 chrX 78497118 A C 2.00E-33 Graves' disease / / 23612905 rs2411961 chrX 78508481 C T 3.21E-04 Bilirubin levels,in serum / / 19389676 rs1736677 chrX 78554311 G A 4.47E-04 Type 2 diabetes / / 17463246 rs1736661 chrX 78576827 C T 4.46E-04 Type 2 diabetes / / 17463246 rs1751119 chrX 78579034 G A 5.49E-04 Type 2 diabetes / / 17463246 rs5912898 chrX 78585891 C T 6.11E-04 Type 2 diabetes / / 17463246 rs1751104 chrX 78607137 T C 5.18E-04 Type 2 diabetes / / 17463246 rs1474563 chrX 78649193 C T 3.00E-06 Height / / 18391951 rs1997637 chrX 78658186 C T 2.10E-04 Parkinson's disease / / 17052657 rs5959353 chrX 78683339 T C 5.47E-04 Parkinson's disease / / 17052657 rs17317738 chrX 78705505 C A 1.30E-05 Urinary metabolites / / 21572414 rs17317745 chrX 78705561 G C 6.15E-04 Alzheimer's disease / / 17998437 rs2898795 chrX 78787906 A G 1.30E-05 Urinary metabolites / / 21572414 rs1898810 chrX 79048392 G A 9.90E-04 Coronary Artery Disease / / 17634449 rs7879087 chrX 79101579 A G 6.83E-04 Coronary Artery Disease / / 17634449 rs2775200 chrX 79102189 T G 8.00E-04 Coronary Artery Disease / / 17634449 rs2263535 chrX 79104179 C T 6.83E-04 Coronary Artery Disease / / 17634449 rs7879375 chrX 79128191 G A 2.68E-05 Interstitial lung disease / / 23583980 rs3903350 chrX 79145448 G A 2.94E-06 Interstitial lung disease / / 23583980 rs589133 chrX 79389391 G A 2.35E-04 Height / / 17255346 rs1026304 chrX 80602174 G C 4.52E-05 Personality dimensions / / 18957941 rs7474037 chrX 80938276 A C 1.80E-05 Urinary metabolites / / 21572414 rs5913597 chrX 80965264 T A 1.60E-05 Urinary metabolites / / 21572414 rs6622546 chrX 80970881 G C 1.10E-05 Urinary metabolites / / 21572414 rs5959950 chrX 80970917 A C 1.70E-05 Urinary metabolites / / 21572414 rs4826238 chrX 80991393 A C 2.50E-05 Urinary metabolites / / 21572414 rs13328540 chrX 80993310 T C 2.50E-05 Urinary metabolites / / 21572414 rs5912551 chrX 80995621 T G 2.10E-05 Urinary metabolites / / 21572414 rs11266659 chrX 81039541 A T 2.50E-05 Urinary metabolites / / 21572414 rs7063814 chrX 81047164 C A 2.50E-05 Urinary metabolites / / 21572414 rs7050653 chrX 81047527 T A 2.10E-05 Urinary metabolites / / 21572414 rs2507047 chrX 81085435 C T 2.40E-05 Urinary metabolites / / 21572414 rs2507041 chrX 81087666 T C 1.90E-05 Urinary metabolites / / 21572414 rs2516171 chrX 81108466 C T 2.70E-05 Urinary metabolites / / 21572414 rs2516151 chrX 81118312 A G 2.30E-05 Urinary metabolites / / 21572414 rs2507013 chrX 81126298 A T 1.30E-06 Urinary metabolites / / 21572414 rs2516141 chrX 81126669 A G 7.20E-06 Urinary metabolites / / 21572414 rs2516138 chrX 81130672 T C 3.40E-07 Urinary metabolites / / 21572414 rs5967417 chrX 81156204 T A 3.40E-07 Urinary metabolites / / 21572414 rs5921971 chrX 81156474 T C 3.60E-07 Urinary metabolites / / 21572414 rs4131395 chrX 81170184 A G 3.70E-07 Urinary metabolites / / 21572414 rs5922805 chrX 81170236 G A 3.50E-07 Urinary metabolites / / 21572414 rs4130662 chrX 81175918 A G 3.50E-07 Urinary metabolites / / 21572414 rs17218533 chrX 81180501 C T 2.16E-04 Smoking quantity / / 24665060 rs5968163 chrX 81182971 A T 3.60E-07 Urinary metabolites / / 21572414 rs6622584 chrX 81190724 A G 2.80E-06 Urinary metabolites / / 21572414 rs5968184 chrX 81194812 T C 2.90E-07 Urinary metabolites / / 21572414 rs5968185 chrX 81194843 C A 2.80E-07 Urinary metabolites / / 21572414 rs1013565 chrX 81212047 T A 3.50E-07 Urinary metabolites / / 21572414 rs1731361 chrX 81213460 A T 2.90E-07 Urinary metabolites / / 21572414 rs1731371 chrX 81231177 G A 4.50E-07 Urinary metabolites / / 21572414 rs5922898 chrX 81243685 C T 3.20E-06 Urinary metabolites / / 21572414 rs1794602 chrX 81245233 G A 3.00E-07 Urinary metabolites / / 21572414 rs1794601 chrX 81250934 C T 8.40E-07 Urinary metabolites / / 21572414 rs1731375 chrX 81264783 A G 9.20E-07 Urinary metabolites / / 21572414 rs473692 chrX 81278268 T C 1.80E-06 Urinary metabolites / / 21572414 rs555136 chrX 81279208 A G 1.80E-06 Urinary metabolites / / 21572414 rs506076 chrX 81283771 A T 5.70E-07 Urinary metabolites / / 21572414 rs613173 chrX 81287499 C G 1.00E-06 Urinary metabolites / / 21572414 rs6622594 chrX 81289422 G A 7.58E-05 Femoral neck bone geometry / / 22087292 rs858776 chrX 81312747 T A 1.10E-06 Urinary metabolites / / 21572414 rs7891385 chrX 81313201 C T 1.10E-06 Urinary metabolites / / 21572414 rs517372 chrX 81315697 C A 1.60E-06 Urinary metabolites / / 21572414 rs511655 chrX 81316564 G A 1.10E-06 Urinary metabolites / / 21572414 rs5967526 chrX 81333002 A G 1.80E-06 Urinary metabolites / / 21572414 rs5967528 chrX 81334350 T C 1.80E-06 Urinary metabolites / / 21572414 rs1590624 chrX 81336124 T C 1.90E-06 Urinary metabolites / / 21572414 rs6524154 chrX 81336734 T C 1.90E-06 Urinary metabolites / / 21572414 rs6524155 chrX 81336748 G A 1.80E-06 Urinary metabolites / / 21572414 rs6524156 chrX 81338460 G T 4.80E-07 Urinary metabolites / / 21572414 rs7055912 chrX 81341180 A G 2.00E-06 Urinary metabolites / / 21572414 rs12012384 chrX 81351886 G A 1.80E-06 Urinary metabolites / / 21572414 rs12392938 chrX 81358988 T C 2.20E-06 Urinary metabolites / / 21572414 rs1409770 chrX 81362511 A C 4.30E-06 Urinary metabolites / / 21572414 rs5967546 chrX 81364855 A C 4.30E-07 Urinary metabolites / / 21572414 rs7053098 chrX 81364942 C T 6.50E-06 Urinary metabolites / / 21572414 rs2094330 chrX 81367744 A T 2.20E-06 Urinary metabolites / / 21572414 rs5968471 chrX 81370149 C T 2.10E-06 Urinary metabolites / / 21572414 rs5968478 chrX 81379450 A G 1.10E-06 Urinary metabolites / / 21572414 rs5968479 chrX 81379519 A C 1.20E-06 Urinary metabolites / / 21572414 rs2223843 chrX 81492309 C T 8.00E-06 Urinary metabolites / / 21572414 rs5967806 chrX 81572223 C T 4.20E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2092063 chrX 81617910 T C 9.20E-06 Urinary metabolites / / 21572414 rs2103531 chrX 81618133 C T 9.50E-06 Urinary metabolites / / 21572414 rs12558690 chrX 81618439 A G 1.90E-05 Urinary metabolites / / 21572414 rs6622622 chrX 81624830 T C 9.50E-06 Urinary metabolites / / 21572414 rs5924180 chrX 81638618 A T 2.40E-05 Urinary metabolites / / 21572414 rs6622626 chrX 81638873 G A 8.80E-06 Urinary metabolites / / 21572414 rs2223215 chrX 81640582 C T 9.05E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12557962 chrX 81656588 G A 1.00E-05 Urinary metabolites / / 21572414 rs5969528 chrX 81668873 A G 9.80E-06 Urinary metabolites / / 21572414 rs5969638 chrX 81682299 G A 7.30E-06 Urinary metabolites / / 21572414 rs12557972 chrX 81684253 T G 9.50E-06 Urinary metabolites / / 21572414 rs6622648 chrX 81827765 T G 2.48E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12393339 chrX 82003237 C T 2.90E-05 Urinary metabolites / / 21572414 rs10081813 chrX 82110897 C T 8.26E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12007416 chrX 82477393 T G 3.37E-05 Bipolar disorder and schizophrenia / / 20889312 rs290379 chrX 82498950 C T 5.27E-05 Bipolar disorder and schizophrenia / / 20889312 rs2046277 chrX 82503057 C T 6.00E-05 Bipolar disorder and schizophrenia / / 20889312 rs771837 chrX 82507485 T G 4.28E-05 Bipolar disorder and schizophrenia / / 20889312 rs12688929 chrX 82519977 A G 4.28E-05 Bipolar disorder and schizophrenia / / 20889312 rs7063188 chrX 82527017 T C 3.91E-05 Bipolar disorder and schizophrenia / / 20889312 rs7064448 chrX 82529564 C T 9.89E-05 Bipolar disorder and schizophrenia / / 20889312 rs1410530 chrX 82535169 G A 4.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs1299087 chrX 82591470 A G 2.71E-05 Bipolar disorder and schizophrenia / / 20889312 rs815869 chrX 82596109 A G 7.24E-05 Type 2 diabetes / / 17463246 rs815869 chrX 82596109 A G 4.84E-05 Bipolar disorder and schizophrenia / / 20889312 rs709201 chrX 82612033 G A 3.63E-05 Bipolar disorder and schizophrenia / / 20889312 rs1068907 chrX 82623043 G A 1.05E-05 Bipolar disorder and schizophrenia / / 20889312 rs212911 chrX 82699898 C A 2.70E-05 Bipolar disorder and schizophrenia / / 20889312 rs213462 chrX 82704455 A C 3.09E-07 Parkinson's disease / / 17052657 rs213443 chrX 82711942 G C 6.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs213444 chrX 82713054 G C 1.72E-05 Bipolar disorder and schizophrenia / / 20889312 rs5922838 chrX 82871195 A G 7.00E-04 Alcohol dependence / / 20201924 rs5922838 chrX 82871195 A G 5.00E-06 Depression and alcohol dependence / / 22064162 rs1126140 chrX 82891589 C T 7.21E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4614152 chrX 82915556 T C 2.00E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs5922854 chrX 82937066 G T 6.61E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs5968205 chrX 82954490 C T 6.70E-04 Alcohol dependence / / 20201924 rs5968205 chrX 82954490 C T 3.00E-06 Depression and alcohol dependence / / 22064162 rs5922858 chrX 82971008 G T 7.10E-04 Alcohol dependence / / 20201924 rs923865 chrX 83231308 C A 2.18E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5968255 chrX 83254692 T C 6.39E-05 Cognitive impairment induced by topiramate / / 22091778 rs12845961 chrX 83289555 G A 3.60E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2340868 chrX 83297012 C T 6.32E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5967469 chrX 83350263 T C 6.92E-04 Amyotrophic Lateral Sclerosis RPS6KA6 intron 17362836 rs5922023 chrX 83514154 G C 2.20E-05 Obesity-related traits / / 17658951 rs5922954 chrX 83548209 G A 3.60E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs5922971 chrX 83619032 A G 6.91E-04 Response to taxane treatment (placlitaxel) HDX intron 23006423 rs2092545 chrX 83631474 A G 8.10E-04 Response to taxane treatment (placlitaxel) HDX intron 23006423 rs4437785 chrX 83671545 C T 6.45E-04 Type 2 diabetes HDX intron 17463246 rs4437785 chrX 83671545 C T 3.96E-04 Alzheimer's disease HDX intron 17998437 rs6623023 chrX 83673619 C T 2.06E-04 Response to taxane treatment (placlitaxel) HDX intron 23006423 rs35161124 chrX 83723541 A G 0.00017 Breast cancer HDX missense 23555315 rs969017 chrX 83808253 T G 0.000032 Breast cancer / / 23555315 rs2342563 chrX 83991290 G A 4.30E-05 Personality dimensions / / 18957941 rs5922091 chrX 84006458 T A 4.04E-04 Type 2 diabetes / / 17463246 rs686181 chrX 84198075 C A 1.56E-05 Endometrial cancer / / 24096698 rs686181 chrX 84198075 C A 2.14E-05 Endometrial cancer / / 24096698 rs2342835 chrX 84219832 T G 7.70E-05 Temperament (bipolar disorder) / / 22365631 rs7066871 chrX 84224371 G A 7.60E-05 Temperament (bipolar disorder) / / 22365631 rs2090436 chrX 84225805 C T 7.10E-05 Temperament (bipolar disorder) / / 22365631 rs1914342 chrX 84227373 T C 5.80E-05 Temperament (bipolar disorder) / / 22365631 rs5922129 chrX 84227862 T A 8.60E-05 Temperament (bipolar disorder) / / 22365631 rs5967534 chrX 84238020 C T 6.30E-05 Temperament (bipolar disorder) / / 22365631 rs5967535 chrX 84238132 A G 7.30E-05 Temperament (bipolar disorder) / / 22365631 rs4828315 chrX 84238433 G A 9.20E-05 Temperament (bipolar disorder) / / 22365631 rs722718 chrX 84241847 A G 7.50E-05 Temperament (bipolar disorder) / / 22365631 rs5922132 chrX 84244214 T C 7.90E-05 Temperament (bipolar disorder) / / 22365631 rs1996379 chrX 84254225 G C 4.10E-05 Temperament (bipolar disorder) / / 22365631 rs4828121 chrX 84274222 A G 5.00E-05 Temperament (bipolar disorder) APOOL intron 22365631 rs5922139 chrX 84282728 T C 7.80E-05 Temperament (bipolar disorder) APOOL intron 22365631 rs675728 chrX 84288726 T C 4.03E-04 Amyotrophic Lateral Sclerosis APOOL intron 17362836 rs1011412 chrX 84304061 A G 7.00E-05 Temperament (bipolar disorder) APOOL intron 22365631 rs1011411 chrX 84304993 C T 6.04E-04 Amyotrophic Lateral Sclerosis APOOL intron 17362836 rs5968444 chrX 84349446 G A 8.96E-04 Amyotrophic Lateral Sclerosis SATL1 intron 17362836 rs5922152 chrX 84393236 T C 8.14E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16980121 chrX 84394032 A G 7.86E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7066472 chrX 84429927 G A 2.20E-05 Urinary metabolites / / 21572414 rs6653043 chrX 84440705 A G 1.60E-05 Urinary metabolites / / 21572414 rs17325012 chrX 84450483 C T 2.60E-05 Urinary metabolites / / 21572414 rs12016134 chrX 84455391 A C 2.40E-05 Urinary metabolites / / 21572414 rs6653046 chrX 84465028 G C 2.50E-05 Urinary metabolites / / 21572414 rs6653047 chrX 84465109 G T 1.24E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6653047 chrX 84465109 G T 2.50E-05 Urinary metabolites / / 21572414 rs2285602 chrX 84467045 C T 1.55E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6623246 chrX 84477048 T G 1.50E-05 Urinary metabolites / / 21572414 rs2188734 chrX 84483335 T C 2.01E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1006628 chrX 84496084 G A 2.40E-05 Urinary metabolites / / 21572414 rs1006629 chrX 84497935 C T 2.40E-05 Urinary metabolites ZNF711 nearGene-5 21572414 rs6653048 chrX 84514196 T A 2.10E-05 Urinary metabolites ZNF711 intron 21572414 rs17004159 chrX 84523972 G A 1.10E-05 Urinary metabolites ZNF711 intron 21572414 rs7892718 chrX 84530317 A C 1.50E-05 Urinary metabolites / / 21572414 rs17278401 chrX 84532273 C T 2.10E-05 Urinary metabolites POF1B nearGene-3 21572414 rs6653050 chrX 84535173 T G 3.30E-06 Urinary metabolites POF1B intron 21572414 rs12014113 chrX 84535890 C T 1.40E-05 Urinary metabolites POF1B intron 21572414 rs6623262 chrX 84556221 A T 1.30E-05 Urinary metabolites POF1B intron 21572414 rs12012683 chrX 84561528 A G 2.00E-05 Urinary metabolites POF1B intron 21572414 rs363776 chrX 84562118 C T 2.10E-05 Urinary metabolites POF1B intron 21572414 rs17004160 chrX 84569256 G C 1.30E-05 Urinary metabolites POF1B intron 21572414 rs12557215 chrX 84582791 T C 2.56E-04 Amyotrophic Lateral Sclerosis POF1B intron 17362836 rs12557215 chrX 84582791 T C 1.40E-05 Urinary metabolites POF1B intron 21572414 rs6617055 chrX 84686012 G A 3.36E-04 Blood pressure / / 17255346 rs12008641 chrX 85072282 A C 5.71E-05 Multiple sclerosis / / 17660530 rs5968700 chrX 85091520 C T 1.09E-06 Smooth-surface caries / / 24556642 rs5968700 chrX 85091520 C T 3.16E-06 Smooth-surface caries / / 24556642 rs5967638 chrX 85095739 G A 1.31E-06 Smooth-surface caries / / 24556642 rs5967638 chrX 85095739 G A 8.00E-07 Smooth-surface caries / / 24556642 rs5967638 chrX 85095739 G A 8.33E-07 Smooth-surface caries / / 24556642 rs7885172 chrX 85162361 A G 4.62E-04 Type 2 diabetes CHM intron 17463246 rs16980342 chrX 85175841 G A 6.22E-04 Type 2 diabetes CHM intron 17463246 rs5968745 chrX 85210562 G A 6.66E-04 Type 2 diabetes CHM intron 17463246 rs5968750 chrX 85213190 C T 7.04E-04 Type 2 diabetes CHM intron 17463246 rs5968752 chrX 85215923 C T 6.58E-04 Type 2 diabetes CHM intron 17463246 rs5968756 chrX 85217837 G C 7.04E-04 Type 2 diabetes CHM intron 17463246 rs5923441 chrX 85333614 G C 6.61E-04 Type 2 diabetes / / 17463246 rs5968783 chrX 85349613 T C 7.05E-05 HIV-1 control / / 20041166 rs2411336 chrX 85378063 G C 8.54E-04 Type 2 diabetes / / 17463246 rs242849 chrX 85400544 A G 1.44E-05 Age-related macular degeneration / / pha000001 rs195034 chrX 85528760 C T 8.79E-04 Prostate cancer mortality DACH2 intron 20978177 rs5968890 chrX 85577260 G T 2.92E-04 Response to taxane treatment (placlitaxel) DACH2 intron 23006423 rs9988269 chrX 85808951 T C 2.70E-05 Urinary metabolites DACH2 intron 21572414 rs2223364 chrX 85811987 T G 2.30E-05 Urinary metabolites DACH2 intron 21572414 rs763554 chrX 85817420 A G 2.60E-05 Urinary metabolites DACH2 intron 21572414 rs6617242 chrX 85829374 G A 1.23E-04 IgE levels DACH2 intron 17255346 rs6524671 chrX 85833765 T C 1.41E-04 IgE levels DACH2 intron 17255346 rs2213478 chrX 86167699 T C 1.26E-06 Schizophrenia / / 21674006 rs2710057 chrX 86192003 G T 1.00E-06 Bone mineral density (hip) / / 19079262 rs2858684 chrX 86208976 T C 2.20E-05 Urinary metabolites / / 21572414 rs2213468 chrX 86212793 T C 5.50E-06 Bone mineral density (spine) / / 19079262 rs11796525 chrX 86308550 C T 2.58E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs3942350 chrX 86554874 A G 7.79E-05 Cognitive impairment induced by topiramate / / 22091778 rs3942350 chrX 86554874 A G 7.13E-04 Smoking cessation / / 24665060 rs17279128 chrX 86600304 T A 1.58E-04 Cholesterol / / 17255346 rs17279128 chrX 86600304 T A 2.10E-08 Urinary metabolites / / 21572414 rs1850428 chrX 86607047 C T 1.80E-08 Urinary metabolites / / 21572414 rs5924006 chrX 86667586 G A 6.06E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6617370 chrX 86686922 G A 1.02E-04 Vaspin levels / / 22907691 rs6617370 chrX 86686922 G A 0.000102 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs4322150 chrX 86697958 C T 1.02E-04 Vaspin levels / / 22907691 rs4322150 chrX 86697958 C T 0.000102 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs6624058 chrX 86705153 G A 8.27E-05 Vaspin levels / / 22907691 rs6624058 chrX 86705153 G A 0.0000827 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs5924028 chrX 86715133 C T 2.47E-05 Cognitive test performance / / 20125193 rs5969240 chrX 86791477 A G 1.19E-04 Amyotrophic Lateral Sclerosis KLHL4 intron 17362836 rs4631605 chrX 86811737 C T 5.97E-04 Response to cytidine analogues (gemcitabine) KLHL4 intron 24483146 rs5924051 chrX 86813262 G A 7.60E-04 Response to cytidine analogues (gemcitabine) KLHL4 intron 24483146 rs2051622 chrX 86822508 G A 2.42E-04 Amyotrophic Lateral Sclerosis KLHL4 intron 17362836 rs5967860 chrX 86852223 G A 1.18E-05 Response to cytidine analogues (gemcitabine) KLHL4 intron 24483146 rs5924103 chrX 86998758 T C 6.27E-05 Cognitive performance / / 19734545 rs5924161 chrX 87113645 T C 5.64E-04 Type 2 diabetes / / 17463246 rs5924161 chrX 87113645 T C 2.58E-04 Smoking initiation / / 24665060 rs5924179 chrX 87155051 C T 2.80E-05 Urinary metabolites / / 21572414 rs12012519 chrX 87190349 T C 7.00E-06 HIV-1 control / / 20041166 rs2745994 chrX 87237560 C A 9.91E-04 Type 2 diabetes / / 17463246 rs17279546 chrX 87398933 T C 3.07E-04 Prostate cancer / / 23023329 rs5967919 chrX 87400150 T A 1.92E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs5967919 chrX 87400150 T A 7.15E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs5969461 chrX 87408357 C T 3.50E-04 Alzheimer's disease / / 17998437 rs5969476 chrX 87432915 T C 7.04E-04 Alzheimer's disease / / 17998437 rs5969586 chrX 87532162 G A 7.69E-06 Personality dimensions / / 18957941 rs5967970 chrX 87562212 T C 4.56E-06 Intelligence / / 21826061 rs5924325 chrX 87610983 A C 9.79E-04 Alzheimer's disease / / 17998437 rs6652491 chrX 87647632 T C 6.29E-04 Alzheimer's disease / / 17998437 rs10482044 chrX 87670104 T C 8.27E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6418053 chrX 87710167 T G 3.99E-04 Type 2 diabetes / / 17463246 rs6617679 chrX 87734129 A C 3.49E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6418063 chrX 87747348 A G 8.40E-06 Urinary metabolites / / 21572414 rs6418064 chrX 87747379 G T 8.40E-06 Urinary metabolites / / 21572414 rs6617699 chrX 87750435 A G 5.20E-06 Urinary metabolites / / 21572414 rs12559754 chrX 87754012 A G 8.50E-06 Urinary metabolites / / 21572414 rs6522112 chrX 87754810 G A 8.40E-06 Urinary metabolites / / 21572414 rs6522113 chrX 87754976 T C 8.40E-06 Urinary metabolites / / 21572414 rs7392313 chrX 87754998 G A 8.40E-06 Urinary metabolites / / 21572414 rs7392297 chrX 87755026 C T 9.40E-06 Urinary metabolites / / 21572414 rs7392320 chrX 87755041 G A 8.40E-06 Urinary metabolites / / 21572414 rs7391794 chrX 87757033 T C 4.50E-06 Urinary metabolites / / 21572414 rs6522115 chrX 87757322 A G 8.40E-06 Urinary metabolites / / 21572414 rs6617702 chrX 87759461 G C 8.40E-06 Urinary metabolites / / 21572414 rs2206685 chrX 87824662 G A 6.95E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16981331 chrX 87927290 G C 6.94E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7064603 chrX 87946633 T C 4.70E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11796706 chrX 87963691 A G 6.48E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7057626 chrX 87969491 T G 6.48E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7058384 chrX 87970031 T A 6.48E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7049592 chrX 87972226 A G 2.92E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7881987 chrX 87982314 A G 2.39E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7877366 chrX 88011155 G T 3.96E-05 Post-operative nausea and vomiting / / 21694509 rs3128260 chrX 88075761 T C 6.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1099986 chrX 88097329 T C 1.19E-05 Post-operative nausea and vomiting / / 21694509 rs847465 chrX 88133267 G A 6.70E-05 Personality dimensions / / 18957941 rs682176 chrX 88179906 T A 9.00E-05 Personality dimensions / / 18957941 rs6617782 chrX 88248910 C T 9.05E-04 Parkinson's disease / / 17052657 rs5942349 chrX 88256308 G T 5.63E-04 Body mass index / / 21701565 rs5942380 chrX 88331911 G A 6.46E-04 Body mass index / / 21701565 rs5942381 chrX 88332738 A G 3.18E-04 Body mass index / / 21701565 rs12559394 chrX 88337898 A G 3.17E-04 Body mass index / / 21701565 rs12839253 chrX 88357018 T G 4.04E-04 Body mass index / / 21701565 rs2051591 chrX 88365553 G T 3.45E-04 Body mass index / / 21701565 rs16981409 chrX 88394007 T C 5.97E-04 Body mass index / / 21701565 rs5942420 chrX 88405389 T A 3.40E-04 Body mass index / / 21701565 rs5942422 chrX 88405948 C T 3.50E-04 Body mass index / / 21701565 rs2534116 chrX 88685058 C T 2.67E-04 Celiac disease / / 23936387 rs223680 chrX 88838130 A G 5.80E-04 Body mass index / / 21701565 rs5941370 chrX 89078553 C T 4.57E-04 Parkinson's disease / / 17052657 rs5941370 chrX 89078553 C T 9.00E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12558785 chrX 89242354 G T 8.70E-06 Urinary metabolites / / 21572414 rs5941420 chrX 89263367 A T 7.86E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs5941421 chrX 89267763 G A 6.98E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs5941428 chrX 89274542 T G 7.52E-05 Cognitive test performance / / 20125193 rs5941436 chrX 89288227 C A 5.00E-06 Cognitive performance / / 20125193 rs4443819 chrX 89290057 T C 6.07E-05 Cognitive test performance / / 20125193 rs5983987 chrX 89298969 A G 4.30E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5941457 chrX 89335033 A G 1.17E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5940807 chrX 89552827 G T 2.28E-04 Endometrial cancer / / 24096698 rs5940807 chrX 89552827 G T 3.76E-05 Endometrial cancer / / 24096698 rs5940807 chrX 89552827 G T 5.45E-04 Endometrial cancer / / 24096698 rs1236624 chrX 89637054 T C 6.59E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2755459 chrX 89804127 A G 9.00E-14 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs513756 chrX 90568001 C T 4.87E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5941909 chrX 90683065 C T 1.60E-05 Urinary metabolites / / 21572414 rs5941910 chrX 90685734 C T 1.00E-05 Urinary metabolites / / 21572414 rs4598427 chrX 90703541 G T 1.70E-06 Urinary metabolites / / 21572414 rs5941922 chrX 90708880 C G 1.10E-05 Urinary metabolites / / 21572414 rs5940972 chrX 90753247 A T 1.20E-05 Urinary metabolites / / 21572414 rs3131174 chrX 90770464 T C 1.30E-05 Urinary metabolites / / 21572414 rs6618677 chrX 90812718 A G 1.20E-05 Urinary metabolites / / 21572414 rs6618677 chrX 90812718 A G 4.00E-08 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs2524594 chrX 91162118 G A 8.91E-07 Testicular cancer PCDH11X intron 19483682 rs5984894 chrX 91393737 A G 3.80E-08 Alzheimer's disease PCDH11X intron 19136949 rs5984894 chrX 91393737 A G 3.90E-12 Alzheimer's disease (late onset) PCDH11X intron 21460841 rs2573905 chrX 91402220 T C 2.00E-07 Alzheimer's disease PCDH11X intron 19136949 rs5942313 chrX 91951616 C T 7.18E-04 Type 2 diabetes / / 17463246 rs35766825 chrX 92119963 A G 1.94E-04 Celiac disease / / 23936387 rs5939991 chrX 92356743 T C 2.00E-06 Urinary metabolites / / 21572414 rs3903988 chrX 92358345 A G 7.80E-06 Urinary metabolites / / 21572414 rs5939995 chrX 92363393 T G 8.00E-06 Urinary metabolites / / 21572414 rs4326550 chrX 92580637 G T 4.60E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4326550 chrX 92580637 G T 9.66E-05 Post-operative nausea and vomiting / / 21694509 rs17321588 chrX 92592359 T C 1.77E-05 Post-operative nausea and vomiting / / 21694509 rs5940163 chrX 92605459 C T 3.44E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5940163 chrX 92605459 C T 1.12E-06 Post-operative nausea and vomiting / / 21694509 rs2139612 chrX 92614918 G T 7.37E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2139612 chrX 92614918 G T 3.13E-05 Post-operative nausea and vomiting / / 21694509 rs5983490 chrX 92634371 A C 4.30E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7060195 chrX 92653385 T G 8.42E-04 Alcohol dependence / / 20201924 rs5940195 chrX 92696380 A G 1.50E-05 Urinary metabolites / / 21572414 rs5940196 chrX 92696396 A G 8.53E-05 Bipolar disorder and schizophrenia / / 20889312 rs5983222 chrX 92710246 G A 1.20E-05 Urinary metabolites / / 21572414 rs5940215 chrX 92712240 A G 5.56E-05 Bipolar disorder and schizophrenia / / 20889312 rs6615531 chrX 92712504 A G 1.20E-05 Urinary metabolites / / 21572414 rs5940217 chrX 92712678 G A 1.20E-05 Urinary metabolites / / 21572414 rs5940228 chrX 92760182 A G 3.51E-07 Statin-induced myopathy / / 21826682 rs4893039 chrX 92913166 T C 2.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5983240 chrX 92923424 C T 1.66E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7059744 chrX 92949378 G T 6.41E-04 Amyotrophic Lateral Sclerosis FAM133A intron 17362836 rs7891218 chrX 92952292 A C 8.99E-04 Amyotrophic Lateral Sclerosis FAM133A intron 17827064 rs4893045 chrX 92955994 G T 8.59E-04 Parkinson's disease FAM133A intron 17052657 rs4893045 chrX 92955994 G T 3.25E-04 Amyotrophic Lateral Sclerosis FAM133A intron 17362836 rs2312033 chrX 92957480 G C 9.12E-07 Statin-induced myopathy FAM133A intron 21826682 rs967299 chrX 92967553 T C 4.70E-04 Parkinson's disease FAM133A nearGene-3 17052657 rs1004991 chrX 93055449 A G 1.10E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6615564 chrX 93093995 G A 1.12E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5939795 chrX 93191921 G A 4.63E-04 Lung function (forced vital capacity) / / 24023788 rs5983336 chrX 93323025 A C 8.58E-04 Celiac disease / / 23936387 rs1338588 chrX 93347945 A G 4.20E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7891633 chrX 93349655 A C 5.50E-05 HIV-1 control / / 20041166 rs5983343 chrX 93351801 G A 3.20E-05 Lung cancer / / 18385738 rs2782724 chrX 93686647 G A 4.41E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6619564 chrX 93760204 T A 1.92E-05 Height / / 22021425 rs1591797 chrX 93938488 C G 3.54E-04 Bilirubin levels,in serum / / 19389676 rs3120900 chrX 94010176 G A 5.84E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1338806 chrX 94013164 A G 7.34E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6615679 chrX 94223083 G A 1.85E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5949507 chrX 94226567 A G 3.87E-05 Coronary Artery Disease / / 17634449 rs6522866 chrX 94235883 T A 2.80E-04 Coronary Artery Disease / / 17634449 rs1166765 chrX 94248220 A G 8.88E-04 Body mass index / / 21701565 rs1780215 chrX 94270627 A G 8.51E-04 Body mass index / / 21701565 rs1936777 chrX 94325122 A C 5.00E-05 Cognitive impairment induced by topiramate / / 22091778 rs5950174 chrX 94354779 G A 1.73E-04 Body mass index / / 21701565 rs2354299 chrX 94365850 G T 7.32E-04 Body mass index / / 21701565 rs17333188 chrX 94379375 T C 3.88E-04 Body mass index / / 21701565 rs2186036 chrX 94391260 C T 7.35E-04 Body mass index / / 21701565 rs2354304 chrX 94396626 T C 4.20E-05 Anger / / 24489884 rs1837941 chrX 94415022 C T 4.16E-04 Body mass index / / 21701565 rs5990755 chrX 94418725 T A 6.53E-04 Body mass index / / 21701565 rs5950224 chrX 94418826 G A 8.04E-04 Body mass index / / 21701565 rs6619773 chrX 94434604 C G 4.63E-04 Body mass index / / 21701565 rs2044112 chrX 94478588 T C 7.92E-04 Body mass index / / 21701565 rs5949649 chrX 95060007 C T 1.08E-05 Major depressive disorder (broad) / / 20038947 rs5990409 chrX 95060938 G T 1.03E-05 Major depressive disorder (broad) / / 20038947 rs5990410 chrX 95061014 G A 1.72E-05 Major depressive disorder (broad) / / 20038947 rs5949650 chrX 95063723 C A 1.09E-05 Major depressive disorder (broad) / / 20038947 rs5949654 chrX 95068770 T C 7.48E-06 Major depressive disorder (broad) / / 20038947 rs12216984 chrX 95070824 T C 1.21E-05 Major depressive disorder (broad) / / 20038947 rs7064559 chrX 95070973 G A 1.22E-05 Major depressive disorder (broad) / / 20038947 rs5990415 chrX 95072450 C T 1.36E-05 Major depressive disorder (broad) / / 20038947 rs5949327 chrX 95073188 T C 1.27E-05 Major depressive disorder (broad) / / 20038947 rs5990145 chrX 95073929 T C 1.26E-05 Major depressive disorder (broad) / / 20038947 rs7062843 chrX 95074041 T C 1.26E-05 Major depressive disorder (broad) / / 20038947 rs2031597 chrX 95074253 T C 1.26E-05 Major depressive disorder (broad) / / 20038947 rs6615747 chrX 95074293 G A 4.23E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs5949657 chrX 95074863 G A 1.23E-05 Major depressive disorder (broad) / / 20038947 rs5949658 chrX 95075156 T C 1.14E-05 Major depressive disorder (broad) / / 20038947 rs11798245 chrX 95076190 T A 3.12E-05 Major depressive disorder (broad) / / 20038947 rs5990417 chrX 95079870 T C 6.00E-06 Major depressive disorder (broad) / / 20038947 rs2761647 chrX 95272658 T G 5.83E-06 Asthma / / 20698975 rs1408095 chrX 95280329 G A 5.46E-05 Cortisol secretion,in saliva / / 21316860 rs12009610 chrX 95754874 A T 2.30E-06 Urinary metabolites / / 21572414 rs4969679 chrX 95823962 G A 6.02E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5990630 chrX 95868715 C T 9.08E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs5949445 chrX 95938582 T C 9.97E-04 Type 2 diabetes DIAPH2 nearGene-5 17463246 rs7880885 chrX 95939077 A T 8.33E-04 Type 2 diabetes DIAPH2 nearGene-5 17463246 rs685712 chrX 96084984 A G 2.15E-04 Amyotrophic Lateral Sclerosis DIAPH2 intron 17362836 rs5921467 chrX 96411668 A G 5.18E-04 Alzheimer's disease DIAPH2 intron 17998437 rs6523076 chrX 96422058 G A 6.26E-04 Parkinson's disease DIAPH2 intron 17052657 rs2497889 chrX 96963011 T C 1.76E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs953712 chrX 96976141 A G 2.90E-05 Urinary metabolites / / 21572414 rs7881334 chrX 97050659 T C 8.53E-05 Cognitive impairment induced by topiramate / / 22091778 rs318177 chrX 97080344 T G 2.30E-05 Urinary metabolites / / 21572414 rs318173 chrX 97081211 C A 1.08E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs318156 chrX 97107750 A T 0.0000164 Panic disorder / / 23149450 rs318156 chrX 97107750 A T 1.64E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs318156 chrX 97107750 A T 6.30E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs318157 chrX 97108881 T C 2.16E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1251046 chrX 97313484 A T 5.66E-05 Bipolar disorder and schizophrenia / / 20889312 rs5966808 chrX 97408528 A G 4.34E-05 Post-operative nausea and vomiting / / 21694509 rs1414298 chrX 97534844 T C 8.23E-04 Alcohol dependence / / 20201924 rs2386574 chrX 97576892 T C 5.25E-05 Femoral neck bone geometry / / 22087292 rs6620471 chrX 97577376 G A 4.57E-05 Femoral neck bone geometry / / 22087292 rs5966826 chrX 97579760 G A 4.98E-05 Femoral neck bone geometry / / 22087292 rs5966842 chrX 97688822 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs5966847 chrX 97717979 A G 9.27E-05 Blood pressure / / 17255346 rs5921139 chrX 97837882 A G 3.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4827947 chrX 97864354 T C 3.00E-07 Immune reponse to smallpox (secreted IL-1beta) / / 22610502 rs5966999 chrX 99087626 A G 8.82E-04 Type 2 diabetes LOC442459 intron 17463246 rs16983292 chrX 99221199 C A 2.30E-05 Urinary metabolites / / 21572414 rs5921523 chrX 99479968 A C 1.90E-04 Alcohol dependence / / 20201924 rs10126713 chrX 99545384 T C 8.83E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5920819 chrX 99584984 G A 7.65E-04 Amyotrophic Lateral Sclerosis PCDH19 intron 17362836 rs4133127 chrX 99667610 A G 0.00014 Coronary artery calcification / / 23727086 rs11796660 chrX 99678848 A C 5.15E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4991657 chrX 99700786 C T 2.34E-05 Cognitive test performance / / 20125193 rs12560106 chrX 99721598 A G 8.97E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4828029 chrX 99730702 A G 3.38E-05 Cognitive test performance / / 20125193 rs12841008 chrX 99747494 C T 1.37E-05 Cognitive test performance / / 20125193 rs768198 chrX 99765085 G C 2.73E-05 Cervical cancer / / 24700089 rs5921594 chrX 99782826 T G 4.82E-04 Parkinson's disease / / 17052657 rs932437 chrX 99837874 G C 2.23E-04 Parkinson's disease TNMD nearGene-5 17052657 rs7058934 chrX 99842230 G A 6.86E-04 Amyotrophic Lateral Sclerosis TNMD intron 17362836 rs5966709 chrX 99844506 G T 1.55E-04 Parkinson's disease TNMD intron 17052657 rs4828037 chrX 99845684 T C 1.59E-04 Parkinson's disease TNMD intron 17052657 rs4828042 chrX 99935857 A G 4.57E-04 Response to cytadine analogues (cytosine arabinoside) SYTL4 intron 24483146 rs5920842 chrX 99943103 A C 1.09E-04 Amyotrophic Lateral Sclerosis SYTL4 intron 17362836 rs5921628 chrX 99948588 C T 2.55E-04 Amyotrophic Lateral Sclerosis SYTL4 intron 17362836 rs5921628 chrX 99948588 C T 4.46E-05 Cognitive impairment induced by topiramate SYTL4 intron 22091778 rs35404864 chrX 100105140 C T 8.42E-09 Triglycerides NOX1 missense 23063622 rs149219547 chrX 100117807 T C 0.00000192 Ratio of free to total prostate-specific antigen NOX1 missense 23555315 rs7049377 chrX 100135488 G A 2.92E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5920868 chrX 100148449 G A 5.51E-05 Height / / 17255346 rs5921691 chrX 100163068 C A 1.10E-05 Myasthenia gravis / / 23055271 rs1204413 chrX 100188535 T C 2.30E-04 Myasthenia gravis / / 23055271 rs5921710 chrX 100278109 T C 6.35E-04 Amyotrophic Lateral Sclerosis TRMT2B intron 17362836 rs4827884 chrX 100305368 A G 1.06E-04 Amyotrophic Lateral Sclerosis TRMT2B intron 17362836 rs4827886 chrX 100308635 T G 5.70E-04 Amyotrophic Lateral Sclerosis TRMT2B nearGene-5 17362836 rs2014595 chrX 100342265 G A 3.33E-04 Parkinson's disease TMEM35 intron 17052657 rs2014595 chrX 100342265 G A 0.00000595 Panic disorder TMEM35 intron 23149450 rs2014595 chrX 100342265 G A 2.79E-05 Serum tamsulosin hydrochloride concentration TMEM35 intron 23151678 rs5921744 chrX 100445964 T C 4.53E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11092298 chrX 100525968 T C 2.84E-04 Celiac disease TAF7L intron 23936387 rs3788765 chrX 100532924 A G 2.84E-04 Celiac disease TAF7L intron 23936387 rs6621025 chrX 100543990 T C 2.40E-05 Urinary metabolites TAF7L intron 21572414 rs1122765 chrX 100604652 C A 1.20E-04 Atrial fibrillation BTK UTR-3 21846873 rs2239461 chrX 100632637 C T 1.16E-05 Parkinson's disease BTK intron 17052657 rs2238983 chrX 100639887 T C 1.60E-05 Urinary metabolites BTK intron 21572414 rs2238983 chrX 100639887 T C 1.19E-04 Telomere length BTK intron 21573004 rs3027575 chrX 100666836 T C 8.29E-04 Response to taxane treatment (placlitaxel) HNRNPH2 intron 23006423 rs6621108 chrX 100820894 A G 9.31E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs5991950 chrX 100831591 T C 9.72E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2858162 chrX 100873832 G A 4.36E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2858165 chrX 100875183 A G 4.36E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2858167 chrX 100877344 T C 4.36E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs5951376 chrX 100915471 G A 5.49E-04 Response to cytidine analogues (gemcitabine) ARMCX2 nearGene-5 24483146 rs6523526 chrX 100917910 T C 5.49E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs3850318 chrX 100938892 G C 5.67E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs5951381 chrX 100941361 C T 5.35E-04 Type 2 diabetes / / 17463246 rs5951381 chrX 100941361 C T 7.82E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs5951290 chrX 100963373 T C 7.82E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs5951406 chrX 100975536 G A 7.82E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs2213369 chrX 101020241 G T 8.84E-05 Type 2 diabetes / / 17463246 rs5944784 chrX 101174719 G A 4.37E-04 Amyotrophic Lateral Sclerosis ZMAT1 intron 17362836 rs5944895 chrX 101180070 C T 2.97E-04 Amyotrophic Lateral Sclerosis ZMAT1 intron 17362836 rs1010973 chrX 101202727 A G 4.33E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5944795 chrX 101203646 G A 1.05E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5944901 chrX 101204202 C T 1.40E-04 Type 2 diabetes / / 17463246 rs5944902 chrX 101204573 C A 1.11E-04 Type 2 diabetes / / 17463246 rs6523584 chrX 101238222 A C 4.71E-05 Type 2 diabetes / / 17463246 rs5986794 chrX 101247433 T C 4.33E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5944987 chrX 101322303 T C 4.33E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5944840 chrX 101334934 A G 7.25E-06 Type 2 diabetes / / 17463246 rs2001141 chrX 101337029 G A 2.00E-05 Urinary metabolites / / 21572414 rs4898334 chrX 101387968 G A 1.79E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2105854 chrX 101389192 A C 1.31E-04 Type 2 diabetes / / 17463246 rs5986849 chrX 101401535 T C 1.77E-04 Type 2 diabetes / / 17463246 rs4898336 chrX 101401786 T C 2.05E-04 Type 2 diabetes / / 17463246 rs4898327 chrX 101410198 A G 1.70E-04 Amyotrophic Lateral Sclerosis BEX5 intron 17362836 rs5986852 chrX 101421291 A G 2.27E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5987697 chrX 102443308 C T 1.22E-06 Post-operative nausea and vomiting / / 21694509 rs1064784 chrX 102471531 G T 6.13E-04 Parkinson's disease BEX4 UTR-3 17052657 rs87951 chrX 102524477 C T 6.47E-04 Schizophrenia / / 21674006 rs5987719 chrX 102547309 C T 2.17E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs5987719 chrX 102547309 C T 2.80E-04 Lung function (forced vital capacity) / / 24023788 rs2743709 chrX 102559848 C T 3.86E-05 Post-operative nausea and vomiting / / 21694509 rs5945683 chrX 102597095 A G 3.82E-05 Post-operative nausea and vomiting / / 21694509 rs3924343 chrX 102640667 G A 4.81E-04 Prostate cancer / / 23023329 rs5987533 chrX 102735916 C A 8.00E-08 Statin-induced myopathy LOC100506901 intron 21826682 rs17285130 chrX 102769946 T C 3.15E-04 Type 2 diabetes RAB40A intron 17463246 rs5987543 chrX 102807182 T C 0.0000802 Colorectal cancer / / 22532847 rs11092456 chrX 102951411 T C 2.80E-04 Type 2 diabetes / / 17463246 rs1016238 chrX 102958574 G A 2.70E-05 Urinary metabolites / / 21572414 rs588849 chrX 103006598 C G 8.76E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs6621809 chrX 103557686 G T 5.71E-05 Paget's disease / / 20436471 rs2385490 chrX 103667679 C T 6.03E-06 Type 2 diabetes / / 17463246 rs1359054 chrX 103672014 A C 6.05E-06 Type 2 diabetes / / 17463246 rs1407804 chrX 103682868 C T 2.96E-05 Type 2 diabetes / / 17463246 rs4457463 chrX 103692645 G A 9.64E-04 Type 2 diabetes / / 17463246 rs16985068 chrX 103796528 A T 9.90E-06 Urinary metabolites / / 21572414 rs17332162 chrX 103996271 C T 1.04E-04 Cholesterol IL1RAPL2 intron 17255346 rs982130 chrX 104037621 T C 3.00E-05 HIV-1 control IL1RAPL2 intron 20041166 rs17347021 chrX 104064869 G A 5.10E-04 Response to taxane treatment (placlitaxel) IL1RAPL2 intron 23006423 rs2752574 chrX 104534812 C G 6.79E-04 Type 2 diabetes IL1RAPL2 intron 17463246 rs10521506 chrX 104770109 A G 1.98E-04 Amyotrophic Lateral Sclerosis IL1RAPL2 intron 17362836 rs5962542 chrX 104780503 G A 4.68E-04 Amyotrophic Lateral Sclerosis IL1RAPL2 intron 17362836 rs5916923 chrX 104785899 A G 5.95E-04 Amyotrophic Lateral Sclerosis IL1RAPL2 intron 17362836 rs440424 chrX 104862182 G A 1.11E-04 Amyotrophic Lateral Sclerosis IL1RAPL2 intron 17362836 rs400000 chrX 104870262 G A 1.26E-04 Amyotrophic Lateral Sclerosis IL1RAPL2 intron 17362836 rs11798133 chrX 104875612 T C 3.63E-05 Height IL1RAPL2 intron 22021425 rs5916938 chrX 104890007 A G 3.50E-04 Amyotrophic Lateral Sclerosis IL1RAPL2 intron 17362836 rs5916940 chrX 104900557 A G 5.94E-04 Amyotrophic Lateral Sclerosis IL1RAPL2 intron 17362836 rs5962570 chrX 104949120 A G 2.20E-04 Height IL1RAPL2 intron 17255346 rs5962570 chrX 104949120 A G 9.85E-04 Amyotrophic Lateral Sclerosis IL1RAPL2 intron 17362836 rs1503195 chrX 105080474 C T 1.35E-04 Amyotrophic Lateral Sclerosis NRK intron 17362836 rs6523856 chrX 105105301 A G 4.38E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) NRK intron 24023788 rs1503198 chrX 105113542 C T 4.36E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) NRK intron 24023788 rs7886541 chrX 105261937 G T 3.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17332369 chrX 105278765 T A 8.82E-05 Alcohol dependence SERPI/7 intron 21314694 rs379742 chrX 105493919 G A 6.00E-07 Pancreatitis / / 23143602 rs4409525 chrX 106140325 G A 4.50E-16 Pancreatitis / / 23143602 rs7057398 chrX 106144529 T C 7.20E-05 Hypothyroidism CLDN2 intron 22493691 rs7057398 chrX 106144529 T C 4.60E-17 Pancreatitis CLDN2 intron 23143602 rs12008279 chrX 106160702 A G 1.60E-09 Pancreatitis CLDN2 intron 23143602 rs5917027 chrX 106162634 C T 9.70E-11 Pancreatitis CLDN2 intron 23143602 rs12014762 chrX 106183670 C T 1.50E-14 Pancreatitis MORC4 nearGene-3 23143602 rs6622126 chrX 106200202 G A 1.90E-10 Pancreatitis MORC4 missense 23143602 rs12688220 chrX 106244767 C T 2.00E-22 Pancreatitis MORC4 nearGene-5 23143602 rs4826962 chrX 106602145 T C 9.57E-04 Parkinson's disease / / 17052657 rs5916791 chrX 106954772 C T 9.70E-06 Urinary metabolites / / 21572414 rs5916791 chrX 106954772 C T 2.46E-05 Cognitive impairment induced by topiramate / / 22091778 rs3747406 chrX 107020969 T C 4.81E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7884248 chrX 107031683 C T 6.36E-04 Type 2 diabetes / / 17463246 rs7064824 chrX 107042109 C G 3.37E-04 Type 2 diabetes / / 17463246 rs1883663 chrX 107177497 A C 3.12E-04 Type 2 diabetes / / 17463246 rs2179582 chrX 107190221 T C 8.30E-06 Urinary metabolites / / 21572414 rs7882791 chrX 107203801 C G 1.20E-05 Urinary metabolites / / 21572414 rs5962423 chrX 107211900 G A 7.60E-06 Urinary metabolites / / 21572414 rs807229 chrX 107235173 G A 7.28E-05 Femoral neck bone geometry / / 22087292 rs1266732 chrX 107450101 T G 2.59E-04 Type 2 diabetes COL4A6 intron 17463246 rs1266734 chrX 107451279 G A 7.31E-04 Type 2 diabetes COL4A6 intron 17463246 rs1266740 chrX 107458949 G A 6.62E-04 Type 2 diabetes COL4A6 intron 17463246 rs927029 chrX 107603482 A C 5.62E-04 Amyotrophic Lateral Sclerosis COL4A6 intron 17362836 rs5929098 chrX 107692305 C T 8.37E-05 Anorexia nervosa COL4A5 intron 24514567 rs2346363 chrX 107842844 T C 7.39E-05 Smoking initiation COL4A5 intron 24665060 rs1547611 chrX 108823476 G A 4.60E-07 Urinary metabolites / / 21572414 rs839375 chrX 108870605 C A 2.83E-04 Height / / 17255346 rs5985403 chrX 108964592 G C 4.08E-05 Alzheimer's disease ACSL4 intron 17998437 rs1012731 chrX 109173476 T C 9.75E-04 Coronary Artery Disease / / 17634449 rs17320646 chrX 109178549 G A 6.33E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2475818 chrX 109186258 G A 1.74E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs5985446 chrX 109365260 A T 1.08E-05 Antineutrophil cytoplasmic antibody-associated vasculitis TMEM164 intron 22808956 rs17254838 chrX 109471360 T G 3.20E-05 Alcohol dependence AMMECR1 intron 20201924 rs5942915 chrX 109549026 G A 7.31E-05 Alcohol dependence AMMECR1 intron 20201924 rs6567867 chrX 109705634 A C 2.20E-05 Urinary metabolites / / 21572414 rs739379 chrX 109708315 A G 1.60E-05 Urinary metabolites / / 21572414 rs7050023 chrX 109789616 T C 2.33E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1573036 chrX 109820068 C T 2.61E-04 Cholesterol / / 17255346 rs1573036 chrX 109820068 C T 3.00E-16 Sex hormone-binding globulin levels / / 22829776 rs1573036 chrX 109820068 C T 4.00E-14 Sex hormone-binding globulin levels / / 22829776 rs1573036 chrX 109820068 C T 2.97E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs5942651 chrX 109827622 A G 2.18E-04 Cholesterol / / 17255346 rs5942651 chrX 109827622 A G 2.82E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12857107 chrX 109926710 A G 3.30E-04 Cholesterol CHRDL1 intron 17255346 rs5943057 chrX 109939205 T G 9.00E-07 Coronary heart disease CHRDL1 intron 21378988 rs197023 chrX 109968387 T C 7.67E-04 Response to taxane treatment (placlitaxel) CHRDL1 intron 23006423 rs975687 chrX 110512005 T A 2.09E-06 Multiple complex diseases CAPN6 intron 17554300 rs7882753 chrX 110515681 G A 2.10E-05 Urinary metabolites CAPN6 nearGene-5 21572414 rs11152676 chrX 111026369 T G 1.09E-04 Bipolar disorder TRPC5 intron 17486107 rs7050529 chrX 111155233 G A 6.00E-06 Smoking behavior TRPC5 intron 19247474 rs7885885 chrX 111160190 G T 6.29E-04 Response to cytadine analogues (cytosine arabinoside) TRPC5 intron 24483146 rs7063059 chrX 111215723 C T 2.40E-05 Urinary metabolites TRPC5 intron 21572414 rs7056863 chrX 111235335 A G 5.10E-06 Urinary metabolites TRPC5 intron 21572414 rs16986725 chrX 111235355 A G 7.90E-06 Urinary metabolites TRPC5 intron 21572414 rs2223497 chrX 111300049 G A 2.16E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) TRPC5 intron 24023788 rs9320062 chrX 111364551 T G 9.53E-04 Alzheimer's disease ZCCHC16 intron 17998437 rs12007973 chrX 111368561 G A 3.19E-04 Alzheimer's disease ZCCHC16 intron 17998437 rs6413652 chrX 111430071 A G 3.33E-04 Smoking initiation ZCCHC16 intron 24665060 rs7881516 chrX 111431405 T C 2.30E-05 Urinary metabolites ZCCHC16 intron 21572414 rs2887316 chrX 111469891 G A 6.32E-04 Smoking initiation ZCCHC16 intron 24665060 rs5982533 chrX 111646464 C T 7.00E-06 Biochemical measures ZCCHC16 intron 19260141 rs10521551 chrX 111820189 C A 9.50E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5929336 chrX 111852161 C T 3.12E-04 Parkinson's disease / / 17052657 rs6568081 chrX 111999888 T C 4.50E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2189809 chrX 112079126 T C 1.20E-05 Urinary metabolites AMOT intron 21572414 rs630489 chrX 112106490 A G 7.60E-06 Urinary metabolites / / 21572414 rs646398 chrX 112107726 A G 7.00E-06 Urinary metabolites / / 21572414 rs547425 chrX 112107745 G C 1.12E-04 Alzheimer's disease / / pha002879 rs648170 chrX 112108124 A G 7.30E-05 Alzheimer's disease / / pha002879 rs5974296 chrX 112113271 A G 1.00E-05 Urinary metabolites / / 21572414 rs4829511 chrX 112119452 A G 6.20E-06 Urinary metabolites / / 21572414 rs4829513 chrX 112119656 T C 5.80E-06 Urinary metabolites / / 21572414 rs11152748 chrX 112130137 A C 5.80E-06 Urinary metabolites / / 21572414 rs6642552 chrX 112154855 G A 1.40E-05 Urinary metabolites / / 21572414 rs5974316 chrX 112155433 C T 1.30E-05 Urinary metabolites / / 21572414 rs12007560 chrX 112173271 T C 1.96E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5929497 chrX 112184753 C G 1.20E-05 Urinary metabolites / / 21572414 rs1858820 chrX 112209234 A G 8.27E-05 Relative hand skill / / 24068947 rs4829526 chrX 112211881 T C 8.26E-05 Relative hand skill / / 24068947 rs4829527 chrX 112214093 A C 2.98E-05 Relative hand skill / / 24068947 rs4829463 chrX 112214202 A G 8.27E-05 Relative hand skill / / 24068947 rs2213995 chrX 112216628 G A 8.26E-05 Relative hand skill / / 24068947 rs7051392 chrX 112218126 A G 7.87E-05 Relative hand skill / / 24068947 rs6568105 chrX 112218542 C G 7.76E-05 Relative hand skill / / 24068947 rs5974348 chrX 112218701 T C 7.75E-05 Relative hand skill / / 24068947 rs5974349 chrX 112218995 C G 7.90E-05 Relative hand skill / / 24068947 rs11796331 chrX 112226539 C T 8.35E-05 Relative hand skill / / 24068947 rs10521560 chrX 112227019 A C 3.85E-05 Relative hand skill / / 24068947 rs5973987 chrX 112227357 C A 1.00E-04 Relative hand skill / / 24068947 rs11796036 chrX 112227602 A G 4.04E-05 Relative hand skill / / 24068947 rs5929509 chrX 112231109 A C 4.25E-05 Relative hand skill / / 24068947 rs1033437 chrX 112238384 T G 7.01E-04 Type 2 diabetes / / 17463246 rs1033437 chrX 112238384 T G 4.58E-05 Relative hand skill / / 24068947 rs3125986 chrX 112255701 G A 4.89E-05 Relative hand skill / / 24068947 rs2369554 chrX 112279724 C T 7.33E-05 Relative hand skill / / 24068947 rs5929245 chrX 112282341 A C 6.66E-05 Relative hand skill / / 24068947 rs3116898 chrX 112288198 A G 5.97E-05 Relative hand skill / / 24068947 rs3116901 chrX 112289478 G T 5.73E-05 Relative hand skill / / 24068947 rs6642572 chrX 112290473 G A 7.45E-04 Body mass index / / 21701565 rs3125990 chrX 112294501 C A 4.33E-05 Cognitive impairment induced by topiramate / / 22091778 rs3125993 chrX 112299551 T C 6.49E-05 Relative hand skill / / 24068947 rs3125994 chrX 112299729 C T 4.06E-05 Relative hand skill / / 24068947 rs3125995 chrX 112299829 A C 6.30E-05 Relative hand skill / / 24068947 rs2179329 chrX 112315252 G A 4.78E-05 Relative hand skill / / 24068947 rs3116911 chrX 112318374 G A 4.49E-05 Relative hand skill / / 24068947 rs3116936 chrX 112330023 T G 3.44E-05 Relative hand skill / / 24068947 rs6642576 chrX 112349088 A G 2.98E-05 Relative hand skill / / 24068947 rs4829535 chrX 112358401 T G 2.68E-05 Relative hand skill / / 24068947 rs5974372 chrX 112360147 G T 2.20E-06 Urinary metabolites / / 21572414 rs3116921 chrX 112360258 A G 6.91E-04 Body mass index / / 21701565 rs3116921 chrX 112360258 A G 2.64E-05 Relative hand skill / / 24068947 rs6643185 chrX 112363490 C G 2.35E-05 Relative hand skill / / 24068947 rs3125966 chrX 112364479 A G 1.26E-04 Fibrinogen / / 17255346 rs6643186 chrX 112365223 T C 2.31E-05 Relative hand skill / / 24068947 rs4829538 chrX 112365858 G A 2.30E-05 Relative hand skill / / 24068947 rs880355 chrX 112371783 C T 1.97E-05 Relative hand skill / / 24068947 rs2887505 chrX 112371823 G A 7.07E-05 Cognitive impairment induced by topiramate / / 22091778 rs1033439 chrX 112373612 A G 1.96E-05 Relative hand skill / / 24068947 rs4829542 chrX 112373707 T G 3.79E-05 Relative hand skill / / 24068947 rs968859 chrX 112375474 G T 1.95E-05 Relative hand skill / / 24068947 rs981430 chrX 112381514 T G 1.95E-05 Relative hand skill / / 24068947 rs4829544 chrX 112383580 G A 1.96E-05 Relative hand skill / / 24068947 rs11797987 chrX 112393542 G A 1.97E-05 Relative hand skill / / 24068947 rs2092271 chrX 112401916 T C 3.21E-05 Relative hand skill / / 24068947 rs7883670 chrX 112406196 G A 1.98E-05 Relative hand skill / / 24068947 rs7885201 chrX 112406217 A G 1.98E-05 Relative hand skill / / 24068947 rs7883842 chrX 112406313 G A 1.98E-05 Relative hand skill / / 24068947 rs6642587 chrX 112406941 G A 2.01E-05 Relative hand skill / / 24068947 rs4829549 chrX 112407813 A C 2.08E-05 Relative hand skill / / 24068947 rs6643204 chrX 112409948 A G 2.10E-05 Relative hand skill / / 24068947 rs6642588 chrX 112410378 C G 2.11E-05 Relative hand skill / / 24068947 rs6568130 chrX 112410706 G T 3.92E-05 Relative hand skill / / 24068947 rs5974389 chrX 112412214 A G 3.83E-04 Fibrinogen / / 17255346 rs7889055 chrX 112421331 C A 2.30E-06 Urinary metabolites / / 21572414 rs2154342 chrX 112517273 T C 4.57E-05 Type 2 diabetes / / 17463246 rs5929597 chrX 112527420 A G 2.06E-04 Type 2 diabetes / / 17463246 rs12558336 chrX 112540460 G A 1.60E-04 Type 2 diabetes / / 17463246 rs5929602 chrX 112552016 G C 2.01E-04 Type 2 diabetes / / 17463246 rs6642610 chrX 112587678 T A 3.37E-05 Type 2 diabetes / / 17463246 rs2744462 chrX 112592075 G T 1.47E-04 Type 2 diabetes / / 17463246 rs7057099 chrX 112653673 T C 9.78E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2223443 chrX 112737321 C T 8.98E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5974049 chrX 112755665 C T 6.55E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2905250 chrX 113022496 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2905273 chrX 113025040 A C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs5929418 chrX 113093415 T A 2.50E-05 Urinary metabolites / / 21572414 rs2905404 chrX 113142068 A G 4.59E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2905403 chrX 113146754 A G 6.30E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7876428 chrX 113150613 T C 1.04E-05 Age-related macular degeneration / / pha000001 rs3007183 chrX 113152000 G A 3.30E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs3007186 chrX 113157717 G A 1.14E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7890512 chrX 113350857 T C 6.76E-05 Post-operative nausea and vomiting / / 21694509 rs2188133 chrX 113386500 A C 2.24E-08 Post-operative nausea and vomiting / / 21694509 rs12156831 chrX 113388185 T C 5.58E-06 Post-operative nausea and vomiting / / 21694509 rs9779655 chrX 113457413 G C 8.42E-04 Type 2 diabetes / / 17463246 rs3813928 chrX 113818282 G A 1 Drug response to Risperidone HTR2C nearGene-5 19997080 rs3813929 chrX 113818520 C T 1 Drug response to Olanzapine HTR2C nearGene-5 15666332 rs3813929 chrX 113818520 C T 1 Drug response to Olanzapine HTR2C nearGene-5 19622037 rs3813929 chrX 113818520 C T 1 Drug response to Olanzapine HTR2C nearGene-5 19636338 rs518147 chrX 113818582 G C 1 Drug response to Olanzapine HTR2C UTR-5 19622037 rs543229 chrX 113820986 A G 6.74E-04 Celiac disease HTR2C intron 23936387 rs5988087 chrX 113934856 C T 7.14E-04 Schizophrenia HTR2C intron 19197363 rs5988087 chrX 113934856 C T 3.93E-04 Celiac disease HTR2C intron 23936387 rs11167436 chrX 113944060 C A 6.47E-04 Celiac disease HTR2C intron 23936387 rs6318 chrX 113965735 G C 1 Drug response to Olanzapine HTR2C missense 19193342 rs4332303 chrX 114047867 T C 3.93E-04 Celiac disease HTR2C intron 23936387 rs1414334 chrX 114138144 C G 1 Drug response to Clozapine HTR2C intron 19142101 rs1414334 chrX 114138144 C G 1 Drug response to Risperidone HTR2C intron 19142101 rs3795175 chrX 114243255 C T 1.76E-08 LDL cholesterol IL13RA2 intron 23063622 rs7891628 chrX 114263036 A C 3.47E-04 Celiac disease / / 23936387 rs1321391 chrX 114280737 A G 1.28E-04 Alzheimer's disease / / 17998437 rs1406996 chrX 114283445 C T 8.47E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5987849 chrX 114285815 G A 7.75E-04 Alzheimer's disease / / 17998437 rs7056311 chrX 114471916 A G 2.75E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4243982 chrX 114474770 A C 2.75E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4911811 chrX 114488536 A G 9.71E-04 Parkinson's disease / / 17052657 rs2843477 chrX 114491901 A C 2.33E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1883921 chrX 114706218 G C 1.96E-07 Statin-induced myopathy / / 21826682 rs5987742 chrX 114728259 T C 5.64E-04 Type 2 diabetes / / 17463246 rs6643974 chrX 114757602 G A 1.30E-05 Urinary metabolites / / 21572414 rs4911799 chrX 114776693 A C 1.17E-05 Bipolar disorder and schizophrenia / / 20889312 rs10218219 chrX 114879876 G A 6.92E-08 CD8+ T cell IFN-gamma response to smallpox vaccine PLS3 intron 22661280 rs9724376 chrX 115028954 A G 1.95E-05 Bipolar disorder and schizophrenia / / 20889312 rs1403543 chrX 115302192 G A 2.00E-06 Cystic fibrosis severity AGTR2 intron 21602797 rs3729979 chrX 115304345 C T 0.000000553 Triglycerides AGTR2 missense 23063622 rs17237820 chrX 115305736 A T 0.000000143 Triglycerides AGTR2 UTR-3 23063622 rs17237820 chrX 115305736 A T 1.74E-12 HDL cholesterol AGTR2 UTR-3 23063622 rs4824388 chrX 115400631 A C 2.63E-04 Smoking initiation / / 24665060 rs2311430 chrX 115406096 T C 6.59E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7879372 chrX 115479765 G A 4.37E-04 Type 2 diabetes / / 17463246 rs12007645 chrX 115480439 A G 7.23E-05 Type 2 diabetes / / 17463246 rs5952155 chrX 115502972 T A 1.72E-11 Metabolite levels / / 22286219 rs7065248 chrX 115510531 T C 4.35E-04 Type 2 diabetes / / 17463246 rs7880810 chrX 115521305 T C 5.53E-04 Type 2 diabetes / / 17463246 rs5952167 chrX 115529372 C T 7.07E-04 Type 2 diabetes / / 17463246 rs7888311 chrX 115539235 C T 7.37E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers / / 21775533 rs12839137 chrX 115565550 G A 1.02E-06 Cystic fibrosis (meconium ileus) / / 22466613 rs5905283 chrX 115565881 A C 1.42E-08 Cystic fibrosis (meconium ileus) CXorf61 nearGene-5 22466613 rs3788766 chrX 115566839 A G 1.02E-12 Cystic fibrosis (meconium ileus) CXorf61 nearGene-5 22466613 rs6608683 chrX 115654237 C T 2.30E-05 Urinary metabolites / / 21572414 rs11260309 chrX 115780226 C T 6.83E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12557613 chrX 115895390 T G 2.64E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6645456 chrX 115897843 T G 3.70E-06 Cognitive impairment induced by topiramate / / 22091778 rs7050617 chrX 115910896 A G 9.97E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs9329384 chrX 115943795 C T 9.96E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4072819 chrX 116162959 T C 3.58E-04 IgE levels / / 17255346 rs5957442 chrX 116204377 G A 4.93E-05 Smoking initiation / / 24665060 rs5910995 chrX 116211035 A G 3.29E-06 Smoking initiation / / 24665060 rs5957479 chrX 116213001 G A 1.30E-04 Smoking initiation / / 24665060 rs4825734 chrX 116219154 A C 3.23E-06 Smoking initiation / / 24665060 rs6646773 chrX 116222263 A G 1.00E-06 Response to citalopram treatment / / 22760553 rs2840722 chrX 116271483 A G 2.38E-05 Post-operative nausea and vomiting / / 21694509 rs2526768 chrX 116361033 G A 6.14E-06 Post-operative nausea and vomiting / / 21694509 rs2840686 chrX 116366211 C T 4.84E-06 Post-operative nausea and vomiting / / 21694509 rs2819656 chrX 116377192 G T 1.11E-05 Post-operative nausea and vomiting / / 21694509 rs6646817 chrX 116438122 G A 2.27E-05 Bipolar disorder and schizophrenia / / 20889312 rs2840746 chrX 116445806 A C 2.45E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs5911672 chrX 116486276 T C 6.56E-06 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs12858772 chrX 116487848 C T 2.57E-06 Alcohol dependence / / 19581569 rs5958340 chrX 116516646 A G 7.90E-05 Femoral neck bone geometry / / 22087292 rs5911865 chrX 116573666 C T 6.37E-05 Bipolar disorder and schizophrenia / / 20889312 rs5911869 chrX 116574486 C G 1.88E-05 Bipolar disorder and schizophrenia / / 20889312 rs2335760 chrX 116605326 T C 8.56E-05 Cognitive impairment induced by topiramate / / 22091778 rs6645795 chrX 116651236 C T 1.93E-05 Odorant perception / / 23910658 rs6646995 chrX 116686151 T G 5.07E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5958727 chrX 116733731 T C 4.21E-05 Post-operative nausea and vomiting / / 21694509 rs12557763 chrX 116794687 T C 1.20E-05 Urinary metabolites / / 21572414 rs4825529 chrX 116813517 T C 3.90E-06 Urinary metabolites / / 21572414 rs7891474 chrX 116816560 G A 8.80E-06 Urinary metabolites / / 21572414 rs5910216 chrX 116852079 T C 2.20E-05 Urinary metabolites / / 21572414 rs5910235 chrX 116869914 A G 7.00E-06 Metabolite levels (5-HIAA/ MHPG Ratio) / / 23319000 rs4825539 chrX 116887154 T C 6.43E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs883955 chrX 116986871 G T 7.10E-06 Schizophrenia / / 21674006 rs5956806 chrX 117023658 A G 1.90E-05 Urinary metabolites / / 21572414 rs2430212 chrX 117088056 T C 2.00E-06 Iron status biomarkers KLHL13 intron 19084217 rs2539952 chrX 117314176 G A 2.19E-04 Vaspin levels / / 22907691 rs2539952 chrX 117314176 G A 0.0002191 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs2539953 chrX 117314383 C T 2.19E-04 Vaspin levels / / 22907691 rs2539953 chrX 117314383 C T 0.0002191 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs2802919 chrX 117317618 T G 1.54E-04 Vaspin levels / / 22907691 rs2802919 chrX 117317618 T G 0.0001544 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs7061829 chrX 117322945 G C 7.56E-11 Metabolite levels / / 22286219 rs1781951 chrX 117421376 T C 7.48E-05 Psoriasis / / 20953190 rs4825587 chrX 117647745 C G 2.10E-05 Urinary metabolites DOCK11 intron 21572414 rs4825589 chrX 117656871 G A 9.10E-06 Urinary metabolites DOCK11 intron 21572414 rs5957022 chrX 117670547 C T 7.30E-06 Urinary metabolites DOCK11 intron 21572414 rs17331656 chrX 117810737 T A 2.90E-04 Type 2 diabetes DOCK11 intron 17463246 rs2275917 chrX 117815650 G A 7.14E-04 Type 2 diabetes DOCK11 intron 17463246 rs2495622 chrX 117852992 T G 3.84E-04 Type 2 diabetes / / 17463246 rs2254586 chrX 117855504 T G 3.63E-04 Type 2 diabetes / / 17463246 rs2495626 chrX 117858918 C T 3.07E-04 Type 2 diabetes / / 17463246 rs2495630 chrX 117859254 G A 2.36E-04 Type 2 diabetes / / 17463246 rs2250747 chrX 117863748 A G 3.57E-04 Type 2 diabetes IL13RA1 intron 17463246 rs2248400 chrX 117907557 T C 2.05E-04 Type 2 diabetes IL13RA1 intron 17463246 rs5909580 chrX 118118677 T C 3.78E-04 Tourette syndrome LONRF3 intron 22889924 rs5956098 chrX 118147618 C A 4.15E-04 Tourette syndrome LONRF3 intron 22889924 rs17261061 chrX 118189421 C A 4.90E-04 Alcohol dependence / / 20201924 rs2428744 chrX 118346838 C G 1.10E-05 Urinary metabolites / / 21572414 rs6603506 chrX 118552412 G A 2.91E-04 Type 2 diabetes SLC25A43 intron 17463246 rs5910578 chrX 118567702 T C 1.00E-07 Paget's disease SLC25A43 intron 21623375 rs16994027 chrX 118576189 A C 1.08E-04 Type 2 diabetes SLC25A43 intron 17463246 rs5910616 chrX 118699320 A G 1.33E-04 Smoking initiation CXorf56 UTR-5 24665060 rs7879933 chrX 118716987 C A 2.00E-10 Brain connectivity UBE2A intron 23471985 rs4825655 chrX 118721419 G A 6.35E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2018358 chrX 118722024 G T 1.25E-04 Amyotrophic Lateral Sclerosis NKRF nearGene-3 17362836 rs5957204 chrX 118788146 G A 3.67E-04 Amyotrophic Lateral Sclerosis SEPT6 intron 17362836 rs2991902 chrX 118885493 C T 8.62E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7885997 chrX 118920809 C T 7.33E-04 Amyotrophic Lateral Sclerosis RPL39 intron 17362836 rs16995689 chrX 119064252 C T 4.35E-04 Amyotrophic Lateral Sclerosis NKAP intron 17362836 rs993973 chrX 119372534 C T 7.49E-04 Type 2 diabetes NKAPP1 intron 17463246 rs12857770 chrX 119393600 C T 4.66E-04 Alcohol dependence FAM70A UTR-3 20201924 rs17332040 chrX 119401762 T C 2.33E-04 Body mass index FAM70A intron 21701565 rs17332040 chrX 119401762 T C 6.64E-04 Body mass index FAM70A intron 21701565 rs5910825 chrX 119440304 G A 1.11E-04 Parkinson's disease FAM70A intron 17052657 rs2075099 chrX 119504439 G A 8.63E-04 Type 2 diabetes ATP1B4 intron 17463246 rs6603622 chrX 119548806 T C 3.76E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs2283738 chrX 119592386 G A 4.78E-04 Amyotrophic Lateral Sclerosis LAMP2 intron 17362836 rs2285550 chrX 119695624 A G 9.78E-05 Lung function (forced expiratory volume in 1 second) CUL4B intron 24023788 rs5957416 chrX 119728001 C T 3.72E-04 Lung function (forced vital capacity) / / 24023788 rs1972809 chrX 119867475 A G 1.00E-24 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs17261621 chrX 119877094 C A 1.10E-05 Urinary metabolites / / 21572414 rs12009643 chrX 119882438 C T 1.10E-05 Urinary metabolites / / 21572414 rs7057602 chrX 119931487 T G 3.20E-04 Type 2 diabetes / / 17463246 rs1978413 chrX 119943375 T G 2.13E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10521692 chrX 119973974 C T 8.16E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs13440470 chrX 120241002 A G 5.82E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5957536 chrX 120279238 A G 6.33E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17282946 chrX 120316909 G A 4.00E-05 Major depressive disorder / / 21042317 rs7885278 chrX 120316970 T C 3.93E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5909807 chrX 120328543 T C 5.76E-05 Cognitive impairment induced by topiramate / / 22091778 rs6608061 chrX 120358529 G C 3.10E-07 Breast cancer / / 20852631 rs5911118 chrX 120376504 A G 6.77E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4142568 chrX 120377132 T C 9.16E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4240003 chrX 120380114 G A 5.24E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs16996480 chrX 120982851 A G 1.99E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11796987 chrX 121025714 G A 7.23E-05 Schizophrenia / / 19571811 rs5909876 chrX 121222248 G A 1.50E-04 Type 2 diabetes / / 17463246 rs12850731 chrX 121222635 G A 8.74E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5957888 chrX 121243084 T C 4.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12010609 chrX 121349797 G A 1.50E-05 Urinary metabolites / / 21572414 rs1970368 chrX 121376342 G C 1.70E-05 Urinary metabolites / / 21572414 rs2448871 chrX 121413203 A G 9.62E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2495683 chrX 121444357 A G 2.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5957979 chrX 121450004 T G 6.61E-04 Alzheimer's disease / / 17998437 rs2495686 chrX 121455213 G A 9.76E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs982834 chrX 121575911 T C 4.35E-05 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs3951521 chrX 121611168 A G 4.12E-05 Cognitive impairment induced by topiramate / / 22091778 rs7881297 chrX 121612919 T G 7.49E-05 Cognitive impairment induced by topiramate / / 22091778 rs1378084 chrX 121624350 T G 1.09E-05 Cognitive impairment induced by topiramate / / 22091778 rs2360128 chrX 121698420 C T 3.42E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs5956483 chrX 121771745 C T 8.05E-04 Parkinson's disease / / 17052657 rs5956483 chrX 121771745 C T 3.46E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5909905 chrX 121836735 T C 2.78E-04 Parkinson's disease / / 17052657 rs5958097 chrX 121906428 A T 5.20E-06 Urinary metabolites / / 21572414 rs5956488 chrX 121907043 G C 9.30E-06 Urinary metabolites / / 21572414 rs5958118 chrX 121963479 A G 8.95E-04 Type 2 diabetes / / 17463246 rs4559365 chrX 121967359 C T 9.00E-06 Metabolite levels (MHPG) / / 23319000 rs5958121 chrX 121969592 C T 7.64E-04 Parkinson's disease / / 17052657 rs1293544 chrX 122129119 C T 4.82E-04 Parkinson's disease / / 17052657 rs1293545 chrX 122129161 G A 6.48E-04 Parkinson's disease / / 17052657 rs3013029 chrX 122141925 A G 7.41E-04 Alcohol dependence / / 20201924 rs4825824 chrX 122163503 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1293468 chrX 122208528 T C 4.34E-04 Parkinson's disease / / 17052657 rs1496795 chrX 122229545 T G 9.68E-05 Age-related macular degeneration / / pha000002 rs6648941 chrX 122249834 C T 6.49E-04 Type 2 diabetes / / 17463246 rs2213537 chrX 122250292 C T 6.20E-04 Type 2 diabetes / / 17463246 rs2213536 chrX 122250456 C A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs3761555 chrX 122316437 T C 2.06E-04 Amyotrophic Lateral Sclerosis GRIA3 nearGene-5 17362836 rs3761555 chrX 122316437 T C 5.16E-05 Vaspin levels GRIA3 nearGene-5 22907691 rs3761555 chrX 122316437 T C 0.0000516 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit GRIA3 nearGene-5 22907730 rs1557544 chrX 122321773 C T 6.50E-06 Urinary metabolites GRIA3 intron 21572414 rs5909973 chrX 122324911 C A 6.90E-08 Urinary metabolites GRIA3 intron 21572414 rs2066921 chrX 122325037 A C 7.50E-08 Urinary metabolites GRIA3 intron 21572414 rs12559898 chrX 122331823 G A 7.78E-04 Nicotine dependence GRIA3 intron 17158188 rs2285127 chrX 122336448 T C 2.90E-06 Urinary metabolites GRIA3 intron 21572414 rs4825476 chrX 122441479 G A 1 Drug response to Citalopram GRIA3 intron 17898344 rs5911588 chrX 122458593 C T 4.00E-04 Suicidal ideation with citalopram treatment GRIA3 intron 19724244 rs7058032 chrX 122471443 G A 9.33E-04 Parkinson's disease GRIA3 intron 17052657 rs5909995 chrX 122475826 T G 1.33E-04 Amyotrophic Lateral Sclerosis GRIA3 intron 17362836 rs5958236 chrX 122522060 T C 5.80E-04 Bipolar disorder (mania) GRIA3 intron 23326512 rs670678 chrX 122539918 T C 7.05E-04 Bipolar disorder (mania) GRIA3 intron 23326512 rs5956545 chrX 122595498 G T 5.25E-04 Response to taxane treatment (placlitaxel) GRIA3 intron 23006423 rs4474149 chrX 122630376 T C 5.88E-06 Cardiovascular disease / / 18179892 rs13002544 chrX 122663541 C CC,CT 3.02E-05 Alcohol and nictotine co-dependence / / 20158304 rs199732820 chrX 122663541 C T 3.02E-05 Alcohol and nictotine co-dependence / / 20158304 rs17259484 chrX 122724000 G A 3.41E-04 Coronary Artery Disease / / 17634449 rs3124045 chrX 122944839 G A 2.90E-05 Celiac disease / / 17558408 rs9698139 chrX 122971560 C T 9.54E-06 Response to taxane treatment (placlitaxel) / / 23006423 rs5911742 chrX 123197557 T C 3.79E-04 Amyotrophic Lateral Sclerosis STAG2 intron 17362836 rs11260460 chrX 123237085 G A 1.20E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5911772 chrX 123283980 A G 1.11E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1279781 chrX 123298002 A G 4.01E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2279726 chrX 123307694 C T 5.86E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1846322 chrX 123315379 C T 6.39E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1781115 chrX 123320332 T C 6.53E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1798138 chrX 123321711 T C 4.96E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1279795 chrX 123324420 G A 2.93E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1279807 chrX 123329635 C T 8.17E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1279815 chrX 123342834 A C 3.18E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10482535 chrX 123351626 T C 6.10E-06 Urinary metabolites / / 21572414 rs9887524 chrX 123359892 A G 1.50E-05 Urinary metabolites / / 21572414 rs5956633 chrX 123366953 T A 2.23E-04 Type 2 diabetes / / 17463246 rs1290227 chrX 123376622 T C 1.42E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1279817 chrX 123392929 T G 1.50E-04 Fibrinogen / / 17255346 rs6608182 chrX 123397104 C T 7.54E-05 Schizophrenia / / 19571811 rs6608183 chrX 123397248 T C 1.39E-04 Fibrinogen / / 17255346 rs5958440 chrX 123402522 T C 2.00E-05 Urinary metabolites / / 21572414 rs5958444 chrX 123412297 T C 8.50E-06 Urinary metabolites / / 21572414 rs12557797 chrX 123449683 G A 2.21E-04 Smoking initiation / / 24665060 rs5958458 chrX 123456069 C T 4.09E-04 Smoking initiation / / 24665060 rs7357894 chrX 123479999 G A 6.67E-04 Smoking initiation SH2D1A nearGene-5 24665060 rs2239478 chrX 123536223 G A 2.48E-05 Lung function (forced vital capacity) ODZ1 intron 24023788 rs2239478 chrX 123536223 G A 8.04E-05 Lung function (forced expiratory volume in 1 second) ODZ1 intron 24023788 rs2283769 chrX 123582309 T C 8.67E-05 Cognitive performance ODZ1 intron 19734545 rs2843518 chrX 123688200 T C 5.63E-05 Parkinson's disease ODZ1 intron 21812969 rs2843520 chrX 123689033 T C 6.37E-05 Parkinson's disease ODZ1 intron 21812969 rs5958542 chrX 123748306 T C 1.50E-04 Hearing function ODZ1 intron 17255346 rs2051589 chrX 124054089 T C 9.31E-04 Amyotrophic Lateral Sclerosis ODZ1 intron 17362836 rs12842370 chrX 124071272 A G 2.98E-04 Parkinson's disease ODZ1 intron 17052657 rs7060947 chrX 124073662 A G 1.00E-07 Immune reponse to smallpox (secreted IFN-alpha) ODZ1 intron 22610502 rs1894516 chrX 124133621 G A 6.25E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1894516 chrX 124133621 G A 0.00000664 Otitis media (children 3 years old or younger) / / 23133572 rs16994560 chrX 124181114 C T 6.07E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2213488 chrX 124276789 T C 2.10E-06 Coronary spasm / / 18075462 rs1964186 chrX 124505129 C T 3.25E-06 Testicular cancer / / 21551455 rs1903096 chrX 124676455 G T 7.51E-05 Prion diseases / / 22210626 rs28801485 chrX 124705950 G A 4.89E-05 Coronary restenosis / / 21878436 rs28473050 chrX 124718412 G A 5.37E-05 Coronary restenosis / / 21878436 rs2213355 chrX 124720741 T C 5.37E-05 Coronary restenosis / / 21878436 rs4830113 chrX 124807054 C T 6.65E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17218023 chrX 124831349 A G 7.62E-05 Intelligence / / 21826061 rs2213346 chrX 124857183 T C 4.24E-05 Intelligence / / 21826061 rs5932693 chrX 124885772 G A 8.31E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5932703 chrX 124894361 T C 2.92E-05 Intelligence / / 21826061 rs5932769 chrX 124949710 G C 3.31E-05 Intelligence / / 21826061 rs28492889 chrX 124962362 T A 4.42E-05 Intelligence / / 21826061 rs5932820 chrX 124992296 C A 3.33E-05 Intelligence / / 21826061 rs5932821 chrX 124994178 A G 5.89E-05 Intelligence / / 21826061 rs7884160 chrX 125161775 A G 5.38E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5933188 chrX 125178713 A C 7.42E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5933191 chrX 125179908 T C 4.69E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7056175 chrX 125200182 C T 1.40E-05 Urinary metabolites / / 21572414 rs5933254 chrX 125201670 G A 1.30E-05 Urinary metabolites / / 21572414 rs5930600 chrX 125211324 C T 1.60E-05 Urinary metabolites / / 21572414 rs1393013 chrX 125211635 C T 1.60E-05 Urinary metabolites / / 21572414 rs5933275 chrX 125216187 A C 9.40E-06 Urinary metabolites / / 21572414 rs5933281 chrX 125217600 T C 1.30E-05 Urinary metabolites / / 21572414 rs5933283 chrX 125217791 A G 1.30E-05 Urinary metabolites / / 21572414 rs1604354 chrX 125222293 C T 1.90E-05 Urinary metabolites / / 21572414 rs1995349 chrX 125223099 T C 3.07E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5975398 chrX 125237900 G A 3.09E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5975398 chrX 125237900 G A 2.70E-05 Urinary metabolites / / 21572414 rs5933317 chrX 125249512 A G 3.90E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10856754 chrX 125255738 T G 6.08E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5977900 chrX 125264414 A G 1.30E-05 Urinary metabolites / / 21572414 rs5933338 chrX 125272129 A G 9.40E-06 Urinary metabolites / / 21572414 rs5933341 chrX 125275765 A C 3.49E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10521737 chrX 125287073 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs5930628 chrX 125292973 G T 3.09E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5930628 chrX 125292973 G T 5.80E-06 Urinary metabolites / / 21572414 rs5933374 chrX 125306223 A G 8.40E-06 Urinary metabolites / / 21572414 rs10521738 chrX 125312105 G A 4.42E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5975445 chrX 125314906 C T 1.20E-05 Urinary metabolites / / 21572414 rs1566587 chrX 125315784 A G 1.00E-05 Urinary metabolites / / 21572414 rs7063788 chrX 125318419 A G 8.40E-06 Urinary metabolites / / 21572414 rs2154173 chrX 125348550 G A 9.33E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5930648 chrX 125354497 A G 9.88E-04 Alzheimer's disease / / 17998437 rs1937245 chrX 125358946 T C 9.03E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5978057 chrX 125391477 A G 2.75E-05 Post-operative nausea and vomiting / / 21694509 rs11797015 chrX 125414651 A G 5.17E-04 Endometrial cancer / / 24096698 rs11797015 chrX 125414651 A G 7.32E-04 Endometrial cancer / / 24096698 rs1290566 chrX 125473571 C T 3.89E-05 Cognitive test performance / / 20125193 rs5930899 chrX 125517310 T C 2.48E-05 Odorant perception / / 23910658 rs5930921 chrX 125523927 C A 2.60E-05 Cognitive test performance / / 20125193 rs5930979 chrX 125568108 G A 6.40E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs17303399 chrX 125678361 C T 4.28E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1937556 chrX 125848550 A C 6.47E-05 Cognitive performance / / 19734545 rs17303497 chrX 125902512 A C 2.60E-06 Urinary metabolites / / 21572414 rs7474176 chrX 125903193 A C 1.70E-05 Urinary metabolites / / 21572414 rs1937563 chrX 125903508 T C 1.70E-05 Urinary metabolites / / 21572414 rs7051815 chrX 125924926 A T 1.70E-05 Urinary metabolites / / 21572414 rs6528700 chrX 125927777 A C 2.10E-05 Urinary metabolites / / 21572414 rs4370666 chrX 125930189 A G 8.35E-05 Cognitive test performance / / 20125193 rs12854061 chrX 125957843 C T 4.95E-05 Major depressive disorder (broad) / / 20038947 rs12557112 chrX 125960729 G A 3.68E-05 Major depressive disorder (broad) / / 20038947 rs6636085 chrX 125960876 C T 4.73E-04 Lung function (forced vital capacity) / / 24023788 rs12835281 chrX 125961388 T C 3.84E-05 Major depressive disorder (broad) / / 20038947 rs5931716 chrX 125963245 A G 3.34E-05 Major depressive disorder (broad) / / 20038947 rs5931717 chrX 125964007 C T 3.28E-05 Major depressive disorder (broad) / / 20038947 rs5930036 chrX 125965102 C T 2.88E-05 Major depressive disorder (broad) / / 20038947 rs4573418 chrX 125969026 A G 3.18E-05 Major depressive disorder (broad) / / 20038947 rs3131422 chrX 125970041 A G 4.08E-05 Major depressive disorder (broad) / / 20038947 rs4458996 chrX 125972757 T C 3.07E-05 Major depressive disorder (broad) / / 20038947 rs12556725 chrX 125977849 G A 3.13E-05 Major depressive disorder (broad) / / 20038947 rs5930039 chrX 125978876 A G 3.15E-05 Major depressive disorder (broad) / / 20038947 rs3131364 chrX 125981732 G A 4.08E-05 Major depressive disorder (broad) / / 20038947 rs3131358 chrX 125990345 G A 4.15E-05 Major depressive disorder (broad) / / 20038947 rs5976457 chrX 126054945 T C 2.63E-04 Lung function (forced vital capacity) / / 24023788 rs204321 chrX 126171889 C T 5.95E-04 Body mass index / / 21701565 rs1871966 chrX 126247795 C T 1.45E-04 Schizophrenia / / 21674006 rs226534 chrX 126902497 A G 2.23E-20 Crohn's disease / / 18587394 rs226644 chrX 126962295 T C 0.00015 Prostate cancer / / 23555315 rs4829673 chrX 126978675 G A 6.19E-04 Parkinson's disease / / 17052657 rs5932200 chrX 126980625 A G 8.25E-04 Type 2 diabetes / / 17463246 rs2101271 chrX 126981514 G T 3.76E-04 Parkinson's disease / / 17052657 rs5930189 chrX 126985659 G A 2.10E-04 Parkinson's disease / / 17052657 rs2200290 chrX 126987467 C T 2.58E-04 Parkinson's disease / / 17052657 rs766417 chrX 127028955 C T 1.46E-05 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs5932245 chrX 127068714 C T 3.62E-04 Parkinson's disease / / 17052657 rs5974980 chrX 127083976 T C 2.74E-05 Psoriasis / / 18364390 rs3948791 chrX 127129653 C T 2.53E-04 IgE levels / / 17255346 rs5932296 chrX 127133817 T C 8.49E-06 Multiple complex diseases / / 17554300 rs472380 chrX 127141606 A G 7.60E-05 IgE levels / / 17255346 rs16294 chrX 127145069 G T 8.31E-05 IgE levels / / 17255346 rs5932307 chrX 127165414 G A 2.62E-05 Schizophrenia / / 19571811 rs683335 chrX 127223056 C A 1.99E-04 Parkinson's disease / / 17052657 rs683335 chrX 127223056 C A 3.49E-05 Psoriasis / / 18364390 rs653618 chrX 127231714 T C 3.09E-04 Parkinson's disease / / 17052657 rs12008102 chrX 127262571 G A 2.20E-05 Urinary metabolites / / 21572414 rs5932371 chrX 127304526 C T 2.20E-05 Urinary metabolites / / 21572414 rs16997636 chrX 127388841 C T 7.66E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs913312 chrX 127388953 A G 1.30E-04 IgE levels / / 17255346 rs913312 chrX 127388953 A G 7.76E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs240199 chrX 127452799 G T 0.000033 Panic disorder / / 23149450 rs240199 chrX 127452799 G T 3.30E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs240202 chrX 127459739 C T 6.99E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs240579 chrX 127505327 A G 5.00E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11096210 chrX 127744066 A G 5.99E-06 Cognitive impairment induced by topiramate / / 22091778 rs2386112 chrX 127817476 C T 1.17E-06 Post-operative nausea and vomiting / / 21694509 rs762874 chrX 127940011 A C 0.0000477 Panic disorder / / 23149450 rs762874 chrX 127940011 A C 4.77E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs916208 chrX 127941251 C T 6.24E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs916208 chrX 127941251 C T 0.0000464 Panic disorder / / 23149450 rs916208 chrX 127941251 C T 4.64E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs2207031 chrX 128013314 G T 1.90E-04 Lung adenocarcinoma / / 21242121 rs974987 chrX 128033762 C A 4.20E-04 Parkinson's disease / / 17052657 rs645 chrX 128035454 C T 4.98E-04 Parkinson's disease / / 17052657 rs12559502 chrX 128048545 A G 1.91E-04 Attention deficit hyperactivity disorder / / pha002875 rs4830105 chrX 128055571 G T 1.19E-04 Attention deficit hyperactivity disorder / / pha002875 rs12687783 chrX 128083203 C A 3.59E-05 Cognitive impairment induced by topiramate / / 22091778 rs961580 chrX 128083855 G T 5.82E-04 Parkinson's disease / / 17052657 rs1204087 chrX 128085987 A C 8.76E-04 Parkinson's disease / / 17052657 rs4830111 chrX 128186756 T C 7.07E-04 Parkinson's disease / / 17052657 rs1341670 chrX 128195767 G A 7.29E-04 Parkinson's disease / / 17052657 rs5932570 chrX 128202425 T C 5.73E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5976955 chrX 128208510 C A 9.61E-04 Parkinson's disease / / 17052657 rs2185655 chrX 128211449 G A 5.70E-04 Parkinson's disease / / 17052657 rs7882525 chrX 128245982 G A 9.20E-05 Post-operative nausea and vomiting / / 21694509 rs5975081 chrX 128268951 A G 4.00E-05 Post-operative nausea and vomiting / / 21694509 rs5975081 chrX 128268951 A G 0.0000289 Adenoma (male) / / 22532847 rs5932592 chrX 128349532 G A 4.96E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1997630 chrX 128361372 A G 5.00E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2103520 chrX 128365045 T C 6.19E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1883105 chrX 128369774 A G 9.49E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7876128 chrX 128449150 G A 1.02E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2206012 chrX 128547239 C A 3.22E-04 Parkinson's disease / / 17052657 rs2072837 chrX 128690832 G A 1.60E-05 Height OCRL intron 21998595 rs16999497 chrX 128735199 T C 6.36E-04 Alcohol dependence / / 20201924 rs859601 chrX 128910654 G A 9.68E-04 Type 2 diabetes / / 17463246 rs859587 chrX 128933657 T G 8.85E-04 Tourette syndrome / / 22889924 rs1538973 chrX 128959846 T C 4.37E-05 Cognitive decline ZDHHC9 intron 22054870 rs2361405 chrX 129104734 A G 5.00E-06 Periodontitis (Mean PAL) / / 24024966 rs138595762 chrX 129105155 C CGT,CTG 4.61E-06 Periodontitis (Mean PAL) / / 24024966 rs58776649 chrX 129105155 C CTG 4.61E-06 Periodontitis (Mean PAL) / / 24024966 rs3788848 chrX 129199812 T C 3.00E-06 Dental caries ELF4 UTR-3 23064961 rs209994 chrX 129227453 C A 2.49E-04 Lung function (forced expiratory volume in 1 second) ELF4 intron 17255346 rs2064179 chrX 129409193 A G 3.44E-05 Alzheimer's disease (late onset) / / 20885792 rs4830185 chrX 129455259 C T 5.82E-04 Type 2 diabetes / / 17463246 rs5977248 chrX 129501487 G T 3.25E-05 Alzheimer's disease (late onset) SLC25A14 intron 20885792 rs12689384 chrX 129536966 G A 3.27E-08 Gender RBMX2 intron 22843499 rs2294956 chrX 129538500 T C 0.000000824 Gender RBMX2 intron 22843499 rs752 chrX 129604423 G A 3.69E-05 Parkinson's disease / / 17052657 rs1034422 chrX 129609529 T A 9.86E-05 Parkinson's disease / / 17052657 rs5977301 chrX 129618467 C A 6.17E-05 Parkinson's disease / / 17052657 rs4830190 chrX 129622677 A G 1.03E-04 Parkinson's disease / / 17052657 rs5977303 chrX 129634228 A G 7.20E-05 IgE levels / / 17255346 rs5975248 chrX 130322937 T C 2.68E-05 Cognitive test performance / / 20125193 rs6634813 chrX 130329502 C A 2.37E-05 Cognitive test performance / / 20125193 rs5930448 chrX 130340623 T G 1.79E-05 Cognitive test performance / / 20125193 rs6418944 chrX 130408431 T C 2.44E-04 Amyotrophic Lateral Sclerosis IGSF1 intron 17362836 rs4830220 chrX 130413979 C T 3.81E-04 Amyotrophic Lateral Sclerosis IGSF1 intron 17362836 rs17250632 chrX 130501597 G T 5.60E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2281667 chrX 130503234 G A 1.64E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5977475 chrX 130509158 G A 1.37E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5977484 chrX 130529347 G T 6.32E-05 Schizophrenia / / 19571809 rs2503369 chrX 130532111 A G 1.95E-04 Birth weight / / 17255346 rs2281668 chrX 130533433 T C 1.01E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5932920 chrX 130603141 G C 2.40E-05 Urinary metabolites / / 21572414 rs859866 chrX 130781153 G A 6.30E-04 Parkinson's disease / / 17052657 rs12014417 chrX 130783134 G A 1.30E-05 Urinary metabolites / / 21572414 rs6634838 chrX 130793579 A C 8.23E-04 Parkinson's disease / / 17052657 rs7061008 chrX 130913493 T G 7.46E-04 Parkinson's disease LOC286467 intron 17052657 rs5930517 chrX 131003149 G T 9.69E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs5930521 chrX 131011355 G A 8.79E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2142522 chrX 131025293 G A 1.47E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs5933028 chrX 131028579 A C 3.11E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs202734 chrX 131039850 G A 1.83E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs202735 chrX 131040342 T A 1.94E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs2022565 chrX 131082021 G A 5.18E-07 Cognitive impairment induced by topiramate / / 22091778 rs202777 chrX 131090813 G A 2.55E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs5930539 chrX 131173588 A G 1.49E-08 Liver disease in chronic hepatitis B virus infection MST4 intron 24065354 rs5930539 chrX 131173588 A G 4.26E-07 Liver disease in chronic hepatitis B virus infection MST4 intron 24065354 rs6637934 chrX 131212642 C T 1.80E-07 Liver disease in chronic hepatitis B virus infection FRMD7 missense 24065354 rs6637934 chrX 131212642 C T 3.70E-06 Liver disease in chronic hepatitis B virus infection FRMD7 missense 24065354 rs5930546 chrX 131234733 G A 1.03E-04 Type 2 diabetes FRMD7 cds-synon 17463246 rs5977652 chrX 131315200 C T 8.33E-04 Type 2 diabetes / / 17463246 rs5977655 chrX 131333070 C T 8.23E-04 Type 2 diabetes / / 17463246 rs726107 chrX 131659975 T G 5.02E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs243475 chrX 131746822 C A 5.96E-04 Parkinson's disease / / 17052657 rs5933189 chrX 131906207 A G 8.98E-04 Parkinson's disease HS6ST2 intron 17052657 rs5977757 chrX 131942593 T C 7.00E-07 Urinary metabolites HS6ST2 intron 21572414 rs5977759 chrX 131946937 G A 1.70E-06 Urinary metabolites HS6ST2 intron 21572414 rs5977762 chrX 131949416 G A 1.40E-06 Urinary metabolites HS6ST2 intron 21572414 rs1547417 chrX 131964549 C T 1.00E-05 Urinary metabolites HS6ST2 intron 21572414 rs5933228 chrX 132011398 T C 1.40E-05 Urinary metabolites HS6ST2 intron 21572414 rs7892161 chrX 132024504 C T 9.00E-06 Periodontitis (Mean PAL) HS6ST2 intron 24024966 rs17324272 chrX 132137156 T C 2.00E-07 HIV-1 control / / 20041166 rs5977837 chrX 132369931 T C 5.50E-10 Common variable immunodeficiency / / 21497890 rs980840 chrX 132406800 C T 5.76E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1048369 chrX 132437337 G A 8.66E-04 Parkinson's disease GPC4 missense 17052657 rs1048369 chrX 132437337 G A 8.24E-04 Amyotrophic Lateral Sclerosis GPC4 missense 17362836 rs1129980 chrX 132438872 C A 7.51E-04 Parkinson's disease GPC4 missense 17052657 rs1129980 chrX 132438872 C A 8.24E-04 Amyotrophic Lateral Sclerosis GPC4 missense 17362836 rs2266797 chrX 132456143 G A 9.83E-04 Tourette syndrome GPC4 intron 22889924 rs41490249 chrX 132556326 G A 1.40E-05 Urinary metabolites / / 21572414 rs17277679 chrX 132564095 C T 3.00E-06 Urinary metabolites / / 21572414 rs5975422 chrX 132928262 C T 3.35E-04 Parkinson's disease GPC3 intron 17052657 rs1264380 chrX 133045336 A C 2.34E-05 Relative hand skill GPC3 intron 24068947 rs1264381 chrX 133078129 G A 2.01E-05 Relative hand skill GPC3 intron 24068947 rs1264382 chrX 133080179 T A 1.96E-05 Relative hand skill GPC3 intron 24068947 rs2267523 chrX 133097682 T A 2.80E-06 Relative hand skill GPC3 intron 24068947 rs2267524 chrX 133097685 T A 2.49E-06 Relative hand skill GPC3 intron 24068947 rs2267527 chrX 133102711 A G 2.25E-06 Relative hand skill GPC3 intron 24068947 rs5933366 chrX 133122835 T C 2.14E-06 Relative hand skill / / 24068947 rs7883190 chrX 133125791 A T 2.00E-06 Relative hand skill / / 24068947 rs11796475 chrX 133144664 C T 2.37E-06 Relative hand skill / / 24068947 rs12558772 chrX 133150848 A G 9.83E-06 Relative hand skill / / 24068947 rs110133 chrX 133258452 A G 6.82E-05 Relative hand skill / / 24068947 rs2312983 chrX 133280911 T C 8.03E-05 Relative hand skill / / 24068947 rs765132 chrX 133322604 C T 1.00E-06 Response to anti-TNF alpha therapy in inflammatory bowel disease / / 20014019 rs12850804 chrX 133345288 C T 1.69E-06 Smooth-surface caries / / 24556642 rs5933404 chrX 133498300 G A 6.25E-04 Parkinson's disease / / 17052657 rs6529631 chrX 133657454 T C 9.04E-04 Tourette syndrome / / 22889924 rs17000676 chrX 133763174 C T 3.10E-05 HIV-1 control PLAC1 intron 20041166 rs5930667 chrX 134066599 C T 4.00E-04 Major depressive disorder / / 19065144 rs5978067 chrX 134067560 T C 5.39E-04 Type 2 diabetes / / 17463246 rs5930669 chrX 134069784 C T 2.94E-04 Type 2 diabetes / / 17463246 rs6635032 chrX 134217301 C T 1.32E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7883362 chrX 134232939 C A 5.39E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4830335 chrX 134332032 T C 3.15E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs4830338 chrX 134339098 T C 4.69E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs5978106 chrX 134343016 G A 2.83E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7887412 chrX 134741516 C T 1.40E-05 Urinary metabolites / / 21572414 rs2501481 chrX 134821538 C T 6.22E-04 Type 2 diabetes LOC644717 intron 17463246 rs6528290 chrX 134906068 G C 8.17E-05 Type 2 diabetes / / 17463246 rs2446132 chrX 134910394 A G 8.88E-04 Type 2 diabetes / / 17463246 rs5975627 chrX 134972878 A G 1.67E-04 Type 2 diabetes CT45A6 nearGene-5 17463246 rs5975628 chrX 134977336 C T 1.25E-04 Type 2 diabetes SAGE1 intron 17463246 rs12014949 chrX 134986870 T C 1.73E-04 Type 2 diabetes SAGE1 intron 17463246 rs5975630 chrX 134987819 T C 8.27E-05 Type 2 diabetes SAGE1 intron 17463246 rs2273221 chrX 135310785 T C 0.00032 Breast cancer MAP7D3 missense 23555315 rs200510790 chrX 135310790 C A 0.00049 Prostate cancer (non-advanced prostate cancer) MAP7D3 missense 23555315 rs1055497 chrX 135313034 T G 0.00058 Breast cancer MAP7D3 missense 23555315 rs12686902 chrX 135402287 G C 1.20E-05 Urinary metabolites GPR112 intron 21572414 rs1203583 chrX 135534948 T C 5.07E-04 Parkinson's disease / / 17052657 rs2807261 chrX 135661799 C T 1.32E-07 Multiple complex diseases / / 17554300 rs5930973 chrX 135732148 G A 1.90E-04 Alcohol dependence CD40LG intron 20201924 rs5930973 chrX 135732148 G A 3.70E-04 Alcohol dependence CD40LG intron 20201924 rs111705907 chrX 135844003 A G 1.62E-11 Metabolite levels ARHGEF6 intron 22286219 rs630967 chrX 135847004 C T 8.97E-04 Type 2 diabetes ARHGEF6 intron 17463246 rs7891017 chrX 135961796 C G 6.04E-04 Response to taxane treatment (placlitaxel) RBMX intron 23006423 rs1190739 chrX 136055295 T C 5.00E-06 Coronary heart disease / / 21347282 rs1201465 chrX 136110849 C T 6.82E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2886230 chrX 136144365 C T 3.41E-04 Smoking quantity / / 24665060 rs6633864 chrX 136150573 C T 5.68E-04 Smoking quantity / / 24665060 rs7053295 chrX 136249833 C T 2.50E-05 Urinary metabolites / / 21572414 rs6528435 chrX 136265178 G A 2.50E-05 Urinary metabolites / / 21572414 rs5931094 chrX 136267623 G C 2.30E-05 Urinary metabolites / / 21572414 rs4829864 chrX 136268740 G A 2.50E-05 Urinary metabolites / / 21572414 rs5931118 chrX 136373714 G A 8.60E-04 Alcohol dependence / / 20201924 rs5931133 chrX 136424092 A G 8.72E-04 Type 2 diabetes / / 17463246 rs2746111 chrX 136613344 T C 4.28E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1005303 chrX 136626238 T C 3.46E-04 Type 2 diabetes / / 17463246 rs7879288 chrX 136660641 A C 4.78E-04 Smoking initiation / / 24665060 rs1324156 chrX 136816568 A T 2.90E-05 Urinary metabolites / / 21572414 rs5931207 chrX 136828762 A G 2.60E-05 Urinary metabolites / / 21572414 rs845926 chrX 136831941 A C 3.92E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs697833 chrX 136841552 C T 4.52E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6635478 chrX 136882025 T C 3.66E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6633928 chrX 136911362 C T 2.05E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs845919 chrX 136931651 A G 1.35E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs845923 chrX 136943831 C T 6.75E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6635500 chrX 136968002 T C 4.24E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7877291 chrX 136986991 T C 8.28E-04 Smoking cessation / / 24665060 rs2366516 chrX 137060087 C T 1.08E-11 Gout / / pha001406 rs6635535 chrX 137070228 G A 5.29E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5931369 chrX 137374381 C T 2.00E-05 Urinary metabolites / / 21572414 rs2050909 chrX 137486165 G A 9.76E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10521792 chrX 138117409 A G 2.00E-07 Response to taxane treatment (placlitaxel) FGF13 intron 23006423 rs728186 chrX 138141507 A G 4.04E-04 Parkinson's disease FGF13 intron 17052657 rs728186 chrX 138141507 A G 7.16E-04 Amyotrophic Lateral Sclerosis FGF13 intron 17362836 rs10521793 chrX 138156505 C T 8.95E-05 Statin-induced myopathy FGF13 intron 21826682 rs5976273 chrX 138185609 T C 2.60E-05 Urinary metabolites FGF13 intron 21572414 rs5931572 chrX 138236517 A G 8.14E-05 Cognitive impairment induced by topiramate FGF13 intron 22091778 rs5931572 chrX 138236517 A G 9.68E-05 Cognitive impairment induced by topiramate FGF13 intron 22091778 rs2213408 chrX 138236818 C T 1.99E-04 Amyotrophic Lateral Sclerosis FGF13 intron 17362836 rs2227059 chrX 138236904 C T 7.51E-05 Epilepsy (remission after treatment) FGF13 intron 23962720 rs12842254 chrX 138267401 T C 1.00E-04 Cognitive impairment induced by topiramate FGF13 intron 22091778 rs61355905 chrX 138295778 C T 1.78E-39 Metabolite levels / / 22286219 rs5974808 chrX 138309597 A G 5.81E-04 Type 2 diabetes / / 17463246 rs4396035 chrX 138559569 C T 8.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs5930009 chrX 138577105 T C 4.99E-04 Type 2 diabetes / / 17463246 rs376165 chrX 138617733 A G 6.11E-04 Type 2 diabetes F9 intron 17463246 rs440051 chrX 138644917 G A 3.73E-04 Birth weight F9 UTR-3 17255346 rs5907636 chrX 138733254 C T 1.16E-04 Body mass index MCF2 intron 21701565 rs1888012 chrX 138770950 T C 2.90E-04 Response to cytidine analogues (gemcitabine) MCF2 intron 24483146 rs17256782 chrX 139035622 G A 2.43E-05 Glycosylated haemoglobin levels / / 17255346 rs5953916 chrX 139060273 C T 6.46E-04 Alzheimer's disease / / 17998437 rs5907577 chrX 139166683 C T 1.63E-06 Bipolar disorder / / 19488044 rs5907577 chrX 139166683 C T 5.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs5907577 chrX 139166683 C T 3.65E-06 Bipolar Disorder / / pha002858 rs11795867 chrX 139184616 C T 1.79E-06 Bipolar disorder / / 19488044 rs5955388 chrX 139188678 A C 9.70E-05 Bipolar disorder / / 19488044 rs4825220 chrX 139214478 A G 2.64E-07 Bipolar disorder / / 19488044 rs4825220 chrX 139214478 A G 1.48E-05 Bipolar disorder and schizophrenia / / 20889312 rs4825220 chrX 139214478 A G 2.01E-05 Bipolar Disorder / / pha002858 rs677033 chrX 139235492 T C 1.49E-06 Bipolar disorder / / 19488044 rs677033 chrX 139235492 T C 2.34E-05 Bipolar disorder and schizophrenia / / 20889312 rs677033 chrX 139235492 T C 2.31E-05 Bipolar Disorder / / pha002858 rs613278 chrX 139238459 T C 1.44E-05 Bipolar disorder / / 19488044 rs613278 chrX 139238459 T C 1.42E-05 Bipolar disorder and schizophrenia / / 20889312 rs613278 chrX 139238459 T C 1.03E-05 Bipolar Disorder / / pha002858 rs5909027 chrX 139238648 C T 1.76E-05 Bipolar disorder / / 19488044 rs5909027 chrX 139238648 C T 5.56E-05 Bipolar disorder and schizophrenia / / 20889312 rs5955415 chrX 139314056 C G 2.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs5955415 chrX 139314056 C G 3.99E-05 Schizophrenia / / pha002857 rs5907591 chrX 139598066 A G 6.39E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5907591 chrX 139598066 A G 2.10E-05 Urinary metabolites / / 21572414 rs5907592 chrX 139598854 C G 7.90E-06 Urinary metabolites / / 21572414 rs5954015 chrX 139632759 C T 2.10E-05 Urinary metabolites / / 21572414 rs17256928 chrX 139633134 T C 2.00E-05 Urinary metabolites / / 21572414 rs1323334 chrX 139634916 C T 7.84E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17322856 chrX 139673372 C T 5.80E-06 Urinary metabolites / / 21572414 rs5954037 chrX 139674220 G A 9.40E-06 Urinary metabolites / / 21572414 rs6634178 chrX 139684832 G C 1.30E-05 Urinary metabolites / / 21572414 rs12834774 chrX 139701503 T G 3.38E-05 Parkinson's disease / / pha002868 rs12842403 chrX 139804618 T C 9.16E-05 Post-operative nausea and vomiting / / 21694509 rs2017077 chrX 139876820 G A 1.94E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7063248 chrX 139911906 C T 1.79E-04 Coronary Artery Disease / / 17634449 rs5907076 chrX 139923039 G T 2.33E-05 Cognitive performance / / 19734545 rs6528780 chrX 139997320 C T 3.38E-05 Schizophrenia / / 21674006 rs7060109 chrX 140041499 T G 9.01E-06 Type 2 diabetes / / 17463246 rs41340748 chrX 140041547 G A 3.63E-05 Type 2 diabetes / / 17463246 rs5954222 chrX 140246962 C T 4.13E-05 Cognitive test performance / / 20125193 rs5954230 chrX 140283896 A G 4.05E-04 Alzheimer's disease / / 17998437 rs845188 chrX 140376888 T C 1.40E-04 Myasthenia gravis / / 23055271 rs1007405 chrX 140386165 C T 2.78E-04 Type 2 diabetes / / 17463246 rs5907882 chrX 140407317 C T 1.93E-05 Cognitive impairment induced by topiramate / / 22091778 rs5907135 chrX 140428448 A G 3.70E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs5907945 chrX 140544892 G A 1.00E-05 Urinary metabolites / / 21572414 rs5908013 chrX 140779598 G A 1.60E-05 Urinary metabolites / / 21572414 rs2093134 chrX 140809884 G T 4.85E-04 Parkinson's disease / / 17052657 rs7883954 chrX 141009134 A G 8.10E-04 Type 2 diabetes / / 17463246 rs6636538 chrX 141033351 G A 8.14E-04 Body mass index / / 21701565 rs17323604 chrX 141086165 A G 5.42E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1534907 chrX 141086626 A C 4.33E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs5908177 chrX 141223393 C T 4.77E-04 Fibrinogen / / 17255346 rs5908177 chrX 141223393 C T 2.63E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2223404 chrX 141232285 A G 6.05E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6636623 chrX 141233946 A C 5.31E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12688226 chrX 141238620 A G 4.20E-05 Personality dimensions / / 18957941 rs12710619 chrX 141264801 G C 2.87E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs5908216 chrX 141270430 A G 2.22E-04 Vaspin levels / / 22907691 rs5908216 chrX 141270430 A G 0.0002224 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs5954560 chrX 141270735 G A 1.66E-04 Vaspin levels / / 22907691 rs5954560 chrX 141270735 G A 0.0001656 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks / / 22907730 rs5907262 chrX 141333121 T C 7.35E-06 Odorant perception / / 23910658 rs5908236 chrX 141337795 C T 7.80E-06 Urinary metabolites / / 21572414 rs5954587 chrX 141344785 A C 2.50E-05 Urinary metabolites / / 21572414 rs764198 chrX 141348313 G A 3.65E-06 Cognitive impairment induced by topiramate / / 22091778 rs5954592 chrX 141349768 G T 2.80E-05 Urinary metabolites / / 21572414 rs5954596 chrX 141360571 C T 5.00E-09 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs3135496 chrX 141416832 G A 9.80E-04 Bipolar disorder / / 19259986 rs5954635 chrX 141450842 A G 1.31E-05 HIV-1 control / / 20041166 rs2869525 chrX 141451485 A G 3.72E-05 HIV-1 control / / 20041166 rs6529005 chrX 141467629 A G 3.40E-05 Parkinson's disease (age of onset) / / 19772629 rs5908365 chrX 141659498 C T 1.70E-05 Urinary metabolites / / 21572414 rs4825134 chrX 141721411 G A 3.24E-04 Blood pressure / / 17255346 rs12844380 chrX 141732008 G A 2.60E-05 Urinary metabolites / / 21572414 rs4576554 chrX 141780184 A G 3.23E-04 Blood pressure / / 17255346 rs4454417 chrX 141803159 T C 1.60E-06 Urinary metabolites / / 21572414 rs10521828 chrX 141889261 T C 2.86E-23 Varicose Veins / / pha001414 rs991072 chrX 141952197 A C 2.35E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17258887 chrX 142086785 T C 1.70E-05 Urinary metabolites / / 21572414 rs5908533 chrX 142164219 T C 1.60E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6636902 chrX 142172078 A G 6.43E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12006890 chrX 142181392 G A 3.68E-04 Parkinson's disease / / 17052657 rs12006890 chrX 142181392 G A 2.55E-06 Post-operative nausea and vomiting / / 21694509 rs2206024 chrX 142182925 T C 9.55E-04 Parkinson's disease / / 17052657 rs2206024 chrX 142182925 T C 2.86E-07 Post-operative nausea and vomiting / / 21694509 rs2235082 chrX 142188516 C T 6.49E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5907396 chrX 142250436 C A 5.90E-06 Urinary metabolites / / 21572414 rs5908575 chrX 142254309 G C 5.90E-06 Urinary metabolites / / 21572414 rs5908577 chrX 142254690 T A 9.70E-06 Urinary metabolites / / 21572414 rs2235087 chrX 142283997 A G 9.92E-04 Type 2 diabetes / / 17463246 rs2207571 chrX 142305364 C T 5.81E-04 Premature ovarian failure / / 19508998 rs5908637 chrX 142355021 A T 1.30E-05 Urinary metabolites / / 21572414 rs5907414 chrX 142364922 G A 1.30E-05 Urinary metabolites / / 21572414 rs7052934 chrX 142601232 T C 2.00E-04 Cognitive impairment induced by topiramate SPANXN3 intron 22091778 rs2207578 chrX 142637742 A C 5.76E-06 Parkinson's disease / / 17052657 rs761697 chrX 142641647 A G 7.52E-04 Parkinson's disease / / 17052657 rs10521846 chrX 142685362 C T 1.80E-05 Urinary metabolites / / 21572414 rs2073252 chrX 142692263 G T 1.06E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5908721 chrX 142696673 A G 7.89E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs192138826 chrX 142823406 G T 6.91E-06 Tuberculosis / / 24057671 rs190796883 chrX 142827026 A C 6.91E-06 Tuberculosis / / 24057671 rs141261373 chrX 142827897 C T 6.91E-06 Tuberculosis / / 24057671 rs145189928 chrX 142830316 T G 6.91E-06 Tuberculosis / / 24057671 rs149912409 chrX 142832475 T C 6.91E-06 Tuberculosis / / 24057671 rs138067008 chrX 142838848 G A 6.20E-06 Tuberculosis / / 24057671 rs139956886 chrX 142842119 C T 6.00E-06 Tuberculosis / / 24057671 rs9306815 chrX 143036520 G A 0.0009 Breast cancer / / 23555315 rs12380897 chrX 143072629 C T 2.10E-05 Urinary metabolites / / 21572414 rs5908868 chrX 143074593 C T 2.10E-05 Urinary metabolites / / 21572414 rs859941 chrX 143348213 A C 1.07E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6637197 chrX 143364654 C T 1.00E-06 Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy) / / 24554482 rs859917 chrX 143383667 A G 4.52E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6649722 chrX 143393781 C T 6.77E-08 Common variable immunodeficiency / / 21497890 rs5908990 chrX 143461391 C A 4.97E-04 Parkinson's disease / / 17052657 rs6637227 chrX 143475222 T C 6.92E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs9698813 chrX 143607592 C A 2.40E-04 Endometrial cancer / / 24096698 rs9698813 chrX 143607592 C A 4.28E-04 Endometrial cancer / / 24096698 rs5945545 chrX 143708995 G T 5.90E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs5945540 chrX 143720904 G A 1.72E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs644429 chrX 143805524 T C 1.70E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer / / 21483023 rs10482174 chrX 143944567 T C 2.62E-06 Post-operative nausea and vomiting / / 21694509 rs6525911 chrX 144127387 C A 8.29E-06 Bipolar disorder and schizophrenia / / 20889312 rs6627057 chrX 144141319 T G 1.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs12689763 chrX 144281413 T C 3.74E-05 Cognitive test performance / / 20125193 rs17244302 chrX 144313765 T C 8.42E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs5966481 chrX 144322637 C A 9.03E-05 Cognitive impairment induced by topiramate / / 22091778 rs2891670 chrX 144521754 G A 9.77E-04 Alzheimer's disease / / 17998437 rs1174067 chrX 144538280 C T 3.04E-04 Bilirubin levels,in serum / / 19389676 rs5919854 chrX 144573953 A G 7.89E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5965863 chrX 144600329 C G 7.92E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12009448 chrX 144623955 C T 4.86E-04 Parkinson's disease / / 17052657 rs6626369 chrX 144630068 T C 3.14E-08 Breast cancer / / 20852631 rs1174258 chrX 144642152 G A 2.62E-04 Smoking quantity / / 24665060 rs5965871 chrX 144673082 A T 2.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17319419 chrX 144732953 C T 5.60E-07 Urinary metabolites / / 21572414 rs5965881 chrX 144733592 G A 2.20E-06 Urinary metabolites / / 21572414 rs5919606 chrX 144734444 A G 1.30E-06 Urinary metabolites / / 21572414 rs5919873 chrX 144744949 T C 1.50E-07 Urinary metabolites / / 21572414 rs12689869 chrX 144745505 G A 2.30E-08 Urinary metabolites / / 21572414 rs5965887 chrX 144745566 T A 1.50E-07 Urinary metabolites / / 21572414 rs5919874 chrX 144745584 T C 1.30E-07 Urinary metabolites / / 21572414 rs5965888 chrX 144745950 A T 2.30E-08 Urinary metabolites / / 21572414 rs5965631 chrX 144746214 G C 9.70E-07 Urinary metabolites / / 21572414 rs5965632 chrX 144746316 G A 3.50E-07 Urinary metabolites / / 21572414 rs4006544 chrX 144830831 C T 2.51E-04 Fibrinogen / / 17255346 rs5919904 chrX 144879512 A G 2.11E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs9698285 chrX 144881342 T C 2.95E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs9698110 chrX 144881368 A G 3.67E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1009776 chrX 144888977 G T 3.13E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7058595 chrX 144983236 A G 6.44E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12851264 chrX 144984818 A G 5.24E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12851714 chrX 144984988 A C 3.58E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7050282 chrX 145002875 G A 8.06E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs905089 chrX 145004093 C T 4.33E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2385424 chrX 145004153 C T 4.02E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs5965655 chrX 145023787 G A 2.42E-04 Parkinson's disease / / 17052657 rs1501476 chrX 145028845 A C 7.16E-05 Intelligence / / 21826061 rs11094290 chrX 145034223 G A 7.20E-05 Parkinson's disease / / 17052657 rs5966005 chrX 145120304 C G 7.47E-04 Type 2 diabetes / / 17463246 rs5966005 chrX 145120304 C G 5.88E-04 Coronary Artery Disease / / 17634449 rs36115511 chrX 145126046 C A 9.00E-06 Urinary metabolites / / 21572414 rs5965673 chrX 145126550 T C 9.60E-06 Urinary metabolites / / 21572414 rs5965674 chrX 145128805 A G 1.70E-05 Urinary metabolites / / 21572414 rs4827689 chrX 145183983 A G 6.79E-05 Schizophrenia / / 19571811 rs5920027 chrX 145240758 A G 3.82E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5965707 chrX 145323912 A G 8.51E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12388178 chrX 145324435 G A 6.49E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4827703 chrX 145380906 C T 9.37E-04 Type 2 diabetes / / 17463246 rs5920117 chrX 145556576 G A 2.05E-05 Parkinson's disease / / 17052657 rs5919700 chrX 145580551 T C 9.86E-05 Parkinson's disease / / 17052657 rs5920181 chrX 145590929 G A 3.29E-06 Post-operative nausea and vomiting / / 21694509 rs5920186 chrX 145592503 C T 1.18E-06 Post-operative nausea and vomiting / / 21694509 rs5920191 chrX 145599585 T A 3.66E-05 Bipolar disorder and schizophrenia / / 20889312 rs4827730 chrX 145628722 A T 8.73E-05 Glycosylated haemoglobin levels / / 17255346 rs996435 chrX 145639678 T C 2.22E-04 Vaspin levels / / 22907691 rs996435 chrX 145639678 T C 0.0002222 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs5966262 chrX 145643498 A G 1.54E-04 Vaspin levels / / 22907691 rs5966262 chrX 145643498 A G 0.0001131 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs5966262 chrX 145643498 A G 0.000154 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs4827618 chrX 145647421 A G 1.96E-04 Glycosylated haemoglobin levels / / 17255346 rs381365 chrX 145748908 T G 2.00E-12 Immune reponse to smallpox (secreted IFN-alpha) / / 22610502 rs5919746 chrX 145916889 T C 4.49E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6525768 chrX 145965406 C A 8.50E-05 HIV-1 control / / 20041166 rs1336838 chrX 145983189 T G 8.45E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1336840 chrX 145991136 T C 8.37E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6626815 chrX 146032616 C A 3.48E-06 Common variable immunodeficiency / / 21497890 rs11094388 chrX 146040013 A G 3.00E-04 Major depressive disorder / / 19065144 rs5904872 chrX 146048871 G A 5.28E-04 Type 2 diabetes / / 17463246 rs6525808 chrX 146116032 C A 1.60E-06 Urinary metabolites / / 21572414 rs5951768 chrX 146120221 G A 5.70E-06 Urinary metabolites / / 21572414 rs6525811 chrX 146123909 C T 3.20E-06 Urinary metabolites / / 21572414 rs5904713 chrX 146241179 G T 3.05E-04 Nicotine dependence / / 17158188 rs5904726 chrX 146322623 A G 9.00E-06 Coronary heart disease / / 21347282 rs4494023 chrX 146441317 G A 9.45E-04 Alzheimer's disease / / 17998437 rs5904735 chrX 146532261 C T 4.48E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs567970 chrX 146584811 C T 6.82E-04 Body mass index / / 21701565 rs543042 chrX 146598387 T C 4.50E-05 Anger / / 24489884 rs5905103 chrX 146770081 A G 5.59E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs5904778 chrX 146899835 T C 8.37E-04 Type 2 diabetes / / 17463246 rs6653423 chrX 146927759 A T 6.08E-04 Type 2 diabetes / / 17463246 rs752880 chrX 146941485 G A 2.56E-04 Type 2 diabetes / / 17463246 rs5904818 chrX 147042774 C T 2.00E-08 Antineutrophil cytoplasmic antibody-associated vasculitis / / 22808956 rs6626288 chrX 147060127 T G 3.87E-04 Lung function (forced vital capacity) / / 24023788 rs764631 chrX 147088249 C T 7.07E-04 Parkinson's disease FMR1NB missense 17052657 rs764631 chrX 147088249 C T 6.94E-04 Amyotrophic Lateral Sclerosis FMR1NB missense 17362836 rs7051766 chrX 147117416 T A 6.00E-06 Urinary metabolites / / 21572414 rs6525877 chrX 147158718 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs5904892 chrX 147247358 G A 4.18E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4090449 chrX 147299796 C T 1.62E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs4090449 chrX 147299796 C T 4.75E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs12388487 chrX 147320335 T C 3.22E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs12388487 chrX 147320335 T C 6.35E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs5936441 chrX 147324256 C T 5.00E-06 Response to acetaminophen (hepatotoxicity) / / 21177773 rs2159767 chrX 147381021 T C 7.00E-06 Schizophrenia / / 18347602 rs2536561 chrX 147401224 C G 7.87E-04 Type 2 diabetes / / 17463246 rs4843993 chrX 147452494 G A 6.26E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs5936206 chrX 147477033 G T 5.51E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs5936352 chrX 147485921 C T 2.75E-04 Type 2 diabetes / / 17463246 rs5936353 chrX 147485985 G A 3.26E-04 Type 2 diabetes / / 17463246 rs2335519 chrX 147489512 G T 5.81E-04 Type 2 diabetes / / 17463246 rs17318101 chrX 147717612 T C 2.80E-05 Urinary metabolites AFF2 intron 21572414 rs2188395 chrX 147729075 C T 2.60E-05 Urinary metabolites AFF2 intron 21572414 rs6540397 chrX 147778643 G T 4.10E-06 Urinary metabolites AFF2 intron 21572414 rs5936418 chrX 147781135 A T 8.50E-06 Urinary metabolites AFF2 intron 21572414 rs986810 chrX 147801125 T C 4.04E-05 Schizophrenia AFF2 intron 19571809 rs12686890 chrX 147829459 C T 0.000000699 HDL cholesterol AFF2 intron 23063622 rs5936428 chrX 147852561 G A 9.00E-04 Major depressive disorder AFF2 intron 19065144 rs6655002 chrX 148015929 T C 2.00E-04 Cognitive impairment induced by topiramate AFF2 intron 22091778 rs6641498 chrX 148120106 A C 2.45E-04 Type 2 diabetes / / 17463246 rs5980419 chrX 148304293 G A 4.74E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7065976 chrX 148313044 T A 6.25E-04 Bilirubin levels,in serum / / 19389676 rs5980427 chrX 148344804 T C 8.56E-04 Type 2 diabetes / / 17463246 rs4844014 chrX 148404622 A C 3.27E-04 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs4844014 chrX 148404622 A C 4.94E-05 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs1120211 chrX 148467311 A G 3.01E-04 Nicotine dependence / / 17158188 rs5980450 chrX 148477956 A G 4.60E-05 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs7064959 chrX 148486762 G A 5.77E-05 Femoral neck bone geometry and menarche (age at onset) / / 23593202 rs985081 chrX 148538099 T C 8.66E-09 Prostate cancer / / 24185611 rs530501 chrX 148567451 C A,G,T 4.00E-06 Cognitive performance IDS intron 20125193 rs6641322 chrX 148576152 G T 2.71E-05 Cognitive test performance IDS intron 20125193 rs525196 chrX 148590467 T C 7.81E-06 Cognitive test performance / / 20125193 rs648923 chrX 148603599 C A 6.94E-06 Cognitive test performance / / 20125193 rs3747443 chrX 148622730 G A,C,T 7.90E-04 Alcohol dependence CXorf40A UTR-5 20201924 rs3747442 chrX 148622745 T A 5.10E-04 Parkinson's disease CXorf40A UTR-5 17052657 rs4843989 chrX 148707711 C T 3.52E-04 Parkinson's disease TMEM185A intron 17052657 rs916016 chrX 148770191 G A 3.11E-04 Amyotrophic Lateral Sclerosis MAGEA11 intron 17362836 rs6608304 chrX 149233232 G A 2.04E-04 Alcohol dependence / / 20201924 rs6608310 chrX 149247783 A C 1.84E-05 stroke (ischemic) / / 17434096 rs3897225 chrX 149372326 G T 8.81E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11797005 chrX 149565979 C A 2.39E-05 Parkinson's disease MAMLD1 intron 17052657 rs2266831 chrX 149624776 A G 4.78E-05 Antineutrophil cytoplasmic antibody-associated vasculitis MAMLD1 intron 22808956 rs17252936 chrX 149635295 A G 6.00E-10 Immune reponse to smallpox (secreted IFN-alpha) MAMLD1 intron 22610502 rs497220 chrX 149676274 A G 1.90E-04 Myasthenia gravis MAMLD1 intron 23055271 rs12557844 chrX 149727091 G A 7.82E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs222382 chrX 149757452 A G 2.00E-05 Urinary metabolites MTM1 intron 21572414 rs222397 chrX 149782156 G A 1.10E-05 Urinary metabolites MTM1 intron 21572414 rs222396 chrX 149782431 G T 2.10E-05 Urinary metabolites MTM1 intron 21572414 rs222385 chrX 149799838 C A 2.70E-05 Urinary metabolites MTM1 intron 21572414 rs16995749 chrX 149999186 C A 8.79E-04 Amyotrophic Lateral Sclerosis CD99L2 intron 17362836 rs34984949 chrX 150053965 G A 4.00E-09 Urinary metabolites CD99L2 intron 21572414 rs374966 chrX 150120419 G A 1.14E-05 Prion diseases / / 22210626 rs4828787 chrX 150164884 T C 1.20E-05 Urinary metabolites / / 21572414 rs4828787 chrX 150164884 T C 3.55E-04 Spine bone size / / 23207799 rs4828789 chrX 150192253 G A 7.57E-04 Type 2 diabetes / / 17463246 rs5925477 chrX 150197721 C G 3.35E-04 Type 2 diabetes / / 17463246 rs5925478 chrX 150197788 C A 2.88E-04 Type 2 diabetes / / 17463246 rs5970539 chrX 150280253 T C 4.70E-06 Urinary metabolites / / 21572414 rs5924874 chrX 150286375 A G 1.20E-04 Interstitial lung disease / / 23583980 rs365250 chrX 150296871 T C 7.11E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs180491 chrX 150322542 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs180449 chrX 150379375 T C 5.80E-06 Urinary metabolites / / 21572414 rs180457 chrX 150383218 G C 2.80E-05 Urinary metabolites / / 21572414 rs760105 chrX 150396570 G A 3.02E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs760106 chrX 150408165 T G 1.13E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6526220 chrX 150411387 G T 7.76E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1149365 chrX 150413907 G C 2.34E-04 Spine bone size / / 23207799 rs1202959 chrX 150418500 C T 5.79E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1202959 chrX 150418500 C T 1.70E-05 Urinary metabolites / / 21572414 rs1202912 chrX 150438571 T C 1.70E-05 Urinary metabolites / / 21572414 rs6627369 chrX 150485440 G A 1.90E-05 Urinary metabolites / / 21572414 rs6627154 chrX 150493100 A G 7.13E-05 Schizophrenia / / pha002859 rs12010819 chrX 150509436 C T 7.69E-04 Type 2 diabetes / / 17463246 rs5969786 chrX 150525821 A T 6.53E-05 Schizophrenia / / 19571809 rs5969786 chrX 150525821 A T 7.52E-05 Schizophrenia / / pha002859 rs5970056 chrX 150658210 C G 6.32E-04 Type 2 diabetes / / 17463246 rs5924961 chrX 150752344 C T 3.33E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) PASD1 intron 24023788 rs5924980 chrX 150792829 G A 2.44E-04 Amyotrophic Lateral Sclerosis PASD1 intron 17362836 rs12861395 chrX 150809447 A G 4.57E-04 Parkinson's disease PASD1 intron 17052657 rs12861395 chrX 150809447 A G 1.95E-04 Amyotrophic Lateral Sclerosis PASD1 intron 17362836 rs5924655 chrX 150815468 G T 3.82E-04 Parkinson's disease PASD1 intron 17052657 rs5924655 chrX 150815468 G T 4.55E-04 Amyotrophic Lateral Sclerosis PASD1 intron 17362836 rs10482211 chrX 150833344 C A 1.21E-04 Parkinson's disease PASD1 intron 17052657 rs7878232 chrX 150846375 T G 6.87E-05 Parkinson's disease / / 16252231 rs7879285 chrX 150847294 A G 2.56E-05 Cognitive test performance / / 20125193 rs6627441 chrX 150851091 G A 6.70E-06 Urinary metabolites / / 21572414 rs6627176 chrX 150851917 T G 6.70E-06 Urinary metabolites / / 21572414 rs6627442 chrX 150852220 A G 8.50E-06 Urinary metabolites / / 21572414 rs4578101 chrX 150852828 G A 7.40E-06 Urinary metabolites / / 21572414 rs6627444 chrX 150854698 A T 6.70E-06 Urinary metabolites / / 21572414 rs3810715 chrX 150884620 C T 7.80E-06 Urinary metabolites FATE1 missense 21572414 rs1882713 chrX 150940155 T C 6.28E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs941401 chrX 150998498 C T 7.26E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6526059 chrX 151096533 A G 4.56E-04 Type 2 diabetes / / 17463246 rs933191 chrX 151097030 A G 7.17E-04 Type 2 diabetes / / 17463246 rs7882041 chrX 151109069 T G 4.65E-04 Type 2 diabetes / / 17463246 rs5970169 chrX 151111678 G T 4.83E-04 Type 2 diabetes / / 17463246 rs12011671 chrX 151124965 T C 1.82E-05 Type 2 diabetes GABRE intron 17463246 rs2256756 chrX 151131340 A G 5.36E-04 Cognitive impairment induced by topiramate GABRE intron 22091778 rs2471366 chrX 151245302 A T 9.76E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2471367 chrX 151245334 C G 9.76E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1844894 chrX 151262143 C T 8.23E-04 Type 2 diabetes / / 17463246 rs12388854 chrX 151279454 G T 9.18E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs210564 chrX 151279508 T G 4.71E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs210564 chrX 151279508 T G 6.58E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2194898 chrX 151299634 G A 9.93E-04 Amyotrophic Lateral Sclerosis MAGEA10-MAGEA5 intron 17362836 rs1844895 chrX 151300722 C T 1.62E-04 Amyotrophic Lateral Sclerosis MAGEA10-MAGEA5 intron 17362836 rs1844895 chrX 151300722 C T 8.50E-04 Alcohol dependence MAGEA10-MAGEA5 intron 20201924 rs17221034 chrX 151416541 T C 1.79E-04 Alzheimer's disease GABRA3 intron 17998437 rs6526107 chrX 151582816 C T 3.02E-04 Amyotrophic Lateral Sclerosis GABRA3 intron 17362836 rs7065528 chrX 151605166 G A 9.85E-04 Amyotrophic Lateral Sclerosis GABRA3 intron 17362836 rs10856240 chrX 151655562 T C 9.00E-06 Cognitive performance / / 19734545 rs4828697 chrX 151666727 C T 5.47E-05 Cognitive performance / / 19734545 rs2142466 chrX 151678490 G A 7.69E-04 Alzheimer's disease / / 17998437 rs6627606 chrX 151706961 G A 2.40E-05 Urinary metabolites / / 21572414 rs6627611 chrX 151769166 A G 2.74E-05 Cognitive performance / / 19734545 rs2471773 chrX 151899355 T C 5.98E-04 Type 2 diabetes MAGEA12 UTR-3 17463246 rs2515832 chrX 151902054 C G 5.98E-04 Type 2 diabetes MAGEA12 intron 17463246 rs5925253 chrX 152081027 G A 2.30E-05 Personality dimensions ZNF185 nearGene-5 18957941 rs6627710 chrX 152104492 G A 1.28E-04 IgE levels ZNF185 intron 17255346 rs2071251 chrX 152134320 G A 1.38E-04 Amyotrophic Lateral Sclerosis ZNF185 intron 17362836 rs5924779 chrX 152134948 T C 1.31E-04 Amyotrophic Lateral Sclerosis ZNF185 intron 17362836 rs5924783 chrX 152149858 A G 1.07E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12156955 chrX 152163329 A G 2.77E-04 Type 2 diabetes PNMA5 nearGene-5 17463246 rs4828734 chrX 152171365 A G 1.83E-04 Type 2 diabetes / / 17463246 rs5970412 chrX 152177878 T C 6.65E-04 Type 2 diabetes / / 17463246 rs6526155 chrX 152226542 T C 5.57E-04 Type 2 diabetes PNMA3 missense 17463246 rs5925342 chrX 152509755 G A 5.20E-04 Lipid levels / / 19016617 rs5925342 chrX 152509755 G A 1.46E-06 Statin-induced myopathy / / 21826682 rs5987017 chrX 152782172 A G 9.84E-08 Common variable immunodeficiency / / 21497890 rs6643623 chrX 152809742 T C 9.11E-04 Celiac disease ATP2B3 intron 23936387 rs4898359 chrX 152828161 T C 9.73E-04 Amyotrophic Lateral Sclerosis ATP2B3 intron 17362836 rs4144871 chrX 152837731 G A 4.80E-05 HIV-1 control ATP2B3 intron 20041166 rs12010175 chrX 152862638 A G 2.00E-09 Type 2 diabetes FAM58A intron 22961080 rs5945326 chrX 152899922 A G 3.00E-10 Type 2 diabetes / / 20581827 rs5945326 chrX 152899922 A G 7.00E-16 Type 2 diabetes / / 22961080 rs5945326 chrX 152899922 A G 0.0000849 HDL cholesterol / / 23063622 rs5945326 chrX 152899922 A G 3.00E-10 Type 2 diabetes / / 23300278 rs5945326 chrX 152899922 A G 2.00E-12 Type 2 diabetes / / 23945395 rs6571284 chrX 152917616 T C 1.89E-06 Bipolar disorder,affective / / 20528957 rs2266870 chrX 152980164 T C 2.58E-04 Hearing function BCAP31 intron 17255346 rs2266870 chrX 152980164 T C 1.19E-05 Bipolar disorder and schizophrenia BCAP31 intron 20889312 rs6643780 chrX 152995219 G A 2.16E-05 Bipolar disorder and schizophrenia ABCD1 intron 20889312 rs7063261 chrX 152997448 G A 1.35E-04 Hearing function ABCD1 intron 17255346 rs5987140 chrX 153000255 T C 3.37E-06 Bipolar disorder and schizophrenia ABCD1 intron 20889312 rs11156606 chrX 153006495 A C 3.00E-06 Bipolar disorder and schizophrenia ABCD1 intron 20889312 rs6643643 chrX 153006659 A G 3.92E-05 Bipolar disorder and schizophrenia ABCD1 intron 20889312 rs5196 chrX 153170618 A T 0.00000147 LDL cholesterol AVPR2 missense 23063622 rs2269368 chrX 153189819 C T 4.74E-07 Schizophrenia ARHGAP4 intron 24043878 rs2269372 chrX 153207545 A G 4.00E-08 Schizophrenia RENBP intron 24043878 rs2266887 chrX 153239587 G T 7.15E-08 Bilirubin levels TMEM187 intron 19419973 rs6643653 chrX 153246018 A G 1.60E-05 Response to radiotherapy in cancer (late toxicity) TMEM187 intron 24785509 rs13397 chrX 153248248 G A 2.70E-08 Celiac disease TMEM187 cds-synon 22057235 rs13397 chrX 153248248 G A 0.000000027 Celiac disease TMEM187 cds-synon 23143596 rs13397 chrX 153248248 G A 0.0000312 Rheumatoid arthritis (CCP negative) TMEM187 cds-synon 23143596 rs13397 chrX 153248248 G A 1.20E-12 Rheumatoid arthritis TMEM187 cds-synon 23143596 rs13397 chrX 153248248 G A 1.23E-12 Rheumatoid arthritis (CCP positive) TMEM187 cds-synon 23143596 rs3027898 chrX 153275890 C A 2.14E-04 Alzheimer's disease IRAK1 nearGene-3 17998437 rs2734647 chrX 153292180 T C 8.78E-07 Schizophrenia MECP2 UTR-3 24043878 rs5987194 chrX 153301467 C G 2.90E-05 Rheumatoid arthritis MECP2 intron 24390342 rs5987194 chrX 153301467 C G 3.00E-12 Rheumatoid arthritis MECP2 intron 24390342 rs5987194 chrX 153301467 C G 5.00E-16 Rheumatoid arthritis MECP2 intron 24390342 rs17435 chrX 153311980 T A 1.93E-04 Alzheimer's disease MECP2 intron 17998437 rs1734791 chrX 153330920 A T 4.66E-04 Alzheimer's disease MECP2 intron 17998437 rs2239464 chrX 153348431 A G 6.71E-06 Schizophrenia MECP2 intron 24043878 rs17174296 chrX 153540977 A G 8.19E-04 Response to taxane treatment (placlitaxel) TKTL1 cds-synon 23006423 rs5987245 chrX 153551383 A G 1.42E-08 Bilirubin levels TKTL1 intron 19419973 rs766420 chrX 153554404 C G 9.00E-09 Bilirubin levels TKTL1 intron 19419973 rs766419 chrX 153554661 A G 1.10E-08 Bilirubin levels TKTL1 intron 19419973 rs2239467 chrX 153555294 A G 1.03E-08 Bilirubin levels TKTL1 intron 19419973 rs2239468 chrX 153555386 T A 1.10E-08 Bilirubin levels TKTL1 intron 19419973 rs12392447 chrX 153724351 G A 2.88E-08 Alcohol dependence / / 19581569 rs1050828 chrX 153764217 C T 1 Drug response to Dapsone G6PD missense 19112496 rs1050828 chrX 153764217 C T 1.20E-13 Blood cell counts and traits,in red and white blood cells G6PD missense 21153663 rs1050828 chrX 153764217 C T 1.20E-15 Blood cell counts and traits,in red and white blood cells G6PD missense 21153663 rs1050828 chrX 153764217 C T 3.00E-18 Blood cell counts and traits,in red and white blood cells G6PD missense 21153663 rs1050828 chrX 153764217 C T 4.30E-21 Blood cell counts and traits,in red and white blood cells G6PD missense 21153663 rs1050828 chrX 153764217 C T 4.00E-19 Red blood cell traits G6PD missense 23446634 rs1050828 chrX 153764217 C T 1.00E-14 Red blood cell traits G6PD missense 23696099 rs1050828 chrX 153764217 C T 4.00E-13 Red blood cell traits G6PD missense 23696099 rs1050828 chrX 153764217 C T 9.00E-09 Red blood cell traits G6PD missense 23696099 rs762516 chrX 153764663 C T 2.00E-16 Red blood cell traits G6PD intron 23446634 rs4526543 chrX 153878001 T C 2.37E-04 Alzheimer's disease / / 17998437 rs5945222 chrX 153887204 C T 2.31E-04 Alzheimer's disease / / 17998437 rs5945109 chrX 153907749 A G 5.48E-04 Alzheimer's disease GAB3 intron 17998437 rs2664170 chrX 153945602 G A 8.00E-09 Type 1 diabetes GAB3 intron 19430480 rs5987027 chrX 154014107 C T 1.00E-11 Hematology traits MPP1 intron 23263863 rs5987027 chrX 154014107 C T 4.00E-10 Mean corpuscular volume MPP1 intron 23263863 rs5987077 chrX 154224425 A T 4.41E-04 Alzheimer's disease F8 intron 17998437 rs17051889 chrX 154229403 A G 1.00E-04 Cognitive impairment induced by topiramate F8 intron 22091778 rs17281398 chrX 154233774 A G 4.00E-07 Antineutrophil cytoplasmic antibody-associated vasculitis F8 intron 22808956 rs5945279 chrX 154272466 C T 7.91E-06 Cognitive impairment induced by topiramate FUNDC2 intron 22091778 rs2051161 chrX 154285851 C G 9.86E-04 Alzheimer's disease / / 17998437 rs5986904 chrX 154307827 T G 4.49E-05 HIV-1 viral setpoint BRCC3 intron 22174851 rs5986908 chrX 154342936 G C 2.70E-05 Urinary metabolites BRCC3 intron 21572414 rs895744 chrX 154345791 G T 1.43E-04 Alzheimer's disease BRCC3 intron 17998437 rs1128863 chrX 154356862 A G 4.33E-05 Cognitive impairment induced by topiramate / / 22091778 rs35296872 chrX 154454087 A G 4.65E-04 Alzheimer's disease VBP1 intron 17998437 rs475025 chrX 154484937 A G 9.92E-04 Alzheimer's disease / / 17998437 rs6642287 chrX 154780283 A C 6.50E-05 HIV-1 control TMLHE intron 20041166 rs5940513 chrX 154789496 A G 6.40E-04 Alzheimer's disease TMLHE intron 17998437 rs479901 chrX 154844287 A T 3.13E-04 Alzheimer's disease TMLHE nearGene-5 17998437 rs574386 chrX 154847489 C T 6.40E-04 Alzheimer's disease / / 17998437 rs672932 chrX 154915975 G A 1.69E-04 Alzheimer's disease / / 17998437 rs2571653 chrY 4935714 C A 7.48E-05 Celiac disease PCDH11Y intron 23936387 rs2578787 chrY 5411068 A G 1.68E-04 Celiac disease PCDH11Y intron 23936387 rs2556916 chrY 5608402 A C 1.47E-04 Celiac disease PCDH11Y UTR-3 23936387 rs111611512 chrY 13469347 T C 2.62E-11 Metabolite levels / / 22286219 rs36141869 chrY 21277640 T C 2.25E-12 Infantile hypertrophic pyloric stenosis / / 22306654